ingredients are mainly, but not restricted to: Ostericum koreanum, Eucommia ulmoides, Acanthopanax sessiliflorus, Achyranthes japonica, Psoralea corylifolia, Saposhnikovia divaricata, Cibotium barometz, Lycium chinense, Boschniakia rossica, Cuscuta chinensis, Glycine max, Atractylodes japonica).
223578219|NCT04182321|DRUG|Metformin & Entecavir|Adding sustained-release metformin hydrochloride (1000 mg, oral, once a day) for 24 weeks to the ongoing entecavir therapy (0.5 mg, oral, once a day)
223467955|NCT03871530|OTHER|Coordinate L|"PIEB Next Bolus: 15 minutes, PIEB Interval: 60 minutes, and PIEB volume: 6.5 mL"
223467956|NCT03871530|OTHER|Coordinate M|"PIEB Next Bolus: 30 minutes, PIEB Interval: 50 minutes, and PIEB volume: 6.5 mL"
223467957|NCT03871530|OTHER|Coordinate N|"PIEB Next Bolus: 30 minutes, PIEB Interval: 50 minutes, and PIEB volume: 6.5 mL"
223467958|NCT05446961|DIETARY_SUPPLEMENT|LCLT : 68% elemental L-carnitine and 32 % Tartric acid|3 g orally capsules
223467959|NCT05446961|DRUG|Placebo|orally capsules
223467960|NCT03391102|OTHER|Observational study|
223467961|NCT00535652|DRUG|Ertapenem|powder for infusion, 1 gram I.V., single dose over 30 min.
223467962|NCT05032014|OTHER|M9|one times a day during the whole treatment
223467963|NCT05032014|OTHER|placebo|placebo
223467964|NCT01516723|DEVICE|Hybrid sirolimus- and everolimus-eluting stents (ORSIRO, XIENCE PRIME)|Recanalization of totally occluded coronary arteries
223467965|NCT02825914|DIETARY_SUPPLEMENT|Casein glycomacropeptide (CGMP)|
223467966|NCT02825914|DIETARY_SUPPLEMENT|Placebo|
223467967|NCT02523430|PROCEDURE|interventional therapy|nasopharyngeal carcinoma patients received HepaSphere interventional therapy using the digital subtraction angiography（DSA）
223467968|NCT00069264|DRUG|E7389|E7389 Dose-escalation starting at 0.25 mg/m\^2 intravenous on Days 1, 8, and 15 of a 28 day cycle.
223467969|NCT05547386|PROCEDURE|Computed Tomography|Undergo PET/CT scan
223467970|NCT05547386|DRUG|Gallium Ga 68 Gozetotide|Given IV
223467971|NCT05547386|PROCEDURE|Positron Emission Tomography|Undergo PET/CT scan
223578220|NCT04182321|DRUG|Placebo & Entecavir|Adding placebo (oral, once a day) for 24 weeks to the ongoing entecavir therapy (0.5 mg, oral, once a day)
223578221|NCT00236496|DRUG|topiramate|
223578222|NCT06465264|DRUG|Allisartan Isoproxil/Amlodipine group 1|"One Allisartan Isoproxil/Amlodipine (240 mg/5 mg) tablet and one placebo of Amlodipine during the double-blind period (Week 4\~Week 16).~One Allisartan Isoproxil/Amlodipine(240 mg/5 mg) tablet during the open-label period(Week 16\~ Week 56) once daily."
223578223|NCT06465264|DRUG|Amlodipine group 1|"One Amlodipine (5 mg) tablet and one placebo of Allisartan Isoproxil/Amlodipine during the double-blind period (Week 4\~Week 16).~One Allisartan Isoproxil/Amlodipine(240 mg/5 mg) tablet during the open-label period(Week 16\~ Week 56) once daily."
224068406|NCT00697567|BIOLOGICAL|Herpes simplex candidate vaccine GSK208141- MPL-containing adjuvant|Intramuscular injection, 3 doses
224068407|NCT03718507|DRUG|Fentanyl|atropine (0.01-0.02 mg/kg i.v. bolus) and fentanyl (0.5-2 mcg/kg i.v. in 5 minutes)
224068408|NCT03718507|DRUG|Sucrose 24% Oral Solution|0.5 ml given orally 2 minutes before LISA procedure
224068409|NCT05729412|OTHER|Mentioned|If prescription is properly filled for specific details than it is compliance
224068410|NCT02837315|BEHAVIORAL|Brief Motivational Intervention (BMI)|This session includes a discussion related to harm reduction and the student's autonomy to make decisions about the information provided in the session; a marijuana use decisional balance exercise; personalized marijuana-related feedback, and goal-setting. Elements included in the feedback are: (a) comparison of the student's perception of how much college students use marijuana and actual student norms, (b) a comparison of the student's marijuana use vs. norms, (c) drug-related problems experienced, (e) money spent on marijuana, and (f) alcohol norms and consequences if participants indicated they also drink alcohol. Participants discuss the personalized feedback with the clinician and review protective behavioral strategies if she or she indicates interest.
223467972|NCT03909646|DRUG|Methyl Aminolevulinate (Mal) for Topical Administration, 16.8%, 1 Gram|A layer of methylaminolevulinc acid 160 mg/g cream (about 1 mm thick) is applied to the lesion, with a clinical margin of 5-10 mm surrounding of normal skin and then covered by an occlusive dressing. After 3 hours the occlusive dressing will be removed and the area is illuminated with Omnilux or Actilite (Galderma). After PDT the treatment site is covered again with the above mentioned occlusive dressings during 48 hours. Treatment is performed by an authorized nurse in the hospital. Two sessions should be administered with an interval of one week between sessions.
223578224|NCT06465264|DRUG|Allisartan Isoproxil/Amlodipine group 2|"One Allisartan Isoproxil/Amlodipine (240 mg/5 mg) tablet and one placebo of Allisartan Isoproxil (240 mg) during the double-blind period (Week 4\~Week 16).~One Allisartan Isoproxil/Amlodipine(240 mg/5 mg) tablet during the open-label period(Week 16\~ Week 56) once daily."
223467973|NCT03909646|DRUG|5Fluorouracil|5-FU is applied on the treatment area by the patient in a thin layer twice daily during 4 weeks.
223467974|NCT03909646|OTHER|Surgical excision|Local anesthesia with lidocain 1% (1-2ml) will be used before performing standard surgical excision with 5 mm safety margin followed by routine histological examination. The skin will be closed using cutaneous sutures, which will be removed after 1-2 weeks. The surgical excision will take place in the hospital by the treating physician
223467975|NCT04622969|BEHAVIORAL|Healthy Child Development Program|The Healthy Child Development Program is a family-based intervention focused on strengthening positive behaviors in children, managing misbehavior, and addressing healthy lifestyle choices.
223578225|NCT06465264|DRUG|Allisartan Isoproxil group 2|"One Allisartan Isoproxil (240 mg) and one placebo of Allisartan Isoproxil/Amlodipine (240 mg/5 mg) during the double-blind period (Week 4\~Week 16).~One Allisartan Isoproxil/Amlodipine(240 mg/5 mg) tablet during the open-label period(Week 16\~ Week 56) once daily."
224159015|NCT03571503|PROCEDURE|Chuna manual therapy|Chuna is a Korean spinal manipulation that incorporates spinal manipulation techniques for joint mobilization involving high-velocity, low amplitude thrusts to joints slightly beyond the passive range of motion and gentle force to joints within the passive range of movement. Chuna manipulation will be administered at the physician's discretion.
224159016|NCT03571503|PROCEDURE|Bee venom pharmacopuncture|Bee venom pharmacopuncture will be administered only after confirming a negative response to hypersensitivity skin test. Diluted bee venom (saline:bee venom ratio, 10,000:1) filtered for allergens will be injected at 4-5 acupoints proximal to the dysfunctional site at the physician's discretion. Each acupuncture point will be injected to a total of 0.5-1 cc using disposable injection needles (CPL, 1 cc, 26G x 1.5 syringe, Shinchang medical co., Korea).
224159017|NCT03571503|PROCEDURE|Pharmacopuncture|Pharmacopuncture consisting of select herbal ingredients will be administered at Ah-shi points and local acupuncture points using disposable injection needles (CPL, 1 cc, 26G x 1.5 syringe, Shinchang medical co., Korea).
224159018|NCT03571503|PROCEDURE|Acupuncture|Acupuncture treatment will be administered using mainly proximal acupuncture points and Ah-shi points.
224159019|NCT03571503|PROCEDURE|Electroacupuncture|Electroacupuncture treatment will be administered using mainly proximal acupuncture points and Ah-shi points.
224159020|NCT03571503|PROCEDURE|Cupping|Cupping treatment will be administered at 1-2 points using mainly proximal acupuncture points and Ah-shi points.
224159021|NCT03571503|OTHER|Other intervention(s)|Patients will be allowed any other additional intervention(s) as deemed necessary by the attending physician regardless of type or dose, and patterns of use will be investigated and recorded as an pragmatic clinical study.
224159022|NCT05156333|DIETARY_SUPPLEMENT|Respecta|"Respecta® complex (mixture of probiotics and milk glycoproteins with prebiotic action); Cornstarch; Anti-caking agents: Vegetable magnesium stearate, Silicon dioxide; Capsule orally administered: Hydroxypropylmethylcellulose (coloring: E171).~Daily oral administration of two capsules of the Giellepi Spa class IIa medical device Respecta or placebo, to be taken with a glass of water preferably between meals, starting from the 30th week of pregnancy until the 37th week after having vagino-rectal swab screening performed."
224159023|NCT03634176|DIAGNOSTIC_TEST|optical nerve sheet diameter|The ONSD in each eye was measured vertically and horizontally 3 mm behind the optic disc, with the two values averaged. No pressure was applied to the orbit. At each time point, measurements were taken within 5 min. The measurements were made before (T1) and after some of the strategies according to group 30 min (T2), 60 min (T3), and 90 min (T4).
224159024|NCT04713111|BEHAVIORAL|Lifestyle (Meditation)|Those in the meditation arm (exercisers) were instructed to complete meditation sessions from the smartphone app, Headspace 2 or more times a week for a duration of 4 weeks.
224159025|NCT04713111|BEHAVIORAL|Lifestyle (Exercise)|Those in the physical activity arm (meditators) were instructed to complete 30 minutes to 1 hour of physical activity for 2 or more sessions per week for 4 weeks.
224159026|NCT00194727|DRUG|Vinorelbine|20 mg/m2 IV weeks 1, 2 and 3 of each 3 week cycle. Treatment continues until disease progression, excessive toxicity or other reason to remove patient from protocol therapy.
223578226|NCT03508193|OTHER|Nutritional therapy|Whole-foods based smoothie designed to emulate formulas used in EEN
223578227|NCT04733170|DIAGNOSTIC_TEST|KnowNow SARS-CoV-2 Rapid Antigen Test|KnowNow SARS-CoV-2 Rapid Antigen Test for the detection of Covid-19 in saliva, as compared to high sensitivity reverse transcription polymerase chain reaction (RT-PCR) of nasopharyngeal swabs as the reference test method
223578228|NCT02961790|DRUG|Oxybutynin Chloride|Given PO
223578229|NCT02961790|OTHER|Placebo|Given PO
223578230|NCT02961790|OTHER|Quality-of-Life Assessment|Ancillary studies
223578231|NCT02961790|OTHER|Questionnaire Administration|Ancillary studies
223578232|NCT04461574|DEVICE|Orcellex Brush|Subjects will receive vaginal vault smear using both Orcellex Brush and Cervex Brush at the same follow-up visit, with order of smear taking decided by randomization.
223578233|NCT04461574|DEVICE|Cervex Brush|Subjects will receive vaginal vault smear using both Orcellex Brush and Cervex Brush at the same follow-up visit, with order of smear taking decided by randomization.
223578234|NCT00183378|BEHAVIORAL|Walking Program|The therapist introduces a walking program and assists the caregiver in establishing a walking routine of 30 minutes/day for the study participant.
223578235|NCT00183378|BEHAVIORAL|Light Exposure Program|The therapist provides a light box and teaches the caregiver how to use the box so that the study participant's daily exposure to bright light is one hour.
223467976|NCT05969730|DRUG|Baricitinib 4 MG|In visit 1 which will be scheduled after the washout period, demographic information and baseline assessment will be conducted and patients will randomize into arms, baricitinib 4-mg daily plus fluocinolone 0.025% topical ointment and daily emollient of urea 10% topical cream (Arm A). Six weeks after visit 1, Visit 2 will be set to follow up on the patient condition, particularly in terms of adverse effects, and reorder their intervention. Visit 3 will be 12 weeks after visit 1 to perform the final assessment.
223467977|NCT05969730|DRUG|Azathioprine 1.5-2.5 mg/kg|In visit 1 which will be scheduled after the washout period, demographic information and baseline assessment will be conducted and patients will randomize into arms, azathioprine 1.5-2.5 mg/kg plus fluocinolone 0.025% topical ointment and daily emollient of urea 10% topical cream (Arm B). Six weeks after visit 1, Visit 2 will be set to follow up on the patient condition, particularly in terms of adverse effects, and reorder their intervention. Visit 3 will be 12 weeks after visit 1 to perform the final assessment.
223467978|NCT02094794|DRUG|etoposide|Given IV
223467979|NCT02094794|DRUG|cyclophosphamide|Given IV
223467980|NCT02094794|RADIATION|total marrow irradiation|Undergo TMLI
223467981|NCT02094794|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Undergo allogeneic peripheral blood stem cell or bone marrow transplant
223467982|NCT02094794|PROCEDURE|allogeneic bone marrow transplantation|Undergo allogeneic peripheral blood stem cell or bone marrow transplant
223467983|NCT04467515|DRUG|CAM-H2|All patients will receive at least 1 cycle of CAM-H2. Patients with CB may receive 4 cycles of CAM-H2, each cycle given as 2 IV administrations, 4 weeks apart.
223467984|NCT05972343|DEVICE|Cryoablation|Takes place at single time point.
223467985|NCT06969014|DEVICE|Microwave ablation|Microwave ablation of lung tumors
223467986|NCT06514430|DRUG|Phenazopyridine|200mg PO Phenazopyridine taken prior to the Botox® injection procedure as an analgesic.
223467987|NCT06514430|DRUG|1% lidocaine with sodium bicarbonate|50cc of 1% lidocaine with 50cc sodium bicarbonate injected into the bladder lumen prior to the Botox® injection procedure.
223467988|NCT04252625|DRUG|Q-Urol|Q-Urol is an over-the-counter herbal supplement manufactured by Farr Laboratories. It is a combination product composed of quercetin, pollen extract, bromelain, and papain.
223467989|NCT04252625|DRUG|Placebo|placebo capsule
223467990|NCT05616013|BIOLOGICAL|Bimagrumab|Human monoclonal antibody to the activin receptor type II
223467991|NCT05616013|DRUG|Semaglutide|Glucagon-like peptide-1 (GLP-1) receptor agonist
223467992|NCT05616013|OTHER|Placebo|Placebo
223467993|NCT06409663|BIOLOGICAL|NVX-CoV2705 Vaccine|All injections will be administered in a 0.5 mL injection volume at an antigenic dose of 5 µg with 50 µg Matrix-M adjuvant at each injection.
223467994|NCT06420089|DRUG|Senza5 CART5|The Senza5 CART5 drug product consists of a dual population of engineered autologous T cells: CD5 knockout (KO)cells and CD5KO-CART5 cells
223467995|NCT05454592|BEHAVIORAL|Stress and Coping Online Outreach Program|3 videos and a resource library disseminated over the course of 9 weeks.
224159027|NCT00194727|DRUG|Capecitabine|825 mg/m2 twice a day; days 1 - 14 of each 3 week cycle. Treatment continues until disease progression, excessive toxicity or other reason to remove patient from protocol therapy.
223467996|NCT06970769|OTHER|Vagus nerve stimulation|In our study, the auricular branch in the pinna was superficially stimulated with a TENS-based vagustim device for non-invasive vagus nerve stimulation. The application was performed in regular sessions with a physiotherapist according to the recorded protocol. This deactivation aimed at modulation of the autonomic nervous system via the vagus nerve.
223467997|NCT06970769|OTHER|Deep Breathing Exercises|In the study, the participants who were given deep breathing exercises were taught the correct technique in a semi-sitting position. During the exercises, deep breathing and relaxation periods were applied for certain periods. The respiratory rhythm was arranged as controlled inspiration and expiration. The participants were given an application practice so that they could continue the exercise at home.
223467998|NCT06970223|DRUG|Cabotegravir long-acting|A single CAB LA injection administered intramuscularly.
223467999|NCT06970223|DRUG|Lenacapavir long-acting|Two LEN LA injections administered subcutaneously.
223468000|NCT04832607|OTHER|Multivirus (CMV, EBV, AdV)-specific T cells|Cell therapy product which is individually produced for each patient and administered via IV bolus injection.
223468001|NCT05010577|DRUG|BX004-A|Combination of nebulized bacteriophages targeting Pseudomonas aeruginosa
223468002|NCT05010577|DRUG|Placebo|Nebulized placebo
223468003|NCT06456788|BIOLOGICAL|MMR vaccination|MMR vaccination status
223468005|NCT05492006|BEHAVIORAL|Indirect contact with nature|The participants will watch a video with validated images of nature from e-Nature Positive Emotions Photography Database (e-NatPOEM). Four fifteen-minute sessions will be held on four consecutive days, totaling 1 hour.
223468006|NCT05492006|BEHAVIORAL|Intentional contact with nature|The participants will take a light walk in a park with green spaces guided by research team in a single 1-hour session, with an emphasis on sense-directed appreciation.
223468007|NCT05116202|DRUG|Nivolumab|Nivolumab will be administered at a dose of 3 mg/kg IV on Day 1 of each 21 day cycle.
223468008|NCT05116202|DRUG|Ipilimumab|Ipilimumab will be administered at a dose of 1 mg/kg by IV on Day 1 of each 21 day cycle.
223468009|NCT05116202|DRUG|RO7247669 2100 mg|RO7247669 will be administered at a dose of 2100 mg by IV infusion on Day 1 of each 21 day cycle.
223468010|NCT05116202|DRUG|Atezolizumab|Atezolizumab will be administered at a dose of 1200 mg IV on Day 1 of each 21 day cycle.
223468011|NCT05116202|DRUG|Tiragolumab|Tiragolumab will be administered at a dose of 600 mg IV on Day 1 of each 21 day cycle.
223468012|NCT05116202|DRUG|RO7247669 600 mg|RO7247669 will be administered at a dose of 600 mg by IV infusion on Day 1 of each 21 day cycle.
223468013|NCT03834506|BIOLOGICAL|Pembrolizumab|IV infusion
223468014|NCT03834506|DRUG|Docetaxel|IV infusion
223468015|NCT03834506|DRUG|Prednisone|Oral tablets
223468016|NCT03834506|DRUG|Placebo|IV infusion
223468017|NCT03834506|DRUG|Dexamethasone|Oral tablets
223468018|NCT05658393|BEHAVIORAL|ReLiver-N App|Web-based mobile health application for patients with liver cirrhosis
223468019|NCT05040087|OTHER|Intensification of diabetes medication based largely on HbA1c levels|Use of diabetes Rx in controls will be guided largely by HbA1c levels.
223468020|NCT05040087|OTHER|Intensification of diabetes medication based on glucose levels|Use of diabetes Rx in the intensive Rx groups will be guided by participants' self-monitored blood glucose levels (SMBG), with management aimed to keep glucose levels within the normal range.
223468021|NCT06801379|DRUG|Inhaled Melatonin (100 μg)|An orally inhaled formulation of melatonin delivered by pressurised metered dose inhaler (pMDI) to be taken before bedtime. The pMDI will deliver a total of 100 μg of inhaled melatonin (2 x 50 μg/actuation). The investigational product is produced under Good Manufacturing Practice by Ab Initio Pharma Pty Ltd, a GMP certified manufacturer of pharmaceutical products.
223468022|NCT06801379|DRUG|Oral Melatonin (4 mg)|Two orally ingested tablets each containing 2 mg of melatonin (4 mg total) to be taken before bedtime. The investigational product is manufactured under Good Manufacturing Practice and is compliant with the TGA Therapeutic Order #101 that stipulates quality control requirements for capsule and pill-based products used in Australia.
223468023|NCT03859050|OTHER|bronchoscopy with intrabronchial administration of lipopolysaccharide|The PI will administer intrabronchial LPS into the lungs of healthy volunteers and then obtaining macrophages by bronchoalveolar lavage (BAL) 24, 48, 72, 96, or 120 hours later.
223578236|NCT00183378|BEHAVIORAL|Combined Education, Walking and Light Exposure Program|The therapist provides a combination of education plus assistance setting up an individualized sleep program, a daily walking routine, and a schedule for daily light exposure.
224159028|NCT01269177|DEVICE|Non invasive ventilation|"Indications for the use of NIV are at least one of the following:~* Respiratory Rate ≥ 30 bpm~* PaO2/FiO2 \< 200~* pH \< 7.35 and PaCO2 \> 45 mmH~Contraindications for the use of NIV are at least one of the following:~* Coma~* Hemodynamic instability / shock~* Lack of compliance~Indications for endotracheal intubation (ETI) are at least one of the following:~* Respiratory or cardiac arrest~* Coma~* Hemodynamic instability"
224159029|NCT04773847|PROCEDURE|Surgical reconstruction of maxillofacial osseous defect with MimetikOss 3D.|Surgical reconstruction of maxillofacial osseous defect with MimetikOss 3D.
224159030|NCT02050451|DIETARY_SUPPLEMENT|Ensure Plus®|
224159031|NCT02050451|DIETARY_SUPPLEMENT|Multivitamin|
224159032|NCT02565953|DEVICE|Paclitaxel-releasing PTA balloon catheter|
224159033|NCT02565953|DEVICE|PTA balloon catheter|
224159034|NCT04437680|DEVICE|Votiva device|A retrospective chart review of the medical records
224159035|NCT01350011|BEHAVIORAL|Innovative System|In IS, they will receive motivational counseling at months 3,6,12, and 18. If they decide to quit smoking they will be offered up to 10 sessions of behavioral counseling and access to NRT (nicotine patch and gum) If they relapse on NRT, they will be offered varenicline, if it is not contraindicated.
224159036|NCT01350011|BEHAVIORAL|Standard Treatment Control (STC)|Participants will receive self help information and referrals for counseling and for pharmacological treatment.
223468024|NCT06298357|BEHAVIORAL|Immediate Start - Virtual Reality|Participants will use a Meta Quest virtual reality headset and play video games for exercise and mindfulness. They will start using the headsets in the hospital and then will continue to do so for 8 weeks after hospital discharge.
223468025|NCT06298357|BEHAVIORAL|Delayed Start - Virtual Reality|Participants will receive usual care in the hospital and outside of the hospital for 8 weeks. After the 8 week post-discharge period, participants will use a Meta Quest virtual reality headset and play video games for exercise and mindfulness for an 8 week period.
223468026|NCT06384027|OTHER|Non-invasive ventilation|Ventilation support that does not require an artificial airway that aims to reverse respiratory muscle fatigue and decrease the work of the respiratory muscles, maintaining a positive pressure, allows alveolar recruitment, preventing atelectasis and airway collapse. NIV can be administered using continuous positive airway pressure (CPAP) or two levels of airway pressure (Bi-level).
223468027|NCT05067972|DRUG|PF-07260437|B7-H4 x CD3 bi-specific mAb
223468028|NCT05067972|DIAGNOSTIC_TEST|B7-H4 IHC|B7-H4 expression
223468029|NCT05608304|BEHAVIORAL|Formal mindfulness induction|The formal mindfulness induction will consist of a 10-minute audio recording of a sitting meditation, guiding the participant to consciously and repeatedly bring their attention to their breath and inner experience with nonjudgmental acceptance.
223468030|NCT05608304|BEHAVIORAL|Informal mindfulness induction|The informal mindfulness induction will consist of on-screen instructions guiding participants through the completion of four routine tasks (washing hands, drinking water, laying down, listening to music) with mindful awareness and acceptance over the course of 10 minutes.
223578237|NCT00183378|BEHAVIORAL|Routine Medical Care with Education|The therapist provides information about the nature of sleep changes in people with Alzheimer's disease, general information about treatments for insomnia, and caregiver support. Participants are free to use whatever medical services they wish during study participation.
224159037|NCT01877824|OTHER|Fast-track training|
223578238|NCT03094078|OTHER|News item with spin|Interpretation of news item with spin
223578239|NCT03094078|OTHER|News item without spin|Interpretation of news item without spin
223578240|NCT04757688|RADIATION|Cardiac radioablation (CRA)|CRA to 25 Gy in 1 fraction
224159038|NCT05818072|PROCEDURE|One biopsy|To do one biopsy at the proximal part of the longest columnar-lined esophagus.
224159039|NCT05818072|PROCEDURE|Three biopsy|To do three biopsy at the proximal, middle and distal part of the longest columnar-lined esophagus.
224159040|NCT05818072|PROCEDURE|Seattle protocol|To do 4-quadrant biopsy every 1-2 cm at the esophagogastric junction. Seattle protocol has been considered as the gold standard biopsy protocol for patients with suspected Barrett's Esophagus.
224159041|NCT05818072|DEVICE|Endoscopy|The participants will receive meticulous endoscopic examination with narrow-band imaging.
224159042|NCT01237301|DEVICE|CGM Group|Using CGM unblinded for 16 weeks versus fingersticks 4 to 7 times a day to evaluate which is more beneficial in type 2 diabetes.
224159043|NCT01237301|DEVICE|SMBG Group|Fingersticks 4 to 7 times a day to evaluate which is more beneficial in type 2 diabetes. Used CGM blinded once every four weeks.
224159044|NCT04888728|DRUG|DWN12088|Prolyl-tRNA synthetase (PRS) inhibitor
224159045|NCT04888728|DRUG|Nebivolol|Nebivolol
224159046|NCT04888728|DRUG|Paroxetine|Paroxetine
223468031|NCT05608304|BEHAVIORAL|Active control task|Participants assigned to the active control condition will be prompted to download a single-page document containing 100 letters, numbers, and symbols, and a grid of 100 boxes. Following along with a guided audio, participants will be instructed to place all of the characters in the grid in a specific order over the course of 10 minutes. A version of this task has been used in previous studies by our team (Carsley \& Heath, 2019; Petrovic et al., 2022) and has been shown not to impact mindfulness levels, and was thus deemed an appropriate neutral attention task for this study.
223468032|NCT04154514|DEVICE|A functional electrical stimulation device for post-stroke rehabilitation|Most of the FDA-approved commercial FES devices deliver therapy that targets specific kinematic impairment in the step cycle (e.g., foot drop). Our device will be unique in that it can stimulate many muscles around multiple joints for a more comprehensive and naturalistic restoration of lower-limb motor functions.
223468033|NCT05217108|DEVICE|FitBit|All participants in each study group will receive a Fitbit. Participants will be asked to wear a Fitbit every day for 8 weeks to record the number of steps you take
223468034|NCT00000411|PROCEDURE|Decompressive laminectomy|Removal of the hypertrophic inferior and superior articular facets will be performed when they are intruding upon the midline and causing both central and lateral recess stenosis.
223468035|NCT00000411|OTHER|Non-surgical treatments|Active physical therapy modality, Education/Counseling with home exercise instruction, and an NSAID if tolerated
223468036|NCT06380062|OTHER|Plasma concentration of choline|The exposure in this observational study is plasma concentrations of choline
223468037|NCT03666247|BEHAVIORAL|HealthMindr Application|From baseline to 3-month post-test, participants in the intervention arm are granted access and instructed to interact regularly with the HealthMindr messaging platform. The HealthMindr messaging platform delivers messages relevant to both general audiences of sexually-active MSM, as well as messages relevant only to specific subgroups of HIV-positive men, and currently higher and lower risk HIV-negative men. Answers provided during the assessments determine which subset of messages are delivered to app users, with information such as HIV status, changes in self-reported risk behaviors, or other factors that influence the relevance of any given message. The HealthMindr application also offers free condoms, lube, and a HIV and STI testing kits.
223468038|NCT03666247|BEHAVIORAL|Waitlist|Participants assigned to the waitlist-control arm will be given a welcome sheet orienting them to the study. The message they view will include the same resources links provided to the intervention arm. The information will cover the importance of testing, links to an online mapping tool about the HIV epidemic in the United States (AIDSVu) and resources to locate HIV testing services and prevention information in their area. No information recommending frequency of testing will be given in the welcome greeting.
223468039|NCT05448742|DEVICE|Biplanar PSI slope-reducing MOWHTO.|High tibial osteotomy (HTO) is a widely performed procedure in case of varus knee with medial compartment osteoarthritis (OA), with medial-opening wedge version performed more often than lateral-closing wedge one. While in most cases the goal of medial-opening wedge HTO (MOWHTO) is isolated correction of coronal limb alignment, intentional or unintentional increase of posterior tibial slope (PTS) after MOWHTO can occur, however its extent is usually limited and depends on accurate hinge axis placement. One of the ideas developed to improve accuracy of hinge axis placement and accuracy of biplanar correction are Patient-Specific Instruments (PSI). Our intervention is novel, biplanar, medial-opening wedge, posterior tibial slope-reducing high tibial osteotomy aided by PSI, with tibial tuberosity serving as hinge axis.
223468040|NCT04391842|COMBINATION_PRODUCT|Sustained Acoustic Device with 1% Diclofenac patch|"Patients apply the Sam Ultrasonic Diathermy Device daily for 4 hours of continuous therapeutic ultrasound at 3 megahertz (MHz) frequency and 0.132 Watts/cm2 with 1% diclofenac patch~Other Names:~* ZetrOZ ultrasound device~* wearable ultrasound device~* long duration ultrasound~* LITUS device~* long duration low intensity device"
223468041|NCT05135936|BEHAVIORAL|Hyperthermia Group|The first hyperthermia treatment of the series is carried out for the second aptitude test, directly following the randomisation in the intervention group at the Hospital for Naturopathy and Integrative Medicine in Bamberg. The hyperthermia treatment is then carried out in a cycle of two treatments per week, with at least one day in between, over a period of three weeks, according to the manufacturer's instructions. According to the guidelines, the rectal (possibly vaginal) temperature (as body core temperature), heart rate and oxygen saturation (Sp02) are continuously determined during the hyperthermia treatment. During the treatment, continuous supervision by trained personnel is guaranteed, and a doctor is on call.
223468042|NCT05135936|BEHAVIORAL|Sham-Group|The number of treatments is equal to the number of treatments in the intervention group.
223468043|NCT00223002|DRUG|Chlorhexidine|sample collected at time of procedure and then analysed for bacterial contamination
224068411|NCT02837315|BEHAVIORAL|Substance-Free Activity Session (SFAS)|The clinician initiates a discussion of the student's college and career goals. Students discuss the values that motivate them as well as how marijuana use may interfere with their ability to accomplish these goals. Students then receive information on graduation rates and income benefits for those who attend and excel in college. They receive personalized feedback on (a) the requirements for their major and intended career, (b) a list of extracurricular activities tailored to their goals, (c) a graph showing time they allocate to their activities, (d) information on stress and depressive symptoms (if applicable) and possible adaptive coping responses and (e) a list of substance-free recreational activities in which they would like to start or continuing engaging.
224068412|NCT02837315|BEHAVIORAL|Relaxation Session|The session includes a clinician-led diaphragmatic breathing exercise, followed by a progressive muscle relaxation protocol (\~30 minutes). At the end of the session, students are asked about their reaction to the relaxation techniques and are provided with relaxation training handouts.
224068413|NCT00746252|DRUG|risperidone|Children will have a flexible dose titration based on their unique response to the medication (assessed using clinical global improvement scores). Children will be treated for six months using daily, bid dosing.
224068414|NCT00746252|DRUG|aripiprazole|children will have a flexible dosing titration based on their unique response (assessed using clinical global improvement scores). Children will be treated with daily medication for six months.
224068415|NCT02242955|DRUG|Diazepam|40 mg per day.
224068416|NCT01240642|DRUG|ASA404|
224068417|NCT00935168|DRUG|6% Hydroxy-ethyl starch (130/0.4)|Maximum dose of 50ml/kg/day of 6% hydroxy-ethyl starch (130/0.4) for intravascular volume fluid resuscitation
224068418|NCT00935168|DRUG|Saline|Maximum dose of 50ml/kg/day of saline for intravascular volume fluid resuscitation
223468044|NCT04296708|OTHER|Exergame Training|An exergame combines exercise and gaming in a holistic approach.
223578241|NCT02501720|PROCEDURE|post burn flexion contractures release under tourniquet control|post burn flexion contractures will be released under tourniquet control
223578242|NCT02501720|PROCEDURE|post burn flexion contractures release using tumescent solution|post burn flexion contractures will be released using tumescent solution
223578243|NCT02501720|PROCEDURE|Contracture release and application of FTSG|Post burn flexion contractures will be released and full thickness skin graft(FTSG) will be applied.
223578244|NCT03586323|DRUG|superior laryngeal nerve block with lidocaine|SLNB was performed with 4 ml of 1.5% lidocaine below the thyroid membrane
223578245|NCT02078102|DRUG|Meloxicam|15 mg tablets of Meloxicam will be taken orally in the morning, with or without food.
223578246|NCT02078102|DRUG|Filgrastim|Filgrastim will be subcutaneously injected in one or two sites at home.
223578247|NCT01011803|OTHER|Combined speech therapy tools, measures of swallowing function|All subjects will be assessed using combined speech therapy tools and ordinal measures of swallowing function. The combined speech therapy tools were \[diadochokinesis, glottal coup, and the Consensus Auditory-Perceptual Evaluation of Voice (CAPE-V)\]. The ordinal measures of swallowing function included Dysphagia Admission Screening Tool (DAST), Modified Barium Swallow (MBS), and Fiberoptic Endoscopic Evaluation of the Swallow (FEES).
223578248|NCT02042534|DRUG|Rivaroxaban|"Rivaroxaban group receive oral rivaroxaban 10 mg once daily for 5 consecutive days, followed by 20 mg or 15 mg in patients with a calculated creatinine clearance of 30-49 ml/min.~The dosage of rivaroxaban is leveraged from results of ROCKET-AF trial, where 20 mg of rivaroxaban was shown to offer balanced efficacy and safety."
223578249|NCT02042534|DRUG|Warfarin|To harmonize the warfarin regimen across the sites, fixed algorithm was used in dose calculation, both loading and maintenance, and age, sex, ethnicity, race, weight, height, smoking history, presence of liver disease, indication, baseline INR, target INR and concomitant medication were considered as cofactors (http://www.warfarindosing.org/Source/InitialDose.aspx). Investigators will manage anticoagulation with warfarin per routine clinical care.
224159047|NCT05305001|GENETIC|Invitae Multi-Cancer Panel ®|Participants will have genetic testing.
224159048|NCT01570062|DEVICE|HEPA Filter|"Two HEPA filters will be placed in participant's homes (one in the bedroom and one in the main living area); each HEPA will run for 2 consecutive 7-day sampling sessions. During one of the 7-day sampling sessions, the HEPA filter will run without the internal filter in place (i.e., placebo filtration)."
224159049|NCT01570062|DEVICE|HEPA Filtration Placebo|for one of the two 7-day sampling sessions, both HEPA filters placed in participants' homes will be run without the actual filter in the housing unit.
224159050|NCT00368472|DRUG|Perampanel|Perampanel 2 mg to 12 mg, once daily during the OLE study
224159051|NCT04261881|DIETARY_SUPPLEMENT|ATP-Fuel|5 capsules daily with breakfast and 5 capsules daily with lunch
223468045|NCT00006146|BIOLOGICAL|Approved influenza virus vaccine.|
223578250|NCT00035360|DRUG|PEG-Intron|
223578251|NCT01657136|DRUG|Ivabradine|comparison of different drugs
223578252|NCT01657136|DRUG|Beta blocker|comparison of different drugs
223578253|NCT01905722|OTHER|3 Tesla|3 Tesla scanning with intravenous infusion of tracers
223578254|NCT01905722|OTHER|7 Tesla|7 Tesla scanning with intravenous infusion of tracers
224159052|NCT04261881|DIETARY_SUPPLEMENT|ATP-II|3 capsules daily with breakfast
224159053|NCT04261881|DIETARY_SUPPLEMENT|ATP-II|3 capsules daily with breakfast and 3 capsules daily with lunch
224159054|NCT00728663|BIOLOGICAL|cetuximab|"Cetuximab: 400 mg/m2 initial dose on day 1, then 250 mg/m2 weekly starting on day 8~\--- for max. 24 weeks or until progression or unacceptable toxicity ---"
224159055|NCT00728663|DRUG|docetaxel|"75 mg/m2 day 1 of a 21 day cycle or 35 mg/m2 day 1,8,15 of a 28 day cycle~\--- for max. 24 weeks or until progression or unacceptable toxicity ---"
224159056|NCT01579149|DRUG|plerixafor|Single subcutaneous (SC) dose of plerixafor (160 μg/kg, 240 μg/kg, or 400 μg/kg),
223468046|NCT00637026|DRUG|Gefitinib|Iressa
223468047|NCT03337620|DEVICE|Tx360|Tx360 used to deliver active and placebo drug interventions to SPG.
223468048|NCT02287038|DRUG|Atomoxetine 80 MG|Subjects will be randomized and assigned by the study investigator into crossover group 1 (Atomoxetine 80mg at Phase I, then placebo at Phase II) or group 2 (placebo at Phase I, then Atomoxetine at Phase II) with both placebo and medication administered through pharmacy. There was a 1-week interval between the two phases.
223468049|NCT00417664|DRUG|Dexmedetomidine|Dexmedetomidine administered as part of anesthesia in cardiac surgery patients
223468050|NCT00417664|DRUG|Propofol|Propofol administered as part of anesthesia in cardiac surgery patients
223468051|NCT00417664|DRUG|Midazolam|Midazolam administered as part of anesthesia in cardiac surgery patients
223578255|NCT01960543|DRUG|fentanyl 15 microg|
223578256|NCT01960543|DRUG|Bupivacaine 7 mg|
223578257|NCT01960543|DRUG|Bupivacaine 9 mg|
223578258|NCT01960543|DRUG|Levobupivacaine 7 mg|
223578259|NCT01960543|DRUG|Levobupivacaine 9 mg|
223578260|NCT02418208|DIAGNOSTIC_TEST|Performint EEG tests and BNA analysis|
223578261|NCT00642148|DRUG|GW856553|Active tablet
223578262|NCT00642148|DRUG|Placebo|Placebo tablet and inhaler
223578263|NCT00642148|DRUG|Seretide|Active comparator inhaler
223578264|NCT01533090|DRUG|polyethylene glycol (PEG)|SELG-ESSE 1000 4 L: 2L THE DAY BEFORE OF COLONOSCOPY AND 2 L THE SAME DAY OF COLONOSCOPY
223578265|NCT01533090|DRUG|PEG low volume with bisacodyl|Lovolesse + Lovoldyl 2L of Lovolesse with 2 or 3 tablets of bisacodyl the day before of colonoscopy or 2L of Lovolesse with 2 or 3 tablets of bisacodyl the same day of colonoscopy
224068419|NCT00082888|OTHER|Laboratory Biomarker Analysis|Correlative studies
224068420|NCT00082888|DRUG|Tipifarnib|Given PO
224068421|NCT01549236|DRUG|Benznidazole 12,5mg or 100mg|"All 80 subjects recruited into the study will receive treatment with:~\- Benznidazole (Laboratório Farmacêutico do Estado de Pernambuco -LAFEPE - Recife - Brazil; tablet 12.5mg or 100mg), 7.5 mg/Kg/day PO (actual range of 5.5-8.5 mg/Kg/d), divided in two daily doses, for 60 days."
224159057|NCT01579149|DRUG|Placebo|Single subcutaneous (SC) dose of placebo
223468052|NCT03821987|DRUG|Fludarabine|Patients enrolled in this study would receive Bu (IV)0.8mg/kg Q6hx2d,Fludarabine 30mg/m2x5d ,CTX (cyclophosphamide) 25mg/kg/dx4d,rATG (thymoglobulin,Sang Stat,France) 2.5mg/kg/dx4d.
223468053|NCT02874313|DEVICE|Continuous positive airway pressure|Nocturnal continuous positive airway pressure by a nasal mask. CPAP pressure will be automatically titrated using a AutoSet device (ResMed).
223468054|NCT02874313|DRUG|Pharmacological treatment|Conventional pharmacological treatment with oral antidiabetic drugs or insulin
223468055|NCT02874313|OTHER|Conventional anti-diabetic diet recommendations|
223468056|NCT00010504|PROCEDURE|Acupuncture|
223468057|NCT06517433|DRUG|upifitamab rilsodotin|"XMT-1536 will be administered once every 28 days until disease progression, unacceptable toxicity, or either the patient or study physician determines it is in the best interest of the patient to discontinue participation in the study.~For sites participating in the sub-study, patients with platinum -resistant ovarian cancer will have the option to enroll in this sub-study to evaluate potential changes in the QTc interval following administration of XMT-1536"
223468058|NCT02731300|DEVICE|tDCS|brain stimulation by cathodal electrode at motor cortex
223468059|NCT03481452|BEHAVIORAL|psychotherapy|NBO is an infant-focused, family relationship-based intervention measure, which aims to exhibit to parents infants' surprised ability, understand infants' strength and aspects needed to be improved, strength parents' parenting confidence, and promote sound development of infant-mother relationship.
223468060|NCT02713178|DRUG|bupivacaine liposome injectable suspension|bupivacaine liposome injectable suspension 133 mg expanded with normal saline to 20 mL or 266 mg in 20 mL
223578266|NCT03093974|DRUG|CMS|"1 MIU equivalent to 80 mg colistimethate sodium diluted in 1 mL saline solution 0.45%. Investigational Medicinal Product (IMP) glass vials were shrink wrapped in opaque white plastic and provided in boxes of 30 vials (two weeks of b.i.d dosing).~The 1 MIU/mL CMS/0.45% saline solution was transferred from the glass vial into a specific nebuliser system fitted with a 0.3 mL medication chamber, for administration by inhalation. This delivered a nominal dose of 0.3 MIU/24 mg CMS (\~10 mg CBA) from the device.~The first dose of the IMP was administered at the site under the supervision of the site staff and subjects were instructed how to prepare and self-administer the IMP at home via a specific nebuliser system, b.i.d (morning and evening) over a period of 12 months.~At least 10 minutes (min) before each administration, an inhaled short-acting bronchodilator (e.g., salbutamol /albuterol), supplied by the Sponsor, could be taken to improve tolerability."
223578267|NCT03093974|OTHER|Placebo|1 ml saline solution 0.45%. the placebo was made up of identical empty glass vials to which the same saline diluent was added in exactly the same way as the reconstitution of the active treatment by injecting the diluent through the rubber stopper. The glass vials were shrink wrapped with opaque white plastic to maintain the blind.
224068422|NCT03874377|BEHAVIORAL|Mindfulness|Mindfulness refers to the experience of paying attention to the present moment in a nonjudgmental manner. The mindfulness intervention consists of 6 weekly sessions focused on: experiential mindfulness exercises, such as mindful eating, loving kindness practices, breath awareness, and mindful movement; hunger and satiety awareness; improving responses to emotions; practicing acceptance and being non-judgmental; and tolerating negative feelings and sensations, including those related to hunger and cravings. Participants will be assigned brief homework exercises (approximately 10 minutes) daily in between appointments.
223468061|NCT02713178|DRUG|Placebo|Normal saline.
223468062|NCT01067534|DRUG|Salbutamol|Inhaler salbutamol 0,1 mg/dose - 4 doses=0,4 mg
223468063|NCT04652557|DRUG|Fampridine SR|Fampridine SR is an inhibitor of voltage gated potassium channels and is approved in Switzerland for treatment of gait problems in patients with Multiple Sclerosis (MS).
223468064|NCT04652557|DRUG|Placebo|no active component
223468065|NCT04485728|BEHAVIORAL|Sleep Improvement Protocol Intervention for Hospitalized Antepartum Patients|Patients are getting sleep hygiene education and a sleep hygiene kit.
223468066|NCT00002314|DRUG|Ro 24-7429|
223468067|NCT05717712|BIOLOGICAL|Ad-TD-nsIL12|After stereotactic biopsy, the Ommaya reservoir will be inserted through the biopsy channel and two injections of Ad-TD-nsIL12 will be delivered after surgery by Ommaya reservoir (with an interval of 3 days). The interval between following injections in the subsequent treatment period will be 3 weeks ±4 days. The assigned dose for each patient will be 3x10\^9vp, 1x10\^10vp or 3x10\^10 vp suspended in 1 ml NS according to cohort design.
223468068|NCT01298167|DEVICE|Cyanoacrylate tissue glue versus Fast absorbing gut|All wounds will be closed using a linear, bilayered closure method, where the buried intradermal absorbing suture (5-0, Polysorb) will be placed along the length of the incision, consistent with standard surgical procedure. Only patients with wounds with a length of 3cm or greater will be enrolled. Each wound will be measured, and the length divided in half. Half of the surgical wound will be randomly selected (by coin toss) for epidermal reapproximation with cyanoacrylate, whereas the other half will be repaired with 6-0 fast absorbing gut suture in standard running fashion.
223468069|NCT00174200|DRUG|Risperidone 2 mg|
223468070|NCT02606240|DEVICE|CO2 removal with PRISMALUNG in ARDS|Observational study of patients with mild to moderate Acute Respiratory Distress Syndrome (ARDS) submitted to Extracorporeal CO2 removal (ECCO2R) with the PRISMALUNG device to allow ultraprotective mechanical ventilation with tidal volume reduction (from 6 to 4 ml/kg, predicted body weight) and plateau pressure reduction from 28-30 to 23-25 cmH2O.
223468071|NCT05537311|BEHAVIORAL|Social Engagement|30-45 minutes of social engagement provided to patients in ICU. Social engagement strategies including meaningful conversation, cognitive stimulation, and emotional support
223468072|NCT00924846|PROCEDURE|High frequency oscillatory ventilation|Mechanical ventilation as high frequency oscillatory ventilation for 8h periods
223468073|NCT04007328|DRUG|Methylprednisolone Sodium Succinate|methylprednisolone vial
223468074|NCT04007328|DRUG|Placebo|Normal saline manufactured to mimic methylprednisolone vial
223468075|NCT01834339|BIOLOGICAL|AlloDerm|
223468076|NCT01834339|BIOLOGICAL|EVPOME|
223468077|NCT03651817|DEVICE|Mechanical ventilation|Patients will be ventilated with anesthesia machine according to the group they belong to
223468078|NCT06354218|DRUG|Serplulimab|Serplulimab （4.5mg/Kg every 3 weeks）
223468079|NCT00280592|DRUG|Cranberry|Dry essence of cranberry presented as 18 mg of proanthocyanidines sachets of powdered cranberry. Cranberry juice is administered twice a day (in the morning and in the evening).
224159058|NCT02384993|BEHAVIORAL|Enhanced Physical Activity|This is a 26-week aerobic exercise intervention. The primary mode of training is treadmill walking, with the initial speed and duration calibrated to each participant's baseline aerobic capacity. Participants will train 3-4 days per week with the goal of attaining 150+ minutes of exercise per week by the seventh week. Exercise will be set between 50-60% of maximum heart rate reserve for weeks 1-4, 60-70% for weeks 5-8, and 70-80% for weeks 9-26. Exercise duration will be approximately 15-20 minutes per session during the first week and then increase by 5 minutes each week until a duration of approximately 38-50 minutes per session is reached. Each training session will begin with a 5-minute warm-up and end with a 5-minute recovery period.
224159059|NCT00349037|BIOLOGICAL|Trivalent DNA vaccine with and without pPJV2012 administered by PMED|
224159060|NCT00044213|DRUG|EDTA|Participants will receive 40 infusions of standard chelation solution.
224159061|NCT00044213|DRUG|EDTA Placebo|Participants will receive 40 infusions of EDTA placebo.
224159062|NCT00044213|DIETARY_SUPPLEMENT|High Dose Vitamin|
224303707|NCT00306150|DRUG|Trasylol (Aprotinin, BAYA0128)|Subjects will be randomized to receive an infusion of aprotinin (a test dose followed by a loading dose of 2 million KIU before skin incision followed by 500,000 KIU/hour until the end of surgery) or matching placebo. The maximal dose of aprotinin, that can be administered is 7,000,000 KIU, regardless of the duration of the operation. When a total of 7 million has been reached the administration of aprotinin must be discontinued.
224303708|NCT00306150|DRUG|Placebo|Placebo is used according to the description of Arm 1
224303709|NCT02833376|OTHER|alcohol antisepsis|
224303710|NCT02833376|OTHER|chlorhexidine antisepsis|
224303711|NCT02680431|OTHER|Blood sample|10 mL venous blood sample for analysis of plasma
224303712|NCT03583632|OTHER|visual acuity testing|testing of visual ycuity by ETDRS charts
224303713|NCT03583632|DEVICE|optical coherence tomography|optical coherence tomography generates sectional slides of the retinal tomography with light
224303714|NCT02410356|DRUG|TV-1106|The volume necessary to provide the required weekly dose will be calculated by the investigator; dose will be adjusted for IGF-I in the normal range.
224303715|NCT02410356|DRUG|dGH|The dose levels of dGH will be the same as the stable rhGH dose taken prior to the study.
224303716|NCT01394952|DRUG|Dulaglutide|Administered subcutaneously
224303717|NCT01394952|DRUG|Placebo|Administered subcutaneously
224303718|NCT00093600|DRUG|cytarabine|
223468080|NCT00280592|DRUG|Placebo|Placebo presented as sachets of powder. Placebo juice is administered twice a day (in the morning and in the evening).
223468081|NCT02408198|BEHAVIORAL|Anxiety intervention|The intervention is based on a brief CBT for psychosis (CBTp) programme, focusing on understanding and managing anxiety processes that contribute to persecutory threat beliefs when in busy urban environments. The novel aspect of this intervention is that it is delivered in a group format. The intervention consists of six sessions which will be delivered on a weekly basis. Throughout the intervention there is an emphasis on setting tasks to practice applying the new skills outside of sessions, to help the person build confidence in being able to manage paranoia and feel less distressed in their daily life.
223468082|NCT01016145|DRUG|Antipsychotics|Quetiapine 25-800 mg; ziprasidone 80-160 mg; olanzapine 5-20mg; risperidone 2-8 mg; aripiprazole 15-30 mg
224159063|NCT00044213|DIETARY_SUPPLEMENT|High Dose Vitamin Placebo|
224159064|NCT01960504|DEVICE|Percutaneous Coronary Intervention (DREAMS) stenting|
224159065|NCT01529619|DRUG|Rivastigmine transdermal patch|
224159066|NCT02814136|PROCEDURE|Ablation|
224159067|NCT01507571|OTHER|Dignity Therapy|"Dignity Therapy is a brief psychotherapeutic intervention consisting of:~1. a tape-recorded session with the patient using the DT question protocol~2. Transcription of the interview, which is then edited~3. A session where the edited transcript is returned to the patient who can give it to family members or friends.~If needed, one or more sessions are added. Dt allows the patient to give voice to the matters of importance concerning himself and his loved ones. Its purpose is to enhance sense of meaning, purpose and worth. It also gives the opportunity to leave something behind to be remembered by."
224303719|NCT00093600|DRUG|daunorubicin hydrochloride|
224303720|NCT00093600|DRUG|midostaurin|
224303721|NCT06412588|DRUG|Vonoprazan+amoxicillin+doxycycline+bismuth for 14 days|Group A:The patient was treated with oral Vonoprazan 20 mg, bid + amoxicillin 1.0 g, bid + doxycycline 0.1 g, bid + bismuth for 14 days.
224303722|NCT06412588|DRUG|Vonoprazan+Amoxicillin|Group B: Patients were treated with oral Vonoprazan 20mg, bid + amoxicillin 1.0g, bid for 14 days.
224303723|NCT06412588|DRUG|Vonoprazan+doxycycline|Group C: Patients were treated with oral Vonoprazan 20 mg, bid + doxycycline 0.1 g, bid for 14 days.
224303724|NCT01587937|OTHER|Antibiotic stewardship audit-and-feedback to prescribers of patients receiving 3rd or 10th day of targeted broadspectrum antibiotics|See primary outcome for list of targeted drugs. See citations for previous publications describing the intervention.
224303725|NCT01986010|BIOLOGICAL|V160 Low Dose IM|V160 administered as a 0.75 mL intramuscular injection
224303726|NCT01986010|BIOLOGICAL|V160 Medium Dose IM|V160 administered as a 0.75 mL intramuscular injection
224303727|NCT01986010|BIOLOGICAL|V160 High Dose IM|V160 administered as a 0.75 mL intramuscular injection
224303728|NCT01986010|BIOLOGICAL|V160 Medium Dose plus Merck Aluminum Phosphate Adjuvant (MAPA) 225 µg /dose IM|V160 plus MAPA administered as a 0.75 mL intramuscular injection
224303729|NCT01986010|BIOLOGICAL|V160 High Dose plus MAPA 225 µg /dose IM|V160 plus MAPA administered as a 0.75 mL intramuscular injection
224303730|NCT01986010|BIOLOGICAL|V160 Maximum Dose IM|V160 administered as a 0.75 mL intramuscular injection
224303731|NCT01986010|OTHER|Placebo IM|Placebo administered as a 0.75 mL intramuscular injection
224303732|NCT01986010|BIOLOGICAL|V160 Medium Dose ID|V160 administered as a 0.1 mL intradermal injection
224303733|NCT01986010|OTHER|Placebo ID|Placebo administered as a 0.1 mL intradermal injection
224303734|NCT05832528|OTHER|Low-FODMAP diet|6-week Low-FODMAP diet in patients with functional dyspepsia
224303735|NCT05666219|DRUG|Aminophylline Injection|Injection Aminophylline IV 240 mg will be given over 10 minutes. After 1 hour, Aminophylline 240 mg second dose will be given over 10 minutes.
224303736|NCT01335997|DRUG|ER niacin/laropiprant (ERN/LRPT)|ER niacin 1 g/laropiprant 20 mg oral tablet taken once daily
223468083|NCT01016145|DRUG|Antipsychotics|Haloperidol 2,5-10 mg; chlorpromazine 25-600 mg.
223468084|NCT06005363|DRUG|Dexmedetomidine|dexmedetomidine infusion
223468085|NCT06005363|DEVICE|anesthesia depth monitoring|intraoperative anesthesia depth monitoring to keep BIS 40-60
223468086|NCT00183651|BEHAVIORAL|Standard dialectical behavior therapy (SDBT)|Standard DBT includes: 1) individual DBT therapy (1 hour per week), 2) DBT group skills training (2.5 hours per week), 3) telephone consultation (as needed), and 4) therapist consultation team (1 hour per week).
223468087|NCT00183651|BEHAVIORAL|Individual DBT with no DBT group sessions (DBT-I)|Individual DBT (DBT-I) is 1 hour per week of individual therapy and 2.5 hours per week with the psychosocial activities group.
223468088|NCT00183651|BEHAVIORAL|Group Skills DBT with no DBT individual sessions (DBT-S)|DBT group skills training is 2.5 hours per week and includes individual case management.
223468089|NCT03338764|DRUG|SM-1|SM-1 3-drug combination product containing 50-mg diphenhydramine, 5-mg delayed-release zolpidem and 0.5-mg delayed-release lorazepam self-administered as needed to promote sleep
223468090|NCT03338764|DRUG|Placebo|Identical in appearance to SM-1 and has the same excipients, but no active ingredients or delayed-release coating materials, self-administered as needed to promote sleep
223468091|NCT00596271|BIOLOGICAL|IC51|
223468092|NCT00596271|BIOLOGICAL|HAVRIX|
223468093|NCT00596271|OTHER|Placebo|
223468094|NCT00953290|DEVICE|Cutera Radio Frequency Device|Up to three treatments, one pass, dosage range of 15-60 kJ.
223468095|NCT01105312|DRUG|letrozole|
223468096|NCT01105312|DRUG|panobinostat|
223468097|NCT01105312|GENETIC|RNA analysis|
223468098|NCT01105312|GENETIC|microarray analysis|
223468099|NCT01105312|GENETIC|reverse transcriptase-polymerase chain reaction|
223468100|NCT01105312|OTHER|enzyme-linked immunosorbent assay|
223468101|NCT01105312|OTHER|immunohistochemistry staining method|
223468102|NCT01105312|OTHER|laboratory biomarker analysis|
223468103|NCT05358548|DRUG|Paclitaxel|Is a chemotherapy drug. Used to treat kinds of cancer, as determined by the doctor
223468104|NCT05358548|DRUG|Pemetrexed|Is a chemotherapy drug. Used to treat kinds of cancer, as determined by the doctor
223468105|NCT05358548|DRUG|5Fluorouracil|Is a chemotherapy drug. Used to treat kinds of cancer, as determined by the doctor
223468106|NCT05358548|DRUG|Carboplatin|Is a chemotherapy drug. Used to treat kinds of cancer, as determined by the doctor
223468107|NCT05358548|DRUG|Pembrolizumab|It is a type of immunotherapy and works by helping your immune system to kill cancer cells
223468108|NCT04866966|BEHAVIORAL|Shared medical appointments for weight loss|Shared medical appointments providing education and lifestyle change recommendations to promote weight loss in obese patients
223468109|NCT00441285|DRUG|Praziquantel|\- Praziquantel 50 mg / kg / d (up to 3600 mg / d ) for 10 days.
223468110|NCT00441285|DRUG|Albendazole|"* Albendazole 15 mg / kg / d ( up to 800 mg /d ) in Arm I for 10 days.~* Albendazole at an increased dose, 22.5 mg / kg / d (up to 1200 mg / d ), in Arm II for 10 days."
223468111|NCT00441285|DRUG|ABZ Placebo|\- Placebo (of Albendazole ) 7.5 mg / kg / d in Arm I and II for 10 days.
223468112|NCT00441285|DRUG|PZQ Placebo|\- Placebo (of Praziquantel) 50 mg / kg / d in Arm II and III for 10 days.
223468113|NCT01754064|DEVICE|Cardiac Rhythm Management device|
223468114|NCT00152607|PROCEDURE|donor right hepatic lobectomy|
223468115|NCT01533116|DRUG|BIA 9-1067|
223468116|NCT01533116|DRUG|Placebo|
223468117|NCT01533116|DRUG|levodopa/carbidopa|
223468118|NCT01533116|DRUG|levodopa/benserazide|
223468119|NCT03361241|OTHER|No Physiotherapeutic Intervention|"Experimental group will perform a balance training program in a virtual environment (using a gaming system with balance board device - eight games of Nintendo Wii Fit®, for 14 sessions) without verbal/manual physiotherapeutic intervention.~Initially, instructions about the rules and strategies of how to play the game and control the avatar will be provided.~Then the patient will be invited to start the game, and in the two attempts of the training no manual or verbal assistance will be provided. Physiotherapist participation during training will be restricted to ensuring patient safety, providing motivational verbal stimuli, and replicating the feedback provided by the game at the end of each attempt."
223468120|NCT03361241|OTHER|Physiotherapeutic Intervention|Control group will perform a balance training program in a virtual environment (gaming system with balance board device - eight games of Nintendo Wii Fit®, for 14 sessions) with verbal and manual physiotherapeutic intervention. Initially, instructions about the rules and strategies of how to play the game and control the avatar will be provided. Then the patient will be invited to start the game, and in the first attempt of the training physiotherapist will provide manual and verbal assistance, providing corrections on movement (avoiding compensatory movements). In the second attempt, no manual or verbal assistance will be provided (only ensuring patient safety, providing motivational verbal stimuli), allowing the patient to organize his or her performance.
223468121|NCT01351818|DRUG|Growth Hormone|
223468122|NCT05225545|DRUG|Sucrosomial Iron|Experimental Arm
223468123|NCT05225545|DRUG|Oral Iron|Active Comparator
223468124|NCT05252741|OTHER|serum samples and punch skin biopsies|we will take serum samples from psoriasis patients and healthy controls and skin punch biopsies from lesional and non-lesional areas in psoriasis patients.
223468125|NCT03024983|OTHER|Glucose|Glucose monohydrate (55 g) dissolved with 500 mL of water
223468126|NCT03024983|OTHER|Semolina soup|Semolina soup (322 g) eaten with 500 mL of water
223468127|NCT03024983|OTHER|Bread|Bread (122 g) eaten with 500 mL of water
223468128|NCT03024983|OTHER|Penne (fresh)|Cooked penne (132 g) eaten with 500 mL of water
223468129|NCT03024983|OTHER|Penne (dry)|Cooked penne (142 g) eaten with 500 mL of water
223468130|NCT03024983|OTHER|Spaghetti (dry)|Cooked spaghetti (142 g) eaten with 500 mL of water
223468131|NCT04826627|OTHER|glycemia|capillary glycemia
223468132|NCT06145126|OTHER|Prednisolone|Predisolone is used as a tool to elicit a physiological response (toolbox trial) and not as a pharmaceutical agent/treatment.
223468133|NCT06145126|OTHER|Placebo|Placebo to predinisolon
223578268|NCT00402714|PROCEDURE|extracorporeal photopheresis|Extracorporeal photopheresis (ECP) is the ex vivo exposure of the leukocyte rich fraction to ultraviolet light in the presence of 8-methoxypsoralen.
223468134|NCT06331663|DRUG|Remifentanil|first start with remifentanil 5.0 ng/ml, and use the up and down method as adjust 0.5 ng/ml of concentration of remifentanil each time. Inadequate antinociception (Surgical Pleth Index(SPI) \> 80 and hyperdynamics (the increased heart rate (HR) and mean blood pressure (MBP) above 20% of baseline or HR\>100bpm and arterial blood pressure(ABP)\>180/100mmHg)) is defined as failure, therefore we increase remifentanil by 0.5 ng/ml; otherwise, the setting is considered successful without abovementioned situations.
223468135|NCT03568578|DRUG|Entecavir 0.5 mg|Patients in this group will be given Entecavir 0.5 mg a day for 2 years.
223468136|NCT03568578|DRUG|Anluohuaxian Pill 12g|Patients in this group will be given Entecavir 0.5 mg and Anluohuaxian Pill 12g a day for 2 years
223468137|NCT03587064|DEVICE|Conventional 3-lead CRT defibrillator system implantation|Conventional 3-lead(1 atrial and 2 ventricular leads) system implantation
223468138|NCT03587064|DEVICE|2-lead CRT defibrillator system implantation|2-lead (2 ventricular leads with dipole for atrial sensing) DX system implantation
223468139|NCT03158168|DRUG|Candida Antigen|Candida Albicans Antigen injection
223468140|NCT03158168|DRUG|Zinc Sulfate|Zinc Sulfate injection
224159068|NCT00880607|DRUG|Intrathecal morphine|Morphine injection is a systemic narcotic analgesic for administration by the intravenous, epidural or intrathecal routes. It is used for the management of pain.
224159069|NCT00880607|DRUG|Extended Release Epidural Morphine|DepoDur™ is a preparation of extended release lipid encapsulated morphine and is used specifically for epidural injection, outside the spinal fluid, for postoperative pain. This study is a prospective randomized double-blinded trial examining the effectiveness of single dose intrathecal morphine versus single dose extended release epidural morphine for postoperative pain control in pediatric posterior spinal fusion patients.
224303737|NCT01335997|DRUG|ER niacin/laropiprant/simvastatin (ERN/LRPT/SIM)|ER niacin 1 g/laropiprant 20 mg/simvastatin 10 mg oral tablet taken once daily
223468141|NCT06310811|DRUG|RD06-04 Cells injection|Patient will be treated with RD06-04 cells when enrolled in the study
223468142|NCT00314158|DRUG|Brinzolamide 10 mg/ml + Timolol 5 mg/ml eye drops, suspension|One drop twice daily in each study eye for six months
223468143|NCT00314158|DRUG|Brinzolamide 10 mg/ml (AZOPT) eye drops, suspension|One drop twice daily in each study eye for six months
223468144|NCT00314158|DRUG|Timolol 5 mg/ml eye drops, solution|One drop twice daily in each study eye for six months
224068423|NCT03874377|BEHAVIORAL|Usual Care|Participants will receive the recommended standard of medical management of overweight and obesity. The clinic team conducts a comprehensive evaluation of the patient to assess dietary and activity behavior change needs of each patient and family, as well as obesity-associated comorbidities. In addition to management of comorbidities, goals for improved physical activity and dietary behaviors are set with the patient and family at each visit.
224068424|NCT04033835|OTHER|Mentalization Based Treatment-Introductory|Mentalization Based Treatment-Introductory
224068425|NCT04033835|OTHER|Treatment as usual|Treatment as usual
224068426|NCT05448872|DRUG|Sacubitril/Valsartan|HF patients treated with Sac/Val
224068427|NCT06299527|OTHER|Exercise Program|Exercise Program In our study, the telerehabilitation program was applied for both synchronous and asynchronous groups, 3 days a week, 1 session per day, for 8 weeks. The exercises were combined individually according to the person's capacity, and the intensity and duration of the exercise will gradually increase according to the patient's tolerance.
224068428|NCT04582578|DEVICE|CRT|The experimental group will be treated with CRT in addition to optimal medical therapy for HF. In addition, the trial will further compare two methods of delivering CRT. One experimental group will receive BiV-CRT, while the second experimental group will receive CS-CRT
224068429|NCT01659320|DRUG|Minocycline|Minocycline 100 mg twice daily for 8 weeks
224068430|NCT01871454|RADIATION|stereotactic ablative radiotherapy (SABR)|standard of care radiation therapy
224068431|NCT01871454|DRUG|Pentoxifylline|pentoxifylline
224068432|NCT06038786|BEHAVIORAL|Resilience Training|A 4 session group-based behavioral intervention which delivers the following skills: mindfulness, metallization, and self-compassion.
224068433|NCT02436850|PROCEDURE|Thoracentesis|An invasive procedure to remove fluid or air from the pleural space for diagnostic or therapeutic purposes.
224068434|NCT01870401|DEVICE|Lutonix DCB|
224068435|NCT01870401|DEVICE|Uncoated PTA Catheter|
224068436|NCT03506542|DEVICE|Ologen|Ologen implant placed over scleral flap during the surgery to avoid usage of Mitomycin C
224068437|NCT03506542|PROCEDURE|Phacotrabeculectomy|Trabeculectomy with cataract extraction
224068438|NCT03506542|DRUG|Mitomycin C|Mitomycin C 0.3 mg/ml for 3 minutes during the surgery (standard procedure)
224068439|NCT04623242|DRUG|Gantenerumab|Subcutaneously every 4 weeks at escalating doses
224068440|NCT04623242|DRUG|Solanezumab|Intravenous infusion every 4 weeks at escalating doses
224068441|NCT04623242|DRUG|Matching Placebo (Gantenerumab)|Subcutaneous injection of placebo every 4 weeks
224068442|NCT04623242|DRUG|Matching Placebo (Solanezumab)|Intravenous infusion of placebo every 4 weeks
224068443|NCT05096988|DIETARY_SUPPLEMENT|PKU sphere liquid|PKU sphere liquid will be prescribed by the study dietitian based on the patient's individual requirements.
224068444|NCT00820898|DRUG|Gemcitabine Hydrochloride|Given IV
224068445|NCT01826747|DRUG|crinone (progesterone 8%, vaginal application)|
224068446|NCT01000662|RADIATION|Daily Radiation Therapy|15 daily radiation fractions of 2.7 Gy, Monday to Friday for 3 weeks, to the whole breast with a daily concomitant boost of 0.5 Gy to the tumor bed, for a total daily dose of 3.2 Gy to the tumor bed (2.7Gy+0.5 Gy). The overall dose will be 40.5 Gy to the breast and 48.0 Gy to the tumor bed.
224068447|NCT01000662|RADIATION|Weekly Radiation Therapy|15 weekly radiation fractions of 2.7 Gy Monday to friday for three weeks to the entire breast with a Friday boost of 2.0 Gy to the tumor bed, for a total dose to the tumor bed on each friday of 4.7 Gy (2.7 Gy+ 2.0 Gy). The overall dose will be 40.5 Gy to the breast and 46.5 gy to the tumor bed.
224068448|NCT02503904|PROCEDURE|Concomitant Tumescent Antibiotic Delivery & IV Delivery|Concomitant subcutaneous infiltration of a dilute antibiotics (cefazolin and metronidazole) in a dilute solution of tumescent lidocaine and epinephrine at the site of a proposed surgical incision.
224068449|NCT02503904|DEVICE|Subcutaneous Tumescent Infiltration|Subcutaneous tumescent infiltration using HK tumescent infiltration cannulas and HK tumescent infiltration pump
223468145|NCT03898193|DRUG|Montelukast|Montelukast, 5 mg Chewable Tablets, manufactured by Pharmtechnology LLC, Republic of Belarus
224159070|NCT00128752|BEHAVIORAL|absorption and conversion of beta-carotene in human gastrointestinal (GI) tract|
224159071|NCT03933072|PROCEDURE|obtaining of autologous human olfactory bulb, autologous sural nerve preparation|The operative procedure will be aimed to obtain one of the patient's olfactory bulbs. The operation will be performed using a minimally invasive intracranial microsurgical endoscopy-assisted or transnasal endoscopic approach. During the same operation the patient sural nerve will be prepared for a future grafting.
224159072|NCT03933072|BIOLOGICAL|production of Glial Neuropatch|The human autologous olfactory ensheathing glia and olfactory fibroblast isolated from the olfactory bulb will be used for production of Glial Neuropatch in a laboratory facility in accordance with good manufacture procedures (GMP). The final Product will consist of the aforementioned cell suspension embedded with collagen scaffold. The European Medicines Agency/Committee for Advanced Therapies (EMA/CAT) considers that the Product Glial Neuropatch falls within the definition of a tissue engineered product of an advanced therapy medicinal product (decision EMA/CAT/293903/2018 from 22 June 2018: Scientific recommendation on classification of advanced therapy medicinal products Article 17 - Regulation (EC) No 1394/2007).
224159073|NCT03933072|PROCEDURE|microsurgical reconstruction of the transected spinal cord with autologous Glial Neuropatch-nerve bridges|The surgery will consists of laminectomy/laminotomy, midline durotomy above the area of spinal cord lesion, detethering of the spinal cord from fibrotic adhesions, resection of the posttraumatic spinal cord glial scar, delivering of cultured OEC/ONFs explants (Glial Neuropatch) to the area of spinal cord injury and finally bridging of the spinal cord gap by harvested autologous sural nerve grafts.
224159074|NCT02104141|DEVICE|ROIA Interbody Cage with VerteBRIDGE plating|
224159075|NCT00444418|DRUG|Naltrexone|Naltrexone, 100 mg. oral dosage, daily for 12 weeks.
224159076|NCT00444418|BEHAVIORAL|Modified Behavioral Self-Control Psychotherapy|Moderation- and cognitive-behaviorally-based psychotherapy. Treatment goal of moderation of alcohol consumption. 12 weekly, 1-hour sessions.
224303738|NCT01335997|DRUG|Simvastatin (SIM)|Simvastatin 10 mg oral tablet taken once daily
224303739|NCT01335997|DRUG|Placebo Run-In|Placebo matches both ER niacin 1 g/laropiprant 20 mg oral tablet and ER niacin 1 g/laropiprant 20 mg/simvastatin 10 mg oral tablet; placebo is taken once daily
224303740|NCT01335997|DRUG|SIM-matching placebo|Placebo for simvastatin 10 mg oral tablet taken once daily
224303741|NCT04368611|PROCEDURE|start with fundus|fundus first dissection then complete cholecystectomy as usual
224303742|NCT04368611|PROCEDURE|calot first dissection|start dissection by calot approach
223468146|NCT03898193|DRUG|Singulair|Singulair, 5 mg Chewable Tablets, marketed by Merck Sharp \& Dohme B.V., the Netherlands
223468147|NCT03856697|DRUG|Abivertinib Maleate Capsules|patients receive the test drug (Abivertinib maleate Capsules) since the first day of cycle 1. One cycle is defined as 21 days. The patient shall take the study drugs twice a day. The first dose is 3 capsules, and the second dose is 3 capsules. The drugs should be administered with water before or after meals.
223468148|NCT03856697|DRUG|Placebo Gefitinib Tablets|patients receive the test drug (Placebo Gefitinib Tablets) since the first day of cycle 1. One cycle is defined as 21 days. The patient shall take the study drugs twice a day. The first dose is 1 tablet. The drugs should be administered with water before or after meals.
223468149|NCT03856697|DRUG|Gefitinib Tablets|patients receive the control drug (Gefitinib Tablets) since the first day of cycle 1. One cycle is defined as 21 days. The patient shall take the study drugs twice a day. The first dose is 1 tablet. The drugs should be administered with water before or after meals.
223468150|NCT03856697|DRUG|Placebo Abivertinib Maleate Capsules|patients receive the control drug (Placebo Abivertinib Maleate Capsules) since the first day of cycle 1. One cycle is defined as 21 days. The patient shall take the study drugs twice a day. The first dose is 3 capsules, and the second dose is 3 capsules. The drugs should be administered with water before or after meals.
223468151|NCT06406335|OTHER|Health education program|Impact of A Multidimensional Health Education Program on Attention deficit hyperactivity disorder (ADHD)
223468152|NCT00190424|DRUG|CpG-ODN|
223468153|NCT05775627|BEHAVIORAL|Sleep Restriction|Participants are randomized into either a group (n=10) that is sleep restricted first or control first (n=10) group; the groups will crossover halfway through the protocol. Both arms are fed 3 meals and have access to ad libitum food between meals. Both groups will also undergo up to 3 mixed-meal tolerance tests to measure glucose tolerance.
223468154|NCT02089048|DRUG|Auranofin|Auranofin is a gold-containing chemical salt available as 3mg capsules. Cohort 1 receives 6mg oral dose of auranofin once every 24 hours for 7 days
223468155|NCT02256813|DRUG|BIRT 2584 XX|
224303743|NCT02838511|OTHER|Modified Frailty Index (MFI)|non-cardiac surgical patients will have frailty evaluated
224303744|NCT02838511|OTHER|Hopkins Frailty Score (HFS)|non-cardiac surgical patients will have frailty evaluated
224303745|NCT01551225|DRUG|Escitalopram|Patients will start at a dosage of 5 mg daily of escitalopram. After the first week of treatment the dosage will be increased to 10 mg daily. During the visits, the dosage can be gradually increased to a maximum of 20 mg daily, depending on the response of the patient.
223468156|NCT02256813|DRUG|Warfarin sodium|
223468157|NCT02256813|DRUG|Omeprazole|
224303746|NCT00548171|BIOLOGICAL|Boostrix™|Intramuscular injection, 1 dose
224303747|NCT01103466|DEVICE|Atlas|Altas base plates are tested for 14 days (minimum 4 base plates) and the degree of leakage under the baseplate is measured and compared to two other types of base plates.
223468158|NCT02256813|DRUG|Dextromethorphan hydrobromide|
223468159|NCT02256813|DRUG|Caffeine|
223468160|NCT02256813|DRUG|Midazolam hydrochloride|
223468161|NCT02256813|DRUG|Vitamin K1|
223468162|NCT01388153|DRUG|Acarbose (Glucobay ODT, BAYG5421)|Day 1: oral sucrose load (75 g sucrose dissolved in 225 mL water) without Glucobay ODT; Day 2: oral sucrose load plus Glucobay ODT taken without water
223468163|NCT01388153|DRUG|Acarbose (Glucobay ODT, BAYG5421)|Day 1: oral sucrose load (75 g sucrose dissolved in 225 mL water) without Glucobay ODT; Day 2: oral sucrose load plus Glucobay ODT taken with water
223578269|NCT00402714|DRUG|Pentostatin|pentostatin 8mg/m2 over 48 hours by continuous infusion
224159077|NCT00444418|BEHAVIORAL|Brief Behavioral Compliance Enhancement Therapy|Brief supportive counseling to enhance compliance with medication and encourage goal-setting concerning alcohol consumption
224159078|NCT02963766|DRUG|Dulaglutide|Administered SC
224159079|NCT02963766|DRUG|Placebo|Administered SC
224159080|NCT05695404|PROCEDURE|Segmentectomy|Lung resection
224159081|NCT04628273|PROCEDURE|encoscopic retrograde cholangio-pancreatography, extracorporeal shock wave lithotripsy|
224159082|NCT02313922|DRUG|etanercept combined with methotrexate or etanercept combined with placebo|
224159083|NCT03222622|DRUG|Icotinib hydrochloride cream|Apply topically twice daily for 12 consecutive weeks
224159084|NCT03222622|DRUG|Placebo cream|Apply topically twice daily for 12 consecutive weeks
224159085|NCT05797363|OTHER|Continuous midwife support|The individuals included in the experimental group will be provided with consultancy services on many issues from the pre-pregnancy period to the postpartum period.
224303748|NCT01103466|DEVICE|SenSura|SenSura base plates are tested for 14 days (minimum 4 base plates) and the degree of leakage under the baseplate is measured and compared to two other types of base plates.
224303749|NCT01103466|DEVICE|Conform 2|Conform 2 base plates are tested for 14 days (minimum 4 base plates) and the degree of leakage under the baseplate is measured and compared to two other types of base plates.
224303750|NCT03446911|RADIATION|SABR|Prior to surgery (lobectomy), patients receive stereotactic ablative radiotherapy.
224303751|NCT03446911|COMBINATION_PRODUCT|SABR + pembrolizumab|Prior to surgery (lobectomy), patients receive stereotactic ablative radiotherapy + 2 rounds of pembrolizumab
224303752|NCT01216852|DRUG|Losartan Potassium|100 mg tablet
224303753|NCT04751084|DRUG|Buscopan 20 milligrams/ML Injectable Solution|cases will be randomized to Buscopan group or Normal Saline group, injection will be given 5 minutes prior to embryo transfer
224303754|NCT02327741|DRUG|plavix|taking plavix more than 12 months
224303755|NCT02327741|DRUG|plavix|taking plavix less than 12 months
224303756|NCT00134693|DRUG|Prednisolone|
224303757|NCT00134693|DRUG|SB-681323|
224303758|NCT02192749|BIOLOGICAL|Umbilical cord mesenchymal stem cells|
224303759|NCT05581290|DEVICE|AI-Flex|A flexible multi-modal bio-sensing device with integrated AI capability used to measure ECG (heart's electrical activity), body temperature, and PPG (blood volume in tissue); primarly mounted on the wrist and chest.
224303760|NCT05051202|OTHER|Sugars from Fiber|Proprietary blend of Sugars from Fiber baked into 50 g flapjack
224303761|NCT05051202|OTHER|Resistant Maltodextrin|Resistant Maltodextrin baked into 50 g flapjack
224303762|NCT02257541|DRUG|BGJ398|
224303763|NCT02257541|DRUG|Imatinib Mesylate|
223468164|NCT01388153|DRUG|Acarbose (Glucobay, BAYG5421)|Day 1: oral sucrose load (75 g sucrose dissolved in 225 mL water) without Glucobay standard tablet; Day 2: oral sucrose load plus Glucobay standard tablet taken with water
223468165|NCT04784078|PROCEDURE|Coronary Angiography and Intervention|Transradial access puncture site
223468166|NCT02740959|DRUG|Astragalus Polysaccharides 500 mg|PG2 Injection 500 mg PG2 (500 mg in 500 ml saline), t.i.w. via i.v. infusion for 2.5-3.5 hours over 2 treatment cycles (8 weeks)
223578270|NCT00402714|RADIATION|Total Body Irradiation|600cGy TBI in 3 200cGy TBI fractions
224159086|NCT05463159|OTHER|Transcutaneous electrical nerve stimulation|All children received 30 min of conventional TENS (continuous stimulation with all parameters constant) with a frequency of 100 Hz and a pulse width of 200 µs.
224159087|NCT06326671|DRUG|Tiotropium Bromide Inhalation Powder|It's a generic product of Spiriva HandiHaler.
224159088|NCT06326671|DRUG|Spiriva HandiHaler|Tiotropium Bromide Inhalation Powder RLD, which binds to M3 receptors, and blocks the action of acetylcholine to relieve spasm of bronchial smooth muscle.
224159089|NCT00002657|BIOLOGICAL|bleomycin sulfate|5 mg/m\^2
224159090|NCT00002657|BIOLOGICAL|recombinant interferon alfa|3.0 x 10\^6 IU/m\^2
224159091|NCT00002657|DRUG|cyclophosphamide|650 mg/m\^2
224159092|NCT00002657|DRUG|cytarabine|300 mg/m\^2
224159093|NCT00002657|DRUG|doxorubicin hydrochloride|25 mg/m\^2
224159094|NCT00002657|DRUG|etoposide|120 mg/m\^2
224159095|NCT00002657|DRUG|methotrexate|120 mg/m\^2
224159096|NCT00002657|DRUG|prednisone|dose varies during initial immunosuppression. During chemotherapy, 60 mg/m\^2.
224159097|NCT00002657|DRUG|vincristine sulfate|1.4 mg/m\^2
224159098|NCT00002657|PROCEDURE|conventional surgery|Simple excision, for those patients who have resectable disease after initial immunosuppression.
224159099|NCT00002657|RADIATION|radiation therapy|For treatment of localized disease that remains after initial immunosuppression.
224303764|NCT01439230|DRUG|Donepezil|10 mg Tablet
224303765|NCT01439230|DRUG|Aricept®|10 mg Tablet
224303766|NCT01520532|OTHER|Magnetic Resonance Imaging (MRI)|MRI's will be performed on all subjects at Enrollment and Pre-Discharge (Post Ablation). Subjects with a positive MRI (cerebral lesion) at the Pre-Discharge will undergo an MRI at the 1 month follow-up visit.
224303767|NCT00397059|DRUG|Escitalopram|
224303768|NCT05476952|PROCEDURE|"he patients who are administered rocuronium according to LBW were categorized as LBW, and The group number for those administer according to TBW was categorized as K."|Patients will be divided equally and validly by the one who will be placed in opaque sealed envelopes on a self-paid basis. One group will be given 0.6 mg/kg rocuronium on an LBW basis (Curon ® 50 mg/5 mL \[Mustafa Nevzat, Istanbul, Turkey\]), and the other group will be given 0.6 mg/kg rocuronium on a TBW basis.
224303769|NCT06148168|DRUG|Bupivacaine plus normal saline|"Unlike specific peripheral nerve blocks, TAP block is a non-dermatomal field block. Even with the same US-guided technique, the extent of spread of local anesthetics can be variable due to individual anatomical variations (18). In order to perform the blocks, abdominal skin will be prepared and covered with sterile drapes. The needle can be introduced by multiple punctures along the oblique subcostal line from the xiphoid process towards the anterior part of the iliac crest .Thus, LA will be injected in the TAP along this line provides both upper and lower abdominal wall analgesia. The OSCTAP block more consistently covers L1 dermatome. After negative aspiration, a test injection with 1 ml of 0.9% normal saline will be performed to confirm the needle location. If the intended sensation will not decreased in surgical dermatomes after 30 min, the patient will be regarded to have a failed block and will be excluded from the study."
224159100|NCT00264667|DRUG|GW677954|
224159101|NCT02693236|BIOLOGICAL|adenovirus-transfected autologous DC vaccine plus CIK cells|
223468167|NCT02740959|DRUG|Astragalus Polysaccharides 250 mg|PG2 Injection 250 mg PG2 (250 mg in 500 ml saline), t.i.w. via i.v. infusion for 2.5-3.5 hours over 2 treatment cycles (8 weeks)
223468168|NCT03442647|DIAGNOSTIC_TEST|sinistrin clearance dynamic measurement|sinistrin clearance measurements will be performed before and 90 min after oral protein load
224159102|NCT03046043|PROCEDURE|pulmonary vein isolation|pulmonary vein isolation is conducted on the junction between the left atrium and pulmonary vein
223468169|NCT04753957|DRUG|micronized Progesterone|200mg micronized progesterone placed vaginally
223468170|NCT02667301|DEVICE|EMG recording|1.3X0.4 mm, sterile subdermal monopolar needle electrodes along with the same type of reference needle electrodes were inserted mTVP and mLVP muscles submucosally through the soft palate trans orally. The point of insertion for mTVP was one mm inferior and lateral of the pterygoid hamulus which is palpable at the posterior-medial of the upper alveolus. The active electrode was fully inserted horizontally into the superior belly of mTVP on the tested side. The reference electrode for mTVP was inserted into the palatine aponeurosis at one centimeter apart from the active electrode. The point of insertion for the mLVP active electrode was one centimeter medial and five mm inferior to the hamulus pterygoideus. Reference electrode of mLVP was inserted into one cm apart of medial side of the passive electrode of the mTVP at palatine aponeurosis.
223468171|NCT02667301|DEVICE|Tympanic Cavity Air Exchange Test|Tympanic cavity air exchange test is done by placing a sensitive pressure sensor in the ear canal and another pressure sensor on one of the nostrils. Patient is asked to to obstruct the other nostril with his/her index finger while holding the probe in place securely and asked to swallow the water during the next ten seconds. Both ear canal and nasal pressure values were simultaneously recorded on tympanic cavity air exchange sensor computer for subsequent analyses. The swallowing action triggers the ET opening and causes a momentary increase of pressure in the nasal cavity. ET opening moves the tympanic membrane which is sensed by the sensors.
223468172|NCT02667301|DEVICE|Tympanometer test|Patient is subjected to tympanometry test on the specific ear and information is recorded.
223468173|NCT00053209|DRUG|gemcitabine hydrochloride|
224159103|NCT03046043|PROCEDURE|Low-Voltage & CFAE guided ablation|In CFAE guided ablation,. Within low voltage zone, CFAE areas defined by shortest SCI and high ICL are identified.-Areas with the shortest SCI and high ICL within low voltage areas should be targeted first, followed by longer SCI regions (up to 120ms). Radiofrequency energy is delivered at target sites for 30-60 sec until the local electrogram is completely eliminated.
224159104|NCT06099353|BEHAVIORAL|Heart Age|Heart Age is the phenotypic age based on the risk of the patient participant using a modified tool for CVD risk from the Framingham risk Score. The Heart Age is the age at which an individual would be expected to develop CVD in the next ten years relative to another individual of the same sex and age if all the current CVD risk factors were to be eliminated.
224159105|NCT06099353|BEHAVIORAL|Heart Age-HOPE-CVD App|Patient participants will use an online mobile, evidence-based behavioural change psychoeducation application for 24 weeks. New psychoeducational content is released every week. The first seven weeks of the programme seeks to resolve ambivalence about initiating a lifestyle change and increase the readiness and motivation to change. Between Weeks 8 and 15, the platform will support action planning and guide users to execute their preferred self-care behaviour safely and effectively. The remaining nine weeks will provide the user with the skills that will help them with coping and planning to manage relapses and temptations.
224159106|NCT06099353|BEHAVIORAL|Communication of Genetic Risk Score|General practitioners will draw 3ml of blood from each patient participant for analysis of the patient's genetic risk score of having cardiovascular disease. This genetic risk score will be communicated to the patient, and the communication will include informing patients what cardiovascular disease genetic risk is, what their genetic risk category compared to the population in Singapore is, and what their score means for the future.
224159107|NCT05679609|DEVICE|incentive spirometry|It is flow-oriented that has 3 chambers, (600, 900, and 1200 cc/s) and it has a mouthpiece and a ball in each chamber. After a quiet exhalation, each participant was instructed to take slow full inspirations and to keep as long as he can for at least 5 seconds, then he slowly expires. The device is used every hour at least 5 to 10 times in the session during wake time.
224159108|NCT01223768|DRUG|Acetyl-l-Carnitine|2g per day
224159109|NCT01223768|DRUG|placebo|twice per day
224159110|NCT02747446|DIETARY_SUPPLEMENT|added sugar|isocaloric substitution of added sugars (honey or FG) for starch
224159111|NCT03182127|RADIATION|Magnetic resonance imaging|MRI of the elbow is performed in either the supine or prone position A high-resolution surface coil is essential in order to obtain high-quality images . Elbow MRI scanning protocols consist of a combination of T1-weighted and fat-suppressed T2- or proton density-weighted images obtained in the axial, coronal oblique, and sagittal oblique imaging planes. Axial images should extend from the distal humeral diaphysis to the level of the bicipital tuberosity of the radius. From the axial images, coronal oblique images should be prescribed parallel to a line drawn through the centre of the humeral epicondyles, with sagittal oblique images prescribed perpendicular to this. Additional sequences may be helpful in certain circumstances; .
224159112|NCT03182127|DEVICE|Ultrasound|ultrasound is performed by patient in supine or setting position,applied superficial probe , 2D image and color doppler if indicated.
224159113|NCT05974007|DRUG|Neoadjuvant immunochemotherapy|Patients with operable stage I-III NSCLC who have previously undergone platinum drugs and immune checkpoint inhibitors(Anti PD-1) and then undergone radical surgery
224159114|NCT05974007|DRUG|Neoadjuvant chemotherapy|Patients with operable stage I-III NSCLC who have previously undergone platinum-based chemotherapy regimens and then undergone radical surgery
224159115|NCT01511991|DRUG|Sevoflurane dosage titration|comparisons of the effect of the 10 min-inhalation of each concentration of sevoflurane, 1.0 inspired vol%, 2.0 inspired vol% and 3.0 inspired vol% (T1, T2 and T3)
224159116|NCT01708538|DRUG|CXL|corneal crosslinking
224159117|NCT02988401|DRUG|Insulin|All patients will receive either insulin or placebo using the Vianase III N2B device during the first 24 weeks of the study.
224159118|NCT02988401|DRUG|Placebo (Sterile diluent)|All patients will receive either insulin or placebo using Vianase III N2B device during the first 24 weeks of the study.
224159119|NCT04472637|DRUG|Atorvastatin|atorvastatin 10 mg, as one tablet /day for 24 weeks.
224068450|NCT02503904|DRUG|cecefazolin and metronidazole (in a dilute solution of tumescent lidocaine, epinephrin and sodium bicarbonate in 0.9% physiologic saline)|
224068451|NCT00272038|DRUG|Tarceva|150mg QD
224159120|NCT04472637|DRUG|Placebo|a placebo in the form of multivitamin tablets similar to the experimental drugs with the same regimen (one tablet /day for 24 weeks)
224159121|NCT02953067|PROCEDURE|Open reduction and internal fixation|Stratum 1: Conservative treatment versus open reduction and internal fixation Stratum 2: Open reduction and internal fixation versus arthrodesis
224068452|NCT00493870|DRUG|Docetaxel|Docetaxel 75 mg/m2 IV over 1 hour on Day 1 followed by cyclophosphamide
224068453|NCT00493870|DRUG|Doxorubicin|• Doxorubicin 50 mg/m2 IV push over 5-15 minutes via sidearm through a running IV line on Day 1, followed by cyclophosphamide 500 mg/m2 IV over 15-30 minutes on Day 1, followed by docetaxel 75 mg/m2 IV over 1 hour on Day 1. Administer pegfilgrastim 6 mg SC on Day 2 (or filgrastim 5 mcg/kg SC per standard of care).
224068454|NCT00493870|DRUG|Cyclophosphamide|600 mg/m2 IV over 15-30 minutes on Day 1.
224159122|NCT02953067|PROCEDURE|Primary arthrodesis|Primary arthrodesis versus ORIF
224159123|NCT02953067|PROCEDURE|Conservative treatment|Conservative treatment versus open reduction and internal fixation
224159124|NCT04720690|DEVICE|Vicorder: pulse wave velocity, pulse wave analysis, stroke volume, cardiac output|Measurement of arterial stiffness and cardiac output
224159125|NCT04720690|DEVICE|NICaS|Measurement of cardiac output
224303770|NCT06148168|DRUG|Bupivacaine plus normal saline containing MgSO4|Bupivacaine plus normal saline containing MgSO4
223468174|NCT00053209|DRUG|pemetrexed disodium|
223468175|NCT04328428|OTHER|acupuncture|Use one acupuncture needle insert in a acupoint.
223468176|NCT03199950|DRUG|Haloperidol|Haloperidol 2dd1mg (08.00am - 10.00pm)
223468177|NCT03199950|DRUG|Placebo Oral Tablet|Placebo oral 2dd (08.00am - 10.00pm)
223468178|NCT00849563|OTHER|Standardized Risk Assessment|patients interested in genetic testing will be randomly assigned to either get testing for type 2 diabetes or not. All arms with receive standardized risk asessements. This study is evaluating behavior after receipt of genetic risk information and different types of counseling.
223468179|NCT01858870|DRUG|lacosamide|routine clinical practice
223578271|NCT00402714|DRUG|Pentostatin|pentostatin 8mg/m2 over 48 hours by continuous infusion
223578272|NCT00402714|RADIATION|Total Body Irradiation|600cGy TBI in 3 200cGy TBI fractions
224068455|NCT03368261|OTHER|HTAP/ clinical complications in the sickle cell disease|At the inclusion in our study the diagnosis of PAH will be performed by transthoracic Doppler-echocardiograms in a group of 306 children (aged between 8 to 16 years old) with either SS or SC genotype with similar medical caring, to avoid a known selection bias. These patients will be followed during a 3 years longitudinal period. The occurrence of the clinical specific complications associated with SCD (acute chest syndrome, painful vaso occlusive crisis, septicemia and stroke) and the observed mortality rate of our children group, will be compared in patients groups stratified according to the occurrence of PAH. The expression of several molecular and cellular genetic biomarkers potentially associated with this complication will also be studied.
224068456|NCT03294018|OTHER|Recording heart rate changes|Recording heart rate changes during planned sugammadex administration.
224068457|NCT03126760|DRUG|Acthar Gel|Acthar Gel 1 mL (80U) for subcutaneous injection
224068458|NCT03126760|DRUG|Placebo|Placebo for subcutaneous injection
224068459|NCT03538509|OTHER|PCI and implantation drug eluting stent or bare metal stent|Percutaneous Coronary Angioplasty
224068460|NCT04804254|DRUG|ABBV-623|Oral Tablets
224068461|NCT04804254|DRUG|ABBV-992|Oral Tablets
224068462|NCT00589446|DEVICE|Hysteroscope|An 8mm hysteroscope with irrigation channel and 30 degree view will be inserted into the uterus prior to curettage in cases of recurrent missed abortion
224068463|NCT04473456|PROCEDURE|Simultaneous EGD and colonoscopy|Patients are examined simultaneously by EGD and colonoscopy
224068464|NCT03372031|BEHAVIORAL|Piano training (Active)|Piano Curriculum. Participants were all trained on one of four 88-key pianos located in the assisted living facility. Piano instructors were 6 undergraduate Music Education and Music Performance majors. Each lesson of the week had a different focus: right and left hands separately, bimanually coupled, and bimanually uncoupled (Loehrer et al., 2016). Each week of the module had a different focus as well: notes played one step apart, notes played multiple steps apart (intervals), and tones played together (two-note chords) (van Vugt et al., 2016; Villeneuve et al., 2014). Each session began with skill exercises and ended with learning a simple, recognizable song. Two participants with extensive piano experience progressed to playing duets with the instructor and hymns out of a hymnal after mastery of the study curriculum. These training protocols were based on those of Schneider and colleagues' 2007 study.
224159126|NCT04720690|DEVICE|Echocardiography and ultrasound of arteries|Measurement of cardiac output; measurement of intima-media thickness of arteries
224159127|NCT00054418|DIETARY_SUPPLEMENT|calcium carbonate|calcium 600 mg daily administered orally for one year
224159128|NCT00054418|DIETARY_SUPPLEMENT|vitamin D|vitamin D 400 U daily administered orally for one year
224159129|NCT00054418|DRUG|risedronate sodium|risedronate 35 mg weekly administered orally
224159130|NCT00054418|OTHER|placebo|placebo tablet weekly administered orally for one year
224159131|NCT01845519|BEHAVIORAL|Tailored Email|Participants will receive tailored emails.
224159132|NCT01845519|BEHAVIORAL|Targeted Email|Participants will receive targeted emails.
224159133|NCT02027974|DEVICE|Iconacy Hip System|Comparison of Iconacy I-Hip system to the Stryker Accolade hip system using a randomized study.
224159134|NCT02027974|DEVICE|Stryker Accolade Hip System|Comparison of Iconacy I-Hip system to the Stryker Accolade hip system using a randomized study.
224159135|NCT02928081|PROCEDURE|Extended lymphadenectomy|Extended lymphadenectomy with nerve tissues around CHA and the SMA and nodes around the celiac trunk and SMA (No.16a2, 16b1)
224159136|NCT02928081|PROCEDURE|Standard lymphadenectomy|Lymph node dissection includes(LN5, LN6),(LN8a, 8b),(LN12b1, 12b2, 12c),(LN13a, 13b),(LN14a, 14b),(LN17a, 17b)
224159137|NCT00644241|BIOLOGICAL|stem cell harvest|stem cells will be harvested from the iliac crest of the patients
224303771|NCT04555850|DRUG|Recombinant Human Thymosin β4|Healthy subjects , were given a dose of rh-Tβ4 for ten consecutive days.
224159138|NCT00644241|PROCEDURE|angiographic transplantation of stem cells|autologous bone marrow derived stem cells will be transplanted in the gastroduodenal artery of the patient angiographically
224159139|NCT02942693|DRUG|Apatinib|Apatinib will be used as induction therapy in experimental arm.
224159140|NCT02942693|RADIATION|Particle Therapy|Same total dose and fractionation will be used in both arms.
224159141|NCT03535090|DRUG|Methylprednisolone|
224159142|NCT02126527|DRUG|auranofin|Given PO
224159143|NCT02126527|DRUG|sirolimus|Given PO
224159144|NCT02126527|OTHER|laboratory biomarker analysis|Correlative studies
224159145|NCT02126527|OTHER|pharmacological study|Correlative studies
224159146|NCT01784250|DRUG|Clonidine|Clonidine 150 mcg tablet single dose, to receive by mouth one hour before surgery
224159147|NCT01784250|DRUG|Propranolol|Propranolol 40 mg tablet single dose, to receive by mouth one hour before surgery
224159148|NCT01784250|DRUG|Placebo|Sugar pill manufactured to mimic a drug
224159149|NCT01779895|DIETARY_SUPPLEMENT|Lactobacillus paracasei probiotic strain|
224159150|NCT01779895|DIETARY_SUPPLEMENT|Placebo|maltodextrin
224159151|NCT06063837|BEHAVIORAL|Live Instruction and Fitness Tracking (LIFT-up)|A 12-week combined aerobic and resistance training exercise protocol
224159152|NCT02673528|PROCEDURE|Laparoscopic appendectomy|Two types of laparoscopic surgery were performed. Total laparoscopic appendectomy or laparoscopic assisted appendectomy
224159153|NCT03991624|DIAGNOSTIC_TEST|cognitive assessment|"* MMSE : Mini-Mental State Examination~* 5 words of Dubois~* Direct Assessment of Functional Status~* Trail Making Test~* BREF : Fast Front End Efficiency Battery~* short battery of praxies~* Quality of Life in Alzheimer's Disease"
224159154|NCT03991624|OTHER|Inhibition evaluation|"* Stroop Victoria : This test consists of 3 sheets of 24 items, organized in 6 lines of 4 (points, neutral words or names of colours), from which the subject must identify the ink of the stimuli as quickly and precisely as possible.~* Stop Signal task on the computer to give a response to the presentation of a target stimulus (Go signal) (e.g. pressing a button when a red circle appears on the screen, but doing nothing when a blue triangle appears), and prevent this response when the stimulus is followed or preceded by a beep (stop signal) (e.g. the appearance of a red circle is immediately preceded or followed by a beep, the subject should not press the button)."
224159155|NCT03991624|OTHER|Assessment of mental flexibility|"* a letter-number pair task. The subject sees 4 blocks of 48 letter-number pairs appear successively on a screen. When the pair appears at the top, the subject must make a parity judgment but when the pair appears at the bottom, the subject must make a consonant / vowel judgment.~* a category change task, which consists in classifying a word according to one category or another according to a visual clue that appears. The task consists of 4 blocks of 48 stimuli."
224159156|NCT03991624|OTHER|Evaluation of the update|"* an update span task for which letters appear on a screen sequentially, and subjects must memorize the last three, without knowing the length of the list. The task will consist of 3 tests of training and then 20 tests. After three errors consecutive, the task ends.~* an n-back task that consists of a sequential presentation of letters, during which the subject must indicate when the stimulus. The task consists of 3 levels, with n = 1, n= 2 or n = 3. For level 1 (with n = 1), the subject must press a button when the same letter appears twice in a row on the screen. This task consists of 75 letters."
224159157|NCT03991624|OTHER|working memory|"* the empan baba task, which mainly involves maintaining information, and which consists in retaining a series of letters, appearing sequentially on a screen, and whose latency time between two word presentations is required for a secondary task: the repetition of baba syllables.~* the task of reading operations which consists in recalling operations series of letters whose presentation is interspersed with the reading aloud of simple operations and of their results.~* the ongoing operational task of recalling a list of letters, the presentation of which is interspersed with operations that are simple to read aloud and to to solve head-on."
224159158|NCT03991624|OTHER|episodic memory|\- A recognition task with a Remember/Know paradigm
224159159|NCT00062595|DRUG|phylloquinone (K1)|
224159160|NCT00062595|DRUG|menatetranone (MK4)|
224159161|NCT04186546|DEVICE|Zephyr Valve Procedure|The Pulmonx Zephyr Endobronchial Valve is an implantable bronchial valve intended to decrease volume in targeted regions of the lung. It is indicated for the treatment of patients with severe emphysema. The Zephyr Valves are placed in the diseased region of the lung using bronchoscopy. As the diseased region of the lung shrinks in size, healthier regions may expand and function more efficiently, resulting in improved breathing.
224159162|NCT04796948|DRUG|Irinotecan liposome；oxaliplatin；5-FU(Fluorouracil Injection)；LV(Calcium Folinate Injection)|irinotecan liposome in combination with oxaliplatin and 5-FU/LV
224159163|NCT00969488|OTHER|High protein diet|"INTERVENTION is to stimulate the consumption of high protein foods and restrict the consumption of carbohydrates in the experimental group.~The women in the intervention group will be incentivized to substitute breads and pastas for high protein foods (legumes, milk and its derivatives, eggs, fish, and lean meats)."
224159164|NCT04880681|DEVICE|Novel needle (18 G, 25 cm with 19 mm sample notch) in a new actuator.|Trans Rectal Ultrasound guided Prostate Biopsy using the assigned needle. Approximately 12 biopsies per patient.
224159165|NCT04880681|DEVICE|Standard Tru Cut biopsy needle (Argon 18G, 25 cm biopsy needle with a 19 mm sample notch) in a standard actuator (Möller Medical Blue RBG-1000-10-1000)|Trans Rectal Ultrasound guided Prostate Biopsy using the assigned needle. Approximately 12 biopsies per patient.
224159166|NCT03938636|DRUG|Tc 99m tilmanocept|Tilmanocept is a radiotracer that accumulates in macrophages by binding to a mannose binding receptor that resides on the surface.
224159167|NCT05038787|DRUG|LY3473329|Administered orally.
224159168|NCT05038787|DRUG|Placebo|Administered orally.
224159169|NCT00131170|PROCEDURE|paravertebral block|
224159170|NCT03537183|OTHER|Exercise training|12 weeks, 3 hours a week, moderate intensity exercise training
224159171|NCT04113278|GENETIC|FGL2 immunohisyochemistry|Correlation between FLG2 expression and progression free survival and overall surviv
224159172|NCT00252317|DRUG|Captopril and Trandolapril|Caps Captopril 6.25 mg test dose and Caps Trandolapril 0.5mg or 1.0mg or 2.0 mg (depending on symptoms ie. hypotension)
224159173|NCT00252317|DRUG|Captopril Test Dose and Trandolapril|Caps Captopril 6.25 mg test dose and Caps Trandolapril 0.5mg or 1.0mg or 2.0 mg (depending on symptoms ie. hypotension)
224159174|NCT04557007|DRUG|Pembrolizumab|Drug trough-level will be measured in patients on Pembrolizumab with or without additional chemotherapy in routine care.
224159175|NCT01231828|DRUG|L-carnitine|L-carnitine 4g per day (4 bottles of 10ml).
224159176|NCT01231828|DRUG|Lactulose|Lactulose (30-60 ml per day)
223468180|NCT05282368|BEHAVIORAL|PHM™ Pathway|"The technological platform referred to as Preparing Heart and Mind™ (PHM™) is designed as a patient engagement pathway. This platform includes GetWellNetwork's proprietary workflow engine, Patient Pathways™ and functionality of the Health Loop platform. Specifically, PHM™ will be created on a customized GetWellNetwork patient engagement pathway, getwell \| Loop, which is a secure platform with a parent-facing app and an interactive dashboard for healthcare providers. The PHM™ getwell \| Loop is a care program with chapters that incorporate interactive resources for patient information and education, trackers as touch points for psycho-social/educational support, and tailors care with condition-specific content, as well as action items."
223468181|NCT01283100|DRUG|GSK1349572|50mg once every 24 hours for 7 days
223468182|NCT01283100|DRUG|GSK2248761|200 mg once every 24 hours for 7 days
223468183|NCT02611947|RADIATION|Low-dose chest CT scans|"Supine chest CT scan after full inspiration. Acquisition parameters: (Topogram 35 mA 120 kV 512 mm length)~35 quality ref mAs with care-dose ON 120 kV Pitch 1.4 Rotation time 0.33 s Acquired images 64 x 0.6 mm"
223468184|NCT02283658|DRUG|Everolimus|Given PO
223468185|NCT02283658|OTHER|Laboratory Biomarker Analysis|Correlative studies
223468186|NCT02283658|DRUG|Letrozole|Given PO
223468187|NCT00239070|DRUG|Enteric-Coated Mycophenolate Sodium (EC-MPS)|
223468188|NCT02076620|DRUG|L19TNFα|L19TNFα will be administered as a 2 hours i.v. infusion on days 1, 3, and 5 of each 3-week cycle.
223468189|NCT02076620|DRUG|Doxorubicin|Doxorubicin will be administered as a 15 minutes i.v. infusion on day 1 of each 3-week cycle prior L19TNFα administration.
223468190|NCT04229043|DIETARY_SUPPLEMENT|Sports drink|Drink that will be ingested
223468191|NCT04229043|DIETARY_SUPPLEMENT|Water|Drink that will be ingested
223468192|NCT00847600|DIETARY_SUPPLEMENT|Pregnenolone|50 mg, caps.
223468193|NCT00847600|DIETARY_SUPPLEMENT|Placebo|caps
223468194|NCT05996939|OTHER|To compare the efficacy of unstable shoes with that of conventional sports shoes in people with lower-limb primary and secondary lymphedema.|Unstable shoes were compared with conventional sports shoes, the objective being to evaluate possible differences in the evolution of lymphedema. During a clinical trial lasting eight weeks, we assessed quality of life, limb volume, and symptoms derived from lymphedema.
223468195|NCT02937480|OTHER|Task-specific training|The task-specific training will be composed by 30 minutes for upper limb and 30 minutes for lower limb tasks. Subjects will performed five minutes of exercise in each station of the circuit and only the last station will last 10 minutes and will involve a walking training with auditory stimulation. Individuals will be encouraged to work as hard as possible at each station and verbal feedback and instructions aimed at improving performance will be taken. Between each task, the participants will be allowed to rest for at least 1-2 minutes, and individual adjustments will be carried out for better adaptations to the training.
223468196|NCT02937480|OTHER|Global stretching, memory exercises, health care orientation|The control intervention will be composed by 40 minutes for global stretching, 20 minutes of memory exercises and health care orientation
223468197|NCT05003544|PROCEDURE|Group A|PENG BLOCK
223468198|NCT05003544|PROCEDURE|Group B|Intra-articular
223468199|NCT05003544|PROCEDURE|Group C|Quadratus lumborum block
223468200|NCT04181671|OTHER|Low Resistance training with venous blood flow restriction|"Total 20 males will participate in this group after warmup , Blood flow restriction will be provided through sphygmomanometer optimum pressure will be measured through following formula occlusion pressure (mmHg) = 0.514 (SBP) + 0.339 (DBP) + 1.461 (Arm circumference) + 17.236 then 30% of 1RM will be used for training . The standard protocol will be used which is four sets (1st set-30 repetitions, 2nd set-15 repetitions, 3rd set-15 repetitions, and 4th set-15 repetitions) with 30-60 s of interval between sets. ( the cuff must be deflated between sets of exercise) for 8 weeks (24) sessions on non-consecutive days. participants will be re-assessed for all baseline variables after 8 weeks of training biceps curls will be used for training.~Heart Rate and oxygen saturation will be measured during the session through Pulse oximeter"
223468201|NCT04181671|OTHER|High Resistance training|Total 20 males will participate in this group after warm up. 80% of 1RM will be used for training, 3 sets of 8 repetitions will be used with 30-60 s of interval between sets. for 8 weeks (24) sessions on non-consecutive days.No blood flow restriction will be applied to this group Participants will be re-assessed for all baseline variables after 8 weeks of training. Bicep curls will be used for training.
223468202|NCT02421354|OTHER|Laboratory Biomarker Analysis|Correlative studies
223468203|NCT02421354|BIOLOGICAL|Nivolumab|Given IV
223468204|NCT02421354|OTHER|Quality-of-Life Assessment|Ancillary studies
223468205|NCT00005067|DRUG|motexafin lutetium|Given IV
223468206|NCT00005067|DRUG|photodynamic therapy|Undergo photodynamic therapy
223468207|NCT04852731|PROCEDURE|Cardiac MRI|Injected cardiac MRI
223468208|NCT04852731|OTHER|Blood collection|Blood collection (including genetics at the inclusion visit)
223468209|NCT04852731|PROCEDURE|Prolongation of the MRI examination|Prolongation of the MRI examination (4D flow sequence ; about 10 min)
224068465|NCT03372031|BEHAVIORAL|Piano Training (Passive)|Participants listened to their research partner complete 8 active piano training sessions across 2 weeks.
224068466|NCT02350270|OTHER|gait and cognitive testing|
224068467|NCT03584867|OTHER|refresher training at six months|a 5 cycles of 30:2 compression to ventilation ratio will be offered to experimental group at six months from BLS certification.
224068468|NCT03756038|DRUG|Placebos|In this study, patients will receive oral placebo, an inactive solution that looks like the study drug, but contains no active ingredients
224068469|NCT03756038|DRUG|Lorazepam|The purpose of this study is to determine whether a single low dose of Lorazepam/Ativan (1mg) can relieve pain and reduce negative mood in the emergency department and for 2 weeks after emergency department treatment.
224068470|NCT01289015|DRUG|NAFT-600 ( naftin 2 % gel )|Topical; applied once daily for two weeks
224068471|NCT01289015|DRUG|Placebo|Topical; applied once daily for two weeks
223578273|NCT03225768|BEHAVIORAL|Guided Training|Guided training is an intervention strategy designed to help individuals identify barriers in their daily life and guide them to generate their own strategies to address these barriers. This intervention strategy is different from traditional direct skill training, in which rehabilitation practitioners are responsible for identifying their patients' challenges to perform activities and teaching them task-specific problem-solving strategies. Guided training has been applied in a variety of clinical populations, including individuals with stroke and TBI, and has demonstrated significant effect on improving independence with daily activities among persons with acute stroke-related cognitive impairments enrolled in inpatient rehabilitation.
223578274|NCT04290793|DRUG|Pyrotinib|400mg administered as continuous oral once daily from the first day of the study
223578275|NCT04290793|DRUG|Epirubicin|90mg/m\^2 d1 iv Q2W for 4 cycles
224303772|NCT04555850|OTHER|Placebo|3 cohorts, with 6 healthy subjects , were given a dose of Placebo for ten consecutive days. Cohorts received ascending doses of either 0.5,2.0 or 5.0 ug/kg .
223468210|NCT03964389|OTHER|"Pain Neuroscience Education (PNE)"|A lecture on neuroscience education (EN). The aim of this intervention is to provide participants with information in a clear and simple way so that patients can change their attitude to pain, inviting them to take a more active and less contemplative role. Neuroscience has shown that it is possible to have persistent pain without tissue damage or with damage that justifies the perceived disproportion of pain.
223468211|NCT05962112|OTHER|Metabolic investigations after night-shifts|Metabolic investigations after night-shifts
223468212|NCT03283735|BEHAVIORAL|Elderly Enablement|The information given in this group will result from the knowledge obtained in previous phase of the study in the shape of small leaflets and other information materials to be made according to the best practice, to be given and remembered at scheduled times to the intervention group
223468213|NCT03528551|DRUG|Turoctocog alfa pegol|Turoctocog alfa pegol 75 IU/kg body weight will be administered once weekly as intravenous injections for a duration of 2 years.
223468214|NCT03528551|DRUG|Turoctocog alfa pegol|Turoctocog alfa pegol 60 IU/kg body weight (for patients younger than 12 years) and 50 IU/kg body weight (for patients, 12 years or older) will be administered twice weekly as intravenous injections for a duration of 2 years.
223468215|NCT03528551|DRUG|Turoctocog alfa pegol|Turoctocog alfa pegol 50 IU/kg body weight will be administered three times weekly as intravenous injections for a duration of 2 years.
223468216|NCT00689338|DRUG|Anidulafungin|Anidulafungin Intravenous Administration
223468217|NCT00689338|DRUG|Fluconazole|Oral Administration of Fluconazole
223468218|NCT00689338|DRUG|Voriconazole|Oral Administration of Voriconazole
223468219|NCT00846586|DRUG|Indacaterol 150 μg|Indacaterol was supplied in powder filled capsules together with a single dose dry powder inhaler (SDDPI) device.
223468220|NCT00846586|DRUG|Tiotropium 18 μg|Tiotropium was supplied in powder filled capsules together the manufacture's proprietary inhalation device (HandiHaler®).
223468221|NCT00846586|DRUG|Placebo to indacaterol|Placebo to indacaterol was supplied in powder filled capsules together with a single dose dry powder inhaler (SDDPI) device.
223468222|NCT06311058|DIETARY_SUPPLEMENT|Whey protein isolate|25g of whey protein isolate
223468223|NCT06311058|DIETARY_SUPPLEMENT|Protein + BAA|"* Protein drink - 25g of whey protein isolate~* Amino Acid Blend - 7g of protein (4g Leucine, 1g iso leucine, 1g valine, 1g arginine)"
223468224|NCT06311058|DIETARY_SUPPLEMENT|Placebo|• isocaloric-matched (25g) maltodextrin supplement
223468225|NCT04118647|DRUG|Wu-Chu-Yu tang|Wu-Chu-Yu tang at a rate of 3.0 g three times per day for 28 days.
223468226|NCT03113110|DRUG|Empagliflozin 10 mg|PTDM patients on previous antidiabetic treatment (\<40 IU insulin (in some cases plus oral antidiabetics)) receive Empagliflozin, ideally as monotherapy
223468227|NCT02464137|RADIATION|radiation|Patients in each dose cohort will all be treated as a single group. The starting dose will be 8.5 Gy per fraction for 5 fractions (total dose = 42.5 Gy). Subsequent cohorts of patients will receive an additional 0.5 Gy per fraction.
223468228|NCT00144430|DRUG|Pentostatin|The drug, Pentostatin, is given every 2 weeks. This drug will be given by intravenous (IV) infusion.
223578276|NCT04290793|DRUG|Cyclophosphamide|600 mg/m\^2 d1 iv Q2W for 4 cycles
223578277|NCT04290793|DRUG|Taxanes|Albumin paclitaxel（125mg/m2 d1、8 iv Q3W for 4 Cycles）/Docetaxel(100mg/m2 d1 iv Q3W for 4 Cycles )
223578278|NCT04290793|BIOLOGICAL|Trastuzumab|the first cycle is a loading dose of 8 mg / kg, followed by 6 mg / kg. Iv Q3W for 1 year
223468229|NCT00655252|DRUG|Everolimus|
223578279|NCT04999215|DRUG|F-choline intravenous injection|Participants will receive one injection of F-choline before undergoing hybrid PET/CT imaging per standard procedures. F-choline PET examinations may be repeated, if this judged to be in the patient's best interest by his referring physician and the study staff, up to a maximum 4 examinations per year.
224068472|NCT06797869|DRUG|CagriSema (Cagrilintide B and Semaglutide I)|Cagrilintide B and Semaglutide I will be administered subcutaneously using DV3384 pen-injector.
224068473|NCT06797869|DRUG|Placebo matched to CagriSema (Cagrilintide B and Semaglutide I)|Placebo matched to Cagrilintide B and Placebo matched to Semaglutide I will be administered subcutaneously using DV3384 pen-injector.
224068474|NCT06477276|DEVICE|Nervio-X|An 8-channel TIS device developed by NEURODOME Corporation.
224068475|NCT03799458|DEVICE|Active High-definition transcranial direct current stimulation (HD-tDCS)|Active HD-tDCS delivers active current through 2-10 electrodes held against the scalp with a lycra cap at specified 10-20 electroencephalography (EEG) coordinates.
224068476|NCT03799458|DEVICE|Sham High-definition transcranial direct current stimulation (HD-tDCS)|Sham HD-tDCS delivers sham current through 2-10 electrodes held against the scalp with a lycra cap at specified 10-20 electroencephalography (EEG) coordinates
224068477|NCT06193486|BIOLOGICAL|MSGV1-PSCA-8T28Z|Autologous Gamma Delta T Cells Genetically Engineered with a Chimeric Receptor to Target the Prostate Stem Cell Antigen.
224068478|NCT06193486|DRUG|Fludarabine|Fludarabine is an antimetabolite given prior to lymphodepletion.
224068479|NCT06193486|DRUG|Cyclophosphamide|Cyclophosphamide is a nitrogen mustard-derivative, polyfunctional alkylating agent given prior to lymphodepletion.
224068480|NCT03757533|BEHAVIORAL|Health Coaching|10 phone calls with a trained health coach
224068481|NCT03757533|OTHER|Surveys|Surveys to assess Behavioural and Psychosocial measures
224068482|NCT04621370|DRUG|Durvalumab|Flat dose of 1500mg delivered intravenously over 30 minutes every 4 weeks.
223468230|NCT01414998|BEHAVIORAL|Stress Ball vs Nicotine-free E-Cigarette|"In a cross over design, participants will be randomly allocated to:~1. use a stress ball for 5 minutes during a 1 hour controlled experiment. They will also use the stress ball for one day outside of the study centre.~2. use a nicotine-free EC for 5 minutes during a 1 hour controlled experiment. They will also use the EC ad-libitum for one day outside of the study centre.~One week later participants will complete the other arm."
223468231|NCT01414998|BEHAVIORAL|Nicotine-free E-Cigarette vs De-nicotinised Cigarette|"In a cross over design, participants will be randomly allocated to:~1. use a nicotine-free EC for 5 minutes during a 1 hour controlled experiment. They will also use the EC ad-libitum for one day outside of the study centre.~2. smoke 1 de-nicotinised cigarette during a 1 hour controlled experiment. They will also be given a pack to smoke ad-libitum for one day outside of the study centre.~One week later participants will complete the other arm."
223468232|NCT00105742|PROCEDURE|Diagnosis|
223578280|NCT04237038|PROCEDURE|laparoscopic Nissen fundoplication short gastric vessel division|Randomized clinical trial conducted in forty patients submitted to SGVD and forty patients without SGVD. Patients were evaluated with standarized questionnaires to measure the degree of satisfaction in relation to surgical procedure and to the quality of life. A randomized clinical trial was conducted with 87 patients submitted to laparoscopic Nissen fundoplication between February 2013 to december 2014 according to the guidelines established by the Mexican Consensus for the study of Gastroesophageal reflux disease (GERD
223578281|NCT01866423|DRUG|orteronel|Given PO
223578282|NCT01866423|OTHER|laboratory biomarker analysis|Correlative studies
223578283|NCT01571908|DRUG|Magnesium perfusion|The patient receives during 15 minutes a perfusion of 60mg/kg of Magnesium sulphate before induction of anaesthesia.
223578284|NCT01571908|DRUG|Rocuronium|Immediately after anaesthesia induction and loss of consciousness 0,6 mg/kg of rocuronium will be injected
223578285|NCT01571908|DRUG|Placebo perfusion|The patient receives during 15 minutes a perfusion of 1 ml/kg of saline before induction of anaesthesia
223578286|NCT01571908|DRUG|Succinylcholine|Immediately after anaesthesia induction at loss of consciousness 1 mg/kg of succinylcholine will be injected
223578287|NCT03085511|BEHAVIORAL|Egg breakfast (EB)|Breakfast is considered as high quality protein diet, but has similar weight, energy, and macronutrients as the active comparator. The details are as follows: weight 291 g,energy 400 kcal, energy density 1.37 kcal/g, carbohydrate 42.9%, fat 35.6%, protein 19.8%, protein digestibility corrected amino acid score (PDCAAS) 100, leucine 1.77 g, glycemic load 24, fiber 1.0 g.
223578288|NCT03085511|BEHAVIORAL|Weight Loss Counseling|Weight loss counseling will be administered by a Registered Dietitian and will utilize information and materials derived from the Evidence Analysis Library (EAL) of the Academy of Nutrition and Dietetics (AND). Topics will include portion control, macronutrient distribution, snacking, eating out, cooking and grocery shopping, as well as behavioral strategies including self-monitoring, motivational interviewing, goal setting, and problem solving.
223578289|NCT03085511|BEHAVIORAL|Weight Loss Diet|Participants will have a 1200-1500kcals diet based on each individual's body weight during the study.
223578290|NCT03085511|BEHAVIORAL|Cereal Breakfast (CB)|Breakfast is considered as low quality protein diet, but has similar weight, energy, and macronutrients as that in experimental group. The details are as follows: weight 293 g, energy 398 kcal, energy density 1.36 kcal/g, carbohydrate 44.8%, fat 35.4%, protein 19.8%, protein digestibility corrected amino acid score (PDCAAS) 42, leucine 0.48 g, glycemic load 30.8, fiber 4.4 g.
223578291|NCT01438801|DRUG|Nutropin [Somatropin (rDNA origin) for injection]|Doses in the diagnostic protocol are 0.7 and 1.4 mg/m2/day, injected by subcutaneous injection at bedtime for 2 weeks, divided by washout periods of preferably 4 weeks (accepted range 4-6 weeks). An additional period of 2 weeks on 2.8 mg/m2/day (after a washout period of 4-6 weeks) will be added if the IGF-I response on either dosage is insufficient (serum IGF-I SDS \<0).
223578292|NCT00215566|DRUG|DDP733|
223578293|NCT06159205|OTHER|standard exercises|Standard exercises for TKA patients.
223578294|NCT06159205|OTHER|core stability exercises|Core stability exercises for TKA patients.
223578295|NCT00378911|DRUG|sunitinib malate|Given orally
223578296|NCT05804630|DRUG|Different dental anesthetic agents during wisdom tooth surgery (Orabloc®, Octocaine®, and Xylestesin-A®)|As mentioned in arm/group descriptions. The amount of dental anesthetic agents used during the surgery will be tailored for patient according to their response, which will not exceed the recommended dosage described in the instruction of the product. The amount of the drug used during the surgery will be recorded.
223578297|NCT03069170|BIOLOGICAL|Stem Cell Transplantation|Intravenous and Intrathecal injections of purified autologus bone marrow-derived stem cells.
223578298|NCT02387164|DRUG|Alum-GAD|Two doses à 20 microgram 30 days apart subcutaneously administrated
223578299|NCT02387164|DRUG|Vitamin D3|2000 Units (IE) (50 microgram) vitamin D3 daily
223578300|NCT03173911|DEVICE|Bandage|Application of Elastic Bandage Therapy by the Therapy Taping method
223578301|NCT05411861|DRUG|Analgesic Non Narcotic|Injection of protocol-specified volume of local analgesic
223578302|NCT00497328|DRUG|N-acetylcysteine|
223468233|NCT05098080|BIOLOGICAL|Hutrukin|Hutrukin that binds the human cytokine IL-1α with high affinity and is an effective blocker of IL-1α biological activity. Hutrukin is a True Human™ therapeutic antibody. That is, the antibody was generated by a natural human immune response and was cloned directly from a human peripheral B lymphocyte. No in vitro affinity maturation or modifications have been made to improve its natural binding affinity. A true human antibody should be effectively non-immunogenic in humans and thus exhibit optimal activity and pharmacokinetics indistinguishable from native IgG1 immunoglobulin.
223468234|NCT05098080|BIOLOGICAL|Placebo|Placebo control for Hutrukin IV push.
223578303|NCT00497328|DRUG|Sodium Bicarbonate|
224303773|NCT00300508|DRUG|Anastrozole|
223468235|NCT00766324|DRUG|PHA-739358|6-hr IV infusion weekly for 3 consecutive weeks in a 4-week cycle
223468236|NCT00766324|DRUG|PHA-739358|24-hr IV infusion every 2 weeks in a 4-week cycle
223468237|NCT01061606|DRUG|temsirolimus|Given IV
223468238|NCT00735007|DRUG|Rebif® New Formulation (RNF) using RebiSmartTM|RNF 44 mg, 3 times a week by subcutaneous injection.
223468239|NCT03664115|DRUG|Itraconazole 200 mg|itraconazole 200 mg oral tablet daily, on a 21-day cycle.
223468240|NCT03664115|DRUG|Chemotherapy|"intravenous doses of cisplatin 80 mg/m2 on day 1 plus gemcitabine 1000 mg/m2 on days 1 and 8 every 3 weeks for a maximum of 6 cycles.~Alternatively, Carboplatin may be used instead of Cisplatin, Carbplatin AUC 5 DAY 1 only Dose = AUC x (GFR + 25) IV in 250 mL Normal Saline over 30 minutes"
223468241|NCT00012025|DRUG|fulvestrant|
223578304|NCT01549535|DEVICE|Colonoscopy done with:PeerMedical System and Olympus/Pentax/Fuji colonoscopy system|endoscopic diagnosis, treatment and video observation of the digestive tract, endoscopy and endoscopic treatment within the lower digestive tract (including the anus, rectum, sigmoid colon, colon and ileocecal valve) of adults patients
223578305|NCT06416176|OTHER|Mindfulness-Based Stress Reduction (MBSR) Program|Participants in the experimental group received an 8-week MBSR program by an MBSR instructor. Each meeting were planned as a 3-hour session that completes the mindfulness training procedures by doing an opening meditation of 30- 45 minutes about that week, after the information about the meeting topic of the week is discussed. Experiences after meditation were shared with the group. Each week, the meeting topic and meditation continued with different contents, and practice meditations on the subject were held every week and home exercises were given. Home practice meditations were performed by listening to the guide audio recording with headphones. All home exercises in the training content were followed up on a daily basis and recorded.
223578306|NCT01780714|OTHER|Conventional cigarettes (CC)|Subjects are randomized in a 1:1 fashion to be assigned either A) continuing CC, or B) switching to THS 2.1
223578307|NCT01780714|OTHER|THS 2.1|Subjects are randomized in a 1:1 fashion to be assigned either A) continuing CC, or B) switching to THS 2.1
223578308|NCT05747482|OTHER|Surgery procedure|Omentectomy vs omental preservations during gastric surgery
223578309|NCT03172091|DEVICE|eNose (electronic nose)|Collection of exhaled breath for an immediate analysis by electronic nose
224303774|NCT06008743|BEHAVIORAL|Belt Accelerations|Intervention used in both healthy and stroke survivors. In this mode, participants are walking on a treadmill with two belts with independent speed control. The speed of each belt will increase with constant acceleration during double support, shortly before push-off of the supported leg.
224303775|NCT06008743|BEHAVIORAL|Belt accelerations combined with an exoskeleton|Intervention used in both healthy and stroke survivors. In this mode, participants are walking on a treadmill with two belts with independent speed control, and using a hip exoskeleton. The velocity of each belt will increase with constant acceleration during double support, shortly before push-off of the supported leg. At the same time, they will be interacting with a wearable motion assistive device (i.e., exoskeleton). The exoskeleton will apply forces to the leg to resist hip extension during accelerations, reducing hip extension relative to the values of that participant at baseline.
224303776|NCT06008743|BEHAVIORAL|Variable Stiffness treadmill|Intervention used in both healthy and stroke survivors. In this mode, participants are walking on a treadmill with two belts with identical speed control. A variable stiffness mechanism under one belt will change the vertical stiffness of one side of the treadmill for one or multiple steps. The walkers will be informed before stepping on the softer surface on one side, which can be either the left or the right side.
223468242|NCT00715403|DRUG|BIBF 1120|
223468243|NCT01789047|DRUG|Topiramate|Topiramate as adjunct to amantadine
223468244|NCT01789047|DRUG|Placebo|Placebo control
223468245|NCT01789047|DRUG|Amantadine|Existing treatment for all participants
223468246|NCT03644017|DEVICE|WRAPSODY Stent Graft Placement|The stent graft will be placed into a target lesion (stenosis or occlusion) of a vein
223468247|NCT02078271|OTHER|FBDG group|The group received food based dietary guidelines for complementary feeding
223468248|NCT02078271|OTHER|Stimulation|The group received psychosocial stimulation
223468249|NCT02078271|OTHER|Combinded FBDG and stimulation|The group received both FBDG and psychosocial stimulation
223468250|NCT02078271|OTHER|Control group|
223468251|NCT06385171|DRUG|Botulinum toxin type A|The intervention involves the administration of Botulinum Toxin Type A, with dosages regulated according to FDA guidelines. Each injection site will receive a maximum of 4 units, adhering to the FDA's recommended dosage limits. Dosages administered will be tailored to each patient's needs and will be recorded in their individual patient information chart.
223578310|NCT03172091|DEVICE|Spectrometry|Collection of exhaled breath for an immediate analysis by mass spectrometry
223578311|NCT01709942|DRUG|degarelix (long acting GnRH antagonist)|20 mg of degarelix the first day of menstrual cycle before starting with gonadotrophins administration
223578312|NCT01709942|DRUG|cetrorelix 0.25mg|0.25mg of cetrorelix during treatment with gonadotrophins when estradiol levels were \>300pg/ml
223578313|NCT00000558|DRUG|angiotensin-converting enzyme inhibitors|
223578314|NCT04688541|DEVICE|Optitip Catheter (LinC Medical)|The Optitip catheter, unlike the Foley catheter design which has a protruding tip, the Optitip has a blunt open end (eyelet) that protrudes slightly beyond a single fluid-filled 10ml balloon. It has an additional drainage eyelet underneath the balloon.
223578315|NCT04688541|DEVICE|Foley catheter|Foley catheter
224303777|NCT05986253|DIETARY_SUPPLEMENT|Seaweed protein|Novel protein extracted from seaweed
224303778|NCT05986253|DIETARY_SUPPLEMENT|Maltodextrin|maltodextrin solution
223468252|NCT00002535|BIOLOGICAL|aldesleukin|
223468253|NCT00002535|BIOLOGICAL|lymphokine-activated killer cells|
223468254|NCT00002535|BIOLOGICAL|therapeutic tumor infiltrating lymphocytes|
223468255|NCT00002535|DRUG|cyclophosphamide|
223468256|NCT00002535|DRUG|indomethacin|
223468257|NCT05944575|DEVICE|active taVNS|The clip electrode will be attached to the cymba conchae of the left ear, the location of the auricular branch of the vagus nerve.
223468258|NCT05944575|DEVICE|sham-taVNS|The clip electrode will be attached to the lobule of the left ear that is not innervated by the auricular branch of the vagus nerve.
223578316|NCT04851821|DRUG|Quercetin|Each patient included, after signing the consent, will have a treatment for ten days: one tablet times three per day 30 minutes before the meal.
223578317|NCT03351686|DRUG|Tranexamic Acid|Tranexamic acid (Kepron, Amoun, Egypt) was given slowly intravenously over 10 minutes just before the skin incision of elective cesarean section to group A. Tranexamic acid injection was prepared by diluting 1g (10 mL) tranexamic acid into 20 ml of 5% glucose.
223578318|NCT03090074|BEHAVIORAL|Diet regime|Randomization to moderate or extreme low-carbohydrate Mediterranean diet advice.
224303779|NCT02283983|OTHER|mittens and booties|
223468259|NCT01143285|OTHER|Early and active nutritional support.|The first nutritional consultation coincides with the 1st CT consultation. An overview of the nutritional support strategy is given, along with specific goals and the twice monthly follow-up schedule that accompanies the chemotherapy courses. The nutritionist once again goes over the various side effects of the medication. Special attention will be given to digestive side effects and their consequences on appetite levels and weight loss during treatment.A qualitative and quantitative 3-day food record will precede the 1st course of CT. This food record is given to patients during the 1st selection visit, in order to evaluate spontaneous oral food intake and dietary habits. Information from the different food groups serves as a starting point for the dietician to explain how to adapt food intake through fortification, portion control according to appetite fluctuations and the onset of side effects.
223468260|NCT00078286|DRUG|Sertraline|Dosage ranging from 50 mg to 200 mg once a day
223468261|NCT00078286|DRUG|Placebo|Dosage ranging from 50 mg to 200 mg once a day
223468262|NCT02340000|DRUG|standard dose amoxicillin/clavulanate|amoxicillin/clavulanate 875/125 + placebo bid x 7 days
223468263|NCT02340000|DRUG|high dose amoxicillin/clavulanate|Time Period I: extended-release amoxicillin/clavulanate 1000/62.5 two tablets bid x 7 days Time Period 2: immediate-release amoxicillin/clavulanate 875/125 plus amoxicllin 875 bid x 7 days
223468264|NCT05108701|BEHAVIORAL|Individual Psychotherapy|Psychotherapy using meditation, yoga, through being in the present moment a non judgmental way and open minded
223468265|NCT02946359|DRUG|Crizotinib, bevacizumab|Eligible patients with ALK translocation or ROS1 translocation or MET amplification will be treated with Crizotinib at the standard dose of 250 mg BID and bevacizumab at the dose of 7.5mg/kg every three weeks. The dose of crizotinib and bevacizumab may be adjusted depending on the type and severity of toxicity encountered
223468266|NCT01284894|DEVICE|Conventional manometry|Conventional esophageal manometry
223468267|NCT01284894|DEVICE|High resolution manometry|High resolution esophageal manometry
223468268|NCT02951312|DRUG|Glycopyrrolate Inhalation Solution 25mg|25 μg oral inhalation via eFlow Nebulizer, once daily
223468269|NCT02951312|DRUG|Glycopyrrolate Inhalation Solution 75mg|75 μg oral inhalation via eFlow Nebulizer, once daily
223468270|NCT02951312|DRUG|Glycopyrrolate Inhalation Solution 200mg|200 μg oral inhalation via eFlow Nebulizer, once daily
223468271|NCT02951312|DRUG|Glycopyrrolate Inhalation Solution 200mg Jet|200 μg oral inhalation via inhalation via jet nebulizer, once daily
223578319|NCT03090074|BEHAVIORAL|Type of psychological support|Randomization to group-based psychological support according to ACT or to traditional cognitive behavioral therapy
223578320|NCT02120092|DRUG|Clopidogrel|1x Loading dose 600 mg 6x maintenance dose 150 mg
223578321|NCT02120092|DRUG|Ticagrelor|1x Loading dose: 180 mg 6x Maintenance dose: 90 mg bid
223468272|NCT02951312|DRUG|Glycopyrrolate Inhalation Solution 500mg|500 μg oral inhalation via eFlow nebulizer, once daily
223468273|NCT02951312|DRUG|Glycopyrrolate Inhalation Solution1000mg|1000 μg oral inhalation via eFlow nebulizer, once daily
223468274|NCT02951312|DRUG|Placebo|Placebo 0.5 mL oral inhalation via jet nebulizer, once daily
223468275|NCT04928781|BEHAVIORAL|Smoking Cessation Counseling|Smoking cessation counseling will be provided following standards set by the institution patients are receiving care at (Dartmouth-Hitchcock Medical Center).
223468276|NCT04549493|BEHAVIORAL|Exposure Therapy|Exposure Therapy is used to reduce the symptoms of PTSD
223468277|NCT01753609|DEVICE|Tulip capsule|swallowing Tulip capsule for up to 29 days
223468278|NCT05414851|OTHER|Whole-Food, Plant-Based Diet and Low-Carbohydrate Diet|Participants will consume two weeks of each diet, with a 4-6 week washout period in between. Meals and snacks are provided for convenience to enhance adherence to each dietary pattern, but subjects can add or include their own home-prepared foods as long as they meet dietary guidelines. Each dietary intervention will include an education session via Zoom teleconference, and at least 2 individual contacts by phone to address questions and assess for adverse events.
223468279|NCT03074877|BEHAVIORAL|Family Check-Up|The Family Check-Up (FCU) is a brief, family-based program to prevent Substance Use/Substance Use Disorder (SU/SUD) with replicated efficacy
223578322|NCT02120092|DRUG|ASA|"7x 100mg acetylsalicylic acid (clopidogrel arm)~1x 300 mg acetylsalicylic acid (ticagrelor arm)"
223578323|NCT02120092|DRUG|Placebo|7x 300mg acetylsalicylic acid placebo
223578324|NCT00966290|DRUG|Anticoagulant (warfarin, acenocoumarol, fluindione)|Anticoagulant clinic based shared-care group
223578325|NCT00966290|DRUG|Anticoagulant (warfarin, acenocoumarol, fluindione)|Usual care group
223578326|NCT04481802|DEVICE|RadiaAce gel|Patients will apply the RadiaAce to the treatment area starting 5 days before radiation treatment. The Hydrogel/cream will be applied three times a day with a minimum of four hours between applications. Treatments will be used through the course of RT and for 6 days after the last fraction of radiation.
223578327|NCT04481802|DEVICE|Biafine|Patients will apply the Biafine to the treatment area starting 5 days before radiation treatment. The Hydrogel/cream will be applied three times a day with a minimum of four hours between applications. Treatments will be used through the course of RT and for 6 days after the last fraction of radiation.
223578328|NCT05873179|OTHER|role-playing for learning the clinical interview|role-playing for learning the clinical interview
223578329|NCT04509245|BEHAVIORAL|Low-calorie diet supported by an app-guided digital education program, nutritional coaching calls via phone|During the 12-week intervention participants were asked to adhere to a real food-based low-calorie diet supported by an app-guided digital education program as well as a low-calorie recipe book and received weekly coaching calls by nutritionists
223578330|NCT01964599|DIETARY_SUPPLEMENT|PF-RS|n=20 will consume PF-RS containing 30 g potato fiber for 14 days and will consume a control containing no fiber for 14 days.
224303780|NCT02283983|OTHER|cooling helmet|
224303781|NCT04796753|OTHER|Basketball Injury Defense|To establish a specific evaluation protocol for youth basketball players.
224303782|NCT01459562|DRUG|NI-0501|
224303783|NCT01459562|DRUG|Placebo|
224303784|NCT03055650|DEVICE|iLux 2020 System|Medical device that applies localized heat and pressure therapy to the eyelid in order to express melted meibum from obstructed glands
224303785|NCT00837772|DEVICE|Standard cutting guide for TKA|Use of the usual cutting guide for surgical replacement of a diseased knee
223468280|NCT04522648|OTHER|Prospective surveillance|A participant with an increase from pre-surgery in total arm volume of ≥6% by self-measurement, or symptoms of BCRL ≥2 NRS will receive an assessment by a lymphedema therapist. At this appointment, participants will receive a physical examination of the arm along with a BIS measurement. A participant is considered having subclinical BCRL if an increase in lymphedema index (L-DEX) ≥7 from pre-surgery measured by BIS is identified. A fitted compression garment and gauntlet is then provided, free of charge, for daily wear 10 hours/day for four weeks along with a recommendation to use the arm for daily activities and maintain regular physical activity. Following the four-week compression period, participants will be re-measured using BIS to evaluate response. Participants who do not respond to compression will receive CDT delivered by the lymphedema therapist.
223578331|NCT01964599|DIETARY_SUPPLEMENT|PF-RO1|n=20 will consume PF-RO1 containing 30 g potato fiber for 14 days and will consume a control containing no fiber for 14 days.
223578332|NCT01964599|DIETARY_SUPPLEMENT|PF-RO2|n=20 will consume PF-RO2 containing 30 g potato fiber for 14 days and then will consume a control containing no fiber for 14 days.
223578333|NCT01964599|DIETARY_SUPPLEMENT|Control|
223578334|NCT01479595|DRUG|QBX258|QBX258 infusion, a combination of VAK694 and QAX576, was supplied to the Investigator as open label bulk medication. The planned dose of VAK694 (lyophilisate in vial, 150 mg/vial), was 3 mg/kg. The planned dose of QAX576 (lyophilisate in vial, 150 mg/vial), was 6 mg/kg.
223578335|NCT01479595|DRUG|Placebo|The placebo infusion was an equal volume of 5% dextrose for infusion and was provided by the clinical site.
223578336|NCT02000011|OTHER|comprehensive geriatric assessment (CGA)|
223578337|NCT02000011|OTHER|Geriatric intervention plan (GIP)|
223578338|NCT06076096|OTHER|Suprainguinal fascia iliaca block|The design of this study involved the retrospective analysis of data. Data was gathered from adult patients falling into the American Society of Anesthesiology (ASA) categories I to III, who were scheduled for elective lower limb surgical procedures. More specifically, patients who had undergone SIFIB either as the primary anesthesia approach or as part of their anesthesia regimen were included. Those who had received general anesthesia, neuraxial anesthesia, or infiltration anesthesia were excluded from the study. Importantly, all patients who participated in the study provided written informed consent for both their involvement in the study and the publication of their data.
223578339|NCT01862341|DIETARY_SUPPLEMENT|ANMUM In-Shape Nutritional Milk Powder for Active Mothers|
223578340|NCT05268744|DRUG|Micronutrient|Subject will take micronutrient supplement daily for 8 weeks
223578341|NCT00028431|BIOLOGICAL|MDX-CTLA4 Antibody; Tyrosinase/gp100/MART-1 Peptides Melanoma Vaccine|
223578342|NCT02255565|DRUG|Very Low Dose Quillivant XR|Oral suspension dose once a day increasing to a 10mg dose
223578343|NCT02255565|DRUG|Low Dose Quillivant XR|Oral suspension dose once a day increasing to a 20mg dose
223578344|NCT02255565|DRUG|Moderate Dose Quillivant XR|Oral suspension dose once a day increasing to a 40mg dose
223578345|NCT02878668|PROCEDURE|hepatopancreatobiliary surgery|hepatopancreatobiliary surgery
223578346|NCT03789695|DRUG|Dabigatran Etexilate|Study drug dabigatran etexilate. There are two dosage regimens of dabigatran etexilate used in the study: 150 mg b.i.d. and 110 mg b.i.d. The dose of dabigatran etexilate will be chosen by the investigator in accordance with Russian PRADAXA SmPC
223578347|NCT02833792|DRUG|Human Mesenchymal Stem Cells and Lactated Riunger's Solution|Intravenous administration
223578348|NCT02833792|OTHER|Placebo|Intravenous administration
223578349|NCT02721121|PROCEDURE|circumferential pulmonary vein isolation|
223578350|NCT02721121|PROCEDURE|Linear ablation in addiction to circumferential pulmonary vein isolation|
224303786|NCT00837772|DEVICE|Otismed MRI generated cutting guide for TKA|Use of the customized MRI generated cutting guide for surgical replacement of a diseased knee
223578351|NCT04151251|BEHAVIORAL|Patient Empowerment|Group to receive a 5 minute video about typical hospital sleep disruptions and what they can do to prevent them, as well as a brochure outlining the importance of sleep
223578352|NCT04151251|OTHER|Sleep Kit|Patients receive a small pouch that includes an eye mask, ear plugs, and headphones, all to be used to aid in falling/staying asleep
223578353|NCT03049267|DRUG|Apremilast|Fifteen patients will be supplied of apremilast for daily oral use; 16 weeks.
223578354|NCT03049267|DRUG|Placebo Oral Tablet|Five patients will be supplied with placebo tablets with identical labeling as apremilast for daily use; 16 weeks.
223578355|NCT02177643|DRUG|Diacerein|Diacerein oral capsules
223578356|NCT02177643|DRUG|Placebo|Placebo oral capsules
223578357|NCT02931604|DEVICE|SinuSafe Medical Device for Maxillary Sinus|Sinus lavage via the natural sinus ostium, without ostial dilation.
223578358|NCT04094649|DEVICE|Ultrasound Vagus Nerve Stimulation (DECIMA)|This is a single-site, double-blind, randomized, prospective, sham-controlled, crossover early feasibility study to determine whether ultrasound Vagus Nerve Stimulation (uVNS) inhibits postprandial hyperglycemia in humans.
223578359|NCT06296160|OTHER|Intervention Group|"A- (Intervention Phase= (Day-1) + (Day-15)~1. Obtain a lung ultrasound after the midweek dialysis session.~2. The 8-zone lung ultrasound method calculates the number of B-line scores.~3. Reduce the dry weight by 500 g if the B-line score is \>0.54/zone (BLS\>5). considered a day one.~4. The dry weight will be reduced only if the arterial blood pressure at the end of the session is BP \>110/60 mmHg and the patient had no hypotension episode during the session.~5. The adjustment of dry weight based on lung ultrasound should not be made on the same day as the standard approach adjustment (Regular monthly clinical standards modification.~6. Check the Blood Pressure 3 times/ day on the non-dialysis following the ultrasound.~7. Check the ambulatory blood pressure for 48 hours (Baseline on day 1 and Follow-up on Day 60).~B - Observational Phase= (Day-30) + (Day-45) + (Day-60)\]."
223578360|NCT00873379|DIETARY_SUPPLEMENT|melatonin|one half of a 1 mg tablet of GNC rapid dissolving Melatonin, NPN (natural product number) 80001380, available over the counter in Canada
223578361|NCT00873379|DIETARY_SUPPLEMENT|placebo|half a white placebo tablet
223578362|NCT02810938|DEVICE|Ablation of atrial flutter|Ablation of atrial flutter using IntellaTip Mifi 8 mm technology in combination with Maximum voltage-guided ablation approach
224303787|NCT04530708|RADIATION|Thoracic radiotherapy|36 Gy to the primary lung tumor and present mediastinal node metastases after three months of medical treatment.
224303788|NCT02553083|DRUG|Nexium 40 mg|Nexium 40 mg twice daily for 14 days
224303789|NCT02553083|DRUG|amoxicillin 1.5 gr|amoxicillin 1.5 gr twice daily for 14 days
223468281|NCT03832647|COMBINATION_PRODUCT|Epiduo|100 per arm Adapalene/ Benzoyl Peroxide
223468282|NCT03832647|DRUG|Salicylic Acid|Salicylic Acid
223468283|NCT03832647|OTHER|Hydréane légère|moisturizer
223468284|NCT05155748|OTHER|Continuous education and knowledge exchange|The intervention is educational and directed at the complete nursing home care team.
223468285|NCT05829499|DEVICE|HPMC-HA eyedrops|Ocular drops based upon HPMC and HA
223468286|NCT05656196|OTHER|Chinese herbal tea VGH-DESJS-1|Chinese herbal tea VGH-DESJS-1.
223468287|NCT02582333|OTHER|Observation for clinical and virological changes|Only observation after stopping nucleos(t)ide analogue
223468288|NCT01883895|DEVICE|Forgionei-Barber pressure-pain stimulator|Pain testing will be conducted using a Forgioni-Barber pressure-pain stimulator to deliver 3000-gm force to the middle digit of the non-dominant middle finger for up to 120 seconds. During stimulation, subjects will press a button attached to a timer when the pressure stimulus first becomes painful (pain threshold) and will also rate their perceived pain intensity using a 0-100 numeric pain rating scale at 20 second intervals during the 2 minute exposure to the pressure stimulus. This validated protocol has been used in previous research by investigators in this study. This will be used for both exercise sessions and the control session. Forgionei-Barber pressure-pain stimulator will be used.
223468289|NCT01883895|OTHER|Concentric Exercise|Concentric testing will utilize a dumbbell with elbow flexion exercise. Subjects will perform 5 sets of 20 reps at 30% MVC. Pain testing will be conducted using a Forgionei-Barber pressure-pain stimulator immediately before and after the exercise.
223578363|NCT03908645|DEVICE|Artificial intelligence assisted bowel preparation quality scoring system|After receiving standard bowel preparation regimen, patients go through colonoscopy under the AI monitoring device. During the withdrawal process, bowel preparation quality is monitored by AI-associated scoring system. Whenever a sub-score below 2 points is detected, endoscopist will be alarmed up to three times to wash and suck the colonic contents. Videos will be recorded and re-evaluated by experts to determine the final BBPS score. The withdrawal time is targeted at least 6min in accordance with colonoscopy quality practice. All detected polyps will be removed and obtained for histological assessment, with the possible exception of diminutive(less than 5mm) rectal polyps.
223578364|NCT03908645|DEVICE|Conventional human scoring|After receiving standard bowel preparation regimen, patients go through conventional colonoscopy without the AI monitoring device. During the withdrawal process, after washing and sucking the colonic contents according to endoscopist's personal experience, bowel preparation quality is evaluated by human. Videos will be recorded and re-evaluated by experts to determine the final BBPS score. The withdrawal time is targeted at least 6min in accordance with colonoscopy quality practice. All detected polyps will be removed and obtained for histological assessment, with the possible exception of diminutive(less than 5mm) rectal polyps.
223578365|NCT02617940|OTHER|fissure sealant|"Surfaces allocated to this group will be treated with resin-based sealant (FluroShield®, Dentsply, United States of America) according to the manufacturer's instructions.~Initially, local anesthesia and rubber dam adaptation will be performed. Then, 37% phosphoric acid will be applied on the surface for 30 seconds, followed by spray of water/air for at least 15 seconds. The sealant will be dispensed on the occlusal surface and light cured for 20 seconds (Optilight Max, Gnatus, Brazil)."
224303790|NCT02553083|DRUG|doxycycline 200 mg|doxycycline 200 mg twice daily for 14 days
223468290|NCT01883895|OTHER|isometric exercise|When undergoing isometric exercise, subjects will perform 5 sets of sustained muscle contraction for 65 seconds using a hand-grip dynamometer. Pain testing will be conducted using a Forgionei-Barber pressure-pain stimulator immediately before and after the exercise.
223468291|NCT03532737|DRUG|Pembrolizumab|Adding PD-1 inhibitor to the standard of care
223578366|NCT02617940|OTHER|oral hygiene orientation|Surfaces allocated to this group will be treated with sterile water application, as a placebo, without anesthesia and rubber dam. The active treatment in this group will be only oral hygiene orientations.
223578367|NCT04792333|DRUG|firibastat|Single oral dose of 500 mg administration on Day 1
223468292|NCT03969615|DEVICE|SuperNO2VA nasal positive airway pressure devic|SuperNO2VA nasal positive airway pressure device utilizes supplemental oxygen and an adjustable pressure limiting valve to maintain upper airway latency
223468293|NCT03969615|DEVICE|Supplemental oxygen|5lpm of supplemental oxygen
223468294|NCT02010112|OTHER|Breath Test Collection bags|Breath Collection bags will be used to collect breath of subjects before and after ingestion of 13-C breath test substrate
223468295|NCT02164955|DRUG|IMNOVID|IMNOVID (pomalidomide) as prescribed in routine clinical practice
223578368|NCT05690620|BEHAVIORAL|laughter yoga|Therefore, the laughter yoga program; It was planned as a face-to-face group session, for four (4) weeks, twice a week, for a total of eight (8) sessions and 20-25 minutes.
224303791|NCT02553083|DRUG|Nexium 20 mg|Nexium 20 mg twice a day for 10 days
223468296|NCT00073918|DRUG|cyclophosphamide|Given IV
223468297|NCT00073918|DRUG|etoposide|Given IV
223468298|NCT00073918|RADIATION|iodine I 131 tositumomab|Given IV
223468299|NCT00073918|PROCEDURE|quality-of-life assessment|Ancillary study
224303792|NCT02553083|DRUG|clarythromicin 500 mg|clarythromicin 500 mg twice a day for 10 days
224303793|NCT02553083|DRUG|amoxicillin 1gr|amoxicillin 1gr twice a day for 10 days
224303794|NCT04453202|BIOLOGICAL|RSV Vaccine|Participants will receive a single IM injection of an Ad26-based RSV vaccine on Day 1.
224303795|NCT04453202|OTHER|Placebo|Participants will receive a single IM injection of placebo on Day 1.
223468300|NCT00073918|PROCEDURE|peripheral blood stem cell transplantation|Undergo ASCT given via central catheter
223468301|NCT01409239|DRUG|Intravenous insulin|24 hr IV insulin administered according to hospital guideline
223468302|NCT01409239|DRUG|Subcutaneous Insulin|basal bolus insulin using carb counting technique and insulin analogues
223468303|NCT05440981|DEVICE|iTind device|Cystoscopy will be performed to assess the anatomy of the bladder and prostate. The iTind device would be inserted under visual guidance into the bladder. The device will then be deployed and under visual guidance, it will be positioned at the prostatic lumen. After confirming the position of the device, cystoscopy will be withdrawn and the position will be finished.
223468304|NCT05593484|OTHER|Standard Referral|Schools in the control condition will use standard referral, as determined by the school district. Standard referral is typically a letter home from the school to parents/caregivers of children who refer screening.
223578369|NCT05690620|OTHER|Control|"The students in the control group did not receive any intervention. Nursing students were followed for four weeks. Before the study, data collection tools were applied to the students. Again, after the start of the study and the end of the study, all other data collection tools except the Student Information Form were applied."
223468305|NCT05593484|OTHER|Specialty Telemedicine Access for Referrals (STAR)|The STAR intervention will include a lay-friendly smartphone or tablet that connects to tools necessary for an ear and hearing evaluation. If a child requires referral from hearing screening, a school nurse/teacher will complete the established protocol for the STAR intervention and send the information asynchronously to an audiologist for review.
223468306|NCT06063200|DRUG|Methylphenidate Pill|Single encapsulated pill
223468307|NCT05456893|PROCEDURE|Procedure: endoscopic biopsy|Per-endoscopic biopsies
223468308|NCT05456893|PROCEDURE|Blood sampling|Blood sampling
223468309|NCT05456893|PROCEDURE|stool sampling|stool sampling
223468310|NCT05816915|BEHAVIORAL|Cognitive behavioral therapy|Subjects will receive professional lifestyle intervention conducted by STOB organization. Using CBT and the so-called third wave of CBT, especially mindfulness, the patients will be guided by certified experts to increase motivation and to change eating and exercise habits, which will be mapped before and after the intervention.
223578370|NCT00732355|DEVICE|Syph-Check POC|Rapid membrane test for syphilis antibodies
224159177|NCT04391153|PROCEDURE|ERCP with tissue sampling|Patients with biliary strictures undergo ERCP o EUS. Tissue specimens obtained via either of brush cytology, forceps biopsy or fine needle aspiration during ERCP or endosonography (EUS) were examined by routine cytology or histology methods. In addition, FISH inlcuding fluorescence-based polynucleotide probes targeting chromosomes 3, 7, 17 and locus 9p21 was performed. Gold standard for final diagnosis is the histology from surgical resection. In patients without surgery, a follow up of 12 months will be considered adequate to exclude or confirm malignant etiology.
224159178|NCT02897154|DIAGNOSTIC_TEST|In-vitro|
224159179|NCT04629586|OTHER|No intervention|Observational research study
224159180|NCT04513041|PROCEDURE|Pinhole surgical technique and tunnel technique in a split mouth design|Each subject will have the each surgical procedure which are both considered routine minimally invasive clinical care for gingival recession. Gum recession on one side will receive Pinhole surgical technique (test procedure). The other side will receive Tunnel technique (control procedure), Research component involved is the capture of digital impression using intra-oral scanner in the baseline (preoperative) and the final visit (6 months postoperative).
224159181|NCT06015841|BIOLOGICAL|Placebo|The placebo is a solution matching the study vaccine formulation.
224159182|NCT06015841|BIOLOGICAL|ACI-7104.056 at Dose A|The study vaccine (ACI-7104.056) consists of an adjuvanted protein peptide conjugate vaccine.
224159183|NCT06015841|BIOLOGICAL|ACI-7104.056 at Dose B (optional)|The study vaccine (ACI-7104.056) consists of an adjuvanted protein peptide conjugate vaccine.
224159184|NCT06015841|BIOLOGICAL|ACI-7104.056 at Dose C (optional)|The study vaccine (ACI-7104.056) consists of an adjuvanted protein peptide conjugate vaccine.
224159185|NCT04507490|DEVICE|Whole body vibration|315/5000 application of whole body vibration with pre-established parameters for each group. All patients will participate in all groups, an interval of at least one week. They will be instructed to climb on the platform and to position a semi knee flexion and remain stationary during the vibration
224159186|NCT03201484|OTHER|FACE-Q questionnaire, 3D photography|FACE-Q questionnaire, 3D photography
224159187|NCT03510403|DEVICE|nastent™|Snorer and OSA patients (mild or moderate OSA) use the nasal airway stent for sleeping, each night for 1 month.
224159188|NCT00351390|OTHER|Drug therapy for HF|Titration of HF meds in an aggressive out patient manner following guideline direction
223468311|NCT04826393|DRUG|ASP8374|every 3 weeks by intravenous infusion
223468312|NCT04826393|DRUG|cemiplimab|intravenous infusion
223468313|NCT06653231|DRUG|local delivery of Curcumin gel|The test site will be completely undiluted curcumin gel through a 2 mL disposable syringe was placed in the test site
223468314|NCT02539017|DRUG|Chemo|Epirubicin,75mg/m2,intravenous ,on day 1 of each 21 day cycle, 4 cycles Cyclophosphamide,0.6g/m2,intravenous, on day 1 of each 21 day cycle, 4 cycles Docetaxel,75mg/m2, intravenous, on day 1 of each 21 day cycle, 4 cycles
223468315|NCT02539017|BIOLOGICAL|Immunotherapy|Immunotherapy with double dendritic cell (DC)and cytokine-induced killer (CIK) cell
223468316|NCT06221371|DRUG|rhTNK-tPA|rhTNK-tPA (0.25 mg/kg, maximum dose 25mg) is given as a single, intravenous bolus (injection over 5 to 10 seconds) immediately upon randomization. EVT should be performed as soon as possible after rhTNK-tPA administration.
223468317|NCT06221371|DEVICE|direct EVT|During the study period, NMPA-approved stents are permitted. EVT included thrombectomy with stent retrievers, thromboaspiration, intraarterial thrombolysis, balloon angioplasty, stenting, or a combination of these approaches at the discretion of the interventional team.
223468318|NCT01325545|OTHER|Mobile cardiac rhythm monitoring|Continuous ambulatory cardiac rhythm monitoring using the CardioNet MCOT device
223468319|NCT03159832|DRUG|SHR3824|All subjects were given SHR3824 20mg only one time.
223468320|NCT02938117|OTHER|cycling exercises|
223468321|NCT01537770|PROCEDURE|Percutaneous vertebroplasty|Using fluoroscopic guidance, the practitioner infiltrates the skin and subcutaneous tissues overlying the pedicle of the target vertebra or vertebrae with 1% lidocaine and infiltrates the periosteum of the pedicles with 0.25% bupivacaine (marcaine). 11-gauge or 13-gauge needles are passed into the central aspect of the target vertebra or vertebrae. Bone cement is prepared on the bench and injected under constant fluoroscopy into the vertebral body. Injection is stopped when the PMMA reaches to the posterior aspect of the vertebral body or leaks into an extraosseous space, such as the intervertebral disk or an epidural or paravertebral vein.
223468322|NCT01537770|PROCEDURE|Lidocaine injection|Using fluoroscopic guidance, the practitioner infiltrates the skin and subcutaneous tissues overlying the pedicle of the target vertebra or vertebrae with 1% lidocaine and infiltrates the periosteum of the pedicles with 0.25% bupivacaine (marcaine). 11-gauge or 13-gauge needles are passed into the central aspect of the target vertebra or vertebrae. 2 ml of 1% Lidocaine is injected in each needle. Bone cement is prepared on the bench simulating the vertebroplasty-procedure.
223468323|NCT05973955|BEHAVIORAL|Insomnia Treatment|The Insomnia Treatment is a version of Cognitive Behavioral Therapy for Insomnia adapted to individuals with hazardous alcohol use. It consists of the standard features of this well-established insomnia treatment in addition to adaptations that focus on alcohol use behaviors and alcohol-related thoughts that may be sleep-interfering as well as the provision of alcohol education material.
223468324|NCT05973955|BEHAVIORAL|Education Control|The Education Control intervention is an educational control that provides psychoeducation related to both sleep and to alcohol use.
223468325|NCT06111222|DEVICE|AT ELANA|The device is CE-approved. The device is a posterior chamber multifocal intraocular lens (IOL) indicated for aphakia after surgical extraction of the cataractous natural lens. The device is also indicated for non-cataractous, presbyopic patients (PRELEX) who seek greater independence from glasses for intermediate and/or near distances. It is an aspheric (aberration-neutral) IOL made of hydrophobic acrylic material, coated with heparin with modified C-loop haptics.
223468326|NCT06987682|OTHER|Balance training|Participants will don a safety harness that is secured to an overhead track. Each balance training session will involve 45 minutes of visual feedback balance training (VFBT) (Figure 1) followed by 45 minutes of reactive balance training (RBT), totaling 90 minutes. This combination will ensure all systems of postural control are targeted by the training, and that both standing and stepping are practiced. For both groups, FES and tSCS will be set up, including placing electrodes and setting stimulation amplitudes.
223468327|NCT06295458|DEVICE|David Delight Plus Device|Flicker exposure via a light and sound device-based stimulation-provided sensory stimulation device. The DAVID Delight Plus device consists of light-emitting goggles and sound-emitting headphones that are turned on and off with a repetition rate of 40 Hz connected to a controller operated by the participant or study partner (if the participant elects to have an optional study partner). At the baseline visit, light and sound intensity levels (auditory: 0-80 dBA, visual: 0-1400 lux) will be programmed into each participant's controller based on their unique response to tolerance and EEG entrainment testing which occurred at screening. The participant may not detect gamma-flicker frequency.
223468328|NCT06295458|OTHER|Sham Therapy|Sham therapy will be provided in the same manner as the flicker light. The difference is that it will be a constant light and sound from the same device instead of the 40hz light treatment and sound.
223468329|NCT04721197|OTHER|Egg vouchers|30-day egg vouchers will be provided monthly, in addition to standard of care.
223468330|NCT04721197|OTHER|Standard of Care|Participants will continue to receive the standard of care. No egg vouchers.
223468331|NCT06610175|DEVICE|Quantitative MRI and anatomical MRI|The total scanning time will be approximately 40 minutes. Additionally, 10 healthy participants and 10 patients with symptomatic CDDD will undergo a second MRI with additional sequences for assessment of reproducibility on another day/time. Also: included participants will undergo neurologic examination and fill out questionnaires for NDI, VAS-arm, VAS-neck, WA-SI, EQ-5D-5L, CSI, mJOA and Nurick.
223468332|NCT06673303|BEHAVIORAL|Dynamic perceptual discrimination task|The study featured two task conditions, each of which required the integration of information from both stimulus dimensions. In each condition, participants viewed a stimulus containing motion and color information and were required to specify one of two possible responses. Within each condition, rules and the response mapping changed occasionally, but always by changing on a fixed feature dimension (ie. rightward/purple, leftward/orange). These uncued intra-dimensional shifts involved translational shifts in the learning boundary, requiring them to adapt their decision making within a familiar dimension. These shifts compelled participants to continuously adjust their learning strategies by focusing on the most relevant feature dimension.
223468333|NCT06673303|DIAGNOSTIC_TEST|fMRI|Participant brain imaging data will be collected concurrently while performing the perceptual discrimination task.
223468334|NCT07016074|DRUG|Sodium Nitrate|The study drug is sodium nitrate capsule at a dose of 12mmol of nitrate. This medication will be given orally 1-8 hours before the planned contrast administration and then once per day for a total of four doses.
223468335|NCT07016074|DRUG|Placebo|The placebo control medication will be a capsule filled with lactose that will be taken in the same manner and schedule as the sodium nitrate capsule
223468336|NCT00919633|DRUG|interferon alfa-2b|subcutaneous continuous infusion at one of three doses for 48 weeks
223468337|NCT00919633|DRUG|peginterferon alfa-2b|1.5 μg/kg subcutaneous weekly for 48 weeks
223468338|NCT00919633|DRUG|ribavirin, USP|All patients will receive oral ribavirin
224159189|NCT00351390|OTHER|NT-proBNP guided HF therapy|Standard of care drug therapy following guideline direction, plus adjustment of medication titrated to achieve NT-proBNP \<1000 pg/mL
224159190|NCT06409104|DRUG|Propofol|will receive 1-2 mgkg-1 propofol injection over 30s followed by of propofol a 0.05 to 0.1 mg /kg/min infusion
224159191|NCT06409104|DRUG|Dexmedetomidine|will receive dexmedetomidine at a loading dose of 1 μg/kg over 10 min, followed by a 0.2-0.7-μg/kg/h infusion.
224159192|NCT01736163|DRUG|Thyrogen|0.9 mg IM, administrated for 2 consecutive days
224159193|NCT01736163|DRUG|131I|28 mCi or ≥ 1.036 GBq.
224159194|NCT01736163|OTHER|Thyroid Hormone Withdrawal|Stop taking hormone therapy
224159195|NCT02269904|DRUG|Fluorouracil Implants|Fluorouracil Implants: 800mg, implanted in the abdominal cavity during operation.
224159196|NCT02269904|DRUG|Xelox regimes|Xelox regimes: Capecitabine,1000 mg/m2，PO.BID, from D1 to D14; Oxaliplatin, 130 mg/m2，IV, D1 in each cycle. The cycle will repeated every 21 days till 6 cycles finished.
224068483|NCT04621370|DRUG|FOLFOX|"Oxaliplatin 85mg/m2 delivered intravenously as per institutional standard on Day 1 of mFOLFOX6 treatment every 2 weeks.~5-fluorouracil bolus 400mg/m2 delivered intravenously as per institutional standard on D1 of mFOLFOX6 treatment every 2 weeks.~5-fluorouracil infusion 2400mg/m2 delivered intravenously over 46 hours continuously as per institutional standard following bolus 5-fluorouracil."
223468339|NCT00919633|DEVICE|external drug infusion pump|pump delivery system for continuous subcutaneous infusion of interferon alfa-2b
223468340|NCT00288119|DEVICE|Balloon Capsule Device|The Esophageal Sampling Device BESD-001 is a non-endoscopic balloon capsule catheter for obtaining an esophageal mucosal sample. At the distal end of the catheter there is a silicone capsule textured balloon assembly. The textured balloon is initially inverted with vacuum for patient to swallow the capsule but then is inflated with 5.6 cc of air (5 cc syringe withdrawn maximally) to a 16-18 mm diameter in order to contact the lumen of the esophagus to collect a sample. The balloon has a textured surface, which enhances the collection of the esophageal sample. Following sample collection the textured balloon is inverted back into the hollow capsule component via syringe draw vacuum in order to maximize \& protect the site-specific sample collection.
223468341|NCT00288119|PROCEDURE|Endoscopy|An upper endoscopy is a procedure used to visually examine your upper digestive system with a tiny camera on the end of a long, flexible tube.
224068484|NCT04621370|RADIATION|Short Course Radiotherapy (Arm A)|25 Gray of photon radiation treatment delivered over 5 fractions.
224068485|NCT04621370|RADIATION|Long course chemoradiation (Arm B)|50 Gray of photon radiation treatment delivered over 25 fractions.
224068486|NCT04621370|DRUG|Capecitabine|Capecitabine is a non-cytotoxic pre-cursor of cytotoxic 5-fluorouracil and delivered in oral form. It is given concomitantly with long course radiation treatment on days of radiotherapy only. The dose is 825mg/m2 and this is delivered twice daily.
224068487|NCT01709149|DRUG|CK-2017357|CK-2017357 125 mg tablets twice daily
224068488|NCT01709149|OTHER|Placebo tablets|Tablets
224068489|NCT01709149|DRUG|Riluzole|Tablets
224068490|NCT03910829|BEHAVIORAL|Action Observation|Action observation training
224068491|NCT03910829|BEHAVIORAL|Motor Imagery|Motor imagery protocol
224068492|NCT03910829|BEHAVIORAL|Placebo Action Observation|Placebo Action Observation
224068493|NCT06179758|DEVICE|icompanion app|use of the icompanion app as a digital telemonitoring solution
224068494|NCT02616289|OTHER|Topical emollient (Sun Flower seed oil)|3 g of oil per kg of infant's weight at study entry of Sunflower Seed oil (SSO) will be applied three times per day at regularly spaced intervals (8-hour intervals) for 10 days. Oil will not be applied to the face (to avoid the possibility of any accidental aspiration or ingestion), ears or under the hairline. Care will be taken to not injure the skin during the massage treatment. The child's anal area will be washed prior to application to avoid the spread fecal flora from the anal region (to which the oil will be applied to last). Prior to bathing the child a minimum of 3-4 hours should have elapsed following the application of the SSO. The amount of oil required will be calculated based on the child's weight and the required amount weighed out each time.
224068495|NCT04622007|DRUG|Tomivosertib|Tomivosertib (eFT508) will be taken at 100 mg twice daily (bid) with meals
224068496|NCT04622007|BIOLOGICAL|Pembrolizumab|Subjects will initiate or continue to receive pembrolizumab at either 200 mg intravenously (IV) at a frequency of every 3 weeks or 400 mg IV at a frequency of every 6 weeks.
224068497|NCT04622007|DRUG|Pemetrexed|Subjects will initiate pemetrexed at 500 mg/m2 intravenously (IV) at a frequency of every 3 weeks.
224068498|NCT04775329|DRUG|Rifaximin|Rifaximin 1000mg OM
224068499|NCT00428974|DRUG|CF101 1mg|CF101 1 mg q12 hours for 12 weeks
224068500|NCT00428974|DRUG|CF101 2mg|CF101 2 mg q12 hours for 12 weeks
224068501|NCT00428974|DRUG|CF101 4mg|CF101 4 mg q12 hours for 12 weeks
224068502|NCT00428974|DRUG|Placebo|Placebo tablets q12 hours for 12 weeks
224068503|NCT00343668|DRUG|S-1, irinotecan|S-1, 40 mg/m2 PO twice daily, days 1-14 irinotecan, 150 mg/m2 IV, day 1
224068504|NCT03279614|DRUG|SOX|OXA：130mg/m2 ，iv drip for 180min d1, S-1 40-60mg p.o. bid d1-14, q3W
224068505|NCT01266863|OTHER|E test method|E test strips directly applied to BAL
224068506|NCT03335332|BEHAVIORAL|High intensity exercise|The exercise groups will receive identical exercise prescription for the first two months of the intervention, after which the HIE group will incorporate HIIT in their exercise regimen. The reason for this approach is to include a period of general conditioning and progressively increase intensity prior to submitting volunteers to HIE. This approach considers participant safety as arrhythmias may be uncovered during the first two months of MIE training. It will also improve participant compliance by increasing exercise self-efficacy and confidence prior to commencing HIIT.
224068507|NCT03335332|BEHAVIORAL|Moderate intensity exercise|A training program will be developed individually for each subject with the goal of increasing duration and intensity consistent with exercise training principles. Workouts will vary with respect to mode (walk, cycle) and duration (30 - 60 minutes). Each subject will be assigned an exercise physiologist and a heart rate monitor so that each session can be tracked and recorded. The first few exercise training sessions in both exercise groups (MIE and HIE) will supervised at our hospital based fitness centre until the subject is confident to complete the training independently.
224068508|NCT02797808|DRUG|Sertraline|Impact of sertraline on functional brain connectivity
224068509|NCT02797808|OTHER|No Intervention|Healthy control non-intervention
224068510|NCT02192827|DRUG|Dexamethasone Sodium Phosphate Injection|
224068511|NCT03269123|DEVICE|Pressop 1|A pressure device attached to the spectacles which mimics a sensory trick (geste Antagoniste)
224068512|NCT05506189|OTHER|mobile application program with human coach|6-months mobile application program with human coach for life-style modifiation including diet and exercise
224068513|NCT04601948|BEHAVIORAL|mHealth Activity Intervention|Eligible participants will receive a Fitbit activity monitor and access to our mHealth physical activity intervention for 6 weeks. The intervention will include regular motivational messages to encourage activity, a social media thread to provide social support, and a series of fun virtual walking races.
224068514|NCT02590588|DRUG|Idelalisib|Idelalisib daily until unacceptable toxicity or disease progression.
224068515|NCT02140814|DIETARY_SUPPLEMENT|Niacinamide|
224303796|NCT01169428|BEHAVIORAL|Mindfulness Based Weight Loss Maintenance (MBWLM)|This mindfulness-meditation based intervention is designed to increase awareness of the factors that affect weight loss maintenance after successful weight loss. Mindfulness meditation is a technique for training awareness. The program will train subjects to increase awareness of the somatic, cognitive, affective, interpersonal and environmental factors that mediate eating and physical activity by incorporating empirically-supported and theoretically-synergized components, including: general mindfulness meditation skills, mindful and intuitive eating, appetite-satiety awareness, mindful movement and yoga, a mindful approach to exercise engagement, and training in enhancing emotion regulation and stress management skills. In addition, the MBWLM group will be supported by Maintenance Partners who are trained as Integrative Health Coaches.
224303797|NCT01169428|BEHAVIORAL|Behavioral: Standard Behavioral Weight-Loss Maintenence|Attention/Education/Support Control group, designed to control for educational content as well as nonspecific treatment factors \[e.g., natural history (time), amount of time and energy spent in the intervention, attention by group leaders, social support, as well as information \& education\]. Like the experimental group(MBWLM), this group meet once a week for 2 hours during the 12-week intervention, and then at 4 weeks, 8 weeks, and 12 weeks post the 12 week intervention. Participants also receive the same amount of telephonic support through Maintenance Partners as the experimental group, but their Maintenance Partners employed empathic listening only rather than myriad coaching techniques.
224303798|NCT03885479|DIAGNOSTIC_TEST|ELISA for the semi-quantitative analysis of serum food-specific IgGs against food-derived antigens|An enzyme-linked immunosorbent assay (ELISA) for the semi-quantitative analysis of serum food-specific IgGs against 7 food-derived antigens (Wheat, rice, beans, cow milk, eggs, chicken and beef)
224303799|NCT02870400|DRUG|REGN2477|Participants will receive ascending doses of REGN2477
224303800|NCT02870400|DRUG|Placebo|Participants will receive matching placebo
224303801|NCT04076488|OTHER|Dividat Fit|tablet based, remote assisted home-training
224303802|NCT04784910|DRUG|DWP14012 20mg|DWP14012 20mg, tablet, orally, once daily for up to 24 weeks
224303803|NCT04784910|DRUG|Lansoprazole 15 mg|Lansoprazole 15mg capsule, orally, once daily for up to 24 weeks
224303804|NCT04784910|DRUG|DWP14012 20mg placebo|DWP14012 20mg placebo-matching tablet, orally, once daily for up to 24 weeks
224303805|NCT04784910|DRUG|Lansoprazole 15 mg placebo|Lansoprazole 15mg placebo matching capsule, orally, once daily for up to 24 weeks
224303806|NCT01483469|DRUG|RO4917523|orally daily, 14 days
224303807|NCT01483469|DRUG|RO5011232|\[11C\]-RO5011232 intravenously
224303808|NCT01095042|BEHAVIORAL|emotion|Show that the susceptibility in the stress (recording of Heart Rate Variability;viewing films;...) is more important at the person affected by digestive pathologies (SII or IBD) in forgiveness than to unhurt subjects of pathologies.
224303809|NCT03092063|BEHAVIORAL|Tomando Control-Nurse|Tomando Control de su Diabetes-Nurse is a community-based intervention given in six 2.5 hour sessions. The Spanish-language sessions are led by two trained Registered Nurses. Subjects covered in these sessions include: 1) techniques to deal with the symptoms of diabetes and associated conditions; 2) appropriate exercise; 3) healthy eating; 4) correct use of diabetes medications; and 5) working more effectively with health care providers in a collaborative partnership. Participants make weekly action plans, share experiences, and help each other solve problems they encounter in creating and carrying out their self-management strategies.
224303810|NCT03092063|BEHAVIORAL|Tomando Control-Promotora|Tomando Control de su Diabetes-Promotora is a community-based intervention given in six 2.5 hour sessions. The Spanish-language sessions are led by two trained promotoras. Subjects covered in these sessions include: 1) techniques to deal with the symptoms of diabetes and associated conditions; 2) appropriate exercise; 3) healthy eating; 4) correct use of diabetes medications; and 5) working more effectively with health care providers in a collaborative partnership. Participants make weekly action plans, share experiences, and help each other solve problems they encounter in creating and carrying out their self-management strategies.
224303811|NCT03092063|BEHAVIORAL|Enhanced engagement|The Tomando Control clinician (either a promotora or a Registered Nurse, depending on the original group assignment), will conduct up to three home visits that are designed to explain the purpose of the TC intervention to a key relative so as to re-engage the family member in the group process
223468342|NCT06466434|OTHER|Prebiotic Food-Enriched Diet|Given by PO
223468343|NCT07034248|OTHER|Electrochemical biosensor|considering benefits of the nitrogen, sulfur-doped graphene quantum dot (NSGQDs) and 3-dimensional gold nanoparticle (AuNP), we used these materials for the construction of a novel electrochemical biosensor to apply the synergy contributions on the enhancement of the potential in clinical and cancer diagnostic applications. The synthesis of a novel nanocomposite through the integration of NSGQDs with AuNP yields a hybrid material (NSGQDs/AuNP) that combines the advantages of both its organic and inorganic properties, potentially revealing unique characteristics to enhance the electrochemical behaviors, which establishes a robust foundation for constructing a label-free electrochemical biosensor. This pioneering biosensor was then conjugated with PhaL (NSGQDs/AuNP/PhaL) through the amide bond between the COOH group of NSGQDs and the NH2 group of PhaL, which has the potential for the ultra-sensitive detection of cancer markers, featuring heightened electrochemical and sensing capabilitie
223468344|NCT06709781|OTHER|Control (no cooling modalities)|Subjects will exercise for 60 minutes in the heat while being exposed to no cooling modality.
223468345|NCT06709781|OTHER|Water Spray|Subjects will exercise for 60 minutes in the heat while being exposed to skin wetting. Skin wetting will be performed by spraying water onto the skin throughout the exercise bout.
223468346|NCT06882733|DEVICE|Transcutaneous Electrical Nerve Stimulation，TENS|low frequency (4Hz) and sympathetic ganglion(T12.L1.L2) low frequency (4Hz) and gastrocnemius high frequency (80Hz) and sympathetic ganglion(T12.L1.L2) high frequency (80Hz) and gastrocnemius
223468347|NCT06884579|OTHER|Strength training, nutrition, and behavioral training|"This arm of the study consists of a supervised strength training program, conducted over 12 weeks with three weekly sessions. The sessions follow a wave-like periodization, with intensities ranging from 70% to 85% of 1-RM. Exercises focus on enhancing neuromuscular strength in the lower limbs, such as leg presses and hip extensions, under the supervision of a multidisciplinary team.~Participants will also receive nutritional guidance based on the Mediterranean diet, as well as cognitive-behavioral therapy strategies aimed at optimizing fatigue management and boosting energy levels."
223468348|NCT06884579|OTHER|Self-Guided and Unsupervised Program with General Recommendations|This arm of the study consists of a self-guided and unsupervised program based on physical exercise (3 times per week), nutrition, and cognitive-behavioral habits. Participants will access online modules that provide guidelines for performing resistance exercises with bands, dietary recommendations following the principles of the Mediterranean diet, and cognitive-behavioral techniques for fatigue management.
223468349|NCT01514942|DIETARY_SUPPLEMENT|Myo-inositol + Folic acid|Myo-inositol (2g) Folic acid (200mcg) (2 per day)
223468350|NCT01514942|DIETARY_SUPPLEMENT|Myo-inositol + Folic acid|Myo-inositol (2g) Folic acid (200mcg) (2 per day)
223468351|NCT01514942|DIETARY_SUPPLEMENT|D-chiro-inositol, manganese, folic acid, vit B12|D-Chiro-inositol (500 mg), manganese (1 mg), folic acid (200 mcg), vit B12 (1.25 mcg) (2 per day)
223468352|NCT01514942|DIETARY_SUPPLEMENT|D-chiro-inositol, manganese, folic acid, vit B12|D-chiro-inositol (500 mg), manganese (1 mg), folic acid (200 mcg), vit B12 (1.25 mcg) (2 per day)
223468353|NCT01514942|DRUG|Folic acid, vit B12|Folic acid (200 mcg), vit B12 (1.25 mcg) (2 per day)
223468354|NCT01514942|DRUG|Folic acid, vit B12|Folic acid (200 mcg), vit B12 (1.25 mcg) (2 per day)
223468355|NCT06686355|DRUG|Yiqilishui formula|Astragalus Root 30g, Angelica sinensis 30g, Honeysuckle Flower 30g, Capillary Artemisia Herb 15g, Giant Knotweed Rhizome 15g, Lepidium Seed 30g, Sichuan Lovage Rhizome 15g, Salvia Root 15g, Jujube Fruit 15g;
223468356|NCT06686355|OTHER|Placebo|5% Yiqilishui Granules + 95% Dextrin;
223578371|NCT06101602|OTHER|Dynamic Stretching with Floss Band|"Floss band involves wrapping a band made of natural rubber around the targeted joint or muscle for 1-3 minutes through active movement. The mechanism behind flossing is thought to have a three-fold effect, compression may stimulate the mechanoreceptors of the underlying fascia layer which causes the hyperemia of the targeted tissue, and leads to increased blood flow.~This intervention was applied in addition to dynamic stretching which involved 3 types of dynamic stretches. These stretches were applied through multidirectional (anteromedial, anterior, and anterolateral) leg swings specifically for the Hamstring muscle. It was performed in 3 sets of 15 repetitions with 30 seconds of rest between each exercise."
224159197|NCT04914195|DRUG|Leuprolide Acetate 3.75 MG/ML|Leuprolide Acetate/ Leuprorelin is a depot injection administered as a subcutaneous injection once every month.
224159198|NCT00492518|DRUG|Acetylcysteine|
224159199|NCT00492518|DRUG|Theophylline|
224159200|NCT00492518|DRUG|Placebo|
224159201|NCT03175952|DIAGNOSTIC_TEST|virtual histology intravascular ultrasound|Patients with saphenous vein graft disease will be examined using virtual histology intravascular ultrasound, and treated with percutaneous coronary intervention. Then they will be followed up at 1, 6 and 12 months.
224159202|NCT03415672|BIOLOGICAL|HBVaxPro|Three doses of HBVaxPro-10μg at 0, 1, and 2 months. The HBVaxPro-10μg vaccines are administered strictly intramuscularly in the deltoid muscle and must not be injected intravascularly.
224159203|NCT03415672|BIOLOGICAL|HBAI20|Three doses of HBAI20 at 0, 1, and 2 months. The HBAI20 vaccines are administered strictly intramuscularly in the deltoid muscle and must not be injected intravascularly.
224159204|NCT00130494|DRUG|Zoledronic acid|
224159205|NCT01964027|DRUG|second line chemoregime for advanced gastric cancer|Irinotecan(Camptosar)150mg /m2 d1,（intravenous infusion of 30-90 minutes) + epirubicin(Pharmorubicin) 50mg/m2 (total dose does not exceed 700mg/m2) every 21days for 1 treatment \* 6 cycles as the second line chemoregime for advanced gastric cancer
224159206|NCT03928340|DRUG|Metformin|"40 patients will be treated with metformin~(1 gm twice daily (with the 2 main meals)), combined with insulin therapy"
224159207|NCT03928340|DRUG|Insulin|40 patients will be treated with insulin alone. (Insulin dosage will be adjusted according to endocrinological recommendations)
224159208|NCT01660646|BEHAVIORAL|Behavioral: community sensitization|Behavioral, enhanced case finding (ECF) by community sensitization via audiovisual presentation in local languages, a session for questions and answers and opportunity to provide sputum specimens for detection of TB
224159209|NCT01876472|BEHAVIORAL|Assessment of music perception skills|A sequence of tones is presented to participants. Then the same sequence is presented again, with the 4th tone being one to six half tones different from the first sequence. Participants are asked to indicate when they hear a difference betweent the first and the second sequence.
224159210|NCT01100658|DRUG|Methylphenidate|1 capsule each day for 1 week, .3 mg/kg dose.
224159211|NCT01100658|DRUG|Placebo|1 capsule per day for 1 week.
224159212|NCT01238705|DRUG|Felodipine add Irbesartan|"Felodipine Sustained Release Tablets,5mg/day,AstraZeneca Pharmaceutical Co.Ltd., Registration Number: H20030415.~Irbesartan,150mg/day, Sanofi - Aventis Pharmaceutical company, Registration Number: H20080074."
224159213|NCT01238705|DRUG|Felodipine add Metoprolol|"Felodipine Sustained Release Tablets,5mg/day,AstraZeneca Pharmaceutical Co.Ltd., Registration Number: H20030415.~Metoprolol Succinate,47.5mg/day,AstraZeneca Pharmaceutical Co.Ltd., Registration Number: J20050061."
224159214|NCT03058302|BEHAVIORAL|CETA (Common Elements Treatment Approach)|The Common Elements Treatment Approach, or CETA, is a transdiagnostic psychotherapy based on cognitive behavioral elements for mood, anxiety and trauma related problems. CETA is based on the fact that most evidence-based mental health treatments (EBTs) consist of similar components. The objective of CETA is to provide a single training in a range of therapy components that are similar across EBTs and to then teach counselors how to design a specific course of treatment for each client based on the client's presenting problems.
224159215|NCT05472376|OTHER|Retrospective study|Retrospective study
224159216|NCT00711412|DRUG|Induction Therapy - Capecitabine|Two 21-day cycles will be given as induction. Capecitabine will be given at 1000 mg/m2 twice daily approximately 12 hours apart for 14 days, followed by seven days off.
223468357|NCT06726473|DIAGNOSTIC_TEST|Wet Blood Gas Analyzer (ABL90)|This group involves the use of the ABL90 wet blood gas analyzer for measuring arterial whole blood samples. The results obtained from the ABL90 analyzer will be compared with those obtained from the EG-i30 dry blood gas analyzer
223468358|NCT06726473|DIAGNOSTIC_TEST|Dry Blood Gas Analyzer (EG-i30)|This group involves the use of the EG-i30 dry blood gas analyzer for measuring arterial whole blood samples. The results obtained from the EG-i30 analyzer will be compared with those obtained from the ABL90 wet blood gas analyzer.
223468359|NCT06737601|DEVICE|shock waves|three sessions, weekly frequency
223468360|NCT06735885|DEVICE|Matter Neuroscience App|An iPhone smartphone application
223468361|NCT06735885|DEVICE|Stock Photos|Stock Photos
223468362|NCT06735885|OTHER|No Home Training|No Home Training
223578372|NCT06101602|OTHER|Dynamic Stretching without Floss Band|In this group, only dynamic stretching was applied which involved 3 types of dynamic stretches. These stretches were applied through multidirectional (anteromedial, anterior, and anterolateral) leg swings specifically for the Hamstring muscle. It was performed in 3 sets of 15 repetitions with 30 seconds of rest between each exercise.
223578373|NCT04583202|OTHER|Exposure to placebo|Patients are exposed to a placebo for 4h in the Alyatec EEC
223578374|NCT04583202|OTHER|Exposure to allergen|Patients are exposed to birch pollen allergens for 4h in the Alyatec EEC
223468363|NCT06634316|OTHER|Mediterranean diet|Mediterranean diet recommendations and daily physical exercise
223468364|NCT06634316|DIETARY_SUPPLEMENT|Hypercaloric, hyperproteic oral nutritional supplement|Hypercaloric, hyperproteic oral supplement combined with Mediterranean diet recommendations (2 per day) and daily physical exercise
223468365|NCT06634316|DIETARY_SUPPLEMENT|Protein module|Protein module (10g/day) combined with Mediterranean diet recommendations and daily physical exercise
223468366|NCT06634316|COMBINATION_PRODUCT|Vitamin D supplementation|Calcifediol supplement administered orally in order to reach sufficiency levels (30 ng/ml)
223468367|NCT06634316|COMBINATION_PRODUCT|Physical exercise|Physical exercise adapted to patients with heart failure (Cardiac rehabilitation)
223578375|NCT03855202|BIOLOGICAL|CBMNC|autologuous umbilical cord blood mononuclear cells 48 hours after birth ,dose is 25 million cells/kg
223578376|NCT03855202|BIOLOGICAL|PS+CBMNC|autologuous umbilical cord blood mononuclear cells 48 hours after birth ,dose is 25 million cells/kg ,PS,dose is 70mg/kg
223578377|NCT03855202|BIOLOGICAL|PS|PS,dose is 70mg/kg
223578378|NCT03855202|OTHER|Placeo|0.9% sodium chloride installation after 24 hours
223578379|NCT00663286|DRUG|IDP-110|Topical application for 12 weeks
223578380|NCT00663286|DRUG|Clindamycin|Topical application for 12 weeks
223578381|NCT00663286|DRUG|Benzoyl peroxide|Topical application for 12 weeks
223578382|NCT00663286|DRUG|Vehicle|Topical application for 12 weeks
223578383|NCT01356732|DRUG|Sufentanil|From 0 to 0,05 µg/kg to a maximum of 4 µg/kg of sufentanil. 7 minutes before nursing 3 nursing per day during 3 days
224068516|NCT00160459|DRUG|Asoprisnil|5 mg Tablet, oral Daily for 12 weeks
224068517|NCT00160459|DRUG|Asoprisnil|10 mg Tablet, oral Daily for 12 weeks
224068518|NCT00160459|DRUG|Asoprisnil|25 mg Tablet, oral Daily for 12 weeks
224068519|NCT00160459|DRUG|Placebo|Tablet, oral Daily for 12 weeks
224068520|NCT01780025|BEHAVIORAL|Auditory evoked potentials and audiometry|
224068521|NCT01780025|BEHAVIORAL|Auditory evoked potentials|Different protocols for audiometry and auditory evoked potentials
224068522|NCT01109888|DRUG|Cetrotide|
224068523|NCT01050270|DRUG|Ondansetron|4mgs iv bolus
224068524|NCT01050270|DRUG|acetylcysteine|100 mg/kg over 2 hours then 200mg/kg over 10 hours, followed by glucose 5% for 8 hours
224068525|NCT01050270|DRUG|acetylcysteine|150 mg/kg over 15 mins 50 mg/kg over 4 hours 100 mg/kg over 16 hours
224068526|NCT00181181|DRUG|atorvastatin|Atorvastatin 80 mg daily for 3 months
224068527|NCT00181181|OTHER|placebo|placebo daily
224068528|NCT05785312|DEVICE|Online EMDR Therapy System|Online EMDR Therapy System will be delivered through online computer system that will be specifically designed for delivering EMDR therapy online
224068529|NCT05785312|OTHER|Face to Face Eye Movement Desensitization & Reprocessing Therapy|The Face to Face Eye Movement Desensitization \& Reprocessing Therapy will be delivered in person inside clinician's room by following standard EMDR therapy protocol
224068530|NCT04163445|DEVICE|MicroPort Orthopedics EVOLUTION Medial Pivot TKA|Subjects will have been implanted with the Microport Evolution Medial Pivot TKA
224068531|NCT04163445|DEVICE|Depuy Synthes ATTUNE PCR TKA|Subjects will have been implanted with the Depuy Attune PCR TKA
224068532|NCT04388150|DIAGNOSTIC_TEST|Upper gastrointestinal endoscopy and biopsy|Gastroscope with technology of VIST video intelligent staining technology for taking biopsies
224068533|NCT06276803|DIAGNOSTIC_TEST|LINFU®|Patients will undergo low intensity non-focused ultrasound excitation of the pancreas for a total of 15 minutes using a GE LOGIQ10 or other FDA approved, FDA cleared or FDA exempt ultrasound insonation. A contrast agent will be administered IV during the ultrasound insonation and the patient will also receive a dose of secretin. The pancreatic juice will then be collected for a total of 15 minutes.
224068534|NCT01791907|BEHAVIORAL|Structured education in carbohydrate counting|
224068535|NCT01791907|BEHAVIORAL|Structured education in healthy food choices and low glycemic index|
224068536|NCT02469285|DIETARY_SUPPLEMENT|Modified pork|Pork with modified fatty acid composition
224068537|NCT02469285|DIETARY_SUPPLEMENT|Pork|Pork with normal fat composition
224068538|NCT02469285|DIETARY_SUPPLEMENT|Pork and berries|Pork with normal fat composition and Finnish berries
224068539|NCT02917889|DRUG|Caffeine|Volunteers will consume 300 mg of caffeine in pills fifteen minutes before treadmill aerobic exercise.
224068540|NCT02917889|DRUG|Placebo|Volunteers will consume 300 mg of placebo in pills fifteen minutes before treadmill aerobic exercise.
224068541|NCT02917889|OTHER|Cardiopulmonary test|"assessment of the maximum oxygen consumption (VO2max) on a treadmill (Inbrasport / Millennium), using Buce protocol.~."
224068542|NCT02917889|OTHER|Treadmill aerobic exercise|30 mim of aerobic exercise (5 minutes at speed of 5.0 km/h for warming-up followed by 25 minutes at 60% of VO2max ).
224070802|NCT06934395|BEHAVIORAL|Healthy Choices|Healthy Choices is an adapted and developmentally tailored intervention designed to address self-management of risk behaviors and HIV from Motivational Enhancement Therapy, a brief alcohol intervention in SAMHSA's registry of evidenced-based programs. For the purposes of this project, this intervention will be delivered as a combination approach, with all participants receiving an initial session via CIAS, and randomized to either receiving a telehealth session with a trained interventionist at week 2, with additional randomizations for telehealth sessions at weeks 4 and 6. The goal is to test if delivering (vs. not delivering) a coaching session increases the likelihood of achieving viral suppression and meeting criteria for no risky alcohol use at month 3
223468368|NCT07047677|OTHER|Early assessment of tissue uptake of experimental ligands|Ex vivo evaluation of the binding of experimental radiolabeled ligands on human tissue using autohistoradiography
223468369|NCT05072210|OTHER|Mobile Intervention|Active mobile data will be used to provide automated, personalized notifications to frontline healthcare workers. Key information on mental health and links to access additional health resources will be available on the mobile platform.
223468370|NCT04183725|DRUG|Reduning injection|"Reduning injection:~2≤Age≤5,0.5ml/kg/day,\<10ml/day+5％GS/0.9％NS 50～100ml,iv drip 30～40gtt/min qd\*5; 6≤Age≤10,10ml/day+5％GS/0.9％NS 100～200ml,iv drip 30～60gtt/min qd\*5; 11≤Age≤13,15ml/day+5％GS/0.9％NS 200～250ml,iv drip 30～60gtt/min qd\*5; Age=14,20ml/day+5％GS/0.9％NS 250ml,iv drip 30～60gtt/min qd\*5.~Oseltamivir phosphate granules simulants:~Weight≤15kg,30mg,po,bid\*5; 15\<Weight≤23kg,45mg,po,bid\*5; 23\<Weight≤40kg,60mg,po,bid\*5; Weight\>40kg,75mg,po,bid\*5."
223468371|NCT04183725|DRUG|Oseltamivir phosphate granules|"Oseltamivir phosphate granules:~Weight≤15kg,30mg,po,bid\*5; 15\<Weight≤23kg,45mg,po,bid\*5; 23\<Weight≤40kg,60mg,po,bid\*5; Weight\>40kg,75mg,po,bid\*5.~+Reduning injection simulants: 2≤Age≤5,0.5ml/kg/day,\<10ml/day+5％GS/0.9％NS 50～100ml,iv drip 30～40gtt/min qd\*5; 6≤Age≤10,10ml/day+5％GS/0.9％NS 100～200ml,iv drip 30～60gtt/min qd\*5; 11≤Age≤13,15ml/day+5％GS/0.9％NS 200～250ml,iv drip 30～60gtt/min qd\*5; Age=14,20ml/day+5％GS/0.9％NS 250ml,iv drip 30～60gtt/min qd\*5."
223468372|NCT02789969|DRUG|Hydromorphone|Hydromorphone 15mcg/kg IV
223468373|NCT02789969|DRUG|Fentanyl|Fentanyl 1.5mcg/kg IV
223468374|NCT01939730|DRUG|Rituximab|375 mg/m\^2 by vein once a week for 4 weeks on Days 1, 8, 15, 22.
223578384|NCT02120365|DRUG|Perampanel|Perampanel is a noncompetitive (allosteric) antagonist of the AMPA-R that is well-absorbed (100% bioavailability), has good blood-brain-barrier penetration, and rapidly reaches peak plasma concentrations (1 hour). To date, there have been no clinical trials of AMPA-R antagonists (e.g., perampanel) for the treatment of alcoholism.
223578385|NCT02120365|DRUG|Placebo|Placebo given in place of perampanel during the pre-treatment period and lab session days.
224159217|NCT00711412|DRUG|Induction Therapy - Oxaliplatin|Two 21-day cycles will be given as induction. Oxaliplatin will be given at 70 mg/m2 intravenously in 5% dextrose over two hours on days 1 and 8 of each cycle.
224159218|NCT00711412|DRUG|Combination Therapy - Capecitabine|Two 21-day cycles will be given for combination therapy. Capecitabine will be given at 825 mg/m2 twice daily approximately 12 hours apart for five days (Monday through Friday) followed by two days off for 51/2 weeks.
224159219|NCT00711412|DRUG|Combination Therapy - Oxaliplatin|Two 21-day cycles will be given. Oxaliplatin will be given at 50 mg/m2 intravenously in 5% dextrose over two hours on days 1, 8 and 15 of each cycle.
224159220|NCT00711412|RADIATION|Combination Therapy - Radiation|1.8 Gy daily Monday through Friday to a total of 50.4 Gy for 6 weeks during combination therapy.
224159221|NCT00711412|PROCEDURE|Evaluation for response and surgery|Four to eight weeks following the completion of therapy subjects will undergo evaluation for response and surgical resection.
224303812|NCT03092063|BEHAVIORAL|Multifamily Group|"The multifamily group consists of three components: three initial joining sessions conducted with each of the families separately; a one-day (six hour) educational workshop; and ongoing multifamily group sessions."
223468375|NCT01939730|DRUG|GM-CSF|250 mcg subcutaneously 3 times a week for 8 weeks.
223468376|NCT03291821|DRUG|human menopausal gonadotropin|human menopausal gonadotropin subcutaneously
223468377|NCT03291821|DRUG|GnRH antagonist|GnRH antagonist subcutaneously
223468378|NCT03291821|DRUG|GnRH analog|GnRH analog subcutaneously
224303813|NCT02931006|OTHER|water|
224303814|NCT02931006|OTHER|bovine milk|
223468379|NCT03291821|PROCEDURE|Trophectoderm biopsy|Trophectoderm biopsy is the process of removing few cells from an in vitro fertilization embryo.
223468380|NCT03291821|DIAGNOSTIC_TEST|MitoScore|The cells removed from an in vitro fertilization embryo during the trophectoderm biopsy will be used to assess the mitochondrial DNA content as a viability indicator in the euploid embryos.
223468381|NCT03291821|PROCEDURE|Intracytoplasmic sperm injection|ICSI is an in vitro fertilization procedure in which a single sperm is injected directly into an oocyte.
223468382|NCT03291821|PROCEDURE|Ovarian puncture|Egg retrieval is a simple procedure. It is performed in an operating room for safety reasons. It is performed vaginally and involves aspirating the follicular fluid through a thin needle. Embryologists then retrieve from this fluid the eggs that have matured during stimulation. It lasts for 5 to 15 minutes, and a mild sedative is administered to prevent any kind of pain during the procedure.
223578386|NCT06284616|BEHAVIORAL|JASP-1|patients following the Juvenile Arthritis Support Program at the Pediatric Rheumatology Clinic
223578387|NCT01056120|DEVICE|Pro Kinetic Energy bare metal stent|PCI
223578388|NCT00424411|DRUG|Inhaled human insulin (EXUBERA™)|
223578389|NCT01726673|DEVICE|Transcranial Direct Current Stimulation (tDCS)|
223578390|NCT01726673|DEVICE|Placebo sham|
223578391|NCT01719003|DRUG|Metformin 500 mg bid|Metformin 500 mg twice daily
223578392|NCT01719003|DRUG|Metformin 1000 mg bid|Metformin 1000 mg twice daily
223578393|NCT01719003|DRUG|Empagliflozin low dose qd|Empagliflozin low dose once daily
223578394|NCT01719003|DRUG|Empagliflozin high dose qd|Empagliflozin high dose once daily
223578395|NCT01719003|DRUG|Empagliflozin low dose bid|Empagliflozin low dose split twice daily
223578396|NCT01719003|DRUG|Metformin 500 mg bid|Metformin 500 mg twice daily
223578397|NCT01719003|DRUG|Empagliflozin high dose bid|Empagliflozin high dose split twice daily
223578398|NCT01719003|DRUG|Empagliflozin low dose bid|Empagliflozin low dose split twice daily
223578399|NCT01719003|DRUG|Metformin 1000 mg bid|Metformin 1000 mg twice daily
224159222|NCT00288522|DRUG|Lanreotide (Autogel formulation). Duration of treatment - 3 injections, 1 every 28 days|
224159223|NCT02790684|DRUG|DS-8500a|
224159224|NCT02527564|DRUG|Suvorexant|
224159225|NCT02527564|DRUG|Placebo|
224159226|NCT01902693|OTHER|No intervention for this study|No intervention
224159227|NCT00420342|DRUG|Drospirenone/17ß-estradiol (Angeliq, BAY86-4891)|SH K 00641 A -Active study medication encapsulated tablet
224159228|NCT00420342|DRUG|Drospirenone/17ß-estradiol (Angeliq, BAY86-4891)|SH K 00641 B - Active study medication encapsulated tablet
224159229|NCT00420342|DRUG|SH K 00641 C - Medroxyprogesterone acetate / conjugated equine (Prempro TM)|Active control encapsulated tablet
224159230|NCT04062526|DRUG|[18F]NOS|\[18F\]NOS is an investigational radiotracer which each subject will have one \[18F\]NOS positron emission tomography/computed tomography (PET/CT) scan performed.
223468383|NCT03291821|DIAGNOSTIC_TEST|Preimplantation genetic test|The cells removed from an in vitro fertilization embryo during the trophectoderm biopsy will be tested for chromosomal normalcy before transferring the embryo to the uterus.
223468384|NCT03291821|PROCEDURE|Embryo transfer|Embryo transfer refers to a step in the process of assisted reproduction in which embryos are placed into the uterus
223468385|NCT03291821|DIAGNOSTIC_TEST|Pregnancy test|A pregnancy test is used to determine whether a woman is pregnant.
223468386|NCT03291821|PROCEDURE|Embryo freezing|Embryo freezing is a method for cryopreserving embryos.
223468387|NCT03291821|PROCEDURE|Embryo thawing|Embryo thawing is the procedure to recover previously frozen embryos prior to an embryo transfer.
223468388|NCT04743622|DRUG|Monoprost|preservative-free latanoprost 1 drop once a day for 12 weeks to target eyes
223468389|NCT04743622|DRUG|Xalatan|preserved latanoprost 1 drop once a day for 12 weeks to target eyes
223468390|NCT01725685|DRUG|FF 400 mcg|FF will be available as 100 mcg strength administered as 4 inhalations from a DPI
223468391|NCT01725685|DRUG|UMEC 500 mcg|UMEC will be available as 125 mcg strength administered as 4 inhalations from a DPI
224159231|NCT05665738|RADIATION|High Dose Rate Monotherapy|High dose rate brachytherapy delivered in 13.5 Gy x 2 fractions over a single implant procedure 3 hours apart
224159232|NCT03550092|BEHAVIORAL|Abstract Semantic Association Network Training (AbSANT)|In each session, the participant will be asked to categorize words, choose/discuss semantic features for each word that accurately describe the word, and generate as many words as possible within a category.
224159233|NCT06061315|DIETARY_SUPPLEMENT|Effect of collagen peptides, in combination with resistance training, on body composition and muscle strength compared to placebo in untrained men|The effects of collagen peptide consumption in combination with resistance training will be tested
224159234|NCT06061315|DIETARY_SUPPLEMENT|Placebo Control intervention: Effect of resistance training in combination with placebo (silicon dioxide), on body composition and muscle strength in untrained men|The effects of placebo consumption in combination with resistance training will be tested
224159235|NCT06403475|DEVICE|Transcutaneous Vagus Nerve Stimulation|"Transcutaneous auricular vagus nerve stimulation using the Nurosym (Parasym Ltd) device.~Stimulation parameters:~Pulse width: 250µs; Frequency: 25Hz; Intensity: Below pain threshold.~The active stimulation will be delivered to the left tragus. Participants will complete the intervention at home once they have received sufficient training on how to use the stimulation device."
224159236|NCT06403475|DEVICE|Sham Transcutaneous Vagus Nerve Stimulation|Stimulation will be delivered at the same parameters however, sham stimulation will be delivered to the left earlobe. Earlobe stimulation has been used as a sham in other studies as it is not thought to activate the vagus nerve.
224159237|NCT06403475|BEHAVIORAL|Computer Based Speech and Language Therapy (Step by Step)|Computer-based Speech and Language Therapy will be completed whilst wearing the stimulation device in all groups. The Step by Step programme uses an errorless learning approach to practice naming. All participants will practice a set of 30 meaningful words during the intervention. Participants will complete the SLT programme at home on an ipad, whilst using the stimulation device.
224159238|NCT04072575|DRUG|PP6M injection Dose 1|Participants will receive Dose 1 PP6M intramuscular (IM) injection at Visit 1 (Day) then once every 6 month up to 24 months.
224159239|NCT04072575|DRUG|PP6M injection Dose 2|Participants will receive Dose 2 PP6M IM injection at Visit 1 (Day) then once every 6 month up to 24 months.
224303815|NCT02651454|DRUG|Daesiho-tang|Usage: 6g, three times a day, each taken before or between meals for 12 weeks Manufacturing company: HANPOONG PHARM \& FOODS Co. Ltd.
223468392|NCT01725685|DRUG|FF/UMEC 400/500 mcg|FF/UMEC will be available as 100/125 mcg strength administered as 4 inhalations from a DPI
223468393|NCT06765356|DEVICE|Farapulse Catheter System|"The FARAWAVE PFA Catheter is a sterile, single use, over-the-wire, non-deflectable device that is used with the FARASTAR Catheter Connection Cable and FARASTAR Generator to enable delivery of Pulsed Field Ablation energy for irreversible electroporation. The FARAWAVE PFA Catheter has five (5) variably deployable splines. The five splines are undeployed during insertion and removal and during use can deploy continuously from an undeployed state through a partially deployed (basket-shaped) configuration to a fully deployed (flower-shaped) configuration with five petals."
223468394|NCT06765356|DRUG|Low-dose Colchicine|For participants in the colchicine sub-study, 0.3 mg BID Colchicine. Colchicine will be prescribed to the patient starting 5 days prior to ablation. Patient will continue the colchicine for 3 weeks post-ablation.
223578400|NCT01719003|DRUG|Metformin 500 mg bid|Metformin 500 mg twice daily
223468395|NCT07062835|BEHAVIORAL|Perioperative Paediatric Application|"Children in the experimental group will start receiving interactive perioperative preparation training with the PeroPap application 1 day before surgery and play the PeroPap game. Children will learn about the operation process by watching and playing the PeroPap character's cartoon story about the operation process. They will also listen to the song PeroPap is having surgery and play the PeroPap Game in the application, which they can play before and after surgery. At the same time, in the parent module, information will be provided for parents with the cartoon story PeroPap is Having Surgery."
223468396|NCT07062835|OTHER|Control|"In order to meet the perioperative health care needs of the children and their parents in the control group, when they applied to the outpatient clinic for anaesthesia consultation on the working day before the operation, standard individualised care interventions will be provided according to their needs preoperatively and until their discharge, and children and parents will be given surgery preparation training with the education booklet PeroPap is Having Surgery."
223578401|NCT01719003|DRUG|Metformin 1000 mg bid|Metformin 1000 mg twice daily
223578402|NCT01719003|DRUG|Empagliflozin high dose bid|Empagliflozin high dose split twice daily
223578403|NCT01719003|DRUG|Metformin 1000 mg bid|Metformin 1000 mg twice daily
223578404|NCT01719003|DRUG|Empagliflozin high dose bid|Empagliflozin high dose split twice daily
223578405|NCT04832139|DRUG|Marstacimab PFP|300 milligrams (mg) subcutaneous injection marstacimab PFP
224303816|NCT02651454|DRUG|Chowiseungcheng-tang|Usage: 6g, three times a day, each taken before or between meals for 12 weeks Manufacturing company: Hanzung Pharmaceutical. co. Ltd.
224303817|NCT02651454|DRUG|Placebo|Usage: 6g, three times a day, each taken before or between meals for 12 weeks Manufacturing company: HANPOONG PHARM \& FOODS Co. Ltd.
224303818|NCT02912650|DRUG|Ibuprofen 250 mg / Acetaminophen 500 mg|2 caplets of Ibuprofen 250 mg / Acetaminophen 500 mg
224303819|NCT02912650|DRUG|Ibuprofen 250 mg|2 caplets of Ibuprofen 125 mg
224303820|NCT02912650|DRUG|Acetaminophen 650 mg|2 tablets of Acetaminophen 325 mg
224303821|NCT02912650|DRUG|Placebo|2 caplets of Placebo
224303822|NCT05445674|COMBINATION_PRODUCT|Plasma Exchange Procedure|Plasma exchanges will be performed with 5% albumin as the replacement fluid. The typical schedule prescribed will be an exchange of 1 volemia. Blood will be separated into cells and plasma; the cells will be combined with reconstituted 5% human serum albumin and reinfused into the patient with normal saline
224303823|NCT05445674|OTHER|Sham Plasma Exchange Procedure|For sham plasma exchange procedures, a sound behind the curtain will be performed imitating the sound of the cell processing platform. In these cases, only one infusion of 200 to 250ml of sterile saline solution 0.9% will be performed during the time stablished for all procedures. Albumin will not be necessary for those patients in the Sham plasma exchange arm
224303824|NCT04416620|OTHER|The PCOS pharmaceutical care service|"The intervention was provided in the format of oral plus written information. The information provided included the importance of exercise and motivational messages to exercise more at home or in the gym.~The 2nd part was about the importance of decreasing the stress levels. Participants were informed to perform a simple breathing exercise on daily basis twice a day.~The 3rd part aimed at improving participants' diets. They were informed to follow specific diet recommendations and to avoid certain types of food, explaining to them how it may negatively affect their PCOS condition.~The 4th part was about the PCOS treatment that was discussed with the participants. Females were advised on the importance of using their correct treatment. They were informed of the importance of adhering to their prescribed medications, accepting that it was a long-term treatment plan, and to consult with their specialist if their treatment was not effective, or in the case of medication side effects."
224303825|NCT01246362|DRUG|Control|Given placebo
224303826|NCT01246362|DRUG|Etoricoxib|Given etoricoxib 120mg 24 hours preoperatively and 120mg 2 hours preoperatively
224303827|NCT05477160|DRUG|STAR-0215 (SC)|STAR-0215 will be administered as an SC bolus injection.
224303828|NCT05477160|DRUG|Placebo (SC)|Placebo will be administered as an SC bolus injection.
224303829|NCT05477160|DRUG|STAR-0215 (IV)|STAR-0215 will be administered as an IV bolus injection.
224303830|NCT05477160|DRUG|Placebo (IV)|Placebo will be administered as an IV bolus injection.
224303831|NCT02562482|BIOLOGICAL|VRC-CHKVLP059-00-VP|VRC-CHKVLP059-00-VP is a virus-like particle (VLP) vaccine that consists of CHIKV VLP composed of E1, E2 and capsid proteins of the CHIKV (strain 37997).
224303832|NCT02562482|OTHER|VRC-PBSPLA043-00-VP|VRC-PBSPLA043-00-VP, a sterile phosphate buffered saline (PBS) is the placebo for the CHIKV VLP vaccine.
224303833|NCT01674647|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Rivaroxaban 20 mg orally once daily; subjects with moderate renal impairment (ie, CrCl of 30 to 49 mL/min, inclusive) will receive the adjusted dose of 15 mg orally once daily in the study
224303834|NCT01674647|DRUG|Vitamin K antagonist (VKA)|VKA orally once daily titrated to a target international normalized ratio (INR) of 2.5 (range 2.0-3.0, inclusive); the VKA type (eg, warfarin, acenocoumarol, phenprocoumon, fluindione, etc) will be assigned by the investigator according to local treatment standards
223578406|NCT04832139|DRUG|Marstacimab PFS|300 mg subcutaneous injection of marstacimab PFS
223578407|NCT02189408|BIOLOGICAL|Platelet rich plasma|
223578408|NCT05451355|BEHAVIORAL|Family Safety Check-In|Prototype decision aid to support within-family communication and decision making about firearm storage.
223578409|NCT05451355|BEHAVIORAL|AAP Firearm Storage Web Page|Educational web page that discusses safe firearm storage practices.
224159240|NCT02473289|DRUG|Sirukumab 50 mg|Participants will receive sirukumab 50 mg as subcutaneous injection on Day 1, 28 and 56.
224159241|NCT02473289|DRUG|Placebo|Participants will receive matching placebo on Day 1, 28 and 56.
224159242|NCT04575844|DRUG|Liraglutide|24 weeks of Liraglutide
224159243|NCT04575844|OTHER|Exercise training|24 weeks of Exercise training
224159244|NCT04575844|DRUG|Liraglutide + Exercise training|24 weeks of Liraglutide + Exercise training
224159245|NCT06061094|DRUG|Imatinib|Imatinib 600mg QD plus Chemotherapy
224159246|NCT06061094|DRUG|Ponatinib|Ponatinib 45 mg QD plus chemotherapy
224159247|NCT06061094|DRUG|Blinatumomab|Patients with molecular failure or intermediate response receive one cycle Blinatumomab before SCT; Patients with molecular CR randomized to the experimental arm receive 3 cycles Blinatumomab + chemotherapy
224159248|NCT06061094|OTHER|Indication for stem cell transplantation|Patients with molecular CR randomized to the standard arm have an indication for SCT; patients with molecular failure or intermediate response have an indication for SCT. SCT is not part of the trial.
224159249|NCT04788758|OTHER|Educational Intervention|Receive G8 screening tool administration training
224159250|NCT04788758|OTHER|Screening Questionnaire Administration|Complete G8 screening tool
224159251|NCT04788758|OTHER|Referral|Receive referral
224159252|NCT04788758|OTHER|Questionnaire Administration|Ancillary studies
224159253|NCT05031520|PROCEDURE|Coronary computed tomography angiography (CCTA)|Participants will undergo CCTA. CCTA performed in this study will be technically identical to CCTA that is commonly performed in clinical practice, for which safety profiles are well defined. Guidelines implemented by the National Institutes of Health Radiation Exposure Committee will be followed. Major risks of CCTA include exposure to ionizing radiation, the requirement for intravenous catheter placement and contrast media administration, and side effects of beta-blockers and nitrates that may be used for vasodilation and heart rate control to optimize CCTA image quality.
224159254|NCT05031520|DRUG|Isovue|CCTA requires intravenous catheter placement and the administration of iodinated contrast media (Isovue).
224159255|NCT05031520|DRUG|Nitroglycerin|Medication to promote coronary vasodilation during the CCTA may be administered immediately prior to CCTA to optimize image quality
224159256|NCT05031520|DRUG|Metoprolol|Medication to promote heart rate reduction during the CCTA may be administered immediately prior to CCTA to optimize image quality
223468397|NCT07066358|PROCEDURE|Simultaneous Bilateral RF Thalamotomy|This intervention involves simultaneous bilateral radiofrequency (RF) lesioning of the ventral intermediate nucleus (Vim) of the thalamus using a stereotactic frame under local anesthesia. The procedure begins with RF ablation on the side contralateral to the dominant hand. Intraoperative MRI is then performed to confirm the absence of hemorrhagic complications. If no bleeding or other adverse events are detected, the procedure proceeds to the contralateral Vim. If hemorrhage is identified, the surgery is terminated after unilateral treatment. This technique allows for immediate bilateral tremor reduction in patients with medication-refractory essential tremor, while prioritizing patient safety through intraoperative imaging-based decision-making.
223578410|NCT03730766|DRUG|Esomeprazole|Proton pump inhibitor
223578411|NCT03730766|DRUG|Amoxicillin|Antibiotics for H. pylori eradication
223578412|NCT03730766|DRUG|Bismuth Potassium Citrate|Gastric mucosal protective drug with anti-H. pylori effect
223578413|NCT01800656|PROCEDURE|"Endoloop-assisted ligate and let go colorectal polypectomy"|The technique implies placement of endoloop snare on the base of large pedunculated colorectal polyps without consecutive snare polypectomy.
223578414|NCT01800656|PROCEDURE|Endoloop-assisted snare colorectal polypectomy|The technique implies placement of endoloop snare on the base of large pedunculated colorectal polyps with consecutive snare polypectomy.
223468398|NCT07063706|OTHER|Pharmaceutical Care|Participants in the intervention group received pharmaceutical care
223578415|NCT02047201|RADIATION|IMRT|IMRT treatment planning using FDG-PET/CT images after induction chemotherapy (IC).
223578416|NCT02047201|RADIATION|PET/CT|Assessing tumor response using FDG-PET/CT.
223578417|NCT02047201|DRUG|Docetaxel|75 mg/m2, IV (in the vein) on day 1 every 3 weeks. Number of cycles: 3.
223578418|NCT02047201|DRUG|Fluorouracil|750 mg/m2 continuous infusion for 120 h IV (in the vein) every 3 weeks. Number of cycles: 3.
223578419|NCT02047201|DRUG|Cisplatin|75 mg/m2, IV (in the vein) on day 1 every 3 weeks. Number of cycles: 3.
223578420|NCT00900146|DRUG|Canakinumab|Canakinumab lyophilized cake (25 mg and 150 mg in individual 6 mL glass vials ) was reconstituted and then used to dilute the 25mg or 150mg solutions to make 5mg, 15mg and 50mg injections.
223578421|NCT00900146|DRUG|Metformin|Before randomization, in drug naïve patients at a dose of 1000 mg with the evening meal or 500 mg b.i.d. (twice daily) with two main meals. At the randomization visit, patients were prescribed with no less than 1,000mg/day.
223578422|NCT00900146|DRUG|Placebo|Placebo lyophilized cake will be reconstituted and then used to dilute the 25mg or 150mg solutions to make 5mg, 15mg and 50mg injections.
223578423|NCT06484010|OTHER|SNAPPS Model of case presentation|"The intervention was the implementation of the SNAPPS model as a method of case presentation in out-patient settings.~All preceptors and residents in the SNAPPS group were sensitized and trained one week before the beginning of case presentations and data collection by a training session that was carried out by the authors at Brayati Primary Health Center training hall for a duration of more than two hours, the session included a preview of the traditional method, introduction to the SNAPPS method, role play and doubts clarification.~The training materials included a presentation explaining the SNAPPS method in details with examples, instructional videos, and handouts highlighting the six steps of the SNAPPS method.~Before the beginning of the presentation by 72 hours, there was a double check by the principal investigator with all participants regarding the method and all doubts were clarified."
224159257|NCT01478061|DEVICE|Anastomosis (C-Port® )|creation of anastomoses in blood vessels and grafts, including use in coronary artery bypass grafting procedures
224159258|NCT04836091|BEHAVIORAL|Waitlist|From day 31 to day 60 (ie., during month 2) of the trial, participants in the waitlist arm will be granted access and instructed to use the OurPlan program as directed. The OurPlan program includes 4 modules covering topics of communication, HIV/STI prevention, HIV/STI statistics, and stigma / discrimination. Each module contains content, questions, and an activity for the participant and couple to complete. OurPlan also includes a resource locator using GPS-capabilities to allow participants to find sexual health resources, as well as a calendar and reminder system. One goal of OurPlan is to help both partners of the couple create and use a risk-reduction plan of evidence-based prevention strategies over time. Answers provided during the assessments will help determine whether participants/couples created a risk-reduction plan and used evidence-based strategies over time, including changes in their own and partner-related attitudes toward these strategies.
223468399|NCT07066501|BEHAVIORAL|Acceptance and Commitment Therapy (ACT)|Acceptance and Commitment Therapy methods were focused on promoting Values clarification, Acceptance, Cognitive defusion, Committed action and Flexible attention to the present moment, and included methods such as the Garden Metaphor or defusion training.
223468400|NCT07072364|BEHAVIORAL|Video on uterine fibroids|Patients will be sent a link to a 5 minute video on uterine fibroids including their diagnosis, symptoms and treatment options prior to their scheduled appointment.
223578424|NCT00415064|DRUG|Perifosine|Perifosine given in either 50 mg or 100 mg / day
223578425|NCT00415064|DRUG|Lenalidomide|Lenalidomide given in either 15 or 25 mg / day
223578426|NCT00415064|DRUG|Dexamethasone|Dexamethasone given in 20 mg / day
223578427|NCT01811303|OTHER|D-fagomine|Measure the changes produced on the postprandial Glycaemic response
223578428|NCT05767580|OTHER|evaluation|The Timed Get Up and Go test to assess dual-tasking, the 4m Walk Test to assess gait, and the Footprint Method to assess cadence
223578429|NCT01028716|DRUG|Cyclophosphamide|Given IV
223578430|NCT01028716|BIOLOGICAL|Filgrastim|Given SQ
223468401|NCT07072884|DRUG|GC012F injection|Subjects who meet the CAR-T cell infusion criteria will receive GC012F Injection infusion within 48-72 hours after completion of lymphodepleting preconditioning.
223468402|NCT07073872|OTHER|IDEAL Discharge Education Program|Participants in the intervention group received the nurse-led IDEAL Discharge Education Program (IDEP) and the control group received a standard 15-minute face-to-face discharge education the day of discharge day. The IDEP is a nurse-led, structured discharge education program in accordance with IDEAL Discharge Planning that uses the teach-back method. IDEP is an individualized discharge educational program for surgical patients that utilizes the teach-back method and a printed booklet.
223468403|NCT07073872|OTHER|control group|This group receives routine hospital discharge instructions for 15 minutes on the day of discharge.
223578431|NCT01028716|DRUG|Fludarabine Phosphate|Given IV
223468404|NCT07072312|BEHAVIORAL|Adjuvant Patient Navigation for Tobacco Treatment|Patients in the study meet with the Patient Navigator two weeks after their first tobacco treatment visit and again after their second visit with the Tobacco Treatment Provider. The Patient Navigator will discuss psychosocial and other cessation barriers. The Patient Navigator will connect the patients with appropriate resources to help overcome these barriers.
223468405|NCT07073846|DRUG|Intravenous Lidocaine infusion + Standard Anesthesia|Continuous IV infusion of lidocaine 1 % (10 mg mL-¹) at 0.3 mL kg-¹ h-¹ (≈ 1.5 mg kg-¹ h-¹) from induction of anaesthesia to skin closure. No loading bolus, no post-operative infusion.
223468406|NCT07073846|DRUG|Intravenous Dexmedetomidine infusion + Standard Anesthesia|Continuous IV infusion of dexmedetomidine 1 µg mL-¹ at 0.3 mL kg-¹ h-¹ (≈ 0.3 µg kg-¹ h-¹) without loading dose, started after induction and stopped at skin closure. No post-operative infusion.
223578432|NCT01028716|DRUG|Mycophenolate Mofetil|Given PO
223578433|NCT01028716|PROCEDURE|Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation|Undergo PBSC
223578434|NCT01028716|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo PBSC
223468407|NCT07073846|DRUG|Lidocaine + Dexmedetomidine Combination (LIDEX) + Standard Anesthesia|Single syringe containing lidocaine 1 % (10 mg mL-¹) + dexmedetomidine 1 µg mL-¹, infused IV at 0.3 mL kg-¹ h-¹ (delivering ≈ 1.5 mg kg-¹ h-¹ lidocaine + 0.3 µg kg-¹ h-¹ dexmedetomidine) from induction to skin closure.
223578435|NCT01028716|DRUG|Tacrolimus|Given IV or PO
223578436|NCT01028716|RADIATION|Total-Body Irradiation|Undergo total-body irradiation (TBI)
223578437|NCT03413098|DEVICE|Nasal CPAP mask|Investigative Nasal Mask to be used for OSA therapy
223578438|NCT03292419|PROCEDURE|Topography-guided LASIK|LASIK surgery
223468408|NCT07073846|DRUG|0.9 % Saline Placebo + Standard Anesthesia|Volume-matched IV infusion of 0.9 % normal saline at 0.3 mL kg-¹ h-¹ for the same duration and through the same delivery line as active arms; identical syringe appearance.
223468409|NCT07072338|BEHAVIORAL|Stress management training|The stress management training is the WHO SH+ (Self-Help Plus) program, a low-intensity, group-based intervention developed by the World Health Organization to improve stress management and psychological flexibility. It combines pre-recorded audio sessions with an illustrated self-help guide and is based on Acceptance and Commitment Therapy (ACT). The program is delivered over five sessions and supported by a digital platform for at-home practice.
223578439|NCT03040869|OTHER||
223578440|NCT05458089|DIAGNOSTIC_TEST|18F-FDG|18F-FDG intravenous injection
223578441|NCT03236168|DRUG|Ivermectin|A single weight based dose of ivermectin
223578442|NCT03236168|DRUG|Permethrin 5%|Permethrin cream is used in conjunction with Malathion shampoo when ivermectin is contra-indicated
223578443|NCT03236168|DRUG|Malathion Shampoo 0.5%|Permethrin cream is used in conjunction with Malathion shampoo when ivermectin is contra-indicated
223578444|NCT00767234|PROCEDURE|Observation|Standard of Care
223578445|NCT00837824|BIOLOGICAL|Fabrazyme (agalsidase beta)|1.0 mg/kg every 2 weeks
223578446|NCT00837824|BIOLOGICAL|Fabrazyme (agalsidase beta)|3.0 mg/kg every 2 weeks
223578447|NCT02182674|DRUG|Placebo Combivent HFA|
223578448|NCT02182674|DRUG|Combivent HFA|
223578449|NCT02182674|DRUG|Combivent (CFC)|
223578450|NCT02182674|DRUG|Placebo Combivent (CFC)|
223578451|NCT05832736|PROCEDURE|Robotic hemi-prostatectomy with urethral preservation|Robotic hemi-prostatectomy with urethral preservation
223578452|NCT02944565|BIOLOGICAL|Daratumumab|Given IV
224068543|NCT05300178|PROCEDURE|coronary artery bypass grafting surgery|Strategies of Complete Arterial Revascularization THE COMPOSITE TECHNIQUE When the distal RIMA bifurcation cannot loosely reach the LAD, we use the RIMA as a free graft, and a T-shaped , or if more suitable, a Y-shaped anastomosis at the level of the main pulmonary artery, is prepared before connection to cardiopulmonary bypass (CPB) THE CROSS TECHNIQUE The cross arrangement is based on the assumption that patency rates of the right internal mammary artery (RIMA) on the left anterior descending coronary artery (LAD) is similar to that of the left internal mammary artery (LIMA) on the LAD. To improve late survival, every effort should be made to use both IMA grafts for the left system THE IN SITU SEQUENCE When a graft to the posterior wall of the heart is not necessary (the circumflex region), the LIMA is grafted to the left anterior descending and the RIMA to the right coronary artery or its posterior de
224068544|NCT03027583|DIETARY_SUPPLEMENT|Probiotic|6 weeks daily oral intake of a probiotic strain.
224068545|NCT03027583|DIETARY_SUPPLEMENT|Placebo|6 weeks daily oral intake of placebo.
224068546|NCT03887897|PROCEDURE|Tracheal Intubation|Tracheal intubation performed by attending anesthesiologists using either Airtraq laryngoscope or Macintosh laryngoscope
224068547|NCT05913414|DRUG|Iron Isomaltoside 1000|Patients receive Iron isomaltoside after IC and CCRT
224068548|NCT05913414|DRUG|Polysaccharide Iron Complex Pill|Patients receive Polysaccharide Iron Complex Pill after IC and CCRT
224068549|NCT05913414|RADIATION|Intensity-modulated radiotherapy|All patients received intensity-modulated radiotherapy before enrolled.
224068550|NCT03524339|DRUG|Placebo oral capsule|Tamsulosin or placebo will be given for 3 days prior to surgery and one week after surgery to determine its effects on postoperative urinary retention.
224068551|NCT03524339|DRUG|Tamsulosin|Tamsulosin or placebo will be given for 3 days prior to surgery and one week after surgery to determine its effects on postoperative urinary retention.
224068552|NCT01976598|OTHER|Sub-Sensory Stimulation|Sub-Sensory Stimulation using Boston Scientific Spinal Cord Stimulation System in patients currently implanted with the system .
223578453|NCT06260137|PROCEDURE|Rhomboid intercostal block|Patients will be injected with a local anesthetic drug under the rhomboid intercostal muscle before surgery.
223578454|NCT06260137|PROCEDURE|Rhomboid intercostal and subserratus plane block|Patients will be injected with a local anesthetic drug under the rhomboid intercostal muscle and the serrates anterior muscle before surgery.
223578455|NCT06254664|DRUG|Tiotropium 18 µg inhalation powder, hard capsule|Tiotropium 18 µg administered using Zephir inhaler
223578456|NCT06254664|DEVICE|Zephir inhaler|Tiotropium 18 µg administered using Zephir inhaler
223468410|NCT07072338|BEHAVIORAL|Multidomain cognitive training|The multidomain cognitive training is a low-intensity, group-based intervention aimed at sustainably improving a healthy lifestyle, which in turn supports brain health and cognitive functioning. It combines pre-recorded audio sessions with an illustrated self-help guide and provides knowledge about aging and how to enhance three key lifestyle factors-social engagement, physical activity, and cognitive stimulation. The training uses metacognitive strategies and monitoring tools to help participants sustainably integrate these behaviors into their daily lives. The program is delivered over five sessions and supported by a digital platform for at-home practice.
223468411|NCT07072338|BEHAVIORAL|Social activities|The social activity intervention consists of a podcast discussion group in which participants listen to short podcasts on aging-related topics during each group session. Topics include driving (Session 1), intergenerational relationships (Session 2), technology (Session 3), the transition to retirement (Session 4), and travel (Session 5). These themes are deliberately chosen to be neutral and are not directly related to the techniques or content used to enhance well-being or cognitive functioning in the SH+ or COG interventions. The program is delivered over five sessions.
223468412|NCT07072065|DRUG|protein purified derivative|tuberculin purified protein derivative with dose 5 tuberculin unit
224070803|NCT06934395|BEHAVIORAL|Text Message Prompts|This within-participant micro-randomization will test whether, on average, delivering (vs. not delivering) a text messaged prompt focused on medication adherence or stress increases the likelihood of medication adherence by the end of the current day .
223468414|NCT07073625|OTHER|Stress Ball|Children arriving at the hospital's emergency department and meeting the study criteria will be randomly assigned to the stress ball group. Before inhalation therapy, the child will begin squeezing the chosen stress ball. This will distract their attention, transforming the frightening hospital environment into a fun one. The questionnaires will be completed by the nurse and family five minutes before, during, and after the inhalation therapy.
223468415|NCT07073625|OTHER|Reading Storybook|The storybook for the children will be selected by child psychologists. The book will be read to the children by their parents. The storybook reading will begin 15 minutes before the inhalation therapy and will be completed before the treatment begins. The storybook will be read to the children only once.
223468416|NCT07072286|PROCEDURE|Regional Anesthesia|"* Supra-inguinal fascia iliaca block (SIFI)~* Lumbar erector spinae plane block (ESP)~* Transmuscular quadratus lumborum block (QLB) All blocks will be performed by experienced anesthesiologists under ultrasound guidance, using long-acting anesthetics (ropivacaine) at fixed concentrations and doses within weight-based safety limits."
223468417|NCT07072286|DRUG|Multimodal analgesia|All enrolled subjects will be treated according to the standard analgesic protocol for pelvic fractures, in accordance with available literature and institutional guidelines. Specifically, the protocols include the use of multimodal analgesia techniques in line with current clinical practice, including paracetamol, non-steroidal anti-inflammatory drugs, opioids.
223468418|NCT07072117|DRUG|Intranasal Dexmedetomidine as a Premedication for Prevention of Anxiety & Respiratory Complications|Intranasal Dexmedetomidine as a Premedication for Prevention of Anxiety and Respiratory Complications in Children Undergoing Adenotonsillectomy
223468419|NCT07072117|DRUG|Intranasal Ketamine as a Premedication for Prevention of Anxiety and Respiratory Complications|Intranasal Ketamine as a Premedication for Prevention of Anxiety and Respiratory Complications in Children Undergoing Adenotonsillectomy
223468420|NCT07072117|DRUG|Intranasal Midazolam as a Premedication for Prevention of Anxiety and Respiratory Complications|Intranasal Midazolam as a Premedication for Prevention of Anxiety and Respiratory Complications in Children Undergoing Adenotonsillectomy
223468421|NCT07072247|GENETIC|CD19 and BCMA-targeted allogeneic CAR-T cells|Lymphodepletion chemotherapy followed by CD19 and BCMA-targeted allogeneic CAR-T cells infusion
223468422|NCT07071961|DRUG|Regorafenib (CT)|Given by po
223468423|NCT07071961|DRUG|Lorigerlimab|Given by IV
223468424|NCT07072949|OTHER|Metformin Monotherapy|Participants in this group (n = 30) received metformin alone, administered in a daily dose of 1000 to 2000 mg divided into two doses, over a period of four weeks.
223468425|NCT07072949|OTHER|Metformin combined with probiotic (Normia® Jadran Galenski Laboratory) supplementation|Participants (n = 30) received metformin (1000-2000 mg/day, divided in two doses) combined with a probiotic supplement (1 capsule three times daily) over a four-week period.
223468426|NCT07072949|OTHER|Triple therapy - metformin, probiotic and ursodeoxycholic acid (Bilexin®, Bosnalijek)|Participants in this group (n = 30) were treated with a combination of metformin (1000 - 2000 mg/day), a probiotic (1 capsule three times daily) and ursodeoxycholic acid (UDCA, 1 capsule (250mg) three times daily) for four weeks.
223468427|NCT07072442|DRUG|Western Medicine|Western medicine treatment only
223468428|NCT07072442|PROCEDURE|herbal medicine and acupuncture|Western medicine combined acupuncture and herbal medicine treatemnt
223468429|NCT07072442|DRUG|herbal medicine|Western medicine combined herbal medicine
223468430|NCT07072442|PROCEDURE|acupuncture|western medicine combined acupuncture
223468431|NCT07072494|DRUG|CD19 CAR-T cells injection|Lymphodepleting pre-treatment will begin one week before the CAR-T cell infusion to reduce the burden of abnormal immune cells in the body, creating a favorable environment for the infused CAR-T cells. The suggested pre-treatment regimen is based on the FC regimen (Fludarabine + Cyclophosphamide).After the pre-treatment, patients will undergo CAR-T cell infusion, where the genetically modified T-cells are infused back into the patient's body.
223468432|NCT07072169|DRUG|ABO2203 Injection|SC or IV
223468433|NCT07072923|DRUG|Antibiotic loaded calcium sulfate beads|Calcium sulfate beads will be loaded with best available antibiotics based on surgeon/infectious disease specialist determination from the following options (vancomycin, daptomycin, cefazolin, cefepime, tobramycin, amphotericin B, micafungin, and voriconazole).
224070804|NCT06942741|DRUG|MK-1084 OCT|Oral tablet
224070805|NCT06942741|DRUG|MK-1084 FCT|Oral tablet
223468434|NCT07072923|DEVICE|Calcium sulfate beads (sham beads)|Calcium sulfate beads will be prepared without added antibiotics and placed during the second surgery.
223468435|NCT05280093|DEVICE|AtriCure ISOLATOR Synergy Surgical Ablation System|Hybrid sinus node sparing ablation procedure using the ISOLATOR Synergy Surgical Ablation System
223468436|NCT06916091|DRUG|Eloralintide|Administered subcutaneously (SC)
223468437|NCT06916091|DRUG|Placebo|Administered SC
223468438|NCT06938828|OTHER|Observational cohort group|As this is an observational cohort study, there will be no intervention. In this study, only retrospective data will be collected for subsequent analysis. Similarly, the aim is to assess the relationship between the time on sick leave and the type of physiotherapy treatment received by patients. As this is an observational and retrospective cohort study, there is no risk derived from the development of the study for the subjects whose data form part of the study.
223468439|NCT04819217|DIETARY_SUPPLEMENT|Active bamboo charcoal|During this 6 months' trial, eligible 120 patients with eGFR 15 \< eGFR \< 45 ml/min/1.73m2 and UACR \> 100 mg/g will be enrolled and randomized into 4 groups. The patients in group 1 will receive CharXenPlus 4g (with ABC 2g) thrice daily + CharXprob 0.8 g once daily in the initial 3 months. Group 2 will receive CharXenPlus 4g thrice daily in the initial 3 months, and CharXprob 0.8 g once daily in the last 3 months. Group 3 will receive CharXprob 0.8 g once daily in the initial 3 months, and CharXenPlus 4g thrice daily in the last 3 months. Group 4 will only receive CharXprob 0.8 g once daily in the last 3 months.
223468440|NCT04819217|DIETARY_SUPPLEMENT|Probiotics|Probiotics
223468441|NCT05333497|DEVICE|the fourth programmed generation of low-frequency acupoint electric stimulation therapy instrument|Conventional electrical stimulation does not produce coordinated movement of multiple joints by stimulating several locally generated single ones simultaneously. The stimulation after the improved program, through different time output electrical stimulation on different parts of the muscles or muscle groups, forming the programmed motion. The purpose of this study is to achieve the rehabilitation goal of single joint - multiple joint - extensive movement, promote the coordination recovery of affected limb movement and relieve muscle fatigue.
223468442|NCT05333497|DEVICE|the fourth generation of low-frequency acupoint electric stimulation therapy instrument|In this study, the instrument of alternate acupoint electrical stimulation of flexor and extensor muscles combines traditional acupoint therapy with modern low-frequency electric stimulation technology, has the advantages of non-invasive and convenient application, and has a good effect on improving the range of motion of joints, relieving spasm, enhancing muscle strength, promoting the recovery of the central nervous system and other aspects.
223468443|NCT01278758|DRUG|ASA404, DMXAA or DXAA|
223468444|NCT06337500|DEVICE|Neurophysiological measure (EEG)|Cerebral electric activity recorded with EEG
223468445|NCT06337500|OTHER|Survey|Participants complete a survey to evaluate their exposure to screens and their assessment of the laboratory task performed
223468446|NCT02481050|DRUG|Eribulin Mesylate|Eribulin Mesylate will be administered as a 1.4 mg/m2 intravenous (IV) injection over 2 to 5 minutes biweekly on Day 1 and Day 15 of each 28-day cycle.
223468447|NCT02605200|BEHAVIORAL|Psychologist Support|Participants will complete several psychological questionnaires that are intended to cover a broad spectrum of physical, mental, and emotional aspects of the health of participants; the Behavior Assessment System for Children (BASC) ,the Children Depression Inventory (CDI 2), the Pediatric Quality of Life Inventory Transplant Module (PedsQL), and the Wechsler Abbreviated Scale of Intelligence II (WASI-II). Data gathered from this testing will be used to guide the provision of psychological care to address psychosocial challenges inherent to the care of children with transplant related diabetes.
223468448|NCT02605200|BEHAVIORAL|Pediatric Certified Diabetes Educators (CDEs) Support|Pediatric Certified Diabetes Educators (CDEs) are specially trained to teach diabetes self-management to children and their families. Participants who are diagnosed with diabetes will receive individualized support from a CDE in conjunction with their routine transplant care.
223468449|NCT03220841|DRUG|Adalimumab Injection|Standard dose adalimumab induction and maintenance
223468450|NCT03220841|DRUG|Thiopurine|Dose optimized thiopurine
223468451|NCT03220841|PROCEDURE|Endoscopic balloon dilatation|Prior to randomization, suitable patients may undergo endoscopic balloon dilatation. Patients undergoing dilatation will be stratified to ensure equal numbers in each study arm.
223468452|NCT03353376|BEHAVIORAL|group care with Empowerment model|Patients with type 2 and type 1 diabetes were followed in a tertiary outpatient clinic with group appointment
223578457|NCT01143896|OTHER|Depression collaborative care model|The intervention will include a stepped-care model. The 5 steps include symptom and self-management monitoring by a depression care manager (DCM) and the following: 1) watchful waiting, 2) treatment recommendations (counseling or pharmacotherapy), 3) pharmacotherapy recommended by a Clinical Pharmacist, 4) combination pharmacotherapy and specialty mental health counseling, and 5) referral to mental health. The DCM: provides education about depression and depression treatment options; assesses the patient's treatment preferences and barriers, and the patient's current depression severity and mental health comorbidity; initiates a patient self-management plan, and assess treatment adherence. The DCM uses standard alcohol screening and brief intervention. The DCM also screens for street drug use and recommends referral for to the local substance abuse treatment programs.
223578458|NCT02398695|OTHER|Oral Samples|Oral samples of saliva, dental plaque and DNA will be collected between the two groups.
223578459|NCT05107973|OTHER|Baduajin|The intervention will consist in a 1 hour supervised Baduajin sessions conducted once a week a certified instructor with more than 10 years of experience. Each session will start with 5 min of warm up, 50 minutes of Baduajin and 5 min of cool down. In the main part the participants exercise the wholes set of Baduajin that consist of eigth forms.
223468453|NCT04159714|DEVICE|Air Optix contact lens|Contact lens will be placed on the surface of the patient's eye and is to be used as a bandage
223468454|NCT06073288|OTHER|Surgical specimens of CD and no-IBD patients|Specimens of CD patients and patients without IBD-related disease (ex. diverticulitis) will be collected during the surgery, without other risks for the patients, since we will use only material left after pathologist analysis
223468455|NCT03933488|DRUG|TAK-994|TAK-994 tablets.
223468456|NCT03933488|DRUG|TAK-994 Placebo|TAK-994 placebo-matching tablets.
223468457|NCT04420988|BIOLOGICAL|COVID-19 Convalescent Plasma|COVID-19 Convalescent Plasma from recovered COVID-19 patients transfusion into severely or life-threateningly ill COVID-19 infected patients
223578460|NCT02074072|DEVICE|15 degree left-lateral tilt wedges|The wedges are made of aluminium
223468458|NCT02676804|OTHER|High-intensity, aerobic exercise.|"Aerobic exercise will blend unsupervised moderate and supervised high intensity exercise. It will consist of walking/jogging modalities, dependent on the subject's level of bradykinesia, paced by the subject's level of perceived exertion. The exercise protocol will be designed to target an total of at least 150 minutes of cardio exercise per week.~Exercise training will be performed 5 times per week for 6 weeks, consisting of 3 supervised high intensity sessions and 2 at home moderate intensity sessions. High intensity sessions will be performed on a treadmill at an intensity rating of \~ 15 and 17 on a rating of perceived exertion (RPE) scale of 6 to 20. The moderate intensity exercise will target an RPE of \~10 - 12 and participants will be asked to complete this on their own."
223468459|NCT03105011|BEHAVIORAL|EpxDiabetes software|Subjects will interact daily with a commercially available telemedicine product, Epharmix Diabetes (EpxDiabetes). They will each undergo a baseline blood draw to establish the control HgbA1C associated with standard of care. Three months later they will undergo an experimental blood draw to establish the HgbA1C associated with the use of EpxDiabetes. Between those procedures, the patient will interact with the intervention daily.
223468460|NCT05139342|DEVICE|expiratory muscle strentgh training (EMST)|"All patients undergo EMST training, and results will be compared between groups.~After individual adjustment of the EMST device for each patient, the patient receives speeach adn instruction from a speech and language pathologist on the correct use of the EMST device. The intervention regime then consists of 5x5 breaths per day for 14 consecutive days."
223578461|NCT02074072|DEVICE|30 degree left-lateral tilt wedges|The wedges are made of aluminium
223578462|NCT05854953|DEVICE|Hawley retainers in dry storage condition|Three months later, an exchange of storage methods from dry to wet conditions will take place.
223578463|NCT05854953|DEVICE|Hawley retainers in wet storage condition|Three months later, an exchange of storage methods from wet to dry conditions will take place.
223743621|NCT07189767|BEHAVIORAL|psychoeducation|The nurse/midwife-led psychoeducation intervention aims to encourage pregnant women to express their feelings about childbirth. It also provides a counseling framework to help women identify and overcome the distressing elements of childbirth. Psychoeducation allows pregnant women to obtain complete, evidence-based information about labor and to discuss their feelings and thoughts about the method of delivery and birth. Providing evidence-based information by nurses/midwives during psychoeducation helps pregnant women make informed decisions about their birth preferences. In addition to evidence-based information, the psychoeducation intervention includes discussing myths and misconceptions, increasing social support, reinforcing positive coping strategies, and focusing on problem solutions. Nurses/midwives encourage pregnant women to develop a positive birth plan through psychoeducation.
223743622|NCT07190859|DIETARY_SUPPLEMENT|L. reuteri|Supplementation with drops containing L. reuteri once daily for 21 consecutive days
223743623|NCT07190859|DIETARY_SUPPLEMENT|Placebo|Supplementation with identical drops without L. reuteri once daily for 21 consecutive days
224068553|NCT04466800|OTHER|Intervention group_rehabilitation program|"Regular physical activity, supervised by a physical education educator, a systematic malnutrition screening and a nutritional follow-up performed by a dietetician.~Patients will follow a 4-week rehabilitation program, comprising 3 physical activity sessions per week for 4 weeks. First sessions will be supervised by a physical activity educator and patients will perform the following sessions at home, using physical training software. The physical activity educator will call patients once a week to ensure the sessions are correctly performed and adapt the program if necessary. Patients will also undergo a nutritional assessment carried out by a dietitian at the beginning of the program. A dietitian will call patients once a week to ensure their nutritional status is appropriate."
224068554|NCT02995616|DEVICE|Regular therapy settings|Patients will walk in the Lokomat according to their regular therapy settings for a minimum of 20 minutes (i.e. minimum tolerable guidance force (GF), minimal tolerable body weight support (BWS) and maximum tolerable walking speed)
223468461|NCT06449352|DRUG|Netarsudil|netarsudil 0.02%
223578464|NCT05854953|DEVICE|VFRs in dry storage condition|Three months later, an exchange of storage methods from dry to wet conditions will take place.
223578465|NCT05854953|DEVICE|VFRs in wet storage condition|Three months later, an exchange of storage methods from wet to dry conditions will take place.
223578466|NCT05854953|DEVICE|Baseline characteristics|Hawley retainers and VFRs that are newly constructed will be used as baseline samples. The samples will be taken for microbial, physical and mechanical tests.
223578467|NCT02275728|OTHER|Pelvic floor muscle training|assessment and intervention group with a training of the pelvic floor muscles, another group with training of the pelvic floor muscles and electromyographic biofeedback and a control group will be held. All groups respond to a questionnaire of quality of life. At the end, all groups will be reassessed and compare the effectiveness of interventions between groups.
223578468|NCT02275728|OTHER|Eletromyography Biofeedback|
224068555|NCT02995616|DEVICE|100% guidance force|Patients will walk in the Lokomat with 100% GF for a minimum of 20 minutes (same amount of body weight support and walking speed as in the first session)
224068556|NCT02995616|DEVICE|60% guidance force|Patients will walk in the Lokomat with 60% GF for a minimum of 20 minutes (same amount of body weight support and walking speed as in the first session)
224068557|NCT05066256|DIAGNOSTIC_TEST|Left ventricular diastolic function|Transthoracic echocardiography Mitral E/e'
224068558|NCT05066256|DIAGNOSTIC_TEST|Inferior vena cava variation|Inferior vena cava variation from ultrasound
224068559|NCT01357486|DRUG|sorafenib|patients receiving sorafenib 400 mg - twice a day
224068560|NCT01357486|DRUG|Pravastatin|patients receiving pravastatin 40 mg - once a day
223578469|NCT06385717|RADIATION|chemo-radiation|different Chemo-radiotherapy regimen
223578470|NCT03209232|DRUG|Infliximab|Accelerated induction of infliximab in moderate to severe ambulatory prdiatric UC patients
223743624|NCT07191197|OTHER|MRI|structural and functional resting state MRI
223743625|NCT07191197|OTHER|Psychometric|2 cognitive research tasks of semantic learning and neuropsychological assessment
223743626|NCT07191366|PROCEDURE|Handstimulation of breast|Hand stimulation of the breast
224159259|NCT04836091|BEHAVIORAL|Intervention|From day 1 to day 60 (ie., entire 2 month duration) of the trial, participants in the intervention arm will be granted access and instructed to use the OurPlan program as directed. The OurPlan program includes 4 modules covering topics of communication, HIV/STI prevention, HIV/STI statistics, and stigma / discrimination. Each module contains content, questions, and an activity for the participant and couple to complete. OurPlan also includes a resource locator using GPS-capabilities to allow participants to find sexual health resources, as well as a calendar and reminder system. One goal of OurPlan is to help both partners of the couple create and use a risk-reduction plan of evidence-based prevention strategies over time. Answers provided during the assessments will help determine whether participants/couples created a risk-reduction plan and used evidence-based strategies over time, including changes in their own and partner-related attitudes toward these strategies.
224159260|NCT05316233|DEVICE|VOLITE XC|Intradermal Injection
224159261|NCT05316233|DEVICE|VOLITE XC|Subdermal Injection
224159262|NCT02283541|BEHAVIORAL|Automatic self-transcending meditation|ASTM is a category of meditation that helps quiet the mind and induce physiological and mental relaxation while the eyes are shut. It utilizes relaxed attention to a specific sound value (mantra) according to specific criteria, in order to draw attention inward.
224159263|NCT02244619|DRUG|Oral acetaminophen|Subjects randomized to the Oral acetaminophen arm will receive 2 Tylenol 500mg capsules. In this study, one arm receives an oral form of active medication and one arm receives an IV form of active medication. To keep the subject and study personnel blinded, subjects receiving Oral acetaminophen will also receive 100ml of IV Normal Saline similar to the delivery method of the IV acetaminophen arm. The Normal Saline IV placebo will be given not as an intervention but rather as a method to maintain study integrity.
224159264|NCT02244619|DRUG|IV acetaminophen|Subjects randomized to the IV acetaminophen arm will receive Ofirmev 1000mg in 100ml Normal Saline IV plus 2 placebo capsules. In this study, one arm receives an oral form of active medication and one arm receives an IV form of active medication. To keep the subject and study personnel blinded, subjects receiving IV acetaminophen will also receive 2 placebo capsules similar to the delivery method of the oral acetaminophen arm. The placebo capsules will be given not as an intervention but rather as a method to maintain study integrity.
224159265|NCT06397391|DEVICE|TREM-AB|Wearing medical device on site during 1 hour
223468462|NCT06449352|DRUG|Brimonidine|brimonidine 0.1%
223468463|NCT03246347|DRUG|ADT+Docetaxel+Enzalutamide|combination therapy as listed above
223468464|NCT06400212|OTHER|Cardiopulmonary exercise test|Participants undergo a cardiopulmonary exercise test following a standardised protocol used in national guidelines
223468465|NCT04923529|DRUG|TAS 102|"Days 1 through 5: TAS-102 (35 mg/m2/dose) orally 2 times daily with the first dose administered in the morning of Day 1 of each cycle and the last dose administered in the evening of Day 5.~Days 6 through 7: Recovery~Days 8 through 12: TAS-102 (35 mg/m2/dose) orally 2 times daily with the first dose administered in the morning of Day 8 of each cycle and the last dose administered in the evening of Day 12.~Days 13 through 28: Recovery"
223468466|NCT04893161|DRUG|Belimumab|All patients with SLE will be enrolled in one year and administrated belimumab 10mg/kg intravenous infusion over 1 hour on days 0, 14, and 28, and every 28 days through week 48.
223468467|NCT04361656|DRUG|PEG-ELS current standard of care|Standard of care for inpatient colonoscopy
223468468|NCT04361656|DRUG|PEG-ELS current standard of care plus Lubiprostone 24 microgram Oral Cap (x2)|The dose of Lubiprostone will be 24 mcg capsule orally (roughly every 12 hours) for total of 2 doses, with the last dose being at least 4 hours prior to the scheduled colonoscopy if it is BEFORE 11 a.m., and Lubiprostone 24 mcg capsule orally 2 hours before each dose of the PEG-ELS if colonoscopy is scheduled AT or AFTER 11 a.m..
223468469|NCT04016974|DRUG|Oral semaglutide|Semaglutide tablets once daily as follows: 3 mg for the first treatment period (day 1-28), followed by 7 mg in the second treatment period (day 29-56), followed by 14 mg in the third treatment period (day 57-84)
223468470|NCT04016974|DRUG|Placebo|Placebo tablets once daily throughout the treatment period (day 1 to 84)
223468471|NCT05675163|DIETARY_SUPPLEMENT|Vitamin K2|(K2VITAL® 1% MCT Oil)
223468472|NCT05675163|DIETARY_SUPPLEMENT|Placebo|Sunflower oil
223468473|NCT02188160|DRUG|KPI-121|KPI-121 drug product will be supplied as 0.25% as a suspension in identically packaged opaque dropper bottles. KPI-121 drug product is a sterile, aqueous, submicron suspension of loteprednol etabonate.
223468474|NCT02188160|DRUG|Placebo|Subjects randomized to placebo control arms will receive the same bottles containing all components at the concentrations used in the KPI-121 drug product with the exception of the active component, loteprednol etabonate.
223468475|NCT04113694|DEVICE|Extended Infusion Set|Each subject is asked to wear each Extended Wear Infusion Set for at least 174 hours.
223468476|NCT05556252|OTHER|Hydrogenated water consumption|Participants will start consuming hydrogenated water on the 16th day of the menstrual cycle and will continue to apply it until the 2nd day of the next cycle. Within the scope of the study, they will be asked to drink of 300-400 ml hydrogenated water each morning before breakfast; 300-400 ml an hour before lunch; 300-400 ml two hours after lunch; 300-400 ml an hour before dinner; 300-400 ml half an hour before going to bed. Participants will be asked to consume a minimum of 1500 ml (1.5 L) and a maximum of 2000 ml (2.0 L) hydrogenated water in total. In this way, participants will be provided with hydrogenated water for three cycles.
223468477|NCT05556252|OTHER|Drinking water consumption|Participants will start consuming drinking water on the 16th day of the menstrual cycle and will continue to apply it until the 2nd day of the next cycle. Within the scope of the study, they will be asked to drink of 300-400 ml drinking water each morning before breakfast; 300-400 ml an hour before lunch; 300-400 ml two hours after lunch; 300-400 ml an hour before dinner; 300-400 ml half an hour before going to bed. Participants will be asked to consume a minimum of 1500 ml (1.5 L) and a maximum of 2000 ml (2.0 L) drinking water in total. In this way, participants will be provided with drinking water for three cycles.
223468478|NCT00464685|DRUG|Dexamethasone|Initial intravitreal injection of 700 µg dexamethasone with up to 1 additional treatment based on re-treatment criteria.
223468479|NCT00464685|DRUG|Sham injection|Initial sham injection with up to 1 additional treatment based on re-treatment criteria.
223743627|NCT07189754|DIETARY_SUPPLEMENT|Sabroxy™ (Oroxylum indicum extract)|Sabroxy™ is a standardized extract derived from the bark of Oroxylum indicum. In this study, participants will receive Sabroxy™ in capsule form. Each capsule contains a fixed dose of the extract and will be administered orally at a regimen of one capsule twice daily after meals for 12 weeks. The supplement is provided in visually identical containers to maintain blinding and is compared to a placebo control. The intervention is designed to evaluate potential improvements in cognitive function, including memory, attention, and executive performance, as well as effects on circulating Brain-Derived Neurotrophic Factor (BDNF) levels.
224159266|NCT03134469|DIETARY_SUPPLEMENT|Probiotic supplement|Probiotic supplement
224159267|NCT03134469|DIETARY_SUPPLEMENT|Placebo supplement|Placebo supplement
223468480|NCT00464685|PROCEDURE|Laser Photocoagulation|Initial laser photocoagulation with up to 3 additional treatments based on re-treatment criteria.
223468481|NCT06432348|OTHER|Reformer pilates|Before starting the exercises, a 5-minute warm-up session was performed. The reformer Pilates exercise program included movements such as the Footwork Series (Toes, Heels, Tendon Stretch, V Position), Supine Arm Series (Pull, Circle, Pull Head Up, Triceps Press), Short Box Series (Round, Flat Back, Twist), Short Box and Arm Series (Chest Fly, The Gift, Rhomboid, Biceps Curl, Rowing, Triceps), Long Box Series (Swan, Pulling Fly), Stomach Massage (Round, Twist), Knee Stretch (Round, Flat Back), Hip Work Series (Double Leg Press, Hamstring Pulls, Leg Circle, Frog), Elephant, and Side Stretch. Participants had two-minute rest intervals after the Supine Arm Series, Short Box, Arm Series, and Knee Stretch movements. Movements were performed with ten repetitions in the first four weeks and 12 repetitions in the following four weeks. The participants underwent six weekly training sessions over eight weeks, comprising three Reformer Pilates sessions and three team training days.
223468482|NCT06432348|OTHER|Mat Pilates|Before the exercises, a 5-minute warm-up session was performed. The mat Pilates exercise program included movements such as Rol Up, One Leg Circle, Double Leg Straight Lower, One Leg Stretch, Criss Cross, Toe Top, Shoulder Bridge, Seated Tracking, Spine Twist, Up-Down Side Kick, Front-Back Side Kick, Circle Side Kick, Flight, Swan, Rest Position, Swimming, Push Up, Long Stretch, Cat Cow, Mermaid Stretch. The participants had two-minute rest breaks after the toe-top, spine twist, and circle side-kick movements. Movements were performed with ten repetitions in the first four weeks and 12 repetitions in the following four weeks. Movements were performed with ten repetitions in the first four weeks and 12 repetitions in the following four weeks. The participants underwent six weekly training sessions over eight weeks, comprising three Mat Pilates sessions and three team training days.
223468483|NCT04100213|BEHAVIORAL|Trier Social Stress Test|The TSST-G is a psychological paradigm which combines high levels of social-evaluative threat and uncontrollability in a group setting. The TSST-G will proceed in groups of three to five participants (from the same diagnostic group). The TSST-G consists of three phases: a briefing; the psychological test itself, followed by a debriefing phase. Each phase will last 40, 20 and 60 minutes, respectively. The briefing and debriefing of the TSST-G will be conducted by experienced psychotherapists. The TSST-G itself will be conducted by personal unknown to the participants.
223468484|NCT01208272|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|
223468485|NCT01208272|BEHAVIORAL|Interpersonal Therapy (IPT)|
223468486|NCT06141967|DEVICE|WITHINGS Sleep Analyzer|"Potentially eligible patients will be offered to participate in the study, the information leaflet will be given to them and the informed consent form will be signed if the patient agrees to participate in the study.~In hospitalization in Endocrinology:~* Realization of the current care report~* Including systematic achievement of EPWORTH and BERLIN scores~* Activation of the WSA throughout the duration of the hospitalization~* Completion of a feasibility questionnaire for the team~* Quantification of the non-usable screening technique~* Completion of a patient experience questionnaire at the end of the stay~* In the event of published positive criteria either for the BERLIN questionnaires, EPWORTH questionnaires or WSA, the patient will be referred to the VISAS center for definitive diagnostic evaluation by polygraphy or polysomnography."
223468487|NCT01802047|PROCEDURE|milk expression with electric pump|
223468488|NCT01092468|PROCEDURE|Diathermy|flap dissection with conventional diathermy
223468489|NCT01092468|PROCEDURE|Harmonic Scalpel|flap dissection using harmonic scalpel (FOCUS)
223468490|NCT06447714|BEHAVIORAL|smoke|cotinine detection
223468491|NCT03088059|DRUG|Afatinib|Afatinib 40 mg given orally, once daily, 1 cycle is 28 days
223468492|NCT03088059|DRUG|Palbociclib|Palbociclib 125 mg given orally, once daily, 1 cycle is 28 days (21 days on treatment, then 7 days off)
223468493|NCT03088059|DRUG|standard of care|Methotrexate, Paclitaxel, Docetaxel, Carboplatin, 5-Fluorouracil, Bleomycine, Gemcitabine, Mitomycine or Best supportive care
223468494|NCT03088059|DRUG|IPH2201|protocol v2.0 and 2.1 : Monalizumab 10mg/kg given intravenously over 60 minutes, once every 14 days, 1 cycle is 14 days protocol v4.0 : Monalizumab 750mg given intravenously over 60 minutes, once every 28 days, 1 cycle is 28 days
223468495|NCT03088059|DRUG|Durvalumab|Durvalumab 1500mg given intravenously over 60 minutes, once every 28 days, 1 cycle is 28 days
223468496|NCT03088059|DRUG|Niraparib|Niraparib 300 mg given orally, once daily, 1 cycle is 28 days
223468497|NCT03088059|DRUG|INCAGN01876|INCAGN01876 300 mg given intravenously over 30 minutes, once every 14 days, 1 cycle is 28 days
223468498|NCT03621956|PROCEDURE|Umbilical Cord Milking|At delivery, the umbilical cord is grasped, and blood is pushed toward the infant 4 times before the cord is clamped. This procedure infuses a placental transfusion of blood into the infant and can be done in 15-20 seconds.
224159268|NCT02382289|PROCEDURE|radiofrequency ablation for sacroiliac joint arthropathy|comparing bipolar RF at 6 points with monopolar RF at 3 and 6 points for the treatment of SI arthropathy
224159269|NCT05320536|DRUG|Guilingji Capsule|This medicine is capsule medicine, take method is oral.
223468499|NCT03621956|PROCEDURE|Early Cord Clamping|The umbilical cord is clamped within 30 seconds of delivery.
223468500|NCT02628977|BEHAVIORAL|Peer Based Sleep Health Education and Social Support|Participants randomly assigned to the intervention arm will receive Obstructive Sleep Apnea education and social support from a trained Peer Educator.
224159270|NCT05320536|DRUG|Placebo|This medicine is capsule medicine（Placebo）, take method is oral.
224159271|NCT02282891|DRUG|Propofol|Induction of general anesthesia using propofol 2mg/kg
223468501|NCT02628977|BEHAVIORAL|Attention Control Group|Participants assigned to this arm of the study will receive standard sleep literature, providing information about OSA and access to available sleep services.
223468502|NCT05280990|DIAGNOSTIC_TEST|mHBS|Preoperative FLRF assessment using 99mTc-mebrofenin hepatobiliary scintigraphy (mHBS).
223468503|NCT05280990|DIAGNOSTIC_TEST|CT/MRI volumetry|Preoperative FLRF assessment using CT/MRI volumetry
223468504|NCT02225418|DRUG|Ropivacaine|
223468505|NCT02225418|DRUG|saline|
223468506|NCT05458778|DEVICE|Daily test with urine by the product|Women perform the hCG test and share the test results
223468507|NCT02242617|DEVICE|Positive Airway Pressure (PAP)|Continuous or auto-adjusting positive airway pressure (i.e. CPAP, APAP, and described here as PAP): a device which consists of a face mask attached to a plastic tube and a machine that blows compressed air through a patient's airway during sleep to keep the airway open
223468508|NCT02242617|DEVICE|Mandibular Advancement Splints (MAS)|Mandibular advancement splints (MAS): dental splints used to keep the mandible in an advanced position opening the upper airway during sleep
223468509|NCT02064244|OTHER|Ultrasound for measurement of Inferior Vena Cava size.|Focused bedside ultrasound will be performed for each patient as part of their routine care and initial assessment. The IVC size will be measured at the subcostal window, during inspiration and expiration, using the Sonosite cardiac probe P-21 (5-1 MHZ). The measurement is obtained by applying the M-mode, perpendicular to the IVC axis and 2 cm caudal from its junction with the right atrium.
223468510|NCT04015362|PROCEDURE|Sub-threshold intermittent pulsed magnetic stimulation|Application of sub-threshold intermittent pulsed magnetic stimulation to spinal cord
223468511|NCT04015362|PROCEDURE|Sham|Application of sham magnetic stimulation to spinal cord
223468512|NCT02414282|DRUG|F 18 T807|Participants will receive a single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807. For those who cannot tolerate the full exam, participants will receive single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807.
223468513|NCT05510817|OTHER|Multiparametric assessment|neuropsychological assessment, PRO measures, non-conventional MRI metrics
223468514|NCT02674503|BEHAVIORAL|Walking|MP patients will participate in a program of progressive walking and transfer training up to three times a day, seven days a week throughout the hospital stay. MP patients will begin with assisted sitting, then standing, progressing to weight shifting and stepping in place, and then to walking as tolerated. The level of mobility recommended to the MP patient by the Walker will be dependent on the individual patient and will incorporate the activities patients were deemed able to do independent of cueing or assistance during each walking session.
223468515|NCT02674503|BEHAVIORAL|Friendly visit|"UC patients will receive three times a day friendly visits, seven days a week by members of the research team to control for the daily attention that MP patients receive."
223468516|NCT03663270|DEVICE|Hypotension probability index (HPI)|The intervention group is managed with the HPI parameter to detect and possibly prevent hypotension during anaesthesia.
223468517|NCT06446622|DEVICE|MRI|Participants will undergo an MRI scan while performing exercise at two intensities (light and moderate/vigorous) using an MRI-compatible stepper device.
223468518|NCT00002557|DRUG|CHOP regimen|
223468519|NCT00002557|DRUG|doxorubicin hydrochloride|
223468520|NCT00002557|DRUG|etoposide|
223468521|NCT00002557|DRUG|leucovorin calcium|
223468522|NCT00002557|DRUG|methotrexate|
223468523|NCT01022203|BEHAVIORAL|Structured Approach Therapy|The Structured Approach Therapy intervention includes education about the impact of PTSD on relationships; skills training to teach couples recognize and stop avoidance behavior; behavior activation training; emotion regulation training; and a couple-based intervention to teach Veterans with PTSD to identify and disclose trauma memories and related emotions to their partners. The couple is then trained to support disclosure while practicing empathic communication.
223468524|NCT01022203|OTHER|PTSD Family Education|The PTSD Family Education intervention provides education for Veterans with PTSD and their partners explaining the signs and symptoms of PTSD; psychological problems that are comorbid with PTSD; and treatments for PTSD. Skills training and psychotherapy are not included.
223468525|NCT04576013|DEVICE|Peripheral nerve stimulation (PNS)|Non-invasive stimulation is applied to 3 nerves of the arm. The stimulation will be set at a level that is not painful or uncomfortable.
223468526|NCT04576013|BEHAVIORAL|Intensive upper extremity motor training|
223468527|NCT06011863|PROCEDURE|Thoracic Epidural Analgesia|Thoracic Epidural Application: The epidural area will be accessed from the 7th (T7)-8th (T8) level of the thoracic vertebral midline with an 18 gauge (G) epidural needle using the hanging drip technique. After 2 ml of 2% lidocaine is administered and no spinal effect is observed, a mixture of morphine and local anaesthetic 3-4 mg morphine hydrochloride + 5 ml 0.5% bupivacaine + 2 ml 0.9% saline will be administered through the epidural needle at once and the epidural needle will be withdrawn and sterile dressing will be applied.
223743628|NCT07189754|OTHER|Placebo|The placebo is an inert capsule formulated to be visually identical to the Sabroxy™ capsules in size, shape, color, and packaging. It contains inactive ingredients only, with no active botanical extract. The placebo will be administered orally at the same regimen as the active intervention: one capsule taken twice daily after meals for 12 weeks. The use of a placebo ensures blinding of participants and study staff, allowing accurate comparison of cognitive and biomarker outcomes between groups.
223743629|NCT07190183|PROCEDURE|washed microbiota transplantation|The prepared microbiota suspension was infused into the patients' gut.
223743630|NCT07190781|DEVICE|Flow-Diverting Dense-Mesh Stent|Surface-Modified Flow-Diverting Dense-Mesh Stent for Mid-Term Follow-Up Study of Endovascular Embolization Therapy for Cerebral Aneurysms
224159272|NCT02282891|DRUG|Propofol-Ketamine|Induction of general anesthesia using a mixture of 1.5 mg/kg:0.75 mg/kg propofol/ketamine
224159273|NCT04617106|PROCEDURE|Radial artery cannulation|cannulation of Radial artery using standard IV cannula (axillary drug port will be taped using opaque adhesive)
224159274|NCT05837000|DRUG|Dexmedetomidine|Patient will receive 0.5 ml/kg bupivacaine 0.25% + 1μg/kg dexmedetomidine caudally
224159275|NCT05837000|DRUG|Ketamine|Patient will receive 0.5ml/kg bupivacaine 0.25% + 0.5mg/kg ketamine caudally
224159276|NCT05837000|DRUG|Magnesium sulphate|Patient will receive 0.5ml/kg bupivacaine 0.25% + 1ml volume containing 50mg of magnesium caudally.
223468528|NCT06011863|PROCEDURE|Erector spinae plane block|Before induction of anaesthesia, the patient is placed on the operating table and placed in a forward tilted position. Asepsis and antisepsis conditions are provided. The linear USG probe is moved approximately 2-3 cm lateral to the spinous process T5 - T6 level on the side to be operated. The trapezius, rhomboid major and erector spinae muscles will be identified to find the correct probe position. A 22 gauge 50 mm or 22 gauge 80 mm single shot nerve blocks needle will be inserted through the skin in a cranio-caudal direction. With the needle resting on the transverse process, the plane between the erector spinae muscle and the transverse process will be verified by hydrodissection with 5 ml saline solution. Then 20 ml of 0.25% bupivacaine will be injected. The ESP block will be considered successful if the local anaesthetic spreads linearly up to the T8 - T9 level. The patient will then be placed in the supine position and general anaesthesia will be administered.
223468529|NCT04472221|PROCEDURE|Arterioarterial synthetic graft|Synthetic poly tetraflouroethylene graft
224159277|NCT06034041|DRUG|Mediclore|After finish the operation, Mediclore group will be applied 1.5 CC of Mediclore at the surgical site. Mediclore is a Poloxamer-based thermosensitive anti-adhesive agent which is in a liquid solution and transform to a gel-state after being in a body temperature.
224159278|NCT06034041|DRUG|Normal Saline|After finish the operation, Control group will be applied 1.5 CC of normal saline at the surgical site.
224159279|NCT05240963|PROCEDURE|Temporal PEEK implant|Temporal PEEK implant to reconstruct temporal fossa after temporalis muscle transfer
224159280|NCT00610077|DRUG|Letrozole|Tablet Letrozole 2.5 mg once a day for 5 days for 3 cycles
224159281|NCT00610077|DRUG|Clomiphene citrate|Clomiphene citrate 100 mg or 150 mg once a day for 5 days in 3 cycles
224159282|NCT06840743|OTHER|Emotional intervention|The participant will watch a short video-clip with negative emotional content while simultaneously experience experimentally induced pain.
224159283|NCT06840743|OTHER|Emotional intervention|The participant will watch a short video-clip with positive emotional content while simultaneously experience experimentally induced pain.
224303835|NCT06863545|DRUG|PCSK9 inhibitors and background lipid-modifying therapy|Patients will receive subcutaneous injections of PCSK9 inhibitors and oral administration of background LMT (including statins and/or cholesterol absorption inhibitors) for the first 12 months after randomization, with PCSK9 inhibitors administered every 2 weeks. After the first 12 months, patients will discontinue the PCSK9 inhibitors but continue background LMT for the remainder of the trial.
223468530|NCT06211023|DRUG|SHR-1921|SHR-1921
223468531|NCT06211023|DRUG|carboplatin|carboplatin AUC 4
223468532|NCT06211023|DRUG|carboplatin|carboplatin AUC 5
223468533|NCT06211023|DRUG|platinum-based doublet chemotherapy|platinum-based doublet chemotherapy
224303836|NCT06863545|DRUG|Placebo plus background lipid-modifying therapy|Patients will receive subcutaneous injections of placebo and oral administration of background LMT (including statins and/or cholesterol absorption inhibitors) for the first 12 months after randomization, with placebo administered every 2 weeks. After the first 12 months, patients will discontinue the placebo but continue background LMT for the remainder of the trial.
223468534|NCT03874793|BEHAVIORAL|Mindfulness-Based Cognitive Therapy|Participants will attend 8 weekly group therapy sessions. Prior to and after therapy participants will have assessments related to their PTSD, fill out surveys, and have an fMRI.
223468535|NCT03874793|BEHAVIORAL|Muscle Relaxation Therapy|Participants will attend 8 weekly group therapy sessions. Prior to and after therapy participants will have assessments related to their PTSD, fill out surveys, and have an fMRI.
223468536|NCT04350593|DRUG|Dapagliflozin 10 milligram (mg)|Active Comparator: Dapagliflozin 10 mg
223468537|NCT04350593|DRUG|Placebo|Placebo Comparator
223468538|NCT02053103|DRUG|PF-05175157|Tablet, 200 mg, twice daily, 6 weeks
223468539|NCT02053103|DRUG|Placebo|Tablet, 0 mg, twice daily, 6 weeks
223468540|NCT03222726|OTHER|exercise group|less than 6000 steps/day or 40,000 steps/week
223468541|NCT03638128|DRUG|Denosumab|Solution for injection
223468542|NCT03638128|DRUG|Alternative osteoporosis medications|Alternative osteoporosis medication/s at the discretion of the investigator.
223468543|NCT03106116|DEVICE|Experimental: Enhanced External Counterpulsation|Enhanced External Counterpulsation (EECP) is a technique for assisting the circulation by decreasing the afterload of the left ventricle and augmenting the diastolic pressure externally by applying a negative pressure to the lower extremities during cardiac systole. EECP therapy has been approved by the United States Food and Drug Administration (FDA) for the treatment of refractory angina and heart failure. Administration of 35-36 hours EECP therapy over a 7 week period, one hour session every working day.
223468544|NCT03106116|DRUG|Standard medical therapy|Guideline- driven standard medical treatment for 7 weeks
223468545|NCT03484169|OTHER|intervention group|"The training of PNF pelvic patterns for motor learning in GI will be performed twice a week by a trained and experienced researcher for six weeks (CHRISTIANSEN et al., 2017). At each training session, there will be three repeated movements in each pelvic pattern:~Combination of isotonic (concentric, stabilizing and eccentric) of the anterior elevation pattern; Combination of isotonic (concentric, stabilizing and eccentric) of the posterior depression pattern; Combination of isotonic (concentric, stabilizing and eccentric) of the previous depression pattern; Combination of isotonic (concentric, stabilizing and eccentric) of the posterior elevation pattern;"
224068561|NCT01357486|DRUG|Sorafenib + Pravastatin|patients receiving sorafenib 400 mg (twice a day) and pravastatin 40 mg (once a day)
224068562|NCT01357486|OTHER|patients receiving best supportive care|palliative management
224068563|NCT02956668|OTHER|Blindsight Training associated to tDCS|The patient undergo visual rehabilitation while his brain is electrically stimulated with tDCS.
224068564|NCT02956668|OTHER|Blindsight Training alone|The patient undergo visual rehabilitation
224068565|NCT03127033|OTHER|Soft liner telescopes|"Soft liner telescopes: Overdenture will be adjusted by relieving acrylic opposite to the abutment about 2 mm using a metal stone. The relieved areas will be painted with an adhesive and the rest of the fitting surface of the denture will be painted with a separating medium.~The soft liner (Silicone based soft liner, mollosil, chairside soft relining-long term, DETAX, Germany) will then be applied in the relieved areas to act as a secondary coping The base and catalyst will be mixed according to the manufacturer's instructions on a glass slab. The mix will be placed on the relieved area, seated in the patient's mouth, the patient is asked to bite in centric relation and the excess liner is removed with a lancet."
223468546|NCT02737761|BEHAVIORAL|Qualitative Interview and Adherence Measurements|Subjects will undergo an open-ended, semi-structured interview within two weeks of enrollment. The interview will be approximately 1 hour in length, performed by study staff who have been trained in qualitative research methods. This interview will be completed again 12 weeks later. Subjects will complete the MOS SAS, Automated Self-Administered 24-hour recall (ASA24), Life Orientation Test-Revised (LOT-R), Positive and Negative Affect Schedule (PANAS), Hospital Anxiety and Depression Scale (HADS), Kansas City Cardiomyopathy Questionnaire (KCCQ), and Medical Outcomes Study Short Form-12 (SF-12) at baseline and again at 12 weeks.
223468547|NCT00489463|DEVICE|intra-uterine device (TCu 380A)|
224159284|NCT06840743|OTHER|Emotional intervention|The participant will watch a short video-clip with neutral emotional content while simultaneously experience experimentally induced pain.
224159285|NCT06840743|OTHER|Emotional intervention|The participant will wait for 2.20 minutes while simultaneously experience experimentally induced pain.
224159286|NCT03215745|BEHAVIORAL|Delirium prevention program|Delirium prevention program Placard with the names of the care team and the calendar days; cognitively stimulating activities three times a day. Pictures, radio, robe. Visual aids large print books, with daily reinforcement of use Maintain adequate lighting opening blinds and curtains during the day, and darken their environment at night. Dissipation wax and special techniques of communication, with daily reinforcement of these adaptations. Go to the patient by name and tone of voice appropriate. Always listen. Use simple and clear language, face-to-face. Avoid excessive familiarity and childish. Promote family involvement in self-care and caregivers and the reorientation of the patient, contact with extended family during the stay.
224159287|NCT00383266|DRUG|Pemetrexed|
224159288|NCT00383266|DRUG|Carboplatin|
223468548|NCT00587067|DRUG|FLOXURIDINE|"\[0.16\* mg/kg/day X 30 ml\] / pump flow rate~\* If the patient is \>25% above ideal body weight, the dose of FUDR will be calculated from an average of the patients actual and ideal body weights. For example, for a patient who is 5ft. 10 inches and weighs 100kg: Ideal Body Weight (kg) = 50 + (2.3 X height in inches over 5 feet) = 50 + (2.3 X 10) = 73 Weight Used for dose calculation = (100 + 73)/2 = 86.5 Therefore, FUDR Dose will be = (0.16 X 86.5 X 30)/Flow Rate If no dose modification due to toxicity is required, the dosages given above (adjusted for changes in weight and pump flow rate) will be repeated on Day 1 of Week 1 of Cycle 2 and all subsequent cycles."
223468549|NCT00903201|DRUG|SB656933|20 mg
223468550|NCT00903201|DRUG|SB656933|50mg
223468551|NCT00903201|DRUG|Placebo|placebo
223468552|NCT03604003|DRUG|potassium losartan|treated with bedtime or awakening doses of potassium losartan
223468553|NCT00329108|DRUG|ziprasidone hydrochloride|Ziprasidone will be initiated at 80 mg/day on Day 1 and titrated to 120 mg/day from Day 3. From Day 7 the dosage may be adjusted on the basis of clinical status between 120 and 160 mg/day.
223468554|NCT00329108|DRUG|olanzapine|Olanzapine will be started at 15 mg/day on Day 1 until Day 7. The dosage will then be adjusted on the basis of clinical status between 15 and 20 mg/day.
223468555|NCT00563290|DRUG|dasatinib|Given PO
223468556|NCT00563290|OTHER|laboratory biomarker analysis|Correlative studies
223468557|NCT01094288|DRUG|Alisertib|Alisertib ECT
223468558|NCT01094288|DRUG|Docetaxel|Docetaxel IV infusion
223468559|NCT03615963|DIAGNOSTIC_TEST|echocardiography and coronary angiography|transthoracic echocardiography will be done for all subjects to measure aortic stiffness and elaticity then coronary angiography was used to differentiate between normal subjects and who have coronary artery disease
223468560|NCT02611882|DRUG|Ga-68 labeled HBED-CC PSMA|The imaging agent (Ga-68 HBED-CC PSMA) will be administered on an outpatient basis. It will be administered a single time intravenously prior to the PET/CT imaging. The one-time nominal injected dose will be 3 to 7 millicurie (mCi) containing 10 - 25 μg Ga-68 HBED-CC PSMA.
223468561|NCT02611882|DEVICE|Positron Emission Tomography (PET) image combined with Computed Tomography (CT) (PET/CT)|Patient shall begin imaging between 55 and 70 minutes after the injection of the radiopharmaceutical. A PET/CT scan includes two parts: a PET scan and a CT scan. The CT portion of the scan produces a 3-D image that shows a patient's anatomy. The PET scan demonstrates function and what's occurring on a cellular level. The PET scan is unique because it images the radiation emitted from the patient while the CT records anatomical x-rays, showing the same area from another perspective
223468562|NCT02611882|DEVICE|Positron Emission Tomography (PET) image combined with Magnetic Resonance Imaging (MRI) (PET/MRI)|Patient shall begin imaging between 55 and 70 minutes after the injection of the radiopharmaceutical. A PET/MRI scan is a two-in-one test that combines images from a positron emission tomography (PET) scan and a magnetic resonance imaging (MRI) scan. Coverage for the scan will extend from the patients vertex through the mid thighs. We will use 4 minute acquisitions per bed position for PET imaging.
223468563|NCT03994380|DRUG|RhDNAse Inhalation Solution|rhDNAse 2.5 mg nebulizer daily for 4 weeks
223468564|NCT04269616|BEHAVIORAL|Order of pictographs provided to participants|The pictographs presented to participants about survival and disability were varied in the order in which they were presented (i.e. survival or disability information first).
223468565|NCT04269616|BEHAVIORAL|Level of description in survival pictograph|The pictographs presented to participants about survival and disability were varied in the level of description provided in the survival pictograph (i.e. only numerical data, or also a description of course of NICU stay).
224068566|NCT02355782|BIOLOGICAL|OMS721|Human IgG4 MASP-2 Monoclonal Antibody
224068567|NCT00513032|DRUG|methylene blue|5mg.kg-1 methylene blue in 250 ml 5% glucose-saline, administered intravenously approximately 60 min before anaesthesia induction
224068568|NCT02163018|DRUG|HAL-MPE1|Subcutaneous administration of increasing doses of HAL-MPE1
224068569|NCT02163018|DRUG|Placebo|Subcutaneous administration of increasing doses of placebo
224068570|NCT00896311|DRUG|IV Nitroglycerin|IV injection, initial dose of 1ml, with further doses of 1-3mL, up to a recommended maximum of 10mL
224068571|NCT00896311|DRUG|Normal saline|IV injection, initial dose of 1ml, with further doses of 1-3mL, up to a recommended maximum of 10mL
224068572|NCT05179317|DRUG|QL1706|"Drug: QL1706 Intravenous Infusion~Drug: Paclitaxel injection Intravenous Infusion~Drug: Cisplatin/Carboplatin Intravenous Infusion~Drug:Bevacizumab Intravenous Infusion"
224068573|NCT01241214|DRUG|ACT-129968|ACT-129968 (Dose 1, Dose 2, or Dose 3) or matching placebo administered orally twice daily
224068574|NCT01241214|DRUG|ACT-129968|ACT-129968 (Dose 4) \& matching placebo administered orally once daily
223468566|NCT01389232|DEVICE|SeriScaffold® Surgical Scaffold|A CE Marked, 510(k) cleared, knitted, multi-filament, bioengineered, silk mesh indicated for use as a transitory scaffold for soft tissue support and repair
223468567|NCT00560729|DIETARY_SUPPLEMENT|Renutryl 500|
223468568|NCT00560729|DIETARY_SUPPLEMENT|Generique|
223468569|NCT00560729|DIETARY_SUPPLEMENT|Generique + Renutryl 500|
223468570|NCT01317940|DIETARY_SUPPLEMENT|Vitamin D and Calcium Citrate|"Vitamin D (10,000 int.units/ml) 100,000 int. units (10ml) by mouth once every two months x 3 times (total treatment period approximately 6-7 months)~Calcium Carbonate (1,000 mg/tab = 400 mg elemental calcium/tab) 2,000 mg (2 chewable tabs) by mouth every day for approximately 6-7 months"
223468571|NCT00002551|DRUG|fluorouracil|See arm assignments.
223468572|NCT00002551|DRUG|leucovorin calcium|See arm assignments.
223743631|NCT07189676|BEHAVIORAL|Dietary advice (PHD)|It consists of a written document outlining the PHD diet recommendations. Participants will receive: 1) information about the PHD guidelines by EAT-Lancet (a high-quality plant-based diet with a low allowance of intake of eggs, dairy, chicken, and fish, but strictly avoiding red and processed meat) adapted to be nutritionally adequate and culturally accepted in Denmark, 2) a meal planner for their calorie demands (templates for 2000 kcal/day; 2500 kcal/day; and 3000 kcal/day), 3) guidance on alternatives for substituting meat when cooking at home or eating out, and 4) information on seasonal fruits and vegetables. The meal planner will specify the amounts of eggs, dairy, chicken, and fish that each participant should consume based on their total energy demands. The PHD dietary advice focuses on limiting certain food groups (without excluding them) based on their health and environmental impact.
223743632|NCT07189676|BEHAVIORAL|Dietary advice (Ovo-lacto-vegetarian diet)|It consists of a written document outlining the ovo-lacto-vegetarian diet guidelines. Participants will receive information to adhere to a stricter plant-based diet with an intake of eggs and dairy, but avoiding chicken, fish, and red and processed meat, and guidance on alternatives for substituting meat when cooking at home or eating out. Recommendations on food quantity or on consuming local and seasonal foods will not be given to pinpoint differences in the environmental aspect between interventions.
223743633|NCT07189676|BEHAVIORAL|Dietary advice (control)|It consists of a written document outlining the general recommendations of a healthy diet (i.e. consumption of fruits and vegetables, decreasing the intake of sugar-sweetened beverages, etc.) without any specific advice on the consumption of animal products.
224068575|NCT01241214|DRUG|Cetirizine|Ceterizine administered once daily
224068576|NCT01241214|DRUG|Placebo|Matching placebo administered twice daily.
223468573|NCT00002551|DRUG|levamisole hydrochloride|See arm assignments.
223468574|NCT00002551|RADIATION|radiation therapy|See arm assignments.
224068577|NCT03759665|DRUG|IB1001|IB1001 (N-Acetyl-L-Leucine) is a modified amino-acid ester that is orally administered.
224068578|NCT05098041|DRUG|Soticlestat|Soticlestat tablets.
224068579|NCT05098041|DRUG|Rifampin|Rifampin capsules.
224068580|NCT00244023|DRUG|Testosterone gel|one sachet of 50 mg applied once a day, possibly titrated to two sachets if insufficient improvement of erectile function
223468575|NCT04678284|BEHAVIORAL|Diabetes Homeless Medication Support (D-Homes)|There will be 10 sessions offered within 12 weeks to participants. Sessions will last 30-60 minutes. During sessions a diabetes wellness coach will use behavioral activation and motivational interviewing to get to know participants and set goals to improve diabetes care. The coach will encourage a focus on medication adherence behaviors to the extent that participants are willing. The coach will also help with resource and care coordination. The coach will also provide brief diabetes education as needed.
223468576|NCT05695703|OTHER|Core Strength Training Group|"The participants of experimental group will perform core strength training regime for 6 weeks (3 days per week). Each exercise session will last for a period of 45 mins, the exercises would be performed in 3 sets of 5 repetitions with 5 seconds hold time and 10 seconds rest between each repetition and a minutes rest in between each set.~Following exercises would be performed :~Bridge, Crunch, Plank, Side Plank, Mountain Climb."
223468577|NCT05695703|OTHER|Conventional Training Group|"The participants of conventional group will perform following exercises :~Running (10 repetitions X 3 sets), Jogging (10 repetitions X 3 sets), Stretching (10 repetitions X 3 sets)~Rest between Exercises : 10-15 Seconds Rest between Set of Exercises : 30-60 Seconds Cricketers will receive exercises for 8 weeks. There will be 3 sessions per week."
223468578|NCT02976883|OTHER|[18F]HX4 diagnostic PET/CT scan|Single intravenous injection of \[18F\]HX4 and PET/CT scan
223468579|NCT02981511|DEVICE|optiflow|Optiflow device used for preoxygenation
224068581|NCT00244023|DRUG|testosterone|testosterone gel, one sachet of 50 mg applied once a day, possibly titrated to 100 mg if insufficient effect
224068582|NCT00244023|OTHER|placebo gel|one sachet of placebo gel once a day possibly titrated to 2 sachets if insufficient efficacy
224068583|NCT06095765|DRUG|Colchicine 0.5 MG Oral Tablet|Oral intake of 0.5 mg colchicine once daily
224068584|NCT06095765|DRUG|Placebo|Oral intake of matching placebo once daily
224068585|NCT01595152|DRUG|solifenacin succinate|8 mg once daily for 60 days
224068586|NCT01595152|DRUG|fesoterodine|8 mg, once daily for 60 dyas
224068587|NCT03554915|OTHER|Ketamine-based protocol|For profoundly agitated (physically violent) patients, intramuscular ketamine 5 mg/kg will be administered first line. For severely agitated patients, intramuscular ketamine 3 mg/kg will be administered first line.
224068588|NCT03554915|OTHER|Midazolam-based protocol|For profoundly agitated patients, intramuscular midazolam 15 mg will be administered. For severely agitated patients, intramuscular midazolam 5 mg will be administered.
224068589|NCT01515657|DRUG|PL2200 Aspirin Capsules|325 mg aspirin; once per day for 3 days
224068590|NCT01515657|DRUG|Immediate-Release Aspirin Tablets|325 mg aspirin; once per day for 3 days
224068591|NCT01515657|DRUG|Enteric-coated aspirin caplets|325 mg aspirin; once per day for 3 days
224068592|NCT03958552|OTHER|Palliative Care Consultation|Trained provider will discuss illness trajectories, establish and communicate patient-directed goals that guide health care decisions, identify and treat illness-related symptoms, and identify psycho-spiritual needs and approaches to mitigate suffering.
224068593|NCT00797732|DEVICE|Acupuncture|
224068594|NCT00915200|DIETARY_SUPPLEMENT|N-acetylcysteine|600 mg orally twice daily for three months
223468580|NCT04187313|OTHER|INSTEP2 intervention package|"The Intervention will comprise: An electronic notification system, a standardized education about the signs and symptoms of TB and TB management and an individualised plan for each PP with respect to their approach to the diagnosis and management of TB suspects.~The electronic system is a refinement of the electronic referral and report-back system using a mobile phone 'app'. The system will enable essential data to be uploaded, consistent with National TB Control Programme forms.~The education package will be focused on TB suspect identification, provisional diagnosis and referral, including how to use the mobile phone 'app'. We will also develop a simple individualised approach for the management of TB suspects, which takes into account the context around each PP's practice, identifying the most efficient and feasible approach to obtaining a diagnosis and notifying TB patients."
223468581|NCT04832737|BEHAVIORAL|ADDapt Ability Framework|12 week individual therapeutic coaching intervention
223468582|NCT02371616|DEVICE|Calcium sodium phosphosilicate|5% w/w calcium sodium phosphosilicate
223468583|NCT02371616|OTHER|Sodium fluoride|1426 ppm fluoride as sodium fluoride
223468584|NCT02371616|OTHER|Sodium monofluorophosphate|1426 ppm fluoride as sodium monofluorophosphate
223468585|NCT04939467|DRUG|Pirfenidone 267 mg Oral Tablet|Fixed sequence use of active product, TID
224159289|NCT05298163|DRUG|Calcitriol capsules|Calcitriol under the name of Oscal, 0.25 mcg/day (minimum dose) will be given for 6 months, starting at the day of the time when inclusion criteria have been met.
224159290|NCT05298163|DRUG|Placebo|One placebo capsule matching the active drug will be given per day for 6 months, starting at the day of the time when inclusion criteria have been met
224159291|NCT03285490|DRUG|KX2-391 Ointment 1%|Dose: 1% (250 mg single-use packets); Dosage form: Ointment; Route of administration: Topical
224159292|NCT03285490|DRUG|Placebo|Dosage form: Ointment; Route of administration: Topical
224159293|NCT03052465|OTHER|Test soup meal feeding intervention|Cream of chicken soup (400g) (or mushroom for vegetarians) (Heinz, Wigan, UK) used as a test meal intervention. The nutrient content /100g is: energy (kcal) 51, protein (g) 1.5, carbohydrate (g) 4.7, fat (g) 2.93
224159294|NCT03745989|DRUG|MK-8353|Participants will receive MK-8353 orally twice daily (BID), escalated sequentially from 50 mg to 250 mg.
224159295|NCT03745989|DRUG|Selumetinib|Participants will receive selumetinib orally BID, escalated sequentially from 25 mg to 75 mg.
223468586|NCT04939467|DRUG|Nintedanib 150 mg Oral Capsule|Fixed sequence use of active product, BID
223468587|NCT04939467|DRUG|BLD-0409 750 mg Oral Tablet|Fixed sequence use of active product, QD
223468588|NCT04802200|OTHER|Data collect|Data collect following a vascular closure by MANTA
223468589|NCT00754741|BEHAVIORAL|Adherence information|Physicians, of the patients randomized to this arm, will have medication adherence information displayed when using the electronic prescribing system.
223468590|NCT00754741|BEHAVIORAL|Adherence information plus motivational interviewing|Physicians, of the patients randomized to this arm, will have medication adherence information displayed when using the electronic prescribing system. Moreover, patients randomized to this arm will be recruited into a clinic run by pharmacists and nurses with delegated prescription power. The clinic personnel will use motivational interviewing techniques with patients to improve adherence to medications and/or to intensify medical treatment if adherence is optimal.
223743634|NCT07189676|BEHAVIORAL|Behavioural support PHD|This component is designed to help participants adhere to the PHD through four individual and personalized dietary visits with a dietitian. Participants will also have access to a digital recipe collection in the study app. Recipes will be tagged by meal type and by season.
224068595|NCT00915200|DIETARY_SUPPLEMENT|silibin|480 mg orally twice daily for three months
224068596|NCT00915200|DIETARY_SUPPLEMENT|high-dose silibin|960 mg orally twice daily for three months
224068597|NCT00915200|DIETARY_SUPPLEMENT|N-acetylcysteine placebo|excipient orally twice daily for three months
224068598|NCT00915200|DIETARY_SUPPLEMENT|silibin placebo|excipient orally twice daily for three months
224068599|NCT05102643|BIOLOGICAL|SARS-CoV-2 DNA Vaccine|A novel vaccine developed for prophylaxis of COVID-19 based on HKU's PD-1-based DNA vaccine platform. It encodes a recombinant antigen comprising a soluble human PD-1 domain (i.e. programmed cell death protein, a member of the Cluster of Differentiation 28 (CD28) family) and the receptor binding domain (RBD) of SARS-CoV-2 (i.e. the key viral entry element).
224068600|NCT05102643|BIOLOGICAL|Matching placebo|Solution for intramuscular injection
224068601|NCT03239717|OTHER|Whey protein powder|Participants in the Control Arm will replace two-thirds of participants dietary protein intake with a commercially available whey protein powder.
224068602|NCT03239717|OTHER|BCAD2|Participants in the Experimental Arm will replace two-thirds of participants dietary protein intake with BCAD2 (Mead Johnson), a BCAA-free medical food.
224068603|NCT02849132|DRUG|Entecavir|oral entecavir 0.5mg daily for 8 years
224068604|NCT04555122|BEHAVIORAL|Social Distancing Advertisements|Participants will receive 3 types of advertisements to increase social distancing/staying at home.
224068605|NCT01763450|DRUG|bevacizumab plus chemotherapy|"1. Bevacizumab:~   7.5mg/kg, iv, on day 1 of each 21 day cycle or 5mg/kg, iv, on day 1 of each 14 day cycle;~2. Oxaliplatin+capecitabine(XELOX):( The total dose not less than 70% of the recommended dose of this standard) Oxaliplatin: 130mg/m2,d1; capecitabine: 850-1,000mg/m2，d1-d14, bid，each 21 day cycle;~3. Oxaliplatin+5-Fluorouracil+ Levomisole（FOLFOX）:~Oxaliplatin: 85mg/m2,iv for 2 hours ,d1; Levomisole（LV）: 400mg/m2,iv for 2 hours,d1; 5-Fluorouracil（5-FU） :400mg/m2 iv,d1,then 1200mg/m2/d ×2d continuous intravenous infusion(volume dose:2400mg/m2,iv for 46-48 hours ) each 14 day cycle;"
224068606|NCT04830670|PROCEDURE|sinus floor elevation with lateral approach|sinus floor elevation with lateral approach. 6 months healing phase. implant site preparation with trephine bur and bone specimen retrieval.
224070806|NCT07142798|DRUG|Bismuth amoxilillin potassium|vonoprazan 20mg， Twice a day amoxicillin 750mg，Four times a day tripotassium dicitrate bismuthate 300mg，Four times a day for 14 days
224070807|NCT07143955|BEHAVIORAL|Structured Dietary Intervention|A comprehensive dietary program consisting of dietary modification (high-fiber, lean protein), daily probiotic supplementation capsule (Bifidobacterium longum, Lactobacillus acidophilus, and Lactobacillus rhamnosus), and encouraged intake of prebiotics and unsaturated fatty acids.
224070808|NCT07143955|BEHAVIORAL|Routine Dietary Care|Standard institutional dietary counseling for patients with HCC, providing general advice on nutrition.
223578471|NCT04101617|BEHAVIORAL|Oral Health education including printed educational material|Printed and online educational materials were developed and provided to pediatricians so they can share relevant information about caries control to parents of toddlers. A previous interview was performed to pediatricians as focus groups to know how they are doing their evaluations and what do they take into account during the children visits in order to identify where to focus for the training what it is necessary to change. After that pediatricians were trained to give oral health recommendations. So, to the intervention group, the pediatricians will give these recommendations to the parents and also they will give them a printed educational material previously developed for the project.
223578472|NCT04423601|DRUG|SHR6390 tablet|single oral dose of SHR6390 or co-administered with itraconazole.
223578473|NCT04423601|DRUG|Itraconazole capsule|200 mg itraconazole was administered in the morning.
223578474|NCT04313322|BIOLOGICAL|WJ-MSCs|"WJ-MSCs will be derived from cord tissue of newborns, screened for HIV1/2, HBV, HCV, CMV, Mycoplasma, and cultured to enrich for MSCs.~WJ-MSCs will be counted and suspended in 25 ml of Saline solution containing 0.5% human serum Albumin, and will be given to patient intravenously."
223578475|NCT04603222|DEVICE|SUMMIT BRUSH|SUMMIT BRUSH used for the treatment of blepharitis
223578476|NCT04603222|OTHER|Ocusoft Lid Scrub Original Foaming Eyelid Cleanser|treating blepharitis with Ocusoft Lid Scrub Original Foaming Eyelid Cleanser
223578477|NCT05932121|PROCEDURE|Thyroid lobectomy via trans-axillary approach|Patient with PTC underwent thyroid lobectomy via trans-axillary approach
223578478|NCT05932121|PROCEDURE|Thyroid lobectomy via open approach|Patient with PTC underwent thyroid lobectomy via open approach
223578479|NCT06213337|OTHER|Foot care training with virtual classroom|Providing foot care training once every two weeks in virtual classes created via the Google meet application.
223578480|NCT06213337|OTHER|Foot care training with SMS support|Total of 60 SMS messages containing foot care information will be sent, one every day.
223578481|NCT06213337|OTHER|Foot care training with virtual classroom and SMS support|Providing foot care training once every two weeks in virtual classes created via the Google meet application. Furthermore, total of 60 SMS messages containing foot care information will be sent, one every day.
223578482|NCT01051206|DRUG|6% hydroxyethyl Stach 130/0.4|After dividing patients medicated with HES 130/0.4(maximum 33ml/kg/day) during surgery and one day after from the surgery with patients medicated with crystalloid only, compare the effect on the volume of bleeding, blood transfusion, and blood coagulation when using IV fluid.
223578483|NCT04410744|DIAGNOSTIC_TEST|Ultrasonographic examination|All clinical examinations (physical exam) and ultrasounds are performed by a single surgeon and a single radiology resident supervised by the same abdominal radiology consultant, respectively.
223578484|NCT02525913|DEVICE|RFA Applicator|
223578485|NCT00885768|PROCEDURE|angiography|all patients undergoing coronary angiography with VISIPAQUE and if they had coronary stenosis then renal artery angiography will be done. the dose of contrast will be chosen according to renal function and clinical conditions which will be varied from 75 to 300 ml.
223578486|NCT05586672|DEVICE|EEG-HR|Passation EEG-HR
224068607|NCT04992819|PROCEDURE|Chronobiological Approach Nutrition Model|In the intervention group, a label containing the time of expressed breastmilk will be affixed. In the milk preparation room, breast milk will be stored in a separate refrigerator as 08:00-19:59 day milk and 20:00-07:59 night milk.
224068608|NCT00488384|DRUG|Chemopreventive application (Acitretin)|Chemopreventive application (Acitretin)
224068609|NCT01679210|BEHAVIORAL|Lifestyle Intervention|Stage-matched physical activity and diet intervention materials and health education.
224303837|NCT02736682|DRUG|Single dose antibiotic|Single dose arm receive 2g of IV Ceftriaxone and 500 mgs ofIntra venous Metronidazole given to the mothers 30-60 minutes pre operative.
223578487|NCT05586672|DIAGNOSTIC_TEST|ADI-R|Passation of ADI-R scale
223578488|NCT05586672|DIAGNOSTIC_TEST|ADOS-2|Passation of ADOS-2 scale
223578489|NCT05586672|DIAGNOSTIC_TEST|IDE|Passation of IDE scale
223578490|NCT05586672|DIAGNOSTIC_TEST|MSEL|Passation of MSEL scale
223578491|NCT05586672|DIAGNOSTIC_TEST|Dunn|Passation of Dunn scale
223578492|NCT02068118|DEVICE|Telecardiology program|"The telecardiology program is a combination of a scale, a device asking the patients questions about the symptoms associated with their heart failure, and regular phone calls made by nurses.~Automatic algorithms have been built-up in order to detect early the need for a hospitalization due to heart failure."
223578493|NCT05185895|PROCEDURE|15 minutes eccentric cycling|The exposure to eccentric exercise will be individualized-intensity stepwise incremental cycle exercise starting at 50 Watt with individually tailored increments every 5 minutes.
223578494|NCT05185895|PROCEDURE|15 minutes concentric (normal) cycling|The exposure to concentric exercise will be individualized-intensity stepwise incremental cycle exercise starting at 50 Watt with individually tailored increments every 5 minutes.
223578495|NCT00012090|DRUG|bicalutamide|
223578496|NCT00012090|DRUG|goserelin acetate|
223578497|NCT03233295|DRUG|Vitamin D3 B.O.N. Injection|cholecalciferol 200,000IU
223578498|NCT05788315|OTHER|Cultural Formulation Interview|The Cultural Formulation Interview will be used at the start of treatment in the intervention group against a standard practice intake in the control group.
223578499|NCT02402686|DRUG|Tocilizumab|Dosing and treatment duration of tocilizumab collected as part of this non-interventional study are at the discretion of the physician in accordance with local clinical practice and local labeling. Observation period is 24 weeks from first SC tocilizumab administration.
224068610|NCT00401752|DRUG|Esomeprazole|
224068611|NCT00401752|DRUG|Ranitidine|
224068612|NCT06267833|BEHAVIORAL|exercise|In the exercise protocol, a personalized, home-based, 30-minute Otago exercise program consisting of strength, balance, and walking exercises performed three times a week will be implemented for 8 weeks with home visits and telerehabilitation sessions (via Videoconferencing) under the supervision of the responsible researcher. In addition to the Otago exercise program, trunk and upper extremity exercises (totaling 45 minutes) will be implemented in study group 1 using traditional methods and in study group 2 using the mobile game method.
224068613|NCT05836337|DEVICE|Tattoo- Black Eye|Device name: Black eye Manufacturer: The Standard Co., Ltd
224068614|NCT05836337|DEVICE|clip- HydroMARK|Device name: HydroMARK Manufacturer: Biopsy Sciences, LLC
223468591|NCT03906864|OTHER|Care Pathway|"The intervention group had the following as part of the integrated care pathway:~1. Medical assessment on admission for risk factors for falls.~2. A weekly assessment of complications including pain, deep venous thrombosis, anaemia, wounds and pressure ulcers, etc. The Confusion Assessment Method and the Geriatric Depression Scale were utilized.~3. Physiotherapy and occupational therapy guidelines with recommended milestones (set for the full, partial and non-weight bearing groups)~4. Physiotherapy Clinical Outcome Variables Scale (PTCOVS)16 was used by the physiotherapists in the intervention group to assess the baseline mobility, to define outcome goals and to direct treatment plans.~5. A postoperative hip precaution handout (containing information on avoiding hip prosthesis dislocation in patients with total hip replacement or hemiarthroplasty) was given to patients and their caregivers."
223468592|NCT01865357|OTHER|Brain MRI - Clinical and cognitive evaluation|"* Clinical evaluation (EDSS, MSFC)~* Cognitive evaluation with tests of information processing speed, attention, working memory, episodic memory and executive functions, assessment of confounding factors (depression (BDI) and anxiety (HAD), mood (EHD), fatigue (M-FIS) and assessment of quality of life (SEP-59)~* Brain MRI (3 Tesla): FLAIR, 3D MPRAGE T1 and DTI"
223468593|NCT01865357|OTHER|Eye movement|Assessment of eye Movements (EyeBrain software) for only the group of 15 healthy subjects at baseline and at 12 months
223468594|NCT01334086|DRUG|Aprepitant|Oral aprepitant will be given to the participant on Days 1-5 of standard induction treatment. A dose of 125 mg will be given on Day 1 and 80 mg will be given on Days 2-5.
223468595|NCT05623410|BIOLOGICAL|ATGC-110|ATGC-110 is a prescription medicine that is injected into muscles and used to improve the moderate to severe glabellar lines. It should be reconstituted with sterile, preservative-free 0.9% saline before use.
223468596|NCT05623410|BIOLOGICAL|Xeomin®|Xeomin® is a prescription medicine that is injected into muscles and used to improve the moderate to severe glabellar lines. It should be reconstituted with sterile, preservative-free 0.9% saline before use.
223468597|NCT05609994|DRUG|PEPIDH1M vaccine + vorasidenib|Patients will receive vaccination with 0.5 mL of Td (tetanus and diphtheria toxoids) intramuscularly into the deltoid muscle. Patients will then receive vorasidenib 40mg orally once a day for 28 days. After two cycles of 28-day vorasidenib and at the start of the 3rd cycle of vorasidenib, patients will receive the PEPIDH1M vaccine intradermally (i.d.) to alternating groin regions on the following schedule: vaccine #1, day 1; vaccine #2, day 15. The day before vaccine #1, patients will receive a vaccine site pre-conditioning injection of a single dose of Td toxoid. This will be administered twelve hours to one day prior to receiving PEPIDH1M vaccine i.d. to the RIGHT groin area. Vaccines #3 and #4 will be given on day 1 and day 15 of cycle 4. Starting on 6th cycle of 28-day vorasidenib, subjects will receive PEPIDH1M vaccine (i.d. to alternating groin regions) every 28 days on day 1 for vaccine #5-#12. Patients will receive up to a total of 14 cycles of vorasidenib.
223468598|NCT00152347|DRUG|Botox|See Detailed Description
223468599|NCT05066529|PROCEDURE|dry-needling|Dry needling is a technique in which a fine needle is used to penetrate the skin, subcutaneous tissues and muscles to mechanically disrupt tissue without the use of anesthesia. Treatment is often used to treat myofascial trigger points.
224159296|NCT03486184|DIAGNOSTIC_TEST|Cystatin-C|"* Laboratory values will be obtained, including level of preoperative serum creatinine, complete blood count, coagulation profile and Cystatin-C (5 ml. venous sample).~* Serum creatinine and hemoglobin will be measured after operation, and thereafter at least once a day as a part of routine clinical care. Postoperative serum Cystatin-C will measured only once."
223468600|NCT04706377|DIETARY_SUPPLEMENT|B12 fix 1000mcg|oral dispersible tablet with vitamin B12 1000mcg
223468601|NCT04706377|OTHER|Placebo|Placebo tablet
223468602|NCT04152200|DRUG|Lumasiran|Lumasiran will be administered by subcutaneous (SC) injection.
223468603|NCT06039189|DRUG|Guselkumab|Guselkumab will be administered as subcutaneous injection.
223468604|NCT06039189|DRUG|Placebo|Placebo will be administered as subcutaneous injection.
223578500|NCT03052140|DEVICE|Lamelleye Dry Eye Drops|Liposomal multi-dose preservative-free sterile suspension which contains soy lecithin phospholipids, sphingomyelin and cholesterol, suspended in saline.
223468605|NCT00511719|DRUG|Technosphere Insulin|48U
223578501|NCT03052140|DEVICE|Optive Plus|Multi-dose sterile solution which contains sodium carboxymethylcellulose, glycerine, Castor Oil, Polysorbate 80, levocarnitine, and erythritol, preserved with PURITE® which breaks down into natural tear components in the eye
224068615|NCT00087009|BIOLOGICAL|beta-glucan|Given orally
224068616|NCT00087009|BIOLOGICAL|rituximab|Given IV
224068617|NCT01895322|DRUG|OPC-41061|
224068618|NCT00689949|DIETARY_SUPPLEMENT|folic acid|0.4 mg of folic acid per day
224068619|NCT02433600|OTHER|Cow's milk-based infant formula|
224068620|NCT02433600|OTHER|Cow milk-based infant formula with enriched protein fractions|
224068621|NCT02011165|PROCEDURE|Positioning measuring device|A tennis ball in the night shirt will prevent supine position during sleep.
224068622|NCT00271323|DRUG|docetaxel and cisplatin|Docetaxel (75 mg/m2, IV, Day 1) and cisplatin (40 mg/m2, IV, Day 1, 2) every 3 weeks for 2 cycles, followed by concurrent chemo-radiotherapy with docetaxel (20 mg/m2, IV) and cisplatin (20 mg/m2) weekly for 6 weeks + radiotherapy 2 Gy/day, 5 days per week to a total dose of 66 Gy.
224068623|NCT00271323|RADIATION|radiotherapy|Docetaxel (20 mg/m2, IV) and cisplatin (20 mg/m2) weekly for 6 weeks + radiotherapy 2 Gy/day, 5 days per week to a total dose of 66 Gy followed by docetaxel (75 mg/m2, IV, Day 1) and cisplatin (40 mg/m2, IV, Day 1, 2) every 3 weeks for 2 cycles.
224068624|NCT02275338|DRUG|Lanreotide Autogel|120mg administered via deep subcutaneous injection at Day 0 and Day 28.
224068625|NCT05146570|DIAGNOSTIC_TEST|D-lactate test|In device-associated meningitis, CSF will be aspirated before, during or after surgery related to the device, according to the standard practice. Lumbar/ventricular punctures (pre-, intra- and/or postoperatively) and external ventricular (EVD) and lumbar drainage (ELD) aspiration will be performed by neurologist or neurosurgeon according to standardized aseptic techniques. In patients with native meningitis, CSF will be aspirated by lumbar puncture, according the standard practice. The D-lactate test will be performed using spectrophotometric enzyme assay according to the manufacturer's instructions (D-Lactate Colorimetric Assay).
224159297|NCT02425969|PROCEDURE|PCI|Patients will have balloon angioplasty and coronary stent insertion for their grey-zone FFR lesion.
223468606|NCT00511719|DRUG|Actrapid|24IU
223468607|NCT04331626|DRUG|Gemcitabine Injectable Product|Low dose chemotherapy drug combined with pd-1 antibody, Gemcitabine should be administered at 50% of the recommended dose, i.e. 500mg/m2, for 30 minutes by intravenous drip. Day 1 and day 8 administration.
223468608|NCT05703542|DRUG|BXCL701|Tablet, taken Orally
223468609|NCT02212067|DRUG|semaglutide|Administered subcutaneously (s.c., under the skin) once weekly for 12 weeks.
223468610|NCT02212067|DRUG|placebo|Administered subcutaneously (s.c., under the skin) once weekly for 12 weeks.
223468611|NCT03988361|DIAGNOSTIC_TEST|Magnetic Activated Cell Sorting|At the moment of ICSI, sibling mature oocytes will be inseminated with spermatozoa from Study group or from Control group. Following ICSI, all the inseminated oocytes will be individually cultured in the same conditions in the same culture dish. The choice of embryo(s) for transfer will be based on embryo quality. The supernumerary good-quality embryos from both arms will be frozen for further use.
223468612|NCT00593814|DEVICE|GORE EXCLUDER® Bifurcated Endoprosthesis-Low Permeability|Implant
223468613|NCT04912076|DRUG|BM41|Subcutaneous injection of increasing doses of BM41
223468614|NCT04912076|OTHER|Placebo|Subcutaneous injections of placebo containing aluminium hydroxide.
223468615|NCT04912076|DRUG|ALK Alutard SQ Betula verrucosa|Subcutaneous injections with increasing doses of Alutard according to cluster up-dosing scheme.
223468616|NCT00829556|DEVICE|Integuseal|
223468617|NCT02593500|DRUG|Budesonida Pulmictan® 200 µg|
223468618|NCT02593500|DRUG|Budesonide 200 µg|
223468619|NCT02022553|PROCEDURE|usual rectal cancer surgery|
223468620|NCT02022553|PROCEDURE|RACHEL|
223468621|NCT06422169|DEVICE|ArToFILL|ArToFILL is an injectable medical device (class III) intended for use as a temporary filler in joints. It is a sterile, non-pyrogenic, colorless and transparent hyaluronic acid gel of non-animal origin. ArToFILL is a hydrogel consisting of a mixture of two different molecular weights of hyaluronic acid, for a total HA concentration of 2.7 %.
223468622|NCT00903643|OTHER|Physical examination|Physical examination and multiple questionnaires will be administered
223468623|NCT02699996|OTHER|Questionnaire Administration|Complete interview
223468624|NCT02699996|BEHAVIORAL|Telephone-Based Intervention|Complete the self management + peer mentoring intervention with videoconferencing
223468625|NCT00151333|DRUG|SRA-333|
223468626|NCT01288599|PROCEDURE|Laparoscopic surgery|Laparoscopic surgery where adnexectomy or cystectomy is performed.
223468627|NCT06258434|DIAGNOSTIC_TEST|multiomics Colorectal Cancer (CRC) screening test (CRC-Appareo)|Patients who are at high risk of developing CRC or confirmed CRC and willing to conduct colonoscopy examination will be asked to collect blood prior to bowl preparation for multiomics CRC screening test which using Reduced Representation Bisulfite Sequencing (RRBS) technology to obtain multidimensional variation information on cell-free DNA (cfDNA) methylation, end sequence, fragment size distribution, and copy number variation in the blood, and integrate analysis through machine learning algorithms to accurately assess the risk of colorectal cancer and advanced adenoma. and will be asked to collect stool sample for commercially available FIT assay. Colonoscopy and histopathologic examination are used as reference. The diagnosis information of each sample was blind to the participants who conduct the multiomics profiling, as well as the informatics who perform the integrate analysis.
223578502|NCT01169584|DRUG|Recombinant Vaccinia GM-CSF; RAC VAC GM-CSF (JX-594)|Intratumoral Injection Dosage from 1 x 10\^6 pfu/kg to 3 x 10\^7 pfu/kg is administered once to 1-3 injectable tumors in pediatric patients.
223578503|NCT04388046|DEVICE|Herbst fixed functional appliance|Herbst appliance could be considered as an artificial joint working between maxilla and mandible. The appliance consists of a bilateral telescope mechanism attached to upper and lower jaws keeping the mandible in an anterior jumped position.
223578504|NCT05343234|DRUG|Placebo|tree different placebo drugs with tree different names and scheduled will be given
223578505|NCT00542737|BEHAVIORAL|Web-Based Educational Program|Participating clinicians at each hospital will access the Web site as often as necessary for a 6-month period. The Web site will contain background and educational information on ALI/ARDS and LPV, including how to recognize ALI/ARDS and how to implement LPV in patients. Scholarly articles and other materials, including a chart to help clinicians determine appropriate ventilator settings for each patient, will be available to download. Clinicians will also be able to email questions to critical care experts.
223578506|NCT05352269|BIOLOGICAL|XBI-302|Fecal Microbiota Transplantation Capsules
224068626|NCT05146570|DIAGNOSTIC_TEST|Standard diagnostic tests|In device-associated meningitis, CSF will be aspirated before, during or after surgery related to the device, according to the standard practice. Lumbar/ventricular punctures (pre-, intra- and/or postoperatively) and external ventricular (EVD) and lumbar drainage (ELD) aspiration will be performed by neurologist or neurosurgeon according to standardized aseptic techniques. In patients with native meningitis, CSF will be aspirated by lumbar puncture, according the standard practice. The standard diagnostic tests will be performed according to standard diagnostic laboratory instructions.
223468628|NCT04009603|DRUG|Probiotic Agent|"Probiotics are live microorganisms, which when administered in adequate amounts confer a health benefit effects on the host.~Many clinical trials have been done on probiotic which show its use as a single or as an adjuvant drug therapy for various diseases with no or rare side effects. It is now frequently used agent for various diseases.~Apart from this many studies have been published related to effects of probiotics on PCOS, which shows effectiveness of probiotics when used for 8 to 12 weeks with no adverse effects observed by these micro-organisms but none of the study have compare it with standarad drug"
223578507|NCT05352269|BIOLOGICAL|XBI-302 Placebo|XBI-302 Placebo
223743635|NCT07189676|BEHAVIORAL|Food boxes PHD|Food boxes will be sent to participants' homes. PHD food boxes will include seasonal and local fruits and vegetables, whole grain products, legumes, nuts, and dairy or milk alternatives. If allergies or intolerances are identified, the food boxes will be modified to maintain safety and dietary compliance.
223743636|NCT07189676|BEHAVIORAL|Group visits PHD|Group visits will provide support through nutritional education, social interaction, and peer learning, all focused on the dietary behavior changes required by the intervention. PHD group visits will cover topics such as PHD principles, and the related environmental and health outcomes.
224068627|NCT04746768|COMBINATION_PRODUCT|exercise and nutritional support|exercise and nutritional support program during an active support phase (0 to 6 months) followed by an empowerment phase (from 6 to 12 months)
224303838|NCT02736682|DRUG|Multiple dose antibiotic|Multiple dose arm receive 1 g of IV Cetriaxone plus 500 mgs during surgery and there after IV ceftriaxone once a day for 3 days and IV Metronidazole 500mgs during surgery and there after every 8 hours for 3 days.
223468629|NCT04009603|DRUG|Metformin|"Metformin, an insulin sensitizer, is an oral biguanide that is most commonly prescribed for the management of type II diabetes mellitus and various symptoms of PCOS. It is derived from the extract of Galega officinalis.~It remediates hyperglycemia through activation of AMPK which stimulates glucose uptake and its consumption; promote fatty acid oxidation along with suppression of hepatic glucose production. It is also involved in increase GLUT4 translocation in the muscle and fat leading to decrease hepatic lipid synthesis. Moreover, It is also reported that it decreases gut absorption of glucose by increasing the glucagon-like peptide-1 (GLP-1) in this way, it reduces the insulin requirement too.All of these actions of metformin decrease insulin resistance and thus improve the state of hyperinsulinemia associated with diabetes and PCOS"
223468630|NCT04069715|DIETARY_SUPPLEMENT|Farlong NotoGinseng™ (Farlong Ginseng Plus® Panax Notoginseng extract)|A product made of highly concentrated pharmaceutical grade notoginseng root extract, and containing high potency bioactive components, notoginsenoside, ginsenoside Rb1, Rg1, Rd, Re and Rb2.
223468631|NCT04069715|OTHER|Placebo|Turmeric 0.4%, Rice Flour 76.6%, Magnesium stearate 23%, capsule shell (gelatin) 61 mg
223468632|NCT02594319|BEHAVIORAL|Monetary incentives|
223468633|NCT02594319|BEHAVIORAL|Self monitoring|
223468634|NCT05471388|DIAGNOSTIC_TEST|serum asprosin|assessment of serum asprosin by a commercially available double-antibody sandwich enzyme-linked immunosorbent assay (ELISA) kit.
223468635|NCT03205150|DRUG|LIK066|Film coated tablet of LIK066 either 30mg or 150 mg was mostly administered once daily before lunch, except on Day 56 when it was administered before breakfast and in fasted state on Day 84
223468636|NCT03205150|DRUG|Placebo|LIK066 0 mg film-coated tablet(Placebo matching tablets) was mostly administered once daily before lunch, except on Day 56 when it was administered before breakfast and in fasted state on Day 84.
223468637|NCT05721664|OTHER|Trianing program for nurse in how to provide evidence based practices for mechanically Ventilated Patients|"Short Name: (EBNPTP) for Caring of Mechanically Ventilated Patients in terms of standardized care.~Duration: Two weeks A number of Contact Hours: 30 hrs. associated arm (interventional arm): for study group of ICU Nurses working at National Hepatology and Tropical Medicine Research Institute (NHTMRI)"
223468638|NCT03040271|OTHER|Health-E-PALS-|Intervention to promote Healthy Eating and Physical Activity in Lebanese School-Children It comprises in class-activities, meetings with parents, improvement of school food service
223468639|NCT05876325|OTHER|FINassist Patient|The FINassist intervention provides access to social, financial and legal services over the duration of 12 months or until issues are resolved
223468640|NCT05876325|OTHER|FINassist Caregiver|The FINassist intervention provides access to social, financial and legal services over the duration of 12 months or until issues are resolved
223468641|NCT01026025|DEVICE|Duet TRS|This is a single arm study.
223468642|NCT05116917|DRUG|Nivolumab|3 mg/kg (up to 240 mg maximum) will be given on day 1 (± 3 days) of each 14-day treatment cycle
223468643|NCT05116917|DRUG|Ipilimumab|1 mg/kg will be given on day 1 cycle 1 (± 3 days) and once more after 6 weeks
223468644|NCT05116917|BIOLOGICAL|Influenza vaccine|Seasonal influenza vaccine is given IM or via PharmaJet Stratis Needle-Free Injection System, 0.5 mL per dose as a single on day 1 cycle 1 (± 3 days)
223468645|NCT05116917|RADIATION|SBRT|"* A total dose of 15 Gy as a single fraction is prescribed as the mean dose to the PTV.~* PTV should be covered by 95% isodose (PTV D99% \> 95%)."
223468646|NCT05538013|OTHER|Survey evaluation|Obesity awareness, physical activity, and sedentary time questionnaires will be applied to these cases.
223468647|NCT03687983|DEVICE|GoldenFlow Peripheral Stent System|Performing anaesthetic and pathological angiography according to the standard method, and select appropriate stent specifications according to the contrast results. After 1:1 pre-expansion, the stent system will be imparted into the lesion location, the stent will be distally positioned and released. The Tip head will be reset and the conveyor will be removed. If necessary, local re-expansion can be carried out. Remove the catheter and suture the wound. Postoperative treatment and anticoagulation.
223468648|NCT02723188|DEVICE|Sham stimulation (1.5 milliampere,30 seconds)|
223468649|NCT02723188|DEVICE|DC stimulation (1.5 milliampere, 20 minutes)|
224068628|NCT05148975|DIAGNOSTIC_TEST|Bronchoalveolar lavage fluid diagnostics|Bronchoalveolar lavage fluid diagnostics for superinfection in patients with COVID-19 pneumonia.
224068629|NCT01612260|DRUG|Shensong Yangxin capsule|ShenSongYangXin Capsule 4 granules t.i.d. po for 12weeks
224068630|NCT01612260|DRUG|placebo Capsule|4 granules t.i.d. po for 12 weeks
224068631|NCT02870855|DRUG|intrauterine injection of HCG|intrauterine injection of HCG berore blastocyst transfer
224068632|NCT01061450|DRUG|Simvastatin|80 mg once a day
224068633|NCT01061450|DRUG|Placebo|1 pill once a day
224068634|NCT02154386|DEVICE|Ridge preservation using DFDBA|tooth extraction followed by ridge preservation grafting using DFDBA
224068635|NCT04092127|OTHER|Video Record|Video Record of the premature infant face before and during the RetCam screening of retinopathy of prematurity
224068636|NCT00564811|DIETARY_SUPPLEMENT|Agaricus blazei (Murrill) ss. Heinemann (sun mushroom)|Agaricus blazei powder, 10 grams/day, for 5 months
224068637|NCT01857869|BIOLOGICAL|GSK257049 Dosage 1|RTS,S/AS01B administered as 0.5 mL dose at 0 and 1 months and 0.1 mL dose at 7 months for 0,1,7 M Group (delayed fractional dose group). In subjects unprotected in the first challenge, to receive a booster with a fractional dose of RTS,S/AS01B followed by rechallenge. In subjects protected in the first challenge, randomization to receive or not receive a booster with a fractional dose of RTS,S/AS01B followed by rechallenge.
224068638|NCT01857869|BIOLOGICAL|GSK257049 Dosage 2|RTS,S/AS01B administered as three doses of 0.5mL given one month apart (0, 1, 2 M group) in the challenge model. In subjects unprotected in the first challenge, to receive a booster with a fractional dose of RTS,S/AS01B followed by rechallenge. In subjects protected in the first challenge, randomization to receive or not receive a booster with a fractional dose of RTS,S/AS01B followed by rechallenge.
223468650|NCT02723188|DEVICE|AC stimulation (1.5 milliampere,1.5 Hertz frequency)|
223468651|NCT00955500|DIETARY_SUPPLEMENT|Branched-chain amino acids|30 grams of oral branched-chain amino acids (leucine: 13.5 grams, isoleucine: 9 grams, valine: 7.5 grams) daily
223578508|NCT04831528|DRUG|Cetuximab Ab; Bevacizumab; Vermofenib + cetuximab;Trastuzumab+lapatinib or trastuzumab+pertuzumab; others|After PD, patients received ctDNA testing, and different research protocols were selected according to different gene states of ctDNA, as follows: 1.No secondary changes related to drug resistance were found. Cetuximab cross-line + second-line chemotherapy (FOLFOX/FOLFIRI/ Irinotecan monotherapy, etc.) was used.2. If there is a RAS secondary mutation, change of beacizumab bead sheet resistance + second-line chemotherapy (FOLFOX/XELOX/stand for kang single-agent FOLFIRI mXEIRI/Iraq, etc.);3. If BRAF secondary mutation occurs, replace it with vimofenib + cetuximab + irinotecan;4. If HER2 amplification occurs, replace it with trastuzumab + lapatinib or trastuzumab + pertuzumab;5. In case of other secondary mutations, bevacizumab plus second-line chemotherapy should be replaced.
223578509|NCT02590601|DRUG|Bromocriptine|
223578510|NCT02590601|OTHER|Guideline-driven medical therapy (GDMT)|
223578511|NCT03558074|DRUG|ALK4290|ALK4290 400 mg tablet twice a day
223578512|NCT02552251|BIOLOGICAL|Hormonal balance measurements|
223578513|NCT02552251|BIOLOGICAL|metabolic balance measurements|
223578514|NCT02552251|BIOLOGICAL|bone balance measurements|
223578515|NCT02552251|BEHAVIORAL|quality of life assessment|
223578516|NCT03819452|DIAGNOSTIC_TEST|Vitamin D Level|Vitamin D level is measured upon the presentation of the case with ischemic stroke
223578517|NCT05787132|OTHER|Balance Board therapy|Balance board therapy will be performed. balance board therapy has been shown to improve the sitting balance in children with cerebral palsy
223578518|NCT05787132|OTHER|Perceptual Motor therapy|Perceptual motor therapy will be performed, it has been shown to improve dynamic sitting in children with cerebral palsy.
223578519|NCT01281228|DRUG|exenatide|The loading dose is 50 ng/min during 30 min, followed by a maintenance dose 20 ng/min for the rest of the tests.
223578520|NCT01281228|DRUG|exenatide + exendin (9-39)|The loading dose is 50 ng/min during 30 min, followed by a maintenance dose 20 ng/min for the rest of the tests. Exendin 9-39 will be infused intravenously at doses of 600 pM/kg • min.
223578521|NCT01281228|DRUG|placebo|saline infusion
223578522|NCT04602767|DRUG|Vasopressin|Vasopressin titrated 0.01 U/min up to 0.04 U/min for MAP \< 65 mmHg
223578523|NCT04602767|DRUG|Phenylephrine|Phenylephrine titrated 0.25 mcg/kg/min up to 1.0 mcg/kg/min for MAP \< 65 mmHg
224068639|NCT01857869|PROCEDURE|Sporozoite-infected mosquitoes challenge|"Mosquitoes infected approximately 2-3 weeks earlier that are likely to contain sporozoites in their salivary glands will be allowed to feed on the volunteers. For each volunteer, five mosquitoes will be allowed to feed over five minutes, after which they will be dissected to confirm how many were infected, and the salivary glands scored.~The challenge is scheduled to occur approximately 21 days (3 weeks) after the last vaccination visit (Study Day 196). Volunteers who reconsent for the boost/rechallenge phase will be rechallenged with sporozoite-infected mosquitoes, scheduled to occur approximately 21 days (3 weeks) after the booster dose (Booster Phase Study Day 21)."
223578524|NCT01755650|RADIATION|18F FPM|
223578525|NCT04738253|DIAGNOSTIC_TEST|Ultrasonography|The ultrasound measurement s of the axillary recess capsule thickness.
223578526|NCT04159363|OTHER|An interactive Colorectal Cancer self-Management enhancement smartphone-based psychosocial intervention programme (iCanManage)|The iCanManage consists of two components: (1a) Existing functions from the BuddyCare mobile application that provide a comprehensive 29 day-by-day perioperative guide for patients who will be undergoing colorectal elective surgery; (1b) a dashboard for healthcare professionals to monitor patients and their caregivers' well-being as well as allow mutual communication; and (2) Newly developed digitalised psychosocial content (e.g., mindfulness-based activities with audio cover, video materials related to positive psychology, patient ambassadors' success stories and relevant psychoeducation) tailored for colorectal cancer patients and caregivers, with the aim of providing them emotional and psychosocial support.
224068640|NCT04505228|DRUG|Safflower (Carthamus Tinctorius) IgG4 &#X7C; Serum &#X7C; Allergy|The designed Chinese herb formulas
223468652|NCT00955500|DIETARY_SUPPLEMENT|Maltodextrin|30 grams of oral maltodextrin daily
223468653|NCT04578704|OTHER|Vacuum formed retainer, fixed bonded retainer, vacuum formed and fixed bonded retainer|"Patients will be instructed to wear the removable vacuum form retainer for 8 to 10 hours per day and only removed the retainers during tooth brushing. (Thickett 2010), (Gill 2007).~The vacuum formed retainer will be constructed using thermoplastic material that will be purchased from manufacturer at 1.0mm thickness.~Meanwhile, bonded retainer will be done using Ormco ® response deadsoft retainer wire size 0.190 round, made in USA by ORMCO Corporation, the fixed bonded wire will be extended distal to the extraction spaces that were previously closed by fixed appliances on both the upper and lower arches. The bonded retainer will be wearing by patients for 24 hours.~Double regime retainer that will be comprised of vacuum formed and bonded retainer will be constructed using the same properties as vacuum formed retainer and bonded retainer. A standard oral and written instruction will be given to patients regarding retainer's uses. (Shawesh M et.al, 2009)."
223468654|NCT01145365|PROCEDURE|Exam under anesthesia (EUA)|EUA established drainage of perianal fistulas \&/or abscesses will be done before patient begins medical therapy with certolizumab (Cimzia)
223468655|NCT00817622|DIETARY_SUPPLEMENT|EPA, Vitamin E|EPA pearls, 500 mg QID for 12 Weeks (2000 mg per day) Vitamin E pearls, 400 mg per day for 12 weeks
223468656|NCT01095835|DRUG|Pegylated interferon (PEG-IFN) alfa-2a, 180 mcg|PEG-IFN alfa-2a 180 micrograms (mcg) was administered subcutaneously, once weekly from Week 0 to 48.
223578527|NCT04179513|BIOLOGICAL|GB224 10mg|"10 mg, 12subjects, abdominal subcutaneous injection, the next dose group can be initiated only after the safety and tolerability are confirmed within 4 weeks after the second dosing is given.~Dosage and administration at enrollment are maintained (10\~15 mg/week), oral administration, a total of 32 doses."
223578528|NCT04179513|BIOLOGICAL|GB224 20mg|"20 mg, 12subjects, abdominal subcutaneous injection, the next dose group can be initiated only after the safety and tolerability are confirmed within 4 weeks after the second dosing is given.~Dosage and administration at enrollment are maintained (10\~15 mg/week), oral administration, a total of 32 doses."
223578529|NCT00394901|DRUG|Placebo|placebo, oral administration for 13 weeks (1 week titration and 12-week fixed dose).
224068641|NCT04505228|DRUG|Atropine Sulfate|The basic treatment for heart disease
223468657|NCT01095835|DRUG|Pegylated interferon (PEG-IFN) alfa-2a, 135 mcg|PEG-IFN alfa-2a 135 mcg was administered subcutaneously, once weekly from Week 49 to 96.
223468658|NCT01095835|DRUG|Lamivudine (LAM)|Lamivudine 100 milligrams (mg) was administered orally, daily from Week 0 to 48.
223468659|NCT04243629|DRUG|Rapid-Acting Insulin|Novorapid or Humalog insulin delivered in a basal-bolus manner.
224159298|NCT02425969|DRUG|Optimal Medical Therapy|Optimal Medical therapy consists of secondary prevention which will include high dose statin and aspirin as well as anti-anginal therapy according to ESC 2013 international treatment guidelines for stable angina as follows; B-Blocker or Calcium channel blocker as first line agents and Nicorandil or Nitrates or Ranolazine as second line treatment titrated against symptoms to maximum tolerated dose. ACE inhibitors or Angiotensin Receptor Blockers will be prescribed if patients also have a diagnosis of hypertension, LVEF ≤40%, diabetes or CKD where appropriate.
224303839|NCT03196414|BIOLOGICAL|CART-138/BCMA/19/more|Cyclophosphamide，Fludarabine，CART-138/BCMA /19/more cells Cyclophosphamide: 300 mg/m2 IV over 30 minutes on days -5 , -4,and -3; Fludarabine: 30 mg/m2 IV over 30 minutes immediately following the cyclophosphamide on day -5, -4, and -3 Biological: Anti-CD138/BCMA/CD19/more total CART cells 5x106- 100x106 CAR+ T cells per kg of recipient bodyweight
224303840|NCT05697055|DRUG|Azvudine|5mg orally, once a day, for no more than 14 days
224303841|NCT05697055|DRUG|Nirmatrelvir-Ritonavir|Nirmatrelvir 300mg combined with Ritonavir 100mg every 12 hours for 5 days. For patients with 30≤ eGFR \< 60 ml/min, it should be reduced to150mg/100mg Nirmatrelvir-Ritonavir every 12 hours for 5 days
224303842|NCT02487381|DRUG|delta-9-tetrahydrocannabinol|
224303843|NCT02487381|DRUG|Cannabidiol|
224303844|NCT02487381|DRUG|Placebo|
224303845|NCT03528473|OTHER|Exercise|"The exercise intervention consists of 60 minutes sessions, divided into 40 minutes of aerobic exercise and 20 minutes of circuit training for muscular strength and flexibility exercises.~Aerobic exercise is performed using treadmill, exercise bikes, syncro and arm-ergometers, gradually increasing the exercise intensity, after a 10 minutes period of warming-up, to 60-80 % of Maximum Heart Rate.~Resistance training consists of resistance exercises for large muscle groups, performed with body weight-exercises and isotonic machines."
223468660|NCT04243629|DRUG|Placebo|Placebo (saline) delivered in a basal-bolus manner at a fixed ratio with insulin.
223468661|NCT04243629|DRUG|Pramlintide Acetate|Pramlintide acetate delivered in a basal-bolus manner at a fixed ratio with insulin.
223468662|NCT04243629|DEVICE|Artificial Pancreas|Tandem insulin pump, Dexcom G6 sensor, study smartphone running the iMAP algorithm.
223468663|NCT05563545|BIOLOGICAL|CAR-NK-CD19 Cells|CAR-NK-CD19 Cells, 1-3×10\^7 /KG, treatment follows a lymphodepletion. Drug: Fludarabine Recommendation: 25-30 mg/m2 (D-5\~D-3), determined by tumor burden at baseline. Drug: Cyclophosphamide Recommendation: 250-300 mg/m2 (D-5\~D-3), determined by tumor burden at baseline.
223468664|NCT06571162|OTHER|Clinical Pharmacy Team|Patients will receive targeted care of their LDL-C through a pharmacist-driven management program.
223468665|NCT06571162|OTHER|Usual Care|Patient will receive usual care for their LDL-C management.
223578530|NCT00394901|DRUG|Pregabalin|Pregabalin 150mg/day (75mg BID), oral administration for 13 weeks (1-week titration and 12-week fixed dose).
224068642|NCT03149081|DRUG|Boswellia|Boswellia is an extract from frankincense
223468666|NCT00350883|BEHAVIORAL|Cognitive Therapy|Goal-oriented talk therapy
223468667|NCT00350883|OTHER|Treatment as Usual|Keep getting usual care
223468668|NCT00871624|DRUG|Dexmedetomidine|Dexmedetomidine will be started at a rate of 0.2mcg/kg/hr and titrated by 0.1 mcg/kg/hr every 30 minutes to a maximum of 0.7 mcg/kg/hr to maintain a Riker-SAS 3-4.
223578531|NCT00394901|DRUG|Pregabalin|Pregabalin 300mg/day (150mg/BID), oral administration for 13 weeks (1-week titration and 12-week fixed dose).
224068643|NCT00388908|BEHAVIORAL|Reminders and opinion leader generated guidelines +/- leaflets and counselling|
224068644|NCT00388908|OTHER|Usual Care|
224068645|NCT03723629|OTHER|No intercention|No intercention
224068646|NCT00731250|DRUG|SB-705498|Subjects will be administered a single dose of 400 mg SB-705498
224068647|NCT00731250|DRUG|Placebo|Subjects will be administered SB-705498 matching placebo tablets
224068648|NCT00731250|OTHER|Caspaicin|Subjects will be challenged with 0.5 µg, 5.0 µg and 50 µg intranasal dose
224068649|NCT06170515|DIAGNOSTIC_TEST|CareSens N-Eco (i-Sens), • CareSens N-Premier (i-Sens), CodeFree (SD Biosensor), GlucoNavii GDH (SD Biosensor)|BGM Test
224068650|NCT06170515|DIAGNOSTIC_TEST|Affinion (Abbott), HbA1c 501 (HemoCue), A1Care (iSens), DCA Vantage (Siemens)|HbA1c Test
224068651|NCT02488395|OTHER|fMRI|The investigators will use a non invasive fMRI technique centred on the superior colliculus during the presentation of flickered check-boards with varying contrast (1, 3, 5 and 9 %).
224068652|NCT02488395|OTHER|Ophthalmologic evaluation|The aim of this experiment is the evaluate the functional state of a visual structure. Therefore, with this ophthalmologic test, the investigators will control if the participant does not present major visual deficits. This examination will evaluate the visual acuity and the visual field. A funduscopic examination will also be performed to check the retina.
224068653|NCT02488395|OTHER|visual psychophysics test|This test will allow to control the sensitivity of the participant to our contrast. The participant will be asked to look at screen on which three static check-boards will be presented. The participant will have to choose the two check-boards with the closest contrast.
224068654|NCT02164656|BEHAVIORAL|mindfulness for smokers|
224068655|NCT03877887|DIAGNOSTIC_TEST|echo cardiogram|Assessment of left ventricular systolic and diastolic function
224068656|NCT03473431|DRUG|Ketamine|single infusion of 0.5 mg / kg ketamine
224068657|NCT03473431|OTHER|control|physiological solution at 0.9 % with the same physical characteristics of ketamine solution,
223468669|NCT00871624|DRUG|Placebo|Placebo infusion will be started at a rate of 0.2mcg/kg/hr and titrated by 0.1 mcg/kg/hr every 30 minutes to a maximum of 0.7 mcg/kg/hr to maintain a Riker-SAS 3-4.
223468670|NCT04779424|OTHER|POCT|Capillary blood sample antibody point of care test
223468671|NCT05719896|DRUG|DT01 tablets|Each subject was given orally 3 DT01 tablets/day for 8 weeks
223468672|NCT05719896|DRUG|Placebo tablets|Each subject was given orally 3 DT01 tablets/day for 8 weeks
223468673|NCT05719896|DRUG|DT01-Placebo tablets|Each subject was given orally 2 DT01 tablets and 1 Placebo tablet, three times per day for 8 weeks
223578532|NCT00394901|DRUG|Pregabalin|Pregabalin 600 mg/day (300 mg/BID), oral administration for 13 weeks (1-week titration and 12-week fixed dose).
224303846|NCT05624827|DIAGNOSTIC_TEST|Testing DNA methylation test for predicting prognosis of untreated CIN 2|After being diagnosed with CIN 2, patients will first be contacted by telephone and invited to participate in the study. If patients agree to participate in the research, they will sign a consent to participate in the research. After that, we will perform a colposcopy and take a cervical swab for analysis with the QIAsure Methylation Test Kit (Qiagen, Gaithersburg, USA), which will determine the methylation of tumor suppressor genes FAM19A4 and has-mir-124. Patients will complete a questionnaire. The total duration of tracking in both groups will be two years. The QIAsure Methylation Test will be performed to analyze methylation. It is a methylation-specific PCR test that detects hypermethylation of the tumor promoter suppressor genes FAM19A4 and has-mir-124. The samples on which we will use this test are bisulfite-converted DNA obtained by triage test for high-risk HPV - Hybrid Capture 2 HPV DNA Test (hc2, Qiagen, Gaithersburg, USA).
223468674|NCT00738712|PROCEDURE|MRI Magnetic Resonance Imaging|MRI
223468675|NCT01797393|OTHER|Air insufflation|Air is inflated into the bowel to help searching the cavity while advancing the colonoscope until reaching the cecum.
223468676|NCT01797393|OTHER|Water injection|Water was injected through the working channel instead of air to follow the intestinal cavity until reaching the caecum .
223468677|NCT01797393|OTHER|" Air assisted water injection."|Cut off air inflating before examination. Water was injected through the working channel to follow the intestinal cavity until reaching the splenic flexure, small amount of air inflating could be given to help searching the cavity until reaching the cecum.
224303847|NCT01490866|DRUG|Axitinib|5-mg tablets PO BID
223468678|NCT01912976|DRUG|Er:YAG AFL-PDT|Er:YAG AFL was performed with 550-600 µm ablation depth, level 1 coagulation, 22% treatment density, and a single pulse. MAL cream was then applied under occlusion for 3 hrs and illuminated with a red light-emitting diode light at 37 J/cm2.
223468679|NCT01912976|DRUG|MAL-PDT|a 1-mm thick layer of MAL (16% Metvix® cream, PhotoCure ASA, Oslo, Norway) was applied to the lesion and to 5 mm of surrounding healthy tissue. The area was covered with an occlusive dressing (Tegaderm, 3M, Saint Paul, MN, US) for 3 hours, after which the remaining cream was removed with saline gauze, and the red fluorescence of porphyrins was visualized with Wood's light. Each treatment area was then separately illuminated with red light-emitting diode (LED) lamps (Aktilite CL128; Galderma, Bruchsal, Germany) with peak emission at 632 nm and total light dose of 37 J cm-2. Areas scheduled to receive MAL-PDT received the second treatment 7 days later.
223468680|NCT02063113|OTHER|Vulnerability and therapeutic changes in older patients with multiple myeloma.|
223578533|NCT05028517|OTHER|FMF Connect|The FMF Connect intervention includes cloud infrastructure and an innovative, multilayered mobile app. It incorporates tailored content for parents/caregivers of children (ages 3-12) with FASD or PAE. The app integrates five main components: 1) Dashboard; 2) Learning Modules; 3) Family Forum; 4) Library; and 5) Notebook. Weekly emails are also sent to support motivational engagement.
223578534|NCT05028517|OTHER|Coaching|A text-based coaching module is added to the FMF Connect app. Coaches support continued use of the app and individualized goal setting.
223578535|NCT04288258|BEHAVIORAL|Telehealth-Based Health and Wellness Program (POWERS-TBI)|The treatment program is interactive and will be delivered via the internet, along with ongoing telephone health coaching calls designed to motivate, problem-solve challenges, reinforce skills learned, and prevent relapse.
223578536|NCT00359567|DRUG|palonosetron|intravenous injections of 0.75 mg palonosetron (5 mL) and then granisetron placebo before administration of highly emetogenic chemotherapy, concomitantly administered with corticosteroids.
223578537|NCT00359567|DRUG|granisetron hydrochloride|intravenous injections of palonosetron placebo and then 40μg/kg granisetron hydrochloride before administration of highly emetogenic chemotherapy, concomitantly administered with corticosteroids.
223578538|NCT01503996|BEHAVIORAL|alter drinking habits|if dehydration is apparent, more fluid intake is recommended
223743637|NCT07189676|BEHAVIORAL|Behavioural support (Ovo-lacto-vegetarian diet)|This component is designed to help participants adhere to the ovo-lacto-vegetarian through four individual and personalized dietary visits with a dietitian. Participants will also have access to a digital recipe collection in the study app. Recipes will be tagged by meal type.
224303848|NCT01490866|DRUG|Bevacizumab|5 mg/kg Days 1 and 15; IV
223468681|NCT04331288|DRUG|PT150|Intervention 1 includes PT150 with alcohol consumption
223468682|NCT04331288|OTHER|Beverage|The alcohol beverage will be prepared by an in-house pharmacist at the MEDVAMC in a volume of 450 ml for a 70 kg individual and adjusted for body weight by varying the volume. Alcohol will be administered in a concentration of 16% alcohol (Everclear, St. Louis, MO) by volume in juice or another flavored beverage. Participants will be allowed 30 minutes to consume the beverages.
223468683|NCT04967053|PROCEDURE|sleeve gastrectomy|Laparoscopic sleeve gastrectomy gives long-standing improvement or resolution of obesity-related conditions and also survival benefit. It is highly cost-effective. Surgical procedures for the treatment of obesity.
223468684|NCT01056692|DRUG|OC000459|Capsules twice daily for 15 days
223468685|NCT01056692|DRUG|Placebo|Capsules twice daily for 15 days
223468686|NCT04539418|DRUG|Vitamin K 2|Patients will be monitored during the whole protocol.
223468687|NCT05362708|DEVICE|Clinical - Hypnosis with VR (VRH)|The VRH intervention will use the Aqua video session developed by Oncomfort during a port-a-cath procedure.
223468688|NCT03884881|DIAGNOSTIC_TEST|metagenomic next generation sequencing|Pathogens in the NGS group will be tested by NGS，then according the NGS results, adjust antibiotics
224303849|NCT01490866|DRUG|5-Fluorouracil|400 mg/m2 Days 1 and 15; IV
224303850|NCT01490866|DRUG|5-Fluorouracil|2400 mg/m2 over 46-48 hours Days 1 and 15; Continuous Intravenous
224303851|NCT01490866|DRUG|Leucovorin|400 mg/m2 Days 1 and 15; IV
223468689|NCT03884881|DIAGNOSTIC_TEST|Conventional pathogen detection|Morphological detection, microbial culture, nucleic acid amplification technology, serological pathogen antibody titer detection and specific pathogen PCR detection. Then, according to the pathogen results, adjust antibiotics
223468690|NCT03884881|DRUG|Meropenem，Imipenem，Caspofene，Osstat|Meropenem，Imipenem，Caspofene，Osstat
223468691|NCT03246464|DEVICE|Orthokeratology lenses|Rigid gas permeable contact lenses
223468692|NCT03246464|DEVICE|Single-vision spectacles|Regular single vision spectacles
223468693|NCT01198002|DRUG|LY2127399|Administered Subcutaneously (SC)
223468694|NCT01198002|DRUG|Placebo Q2W|Administered SC
223578539|NCT05280106|PROCEDURE|Pre-dilution online hemodiafiltration with citrate dialysate|After enrollment, all patients began a 2-week run-in period with conventional dialysis fluid containing acetate and the lowest dose of unfractionated heparin. The investigator titrated the heparin dose by reducing the dose step by step, 25% in each step, until the final minimal dose was achieved. The experimental study consisted of 3 phases, 4 weeks in each phase, and the phases were separated by 1-week washout periods. Phase 1 used CD with 50% of the heparin dose of the baseline. Phases 2 and 3 used 25% heparin and no heparin, respectively. New dialyzers were introduced at the beginning of each phase and the heparin dose was resumed during the washout phase. The calcium concentration in the dialysis fluid was kept constant (1.5 mmol/L) to allow evaluation of the effect of CD on calcium balance
223578540|NCT05280106|PROCEDURE|Post-dilution hemodiafiltration with citrate dialysate|same protocol with post-dilution Ol-HDF in these same patients for the later 12 weeks.
223468695|NCT01198002|DRUG|Placebo Q4W|Administered SC
223468696|NCT01198002|DRUG|Methotrexate|Methotrexate is a background therapy.
223468697|NCT01127100|DRUG|transdermal fentanyl matrix, gabapentin|"transdermal fentanyl matrix: during 1st to 6th days, 12ug/h of fentanyl matrix will be applied. During 7th to 28th days, the dosage of fentanyl matrix will be increased until the pain score decrease not more than 2 every 6 days. The maximal dosage is 100ug/h. During 29th to 56th days, the dosage will be maintained.~Gabapentin: the 1st day, 300mg hs, the 2nd day, 300mg bid, the 3th to 4th days, 300mg tid, the 5th to 6th days, 300mg-300mg-600mg the 7th to 28 days, the dosage will be increased until the pain score decreased not more than 2 and the maximal dose is 2400mg per day. During 29th to 56th days, the dosage will be maintained."
223468698|NCT00001322|DRUG|Leuprolide Acetate 3.75|Eight to 12 weeks of GnRH agonist, Leuprolide Acetate 3.75 mg given intramuscularly monthly
223578541|NCT05109221|DEVICE|ultrasound|using of ultrasound in prediction of difficult intubation in obese surgical patients
223578542|NCT00777400|DRUG|Efalizumab|1 mg/kg of efalizumab administered sub q once weekly
223468699|NCT00001322|DRUG|Estradiol|Transdermal Estradiol, 100mcg/day by skin patch
223468700|NCT00001322|DRUG|Progesterone|Progesterone suppository, 200mg vaginally twice/day
223468701|NCT00001322|DRUG|Placebo suppository|Placebo suppository twice daily
223468702|NCT00001322|DRUG|Placebo patch|Placebo by skin patch
223468703|NCT00057291|BEHAVIORAL|Responsive caregiving|Responsive caregiving consisted of operational circumstances and training of caregivers.
224068658|NCT05037110|BEHAVIORAL|Physical activity|For 12 weeks, do 150 minutes of moderate physical activity per week and wear a smart watch to monitor this physical activity goal. This is done remotely. Then, every two weeks, attend a remote individual meeting with a kinesiologist using a secured application (15 minutes each). Each online meeting will contain the following steps: 1) Review of health and activities recorded by the activity watch/app provided to the participant; 2) Discussion on how to reach/maintain the physical activity goal in the coming weeks according to individual health status, facilitators and barriers; 3) Elaboration of the next 2-week action plan.
224303852|NCT01490866|DRUG|Oxaliplatin|85 mg/m2 Days 1 and 15; IV
223468704|NCT01719549|DRUG|Dovitinib|"* Study treatment: TKI258 single agent on a 5 days-on/2 days-off schedule~* Study drug: TKI258 capsule~* Dose: 500mg p.o. qd~* Every 3 weeks"
223578543|NCT02256267|DRUG|LY2835219|Administered orally
223578544|NCT02256267|DRUG|Rifampin|Administered orally
223578545|NCT01898949|OTHER|Cold Exposure|Participants will spend 20 minutes per day 5 times a week (workdays) in a cold room wearing light clothes (T-shirt, shorts and light shoes) for 4 weeks.
223578546|NCT02818114|BEHAVIORAL|Peer Enhanced Prolonged Exposure|Peer support interventions as adjunct to prolonged exposure
223578547|NCT05692310|OTHER|placing a standard central venous line|Patients will benefit from the technique of central venous line placement by conventional ultrasound.
223578548|NCT05692310|OTHER|placement of a central venous line using an ultraportable ultrasound device|Patients will have a central venous line placed using an ultraportable ultrasound device
223578549|NCT03891628|BEHAVIORAL|Modified Attachment and Biobehavioral Catch-up|Intervention targets include enhancing nurturance and following the child's lead, as well as supporting use of kangaroo care, swaddling, and breastfeeding.
224303853|NCT03433716|OTHER|Ultrasound-guided Percutaneous Neuromodulation|It's a new intervention of sport physiotherapy. It´s an invasive technique. It is necessary an ultrasound
223468705|NCT04970212|DEVICE|BioTraceIO Lite|The BioTraceIO software will analyze the ultrasound images, and provide the physician with an estimated tissue damage map.
223468706|NCT02184819|DRUG|levosimendan|24 hour continuous infusion at the rate of 0,1 µg/kg/min
223468707|NCT02184819|DRUG|Placebo|24 hour infusion at a rate of 0,1 µg/kg/min assuming that it contains study drug
223468708|NCT00238407|DRUG|Docetaxel and Cisplatin|Patients receive docetaxel IV over 30-60 minutes and cisplatin IV over 1 hour on days 1, 22, 43, 50, 57, 64, and 71.
223468709|NCT00238407|RADIATION|Radiotherapy|Beginning on day 43 (week 7) of chemotherapy, patients undergo radiotherapy once daily, 5 days a week, for 7 weeks.
223468710|NCT06135181|DRUG|Gadoquatrane (BAY1747846) 0.03 mmol Gd/kg|0.03 mmol Gd/kg by intravenous injection (at 2 mL/s)
223468711|NCT06135181|DRUG|Gadoquatrane (BAY1747846) 0.1 mmol Gd/kg|0.1 mmol Gd/kg by intravenous injection (at 2 mL/s)
223468712|NCT06135181|DRUG|Matching placebo|0.9% sodium chloride by intravenous injection (at 2 mL/s)
224303854|NCT00433316|DRUG|ropivacaine|1% ropivacaine
224303855|NCT00433316|DEVICE|Aeroneb Pro Nezulizer, Aerogen, Ireland|Aeroneb Pro Nezulizer, Aerogen, Ireland
224303856|NCT01665924|DRUG|GLPG0634 100mg capsule once a day for 10 days|
224303857|NCT00598624|DRUG|Treosulfan IV|Treosulfan i.v.: 14 g/m²/d from day -6 to day -4
223468713|NCT03273478|DEVICE|Endovascular treatment of bifurcation aneurysm with pCONUS2|"Patients suffering from a bifurcation aneurysm will be treated endovascularly with the pCONUS2 device.~* The patients do not face any additional risks by participating in the study as the treatment does not differ from the standard of care in any way.~* The patients will only be enrolled in the study if they give their written consent.~* If they do not wish to participate in the observational study or if they wish to withdraw from it at a later date, they will not have any disadvantages."
223468714|NCT04415801|DIAGNOSTIC_TEST|Repeated removal and re-placement of healing and prosthetic abutments|Repeated removal and re-placement of healing and prosthetic abutments
223468715|NCT02887703|BEHAVIORAL|Sensory Augmentation|Sensory augmentation is a technique of augmenting or replacing compromised sensory information. In the context of sensory-based balance impairments, a sensory augmentation device provides cues of body motion that supplement an individual's remaining intact sensory systems.
223468716|NCT03082508|DEVICE|Algisyl|Algisyl device (implants) administered during a surgical procedure
223468717|NCT03082508|DRUG|Standard Medical Therapy|as per protocol
223468718|NCT03566225|DRUG|Pioglitazone|Insulin sensitizing agents
223468719|NCT03566225|DRUG|Metformin|Insulin sensitizing agent
223468720|NCT03566225|DRUG|Clomiphene Citrate|Induction drug
223468721|NCT06379373|OTHER|Spine manipulation; westren medicine|"First Cervical traction,than spine release method,Massage the neck for about 10 minutes to realease muscles.Doctor use his two hands work together to pull the neck forward and upward,meanwhile, the patient's head is passively rotated to the right to the maximum, being rotated slightly with appropriate force, Doctor's left thumb pushes the crooked spinous process to the right, and the reduction sound can be heard at this time.~If patient has upper thoracic spine misalignment, the dislocated segment needs to be adjusted.~If patient has scoliosis, the affected spine segment should also be adjusted. If patient's lumbar facet joints are misaligned, or one of the lumbar muscles is spasmal, also the disorder joints need to be adjusted."
223468722|NCT02402517|OTHER|Control|Non pulse extruded snack
223468723|NCT02402517|OTHER|Small particle size pea flour|Pulse extruded snack
223468724|NCT02402517|OTHER|Large particle size pea flour|Pulse extruded snack
223468725|NCT02402517|OTHER|Lentil flour|Pulse extruded snack
223468726|NCT02402517|OTHER|Navy bean flour|Pulse extruded snack
223468727|NCT02402517|OTHER|Pinto bean flour|Pulse extruded snack
223468728|NCT01328015|DRUG|Oxybutynin 5 mg pills|"½ pill oral 12/12h for 3 days~01 ½ pills oral morning and evening for 3 days Continue 1 pill oral 2x/day for three weeks."
223468729|NCT01530269|DRUG|C11-Sodium Acetate|PET Imaging with C11-Sodium Acetate
223468730|NCT01668420|OTHER|thermal stimulation|hot and cold/warm and cool pads applying.
223468731|NCT04744298|OTHER|TheraPPP|"TheraPPP Steps:~Step 1. All mechanically ventilated patients will have a height measured and documented. Step 2. Screening for HRF. Step 3. Initiate Lung Protective Ventilation (LPV). Step 4. Paralysis. Step 5. Prone Positioning."
223468732|NCT00789321|DRUG|Comparator: amlodipine besylate|Two 5 mg tablets amlodipine daily for 6 weeks.
223468733|NCT00789321|DRUG|Comparator: Placebo|Two 5 mg tablets placebo to amlodipine daily for 6 weeks
223468734|NCT06443294|BEHAVIORAL|Smoking cessation video series.|The intervention in this study is a series of six videos totally approximately 40 minutes. These videos are led by a doctoral psychology student with experience in working with tobacco smokers. Videos utilize empirically-supported strategies for smoking cessation.
223468735|NCT00005793|DRUG|Cytarabine|
223468736|NCT00005793|DRUG|Daunorubicin|
223578550|NCT03891628|BEHAVIORAL|Modified Developmental Education for Families|Intervention targets include supporting developmental monitoring and parental engagement in activities that promote cognitive and motor development.
224303858|NCT02672202|DRUG|Duloxetine|"* 60 mg/d - twice before surgery and once a day for post operative days 3-7~* 30 mg/d - once a day for post operative days 1-2"
224303859|NCT02672202|DRUG|Pregabalin|"* 75 mg/d - twice a day for post operative days 1-2~* 150 mg/d - twice a day for post operative days 3-7 300 mg/d - twice before surgery"
223468737|NCT00005793|DRUG|Etoposide|
223468738|NCT00005793|DRUG|Topotecan|
223468739|NCT00454961|DRUG|artemether-lumefantrine|
223468740|NCT02660255|DRUG|Cannabidiol|Formulation: 100mg/ml CBD (Epidiolex) Solution
223468741|NCT02048423|DRUG|Ketamine|IV Ketamine, 0.5 mg/kg X 15 mins. in PACU
223468742|NCT02334163|DRUG|Nitazoxanide|500 mg nitazoxanide tablets twice daily
223468743|NCT02334163|DRUG|Oral lactulose|Oral lactulose (65%)
223468744|NCT02334163|DRUG|Metronidazole|250 mg metronidazole tablets every 8 hours
223468745|NCT02334163|DRUG|Rifaximine|Two 200 mg rifaximine tablets every 8 hours
223468746|NCT00729521|OTHER|facilitative system|The facilitative system links communities with academic partners to provide communities with the skills and resources needed to help facilitate the community health improvement process. The system identifies what assets are available within communities, as well as the skills and resources needed to work through the community health improvement process. The facilitative system will then provide technical assistance, best practices guides, and direct consultation in carrying out all phases of the community health improvement process. This information is designed to increase community capacity in community assessment, coalition development, accessing and interpreting local injury prevention data, searching and selecting evidence-based research, and program planning and evaluation.
223468747|NCT00729521|OTHER|Standard Program|"a Standard Program group receiving modest funding to implement an evidence-based fall prevention program in their local community;"
223468748|NCT05788263|OTHER|neuroscience based aproach|exercise for pain
223468749|NCT03980548|PROCEDURE|CABG|Patients undergoing coronary artery bypass graft and patient presented with ACS undergoing PCI
223468750|NCT04260620|DEVICE|Reading of Automated Breast Ultrasound in conjunction with Screening Mammography|Reader performance when SoftVue automated breast ultrasound (SV) and digital screening mammography (DM) are combined, compared to screening mammography alone.
223578551|NCT02916407|DRUG|Sevoflurane|"Intravenous ketamine will administrate to the patients for decreasing of separation anxiety of children.~General anesthesia will maintained with sevoflurane 2-3 vol%."
223578552|NCT02916407|DRUG|Desflurane|"Intravenous ketamine will administrate to the patients for decreasing of separation anxiety of children.~General anesthesia will maintained with desflurane 6-7vol%."
223578553|NCT05122923|DEVICE|Serious Game S'TIM|Video Game S'tim : the patient is inside a bedroom and he has to find a friend outside. this game will study the orientation, the memory of the patient
223578554|NCT06545266|PROCEDURE|micro-fragmented adipose tissue injection|Micro-fragmented adipose tissue was obtained through the Lipogems kit and intraarticularly injected after an arthroscopic debridement.
223578555|NCT03286777|DIETARY_SUPPLEMENT|Placebo|Mannitol and silicon dioxide capsules
223578556|NCT03286777|DIETARY_SUPPLEMENT|Native 6-prenylnaringenin|250 mg native 6-PN plus mannitol and silicon dioxide capsules
223578557|NCT03286777|DIETARY_SUPPLEMENT|Micellar 6-prenylnaringenin|250 mg 6-PN in a micellar formulation with Tween-80 as adjuvant capsules
223578558|NCT04448015|OTHER|Perinatal Opioid Use Disorder Education and Enhanced Perinatal Care|University of Utah clinicians will provide face-to-face, online, and written training materials for health, mental health, and substance use service providers in Carbon and Emery Counties, UT.
223578559|NCT06218381|OTHER|Very Brief Exposure to Combat Images|In VBE, a series of pictures representing a person's fears (e.g., a combat scene with arousing visuals) is presented very briefly (17 ms), followed by a masking stimulus that prevents conscious recognition of each picture. This sequence of picture-mask stimuli is repeated many times in an exposure session.
223578560|NCT00349687|BEHAVIORAL|self-control practice|
223578561|NCT03250039|DRUG|PF-04965842|14C labeled PF-04965842
223578562|NCT03250039|DRUG|Absolute Bioavailability|Oral dose of unlabeled PF-04965842 and an IV dose of 14C labeled PF- 04965842
223578563|NCT03182595|DRUG|Paracetamol|Volunteers will be screened at visit 1, and if they meet the inclusion/exclusion criteria they will receive the intervention at visit 2. At visit 2, complying subjects will receive a tablet containing 1 gram of paracetamol and have a blood sample collected 2 hours after administration; these procedures will be repeated on 2 more occasions (visits 3 and 4). The subjects will come for 5 visits during the study. Visit 1 and 2 must occur within 7 days of each other, visits 2, 3 and 4 will be four weeks (± 3 days) apart and visit 5 scheduled four weeks (± 3 days) after visit 4.
223578564|NCT00000504|DRUG|encainide|
223578565|NCT00000504|DRUG|moricizine|
223578566|NCT00000504|DRUG|flecainide|
223578567|NCT00000504|DRUG|imipramine|
223578568|NCT04609930|DRUG|Anti-PD-1 or anti-PD-L1|Immunotherapy treatment via anti programmed death 1 and/or anti-programmed death ligand 1.
223578569|NCT04521998|DEVICE|electroacupuncture|Electroacupuncture used to reduce the inflammation was proved previously.
223578570|NCT04521998|DEVICE|TENS|Patients who unlike needles would like to choose TENS as treatment for pain relief.
224068659|NCT05037110|OTHER|Smell training|For 12 weeks, morning and evening, smell four odors namely eucalyptol, phenyl ethanol, citronellal, and eugenol, for a total of five minutes per session. For each smell training session, complete a short, online survey regarding the pleasantness and intensity of the smell. This is done remotely. Then, every two weeks, attend a remote individual meeting with a research professional using secured application (15 minutes each). Each online meeting will contain the following steps: 1) Review of smell training; 2) Discussion on how to reach/maintain the training protocol in the coming weeks according to individual health status, facilitators and barriers; 3) Elaboration of the next 2-week action plan.
224068660|NCT03988335|DRUG|RIST4721|RIST4721 oral solution
224068661|NCT03988335|DRUG|Placebo|Placebo oral solution
224068662|NCT00540878|DRUG|SB-751689 oral tablets (400 mg)|
224068663|NCT04517188|DRUG|Povidone-Iodine Solution 1.25% w/w [0.125% available iodine] USP|Single topical administration
224068664|NCT03936374|DRUG|BMS-986205|Participants will receive BMS-986205 on Days 1 and 15
224303860|NCT02672202|DRUG|Placebo|"* non-active - twice before surgery~* non-active - twice a day for post operative days 1-7"
224303861|NCT03996161|OTHER|patient position|After the induction of anesthesia, mask ventilation is performed in the supine and semi-sitting position in a cross-over, randomized order.
224303862|NCT01264159|DEVICE|Lung impedence-guided therapy|
223578571|NCT01448005|DEVICE|wearable defibrillator (LifeVest)|A wearable defibrillator automatically detects and treats ventricular tachycardia and ventricular fibrillation without the need for bystander intervention.
223578572|NCT03362229|PROCEDURE|Fixation|A well reduced medial malleolus fracture will undergo internal fixation, guided by the surgeon's skill and expertise
223578573|NCT03362229|PROCEDURE|Non-fixation|A well reduced medial malleolus fracture will be left without fixation
223578574|NCT04591743|DEVICE|Active TCS|TCS active at 1 Hz on the right DLPFC for 6 weeks
223578575|NCT04591743|DEVICE|Placebo TCS|Inactive TCS (placebo coil) at 1 Hz on right DLPFC for 6 weeks
223578576|NCT04591743|DRUG|nicotine treatment|at least 21/14/7 mg/d + oral nicotine cp from 2 to 30 mg/d)
223578577|NCT04591743|OTHER|Questionnaires|"EVA on craving, TCQ, QSU, BDI-II, CO tester, IGT, BART"
223578578|NCT03947970|DRUG|[14C] CR845|Subjects will receive a single dose of 230 mcg CR845 solution containing 100 microcuries \[14C\] CR845, administered via IV bolus (the total dose of CR845 will range from 1.7 to 3.1 mcg/kg)
223578579|NCT01066780|DEVICE|ClearVoice|ClearVoice is a sound processing strategy designed to improve listening ability in some challenging everyday listening environments for users of the Harmony® HiResolution® Bionic Ear System (Harmony®)
223578580|NCT02671149|DIETARY_SUPPLEMENT|Water|Participants will receive two cups of 150ml plain water
223578581|NCT05336825|DEVICE|CO2 laser|Mona Lisa CO2 laser
223578582|NCT05336825|DRUG|Lidocaine patch 5%|lidocaine
223743638|NCT07189676|BEHAVIORAL|Food boxes (Ovo-lacto-vegetarian diet)|Food boxes will be sent to participants' homes. Ovo-lacto-vegetarian food boxes will include fruits and vegetables, whole grains, legumes, nuts, soy-based products, eggs, and cheese. Local and seasonal aspects will not be taken into consideration. If allergies or intolerances are identified, the food boxes will be modified to maintain safety and dietary compliance.
224068665|NCT03936374|DRUG|omeprazole|Participants will receive omeprazole on Days 10 to 15
224068666|NCT01378286|DRUG|ARTESUNATE + AMODIAQUINE|"Pharmaceutical form:~Route of administration:"
224068667|NCT01378286|DRUG|Chloroquine|Pharmaceutical form:tablet Route of administration: oral
224068668|NCT05112783|DEVICE|Henan Tuoren Endotracheal Tube|The endotracheal tube is used under the direct view of the electronic imaging laryngoscope.
224068669|NCT05112783|DEVICE|Smiths Portex Tracheal Tubes|The endotracheal tube is used under the direct view of the electronic imaging laryngoscope.
223468751|NCT00933595|OTHER|Smoking Cessation|"A Motivational Interview session (\~40-50 minutes) will be delivered by a trained nurse coordinator.~Treatment with varenicline (1 mg daily during week 1 (pre-quit week) followed by 1 mg twice daily for weeks 2-12)or nicotine replacement therapy (21 mg of a skin patch + nicotine gum 4 mg ad lib added for breakthrough craving up to 20 pieces/day."
223468752|NCT01474395|DRUG|D-serine|Subjects will then undergo three treatment visits. Each visit will begin with a pre treatment MMN/visual motion paradigm. Subjects will then receive DSR (60 mg/kg) or placebo and begin a one-hour SBR intervention. SBR will begin approximately 30 minutes after drug administration, to coincide with peak serum DSR level. Finally, to evaluate the effects of SBR and NMDA treatment on neurophysiology, subjects will complete a post treatment ERP paradigm. Treatment days will be separated by 1 week to reduce carryover effect. To increase power, each subject will undergo two DSR treatment days and 1 placebo day, with the placebo day selected randomly from among the three treatment days, in counter balanced order. Treatment assignment (drug and SBR) will be double blinded. Follow-up cognitive and safety measures will also be completed on the final treatment day.
223578583|NCT02360293|BEHAVIORAL|Stay Strong w/coaching|Pts randomly placed in the Stay Strong w/coaching group receive an app-mediated physical activity intervention. Pts are asked to wear a physical activity monitoring device and weigh regularly using a Bluetooth scale while participating in the study. Pts will be asked to upload the device data at least weekly and will receive tailored push notifications. Each week the pt will receive a new automatically calculated personalized physical activity goal. Stay Strong coaches will call pts up to 3 times in the first 6-8 weeks of the study to help pts meet physical activity goals including problem solving support. Pts will also be reminded to follow-up with their healthcare provider as needed for the remainder of the 12-month program.
223578584|NCT02360293|BEHAVIORAL|Stay Strong|Pts randomly placed in the Stay Strong arm are asked to wear a physical activity monitoring device and weigh regularly using a Bluetooth scale while participating in the study. Pts will be asked to upload the device data at least weekly. Pts will have access to a standard app-mediated intervention that is linked to the wearable device.
223578585|NCT04316741|BEHAVIORAL|Snapcoach|A brief motivational interviewing-based intervention combined with health coaching via social media for 4 weeks
223578586|NCT02576665|BIOLOGICAL|Toca 511|Toca 511 consists of a purified retroviral replicating vector encoding a modified yeast cytosine deaminase (CD) gene. The CD gene converts the antifungal 5-fluorocytosine (5FC) to the anticancer drug 5-FU in cells that have been infected by the Toca 511 vector
223578587|NCT02576665|DRUG|Toca FC|"Toca FC is an extended-release formulation of flucytosine. Toca FC is supplied as 500 mg white, oblong tablets with TOCA FC embossed on one side and 500 embossed on the other side"
223578588|NCT05647668|PROCEDURE|Laparoscopic fundoplication|Creation of either a 360° (in Nissen group) or a 270° (in Toupet group) fundoplication wrap over a 30-Fr intra-esophageal bougie.
223578589|NCT04424056|DRUG|Anakinra +/- Ruxolitinib (stages 2b/3)|administration of Anakinra +/- ruxolitinib, depending of evolution
223578590|NCT04424056|DRUG|Anakinra and Ruxolitinib (Advanced stage 3)|administration of Anakinra and ruxolitinib
224159299|NCT05386875|DIAGNOSTIC_TEST|rK28|"rK28 RDT (Index): The Leishmania Ab Rapid Test is a rapid immunochromatographic test that uses the recombinant antigen rK28 to detect antibodies against Leishmania species in human serum, plasma, or whole blood samples intended for primary VL diagnosis. It is a Research Use Only product commercialized by CTK Biotech, Inc. (USA).~IT-Leish rK39 RDT: Rapid immunochromatographic test for detection of antibodies against Leishmania species in human serum, plasma, or whole blood samples of utility in the VL diagnosis algorithm. It is a CE marked product commercialized by Bio-Rad (France). This is currently the recommended RDT for VL diagnosis in Kenya.~Kalazar Detect rK39, RDT: Rapid immunochromatographic test for detection of antibodies against Leishmania species in human serum, plasma, or whole blood samples of utility in the VL diagnosis algorithm. It is a CE marked product commercialized by InBios (United States)."
224159300|NCT01687049|DRUG|Red yeast rice|
223578591|NCT04424056|DRUG|Tocilizumab +/- ruxolitinib (stages 2b/3)|administration of Tocilizumab +/- ruxolitinib, depending of evolution
223743639|NCT07189676|BEHAVIORAL|Group visits (Ovo-lacto-vegetarian diet)|Group visits will provide support through nutritional education, social interaction, and peer learning, all focused on the dietary behavior changes required by the intervention. Ovo-lacto-vegetarian group visits will cover topics such as plant-based eating and nutritional adequacy.
224068670|NCT05847088|DRUG|Intravitreal Dexamethasone Implant for refractory Diabetic macular edema:|Intravitreal Dexamethasone implants (DEX) (0.7 mg) (Ozurdex, Allergan, Inc, Irvine, CA, USA) had been used with greater efficacy and safety in DME.
224068671|NCT00985205|DIETARY_SUPPLEMENT|Enteral Glutamine|0.5g/kg/day powdered glutamine to be mixed in with water and given via nasogastric or feeding tube q4 hrs or TID or QID if po.
224068672|NCT00985205|DIETARY_SUPPLEMENT|Placebo|Maltodextrin mixed with water given via NG or feeding tube Q 4 hours or TID or QID if po.
224068673|NCT01281566|DRUG|Placebo|liquid suspension identical in appearance to Cisapride 4 times a day (q.i.d.) for up to 42 days
224068674|NCT01281566|DRUG|Cisapride|0.2 mg/kg liquid suspension 4 times a day (q.i.d.) for up to 42 days
224068675|NCT03439709|RADIATION|Gamma knife radiosurgery|Minimum 25 Gy of marginal dose is applied for residual tumor or resection cavity. Depending on the size of tumor, the dose can be varied.
224159301|NCT03178175|PROCEDURE|Acupuncture|"In the acupuncture with De Qi group, using stainless tiny needles is inserted to the specific acupoints over the scalp (Si Shen Cong and Baihui) until the De Qi phenomenon occurs. The duration is about 30 minutes, and all patients will receive the procedure 16 times within 2 months."
224303863|NCT01264159|OTHER|Usual treatment of patients with developing acute heart failure|
223578592|NCT04424056|DRUG|Tocilizumab and Ruxolitinib (Advanced stage 3)|administration of Tocilizumab and Ruxolitinib
223743640|NCT07189676|BEHAVIORAL|Behavioral support (control)|Participants will attend four short individual dietary visits with a dietitian, where they will review the recorded dietary data. Participants of the control group will not have access a recipe collection or meal planner.
224068676|NCT03439709|DRUG|Lanreotide 60Mg Solution for Injection|Lanreotide injection.
224068677|NCT00754910|DRUG|porfimer sodium|Given IV
224068678|NCT00754910|PROCEDURE|bronchoscopy|Patients undergo bronchoscopy
223468753|NCT01474395|DRUG|placebo|Subjects will then undergo three treatment visits. Each visit will begin with a pre treatment MMN/visual motion paradigm. Subjects will then receive DSR (60 mg/kg) or placebo and begin a one-hour SBR intervention. SBR will begin approximately 30 minutes after drug administration, to coincide with peak serum DSR level. Finally, to evaluate the effects of SBR and NMDA treatment on neurophysiology, subjects will complete a post treatment ERP paradigm. Treatment days will be separated by 1 week to reduce carryover effect. To increase power, each subject will undergo two DSR treatment days and 1 placebo day, with the placebo day selected randomly from among the three treatment days, in counter balanced order. Treatment assignment (drug and SBR) will be double blinded. Follow-up cognitive and safety measures will also be completed on the final treatment day.
223468754|NCT01474395|BEHAVIORAL|Sensory Based remediation paradigm|Every subject will receive sensory based remediation on each treatment visit: Three 80-tone pair blocks will be used per session (\~1 hour with breaks). To minimize practice effects, we will use a different base tone for each treatment day (e.g. 500, 1000, and 2000 Hz), also in a randomized counter-balanced order. To assess the improvement over a treatment day, we will record the ratio of the frequencies in all tone pairs. To correct this non-normal distribution we take the natural log of each of these ratios to determine the tone matching threshold.
223468755|NCT00092196|DRUG|MK0869, aprepitant / Duration of Treatment: 3 days|
223468756|NCT03628443|DIAGNOSTIC_TEST|Fibroblast Growth Factor 23|A sample of blood is tested for levels of fibroblast growth factor 23
223468757|NCT00226252|PROCEDURE|Instruction Only|Video details an individual propelling a manual wheelchair with biomechanically correct propulsion technique.
223468758|NCT00226252|PROCEDURE|Instruction and Feedback|Individuals will watch video of correct propulsion technique and will receive real-time feedback from the SMART Wheel as they push their wheelchair to help optimize their propulsion technique.
223468759|NCT02785393|DRUG|Sugar Pill|The administration of a sugar pill
223468760|NCT02785393|DRUG|Doxazosin|The administration of the Doxazosin medication
223468761|NCT02355678|DRUG|dexamethasone|IV 0.5 mg/kg
223468762|NCT02355678|DRUG|Local anesthetic infiltration|Using 25 G-3.5 cm curved needle
223468763|NCT02355678|DRUG|General anesthesia|"Induction by intravenous fentanyl (1.5 µg kg-1) and propofol (2.5 mg kg-1) followed by endotracheal intubation facilitated by atracurium (0.5 mg kg-1).~Maintenance with sevoflurane 1-3%, fentanyl (1-2 µg kg-1), nitrous oxide 70% and oxygen 30%."
223468764|NCT02355678|PROCEDURE|Tonsillectomy|Mono-polar electrocautery or cold dissection
223468765|NCT02355678|PROCEDURE|gastric content suction|By orogastric tube
223468766|NCT02355678|DRUG|Tramadol hydrochloride|If Visual Analogue Scale was greater than 5
223468767|NCT02355678|DRUG|Propacetamol hydrochloride|If Visual Analogue Scale was between 4 and 5
223468768|NCT02355678|DRUG|Paracetamol Suppository|If Visual Analogue Scale was less than 4
223743641|NCT07189676|BEHAVIORAL|Food boxes (control)|Food boxes will be sent to participants' homes. Control food boxes will include fruits and vegetables, potato, nuts, cheese, animal protein products and canned food. Local and seasonal aspects will not be taken into consideration. If allergies or intolerances are identified, the food boxes will be modified to maintain safety.
224068679|NCT04754100|DRUG|agenT-797|agenT-797 is an off-the-shelf cell therapy consisting of ≥ 95% allogeneic human unmodified iNKT cells isolated from 1 healthy donor mononuclear cell apheresis unit and expanded ex vivo.
223743642|NCT07189676|BEHAVIORAL|Group visits (control)|Group visits will provide support through general health education, social interaction, and peer learning. Control group visits will cover topics such as the role and importance of controls in RCTs and general well-being.
223743643|NCT07191340|DEVICE|Vagus nerve stimulator|Vagus nerve stimulator placed on neck and activated
223743644|NCT07191340|DEVICE|Placebo comparator sham|Vagus nerve stimulator placed on neck and not activated
223743645|NCT07189780|PROCEDURE|Surgical approach|"Control Group:Incising the peritoneum 0.5-1 cm above the lowest point of the peritoneal reflection to enter the dissection plane.~Experimental Group:Incising the peritoneum precisely at the lowest point of the peritoneal reflection (in the rectovesical or rectouterine pouch) to enter the dissection plane."
223743646|NCT07190898|OTHER|core exercises|The participants performed core exercises three times per week for a total of six weeks
224068680|NCT05429294|DRUG|Pyrotinib|Patients with HER2-positive advanced/metastatic breast cancer are treated with pyrotinib combined with trastuzumab and albumin paclitaxel in the first-line setting.
224068681|NCT02230280|OTHER|Strengthening Community-Based Stroke Care: A Pilot Study of a Community Navigation and Rehabilitation Intervention that Includes a Mobile Health Solution|Participants will be offered regular in-home visits over the 6-month study period in addition to usual outpatient rehabilitation services. The health care providers will have access to a mobile health application (MYST) to share real-time information and access community resources and best practice guidelines.
223743647|NCT07190898|OTHER|functional strength exercises|The participants performed functional strength exercises three times per week for a total of six weeks.
223743648|NCT07190898|OTHER|education group|During the educational session, participants were provided with information on proper posture, ergonomic movements, the importance of posture in daily life, and pain management.
223468769|NCT04718597|PROCEDURE|Robotic assisted inguinal hernia repair|Robotic assisted inguinal hernia repair with DaVinci Xi system instead of open repair
223468770|NCT04718597|PROCEDURE|Open inguinal hernia repair|Classical approach (open repair)
223468771|NCT01935999|DEVICE|One piece closed pouch|A one piece closed pouch for the collection of stool from a colostomy stoma
223468772|NCT05190796|OTHER|platelet indices|One sample of 20 mL venous blood was drawn by standard phlebotomy from all of the participants. This sample was kept for the evaluation of hemoglobin, hematocrit, mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC), red cell distribution width (RDW), erythrocyte count, leukocyte count, platelet count, platelet distribution width (PDW), MPV and plateletcrit by means of an automated commercial counter (Coulter counter, Max Instruments Laboratory). After this venous blood sample was conveyed into a sodium citrate tube, it was transported in a temperature-controlled container and collected in plastic provettes (Falcon blue cap) containing 3 mL of 3.8% sodium citrate dihydrate and 136 mM glucosium. Then the samples were sent to the laboratory.
223578593|NCT04424056|OTHER|Standard of care|Treatment with drugs or procedures in routine clinical practice
223468773|NCT04493606|OTHER|SCI ProACTIVE Coaching (objective 1)|Peer coaches will conduct an assessment to understand patient's readiness, goals, barriers, preferences, and access to physical activity resources and mutually select tailored physical activity-enhancing strategies based on the assessment. These strategies include education (SCI exercise guidelines, safety, benefits, basics of physical activity, behaviour change techniques) and referral to appropriate peers, programs, and organizations. Goals will be based on the SCI Fitness Guidelines (targeting a goal of 20min of moderate to vigorous intensity aerobic exercise + 3 sets of strength training exercises for each major functioning muscle group at a moderate to vigorous intensity each 2x/week) and if ready, the Canadian SCI Physical Activity Guidelines (30 min 3x/week of moderate to vigorous intensity aerobic exercise + strength training 2x/ week). Ten 15-minute, video-conference or telephone sessions will be scheduled in accordance with patient needs and readiness with the peer coaches.
223468774|NCT04493606|BEHAVIORAL|Implementation Intervention (objective 2)|"A training on how to deliver the ProACTIVE intervention will be delivered. Day 1 training will include an overview of the intervention, demonstration of the delivery of the intervention, and behavioural practice. Interventionists will practice delivering the intervention and record issues or questions to bring to the day 2 training. Day 2 training will include a refresher on intervention content, barriers identified during in-clinic/community practice will be addressed, and further behavioural practice with volunteer clients with additional feedback provided.~The trainer (Dr. Jasmin Ma) will provide monitoring and feedback during the first two months of implementation. Community of practice meetings will be held as needed to discuss challenges and facilitators to implementation. Feedback provided during community of practice meetings will be collected and used for iterative quality improvement of the intervention approaches."
223468775|NCT03652818|DRUG|Pre-Op pregabalin|Pre-op pregabalin will be administered 60 min prior to surgery.
223468776|NCT03652818|DRUG|Pre-Op Placebo 1|Placebo 1 will be administered 60 min prior to surgery.
223468777|NCT03652818|DRUG|Post-Op pregabalin|Post-op pregabalin will be administered Post-operatively.
223578594|NCT03100812|BEHAVIORAL|More intensive CHW Intervention|Group A participants will attend 4 monthly 90 minute group health education sessions that provide the tools and strategies to promote heart health to Filipino American individuals, families, and communities on high blood pressure and CVD. The CHWs will lead these sessions utilizing NHLBI's Healthy Heart Healthy Family, A CHW's Manual for the Filipino Community. Each of the group health education sessions will discuss different content related to CVD, hypertension, and other CVD risk factors. The first session focuses on assessing heart disease risk and recognition of heart attack signs. The second session focuses on physical activity and weight management and blood pressure control. The third session addresses control of cholesterol, and diabetes. The final 4th session teaches participants about nutrition and living smoke free.
223578595|NCT03100812|BEHAVIORAL|Less Intensive CHW Intervention|Individuals randomized to the less intensive CHW intervention will have the baseline, 4 month, and 8 month interviews and blood pressure measurements will be collected in those succeeding time points. Participants will also receive a 30 minute one on one session from the CHW and a referral to a physician if needed.
224159302|NCT03178175|PROCEDURE|Needle Insertion|"In the Sham acupuncture group, using stainless tiny needles is inserted to the specific acupoints over the scalp (Si Shen Cong and Baihui) but the needle doesn't reach the exact depth and De Qi phenomena doesn't occur. The duration is about 30 minutes, and all patients will receive this procedure 16 times within 2 months."
224159303|NCT06247475|OTHER|Answers generated by ChatGPT|Participants will assign a satisfaction score based on the appropriateness of each answer.
224159304|NCT06305923|OTHER|colostrum cream|the intervention in our study is everyday using a cream with active ingridient
224159305|NCT06305923|OTHER|placebo cream|using a placebo cream
224159306|NCT01633528|DRUG|Asprin|100 mg
224159307|NCT01633528|DRUG|placebo|100mg
224159308|NCT03381703|DRUG|YH12852|YH12852 administration
223578596|NCT01268917|DRUG|aspirin|aspirin 100mg daily until the surgery day
223578597|NCT01268917|DRUG|aspirin|aspirin is stopped 5-7 days before operation
223578598|NCT00350467|DRUG|ER OROS paliperidone and Olanzapine|
224159309|NCT03381703|DRUG|14C-labeled YH12852|14C-labeled YH12852 administration
224159310|NCT05529134|DRUG|PTW-002 10 mg/g gel|poloxamer hydrogel for topical administration
224159311|NCT05529134|DRUG|Placebo|placebo poloxamer hydrogel for topical administration
224159312|NCT00287755|DRUG|S-1|S-1 capsule at a dose of 80 mg/m2 b.i.d. for 4 weeks followed by 2 weeks rest.
224159313|NCT01620658|DEVICE|0.5mm XPF cap|"Interventionalist wear a XPF 0.5mm lead equivalent cap during fluoroscopy guided interventions.~XPF is a trademark of BloXR (Salt lake City, UT) for a new bi-layer (Barium/Bismuth) radiation attenuation material."
224159314|NCT01620658|DEVICE|0.3mm XPF cap|"Interventionalist wear a XPF 0.3mm lead equivalent cap during fluoroscopy guided interventions.~XPF is a trademark of BloXR (Salt lake City, UT) for a new bi-layer (Barium/Bismuth) radiation attenuation material."
224159315|NCT01620658|DEVICE|Standard cap|Interventionalist wear a standard fabric cap during fluoroscopy guided interventions.
224159316|NCT04437602|DIAGNOSTIC_TEST|Contrast Enhanced Mammography (CEM)|Additional CEM in preoperative staging
224159317|NCT01250301|OTHER|De-nicotinised cigarettes + standard treatment|"Participants will receive de-nicotinised cigarettes to use as required for 2 weeks after their quit day. These cigarettes are intended to provide a replacement for the behavioural and sensory aspects of smoking without supplying nicotine.~Participants will also receive standard NHS Stop Smoking Service treatment. This is a combination of weekly behavioural support and medication (e.g. nicotine replacement therapy/varenicline)."
224159318|NCT01250301|OTHER|Standard Treatment|Participants will receive standard treatment from the NHS Stop Smoking Service.
224159319|NCT03908931|RADIATION|MRI|Follow up of osteochondral surgery by MRI and clinical examination
224159320|NCT05192044|OTHER|Fast track Care pancreatico-duodenectomy.|Enhanced recovery after pancreatico-duodenectomy, with early oral intake, mobilization \& discharge
224159321|NCT05192044|OTHER|Conventional Care|Conventional Care
224303864|NCT01625130|DIETARY_SUPPLEMENT|Broccoli sprout homogenate|Commercially available Broccosprouts® (Brassica Protection Products LLC) will be homogenized with water using a ratio of 1:1.2 in a clean blender. The homogenate will then be frozen in aliquots at -20 degrees C.
223578599|NCT01842594|DRUG|Sirolimus and hydroxychloroquine|"Both hydroxychloroquine 200 mg/tab and sirolimus 1 mg/tab are pills each are taken 2 tablet orally QD for 2 cycles .~Each treatment cycle is 28 days."
223468778|NCT03652818|DRUG|Post-Op Placebo 1|Placebo 1 will be administered post-operatively.
223468779|NCT03652818|DRUG|Post-Op Placebo 2|Placebo 2 will be administered post-operatively.
223468780|NCT03652818|DRUG|Post-Op acetaminophen|Acetaminophen will be administered Post-operatively.
223468781|NCT05724303|OTHER|8-week neuromuscular training program|Training program consisting of two neuromuscular training sessions per week
223468782|NCT03583957|DEVICE|Observational only|Device is only observational and used to record EEG.
223578600|NCT01046240|DRUG|Palonosetron|Palonosetron 3 mg administered SC or IV
223578601|NCT01993316|DEVICE|Mitsar 201 neurofeedback|
223578602|NCT01498185|DRUG|Dapagliflozin|Tablets, Oral, 1 mg, Once daily, 14 days
223578603|NCT01498185|DRUG|Placebo matching Dapagliflozin|Tablets, Oral, 0 mg, Once daily, 14 days
223578604|NCT04148612|DIAGNOSTIC_TEST|Opti-Me|Opti-Me algorithm provides the likelihood of response to the 3 treatment options: SSRIs, SNRIs or TMS in MDD patients.
223578605|NCT02004145|BEHAVIORAL|Positive Psychology|The Positive Psychology intervention consists of 6 exercises that will be completed by the participant with the guidance of a trainer.
223578606|NCT02004145|BEHAVIORAL|Control Condition|The Control Condition consists of 6 exercises that will be completed by the participant with the guidance of a trainer.
223578607|NCT02073032|OTHER|No intervention, only observation|
223578608|NCT03234439|BEHAVIORAL|myStrength|myStrength is a digital self-care behavioral and wellness platform
223578609|NCT04118907|DEVICE|multiple sensory stimulation|The patients were recruited to record their medical history, and the hearing level, tinnitus indicators, vestibular function and tinnitus disability indicators were tested. Then the patients were randomly divided into six groups. They received the corresponding stimulation 20 minutes a day, 5 days a week for 3 weeks. After the last stimulation, the above tests were repeated immediately, one week later and three months later.
223578610|NCT00266838|DRUG|Maxidex; Lacrystat|6 times daily, for 20 weeks.
223578611|NCT01922063|BEHAVIORAL|Physiotherapy Intervention|20x 30 min sessions of physiotherapy
223578612|NCT01922063|BEHAVIORAL|Sham neck massage|20x 30 minutes sessions of neck massage
223578613|NCT00849602|DRUG|Placebo|Placebo bid for three days
224159322|NCT01291511|DRUG|Iloperidone|Over-encapsulated iloperidone tablets were administered orally using a bid schedule; the strengths used include 1, 2, 4, 6, 8, 10, and 12 mg.
223578614|NCT00849602|DRUG|Chloroquine|Chloroquine bid for three days
224159323|NCT01291511|DRUG|Placebo|Matching placebo capsules were administered orally using a bid schedule during the double-blind period.
224159324|NCT04367649|OTHER|Hall technique|"* Orthodontic separators will be used to create space for fitting the stainless crown, then removed after 3-5 days~* Occlusion will be measured assessing the patient's occlusal-vertical dimensions (OVD) using a modified version of van der Zee and van Amerongen method with a millimeter probe measuring the distance from the lowest point of the gingiva, around the lower canine on the vestibular side up to the point where the tip of the upper canine ends in order to assess the degree of overbite after mounting of the crown.~* The correct crown size will be selected. The crown should cover all the cusps and approaches the contact points, with a slight feeling of spring back. till reaching the gingival margin. Cementation will be done using glass ionomer cement"
223578615|NCT05145855|OTHER|Patient-tailored multimodal neglect rehabilitation|Patient-tailored neglect rehabilitation program which comprises 30-45 minutes of sessions, five times per week includes a combination of reading, copying, and representational drawing tasks with visual or verbal cueing, visual scanning, mirror therapy, and allocation of attention to the neglected side using multimodal stimulus in daily activities.
223743649|NCT07189585|DRUG|inulin|Inulin is a fermentable prebiotic fiber derived from chicory root. For this study, inulin is packaged into single-dose sachets containing 5 g, 10 g, or 15 g of powder. Participants in the 10 g arm escalate from 5 g/day for 3 days to 10 g/day, then continue with sachets containing a 2:1 blend of inulin and maltodextrin to provide a daily 10 g inulin dose. Participants in the 15 g arm escalate from 5 g/day for 3 days, 10 g/day for 4 days, then 15 g/day for the remaining 8 weeks. Sachets are mixed with food or beverage and taken once daily with the largest meal.
223468783|NCT03583957|BEHAVIORAL|Psychological and Behavioral interaction with a seizure forecasting mobile app|Participants will be interacting with a mobile app to input perceived behavioral (e.g., number of hours slept and sleepiness) and psychological (perceived stress).
223468784|NCT03583957|COMBINATION_PRODUCT|Seizure Alerting and Prediction System|The combination of Epilog (device) and the Aura app (psychological and behavioral interaction) will be used to create a real-time seizure alerting and an hourly seizure forecasting system.
223468785|NCT06032728|DRUG|Sunitinib|The investigators randomly assign multimodal recurrence scoring system defined high risk patients of stage III ccRCC into intervention group and observation group. The intervention group should receive adjuvant targeted therapy while the control group deserve observation
223468786|NCT05190614|DIAGNOSTIC_TEST|The biotype of gingiva|The biotype of gingival was determined by periodontal probe.
223468787|NCT03735290|BIOLOGICAL|ilixadencel|Intra-tumoral injection
223468788|NCT03735290|DRUG|Pembrolizumab|Administered intravenously over 30 minutes, every 3 weeks, at a dose of 200 mg
223468789|NCT03713463|OTHER|Oral Nutritional Supplement (ONS)|Per standard of care (SOC)
223468790|NCT01669434|DRUG|ACEI continuation|These chronic medications will be taken without interruption preoperatively.
223468791|NCT01669434|DRUG|ACEI omission|Although taken chronically by patients in this intervention, the final preoperative dose of these medications will be omitted, whether it was scheduled for the morning of surgery or the day prior.
223578616|NCT05876247|OTHER|Electromagnetic Articulography|Motion tracking sensors will track articulatory movements of the tongue, jaw and lips
223578617|NCT00170989|DRUG|valsartan plus hydrochlorothiazide|
223578618|NCT04515368|BIOLOGICAL|Immunization|Immunisation with one of four licensed vaccines
223578619|NCT05021692|BEHAVIORAL|Web-based support program for pregnant women with preeclampsia based on the Health Promotion Model|support program
223578620|NCT03206632|DRUG|BI 690517|single dose
223578621|NCT03206632|DRUG|Placebo|single dose
223468792|NCT04535427|DRUG|L-arginine|Low (3g every time, 3 times a day)or high dose (5g every time, 3 times a day) of L-arginine will be administered to the experimental groups for at least 24 weeks as an add-on treatment to the current DMARDs treatments for rheumatoid arthritis.
223468793|NCT04535427|DRUG|Placebo|Placebo will be administered to the control group for at least 24 weeks as an add-on treatment to the current DMARDs treatments for rheumatoid arthritis.
223578622|NCT01840254|DRUG|dexmedetomidine|
224159325|NCT04367649|OTHER|Atraumatic restorative treatment|Caries removal using excavators, then restoration using glass ionomer (GIC)
224159326|NCT04367649|OTHER|Conventional restorative treatment|Complete caries removal using high-speed hand piece, and an excavator to clear carious dentin from the pulpal wall. Then, stainless steel crown preparation, selection of the proper size with the smallest crown size that completely covers the preparation chosen. The correct occlusogingival crown length will be established. Cementation will be done using glass ionomer cement
224159327|NCT02367859|DRUG|Dabrafenib|Given PO
224159328|NCT02367859|DRUG|Trametinib|Given PO
224159329|NCT02901340|DIETARY_SUPPLEMENT|one to two liters of water daily|
224159330|NCT03529929|DRUG|Methylprednisolone|6 day dosing as dictated by Medrol 6 Day Dose Pack
224159331|NCT03959956|DIAGNOSTIC_TEST|Recording lung sound by a Smartscope|Lung sound will be recorded from four chest points by an electronic stethoscope called Smartscope which can also classify the recorded lung sound.
224303865|NCT01625130|DIETARY_SUPPLEMENT|alfalfa sprout homogenate|200 grams of alfalfa sprouts will be homogenized with water using a ratio of 1:1.2 in a clean blender. The homogenate will then be frozen in aliquots at -20 degrees C.
224303866|NCT02351583|DEVICE|CytoCam|The side-stream darkfield camera ( CytoCam) will be put under the subjects tongue for 5-10 minutes. Multiple pictures of the small blood vessels will be taken.
224303867|NCT02351583|DEVICE|NIRS Artinis PortaLite with OxySoft softwear|. The NIRS probe will be applied to one of the patient's thenar muscle and over the patient forehead and tissue oxygenation (TOI) will be recorded for 5 minutes.
224303868|NCT02980874|DRUG|suprachoroidal CLS-TA|suprachoroidal injection of CLS-TA
224303869|NCT02980874|DRUG|suprachoroidal sham|suprachoroidal sham procedure
224303870|NCT02980874|DRUG|IVT aflibercept|2 mg intravitreal injection of aflibercept
224303871|NCT00456430|DRUG|Escitalopram|10 mg a day of escitalopram by mouth per day for 4 weeks. Dose may be increased to 20 mg a day after the 4th week depending on tolerance and treatment response.
224303872|NCT03817801|DEVICE|NSE balloon|NSE (Goodman®) predilation + DCB (Sequent® Please) treatment
224303873|NCT03817801|DEVICE|NC balloon|NC balloon predilation + DCB (Sequent® Please) treatment
224303874|NCT03570086|DIAGNOSTIC_TEST|diagnostic|using radiomics features from multiparametric thick-section clinical-quality brain MRI to distinguish migraineurs from health controls.
224303875|NCT05077371|BEHAVIORAL|Peer support program|The intervention will consist of 8 face-to-face peer social support sessions conducted by volunteers diagnosed with breast cancer who have finished their medical treatment (chemotherapy, radiotherapy, surgery) or who have been in a stable phase for at least two years and who are motivated to participate in this type of intervention.
224303876|NCT05032313|DIAGNOSTIC_TEST|IUO CLPD Limited Panel|This Investigational Panel , comprised of 2 reagents , is intended for in vitro diagnostic use for qualitative flow-cytometric immunophenotyping of mature lymphocyte populations. These reagents are used as an aid in the differential diagnosis of hematologically abnormal patients having Chronic Lymphoproliferative Disease .
224303877|NCT00238875|PROCEDURE|stereotactic body radiation therapy|Procedure/Surgery: stereotactic body radiation therapy
224303878|NCT03721536|DIAGNOSTIC_TEST|hemodynamic parameters|vital signs on the monitor including heart rate, mean arterial pressure, peripheral oxygen saturation and End-tidal Carbon Dioxide
224303879|NCT03721536|DIAGNOSTIC_TEST|arterial blood gase|Arterial blood gas including partial oxygen pressure and partial carbon dioxide pressure is an important routine investigation to monitor the acid-base balance of patients, effectiveness of gas exchange, and the state of their voluntary respiratory control.
224303880|NCT04019184|DRUG|L-Alanyl/L-Glutamine|Immediately after randomization (not longer than 30 min after fulfilling eligibility criteria), patients will receive intravenous infusions with the investigational drug
224303881|NCT04019184|DRUG|Placebo|Immediately after randomization (not longer than 30 min after fulfilling eligibility criteria), patients will receive intravenous infusions with the placebo
223468794|NCT01737606|DEVICE|Fast Cerebral Pulsatility Imaging|Cerebral ultrasonic exploration using with neuro-navigation system : 4 acquisitions on 12 or 6 section planes
223468795|NCT05199246|DEVICE|Lower-limb powered dermoskeleton|Patients and healthy subjects will wear the movement assistance device to perform different standardised physical evaluations.
223468796|NCT01968421|DRUG|OM-85 BV|two courses of 7mg of OM-85 or matching placebo to take one oral capsule per day for 10 days a month for 3 consecutive months at the beginning of the study, then 3 months later with the same schedule for 1 year.
223468797|NCT01930539|DEVICE|Ultraviolet B lamp|Ultraviolet-Fluorescent lamp (KBD, Inc, Crescent Springs, Kentucky, USA) was designed to use Ultraviolet B emitting fluorescent bulbs that have lower heat emission and allows a larger area of skin exposure. The Lamp is equipped with a timer for improved safety. This device is FDA (Food and Drug Administration) approved.
223468798|NCT02899520|OTHER|Reference method|Electrostimulation associated to perineal training
223468799|NCT02899520|OTHER|CMP ® method|Method based on Knowledge and Control of Perineum
223468800|NCT05697913|OTHER|Continued treatment adapted to the response|Instead of receiving a pre-specified number of treatment cycles, regardless of the result obtained, in the MRDI-driven treatment group patients continue receiving treatment until reaching a complete remission with negative MRD and Image, changing the therapeutic line if it is not obtained with the line current therapy. In this group of the patients the treatment was stopped only when this degree of deep response was achieved.
223468801|NCT02959801|PROCEDURE|Percutaneous mechanical thrombectomy|Aspirex catheters(Straub Medical AG, Wangs, Switzerland)
223468802|NCT01078493|DEVICE|MyCells® (injection of platelet rich plasma)|PRP contains at least 1,000,000 platelets per mm3 or 2-6 times the native concentration of whole blood at a pH of 6.5 to 6.7
223468803|NCT02960412|DRUG|furosemide|10mg lasix given intraoperatively
223468804|NCT02960412|DRUG|Normal Saline|Normal saline given intraoperatively as placebo
223468805|NCT02516072|OTHER|RIPC|IV hydration prior to procedure dependent on classification of risk as per eGFR + RIPC
223468806|NCT04686916|DRUG|IP2018|Test drug
223468807|NCT04686916|DRUG|Placebo|Placebo
223468808|NCT04891172|BIOLOGICAL|Anti COVID 19 Intravenous Immunoglobulin (C-IVIG)|"Intervention arm will receive single dose of 0.15g/kg C-IVIG. This will be infused within period of 16 hours intravenously. Additionally, all participants will receive same standard care.~Standard Care as per hospital protocol, which may include:~Airway support, Anti-Viral medication, Antibiotics, Fluid Resuscitation, Hemodynamic Support, Steroids, Painkillers, Anti-Pyretics, anti coagulant"
223468809|NCT02292576|OTHER|Cocoa Pure|Cocoa Pure.
223468810|NCT02292576|OTHER|Placebo|Placebo.
223468811|NCT00830219|DRUG|Ropinirole HCl 0.25 mg Tablets|1 x 0.25 mg, single dose fed
223468812|NCT00830219|DRUG|Requip® 0.25 mg Tablets|1 x 0.25 mg, single dose fed
223468813|NCT05609669|OTHER|CADENCE program|The CADENCE program will consist of an integrated care pathway between the OBOT clinic, obstetric clinic, pediatric clinic, and behavioral health with multiple entry points, including emergency rooms, existing mobile harm reduction clinics, obstetric clinics, and delivery facilities. We also seek to provide wrap-around care for these families with peer support, care navigation, and robust community support, using existing Hillsborough County resources such as doula programs, Healthy Start, and other home visiting programs.
223468814|NCT06458114|OTHER|Assessment of caregiver feeling|The study group includes any caregiver who supported an extremely preterm newborn in a palliative care approach in the delivery room with as intervention type a questionnaire and individual semi-structured interview.
223468815|NCT06473350|OTHER|The application of right lateral, supine, and prone positions to preterm infants after feeding|Each infant included in the sample group is fed at their routine feeding time (9:00 a.m.), followed by placement in the right lateral position. Immediately after this position is applied, as well as one hour and three hours later, data on heart rate, oxygen saturation, respiratory rate, pain level, and comfort level are recorded. This procedure is repeated after the subsequent feeding time (12:00 p.m.) for the supine position and after the feeding time following that (6:00 p.m.) for the prone position. This procedure is repeated for three consecutive days at the same feeding times and in the same sequence.
224159332|NCT05821036|BEHAVIORAL|Activitiy Management|"Activity Management training will be applied for 5 weeks, 2 sessions per week, and the 1st and 10th sessions will be pre and post-training evaluation, a total of 10 individual, internet-based sessions.~Week 1:Awareness training and ergonomics training including spine anatomy, correct posture use, ergonomic strategies were planned to increase awareness about FMS. Week 2:Focusing on the challenging activities stated by the individuals, it is aimed to change the behavior by arranging the activity resting cycle in daily life. In addition, the management, adaptation and modification of the activities will be provided within the scope of time management training. Week 3: Joint and energy conservation principles training will be given and it is aimed to create body mechanics and proper posture suitable for activities.Week 4: Relaxation training will be provided as a method of coping with pain.Week 5: Re-evaluation/review of the targets set to reduce pain during activities will be provided."
223468816|NCT05053906|DEVICE|Endoscope|effect of FESS on eustachian tube function
223468817|NCT01953029|PROCEDURE|cardiac imajing|Cardiac MRI
223468818|NCT01811732|DRUG|Delafloxacin|Delafloxacin
223578623|NCT01840254|DRUG|normal saline|
224068682|NCT05598892|DEVICE|Training with Robotic Hand Exoskeleton|The intervention consists in Robotic Hand training sessions. Each subject received 16 sessions lasting 60 minutes each and a frequency of 2 sessions per week. The sessions will be applied by an Ocupational Therapist with experience in Robotic training. Robhand exoskeleton (ITAP, Valladolid, Spain) is an exoskeleton-type electromechanical device, which is attached to the patient's hand and provides assistance for performing different types of finger movement rehabilitation therapies. The exoskeleton is composed of five independent subassemblies that are placed on a platform which is located on the back of the hand, with the exception of the thumb subassembly that is mounted on a separated module connected to the hand support platform through a linkage device.
224068683|NCT01272700|PROCEDURE|volume control|Volume controlled ventilation of tidal volume 10 ml/kg
223468819|NCT01811732|DRUG|Vancomycin|Vancomycin
224068684|NCT01272700|PROCEDURE|pressure control|Pressure controlled ventilation for peak airway pressure to deliver tidal volume 10 ml/kg.
224068685|NCT00743379|DRUG|TH-302|TH-302 will be administered by IV infusion over 30 minutes on Days 1, 8 and 15 of a 28- day cycle for Arm A and on Days 1 and 8 of a 21 day cycle for Arms B and C.
224068686|NCT00239876|DRUG|FTY720|
224068687|NCT02096341|DRUG|RRx-001|"RRx-001 Dose level 1 (16 mg/m2) twice weekly~RRx-001 Dose level 2 (27 mg/m2) twice weekly"
224159333|NCT03960658|DRUG|ketamine-enhanced prolonged exposure|Subjects will receive a single infusion of racemic ketamine at 0.5mg/kg (ideal body weight) for 40 minutes. The next day, patients will have a standardized prolonged exposure session which lasts approximately 90 minutes. This co-jointed intervention will be repeated for 3 weeks. Then, patients will continue with therapy sessions to complete a total of 10-12 sessions.
224303882|NCT00914459|BIOLOGICAL|Moroctocog alfa ( AF-CC)|Dosing is at the discretion of the Investigator
223468820|NCT01811732|DRUG|Aztreonam|Aztreonam
223468821|NCT01811732|DRUG|Placebo|Placebo
223468822|NCT05345184|BEHAVIORAL|Cognitive Behavioral Suicide Prevention for psychosis (CBSPp)|Cognitive and behavioral approach to suicide prevention tailored for individuals with psychosis
223468823|NCT05345184|BEHAVIORAL|Services as Usual (SAU)|Standard psychiatric and behavioral services provided at community mental health (e.g., case management, medication management)
223468824|NCT01962675|DEVICE|Transcranial direct current stimulation + step training|Direct current stimulation of motor cortex with low stimulation intensity
223468825|NCT01962675|BEHAVIORAL|Sham transcranial direct current stimulation + step training|Stepping over specified soft foam obstacles
223468826|NCT04173091|DIAGNOSTIC_TEST|No Intervention|No Intervention planed
223578624|NCT01827332|DRUG|Oxytocin|Subjects will be administered 40 IUs of oxytocin nasal spray or matching placebo prior to two individual sessions of MET.
223578625|NCT01827332|DRUG|Saline|Subjects will be administered 40 IUs of oxytocin nasal spray or matching placebo prior to two individual sessions of MET.
223578626|NCT00600691|DRUG|Finasteride|one tablet (5mg) of finasteride
223468827|NCT06307353|OTHER|trends of contraception methods|family planning practice will include number of women current use of family planning methods and its type planning fot ffuture pregnancy suggested duration before next pregnancy.women'ssatisfaction with family planning services atElBalyana urban Medical Center accessibility of the site suitability of waiting time
223468828|NCT00573664|DRUG|Gabapentin|single oral dose of 600mg gabapentin
223468829|NCT00573664|OTHER|lactose|Single dose
223468830|NCT03521310|PROCEDURE|Skin-to-skin|Neonates will get Skin-to-skin Contact with parent/caregiver continuously the first 6 hours after birth and as much as possible the first 72 hours after birth.
223468831|NCT03521310|PROCEDURE|Conventional care|Neonates will get Conventional care the first 72 hours after birth
223468832|NCT03952819|DIAGNOSTIC_TEST|serum sclerostin|blood samples obtained
223468833|NCT06472752|RADIATION|Neoadjuvant radiotherapy|Patients with a clear pathological diagnosis of high-risk UTUC were treated with a short course of 5 days of naSBRT: radiotherapy irradiation was directed to the primary lesion on the affected side and to the lymphatic drainage area, with a dose of 25 Gy (5 Gy\*5 days).The safety of the neoadjuvant radiotherapy dose and regimen can be evaluated by metrological ramping in the initial 5 patients, with subsequent patients following the optimal dose from ramping.
223468834|NCT06472752|COMBINATION_PRODUCT|Neoadjuvant drug therapy|Patients will concurrently complete at least 2-4 cycles of preoperative neoadjuvant chemotherapy/immunotherapy/ADCs as well.
223468835|NCT04820907|DRUG|HCP1904-1|Take it once daily for 8 weeks orally.
223468836|NCT04820907|DRUG|RLD2001-1|Take it once daily for 8 weeks orally.
223468837|NCT00927407|DRUG|Malathion gel 0.5%|Malathion gel 0.5% applied to the scalp for 30 minutes
223468838|NCT00927407|DRUG|Malathion lotion 0.5%|Malathion lotion 0.5% applied to scalp for 12 hours
223468839|NCT03830021|BEHAVIORAL|Salt reduction program|Dietary and behavioural change program, led by nutritionists, including low sodium dietary advice; use of aromatic herbs and spices in food instead of salt; motivational activities; food diaries; restrict salty processed foods; eat more fresh foods and seasoning advice; problem solving exercises; digital bulletins; individual counselling reinforced at each clinic visit and shopping counselling at local supermarket.
223468840|NCT03830021|BEHAVIORAL|Healthy lifestyle program|Participants receive an educational healthy lifestyle program that includes 1) methods to cook healthier and the Mediterranean diet based on a high intake of fresh fruit and, vegetables, beans, grain legumes, lentils, nuts, cereals, and olive oil as source of fat; moderate intake of fish, poultry, yoghurt and cheese, low intake of salt, red meat, processed meats and sugar; 2) physical activity; 3) drink more water and reducing alcohol consumption; and 4) sleep education.
223468841|NCT06228976|BEHAVIORAL|Mindfulness-based, smoking cessation focused text messages.|Participants will receive mindfulness-based, smoking cessation focused text messages everyday for 12 weeks.
224068688|NCT05231382|PROCEDURE|Raltitrexed, oxaliplatin (SALOX) treatment|Hepatic arterial infusion (HAI) of Raltitrexed, oxaliplatin (SALOX) treatment
224159334|NCT04030468|OTHER|Educational intervention addressed to general practitioners|"* feedback reports regarding the status of their patients according to the appropriateness indicators determined at baseline and the pooled prevalences for their patients, Local Health Units, and region~* Continuous Medical Education (CME) course"
224159335|NCT04030468|OTHER|Informative intervention addressed to patients|• leaflets and posters distributed in primary care ambulatories and community pharmacies, focusing on correct drug use
223468842|NCT06228976|BEHAVIORAL|Educational messages|Text messages focus on the health risks of smoking and secondhand smoking, once everyday for 12 weeks.
223468843|NCT06228976|BEHAVIORAL|Control messages|Text messages focus on the general healthy lifestyle, once everyday for 12 weeks.
223468844|NCT02908334|DRUG|Sertraline|400 mg/day sertraline
223468845|NCT00288912|BEHAVIORAL|Health Education|12-month intervention consisting of monthly phone calls about common health conditions and screening. Also includes written educational materials on these topics.
223468846|NCT00288912|BEHAVIORAL|Osteoarthritis Self-Management|12-month intervention consisting of monthly phone calls about topics related to self-care for osteoarthritis. Also includes written educational materials on these topics. Participants set goals and action plans, with assistance from health educator, about managing their osteoarthritis.
223468847|NCT02410759|DRUG|Carbetocin|100 women with atonic PPH will receive Carbetocin 100 µgm IM
224068689|NCT05231382|PROCEDURE|Oxaliplatin, fluorouracil/leucovorin (FOLFOX) treatment|Hepatic arterial infusion (HAI) of oxaliplatin, fluorouracil/leucovorin (FOLFOX) treatment
224068690|NCT02215356|DRUG|Icotinib with concurrent radiotherapy|Icotinib: 125 mg is administered orally three times per day.
224068691|NCT02215356|DRUG|Chemoradiotherapy|Etoposide 50mg/m2, ivgtt, d1-d5; cisplatin 50mg/m2, ivgtt, d1 and d8, every 28 days for a cycle, a total of 2 cycles
224068692|NCT02302898|BEHAVIORAL|Eating Behavior Evaluation|Scores will be measured on binge eating behaviors and an increased craving for sweets.
224068693|NCT02302898|OTHER|Measurement of Functional gastric volume|The functional gastric volume is the amount of food or liquid that can be consumed to a feeling of comfortably full in one meal.
224068694|NCT02302898|OTHER|Measurement of gastric pouch and GJ size|Anatomical dimensions of the gastric pouch and GJ will be determined by using an articulated measuring tool during upper GI tract endoscopy.
224068695|NCT01425151|DEVICE|i-Gel|Oropharyngeal leak pressure Insertion success
224068696|NCT01425151|DEVICE|ProSeal|Oropharyngeal leak pressure Insertion success
224068697|NCT04479579|DRUG|Apixaban 2.5 milligram|apixaban 2.5 milligram twice daily from discharge until postoperative day 29 +/- 1 day
224068698|NCT02610595|DRUG|Jianpixiaozhong particles and Wuse Dietotherapy|Jianpixiaozhong particles: Three packs once,bid po; Wuse Dietotherapy: one packs once,bid po
224068699|NCT05411419|PROCEDURE|Spinal cord stimulation|Two leads for spinal cord stimulation would be implanted.
224068700|NCT01216436|BIOLOGICAL|Vaccination with RNA-transfected mature autologous DC|Dendritic cells (DC) will be administered at a dose of 20 million cells by intranodal injection under ultrasound guidance. Each subject will receive a total of six vaccinations at one week intervals
224068701|NCT03900403|OTHER|Walnut Intake|40g of daily walnut intake for 12 weeks
224068702|NCT00283075|BIOLOGICAL|Cancer Macrobead placement in abdominal cavity|8 macrobeads per kg
224159336|NCT03753386|OTHER|Oxygen therapy simulation|"The intervention consists of reproducing oxygen therapy situations in healthy individuals by replacing oxygen bottles with bottles of air. A TeleOx® device will be placed on the circuit between the source and the nasal cannula for respiratory signals recording.~The intervention will last 30 minutes, containing the following activities in the given order:~* rest (9 minutes);~* drinking water (1 minute);~* rest (1 minute);~* coughing (1 minute);~* rest (1 minute);~* reading aloud (1 minute);~* rest (1 minute);~* breathing by the mouth (1 minute);~* rest (1 minute);~* exercising (running) (3 minutes) and~* rest (10 minutes)~Recordings will be retrieved after each test."
224303883|NCT00914459|PROCEDURE|Laboratory tests|Factor VIII PK samples, Hematology, Chemistry and Coagulation testing, FactorVIII Inhibitor and Anti Factor VIII antibody
224303884|NCT05901259|DEVICE|Exopulse Mollii Suit|The registry is designed to demonstrate the impact of Exopulse Mollii Suit on improvement of muscle relaxation, muscle activation, local blood circulation and/or chronic pain relief. The subjects included use the suit for 60 minutes every other day, unless other is specified by the Investigator, in their home environment for up to a maximum of 12 consecutive weeks. Qualitative and quantitative measures will be collected at baseline (T0), after 60 minutes stimulation (T1), after 4 weeks (T4) and at the end of the 12-week intervention period (T12).
224303885|NCT00453778|DRUG|FLIXOTIDE Diskus 500 mcg (Fluticasone Propionate)|
224303886|NCT03175289|OTHER|Best Practice|Undergo therapy session conducted by a speech pathologist
224303887|NCT03175289|OTHER|Educational Intervention|Receive standard of care patient education materials focusing on oral care, signs/symptoms of dysphagia/aspiration, and trismus
224303888|NCT03175289|OTHER|Exercise Intervention|Perform prescribed home exercises
224303889|NCT03175289|OTHER|Expiratory Muscle Strength Training|Participate in EMST
224303890|NCT03175289|OTHER|Quality-of-Life Assessment|Ancillary studies
224303891|NCT03175289|OTHER|Questionnaire Administration|Ancillary studies
224303892|NCT01661179|DRUG|Vandetanib 300mg|300 mg oral dose once daily (100 mg x 3 tablets)
224303893|NCT03344926|BEHAVIORAL|ACTsmart|"Participant receive ACT treatment via a smart phone application, including psychologist support via a message function within the application.~Treatment content is divided into four modules:~1. education about pain behaviors, exposure and acceptance and commitment therapy~2. education about pain physiology~3. exercises on changing behaviors, acceptance, mindfulness, defusion and exposure~4. value based exposure in the participant's daily life"
224303894|NCT02107326|DEVICE|Webdia Software|
224303895|NCT01019473|DRUG|AFQ056|
224303896|NCT01019473|DRUG|Placebo|
223468848|NCT02410759|DRUG|Ergometrine|100 women with atonic PPH will receive Ergometrine 0.5 µgm IM
223468849|NCT05672563|DRUG|Saline infusion sonography for evaluation of cesarean scar|The intervention included the usage of balloon-less GIS catheter with a soft tapered tip inserted into the endocervical canal, with no use of a tenaculum or a cervical dilatator. Normal saline is slowly introduced into the uterine cavity via the catheter until achieving satisfactory distension and visualization of the uterine cavity using trans-vaginal ultra-sonographic imaging.
223468850|NCT01868646|DRUG|Subetta|"Each Subetta tablet contains a mixture of affinity purified polyclonal antibodies to β-subunit of the rINS (6 mg) and antibodies to eNOS (6 mg) in released-active form produced by the patented technology in accordance with the applicable European Pharmacopeia requirements.~Standard therapy of type II diabetes mellitus + Subetta (1 tablet 4 times a day) for 36 weeks.~Subetta: oral administration, per 1 intake - 1 tablet (keep in the mouth until complete dissolution, not at mealtime)."
223468851|NCT01868646|DRUG|Placebo|"Placebo (identical to Subetta in shape and taste tablet containing exсipients). Standard therapy of type II diabetes mellitus + Placebo (1 tablet 4 times a day) for 36 weeks.~Placebo: oral administration, per 1 intake - 1 tablet (keep in the mouth until complete dissolution, not at mealtime)."
223468852|NCT03613831|DEVICE|patient who used Rhythmia system and Orion catheter|suitable for Rhythmia system and Orion catheter according to relevant clinical guidelines and products instruction for use, per investigator's discretion
223468853|NCT00751127|DRUG|PhXA41|One drop in the affected eye once daily for six months.
224303897|NCT02010788|BIOLOGICAL|botulinum toxin Type A|Botulinum toxin Type A treatment for Neurogenic Detrusor Overactivity or Overactive Bladder as per local standard of care in clinical practice.
224303898|NCT00173537|PROCEDURE|for BMPR II study|
224303899|NCT00173537|GENETIC|BMPRII|
224303900|NCT04395651|DEVICE|PET/CT|It is a prospective clinical study that will include patients known to have lung cancer and referred to nuclear medicine unit to perform 18F-FDG PET/CT for staging and therapy planning as well as patients referred for assessment of response of therapy and restaging.
224303901|NCT04979273|DRUG|Dextrose 40 % in Water|injection of adrenaline 1:20.000, followed by dextrose 40% spray
224303902|NCT04979273|DRUG|Adrenaline 1 Mg/mL Solution for Injection|injection of adrenaline 1:20.000, followed by thermocoagulation or hemoclip
224303903|NCT04979273|PROCEDURE|argon plasma coagulation|Thermocoagulation
224303904|NCT04979273|PROCEDURE|Hemoclip|Hemoclip
224303905|NCT02833766|DRUG|anti-EGFR-IL-dox|First-line treatment with anti-EGFR-IL-dox, given at a dose of 50 mg/m2 intravenous, on day 1 of each cycle, cycle length is 28 days
224303906|NCT04979286|OTHER|Kinesiotaping|"Y strip kinesiotaping will be applied to both the gastrocnemius muscles while keeping the participant's ankle in full dorsiflexion. The tape will start from the plantar surface of the toe and continue proximally. The medial Y tail will be applied along the medial border of the gastrocnemius and the lateral Y tail along the lateral border of the gastrocnemius, at approximately 20% tension from the resting length. End points will end just below the popliteal crease."
224303907|NCT04979286|OTHER|Placebo Kinesiotaping|Placebo kinesiotaping, approximately 5x5 cm in size, will be applied to the body of both gastrocnemius muscles without any tension.
224303908|NCT03947424|DEVICE|LP Er:YAG|LP Er:YAG applied to oral mucosa
224303909|NCT03947424|DEVICE|SMOOTH mode Er:YAG|SMOOTH mode Er:YAG applied to oral mucosa
223468854|NCT00751127|DRUG|timolol|One drop in the affected eye twice daily for six months.
224303910|NCT03947424|DEVICE|sham|Er:YAG laser applied to oral mucosa with no energy
224303911|NCT01046266|DRUG|RO5083945|700mg iv weekly
224303912|NCT01046266|DRUG|cetuximab|400mg/m2 iv 1st dose, 250mg/m2 iv subsequent weekly doses
224303913|NCT01142479|DRUG|Chinese herbal medicine decoction|100 ml /Qd for 6 weeks(42 days)
223468855|NCT05037162|DIAGNOSTIC_TEST|Biochemistry blood test|preformed on days 1-14 and day 28. Sodium (Na), Potassium (K), Chloride (Cl), Creatinine, Glucose, Urea, Albumin, Calcium total, Alkaline Phosphatase (ALP), ALT, AST, Total Bilirubin, Direct Bilirubin, LDH, Total Protein, Uric Acid, CRP, and Lipid Profile (including Total Cholesterol, HDL,
223468856|NCT05037162|DIAGNOSTIC_TEST|Hematology blood test|preformed on days 1-14 and day 28. complete CBC.
223468857|NCT05037162|DIAGNOSTIC_TEST|D-Dimer test (coagulation)|performed on days 1,2,7,14 and 28.
223468858|NCT05037162|DIAGNOSTIC_TEST|Inflammatory markers|performed on days 1-7, 14 and 28. IL-6, IL-1β, IL-12, TNF α, IFN-γ
223468859|NCT05037162|DIAGNOSTIC_TEST|Vital signs|performed on days 1-14 and day 28. blood pressure, pulse, weight, weight, body temperature (PO), saturation, respiratory rate.
223468860|NCT05037162|DIAGNOSTIC_TEST|VAS scale|performed on all study visits. score: 0-10 ; a higher score indicates a higher pain level.
223468861|NCT05037162|DIAGNOSTIC_TEST|WHO Ordinal Score|performed on days 1,7,14 and 28. score: 0-3 ; a higher score indicates more symptoms.
223468862|NCT05037162|DIAGNOSTIC_TEST|COVID-19-Related Symptoms assessment|performed on days 1,7,14,21 and 28. score: 0-3 ; a higher score indicates more symptoms.
223468863|NCT05037162|DIAGNOSTIC_TEST|COVID-19-Impact on Quality-of-Life Questionnaire|performed on days 1,7,14,21 and 28. score: 1-5 ; a higher score indicates a lower quality of life.
223468864|NCT05037162|DIAGNOSTIC_TEST|POST- COVID-19 Functional Status Scale:|performed on day 28. score: 0-3 ; a higher score indicates better recovery.
223468865|NCT05037162|DIAGNOSTIC_TEST|Pregnancy test|performed on days 1 and 28. women of childbearing potential must undergo a urine pregnancy test.
223468866|NCT05037162|DIAGNOSTIC_TEST|Physical examination|performed on days 1-14 and day 28. a full examination by a doctor.
223468867|NCT05037162|DIAGNOSTIC_TEST|PK parameters|"performed on day 1. will be performed only on 14 patients that will agree to participate in the PK analysis (only for Brazil,Spain).~The PK will be performed only for the first dose of drug, after patient received the first dose (5 puffs) the study staff need to follow the table below.~For each test, approximately 5 ml of blood will be drawn (equivalent to one teaspoon)"
223468868|NCT05037162|DIAGNOSTIC_TEST|SARS-CoV-2 test (PCR)|performed on days 1,14 and 28.
223468869|NCT05037162|DIAGNOSTIC_TEST|ECG|performed on days 1 and 28.
223468870|NCT05037162|DRUG|Treatment administration (twice a day)|performed on days 1 and 2. twice a day, morning, and evening 1:1:1 ratio to study drug (CimetrA-1) (Arm 1) or study drug (CimetrA-2) or to Placebo (Arm 3)
223468871|NCT01107145|DRUG|Mefloquine- Artesunate|Tablets of 100 mg artesunate and 220 mg mefloquine (fixed dose combination), given once daily for 3 days.
224068703|NCT03053479|PROCEDURE|Laparoscopic sacrocolpopexy|see arm/group descriptions
224159337|NCT05969262|DIAGNOSTIC_TEST|Proteomics technology and liquid biopsy|using proteomics technology and liquid biopsy to investigate the changes of plasma and urine metabolites in different liver diseases during the development of liver cancer by collecting residual blood and urine from routine diagnosis and treatment or physical examination
223468872|NCT01107145|DRUG|Artemether-Lumefantrine|4 tablets containing 20 mg of artemether plus 120 mg of lumefantrine per tablet twice daily for three days as 2 doses 8 hours apart on the 1st day and then 2 doses 12 hours apart on the 2nd and 3rd days, administered with a fatty meal
223468873|NCT01107145|DRUG|Chloroquine|Tablets containing 250 mg Chloroquine salt given as 4 tablets at once on the first day (or 10 mg/kg) followed by 3 tablets once daily for the next 2 days (or 7,5 mg/kg)
223468874|NCT01702467|DRUG|GSK2647544|Capsules containing 0.5mg to 50mg of GSK2647544.
223468875|NCT01702467|DRUG|Placebo|Matching placebo capsules.
223468876|NCT03907696|OTHER|Anti-stigma interventions curriculum|educational curriculum aimed at reducing stigma
223468877|NCT04065243|OTHER|Overfeeding diet|Two weeks of overfeeding
223468878|NCT04065243|OTHER|Isocaloric diet|Two weeks of isocaloric weight maintenance
223468879|NCT01327794|GENETIC|polymorphism analysis|
223468880|NCT01327794|OTHER|immunologic technique|
223468881|NCT01327794|OTHER|laboratory biomarker analysis|
223468882|NCT01327794|OTHER|medical chart review|
223468883|NCT00327223|DRUG|imexon|
223468884|NCT04301050|OTHER|Yoga Intervention|Weekly 75-minute yoga classes.
223468885|NCT00565461|BIOLOGICAL|heat-labile enterotoxin of E. coli (LT)|37.5ug patch applied on either the deltoid or the thigh
223468886|NCT02789501|DEVICE|4% citrate lock solution regimen|(CitraFlow™ 4%, MedXL, Montreal, Canada) will be injected in each of the 2 lumens of the tunneled catheters after each dialysis session (2ml/lumen, 3x/week).
223468887|NCT02789501|DEVICE|TauroLock lock solution regimen|After the first two dialysis sessions of the week (before the short intervals) 2 ml of TauroLock™-Hep500 containing 1% (cyclo)-taurolidine, 4% citrate and 500 IU/mL heparin will be injected into each of the two lumens of the tunneled catheter. After the third dialysis of the week, thus before the long interval, 2 ml of TauroLock™-U25.000 which contains 1% (cyclo)-taurolidine, 4% citrate and 25.000 IU urokinase will be applied into each lumen.
223468888|NCT04752371|DRUG|Camoteskimab (CERC-007, AVTX-007, AEVI-007)|Intravenous (IV) Infusion
223468889|NCT04794907|OTHER|Observation|Patient data will be collected from eye exams, surveys and medical record review.
223468890|NCT03139734|DEVICE|Sacral Neuromodulation|S3 nerve root (sometimes S4) is stimulated with low electrical current via an electrode placed through a sacral foramen. This electrode is connected to a stimulator resembling a cardiac pacemaker.
223468891|NCT00596219|DRUG|celecoxib|celecoxib
223468892|NCT00119574|PROCEDURE|Collaborative Chronic Illness Model|
224068704|NCT03053479|PROCEDURE|Transvaginal mesh procedure|see arm/group descriptions
224068705|NCT03053479|PROCEDURE|Amreich-Richter procedure|see arm/group descriptions
224068706|NCT01127724|DRUG|vitamin B12 treatment|Group I- will receive sublingual vitamin B12 treatment, 1000 mcg per day for 6 months Group II- will receive sublingual vitamin B12 treatment, 100 mcg per day for 6 months Group III- will receive sublingual vitamin B12 treatment, 2000 mcg per day for 6 months
224068707|NCT03979157|DEVICE|Multispectral Optoacoustic Tomography|Non-invasive transcutaneous imaging of subcellular muscle components
224068708|NCT00080782|DRUG|Celecoxib|Oral celecoxib twice daily in the absence of disease progression.
224068709|NCT00080782|DRUG|Doxorubicin Hydrochloride|By vein (IV) over 30 minutes on days 1, 8, 15, and 22
224068710|NCT00080782|RADIATION|Strontium chloride Sr 89|IV on day 1
223468893|NCT01198405|DEVICE|Enhanced external counterpulsation|Treatment of enhanced external counterpulsation (EECP) with a prespecified protocol on top of a guideline-driven standard medical therapy. EECP Protocol is defined as a standard session of a total of 36 hours of EECP treatment, given one hour per day, six days per week. The same session is thereafter repeated at least once every year.
223578627|NCT05172453|OTHER|comprehensive management algorithm for preventing mother-to-child transmission of HBV|"To standardize the clinical management of preventing MTCT of HBV and reduce incidences of MTCT, the Chinese Foundation for Hepatitis Prevention and Control (CFHPC) organized experts to compile the Management algorithm for prevention of mother-to-child transmission of hepatitis B virus based on the latest research progress and recently published guidelines, which includes 10 steps of pregnancy management and postpartum follow-up, among which screening, antiviral treatment, and infant immunization are its core contents."
223578628|NCT06201351|DEVICE|adaptive radiotherapy|MRI was performed and adaptive radiotherapy was administered at farction10 and fraction 20 during radiotherapy.
223578629|NCT01819987|BEHAVIORAL|Tablet computer|Participants in the intervention group will receive eight weekly online sessions and interactive activities delivered through tablet computers. Intervention participants will receive instructions for accessing the program via the tablet at an in-person session. Automated weekly emails will be sent to participating mothers for the intervention duration to encourage study engagement.
223578630|NCT01819987|BEHAVIORAL|Mailing information|Participants in the control group will receive general health promotion topics relevant to preschool-age children (such as immunization, injury prevention and school readiness) via mailing materials that are bilingual weekly for eight weeks. These materials will be obtained from CDC and AAP.
223578631|NCT00000262|DRUG|30% Nitrous oxide|
223578632|NCT00000262|DRUG|0.4% Sevoflurane|
223578633|NCT00000262|DRUG|0.2% sevoflurane|
223578634|NCT00000262|OTHER|Placebo|
223578635|NCT00088790|DRUG|AZD5438|
223578636|NCT04297969|DIAGNOSTIC_TEST|"objective pediatric vision screen GCK glow fixation"|2-axis, smart phone flash concentrated photoscreen using novel, low-detail, color glow fixation device
223578637|NCT02606227|BEHAVIORAL|Financial incentive|Vouchers
223578638|NCT02606227|OTHER|No financial incentive|No financial intervention
223578639|NCT02956304|OTHER|PMv stimulation (iTBS)|PMv stimulation (iTBS)
223743650|NCT07189585|DRUG|Maltodextrin (Placebo)|Maltodextrin is a carbohydrate powder widely used as a food additive. For this study, maltodextrin is used as the placebo comparator. It is packaged into single-dose sachets identical in appearance and taste to inulin sachets. Participants receive escalating doses (5 g/day for 3 days, 10 g/day for 4 days, then 15 g/day) for a total of 8 weeks. Sachets are mixed with food or beverage and taken once daily with the largest meal.
224159338|NCT02837861|DRUG|Routine Nutritional Support plus supplemental IV amino acids|Enteral nutrition as tolerated Plus supplemental IV AA infusion to meet the target of approximately 1.5-2.0gm protein/kg/day total starting within 24 hours of injury for 5 days.
223468894|NCT01198405|DRUG|Guideline-driven standard medical therapy|Standard management, both pharmacological and non-pharmacological, given according to current practice guidelines at the discretion of clinicians
223468895|NCT00932256|DRUG|STAHIST NDC #58407-536-01|Oral tablet containing Pseudoephedrine hydrochloride 90mg, chlorpheniramine maleate 8mg, atropine sulfate .24mg, one tablet BID.
223468896|NCT02672241|DRUG|Nimotuzumab|Nimotuzumab given during radiotherapy, is administered via intravenous drip with a dosage of 150mg/m2, weekly, for 6 consecutive weeks. After radiotherapy and evaluation, disease progression-free patients will continue to receive Nimotuzumab treatment biweekly until disease relapse or progression.
223578640|NCT02956304|OTHER|PMv inhibition (cTBS)|PMv inhibition (cTBS)
223578641|NCT02956304|OTHER|Control (SHAM)|Control (SHAM)
223578642|NCT02644902|OTHER|Avatar assisted cascade training|Training of health workers in THP through tablets including avatar characters , and cascaded supervision model.
223578643|NCT02644902|OTHER|Specialist led training in THP|Training and supervision of lady health workers by specialists as in original THP
223578644|NCT05764031|OTHER|Clinical pilates exercise|Clinical pilates is an exercise modality in which postural muscles are worked out with various body movements, and involves multi-muscle synergies that improve spinal stabilization, flexibility and endurance.
223578645|NCT05764031|OTHER|Aerobic exercise|Aerobic exercise (also known as endurance activities, cardio or cardio-respiratory exercise) is physical exercise of low to high intensity that depends primarily on the aerobic energy-generating process.
223578646|NCT02725593|DRUG|Dapagliflozin|Dapagliflozin 10 mg tablets administered orally once daily, for the 24-week blinded treatment period. Dapagliflozin 10mg tablets administered orally once daily, for the 28-week site and subject blinded long term extension.
223578647|NCT02725593|DRUG|Dapagliflozin placebo|matching placebo tablets, administered orally once daily, for the 24-week blinded treatment period. Dapagliflozin 10mg tablets administered orally once daily,for the 28-week site and subject blinded long term extension.
223578648|NCT05221112|OTHER|diagonal pattern training|patients will receive proprioceptive neuromuscular facilitation technique's chopping and lifting pattern to create 10 movements.
223578649|NCT05221112|OTHER|single plane training|patients will receive single plane training of proprioceptive neuromuscular facilitation in control group
223578650|NCT00000429|DRUG|Calcium carbonate|
223743651|NCT07190300|DRUG|Tulmimetostat|Doses of tulmimetostat beyond DL1 once a day (QD) will be opened depending on outcome of Dose Escalation Meetings (DEM(s))
223743652|NCT07190300|DRUG|Darolutamide|600 mg is administered orally BID
223743653|NCT07190300|DRUG|Abiraterone|abiraterone 1000 mg is administered orally QD
223743654|NCT07190027|DRUG|Arm 1： Standard Synchronous Group|Arm 1: Concurrent PD-1 + Chemotherapy (Standard Synchronous Group) Participants in this group will receive PD-1 inhibitor and chemotherapy on the same day (D1) during each treatment cycle.
223743655|NCT07190027|DRUG|Arm 2：Fixed Delay Group|Fixed Delay Arm Delayed PD-1 + Chemo PD-1 inhibitor (e.g., Sintilimab/Keytruda/Tislelizumab/Camrelizumab/Toripalimab/Nivolumab/Atezolizumab/Sugemalimab) Immune checkpoint inhibitor + Chemo (Day 3)
224159339|NCT02837861|OTHER|Routine Nutritional Support|Enteral nutrition as tolerated.
224159340|NCT03710694|DEVICE|DAV132|"DAV132:~* Dosage: 15 g/day activated charcoal (22.5 g/day DAV132)~* Route: Oral~* Duration: duration of fluoroquinolone treatment + 2 days~DAV132 is regulated as a medical device in Europe and as a drug in the United States of America."
223578651|NCT02813395|DEVICE|Low Level Laser Therapy|"Low Level Laser Therapy was applied at four points to the dominant upper limb of the volunteers on the muscle belly of the biceps. Delineation was done using a measuring tape from the elbow joint line to the acromion marked at points corresponding to 20%, 30%, 40% and 50% of this distance, focusing the application on the muscle belly region, thereby excluding the tendinous region.~An 808 nm equipment was used for applying laser therapy, with a power of 100 mW and total energy of 20 J."
223468897|NCT02672241|DRUG|Temozolomide|Temozolomide is applied to these patients as a chemotherapy drug with a dosage of 75mg/m2, daily. The chemotherapy and radiation are combined as temozolomide is taken 1 hour prior to every fraction of radiotherapy. In 4 weeks after the completion of radiotherapy, temozolomide is given for 8 cycles (dosage: the 1st cycle, 150mg/m2, daily × 5 days, 4 weeks a cycle; the 2-8th cycle, 200mg/m2, daily × 5 days, 4 weeks a cycle and repeated again).
223468898|NCT05218876|OTHER|Low- to moderate intensity strength and endurance training|Combination of strength and endurance training with low- to moderate intensity during chemotherapy
223468899|NCT05218876|OTHER|High intensity strength and endurance training|Combination of strength and endurance training with high intensity during chemotherapy
223468900|NCT01748370|DRUG|Vitamin D supplementation in hypogonadal men|
223468901|NCT01748370|DRUG|Vitamin D supplementation in eugonadal men|
223468902|NCT01748370|DRUG|Placebo hypogonadal|
223468903|NCT01748370|DRUG|Placebo eugonadal|
223468904|NCT02995993|DRUG|Moss-aGal (recombinant human alpha-galactosidase A produced in moss)|Single i.v. Infusion of 0.2 mg/kg moss-aGal over 60 minutes
223468905|NCT01783743|OTHER|TT Training Program and TT Screening Card|The intervention is an additional half day training program on trichiasis recognition (TT Training Program) and a TT Screening card to assist community treatment assistants in recognizing TT cases and referring them to surgery.
223468906|NCT00358696|DRUG|tenofovir|See Detailed Description.
223578652|NCT02813395|DEVICE|Placebo Laser|Laser application simulation with a second pen of the laser device, which was disconnected and did not effectively irradiate energy.
223578653|NCT01667146|OTHER|PHARLAP mechanical ventilation strategy|Pressure control ventilation to maintain tidal volume 4-6 ml/kg and plateau pressure ≤ 30 cmH2O while tolerating respiratory acidosis if pH \> 7.15; daily staircase recruitment manoeuvre and individualised PEEP titration.
223468907|NCT01607593|DRUG|sertraline (Zoloft)|Dosage form: Tablet, Dosage: over 25 mg/day, duration: Not defined
223578654|NCT01667146|OTHER|Control group mechanical ventilation strategy|Mechanical ventilation based on the ARDSnet protocol using volume control ventilation with tidal volume 6 ml/kg, plateau pressure ≤ 30 cmH2O and FiO2/PEEP titration according to a FiO2/PEEP/oxygen saturation combination chart. This has been modified for Australian and New Zealand practice to allow pressure control and pressure support ventilation.
223468908|NCT04281082|DRUG|ursofalk|To study the genetic polymorphisms in pregnant women with ICP treated with ursoflak and in their first degree relatives
223468909|NCT02966704|DIETARY_SUPPLEMENT|intrinsically labeled milk protein|
223468910|NCT04016376|DRUG|PVB Protocol|Patient will be placed in the prone, lateral, or sitting position. With an ultrasound probe placed in the parasagittal or transverse position, the paravertebral space will be identified. Injections will be done in an in-plane manner relative to the ultrasound probe. Local anesthesia will be injected to cover T1-T6 dermatomes.
223468911|NCT04016376|DRUG|PECS-1|For PECS-1, the patient will be placed in the supine position with an ultrasound probe placed inferolaterally starting at the mid-clavicular level the pectoralis major and minor will be identified. Injection of local anesthesia will be performed between the pectoralis major and minor
223468912|NCT04016376|DRUG|Serratus|For the serratus block, the patient will be placed in the supine or lateral decubitus position and with an ultrasound probe, in the parasagittal plane, the serratus muscles will be identified. Injections will be done in-plane below the serratus anterior.
223743656|NCT07190027|DRUG|Arm 3： Individualized Delay Group|"Arm 3: Individualized PD-1 Timing Based on Immune Window Score (IWS) (Individualized Group) Participants in this group will receive chemotherapy on D1 and undergo daily immune monitoring (CD8⁺PD-1⁺ T cells, Treg, IFN-γ, NLR, ALC, CRP).~Based on the immune window score (IWS):~If IWS ≥ 2, PD-1 inhibitor will be administered the same day. If IWS = 1-1.5, dosing may be delayed to D3-D5 depending on immune recovery. If IWS remains 0 by D5, PD-1 inhibitor will be administered on D6 as fallback."
224159341|NCT02565576|DRUG|Placebo|
223468913|NCT00003146|DRUG|busulfan|
223468914|NCT00003146|DRUG|melphalan|
223468915|NCT00003146|DRUG|thiotepa|
223468916|NCT00003146|PROCEDURE|bone marrow transplantation|
223468917|NCT00003146|PROCEDURE|peripheral blood stem cell transplantation|
223468918|NCT04530045|OTHER|dosage of concentration of piperacillin and cefepim|Dosage of total plasma concentration of piperacillin and cefepim at different timepoints
223468919|NCT02771275|DEVICE|Harpoon Medical Device|It is expected that the Harpoon Medical transapical suturing device will be a valuable treatment alternative for patients suffering from mitral valve regurgitation because it can access the left ventricle with a small shaft or via a small valved introducer with a secure anchoring mechanism that can be deployed anywhere on the mitral valve leaflet.
224159342|NCT02565576|DRUG|CFZ533|
223468920|NCT03899727|DEVICE|Polysomnography|Polysomnography, also called a sleep study, is a test used to diagnose sleep disorders. Polysomnography records your brain waves, the oxygen level in your blood, heart rate and breathing, as well as eye and leg movements during the study
223468921|NCT02512887|DRUG|Caudal Block Anesthesia|Anesthesia will be delivered via inhalation induction with air/nitrous oxide and sevoflurane, and injection of 0.25% bupivacaine 1mL/kg without epinephrine into the caudal canal, which is the sacral portion of the spinal canal.
223468922|NCT02512887|DRUG|Dorsal Penile Block Anesthesia|Anesthesia will be delivered via inhalation induction with air/nitrous oxide and sevoflurane, and injection of 0.25% bupivacaine without epinephrine into the dorsal portion of the penis.
223468923|NCT03495063|DIETARY_SUPPLEMENT|Natural Caffeine|Consumption of 400mg of natural caffeine
223468924|NCT03495063|DIETARY_SUPPLEMENT|Synthetic Caffeine|Consumption of 400mg of synthetic caffeine
223468925|NCT03540693|PROCEDURE|RYGB|RYGB-weight loss surgery
223468926|NCT03540693|PROCEDURE|SG|SG- weight loss surgery
223468927|NCT03540693|PROCEDURE|LAGB|LAGB- weight loss surgery
223468928|NCT06499194|OTHER|DASH diet|The Dietary Approaches to Stop Hypertension (DASH) diets rich in fruits and vegetables and reduced in saturated fat can lower the risk for high blood pressure and assist with blood pressure control in hypertensive persons
223468929|NCT04630678|OTHER|Virtual Reality Therapy|Virtual reality games were applied to participants for 30 minutes.
223468930|NCT04630678|OTHER|Conventional Physiotherapy|Joint and muscle mobilization, strengthening, and stretching exercises by neurodevelopmental treatment principles were applied to participants for 30 minutes.
223468931|NCT04630678|OTHER|Activity Training|Unilateral, bilateral, and bimanual activity training that supported manual skills for 30 minutes.
223468932|NCT05225948|PROCEDURE|Remote ischemic conditioning|Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflations of a blood pressure cuff to 200 mmHg. RIC will be conducted twice daily during the period of hospitalization.
223468933|NCT05225948|PROCEDURE|Sham remote ischemic conditioning|Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflations of a blood pressure cuff to 60 mmHg. RIC will be conducted twice daily during the period of hospitalization.
223468934|NCT01911832|PROCEDURE|esophagojejunostomy after total gastrectomy|
223468935|NCT01911832|PROCEDURE|Roux-en-Y gastrojejunostomy after subtotal gastrectomy|
223468936|NCT01911832|PROCEDURE|wide tube reconstruction after subtotal gastrectomy|
223578655|NCT01564524|PROCEDURE|Fat graft surgical procedure|The fat graft surgical procedure will concentrate the adipose stromal cells (ASCs) in the fat graft material. A blunt tip hollow cannula is used to aspirate approximately 200-400cc of fat tissue. The aspirated fat is divided into two portions: one portion will be processed as standard graft material, the other portion will be used in a processing step that concentrates the ASCs. The aspirated fat processed as standard graft material will be divided into small alioquots and centrifuged to separate the aqueous and oil layers, and transferred into 1ml syringes. Standard fat graft material will serve as a control treatment and will be injected into one area of the face. The ASC concentrated graft material will be processed so it first separates the ASCs in a brief collagenase digestion and then resuspends the ASCs in the native fat tissue from which the stromal cells were derived. The ASC concentrated fat will be injected into another region of the face.
224159343|NCT01496144|PROCEDURE|Manual therapy and active exercises|"Spinal manipulation/mobilisation (5-10 minutes), consisting of passive accessory intervertebral movements, muscle-energy techniques and high velocity, low amplitude dynamic thrust.~Active exercises (20 minutes), consisting of mobility, stretching, strengthening and motor control exercises"
223468937|NCT01911832|PROCEDURE|narrow tube reconstruction after subtotal gastrectomy|
223468938|NCT02647138|OTHER|white noise|exposure to white noise
223468939|NCT06090838|PROCEDURE|Balloon Pulmonary Angioplasty (BPA)|A balloon pulmonary angioplasty is a minimally invasive intervention procedure to remove blood clots from the pulmonary arteries.
223578656|NCT05655143|BEHAVIORAL|Balance training|"Participants will undergo a 4-week balance training protocol modified from that described previously.~Participants will undergo supervised exercise three times per week for approximately 30 minutes per session. The exercise consists of single-leg balance training, hop to stabilization, and hop to stabilization plus reaching activities as presented in Figure 1. Particularly, the levels of difficulty will be progressed with visual conditions (eyes open and eyes closed), time (sec), and base of support (floor and foam pad) while hopping distance (inches) for single-leg and hopping activities, respectively. These activities will be progressed in difficulty as participants become proficient at the task."
224159344|NCT01496144|PROCEDURE|Detuned ultrasound and active exercises|Electrotherapy device inactivated and ineffective. Active exercises, consisting of mobility, stretching, strengthening and motor control exercises
224159345|NCT00902512|DRUG|Treatment A|Viagra® 100 mg tablet, administered with water single dose
224159346|NCT00902512|DRUG|Blood samples for the analysis of sildenafil in plasma|Blood samples for the analysis of sildenafil in plasma
224159347|NCT00902512|DRUG|Treatment B|Sildenafil 100 mg CT administered with water single dose
224159348|NCT00902512|OTHER|Blood samples for the analysis of sildenafil in plasma|Blood samples for the analysis of sildenafil in plasma
224159349|NCT00902512|DRUG|Treatment C|Sildenafil 100 mg CT administered without water single dose
224159350|NCT00902512|OTHER|Blood samples for the analysis of sildenafil in plasma|Blood samples for the analysis of sildenafil in plasma
224159351|NCT01500265|BIOLOGICAL|plasma and urine samples, sample with ADN|plasma and urine samples every three months Sample with ADN at baseline
224303914|NCT00317252|DRUG|Hold ACEI or ARB|Angiotensin converting enzyme inhibitor or angiotensin receptor blocker held at least 24 hours pre-cardiac catheterization and restarted 48-96 hours post-catheterization (after creatinine measurement)
223468940|NCT02799927|PROCEDURE|Indirect Pulp Treatment with Bioactive Dentin Substitute|The indirect pulp treatment (IPT), with Biodentine is a vital pulp procedure for dep cariously primary teeth without carious exposure, involving the removal of the softened, humid and infected dentin layer, leaving intact intentionally the deepest layer of the dentin-pulp complex, followed by the placement of Biodentine and a hermetic restoration to provide a seal against microleakage, without the necessity to reenter for removing the residual caries.
223468941|NCT02799927|PROCEDURE|Indirect Pulp treatment with Calcium hydroxide|The indirect pulp treatment (IPT), with Biodentine is a vital pulp procedure for dep cariously primary teeth without carious exposure, involving the removal of the softened, humid and infected dentin layer, leaving intact intentionally the deepest layer of the dentin-pulp complex, followed by the placement of Ultra-Blend plus, and a hermetic restoration to provide a seal against microleakage, without the necessity to reenter for removing the residual caries.
223468942|NCT02354287|PROCEDURE|Cold forceps polypectomy with pre lift|"Polyps ≤7mm will be included in the study if deemed appropriate by the colonoscopist..~These polyps will be resected with cold forceps after pre injection into the submucosa with a few millilitres of pre injection solution (19 ml gelofusine, 1ml 1:10000 adrenaline and 1ml indigo carmine). Polyps are grasped with the cold forceps and pulled away from the rest of the colonic mucosa. Attempt will be made to remove polyps with single attempt with the forceps however several grasps may be required for complete visual resection of the polyp.~The polypectomy site and a 5mm rim of normal appearing tissue will then be resected with endomucosal resection (EMR) using conventional snare method. This is to ascertain if there is any residual polyp tissue."
223468943|NCT04478058|BEHAVIORAL|Live CBT|Weekly in-person Cognitive Behavioural Therapy
223578657|NCT04546373|DRUG|Niraparib|Patient's medical records will be screened by local clinical staff to assess for eligibility according to selection criteria. The study comprises a single study visit, in which the patient will give her informed consent to participate (when the patient is alive) and the physician will extract the study data from the patient's medical charts. All eligible deceased and consenting living patients at the participating centers will be included. Data will be directly retrieved from hospital medical records and reported in the electronic Case Report Form (eCRF).
223468944|NCT04478058|BEHAVIORAL|e-CBT|Weekly online Cognitive Behavioural Therapy
223468945|NCT00249704|DRUG|Vitamin D + Sham Exercise|1000 IU per day of Vitamin D + Sham (equivalent to placebo) Exercise
223578658|NCT00823277|OTHER|Chronic care multidisciplinary intervention of childhood obesity|Overweight and obese Children, 5-20 Years old, followed by Paediatricians and other Health Personals (multidisciplinary team). Included at their first visit in the clinic (baseline)and follow-up after \~ 1 Year.
223578659|NCT03622034|OTHER|posterior condylar offset measurement|the tangent to the medial tibial plateau is considered to be the proximal reference line. This is the line connecting the highest anterior and posterior points of the medial plateau. The second reference is the axis of the tibia, defined as a line through the middle of the shaft at 10 and 20 cm. The angle between these two lines is the tibial slope
223578660|NCT05801055|DRUG|Evaluation of gastric visibility following the combination drink of N-acetyle cysteine and simethocone|The combination drink containing N-acetyl cysteine and simethicone help to disperse bubbles and mucus present in the stomach. During routine upper gastrointestinal endoscopy mucus and bubbles sometimes may hinder mucosal visibility, so small submucosal lesions, ulcers, erosions, and even flat pre-malignant lesions can be missed during endoscopy. The Japanese guidelines also recommend the use of this combination drink to detect early gastric cancers. So we plan to evaluate the role of this drink in improving gastric mucosal visibility in patients undergoing upper gastrointestinal endoscopy.
223578661|NCT03582904|PROCEDURE|tDCS|real or sham tDCS delivered to primary motor cortex
223578662|NCT03823872|OTHER|Time restricted feeding|Time restricted feeding= consume food only from 12:00pm-8:00pm
223578663|NCT03823872|OTHER|Normal feeding|Normal feeding= consume food per normal schedule
223578664|NCT05154604|DRUG|SHR-A1921|Treatment group: Subjects will receive an intravenous infusion of SHR-A1921 in a dose escalation until confirmed progression, unaccepted toxicity, or any criterion for withdrawal from the study.
223468946|NCT00249704|PROCEDURE|Vitamin D Placebo + Exercise|Vitamin D placebo + Exercise
223468947|NCT00249704|PROCEDURE|Vitamin D Placebo + Sham Exercise|Vitamin D placebo + Sham (equivalent to placebo) Exercise
223468948|NCT00249704|DRUG|Vitamin D + Exercise|1000 IU per day of Vitamin D + Exercise
223468949|NCT03168373|PROCEDURE|language rehabilitation therapy|language therapy is language rehabilitation by language therapist during subacute phase in stroke patients
223468950|NCT04204005|DIETARY_SUPPLEMENT|Probiotics|"Active composition: 5x109 of Bifidobacterium longum (mix DLBL), 1x 109 Lactobacillus reuteri LRE02 (DSM 23878) and maltodextrin (total 2 grams). The probiotic species employed were granted the Qualified Presumption of Safety (QPS) status by the European Food Safety Authority (EFSA) in 2007. Two envelopes per day and one envelope per day will be recommended for one and two months, respectively.~Placebo composition: maltodextrin (2 grams). Two envelopes per day and one envelope per day will be recommended for one and two months, respectively."
223468951|NCT01262144|RADIATION|Radiotherapy|Radiotherapy for cervical cancer
223578665|NCT02698722|OTHER|End-stage renal disease treatment options|This group will receive the intervention which is a 11.5 minute video about dialysis and non-dialytic therapies.
223743657|NCT07189533|BEHAVIORAL|Co-created intervention|Intervention generated by a participatory research process (co-creation) in the elderly population living in rural areas to co-create solutions to improve their lifestyles, quality of life and health.
223743658|NCT07191132|BEHAVIORAL|Standardised Verbal Instructions|Participants receive verbal post-extraction care instructions delivered by a trained investigator using a calibrated script. The content includes guidance on bleeding control, diet, oral hygiene, activity restrictions, and medication use.
223743659|NCT07191132|BEHAVIORAL|Verbal Instructions + PDEC-kit|Participants receive the same standardised verbal instructions as the control group, supplemented with the PDEC-kit. The kit includes a two-minute educational video, illustrated flashcards, a live gauze demonstration using a dental model, and a bilingual (English and Bahasa Melayu) illustrated brochure with QR code access to a digital version.
223743660|NCT07189442|DIETARY_SUPPLEMENT|L-theanine and paraxanthine|200 mg L-theanine + 200 mg paraxanthine capsule
223743661|NCT07189442|DIETARY_SUPPLEMENT|Placebo|400 mg corn starch capsule
223743662|NCT07191210|BEHAVIORAL|Comprehensive Transition Programme (CTP)|A co-designed, multicomponent educational programme delivered over three months to support nurses transitioning into first-line management roles. The programme integrates classroom training modules, online learning, mentorship by senior nurse managers, and structured reflective practice.
223743663|NCT07190001|DRUG|YOLT-204|The intervention group will receive YOLT-204 on day0
223468952|NCT04821063|DRUG|ITF2357 10 mg/mL|Dose: 100 mg (administered as 10 mL); Dosage form: suspension; Route of administration: oral
223468953|NCT04821063|DRUG|ITF2357 10 mg/mL|Dose: 300 mg (administered as 30 mL); Dosage form: suspension; Route of administration: oral
223468954|NCT04821063|DRUG|Placebo|Dose: 20 mL; Dosage form: suspension; Route of administration: oral
223468955|NCT04821063|DRUG|Moxifloxacin Hydrochloride|Dose: 400 mg; Dosage form: tablet; Route of administration: oral
223468956|NCT04821063|DRUG|Placebo|Dose: 30 mL; Dosage form: suspension; Route of administration: oral
223468957|NCT06435013|DRUG|Lenvatinib|Lenvatinib combined with hepatic arterial infusion chemotherapy and PD-1/PD-L1;
223468958|NCT05064254|OTHER|Treatment as usual (TAU)|TAU may include self-help methods, physician visit, provision of resources etc.
223468959|NCT05064254|OTHER|Mindful Adaptive Practice in Pregnancy Therapy|MAP teaches: a) recognition of personal maladaptive/ distressing patterns driving anxiety; b) how to relate differently; and c) cultivation of more adaptive ways of dealing with anxiety and learning how to effectively control it rapidly which allows re-engagement with life in more flexible ways.
223468960|NCT05201092|DRUG|[14C]-Lu AG06466|\[14C\]-Lu AG06466 will be administered per schedule specified in the arm description.
223468961|NCT03054142|OTHER|no intervention|
223468962|NCT03228641|DEVICE|micro-excisional skin removal with coring needle|
223468963|NCT01380236|DRUG|ASM8|
223468964|NCT04149444|DRUG|Trifluridine/Tipiracil|Oral medication
223468965|NCT03345641|OTHER|describe precocious maternal impressions when confronting the premature birth of her infant|
223468966|NCT04608071|PROCEDURE|A modified method for blind bedside placement of post-pyloric feeding tube.|Modified post-pyloric feeding tube bedside catheterization as an optimized bedside blind post-pyloric tube placement, significantly shortened the time for passing pylorus without causing any severe adverse reactions.
223468967|NCT00000638|DRUG|Isoniazid|
223468968|NCT00000638|DRUG|Pyrazinamide|
223468969|NCT00000638|DRUG|Pyridoxine hydrochloride|
223468970|NCT00000638|DRUG|Rifampin|
223468971|NCT01350635|BIOLOGICAL|BM32|BM32 will be applied in sterile phosphate buffer solution. Drug will be applied in concentrations of 11,33 and 100 micrograms/ml
223468972|NCT04140773|DIETARY_SUPPLEMENT|D-serine|Capsule D-serine
223468973|NCT04140773|OTHER|Placebo|Capsule D-serine
223468974|NCT03289338|DRUG|Zoledronic Acid|Zoledronic acid 5mg intravenous once a month for 3 months
223468975|NCT03289338|DRUG|Methylprednisolone|Methylprednisolone 1gm intravenous once a month for 3 months
223468976|NCT03289338|DRUG|Placebos|Normal saline intravenous once a month for 3 months
223468977|NCT05105074|DRUG|Intrathecal Morphine|Group 1 - Patients will receive intrathecal morphine 100 mcg in addition to the standard dose of bupivacaine and 15 mcg of fentanyl for spinal anesthesia.
223468978|NCT05105074|DRUG|Placebo|Group 2 - Patients will not receive intrathecal morphine. Patients will receive only bupivacaine and 15 mcg of fentanyl for spinal anesthesia.
223468979|NCT06059040|PROCEDURE|eliminating gastric residual volume monitoring|eliminating gastric residual volume monitoring from routine care
223468980|NCT00728494|BIOLOGICAL|PegIntron (peginterferon alfa-2b; SCH 54031)|Peginterferon alfa-2b will be administered according to the product's labeling.
223468981|NCT00728494|DRUG|Rebetol (ribavirin; SCH 18908)|Ribavirin will be administered according to the product's labeling.
223468982|NCT00728494|BEHAVIORAL|Patient Assistance Program|"The patient assistance program includes the following:~* Training by physicians or specialized nurses.~* Informational materials based on the To beat HCV program.~* Management of specific side effects."
223468983|NCT03472131|PROCEDURE|Unilateral Posterolateral Approach and Debridement|
223468984|NCT03472131|OTHER|Titanium cage insertion supplemented by screw fixation|
223468985|NCT00914147|PROCEDURE|pulmonary function testing|After signing consent, patients will undergo a complete spirometry test, lung volumes and diffusing capacity (DLCO) measurement utilizing the single-breath breath holding technique, according to the ATS/ERS consensus and standardization.
223468986|NCT05192265|DRUG|Antimalarials, pyronaridine-artesunate|The main interventions investigated are pyronaridine-artesunate granules or tablets (Pyramax™) manufactured by Shin Poong Pharmaceuticals, Seoul, Korea. Pyramax granules come in sachets with each containing 60mg of pyronaridine/20mg of artesunate while Pyramax tablets contain 180mg pyronaridine/60mg artesunate.
223468987|NCT05192265|DRUG|Antimalarials, Artemether + Lumefantrine|Artemether-lumefantrine dispersible tablets (Coartem™, Novartis pharma) twice daily according to body weights. Each dispersible tablet of AL contains 20mg of artemether/120mg of lumefantrine).
223468988|NCT05638282|DRUG|Cendakimab|Specified dose on specified days
223468989|NCT05638282|DRUG|Placebo|Specified dose on specified days
223468990|NCT04772066|OTHER|Measure of medication adherence|Measure of medication adherence
223468991|NCT05925439|DEVICE|Tuohy needle group|Ultrasound-guided S1 transforaminal epidural block with Touhy needle
223468992|NCT05925439|DEVICE|Quincke needle group|Ultrasound-guided S1 transforaminal epidural block with Quincke needle
223468993|NCT00324922|DRUG|trimethoprim-sulfamethoxazole|trimethoprim/sulfamethoxazole 320/1600 mg po bid
223468994|NCT00324922|DRUG|vancomycin|1g iv bid
223468995|NCT03588273|DRUG|Amoxil 500 MG Oral Capsule|
223468996|NCT01861067|PROCEDURE|LESS-TLH|
223468997|NCT01861067|PROCEDURE|LESS-LAVH|
223468998|NCT02294279|DRUG|Qvar (100 mcg)|2 puffs twice daily; 400 mcg daily over 4 weeks treatment period
223468999|NCT00000798|BIOLOGICAL|HIV-1 Peptide Vaccine, Microparticulate Monovalent|
223469000|NCT02308800|DEVICE|Quantum™ Therapy - NPWT with Prontosan|Negative pressure wound therapy with Prontosan irrigation.
223469001|NCT02308800|DEVICE|Quantum™ Therapy|Negative pressure wound therapy without irrigation.
223578666|NCT05280249|OTHER|both aerobic and resistance exercises in the green exercise concept|Green exercise is a type of exercise done outdoors. It is an advantageous type of exercise in benefiting from sunlight and reducing anxiety. Participants in this group will be given aerobic and resistance exercises in the open air.
223578667|NCT03826823|DEVICE|HSG cannula|a thin catheter originally designed for IUI was introduced through the cervical canal into the lower part of the uterine cavity. After introducing the catheter, the screw of the vaginal speculum was loosened to allow the two valves of the speculum to press on the portiovaginalis of the cervix to prevent leakage of the dye. Then the dye was injected slowly and the procedure was watched on the screen and x-ray films were taken.
223578668|NCT00629473|DRUG|NPI-0052 on Days 1, 8, 15 every 28 days|NPI-0052 dose ranging from 0.1 to 0.9 mg/m2 NPI-0052 IV injection over 1 to 120 minutes on Days 1, 8, and 15 of 4-week cycles
224159352|NCT04172376|PROCEDURE|Minimally invasive puncture aspiration plus rt-PA|Stereotactic puncture aspiration to evacuate basal ganglion hematoma with use of thrombolytic agent
224159353|NCT04172376|DRUG|Conservative medical treatment|Drugs for symptomatic treatment such as hemostasis and nerve nourishing.
224303915|NCT04696107|BEHAVIORAL|Psychoeducative intervention|"This workshop is centred in psychoeducational and training action in emotional self-regulation in a group modality and participatory character, aimed at patients with mCNCP to acquire basic knowledge in:~* Neurology and psychoneuroimmunology.~* The role of beliefs in our manifestation of the disease.~* Body language and modulation of pain perception.~* Relaxation body-mind techniques.~* Creative visualization for pain management.~* Mirror feed-back.~The workshop will take place at the Hospital San Juan de Dios del Aljarafe, in four weeks, once a week, three hours each. Until now, the attendance was 24 patients per workshop. After the pandemic, we will reduce to 15 to increase safety distance. We will also conduct a telephone survey of each patient on symptoms of Covid infection in the 24 hours prior to the workshop."
224303916|NCT02849327|DEVICE|Cryosurgery|Percutaneous ablation under CT or ultrasound guidance
224303917|NCT02849327|BIOLOGICAL|NK immunotherapy|Each treatment: 8\~10 billion cells in all, transfuion in 3 times, i.v.
224159354|NCT05939700|DRUG|Mavacamten|Observational study of individuals exposed to at least 1 dose of mavacamten at any time during pregnancy and/or breastfeeding
224159355|NCT00045045|PROCEDURE|positron emission tomography|
224159356|NCT00045045|RADIATION|fludeoxyglucose F 18|
224159357|NCT04123444|DRUG|Iloprost|Continuously infusion for 72 hours. treatment dose 1 ng/kg/min
224159358|NCT04123444|DRUG|Isotonic saline|Continuously infusion for 72 hours.
224159359|NCT00553761|DEVICE|Pattern electroretinogram|Full field and hemifield (nasal and temporal) stimulation transient pattern electroretinogram (PERG) were recorded both in patients and controls.
224159360|NCT00657930|DRUG|insulin detemir|observational study - dose and frequency to be prescribed by the physician as a result of standard clinical practice.
224159361|NCT00644813|OTHER|Scapular with glenoid neck fractures|
224159362|NCT02918318|DRUG|Placebo|Participant will receive 1 spray of placebo to each nostril at 0 minute, 5 minutes and 10 minutes.
224159363|NCT02918318|DRUG|Intranasal esketamine (28 mg)|Participant will receive 1 spray of Esketamine to each nostril at 0 minute and placebo at 5 minutes and 10 minutes.
224159364|NCT02918318|DRUG|Intranasal esketamine (56 mg)|Participant will receive 1 spray of Esketamine to each nostril at 0 minute, 5 minutes and placebo at 10 minutes.
224303918|NCT00727727|DRUG|Piribedil|
224303919|NCT03533127|DRUG|LY01008|LY01008+Carboplatin/Paclitaxel
224303920|NCT03533127|DRUG|Bevacizumab|Bevacizumab + Carboplatin/Paclitaxel
224159365|NCT02918318|DRUG|Intranasal esketamine (84 mg)|Participant will receive 1 spray of Esketamine to each nostril at 0 minute, 5 minutes and 10 minutes.
224159366|NCT03981744|DRUG|Ustekinumab 6 mg/kg|Participants will receive body weight-range based IV dosing of 6 mg/kg of ustekinumab at Week 0 in Group 1 and at Week 24 in Group 2.
224159367|NCT03981744|DRUG|Ustekinumab 90 mg|Participants will receive ustekinumab 90 mg SC at Week 8 and every 8 Weeks (q8w) through Week 72 in Group 1 and q8w Week 32 through Week 72 in Group 2.
224159368|NCT03981744|DRUG|Placebo IV|Participants will receive IV dosing of placebo at Week 24 in Group 1 and at Week 0 in Group 2.
224159369|NCT03981744|DRUG|Placebo SC|Participants will receive SC dosing of placebo at Weeks 8,16 and 24.
224303921|NCT06157762|PROCEDURE|Erector spinae plane block|ultrasound guided lumbar erector spinae plane block
224303922|NCT06157762|PROCEDURE|Erector spinae plane block performed by surgeon|Erector spinae plane block performed by surgeon
224303923|NCT04971265|BEHAVIORAL|Low SES/High Supports|Participant will read the following scenario: Michael and Kim are a young couple living with their 2-year-old child. Michael works as a janitor in a residential building, while Kim works as a cashier in a supermarket. Where they live, all parents have 12 weeks of paid parental leave, access to free full-day center-based daycare for children aged 0 to 3, free full-day preschool for children aged 3 to 5 (early education programs to prepare for kindergarten), and free parenting classes.
224303924|NCT04971265|BEHAVIORAL|Low SES/ Low Supports|Participants will read the following scenario: Michael and Kim are a young couple living with their 2-year-old child. Michael works as a janitor in a residential building, while Kim works as a cashier in a supermarket. Where they live, parents have 1 week of paid parental leave, full-day center-based daycare for children aged 0 to 3 is available for around $900 per month, full-day preschool for children aged 3 to 5 (early education programs to prepare for kindergarten) is available for around $1400 a month, and they can take parenting classes for $50 per hour.
224303925|NCT04971265|BEHAVIORAL|High SES/High Supports|Participants will read the following scenario: Michael and Kim are a young couple living with their 2-year-old child. Michael works as a lawyer in a private company, while Kim works as a manager at a bank. Where they live, all parents have 12 weeks of paid parental leave, access to free full-day center-based daycare for children aged 0 to 3, free full-day preschool for children aged 3 to 5 (early education programs to prepare for kindergarten), and free parenting classes.
223578669|NCT00629473|DRUG|NPI-0052 on Days 1, 4, 8, 11 every 21 days|NPI-0052 dose ranging from 0.075 to 0.6 mg/m2 NPI-0052 IV injection over 1 to 120 minutes on Days 1, 4, 8, and 11 of 3-week cycles
223578670|NCT00629473|DRUG|Dexamethasone|20 mg oral or IV day before and day after NPI-0052 dosing.
223578671|NCT04050267|DRUG|Nitrous Oxide|Breathing nitrous oxide, concentrations 5, 7, 10, 12, 15, 20 % in air with 21 % oxygen, in random order.
223578672|NCT04050267|OTHER|Placebo - air|Breathing air with 21 % oxygen, no nitrous oxide.
223578673|NCT00387647|DRUG|Azacitidine|Azacitidine given subcutaneously as outlined in treatment arm.
223578674|NCT03556020|DRUG|Pemziviptadil (PB1046)|Pemziviptadil (PB1046), Once Weekly Subcutaneous Injection
223469002|NCT02706288|OTHER|Weight loss with very low fat plant-based diet and regular exercise|Participants will lose \~7-10% of their body weight while on a calorie-restricted very low fat plant-based (PB) diet and performing exercise 6 days/week (4 sessions/week under direct supervision). The macronutrient composition of the diet is approximately 70% of energy from carbohydrate, 15% from protein, and 15% from fat. Food will be provided in the form of take-out meals and will be picked up by participants during weekly study visits with a weight management dietitian. To promote adherence to the diet and exercise intervention, subjects will participate in a lifestyle intervention program that includes dietary and behavioral education topics. Treatment will be provided in weekly individual or group sessions depending on subject availability. (Note: this is the only intervention for the study; the hyperinsulinemic euglycemic clamp is not an intervention but is the gold standard for evaluating insulin sensitivity, a primary study outcome.)
223578675|NCT03809910|DEVICE|Reference MTB|Participants will brush their teeth with manual toothbrush and 1.3 g ± 0.1 g of fluoride toothpaste (containing 0.76% w/w sodium monofluorophosphate) for 1-timed minute under supervision of study staff.
223578676|NCT03809910|DEVICE|Reference PTB|Participants will brush their teeth with power toothbrush and 1.3 g ± 0.1 g of fluoride toothpaste (containing 0.76% w/w sodium monofluorophosphate) for 2-timed minute under supervision of study staff.
223578677|NCT03809910|DEVICE|Prototype PTB (Gum line mode)|"Participants will brush their teeth with prototype PTB toothbrush and 1.3 g ± 0.1 g of fluoride toothpaste (containing 0.76% w/w sodium monofluorophosphate) for 2-timed minute in Gum Line mode under supervision of study staff."
223578678|NCT03809910|DEVICE|Prototype PTB (Combined mode)|"Participants will brush their teeth with prototype PTB toothbrush and 1.3 g ± 0.1 g of fluoride toothpaste (containing 0.76% w/w sodium monofluorophosphate) for 2-timed minute in Gum Line mode and 1-timed minute in Interdental mode under supervision of study staff."
223578679|NCT05408910|DRUG|Rifaximin 550 MG Oral Tablet [XIFAXAN]|Participants in this arm will receive Rifaximin 550 mg three times daily for 14 days.
223578680|NCT05408910|DRUG|Placebo|Participants in this arm will receive placebo three times daily for 14 days.
223578681|NCT02726061|BEHAVIORAL|Internet-based psychological support|A behavioral therapy called Problem Solving Therapy, conflict management training, and stress management training will be administered via an interactive multimedia program (PATH) to participants referred from their Employee Assistance Program and the general public for the management of depression, stress, and conflict.
223578682|NCT05332808|OTHER|questionnare|collecting data about treatment and quality of life
224303926|NCT04971265|BEHAVIORAL|High SES/Low Supports|Participants will read the following scenario: Michael and Kim are a young couple living with their 2-year-old child. Michael works as a lawyer in a private company, while Kim works as a manager at a bank. Where they live, parents have 1 week of paid parental leave, full-day center-based daycare for children aged 0 to 3 is available for around $900 per month, full-day preschool for children aged 3 to 5 (early education programs to prepare for kindergarten) is available for around $1400 a month, and they can take parenting classes for $50 per hour.
223578683|NCT04948307|DEVICE|OXD01 digital therapy|OXD01 digital therapy, 1-2 times per week 15-30 minutes each time.
223578684|NCT04948307|OTHER|Standard of Care|Sublingual buprenorphine/naloxone Medication-assisted treatment, the current standard for opioid addiction; the use of medications in combination with counseling
223578685|NCT05918055|DRUG|KPT-8602|5-10 mg PO daily for 10-14 days based on dose level
223578686|NCT05918055|DRUG|Inqovi|Inqovi will be administered via oral route once daily on Days 1-5 of each treatment cycle, according to guidelines outlined in the FDA product label.
223578687|NCT04758923|PROCEDURE|Cholecystectomy|Under General anaesthesia cholecystectomy and CBD exploration
223578688|NCT04870463|PROCEDURE|Maxillary and mandibular Cone Beam Computed Tomography record|A Cone Beam Computed Tomography image of each patient of each group at three different moments of the study (baseline/T0, 8-9 months of treatment/T1 and end of treatment/T2)
224068711|NCT06076915|BEHAVIORAL|Exergame training|"During the exergame intervention period, the participants in the respective group will be asked to train at least two times per week for 10 minutes per session. The proposed 10 to 15 min-sessions can also be split up into multiple short training slots during the day, to thus reach the targeted 10 minutes. Moreover, the participants are allowed to train even more during their exergame-intervention period of six weeks. However, during the control period of six weeks, they are prohibited from training on the device.~The training program will start with four pre-defined programs of the Dividat Senso (Dividat AG, Schindellegi, Switzerland; CE certification) program. This training program will be adapted weekly by the investigator to generate new stimuli through varying games and thereby also further support the motivation."
224068712|NCT05726500|DIAGNOSTIC_TEST|Arterial blood gas analysis|The researches will collect 2 ml of arterial blood using an arterial line already in place for clinical purposes to perform and arterial gas analysis.
223469003|NCT06258850|DRUG|Calcifediol Oral Capsule|One Hydroferol® soft capsule (0.266 mg) will be administered once weekly for the first 12 weeks and one capsule every two weeks for the next 12 weeks.
223469004|NCT06258850|DRUG|Placebo|One soft capsule will be administered once weekly for the first 12 weeks and one capsule every two weeks for the next 12 weeks.
224068713|NCT05726500|DIAGNOSTIC_TEST|Venous blood gas analysis|The researches will collect 2 ml of arterial blood using a central venous line already in place for clinical purposes to perform a gas analysis.
224068714|NCT05726500|DIAGNOSTIC_TEST|Esophageal pressure monitoring|The researchers will position an esophageal balloon to evaluate esophageal pressure
224303927|NCT02038465|DEVICE|Questionary|Test the effectiveness of two techniques of cognitive remediation of autobiographical memory using an innovative tool called SenseCam ® for patient
224068715|NCT05726500|DIAGNOSTIC_TEST|Intrabdominal pressure|The researches will assess intrabdominal pressure using the urinary catheter system already in place for clinical purposes .
223469005|NCT04835545|OTHER|extreme hypercapnia induced by ventilation insufficiency|extreme hypercapnia
223578689|NCT03452826|DEVICE|Antibiotic therapy according to the result of mPCR (device)|"* Phone call at D28 and D90, unless the patient is still hospitalized;~* Collection of a respiratory tract sample (either distal, i.e. tracheal aspirate or bronchoalveolar lavage, or proximal, i.e. sputum) for broad panel respiratory mPCR in the intervention arm.~* Collection of an additional respiratory tract sample for biological banking in both arms."
223469006|NCT06047405|DEVICE|Average Volume-Assured Pressure Support (AVAPS)|A setting on noninvasive ventilator that allows setting of maximum and minimum inspiratory pressure and sets a target tidal volume. The inspiratory pressure varies breath to breath to ensure pre-set tidal volume is delivered.
223469007|NCT06047405|DEVICE|Bilevel Positive Airway Pressure Spontaneous Timed (BIPAP S/T)|A setting on noninvasive ventilator that allows setting of inspiratory pressure, inspiratory time, expiratory pressure, and backup rate to deliver variable tidal volumes.
224303928|NCT02038465|DEVICE|Questionary|Test the effectiveness of two techniques of cognitive remediation of autobiographical memory using an innovative tool called SenseCam ® for healthy volunteers
223578690|NCT03131596|PROCEDURE|IUB dilatation therapy|A Foley catheter (size 14fr) will be prepared by cutting the excess catheter tip protruding beyond the balloon prior to insertion into the uterine cavity. Once the catheter has reached the fundus, 3-4.5mls of saline will be slowly introduced into the balloon under ultrasound guidance, in order to directly visualize the distention of the cavity and division of any intrauterine adhesions, if present.
223578691|NCT05837858|OTHER|whole grain-wheat flour food+standardized meals|whole grain food made by 50 g whole grain wheat flour
223578692|NCT05837858|OTHER|refined wheat flour food+standardized meals|refined grain food made by 50 g refined wheat flour
224068716|NCT05726500|DIAGNOSTIC_TEST|Electrical impedance tomopgraphy|The researches will evaluate regional ventilation distribution using Electrical impedance tomography at different levels of positive end-expiratory pressure
223469008|NCT06422728|OTHER|Unified Protocol for Anxiety Disorders|"The UP is planned in group therapy format and includes interventions on common transdiagnostic features. The sessions in the protocol are planned as follows:~Session 1 - Assessment: introduction, talking on group rules and the process, setting goals~Session 2 - Psychoeducation: the CBT model is introduced.~Session 3 - Emotions: the role of emotions are discussed.~Session 4, 5 \& 6 - Thoughts: the role of thoughts is mentioned. The participants learn to challenge unfunctional thoughts and generate alternative explanations. Also, exercises on excessive worry are applied.~Session 7 - Behaviors: the role of behaviors and the things that can/cannot be controlled are discussed.~Session 8 - Evaluation \& Maintaining Accomplishments: includes a review of what has been learnt during the group therapy and an evaluation on maintaining the accomplishments.~Session 9 - Follow-up session: one month later."
223469009|NCT06422728|OTHER|Client-centered Supportive Therapy|Client-entered therapy provides a non-directive supportive environment for the participants, that includes reflective listening and nonjudgmental and empathic communication. In this group, no CBT intervention will be applied. Through the supportive and non-directive environment, only the effect of relationship will be investigated as a common factor in psychotherapy.
223469010|NCT04414007|BEHAVIORAL|Internet+ home-based cardiac rehabilitation|The Internet+ home-based cardiac rehabilitation group receive home-based cardiac rehabilitation program through Internet platform and intelligent wearable devices .
223578693|NCT01095120|DRUG|Tesetaxel|"For subjects in Cohort A, a flat dose of 40 mg will be administered in Cycle 1; the dose will be adjusted based on body weight. In subsequent cycles, depending on tolerability, the Cycle 1 flat dose may be increased by 5 mg in Cycle 2, and the Cycle 2 flat dose may again be increased by 5 mg in Cycle 3.~For subjects in Cohort B, a flat dose of 50 mg will be administered in Cycle 1; the dose will be adjusted based on body weight. In subsequent cycles, depending on tolerability, the dose may be increased by 10 mg in Cycle 2.~For subjects in Cohort C, a dose of 27 mg/m2 will be administered in Cycle 1. In subsequent cycles, depending on tolerability, the dose will be increased to 35 mg/m2 in Cycle 2."
223578694|NCT06957158|DIAGNOSTIC_TEST|Peripheral venous blood|Peripheral venous blood was collected before and after the surgery to measure the total serum calcium levels.
223578695|NCT06957158|DIAGNOSTIC_TEST|Arterial blood|Arterial blood was collected before anesthesia induction and after removal of the artificial airway to measure ionized calcium levels.
224068717|NCT00832559|BIOLOGICAL|CVA21|1, 3 or 6 doses of CAVATAK (10\^9 TCID50) at 48 hour intervals.
224068718|NCT05739786|DRUG|liq nitrogen|In Group A patients were subjected to liquid nitrogen cryotherapy (-196 0C) for 3 sessions at every 3 weeks interval. Effectiveness in was ascertained in terms of \> 50% reduction in wart size by an expert dermatologist on physical examination at the end of third session. Patients were followed for further 6 weeks after last session to look for any sort of recurrence and remission.
224068719|NCT05739786|DRUG|intralesional vitamin D3|Group B were subjected to vitamin D3 (5mg/ml) for 3 sessions at every 3 weeks interval. Effectiveness was ascertained in terms of \> 50% reduction in wart size by an expert dermatologist on physical examination at the end of third session. Patients were followed for further 6 weeks after last session to look for any sort of recurrence and remission.
224068720|NCT02365714|RADIATION|CK Stereotactic Accelerated Partial Breast Irradiation|Adjuvant radiation therapy will be delivered to the region of the lumpectomy cavity once daily for 5 treatments over 5-10 days.
224068721|NCT00870961|DIETARY_SUPPLEMENT|cholecalciferol|Given orally
224068722|NCT00870961|OTHER|placebo|Given orally
224068723|NCT00083993|DRUG|Temsirolimus (CCI-779) for 34 months|
224068724|NCT00083993|DRUG|Letrozole for 34 months|
224068725|NCT01797575|DRUG|Aspirin|aspirin 1000mg (2 capsules of 500mg) every morning in addition to his/her antidepressant and/or mood stabilizer medicine
224068726|NCT01797575|DIETARY_SUPPLEMENT|N-acetyl-cysteine (NAC)|taking N-acetyl-cysteine (NAC) 1000mg (2 capsules of 500mg) two times a day in addition to his/her antidepressant and/or mood stabilizer medicine
224068727|NCT01797575|DRUG|Sugar Pill|research subject will be taking placebo in addition to his/her antidepressant and/or mood stabilizer medicine
224068728|NCT03603821|DIAGNOSTIC_TEST|CLINICAL ASSESMENT|IPSS questionnaire, uroflowmetry, prostate and bladder ultrasonography, voiding diary, medical interview
224303929|NCT05174676|DEVICE|Dextreme|"A unique robotic device capable of applying motor error enhancement forces during upper limb practice in a virtual environment. The forces stimulate the body's instinctive adaptive response, which does not require the use of cognition to correct the movement.~The setting of stroke patients in a simulated environment enhances patient motivation and participation. The completion of games (tasks) is a great indicator for the patients that they are progressing in the treatment and are on their way to recovery."
224068729|NCT02826642|DRUG|IDH305|
224068730|NCT03704870|DIAGNOSTIC_TEST|Chest Xray|Daily chest xray
224068731|NCT03704870|DIAGNOSTIC_TEST|No daily chest xray|Chest xray will be done post chest tube removal only
223469011|NCT04414007|BEHAVIORAL|Conventional rehabilitation|We provide patients with cardiac rehabilitation manuals and exercise logs. 4 weeks after ablation，Patients have CPET.Their exercise prescription was made according to CPET .The patients have rehabilitation training at home and recorded their exercise data including exercise time、type、frequency and average heart rate.
223469012|NCT02815306|DEVICE|Polyaxial brace|The Polyaxial brace were made by a technician trained by the China National Disabled Persons Federation. For all patients, gypsum models were prepared first, and then braces were fabricated according to the models. The detailed technique was fully in accordance with the Ponseti method.
223469013|NCT01682824|OTHER|Nutritional Assessment|Complete dietary intake assessment
223469014|NCT01682824|OTHER|Questionnaire Administration|Complete TFEQ-R18v2 questionnaire
223469015|NCT01682824|OTHER|Questionnaire Administration|Complete EQ-EMA questionnaire
223469016|NCT02460510|DRUG|Mannitol|
223469017|NCT02460510|DRUG|3% hypertonic saline|
223469018|NCT05709665|OTHER|Time to Decision for eCPR|We evaluate during high quality CPR the time for decision for eCPR
223469019|NCT01192165|DRUG|Trametinib (GSK1120212)|Investigational small molecule targeted therapy (MEK1/2 inhibitor)
223469020|NCT01192165|DRUG|Docetaxel|Chemotherapy
223469021|NCT01192165|DRUG|Erlotinib|Small molecule targeted therapy (EGFR inhibitor)
223578696|NCT03143751|DRUG|NaCl20% (Continuous hyperosmolar therapy)|"Early intravenous administration (\<24 hours after traumatic brain injury) of NaCl20% for a minimal duration of 48 hours (continued for as long as is necessary to prevent intracranial hypertension)~1-hour bolus (15 g if Na+ \< 145 mmol/L; 7.5 g if 145 \< Na+ \< 150 mmol/L; or no bolus) followed by 1 g/hour as long as Na+\< 150 mmol/L, reduced to 0.5 g/L if 150 \< Na+ \< 155 mmol/L, Discontinuation when 155 mmol/L\<Na+"
223578697|NCT02491424|DEVICE|Direct skeletal fixation of ITAP to lower limb amputees.|Intraosseous Transcutaneous Amputation Prosthesis (ITAPTM) fitting. The core ITAP™ design comprises of three discrete sections, the proximal section, which is the intramedullary stem secured into the medullary canal, the soft tissue integration flange and the transcutaneous component that passes through the skin.
223578698|NCT02461316|OTHER|No intervention|No intervention administered in this study: Rituximab in combination with fludarabine and cyclophosphamide for 6 months according to registered indication.
223578699|NCT06195995|DEVICE|Transcranial alternating current stimulation-true stimulus|Three conductive electrodes are placed overhead. In the 10/20 international placement system, a 4.45 9.53 cm electrode is placed on the forehead corresponding to Fpz, Fp1 and Fp2. Two 3.18 3.81 cm electrodes are placed on the mastoid region of each side. The tACS stimulation waveform includes ramp-up and ramp-down periods of 180 and 12 s, respectively. The frequency of stimulation is 77.5Hz, and the current is 15mA.
223578700|NCT01551524|BIOLOGICAL|mPEG-r-crisantaspase|IV infusion over 60 minutes of mPEG-r-crisantaspase given once every two or four weeks for two administrations. Based on non-clinical data, 500IU/m2 has been selected as the starting dose. Dose selection will proceed based upon safety and pharmacokinetic data but escalation will not exceed 100%
223578701|NCT06219421|OTHER|Clinical data reuse|Clinical data reuse
223578702|NCT05397639|DRUG|Masupirdine 50 mg|Tablet, Once Daily
223578703|NCT05397639|DRUG|Masupirdine 100 mg|Tablet, Once Daily
223578704|NCT05397639|DRUG|Placebo|Matching Placebo Tablet, Once Daily
224303930|NCT06314880|BIOLOGICAL|Recombinant Meningococcal Group B Vaccine (E. Coli) (low-dose)|Each dose contains 60μg of MenB-fHBP-A and MenB-fHBP-B respectively. Administer one dose of 0.5mL each time. 20 people/group.
223469022|NCT01192165|DRUG|Pemetrexed|Chemotherapy
223469023|NCT01192165|DRUG|Carboplatin|Chemotherapy
223469024|NCT01192165|DRUG|nab-Paclitaxel|Chemotherapy
223469025|NCT01192165|DRUG|Cisplatin|Chemotherapy
223469026|NCT01565863|BEHAVIORAL|Progressive Goal Attainment Program|The Progressive Goal Attainment Program (PGAP) is a behavioral intervention originally developed in Canada at McGill University in order to increase return to work and community integration for individuals who receive worker's compensation. PGAP is the first disability program that is specifically designed to target the psycho-social risk factors of disability. The premise behind PGAP is that inactivity and attitudinal barriers increase work disability, and these issues are a primary cause of unemployment for individuals with physical and mental disabilities. PGAP is a structured, 10-week intervention that focuses upon helping clients develop a planned activity schedule to assist them in resuming desirable life activities.
223469027|NCT02064036|RADIATION|Stereotactic Radiosurgical Boost|Intensity Modulated Radiotherapy (IMRT)2 with Concurrent Androgen Blockade to Whole Pelvis, Prostate, and Seminal Vesicles Followed by: Stereotactic Radiosurgical Boost3 to the Prostate with Implanted Electromagnetic Transponder Beacon Intrafraction Guidance
223469028|NCT02064036|DRUG|Casodex|Neoadjuvant Androgen Blockade before radiation therapy and Adjuvant Androgen Blockade after radiation therapy
223469029|NCT02064036|DRUG|Leuprolide|Neoadjuvant Androgen Blockade before radiation therapy and Adjuvant Androgen Blockade after radiation therapy
223469030|NCT05811481|PROCEDURE|TACE|Transcatheter Arterial Chemoembolization
223469031|NCT05811481|DRUG|Regorafenib|Regorafenib alone
223469032|NCT00364065|DEVICE|Ferris PainWrap|
223469033|NCT06235671|PROCEDURE|Chiropractic care|6 weeks of chiropractic care
223469034|NCT00572091|DEVICE|PTMA Implant|Percutaneous assessment from right or left subclavian vein, with PTMA implant in the coronary sinus, great cardiac vein.
223469035|NCT04067869|PROCEDURE|Blood samples|Blood sample containing 3 ethylene-diamine-tetra-acetic acid tubes (7ml), 3 dry tubes (7ml) and 5 citrated tubes, ie 9 tubes
223469036|NCT02271321|OTHER|White noise|White noise is a simple, convenient, non-invasive and effective intervention. it sounds like the sound of running water, ocean or fan operation sounds. In this study, Subjects will receive 20 minute white noise of the ocean and the sound of running water at 16:00 to 17:00 for four weeks periods.
223469037|NCT00520143|BIOLOGICAL|alglucosidase alfa (recombinant human acid alpha-glucosidase [rhGAA])|IV infusion: 20mg/kg qow
223469038|NCT00782197|DEVICE|PRGF Intraarticular injection|Three consecutive PRGF injections each one week apart.
223469039|NCT00782197|DEVICE|Hyaluronic Acid Intraarticular injection|Three consecutive Hyaluronic acid (EUFLEXXA) injections, each one week apart.
223469040|NCT03674268|DIAGNOSTIC_TEST|Management of the Contraversive Pushing Scale|Scale of evaluation of trunk control and pushing behavior in patients with stroke.
223469041|NCT02091232|BIOLOGICAL|T Regulatory Cell Infusion|After blood is collected from the donor and recipient, the facility will sort out one particular kind of immune cell called a regulatory T cell which is strongly influenced by tolerance induction to minimize (suppress) responses to the donor cells. In this study, these regulatory T cells are the cells which will be given back to the recipient on Day 7 (+3 days) post-transplant.
223469042|NCT03468842|BIOLOGICAL|Probiotic|Already described
223578705|NCT02525406|OTHER|All surgeries performed from Jan 01, 2010 to Aug 31, 2020|
223578706|NCT06570642|BEHAVIORAL|Physical Activity Goals mHealth Intervention|On days participants plan to exercise, they engage in two daily goal sessions (morning and evening). Morning sessions provide an activity goal for the day and ask the participant to create a plan, anticipate barriers, and brainstorm solutions for achieving this goal. The affect-based goal condition asks participants to engage in either (1) a type (50% of daily goals) or (2) a context (50% of daily goals) of physical activity that allows them to experience positive affect. Goals focused on context are randomly generated to suggest that the participant performs activity (1) in a place; (2) in a social situation; or (3) while listening to something that makes them feel good. The intensity-based goal condition asks participants to maintain a certain target heart rate range during physical activity. Starting heart rate reflects the approximate age-adjusted heart rate max, with goals progressively increasing from 55% to 70% heart rate max.
223578707|NCT06570642|BEHAVIORAL|TYPE/CONTEXT enhancement|TYPE/CONTEXT augments intervention effects by providing tailored recommendations for activity types and contexts that satisfy personally-important psychological needs as rated by each participant at baseline. Ratings from a crowdsourced panel of adults on Amazon Mechanical Turk will be used to determine the potential for specific activity types and contexts to satisfy psychological needs; our tailoring algorithm will then recommend the corresponding activity type or context while accounting for reported constraints (e.g., ability, access). These details will be incorporated into a tailored recommendation provided to participants each Sunday as they make activity plans for the upcoming week. Specifically, the program will randomly select either type or context (i.e., location, audio, social) recommendations and will rotate every two weeks. For TYPE, participants' top 3 activity types are recommended; for CONTEXT, participants' top 3 activity contexts are recommended.
223743664|NCT07191457|DEVICE|Elimax Green Lotion with Emogreen|"STEP 1:~Apply the lotion to dry hair, completely saturating hair and scalp. Use a towel to cover eyes and exposed skin areas. Massage from the roots to the tips, paying particular attention to the area behind the ears and the hairline at the back of the head. Leave the lotion in the hair for 10 minutes (no longer). In the case of long hair, pin the hair up away from the skin after application.~STEP 2:~Wash out by applying shampoo to the hair and rinsing thoroughly. Repeat if needed to fully rinse out the lotion.~STEP 3:~Comb to remove lice and nits. Part the hair into sections and comb one section at a time. Place the teeth of the comb as close as possible to the scalp and comb away from the scalp to the end of the hair. Use clips to pin back each section of combed hair. Clean the comb during use by wiping onto a tissue. Discard the tissue into a sealable bag. Discard the sealed bag.~Check hair for the following 7 to 10 days. If lice or nits are present, repeat steps 1-3."
223743665|NCT07191457|DRUG|Walgreens Lice Killing Shampoo|"Apply thoroughly to dry hair or other affected area. For head lice, first apply behind ears and to back of neck Allow product to remain for 10 minutes, but no longer Use warm water to form a lather, shampoo, then thoroughly rinse For head lice, towel dry hair and comb out tangles Remove lice and their eggs (nits) Use a fine-tooth or special lice/nit comb. Remove any remaining nits by hand (using a throw-away glove) Hair should remain slightly damp while removing nits If hair dries during combing, dampen slightly with water For head lice, part hair into sections. Do one section at a time starting at the top of the head. Longer hair may take 1 to 2 hours. Lift a 1- to 2- inch wide strand of the hair. Place comb as close as possible to the scalp and comb with a firm, even motion away from the scalp.~Pin back each strand of the hair after combing Clean comb often. Wipe away nits with tissue and discard in a plastic bag. Seal bag and discard bag to prevent lice from coming back."
224068732|NCT04723121|DIAGNOSTIC_TEST|Urine ELISA for immunological markers (IL-2 and IL-10)|IL-2 and IL-10 levels were measured in the supernatants. Natural human-produced IL-2 and IL-10 concen¬trations were determined in the urine of all patients and controls by solid phase ELISA Quantikine IL-2 Immunoassay and IL-10 Immunoassay, respectively
224068733|NCT04723121|DIAGNOSTIC_TEST|Reverse transcriptase-quantitative polymerase chain reaction (RT-qPCR) analysis|blood samples using QIAamp® RNA Blood Mini kit (QIAGEN, USA). 1 μg of total RNA was reverse transcribed with random primers, using High Capacity cDNA Archive Kit (Applied Biosystems, Foster City, CA, USA). RT-qPCR analysis was carried out with SYBER Green PCR Master Mix (Applied Biosystems, Foster City, CA, USA). Primers for TNF-α, CTLA4, T-bet+, GATA3+, FoxP3+ and GABDH as PCR control
223469043|NCT03468842|BIOLOGICAL|Placebo|Placebo
223469044|NCT02099513|DEVICE|The Mobile Health Platform|
223469045|NCT04654013|DEVICE|Spectacles|Intervention group workers receive free glasses within one week of undergoing vision assessment (May 2022). The duration of the treatment for the Intervention participants will depend on when they leave employment at the factor. If they stayed for the full duration of the trial, they will have undergone a maximum of 18 months (December 2023).
223469046|NCT01893606|DRUG|N-acetyl-D-glucosamine|
223469047|NCT01893606|DRUG|placebo|
224068734|NCT03413930|PROCEDURE|Transanal total mesorectal excision|Patients undergo transanal total mesorectal excision.（assisted by laparoscopy to control the IMA）
224068735|NCT03413930|PROCEDURE|Laparoscopic total mesorectal excision|Patients undergo Laparoscopic total mesorectal excision.
224068736|NCT03490643|OTHER|Postural Analysis|posture and plantar pressure analysis
224068737|NCT03490643|OTHER|plantar pressure analysis|posture and plantar pressure analysis
223469048|NCT06521177|OTHER|Hand Serum and Glove|Participants will apply the Hand Serum to both hands daily for 8 weeks. During Weeks 7-8, participants will also wear a glove on one hand. The intervention aims to improve skin health and appearance on the hands, assessed through questionnaires and expert skin grading.
223469049|NCT03986099|DIAGNOSTIC_TEST|Monitoring virus load|Near point of care
223469050|NCT06360861|BIOLOGICAL|Allogenic placenta derived mesenchymal stem cells|Allogenic placenta derived mesenchymal stem cells, 3 million cells/kg body weight via intravenous injection.
223469051|NCT03439137|DRUG|MT-6548|Oral tablet
223469052|NCT03439137|DRUG|Darbepoetin alfa|Intravenous administration
223469053|NCT03439137|DRUG|MT-6548-matching placebo|Oral tablet
223469054|NCT03439137|DRUG|Darbepoetin alfa-matching placebo|Intravenous administration
223469055|NCT02517281|PROCEDURE|Biopsy|
223469056|NCT06375551|BEHAVIORAL|Optimizing Responses with Collaborative Assessments-Automated (ORCA-A)|"Participants will receive automated facilitation in the ORCA platform. This will entail prompts for group discussion based on group model building scripts and decision hygiene approaches proposed by Kahneman, Sibony, and Sunstein (2021). Participants will have the option of using these prompts to discuss ORCA results in group decision discussions.~Optimizing Responses with Collaborative Assessments (ORCA) is a technical decision support tool based in multi-criteria decision analysis. Decision makers rate and compare evidence-based programs or other practices with ORCA, then prioritize practices for local implementation based on ORCA results. ORCA will be on a virtual platform to allow for web-based completion, automated analysis, and automated facilitation."
224159370|NCT02782104|DRUG|Esketamine Nasal Spray|Open-Label Induction Phase: Participants will self-administer with esketamine nasal spray twice per week for 4 weeks as a flexible dose regimen (56 milligram \[mg\] or 84 mg for those \< 65 years; 28 mg, 56 mg or 84 mg for those \>= 65 years). Participants \>= 65 years old will start at a dose of 28 mg on Day 1. Optimization/Maintenance Phase: Participants entering from studies ESKETINTRD3001 (NCT02417064), ESKETINTRD3002 (NCT02418585) or ESKETINTRD3006 (US sites only) will self-administer esketamine nasal spray (same dose) once weekly. Participants entering from study ESKETINTRD3005 (NCT02422186) will self-administer esketamine nasal spray (28 mg in week 1; 28 or 56 mg in week 2; and 28, 56 or 84 mg in week 3 and 4) once weekly. After Week 4 (starting at Week 5), based on the Investigator's clinical judgment, the dose of esketamine for all participants can be adjusted based upon efficacy and tolerability.
224159371|NCT03185819|DRUG|Intranasal Placebo|Participants will receive placebo as intranasal dose to match intranasal esketamine.
224159372|NCT03185819|DRUG|Midazolam Placebo Solution|Participants will receive placebo as oral dose to match midazolam drug.
223469057|NCT06375551|BEHAVIORAL|Optimizing Responses with Collaborative Assessments-Live (ORCA-L)|"A facilitator will guide group decision discussions using group model building scripts and decision hygiene approaches proposed by Kahneman, Sibony, and Sunstein (2021). Facilitation will be either in-person or virtual, but occur live as in during real-time.~Optimizing Responses with Collaborative Assessments (ORCA) is a technical decision support tool based in multi-criteria decision analysis. Decision makers rate and compare evidence-based programs or other practices with ORCA, then prioritize practices for local implementation based on ORCA results. ORCA will be on a virtual platform to allow for web-based completion, automated analysis, and automated facilitation."
223469058|NCT00848016|DRUG|R-(-)-gossypol acetic acid|Participants take 20mg oral R-(-)-gossypol acetic acid once daily on days 1-21. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
223469059|NCT04816916|DRUG|AXA1665|AXA1665 administered TID with food
223469060|NCT04816916|DRUG|Placebo|Matching placebo administered TID with food
223469061|NCT04866576|DIETARY_SUPPLEMENT|Q CAN PLUS|Active powder with fermented soy, 2 pouches per day, each pouch contains 12-15 gms of fermented soy
223469062|NCT04866576|DIETARY_SUPPLEMENT|Placebo|Maltodextrin powder with Whey protein and flavor (provided by BESO Biological Research, Inc.)
223578708|NCT06570642|BEHAVIORAL|SAVOR enhancement|SAVOR implements a brief savoring exercise on the smartphone that takes place either after the planned physical activity session or during the evening goal session (after the self-monitoring module). Participants will respond to questions that are intended to enhance and prolong positive experiences during physical activity. To trigger attentional deployment, a common savoring strategy that involves intensifying experiences by focusing on them, participants will answer three open-ended prompts. These prompts are drawn from a prompt pool with slightly varied wording to promote a sense of novelty. Savoring prompts will rotate daily and have a day lag built in every week (i.e., Week 1 Monday Savoring Prompts are Week 2 Tuesday Savoring Prompts).
223578709|NCT04411420|BEHAVIORAL|Pain modulation with physical pain treatment|Examples of pain modulation with physical pain treatment include spinal manipulation, massage, or transcutaneous electrical nerve stimulation
224068738|NCT05521230|DRUG|Placebo Mouthwash|Application of mouthwashes
224068739|NCT05521230|DRUG|Cymenol mouthwash|Application of mouthwashes
224068740|NCT04312490|DIAGNOSTIC_TEST|endomyocardial biopsy|Endomyocardial biopsies will be stained with Masson's trichrome as well as Giemsa and examined by light microscopy. For immunohistology, tissue sections will be treated with an avidin-biotinimmunoperoxidase method (Vectastain-Elite ABC Kit, Vector, Burlingame, Calif), with application of the following monoclonal antibodies: CD3 (T cells; Novocastra Laboratories, Newcastle, UK), CD68 (macrophages, natural killer cells; DAKO, Hamburg, Germany), and HLA-DR-α (DAKO, Hamburg, Germany
224159373|NCT03185819|DRUG|Midazolam|Participants will receive midazolam solution 0.125 mg/kg as oral dose to match placebo.
224159374|NCT03185819|DRUG|Esketamine|Participants will receive esketamine at a dose of 28 mg as intranasal solution.
224159375|NCT03185819|DRUG|Esketamine|Participants will receive esketamine at a dose of 56 mg as intranasal solution.
224159376|NCT03185819|DRUG|Esketamine|Participants will receive esketamine at a dose of 84 mg as intranasal solution.
224159377|NCT02438787|DRUG|Placebo|Placebo subcutaneous (SC) injection at Weeks 0, 4, and 16 in Group 1.
224303931|NCT06314880|BIOLOGICAL|Recombinant Meningococcal Group B Vaccine (E. Coli) (hign-dose)|Each dose contains 100μg of MenB-fHBP-A and MenB-fHBP-B respectively. Administer one dose of 0.5mL each time. 20 people/group.
224303932|NCT06314880|BIOLOGICAL|Placebo control|Placebo control. 20 people/group.
224303933|NCT00415844|DRUG|ELC200 (carbidopa+levodopa+entacapone)|
224303934|NCT04331444|DEVICE|CGM|Using the CGM during the entire study period of 12 months.
223469063|NCT01297686|OTHER|Karaoke Exercise|lateral side step movement involving crossing one foot over the next for 5 sets of 15 cross-overs in each direction
223469064|NCT01297686|OTHER|Balance walking exercise|Walking along a straight line on the ground, for 5 sets of 30 strides
223469065|NCT01297686|OTHER|Forefoot extension exercise|The subject stands feet shoulder width apart with one foot ahead of the other and then contracting only calf muscles of the back leg, lifts the heel of the back leg until the metatarsophalangeal joint of that foot is maximally extended. The subject is instructed to concentrate on maintaining balance on the back leg over the first and second metatarsophalangeal joints throughout movement for 5 sets of 15 repetitions.
224159378|NCT02438787|DRUG|Ustekinumab 45 mg|Ustekinumab 45 mg SC injection at Weeks 24 and 28 followed by every 12 weeks (q12w) dosing, with the last administration of study agent at Week 52 in Group 1. Participants will start with ustekinumab 45 mg SC injection at Weeks 0 and 4, followed by q12w dosing, with the last administration of study agent at Week 52 in Group 2.
223469066|NCT01297686|OTHER|Standing one-legged balance exercise:|This exercise is performed initially with eyes open, then with mastery exhibited by being able to hold balance and not touch the ground with contralateral leg performed with eyes closed, then on an unstable surface with and without eyes open for 1 minute.
224159379|NCT02438787|DRUG|Ustekinumab 90 mg|Ustekinumab 90 mg SC injection at Weeks 24 and 28 followed by q12w dosing, with the last administration of study agent at Week 52 in Group 1. Participants will start with ustekinumab 90 mg SC injection at Weeks 0 and 4, followed by q12w dosing, with the last administration of study agent at Week 52 in Group 3.
223578710|NCT04411420|BEHAVIORAL|Telephone delivered self-management counseling for increasing physical activity|Centrally located physical therapy assistants will provide six weeks of telehealth consults to increase physical activity for the patient
223578711|NCT04411420|BEHAVIORAL|Telephone delivered behavioral treatment for participants with high risk for continued disability|Patients with a higher risk of developing chronic or persistent back pain will be identified using the nine question risk stratification start back screening tool (SBST) and will receive six additional weeks of physical activity instructions and additional pain modulation treatments as needed.
223578712|NCT04411420|BEHAVIORAL|Patient preference treatment protocol|the pain navigator will work through a shared decision making process with the patient to determine the preferred treatment protocol
223578713|NCT04411420|BEHAVIORAL|Nonpharmacological guideline adherent treatment protocol|the pain navigator will select only nonpharmacological guideline adherent treatment options for the patient
223578714|NCT04411420|BEHAVIORAL|Facilitated referrals to existing VA or non-VA pain management resources|the pain navigator will work with the referring physician to select only existing VA or non-VA pain management resources for the patient.
224068741|NCT03603496|BEHAVIORAL|Transitional Tobacco Care Management (TTCM)|PTCM will provide sustained care after discharge by offering (1) 8 weeks of nicotine replacement therapy at no cost provided at hospital discharge and (2) up to 7 proactive contacts over 3 months delivered by automated IVR call, supplemented by text messaging and email (patient choice). At each contact the patient is offered a return call from the hospital-based tobacco coach who offer counseling, medication advice, and coordination of care with the patient's outpatient health care team.
224068742|NCT03603496|BEHAVIORAL|eReferral to State Tobacco Quitline (QL)|Referral from hospital to the state Quitline will be made by the research team on behalf of each enrolled patient. Feedback from the Quitline will be included in the patient's medical chart.
224068743|NCT03603496|DRUG|Nicotine replacement therapy|Up to 8 weeks of nicotine replacement therapy provided at no cost to the patient.
224159380|NCT02438787|DRUG|Golimumab 50 mg|Participants who meet EE criteria (less than \[\<\] 10 percent \[%\] improvement from baseline in both total back pain and morning stiffness measures at both Week 12 and Week 16) will be administered open-label golimumab 50 mg SC administrations at Week 16 and every 4 weeks (q4w) thereafter through Week 52 in Group 1, 2 and 3.
224303935|NCT04331444|BEHAVIORAL|training course|The participants in the three groups will attend a three-hour training course with different content depending on the group allocation. The aim of this training course is to ensure that the participants have the knowledge, support and confidence to work collaboratively with their HCPs to increase TIR and decrease HbA1c.
224303936|NCT04331444|BEHAVIORAL|Peer-support|The peer-support will be facilitator-led by the primary investigator with peer exchange in group sessions (3 sessions over the study period, 3 hours per session) with 6-8 participants in every group.
224303937|NCT04884867|BEHAVIORAL|CBT-based supportive skills delivered by phone by lay coaches|8-10 weekly coaching sessions delivered by telephone
224303938|NCT04188301|DRUG|IVM w/ ALB|Participants will be given a single dose of oral IVM (150 µg/kg) plus ALB (400 mg) (IVM/ALB)
223578715|NCT04424927|BIOLOGICAL|PRV-015|Fully human monoclonal antibody against interleukin 15 (IL-15)
223578716|NCT04424927|OTHER|Placebo|Placebo
223578717|NCT05313529|DRUG|Liraglutide|Liraglutide will be titrated from 0.6mg/day to 1.8mg/day during the first 2 weeks, if well tolerated. All patients will also continue on their existing dose and regimen of metformin throughout the study
224068744|NCT05344521|DEVICE|Integra®|A commercially available dermal bovine matrix that is widely used for wound and burn care, Integra® Dermal Regeneration Template licensed device (Medical Device Active License Listing No. 229).
224068745|NCT05344521|DEVICE|Integra®-SC|A combination of Integra® incorporated with 5,000-20,000 cells/cm2 of autologous burned derived stem cells.
224159381|NCT06527196|BEHAVIORAL|Team Communication Training|Participants in the experimental arm will receive enhanced Team Communication Training developed during Aim I of the trial. This will occur over a period of six months.
224159382|NCT06527196|BEHAVIORAL|Early Identification Universal Depression Screening|Providers in the early identification universal depression screening condition will be asked to continue communications and response to depression screening as currently implemented.
224159383|NCT02907086|OTHER|blood collection|Patients will receive a research draw for circulating tumor material analysis with standard clinical labs
224159384|NCT00220584|DRUG|donepezil|donepezil 5 mg daily for 3 weeks (days 1-21); 10 mg daily for 3 weeks (days 22-42)
224159385|NCT00479349|DRUG|SAM-531|Multiple ascending doses of SAM 531: 1,5; 3 and 5 mg.
223469067|NCT01297686|OTHER|Ankle inversion/eversion exercise|The foot is placed sideways at the edge of a step. After stabilizing the remainder of the foot and leg, the ankle is inverted and everted to the limits of the range for 3 sets of 15 repetitions.
223743666|NCT07189429|DIAGNOSTIC_TEST|PA-100 AST|Results of the PA-100 AST were made available to the treating physician
224068746|NCT05382832|COMBINATION_PRODUCT|SCS|SCS-experimental treatment
224068747|NCT05382832|COMBINATION_PRODUCT|SCS|SCS-placebo
224068748|NCT01441531|DRUG|gabapentin 600 mg po|Given one hour before surgery
224068749|NCT01441531|DRUG|Placebo pill given one hour before surgery|Placebo pill given
224159386|NCT00732641|DRUG|Peginterferon|Peginterferon α-2b 35 μg, weekly, subcutaneous (SC), until disease progression or relapse, or for up to a maximum of 5 years.
223469068|NCT01297686|OTHER|Gastrocnemius and soleus stretching|This stretch is performed while standing in a neutral position and the knee extended the foot is placed on top of a ramp or phone-book elevating the forefoot on the rearfoot (talocrural dorsiflexion) and held for 3 sets of 30 seconds each. Next the foot is again placed on top of a phone-book with the knee flexed approximately 15-20 degrees and held for 3 sets of 30 seconds each.
223469069|NCT01297686|OTHER|Tissue-specific plantar fascia self massage|This deep massage is performed in a sitting position the right foot is crossed over the left while one hand passively extends the right forefoot. The left hand then applies light to moderate pressure in 3-5 second intervals along the length of the medial longitudinal arch. Same procedure is then repeated for the left foot.
223469070|NCT01297686|DRUG|Dexamethasone|"A 22-gauge, 1.5 needle and 3 cm syringe filled with 1ml of dexamethasone mixed with 0.5ml of 1% lidocaine. Prior to injection, the skin will be sterilized with povidone-iodine. The needle is inserted 2-3 cm anteromedial to the focal point of pain in the inferior heel near the calcaneal tuberosity and moved toward the tenderest area."
223469071|NCT05087589|DRUG|Tofacitinib|Tofacitinib 5mg was taken orally twice a day for 6 months
223469072|NCT04671199|OTHER|MP 3000 monitor|Additional monitoring
223469073|NCT01240382|DRUG|3% DE-089 ophthalmic solution|
223469074|NCT01240382|DRUG|0.1% sodium hyaluronate ophthalmic solution|
223469075|NCT05746806|RADIATION|Ultrahypofractionated salvage radiotherapy to a local recurrence after radical prostatectomy|Ultrahypofractioned radiotherapy for patients with isolated local recurrence after radical prostatectomy in 5 fractions
223469076|NCT05746806|DRUG|Androgen deprivation therapy|"In combination to the radiotherapy a short term androgen deprivation drug for 6 months will be applied.~The preferred drug concept used is:~\- LHRH(Luteinizing hormone releasing hormone)-agonist with 3-month subcutaneous depot injection (e.g. Pamorelin® LA (Triptorelin) 11.25mg s.c.) in combination with nonsteroidal antiandrogen (e.g. Bicalutamide 50mg/day) as flare protection at least 5 days before and max. 15 days after first LHRH-injection~Alternatively the following oral drug concept can be used, if the patient rejects injections:~\- GnRH (gonadotropin-releasing hormone)-antagonist with tablet intake for 6 months (e.g. Orgovyx® Tablets 120mg; first day 360mg, after second day 120mg per day)"
223469077|NCT06029972|DRUG|Tilpisertib Fosmecarbil|Tablets administered orally
223469078|NCT06029972|DRUG|Placebo|Tablets administered orally
223469079|NCT02456727|PROCEDURE|Group/Community Acupuncture|Acupuncture treatment in a group setting.
223469080|NCT02456727|PROCEDURE|Individual Acupuncture|Acupuncture treatment in an individual setting.
223469081|NCT00346866|DRUG|anecortave acetate|
223469082|NCT01616043|PROCEDURE|Glyaderm|acellular dermis
223469083|NCT01616043|PROCEDURE|STSG|autologous split skin only
223469084|NCT02643693|OTHER|P3L|"Ad libitum use for a maximum of three hours.~P3L delivers, on average, 80 µg of nicotine per puff under Health Canada Intense smoking regime."
223469085|NCT02643693|OTHER|VUSE|"Ad libitum use for a maximum of three hours.~VUSE delivers, on average, 80 µg of nicotine per puff based on the CORESTA e-cigarette recommended smoking regime."
223469086|NCT02643693|OTHER|CC|Ad libitum use of the subject's own brand of non-menthol CC for a maximum of three hours.
223469087|NCT00016536|DRUG|Naphthalene 2-sulfonate polymer|
223469088|NCT00016536|DRUG|Carbopol polymer|
223469089|NCT03693196|OTHER|PICF, Perio-paper®|PICF was collected from the mesio-buccal area of the implant by using paper tapes. Paper tapes were placed 1-2 mm inside the peri-implant sulcus by using a dental tweezer. After they were kept for 30 s, the paper tapes were placed in sterile microcentrifuge tubes which contained 200 µL phosphate-buffered saline (PBS). The tubes were kept at -80°C until the analysis day. TNF-α, PGE2, RANKL, RANK, and OPG, which are immunological markers of peri-implant disease were compared between groups.
223469090|NCT03693196|OTHER|Subgingival Plaque, Hu-Friedy®|Subgingival plaque samples were collected about 15 min after PICF was collected. Supragingival plaque was carefully removed by using a sterile scale. Implants were isolated using cotton rolls and dried with an air spray. Subgingival plaque samples were collected from the mesio-buccal area of the implant by using sterile plastic Gracey curettes during 30 s (Hu-Friedy). The samples collected were transferred to sterile microcentrifuge tubes containing 200 µL PBS. The tubes were kept at -80°C until the analysis day. Porphyromonas gingivalis, Treponema denticola, Tannerella forsythia, Fusobacterium nucleatum, Prevotella intermedia, and Streptococcus oralis, which are microbiological agents of peri-implantitis were compared between groups.
223469091|NCT03693196|OTHER|Williams probe, PCPNU-15 Hu-Friedy®|Clinical periodontal measurements were recorded using Williams probe. The plaque index, gingival index, pocket depth, bleeding on probing, clinical attachment level, and keratinised tissue width around the implant were recorded. The implants included were categorised into three groups, namely, healthy, peri-implant mucositis, and peri-implantitis. Panoramic radiographs were acquired to assess the interproximal bone levels around the implant.
224068750|NCT02026609|OTHER|Oral glutamine challenge|Blood ammonia determination before, 30-, 60-, and 90-minute, after intake of 10 g of L-glutamine
224068751|NCT02026609|OTHER|Psychometric Tests|PHES (portosystemic hepatic encephalopathy score) and ICT (inhibitory control test)
223469092|NCT03693196|OTHER|Demographic|Age, gender and state of smoking were compared between groups.
223469093|NCT06063889|DIAGNOSTIC_TEST|Maximal Rate of Force Development Test for Ankle Muscles|This test is designed to measure the maximal rate of force development in the ankle muscles, specifically the plantar flexors. It aims to assess the relationship between the strength of these muscles and the functional ability in patients with knee osteoarthritis. The results from this test will help to understand how lower limb muscle strength influences the symptoms and progression of knee osteoarthritis.
223469094|NCT02758782|BIOLOGICAL|Golimumab|
223469095|NCT02758782|DRUG|Celecoxib|
223743667|NCT07190729|DEVICE|Propofol sedation + Audiovisual distraction|The participants will receive standard propofol sedation procedure and the mask -RV Deepsen™
224068752|NCT00261872|DRUG|Methylphenidate|
224068753|NCT02022488|DRUG|midazolam|Group M
224068754|NCT02022488|DRUG|alfentanil|Group MA
224068755|NCT02022488|DRUG|ketamine|Group MK
224068756|NCT02806297|PROCEDURE|Early cholecystectomy with IOC|The intervention will be laparoscopic cholecystectomy with intraoperative cholangiogram (IOC) on admission within 24 hours of presentation regardless of whether pain or tenderness are present or laboratory values are elevated.
223469096|NCT05804812|BEHAVIORAL|laughter therapy|Assigned Interventions Laughter therapy session will be applied online for 25-30 minutes once a week for 2 months by the researcher who has the Laughter therapy certificate to the application group. In the laughter therapy session, the practices of introducing the practitioner and introducing the therapy, breathing exercises for a healthy life, keeping the rhythm accompanied by music, turning the laughter that started as if it were childlike games into reality will be carried out.
223469097|NCT00888654|DRUG|B-Dim|B-DIM 225 mg orally twice daily x 14-72 days (based on scheduling of surgery)
223469098|NCT00888654|PROCEDURE|Radical Prosatectomy|
223578718|NCT05313529|DRUG|Empagliflozin|Empagliflozin will be initiated and maintained at 10mg/ day every morning until the completion of the study. All patients will also continue on their existing dose and regimen of metformin throughout the study.
223578719|NCT05313529|DRUG|Linagliptin|Iinagliptin will be initiated at 5mg/ day every morning until the completion of the study. All patients will also continue on their existing dose and regimen of metformin throughout the study.
223578720|NCT05538988|DRUG|Cemiplimab|Cemiplimab is a recombinant human IgG monoclonal antibody known as a programmed cell death 1 (PD-1) immune checkpoint inhibitor. The PD-1 pathway is an immune system checkpoint that may be exploited by tumour cells to escape active T-cell surveillance. Cemiplimab binds to PD-1 on T cells and blocks the interaction with its ligands, PD-L1 and PD-L2. Inhibition of the receptor/ligand signaling restores the anti-tumour immune response
223578721|NCT05053841|DRUG|Metformin|
223578722|NCT05013268|DRUG|Tislelizumab, paclitaxel/docetaxel, cisplatin/carboplatin|"* Drug: Tislelizumab 200mg, d1, ivgtt, every 3 weeks, for 3 cycles~* Drug: Paclitaxel; docetaxel Dose: 175mg/m2 d1; 75mg/m2 d1, every 3 weeks, for 3 cycles Other Name: none~* Drug: Cisplatin; Carboplatin Dose: 75mg/m2 d1; AUC=5, d1, every 3 weeks, for 3 cycles Other Name: none"
223578723|NCT05063266|OTHER|Deep Breathing Exercise|control groups received deep breathing exercise 6 days a week for two weeks. Deep breathing exercises includes diaphragmatic breathing and pursed lip breathing.
223578724|NCT05063266|OTHER|Inspiratory muscle Training|Treatment group received inspiratory muscle training 20 minutes 6 days a week for two weeks.IMT was done by using pressure threshold device.
223578725|NCT00340379|DRUG|Ziprasidone|Target dosage 120-160mg/day based on tolerance
223578726|NCT00340379|DRUG|Sertraline|Target dosage 150-200mg/day based on tolerance.
223578727|NCT00340379|DRUG|Haloperidol|Target dosage 6-8mg/day based on tolerance.
223578728|NCT02008422|DRUG|Oxaliplatin|130mg/m2 , iv, 3-4h, d1, 21 d as a cycle.
223578729|NCT02008422|DRUG|Gimeracil and Oteracil Potassium Capsule|40 mg/m2, po., Bid., d1-14, 21 d as a cycle.
223578730|NCT02008422|DRUG|Endostar injection|7.5 mg/m2/d, 2 mL/h continuous pumping into vein, d1-10, 21 d as a cycle.
223578731|NCT05351268|RADIATION|Radioactive seed brachytherapy|The radioactive Iodine-125 seed can release low dose of irradiation persistently which kills tumors cell and causes less damage to normal tissue at the same time. The treatment was performed under CT monitoring. 3D-printing coplanar template includes information on the path of the implantation needle, the needle path can be controlled accurately which can make the operation more accurate.
223578732|NCT05662852|BIOLOGICAL|Tdap|Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed Suspension manufactured by Sanofi Pasteur
223578733|NCT05467592|OTHER|Standard Physical Therapy care|All therapy will be given as it would have routinely been administered in the clinic. Standard care for all patients includes physical therapy and chiropractic treatment at each visit. There is a nurse practitioner on site. If necessary, patients can receive trigger point injections to the musculature around the back and neck, platelet rich plasma, or headache injections by the nurse practitioner. These interventions vary on a case by case basis. Involvement in the study will not impact the patients plan of care. We will collect this information as confounders and factor into statistical analysis.
223578734|NCT06265623|OTHER|No active intervention, but observational follow-up|Patients remain in usual care by their pulmonary medicine specialists and are being observed during annual follow-up investigations during up to 3 years
223578735|NCT06507800|OTHER|Observational cohort|Cancer incidence after AHSCT for an autoimmune indication.
223578736|NCT05713539|OTHER|Metal block|Small sheet of copper will be used when cooled to the designated temperature
223578737|NCT02048410|DIETARY_SUPPLEMENT|Lactobacillus paracasei B21060|combination of probiotic (Lactobacillus paracasei B21060) and prebiotics (arabinogalactans, xyloooligosaccarides) and amine (L-glutamine)
224068757|NCT02806297|PROCEDURE|Late cholecystectomy with IOC|The control will be laparoscopic cholecystectomy with IOC once the patient has met the following criteria: (a) a score of less than 2 on the Visual Analogue Pain Scale, (b) no tenderness on physical exam, and (c) decreased lipase to either less than half of the peak value or within normal range (73-393 U/L).
224159387|NCT00732238|OTHER|Shortened course of antibiotic therapy|By obtaining a urine culture from a newly inserted catheter we hope to find the true urinary pathogen. In so doing we feel a shorter but pathogen specific course of antibiotic therapy will more successfully prevent urinary tract infection relapse.
223578738|NCT02048410|OTHER|low satured diet|
223578739|NCT02947399|RADIATION|Radioactive Iodine 124|After thyroid hormone withdrawal for 3-5 weeks, a dose of radioactive iodine 124 ( I-124) 1.7 mCi is administrated orally and PET imaging is done for 5 continuous days including the day of the dose administration. On each day, just before imaging, 5 ml of blood is drawn.
223743668|NCT07190729|OTHER|Propofol sedation|The participants will receive standard propofol sedation procedure
223743669|NCT07191067|DEVICE|Pulsed radiofrequency|Pulsed radiofrequency will be applied to the femoral and sciatic nerves prior to TKA.
223743670|NCT07191067|DEVICE|Non-therapeutic stimulation|Electrical square wave stimulation performed to mimic the duration of the active arm and mimic the procedure for blinding purposes.
224068758|NCT03669458|DEVICE|Below the Knee peripheral intervention|Treatment of infrapopliteal disease using SPUR/DCB, SPUR only and DCB alone
224068759|NCT03419715|DRUG|Bimatoprost Topical Solution|One drop of bimatoprost topical solution is applied daily to the lunula region of the fingernail bed
224159388|NCT00732238|OTHER|Standard Therapy|Patients entered into this arm of the study will receive the standard duration of antibiotic therapy, which will be determined by urine culture results obtained from existing urinary catheter.
224159389|NCT04883918|BIOLOGICAL|ASC930|4 intravenous doses of ASC930
223469099|NCT04758728|PROCEDURE|Great saphenous vein stripping and varicectomies|Removal of the great saphenous vein (partially - from just below the knee up to the saphenofemoral junction) by two 3cm skin and subcutaneous fat incisions and the introduction of a conventional vein stripper device, under general or epidural/regional anesthesia. Removal of varicose veins of the lower limb by 0,5cm skin incisions and the use of a conventional phlebectomy stainless steel hook. Mechanical hemostasis by direct compression of the thigh for 10 minutes.
223469100|NCT04758728|DRUG|Epinephrine Topical|Use of epinephrine/adrenaline solution 1:1000 topically
223469101|NCT04758728|DRUG|normal saline|Use of normal saline solution NaCl 0,9% topically
223469102|NCT00055341|DRUG|Peginterferon alfa-2a|
223578740|NCT00946907|DRUG|Aspirin|3000mg/day of aspirin during the 4th first days and 2000mg/day of aspirin during the 17th following days
223469103|NCT00055341|DRUG|Ribavirin|
223469104|NCT05262920|BEHAVIORAL|The BSM Intervention|The BSM intervention entailed a daily electronic journal for monitoring BF and BNP with feedings, bi-weekly texting for 6 weeks from a research nurse for informational support and to promote personalized goal-setting and problem-solving, and hyperlinks to eight uniform BNP educational modules (knowledge and skills) and online resources. 1. Fundamentals of BF (FBF), 2. Deep breathing (DB), 3. BNP non-pharmacological strategies (BNPS), 4. Guided imagery (GI), 5. Pain neurophysiology specifically related to BF (PN-BF), 6. Catastrophizing, 7. Stress reactivity, and 8. Common pumping issues and interventions (CPI).
223469105|NCT05262920|BEHAVIORAL|Attention Control|The Attention Control and Intervention groups both receive fourth-trimester care videos. The educational modules are the following: Urgent maternal warning signs, caring for the maternal body after birth; infant care; COVID-19 and infant health prevention; maternal and infant immunization; infant safety in the home; maternal and infant dietary recommendations; and national and health resources to support BF in the workplace
223469106|NCT00676117|DRUG|Esomeprazole (D961H)|20mg
223469107|NCT00676117|DRUG|Loxoprofen|60mg tablet
223469108|NCT01711697|RADIATION|stereotactic body radiation therapy|Undergo SBRT
223469109|NCT01711697|DRUG|carboplatin|
223578741|NCT00946907|DRUG|placebo|3000mg/day of aspirin during the 4th first days and 2000mg/day of placebo during the 17th following days
224068760|NCT03419715|DRUG|Control|One drop of saline solution is applied daily to the lunula of the fingernail bed on one hand.
224159390|NCT02910089|BEHAVIORAL|Shared Decision Making|This prospective study will include 700 beneficiaries of Horizon Blue Cross Blue Shield of New Jersey (BCBSNJ).
223469110|NCT01711697|DRUG|paclitaxel|
223469111|NCT01711697|RADIATION|radiation therapy|Undergo radiation therapy
223469112|NCT05295381|DEVICE|cough machine (CM)|Cough machine training is based on the cough assist machine Comfort Cough II (CC20), in which the inhalation and exhalation times are adjusted to 1-3 seconds, and the positive and negative pressure of the lower pressure 10-15 cmH2O is gradually increased to 30-40 cmH2O for the first time, 4-6 cycles/time, repeated 4-6 times, twice a day, five days a week, until the subject is weaned off the ventilator or transferred out of the ward. A modified Borg scale was used as an indicator of perceived dyspnea.
223578742|NCT03247127|RADIATION|Hippocampal avoidance whole brain radiotherapy|Planning target volume(PTV) for whole brain is Whole brain parenchyma plus2mm margin excluding metastases and HA region, 30Gy in 10 fractions will be delivered to PTVwhole brain. Bilateral Hippocampus will be contoured according to Radiation Therapy Oncology Group 0933 and hippocampal avoidance region is Hippocampi + 5mm margin. According to Radiation Therapy Oncology Group 0933 trial, dose to 100% of the hippocampus could not exceed 9 Gy, and maximal hippocampal dose could not exceed 16 Gy; dose to 100% of the hippocampus exceeding 10 Gy
224159391|NCT04212403|DRUG|Levofloxacin|The control group receives AMP.
224159392|NCT00736606|DRUG|simvastatin|One single dose of 40mg
223578743|NCT05205655|BEHAVIORAL|collection of odour samples|Odours will be collected by participants by putting sterile compresses under the armpits for at least 4 h.
223578744|NCT03481426|OTHER|Workplace intervention|The study contains normal services of occupational health. Both intervention groups are based on voluntary will, and the normal care and services are guaranteed. In the intervention group new working method which improve co-operation between occupational health services and workplaces.
223578745|NCT03769311|DRUG|Cetuximab|Monoclonal antibody against epidermal growth factor receptor (EGFR)
224068761|NCT00352651|DRUG|Pregabalin|
224068762|NCT03893968|BEHAVIORAL|Information by an assistant nurse|Information received by patients after ambulatory hand surgery under local anaesthetic about postoperative self care given by an assistent nurse.
224159393|NCT00736606|DRUG|AZD9056 + simvastatin|AZD9056: 400 mg od, 8 days simvastatin: one single dose of 40 mg on day 7
224159394|NCT01880203|PROCEDURE|aspiration in thyroid node for Molecular Cytogenetic Analysis.|
224159395|NCT02174809|BEHAVIORAL|Use of 5As to discuss gestational weight gain|
224159396|NCT02174809|BEHAVIORAL|Usual care|
224159397|NCT05756205|DEVICE|Immersive Virtual Reality (IVR)|"The intervention will consist of an Immersive Virtual Reality (IVR) application with virtual reality goggles Oculus GO, to reduce anxiety during pregnancy. This application lasts 14 minutes by the use of mindfulness techniques based on breathing, mindfulness and passive muscle relaxation. It consists of three modules that can be chosen completely or separately.~The aspects that conform this intervention will be: information about, the most common perinatal mental health problems, exercises based on attention to breathing (mindfulness-relaxation), 6 weeks of duration, for 14 minutes a day, knowledge from involved personnel of the number of times the woman has connected and the time she has done the exercise, satisfaction questions to pregnant women after pregnancy, alerts to notify the principal investigator if there is a problem with e-health, and, finally, an email address to contact the principal investigator."
224068763|NCT03893968|BEHAVIORAL|Information by a doctor|Information received by patients after ambulatory hand surgery under local anaesthetic about postoperative self care given by a doctor.
224068764|NCT00774345|DRUG|Lenalidomide|Lenalidomide capsules given orally on days 1-28 of a 28 day cycle
224068765|NCT00774345|DRUG|Placebo|Placebo capsules given orally on days 1 - 28 of a 28 day cycle
224068766|NCT00977821|OTHER|IVF|
224159398|NCT06181708|OTHER|N/A - Questionnaire based study|Questionnaire based study
224303939|NCT04188301|DRUG|Single dose of IDA|Participants will be given a single dose of oral IVM (150 µg/kg), DEC (6 mg/kg) and ALB (400 mg)
223469113|NCT05295381|DEVICE|abdominal weight training (AWT)|abdominal weight exercise training (sandbag) is maintained for 30 minutes; the starting weight is 1kg to 2kg, and the previous day's weight is maintained each day as well as adding 0.5kg daily.
223469114|NCT02633722|BEHAVIORAL|Lifestyle intervention B|Time limiting feeding from 8-5pm (TRFb)
223469115|NCT02633722|BEHAVIORAL|Lifestyle Intervention D|Time limiting feeding (12-9pm)
223469116|NCT06834126|PROCEDURE|Biospecimen Collection|Undergo blood and tissue sample collection
223469117|NCT06834126|PROCEDURE|Computed Tomography|Undergo CT
223469118|NCT06834126|DRUG|Consolidation Therapy|Receive CC with mFOLFOX6 or CAPOX
223469119|NCT06834126|PROCEDURE|Functional Magnetic Resonance Imaging|Undergo fMRI
223469120|NCT06834126|PROCEDURE|Gastrointestinal Endoscopy|Undergo endoscopy
223469121|NCT06834126|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223469122|NCT06834126|DRUG|Papaverine|Given IV
223469123|NCT06834126|RADIATION|Radiation Therapy|Undergo RT
223469124|NCT06834126|PROCEDURE|Total Mesorectal Excision|Undergo ToME
223469125|NCT04683640|DIETARY_SUPPLEMENT|GABA|Daily oral GABA for 4 weeks
224159399|NCT06297798|OTHER|Telerehabilitation|"The telerehabilitation program will be implemented using Whatsapp and Zoom applications for 40 minutes, 5 days a week. Posture and stabilization exercises will be performed, and the exercises will be performed for 10 weeks.~Posture and Stabilization Exercise Program:~1. Stretching of neck flexor, extensor, and lateral flexor muscles (30 seconds each)~2. Pectoral muscle stretching (30 seconds, 3 repetitions)~3. Isometric neck exercises (10 seconds, 10 repetitions)~4. Rhomboid strengthening exercise (bringing shoulder blades closer together against resistance using a TheraBand) (10 seconds, 10 repetitions)~5. Stretching of hamstring, lumbar lordosis and gastrocnemius muscles (sitting and standing) (30 seconds, 3 repetitions)~6. Pelvic posterior tilt exercise (10 seconds, 10 repetitions)~7. Bridge exercise (20 seconds, 10 repetitions)~8. Single-leg bridge exercise (Right-Left) (10 seconds, 10 repetitions)~9. Plank (starting with 60 seconds, increasing by 10 seconds each week)"
223469126|NCT04683640|DRUG|Placebo|Daily oral Placebo for 4 weeks
223469127|NCT05796791|DRUG|Ketamine Hydrochloride|IM ketamine given in weekly session for a total of 3 weeks
223469128|NCT05796791|BEHAVIORAL|Motivational enhancement therapy|Brief motivational based therapy
224303940|NCT04188301|DRUG|Three daily doses of IDA|Participants will be given one daily dose for 3 days of oral IVM (150 µg/kg), DEC (6 mg/kg) and ALB (400 mg)
223469129|NCT06408207|BEHAVIORAL|CGM Academy|Educational materials as well as online sessions with diabetes educators.
223469130|NCT03899779|OTHER|Face-to-face hypnotherapy|12 weeks treatment with face-to-face hypnotherapy (6 individual, bi-weekly sessions)
223469131|NCT03899779|OTHER|Online hypnotherapy|12 weeks treatment with online hypnotherapy
223469132|NCT03899779|OTHER|Online psychoeducation|12 weeks treatment with online psychoeducation
223469133|NCT03829462|DRUG|Regorafenib|regorafenib tab 40 mg i.e 160 mg/day
223469134|NCT03829462|DRUG|Irinotecan|irinotecan 120 mg/m2 cycle 1, 150 mg/m2 cycle 2, 180 mg/m2 cycle 3 and more
223469135|NCT05621863|OTHER|Aim 1 Meal Challenge 1|A meal challenge will be provided that contains 1 serving of peaches and 2 servings of strawberries as a smoothie and 2 servings of tomatoes and 1 serving of carrot as a vegetable dish.
223469136|NCT05621863|OTHER|Aim 1 Meal Challenge 2|A meal challenge will be provided that contains 1 serving of banana and 2 servings of peaches as a smoothie and 1 serving of tomatoes and 2 servings of green beans as a vegetable dish.
223469137|NCT05621863|OTHER|Aim 1 Meal Challenge 3|A meal challenge will be provided that contains 2 serving of bananas and 1 serving of strawberries as a smoothie and 1 serving of green beans and 2 servings of carrots as a vegetable dish.
223469138|NCT05621863|OTHER|Aim 2 Typical American Diet|The diet will provide sufficient calories for weight maintenance and will contain refined grains and low amounts of fruits and vegetables, representative of the typical American diet. No bananas, strawberries, peaches, green beans, carrots, or tomatoes will be provided.
223469139|NCT05621863|OTHER|Aim 2 Typical American Diet Plus Test Foods|This diet will provide sufficient calories for weight maintenance and will contain refined grains and low amounts of fruits and vegetables, representative of the typical American diet. Bananas, strawberries, peaches, green beans, carrots, and tomatoes will be provided in amounts less than or equal to 1 serving per day each.
223469140|NCT05621863|OTHER|Aim 2 Dietary Guidelines for Americans Diet Plus Test Foods|This diet will provide sufficient calories for weight maintenance and will contain whole grains and high amounts of fruits and vegetables, representative of the Dietary Guidelines for Americans. Bananas, strawberries, peaches, green beans, carrots, and tomatoes will be provided in amounts greater than or equal to 1 serving per day each.
223469141|NCT05701111|BEHAVIORAL|Start with the Heart Students|The Start with the Heart curriculum includes psychoeducation, lessons, and activities, on mindfulness, neurobiology, meditation, positive thinking, movement, and nutrition to promote well-being. The curriculum will be taught in the classroom to students for 15-20 min per day for 6-8 weeks.
223469142|NCT05701111|BEHAVIORAL|Start with the Heart Teachers|Pure Edge Inc will train teachers to deliver the Start with the Heart curriculum. The training emphasizes the neuroscience of stress and educator self-care. The teachers will implement the training in their respective classrooms for 6-8 weeks.
223469143|NCT05701111|BEHAVIORAL|Cue Centered Therapy Counselors|The Early Life Stress and Resilience Program team members will train school counselors on Cue-Centered Therapy through self-paced online modules, virtual and in-person live training, and office hours as needed. Counselors will implement the intervention with eligible students for 15-18 weeks.
223469144|NCT05701111|BEHAVIORAL|Cue Centered Therapy Students|Students who report a threshold of PTSD symptoms will be offered participation in Cue-Centered Therapy with their school counselors. They will have one-on-one therapy that targets trauma experiences through cognitive behavioral tools, narrative therapy, exposure therapy, psychoeducation, and more. Their caregivers will be involved as needed. They will enroll in treatment for 15-18 weeks.
223469145|NCT05701111|GENETIC|iSWAB-DNA|Eligible students will give DNA buccal swabs at 2-3 time points for later analysis of genetic markers.
223469146|NCT03041636|DRUG|Ruxolitinib|Given PO
223469147|NCT03041636|DRUG|Ruxolitinib Phosphate|Given PO
223469148|NCT06441318|DRUG|Povorcitinib|Povorcitinib will be administered at protocol defined dose.
223469149|NCT06441318|DRUG|Placebo|Placebo will be administered at protocol defined dose.
224303941|NCT03683368|DEVICE|YpsoPump Orbit soft|Insulin infusion sets will be used for up to 7 days or until failure
224303942|NCT03683368|DEVICE|YpsoPump Orbit micro|Insulin infusion sets will be used for up to 7 days or until failure
224303943|NCT01204450|DRUG|Temsirolimus|60-230mg/m2 weekly during each 28 day course, for up to 12 courses
223469150|NCT06441318|DRUG|Moxifloxacin|Moxifloxacin will be administered at protocol defined dose.
223469151|NCT03288038|DRUG|Rosuvastatin|
223469152|NCT03288038|DRUG|Ezetimibe|
223578746|NCT06263322|BEHAVIORAL|Actionable remotely generated health data|Remotely captured, patient generated health data will be used to inform provider care following re-vascular surgery in patients with chronic limb threatening ischemia
223578747|NCT06263322|BEHAVIORAL|Non-Actionable remotely generated health data|Remotely captured, patient generated health data is captured, but will not be used to inform provider care following re-vascular surgery in patients with chronic limb threatening ischemia
223578748|NCT03622164|RADIATION|Radiotherapy to ipsilateral neck lymphatics and tumor bed (radiotherapy to one side of the neck)|CTV54 includes only the ipsilateral neck, including levels 2-4 plus levels 1 and/or 5 as clinically indicated.
223578749|NCT03622164|RADIATION|Radiotherapy to the bilateral neck lymphatics and tumor bed (radiotherapy to both sides of the neck)|CTV54 includes the entire surgical bed, including bilateral neck lymphatics at risk of harboring microscopic disease
223578750|NCT05740124|BEHAVIORAL|slip recovery training|Participants practice volitional and reactive stepping responses that mimic those needed when recovering balance after slipping.
224303944|NCT01204450|DRUG|Valproic Acid|All patients will be given oral VPA (5 mg/kg, 3 times a day for each 28 day course, up to 12 courses
224303945|NCT05499013|DRUG|SLN124|SLN124 is a double-stranded small interfering ribonucleic acid (siRNA) targeting transmembrane protease, serine 6 (TMPRSS6) messenger ribonucleic acid (mRNA).
224303946|NCT05499013|DRUG|Placebo|sodium chloride, solution for injection
223578751|NCT05740124|BEHAVIORAL|alternative balance training|Participants practice standing and walking under varied sensory conditions.
223578752|NCT05996471|BIOLOGICAL|VH3810109|VH3810109 will be administered.
223578753|NCT05996471|DRUG|Cabotegravir|Cabotegravir will be administered.
224303947|NCT01200264|DRUG|apremilast|apremilast 10 mg tablets with dose titration to 30 mg BID for 169 days
224303948|NCT02642536|BEHAVIORAL|MH MOVE|provides the standard MOVE! weight management program plus a workbook containing education for management of depression, anxiety and PTSD symptoms to be used during 10 phone based clinician led CBT sessions
224303949|NCT02642536|BEHAVIORAL|Enhanced Usual Care|provides the standard MOVE! weight management program plus a workbook containing education for management of depression, anxiety and PTSD symptoms but not phone calls are provided.
224303950|NCT00486564|DRUG|Nifurtimox|Escalating dose by cohort starting at 20mg/kg/day. PO drug taken TID.
223469153|NCT01704365|BIOLOGICAL|Low dose RSV-F Vaccine with Adjuvant|0.5mL IM Injection
223469154|NCT01704365|BIOLOGICAL|Low dose RSV-F Vaccine without Adjuvant|0.5ml IM Injection
223469155|NCT01704365|BIOLOGICAL|High dose RSV-F Vaccine with Adjuvant|0.5mL IM Injection
223578754|NCT05996471|DRUG|Standard of care (SOC)|Pre-baseline SOC antiretroviral therapy (ART) will be administered.
223578755|NCT05996471|BIOLOGICAL|rHuPH20|rHuPH20 will be administered.
224303951|NCT03035721|DIETARY_SUPPLEMENT|Low protein formula|Infants were enrolled to receive low protein formula (energy: 65 kcal/100 mL, protein: 1.2 g/100 mL, protein-to-energy ratio:1.9 g/100 kcal, carbohydrates: 8 g/100 mL, fat: 3.1 g/100 mL) for the firsts 4 months of life.
223469156|NCT01704365|BIOLOGICAL|High dose RSV-F Vaccine without Adjuvant|0.5mL IM Injection
223469157|NCT01704365|BIOLOGICAL|Low dose RSV-F Vaccine with Adjuvant [Bedside Mixing]|0.5mL IM Injection
223469158|NCT01704365|BIOLOGICAL|Placebo|0.5mL IM Injection
223469159|NCT00209001|PROCEDURE|Acupuncture|Acupuncture using enhanced Ming Men technique for 20 minutes, twice during 1st week, then once during week 2, 3,and 4.
223469160|NCT00209001|PROCEDURE|Sham acupuncture therapy|Sham procedure will be insertion of 5 needles for 20 minutes provided twice during first week, then once per week thereafter.
223469161|NCT00076037|BIOLOGICAL|HIV CTL MEP administered with RC529-SE adjuvant|
223469162|NCT00076037|DRUG|GM-CSF|
223469163|NCT00205114|BEHAVIORAL|Individualized multifactorial intervention for community-living high-risk older adults|
223469164|NCT00205114|BEHAVIORAL|Health professional education program about fall prevention|
223578756|NCT03635164|DRUG|Durvalumab|Patients will receive one dose of neoadjuvant durvalumab 1500 mg approximately 3-6 weeks prior to standard of care surgery. It will be given concurrently with the first dose of radiation (RT). Patients will receive up to six doses of durvalumab and radiation post-operatively.
223578757|NCT03635164|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|The starting RT dose level will be given as 6 Gy for 2 fractions (12 Gy total) every other day over approximately one week to sites of gross disease only to minimize exposure to normal tissue. If toxicity develops and surgery is delayed by more than 8 weeks (qualifying as a DLT), the radiation dose will be dropped per protocol for the next set of patients. If this dose is tolerated, the dose will be increased to 6 Gy for 3 fractions (18 Gy total) for the next 3 patients.
223578758|NCT03635164|PROCEDURE|Standard of Care Therapy|Patients will proceed to surgical resection 3-6 weeks after radiation as recommended by the ENT surgeon.
223578759|NCT04730869|OTHER|Standard Treatment Plus Metabolic Therapy Program|"See description under Arms."
224068767|NCT00977821|OTHER|Oocyte Vitrification|
224068768|NCT04505241|BEHAVIORAL|Remotely-delivered physical activity promotion|Over video-call, participants will receive educational content on safely increasing their levels of physical activity (e.g., selecting an appropriate form of exercise, minimizing health risks, the importance of planning), will receive daily text messages (see arm descriptions) for six weeks and complete a 10-15 minute check-in call at the 3-week point of the intervention to assess compliance with daily step goals as well as to help problem-solve barriers to compliance.
224068769|NCT04933929|BEHAVIORAL|Post-hospitalization nutritional monitoring|Post-hospitalization nutritional monitoring, carried out by dieticians from Saveurs \& Vie. Consultations are done remotely, by phone only. Dietitians have gained experience in home nutritional monitoring of elderly people over the phone during the first wave of Coronavirus disease 2019 (COVID-19) .
223469165|NCT05668897|DRUG|GST-HG171|This study includes single-dose ascending and multiple-dose ascending studies. SAD study contains at least 4 dose groups of 150 mg, 300 mg, 600 mg and 900 mg. MAD study contains 1-3 dose groups which were evaluated in SAD study to be tolerated.
223578760|NCT01633203|DRUG|epirubicin + cisplatin + capecitabine polychemotherapy|"EPIRUBICIN (LKM)at a dose of 50 mg/m2 over 15 minutes is administered every 21 days.~CISPLATIN (LKM) at a dose of 60 mg/m2 over 4 hours is administered every 21 days. Patients must receive standardized hydration per protocol.~CAPECITABINE (Xeloda®) at a dose of 625 mg/m2 BID (i.e. 1250 mg/m2/day) 30 minutes after meals from day 1 to day 21 of every cycle of chemotherapy.~Antiemetic therapy:~* Dexamethasone 8 mg IV and Ondansetron (LKM) 8 mg IV o Granisetron (Kytril®) prior to chemotherapy~* Rescue Ondansetron (LKM) 8 mg IV will be given during 24-hour hospitalization in case of emesis~* Symptomatic antiemetic therapy with thiethylperazine will be prescribed.~Loperamide will be prescribed in case of diarrhea."
223578761|NCT01596335|DRUG|TA-650|TA-650 at 5 mg per kg body weight on the day of TA-650 administration (day 0) is administered by intravenous infusion slowly over at least 2 hours.
223578762|NCT01596335|DRUG|Polyethylene Glycol-treated Human Immunoglobulin (VGIH)|VGIH at 2 g per kg body weight on the day of VGIH administration (day 0) is administered by intravenous infusion slowly over at least 20 hours.
223578763|NCT02246192|PROCEDURE|sinus pilonidal excision+ PRGF|open sinus pilonidal excision and plasma rich grow factor infiltration intra and postoperatively
224303952|NCT03035721|DIETARY_SUPPLEMENT|Standard protein formula|Infants were enrolled to receive standard protein formula (energy: 68 kcal/100 mL, protein: 1.7 g/100 mL, protein-to-energy ratio:2.5 g/100 kcal, carbohydrates: 7.1 g/100 mL, fat: 3.5 g/100 mL) for the firsts 4 months of life.
223469166|NCT05668897|DRUG|placebo of GST-HG171|This study includes single-dose ascending and multiple-dose ascending studies. SAD study contains at least 4 dose groups of 150 mg, 300 mg, 600 mg and 900 mg. MAD study contains 1-3 dose groups which were evaluated in SAD study to be tolerated.
223469167|NCT00791999|DRUG|CDP870 400mg|400mg CDP870 given every 2 weeks until Week22 (SC)
224159400|NCT04517916|DEVICE|Zephyr Valve|Subjects prescribed Zephyr Valve treatment for their emphysema/COPD and treated with the Zephyr Valves.
224159401|NCT03892434|DRUG|Intravitreal bevacizumab and dexamethasone implant Injection|Bevacizumab 1.25mg is injected into the vitreous cavity through the pars plana using 30G needle-attached syringe for branch retinal vein occlusion, and Dexamethasone 0.75mg implant is injected using injector.
224159402|NCT03892434|DEVICE|Intravitreal dexamethasone implant|Dexamethasone implant insertion using approved kit
224159403|NCT05074394|BIOLOGICAL|COVI-DROPS|COVI-DROPS is a fully human monoclonal antibody that is a neutralizing antibody to SARS-CoV-2
224159404|NCT05074394|DRUG|Placebo|Diluent solution
224159405|NCT00979472|DRUG|Solifenacin|oral
224303953|NCT04076384|BEHAVIORAL|Guided Self-Determination|Structured team-based consultations
224303954|NCT04076384|BEHAVIORAL|Standard care|Standard consultations
224303955|NCT02511899|DIETARY_SUPPLEMENT|Mango fruit powder|Dietary supplement; Mango fruit powder
223469168|NCT00791999|DRUG|CDP870 200mg|400mg CDP870 given at Week0, 2, 4 and thereafter 200mg CDP870 given every 2 weeks until Week22 (SC)
223469169|NCT00791999|DRUG|CDP870 100mg|200mg CDP870 given at Week0, 2, 4 and thereafter 100mg CDP870 given every 2 weeks until Week22 subcutaneously(SC)
223469170|NCT00791999|DRUG|Placebo of CDP870|given every 2 weeks until Week22 (SC)
223469171|NCT03200210|DRUG|Febuxostat|Febuxostat tablets would be given to patients at dose of 20mg/d, once a day, and dose would be adjusted according to serum uric acid at specific visits.
223578764|NCT02246192|PROCEDURE|sinus pilonidal excision and standard cares|sinus pilonidal excision and postoperative standard care with povidone daily
223578765|NCT00499382|PROCEDURE|Nuclear Medicine Cardiac Scan|Scan lasting 30 minutes while being hooked up to a heart monitor that takes pictures every time your heart beats.
223578766|NCT00499382|PROCEDURE|PET/CT Cardiac Scan|Scan lasting 10-15 minutes and performed after the normally scheduled PET/CT scan.
223578767|NCT03627065|DRUG|Parsaclisib|Parsaclisib administered orally once daily at the protocol-defined dose.
223578768|NCT01883011|DRUG|Piracetam|
223578769|NCT01883011|OTHER|Placebo|
224159406|NCT03525873|OTHER|Laboratory Biomarker Analysis|Correlative studies
224159407|NCT03525873|DRUG|Methylphenidate|Given PO
224159408|NCT03525873|OTHER|Physical Activity|Participate in physical activity
224159409|NCT03525873|OTHER|Placebo|Given PO
224159410|NCT03525873|OTHER|Quality-of-Life Assessment|Ancillary studies
224159411|NCT03525873|OTHER|Questionnaire Administration|Ancillary studies
223469172|NCT03200210|DRUG|Placebo|Pills manufactured to mimic Febuxostat tablets
224159412|NCT02939976|DEVICE|Single Vessel Disease|Revascularization with Medtronic Resolute family of stents in infarct related artery; Possible use of Terumo Glidesheath Slender and Terumo TR Band Radial Compression Device
224159413|NCT02939976|PROCEDURE|Multi-vessel Disease, Culprit Vessel Only|Revascularization with Medtronic Resolute family of stents in infarct related artery; Possible use of Terumo Glidesheath Slender and Terumo TR Band Radial Compression Device
224159414|NCT02939976|PROCEDURE|Multi-vessel Disease, Complete Revascularization|Complete revascularization of all diseased arteries
224159415|NCT02939976|DEVICE|Medtronic Resolute family of stents|Revascularization with Medtronic Resolute family of stents in infarct related artery
224159416|NCT02939976|DEVICE|Volcano based pressure wires Verrata, Verrata Plus and any subsequent marketed Volcano pressure wire technology|Complete revascularization of all diseased arteries
223469173|NCT05450913|DRUG|Priformis intramuscular injection with %2 lidocain|Priformis intramuscular injection will be administered with 5 cc 2% lidocaine, accompanied by a nerve stimulator under ultrasound guidance
223469174|NCT00509717|OTHER|intensive implementation programme|educational manual; interactive educational meeting tailored to individual needs; reminders and feedback by 3 newsletters and at least 3 telephone calls.
223469175|NCT00509717|OTHER|control|educational manual
223469176|NCT00427908|BIOLOGICAL|GSK Biolgicals' meningococcal vaccine 134612 (Nimenrix)|One intramuscular dose.
224159417|NCT02939976|DEVICE|Terumo Glidesheath Slender|Possible use of Terumo Glidesheath Slender
223469177|NCT00427908|BIOLOGICAL|Mencevax™ ACWY|One subcutaneous dose.
223469178|NCT00427908|BIOLOGICAL|Meningitec™|One intramuscular dose.
223469179|NCT01710020|DRUG|CP-690,550|CP-690,550 10 mg oral powder for constitution
223469180|NCT06328972|BEHAVIORAL|systemic therapy|All participants were given routine rehabilitation treatment by professional rehabilitation therapists, including exercise therapy, guided education, psychological therapy, acupuncture and massage therapy, to promote the development of motor and cognitive function, as well as to improve intellectual development\[. Besides, swallowing function training was also provided, including direct training, indirect training, and compensatory training, as follows The mendelson maneuver: performed 5 days per week, twice per day, 5-10 minutes each time. Passive head extension: to stretch the submental muscle for 2-3 seconds, with upward resistance applied to the lower cheek for no less than 5 times a day and no less than 5 minutes each time. Direct feeding training: with powdered milk, once a day, 5 days a week.
223469181|NCT06328972|DEVICE|Intermittent Oro-Esophageal Tube Feeding|Within 4 hours of admission, the observation group were required to undergo nasogastric tube removal and initiated Intermittent Oro-Esophageal Tube Feeding for nutrition support. Before each feeding, the infant should rest for approximately 1 hour and undergo oral clean. During feeding, the infant should be held by the caregiver in a semi-reclined or upright position. Firstly, the tail of the tube was inserted via mouth into the upper part of the esophagus with a depth of 18-20cm, and the external part of the tube should be placed in water with the absence of bubbles indicating the successful tube placement. Subsequently, 1ml of water was slowly injected, followed by liquid food or water at a rate of approximately 50ml/min through a syringe connected to the feeding tube. After feeding, the tube should be slowly removed, and the feeding position should be maintained for 30-60 minutes to prevent reflux.
223469182|NCT06328972|DEVICE|Persistent Nasogastric Tube Feeding|The control group was given nutrition support with Persistent Nasogastric Tube Feeding, of which the tube passed through the nasal cavity into the stomach. After successful intubation, the tube was secured on the cheek. Liquid food was then syringe-fed into the stomach and the feeding was conducted every 2-3 hours, with each meal not exceeding 200 ml. The daily intake was generally consistent with that of the observation group. Besides, after successful intubation, the tube was secured on the infant's face and changed every one to two weeks.
223469183|NCT00463645|PROCEDURE|microdialysis|
223469184|NCT00463645|PROCEDURE|microperfusion|
224159418|NCT02939976|DEVICE|Terumo TR Band Radial Compression Device|Possible use of Terumo TR Band Radial Compression Device
224159419|NCT02058641|DRUG|Darapladib|EC tablet with a unit dose strength of 160 mg administered once daily orally for 11 days.
224159420|NCT03438513|BEHAVIORAL|Occupational Therapy Assessment|The occupational therapy assessment includes a functional evaluation of the disorders impact (activities of daily living)
223469185|NCT03511768|DRUG|18F-AlF-NOTA-octreotide|One injection of 18F-AlF-NOTA-octreotide
223469186|NCT03511768|DEVICE|PET/CT|Following injection of 18F-AlF-NOTA-octreotide the participants will be subjected to whole body PET/CT
223469187|NCT04014218|DRUG|Inhalation Sedation|Inhalation Sedation by Administration of Sevoflurane
224159421|NCT03438513|BEHAVIORAL|Psychological Assessment|It consists of a detailed history of the patient's experience, an evaluation with the patient (cognitive, emotional, motivational ...), an interview with the caregiver to see the repercussions of the disorders on a daily basis, how they are managed, and how they cope in order to give information and advice.
224159422|NCT03438513|BEHAVIORAL|Problem Solving Therapy|Problem-solving learning program for all situations of daily living, done in groups (10 people per group)
224159423|NCT03438513|BEHAVIORAL|Speaking group|Intervention, carried out in groups (10 people per group) which will consist of sharing experiences, sufferings, exchange and allow people who attend to share their experiences.
224159424|NCT00120510|DRUG|Efavirenz|Non-nucleoside reverse transcriptase inhibitor dosed at 600mg taken by mouth every 24 hours at bedtime
224159425|NCT00120510|DRUG|Lamivudine/Zidovudine|Nucleoside reverse transcriptase inhibitor dosed at 150mg/300mg fixed dose combination taken by mouth every 12 hours
224159426|NCT04768049|OTHER|Tool Translation|Data Collection procedure will be done in two phases. The first phase will revolve around the translation of the instrument. Firstly the tool will be translated into Urdu with help of two professional translators and then it will be back translated into English to cross check the clarity of text. The translation will focus more on the context and understanding of the text rather literal word-to-word meanings. The translation will be done according to the WHO guidelines
224159427|NCT01872897|DRUG|Sodium Alginate Double Action Chewable Tablets|4 tablets as a single dose
224159428|NCT01872897|DRUG|Placebo|4 tablets as a single dose
224159429|NCT04254796|BEHAVIORAL|Training for Awareness, Resilience, and Action (TARA)|This will be a 12-week group meditation training - Training for Awareness, Resilience, and Action (TARA)
223469188|NCT04014218|DRUG|Intravenous Sedation|Intravenous Sedation by Administration of Propofol
223469189|NCT04298580|PROCEDURE|PVB block|PVB block before surgery versus after surgery
224159430|NCT00047593|DRUG|IOP Lowering Medications|
224159431|NCT01830322|DRUG|CPI-613|CPI-613 drug product, provided in concentrated form at 50 mg/mL, must be diluted with D5W prior to administration. CPI-613 is to be infused intravenously (IV) via a central venous catheter. CPI-613 will be given 2x weekly, administered on Days 1 and 4 of each of the 3 treatment weeks, followed by a week of rest. The dose of CPI-613 will be 3,000 mg/m2 infused IV over 2 hours (this is approximate maximum tolerated dosing \[MTD\]), via a central venous catheter with D5W running at a rate of about 125-150 mL/hr.
224159432|NCT01830322|DRUG|Gemcitabine|
224159433|NCT01830322|DRUG|Any non-gemcitabine chemotherapies or best supportive care|
224159434|NCT00558233|BEHAVIORAL|CHOICE decision aid|computer-based patient decision aid about colorectal cancer screening delivered immediately before a healthcare provider visit
224159435|NCT00558233|BEHAVIORAL|YourMeds patient education program|computer-based patient education program about prescription drug safety seen immediately before a healthcare provider visit
224159436|NCT02621255|DRUG|Sevoflurane|Anesthesia type of performed for patient which has femur fracture.
224159437|NCT02621255|DRUG|Bupivacaine|Anesthesia type of performed for patient which has femur fracture.
224159438|NCT02957474|DRUG|GED-0301|
224159439|NCT02957474|DRUG|Omeprazole|
224159440|NCT04159701|DRUG|LY3454738|Administered IV
224159441|NCT04159701|DRUG|Placebo|Administered IV
223469190|NCT00461825|DRUG|Cyclosporin A: C0: 75-125ng/ml-dose adapted in the 3 groups|
223469191|NCT00461825|DRUG|Group A: CsA + Azathioprine(1 to 2 mg/kg/day)|
223469192|NCT00461825|DRUG|Group B: CsA + CellCept(500 mg x 2/day)|
223469193|NCT00461825|DRUG|Group C: CsAm|
223469194|NCT06291857|BIOLOGICAL|CIC Vaccine Co-formulated tNIV2 , SARSCoV-2 rS and Matrix-M Adjuvant|CIC will contain SARs-CoV-2 antigen (35 μg), tNIV antigens (2 influenza A \[H1N1 and H3N2\] and 1 influenza B-Victoria lineage strains; 60 μg/strain
223469195|NCT06291857|BIOLOGICAL|Novavax COVID-19 Vaccine|Each 0.5 mL dose comprises 5 µg SARS-CoV-2 S protein and 50 µg Matrix-M adjuvant
223469196|NCT06291857|BIOLOGICAL|tNIV Vaccine|2 influenza A \[H1N1 and H3N2\] and 1 influenza B-Victoria lineage strains (60 μg/strain), and Matrix-M adjuvant (75 μg)
223469197|NCT06291857|BIOLOGICAL|Fluzone High Dose|Fluzone High-Dose is supplied as a suspension for IM injection 0.5 mL with 60 µg per strain
223469198|NCT01604889|DRUG|Epacadostat|
223469199|NCT01604889|DRUG|Placebo|Placebo
223469200|NCT01604889|DRUG|ipilimumab|ipilimumab 3 mg/kg IV
223469201|NCT01604889|DRUG|ipilimumab|Doses to be determined following the completion of Phase I of the study
223469202|NCT05749016|DRUG|inetetamab with pertuzumab and paclitaxel/carboplatin (TCbIP) regimen|Inetetamab (Cipterbin) is a newly marketed anti-HER2 monoclonal antibody with amino acid modified Fc region and enhanced antibody-dependent cellular cytotoxicity (ADCC) effect. There was no robust evidence evaluating the combination of inetetamab with pertuzumab and neoadjuvant chemotherapy (paclitaxel + carboplatin) in the neoadjuvant setting. This study aimed to evaluate the efficacy and safety of inetetamab + pertuzumab+paclitaxel + carboplatin (TCbIP) as a neoadjuvant chemotherapy regimen in the treatment of patients with locally advanced HER2-positive breast cancer.
223469203|NCT03007355|OTHER|peripheral perfusion index measurement|
223469204|NCT01374022|OTHER|ART Strategy|Maximum alveolar recruitment maneuver in association with PEEP titrated by the static compliance of respiratory system.
223469205|NCT01374022|OTHER|ARDSNet Strategy|Conventional mechanical ventilation strategy.
223469206|NCT01190813|DRUG|Levodopa/Carbidopa|Oral levodopa 0.76 mg/kg tid with carbidopa 0.17 mg/kg tid
223469207|NCT01190813|DRUG|Placebo|Oral placebo tid
223469208|NCT01190813|OTHER|Patching|Two hours of daily patching
223469209|NCT05837455|DEVICE|VENTANA MIB-1 Ki67 assay|Ki67 scoring determination (standard of care) utilizing the Ki67 MIB-1 assay (clone 30-9) (VENTANA) will be performed at baseline, Week 4 (+/- 14 days - high-risk group only), and at time of surgery in accordance with the International Ki67 in Breast Cancer Working Group guidelines.
223469210|NCT05837455|DEVICE|Oncotype DX® Recurrence Score|Oncotype DX® Recurrence Score (RS) testing - assessing expression of 21 genes including 16 cancer-related genes and 5 reference genes - will be performed as standard of care in a central laboratory (Exact Sciences) on RNA extracted from formalin-fixed paraffin-embedded core-biopsy samples.
223469211|NCT05837455|DEVICE|PAM50-based Prosigna breast cancer gene signature assay|This PAM50-based Prosigna breast cancer gene signature assay for intrinsic molecular subtype determination will be performed on formalin-fixed, paraffin-embedded (FFPE) core-biopsy samples.
223469212|NCT05837455|DRUG|Anastrozole|Standard of care
223578770|NCT05549375|DEVICE|MyHand System Hand Rehabilitation|15 1-hour patient specific sessions using the MyHand System to help improve Hand function in the affected hand of stroke survivors
223469213|NCT05837455|DRUG|Combination anthracycline and/or taxane based treatment|Standard of care
223469214|NCT07073144|BEHAVIORAL|Virtual walking|Participants in the intervention group will wear a head-mounted display and hold a controller to swing their arm and control the virtual avatar walking in the virtual world. The intervention will include 10 scenarios of virtual walking intervention (1 scenario daily, each lasting for 15-20 minutes).
223469215|NCT07073144|BEHAVIORAL|Passive observing walking|Participants in the control group will be given 10 different walking videos in total, one for each day, each approximately 15 minutes in length.
223578771|NCT01066351|DRUG|beta erythropoietin|The patients were assigned to receive beta erythropoietin (Recormon) dose 200 unit/kg at 3 day before cardiac surgery and 100 unit/kg in the morning before cardiac surgery.
223578772|NCT01066351|DRUG|placebo|The patients were assigned to receive normal saline same volume at 3 day before cardiac surgery and in the morning before cardiac surgery.
223469216|NCT07072156|OTHER|Stress ball|"First Interview: Consent is obtained; group allocation is done.~Pre-test: Patient information form, DT, STAI, and vital signs are assessed.~Intervention: Stress ball use for 15-20 minutes during chemotherapy.~Post-test: Same measurements are repeated."
223469217|NCT07073729|PROCEDURE|Corneal Neurotization|Surgical technique involving the transfer of healthy donor sensory nerves to the anesthetic cornea to restore corneal innervation and sensation in patients with neurotrophic keratitis.
223469218|NCT07073729|DRUG|Cenergermin|Topical recombinant human nerve growth factor (rhNGF) approved for the treatment of neurotrophic keratitis. Administered as eye drops, it promotes epithelial healing and nerve regeneration.
223469219|NCT07073898|OTHER|Repeated Text Messages (TM+)|The text message notifies patients that they may be eligible for LCS and provides the patient with a connection to an registered nurse (RN) for LCS eligibility assessment and Shared Decision-Making (SDM) discussion. Response options include YES (to request that the HUB RN call the patient) or STOP (to opt out of any further messages).
223469220|NCT07073898|OTHER|Conversational Agent (CA)|The CA is designed to address specific hesitancy factors and barriers to Lung Cancer Screening (LCS). The CA uses a rule-based approach. CAs use a predefined conversation script with a fixed set of possible questions and responses to educate patients regarding the importance of LCS and engage them to be connected with RN for eligibility assessment and SDM.
223578773|NCT05295147|OTHER|Palmar Grasp Reflex Stimulation|The palmar grasp reflex is an involuntary flexion-adduction movement involving the hands and fingers.
223578774|NCT04524455|DRUG|Blinatumomab|Blinatumomab will be administered as a continuous intravenous infusion (cIV).
223578775|NCT04524455|DRUG|AMG 404|AMG 404 will be administered as an intravenous infusion (IV).
223469221|NCT07073898|OTHER|Educational Video|The educational video provides patients with information and answers commonly asked questions about LCS.
223469222|NCT07073898|OTHER|Proactive Patient Navigation (PPN)|Proactive patient navigation enables trained navigators to actively identify and reach out to patients who may need assistance completing LCS, rather than waiting for patients to seek help on their own.
223469223|NCT07073898|OTHER|Reactive Patient Navigation (RPN)|Reactive patient navigation makes trained navigators available to those who seek assistance in completing LCS.
223469224|NCT07073105|DIAGNOSTIC_TEST|tracheal ultrasound ( expert radiologist)|tracheal ultrasound, performed by expert radiologist, for preterm neonates for confirmation of ETT site
223469225|NCT07073105|DIAGNOSTIC_TEST|tracheal ultrasound by trainee neonatologist|tracheal ultrasound, performed by trainee neonatologist ( after receiving training for the procedure) , for preterm neonates for confirmation of ETT site
223469226|NCT07073105|DIAGNOSTIC_TEST|Chest x-ray|chest xray done for confirmation of ETT site
223469227|NCT07072897|OTHER|Fluid bolus administration|fluid boluses 250 ml were given when required
223469228|NCT07072897|OTHER|Frusemide was given when required|fluid is given in a fixed regimen
223469229|NCT06899776|DEVICE|Abbott i-STAT point of care (POC) device|During the study period all ED patients with chest pain will have an extra lithium heparin blood sample obtained for each troponin test ordered and collected in the ED (typically 2, but this may range from 1-3 troponin measures), which will be used for immediate hs-cTnI measurement by research personnel using an Abbott i-STAT POC device.
223469230|NCT07073859|OTHER|Fluid expansion|Data will be collected retrospectively, after fluid expansion administration, by the prescribing physician through. These data will be collected from standard monitoring and/or from the patient's medical record. Data will therefore only be collected at a single point in time.
223469231|NCT07073742|PROCEDURE|CLaCS|CLaCS is hybrid outpatient procedure combining Nd:YAG 1064 nm laser treatment with injection of a sclerosant (either 70% glucose or 0.2% polidocanol foam).
223469232|NCT07073599|OTHER|Creative Drama Education|"This study is a pre-test/post-test controlled experimental design aimed at evaluating the effectiveness of creative drama education on awareness of breast and gynecological cancers.~Students in the intervention group will receive creative drama-based training structured and implemented by the researcher. This training is designed to increase awareness of breast and gynecological cancers.~The effectiveness of the training will be assessed by comparing participants' awareness levels before and after the intervention. For this purpose, the following data collection tools will be used:~Personal Information Form Breast Cancer Awareness Scale Gynecological Cancers Awareness Scale The impact of the creative drama education on the awareness levels of students in the intervention group regarding breast and gynecological cancers will be evaluated through statistical analysis."
223469233|NCT07064629|BEHAVIORAL|Relaxation in virtual reality with biofeedback.|In this intervention, biofeedback is provided based on the respiratory rate measured by a Vernier Go respiration belt. This belt sends signals (respiratory effort) to the application that calculates the level of synchronisation and gives the visual biofeedback in two forms: 1) a deer simultanously breathing with the participant (realtime biofeedback, present in the initial phase only), 2) a growing tree - if breathing is regulated following a given rhytm, a growing tree is giving the targeted biofeedback.
223743671|NCT07190456|OTHER|Exposure to neutral images visualization|The patient will have to walk on a treadmill at their preferential walking speed for 10 minutes while visualizing neutral images (landscapes, monuments...)
223743672|NCT07190456|OTHER|Exposure to nocive images visualisation|The patient will have to walk on a treadmill at their preferential walking speed for 10 minutes while visualizing images interpreted as nocive (cutting, jumping, contact...)
224068770|NCT05841823|BEHAVIORAL|Virtual reality exposure therapy (VRET)|The relaxation scene includes four beautiful landscapes, and patients can choose any of these four, as perceived to be the most comfortable landscape. The visual stimulation of high-risk scene is designed as any combination of four different scenes (street barbecue stands, restaurant, bar and home) and four kinds of alcoholic beverages (Chinese liquor, beer, grape wine and cocktail), which are customized according to the patient's personal preference. At the same time, the odor of the alcoholic beverage of the patient's choice will be provided as an olfactory stimulation. The aversive situation will be the visual and auditory stimulation provided by a video of an alcoholic vomiting, while olfactory stimulation will be provided by cotton balls soaked in fermented dairy products.
224068771|NCT05841823|BEHAVIORAL|Acceptance and commitment therapy (ACT)|The initial session began with case formulation. Subsequent sessions involved learning on acceptance and acknowledgement of unpleasant thoughts and feelings associated with alcohol craving and clinical features of alcohol use disorder, cognitive defusion on how to dissociate self avoidance of unpleasant thoughts and feelings, learning and practicing mindfulness exercise (such as mindfulness breathing) to make self aware of the many things that occurred presently which can be enjoyed and focus on rather than focusing on unpleasant thoughts and feelings, and learning to be aware of the safe self which is separated from the unpleasant thoughts and feelings and identifying values in life and strategies to achieve these values (therapeutic processes in hexaflex).
224068772|NCT01097278|DIETARY_SUPPLEMENT|cholecalciferol|Given orally
224068773|NCT01097278|OTHER|placebo|Given orally
224068774|NCT00891579|DRUG|Pemetrexed (Alimta)|treatment of single pemetrexed with vitamin supplement until discontinued conditions are met
223469234|NCT07064629|BEHAVIORAL|Relaxation in virtual reality without biofeedback|In this control intervention, participants' respiratory rate is still being measured by the respiratory belt VernierGo; however, they are not receiving any visual biofeedback inside the virtual relaxation application (no deer is present, the tree is constantly growing regardless of the breathing pattern of the participant).
223469235|NCT07073716|OTHER|aerobic exercise|"the exercise protocol was applied following these characteristics~* frequency: 3-5 times /week along the whole study period~* intensity: 70% of the maximal heart rate (220- age x 70/100)~* duration: 50 min (warming up exercise movements (stretching and flexibility) in standing position, active phase of walking on a computerized treadmill, cooling down exercise movements (stretching and flexibility) performed in the seated position. being supervised by two trainers and the researcher. The researcher controlled the heartbeat 2 times through carotid pulse and At the end in order to restore the body to its initial state. all the patients could drink water during their training."
223469236|NCT07073716|DIETARY_SUPPLEMENT|phoenix seed|consuming 2 grams of phoenix seed powder dissolved in about 100 ml water 3 times/day
223469237|NCT07073716|COMBINATION_PRODUCT|aerobic exercise+ phoenix seed|"a specialized programme of aerobic exercise.the exercise protocol follow these characteristics~* frequency: 3-5 times /week along the whole study period~* intensity: 70% of the maximal heart rate (220- age x 70/100)~* duration: 50 min (warming up exercise movements (stretching and flexibility) in standing position, active phase of walking on a computerized treadmill, cooling down exercise movements (stretching and flexibility) performed in the seated position. being supervised by two trainers and the researcher. The researcher controlled the heartbeat 2 times through carotid pulse and At the end in order to restore the body to its initial state. all the patients could drink water during their training.~the specialized program of phoenix seed consumption (consuming 2 grams of phoenix seed powder dissolved in about 100 ml water 3 times/day)"
223469238|NCT07072858|DIAGNOSTIC_TEST|Cardiac Magnetic Resonance Imaging (CMR)|Cine CMR imaging was performed with steady-state free precession covering short axis continuously from the mitral annulus to the apical level in the 2-, 3- and 4- chamber views using the following parameters: repetition time (TR) = 3.73 ms, echo time (TE) = 1.87 ms, flip angle = 60°, slice thickness 8.0 mm. Cine images of all included patients were acquired prior to contrast administrations. Late gadolinium enhancement images (LGE) images were obtained 10-15 minutes after intravenous injection of gadolinium (0.1 mmol/kg at 3ml/s) at end-diastolic phase on the short axis (TR=6.09 ms; TE= 3.0 ms; flip angle 60°; thickness 8.0 mm) with breath-hold phase-sensitive segmented inversion recovery (PSIR) fast field echo sequence. T2-weighted sequence was performed using turbo spin-echo (TSE)-sequence (TR=1714-2000 ms; TE=8.04 ms; slice thickness 8.0 mm) to estimate myocardial edema. Images were analyzed on freely available validated cardiovascular image analysis software CVI42 (Circle Cardiovas
223469239|NCT06821477|OTHER|Superficial EMG|Superfiscial EMG during ASLR without knee brace follow by EMG during ASLR with knee brace under certain commands
223469240|NCT05619289|DRUG|Ergocalciferol|One-time, oral dose of 300,000 IU of Ergocalciferol administered via 6 capsules.
223469241|NCT05619289|DRUG|Placebo|One-time, oral dose of 6 inert capsules matched to the active comparator
223469242|NCT07072052|OTHER|No intervention planned|No interventions planned
223469243|NCT07072715|BEHAVIORAL|PAPE Training|A neuromuscular activation protocol involving heavy banded squats (\~85% 1RM) to induce post-activation performance enhancement. Applied three times weekly over 8 weeks following the warm-up. Participants then continued with regular football training.
223469244|NCT07072715|BEHAVIORAL|Plyometric Training|A program of depth jumps designed to enhance explosive power, speed, and agility. Applied 3 times weekly over 8 weeks following the warm-up. Participants then continued with their regular football training.
223469245|NCT07072299|PROCEDURE|DEB-BACE|Drug-Eluting Bead microspheres used for embolization: Drug-Eluting Bead microspheres 1tube was loaded and adsorbed chemotherapy. End point of embolization: stagnation of blood flow in tumor feeding artery
223469246|NCT07073196|PROCEDURE|Dental implant treatment (narrow implants)|Replacement of a missing molar tooth with a narrow dental implant
223469247|NCT07073196|PROCEDURE|Dental implant treatment (standard implants)|Replacement of a missing molar tooth with a standard dental implant
223469248|NCT07072767|BEHAVIORAL|Digital education outreach intervention for kidney transplant access and human guide|Receives (1) donor search materials, (2) electronic resource access messages, (3) practical assistance to use the intervention and empower taking the outreach action and (4) telephonic human guide
223469249|NCT07072767|BEHAVIORAL|Digital education outreach intervention for kidney transplant access only (unguided)|Receives (1) donor search materials, (2) electronic resource access messages, and (3) practical assistance to use the intervention and empower taking the outreach action.
224068775|NCT00891579|DRUG|Gefitinib (IRESSA)|treatment of Gefitinib will be applied until discontinued conditions are met
224068776|NCT03732300|OTHER|ASSIP|Three PSychotherapy Sessions plus after 3/6/9/12 months individualized letters
224068777|NCT00841685|DEVICE|Goldlock|Insertion of Goldlock marker
223469250|NCT07073222|OTHER|Escape room game|Escape room games are live action team-based games where players discover clues, solve puzzles and complete tasks in one or more rooms to accomplish a specific goal within a limited time.
223469251|NCT07072533|OTHER|blood flow restriction training|individual will do aerobic training .
223578776|NCT04524455|DRUG|Dexamethasone Premedication|Dexamethasone will be administered orally or intravenously prior to blinatumomab treatment, as needed.
224068778|NCT00841685|DEVICE|Visicoil smallest size|Insertion of Visicoil, smallest size, marker
223578777|NCT02161276|DRUG|TNTL capsule|Patients were asked to taken drugs 3 times a day, with each time 3 grains
224068779|NCT00841685|DEVICE|Visicoil larger size|Insertion of Visicoil, larger size, marker
223578778|NCT02161276|DRUG|Placebo|Patients were asked to taken drugs 3 times a day, with each time 3 grains
223578779|NCT02961192|BEHAVIORAL|Supportive social incentive|A family member or friend will be used as a support person in this study, to receive updates and support the participant in their progress.
223578780|NCT02961192|BEHAVIORAL|Competitive social incentive|Participants in this intervention will be competing against each other in the game.
224068780|NCT00841685|DEVICE|Bard goldmarker smallest size|Insertion of Bard goldmarker, smallest size
224068781|NCT00841685|DEVICE|Bard goldmarker larger size|Insertion of Bard goldmarker, larger size
224068782|NCT03889977|OTHER|Resistance exercise|2 major muscle groups (lower extremity, chest)
224159442|NCT03288727|OTHER|interviews with a psychologist|an interview with a psychologist / sociologist will take place after completion of the on-site questionnaires to find out the reasons for their choice of accessing their secondary data and their experiences with the secondary data reported.
224159443|NCT04964804|PROCEDURE|real-time ultrasound-CT fusion imaging|selective lumbar nerve root block puncture under real-time ultrasound-CT fusion imaging
224159444|NCT04964804|PROCEDURE|ultrasound alone|selective lumbar nerve root block puncture under the guidance of ultrasound alone
224159445|NCT02114060|BIOLOGICAL|GEN-003 Vaccine (30μg of each antigen)|HSV-2 protein subunit vaccine consisting of 2 recombinant T cell antigens: internal fragment of the immediate early (IE) protein ICP and glycoprotein D
224159446|NCT02114060|BIOLOGICAL|GEN-003 Vaccine (60μg of each antigen)|HSV-2 protein subunit vaccine consisting of 2 recombinant T cell antigens: internal fragment of the immediate early (IE) protein ICP and glycoprotein D
224159447|NCT02114060|BIOLOGICAL|Matrix-M2 Adjuvant (25μg)|Matrix-M2 is derived from fractionated Quillaja saponins, phosphatidylcholine, and cholesterol.
223469252|NCT07072039|PROCEDURE|Paramedic Evaluation for acute COPD Exacerbation|The Paramedic Evaluation for Acute COPD Exacerbation (PEACE) program is a mobile integrated health initiative that aims to evaluate and treat COPD exacerbation in the home. The goal of the intervention is to expedite the recognition and treatment of COPD exacerbation as well as For this intervention, ambulatory teams can refer patients for PEACE visits when a patient has been identified as suffering from symptoms consistent with COPD exacerbation. Once a visit is requested via electronic health record order, a community paramedic presents to the patient's home within 2 hours, evaluates the patient using mobile diagnostic testing, and initiates pharmacological therapies protocolized by the pulmonary team. A standardized clinical approach and documentation strategy is used including a focused history and physical exam, venous blood gas, trending pulse-oximetry, and mobile x-ray. The community paramedic is supervised in real-time by an emergency physician to establish a care plan and di
223469253|NCT05231200|BEHAVIORAL|QI Team Building|Each NICU will create a core QI team composed of 6-8 multidisciplinary members including a parent advisor, when feasible. This team will lead the QI activities and education, and champion the culture and practice change in the unit.
224303956|NCT04191837|OTHER|Self-administered acupressure treatment group|Subjects in the self-administered acupressure exercise group will receive two training sessions (2 hours each, 1-week apart). The self-administered acupressure treatment protocol was developed based on Chinese medicine meridian theory by previous studies and modified. The acupoints are indicated for knee pain and have been commonly used and tested for feasibility in pilot study. The training will be conducted in a group format with 4-6 subjects per group. Each subject will then receive a handout and an acupressure log. They will be told to perform the self-acupressure twice per day for 12 weeks.The capability of participants for self-administered acupressure will be inspected by the instructor with a competency checklist in each session. And a demonstration video will be sent to the participants via WhatsApp for their reference at home.
223469254|NCT05231200|BEHAVIORAL|QI education|Each NICU QI team will receive standardized QI education using the 6-hour EPIQ Workshop which involves hands-on approach to enable teams to successfully implement QI projects together. EPIQ 10 Steps and QI Tools will be used to build the team's understanding of QI using realistic improvement opportunities based on the standardized care bundles identified in the trial.
223469255|NCT05231200|OTHER|Standardized care bundle- respiratory care|"A care bundle is a small, simple set (3-5 elements) of evidence-based practices that, when performed collectively and reliably, will result in improved patient outcomes. This bundle will aim to implement best practices for stabilization and respiratory care in moderate and late preterm infants (MLPIs) including~1. establishing effective ventilation in the delivery room~2. prevention of hypothermia~3. early diagnosis and management of respiratory distress with continuous positive airway pressure (CPAP)~4. standardized approach for surfactant indications and administration~5. standardized approach for early extubation."
223469256|NCT05231200|OTHER|Standardized care bundle- nutritional care|"A care bundle is a small, simple set (3-5 elements) of evidence-based practices that, when performed collectively and reliably, will result in improved patient outcomes. This bundle will aim to implement best practices for nutritional support in MLPIs including~1. early initiation of enteral or parenteral nutrition;~2. standardized tables for feeding initiation and progression~3. optimizing breastfeeding and use of mother's own milk~4. standardized approach for a transition from enteral nutrition via tube feeds to oral feeds."
223469257|NCT05231200|BEHAVIORAL|QI mentoring|Each NICU in the intervention arm will have one or more assigned members of the study team who are experienced in collaborative QI and EPIQ methods. The mentors will help local QI teams to engage frontline staff in QI and navigate the unit-specific challenges.
223578781|NCT02961192|BEHAVIORAL|Collaborative social incentive|Participants in this intervention will be working with each other in the game.
223578782|NCT02120963|BEHAVIORAL|Person-centered physical therapy intervention program|Comparison of person-centered physical therapy and control group
223578783|NCT03361904|PROCEDURE|Colonoscopy|Total colonoscopy : All consecutive patients who were scheduled for colonoscopy were included. Exclusion criteria were: patients scheduled for partial colonoscopy, interventional colonoscopy (for stent insertion, stenosis dilation).
223578784|NCT05348746|OTHER|Advanced Analysis of Polymorphism|Assessment of Plasmodium falciparum drug resistance. Target P. falciparum drug resistance genes: Pfk13 propeller, Pfdhfr and Pfdhps. The polymorphisms analysis of the propeller domain of the Pfk13 gene will be performed by PCR amplifications and subsequent sequencing. Analysis of Pfdhfr gene at codons 51, 59, 108 and Pfdhps gene at codon positions 436, 437, 540, 581, 613 will be done by means of amplifications and subsequent Sanger sequencing. Molecular studies will be performed only for research purposes and will have no impact on the clinical management of study patients.
223578785|NCT04757948|PROCEDURE|Acupuncture|Acupuncture of acupoints P-6 and St-36
223578786|NCT04757948|DEVICE|TENS|TENS of acupoints P-6 and St-36
223578787|NCT04757948|DEVICE|Sham-TENS|Sham-TENS of acupoints P-6 and St-36
223578788|NCT02630017|DRUG|ADHD methylphenidate first, placebo second|double-blind, counter-balanced administration
223578789|NCT02630017|DRUG|ADHD placebo first, methylphenidate second|double-blind, counter-balanced administration
223578790|NCT02630017|DRUG|Non-ADHD methylphenidate first, placebo second|double-blind, counter-balanced administration
223578791|NCT02630017|DRUG|Non-ADHD placebo first, methylphenidate second|
223578792|NCT03066362|OTHER|Echocardiography-Doppler|Ultrasonographic recordings are recorded immediately before and after volume expansion (VE), performed as a 30-minute infusion of 500 mL of 4% gelatin. Inferior Vena Cava diameters are measured during spontaneous and standardized respiratory cycles. Stroke volume is measured during spontaneous respiratory cycles.
223578793|NCT02335632|DRUG|Probiotics (Lacidofil®)|7 days of cultured Lactobacillus rhamnosus R0011/acidophilus R0052 (120 mg/day)
223578794|NCT02335632|DRUG|Placebo|For probiotics
223578795|NCT02144831|DRUG|anti-thrombotic treatment using Aspirin (ASA 75-325mg) and Clopidogrel (75mg)|comparisson of what is the efficacy and safety of 10 days to 30 day treatment of aspirin (ASA)+Clopidogrel
223743673|NCT07190456|OTHER|Exposure to anticipated realisation of a feared movement|Before the start of the experimental condition, the patient will be asked to think about their willingness to perform the first movement visualised in the video, while a researcher places a jumping platform inside the laboratory. During the test, the patient will have to walk on a treadmill at their preferred speed for 10 minutes, while watching a video showing a drop jump followed by images interpreted as nocive for the rest of the time.
223469258|NCT05231200|BEHAVIORAL|Collaborative networking|The study team will conduct virtual meetings every 2 months for the NICUs in intervention arm allowing local QI teams to discuss progress, and share data. The investigators will arrange annual in-person or virtual meetings for the NICUs in the intervention arm to present projects, successes, and lessons learned. These NICUs will have continuing access to the data and will receive quarterly reports using statistical process control charts outlining the unit's performance compared to other units and to the group average.
223469259|NCT05231200|OTHER|Current practice- standard of care|All participating NICUs will be in the control arm during the first year prior to randomization to create a baseline of the current practices and between-units variation. NICUs in the control arm can continue conducting QI activities relevant to current practice, but without receiving the interventions outlined above until they transition to the intervention arm. The investigators will capture these activities and account for them in the analysis.
223469260|NCT07072013|OTHER|ribociclib|This is an observational study. There is no treatment allocation. The decision to initiate ribociclib was based solely on clinical judgement.
223469261|NCT06500741|OTHER|No Intervention|No investigational drug will be administered to participants in this study.
223469262|NCT06776705|DEVICE|Low-intensity transcranial ultrasound stimulation|Low-intensity TUS, as an advanced modality of transcranial brain stimulation, enables to stimulate the deep brain structures with optimized focality and specific frequency.
223469263|NCT01408212|PROCEDURE|Acupuncture treatment|"Acupuncture treatment will be performed by licensed doctors in Korean Medicine using 0.20 mm (diameter) X 0.30 mm (length) sized disposable acupuncture on seven to ten consecutive days after admission to the Korean Medicine Hospital of Pusan National University. At least two sessions and a maximum of five sessions of acupuncture therapy will be administered per day. Acupuncture points consist of common points and additional points selected for typical complaints common in patients under chemotherapy. These points are as follows.~* Common points: LI4 (bilateral), LU5 (bilateral), LU7 (bilateral), BL13 (bilateral), BL23 (bilateral), SP3 (bilateral), LU9 (bilateral), ST36 (bilateral) and CV22~* Additional points Nausea/vomiting PC6 (bilateral) Dyspepsia: CV12, LU6 (bilateral) Insomnia: Yintang, KI5 (bilateral) Pain: Ashi points (tender spots)"
223469264|NCT02216279|DRUG|PulmoBind|PulmoBind is a peptide derived from human adrenomedullin (hAM1-52), labelled with 99mTc (imaging isotope used in clinical medicine).
223469265|NCT04884139|DRUG|Dolutegravir/Lamivudine as a single pill|\- Dose: Dolutegravir 50mg/ Lamivudine 300 mg -Route of adminstration: oral -Schedule of administration: once a day for 96 weeks.
223469266|NCT04884139|DRUG|Bictegravir/Emtricitabine/Tenofovir alfenamide as a single pill.|"* Dose: Bictegravir 50 mg/Emtricitabine 200 mg /Tenofovir alafenamide 25 mg~* Route of adminstration: oral~* Schedule of administration: once a day for 96 weeks."
223469267|NCT06919653|BEHAVIORAL|The Workplace program to Improve the Safe Handling of hazardous drugs (WISH)|The WISH intervention is targeted to promote the adherence to chemotherapy handling guidelines among oncology nurses. The WISH intervention will include two components 1) an individualized online educational component on chemotherapy exposure and the safe handling guidelines with incorporating novel instructional technology tools and 2) debriefing sessions on the incidents of chemotherapy exposure.
223469268|NCT06934018|PROCEDURE|Surgery and procedure|"According to the Chinese Guidelines for the Diagnosis and Comprehensive Treatment of Liver metastases of Colorectal Cancer (2023 edition), R0 resection of metastatic tumors is satisfied, and the objective is to preserve sufficient functional liver tissue, and the surgical margin width is less than 7mm"
223469269|NCT06934018|PROCEDURE|Surgery and procedure|Combined with intraoperative B-ultrasound guidance, 3D reconstruction and intraoperative navigation, the surgical margin width of metastatic tumor was greater than or equal to 7mm
223743674|NCT07190092|PROCEDURE|Deep brain stimulation electrode implantation with an electrode target in the dentate nucleus|The intervention will involve implantation of a directional electrode with a target in the dentate nucleus of the cerebellum, ipsilateral to the limbs affected by spasticity. Electrode implantation will be performed using a stereotaxic frame, following prior planning of the electrode trajectory and tractography of the dento-ruborothalamic tract using a planning station. The procedure will be performed under general anesthesia. The IPG stimulator will be placed in the subclavicular region.
224068783|NCT03017170|DRUG|Dried Cranberry|"Dried cranberry powder is not an extract of cranberries, but a full spectrum ingredient. It is comprised of a proprietary ratio of dried cranberry fruit, cranberry pomace, and cranberry seeds, each of which is a recognized food and/or dietary ingredient. One 500 mg capsule of dried cranberry powder consists of approximately 25 grams of cranberry fruit."
224068784|NCT03017170|DRUG|Placebo Oral Capsule|Colored Maltodextrin: Proprietary mixture of: maltodextrin and food grade colors
224068785|NCT01600443|DEVICE|LoFric|Three catheterizations at least two hours apart using LoFric Primo 40 cm CH14.
224068786|NCT01600443|DEVICE|SpeediCath|Three catheterizations at least two hours apart using SpeediCath 40 cm CH14.
224068787|NCT01600443|DEVICE|SpeediCath Compact Male|Three catheterizations at least two hours apart using SpeediCath Compact Male 30 cm.
224068788|NCT05151055|DIETARY_SUPPLEMENT|Lactezin|100 mg lactoferrin, 11 IU vitamin E (as alpha tocopherol), and 5 mg zinc (as zinc gluconate)
224068789|NCT05151055|DIETARY_SUPPLEMENT|Placebo|starch
224068790|NCT04705194|PROCEDURE|Hepatectomy|Resection of one or more liver segments as treatment for primary or metastatic liver cancer
224068791|NCT04705194|PROCEDURE|PVE or ALPPS|Embolization of the portal vein feeding the diseased liver segments or surgical liver partition and portal vein ligation of the diseased liver segments in order to induce growth of the future liver remnant ahead of the resection.
224159448|NCT02114060|BIOLOGICAL|Matrix-M2 Adjuvant (50μg)|Matrix-M2 is derived from fractionated Quillaja saponins, phosphatidylcholine, and cholesterol.
224159449|NCT02114060|BIOLOGICAL|Matrix-M2 Adjuvant (75μg)|Matrix-M2 is derived from fractionated Quillaja saponins, phosphatidylcholine, and cholesterol.
224159450|NCT02114060|BIOLOGICAL|Placebo|0.9% Normal Saline (NaCl)
224159451|NCT05682768|PROCEDURE|Duct to Mucosa Pancreatico-Gastrostomy with trans-pancreatic transverse mattress U- Shaped sutures|Adding suporting sutures between th posterior gastric wall and ancreatic stump in whipple procedure, the sutures are Duct to Mucosa Pancreatico-Gastrostomy with trans-pancreatic transverse mattress U- Shaped sutures.
223469270|NCT06933940|BEHAVIORAL|Nutrition Matters|The intervention will consist of two components: educational sessions and a structured PA component. The primary purpose of the educational sessions is to increase experimental group participants' scientific knowledge and skills in healthy cooking and eating. NUTRITION-MATTERS includes weekly 1.5-hour education sessions for a total of 12 weeks. The sessions will be sequenced carefully to blend brief lectures by experts, experience sharing by participants, and an interactive cooking demonstration. All participants will be provided with $20 of food that corresponds to the cooking demonstration and recipes in the participant handbook.The curriculum will include evidence based information on managing chronic diseases with nutrition and will be culturally tailored to include foods, music, and/or same race/ethnicity role models.
223469271|NCT06942104|DRUG|18F-TRX|Given Intravenously (IV)
223469272|NCT06942104|PROCEDURE|Positron Emission Tomography (PET)/Computerized tomography (CT)|Imaging procedure
223469273|NCT06942104|PROCEDURE|Tumor Biopsy|May undergo tumor biopsy
223469274|NCT06942104|PROCEDURE|Blood Specimen Collection|Undergo blood sample collection
223469275|NCT06954038|DIETARY_SUPPLEMENT|Leonurus cardiaca extract 250 mg|Participants will receive a dietary supplement containing 250 mg of Leonurus cardiaca extract formulated in phospholipids. The supplement is administered as a single oral capsule, once daily in the morning, for 30 consecutive days.
223578796|NCT06414161|DIETARY_SUPPLEMENT|mix of (green tea and peppermint)|"Dried green tea leaves (100 gm) will be soaked into 500 ml of methanol solution for two days. The solution obtained will then be strained by a strainer and shifted to a glass plate. The plates will be left at room temperature from three to four days. Scraping out of the crystal powder of the extract from the plates will be carried out \[27\].~The peppermint mouth rinse that was used in this study had 1% peppermint base, 10% xylisorb, 5% glycerin, 1% Tween 20%, 5% alcohol 96%, 0/18% methyl paraben, and 0/02% propyl paraben \[28\].~Similarly, green tea plus peppermint mouthwash will be prepared at the same way but by adding 50% green tea leaves and 50% peppermint in the extract."
223469276|NCT06954038|DIETARY_SUPPLEMENT|Placebo|Participants will receive a placebo capsule identical in appearance to the active supplement, administered twice daily for 30 consecutive days.
223469277|NCT06954038|DIETARY_SUPPLEMENT|Leonurus cardiaca extract 500 mg|Participants will receive a dietary supplement containing 500 mg of Leonurus cardiaca extract formulated in phospholipids. The supplement is administered as a single oral capsule, once daily in the morning, for 30 consecutive days.
223469278|NCT05379205|BEHAVIORAL|Prehabilitation program (4 week before the surgery)|This intervention will include 3 complementary modules: (i) supervised physical exercise: aerobic and strength High Intensity Interval Training (HIIT), 3 times per week (ii) dietary behavior change: nutritional talk + an informative brochure + a video summary, a session per week and (iii) psychological support: psychoeducation, written and verbal emotional expression, promotion of coping strategies, progressive muscle relaxation training, problem-solving and social skills, and self-efficacy enhancing, among others. This psychological component will also include counseling regarding smoking and alcohol cessation and sleep hygiene.
223469279|NCT05379205|BEHAVIORAL|Postoperative program (12 week after the surgery)|"This intervention will include 3 complementary modules: (i) supervised physical exercise: aerobic and strength High Intensity Interval Training (HIIT), 3 times per week (ii) dietary behavior change: nutritional talk + an informative brochure + a video summary, a session per week and (iii) psychological support: psychoeducation, written and verbal emotional expression, promotion of coping strategies, progressive muscle relaxation training, problem-solving and social skills, and self-efficacy enhancing, among others. This psychological component will also include counseling regarding smoking and alcohol cessation and sleep hygiene.~NOTE: Both preoperative and postoperative programs will be administer to the participants assigned to the intervention group."
223469280|NCT05379205|OTHER|Usual Care|Usual care group will follow the usual institutional pre-surgery care: (i) medication management, (ii) assessment of the surgery-derived risks, (iii) smoking cessation and peri-operative blood management. A trained nutritionist will evaluate the nutritional status of all patients at the baseline providing oral protein/vitamin supplementation, when necessary. Patients allocated to the control group will receive basic expert' advice on lifestyle changes.
223469281|NCT02503163|DRUG|KCT-0809 ophthalmic solution|
223578797|NCT01013415|DRUG|HAART|
224159452|NCT01655641|DRUG|Tranexamic acid|"Drug: Tranexamic acid~1gm stat, preoperatively (30 mins) 10mg / kg body weight, 8 hourly for 5 days via IV For non-renal impaired subjects.~Alternate IV dosing for renally-impaired subjects: 10mg/Kg BID (1.36 - 2.83 mg/dl clearance); 10mg/Kg QD (2.84 - 5.66 mg/dl clearance; and 10mg/Kg Q48H or 5mg/Kg (.5.66mg/dl clearance)"
223469282|NCT04194814|DRUG|crisaborole (2%) ointment|twice daily application on one forearm for 4 weeks (randomised site allocation)
223469283|NCT04194814|DRUG|betamethasone valerate 0.1% cream|twice daily application on one forearm for 4 weeks (randomised site allocation)
223469284|NCT04273815|DRUG|TQ-A3334|TQ-A3334 is a highly efficient and highly selective TLR-7 agonist. TLR-7 can induce the release of a series of pro-inflammatory cytokines, including IFN-α (interferon-α), IL-12 (Interleukin 12), TNF-α, and promote the maturation and antigen presentation of dendritic cells, play an antitumor effect.
223469285|NCT04273815|DRUG|Anlotinib|Anlotinib is a multi-target receptor tyrosine kinase inhibitor.
223469286|NCT05036213|DRUG|BEET IT - Concentrate Beet root juice|Each bottle contains 75ml of concentrated beetroot juice with approximately 6.2mmol of inorganic nitrate. The product is provided by BEET IT, James White Drinks, Ipswich, UK.
223469287|NCT05036213|DRUG|BEET IT - Concentrate Beet root juice (nitrate depleted)|Each bottle contains 75ml of concentrated beetroot juice with depleted nitrate, thus, no inorganic nitrate is found in thisbeverage. The product is also provided by BEET IT, James White Drinks, Ipswich, UK.
223469288|NCT00461058|DRUG|Actos|Titrated to an individual maximum tolerated dose up to 45mg p.o. daily
223578798|NCT01013415|BIOLOGICAL|T cells|
223578799|NCT03227068|OTHER|PEDSS - symptom management|All subjects will receive education regarding their specific disease and treatment in accordance with current practices. Cancer care providers describe detailed side effects of treatment to parents during the treatment consent process. In addition, all parents will receive standard discharge education before hospital discharge, which includes a list of home medications and information regarding whom to call for emergencies. The PEDSS - symptom management will be delivered prior to the initial hospital discharge. The nurse will review the symptom management worksheet verbally with the parent, then distribute the written worksheet to the parent.
224159453|NCT01655641|OTHER|Standard of care|Includes routine surgical care involved in preventing blood loss during and after surgery.
223469289|NCT00461058|DRUG|aleglitazar|Titrated to an individual maximum tolerated dose up to 0.3mg p.o. daily
223469290|NCT01102023|OTHER|ordinary salt based- diet|
223469291|NCT06325163|DIAGNOSTIC_TEST|CBCT|Mandibular molar indicated for retreatment will be scanned using limited field of view CBCT to examine the number of canals
223469292|NCT06325163|DIAGNOSTIC_TEST|clinical examination under dental operating microscope|the number of canals will be examined by an a randomly assigned operator following gutta percha removal under dental operating microscope
223469293|NCT06325163|DIAGNOSTIC_TEST|canal detection AI software (diagnocat)|software used to analyze CBCT images and report the number of canals
224159454|NCT04685369|OTHER|Medical Data extraction|Medical Data extraction
224159455|NCT05538429|PROCEDURE|erector spinal plane combined with serratus anterior plane block|The experimental group received ultrasound-guided erector spinal block combined with serratus anterior plane block, and erector spinal block was performed at the T5 and T7 levels with 10ml 0.4% ropivacaine for each level, and 20ml 0.4% ropivacaine for serratus anterior plane block. The control group received ultrasound-guided thoracic paravertebral block at T5 and T7 levels, respectively, with 20ml 0.4% ropivacaine at each level.
223469294|NCT01041170|DRUG|THC|
223469295|NCT01041170|DRUG|Rimonobant|
223469296|NCT01041170|DRUG|Rimonabant|
223469297|NCT02737358|DRUG|N-acetylcysteine (NAC)|NAC or matched placebo will be given to study participants for 8 weeks.
224159456|NCT04018105|OTHER|Oral glucose tolerance test (OGTT) with or without metformin|Each participant will have 3 OGTT, one without metformin, one with metformin30 minutes before the test, one with metformin 60 minutes before the test. The order for each test will be randomized.
224159457|NCT03605836|DRUG|Centanafadine SR|100 mg, BID, oral tablets
224159458|NCT03605836|OTHER|Placebo|BID, oral tablet
223469298|NCT02737358|OTHER|Placebo|Matched placebo (2 capsules taken in the morning and evening) will be taken by study participants for eight weeks. All participants will receive brief smoking cessation counseling and support.
223469299|NCT01217593|PROCEDURE|ultrasound|Ultrasound guidance will be used for paravertebral space localization when performing paravertebral blocks on females 25-85 having unilateral mastectomy.
224159459|NCT03605836|DRUG|Centanafadine SR|200 mg, BID, oral tablets
224159460|NCT06186024|DEVICE|Bridge|Stent implantation
223469300|NCT01217593|PROCEDURE|predetermined distance|The predetermined distance technique will be used for paravertebral space localization when performing paravertebral blocks on females 25-85 having unilateral mastectomy.
223469301|NCT03013400|DRUG|Ebselen|Ebselen is an opaque capsule containing 200 mg of ebselen is a selenium-based GPx mimic and IMPase inhibitor.
223469302|NCT03013400|DRUG|Placebo oral capsule|Placebo is identical in appearance to the ebselen capsules
223469303|NCT04341935|DRUG|Linagliptin|5 mg Linagliptin administered by mouth once daily
223469304|NCT04341935|DRUG|Insulin regimen|Standard of care insulin regimen as per hospital protocol
223469305|NCT03881683|DIAGNOSTIC_TEST|HRD and BRCA mutations|Compare BRCA1/2 and HRD genes mutation detected from blood sample (20 ml) and biopsy
223469306|NCT04710212|OTHER|No intervention.|Observational study with no intervention.
223469307|NCT03532763|DIETARY_SUPPLEMENT|Tocotrienol-rich fraction|1 capsule to be taken twice daily after meals for 6 months. Each capsule contains: 200 mg Tocotrienol-rich fraction
223469308|NCT03532763|DIETARY_SUPPLEMENT|Placebo|1 capsule to be taken twice daily after meals for 6 months. Each capsule contains: Palm olein
223469309|NCT01878799|DRUG|GS-7977/GS- 5885 FDC|The GS-7977/GS-5885 FDC product combines a potent HCV nucleotide inhibitor and a potent HCV NS5A inhibitor and will be given for 12 weeks.
223469310|NCT00291369|DRUG|Interleukin-2|
223469311|NCT00291369|DRUG|Interferon alfa|
223469312|NCT00291369|DRUG|medroxyprogesterone acetate|
223469313|NCT00896064|BIOLOGICAL|Pneumococcal vaccine GSK2189242A (formulation 1)|One dose will be administered intramuscularly at Study Day 0.
223469314|NCT00896064|BIOLOGICAL|Pneumococcal vaccine GSK2189242A (formulation 2)|One dose will be administered intramuscularly at Study Day 0.
223469315|NCT06320210|BEHAVIORAL|Multicomponent program|The intervention is a multi-component program that includes in-depth training for current school teachers/staff who are critical in asthma care, restructured processes to identify students with asthma, technological adaptations to support integrated systems for asthma care and absenteeism, strategies to enhance communication about asthma within school and between school and home, protocols for routine care (e.g., participation in gym/recess) and emergencies, and education for all students about asthma.
223469316|NCT00941850|PROCEDURE|Upgrade to triple ventricular site CRT|Patients in this arm will continue to receive CRT via the original unit, but some will have a change in the mode of delivery of therapy (by placing a second pacing lead to reach a different part of the left ventricle from the part originally paced).
224159461|NCT00964639|DRUG|Ropivacaine|During the surgery infiltration with Naropine 2 mg/ml. The dosage in the infiltration is 2 mg/kg. Thereafter bolus 3 times a day
224159462|NCT00964639|DRUG|Saline|During the surgery infiltration with saline. Thereafter bolus 3 times a day
224159463|NCT06315686|DRUG|pemetrexed|The efficacy of Furmonertinib combined with OMMAYA lateral ventricle chemotherapy (pemetrexed) was evaluated once a week during the treatment phase. After the brain lesions were evaluated as CR, the drug holiday study phase was added. During the study period, the patients were followed up once a week until the investigators deemed the subjects unfit to continue to participate in the study or the efficacy was evaluated as disease progression (PD).
224159464|NCT03968211|BIOLOGICAL|Salmonella typhi polysaccharide vaccine|Salmonella typhi polysaccharide vaccine
224159465|NCT04696328|BIOLOGICAL|Human (allogeneic) iPS cell derived-cardiomyocyte sheet|Transplantation
224159466|NCT03746340|DRUG|Propofol|Propofol group: intravenous Propofol (2.0mg / kg) for general anesthesia induction, maintained for 30\~60s. Continuous intravenous infusion of Propofol (7\~8 mg·kg-1·h-1) with a syringe pump maintains a smooth general anesthetic sedative effect.
224159467|NCT03746340|DRUG|Sevoflurane|Sevoflurane group: Inhalation of 1-8% sevoflurane for induction.Then Inhalation of sevoflurane (2.0\~2.5Vol%) was maintained
224159468|NCT05651269|DRUG|Milciclib Dose: 150 mg/day Mode of administration: oral|milciclib plus gemcitabine
223469317|NCT03191799|DRUG|Emicizumab|Initial dosing will be 3 mg/kg/week subcutaneously for 4 weeks; Maintenance dosing will follow at 1.5 mg/kg/week subcutaneously for the remainder of the 2-year treatment period
223469318|NCT04158765|OTHER|DNeasy Tissue Kit (QIAGEN Inc., Mississauga, Ontario, Canada) and PCR- based assay (TRAPeze Telomerase Detection Kit; Millipore, Billerica, MA).|DNA will be extracted from sperm using the DNeasy Tissue Kit and Telomerase activity in samples will be measured using a PCR- based assay.
223469319|NCT03893578|DEVICE|Mitral valve-in-valve|The Synecor Conveyor System shall be used to position the Edwards SAPIEN 3 valve at the mitral location.
223469320|NCT05925192|OTHER|Observational study|N/A - observational study
223578800|NCT03227068|OTHER|PEDSS - support for the caregiver|All subjects will receive education regarding their specific disease and treatment in accordance with current practices. Cancer care providers describe detailed side effects of treatment to parents during the treatment consent process. In addition, all parents will receive standard discharge education before hospital discharge, which includes a list of home medications and information regarding whom to call for emergencies. The PEDSS - support for the caregiver will be delivered prior to the initial hospital discharge. The nurse will review the worksheet verbally with the parent, then distribute the written worksheet to the parent.
223469321|NCT03059914|DEVICE|InterOss|Anorganic bovine bone mineral - Xenograft
223469322|NCT03059914|DEVICE|Bio-oss|Anorganic bovine bone mineral ( Xenograft)
223578801|NCT06070090|PROCEDURE|Acupuncture|The traditional East Asian methods of treating disease by inserting needles along specific pathways or meridians.
223469323|NCT00956085|DRUG|Memantine|Open label memantine titrated in 5mg increments weekly to target dose of 10mg po bid for up to 6 weeks. Memantine was continued to 12 weeks in those with treatment response,13 either previous response to ketamine (≥ 35% Y-BOCS reduction 1 week after IV ketamine) or current response to memantine (≥ 35% Y-BOCS reduction from pre- to post-6 weeks of memantine).
223469324|NCT00915590|DRUG|Placebo|Custom eye drop eye three times a day in both eyes for a period of 6 weeks
223469325|NCT00915590|DRUG|IL-1Ra|5% custom made topical IL-1Ra 3 times a day in both eyes for a period of 6 weeks
223469326|NCT05577416|PROCEDURE|Biopsy|Patients will undergo stereotactic biopsy by craniotomy or burr hole.
223469327|NCT05577416|DRUG|Part A: Safusidenib Erbumine|Part A: Safusidenib Erbumine orally 250 mg BID for 28 days.
223469328|NCT05577416|PROCEDURE|Surgery (maximal resection)|Surgery: Maximal safe resection, within 24 hours of last dose of Safusidenib Erbumine.
223578802|NCT01062061|BIOLOGICAL|VARIVAX™|Attenuated live varicella vaccine
223578803|NCT05436977|DIAGNOSTIC_TEST|coronary OCT|Intermediate coronary lesions will be evaluated by OCT
223578804|NCT05436977|DIAGNOSTIC_TEST|68GaDOTATATE PET/CTCA|Intermediate coronary lesions will be evaluated by68GaDOTATATE PET/CTCA
223578805|NCT06773299|BEHAVIORAL|PAT+HEALTH curriculum - Nigeria|This intervention is an adaption of the PAT Curriculum and the HEALTH intervention specifically tailored for the Nigerian context.
223578806|NCT04298905|OTHER|CHW mHealth patient intervention for trigger escalation|"The CHW dashboard is a tablet-based, per-patient summary of the patient intervention. It is this dashboard that identifies a trigger to escalate the adherence intervention. This dashboard is created by receiving information from the patient's smartphone application as well as the National Health Laboratory Service (NHLS) data feed of laboratory results. The monitoring features included in this dashboard:~1. NHLS laboratory results: Dashboard receives and flags NHLS results for any positive smear or culture (new positive after prior negative results) or detectable viral load (with prior viral suppression)~   1. Triggered, escalating adherence coaching:~  2. Safety monitoring: reports all abnormal laboratory values to provider~2. Appointment keeping (RETAIN):~   a. Triggered, escalating adherence coaching~3. vDOT submissions:~   a. Triggered, escalating adherence coaching~4. Symptom reports:~   1. Triggered, escalating adherence coaching"
223578807|NCT04786418|OTHER|Standard of care|Participants allocated to the control group will be given standard clinical information regarding healthy eating, physical activity and management of weight, in line with current NHS practise.
223578808|NCT04786418|DIETARY_SUPPLEMENT|Low-calorie diet|The LCD intervention group, will received a well validated, commercially available, intensive weight management protocol Counterweight-Plus.
223578809|NCT05713695|BEHAVIORAL|Full MISSION|MISSION is a time-limited, cross disciplinary, team-based wraparound approach that provides 6 months of psychosocial treatment combined with assertive outreach, empowering clients to access and engage in care and community services to promote recovery. The MISSION treatment curriculum integrates 3 evidence-based practices: 1) Critical Time Intervention (CTI), a time-limited form of assertive community treatment; 2) Dual Recovery Therapy (DRT), which is integrated mental health and substance use group therapy; and 3) Peer Support (PS), offering support for people in recovery by people in recovery.
223578810|NCT05713695|BEHAVIORAL|Linkage Only Delivered by a Peer Specialist|Linkage only is provided via Peer Specialists whom have lived experiences similar to that of our participants. Linkage only includes informal treatment planning and linkages and supports to needed community services.
223469329|NCT05577416|DRUG|Part B: Safusidenib Erbumine|Part B: Safusidenib Erbumine orally 250 mg BID for 28 days for a minimum of 12, 28-day cycles subject to ongoing documented evidence of clinical benefit, until disease progression or unacceptable toxicity.
223469330|NCT00748241|DEVICE|Astra Tech Fixture ST|Astra Tech Fixture ST Ø 3.5 and 4.5 cm in lengths of 9, 11, 13, 15, 17 and 19 mm.
223469331|NCT02076100|DRUG|Ruzasvir|Ruzasvir capsules, orally, starting at a dose of 60 mg once per day (QD) x 5 days with doses increasing or decreasing as clinically indicated.
223469332|NCT04654741|DRUG|Medroxyprogesterone Acetate|1 pill per day
223578811|NCT05929586|OTHER|"The combined C-it DU-it intervention: community data use for ANC"|"Combining data linkage (C-it) with work improvement teams for community data use (DU-it) to improve antenatal clinic uptake. Our short name C-it DU-it (pronounced see-it; do-it) is an acronym intended to convey 'seeing' linked data (C-it) and 'doing' or acting on the data (DU-it)"
223578812|NCT05567419|DIAGNOSTIC_TEST|Biological assays|PCR and NGS-WGS on stools and respiratory samples
223578813|NCT06512896|OTHER|FOLactis|Evaluate the safety,tolerability, efficacy of intraluminal injection of FOLactis combined with chemotherapy, target therapy, and immunotherapy
223578814|NCT00524589|DIETARY_SUPPLEMENT|calcitriol|IV
223578815|NCT00524589|DRUG|dexamethasone|Oral
223469333|NCT04654741|DRUG|Ganirelix Acetate|1 injection per day
223578816|NCT00524589|GENETIC|protein expression analysis|Correlative Study
223578817|NCT00524589|OTHER|laboratory biomarker analysis|Correlative Study
223578818|NCT03579212|DEVICE|Y-STRUT® (Hyprevention, Pessac, France)|The studied medical device consists of two components implanted in the proximal femur, combined with bone cement.
223578819|NCT05792527|DRUG|L-carnitine|One 500 mg tablet twice daily after meals
223578820|NCT00098722|DRUG|Maraviroc (UK-427,857)|maraviroc (UK-427,857) 150 mg taken once daily, OBT + maraviroc (UK-427,857) 150 mg taken twice daily, or OBT alone.
223578821|NCT00098722|DRUG|optimized background therapy|\[OBT (3-6 drugs based on treatment history and resistance testing)\]
223578822|NCT00098722|DRUG|Maraviroc (UK-427,857)|maraviroc (UK-427,857) 150 mg taken twice daily
223578823|NCT00098722|DRUG|optimized background therapy|\[OBT (3-6 drugs based on treatment history and resistance testing)\]
223578824|NCT00098722|DRUG|optimized background therapy|\[OBT (3-6 drugs based on treatment history and resistance testing)\]
224068792|NCT02497859|BEHAVIORAL|Egg Breakfast (EB)|The EB will receive a breakfast of higher quality protein, but similar in macronutrient and energy density than the active comparator. The EB will have the following energy density, macronutrient composition, and protein score: weight 291 g,energy 400 kcal, energy density 1.37 kcal/g, carbohydrate 42.9%, fat 35.5%, protein 19.8%, protein digestibility corrected amino acid score (PDCAAS) 100, leucine 1.77 g, glycemic load 24, fiber 1.0 g.
224068793|NCT02497859|BEHAVIORAL|Cereal Breakfast (CB)|The CB will receive a breakfast of lower quality protein, but similar in macronutrient and energy density than the experimental treatment. The CB will have the following energy density, macronutrient composition, and protein score: weight 293 g, energy 398 kcal, energy density 1.3 kcal/g, carbohydrate 44.8%, fat 35.4%, protein 19.8%, protein digestibility corrected amino acid score (PDCAAS) 42, leucine 0.48 g, glycemic load 30.8, fiber 4.4 g.
224159469|NCT02845440|OTHER|Academic Detailing|Academic detailing (AD) is a targeted continuing medical education (CME) strategy that adapts social marketing techniques, using mixed interactive and didactic formats in individual and group settings integrated into the practice setting to promote beneficial changes in medical care. AD helps clinicians understand and adopt targeted evidence-based practices and is one of the few Continuing Medical Education (CME) interventions that has consistently demonstrated improved alignment of physician prescribing behavior with evidence-based practice.
224159470|NCT02845440|OTHER|Community Health Worker|Community Health Worker (CHW) The CHW will offer to support patients and prescribers in health promotion and preventive care in general and specifically to support communication between the primary care provider and patient regarding smoking status, smoking cessation, and to aid implementation of any smoking cessation treatments recommended by prescribers. CHWs will complete the standard CHW certificate training program in general preventive medicine, available through the Boston Public Health Commission. CHWs will then receive the additional specialized training.
224159471|NCT02845440|OTHER|Treatment as Usual (TAU)|Usual care (TAU) for adults with SMI in Massachusetts consists of rehabilitation services publicly funded by the state and traditional fee for service outpatient medical and psychiatric care. Importantly, medical care is not programmatically integrated with the psychiatric rehabilitation services.
224303957|NCT04191837|OTHER|Knee health education control group|Subjects in the health education control group will receive knowledge related to knee OA symptom management. The health education will be conducted in a talk format for 2 hours for two sessions. The course content is developed from the course materials from the websites of Elderly Health Service, Department of Health, Hong Kong SAR and reviewed. Subjects in knee health education group will be told to follow the knee health instruction for 12 weeks.
224303958|NCT02434432|BEHAVIORAL|music therapy selected by mothers|mothers' choice of music
224303959|NCT02434432|BEHAVIORAL|Music therapy recorded lullaby|recorded lullaby
224303960|NCT03056820|OTHER|25° head-up position|Participant will be positioned at 25° angle for procedure.
224303961|NCT03056820|OTHER|55° head-up position|Participant will be positioned at 55° angle for procedure.
224303962|NCT03693573|DRUG|Atezolizumab|Atezolizumab will be administered by intravenous (IV) infusion at a fixed dose of 1200 mg on Day 1 of each 21-day cycle. Administration of study drugs will continue until unacceptable toxicity; loss of clinical benefit as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status; investigator or patient decision to withdraw from therapy; or death (whichever occurs first).
223578825|NCT00002055|DRUG|Pentamidine isethionate|
223578826|NCT05688826|DIETARY_SUPPLEMENT|Sugar|75 g sugar dissolved in 0.8 dl water and flavored with lemon. Ingested during 5 minutes
223578827|NCT02351349|OTHER|multidisciplinary intervention|multidisciplinary intervention
223578828|NCT06105294|BEHAVIORAL|time-restricted eating|Restrict eating to a 10-hour window.
223578829|NCT01971268|DEVICE|Dental Implant|place dental implants according to manufacturer guidelines
223578830|NCT01971268|DEVICE|Platform-Switch Dental Implant|Place Dental Implant with an abutment narrower than the implant platform
223578831|NCT01971268|DEVICE|Platform-Matched dental implant|Place Dental Implant with abutment with same size as the platform
223578832|NCT01357876|OTHER|Metformin|withdrawral
223578833|NCT03895177|DIAGNOSTIC_TEST|contrast enhanced computed tomography|pancreatic protocol CT with 80kVp tube voltage and more than 500mA tube current acquire late arterial phase and portal venous phase using volus tracking method
223578834|NCT00902148|DEVICE|Polylactic Acid Sheet|SurgiWrapTM bioresorbable sheet will be secured directly below the abdominal incision.
223578835|NCT00440310|DRUG|Talaporfin sodium|LS11 (Talaporfin Sodium) dose is 1mg/kg administered intravenously slow push (3-5 minutes).
223578836|NCT00440310|PROCEDURE|Percutaneous placement of device in liver metastases|Light Source placement will be conducted under placement imaging using ultrasound or CT guidance. No more than four Light Sources will be used at a single treatment session. The Light Sources may be used in a single lesion or in multiple lesions.
223578837|NCT00440310|DEVICE|Interstitial light emitting diodes|200 J/cm per Light Source at 20 mW/cm light energy
223578838|NCT00440310|DRUG|FOLFOX4 regimen|Standard care chemotherapy regimen consisting of leucovorin, 5-FU and oxaliplatin
223578839|NCT00440310|DRUG|FOLFIRI regimen|Standard care chemotherapy regimen consisting of leucovorin, 5-FU and irinotecan
223578840|NCT01650415|DRUG|Erythropoietin|twice a week for 1 month
224303963|NCT03693573|DRUG|Bevacizumab|Bevacizumab will be administered by IV infusion at 15 mg/kg on Day 1 of each 21-day cycle. Administration of study drugs will continue until unacceptable toxicity; loss of clinical benefit as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status; investigator or patient decision to withdraw from therapy; or death (whichever occurs first).
224303964|NCT06253026|OTHER|Search and rescue mission|Air search and rescue missions lasting 15 consecutive days
224303965|NCT01382745|DRUG|Nimotuzumab|200mg Nimotuzumab once a week for 12 weeks
224303966|NCT01382745|RADIATION|Intensity Modulated Radiation Therapy (IMRT)|IMRT radiation therapy with doses varying from 45Gy-54Gy in 25-30 fractions
224303967|NCT02242565|DEVICE|ShangRing|ShangRing device for male circumcision
224303968|NCT05191303|DEVICE|Mobile intervention of breastfeeding counseling|The mobile intervention of breastfeeding counseling includes an evidence-based information of breastfeeding, which is based on Ten steps of breastfeeding of Baby Friendly Hospital Initiative (BFHI) and Finnish Institute for Health and Welfare recommendation. The links provide more information and videos related to breastfeeding topic. The mobile intervention of breastfeeding counseling allows the client to write comments or notes that can be used in counseling at maternity clinic or hospital. The mobile intervention of breastfeeding counseling also provides an e-mail to non-urgent questions related to breastfeeding. Questions will be answered within 3 or 4 days by a lactation consultant (IBCLC).
223469334|NCT04236037|PROCEDURE|ultrasound-guided pleural biopsy|Using ultrasound the optimal point of entry for thoracentesis is located. Local anesthesia is obtained with 10 mL of 2% lidocaine with adrenalin injected in cutis, subcutis, muscle and pleura. Before removing the syringe, aspiration of pleural fluid confirms the relevance of the chosen site . Again, the area is wiped with disinfectant and a millimeter small skin incision is made with a pointed scalpel. Six US-guided biopsies of 1.2 millimetres using closed needle biopsies (Quick-core Biopsy Needle 18G, COOK Medical, Bloomington, Indiana, USA or Bard Max Core needle 18G, Temple, Arizona, USA). ) are taken from the parietal pleura. Thoracentesis is performed as described above using the same incision as the pleural biopsy.
223469335|NCT04236037|PROCEDURE|Thoracentesis|The optimal point of entry (the largest distance between parietal and visceral pleura) is identified using ultrasound. This is usually on the lower, dorsal side of the chest. Local anesthesia is obtained with 10 mL of 2% lidocaine with adrenalin injected in cutis, subcutis, muscle and pleura. Before removing the syringe, aspiration of pleural fluid confirms the relevance of the chosen site. The area is wiped with disinfectant and a millimeter skin incision is made with a pointed scalpel. A 7 French (or up to 16 French, to the choice of the clinician) pigtail catheter is inserted and connected to sealed bag. Fluid is aspirated via a 3-way valve, and transferred to relevant bottles for culture, analysis of albumin and LDH, protein, and for cytology.
223469336|NCT00005998|DRUG|carmustine|
223469337|NCT00005998|DRUG|cyclophosphamide|
223469338|NCT00005998|DRUG|cytarabine|
223469339|NCT00005998|DRUG|dexamethasone|
223469340|NCT00005998|DRUG|etoposide|
223469341|NCT00005998|DRUG|filgrastim|
223469342|NCT00005998|DRUG|mitoxantrone hydrochloride|
223469343|NCT00005998|DRUG|retrovirus vector LN|
223469344|NCT00005998|PROCEDURE|in vitro-treated peripheral blood stem cell transplantation|
223469345|NCT00005998|PROCEDURE|peripheral blood stem cell transplantation|
223469346|NCT00005998|PROCEDURE|radiation therapy|
223469347|NCT03541837|DRUG|Ropivacaine|ESP catheter
223469348|NCT04343352|OTHER|implementation of mobile epilepsy training program|"Mobile epilepsy training program will be applied to the application group for 3 months.~The mobile epilepsy training program developed within the scope of the thesis will be introduced to the parents in the application group and the participants will be uploaded to their phones via computer, and the use of the program will be taught in practice. In addition, the participants in the application group will be informed that the mobile epilepsy training program is not open to everyone during the research process, only the application group can use it. After the work is completed, the mobile application control group will be installed on the phones of the parents via computer, their application will be taught and applied."
223578841|NCT01650415|DRUG|Placebo erythropoietin|twice a week for 1 month
223578842|NCT00460590|BIOLOGICAL|MVA 85A|ID vaccine
223578843|NCT00534378|DRUG|Midazolam|The study drug was administered IM into the anterior thigh using the preloaded autoinjector. The autoinjectors were preloaded with midazolam 5 mg or 10 mg with a total volume of 1 or 2 mL. Healthy subjects were assigned to one of six target dosage groups (0.10, 0.18, 0.25, 0.33, 0.40, 0.49 mg/kg) and, based on their weight, received the necessary combination of fixed 5 or 10 mg doses to provide the assigned target dose.
223469349|NCT06027840|DRUG|Varenicline|Varenicline prescription will follow the standard induction period: varenicline 0.5 mg once per day for Days 1-3, varenicline 0.5 mg twice per day for Days 4-7, then varenicline 1 mg twice per day (when varenicline reaches peak efficacy for tobacco cessation). Participants will remain on varenicline for 12 weeks total. Dose adjustments (e.g., reduction to 0.5 mg twice per day if 1 mg is not well tolerated) will be allowed at the discretion of the clinical pharmacist/APRN/physician.
223469350|NCT06027840|BEHAVIORAL|Counseling|Tobacco Treatment Service clinicians will deliver weekly counseling sessions, monitor participants for adverse events, and record participants' weekly cigarette and e-cigarette use. At the first counseling session clinicians will review medication proper use instructions, and potential side effects and strategies to address them at the first counseling session. Study medication refills will be distributed at 4-week intervals. Sessions will focus on quit plan preparation, supportive and practical cessation counseling, resetting quit dates, and relapse prevention.
223469351|NCT06027840|BEHAVIORAL|Guided Self-Change Booklets|The booklet includes information on how to reduce and quit both cigarettes and e-cigarettes on their own, how to prevent relapse, how to set a quit date, and how to enroll in text-based support resources.
223578844|NCT05022823|DEVICE|Compression sleeve, worn during exercise|Participants wear their daytime compression sleeve during the DPRE program.
223578845|NCT05022823|DEVICE|Adjustable Compression (AC) garment, worn during exercise|Participants wear an Adjustable Compression (AC) garment during the DPRE program. Participants will be fitted for an Adjustable Compression garment and instructed in its application by a physical therapist.
223578846|NCT05022823|DEVICE|Compression sleeve, daytime wear|Compression sleeve worn for at least 12 hours per day, seven days a week.
223469352|NCT02666976|DRUG|Ilaprazole|Patients who were diagnosed clinically as NERD and were treated with ilaprazole 20mg once daily for 4 weeks. Biopsies were obtained from 3cm above the EG junction before and after treatment. GERD Q questionnaire, histologic findings (basal cell hyperplasia, papillary elongation, dilated intercellular spaces, intraepithelial eosinophils and intraepithelial T lymphocyte) and inflammatory biomarkers (TNF-α, IL-8, IL-1β, TRPV1 and MCP-1) were accessed.
223469353|NCT04151069|OTHER|Procedure A|Up-dosing nut drink at home
223469354|NCT04151069|OTHER|Procedure B|Up-dosing nut drink at the hospital
223469355|NCT04151069|OTHER|Control group|Strict avoidance of tree nut consumption
224303969|NCT01296659|DRUG|ridaforolimus|Ridaforolimus administered orally 5 days per week in combination with standard chemotherapy
223469356|NCT00685815|DRUG|Ferric Carboxymaltose (FCM)|500mg FCM in 250cc normal saline (NS) IV over one hour, once on Day 3, once on Day 4
223469357|NCT00685815|DRUG|Placebo|250cc normal saline (NS) IV over one hour, once on Day 3, once on Day 4
223578847|NCT05022823|BEHAVIORAL|Decongestive Progressive Resistance Exercise program|"Supervised DPRE exercise program, twice a week for 12 weeks. Exercises will be individualized and offered in a group-based format.~After the 12-week intervention, participants will continue the same program (independently) twice weekly for an additional 12 weeks at home or in a community-based fitness center or attend supervised group exercise sessions virtually."
223469358|NCT03071211|DEVICE|Plug-unplug catheter management|Transurethral catheter is plugged with a plastic cap and participants are taught to unplug during the day when they feel the urge to void or at least every 4 hours.
223469359|NCT03071211|DEVICE|Continuous drainage catheter management|Transurethral catheter is attached to a continuous drainage bag.
223469360|NCT03241095|PROCEDURE|OMT (Osteopathic Manipulative Treatment)|The co-hort will receive OMT. Each participant will perform 10 swings golf swings to determine a baseline measure the strength of their golf swing. This co-hort will then be evaluated by the physician and be given OMT.
223578848|NCT05022823|BEHAVIORAL|Home exercise program|Participants are provided with a home exercise program that follows the decongestive exercise sequence and instructed to perform the exercise sequence once daily for a 10-15 minute period.
224068794|NCT02497859|BEHAVIORAL|Weight Loss Counseling|Weight loss counseling will be administered by a Registered Dietitian and will utilize information and materials derived from the Evidence Analysis Library (EAL) of the Academy of Nutrition and Dietetics (AND). Topics including portion control, macronutrient distribution, snacking, eating out, cooking and grocery shopping, will be discussed. Self-monitoring, motivational interviewing, goal setting, and problem solving will be the behavioral strategies used during counseling.
224068795|NCT02497859|BEHAVIORAL|Weight Loss Diet|Energy intake for study duration will be prescribed at 1,200-1,500 kcals adjusted for each individual's body weight.
224068796|NCT05574205|OTHER|Resistance Exercise|Supervised single-leg (unilateral) exercise will be undertaken every other day throughout the dietary intervention
224068797|NCT05574205|DIETARY_SUPPLEMENT|Protein supplementation|Participants will consume a protein supplement alongside a provided diet to control protein amount and quality.
224068798|NCT00835237|BIOLOGICAL|Boostrix®|Intramuscular, single dose.
224068799|NCT00835237|BIOLOGICAL|Decavac™|Intramuscular, single dose.
224303970|NCT04805918|BEHAVIORAL|VIPP-SD|Parenting program
224303971|NCT05646420|OTHER|Blood sampling|A blood sample of 15 ml will be collected for each patient.
224303972|NCT06182176|DRUG|Sulphadoxine-pyrimethamine and Amodiaquine|The intervention drugs are standard drugs approved by the World Health Organisation for the preventive treatment of malaria (sulphadoxine-pyrimethamine and amodiaquine), schistosomiasis (praziquantel) and soil-transmitted helminths (albendazole).
224303973|NCT00220987|OTHER|Intensive Insulin Therapy|Maintain blood glucose 4.5 - 6.o mmol/L
223469361|NCT03241095|PROCEDURE|Sham intervention|The co-hort participants will each perform 10 swings golf swings to determine a baseline measure the strength of their golf swing. Theythen be given a sham OMT procedure.
223469362|NCT06282991|DRUG|Lorlatinib|ALK/ROS1 tyrosine kinase inhibitor
223469363|NCT03492229|OTHER|tDCS|1 mA of tDCS
223469364|NCT03492229|OTHER|AMT|Ankle motor training
223469365|NCT03492229|BEHAVIORAL|Treadmill training|High intensity treadmill training
223469366|NCT03957785|DEVICE|AlterG Treatment|All participants practiced one session a day of AlterG or TGT (for 40min), six days a week, for four weeks (for a total amount of 24 sessions). All patients were trained using BWS, FAC-tailored physiotherapist assistance, and treadmill speed (S) to allow the participant to walk with the intermittent support of one physiotherapist to help with balance and coordination (FAC 2), with the visual supervision of one physiotherapist (FAC 3), or independently without using the handrails (FAC 4). BWS, physiotherapist assistance, and S were checked and adapted to subjects' progresses across the AlterG sessions. A qualitative (using FAC) and quantitative (spatio-temporal parameters and dynamic electromyography) gait assessment before and after the end of the monthly LBPP gait training was carried out.
223469367|NCT04577599|OTHER|Mobile Low-dose Computed Tomography (LDCT) Screening|Low Dose CT Scan of the Chest
223469368|NCT02377856|DRUG|pegylated interferon alpha 2a, ribavirin|pegylated interferon alpha 2a 180 mcg/week and Ribavirin 1000-1200 mg/day for 24 weeks, follow up for 24 weeks
224068800|NCT00092846|DRUG|MK0803, lovastatin|
224068801|NCT00092846|BEHAVIORAL|Self-Management System|
224068802|NCT02102321|DRUG|albendazole|
224068803|NCT02102321|DRUG|placebo|
224068804|NCT03108950|BEHAVIORAL|Movement to Music|The Movement to Music classes are composed of a set of exercises tailored to the specific needs and capabilities of each target group. The class will consist of and aerobic component and a strength component performed to varying music tempos. All movements will be choreographed by qualified dance instructors. Intervention is delivered using video-conferencing to connect the participant to their instructor.
224068805|NCT01926184|BEHAVIORAL|Affect Regulation Treatment to Enhance Meth Intervention Success (ARTEMIS)|5-session integrative intervention to improve positive affect as well as boost and extend the effectiveness of contingency management (CM).
224068806|NCT01926184|BEHAVIORAL|Contingency Management (CM)|12-week CM protocol that provides escalating monetary reinforcement for biological evidence of methamphetamine abstinence. Delivered as the standard of care for non-treatment-seeking methamphetamine-using MSM in San Francisco. Delivered to both the intervention and attention-control arms
224068807|NCT01265550|DEVICE|Nissen fundoplication|laparoscopic antireflux surgery
224159472|NCT03180021|PROCEDURE|MRI|"This is a multicenter, non-interventional, pilot study. Eligible subjects will have a baseline MRI of the kidney, including anatomical, DWI, BOLD, T1rho, and DCE-MRI, utilizing a macrocyclic gadolinium-based contrast agent (GBCA), followed by planned standard of care (SOC) renal biopsy and clinical laboratory assessments. Additional serum and urine will be collected from subjects at baseline for analysis of research biomarkers. Following the results of the biopsy and clinical laboratory assessments, subjects will be treated for their underlying disease at the discretion of the investigator.~At 6 months, subjects will return to the clinic for a second MRI, SOC clinical and laboratory evaluation and collection of serum and urine for analysis of research biomarkers."
224159473|NCT03497390|OTHER|EMERALD intervention|EMERALD consists of a 1-year multi-component structured program led by nurses and held 4-weekly for the first 3 months, followed by maintenance program, peers support and telephone calls.
224159474|NCT03497390|OTHER|Usual care|Usual care without any workshop or program
224159475|NCT04428762|DEVICE|I-Port Advance use|participants will apply I-port advance for 4 weeks and will inject all insulin through the port. follow up 3 months with/ without i-port.
223469369|NCT01947348|PROCEDURE|treatment with A3 SVF|Treatment interarticular and IV with A3 SVF
223469370|NCT00004658|DRUG|ribose|
223469371|NCT00004658|DRUG|thymidine|
223469372|NCT00004658|DRUG|uridine|
223469373|NCT04071041|DRUG|Albumin Human|Administration of albumin 20%, 20g in 100ml (Albutein Instituto Grifols, S.A. Can Guasch 2, Parets del Vallès, 08015 Barcelona, Spain) intravenously every 12 hours for 4 days or until death, discharge or clinical stability if occurring before.
223469374|NCT05068843|PROCEDURE|arthroscopic partial meniscectomy|In the surgery group, the orthopaedic surgeon performed an arthroscopic partial meniscectomy within 4 weeks after allocation. The surgeon removed the damaged part of the meniscus, until a stable and solid meniscus remained. All patients received written post-operative instructions. Eight weeks after surgery, patients received a consult in the outpatient orthopaedic clinic. In agreement with the Dutch Orthopaedic Association Guidelines, patients were referred to physical therapy when signs of abnormal recovery were present.
223578849|NCT04578639|DRUG|Rituximab|A prospective randomized double blinded multicenter non-inferiority study designed to establish non-inferiority of the study treatment rituximab compared with the comparator ocrelizumab for consecutively included patients (male or female) with active relapsing-remitting multiple sclerosis aged 18-60 years. Active substance is biosimilar rituximab iv infusion and comparator is ocrelizumab (Ocrevus ®) iv infusion. Both treatments are given as infusion at month 0, month 6, month 12, month 18 and month 24. Randomization rituximab: ocrelizumab is 3:2. The primary end-point is proportion of patients with no new or enlarging T2-weighted brain MRI lesions between re-baselining at month 6 and month 24.
223578850|NCT04578639|DRUG|Ocrelizumab|A prospective randomized double blinded multicenter non-inferiority study designed to establish non-inferiority of the study treatment rituximab compared with the comparator ocrelizumab for consecutively included patients (male or female) with active relapsing-remitting multiple sclerosis aged 18-60 years. Active substance is biosimilar rituximab iv infusion and comparator is ocrelizumab (Ocrevus ®) iv infusion. Both treatments are given as infusion at month 0, month 6, month 12, month 18 and month 24. Randomization rituximab: ocrelizumab is 3:2. The primary end-point is proportion of patients with no new or enlarging T2-weighted brain MRI lesions between re-baselining at month 6 and month 24.
224303974|NCT00220987|OTHER|Conventional Insulin therapy|Maintain blood glucose 8-10mmol/L
224303975|NCT03511443|DIAGNOSTIC_TEST|hsRDT|Testing highly sensitive RDT detection for low parasitemia
223469375|NCT05068843|OTHER|Physical therapy|The treatment protocol consisted of a physical therapist-led incremental exercise program over a period of eight weeks, containing 16 sessions of 30 minutes each.
223469376|NCT02605330|PROCEDURE|Fibrinogen plasma level|At 12 different time points investigators plan to measure the plasma fibrinogen level with conventional coagulation tests (Clauss fibrinogen) and with ROTEM.
223469377|NCT02121171|DEVICE|Ologen Collagen Matrix|Use of ologen Collagen Matrix in trabeculectomy (ologen) Place ologen CM on the top of the loosely-sutured scleral flap under conjunctiva before suturing. It is recommended to suture the scleral flap with 1 or 2 stiches loosely and to coordinate with the tamponading effect of ologen CM to create a fluctuating scleral flap that prevents bleb wound adhesion and modulates aqueous humor outflow for ideal IOP control without leakage.
223469378|NCT02121171|PROCEDURE|Combined trabeculotomy-trabeculectomy|Combined trabeculotomy and trabeculectomy is a standard surgery for congenital glaucoma, however, it has its known complications.
223578851|NCT06378463|OTHER|Cognitive remediation + active tDCS|"The cognitive remediation program Computerised Interactive Remediation of Cognition - a Training for Schizophrenia (CIRCuiTS) improves cognitive and metacognitive skills and strategies and is specifically aimed at the generalization of newly learnt skills to daily life. This method also offers the possibility to personalize the training program based on individual goals and cognitive functioning of the service user.~Transcranial Direct Current Stimulation is used to promote neural plasticity, which applies a small electrical current over the cortex. This can alter the excitability of neurons, such that it increases or decreases spontaneous network activity. When applied to fronto-parietal neural networks simultaneously with their engagement in cognitive tasks of CIRCuiTS, it is expected that plasticity of these networks will be modulated, resulting in improvements in cognitive functioning.~In this condition, participants will receive active brain stimulation."
224303976|NCT04204759|DEVICE|Transcranial direct current stimulation|Non-invasive stimulation will be conducted using a tDCS device (StarStim, Neuroelectrics, Spain).
224303977|NCT04204759|DEVICE|Sham transcranial direct current stimulation|The same device will be used as in the active stimulation group, but stimulation will be terminated after 30 seconds.
223469379|NCT02974868|DRUG|PF-06651600|200 mg QD during induction and 50 mg QD during Maintenance
223469380|NCT02974868|DRUG|PF-06700841|60 mg QD during induction and 30 mg QD during maintenance
223469381|NCT02974868|DRUG|Placebo|Placebo
223469382|NCT02193750|DIETARY_SUPPLEMENT|Placebo|1 placebo muesli bar and 1 serving placebo muesli per day (0.55 g total fructans/GOS)
223469383|NCT02193750|DIETARY_SUPPLEMENT|Moderate Oligosaccharide Group|1 placebo muesli bar and 1 serving intervention muesli per day (3.25 g total fructans/GOS)
223469384|NCT02193750|DIETARY_SUPPLEMENT|High Oligosaccharide Group|1 placebo muesli bar and 1 serving placebo muesli per day (5.43 g total fructans/GOS)
223469385|NCT01755507|DRUG|norUDCA|Comparison of different dosages of norUDCA acid administered orally.
223469386|NCT01755507|DRUG|Placebo|
223469387|NCT00706004|DRUG|lubiprostone|lubiprostone 24 microgram capsule taken twice daily for 4 weeks
223469388|NCT04197271|PROCEDURE|Emergency Hernia Repair|Emergency repair of hernia using method selected by treating surgeon.
223469389|NCT04197271|OTHER|Conservative management|Treatment of hernia without resort to surgery
223469390|NCT04726735|BIOLOGICAL|Samples of bladder tissue|Samples of bladder tissue collected between 2007 and 2011.
223469391|NCT05385146|OTHER|qigong|Chan-Chuang qigong with breathing meditation for 15 weeks
223469392|NCT00229671|OTHER|Survey 1|During the initial survey, we reviewed dispensed medications by having parents of patients with prescriptions under 21 read the medication label. We then asked questions about potential side effects, method of medication administration, communication regarding the medication with the pharmacist and the health care provider, and demographic information. Research assistants underwent several weeks of training to ensure a standardized approach to surveys.
223469393|NCT00229671|OTHER|Survey 2|If the parent completed the initial survey, we attempted a second survey 2 months after the index visit to capture persistent symptoms. Surveys were translated and back translated into Spanish and Cambodian and conducted by fluent bilingual interviewers. Surveys were pretested and revised based on 2 focus groups of parents representing a broad array of socioeconomic backgrounds.
223469394|NCT03817606|DEVICE|Tritanium Posterior Lumbar Cage|Placement of Tritanium Posterior Lumbar Cage via TLIF procedure
223469395|NCT03817606|DEVICE|AVS UniLIF PEEK Posterior Lumbar Cage|Placement of AVS UniLIF PEEK Posterior Lumbar Cage via TLIF procedure.
223469396|NCT00216255|DRUG|Pagoclone|
223469397|NCT00216255|DRUG|Placebo|
223469398|NCT02436824|DRUG|AB001 patch|Two AB001 patches will be applied to the low back once daily for 14 days, the patches shall be removed after approximately 12 hours after daily application.
223469399|NCT02436824|OTHER|Placebo patch|Two placebo patches will be applied to the low back once daily for 14 days, the patches shall be removed after approximately 12 hours after daily application.
223469400|NCT06074185|DRUG|Ipratropium Bromide|The study intervention involves implementing a treatment bundle that includes inhaled ipratropium bromide and dexamethasone.
223469401|NCT03089476|OTHER|Evaluating atopy in infants|This study does not have an intervention. There is the evaluation of the predictive value of TEWL and STS in atopic infants at risk of developing eczema and TEWL and STS in parents of infants.
223469402|NCT03089476|OTHER|Evaluating TEWL and STS in adults|This study does not have an intervention. There is the evaluation of the predictive value of TEWL and STS in atopic infants at risk of developing eczema and TEWL and STS in parents of infants.
223469403|NCT00937339|DEVICE|Whole body vibration therapy|Experimental group: One session per day, 3 sessions per week, for consecutive 8 weeks. The total duration of whole body vibration therapy will be about 10 minutes per session.
223469404|NCT00937339|DEVICE|Exercise on the vibration platform with the device turned off|Control group: One session per day, 3 sessions per week, for consecutive 8 weeks. The subjects will perform the same exercises on the vibration platform but no vibration will be applied.
223469405|NCT06115018|PROCEDURE|Palatal surgery|Palate surgery has evolved from the ablative partial palate resections, which favored the removal of the soft tissue that obstructed the upper airway (UA), to more recent innovative reconstructive procedures that not only address the level of palatal obstruction, but the type of palatal or lateral pharyngeal wall collapse.
223469406|NCT06115018|BEHAVIORAL|Oropharyngeal rehabilitation|Oropharyngeal rehabilitation (OPR) focus on the upper airway muscle including tongue muscle, palatal muscles and paryngeal muscles. The OPR for the treatment groups included three 30-minute sessions of OPR per day, and the exercise would be performed 3-5 days per week for 3 months. The performance of the home exercise will also be recorded by the force-sensing resistor. In addition to home exercise sessions, there will also be twice-weekly clinical visits to adjust the contents of OPR program and monitor training progress.
223469407|NCT06115018|COMBINATION_PRODUCT|Palatal surgery combined oropharyngeal rehabilitation|Participants will receive palatal surgery and post-surgery oropharyngeal rehabilitation (OPR). The palatal surgery and OPR describe as above.
223469408|NCT04423471|DIAGNOSTIC_TEST|Sociodemographic variables|"* Sociodemographic variables: Sex / Age / Marital status / Level of studies completed / Employment status.~* General clinical variables: Body mass index (BMI), Medical comorbidities and Charlson Comorbidity Index, Active drug treatments~* Clinical psoriasis variables: BSA, PASI, ScalpPASI, PPPASI, DLQI, time since the diagnosis of psoriasis, previous treatments for psoriasis.~* Clinical depression variables: Psychiatric diagnoses according to clinical interview and DSM-5 criteria, age of onset and time of evolution from the first episode of major depression, time of evolution of the current episode of major depression, previous treatments for depression.~* Psychopathological variables: HADS, PHQ-9, MADRS, GAD-7, SHAPS, The Irritability Questionnaire, PSS, FSS, MoCA.~* Immunological and biochemical variables: Acute phase biomarkers, Proinflammatory cytokines, Anti-inflammatory cytokines, HPA axis, Microglia activation, Neurogenesis.~* Result variables: Changes in PASI or MADRS scores"
223578852|NCT06378463|OTHER|Cognitive remediation + sham tDCS|"The cognitive remediation program Computerised Interactive Remediation of Cognition - a Training for Schizophrenia (CIRCuiTS) improves cognitive and metacognitive skills and strategies and is specifically aimed at the generalization of newly learnt skills to daily life. This method also offers the possibility to personalize the training program based on individual goals and cognitive functioning of the service user.~Transcranial Direct Current Stimulation is used to promote neural plasticity, which applies a small electrical current over the cortex. This can alter the excitability of neurons, such that it increases or decreases spontaneous network activity. When applied to fronto-parietal neural networks simultaneously with their engagement in cognitive tasks of CIRCuiTS, it is expected that plasticity of these networks will be modulated, resulting in improvements in cognitive functioning.~In this condition, participants will receive sham brain stimulation."
223469409|NCT00575354|DRUG|Sevoflurane|3-6% sevoflurane inhaled for anesthesia induction, and 2-3% sevoflurane was used to maintain the anesthesia till the end of the operation.
223469410|NCT00575354|DRUG|Isoflurane|3-6% isoflurane inhaled for anesthesia induction, and 2-3% isoflurane was used to maintain the anesthesia till the end of the operation.
223469411|NCT03940872|DIAGNOSTIC_TEST|Self-questionnaire 3PDQ|"Visit 1 : - The patient will have to complete the 3PDQ self-questionnaire. - The investigator will conduct an interrogation and a neurological examination in order to ask or not the diagnosis of parkinsonian primary pain, without knowing the result of the 3PDQ.~Visit 2 : - The patient will have to complete the 3PDQ self-questionnaire.~\- An investigator, obligatorily different from the investigator of the visit 1, will conduct to the same interrogation and the same neurological examination in order to ask or not the diagnosis of parkinsonian primary pain, without knowing the result of the 3PDQ.~Visits 1 and 2 can be made on the same day. In this case the patient will fill the 3PDQ self questionnaire only once."
223578853|NCT05403892|DIAGNOSTIC_TEST|level laser lunge test|In order to perform the Level Laser Test, the operator 1 places a laser lever on the ground one metre aside and 50 cm forward the ankle to be examined. This laser (a 2-class laser not harmful to the eyes) maintains a linear laser light beam perpendicular to the floor. The examined leg is placed further forward to the other one, as it happens in the DLT. The teenage performs a forward lunge perpendicularly to the laser line, the heel positioning 50 cm from the laser line. Operator 1 has the subject perform a lunge while operator 2 measures the distance from the kneecap to the laser line. The measurement, deducted by 50 cm, leads to the heel-to-wall distance (value used to DLT).
223578854|NCT05403892|DIAGNOSTIC_TEST|dorsiflexion Lunge test|The dorsiflexion lunge test (DLT) will be used to measure ankle dorsiflexion. To perform this test, the teenage stands in front of a wall holding the foot of their limb to be measured perpendicularly to it. The other foot is to be kept behind it. The teenage is asked to perform a lunge (to dorsiflex the ankle and bring the knee into flexion) until the front knee touches the wall without the heel lifting off the ground. The teenage steps away from the wall as much as possible as long as the knee keeps touching the wall. Measurement in centimeters is taken from the heel of the examined leg to the wall.
223578855|NCT03671408|OTHER|clinical measurements|only clinical parameters were recorded
223578856|NCT01519999|BEHAVIORAL|Shared Decision Making for Colorectal Cancer Screening|Age-eligible adults in the intervention communities will be exposed to the shared decision-making intervention when they are seen in the primary care clinics (N=all patients 50-75 years seen during the study period who are non-adherent to CRCS recommendation). Additionally, among patients with primary care visits scheduled one week or more before the visit, they will be randomized to receive either a mailed decision aid booklet or an informational flyer on shared decision making and CRCS prior to the visit. Patients with primary care visits scheduled less than one week prior to the visit will not be mailed materials in advance. The effect of the pre-visit materials on referral to SDM session and CRCS adherence between these groups will be compared. They will also be exposed to shared decision-making tools and resources available through the community-wide intervention activities.
224068808|NCT01265550|DRUG|baclofen|"Baclofen will be prescribed in a dose of 5 mg three times a day (TID) with meals.~The dose of baclofen will be increased by 5 mg TID every week until a total dose of 20 mg TID has been achieved."
224068809|NCT01265550|DRUG|Desipramine|Dose of 25 mg at bedtime (HS) for 1 week, then 50 mg HS for 1 week, then 100 mg HS until the next quarterly visit.
224068810|NCT00684788|COMBINATION_PRODUCT|employment-based reinforcement|"Participants in the Work Plus Naltrexone Contingency condition were required to take scheduled doses of depot naltrexone to work and earn wages."
224068811|NCT00003737|DRUG|becatecarin|
224068812|NCT04558814|DIAGNOSTIC_TEST|Serum galectin-9 level|Determining level of galectin-9 in sera of patients of SLE with different disease activity and organ affection and Sera of control group
224068813|NCT06373289|DEVICE|higher oxygen saturation target using Nellcor pulse oximetry sensors|The intervention will be a cross over exposure to the higher oxygen saturation target.
224068814|NCT06373289|DEVICE|lower oxygen saturation target using Nellcor pulse oximetry sensors|The intervention will be a cross over exposure to the lower oxygen saturation target.
224068815|NCT02639000|PROCEDURE|Embryo transfer|Embryo transfer of maximum of 2 embryos at cleavage or blastocyst stage
224068816|NCT00623428|DRUG|peginterferon alfa-2a|
224159476|NCT03422757|DEVICE|adaptive Deep Brain Stimulation|"The investigational medical device (AlphaDBSvext) is a portable, external, dual mode stimulator that can deliver adaptive DBS or conventional DBS for the treatment of PD.~In the adaptive mode, the device records Local Field Potential activity from the implanted DBS electrode and simultaneously delivers stimulation through the same electrode based on the recorded signal."
224159477|NCT03422757|DEVICE|conventional Deep Brain Stimulation|"The same investigational medical device (AlphaDBSvext) is used to deliver conventional DBS for the treatment of PD. In the conventional mode it delivers constant stimulation."
224159478|NCT03316742|COMBINATION_PRODUCT|Intervention 1|Intervention 1 includes providing participants with a high fiber food product, protein source, high intensity sweetener and adult multivitamin.
224159479|NCT03316742|COMBINATION_PRODUCT|Intervention 2|Intervention 2 includes providing participants with an alternative dietary fiber source, milk protein, high intensitysweetener and adult multivitamin.
224159480|NCT06261411|DIAGNOSTIC_TEST|Lung Ultrasound|Diagnostic ultrasound of pulmonary tissues such as pleura, plural spaces, and parenchyma.
223469412|NCT02130947|BEHAVIORAL|Exercise|
223469413|NCT00297648|BIOLOGICAL|Certolizumab pegol|Certolizumab pegol (CDP870) 400 mg administered subcutaneously (sc) at Weeks 0, 2 and 4 (induction doses), then every 4 weeks (Q4W) until Week 52. Investigators can escalate dosage to CDP870 400 mg 2-weekly (Q2W) at any time after Week 10 for lack of response/remission. After Week 52 patients can continue to receive treatment until study drug end, either Q4W or Q2W, according to their administration frequency at Week 52.
224159481|NCT05431231|DIAGNOSTIC_TEST|Outcome Questionnaire-45|a questionnaire that evaluates the patient's level of distress. The questionnaire was developed by Lambert et al. in 1996 and was translated to Hebrew by Gross, Glasser, Elisha et al. in 2015. The questionnaire is composed of 45 statements that describe emotional states, assessing three main components: subjective discomfort, interpersonal relationships and performance of social roles. The participants are asked to rate how often they have felt the states described by each statement using a five-level Likert scale (0 - never, 4 - almost always). This questionnaire has been used extensively and has showed good internal consistence of 0.93 for its English version and 0.91 for its Hebrew version.
224068817|NCT00623428|DRUG|Ribavirin|
224068818|NCT03948828|BIOLOGICAL|Autologous NK cell therapy|After conventional treatment, the patients were treated with autologous NK cells.
223469414|NCT04566068|BEHAVIORAL|Intervention- Adapted Virtual Insomnia Program|4 sessions (approximately 45 min/each, weekly) plus 3 check-ins (approximately 15 min/each, between-sessions) delivered virtually. Sessions are modeled after a published, evidence-based CBT-I protocol and adapted to target needs and preferences identified by cancer survivors.
223469415|NCT04566068|BEHAVIORAL|Control- Enhanced usual care|Enhanced usual care. Referral to the Massachusetts General Hospital Behavioral Sleep Medicine service plus an educational handout on the topic of sleep hygiene.
223469416|NCT02882334|DEVICE|Finger Force Manipulandum|
223469417|NCT02882334|OTHER|Conventional physiotherapy|
223469418|NCT00480571|DRUG|BL-1020|BL-1020 Low Dose
223469419|NCT00480571|DRUG|BL 1020 High Dose|BL 1020 High Dose
223469420|NCT03313739|OTHER|An Educational Program|An educational program was designed for self-care during menopause using teach back method.
223469421|NCT06529341|OTHER|High-definition transcranial direct current stimulation|HD-tDCS stimulated AD left OFC (2 mA, 20 minutes, cathode electrode placed in the Fp 1 area, and the remaining four positive electrodes placed AF3, AF7, Afz, Fpz, forming a circular 41 focused electric field mode for stimulation, twice a day, 20 minutes interval for 5 days)
223469422|NCT06529341|OTHER|High-definition transcranial direct current stimulation pseudo-stimulation control group|The treatment parameters of the electrode were the same as the test group, the stimulation current rose to the same 2 mA current in the test group within 30 seconds, and the pre-stimulation for 1 minute, then gradually to 0 mA.
223578857|NCT01459991|OTHER|Walnut|Participants will consume 1 ounce walnuts daily and follow a Mediterranean style diet.
223578858|NCT01459991|OTHER|MyPyramid|Participants will follow a USDA MyPyramid style diet for lactating moms.
223578859|NCT02421263|DRUG|Psilocybin|Participants will receive 20 mg/70 kg of psilocybin in the first session and will receive either 20 or 30 mg/70 kg in the second session.
223469423|NCT06125093|BEHAVIORAL|Incredible Years Autism Spectrum and Language Delays Parent Program (IY-ASLD®)|"The IY-ASLD® program is a weekly group-based intervention for parents of children presenting neurodevelopmental problems (ASD symptoms, communication or language difficulties). The group is formed by 6-10 parents, and it is led by a group leader and a co-therapist, trained in the model.~The intervention is manualized. It includes video modelling and emphasizes the importance of practice-based learning through role-playing. The IY-ASLD® program takes into consideration the different developmental levels of each child and pairs parents according to this variable in role-play and other one-to-one discussions. Weekly home tasks will be assigned to parents, and families will be phoned each week to encourage home-based practice.~The intervention will be conducted online. Even though the IY-ASLD® original intervention comprises 14 sessions, the online format requires 22 weekly sessions.~Fidelity to the intervention will be assessed in accordance with the regulations of the program."
223469424|NCT04619017|BIOLOGICAL|Segmental allergen challenge|All subjects will undergo bronchoscopy with administration of standardized allergen extract to one segment of the lung.
223469425|NCT00750802|DRUG|AZD6280|10mg Capsule, oral, single-dose
223469426|NCT00750802|DRUG|AZD6280|40mg Capsule, oral, single-dose
223469427|NCT00750802|DRUG|Lorazepam|2mg tablet, oral single-dose
223469428|NCT00750802|DRUG|Placebo|
223578860|NCT01987219|DRUG|Albuterol-sulphate|Beta-2-adrenergic agonist 2.5 mg 3 cc inhalation Peak effect 15 - 30 mins. Mean duration of effect 3 hours
223578861|NCT01987219|DRUG|Ipratropium-bromide|Anti-cholinergic 500 mcg 3 cc inhalation Peak effect 30 - 90 mins. Duration of effect 2 - 4 hours.
223578862|NCT01987219|OTHER|placebo|Saline solution 3 cc NA
223469429|NCT00485355|PROCEDURE|conventional laparoscopic hysterectomy|Total laparoscopic hysterectomy
223469430|NCT00485355|PROCEDURE|robotic assisted laparoscopic hysterectomy|Robotic assisted laparoscopic hysterectomy with DaVinci robot
223469431|NCT00659087|PROCEDURE|Femoral Block|Those receiving femoral block postoperatively
223578863|NCT01610596|DRUG|Halobetasol Propionate Lotion 0.05%|Apply twice daily for 1-2 weeks, not to exceed 50 grams per week
223578864|NCT01610596|DRUG|Placebo|
223578865|NCT01519674|DRUG|biphasic insulin aspart 30|BIAsp 30 will be injected subcutaneously (under the skin) twice daily. Individually adjusted dose.
223578866|NCT01519674|DRUG|biphasic insulin aspart 30|BIAsp 30 will be injected subcutaneously (under the skin) once daily. Individually adjusted dose.
224068819|NCT03948828|DRUG|GnRHa combained with reverse addition therapy|Postoperative patients were treated with GnRHa combined with reverse addition treatment.
224068820|NCT03592095|DEVICE|Dry needling|Real dry needling will be conducted according to Hong description, fast-in and fast-out interventions. The intervention will be applied until a total of four local twitch responses will be elicited
224068821|NCT03592095|DEVICE|Placebo needle|Sham dry needling with be conducted with a sham needle (Steitberger's Park sham device (PSD). This needle has a blunt tip and retractable handle that created the illusion of a needle penetrating the skin. When this needle touches the skin, a pricking sensation will be created. However, when pressure will be increased, the shaft of the needle disappears into the handle creating a sensation on the patient.
224068822|NCT04519385|DRUG|Tocilizumab|Tocilizumab therapy
224068823|NCT04519385|DRUG|Dexamethasone|dexamethsone pulse therapy
223469432|NCT00659087|OTHER|Usual Care|Those receiving only usual pain management postoperatively
223469433|NCT05238636|PROCEDURE|Anti-reflux surgery - Stretta procedure or LINX device or laparoscopic fundoplication|This is an observational study. Patients will choose which anti-reflux procedure (Stretta, LINX or fundoplication) they undergo with their clinician, as is standard practice, after which they will be offered recruitment to this study, which will perform investigations to assess for changes in physiology and symptoms.
224068824|NCT00343174|DRUG|Ancrod|
223469434|NCT02410447|DEVICE|Defocused shock wave therapy (DUOLITH® SD1)|
223469435|NCT03641261|OTHER|Therapeutic patient education program|WebIchtyose is a specific therapeutic patient education program for patients with hereditary Ichthyosis targeting the problems of each patient by means of a personalized follow-up and a constant interaction between the patient and the educational team
223578867|NCT01519674|DRUG|sitagliptin|Subjects will continue on their pre-trial sitagliptin treatment.
223578868|NCT01519674|DRUG|metformin|Subjects will continue on their pre-trial metformin treatment.
224068825|NCT00479791|BEHAVIORAL|Test meals rich in different fatty acids|
223578869|NCT04523090|DRUG|Nitazoxanide|Nitazoxanide (NTZ) is licensed in the USA for treatment of diarrhoea caused by Cryptosporidium parvum and Giardia lamblia. NTZ is a pro-drug for tizoxanide, which also has broad spectrum antiviral properties, has many viral indications and shows promising pharmacodynamics against Coronaviridae. NTZ was identified as a first-in-class broad-spectrum antiviral drug and has been repurposed for the treatment of influenza. In vitro studies evaluating tizoxanide, the active circulating metabolite of NTZ, inhibits the replication of broad range of influenza A and B, HIN1, H3N2, H3N2V, H3N8, H5N9, H7N1 and oseltamivir resistant strain and coronaviruses . It has been shown to have anti-viral activity against several viruses including Ebola, hepatitis B and C, rotavirus and norovirus.
224159482|NCT05431231|DIAGNOSTIC_TEST|Hopkins symptoms checklist - short form|a questionnaire for assessing symptomatic distress. The questionnaire was developed by Lutz, Tholen, Schürch, and Berking in 2006. It is a short version of the SCL-90-R, that was developed by Derogatis in 1992. The checklist includes 11 items that describe negative feelings and thoughts. Participants are asked to rate the extent to which a given feeling or thought has troubled them in the past week using a four-level Likert scale (1 - not at all, 4 - very much). This tool is highly correlated with the Global Severity Index (r=.91) and has shown high internal consistency.
223469436|NCT03212040|DIAGNOSTIC_TEST|needle biopsy|breast biopsy using different needle gauges
223469437|NCT06028789|DIAGNOSTIC_TEST|Blood sample test|"The following groups of biomarkers will be examined:~* standard panel of inflammation markers: CRP, PCT, IL-6, Leukocyte count, differential blood count~* microbiology cultures according to the clinical status~* serum biomarkers: sCD64, sTREM-1, calprotectin, pentraxin 3~* flow cytometry: HLA-DR, CD14, CD16, CD40, CD45, CD64, CD163 expression on granulocytes and monocytes~* cell function assay: IL-18 and IFN-γ~* hematology: ICIS, Neutrophil-to-lymphocyte ratio - examined together with conventional hematological parameters.~The schedule of blood sample taking will be as follows:~A. the study group: preoperatively (T-1), 1st postoperative day (T1), 3rd postoperative day (T2), 7th postoperative day (T3), 10th postoperative day (T4)~B. the control group: at admission or the next day (T1), 3rd day of hospital stay (T2), 7th day of hospital stay (T3), 10th day of hospital stay (T4)"
223469438|NCT06028789|PROCEDURE|Thoracic Aortic Surgery|Scheduled surgical intervention, i.e. replacement of pre-specified part of thoracic aorta by a vascular prosthesis.
223469439|NCT00025389|BIOLOGICAL|bevacizumab|
223469440|NCT00025389|DRUG|carboplatin|
223469441|NCT00025389|DRUG|paclitaxel|
223469442|NCT00025389|PROCEDURE|conventional surgery|
223469443|NCT00025389|PROCEDURE|neoadjuvant therapy|
223469444|NCT03522116|OTHER|No intervention|No intervention
223469445|NCT05705999|DEVICE|transcranial magnetic stimulation|The neurostimulation protocol will include 1-Hz rTMS over the bilateral SMA at 110% RMT. The SMA will be identified as 4 cm anterior to the vertex (Cz in standard 10-20 EEG setup). Each session will consist of 6 trains lasting 5 minutes each (300 pulses per train) with an intertrain interval of 1 minute for a total duration of 35 minutes (1800 pulses). Patients will receive 4 sessions each day on 4 consecutive days for a total of 16 sessions. Daily duration of this study protocol should last approximately 170 minutes including a 10-minute break in between each session
223469446|NCT02515435|DRUG|apatinib single agent|For those heavily treated non-squamous non-small cell lung cancer, treat with apatinib single agent, 500mg or 750mg Qd, p.o based on the status of patient, continue until disease progression, dose reduction was admitted
223469447|NCT01876524|DEVICE|Transcranial Random Noise Stimulation|Random Noise Stimulation between 100 and 500 Hz and 400-500 microAmperes are applied over head in particular areas
223469448|NCT03575702|DRUG|Uritos®|film-coated tablets 0.1 mg
223469449|NCT03575702|DRUG|Urotol®|film coated tablets, 2 mg
224068826|NCT03333031|DRUG|HS-196|HS-196 will be administered intravenously as a single dose
224068827|NCT00864435|DRUG|Carvedilol 12.5 mg Tablets, single dose|A: Experimental Subjects received Shasun Chemicals and Drugs Ltd. formulated products under fasting conditions
224068828|NCT00864435|DRUG|Coreg® 12.5 mg Tablets , single dose|B: Active comparator Subjects received GlaxoSmithKline, USA formulated products under fasting conditions
224068829|NCT01212302|DRUG|Optimizing ASA and clopidogrel treatment|"ASA 100 mg, ASA 300 mg, ASA 500 mg~Clopidogrel 75 mg, Clopidogrel 150 mg, Ticlopidine 2x 250 mg, Prasugrel 10 mg. Intervention List:~In the case of clopidogrel low-response, the maintenance dose was doubled (repeated loading dose followed by 150 mg daily), and when still ineffective ticlopidine or prasugrel, if available and not contraindicated, were used. ASA low-responders were treated by increasing the dose to 300 mg in a first step or to 500 mg ASA when the first modification was not sufficient."
223469450|NCT00368628|PROCEDURE|continuous positive airway pressure|Continuous Positive Airway Pressure initiated within 48 hours of stroke onset and continued for 90 days.
223469451|NCT01106131|DRUG|CKD-501 0.5mg|CKD-501 0.5mg, orally, 1 tablet once a day for 24weeks or 52weeks(if extension study) with metformin.
224068830|NCT01188083|DIETARY_SUPPLEMENT|Fructose Drink|Fructose Based beverage 8 oz
224068831|NCT01188083|DIETARY_SUPPLEMENT|Glucose Drink|Glucose Based beverage 8 oz per drink x 3 per day x 4 weeks
223469452|NCT01106131|DRUG|Pioglitazone 15mg|Pioglitazone 15mg, orally, 1 tablet or 2 tablet(if confirmed case) once a day for 24weeks with metformin.
223469453|NCT03903172|DEVICE|Abdominal binder|Abdominal binder
223469454|NCT01545388|DRUG|Sitagliptin|Sitagliptin, orally, 50 or 100 mg tablet (continuation of the pre-study dose)
223469455|NCT01545388|DRUG|Metformin|Metformin, orally, 500 mg daily (single dose; two 250 mg tablets) for 24 weeks
223469456|NCT01545388|DRUG|Metformin|Metformin, orally, 500 mg daily (divided dose; 250 mg tablet b.i.d.) for 24 weeks
224068832|NCT04336995|DIAGNOSTIC_TEST|contrast echocardiography|giving echocardiographic contrast and taking echocardiographic images before and after exercise
224068833|NCT04577235|OTHER|severity of lung involvement with COVID-19.|transthoracic lung ultrasound and throcic CT
224068834|NCT00892307|RADIATION|Dual Source Multidetector CT (DSCT) w/ Adenosine enhancement|Somatom Definition Dual Source CT Scanner Stress/Rest Image scan using weight based CT contrast dye
224068835|NCT00232102|DRUG|Tegaserod|
224068836|NCT03699176|DRUG|Vilaprisan (BAY1002670)|2 mg, once daily, oral
224068837|NCT03699176|DRUG|Placebo|Once daily, oral
223469457|NCT01545388|DRUG|Placebo|Placebo to match metformin 250 mg tablets, orally, for 24 weeks
223469458|NCT00529711|DRUG|Hypertonic lactate|"Solution given parenterally as follows:~Intraoperative 3 ml./kg BW for 15 minutes at beginning of surgery; During surgery 1.5 ml/kg BW/hour; Second loading 1.5 ml/kg BW for 15 minutes after protamin administration; Post-operative 1 ml/kg BW/hour for 12 hours."
223469459|NCT00529711|DRUG|Ringer's lactate|"Solution given parenterally as follows:~Intraoperative 3 ml./kg BW for 15 minutes at beginning of surgery; During surgery 1.5 ml/kg BW/hour; Second loading 1.5 ml/kg BW for 15 minutes after protamin administration; Post-operative 1 ml/kg BW/hour for 12 hours."
223469460|NCT03780582|BEHAVIORAL|AI-human interaction|Exploring what kinds of AI-human interaction improve radiologists detection accuracy.
223578870|NCT04523090|DRUG|Placebo|Placebo pills with no active ingredient.
223469461|NCT00358358|DRUG|Fluticasone Propionate/Salmeterol 500/50mcg combination|
223469462|NCT00358358|DRUG|Fluticasone Propionate 500mcg|
223469463|NCT00358358|DRUG|Salmeterol 50mcg|
223469464|NCT02541617|PROCEDURE|Programming by community Neurologist|Deep Brain stimulator with be programmed by a community Neurologist
223469465|NCT02541617|PROCEDURE|Standard of care|Deep Brain Stimulator will be programmed with at the implanting movement disorders center
223469466|NCT03619473|BEHAVIORAL|Standard motorcycle child safety helmet|"Educational session followed by demonstration on~* proper helmet wearing~* how to differentiate non-standard and standard helmets~* how to keep motorcycle safe using ABCD concept~* importance of wearing bright clothes~* police summon for not wearing helmets~* live demo on poor performance of non-standard helmet~* giving away standard motorcycle child safety helmets~* oath taking by parents and children~* distribution and placement of VEM on parents' motorcycles"
223469467|NCT01584713|DRUG|Adipose-derived stem cells without expanded|Administration will be intralesional injection of cells suspension. They will be placed into fistula walls
223469468|NCT01255163|DRUG|Exendin-4 SC|Exenatide 5 mcg or 10 mcg SC twice daily
223469469|NCT01255163|DRUG|Placebo SC|Placebo SC twice daily
223469470|NCT02423226|PROCEDURE|Computed tomography guided radioactive seeds implant|Computed tomography guided radioactive seeds implant were performed one week before chemotherapy.
223469471|NCT02423226|DRUG|Systemic chemotherapy (FOLFIRI)|irinotecan 180mg/m2 d1,leucovorin 400mg/m2 d1, 5-fluorouracil 400mg/m2 iv, 2.4g/m2 civ 46h, repeated every 2 weeks
223469472|NCT04078464|OTHER|Mindfulness Training Alone|Participants will lie down and listen to a pre-recorded guided mindfulness meditation for 36 minutes.
223469473|NCT04078464|OTHER|Acute Physical Activity Alone|Physical activity will include a 6 minute stretching session, 1 minute transition to treadmill, 3 minute warm up at a participant chosen pace on the treadmill, 20 minutes of walking at a moderate pace at target heart rate, 3 minute cool down at 2.0-2.5 mph, 1 minute transition off treadmill and 2 minutes of stretching.
223469474|NCT04078464|OTHER|Acute Physical Activity and Mindfulness Training Together|Participants will listen to a pre-recorded mindfulness meditation which will guide them through a 6 minute stretching session, 1 minute transition to treadmill, 3 minute warm up at a participant chosen pace on the treadmill, 20 minutes of walking at a moderate pace at target heart rate, 3 minute cool down at 2.0-2.5 mph, 1 minute transition off treadmill and 2 minutes of stretching.
223469475|NCT04477135|OTHER|upper extremity pain|upper extremity pain in perinatologists due to working actively and performing ultrasonography every day
223469476|NCT04477135|PROCEDURE|ultrasonography|ultrasonography
223469477|NCT02338817|DEVICE|Diabetes Sentry|The Diabetes Sentry device will be monitored for alarms for possible hypoglycemic. A blood sample will be taken to confirm blood glucose levels, lactate, and ketone values.
223469478|NCT04976127|DRUG|Talineuren|Talineuren is a liposomal formulation of the GM1 Ganglioside for intravenous administration
223469479|NCT04952259|DRUG|Shexiang Tongxin Dropping Pills + routine treatment|oral+percutaneous coronary intervention
223469480|NCT04952259|PROCEDURE|routine treatment|percutaneous coronary intervention
223469481|NCT02495389|DRUG|Mirabegron|Mirabegron is a medication for the treatment of overactive bladder. It was developed by Astellas Pharma and was approved by the United States Food and Drug Administration (FDA) in July 2012.
223578871|NCT00799591|OTHER|Observational study so no intervention in the patient.|Observational study so no intervention in the patient.
224068838|NCT04186741|DRUG|Hyperbaric oxygen|Patients already on treatment by hyperbaric oxygen therapy for medical conditions requiring treatment by it
224068839|NCT03682523|BEHAVIORAL|Sedentary behavior reduction intervention|Participants will be provided with a device to measure physical activity and sedentary behaviours. A tablet will be in the research office and each afternoon, it will be synced to the device to assess the activity progress of the patient. The research team will deliver an upright time goal and will target a 20% increase in upright time from the previous hospital day. Physiotherapist research assistants will visit the participants every afternoon to monitor progress and safely mobilize participants to their maximum ability if they have not met their daily goal (including weekend). The maximum level of ability will be determined in consultation with the healthcare team. Participants who do not meet their goal will be mobilized in the late afternoon/ early evening.
224068840|NCT03325725|DEVICE|NewBreez LD intra-laryngeal implant|NewBreez LD intra-laryngeal implantation
224068841|NCT02788747|DRUG|4 mg elamipretide|Subcutaneous injection of 4 mg elamipretide administered once daily for 28 consecutive days
224068842|NCT02788747|DRUG|40 mg elamipretide|Subcutaneous injection of 40 mg elamipretide administered once daily for 28 consecutive days
223469482|NCT05233735|OTHER|Enhanced Transcutaneous Delivery of Topical Betamethasone after the treatment with Tixel|Tixel Parameters: exposure time 6-8 milliseconds, 400-600 μm protrusion
223469483|NCT05233735|OTHER|Topical treatment|betamethasone ointment treatment once per day
223469484|NCT04351620|DRUG|Hydroxychloroquine|Tolerability study of HCQ 1200 mg administered daily in divided doses for a duration of 5-10 days
223469485|NCT04474925|PROCEDURE|Brain Surgery|Surgery to remove brain metastases
223469486|NCT04474925|RADIATION|Stereotactic Radiosurgery|SRS uses many focused radiation beams to treat tumors within the brain
223469487|NCT01297283|OTHER|LECG first|Measurement of the pacing threshold with the support of a leadless ECG
223469488|NCT01297283|OTHER|Programmer ECG first|Pacing threshold measurements are done with the support of the programmer ECG
223469489|NCT05396287|DEVICE|MRI|Participants will undergo an MRI scan while participating in two breathing tests (hypercapnia and hypoxia) to measure brain blood flow.
223469490|NCT06355024|DRUG|Inosine|oral inosine 200mg tid
223469491|NCT06355024|DRUG|Taxane/Anthracycline/Eribulin Mesylate/Vinorelbine/Capecitabine/Carboplatin/UTD1/platinum|Taxane/Anthracycline/Eribulin Mesylate/Vinorelbine/Capecitabine/Carboplatin/UTD1/platinum
223469492|NCT03617003|DRUG|WST11 mediated vascular targeted phototherapy (VTP)|All patients will receive intravenous administration of WST11 at a dose of 4 mg/kg, infused over 10 minutes while patients are under anesthesia during their endoscopy procedure, followed by immediate laser light application.
223469493|NCT03617003|PROCEDURE|Endoscopy|Endoscopy of the bladder
223469494|NCT02265965|DRUG|intravenous nitroglycerin|Infusion at started at time of hysterotomy and stopped at neonate delivery
223469495|NCT01597986|DRUG|isavuconazole|oral
223469496|NCT01597986|DRUG|Oral Contraceptive (ethinyl estradiol / norethindrone)|contraceptive pill consisting of ethinyl estradiol and norethindrone
223469497|NCT06552117|OTHER|an elastoMRI sequence|Addition of an MRI elasto sequence performed during MRI performed as part of the treatment
223469498|NCT00662077|DRUG|Ibandronate|Ibandronate endovenous 3 mg every 3 months
223469499|NCT00662077|BEHAVIORAL|Lifestyle modifications|Lifestyle modifications: counseling every 3 months
223469500|NCT04362124|BIOLOGICAL|vaccine BCG|Performance evaluation of a single dose of BCG vaccine in reducing the severity of SARS-COV-2 infection compared to placebo, in healthcare personnel.
223469501|NCT04362124|OTHER|Placebo|A single dose intradermal application of normal saline solution.
223469502|NCT05739318|DEVICE|The cuff of endotracheal and endobronchial is collapsed|The diameter of double-lumen tube at the cuff of endotracheal and endobronchial when the cuff is collapsed as the diameter of double-lumen tube and select a double-lumen tube that matches the patient's trachea and bronchial innerdiameter based on this diameter
223469503|NCT05739318|DEVICE|The cuff of endotracheal and endobronchial is inflated|The diameter of double-lumen tube at the cuff of endotracheal and endobronchial when the cuff is inflated as the diameter of double-lumen tube and select a double-lumen tube that matches the patient's trachea and bronchial innerdiameter based on this diameter
223469504|NCT00666302|DRUG|tacrolimus ointment|topical
223469505|NCT00666302|DRUG|pimecrolimus cream|topical
223469506|NCT02142816|DEVICE|Doppler|Fluid therapy guided by doppler
223469507|NCT02142816|OTHER|PVI'|Fluid therapy guided by PVI
224068843|NCT02788747|DRUG|Placebo|Subcutaneous injection of placebo administered once daily for 28 consecutive days
224068844|NCT03028571|DRUG|Trimethaphan|Trimethaphan 4 mg/min IV will be given as a pharmacological tool to study the role of the autonomic nervous system on the regulation of endogenous glucose production by the liver.
224068845|NCT03028571|OTHER|Saline|IV saline at a rate of 48 mL/hr, will be given during the insulin clamp to resemble the volume infused in the intact day
224068846|NCT05941975|DEVICE|Visual Evoked Potential (VEP)|To assess the integrity of visual pathways through the optic nerves to the visual cortex, latencies and amplitudes of P100 will be measured after pattern-reversal stimuli.
224068847|NCT05941975|DEVICE|Somatosensory evoked potential (SSEP)|To assess the integrity of sensitive pathways through the peripheral nerves and dorsal spinal cord to the somatosensory cortex. For the upper limbs, latencies and amplitudes of N9, N13, P14, N20 and P25 will be measured after median nerve stimulation. For the lower limbs, latency and amplitude of P40 will be measured after tibial nerve stimulation.
224068848|NCT05941975|DEVICE|Transcranial magnetic motor evoked potentials (TCmMEP)|To measure the integrity of motor pathways, the central conduction times will be measured for upper and lower limbs through magnetic stimulations of the primary motor cortex and the spinal cord, at cervical and lumbar levels.
224068849|NCT05941975|DEVICE|Tesla Brain MRI|All patients will undergo a single brain MRI on a 3T scanner. The acquisition protocol will include high-resolution three-dimensional (3D) T2\*-weighted echo-planar imaging and 3D T2-FLAIR images acquired, respectively, during or after intravenous injection of a single dose (0.1mmol/kg) of gadolinium-based contrast material.
224068850|NCT05941975|DIAGNOSTIC_TEST|Blood test - Neurofilament light chain (NfL)|\- Neurofilament light chain (NfL) will be tested (Quanterix's Simoa® Technology) in the serum of patients. To evaluate their variation over time, 3 time-point tests will be obtained at 6 months apart (at baseline, at 6- and 12-month follow-up).
224303978|NCT04555681|DIAGNOSTIC_TEST|Collection of subgingival dental plaque|Identification and quantification using q-PCR of the 21 bacteria most frequently found in the dental plaque (including the periopathogenic bacteria) and Candida albicans.
224303979|NCT06927349|DRUG|BA1301|BA1301 is administered intravenously once every three weeks.
223469508|NCT02262780|DRUG|Low dose of telmisartan|
223469509|NCT02262780|DRUG|High dose of telmisartan|
223469510|NCT02262780|DRUG|HCTZ|
223469511|NCT03356652|PROCEDURE|Noninvasive electrical dyssynchrony study|"Ventricular activation maps will be acquired simultaneously with hemodynamic measurements using noninvasive mapping system (ECVUE, Medtronic Inc, USA). A thoracic computed tomographic scan will be acquired with the electrodes attached to the patient. Local ventricular activation times will be defined as the onset of the QRS complex or the pacing spike to the maximal negative slope of each unipolar electrogram.~Pacing leads will be placed in high right atrium, His-bundle region, right ventricular apex, high septal RV, coronary sinus posterior/lateral branch, coronary sinus anterior branch, lateral and septal region of endocardial LV in order to deliver CRT in 8 different configurations."
223469512|NCT04182919|DRUG|Phlai|Each capsule contains 4 mg compound D. Using orally in the evening everyday in 4 weeks
223469513|NCT04182919|DRUG|Placebo oral capsule|Like Phlai capsule extract : :PVP K30, Calcium carbonate, Dibasic calcium phosphate, Sodium starch glycolate, Colloidal silicon dioxide, Ethanol 96%, Purified water, Magnesium stearate. Not having compound D. Using orally in the evening everyday in 4 weeks
223469514|NCT02276469|BEHAVIORAL|peer support|peer support is delivered by persons with a severe mental illness after the experience of recovery and after absolving a one year education to support others on their way to recovery
223469515|NCT05176639|DRUG|VRDN-001 Phase 3 Cohort (THRIVE)|5 IV Infusions of veligrotug (VRDN-001) 10mg/kg
223469516|NCT05176639|DRUG|VRDN-001 Placebo|5 IV Infusions of veligrotug (VRDN-001) placebo
223469517|NCT03642028|DRUG|Suvorexant|Suvorexant, a dual orexin receptor antagonist, is the first in a new class of drugs with great promise of addressing insomnia in Veterans with PTSD. Suvorexant targets the orexin neuropeptide system and has been shown to be highly successful in treating insomnia.
223469518|NCT03642028|OTHER|Placebo|Visibly matched, equally weighted placebo tablets. In addition to matching in appearance and weight, they will have identical packaging and labeling as randomized, blinded study medication.
223469519|NCT01802385|DRUG|Sertraline|Sertraline 400mg/day for 2 weeks, then 200mg/day for 12 weeks, then tapered over 3 weeks.
223578872|NCT05982119|DEVICE|ActiMyo/Syde|"The two watches can be worn as wristwatch or placed near the ankle and on the wheelchair.~* Patients with DMD or FKRP mutation will wear the ActiMyo°/Syde° during 3 months at baseline and then for one month every 3 months.~* Patient with FSHD, DM1, CMT, CNM will wear the ActiMyo°/Syde° will wear the ActiMyo/Syde° during 3 months at baseline and then for one month every 6 months.~* Control subjects \>4years will wear the ActiMyo°/Syde° during one month after inclusion and during one other month 11 months after inclusion.~* Control subjects \<4years will wear the ActiMyo°/Syde° during one month after inclusion and during one other month every 6months after inclusion."
223578873|NCT06397560|RADIATION|PRDR|Proton pulsed reduced dose rate (PRDR) technique, to a dose of 54 Gy in 30 fractions (treatments) with proton radiotherapy. Treatments will occur once per day on consecutive weekdays.
223578874|NCT02317809|DRUG|Liquid pergoveris|All subjects will be administered with 900 IU of r-hFSH and 450 IU of r-hLH solution (Liquid Pergoveris) as subcutaneous injection using a disposable pen-injector on Day 1 in either first intervention period or second intervention period.
223578875|NCT02317809|DRUG|Freeze-dried pergoveris|All subjects will be administered with 900 IU of r-hFSH and 450 IU of r-hLH freeze-dried powder (Freeze-dried Pergoveris) as subcutaneous injection on Day 1 in either first intervention period or second intervention period.
224068851|NCT05941975|DIAGNOSTIC_TEST|Blood test - EBV serology|EBV serology will be assessed (VCA IgG) in the serum of patients to evaluate the variation of antibody titers over time (at baseline, at 6- and 12-month follow-up), and compare to titers at the time of diagnosis (when available in their medical record).
223469520|NCT03834493|BIOLOGICAL|Pembrolizumab|IV infusion
223469521|NCT03834493|DRUG|Enzalutamide|Capsules/Tablets
223469522|NCT03834493|DRUG|Placebo|IV infusion
223578876|NCT00379977|BIOLOGICAL|diphtheria, tetanus, pertussis & Hib vaccine|
224068852|NCT04091633|BEHAVIORAL|WHO School Mental Health Program|World Health Organization (WHO) School Mental Health Program (SMHP) is a manual based multi-component, multi-tiered and evidence-informed intervention for common mental health problems in school going children. SMHP is designed to be introduced into the normal classroom and school setting by trained teachers. The intervention has a universal component which takes a whole school approach that aims to promote mental health among all school children. It includes basic counseling skills for teachers, core values of mental health promoting schools and other health promoting efforts that impact upon mental health and can be administered to all students in school and classroom settings. The manual also contains targeted intervention strategies on anxiety, separation anxiety/ school refusal, post-trauma, depression, suicide, ADHD, autism, psychosis, conduct problems and substance use problems that can be implemented by teachers in classroom settings.
223469523|NCT06780267|DRUG|HRS-2129|HRS-2129; low dose
223469524|NCT06780267|DRUG|HRS-2129|HRS-2129; high dose
223469525|NCT06780267|DRUG|HRS-2129 placebo|HRS-2129 placebo
223469526|NCT05078775|OTHER|NEAAR Medical Food|Standardized non-essential amino acid restricted medical food.
223469527|NCT05929027|BEHAVIORAL|NoNo|"Participants in the G2 group will use the Twirlstone (knob-like) device to play a videogame called Nono's World. The Twirlstone is an electromechanical device that resembles a knob and a standard joystick (identical to the discontinued Atari CX-20 Controller). The knob can rotate or move in a push-pull fashion. To control the game's character (an axolotl called Nono), a signal about the knob motion is relayed to the computer wirelessly. This device has been certified by Johns Hopkins University's Clinical Engineering Services, where it was deemed less than minimum risk. The game has been custom built to allow participants to take control of the character using subtle manipulative finger movements to accomplish game-like tasks.~The investigators will use portable communication devices to carry out telemedicine sessions. All devices and are low-power battery-operated tools for encouraging hand movement and the components are approved for use in the commercial market."
223578877|NCT04100694|DRUG|MCLA-128|
223578878|NCT00851578|DEVICE|WATCHMAN|WATCHMAN LAA Closure Device
223578879|NCT00315107|DRUG|Alesse|
223578880|NCT05423938|DIETARY_SUPPLEMENT|Diabetic|It is a hypercaloric and hyperproteic dietary supplement formulated to contribute to control the glycemia with: a specific mix of carbohydrate with a low GI, fiber, EVOO and EPA\&DHA
223578881|NCT05423938|DIETARY_SUPPLEMENT|Control|It is a hypercaloric and hyperproteic dietary supplement formulated without the ingredients to contribute in the glycemia control
223578882|NCT00005574|DRUG|Gentamicin|
224068853|NCT04091633|BEHAVIORAL|Enhanced School Mental Health Program (eSMHP)|Informed by the results of pilot implementation, a number of content and delivery adaptations have been made to the School Mental Health Program (SMHP) to address the implementation challenges to scale-up of program in Pakistan. The adapted version of the intervention is called Enhanced School Mental Health Program (eSMHP). Enhancements to conventional SMHP have occurred at two levels: A) Content enhancements, such as a collaborative care model for engaging parents/primary caregivers, strategies for teacher's well-being, and adaptation and operationalization of particular clinical intervention strategies and B) Technological enhancements which include adaptation of the training manual for delivery using an online training platform, and a 'Chat-bot' to aid the implementation of intervention strategies in classroom settings.
224068854|NCT00295984|DRUG|nicotine|
224068855|NCT04589273|DIETARY_SUPPLEMENT|Alginate|Volunteers will be asked to consume the alginate capsules with each of their three main meals per day.
224068856|NCT04589273|OTHER|Placebo|Volunteers will be asked to consume the placebo capsules with each of their three main meals per day.
224068857|NCT03831841|BEHAVIORAL|Multicomponent exercise programe|An intervention consisting of training by a multicomponent program 3 times a week, working on aerobic capacity, flexibility, balance and strength.
224068858|NCT03222206|DRUG|Salsalate|"1. Medicate salsalate 2g/day after run-in period~2. Check side effect after 1 month and Control dosage (2g/day or 3g/day)~3. Check side effect after 2 month"
223578883|NCT04424225|DRUG|Psilocybin|25 mg capsules (white opaque, Capsugel Vcaps Plus HPMC size 2)
223578884|NCT04424225|DRUG|Niacin|100 mg capsules (white opaque, Capsugel Vcaps Plus HPMC size 2)
223469528|NCT05929027|BEHAVIORAL|occupational therapy - self directed|"Participants 5 daily sessions over 3 weeks consisting of self-administered, unsupervised occupational therpay. Additionally, participants will have 2, \<15 minutes telemedicine check-in appointments (not standard of care) provided by a licensed occupational therapist for the purposes of assessing safety and providing guidance for the unsupervised sessions. The intervention will focus on stretches, warm-up and strengthening exercises aimed at improving hand function.~The investigators will use portable communication devices for the purposes of carrying out telemedicine sessions. All devices and are low-power battery-operated tools for encouraging hand movement and the components are approved for use in the commercial market."
223469529|NCT05559905|DRUG|Molnupiravir|Four molnupiravir 200 mg capsules (800 mg total dose) taken twice daily by mouth.
223469530|NCT05559905|DRUG|Placebo|Placebo capsule matched to molnupiravir taken twice daily by mouth.
223469531|NCT05559905|BIOLOGICAL|RSV A Memphis 37b|RSV A Memphis 37b viral challenge given once by intranasal administration at a dosage of \~4 Log10 plaque forming units (PFUs).
223578885|NCT06645028|BEHAVIORAL|Intensive treatment programme|"Intervention Group: 8-day intensive treatment where each treatment day consists of the following schedule:~Physical activity: 30 minutes Prolonged Exposure (PE): 90 minutes Physical activity: 30 minutes Lunch Physical activity: 60 minutes Eye Movement Desensitization and Reprocessing (EMDR): 90 minutes Physical activity: 30 minutes (omitted on days 4 and 8) Dinner Psychoeducation (omitted on days 4 and 8) Participants stay at the SÄS patient hotel during the treatment (with a three-day weekend break between treatment days 1-4 and 5-8). The treatment concept includes therapist rotation, meaning that participants switch therapists between PE and EMDR sessions. The purpose of this is to increase focus on the processing process rather than the relationship between the therapist and the client."
223578886|NCT06645028|BEHAVIORAL|Treatment as Usual (TAU)|Control group: 16 treatment sessions (90 minutes in duration) either Eye movement desensitisation and reprocessing (EMDR) or Prolonged Exposure (PE) in a standard outpatient format-weekly sessions. Participants can choose to attend 6 sessions of Psychoeducation for PTSD in a group format before starting EMDR or PE.
223578887|NCT06980116|DRUG|EXS73565|EXS73565 oral administration
223578888|NCT06980389|COMBINATION_PRODUCT|Node-Sparing Radiotherapy plus first-line therapy|Patients will receive node-sparing modified short-course radiotherapy, followed by standard first-line chemotherapy combined with a PD-1 inhibitor starting 2-5 days after radiotherapy. Treatment will continue until disease progression or the occurrence of unacceptable toxicity.
223578889|NCT06980389|COMBINATION_PRODUCT|First-line treatment|Patients will receive standard first-line chemotherapy combined with a PD-1 inhibitor. Treatment will continue until disease progression or the occurrence of unacceptable toxicity.
223578890|NCT06980129|OTHER|Rehabilitation in the home|Participants will receive home-based therapy from a MDT team, including physiotherapists, occupational therapists, social workers, dietitians, medical practitioners, psychologists, and pharmacists. Participants will be transferred to RITH once they achieve a level of mobility (+/- assistance) that enables them to manage at home. As per usual care, the disciplines required, frequency of visits, duration of visits, and duration of rehabilitation will be based on the patient's specific needs. There will be weekly MDT conferences to discuss patient progress led by medical staff. Telehealth care may be incorporated into the RITH program, subject to patient preference and provider availability. If the participant deteriorates during the RITH program, the escalation plan mandated by the LHD HITH Department will be followed to ensure appropriate care is provided. As for UCIR, discharge occurs when patients achieve sufficient walking and functional ability with available assistance.
223578891|NCT06980129|OTHER|Usual care inpatient rehabilitation|Participants will receive care in a rehabilitation ward or subacute hospital, including therapy from a MDT team. Discharge occurs when patients achieve sufficient walking and functional ability with available assistance, typically within 1-3 weeks, though this varies.
224068859|NCT03222206|OTHER|Placebo|"1. Medicate placebo 2g/day after run-in period~2. Check side effect after 1 month and Control dosage (2g/day or 3g/day)~3. Check side effect after 2 month"
224068860|NCT06383273|DRUG|MELT-300 sublingual tablet|Each dose of MELT-300 will be provided as a single sublingual tablet, containing 3 mg midazolam and 50 mg ketamine. Participants will receive 1 sublingual tablet of study medication 30 (± 5) minutes prior to planned surgery start, without food or water.
224068861|NCT06383273|DRUG|Midalozam sublingual tablet|Each dose of midazolam will be provided as a single sublingual tablet, containing 3 mg midazolam. Participants will receive 1 sublingual tablet of study medication 30 (± 5) minutes prior to planned surgery start, without food or water.
224068862|NCT06383273|DRUG|Placebo sublingual tablet|Each dose of placebo will be provided as a matching sublingual tablet, containing placebo. Participants will receive 1 sublingual tablet of study medication 30 (± 5) minutes prior to planned surgery start, without food or water.
224068863|NCT04218253|DIETARY_SUPPLEMENT|300 calories or 500 calories nutrient rich in branched chain amino acids and dietary fiber|300 kcal rich in branched chain amino acids and water soluble dietary fiber (12g) for Mild malnutrition, or 500 kcal rich in branched chain amino acids and water soluble dietary fiber (12g) for moderate to severe malnutrition. The degree of malnutrition is determined by Patient-Generated Subjective Global Assessment (PG-SGA).
224068864|NCT04218253|BEHAVIORAL|Dietary mission|Dietary education was conducted according to preoperative nutritional requirements
224068865|NCT03826550|DRUG|Diclofenac Sodium Gel|Twice daily for 60 days. Each patient is expected to receive 120 doses
224068866|NCT03826550|DRUG|Solaraze 3% Topical Gel|Twice daily for 60 days. Each patient is expected to receive 120 doses
224068867|NCT03826550|OTHER|Placebo|Twice daily for 60 days. Each patient is expected to receive 120 doses
224068868|NCT00549367|BEHAVIORAL|Nutrition Counselling|Clients will receive ongoing nutrition assessment and dietary counselling. The intervention arm will receive all baseline assessments and individual nutritional assessment, counselling and nutrition management plans using standards of practice
224068869|NCT03452696|DIETARY_SUPPLEMENT|Calcium supplement|Calcium supplement for low contribution of elemental calcium in the daily diet
224068870|NCT00005071|PROCEDURE|biopsy|
224068871|NCT00005071|PROCEDURE|bronchoscopy|
224068872|NCT00005071|PROCEDURE|computed tomography|
224068873|NCT00005071|PROCEDURE|quality-of-life assessment|
223469532|NCT06283212|DRUG|ETX101|ETX101 is composed of a non-replicating, recombinant adeno-associated viral serotype 9 (rAAV9) vector used to deliver a GABAergic regulatory element (reGABA) and an engineered transcription factor that increases transcription of the SCN1A gene (eTFSCN1A)
223469533|NCT00388245|PROCEDURE|Percutaneous Coronary Intervention|
223469534|NCT00388245|PROCEDURE|Coronary Artery Bypass Grafting|
223469535|NCT04003103|DRUG|Islatravir|Islatravir 30 mg capsules taken by mouth.
223469536|NCT04003103|DRUG|Placebo|Placebo capsules taken by mouth.
223469537|NCT06958978|DEVICE|Quantum RF|Patented handpiece device designed for skin rejuvenation and tightening through intraoperative subdermal Radiofrequency treatment.
223469538|NCT02756910|DEVICE|iThermonitor (WT701)|Continuously monitor the axillary temperature during surgery
224068874|NCT01852994|DRUG|Testosterone replacement|Application quarterly of Testosterone Undecylate
224068875|NCT01852994|OTHER|Exercise training|Aerobic and strength exercise training
224068876|NCT03143140|OTHER|PAFA|percutaneous ablation of tumor feeding artery
224068877|NCT03143140|OTHER|tumor ablation|ablation of tumor area directly
224068878|NCT00510926|DRUG|Imatinib Mesilate (Glivec)|
224068879|NCT02725983|BEHAVIORAL|SPT consultation|
224068880|NCT02725983|DEVICE|SOPROCARE®|
224068881|NCT03912675|PROCEDURE|Integra® dermal substitute and RigeneraTM protocol|Integra® dermal substitute enriched with the autologous dermal micro-grafts obtained with RigeneraTM protocol
223469539|NCT03555851|DRUG|Cyclophosphamide|Pharmacogenomics of candidate genes and pharmacokinetic analyses of cyclophosphamide administered as part of a reduced intensity conditioning (RIC) regimen and as post-transplant GVHD prophylaxis will be examined.
223469540|NCT03555851|OTHER|Specimen collection|Buccal swabs will be obtained from donors for pharmacogenomics.
223469541|NCT06523621|DRUG|Nivolumab|2 cycles of nivolumab at a dose of 480 mg given over approximately 30-minutes intravenously on Day 1 of each treatment cycle
223469542|NCT05674240|DEVICE|Intrathecal Targeted Drug Delivery|Intrathecal drug delivery systems (IDDs) deliver small doses of analgesics directly to the spinal cord.
224068882|NCT04634500|DRUG|Dapagliflozin|Dapagliflozin Tablet
224159483|NCT05431231|DIAGNOSTIC_TEST|Prodromal Questionnaire - Brief Version|a patient questionnaire that assesses the existence of a prodromal state or fully developed psychosis. It was developed by Ising et al. in 2012 and was translated to Hebrew by Koren et al. in 2016. The tool is based on a more extensive questionnaire - PQ-92 - that was developed by Loewy et al. in 2005 - and constitutes an attempt to create an improved shorter version. The PQ-16 includes 16 items that refer to thoughts, feelings and experiences that describe various symptoms, including abnormal perception (9 items), unconventional thinking and paranoia (5 items) and negative symptoms (2 items). For each item, first, the participant is asked to indicate whether he had experienced that phenomenon in the past month, and if he had, he is asked to describe the extent to which the phenomenon had caused him distress, using a four-level Likert scale (0 - no distress, 3 - severe distress). Ising et al. found that Kronbach's α was 0.774 for the whole questionnaire.
224303980|NCT06926751|DRUG|Telpegfilgrastim Injection|subcutaneous injections of Telpegfilgrastim (33 μg/kg, single dose) 24 hours after each chemotherapy cycle
223469543|NCT05674240|COMBINATION_PRODUCT|Conservative medical management|Including physical therapy, oral or transdermal medications and injections
223469544|NCT06889129|OTHER|Experimental- Heat application|"Heat application + standard protocol=Hot Application Protocol~Hot application will start daily and continue until the completion of 4 weeks. The area will be checked for infection, scar tissue, inflammation, and incision before the application, and the procedure will be explained to the patient and their family.~The first application will be performed on the day the patient comes for chemotherapy, ensuring privacy by exposing only the application area and positioning the patient appropriately.~Patients will be asked to sit on a chair or couch with both feet immersed in a foot bath containing 5 liters of water, approximately 5 cm above their ankles, every night before bed for one month. The water temperature will be 40°C. The application will last for 30 minutes.~Patients will be advised to avoid contact with cold water, as well as the consumption of cold food and beverages."
223469545|NCT06889129|OTHER|Experimental-Cold application|"Cold application + standard protocol=Cold application will start daily and continue until the completion of 4 weeks.~The area will be checked for infection, scar tissue, inflammation, and incision before the application, and the procedure will be explained to the patient and their family.~The first application will be performed on the day the patient comes for chemotherapy, ensuring privacy by exposing only the application area and positioning the patient appropriately.~Patients will be asked to sit on a chair or couch with both feet immersed in a foot bath containing 5 liters of water, approximately 5 cm above their ankles, every night before bed for one month. The water temperature will be between 23-26°C. The application will be performed by the researcher on the day the patient comes for weekly chemotherapy treatment.~Patients will be advised to avoid contact with hot water, as well as the consumption of hot food and beverages."
223469546|NCT06551688|DIAGNOSTIC_TEST|Serum 25(OH)D level|The characteristics of 25 (OH) D3 are relatively longer half-life than 1.25 (OH)2 D3, stability, strong detection repeatability, and no biological activity. Generally, systemic levels of the more stable 25 (OH) D3 are considered to be the best index to reflect status of vitamin D in the individual patient
223469547|NCT05193513|DEVICE|hybrid expanders|tow maxillary hybrid expanders supported anteriorly with tow miniscrews
223469548|NCT02277028|BEHAVIORAL|priming and task specific training|This task specific training protocol has been used in several clinical trials.
223469549|NCT04192240|OTHER|WB Training with external feedback|WB during sit-to-stand and stepping with external feedback, follow by overground walking.
223469550|NCT04192240|OTHER|WB Training without external feedback|WB during sit-to-stand and stepping without external feedback, follow by overground walking.
223469551|NCT04295577|OTHER|Niraparib|Niraparib - Niraparib is an oral, highly selective PARP-1 and -2 inhibitor. However, it also inhibits other members of the PARP family, including PARP 3, -4, -10, 12, -14, and -15\[13\].
224068883|NCT02814630|BIOLOGICAL|Xolair|The patients will receive one subcutaneous injection of Xolair® (omalizumab) at a dose of 300 mg on Days 1, 30, and 60. This dose is based on the results of the international, multicenter, randomized, double-blind, placebo-controlled study which demonstrated that omalizumab significantly decreased clinical symptoms and signs of chronic idiopathic urticaria in patients who had remained symptomatic despite the use of H1-antihistamines (Maurer et al., 2013)
223469552|NCT06332196|OTHER|Analysis of biological sample and clinical data|Analysis of biological sample and clinical data
223469553|NCT02718911|DRUG|LY3022855|Administered IV
223469554|NCT02718911|DRUG|Durvalumab|Administered IV
223469555|NCT02718911|DRUG|Tremelimumab|Administered IV
223469556|NCT01132183|DRUG|Divalproex Sodium|Divalproex Sodium Coated Particles in Capsules, 125 mg of Dr. Reddy's Laboratories Limited
223469557|NCT05259826|OTHER|biopsy sampling|"1. Biopsies are homogenised in buffer and used for the determination of mucosal IgE and inflammatory parameters.~2. Biopsies are used to isolate organoids, stimulate them with blood cells and food antigens and to study gene and protein expression."
223469558|NCT02728063|DIETARY_SUPPLEMENT|Lactibiane Tolerance|probiotics
223469559|NCT00993551|PROCEDURE|primary surgery for cleft palate|Surgery completed using the Sommerlad technique
223469560|NCT02398110|PROCEDURE|transvaginal NOTES nephrectomy|A 5- and 10-mm trocar were placed at the right and left medial margin of umbilicus. A lengthened 10-mm trocar was placed through the vagina into the abdominal cavity
223469561|NCT02398110|PROCEDURE|conventional laparoscopic nephrectomy|One 10-mm trocar was inserted at the midclavicular line 2 cm below the umbilicus, another 10-mm periumbilical trocar was placed for the camera, and a 5- or 10-mm trocar was placed 3 cm below the costal margin
223469562|NCT04198831|OTHER|acupuncture|Patients receiving acupuncture and mild moxibustion, whom were treated 3 times per week for 12 weeks and followed up for 36 weeks. Bilateral ST37, SP6, SP4, LR3, KI3, LI4 and LI11 were selected for acupuncture and CV8, CV12 and bilateral ST36 were selected for moxibustion. Hwato acupuncture device was used to blind the subjects, and had the deqi sensation. The surface temperature of acupoints was maintained at 43℃± 1℃ for moxibustion.
223469563|NCT04198831|OTHER|Sham acupuncture|Patients receiving sham acupuncture and sham mild moxibustion, whom were treated 3 times per week for 12 weeks and followed up for 36 weeks. Bilateral ST37, SP6, SP4, LR3, KI3, LI4 and LI11 were selected for acupuncture and CV8, CV12 and bilateral ST36 were selected for moxibustion. Same Hwato acupuncture device was used to blind the subjects, but do not puncturing into the skin and do not have the deqi sensation. The surface temperature of acupoints was maintained at 37℃± 1℃ for moxibustion.
223469564|NCT04739228|BEHAVIORAL|Guided Written Disclosure Protocol Group|The writing task consists of three sessions of 20 minutes each, with an interval of one week between each other. In the first session, patients were asked to describe the onset of illness, describing chronologically and detailed places, images, sounds and actions, as they are followed and detached from the emotions. In the second session, the patients were asked to write about thoughts and emotions felt during the illness experience, talking about the impact that illness had on their daily lives and how it had changed their personal attitude to life itself. In the third and final session, the patients were asked to analyze subjective new skills acquired.
223469565|NCT04739228|BEHAVIORAL|Active Control Group|The writing task also consists of three sessions of 20 minutes each, with an interval of one week between each other. In all three writing sessions, patients were asked to report the daily activities during the last week, without focusing on the emotional aspects.
223469566|NCT05002972|BEHAVIORAL|walking group led by a community organizer|Subjects will walk 1 kilometer from a pre-determined point to a local farmer's market.
224068884|NCT01208714|DRUG|Optimal medical therapy|"Optimal medical therapy, including optimal antihypertensive therapy as defined by ESH/ESC Guidelines Mancia G. J Hypertens 2007; 25: 1105), antiplatelet and, if necessary, hypolipemic and hypoglycemic treatment.~All patients will receive antiplatelet treatment with the same dose of aspirin (100 mg o.d.) or ticlopidine (250 mg b.i.d) if intolerant ASA, or clopidogrel (75 mg o.d.), if intolerant to ASA and ticlopidine, throughout the study period. LDL-cholesterol will be lowered to below 100 mg/dl, homocysteine if elevated will be lowered and treatment for diabetes will be optimized (HbA1c \< 6.5%)."
224303981|NCT06926751|DRUG|filgrastim|subcutaneous injections of Filgrastim (5 μg/kg/day, multiple doses) 24 hours after each chemotherapy cycle
223469567|NCT06101498|DIAGNOSTIC_TEST|Akut kidnet injury(AKI)|postoperative 24 hours
223469568|NCT06270108|DRUG|Riluzole|50mg twice daily (100mg total daily) for 56 days.
223469569|NCT04195594|OTHER|Nic's Keto Diet|Participants will be instructed to follow Nic's keto diet plan for 140 days. They will be asked to not exceed 20 g of carbohydrates (up to 5% caloric intake) and to consume the remaining 70% of calories from fat sources and 25% from protein sources.
223469570|NCT05564572|OTHER|Routine Health Status Assessment|Completion of a patient-reported health status assessment preceding each clinic visit. The health status assessment consists of the Kansas City Cardiomyopathy Questionnaire-12 (KCCQ-12) along with additional select questions. The results of the assessment will be available to clinicians in the electronic health record.
223469571|NCT03184740|DEVICE|Active Transcranial Direct Current Stimulation|For electrode placement, the criteria used by the 10/20 electroencephalography system will be obeyed and the electrodes will be positioned over Primary motor cortex, C3 area for the anode and Fp2 (contralateral supraorbital area) for the cathode electrode. A constant current of 2mA will be applied for 20 minutes.
223469572|NCT03184740|DEVICE|Sham Transcranial Direct Current Stimulation|For electrode placement, the criteria used by the 10/20 electroencephalography system will be obeyed and the electrodes will be positioned over primary motor cortex, C3 area for the anode and Fp2 (contralateral supraorbital area) for the cathode electrode, but the stimulator will be turned off after 30 seconds of stimulation.
223469573|NCT03812419|DRUG|Esomeprazole 40 mg|Esomeprazole 40 mg In addition, the immunosuppressant combination of CsA (Sandimmune; Novartis, East Hanover, NJ, USA), MMF (Cellcept; Roche, Basel, Switzerland) and the corticosteroid prednisolone (Solupred; Sanofi Aventis, Tours, France).
223469574|NCT03812419|DRUG|Pantoprazole 40mg|Pantoprazole 40 mg In addition, the immunosuppressant combination of CsA (Sandimmune; Novartis, East Hanover, NJ, USA), MMF (Cellcept; Roche, Basel, Switzerland) and the corticosteroid prednisolone (Solupred; Sanofi Aventis, Tours, France).
223469575|NCT01447888|DRUG|150% Oral Morphine Equivalent (OME)|Patients will receive 150% of their oral morphine equivalent (OME) utilizing the drugs Dilaudid and Fentanyl.
223469576|NCT01447888|OTHER|Clinical Judgment|This method of perioperative parenteral opioid dosing has been used on spine surgery patients, based on clinical decision of the anesthesiologist.
223469577|NCT01172873|DRUG|D-cycloserine|50 mg dose of D-cycloserine administered at the end of each session of Cognitive Behavioral Therapy With Exposure and Response Prevention: twice weekly CBT/ERP of 60 minutes
223469578|NCT01172873|BEHAVIORAL|Exposure and Response Prevention (EX/RP)|Exposure and response prevention treatment. Participants complete graded exposure during twice weekly treatment sessions with therapist
223469579|NCT05870852|DEVICE|Extracorporeal Shock Wave Therapy (ESWT)|ESWT will be done once a week for 4-5 minutes in total 3 times with ESWT. 2000 impulses will be applied on calcinosis with 2.4 bar pressure and 5.0 Hz frequency.
223469580|NCT05870852|OTHER|PNF|PNF stretching techniques: It will be done with isometric contraction for 10 seconds against maximum resistance. 8-10 repetitions will be done. A 10-second listening interval will be left for active relaxation of the patient between the applications. PNF application will be done by the physiotherapist once a week. You will be asked to do the PNF stretching exercises taught once daily as a home program.
223469581|NCT00983372|DRUG|Colchicine|A single dose of 0.6 mg colchicine administered alone at 7:15 am on Day 1 after an overnight fast of at least 10 hours.
223469582|NCT00983372|DRUG|Diltiazem ER|One 240 mg diltiazem ER capsule administered daily at 7:15 am on Days 15 to 21.
223469583|NCT00983372|DRUG|Colchicine|A single dose of 0.6 mg colchicine administered along with diltiazem ER at 7:15 am on Day 21 after an overnight fast of at least 10 hours.
223469584|NCT01268163|DRUG|European Taxotere®|60-100 mg/m\^2 IV
223469585|NCT01268163|DRUG|American Taxotere®|60-100 mg/m\^2 IV
223469586|NCT01268163|DRUG|Hospira Docetaxel Injection|60-100 mg/m\^2 IV
223469587|NCT04175171|DRUG|Coprelotamab Injection|The single intravenous infusion of 8mg/kg Coprelotamab shall be administered within 90 minutes through infusion pump.
223469588|NCT04175171|DRUG|Trastuzumab Injection|The single intravenous infusion of 8mg/kgTrastuzumab shall be administered within 90 minutes through infusion pump.
223469589|NCT02240667|DRUG|Dabigatran etexilate|150 mg or 110 mg capsules twice daily
223469590|NCT02240667|DRUG|Vitamin K antagonists|International Normalized Ratio (INR) 2-3
223469591|NCT06281561|DRUG|Normal Saline|Female patients undergoing hysteroscopy receive nasal spray with normal saline before anesthesia
223469592|NCT06281561|DRUG|Dexmedetomidine|Female patients undergoing hysteroscopy receive nasal spray with dexmedetomidine before anesthesia
223469593|NCT05179954|OTHER|Metabolic testing|Participants will complete a metabolic testing protocol that includes intravenous infusion of stable isotope labeled tracers and blood sampling to determine lipoprotein kinetics
223469594|NCT05518539|DEVICE|The Clareon™ PanOptix™ Trifocal (toric and non-toric models)|Bilateral implantation with the Clareon PanOptix Trifocal (toric and non-toric models)
223469595|NCT03077893|DEVICE|Active Provant Therapy System|Treatment with active Provant Therapy System
223469596|NCT03077893|DEVICE|Inactive (sham) Provant Therapy System|Treatment with Inactive (sham) Provant Therapy System
223469597|NCT04690348|PROCEDURE|Craniotomy|Craniotomy
223469598|NCT04690348|RADIATION|Cesium-131 brachytherapy|Intracavitary Cesium-131 brachytherapy
223469599|NCT00359203|DEVICE|Dual chamber pacemeker|
223469600|NCT02690272|BEHAVIORAL|Psychic processes|Quantitative and qualitative aprroche of the psychic process
223469601|NCT04860479|DEVICE|ultrasound|ultrasonography to inguinal region
223469602|NCT00190788|DRUG|Drotrecogin Alfa (Activated)|
224068885|NCT01208714|PROCEDURE|revascularization|The patients randomized to this treatment will undergo digital scan angiography (DSA) and PTA with stenting of the renal artery. PTA will be performed at the ostium or at truncular level. Stenoses involving more distal arterial vessels will be recorded and considered for data analysis but will not be treated. The patients randomized to revascularization will continue on their antihypertensive drug regimen. The dose and number of drugs will be down-titrated with the aim of pursuing the target BP values.
224303982|NCT06927128|DRUG|Gemcitabine, Cisplatin|Gemcitabine (1000mg/m²) and cisplatin (70mg/m²). Gemcitabine is used on the 1st and 8th days of a 21 - day cycle, and cisplatin is used on the 2nd day of the cycle. A total of 3 - 4 cycles are carried out.A dose reduction to 60% of the original dose (adjusted to 0.6 times the initial dose) will be implemented if deemed clinically necessary, contingent upon meeting either of the following criteria: 1) occurrence of grade 3 or higher treatment-related adverse events as per CTCAE v5.0 guidelines, or 2) evidence of renal impairment manifested by a ≥40% decline in glomerular filtration rate (GFR) from baseline measurements.
223469603|NCT00190788|DRUG|placebo|
223469604|NCT02053493|DRUG|Isosorbide Mononitrate|"Dispense phase 1 study drug:~Weeks 1 and 2: No study drug (baseline) Week 3: 30 mg ISMN Week 4: 60 mg ISMN Weeks 5 and 6: 120 mg ISMN~Dispense phase-2 study drug:~Weeks 7 and 8: No study drug (washout) Week 9: 30 mg ISMN Week 10: 60 mg ISMN Weeks 11 and 12: 120 mg ISMN"
223469605|NCT02053493|DRUG|Placebo|"Dispense phase 1 study drug:~Weeks 1 and 2: No study drug (baseline) Week 3: 30 mg Placebo Week 4: 60 mg Placebo Weeks 5 and 6: 120 mg Placebo~Dispense phase-2 study drug:~Weeks 7 and 8: No study drug (washout) Week 9: 30 mg Placebo Week 10: 60 mg Placebo Weeks 11 and 12: 120 mg Placebo"
223469606|NCT02084901|DEVICE|Drug-eluting biodegradable stent Orsiro implantation|Drug-eluting biodegradable stent Orsiro implantation
223469607|NCT02084901|DEVICE|Drug-eluting biodegradable stent BioMatrix or BioMatrix Flex implantation|Drug-eluting biodegradable stent BioMatrix or BioMatrix Flex implantation
223469608|NCT01429844|DRUG|Tacrolimus|Tacrolimus therapy was started immediately after transplantation with a continuous intravenous infusion of 0.01-0.03 mg/kg/d. After extubation, the mode of delivery was switched to oral administration (b.i.d.) with doses of 0.05-0.3 mg/kg/d. Tacrolimus doses were adjusted to trough levels. Target C0 (trough) levels were 10-15 ng/ml for the first 3 months after transplantation and 8-12 ng/ml thereafter with dose adjustments according to patient outcome.
223469609|NCT01429844|DRUG|Cyclosporine|Cyclosporine therapy was started immediately after transplantation with a continuous intravenous infusion of 1-3 mg/kg/d. After extubation the mode of delivery was switched to oral administration (b.i.d. or t.i.d.) with doses of 4-18 mg/kg/d. Cyclosporine doses were adjusted to C0 or C2 levels according to local practice. Target trough levels were 200 - 300 ng/ml for the first 3 months after transplantation and 150 - 200 ng/ml thereafter.
223469610|NCT00371956|DRUG|raloxifene|60mg/day
223469611|NCT00371956|DRUG|placebo|tab 1 daily
223469612|NCT02965404|BIOLOGICAL|Investigational live attenuated varicella vaccine|The investigational vaccine was manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd.
223469613|NCT02965404|BIOLOGICAL|control live attenuated varicella vaccine|The control vaccine was manufactured by Shanghai Institute of Biological Products Co., Ltd. (SIBP)
223469614|NCT02965404|BIOLOGICAL|diluent of lyophilized vaccine|The diluent of lyophilized vaccine was manufactured by Sinovac (Dalian) Vaccine Technology
223469615|NCT04881344|PROCEDURE|laser hemorrhoidoplasty|"* Under local anesthetic (or general anesthetic if contraindications to local anesthetic),~* A laser optic fiber connected to a diode platform (Leonardo, Biolitec AG, Jena, Germany) will be applied threw a anoscope. After making a 1-mm opening at the external border of hemorrhoid pocket, the fiber will be introduced in the hemorrhoidal tissue. Several pulses, each lasting for 1.2 s, with a 0.6-s pause between pulses, will be delivered to the tissue.~* As a day-case procedure (or short-stay if medical or social factors precluded ambulatory intervention),~* Postoperative care will consist of: normal diet, bulking laxatives, self-irrigation to the anal wound at six times per day and painkiller. Absence for work certificate will be made for 7 days for each patient and they will be told to return to work and normal daily activities as soon as they felt able."
223469616|NCT04881344|PROCEDURE|mucopexy|"* Threw an anoscope, the hemorrhoidal cushion will be sutured using a half-circle (size 26) needle with a 2-0 poliglecaprone (Monocryl®, Ethicon, USA). Then, a continuous suture will be performed on the mucosa of the anal canal, and will terminate above the dentate line. The hemorrhoidal artery will be ligated by this suture. Then, the ligation will be tied to realize the hemorrhoidopexy.~* Same anesthetic technique and postoperative care as the intervention group. As a day-case procedure (or short-stay if medical or social factors precluded ambulatory intervention)."
223469617|NCT03569397|OTHER|Music Therapy|Patients will be administered music therapy during the operation.
223469618|NCT04613518|DRUG|BMS-986165|Specified Dose on Specified Days
223469619|NCT04613518|OTHER|Placebo Comparator|Specified Dose on Specified Days
223469620|NCT02764502|DEVICE|Pressure Gauge Manometer|Identification of epidural space
223469621|NCT02216383|DRUG|Carbetocin|The intervention is the administration of one dose of study drug to the recruited patient at the time of delivery. Carbetocin, listed here, is one of the of the three study drugs.
223469622|NCT02216383|DRUG|Syntocinon|The intervention is the administration of one dose of study drug to the recruited patient at the time of delivery. Syntocinon, listed here, is one of the of the three study drugs.
223469623|NCT02216383|DRUG|Syntometrine|The intervention is the administration of one dose of study drug to the recruited patient at the time of delivery. Syntometrine, listed here, is one of the of the three study drugs.
223469624|NCT00026091|DRUG|fenretinide|Given orally
223469625|NCT00026091|OTHER|laboratory biomarker analysis|Correlative studies
223469626|NCT00026091|OTHER|pharmacological study|Correlative studies
223469627|NCT05252715|BIOLOGICAL|Meningococcal ACYW135 Polysaccharide Conjugate Vaccine|Single intramuscular dose contains 5 µg each of Serogroup A, C, Y, and W135 meningococcal polysaccharide combined with tetanus toxoid.
223469628|NCT05252715|BIOLOGICAL|Meningococcal A and C Polysaccharide Conjugate Vaccine|Single intramuscular dose contains 10 µg each of Serogroup A and C meningococcal polysaccharide combined with tetanus toxoid.
223469629|NCT04528316|BEHAVIORAL|Pilates Core Stability Exercises program|"Twenty patients will receive Pilates core stability exercises program ONLY. Total Period: 12 Weeks~Stages: Three stages:~* Stage I: Warm-up: consists of four Pilates motions:~  1. Breathing:~ 2. Rolling back:~ 3. Coccyx-curl:~ 4. Hundred breathing:~* Stage II: Work-out: consists of twelve Pilates motions:~  1. Single leg stretch:~ 2. Straight leg raise:~ 3. Basic bridge:~ 4. Bridging variation:~ 5. Quadruped:~ 6. Clap with seal motion~ 7. Mermaid twist:~ 8. Swimming:~ 9. Double leg stretch:~ 10. Shoulder bridge:~ 11. Swan dive:~ 12. Leg full front:~* Stage III: Cool-down: consists of three Pilates motions:~  1. Rest position:~ 2. Cat with arm/leg extension:~ 3. Breathing:"
223469630|NCT04528316|BEHAVIORAL|Balance Program|Total Period: 12 Weeks. The designed HUMAC program will work on the modified clinical test of sensory integration of balance (mCTSIB) with eyes open and with eyes closed, the center of pressure (COP) and the limit of stability test (LOS).
223469631|NCT04528316|BEHAVIORAL|Coordination|"Total Period: 12 Weeks. Coordination will be assessed using BOT2, Bilateral coordination (Sub test No.4) composed of 7 items and Upper-Limb coordination (Sub test No.7) composed of 7 items too.~The raw scores are recorded first then it is converted into point scores, then subtest total point score is obtained by adding point scores."
223469632|NCT02828488|OTHER|No intervention|It is a descriptive study. No intervention
223469633|NCT04852250|OTHER|Virtual centralized multidisciplinary tumour board|Evaluation of radiologic imaging and general condition by a multidisciplinary expert gremium to recommend either secondary intervention or resection of metastases or continuation of systemic treatment
223469634|NCT04770506|OTHER|Data extraction from medical files|Data extraction from medical files
223469635|NCT05098873|OTHER|psychodynamic|intervention with adolescents through the presentation of questions to be completed
223469636|NCT00160108|BEHAVIORAL|dietary intervention|
224068886|NCT04840108|BEHAVIORAL|Support Person Coaching Intervention|The intervention condition will include, for the SPs, a manualized, 1-session coaching intervention delivered by a research coach. The call will be delivered by phone using VA-permitted remote audio or video communication technology (e.g., doximity dialer, Zoom, or VA Video Connect if a Veteran). Coaches will use behavior change strategies delivered with a MI style.
223469637|NCT04805138|OTHER|Spectrophotometer|To objectively measure the discoloration of the peri-implant mucosa, spectrophotometric measurements of the buccal mucosa will be performed at study implant and at control tooth.
224068887|NCT04840108|BEHAVIORAL|Support Person Written Materials|Support persons will receive existing written materials on effective social support strategies for smoking cessation. Materials will be sent via postal mail.
224068888|NCT02690311|DEVICE|smartphone display|
224068889|NCT02813200|DRUG|Seretide® Diskus® 500/550 μg|Every day during 7 days
223469638|NCT02756702|DEVICE|All-Poly|Implantation of the VEGA PS using all-polyethylene tibia components
223469639|NCT01619865|DRUG|68Ga-DOTATOC PET/CT|1 -5 mCi 68Ga-DOTATOC (10-50 ugm DOTATOC)administered once via IV.
223469640|NCT01494818|DEVICE|Hydrogen peroxide-based contact lens care system|
224068890|NCT02813200|DRUG|Ultibro® Breezhaler® 110/50 μg|Every day during 7 days
224068891|NCT02813200|DRUG|Spiriva® Respimat® 2,5 μg|Every day during 7 days
224068892|NCT01040455|DRUG|Lansoprazole|lansoprazole 15mg (Takepron®, Takeda Pharmaceutical Company, Osaka, Japan) once daily for eight weeks
223578892|NCT06980441|BEHAVIORAL|Problem Management Plus with Emotional Processing module|PM+ EP comprises of Problem Management Plus, an evidence-based low intensity psychological intervention developed by the World Health Organization (WHO), with an additional Emotional Processing module specifically to address psychological distress related to trauma exposure. The core of the intervention is designed for adults impaired by distress in communities exposed to conflict and adversity; it consists of CBT techniques that have been adapted for communities that do not have good availability of specialist care. The additional module was developed by researchers treating refugee youth (Alozkan Sever et al, 2021). For this study, PM+ EP will be a six-session individual and guided support program. The original sections of PM+ are available in many languages including Farsi, and the additional EP module will be translated by PoMA's Afghan translator. The sessions cover the topics of managing stress, strengthening social support, staying well and persevering.
223578893|NCT02259140|PROCEDURE|Proximal Femoral Resection Arthroplasty|Drains will be placed at the surgeon's discretion. Patients will be placed in skin traction on the operative side. Post-operative bracing or casting will be at the surgeon's discretion. All patients will receive standardized post-operative prophylactic radiation to minimize heterotopic ossification.
223578894|NCT02259140|PROCEDURE|Subtrochanteric Valgus Osteotomy|Drains will be placed at the surgeon's discretion. Post-operative bracing or casting will be at the surgeon's discretion. All patients will receive standardized post-operative prophylactic radiation to minimize heterotopic ossification.
223469641|NCT01494818|DEVICE|PHMB-containing contact lens solution|
223578895|NCT01563289|DRUG|Ibuprofen|3 times a day
223578896|NCT01563289|DRUG|Placebo|3 times a day
223578897|NCT04646226|DEVICE|AV graft|The purpose of the surgery is to connect a large vein in the arm to a nearby artery indirectly by inserting a graft material (graft surgery)
223578898|NCT04646226|PROCEDURE|surgical intervention for creation of a fistula|The purpose of the surgery is to connect a large vein in the arm to a nearby artery directly (fistula surgery)
223469642|NCT01494818|DEVICE|Soft contact lenses|Contact lenses identical to habitual prescription worn per usual replacement regimen
223578899|NCT06604845|BEHAVIORAL|Group cognitive behavioural therapy (CBT)|"CBT based on Safren's manual CBT for ADHD/Mastering Your Adult ADHD20 adapted for group format. The program includes psychoeducation and cognitive restructuring and aims to improve ADHD symptoms, especially planning, organisation, attention and adaptive thinking. The CBT groups will meet at the clinic weekly for 12 weeks for 2 hours including a break in the middle. The groups are led by two clinicians."
223469643|NCT04737850|DRUG|Hetrombopag|Thrombopoietin receptor agonist
223469644|NCT04737850|DRUG|Placebo|Placebo with no active pharmaceutical ingredient
223578900|NCT06604845|OTHER|Activity group|The Activity group is a structured manualised group intervention designed for this and planned future studies of psychosocial treatments for adults with ADHD and/or autism. The program includes group discussions, peer-sharing and social every-day life activities. The Activity groups will meet at the clinic weekly for 12 weeks for 2 hours including a break in the middle. The groups are led by two trainers.
223578901|NCT05821374|DRUG|Deucravacitinib|6 mg tablet
223578902|NCT03494218|DIAGNOSTIC_TEST|Nociception Coma Scale (NCS)|Patients have been assessed with both the Nociception Coma Scale (NCS) and the FLACC.
223578903|NCT00722202|DRUG|ERB-257|
223578904|NCT00722202|OTHER|placebo|
223578905|NCT00123266|DRUG|Microplasmin|2 mg/kg, IA over 75 mins
223578906|NCT06660498|DRUG|Pomalidomide 2 mg|Participants will receive pomalidomide 2 mg/d concurrently with aspirin 75 mg for three cycles, each consisting of 21 days on and a minimum of 7 days off.
223578907|NCT06660498|DRUG|Placebo|Participants will receive placebo concurrently with aspirin 75 mg for three cycles, each consisting of 21 days on and a minimum of 7 days off.
223578908|NCT06660498|DRUG|Aspirin 75 mg|Auxiliary Medicinal Product
223469645|NCT04843982|DRUG|Esketamine hydrochloride|After inclusion, septic patients will be received a single intravenous injection of esketamine (0.7 mg/kg), and then followed by an intravenous administration of esketamine (0.07 mg/kg/h) with an infusion pump for three consecutive days.
223469646|NCT06335771|OTHER|Dietary consultation weight loss intervention|Participants will meet with a member of the study team biweekly for about 6 months.
223469647|NCT04790578|DEVICE|ZoeInsights Application|ZI is designed to promote PA behavior change and maintenance via self-monitoring of PA, symptoms, and other health data. Additional information for using ZI will be provided via a PDF-based user guide on installing and using the application, a live instructional webinar hosted by ZI developer Hanalytics Solutions, and access to continued support via email/telephone communication with study staff as well as Hanalytics Solutions. Reminders to complete self-monitoring tasks will be provided using daily push notifications scheduled according to participant preferences. Automatic graphs will be generated and displayed within the app to allow participants to visualize trends in physical activity, symptoms, and other health data. ZI can be accessed via a web browser on any device that is connected to the internet (e.g. computer, laptop, tablet, smartphone), or via a native android or iOS mobile application on a smartphone or tablet.
223469648|NCT04790578|BEHAVIORAL|EXCEL Exercise Class|The group based remote exercise program is delivered twice a week over the Zoom application. Classes are one hour long with a ten minute warm up, 40 minute strength and conditioning focused exercise circuits, and a ten minute stretching. Each class is followed by additional time to provide participants with an opportunity to interact with each other, fostering social support.
223469649|NCT00294814|DEVICE|Proximal anastomosis using Heartstring anastomotic device|
223578909|NCT03309293|BIOLOGICAL|blood samples|blood samples
224068893|NCT01040455|DRUG|placebo|placebo once daily for eight weeks
224068894|NCT02500121|OTHER|Placebo|Normal saline
224068895|NCT02500121|DRUG|Pembrolizumab|Pembrolizumab, 200mg IV every 3 weeks until progressive disease, unacceptable toxicity, or for up to 24 months
224068896|NCT05500209|BEHAVIORAL|Personal resources' enhancement: self-efficacy|Participants in this condition are asked to take part in a 7-day psychological intervention delivered through Facebook Messenger chat-bot. Each day one CBT-framed exercise aimed at coping self-efficacy enhancement is delivered. An exercise takes form 5 to 30 minutes to complete.
224068897|NCT00366587|DEVICE|Cataract surgery and IOL implantation|
224303983|NCT06895343|DRUG|ABBV-701|Subcutaneous
224303984|NCT06895343|DRUG|Placebo|Subcutaneous
223469650|NCT02898233|OTHER|Deprexis|Deprexis is an experimental internet-based treatment program for depression created by Gaia (Hamburg, Germany).
224159484|NCT05431231|DIAGNOSTIC_TEST|Manchester Short Assessment of Quality|a patient questionnaire that assesses quality of life. This questionnaire was developed by Priebe, Huxley, Knight and Evans in 1999. It is based on a longer questionnaire - Lancashire Quality of Life Profile (LQLP) - and was created as an attempt to form an improved shorter version. The questionnaire is composed of two parts: personal details that can change over time and 16 questions that assess objective and subjective quality of life. The objective items are presented as yes or no questions, while regarding the subjective items, participants are asked to describe, using a 7-level Likert scale, the extent to which they are satisfied with their lives. Priebe et al. reported an alpha internal consistency of 0.74.
223469651|NCT02898233|DEVICE|Active low-level light therapy|Administration of LLLT consists of applying light of a specific wavelength (1064 nanometers) that intersects with the absorption spectrum of cytochrome oxidase, using a laser diode, the high density laser (HD laser; Cell Gen Therapeutics, LLC). Active LLLT includes 4 days, once per week for 4 weeks, during which LLLT is applied to two alternating positions on the participant's right forehead for 8 minutes total.
223469652|NCT02898233|DEVICE|Sham low-level light therapy|Administration of LLLT consists of applying light of a specific wavelength (1064 nanometers) that intersects with the absorption spectrum of cytochrome oxidase, using a laser diode, the high density laser (HD laser; Cell Gen Therapeutics, LLC). Sham LLLT includes 4 days, once per week for 4 weeks, during which sham LLLT (5 seconds active, 55 seconds sham) is applied to two alternating positions on the participant's right forehead for 8 minutes total.
224159485|NCT05431231|DIAGNOSTIC_TEST|Self-Stigma of Mental Illness Scale|a patient questionnaire that assesses internalized self-stigma. It was developed by Corrigan, Watson, and Barr in 2006. The questionnaire is composed of four dimensions. The questionnaire includes 40 items, 10 items for each dimension. The participant is asked to rate the extent to which he agrees with each item using a 9-level Likert scale. The questionnaire yields four separate scores for each dimension, and each dimension can be administered separately and independently. In the current study, only one 10-item dimension will be administered - the extent to which the participant has internalized stereotypes concerning mental illness. Corrigan et al (2006) reported an internal consistency alpha of 0.81 and a test-retest reliability ratio of 0.82 for this dimension.
223469653|NCT00430846|DRUG|SGN-35|Every 21 days. Dose Escalating. 0.1 - 3.6 mg/kg
223469654|NCT04694001|DEVICE|Use of the Atalante exoskeleton|A session includes stand-up, walks, exercises with or without the assistance of the exoskeleton, rotation, side and back step, squat and sitting.
223469655|NCT01876108|DRUG|H.pylori eradication (Omeprazole, Amoxicillin, Bismuth subcitrate, Azithromycin)|The regimen consists of Omeprazole (20 mg/BD)+ Amoxicillin (1 g/day)+ Bismuth subcitrate (240 mg/BD)+ Azithromycin (500 mg/BD)for two weeks.
223469656|NCT02993848|OTHER|No intervention|
223469657|NCT01077323|DRUG|exenatide|subcutaneous injection, dosing according to normal clinical practice
223469658|NCT01077323|DRUG|Other antidiabetic therapies|Includes metformin, thiazolidinediones, insulins, sulfonylureas, non-sulfonylurea secretagogues, sitagliptin, and alpha-glucosidase inhibitors; In all cases, dosing according to normal clinical practice
223469659|NCT01077323|OTHER|No diabetes therapy|Subjects not diagnosed with diabetes
223469660|NCT05628701|PROCEDURE|Ileorectal anastomosis (IRA)|After subtotal colectomy for ulcerative colitis the patients can either keep their end ileostomy or be reconstructed with an anastomosis (connection) between the ileum and the rectal remnant (Ileorectal anastomosis(IRA))
223469661|NCT05628701|PROCEDURE|Ileal pouch anal anastomosis (IPAA)|The rectum is removed and a pouch constructed with the distal part opf the ileum which in subsequently anastomosed (connected) to the anus(Ileal pouch anal anastomosis (IPAA)).
223469662|NCT05628701|PROCEDURE|ileostomy|no reconstruction is performed and the patient is left with his/her ileostomy
223469663|NCT01654770|DEVICE|video capsule endoscopy|
223469664|NCT01654770|DEVICE|double balloon enteroscopy|
223469665|NCT00120237|DRUG|Misoprostol|600 mcg oral misoprostol administered during third stage of labor
223469666|NCT06404892|PROCEDURE|Single-lung ventilation|Patients undergoing thoracic surgery and intraoperative single-lung ventilation.
223469667|NCT03906812|OTHER|Telemetry|Bed type assignment
223469668|NCT03906812|OTHER|Unmonitored|Bed type assignment
223469669|NCT04873089|OTHER|Cosmetic product|"It is a comparative study with two parallel groups of subjects:~* Tested group: twice daily application of the cream RV3278A cosmetic product on the whole face~* Comparative group: no application of study product or reference product"
223469670|NCT03898622|DRUG|Levothyroxine|levothyroxine with a safe dose for our population with high cardiovascular risk of 0.25mcg so that the patient's weight range between 50-80kg maintains a dosage of 0.3-0.5mcg / kg / day that does not affect the thyroid axis) fasting levothyroxine (in the case of taking a drug that interacts with absorption, use of it is changed according to the specified hours, see Table 2), and adjusted according to TSH levels \> 1 and normal T4L
223469671|NCT05560620|BEHAVIORAL|Sleep Deprivation|Participants will be randomized into either the sleep deprivation group or the control group, who will sleep regularly.
223469672|NCT05560620|OTHER|Caffeine|On Day 2 morning, after the sleep deprivation or sleeping, participants will be randomized into receiving caffeinated or de-caffeinated coffee, which they will be blinded to.
223469673|NCT05560620|OTHER|No Caffeine|De-caffeinated coffee
223469674|NCT02415543|PROCEDURE|SIL-TEP Inguinal Hernia Repair|perform the laparoscopic total extraperitoneal inguinal hernia repair using a single incision
223469675|NCT02415543|PROCEDURE|TEP Inguinal Hernia Repair|perform the multiport laparoscopic total extraperitoneal inguinal hernia repair
223469676|NCT01768663|DRUG|Lumacaftor|tablet, 200mg taken every 12 hours
223469677|NCT01768663|DRUG|Ivacaftor|tablet, 250mg taken every 12 hours
223469678|NCT01768663|DRUG|Ciprofloxacin|750 mg taken every 12 hours
223469679|NCT01768663|DRUG|Itraconazole|200mg taken once daily
223578910|NCT05859815|BEHAVIORAL|Physical Therapy|As part of their normal care, participants will receive any combination of the following interventions to address their specific needs identified during the initial evaluation: cervical spine repeated movements (active range of motion), cervical spine stabilization exercise, aerobic exercise, motor control training, oculomotor/vestibular rehabilitation, stretching, soft-tissue mobilization, joint mobilization, and postural re-education activities.
223578911|NCT02775331|OTHER|Shift planning with self-rostering and shift ergonomics|Employees working in shift planning units (clusters) using an interactive shift planning software (Titania1) with sub-tools for individual shift planning (self-rostering) and an option for shift ergonomics evaluation to both the shift planner and the employees
223578912|NCT02775331|OTHER|Shift planning with shift ergonomics|Employees working in shift planning units (clusters) where shift planners use a non-interactive shift planning software (Titania2) providing guidance for health-supporting shift ergonomics.
223578913|NCT06614504|OTHER|Varying the nicotine content of cigarettes|Altering the nicotine content of the tobacco research cigarettes
223578914|NCT06614504|OTHER|Varying the nicotine content of e-cigarettes|Altering the nicotine content of the research e-cigarettes
223578915|NCT05748704|OTHER|Short-term modified fasting|STMF regimen consists of a low-calorie diet aimed at providing 800-1,000 kcal/day, lasting five days and with the following composition: 10% carbohydrates, 15% proteins, 75% lipids. During the days of STMF, patients will be required to write down the foods consumed in a food diary in order to calculate calorie and nutrients intake. The STMF regimen will be administered tentatively on a monthly basis (depending on the therapeutic regimen the patient undergoes) and in any case no more frequently than once every three weeks.
223743675|NCT07190313|OTHER|Swedish Massage Therapy|"The therapist uses non-aromatic cream to facilitate making long strokes over the body. Swedish massage is done with the subject covered by a sheet, a technique called draping. One part of the body is uncovered, massaged, and then re-draped before moving to another part. The primary techniques used in the research protocol therapy are effleurage, petrissage, kneading, tapotement and thumb friction. These techniques are performed in a very precise, carefully elaborated manner. The session starts with the subject fully draped in a prone position on the massage table and after approximately 22 minutes the subject is instructed to turn to the supine position. Finally, the therapist moves to the head area of the subject, begins working on the shoulders, neck and head using effleurage and thumb friction, and concludes by using light tapotement on the head. The total time for the entire massage is 45 minutes. Subjects randomized to SMT will undergo a single session."
223743676|NCT07190313|OTHER|Light Touch Control|The Light Touch Control protocol entails the same duration and sequence of procedures as the massage protocol, except that the therapist employs only light-touch hand placement on the subject's body. This condition isolates the effect of the mechanical intervention of SMT. Subjects randomized to LT will undergo a single session.
224068898|NCT03111446|PROCEDURE|Spinal Anesthesia|Spinal needle 25G with Quincke's bevel will be used. It will be induced with a total of 10 mg of 0.5% hyperbaric bupivacaine and 20 mcg fentanyl (total volume 2.4 ml) at the L3-4 interspace. The parturient will be returned to the supine position with a left lateral tilt of 15° to facilitate left uterine displacement. The upper sensory block level will be checked 5 min after the spinal injection by assessing the loss of cold sensation from alcohol swabs, to ensure that a Th6 sensory block level has been achieved.
224068899|NCT03111446|PROCEDURE|General Anesthesia|Pre-oxygenation with oxygen 100% via a tight fitting mask rapid sequence technique. Induction is by thiopental (5 mg kg lean body weight) and succinylcholine1.5 mg kg body weight), cricoid pressure should be applied before consciousness is lost and kept in place until confirmation of tracheal intubation with capnography and the cuff of the tracheal tube is inflated. Auscultating the chest helps exclude endobronchial intubation. At this point, surgery may commence.
224068900|NCT03730116|DRUG|bisoprolol/perindopril FDC|the first and only single-pill combination of beta-blocker and ACE inhibitor
224068901|NCT00852995|BIOLOGICAL|HP802-247|One dose of HP802-247 consists of 260 microliters (uL) containing keratinocytes and fibroblasts totaling 0.5 x 10-6 power or 5.0 x 10-6 power cells per mL, plus fibrin.
224068902|NCT00852995|BIOLOGICAL|Placebo (Vehicle)|"Placebo (Vehicle) consisting of:~Component 1 - acellular fibrinogen solution; Component 2 - acellular thrombin solution"
224068903|NCT00445419|BIOLOGICAL|PEV2A PEV2B|
224068904|NCT02133989|DRUG|Ticlopidine + Ginko biloba|ticlopidine hydrochloride 250mg, ginko leaf ext. 80mg, twice daily
223743677|NCT07190261|DRUG|enatumab|The recommended subcutaneous injection dose of this product is as follows: an incremental dose of 12mg on day 1, an incremental dose of 32mg on day 4, an initial treatment dose of 38mg on day 8, and subsequent treatment doses of 38mg in weeks 4 and 6.
223743678|NCT07190755|OTHER|Remote symptoms moniotring|Participants in the intervention arm will use Resilience PRO, a mobile phone application regularly asking participants about their symptoms. For clinically important symptoms, an alert is sent to the care team that can incorporate that information to timely adjust the care of the participants.
223743679|NCT07190664|OTHER|Patients were randomly grouped|All patients included in the study, were randomized
223743680|NCT07191392|DEVICE|Temporal Interference Stimulation (TIS)|The total stimulation duration was 30 minutes, including a 30-second current ramp-up at the beginning and a 30-second ramp-down at the end.
223469680|NCT01768663|DRUG|Rifampin|600mg taken once daily
223469681|NCT01811537|DEVICE|Artificial Chordae|
223469682|NCT00617357|DEVICE|LTM (Strattice Reconstructive Tissue Matrix)|Surgical mesh
223469683|NCT05868590|OTHER|Toothpaste|Using two different toothpastes for removal of the dental plaque in children.
223469684|NCT02153918|BIOLOGICAL|PROSTVAC-V/TRICOM|A recombinant vaccinia virus vector vaccine containing the genes for human prostatic specific antigen (PSA) and three co-stimulatory molecules.
223469685|NCT02153918|BIOLOGICAL|PROSTVAC-F/TRICOM|A recombinant fowlpox virus vector vaccine containing the genes for human PSA and three co-stimulatory molecules.
223469686|NCT03792646|DIETARY_SUPPLEMENT|Whey protein|Exercise training + 20g whey protein
223469687|NCT03792646|OTHER|Exercise training|Strength exercise
223469688|NCT01917279|DRUG|Docetaxel plus Capecitabine|"Eligible patients will receive treatment with Capecibatine (1000 mg/ m2 twice daily D1-14 Q3W) plus docetaxel(75 mg/m2, D1,Q3W) for a maximum of 6 cycles, or be treated until disease progression, unacceptable toxicity or patient request for withdrawal, whichever occurs first. Each cycle is 3 weeks in duration.~For the the patients with SD, PR or CR after initiate treatment phrase will enter into maintenance treatment phase."
224303985|NCT06927336|DRUG|XinNaoJing injection|XingNaoJing injection is a kind of traditional Chinese medicine preparation, which has the effects of clearing heat and detoxifying, cooling blood and activating blood circulation, resuscitating the brain. In recent years, it has been often used in the treatment of related symptoms caused by qi and blood disturbance and cerebral blood stasis, and has achieved certain results. Xingnaojing injection contains Yujin to resuscitate phlegm, invigorate blood circulation and promote qi; Zhizi dissipates blood stasis and cleans heat; Both are subject medicine. Natural musk cleans the brain, Shujin Tongluo, Jun medicine; Borneol awaken awaken, for adjuvant. Small doses of musk restored brain function and improved cerebral circulation. Xingnaojing injection can promote the recovery of consciousness, reduce the level of plasma β-endorphin, and restore brain function. Borneol bi-dimensionally regulates the central nervous system, calms, prolongs the level of arousal, and protects the brain tissue.
224303986|NCT06927336|DEVICE|tDCS|tDCS stimulated the cerebellum for 20 minutes, once a day, 5 times a week, a total of 10 times, and the stimulation intensity was 2mA.
223469689|NCT01917279|DRUG|Intermittent Capecitabine|Capecitabine 1000 mg/m2 twice daily on days 1-14 of each 3-week cycle
223469690|NCT01917279|DRUG|Metronomic Capecitabine|Capecitabine 500 mg three times daily on days 1-21 of each 3-week cycle
223469691|NCT01764841|DRUG|Ciprofloxacin DPI (BAYQ3939)|Participants received 32.5 mg ciprofloxacin hydrated (corresponding to 50 mg dry powder) administered BID (every 12 hours) using T-326 powder inhaler device.
223469692|NCT01764841|DRUG|Placebo|Participants received placebo matched to ciprofloxacin 32.5 mg powder (containing 40 mg dry powder) administered BID (every 12 hours) using T-326 powder inhaler device.
223469693|NCT03311191|DEVICE|Measurement of skin oxygenation and oxygen consumption|Oxygenation properties will be measured using a transparent paint-on bandage formulation that consists of New-Skin liquid bandage, an oxygen-sensing metallo-porphyrin exhibiting bright red phosphorescence, and the green-fluorescing reference dye fluorescein.
223469694|NCT05639517|OTHER|Augmented Reality Based Telerehabilitation Application|Spinal stabilization training with augmented reality-based telerehabilitation will be applied twice a week for 8 weeks.
223469695|NCT05639517|OTHER|Training face-to-face|Spinal stabilization training will be applied face-to-face twice a week for 8 weeks.
223469696|NCT00006015|BIOLOGICAL|trastuzumab|4 mg/kg IV infusion Day 1, then weekly 2 mg/kg IV infusion (on Days 8, 15, \& 22)
223469697|NCT00006015|DRUG|fluorouracil|500 mg/sq m IV push weekly for 3 weeks, followed by a 1 wk break
223469698|NCT00006015|DRUG|leucovorin calcium|500 mg/sq m IV infusion over 2 hours weekly for 3 weeks, then a 1 wk break
223469699|NCT00006015|DRUG|oxaliplatin|85 mg/sq m IV infusion over 2 hours Days 1 \& 15 of each cycle
223469700|NCT05344846|OTHER|Guided imagery|The individuals in this group will be provided with guided imagery application. Guided imagery will be applied to the participants in the hospital environment 6-10 hours after the cesarean section. Afterwards, guided imagery application will be requested every day for two weeks.
224068905|NCT02133989|DRUG|Clopidogrel|clopidogrel bisulfate 97.875mg(75mg as clopidogrel)
224068906|NCT05260619|DRUG|lenalidomide|Patients with MRI documented response CR or PR after induction chemotherapy will enter the study protocol of lenalidomide maintenance (at a dose of 15 mg per day, on days 1 to 21 of each 28-day cycle) for up to 12 cycles or until the patients withdrew consent, the disease progressed, or unacceptable toxic effects occurred.
224068907|NCT03380689|DRUG|S-1|\- S-1 is administered orally on days 1 to 7 of a 14-day cycle. Patients are assigned on the basis of body surface area (BSA) to receive one of the following oral doses twice daily: 40 mg (BSA \<1.25m2), 50 mg (BSA \>1.25 to \<1.50 m2), or 60 mg (BSA \>1.50 m2).
224068908|NCT03380689|DRUG|Irinotecan|\- CPT-11 was administrated as a 90-min intravenous infusion on day 1 of a 14-day cycle. Five escalating dose levels of CPT-11 were prepared, at an initial dose of 75mg/m2/day (level 1), stepping up to 100 (level 2), 125 (level 3), 150 (level 4) or 175 (level 5) mg/m2/day.
224068909|NCT03380689|DRUG|Bevacizumab|\- Bevacizumab (5 mg/kg) is administered by intravenous infusion over the course of 30 to 90 min on day 1 of each 2-week cycle.
224068910|NCT04195152|OTHER|Observational|No intervention
224068911|NCT02868008|PROCEDURE|Microsurgical resection of brain AVMs|fMRI guided microsurgical resection of brain AVMs
224068912|NCT04031651|DRUG|Pudilan Xiaoyan Oral Liquid|In the respiratory and emergency departments of the hospitals under surveillance, the medication of Pudilan Xiaoyan Oral Liquid is observed for those aged 18-80 years who strictly follow the prescription of the instructions.
224068913|NCT00118014|DRUG|Sertraline|
224068914|NCT00118014|BEHAVIORAL|Habit Reversal Training|
224068915|NCT00661115|DRUG|Levitra (Vardenafil, BAY38-9456)|Vardenafil 10 mg. After a 4 week run-in period, subjects were randomized in order to enroll 3 times more subjects in the vardenafil group than in the placebo group. The duration of the active treatment phase was 12 weeks
224068916|NCT00661115|DRUG|Placebo|Placebo. After a 4 week run-in period, subjects were randomized in order to enroll 3 times more subjects in the vardenafil group than in the placebo group. The duration of the active treatment phase was 12 weeks
224068917|NCT01505569|DRUG|Ifosfamide|"* Arms A\&B: 1.8 g/m\^2/day intravenously (IV) over 1 hour; given in a window of 30-100 days before transplant for 5 days before conditioning regimen~* Arm C: 2000 mg/m\^2 IV daily on Days 1-3 every 14 days for 2 cycles"
224068918|NCT01505569|DRUG|Etoposide|"* Arms A\&B: 100 mg/m\^2/day intravenously (IV) over 1 hour; given in a window of 30-100 days before transplant for 5 days prior to conditioning regimen.~* Arm C: 400 mg/m\^2 daily on days -4, -3, and -2 every 21 days~* Arm D: Etoposide 8.3 mg/kg (or 250mg/m² if age \>36 mos.) approx. hour 75 on days -5, -4, and -3"
224068919|NCT01505569|DRUG|Mesna|"* Arms A\&B: 1.8 g/m\^2/day divided in every 6 hrs dosing; given in a window of 30-100 days before transplant for 5 days prior to conditioning regimen.~* Arm C: 2000 mg/m\^2 IV daily on Days 1-3 every 14 days for 2 cycles"
223469701|NCT03970525|DEVICE|Venturi pump|The venturi pump makes use of the venturi effect to create a vacuum. The venturi effect creates a vacuum by the flow of a fluid, typically air, over an opening. In many phacoemulsification machines, this requires nitrogen tanks or a self-contained air compressor. The vacuum level is created within a rigid drainage cassette, to which the phaco aspiration tubing is connected. Since there is no milking of the aspiration line, the phaco tubing can be made rigid with low compliance.
223469702|NCT03970525|DEVICE|Peristaltic vacuum pump|"The peristaltic pump uses rollers to compress the phacoemulsification outflow tubing in a peristaltic manner, thereby creating flow and vacuum. The compression of the rollers on the tubing with the rotation of the pump physically moves fluid and creates a continuous milking action on the fluid column, The phaco machine can directly control this flow level, hence the term flow based, however, the preset vacuum level is only achieved once there is occlusion of the outflow line, typically at the phaco needle tip with cataract material."
223469703|NCT03832283|DIAGNOSTIC_TEST|CAD-MDD/CAT-DI screening via MyChart|Patients will receive invitations via MyChart to complete the CAD-MDD to screen for major depressive disorder (MDD). For patients who screen positive for MDD, CAT-DI will launch automatically and assess depression severity. CAT-DI assigns a score of 0 to 100 in four severity categories (\<50=normal, 50 to 65=mild, 66 to 75=moderate, and \>75=severe).
223469704|NCT03832283|DIAGNOSTIC_TEST|CAD-MDD/CAT-DI screening during clinic visit|During routine in-clinic visits, medical assistants or providers will ask patients to complete the CAD-MDD to screen for major depressive disorder (MDD). For patients who screen positive for MDD, CAT-DI will launch automatically and assess depression severity. CAT-DI assigns a score of 0 to 100 in four severity categories (\<50=normal, 50 to 65=mild, 66 to 75=moderate, and \>75=severe).
223469705|NCT03832283|OTHER|CAT-DI monitoring via MyChart|Patients with active MDD will receive invitations via MyChart to complete the CAT-DI to assess MDD severity and remission. A normal CAT-DI score (\<50) will indicate that a patient's MDD is in remission.
224068920|NCT01505569|BIOLOGICAL|G-CSF|"* Arms A\&B: Beginning 24 hours after treatment with ifosfamide, etoposide and mesna, administer 10 mcg/kg/day subcutaneously (SQ) or intravenously (IV) until absolute neutrophil count (ANC) is greater than (\>) 1,000/mm\^2. Starting that day, increase dose to 15 mcg/kg/day SQ or IV given as a single injection for 3 doses. G-CSF, 5 ug/kg/day IV as a bolus injection each evening beginning on day 0 until the ANC is \>2500 x 10\^9/L for 2 consecutive days. G-CSF will subsequently be restarted at 5 ug/kg/day SC or IV if the ANC falls below 1000/mm\^3~* Arm C: 10 μg/kg SQ daily beginning 6 hours after ifosfamide on day 3 until adequate CD34+ cell collection or day 15, whichever occurs first.~* Arm D: Beginning day +1 following hematopoietic cell reinfusion, patients receive filgrastim at a dose of 5mcg/kg SQ once daily (or 5mcg/Kg IV either daily or twice daily, per institutional preference)~* Arm E: 5 micrograms/kg/dose beginning on Day 0 and continue per institutional preference"
224068921|NCT01505569|DRUG|Busulfan|Arm A: 1.1 mg/kg IV every 6 hours on days -8 through -6 Arm E: first dose of busulfan is dosed by mg/kg as appropriate for age and weight. Once the results of pharmacokinetic (PK) studies are known, subsequent daily doses are based upon those results,
224068922|NCT01505569|DRUG|Melphalan|Arm A: 50 mg/m\^2 intravenously (IV) over 30 min on Days -4 and -5 Arm E:140 mg/m2 AT LEAST 24 hrs after last busulfan dose. Day: -1
224068923|NCT01505569|DRUG|Thiotepa|Arm A: 250 mg/m\^2 intravenously (IV) over 2 hrs on days -2 and -3 Arm B: 10 mg/kg/day or 300 mg/m\^2 IV on days -3 and -2 Arm D: Thiotepa 10 mg/kg (or 300mg/m² if age \>36 mos.) approx. hour 72 on days -5, -4, and -3
224068924|NCT01505569|BIOLOGICAL|Autologous stem cell infusion|"Arms A, B \& C: On Day 0, stem cells will be infused immediately after thawing over 15-60 minutes per institutional guidelines.~Arm D: On day 0, peripheral blood hematopoietic progenitor cells (PHPCs) or bone marrow cells will be thawed and re-infused about 72 hours following completion of the last dose of chemotherapy.~Arm E: stem cells will be infused on Day 0 of Consolidation. Where the DMSO volume in the stem cell product would exceed accepted level for infusion within a 24 hour period, stem cell products may be infused over 2 days to meet this standard."
224068925|NCT01505569|RADIATION|Radiation|"Arm A: If a patient is considered for post-transplant irradiation, a disease appropriate full tumor restaging should be done prior to starting.~Whole lung irradiation (1500cGy in 10 fractions) may be given in patients with prior lung metastasis. Areas of known metastatic disease or PET areas may receive spot irradiation using a dose and method determined to be tolerable by radiation oncology staff. Additional radiation will be given if primary disease has not been irradiated to maximum tolerated dose."
224068926|NCT01505569|DRUG|Carboplatin|Arm B: depending on age and GFR 17mg/kg/day IV over 4 hours or 510 mg/m\^2/day IV over 4 hours Arm C: AUC=8 daily on days -4, -3, and -2 every 21 days Arm D: as calculated from AUC of 7 approx. hour 0 on days -8, -7, and -6
224068927|NCT01505569|DRUG|Paclitaxel|Arm C: 200 mg/m2 IV over 3 hours on Day 1 every 14 days for 2 cycles
224068928|NCT01505569|PROCEDURE|Leukapheresis|Arm C: Blood will be taken by a needle placed in one arm and processed through a machine, which spins the blood so that the white blood cells will be separated out in the machine for purposes of this research and the rest of the blood will be returned through a needle in the other arm.
224068929|NCT01505569|DRUG|Anti-seizure prophylaxis|"Arm E: Lorazepam OR Levetaracetam~* Lorazepam should be given 0.02-0.05 mg/kg/dose, given 30 minutes prior to each busulfan dose and then continuing every 6 hours, maximum dose: 2 mg.~* Levetiracetam should be given 10 mg/kg/dose PO, administered BID, staring 12 hours prior to busulfan, maximum single dose: 1000mg."
224068930|NCT01505569|DRUG|Ursodiol|Arm E: 150 mg/m2/dose PO, administered BID, beginning on Day -7 and continuing a minimum of 28 days post-transplant, or until the end of Consolidation.
224068931|NCT02902952|BEHAVIORAL|Physical Exercise|An eight week physical exercise intervention
224068932|NCT02902952|BEHAVIORAL|Control Intervention|An eight week sedentary control intervention
224068933|NCT00150254|DRUG|CP-526,555 (varenicline)|
224068934|NCT01836783|OTHER|Amnion Allograft|Atraumatic extraction and grafting procedures will be followed by insertion of a dental implant into the grafted area at week-8. The implant will be restored and be monitored for 24 months post-insertion. Two special dental cone-beam CT images (pre-baseline and week-7) and a minimum of 6 intraoral radiographs will be taken during the study
224068935|NCT01836783|OTHER|Allograft|Atraumatic extraction and grafting procedures will be followed by insertion of a dental implant into to the grafted area at week-8. The implant will be restored and be monitored for 24 months post-insertion. Two special dental cone-beam CT images (pre-baseline and week-7) and a minimum of 6 intraoral radiographs will be taken during the study
223469706|NCT03832283|OTHER|PHQ-9 monitoring during clinic visits|During routine in-clinic visits, medical assistants or providers will ask patients to complete the PHQ-9 to assess MDD severity and remission. A PHQ-9 score \< 5 will indicate that a patient's MDD is in remission.
223469707|NCT02616783|DRUG|E/C/F/TAF|150/150/200/10 mg FDC tablet administered orally once daily
223469708|NCT02616783|DRUG|TDF|300 mg tablet administered orally once daily
223469709|NCT02616783|DRUG|FTC|200 mg capsule administered orally once daily
223469710|NCT02616783|DRUG|FTC/TDF|200/300 mg tablet administered orally once daily
223469711|NCT02616783|DRUG|3TC|Tablet administered orally
223469712|NCT02616783|DRUG|Third agent|"Third agent may include one of the following regimens: lopinavir+ritonavir (LPV/r; Kaletra®), atazanavir (ATV; Reyataz®) + ritonavir (RTV; Norvir®), ATV + cobicistat (COBI;Tybost®) (or ATV/COBI FDC), DRV + RTV, darunavir (DRV; Prezista®) + COBI (or DRV/COBI FDC), fosamprenavir (FPV; Lexiva®) + RTV , saquinavir (SQV; Invirase®; Fortovase®) + RTV, efavirenz (EFV;Sustiva®), rilpivirine (RPV;Edurant®), nevirapine (NVP;Viramune®), etravirine (ETR;Intelence®), raltegravir (RAL; Isentress®), elvitegravir (EVG) + COBI, or dolutegravir (DTG;Tivicay®)~Drug classes:~* Protease inhibitors (PI): LPV/r, ATV, RTV, ATV, DRV, FPV, and SQV~* Pharmacokinetic enhancer: COBI~* Non-nucleoside reverse transcriptase inhibitors (NNRTI): EFV, RPV, NVP, and ETR~* Integrase inhibitors: RAL and DTG"
223469713|NCT00203801|DRUG|Sulfadoxine-pyrimethamine|
223469714|NCT00203801|DRUG|Artesunate plus sulfadoxine-pyrimethamine|
223578916|NCT01313819|DRUG|PK-Merz® 200mg/500ml inj(Amantadine) , Normal saline 500ml inj|IV amantadine at 200 mg in 500 cm3 of saline solution or normal saline 500 cm3 given over a 3-h period, twice a day for 2 days along with the pre-existing dopaminergic and non-dopaminergic medication
223578917|NCT06607055|DIAGNOSTIC_TEST|Blood collection|HLA-DR dosage, at the time of inclusion and once a week then
223578918|NCT05734521|BIOLOGICAL|avalglucosidase alfa-NGPT (GZ402666) IV|intravenous infusion
223578919|NCT05734521|BIOLOGICAL|avalglucosidase alfa-NGPT (GZ402666)|exposed via pregnancy and lactation
223469715|NCT00203801|DRUG|Artemether-lumefantrine|
223469716|NCT04344301|OTHER|Audio recording|The investigators will audio record the visits of patients in the intervention group. An RA will enter the exam room and begin the recording with the patient's permission. The patient and clinician can choose to stop or start the recording at any time. Once the visit is complete, the RA will enter the room, turn off the recording, and bring the patient to a private room where the RA will follow standardized instructions demonstrating how to access recordings. Patient access to recordings will be possible via a secure web-based platform. Patients will also receive reminders to listen to their recordings.
223469717|NCT00955799|DRUG|Neramexane mesylate|Double-blind treatment period of 29 weeks up to 75 mg Neramexane mesylate per day
223469718|NCT00955799|DRUG|Placebo|Double-blind treatment period of 29 weeks placebo
223469719|NCT03973580|BEHAVIORAL|Attentional Bias Modification (ABM) task|Participants will be presented with a fixation cross (500ms) followed by a pair of identity-matched, angry-neutral faces (1000ms). The pair presentation is replaced by a single arrow-probe (1000ms) in the position of the neural face. Inter-trial intervals (ITI) are 500ms. Participants indicate arrow direction (left or right) by pressing one of two buttons as quickly as possible. By responding to the probe that always replaces the neutral face, participants learn to attend to the non-threat cues and away from threat cues. There are 120 trials of angry-neutral faces in total, and 40 other catch trials with neutral-neutral faces.
223578920|NCT04060628|DRUG|NanoDoce (sterile nanoparticulate docetaxel) Powder for Suspension|
223578921|NCT07029425|PROCEDURE|Procedure: craniosacral therapy techniques.|Participants in the experimental group will receive Manual Therapy (MT) designed for this study, which will include craniosacral therapy techniques. The sessions will last 40 minutes and will be conducted twice a week for the first 4 weeks, followed by once a week for the final 4 weeks.
223578922|NCT07029425|PROCEDURE|Placebo Group|The placebo group will receive a dummy treatment with a duration of 40min, twice a week for the firt 4 week, follwed by once a week for the final 4 week.
224068936|NCT02565979|DIETARY_SUPPLEMENT|resveratrol|Resveratrol will be given for 6 months, twice daily. One pill, which contains 75 mg of resveratrol, will be provided with lunch, and the other pill, also containing 75 mg will be given with dinner. So in total a dose of 150 mg/day will be given.
224068937|NCT02565979|DIETARY_SUPPLEMENT|placebo|A placebo will given for 6 months, twice daily. One pill will be provided with lunch, and the other pill will be provided with dinner.
223578923|NCT07041229|PROCEDURE|EMR|"3-4 ml of high-osmolar solution or saline solution stained with indigo carmine are introduced into the submucosal layer under the formation. The formation and the surrounding mucous membrane (at least 5 mm from the edge of the formation) are removed using a standard diathermic polypectomy loop available to the operator. The formation is removed using electric current in the EndocatQ mode. After the formation is removed, the resection site is examined in white light, then virtual chromoscopy (NBI), and then examined with magnification. If residual tissue of the formation is detected, it is removed using the same technique. If the removal of residual tissue of the formation was performed by another method, indicate which one and why.~The removed formation is extracted using a snare loop; if it is removed in parts, then all fragments, if possible, are extracted through the aspiration channel of the endoscope; for large fragments, a snare loop is used."
223578924|NCT07041229|PROCEDURE|ESD|After assessing the boundaries of the formation, a mark is made at least 5 mm from the edge, then a circular or semicircular incision of the mucosa is made, after which the formation is removed by dissection of the submucosal layer using a scarecrow knife, a knife with a ceramic head at the end in EndocutQ mode, spray-coag swift-coag. The EDPS technique - a tunnel method, will also be used where feasible. The essence of the technique is a semilunar incision of the mucous membrane, retreating from the marks, and creating a tunnel under the formation to the proximal edge of the marks, with subsequent cutting off of the formation along the edges. The removed neoplasm is extracted and stretched on a plate. After removal, the edges and bottom of the wound are assessed, if necessary, prophylactic coagulation of visible vessels and clipping are performed.
223578925|NCT02608580|OTHER|Survey|
223578926|NCT01101698|DRUG|Vitamin K2+10μg cholecalciferol|Pills of: 90 μg vitamin K2+10μg cholecalciferol once daily during 9 months
224303987|NCT06915987|BEHAVIORAL|Exercise Intervention|Exercise snack group will be higher intensity movements designed to elevate heart rate while active movement break will have low intensity / stretching exercises assigned to them.
223469720|NCT03973580|BEHAVIORAL|Control task|The control task is identical with the ABM task, except that in the 120 angry-neutral trials, the arrow-probe replaces the angry face and the neutral face with equal probabilities (60 trials each).
224159486|NCT05431231|DIAGNOSTIC_TEST|Session Alliance Inventory - for patient|this questionnaire has two versions, one for patients and one for the main therapist in the therapeutic team, and its goal is to evaluate the therapist-patient relationship (therapeutic alliance). It is composed of 6 statements that relate to the therapeutic relationship. The participants are asked to rate the extent to which the statements describe their experience accurately using a 7-level Likert scale (1 - does not describe my experience in any way, 7 - describes my experience exactly). In the current study, patients will define who their main therapist is. Falkenstrom et al. reported that in their three tested samples, the alpha coefficients ranged from 0.89 to 0.94.
224159487|NCT05431231|OTHER|Quality of service/satisfaction questionnaire|measured by the quality of service department at Sheba Medical Health Center (or - PROMS, to be decided). Here customer's experience of the online services would be measured as well.
224159488|NCT05431231|DIAGNOSTIC_TEST|Clinical decision-making style|a questionnaire with two - patient and therapist - versions, meant to evaluate decision making style. It was developed by Puschner, Neumann, Jordan, et al. in 2013. The questionnaire constitutes a modified version of the Autonomy Preference Index (API), which was developed by Ende, Kazis, Ash, \& Moskowitz in 1989 for mental health patients. In the current study, only the therapist/psychiatrist version would be administered. The questionnaire is composed of 21 items and yields two components related to clinical decision making: preferences in decision making style and information seeking during decision making. Puschner et al (2013) reported that Kronbach's α coefficient ranged from 0.87 to 0.89.
224159489|NCT05431231|DIAGNOSTIC_TEST|Global Assessment of Functioning Scale|a questionnaire meant to assess the patient's global functioning. It was developed by Jones, Thornicroft, Coffey, \& Dunn in 1996. The GAF was used in DSM-IV as the fifth axis of psychiatric evaluation. The therapist is asked to determine for each patient a general score ranging from 10 to 100 to describe his everyday functioning in psychological, social and occupational fields. A score of 10 refers to a state of persistent danger of severely hurting the self or others, and a score of 100 refers to superior functioning in all areas of life. Jones et al. reported that Kronbach's α ranged from 0.74 to 0.76.
224159490|NCT05431231|DIAGNOSTIC_TEST|Session Alliance Inventory - for therapist|a questionnaire that has two - patient and therapist - versions, meant to assess the therapist-patient relationship (therapeutic alliance). It was developed by Falkenstrom, Hatcher, Skjulsvik, Larsson, \& Holmqvist in 2014. Each questionnaire (patient/therapist) is composed of 6 statements that refer to the therapeutic relationship. The participants are asked to rate the extent to which the statements describe their experience accurately using a 7-level Likert scale (1 - does not describe my experience in any way, 7 - describes my experience exactly). Falkenstrom et al reported that Kronbach's α coefficient ranged from 0.89 to 0.94 for their three tested samples. In the current study, patients will define who their main therapist is.
223578927|NCT01101698|DRUG|Vitamin D|Pills of: 10μg cholecalciferol (Vitamin D)once daily during 9 months
224159491|NCT03944265|OTHER|Counseling|Participate in treatment decision counseling session
224159492|NCT03944265|OTHER|Questionnaire Administration|Ancillary studies
224159493|NCT03944265|OTHER|Medical Chart Review|Ancillary studies
224159494|NCT03127462|BEHAVIORAL|Nurse-led educational intervention|Patients in the intervention group will receive an individual face-to-face conversation with a duration of 45 min. All patients will have access to telephone counselling by their primary nurse when needed and able to arrange a new face-to-face conversation. After 4-6 weeks the face-to-face the nurse will of conversation reach out to the patient by phone to follow up on the earlier conversation. Three months after the face-to-face conversation the nurse will offer the patient a closing face-to-face conversation of 15 min at the same time where the patient has a doctor appointment at the department. Those who are in the control group will continue standard care and not receive any conversation and be used as the control group.
223578928|NCT02426190|OTHER|Anti-gravity treadmill|The intervention is to ask study participants to ambulate using an anti-gravity treadmill that integrates patented, NASA Differential Air Pressure (DAP) technology -- a precise air calibration system -- to uniformly reduce gravitational load and body weight during the warm-up phase of an outpatient physical therapy following a single total knee replacement.
223469721|NCT00571623|OTHER|Chest Physiotherapy|10-minutes of chest physiotherapy using programmed parameters that are components of the specialty beds used in ICU
224068938|NCT05805722|BEHAVIORAL|Behavioral counseling for tobacco cessation|"Participants can choose to receive behavioral counseling in group v. individual format:~Group Sessions: Participants will be offered the opportunity to attend 6 weekly 60-90 minute sessions Individual Sessions: Participants will be offered the opportunity to attend up to 12 30-45 minute sessions on a schedule mutually agreed upon between interventionist and participant"
224068939|NCT04336631|BEHAVIORAL|Intervention on DCP3 based strategies for Hypertension Management and Control|Intervention on DCP3 based strategies for Hypertension Management and Control was developed after formative research findings and evidence built on desk review which was conducted prior to implementation of the multi-componnet strategy. It was tested and implemented in a tertiary care hospital of cardiology among hypertensive patients visiting out-patient department in Rawalpindi, Pakistan.
224068940|NCT02852512|PROCEDURE|sacrocolpopexy|Peritoneal incision from the sacral promontory to the Pouch of Douglas. After careful dissection of the inter-rectovaginal space, a two-piece Y-shaped polypropylene mesh was fixed posteriorly to the levator ani muscles using a absorbable suture. The midpoint of the mesh is anchored to the posterior wall of the vagina. The anterior portion of mesh was then introduced and fixed within the intervesico- vaginal space to the anterior/apical vaginal wall with a running suture. The tails of both meshes were fixed to the sacral promontory with a strong non-absorbable polypropylene suture. The peritoneal incision was re- approximated with a running absorbable suture
223469722|NCT04036487|DRUG|Desflurane|Anesthesia is maintained by desflurane in an oxygen air mixture of 60/40%. If inadequate depth of anesthesia is observed, the end-expiratory concentration of desflurane would be increased.
223469723|NCT04036487|DRUG|Propofol|Anesthesia is maintained by propofol 100-200 μg/kg/min. If inadequate depth of anesthesia is observed, the rate of propofol infusion would be increased.
223469724|NCT03111524|OTHER|Classroom Communication Resource|The Classroom Communication Resource intervention is a classroom- and group-based interventions administered by teachers. It includes a social story, role-play and teacher-led discussion
223469725|NCT03111524|OTHER|No intervention|No intervention is administered in this group as these are control groups
223469726|NCT00165126|PROCEDURE|Radiation therapy|Given as standard therapy
223469727|NCT02903446|DRUG|Denosumab|Participants will be randomized (1:1) allocation to denosumab 60 mg administered subcutaneously (SC) every 6 months for a year + ULT standard of care OR ULT standard of care therapy
223469728|NCT05506423|DEVICE|CycloPen Cyclodialysis System|The CycloPen Micro-Interventional Cyclodialysis System is used to create and cyclodialysis cleft and deliver allograft scleral tissue and/or viscous material to reinforce and maintain the cleft postoperatively.
223469729|NCT06120205|DEVICE|Teal Wand Self-Collection Device Group|Participants will use the Instructions for Use to perform self-collection of vaginal cells and material using the Teal Wand Self-Collection Device, and will fill out a usability survey and a satisfaction and needs survey. A healthcare provider collected sample will be performed by a clinician after self-collection. The patient will serve as their own comparator/control.
223469730|NCT05794295|OTHER|Acoustic Stimulation (AS)|Acoustic Stimulation will be administered while participants have their sleep monitored.
223469731|NCT05794295|OTHER|SHAM Stimulation|No stimulation will be administered while participants have their sleep monitored.
223469732|NCT06469463|DEVICE|MRI|The healthy subjects in the control group will perform an MRI head scan, which will be used to construct 3D head models and headcasts.
223469733|NCT06469463|DEVICE|MEG|The healthy subjects will undergo hpMEG data while wearing 3D-printed headcasts created from high resolution MRI
223469734|NCT06469463|DEVICE|EEG|"The healthy participants will undergo a similar session using EEG recording, using a Polhemus Fastrak system for localization of EEG electrodes and precise co-registration with anatomy and hpMEG data.~The patients group will take part in the same EEG recording session."
223469735|NCT05511922|DRUG|KVD900 600 mg|KVD900 Tablet 600 mg (2 x 300 mg)
223578929|NCT02426190|OTHER|PENS - neuro-muscular stimulation|The intervention is to ask study participants to warm up using Patterned Electrical Neuromuscular Stimulation (PENS) - that closely replicates the body's normal muscle and nerve firing patterns -- on his/her surgical leg in conjunction with a recumbent bike or a Nu-step bike during the warm-up phase of an outpatient physical therapy following a single total knee replacement.
223578930|NCT02426190|OTHER|Anti-gravity treadmill & PENS - neuro-muscular stimulation|The intervention is to ask study participants to ambulate using an anti-gravity treadmill in conjunction with use of Patterned Electrical Neuromuscular Stimulation (PENS) during the warm-up phase of an outpatient physical therapy following a single total knee replacement.
223743681|NCT07191392|DEVICE|Sham temporal interference stimulation (TIS)|Sham stimulation had only 30 seconds of current ramping-up and ramping-down at the beginning and end of the stimulation, respectively, to simulate the sensation of actual stimulation
224068941|NCT02565407|BEHAVIORAL|Proprioceptive training|Training includes a virtual balance board and center-out task. Small vibratory motors placed on forearms provide vibro-tactile movement feedback (VTF). During familiarization participants learn to associate VTF with wrist movement and visual feedback. Vision is occluded after this phase. In the virtual balance board task participants use wrist motion to roll a ball to a target on the board. VTF indicates the desired movement direction and ball velocity. The center-out task involves wrist motion to control a cursor to reach a target. The wrist robot delivers an assistive force towards the target. VTF signals magnitude and direction of the cursor deviating away from the desired path.
224068942|NCT02565407|BEHAVIORAL|Usual care|Usual care refers to care that participants receive through their healthcare providers. It may range from no treatment to various sessions of occupational and physical therapy received at in- or outpatient rehabilitation clinics or at home.
224068943|NCT02537171|DRUG|apatinib|Patients will be randomly assigned on a 1:1 basis to treatment with Apatinib 750mg group or Apatinib 500mg group.
224068944|NCT00717171|DEVICE|SurgiStim3|Electrical stimulation device that provides interferential, high voltage pulsed current and neuromuscular waveforms in sequence. The device runs continuously for the first 2 days following surgery, then runs 3 times a day for 1 hour on days 3 through 42.
224068945|NCT00717171|DEVICE|SurgiStim3|The placebo device is programmed to run for the same amount of time, at the same schedule, using the same waveforms as the functional device over the course of the 42 days. The placebo device, however, will only increase to 80% of the patient-set amplitude after a one minute set-up period and will only turn on for 6 seconds of every minute (3s ramp up, 1s on time, 2s ramp down).
224068946|NCT00642915|DRUG|Lantus, Amaryl|
224159495|NCT04802928|DRUG|Isoniazid 300 milligram|Tablets 150 milligram b.i.d.
224159496|NCT04802928|DRUG|Placebo|Placebo
224159497|NCT00175838|DRUG|Hydroxyurea|Hydroxyurea (or hydroxycarbamide) is an antineoplastic drug commonly used to treat haematological malignancies.
224159498|NCT00175838|DRUG|Aspirin|Aspirin is an anti-aggregating agent, and has been shown to reduce/alleviate minor ischaemic symptoms.
224159499|NCT04192318|BEHAVIORAL|Bridging the Gap|Bridging the Gap is a hybrid model for violence prevention which integrates a hospital-based brief violence intervention (BVI) delivered to the patient while in hospital with a wrap-around community case management prevention strategy.
224303988|NCT01648504|OTHER|eGuide to Colonoscopy and in office ipad education|The investigators will follow patients who receive in office Ipad video education and at home web portal access to the Johns Hopkins eGuide to Colonoscopy.
223469736|NCT05511922|DRUG|Drug: KVD900 300 mg|KVD900 Tablet 300 mg
223469737|NCT05214118|BEHAVIORAL|technology-based program|Participants will be asked to complete three 25-minute modules covering the transition from pregnancy to postpartum, possible neonatal abstinence syndrome (NAS) or neonatal withdrawal syndrome (NOWS), and interactions with child welfare.
223469738|NCT05885451|DRUG|AMG 592|Administered as SC injection
223469739|NCT05885451|OTHER|Placebo|Administered as SC injection
223469740|NCT06020703|BEHAVIORAL|Fermented Food Diet|Subjects will incorporate 1 serving of fermented food a day and increase to 6 more each day as tolerated for 4 weeks. After the initial 4 weeks, subjects will eat 6 or more servings of fermented foods each day for 8 weeks.
223469741|NCT00727935|DRUG|Lidocaïne|
223469742|NCT00727935|DRUG|Ropivacaïne|
223469743|NCT00727935|DRUG|Placebo|
223469744|NCT04010461|DEVICE|TMS|Intermittent theta burst stimulation TMS applied to the cortex to excite cerebral cortex
223469745|NCT04010461|BEHAVIORAL|n-back working memory task|Subjects perform an executive function task, in which they view the serial presentation of letters and decide whether or not a letter matches a letter presented 'n' letters back (2 letters or 1 letter)
223469746|NCT02619097|DRUG|Pegol-sihematide injection|single dose
223469747|NCT03797898|OTHER|Parent Coach|The Parent Coach intervention uses a health educator who provides anticipatory guidance, psychosocial screening/ referral, and developmental/behavioral surveillance, screening, and guidance at each well-visit. The Parent Coach uses a parent-focused, pre-visit questionnaire to customize the visit to the parents' needs. Every well-visit includes a brief, problem-focused encounter with a clinician for a physical exam and any concerns that require a clinician's attention. Finally, an automated text message service provides for periodic, age-specific messages to reinforce key health messages from Parent Coach-led well-visits.
223469748|NCT04733586|PROCEDURE|Sonar guided fascia iliaca|Sonar guided fascia iliaca
223469749|NCT04733586|PROCEDURE|Sonar guided quadratus lumborum block|Sonar guided quadratus lumborum block
223469750|NCT04543175|OTHER|Taste disorder´s test|Each patient performed their own test placing three drops with a disposable dropper from each bottle into the center of the tongue for whole-mouth testing.
223469751|NCT00254865|DRUG|EVRA® transdermal contraceptive patch containing 6 mg of norelgestromin and 0.75 mg of ethinyl estradiol (versus CILEST® tablets).|
223469752|NCT05901337|COMBINATION_PRODUCT|Cupping therapy with convential medical treatment|"Device:Cupping therapy device~Group A participants received Dry cupping therapy one session per week for 8 weeks with 6 days intervals between sessions and with cups applied to the skin for around 8 minutes. (In addition to convential medical treatment for 8 weeks in the form of :~1. Vitamin D: The recommended dietary dose of vitamin D is 600 IU each day for adults 70 and younger .~2. Vitamine C: The recommended dietary dose 200 mg/day vitamin c~3. Anticoagulation drugs (blood thinners)Doctors usually prescribe low-molecular-weight heparin (enoxaparin) (30 mg), each given subcutaneously every 12 hours ."
223469753|NCT05901337|DRUG|Convential medical treatment|"Group B participants received convential medical treatment for 8 weeks in the form of :~1. Vitamin D: The recommended dietary dose of vitamin D is 600 IU each day for adults 70 and younger .~2. Vitamine C: The recommended dietary dose 200 mg/day vitamin C~3. Anticoagulation drugs (blood thinners)Doctors usually prescribe low-molecular-weight heparin (enoxaparin) (30 mg), each given subcutaneously every 12 hours ."
223469754|NCT03414190|BEHAVIORAL|Mobile phone text message|The treatment group will receive the usual discharge treatment, instructions and information for acute coronary syndrome patients as well as the text-messaging intervention. The program will include a variety of topics such as standard follow-up care reminders as well as general self-management and healthy living habits texts. There will be four streams: one for patients who are non-smokers and are free of diabetes; one for current/recent smokers; one for diabetic patients; and one for smoker and diabetic patients. Texts will be sent out 4 times per week for 180 days. All participants in the same stream will receive the same texts in the same order. The usual care group will receive standard discharge treatment, instructions, and information for patients with acute coronary syndrome. They will also receive simple and short text messages related to the importance of trial participation.
223469755|NCT05304845|DRUG|DWP14012|Potassium-competitive acid blocker
223469756|NCT05304845|DRUG|Aspirin|acetylsalicylic acid
223469757|NCT06558331|OTHER|Preoperative Quality of Recovery-15 (QoR-15T)|The quality of recovery score (QoR)-15 questionnaire, preoperative
223469758|NCT06558331|OTHER|Postoperative 24th hour Quality of Recovery-15 (QoR-15T)|The quality of recovery score (QoR)-15 questionnaire, postoperative 24th hour
223469759|NCT05074953|OTHER|Exposed to a SARS-CoV-2 infection|The study compared humans exposed to the SARS-CoV-2 infection with a matched group of those not exposed. No Intervention was applied.
223469760|NCT05572645|DRUG|Pyrotinib Plus Trastuzumab|treatment based on Pyrotinib(320-400 mg, po, qd) Plus Trastuzumab(8 mg/kg q3w, and then 6 mg/kg q3w)
223469761|NCT05572645|DRUG|Pertuzumab Plus Trastuzumab|treatment based on Pertuzumab(840mg q3w, and then 420 mg q3w) Plus Trastuzumab(8 mg/kg q3w, and then 6 mg/kg q3w)
223469762|NCT01717222|DRUG|Intraperitoneal Lignocaine|Patients will receive 100 ml of 0.2% lignocaine
223469763|NCT01717222|DRUG|Intravenous Lignocaine|Intravenous group patients will receive 1.5mg/kg of lignocaine as bolus dose at induction and 2mg/kg/hour as continuous infusion until one hour after surgery
223469764|NCT06054386|OTHER|Attentional Bias Modification Training (ABMT)|The ABMT is aimed to modify attentional bias for negative stimuli in social anxiety by deliberately inducing the participant's attention to positive or neutral stimuli. In the training, after a pair of facial stimuli (e.g., threatening-neutral, neutral-neutral) are presented, a left or right arrow appears in one of the location. Participants are instructed to press the button in the correct direction as quickly and accurately as possible.
224159500|NCT04192318|OTHER|Communities that Care (CTC)|In CTC programs stakeholders elect evidence-based prevention strategies that are most appropriate for their community. These evidence-based strategies target their community's specific needs, such as reducing risk factors while supporting and increasing protective factors.
223469765|NCT06054386|OTHER|General Attention Control Training|The general attention control training aimed to improve participants' general attention control ability by asking them to press a left or right arrow in the correct direction. The basic design of attention control training is the same as the ABMT, but the attention control training does not aim to alter the direction of attention toward or away from certain stimuli.
223469766|NCT01081613|OTHER|89Zr-bevacizumab PET imaging|injection 89Zr-bevacizumab and 89 Zr-bevacizumab PET scan
223469767|NCT00086190|DRUG|paroxetine|Paroxetine 10 mg tablets or matching placebo given once a day for the first two weeks. If depression is not being effectively treated then the paroxetine or matching placebo will be increased to 20 mg, followed by a 10 mg increase every two weeks (if tolerated). Dosage for this study will not exceed 40 mg.
223578931|NCT02426190|OTHER|Recumbent or Nu-step bike|This is the active comparator of the trial that participants are asked to use either a recumbent or Nu-step bike normally seen in an outpatient physical therapy clinic to warm-up during a physical therapy session following a single total knee replacement.
223578932|NCT05203978|PROCEDURE|colonoscopy|Colonoscopy
223578933|NCT00685646|DRUG|antiandrogen therapy|Up to 24 courses of therapy
223578934|NCT00685646|DRUG|zoledronic acid|Up to 24 courses of therapy
223469768|NCT00086190|DRUG|venlafaxine|Venlafaxine XR 37.5 mg capsules or matching placebo given once a day for the first two weeks. If depression is not being effectively treated then the venlafaxine XR capsules or matching placebo will be increased to 75 mg followed by 75 mg increments every 2 weeks (if tolerated). Dosage for this study will not exceed 225 mg.
223469769|NCT00086190|OTHER|placebo|an inactive substance
223469770|NCT03115034|DRUG|Melatonin|Patients under CEA taking 6mg/day melatonin orally from 3 days before operation to 3 days after operation.
223469771|NCT03115034|DRUG|placebo|Patients under CEA taking placebo orally from 3 days before operation to 3 days after operation.
223469772|NCT03115034|OTHER|blank|Patients under CEA without taking melatonin or placebo
223469773|NCT06457139|DIAGNOSTIC_TEST|Glucose tolerance test (2 hour)|Early testing with the 2 hour glucose tolerance test will occur during their inpatient postpartum hospitalization.
223469774|NCT06457139|OTHER|Active Comparator|Subjects randomized to the comparison condition will receive the usual standard of care. The standard of care will consist of administration of educational materials adapted from the American Diabetes Association that discusses healthy lifestyle behaviors and the increased risks of developing T2DM after a pregnancy complicated by GDM.
223578935|NCT02969590|DRUG|Leuprolide acetate|Following this spontaneous cycle, participants received a single intramuscular injection of leuprolide acetate (11.25mg, LupronVR; Abbvie, Chicago, IL), a dose documented to suppress ovarian function for at least 3 months. Ovarian suppression is confirmed with serum E2 less than or equal to 35 pg/ml 21-28 day post-injection.
223578936|NCT02969590|DRUG|Estrogen and Progesterone Replacement|Replace hormones exogenously to create an artificial cycle
223578937|NCT02969590|DRUG|Progestin|Synthetic progestin to assess effects on cervical mucus.
223578938|NCT02704923|DRUG|Atropine|Atropine eye drops (1%) administered by sublingual way (2 drops) every 6 hours
223578939|NCT02704923|DRUG|Placebo|Placebo eye drops characterized by saline administered by sublingual way (2 drops) every 6 hours
223578940|NCT05346991|OTHER|Tobacco Free Teachers, Tobacco Free Society program|"The Tobacco Free Teachers, Tobacco Free Society (TFT-TFS) program provides teachers with the knowledge and skills to quit tobacco use, or to help someone else quit; it also helps schools comply with national tobacco control policies. School principals implement four TFT-TFS program components with teachers in their schools during school hours across an academic year (August-April):~* Adopting a school tobacco control policy~* Providing cessation support (e.g. distribution of self-help quit booklets and referrals to government cessation resources)~* Conducting monthly group discussions with teachers about tobacco~* Hanging six thematic posters in the school~With the goal of establishing a tobacco-free school environment, the program incorporates six program themes: 1. Teachers as Role Models; 2. Health Effects of Tobacco; 3. Motivation to Quit-or Help Others to Quit; 4. Skills to Quit; 5. Dealing with Withdrawal; and 6. Maintenance and Celebration."
223743682|NCT07189715|BEHAVIORAL|Imagery Rescripting Intervention (AI-Generated)|Participants listened to a series of personalized audio scenarios based on their childhood memories of parental criticism and neutral events. At the end of the session, one critical scenario was presented in a modified version that included a therapeutic imagery rescripting (ImRs) intervention. In this script, a therapist figure entered the scene and addressed the child's unmet needs, following the standard rescripting format. The scripts were generated using the Gemini large language model and reviewed by trained experimenters to ensure coherence and therapeutic validity. The intervention aimed to reduce distress and intrusive thoughts related to the memory.
223743683|NCT07191262|OTHER|0.12% CHX and Essential Oil mouthrinse|0.12% CHX mouthrinse will be used to rinse for 1 minute with 15 mL twice daily starting day 1 after surgery through day 14. Patients will be instructed to use OTC essential oil mouthrinse 15mL once daily until the conclusion of the study (day 15 to day 84).
223743684|NCT07191262|OTHER|2.6% EDTA and 0.2% EDTA mouth rinse|.6% EDTA mouthrinse will be used to rinse for 1 minute with 15 mL twice daily starting day 1 after surgery through day 14. Patients will be instructed to use 0.2% EDTA mouthrinse 15mL once daily until the conclusion of the study (day 15 to day 84).
223743685|NCT07190248|DRUG|MK-1084|Administered as an oral tablet
223743686|NCT07190248|BIOLOGICAL|Pembrolizumab (+) Berahyaluronidase alfa|Administered as a SC injection
223743687|NCT07190248|DRUG|Pemetrexed|Administered as an IV Infusion
223743688|NCT07190248|DRUG|Cisplatin|Administered as an IV Infusion
223743689|NCT07190248|DRUG|Carboplatin|Administered as an IV Infusion
223743690|NCT07191093|PROCEDURE|pulmonary valvuloplasty|Pulmonary balloon valvuloplasty (PBV) is the treatment of choice for moderate to severe valvular pulmonary stenosis. It is a minimally invasive, catheter-based intervention that involves dilation of the stenotic pulmonary valve using an appropriately sized balloon. The goal is to relieve obstruction, reduce right ventricular pressure, and prevent long-term complications such as RV hypertrophy, dysfunction, and arrhythmias. The procedure has shown excellent immediate and long-term outcomes, particularly in patients with a pliable, doming pulmonary valve and no significant regurgitation or associated congenital lesions.
223743691|NCT07189455|DRUG|ZG006|ZG006 will be administered as an intravenous (IV) infusion.
223743692|NCT07189455|DRUG|Topotecan|Topotecan will be administered per local standard of care
223743693|NCT07190872|BEHAVIORAL|sleep hygiene education|Students in the intervention group will receive face-to-face sleep hygiene training in a total of 4 sessions, once a week for 40 minutes over a period of four weeks. The education is designed within the framework of the Transtheoretical Model and focuses on topics such as the concept of sleep hygiene, regular sleep hours, limiting caffeine and screen use, organizing the sleep environment, and stress management. The training will be provided by a nurse experienced in sleep health.
223743694|NCT07189949|DRUG|HRS-2329 Tablet|Oral HRS-2329 tablet.
223743695|NCT07191418|DEVICE|Habib™ EndoHPB|This study will hold greater weight compared to previous ones, as it is randomized. It includes 178 patients, exclusively with pancreatic cancer, and is designed as a prospective investigation.
223743696|NCT07191418|PROCEDURE|ERCP|Endoscopic retrograde cholangiopancreatography (ERCP) as part of clinical routine.
223743697|NCT07189520|OTHER|Artificial Intelligence|Benchmark AI scoring vs expert raters (GEARS/OCHRA κ ≥0.75)• Assess performance gains after GenAI feedback (≥15% improvement)• Measure usability, cognitive load, and ecological footprint reduction
223743698|NCT07190833|DRUG|OTS-412|1×10E8 pfu, once, 1 cycle, IT
223743699|NCT07190833|DRUG|Hydroxyurea (HU)|15 mg/kg/day, 14 days, 1 cycle, PO
223469775|NCT02574169|OTHER|alveolar recruitment maneuvers group 1|"Patients are randomized to receive in cross-over 2 ARM: CPAP at first and then eSigh.~The continuous positive airway pressure, or CPAP with application of a positive pressure of 40 cmH2O for 40 seconds without tidal volume.~The eSigh or extended sigh with increase of PEEP for 10 minutes to maintain plateau pressure at 40 cmH2O. During ARM, the peak pressure is limited to 50 cmH2O with decrease of tidal volume (Vt) if necessary.~The following data: PtiO2, respiratory parameters, systemic and intracerebral hemodynamic parameters are collected before, after 1 minute, 10 minutes and 60 minutes for each ARM."
223469776|NCT02574169|OTHER|alveolar recruitment maneuvers group 2|"Patients are randomized to receive in cross-over 2 ARM: eSigh at first and then CPAP.~The eSigh or extended sigh with increase of PEEP for 10 minutes to maintain plateau pressure at 40 cmH2O. During ARM, the peak pressure is limited to 50 cmH2O with decrease of tidal volume (Vt) if necessary.~The continuous positive airway pressure, or CPAP with application of a positive pressure of 40 cmH2O for 40 seconds without tidal volume.~The following data: PtiO2, respiratory parameters, systemic and intracerebral hemodynamic parameters are collected before, after 1 minute, 10 minutes and 60 minutes for each ARM."
223469777|NCT00248209|DRUG|Wellbutrin XL|Patients randomized to the bupropion treatment group will receive bupropion XL150 mg in the AM for 7 days increasing to 300mg/day (single daily dose). The investigator can increase the dose to 450mg per day at Day 28 if clinically indicated.
223469778|NCT03012932|BEHAVIORAL|HPV self-sampling|All participants will receive HPV self-sampling intervention. HPV self-sampling is a cervical cancer screening that can be done in private, using a device that is similar to a tampon. This intervention tests for high-risk HPV, the primary cause of cervical cancer. Each participant will complete the intervention one time only.
223469779|NCT05588986|OTHER|ultrasonography|Umbilical artery Doppler evaluation by ultrasonography just before the first dose of antenatal corticosteroid, 24 hours and 48 hours after the last dose.
223469780|NCT04232345|DRUG|AZD4831|Subjects will be fasted for at least 10 hours before receiving the AZD4831 in the form of an oral suspension.
223469781|NCT04232345|DRUG|Placebo|Subjects will be fasted for at least 10 hours before receiving the placebo in the form of an oral suspension.
223469782|NCT03902613|DRUG|Lurasidone|Participant will have an open label trial of lurasidone for eight weeks.
223469783|NCT00004547|PROCEDURE|Surgery|Patients will undergo cytoreductive surgery to remove as much tumor as possible. Part of the intestines, pancreas, stomach or the entire spleen may also be removed if they are affected.
223469784|NCT00004547|PROCEDURE|Continuous hyperthermic peritoneal perfusion (CHPP) with Cisplatin|
223578941|NCT04053751|PROCEDURE|closed suctioning system|a randomized allocated patient will be monitored for two days. Closed suctioning system will evaluate as experimental group. open suctioning system will evaluate as control group.
223578942|NCT01280539|DEVICE|Transcutaneous electrical nerve stimulation|3 weeks, 5 times a week, 60 minutes a day.
223578943|NCT02208453|DEVICE|InSpace Implantation|InSpace device Implantation
223578944|NCT01956136|BEHAVIORAL|Music-based Neurological Rehabilitation (MBNR)|Music-based Neurological Rehabilitation (MBNR) will involve 10 weeks of individual training (30 sessions, 1 hour per session, 3 days per week) given by a trained music therapist. The MBNR protocol utilizes structured cognitive-motor training with drums (drum set, djembe drums) and creative musical expression (music playing, song writing) with piano that are geared towards engaging and training attention, executive functions, working memory, and upper-extremity functions and for enhancing emotional self-expression, adjustment, and mood after TBI.
224159501|NCT04192318|OTHER|Treatment as usual|Treat and release
224159502|NCT03210064|DRUG|Apatinib|Apatinib Mesylate Tablets 500 mg qd po
223469785|NCT00004547|DRUG|Postoperative dwell with paclitaxel and 5-FU|Intraperitoneal dwell chemotherapy with a combination of 5-FU and Paclitaxel will be delivered in the early postoperative period (day 7 today 12 after surgery). Patients will be premedicated with hydrocortisone (100 mg/intravenous push (i.v.p.)), diphenhydramine (50 mg i.v.p.) and ranitidine (50 mg i.v.p.) 30 minutes prior to delivering intraperitoneal chemotherapy. One liter of normal saline will be infused containing 5-FU (800 mg/M\^2) and 1 L of normal saline containing paclitaxel (125 mg/M\^2) will be infused over 60 minutes. The chemotherapy solution will be left in the abdominal cavity permanently for slow absorption.
223469786|NCT00852813|DIETARY_SUPPLEMENT|arabinoxylan-oligosaccharides (AXOS)|intake period: 3 weeks, 10 g/day
223469787|NCT02262910|BIOLOGICAL|ES414|ES414 is a novel humanized bispecific antibody which is designed to treat mCRPC by redirecting T-cell cytotoxicity against prostate cancer cells expressing prostate-specific membrane antigen (PSMA).
223469788|NCT02027025|DRUG|SPARC1103 low dose|once daily
223743700|NCT07190833|DRUG|Hydroxyurea (HU)|25 mg/kg/day, 14 days, 1 cycle, PO
223469789|NCT02027025|DRUG|SPARC1103 high dose|once daily
223469790|NCT02027025|DRUG|SPARC Placebo|
223469791|NCT04044105|OTHER|Pamphlet education|Patients receive an educational intervention explaining proper opioid disposal
223469792|NCT04044105|OTHER|Pamphlet education + texts|Patients receive an educational intervention and text message explaining proper opioid disposal
223578945|NCT01956136|OTHER|Standard Care (SC)|Standard Care (SC) consists of other types of conventional rehabilitation (physical therapy, occupational therapy, speech therapy, and/or neuropsychological rehabilitation) and medical care for TBI that the patients receive in Finnish private or public health care.
224159503|NCT03210064|DRUG|5-fluorouracil|5-Fluorouracil 400mg/m2 iv d1，2400mg-3000mg/m2 civ 46h,q2w.5-Fluorouracil derivatives(Capecitabine 1000mg/m2 bid po d1-d14 q3w.S1 40mg/m2 bid po d1-d14 q3w).
224159504|NCT01222897|DRUG|Valacyclovir hydrochloride|
224159505|NCT00476398|PROCEDURE|Capsule endoscopy|Patient will undergo a capsule endoscopy for the evaluation of their chest pain.
224159506|NCT00865046|OTHER|Periosteal stimulation|Four acupuncture needles are placed around the knee to the level of the periosteum and two needles are placed pretibially in the soft tissue. All needles are stimulated with 100 Hz current. The stimulation of the needles in the soft tissue is discontinued after one minute.
224159507|NCT00865046|OTHER|Control-Periosteal Stimulation|Acupuncture needles are placed as per the PST intervention, but only the soft tissue needles receive electrical stimulation for one minute.
224159508|NCT02839044|DIETARY_SUPPLEMENT|Menaquinone-7|
224159509|NCT02839044|DIETARY_SUPPLEMENT|Placebo|
224159510|NCT04146038|DRUG|Azacitidine|Given IV
224159511|NCT04146038|DRUG|Decitabine|Given IV
223469793|NCT06852170|OTHER|Co-Design Sessions (CDS)|CDS uses principles and activities from Liberating Structures (LS) and Group Model Building (GMB). Each method uses semi-structured processes for engaging partners to collaborate with one another and address complex problems. Example activities and discussions include: identifying a shared vision for how data can inform decisions related to substance use service delivery and overdose prevention; identifying relevant data that should be disseminated; identifying decisions to be supported with data. Methods from human-centered design - an approach for developing products that are useful and easy to use - will be used to refine data products developed by the study team so that the data products are acceptable and useful to end users. Together, these three methods (Liberating Structures, group model building, human-centered design) will be used to engage partners to iteratively co-design products for disseminating data back to partners to inform their daily substance use service delivery.
223469794|NCT06852170|OTHER|Data products|Data products disseminate localized data from local, state, or regional-level data sources to local (i.e., county) decision makers to inform their daily decision-making. Data products in counties assigned to CDS will receive fully tailored data products, while no-CDS counties will receive standardized data products. A suite of data products will be made available to inform diverse decisions by a variety of end users. Data products will be identified and prioritized during CDS, but may include reports, policy briefs, journey maps, and technical assistance for data interpretation.
223469795|NCT04087239|OTHER|HIV|
223469796|NCT05750030|COMBINATION_PRODUCT|FMT combined with Atezolizumab plus Bevacizumab|Single FMT from patients with HCC who responded to PD-(L)1-based immunotherapy to patients with HCC who failed to achieve complete or partial response (according to mRECIST) to atezolizumab/bevacizumab. After single FMT, patients will continue to receive atezolizumab/bevacizumab every 21-days according to protocol.
223469797|NCT06031259|DRUG|Idursulfase-IT|Idursulfase-IT intrathecally via IDDD.
223469798|NCT06031259|DRUG|Elaprase|Elaprase IV infusion.
223469799|NCT03494127|DEVICE|Use of GEL BALL FITTED MODULAR CUSHION|DAILY COMMUNITY USE OF GEL BALL FITTED MODULAR CUSHION for 2 weeks
223469800|NCT03494127|DEVICE|Use of SQUISHINS FITTED MODULAR CUSHION|DAILY COMMUNITY USE OF SQUISHINS FITTED MODULAR CUSHION for 2 weeks
223469801|NCT05977608|BEHAVIORAL|Telephone Reminiscence Intervention|Participants will receive automatic calls three times a week asking their life experiences and personal memories. They can share as much or as little as they would like. They have up to 10 minutes to record their answer and can end the call at any time by hanging up.They will be able to share the stories online with their families if they want.
223469802|NCT05141513|RADIATION|High Dose Rate Brachytherapy (HDR) Intraoperative Radiation Therapy (IORT)|After the patient receives standard of care treatment, they will receive a single dose of radiation (15 Gy) at the time the tumor is surgically removed. Surgeons will then place clips along the blood vessels around the surgical area. These clips will be used to confirm (after surgery) that the expected dose of radiation was received during surgery.
223469803|NCT04795999|BEHAVIORAL|Project With|There are 12 lessons in Project With, typically delivered in six weekly sessions, with each session having two one-hour long lessons and a meal with facilitators in between the two lessons. Each lesson includes a discussion of selected literary works, including poetry, short stories, and excerpts from films and other videos. The curriculum is intended to be delivered to groups of 8-12 youth. In ideal program delivery, participants also share a meal with each other and with the Youth Advocate. Shared mealtimes create group cohesion and allow Youth Advocates to connect with participants on a personal level, building trust. At the end of the Project With curriculum, youth will partake in an offsite day excursion to Camp Eaton, a wooded camp outside of Los Angeles. At Camp Eaton, Youth Advocates will lead a Project With session, lunch, bonding activities and games, and an opportunity to engage in an outdoor activity.
223469804|NCT05714033|PROCEDURE|Ventilatory Strategy To Prevent Atelectasis|Given
223469805|NCT05714033|PROCEDURE|Lateral Decubitus Strategy (LADS)|Given
223578946|NCT00273754|DRUG|Caffeine|Children in group one will receive caffeine benzoate 20 mg/kg i.v., which is equal to a 10 mg/kg caffeine base.
223578947|NCT00273754|DRUG|Placebo|Children in group two will receive an amount of normal saline equal to Caffeine
224068947|NCT03799393|BEHAVIORAL|CIAS (Computer Intervention Authoring Software)|This is a digital application that allows families to interact with a tablet computer to receive educational information customized to the patient's age and size. allows authors to develop screening, assessment, and intervention tools for patients without requiring new programming. The CIAS intervention is programmed using tailored branching logic to allow a custom path through the intervention based on the respondent's answers. Delivery of the intervention uses a two-dimensional avatar narrator character that mimics the conversational structure of person-delivered brief interventions.
224068948|NCT03799393|BEHAVIORAL|Standard Printed Discharge Instructions|Patients/families will receive standard, printed discharge instructions. This is a 5 page general document from our Injury Prevention Center that describes appropriate car restraint safety for all age groups, not specific to the child enrolled.
224068949|NCT00385632|DRUG|Antiretroviral Regimens|Various antiretroviral therapy combinations already being administered to participants
224068950|NCT03284736|PROCEDURE|Resorbable membrane|
224303989|NCT06928233|PROCEDURE|blood sampling|Blood sampling for experimental analyses.
223578948|NCT03523273|DRUG|Liraglutide|Initiate at 0.6mg S.C. daily for 1 week; subjects will return to the Clinical Research Unit (CRU) each week until an increase by 0.6mg/day in weekly intervals to a dose of 3.0 mg/day is achieved (\~4 weeks). Once maintenance dose of 3.0 mg is achieved, subjects will return approximately every 4 weeks to obtain new supply of study medication.
223578949|NCT03523273|DRUG|Placebo|Placebo administration will match the study drug.
223578950|NCT00974688|BEHAVIORAL|Information Intervention|The information intervention is designed to ensure that the parent(s) and child have a clear understanding of the range of physical activity opportunities that are appropriate and recommended for the child. The information intervention will be comprised of discussions and written information.
223743701|NCT07190833|DRUG|Hydroxyurea (HU)|35 mg/kg/day, 14 days, 1 cycle, PO
224303990|NCT01829087|DRUG|Botox|
224303991|NCT01829087|DRUG|placebo|
223469806|NCT03828227|DRUG|OPTIMOX-bevacizumab|"Induction Adapted FOLFOX7 (aFOLFOX7)-bevacizumab for 6 cycles (3 months)~* Bevacizumab: 5 mg/kg IV (day 1, every 2 weeks \[q2w\]),~* Folinic acid (FA): 400 mg/m² IV/2h (day 1, q2w),~* Oxaliplatin: 85 mg/m² IV/2h (day 1, q2w),~* 5-fluorouracil (5-FU) continuous infusion 2400 mg/m² IV/46h (day 1-2, q2w),~* No 5-FU bolus.~then Maintenance Adapted LV5FU2 (aLV5FU2)-bevacizumab (until progression or or unacceptable limiting toxicity)~* Bevacizumab: 5 mg/kg IV (day 1, q2w),~* FA: 400 mg/m² IV/2h (day 1, q2w),~* 5-FU continuous infusion 2400 mg/m² IV/46h (day 1-2, q2w)~* No 5-FU bolus"
224159512|NCT04146038|DRUG|Salsalate|Given PO
224159513|NCT04146038|DRUG|Venetoclax|Given PO
224159514|NCT00881140|DRUG|mifepristone vaginal tablets|Daily use of 10 mg administrated per vagina for 3 months
223469807|NCT03828227|DRUG|Capecitabine plus bevacizumab|"* Bevacizumab: 7.5 mg/kg intravenous infusion \[IV\] (day 1; q3w),~* Capecitabine: 1000 mg/m² orally twice a day (day 1 through day 14, q3w)."
223469808|NCT00918593|DRUG|Electrochemotherapy|Intratumoral or intravenous bleomycin followed by electric pulses. Once only treatment.
223469809|NCT00918593|RADIATION|Radiotherapy|Radiotherapy according to hospital procedures.
223469810|NCT00918593|DRUG|Bleomycin|Intratumoral or intravenous bleomycin followed by electric pulses. Once only treatment.
223469811|NCT03775083|DRUG|Currently approved medications|subjects will be treated according to current Department of Health and Human Services (DHHS) Center for Disease control and prevention (CDC), Society for Healthcare Epidemiology of American (SHEA guidelines for nPEP
223578951|NCT00974688|BEHAVIORAL|Demonstration Intervention|The demonstration intervention will be designed to demonstrate to the child and parent(s) specifically what the child is able to do in relation to fitness and motor skill activities. The demonstration intervention will consist of having the child complete a standardized exercise testing protocol on the treadmill, followed by discussions with the child and parent(s) to convey the results of the study testing of fitness and gross motor skill.
223578952|NCT03668054|DRUG|Bevacizumab (Lumiere®)|The first three doses of bevacizumab (Lumiere®) were administered via intravitreal injection on a monthly basis. A safety evaluation was conducted in the first month. Following the first three doses, continuation of the treatment (up to 6 doses) was decided according to response.
223578953|NCT03081676|DRUG|Glimepiride 1Mg Tablet|Glimepiride
223578954|NCT03081676|DRUG|Glucagon-like Peptide-1|GLP-1 infusion
223578955|NCT03081676|DRUG|Glucose-Dependent Insulinotropic Polypeptide|GIP-infusion
223578956|NCT03081676|DRUG|Placebo Oral Tablet|Placebo
223469812|NCT05617807|PROCEDURE|Nanoscopic partial meniscectomy|Patients will have a partial meniscectomy performed using the arthrex nanoscope and it will be compared to partial meniscectomy performed using standard arthroscopic equipment
223469813|NCT05617807|PROCEDURE|Standard Partial Meniscectomy|Patients will have partial meniscectomy performed using standard arthroscopic equipment
223469814|NCT01897051|DRUG|Rifaximin + propranolol|"1. Rifaximin : taking 400mg three times a day in the study period (total 1,200 mg per day)~2. Propranolol : taking 40mg twice a day to start. If patient is tolerable and systolic blood pressure is above 90 mmHg, the dosage can be increased by doubling to every other day upto the 360mg per day.~(Target heart rate : 25% reduction in baseline heart rate or at least 55 times per minute).~If patient is not tolerable, we can reduce the dosage step-by-step until the adverse symptoms is disappeared."
223578957|NCT03081676|DRUG|Placebo infusion|Placebo (saline)
223578958|NCT02590562|OTHER|Routine clinical practice|
223578959|NCT03481920|DRUG|PEGylated Recombinant Human Hyaluronidase (PEGPH20)|PEGPH20 will be administered at a dose of 3.0 micrograms per kilogram (μg/kg) as an intravenous (IV) infusion.
223578960|NCT03481920|DRUG|Avelumab|Avelumab will be administered as at a dose of 10 milligrams per kilogram (mg/kg) as an intravenous (IV) infusion once every 2 weeks.
223578961|NCT03180398|DEVICE|Multiparametric MRI|MRI will be acquired before, during and after radiation treatment to evaluate treatment response
223578962|NCT00295230|PROCEDURE|PSV+VG mode versus SIMV+VG mode|fully assisted mechanical ventilation versus assistance on only a select number of breaths
223578963|NCT05991765|OTHER|Digit Tip Wound|Digit Tip Wound Exudate Sample Collected while Dressing Change
223578964|NCT05991765|OTHER|Split Skin Donor Site Wound|Split Skin Donor Site Wound Exudate Sample while Dressing Change
223578965|NCT02495064|DRUG|Mometasone Furoate Cream|One side of patients' neck will begain to use MF cream from the first day of radiation therapy.
223578966|NCT06066905|DRUG|chidamide and azacitidine|"chidamide：10mg orally,day 1 to day 6 every week, Take it for two weeks, rest for two weeks,so 28 days for a circle, 12 circles totally.~azacitidine:50mg,subcutaneous injection,day 1 to day 5 every week, 28 days for a circle, 6 circles totally."
223578967|NCT05848700|DRUG|SEP-363856|SEP-363856 Tablet
223578968|NCT05848700|DRUG|Placebo|Placebo Tablet
223578969|NCT01448785|DEVICE|abiliti system implant|Subjects will receive implanted abiliti System.
224159515|NCT05326568|OTHER|Complementary treatment practice|Applying sesame oil to the patients assigned to the intervention group by applying 10 drops to the 10 cm circumference of the cannula for 10 minutes
223578970|NCT01448785|DEVICE|Laparoscopic adjustable gastric band (Allergan Lap Band)|Subjects will receive an implanted laparoscopic adjustable gastric band. Specific brand is at the investigator's discretion.
224159516|NCT03996889|DEVICE|Endovascular treatment of aneurysms of the popliteal artery by GORE VIABAHN® stent in elective surgery|"The intervention can be performed under local anesthesia (LA), regional locus (ALR) or general anesthesia (AG) (data collected) by first approach: percutaneous or conventional.~The data collected are:~* Number of GORE VIABAHN® stent used (length and diameter of each)~* Embolization of collaterals and other related actions~* Operative complications~* Intraoperative fibrinolysis~* Collar cover\> 2 cm~* Lack of overlap in the overlap zone (nb: between 4 and 8 cm above the joint spacing)~* Arteriography in profile, kink"
224159517|NCT02680561|DRUG|Fluticasone Propionate MDPI|
224159518|NCT02680561|DRUG|Fluticasone Propionate/Salmeterol MDPI|
224159519|NCT02680561|DRUG|Fluticasone propionate/salmeterol|
224159520|NCT03447821|DRUG|400 mg Rifamycin SV dosage|
224159521|NCT03447821|DRUG|800 mg Rifamycin SV dosage|
224159522|NCT03447821|DRUG|1200 mg Rifamycin SV dosage|
224159523|NCT03431506|BEHAVIORAL|Vestibular rehabilitation|Vestibular Rehabilitation Exercises
224159524|NCT03929783|PROCEDURE|Contrast Enhanced Digital Mammography|Undergo CEM
223578971|NCT03362099|DRUG|Varenicline Tartrate or bupropion|the drug treatment will be chosen related to the polymorphism. If the polymorphism is favorable to varenicline the patient will receive varenicline, If it is favorable to bupropion the patient will receive bupropion, if not favorable to varenicline and bupropion the patient will receive bupropion + varenicline. If the patient has both favorable polymorphisms he will receive bupropion. Bupropiona dosage 150 mg once a day seven days, after twice a day until complete week twelve. Varenicline dosage 0,5 mg once a day for 3 days, after this 0,5 mg twice a day until seven day .At day eight 1 mg twice a day until complete week twelve.
223469815|NCT01897051|DRUG|Propranolol + Placebo|"1. Placebo of Rifaximin : taking 400mg three times a day in the study period (total 1,200 mg per day)~2. Propranolol : taking 40mg twice a day to start. If patient is tolerable and systolic blood pressure is above 90 mmHg, the dosage can be increased by doubling to every other day upto the 360mg per day.~(Target heart rate : 25% reduction in baseline heart rate or at least 55 times per minute).~If patient is not tolerable, we can reduce the dosage step-by-step until the adverse symptoms is disappeared."
223469816|NCT06553690|OTHER|Brain Gym Therapy|Brain Gym Therapy is a structured program of physical movements designed to enhance cognitive function, reduce stress, and promote relaxation. The therapy is based on the principle that specific physical activities can stimulate brain function and improve overall mental and physical well-being.
223469817|NCT06232967|PROCEDURE|Primary tumor resection or not|For patients with non-small-cell lung cancer (NSCLC) and dry pleural dissemination, surgical decisions to perform exploratory thoracotomy only or primary tumor resection with wedge resection, segmentectomy, or lobectomy were based on surgeon experience and patient preference.
223578972|NCT01013155|DRUG|perindopril erbumine|8 mg tablet
223578973|NCT00987896|DEVICE|Colonoscopy with Megachannel™ device loaded|Before colonoscopy, megachannel is loaded on the endoscope, during colonoscopy megachannel will be inserted into the patient via the endoscope placed in the colon
223578974|NCT02094742|PROCEDURE|biopsy|
223578975|NCT01391598|DRUG|Lidocaine|After completion of the inclusion criteria all patients receive a dose of amitriptyline 12.5 mg in the first week, and 25 mg in the eight subsequent weeks, orally, once daily at night. At lidocaine group 20 pacients will receive lidocaine at a dose of 4 mg / kg, not exceeding a dose of 240 mg diluted in 125ml of solution 0.9% saline.The solutions will be infused in 1 hour once a week in the four weeks following the start of the study..:Patients may use as additional analgesics up to 4g/day acetaminophen, and if necessary, they can use tramadol, recording the dose
223743702|NCT07190833|DRUG|Hydroxyurea (HU)|optimal dose, 14 days, 1 cycle, PO
223743703|NCT07190833|DRUG|Atezolizumab|1,200 mg, once, 1 cycle, IV
223743704|NCT07190833|DRUG|OTS-412|3×10E8 pfu, once, 1 cycle, IT
223743705|NCT07190833|DRUG|OTS-412|optimal dose, once, 1 cycle, IT
224068951|NCT03284736|PROCEDURE|periapical surgery without membrane|after removing pathology and retro-filling the tooth /teeth wit MTA the defect area is left as it is and flap is closed without resorbable membrane.
224068952|NCT00418197|DEVICE|Total Facet Arthroplasty System® (TFAS®)|
224068953|NCT06505109|BEHAVIORAL|RESST|Subjects randomized to the RESST intervention will receive on top of standard rehabilitation a behavioural group intervention focussing on improving sleep and stress. This intervention will consist of 5 till 6 meetings of 90 till 120 minutes in the local rehabilitation centre during a time period of 3 till 4 months.
223743706|NCT07191015|BEHAVIORAL|Low-Intensity Continuous Exercise|Participants ran continuously for 30 minutes at 50% of their MAS without rest.
223743707|NCT07191015|BEHAVIORAL|Moderate Intensity Interval Exercise|Participants ran continuously for 30 minutes at 70% of their MAS without rest.
223743708|NCT07191015|BEHAVIORAL|High-Intensity Interval Exercise|Participants ran at 105-110% of their MAS for 15-second intervals, covering a pre-calculated distance during each bout. After each 15-second sprint, they rested passively for 15 seconds and returned to their starting point. This was repeated continuously for 5 minutes, constituting one set. A total of four 5-minute sets were completed, interspersed with 2,5-minute passive rest periods, yielding a total exercise time of 30 minutes.
223743709|NCT07191444|BIOLOGICAL|Firsekibart|Firsekibart will be administered according to the protocol
223743710|NCT07191444|BIOLOGICAL|Anakinra|Anakinra will be administered according to the protocol
223743711|NCT07190352|DEVICE|iTBS to the DMN|Intermittent theta-burst frequency rTMS (iTBS) targeted to the parietal node of the default mode network.
223743712|NCT07190352|DEVICE|cTBS to the DMN|Continuous theta-burst frequency rTMS (cTBS) targeted to the parietal node of the default mode network
223743713|NCT07190352|DEVICE|Sham rTMS|Sham rTMS: coil flipped 180 degrees and applied to the parietal node of the DMN using an iTBS sequence. For this sham condition, rTMS felt and sounded like active stimulation, but no actual stimulation was delivered.
223743714|NCT07190768|OTHER|Kinesio Taping|"Participants received Kinesio Taping (KT) applied to the affected shoulder using standard 5-cm Kinesio Tex tape. Before application, an allergy test was performed by placing a small patch of tape on the contralateral forearm for 15 minutes. The taping procedure included three regions: supraspinatus muscle, deltoid muscle, and glenohumeral joint.~Application technique:~Supraspinatus: Y-strip applied from insertion on the greater tubercle along the muscle to its origin with 20-25% stretch.~Deltoid: Y-strip applied from 3 cm below insertion to the origin, with anterior and posterior tails placed along corresponding edges.~Glenohumeral joint: I-strip applied from the coracoid process, laterally under the acromion, around the posterior deltoid edge.~Schedule: Tape was applied at baseline (Day 0), reapplied at Day 7, and removed permanently at Day 14."
224068954|NCT05595187|DEVICE|Tricuspid repair|Tricuspid repair included suture placement and the type of prosthetic annuloplasty.
224068955|NCT06394011|DRUG|venetoclax, azacitidine and HAAG regimen|Venetoclax:100mg, qd, d1;200mg, qd, d2;400 mg, qd, d3\~10, per os; Azacitidine:75mg/m2/d, d1\~7, subcutaneous injection; Homoharringtonine:1mg/d, d4\~10, intravenous infusion; Aclarubicin:10mg/d, d4\~7, intravenous infusion; Cytarabine:10mg/m2,q12h,d4\~10, subcutaneous injection; Granulocyte colony-stimulating factor (G-CSF): 50-300μg/d (when WBC counts are less than 20×10\^9/L ),subcutaneous injection;
224068956|NCT01647971|DRUG|Ublituximab|Ublituximab is a novel monoclonal antibody targeting cluster of differentiate 20 (CD20)
224068957|NCT01317433|DRUG|Doxycycline|Doxycycline 100 mg daily per os to start 7 days before Cetuximab for 6 weeks.
224068958|NCT01317433|DRUG|Cetuximab|500 mg/m² IV infusion of 60 minutes every 15 days
224068959|NCT04109820|DIETARY_SUPPLEMENT|MitoQ|Oral; 20mg once a day for 14 days
223578976|NCT01391598|DRUG|lidocaine|After completion of the inclusion criteria all patients receive a dose of amitriptyline 12.5 mg in the first week, and 25 mg in the eight subsequent weeks, orally, once daily at night. At saline group 20 pacients will receive 125ml of solution 0.9% saline.The solutions will be infused in 1 hour once a week in the four weeks following the start of the study. Patients may use as additional analgesics up to 4g/day acetaminophen, and if necessary, they can use tramadol, recording the dose
223578977|NCT05210868|DRUG|CM355|"1. Dose Escalation Phase CM355 will be taken by patients and will be treated follow the 3+3 dose escalation scheme~2. Expansion Phase CM355 will be taken by patients and will assess the efficacy of CM355 in patients with specific histopathological Non-Hodgkin's Lymphoma, and the safety of drug"
223578978|NCT05878756|OTHER|Functional Strength Training|In addition to conventional therapy, experimental group was also given functional strength training program. Functional strength training was given as home program consisting of ten tasks.The ten tasks were STS, one leg standing, weight shifting(from one side of body to other), step-ups, lateral step-ups, squatting against wall, picking an object from standing position, walking forward, walking backward and kicking the ball.
223578979|NCT04025502|DEVICE|Event-Related Potentials (ERP) and Electroencephalogram (EEG) testing with the COGNISION® System|The testing protocol consists of an auditory oddball Event-Related Potential (ERP) paradigm, 40Hz ASSR, and the collection of 6 minutes of resting electroencephalogram (EEG). During the ERP paradigm a variety of auditory stimuli are played through the system's earphones while voltage potentials are recorded from the subject's scalp. At the end of the ERP session, 6 minutes of EEG data will be recorded while the subject is resting. The entire procedure, including set up, instructions to the subject and actual test is expected to take 60-75 minutes.
223578980|NCT02823184|BIOLOGICAL|RNA sample of total leukocytes before start of treatment|RNA sample of total leukocytes before start of treatment
223578981|NCT01007071|DRUG|Human Growth Hormone (1-134)|Subjects randomized to human growth hormone (1-134) for 16 weeks. In this arm, growth hormone is dosed sc on a daily basis and increased over first 6 weeks (Men: start at 0.2 mg sc/d, increase to 0.6 mg sc/d after 4 weeks. Women, postmenopausal: start at 0.3 mg sc/d, increase to 0.9 mg sc/d after 4 weeks. Women premenopausal or on estrogen: start at 0.6 mg sc/d, increase to 1.3 mg sc/d after 4 weeks.) Dose adjustments based on serum IGF-1 levels at 6 and 12 weeks, with final IGF-1 measurement for efficacy performed at 16 weeks, with goal in range of -0.5 SD to +2SD. An elevated serum IGF-1 value will result in a 20% dose reduction in GH in an active and random placebo patient. Similarly, a low serum IGF-1 will result in a 20% dose increase in an active and random placebo subject.
223578982|NCT01007071|DRUG|Placebo|Subjects randomized to placebo
223578983|NCT01741714|OTHER|Sham chiropractic manipulative therapy|Sham manipulation
223578984|NCT01741714|OTHER|Chiropractic spinal manipulative therapy|Chiropractic spinal manipulative therapy
223578985|NCT00102297|DRUG|FG-3019|
223578986|NCT01073540|DRUG|Cephalexin suspension (Optocef, BAYO5448)|Single dose of 500 mg / 10 mL
223578987|NCT01073540|DRUG|Cephalexin suspension (Keflex)|Single dose of 500 mg / 20 mL
223578988|NCT01025570|DRUG|Gemcitabine, Bosutinib|Gemcitabine, 1000 mg/m2 on D1,8,15 over 30 mins standard infusion rate Bosutinib 400 mg, oral, once daily
223578989|NCT02510365|BIOLOGICAL|Functional collagen scaffold|Patients will receive functional neural regeneration collagen scaffold and patients will undergo a comprehensive rehabilitation and psychological measures after surgery.
223469818|NCT04796766|DIAGNOSTIC_TEST|High frequency stimulation (HFS)|Electrical stimuli via circular electrode array. The electrode array serves as cathode placed above the eyebrow. A surface electrode (anode) will be placed on the temple. Electrical stimuli will be applied via a constant current stimulator. The stimulus intensity for the electrophysiological protocol is adjusted to the 10-fold of the detection threshold. A number of 5 electrical pulses (2 ms, 100 Hertz (Hz)), 10 second intervals.
223469819|NCT04796766|DIAGNOSTIC_TEST|Low-frequency sinusoidal transcutaneous stimulation (sLFS)|Stimulation of C-nociceptors with constant current stimulator. Electrodes (placed on the proband's forehead. Stimulation by sine wave pulses of 250 ms duration (4 Hz), intensities inducing a pain intensity of 50/100 on a visual analogue scale from 0-100.
223578990|NCT00885638|DRUG|Sitagliptin|100 mg sitagliptin before ingestion of macronutrient
223578991|NCT00885638|DRUG|placebo|A placebo tablet is given before ingestion of macronutrients
223743715|NCT07190768|OTHER|Dry Needling|"Participants received dry needling (DN) applied with sterile, disposable stainless-steel needles (0.30 mm × 50 mm). Target muscles included the supraspinatus, deltoideus, infraspinatus, subscapularis, and pectoralis major.~Technique: The fast-in, fast-out method (Hong technique) was used. After cleaning the skin with alcohol, the needle was inserted into a palpable taut band until the first local twitch response (LTR) was elicited. The needle was moved vertically (5-10 mm) at \~1 Hz for 25-30 seconds. DN was applied for 45-60 seconds per muscle.~Schedule: Twice per week, for 3 weeks (total of 6 sessions)."
224068960|NCT05367817|OTHER|Neuromuscular exercise therapy|Participants perform specific neuromuscular exercises aimed at enhancing the sensorimotor control of the wrist.
224068961|NCT05367817|OTHER|Training program|Participants perform range of motion exercises for the wrist.
224068962|NCT05163119|BEHAVIORAL|Commercial Cellphone-Blocking App (Active)|The Fleetsafer app, which is a commercial cellphone app that uses a cellphone's standard sensors and function to block handheld cellphone use while driving, will be downloaded on the participant's smartphone.
224068963|NCT05163119|BEHAVIORAL|Driving Mode|"Apple's Do Not Disturb driving mode provided by Apple for iPhones or Google Do Not Disturb, Verizon Messages +, Android Auto or have another app, called LifeSaver installed on their Android phone (collectively referred to as driving modes; the specific driving mode for participants in this arm will be determined based on smartphone type and service provider)."
223578992|NCT00645879|DRUG|ornithine alpha ketoglutarate|A dose of 400 mg/kg up to 16 g per day was selected. Split into 2 doses taken for 4 weeks. If determined the drug with the best effect, drug will be taken for 30 weeks.
223578993|NCT00645879|DRUG|glutamine|A dose of 400 mg/kg up to 16 g per day was selected. Split into 2 doses taken for 4 weeks. If determined the drug with the best effects, drug will be taken for 30 weeks.
223578994|NCT00645879|DRUG|disodium citrate|Dose: 7.5 mEq/Kg or 658 mg/kg up to 16 g per day Split into 2 doses taken for 4 weeks. If determined the drug with the best effects, drug will be taken for 30 weeks.
224068964|NCT01441479|DEVICE|In Vitro Diagnostic Device aid in diagnosing|
224068965|NCT04818684|OTHER|questionnaire|a questionnaire consisting of a list of support practices
224159525|NCT04632745|OTHER|Wrist Rehabilitation|participants will undergo immobilization for the first 6 weeks of treatment
224159526|NCT04152746|OTHER|Periostin level|The serum periostin levels were planned to compare between the serum samples that were obtained from the two groups. The evaluation of the periostin levels of adenoid tissue and normal healthy mucosa were also planned.
223469820|NCT00732069|DRUG|Placebo|Patients receiving an angiotensin converting enzyme inhibitor or angiotensin receptor blocker before the study underwent washout for 3 weeks. Subjects were treated with study drug for 7 days and each treatment period was separated by a 3-week washout period. Ramipril was given at dose of 2.5mg/d for two days, then 5mg/d for 5 days. Valsartan was given at 80mg/d for 2 days followed by 160mg/d for 5 days. On the seventh day of each treatment blood samples were collected prior two, during and two hours after dialysis
223469821|NCT00732069|DRUG|Ramipril|Patients receiving an angiotensin converting enzyme inhibitor or angiotensin receptor blocker before the study underwent washout for 3 weeks. Subjects were treated with study drug for 7 days and each treatment period was separated by a 3-week washout period. Ramipril was given at dose of 2.5mg/d for two days, then 5mg/d for 5 days. Valsartan was given at 80mg/d for 2 days followed by 160mg/d for 5 days. On the seventh day of each treatment blood samples were collected prior two, during and two hours after dialysis
223469822|NCT00732069|DRUG|Valsartan|Patients receiving an angiotensin converting enzyme inhibitor or angiotensin receptor blocker before the study underwent washout for 3 weeks. Subjects were treated with study drug for 7 days and each treatment period was separated by a 3-week washout period. Ramipril was given at dose of 2.5mg/d for two days, then 5mg/d for 5 days. Valsartan was given at 80mg/d for 2 days followed by 160mg/d for 5 days. On the seventh day of each treatment blood samples were collected prior two, during and two hours after dialysis
223469823|NCT04460326|DRUG|Insulin glargine|Insulin glargine doses will be determined by calculating the total daily dose (TDD) of insulin and providing 50% of the TDD as follows: start at 0.5 units/kg/day and subtract 0.1 unit/kg/day for 70+ yrs of age, renal insufficiency, pancreatic deficiency and add 0.1 unit/kg/day if hemoglobin A1c in \>10%
223469824|NCT04460326|DRUG|NovoLog|Novolog will be administered with each meal if premeal glucose is ≥ 150 mg/dL and at bedtime if glucose is ≥ 200 mg/dL by calculating an individualized insulin sensitivity factor for each subject per the following formula: 1500/total daily dose of insulin = sensitivity factor.
223469825|NCT04460326|DRUG|Insulin Fiasp|Fiasp will be administered with each meal if premeal glucose is ≥ 150 mg/dL and at bedtime if glucose is ≥ 200 mg/dL by calculating an individualized insulin sensitivity factor for each subject per the following formula: 1500/total daily dose of insulin = sensitivity factor.
223469826|NCT04460326|OTHER|Standard carbohydrate diet|Standard carbohydrate diet as per usual hospital care (75g with each meal)
223469827|NCT00577317|PROCEDURE|Management of Therapy Complications|Receive standard home maintenance therapy and perform self-manual lymphatic drainage
223469828|NCT00577317|PROCEDURE|Management of Therapy Complications|Receive Flexitouch home maintenance therapy
223469829|NCT00577317|OTHER|Quality-of-Life Assessment|Ancillary studies
223469830|NCT00631254|PROCEDURE|Allergen challenge|"Conventional allergen challenge: increasing allergen doses given by nebulisation through the mouth and stopped when a 20% fall in forced expiratory volume in one second is obtained.~Low dose allergen challenge: very low allergen doses given by nebulisation through the mouth. No more than a 5% fall in forced expiratory volume in one second.~Nasal allergen challenge: One drop of increasing allergen doses on nasal mucosa."
223469831|NCT00631254|PROCEDURE|Allergen challenge|"Low dose allergen challenge: very low allergen doses given by nebulisation through the mouth. No more than a 5% fall in forced expiratory volume in one second.~Nasal allergen challenge: One drop of increasing allergen doses on nasal mucosa."
223469832|NCT02209363|DEVICE|auto-adjusting positive airway pressure|nightly use for 6 months
223469833|NCT02209363|OTHER|Nasal dilator strips|nightly use for 6 months
223469834|NCT01331369|BEHAVIORAL|Intensification of Care|Usual provided care plus social-psychological intervention: 6 consultation with doctors and 9 with community health workers, both oriented by protocol.
223469835|NCT01331369|OTHER|Usual Care|Usual care provided (medical and/or nurse consultation and medicines)
223469836|NCT01345812|DRUG|HP-HMG|100 - 300 IU for stimulation of women in ART treatment
223469837|NCT01345812|DRUG|recombinant FSH|100 -300 IU for stimulation of women in ART treatment
223469838|NCT00004293|DRUG|glucocerebrosidase|
223578995|NCT00598078|DRUG|Sodium Oxybate|Dose 1
223578996|NCT00598078|DRUG|Sodium Oxybate|Dose 2
224159527|NCT01704976|DEVICE|SR-WBV|Participants will undergo a training program set over four weeks, three times a week with 3 to 6 Hz, Noise 4.
223578997|NCT00598078|OTHER|Placebo|Dose 3
223578998|NCT00747669|DRUG|lidocaine 70mg and tetracaine 70mg topical patch|One Synera Patch applied for 30 minutes.
223578999|NCT04014140|PROCEDURE|Coronary artery bypass grafting surgery (CABG)|Patients with MVCAD will undergo CABG as per standard of care.
224159528|NCT01704976|DEVICE|SR-WBV|Participants will undergo a training program set over four weeks three times a week with 1 Hz, Noise 1.
224159529|NCT04073641|OTHER|No intervention|No intervention
224159530|NCT05451602|DRUG|HEC169096|Multiple doses of HEC169096 during Phase 2；Oral dose of HEC169096 as determined during Phase 2.
224159531|NCT06009198|DRUG|Iron folate tablets|Iron folate tablets will be administered to the underweight school going adolescents girls and boys to see the affect on BMI and micronutrients
223469839|NCT01124669|GENETIC|DNA analysis|
223469840|NCT01124669|GENETIC|mutation analysis|
223579000|NCT01897753|DRUG|growth hormone|36 months
223579001|NCT05995223|OTHER|Submaximal exercise protocol|Participants will complete a submaximal walking protocol on a motorized treadmill, which consists of 4 times 6 minutes of walking at a moderate intensity speed and incline while their breathing, cardiac output, and muscle oxygen use is measured, with 10 minutes rest in between each bout.
224159532|NCT03030391|OTHER|PET|
224159533|NCT03030391|OTHER|MRI|
223469841|NCT01124669|OTHER|laboratory biomarker analysis|
223469842|NCT03686072|PROCEDURE|Cataract surgery with endoscopic goniosynechialysis|Phacoemulsification was performed first. Immediately after implantation of the IOL, a 23G ophthalmic endoscope (OE) probe was inserted into the anterior chamber to visualize the PAS through the main incision and side incision. A viscoelastic agent and a blunt iris spatula were used to release the areas where where PAS existed.
223469843|NCT00583310|BEHAVIORAL|Telephone-based lifestyle counseling|Four 30-minute telephone sessions including education and behavioral counseling strategies that have been shown to be effective in promoting behavior change and reducing blood pressure.
223469844|NCT04794751|DEVICE|JJVC Investigational Multifocal Contact Lens|senofilcon A C3
223469845|NCT04794751|DEVICE|Dailies Total 1® Multifocal Contact Lens|delefilcon A
223469846|NCT04036721|DRUG|Prolonged glucocorticosteroid (prednisone) regimen|Prolongation of maintenance therapy with prednisone of patients with pneumonitis inducted by anyi-PD-1/anti-PD-L1 antibodies.
223469847|NCT04036721|DRUG|Short glucocorticosteroid (prednisone) regimen|Prednison regimen based upon American Society of Clinical Oncology and European Society for Medical Oncology Clinical Practice Guidelines on pneumonitis treatment in patients receiving immunotherapy agents
223469848|NCT02360488|DEVICE|Telerehabilitation Therapy|18 days of supervised sessions via videoconference and 18 days of unsupervised sessions.
223469849|NCT02360488|BEHAVIORAL|In-Clinic Therapy|18 days of therapist supervised sessions and 18 days of unsupervised in home sessions.
223469850|NCT05662020|BIOLOGICAL|Recombinant Nonavalent (types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (HPV) Vaccine (Escherichia coli)|9-19 years group (3 doses) and 20-26 years group (3 doses) will be vaccinated at months 0, 2, 6. 9-14 years group (2 doses) will be vaccinated at months 0, 6.
223469851|NCT05662020|BIOLOGICAL|GARDASIL® 9|20-26 years possitive control group will be vaccinated at months 0, 2 and 6
223469852|NCT02928796|BEHAVIORAL|Cognitive Stimulus|Participants to pay attention to a supplementary display monitor and respond to specified stimulus images, all while performing the simulated cardiology-based procedure.
223469853|NCT00914407|DRUG|Oxygen|100% Oxygen inhalation for 30 minutes
223469854|NCT04892732|DRUG|Budesonide|Budesonide dispensing claim is used as the reference group.
223469855|NCT04892732|DRUG|Budesonide-Formoterol|Budesonide-Formoterol dispensing claim is used as the exposure group.
223469856|NCT04426097|PROCEDURE|Cervical Vagal Blockade|Cervical Vagal Blockade with 0.5 % ropivacaine 2.5 ml and 2% xylocaine 2.5 ml
223469857|NCT04426097|PROCEDURE|Without Blockade|Without Blockade
223469858|NCT00426881|BEHAVIORAL|Exercise Training|Twice weekly resistance training for 52 weeks.
223469859|NCT00426881|BEHAVIORAL|Exercise training|Once weekly resistance training for 52 weeks.
223469860|NCT00426881|BEHAVIORAL|Exercise training|Twice weekly resistance training for 52 weeks.
223469861|NCT00633607|OTHER|Research Registry|Information regarding medical and family history is stored in the registry to be used for potential future studies
223469862|NCT01651364|DRUG|Placebo|Enrolled volunteers will be randomized on Day 8 to receive placebo (n=2) or study medication (n=8). Placebo serves only to maintain the blind and is not a comparator.
223469863|NCT01651364|DRUG|Cabergoline|Enrolled volunteers that receive study medication (n=8) will receive cabergoline 0.25 mg twice weekly.
223579002|NCT03336372|DRUG|Picato|Picato 0.05% or 0.015% topical gel applied nightly for 3 consecutive nights
223579003|NCT01163773|OTHER|MILK|"Consumption of the 2 experimental diets~1. Milk diet~2. Control diet"
223579004|NCT05418153|DEVICE|Tecnis Synergy IOL|Intraocular lens replaces the natural lens removed during cataract surgery in both eyes.
223469864|NCT03512522|BEHAVIORAL|Online Group|An 8-week remotely-delivered pain self-management program tailored to older adults that will be delivered in an online format.
223469865|NCT03512522|BEHAVIORAL|Workbook Group|An 8-week remotely-delivered pain self-management program tailored to older adults that will be delivered in a printed (workbook) format.
223469866|NCT02930694|DRUG|JNJ-54175446 (capsule)|Participants will receive JNJ-54175446 capsule at a dose of 50 mg or 100 mg, orally.
223469867|NCT02930694|DRUG|JNJ-54175446 (suspension)|Participants will receive JNJ-54175446 suspension at a dose of 50 mg or 100 mg, orally.
223469868|NCT03669588|BIOLOGICAL|ARGX-113|Intravenous administration of ARGX-113
223469869|NCT03669588|BIOLOGICAL|Placebo|Intravenous administration of placebo
223469870|NCT05150665|PROCEDURE|En-masse retraction|"Power chain and Crimpable hook for En-Masse Retraction Retraction will start on a 0.017x0.025 Stainless steel wire using elastomeric chain (force applied will be 200 g per side) extending between the crimpable hooks and the miniscrew"
223469871|NCT05150665|PROCEDURE|Two step Retraction|"Retraction of canine started on a 0.017x0.025 Stainless steel wire using elastomeric chain (force applied will be 150 g per side)followed by anterior teeth retraction on 0.017x0.025 Stainless steel wire using elastomeric chain (force applied will be 160 g per side) extending between the crimpable hooks and the mini-screw."
223469872|NCT01705041|DEVICE|Diagnostics for All liver function test (LFT)|HIV clinic patients meeting targeted enrollment criteria will give fingerstick blood for use on investigational LFT in comparison to routine transaminase test performed at the clinic lab (gold standard)
223469873|NCT06167941|BIOLOGICAL|Lung cancer types|Cancer tissue matched to normal tissue, all from the same patient
223469874|NCT02530437|DRUG|Carboplatin|Given IV
223469875|NCT02530437|RADIATION|External Beam Radiation Therapy|Undergo external beam radiation therapy
223469876|NCT02530437|OTHER|Laboratory Biomarker Analysis|Correlative studies
223469877|NCT02530437|DRUG|Paclitaxel|Given IV
223469878|NCT02530437|DRUG|Taladegib|Given PO
223469879|NCT05988372|DRUG|Surufatinib + Serplulimab+Albumin-paclitaxel + Gemcitabine|Surufatinib:250mg orally once a day for 3 weeks(3 weeks 1 cycle) Serplulimab:4.5mg/Kg by intravenous infusions on day1 every 3 weeks Albumin-paclitaxel:125mg/m2 by intravenous infusions on day1 and 8 every 3 weeks Gemcitabine:1000mg/m2 by intravenous infusions on day1 and 8 every 3 weeks
223579005|NCT04287569|DEVICE|Record during endoscopy of video-endoscopy sequences and reflectance|Record of video-endoscopy sequences and reflectance, during endoscopy with biopsy.
223579006|NCT03271073|DRUG|Apatinib|Apatinib,500mg,qd,po,d1-21;S1,40mg,bid,d1-14;every 21days a cycle
223579007|NCT00353431|DRUG|Novorapid ®, Novo Nordisk, Denmark|Comparison of a sliding scale with an intensive s.c. scale
223469880|NCT05988372|DRUG|Albumin-paclitaxel + Gemcitabine|Albumin-paclitaxel:125mg/m2 by intravenous infusions on day1 and 8 every 3 weeks Gemcitabine:1000mg/m2 by intravenous infusions on day1 and 8 every 3 weeks
223469881|NCT01107548|OTHER|Systematic detection of vascular risk factors and subsequent evidence-based treatment|
223469882|NCT01163552|PROCEDURE|Surgical debulking and Intrathoracic Hyperthermic Chemotherapy|Surgical debulking of intrathoracic metastases will be performed, followed by perfusion of the chest with heated Cisplatin for 60 minutes.
223469883|NCT01206023|OTHER|NA-NOSE artificial olfactory system|NA-NOSE is an artificial olfactory system that is based on nanomaterials and connected with machine learning. NA-NOSE can diagnosis diseases or disorders based on volatile biomarkers that are emitted from exhaled breath, blood, or from clinical tissue.
223579008|NCT01144260|DRUG|bafetinib|250 mg orally twice daily. Treatment continues until clinically significant disease progression or unacceptable toxicity is documented.
223579009|NCT02085525|OTHER|Nurse Practitioner Clinic|"The nurse practitioner (NP) clinic is staffed by two NPs, one registered nurse, and several medical assistants. Patients can be seen by either NP during their treatment course. Patients will be scheduled to be seen in the (NP) clinic based on randomization assignment.~Each clinic visit focuses on specific concerns and toxicities of the patient and their significant other. This will include physical as well as psychological, social and spiritual needs."
223579010|NCT03221790|OTHER|Low FODMAP Diet followed by a High FODMAP Diet|3 weeks on a low FODMAP diet followed by 3 weeks on a high FODMAP Diet
223579011|NCT05518370|OTHER|Hippotherapy simulator training|Hippotherapy simulator training will be designed for the individual basis.
223579012|NCT05518370|OTHER|Traditional physiotherapy|Traditional physiotherapy within a specific program
223579013|NCT02526862|DEVICE|Allevyn Thin®|Protection of the dermis with autoadhesive polyurethane dressing. The dressing will be standardized cut to avoid bias. The edges shape will be circular. They will be set in nasal bridge and cheekbones, avoiding frontal level. It will be checked every six hours, and if not properly fixed it will be applied again in the same way.
224068966|NCT06192511|BEHAVIORAL|Educational Website and Video|The website offers users the opportunity to choose to watch a 4-minute video or read relevant information about Newborn Screening and the Michigan BioTrust. If they choose to read, the website is designed to present information in an engaging manner, while providing optional voiceover. The video uses a mixture of live action shots and animation, all with voiceover. All materials are available in English, Spanish and Arabic.
223579014|NCT02526862|DEVICE|Askina Transorbent Border®|Protection of the dermis with semi-permeable hydrogel-foams adhesive dressing. The dressing will be standardized cut to avoid bias. The edges shape will be circular. They will be set in nasal bridge and cheekbones, avoiding frontal level. It will be checked every six hours, and if not properly fixed it will be applied again in the same way.
223579015|NCT02526862|DEVICE|Linovera®|Protection of the dermis with hyper hydrogenated fatty acids. It will be applied with its doser and gently massaged in chin, cheekbones, nasal and frontal bridge as indicated in the product. It will be checked every six hours for proper hydration and if needed it will be applied again in the same way.
223579016|NCT00706329|DEVICE|Deflux|Patients undergo surgery using Deflux to correct umbilical hernia
224068967|NCT04378816|OTHER|Shared decision making support tool|Health education materials containing treatments and questions about patient values to help patients make the most appropriate decisions.A question prompt list (QPL) is a structured list of questions that serves as a prompt for patients to consider questions to ask their physician.
224068968|NCT05146921|DIETARY_SUPPLEMENT|Multi-strain probiotic|"The intervention in this study is a multi-strain probiotic which contains four live strains of bacteria:~Lacticaseibacillus rhamnosus NCIMB 30174 Enterococcus faecium NCIMB 30176 Lactobacillus acidophilus NCIMB 30175 Lactiplantibacillus plantarum NCIMB 30173~10 billion colony-forming units (CFU) per 70 ml cup"
223469884|NCT01721447|DRUG|Optison echocardiography contrast agent|Subjects undergoing transesophageal echocardiography who will receive the Optison contrast agent during the procedure to test if the image quality improves to provide accurate assessment of the presence of left atrial thrombus.
223469885|NCT00369343|DRUG|Desvenlafaxine administered as a succinate salt in a sustained-release form (DVS SR)|DVS-SR 50-200mg, daily (QD), tablet form, treatment period up to 34 weeks
223579017|NCT03808753|DIAGNOSTIC_TEST|End-expiratory occlusion test (EEOT)|The EEOT is performed by interrupting the mechanical ventilation for 30 seconds, by using and end-expiratory hold on the ventilator.
223579018|NCT03808753|OTHER|mini fluid challenge (mFC)|The mFC is performed by injecting a first aliquot of 100 ml of crystalloid over 1 minute before completing the 4 ml/kg-FC over the residual 9 minutes.
223579019|NCT05845944|OTHER|Video-supported education group|Providing training on nutrition with a nasogastric tube in pediatric patients with a video-supported education method
224068969|NCT05146921|OTHER|Placebo|placebo similar in appearance and taste to the active intervention but with no active bacteria
224068970|NCT00247026|DRUG|curcumin; coenzyme q10|
224068971|NCT05863104|DRUG|Glycopyrronium Bromide (GPB) Cream|Application of cream to each axilla
224068972|NCT02323269|DRUG|dimethyl fumarate|administered according to the local product label (i.e., Canadian Product Monograph).
224068973|NCT01222676|DRUG|cisplatin|
224068974|NCT01222676|DRUG|gemcitabine hydrochloride|
224068975|NCT01222676|DRUG|sorafenib tosylate|
224068976|NCT01222676|OTHER|imaging biomarker analysis|
224068977|NCT01222676|OTHER|laboratory biomarker analysis|
224068978|NCT01222676|PROCEDURE|computed tomography|
224068979|NCT01222676|PROCEDURE|neoadjuvant therapy|
224068980|NCT01222676|RADIATION|fludeoxyglucose F 18|
224068981|NCT04518462|DRUG|Exparel|EXPAREL (bupivacaine liposome injectable suspension)
224068982|NCT04518462|DRUG|Bupivacaine Hydrochloride|0.25% bupivacaine
224068983|NCT05914142|DEVICE|Proton radiation therapy|Radiation: Proton Therapy System (ProBeam)
224068984|NCT02528903|DRUG|MHAB5553A|Single intravenous administration, at various doses, depending on the cohort
224068985|NCT02528903|DRUG|Matching placebo|Single intravenous dose
224068986|NCT02866279|DEVICE|Etonogestrel Contraceptive Implant|Women will be randomized to the TIMING of implant placement
223469886|NCT00369343|DRUG|Placebo|Placebo, daily (QD), tablet form, treatment period up to 8 weeks
223469887|NCT05796700|PROCEDURE|Microwave Ablation|"Microwave Ablation: A minimally invasive technique for HCC, MWA has the potential to eradicate larger HCCs with larger coagulation areas and is less affected by the heat sink effect caused by vessels around the tumor.~Laparoscopic Hepatectomy: The technique has been widely promoted worldwide with technical progress. In patients with cirrhosis, LLR has the potential advantage of reducing the risk of postoperative liver decompensation"
223469888|NCT04208672|DEVICE|UMindSleep|CPAP titration will be provided for Obstructive Sleep Apneas Syndrome.
223469889|NCT01124747|DRUG|ASP1585|Oral
223469890|NCT01124747|DRUG|14C-Labeled ASP1585|Oral
223469891|NCT01623921|DRUG|standard care treatment|Group 1: control :(standard care treatment for individual lung contusion inluding analgesia with paracetamol/dypiron/ tramal)
223469892|NCT01623921|DRUG|Celecoxib|Celecoxib 200 mg × 2/d+:(standard care treatment for individual lung contusion inluding analgesia with paracetamol/dypiron/ tramal)
223469893|NCT01623921|DRUG|Rosuvastatin|Rosuvastatin 40mg × 1/d+:(standard care treatment for individual lung contusion inluding analgesia with paracetamol/dypiron/ tramal)
223469894|NCT01623921|DRUG|Combined therapy|Combined therapy with Celecoxib 200 mg× 2/d + Rosuvastatin 40× 1/d +:(standard care treatment for individual lung contusion inluding analgesia with paracetamol/dypiron/ tramal)
223469895|NCT04405323|DRUG|Lu AG06466|hard capsules, orally, single doses
223469896|NCT04405323|DRUG|Itraconazole|200 and 300 mg, capsules, orally
223469897|NCT04153279|BIOLOGICAL|CMV-TCR-T cells|Patients with CMV emias or CMV disease will be enrolled, and donor derived CMV-TCR-T(HLA-A\*1101\\0201\\2402) cells will be intravenously infused with a escalated dose of 0.1-1×106 CMV-TCR-T cells. The CMV DNA copies and CMV-TCR-T cell proliferation will be monitored in the scheduled time (day 0, day 4, day 7, day 10, day 14,day 28).
223469898|NCT03189212|BEHAVIORAL|Usual Care Visit|Routine 6-month follow up appointment at the NYULMC transplant center
223469899|NCT03189212|BEHAVIORAL|Telemedicine Visit|TM visit conducted at the patient's dialysis unit as a replacement to usual 6 month routine f/u visit
223579020|NCT03695380|DRUG|Cobimetinib|Cobimetinib will be administered at a starting dose of 60 mg by mouth (PO) daily (QD) on Days 1-21 of each 28-day cycle (Stage 1) and PO QD on Days 1-21 (21/7 schedule) at the established dose for the doublet regimen in Stage 1 (Stage 2).
223469900|NCT03035513|OTHER|Continuous spikes and waves during slow sleep (CSWS)|
223469901|NCT03132545|DIAGNOSTIC_TEST|SenseWear Armband (SWA) monitoring|Participants wore the SWA on their right arm
223469902|NCT03132545|DIAGNOSTIC_TEST|total body dual-energy X-ray absorptiometry|DEXA was used to estimate abdominal visceral adipose tissue and subcutaneous adipose tissue
223469903|NCT05211440|DIETARY_SUPPLEMENT|Placebo + Meal|Subjects will be directed to consume 1 placebo capsule containing maltodextrin, twice daily, for 21 days. Subjects will be directed to consume the capsules with their two largest meals, in between the third and second bites of food. During the MMTT, a placebo capsule will be consumed with a standardized test meal containing chicken, peas, potatoes, and butter.
223579021|NCT03695380|DRUG|Niraparib|Niraparib will be administered at a starting dose of 200 mg of niraparib PO QD on Days 1-28 of each 28-day cycle (Stage 1) and PO QD on Days 1-28 of each 28-day cycle at the established dose for the doublet regimen in Stage 1 (Stage 2).
223469904|NCT05211440|DIETARY_SUPPLEMENT|BC-006 + Meal|Subjects will be directed to consume 1 capsule containing BC-006, twice daily, for 21 days. Subjects will be directed to consume the capsules with their two largest meals, in between the third and second bites of food. During the MMTT, a BC-006 capsule will be consumed with a standardized test meal containing chicken, peas, potatoes, and butter.
223469905|NCT00924924|BEHAVIORAL|Act Healthy!|Six-week class of 50 minute sessions of self-management training for health behaviors
223469906|NCT00924924|BEHAVIORAL|Delayed treatment control|Delayed self-management training group - begins following completion of the experimental group training
223469907|NCT06316635|PROCEDURE|ventilation tube insertion|a paracentesis will be done to tympanic membrane. Glu will be aspirated and trapped.
223469908|NCT02171000|DRUG|BIBR 1048 MS|150 mg capsules, b.i.d, 7 days
223579022|NCT03695380|DRUG|Atezolizumab|Atezolizumab will be administered by IV infusion at the fixed dose of 840 mg on Days 1 and 15 (+/-3 days) of each 28-day cycle (Stages 1 and 2).
224068987|NCT05723705|OTHER|European Multicentre Training Program for Robotic Liver Surgery|LIVEROBOT is a pan-european multicentre training program for robotic liver surgery involving simulation training, a procedure video-library, on and off-site proctoring, and video-assessment.
224068988|NCT04418076|DEVICE|Group A_No feedback|In the control (Group A), the feedback option will be deactivated on the device on the TowerView Health® smart pill box, effectively serving to only monitor natural pill-taking patterns.
224303992|NCT05460559|PROCEDURE|Group A (p-PCNL) procedure|In lithotomy position, ureteric catheter will be inserted allowing injection of contrast to obtain a pyelogram. Shifting the patients in prone position will be done. Under fluoroscopic guidance, the desired calyces will be punctured using an 18 G coaxial needle. Then 0.038 mm hydrophilic guidewires will be passed percutaneously through the needle into the pelvis. Using metal dilators dilatation will be carried out. Amplatz sheath will be inserted to allow nephroscope to enter the collecting system. Stone disintegration will be performed using pneumatic, ultrasonic or laser lithotripsy. Eventually after removal of all stone fragments, a nephrostomy tube will be placed.
223469909|NCT05995938|BEHAVIORAL|Mindfullnes-Based Cognitive Therapy|Mindfullnes-Based Cognitive Therapy Effect on Adherence to Immunosuppressive Therapy in Liver Transplant Recipients
223579023|NCT03225261|DIETARY_SUPPLEMENT|Citrus extract|Citrus extract
223579024|NCT03225261|DIETARY_SUPPLEMENT|Placebo|Maltodextrin
223579025|NCT02699450|DRUG|Faricimab|Faricimab will be administered by IVT injection in the study eye.
223579026|NCT02699450|DRUG|Ranibizumab|Ranibizumab will be administered by IVT injection in the study eye.
223579027|NCT02798991|DRUG|GSK3179106|It is uncoated round or oblong tablet with 3 strengths viz;. 5, 25 and 100 mg. It is White to slightly colored tablet and will be administered orally
223579028|NCT02798991|DRUG|Matched Placebo|It is uncoated round or oblong placebo tablet prepared to match actives across all strengths. It is White to slightly colored tablet and will be administered orally
223579029|NCT02719119|PROCEDURE|monthly Endoscopic Variceal Ligation (EVL)|Patients in this group will underwent endoscopic variceal ligation monthly.
223579030|NCT02719119|PROCEDURE|bi-weekly Endoscopic Variceal Ligation (EVL)|Patients in this group will underwent endoscopic variceal ligation bi-weekly.
223579031|NCT02466113|OTHER|A 6 microRNA stratified tool|Investigators randomly assign patients to be assessed by a 6 microRNA stratified tool. MicroRNA(miRNA) tool contains miRNA of miR-21、miR-20a-5p、miR-103a-3p、miR-106b-5p、miR-143-5p and miR-215. Investigators evaluate these miRNA status of surgical specimens using qRT-PCR and calculate their risk score(risk score =(0.108×status of miRNA-21-5p)+(0.086×status of miRNA-20a-5p)+(0.240×status of miRNA-103a-3p)+(0.095×status of miRNA-106b-5p)-(0.238×status of miRNA-143-5p)-(0.237×status of miRNA-215),low expression status equals 0 and high expression status equals 1). Investigators defined high risk patient if their score larger than 1, the others as low risk patient.The high risk group should receive adjuvant chemotherapy while the low risk group deserve observation.
223743716|NCT07190768|BEHAVIORAL|Exercise Program|"All participants were instructed in a standardized home-based exercise program designed to improve shoulder mobility and stability.~Content: Exercises included active range-of-motion movements, scapular stabilization, and strengthening of rotator cuff and periscapular muscles. Ergonomic advice and posture correction were also provided.~Delivery: Participants were taught the program in person and instructed to perform the exercises at home.~Schedule: Exercises were performed daily for 3 weeks, in addition to the assigned intervention for each study arm."
224159534|NCT03662555|DEVICE|Neuromuscular electrical stimulation|"Neuromuscular electrical simulation (NMES) Two self-adhesive electrodes (2 mm thick) will be placed over the rectus femoris, vastus medialis and vastus lateralis muscles. The electrodes will be placed on the motor points of each muscle. The stimulator discharges biphasic rectangular pulses. The stimulation frequency and duty cycle will be 50 Hz and 5 s of stimulation followed by a 5 s pause for each rep. The intensity of electrical flow will be at each subject's maximum that they can tolerate. The stimulation will be for 5 x 5 min sets with 1 min rest between sets.~Blood flow restriction~A handheld Doppler probe (Hi-Dop) will detect their auscultatory and visual pulse using the doppler's screen. The cuff will be inflated initially up to their systolic blood pressure and then incrementally by 10 mmHg until no auscultatory or visual pulse is detected. A percentage of 40% or 80% of each subject's LOP will then be used during the BFR conditions."
224159535|NCT06424392|OTHER|General Health Questionnaire (GHQ-12)|Anxiety and depression self-reported scales for both parents
224159536|NCT06424392|OTHER|State-Trait Anxiety Inventory (STAI-Y)|Anxiety and depression self-reported scales for both parents
224159537|NCT06424392|OTHER|Revised Children's Manifest Anxiety Scale (RCMAS)|Anxiety and depression self-reported scales for children
224303993|NCT05460559|PROCEDURE|Group B (s-ECIRS) procedure|The patients will be in Galdakao-Modified Supine Valdivia (GMSV) position . Under fluoroscopic guidance, the desired calyces will be punctured using an 18 G coaxial needle. Then 0.038 mm hydrophilic guidewires will be passed percutaneously through the needle into the pelvis. Using metal dilators dilatation will be carried out till 30 Fr. Amplatz sheath will be inserted to allow a 26 Fr nephroscope to enter the collecting system. Retrograde intrarenal surgery will be applied simultaneously by a second surgeon using flexible ureteroscopy. The stones will be fragmented with holmium-yttrium-aluminum-garnet (YAG) laser and stone fragments will be evacuated by basket or removed through PCNL tract under nephroscopy.
224303994|NCT02140866|OTHER|Hand Exercise|
224303995|NCT02140866|OTHER|Compensatory Intervention Program (CIP)|
224303996|NCT02288390|PROCEDURE|Oral care in mechanically ventilated patients|Oral care comparing Chlorhexidine and toothbrush versus Miswak ( the twig of Arak, Salvadora perscia, tree)
224304963|NCT06295640|OTHER|Oral glucose tolerance test with double-tracer dilution and intranasal placebo spray|Subjects will undergo a 75 g OGTT (180 min) combined with a double tracer dilution. The double-tracer dilution technique will be used to quantify endogenous glucose production, glucose appearance and disappearance rate. \[6,6-2H\]glucose will be infused for a total of 300 minutes,while the infusion will start 120 minutes prior the OGTT and will last until the end of the OGTT. Placebo spray will be administered 15 minutes prior to the start of the OGTT. The drink consumed at time point 0 min contains 75 gram glucose, enriched with \[U-13C6\]-glucose. To mimic insulin spill-over from nasal spray into systemic circulation, an i.v. insulin bolus of 3 mU × kg-1. will be administered over ten minutes starting at time point -15 minutes on the placebo spray day. On the insulin spray day a comparable amount of saline will be infused.
224304964|NCT00045292|DRUG|acyclovir|
224304965|NCT00045292|DRUG|acyclovir sodium|
224304966|NCT00045292|DRUG|valacyclovir|
224304967|NCT01589965|BEHAVIORAL|Financial incentive through lotteries|Introduction of financial incentives in the form of a lottery to remain/become STI-negative, which we believe is both replicable and relatively easy to scale-up.
224304968|NCT06006065|BEHAVIORAL|Upper limb somatosensory discrimination therapy|"Participants will receive three 45 minute sessions of upper limb somatosensory discrimination therapy per week for a period of 8 weeks.~Each session includes 30 minutes of component-based training, including graded practice of three components of somatosensation (i.e., tactile object recognition, texture discrimination and proprioception). Next, 15 minutes of occupation-based practice will be completed to enhance transfer to a functional context. This includes repetitive and structured practice of self-chosen activities of daily living, while attention is designated to the somatosensory aspects necessary for successful task completion (e.g., identification of button based on touch)."
224304969|NCT06006065|BEHAVIORAL|Upper limb motor therapy|Participants in the control group will receive an equal amount of motor training, including 30 minutes of unimanual motor tasks and 15 minutes of bimanual goal directed training. The unimanual motor tasks will be selected based on the main difficulties of the child (e.g., grip strength, supination). Bimanual goal directed training includes whole task practice of self-chosen activities of daily living. All therapy sessions will be performed under supervision of a trained physical and/or occupational therapist. Therapy adherence and progression will be closely monitored by the therapist.
224304970|NCT04229459|DRUG|Cisplatin|Cisplatin 100mg/m2 IV on day 1 of induction chemotherapy, 75mg/m2 IV on day 1 and 29 of chemoradiation
224304971|NCT04229459|DRUG|5-FU|5-FU 1000mg/m2/d IV on days 1-5 of induction chemotherapy, 1000mg/m2/d IV on days 1-4 and days 29-32 of chemoradiation
224304972|NCT04229459|RADIATION|Radiation therapy|1.8 Gy/fraction, 5 days a week for a total of 28 days
223469910|NCT06069804|DRUG|The TR group|Miscible liquid of triamcinolone acetonide and ropivacaine in this study will be peri-incisional scalp infiltration with 10ml ropivacaine 1% wt/vol, 0.25ml triamcinolone acetonide (40mg/ml), plus 10 ml saline miscible liquids for participants who will undergo elective craniotomy. Local infiltration of the study solution was performed by the neurosurgeon after induction of general anesthesia and intubation, once all equipment and catheters had been placed, during stable and steady state anesthetic conditions before skin incision. The solution was infiltrated with a 22-gauge needle introduced into the skin at a 45° angle throughout the entire thickness of the scalp along the planned incision site and the head-holder sites, by the same neurosurgeon. The total volume of the study solution used for each patient was determined by the neurosurgeon mainly based on the length of the incision and recorded by the investigator.
223469911|NCT06069804|DRUG|The R group|Miscible liquid of ropivacaine in this study will be peri-incisional scalp infiltration with 10ml ropivacaine 1% wt/vol, plus 10 ml saline miscible liquids for participants who will undergo elective craniotomy. Local infiltration of the study solution was performed by the neurosurgeon after induction of general anesthesia and intubation, once all equipment and catheters had been placed, during stable and steady state anesthetic conditions before skin incision. The solution was infiltrated with a 22-gauge needle introduced into the skin at a 45° angle throughout the entire thickness of the scalp along the planned incision site and the head-holder sites, by the same neurosurgeon. The total volume of the study solution used for each patient was determined by the neurosurgeon mainly based on the length of the incision and recorded by the investigator.
224159538|NCT06424392|OTHER|World Health Organization Quality of Life (WHOQOL-BREF)|Quality of life self-reported scales for parents
223469912|NCT05763927|DRUG|Fruquintinib|Fruquintinib 5mg 2w on/1w off, 21d/cycle, totally 4 cycle.
223469913|NCT05763927|DRUG|Toripalimab|Toripalimab 200mg d1, 21d/cycle, totally 4 cycle.
223469914|NCT05763927|RADIATION|Short-course radiotherapy|25 Gy in 5 fraction, d22-26.
223469915|NCT05763927|PROCEDURE|TME|Surgical resection of the primary tumour in the rectum, 2-4weeks after the last dose of fruquintinib
223579032|NCT02466113|OTHER|A classic stratified tool|Investigators randomly assign patients to be assessed by by classical pathological features. Pathological features include poorly differentiated histology(exclusive of those cancers that are MSI-H),lymphatic/vascular invasion,bowel obstruction and \<12 lymph nodes examined. Investigators defined high risk patient if they had any pathological features, the others as low risk patient. The high risk group should receive adjuvant chemotherapy while the low risk group deserve observation.
224159539|NCT06424392|OTHER|"Parental Educational Competence Self-Evaluation Questionnaire Questionnaire d'Auto-Évaluation de la Compétence Éducative Parentale (QAECEP)"|Parental Educational Competence Self-Evaluation self-reported Questionnaire for parents
224159540|NCT06424392|OTHER|Parental interview|The interview will only last about ten minutes and will take place during the first call, if the parents have agreed and are sufficiently available to answer. If the parents are not available, an appointment can be made at a later date
223743717|NCT07190768|DEVICE|Conventional Physical Therapy (TENS/Ultrasound/Heat pack)|"Participants in this arm received conventional physical therapy modalities commonly used for the management of subacromial pain syndrome.~Modalities: Transcutaneous electrical nerve stimulation (TENS), therapeutic ultrasound, or superficial heat pack were applied based on standard clinical practice.~Additional care: Sessions also included passive mobilization of the shoulder into end range, scapular stabilization exercises, and ergonomic/postural advice.~Schedule: One-hour treatment sessions, 5 days per week, for 3 consecutive weeks."
224159541|NCT06410469|PROCEDURE|rug weaving-like plication technique|anterior vaginal wall repair with the rug weaving-like plication technique in cystosel
224303997|NCT06459037|DIAGNOSTIC_TEST|Saliva obtaining|The patient was asked to sit upright and tilt his/her head forward to collect saliva samples. İn this way, unstimulated saliva was allowed to accumulate in the floor of the mouth. The accumulated saliva was collected in a sterile container. It was then transferred to a propylene tube. The tubes were centrifuged and the clear part at the top of the tube was taken with a sterile syringe and transferred to a different propylene tube with 0.5 ml in each tube. Tubes were stored at -80ºC until the day of analysis.
224303998|NCT04997200|BEHAVIORAL|One night's sleeplessness|A night without sleep. No daytime sleeping the day before the test. Participants are observed by staff at the trial unit during the night before the test.
223579033|NCT02022241|DRUG|triptorelin|0.2 mg, ih, at night and 0.2 mg, ih, 12 hours later when at least one of the following criteria was reached: (i) serum E2 ≥3500 pg/ml, (ii) ≥18 follicles measuring ≥11 mm.
224159542|NCT06039969|OTHER||This is an obvertional study and there is no intervention
224159543|NCT02977507|OTHER|Lytera 2.0|Lytera 2.0 applied to the affected areas twice a day, in the morning and evening, every day for 12 weeks.
224303999|NCT06726161|DIAGNOSTIC_TEST|RYZ811|Ga-68
224304000|NCT06726161|DRUG|RYZ801|Ac-225
224159544|NCT02977507|DRUG|4% Hydroquinone Topical Cream|4% Hydroquinone Topical Cream applied to the affected areas twice a day, in the morning and evening, every day for 12 weeks.
224159545|NCT02977507|OTHER|SkinMedica Facial Cleanser|SkinMedica facial cleanser applied to the face as directed.
224159546|NCT02977507|OTHER|SkinMedica Rejuvenative Moisturizer|SkinMedica rejuvenative moisturizer applied to the face as directed.
224159547|NCT02977507|OTHER|SkinMedica Essential Defense Mineral Shield Broad Spectrum SPF 35 Sunscreen|SkinMedica Essential Defense Mineral Shield Broad Spectrum SPF 35 sunscreen applied to the face as directed.
224304001|NCT06953245|OTHER|Non-Interventional Study|Non-interventional study
224304002|NCT04221789|OTHER|TB treatment assistant|Cell phone app to support self administered treatment and monitor adherence
224304003|NCT03778060|DEVICE|Cala TWO stimulator|Treatment intervention will consist of subjects undergoing 40 minute sessions of transcutaneous stimulation with the Cala TWO stimulator twice daily for 3 months to reduce hand tremors prior to their undergoing deep brain stimulation 'surgery for treatment of essential tremor at Mayo Clinic.
224304004|NCT04578665|BEHAVIORAL|Behavioral Interaction Conditions|The participants will be single-blinded and complete a tracking task as either: solo task, collaboration task (both participants work on a common task synchronously to achieve a goal; this is a summative effort to achieve the goal), competition task (each participant has to achieve a goal at the expense of his or her partner, therefore maximizing effort or error of the partner in reaching the goal), or cooperation task (an asymmetric partnership with an active partner and a passive partner working towards a goal).
223469916|NCT01406535|DRUG|Vardenafil|5 mg vardenafil per os twice daily
223469917|NCT01406535|OTHER|Placebo|5 mg placebo per os twice daily
223469918|NCT01100502|DRUG|brentuximab vedotin|Every 21 days by IV infusion (1.8 mg/kg)
223469919|NCT01100502|DRUG|placebo|Every 21 days by IV infusion
223469920|NCT02546011|OTHER|Fetal Heart Rate Monitor|Standard of care, not part of research
223469921|NCT01531400|OTHER|self-selected music|Investigators played self-selected background music in the music group
223469922|NCT05571410|BEHAVIORAL|HTN Chat bot|Remote monitoring via automated messaging program
223469923|NCT02358122|OTHER|Wholegrain rye|A variety of cereal foods providing \>100g/day wholegrain from rye
223469924|NCT02358122|OTHER|Wholegrain wheat|A variety of cereal foods providing \>100g/day wholegrain from wheat
223469925|NCT02358122|OTHER|Refined wheat|A variety of cereal foods providing 0g/day wholegrain
223469926|NCT02841358|BIOLOGICAL|Blood sampling|
223469927|NCT02841358|BIOLOGICAL|Biopsy|
223469928|NCT06327412|OTHER|Aerobic exercise on the treadmill|According to the cardiopulmonary exercise (CPET) test, 40 minutes (5 minutes warm-up, 30 minutes exercise, 5 minutes cool-down) at an exercise intensity of 50-60% of the VO2 max (the maximum amount of oxygen that an individual can utilize during intense or maximal exercise) level recorded individually in patients, 5 days a week for 4 weeks.Both patient groups will be given lymphedema-specific remedial exercise program training. Anatolian Lymphedema Association lower extremity lymphedema exercise sheets will be delivered to the patients in writing, and training on exercise practices will be given face to face as a session by a physiotherapist at the physical therapy lymphedema outpatient clinic. Patients will be asked to perform these exercises daily as stated in the leaflet and in the number of repetitions. Patients will be given an exercise diary to ensure their compliance with exercise and will be asked to mark this form daily
223469929|NCT06327412|OTHER|Walking between 12-13 RPE (The Borg Rating of Perceived Exertion) according to the Modified Borg Scale|He/she will be asked to walk 40 minutes a day, 5 days a week, for 4 weeks. Training will be given for the first session in the hospital to ensure that the patient's walking pace is between 12-13 RPE according to the Modified Borg scale.Both patient groups will be given lymphedema-specific remedial exercise program training. Anatolian Lymphedema Association lower extremity lymphedema exercise sheets will be delivered to the patients in writing, and training on exercise practices will be given face to face as a session by a physiotherapist at the physical therapy lymphedema outpatient clinic. Patients will be asked to perform these exercises daily as stated in the leaflet and in the number of repetitions. Patients will be given an exercise diary to ensure their compliance with exercise and will be asked to mark this form daily.Treatment compliance will be increased by making weekly phone calls to patients in order to increase treatment compliance and evaluate compliance.
224159548|NCT06236763|DEVICE|TOFscan foot|TOFscan will be applied on the foot and recovery from neuromuscular blockade will be observed over time. These will be compared with the control (TOFscan at the hand) on the same patient (gold standard monitor).
223469930|NCT03503279|DEVICE|McGrath MAC® Video Laryngoscope|McGrath MAC® Video Laryngoscope have been developed to secure the airway and improve the management of difficult intubation. McGrath MAC® is a self-contained VL with a single-use blade; its structure is similar to the ML, but without the channel that guides the tube and a mounted LCD screen on the handle that is connected to a miniature camera with a light source at the tip of the blade, allowing the clinicians to directly observe surrounding anatomical airway structures during a tracheal intubation
223469931|NCT05005624|OTHER|ADL performance|"All validation groups address the following ten ADL tasks in 9 different combinations of light temperature (in Kelvins - K) and light intensity (in foot candles - fc) in order possible differences to be revealed among the validation groups and light combinations:~1\. Phone Book Search (PBS), 2. Supermarket receipt (SupRe), 3. Book reading (BR), 4. Cellular message (CM), 5. Cellular entry search (CES), 6. Reading computer screen (RCS), 7. Drops bottle reading (DR), 8. Subtitles reading (SubRe), 9. Open door test (ODT), and, 10. Screwdriver test (ST).~The 9 light combinations are the following:~3000 K - 25 fc, 3000 K - 50 fc, 3000 K - 75 fc 4000 K - 25 fc, 4000 K - 50 fc, 4000 K - 75 fc 6000 K - 25 fc, 6000 K - 50 fc, 6000 K - 75 fc"
223469932|NCT03482271|OTHER|No intervention - data collection only|No intervention - data collection only
223469933|NCT02322749|DRUG|selumetinib 75mg single dose|3 blue capsules of 25 mg given as a single dose
223743718|NCT07190365|BEHAVIORAL|GOALS TH|The Goal-Oriented Attentional Self-regulation training involves ten 2-hour sessions of group-based telehealth training, three individual 1-hour telehealth training sessions, and approximately 20 hours of home practice. It is conducted in a small group format.
223743719|NCT07190365|BEHAVIORAL|EDU TH|The EDU TH training is an active control training matched with GOALS TH for therapist time, homework load, and participation in a group. It involves ten 2-hour telehealth sessions of group-based training, three individual 1-hour telehealth training sessions, and approximately 20 hours of home practice.
224159549|NCT00949845|DRUG|Endotoxin|
224159550|NCT06180876|DRUG|remimazolam|continuous infusion
224159551|NCT06180876|DRUG|propofol|continuous infusion
223469934|NCT02322749|DRUG|selumetinib 75mg single dose|3 capsules of 25 mg given as a single dose
223469935|NCT02322749|DRUG|selumetinib 75mg single dose|3 capsules of 25 mg given as a single dose
223469936|NCT05895357|OTHER|Musictherapy|The patients were asked about the type of music they wanted to listen to. Especially in the last meta-analyses, it was determined that listening to the music that patients chose was more effective (Witten 2020). For this reason, after the intervention group is asked about the music they want to listen to, the music they want will be played from the music application.
223469937|NCT03675568|PROCEDURE|Non-cultured keratinocyte suspension|A new method for treatment of burn wounds
223469938|NCT03675568|PROCEDURE|Split skin Graft|A traditional method for treatment of burn wounds
223469939|NCT02121860|DRUG|IDN-6556|
223469940|NCT05265117|PROCEDURE|HIPEC|HIPEC is given after primary or interval debulking surgery.
223743720|NCT07189871|DRUG|177Lu-BetaBart|BetaBart administered by intravenous (IV) infusion every 6 weeks
224159552|NCT01188460|BEHAVIORAL|Self-help manual for insomnia|Implementation of chapters of self-help manual at home, and completion of sleep diary in terms of time in bed, hours of sleep, time to fall asleep, number of awakenings, and sleep quality
224159553|NCT01188460|BEHAVIORAL|Sleep diary|
224159554|NCT00633360|DRUG|Drospirenone and ethinyl estradiol|Once daily by mouth
223469941|NCT02851602|BIOLOGICAL|Blood sample|
223469942|NCT06075472|OTHER|Inspiratory Muscle Training|Inspiratory muscle training (IMT) is a therapeutic technique which involves specific training of respiratory muscles to yield improvements in inspiratory muscle strength and respiratory function.
223579034|NCT02421926|DRUG|IDEAL-E observation (investigators choice of imatinib, nilotinib, dasatinib, radotinib)|After the end of follow-up period of IDEAL study, subjects who agree with this extension study (IDEAL-E) will be enrolled and be followed up for additional 4 years to evaluate the duration of treatment response, disease progression, and survival status. Subjects who will be enrolled in this prospective observational study will be treated with drugs - imatinib 300-600mg / nilotinib 600mg / dasatinib 100mg / radotinib 800mg - which has been chosen by the each investigator according to the drug compliance and overall response. The drug choice will be at the discretion of each investigator, and the overall adverse event / molecular response will be monitored every 6 months in this prospective observational study.
223469943|NCT06075472|OTHER|Balance Exercises|Balance exercises involve functional movements at the individual's maximum level of independence.
223469944|NCT05748730|BEHAVIORAL|iCHART|"The Safety Planning App will guide primary care providers or mental health clinicians in the use of an emotion regulation and safety planning app (BRITE) to be loaded on the phone of depressed and suicidal adolescents in order to improve depression and reduce the likelihood of a suicide attempt.~The Mental Health Screener is a decision support tool to guide the primary care provider to make a referral that reflects patient clinical needs and patient and parental treatment preferences and perceived barriers to treatment.~The Text Messages is a personalized text messaging intervention for patients and parents that targets engagement with the safety plan to increase the likelihood that a depressed or suicidal patient will maintain or initiate recommended services.~Participants will receive usual care at their pediatric primary care practice following screening including information, psychoeducation, and referral to a mental health treatment provider."
223469945|NCT05748730|BEHAVIORAL|Treatment As Usual|Participants in this group will receive usual care from their primary care provider or mental health care provider which may include development of a paper safety plan.
223469946|NCT04344028|BEHAVIORAL|True Cognitive Training Program|The training program is a personal device-based adaptive version of a visual N-back task.
223579035|NCT04564248|OTHER|Website access|website access will be provide to families
223579036|NCT00094718|BIOLOGICAL|WN/DEN4-3'delta30|Live attenuated WN/DEN4-3'delta30 vaccine (one of three doses)
223579037|NCT00094718|BIOLOGICAL|Placebo|Placebo for WN/DEN4-3'delta30 vaccine
223579038|NCT03829345|DRUG|Olaparib|Patients will be administered olaparib orally twice daily (BD) at 300mg continuously for each 28 day cycle.
223579039|NCT00231231|DEVICE|-PRECISE Nitinol Stent System (5F, 5.5F and 6F)|
223579040|NCT00231231|DEVICE|ANGIOGUARD™ XP Emboli Capture Guidewire (ECGW)|
224068989|NCT04418076|DEVICE|Group B_Automated feedback|For participants in Group B (automated feedback), missed dosages will prompt an automated text message to be sent to the participants' smartphone. The TowerView Health® pill box consists of in-built alarm and flashing color lights, and the ability to send text messages to the participants' phone either as reminder in the event of missed dosage or a message of encouragement when all dosages are taken.
224068990|NCT04418076|DEVICE|Group C_Automated feedback + Clinician feedback|For participants in Group C, the survey app responses will be assessed each week by the RA who in turn will communicate the results to a clinical nurse. The clinical nurse will be funded through this study; he/she will be responsible for providing personalized feedback to all Group C participants. The clinic nurse will contact the subject with appropriate feedback about their health behavior and suggestions for sustained adherence.
224159555|NCT00633360|DRUG|Placebo|Once daily by mouth
223469947|NCT04344028|BEHAVIORAL|Control Cognitive Training Program|The training program is a personal device-based adaptive version of a knowledge task (control).
223469948|NCT04344028|BEHAVIORAL|Positive Expectation Induction|The message given to the participants emphasizes that the given training results in a positive change in cognitive abilities.
223469949|NCT04344028|BEHAVIORAL|Negative Expectation Induction|The message given to the participants emphasizes that the given training results in a negative change in cognitive abilities.
223469950|NCT01542008|BEHAVIORAL|Customized Adherence Enhancement (CAE)|CAE consists of the application of a series of up to four psychosocial treatment modules based upon a baseline evaluation of adherence vulnerabilities/needs. The standardized modules (Psychoeducation, Modified Motivational Enhancement Therapy, Communication with Providers, Medication Routines), are assigned based upon pre-established criteria designed to fit the needs of the patient.
223579041|NCT03910166|PROCEDURE|drug-coated balloon catheter（Orchid, Acotec）|After predilation, using drug-coated balloon catheter to cover the whole treated segment
223579042|NCT03910166|PROCEDURE|Intracranial artery stent system（APOLLO）|stent assisted angioplasty
223579043|NCT05909774|DEVICE|"Test with Atalante exoskeleton in continuous walk type"|"The continuous walk is smoother and more physiologic than the push and swing walk"
223579044|NCT03897530|BEHAVIORAL|Smoking Cessation Intervention|View and purchase hypothetical tobacco products during four distinctly different ETM
223579045|NCT03897530|OTHER|Functional Assessment|Visual attention is evaluated via eye-tracking equipment
223579046|NCT03897530|OTHER|Questionnaire Administration|Ancillary studies
223579047|NCT04846530|DEVICE|RHA® 1, RHA® 2, RHA® 3, and RHA® 4|For each subject, two spaced boluses (0.2 mL each) of the product will be implanted on the same side (left or right side) in the post auricular area of the subject per treatment assignment. The assignment will specify one of the RHA® products to the left ear and another product to the right ear. Each subject will have a total of four boluses.
223579048|NCT00212186|DRUG|Selenium Supplements (essential nutrient)|
223579049|NCT01133275|DRUG|Prednisone|Prednisone therapy for 6 cycles (24 weeks).
223579050|NCT01133275|DRUG|Lenalidomide|Lenalidomide therapy for 6 cycles (24 weeks).
223579051|NCT00700102|DRUG|Chemotherapy|As prescribed
223579052|NCT00700102|DRUG|Bevacizumab|Bevacizumab, 5 mg/kg intravenously (IV) on days 1 and 14 of each 4 week cycle, or 7.5 mg/kg IV on days 1 and 22 of each 6 week cycle.
223579053|NCT02525939|DRUG|dalcetrapib|Cholesterol Ester Transfer Protein inhibitor
224159556|NCT01964287|DRUG|GEMBRAX|
224159557|NCT01964287|DRUG|FOLFIRINOX|
224159558|NCT06617949|DRUG|Regional Anesthesia|Transverse abdominal Plane(TAP) Block with long acting Exparel placed by a regional anesthesiologist.
223579054|NCT02525939|DRUG|Placebo|matching placebo tablets
223469951|NCT01542008|BEHAVIORAL|broadly-directed, non-individualized education (EDU)|"EDU will consist of 4 core in-person sessions using the patient work-book from the NIMH funded study, Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD), and following the general educational format of the Collaborative Care control intervention in the STEP study. EDU addresses BD treatment broadly, including diagnosis and management, and the sessions will review the materials and allow time for questions as needed."
223469952|NCT04037371|OTHER|Cold exposure|Participants were tested for white fat thermogenic activity against their environmental temperature exposure
223469953|NCT03666442|DRUG|XELOX|Xelox chemotherapy,that oxaliplatin 130mg/m2 d1,capecitabine 1000mg/m2 twice daily d1-14,every 3 weeks
223469954|NCT05158140|BIOLOGICAL|V110|Single intramuscular (IM) dose of 0.5 mL V110, a pneumococcal polysaccharide vaccine (PCV), containing the 23 serotypes: 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F
223469955|NCT05158140|BIOLOGICAL|V114|Single IM dose of 0.5 mL V114 a 15-valent PCV containing the 15 serotypes: 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, 33F
223469956|NCT05158140|BIOLOGICAL|mRNA-1273|Single IM dose of 50 μg/0.25 mL mRNA-1273
223469957|NCT05158140|BIOLOGICAL|Placebo for V110|Single IM dose of 0.5 mL placebo for V110
223469958|NCT05158140|BIOLOGICAL|Placebo for V114|Single IM dose of 0.5 mL placebo for V114
223469959|NCT04000438|DRUG|DF01|DF01: The subject receives sc injections of tafoxiparin solution once daily for up to 7 days until spontaneous onset of labor or ripe cervix (Amniotomy/oxytocin without restriction).If not enough ripening cervical ripening according to clinical practice with intracervical ballon/prostaglandins
223579055|NCT03344263|DIAGNOSTIC_TEST|tests of attentional performance|tests of attentional performance before and after 6 months of continuous positive airways pressure
223579056|NCT01635764|BIOLOGICAL|adalimumab|Adalimumab pre-filled syringe, administered by subcutaneous injection
223579057|NCT04641949|PROCEDURE|Lower body negative pressure (LBNP)|LBNP is a model of experimental hypovolemia, whereby the lower body is exposed to negative pressure leading to sequestering of blood in the lower body and central hypovolemia. LBNP will be induced stepwise with increments of 10 mmHg, each level lasting 1 min. LBNP will be terminated at symptoms or signs of impending hemodynamic collapse.
223579058|NCT04118569|BEHAVIORAL|Narrative Intervention|Research staff conducts an open-ended, audio-recorded interview with the patient about their illness and how this illness has affected their psycho-social-spiritual well-being. The investigators will use the interview transcription to create a meta-narrative, which is then uploaded to the electronic medical record and the patient's primary nurse is notified that it is available to read.
223579059|NCT06196398|DRUG|Standard Medical Treatment on the basis of anti-platelet therapy|"1. Anti-platelet therapy: aspirin 75mg+clopidogrel 100mg will be applied for patients with severe ICAS stenosis (70%-90%) suffering stroke or TIA within 30 days. After 90 days, single anti-platelet therapy will be continued.~2. Intensive statin therapy: Statins with high doses~3. Blood pressure: below 140/90mmHg~4. LDL: less than 1.81mmol/L(70mg/dl)~5. Fasting blood glucose controlled to 5.9mmol/L, and glycosylated hemoglobin A1c reduced to less than 7%~6. Cigarette and alcohol quitting~7. Oral anticoagulants for atrial fibrillation"
223579060|NCT00040508|DRUG|Sirolimus|
223579061|NCT01186640|DRUG|Fludarabine, Mitoxantrone, Cyclophosphamide and Alemtuzumab|"I. First treatment phase: Chemoimmunotherapy A-FMC~Alemtuzumab:~Cycle 1+2:~10 mg s.c., days 1-3~Cycle 3+4:~CR: 10 mg s.c., days 1-3 PR/SD: 30 mg s.c., days 1-3 Fludarabine: 20 mg/m2 i.v., days 1-3 Mitoxantrone: 6 mg/m2 i.v., day 1 Cyclophosphamide: 200 mg/m2 i.v., days 1-3 Repeat day 29, maximum 4 cycles. II. Second treatment phase: Maintenance-treatment with 30mg Alemtuzumab s.c. The maintenance therapy will start one month after the Final Staging and will be administered monthly during the first six months plus once in month 10 and 13."
223579062|NCT01186640|DRUG|Alemtuzumab|maintenance with Alemtuzumab following a induction with combined immunochemotherapy consisting of Fludarabine, cyclophosphamide, mitoxantrone and alemtuzumab
223579063|NCT01174004|DRUG|pimavanserin tartrate|pimavanserin tartrate, 40 mg, tablet, once daily by mouth for 6 weeks
223579064|NCT01174004|DRUG|placebo|placebo, tablet, once daily by mouth for 6 weeks
223579065|NCT05114122|PROCEDURE|Vonlay Ceramic restorations|vonlay is a hybrid of an onlay with an extended buccal veneer surface for use in bicuspid regions where there is mostly enamel to bond to. The vonlay is less invasive, more readily repairable, less technique-sensitive to attain adequate bonding, and will leave sounder tooth structure remaining if further treatment is required in the future
223579066|NCT05114122|PROCEDURE|Onlay Ceramic restorations|Onlays are used to restore large areas of decay and also used to replace old restorations, whether they are defective amalgam fillings, old cast-gold onlays, or fabricated from some other material
223579067|NCT00693472|DRUG|Preladenant|Preladenant, one 25 mg capsule, administered orally every 12 hours
223579068|NCT00693472|DRUG|Placebo|Matching placebo capsule administered orally every 12 hours
223579069|NCT00693472|DRUG|Anticholinergic agents or propanolol|"Part 1 (as rescue therapy only): participants who develop akathisias may be treated with either anticholinergic agents or propranolol as a rescue medication at the discretion of the treating physician. Individual anticholinergic agents were not pre-specified per protocol.~Part 2 (standard of care): anticholinergic agents or propanolol at a dose determined by the investigator according to the local standard of care. Individual anticholinergic agents were not pre-specified per protocol."
223579070|NCT00693472|DRUG|Haloperidol|Participants continued pre-study haloperidol, admistered orally, at a dose of at least 7.5 mg/day
223579071|NCT01556061|DEVICE|DMAC|The D blade will constitute the experimental treatment and in a cross over fashion will be tested against CMAC blade
224068991|NCT04418076|DEVICE|Group D_Automated feedback + Social Network feedback|For participants in Group D, a social network designee will be chosen based on the names provided by the participants during screening. One social network designee will be consented and chosen to send the participant a weekly text reminder the participant to take their medication. The text for the message will be chosen by the social network designee.
223469960|NCT04000438|DRUG|PL1|DF01: The subject receives sc injections of placebo solution once daily for up to 7 days until spontaneous onset of labor or ripe cervix (Amniotomy/oxytocin without restriction).If not enough ripening cervical ripening according to clinical practice with intracervical ballon/prostaglandins
223469961|NCT04279067|DEVICE|BCI-FES dorsiflexion therapy|"BCI technology enables direct brain control of external devices such as assistive devices and prostheses by translating brain waves into control signals. When BCI systems are integrated with functional electrical stimulation (FES) systems, they can be used to deliver a novel physical therapy to improve movement after stroke. The automated software will analyze the data to generate and calibrate a BCI decoder. In the online phase, the subjects will perform 20-25 BCI-FES runs. In each run, subjects will follow 10 alternating epochs of 10-s long idling/dorsiflexion textual cues, and respond by either idling or attempting dorsiflexion to elicit BCI-FES mediated contractions of the TA muscle."
223469962|NCT04279067|BEHAVIORAL|Physiotherapy one hour|This will consist of a standardized regimen of activities typical of conventional post-stroke gait therapy, including passive/active range of motion exercises (to reduce/prevent excessive plantarflexor contractures), lower-extremity muscle strengthening, and a progression from treadmill to overground walking exercises. A total of 12 sessions will be performed at 3x/week.
223469963|NCT04279067|BEHAVIORAL|Physiotherapy two hours|This will consist of a standardized regimen of activities typical of conventional post-stroke gait therapy, including passive/active range of motion exercises (to reduce/prevent excessive plantarflexor contractures), lower-extremity muscle strengthening, and a progression from treadmill to overground walking exercises. A total of 12 sessions will be performed at 3x/week.
223469964|NCT06810713|BEHAVIORAL|Gatekeeper training (e-learning)|"This training supplements existing modules for healthcare providers working with individuals experiencing suicidal thoughts (https://sp-reflex.zelfmoord1813.be/e-learning).~Specific information on working with men will be added:~* Information on suicidality among men and the importance of gender-sensitive care.~* Guidance on recognizing signs of suicidality in men and understanding gender differences in suicide-related communication.~* Insights into the impact of gender norms and socialization on suicidality and help-seeking behavior in men experiencing suicidal thoughts.~* Awareness of providers' own gender biases and the influence of societal gender norms in treating men with suicidal ideation.~* Recommendations for engaging men in treatment, with specific guidance on language and approaches for interacting with men who have suicidal thoughts.~Additionally, the e-learning will a model psychoeducation about the role of norms for men experiencing suicidal ideation."
223469965|NCT04414787|BEHAVIORAL|PCplanner|PCplanner-augmented care. The PCplanner mobile app will allow patients / family members to report their needs in a platform viewable by ICU physicians. Should the needs not improve over time, the palliative care team will be activated to contribute to care.
223469966|NCT06154837|DRUG|GSK3862995B|GSK3862995B will be administered.
223469967|NCT06154837|DRUG|Placebo|Placebo will be administered.
223469968|NCT02214342|OTHER|Balance Training|"Experimental: Balance Training Balance training will be conducted individually two times per week for 4 weeks. Each training session will include virtual reality tasks such as ankle reaching and obstacle crossing using a virtual obstacle shown on a computer screen. Each session will last 30 - 45 minutes."
223469969|NCT05138978|DRUG|Colgate Maximum Cavity Protection plus Sugar Acid Neutralizer|Toothpaste
223469970|NCT05138978|DRUG|Colgate Cavity Protection|Toothpaste
223469971|NCT06979531|DRUG|IMVT-1402|Administered once weekly by subcutaneous injection
223579072|NCT01556061|DEVICE|CMAC|The CMAC Blade will constitute the active comparator treatment and in a cross over fashion will be tested against D-blade
223579073|NCT00000120|DRUG|Erythromycin Ointment|
223743721|NCT07189884|DRUG|Pyrotinib Maleate Tablets + Dalpiciclib Isethionate Tablets + Standard Endocrine|"Pyrotinib Maleate Tablets: 320 mg/day administered continuously from the first day of the first course of treatment, orally within 30 minutes after breakfast, missed doses without refill, every 21 days as a cycle.~Dalpiciclib Isethionate Tablets: 125 mg orally every 28 days as a treatment cycle, with continuous medication for the first 3 weeks (Day 1 to Day 21), and rest (no medication) for the next 1 week (Day 22 to Day 28).~Endocrine therapy: The endocrine therapy drug is selected by the investigator."
223743722|NCT07191249|DRUG|Mosunetuzumab is a bispecific monoclonal antibody targeting CD20 on B cells and CD3 on T cells, redirecting T cells to eliminate malignant B cells.|In this study, Mosunetuzumab will be administered subcutaneously over 8 treatment cycles: 5 mg on Day 1 of Cycle 1, followed by 45 mg in all subsequent cycles.
223743723|NCT07190846|OTHER|No Intervention (Observational Echocardiographic Evaluation)|This is an observational study. No therapeutic intervention is administered. Participants undergo standard echocardiographic assessment of left ventricular diastolic function during pregnancy.
224068992|NCT04133467|OTHER|scalp block|intravenous acetaminophen according to the body weight, plus intravenous tramadol 1 mg/kg)
224068993|NCT06267196|OTHER|The use of a stress ball|The effect of the stress ball used during spinal anesthesia on pain and anxiety
224068994|NCT02554097|PROCEDURE|endoscopic sphincterotomy|Sphincterotomy (EST) is performed to remove the common bile duct stone.
223579074|NCT00000120|DRUG|Silver Nitrate Drops|
223579075|NCT04668924|PROCEDURE|Epi-on PiXL in high oxygen|After local anaesthetics, the keratoconus cornea is soaked in Riboflavin by repeated topical application during 10 minutes. A Riboflavin soaked sponge is used to lightly disrupt the epithelium tight junctions, without epithelium debridement. The cornea is illuminated with PiXL under 16:40 minutes during continuously delivery of humidified high oxygen via specific oxygen googles. The UV-dosage is individually customized based upon Kmax; for \< 45 Diopters (D) 7.2J/cm\^2 will be used; for 45-50D 10J/cm\^2 will be used; for \> 50D 15 J/cm\^2 will be used.
223579076|NCT00533858|DRUG|lacidipine (4 mg) or losartan (50 mg)|lacidipine (4 mg) or losartan (50 mg), both given once daily at the same hour in the morning (approximately at 8 AM) for 12 weeks
223579077|NCT00675896|DRUG|Quetiapine Fumarate Sustained Release|50 mg/day for the first 2 days and then up to 150mg/day. After two weeks the dose will be doubled up to 300mg at night at the discretion of the investigator
223579078|NCT00675896|DRUG|Placebo|1 tablet at HS for 2 days then 3 tablets at HS for 2 weeks
223579079|NCT06519461|BEHAVIORAL|Family-centered teaching model|The program comprised two parts: (1) Didactic lessons: and (2) Hands-on practice. The didactic lessons were designed to prepare interns' knowledge and skills. The hands-on practice were designed to provide opportunities of family-centered experience to work with caregivers and children.
223579080|NCT01077180|DEVICE|Implantation of the Rheos System|Open label
223579081|NCT01077180|OTHER|Standard of care medical management|Patients will continue with medical therapy for standard of care of their hypertension.
223469972|NCT06979531|DRUG|Placebo|Administered once weekly by subcutaneous injection
223469973|NCT06374459|DRUG|Zumsemetinib|Patients should take zunsemetinib at approximately the same times every day, with or without food with 8 oz of water.
223469974|NCT06374459|DRUG|Capecitabine|Patients should take capecitabine at approximately the same times every day, within 30 minutes after a meal.
223469975|NCT06374459|DRUG|Zoledronic acid|Standard of care. Will receive zoledronic acid or denosumab.
223469976|NCT06374459|DRUG|Denosumab|Standard of care. Will receive zoledronic acid or denosumab.
223469977|NCT06657560|DRUG|HRS-9231|HRS-9231
223469978|NCT03304080|DRUG|Anastrozole|1 mg orally daily, day 1 to day 28
223469979|NCT03304080|DRUG|Palbociclib|Dose I: 100 mg orally daily, day 1 to day 21, then 7 days off in a 28 day cycle (Phase 1 only) Dose II: 125 mg orally daily, day 1 to day 21, then 7 days off in a 28 day cycle
223579082|NCT03358641|OTHER|level of physical activity|According to the result of IPA-Q questionnaire, participants are divided in three groups: low level, moderate level, high level of physical activity.
223469980|NCT03304080|DRUG|Trastuzumab|8 mg/kg IV initial loading dose, followed by 6 mg/kg IV every 21 days
223579083|NCT00849875|BIOLOGICAL|Immunotherapeutic GSK2132231A|Intramuscular administration
223579084|NCT00849875|DRUG|Dacarbazine|Intravenous administration Chemotherapy
223579085|NCT03510871|DRUG|nivolumab, ipilimumab|All enrolled subjects will receive nivolumab 3 mg/kg plus ipilimumab 1 mg/kg intravenously on day 1 of each cycle (every 3 weeks). Tumor assessment will be done after 6 weeks (2 cycles) and 12 weeks (4 cycles).
223579086|NCT05747417|OTHER|prismatic glasses|prism glasses ranging from 4-10 prism diopters
223579087|NCT00086502|DRUG|Comparator: Sitagliptin|Sitagliptin 100 mg once daily, from Visit 4 through Visit 8. Day 1 through week 24
223469981|NCT03304080|DRUG|Pertuzumab|840 mg IV followed by a maintenance dose of 420 mg IV every 21 days
223469982|NCT05870540|DRUG|BPL-003|A single dose administered intranasally
223469983|NCT05870540|DRUG|BPL-003|A single dose administered intranasally (administered as 2 nasal sprays minutes apart)
223469984|NCT06659796|DEVICE|LifeVac|Removal of airway obstruction during choking emergency
223469985|NCT06660914|PROCEDURE|Flexible Ureteroscopy|Ureteroscopic lithotripsy
223469986|NCT00185042|DRUG|Pactimibe, CS-505|
223469987|NCT00807365|DRUG|GHRH|GHRH administered subcutaneously at 2.0 mg/kg/dose bolus each night at 11:00 Post Meridian (PM), 1:00 Ante Meridian (AM), 3:00 AM, \& 5:00 AM for 6 months.
223469988|NCT06612164|OTHER|kefir|Commercial lactose-free kefir (Altinkilic, Turkey) beverage, which is produced from cow milk with 3.1% fat and 7.5% protein content and stored in appropriate conditions, was used in this study. The kefir (intervention) group was provided with 250 mL of plain lactose-free kefir containing at least 107-1010 probiotic bacterial strains (Lactobacillus, Lactic acid, Streptococcus, Acetic acid bacteria sp) and yeasts (Kluyveromyces marxianus, Torulaspora delbrueckii, Saccharomyces cerevisiae, Candida). The participants were asked to consume 250 mL of plain lactose-free kefir daily for 6 weeks. Any particular time was not specified for kefir consumption. Kefir consumption routine of participants was followed up by regular phone calls every week and evaluated by examining their consumption records. Those who consumed less than 85.0% (skipping kefir consumption maximum once a week) of the planned kefir consumption during the study period were excluded from the study.
223469989|NCT06611943|BEHAVIORAL|DietCoach|Participants are invited to give at least one dietary recommendation to a patient\&#39;s food purchase data using the DietCoach platform.
223469990|NCT06993220|DIAGNOSTIC_TEST|Evaluation of residual congestion at discharge|"Evaluation of residual congestion at discharge will be made using:~* Clinical variables: composite congestion score calculated by summing the individual scores for orthopnoea, jugular venous distension and pedal oedema;~* Imaging variables: non-invasive left ventricular filling pressure, number of LUS B lines and the presence of pleural effusion, Venous Excess UltraSound (VExUS) score;~* Laboratory variables: hemoglobin and hematocrit, NT-proBNP, CA-125, ST2, troponin T, creatinine, AST, ALT, Na, K, urea, bilirubin, C-reactive protein."
223469991|NCT06871865|OTHER|Oculomotor Exercises|Oculomotor exercises are designed to improve eye movement control, coordination, and visual tracking.
223469992|NCT06871865|OTHER|Posture Exercises|Postural exercises help strengthen core muscles, improve alignment, and enhance stability. They are essential for maintaining proper posture, preventing pain, and reducing the risk of musculoskeletal imbalances.
223469993|NCT06871865|OTHER|Neck Stretching and Strengthing Exercises|Neck stretching and strengthening exercises help improve flexibility, reduce stiffness, and enhance muscle support for the cervical spine. They are beneficial for relieving neck pain, improving posture, and preventing injuries.
223469994|NCT06177171|DRUG|Olaparib|Given orally
223469995|NCT06177171|DRUG|ASTX727|Given Orally
223469996|NCT06687538|OTHER|Mobile application|The content of the mobile application training to be developed for patients who will undergo transurethral prostate resection will consist of 3 modules including preoperative, postoperative and discharge training process.
223579088|NCT00086502|DRUG|Comparator: Placebo|Placebo (to match Sitagliptin 100 mg) once daily, from Visit 4 through Visit 8. Day 1 through Week 24
223579089|NCT00086502|DRUG|Comparator: Pioglitazone|Pioglitazone 30 mg or 45 mg once daily, Visit 2 through Visit 8
223579090|NCT00086502|DRUG|Metformin|"Metformin rescue for patients meeting~pre-specified glycemic criteria. Metformin 500 mg,once daily, Visit 4 through Visit 8"
223579091|NCT06373783|PROCEDURE|subepithelial connective tissue graft|The area where the gingival recession occurred was prepared with the modified coronally positioned flap technique developed by Zuchelli. The subepithelial connective tissue graft was obtained in each patient using the single incision technique from the region between the mesial of the canine and the mesial of the first molar in the palate. Connective tissue dimensions were approximately 10x5x2 mm. The graft thickness was measured with an endodontic spreader from 3 points (mesial, buccal, and distal) and an electronic caliper during surgery.
224068995|NCT02554097|PROCEDURE|laparoscopic common bile duct exploration|Transductal exploration was carried out to remove the common bile duct stone. Primary closure or a T tube drainage was performed according to the results of transductal surgery.
224159559|NCT06617949|DRUG|Hydromorphone Patient Controlled Analgelsic|This group will be administered epidural PCA as a modality for pain control post cesarian section
224159560|NCT06617949|PROCEDURE|Epidural local anesthetic infusion|Epidural group will receive pain control via a local anesthetic intermediate bolus infusion
223469997|NCT01526785|DRUG|Alglucosidase alfa|4000 L alglucosidase alfa administered by IV infusion at the same dose and dose regimen used for the patient's routine treatment prior to the study for 52 weeks.
223469998|NCT07048366|BEHAVIORAL|Integrated Rehabilitation Program at the University Museum|This intervention consists of an 8-week integrated rehabilitation program, with weekly 60-minute sessions, conducted at the University Museum (Museo Universitario UD'A). The program includes mindfulness techniques, conscious breathing exercises, body scan meditation, mindfulness walking within the museum's exhibition spaces, specific stretching and mobilization techniques, and gratitude and recognition exercises, all framed by the artistic and cultural context of the museum. The museum environment is utilized as a therapeutic setting to amplify the benefits of the behavioral techniques.
223469999|NCT07048366|OTHER|Waitlist for Conventional Treatments|This arm of the study serves as the control group. Participants in this group will be placed on a waitlist for conventional treatments and will not receive the museum-based integrated rehabilitation program during the study period. They will not undergo any active intervention specifically tested within the scope of this study.
223470000|NCT05163392|DEVICE|Silverlon|SIlver-plated biopatch
223470001|NCT05163392|DEVICE|Control|Tegaderm without biopatch
223470002|NCT00738426|DEVICE|Erchonia ML Scanner (MLS)|Red diode low level laser light energy.
223470003|NCT00738426|DEVICE|Sham device|non-therapeutic light energy output
223470004|NCT02522416|DEVICE|Central corneal thickness measurement|
223470005|NCT01461733|DRUG|amiodarone|standard dose amiodarone
223470006|NCT01461733|DRUG|Placebo|placebo delivered blinded
223470007|NCT03416192|DEVICE|MCO-HD|Measurements will be done after 0,4,8 and 12 weeks of hemodialysis with Medium Cut-Off filter.
223470008|NCT03416192|DEVICE|high-flux HDF|Measurements will be done after 0,4,8 and 12 weeks of hemodiafiltration with standard high-flux filter
223470009|NCT01505413|DRUG|Erlotinib|Erlotinib 100 mg po qd daily
223470010|NCT01505413|DRUG|Gemcitabine|Gemcitabine 1000 mg/m² with 150mL of normal saline intravenously infusion over 100min on Day 1
223470011|NCT01505413|DRUG|Oxaliplatin|Oxaliplatin 100 mg/m2 with 500mL of 5DW intravenously a 2-hour infusion on D2
223470012|NCT02391051|RADIATION|HDR-Brachytherapy|HDR-Brachytherapy 2x 13,5 Gy
223470013|NCT04406467|DEVICE|Xen Gel Stent|Ab-interno or Ab-Externa Xen with closed or open conjunctiva.
223470014|NCT07061860|DEVICE|digital complete denture|different method of denture construction
223470015|NCT07061860|DEVICE|metal reinforced complete denture|different method of denture construction
223470016|NCT04350827|DEVICE|Platelet Rich Plasma|Platelet rich plasma injection into patellar tendon
223470017|NCT04350827|DEVICE|Platelet Rich Plasma plus IGF|Platelet rich plasma plus IGF injection into patellar tendon
223470018|NCT06420388|DRUG|2% Lidocaine Gel|"The intervention group received 5 mL of 2% lidocaine gel applied topically 3 times per day after undergoing Ferguson hemorrhoidectomy surgery.~The control group received 5 mL of a non-anesthetic water-based lubricant gel applied topically 3 times per day after surgery.~The application of the gels began immediately after surgery and continued for the postoperative period evaluated in the study.~Both groups received standard postoperative analgesics (acetaminophen, celecoxib, Dynastat/parecoxib as needed) in addition to the topical gel applications."
223470019|NCT06420388|DRUG|Water-based Lubricant Gel (K-Y Gel)|The intervention group received 5 mL of mL of a non-anesthetic water-based lubricant gel (K-Y gel) applied topically 3 times per day after undergoing Ferguson hemorrhoidectomy surgery.
224068996|NCT02554097|PROCEDURE|laparoscopic transcystic common bile duct exploration|A wide local dissection of Calot's triangle is performed and a 2.8mm, 3-mm or 5-mm flexible choledochoscope according to the diameter of the cystic duct is inserted through the cystic duct into the common bile duct. After the common bile duct stone is removed, the cystic duct was ligated with Hem-o-lok.
223470020|NCT06420388|DRUG|Standard Postoperative Analgesics|"Acetaminophen (Paracetamol)~Dosage: 500 mg per tablet Frequency: Every 6 hours Route: Oral~Acetaminophen is a common over-the-counter pain reliever and fever reducer. It works by blocking the production of prostaglandins, which are responsible for causing pain and inflammation.~Celecoxib~Dosage: 200 mg per tablet Frequency: Every 12 hours Route: Oral~Celecoxib is a nonsteroidal anti-inflammatory drug (NSAID) that specifically inhibits the cyclooxygenase-2 enzyme. By reducing the production of prostaglandins, celecoxib helps alleviate pain and inflammation.~Dynastat (Parecoxib)~Dosage: 40 mg per injection Frequency: Every 12 hours as needed for poorly controlled pain Route: Intravenous"
223470021|NCT07063147|DIAGNOSTIC_TEST|TTE|All patients underwent TTE according to established guidelines and local institutional protocols. The imaging data were evaluated using different image post-processing software to comprehensively analyse anatomical, functional and histological information of coronary.
223470022|NCT07066761|DEVICE|Laparoscopic lateral suspension with surgical mesh (LatGYNious)|Laparoscopic lateral suspension with LatGYNious (with uterus preservation or after hysterectomy)
223470023|NCT07068672|BEHAVIORAL|Kaleidoscope|A handheld kaleidoscope was used as a passive distraction tool during venipuncture. The device was introduced to the child 2 minutes before the procedure and remained in view during blood collection. It provided dynamic, colorful visual stimuli to help reduce pain and anxiety.
223470024|NCT07068672|BEHAVIORAL|Helicone|A helicone toy was used as an active distraction tool. Children held and rotated the device beginning 2 minutes before and during venipuncture. The interactive movement and shape-shifting design engaged the child's attention to reduce procedural pain and anxiety.
223470025|NCT07066644|PROCEDURE|central node dissection|dissection of level VI compartment by AAHNS (American association of head and neck surgeons) classification
223470026|NCT07072390|OTHER|Measurement Tool for Clinical Competencies in Physiotherapy (MTCCP)|A culturally adapted Turkish version of the Measurement Tool for Clinical Competencies in Physiotherapy (MTCCP), used to evaluate clinical skills in final-year physiotherapy students.
224068997|NCT02554097|PROCEDURE|laparoscopic cholecystectomy|Laparoscopic cholecystectomy is performed to remove the gallbladder.
224068998|NCT05424653|DEVICE|Transcatheter Aortic Valve System|Procedure: Transcatheter Aortic Valve Replacement
224159561|NCT02036268|BEHAVIORAL|Standard|Standard ostomy education
224159562|NCT02036268|BEHAVIORAL|Pre-operative Education|In addition to standard ostomy education, an additional pre-operative ostomy education session will be conducted with the subject.
223470027|NCT07072702|BEHAVIORAL|Managing Post-Injury Challenges (MPIC)|A brief evidence-informed intervention was developed to reduce post-injury perceptions of injustice. The intervention is referred to as 'Mastering Post-Injury Challenges' (MPIC). MPIC consists of 4 weekly 30-minute virtual meetings with a psychologist trained in the delivery of the intervention. MPIC is delivered concurrently with the physiotherapy treatment to which the injured worker has been referred. MPIC combines elements of validation, motivational interviewing, acceptance and problem-solving .
223470028|NCT07073703|PROCEDURE|APA|2 adapted physical activity (APA) sessions per week for 4 weeks before and after surgery
223470029|NCT07073703|BEHAVIORAL|Therapeutic education workshops|Therapeutic education workshops tailored to individual needs, covering topics as physical activity, nutrition, treatments, fatigue, and relaxation.
223470030|NCT07073703|PROCEDURE|DAPAP|"Referral to the department's DAPAP for a 12-week bridge program, consisting of one session per week."
223470031|NCT07072104|BEHAVIORAL|Multidomain Neuropsychological and Reading-Free Screening Tool (RSFT) Assessment Battery - Grade 2|"* Behavioral testing: standardized neuropsychological battery (language, reading, attention, memory, intelligence)~* RFST: Reading-Free Screening Tool assessing pre-reading cognitive markers"
223470032|NCT07072104|DIAGNOSTIC_TEST|MRI - Grade 2|■ Diagnostic Imaging: structural and resting-state functional MRI (T1-weighted and rs-fMRI)
224159563|NCT02036268|BEHAVIORAL|Two-week Post Operative Education|In addition to standard ostomy education and an additional pre-operative ostomy education session, another ostomy education session will be conducted with the subject two weeks post-op.
224159564|NCT02200068|OTHER|SANOIA Website|
224159565|NCT03749213|DRUG|Icotinib|Patients with EGFR-mutant Stage ⅢA-N2 Non-small Cell Lung Cancer which can be potentially radical treated by surgery are arranged to receive Icotinib with a dose of 125 mg three times per day orally for 8 weeks as neoadjuvant therapy before surgery and for 2 years as adjuvant therapy or till progressive disease or unaccepted toxicity.
224159566|NCT05437913|OTHER|Psychological intervention (self-compassion based)|4 weeks intervention for both primary caregivers and adolescents with T1D will be done online through videoconferencing and will be based on three validated protocols that use self-compassion (MSC and MSC Teens).
224159567|NCT04255992|DIETARY_SUPPLEMENT|Calcium Arm|1000 mg Calcium tablet / day will be added to the usual treatment for each patient for a period of 8 weeks.
224159568|NCT04255992|DIETARY_SUPPLEMENT|Vitamin D/Calcium|1000 mg/800UI of the association Vitamin D/Calcium tablet / day will be added to the usual treatment for each patient for a period of 8 weeks.
224159569|NCT03158090|PROCEDURE|Transnasal butterfly surgery|The patient will be treated in accordance with the advice of the local doctor in charge, and this study does not interfere with any treatment of the patient.
223470033|NCT07072104|BEHAVIORAL|Multidomain Neuropsychological and Reading-Free Screening Tool (RSFT) Assessment Battery - Grade 3|"* Behavioral testing: standardized neuropsychological battery (language, reading, attention, memory, intelligence)~* RFST: Reading-Free Screening Tool assessing pre-reading cognitive markers"
223470034|NCT07073638|DRUG|RESP30TB|Nitric Oxide agent
223470035|NCT07073638|DRUG|HRZE (Rifampicin, Isoniazid, Pyrazinamide, Ethambutol combination)|isoniazid 75 mg (H), rifampicin 150 mg (R), pyrazinamide 400 mg (Z), ethambutol 275 mg (E)
223470036|NCT07072130|OTHER|Control group (wet cotton)|The diaper area of the newborns in the control group was cleaned using only cottons moistened with boiled and warmed water. In the preparation stage, the cottons were placed in disposable containers and boiled and warmed water was poured over them to moisten the entire surface of the cottons. Excess water was removed by gently squeezing the cottons. After cleaning, the application was completed by drying the gland area with dry cotton.
223470037|NCT07072130|OTHER|Experimental group (baby oil-impregnated cotton)|Diaper area cleaning of newborns in the experimental group was performed only with cottons impregnated with baby oil. In the preparation of these cottons, a sufficient amount of baby oil was added to the cottons placed in disposable containers and the entire surface of the cottons was allowed to absorb the oil. Excess oil was removed by gently squeezing the cottons. After the cleaning process was completed, the diaper area was dried with dry cotton wool and the process was terminated.
223470038|NCT07072260|OTHER|Sham Stroking|Participants in this group receive a sham intervention consisting of light soft tissue stroking around the talocrural joint without joint manipulation. The application mimics the duration and setup of the experimental group but does not include any mechanical stimulus.
223470039|NCT07072260|OTHER|Activator Manipulation|Participants in this group receive a single session of activator-assisted manipulation using the Activator Adjustment Instrument (AAI) to the talocrural (ankle) joint. Six impulses (three anterior and three posterior) are applied with the ankle in a neutral position.
223470040|NCT07073651|OTHER|Moderate Intensity Aerobic Exercise|moderate intensity aerobic exercises (using treadmill training) 5 times per week for 12 weeks. Each participating child started the session with 5 minutes of warming-up exercises. Then the main exercise phase is performed at 50-60% of age-predicted peak heart rate using a treadmill for 30 minutes. Finally, a 5 min cool-down period is allowed, the total session took 40 minutes.
224159570|NCT03158090|DRUG|sandostatin|The patient will be treated in accordance with the advice of the local doctor in charge, and this study does not interfere with any treatment of the patient
224159571|NCT03158090|RADIATION|radiotherapy|The patient will be treated in accordance with the advice of the local doctor in charge, and this study does not interfere with any treatment of the patient
224159572|NCT04663542|PROCEDURE|immobilization duration|brace immobilization duration after open surgery for Achilles tendon rupture
224159573|NCT00481988|DEVICE|transcranial direct current stimulation|Two damp sponges, one placed on the left side of the forehead, the other on the left arm. 0.1mA of current is passed for 20 minutes.
224159574|NCT00481988|DEVICE|transcranial direct current stimulation|transcranial direct current stimulation delivers one milliamp of direct current, supplied by a constant current generator, the the left dorsolateral prefrontal cortex through a scalp electrode. The treatment is given for 20 minutes a day.
224159575|NCT00481988|DEVICE|transcranial direct current stimulation|one milliamp of direct current applied to the left dorsolateral prefrontal cortex through a scalp electrode
224159576|NCT00481988|DEVICE|iomed phoresor transcranial direct current stimulation|for the sham group the current is turned off after 10 seconds
224159577|NCT01229956|GENETIC|DNA methylation analysis|
224159578|NCT01229956|GENETIC|gene expression analysis|
223470041|NCT07073651|OTHER|Dietary Advices|The Obese adolescent children participated in the study received diet advices based on a balanced low calorie diet (1500 Kcal)
223470042|NCT07073651|OTHER|Virtual reality games exercise|Virtual reality games exercises 5 times per week for 12 weeks. Each participating child started the session with 5 minutes warming up exercises then followed by the main part which was consisted of 30 min of exercise where the child played the game using virtual reality X-Box and did different physical activities that included both the upper and lower extremities according to the game's requirements, and after that a 5 min cool-down part that involved some static flexibility exercises to allow the heart rate to lower, the total session that would be applied about 40 min (including 30 mins of Virtual reality exercises)
223470043|NCT07073131|OTHER|Vicryl Rapide suturing|Post episiotomy vicryl rapide suturing material is used for stitching episiotomy laceration.
223470044|NCT07073131|OTHER|Chromic catgut suturing|Post episiotomy chromic catgut suturing material is used for stitching episiotomy laceration
223470045|NCT07072273|OTHER|Probiotic Ointment|Ointment containing Lactobacillus reuteri BGR46
223470046|NCT07072780|DEVICE|Low-Level Laser Therapy (904 nm)|Low-level laser therapy using the LTU-904 device (RianCorp, Australia) at a wavelength of 904 nm, applied to the fibrotic area of the upper limb after CDPT.
223470047|NCT07072780|DEVICE|Low-Level Laser Therapy (650 nm)|Low-level laser therapy using the Salus Talent device (Remed, USA) at a wavelength of 650 nm, applied to the fibrotic area of the upper limb after CDPT.
223470048|NCT07072780|DEVICE|Sham Laser Therapy|Placebo laser therapy with no active laser emission, administered after CDPT.
223579092|NCT06373783|PROCEDURE|de- epithelize gingival graft|The area where the gingival recession occurred was prepared with the modified coronally positioned flap technique developed by Zuchelli. A shallow horizontal incision was made at ≈3 mm apical from the gingival margin of the maxillary molar teeth using a number 15 scalpel blade. Subsequently, a parallel horizontal incision, at ≈ 4 mm apical from the first horizontal incision, was traced in conjunction with two vertical releasing incisions to delineate a rectangular area. Then, the uppermost epithelial layer was scraped off using a size 11 scalpel tip. The connective tissue graft to be taken from the palate area was 10x5x2 mm in size, and the graft thickness was measured with an endodontic spreader from 3 points (mesial, buccal, and distal) and electronic caliper during surgery.
223579093|NCT06373783|DIAGNOSTIC_TEST|ultrasonography|"Clinical parameter measurements (probing depth (PD), clinical attachment level (CAL), gingival recession depth and width, keratinized tissue width and height) were taken on the day of surgery, the 3rd days, the 14th days, the 1st month, the 3rd months and the 6th months.~Ultrasonography measurements A 6-18 MHz intraoral probe was used in intraoral USG examinations. Sterile gel was applied to the intraoral probe and covered with a stretch film. Then, it was placed directly on the mucosal surface of the receiver site in the buccal area. Mucosal thickness was evaluated using the B-mode of the device, and vascularization was evaluated using the color doppler and pulsed wave doppler modes of the device. The following equation is used and calculated by US unit pulsatility index (PI) = (Vmax-Vmin) (Vmean) (Vmax is peak systolic flow velocity. Vmin is diastolic flow velocity and Vmean is mean flow velocity.) The mean PI values of each patient were measured."
223579094|NCT02662179|OTHER|Quality of life evaluation|Assess the quality of life ('SF-36' questionnaire) of patients 3 and 6 months after oncologic treatment. Since a diagnosis of frailness will have been established before the oncologic treatment, a correlation between the decline and the 'frail' categorization according to the Fried criteria can be established or denied.
224159579|NCT01229956|GENETIC|microarray analysis|
224159580|NCT01229956|GENETIC|reverse transcriptase-polymerase chain reaction|
224159581|NCT01229956|OTHER|laboratory biomarker analysis|
224159582|NCT03101449|OTHER|Finnish tube|Practice the exercise with Finnish tube before choir practice once a week for a period of 14 weeks.
223470049|NCT07072754|OTHER|Mind-body therapy|The yoga program, led by a physiotherapist who is also a certified yoga instructor , with two sessions per week lasting one hour each. Foam yoga blocks, belts, and armless chairs were also available in the classes, where the participants were to support compliance with the program. The yoga program was planned as 10 minutes of centering and breathing practice, 10 minutes of warm-up practice, 30 minutes of supine, standing, sitting, prone, and supine yoga postures, and 10 minutes of relaxation. New postures were introduced every two weeks as the program progressed. After the eight-week session, the participants were encouraged to continue the program at home twice a week
224159583|NCT03101449|OTHER|Staw phonation|Practice the exercise straw phonation before choir practice once a week for a period of 14 weeks.
224159584|NCT04373213|DIAGNOSTIC_TEST|Pleth variability index|The usefulness of Pleth variability index in predicting fluid response in patients with COVID 19
224159585|NCT04655690|DRUG|NNC0471-0119|Participants will be randomised to either of five dose levels 0.3, 0.6, 1.2, 2.4 or 3.6 of NNC0471-0119 nanomol per kilogram body weight, which will be administered as a single dose. NNC0471-0119 will be administered subcutaneously (s.c., under the skin) in fasting state.
224159586|NCT04655690|DRUG|Fast-acting insulin aspart|Participants will get a fixed dose of 0.2 units of fast-acting insulin aspart (Fiasp®) per kilogram body weight, administered subcutaneously (s.c., under the skin) in fasting state.
224304973|NCT04229459|DRUG|Cetuximab|Cetuximab 400mg/m2 IV on day 1 followed by 250mg/m2 IV weekly on induction chemotherapy, 250mg/m2 IV weekly on chemoradiation, 500mg/m2 IV on day 1 of each treatment cycle, every two weeks during immunotherapy
224304974|NCT04229459|DRUG|Nivolumab|Nivolumab 3mg/kg IV on day 1 of each treatment cycle, every two weeks during immunotherapy
224304975|NCT00822406|DRUG|homeopathic medicine|individualized homeopathic medicine
223470050|NCT07072754|OTHER|Exercise|Patients in the exercise group were given a program that included warm-up, low-impact aerobic, strengthening, and cooling phases, totaling 60 minutes, repeated twice a week for eight weeks. Aerobic exercise was performed by standing still for 25 minutes at moderate intensity based on perceived effort. Strengthening exercises included one set of 10 repetitions for each movement. Exercises were progressed according to the modified Borg's scale. Strengthening exercises included core muscles such as the deltoid, abdominals, quadriceps femoris, and hamstrings and were performed using body weight or elastic resistance bands
223470051|NCT07073053|DRUG|Semaglutide 1.0 mg|add-on current standard treatment which includes SGLT2 inhibitor
223470052|NCT07073053|DRUG|Semaglutide 0.5 mg|add-on current standard treatment which includes SGLT2 inhibitor
223470053|NCT07073677|DRUG|IN-115314 Ointment 1%|Twice daily(BID), for 56 day
223470054|NCT07073677|DRUG|IN-115314 Ointment 3%|Twice daily(BID), for 56 day
223470055|NCT07073677|DRUG|IN-115314 Ointment placebo|Twice daily(BID), IN-115314 Ointment Placebo for 28 days+ IN-115314 Ointment 3% for 28 days
223470056|NCT07072377|BEHAVIORAL|Intensity of Nutritional Intervention|Participants will either receive High or Low intensity nutritional support.
224159587|NCT02781415|PROCEDURE|Traditional Acupuncture Session|"Skin disinfection was made by an antiseptic solution in the sites of insertion and sterile acupuncture needles were used (0.25 x 0.5 mm).~Patients were installed in a seated position and needles were inserted perpendicularly through the skin to a depth of 1 - 2 cm until the De Qi was achieved.~The DeQi corresponds to a feeling of numbness and tingling within the range of acupoint, The insertion sites are represented by the urinary bladder meridian points to the side of the pain (UB21, UB22, UB23, UB24, UB26, UB45, UB46, UB47, UB48 and UB49)."
224159588|NCT02781415|DRUG|Morphine Titration|"Morphine was previously prepared by a study nurse by diluting a 10 mg / 1 ml flakon of morphine chlorhydrate in a 9 ml solution of serum saline to obtain a 10 ml preparation (1 ml = 1 mg).~An initial bolus of 0.1 mg per Kg of actual body weight of morphine chlorhydrate solution is administered.~A titration dose of 0.1 mg / Kg of body weight was repeated every 5 minutes' interval until reaching the therapeutic goal."
223470057|NCT07072377|BEHAVIORAL|Remote or In-Person|Patients will either receive their support in-person or remotely.
223470058|NCT01778413|DRUG|ATRIPLA|
223470059|NCT06148792|DRUG|Tafenoquine|oral treatment
223470060|NCT06148792|DRUG|Primaquine|oral treatment
223470061|NCT07073352|DIETARY_SUPPLEMENT|Nicotinamide Riboside|Participants will consume 1,000 mg of nicotinamide riboside (NR) upon waking and with an evening meal, and complete a daily supplementation log to assist with compliance monitoring. NR is a naturally occurring vitamin B3 derivative readily taken up by cells as a direct NAD+ precursor. Similar NR supplementation protocols are well-tolerated, boost NAD+ concentrations by \~100-140% achieving a steady state within 1-2 weeks, and increase SIRT activity in humans.
223470062|NCT07073352|DIETARY_SUPPLEMENT|Placebo|Participants will consume 1,000 mg of placebo (microcrystalline cellulose) upon waking and with an evening meal, and complete a daily supplementation log to assist with compliance monitoring.
223470063|NCT07072182|DEVICE|Palatal wound will be covered with Ora-aid patch|Palatal wound will be covered with Ora-aid patch
223470064|NCT07072182|DEVICE|Palatal wound will be covered with Composite stent|Palatal wound will be covered with Composite stent
223470065|NCT07072182|COMBINATION_PRODUCT|Palatal wound will be covered with PRF|Palatal wound will be covered with PRF
223470066|NCT07073326|OTHER|HYPOTRAIN|8 weeks of 2/3 times per week, 1-h aerobic training (walking on a treadmill at 60-65% HRmax) while wearing a mask and air is delivered between 15 and 16 FiO2%
223470067|NCT07073326|OTHER|NORMOTRAIN|8 weeks of 2/3 times per week, 1-h aerobic training (walking on a treadmill at 60-65% HRmax) while wearing a mask and air is delivered between at normal (around 21) FiO2%
223470068|NCT07072936|BEHAVIORAL|mediterranean diet|All questions of the intervention group, in which behavioural change was expected, were answered by the dietitian throughout the study and compliance with the diet was monitored with food consumption records.
223470069|NCT06259695|DEVICE|Adjustable Aquatic Therapy Prosthesis|We will recruit up to three participants, who will attend up to two fitting appointments lasting up to one hour to assist in the design development. After the design of the prosthesis is completed, participants will attend three, 30-minute, aquatic therapy sessions with a physical therapist trained in aquatic therapy and utilize the prosthesis.
223470070|NCT06780930|DRUG|Vorasidenib|For oral administration once daily
223470071|NCT06780930|DRUG|Placebo|For oral administration once daily
223470072|NCT04236908|DRUG|NSAIDS|Naproxen 500mg by mouth twice a day as needed.
223470073|NCT04236908|DEVICE|Battlefield Acupuncture|"Battlefield Acupuncture in both ears (which includes the points cingulate gyrus, thalamus, omega-2, point zero and shen men).~Battlefield acupuncture utilizes up to 10 ASP acupuncture needles (5 in each ear). The Battlefield Acupuncture points include: cingulate gyrus, thalamus, omega-2, point zero, and shen men. The semi-permanent needles are left in place and typically stay in place for 2-7 days. Needles will usually fall out on their own, can be removed by the patient or the patient can call study staff and come in for removal if desired."
223470074|NCT04236908|DEVICE|GV26 with manual tonification|"Acupuncture to include use of GV 26 with manual tonification (twisting or rotating the needle).~The protocol for using GV26 is as follows: With the patient in a seated position the acupuncturist places a 40mm needle in the acupuncture point GV26 (located on the philtrum, on the anterior midline, at the junction of the upper 1/3 and lower 2/3 of the distance from the nose to the margin of the upper lip). The acupuncturist then rapidly rotates the needle at the handle clockwise and counterclockwise (known as manual tonification) for 20-40 seconds at a time. The patient then stands up and assesses their pain. This will be performed up to 6 cycles. If a patient is unable to sit or stand, this may also be performed in a supine position with the patient attempting to sit or stand every 20-40 seconds."
223470075|NCT06497504|DRUG|Bepirovirsen|Bepirovirsen will be administered.
223470076|NCT06497504|DRUG|Placebo|Placebo will be administered.
223470077|NCT07072741|OTHER|Shamiri Queen of Katwe Intervention|The intervention involves screening the film Queen of Katwe to high school students in a school setting.
223470078|NCT07072806|DRUG|Letibotulinum toxin A|Letibotulinum toxin A (Botulax) is a botulinum toxin type A formulation developed for aesthetic indications. In this trial, it was administered as the test intervention. Each participant received 2 units injected at four forehead sites (total 8 units), diluted to 20 U/mL, on one side of the forehead. The diffusion characteristics and efficacy were compared with those of onabotulinum and prabotulinum toxin A in a double-blind, randomized, split-face design.
223470079|NCT07072806|DRUG|Prabotulinum toxin A|Prabotulinum toxin A (Nabota) is a botulinum toxin type A product approved for aesthetic use in South Korea and other countries. It was used as a comparator agent in this trial. Participants received subcutaneous injections at four forehead sites (2 units per site, 8 units total), diluted to 20 U/mL, on one side of the forehead in a randomized, split-face design.
223470080|NCT07072806|DRUG|Onabotulinum toxin A|Onabotulinum toxin A (Botox) is an FDA-approved botulinum neurotoxin type A formulation used for cosmetic treatment of glabellar lines and other facial wrinkles. In this study, it was injected subcutaneously into the forehead at four standardized sites at a dose of 2 units per site (8 units total), diluted to 20 U/mL, and used as a comparator in the split-face design.
223470081|NCT07073118|DEVICE|Endovascular treatment with placement of a flow-diverting stent|Flow diverter stents (FDS) are braided stents with specific porosity that promotes the flow redirection within the parent vessel and outside the aneurysm sac, and the endothelialization. The FDS placed in the parent artery and covering the aneurysm sac will promote the intra-aneurysmal blood stagnation and parent vessel wall healing. All of these promoting, the aneurysm's thrombosis and ist regression
223470082|NCT07073287|DEVICE|Cerebello-spinal direct current stimulation|csDCS influences both ascending and descending spinal pathways and reflex excitability, promoting prolonged functional neuroplastic changes.
223470083|NCT07073287|DEVICE|Sham Comparator|Masking for cerebello-spinal direct current stimulation involves the electric current stopping after 30 seconds, providing a sensation without producing neuromodulation.
223470084|NCT06290622|DRUG|Retifanlimab, INCAGN02385, INCAGN02390|"Treatment:~Retifanlimab -infused over 60 minutes for C1D1 followed by a 60-minute observation period. If no infusion related reactions are observed infusion may be reduced to 30 minutes and no further observation period is needed for future cycles. If there is a reaction continue with 60 minute infusion and observation period for following cycle. Retifanlimab should always be administered first.~INCAGN02385 and INCAGN02390 -individually administered over 30 minutes one after another. For first infusions of retifanlimab, INCAGN02385 and INCAGN02390, a 4 hour observation period is necessary after completion of all infusion. If no infusion related reactions are observed, for subsequent infusions no further observation period is needed for future cycles."
223470085|NCT06935188|DRUG|Dalpicilib combined with cetuximab|The participants receive cetuximab in combination with Dalpiciclib until termination criteria are met. Participants receive cetuximab intravenously at a dose of 500 mg/m2 biweekly, or an initial dose of 400 mg/m² followed by weekly maintenance dose of 250 mg/m2. Dalpiciclib is administered orally at a dose of 150 mg once daily for 21 consecutive days, followed by a 7-day break. Each 28 days were deemed as a treatment cycle. If the patient vomits or misses a dose, it should not be made up on the same day. The next dose should be taken as usual.
223470086|NCT06935188|DRUG|cetuximab|The participants receive cetuximab alone until termination criteria are met. Participants receive cetuximab intravenously at a dose of 500 mg/m2 biweekly, or an initial dose of 400 mg/m² followed by weekly maintenance dose of 250 mg/m2.
223470087|NCT01009853|DRUG|Codeine Sulfate|15 mg tablet
223579095|NCT02662179|OTHER|Functional decline assessment|Assess functional decline ('Katz ADL' Score and 'Lawton IADL' Score) 3 and 6 months after oncologic treatment. Since a diagnosis of frailness will have been established before the oncologic treatment, a correlation between the decline and the 'frail' categorization according to the Fried criteria can be established or denied.
223579096|NCT02662179|OTHER|Physical decline assessment|Assess physical decline (walking speed and prehension force) 3 and 6 months after oncologic treatment. Since a diagnosis of frailness will have been established before the oncologic treatment, a correlation between the decline and the 'frail' categorization according to the Fried criteria can be established or denied.
223579097|NCT02662179|OTHER|Cognitive decline assessment|Assess cognitive decline 3 and 6 months ('MMSE 30' questionnaire) after oncologic treatment. Since a diagnosis of frailness will have been established before the oncologic treatment, a correlation between the decline and the 'frail' categorization according to the Fried criteria can be established or denied.
223470088|NCT02507076|DRUG|isolated limb perfusion|Undergo ILP with melphalan
223470089|NCT02507076|DRUG|melphalan|Undergo ILP with melphalan
223470090|NCT02507076|PROCEDURE|quality-of-life assessment|Ancillary studies
223579098|NCT02973568|OTHER|Observational Study|
223579099|NCT01897649|DIETARY_SUPPLEMENT|NUTRIOSE FB06|15g/day NUTRIOSE FB06
223579100|NCT01897649|DIETARY_SUPPLEMENT|GLUCIDEX 21|15g/day GLUCIDEX 21
224159589|NCT03080051|DRUG|[18F]MNI-952|Subjects will undergo PET imaging using \[18F\]MNI-952, a PET radioligand for imaging tau.
224159590|NCT03080051|DRUG|[18F]Florbetapir|Subjects with Alzheimer's disease will receive a \[18F\]florbetapir scan to compare distribution of tau in the brain compared to that of \[18F\]MNI-952.
224159591|NCT05821192|DRUG|Rituximab|375mg/m2 by IV infusion once every 3 weeks
223470091|NCT03071601|DRUG|Lidocaine-Prilocaine Cream 2.5-2.5%|Topical anesthesia using a cream containing 2.5% Lidocaine and 2.5 % Prilocaine for at least 30 minutes on and around the wound before suture
223470092|NCT03071601|DRUG|Lidocaine 1% Epinephrine 0.005mg/mL solution|Local anesthesia by subcutaneous injection of a solution containing 1% Lidocaine and 0.005mg/mL Epinephrine in and around the wound in the minutes preceding the suture of the wound
223470093|NCT01528371|DRUG|Midazolam|"1. Investigators select subject from patients for whom the doctor has ordered intravenous sedation. Inclusion criteria is SBP\>=140mmHg or DBP\>=90mmHg measuring when the patient sits on dental chair and has settled down for 5 minutes. Informed consent is obtained from the patient.~2. Patient conducts Japanese version of STAI and VAS about anxiety to dental treatment.~3. Investigators take venous line on the upper limb and inject the drug (midazolam at dose of 0.02mg/kg) intravenously. Investigators measure blood pressure, heart rate, and oxygen saturation every 2 minutes until 10 minutes after drug administration.~4. 10 minutes later, patient conducts Japanese version of STAI and VAS about anxiety to dental procedure again.~5. Investigators inject an additional sedative agent and the dental treatment is started."
223579101|NCT01174017|RADIATION|Iodine 125 standard loose brachytherapy seeds|radioactivity 0.4 U per seed, prescribed dose 144 Gy
223579102|NCT01174017|RADIATION|AnchorSeed Iodine 125 brachytherapy prostate implant|activity 0.4 U per seed, prescribed dose 144 Gy
223579103|NCT02964832|DEVICE|Grasp method|
223579104|NCT02964832|DEVICE|Armband-in-hand method|
223579105|NCT02964832|DEVICE|Armband-on-arm method|
223579106|NCT06367907|OTHER|schema therapy|In this study, we aim to investigate the mode of action of the core therapeutic techniques implemented in schema therapy (ST), a psychotherapy that particularly addresses deficits of emotion regulation and of social interaction in personality disorders.
223579107|NCT04416607|DRUG|Corifollitropin Alfa|Primary outcome measure is ovarian response measured by FORT. Drugs are administrated for controlled ovarian stimulation prior in vitro fertilization.
224159592|NCT05821192|DRUG|Gemcitabine|1 g/m2 on Days 1 by IV infusion once every 3 weeks
224159593|NCT05821192|DRUG|Dexamethasone|40 mg on Days 1 to 4 of each 3-week cycle by IV infusion
224159594|NCT05821192|DRUG|Cisplatin|75 mg/m2 on Days 1 by IV infusion once every 3 weeks
224159595|NCT05821192|DRUG|PD-1 monoclonal antibody|200mg on Days 2 by IV infusion once every 3 weeks
223470094|NCT01528371|DRUG|Normal Saline Solution (NSS)|"1. Investigators select subject from patients for whom the doctor has ordered intravenous sedation. Inclusion criteria is SBP\>=140mmHg or DBP\>=90mmHg measuring when the patient sits on dental chair and has settled down for 5 minutes. Informed consent is obtained from the patient.~2. Patient conducts Japanese version of STAI and VAS about anxiety to dental treatment.~3. Investigators take venous line on the upper limb and inject the drug (saline solution at dose of 0.004ml/kg) intravenously. Investigators measure blood pressure, heart rate, and oxygen saturation every 2 minutes until 10 minutes after drug administration.~4. 10 minutes later, patient conducts Japanese version of STAI and VAS about anxiety to dental procedure again.~5. Investigators inject an additional sedative agent and the dental treatment is started."
223470095|NCT05005598|OTHER|catheter dysfunction|prevalence of catheter dysfunction
223470096|NCT00884442|DRUG|Nifedipine (Gen-nifedipine extended release, previously referred to as Gen-Nifedipine XL)|60 mg nifedipine
223470097|NCT00884442|DRUG|Nifedipine (Bayer Healthcare AG manufactured as Adalat® XL®, Adalat® LA, Adalat® Crono, Adalat® OROS)|60 mg nifedipine
223470098|NCT01152671|DRUG|Placebo|single oral dose
223470099|NCT01152671|DRUG|RO5024048|single oral dose
223470100|NCT01493622|DRUG|minocycline|variable dose SGA and minocycline,100mg per capsule po（take orally） bid，16 weeks；
223470101|NCT01493622|DRUG|placebo|variable dose SGA and 100mg per capsule po（take orally） bid，16 weeks；
223470102|NCT06134063|DRUG|Xuanfei Baidu granule|Xuanfei Baidu granule will be administered twice daily for 7 days on the basis of basic treatment
223470103|NCT06134063|DRUG|Xuanfei Baidu granule Placebo|Xuanfei Baidu granule Placebo will be administered twice daily for 7 days on the basis of basic treatment
223470104|NCT01571843|OTHER|Forearm exercise program|Participants assigned to forearm exercise will receive training in forearm strengthening exercises from a doctoral occupational therapy student. Participants will be taught 8 exercises and are performed at home. The exercise program is designed to take about 30 minutes per session.
223470105|NCT01571843|OTHER|Walking program|Walking will consist of 30 minutes at a moderate pace every other day for 52 weeks. The walking program for all participants constitutes the control/placebo comparator.
223470106|NCT02859298|DEVICE|Uterine Cervix Polarimetric Imaging|Polarimetric imaging is a promising optical technique that can provide information in large field and potentially in vivo about the abundance and 3D structure of collagen. Images will be taken with a polarimetric colposcope. As the imaging is realized with visible light from classical sources (lamps or LEDs, neither lasers or other high intensity sources, nor any ionizing UV radiation) and without any chemicals, it is totally innocuous, just like the intensity imaging used in conventional colposcopy.
224159596|NCT01673425|DRUG|Live Attenuated Influenza Vaccine|All participants will be given FluMist.
223470107|NCT00916578|RADIATION|Radiation Therapy|50-57 Gy per faction once or twice a day, 5 days a week, for about 5 -7 weeks, about 15-30 minutes each time.
223470108|NCT00916578|DRUG|Capecitabine|During 5-7 weeks of radiation therapy, 825 mg/m2 (pills) by mouth, 2 times a day, about 12 hours apart, 30 minutes after eating food and about 2 hours before radiation therapy.
223470109|NCT00001038|DRUG|Valacyclovir hydrochloride|
223470110|NCT00001038|DRUG|Acyclovir|
223470111|NCT03847571|DRUG|Acetazolamide|Correction of metabolic alkalosis by inhibition of the filtered bicarbonate load reabsorption in the proximal tubules using acetazolamide (AZ)
223470112|NCT03272204|BEHAVIORAL|No pubic hair|Natural pubic hair to fully removed pubic hair
223470113|NCT03272204|BEHAVIORAL|Pubic Hair|Removed pubic hair to natural pubic hair
223470114|NCT02117518|OTHER|blood drawing|
224159597|NCT02613988|DEVICE|3 Tesla magnetic resonance imaging|High resolution structural imaging (contrast-enhanced T1-weighted image, T2-weighted image, Fluid-attenuated inversion recovery)
223470115|NCT00641563|DRUG|Dexmedetomidine|Infusion of dexmedetomidine
223470116|NCT00641563|DRUG|Midazolam|Midazolam infusion
223470117|NCT00641563|DRUG|Remifentanil|Infusion of remifentanil
223579108|NCT04416607|DRUG|Menotropins|Primary outcome measure is ovarian response measured by FORT. Drugs are administrated for controlled ovarian stimulation prior in vitro fertilization.
224159598|NCT02613988|DEVICE|Chemical exchange saturation transfer MRI|Amide proton transfer-weighted image
224159599|NCT02613988|DEVICE|Diffusion weighted MRI|diffusion-weighted image with b value 0, 1000, and 3000
224159600|NCT02613988|DEVICE|Dynamic susceptibility contrast MRI|dual echo EPI sequence
224159601|NCT01525420|BEHAVIORAL|Acceptance Therapy (ACT)|ACT
223470118|NCT00934375|DRUG|Aricept (donepezil hydrochloride)|5 mg or 10 mg of donepezil hydrochloride (Aricept) taken orally once a day.
223470119|NCT00934375|DRUG|placebo|
223470120|NCT04243278|DRUG|Low-dose aspirin|81 mg of low dose aspirin PO for 6 months
223470121|NCT04243278|DRUG|Placebo oral tablet|placebo PO for 6 months
223470122|NCT00729742|DRUG|Comparator: erlotinib + dalotuzumab|"Part II: All patients will receive 1 week of erlotinib 150 mg tablets per day.~Arm 1: Patients who experience a PET response will continue on erlotinib monotherapy until disease progression.~Arm 2: Patients who fail to receive a PET response will continue to take erlotinib in combination with dalotuzumab 10 mg/kg IV infusion once weekly. At the time of disease progression, patients on erlotinib monotherapy will be offered to crossover to dalotuzumab 10 mg/kg IV infusion once weekly in combination with erlotinib."
223470123|NCT00729742|DRUG|Comparator: erlotinib monotherapy|Part I: All patients will receive erlotinib 150 mg tablets per day until disease progression.
223579109|NCT00062608|BEHAVIORAL|Written self-disclosure|
223579110|NCT05331703|OTHER|designed physical therapy program in addition to program of virtual reality.|physical therapy program in addition to program of virtual reality.
223579111|NCT05331703|OTHER|designed physical therapy program in addition to program of mirror therapy.|physical therapy program in addition to program of mirror therapy.
224159602|NCT01525420|OTHER|Cognitive Behavioral Therapy (CBT)|CBT
224159603|NCT04682249|DRUG|Systemic Chemotherapy|Systemic Chemotherapy (Oxaliplatin#5-fluorouracil and leucovorin)
224159604|NCT04682249|DRUG|Sintilimab|Sintilimab
224159605|NCT04682249|DRUG|Apatinib|Apatinib
224159606|NCT06268509|DIAGNOSTIC_TEST|Nutritional panel laboratory examination|As stated in group description
224159607|NCT06268509|DIETARY_SUPPLEMENT|Pregnancy supplements (other than provided by Ministry of Health)|As stated in group description
223579112|NCT01592617|DRUG|S-488410|In multicenter HLA-blinded open study, patients will be vaccinated subcutaneously once a week with S-488410 (S-488401, S-488402, S-488403, 1mg each).
223470124|NCT01782339|DRUG|Combination Chemotherapy|"4 cycles of: Day 1 Actinomycin D 1mg/m2, Paclitaxel 80mg/m2, Methotrexate Day 4 Oxaliplatin 100mg/m2 Pegfilgrastim 6mg Day 8\* Paclitaxel 80mg/m2 Day 15 Paclitaxel 80mg/m2~\*Day 8 will be omitted for the first three patients treated in this study and will be given at the end of treatment in a fifth cycle where Paclitaxel 80mg/m2 will be administered on Days 1, 8, 15 and 22. Before adding the extra Paclitaxel 80mg/m2 dose on day 8 the safety data for these patients will be reviewed by a DMC.~NB This 5th cycle for patients 1-3 has been included to ensure that the four 'missed doses of paclitaxel are not omitted from the patients treatment regimen. Cycles 1-4 are 21 days cycles; Cycle 5 (for the first three patients only) is a 28 day cycle."
223470125|NCT00860639|DRUG|gemtuzumab ozogamycin|gemtuzumab ozogamycin = 6mg/m² during the induction course (Day 4) gemtuzumab ozogamycin = 6mg/m² during the first intensive consolidation course (Day 4)
223470126|NCT02019355|DRUG|5-fluorouracil 5% cream|
223470127|NCT02019355|DRUG|Calcipotriol 0.005% ointment|
223470128|NCT02019355|DRUG|Vaseline|
223579113|NCT00099229|DRUG|Licarbazepine|
223579114|NCT04408417|DEVICE|Prototype child safety seat with tension indicator lights|The prototype child safety seat is a convertible rear-facing seat with a harness system that includes tension indicator lights.
223579115|NCT04408417|DEVICE|Control child safety seat|The control child safety seat is a convertible rear-facing seat without tension indicator lights.
223579116|NCT03135925|OTHER|Supervised Exercise Program|Participants will be invited to attend a weekly supervised exercise program over six weeks, in the time before their bone marrow transplantation
223579117|NCT00525629|DIETARY_SUPPLEMENT|Walnuts|48 Grams of Walnuts Daily
223579118|NCT00525629|DIETARY_SUPPLEMENT|Control|Control Diet with No Walnuts
223579119|NCT01651390|DEVICE|Percutaneous coronary intervention|Up to 140 patients meeting the inclusion criteria and none of the exclusion criteria are randomly selected and stratified according to diabetic status at screening are treated with the Pantera Lux drug coated balloon.
223743724|NCT07190235|DEVICE|Transcranial Magnetic Stimulation|The repetitive transcranial magnetic stimulation (rTMS) at different frequencies will deliver 10 sessions over 2 weeks. The participants will receive 25 Hz rTMS, 1 Hz rTMS, or sham stimulation protocol to the supplementary motor area while seated using a double-cone coil connected to a transcranial magnetic stimulator.
224159608|NCT06268509|DIAGNOSTIC_TEST|Fetomaternal ultrasound|As stated in group description
224159609|NCT03383068|DRUG|Acarbose 100 MG|for metformin uneffective subjects, using acarbose for 3 months
224159610|NCT03383068|DRUG|Exenatide|for metformin uneffective subjects, using Exenatide for 3 months
224159611|NCT03383068|DRUG|Orlistat|for metformin uneffective subjects, using Orlistatfor 3 months
224159612|NCT03383068|DRUG|Metformin|metformin effective subjects,act as control group
224159613|NCT02052323|DRUG|Artesunate/mefloquine (AS/MQ)|"* artesunate (AS) 4mg/kg by mouth once daily at 0, 24 and 48 hours~* mefloquine (MQ) 15mg/kg by mouth once at 72 hours, and 10mg/kg once by mouth at 84-96 hours~* primaquine (PQ) 0.5mg/kg single dose by mouth at 84-96 hours"
224159614|NCT06087094|DRUG|HRS-7450 ；Placebo|HRS-7450 or Placebo
224159615|NCT00776490|DRUG|Glimepiride 1mg Tablets|
224159616|NCT06347692|OTHER|antigravity treadmill|An Alter G treadmill (Alter G Pro 200, Alter G Inc, USA) was used to provide training to the patients in the antigravity treadmill group. The Alter G allows the patient to change their body weight from 20% to 100% in 1% increments. The air pressure inside the lower body positive pressure chamber can be adjusted from 0 to 2.0 kilopascal above atmospheric pressure. They are very comfortable to train in for long periods of time and have simple controls for adjusting body weight, speed, and inclination.
224304976|NCT00822406|DRUG|placebo|placebo - 6 months
223470129|NCT02262897|DRUG|Nab-paclitaxel|Nab-paclitaxel weekly chemotherapy 130mg/m2, d1,8,15,every 4 week or Nab-paclitaxel chemotherapy once a time with a dose of 230 mg/m2 every 3 weeks
223470130|NCT05601349|BEHAVIORAL|Telehealth-based strategy|Teleducation course, based on the CPG recommendations
223470131|NCT00945243|DEVICE|Zero-P|The Zero-P PEEK is a stand-alone device intended for use in cervical interbody fusion. The device consists of a plate and a spacer with four rigid screws to provide similar stability to a traditional cervical plate and interbody spacer. It is intended for use in skeletally mature patients with symptomatic cervical disc disease (SCDD) with accompanying radicular symptoms, at one level from C3 to C7.
223470132|NCT03256578|DEVICE|New Life Box Respiratory Function Monitor|The intervention is the use of a visible New Life Box Respiratory Function Monitor display in infants born between 24 and 27 6/7 weeks gestation receiving PPV for resuscitation after birth.
223579120|NCT01651390|DEVICE|Percutaneous coronary intervention|Up to 70 patients meeting the inclusion criteria and none of the exclusion criteria are randomly selected and stratified according to diabetic status at screening are treated with the Orsiro drug eluting stent.
223579121|NCT05528900|DIAGNOSTIC_TEST|allergy test|allergy test are oral food challenge , prick test and IgE blood rate
223579122|NCT05500300|DEVICE|Neo-Russian|"Subjects will receive Neo-Russian electrical stimulation with three reps (5 sec work x 60 sec rest), and the Maximal Electrical Induced Contraction (MEIC) will be measured.~They will be asked how uncomfortable the stimulation was, using Visual Analogue Scale (VAS).~One week later, subjects will receive a fatigue protocol that consists in 21 reps (5 sec work x 5 sec rest), and the Maximal Electrical Induced Contraction (MEIC) will be measured for each contraction."
223579123|NCT05500300|DEVICE|Aussie|"Subjects will receive Aussie electrical stimulation with three reps (5 sec work x 60 sec rest), and the Maximal Electrical Induced Contraction (MEIC) will be measured.~They will be asked how uncomfortable the stimulation was, using Visual Analogue Scale (VAS).~One week later, subjects will receive a fatigue protocol that consists in 21 reps (5 sec work x 5 sec rest), and the Maximal Electrical Induced Contraction (MEIC) will be measured for each contraction."
223743725|NCT07191496|OTHER|Questionnaire|The questionnaires include the Ferrans and Powers QLI, EORTC QLQ-C30, FCR-7 Scale, HADS, and MOS Social Support Survey.
223743726|NCT07189910|DRUG|Eltrombopag|Participants assigned to the observation group will be treated with eltrombopag oral suspension (EPAG-pfos).
224304977|NCT02752906|BIOLOGICAL|Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine|0.5 milliliter (mL), Intramuscular
223470133|NCT04694092|DRUG|Intensive heart rate control with landiolol|Intensive heart rate control preferably with the use of short-acting betablocker landiolol in combination with digoxin
223470134|NCT04694092|DRUG|Standard approach to heart rate control|Standard heart rate control with intravenous or oral beta-blockers and/or antiarrhythmic in combination with digoxin
223470135|NCT05974761|OTHER|massage|The patient was placed in a lateral decubitus position with the physician standing on the ventral side of the patient, with the crotch resting on the anterior edge of the superior iliac crest, and the elbow rising from the medial side of the highest point of the superior iliac crest, follow the palpation (avoiding the L3 transverse process) along the steep edge of the skeleton slowly toward the spine, and focus on the painful points or cords by repeatedly applying the elbow press method and the elbow flick method for 1-2 minutes, and then the elbow tip contact to find the sinew knot and along the vertical direction of 3-5 times, the force should be deep penetration.
223470136|NCT05974761|OTHER|Traditional Chinese massage|Through the point, massage, bone-setting treatment
223470137|NCT02266017|BEHAVIORAL|Pain Coping Skills Training|
223470138|NCT05771870|OTHER|Peer mentoring|"Mentoring is a support network in which a more talented or experienced individual serves as a role model for a less talented individual in order to encourage professional and personal growth. Mentoring improves students' learning, abilities, and self-efficacy while decreasing stress and anxiety in nursing students through more effective communication, collaborative learning, and critical thinking.~After understanding about the study, two master's degree students from Karabük University Institute of Graduate Studies of Child Health and Diseases Nursing consented to participate on a volunteer basis and became peer mentors in the study. All postgraduate students are pediatric nurses with at least two years of clinical experience who have completed their undergraduate nursing program."
223470139|NCT05771870|OTHER|Nurse mentoring|"Mentoring is a support network in which a more talented or experienced individual serves as a role model for a less talented individual in order to encourage professional and personal growth. Mentoring improves students' learning, abilities, and self-efficacy while decreasing stress and anxiety in nursing students through more effective communication, collaborative learning, and critical thinking.~After providing information about the research to bachelor's degree nurses who have worked in the Children's Units of Karabuk Training and Research Hospital for at least two years, two mentors for the nurse mentoring group were chosen on a volunteer basis. Mentors were taught on the concept of mentoring, the roles of the mentor, interpersonal relationships, and communication skills prior to the study."
223470140|NCT04492423|DIAGNOSTIC_TEST|VerifyNow PRUTest|VerifyNow PRUTest for platelet aggregation
223470141|NCT05796713|OTHER|Hydrocephalus|Interview
223470142|NCT01321671|DRUG|Pregabalin controlled release, 330 mg, 600- 750 calorie|A single oral dose of 330 mg controlled release tablet administered following a 600 to 750 calorie evening meal
223470143|NCT01321671|DRUG|Pregabalin controlled release, 330 mg, fasted|A single oral dose of 330 mg controlled release tablet administered fasted in the evening
223470144|NCT01321671|DRUG|Pregabalin immediate release, 300 mg|A single oral dose of 300 mg immediate release capsule administered in the evening
223470145|NCT00683228|BEHAVIORAL|Counseling|Consecutive newborns exposed to secondhand smoke will be recruited into the study and randomized to have parents receive or not receive specific counselling on harmful effects of SHS exposure. Urine cotinine will be measured at several points during the study for each group
223470146|NCT00405171|DRUG|Nevirapine|
223470147|NCT03756415|DEVICE|"DiMax Zero Total face mask R,"|a non-CO2 rebreathing device included directly in the full face mask
223579124|NCT05500300|DEVICE|RBS|"Subjects will receive RBS electrical stimulation with three reps (5 sec work x 60 sec rest), and the Maximal Electrical Induced Contraction (MEIC) will be measured.~They will be asked how uncomfortable the stimulation was, using Visual Analogue Scale (VAS).~One week later, subjects will receive a fatigue protocol that consists in 21 reps (5 sec work x 5 sec rest), and the Maximal Electrical Induced Contraction (MEIC) will be measured for each contraction."
223579125|NCT05500300|DEVICE|RBS-IPI|"Subjects will receive RBS-IPI electrical stimulation with three reps (5 sec work x 60 sec rest), and the Maximal Electrical Induced Contraction (MEIC) will be measured.~They will be asked how uncomfortable the stimulation was, using Visual Analogue Scale (VAS).~One week later, subjects will receive a fatigue protocol that consists in 21 reps (5 sec work x 5 sec rest), and the Maximal Electrical Induced Contraction (MEIC) will be measured for each contraction."
223579126|NCT05500300|DEVICE|HIFEM|"Subjects will receive HIFEM electrical stimulation with three reps (5 sec work x 60 sec rest), and the Maximal Electrical Induced Contraction (MEIC) will be measured.~They will be asked how uncomfortable the stimulation was, using Visual Analogue Scale (VAS).~One week later, subjects will receive a fatigue protocol that consists in 21 reps (5 sec work x 5 sec rest), and the Maximal Electrical Induced Contraction (MEIC) will be measured for each contraction."
223579127|NCT02191839|DRUG|Alpha 1-Antitrypsin|
223743727|NCT07189910|OTHER|Placebo|Participants in the control group will receive a placebo at the same dose, instead of eltrombopag oral suspension (EPAG-pfos).
224159617|NCT06347692|OTHER|physical therapy exercise program|Both groups received the same traditional physical therapy program for 12 weeks, three times a week, for 30 min each. The conventional physical therapy treatment consisted of acupuncture transcutaneous electrical nerve stimulation, Hot moist pack, Ultrasound and quadriceps setting
224159618|NCT02001506|DRUG|FEC3-D3|"Fluorouracil 500 mg/m2, every 3 weeks Epirubicin 100 mg/m2, every 3 weeks Cyclophosphamide 500, every 3 weeks~Docetaxel 75 mg/m2, every 3 weeks"
224159619|NCT00882830|PROCEDURE|EMS|EMS sessions on both lower extremities (quadriceps and peroneus longus) simultaneously.
223470148|NCT03756415|DEVICE|traditional face mask|a traditional mask without a non-CO2 rebreathing device included directly in the full face mask
223470149|NCT05251350|PROCEDURE|surgery|our study is observational and we use secondary data
223470150|NCT03160391|BEHAVIORAL|Music Training|Training curriculums were developed using guidelines set by the Ontario Ministry of Education (The Ontario Curriculum, 2009) for teaching music to grades 1 to 3. Music was delineated into duration, pitch, dynamics and other expressive controls, timbre, texture/harmony, and form. training included direct instruction and group activities. All training programs had the same structure: a warm-up period, following by instruction from a teacher, and then group activities to practically demonstrate the concepts learned. Both programs involved working towards a variety of ensembles.
223470151|NCT03160391|BEHAVIORAL|Dance Training|As with music training, dance was operationally defined by fundamental concepts for the art form, namely elements for body, space, time, energy, and relationship. The intervention involved both individual and group activities, with a combination of instruction and practical activities, and preparation for a final performance.
223470152|NCT03586310|DEVICE|ear-EEG|soft silicone electrode array placed in each ear (outer ear-canal and concha), connected to a battery powered EEG amplifier.
223470153|NCT04437758|DIETARY_SUPPLEMENT|Collagen and Vitamin C powder mix nutritional intervention|20 g collagen + 50 mg vitamin C daily, 60 min prior to exercise
223470154|NCT04437758|OTHER|Maltodextrin placebo powder|20 g maltodextrin placebo daily, 60 min prior to exercise
223470155|NCT04437758|OTHER|Maximum power training exercise|Explosive/power-based exercise training program 3 times/week at home consisting of drop jumps, box jumps, weighted jump squats loaded in a progressive manner weekly for 3 weeks. At baseline and at the end of each of the 3 weeks, measures of explosive performance are assessed in the lab (maximal isometric squat, counter-movement jump and squat jump)
223470156|NCT02007317|DRUG|Oshadi D & Oshadi R|Anti tumor agents
223470157|NCT03332186|DRUG|BMS-986231|Intravenous infusion administration
223470158|NCT00648180|DRUG|Doxycycline Monohydrate Tablets 100 mg|100mg, single dose fed
223470159|NCT00648180|DRUG|Adoxa Tablets 100 mg|100mg, single dose fed
223470160|NCT00004862|BIOLOGICAL|filgrastim|
223470161|NCT00004862|BIOLOGICAL|oblimersen sodium|
223470162|NCT00004862|DRUG|cytarabine|
223470163|NCT00004862|DRUG|fludarabine phosphate|
223470164|NCT03028142|DRUG|1.5 mg RPL554 plus tiotropium|
223470165|NCT03028142|DRUG|6 mg RPL554 plus tiotropium|
223470166|NCT03028142|DRUG|Placebo plus tiotropium|
223470167|NCT02644044|DRUG|Intrathecal methotrexate|12.5 mg of methotrexate diluted to a concentration of up to 4 mg/mL in 0.9 percent sodium chloride with 4 mg Dexamethasone via lumbar puncture needle.
223470168|NCT00125450|PROCEDURE|Chest Physiotherapy with Forced Expiratory Technique|Chest Physiotherapy with Forced Expiratory Technique
223470169|NCT00125450|PROCEDURE|Nasopharyngeal Aspiration|Nasopharyngeal Aspiration
223470170|NCT02810418|DRUG|LMB-100|Arms A1 and A2 (short infusion): Administered intravenously (IV) on days 1, 3 and 5 of a 21 day cycle for a maximum of 2 cycles Arm B1 (continuous infusion): Administered IV for 24, 48, 72 or 96 hours continuously on the first 1 - 4 days or 24 hour infusions on days 1 and 4 (depending on dose level) of each 21 day cycle for a maximum of 2 cycles. Arm B2 (continuous infusion): Administered IV for 24,48, 72 or 96 hours continuously on the first 1 - 4 days or 24 hour infusions on days 1 and 4 (depending on dose level) of each 14 day cycle for a maximum of 3 cycles.
223470171|NCT02810418|DRUG|Nab-Paclitaxel|Administered intravenously (IV) on days 1 and for Arms A1, A2 and B1 on day 8 of each 14-21 day cycle for a maximum of 2 (Arms A1, A2 and B1) or 3 (Arm B2) cycles
224068999|NCT04338750|BEHAVIORAL|Telephone Acceptance and Commitment Therapy Intervention for Caregivers|Participants randomized to TACTICs will receive a manualized acceptance and commitment therapy intervention delivered via phone in 6 weekly 1-hour sessions by a trained Bachelor's-level interventionist. Participants in this intervention will practice various mindfulness exercises, clarify their values, and set specific goals consistent with their values. Sessions will incorporate discussion of patients' caregiving experiences. Through in-session and home practice of skills, participants will learn new and more adaptive ways to respond to anxiety and caregiving challenges. Participants will receive handouts on session topics and a CD with guided mindfulness practices.
223470172|NCT02810418|DEVICE|Mesothelin Expression|Research blood test for Arm B1 eligibility
223470173|NCT02810418|DRUG|LMB-100|A 40 mcg/kg loading dose of LMB-100 is administered over 30 minutes immediately prior to the start of each long infusion.
223470174|NCT06286917|OTHER|NIV initiation in patients with ALS|NIV initiation according to standard care
224159620|NCT01960192|DRUG|HD-MTX-Ara-C regimen|high-does metrotrexate 3.5g/m2 d1 ivgtt 6h,cytarabine 1g/m2 bid d2-3.Continued use to the end of chemotherapy .Every 21 days for one cycle and four cycles are required. Efficacy was evaluated every two cycles
223470175|NCT04271124|OTHER|exercise training|The patients are allocated to PR+ET group or PR Each group receive an exercise training
223470176|NCT01799759|BEHAVIORAL|Online intervention|Child online intervention is 8 modules based on the Health Promotion/Transtheoretical Model Parent online intervention is 6 modules based on enhancing authoritative parenting,support and role models for improved nutrition, physical activity and health child body mass percentile
223470177|NCT01799759|OTHER|Completion of instruments only|Parent and child subejects in the waiting list control only complete surveys, body composition and fitness tests
223470178|NCT02766647|BIOLOGICAL|Filgrastim Hospira (US)|5 micrograms/kilogram (ug/kg) subcutaneous (SC) injection
223579128|NCT01643876|BEHAVIORAL|Palatal brushing|Participants will be instructed to brush their palate with a manual soft-bristle brush after each meal and before sleeping for a period of 3 months. They will be asked to keep to their usual oral and denture hygiene routine during the trial to allow the isolation of the effect of palatal brushing.
223579129|NCT02469714|BEHAVIORAL|Peer Navigator Intervention|Peer navigators will be Hispanics/Latinos with a mental illness in recovery who will complete and meet certification for the peer navigator training program that will be evolved out of the mixed methods process. Investigators propose the peer navigators will enhance patient engagement in integrated care which will, in turn, improve physical and mental health and wellness of patients in this group
223743728|NCT07189988|OTHER|psilocybin|All study participants were provided low dose psilocybin.
224159621|NCT01960192|DRUG|FVD regimen|FVD regimen(fotemustine, teniposide and dexamethasone),fotemustine 100mg/m2 d1 ivgtt,teniposide 60mg/m2 d2-4 ivgtt,dexamethasone 40mg d1-5 ivgtt.Continued use to the end of chemotherapy .Every 21 days for one cycle and four cycles are required. Efficacy was evaluated every two cycles
223470179|NCT02766647|BIOLOGICAL|US-approved Neupogen®|5 micrograms/kilogram (ug/kg) subcutaneous (SC) injection
223470180|NCT04125069|PROCEDURE|Coronary Artery Bypass Graft (CABG)|Mitochondrial function will be studied on cardiac tissue collected intraoperatively at the time of placement of the ECC cannulas by the surgeon. Fragments from auricle dissection of the right atrium of the patient will be requalified as sample residues, and will be used immediately by the surgeon to measure mitochondrial respiration (measurement of oxygen consumption by oxygenation and permeability test of the external mitochondrial membrane by the addition of cytochrome C in the oxygen chamber).
223470181|NCT01347463|PROCEDURE|SCM triangle - ipsilateral nipple|draws the tract of the IJV using the SCM triangle head and the ipsilateral nipple
223470182|NCT01547715|BIOLOGICAL|Meningococcal ACWY conjugate vaccine|All subjects received a single dose of Meningococcal ACWY conjugate vaccine
223470183|NCT02309086|BIOLOGICAL|Autologous dendritic cells transduced with Ad encoding NS3|Patients will receive 3 different dosis of the vaccine via subcutaneous injection
223470184|NCT02991391|OTHER|None, use of a questionnaire|Telephone health survey using 2015 Behavioral Risk Factor Surveillance Survey in Texas, Florida, South Carolina, and Kentucky that includes questions regarding tobacco exposure and respiratory symptoms
223470185|NCT06221709|PROCEDURE|Conventional Radiofrequency (CRF group)|Radiofrequency will be performed with a 22-gauge CRF cannula, 10/15 cm long, 10mm curved active tip, at 90º for 90 seconds, introduced in the anteroposterior and lateromedial directions, to reach the teardrop landmark. Denervation of the articular branches of the Obturator Nerve will be performed in 2 cycles, starting lateral to the lateral edge of the obturator foramen, followed by a point approximately 1cm lateral to the first point. Next, the cannula will be repositioned in a more cranial location, parallel to the superolateral edge of the acetabular dome, to reach the sensory branches of the Femoral Nerve, performing 3 cycles at the 01, 12, and 11 o'clock positions. All lesions will be preceded by motor stimulation at 2,5V and cycles will be followed by the infusion of 2ml of 1% ropivacaine. After concluding the procedure, hip intraarticular infiltration will be performed as described for the control group.
223470186|NCT06221709|PROCEDURE|Intraarticular Infiltration ( Control group)|For the control group (IA), an epidural anesthesia needle (22G spinal needle) will be used, positioned anteroposteriorly towards the central portion of the femoral neck, which will be introduced until transfixion of the anterior hip capsule through tactile sensitivity. After checking the correct positioning with the use of fluoroscopy and infusion of 3 ml of 50% diluted iodinated contrast, an infusion of 4 ml of 1% Ropivacaine and 80mg of methylprednisolone 40mg/ml will be done.
223470187|NCT04758455|DIAGNOSTIC_TEST|P53, Ki67 and Cyclin A IHC.|P53, Ki67 and Cyclin A immunohistochemical staining of formalin-fixed paraffin-embedded specimens of Wilms' tumour.
223470188|NCT00511381|GENETIC|No intervention|No intervention
223579130|NCT05911438|DRUG|Ferric Derisomaltose Injection (Monoferric) and Human Erythropoietin Injection (EPIAO)|Ferric Derisomaltose Injection (Monoferric): 1000 mg, intravenous infusion 6±2 days before surgery; Human Erythropoietin Injection (EPIAO): 36000 IU, subcutaneous injection 6±2 days before surgery and 3±1 days after surgery.
223579131|NCT05911438|OTHER|Basic Treatment|Daily energy intake of 20-30 kcal/kg, with fat accounting for 20-30% of total energy; Iron: ≥15 mg/d, protein intake of 1.2-1.5 g/kg/d; Simultaneously enhance functional exercises.
223579132|NCT01656369|PROCEDURE|Group I: delorme operation only.|A circumferential incision was made in the rectal mucosa approximately 1 cm away from the dentate line. Using electrocautery, the mucosa was stripped to the apex of the prolapse. The muscular layers of the rectal wall were reduced as the mucosa was stripped. Mucosal stripping continued past the apex of the prolapse and then continued inside the prolapsed segment to a point internally that is equivalent to the point of the initial mucosal incision. The underling muscle was plicated by vicryl 2/0.The muscle bite was taken longitudinally from 8 sides to reach a horizontal line of plication at the end. The mucosa was then reanastomosed.
224159622|NCT01816373|DEVICE|Vacuum Bell|Patients with pectus excavatum will be submitted to a negative pressure treatment with the Vacuum Bell device
223470189|NCT05550636|DRUG|BI 1015550|BI 1015550
223470190|NCT05550636|DRUG|midazolam|midazolam
223470191|NCT05063253|DRUG|TG103|TG103 injection, SC, once weekly
223470192|NCT05063253|DRUG|Placebo|Placebo, SC, once weekly
223470193|NCT03011203|OTHER|physical exercise|In session II and III participants will perform an exercise test on a bicycle inside and outside the MR scanner.
223470194|NCT06419491|OTHER|Partner notification by a trained counsellor|"One (or more if needed) interview with a partner notification trained counsellor is offered to index patients. During the interview, the counsellor gives information on partner notification, helps the index patients to remember their partners, to assess their HIV/sexually transmitted infection exposure and explains options to notify them.~During the interview, the index patient can choose to entrust the notification of some of their partners to the counsellor. However, according to French law, provider referral is permitted only when it is anonymous. Therefore, this option is reserved to partners with a lot of partners in order to limit the risk of identifying the index patient"
223470195|NCT05145985|DIAGNOSTIC_TEST|Senior Fitness Test|"Senior Fitness Test is comprised of 6 individual test items and for a description of the trials. All fitness tests (1-6) were selected for analysis:~1. Arm Curl (AC) - measurement of upper body muscle endurance - numbers of arm curls as possible in 30 seconds (n)~2. 30-second Chair Stand (30SCS) - measurement of lower body strength; numbers of chair stand as possible in 30 seconds (n)~3. Back Scratch Test (BST) - measurement of upper-body flexibility; the best score to the nearest centimeter (cm)~4. Chair Sit and Reach Test (CSRT)- measurement of lower-body flexibility (specifically hamstring flexibility); the best score to the nearest centimeter (cm)~5. 8-Foot Up and Go (TUG) - measurement of agility (dynamic balance) and aerobic endurance; the best time of the two trails to the nearest 1/10th second (s)~6. 2-Minute Walk Test (2MWT) - measurement of (aerobic) endurance; the total number of times the right knee reaches the tape level in two minutes (n)"
223470196|NCT06249516|BEHAVIORAL|Rehabilitation training|Including 1) Basic treatment, including corresponding control of risk factors and education on healthy lifestyles. 2)Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training.
223470197|NCT06249516|BIOLOGICAL|Active Breathing Exercises|Active breathing exercises aim to enhance the strength and flexibility of respiratory muscles through a series of exercises, improving breathing patterns and increasing respiratory efficiency. The following are common components of active breathing exercises: 1) Deep Breathing. 2) Chest Expansion. 3) Diaphragmatic Breathing. 4) Coughing Techniques. 5) Expiratory Resistance Training. 6) Gradual Increase in Activity.
224159623|NCT00334698|DRUG|Cetirizine|
224159624|NCT00334698|DRUG|Pseudoephedrine|
224159625|NCT00334698|DRUG|Cetirizine with Pseudoephedrine|
224159626|NCT00610207|DEVICE|Surgisis Biodesign Anal Fistula Plug (SurgiSIS AFP)|Surgical placement of the Surgisis AFP is performed under general anesthesia
224159627|NCT06507332|DRUG|Letrozole 2.5mg|to assess and compare the efficacy of Combination of letrozole and clomiphene citrate versus letrozole alone for ovulation induction in women with polycystic ovary syndrome (PCOS)
223470198|NCT02626416|DEVICE|LenZOC (mobile application)|The transparency of the visual axial at the anterior segment is observed through a dilated pupil. Image of the eye of a patient taken with LenZOC is calibrated with a standardized white and black bar adhered to the patient's eyelid. Calibrated images are dimmed as graysalegrayscale. The intensity and progress of visual axial opacification (VAO) is quantified as absolute area and relative area (calculated as: absolute area of VAO/ absolute area of dilated pupil).
223470199|NCT05441800|OTHER|Observational Study|observational study to include participants with a spectrum of emerging or unknown pathogens with the objective to determine etiology and clinical characteristics of those diseases
223470200|NCT00257790|DRUG|Tobramycin once a day|
223470201|NCT04273321|DRUG|Methylprednisolone|Methylprednisolone 1mg/kg/day ivgtt for 7 days.
223470202|NCT01980953|DRUG|GDC-0032 Phase III Tablet|Participants will receive 2 mg or 3 mg Phase III tablet after 10 hour fasting from food.
223470203|NCT01980953|DRUG|GDC-0032 Tablet|Participants will receive 3 mg Tablet A or Tablet B formulation after 10 hour fasting from food.
223470204|NCT01980953|DRUG|GDC-0032 Capsule|Participants will receive 3 mg GDC-0032 capsule formulation after 10 hour fasting from food.
223579133|NCT01656369|PROCEDURE|delorme operation with post anal repair|In group II : post anal repair was added by making transverse incision 7cm behind the anal canal.dissection of intersphincteric plain,plication of internal sphincter by using 3/0 vicryl.The levator ani and external sphincter were then sutured to each other by vicryl 2/0 behind the anal canal followed by skin closure without drain.
223579134|NCT01172730|DEVICE|Ultrasound scanning|Ultrasound scanning is used to define needle insertion point and depth of epidural space.
223470205|NCT01603680|PROCEDURE|Circumferential spread of the mepivacaine ultrasonographic guided around the median and ulnar nerves at the elbow|Homogeneous spread of 6 ml of mepivacaine 1% around the median and ulnar nerves in each one using several needle passes and active hydrodissection
223470206|NCT01603680|PROCEDURE|Non circumferential spread in ultrasound-guided median and ulnar nerves block|Asymmetric spread of 6 ml of mepivacaine 1% in contact with median and ulnar nerves block in each one, using only one needle pass
223470207|NCT03370952|PROCEDURE|laproscopy|laparoscopic ovarian cystectomy
223470208|NCT03370952|PROCEDURE|combined laproscopic and minilaparotomy ovarian cystectomy|"Under general anaesthesia, the patient is placed in the modified dorsal lithotomy position a 10-mm umbilical trocar is inserted. A panoramic view of the pelvis was obtained together with full assessment of the ovarian mass(es).~Aspiration of the cyst:Delivery of affected ovary outside the abdominal cavity:~Ovarian cystectomy:~Re-introduction of the ovary to inside the abdominal cavity:"
223470209|NCT01929889|DRUG|Iloperidone|Patients in this study will be treated with Fanapt® (iloperidone). They will begin a standardized up-titration starting with a dose of 2 mg daily. Dose increases will continue until the subject has achieved clinical stability, has achieved the maximum dose of 24 mg/day, or until 8 weeks have elapsed. Once clinical stability has been achieved, the patient will continue into the treatment phase. If clinical stability is not achieved after 8 weeks, the patient will be excluded from the study.
223470210|NCT05037630|BEHAVIORAL|Self-guided Digital Tool for Problematic Alcohol Use|See arm/group-description
223579135|NCT03844113|DRUG|Carnosine|Each participant will be given a daily oral dose 2 g of carnosine for 6 months
223579136|NCT03844113|DRUG|Placebo|Each participant will be given a daily oral dose 2 g of methycellulose powder for 6 months
223579137|NCT02784015|DRUG|Cisplatin|
223579138|NCT02784015|DRUG|Etoposide|
223579139|NCT02784015|DRUG|Doxorubicin|
223579140|NCT02784015|DRUG|Cyclophosphamide|
223579141|NCT02784015|DRUG|Ifosfamide|
223470211|NCT04531865|DRUG|Rituximab|Rituximab: 375 mg/m2 intravenously on day 0 and day 7
223470212|NCT04531865|DRUG|Mycophenolate Mofetil|Addition of Maintenance Mycophenolate Mofetil from 4 Month onwards. Dose: 20\~30mg/kg/day，BID. Total duration : 8 months.
223470213|NCT04531865|DRUG|Placebo tablets matching Mycophenolate Mofetil|Addition of Maintenance Placebo tablets matching Mycophenolate Mofetil from 4 Month onwards. Dose: 20\~30mg/kg/day，BID. Total duration : 8 months.
223470214|NCT02657330|DRUG|SBP-101|Subcutaneous drug, escalating dose cohorts
223470215|NCT03814564|DEVICE|NIRS monitoring|Cerebral and peripheral NIRS monitoring of brain and tissue oxygenation. Of the 400 patients, a subpopulation of the first 250 adult critically ill patients (≥18 years) requiring ICU care, including both surgical and medical ICU patients with circulatory shock will be included in the NIRS-substudy. All 400 patients will be analyzed for endotheliopathy incidence, metabolomics, genetic data Representation of the study population will be ensured by enrolment of all consecutive patients at the study sites who meet the study enrollment criteria
223470216|NCT03316846|BEHAVIORAL|Internet-Delivered Cognitive Behavioral Therapy|
223470217|NCT01003106|DRUG|Ranibizumab 0.5mg (monthly)|Branch retinal vein occlusion- Intravitreal injection of 0.5mg ranibizumab alone
223470218|NCT01003106|DRUG|Ranibizumab 2.0mg (monthly)|
223470219|NCT01003106|DRUG|Pro re nata (prn) ranibizumab|
223470220|NCT01003106|PROCEDURE|Pro re nata (prn) Laser photocoagulation|
223743729|NCT07190989|DIETARY_SUPPLEMENT|Nutritional Supplement|A mixed juice containing 15000 mg cherry juice concentrate, 220 mg cherry extract, 250 mg cocoa extract, 200 mg of tryptophan, 100 mg of L-5-Hydroxytryptophan, 3000 mg of glycine, 300 mg of magnesium, 200 mg of theanine manufactured by Science in Sport (https://sport.wetestyoutrust.com/supplement-search/science-sport/rest-juice).
224159628|NCT02621372|OTHER|platelet count|Correlation of esophageal varices with platelet count
223470223|NCT00947206|BEHAVIORAL|LHWO about CRC|2 LHWO sessions and 2 telephone calls aimed at increasing their CRC screening receipt
223470224|NCT00947206|BEHAVIORAL|Nutrition Education + CRC brochure|Bilingual CRC brochure as well as a lecture on healthy nutrition for cardiovascular health and a post-intervention LHWO session on CRC screening.
223470225|NCT06332222|DIETARY_SUPPLEMENT|Tart Cherry|7 day supplementation
223579142|NCT02784015|DRUG|Carboplatin|
223579143|NCT02784015|RADIATION|Radiotherapy|
223579144|NCT02784015|DRUG|Thiotepa|
223579145|NCT02784015|DRUG|Melphalan|
223579146|NCT00374894|DRUG|2,3-dimercaptosuccinic acid|
223579147|NCT00461994|BEHAVIORAL|diet|
223579148|NCT00461994|BEHAVIORAL|exercise|
223579149|NCT00461994|BEHAVIORAL|diet and exercise|
224159629|NCT00481741|DEVICE|SafeSeal(TM) Hemostasis Patch|
223470226|NCT06332222|OTHER|Placebo|7 day supplementation
223470227|NCT00809796|DRUG|pentamidine|one dose of 4 mg/kg to two dose of 4 mg/kg with possibility of escalated to two dose of 6 mg/kg with or without standard chemotherapy.
223579150|NCT05531721|OTHER|Observation|Observation and retrospective data collection
223579151|NCT04399954|DIETARY_SUPPLEMENT|Ketoflo|Ketoflo is a ready to use liquid feed for the dietary management of epilepsy and other conditions that may require a ketogenic diet. It has a 4:1 ratio of fat to carbohydrate and protein and can be administered enterally via a tube feeding or oral consumption.
223579152|NCT04373447|PROCEDURE|lap fundus-calot cholecystectomy|use laparoscopic fundus-calot approach
223470228|NCT02860988|BEHAVIORAL|MCCC treatment|Participants in this condition received newly-supported reentry services to enhance fatherhood and parenting for individuals with substance use issues. These services focus on responsible parenting, economic stability and mobility, and healthy marriage and relationships.
223470229|NCT02420639|DEVICE|Esophageal Cooling Device (ECD), manufactured by Advanced Cooling Therapy, Inc.|Use of the Esophageal Cooling Device for control of patient temperature.
223470230|NCT01857752|DRUG|Temozolomide|
223579153|NCT04373447|PROCEDURE|open cholecystectomy|use open approach
223579154|NCT01515475|PROCEDURE|Glasses|Glasses will be prescribed at enrollment with the sphere cut symmetrically by 1.00D and full cylinder correction.
224069000|NCT04338750|BEHAVIORAL|minimally-Enhanced Usual Care|Participants randomized to mEUC will receive a letter thanking them for participating in the trial along with the Alzheimer's Caregiving guide from the National Institute of Aging of the National Institutes of Health (https://www.nia.nih.gov/health/alzheimers/caregiving), coupled with a listing of the five Alzheimer's Association sponsored support groups closest to their home address.
224069001|NCT02844556|PROCEDURE|SMILE surgery|SMILE surgery and FS-LASIK surgery are both effective method for the correction of myopia and myopic astigmatism. They have been proved to offer many advantages in terms of visual acuity, corneal sensitivity and corneal biomechanics compared with traditional refractive surgeries.
224069002|NCT02844556|OTHER|FS-LASIK surgery|SMILE surgery and FS-LASIK surgery are both effective method for the correction of myopia and myopic astigmatism. They have been proved to offer many advantages in terms of visual acuity, corneal sensitivity and corneal biomechanics compared with traditional refractive surgeries.
224069003|NCT00978211|DRUG|DOTA-TOC Treatment|"Intravenous injections of DOTA-TOC. Repeated treatment cycles for responders, except in case of~* renal toxicity~* loss of patient transferability or~* denial of further treatment."
224069004|NCT00999531|DRUG|GS-9411|Inhaled GS-9411 dissolved in sterile saline
224069005|NCT00999531|DRUG|Placebo|Inhaled Placebo, sterile saline
224069006|NCT04689529|DIAGNOSTIC_TEST|Preoperative imaging study|MRI, Breast ultrasound sonography, mammography
224069007|NCT00429208|DRUG|Nicotine|
224069008|NCT05378451|PROCEDURE|Totally Extraperitoneal Groin Hernia Repair|"Patients will undergo totally extraperitoneal groin hernia repair, by a single senior experimented surgeon and without modifications from the routine clinical practice due to study inclusion. TEP approach will be assessed by placement of 3 trocars in the lower midline. Preperitoneal space will be dissected under direct vision using Spacemaker Dissection Balloon (Applied Medical®). Systematic complete dissection of the myopectineal orifice, Retzius and Bogros spaces will be performed to identify all potential sites of hernia formation. It will be used a laparoscopic self-fixating mesh (ProGrip™). Preperitoneal instillation of local anesthesia (15 mL of 0.5% bupivacaine) will be placed placed by the surgeon under direct visualization into triangle of pain. Local anesthesia (levobupivacaine 10mL 1%) will be applied in all the incisions."
224069009|NCT03080909|DIETARY_SUPPLEMENT|Encapsulated nutrients|Amino acid + Lipid; Probiotic bacteria; Lipid; Amino acid selected on their ability to stimulate release of GLP-1 and PYY
224069010|NCT03080909|DIETARY_SUPPLEMENT|Placebo|Maltodextrin, which is not expected to stimulate release of GLP-1 and PYY
224069011|NCT04292509|DEVICE|SAP with stop before low|cross-over comparison from stop on low to stop before low
224069012|NCT04292509|DEVICE|SAP with stop on low|cross-over comparison from stop before low to stop on low
224069013|NCT04372277|DRUG|Enstilar|topical Enstilar foam
224069014|NCT00309231|PROCEDURE|Islet Allotransplantation|Clinical islet transplantation using the Edmonton protocol, steroid free immunosuppression using sirolimus and tacrolimus and basilixumab induction therapy
224159630|NCT02117804|OTHER|Early Screen for Discharge Planning|This screen is completed by a study coordinator within 24 hours of patient admission to the hospital. The screen measures four variables available from routine hospital admission clinical data (walking limitation, age, living alone prior to admission, and level of disability) that exhibit high sensitivity and specificity (AUC's were .82 and.84) in identifying patients who should receive targeted attention from a DP expert.
224159631|NCT06231030|OTHER|Validity, Reliability and Adaptation|Expanded Disability Status Scale (EDSS) will be applied by a neurologist to determine the disability level of the individuals included in the study. In addition to the USE-MS scale, the GSE questionnaire, MuSiQoL and NFI-MS will be administered by an expert physiotherapist. The questionnaires and scales to be used in the study will be administered by face-to-face interview method twice in total with two weeks intervals. In addition to the USE-MS scale, the GSE questionnaire, MuSiQoL and NFI-MS will be applied. The questionnaires and scales to be used in the study will be administered by face-to-face interview method 2 times in total with a 2-week interval.
224159632|NCT02171039|DRUG|Dabigatran|
224159633|NCT02171039|DRUG|Atorvastatin|
224304978|NCT02752906|BIOLOGICAL|Meningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine|0.5 mL, Intramuscular
224304979|NCT03153761|OTHER|CSD170201AA|A moist snuff product
223470231|NCT06037317|DRUG|SY-3505|LTK tyrosine kinase inhibitor
223470232|NCT02047578|DRUG|Busulfan|First dose: busulfan (120 mg/m2 ivs once daily) (if age\<1 yr: 80 mg/ m2) Second to forth dose: according to the daily pharmacokinetic study
223579155|NCT01852279|DEVICE|BCI-FES|Brain computer Interface delivered Function Electrical Stimulation
223579156|NCT01852279|DEVICE|Passive muscle stimulation|Functional Electrical stimulation delivered by therapist
223743730|NCT07190989|DIETARY_SUPPLEMENT|Maltodextrin (Placebo)|A 40g dual-source carbohydrate gel, having a 1:0.8 ratio of maltodextrin and fructose manufactured by Science in Sport (https://sport.wetestyoutrust.com/supplement-search/science-sport/beta-fuel-dual-source-energy-gel-beta-fuel-maltodextrin-fructose).
224304980|NCT03153761|OTHER|CSD170201AB|A moist snuff product
223470233|NCT05831800|DEVICE|Wearable bioimpedance sensor|The investigational device is an electronic bioimpedance-based, body-worn, battery-powered sensor intended to monitor changes in fluid balance. It is designed as an adhesive patch with four integrated electrodes. The outer electrodes are used to supply a low current, while the inner electrodes are used for voltage measurements.
223470234|NCT05469646|DRUG|BI 1819479|BI 1819479
223470235|NCT05469646|DRUG|Matching placebo|Matching placebo
223470236|NCT01082029|DRUG|Lansoprazole|The dosage of Lansoprazole will be administered based on guidelines set out by the prescription drug information outlined in the official Lansoprazole package insert and will remain the same for each patient during the 3 month period and is as follows: a) 1 to 11 years of age, weight less then or equal to 30 kg, 15 mg orally once daily. b) 1 to 11 years of age, weight greater then 30 kg, 30 mg orally once daily. c) 12 years of age and older, 15 mg orally once daily. The doses of Lansoprazole will be prepared in liquid form by the Inpatient Pharmacy at Hamilton Health Sciences.
223470237|NCT01082029|DRUG|Placebo|Lactose powder in 8.4% Sodium Bicarbonate (Liquid placebo)
223470238|NCT04720443|DRUG|NIP292 tablet|NIP292 (oral tablet at 10 mg) or placebo
223470239|NCT04720443|DRUG|NIP292 tablet|NIP292 (oral tablet at 30 mg) or placebo
223470240|NCT04720443|DRUG|NIP292 tablet|NIP292 (oral tablet at 100 mg) or placebo
223470241|NCT04720443|DRUG|NIP292 tablet|NIP292 (oral tablet at 300 mg) or placebo
223470242|NCT04720443|DRUG|NIP292 tablet|NIP292 (oral tablet at 500 mg) or placebo
223470243|NCT04720443|DRUG|NIP292 tablets|NIP292 (oral tablet at dosage 1) or placebo
223470244|NCT04720443|DRUG|NIP292 tablets|NIP292 (oral tablet at dosage 2) or placebo
223470245|NCT00569985|BIOLOGICAL|lentivirus vector rHIV7-shI-TAR-CCR5RZ-transduced hematopoietic progenitor cells|Undergo autologous hematopoietic stem cell transplantation comprising lentivirus vector rHIV7-shI-TAR-CCR5RZ-transduced hematopoietic progenitor cells and non-bound CD34+ cells
223470246|NCT00569985|DRUG|carmustine|Given IV
223470247|NCT00569985|DRUG|cyclophosphamide|Given IV
223470248|NCT00569985|DRUG|etoposide|Given IV
223470249|NCT00569985|PROCEDURE|autologous hematopoietic stem cell transplantation|Undergo autologous hematopoietic stem cell transplantation comprising lentivirus vector rHIV7-shI-TAR-CCR5RZ-transduced hematopoietic progenitor cells and non-bound CD34+ cells
223470250|NCT06371391|OTHER|No intervention|No intervention
223470251|NCT01735604|BIOLOGICAL|anti-CD20-CAR vector-transduced autologous T cells|anti-CD20-CAR vector-transduced autologous T cells
223470252|NCT01735604|OTHER|genetically engineered lymphocyte therapy|genetically engineered lymphocyte therapy
223470253|NCT02687854|DRUG|Apixaban|As prescribed by treating physicians
223470254|NCT02687854|DRUG|Vitamin K antagonist|As prescribed by treating physicians
223470255|NCT05418829|DRUG|AT-007|AT-007 20 mg/kg once daily
223470256|NCT03562078|BEHAVIORAL|Tai Chi Quan|the first section of Yang style 108 form, including 10-minute warm-up, 40-minute training, and 10-minute cool-down exercise, twice a week
223470257|NCT02830568|PROCEDURE|open donor nephrectomy|open donor nephrectomy
223470258|NCT02830568|PROCEDURE|standard and hand-assisted laparoscopic donor nephrectomy|standard and hand-assisted laparoscopic donor nephrectomy
223579157|NCT04407065|DRUG|Double trigger|Final follicular maturation is triggered by the co-administration of GnRH-agonist (Triptorelin acetate, decapeptyl 0.2 mg, Slough, United Kingdom) and 10000 IU of HCG, 40 and 34 h prior to oocyte retrieval, respectively
223470259|NCT02830568|PROCEDURE|laparoscopic robotic-assisted nephrectomy|laparoscopic robotic-assisted nephrectomy
223470260|NCT04578366|DEVICE|Extracorporeal Shockwave Therapy|ESWT along with conventional therapy ESWT + hot pack(10min), ultrasound (5min), mobilizations, stretching, pendulum exercises, isometrics of shoulder
223470261|NCT04578366|OTHER|Conventional Treatment|hot pack(10min), ultrasound (5min), mobilizations, stretching, pendulum exercises, isometrics of shoulder
223470262|NCT06001671|DRUG|BEBT-109|"BEBT-109 is based on the 3+3 model, with a dose ascent starting from 120mg qd"
223470263|NCT00963534|DRUG|lenalidomide, bendamustine, rituximab|"Phase I: Maximally tolerable dose of lenalidomide will be determined, starting with 5 mg per day, and up to maximally 25 mg per day. This treatment is given in combination with bendamustine and rituximab.~Phase II: Determination of progression free survival with treatment with lenalidomide (dosing determined in phase I) in combination with bendamustine and rituximab."
223470264|NCT00963534|DRUG|lenalidomide, bendamustine, rituximab|lenalidomide: day 1-21, maximum 13 cycles bendamustine: days 1-2, cycle 1-6 rituximab: day1, cycle 1-6
223470265|NCT03320356|OTHER|the French version of the Oxford Shoulder Score|
223470266|NCT04635839|DRUG|Standard Dose of Unfractionated Heparin|5,000 units subcutaneous unfractionated heparin every 12 hours
223470267|NCT04635839|DRUG|Gestational Age-Based Dose of Unfractionated Heparin|"* First trimester (\< 14 weeks of gestation): 5,000 units subcutaneous unfractionated heparin every 12 hours~* Second trimester (14-28 weeks of gestation): 7,500 units subcutaneous unfractionated heparin every 12 hours~* Third trimester (\> 28 weeks of gestation): 10,000 units subcutaneous unfractionated heparin every 12 hours"
223470268|NCT03469544|OTHER|complete blood picture ,serum urea and creatinine,liver function test,T3,T4,thyroid stimulating hormone,thyroglobuline and thyroglobuline anti body specific test Real time polymerase chain reaction|"complete blood picture ,serum urea and creatinine,liver function test,T3,T4,thyroid stimulating hormone,thyroglobuline and thyroglobuline anti body .~specific test is quantitation of long non coding RNA HOTAIR by Real time polymerase chain reaction in peripheral blood,Enzyme linked Immunosorbent Assay for serum midkine level"
223470269|NCT02870868|BEHAVIORAL|Slow breathing|Slow breathing techniques from yoga
223579158|NCT04407065|DRUG|HCG trigger|Final follicular maturation is triggered by a dose of 10000 IU of HCG 36 h prior to oocyte retrieval
223579159|NCT02501564|DRUG|Naproxen Sodium Codeine|One tablet twice a day
223579160|NCT02501564|DRUG|Placebo|One tablet twice a day
223579161|NCT02496169|DEVICE|eucaLimus|Percutaneous Coronary Intervention (PCI)
223579162|NCT01420627|BIOLOGICAL|EZN-2279|Weekly administration of EZN-2279 via IM injection
223579163|NCT01420627|BIOLOGICAL|Adagen|
224159634|NCT04179604|DRUG|Levosimendan|Levosimendan SIMDAX 2.5 mg / ml concentrate for solution for infusion. The concentrate is a clear solution, yellow or orange, for dilution before administration. A 5 ml vial contains 12.5 mg of levosimendan. The study drug infusion will start one day before surgery in an Intensive Care Unit with at least 8 hours of administration before surgery. A continuous infusion at 0.1 µg/kg/min will be administered to complete 24h duration.
223470270|NCT04306523|OTHER|Observation|4 months: observation of infant feeding behavior, behavior/temperament; bio-specimen collection; body composition, sucking intensity/frequency, activity intensity/frequency; maternal reports of feeding and behavior/temperament; maternal biospecimen. 6 month: behavior/temperament assessment, physical activity, and body composition. 12 month: Feeding behavior, behavior/temperament assessment, physical activity, and body composition. 24 month: maternal reports of children's eating behavior, behavior/temperament.
223470271|NCT00744939|DRUG|Gadopentetate dimeglumine (Magnevist, BAY86-4882)|Patients will be followed for 2 years after the administration of Magnevist at the approved dose to see if symptoms consistent with NSF develop
223470272|NCT03019848|DIETARY_SUPPLEMENT|Curcumin|
223470273|NCT03019848|OTHER|Placebo|
223470274|NCT04211584|DEVICE|transradial interventions|percutaneous coronary interventions in stable patients - diagnostic and treatment
223470275|NCT05827848|DEVICE|Percutaneous peripheral nerve stimulation system|All subjects underwent a 7-day baseline assessment (VAS score for at least 4 days) during the screening/baseline period. Eligible subjects underwent PNS surgery and implanted electrode leads and entered the 7-day test period. During the test period, subjects with an average VAS score improvement of ≥30%(VAS score for at least 4 days) will be randomly assigned to the experimental group (on state) or the control group (off state) in a 1:1 ratio for 7 days observation. All subjects were enrolled in the observation period until 28 days after implantation. Safety assessment was performed at a 14-day follow-up after removal of the device.
224159635|NCT04179604|DRUG|Placebos|Patients in the placebo group will receive a water-soluble vitamin B2 concentrate with 0.4 mg / ml sodium riboflavin phosphate to obtain the same color as the preparation of levosimendan and ethanol anhydrous 100 mg / ml to resemble the levosimendan odor, which will be administered at the same levosimendan infusion rate.
224159636|NCT03241589|OTHER|Direct to patient facing mobile apps introduction|VA employees and Veterans begin use of OCC's direct to patient facing mobile app.
224159637|NCT02465489|DRUG|Deferiprone extended release|Deferiprone 1000 mg extended release tablet formulation
224159638|NCT02465489|DRUG|Deferiprone immediate release|Ferriprox (deferiprone) 500 mg immediate release tablet formulation
224159639|NCT00264095|PROCEDURE|Oncological surgery|surgery is primary observed intervention and blood loss is between 500-3000 ml
224159640|NCT02572804|DEVICE|Epidural|Patients in this group will have an epidural inserted in a standard fashion, prior to the induction of anesthesia. These will be infused with 0.125% Bupivicaine at an initial rate of 5mls/hour, titrated to response. Patients will also receive a patient controlled analgesia with hydromorphone 0.2mg/ml, bolus of 200 micrograms with 6 minute lock out (variable in accordance with anesthetic preference).
224159641|NCT02572804|DEVICE|Rectus Sheath Catheters|Patients in this group will have surgically inserted rectus sheath catheters (bilaterally), immediately prior to closure of the anterior abdominal wall. These will be infused with 0.125% Bupivicaine at 5mls an hour at a standard rate.Patients will also receive a patient controlled analgesia with hydromorphone 0.2mg/ml, bolus of 200 micrograms with 6 minute lock out (variable in accordance with anesthetic preference).
224159642|NCT00408291|PROCEDURE|Winsta PH osteosynthesis device|The Winsta PH osteosynthesis device have been developed for use in treatment of proximal humerus fractures.
224159643|NCT01977157|DEVICE|bioimpedance mesurements|Bioimpedance measurements were conducted with a BIS device (SFB7, ImpediMed, Pinkeba, Australia) covering a frequency range between 5 kHz and 1 MHz and an ICG device (Niccomo, medis, Ilmenau, Germany)
224159644|NCT04306757|DEVICE|Evone|Airway ventilation device
224159645|NCT04306757|DEVICE|Primus|Airway ventilation device
224159646|NCT03476434|DEVICE|chromoendoscopy with indigo carmine|the lumen of the colon is sprayed in a segmental fashion using 0.4% indigo carmine delivered via a specially designed dye spray catheter (Olympus PW-5V1) or via the accessory channel with a 50cc syringe filled with indigo carmine and air.
224159647|NCT06047860|RADIATION|Radiotherapy|hypofractionated radiotherapy/SBRT
224159648|NCT06047860|DRUG|PD-1/PD-L1 inhibitor|PD-1/PD-L1 inhibitor within one week of radiotherapy
224159649|NCT06047860|DRUG|Granulocyte-macrophage colony-stimulating factor subcutaneous injection|IL-2 2 million IU the day after the end of GM-CSF, administered subcutaneously daily for 7 days;
224159650|NCT06047860|DRUG|Interleukin 2 subcutaneous injection|IL-2 2 million IU the day after the end of GM-CSF, administered subcutaneously daily for 7 days;
223579164|NCT00837876|DRUG|Sorafenib|400 mg taken by mouth 1 time per day.
224159651|NCT06047860|DRUG|Endostatin|Recombinant human vascular endothelial inhibitor (Endo) 210 mg CIV72h was started on the first day of treatment, every 21 days for a minimum of ≥ 2 cycles of this combination therapy.
224159652|NCT00028795|DRUG|temozolomide|
224159653|NCT00028795|PROCEDURE|adjuvant therapy|
224159654|NCT00028795|RADIATION|radiation therapy|
224159655|NCT01407289|DRUG|Insulin Aspart, Insulin Glargine|The Intervention is a paper based protocol, which provides suggestions for new insulin doses (basal-bolus regime).
224159656|NCT00374036|DRUG|ECC|capecitabine
224159657|NCT00374036|DRUG|FOLFIRI|Irinotecan
224159658|NCT03394118|DRUG|Osimertinib|A cycle of study treatment is defined as 28 days. Each subject will continue the study drug(Osimertinib) until disease progression or manifestation of unacceptable toxicity during the study period. The study drug will be administered orally as one 80 mg tablet once a day. The initial dose of the study drug 80 mg daily can be reduced to 40 mg once daily.
223470276|NCT06019871|PROCEDURE|Dialysis|Patients who have decided for dialysis either center haemo-dialysis or peritoneal dialysis
223470277|NCT03151369|DRUG|Morphine|patients with the visual analog scale over 3 will receive morphine
223579165|NCT00837876|DRUG|Erlotinb|150 mg taken by mouth 1 time per day.
223579166|NCT01199276|DRUG|Xenon|Group A: xenon 60% (55%-65%)(1 MAC) in oxygen (FiO2 = 0.35-0.45)
223579167|NCT01199276|DRUG|Sevoflurane|Group B: sevoflurane 1.1-1.4%(1 MAC) in oxygen (FiO2 = 0.35-0.45) and Medical air
223579168|NCT02716701|BEHAVIORAL|Exercise Group|
223470278|NCT02532400|DRUG|Neoadjuvant endocrine therapy|Goserelin: 3.6mg, d1, hypodermic injection , q28d\*7 plus exemestane: 25mg, po, qd\*24w, or anastrozole: 1mg, po, qd\*24w
223579169|NCT02716701|OTHER|Control Group|
224159659|NCT00159380|DRUG|Aminoguanidine|500mg
224159660|NCT00159380|DRUG|Placebos|2ml
224159661|NCT01942304|PROCEDURE|Calcium phosphosilicate alloplastic bone putty in direct sinus augmentation|
223470279|NCT02532400|DRUG|Neoadjuvant chemotherapy|Docetaxel: 75mg/m2, d1, q3w\*6, Epirubicin 75mg/m2, d1, q3w\*6 and Cyclophosphamide: 500mg/m2, d1, q3w\*6
223470280|NCT01249911|DIETARY_SUPPLEMENT|Lreuteri|L. reuteri DSM 17938 will be given at a dose of 5 drops containing 1x108 colony-forming units (CFU) once time per day in an oil formulation delivered from a drop bottle. In the active study product, freeze-dried L. reuteri is suspended in a mixture of pharmaceutical grade medium chain triglycerides and sunflower oil together with pharmaceutical grade silicon dioxide to give the product the correct rheological properties.
223470281|NCT01249911|OTHER|Placebo|The placebo consists of an identical formulation except that the L. reuteri is not present
223470282|NCT00180908|DRUG|Etoposide, Ifosfamide, Methotrexate|
223470283|NCT00180908|DRUG|Doxorubicin, Methotrexate|
223470284|NCT04882371|DRUG|Chemotherapy|Neoadjuvant Chemotherapy for Breast Cancer
223470285|NCT04882371|DIAGNOSTIC_TEST|Magnetic Resonance Imaging (MRI)|Performed contrasted MRI for evaluate response of neoadjuvant chemotherapy
223470286|NCT04882371|DIAGNOSTIC_TEST|Positron emission tomography - Copmputer Tomography (PET-CT)|Performed contrasted PET-CT for evaluate response of neoadjuvant chemotherapy
223470287|NCT04768140|PROCEDURE|Bobath treatment approach|scapulothoracic mobilization exercise, reaching in different directions in the supine position and upper extremity weight transfer exercise.
223470288|NCT04768140|PROCEDURE|Conventional physiotherapy|range of motion, stretching, strengthening exercises, electrotherapy, thermotherapy, balance and mobility exercises and exercises for daily living activities.
223470289|NCT03991871|DEVICE|External Counter Pulsation (ECP) therapy|35 hours ECP treatment in 35 sessions
223470290|NCT05461066|BEHAVIORAL|CESAR training|Intervention community pharmacists received the CESAR training to improve their smoking cessation services, consisting of an initial interview and follow-up visits to identify obstacles and reinforce behaviours.
223470291|NCT05310877|BEHAVIORAL|Values-Affirmation|Participants will engage in a brief values-affirmation exercise to target personal motivation and openness to medication adherence. The interventionist will then review tailored medication education and individual skills training recommendations. Following the intervention session, participants will receive electronic pill box(es) that are labeled with the participants' most important core value(s) and will be asked to use these pill box(es) to take their HF medications for 4 weeks.
223470292|NCT05332223|DIAGNOSTIC_TEST|Full Polysomnography|Overnight PSG will be conducted using Alice version 6 system (Respironics, Pittsburgh, PA, USA). During PSG, the following variables will be monitored and captured. Sleep staging using electroencephalogram (four channels: C3-A2, C4-A1, O1-A2, O2-A1), electrooculogram (two channels: LOC-A2, ROC-A1), electromyogram (two channels: submental and anterior tibialis muscles). Respiratory effort using inductive plethysmograph sensors to detect thoracoabdominal movements. Oro-nasal airflow using pressure flow transducer and thermistor. Oxygen saturation using pulse oximetry and cardiac rhythm using electrocardiography. Other parameters that will also be monitored includes body position, presence of snoring and end tidal CO2 (EtCO2) measurement to detect hypercapnia. The attended PSG will be conducted in the sleep laboratory in Respiratory Unit, Hospital Taiping
223470293|NCT02691715|PROCEDURE|Endometrial saline plus curettage|
223470294|NCT02691715|PROCEDURE|Endometrial curettage|
223470295|NCT04325880|DRUG|Mirabegron 50 MG|Patients in this arm will receive Mirabegrone 50 MG once daily
223470296|NCT04325880|DRUG|Tamsulosin|Patients in this arm will receive Tamsulosin o.4 MG once daily
223470297|NCT04325880|DRUG|Solifenacin Succinate 10 MG|Patients in this arm will receive Solifenacin Succinate 10 MG once daily
223470298|NCT04325880|DRUG|Placebo oral tablet|Patients in this arm will receive placebo oral tablet once daily
223470299|NCT06429904|DRUG|Nimotuzumab+ NALIRIFOX|"Drug: Nimotuzumab Patients will receive Nimotuzumab 400 mg weekly or Nimotuzumab 600mg, 600mg, 400mg on Day 1, 8, 15, respectively, 28 days as a cycle, up to 6 cycles.~Other Names: h-R3~Drug: NALIRIFOX Patients will receive NALIRIFOX (liposomal irinotecan 50 mg/m2, oxaliplatin 60 mg/m2, leucovorin 400 mg/m2, and fluorouracil 2400 mg/m2, administered sequentially as a continuous intravenous infusion over 46 h) on days 1 and 15 of a 28-day cycle, up to 6 cycles.~Other Names: NALIRIFOX"
223470300|NCT03792334|DEVICE|depth of anesthesia|monitoring of depth of anesthesia
223470301|NCT02555592|PROCEDURE|Primary surgical resection with sequential adjuvant therapy|First, surgery resection of the affected lung with mediastinal lymph node dissection, including sub- and para-aortic lymph node, will be performed. If malignant tumor involvement only in the sub- or para-aortic lymph nodes is identified, adjuvant chemotherapy will be initiated within 8 weeks after surgery. After completion of adjuvant chemotherapy, post-operative radiotherapy will be initiated within 2\~4 weeks after adjuvant chemotherapy.
223470302|NCT03280407|DRUG|Capecitabine|Radio-chemotherapy with 50.4 Gy in 28 fractions to tumor and regional lymph nodes concomitantly with capecitabine 825 mg/m2 b.i.d
223470303|NCT03280407|DRUG|FOLFOX regimen (oxaliplatin/leucovorin/5FU)|Six cycles: Oxaliplatin 85 mg/m2 day 1, leucovorin 400 mg/m2 day 1, 5FU 400 mg/m2 bolus day 1 and 5FU 2400 mg/ m2 over 46-48 hours day 1-3, repeated every two weeks.
223470304|NCT03280407|DRUG|CAPOX (oxaliplatin/capecitabine)|Four cycles: Oxaliplatin 130 mg/m2 day 1 and capecitabine 1000 mg/m2 b.i.d. days 1-14, repeated every 3 weeks.
223470305|NCT04212767|PROCEDURE|Alveolar socket preservation with Platelet-rich fibrin|The sockets of the test group will be filled with two platelet-rich fibrin membranes followed by suture
223470306|NCT05282147|DEVICE|Neocam|Screening within 72 hours of birth will be completed using the digital imaging device Neocam which painlessly images the eye's reflection firstly to infrared light and then to a brief green light flash.
223470307|NCT00243763|DRUG|TKI258|
223579170|NCT02716701|OTHER|wristband activity tracker|
223579171|NCT00391001|DRUG|Taurine|double-blind, placebo-controlled, adjunctive medication
224159662|NCT01942304|PROCEDURE|Anorganic bovine bone mineral in direct sinus augmentation|
224159663|NCT02287805|OTHER|qualitative survey|
224159664|NCT02287805|OTHER|quantitative survey|
223470308|NCT00619788|DEVICE|4.0-5.0mm AngioSculpt Scoring Balloon Catheter|The AngioSculpt Scoring Balloon Catheter is a line of innovative angioplasty catheters comprising an angioplasty balloon surrounded by a unique system of nitinol scoring elements. Creating focal concentrations of dilating force, the scoring elements score arterial lesions as the balloon expands.
223470309|NCT01674725|DRUG|ABT-450/r/ABT-267, ABT-333|Tablet; ABT-450 coformulated with ritonavir and ABT-267, ABT-333 tablet
223470310|NCT01674725|DRUG|Ribavirin|Tablet
223579172|NCT05543018|DIAGNOSTIC_TEST|Electroretinogram|Retinal function assessment using electroretinogram
223579173|NCT05543018|PROCEDURE|Vitrectomy operation|Vitrectomy operation to treat retinal detachment
223579174|NCT00453973|DRUG|peginesatide|Participants received the same initial peginesatide dose via the same route, intravenously or subcutaneously, as was administered at the end of the previous peginesatide treatment study in which the participant was enrolled. The median first dose at study start was 0.044 milligram per kilogram (mg/kg) with an interquartile range of 0.028 to 0.076 mg/kg. Each participant was to receive peginesatide as an injection administered once every 4 weeks for approximately 54 months in this trial.
223579175|NCT00453973|DRUG|peginesatide|Participants received the same initial peginesatide dose via the same route, intravenously or subcutaneously, as was administered at the end of the previous peginesatide treatment study in which the participant was enrolled. The median first dose at study start was 0.024 mg/kg with an interquartile range of 0.017 to 0.035 mg/kg. Each participant was to receive peginesatide as an injection administered once every 4 weeks for approximately 54 months in this trial.
224069015|NCT05288270|DEVICE|Aramis|"ARAMIS is composed of two computer-controlled, symmetric and interacting exoskeletons able to compensate the inadequate strength and accuracy of the paretic arm movements, of which it measures residual motor function, and the effect of gravity during rehabilitation. It acts through motion capture of the movements of the unaffected arm. In so doing, the patient is able to replicate the movements of the healthy arm with the paretic arm in synchronous, asynchronous or active-assisted manner. The robot-assisted neurorehabilitation using ARAMIS consists in 60-min sessions for 8 weeks,structured as follows:~* 1 to 4 weeks: asynchronous exercises of repletion by the paretic arm of basic exercises 20 times for a total of 200 repetitions per session;~* 5 to 8 weeks: replaced by synchronous exercises (100/session) with active-assisted modality."
224069016|NCT05288270|OTHER|Conventional therapy|The control group will receive conventional rehabilitation consisting in passive mobilization of upper and lower limbs, coordination respiratory exercises, cardiovascular conditioning in the setting posture, conditioning in the upright posture, exercises for the trunk control.
224069017|NCT01697735|DRUG|Berberine;Atorvastatin or Rosuvastatin|Participants will receive 500mg Berberine twice a day for 8 weeks; Follow the previous administration program，participants will continue to receive 20mg Atorvastatin daily or 10mg Rosuvastatin daily.
224069018|NCT01697735|DRUG|Atorvastatin or Rosuvastatin|Due to the different clinical prescriptions by different doctors and similar Efficacy in lowering lipids.Usually,Participants receive 20mg Atorvastatin daily or 10mg Rosuvastatin to treat hyperlipidemia.
224159665|NCT03923504|OTHER|Physical Activity Intervention (PAI)|Those who opt-in to attend in-person study visits and to undergo COVID testing will also complete an MRI exam and CPET testing. Participants unwilling to have COVID testing done will only complete an MRI exam and home-based testing. All testing will take place either within 6 weeks of initiating systemic treatments or within 8 weeks of completing radiation then at 3 \& 6 months. Patients may participate in 1-2 training sessions per week offered under the direct supervision of a master's level clinical exercise physiologist, as well as 1-2 sessions at home. PAI sessions consist of slow aerobic warm-up, followed by 20 minutes of strength training,15 minutes of progressive intensity aerobic exercise (AE), and then 10 minutes of stretching for cool-down. Participants will have the ability to participate in training sessions facilitated via online channels at home.
223470311|NCT03567408|PROCEDURE|Selective PCI|Selective PCI for treatment of elderly patients (age≥65) presenting with diabetes mellitus.
223470312|NCT03567408|DRUG|Bivalirudin|Before, during and after surgery, bivalirudin was used according to the dosage regimen to assess it's impact on elderly patients with diabetes mellitus undergoing selective PCI.
223470313|NCT02870647|OTHER|Echocardiographic, polygraphy, electrocardiography measurements and sleep questionnaire|each patient is asked to undergo an echocardiographic, polygraphy, electrocardiography measurements, and respond to 2 sleep questionnaires, both at inclusion and after 6 months
223579176|NCT03480789|DRUG|Dexmedetomidine|given dexmedetomidine to meet RASS -1 from 22:00 to 6:00 of the next day
223579177|NCT03480789|DEVICE|eye patch|wearing the eye patch from 22:00 to 6:00 of the next day
223579178|NCT05682989|PROCEDURE|Urodynamic investigations before and after a mesh surgery protocol.|Urodynamic investigations (The urodynamic study included free uroflowmetry, postvoid residual, filling and voiding cystometry, and a urethral pressure profile. The filling cystometry and urethral pressure profile were performed with 37 degrees C normal saline similar to body temperature at an infusion rate of 80 ml/min.
224069019|NCT01950871|DEVICE|Prostate HistoScanning|In a single visit, subjects will first be imaged with TRUS for the purpose of generating data for prostate HS analysis. The results of HS analysis will be used later in the procedure. Subjects will then undergo two consecutive biopsy procedures. First, using TRUS, a systematic 10- to 12-core biopsy procedure will be performed. In turn, prostate HS data taken at the beginning of the procedure will be used to determine suspicious areas (displayed as red on an imaging monitor) and used to guide the biopsy procedure. Areas that are identified as suspicious (zero to a maximum of 3 areas) will then be sampled with two biopsy cores. Depending on the number of suspicious areas identified by prostate HS, the number of cores will be zero to a maximum of 6 cores.
223470314|NCT01403662|DRUG|Minocycline|Minocycline (100 mg bid) will be administered as an adjunctive agent to conventional Health Canada-approved, or first-line CANMAT bipolar guideline-recommended, agents for bipolar disorder.
223470315|NCT05775380|DRUG|Pioglitazone 45 mg|We investigated the role of pioglitazone hydrochloride 45mg/day for five days in patients admitted for coronary artery bypass grafting (CABG) in order to investigate vascular SPhk1 expression, vascular transcriptome and proteome remodeling, as well as S1P content in HDL
224069020|NCT01471782|BIOLOGICAL|Blinatumomab|Administered by continuous intravenous infusion
223470316|NCT01304797|DRUG|MM-302 Monotherapy|Escalating doses of MM-302 as a single agent
223470317|NCT01304797|DRUG|MM-302 in combination with trastuzumab|Escalating MM-302 at an every 4 week dosing schedule, while the dose of trastuzumab is fixed at an every 2 week dosing schedule
223470318|NCT01304797|DRUG|MM-302 in combination with trastuzumab q3w|Escalating MM-302 at an every 3 week dosing schedule, while the dose of trastuzumab is fixed at an every 3 week dosing schedule
223470319|NCT01304797|DRUG|MM-302 in combination with trastuzumab and cyclophosphamide|Escalating MM-302 at an every 3 week dosing schedule, while the dose of trastuzumab and cyclophosphamide is fixed at an every 3 week dosing schedule
223470320|NCT04184401|DRUG|Ascites replacement with albumin and hartmann's solution|"Combined strategy for ascites replacement~* 30% of ascites: replacement with 5% albumin~* 40% of ascites: replacement with Hartmann's solution"
223470321|NCT04184401|DRUG|Ascites replacement with hartmann's solution|"Hartmann's solution only strategy for ascites replacement~\- 70% of ascites: replacement with Hartmann's solution"
223579179|NCT05682989|PROCEDURE|Urodynamic investigations before and after a robotic-assisted sacrocolpopexy protocol.|All surgeries were performed using a DaVinci robotic system (Intuitive® Surgical Inc., Sunnyvale, California,US) with standardized technique and materials. Patients were positioned in dorsal lithotomy and steep Trendelenburg position. Trocars were placed bilaterally, and an assistant port was placed laterally. The peritoneum was opened medial to the ureter to develop an avascular space. The mesh was placed on the posterior and anterior vaginal wall and fixed at the level of anterior longitudinal ligaments S1/S2 by sutures. An intraoperative clinical examination was performed to ensure the mesh was in a tension-free position.
223579180|NCT05682989|PROCEDURE|Urodynamic investigations before and after a hysterectomy with trans-vaginal mesh repair|In summary, a vertical incision was made in the anterior vaginal wall to access the vesicovaginal space. The sacrospinous ligament was dissected, and an applicator was inserted and positioned over the SSL. The anchor was fixed to the SSL and the thread was attached to the mesh. The mesh was then adjusted in a tension-free manner, excess mesh was cut, and the incision was closed with suture.
223579181|NCT03422692|BIOLOGICAL|BioXclude amnion-chorion membrane|BioXclude will be used for the prevention of alveolar ridge resorption via socket bone graft and amnion-chorion membrane closure
224159666|NCT03923504|OTHER|Healthy Living Control|Patients randomized to the control arm will either attend online sessions via secure video conferencing (e.g. Zoom) or telephone or to come to a centralized meeting location (if safety allows) to participate in organized health workshops. Session attendance will be required 2 times/month (over the 6 months). Make up sessions will be offered for those participants who have to miss a group session. Each session lasts 60 minutes and matches the number of visits made by the PAI group as much as possible.
224159667|NCT01259921|BEHAVIORAL|neurofeedback|Operant conditioning of the EEG provided by computer reinforcement.
224159668|NCT00937508|BEHAVIORAL|Smoking counseling|Preoperative and postoperative counseling sessions provided by a trained smoking counselor along with placebo.
224159669|NCT00937508|DRUG|varenicline|varenicline (an approved medication for smoking cessation)
224159670|NCT00937508|DRUG|placebo|sugar pill without any active medication
224159671|NCT05923151|PROCEDURE|The cranial-caudal mixed medial approach|"Expose the fusion fascia of Transverse colon mesocolon and stomach, and cut the gastrocolic ligament. The mesentery of Transverse colon was dissociated from the medial side to the lateral side along the gastroepiploic vessels to expose the branches of Henle's trunk and the right colon vessels. The dorsal mesentery of the small intestine is cut along the yellow white line, and free cephalically along the Toldt space to separate the posterior space of the Ascending colon and the anterior space of the pancreas and duodenum behind the Transverse colon. The right colon blood vessels were dissected along SMV from the projection of ileocolic blood vessels, and the blood vessels were cut off by high ligation, and the lymph nodes at the root of Mesentery were cleared. Through a small incision in the middle of the abdomen, the right colon and mesentery were completely removed to complete digestive tract reconstruction."
224304981|NCT00106067|BEHAVIORAL|coping and communication support (CCS) intervention|"Trained clinical nurse specialists with masters� degrees in mental health will serve as CCS practitioners and they will be available to patients and family caregivers on a 24/7 basis to assist with coping and communication challenges as they may arise.~The CCS intervention is tailored to individual preferences over time, and designed to accommodate different age groups, especially older adults and their families."
223470322|NCT03758469|DRUG|HSK3486|Sequence 1: Intravenously infuse 0.4 mg/kg HSK3486 in the morning on an empty stomach. Complete infusion within 1 min.
224159672|NCT04137562|BIOLOGICAL|ADSTEM Inj.|Two 5mL of the following study drug is pre-mixed with 320mL of 0.9% normal saline is injected intravenously twice for the duration of the study. Treatment group: ADSTEM Inj. 0.5x10\^8 cells/5mL
224159673|NCT04137562|OTHER|Placebo|330mL of 0.9% normal saline is injected intravenously twice for the duration of the study.
224159674|NCT00650182|DRUG|fentanyl; naltrexone|
224159675|NCT03466112|OTHER|endurance training|endurance training with stationary bicycles
224159676|NCT03466112|OTHER|balance and tone program|flexibility, core strength, balance, relaxation
224159677|NCT00263835|BEHAVIORAL|Empowerment|
224159678|NCT04233710|COMBINATION_PRODUCT|Robot Rehabilitation + tDCS|Robotic therapy with Kinarm Exoskeleton Robot and 1 mA cathodal tDCS applied to contralesional M1 for 20 minutes.
224304982|NCT00002282|DRUG|Clotrimazole|
224304983|NCT00002282|DRUG|Fluconazole|
224159679|NCT04233710|BEHAVIORAL|Robotic Rehabilitation + sham tDCS|Robotic therapy with Kinarm Exoskeleton Robot and sham tDCS.
223470323|NCT03758469|DRUG|rifampin , HSK3486|Sequence 2: Orally take 600 mg rifampin once a day for 8 consecutive days in the morning on an empty stomach, followed by 1 min intravenous infusion of 0.4 mg/kg HSK3486 30 min later.
223470324|NCT03568201|DIAGNOSTIC_TEST|Transcutaneous oximetry|Measurement of TcpO2 on calves and chests. Calculation of the DROP index (decrease from rest of oxygen pressure)on both calves.
224159680|NCT00004210|OTHER|loss of heterozygosity analysis|
224159681|NCT00004210|OTHER|microsatellite instability analysis|
224159682|NCT00004210|OTHER|mutation analysis|
224159683|NCT00004210|OTHER|counseling intervention|
224159684|NCT00003852|BIOLOGICAL|filgrastim|
224159685|NCT00003852|DRUG|carboplatin|
223470325|NCT00103454|DRUG|GW685698X|
223470326|NCT00644761|DRUG|Adefovir Dipivoxil|Adefovir dipivoxil 10 mg once daily for 14 days co-administered with tacrolimus or cyclosporine
223470327|NCT02672072|OTHER|Simulation during the study (5-day specific training with dedicated scenario done by an ICU expert simulation team)|
223470328|NCT02672072|OTHER|questionnaire to define the presence of job strain at 6 months|
223470329|NCT02672072|OTHER|questionnaire to define the presence of job strain at 12 months|
223470330|NCT05343325|DRUG|Tislelizumab|Tislelizumab: 200 mg D1, Q3W for two cycles. Albumin-bound paclitaxel: 100mg/m2, D1, D8, D15, Q3W for two cycles. Cisplatin: 25mg/m2, D1, D8, D15, Q3W for two cycles.
223470331|NCT05343325|RADIATION|Low-dose radiotherapy|Low-dose radiotherapy: 1GY/1F, D1, D2, D8, D15, Q3W for two cycles. The total radiation dose will be GTV 8Gy/8F, GTVnd 8 Gy/8F.
223470332|NCT02900352|DRUG|Zonisamide|Titration of dose to 500mg oral, daily, over 8 weeks, then 7 weeks of treatment at that dose
223470333|NCT02900352|DRUG|Placebo|Placebo
223470334|NCT03074695|PROCEDURE|Dural puncture epidural (DPE)|Epidural with spinal needle placed to confirm cerebral spinal fluid (CSF) position. No intrathecal dosing
223470335|NCT03074695|PROCEDURE|Standard Epidural (EPL)|Standard epidural placement
223470336|NCT03074695|DRUG|Dural puncture epidural (DPE)|Epidural with spinal needle placed to confirm CSF position. No intrathecal dosing. Ropivacaine 0.1% and Fentanyl 2mcg/mL.
223470337|NCT03074695|DRUG|Standard Epidural (EPL)|Standard epidural placement. Ropivacaine 0.1% and Fentanyl 2mcg/mL.
223470338|NCT02419872|DRUG|Marketed antagonists|Medication for each patient is determined by the physician based on the patient's individual clinical profile and in accordance with the approved indication and label of the prescribed drug
223470339|NCT02945436|BEHAVIORAL|Substance Use Brief Intervention|SUBI is a counseling intervention based on Motivational Interviewing techniques that focuses on the substance use and sexual health risks of participants.
223470340|NCT02945436|BEHAVIORAL|Standard of Care (SOC)|Standard of care is Counseling Testing and Referral (CTR). CTR is a standardized service in which counselors provide HIV testing, risk-related counseling and appropriate referrals (medical, social, prevention, and partner services) to clients.
223470341|NCT02552485|OTHER|No intervention was applied, because it is an observational study|
223470342|NCT03017807|BIOLOGICAL|Recombinant Anti-EGFr Antibody|Low-dose level patients received cetuximab initial dose 100 mg/m2 and 4 weeks later 250 mg/m2 weekly maintenance to the disease progression or unacceptable toxicity or death or withdraw informed consent.High-dose level patients received cetuximab initial dose 400 mg/m2 and 4 weeks later loading 400 mg/m2 and 250 mg/m2 weekly maintenance to the disease progression or unacceptable toxicity or death or withdraw informed consent.
223470343|NCT00061789|DRUG|SPECT Imaging of Nicotinic Acetylcholine Receptors in Brain|
223470344|NCT04345003|DEVICE|Myoma elastography|"The standard pre-therapeutic assessment includes a pelvic US to eliminate the presence of calcification of fibroids. If this absence is confirmed, the elasticity of uterine myoma (by ARFI method) will be measured.~The standard pre-therapeutic MRI performed allows to classify and measure the myoma in order to determine if it is accessible for HIFU treatment. MRI elastography sequence with the Resoundant® system will be performed during this exam."
223470345|NCT01774981|DRUG|Placebo|Administered IV
223470346|NCT01774981|DRUG|LY3016859|Administered IV
223470347|NCT00407225|DRUG|Difluprednate Ophthalmic Emulsion|
223470348|NCT00960193|DRUG|Colchicine|A single dose of 0.6 mg colchicine administered alone in the morning on Day 1 and a single dose of 0.6 mg colchicine administered with Seville orange juice in the morning on Day 18 after an overnight fast of at least 10 hours.
224159686|NCT00003852|DRUG|cyclophosphamide|
223470349|NCT00960193|OTHER|Seville Orange Juice|240 mL of Seville orange juice administered in the morning and evening on Days 15 to 18.
223470350|NCT02625701|PROCEDURE|Goal-directed therapy|Optimize CO with additional fluid according to dynamic indices (PPV, SVV, Stroke volume)
223470351|NCT02625701|PROCEDURE|Restrictive fluid therapy|Keep normovolemia with basal crystalloids infusion (3-6 ml/kg/h) and compensate additional fluid losses with colloids or crystalloids.
223470352|NCT01227369|OTHER|OPSAT-Q|A linguistically validated Korean version of OPSAT-Q
223470353|NCT02360046|DRUG|Hydrocortisone|Established Hydrocortisone replacement therapy plus Hydrocortisone (10mg/day)
223470354|NCT02360046|DRUG|Placebo|Established Hydrocortisone replacement therapy plus Placebo (0mg Hydrocortisone)
223470355|NCT05719181|BIOLOGICAL|rhBMP-2|Recombinant Human Bone Morphogenetic Protein-2 with an Absorbable Collagen Sponge .
223470356|NCT03006237|DRUG|IS-001|10mg, 20mg or 40 mg IV IS-001 drug administered during surgery
223470357|NCT03006237|DEVICE|da Vinci® Si/Xi Surgical System|robot-assisted minimally invasive hysterectomy surgery performed with da Vinci® Si/Xi Surgical System with Firefly® Fluorescent Imaging
223470358|NCT05482802|BEHAVIORAL|An active training tool on weight bias and knowledge about obesity|The intervention will take place at the university simulation center and include three components. First, a short lecture on obesity and weight bias. Second, four scenarios that simulate meetings between health professionals and people with obesity which will be presented by professional role-players in sequence. Each scenario will include a different therapeutic situation and include varying degrees of weight bias, stigma, and discrimination to stimulate students to think and react. Third, an active open discourse with a person with obesity will be held.
223470359|NCT05482802|BEHAVIORAL|A short-written document on obesity|A short-written document on obesity which will be based on current literature.
223470360|NCT02310074|DRUG|Pulsatile Gonadotropin Releasing Hormone|
223470361|NCT02310074|DRUG|Human chorionic gonadotropin|Human chorionic gonadotropin (hCG)
223470362|NCT02310074|DRUG|Urinary Follicle-Stimulating Hormone|Urinary Follicle-Stimulating Hormone (uFSH)
223470363|NCT00716612|DRUG|Coenzyme Q 10|PO Coenzyme Q 10 120 mg QD
223470364|NCT00716612|DRUG|Placebo control|po Placebo QD
223470365|NCT05455827|OTHER|fMRI neurofeedback (A)|Participants will be shown feedback about the BOLD activation within the subgenual anterior cingulate cortex to enhance differences between the self-blame and other-blame conditions
223470366|NCT05455827|OTHER|fMRI neurofeedback (B)|Participants will be shown feedback about the BOLD activation within the subgenual anterior cingulate cortex to minimise differences between the self-blame and other-blame conditions
224159687|NCT00003852|DRUG|epirubicin hydrochloride|
223579182|NCT03422692|BIOLOGICAL|Mem-Lok collagenous membrane|Mem-Lok will be used for the prevention of alveolar ridge resorption via socket bone graft and collagenous membrane closure
223579183|NCT00276094|DRUG|Ospemifene 30 mg|1 tablet (dose 30 mg/day) taken each morning with food for 12 weeks - from Visit 2 (Randomization, Day 1) to Visit 4 (Week 12).
223470367|NCT03918265|DRUG|Tacrolimus|On refractory autoimmune cytopenia patients, tacrolimus was tried. Dosage: 1mg bid and tacrolimus trough targets were 5-10 ng/ml throughout the study
223579184|NCT00276094|DRUG|Ospemifene 60 mg|1 tablet (dose 60 mg/day) taken each morning with food for 12 weeks - from Visit 2 (Randomization, Day 1) to Visit 4 (Week 12).
223579185|NCT00276094|DRUG|Placebo|1 tablet taken each morning with food for 12 weeks - from Visit 2 (Randomization, Day 1) to Visit 4 (Week 12).
223579186|NCT00276094|DRUG|Nonhormonal vaginal lubricant|Subjects should apply the vaginal lubricant as needed and record the usage in the medication diary.
223470368|NCT01978457|DRUG|cocaine hydrochloride|
223470369|NCT01978457|DRUG|propranolol|
223470370|NCT01978457|DRUG|placebo|
223470371|NCT05540145|DRUG|SOX plus Paclitaxel with or without antiangiogenesis followed by PD-1 antibody|"Drug: Paclitaxel(albumin-bound) 130mg/m2, ivgtt, D1, Q2w Drug: Oxaliplatin 70 mg/m2, ivgtt, D1, q2w Drug: S-1 40mg (body surface area \< 1.25m2), bid, D1-8, Q2w 50mg (body surface area \>1.25m2, \<1.5 m2), bid, D1-8, Q2w 60mg (body surface area \>1.5m2), bid, D1-8, Q2w Drug: Bevacizumab, 5mg/kg, ivgtt, D1, Q14d Drug: PD-1 antibody, 200mg, ivgtt, D1, Q21d Patients with Her-2 negative, MMR-proficient locally advanced esophagogastric junction or gastric adenocarcinoma will receive 6 cycles of neoadjuvant chemotherapy with or without antiangiogenesis. After comprehensive evaluations, patients who respond to chemotherapy will further receive 2 cycles of PD-1 antibody comibed with antiangiogenesis and chemotherapy as neoadjuvant therapy.~Drug: Pembrolizumab or sintilimab, 100\~200mg, ivgtt, D1, Q3w. Patients will make the final decision of PD -1 antibody according to their economic condition."
223579187|NCT01690351|DRUG|PF-05089771|Oral dispersion TS formulation- fasted
223743731|NCT07191470|DEVICE|The Anaesthetic Conserving Device (AnaConDa)|The Anaesthetic Conserving Device (AnaConDa) was developed to facilitate the use of volatile anesthetics like isoflurane and isoflurane in mechanically ventilated patients outside the operating room. The device functions as a passive vaporizer, conserving anesthetic agents and reducing environmental contamination. Studies have demonstrated that AnaConDa-based inhaled sedation offers several advantages over intravenous sedation like better hemodynamic stability, reduced systemic inflammation, and faster recovery times.
223579188|NCT01690351|DRUG|PF-05089771|Capsules TS formulation- fasted
223579189|NCT03542851|DRUG|Pentetrazol (PTZ)|BTD-001 is an oral capsule of PTZ.
223743732|NCT07191405|DIETARY_SUPPLEMENT|oral Lactobacillus johnsonii (1×10¹¹ CFU, twice daily)|Lactobacillus johnsonii, as a member of gut probiotics, has recently gained attention for its potential role in tumor immunotherapy due to its ability to modulate the immune system and maintain gut microbiota balance. Below is a summary of its possible mechanisms and applications: 1.Modulating Gut Microbiota and Immune Microenvironment. 2.Direct or Indirect Activation of Anti-Tumor Immunity. 3.Enhancing Efficacy of Immune Checkpoint Inhibitors (ICIs) . 4.Anti-Tumor Effects of Microbial Metabolites. 5.Preclinical and Clinical Research Progress.
223743733|NCT07191405|DIETARY_SUPPLEMENT|Placebo|oral take placebo twice a day
223743734|NCT07191145|DRUG|Eptinezumab|Eptinezumab 300mg IV
223743735|NCT07191145|OTHER|Placebo|Control - placebo IV
224069021|NCT02164695|PROCEDURE|PPCI plus RIPC|All patients will be prepared with an upper-arm blood pressure cuff before arterial puncture (contralateral in case of radial access). In patients allocated into PPCI plus RIPC group, the protocol will be started immediately after cuff preparation. Upper-arm will be exposed to 4 cycles of ischemia/reperfusion, each obtained by 5 min cuff inflation at 200mmHg, followed by 5 min complete deflation.
224069022|NCT02164695|PROCEDURE|PPCI only|All patients randomized to PPCI only arm, the blood pressure cuff will be applied to the arm or the calf but will not be inflated.
224069023|NCT03363815|DRUG|CC-90001|CC-90001
224069024|NCT03363815|DRUG|Omeprazole|Omeprazole
224069025|NCT03363815|DRUG|Midazolam|Midazolam
224069026|NCT03363815|DRUG|Warfarin|Warfarin
224069027|NCT03363815|DIETARY_SUPPLEMENT|Vitamin K|Vitamin K
224069028|NCT03363815|DRUG|Rosuvastatin|Rosuvastatin
224069029|NCT03363815|DRUG|Metformin|Metformin
224069030|NCT03363815|DRUG|Digoxin|Digoxin
224069031|NCT03363815|DRUG|Nintedanib|Nintedanib
224069032|NCT04117971|OTHER|Questionnaire|The study will involve structured questionnaire asking questions about knowledge, attitude, and practice of child abuse diagnosis and reporting among dentists.
224069033|NCT03473288|BEHAVIORAL|Exercise|Participants will undergo supervised exercise 3 times a week for 10-12 weeks.
223470372|NCT04555603|DRUG|Inlyta|axitinib
223470373|NCT04555603|DRUG|Bavencio|avelumab
223470374|NCT04555603|DRUG|Keytruda|Pembrolizumab
223579190|NCT03542851|DRUG|Placebo oral capsule|Placebo will be presented as oral capsule.
223579191|NCT00991783|DRUG|Digoxin + Fimasartan|Digoxin (7 days), Digoxin + Fimasartan (7 days)
223579192|NCT05585515|BEHAVIORAL|Sleep deprivation|Total sleep deficit of consecutive 8 hours
223579193|NCT05585515|BEHAVIORAL|Sleep restriction|Total sleep deficit of cumulative 8 hours
224069034|NCT03473288|BEHAVIORAL|Sedentary|Participants will be asked to maintain the sedentary lifestyle that they already have for 10-12 weeks.
224069035|NCT05779137|BEHAVIORAL|MBCT|Patients will join a mindfulness-based cognitive therapy course at the Radboudumc Center for Mindfulness. The course consists of eight weekly sessions of 2.5-hour and one 6-hour silence day between the 6th and 7th session. The sessions include meditation exercises (body-scan, sitting meditation, gentle movement exercises, three-minute breathing space, daily activities with attention), psychoeducation and group discussion. Psychoeducation includes information on cognitive techniques, like monitoring and scheduling of events and identification of negative automatic thoughts. In addition, all participants will be encouraged to perform daily practice assignments at home for about 30-45 minutes per day, mainly consisting of meditation exercises.
224159688|NCT00003852|DRUG|etoposide|
224159689|NCT00003852|DRUG|ifosfamide|
224159690|NCT00003852|DRUG|paclitaxel|
224159691|NCT00003852|DRUG|thiotepa|
224159692|NCT00003852|PROCEDURE|bone marrow ablation with stem cell support|
223470375|NCT01239797|DRUG|Lenalidomide|Capsules, Oral, 25 mg, once daily, on Days 1-21, Repeat every 28 days until subject meets criteria for discontinuation of study drug
224159693|NCT00003852|PROCEDURE|peripheral blood stem cell transplantation|
223470376|NCT01239797|DRUG|Dexamethasone|Tablets, Oral, 40 mg, weekly, on Days 1, 8, 15, 22, Repeat every 28 days until subject meets criteria for discontinuation of study drug
223470377|NCT01239797|DRUG|Dexamethasone (Oral)|"On weeks without Elotuzumab dosing: Tablets, Oral, 40mg, Repeat every 28 days until subject meets criteria for discontinuation of study drug.~On weeks with Elotuzumab dosing: Tablets, Oral, 28 mg, Repeat every 28 days until subject meets criteria for discontinuation of study drug"
223470378|NCT01239797|DRUG|Dexamethasone (IV)|"On weeks without Elotuzumab dosing: Not Applicable (N/A)~On weeks with Elotuzumab dosing: Solution, Intravenous (IV), 8 mg, weekly, Repeat every 28 days until subject meets criteria for discontinuation of study drug"
223470379|NCT01239797|BIOLOGICAL|Elotuzumab (BMS-901608; HuLuc63)|Solution, IV, 10 mg/kg, weekly, on Days 1, 8, 15, 22 (cycles 1\&2); Days 1 and 15 (cycles 3 and beyond), Repeat every 28 days until subject meets criteria for discontinuation of study drug
223470380|NCT01276977|DRUG|Zolmitriptan 5 mg Nasal Spray|Patients will treat 2 migraine attacks with zolmitriptan 5 mg nasal spray and 2 migraine attacks with eletriptan.
223470381|NCT01276977|DRUG|Eletriptan 40 mg tablet|Patients will treat 2 migraine attacks with Eletriptan and 2 migraine attacks with zolmitriptan 5 mg nasal spray
223470382|NCT06043466|BIOLOGICAL|CEA-targeted CAR-T cells|Administration method: intravenous infusion； Subjects will receive conditioning therapy by Fludarabine and Cyclophosphamide before cell infusion.
223470383|NCT05567536|DRUG|Antiplatelet Agents|Patients who received a single antiplatelet agent will be analyzed according to the prescribed antiplatelet agent
223470384|NCT00122057|DRUG|antibiotic treatment|
223470385|NCT05117853|DRUG|Autofluorescent detection + Injection of indocyanine green|"All four parathyroid glands will be actively sought for in every case selected for the use of AF/ICG, with AF verification of parathyroid tissue.~The timepoints of AF will be:~* 1 = after lateral dissection side 1 (side 1)~* 2= after lateral dissection side 2 (side 2)~The timepoints of ICG injection will be:~* 1 = after the first thyroid lobectomy (side 1)~* 2 = after the second thyroid lobectomy (side 2)~Scoring of the viability of parathyroid glands (adapted from Vidal Fortuny et al., 2016):~* 1 = black = not viable/vascularized~* 2 = grey = moderately viably/ moderately vascularized~* 3 = white = viable/well-vascularized"
223470386|NCT05117853|PROCEDURE|Gold standard of visual identification and evaluation of viability of the parathyroid glands.|Gold standard of visual identification and evaluation of viability of the parathyroid glands.
223470387|NCT05670444|DRUG|kelavit|The treatment group received two pills in the morning containing Vit C Vit D zinc and minerals and one pill of 2 mg of melatonin in the evening
223470388|NCT01854814|DRUG|Mycophenolate mofetil|Mycophenolate mofetil 1.5g/day plus maximum tolerated labeled dose losartan
223470389|NCT01854814|DRUG|Losartan|Maximum tolerated labeled dose of Losartan
223470390|NCT02135952|PROCEDURE|SRP|SRP in four to six appointments lasting approximately 1 h each, using manual curettes and ultrasonic device under local anesthesia.
223470391|NCT02135952|OTHER|Placebo|Administration of placebo for 14 days started immediately after the first session of SRP.
223470392|NCT02135952|DRUG|MTZ+AMX|Administration of antibiotics (metronidazole and amoxicillin) for 14 days started immediately after the first session of SRP.
223470393|NCT00434824|DRUG|Oral testosterone undecanoate (Andriol)|treatment for 12 months with oral TU 80 mg/d, oral TU 160 mg/d or oral TU 240 mg/d in divided doses
223470394|NCT00434824|DRUG|Placebo|treatment for 12 months with placebo in divided doses
223470395|NCT03108482|DRUG|Co-crystal E-58425 (Tramadol/Celecoxib)|Co-crystal E-58425 (Tramadol/Celecoxib): Two immediate release oral over-encapsulated tablets of 100 mg, every 12 hours for 48 hours.
223470396|NCT03108482|DRUG|Tramadol (Ultram®)|Tramadol: One immediate release oral over-encapsulated tablet of 50 mg, every 6 hours for 48 hours.
223579194|NCT01511809|DRUG|Atazanavir/ritonavir monotherapy|Monotherapy Simplification Strategy with Atazanavir/ritonavir 300/100 mg once daily for 96 weeks.
223743736|NCT07189975|OTHER|High intensity eccentric cycling training|This intervention is a high intensity interval training using an eccentric ergocycle
224069036|NCT05567237|OTHER|Microcurrent treatment with resistance exercise programme|This intervention will allow us to explore the effects of microcurrent added to resistance exercise.
224069037|NCT05567237|OTHER|Resistance exercise programme|This intervention works as a control group for the participants undergoing the exercise programme.
223470397|NCT03108482|DRUG|Celecoxib (Celebrex®)|Celecoxib: One immediate release oral over-encapsulated capsule of 100 mg, every 12 hours for 48 hours.
223470398|NCT03108482|DRUG|Placebo|Placebo 100 mg or 200 mg oral over-encapsulated tablets every 6 hours for 48 hours.
223579195|NCT02020772|OTHER|coordinating primary health care|
223579196|NCT02020772|OTHER|usual primary health care|
223579197|NCT00788580|DRUG|pazopanib hydrochloride|
223579198|NCT00788580|DRUG|temsirolimus|
223579199|NCT00788580|PROCEDURE|immunoenzyme technique|
223579200|NCT00788580|PROCEDURE|laboratory biomarker analysis|
224069038|NCT05567237|OTHER|Microcurrent treatment|This intervention will allow us to explore the effects of microcurrent alone.
224069039|NCT05567237|OTHER|No treatment|This intervention works as a control group for the participants who are not taking part into the exercise programme.
223579201|NCT00788580|PROCEDURE|pharmacological study|
224069040|NCT03976973|DRUG|Bromelain|Intratumoural injections of Bromelain 600ug/ml (maximum dose 90mg daily diluted in 150ml 0.9% NaCl) via a radiologically placed drain in combination with Acetylcysteine in 0.9% sodium chloride (normal saline).
224069041|NCT03976973|DRUG|Acetylcysteine|Intratumoural injections of Acetylcysteine 20mg/ml (maximum dose 3g daily diluted in 150ml 0.9% NaCl) via a radiologically placed drain in combination with Bromelain.
224159694|NCT01536652|DRUG|biphasic insulin aspart 30|Prescription at the discretion of the treating physician
224304984|NCT03097510|BEHAVIORAL|Transcendental meditation|The TM technique was taught as a standard 7 step course over 4 consecutive days. Thereafter, subjects attended bimonthly group meetings for more advanced knowledge over the four month intervention period.
224304985|NCT00788138|DIETARY_SUPPLEMENT|Vitamin D3|250,000 IU of vitamin D3
224304986|NCT00788138|DIETARY_SUPPLEMENT|Placebo|Matching Placebo
223470399|NCT02675166|OTHER|Pediatric cancer young adult survivors|Patients will receive a questionnaire, a consultation with an oncologist and a psychologist will be planned, and two years later, patients will have to answer again to the questionnaire.
223470400|NCT04212117|OTHER|The Patient Activated Learning System (PALS)|Randomization into PALS arm.
223470401|NCT04212117|OTHER|WebMD|Randomization into WebMD arm.
223470402|NCT01189097|DRUG|Dextromethorphan|Subjects who have not used opioid for at least one week before baseline evaluation will take one-week placebo for the wash-out period first and then will be categorized into the opioid free group. The subjects of the opioid using group will be assigned randomly into the following six groups: 1) Methadone + DM 60mg; 2) Methadone + DM 120mg; 3) Methadone + Placebo; 4) Methadone + DM 60mg + motivation and cognitive behavior therapy; 5) Methadone + DM 120mg + motivation and cognitive behavior therapy; 6) Methadone + Placebo + motivation and cognitive behavior therapy. The opioid free group will be 1) DM 30mg; 2) DM 60 mg; 3) Placebo.
223470403|NCT01189097|DRUG|Dextromethorphan|Subjects who have not used opioid for at least one week before baseline evaluation will take one-week placebo for the wash-out period and then randomly assigned into six groups: 1) Methadone + DM 60mg; 2) Methadone + DM 120mg; 3) Methadone + Placebo; 4) Methadone + DM 60mg + motivation and cognitive behavior therapy; 5) Methadone + DM 120mg + motivation and cognitive behavior therapy; 6) Methadone + Placebo + motivation and cognitive behavior therapy. The opioid free group will be 1) DM 30mg; 2) DM 60 mg; 3) Placebo. If the subjects of the opioid free group suffer from relapses and begin to use heroin, they will receive methadone treatment. The dosage of methadone will be increased or decreased maximal 5 mg each time as necessary.
223470404|NCT02735031|DRUG|Exenatide|6 weeks treatment with exenatide on top of insulin treatment
223470405|NCT02735031|DRUG|Placebo|6 weeks treatment with placebo on top of insulin treatment
223470406|NCT00021788|PROCEDURE|islet cell transplantation|
223470407|NCT05387616|DRUG|Copanlisib|"Induction therapy will comprise 6 cycles of copanlisib, administered by intravenous Infusion at a dose of 60 mg on day 1,8,15 of cycles 1-6 to be given every 28 days.~Consolidation therapy will comprise another 24 weeks of copanlisib in patients with clinical Remission 28 days after the last induction cycle. It will be administered by intravenous Infusion at a dose of 60 mg on days 1 and 15 of cycles 7 - 12 to be given every 28 days.~Maintenance therapy will comprise another 72 weeks of copanlisib in patients with clinical remissions 28 days after the last consolidation cycle."
223470408|NCT05387616|DRUG|Obinutuzumab|"Induction therapy will comprise 6 cycles of obinutuzumab, administered by intravenous infusion at a dose of 1000 mg on days 1,8, 15 of cycle 1 and on day 1 of cycles 2 - 6 to be given every 28 days.~Consolidation therapy will comprise of another 24 weeks of obinutuzumab in patients with clinical remission 28 days after the last induction cycle. Obinutuzumab will be applied at a dose of 1000 mg by intravenous infusion every 8 weeks.~Maintenance therapy will comprise another 72 weeks in patients with clinical remission 28 days after the last consolidation cycle. Obinutuzumab will be applied at a dose of 1000 mg by intravenous infusion every 8 weeks."
223470409|NCT00873158|DEVICE|Dynasplint|"Dynamic splinting utilizes the protocols of Low-Load Prolonged Stretch (LLPS) with calibrated adjustable tension to increase Total End Range Time (TERT)to reduce contracture. The Dynasplint or Experimental group will add this therapy to their standard of care regimen"
223470410|NCT06445933|COMBINATION_PRODUCT|Vitamin B6|The intervention is taking Vitamin B6 orally from recruitment around 24-28 gestational weeks to 6 weeks post-partum. 75mg/ day before delivery and 50mg/ day after delivery.
223470411|NCT06445933|COMBINATION_PRODUCT|Placebo|Placebo
223470412|NCT02631941|DRUG|Z7200 without oral activated charcoal|160 ug budesonide and 4.5 ug formoterol fumarate dihydrate, administered as two inhalations (2 x Z7200 capsules) of budesonide 80 ug/inhalation and formoterol 2.25 ug/inhalation, using an RS01 inhaler (Treatment A).
223470413|NCT02631941|DRUG|Symbicort Turbohaler without oral activated charcoal|320 ug budesonide and 9 ug formoterol fumarate dihydrate, administered as two inhalations of budesonide 160 ug/inhalation and formoterol 4.5 ug/inhalation (Treatments B1 and B2 denote Symbicort without oral activated charcoal administered in two different periods).
223470414|NCT02631941|DRUG|Z7200 with oral activated charcoal|160 ug budesonide and 4.5 ug formoterol fumarate dihydrate, administered as two inhalations (2 x Z7200 capsules) of budesonide 80 ug/inhalation and formoterol 2.25 ug/inhalation, using an RS01 inhaler with a charcoal blockade (Treatment C).
223470415|NCT02631941|DRUG|Symbicort Turbohaler with oral activated charcoal|320 ug budesonide and 9 ug formoterol fumarate dihydrate, administered as two inhalations of budesonide 160 ug/inhalation and formoterol 4.5 ug/inhalation from a Symbicort Turbohaler, with charcoal blockade (Treatment D).
223470416|NCT04246463|DEVICE|Thoracic|Implant of a Relay stent graft system
223470417|NCT04246463|DEVICE|Abdominal|Implant with an Anaconda or Treo Stent graft system
223743737|NCT07189975|OTHER|Moderate intensity eccentric cycling training|This intervention is a moderate intensity continuous training using an eccentric ergocycle
224069042|NCT03976973|PROCEDURE|Interventional radiology insertion of drain|Under radiological guidance (CT), a needle, wire, dilator will be placed directly into the tumour, then a pigtail drain (10Frg) will be secured into the tumour by an experienced, interventional radiologist, under standard procedures. This drain is utilised as access to the tumour for injections of the investigational drug product BromAc, and subsequent aspirations.
224069043|NCT01403012|OTHER|Withdrawal of venous blood samples|"Withdrawal of venous blood samples (approx. 20 ml) and 2 skin biopsies (5 mm)~Laboratory measurements:~Fasting serum concentrations of 200 metabolites covering a biologically relevant panel of amino acids, sugars, acylcarnitines and phospholipids Genome-wide expression profiles generated from RNA derived from peripheral leukocytes"
224069044|NCT03927274|DRUG|Topotecan|Intratumorally-administered topotecan using convection-enhanced delivery (CED) in patients with suspected recurrent/progressive High Grade Glioma (HGG) requiring stereotactic biopsy and is focused on investigating topotecan brain tissue distribution and determining the safety, toxicity, and tolerability of intratumorally-administered topotecan.
224159695|NCT05103475|BEHAVIORAL|Rage Against the Pain (RAP)|The sets of body positions used in the RAP program will mirror those used in the Hatha Yoga classes, but the RAP program will differ from this traditional yoga practice in a number of ways: (1) the classes will be set to rock/heavy metal music; (2) meditation will not be incorporated; (3) yoga terms will not be used to describe the body positions (rather, positions will be cued in plain descriptive English terms); (4) the culminating activity for the class will be called a 'cool down' (rather than the savasana exercise typically used in yoga practice).
223470418|NCT04246463|DEVICE|Custom Device|Implant of a Fenestrated device such as Fenestrated Anaconda or Fenestrated TREO, Relay Branch or other customised device
223470419|NCT04246463|DEVICE|Illiac Artery|Implant with an Anaconda Iliac leg only
223470420|NCT06227650|DEVICE|hybrid closed loop insulin delivery system|Patients with secondary pancreatic diabetes equipped with a hybrid closed loop insulin delivery device
223470421|NCT01054963|BEHAVIORAL|peer mentor training|A quasi-experimental, before and after study design is proposed to obtain data for planning and implementing a larger-scale study. A training workshop for individuals with IA to become peer mentors will increase peer mentors' confidence and skills to provide one-on-one support to individuals with EIA. Using a combination of lectures, experiential learning and question/answer sessions, peer mentors will learn and practice informational, emotional, appraisal support techniques and skills (communication skills, problem-solving strategies, use of decision tools). Training will be conducted face-to-face, in small-group format by research team and others (2 sessions approx. 5 hours each), in a private meeting room at SHSC. Peer mentors will then provide support to individuals newly diagnosed with IA for 12 weeks (once per week) by telephone and /or face-to-face. Peer mentors will receive ongoing support from the research team (telephone, meetings).
223470422|NCT02280330|DIETARY_SUPPLEMENT|MNP group|MNP contains 15 vitamins an minerals, including Vitamin ADEC, B1, B2, B6, B12, Niacin, Folic Acid, Iron, Zine, Copper, Selenium and Iodine. There is 90 microgram of iodine per sachet of one gram of MNP.
223470423|NCT02280330|OTHER|Placebo group|The placebo is maltodextrin which is prepared as a white powder with similar physical characteristics and taste as MNP.
223470424|NCT00880841|DRUG|Buprenorphine / Naloxone|oral formulation of buprenorphine / naloxone
223470425|NCT02915835|DRUG|Riociguat|riociguat 0.5 mg, 1 mg, 1.5 mg, 2 mg and 2.5 mg administered TID; dose titration starting with 1.0 mg (planned up-titration every 2 weeks, with possibility of dose reduction for tolerability; 0.5 mg is the lowest dose and 2.5 mg is the highest dose to be administered)
223470426|NCT02915835|DRUG|Placebo|Placebo 0.5 mg, 1 mg, 1.5 mg, 2 mg and 2.5 mg administered TID;
223470427|NCT00967122|PROCEDURE|Band adjustment and specimen collection|Clinical evaluation and sample collection before and after band adjustment
223579202|NCT04259684|DRUG|gases Nitric Oxide (gNO)|Participants in the intervention group will receive gNO blended into the fresh gas flow of the cardiopulmonary bypass (CPB) oxygenator and maintained at 20 ppm via an Ikaria INO Max DSIR (Mallinckrodt Pharmaceuticals, St. Louis, Missouri, USA), with continuous sampling of NO and NO2 concentration from a port adjacent to the oxygenator. The gNO delivery will be initiated when the patient is on CPB and stopped once the patient comes off CPB.
223579203|NCT06090032|DEVICE|Ultrasound|We will use ultrasongraphy as a part of assessment in respiratory intensive care unit patients with ventilator associated pneumonia
223579204|NCT00170196|DRUG|prednisone|
223579205|NCT01747252|DIETARY_SUPPLEMENT|RGC|
223579206|NCT01747252|DIETARY_SUPPLEMENT|RGC|
224069045|NCT02479009|DEVICE|Fluoroscopy|Each patient will undergo fluoroscopy-imaging evaluation in the office to determine whether the fracture moves (instability). The investigators will deviate the wrist from ulnar to radial and back in posteroanterior, oblique and lateral views with the wrist in neutral flexion. Any angulation or translation at the fracture site or more than one millimeter displacement or gap will be considered as a sign of instability. The fluoroscopy will be viewed and an image showing the largest gap will be saved. The diagnosis of instability (which is the same as displacement with this test) will be made by consensus of the research team.
224069046|NCT06330038|DRUG|Propofol|Propofol will be used for the induction and maintenance of general anesthesia.
224069047|NCT06330038|DRUG|Inhaled anesthetics|Inhaled anesthetics will be used for the maintenance of general anesthesia.
224069048|NCT04290832|BEHAVIORAL|CO Intervention|"South Africa: Values clarification and attitude transformation (VCAT) workshop with conscientious objection content, debrief session(s) with termination of pregnancy (TOP) providers to give them an opportunity to share concerns/challenges, meeting(s) with facility mangers to facilitate continued support and provision of TOP care~Mexico: Training on abortion and conscientious objection law, posters on law, offer of legal assistance for abortion providers, scholarship to attend conference awarded on basis of quality of abortion care"
224069049|NCT02922062|OTHER|Canola Oil|Subjects will be provided with all their meals prepared in our metabolic kitchen in order to control their diets. The major cooking oil used in food preparation will be canola oil. The meals will be tailored to the caloric needs of each individual in order to maintain their body weight.
224069050|NCT02922062|OTHER|Palm Oil|Subjects will be provided with all their meals prepared in our metabolic kitchen in order to control their diets. The major cooking oil used in food preparation will be palm oil. The meals will be tailored to the caloric needs of each individual in order to maintain their body weight.
224159696|NCT05103475|BEHAVIORAL|Control|The control group will comprise a program akin to Hatha yoga with chair modifications available to all Veterans who choose/need to use them.
223470428|NCT03046849|OTHER|next-generation sequencing|Use next-generation sequencing to test germline mutation.
223470429|NCT02426801|DEVICE|Inhaler sensor|Inhaler sensor strap that tracks inhaler use via a pressure sensitive switch.
223470430|NCT02426801|BEHAVIORAL|Mobile application for asthma adherence|Mobile phone application that sends reminders, allows patients to see their medication use, and provides points and other incentives for medication use.
223470431|NCT03722576|DRUG|Vidofludimus calcium|During the 6-month treatment period, subjects will receive 30 mg VC orally once daily. This will be preceded by a lead-in dosing period where subjects will receive 15 mg VC once daily for 1 week.
223470432|NCT05803460|BEHAVIORAL|Stage 1 Experimental A group: actual natural environment|Participants will go to the park and sit still for 20 minutes.
223470433|NCT05803460|BEHAVIORAL|Stage 1 Experimental B group: virtual reality natural environment|Participants will experience the virtual reality natural environment by the researcher for 20 minutes
223470434|NCT05803460|BEHAVIORAL|Stage 1 Control group: city environment|Participants will sit still for 20 minutes in a city environment.
223579207|NCT01747252|DIETARY_SUPPLEMENT|Resveratrol|The equivalent of 150 mg resveratrol
223470435|NCT05803460|BEHAVIORAL|Stage 2 group|tree element virtual natural environment and tree and water element virtual natural environment experiences
224159697|NCT06508528|BEHAVIORAL|a 12-week growth mindset intervention|This is a 12-week growth mindset intervention for the nursing students during clinical rotation practice. It aims at promoting the core self-evaluation and professional sefl-efficacy for them. The intervention has 12 themes, with each intervention lasting 15 to 20 minutes. Intervention will be carried out through a combination of online and offline methods.
223470436|NCT05803460|BEHAVIORAL|Stage 3 Experimental group: virtual reality natural environment|virtual reality natural environment programs for 2 time a week (40 mins/ every week) and 8weeks.
223470437|NCT05803460|BEHAVIORAL|Stage 3 Control group: routine care|Control group received routine care last for 8 weeks.
224159698|NCT06508528|OTHER|Hospital mentoring|The control group will receive guidance from the hospital. Including self-regulation of stress, self-protection in clinical practice, and so on
223470438|NCT01958905|DRUG|Artemether-lumefantrine fixed combination|
223470439|NCT06375382|OTHER|acupuncture|We selected acupoints including Zhongwan (CV12) and bilateral Shangjuxu (ST37), Sanyinjiao (SP6), Gongsun (SP4), Taichong (LR3), Taixi (KI3), Hegu (LI4), and Quchi (LI11)17 according to the World Health Organization standard. Single-use 0.30×40 mm or 0.30×25 mm acupuncture needles (Hwato, Suzhou, China) 27,28 were vertically inserted into each acupoint to 20-30 mm depth to obtain a deqi sensation (a soreness, distention, numbness or heaviness sensation). Bilateral Zusanli (ST36) and Tianshu (ST25) were selected for moxibustion. Pure moxa sticks (diameter: 2.8 cm; Hanyi, Nanyang, China) were ignited and fixed on a moxibustion stand at a distance of 3-5 cm to the surface of acupoints. The temperature of skin surface at the acupoints was maintained at 43 ± 1°C and monitored with a miniature infrared thermometer (Fluke 62, Fluke Corporation, Everett, WA, USA). Acupuncture and moxibustion were concomitantly performed for 30 min.
223470440|NCT06375382|OTHER|Sham acupuncture|Sham acupuncture needles (0.35×40 mm) with flat tips (Hwato, Suzhou, China) were inserted towards the same acupoints to induce slight pain but without penetrating the skin. Sham moxibustion was made by igniting the same type of moxa sticks but fixing them at a distance of 8-10 cm from the skin of acupoints to maintain the temperature at 37 ± 1°C. Sham acupuncture and moxibustion were concomitantly performed for 30 min.
223470441|NCT04615936|OTHER|Methylene-Blue Photodisinfection|Participants will receive a pre-treatment nasal swab followed MB-PDF, this involves an MB nasal spray, followed by five minutes of red-light exposure into each nostril. Ten minutes after the treatment, a post treatment nasal swab will be performed.
223470442|NCT03634423|BEHAVIORAL|Sweet Spot: Flexible high incentive condition|Participants receive text reminders 30 minutes before their workouts and weekly emails reminding them of their schedule.
223470443|NCT03634423|BEHAVIORAL|Sweet Spot: Flexible low incentive condition|Participants receive text reminders 30 minutes before their workouts and weekly emails reminding them of their schedule.
223470444|NCT03634423|BEHAVIORAL|Sweet Spot: Rigid high incentive condition|Participants receive text reminders 30 minutes before their workouts and weekly emails reminding them of their schedule.
223579208|NCT00130923|DRUG|Risperidone Long Acting|Dose 25.00, 37.50 or 50.00 mg q two weeks
223579209|NCT00130923|DRUG|oral risperidone|0.50-6.00 mg oral risperidone daily
223470445|NCT03634423|BEHAVIORAL|Sweet Spot: Rigid low incentive condition|Participants receive text reminders 30 minutes before their workouts and weekly emails reminding them of their schedule.
223579210|NCT02488291|DRUG|0.25 sufentanil|with different dosage
223579211|NCT02488291|DRUG|0.5µg/ml sufentanil|0.5µg/ml sufentanil
223579212|NCT02488291|DRUG|0.1% ropivacaine|0.1% ropivacaine
224069051|NCT02922062|OTHER|Butter|Subjects will be provided with all their meals prepared in our metabolic kitchen in order to control their diets. The major cooking oils used in food preparation will be butter. The meals will be tailored to the caloric needs of each individual in order to maintain their body weight.
224069052|NCT04454190|DIAGNOSTIC_TEST|Collection of genetic material|Blood samples will be processed for extraction of DNA and genotyping. 10 ml of blood will be collected using standard procedures. The samples will be de-identified and receive a masked ID which will correspond to the existing masked ID in the DGR database. 2 ml will be sent to Genentech using frozen samples for genotyping using the Illumina Global Screening Array (GSA) kit. The remaining will be processed and stored at the Duke Eye Center. These samples may be maintained indefinitely or until they are exhausted. These samples will not be available for diagnostic or therapeutic purposes.
223743738|NCT07189975|OTHER|High intensity concentric cycling training|This intervention is a high intensity interval training using a concentric ergocycle
223743739|NCT02064907|DRUG|Dexlansoprazole Delayed Release Orally Disintegrating Tablets|Dexlansoprazole delayed-release, orally disintegrating (OD) tablets
224069053|NCT01452152|DRUG|clopidogrel|clopidogrel 75 mg/day plus aspirin 81-162 mg/day for one year
224159699|NCT00045630|DRUG|carboplatin|
224159700|NCT00045630|DRUG|gemcitabine|
224159701|NCT00045630|DRUG|paclitaxel|
224159702|NCT00045630|PROCEDURE|surgery|
223470446|NCT03634423|BEHAVIORAL|FOTW: High incentive control condition|Participants receive text reminders 30 minutes before their workouts and weekly emails reminding them of their schedule.
223470447|NCT03634423|BEHAVIORAL|FOTW: Low incentive control condition|Participants receive text reminders 30 minutes before their workouts and weekly emails reminding them of their schedule.
223470448|NCT03634423|BEHAVIORAL|FOTW: High incentive treatment condition|Participants receive text reminders 30 minutes before their workouts and weekly emails reminding them of their schedule.
223470449|NCT03634423|BEHAVIORAL|FOTW: Low incentive treatment condition|Participants receive text reminders 30 minutes before their workouts and weekly emails reminding them of their schedule.
223470450|NCT03634423|BEHAVIORAL|Think Twice: Control condition|Participants receive text reminders 30 minutes before their workouts and weekly emails reminding them of their schedule.
223579213|NCT01229748|BEHAVIORAL|Standard Care|Clients attend two 90-minute group sessions per week.Treatment lasts for three months.
223579214|NCT01229748|BEHAVIORAL|Multidimensional Family Therapy|Multidimensional Family Therapy is an outpatient family-based treatment for troubled youth (Liddle, 2002). Treatment duration is 3 months, sessions last 60-90 minutes, with an average of 2 sessions per week and additional extrafamilial work and phone contacts as needed.
223743740|NCT02064907|DRUG|Dexlansoprazole Delayed Release Capsules|Dexlansoprazole delayed-release capsules
223470451|NCT03634423|BEHAVIORAL|Think Twice: Treatment condition|Participants receive text reminders 30 minutes before their workouts and weekly emails reminding them of their schedule.
223470452|NCT03634423|BEHAVIORAL|WDR: Control condition|Participants receive text reminders 30 minutes before their workouts and weekly emails reminding them of their schedule.
223579215|NCT01229748|BEHAVIORAL|Family Motivational Interviewing Intervention|Youth and parents receive 2 FMII sessions in their homes within 72 hours of the ER incident, and youth will be linked with group treatment lasting 3 months.
223743741|NCT00265473|BIOLOGICAL|Allogeneic Islets of Langerhans|Intraportal infusion of islets of Langerhans
223743742|NCT02409836|DRUG|Marketed Dentifrice|Marketed Dentifrice
223743743|NCT02409836|DRUG|Marketed Flavored Dentifrice|Hawaiian Punch Flavored
224069054|NCT01452152|DRUG|prasugrel|Prasugrel 5-10 mg/day plus aspirin 81-162 mg/day for one year
223579216|NCT00480259|BEHAVIORAL|hyperproteic nutrition|
223579217|NCT02922166|DRUG|SRX246|oral capsule
223579218|NCT02922166|DRUG|Placebo|oral capsule
223579219|NCT04741191|OTHER|Cycle ergometer training|Hospital-based ergometer cycling for 20 minutes (Including warm-up and cooldown), 3x/week on alternate days for 6 weeks at 40-60% of VO2max.
223579220|NCT04741191|OTHER|Conventional therapy|In bed activities (Active ankle and hand pumping exercise\* 15 Rep\* BD AROMS of extremities\* 15 Rep\* BD, Deep breathing exercises\* 15 Rep\* BD, Ambulation (walk 10-15 minutes below fatigue and onset of symptoms level\* BD) for 6 weeks.
223579221|NCT02075632|DRUG|Alclometasone dipropionate cream|Alclometasone dipropionate cream 0.05% (15 g)
223579222|NCT00005632|BIOLOGICAL|MUC1-KLH vaccine/QS21|
224069055|NCT03784079|DRUG|GSK3640254|GSK3640254 will be available with dosing strengths of 5 mg, 20 mg, and 100 mg to be administered as an oral capsule along with 240 mL of water.
223579223|NCT04373499|BEHAVIORAL|Virtual Teach to Goal|Virtual Teach-to-Goal is an educational module that teaches children how to use their inhaler properly; this is done with an IPAD. In the module, the child will complete a series of questions as a pre-assessment, watch a video about how to use the inhaler properly, and then answer a series of questions as a post-assessment. If a child answers any questions incorrectly, they will watch the video again and have another chance to answer the incorrect questions. The child will receive instruction by video one or multiple times (up to 3 times), depending on how much they understand after each round of instruction, as demonstrated by their responses to questions.
224069056|NCT03784079|DRUG|Placebo matching GSK3640254 Mesylate salt|Placebo to match GSK3640254 Mesylate salt will be given as an oral capsule along with 240 mL of water
224069057|NCT07003490|PROCEDURE|Radical Resection with Bilateral Lymph Node Dissection|The patient will be positioned in a contralateral decubitus position based on the location of the primary tumor, with the axillary region on the side of the primary tumor exposed. For example, if the patient is diagnosed with left-sided primary lung cancer with right-sided lymph node metastasis, investigators perform left axillary incision to resect the tumor. And then investigators change the patient's position to perform right axillary incision to resect the lymph nodes. Thoracoscopy surgery will be used to access and resect the primary lesion and lymph node metastasis.
223470453|NCT03634423|BEHAVIORAL|WDR: Treatment condition|Participants receive text reminders 30 minutes before their workouts and weekly emails reminding them of their schedule.
223470454|NCT00299520|DRUG|intravenous iclaprim or intravenous linezolid|
223470455|NCT03118180|BIOLOGICAL|CD19 targeted chimeric antigen receptor T cells|CD19 targeted chimeric antigen receptor T cells for refractory and relapsed B cell lymphoma
223470456|NCT05278897|DEVICE|Soft Tissue Adapted Biocompatible Hyaluronic Acid|1% sodium hyaluronate
223579224|NCT04373499|BEHAVIORAL|Brief Intervention|There is a handout that describes proper inhaler technique. The RA reads the handout to the child.
223579225|NCT03351556|BEHAVIORAL|Active Arm 1|Participants in this arm will receive the standard HIV primary care services according to Tanzania's National Guidelines for the Management of HIV and AIDS plus the opportunity to earn 10,000 TZS/month conditional on visit attendance.
223743744|NCT02409836|DRUG|Marketed Flavored Dentifrice|Bubble Gum Flavored
223743745|NCT02259153|BEHAVIORAL|Changes in cholesterol metabolism|
223743746|NCT02259153|OTHER|Lean red meat diet|
223743747|NCT02259153|OTHER|Fat red meat diet|
223743748|NCT04802265|PROCEDURE|Epiretinal membrane surgery|"The surgery consists of a 23 or 25-gauge pars plana vitrectomy (PPV). The surgery was performed peri-bulbar anesthesia and could be combined with phacoemulsification.~An intraocular dye is used to well visualized and facilitate ERM peeling. The ILM is not actively peeled. A search for iatrogenic breaks is performed towards the end of the procedure. Areas suspicious for breaks are treated with cryotherapy or peripheral endolaser."
223470457|NCT00072553|DRUG|celecoxib|
223470458|NCT00072553|DRUG|fluorouracil|
223470459|NCT00072553|DRUG|leucovorin calcium|
223470460|NCT00072553|DRUG|oxaliplatin|
223470461|NCT00072553|PROCEDURE|adjuvant therapy|
223470462|NCT00072553|PROCEDURE|conventional surgery|
223470463|NCT00072553|PROCEDURE|neoadjuvant therapy|
223470464|NCT00299858|DRUG|Theophylline|"Patients assigned to study group, will receive slow-release theophylline at a dose of 10 mg/kg, titrated to blood levels between 55-110 umol/L, for a period of 4 weeks.~Patients assigned to placebo group will receive identical-appearing placebo tablets for the same period of time."
223470465|NCT05551416|OTHER|Identification of risk factors|Demographics, life habits and risk factors studies
223743749|NCT05575323|OTHER|Same-day SBRT and spinal surgery|SBRT and surgical stabilization with or without decompression within 24 hours
223743750|NCT05575323|OTHER|Standard of care|Surgical stabilization with or without decompression followed by cRT or SBRT as soon as the wound is healed sufficiently
223743751|NCT05455606|OTHER|Best Practice|Receive usual care
223743752|NCT05455606|OTHER|Chart Abstraction|Ancillary studies
223743753|NCT05455606|OTHER|Educational Intervention|Physicians access genomic testing education materials
223743754|NCT05455606|PROCEDURE|Genomic Profile|Patients undergo genomic testing
223743755|NCT05455606|OTHER|Interview|Ancillary studies
223743756|NCT05455606|OTHER|Questionnaire Administration|Ancillary studies
223743757|NCT05455606|OTHER|Tumor Board Review|Patients undergo genomic tumor board review
224159703|NCT02902822|PROCEDURE|Screening|"The screening visit consists in a general dermatological examination of the subject, with special focus on the onset of the following skin diseases during the follow-up period:~1. bacterial skin infections - pyoderma - or viral (erysipelas, impetigo, herpes zoster, molluscum contagiosum, viral warts);~2. fungal skin infections (tinea corporis, cruris, pedis);~3. pigmented tumors (melanoma);~4. non-melanocytic tumors (actinic keratoses, basal cell or squamous cell carcinoma)."
223470466|NCT05551416|OTHER|Characterization of premalignant gastric lesions|Identification and characterization of premalignant gastric lesions through high definition endoscopic study. Concordance between endoscopic and histological classifications
223470467|NCT05551416|OTHER|Identification of biomarkers|Multiomic studies
223470468|NCT05551416|OTHER|Identification of gastric cancer hereditary predisposition|Genomic studies for the identification of individuals with hereditary GC predisposition
223470469|NCT00889239|OTHER|lithia-disilicate-based crown|all-ceramic crown
223470470|NCT03371914|BEHAVIORAL|Management training and data feedback|The management training will consist of a variety of management topics, such as financial, workplace and staff management. The training will include a number of tools that the managers will be expected to bring back with them and use regularly at their site. There will be monthly refresher trainings for the managers via an online platform, where participants will interact about the topics covered in the training and others relevant to their work as managers. Participants will also receive monthly visualizations that compare the data that they enter via tablet monthly to both (1) their baseline data, and (2) to other sites' data. Outcomes that will be measured and reported back to sites include cost per client tested, number of condoms distributed, and number of FSW reached by educational interventions.
223470471|NCT03059667|DRUG|Atezolizumab|Atezolizumab at 1200 mg IV every 3 weeks
223470472|NCT03059667|DRUG|Topotecan|oral 2.3 mg/m² or IV 1.5 mg/m² day 1-4 recommended
223470473|NCT03059667|DRUG|Carboplatin|In accordance with the summary of product characteristics.
223470474|NCT03059667|DRUG|Etoposide|In accordance with the summary of product characteristics.
223470475|NCT02530775|PROCEDURE|instrumented spinal fusion with laminectomy|"Once determined that a patient has single level static degenerative spondylolisthesis and is planning to schedule surgery the patient will be approached by a research team member explaining the study and reviewing the informed consent document. If the patient chooses to participate, he or she will be randomized to be apart of the non-instrumented arthrodesis with laminectomy group or the instrumented arthrodesis with laminectomy group. Both are standard approved surgical approaches; however, using instrumentation is the more commonly used approach."
223470476|NCT02530775|PROCEDURE|non-instrumented spinal fusion with laminectomy|"Once determined that a patient has single level static degenerative spondylolisthesis and is planning to schedule surgery the patient will be approached by a research team member explaining the study and reviewing the informed consent document. If the patient chooses to participate, he or she will be randomized to be apart of the non-instrumented arthrodesis with laminectomy group or the instrumented arthrodesis with laminectomy group. Both are standard approved surgical approaches; however, using instrumentation is the more commonly used approach."
223579226|NCT03351556|BEHAVIORAL|Active Arm 2|Participants in this arm will receive the standard HIV primary care services according to Tanzania's National Guidelines for the Management of HIV and AIDS plus the opportunity to earn 22,500 TZS/month conditional on visit attendance.
223579227|NCT03356509|BEHAVIORAL|Exercise|Exercise will be performed on a stationary bicycle ergometer.
223579228|NCT00599456|DIETARY_SUPPLEMENT|Omega 3 fatty acid vitamins|Omega 3 fatty acid vitamins, 2 capsules, by mouth, daily, for 3 months
223579229|NCT00599456|DIETARY_SUPPLEMENT|Placebo capsules|Placebo capsules,2 capsules, by mouth, daily for 3 months
223579230|NCT04299763|DIETARY_SUPPLEMENT|Oat Beta-glucan as a Supplement in Type 2 Diabetics|44 subjects were randomized into two groups, placebo (PL) and β-glucan (BG). Each person received a package with a supplement sufficient for 12 weeks, adding 5 g of supplement to breakfast, which could contain beta-glucan or not. Blood and stool samples were requested at the beginning and at the end of the intervention.
223579231|NCT03924999|COMBINATION_PRODUCT|Combined decongestive treatment (CDT) & Combined exercise|Combined decongestive treatment consists of manual lymphatic drainage and compression bandaging for 30 sessions.
223743758|NCT04095624|BEHAVIORAL|Spinal Fusion Preoperative Opioid Taper|Guided weekly opioid pain medication reduction via telephone calls prior to elective spinal fusion surgery.
223743759|NCT04095624|OTHER|Non-taper Control|Weekly phone calls prior to elective spinal fusion surgery, without opioid pain medication reduction recommendation or guidance.
223743760|NCT05793528|PROCEDURE|Fluoroscopy Guided Transforaminal Epidural Steroid Injection|The patients are positioned prone. The injection site is cleaned with povidone-iodine 3 times and a sterile drape was applied. Short-acting local anesthesia (3 mL of 2% prilocaine) is applied to the skin and subcutaneous tissue. A 3.5-inch, 22-gauge spinal needle is inserted just below the pedicle. It is advanced into the subpedicular space using the coaxial technique under the intermittent guidance of fluoroscopy. The needle position is confirmed through a lateral view. Using lateral views, the needle is placed at the posterior one-third of the foramen. Using the anteroposterior view, one to 2 mL of the contrast agent (300 mg/50 mL iohexol) is given and the distribution pattern is visualized. Once the epidural distribution of the contrast agent is confirmed without vascular flow, a mixture of 8 mg (two mL) of dexamethasone, 1 mL of physiological saline, and 1 mL (0.5%) of bupivacaine hydrochloride is injected.
223579232|NCT03924999|COMBINATION_PRODUCT|Intermittent pneumatic compression & Combined exercise|Intermittent pneumatic compression for 5 days a week, for 6 weeks (totally, 30 sessions).
223470477|NCT04474483|DRUG|Melatonin|Melatonin will be administered orally as a 10 mg dose three times a day for 14 days. Size 4 clear vegetable cellulose capsules containing 10 mg melatonin, microcrystalline cellulose, and rice concentrate prepared by Life Extension® will be over-encapsulated in opaque gelatin capsules. Over-encapsulation of melatonin treatments will be done by the research pharmacist and will be mailed to study subjects directly by courier. Melatonin capsules will be stored at room temperature.
223470478|NCT04474483|OTHER|Placebo (Methylcellulose) capsule|Placebo capsules will be prepared with opaque gelatin capsules, filled using methylcellulose and over-encapsulated to appear identical to interventional drug. Placebo capsules will be given orally in the same regimen as intervention (three times daily for 14 days). Capsules will be prepared by the research pharmacist and will be mailed to study subjects directly by courier. Placebo capsules will be stored at room temperature.
223470479|NCT04644172|BEHAVIORAL|Speed of Processing Training|"Testing involves trainer-guided practice of computerbased video games. The games require the player to identify targets that are presented very briefly. In the first level, the player has to identify a target at the center of the screen. In the second level, the player has to identify targets at the center and edge of the screen simultaneously. In the third level, other objects, which serve as decoys, are added. SOPT is aimed at improving the fluidity of mental processing speed (not psychomotor reaction time) so that trainees can process more complex information over briefer periods of time. The training involves practice with feedback. The trainer teaches some task-specific strategies, offer suggestions, encouragement, and personalized modification of difficulty for enhancing performance. Speed and task difficulty level are tailored to trainee ability, trainees practice blocks of 16 trials with a goal of achieving performance of 10 to 12 correct trials for each training block."
223470480|NCT04644172|BEHAVIORAL|Instrumental Activities of Daily Living Shaping|In addition to training on the SOPT software, participants will train on tasks that simulate everyday activities that have important cognitive components (e.g., selecting medicine bottles from a cabinet, measuring ingredients to bake a cake, finding information online). The training will follow shaping principles. Activity periods will be divided into trials of specific length, and the performance of the participant will be measured and graphed to provide the participant with feedback on their performance. Verbal praise will be used to reward a participant for improvements in performance. The difficulty of the task will be increased in small increments as a participant gains mastery. The purpose of this component is to serve as a bridge between the SOPT training, which exercises a basic aspect of cognitiven function, and cognitive function in everyday life, which is embedded in the context of multi-part, and multidimensional tasks.
224069058|NCT07028502|PROCEDURE|J Wire|The movement of the puncture needle was monitored using intracardiac echocardiography rather than fluoroscopy. All other steps followed the conventional approach.
224069059|NCT07028502|PROCEDURE|3D mapping system|Guided by the ablation catheter image on the 3D mapping system, the long sheath was advanced to the puncture site and then exchanged for a puncture needle. The entire procedure was monitored with intracardiac echocardiography.
224069060|NCT07029841|DEVICE|catheter-based therapy|catheter-based therapy
224069061|NCT07028658|OTHER|Speechreading training|The patient will undergo 16 lip reading training sessions. By developing functional lip reading skills, they will be able to fill in the gaps in auditory information they miss, especially in loud or noisy settings
224069062|NCT07029685|OTHER|Physical|They will carry out a physical activity intervention based on the ecological model
224069063|NCT05458284|PROCEDURE|Real Acupuncture|Real Acupuncture weekly till taxane completion
224069064|NCT05458284|OTHER|Sham Acupuncture|Sham Acupuncture weekly till taxane completion
224069065|NCT05850598|DEVICE|sham rTMS|The coil was held while disconnected from the stimulator, and rTMS noise was presented with computer loudspeakers with recorded sound from a real stimulation (20 minutes for each side of the lateral cerebellum everyday for 2 weeks).
224069066|NCT05850598|DEVICE|active rTMS|Low-frequency (1 Hz) rTMS at with a stimulation intensity of 95% of the motor threshold will be delivered over the bilateral cerebellum for patients with Parkinson's disease (20 minutes for each side of the lateral cerebellum everyday for 2 weeks).
224069067|NCT04306588|OTHER|Exercise|Participants are undergoing a 12 weeks tele-rehabilitation program.
224069068|NCT01777802|RADIATION|SBRT|
224069069|NCT01777802|RADIATION|IMRT|
224069070|NCT01777802|RADIATION|Brachytherapy|
224069071|NCT06829459|DRUG|Glumetinib|Patients will be administered glumetinib 300 mg/dose once daily once daily under fasting conditions in each 21-day treatment cycle.
224069072|NCT06829459|DRUG|Osimertinib mesylate|Patients will be administered osimertinib mesylate 80 mg/dose once daily under fasting conditions in each 21-day treatment cycle.
224069073|NCT06829459|DRUG|Pemetrexed|Patients will be administered pemetrexed 500 mg/m\^2 via intravenous infusion on the first day of each 3-week cycle.
224069074|NCT06829459|DRUG|Cisplatin or carboplatin|Patients will be administered cisplatin 75 mg/m\^2 or carboplatin AUC=5 via intravenous infusion on the first day of each 3-week cycle
224069075|NCT04748094|DEVICE|Compression belt|The abdominal belt is fastened around the lower abdomen and inflated (like an inner tube) to apply pressure to the belly and reduce the motion associated with respiration (breathing)
224069076|NCT04748094|OTHER|Visual Guided Breath-hold|A small tracer will be place on the lower abdomen that will feedback to a computer screen that will have graphics to show you if the participant is in breath-hold or not.
224069077|NCT05772832|DRUG|Dexmedetomidine|Efficacy of dexmedetomidine on postoperative pain in patients undergoing transsphenoidal pituitary surgery
224069078|NCT05772832|DRUG|Remifentanyl|Efficacy of remifentanyl on postoperative pain in patients undergoing transsphenoidal pituitary surgery
224069079|NCT06963411|DRUG|KP001|Epinephrine Inhalation Aerosol (0.125 mg per inhalation)
224069080|NCT06963411|DRUG|Placebo|Matched Placebo control (KP001 vehicle only)
224069081|NCT04752995|PROCEDURE|osteotomy|osteotomy osteoclasis of upper tibia
224069082|NCT01850056|DEVICE|drug eluting balloon catheter (trade name: Orchid)|
224069083|NCT01850056|DEVICE|common percutaneous transluminal angioplasty balloon catheter (trade name: Admiral)|
224069084|NCT00193765|PROCEDURE|Elective neck dissection in early oral cancer|Elective neck dissection in early node negative oral cancers at the time of primary surgery
224069085|NCT00193765|PROCEDURE|Therapeutic Neck Dissection|There is no active intervention for the neck at the time of primary surgery. Therapeutic Neck Dissection at the time of nodal relapse
224159704|NCT02902822|DEVICE|Tele-dermatology|"The system consists in a simple web-based/smartphone application through which subjects can send pictures of recently onset non-widespread skin lesions with special focus on the following diseases:~1. bacterial skin infections - pyoderma - or viral (erysipelas, impetigo, herpes zoster, molluscum contagiosum, viral warts);~2. fungal skin infections (tinea corporis, cruris, pedis);~3. pigmented tumors (melanoma);~4. non-melanocytic tumors (actinic keratoses, basal cell or squamous cell carcinoma).~A dermatology will judge online pictures based on a standard scale. Each subject who will use the system will be also seen by routine clinical visit to confirm the online diagnosis. Subjects who will not send any picture will be seen for a dermatological examination at the end of each year."
224159705|NCT04035538|DRUG|CKD-320, D012|R: D012 1tablet, QD, PO T: CKD-320 2tablets, QD, PO
224159706|NCT01316029|PROCEDURE|Okada Purifying Therapy|Each participant received a single session of Okada Purifying Therapy lasting 30 minutes or longer, administered by a voluntary certified practitioner.
224304005|NCT04578665|DEVICE|Haptic Impedance Level|The subjects will complete their task at 3 impedance levels: high (a virtual stiffness 160-200 N/m and damping 0\~10 Nm/s; this will be a stiff connection in which the subjects feel like they are connected via rigid links and each subject will perceive the other partner's movement directly), medium (a virtual stiffness 100-140 N/m and damping 0\~10 Nm/s; this will be a spring like-connection in which the subjects feel like they are connected with a spring and each subject will perceive the other partner with a force that is proportional to the trajectory difference of the two participants), and soft (a virtual stiffness 40-80 N/m and damping 0\~10 Nm/s; this will be a spring like connection in which the subjects feel like they are connected with a loose spring and each subject will perceive the other partner with a force that is proportional to the trajectory difference of the two subjects, however, this force will be smaller than that of the medium impedance).
224304006|NCT04578665|BEHAVIORAL|Skill Level of Partner|There will be two skill levels: novice (a participant who has no prior experience with the trajectory tracking experiment; in testing with the clinical populations, the investigators will assign this condition to the clinical participant) and expert (a participant who is experienced with the trajectory tracking experiment and who can achieve a tracking error \[difference of the desired trajectory and actual trajectory\] below a certain threshold; in testing with the clinical population, the investigators will assign this condition to the therapist). Participants will start experimentation paired as novice-novice, and at the end of the session may be invited to continue additional sessions to be paired as the expert in a novice-expert dyad.
224304007|NCT04578665|DEVICE|Robot Controller Showcase|The subjects will complete 10 training sessions per assistive robot for the researchers to observe motor learning and functional outcomes.
224304008|NCT03747601|DEVICE|Temporal Interference (TI) Stimulation|2-4 Temporal Interference stimulation sessions. The device is an experimental non-invasive electrical brain stimulator that functions similar to existing non-significant risk devices for electrical stimulation, including human non-invasive brain stimulation. Briefly, the device produces alternating current electrical stimulation in a kilohertz (kHz) range and results in less net charge applied within the brain. The device is powered by rechargeable 20 volt (V) battery (i.e. there is no connection to building power supply). The current is hardwired and limited to 5 milliamp (mA) via internal resistors. It includes extra safety features such as onboard fuses to limit any abrupt high current, and an emergency stop button which effectively insulates the subject and resets the device. The device was tested and characterized at all the required load conditions.
224304009|NCT03303625|BIOLOGICAL|Ad26.RSV.preF (1*10^11 vp)|Participants will receive two doses of 0.5 milliliter (mL) (1\*10\^11 vp) via IM route on Day 1 and 29 of Ad26.RSV.preF.
224304010|NCT03303625|BIOLOGICAL|Ad26.RSV.preF (5*10^10 vp)|RSV seropositive participants will receive two doses of 0.25 mL (5\*10\^10 vp) via IM route on Day 1 and 29 of Ad26.RSV.preF.
224304011|NCT03303625|DRUG|Placebo|Participants will receive either 0.5 mL (cohort 0) or 0.25 mL (cohort 1) of placebo via IM route on Day 1 and 29.
224304012|NCT06138899|OTHER|Club 25|The Club 25 donation program will involve students pledging to donate blood 25 times in their lifetime. In order to achieve this objective, students also pledge to lead a healthy lifestyle, to avoid acquiring HIV and other TTIs and to continue donating blood after leaving school. The Club 25 donation program includes activities in-between blood donation events as well as peer leadership and peer education in schools and in communities.
224304013|NCT05428826|DRUG|Prednisone|Phase 4 Prednisone Dose : 1mg/kg/day at inclusion Route of administration : oral Duration of treatment: 9 to 21 months.
224304014|NCT06076850|DEVICE|Low-Intensity Extracorporeal Shockwave Therapy (LiEWST) - Active|"Treatment protocol:~* EFD 0.096 mJ/mm2~* 2 sessions / week; 5000 shocks / session~* 6 weeks treatment~* total: 12 sessions~* Li-ESWT to start after removal of indwelling catheter"
224304015|NCT06076850|DEVICE|Low-Intensity Extracorporeal Shockwave Therapy (LiEWST) - Sham|"Treatment protocol:~* EFD 0 mJ/mm2~* 2 sessions / week; 5000 shocks / session~* 6 weeks treatment~* total: 12 sessions~* Li-ESWT to start after removal of indwelling catheter"
224304016|NCT05854394|BEHAVIORAL|Multimodal prehabilitation management Multimodal prehabilitation management|Multimodal prehabilitation strategy includes physical exercise (moderate aerobic exercise combined with resistance exercise ), nutritional suggestion and optimization（whey protein supplement）, and psychological therapy, as well as conventional guidance (including drug treatment recommendations for chronic disease, quit smoking and abstinence).
224304017|NCT01367665|DRUG|vismodegib|150 mg once daily until disease progression or unacceptable toxicity
224304018|NCT00182468|OTHER|Screening for intimate partner violence|Women are screened for intimate partner violence prior to seeing a health care provider.
224304019|NCT01717716|DIETARY_SUPPLEMENT|water with Sucralose|
224304020|NCT01717716|DIETARY_SUPPLEMENT|water with HFCS|
224069086|NCT02068547|BIOLOGICAL|locally harvested autograft, demineralized bone matrix, and cadaveric allograft|
224069087|NCT02068547|BIOLOGICAL|Bone Marrow Aspirate|
224069088|NCT04864431|DIETARY_SUPPLEMENT|Vitamin D|Vitamin D capsules: each capsule contain 2 tablets of vitamin D 1000 IU. One capsule will be taken on day 1 through 180
224069089|NCT04864431|OTHER|Placebo|Placebo capsule: Each capsule contain saccharum lactis. One capsule will be taken on day 1 through 180
224069090|NCT02561091|OTHER|Placebo|
224069091|NCT02561091|DRUG|AM-111 0.4 mg/ml|
223470481|NCT04644172|BEHAVIORAL|Transfer Package from CI Therapy|Behavioral Contract. At the outset of treatment, the therapist negotiates a contract with the participant and caregiver, if one is available.Daily home diary. During treatment, the participants catalog the ADL and IADL for the part of the day spent outside the laboratory. Daily administration of the Cognitive Task Activity Log (CTAL). The CTAL collects information about attempts by the participant to complete ADL and IADL. Problem Solving. The therapist helps participants to think through any barriers to completing ADL and IADL independently. Home skill assignments during treatment. Participants are assigned on a written check-off sheet 10 specific ADL tasks. Home skill assignments after treatment. Toward the end of treatment, a written individualized post-treatment program is developed containing a list of up to 10 IADL for each day of the week. Post-treatment telephone contacts. Participants are contacted during the 12 month period after treatment to evaluate treatment outcomes.
223470482|NCT04644172|OTHER|Usual Care|Healthcare that is available for adults with cognitive impairment subsequent to COVID-19 in the community on a clinical basis. This includes commercially available, gamified, computerized cognitive training programs.
223470483|NCT04499079|OTHER|Learning Health System|This is a system-level intervention designed to improve collaboration among personnel from the juvenile and behavioral healthcare systems.
223579233|NCT03924999|COMBINATION_PRODUCT|Combined exercise|30 minutes aerobic exercise program including treadmill training consisted of a 5-minute warm-up and cool-down period and 25-minute submaximal aerobic exercise 5 days a week, for 6 weeks. Exercise intensity was calculated from the initial 6MWT. Each session was completed with 15 minutes of strengthening and stretching exercises.
223579234|NCT02251132|DRUG|TPV low 1|
223579235|NCT02251132|DRUG|TPV low 2|
223579236|NCT02251132|DRUG|TPV medium|
223579237|NCT02251132|DRUG|TPV high 1|
223579238|NCT02251132|DRUG|TPV high 2|
223579239|NCT02251132|DRUG|RTV low|
223579240|NCT02251132|DRUG|Ritonavir high|
223470484|NCT02513550|DRUG|Ixekizumab|Administered SQ
223470485|NCT02513550|DRUG|Placebo|Administered SQ
223470486|NCT00685516|DIETARY_SUPPLEMENT|green tea|6 cups of green tea daily for 2-8 weeks
223470487|NCT00685516|DIETARY_SUPPLEMENT|placebo|6 cups of water daily for 2-8 weeks
223470488|NCT00685516|DIETARY_SUPPLEMENT|decaffeinated black tea|6 cups of decaffeinated black tea daily for 2-8 weeks
223470489|NCT00074893|DEVICE|piezoelectric wrist brace|
223579241|NCT02251132|DRUG|Radiolabelled erythromycin|
223579242|NCT00509743|DRUG|Intravenous diclofenac sodium (DIC075V)|High dose Diclofenac
223579243|NCT00509743|DRUG|Intravenous diclofenac sodium (DIC075V)|Low Dose Diclofenac
223579244|NCT00764907|DRUG|asparaginase|Given IV during reinduction
224069092|NCT02561091|DRUG|AM-111 0.8 mg/ml|
223470490|NCT03804658|DEVICE|Continue glucose monitor system|The cardiovascular risks and data from continue glucose monitor system
223470491|NCT00192114|DRUG|Enzastaurin HCl|1200 milligrams (mg) loading dose orally, then 500 mg, orally, daily, up to six 28-day cycles.
223470492|NCT04122261|DEVICE|the MicroHand S endoscopic instrument control system|Using the MicroHand S endoscopic instrument control system to treat gallstone or cholecystitis in minimal invasive surgery.
223470493|NCT04122261|DEVICE|the da Vinci endoscopic instrument control system|Using the da Vinci endoscopic instrument control system to treat gallstone or cholecystitis in minimal invasive surgery.
223579245|NCT00764907|DRUG|cyclophosphamide|Given IV during reinduction
223579246|NCT00764907|DRUG|cytarabine|Given IV during reinduction
223579247|NCT00764907|DRUG|daunorubicin hydrochloride|Given IV during reinduction
223579248|NCT00764907|DRUG|dexamethasone|Given IV or orally during reinduction
223579249|NCT00764907|DRUG|doxorubicin hydrochloride|Given IV during reinduction
223579250|NCT00764907|DRUG|etoposide|Given IV during reinduction
224069093|NCT01736579|DRUG|Immune Globulin Intravenous (Human), 10% (IGIV, 10%)|
224069094|NCT04455555|DRUG|LY03003( the name of rotigotine)|LY03003 (Continuous Dopamine Stimulation) sustained release microspheres / injection once a week 4 weeks followed by 24 weeks until 28 weeks.
224304021|NCT01717716|DIETARY_SUPPLEMENT|water with glucose|
223579251|NCT00764907|DRUG|ifosfamide|Given IV during reinduction
223579252|NCT00764907|DRUG|leucovorin calcium|Given IV during reinduction
223579253|NCT00764907|DRUG|mercaptopurine|Given orally during reinduction
223579254|NCT00764907|DRUG|methotrexate|Given orally during reinduction
223579255|NCT00764907|DRUG|prednisone|Given intrathecally during reinduction
223579256|NCT00764907|DRUG|thioguanine|Given orally during reinduction
223579257|NCT00764907|DRUG|vincristine sulfate|Given IV during reinduction
223579258|NCT00764907|DRUG|vindesine|Given IV during reinduction
223579259|NCT03022500|DRUG|durvalumab + tremelimumab|Durvalumab: 1.5g Q4W plus Tremelimumab: 75mg Q4W up to 4cycle then Durvalumab 750mg Q2W, till PD or unacceptable toxicity.
223579260|NCT02067325|OTHER|Thai massage|
223579261|NCT02579681|DRUG|dimethyl fumarate|dimethyl fumarate administered as per the arm description
223579262|NCT04683458|DEVICE|Drug-coated device|The endovascular (intraluminal) application of a medical-device that was coated with paclitaxel
223579263|NCT03758690|DEVICE|High-Intensity Focused Electromagnetic (HIFEM) Field Device|The High-Intensity Focused Electromagnetic (HIFEM) Field device will be applied.
223579264|NCT03652519|BEHAVIORAL|Exercise Training|Treatment in both arms consists of specific of aerobic exercise training modalities. Exercise has become an efficient strategy within rehabilitative programs and is part of a goal-orientated multidisciplinary approach to improve disability and participation in persons with MS. Recently, short and exhaustive bouts of exercise have gained much attention as a promising option in supportive care in MS.
223579265|NCT05918653|OTHER|Home Healthcare|No intervention in this study
223579266|NCT02087202|DRUG|Magnesium Sulfate|magnesium sulfate is added to the patients
223579267|NCT02087202|DRUG|ketamine|ketamine is added to the patients.
224069095|NCT04455555|OTHER|Placebo|Null sustained release microspheres placebo / injection once a week 4 weeks followed by 24 weeks until 28 weeks.
224304022|NCT01717716|DIETARY_SUPPLEMENT|water with sucrose|
224304023|NCT00193466|DRUG|Rituximab|
224304024|NCT00193466|DRUG|Fludarabine|
224304025|NCT00193466|DRUG|CAMPTH-1H|
223470494|NCT06270641|OTHER|ExerciseRx intervention|ExerciseRx is a cloud-based, HIPPA-compliant free software platform created for healthcare providers to prescribe and monitor physical activity as part of routine care. ExerciseRx translates clinically relevant activity data collected by the patient's existing personal smart devices (Android or iOS phone) into actionable metrics on a dashboard within the Epic electronic health record. Providers then use the platform to prescribe physical activity tailored to patients' ability levels and preferences. The platform incorporates behavior change strategies, including motivational feedback and nudges. It also facilitates a feedback loop with the provider, fostering caring patient-provider connections around activity promotion and behavior change. ExerciseRx leverages patients' personal smartphone capabilities to track, quantify, and tailor personalized physical activity solutions, which makes it more readily scalable as a solution across diverse patient populations.
223470495|NCT01792739|DRUG|Lactobacillus casei variety rhamnosus granules|"Lactobacillus casei variety rhamnosus granules~: 3 gram per day (1g-1g-1g, 3 times per day)"
223470496|NCT01792739|DRUG|Placebo|"Placebo granules~: 3 gram per day (1g-1g-1g, 3 times per day)"
223470497|NCT00492297|DRUG|Sorafenib (Nexavar, BAY43-9006) + Dacarbazine (DTIC)|Dacarbazine 1000 mg/m\^2 on day one of repeated 21 day cycles, in combination with daily continuous oral sorafenib (Nexavar, BAY 43-9006), 400 mg twice a day (bid)
223470498|NCT04487990|DRUG|unfractionated Heparin|Addition of unfractioned heparin to CVVHD system already running under citrate regional anticoagulation.
224159707|NCT03838380|OTHER|Smartphone application|Mobile management group participants were given monitoring system devices including a glucometer with Bluetooth connectivity and an accelerometer to detect physical activity level. The mobile phone application specifically designed for this study was installed at enrollment for the mobile management group to collect clinical data and messages from the patients. The application consisted of four sections: clinical data, nutrition and diet, medication, and messaging system and information. Patients allocated to the mobile management group recorded their blood glucose level and diet via the smartphone application, and health care providers regularly scanned clinical data and messages from patients and sent return messages with tailored medical and nutritional guidance.
224159708|NCT00701103|DRUG|Dalotuzumab|IV infusion
224159709|NCT04218604|PROCEDURE|Personalized atrial fibrillation ablation|Atrial fibrillation (AF) ablation adapting the ablation index (AI) target in a point-by-point manner, according the local left atrial wall thickness (LAWT), as measured by multidetector cardiac tomography (MDCT)
223470499|NCT00193453|DRUG|Gemcitabine|1000mg/m2 30min IV, Day 1 \& 8
223470500|NCT00193453|DRUG|Docetaxel|30mg/m2, 30min IV, day 1 \& 8
224159710|NCT01929707|DRUG|LY3050258|
224159711|NCT01929707|DRUG|Placebo|
224159712|NCT00143988|BEHAVIORAL|Treadmill testing|Patients will have a exercise stress test using a Bruce protocol during which time heart rates and blood pressures will be monitored and the patient's percieved exertion level monitored and recorded
224159713|NCT00143988|BEHAVIORAL|Ambulatory Blood Pressure and Heart Rate Monitoring|Patients will wear an ambulatory blood pressure monitor and an heart rate monitor during one sexual encounter.
224159714|NCT03432611|OTHER|Self-care information feature|The self-care feature offers information on self-care for menstrual pain. The following topics are shown: exercise, dietary supplementation, heating pad/hot water bottle, yoga, and information on when to consult a doctor and how primary dysmenorrhoea is often treated. Notifications from the app which can be deactivated remind women of surveys and activities.
224159715|NCT03432611|OTHER|Self-acupressure feature|The acupressure feature offers detailed written and multimedia descriptions of an acupressure used for menstrual pain. Three acupressure points are described, which should be massaged bilaterally twice a day up to five times a day on the 5 days before menstruation and during menstruation. Each point should be massaged for 2 minutes. A timer for the acupressure and notifications from the app which can be deactivated remind women of surveys and acupressure.
224159716|NCT02458677|DRUG|PRX003|
224159717|NCT02458677|OTHER|Placebo|
223470501|NCT00193453|DRUG|Cetuximab|100mg/m2 IV, Cycle 1 Day 1, 250mg/m2 IV day 8 \& 15, all subsequent cycles 250mg/m2 IV day 1, 8, \& 15
223470502|NCT02774317|BIOLOGICAL|Plasma|FFP (plasma frozen within 8 hrs of collection) or FP24 (plasma frozen within 24 hrs of collection)
223470503|NCT01408706|DEVICE|Miller Air tip|Miller Enema Air Tip is inserted into rectum prior to simulation and each radiation treatment.
223470504|NCT01408706|DEVICE|Radiadyne Immobilizer|Radiadyne Immobilizer is inserted into rectum prior to simulation and each radiation treatment
223470505|NCT06138210|DRUG|exosomes derived from human induced pluripotent stem cell for injection|Exosomes derived from human induced pluripotent stem cell for injection (3.0ml, 1×10\^11particles/ml).
223470506|NCT06138210|DRUG|a placebo of exosomes derived from human induced pluripotent stem cell for injection|Exosomes placebo, 3.0ml
223470507|NCT00919880|DRUG|carboplatin+ paclitaxel|carboplatin AUC 2mg/mL\*min/week, 3 week cycle up to 4 cycles; paclitaxel 80mg/m2/week, 3 week cycle up to 4 cycles
223579268|NCT04943458|OTHER|Monitoring of cerebral autoregulation|Patients will be monitored for cerebral autoregulation using a Vittamed 505 monitor to identify the dynamics of the autoregulation index VRx (t). Intracranial pressure (ICP) will also be measured by non-invasive ultrasound using a robotic TCD device, Dolphin4D (Israel), which simultaneously records MCA blood flow in both hemispheres of the brain. APAs will be assessed using mathematical models.
223579269|NCT01744678|BEHAVIORAL|blue-wavelength enriched ceiling light|Subjects will be in the experimental break room for four 20-minute periods for each Orbit 1 work shift.
224159718|NCT04459494|PROCEDURE|Flapless implant surgery.|"Local anesthesia will be applied to the patients in the test group, and then the implant socket will be prepared without removing the flap and a dental implant will be placed.~Bite-wing film will be taken to control the implants in the same session after surgery, and patients will be given VAS (visual analog scale) to perform their assessment of pain on the 3rd day and 7th day. Patients will be given an appointment again after 3 months of treatment. In this session, implants will be evaluated with bite-wing film."
224304026|NCT04136457|OTHER|Endurance training|Subjects perform a period of endurance training
224304027|NCT04136457|OTHER|Resistance training|Subjects perform a period of resistance training
223470508|NCT00919880|DRUG|paclitaxel|paclitaxel 80mg/m2/week, 3 week cycle up to 4 cycles
223470509|NCT06523127|OTHER|Recording data from the ICU stay and the post-ICU follow-up.|Record analysis of the post-ICU follow-up with the Interpretative Phenomenological Analysis
223470510|NCT05414214|PROCEDURE|Thyromental Height Test|Thyromental Height Test (TMHT) : will be measured while a patient is lying supine with the head and neck are maintained in a neutral position using a pillow under the head. By using a digital depth gauge, the TMH is the vertical distance measured between the anterior border of the thyroid cartilage directly on the thyroid notch and the anterior border of the mentum.
223579270|NCT01744678|BEHAVIORAL|mild exercise|Subjects will be asked to achieve 65% of maximum heart rate on either a treadmill or exercise cycle for 10-minutes, three times during each Orbit 1 work shift.
224069096|NCT02542475|DEVICE|Low Field Magnetic Stimulation|The Low Field Magnetic Stimulation (LFMS) procedure is an application of a series of electromagnetic pulses to the brain. The field and timing parameters of the LFMS pulses, such as pulse timing, duration, frequency, and electric and magnetic field distribution and direction are different from other neurostimulation methods. LFMS electromagnetic fields are significantly weaker (\< 100x) than those used in ECT and rTMS.
224069097|NCT00479154|DRUG|Botulinum Toxin A|Maximum dose of 90 units/leg was injected.
224069098|NCT02650037|PROCEDURE|Air Test|The Air Test simply consisted in breathing room air for 5 min on arrival into the postoperative anesthesia care unit while measuring peripheral oxygen saturation by Pulse oximetry
224069099|NCT06045338|BEHAVIORAL|Mind Body Intervention #1|The mind-body intervention will include regular 1 to 2 hour educational sessions and lectures, as well as supplemental reading material. In addition, individualized sessions will be offered each week for students who have additional questions and/or need additional time with the material.
224069100|NCT05745935|DRUG|Oxytocin|This study will include 100 elective cesarean section in parous women who will be randomized into two groups each of 50 patients,
224069101|NCT01317680|DEVICE|Omnispec model ED1000|Device: Extracorporeal Shockwave Therapy Generator (Omnispec model ED1000) Gel is spread around the penis and on the Shock Wave applicator and Treatment (12 sessions in total) of 300 shocks per site, on 5 penile anatomical sites.
224069102|NCT01317680|DEVICE|Sham control|We use the same probe that induces the same sensation on the penis and the same noise yet no energy
224069103|NCT05786625|DEVICE|Ablation|Bronchoscopy and microwave ablation of lung nodule
224069104|NCT06390085|OTHER|Soft tissue manipulation|The clinician will perform a soft tissue massage intervention where she/he will use moderate massaging and compression. The amount of pressure is less than 5 N, the velocity is low at a controlled rate of 1 Hz, the duration of 30 seconds, angle 90 and 45 degrees.
224069105|NCT02543528|DEVICE|Investigational Lens 1|One fresh pair of Investigational Lens 1 contact lenses worn continuously in 6 nights/7 days wear cycles for 6 months of total wear.
224069106|NCT02543528|DEVICE|Investigational Lens 2|One fresh pair of Investigational Lens 2 contact lenses worn continuously in 6 nights/7 days wear cycles for 6 months of total wear.
224069107|NCT02543528|DEVICE|Investigational Lens 3|One fresh pair of Investigational Lens 3 contact lenses worn continuously in 6 nights/7 days wear cycles for 6 months of total wear.
224069108|NCT02543528|DEVICE|etafilcon A (Reusable)|One fresh pair of etafilcon A (Reusable) contact lenses worn continuously in 6nights/7 days wear cycles for 6 months of total wear.
224069109|NCT02543528|DEVICE|etafilcon A (1-Day)|2-week contact lens adaptation period wearing prior to randomization
224069110|NCT04437212|DRUG|Toripalimab|Patients received toripalimab 240mg every 3 weeks 1-7 days after neoadjuvant chemoradiotherapy for 2 cycles before operation and 28-42 days after operation for 4 cycles.
224069111|NCT04506697|PROCEDURE|Uroflowmetry|The patient is given a portable uroflowmeter for performing uroflowmetry at home, and the NetHealth app is installed on his smartphone. The patient registers his account in the app. A personal uroflowmeter is paired with the patient's smartphone using the installed app via a Bluetooth connection. The investigator trains the patient how to use the app and how to conduct uroflowmetry at home. The patient within 1 day (24 hours) at home performs uroflowmetry during all urination, including night urination.
224069112|NCT03754244|DRUG|TQB3456|Observe the safety and pk when the subjects take TQB3456 p.o. qd
224069113|NCT05088707|DRUG|sublingual misoprostol|"All patients will receive three doses of sublingual misoprostol every four hours The first dose of misoprostol 800 mcg will be administrated at the hospital. Then the patient will be observed for 1 hour for any immediate adverse reaction Clear instructions about the method and timing of second dose will be given upon sending home.~Two doses of misoprostol 800 mcg each (four tablets of 200 mcg per dose). Paracetamol, eight hourly, will be provided as analgesic or antipyretic. A specimen bottle to collect the POC if passed out. Two pairs of disposable gloves. Pre-filled histopathological examination form to be sent to the laboratory together with the products of conception"
224069114|NCT05088707|DRUG|vaginal misoprostol|"All patients will receive three doses of vaginal misoprostol every four hours The first dose of misoprostol 800 mcg will be administrated at the hospital. Then the patient will be observed for 1 hour for any immediate adverse reaction Clear instructions about the method and timing of the second dose will be given upon sending home.~Paracetamol, eight hourly, will be provided as analgesic or antipyretic"
224069115|NCT01531283|DRUG|unacylated ghrelin|IV, UAG (4.0 µg/kg/hr), one time, duration of study visit (approximately 5 hours)
224069116|NCT01531283|DRUG|acyl ghrelin|IV, AG (1.0 µg/kg/hr), one time, duration of study visit (approximately 5 hours)
224069117|NCT01531283|DRUG|combined acyl and desacyl ghrelin|IV, the combination of AG (1 µg/kg/hr) and UAG (4 µg/kg/hr), one time, for the duration of the study visit (approximately 5 hours)
224069118|NCT01531283|DRUG|saline|IV, saline, one time, for the duration of the study visit(approximately 5 hours)
224069119|NCT00650754|DIETARY_SUPPLEMENT|Dehydroepiandrosterone|25 mg PO TID
224069120|NCT00650754|OTHER|Placebo|Placebo
224069121|NCT03090126|OTHER|Therapeutic education|Questionnaires
224304028|NCT04136457|OTHER|Sprint training|Subjects perform a period of sprint training
224304029|NCT03673657|DIETARY_SUPPLEMENT|Early Nutrition Intervention from the start of CCRT|Nutrition counseling and oral nutritional supplements from the start of radiotherapy; weekly counseling sessions; daily energy intake of approximately 30 kcal/kg.
224304030|NCT03673657|RADIATION|Thoracic radiotherapy|Definitive thoracic radiotherapy with total radiation doses of 60-68 Gy
223579271|NCT01480713|DRUG|Isentress® (Raltegravir, 400 mg every 12 hours)|Lopinavir/r 200/50 mg every 12 hours + Raltegravir 400 mg every 12 hours
223579272|NCT01480713|DRUG|Isentress® (Raltegravir, 400 every 12 hours)|Darunavir/rit 800/100 mg every 24 hours + Raltegravir 400 mg every 12 hours
223470511|NCT05414214|PROCEDURE|Sternomental displacement|Sternomental displacement (SMDD): While the patient is sitting with the head in a neutral position, SMD-neutral will be measured using a tape as the distance between upper borders of the manubrium sterni and the mentum. The SMD-extension will then be measured in the same way with the head extended on the neck. The difference between SMD-extension and SMD-neutral will then be calculated as SMDD.
223470512|NCT05414214|PROCEDURE|General anesthesia|patients will be pre-oxygenated with 100% oxygen for 3 minutes, anesthesia will be then induced intravenously using fentanyl 2 μg/kg, propofol 1 -1.5 mg/kg, and succinylcholine 1 mg/kg lean body weight. Mask ventilation will be maintained till complete muscle relaxation guided by a peripheral nerve stimulator. Using Macintosh laryngoscopy, an anesthetist who has at least three years experience and who will be blinded to the preoperative tests' results, determined the best laryngeal view by using Cormack-Lehane (CL) grading system from I-IV. External neck manipulation will be used when needed to obtain the best laryngoscopic view. Endotracheal intubation will then be accomplished. The number and duration of intubation attempts will be recorded.
223470513|NCT00290563|DRUG|MK0594|
223470514|NCT05475509|OTHER|Virtually reality|Before chemotherapy, saliva samples will be taken from the control group, Personal Information Form, State Anxiety Scale and Visual Analogue Scale (VAS) pre-test questionnaires will be applied to the patients who accepted to participate in the study, vital signs measurements will be made and post-test questionnaires will be applied at the 30th minute of chemotherapy, vital signs measurements will be made, and A saliva sample will be taken. In the experimental group, a saliva sample will be taken before chemotherapy.
223470515|NCT00113607|DRUG|Trabectedin|Type=exact number, unit=mg/m2, number=1.1, form=solution, route=IV. Trabectedin will be administered over 3 hours every 3 weeks.
223470516|NCT00113607|DRUG|DOXIL|Type=exact number, unit=mg/m2, number=30, 50, form=solution, route=IV. DOXIL will be administered over 90 minutes every 4 weeks when administered alone (monotherapy) and every 3 weeks when administered with trabectedin.
223470517|NCT00113607|DRUG|Dexamethasone|Type=exact number, unit=mg, number=20, form=solution, route=IV. Dexamethasone or its equivalent will be administered over 30 minutes prior to the DOXIL infusion.
223470518|NCT06466343|PROCEDURE|hysteroscopic resection of lower edge of cesarean scar niche|"Operative hysteroscopy will be used for surgical treatment in the cases. Hysteroscopic management of niche will be done according to the following steps: Operative procedure will be done postmenstrual, cervical preparation will be done by giving the patients misoprostol (misotac®) 400mcg two hours preoperative. Surgically, operative resectoscope (KARL STORZ, Germany,27 Fr gauge) will be inserted into the uterine cavity after cervical dilatation by Hegar uterine dilator up to 8. Distilled water will be used as distension media. Using a resectoscope, the lower edge of the niche will be trimmed, the base will be coagulated by using monopolar cutting current at 30-50 MHz.~The resected parts will be submitted together as one sampled specimen in one container of formaldehyde 30% (dissolved 800 ml water and 200 ml formaldehyde)"
223470519|NCT04046900|BIOLOGICAL|Vaginal microbiome transplant|Vaginal fluid from healthy donors
223470520|NCT04046900|DRUG|Oral Metronidazole|500mg oral metronidazole twice daily for 7 days
224069122|NCT05896020|DRUG|SHR- A1811|Subjects with gynaecological malignancies
224159719|NCT04459494|PROCEDURE|Conventional implant surgery.|"Local anesthesia will be applied to the patients in the control group, and then the implant socket will be prepared after reflecting the flap and a dental implant will be placed.~Patients in the control group will receive a full thickness flap elevation and an implant socket will be prepared afterwards the implant will be placed and then the flap will be closed with 4-0 silk suture.~Bite-wing film will be taken from both groups to control the implants in the same session after surgery, and patients will be given VAS (visual analog scale) to perform their assessment of pain on the 3rd day and 7th day. Patients will be given an appointment again after 3 months of treatment. In this session, implants will be evaluated with bite-wing film."
224159720|NCT01976169|DRUG|PD-0332991 and T-DM1|"The subjects will be administered T-DM1 by intravenous infusion at 3.6 mg/kg for 90 minutes on day 1 of each 21 day cycle. Infusion timing may vary from 30-90 minutes depending on how well the subject tolerates the treatment.~A standard 3+3 trial design will be used for PD-0332991 dose escalation cohorts.The dosing of PD-0332991 will be divided into 3 cohorts, the subjects will receive PD-0332991 on days 5-18 of each 21 day cycle.~Cohort 1 : PD-0332991 - 100 mg daily (oral) Cohort 2 : PD-0332991 - 150 mg daily (oral) Cohort 3 : PD-0332991 - 200 mg daily (oral)"
224159721|NCT01804491|OTHER|Motion Analysis|3D Motion analysis with retroflective markers on the skin (Vicon camera system) of the foot and lower leg (kinematics), walking over force plate (kinetics) and pressure plates (plantar pressure distribution).
223470521|NCT04046900|OTHER|Sterile saline|700 uL of sterile saline placed in the vagina as a placebo intervention.
223470522|NCT01307956|DRUG|Fluorouracil|Given IV
223470523|NCT01307956|OTHER|Laboratory Biomarker Analysis|Correlative studies
223470524|NCT01307956|DRUG|Leucovorin Calcium|Given IV
223470525|NCT01307956|DRUG|Oxaliplatin|Given IV
223470526|NCT01307956|BIOLOGICAL|Panitumumab|Given IV
223470527|NCT01307956|OTHER|Pharmacological Study|Correlative studies
224069123|NCT04710342|DEVICE|CapBuster|Evaluate the safety and effectiveness of the CapBuster System in crossing de novo or restenotic chronic total occlusions in infrapopliteal peripheral arteries.
223470528|NCT01307956|RADIATION|Radiation Therapy|Undergo radiation therapy
223470529|NCT01307956|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgical resection
223579273|NCT02980744|BEHAVIORAL|Sedentary behaviour intervention|The intervention is based on socio-cognitive theory and focuses on building and increasing confidence (self-efficacy) to make a behaviour change. Output from the activity monitor (i.e. activPAL) will provide visual feedback of usual activity. Action plans targeting areas of high sedentary behaviour will be developed. A wrist-worn Misfit activity monitor is used as a self-monitoring tool throughout the intervention. This commercially available device provides activity information in real time, and sets daily targets for physical activity. A checklist will be used to address: 1) use of walking aids; 2) incidence of falls; 3) review and progression of home exercise program; and 4) quality of walking. The intervention visits will be conducted by a physical therapist.
224069124|NCT05808036|OTHER|Dietary intervention: DOMINO app|Life style intervention and diet low in FODMAPs.
224069125|NCT05808036|OTHER|Dietary intervention: low FODMAP diet|Strict low FODMAP diet.
224069126|NCT00364312|BEHAVIORAL|diet and physical activity|
223579274|NCT05920044|OTHER|balance and proprioception training program.|"The program will include exercises focused on improving ankle stability and joint position sense, such as single-leg stance, wobble board, and resistance band exercises.~Participants will attend two supervised sessions per week and perform home-based exercises 3-4 times per week.~Progression of exercises will be individualized based on participant performance and tolerance."
223579275|NCT05920044|OTHER|Usual care|"Participants will continue their usual care, including general strength and flexibility exercises.~No specific balance and proprioception training will be provided."
223579276|NCT04938999|BEHAVIORAL|Music-visual guided physical activity (MVgPA)|"The MVgPA adopts the information-motivation-strategy model to address the personal and environmental challenges in PA initiation and maintenance of adults with intellectual disability.~To support the staff of residential care facilities in implementing 24 sessions of MVgPA in 12 weeks, the first six sessions will be led by the RA1 and co-facilitated by the staff, while the subsequent sessions will be conducted by the staff only. At week 6, another set of MVgPA will be implemented to increase the participant's interest; two sessions will be co-facilitated by RA1. At weeks 6 and 9, the RN and RA1 will hold a meeting with the staff of the residential care facilities to acknowledge the achievement of the staff and adults with ID, as well as to address any of their concerns related to the implementation of MVgPA, and to identify the facilitators and tackle barriers to the implementation of the MVgPA."
223579277|NCT04938999|BEHAVIORAL|Usual care|As control group, residential care facilities will conduct their usual activities during the study period. A trained RA will record the activities conducted by the residential care facilities during the study period.
223579278|NCT04524650|DIAGNOSTIC_TEST|the level of vWF|the peripheral level of vWF
223579279|NCT05164588|OTHER|Statistics|Study and analyze the medicolegal aspects of different eye trauma cases ( patterns of injuries, mechanisms, causes, site of trauma and outcome)
223579280|NCT04598126|OTHER|Traditional physical therapy|Traditional physical therapy Ultrasound posteriorly 6 mints 4 days/week hydrocollateral pack anteriorly 10 mints 4 days/week Quadriceps isometrics 10 repetitions×1 set, 4 days/week and Hamstring muscle strechings 10 repetitions×1 set, 4 days/
224159722|NCT00179517|DRUG|Anastrozole 1mg|
224159723|NCT00179517|DRUG|Placebo Oral Tablet|
224159724|NCT02853149|BEHAVIORAL|Spinal Cord Injury (SCI)|"The SCI Intervention group will undergo intense exercise, a defined nutrition program, and an educational program taught by the study investigators. The exercise will require them to undergo supervised activity 3 times weekly for 6 months. They will also participate in a series of educational sessions that examine their lifestyle, and modify exercise/nutritional habits. After 6 months they will advance to another 6 months or extension phase in which the investigators expect them to continue to exercise up to 3 times per week at our center or at home by using elastic exercise bands (Thera-band) and handles that the Investigators will provide and teach how to use. They will also be expected to continue the modified nutritional program."
224159725|NCT02853149|BEHAVIORAL|Caregiver Intervention(CCC)|"The Caregiver Intervention group will undergo intense exercise, a defined nutrition program, and an educational program taught by the study investigators. The exercise will require them to undergo supervised activity 3 times weekly for 6 months. They will also participate in a series of educational sessions that examine their lifestyle, and modify exercise/nutritional habits. After 6 months they will advance to another 6 months or extension phase in which the investigators expect them to continue to exercise up to 3 times per week at our center or at home by using elastic exercise bands (Thera-band) and handles that the Investigators will provide and teach how to use. They will also be expected to continue the modified nutritional program."
224159726|NCT02853149|BEHAVIORAL|Caregiver Control (CC)|The Caregiver Control group will also discuss ways in which health and fitness can be improved through exercise and nutrition and will also be offered a fully paid membership to the an exercise fitness center to encourage them to exercise and consume a healthy diet. Unlike the Caregiver Intervention group(CCC) the lifestyle recommendations will be provided by internet authorities such as Web Medical(WebMD), the US Department of Agriculture, and the US Department of Human Health Services, which are dependable websites that promote healthy ways of living.
224159727|NCT01920438|PROCEDURE|Percutaneous Endoscopic Gastrostomy|PEG
224159728|NCT01920438|PROCEDURE|Radiologically-guided insertion of Gastrostomy|RIG
224304031|NCT03673657|DRUG|Weekly DP chemotherapy concurrent with thoracic radiotherapy|Weekly docetaxel (25mg/㎡) and nedaplatin (25mg/㎡) concurrent with thoracic radiotherapy
224304032|NCT02743338|BEHAVIORAL|Sleep Restriction|Behavioral component of CBT-i. Sleep restrictions includes curtailing bed time to match sleep time as registered during the first week of treatment, and expanding bed time contingent upon increased sleep efficiency, until optimal balance between sleep time and sleep efficiency is reached. The first five weeks, therapist support is provided via written messages. The next five weeks, patient works independently. At the end of tenth treatment week, therapist and patient make plan for future.
224304033|NCT02743338|BEHAVIORAL|Sleep Compression|Behavioral component of CBT-i. Sleep compression includes gradually compressing bed time over several weeks to approach sleep time as registered during the first week of treatment, and stopping compression when optimal balance between sleep time and sleep efficiency is reached. The first five weeks, therapist support is provided via written messages. The next five weeks, patient works independently. At the end of tenth treatment week, therapist and patient make plan for future.
224304034|NCT02743338|BEHAVIORAL|Additional CBT-i components|After 5+5 weeks of either Sleep Restriction or Sleep Compression, a randomized sample from each treatment Group is offered additional components of CBT-i, such as Stimulus Control, Cognitive Restructuring, Relaxation and Visualization for 10 weeks, without therapist support. Component allocation based on individual analysis.
224304035|NCT04791878|DRUG|Mesenchymal stem cells|Direct injection of 75 million allogeneic bone marrow derived mesenchymal stem cells at baseline and again after 3 months if not completely healed
224304036|NCT00039026|DRUG|AC2993|Placebo Lead In (0.02 mL) for 4 weeks / AC2993 5mcg (0.02 mL) for 4 weeks / AC2993 5mcg (0.02 mL) for 26 weeks - All are subcutaneously injected twice daily
223470530|NCT01418339|DRUG|Aripiprazole|Aripiprazole tablet administered orally once a week.
223470531|NCT01418339|DRUG|Placebo|Aripiprazole-matching placebo tablet administered orally once a week.
223470532|NCT06203938|DEVICE|Transcranial infrared light stimulation|Trancranial infrared light stimulation administered via light-emitting diodes
223470533|NCT06203938|DEVICE|Sham|Identical to TILS, but with lights off
223470534|NCT04737525|DEVICE|Dental implant placement, bone and soft tissue augmentation on buccal site|"1. Atraumatic extraction~2. Palatinal positioning of tapered implant (BLX) 3.75mm diameter~3. 3-4 mm below vestibular gingival line or 1 mm below bone crest~4. Implant placement~5. Allogenic bone packing of the jumping distance and soft tissue grafting~6. Connective tissue graft (CTG) or porcine-derived membrane~7. Provisional restoration out of occlusion and mandibular movements~8. X-ray"
224159729|NCT00437203|DRUG|PF-00477736|"* Escalating doses of PF-00477736 will be administered intravenously on Days 2 and 9 and gemcitabine will be administered intravenously on Days 1 and 8 of a 21-day cycle (doses to be evaluated range from 750 to 1250 mg/m2 in three separated cohorts).~* If a patient is administered Cycle 0 - only PF-0047736 will be administered intravenously on Days 1 and 8 of a 21-day cycle for patients who have a 3-hour infusion and Days 1 and 8 of a 14-day cycle for patients who have a 24-hour infusion."
224159730|NCT00437203|DRUG|gemcitabine|gemcitabine will be administered intravenously on Days 1 and 8 of a 21-day cycle (doses to be evaluated range from 750 to 1250 mg/m2 in three separated cohorts).
224159731|NCT05048199|DEVICE|pressure regulated volume-controlled mode of ventilation|"Cardiac output non-invasive monitor for measuring SV. Hemodynamic variables including heart rate (HR), mean arterial blood pressure (MAP), central venous pressure (CVP), stroke volume (SV), stroke volume index (SVI), cardiac output (COP), cardiac index (CI), systemic vascular resistance (SVR), systemic vascular resistance index (SVRI), thoracic fluid content (TFC), corrected flow time (FTC), index of contractility (ICON), and systolic time ratio (STR), Arterial oxygen saturation (Sao2), oxygen delivery (DO2) and oxygen delivery index (DO2I) will be recorded.~These variables will be obtained before induction of anaesthesia (T1) skin incision (T2), then every 30 min till the resection of the urinary bladder (T3a, T3b, T3c, …. etc). The mode of ventilation will swift to the other mode 5 minutes after cystectomy (T4), then every 30 min till end of the urinary diversion (T5a, T5b, T5c, …. etc), end of surgery (T6), and postoperative every 4h for 24 hours( P1-P6)."
224159732|NCT05048199|DEVICE|volume-controlled mode of ventilation|"Cardiac output non-invasive monitor will be used for measuring SV. Hemodynamic variables including heart rate (HR), mean arterial blood pressure (MAP), central venous pressure (CVP), stroke volume (SV), stroke volume index (SVI), cardiac output (COP), cardiac index (CI), systemic vascular resistance (SVR), systemic vascular resistance index (SVRI), thoracic fluid content (TFC), corrected flow time (FTC), index of contractility (ICON), and systolic time ratio (STR), Arterial oxygen saturation (Sao2), oxygen delivery (DO2) and oxygen delivery index (DO2I) will be recorded.~These variables will be obtained before induction of anaesthesia (T1) skin incision (T2), then every 30 min till the resection of the urinary bladder (T3a, T3b, T3c, …. etc). The mode of ventilation will swift to the other mode 5 minutes after cystectomy (T4), then every 30 min till end of the urinary diversion (T5a, T5b, T5c, …. etc), end of surgery (T6), and postoperative every 4 hours for 24 hours (P1-P6)."
224304037|NCT00039026|DRUG|AC2993|Placebo Lead In (0.02 mL) for 4 weeks / AC2993 5mcg (0.02 mL) for 4 weeks / AC2993 5mcg (0.02 mL) for 26 weeks - All are subcutaneously injected twice daily
223470535|NCT05494528|DRUG|Ropeginterferon alfa-2b|Ropeginterferon alfa-2b 450 µg subcutaneous injection every two weeks
223470536|NCT05494528|DRUG|Entecavir|Entecavir 0.5 mg once per day
223470537|NCT03885908|OTHER|in-person geriatric co-management|"The geriatrics service sees these patients for at least 2 postoperative days, if deemed clinically necessary by the geriatrician. During the inpatient hospital course, the geriatrics service will ensure the execution of preoperative recommendations and will discuss with the surgical team, who will act as a primary team, any additional recommendation in order to improve postoperative care. In-person geriatric consults to be done via telemedicine due to the current pandemic and consideration for patient safety."
223470538|NCT03885908|OTHER|automated geriatric co-management|Following completion of the eRFA, the summary of impairments as well as the recommendations generated by the study team (hard-copy or email) will be provided in real-time to the surgery team for their attention.
223470539|NCT04080726|DRUG|HIP1601|Oral esomeprazole
223470540|NCT04080726|DRUG|HGP1705|Oral Nexium Tab
223470541|NCT04080726|DRUG|HIP1601 Placebo|Oral Placebo
223470542|NCT04080726|DRUG|HGP1705 Placebo|Oral Placebo
223470543|NCT02204917|DRUG|OPTISON|Contrast enhanced Voiding Urosonography (ceVUS) with intravesical administration of OPTISON for vesicoureteral reflux detection and urethral imaging in children. Voiding Cystourethrography (VCUG) examination will be subsequently performed as part of the standard care.
223470544|NCT04566107|BEHAVIORAL|mHealth intervention|The intervention promotes self-management and adherence to treatment regimens in patients with multimorbidity. This 8-week SM intervention uses mobile health (m-Health) technology for daily messages and reminders to promote self-monitoring activities. Bluetooth devices provided will depend on the participant's need for self-management; heart failure (scale), diabetes (glucometer), COPD (pulse oximeter) or hypertension (BP machine).
223470545|NCT04566107|BEHAVIORAL|mHealth Plus|The intervention promotes self-management and adherence to treatment regimens in patients with multimorbidity. This 8-week SM intervention uses tailored self-management strategies (action planning, goal setting, and individual identified support needs) and mobile health (m-Health) technology for virtual visits, daily messages, and self-monitoring activities. The investigators will test the additive impact of having the nurse practitioner/community health worker (NP/CHW) team with the m-health platform. The NP will evaluate physiological and psychosocial status while the CHW will assist in recognizing possible solutions to challenging social determinants of health by identifying community resources and guidance in overcoming barriers. Bluetooth devices provided will depend on the participant's need for self-management; heart failure (scale), diabetes (glucometer), COPD (pulse oximeter) or hypertension (BP machine). Participants will receive reminders through the platform.
223579281|NCT04598126|OTHER|patient education manual +traditional physical therapy|"Patient educational Manual~\+ Traditional physical therapy Ultrasound posteriorly 6 mints 4 days/week hydrocollateral pack anteriorly 10 mints 4 days/week Quadriceps isometrics 10 repetitions×1 set, 4 days/week and Hamstring muscle strechings 10 repetitions×1 set, 4 days/"
223579282|NCT02072187|DIETARY_SUPPLEMENT|Active|
223579283|NCT02072187|DIETARY_SUPPLEMENT|Placebo|
223579284|NCT05730647|OTHER|None intervention (observational study)|None intervention (observational study)
223579285|NCT04200768|OTHER|Prospective data and sample collection|Performance of measurements of adiposity, extra collection of blood samples
223470546|NCT04907292|OTHER|Obstetric Quality of Recovery-10 (ObsQoR-10©) Scoring Tool|The ObsQoR-10 tool aims to quantitatively measure functional recovery at 24 hours postpartum. It includes 10 questions on a 0 to 10 scale, aimed at pain management, the adverse effects of narcotics and the perception of recovery by the patient.
223470547|NCT05896436|BEHAVIORAL|Emotion Focused Therapy|12 sessions of Emotion Focused Therapy (EFT). The focus in EFT is to promote the individual's experiencing and facilitate participants' self-disclosure and openness to their own experience, rather than the therapist's agenda or techniques. Key processes within EFT include helping people overcome their avoidance of emotion, maintaining a collaborative focus on emotions, and exploring emotions in therapy.
223470548|NCT03669549|DRUG|Nevanimibe hydrochloride|During the 16-week treatment period, all subjects will begin dosing with nevanimibe HCl 500 mg BID and be dose titrated to 1000 mg BID, 1500 mg BID, and 2000 mg BID as needed based on serum 17-OHP assessments every 4 weeks.
223470549|NCT02238730|DEVICE|Ultrabrief Right Unilateral|The first six electroconvulsive therapy sessions using ultrabrief (0.25 ms) right unilateral electroconvulsive therapy
223470550|NCT02238730|DEVICE|Brief Pulse Bitemporal|The first six electroconvulsive therapy sessions using brief pulse (0.5 ms) bitemporal electroconvulsive therapy
223470551|NCT00909844|DRUG|Triptorelin (I.N.N.)|Decapeptyl® SR 11.25mg
223470552|NCT01766362|PROCEDURE|PRPC using Pascal laser|
223470553|NCT03003234|PROCEDURE|Duodenogastroscopy|Catheter goes through the mouth in the duodenum to take duodenal biopsies.
223470554|NCT03003234|DEVICE|Duodenal aspiration catheter|Catheter goes through the nose in the duodenum to aspirate duodenal fluid in fasted and fed state.
223470555|NCT03003234|DIETARY_SUPPLEMENT|Nutri drink|Liquid meal of 200 ml.
223470556|NCT04614298|DRUG|KHK4827-Active|Single SC administration
223470557|NCT04614298|DRUG|KHK4827-Placebo|Single SC administration
223470558|NCT04845997|BIOLOGICAL|COVID-19 Vaccine|Patients with rheumatic diseases who have been vaccinated for COVID-19
223470559|NCT00984932|DRUG|Rosuvastatin|40 mg of rosuvastatin daily
223470560|NCT04624113|DRUG|Tazemetostat|Epizyme will supply the study agent, which will be provided free of charge to the patient.
223470561|NCT04624113|DRUG|Pembrolizumab|Pembrolizumab is commercially available
223579286|NCT00843544|BEHAVIORAL|Integrative Medicine|"Participants assigned to the treatment group will begin in groups of ten. The treatment protocol will consist of six 1-2 hour sessions over a six-week period as follows:~1. Subjects will attend a two-session class on healthy eating focused on reducing inflammation-promoting foods in the diet. All subjects will also be started on fish oil and vitamin C supplements, as well as on a supplement called Kaprex, which is an extract from hops and rosemary with anti-inflammatory action. Supplements willl be provided free of charge. Subjects will be provided with a take home supply to begin using.~2. Subjects will attend two classes at CCHH in yoga breathing techniques and will then be provided with a CD for home study and practice~3. Subjects will attend two guided journaling sessions at CCHH in which subjects will be asked to write for a 30-minute period about the most traumatic or stressful life experience to date."
223579287|NCT02768025|OTHER|Traditional & Complementary Medicine treatment|Body acupuncture, Ear acupuncture and aromatic therapy
223470562|NCT00750763|DRUG|Colonlytely|Bowel preparation
223470563|NCT00750763|DRUG|Picolax/Picoprep|Bowel preparation
223470564|NCT00750763|DRUG|Fleet|Bowel preparation
223470565|NCT05537857|OTHER|High dietary salt|Controlled feeding study that varies in salt content.
223470566|NCT04256343|OTHER|Deuterium Oxide (D2O) Dose|1 of 3 differing deuterium oxide (D2O) doses will provided to each of the participants to be consumed daily to assess muscle protein synthesis.
223470567|NCT05701813|DIETARY_SUPPLEMENT|INOSITOLS|4000 mg of myo-inositol and 300 mg of D-chiro-inositol. Once a day for 90 days.
223470568|NCT05701813|DIETARY_SUPPLEMENT|CELLULOSE|4.3 grams of cellulose once a day for 90 days.
223470569|NCT00698815|OTHER|Laboratory Biomarker Analysis|Correlative studies
223470570|NCT00698815|DRUG|Pemetrexed Disodium|Given IV
223470571|NCT00698815|DRUG|Sunitinib Malate|Given PO
223470572|NCT01362764|DRUG|Abiraterone acetate suspension Formulation 1|Type=exact, unit=mg/mL, number=25, form=oral suspension, route=oral use, as a single dose of 10 mL
223470573|NCT01362764|DRUG|Abiraterone acetate suspension Formulation 2|Type=exact, unit=mg/mL, number=25, form=oral suspension, route=oral use, as a single dose of 10 mL
223470574|NCT01362764|DRUG|Abiraterone acetate tablets|Type=exact, unit=mg, number= 250, form=tablet, route=oral use, as a single dose
223470575|NCT01885013|DRUG|Metformin + Myocet + Cyclophosphamide|"Metformin + Myocet + Cyclophosphamide:~Metformin 1000 mg, 2 times daily per os\*. Myocet 60 mg/m2, intravenous infusion, on day 1, every 21 days Chemotherapy will be performed for 8 cycles Cyclophosphamide 600 mg/m2, intravenous infusion, at day 1 every 21 days.~\* During cycle 1, patients will assume only metformin from day 1 to day 13 and will begin chemotherapy from day 14. From day 1 to day 3, patients will assume Metformin 1000 mg once a day. Starting from day 4 patients will assume Metformin 1000 mg 2 times a day."
223470576|NCT01885013|DRUG|Myocet + Cyclophosphamide|"Myocet + Cyclophosphamide:~Myocet 60 mg/m2, intravenous infusion, on day 1, every 21 days Cyclophosphamide 600 mg/m2, intravenous infusion, on day 1, every 21 days Chemotherapy will be performed for 8 cycles"
223470577|NCT01064479|DRUG|Carboplatin|Given IV
223470578|NCT01064479|DRUG|Cisplatin|Given IV
223470579|NCT01064479|DRUG|Docetaxel|Given IV
223470580|NCT01064479|DRUG|Erlotinib Hydrochloride|Given PO
223470581|NCT01064479|OTHER|Laboratory Biomarker Analysis|Optional correlative studies
223470582|NCT01064479|OTHER|Pharmacological Study|Optional correlative studies
223470583|NCT01064479|OTHER|Placebo|Given PO
223470584|NCT01064479|OTHER|Quality-of-Life Assessment|Ancillary studies
223470585|NCT05938218|DEVICE|Intervention|Virtual Reality assisted information Patients in the intervention group receive a VR instructional application lasting approximately 25 minutes. This intervention takes place in the waiting room prior to the actual physician-patient conversation and complements the usual care provided through brochures.
223470586|NCT04479839|DIAGNOSTIC_TEST|Ultrasound of the airway|Placing ultrasound on the neck after intubation
223470587|NCT03901846|DEVICE|ColdZyme|ColdZyme is a Class I medical device (CE-marked) with the following composition: glycerol, water, Tris buffer, CaCl2, menthol and trypsin
223470588|NCT06202846|GENETIC|cfDNA analysis|"In order to compare the performance of the ctDNA test with techniques used in routine diagnostics, we will compare the results obtained by the ctDNA test with those obtained by FISH.~compare the results obtained by the ctDNA test and FISH. This will enable us to identify a potential diagnostic gain. We will compare the percentage of patients for whom a positive test result result was obtained by the lncDNA test (Y chromosome detection) to the percentage of patients for whom a positive result was obtained by FISH."
223470589|NCT00994305|DRUG|N-acetylcysteine|600 mg bid po 0-7 PO
223470590|NCT00994305|DRUG|control|No treatment: standard care provided. No N-acetylcysteine administration.
223579288|NCT02768025|OTHER|NRT, counselling|Nicotine Replacement Therapy, counselling
223470591|NCT00466817|OTHER|Placebo|9 grams of powder which contains no Valganciclovir free base. The oral solution formulation comprises the following excipients: mannitol, lactose anhydrous, fumaric acid, sodium benzoate, saccharin sodium, flavor, and purified water.
223470592|NCT00466817|DRUG|Valganciclovir|Mono-valyl ester pro-drug of ganciclovir, oral solution, provided as a 12 grams of powder containing 5 grams of Valganciclovir free base. The oral solution formulation comprises the following excipients: Providone K30, fumaric acid, sodium benzoate, sodium saccharin, mannitol, flavor, and purified water.
223470593|NCT01639352|BIOLOGICAL|SOM230|Patients will be given a starting of 60mg of SOM230 via injection, intramuscularly every 28 days.
223470594|NCT02499055|BEHAVIORAL|FearFighter|FearFighter™ is a nine session cognitive behavioural self-help therapy program delivered over the internet during nine weeks. Each session on FearFighter excluding the homework takes about 30-40 minutes to finish. A support person will make a weekly contact of 10 minutes in average to secure understanding of the program and compliance.
223470595|NCT00317915|DRUG|Irbesartan treatment|
223470596|NCT05294861|OTHER|YesMdiet|In the YesMdiet, participants will consume Milk and Dairy products
223470597|NCT05294861|OTHER|NoMdiet|In the YesMdiet, participants will not consume Milk and Dairy products, only other sources of protein
223579289|NCT00319657|BIOLOGICAL|Hematopoietic cell transplantation|Transplantation of hematopoietic stem cells from the living donor.
223579290|NCT00319657|RADIATION|Total lymphoid irradiation|Total lymphoid irradiation is used as part of the conditioning regimen for the hematopoietic stem cell transplant.
223579291|NCT02645435|PROCEDURE|hip replacement|Total hip replacement
223579292|NCT06141837|OTHER|Observation|No intervention: observational study
223470598|NCT04517292|DRUG|Eribulin,cisplatin|Eribulin 1.4mg/m2, IV , D1, D8；Cisplatin 75 mg/m2, IV，D1
223470599|NCT04517292|DRUG|Gemcitabine,cisplatin|Gemcitabine 1250 mg/m2, IV , D1, D8； Cisplatin 75 mg/m2, IV, D1
223470600|NCT00379145|DRUG|trabectedin|
223579293|NCT04401670|OTHER|HPV screening and triage tests|The participants underwent a pelvic exam to have a provider-collected sample placed in PreservCyt \[Hologic, Inc., Bedford, MA, USA\] and a visual inspection by acetic acid (VIA) by a nurse.
224159733|NCT06211452|DRUG|ARM A: Active Comparator Drug|Consolidation 6-thioguanine 60 mg/m2/d, 1 to 43 po; prednisone 40 mg/m2/d, on days 1-28 orally; vincristine 1.5 mg/m2/d, days 1, 8, 15, 22; idarubicin 7 mg/m2/d, on days 1, 8, 15, 22; cytarabine 75 mg/m2/d, on days 3-6, 10-13, 17-20, 24-27, 31-34, 38-41; intrathecal cytarabine on days 1, 15, 29, 43; cyclophosphamide 500 mg/m2/d, days 29, 43.
223470601|NCT00038766|DRUG|semapimod|semapipmod 60 mg IV x 5 days
223579294|NCT04401670|BEHAVIORAL|HPV self-sampling|"The participant was escorted by the nurse to a private room and given instructions on how to self-collect their sample using Just for Me sampler \[Preventive Oncology International, Cleveland, OH, USA\]."
223579295|NCT00600041|DRUG|Pantoprazole|80 mg IV over 2 minutes, followed by 8 mg/h IV for 60 minutes
223579296|NCT00600041|DRUG|Placebo|Identical infusion manner like experimental arm
223579297|NCT04557787|DEVICE|SpeediCath® Standard female|Intermittent catheterization through the urethra draining the bladder, using SpeediCath® Standard female.
223470602|NCT00038766|DRUG|semapimod|IV 30 mg x 5 days
223470603|NCT00038766|DRUG|placebo|placebo IV
223470604|NCT02765152|OTHER|Conventional Physical Therapy|Combination of joint mobility exercises, specific exercises for muscle strength and motor coordination exercises, unilateral and bilateral motor tasks as well as task-oriented training of the upper limb with a focus on functional tasks. Patients will receive 10 sessions of treatment over a period of five weeks (two sessions/week)
223470605|NCT02765152|OTHER|Discrete movement training group|Aiming movements training with the affected upper limb (unilateral training) or both limbs (bilateral training) on the surface of a table. The starting point of the movement and its target are predetermined. Targets will be placed in different directions and distances from the starting point and the therapist ask for variations on speed and assistance, if necessary.
223470606|NCT02765152|OTHER|Rhythmic movement training group|Aiming movements training with the affected upper limb (unilateral training) or both limbs (bilateral training) on the surface of a table. The movement begins in a predetermined starting point, directed to a target and returns to the starting point. This activity is performed several times with rhythmic movements. Targets will be placed in different directions and distances from the starting point and the therapist ask for variations on speed and assistance, if necessary.
223470607|NCT05620589|DRUG|Amoxicillin + Tetracycline + Bismuth + Esomeprazole|Amoxicillin 1000mg bid+ Tetracycline 500mg qid+ Bismuth + Esomeprazole 40mg bid or Amoxicillin 1000mg bid+ Tetracycline 500mg tid+ Bismuth + Esomeprazole 40mg bid
223579298|NCT04557787|DEVICE|New intermittent Variant 1 catheter for females|Intermittent catheterization through the urethra draining the bladder, using the new Variant 1 catheter.
223579299|NCT04557787|DEVICE|New intermittent Variant 2 catheter for females|Intermittent catheterization through the urethra draining the bladder, using the new Variant 2 catheter.
223579300|NCT05182580|DIAGNOSTIC_TEST|Results utilized from autonomous AI diagnostic system for diabetic retinopathy and/or diabetic macular edema|If patients receive a negative result they do not see the retina specialist
223579301|NCT02109523|BEHAVIORAL|Motivational Interviewing (MI|Five weekly motivational and volitional session sessions and each last about 50 minutes. Five registered psychologists will moderated the session. All MI technique and planing intervention will be used.
223579302|NCT02109523|BEHAVIORAL|volitional intervention|Five weekly motivational and volitional session sessions and each last about 50 minutes. Five registered psychologists will moderated the session. All MI technique and planing intervention will be used.
223470608|NCT05620589|DRUG|Amoxicillin + Tetracycline + Bismuth + Vonoprazan|Amoxicillin 1000mg bid+ Tetracycline 500mg qid+ Bismuth +Vonoprazan 20mg bid or Amoxicillin1000mg bid+ Tetracycline 500mg tid+ Bismuth + Vonoprazan 20mg bid
223470609|NCT05620589|DRUG|Amoxicillin + Tetracycline + Bismuth + Tegoprazan|Amoxicillin 1000mg bid+ Tetracycline 500mg qid+ Bismuth + Tegoprazan 50mg bid or Amoxicillin 1000mg bid+ Tetracycline 500mg tid+ Bismuth + Tegopraza 50mg bid
223470610|NCT01663402|DRUG|Alirocumab|Alirocumab administered as SC injection of 1 mL in the abdomen or thigh with a disposable auto-injector.
223470611|NCT01663402|DRUG|Placebo|Placebo matched to alirocumab administered as a SC injection of 1 mL in the abdomen or thigh with a disposable auto-injector.
223470612|NCT01663402|DRUG|LMT|Statins (atorvastatin or rosuvastatin) at stable maximal tolerated dose of statin with or without other LMT as clinically indicated.
223470613|NCT04283786|OTHER|Qualitative Interview|A single qualitative interview about experiences of bisphosphonate regimens, as well as wider experiences of service quality and delivery.
223470614|NCT05983263|DRUG|Capsaicin|Capsaicin 8% patch (QUTENZA) apposed in coccygeal area
223470615|NCT03851263|BIOLOGICAL|Evolocumab|Subcutaneous injection, using a pre-filled auto-injector pen. Each pen contains 1.0 ml fluid (containing 140 mg evolocumab) which is injected in the abdomen, thigh or outer area of upper arm every 2 weeks (q2w).
223470616|NCT00678418|DRUG|VIVITROL® 380 mg|Administered via intramuscular (IM) injection once every 4 weeks for 24 weeks during Part A, followed by once every 4 weeks for 52 weeks in Part B.
223470617|NCT00678418|DRUG|Placebo|Administered via IM injection once every 4 weeks for 24 weeks during Part A, followed by VIVITROL® 380 mg via IM injection once every 4 weeks for 52 weeks in Part B.
223470618|NCT00514618|DRUG|Misoprostol|patients will be treated with misoprostol 50 mcg PO q day for two days (days 1 and 4)
223470619|NCT00514618|DIETARY_SUPPLEMENT|Placebo|patients will receive placebo (vitamin C) q day for two days (days 1 and 4)
223470620|NCT03924323|DRUG|Escitalopram|8-weeks of treatment followed by 1-week taper down period
223470621|NCT03924323|OTHER|Placebo|Matching oral administration of inactive substance once daily
223470622|NCT00706680|DRUG|Thymoglobulin|methyl prednisone intravenously pre-operatively, as per institutional practice. Thymoglobulin, initiated prior to completion of the anastomosis, or if not possible, within 24 hours of transplantation for a total dose of 6-7.5mg/kg given over 3-5 doses. Steroids initiated post-operatively at 1mg/kg/day for 2 days, then 0.5mg/kg/day for 2 days, then 0.25mg/kg/day for 2 days. Patients will be placed on 5mg daily for the remainder of the study. All patients will receive Mycophenolic acid at a dose of 2gm/day (Cellcept) or 1440mg/day (Myfortic) post-transplantation with dose adjustment as needed. Cyclosporine micro-emulsion will be initiated when renal function is established or no later than day 10 in a dose of 3mg/kg twice daily with adjustment to achieve a C2 target of 600-800 nanograms/ml.
223470623|NCT03351712|BEHAVIORAL|ACT-Based Intervention and Activity Tracker WITH Feedback|Combining ACT and Behavioral Change
223470624|NCT03351712|BEHAVIORAL|Gold Standard Intervention + Activity Tracker WITHOUT Feedback|Medical Rehabilitation, Motivational Support and Psycho-Education
223470625|NCT03351712|BEHAVIORAL|Gold Standard Intervention and Activity Tracker WITH Feedback|Behavioral Change Condition - Activity Tracker
223470626|NCT03351712|BEHAVIORAL|ACT-Based Intervention and Activity Tracker WITHOUT Feedback|ACT-Based Intervention Standalone
223470627|NCT04710004|DEVICE|Asynchronous distributed multi-electrode stimulation (ADMES) using an implantable neurostimulation device|Participants will receive asynchronous pulses distributed across a multi-electrode array of 16 micro-electrodes and stimulating at low (theta) frequencies.
223470628|NCT03405727|DIETARY_SUPPLEMENT|Oral dietary supplements|Protein enriched diet
223470629|NCT01088971|DIETARY_SUPPLEMENT|Duolac7S|1 capsule two times everyday for 6 weeks
223470630|NCT01088971|DIETARY_SUPPLEMENT|starch|1capsule two times everyday for 6 weeks
223470631|NCT06050213|DEVICE|Maxillary implant overdenture|maxillary overdenture retained by different number of implants
223470632|NCT06550479|PROCEDURE|AVF|Distal forearm AVF for hemodialysis.
223470633|NCT02805738|DRUG|CKD-390|CKD-390 1 Tablet (48 weeks)
223470634|NCT02805738|DRUG|viread|viread1 Tablet (24 weeks), CKD-390 1 Tablet (from 24 weeks to 48 weeks)
223470635|NCT03418259|DEVICE|KCS Medical Device|Patient treated 6 times with the Active KCS Medical Device during 2 weeks.
223470636|NCT03418259|DEVICE|KCS Medical Device|Patient treated 6 times with the Inactive KCS Medical Device during 2 weeks.
223470637|NCT05510258|OTHER|Physiotherapy|TWO GROUPS CONTROL ND EXPERIMENTAL
223470638|NCT00889941|PROCEDURE|LASIK|laser-assisted in situ keratomileusis
223470639|NCT04002791|DEVICE|VasoBand|Dual-bladder radial artery hemostatic compression device capable of ipsilateral ulnar artery compression
223470640|NCT03368313|DEVICE|Circaid|Circaid is a velcro compression device for the calf (Circaid Juxtalite® Lower Leg; Medi Gmbh, Bayreuth, Germany), thigh and knee (Circaid Juxtafit; Medi Gmbh, Bayreuth, Germany). The Circaid device will be applied with an average pressure of more than 40 mmHg, verified through a BPS (built-in pressure system).
223470641|NCT05469529|DRUG|Dexmedetomidine|5mcg dexmedetomidine to be given intrathecally along with 0.5% bupivacaine.
223470642|NCT03147872|OTHER|2% Oxygen|2% oxygen concentration in the incubator in which embryos are being cultured after day 3 of development
223470643|NCT01956890|DRUG|PET|18F-FLT PET and MRI of the breast
223579303|NCT02109523|BEHAVIORAL|Routine discharge counseling|
223579304|NCT02476110|DIETARY_SUPPLEMENT|Oral nutritive supplements|
223579305|NCT06477471|OTHER|MetProrenes|Take one slow-release capsule twice a day, after meal.
223579306|NCT05569876|OTHER|Controlled hypoglycemic state|Voice sampling is performed in different glycemic states (euglycemia and hypoglycemia).
223579307|NCT04014543|OTHER|gastronomy|"to study the quality of life of caregivers and children with generic questionnaires (13-16), validated and used in other pathologies and chronic diseases of the child.~This will allow reproducibility and comparisons to other populations, general or other chronic diseases (acute leukemias ...) This is to conduct a pilot study, preliminary to the construction of a larger study, longitudinal with several evaluation times."
223579308|NCT06486688|BEHAVIORAL|Centralized Virtual SBIRT|Brief interventions are delivered virtually by video or telephone by a centralized behavioral health clinician
223579309|NCT01969500|BEHAVIORAL|Mobile Application|
223579310|NCT01969500|BEHAVIORAL|Treatment as Usual (TAU)|
223579311|NCT00331227|DRUG|Isotonix OPC-3 (flavonoid supplement)|
223579312|NCT00000765|DRUG|Zidovudine|
224069127|NCT04943705|DEVICE|Yin and Yang Regulating Moxibustion|Before making Wenyang Yishen moxibustion, the width and length of the patient's moxibustion site were evaluated by the same body measurement method. Take about 700g of fresh ground ginger with moderate dryness and wetness, and place it on the treatment towel to make a round cake with a diameter of about 20cm and a thickness of about 2.5cm. Spread 25g of moxa moxa with a diameter of about 18cm on top of ginger and light it. When the bottom temperature reaches about 37 degrees, the door can be placed on the patient's waist for treatment. According to the patient's tolerance, the temperature should be controlled at 43-45 degrees. It is better to replace the moxa biscuit every time when the moxa biscuit is burned for about 10 minutes. The patient's local skin has a slight redness and burning. The moxibustion time is 60 minutes. Peiyuan Guben moxibustion is centered on Shenque, and the operation is the same as that of WenYang and Yishen moxibustion.
223470644|NCT04091464|BEHAVIORAL|Backward Walking Training|Training will consist of BW training on both a treadmill and overground. All participants will receive 1x/week training with a trained member of the research team, who will progress the participant week-to-week and ensure safety. Treadmill speed will be determined by baseline BW walking speed and incrementally increased with each training week to subject tolerance. Participants will follow a home exercise program for the remainder of the week that includes BW, backward stepping, and functional exercises that incorporate BW movements.
223470645|NCT04091464|BEHAVIORAL|Forward Walking Training|Training will consist of FW training on both treadmill and overground. All participants will receive 1x/week training with a trained member of the research team, who will progress the participant week-to-week and ensure safety. Treadmill speed will be determined by baseline FW walking speed and incrementally increased with each training week to subject tolerance. Participants will follow a home exercise program for the remainder of the week that includes FW, forward stepping, and functional exercises that incorporate FW movements.
223470646|NCT05499975|OTHER|Self-reported online geriatric assessment (CHAMP)|The CHAMP tool is a self reported online tool that has been developed to increase patients' accessibility to geriatric assessment and improve treatment decision making. The tool includes questions about function, mobility, cognition, nutrition, social support, depression substance use disorders, and miscellaneous items. Based on usability testing in the previous phase of this study, the tool can be completed in approximately 10-15 minutes. The tool generates a summary report with recommendations for patients and clinicians.
223470647|NCT01898247|OTHER|Simulation-based mastery learning|Internal Medicine residents are randomly selected to undergo simulation-based mastery learning.
224069128|NCT06277752|DRUG|dose-5 group|IBI128 300mg po. QD(Quaque Die)
224069129|NCT06277752|DRUG|dose-1 group|IBI128 25mg po. QD(Quaque Die)
224069130|NCT06277752|DRUG|dose-2 group|IBI128 50mg po. QD(Quaque Die)
224069131|NCT06277752|DRUG|dose-4 group|IBI128 200mg po. QD(Quaque Die)
224069132|NCT06277752|DRUG|dose-3 group|IBI128 100mg po. QD(Quaque Die)
224159734|NCT06211452|DRUG|ARM B: Blocks Therapy Drug|"Blocks AI Cytarabine 500 mg/m2 as 24 infusion infusion x 4 d; Idarubicin 7 mg/m2 on days 3 and 5; Intrathecal cytarabine on days 0 and 6.~haM Cytarabine 1 g/m2 every 12 hours for 3 days; Mitoxantrone 10 mg/m2 days 4 and 5; Intrathecal cytarabine days 6 and 15."
223470648|NCT05863819|OTHER|No Intervention|As this is an observational study, no intervention will be administered in this study.
223470649|NCT01463787|PROCEDURE|microsurgical varicocelectomy in inguinal approach|In inguinal approach, the incision, which was about 3cm, was made two fingers up the pubic symphysis, from external inguinal rings parallel to the inguinal ligament.
223579313|NCT04969848|OTHER|Wearable sensor|IMU sensor (as part of eMSGait device) worn at the hip during T25FW
223579314|NCT03589365|OTHER|Magnetic resonance imaging (MRI)|"Compare the left ventricular mass of a young adult population born prematurely (Prema group) to that of a group of young adults born at term (Witness group~The measurements made during this examination are:~Coronary Reserve Presence of fat in the myocardium Left ventricular mass Left ventricular volume~The measurements made during this examination are:~Coronary Reserve Presence of fat in the myocardium Left ventricular mass Left ventricular volume"
223579315|NCT01873729|DRUG|Naltrexone|Adults with ADHD
223579316|NCT00797238|OTHER||No intervention in this study
223579317|NCT02630420|DRUG|cetuximab and savolitinib|Dosage of combined cetuximab and savolitinib will be determine in Part 1 of the study, Part 2 will use the findings of Part 1 to further assess safety and to assess efficacy of this drug combination.
224159735|NCT01485432|DEVICE|PiCCO® Monitoring|Fluid and vasopressor management according to PiCCO measurements
223579318|NCT02463032|DRUG|GTx-024|To determine whether either or both doses result in an acceptable clinical benefit rate.
223579319|NCT00532792|BIOLOGICAL|A/H5N1|Low dose A/H5N1 (0.5mL); Route IM - Day 0 and Day 21; No LT Patch Day 0 or Day 21
223579320|NCT00532792|BIOLOGICAL|A/H5N1|Low dose A/H5N1 (0.5mL); Route IM - Day 0 and Day 21; no LT patch on Day 0; LT Patch on Day 21
224159736|NCT00003413|BIOLOGICAL|filgrastim|
224159737|NCT00003413|DRUG|carmustine|
224159738|NCT00003413|DRUG|cisplatin|
224159739|NCT00003413|DRUG|melphalan|
224159740|NCT00003413|DRUG|paclitaxel|
224159741|NCT00003413|PROCEDURE|peripheral blood stem cell transplantation|
224159742|NCT00003413|PROCEDURE|surgical procedure|
223579321|NCT00532792|BIOLOGICAL|A/H5N1|Low dose A/H5N1 (0.5mL); Route IM - Day 0 and Day 21; LT patch on Day 0 and Day 21
223579322|NCT00532792|BIOLOGICAL|A/H5N1|Medium dose A/H5N1 (0.5mL); Route IM - Day 0 and Day 21; no LT patch on Day 0 or Day 21
223579323|NCT00532792|BIOLOGICAL|A/H5N1|Medium dose A/H5N1 (0.5mL); Route IM - Day 0 and Day 21; no LT patch on Day 0; LT Patch on Day 21
223579324|NCT00532792|BIOLOGICAL|A/H5N1|Medium dose A/H5N1 (0.5mL); Route IM - Day 0 and Day 21; LT patch on Day 0 and Day 21
223579325|NCT00532792|BIOLOGICAL|A/H5N1|High dose A/H5N1 (0.5mL); Route IM - Day 0 and Day 21; no LT patch on Day 0 or Day 21
223579326|NCT00532792|BIOLOGICAL|A/H5N1|High dose A/H5N1 (0.5mL); Route IM - Day 0 and Day 21; no LT patch on Day 0; LT Patch on Day 21
223579327|NCT00532792|BIOLOGICAL|A/H5N1|High dose A/H5N1 (0.5mL); Route IM - Day 0 and Day 21; LT patch on Day 0 and Day 21
223579328|NCT00532792|BIOLOGICAL|Placebo|Placebo (0.5ml); Route IM - Day 0 and Day 21; no LT patch on Day 0 or Day 21
223579329|NCT00376701|DRUG|Avastin (Bevacizumab)|Avastin 1.25 mg intravitreal
223470650|NCT01463787|PROCEDURE|microsurgical varicocelectomy in subinguinal approach|In subinguinal approach, the incision was about 3 cm horizontal and 1 cm below the external inguinal ring.
223470651|NCT05801003|DEVICE|Predilation with cutting balloon.|PCI will be performed under OCT guidance. Predilation of the lesion will be done with cutting balloon.
223470652|NCT05801003|DEVICE|Predilation with conventional balloon|PCI will be performed under OCT guidance. Predilation of the lesion will be done with conventional balloon (semi-compliant or non-compliant)
223470653|NCT00904007|OTHER|Interactive Spaced Education (ISE) --- online education|"ISE is a novel educational methodology based on the spacing effect, the psychological finding that repeated presentations of educational material over spaced intervals increase learning efficiency and improve knowledge retention. ISE is delivered using periodic emails that contain clinical case scenarios and multiple-choice questions."
223470654|NCT04458675|DEVICE|Vibrant capsule|The capsule vibration mechanically stimulates the inner wall of the GI and stimulates motility
223470655|NCT04458675|DRUG|Placebo|A biodegradable capsule, which visually similar to the Vibrant active capsule
223470656|NCT00902070|DRUG|Rocuronium|Normally, for adults, 0.6 mg/kg of rocuronium bromide is intravenously administered to support endotracheal intubation. If additional administration is necessary, 0.1 - 0.2 mg/kg is intravenously administered. In the case of continuous infusion, infusion is initiated at a rate of 7 μg/kg/min. Dosage should be adjusted based on the age or symptom. The upper limit of this drug for the intubation is 0.9 mg/kg.
223470657|NCT05626309|DRUG|Qizhu Yuling Prescription|The dosage form of the test drug is granule. Patients need to take 2 small packets in the morning and 2 small packets in the evening. The medicine needs to be melted in hot water before being taken. Every 4 weeks is a course of treatment, a total of 6 courses,The patients were followed up to 3 years after esophageal cancer surgery.
223470658|NCT05626309|DRUG|Placebo|It is prepared from maltodextrin and food coloring. The raw materials of maltodextrin conform to the relevant provisions of excipients - maltodextrin in the fourth part of Chinese Pharmacopoeia 2015 edition. Food coloring includes caramel coloring, egg yolk coloring and milk chocolate brown pigment, all of which are edible grade ingredients. Patients need to take 2 small packets in the morning and 2 small packets in the evening. The medicine needs to be melted in hot water before being taken. Every 4 weeks is a course of treatment, a total of 6 courses,The patients were followed up to 3 years after esophageal cancer surgery.
223470659|NCT02793765|DRUG|Docetaxel|
223470660|NCT02793765|BIOLOGICAL|Sipuleucel-T|
223470661|NCT04521595|BEHAVIORAL|Weigh Smart Telehealth intervention|Trial of the group program (nutrition, exercise) delivered via telehealth through fruit street on the Eastern Shore and Western Maryland with use of noninvasive lifestyle tracking options (drink water aquarium app for water consumption and fitbit - steps, sleep monitoring) provides novel options for expansion of family- based lifestyle intervention to underserved areas. We plan as a pilot study to assess the sensitivity of noninvasive measures for the detection of sleep apnea (pediatric sleep questionnaire (PSQ) and fitbit sleep data) in comparison to clinically indicated polysomnography among children with clinical suspicion for sleep apnea.
223470662|NCT01032447|BEHAVIORAL|Navigator Support|Standard of Care
223470663|NCT03838939|OTHER|Therapeutic education|"Individual and group therapeutic education sessions will consist of :~* acquisition by patient of self-care skills such as performing subcutaneous injection,~* acquisition by patient of safety skills such as identifying symptoms that should lead to consult general practitioner, and stop treatment ..."
223579330|NCT00376701|DRUG|Bevacizumab|Intravitreal 1.25 mg
223579331|NCT00376701|DRUG|Bevacizumab|Intravitreal 1.25 mg
223579332|NCT00376701|DRUG|Bevacizumab|Intravitreal Avastin 1.25 mg and sham reduced fluence PDT
223579333|NCT00613080|DRUG|capecitabine|1650 mg/m\^2/day orally 5 days/week during radiotherapy.
223470664|NCT03490955|OTHER|salad dressing (canola oil) and black pepper|Subjects will consume a vegetable salad with black pepper and dressing (canola oil) one time in the morning
223470665|NCT03490955|OTHER|salad dressing (canola oil)|Subjects will consume a vegetable salad with dressing (canola oil) one time in the morning
224159743|NCT00084604|DRUG|irinotecan hydrochloride|Given IV
224159744|NCT00084604|BIOLOGICAL|bevacizumab|Given IV
223470666|NCT03490955|OTHER|black pepper|Subjects will consume a vegetable salad without dressing (canola oil) but with black pepper one time in the morning
223470667|NCT03490955|OTHER|salad|Subjects will consume a vegetable salad without dressing (canola oil) and without black pepper one time in the morning
223470668|NCT03490955|OTHER|Salad dressing (olive oil) and black pepper|Subjects will consume a vegetable salad with black pepper and dressing (olive oil) one time in the morning
223470669|NCT03490955|OTHER|Salad dressing (corn oil) and black pepper|Subjects will consume a vegetable salad with black pepper and dressing (corn oil) one time in the morning
223470670|NCT03490955|OTHER|Salad dressing (sunflower oil) and black pepper|Subjects will consume a vegetable salad with black pepper and dressing (sunflower oil) one time in the morning
223579334|NCT00613080|DRUG|oxaliplatin|
224159745|NCT00084604|DRUG|cisplatin|Given IV
223579335|NCT00613080|PROCEDURE|resection|All patients undergo surgery 4 to 8 weeks following the completion of radiation therapy. The choice of procedure (abdominoperineal resection (APR), low anterior resection (LAR), or LAR/coloanal anastomosis) is at the discretion of the surgeon.
223579336|NCT00613080|RADIATION|radiation therapy|Pelvic intensity modulated radiation therapy (IMRT): 45 Gy in 25 fx Three dimensional conformal radiation therapy (3D-CRT) boost: 5.4 Gy in 3 fx to total dose of 50.4 Gy in 28 fx
223579337|NCT00613080|DRUG|FOLFOX|"Postoperative chemotherapy is administered to all patients who have a complete resection of rectal cancer with negative surgical margins and begins within 4-8 weeks following surgical resection, consisting of a total of 9 14-day cycles. Oxaliplatin 85 mg/m\^2, IV over 2 hours, day 1.~Leucovorin 400 mg/m\^2, IV over 2 hours, day 1. 5-fluorouracil bolus 400 mg/m\^2, IV push, day 1. 5-fluorouracil infusion 2400 mg/m\^2, IV continuous infusion over 46 hours, day 1."
223579338|NCT04140201|DRUG|Simvastatin 40mg|Drugs that lower lipid level
223579339|NCT04140201|DRUG|Fenofibrate 200mg|Drugs that lower lipid levels
223579340|NCT04140201|DRUG|Omega 3 fatty acid|Drugs that lower lipid levels
224159746|NCT00084604|PROCEDURE|computed tomography|Correlative studies
224159747|NCT00084604|OTHER|laboratory biomarker analysis|Correlative studies
223470671|NCT03490955|OTHER|Salad dressing (flaxseed oil) and black pepper|Subjects will consume a vegetable salad with black pepper and dressing (flaxseed oil) one time in the morning
223470672|NCT03151850|OTHER|ulcerative colitis|We take 2 pieces of biopsies in the sigmoid colon mucosa inflammation area during the colonoscopy and then perform gene sequencing.
223470673|NCT03151850|OTHER|Control|We take 2 pieces of biopsies in the sigmoid colon mucosa during the colonoscopy and then perform gene sequencing.
223470674|NCT01826942|DEVICE|Lumenis UltraPulse single fractional CO2 laser treatment thin skin|
223470675|NCT01826942|DEVICE|Single fractional CO2 treatment at surgical area closure procedure on thick skin|
223470676|NCT04666545|BEHAVIORAL|MuST AKT|A behavioural intervention designed to help participants identify and communicate with their social network about living kidney donation.
223470677|NCT01559805|BEHAVIORAL|Positive Choices|A two-session, individually-focused intervention focusing on engagement in care, disclosure decision-making, and sexual risk reduction, with booster sessions after 1, 3 and 6 months.
223470678|NCT01559805|BEHAVIORAL|Personalized Cognitive Counseling|A one-session, individually-focused risk reduction intervention for MSM that has been selected by the CDC as a DEBI.
223470679|NCT06515548|DRUG|Vitamin D3 mouth wash|topical vitamin D oral mouth wash as every 10ml of the solution contains 3000 IU
223470680|NCT02631395|OTHER|Exercise|Three teams participated in a seven--month, three--times--a--week shoulder--muscle strength--training program while three teams participated in a comparable handball training program but did not conduct any specific upper--body strength training.
223579341|NCT03757130|DRUG|AMG 598|AMG 598 administered by subcutaneous injection
223579342|NCT03757130|DRUG|Placebo|Placebo matching to AMG 598 administered by subcutaneous injection
224159748|NCT05849636|BEHAVIORAL|ALERTA CANNABIS|The intervention consists of preventive messages about the benefits of not consuming cannabis, reducing the positive attitudes and encouraging the negative attitudes towards cannabis use, as well as social influence and self-efficacy, by personalized feedback. Skills and action plans are encouraged to help the student to reject cannabis use. This information is presented through different tailored messages. In addition, the participants will be able to choose avatars to accompany them during the intervention. The intervention consists of a short story about the cannabis use by adolescents.The stories take place in three different scenarios (at home, at school leaving, and in public places).
224159749|NCT01220713|PROCEDURE|Hyperbaric Oxygen Therapy|1.5 atm abs oxygen equivalent of 75% oxygen (balance 25% nitrogen), 40 treatments of 60 minutes each during a time period of up to ten weeks.
224159750|NCT01220713|PROCEDURE|Hyperbaric Oxygen Therapy|2.0 atm abs oxygen equivalent of 100% oxygen (no nitrogen), 40 treatments of 60 minutes each during a time period of up to ten weeks.
224159751|NCT01220713|PROCEDURE|Hyperbaric Oxygen Therapy|sham--air equivalent of 10.5% oxygen (balance 89.5% nitrogen), 40 treatments of 60 minutes each during a time period of up to ten weeks.
223470681|NCT02631395|OTHER|Control group|The three teams in the Control Group trained as normal throughout the season and participated in a comparable handball training program, but did not conduct any specific upper--body strength training
223470682|NCT03806543|DRUG|Vancomycin|adult patients treated with intravenous vancomycin in intensive care unit
223470683|NCT00373503|DRUG|Lofexidine|alpha 2 adrenergic agonist, hypothesized to decrease noradrenergic activity
223470684|NCT00373503|DRUG|dronabinol|cannabinoid agonist hypothesized to decrease MJ withdrawal
223470685|NCT00373503|DRUG|Marijuana|marijuana intoxication, withdrawal and relapse assessed
223470686|NCT02984982|DRUG|Alirocumab SAR236553|"Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous"
223470687|NCT02984982|DRUG|Atorvastatin|"Pharmaceutical form: tablet~Route of administration: oral"
223470688|NCT02984982|DRUG|Rosuvastatin|"Pharmaceutical form: tablet~Route of administration: oral"
223470689|NCT02984982|DRUG|Fenofibrate|"Pharmaceutical form: tablet~Route of administration: oral"
223470690|NCT02984982|DRUG|Bezafibrate|"Pharmaceutical form: tablet~Route of administration: oral"
223470691|NCT02984982|DRUG|Ezetimibe|"Pharmaceutical form: tablet~Route of administration: oral"
223470692|NCT02984982|DRUG|Antiplatelets|"Pharmaceutical form: tablet or capsule~Route of administration: oral"
223470693|NCT02984982|DRUG|Anticoagulants|"Pharmaceutical form: tablet or capsule~Route of administration: oral"
223470694|NCT02524639|DRUG|Sirolimus|Subjects will receive 1 mg/m2/day orally for 6 weeks. Maintenance dose will be titrated up or down by 0.25-0.5 mg/m2/day every 4 days. Serum concentration will be checked on day 4 after initial therapy and 4 days after any dose adjustment. Levels will be checked at lease once a week during the duration of the study. Target serum concentration range is 5-10 ng/mL.
223470695|NCT05289700|DEVICE|HBOT in Hyperbaric chamber|HBOT is the administration of oxygen (FIO2 = 100%) at a pressure higher than atmospheric pressure (2 ATA). The pressure increase is achieved by introducing compressed air into the hyperbaric chamber. This study will use a hyperbaric chamber that is already marketed, licensed and used in other diseases.
223470696|NCT05289700|DEVICE|Hyperbaric chamber for placebo|Hyperbaric chamber is the same chamber used for HBOT, but here with a limited hyperpressure (1.3 ATA) and using ambient air (FIO2=0.21), with illusion of treatment in healthy volunteers. All other aspects of the procedure are identical to those of the intervention. As in the intervention arm, there will be a compression period (although shorter), of 5 min, followed by 85 min at 1.3 ATA, then a decompression period of 5 min (total duration of 95 min).
223470697|NCT02865863|DIETARY_SUPPLEMENT|Eurycomalongifoliawater extract (Physta®)|
223470698|NCT02865863|DIETARY_SUPPLEMENT|Placebo|
223470699|NCT02865863|DIETARY_SUPPLEMENT|Multivitamin|
224159752|NCT00292955|DRUG|Cetuximab|monotherapy (day 1), then weekly thereafter along with radiation. dose is at 200mg/m2.
224159753|NCT03037606|DRUG|Rabelis DDR 50 mg Capsules|Rabelis DDR 50 mg Capsules once daily for seven days.
224159754|NCT03037606|DRUG|Pariet 20 mg Enteric Coated Tablets|Pariet 20 mg Enteric Coated Tablets once daily for seven days.
223470700|NCT00866905|DRUG|Ixabepilone|40 mg/m2 IV infusion over 3 hours on day 1 of a 21 day cycle for 6 cycles
223579343|NCT03757130|DRUG|Liraglutide|Liraglutide administered by subcutaneous injection. The starting dose is 0.6 mg/day, and increased by 0.6 mg/day dose increment every 7 days, up to the full dosage of 3.0 mg/day by week 5.
223579344|NCT02523768|DRUG|ATG-F|
223579345|NCT02523768|DRUG|Simulect|
223579346|NCT01257490|BEHAVIORAL|counseling vs. advice|1 session of brief physician advice to quit smoking plus bupropion (12 weeks) compared to 4 sessions of intensive counseling plus bupropion (12 weeks)
223579347|NCT02226549|DRUG|LDV/SOF|LDV/SOF (90/400 mg) FDC tablet administered orally once daily
223579348|NCT02226549|DRUG|VDV|VDV 80 mg tablet administered orally once daily
223579349|NCT02226549|DRUG|RBV|RBV tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
223579350|NCT04304183|PROCEDURE|total colectomy, ileorectal anastomosis|all patients underwent total colectomy and ileorectal anastomosis.The anastomosis was stapled in all patients.
223579351|NCT04983797|DEVICE|OPTRELL Mapping Catheter|Participants scheduled to have a clinically-indicated catheter mapping and ablation using OPTRELL mapping catheter for the management of Atrial procedure (Scar-related Atrial Tachycardia, Persistent Atrial Fibrillation, Paroxysmal Atrial Fibrillation) and Ventricular procedures (Ventricular Tachycardia, Premature Ventricular Complex).
223579352|NCT04956029|OTHER|There are no any interventions. This is to observe and test hospital cleanliness.|There are no any interventions. This is to observe and test hospital cleanliness.
223579353|NCT05551676|PROCEDURE|transforaminal group|Epidural steroid injection will be applied with transforaminal approach accompanied by fluoroscopy.
223743761|NCT05793528|PROCEDURE|Ultrasound Guided Transforaminal Epidural Steroid Injection|The patients are positioned prone placed. Following the provision of aseptic conditions, the spinous process of the vertebral midline is visualized using a low-frequency convex ultrasound probe. The lateral edge of the relevant vertebral lamina is visualized by sonographic scanning in the horizontal plane. Local anesthesia is applied to the skin and subcutaneous tissue. A 3.5-inch, 22-gauge spinal needle is advanced to the lateral edge of the relevant vertebral lamina under ultrasound image guidance. Then, anteroposterior imaging is performed with fluoroscopy to confirm needle localization when the lamina margin is reached, and the needle is guided into the foramen under the guidance of fluoroscopy. The contrast agent is given and the distribution pattern is visualized. Once the epidural distribution of the contrast agent is confirmed without vascular flow, a mixture of 2 mL of dexamethasone, 1 mL of physiological saline, and 1 mL (0.5%) of bupivacaine hydrochloride is injected.
223743762|NCT00001749|DRUG|Antithymocyte globulin|
224159755|NCT05771506|OTHER|Balance Assessment|"Balance assessment will be done with the Biodex Balance System® (Biodex Medical Systems, Shirley, New York, United States). Postural stability test overall score, stability limits test overall score, and sensory integration test of balance composite score will be recorded."
224159756|NCT05771506|OTHER|Pulmonary function test|"Pulmonary function test will be performed with a spirometer (COSMED Pony FX (COSMED; Italy) in accordance with ATS/ERS criteria. Forced vital capacity (FVC), forced expiratory volume in 1 second (FEV1), FEV1/FVC, peak expiratory volume measured at 25% and 75% of forced expiratory time (FEF 25-75%), and peak expiratory volume (PEF) parameters will be measured. The results will be recorded both as a percentage of measured values and expected values."
223470701|NCT00866905|DRUG|Cyclophosphamide|600 mg/m2 IV infusion per institutional guidelines on day 1 of a 21 day cycle for 6 cycles
223470702|NCT00040599|DRUG|hMN14 (labetuzumab)|
223470703|NCT05030844|BEHAVIORAL|IMB model based Diabetes Education and Motivational Interviewing|"IMB model-based interventions were applied to the intervention group for 3 month. For the information component of the IMB model, diabetes education consisting of four sessions was given in groups of five in the first two weeks. Each patient was given a Diabetes Management Education Booklet prepared by the researchers. For the motivation component of the IMB model, total 5 sessions 30-minute motivational interview was made with individual Whatsapp calls once every two weeks starting from the third week."
223470704|NCT02162160|DEVICE|probiotic creme|Probiotic creme applied
223470705|NCT02162160|DRUG|Placebo|Creme without probiotics applied in same manner
223470706|NCT00447668|BEHAVIORAL|Yoga|Yoga for back pain
223470707|NCT00447668|BEHAVIORAL|Exercise|exercises for back pain
223470708|NCT00447668|BEHAVIORAL|Self-care book recommendations|Self-care book for back pain
223470709|NCT01367015|OTHER|Early Feeding|Feeding with expressed breast milk @ 8ml/kg/day for 48 hrs after randomization at 60+/-12 hrs of life
223470710|NCT01367015|OTHER|Late Feeding|Nil per oral for another 48 hrs after randomization at 60+/-12 hrs of life followed by Feeding with expressed breast milk @ 8ml/kg/day for 48 hrs
223470711|NCT05767489|COMBINATION_PRODUCT|electroencephalogram (EEG) and magnetic resonance (MR)|"High-resolution 3D T1 and T2 sequences, acquired in the sagittal plane and MR reconstructed in the remaining orthogonal planes, for morphological assessment of different cortical and subcortical.~EEG tracing involving recording channels such as eye tracking (eye-tracking: electrooculogram, pupillometry, saccades, fixation times on areas predefined areas), performance measures (response times), electrocardiogram and electromyogram proper to clinical acquisition"
223470712|NCT01747499|DRUG|Azacitidine|
223470713|NCT03656627|DRUG|Nivolumab|"Nivolumab will be given as an IV infusion every two weeks, in an outpatient setting. One cycle is a 28-day period, with Nivolumab given on days 1 and 15 of a 28-day cycle.~For each cohort, all patients will be dosed at 240 mg IV. There will be no dose de-escalation or escalation from this dose level."
223470714|NCT05733897|DRUG|hydroxychloroquine|Using hydroxychloroquine to treat nonalcoholic steatohepatitis
223470715|NCT00863382|DEVICE|Standard Event Monitor|Standard Event Monitor
223470716|NCT00863382|DEVICE|Sleuth Monitor|Implantable Sleuth Recorder
223470717|NCT04809441|OTHER|Diet change|A specific very low-calorie diet (\<800kcal/day), and 2 daily sessions of 15 minutes of anaerobic physical exercise depending on the capacity of the participants, were designed
223470718|NCT05928923|DEVICE|CPAP|CPAP usage 3 months
223470719|NCT01103323|DRUG|Regorafenib (Stivarga, BAY73-4506)|160 mg per oral once daily for 3 weeks of every 4 week cycle (i.e., 3 weeks on, 1 week off)
223470720|NCT01103323|DRUG|Placebo|matching placebo tablets for 3 weeks of every 4 week cycle (i.e., 3 weeks on, 1 week off)
223470721|NCT01103323|OTHER|Best Supportive Care (BSC)|BSC includes any concomitant medications or treatments: antibiotics, analgesics, radiation therapy for pain control (limited to bone metastases), corticosteroids, transfusions, psychotherapy, growth factors, palliative surgery, or any other symptomatic therapy necessary to provide BSC, except other investigational anti-tumor agents or anti-neoplastic chemo/hormonal/immuno-therapy.
223743763|NCT00001749|DRUG|Cyclosporine|
223743764|NCT03012100|DRUG|Cyclophosphamide|Given PO
223743765|NCT03012100|OTHER|Laboratory Biomarker Analysis|Correlative studies
223470722|NCT00372424|DRUG|Herceptin|Trastuzumab will be administered intravenously on Day 1 before docetaxel - loading dose of 4 mg/kg over 90-minute on Day 1 followed by weekly maintenance doses of 2 mg/kg on Days 1, 8, 15 given as 30-minute infusions if the initial loading dose was well tolerated. Loading dose of 8 mg/kg over 90-minute on Day 1 followed by 3-weekly maintenance doses of 6 mg/kg given as 90-minute infusions. The administration of 6 mg/kg will be repeated on Day 1 every 3 weeks.
223743766|NCT03012100|BIOLOGICAL|Multi-epitope Folate Receptor Alpha Peptide Vaccine|Given ID
224069133|NCT06500832|OTHER|Survey-based Data Collection Tool|"The data collection tool to be presented to the participants is planned as a three-part survey. The first part of this form asked 9 questions about the demographic characteristics of the participants consisted of age, gender, marital status, duration in the profession, specialization in dentistry, type of workplace, and off-the-clock work.~The second part of the data collection tool consisted of the 'Defensive Dentistry Practice Survey,'(DDPS) DDPS which is the original language of which is Turkish, is a 5-point Likert-type scale. A total of 12 statements about DDPS which measure the opinions, attitudes, or behaviors of the participants in terms of DDP, the following options are used: strongly disagreed, disagreed, neither disagreed nor agreed, agreed and strongly agreed, each expressing groups of 20%.~The last part of the survey had 3 close-ended questions with yes-no options expressing 50% groups is used."
224069134|NCT06220734|PROCEDURE|transurethral resection of the prostate|transurethral resection of the prostate for indicated patients then US was done for early detection of fluid accumulation in the lungs
224069135|NCT02049944|DRUG|Cefazolin|Participants who are undergoing an elective cesarean section at term will receive 3 grams of Cefazolin at least 30, but no more than 60 minutes prior to skin incision administered through an intravenous line.
224069136|NCT00004941|DRUG|monoclonal antibody cA2|
224069137|NCT06373861|OTHER|no intervention|This study is an observational study without treatment intervention.
224069138|NCT01408147|BEHAVIORAL|Online postpartum weight control|The intervention group will be given access to an online weight loss program supplemented by monthly group meetings.
224069139|NCT05926310|DEVICE|TWIICE Rise|"TWIICE Rise is a lower-limb overground robotic exoskeleton intended for patients with spinal cord injury (SCI).~TWIICE Rise is intended to perform ambulatory functions in rehabilitation institutions, home, or community environment under the supervision of a specially trained coach."
224069140|NCT01564927|DEVICE|Electroacupuncture to right LI4 and LI11 (ITO, EX-160)|Electroacupuncture at 2Hz, 0.4m/sec pulse duration
223470723|NCT00372424|DRUG|Sunitinib|SU011248 will be administered at 37.5 mg once daily for 2 weeks every 3 weeks (Schedule 2/1) starting from Day 2, when in combination with docetaxel. SU011248 will be administered at the starting dose of 37.5 mg daily in a continuous regimen when docetaxel is discontinued.
223470724|NCT00372424|DRUG|Taxotere|The starting dose of docetaxel will be 75 mg/m2 every 3 weeks, administered on Day 1 of each cycle as a 1-hour IV infusion.
223470725|NCT00072410|BIOLOGICAL|90Y-hu3S193|Patients received a single dose of 10 mg of hu3S193 radiolabeled with the intended dose (mCi) of 90Y.
223470726|NCT00072410|BIOLOGICAL|111In-hu3S193|Patients received a single dose of 5 mCi 111In-hu3S193 together with the 90Y-hu3S193.
223470727|NCT05181371|PROCEDURE|Ultrasound Guided ESP Block with Programmed Intermittent Bolus (PIB) for VATS|Programmed Intermittent Bolus (PIB) of Levobupivacaine
223470728|NCT05181371|PROCEDURE|Ultrasound Guided ESP Block with Continuous Infusion (CI) for VATS|Continuous Infusion (CI) of Levobupivacaine
223470729|NCT00608400|DIETARY_SUPPLEMENT|Clarinol CLA|0, 1.5 or 3.0 g/d dietary conjugated linoleic acids glycerides for 4 months, capsule form
223470730|NCT02133430|DEVICE|Bispectral index, as measured by a BIS processor|Comparisons of incidence of postoperative delirium.
223470731|NCT03597737|DEVICE|Pain APP|pain app Pain Monitor app has been developed by a multidisciplinary pain expert panel, including physicians, psychologists, and nurses. Content has been validated in a previous study and usability has been shown to be excellent.
223470732|NCT02306876|DRUG|PF-06412562 3mg BID|PF-06412562
223470733|NCT02306876|DRUG|PF-06412562 15mg BID|PF-06412562
223470734|NCT02306876|OTHER|Placebo|Placebo
223470735|NCT04458519|OTHER|Probiorinse|Nasal irrigations with probiotic twice-daily for a period of fourteen days
223470736|NCT04458519|OTHER|Saline solution|Nasal irrigations with saline-only twice-daily for a period of fourteen days
223470737|NCT05646368|DIETARY_SUPPLEMENT|Formulation #1|Subject will receive a single dose of formulation #1 of a multivitamin/mineral supplement
223470738|NCT05646368|DIETARY_SUPPLEMENT|Formulation #2|Subject will receive a single dose of formulation #2 of a multivitamin/mineral supplement
223470739|NCT03640169|OTHER|Health management of TCM preventive medicine|The Health management model include: (1) Body constitution measurement (2) Health promotion literacy education lectures (3) Duo-in qigong practice.
223470740|NCT06209073|OTHER|Virtual Reality exercise|after explaining the treatment method for patients, the patients will perform full body aerobic exercise by applying kick boxing to destroy walls of rock; the patient moves most of body muscles in this game. He or she flex and extend the shoulder and the elbow with flexion and extension in the knee. squatting exercise, endurance exercise, coordination for arm and shoulder exercise will also performed in virtual reality
223470741|NCT06209073|OTHER|conventional treatment|the patients will receive conventional treatment in the form of aerobic exercise, resistance exercise and endurance exercise.
223470742|NCT00767572|DRUG|atorvastatin|Atorvastatin 80mg daily vs. placebo daily X 12 weeks, then 4 week washout period, then cross over groups to complete another 12 weeks. (Total study time is 28 weeks (12+4+12)
223470743|NCT00767572|DRUG|Sugar pill|atorvastatin 80mg daily vs. placebo daily X 12 weeks, then 4 week washout, then cross over groups X 12 weeks. Total study time is 28weeks (12+4+12).
223743767|NCT03012100|OTHER|Placebo Administration|Given ID
223743768|NCT03012100|BIOLOGICAL|Sargramostim|Given ID
224069141|NCT01564927|DEVICE|Sham Electroacupuncture to knee caps|Electroacupuncture at 2Hz, 0.4m/sec pulse duration
224069142|NCT01564927|DEVICE|Sham electroacupuncture to LI4 and LI11|Electroacupuncture at 2Hz, 0.4m/sec pulse duration
223470744|NCT06255080|OTHER|Training intervention|"The intervention consists of making the intervention group practice till proficiency using the 2019-version.~The control group practices till they have reached proficiency using the standard 2016-version.~We wanted to compare time to completetion for the intervention. For the follow-up test we invited all participants to return after 4-6 weeks (where no training was allowed) and made them practice till proficiency again using the standard 2016-version. Time to reach proficiency for the follow-up test was compared."
223470745|NCT03160716|DEVICE|Restylane Lyft with Lidocaine|a sterile gel of hyaluronic acid (HA)
223470746|NCT02151617|DRUG|PF-06743649|40 mg tablet one time once with a meal and once without a meal, followed by once daily dosing for 14 days
223470747|NCT02151617|DRUG|Placebo|Placebo tablet one time once with a meal and once without a meal, followed by once daily dosing for 14 days
223470748|NCT02151617|DRUG|PF-06743649|To be decided dose, tablet once daily dosing for 14 days
223470749|NCT02151617|DRUG|Placebo|Placebo tablet once daily dosing for 14 days
223470750|NCT02151617|DRUG|PF-06743649|To be decided dose, tablet, one time once with a meal and once without a meal, followed by once daily dosing for 14 days
223470751|NCT02151617|DRUG|Placebo|Placebo tablet one time once with a meal and once without a meal, followed by once daily dosing for 14 days
223470752|NCT02151617|DRUG|PF-06743649|To be decided dose, tablet, one time without a meal, followed by once daily dosing for 14 days
223470753|NCT02151617|DRUG|Placebo|Placebo tablet one time once without a meal, followed by once daily dosing for 14 days
223470754|NCT02151617|DRUG|PF-06743649|Tablet, to be decided dose, once daily, 14 days
223470755|NCT02151617|DRUG|Placebo|Tablet, once daily, 14 days
223470756|NCT01443169|DRUG|Sequence 1 - Treatment A: Controlled Release Pregabalin|330 mg CR tablet (fast dissolution, heavier tablet) administered after a 600 to 750 calorie medium-fat evening meal.
223470757|NCT01443169|DRUG|Sequence 1 - Treatment B: Controlled Release Pregabalin|330 mg CR tablet (fast dissolution, lighter tablet) administered after a 600 to 750 calorie medium-fat evening meal.
223470758|NCT01443169|DRUG|Sequence 1 - Treatment C:Controlled Release Pregabalin|330 mg CR tablet (slow dissolution, lighter tablet) administered after a 600 to 750 calorie medium-fat evening meal.
223470759|NCT01443169|DRUG|Sequence 1 - Treatment D: Controlled Release Pregabalin|330 mg CR reference tablet administered after a 600 to 750 calorie medium-fat evening meal.
223470760|NCT01443169|DRUG|Sequence 1 - Treatment E: Immediate Release Pregabalin|300 mg IR capsule administered in the evening in the fasted state.
223470761|NCT01443169|DRUG|Sequence 2 - Treatment B: Controlled Release Pregabalin|330 mg CR tablet (fast dissolution, lighter tablet) administered after a 600 to 750 calorie medium-fat evening meal.
223470762|NCT01443169|DRUG|Sequence 2 - Treatment D: Controlled Release Pregabalin|330 mg CR reference tablet administered after a 600 to 750 calorie medium-fat evening meal.
223470763|NCT01443169|DRUG|Sequence 2 - Treatment A: Controlled Release Pregabalin|330 mg CR tablet (fast dissolution, heavier tablet) administered after a 600 to 750 calorie medium-fat evening meal.
223470764|NCT01443169|DRUG|Sequence 2 - Treatment C: Controlled Release Pregabalin|330 mg CR tablet (slow dissolution, lighter tablet) administered after a 600 to 750 calorie medium-fat evening meal.
223470765|NCT01443169|DRUG|Sequence 2 - Treatment E: Immediate Release Pregabalin|300 mg IR capsule administered in the evening in the fasted state.
223470766|NCT01443169|DRUG|Sequence 3 - Treatment C: Controlled Release Pregabalin|330 mg CR tablet (slow dissolution, lighter tablet) administered after a 600 to 750 calorie medium-fat evening meal.
223470767|NCT01443169|DRUG|Sequence 3 - Treatment A: Controlled Release Pregabalin|330 mg CR tablet (fast dissolution, heavier tablet) administered after a 600 to 750 calorie medium-fat evening meal.
223470768|NCT01443169|DRUG|Sequence 3 - Treatment D: Controlled Release Pregabalin|330 mg CR reference tablet administered after a 600 to 750 calorie medium-fat evening meal.
223470769|NCT01443169|DRUG|Sequence 3 - Treatment B: Controlled Release Pregabalin|330 mg CR tablet (fast dissolution, lighter tablet) administered after a 600 to 750 calorie medium-fat evening meal.
223470770|NCT01443169|DRUG|Sequence 3 - Treatment E: Immediate Release Pregabalin|300 mg IR capsule administered in the evening in the fasted state.
223470771|NCT01443169|DRUG|Sequence 4 - Treatment D: Controlled Release Pregabalin|330 mg CR reference tablet administered after a 600 to 750 calorie medium-fat evening meal.
223470772|NCT01443169|DRUG|Sequence 4 - Treatment C: Controlled Release Pregabalin|330 mg CR tablet (slow dissolution, lighter tablet) administered after a 600 to 750 calorie medium-fat evening meal.
223470773|NCT01443169|DRUG|Sequence 4 - Treatment B: Controlled Release Pregabalin|330 mg CR tablet (fast dissolution, lighter tablet) administered after a 600 to 750 calorie medium-fat evening meal.
223470774|NCT01443169|DRUG|Sequence 4 - Treatment A: Controlled Release Pregabalin|330 mg CR tablet (fast dissolution, heavier tablet) administered after a 600 to 750 calorie medium-fat evening meal.
223470775|NCT01443169|DRUG|Sequence 4 - Treatment E: Immediate Release Pregabalin|300 mg IR capsule administered in the evening in the fasted state.
223470776|NCT01831895|DEVICE|MobiusHD™|Implant that is placed in the carotid sinus to control hypertension.
223470777|NCT05525546|BIOLOGICAL|Trivalent Salmonella Conjugate Vaccine (TSCV) Full-Strength Formulation|One dose of the full-strength conjugate vaccine is administered via an intramuscular injection in to the deltoid muscle on Study Day 1. The full-strength conjugate vaccine consists of 25 mcg of each conjugate; Salmonella Enteritidis, Salmonella Typhimurium, and Salmonella Typhi Vi.
223470778|NCT05525546|BIOLOGICAL|Trivalent Salmonella Conjugate Vaccine (TSCV) Half-Strength Formulation|One dose of the half-strength conjugate vaccine is administered via an intramuscular injection in to the deltoid muscle on Study Day 1. The half-strength conjugate vaccine consists of 12.5 mcg of Salmonella Enteritidis, 12.5 mg of Salmonella Typhimurium, and 25 mcg of Salmonella Typhi Vi.
223470779|NCT05525546|BIOLOGICAL|Trivalent Salmonella Conjugate Vaccine (TSCV) Dilutional Half-Strength Formulation|One dose of the dilutional half-strength conjugate vaccine is administered via an intramuscular injection in to the deltoid muscle on Study Day 1. The dilutional half-strength conjugate vaccine consists of 12.5 mcg of each conjugate; Salmonella Enteritidis, Salmonella Typhimurium, and Salmonella Typhi Vi.
223579354|NCT05551676|PROCEDURE|Lateral parasagittal group|Epidural steroid injection will be applied with lateral parasagittal approach accompanied by scopy.
223470780|NCT05525546|OTHER|Placebo|One dose of placebo is administered via an intramuscular injection in to the deltoid muscle on Study Day 1. The placebo consists of sterile phosphate-buffered saline (PBS) solution containing polysorbate 80, and 2-phenoxyethanol preservative.
223470781|NCT02395068|DRUG|Nimotuzumab|single dose of nimotuzumab (100、200、400、600mg), with 3 weeks observation；Set 4 dose groups for Nimotuzumab, namely 100,200,400,600mg. Each group administered once a week for 6 weeks；600mg, administered once every 2 weeks for 8 weeks.
223470782|NCT02395068|DRUG|irinotecan|"Single-dose PK：1 week after nimotuzumb administration, irinotecan (CPT-11) will be given at a dose of 180 mg/m2 once every 2 weeks, 2 weeks a cycle.~Bioweekly fixed dose PK：Nimotuzumab combined with irinotecan (180mg/m2), administering once every 2 weeks and considering 2 weeks as a period. If chemotherapy and Nimotuzumab are administered in the same day, chemotherapy should be infused after Nimotuzumab for at least 1h"
223470783|NCT04321902|PROCEDURE|Laparoscopic cholecystectomy|"Method of operation~1. Surgery was started under general anesthesia~2. A trocar of 10 mm was placed on the navel, 5 mm under the blade, and 5 mm trocar was placed on the right upper abdomen.~3. Pneumoperitoneum was performed using CO2 gas in the abdominal cavity.~4. Dissection started from Calot's triangle and the operation was performed by retrograde cholecystectomy.~5. The excised gallbladder was placed in a laparoscopic pocket and extracted through the umbilicus.~6. The trocar was removed and the skin was sutured~On the 1st day after surgery, hematology, blood chemistry, urine, blood clotting, and chest x-rays were performed. (Inspection and treatment were performed according to the current clinical pathway of gallbladder surgery)"
223470784|NCT02491138|BEHAVIORAL|Appearance-based intervention|
223470785|NCT02491138|OTHER|Pamphlets|
223579355|NCT05506488|DRUG|Dasatinib 100 MG + Quercetin (1000 MG)|The intervention group will receive intermittent orally administered dasatinib (100 mg/day) plus quercetin (1000 mg/day) on three consecutive days for three consecutive weeks followed by a four-week medication free period. This cycle will be repeated three times.
223579356|NCT05506488|OTHER|Placebo|The placebo group will receive intermittent orally administered placebo tablets on three consecutive days for three consecutive weeks followed by a four-week medication free period. This cycle will be repeated three times.
223579357|NCT02726880|BEHAVIORAL|Behavioral therapy|6-week behavioral intervention designed to assist with better monitoring and regulating the child's game playing behaviors.
223579358|NCT02726880|BEHAVIORAL|Referral for care|Referral for mental health issues and family support services
223579359|NCT06053736|DEVICE|REVIVE Contact Lens|REVIVE Contact Lens
223579360|NCT01058135|OTHER|Hi-maize starch (Low dose)|resistant starch
223579361|NCT01058135|OTHER|Hi-maize starch (High-dose)|resistant starch
223579362|NCT01058135|OTHER|Control (starch)|rapidly digestible starch
223579363|NCT01900977|OTHER|Universal Testing with immediate ART|"• Combination prevention package including:~o House-to-house deployment of: Universal HIV counseling and testing; Active linkage to care for individuals diagnosed as HIV-infected, with immediate eligibility for ART; Promotion of male circumcision and prevention of mother to child transmission (PMTCT) services; Provision of condoms; Strengthening of HIV testing and services at health facilities and other venues; Strengthening of male circumcision and prevention of mother-to-child transmission of HIV services available in the community; and Treatment of sexually transmitted infections (STIs) and provision of condoms at health units"
223579364|NCT01900977|OTHER|Universal Testing with ART eligibility according to National Guidelines|"Combination prevention package including:~House-to-house deployment of: Universal HIV counseling and testing; Active linkage to care for individuals diagnosed as HIV-infected, with ART eligibility according to national guidelines; Promotion of male circumcision and PMTCT services; Provision of condoms; Strengthening of HIV testing and services at health facilities and other venues; Strengthening of male circumcision and PMTCT services available in the community; and Treatment of STIs and provision of condoms at health units."
223579365|NCT01900977|OTHER|Standard of Care|
223743769|NCT04838366|DIETARY_SUPPLEMENT|Carbohydrate loading|study group will be intervened with carbohydrate loading as the protocol made by ERAS(Li et al., 2021). Surgical patients will be asked to drink a beverage containing 100 grams carbohydrate the night before surgery. On the day of surgery, patients will drink a beverage containing 50 grams carbohydrate 2 hours before surgery under the supervision of research team member. We will provide glucose-D (Dabur Nepal Private Limited, Bara, Nepal, (Regd No.: 3506/045/046, DFTQC No.: 01-33-55-03-218).
223743770|NCT04439253|DRUG|Crizotinib|Given PO
224159757|NCT05771506|OTHER|Respiratory muscle strength test|Respiratory muscle strength will be measured in accordance with ATS/ERS criteria using an electronic, mobile, (MicroRPM, Micro Medical; UK) intraoral pressure measuring device. Maximal inspiratory pressure (MIP) and maximal expiratory pressure (MEP) values will be recorded. Three measurements will be repeated for each maneuver and the highest value recorded as cmH2O.
224159758|NCT05771506|OTHER|Peripheral muscle strength test|Peripheral muscle strength will be assessed by measuring M. Quadriceps muscle strength with a digital handheld dynamometer (MicroFET® Hoggan Scientific; USA). The test will be done in three measurements for the dominant side lower extremity. The average of the obtained values will be recorded in kilograms.
224159759|NCT05771506|OTHER|6-minute walk test|Functional capacity will be assessed with the 6-minute walk test (6MWT). 6MWT will be performed in accordance with the criteria of the American Thoracic Society. The 6MWT distance will be recorded in meters.
223579366|NCT04398173|DIAGNOSTIC_TEST|multiparametric MRI|T1-w, T2-w, diffusion weighted and dynamic contrast-enhanced imaging
223579367|NCT04552548|OTHER|regional nerve block|Abdominal field blocks have been used in anesthesia for surgery involving the anterior abdominal wall with ultrasound-guided technique. TAP block is a regional anesthetic technique that blocks neural afferents of the anterolateral abdominal wall. Using anatomical landmark guidance or with the aid of ultrasound (US), local anesthetic is injected into the transversus abdominis fascial plane, where the nerves from T6 to L1 are located. Ultrasound-guided quadratus lumborum (QL) block is considered now as one of the novel truncal abdominal blocks, as it is effective in preventing somatic pain associated with upper and lower abdominal surgeries.
223743771|NCT06451952|OTHER|Virtual darkness|Chronotheraphy
223743772|NCT04887792|DRUG|Acetazolamide|ACZ 250 mg/day in gelatin capsules will be administered initially and increased over 7-10 days to 2g/day.
223743773|NCT04887792|DRUG|Placebo|Identical gelatin capsules will be prepared by filling with inert excipients.
223470786|NCT05476393|OTHER|Postoperative management|1 g paracetamol will be administered 3 x 1. If the NRS score is ≥ 4, 1 mg kg-1 iv tramadol will be administrated.
223579368|NCT05351723|OTHER|Exercise + cognitive training + education|"The research team will record videos for the Intervention group. The intervention procedure includes 3 sections: (1) 50 min of physical exercise, (2) 20 min of break time or lecture on dementia and lifestyle habits, and (3) 50 min of cognitive training. Investigators will be recruited from the National Geriatrics Hospital and trained the technicians for 1 week.~Prior to intervening, patients who agree to participate will be screened and evaluated cognitive function, physical function, assessment of Activities of Daily Living, quality of life, depression, anxiety, stress, and sleep quality.~Technicians will record every training session, monitor participants' health, and ensure that those in the intervention group do the exercises correctly.~We will evaluate the participants in the group after 3 months and after 6 months of intervention."
223579369|NCT02357862|PROCEDURE|Mitral Valve Annuloplasty|Mitral valve annuloplasty by a rigid mitral ring, a semi-rigid ring, or a fully flexible band, at the surgeon's discretion
223579370|NCT01239888|DRUG|Oxytocin|20 IU of intranasal oxytocin twice per day for 8 weeks, and a placebo (oral) for the 8 week trial
223579371|NCT01239888|DRUG|Oxytocin and Tibolone|20 IU of intranasal oxytocin twice per day for 8 weeks, and 2.5mg oral tibolone for the 8 week trial
224159760|NCT05771506|OTHER|Cognitive assessment|Cognitive function will be assessed with the Montreal Cognitive Assessment (MoCA) test. The MoCA test is a questionnaire developed to evaluate different cognitive functions and mild cognitive impairment. The maximum score that an individual can obtain from the test is 30, and a score of 21 or above is considered as mild cognitive impairment. Test; will be administered by a certified physiotherapist who has received training on practice and scoring directives
223579372|NCT01239888|DRUG|Placebo|20 IU of intranasal placebo twice per day for 8 weeks, and a placebo (oral) for the 8 week trial
223579373|NCT02903758|OTHER|cross sectional|
223579374|NCT00854217|PROCEDURE|acute normovolemic hemodilution|
223579375|NCT05529355|DRUG|Envafolimab plus Endostar and S-1|Immunotherapy combined with chemotherapy and anti VEGFR therapy
223579376|NCT05529355|DRUG|Envafolimab plus Endostar|Immunotherapy combined with anti VEGFR therapy
223579377|NCT05529355|DRUG|Envafolimab plus S-1|Immunotherapy combined with chemotherapy
223579378|NCT06157944|OTHER|GPT-4|OpenAI's GPT-4 large language model with chat interface.
223579379|NCT00152568|BEHAVIORAL|Car Seat Check (behavior)|At time of well child visit, family receives the services of a certified child passenger safety technician, including assessment, car seat distribution if needed and training.
223579380|NCT02312219|DRUG|Folic Acid|1 mg folic acid once daily
223579381|NCT02312219|DRUG|Placebo|placebo once weekly
223579382|NCT02312219|DRUG|Low Dose Methotrexate|An anti-inflammatory drug
223579383|NCT01269385|BIOLOGICAL|alemtuzumab|Given subcutaneously
223579384|NCT01269385|BIOLOGICAL|rituximab|Given IV
224159761|NCT01449955|DRUG|Rapamycin|"Sirolimus is an FDA approved immunosuppressant drug used to prevent rejection in organ transplantation, and is especially useful in kidney transplants. It is non-toxic to kidneys, unlike other immunosuppressants. In this study, the medication will be administered once to see if it interferes with emotional memory reconsolidation. This is based on the fact that it inhibits the mammalian target of Rapamycin (mTOR) through directly binding the mTOR Complex1 (mTORC1). mTOR is a serine/threonine protein kinase that regulates cell growth, cell proliferation, cell motility, cell survival, protein synthesis and transcription.~a single dosage of 15mg will be administered during this study."
224159762|NCT01449955|DRUG|Placebo|Inactive
223579385|NCT01269385|DRUG|PGG beta-glucan|Given IV
223579386|NCT01269385|OTHER|flow cytometry|Correlative studies
223579387|NCT01269385|OTHER|laboratory biomarker analysis|Correlative studies
224159763|NCT03611049|DIETARY_SUPPLEMENT|High dose Vitamin D3|High dose arm- 5000IU given daily
223470787|NCT04297202|DRUG|Apatinib Combined With SHR-1210 Injection|"3 cycles of neoadjuvant therapy before surgery, two weeks is a treatment cycle: D1、D15、D31 : SHR-1210 200mg, I.V, q2w； D1-D20 : Apatinib 250 mg, orally, qd; D46 : Patients were preoperatively evaluated. Operable patients were scheduled for hepatectomy with/without microwave ablation; After 4 to 8 weeks after liver resection, a postoperative adjuvant program is performed. Three weeks is a treatment cycle with a total of 8 cycles~In each cycle:~D1: SHR-1210 200mg, I.V, q3w; D1-D21: Apatinib 250mg, orally, qd;"
223579388|NCT01269385|GENETIC|DNA analysis|Correlative studies
223579389|NCT01269385|GENETIC|fluorescence in situ hybridization|Correlative studies
223579390|NCT01269385|GENETIC|polymerase chain reaction|Correlative studies
223579391|NCT01269385|GENETIC|polymorphism analysis|Correlative studies
223579392|NCT01269385|GENETIC|mutation analysis|Correlative studies
223579393|NCT01375803|DIETARY_SUPPLEMENT|Novel dietary fiber|oral consumption in beverage
223579394|NCT01375803|DIETARY_SUPPLEMENT|Novel dietary fiber|Oral consumption in beverage
223579395|NCT01375803|OTHER|Placebo|Oral consumption in beverage
223579396|NCT00023686|PROCEDURE|surgery|
223579397|NCT00023686|RADIATION|radiation|
223579398|NCT00546260|DRUG|placebo|administration of iv bolus prior to angiography
223579399|NCT00546260|DRUG|PRT060128 Potassium|administration of iv bolus prior to angiography
223579400|NCT05285124|DRUG|Melatonin|Participants assigned to the melatonin group were given a 3-mg fast-release oral dose of melatonin administered at approximately 21:00
223579401|NCT05285124|OTHER|Placebo|Participants in this group were treated according to a protocol identical to those receiving active medication at approximately 21:00. For the sham tDCS groups, the same stimulation parameters were employed, except that the stimulator had a built-in placebo mode; when it was activated, two ramp fade-in/fade-out periods in the beginning and the end of sham stimulation mimicked the somatosensory artifact of real tDCS
223579402|NCT05285124|OTHER|HD-tDCS|Direct current was applied using a battery-driven constant-current stimulator through saline-soaked surface sponge electrodes (7cm×5cm) with the anode placed over the left DLPFC (F3 according to the 10-20 international EEG system) and the reference cathode placed over the right supraorbital region (Fp2). During real tDCS, the current was increased to 2 mA from the onset of stimulation and applied for 20 minutes
223579403|NCT01976897|OTHER|Knee flexion measurement 1|The angle of knee flexion during resting, supine position is measured by a first person.
223470788|NCT02383524|PROCEDURE|Lumbar Radiofrequency Medial Branch Neurolysis|Numerous studies have concluded that facet joint pain can be accurately diagnosed if a significant (but temporary) reduction in pain is achieved with a procedure called a Medial Branch Block (MBB). The clinician delivers a targeted injection of local anesthetic to the joint itself, or in close proximity to the medial branch of the posterior rami of the dorsal root. A significant decrease in pain confirms that the pain originates from the facet joint. If or when the pain returns after successful MBB treatment the patient may be considered for radiofrequency denervation (neurotomy) which selectively disrupts the joint's nerve supply and provides longer-term sustained relief
224159764|NCT03611049|DIETARY_SUPPLEMENT|Low dose Vitamin D3|Low dose arm-800 IU given daily
223470789|NCT02038556|BEHAVIORAL|cognitive behaviorial therapy -Insomnia|
223470790|NCT04221919|DRUG|β -Blockers|Target doses of carvedilol, bisoprolol, metoprolol tartrate, or metroprolol succinate
223470791|NCT00974363|PROCEDURE|Blood Sampling|A blood sample will be taken yearly at each long-term follow-up visit (i.e. Year 2 through Year 5) after vaccination during the primary study. No vaccines are administered in the long-term follow-up study
223470792|NCT05705830|DEVICE|Pulse magnetic therapy|Pulse magnetic therapy SM-II (2019102133903)
223470793|NCT05705830|DRUG|Selective serotonin reuptake inhibitors （SSRI）|Anti-anxiety Drugs
223470794|NCT05705830|DEVICE|Shame magnetic therapy|Shame magnetic therapy
223470795|NCT04145856|DIETARY_SUPPLEMENT|I31 probiotic|I31 probiotic formula (dietary supplement), consisting of 3 billion cfus of strains P. acidilactici CECT7483, L.plantarum CECT7484 and L.plantarum CECT7485, once daily (u.i.d)
223470796|NCT04145856|COMBINATION_PRODUCT|I31 probiotic combined to Alverine/Simethicone|"* I31 probiotic formula (dietary supplement), consisting of 3 billion cfus of strains P. acidilactici CECT7483, L.plantarum CECT7484 and L.plantarum CECT7485, once daily (u.i.d)~* Antispasmodic/antifoam drug, consisting of Alverine Citrate 60 mg and Simethicone 300 mg, thrice daily (t.i.d)"
223470797|NCT04145856|OTHER|Placebo|Placebo treatment (maltodextrin), once daily (u.i.d)
223470798|NCT03280459|PROCEDURE|robot-assisted cystectomy|Removal of urinary bladder in oncologic or functional setting using a assistance of a operation robotic for laparoscopy
223470799|NCT04103190|DEVICE|cerebral MRI|"Patients who agree to participate in the study will perform a 3T multi-parametric MRI with advanced spectroscopic imaging techniques and standard protocol.~A neurological consultation will take place during the inclusion visit as well as a questionnaire and a control MRI at 1 year and 2 years +/- 1 month."
223470800|NCT03459625|BEHAVIORAL|Mindfulness-Based Stress Reduction (MSBR)|MBSR includes eight weekly 2.5-hour group sessions, a day-long (6hr) meditation retreat on the weekend during week six, 45 minutes of daily home practice guided by instructional audio CDs, and an MBSR parent workbook. Formal mindfulness exercises aim to increase the capacity for mindfulness and include a body scan, mindful yoga, and sitting meditation. Participants are also taught to practice mindfulness informally in everyday activities. In session, didactic instruction on stress physiology and using mindfulness for coping with stress in daily life is provided. Participants practice formal mindfulness exercises, break into dyads to discuss their daily homework practice, and meet as a larger group to ask questions related to the practice of mindfulness in everyday life.
223470801|NCT03459625|BEHAVIORAL|Psychoeducational Support Group (PE)|The PE consists of 8-weekly 2.5-hour sessions, a day-long (6hr) Family Resource Fair during week six, daily homework that includes monitoring progress on goals identified at the end of each session, and a workbook for parents of children with special needs that provides parents with information regarding their child's development, disability, and associated considerations. Weekly topics for discussion include Preparing for Individualized Education Plan (IEP) meetings, Communicating with Teachers, Advocacy, Sibling Issues, and Community Resources.
223470802|NCT01981668|DRUG|cabazitaxel|Concurrent cabazitaxel, radiotherapy and Eligard for 3 years
223470803|NCT00780975|DRUG|Aplidin (plitidepsin)|Aplidin® administered at a starting dose of 5 mg/m2, as a 3-hours intravenous infusion, every 2 weeks.
223470804|NCT02145455|DEVICE|Unity Total Knee Replacement System|
223470805|NCT02145455|DEVICE|Unity Total Knee Replacement System|
223470806|NCT04525430|OTHER|childbirth education|"The 1st Session: General information about labor: Factors affecting labor, early signs of labor, signs of the start of labor, steps of labor, and procedures applied during labor.~The 2nd Session: Methods of coping with birth contractions: Breathing exercises, relaxation exercises, massage, changing position, music, cold/warm application, focus, and walking."
223470807|NCT04525430|OTHER|childbirth education and was subjected to a birth plan|In the birth plan created by the researchers, the pregnant women considered the process from the start of labor to the end of labor and marked the expectation from and preferences about this process on the birth plan.
223470808|NCT01939314|DRUG|Bupivacaine|Bupivavaine Delivered by the Tx 360 Device to the Sphenopalatine Ganglion
223470809|NCT01939314|DRUG|Placebo|Normal Saline Delivered by the Tx 360 Device to the Sphenopalatine Ganglion
223470810|NCT02993198|DRUG|Carvedilol|
223470811|NCT04471701|BEHAVIORAL|Environmental exposure and clinical features|Environmental exposures and clinical features are measured by means of a self-administered 38-item on-line questionnaire containing mainly mandatory and closed questions divided into six sections: i) socio-demographic data; ii) clinical evaluation; iii) personal characteristics and health status; iv) housing conditions; v) lifestyle; and vi) behaviours following the lockdown.
223470812|NCT04879017|DRUG|FHD-286|FHD-286 as a single agent
223470813|NCT00100399|BIOLOGICAL|Fluarix|
223470814|NCT04054544|DIETARY_SUPPLEMENT|Gluten powder 4g|Gluten powder 4g oral BID
223579404|NCT01976897|OTHER|Knee flexion measurement 2|The angle of knee flexion during resting, supine position is measured by a second person.
223743774|NCT05402150|BEHAVIORAL|Behavioral Activation|"* instruction to create a list of individual positive activities.~* instruction to include daily positive activities and fill out a mood protocol, which covers the time period shortly before, during and after the activity."
224159765|NCT05387213|BEHAVIORAL|Team Huddles|Brief multidisciplinary meeting occurring twice a week for staff working at a LTC home led by a Nurse Practitioner. Huddles focused on discussing resident-care and staff-wellbeing.
224159766|NCT01332097|DRUG|BCT197|
224159767|NCT01332097|DRUG|Prednisone placebo|capsules
224159768|NCT01332097|DRUG|BCT197 placebo|capsules
224159769|NCT01332097|DRUG|Prednisone|capsules
223470815|NCT03179735|DRUG|Essential oils|"Patients will be submitted to one-stage ultrasonic debridement to remove plaque, stain(s), and any possible supragingival dental calculus. Further, oral instructions and an oral hygiene kit with fluoride dentifrice, toothbrush and plastic cups marked to indicate the rinse volume will be provided. According to study group, the first rinse will be performed under supervision at the study center and the remaining rinses will be performed unsupervised at home.~First rinse will be performed 15 days before orthodontic appliances bonding while the last rinse will be performed 6 months after bonding."
223470816|NCT03179735|DRUG|Cetylpyridinium Chloride 0.7 mg/ml|"Patients will be submitted to one-stage ultrasonic debridement to remove plaque, stain(s), and any possible supragingival dental calculus. Further, oral instructions and an oral hygiene kit with fluoride dentifrice, toothbrush and plastic cups marked to indicate the rinse volume will be provided. According to study group, the first rinse will be performed under supervision at the study center and the remaining rinses will be performed unsupervised at home.~First rinse will be performed 15 days before orthodontic appliances bonding while the last rinse will be performed 6 months after bonding."
223470817|NCT03179735|DRUG|Placebos|"Patients will be submitted to one-stage ultrasonic debridement to remove plaque, stain(s), and any possible supragingival dental calculus. Further, oral instructions and an oral hygiene kit with fluoride dentifrice, toothbrush and plastic cups marked to indicate the rinse volume will be provided. According to study group, the first rinse will be performed under supervision at the study center and the remaining rinses will be performed unsupervised at home.~First rinse will be performed 15 days before orthodontic appliances bonding while the last rinse will be performed 6 months after bonding."
223470818|NCT02743364|OTHER|Laboratory Biomarker Analysis|Correlative studies
223470819|NCT02743364|OTHER|Placebo Administration|Given PO
223579405|NCT01976897|OTHER|Heel - interface pressure measurements|"The pressure analysis system used is the X Sensor X3 model (Xsensor Technology Corporation, Calgary, Canada). The sensor mat is made up of transducer cells, each measuring 1.6 cm\^2. The digital signal is transmitted to a PC via a USB port at a sampling frequency of 10Hz. Before each measurement, the sensor mat is calibrated from 10 to 220 mm Hg, according to the manufacturer's recommendations.~The sheet of pressure sensors is disposed on the dedicated bed. The patient is then asked to take his/her usual position in the supine position and a latency of 5 minutes is observed. The recording time pressure is then performed for 90 seconds in the optical observing time to adapt to changes in media."
223470820|NCT02743364|OTHER|Quality-of-Life Assessment|Ancillary studies
223470821|NCT02743364|OTHER|Questionnaire Administration|Ancillary studies
223470822|NCT02743364|DRUG|Simvastatin|Given PO
223470823|NCT01338324|DRUG|Simvastatin|Simvastatin 20 mg single dose on day 1
223470824|NCT00969228|BIOLOGICAL|Rotarix ™|Two oral doses
223470825|NCT00969228|BIOLOGICAL|Placebo|Two oral doses
223470826|NCT04751695|BIOLOGICAL|CoronoVac Vaccine|CoronaVac vaccines will be inoculated in 2 doses with an interval of 24 days.
223579406|NCT03759041|DRUG|Vancomycin Pre-Treatment|Four times per day dosing of vancomycin pre-treatment
223579407|NCT03759041|DRUG|Placebo for Vancomycin Pre-Treatment|Four times per day dosing of placebo pre-treatment
223579408|NCT03759041|DRUG|SER-287|Once-daily dosing of SER-287
223579409|NCT03759041|DRUG|Placebo for SER-287|Once-daily dosing of Placebo for SER-287
223579410|NCT06464094|OTHER|User-testing of Vitaliti Continuous Vital Sign Monitor Model CVSM-1A|Single group enrollment to examine user-acceptance and user experiences, while soliciting user feedback on wearability compliance (patient) and proposed clinical workflows using the most recent Vitaliti™ CVSM device.
223470827|NCT02563899|DRUG|Umeclidinium|Umeclidinium (GSK573719) 1.85% will be supplied as a clear, colorless solution, free from visible particulates, for topical application. This formulation will be available at a concentration of 18.5 milligrams (mg) umeclidinium parent per gram. 2 mg of this formulation will be applied per square centimeter of the axilla, once a day at night before going to bed for 14 days. The total amount of formulation applied daily to both axillae is expected to range between approximately 204 and 680 mg. Total daily dosage of the active pharmaceutical ingredient (umeclidinium parent) to both axillae will range between approximately 3.8 and 12.6 mg. If certain pre-specified criteria for safety and tolerability are met, consideration will be given to decreasing the dose by decreasing the concentration of the topical formulation to 1.15% for the remaining subjects. This lower strength formulation will contain 11.5 mg parent per gram.
223470828|NCT02563899|DRUG|Vehicle|The vehicle will be supplied as a clear, colorless solution, free from visible particulates, for topical application. This formulation will be similar to the umeclidinium formulation except that it will be devoid of the umeclidinium parent. 2 mg of the vehicle will be applied per square centimeter of the axilla, once a day at night before going to bed for 14 days. The total amount of vehicle applied daily to both axillae is expected to range between approximately 204 and 680 mg.
223470829|NCT01690182|DIETARY_SUPPLEMENT|Study test meal 1|Volunteers will be fed with a high volume, high energy density test meal.
223579411|NCT03855631|GENETIC|Intervention on primary cultured cells|The intervention includes primary cultured cells, reprograming them into mesenchymal stem cells and CRISPR/Case9 gene therapy treatment on patients' cells
223579412|NCT04294550|OTHER|Naloxegol|28 days of therapy with 25 mg/day of Naloxegol on cancer patients using opioids and suffering for opioids induced constipation not relieved by first-line laxatives.
224159770|NCT04734977|DEVICE|High-intensity laser therapy (HILT)|High intensity laser therapy-Patients received pulsed laser treatment, using a HIRO 3 device (ASA Laser, Arcugnano, Italy), five times a week for a period of four weeks, and one session per day for a total of 20 sessions. A 3-phase treatment program was performed in each session.
223470830|NCT01690182|DIETARY_SUPPLEMENT|Study test meal 2|Volunteers will be fed with a high volume, low energy density test meal
223470831|NCT01690182|DIETARY_SUPPLEMENT|Study test meal 3|Volunteers will be fed with a low volume, high energy density test meal
223470832|NCT00410358|DRUG|Gimatecan|
223470833|NCT06157229|OTHER|MAT|"The protocol consists of four phases: 1) immobilization phase, 2) early protective phase, 3) intermediate phase and 4) late phase. The detailed guideline can be found in the following article:~Gaunt, B. W., Shaffer, M. A., Sauers, E. L., Michener, L. A., McCluskey, G. M., \& Thigpen, C. A. (2010). The American Society of Shoulder and Elbow Therapists' Consensus Rehabilitation Guideline for Arthroscopic Anterior Capsulolabral Repair of the Shoulder. Journal of Orthopaedic \& Sports Physical Therapy, 40(3), 155-168. https://doi.org/10.2519/jospt.2010.3186"
223470834|NCT06157229|OTHER|CABRR|"The protocol consists of four phases: 1) immobilization phase, 2) early phase, 3) intermediate phase and 4) advanced phase.~The protocol comprises education, modified cognitive behavioral therapy, neuromuscular control exercises, kinetic chain exercises, range of motion enhancing exercises, strength and conditioning exercises, and sport-specific exercises. The protocol is currently unpublished."
223470835|NCT02245711|BIOLOGICAL|Stem Cell|
223470836|NCT00661635|DRUG|placebo|valdecoxib 40 mg by mouth within 8 hours after the end of surgery, followed by a second dose of valdecoxib 20 mg within 1 to 12 hours (or by midnight on the Day 1, whichever was earlier); then, placebo twice daily (BID) on Days 2 to 5
223470837|NCT00661635|DRUG|valdecoxib|valdecoxib 40 mg by mouth within 8 hours after the end of surgery, followed by a second dose of valdecoxib 20 mg within 1 to 12 hours (or by midnight on the Day 1, whichever was earlier); then, valdecoxib 20 mg once daily (QD)on Days 2 to 5.
223470838|NCT00661635|DRUG|valdecoxib|valdecoxib 40 mg by mouth within 8 hours after the end of surgery, followed by a second dose of valdecoxib 20 mg within 1 to 12 hours (or by midnight on the Day 1, whichever was earlier); then, valdecoxib 20 mg twice daily (BID) on Days 2 to 5.
223579413|NCT04384107|BIOLOGICAL|V114|15-valent pneumococcal conjugate vaccine containing 13 serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F) present in PCV13 plus 2 additional serotypes (22F, 33F) in each subcutaneous 0.5 mL single dose.
223579414|NCT04384107|BIOLOGICAL|PCV13|13-valent pneumococcal conjugate vaccine containing 13 serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F) in each subcutaneous 0.5 mL single dose.
223579415|NCT03342352|DRUG|Nivolumab|Nivolumab administered intravenously at the protocol-defined dose every 3 weeks.
223579416|NCT03342352|DRUG|Epacadostat|Epacadostat administered orally at the protocol-defined dose twice daily.
223470839|NCT00794664|DRUG|Mipomersen|200 mg (1 mL), weekly subcutaneous injections for 26 weeks
223579417|NCT03342352|DRUG|Placebo|Matching placebo for epacadostat administered orally twice daily.
223579418|NCT03342352|DRUG|Carboplatin|Carboplatin administered intravenously at the protocol-defined dose every 3 weeks for 6 cycles.
223579419|NCT03342352|DRUG|Cisplatin|Cisplatin administered intravenously at the protocol-defined dose every 3 weeks for 6 cycles.
223579420|NCT03342352|DRUG|Cetuximab|Cetuximab administered intravenously at the protocol-defined dose weekly.
223579421|NCT03342352|DRUG|5-Fluorouracil|5-Fluorouracil administered intravenously at the protocol-defined dose on Days 1-4 for 6 cycles.
223579422|NCT00276614|DRUG|bortezomib|
223579423|NCT00229580|BEHAVIORAL|3 session brief intervention with health behavior feedback|
223579424|NCT00229580|OTHER|treatment as usual|
223579425|NCT00044824|DRUG|Fexofenadine|
223579426|NCT00552448|DEVICE|High Frequency Chest Compression VEST|every 6 hours for 20 minutes
223470840|NCT00794664|DRUG|Placebo|1 mL weekly subcutaneous injections for 26 weeks
223470841|NCT03708445|DIAGNOSTIC_TEST|Cytology staining|"Two staining will be performed in cytology specimens obtained from same patient. The cytology specimen will be obtained through brushing cytology using endoscopic retrograde cholangiopancreatography~1. conventional cytology staining method~2. new cytology staining method using antibody of aminoacyl-tRNA synthetases"
223470842|NCT01173315|DIETARY_SUPPLEMENT|vitamin and mineral supplementation|Group MV: Zinc sulfate and Magnesium oxide (providing 10 mg Zn and 125 mg Mg) and vitamin C (100 mg) and vitamin E (100 mg); Group MVB: both of the above mineral and vitamin supplements plus vitamin B1 (5 mg), vitamin B2 (5 mg), vitamin B6 (5 mg), biotin (50 µg), vitamin B12 (5 µg) and folic acid (0.5 mg); Group P: starch (placebo).
223470843|NCT02434874|DEVICE|StimGuard Sacral Nerve Stimulator System|The StimGuard Sacral Nerve Stimulator System is a wirelessly powered neurostimulator for urge urinary incontinence. This technology includes a quadripolar stimulator with an embedded receiver. The energy source is a small, external, rechargeable transmitter, which is worn by the patient. The transmitter sends the therapy program and power through the skin and to the receiver.
223579427|NCT00801060|DRUG|Lumiliximab + FCR|Dose, schedule, and duration in the protocol
223579428|NCT00801060|DRUG|FCR|Dosage, schedule, and duration in the protocol
223579429|NCT02990195|OTHER|Chyme reinfusion|
223579430|NCT00744666|DRUG|Prednisolone 1% topical eye drops|Prednisolone 1% 1gtt qid to the eye requiring IVTA
223579431|NCT03928626|BEHAVIORAL|Regulation of craving|Participants in the ROC-T condition will be trained to use a strategy that instructs them to think of the negative outcomes associated with alcohol drinking while looking at alcohol-related images.
223579432|NCT03928626|BEHAVIORAL|Control (NO REGULATION)|In the CONTROL condition, participants would simply observe non-alcohol-related images and allow natural responses to come
223579433|NCT00523497|DEVICE|Non invasive mechanical ventilation|
223579434|NCT03002272|DEVICE|TAVR|subjects that underwent TAVR more than 3 years ago
223579435|NCT03002272|DEVICE|SAVR|Historical controls will be selected from among patients at the same site who underwent isolated bioprosthetic SAVR more than 3 years ago
223579436|NCT04412694|DRUG|Dexamethasone oral tablet 8mg (Dexamethasone Krka tablets(8mg), Warsaw, Poland).|Preoperative oral dexamathasone supplementation in a single dose of 8mg.
223579437|NCT04412694|DRUG|Placebo oral sweetener (Clio tablets, sweetener with a dispenser, Instantina GES, Vienna, Austria).|Preoperative oral supplementation of sweetener in a single dose.
223579438|NCT04412694|DIAGNOSTIC_TEST|Preoparative blood laboratory tests|Preoperative parameters such as blood count, calcium, inorganic phosphates, albumin, alkaline phosphatase, C reactive protein, procalcitonin, 25-hydroxyvitamin D, fibrinogen, parathormone, magnesium, interleukin 1β, interleukin 6, interleukin 10, thyroid stimulating hormone, free thyroxine, free triiodothyronin will be measured in serum.
223579439|NCT04412694|DIAGNOSTIC_TEST|Postoperative laboratory blood tests at 6 hour|At 6 hour after surgery such parameters as blood count, calcium, inorganic phosphates, albumin, alkaline phosphatase, C reactive protein, procalcitonin, 25-hydroxyvitamin D, fibrinogen, parathormone, magnesium will be measured in serum.
223579440|NCT04412694|DIAGNOSTIC_TEST|Postoperative laboratory blood tests at 24 hour|At 24 hour after surgery such parameters as blood count, calcium, inorganic phosphates, albumin, alkaline phosphatase, C reactive protein, procalcitonin, 25-hydroxyvitamin D, fibrinogen, parathormone, magnesium, interleukin 1β, interleukin 6, interleukin 10 will be measured in serum.
223579441|NCT04412694|DIAGNOSTIC_TEST|Postoperative laboratory drainage fluid tests at 24 hour|At 24 hour after surgery such parameters as interleukin 1β, interleukin 6, interleukin 10 will be measured in drainage fluid.
223470844|NCT01062308|PROCEDURE|Taping and Sham Taping|"Taping shoulder with Hospiplast tape.~Taping the shoulder after acute stroke to prevent shoulder injury and pain.~Taping the shoulder after acute stroke and compare with sham taping group.~Treatments:~1. Positioning technique~2. Handling technique~3. Range of motion exercises~4. Taping technique"
223470845|NCT01062308|PROCEDURE|Sham Taping|Shoulder Taping for 14 days which will be changed after every 3 days.
223470846|NCT04890808|DIETARY_SUPPLEMENT|Inosine|Patients will be dosed with two 500 mg capsules of Inosine twice daily for 36 months
223470847|NCT04890808|DIETARY_SUPPLEMENT|IP6|Patients will be dosed with two 500 mg capsules of IP6 twice daily for 36 months
223470848|NCT02923999|DRUG|P2G12 Dose Cohort 1|single dose of intravenous infusion: 0.125g of the P2G12 human monoclonal antibody
223470849|NCT02923999|DRUG|P2G12 Dose Cohort 2|single dose of intravenous infusion: 0.25g of the P2G12 human monoclonal antibody
223470850|NCT02923999|DRUG|P2G12 Dose Cohort 3|single dose of intravenous infusion: 0.5g of the P2G12 human monoclonal antibody
223470851|NCT05867056|DRUG|IMC-I109V Single Ascending Dose|Single dose administration of IMC-I109V
223470852|NCT05867056|DRUG|IMC-I109V Multiple Ascending Doses|Multidose administration of IMC-I109V
223470853|NCT05867056|DRUG|HBV HCC Module MAD|Multidose administration of IMC-I109V
223579442|NCT04412694|PROCEDURE|Total thyroidectomy|Patients will undergo total thyroidectomy under general anesthesia.
223579443|NCT04412694|OTHER|Symptomatic hypocalcaemia at 6 hour|At 6 hour after surgery patients will be assessed for signs of hypocalcaemia.
224159771|NCT04734977|DEVICE|Sham high-intensity laser therapy (Sham HILT)|Sham High intensity laser therapy was applied in five sessions a week for four weeks, with a total of 20 sessions a day, with no current flowing through the device using a HIRO 3 device (ASA Laser, Arcugnano, Italy).
224159772|NCT04734977|OTHER|Therapeutic Exercise|"As therapeutic exercise program; active cervical ROM, cervical isometric and progressive (self-exercise with Thera-Band) strengthening muscles; trapezius, scalene, rhomboid, levator scapular, pectoral, suboccipital muscles stretching exercises, scapular stabilization exercises.It was planned to implement a total of 20 sessions 5 days a week for 4 weeks, for approximately 30 minutes.~Exercises will be performed by a trained (at least 5 years experienced) physiotherapist, three times a day, in 3 sets, 10 repetitions."
224159773|NCT00964262|DRUG|SR Exenatide (PT302)|0.5 mg, 1.0 mg, 2.0 mg and 4.0 mg dosage(dose escalation), single subcutaneous injection
223470854|NCT00457730|DRUG|Duloxetine|Patients will be randomly assigned to Duloxetine 30mg/d for 1 week, 60mg/d for 5 weeks and 30mg/d for 1 week or placebo for 7 weeks under double-blind conditions.
223470855|NCT00457730|DRUG|Placebo|Subjects are randomized to either Duloxetine or Placebo
223470856|NCT02195635|DRUG|Telotristat etiprate|500 mg telotristat etiprate
223470857|NCT02195635|DRUG|Octreotide acetate|200 µg octreotide acetate three times daily
223470858|NCT01305564|DEVICE|Denali inferior vena cava filter|The Denali inferior vena cava filter is a mechanical filtration device consisting of two levels of filtration (upper arms, lower legs), a retrieval hook to allow for retrieval using a standard snare, cranial and caudal anchors, and penetration limiters. The Denali filter is made from a laser cut nitinol tube.
223579444|NCT04412694|OTHER|Symptomatic hypocalcaemia at 24 hour|At 24 hour after surgery patients will be assessed for signs of hypocalcaemia.
223579445|NCT04412694|OTHER|Postoperative pain at 6 hour|At 6 hour after surgery the incidence and intensity of postoperative pain will be evaluated according to Visual Analogue Scale (VAS).
223579446|NCT04412694|OTHER|Postoperative pain at 24 hour|At 24 hour after surgery the incidence and intensity of postoperative pain will be evaluated according to Visual Analogue Scale (VAS).
223579447|NCT04412694|OTHER|Postoperative nausea and vomiting at 6 hour|At 6 hour after surgery the incidence and intensity of postoperative nausea and vomiting will be evaluated.
223579448|NCT04412694|OTHER|Postoperative nausea and vomiting at 24 hour|At 24 hour after surgery the incidence and intensity of postoperative nausea and vomiting will be evaluated.
223579449|NCT04412694|OTHER|Postoperative sore throat and hoarseness at 6 hour|At 6 hour after surgery the incidence and intensity of postoperative sore throat and hoarseness will be evaluated.
224069143|NCT06341673|DEVICE|Active Transcutaneous Electrical Nerve Stimulation (TENS)|For active group: TENS is to be used to stimulate tibial Nerve at medial aspect of the foot. The stimulation is proved by flexion of the big toe (motor response) and/or tingling sensation of ipsilateral sole of foot (sensory response) by raising the current amplitude, mA, intensity. Increasing the intensity above sensory threshold is recommended but should not be painful
224069144|NCT06341673|DEVICE|Sham Transcutaneous Electrical Nerve Stimulation (TENS)|TENS on the lateral side of the foot, the negative electrode on the top of the foot just above the small toe for conduction and the positive electrode on the bottom of below the smallest toe to avoid the tibial nerve and relevant cutaneous nerves. Participants will be instructed to raise up the intensity until the first and slight tingling sensation on the sole of the foot or toe
224069145|NCT06391138|DEVICE|Continuous Positive Airway Pressure|The intervention in this study involves the use of Continuous Positive Airway Pressure (CPAP) treatment. CPAP is a commonly used therapy for obstructive sleep apnea (OSA) and other sleep-related breathing disorders. The principle of CPAP treatment lies in maintaining a constant airway pressure during sleep to prevent the collapse of the upper airway and ensure unobstructed breathing. The patient wears a mask connected to a CPAP machine, which generates a steady stream of air to provide the necessary pressure.
224159774|NCT00964262|DRUG|Placebo|Plcacebo of each doasage, single subcutanoeus injection
223470859|NCT04692987|OTHER|Decision-aid video|Decision-aid video will be developed to disseminate knowledge and to raise awareness on colorectal cancer screening
223470860|NCT01289886|DRUG|BR-A-657|20, 60, 120, 240, 360, 480mg or placebo tablet
223579450|NCT04412694|OTHER|Postoperative sore throat and hoarseness at 24 hour|At 24 hour after surgery the incidence and intensity of postoperative sore throat and hoarseness will be evaluated.
223579451|NCT06508372|DRUG|Topical thymoquinone Ointment|One plaque per patient on one side of the body will be selected, whose diameter would not exceed 5-10 cm2 to apply Thymoquinone ointment as a monotherapeutic ttt twice daily for 3 months.
224159775|NCT00004125|DRUG|cyclophosphamide|
224159776|NCT00004125|DRUG|docetaxel|
224159777|NCT00004125|DRUG|doxorubicin hydrochloride|
224159778|NCT00004125|DRUG|paclitaxel|
224159779|NCT00004125|DRUG|tamoxifen citrate|
223470861|NCT02150928|DRUG|Erwinaze® (Asparaginase Erwinia Chrysanthemi)/Erwinase® (Crisantaspase)|"* Enrolled patients will receive asparaginase Erwinia chrysanthemi 25,000 IU/m2 administered intramuscularly (IM) on a Monday/Wednesday/Friday schedule (all dosing regimens will start on a Monday)~* All patients will receive at least 1 course (2 weeks) of treatment with asparaginase Erwinia chrysanthemi (1 course=6 doses), and a maximum number of courses needed to complete their remaining asparaginase therapy (up to 15 courses)~* Eligible patients may not begin treatment with asparaginase Erwinia chrysanthemi until their serum asparaginase activity level is below the assay detectable limit"
223470862|NCT01967459|DRUG|Cholecalciferol|Single dose D-cura cholecalciferol drink 100 000 IU/ml, in total 300 000 IU (=3ml)
223470863|NCT01967459|DRUG|Cholecalciferol|Single dose D-cura cholecalciferol drink 250 000 IU/ml, in total 75 000 IU (=3ml)
223470864|NCT04953507|PROCEDURE|Thermal Radiofrequency|Radiofrequency lesioning at level of T2 and T3 using 80°c for 120 seconds
223470865|NCT04953507|PROCEDURE|Chemical Neurolysis|injection of 1.5 ml of the chemical neurolytic agent (phenol in saline 8%) at each level
223579452|NCT06508372|DRUG|topical placebo ointment|In each patient a single similar psoriatic plaque on the other side of the body \[as regard anatomical site, size and TES (thickness, erythema, scales) score\] will be treated with placebo ointment twice daily for 3 months as a control.
223470866|NCT00081887|DRUG|Clofarabine|Starting dose is 10 mg/m\^2 as a 1-hour infusion into a vein once every 2 weeks for 4 weeks (1 cycle).
223470867|NCT03883243|DEVICE|Telecoaching|A telecoaching application linked to a step counter will be installed on a patients smartphone for 8 weeks. The application shows a daily goal (expressed as amount of steps per day) to the patient. This goal is weekly revised and patients themselves are able to increase the goal every week with 500 or 1000 steps/day. Every evening, they are able to check the daily feedback platform, which gives them insights in their physical activity pattern of the day and previous weeks. At a regular basis, 'tip of the day' messages appear as a pop-up, to keep patients motivated.
223579453|NCT01447160|DRUG|Cortisone|intraarticular infiltration with 1ml of triamcinolone hexacetonide versus intramuscular injection with 1 ml of triamcinolone acetonide
223579454|NCT05478291|OTHER|Vitamin D supplementation|Appropriate diet and physical activity counselling to both groups. Supplementation with Vitamin D and oral Calcium-Doses of cholecalciferol (commercial name, Calcirol) 60,000 IU (sachets, dissolved in half glass milk) once per week for eight weeks for the intervention group and placebo (Lactose granules) to the placebo group according to the random numbers generated by the computer. After every 24 weeks blood 25 (OH) D levels will be assessed. If the subjects are found to be still deficient then supplementation of cholecalciferol 60,000 IU per week for eight weeks will be repeated.If the 25 (OH) D levels are normal, then cholecalciferol supplementation in doses of 200 IU per day will be given as a maintenance dose. Equal doses of calcium carbonate (1gm per day, commercial name Calcal) will be given to both the groups.
223579455|NCT04001595|OTHER|Patient Registry|Participants who have volunteered to participate will complete various questionnaires relating to their condition.
223579456|NCT02337166|DEVICE|a gel containing 4mg/ml rhFGF-2 in sodium hyaluronate|0.2ml of a gel containing 4mg/ml rhFGF-2 in sodium hyaluronate MW 1.3 x 106
224069146|NCT03678597|OTHER|Medium Supplemented with Latrunculin B|A medium with in-house supplementation of Latrunculin B to decrease oocyte degeneration after ICSI and improve the survival rate
224069147|NCT00916240|BEHAVIORAL|Multisystemic Therapy|Treatment will consist of a home- and community-based intensive intervention. Psychological treatment sessions will be provided in participants' homes, at a time designated by the participant and will last about 1 hour.
224069148|NCT00916240|BEHAVIORAL|Home-based, Non-Directive Family Support|Treatment will consist of Rogerian, client-centered, non-directive counseling. Participants will receive weekly home-based, supportive family counseling, with sessions lasting about 45 minutes.
224069149|NCT05881187|DRUG|Riboflavin|topical application of riboflavin followed by cross linking
223470868|NCT01190085|DRUG|Ghrelin|A 1 microg/kg dose of intravenous human acetylated ghrelin was administered once approximately 10 minutes before the start of the alcohol cue-reactivity experiment.
223470869|NCT01190085|DRUG|Ghrelin|A 3 microg/kg dose of intravenous human acetylated ghrelin was administered once approximately 10 minutes before the start of the alcohol cue-reactivity experiment.
223579457|NCT02337166|PROCEDURE|Periodontal flap surgery|
223579458|NCT01397604|DRUG|GLA-AF|GLA-AF contains GLA, a new synthetic lipid A molecule that combines 6 acyl chains with a single phosphorylation site. GLA-AF contains GLA in an aqueous solution. One 2 mcg injection will be given per patient in the upper arm, each randomized to either subcutaneous or intramuscular routes.
223579459|NCT01397604|DRUG|GLA-SE|GLA-SE contains GLA, a new synthetic lipid A molecule that combines 6 acyl chains with a single phosphorylation site. GLA-SE contains GLA in a squalene oil emulsion. One 2 mcg injection will be given per patient in the upper arm, each randomized to either subcutaneous or intramuscular routes.
223579460|NCT01397604|OTHER|Squalene|Squalene is a natural organic compound obtained from shark liver oil. In this study, it is used to solubilize GLA in the GLA-SE formulation. Patients randomized to receive the squalene will be given one 2mcg injection of the squalene oil in the upper arm, each patient randomized further to either subcutaneous or intramuscular routes.
224069150|NCT05881187|DRUG|Antibotice.g vigamox ED Antifungal e.g Dflucan|topical application of antimicropial therapy
224069151|NCT05881187|DEVICE|pack cross linking|TOPICAL application of cross linking after application of Riboflavin TO TREAT INFECTIOUS KERATITIS
224069152|NCT01311947|DRUG|Peginterferon alfa-2a|Peginterferon alfa-2a at 180 ug weekly for 24 weeks
224069153|NCT01272466|BIOLOGICAL|peptides derived from antiapoptotic proteins|8 Vaccinations on day 2 and 9 in every bortezomib treatment series
224069154|NCT05273580|DEVICE|Garmin VivoSmart 4|Wearable sensor to record; sleep, stress, heart rate etc.
224069155|NCT05273580|DEVICE|mema - ilumivu|mEMA is the a self-service platform running on both iOS and Android that is specifically designed for the administration of mobile Ecological Momentary Assessment or Experience Sampling research studies.
224159780|NCT00004125|RADIATION|radiation therapy|
224159781|NCT06114030|PROCEDURE|Deep margin elevation with composite resin and Lithium disilicate glass-ceramic crowns|Restoration of the deep margin by composite restorations such as: Filtek Supreme XTE, Tetric EvoCeram, Estelite Sigma Qquick followed by Lithium disilicate glass-ceramic CAD/CAM crowns (IPS e.max CAD).
224159782|NCT02048358|DRUG|2B3-201|
224159783|NCT02048358|DRUG|Placebo|
223579461|NCT01522404|DRUG|Atomoxetine|Subjects in this intervention will receive Atomoxetine up to 29 weeks, crossover, dose escalating (up to a maximum dose of 100 mg per day) of oral atomoxetine
224159784|NCT02048358|DRUG|Methylprednisolone hemisuccinate|
223470870|NCT01190085|DRUG|Saline solution|Intravenous saline solution (matched placebo) was administered once approximately 10 minutes before the start of the alcohol cue-reactivity experiment.
223470871|NCT06983366|DIAGNOSTIC_TEST|Lung Ultrasound|All enrolled patient will be subjected to Lung Ultrasound examination LUS
223470872|NCT02706262|OTHER|Metabolically abnormal obese - Mediterranean diet|The effect of consuming a Mediterranean diet will be examined over 3 different phases: (i) weight maintenance for 4 to 8 weeks, with all meals provided; (ii) controlled 7-10% weight loss with caloric intake reduced by 25% to achieve the desired amount of weight loss in about 4 to 5 months with all meals provided; and (iii) Independent weight loss for about 4 months. During the independent weight loss phase of the study subjects will be asked to continue to consume a Mediterranean diet but will prepare all their food at home. No food will be provided during this portion of the study.
223579462|NCT01522404|DRUG|Placebo|Subjects in this intervention will receive inactive compound up to weeks 29 and will cross over to the other group
223579463|NCT03237130|PROCEDURE|preoperative enhanced chest CT examination|Each patient will receive preoperative enhanced chest CT examination, and their CT images will be used for analysis
223579464|NCT04866355|OTHER|Lumbar spine manipulation|Lumbar spine manipulation
223579465|NCT04866355|DRUG|Hyoscine and Ibuprofen|hyoscine (20 mg) and ibuprofen (400 mg) administered by oral via.
223579466|NCT03654287|OTHER|Treatment|The CELS way to intervene severe sepsis and refractory shock
223579467|NCT01349062|DRUG|"Kallunk oxide (Immunotherapy) "|"The study is assigned Arm 1 above 450 cu/mm\^3 baseline CD + T cells. HIV type-1 subjects will receive one drug, a daily regimen of Kallunk oxide(Immunotherapy) + Long Pepper, that is a combination of a traditional alternative medicine (Complementary and Alternative Medicine CAM) as Kallunk oxide and appropriate drug carrier antidote. The drug assigns to 5 mg Kallunk oxide molecules with1995 mg Antidote( This antidote was used as a carrier of Kallunk oxide molecules), respectively, for children and adults. Dosage: 2000 mg for children and adults. This powder form sample size product will be administered once daily dose on 7 days treatment. The Botanical name of the antidote is Piper Longum."
224159785|NCT05834101|OTHER|Myofacial Release|Illiopsoas , quadriceps, hamstrings, hip adductors, hip abductors ,tensor fasciae lata and gluteus, Foot flexors and extensors received thirty seconds flexibility by foam rolling.Although there appears to be a correlatiomuscle goups between higher SMR length and bigger impact size, the exact link between SMR duration and effect size is uncertain. The time was 30 seconds each muscle group was chosen since it is more realistic than the 60 seconds utilized by MacDonald et al., and it was also used by Peacock et al. Similar to the Grid roller, a commercially available foam roller had net diameter of 12.7 cm and a 5-mm thick empty core of plastic coated with a 12-mm layer of dense foam. In this study, participants were instructed to do the motions in sequenced and save manner, covering the complete muscular area, applying consistent pressure that was felt comfortable. For a total of 16 minutes, the therapy lasted 8 minutes on one leg and 16 minutes on both legs
224159786|NCT05834101|OTHER|Dynamic streching|The regimen included ten dynamic workouts lasting 10 minutes and varying in intensity from medium to high. At a distance of 13 meters, each Dynamic stretching exercise was completed. Before each workout, the subjects were given a 10-second rest time. During the exercises, the participants were given verbal comments on their posture, and video recordings of the activities were displayed to them. Dynamic stretching included High knee walk, Straight-leg march, Hand walk, Lunge walks, Backward lunge, High-knee skip, Lateral shuffle, Back pedal, Heel-ups, and High-knee run
223579468|NCT04858685|OTHER|early mobilization|early mobilization was defined, on the basis of the ERAS protocol, as mobilization of a few steps or a few meters from the bed within the first 24 hours after surgery with another person's support/control and/or a walking aid.
223579469|NCT04836676|DEVICE|C-REX Device|"The investigational devices are C-REX LapAid Cath or C-REX RectoAid Cath. C-REX LapAid Cath consists of an invasive surgical part, i.e. anastomotic ring comprised of two LapAn coupled by DMC/DM, intended for short-term use, and surgical instruments for assisting the placement of the anastomotic ring to intestine.~C-REX RectoAid Cath consists of an invasive surgical part, i.e. an anastomotic ring comprised of RectoAn and LapAn, intended for short-term use, and surgical instruments for assisting the placement of the anastomotic ring to intestine.~C-REX LapAid Cath and C-REX RectoAid Cath are easy to use, with unique possibility to control and validate the integrity of the anastomosis during and after surgery."
223579470|NCT02498574|DEVICE|Transcranial Direct Current Stimulation|Non-invasive brain stimulation applied to the surface of the scalp
223579471|NCT02498574|BEHAVIORAL|Working Memory Training|Cognitively challenging game played concurrently with transcranial direct-current stimulation
224069156|NCT01765673|DEVICE|Vibrotactile stimulation|Comparison of the effects of different vibratory characteristics on the frequency of swallowing, time of initiation of swallowing with stimulation and urge to swallow. Will compare frequency of vibration, mode of vibration, pressure of device against neck, and duration of vibration. Each session will last no more than 1 hour with short breaks. Each participant can volunteer for up to three nonconsecutive sessions.
224069157|NCT05174000|DRUG|Test Euthyrox®|Participants will receive single oral dose of Test Euthyrox® either in treatment period 1, 2, 3 or 4.
224069158|NCT05174000|DRUG|Reference Euthyrox®|Participants will receive single oral dose of Reference Euthyrox® either in treatment period 1, 2, 3 or 4.
224069159|NCT04170595|BIOLOGICAL|GB221,2 mg/kg|Single dose, 2mg/kg group: lyophilized powder of Coprelotamab Injection; strength 110mg/bottle; 2 mg/kg for one dose, intravenous infusion, completed for over 90 minutes
224069160|NCT04170595|BIOLOGICAL|GB221,6 mg/kg|Single dose 6mg/kg group: lyophilized powder of Coprelotamab Injection; strength 110mg/bottle; 6 mg/kg for one dose, intravenous infusion, completed for over 90 minutes
224069161|NCT04170595|BIOLOGICAL|Herceptin,6 mg/kg|Single dose group: lyophilized powder of Trastuzumab Injection; strength 440 mg/bottle; 6 mg/kg for one dose, intravenous infusion, completed for over 90 minutes
224069162|NCT04170595|BIOLOGICAL|GB221,8mg/kg|Single dose 8mg/kg group: lyophilized powder of Coprelotamab Injection; strength 110mg/bottle; 8mg/kg for one dose, intravenous infusion, completed for over 90 minutes
223470873|NCT02706262|OTHER|Metabolically abnormal obese - Low carbohydrate ketogenic diet|The effect of consuming a low-carbohydrate, ketogenic diet will be examined over 3 different phases: (i) weight maintenance for 4 to 8 weeks, with all meals provided; (ii) controlled 7-10% weight loss with caloric intake reduced by 25% to achieve the desired amount of weight loss in about 4 to 5 months with all meals provided; and (iii) Independent weight loss for about 4 months. During the independent weight loss phase of the study subjects will be asked to continue to consume a low carbohydrate ketogenic diet but will prepare all their food at home. No food will be provided during this portion of the study.
224069163|NCT04170595|BIOLOGICAL|GB221:2mg/kg and Capecitabi:1000mg/kg|GB221:Lyophilized powder of Coprelotamab Injection; strength 110mg/bottle; 2mg/kg, the first infusion is completed over 90 minutes. If no serious adverse reaction is observed, the subsequent infusion can be completed over 30 minutes. The administration shall be continued until disease progression or intolerable toxic reactions or ICF withdrawal of subjects. Multiple dose group; Capecitabine:1000mg/kg, orally twice daily (one dose each in the morning and evening; total daily dose of 2000 mg/m2), administration for 2 weeks followed by a 1-week rest period, as a 3-week cycle.
224069164|NCT04170595|BIOLOGICAL|Herceptin:2mg/kg and Capecitabin:1000mg/kg|Herceptin:Lyophilized powder of Trastuzumab Injection; strength 440 mg/bottle; 2mg/kg, the first infusion is completed over 90 minutes. If no serious adverse reaction is observed, the subsequent infusion can be completed over 30 minutes. The administration shall be continued until disease progression or intolerable toxic reactions or ICF withdrawal of subjects. Multiple dose groups; Capecitabine:1000mg/kg, orally twice daily (one dose each in the morning and evening; total daily dose of 2000 mg/m2), administration for 2 weeks followed by a 1-week rest period, as a 3-week cycle.
223470874|NCT02706262|OTHER|Metabolically abnormal obese - Plant-based, very-low-fat diet|The effect of consuming a plant-based, very-low-fat diet will be examined over 3 different phases: (i) weight maintenance for 4 to 8 weeks, with all meals provided; (ii) controlled 7-10% weight loss with caloric intake reduced by 25% to achieve the desired amount of weight loss in about 4 to 5 months with all meals provided; and (iii) Independent weight loss for about 4 months. During the independent weight loss phase of the study subjects will be asked to continue to consume a plant-based, very-low-fat diet but will prepare all their food at home. No food will be provided during this portion of the study.
224069165|NCT01042600|DEVICE|Endotracheal tube insertion|Endotracheal tube insertion after premedication with atropine (0.02 mg/kg) and morphine (0.1 mg/kg)
224069166|NCT01042600|DEVICE|Laryngeal mask airway insertion|Laryngeal mask airway insertion after premedication with atropine (0.02 mg/kg)
224069167|NCT06548204|DRUG|Fexofenadine Hydrochloride 60mg bid|Fexofenadine hydrochloride 60mg bid treatment for 6 months.
224069168|NCT06548204|OTHER|Placebo|Placebo administration for 6 months.
224069169|NCT06548204|DRUG|Fexofenadine Hydrochloride 120mg bid|Fexofenadine hydrochloride 120mg bid treatment for 6 months.
224069170|NCT04647955|DRUG|Itopride|Itopride is a D2 antagonist and cholinesterase inhibitor with prokinetic effects on gastric motility used to treat functional dyspepsia. Patients were treated for 8 weeks.
224069171|NCT04647955|DRUG|Placebo|Patients were treated for 8 weeks.
224069172|NCT02205684|OTHER|Computer game skills training|Playing Nintendo Wii Sports
224069173|NCT02205684|OTHER|Physical activity|Aerobic High Intensity Training (HIT)
224069174|NCT00000873|DRUG|Infant Formula|
224069175|NCT05568342|BEHAVIORAL|The Effect of Roy Adaptation-Based Nursing Intervention on Stress, Psychosocial Adjustment and Self-Care Power in Hemodialysis Patients: A Randomized Controlled Experimental Study|Pre-test was applied to the patients in Roy and clinical groups using data collection tools. After the pre-test, the patients in the Roy group were trained 6 times in 3 months, twice a month, at home and in the clinic. Nursing interventions were performed using the Roy Adaptation Model in the trainings. At the end of the third month, the post-test data of both groups were collected. During the study, no training or intervention was given to the patients in the clinical group. The nursing education and interventions of this group were carried out by nurses working in the dialysis clinic within the scope of routine practices.
224069176|NCT05392348|DIETARY_SUPPLEMENT|stachyose|Stachyose is a tetrasaccharide consisting of sucrose having an alpha-D-galactosyl-(1-\>6)-alpha-D-galactosyl moiety attached at the 6-position of the glucose.
224069177|NCT05392348|DIETARY_SUPPLEMENT|Maltodextrin|Maltodextrin is a polysaccharide that is used primarily in foods and beverages as a thickener, sweetener, and/or stabilizer. It is a relatively short-chain polymer (some would call it an oligomer); commercial products contain an average of ≈3 to ≈17 glucose units per chain. It is manufactured by partially hydrolyzing grain starches, usually corn or wheat.
224069178|NCT02485145|DRUG|A/B|This arm uses the test product first, which consists of Diclofenac 3%, Baclofen 2%, Orphenadrine 5%, and Bupivacaine 2% in a VersaPro cream. This is the A arm. The B arm is the second arm, and consists of the VersaPro cream alone.
224069179|NCT02485145|DRUG|Placebo|The placebo, which consists of the VersaPro cream, will be utilized in the study.
224069180|NCT02485145|DRUG|B/A|This arm uses the placebo product first, which consists of the VersaPro cream alone. This is the B arm. The A arm is the second arm, which consists of the test product which consists of Diclofenac 3%, Baclofen 2%, Orphenadrine 5%, and Bupivacaine 2% in a VersaPro cream. This is the A arm.
224159787|NCT05300646|BEHAVIORAL|Prenatal mindfulness-based stress reduction|An adapted mindfulness-based stress reduction (MBSR) program with a particular focus on pregnancy and early motherhood.
224159788|NCT00431496|DRUG|Cinacalcet|Cinacalcet tablets
224159789|NCT00004041|BIOLOGICAL|Ad5CMV-p53 gene|
224159790|NCT00004041|PROCEDURE|conventional surgery|
224159791|NCT01651312|DRUG|14C-labeled YM178|oral solution (1.85 MBq)
224159792|NCT04018612|DRUG|Acetaminophen|Acetaminophen is an analgesic and antipyretic
223470875|NCT02706262|BEHAVIORAL|Annual Follow-up Visits|Metabolic health will be assessed 1 and 2-years after competing the diet intervention study. No intervention will be performed during the time.
223743775|NCT05402150|BEHAVIORAL|Mindulness and Gratitude|"* instruction to fill out a mindfulness diary: reflection of daily pleasant situation, instructing the participants to revisit the impressions of their 5 senses during this situation, in addition they should specify how long they have actually dealt with these pleasant impressions of the situation they reflected upon~* instruction to do a gratitude exercise and name one or more things they are generally grateful for each day."
223743776|NCT05402150|BEHAVIORAL|Combination of Behavioral Activation and Mindfulness and Gratitude|This group will do a combination of the two intervention types.
223470876|NCT06981533|OTHER|Auricular acupressure therapy|Auricular acupressure will be performed using Cowherb seeds (Wangbuliuxing seeds) applied to specific acupoints, including Shenmen (TF4), Sympathetic (AH6a), Endocrine (CO18), Liver (CO12), Kidney (CO10), Subcortex (AT4), and Zero Point on one ear, with treatment administered once a week, alternating between the left and right ears. In total, auricular acupressure was applied 8 times over a period of 8 weeks. The first treatment session occurred 5-7 days prior to the onset of menstruation. Participants were instructed to perform acupressure at the acupoint sites three times daily-morning, noon, and evening-pressing each point for 1 minute per session.
223470877|NCT06981533|OTHER|Sham auricular acupressure therapy|Sham auricular acupressure therapy will be performed using similarly sized adhesive patches without seeds, applied to the same acupoint locations as in the intervention group. The procedure steps and the duration of the trial were the same as in the auricular acupressure group.
223470878|NCT06981533|OTHER|Lifestyle modifications|"Lifestyle modifications will be followed according to the Guidelines for the Management of Premenstrual Syndrome by the Royal College of Obstetricians and Gynaecologists (RCOG), which will include: Regular moderate exercise (such as walking, yoga, or swimming), stress reduction, and ensuring quality sleep (7-8 hours per night); Reducing intake of salt, sugar, and foods containing saturated fats; Increasing intake of high-fiber foods such as fruits and vegetables; Avoiding smoking, and limiting alcohol, and other stimulants."
223470879|NCT03933306|DRUG|Dexmedetomidine|Loading dose dexmedetomidine (0.6 mcg/kg for 10 min) administered before anesthesia induction, followed by a continuous infusion (0.5 mcg/kg/h) until 1 hour before the end of surgery.
223470880|NCT03933306|DRUG|Placebo|Loading dose placebo administered before anesthesia induction, followed by a continuous infusion until 1 hour before the end of surgery.
223470881|NCT03933306|OTHER|Goal-directed blood pressure management|Blood pressure is maintained within ±10% of baseline with noradrenaline infusion and fluid management.
223470882|NCT03933306|OTHER|Routine blood pressure management|Blood pressure is maintained according to routine practice, i.e., systolic blood pressure \> 90 mmHg or within ±30% of baseline within intermittent ephedrine or phenylephrine.
223470883|NCT06611995|OTHER|observational study|Observational study without intervention
223470884|NCT06612216|OTHER|No intervention was carried out|This study observed differences in microbiota among different groups and therefore did not involve intervention.
223470885|NCT06612905|OTHER|Detection of the time spent on social media|The time spent on social media will be assessed by using the social networking usage questionnaire (SONTUS) for all women in both groups (A and B).
223470886|NCT06612905|OTHER|Evaluation of body composition and basal metabolic rate|They will be evaluated using Inbody (Bodecoder)(CHL-818, made in China) and its software (2.2.1 apk)
223470887|NCT06612905|OTHER|Evaluation of eating behavior among social media users|Scale of effects of social media on eating behavior (SESMEB) will be used for all women in both groups (A and B) to assess the effect of social media on their eating behavior. The SESMEB consists of one subscale and eighteen items. It is a reliable and valid scale, items scale is evaluated with five-point Likert scale. Each item is evaluated as 'always' five points, 'often' four points, 'sometimes' three points, 'seldom' two points and 'never' one point. There is no reverse coded substance. As it is mentioned in item analysis part, total score can be calculated. According to this minimum eighteen and maximum ninety points from SESMEB scale can be taken as total point. As a result, the increase in the person's scale score means that the level of being affected by the eating media increases.
223470888|NCT07001956|BIOLOGICAL|UTAA91 injection|After signing the informed consent form, eligible subjects will receive an infusion of UTAA91 injection. Blood samples will be collected from the subjects before and after the infusion for the evaluation of pharmacokinetics, pharmacodynamics, immunogenicity, and safety.
223743777|NCT00702403|DRUG|nilotinib|Given PO
223743778|NCT00702403|DRUG|imatinib mesylate|Given PO
223743779|NCT00702403|OTHER|pharmacological study|Correlative studies
223743780|NCT06376162|DRUG|Ziftomenib|Oral capsule
224069181|NCT00742339|DRUG|Terlipressin plus albumin|The terlipressin will be give at the initial dose of 3 mg/24 hours by intravenous continuous infusion. If during the following 48 hours the serum value of creatinine will not change or will go down less than 25%, the dose of terlipressin will be increased to 6 mg/24 hours. If no response will ensue, the dose of terlipressin will be increased to the maximal dose of 12 mg/24 hours. Twenty percent human albumin solution will be administrate together with terlipressin at the dosage of 1 g/Kg of body weight, on first day, and then, to the dosage of 20-40 g/Kg in order to maintain the central venous pressure (CVP) between 10 and 15 cm H2O.The treatment with terlipressin and albumin will be maintained for 24 hours after complete or incomplete resolution. The length of the study in patients with complete and incomplete resolution will reach a maximum of 15 days. In the patients without response the treatment with the high dosage of terlipressin will go on for a maximum of 7 days.
224069182|NCT00742339|DRUG|Midodrine plus octreotide plus human albumin|Midodrine will be give orally at the initial dose 7.5 tid together with octreotide at the initial dosage of 100 µg subcutaneously tid. If during the following 96 hours the serum value of creatinine will not change or will go down less than 25%, the dose of midodrine will be increased to 12.5 mg tid Twenty percent human albumin solution will be administrate together with midodrine and octreotide at the dosage of 1 g/Kg of body weight, on first day, and then, to the dosage of 20-40 g/Kg in order to maintain the central venous pressure (CVP) between 10 and 15 cm H2O.The treatment with terlipressin and albumin will be maintained for 24 hours after complete or incomplete resolution. The length of the study in patients with complete and incomplete resolution will reach a maximum of 15 days. In the patients without response the treatment with the high dosage of terlipressin will go on for a maximum of 7 days.
224069183|NCT05048719|DRUG|LY3502970|Administered orally
224069184|NCT05048719|DRUG|Dulaglutide|Administered subcutaneously
224069185|NCT05048719|DRUG|Placebo|Administered orally
224069186|NCT05048719|DRUG|Placebo|Administered subcutaneously
224069187|NCT04541004|BIOLOGICAL|HDM SLIT-tablet|Sublingual allergy immunotherapy tablet, for daily administration (1 tablet per day)
224069188|NCT01179074|PROCEDURE|oesophageal stenting with self expandable metal stent|oesophageal stent placement for high grade dysphagia in inoperable oesophageal cancer
224069189|NCT01179074|PROCEDURE|Oesophageal stent followed by external beam radiotherapy|30 Gy in 10 fractions over 2 weeks administered in the stent followed by EBRT group
224069190|NCT04818515|DRUG|Atogepant|Oral; Tablet
224069191|NCT04818515|DRUG|Ubrogepant|Oral; Tablet
223470889|NCT03893929|DIAGNOSTIC_TEST|New Biological markers for prostate cancer diagnosis and management|To identify potential new blood and urine markers for the diagnosis, risk stratification and prognosis prediction for prostate cancer in Chinese population.
223470890|NCT07016646|COMBINATION_PRODUCT|Self-Help Plus (SH+) and cash transfer|"SH+: Self-Help Plus (SH+) is a five-session stress management program developed by the World Health Organization (WHO) for groups of up to 30 participants. It is facilitated by non-specialists who undergo brief training and use pre-recorded audio along with an illustrated guide, Doing What Matters in Times of Stress, to teach stress management techniques. Designed for adults experiencing stress, SH+ is adaptable to diverse living situations and circumstances. Research has demonstrated its effectiveness in alleviating psychological distress and preventing the onset of mental health disorders. Its flexible format makes it an excellent complement to other mental health interventions, whether as an initial step in a stepped care approach or as a community-based program integrated with broader community initiatives.~Cash Assistance: A cash transfer of $300 or equal amount in Turkish Lira per participant ($60 or equal amount in Turkish Lira after each session)"
223470891|NCT07016646|OTHER|Cash transfer|A cash transfer of $300 or equal amount in Turkish Lira per participant ($60 or equal amount in Turkish Lira each week for 5 weeks)
223470892|NCT07021222|PROCEDURE|Full Analysis|Population 1 receives all three groups of analyses:Clinical-metabolical analyses, Biological-biochemical analyses, and Biomechanical-functional analyses.
223470893|NCT07021222|PROCEDURE|Partial Analysis|Population 2 receives two groups of analyses:Clinical-metabolical analyses and Biological-biochemical analyses.
223470894|NCT06185686|OTHER|Cognitive testing|NIH Toolbox Cognitive Battery and the Novel Cognitive Measure (NCM)
223470895|NCT06185686|DEVICE|Resting State MRI/Precision functional mapping|At baseline (before the end of radiation therapy) and approximately 12 months after the completion of radiation therapy.
223470896|NCT07024550|DEVICE|Treatment with BTL-699-2 device|The treatment schedule with BTL-699-2 device will consist of six 24.5-minute treatments spaced 3-7 days apart. The therapy parameters will be adjusted according to patient feedback, but should never exceed 70% of the individual's MT in the active group.
223470897|NCT07024550|DEVICE|Treatment with BTL-699-2 device with intensity below therapeutic threshold|The treatment schedule with BTL-699-2 device will consist of six 24.5-minute treatments spaced 3-7 days apart. The intensity of the energy will be set below the therapeutic threshold.
223470898|NCT07028723|OTHER|proprioceptive profile measurement|"Proprioceptive profile is measured by assessing static bipodal balance on a force platform. The patient is asked to stand motionless in bipodal support on a stable and then unstable floor, with vision masked by an eye mask. The investigators randomly apply a tendon vibration (80Hz) to the subjects' Achilles tendons or paravertebral muscles.~This vibration alters proprioceptive information in the vibrated zone, leading to a disturbance in postural balance and an increased displacement of the center of pressure, whose position is continuously calculated from the force platform's sensors.~Thus, depending on the amount of displacement of the center of pressure, the investigator calculates a proprioceptive weighting ratio (PWR) to deduce the weight assigned by the Central Nervous System to the various proprioceptive inputs during the postural task.~An PWR of 1 indicates 100% use of information from the ankle, while an PWR of 0 means 100% use of information from the hip."
224159793|NCT04018612|OTHER|Placebo|Saline
224159794|NCT02537223|DRUG|BYL719|
224159795|NCT02537223|DRUG|Cisplatin|
224304038|NCT00039026|DRUG|Placebo|Placebo Lead In (0.02 mL) for 4 weeks / Placebo (0.02 mL) for 4 weeks / Placebo (0.02 mL) for 26 weeks - All are subcutaneously injected twice daily
223470899|NCT06462391|BEHAVIORAL|Acceptance and Commitment Therapy (ACT) Group|Psychotherapy group (delivered virtually)
223470900|NCT01702909|DRUG|Interleukin-2|Interleukin-2
223470901|NCT02440061|DRUG|Synthetic human AG|Synthetic human AG (0.28 μg/kg) bolus over 1 minute followed by 2 μg/kg/hr continuous infusion for 4.5 hours.
223470902|NCT02440061|DRUG|Arginine|Arginine hydrochloride (5 g) intravenously over 45 seconds.
223743781|NCT06376162|DRUG|Cytarabine|Intravenous (IV) infusion
223743782|NCT06376162|DRUG|Fludarabine|IV infusion
224069192|NCT00501982|DRUG|Poractant alfa (Curosurf®)|
224069193|NCT05332119|DEVICE|VR glasses|Patients will watch a virtual world in VR glasses during the painful procedure. They will be able to choose between 3 VR content based on their preferences.
224069194|NCT05332119|OTHER|Control group|Patients will not receive distraction during chest drain removal
224069195|NCT04088344|DIETARY_SUPPLEMENT|isocaloric diet|a 7-day isocaloric diet
224069196|NCT04088344|DIETARY_SUPPLEMENT|Hypercaloric diet|A 7-day hypercaloric diet supplemented with carbohydrate-rich food (+ 50% of the subject's energy needs).
224069197|NCT04088344|OTHER|Liquid meal|
224069198|NCT04088344|RADIATION|PET imaging|
224159796|NCT02537223|RADIATION|Intensity modulated radiation therapy (IMRT)|
224159797|NCT06396455|PROCEDURE|interscalene block group|The ISB group scanning was done by linear ultrasound probe just below the level of the cricoid cartilage medial to the sternocleidomastoid muscle; the skin was disinfected, and the transducer was positioned in the transverse plane to identify the carotid artery. Once the artery was identified, the transducer was moved slightly laterally across the neck to identify the scalene muscles and the brachial plexus that is present between the anterior and middle scalene muscles. 3 ml lidocaine 1% was injected at puncture site The needle was then inserted in-plane toward the brachial plexus, in a lateral-to-medial direction. After a careful aspiration, 20 ml of bupivacaine 0.25% was injected.
224069199|NCT04088344|OTHER|perfusions of stable tracers|
224069200|NCT04088344|DEVICE|Indirect calorimetry|
224069201|NCT06763913|DEVICE|taVNS|Set the pulse width to 200 microseconds, frequency to 30 Hz, and start the current at 10 mA. Gradually increase the current until the patient reaches their pain tolerance threshold, and cap it at 50 mA，last for one hour.During the intervention, dynamic ECG monitoring was conducted using an ECG monitor, starting 10 minutes before the stimulation and ending 10 minutes after the stimulation.
224069202|NCT06763913|DEVICE|sham taVNS|Set the pulse width to 200 microseconds, frequency to 1 Hz, and start the current at 10 mA. Gradually increase the current until the patient reaches their pain tolerance threshold, and cap it at 50 mA，last for one hour.During the intervention, dynamic ECG monitoring was conducted using an ECG monitor, starting 10 minutes before the stimulation and ending 10 minutes after the stimulation.
223470903|NCT02440061|DRUG|0.9% saline solution|A continuous infusion of 0.9% saline solution (control) for 4.5 hours.
224069203|NCT00616109|DRUG|sunitinib|Sunitinib will be given at 50 mg/day as a single agent for 4 consecutive weeks followed by a 2-week rest period to form a complete cycle of 6 weeks.
224159798|NCT06396455|PROCEDURE|Suprascapular nerve block group|After cleaning the skin with an antiseptic solution, an ultrasound probe was put in sagittal orientation at the superior medial border of the scapula to identify the pleura and then moved laterally; when it was parallel to the spine of the scapula, the transducer was moved cephalad and the suprascapular fossa was identified, and then the transducer was moved lateral to locate the suprascapular notch. The suprascapular nerve was a round hyperechoic structure beneath the transverse scapular ligament in the scapular notch. 3 ml lidocaine 1% was injected at puncture site then the needle was inserted along the longitudinal axis of the ultrasound beam, and 10 ml of bupivacaine 0.25% was injected.
224159799|NCT00361218|DRUG|open-label selective serotonin reuptake inhibitor (SSRI)|Duration is 8 weeks. For escitalopram, starting dose is 10mg po qd,which can be increased up to 30mg po qd per clinical discretion. For citalopram, starting dose is 20mg po qd, which can be increased up to 60mg po qd per clinical discretion.
224159800|NCT03581682|OTHER|Tele-Clinic Visits Using Parent-Acquired Echos|"Every patient will have a tele-visit and an on-site clinic visit 1 day apart 3-6 months after the training session. Parents will have a 1-hour hands-on training session to acquire basic echo images on their children with the same hand-held device that they will use during the tele-visit. The parents will also have an in-service on how to take weight, height, and blood pressure measurements, and how to use the digital stethoscope.~A tele-visit will be schedule a day prior to the patient's regularly scheduled clinic visit. Tele-visit elements will include interim medical history by the parent and patient, and weight, height, vital signs, digital cardiac auscultation, and home echo, all obtained by the parent. Two MFS physicians, following our routine MFS care protocol, will administer either the tele-visit or on-site clinic visit, masked to the findings of the other."
224159801|NCT00493194|DRUG|sirolimus|
224159802|NCT00493194|DRUG|cyclosporine|
224159803|NCT00493194|DRUG|daclizumab|
224159804|NCT02671760|DRUG|SM-1|3-drug combination product containing 50 mg diphenhydramine, 5 mg zolpidem and 0.5 mg lorazepam
224159805|NCT02671760|DRUG|Comparator|2-drug combination comprised of 5 mg zolpidem and 0.5 mg lorazepam
224159806|NCT02671760|DRUG|Placebo|Placebo
224159807|NCT00138229|BIOLOGICAL|aldesleukin|
224159808|NCT00138229|BIOLOGICAL|filgrastim|
224159809|NCT00138229|BIOLOGICAL|therapeutic autologous lymphocytes|
224159810|NCT00138229|DRUG|cyclophosphamide|
224159811|NCT00138229|DRUG|fludarabine phosphate|
224159812|NCT04734769|OTHER|Collect retrospectively clinical data on reproductive outcomes|Collect retrospectively clinical data on reproductive outcomes
224159813|NCT00876486|DRUG|Genexol-PM®|Genexol-PM® 260mg/m2, intravenous infusion over 3 hours, every 3 weeks
224159814|NCT00876486|DRUG|Genexol®|Genexol® 175mg/m2, intravenous infusion over 3 hours, every 3 weeks
223470904|NCT05231889|DEVICE|Silverway guidewire|The Silverway guidewire is a newly developed guidewire to overcome the problems the Radifocus guidewire has
223470905|NCT05231889|DEVICE|Radifocus guidewire|The Radifocus guidewire is a hydrophilic coated guidewire that is used when a standard J-tip guidewire does not cross a vascular anomaly
223470906|NCT01814007|DEVICE|The Zeltiq CoolSculpting System|Non-invasive cooling is applied to the treatment area with a defined cooling rate and duration.
224159815|NCT03678818|OTHER|Medium Supplemented with Latrunculin A|A medium with in-house supplementation of Latrunculin A to decrease oocyte degeneration after ICSI and improve the survival rate
224159816|NCT06034912|DEVICE|Low-Intensity Red Light Therapy|myopia and amblyopia comprehensive treatment instrument red light feeding treatment
223470907|NCT02670369|BEHAVIORAL|Sitting time prompt|Participants will receive a device that prompts them to take breaks from sitting approximately every 15-20 minutes.
223470908|NCT03940833|BIOLOGICAL|BCMA CAR-NK 92 cells|The subject will be observed for any side effects during this time and all the adverse events will be recorded.
223470909|NCT04178304|DRUG|Prolotherapy with 25% Dextrose|Intra-articular injection of 6mL of 25% dextrose Extra-articular injection at tender sites with 25% dextrose
223470910|NCT01265186|DEVICE|Bispectral Index|The Bispectral-Index is continuously recorded for up to 72 hours in the group of ventilated newborns. Every 15 minutes, a value that was generated by averaging the BIS values of the last 15 minutes will be recorded (automatically calculated by the software of the readout device). The Bispectral-Index is continuously recorded for a minimum of 4 hours in the controls.
224069204|NCT05829525|OTHER|Evaluation of sleep quality, sleep duration, heart rate and step count|Evaluation of sleep quality with the Pittsburgh Sleep Quality Index Evaluation of sleep duration, heart rate, and step count with the Fitbit® Inspire 2 (Fitbit, Inc., San Francisco, California, USA) Evaluation of quality of life with the Nottingham Health Profile
224069205|NCT04480281|DRUG|Lidocaine Iv|Patients in the Lidocaine group received a bolus of lidocaine 1% 1.5mg/kg at the induction of general anesthesia followed by a continuous infusion of lidocaine 1% 2mg/kg/h just before surgical incision and continued until 24h after the surgery
224069206|NCT04480281|DRUG|Normal Saline|Patients in Group Placebo received an equal bolus volume of normal saline solution at induction, and then a continuous infusion started before surgical incision and maintained up until 24h postoperatively
224069207|NCT05762328|BEHAVIORAL|Reminders to the assistant clinicians of the need to adhere to clinical guidelines regarding the duration of antibiotic treatment community-acquired pneumonia|Automatic reminders through pop-up windows in the computerized prescription software, reminding the clinician responsible for each patient of the need to adhere to clinical guidelines regarding the duration of antibiotic treatment in patients with clinical stability
224159817|NCT01983618|PROCEDURE|Interscalene nerve block and catheter|
224159818|NCT01983618|PROCEDURE|Interscalene catheter|
224159819|NCT05911113|OTHER|sensory re-education training|the patients will receive sensory re-education training in the form of texture discrimination training, limb position sense and tactile object recognition
224159820|NCT05911113|OTHER|traditional treatment|the Patients in this group will receive traditional treatment in the form of proprioception neuromuscular facilitation (PNF) and graduated active and resisted wrist and hand muscle strengthening exercises.
223470911|NCT01265186|DEVICE|Amplitude-integrated EEG|A aEEG is recorded once daily for a minimum of four hours in the group of ventilated newborns. In Controls an aEEG is recorded once for a minimum of four hours.
223470912|NCT00545623|PROCEDURE|Acupuncture|acupuncture twice/week for the first 4 weeks and once/week for another 4 weeks
223470913|NCT00545623|BEHAVIORAL|Relaxation Response|listening to CDs with verbal instructions of techniques to elicit relaxation response
223470914|NCT00545623|OTHER|sham acupuncture|sham acupuncture twice/week for the first 4 weeks and once/week for another 4 weeks
223470915|NCT07073040|DEVICE|Cold atmospheric plasma (CAP)|"CAP therapy will be administered once daily for the first five days and then every other day thereafter, for a total of 13 sessions. Each session will last approximately 25 minutes, as recommended by the manufacturer. During treatment, the affected limb will be enclosed in a sterile treatment bag, sealed with medical adhesive tape. The CAP device will operate in two sequential modes: a disinfection mode delivering ozone-rich (O₃) plasma-activated gas for 20 minutes, followed by a healing mode delivering nitric oxide (NO)-rich plasma-activated gas for 5 minutes. All procedures will be performed in accordance with the manufacturer's instructions and the device's standard operating protocol."
223579472|NCT01930760|BEHAVIORAL|Standard Medical Training Educational|"Educational is modeled on the Theory of Planned Action, which proposes that unless people believe that their actions can have an effect on the desired outcome they have little incentive to act or persevere in the face of difficulties. Based on this theory we will be providing physicians with information on how to calculate, plot and track BMI and how this can be associated with identification of overweight children before they present with symptoms of obesity. This intervention will attempt to demonstrate that BMI calculating, plotting and tracking are useful diagnostic monitoring tools and that their actions may lead to more effective prevention and/or treatment.~The education intervention will not prescribe specific discussion initiation tools, although the participants will not be prevented from independently changing their communication behaviour."
223579473|NCT01930760|BEHAVIORAL|Motivational Interviewing behavioural|The behavioural intervention will incorporate specific Motivational Interviewing (MI) tools and information from a previously completed qualitative study with obese children (Obadia et al.). This study generated suggestions of how physicians can encourage children to think positively about making changes towards a healthier body weight. This intervention is designed to address physicians' lack of self-efficacy in communicating with children and their families about achieving a healthy body weight, and therefore would likely benefit from the input from children and the patient-centred theme of MI. It is based on the Trans-Theoretical Model and Stages of Change which postulates that people follow a step-wise progression towards change with specific constructs that need to be addressed before moving to the next step. These constructs are integral to the principles of MI
223579474|NCT05286372|DRUG|AMX0035|Proprietary formulation of sodium phenylbutyrate and taurursodiol
223579475|NCT04794660|DIAGNOSTIC_TEST|HPV DNA Test|Screening for HPV using a HPV DNA test
223743783|NCT05533853|OTHER|Posture corrective exercises|The exercises are of two types strengthening exercises and starching exercise ,). The strengthening exercises are to be done for 15 repetitions in 2 sets, Progression will be by increasing to 3 sets and adding 1 Kilogram of resistance in dumbbells exercises, the targeted muscles are teres minor, infraspinatus, medial and lower trapezius, rhomboids, and cervical flexor muscles. On the other hand, stretching exercises are to be hold for 30 seconds for 2 sets then progressed to 3 sets, the targeted muscles are pectoralis minor, sternocleidomastoid and levator scapulae.
223470916|NCT07073040|DEVICE|Sham Procedure|Participants in the placebo group will undergo a sham procedure, in which the electric field required for plasma generation will be disabled, so that no plasma will be produced. Only the operating sounds of the device will be simulated, ensuring blinding for both participants and clinical staff.
223470917|NCT07073040|OTHER|Successful infrapopliteal angioplasty|All patients will undergo successful infrapopliteal angioplasty, with less than 30% residual stenosis confirmed by digital subtraction angiography.
223470918|NCT07073391|DEVICE|Recording with laminar arrays|Part of the intervention is reliant on FDA approved laminar recording electrodes already available in the US. The other part will be an investigational device that is currently being considered by the FDA for an Investigational Device Exclusion.
223579476|NCT04794660|DIAGNOSTIC_TEST|VIA triage test|"VIA is a technique in which cervical neoplastic lesions are visually diagnosed after application of 3-5% acetic acid without using any magnification device.~After application of 3 - 5% acetic acid, using the naked eye, the cervix is examined for the presence of an aceto-white lesion located in the transformation zone. The results are classified as either positive or negative, inadequate or suspicion of cancer"
223579477|NCT04794660|PROCEDURE|Treatment by ablative treatment|Cryotherapy or Thermal Ablation are performed on the cervix.
223579478|NCT04794660|PROCEDURE|Colposcopy|Colposcopy visit are offered to women with non visible squamous columnar junction or ineligible for ablative treatment.
223579479|NCT00316524|BIOLOGICAL|MVA-BN® (IMVAMUNE)|1x 10E8\_TCID50
223579480|NCT00316524|BIOLOGICAL|Placebo|Tris-Buffer
223579481|NCT04945967|PROCEDURE|New Method|Physiological flexion in therapeutic positioning, oral stimulation, stimulation of synergistic movements, and stimulation for non-nutritive sucking by using special designed pacifier for premature infant.
224159821|NCT02566109|DIAGNOSTIC_TEST|Fast MRI|The fast MRI is a 10 minute MRI scan that will be used to determine if cardiovascular injury can be detected early while patients are receiving chemotherapy treatment.
224159822|NCT02938507|DRUG|Formulation 1 solabegron|
223470919|NCT07072000|RADIATION|standard CTV delineation|The anterior border of CTV2 is delineated at the posterior 1/3 of the nasal cavity.
223470920|NCT07072000|RADIATION|reduced CTV delineation|The anterior border of CTV2 is defined as 5 mm anterior to the posterior nasal cavity anteriorly from the choanae.
223470921|NCT07072793|DRUG|nirmatrelvir-ritonavir|Participants with confirmed diagnosis of Covid-19 and with mild to moderate symptoms at high-risk for progressing to severe disease
223470922|NCT07073092|DRUG|propolis|propolis medicated jelly candy.
223470923|NCT07073092|DRUG|chlorohexidine mouthwash and topical antifungal|chlorohexidine mouthwash and topical antifungal
223579482|NCT04945967|PROCEDURE|Conventional Method|Oral stimulation and non-nutritive sucking stimulation using usual pacifier.
224159823|NCT02938507|DRUG|Formulation 2 solabegron|
223470924|NCT07073443|BEHAVIORAL|Experimental: Memory Therapy Group|Evaluation of the Effect of Memory-Based Recall Therapy on the Cognitive Status, Psychological Flexibility, and Cognitive Flexibility of Elderly Individuals Diagnosed with Dementia
223470925|NCT07071987|PROCEDURE|Thread Embedding Acupuncture+Electroacupuncture|Thread embedding acupuncture will be administered at bilateral ST36, ST37, and PC6 acupoints at 2h after surgery and electroacupuncture at same acupoints at 2h 24h, 48h, and 72h after surgery. Absorbable polydioxanone sutures will be embedded into subcutaneous tissue using sterile embedding needles. All procedures will be conducted by licensed acupuncturists following standardized operating protocols.
223470926|NCT07071987|PROCEDURE|Electroacupuncture|Electroacupuncture will be performed at the same bilateral acupoints (ST36, ST37, and PC6)
223470927|NCT07073482|OTHER|Using stress ball|The participant will be told that the stress balls will be used for 15 minutes during the surgery, and the researcher will inform the participant when the 15 minutes are up and the patient will be asked to release the balls.
223579483|NCT02261233|PROCEDURE|Osteopathic manipulative treatment|Up to 4 sessions of osteopathic manipulative treatment (once per week)
223579484|NCT01375465|DEVICE|DIOR drug-eluting PTCA balloon|Treatment for 45 seconds with the DIOR balloon (3 µg/mm2 Paclitaxel concentration on balloon surface)
223579485|NCT00287794|DRUG|diazepam, melatonin|Administration of diazepam or such drugs may improve the sleep disturbance of patients with RA.
223579486|NCT01591863|DRUG|fidaxomicin|"6 months-5 years 11 months: oral suspension, 32 mg/kg/day with a maximum dose of 400 mg/day, divided into two doses, every 12 hours for 10 days.~6 years-17 years 11 months: tablets, 200 mg every 12 hours for 10 days."
223579487|NCT03056963|BEHAVIORAL|Positive Self-Reference Training|Participants in this intervention will review a brief psychoeducational video describing the training, and then be given cues every other day designed to practice skills. Participants will then practice visualizing and describing scenes based on these cues. This training will be focused on positive self-referent material.
223579488|NCT03056963|BEHAVIORAL|Neutral Training Control|Participants in this intervention will review a brief psychoeducational video describing the training, and then be given cues every other day designed to practice skills. Participants will then practice visualizing and describing scenes based on these cues. This training will be focused on neutral, non-self-referent material.
223579489|NCT00070681|PROCEDURE|Polysomnography|
223579490|NCT02282371|DRUG|Cetuximab|
223579491|NCT02282371|DRUG|BYL719|
223579492|NCT02282371|RADIATION|IMRT (Intensity-Modulated Radiation Therapy)|
223579493|NCT06002516|OTHER|RELIEF-pathway|"The personalized web-based education tool contains information on:~* Information of cause and symptoms of functional dyspepsia, irritable bowel syndrome and uncomplicated symptomatic cholecystolithiasis;~* Symptom checker based on the ROME III and ROME IV criteria;~* Red flags symptoms defined as direct or indirect signs of upper GI hemorrhage.~* Lifestyle adjustments to improve abdominal symptoms and quality of life.~* Information on effect of upper gastrointestinal endoscopy, colonoscopy and laparoscopic cholecystectomy.~After the web-based education tool is completed we will offer an additional visit at the Prevention and Lifestyle clinic, this is optional and not obligatory."
224159824|NCT05944159|BEHAVIORAL|Study Group|Study Group (n= 20) was recieved Temporomandibular joint ve soft tissue techniques. The techniques were applied 30 minutes once a week for 4 weeks by physiotherapist to the study group.
223579494|NCT01800318|DEVICE|NESAP|Electrical stimulation will be administered via the Empi Select, a standard TENS unit. To produce analgesia, small electrodes will be placed in treatment groups on the baby's legs at specific acupuncture points: ZuSanLi (ST36), SanYinJiao (SP6), Shen Mai (Bl60), and Shui Quan (KI3)46. StimCare electrodes with a gel base will be applied to the skin ; the skin will not be punctured by these procedures. A low continuous current will be provided with minimal voltage of 3.5 mA. The frequency will be delivered using a stimulation of 10 Hz for 10±1 minutes prior to the heelstick, with continued stimulation during and for 2 minutes after the heel stick. The display will be hidden from view to prevent the rater from being able to observe whether the unit is on.
223579495|NCT01800318|BEHAVIORAL|24% oral Sucrose|One ml 24% sucrose will be given approximately two minutes before the heel stick. Sucrose will be given via oral syringe along with a pacifier.
223579496|NCT01800318|DEVICE|Sham NESAP|Four electrodes will be placed on the infant's lower leg, but the TENS unit will not be turned on. The TENS unit will be covered and investigators will not know whether the TENS unit is turned on or not (sham NESAP).
223579497|NCT01800318|BEHAVIORAL|Oral water|For infants in the control group, 1 ml of water will be given via oral syringe along with a pacifier 2 minutes before the heel stick. Investigators will be blinded on whether the infants are receiving water or oral sucrose.
223579498|NCT00664326|DRUG|Regorafenib (Stivarga, BAY73-4506)|Patients will be treated with BAY73-4506 160 mg po qd for 3 weeks of every 4 week cycle (i.e., 3 weeks on, 1 week off). Patients will continue treatment with BAY73-4506 until disease progression, intolerable toxicity, or patient refusal to continue with the study or investigator decision to remove the patient from study.
223579499|NCT03612843|OTHER|Observational dry needle|No intervention provided by the study. Observation of any adverse events that occur surrounding dry needling by a physical therapist.
223579500|NCT04458831|DRUG|isatuximab SAR650984|"Pharmaceutical form: solution for infusion~Route of administration: intravenous"
223579501|NCT04458831|DRUG|Pomalidomide|Pharmaceutical form: oral
223579502|NCT04458831|DRUG|Dexamethasone|Pharmaceutical form: oral
223579503|NCT04458831|DRUG|Carfilzomib|Pharmaceutical form: solution for infusion
223579504|NCT04066348|BIOLOGICAL|Etanercept|To treat blast or noise induced tinnitus
224159825|NCT05944159|OTHER|Control Group|Routin medication therapy was applied to the control group. Both groups were asked to do the home exercise program twice a day consisting of vestibular exercise videos sent over whatss app. It was questioned with a phone call once a week whether the exercises were done or not.
224159826|NCT04203940|PROCEDURE|Cyanoacryale|mesh fixation was done using dots of N-butyl 2-cyanoacrylate tissue glue
224159827|NCT04203940|PROCEDURE|Suture|mesh fixation was done with polypropylene 2/0 sutures
224159828|NCT02167724|OTHER|Bucco-dental examination|
224159829|NCT02167724|OTHER|Blood sample|
224159830|NCT02167724|OTHER|Clinical and social questionnaire|
224159831|NCT05670249|PROCEDURE|suboccipital decompressive craniectomy|extensive bilateral suboccipital decompressive craniectomy with duraplasty
223470928|NCT07072663|OTHER|Baseline and 3-month follow-up|"At baseline and day 90 (±14) post-enrollment:~1. Collect clinical data;~2. Administer multiple scales to assess clinical symptom severity and neuropsychological status;~3. Perform cranial diffusion tensor imaging (DTI) to evaluate glymphatic function and white matter integrity;~4. Collect peripheral blood and cerebrospinal fluid (CSF) samples for biomarker level analysis."
223579505|NCT04066348|OTHER|Saline|Placebo
223579506|NCT06394869|DIAGNOSTIC_TEST|Cxbladder Triage Plus|Cxbladder Triage Plus is a lab developed, test that is using RNA and DNA biomarkers in the urine to assess the likelihood of the presence of urothelial carcinoma in the bladder.
223579507|NCT01829568|DRUG|Ibrutinib|Given PO
223579508|NCT01829568|DRUG|Lenalidomide|Given PO
223470929|NCT07072663|OTHER|Baseline|"At baseline:~1. Collect clinical data;~2. Assess intracranial and extracranial arterial and venous systems;~3. Administer multiple scales to assess neuropsychological status;~4. Perform cranial diffusion tensor imaging (DTI) to evaluate glymphatic function and white matter integrity;~5. Collect peripheral blood samples for biomarker level analysis."
223470930|NCT06754046|DEVICE|RP-MUS|a standard urethral sling placement for treatment of stress urinary incontinence
223470931|NCT06754046|PROCEDURE|PAHG|A standard 2 mL dose injection of bulkamid (order and number will be at the discretion of the surgeon) will be given. Patients undergoing PAHG will be given sham incisions consisting of superficial suprapubic epidermal scratches with a needle and fibrin glue at expected sling exit sites.
223470932|NCT06767072|BEHAVIORAL|Tailored Multichannel interventions|"To ensure the feasibility of the intervention, the intervention will be designed by an interdisciplinary team including academic researchers from different specialties (experts in the fields of community health, psychiatry health, and nutrition), as well as 3 research assistants.~The designing process for each individual in the intervention group involved the following 4 subsequent steps: (1) intervention nurses assess HBM constructs, which are used to collect data on each unique perception regarding overweight(Saghafi-Asl et al., 2020). (2) data are reviewed, identified, and summarized by the interdisciplinary team; (3) the interdisciplinary team then creates an intervention plan based on the summarized needs and (4) the intervention plan will be shared with the participant to ensure collaboration.~The intervention will adopt the strategies of the Diabetes Prevention Program (DDP) (The Diabetes Prevention Program (DPP), 1996)."
223470933|NCT06903208|DEVICE|STARMed VIVA Combo RF System|RFA is a kind of treatment that uses a long thin needle, called a probe, to melt the lipoma. After numbing the skin with a local anesthetic, using an ultrasound machine as a guide, the study surgeon will insert the probe into the center of the lipoma. The probe will then deliver heat to the lipoma, melting it. The ultrasound is a machine which bounces sound waves to create an image that the study doctor sees on a screen. These ultrasound images will help the study surgeon to accurately guide the probe to the correct location of the lipoma. Once the lipoma is melted, the study surgeon will aspirate any residual liquid out.
223470934|NCT06809725|DIAGNOSTIC_TEST|SPARK Cognitive Status Indicator (software support data collected via EEG)|"The SPARK Cognitive Status Indicator software (collected via EEG) is being validated to aid in the diagnosis of Alzheimer's disease in persons aged 65-90 with suspected cognitive impairment. The device, once validated, shall provide a clinician with a positive or negative output to indicate whether the subject's electroencephalogram (EEG) is consistent with EEGs of subjects diagnosed with Alzheimer's disease."
223470935|NCT06751576|DEVICE|Median LCS|End-to-end processing of chest LDCT DICOM images by an AI/ML tech-based SaMD to detect, localize, and characterize (assign a malignancy score) each detected pulmonary nodule. The output of the device is a DICOM File (Median LCS result report) summarizing results per patient.
223470936|NCT06055244|DRUG|Amantadine|Subjects will be give amantadine 100 mg twice daily.
223470937|NCT03218501|DRUG|SK-1405 high dose|SK-1405 high dose is to be administered orally once daily for 2 weeks
223470938|NCT03218501|DRUG|SK-1405 low dose|SK-1405 low dose is to be administered orally once daily for 2 weeks
223470939|NCT03218501|DRUG|Placebo|Placebo is to be administered orally once daily for 2 weeks
223470940|NCT01626170|OTHER|laboratory biomarker analysis|Correlative studies
223470941|NCT00025779|DRUG|methylphenidate|
223470942|NCT00025779|DRUG|guanfacine|
223470943|NCT01655901|BEHAVIORAL|Active video gaming|
223470944|NCT01655901|BEHAVIORAL|Passive video gaming|
223470945|NCT01655901|BEHAVIORAL|Resting|
223579509|NCT01829568|BIOLOGICAL|Rituximab|Given IV
223579510|NCT04521686|DRUG|LY3410738|Oral LY3410738
224159832|NCT01906476|BEHAVIORAL|Stepped Care|Participants will receive an Internet guided cognitive behavioral treatment (iCBT) with support from a telephone coach with the possibility of being stepped up to receiving telephone cognitive behavior therapy (T-CBT) with a therapist
224159833|NCT01906476|BEHAVIORAL|Telephone Cognitive Behavior Therapy|Participants will receive telephone-administered cognitive behavioral therapy (T-CBT).
224304039|NCT00039026|DRUG|Placebo|Placebo Lead In (0.02 mL) for 4 weeks / Placebo mcg (0.02 mL) for 4 weeks / Placebo (0.04 mL) for 26 weeks - All are subcutaneously injected twice daily
223579511|NCT04521686|DRUG|Gemcitabine|Intravenous gemcitabine
223579512|NCT04521686|DRUG|Cisplatin|Intravenous cisplatin
223579513|NCT04521686|DRUG|Durvalumab|Intravenous durvalumab
223579514|NCT05031065|RADIATION|Breast Cancer Radiotherapy|4000-4250 cGy in 15-16 daily fractions
223579515|NCT05627583|OTHER|Rehabilitation|Hospitalized patients with AN under treatment for rehabilitation
223579516|NCT05339984|PROCEDURE|Partial hepatectomy (open approach)|preoperative flow MRI + intraoperative measures of flow and pressures + pre/intra/post-procedural ultrasonographic flowmetry
223579517|NCT05339984|PROCEDURE|liver transplantation|preoperative flow MRI + intraoperative measures of flow and pressures + pre/intra/post-procedural ultrasonographic flowmetry
223579518|NCT05339984|PROCEDURE|Portal vein embolization|preoperative flow MRI + intraoperative measures of flow and pressures + pre/intra/post-procedural ultrasonographic flowmetry
223579519|NCT05048433|BEHAVIORAL|implementation strategy for active learning to promote physical activity|The experimental arm includes using a multifaceted implementation strategy to support the use of active learning approaches. The strategy will consist of a series of skills-based staff trainings, identifying program champions to help lead efforts within the school, establishing an audit and feedback system to monitor the use of active learning, and a reinforcement system to recognize staff who are successfully implementing.
223470946|NCT01220570|DRUG|Ridaforolimus + Dalotuzumab|Ridaforolimus (MK-8669) once daily for 5 consecutive days per week and Dalotuzumab (MK-0646) intravenously (IV) once weekly for 2 weeks
223470947|NCT01220570|DRUG|Ridaforolimus|Ridaforolimus 40 mg (once daily for 5 consecutive days per week) for 2 weeks, 10 mg enteric-coated tablets
223470948|NCT01220570|DRUG|Dalotuzumab|Dalotuzumab, intravenously (IV) at 10 mg/kg/week for 2 weeks
223470949|NCT01757015|DRUG|NVA237|NVA237 (50µg, o.d. via SDDPI) in the morning,
223470950|NCT01757015|DRUG|Placebo to NVA237|Placebo to NVA237
223470951|NCT00265434|DRUG|Pulmozyme|
223470952|NCT04292236|DIETARY_SUPPLEMENT|Lauric Acid, Perilla Oil and Diindolylmethane|Colonic release capsules containing lauric acid (2400mg), perilla oil (2100mg) and diinodlylmethane (500mg) given to volunteers 1 hour prior to standardised breakfast and lunch meal. Placebo group given cellulose capsules of same volume prior to standardised breakfast and lunch meal.
223470953|NCT04670601|DRUG|Flurbiprofen Test 8.75 MG|Subjects will be asked to swallow saliva before dosing. For each administration, subjects will move the lozenge around in their mouth, suck on the lozenge continually for 15 min and swallow saliva at any time during the product administration procedures, being very careful not to swallow the lozenge.
223470954|NCT04670601|DRUG|Flurbiprofen Reference 8.75 MG|Subjects will be asked to swallow saliva before dosing. For each administration, subjects will move the lozenge around in their mouth, suck on the lozenge continually for 15 min and swallow saliva at any time during the product administration procedures, being very careful not to swallow the lozenge.
223470955|NCT06349876|PROCEDURE|laparoscopic cholecystectomy|slandered laparoscopic cholecystectomy
223470956|NCT03571035|DIAGNOSTIC_TEST|Mandibular movements recordings by a mono vision system|To examine the mandible's movements, vision analysis was employed and performed with the digital camera which featured 1920 x 1080 resolution and was fixed on an aluminium extension arm attached to a headset worn by the subject.The camera was aligned parallel to the subject's face at a distance of 0.3 meters. The study used two 10 mm x 5 mm reference markers, which were accurately reproduced on the camera recorded images. In line, one marker was put on the medial cleft above the upper lip, and the other one was positioned below the first one in a straight line, in the middle of the chin. Then, the patient was asked to open maximally and close the mouth twice.To establish the mandible's trajectory, the line was drawn between the positions of the two markers to connect the two points. The line's parameters were calculated only during initial measurements and were constant throughout the study.
223470957|NCT02576899|BEHAVIORAL|Acceptance and Commitment Therapy for PTSD and Tobacco Use|ACT-PT is an acceptance and mindfulness-based smoking cessation treatment for Veterans with PTSD and tobacco dependence. ACT-PT specifically targets smoking cravings related to PTSD symptoms and memories of trauma, in addition to difficulties managing PTSD symptoms. negative affect and nicotine withdrawal symptoms during quit attempts. ACT-PT includes structured intervention components that guide Veterans to replace smoking as a coping strategy for PTSD symptoms and memories with alternative coping strategies (e.g., mindfulness, acceptance). And healthy living activities (e.g., engaging in work, expanding social networks, engaging in physical exercise) that are consistent with Veterans' values.
223470958|NCT02576899|BEHAVIORAL|Freedom From Smoking|The American Lung Association's Freedom from Smoking program (FFS) is a commonly used smoking cessation intervention that is used in community treatment programs.
223470959|NCT02316925|DIETARY_SUPPLEMENT|Setria glutathione supplement|500 mg/day capsule taken in the morning
223470960|NCT02316925|DIETARY_SUPPLEMENT|Crystalline Cellulose|500 mg/day capsule taken in the morning
223470961|NCT00922636|DRUG|LY2216684|Taken in tablet form QD po.
224159834|NCT01807767|DRUG|Everolimus, Myfortic and Tacrolimus|"Tacrolimus discontinued (within 8 weeks of initiation of everolimus conversion).~Everolimus 1mg BID started (targeted trough 6-12ng/mL). Patients must have an everolimus concentration between 6-12ng/mL before tacrolimus is discontinued.~Myfortic 360-720 mg BID"
224159835|NCT01807767|DRUG|Myfortic and Tacrolimus|Myfortic BID 360-720 mg Tacrolimus (5-12ng/mL)
224159836|NCT01993667|DRUG|Low Dose Acetazolamide|Administration of low dose acetazolamide
224159837|NCT01993667|DRUG|Normal Dose Acetazolamide|Administration of normal dose acetazolamide
223470962|NCT00922636|DRUG|Methylphenidate|Extended-release methylphenidate 18 mg/day to 54 mg/day, based on weight, QD po as a capsule for the 8-week double-blind treatment phase.
223470963|NCT00922636|DRUG|Placebo (tablet)|Placebo given as a tablet for LY2216684 blind QD po for the 8-week double-blind treatment phase, followed by 2 weeks in the taper phase.
223470964|NCT00922636|DRUG|Placebo (capsule)|Placebo given as a capsule for methylphenidate blind QD po for the 8-week double-blind treatment phase followed by 2 weeks in the taper phase.
223470965|NCT01861392|PROCEDURE|sensorio-motor training|
223470966|NCT04969289|BEHAVIORAL|Dr. Eric Digital Health Intervention|Dr. Eric is a user-informed, theory-based, digital health intervention that aims to improve adolescent male SRH. This ED-based intervention consists of two parts-an interactive, tailored app and 3 months of personalized, two-way text messaging. It is based on an evidence-based sexual health curriculum we developed using established behavioral theories, prior literature, input from key stakeholders, qualitative patient interviews, and our prior ED-based work.
223470967|NCT00824668|DRUG|biphasic insulin aspart 30|
223470968|NCT00824668|DRUG|insulin glargine|
223470969|NCT00824668|DRUG|insulin glulisine|
223470970|NCT05953727|OTHER|Low level laser therapy with proprioceptive stimulation|10 minutes of low level laser therapy and 10-15 minutes of proprioceptive stimulation and 10 minutes of heating pack. Assessment and data collection will be done at baseline (initial), after 4 weeks of treatment protocol and patients will be followed up for the further 2 weeks to notice and report any change in condition and health status.
223743784|NCT05533853|OTHER|Denneroll extension traction|The participants will be instructed to lie supine and keep their legs extended. Based on the apex of each participant's cervical curvature on the initial radiograph, the therapist will position the apex of the denneroll in one of two regions (mid cervical placement or lower cervical placement). The duration of the traction session will start at 2-3 min and increased 1 min per session until reaching the goal of 20 min, the traction will repeated three times per week for 6 weeks
223743785|NCT00102674|DRUG|cangrelor|
224159838|NCT03119441|DEVICE|Dental Water Jet|Dental Water Jet will be used by subjects to clean their teeth in the interproximal areas.
223470971|NCT05953727|OTHER|Low level laser therapy without proprioceptive stimulation|10 minutes of low level laser therapy and 10 minutes of heating pack. Assessment and data collection will be done at baseline (initial), after 4 weeks of treatment protocol and patients will be followed up for the further 2 weeks to notice and report any change in condition and health status.
223470972|NCT04377867|DRUG|Abatacept Injection [Orencia]|Patients on abatacept to control disease symptoms
223470973|NCT00054288|DRUG|gemcitabine hydrochloride|
223470974|NCT00054288|DRUG|irinotecan hydrochloride|
223470975|NCT00557466|DRUG|indacaterol|Indacaterol delivered by multiple dose dry powder inhaler (TWISTHALER® device).
223470976|NCT00557466|DRUG|formoterol|Formoterol delivered by oral inhalation via AEROLIZER® inhalation device.
223579520|NCT05048433|BEHAVIORAL|Usual Implementation support|Usual support consists of the potential to access general resources from the district wellness department. These resources include access to funds to send staff to external trainings and general guidance for how to use active learning approaches.
223579521|NCT06455878|BEHAVIORAL|Full usage of diet management app group and with the full usage of an intelligent weight scale|Subjects will use the fully functional diet management application and an intelligent weight scale with full function designed for obese heart failure patients to help them losed weight and invitigate some important composite cardiovascular endpoint.
223579522|NCT06455878|BEHAVIORAL|Limited usage of diet management app group and with the limited usage of an intelligent weight scale|Subjects will use the limited function diet management application and an intelligent weight scale with limited function designed for obese heart failure patients as a comparator.
223579523|NCT04066569|OTHER|Performed 3 diagnostic tests (2 OGTT tests with 75 g of Glucose and 1 placebo test with 375 mg of Aspartam|"After inclusion, the study will include the sequential realization of 3 dynamic GH secretion tests, separated by a period of 24 hours to 30 days. Each subject will have two OGTT tests (oral administration of 75 g of glucose in 100 mL of water) and a placebo test (oral administration of 375 mg of aspartame in 100 mL of water). The order of the three tests (2 OGTT and 1 placebo) in acromegalic patients will be randomized.~The tests will be performed under the same conditions"
224159839|NCT03119441|DEVICE|Dental Floss|Dental Floss will be used by subjects to clean their teeth in the interproximal areas.
224159840|NCT04220710|DIAGNOSTIC_TEST|DNA extraction and methylation detection|DNA extraction and methylation detection
224159841|NCT04777123|OTHER|sitting position|patients will be left seated for 2 minutes after subarachnoid injection
224159842|NCT03889964|OTHER|Measurement of lung function, electrocardiography, echocardiography and cardiopulmonary exercise testing|Measurement of lung function, electrocardiography, echocardiography and cardiopulmonary exercise testing
224159843|NCT01931150|DRUG|Topical Dapsone 5% Gel|
223470977|NCT00557466|DRUG|placebo to indacaterol|Placebo TWISTHALER® device
223470978|NCT00557466|DRUG|placebo to formoterol|Placebo AEROLIZER® device
223470979|NCT00557466|DRUG|short acting β2- agonist|100 μg / 90 μg salbutamol/albuterol Metered Dose Inhaler (MDI) or equivalent dose of Dry Powder Inhaler (DPI).
223743786|NCT04612647|OTHER|12-week FMS Intervention|4 sessions, no more than 3 hours per session covering 1) Sensory Integration, 2) Communication, 3) Aquatic Opportunities, and 4) Physical activity and Sports (during intervention)
224159844|NCT01931150|OTHER|Moisturizer|The moisturizer for the study will be Vanicream™ Lite Lotion.
224159845|NCT01931150|DRUG|oral antibiotics|
224159846|NCT05527106|DIETARY_SUPPLEMENT|Citicoline|Every subject randomized into this group have to take 2 sachets of Cebrolux 800 (362 mg of citicoline per day), every day, for 3 months.
224159847|NCT05527106|DIETARY_SUPPLEMENT|Docosahexaenoic Acid (DHA)|Every subject randomized into this group have to take 3 pills of Brudypio 1.5g (1050 mg of DHA per day), every day, for 3 months.
224159848|NCT05527106|DIETARY_SUPPLEMENT|Citicoline and Docosahexaenoic Acid (DHA)|Every subject randomized into this group have to take 2 sachets of Cebrolux 800 and 3 pills of Brudypio 1.5g per day, every day, for 3 months.
224159849|NCT05527106|DIETARY_SUPPLEMENT|Vitamin C|Every subject randomized into this group have to take 1 pills of Vitamin C (500 mg per day), every day, for 3 months.
224159850|NCT01248585|DRUG|Dexamethasone|2 x 4 mg dexamethasone (dex) tablets taken once daily for 5 days
224159851|NCT01248585|DRUG|Placebo|2 placebo tablets taken once daily for 5 days
224159852|NCT06382961|DRUG|Dexmedetomidine injection|Combining with 3 μg.kg-1 sufentanil, 3 μg.kg-1 dexmedetomidine is injected through intravenous patient controlled anesthesia pump in a 2 ml bolus with 20 minutes lock-out, and a background infusion rate of 2 ml per hour.
224159853|NCT06382961|DRUG|Sufentanil injection|3 μg.kg-1 sufentanil is injected through intravenous patient controlled anesthesia pump in a 2 ml bolus with 20 minutes lock-out, and a background infusion rate of 2 ml per hour.
224159854|NCT04822311|BEHAVIORAL|Experimental: Investigate the effects of an exercise intervention on retired APF players|Enrolled participants will perform a 18 months exercise intervention which involves 90 exercise rehabilitation training visits. In addition, participants will also be tested on various measures of health and function both at baseline (prior to intervention), at 6 months, 12 months, and 18 months (post intervention).
224159855|NCT05664555|DRUG|Fluorescein Sodium|Patients will receive Fluorescein Sodium 3mL (300mg) or 1mL (100mg) intravenously prior to fluorescein angiography.
224159856|NCT01570309|DRUG|Ergocalciferol|Oral capsule, 50,000 units, once a week, 12 weeks
224159857|NCT01570309|OTHER|Sugar pill|Oral capsule, once a week, 12 weeks
223470980|NCT00435344|BEHAVIORAL|Pediatric Practice-Based Smoking Intervention|
223470981|NCT03268343|DRUG|Cytisine|Cytisine 1.5 mg Film-Coated Tablets
223470982|NCT02626598|DEVICE|Blended Belotero|Belotero blended with 0.1 cc of 1% lidocaine with epinephrine per 1.0 cc Belotero will be injected to etched in fine facial lines
223470983|NCT00764101|BEHAVIORAL|Attentional Bias Modification|computerized training to reduce attentional bias in posttraumatic stress disorder
223470984|NCT02365350|PROCEDURE|STEINER-TAN Needle®|A purpose built new double lumen needle with little dead space.
223470985|NCT02365350|PROCEDURE|17 G single lumen needle|A conventional single lumen IVF aspiration needle.
223470986|NCT03925142|OTHER|Controlled healthy vegetarian diet|The controlled healthy vegetarian diet will follow the Dietary Guidelines for American's recommendations. All foods and beverages will be provided during intervention to achieve the desired eating pattern.
223470987|NCT03925142|OTHER|Controlled beef diet|The controlled beef diet will incorporate various cuts of lean unprocessed red meat into the healthy vegetarian eating pattern, as approved by the American Heart Association's Food Certification Program. The beef diet will isocalorically replace starchy vegetables and/or refined grains with 6 oz. of beef/day for five weeks.
223579524|NCT04066569|OTHER|Performed 2 diagnostic tests (2 OGTT tests with 75g of Glucose)|"After inclusion, the study will include the sequential realization of 2 dynamic GH secretion tests, separated by a period of 24 hours to 30 days. Each subject will have two OGTT tests (oral administration of 75 g of glucose in 100 mL of water).~The tests will be performed under the same conditions (fasting, semi-recumbent position, start of the test at 9 am) and will include a measurement of blood glucose, GH, insulinemia at -15, 0, 30, 60, 90, 120 min after ingestion of glucose or placebo."
223579525|NCT05324020|BEHAVIORAL|Medication adherence eHealth intervention|"The eHealth intervention consists a Medication Event Monitoring Systems (MEMS®) Helping Hand and MEMS Adherence Software application. The eHealth intervention will support BCS to adhere to their OHT (i) by alerting them to take their OHT, and (ii) by allowing patient-physician communication.~The eHealth intervention comprises a questionnaire that should be filled-out weekly and that informs about the presence and severity of side effects. These data are collected in real-time and monitored on a weekly basis by the clinical research nurse (CRN) in charge of the study. In case of an alert, meaning recurrent non-adherence and/or reporting of side-effects, the CRN will contact the breast cancer nurse (BCN) in charge of the patient. Thus the BCN will contact the patient by phone to check on their health status and together define the future procedures (behavioral strategies)."
223579526|NCT02546089|OTHER|Autologous Blood Injection|ultrasound-guided autologous blood injection procedure
223579527|NCT02546089|OTHER|Structured rehabilitation programme|(this intervention is given to patients in both arms of the study) - a standardised structured rehabilitation programme of home exercises that the patient is instructed on how to start, and how to progress during the study period
223579528|NCT02546089|OTHER|dry needling injection|(this intervention is given to patients in both arms of the study) - ultrasound-guided dry needling injection performed under ultrasound guidance
223579529|NCT01266317|DRUG|Combined Plasma Exchange (PEX), Rituximab, and Corticosteroids|Standard Steroid Treatment, Plasma exchange will consist of 1.5x estimated plasma volume exchanges, Rituximab
223579530|NCT00296153|DRUG|Omega-3-acid ethyl esters 90|Omacor capsule 1000mg x 4 per day. Duration 12 weeks
223579531|NCT01940536|DRUG|Tranexamic Acid|antifibrinolytic
223579532|NCT01940536|DRUG|Placebo|Placebo
223579533|NCT00490776|DRUG|Panobinostat|Panobinostat, 20 mg, hard gelatin capsules, orally, thrice weekly.
223579534|NCT03591172|DRUG|Propolis|Using propolis as a final irrigation in revascularization
223579535|NCT03591172|DRUG|Nano-propolis|Using Nano-propolis as a final irrigation in revasculariztion
223579536|NCT03591172|DRUG|saline|Using saline as a final irrigation in revasculariztion
223579537|NCT02886871|BEHAVIORAL|Step Goal Delivery by Smartphone|
223579538|NCT02975726|DEVICE|Peritoneal Dialysis Catheter|Peritoneal dialysis catheter insertion in order to drain access fluid within the belly for patients with liver cirrhosis and refractory ascites.
223579539|NCT02975726|PROCEDURE|Large Volume Paracentesis|Insertion of a needle into the peritoneal cavity where ascites accumulates, then attaching the needle to a collection system that drains the ascites by gravity. This procedure is part of the standard care for the treatment of refractory ascites.
223579540|NCT02975726|BIOLOGICAL|25% Human Serum Albumin injection|Patients will be given Human Serum Albumin after the initial drain of ascites fluid: 100cc for 5-10L drainage, 200cc for 10-15L drainage.
223579541|NCT02975726|PROCEDURE|Bloodwork|Monthly bloodwork will be done as part of usual standard of care.
223579542|NCT04964596|DIAGNOSTIC_TEST|colonoscopy|colonoscopy
224159858|NCT03825497|OTHER|Promotion of activity during and after hospitalization|1\) a welcome folder encouraging physical activity; 2) encouragement to use a walk path established in the ward; 3) encouragement to use posters containing exercise suggestions;4) prescription of a walk-plan for in-hospital use; 5) encouragement to pick up clothes and beverages by oneself; 6) prescription of a walk-plan at discharge for at home use 7) follow-up on walk plan after discharge by municipality
223470988|NCT01799447|BEHAVIORAL|Early intervention|Interventions by health visitors with 18 months training in the Marte Meo method in order to promote relations between parents and infants.
223470989|NCT00236054|DRUG|Gabitril|
223470990|NCT01251952|DRUG|Denileukin Diftitox (Ontak)|"After receiving their stem cell transplant on Day 0, participants will receive study agent via a 30 minute infusion. Participants will also receive a 30 minute infusion of study agent on Day 21.~Follow-up visits for clinical assessment, blood draws for routine clinical laboratory studies and for immuno-correlative studies will also take place on days 42, 90, 180 and 360."
223579543|NCT04964596|DIAGNOSTIC_TEST|FIT test|faecal immunochemical test
223579544|NCT04964596|DIAGNOSTIC_TEST|CT colonography|noninvasive medical imaging technique that uses computed tomography to visualize the interior of the colon and rectum especially to screen for polyps or cancerous growths
223579545|NCT02937766|DRUG|Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL)|
224159859|NCT01399840|DRUG|BMN 673|Oral capsule with multiple dosage forms given once daily
224159860|NCT01024101|DRUG|Paclitaxel|Solution, IV, 100 mg/m², Weekly for 6 of 7 weeks, until disease progression or unacceptable toxicity became apparent
223470991|NCT02797834|PROCEDURE|Endometrial fluid collection|
223470992|NCT05598060|RADIATION|Neoadjuvant stereotactic body radiation therapy (Multiple ascending dose) followed by hepatectomy for centrally located hepatocellular carcinoma.|Neoadjuvant stereotactic body radiation therapy (Multiple ascending dose) followed by hepatectomy for centrally located hepatocellular carcinoma.
223470993|NCT00680329|DRUG|Travoprost 0.004%/timolol 0.05% fixed combination eye drops (DuoTrav)|One drop in study eye(s) once daily in the evening for four months
223579546|NCT02937766|DRUG|Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL)|
223743787|NCT04612647|BEHAVIORAL|Physical Activities & Activity Booklets|expected to engage in physical activity at least 3 hours per week
223743788|NCT00275210|DRUG|Oxaliplatin (SR96669)|
223470994|NCT00680329|DEVICE|Travalert Dosing Aid|Approved device used with DuoTrav and intended to provide an objective system for quantifying dosing and improving patient adherence
223470995|NCT01726296|OTHER|educational intervention|Complete an educational intervention based on NCCN guidelines and disease-specific issues related to survivorship care
223470996|NCT01726296|OTHER|medical chart review|Complete patient medical chart audit
223470997|NCT06524388|DEVICE|adaptive cognitive training|The intervention was computerized, multi-domain, adaptive cognitive training. Training areas include processing speed, attention, perception, long-term memory, working memory, computation, executive control, reasoning, and problem-solving. Embedded in the Adaptive Cognitive training application is an adaptive algorithm that will help provide each participant with a cognitive training task at the right level of difficulty based on their profile and real-time performance.
223470998|NCT06524388|DEVICE|placebo cognitive training|Participants received cognitive training tasks of fixed difficulty.
223470999|NCT01571960|BIOLOGICAL|GEO-D03 DNA vaccine|Either a 0.3-mg (Group 1: study vaccine) or 3-mg dose (Groups 2 and 3: study vaccine) administered as a 1-mL IM injection into the deltoid
223471000|NCT01571960|BIOLOGICAL|MVA/HIV62B (MVA62B) vaccine|1 x 10\^8-TCID50 dose of MVA62B vaccine, administered as a 1-mL IM injection into the deltoid
223471001|NCT01571960|BIOLOGICAL|Placebo for GEO-D03 DNA|Administered as a 1-mL IM injection into the deltoid
223471002|NCT01571960|BIOLOGICAL|Placebo for MVA62B:|Administered as a 1-mL IM injection into the deltoid
223471003|NCT05173077|PROCEDURE|Identification of specific VOCs in CRC tissue surgery material|Paired tissue samples will be taken during surgery for CRC. Tissue material from the same patient will be obtained from the cancerous tissue as well as from normal resected material without malignant infiltration. Minimum of 100 mg of each tissue per sample will be obtained. To compare the emission of VOCs in the CRC tissue surgery material to the emissions from normal tissue by GC-MS in a reasonable number of cancer cases.
223471004|NCT05173077|OTHER|Secondary validation study in general CRC screening settings|"Altogether at least 1000 individuals relatively healthy 40-64 years old population-based collected individuals will get recruited. Breath samples will be collected by asking the study subjects to breath into hybrid breath analyser.~To exclude significant colorectal lesions, laboratory-based FIT testing will be offered to the population cohort group for faecal occult blood in faeces. Serum and plasma samples will also be obtained to have them available if additional testing will be required. Individuals with a FIT test value over the cut-off value (\>10 microg/g faeces) will be invited to colonoscopy. The data analysis procedures and classification models will be tested in this general population and cross-checked against FIT and colonoscopy results."
223471005|NCT05173077|DEVICE|Breath sampling for VOC detection|Breath sampling will be performed by using a hybrid sensor device and or GC-MS analysis (by collecting breath samples in adsorbent tubes). Strict requirements for subjects will be imposed prior to the breath sampling to standardise the breath sampling and to limit the influence of confounding factors.
223471006|NCT05173077|OTHER|Blood sample collection|Serum, plasma sampling for group description and stratification.
223471007|NCT05173077|DIAGNOSTIC_TEST|Microbiota testing|Faecal samples for microbiota testing.
223471008|NCT05173077|DIAGNOSTIC_TEST|Colonoscopy|Colonoscopy will be used only according to the clinical indications.
223471009|NCT02486692|OTHER|AboutFace Website|AboutFace is an informational website that utilizes digital storytelling to describe PTSD symptoms and different treatments for PTSD.
223471010|NCT00496769|DRUG|Apixaban|Tablets, oral, 5 mg (2.5 mg in patients meeting any 2 of the following criteria: 80 years of age and older, weight of 60 kilograms or less, and a serum creatinine level of 1.5 mg/dL or higher), twice daily, up to 156 weeks
223471011|NCT00496769|DRUG|Acetylsalicylic acid|Tablets, oral, 81-324 mg, once daily, up to 156 weeks
224159861|NCT04165304|DIETARY_SUPPLEMENT|sugar reduction|sugar reduction in the offered drinks
223471012|NCT00699777|DRUG|Risedronate|1 risedronate 150 mg tablet administered orally
223471013|NCT00699777|DRUG|Risedronate|2 risedronate 75 mg tablets administered as a single oral dose
223471014|NCT02344329|DEVICE|Topical wound dressing|Topical Wound Dressing
223471015|NCT02344329|BIOLOGICAL|Human Amnion Allograft|Change dressing every two to three weeks and TCC-EZ is changed weekly for 12 or until healed.
223471016|NCT02344329|OTHER|usual wound care|assessment, wound cleansing, debridement, moist wound environment, and off-loading
223471017|NCT02477176|OTHER|Discectomy|Lumbar discectomy
224159862|NCT06391567|OTHER|There was no intervention in this study.|There was no intervention in this study.
224159863|NCT02949713|BEHAVIORAL|Text messaging-motivational interviewing|Interactive weekly mobile phone text messaging plus prospective motivational interviews
224159864|NCT00741806|BIOLOGICAL|GHB04L1|single dose intranasal administration of GHB04L1
224159865|NCT00741806|OTHER|Placebo|SPGN buffer
223471018|NCT03278574|PROCEDURE|Mitral valve repair|Mitral valve repair with standard technique: resection of prolapsed leaflet and/or artificial neochordae implantation
223471019|NCT03278574|DEVICE|Ring annuloplasty with posterior band|Mitral valve annuloplasty using Cardiamed (Penza, Russia) flexible posterior annuloplasty band
223471020|NCT03278574|DEVICE|Ring annuloplasty with complete ring|Mitral valve annuloplasty using Cardiamed (Penza, Russia) complete semirigid ring
223471021|NCT00653874|DEVICE|BiliChek (jaundice assessment)|assessment of jaundice was done by either transcutaneous bilirubinometry (TcB) method or by clinical assessment of bilirubin (CaB)
223471022|NCT00653874|PROCEDURE|Transcutaneous bilirubinometry (TcB)|transcutaneous bilirubinometry was used for jaundice assessment in healthy term and near-term jaundiced neonates between 24 to 168 hours of life
223471023|NCT00653874|OTHER|Clinical asessment of bilirubin (CaB)|Clinical assessment of bilirubin (CaB) was used for jaundice assessment in healthy term and near-term jaundiced neonates between 24 to 168 hours of life
223471024|NCT05511857|BEHAVIORAL|Self-distancing, third-person self-talk.|The participants will engage in self-distancing, third-person self-talk.
223471025|NCT05511857|BEHAVIORAL|Self-immersed, first-person self-talk.|The participants will engage in self-immersed, first-person self-talk.
223471026|NCT05511857|BEHAVIORAL|Distraction|The participants will engage in a distraction task.
224159866|NCT02820688|DRUG|Bupivacaine 0.25%|
224159867|NCT02820688|DRUG|Prilocaine 1%|
224159868|NCT02820688|PROCEDURE|Infraclavicular Nerve Block|Ultrasound guided infraclavicular nerve block
223471027|NCT06102317|OTHER|nursing consultancy with smartphone support|In the study, mobile application will be installed on the phones of the mothers in the initiative group and individual information will be provided about how the patients will use the smartphone application. . Information will be provided to patients for subsequent follow-ups. After the application is started to be used, notifications of the applications developed in Smart Mobile for the disease management process will be made to the mothers of the Initiative Group every two weeks for six months. In addition, the Initiative Group will continue to receive standard care practices such as examinations, examinations, tests, treatment, medical care and rehabilitation offered by the Home Health Services unit.
223471028|NCT05229328|DIAGNOSTIC_TEST|Peripheral blood test|Collect peripheral blood to separate and extract plasma, PBMC, and plasma exosomal miRNA, and sequence to find indicators related to disease deterioration and prognosis
223471029|NCT01183364|DRUG|STA-9090 (ganetespib) with Docetaxel|One treatment cycle will consist of weekly treatments for 2 weeks followed by a 1-week rest period. Treatment cycles will be repeated every 3 weeks. STA-9090 will be administered on Days 1 and 8 of each cycle and docetaxel will be administered on Day 1 of each cycle. Each agent will be administered as a separate 1-hour intravenous infusion.
223471030|NCT01477801|DRUG|CHOLECALCIFEROL|"Standard guideline based therapy plus cholecalciferol:~Loading dose 300.000 U then 50.000 U every month for six months"
223471031|NCT01477801|DRUG|PLACEBO|Standard guideline based therapy plus placebo
223471032|NCT03482050|BIOLOGICAL|AstroRx|Astrocytes derived from human embryonic stem cells
223471033|NCT00607243|BIOLOGICAL|smallpox vaccine CJ-50300|Conventional dose group: 2.5 x 10 5 pfu/dose Diluted dose group:2.5 x 10 4 pfu/dose
224159869|NCT02820688|DRUG|Bupivacaine 0.167%|
223471034|NCT06238180|DEVICE|VIOSync-SPI|The intervention in this study involves an AI-driven clinical decision-support system, VIOSync Sepsis Prediction Index (SPI), designed for the early prediction of sepsis in patients undergoing abdominal surgery. VIOSync integrates data from PPG-based wearable wireless devices that monitor vital signs, electronic health records, and laboratory tests. The AI model analyzes this multimodal data to proactively identify signs of sepsis providing an early warning score, the SPI, to clinicians. The distinguishing feature of this intervention is its use of real-time data and advanced AI analytics to enhance early sepsis detection, aiming to improve patient outcomes in postoperative care.
224159870|NCT02820688|DRUG|Bupivacaine 0.125%|
224159871|NCT02820688|DRUG|Prilocaine 0.66%|
223579547|NCT06583551|DRUG|Botulinum toxin|Botulinum toxin, produced by Clostridium botulinum, is a neurotoxin. Presently, there are 7 serotypes (A, B, C1, D, E, F, G). Botulinum neurotoxin A (BoNT-A) is the most frequently used variant in clinical applications.
224159872|NCT02820688|DRUG|Prilocaine 0.5%|
223471035|NCT02224625|DRUG|2% CHG Cloth solution|Investigational CHG
223471036|NCT02224625|DEVICE|Vehicle Cloth|Excipients from CHG cloth only
223471037|NCT02224625|DRUG|Active Comparator|Active comparator
223471038|NCT02224625|OTHER|Saline|Negative control
223471039|NCT02224625|OTHER|SLS|Provides a slight irritation for a positive control
223471040|NCT02118103|PROCEDURE|Spinal Manipulation|Lumbar spinal manipulation
223471041|NCT00230035|PROCEDURE|Leukapheresis|
223471042|NCT00230035|PROCEDURE|Non-myeloablative high dose immunosuppressive therapy conditioning (HDIT)|
223471043|NCT00230035|PROCEDURE|Autologous CD34+HPC transplantation (HSCT)|
223579548|NCT06583551|PROCEDURE|Dry needling|Dry needling (DN) is a type of acupuncture therapy, that uses a thin filiform needle to penetrate the skin and stimulate underlying myofascial trigger points (MTrPs) and muscular, and connective tissues.
224159873|NCT02820688|DEVICE|Ultrasound|All nerve blocks will be performed with ultrasound guidance
224159874|NCT01394367|OTHER|respiratory and exercise therapy|Conventional therapy with diet, massage, relaxation baths, plus easy strolls specific respiratory and physical therapy plus mental walking training
223471044|NCT00230035|PROCEDURE|Plasmapheresis|
223471045|NCT00230035|DRUG|Rabbit anti-thymocyte globulin|
223471046|NCT00230035|DRUG|Methylprednisolone|
223471047|NCT00230035|DRUG|Growth colony stimulating factor (G-CSF)|
223471048|NCT00230035|DRUG|Corticosteroids|
224159875|NCT01313468|BEHAVIORAL|1 x 4 minute interval|1 x 4 minutes of high intensity intervals at 90-95% of maximal heart rate
224159876|NCT01313468|BEHAVIORAL|4 x 4 minutes Intervals|4 x 4 minutes of high intensity intervals at 90-95% of maximal heart rate separated by 3 minutes of active brakes in between at 70% of maximal heart rate.
224159877|NCT01313468|BEHAVIORAL|Moderate continuous Training|47 minutes of Moderate continuous Training
224159878|NCT01766544|OTHER|Standard Practice Group (SPG)|The investigators planned to send a copy of the latest Canadian asthma and COPD guidelines to all PCPs in the Standard Practice (SP) Group at the start of the study period, by mail. No other intervention would be offered during the study, but upon study completion, all control participants would be offered the educational intervention received by the Targeted Intervention Strategy (TIS) Group.
224159879|NCT01766544|OTHER|TISG|interactive educational interventions, expert mentorship and practice-based tools. 3 interactive sessions, 2 of which would be live meetings of 3h each, and the third hour teleconference.
224159880|NCT02390960|DRUG|Sildenafil Cream|Patients will be instructed to apply pre-weighed SST-6006 to the non-erect penile skin area at the time of dosing. Patients will then massage the cream into the penile shaft and glans for a maximum of 3 minutes.
224159881|NCT02390960|DRUG|Placebo Cream|Patients will be instructed to apply the pre-weighed placebo cream to the non-erect penile skin area at the time of dosing. Patients will then massage the cream into the penile shaft and glans for a maximum of 3 minutes.
224159882|NCT02390960|DEVICE|Penile Plethysmography (RigiScan)|During each dosing period, penile plethysmography will be utilized to evaluate efficacy of SST-6006 verses placebo cream. Each plethysmography session will be approximately 75 minutes.This includes a 15 minute 'baseline' period where patients are told to remain in the flaccid state and 60 minutes during which time patients will watch a series of erotic videos.
223471049|NCT00230035|DRUG|Mycophenolate mofetil|
223471050|NCT00230035|DRUG|Azathioprine|
223471051|NCT00230035|DRUG|Intravenous immunoglobulin|
223579549|NCT06583551|DRUG|Myorel|Metacarbamol (380mg), paracetamol (300mg)
223743789|NCT02916615|OTHER|High nitrate vegetables|vegetables naturally high in nitrate
224304040|NCT06035263|OTHER|FUNCTIONAL REEDUCATION AND ENVIRONMENTAL ADAPTATION PROGRAMME|the prescription of reeducation in activities of daily living and the prescription of assistive devices and environmental adaptations, for one month from the first baseline assessment at the time of hospital discharge.
224304041|NCT06035263|OTHER|Health education programme:|"instructions and recommendations for maintaining an active and healthy life will be given as part of a health education programme. These will focus on the benefits of an active lifestyle and general guidelines to follow, as well as the importance of nutrition and hydration in a healthy lifestyle.~They will receive the dossier of instructions and recommendations of the health education programme, as in the experimental group."
224304042|NCT04053049|OTHER|Diet|Meals composed of either high fat vs. high carbohydrate and semi-solid vs. solid
224304043|NCT06168279|PROCEDURE|hand occlusal articulation|The upper and lower cast will be scanning separately then will be articulated manually in the final occlusion then scanned after that the stl file will insert to the software to complete virtual planning of orthognathic surgery to made splints that will be using in the operation
224304044|NCT06168279|PROCEDURE|digital occlusal articulation|Both upper and lower casts will be scanning separately, then the 3D casts will be articulating by using 3d virtual program to obtained the final occlusion after that the stl file will insert to the software to complete virtual planning of orthognathic surgery to made splints that will be using in the operation
224304045|NCT02906930|DRUG|semaglutide|Oral administration once daily.
224304046|NCT02906930|DRUG|placebo|Oral administration once daily.
223471052|NCT00230035|DRUG|Methotrexate|
223471053|NCT00230035|DRUG|Rituximab|
223471054|NCT00230035|DRUG|Leflunomide|
223471055|NCT01276158|PROCEDURE|Ultrasound|Ultrasound used to place arterial line
223471056|NCT01276158|PROCEDURE|Doppler|Doppler used to place arterial line
223579550|NCT06583551|PROCEDURE|Manual therapy|Manual therapy (MT) entails the use of the hands to apply a force with a therapeutic intent, including techniques such as massage, joint mobilization/manipulation, myofascial release, nerve manipulation, strain/counterstrain, and acupressure.
223579551|NCT06583408|OTHER|Automated Self-Administered 24-hour Dietary Assessment Tool (ASA24)|Subjects will complete the ASA food diary for 2 weekdays and 1 weekend day
224159883|NCT02788591|DRUG|Proton Pump Inhibitor (PPI) Therapy|Subject will take a proton pump inhibitor (PPI) of their choice (Omeprazole, Esomeprazole, Pantoprazole, or Lansoprazole) 2 times a day for 8 weeks.
224159884|NCT02788591|DRUG|Sucralfate|Subject will take Sucralfate 4 times a day for 8 weeks.
224304047|NCT04198636|DRUG|LY01011|LY01011 injection (120mg) by subcutaneous injection once on the first day subcutaneous injection of 120 mg (1.7 ml)only once
224304048|NCT04198636|DRUG|Xgeva 120 MG in 1.7 ML Injection|Xgeva® injection (120mg) by subcutaneous injection once on the first day subcutaneous injection of 120 mg (1.7 ml)only once
224304049|NCT03058419|DRUG|JNJ-54175446 150 mg|Subjects will receive JNJ-54175446 150 mg capsules orally (1\*100 mg + 1\*50 mg) under fasted conditions on Day 7, 9, 10 and 11.
224304050|NCT03058419|DRUG|JNJ-54175446 600 mg|Subjects will receive JNJ-54175446 600 mg (6\*100 mg capsules) orally on Day 8.
224304051|NCT03058419|DRUG|Midazolam 2 mg|Subjects will receive midazolam 2 mg oral emulsion \[2 (milligram per milliliter (mg/mL)\] as a drug cocktail on Day 1, 7 and 11.
223471057|NCT00048152|DRUG|Corticosteroids|As prescribed
223471058|NCT00048152|DRUG|Neoral|Low dose (target trough level 50-100ng/mL)
223471059|NCT00048152|DRUG|Neoral|Standard dose (target trough level 150-300ng/mL)
223471060|NCT00048152|DRUG|Zenapax|2mg/kg iv first dose, then 1mg/kg every 2 weeks
223471061|NCT00048152|DRUG|mycophenolate mofetil [CellCept]|1g po bid
224159885|NCT04006067|OTHER|changing surgical gloves|All the surgical team including surgeons, surgical assists and scrub technicians replaced their outer surgical gloves with a new pair of sterile gloves just prior to abdominal closure.
224159886|NCT00757367|DRUG|TI Inhalation Powder|1 60-U dose of TI Inhalation Powder before the bronchoscopy. Cohort 1 will undergo bronchoscopies at 30 minutes and again at 6 hours after the 60-U dose inhalation of TI Inhalation Powder. Cohort 2 bronchoscopies will occur at 4 hours and again at 8 hours after TI Inhalation Powder. The need to run and the timepoints for bronchoscopies for Cohort 3 will be determined based on the results from Cohort 1 and 2. All subjects will undergo 2 bronchoscopies at Visit 2.
223471062|NCT00697099|DRUG|Semuloparin sodium|"0.4 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml pre-filled syringe~Subcutaneous injection"
223471063|NCT00697099|DRUG|Enoxaparin sodium|"0.4 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml pre-filled syringe~Subcutaneous injection"
223471064|NCT00697099|DRUG|Placebo|"0.4 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml pre-filled syringe strictly identical in appearance but without active component~Subcutaneous injection"
223471065|NCT01988467|OTHER|exposure to second hand smoking|The duration of the exposure to second hand smoke both days was for 20 minutes within a 250mgr/m3 concentration box room. A smoking machine was used, which mimics the smoker (up to 6 breaths per minute in tobacco volume 80ml for each inhalation). The exposure was sometimes with closed mouth and others with closed nose in random sequence.
223579552|NCT06583408|OTHER|REVEAL Questionnaire|Subjects will complete the REVEAL questionnaire form. This form includes questions about current and past medical history, including reproductive history, lifestyle specifics, and assessment of current health status.
223579553|NCT06583811|DRUG|Remifentanil|to compare remifentanil and remimazolam to limit patient movement during long-eye surgeries under local anesthesia.
223579554|NCT06583785|OTHER|Black rice (Intervention)|210 g of cooked black rice
223579555|NCT06583785|OTHER|Brown rice (Control)|210 g of cooked brown rice
223743790|NCT02916615|DIETARY_SUPPLEMENT|Low nitrate vegetables + nitrate|pill containing KNO3
224159887|NCT05154565|BEHAVIORAL|Guided meditation|App-based guided meditation intervention through Headspace. This can be accessed through various mobile devices.
224304052|NCT03058419|DRUG|Warfarin 10 mg|Subjects will receive warfarin 10 mg tablets (2\*5 mg) orally as a drug cocktail on Day 1, 7 and 11.
224304053|NCT03058419|DRUG|Caffeine 50 mg|Subjects will receive caffeine 50 mg tablet (1\*50 mg) orally as a drug cocktail on Day 1, 7 and 11.
224304054|NCT03058419|DRUG|Dextromethorphan 30 mg|Subjects will receive dextromethorphan 30 mg capsule (1\*30 mg) orally as a drug cocktail on Day 1, 7 and 11.
223471066|NCT02812186|PROCEDURE|Deep to Moderate NMB|"Rocuronium infusion will be paused and the Train of Four (TOF) monitor will be set to every 1-2 min. Once the patient has achieved a moderate NMB state (one to two twitches), the infusion of the muscle relaxant will be resumed at a low dose to maintain the patient at this level of blockade."
224159888|NCT00113412|DRUG|SP01A|
224159889|NCT05817981|OTHER|Semi-structured interview|Before the questionnaire survey, 30 cancer survivors and 30 clinical oncology medical staff will respectively participate in different semi-structured interview individually.
224159890|NCT05817981|OTHER|Questionnaires set|Except for participants who participated in semi-structured interviews, other cancer survivors who met the inclusion criteria will be asked to respond to the demographic information sheet, the cancer related sexual and reproductive health knowledge and attitudes questionnaire, and the access methods and demand for cancer-related fertility information.
224159891|NCT00750217|DRUG|Buprenorphine patch and sublingual tablets|"Buprenorphine patch: 35 micro grams per hour 12 to 48 hours after last methadone intake.~Buprenorphine sublingual tablets: 2mg 48 and 60 hours after last methadone intake; 8mg 72 and 84 hours after last methadone intake; 8mg 96, 102 and 109 hours after last methadone intake."
224159892|NCT01390038|DEVICE|Simpliciti™ Shoulder System|Total shoulder arthroplasty system
224159893|NCT04125303|BEHAVIORAL|brief motivational psychoeducational therapy|The brief motivational psychoeducational therapy (BMPT) it lasted an average of 90 min and followed the following structure: (i) brainstorming the concepts of health, lifestyle, and substance-use prevention; (ii) analysis of a work accident at an international rock group concert, which was used to generate (iii), a debate on consumer habits (30 min); (iv) discussion of the substance types and classifications known by the participants; (v) Prochaska and DiClemente's stages of change and (vi), the consequences of drug use (50 min); and finally, (vii) a true/false quiz used to discuss myths and beliefs about drugs (10 min).
224159894|NCT05198427|OTHER|review of medical patient file|"The outcome measure is the evolution of HPV related lesions between :~* favourable evolution including partial or total regression~* unfavourable evolution including non-evolution or aggravation or recurrence."
224159895|NCT01361880|BEHAVIORAL|Reduce Infant Mortality|The study's long term goal is to disseminate a new easily implemented and reproducible intervention that based on our previous research is culturally competent and provides a rationale for changing infant sleep position and sleep environment. This intervention if successful will quickly be disseminated and will be an important change to the system of newborn care; the resultant change in parental behavior would ultimately result in a reduction in sleep-related infant mortality rates thereby promoting healthy development.After written consent has been obtained, a brief survey about knowledge of and attitudes toward safe sleep position recommendations, current intent with regards to safe sleep recommendations, and demographics will be completed. Contact information will be obtained from participants to facilitate study follow-up at two weeks of infants birth 2-3 months and 5-6 months.
223471067|NCT02812186|PROCEDURE|Moderate to Deep NMB|"Rocuronium infusion will be increased in increments of 0.1-0.2 mg/kg/hr. and the TOF monitor will be set to every 1-2 min. Once the patient has no twitches and a PTC of 0-1 (deep NMB) the infusion will be adjusted to maintain the patient at this level of NMB."
223471068|NCT02812186|DRUG|Rocuronium|
224159896|NCT00300716|DRUG|Memantine|
224159897|NCT02468141|DRUG|SJDBT|Sipjeondaebo-tang
223471069|NCT02169440|DRUG|BIA 9-1067|BIA 9-1067 25 mg
223471070|NCT02169440|DRUG|Warfarin|Warfarin 25 mg
223471071|NCT04897386|DRUG|Duvalizumab|Pemetrexed 850 mg, IV, Day1; Platinum 50mg / m2, IV, day1, once every 3 weeks, duvalizumab treatment, 1500mg, day1, a total of 4 cycles, once every 3 weeks. 4 cycles in total
224159898|NCT02468141|DRUG|Placebo|Placebo
224304055|NCT03058419|DRUG|Bupropion 150 mg|Subjects will receive Bupropion 150 mg tablet (1\*150 mg) orally as a drug cocktail on Day 1, 7 and 11.
224159899|NCT01545414|BEHAVIORAL|ICBT|12 weeks of Internet-based Cognitive Behavioral Therapy with a focus on behavioral activation
224304056|NCT03058419|DRUG|Omeprazole 20 mg|Subjects will receive omeprazole 20 mg capsule (1\*20 mg) orally as a drug cocktail on Day 1, 7 and 11.
224304057|NCT03244943|PROCEDURE|Non surgical periodontal Treatment|The NSPT, which consisted of subgingival debridement - scaling and root planning (SRP) under local anesthesia. On average, the treatment of the entire oral cavity was completed within four sessions (sessions of 50 minutes). The SRP was performed by one experienced periodontist (KRVV) using Gracey curettes (Hu-Friedy MFG. Co. Inc., Chicago, IL, USA), ultra-sonic devices (Bob-Cat, Dentsply/Cavitron, Long Island City, NY, USA) and, if necessary, with multilaminated drills.
224304058|NCT02868918|DRUG|biodentine|tricalcium silicate cement used to replace the carious dentin
224304059|NCT02868918|DRUG|glass ionomer cement|high viscosity glass ionomer used as a base material
224304060|NCT02868918|DEVICE|DigoraH optium|digital Xray for follow up
223471072|NCT04702360|DRUG|ELX/TEZ/IVA|Fixed-dose combination tablet for oral administration.
223471073|NCT04702360|DRUG|IVA|IVA monotablet for oral administration.
223471074|NCT00327483|BEHAVIORAL|Internet based education software|
223471075|NCT03894995|OTHER|Installation of ventilation|The intervention is installation of a ventilating structure, in this case a window in the house roof.
223471076|NCT01299558|DRUG|fluticasone furoate//GW642444|Single inhaled dose of FF (800mcg)/GW642444M (100mcg) Inhalation Powder administered in the morning
223471077|NCT01299558|DRUG|fluticasone furoate|Single IV dose of FF (250mcg)
223471078|NCT01299558|DRUG|GW642444|Single IV dose of GW642444 (55mcg)
223471079|NCT02746835|OTHER|Exercise program for fall prevention|"Set of exercises to improve the following parameters:~balance, endurance, muscle strength, flexibility."
223471080|NCT00455286|DRUG|Methotrexate|
223471081|NCT00455286|DRUG|Methylprednisolone|
223471082|NCT00455286|DRUG|Temozolomide|
223471083|NCT02303665|OTHER|The dual therapy|TCM prescriptionⅡof cultivated emotion and assisted reproduction +auricular acupoint therapy
223471084|NCT02303665|OTHER|The triple therapy|TCM prescriptionⅡof cultivated emotion and assisted reproduction + auricular acupoint therapy+ retention enema of TCM
223743791|NCT02916615|OTHER|Low nitrate vegetables|vegetables naturally low in nitrate
223471085|NCT01614301|DRUG|dacarbazine (DTIC), Trofosfamide, Etoricoxib, Pioglitazone, Temsirolimus|"Dacarbazine (DTIC) 1000 mg/m2 day 1, every 3 weeks The total number of DTIC cycles should not exceed 6 cycles due to cumulative toxicity.~Temsirolimus: 15 or 25 mg iv weekly , week 1+.In the phase I part of the study the finally used dosis will be determined. Pioglitazone (Actos) 60 mg p.o. daily, day 1+. Etoricoxib (Arcoxia) 60 mg p.o. daily, day 1+. Trofosfamide (Ixoten) 50 mg p.o. thrice daily as metronomic angiostatically and immunomodulatory actingtherapy, day 1+. Treatment until disease progression or toxicity"
223579556|NCT06583421|BEHAVIORAL|4-week MVPA intervention|The 4-week MVPA intervention engaged in supervised aerobic exercise, resistance training and interesting sport for 60 minutes, 3 days/week (Monday, Wednesday and Friday). As shown in Table S1, participants completed four sessions including preparation module (15 min), training module (30 min), and relaxation module (15 min). Another aerobic module (15 min) was added in each Friday.
224159900|NCT01545414|BEHAVIORAL|ICONTROL|12 weeks of Internet-based treatment with a focus on relaxation training
223579557|NCT06584123|DIAGNOSTIC_TEST|18F-Fluoro-ethyl-tyrosine (FET) PET|18F-Fluoro-ethyl-tyrosine PET study of the pituitary
223579558|NCT06583772|DIAGNOSTIC_TEST|VR-based 9-hole peg test|The volunteers will first undergo a physical 9-hole peg test. After the physical test is completed, the VR-based 9-hole peg test will be performed.
223579559|NCT06584019|OTHER|Range Of Motion applied group|Range Of Motion was applied once a day for approximately 20 minutes for 5 days.
223579560|NCT02180841|DIETARY_SUPPLEMENT|Soy Protein Powder (25g/d)|Participants will consume 25g soy protein powder daily for a 6 week treatment period.
223579561|NCT02180841|DIETARY_SUPPLEMENT|Placebo|Participants will consume a placebo control powder containing 0g soy protein powder daily for a 6 week treatment period.
223579562|NCT02180841|DIETARY_SUPPLEMENT|Soy Protein Powder (50g/d)|Participants will consume 50g soy protein powder daily for a 6 week treatment period.
224159901|NCT03367611|DIAGNOSTIC_TEST|Immunochemical faecal occult blood test (iFOBT)|All participants in the study will collect a single faecal sample for haemoglobin measurement.
223579563|NCT06402396|DRUG|bDMARDS|Patients at time of the PDQ assessment and up to 4 months thereafter being on ongoing bDMARDs treatment or on switch of bDMARD treatment.
223579564|NCT05525598|BEHAVIORAL|"One step at a time"|\[see 'arms' section for full description\]
223579565|NCT05525598|BEHAVIORAL|"Get started"|\[see 'arms' section for full description\]
223579566|NCT05542914|BEHAVIORAL|electronic screening and brief intervention.|e-SBIs is an evidence based approach to engage non-treatment-seeking individuals who use substances to reduce use or enter treatment. It consists of completing screening instruments related to substance use and sexual risk behavior and receiving a tablet-based, Motivational Interviewing intervention to help individuals build motivation to reduce their use and plans to achieve their substance use and HIV risk reduction goals.
223579567|NCT05542914|BEHAVIORAL|Men's Health Project (MHP)|This intervention will be offered to participants with moderate or greater severity substance use. This is a 4-session Motivational interviewing based intervention that has shown efficacy in prior studies. We are providing this as a possible referral program for study participants (either arm) who are interested in receiving substance abuse intervention.
224159902|NCT00772811|DRUG|Flu-Mel|"* Fludarabine and Melphalan will be infused intravenously over 30 minutes in D5W 100 mL.~* Melphalan will be administered following the completion of Fludarabine infusion at day -2."
224159903|NCT04078529|OTHER|5 day falls prevention training|Intensive training on balance, gait re-education, functional activities, backwards chaining and postural control, completed at 0 and 12 weeks.
224159904|NCT04078529|OTHER|Home exercise programme|A modified version of the Falls Management Exercise programme (FaME) provided in written or audio format and completed over 12 weeks.
224159905|NCT04078529|OTHER|Environmental Assessment|Use of the Homefast assessment tool to reduce risk of falls at home.
223579568|NCT04694495|DIAGNOSTIC_TEST|16S rRNA gene sequencing of cervical secretions|"1. 16S rRNA gene sequencing of vaginal secretions: using NGS technology to assess the microbiota of the vaginal secretions~2. Microecology assessment of vaginal secretions: morphology test, functional assessment and Nugent score assessment of the vaginal secretions are included.~3. Genotyping of HPV and detection of sexually transmitted diseases pathogens based on the cervical exfoliated cells~4. Thinprep cytologic test of cervical exfoliated cells: to evaluate the grade of cervical intraepithelial neoplasia"
223743792|NCT02577237|BEHAVIORAL|In-person education sessions|The intervention will be delivered by a radiation oncology nurse. Each of the four in-person sessions consists of approximately 30 minutes of educational content/simulation that addresses a specific caregiving topic and any issues or concerns that the caregiver may be experiencing.
224159906|NCT05458362|BEHAVIORAL|Brief Enhanced Anxiety Sensitivity Treatment (Group BEAST)|"Group BEAST consists of a 1.5-hour-long intervention session, followed by a 2-week-long EMI. During the intervention session, participants will receive psychoeducation (e.g., defining common terms like anxiety and stress), discuss popular misconceptions they may have about anxiety symptoms, and complete exposure exercises (e.g., practicing facing feared physical sensations such as trembling or elevated heart rate). Homework exposure exercises will be completed by all participants. They will receive phone app reminders about completing homework.~Only the EMI group will receive EMI prompts and intervention."
224159907|NCT05458362|BEHAVIORAL|Control group Anxiety Sensitivity Treatment|Control group Anxiety Sensitivity Treatment consists of a 1.5-hour-long intervention session, followed by a 2-week-long EMI. During the intervention session, participants will receive psychoeducation (e.g., defining common terms like anxiety and stress), discuss popular misconceptions they may have about anxiety symptoms, and complete exposure exercises (e.g., practicing facing feared physical sensations such as trembling or elevated heart rate). Homework exposure exercises will be completed by all participants. They will receive phone app reminders about completing homework.
224159908|NCT02984891|PROCEDURE|Optical Coherence Tomography (OCT)|Procedure will be performed using the OCT Dragonfly catheter is a hydrophilic-coated catheter that uses infrared light with a central wavelength between 1,250 and 1,350 nm. Axial resolution with OCT is 10-20 microns, and maximum tissue penetration with OCT is approximately 1.5 mm-3 mm.
224304061|NCT03230799|PROCEDURE|minimal invasive lens surgery|We decreased the size of the capsulorhexis opening to 1.0-1.5 mm in diameter. Then we moved the location of the capsulorhexis to the peripheral area of the lens instead of the central area. A 0.9 mm phacoemulsification probe was used to remove the lens contents and/or cortical opacities.
223471086|NCT02425137|DRUG|S-1/Gemcitabine|Eligible patients will receive gemcitabine 800 mg/m2/day on day 1 and S-1 orally 80-120 mg/day (depending on patient's body surface area (BSA)) on day 1 to 10 in a 2-week cycle.
223471087|NCT05252403|GENETIC|PTG-CARCIK-CD19|PTG-CARCIK-CD19 cells is a gene therapy medicinal product (GTMP) composed of genetically modified allogeneic T lymphocytes formulated as cell suspension in normal saline solution and freezing media
223471088|NCT00945841|BIOLOGICAL|inactivated split influenza vaccine|1 dose of inactivated split influenza vaccine, using the strain composition 2009/2010
223471089|NCT01307787|OTHER|experimental Fit-program|Participants in the intervention group followed an eight week multi-disciplinary group rehabilitation program, consisting of a physical exercise part and an educational component. The physical exercise part consisted of a muscle exercise circuit and bicycle training,sport and aqua jogging. The educational part consisted of a weekly sixty minutes session. A multi-disciplinary group of healthcare professionals gave specialist orientated informational advice about how to handle the consequences of RA. Special attention was paid to ensure adjusting the level of each patients activity level to the participants' actual energy level. Further information was given about body sensations, sports, food and energy, pain, fatigue, emotional changes, sleeping disturbance and daily routine.
223471090|NCT01307787|OTHER|no intervention|waiting list control group with no intervention
223471091|NCT02586376|DEVICE|0J LLLT|Sham Low-Level Laser Therapy (Sham LLLT): perform with the machine off.
223471092|NCT02586376|DEVICE|4J LLLT|4J Low-Level Laser Therapy (4J LLLT) irradiation will be perform with 4J.
223471093|NCT02586376|DEVICE|6J LLLT|6J Low-Level Laser Therapy (6J LLLT) irradiation will be perform with 6J.
223471094|NCT02586376|DEVICE|8J LLLT|8J Low-Level Laser Therapy (8J LLLT) irradiation will be perform with 8J.
223471095|NCT01573000|BIOLOGICAL|Iodine-131 Anti-B1 Antibody Versus Anti-B1 Antibody in Chemotherapy-Relapsed/Refractory Low-Grade or Transformed Low-Grade Non-Hodgkin's Lymphoma (NHL)|Subjects will be randomized to receive tositumomab and iodine-131 tositumomab (Arm A) or unlabeled tositumomab (Arm B). Subjects randomized to receive unlabeled tositumomab may crossover and receive radiolabeled Iodine-131 tositumomab following progression of their lymphoma. Response in both arms will be assessed at 7 weeks, 13 weeks, and then at 3-monthly intervals for up to 2 years.
223471096|NCT02324686|DRUG|vitamin K1|Vitamin K1 400 mcg orally three times a week on dialysis days for four months
223471097|NCT06481787|DRUG|Vonorasan Fumarate|Vonorasan fumarate is taken 30min before breakfast and dinner.
223471098|NCT06481787|DRUG|Zuojin Pills|Zuojin Pills should be taken 30min after breakfast and dinner.
223471099|NCT03353792|DEVICE|CL/AP system|CL/AP system enabled insulin pump/CGM combination
223471100|NCT03353792|DEVICE|usual diabetic care|usual diabetic care (insulin pump therapy) along with CGM recording
223579569|NCT05365048|OTHER|Local Tailoring implementation strategy|"The local-tailored approach will be guided by a structured process involving the following: (1) convening a local HPV vaccine project team, (2) conducting a local diagnostic process to identify top barriers, (3) selecting from a menu of intervention options that will be offered in this study, categorized by core function (i.e., the forms and functions menu) that address top local barriers, and (4) deploying the selected interventions. The barrier assessment and intervention customization are key processes for the local-tailored strategy, which allow clinics to devote resources to respond to unique local barriers in addition to common barriers."
223579570|NCT05365048|OTHER|Prescribed Strategy|"The prescribed strategy is the standard implementation approach used by most health systems. Our prescribed approach will be guided by the evidence-based, award-winning 4 Pillars™ Practice Transformation Program for improving vaccination rates in the outpatient setting. The 4 Pillars™ address 4 main functions, i.e., convenience, communication, office systems, and motivation to guide the selection of interventions. For adolescent HPV vaccination, the 4 Pillars has demonstrated moderate effectiveness."
223579571|NCT05632328|DRUG|AGEN1423|via IV, dosage per protocol, once every 2 weeks for up to 8 weeks
223579572|NCT05632328|DRUG|Botensilimab|via IV, dosage per protocol, once evert 2 weeks, up to 2 years
223579573|NCT05632328|DRUG|Gemcitabine|per standard care
223579574|NCT05632328|DRUG|Nab-paclitaxel|per standard care
223579575|NCT01611051|DRUG|Drug: Pegylated rhG-CSF: 100µg/kg|Patients were administered pegylated rhG-CSF 100 ug/kg once at the 3rd day of every chemotherapy cycle. Chemotherapy regimen: EC (epirubicin 100 mg/m2 +cyclophosphamide 600 mg/m2) or ET (epirubicin 75 mg/m2 + docetaxel 75 mg/m2).
223471101|NCT05402709|OTHER|Posterior mobilisation technique|Posterior mobilisation technique were applied
223471102|NCT05402709|OTHER|Posterior capsule stretching|Posterior capsule stretching were applied
223471103|NCT06416631|PROCEDURE|artificial intelligence based screw planning|artificial intelligence technology helps to plan screws in robot assisted spinal surgery
223471104|NCT06416631|PROCEDURE|manually screw planning|the screw trajcetories are manually planned
223471105|NCT03614403|DRUG|vitamin D|Fat-soluble vitamin D injection contain of 300,000 IU vitamin D that given via intramuscular injection
223471106|NCT02598453|DRUG|Ibandronate|Either 150 mg oral tablet once monthly or 3 mg IV injection once every 3 months
223471107|NCT02814071|OTHER|Early enteral feeding|Early enteral feeding as per description
223471108|NCT01739881|DEVICE|Olympus Ultrathin Bronchofibervideoscope (XP260F)|The bronchovideoscope will be used together with an assisted image-guided bronchoscopic navigation software system called LungPoint®, to view lungs in a real time 3D manner.
223471109|NCT01477281|DRUG|Daflon|Administer one tablet 2 times daily (oral), the main meals (lunch and dinner).
223471110|NCT01477281|DRUG|Venaflon (Diosmin and Hesperidin)|Administer one tablet 2 times daily (oral), the main meals (lunch and dinner).
223471111|NCT06151379|OTHER|Neoadjuvant therapy|To measure muscle mass and predict pCR to NAC and its effect on clinical outcomes.
223471112|NCT00372138|PROCEDURE|PRP + autologous thrombin|simultaneous perioperative PRP and autologous thrombin in the aneurysm sac, during the endovascular treatment of unruptured abdominal aortic aneurysms
223471113|NCT02510937|DRUG|CC-90001|
223471114|NCT01364155|DRUG|LIM-0705|
223471115|NCT01364155|DRUG|Placebo capsules|
223471116|NCT00194129|DRUG|Lithium|Lithium monotherapy was initiated at 300 mg twice daily and titrated over 3-6 weeks to minimum blood levels of 0.8 meq/L.
223471117|NCT00194129|DRUG|Divalproex|Divalproex was then initiated at 250 mg twice daily and increased over 3-6 weeks to minimum blood levels of 50 ug/ml.
223471118|NCT00194129|DRUG|Placebo|Placebo pills that looked exact to divaloproex were provided to subjects and take twice daily.
223471119|NCT02198534|DEVICE|Methodology of visual acuity assessment|
223471120|NCT04072874|DRUG|Experimental topical (Curaleish Topical)|Curaleish is a formulation in lotion and cream. Curaleish lotion and Curaleish cream will be applied topically by each participant in all lesion until day 28 or 42, depending on the regimen to be evaluated. Study staff will be closely observing the safety assessment. The application until Day 28 or 42 will continue, even if the lesion has shown 100% re-epithelization before day 28 or day 42.
223471121|NCT05088772|DEVICE|Hyperbaric Oxygen Therapy|"Hyperbaric Oxygen Therapy performed at 100% oxygen at 2.0-2.4 ATA, with 1-3 air breaks, typically at 5 sessions per week, with limited variation depending on the treatment indication and patient/clinician preference."
223471122|NCT01125098|OTHER|PRO-CT values|"* continue antibiotics for 10 days if a single PRO-CT value is 0.25 mcg/L or greater, that will be judged suggestive of bacterial infection~* continue antibiotics from day 3 to day 10 if one or more PRO-CT values are 0.1 to 0.25 mcg/L, indicative of possible bacterial infection, PLUS acute respiratory failure or clinical instability~* stop antibiotics on day 3, if one or more PRO-CT values are between 0.1 to 0.25 mcg/L, indicative of possible bacterial infection, BUT the patient has not acute respiratory failure or clinical instability~* stop antibiotics if all the PRO-CT values are \< 0.1 mcg/L or if there is a consistent trend to normalization of PRO-CT with the last value \< 0.1 mcg/L, that will be judged suggestive of absence of bacterial infection."
223471123|NCT00801944|DRUG|Solifenacin succinate|oral
223471124|NCT00801944|DRUG|Placebo|oral
223471125|NCT01266616|BIOLOGICAL|Profectus HIV MAG pDNA vaccine|3,000 mcg admixture of two vaccine plasmids: ProfectusVax DNA Plasmid (HIV-1 gag/pol) and ProfectusVax DNA Plasmid (HIV-1 nef/tat/vif, env) at Weeks 0, 4, and 12
223471126|NCT01266616|BIOLOGICAL|IL-12|Administered at Weeks 0, 4, and 12
223579576|NCT01611051|DRUG|Pegylated rhG-CSF: 6mg|Patients were administered pegylated rhG-CSF 6mg once at the 3rd day of every chemotherapy cycle. Chemotherapy regimen: EC (epirubicin 100 mg/m2 +cyclophosphamide 600 mg/m2) or ET (epirubicin 75 mg/m2 + docetaxel 75 mg/m2).
224159909|NCT02984891|PROCEDURE|Intravascular Ultrasound (IVUS)|Procedure will be performed using the IVUS Kodama catheter is a hydrophilic-coated catheter that used high-fidelity ultrasound transmission to capture high-definition images of coronary artery anatomy. It uses ultrasound waves with a frequency of 40 or 60 MHz, as opposed to 20 MHz in conventional IVUS, to improve resolution while optimizing tissue penetration. It provides axial resolution of \< 40 microns and tissue penetration of 10 mm.
224159910|NCT01024660|DRUG|Donepezil|5 mg capsule, orally, once daily, first 14 days of treatment
223743793|NCT02577237|BEHAVIORAL|NCI Booklet|Radiation Oncology Nurse will hand participant the NCI booklet
223743794|NCT02577237|OTHER|Survey|written, qualitative assessments of areas including depression and anxiety, caregiver self-efficacy, care-giver self efficacy for head and neck cancer, health-related quality of life, patient performance status, demographics, and medical history.
224159911|NCT01024660|DRUG|Donepezil|10 mg, orally, once daily, for remaining 70 days of treatment
224159912|NCT01024660|DRUG|Placebo to match Aricept|Placebo capsule, orally, 84 days of treatment
224159913|NCT03304912|BEHAVIORAL|PrEP Education and option to accept a PrEP prescription|Participants will receive educational information about PrEP, be offered a PrEP prescription, and those who choose to initiated PrEP will be monitored for side-effects and adherence at their follow-up visit. There is no group assignment within this study and WWID do not have to choose to initiate PrEP. Rather, the goal of this study is to understand factors that impact PrEP initiation (and engagement in the PrEP care continuum).
223471127|NCT01266616|OTHER|Placebo|Saline injections at Weeks 0, 4, and 12
223471128|NCT00482937|DRUG|CD-NP|
223471129|NCT03342001|DRUG|Calcitonin|calcitonin nasal spray
223471130|NCT04212429|DRUG|Levofloxacin Ophthalmic Product|Levofloxacin hydrate, an aqueous ophthalmic solution, to be given one drop at a time, 4 times daily for 3 days pre-operatively and one drop on the day of operation.
223471131|NCT04212429|DRUG|Moxifloxacin Ophthalmic Solution|Moxifloxacin hydrochloride, an aqueous ophthalmic solution, to be given one drop at a time, 4 times daily for 3 days pre-operatively and one drop on the day of operation.
223471132|NCT02332603|DRUG|Methylprednisolone|Comparison of preoperative single high dose of Methylprednisolone 125 mg iv. and isotonic Sodium Chloride
223471133|NCT02332603|DRUG|Isotonic Sodium Chloride|Placebo
223579577|NCT01611051|DRUG|rhG-CSF 5ug/kg/day|Patients were administered pegylated rhG-CSF 6 ug/kg/day from the 3rd day of every chemotherapy cycle. Chemotherapy regimen: EC (epirubicin 100 mg/m2 +cyclophosphamide 600 mg/m2) or ET (epirubicin 75 mg/m2 + docetaxel 75 mg/m2).
224159914|NCT00185172|OTHER|placebo|Placebo oral tablets for 2 weeks
224159915|NCT00185172|DRUG|olmesartan medoxomil|olmesartan medoxomil oral tablets for 8 weeks
224159916|NCT00185172|DRUG|olmesartan medoxomil oral tablets, hydrochlorothiazide oral tablets|olmesartan medoxomil oral tablets,or olmesartan medoxomil oral tablets + hydrochlorothiazide oral tablets
224159917|NCT05481970|DRUG|dexmedetomidine,ketamine,lidocaine,propofol|Group (A): Induction of general anesthesia will be done using lidocaine (1.5 mg/kg), propofol (2-3 mg/kg), and atracurium (0.5 mg/kg). Dexmedetomidine 0.5 µg/kg over 10 min, started 10 min before induction. Following tracheal intubation, dexmedetomidine infusion generally will be initiated at 0.6 μg/kg/h and titrated between 0.2 and 1.0 μg/kg/h according to the heart rate maintaining bispectral index (BIS) between 40-60, lidocaine (1.5 mg/kg/h). ketamine will be given as a bolus dose of 0.3 mg/kg after induction and prior to skin incision then 0.2 mg/kg/h as an infusion. Patients will receive dexamethasone (8 mg i.v.) after induction.
223471134|NCT02158689|DRUG|Letrozole|
223471135|NCT02158689|DRUG|human menopausal gonadotropin (hMG)|
223471136|NCT04907123|OTHER|Intensive sodiuria-guided diuretic treatment|Intensive stepwise diuretic treatment based on combined diuresis and urinary sodium assessment
223471137|NCT04907123|OTHER|Standard diuretic treatment|Stepwise diuretic therapy based on diuresis assessment
223471138|NCT00452374|DRUG|Cytarabine|1 g/m\^2 given IV for two days (Days 2 and 3).
223471139|NCT00452374|DRUG|Fludarabine|30 mg/m\^2 given IV for two days (Days 2 and 3).
223471140|NCT00452374|DRUG|Oxaliplatin|Starting dose of 17.5 mg/m\^2 IV for 4 days (Days 1 through 4).
223471141|NCT00452374|DRUG|Rituximab|375 mg/m\^2 IV on Day 3 of the first cycle over 4-6 hours and on Day 1 on every cycle following.
223471142|NCT01433159|DRUG|HP011-101 (Xenaderm Ointment)|The test article will be applied at approximately the thickness of a dime twice daily, or more often if removed incidental to cleansing for 14 days treatment with HP011 101.
223471143|NCT01433159|DRUG|Standard Care|No restrictions are placed on the nature of this care, except that it conform to the typical practices in place during the prior 3 months and that the regimen does not include the use of a BCT ointment (ointments containing Balsam Peru, castor oil and trypsin).
223471144|NCT02144766|DRUG|ropivacaine|caudal block with 1 ml/kg of ropivacaine 0.2%
223471145|NCT02144766|DRUG|saline|caudal block with 1 ml/kg of saline
223471146|NCT05209659|OTHER|Pragmatic Mobilization|"The techniques will of consist of passive, low velocity, oscillatory movements within the physiological range of the joint, applied to the comparable spinal level of the patient (defined as the spinal level that reproduced the patient's familiar pain). The techniques will be modified based on clinician assessment and patient feedback and consist of Grade I through Grade IV movements. Common techniques used may include unilateral posterior-anterior movements, central posterior-anterior movements, and sidelying rotations (without thrust). Since the pragmatic approach is clinician-driven, no time limit will be placed on the application and the number of mobilizations used will depend on the patient feedback (the exact definition of a pragmatic treatment). Patients will be seen for 4 visits.~Other Name: Non-thrust manipulation (pragmatically applied)"
224159918|NCT05481970|DRUG|fentanyl,propofol|In group (B) for induction of anesthesia, patients will receive propofol 2-3mg/kg, fentanyl 1-2mcg/kg and atracurium 0.5 mg/kg as a muscle relaxant to facilitate intubation. Fentanyl bolus doses of 0.5-1 mcg/kg will be given to keep BIS score 40-60 during surgery.
224159919|NCT01044056|DRUG|Levonorgestrel (LNG)/Ethinylestradiol (EE) oral contraceptive tablets|LNG/EE oral contraceptive tablets (Microgynon® 30), 21 in total, containing 0.150 mg LNG and 0.030 mg EE per tablet administered once daily orally for 21 consecutive days.
224159920|NCT01044056|DRUG|norelgestrominum and ethinylestradiol patch oral contraceptive patch|A contraceptive patch (EVRA ™), one patch for 7 days for three consecutive weeks, 3 patches in total, applied on the lower abdomen. Dose: per patch 6 mg norelgestromin and 0.750 mg EE releasing 0.150 mg norelgestromin and 0.020 mg EE per day.
223471147|NCT01100853|DRUG|VIVITROL injection and VIVITROL Placebo Injection , 24 weeks|Efficacy of 24 week course of VIVITROL with counseling as compared to 24 week course of VIVITROL placebo with counseling (monthly injections)
223471148|NCT00084240|DRUG|Azithromycin/Chloroquine|
223471149|NCT00084240|DRUG|Sulfadoxine-Pyrimethamine/Chloroquine|
223471150|NCT03477162|DRUG|Metformin|Metformin will be given to patients prior to surgery.
223471151|NCT01507181|DRUG|Ketamine|single dose IV ketamine, .5mg/kg infused over 40 minutes
223471152|NCT01507181|DRUG|Midazolam|single dose IV midazolam, .45mg/kg infused over 40 minutes
223471153|NCT03277937|PROCEDURE|angiography in EUS-injection of coils + CYA|Doppler imaging will be used to allow direct visualization of the varices flow. The gastric vessels will be followed from the cardia to the proximal part of the esophagus, to detect the feeding vessel (FV). Once the FV has been found, a 19-gauge EUS-FNA will be used to access the vessel. An angiography will be performed using 5-10 ml of water-soluble contrast under fluoroscopy, to ensure intravascular location and study varix flow direction. Finally, patients will be treated by EUS-deployment of coils followed by CYA injection. The coils will be delivered into the vessel through the FNA needle, using the stylet as a pusher. The 2-Octyl-CYA will be used. It will be injected always after the coils deployment and then 1 mL of saline solution will be used to flush the glue completely.
223471154|NCT04161391|DRUG|TPX-0046|Oral TPX-0046 capsules
223471155|NCT03136393|BEHAVIORAL|Community based dietary counselling|The dietary counseling will be delivered to mothers through group sessions (will include cooking demonstration) and home visits by lay health workers. The counseling will promote foods that are nutritious and locally available and general better food preparation practices. The choices of the foods to be promoted will be based on linear programming results from a preceding survey on dietary intake of pregnant women in the area as well as results of analysis of foods associated with infant birth size (same data). The goal in the linear programming was to find a model of food combinations among the most frequently consumed foods which better meets required intakes during pregnancy. Additionally, adherence to pregnancy iron supplements will also be promoted.
223579578|NCT01283308|BEHAVIORAL|Lifestyle Intervention|Intervention arm participants will attend 6 months of weekly classes where they will be taught the skills necessary to reach these goals. The curriculum for the classes is based on the DPP lesson plans. Social support will be provided by trained lay health educators and peer support groups. Participants who remain at highest risk of T2DM after four or more months in the program will be prescribed metformin in addition to continuing the lifestyle program. Metformin dosages will start at 500 mg per day, and, when appropriate, will increase to 1000 mg per day (given as 500 mg twice per day). This group will be comprised of individuals who have (1) Fasting plasma glucose values of 100 mg/dl or more and (2) elevated fasting HbA1c measures of 5.7% or more.
223471156|NCT03136393|BEHAVIORAL|Community based antenatal counselling|The antenatal counselling will focus on preparations for neonatal care and encouragement for facility based delivery.
223579579|NCT01283308|BEHAVIORAL|Standard of Care|Participants randomized to the standard of care group will meet with a physician and a dietician, attend one class/awareness lecture on diabetes prevention through weight loss and diet change and one class on exercise, and receive handouts reinforcing what they learn in class and with the dietician, fitness consultant, and physician.
223579580|NCT05792644|DRUG|crizotinib for rearrangement-negative, high phosphorylated ALK patients|Patients with positive ALK phosphorylation expression were treated with crizotinib 250 mg/day orally. A treatment cycle was defined as 30 days of once-daily crizotinib treatment. Treatment with crizotinib continued until the patient experienced unacceptable toxicity, was pregnant, or started new cancer therapy.
223579581|NCT01453517|BEHAVIORAL|Behavioral intervention for regain after bariatric surgery|6 week intervention targeting dietary behavioral adherence, stress management, and distress tolerance skills to prevent weight regain
223579582|NCT00504140|DRUG|Etoposide|100 mg/m\^2 Intravenous Daily for 5 days, beginning one hour after IFN-alpha treatment.
223579583|NCT00504140|DRUG|Interferon Alpha|5x10\^6 mu/m\^2 Subcutaneously Daily for 5 Days
224159921|NCT01044056|DRUG|Nuvaring ™ (etonorgestrel/ethinylestradiol)|NuvaRing ™ , one ring for a period of 21 days, inserted vaginally. Dose: per ring 11.7 mg etonogestrel and 2.7 mg EE releasing a daily average amount of 0.120 mg etonogestrel and 0.015 mg EE.
224159922|NCT01675206|DIETARY_SUPPLEMENT|Vitamin K2 supplementation|
224159923|NCT04434105|DRUG|platlet rich plasma (PRP)|Platelet-rich plasma (PRP) promotes angiogenesis, neurogenesis, and nerve regeneration, also it could reduce swelling and inflammation of the flexor tenosynovitis.
224159924|NCT04434105|DRUG|Triamcinolone Acetonide|40 mg triamcinolone acetonide
224159925|NCT04434105|DRUG|Saline|Saline
224159926|NCT01570205|DRUG|XG-102|single intravenous infusion
224159927|NCT03619837|DRUG|Sofosbuvir/Velpatasvir|Sofosbuvir/Velpatasvir starting early post-transplant for total of 12 weeks.
224159928|NCT03619837|DRUG|Sofosbuvir/Velpatasvir/Voxilaprevir|"Only for patients who fail initial treatment with Sofosbuvir/Velpatasvir.~Dosage: 400mg/100mg/100mg daily for 12 weeks."
224159929|NCT04095793|DRUG|ampreloxetine|Oral tablet, QD
224159930|NCT03366597|DRUG|Sevoflurane|1.5%-3% Sevoflurane will be given during the cardiac surgery except cardiopulmonary bypass.
224159931|NCT05580185|DEVICE|RESPINOR DXT|Blinded, continuous diaphragmatic excursion measurements by DXT will be conducted during the patients' first SBT. The recording shall be initiated 15 minutes prior to the first SBT and will end 15 minutes post SBT.
224159932|NCT02224937|DRUG|Melatonin|
224159933|NCT02224937|DRUG|Placebo|
224159934|NCT05065268|DEVICE|Immersive Virtual-Reality Stimulation|IVR stimulation every 2 days (± 1 day) at any time during the day (delivery).
224159935|NCT01372813|DRUG|vandetanib|Daily dose 300mg/day by mouth, 28 day cycle
224159936|NCT03785470|OTHER|Fructose and physical inactivity|Subjects will drink 6 cans of regular sodas daily (divided throughout the day) and will decreased physical activity to less than 5000 steps daily for 10 days.
224159937|NCT05097170|PROCEDURE|NIRS during ventricular tachycardia ablation|"NIRS: Near-infrared spectroscopy is a measurement technique that non-invasively and continuously monitors the balance between cerebral oxygen consumption and delivery.~BIS: BIS is an electroencephalogram-derived parameter developed to monitor the hypnotic effects of anesthesia."
224159938|NCT01680939|DRUG|Morphine|0.2-0.5 mg/kg PO q4h
223743795|NCT02577237|OTHER|Interview|A structured series of open-ended questions will be used during a telephone interview with participants at four weeks post radiation treatment.
224159939|NCT01680939|DRUG|Ibuprofen|10mg/kg PO q6hrs
224159940|NCT01927068|DEVICE|"Stellarex 0.035 Over-the-Wire (OTW) drug-coated angioplasty balloon (Stellarex DCB)"|Percutaneous Transluminal Angioplasty will be completed using a 2.0 micrograms per square millimeter. Paclitaxel-Coated Balloon. Balloon will be inflated to a size appropriate for the target vessel, as determined by the physician. Total balloon inflation time is determined by the physician, but no less than one minute.
224304062|NCT03230799|PROCEDURE|traditional cataract surgery|ACCC+ I/A + PCCC + Anti-vit: anterior continuous capsulorhexis + irrigation/aspiration + posterior capsulorhexis + anterior vitrectomy
224304063|NCT05355649|DEVICE|PREGNOLIA SYSTEM|"The Pregnolia System is composed of two products: an active device (Pregnolia Control Unit) and a single-use sterile probe (Pregnolia Probe).~The intended use of the Pregnolia System is to provide information about the mechanical properties of the uterine cervix by assessing the tissue stiffness through a proxy parameter (the closing pressure, denominated CSI, or Cervical Stiffness Index, in mbar). The Pregnolia System is intended to be used in conjunction with the information obtained from the clinical evaluation of the patient and in addition to other standard examinations."
223471157|NCT02624999|BIOLOGICAL|AlloVax™|AlloVax™ combines an anti-tumor effect of mini-transplant procedures with patient specific tumor antigens
223471158|NCT02624999|DRUG|Cisplatin|Subjects in the chemotherapy arm will receive up to 6 cycles of cisplatin on day 0 of the 3-week cycle at dose of 80-100 mg/m2 IV and 1000 mg/m2 IV 5FU on days 1-4 of the cycle
223743796|NCT02245542|DRUG|ALNA®OCAS®|
224159941|NCT00118404|BEHAVIORAL|Continuation phase cognitive therapy|Continuation phase cognitive therapy included 10 sessions over 8 months.
224159942|NCT00118404|DRUG|Continuation phase fluoxetine|The dosage of fluoxetine was increased to 40 mg over 8 months.
224159943|NCT00118404|OTHER|Continuation phase pill placebo|The dosage of pill placebo was increased to 40 mg over 8 months.
224159944|NCT00118404|BEHAVIORAL|Acute phase cognitive therapy|For the first 12 weeks, all participants received between 16 and 20 cognitive therapy sessions.
223471159|NCT03991390|OTHER|Visual Feedback and Core Stability exercises protocol|"This arm consists of 5 sessions per week, 60 minutes each. One session consists of 30 minutes of conventional physiotherapy and 30 minutes of Core Stability exercises and laser visual feedback exercises, on alternate days.~All sessions will be performed by the same physiotherapist."
223471160|NCT03991390|OTHER|Control stroke|"This arm consists of 5 sessions per week, 60 minutes each comprising usual physiotherapy treatment.~All sessions will be performed by the same physiotherapist."
223471161|NCT02858466|RADIATION|MRI scan|
224159945|NCT05240612|BIOLOGICAL|MT-3921|Solution for infusion; Intravenous (IV)
224159946|NCT05240612|BIOLOGICAL|Placebo|Solution for infusion; Intravenous (IV)
224159947|NCT02121314|DRUG|intravenous administration of 1st line TB drugs, day 1|TB drugs IV on day 1 for calculation of bioavailability while fasting or fed
224159948|NCT00735527|DRUG|Lorazepam|Intra-nasal 0.1 mg/kg (maximum 4 mg) once
224159949|NCT00735527|DRUG|Lorazepam|Intra-venous 0.1 mg/kg (maximum 4 mg) once
224159950|NCT05846269|OTHER|Educational Intervention|Educational intervention addressing trauma-informed care and resiliency.
224159951|NCT01406158|DRUG|Solifenacin Succinate Formulation A|oral suspension
224159952|NCT01406158|DRUG|Solifenacin Succinate Formulation B|oral suspension
224159953|NCT01406158|DRUG|Solifenacin Succinate|oral tablet
224159954|NCT02654041|DRUG|Combined T3 and Methimazole treatment|Oral administration of T3 and Methimazole
224159955|NCT00331084|DRUG|antibiotic/steroid combination|1 gtt, 4x/day, 15 days
224304064|NCT00497952|BIOLOGICAL|hematopoetic stem cell infusion|Enriched hematopoietic stem cell infusion
224304065|NCT02564211|DRUG|Ipragliflozin|one 50 mg tablet QD
224304066|NCT02564211|DRUG|Sitagliptin|one 50 mg tablet QD
223471162|NCT00532051|DEVICE|OCT measurements|This study is about a new imaging method to study the front part of the eye. This imaging method is called Optical Coherence Tomography (OCT) which provides detailed cross-sectional (layered) views of structures in the eye. The OCT system scans a beam of light across the eye to take a picture. OCT provides a more detailed image than other imaging methods of the eye such as ultrasound, CT scan (computed tomography), and MRI (magnetic resonance imaging). In addition, OCT imaging does not touch the eye. OCT is routinely used in imaging structures in the back of the eye (retina) and cornea. This study uses high-speed FDA approved OCT systemsThe measurements from the OCT systems are used in selecting IOL power.
223471163|NCT05684848|DEVICE|Resveratrol + CMG|As prevention (resveratrol or its placebo) 2 puffs per nostril 2 times a day (morning and evening) for a period of 3 months. If during the preventive administration of the spray the first symptoms of a viral infection should appear, the parent should increase the dosage of the nasal spray to 2 puffs per nostril 4 times a day.
224159956|NCT00331084|DRUG|moxifloxacin / dexamethasone|1 gtt 4x/day, 15 days
224159957|NCT00433667|DRUG|RWJ-333369|
223471164|NCT05684848|DEVICE|Isotonic solution|As prevention (resveratrol or its placebo) 2 puffs per nostril 2 times a day (morning and evening) for a period of 3 months. If during the preventive administration of the spray the first symptoms of a viral infection should appear, the parent should increase the dosage of the nasal spray to 2 puffs per nostril 4 times a day.
223471165|NCT01423825|BIOLOGICAL|Sub C gp140 Vaccine|100 mcg of Sub C gp140 vaccine admixed with MF59C.1 adjuvant administered as one 0.5 mL injection intramuscularly (IM) in either deltoid
223471166|NCT01423825|BIOLOGICAL|MF59C.1 Adjuvant|MF59C.1 adjuvant admixed with 100 mcg of Sub C gp140 vaccine administered as one 0.5 mL injection intramuscularly (IM) in either deltoid. MF59C.1 adjuvant contains no biologicals.
223471167|NCT01423825|OTHER|Sodium chloride|Sodium chloride as 0.5 mL IM injection in either deltoid to act as placebo
223471168|NCT02442609|OTHER|questionaire|questionaire before surgery
223471169|NCT01682096|RADIATION|computed coronary angiography|Patients will be pre-medicated with atenolol 50 mg 1h prior to the scan.
223471170|NCT01682096|PROCEDURE|Exercise stress echocardiography|Limited by symptoms
223471171|NCT04744818|DIETARY_SUPPLEMENT|Iron syrup|Daily supplementation with iron
223471172|NCT04744818|DIETARY_SUPPLEMENT|Multivitamin syrup|Daily supplementation with multivitamins
223471173|NCT03788694|DRUG|Ketamine|8 doses of intranasal ketamine; 40 mg per dose.
223579584|NCT00360932|DEVICE|SCULPTRA (poly-L-lactic acid injection)|Subjects will be treated with SCULPTRA® according to the investigator's judgment, and in accordance with the SCULPTRA® package insert. Details of the exact amount and the time of administration of SCULPTRA® (date, amount, location) will be documented in the CRF at each protocol and non-protocol visit.
223579585|NCT05891054|BEHAVIORAL|Active breaks|Two active breaks are taken daily in a predetermined time slot. The development of each break is done through access to a specific digital platform where students follow the instructions of an avatar, which is in charge of guiding the realization of the active break. Each active rest involves a total of 4 minutes of activity, in which two sets of 20 seconds of work and 10 seconds of rest of four different exercises are performed, ending with a brief return to calm consisting of two deep breaths. The activities selected for each of the active breaks include aerobic and strengthening activities of moderate and vigorous intensity.
223579586|NCT05891054|BEHAVIORAL|Physically active learning|"The physically active learning is carried out once a week for 1 hour outside the classroom, where physical activity (through movement, jumping, strengthening exercises, throwing, etc.) is incorporated into academic mathematics classes.~The mathematics teachers (with the support of the research team) are in charge of teaching the physically active classes. Prior to the development of each class, the research team, together with the mathematics teachers involved, meet and design the class according to the contents to be addressed."
223579587|NCT00308165|PROCEDURE|Convection-Enhanced Delivery|microinfusion pumps to deliver chemotherapy directly into brain tumors
223579588|NCT00308165|DRUG|Topotecan|chemotherapeutic drug for the treatment of brain tumors
223579589|NCT05880914|PROCEDURE|miRNAseq analysis|Identify miRNA in serum and prepare a miRNA sequencing library for novel analysis.
223579590|NCT05880914|DRUG|Standard treatment for bone disorder|Participants will be prescribed a clinically indicated bone-targeted treatment for osteoporosis or bone disorder related to CKD. (non-experimental)
223579591|NCT06546709|BIOLOGICAL|LASSARAB+ aPHAD-SEat 700rU|Rabies-Vectored Monovalent Lassa Fever Vaccine (LASSARAB) with 3D-(6- acyl) Phosphorylated Hexaacyl Disaccharides (PHAD)-Stable squalene oil-in-water nanoemulsion (aPHAD-SE) adjuvant administered by IM injection
224159958|NCT04616794|BEHAVIORAL|Cognitive Engagement Group|Participants in this group will be encouraged to lead a cognitively stimulating lifestyle, as a means for cognitive decline/dementia risk reduction. This will be achieved by providing educational materials, practical tips and strategies, and suggestions about the different options to increase cognitively stimulating activities and by assisting participants outlining goals to progressively adopt a more cognitively active lifestyle.
223471174|NCT00419185|PROCEDURE|Delamination of the Internal limiting membrane|
223471175|NCT03109483|OTHER|Geriatric Activation Program Pellenberg|intensive multicomponent physical therapy week program
223471176|NCT05299866|DRUG|S-ketamine|After surgery, patient-controlled analgesia is provided. The pump is established with S-ketamine 1mg/kg, sufentanil 2microgram/kg, andondansetron16mg, diluted with normal saline to 100 ml. The pump is programmed to deliver 2 ml boluses with a background infusion rate at 2 ml /h and a 30 min lockout interval.
223471177|NCT05299866|DRUG|Placebo|After surgery, patient-controlled analgesia is provided. The pump is established with sufentanil 2microgram/kg, andondansetron16mg, diluted with normal saline to 100 ml. The pump is programmed to deliver 2 ml boluses with a background infusion rate at 2 ml /h and a 30 min lockout interval.
223471178|NCT03794492|DRUG|Mycophenolate mofetil 500mg Tab. or 250mg Cap.|\- Orally, up to 1g BID(total 2g daily)
223471179|NCT03794492|DRUG|Tacrolimus|\- Orally, check the blood ceocentration of tacrolimus at each visit and adjust the dose to acheive the blood concentration maintaining at 3-8ng/ml
223471180|NCT03794492|DRUG|Methylprednisolone/prednisolone|\- Methyprednisolone 500mg / Prednisolone 5mg
223471181|NCT03794492|DRUG|Basiliximab|\- IV, 20mg(before Kidney transplat) / 20mg(Day 4 of kidney transplant)
223471182|NCT00670059|GENETIC|single embryo transfer without aneuploidy screening|without aneuploidy testing for the chromosomes XY, 13, 16, 18, 21, 22
223471183|NCT00670059|GENETIC|single embryo transfer with aneuploidy screening|with aneuploidy testing for the chromosomes XY, 13, 16, 18, 21, 22
223471184|NCT05423418|BIOLOGICAL|A244|Dose of A244 is 300μg. Vaccine will be administered via IM injection into the same deltoid muscle (same side) for all injections at Month 0 (Day 1), Month 1 (Day 29), and Month 2 (Day 57).
223471185|NCT05423418|BIOLOGICAL|B.63521|Dose of B.63521 is 300μg. Vaccine will be administered via IM injection into the same deltoid muscle (same side) for all injections at Month 0 (Day 1), Month 1 (Day 29), and Month 2 (Day 57).
223471186|NCT05423418|BIOLOGICAL|50μg ALFQ|Dose of ALFQ is 50μg. Vaccine will be administered via IM injection into the same deltoid muscle (same side) for all injections at Month 0 (Day 1), Month 1 (Day 29), and Month 2 (Day 57).
223471187|NCT05423418|BIOLOGICAL|100μg ALFQ|Dose of ALFQ is 100μg. Vaccine will be administered via IM injection into the same deltoid muscle (same side) for all injections at Month 0 (Day 1), Month 1 (Day 29), and Month 2 (Day 57).
223471188|NCT05423418|BIOLOGICAL|200μg ALFQ|Dose of ALFQ is 200μg. Vaccine will be administered via IM injection into the same deltoid muscle (same side) for all injections at Month 0 (Day 1), Month 1 (Day 29), and Month 2 (Day 57).
223471189|NCT02579629|DRUG|Ropivacaine 0.1%|Ropivacaine 0.1% is a local anaesthetic drug and will be administered as a single bolus dose of 8ml of 0.1% ropivacaine followed by an infusion of 8ml/hr of 0.1% ropivacaine using the On-Q® elastomeric pump. The bolus dose of 8ml of 0.1% ropivacaine will be administered via a multiport, silver-impregnated catheter (6-10cm) placed above the rectus muscle parallel to the fascial incision, using a preloaded syringe. The infusion will be delivered by the On-Q® elastomeric pump pre-set to deliver 8ml/hr of 0.1% ropivacaine for 72 hours post-operatively.
223471190|NCT02579629|DRUG|Ropivacaine 0.2%|Ropivacaine 0.2% is a local anaesthetic drug and will be administered as a single bolus dose of 8ml of 0.2% ropivacaine followed by an infusion of 8ml/hr of 0.2% ropivacaine using the On-Q® elastomeric pump. The bolus dose of 8ml of 0.2% ropivacaine will be administered via a multiport, silver-impregnated catheter (6-10cm) placed above the rectus muscle parallel to the fascial incision, using a preloaded syringe. The infusion will be delivered by the On-Q® elastomeric pump pre-set to deliver 8ml/hr of 0.2% ropivacaine for 72 hours post-operatively.
223471191|NCT02579629|DRUG|Normal saline|Normal saline will be administered as a single bolus dose of 8ml of normal saline followed by an infusion of normal saline using the On-Q® elastomeric pump. The bolus dose of 8ml of normal saline will be administered via a multiport, silver-impregnated catheter (6-10cm) placed above the rectus muscle parallel to the fascial incision, using a preloaded syringe. The infusion will be delivered by the On-Q® elastomeric pump pre-set to deliver 8ml/hr normal saline for 72 hours post-operatively.
223471192|NCT02579629|DEVICE|On-Q ® elastomeric pump|The On-Q® elastomeric pump automatically and continuously delivers a regulated flow of 0.1% or 0.2% ropivacaine or normal saline locally to the surgical site for 72 hours post-operatively. The infusion will be delivered by pre-setting the On-Q® elastomeric pump to deliver at the rate of 8ml/hr for 72 hours post-operatively.
223471193|NCT00825123|DRUG|Ivabradine|Ivabradine 10 mg once
223471194|NCT00825123|DRUG|Metoprolol|Metoprolol 50 mg once
223471195|NCT00825123|DRUG|Placebo|Lactose powder
223471196|NCT01190891|PROCEDURE|Manual Physical Therapy|Same as arm description
223471197|NCT01190891|PROCEDURE|Corticosteroid Injection|Dose represents a glucocorticoid potency of 400 hydrocortisone equivalents/injection (mg).
223471198|NCT00044291|DRUG|atamestane|
223471199|NCT00044291|DRUG|toremifene|
223471200|NCT00044291|DRUG|letrozole|
223471201|NCT00044291|DRUG|aromatase inhibition|
223471202|NCT00044291|PROCEDURE|hormone therapy|
223471203|NCT00044291|PROCEDURE|endocrine therapy|
223579592|NCT06546709|BIOLOGICAL|HDCV Comparator|Sterile, stable, freeze-dried suspension of rabies virus prepared from strain PM-1503-3M
223579593|NCT06546709|OTHER|Normal Saline Placebo|Sterile 0.9% sodium chloride for injection, USP, or normal saline, is a sterile, nonpyrogenic, isotonic solution; each mL contains sodium chloride 9 mg
223579594|NCT06546709|BIOLOGICAL|LASSARAB+ aPHAD-SEat 1400rU|Rabies-Vectored Monovalent Lassa Fever Vaccine (LASSARAB) with 3D-(6- acyl) Phosphorylated Hexaacyl Disaccharides (PHAD)-Stable squalene oil-in-water nanoemulsion (aPHAD-SE) adjuvant administered by IM injection
223579595|NCT05871996|OTHER|Palliative Care and Oncology Survey on Terminology (POST)|Each group receives a survey to complete. The only difference between the two is the inclusion criteria; the surveys are the same.
223471204|NCT00044291|PROCEDURE|antiestrogen therapy|
223471205|NCT00266708|DRUG|Risedronate|risedronate 35 mg weekly
223579596|NCT05155501|PROCEDURE|Robot-assisted radical prostatectomy (RP)|The conventional approach to prostate cancer surgery
223579597|NCT05155501|PROCEDURE|Pelvic fascia-sparing robot-assisted radical prostatectomy (PFS-RP)|A novel, posterior approach to radical prostatectomy that preserves the dorsal vascular complex, nerves and fascial support structures that overlie the anterior prostate.
223579598|NCT06204159|DEVICE|TACE Catheters|"End Hole and TriNav catheters are FDA approved. This study is comparing the two for chemotherapy delivery during the TACE procedure.~This study will randomize which catheter is used for the first TACE procedure and the other catheter will be used for the second TACE procedure"
223471206|NCT00266708|DRUG|Placebo|Risedronate Placebo 35 mg weekly
223471207|NCT01926028|BIOLOGICAL|NDV-3A|0.5mL injection IM
223471208|NCT01926028|BIOLOGICAL|NDV-3|0.5mL injection IM
223471209|NCT01926028|BIOLOGICAL|Placebo|aluminum hydroxide and buffered saline
223471210|NCT00348400|DRUG|Brimonidine Purite 0.15%, Dorzolamide 2%, Latanoprost|
223471211|NCT03012269|BEHAVIORAL|Working memory training|
223471212|NCT04892069|DRUG|Insulin Degludec/Insulin Aspart|All patients have been treated at the discretion of the treating physician in accordance with the Ryzodeg® label in Lebanon. Decision to initiate treatment with commercially available Ryzodeg® has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician before and independently from the decision to include the patient in this study.
223471213|NCT02932436|DRUG|Empagliflozin|10 mg per os daily for 12 weeks
223471214|NCT02932436|DRUG|Placebo|amount of Placebo corresponding to empagliflozin 10 mg per os daily for 12 weeks
223471215|NCT04577872|OTHER|Pelvic floor muscle training|The treatment for the sitting group comprised 8 sessions, with a 1-hour combined pelvic floor muscle training (cPFM-T) session each week in a group and 15 minutes of individual home training, six times a week for a total of 8 weeks of treatment. All training sessions comprised warming-up, gradual muscle strengthening and relaxation exercises. In the study, before and after the training programme, we used a self-administered questionnaire.We measured changes in pelvic floor muscle activity with a vaginal surface electromyographic instrument. We performed the transversus abdominis measurements at the same time as the vaginal measurements and pelvic floor muscle tasks.
224159959|NCT04616794|BEHAVIORAL|Physical Activity Group|Participants in this group will be encouraged to lead a physically active lifestyle, as a means for cognitive decline/dementia risk reduction. This will be achieved by providing educational materials, practical tips and strategies, and suggestions about the different options to increase physical activities and by assisting participants outlining goals to progressively adopt a more physically active lifestyle.
224159960|NCT04616794|BEHAVIORAL|Diet Group|Participants in this group will be encouraged to adopt a healthy diet, as a means for cognitive decline/dementia risk reduction. This will be achieved by providing educational materials, practical tips and strategies, and suggestions about the different options to change their diet and by assisting participants outlining goals to progressively adopt a Mediterranean-like diet.
224159961|NCT04616794|BEHAVIORAL|Multimodal group|Participants assigned to this group will select which domain they wish to tackle first. Interventions are as described for the single-domain interventions.
223471216|NCT01130272|DRUG|Eluxadoline|Tablets, orally, twice daily.
223471217|NCT01130272|DRUG|Placebo|Matching placebo oral tablets twice daily.
223471218|NCT03559634|DIAGNOSTIC_TEST|Intervention Group|The electronic application will collect screening health information and contraceptive preferences about the participant. Then, using branch logic, decide which contraceptive options the participant would qualify for based on health history answers. Contraceptive choices being offered include the contraceptive implant, injection, pill, patch, or ring. They will then be able to watch videos about methods they are eligible for. The participant can then decide if they would like to start a medication they qualify for in the ED.
223471219|NCT03559634|OTHER|Control Group|The electronic application will collect screening health information and contraceptive preferences about the participant. Then, using branch logic, decide which contraceptive options the participant would qualify for based on health history answers. This includes the contraceptive implant, injection, pill, patch, or ring. They will then be able to watch videos about methods they are eligible for. Participants will then be given follow up information on outpatient locations where they can receive these contraceptive methods.
223471220|NCT01548404|DRUG|Placebo|Subcutaneous injection altered between back of arms, abdomen and upper thighs.
223471221|NCT01548404|DRUG|Dupilumab|Subcutaneous injection altered between back of arms, abdomen and upper thighs.
223471222|NCT00641056|DRUG|Exenatide Once Weekly|subcutaneous injection, 2.0mcg, once weekly
223471223|NCT00641056|DRUG|Insulin Glargine|subcutaneous injection, variable dose, QD
223471224|NCT00737048|DRUG|Tramadol Hydrochloride|Tramadol hydrochloride two oral capsules will be administered once as 75 milligram (mg).
223471225|NCT00737048|DRUG|Acetaminophen|Acetaminophen two oral capsules will be administered once as 650 mg.
223471226|NCT00737048|DRUG|Placebo|Two oral tablets or capsules of matching Placebo will be administered once along with Tramadol Hydrochloride and/or acetaminophen.
223471227|NCT00737048|DRUG|Tramadol plus Acetaminophen|Tramadol hydrochloride and acetaminophen combination tablet will be administered as single oral dosing of two tablets at a dose of 75 and 650 milligram respectively.
223471228|NCT04175717|OTHER|physiotherapy-led follow-up programme|In this study arm, the participants will receive a nine weeks exercise programme and four education sessions. During the exercise programme, the patients will exercise twice per week under supervision and once by themselves. The supervised exercise sessions will consisted out of a combination of a cardiopulmonary and strength training and the unsupervised session will be an activity, which the participants like doing. Additionally, when the patient shows a reduced maximal inspiratory pressure (indication for a reduced diaphragm strength), the patient will also be ask to do an inspiratory muscle training at home. Furthermore, they will participate in education sessions, where they learn things about the intensive care unit, the post-intensive care syndrome, relaxation techniques and how to carry on with exercising.
223471229|NCT05352646|DRUG|Autologous memory lymphocyte Injection (NewishT), low-dose group|Recruited participants in low-dose group will receive autologous memory lymphocyte (NewishT) intravenous infusion every 4 weeks, a total of 2 times.
223471230|NCT05352646|DRUG|Autologous memory lymphocyte Injection (NewishT), high-dose group|Recruited participants in high-dose group will receive autologous memory lymphocyte (NewishT) intravenous infusion every 2 weeks, a total of 4 times.
223471231|NCT05591521|OTHER|Using different survey to evaluate pain|Survey will be at different time of the IVF protocol (at the first medical appointment in the medically assisted department, after stimulation, after oocytes retrieval, after embryo transfer, one month after the IVF protocol)
224159962|NCT05270083|DIAGNOSTIC_TEST|NeuraCeq PET imaging with intravenous (IV) dose of 300MBq of Neuraceq™ ([F-18]Florbetaben)|Participants will receive an intravenous (IV) dose of 300 MBq of Neuraceq™ in a volume of 10 mL or less. A 30 minute duration PET image will be acquired starting immediately after Neuraceq™ injection. A second 20-minute duration PET image will be acquired starting 90 minutes after Neuraceq™ injection.
224159963|NCT06135454|PROCEDURE|Open Wedge High Tibial Osteotomy|For OWHTO,The osteotomy plane, directed from 30 to 35 mm distal to the medial tibial plateau to 10-15 mm distal to the lateral tibial plateau in the coronal plane, was marked by two Kirschner wires with threaded tips. A transverse osteotomy was performed, leaving the lateral cortex intact as a hinge. After the ascending osteotomy and opening. The medial opening gap was filled with two β-TCP wedges and fixed with a TomoFix anatomical plate and locking screws .
223471232|NCT02351934|DRUG|Furosemide|
223471233|NCT02351934|DRUG|Celecoxib|Celecoxib is a nonsteroidal anti-inflammatory drug (NSAID) used to treat pain or inflammation.
223471234|NCT02351934|DRUG|Gabapentin|Gabapentin is a oral drug used to treat seizures, postherpetic neuralgia, and restless legs syndrome.
223471235|NCT00896493|DRUG|anti-thymocyte globulin|ATG will be administered five times intravenously at 1.5 mg/kg/day from day -11 through day -7 for a total dose of 7.5 mg/kg
223471236|NCT00896493|DRUG|cyclosporine|5 mg/kg PO or IV
223471237|NCT00896493|RADIATION|Lymphoid radiation|TLI is administered ten times in 80c- 120c Gy fractions on day -11 through day -7 and day -4 through day -1
223471238|NCT01530542|DRUG|oxycodone hydrochloride|oxycodone hydrochloride 5 mg tablet under fasted conditions
223471239|NCT01530542|DRUG|oxycodone hydrochloride|2 x oxycodone hydrochloride 5 mg tablets under fasted conditions
223471240|NCT01530542|DRUG|oxycodone hydrochloride|2 x oxycodone hydrochloride 7.5 mg tablets under fasted conditions
223471241|NCT01530542|DRUG|oxycodone hydrochloride|2 x oxycodone hydrochloride 7.5 mg tablets under fed conditions
223471242|NCT01530542|DRUG|marketed oxycodone hydrochloride|1 x oxycodone hydrochloride 15 mg tablet under fed conditions
224159964|NCT06135454|PROCEDURE|Double Level Osteotomy|The DLO was started from a lateral DFO. A 5-6-cm incision was made proximally at the distal femur from the lateral femoral epicondyle.Two Kirschner wires with threaded tips were inserted to make a length between the wires that was preoperatively planned as the lateral closed osteotomy. Transverse and ascending osteotomies were performed using a Precision Oscillating Tip Saw. The gap was closed and fixed using a TomoFix medial distal femur anatomical plate , which was bent for the lateral distal femur. The subsequent OWHTO was performed as described above.
224159965|NCT00499460|DIETARY_SUPPLEMENT|garlic powder tablets|Each Garlicin tablet has a claimed allicin content of 3,200 microgram per tablet
224159966|NCT00499460|DRUG|oxycodone|Single administration of three 5-mg oxycodone tablets or a 15-mg dose
224159967|NCT05268705|OTHER|7-day diet|The participants must follow a 7-day high-carbohydrate-low-fat-low-protein diet before the inclinic study visit at day 8. The in-clinic study visits are identical for all the three study arms.
224159968|NCT05268705|OTHER|7-day diet|The participants must follow a low-carbohydrate-high-fat-low-protein diet before the inclinic study visit at day 8. The in-clinic study visits are identical for all the three study arms.
223471243|NCT03185000|DRUG|TR004 (Treg immunotherapy)|Administered Intravenously (IV)
223471244|NCT03821961|PROCEDURE|Metabolic Surgery|Roux-en-Y gastric bypass, Sleeve gastrectomy
224159969|NCT05268705|OTHER|7-day diet|The participants must follow a low-carbohydrate-low-fat-high-protein diet before the inclinic study visit at day 8. The in-clinic study visits are identical for all the three study arms.
224159970|NCT06507085|RADIATION|Radio-guided interventions to correct heart rhythm disorders|"All patients in the cohort will be undergoing one of the following radio-guided procedures :~* Insertion of a single-chamber pacemaker with lead~* Insertion of a dual-chamber pacemaker with lead~* Implantation of a multi-site pacemaker~* Implantation of a single-chamber endovascular defibrillator~* Implantation of a dual-chamber endovascular defibrillator~* Placement of multi-site defibrillator~* Typical Primary Atrial Flutter Ablation: Cavotricuspid Isthmus only~* Primo Ablation tachycardia by intra nodal re-entry~* Accessory pathway ablation~* Paroxysmal atrial fibrillation ablation (4 pulmonary veins only, all technologies combined~* Primo Ablation Persistent atrial fibrillation (4 pulmonary veins ± lines ± substrate"
224159971|NCT01525524|DEVICE|Transcranial Direct Current Stimulation|In active stimulation(active Transcranial Direct Current Stimulation), the anode is placed over the left dorsolateral prefrontal cortex and the cathode is placed over the right prefrontal cortex. They are located five centimeters ventrally of the primary motor area, which are located five centimeters laterally of the central point of the scalp (which is located on the intersection of the sagittal and median curves). The device will deliver a charge of 2mA for 30 minutes.
224159972|NCT04459923|PROCEDURE|ultrasound-guided erector spinae plane block catheter|for postoperative pain management ultrasound-guided erector spine plane block catheter placement
224159973|NCT04459923|PROCEDURE|thoracic epidural catheter|for postoperative pain management thoracic epidural catheter placement
224159974|NCT02210455|BEHAVIORAL|Strongest Families FASD intervention|
224159975|NCT02210455|OTHER|Psychoeducation|
224159976|NCT03871465|DRUG|Triamcinolone SASD injection|2ml triamcinolone (1ml/10mg) and 3ml 1% xylocain will be injected into the affected SASD bursa under ultrasound guidance.
223471245|NCT03210740|DRUG|AM001 Cream, 7.5%|Active Cream
223471246|NCT03210740|DRUG|Vehicle Cream|Placeo
223471247|NCT01115452|DRUG|5% Potassium nitrate|5% potassium nitrate solution
223471248|NCT01115452|DRUG|2.5% Potassium nitrate|2.5% potassium nitrate solution
223471249|NCT01115452|OTHER|Sterile water|Sterile water
223471250|NCT06290986|PROCEDURE|Pyrocardan® implant|Biconcave-shaped CMC-1 interposition implant
223471251|NCT06290986|PROCEDURE|Ligament reconstruction and tendon interposition (LRTI)|Weilby slightly modified as described by Burton and Pellegrini
223471252|NCT05645198|DRUG|Oozfix|Directly apply carboxymetyl starch (Oozfix) 5 gram evenly at the suprapancreatic surgical bed after gastrectomy
223471253|NCT05645198|DRUG|Greenplast|Directly apply Greenplast (Aprotinin 1000kIU/mL, Thrombin 500IU/mL, Fibrinogen 95mg/mL) 4 gram evenly at the suprapancreatic surgical bed after gastrectomy
223471254|NCT05941806|DRUG|pr Sandoz Tamsulosin|Sandoz Tamsulosin, the study drug, is an alpha1-adrenergic blocking agent approved by Health Canada for men with bladder outlet obstruction symptoms associated with benign prostatic hyperplasia.
223471255|NCT05941806|DRUG|Glucose|Patients assigned to the placebo group will receive glucose capsules according to the same protocol. The glucose capsules will be manufactured by the pharmacy of the CHU de Quebec
223471256|NCT04315441|DIAGNOSTIC_TEST|STEPS and AUDIT questionnaires|assessment was done according to World Health Organization STEPS manual for surveillance of risk factors of Non-communicable chronic diseases; and the Alcohol Use Disorders Identification Test. Five cardiovascular risk factors were assessed, smoking, harmful alcohol consumption, obesity/overweight, hypertension and diabetes. Cardiovascular risk was considered high in subjects with three or more cardiovascular risk factors.
223471257|NCT00004817|DRUG|phenytoin|
223471258|NCT00004817|DRUG|valproate sodium|
223471259|NCT02744716|DRUG|Aspirin|low dose of Aspirin after operation
223471260|NCT02744716|DEVICE|intrauterine balloon|insert intrauterine balloon after operation
223471261|NCT04718922|DRUG|Chlorhexidine Gluconate 0.12 % Mouthwash|Intervention with chlorhexidine mouthrinse will be performed approximately 10 min before the start of EBUS-TBNA
224159977|NCT03871465|PROCEDURE|Physiotherapy|The physiotherapy program consists of hot pack, interferential therapy, and exercise program, which includes stretch exercise, mobilization of the glenohumeral joint, manual pressure to the possible trigger points, scapular stabilization exercise, and strengthening exercise of the rotator cuff, trapezius, and serratus anterior muscles.
224159978|NCT03871465|DRUG|Triamcinolone injections & Physiotherapy|"2ml triamcinolone (1ml/10mg) and 3ml 1% xylocain will be injected into the affected SASD bursa under ultrasound guidance.~The physiotherapy program consists of hot pack, interferential therapy, and exercise program, which includes stretch exercise, mobilization of the glenohumeral joint, manual pressure to the possible trigger points, scapular stabilization exercise, and strengthening exercise of the rotator cuff, trapezius, and serratus anterior muscles."
224159979|NCT04509362|DEVICE|Advanced Hybrid Closed Loop System|Evaluation of the use of an 8-day structured protocol to initiate patients from MDI to the AHCL system, in achieving safe glycemic control
224159980|NCT05448508|DEVICE|Automatic lancet|An automatic lancet, which can reach a depth of 2.4 mm-3 mm, was used for safe piercing in babies.
223471262|NCT01739335|DRUG|Mifepristone Oral Tablet [Korlym]|2 Mifepristone 300 MG Oral Tablets once daily (600mg total) for 7 days
223471263|NCT01739335|DRUG|Placebo Oral Tablet|2 Placebo Oral Tablets once daily for 7 days
223471264|NCT00619840|DRUG|methylphenidate hydrochloride|sustained release, 10 mg capsule 1-3 capsules twice daily according to an individual titration schedule
223471265|NCT00619840|DRUG|Placebo|10 mg capsule 1-3 capsules twice daily according to an individual titration schedule
223471266|NCT04333693|PROCEDURE|Vascular surgery|Open vascular, endovascular or hybrid procedures
223471267|NCT01086488|DRUG|FOSCAN|Patients will be randomised to one of two treatment groups. The first group of 26 patients will receive 0.1 mg/kg Foscan® at a drug-light interval of 48 hours (2 days). A single surface illumination light dose of 20 J/cm2 fluence rate of 50 mW at 652 nm will be used. The second reference group of 26 patients will be treated by intracavitary brachytherapy
223471268|NCT03498677|BEHAVIORAL|presentation order|section presentation one
223471269|NCT03498677|BEHAVIORAL|alternative presentation order|section presentation two
223471270|NCT05885217|OTHER|measure serum MicroRNA in acne vulgaris|Quantitively assay of serum microRNA level will be measured control by performing an enzyme-linked immune sorbent assay (E LISA)
223471271|NCT01657617|RADIATION|Boost Stereotactic Body Radiation Therapy|"The dose and fractionation scheme utilized will be based on the location of the patient's residual disease. For patients with:~Peripheral Tumors: Treatment will consist of 2 fractions of radiation, with a minimum of 40 hours separating each fraction. Two fractions of 10 Gy with inhomogeneity correction will be delivered to the prescription line at the edge of the PTV for a total of 20 Gy. This will yield a total BED of 110 Gy.~Medial Tumors: Treatment will consist of 3 fractions of radiation, with a minimum of 40 hours separating each fraction. Three fractions of 6.5 Gy with inhomogeneity correction will be delivered to the prescription line at the edge of the PTV for a total of 19.5 Gy. This will yield a total BED 102.2 Gy."
223471272|NCT03057574|DRUG|Follitropin Alfa|Patients must be prescribed Follitropin Alfa (Gonapure®)
223471273|NCT02105324|DEVICE|Bionic Pancreas|Automated blood glucose control via a closed-loop bionic pancreas device.
223471274|NCT02105324|OTHER|Usual Care|As a comparator control, usual diabetes camp care with the participant's own insulin pump.
223471275|NCT04020367|PROCEDURE|biopsy of mucosa's olfactory|intervention under general or local anesthesia
223471276|NCT04609137|PROCEDURE|Early drain removal|"Patients randomized to the experimental group, will have an early drain removal if DFA on POD1 is lower than 2000 U/L and/or the drain fluid does not appear sinister (i.e. varying from dark brown to greenish fluid to milky water to clear spring water pancreatic juice like appearance) according to the clinical team. If DFA is greater than 2000 U/L, the drain will be maintained in place. If the sample on POD1 DFA is not available (e.g. drainage fluid is viscous and amylase value cannot be evaluated) or the sample could not be analyzed DFA will be evaluated on POD2, and drain removal will be considered if DFA is lower than 2000 U/L. If DFA on POD 3 is lower than 300 U/L, that is 3-fold the upper limit of normal serum amylase value, and/or the drain fluid does not appear sinister according to the clinical team, the drain will be removed. Otherwise, the drain will be kept in place and the patient will then follow standard postoperative drain management."
223471277|NCT04609137|PROCEDURE|Standard drain removal|"Patients randomized to this group will receive the current standard of care, thus the drain will be maintained at least until postoperative day 5. If DFA on POD 5 is lower than 3-fold the upper limit of normal serum amylase value, and/or the drain fluid does not appear sinister (i.e. varying from dark brown to greenish fluid to milky water to clear spring water pancreatic juice like appearance) according to the clinical team, the drain will be removed. If the drain is maintained in place beyond POD 5, it will be removed inhospital or after discharge when the daily amount is lower than 10 ml and there are no signs of ongoing infection"
223471278|NCT01679743|DRUG|Trastuzumab|Trastuzumab will be administered after GRN1005 in patients with HER2+ metastatic breast cancer.
223471279|NCT01679743|DRUG|GRN 1005|GRN1005 will be administered at a dose of 550 mg/m2 as an IV infusion at a rate of 8.0 - 8.5 mL/minute on Day 1 of 21-day cycle ( 3 days) and a second dose will be given on the day of surgery (day 21) 3-6 h prior to surgery.
224159981|NCT05625633|BIOLOGICAL|Human Papillomavirus 9-valent Vaccine, Recombinant|0.5-mL suspension of 9-valent Gardasil administered as intramuscular injection at weeks 0, 4, and 20
224159982|NCT05625633|OTHER|Normal Saline|0.5-mL normal saline administered as intramuscular injection at weeks 0, 4, and 20
224159983|NCT04313088|DRUG|Eluxadoline 100 mg|Eluxadoline 100mg by mouth twice daily with food
224159984|NCT02740218|OTHER|Patient questionnaire|Patients will be asked to complete a questionnaire regarding their expectations, experience and satisfaction in taking OTEZLA (apremilast) treatment
224159985|NCT05337150|BEHAVIORAL|Lifestyle Modification Intervention|For the first 12-weeks of the study, participants will complete weekly web modules in which they will learn cognitive-behavioral strategies to support lifestyle modification. Participants will also receive weekly phone coaching calls for the first 12-weeks of the study, and monthly coaching calls thereafter for the remainder of the 24-week study period.
223471280|NCT06257732|OTHER|Exercise|The exercise interventions in this study include High-Intensity Interval Training (HIIT), involving brief bursts of intense exercise; Resistance Exercise, focusing on strength and muscle endurance; and Fatmax Exercise, tailored to optimize fat oxidation during aerobic activity.
223471281|NCT06257732|BEHAVIORAL|Motivational Interviewing|Motivational Interviewing will be employed as a counseling technique to elicit behavior change by fostering collaborative and empathetic conversations, enhancing motivation for positive lifestyle modifications in individuals with liver fat accumulation.
223471282|NCT04602286|OTHER|Meditation (1 x 20-minute guided audio training)|Participants will complete a single session of 20-minutes online guided audio-delivered training session of one of the four conditions.
223579599|NCT02993042|DEVICE|Robot-assisted gait training|Patients should use their belts (Harness) to support their weight when walking in equipment. In the first training session, the patient focuses on fitting and adapting the equipment and helps the patient learn. To minimize skin damage, the patient can wear a protector. The initial walking speed starts at 1.5km / h (0.42m / s) and can be increased gradually to 3.0km / h (0.83m / s) by increasing to 0.2km / h (0.06m / s) per session. The therapist provides appropriate visual and auditory instructions to allow the patient to participate as fully as possible in the walking cycle provided by the walking robot. The treatment time per session is 30 minutes except for the time of wearing and releasing.
223579600|NCT00795834|DIETARY_SUPPLEMENT|High polyphenol beverage|"Antioxidant capacity umol TE/L(ORAC): 19987 Polyphenolic Content(mcg/ml): 1445 Vitamin C (mg/100ml): 35.35 Calorie Content (Kcal/250ml):40.0~250ml twice daily for 1 month (56 doses)"
223579601|NCT00795834|DIETARY_SUPPLEMENT|Placebo Beverage|"Antioxidant capacity umol TE/L(ORAC): negligible Polyphenolic Content(mcg/ml): negligible Vitamin C (mg/100ml): 0.00 Calorie Content (Kcal/250ml):40.0~250ml twice daily for 1 month (56 doses)"
223579602|NCT05216055|COMBINATION_PRODUCT|Ropivacaine, Dexmedetomidine, Dexamethasone sodium phosphate, Normal saline|Ropivacaine 0.5% HCl, 40 mL (5 mg per mL) (200 mg) Dexmedetomidine HCl, 0.50 ml (100 ug per mL) (50 ug) Dexamethasone sodium phosphate, 1 mL (10 mg per mL) (10 mg) Normal saline 0.9%, 18.5mL
223743797|NCT03257553|DIAGNOSTIC_TEST|fecal calprotectin , doppler and ultrasound|faecal sample for measurement of calprotectin level ultrasound and doppler
223743798|NCT02121587|BEHAVIORAL|Pain self-management course|This is an observational study of patient-reported outcomes from an experiential pain self-management course which integrates mindfulness and acceptance-based exercises into osteopathic manual therapy treatment. The intervention consists of six, individual, one-hour osteopathic evaluation and treatment sessions which incorporate pain education, the development of mindfulness skills to enhance body awareness, and the identification of personal values to promote compassionate self-care and sustain commitment to active coping strategies. The intervention aims to enhance patients' well-being and resilience through developing psychological and behavioural flexibility in response to persistent pain.
224159986|NCT05337150|BEHAVIORAL|Balanced Calorie Deficit Eating Plan|Participants will be prescribed a calorie target between 1200 and 1800 depending upon baseline weight and personal preference. Participants will be asked to monitor their dietary intake using MyFitnessPal and to submit food logs weekly. Calorie reduction content will be based primarily on the Diabetes Prevention Program protocol and adapted from existing behavioral treatment protocols. Individuals will receive general guidelines on eating a healthy diet, including reducing saturated fat, processed foods, refined sugars, and refined carbohydrates, and increasing intake of lean proteins, whole grains, and fruits and vegetables, but will be encouraged to flexibly decide which areas of their diet to modify to reduce calorie intake.
224159987|NCT05337150|BEHAVIORAL|Ad Libitum Whole Food Plant-Based Eating Plan|Participants will be prescribed a whole food plant-based (WFPB) low-fat vegan diet promoting intake of fruits, vegetables, starches, legumes, and whole grains. Participants will be encouraged to avoid processed foods, refined oils, and animal products (meat, fish, eggs, and dairy products), and to minimize consumption of high-fat plant-based foods. An adapted traffic-light diet chart will outline foods to eat daily, limit, and avoid. Participants will be advised to eat until satiation and not restrict energy intake. Participants will be asked to consume 50 μg vitamin B12 (methylcobalamin) daily. WFPB nutrition counseling content will be based upon existing successful programs. Each week, participants will complete a simplified dietary self-monitoring food frequency questionnaire aligned to correspond with the traffic light diet chart.
224159988|NCT02290340|DRUG|Placebo|Participants will receive placebo intramuscularly.
224159989|NCT02290340|DRUG|MEDI8897 10 mg|Participants will receive a single dose of MEDI8897 10 milligram (mg) intramuscularly.
224159990|NCT02290340|DRUG|MEDI8897 25 mg|Participants will receive a single dose of MEDI8897 25 mg intramuscularly.
224159991|NCT02290340|DRUG|MEDI8897 50 mg|Participants will receive a single dose of MEDI8897 50 mg intramuscularly.
224159992|NCT00118469|BEHAVIORAL|Psychoeducation|
223471283|NCT03774108|DRUG|Metformin Hydrochloride 850 MG|8 weeks tratment with oral metformin
223471284|NCT03774108|OTHER|Placebo|8 weeks tratment with oral placebo
223471285|NCT02659501|DRUG|Liposomal bupivacaine|Liposomal Bupivacaine is an aqueous suspension of multivesicular liposomes containing bupivacaine. After injection into soft tissue, bupivacaine is slowly released from the multivesicular liposomes, extending this drug's duration of action.
223471286|NCT02659501|DRUG|Bupivacaine with epinephrine|Bupivacaine, like other local anesthetics reduces the flow of sodium in and out of nerves. This decreases the initiation and transfer of nerve signals in the area in which the drug is injected. This leads first to a loss of sensation of pain, temperature, touch, and deep pressure. This drug is the current standard of care for local, postoperative local anesthesia following breast reconstruction. Epinephrine, a vasoconstrictor, is included in bupivacaine formulations to improve the duration of local anesthesia.
223471287|NCT02659501|DRUG|Morphine sulfate|Morphine is an opiate pain medication administered intravenously for severe, breakthrough post-operative pain.
223471288|NCT02659501|DRUG|Hydrocodone/acetaminophen|Hydrocodone acetaminophen is a combination of an opiate pain medication (hydrocodone) and a non-steroidal anti-inflammatory drug (acetaminophen) given orally to patients for moderate post-operative pain.
223471289|NCT02659501|DRUG|Diazepam|Diazepam is a benzodiazepine medication that is administered orally to treat muscle spasms in patient's following expander and implant-based breast reconstruction.
223471290|NCT00691275|DRUG|Ondansetron|
223471291|NCT00691275|DRUG|Saline|
223579603|NCT05216055|DRUG|Liposomal bupivacaine|Liposomal bupivacaine, 20 mL (13.3 mg/ml) (266 mg) Normal saline 0.9%, 40mL
223471292|NCT03228082|DEVICE|Home Blood Pressure Monitoring (HBPM)|Home blood pressure monitoring using the Withings Wireless BP monitor. Patients will be asked to measure their blood pressure twice daily for 7 consecutive days. This will be repeated for every month for 1 year.
223471293|NCT04040439|DRUG|Dexmedetomidine Hydrochloride|"\[Sedation during and after mechanical ventilation in the intensive care setting\] For pediatric patients ages of 6 years and over, dexmedetomidine is usually administrated by continuous intravenous (IV) infusion of at a rate of 0.2 μg/kg/hr, following by continuous infusion at a range of 0.2 to 1.0 μg/kg/hr adjusted to achieve the optimal level of sedation depending on the patient's condition.~For pediatric patients with corrected gestational ages (gestational age + postnatal age) of 45 weeks to under 6 years, dexmedetomidine is usually administrated by continuous IV infusion at a rate of 0.2 μg/kg/hr, following by continuous infusion at a range of 0.2 to 1.4 μg/kg/hr adjusted to achieve the optimal level of sedation depending on the patient's condition. The dosing rate could be decreased according to the patient's condition as appropriate."
223471294|NCT02982759|BEHAVIORAL|Multi-Level Intervention|The multi-level interventions will include activities at the individual level, family level, school level, and community level.
223471295|NCT02982759|BEHAVIORAL|Genetic Newsletters|The comparison will receive generic newsletters
223471296|NCT03243149|DEVICE|fMRI - GE Medical System|"Recovery from PTSD symptoms has been modeled experimentally as fear extinction that depends on three interconnected brain regions that involve the amygdala where extinction memories are stored, the subcallosal/subgenual cortex within the medial PFC involved in consolidation of the extinction memory, and the hippocampus which mediates the context specificity of context specificity of extinction.~The two MRI systems are used for human research by many faculty and research groups at Duke and UNC, Chapel Hill. The center has two research dedicated General Electric MR 750 scanners with a field strength of 3 Tesla. These systems use a combination of General Electric production pulse sequences and custom research pulse sequences that have been developed by Brain Imaging and Analysis Center faculty and other MR physicists. The scanners are used for imaging and spectroscopy."
223471297|NCT03485534|DRUG|Tenofovir Disoproxil Fumarate|Viread 300mg
223471298|NCT03485534|DRUG|Tenofovir Disoproxil|Virehepa 245mg
223471299|NCT05495178|PROCEDURE|laparoscopic restorative proctocolectomy|laparoscopic restorative proctocolectomy
223579604|NCT00046930|BIOLOGICAL|filgrastim|250 μg/m2/day by either intravenous or subcutaneous injection starting day 12, provided marrow aplasia is achieved, through recovery of absolute neutrophil count (ANC) to \> 500 cells/μl, sustained for 3 consecutive days. The dose may be rounded to the nearest vial size.
223579605|NCT00046930|BIOLOGICAL|sargramostim|5 μg/kg/day by either intravenous or subcutaneous injection starting day 12, provided marrow aplasia is achieved, through recovery of absolute neutrophil count (ANC) to \> 500 cells/μl, sustained for 3 consecutive days. The dose may be rounded to the nearest vial size.
223579606|NCT00046930|DRUG|cytarabine|100 mg/m²/day by continuous intravenous infusion for 7 days (days 1-7).
224159993|NCT00118469|BEHAVIORAL|Cognitive behavior therapy|
224159994|NCT05366257|OTHER|CAR-T|infusion of CAR-T therapy among patients with r/r DLBCL
223579607|NCT00046930|DRUG|daunorubicin hydrochloride|45 mg/m²/day by 10 - 15 minute intravenous infusion for 3 days (days 1, 2, and 3).
223579608|NCT00046930|DRUG|zosuquidar trihydrochloride|"Zosuquidar 550 mg/day by continuous intravenous infusion through a central venous catheter over approximately 6 hours on days 1, 2, and 3.~The infusion will begin approximately one hour prior to daunorubicin on days 1, 2 and 3."
223579609|NCT00046930|DRUG|Placebo|"Placebo 550 mg/day by continuous intravenous infusion through a central venous catheter over approximately 6 hours on days 1, 2, and 3.~The infusion will begin approximately one hour prior to daunorubicin on days 1, 2 and 3. Placebo consisted of a 1:1000 dilution of Infuvite, appropriately colored."
223579610|NCT02606266|DRUG|Valganciclovir|Oral valganciclovir (Rovalcyte 50 mg/ml, powder for oral suspension) at a dose of 16 mg/kg 2 times/day (max 900 mg/d) for 6 weeks.
224159995|NCT05366257|OTHER|Allo-HSCT cohort|Patients received allogeneic hematopoietic stem cell transplant
223471300|NCT06313645|OTHER|Several biomarkers|Telomere length Mitochondrial DNA copy number (mtDNAcn) MitomiR long non-coding (lnc) RNA TERRA pro-oxidant cytokines \& chemokines
223471301|NCT01309386|DRUG|Tapentadol ER|Tapentadol ER 100 to 400 milligram (mg) orally daily for 8 weeks (maximum up to 500 mg daily), as per Investigator's discretion.
223471302|NCT01309386|DRUG|Morphine SR|Morphine SR 30 to 120 mg orally daily for 8 weeks (maximum up to 140 mg daily), as per Investigator's discretion.
223471303|NCT04785729|DRUG|Almonertinib combine with Pyrrolitinib|110mg,qd Almonertinib+（240mg/320mg/400mg）,qd Pyrrolitinib
223471304|NCT00778050|DRUG|Amoxicillin 600mg|
223471305|NCT00937963|DIETARY_SUPPLEMENT|Palm DAG Oil|Use of Palm DAG Oil to replace palm oil traditionally used in foods
223471306|NCT01414478|OTHER|Protein Shake|Protein shake contains 30 grams of protein in 11 fluid ounces.
223471307|NCT04715490|OTHER|The Multimedia Symptom Management Program Intervention|"The program is composed of two parts: 1) a face-to-face presentation about the contents of the program, and 2) structured telephone support. The first part of the program will be conducted in the cardiology outpatient department. Participants will be instructed to read a HF handbook.~The second part of the program, structured telephone support, allowed the nurses to maintain contact with the participants in order to follow their progress. The participants will be scheduled to receive eight telephone coaching calls over a 3-month period."
223579611|NCT02311569|DRUG|Mirabegron|25 mg daily during the first week followed by 50 mg Mirabegron daily during the remaining treatment period.
223579612|NCT03924921|OTHER|autogenic training|autogenic training
224159996|NCT02509676|OTHER|stretching exercise|dynamic stretching exercises with 5 repetitions, each lasting 45 seconds, for 5 days a week and 3 times a day
224159997|NCT04213183|DIAGNOSTIC_TEST|Hepatobiliary Disorders|The training dataset was used to train the deep learning model, which was validated and tested by the other two datasets.
224159998|NCT02861053|OTHER|regular and moderate physical activity|regular and moderate physical activity will be done 3 times per week more than usual
224159999|NCT02861053|OTHER|No regular and moderate physical activity more than usual|regular and moderate physical activity will be done as usual
224160000|NCT03307018|PROCEDURE|Postoperative systematic bronchial aspiration.|Postoperative flexible bronchoscopy and systematic bronchial aspiration.
223471308|NCT04715490|OTHER|Control group|The control group will be provided with the HF handbook at the beginning of the 3-month period, and also will be received usual care, which included medical consultations, and two telephone calls.
223471309|NCT04596969|OTHER|Soluble Fiber Dextrin|Ingredient based on resistant starch
223471310|NCT00224263|DRUG|Lingzhi (Ganoderma)|
223471311|NCT05676229|DIETARY_SUPPLEMENT|Probiotic blend|Lactobacillus gasseri CCT 7850 and Bifidobacterium lactis CCT 7858
223471312|NCT05676229|DIETARY_SUPPLEMENT|Placebo|Maltodextrin only (vehicle)
223743799|NCT05798572|DRUG|Sildosin group|Patients in this group had flexible ureteroscopy (F-URS) with preoperative daily uptake of 8 mg silodosin for one week.
223579613|NCT03476161|DEVICE|3M Unitek Victory Series™ Superior Fit Buccal Tube with APC™ Flash-Free Adhesive. 4069-6103 / 4069-6114 / 4069-6203 / 4069-6214|One type of first permanent molar buccal tube used for fixed orthodontic treatment. One types of adhesive, with same buccal tube base.
223579614|NCT03476161|DEVICE|3M Unitek Victory Series™ Superior Fit Buccal Tube with APC™ II Adhesive. 3069-6103 / 3069-6114 / 3069-6203 / 3069-6214|One type of first permanent molar buccal tube used for fixed orthodontic treatment. One types of adhesive, with same buccal tube base.
223579615|NCT02714881|DRUG|certolizumab|Subjects who are about to start TNFi therapy as part of usual therapy will be enrolled. In this study we will provide the drug, certolizumab.
223471313|NCT04811157|DIETARY_SUPPLEMENT|Test product|200 g/day of unsweetened yogurt supplemented with a dietary fiber blend
223471314|NCT04811157|DIETARY_SUPPLEMENT|Control product|200 g/day of unsweetened yogurt
223471315|NCT05626569|DRUG|PD-1 combined with SBRT|Anti-PD1 monoclonal antibody combined with SBRT. The SBRT defined as the radiation prescription with single dose equal or over 4Gy and the fractions less or equal to 10 fractions. BED equal or over 50Gy is required.
223471316|NCT04249479|OTHER|CM Temperature (20° C)|CM will be administered at 20° C (room temperature).
223471317|NCT04249479|OTHER|CM Temperature (37° C)|CM will be administered at 37° C (pre-heated).
223579616|NCT02714881|RADIATION|Stress myocardial perfusion PET|We will measure coronary flow reserve (CFR) using cardiac PET before the patients starts TNFi and 24 weeks after starting TNFi.
223579617|NCT00623662|OTHER|Preoperative glucose infusion|Glucose infusion from 15:00 on the day before the operation until beginning of surgery.
223471318|NCT04249479|OTHER|Weight|The patients' weight is measured prior to scanning by a technician on a weighing scale available in the scanner room.
223471319|NCT03529500|DIAGNOSTIC_TEST|Caries detection - dmtf index|"Dental caries experience was recorded using the dmft index, which was employed following the recommendations of the WHO to establish the prevalence and severity of caries. Active visible white spots were also recorded. The examinations were performed in duplicate for each child with the aim of establishing inter-examiner agreement using the Kappa statistic which demonstrated good agreement (K = 0.81).~The criteria adopted for the determination of prevalence followed by guidelines of the Oral Health Surveys - Basic Methods, 4th edition (WHO, 1997) described in the examiner's manual and annotator's manual produced by the coordination team of the Brazil Oral Health Project. The severity and prevalence of dental caries were determined based on the dmft index."
223471320|NCT03529500|DIAGNOSTIC_TEST|Saliva flow rate|Samples of non-stimulated saliva were collected from the participants for five minutes using two aspirator tubes connected to a 15-ml Falcon tube. One aspirator tube was positioned under the child's tongue and the other was attached to the aspirator device. After five minutes, the amount of saliva was measured for the determination of salivary flow. Collections were performed between 9 and 11 am and the time of the last meal was recorded. At least a one-hour interval was required between the last meal and the collection of the saliva sample. The volume of saliva was measured. The salivary flow volume was calculated and expressed as ml/min. The following categories were considered in the analysis of salivary flow: \< 0.1 ml/min = xerostomia; 0.1 to 0.6 ml/min = very low flow; 0.7 to 0.9 mL/min low flow; 1.0 to 2.0 ml/min = normal flow; and \> 2.0 ml/min = high flow.
223579618|NCT00623662|OTHER|Preoperative normal saline infusion|Normal saline infusion from 15:00 on the day before surgery until beginning of the operation.
223579619|NCT00290875|BEHAVIORAL|Use of Xrays for diagnosis|
223743800|NCT05798572|PROCEDURE|Placebo/control group|included 70 patients for whom flexible ureteroscopy (F-URS) was done with daily preoperative intake of placebo tablets.
223743801|NCT00861107|BIOLOGICAL|AlloStim-7|intradermal injection once a week for 3 weeks
223743802|NCT00861107|PROCEDURE|percutaneous tumor cryoablation|ablation of a tumor by percutaneous cryoablation under CT guidance
224160001|NCT04374149|PROCEDURE|Therapeutic Plasma Exchange|TPE, five single plasma volume exchanges over 7 days (every day x 2 then every other day x 3) with albumin or FFP replacement if underlying coagulopathy
224160002|NCT04374149|DRUG|Ruxolitinib|TPE, five single plasma volume exchanges over 7 days (every day x 2 then every other day x 3) with albumin or FFP replacement if underlying coagulopathy combined with ruxolitinib 5mg po BID beginning day prior to first TPE and continuing BID for total of 14 days.
223579620|NCT02994368|OTHER|Observation|
223743803|NCT00861107|BIOLOGICAL|AlloStim-7|intratumoral injection into cryoablated tumor lesion 1 hour after ablation
223743804|NCT00861107|BIOLOGICAL|AlloStim8 or AlloStim-9|intravenous infusion of AlloStim one week following ablation procedure. First cohort to receive 10\^8 cell dose and if no toxicity dose escalates to 10\^9 cell dose.
223743805|NCT05094934|DRUG|NNC0385-0434 A 100 mg|All participants will receive the same dose (100 mg) of the study medicine NNC0385-0434, which will be given for 10 days in a row. Participants will get the study medicine in a tablet taken orally once-daily. The study medicine needs to be taken in the morning after overnight fasting and 30 minutes before the first meal of the day.
223743806|NCT03669835|DIETARY_SUPPLEMENT|Mare milk supplement|Supplement consisting of sublimated mare's milk with single-dose 20 mg sachet. The supplement is dissolved in 36-27 degrees of Celsius water and taken 15-20 minutes before meal.
223743807|NCT03669835|DRUG|Standard therapy|For hepatitis virus C genotype 1: sofosbuvir 400 mg + lepidavir 90 mg for 12 weeks OR sofosbuvir 400 mg + daclatasvir 60 mg for 12 weeks; For hepatitis virus C genotypes 2 and 3: sofosbuvir 400 mg + daclatasvir 60 mg for 12 weeks.
224160003|NCT04819724|DIAGNOSTIC_TEST|3D motion analysis|30° arm abduction in the scapular plane will be performed with and without a handheld weight of 1, 2, 3, and 4 kg. All movements will be done bilaterally. Electromyographic (EMG) data of arm and trunk muscles will be recorded using surface electrodes. Participants will be asked to perform full arm abduction with different rotations (internal, neutral and external rotation), flexion and internal-/external rotations movements (without additional handheld weight).
224160004|NCT04819724|DIAGNOSTIC_TEST|isometric shoulder strength by dynamometer|isometric shoulder strength for abduction and internal/external rotation will be assessed with a isometric shoulder strength for abduction and internal/external rotation will be assessed with a dynamometer
224160005|NCT04819724|DIAGNOSTIC_TEST|fluoroscopic images of each shoulder|fluoroscopic images (Multitom Rax, Siemens Healthineers, Erlangen, Germany) of each shoulder will be taken during the 30° arm abduction test with and without a handheld weight (0, 2, and 4kg)
224160006|NCT04819724|DIAGNOSTIC_TEST|Bilateral shoulder Magnetic Resonance Imaging (MRI)|MRI of both shoulders will be taken
224304067|NCT00982176|OTHER|Brain MRI and cerebral perfusion scintigraphy|"A standard neuropsychological assessment will be performed by a neuropsychologist. The daily life experience study will be performed. Questions will be asked to the patients by a pocket computer (Palm).~MRI will be performed on a 3 Tesla research MRI. Two Tc-99m-HMPAO SPECT studies will be performed The second SPECT study will be performed after intravenous injection of acetazolamide."
223471321|NCT03529500|DIAGNOSTIC_TEST|Saliva Buffering Capacity|an aliquot of 1 ml was transferred to a test tube with 3 ml of hydrochloric acid (HCl 5 mM) for titration and the determination of salivary buffering capacity (SBC). The saliva/acid solution was shaken in a q 220 vortex tube agitator (Quimis, Diadema, SP, Brazil) for 15 seconds. Next, pH was determined in a portable pH meter (KASVI K39-0014P, Curitiba, PR, Brazil) for the determination of the SBC. The following categories were considered: ≥ 5.5 = very good buffering capacity; 5.4 to 5.0 = good buffering capacity; 4.9 to 4.5 = medium good buffering capacity; 4.4 to 4.0 = low buffering capacity; and ≤ 3.9 very low buffering capacity.
223471322|NCT05449899|DRUG|Granulocyte Colony-Stimulating Factor(G-CSF)|G-CSF was administered at 5 ug/kg/day on days-17 to -10. When white blood cell is more than 20G/L, stop using G-CSF.
223471323|NCT05449899|DRUG|Decitabine (DAC)|Decitabine was administered at 20mg/m2/day on days -14 to -10.
223471324|NCT05449899|DRUG|Busulfan (BU)|Busulfan was administered at 3.2 mg/kg/day on days -7 to -4 in G-CSF+DAC+BUCY group, and it was administered at 3.2 mg/kg/day on days -6 to -3 in G-CSF+DAC +BF group .
223471325|NCT05449899|DRUG|Fludarabine (FLU)|Fludarabine was administered at 30 mg/m2/day on days -7 to -3.
223471326|NCT05449899|DRUG|Cyclophosphamide (CY)|Cyclophosphamide was administered at 60 mg/kg/day on days -3,-2.
223471327|NCT00146562|DRUG|Darbepoetin Alfa|Given day before chemotherapy of red blood cell count is below normal
223471328|NCT00146562|DRUG|Pegfilgrastim|Given as an injection the day before chemotherapy for a total of 8 injections
224160007|NCT04819724|OTHER|data collection by health questionnaires|data collection by health questionnaires
224160008|NCT04841681|BEHAVIORAL|Video-based Psychotherapy|"Participants in the group watched three short videos. Therapeutic elements in the three consecutive short videos included relaxation therapy, managing thoughts and feelings, and mindfulness. Each video has a duration of just over 10 minutes.~In the first video, the participants were introduced to the purpose and benefits of relaxation techniques. These included rhythmic breathing techniques, progressive muscle relaxation, imagining a comforting and quiet place, and positive self-talk. In the second video about managing thoughts and feelings, the participants were introduced to the notion of acceptance of their condition. They were invited to recognize the emergence of negative feelings and thoughts related to acceptance. In the last video about mindfulness, patients were introduced to three basic mindfulness skills: observation, elaboration, and participation."
224160009|NCT03491475|DRUG|Ajmaline test|Administration of Ajmaline
224160010|NCT04315298|DRUG|Sarilumab|Single or multiple intravenous (IV) doses of sarilumab. Additional doses may be administered if the patient meets protocol defined criteria.
224160011|NCT04315298|DRUG|Placebo|Single or multiple intravenous (IV) doses of placebo to match sarilumab administration
224160012|NCT00736385|DRUG|Glucophage (Metformin)|metformin XR 2000 mg daily for 12 months
224304068|NCT05209217|DRUG|Ketamine|Intranasal administration of their customary prescribed dose
224304069|NCT00658749|DRUG|AIR645|AIR645 (blinded) by nebulization, range of doses, maximum of one dose per day, maximum of 6 doses in 22 days.
224304070|NCT00658749|DRUG|Physiologic saline solution|Placebo (blinded) by nebulization, range of doses, maximum of one dose per day, maximum of 6 doses in 22 days.
223471329|NCT00146562|DRUG|Paclitaxel|As part of standard adjuvant chemotherapy: Given every two weeks for 8 cycles
223471330|NCT00146562|DRUG|Doxorubicin|As part of standard adjuvant chemotherapy: Given every two weeks for 8 cycles
223471331|NCT00146562|DRUG|Cyclophosphamide|As part of standard adjuvant chemotherapy: Given every two weeks for 8 cycles
223471332|NCT00989885|OTHER|Questionnaire and polysomnography|Comparison of polysomnography data records and previously made questionnaire, with the Epworth Sleepiness Scale.
223471333|NCT00756626|BEHAVIORAL|Bottle Weaning Intervention|WIC Nutritionist will deliver bottle weaning intervention education with participants in intervention group at 12 month baseline and at 15, 18, 21, and 24 month follow-up as needed
223471334|NCT06195423|BEHAVIORAL|Stop OsteoARthritis (SOAR) program|"The SOAR program is a 6-month, online-delivered (videoconferencing), PT-guided knee health program which consists of;~1. Knee Camp: Includes interactive education, and 1:1 physiotherapy knee exam and counseling session to co-identify home-based exercise-therapy and physical activity goals to address participants' unique functional limitations. Participants are given a wrist-worn activity monitor to wear 24hours/day.~2. Individualized Weekly Home-based Exercise-Therapy and Physical Activity Program: At home, participants work to meet their exercise-therapy and physical activity goals. Exercises and physical activity are tracked with an online form and the activity monitor. Participants can also attend an optional weekly group class.~3. Weekly PT-guided Exercise-Therapy and Physical Activity Counselling: Each week, participants attend a 1:1 physiotherapist counseling session to modify exercise-therapy and physical activity goals."
223743808|NCT06251856|BEHAVIORAL|lymphedema education program|On post-op day 2, patients will receive Symptom Management Model-Based Lower Extremity Lymphedema Training. Brochures will be introduced and delivered to the patient.
223471335|NCT06195423|BEHAVIORAL|Living Well after ACLR program|Participants in the minimal intervention CONTROL group will receive access to a 30-minute educational video (knee anatomy, ACLR information, general exercise, physical activity, and goal-setting principles), a best practice workbook, one video-recorded virtual session with a physiotherapist (naïve to SOAR) who will explain the booklet and answer questions but not volunteer information beyond the video or booklet and the same wrist-worn activity tracker as the experimental group.
224160013|NCT00736385|DRUG|Placebo|placebo 2000 mg daily for 12 months
223471336|NCT01228006|DIETARY_SUPPLEMENT|NatusGerin|1 capsule, 2 times a day.
223471337|NCT01228006|OTHER|Placebo capsules|1 capsule, 2 times a day
223579621|NCT03631277|DEVICE|photo-activated oral disinfection|Application of PAD solution using disposable tip with agitation of the solution for 60 seconds using a brush; Placement of the light disposable tip in center of lesion and holding it just above the surface; Activation of the red light for 60 seconds; (h)Sealing the cavity with glass ionomer and then filling with composite resin as a final restoration
223579622|NCT03631277|DRUG|Calcium Hydroxide|calcium hydroxide( Dycal ® Dentsply Caulk )was applied using calcium hydroxide applicator followed by glass ionomer and then composite resin as a final restoration
224160014|NCT04780594|PROCEDURE|The study evaluates all surgical patients operated, both elective scheduled and emergent cases|Administrative database was automatically collected. That included demographic, clinical antecedents, surgical team and surgical procedure, primary and secondary diagnoses and principal and secondary surgical procedures. A case-mix grouping system administrative automatic recorded based on the ICD-10-AM International Classification of Diseases. According to the Diagnoses-related Groups (DRG's). the Severity of Illness Index assigns to each patient an overall severity score (from 1 to 4) and mortality risk score (from 1 to 4)
223471338|NCT00752089|DRUG|NaF/ KNO3/isopentane Dentifrice|Experimental toothpaste
223579623|NCT01934309|BEHAVIORAL|TB reminders|The intervention to be studied involves providing clinic-based medical care providers (e.g., nurses, clinical officers, medical officers, consultants) with patient-speciﬁc clinical reminders regarding TB that are generated from a patient's electronic medical record and based on accepted clinical algorithms for TB screening and treatment.
224069208|NCT06840028|OTHER|mHealth/sFitRx|Experimental Group - Will receive a personalized mHealth application and fitness tracker. Specifically, Experimental Group participants will receive the sFitRx smartphone application that provides weekly personalized PA interventions informed by big data analysis. They will also receive a Fitbit Inspire 3 to track real-time PA, with PA data uploaded to Fitabase. Importantly, the PA data from the Fitbit Inspire 3 will inform the big data analyses used to generate the personalized PA intervention provided by the sFitRx application.
224160015|NCT00131131|BEHAVIORAL|Exercise|
224160016|NCT02411994|DRUG|Pyronaridine-artesunate|
224160017|NCT02411994|DRUG|Artemether-lumefantrine combination|
224160018|NCT02150785|DRUG|Streptokinase|
224160019|NCT01976494|DEVICE|The domestic PCA equipment 'Accufuser Omnibus®'|"* Subject patient selection: the purpose and method of this research will be explained to the patients who satisfy the exclusion criteria before surgery, and written consent regarding research participation will be obtained.~* Use of PCA equipment by patients is determined by randomization. Regardless of the PCA equipment type, the basal rate and bolus dose are equally set to 2 mL/hr and 2 mL for the entire research period.~* Epidural PCA regime: normal saline added to 0.75% ropivacaine 40 mL and fentanyl 15-20 mcg/kg for a total volume of 100 ml.~* After pretreatment, the chest epidural catheter is mounted in the pretreatment room or operating room. The catheter tip is adjusted to be fixed between T6-7 or T7-8.~* After mounting the catheter, a test dose of 1% lidocaine 3 ml and epinephrine 1:200.000 is injected. Ten minutes later, sensory loss and skin dermatome will be checked using an alcohol swab."
223471339|NCT00752089|DRUG|NaF/KNO3 Dentifrice|Experimental toothpaste
223471340|NCT00752089|DRUG|NaF Dentifrice|Active comparator
223471341|NCT00752089|OTHER|Placebo Dentifrice|Placebo comparator
223471342|NCT00053885|DRUG|PTK787/ZK 222584|oral
223471343|NCT05022498|BEHAVIORAL|Exercise|60 min treadmill exercise performed at 60% of maximum oxygen uptake.
223471344|NCT01324102|BEHAVIORAL|Yoga therapy|For the second aim of the study, individuals will complete an 8 week yoga intervention in a non-randomized trial to establish safe procedures for yoga for an older post colorectal cancer veteran population.
223471345|NCT03362944|BEHAVIORAL|Active Music Therapy|The intervention consists of a standardized series of Music Therapy tasks, all based at a constant rhythmic pulse.
223471346|NCT03362944|BEHAVIORAL|Passive Music Therapy|The intervention consists of a series of recorded listening tracks, matched in style to the active intervention, all based at a constant rhythmic pulse.
223471347|NCT01235065|DEVICE|type of laryngoscope|Patients who require emergency rapid sequence intubation are randomized to intubation with either the direct laryngoscope or the video laryngoscope
223471348|NCT00468117|PROCEDURE|Islet transplantation|
223579624|NCT05744557|OTHER|num Vapocoolant|Spray will be administered for 4 to 6 seconds from a distance of 3 to 6 inches to desired sites of skin
223579625|NCT06975358|PROCEDURE|Alveolar decortication plus CGF injection|Experimental sides will receive CGF injection (70 units) disto-buccal and disto-palatal to the maxillary canine after performing decortication. After administration of local anesthesia, two-line flap will be performed from the mesial surface of the maxillary second premolar to the distal surface of the maxillary canine Mucoperiosteal flap will be reflected in the buccal side. Two millimeters of marginal crestal bone will be held intact and using a high-speed drill and a round carbide bur (1mm diameter) under copious saline irrigation, the cortical wall will be penetrated to reach marrow spaces. Multiple perforations (10 holes for standardization) in the cortical bone will be created. The surgical site will then rinsed, and the flap will be repositioned and sutured.
223579626|NCT06975358|PROCEDURE|canine retraction without acceleration|in the control side, the maxillary canine will be retracted without any acceleration procedure
224069209|NCT06840028|OTHER|Fitness Tracker|Comparison Group - Will receive the Fitbit Inspire 3 only.
224069210|NCT06343194|DEVICE|Bruxoff ®|Bruxoff ® is a holter that measures the masseter muscle contraction and heart rate.
223471349|NCT00468117|BIOLOGICAL|Antithymocyte Globulin|Participants will begin receiving ATG 2 days prior to the initial islet transplant and will continue to receive ATG until Day 2 post-transplant.
223471350|NCT00468117|BIOLOGICAL|Daclizumab or Basiliximab|Daclizumab or Basiliximab will be used for subsequent transplants.
223471351|NCT00468117|BIOLOGICAL|Etanercept|Etanercept will be given on the day of transplant and on Days 3, 7, and 10 post-transplant.
223471352|NCT00468117|BIOLOGICAL|Allogenic human purified pancreatic islets|200 ml suspension of allogenic human purified islets
223471353|NCT01091922|DIETARY_SUPPLEMENT|Low flavanol cocoa beverage|23 mg of total flavanols from cocoa
223471354|NCT01091922|DIETARY_SUPPLEMENT|High flavanol cocoa beverage|495 mg of total flavanols from cocoa
223471355|NCT00386334|DRUG|Eszopiclone|2 mg tablet once per day in the evening
223471356|NCT00386334|DRUG|Placebo|Tablet one per day in the evening.
223471357|NCT03843372|DEVICE|High flow nasal cannula|All of participants will be received one night high flow nasal cannula and another night for continuous positive airway pressure.
223471358|NCT00902577|DRUG|FMISO|FMISO PET scans
223471359|NCT00902577|OTHER|MRI|Undergo MRI
223471360|NCT00902577|OTHER|PET|Undergo FMISO PET scan
224069211|NCT04012047|DRUG|Levcromakalim|To investigate the role of levcromakalim compared with placebo in migraine with aura patients
224304071|NCT01425918|BEHAVIORAL|Social Enhancement Intervention|The intervention will be conducted at our center and focuses on providing an invigorating learning environment in which emerging social skills/knowledge are the focus of intervention with the aim of bringing them to a higher level of maturity, integrated with existing abilities, and used functionally. Learning with and through peers, provides the opportunity to address abnormal peer relationships for developmental level. Providing an enriched environment with toys, structured learning, and opportunities for ongoing engagement we offer the children robust learning experiences. Parent training sessions will focus on strategies aimed at improving child social engagement and communication.
223471361|NCT00902577|OTHER|MRS|
223471362|NCT05781867|OTHER|Manual therapy and conventional physical therapy treatment|manual therapy (chest mobilization, diaphragmatic myofascial release, myofascial release for pectoralis minor, pectoralis major, scaleni ),pursed lip breathing, diaphragmatic breathing and active range of motion exercises of upper limbs
223471363|NCT03537066|DEVICE|CPAP|All patients included will be treated by CPAP
223471364|NCT03702660|OTHER|GIP(3-30)NH2|Peptide derived from the naturally occuring gut hormone GIP
223471365|NCT03702660|OTHER|Peripheral venous cannulation|Intravenous access for infusions
223471366|NCT03702660|OTHER|GLP-1|Peptide infusion
223471367|NCT02337062|DRUG|APD421|
223471368|NCT02337062|DRUG|Placebo|
223471369|NCT01236924|OTHER|Global postural reeducation|
223471370|NCT06078215|COMBINATION_PRODUCT|Cerebrolysin|Intravenous infusion of 30 ml Cerebrolysine in 500 ml of buffered crystalloid solution intravenously initiated within 12 hours from symptoms onset
223471371|NCT06213558|DEVICE|Rectangular and square striaght archwire technique|The Effect of Rectangular Versus Square Archwire on Maxillary Canine Retraction
223471372|NCT06082479|PROCEDURE|intraoral cryotherapy,ice gel|A cold pack (ice gel enveloped by a sealed plastic cover) measuring 2.5 x 5 centimetres was placed intraorally on the vestibular surface of the treated tooth. Each cold pack was kept for ten minutes.3 packs were used for each patient, for a total time of 30 minutes.Patients were instructed to remove the cold pack for 1-2 minutes if they felt extreme cold or a burning sensation .The temperature of the gel was checked by a digital thermometer (Brannan, UK) after it was removed from the freezer and kept in an ice box (Cosmoplast, UAE) containing a cooling gel (Exam Packaging, Belgium).
223471373|NCT05342896|BEHAVIORAL|MIND diet|MIND diet intervention will be a 3-month nutrition programme consisting of 4 face-to-face nutrition counselling sessions (one session per week, 60 min per session) in the activity room of each participating community centre. All intervention sessions will be conducted by a registered nutritionist and trained student helpers. In the nutrition sessions, the participants will learn to modify their diet to meet MIND diet guidelines.
223471374|NCT05342896|BEHAVIORAL|Mind diet plus Forest Bathing|MIND diet intervention will be a 3-month nutrition programme consisting of 4 face-to-face nutrition counselling sessions (one session per week, 60 min per session) in the activity room of each participating community centre. All intervention sessions will be conducted by a registered nutritionist and trained student helpers. In the nutrition sessions, the participants will learn to modify their diet to meet MIND diet guidelines. Forest Bathing will be another session per week, 2 hours forest bathing sessions on 4-consecutive weekends in a country park at daytime with sunny, cloudy or drizzling conditions. The walking distance for each forest bathing is one to two kilometres. The coach-to-participant ratio is approximately 1:16. Participants will then be required to self-practice 2h FB in the country park at daytime at the weekends of 8th week and 12th week of the intervention.
223471375|NCT02871674|BEHAVIORAL|Good Night Project|The behavioural interventions have been designed on the basis of three sources. Firstly, a systematic review conducted by the research team that examined the best evidence in the field in different countries. Secondly, a Delphi study, which aimed to identify behavioural interventions that can be used to manage sleep difficulties in Saudi Arabia in accordance with professionals' views and primary caregivers' needs, and which was also conducted by the research team. Thirdly, evidence-based practice resources that help in understanding and managing sleep difficulties will be translated into Arabic.
223471376|NCT04343183|DEVICE|Hyperbaric Oxygen Therapy|Hyperbaric Oxygen Therapy delivered at a specific uniformed pressure and duration.
223471377|NCT01210638|DRUG|Oxymorphone|10 mg tablet
223471378|NCT00785356|DRUG|Proellex 25 mg|Proellex 25 mg, 1 - 25 mg capsule and 1 placebo capsule daily for 3 months
224069212|NCT04012047|DRUG|Saline|To investigate the role of levcromakalim compared with placebo in migraine with aura patients
224069213|NCT02706821|DIETARY_SUPPLEMENT|Persimmon leaf extract|Persimmon leaf extract (PLE), crossover design
224069214|NCT02706821|DIETARY_SUPPLEMENT|Placebo|Placebo, crossover design
224069215|NCT02670642|DRUG|Esomeprazole|Proton pump inhibitor
224069216|NCT04880200|DIAGNOSTIC_TEST|POC NAT & Adherence Intervention|The POC NAT test will be the SAMBA Semi-Q HIV test. The adherence intervention will be developed by study staff and tailored for delivery along with the POC NAT results.
223471379|NCT00785356|DRUG|Proellex 50 mg|Proellex 50 mg, 2 - 25 mg capsules daily for 3 months
223471380|NCT00785356|DRUG|Placebo|Placebo, 2 capsules daily for 3 months
223471381|NCT02560168|DEVICE|MyoVista device|MyoVista device is a standard EKG device with additional capabilities in detecting cellular level myocardial electrophysiological signals. The device involves placing leads on the chest, similar to a traditional EKG device
223471382|NCT02560168|DEVICE|Computed tomographic coronary angiography|Traditional method of detecting coronary artery disease. CTA will be performed using 64-detector row or higher scanners with electrocardiographic gating in accordance with the Society of Cardiovascular Computed Tomography (SCCT) guidelines. Approximately 80 to 100 ml of intravenous contrast, followed by 50 to 80 ml of saline, will be administered at a rate of 5 ml/s via a power injector through an antecubital vein (on forearm near the elbow).
223471383|NCT02560168|DEVICE|Transthoracic Echocardiography|
223471384|NCT02888834|OTHER|Adverse drug reaction|
223471385|NCT03758729|DRUG|Nivolumab|Nivolumab 3mg/kg + NS 100mL MIV over 1hr every 2 weeks
223471386|NCT03758729|RADIATION|Radiation Therapy|Radiation Therapy
223471387|NCT05452265|PROCEDURE|Endoscopic resection|Complete resection of gastric SETs was recommended if the tumor size was \>2 cm, presence of malignant features, or if the patient was symptomatic, declined periodical surveillance, and preferred to undergo diagnostic and therapeutic resection.
223471388|NCT01559662|DIETARY_SUPPLEMENT|Sugared Chewing Gum (Juicy Fruit)|One stick of gum, 3 times daily from Postoperative day 1 to 7
223471389|NCT02280252|DRUG|Paclitaxel|Paclitaxel (including Abraxane), 30 mg/m2 twice per week. Paclitaxel will be given IV over 1 hour, Abraxane® will be administered over 30 min, and administered on a Monday/Thursday or Tuesday/Friday schedule.
223743809|NCT04874337|OTHER|Disaster nursing and management training will be given to students using Jenning's Disaster Nursing and Management Model.|The subjects for the training program were prepared by the researchers by scanning the relevant literature. In particular, the ICN Framework of Disaster Nursing Competencies developed by the International Nurses Association (ICN) and the World Health Organization (WHO), the second is the universal standards that should be fundamental in nursing and midwifery education (Global Standards for the Initial Education of Professional Nurses and Midwives). The training program was conducted both theoretically and practically. The theoretical section is based on Jenning's disaster nursing management model. Investigator is a First and Emergency Aid instructor. In addition, support was received from an experienced psychologist and AFAD trainers who provided support to the victims of the Izmir earthquake during the training process. In this context, an 8-module training program was created.
223743810|NCT00009048|DRUG|EMD 128130|
223471390|NCT02280252|RADIATION|Radiation therapy|Patients will receive a total dose of 45 Gy to the breast, axilla and supraclavicular area at 1.8 Gy/fraction, +14 Gy to the original palpable tumor at 2 Gy/fraction (total 32 fractions)
223471391|NCT04267978|DRUG|recombinant human endostatin,temozolomide,irinotecan|"Temozolomide was given orally 200mg/m2 for 5 days in each cycle. Day 1 TMZ was administered 3-6 hours prior to irinotecan.~Irinotecan was administrated 125mg/m2 on day 1 and day 15. Recombinant human endostatin was administrated 15mg/d, daily for 14 days. One treatment cycle was defined as 28 days (4 weeks), even if treatment is held mid-cycle for toxicity.~Treatment was continued until disease progression, patient withdrawal, or unacceptable toxicity.~The maximum number of treatment cycles was 12. After 12 cycles of treatment, if the investigator judges that the subject may continue to benefit from the regimen, the duration of treatment may be extended with the subject's consent."
223471392|NCT00002441|BIOLOGICAL|MN rgp120/HIV-1 and GNE8 rgp120/HIV-1|
223471393|NCT03102502|DEVICE|EECP|Enhanced external counterpulsation (EECP) is a technique for assisting the circulation by decreasing the afterload of the left ventricle and augmenting the diastolic pressure externally by applying a negative pressure to the lower extremities during cardiac systole. EECP therapy is done by sequential inflation of 3 sets of cuffs wrapped around the lower extremities during diastole and deflation of the cuffs during systole. EECP enhances the aortic diastolic blood flow and coronary perfusion, leading to increased arterial wall shear stress in a pulsatile manner.
223471394|NCT03102502|DRUG|Medical therapy|Guideline- driven standard medical treatment including statins,antiplatelet drugs（aspirin or Clopidogrel ）, anti-ischemic drugs （Nitroglycerin）
223471395|NCT01232790|DIETARY_SUPPLEMENT|N-Acetylcysteine|N-acetylcysteine 1200mg bid for 3 days
223471396|NCT01232790|DRUG|Placebo|Placebo
223743811|NCT00009048|DRUG|IV Levodopa|
224069217|NCT03535753|DRUG|Decitabine and R-GDP|Decitabine and R-GDP
224069218|NCT02303379|OTHER|Continuous Endurance Training|Endurance training with constant work load 31min at 65-75% Hrmax
224069219|NCT02303379|OTHER|Pyramid Training|One pyramid consists of 8 one-minute blocks. Those are grouped starting with one block of 70-75% HRmax, followed by one block at 75-80% HRmax and another one at 80-85% HRmax. The top of the pyramid are 2 blocks of 85-90% HRmax. Intensity is lowered afterwards with one block of 80-85% HRmax, followed by one block at 75-80% HRmax and last one at 70-75% HRmax. Two more pyramids follow, each divided by 2min of active recovery at 65-70% HRmax, making it a total of 28min.
224069220|NCT02303379|OTHER|High-intensity interval training|HIT: 4x4 min intervals at85-95% HRmax divided by 3x3min of active recovery at 60-70% HRmax, making it a total of 25min.
224069221|NCT00817531|DRUG|Dasatinib|pill form, 100 mg daily
224069222|NCT02239939|BEHAVIORAL|Vest|light weight, adjustable, vest to be worn underneath clothes that weight can be added to
224069223|NCT02239939|BEHAVIORAL|Diet|Participants will undergo a 22 week dietary weight loss intervention which will incorporate dietary practices for achieving weight loss while minimizing muscle and bone loss. Participants will be instructed by the Registered Dietitian to follow a low calorie diet. Individual calorie goals will be adjusted during the study if necessary to achieve a targeted weight loss goal of at least 8%, but no more than 12%, within the intervention time frame.
224069224|NCT03678402|DEVICE|PUP™ sock|The Palarum Fall Prevention System that includes the PUP™ (Patient is Up) System, is made upon of seven tangible elements: an inpatient room Android tablet (IRT), a nurse station Android monitor (HUC), a local server (PLS), a cloud server (PCS), a Bluetooth Low Energy beacon(s), an Android smart watch, and an e-textile sock connected sensor transmitter (PUP™ sock). The PUP™ sock monitors and transmits pressure, force, acceleration and motion data.
223471397|NCT02815085|OTHER|RecoverLINK technology|HF patients will receive the RecoverLINK app upon study enrollment for 30-days. The Mount Sinai HF care team will interact with patients via the RecoverLINK cloud-based system during this period
223579627|NCT06816043|DRUG|MK-8527|Oral Capsule
223579628|NCT06816043|DRUG|FTC/TDF|Oral Tablet
223579629|NCT03035253|DRUG|OMP-305B83|
223579630|NCT03035253|DRUG|FOLFIRI|Treatment will consist of OMP-305B83 and the FOLFIRI chemotherapy regimen.
223579631|NCT03035253|DRUG|FOLFOX|Treatment will consist of OMP-305B83 and the FOLFOX chemotherapy regimen.
223471398|NCT03238417|OTHER|Evidence-Based Quality Improvement|Multilevel research-clinical partnership approach to supporting local strategic planning, priority setting, skill building and engagement in addressing targeted healthcare delivery problems. Launched at participating VA facilities through advance key stakeholder interviews, in-person site visits, data review (e.g., structure and environment of care, gender disparities in quality and patient experience), QI education/training, technical support (e.g., QI project and measures development), additional formative feedback from the evaluation (e.g., provider/survey measure summaries), external and internal practice facilitation, and across-EBQI site collaboration calls. Local leadership, EBQI champions and QI teams develop and implement innovation projects aimed at improving prioritized quality targets related to women Veterans' health and healthcare needs as well as facility-level structural changes needed to improve compliance with VA guidelines.
223471399|NCT04163848|OTHER|Pollution|CO2 equivalent productions related to anesthetic gases use during general anesthesia for laparoscopic surgery
223579632|NCT06980324|OTHER|integrated neuromuscular inhibition technique|"integrated neuromuscular inhibition technique consists of:~* ischemic compression~* Positional release~* Muscle energy technique"
223579633|NCT06980324|OTHER|conventional physical therapy treatment|"Conventional physical therapy treatment:~* Ultrasound~* Hotpacks~* Iliotibial band stretching~* Static quadriceps and hamstring exercises"
223579634|NCT06979661|DIAGNOSTIC_TEST|Haystack™ ctDNA Assay|A personalized, tumor-informed circulating tumor DNA (ctDNA) test that analyzes blood samples to detect minimal residual disease (MRD) and guide postoperative treatment decisions for patients with Stage II-III non-small cell lung cancer (NSCLC) following surgical resection. The test results will help determine whether patients should receive postoperative radiation therapy (PORT) and/or systemic therapy adjustments.
223579635|NCT06980597|BIOLOGICAL|OL-108|OL-108 will be given through IV bolus with ascending dose levels to determine the maximum tolerated dose (MTD)
223579636|NCT06979869|OTHER|Multi-gene methylation testing|Undergo multi-gene methylation testing in blood during follow-up
223579637|NCT06979869|OTHER|Multi-gene methylation testing|Undergo multi-gene methylation testing in blood during follow-up
223579638|NCT06979869|OTHER|Multi-gene methylation testing|Undergo multi-gene methylation testing in blood during follow-up
223471400|NCT05306990|DRUG|Atorvastatin 40 Mg Oral Tablet|patients followed up for 3 months
223471401|NCT05306990|DRUG|Rosuvastatin 20 Mg Oral Tablet|patients followed up for 3 months
223471402|NCT00821535|DRUG|maraviroc (Selzentry, Celsentri)|12 subjects will receive a single dose of 300 mg maraviroc (two 150 mg maraviroc commercial tablets) under fasting conditions.
223471403|NCT02788487|DEVICE|Tongue retaining device|Tongue retaining device is used for 3 weeks
223579639|NCT06979869|OTHER|Multi-gene methylation testing|Undergo multi-gene methylation testing in blood during follow-up
223579640|NCT04319627|DRUG|Rosuvastatin Calcium|Each participant will receive the usual treatment for their newly diagnosed blood clot in addition to the intervention they are randomized to.
223579641|NCT04319627|DRUG|Placebo Oral Tablet|Each participant will receive the usual treatment for their newly diagnosed blood clot in addition to the intervention they are randomized to.
223579642|NCT06979843|OTHER|A psychosocial model|"The first aim is to evaluate if participating in the psychosocial model (including Team Young and PRISM) maintains or improves psychological resilience, psychological wellbeing, quality of life and hope among AYAs at a six-month follow-up, compared to time of diagnosis. The second aim is to evaluate how participants in the model of psychosocial support (including Team Young and PRISM) experience it with regard to acceptability, relevance and benefit.~The design is a longitudinal cohort study."
223579643|NCT05837767|RADIATION|Stereotactic body radiotherapy|The primary site requiring palliative radiotherapy will receive conventional SBRT dosing of SBRT (or an alternate standard-of-care schedule).
223579644|NCT05837767|RADIATION|Lattice Radiation Therapy|A second metastatic site (GTV volume at least 100 cc) will receive elective palliation with a lattice RT pattern (LRT).
223579645|NCT03887559|BEHAVIORAL|Group-based stabilization and skill training in addition to individual treatment|"Group-based stabilization and skill training, weekly 2-hour sessions during 20 weeks. Based on the manual Tilbake til Nåtid (Back to here and now) (Holbæk, 2014) developed by clinicians in the highly specialized national trauma clinic 'Modum Bad's Trauma Clinic'."
223579646|NCT03887559|OTHER|Treatment as usual|Treatment as usual: conventional individual treatment (outpatient). Not standardized.
223579647|NCT07018089|BEHAVIORAL|iWork.Comp|The iWork.COMP is a short-term and low-time consuming internet delivery CFT-based intervention specifically designed to mitigate the impact of toxic leadership styles through the development of compassionate motivation in the workforce of EU hospitals. The iWork.COMP encompasses 8 individual sessions (20 minutes each; mixed format including text, audio and video presentations), which will be available weekly for participants at the KEEPCARING website (https://keepcaring.eu). Each session has three parts. Part 1 encompasses a brief check-in on the stress level of the participant at that moment and on the source of their stress (if applicable). In Part 2, the theme of the session is developed. Finally, Part 3 encompasses a brief check-in on the stress level of the participant at the end of the session and on the usefulness of the session; an optional open question to provide feedback will also be displayed.
223579648|NCT07016152|BIOLOGICAL|Glyconjugate Klebsiella pneumoniae bivalent vaccine|CHO-V08 is a glycoconjugate bivalent vaccine in sterile suspension.
223471404|NCT02788487|DEVICE|CPAP|CPAP is used for 3 weeks
223471405|NCT00083915|DRUG|Cisplatin|20mg/m2 continuous infusion days -3 and -2.
223579649|NCT06111729|DEVICE|HabitAware group|A device that provides gentle vibration when the motion of nail biting is sensed will be provided to all participants. Participants will use an app that connects to the device to track the frequency of their nail biting over the study period.
223579650|NCT04912895|DEVICE|PneumoniaCheck|Participants are asked to do 5 sets of 10 coughs, with at least 15 minutes between sets, into the PneumoniaCheck device.
224304072|NCT01425918|BEHAVIORAL|Parent Education|Parent education sessions will focus on topics related to autism, learning styles, interventions, and resources. The curriculum provides parents with information about child development and autism as well as instructional strategies (e.g., responsive teaching strategies, principles of applied behavior analysis) for use at home to enhance their children's communication, engagement, and play development. Concrete examples for home-based implementation are presented. Each week, homework will be given and parents will be encouraged to practice the strategies daily at home. No direct coaching to parents during interaction with their children or direct intervention with the child will be provided.
223579651|NCT06703892|BIOLOGICAL|GF-CART01|CAR positive viable T cells-Mid
223579652|NCT06703892|BIOLOGICAL|GF-CART01|CAR positive viable T cells-High
223579653|NCT06703892|BIOLOGICAL|GF-CART01|CAR positive viable T cells-Low
223579654|NCT07041034|BEHAVIORAL|Active Comparator Group|"The group will receive:~1.Foundational Education: A structured session introducing key concepts of BPSD, symptom recognition, and general management approaches. 2.Simulation-Based Training: An interactive training module using case-based simulation to illustrate common BPSD scenarios and guide caregivers in applying appropriate strategies.~This group will not receive the protocol-based intervention component."
223579655|NCT07041034|BEHAVIORAL|Experimental Group|"The intervention consists of three components:~1. Foundational Education: A structured session introducing key concepts of BPSD, symptom recognition, and general management approaches.~2. Simulation-Based Training: An interactive training module using case-based simulation to illustrate common BPSD scenarios and guide caregivers in applying appropriate strategies.~3. SUNAM Protocol Training: Instruction on a structured, theory-informed protocol aimed at identifying and addressing underlying factors that contribute to BPSD in institutionalized residents."
223579656|NCT07041463|OTHER|Psychoeducation program coordinated by an APRN|"Individual and group psycho-education programs. Each investigating center will be trained in the same tools, in order to harmonize practices:~* BREF: This is a 3-session psycho-educational program in which each family is received individually by a pair of caregivers who are not involved in the patient's care.~* PEPs Caregiver: This is a group psycho-education program in 5 2-hour sessions developed in the coordinating center."
224304073|NCT00037102|DRUG|interferon beta 1a|
224304074|NCT00037102|DRUG|methotrexate|
224304075|NCT02212288|OTHER|Blood sample|Blood samples are for metabolic and genetic and biological investigation
224304076|NCT02212288|OTHER|Urine sample|Urine sample for biological investigation
224304077|NCT01533766|DRUG|CombiflexOmega|intravenously over 5 days infusion
224304078|NCT01533766|DRUG|SmofKabiven|intravenously over 5 days infusion
224304079|NCT05042050|BEHAVIORAL|A-iMAPS|Imagery therapy targeting Psychosis-Related PTSD
224304080|NCT00266396|BEHAVIORAL|Recommend full weight-bearing|The full weight-bearing group is trained in 4-point gait with crutches and is recommended to put as much weight as tolerated on the leg on which surgery has been performed, immediately after surgery
224304081|NCT00266396|BEHAVIORAL|Recommend parital weight-bearing|The partial weight-bearing group is trained in 3-point gait with crutches and is instructed to limit weight-bearing of the affected leg to 20kg for a period of six-weeks. Scales are used to train these participants not to exceed 20kg
224304082|NCT01081535|DRUG|ketorolac, fentanyl|intravenous PCA
223471406|NCT00083915|DRUG|Cyclophosphamide|800 mg/m2 continuous infusion days -3 and -2.
223471407|NCT00083915|DRUG|Adriamycin|20mg/m2 continuous infusion -3 and -2.
223471408|NCT00083915|DRUG|Etoposide|80mg/m2 continuous infusion -3 and -2.
223471409|NCT00083915|DRUG|Melphalan|200 mg/m2 IV over \<20 minutes on -1 on Arm 1. 50mg/m2 IV over 20 minutes days -3 and -2 on Arm 2.
223471410|NCT00083915|DRUG|Thalidomide|200mg PO Continuing to Day +5, then hold until platelets \>50 thousand (K).
223471411|NCT00083915|DRUG|Dexamethasone|40 mg po days 1 - 4 (4 days)
223471412|NCT00458237|DRUG|Everolimus|Everolimus is being administered orally 7 days per week.
223471413|NCT00458237|DRUG|Trastuzumab|Trastuzumab is being administered at a dose of 6 mg/kg intravenously once every 21 days.
223471414|NCT01126216|DRUG|Paclitaxel/Cisplatin|Experimental: Paclitaxel (20mg/m\^2/d) on days 2, 5, 8, 11 and 25, 30, 33, 36) and Cisplatin (20mg/m\^2/d) on days 1-4 and 29-32,
223579657|NCT07041463|OTHER|Usual Care|"The caregiver will benefit from the interventions and referrals provided for caregivers as usual at each center."
223579658|NCT07040293|DEVICE|Absorbable bone wax for hemostasis in the osteotomy surface of the facet joint|"Following the enrollment of patients who underwent posterior lumbar decompression, intervertebral bone graft, and internal fixation surgery, a V-shaped osteotomy was executed at the facet joint contralateral to the decompression site, with 0.5g absorbable bone wax subsequently applied to the osteotomy surface."
223579659|NCT07040293|DEVICE|Traditional bone wax for hemostasis in the osteotomy surface of the facet joint|"Following the enrollment of patients who underwent posterior lumbar decompression, intervertebral bone graft fusion, and internal fixation surgery, a V-shaped osteotomy was executed at the facet joint contralateral to the decompression site, with 0.5g traditional bone wax subsequently applied to the osteotomy surface."
223579660|NCT07040553|BEHAVIORAL|Motivational Interviewing and WhatsApp Support|This intervention consists of weekly face-to-face motivational interviews and supportive WhatsApp messages, delivered over 8 weeks. It is based on the principles of Motivational Interviewing (Miller \& Rollnick, 2012) and aims to support symptom management and emotion regulation in participants with moderate to severe premenstrual syndrome.
223579661|NCT07041047|DEVICE|APAISANT SERUM - INGROWN NAILS|Topical application of APAISANT SERUM - INGROWN NAILS twice daily for 7 days.
223579662|NCT00520013|DRUG|bevacizumab|
223579663|NCT00520013|DRUG|erlotinib|
223579664|NCT00520013|DRUG|paclitaxel|
223579665|NCT00520013|DRUG|carboplatin|
223579666|NCT02082223|BEHAVIORAL|Interventions to improve preop QOL/resilience deficits|Identify patients' and patients' care givers quality of life/resilience deficits and supply information and resources prior to undergoing complex GI surgery.
224160020|NCT01976494|DEVICE|Imported PCA equipment 'Infusor SV®, Baxter, USA'|"* Subject patient selection: the purpose and method of this research will be explained to the patients who satisfy the exclusion criteria before surgery, and written consent regarding research participation will be obtained.~* Use of PCA equipment by patients is determined by randomization. Regardless of the PCA equipment type, the basal rate and bolus dose are equally set to 2 mL/hr and 2 mL for the entire research period.~* Epidural PCA regime: normal saline added to 0.75% ropivacaine 40 mL and fentanyl 15-20 mcg/kg for a total volume of 100 ml.~* After pretreatment, the chest epidural catheter is mounted in the pretreatment room or operating room. The catheter tip is adjusted to be fixed between T6-7 or T7-8.~* After mounting the catheter, a test dose of 1% lidocaine 3 ml and epinephrine 1:200.000 is injected. Ten minutes later, sensory loss and skin dermatome will be checked using an alcohol swab."
223471415|NCT01126216|RADIATION|Reduced RT|Experimental: 63,6 Gy accelerated hyperfractionated radiotherapy
223471416|NCT01126216|DRUG|5-FU/Cisplatin|Active Comparator: 5-Fluorouracil(600mg/m\^2/d) on days 1-5 and 29-33) and Cisplatin (20mg/m\^2/d) on days 1-5 and 29-33
223471417|NCT01126216|RADIATION|Standard RT|Active Comparator: 70,6 Gy accelerated hyperfractionated radiotherapy
223471418|NCT03614000|OTHER|Screening Questionnaires|"Measurement tools:~* Social Responsiveness Scale (SRS-2) is a validated 65-item scale for the screening of ASD that requires parents to rate the child's behaviors in the previous 6 months. The questionnaire assesses interpersonal behavior, communication and repetitive/stereotypic behavior characteristics of ASD.~* The Aseba Questionnaires are validated diagnostic tools that can be filled in by the parents, teachers or children to evaluate various behavioral and emotional problems. The CBCL assesses internalizing (i.e., anxious, depressive and over-controlled) and externalizing (i.e., aggressive, hyperactive, noncompliant and under-controlled) behaviors.~* The VG\&O The VG\&O is a questionnaire developed in Dutch that gives a subscale of parental stress (OBVL), family functioning (VGFO), education habits (VSOG) and life events (VMG). The OBVL will be used"
223579667|NCT06909461|OTHER|Pain neuroscience education|The pain neuroscience education group will be receive a 70-min pain neuroscience education.
223579668|NCT06909461|OTHER|Red-flags education|The control group will be receive a 70-min red-flags education.
223579669|NCT05977452|DIAGNOSTIC_TEST|Michigan Risk Score, Caprini Risk Assessment Model , Maneval scale|Patients with PICC placement will be assessed by the Michigan Risk Score, Caprini Risk Assessment Model , Maneval scale（Chinese version） to predict the risk of PICC-related thrombosis. The time of evaluation are the day during PICC placement, 24-48h after PICC placement, and every time when patients receive PICC maintenance.
223743812|NCT03303404|DEVICE|Ambulatory (24-hour) Blood Pressure|Unlike casual blood pressure measurements, 24-hour ambulatory blood pressure monitoring provides an insight into blood pressure changes in everyday life and an estimate of the overall blood pressure load exerted on the cardiovascular system over 24 hours. Blood pressure recordings over a 24-hour period of normal daily activity will be made using a noninvasive ambulatory monitor (Spacelabs, Redlands, WA). The ambulatory system will be calibrated against a mercury sphygmomanometer, and the cuff will be programmed to inflate automatically every 15 min from 6 AM to 11 PM and every 20 min between 11 PM and 6 AM. For each individual subject, the nighttime period will be defined as the time when the subject goes to bed at night until rising in the morning. Daytime will be defined as the remainder of the 24-hour period. Daytime and nighttime states will be monitored by an Actiwatch (Mini-MItter, Bend, OR), a watch-like device placed on the wrist that measures gross motor activity.
224160021|NCT02251366|PROCEDURE|Physician-guided diagnostic|NVAMD participants in the physician-guided diagnostic arm will have receive injections based on diagnostic imaging provided by optical coherence tomography and optional fluorescein angiography, those in this group will only receive retinal examinations at the 4- and 8-month clinic visits.
224160022|NCT00010244|RADIATION|radiation therapy|
224160023|NCT02255240|BEHAVIORAL|Physical activity intervention|Participants will receive counseling on self-regulatory skill building that has been adapted to complement the video games used. We anticipate that the games used will consist of fitness, sports, and dance games and will be played on a Wii U console. The games played will be chosen by each participant from a pool of potential appropriate games.
224160024|NCT01910272|DEVICE|All subjects are wearing the non-lead attenuation cap (BLOXR)|The cap is worn by all subjects with dosimeters secured both inside and outside the cap.
224160025|NCT01183104|DRUG|Sitagliptin|Starting dose for sitagliptin is 50mg per day, can be increased up to 100mg (25-50mg; estimate glomerular filtration rate (eGFR) 30=\< \<50).
224160026|NCT01183104|DRUG|Glimepiride|Starting dose for glimepiride is 0.5mg per day, can be increased up to 6.0mg
224160027|NCT02734472|OTHER|Incidence and risk factors of hypertension|During the follow-up period,General information(age, sex, BMI, blood pressure, the history of drink and smoke, medical history, etc).Blood biochemistry parameters（Lipid, hsCRP levels, etc）and other laboratory examination parameters(arterial stiffness,IMT, FMD) will be collected.
224160028|NCT01242072|DRUG|palifosfamide-tris|Intravenous on days 1, 2 and 3 of each 21-day cycle for up to 4 cycles
224160029|NCT04056962|DRUG|Tacrolimus ointment|topical application of tacrolimus at different concentrations for treatment of superficial Kaposiform hemangioendothelioma (KHE) and tufted angioma (TA).
223471419|NCT00253136|DRUG|risperidone|
223471420|NCT02787980|BIOLOGICAL|Additional taking blood|Additional blood collection of 1 ml during the biological workup usually done.
223471421|NCT00001567|DRUG|Roferon-A|
223579670|NCT06905054|DRUG|Fenofibrate (drug)|Once daily fenofibrate for 36 months
223579671|NCT06905054|DIAGNOSTIC_TEST|Blood draw for the laboratory assessment|Serum assessments will be performed every 3 months during the study period
223579672|NCT06905054|DIAGNOSTIC_TEST|MRI using a hepatobiliary phase contrast agent (Gd-EOB-DPTA)|Participants will undergo a quantitative gadoxetate-enhanced MRI and MRCP at baseline, and at 12 months and 36 months of trial participation.
223579673|NCT00856141|DEVICE|phacoemulsifcation|A sensor (Blumenthal cannula) connected to a transducer, a signal amplifier, an IOP recording device, and a display unit
223579674|NCT00856141|DEVICE|phacoemulsifcation|A sensor (Blumenthal cannula) connected to a transducer, a signal amplifier, an IOP recording device, and a display unit
223471422|NCT02899611|DRUG|Valproate|ICV Valproate is a dilution of the commercially available Epilim product, which is a sterile intravenous (IV) formulation of Sodium Valproate.
223471423|NCT00853762|DRUG|Atacicept 25 mg|Subjects who received atacicept 25 milligram (mg) subcutaneously (SC) as loading dose twice weekly for first 4 weeks, followed by atacicept 25 mg SC for 32 weeks, in 28063 study will continue with atacicept 25 mg SC once weekly up to 5 years or up to early termination of treatment or early termination of the study.
223471424|NCT00853762|DRUG|Atacicept 75 mg|Subjects who received atacicept 75 mg SC as loading dose twice weekly for first 4 weeks, followed by atacicept 75 mg SC for 32 weeks, in 28063 study will continued with atacicept 75 mg SC once weekly up to 5 years or up to early termination of treatment or early termination of the study.
223579675|NCT04839848|DEVICE|Lichtenstein mesh repair|A groin hernia repair, reinforced by synthetic mesh. The mesh is affixed with sutures
223579676|NCT05124587|OTHER|No intervention group|No intervention group
223579677|NCT02677844|DRUG|Abemaciclib|Administered orally
223579678|NCT02677844|DRUG|Placebo|Administered orally
223579679|NCT02677844|DRUG|Loperamide|Administered orally
223579680|NCT01555554|DRUG|Propranolol Hydrochloride|"Propranolol will be taken for a total of 14 days. On the morning of the surgery, prior to entry into the operating room, patients will receive the first dose of the study drug (the PDR recommended starting dose of Propranolol XL- Extended Release). Patients will take one 60 mg pill on the morning of surgery.~On post operative day #1, patients will take one pill of receive propranolol XL 80 mg (once daily by mouth).~On post operative days #2-#9, patients will take one pill of propranolol XL 120 mg (once daily by mouth).~On post operative days #10-11, patients will take one pill of propranolol XL 80 mg (once daily by mouth).~On post operative days #12-13, patients will take one pill of propranolol XL 60 mg (once daily by mouth).~This will complete the course of propranolol."
223579681|NCT01555554|OTHER|Placebo|"The placebo pill will be taken for a total of 14 days. On the morning of the surgery, prior to entry into the operating room, patients will receive the first placebo pill to be taken once daily by mouth.~On post operative days #1-13, patients will take one placebo pill (once daily by mouth).~This will complete the course of the placebo."
223579682|NCT02083887|BIOLOGICAL|ChAd63 ME-TRAP / MVA ME-TRAP|Intramuscular administration of ChAd63 ME-TRAP 5 x 10\^10 vp and MVA ME-TRAP 1 x 10\^8 pfu
223579683|NCT06306664|DEVICE|Bioptron|Bioptron safely treats arthritis, neck \& back pain by stimulating blood circulation, reducing inflammation and relieving muscle spasms. For just ten minutes per day, our life-transforming technology offers the highest levels of pain relief by reaching deep into joints, muscles and ligaments.
223579684|NCT06306664|OTHER|Placebo Comparator|Patients will receive ice application+Exercises program designed for jumper knee
223579685|NCT03924583|DIAGNOSTIC_TEST|Duplex ultrasonography|Ultrasound examination of whole vena cava venous system with central venous catheter inserted, using duplex US method to detect catheter related thrombosis
223579686|NCT04790825|PROCEDURE|Full mouth scaling and root planing (FMSRP)|Subgingival instrumentation with ultrasonic devices and curettes of all periodontal pockets completed within 48 hours
223579687|NCT05826730|OTHER|Eccentric Exercises|Eccentric Exercises for neck muscles.
224160030|NCT03267511|DRUG|5% KNO3 / 0.2542% NaF dentifrice with 0.5% spherical silica|Participants will be instructed to apply a full brush head of their dentifrice containing 5% KNO3 / 0.2542% NaF dentifrice with 0.5% spherical silica and brush twice daily (morning and evening) for one timed minute (in their usual manner).
223471425|NCT00853762|DRUG|Atacicept 150 mg|Subjects who received atacicept 150 mg SC as loading dose twice weekly for first 4 weeks, followed by atacicept 150 mg SC for 32 weeks, in 28063 study will continue with atacicept 150 mg SC once weekly up to 5 years or up to early termination of treatment or early termination of the study.
224160031|NCT03267511|DRUG|5% KNO3 / 0.2542% NaF dentifrice with 1% spherical silica and 5% STP|Participants will be instructed to apply a full brush head of their dentifrice containing 5% KNO3 / 0.2542% NaF dentifrice with 1% spherical silica and 5% STP and brush twice daily (morning and evening) for one timed minute (in their usual manner).
224160032|NCT03267511|DRUG|5% KNO3 / 0.2542% NaF dentifrice with 6% abrasive silica|Participants will be instructed to apply a full brush head of their dentifrice containing 5% KNO3 / 0.2542% NaF dentifrice with 6% abrasive silica and brush twice daily (morning and evening) for one timed minute (in their usual manner).
224160033|NCT03267511|DRUG|5% KNO3 / 0.2543% NaF dentifrice with 16% abrasive silica and 5% STP|Participants will be instructed to apply a full brush head of their dentifrice containing 5% KNO3 / 0.2543% NaF dentifrice with 16% abrasive silica and 5% STP and brush twice daily (morning and evening) for one timed minute (in their usual manner).
224160034|NCT01834937|DEVICE|ExAblate MRgFUS (Magnetic Resonance guided Focused Ultrasound Surgery)|Focused Ultrasound Surgery - FUS delivered by ExAblate for the palliation of pain due to bone metastases.
224160035|NCT02265575|DRUG|Hyaluronic Acid|rehydration using hyaluronidase-assisted subcutaneous infusion
223471426|NCT00853762|DRUG|Atacicept 150 mg|Subjects who received placebo SC twice weekly for first 4 weeks, followed by placebo SC for 32 weeks, in 28063 study will continue with atacicept 150 mg (without loading dose) SC once weekly up to 5 years or up to early termination of treatment or early termination of the study.
223579688|NCT04291794|DRUG|Propofol|2mg/kg single bolus
223579689|NCT04291794|DRUG|Propofol Injection [Diprivan]|Tritiated Target-Controlled Infusion
223579690|NCT06122883|BEHAVIORAL|Evaluation the effectiveness of distraction in the reception area in the management of anxious pediatric patients during dental local anesthesia|Buccal and palatal infiltration will be administrated with basic behavior guidance techniques while the dentist wearing conventional attire in the treatment room after meeting the child in the reception area while wearing the friendly attire.
223579691|NCT06122883|BEHAVIORAL|Evaluation the effectiveness of distraction in the treatment area in the management of anxious pediatric patients during dental local anesthesia|Buccal and palatal infiltration will be administrated with basic behavior guidance techniques while the dentist wearing friendly attire in the treatment room after meeting the child in the reception area while wearing the conventional attire.
224160036|NCT01594749|DRUG|Fosaprepitant dimeglumine|
224160037|NCT01594749|DRUG|Fosaprepitant Placebo|
224160038|NCT01594749|DRUG|Dexamethasone|
223471427|NCT03528148|BEHAVIORAL|cycling|Active cycling
223471428|NCT03528148|BEHAVIORAL|Physical therapy|Conventional physical therapy
223471429|NCT02873234|DRUG|Traditional Chinese Medicine|Participants are treated with TCM twice per day according to syndrome differentiation. For example, the syndrome of one participant with depression is kidney deficiency. He will take Zishui Qinggan Yin twice per day before the breakfast and dinner.
224160039|NCT01594749|DRUG|Ondansetron|
224160040|NCT01594749|DRUG|Dexamethasone Placebo|
224160041|NCT01594749|DRUG|Ondansetron Placebo|
223471430|NCT02873234|DRUG|Antidepressants|Participants are treated with different antidepressants. The dosage, frequency and duration are determined according to guideline.
223471431|NCT05866913|PROCEDURE|Sciatic nerve slippage.|Sciatic nerve slippage.
223471432|NCT05866913|PROCEDURE|Passive stretching of the hamstring muscles.|Passive stretching of the hamstring muscles.
223579692|NCT06122883|BEHAVIORAL|Evaluation the effectiveness of distraction in both reception and treatment areas in the management of anxious pediatric patients during dental local anesthesia|Buccal and palatal infiltration will be administrated with basic behavior guidance techniques while the dentist wearing friendly attire in the reception area and treatment room.
223579693|NCT06122883|BEHAVIORAL|Evaluation of the effectiveness of basic behavior guidance techniques without using any type of distraction aids in the management of anxious pediatric patients during dental local anesthesia|Buccal and palatal infiltration will be administrated with basic behavior guidance techniques while the dentist wearing conventional attire in the reception area and treatment room.
223579694|NCT00550433|DEVICE|Bazedoxifene/Conjugated Estrogens|
223579695|NCT02084680|BEHAVIORAL|community health workers|community health workers offering individual prenatal education to pregnant women
223579696|NCT04052438|DIAGNOSTIC_TEST|HLA-C and KIR determination for patients, couples, oocyte or semen donors, abortive tissue and newborn.|
223743813|NCT03121092|DRUG|ACEI or ARB|Angiotensin converting enzyme inhibitors (ACEI's) and Angiotensin receptor blockers (ARB's) - commonly used anti-hypertensive medications
224069225|NCT03485833|DIAGNOSTIC_TEST|EEO and EIO test|velocity time integral of the aorta measured by transesophageal echocardiography after end-expiratory and end-inspiratory occlusion test
223471433|NCT05866913|PROCEDURE|passive shoulder mobilization.|passive shoulder mobilization.
223471434|NCT02321852|DRUG|Triflusal|Once daily oral administration of 600 mg triflusal Disgren® for 7 days.
223471435|NCT02321852|DRUG|Placebo|Once daily oral administration of placebo mannitol for 7 days
223471436|NCT02479750|DEVICE|ColdZyme® mouth spray|
223471437|NCT02479750|DEVICE|Placebo|
223471438|NCT01800045|DRUG|Pitolisant|1 capsule in the morning before breakfast
223471439|NCT01800045|DRUG|Placebo|1 capsule in the morning before breakfast
223579697|NCT01149486|DRUG|Losartan potassium/Hydrochlorothiazide|100/25 mg Tablets
223579698|NCT01149486|DRUG|Hyzaar®|100/25 mg Tablets
223579699|NCT01004016|DRUG|KPS-0373|
223579700|NCT01004016|DRUG|Placebo|
223579701|NCT05068063|DRUG|Bupivacaine Injection|Ultrasound-guided Femoral Triangle block with 20 mL of Bupivacaine 0.25% and IPACK block with 20 mL of Bupivacaine 0.25%
224069226|NCT05572762|DEVICE|Cannula plastic part while applying peribulbar block|Using the cannula and introducing it peribulbar to apply regional ophthalmic anesthesia avoiding by this causing trauma to the globe, as the normal globe consistency is marble-like, the cannula can't puncture except in case of presence of staphyloma, so the cannula will either curve around it or will be kinked causing failure of the technique.
224069227|NCT05572762|PROCEDURE|traditional technique|the patients are going to receive the local anesthetic standard of care technique by using 23- or 24-gauge needle introduced through the skin extra-conal and local anesthetic solution will be injected with volume AND concentration according to the surgery going to be done
224069228|NCT06445868|OTHER|Sedentary behaviour intervention|COM-B-based development of specific sedentary behavioral interventions to reduce sedentary time, promote healthy activity, and improve quality of life in older stroke patients
224069229|NCT00272974|BEHAVIORAL|Clinic-based counseling|
224069230|NCT01450033|BEHAVIORAL|Peer Mentoring|Subjects will be assigned a peer mentor who will provide social support primarily via e-communication. They will also meet in-person at study entry, 6 months and 1-year.
224069231|NCT01450033|BEHAVIORAL|e-Communication with mentor|Subjects will interact on a mutually agreeable basis via their choice of text messaging, Facebook, phone calls, emails, and other formats
224069232|NCT04001816|OTHER|Orthodontic Brackets|Self ligating and Conventional brackets
224069233|NCT02323698|DRUG|Caffeine|Subjects will ingest capsules containing caffeine (up to 6mg/kg). Experiments will begin 30min after consumption to approximately coincide with peak plasma concentrations.Throughout the 30min wait time and experimentation, blood pressure and heart rate will be monitored.
224069234|NCT02323698|OTHER|AIH|Participants will breathe intermittent low oxygen via air generators. The generators will fill reservoir bags attached to a non-rebreathing face mask. Oxygen concentration will be continuously monitored to ensure delivery of FIO2 (fraction of inspired oxygen) = 0.10±0.02 (hypoxia). Throughout experimentation, blood pressure and heart rate will be monitored.
224069235|NCT02323698|OTHER|Placebo|This is a placebo counterpart to the caffeine drug. Subjects will ingest capsules containing dextrose. Experiments will begin 30min after consumption to mimic the caffeine drug protocol. Throughout experimentation, blood oxygenation, blood pressure and heart rate will be monitored.
224069236|NCT02323698|OTHER|SHAM|This is a placebo counterpart to breathing intermittent low oxygen. Participants will breathe intermittent room air via air generators. The generators will fill reservoir bags attached to a non-rebreathing face mask. Oxygen concentration will be continuously monitored to ensure delivery of FIO2 (fraction of inspired oxygen) = 0.21±0.02 (normoxia). Throughout experimentation, blood pressure and heart rate will be monitored.
224069237|NCT02482454|PROCEDURE|Radiofrequency ablation|Radiofrequency ablation is performed percutaneously under CT/US guidance
224069238|NCT02482454|BIOLOGICAL|Cytokine-induced killer cells|The patients received autologous cytokine-induced killer cells transfusion one week after RFA treatment.
224069239|NCT01069562|OTHER|Conventional control|The isoflurane administration to deliver anesthesia will be done conventionally through a Tec 7 vaporiser to maintain the bispectral index at 50.
223471440|NCT00560365|OTHER|laboratory biomarker analysis|
223471441|NCT00560365|PROCEDURE|computed tomography|
223579702|NCT05068063|DRUG|normal Saline|Ultrasound-guided Femoral Triangle block with 20 mL of Bupivacaine 0.25% and IPACK block with 20 mL of normal saline 0.9%
223579703|NCT03078738|DRUG|OMT-28|OMT-28 is a fully synthetic small molecule that belongs to the family of 17,18-epoxyeicosatetraenoic acids (17,18-EEQ) analogs, a natural metabolite of the omega-3 fatty acid eicosapentaenoic acid (EPA).
224160042|NCT01594749|DRUG|Rescue Therapy|
223579704|NCT03078738|OTHER|Matching Placebo|Microcrystalline cellulose
223579705|NCT00874406|DRUG|tac + folfox4|tac: oxaliplatin 100mg + fudr 1g + mmc 10mg 7 days later： operation within 28 days after operation: folfox4
224160043|NCT00297284|DRUG|Modafinil|
224160044|NCT02292615|OTHER|Medical Imaging|
223579706|NCT00874406|DRUG|folfox4|folfox4 will be done within 28 days after liver resection
223579707|NCT04364061|OTHER|Moderate Intensity Continuous Exercise|Participant completed a moderate intensity continuous cycling exercise (MICE) during 35 min at 60-65% thPHRmax
223579708|NCT04364061|OTHER|High-Intensity Interval Exercise (1)|Participant completed a high-intensity interval cycling exercise (HIIE 1) during 20min with 60 cycles of speeding up for 8s and pedaling slowly for 12s at 80-90% thPHRmax
224160045|NCT00364351|DRUG|Vandetanib|once daily oral tablet
224160046|NCT00364351|DRUG|Erlotinib|oral dose
224160047|NCT05340179|PROCEDURE|Interlaminar cervical epidural injection|Fluoroscopy-guided interlaminar cervical epidural injection
224160048|NCT05340179|PROCEDURE|Cervical selective nerve root block|Ultrasound-guided cervical selective nerve root block
224160049|NCT05906368|DIAGNOSTIC_TEST|ClearSight HPI Monitoring system|Continuous blood pressure monitoring for precision hypotensive event response
224160050|NCT05906368|DIAGNOSTIC_TEST|Standard of Care Blood Pressure Monitoring|Blood pressure (BP) monitoring using a conventional arm cuff and inflation after epidural anesthesia as standard procedure. Standard of care blood pressure monitoring includes measurement of blood pressure at the time of epidural test dose delivery, 3-minute cycles of BP monitoring for 30 minutes after epidural placement, and then BP monitoring every 15 minutes per existing clinical standards for at least 4-hours, or until delivery.
224160051|NCT06334380|OTHER|Virtual Reality Modules Only|Participants will complete self-paced VR modules prior to and after surgery (prehab/rehab) and will be provided with technical assistance from the study team.
224160052|NCT06334380|OTHER|Virtual Reality Modules + Live Physical Therapist Support|Participants will complete self-paced VR modules prior to and after surgery (prehab/rehab) and will be provided with technical assistance from the study team. Participants will also have access to up to three live PT sessions via Zoom where they can ask questions and complete modules with PT feedback.
224160053|NCT06424041|OTHER|Fecal Microbiome Transplantation|Healthy donor fecal microbiome transplantation, following depletion of the endogenous microbial communities using antibiotics and bowel cleansing
224160054|NCT06424041|OTHER|Sham Fecal Microbiome Transplantation|Capsules containing preservative solution only, following depletion of the endogenous microbial communities using antibiotics and bowel cleansing
224160055|NCT00922974|RADIATION|External beam radiation therapy|Single fraction dose of 8 Gy external beam radiation therapy
224160056|NCT00922974|RADIATION|Radiosurgery/SBRT|Single fraction dose image-guided radiosurgery / stereotactic body radiotherapy (SBRT). The phase II component uses 16 Gy. The phase III component allows 16 or 18 Gy as preferred by the treating physician.
223579709|NCT04364061|OTHER|High-Intensity Interval Exercise (2)|Participant completed a high-intensity interval cycling exercise (HIIE 2) during 20min with 10 x 1-min bouts at 80-90% thPHRmax, separated by 1-min recovery bouts
223579710|NCT01836796|DIETARY_SUPPLEMENT|Lactobacillus Reuteri|100 million Lactobacillus Reuteri once daily or 10 billion Lactobacillus Reuteri once daily for 12 weeks.
224160057|NCT06573814|DIETARY_SUPPLEMENT|Bio Gelee Royale Forte|Two capsules of Bio Gelee Royale Forte will be taken in the morning on empty stomach once per day for 98 days.
223471442|NCT00560365|PROCEDURE|magnetic resonance imaging|
223471443|NCT00560365|PROCEDURE|quality-of-life assessment|
223471444|NCT05584995|PROCEDURE|Control group|Women will undergo normal cesarean section without Postpartum Hemorrhage or Idiopathic pulmonary hemosiderosis (IPH)
223579711|NCT01836796|DIETARY_SUPPLEMENT|Lactobacillus Reuteri DSM17938|Powder corresponding to 100 million or 10 billion Lactobacillus Reuteri is added to water once daily for 12 weeks.
223579712|NCT02362230|DRUG|Icotinib|Icotinib 125 mg BID
223579713|NCT03029195|DEVICE|Nasoalveolar molding therapy|Presurgical infant orthopedics
223579714|NCT00003136|BIOLOGICAL|filgrastim|
223579715|NCT00003136|DRUG|amifostine trihydrate|
223579716|NCT00003136|DRUG|carboplatin|
223579717|NCT00003136|DRUG|cyclophosphamide|
223579718|NCT00003136|PROCEDURE|peripheral blood stem cell transplantation|
223579719|NCT05389475|PROCEDURE|anoplasty in treatment of post hemorroidectomy anal stenosis|Diamond flap versus V-Y flap
223579720|NCT02435407|BEHAVIORAL|SOS|Ten (10) children will be randomized to participate in the SOS intervention arm. The intervention will be divided into two groups of 5 children with 2 therapists assigned. The children will attend 1 hour intervention sessions once a week for 12 weeks. Here they will be introduced to different types of foods that they would not have typically eaten in a play based group session. The SOS intervention utilizes the principle of hierarchal desensitization.
224160058|NCT06573814|OTHER|Placebo|Two capsules of placebo will be taken in the morning on empty stomach once per day for 98 days.
224160059|NCT04335656|DIETARY_SUPPLEMENT|Lactiplantibacillus plantarum|Probiotic capsule in powder form, which can be swallowed or opened and contents sprinkled on cold foods or beverages
224160060|NCT04335656|OTHER|Placebo|Placebo capsule in powder form, which can be swallowed or opened and contents sprinkled on cold foods or beverages
224160061|NCT04062799|OTHER|no intervention|It is an observationa study. There is no intervention.
224160062|NCT05480800|BIOLOGICAL|Invasive nontyphoidal Salmonella-typhoid conjugate vaccine (iNTS-TCV) low dose|3 doses of iNTS-TCV low dose vaccine administered intramuscularly at Day 1, Day 57, and Day 169 to participants in the iNTS-TCV low dose Group in Stage 1 (Europe).
224304083|NCT04902092|BEHAVIORAL|High Intensity Interval Training|Exercise sessions will commence with an initial 3-week accustomization period whereby training load will increase incrementally from 2 x 45min sessions with effort peaking at 60% VO2 max (week 1) increasing to 3 x 45minute with effort peaking at 80% VO2max (week 3). Participants will transition to the full HIIT protocol for the remaining weeks. The HIIT component will comprise a work-rest ratio of ≥1:1minutes, with alternating exertion epochs at \>80% VO2max and \<60% VO2max. As VO2max is likely to increase as fitness improves toward the end of the 3-month program, adjustments to HIIT will be made by the exercise physiologist based on real-time heart rate monitoring, ensuring greater accuracy in participants achieving their heart rate targets.
224304084|NCT04902092|BEHAVIORAL|Strength and Resistance Training|Exercise sessions will comprise a combination of strength, coordination and mobility exercises. The strength component will consist of 2-3 sets of resistance exercises at ≤70% of a predicted 1 repetition maximum, targeting all body segments. Heart rate tracking will occur to ensure participants do not exceed 70% v02 (or exceed Lactate Threshold).
223471445|NCT05584995|PROCEDURE|BUAL group|"Bilateral Uterine Artery Ligation Technique:~All uterine surgeries will be conducted by externalizing the uterus as much as possible and holding it by the fundus. The BUAL will be done using absorbable suture no. 1 Vicryl (Vicryl 1, Ethicon, France, Neuvilly-sur-Seine, France) will be placed through an avascular space in the broad ligament and tied from the anterior to posterior aspects of the myometrium 2-3 cm medial to the descending portion of the uterine vessels. In all patients, the suture will be carried from the anterior to the posterior at 1 cm to the myometrium medial to the Uterine artery and will be knotted after passing it through the avascular region at 1 cm to the wide ligament section adjacent to the uterus in both sides. All patients will be examined for uterotonics during and after the surgery. The ovarian arteries will be assessed at the level of the ovarian hilum."
223471446|NCT04761003|DEVICE|Thoracoscopy forceps|take pleural biopsy
223471447|NCT02461693|DRUG|Caffeine|200mg delivered as pill; one-time dose
223471448|NCT02461693|DRUG|Placebo|Lactose-based pill; one-time dose
223471449|NCT04664218|DEVICE|HIPEC device|To report the affordability on using the HIPEC machine of our design compared to the standard ones in poor places.
223471450|NCT00945646|DRUG|FST-201 (dexamethasone 0.1%) Otic Suspension|Instill four drops times two times a day.
223471451|NCT00945646|DRUG|Vehicle|Instill four times two times a day
223471452|NCT04998708|OTHER|Relaxation technique|The intervention group performed two types of relaxation techniques, that have shown their positive effects on immune functions, including progressive muscle relaxation exercise (PMRs)16 and cognitive-behavioral stress management (CBSM)32. We used two types of relaxation techniques to produce maximum effects of relaxation techniques within the limited period of COVID-19 quarantine (2 weeks). the control groups did not receive any treatment during the study; however, they were treated afterwards.
223471453|NCT02653846|PROCEDURE|RT-2D-SWE measurement|measurement of liver and spleen stiffness by ultrasound real-time 2D shear wave elastography (SWE™)
223471454|NCT02653846|PROCEDURE|HVPG measurement|assessment of portal hypertension assessed by hepatic venous pressure gradient measurement
223579721|NCT02435407|OTHER|Education|Parents will be given three 1 hour educational talks around the aetiology and management of feeding difficulties in children with autism spectrum disorder. This will be administered at 3 distinct time points; baseline, week 6 and week 12 of the study.
223579722|NCT01480973|RADIATION|Stereotactic Body Radiation Therapy|SBRT involves highly precise delivery of very high dose Radiotherapy (RT) over a very few fractions (hypofractionation) to accurately delineated, size-restricted malignant targets in which motion has been accounted for during the delivery process. SBRT administration achieves avoidance of normal tissue exposure to radiation during the planning process, by providing for sharp fall-off dose gradients outside the target.
223579723|NCT05207332|DIETARY_SUPPLEMENT|CHO+PRO|A vegan product containing carbohydrate and protein
223579724|NCT05207332|DIETARY_SUPPLEMENT|CHO|containing carbohydrate
224069240|NCT01069562|OTHER|Closed loop control|The isoflurane administration to maintain anesthesia will be by infusion to the anesthesia circuit using syringe pump (injection technique). The rate of delivery of isoflurane will be regulated by computer that uses a control algorithm.
224160063|NCT05480800|BIOLOGICAL|Invasive nontyphoidal Salmonella-generalized modules for membrane antigens vaccine (iNTS-GMMA) low dose|3 doses of iNTS-GMMA low dose vaccine administered intramuscularly at Day 1, Day 57, and Day 169 to participants in the iNTS-GMMA and TCV low doses Group in Stage 1 (Europe).
224160064|NCT05480800|BIOLOGICAL|Typhoid conjugate vaccine (TCV) low dose|3 doses of TCV low dose vaccine administered intramuscularly at Day 1, Day 57, and Day 169 to participants in the iNTS-GMMA and TCV low doses Group in Stage 1 (Europe).
224160065|NCT05480800|BIOLOGICAL|Invasive nontyphoidal Salmonella-typhoid conjugate vaccine (iNTS-TCV) full dose|3 doses of iNTS-TCV full dose vaccine administered intramuscularly at Day 1, Day 57, and Day 169 to participants in the iNTS-TCV full dose\_1 Group in Stage 1 (Europe) and to participants in iNTS-TCV full dose\_2 Group in Stage 2 (Africa).
223471455|NCT02000921|OTHER|VLNC cigarettes|Modified risk tobacco product
223471456|NCT02000921|OTHER|Combusted Products|Options for combusted tobacco products include cigars, cigarillos, and little cigars, .
223471457|NCT02000921|OTHER|Non-combusted products|Options for non-combusted tobacco products include smokeless tobacco, novel snus products, e-cigarettes and medicinal nicotine.
223471458|NCT02000921|OTHER|CN cigarettes|Experimental cigarettes with conventional nicotine content.
223471459|NCT01517217|PROCEDURE|No girdle|No girdle is used for the first five postoperative days
223471460|NCT01517217|PROCEDURE|Girdle|Girdle the first five postoperative days
223471461|NCT04009616|DRUG|Aloe Vera mouthwash|rinsing with aloe vera mouthwash for 5 days.
223579725|NCT00359333|DRUG|Gemcitabine , Docetaxel|Gemcitabine 800 mg/m2 IV over 80 minutes on day 1 and day 8, and Docetaxel 60 mg/m2 IV over 60 minutes on day 1 of a 21-day cycle
223579726|NCT01298102|BIOLOGICAL|Influenza A/H1N1 2009-AS03 adjuvanted (Pandemrix)|intramuscular injection of 1 dose vaccine
224069241|NCT06244238|OTHER|Observational study|Observational study
224069242|NCT02564315|DRUG|Nicotine Mini-Lozenge for 11 Months|Participants receive up to 11 months of Nicotine Mini-Lozenges as part of this treatment (dosing based on their nicotine dependence as measured when they started the study: 4 mg if they smoked within 30 minutes of waking and 2 mg if they smoked more than 30 minutes after waking, as per the package insert), along with instructions for use.
224160066|NCT05480800|BIOLOGICAL|Invasive nontyphoidal Salmonella-generalized modules for membrane antigens vaccine (iNTS-GMMA) full dose|3 doses of iNTS-GMMA full dose vaccine administered intramuscularly at Day 1, Day 57, and Day 169 to participants in the iNTS-GMMA and TCV full doses\_1 Group in Stage 1 (Europe) and to participants in the iNTS-GMMA and TCV full doses\_2 Group in Stage 2 (Africa).
224160067|NCT05480800|BIOLOGICAL|Typhoid conjugate vaccine (TCV) full dose|3 doses of TCV full dose vaccine administered intramuscularly at Day 1, Day 57, and Day 169 to participants in the iNTS-GMMA and TCV full doses\_1 Group in Stage 1 (Europe) and to participants in the iNTS-GMMA and TCV full doses\_2 Group in Stage 2 (Africa).
224160068|NCT05480800|BIOLOGICAL|GSK's Meningococcal A, C, Y and W-135 conjugate vaccine|1 dose of GSK's Meningococcal A, C, Y and W-135 conjugate vaccine administered intramuscularly at Day 1 to participants in the Control\_Stage 2 Group in Stage 2 (Africa).
224160069|NCT05480800|COMBINATION_PRODUCT|GSK's Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine|1 dose of GSK's Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine administered intramuscularly at Day 57 to participants in the Control\_Stage 2 Group in Stage 2 (Africa).
224160070|NCT05480800|COMBINATION_PRODUCT|Sanofi Pasteur's Typhoid Vi polysaccharide vaccine|1 dose of Sanofi Pasteur's Typhoid Vi polysaccharide vaccine administered intramuscularly at Day 169 to participants in the Control\_Stage 2 Group in Stage 2 (Africa).
224160071|NCT05480800|DRUG|Placebo|3 doses of Placebo administered intramuscularly at Day 1, Day 57, and Day 169 to participants in the Placebo\_Step 1 and Placebo\_Step 2 in Stage 1 (Europe).
224160072|NCT05480800|OTHER|Saline|3 doses of saline solution administered intramuscularly at Day 1, Day 57, and Day 169 to participants in the iNTS-TCV low dose, Placebo\_Step 1, iNTS-TCV full dose\_1, Placebo\_Step 2 groups in Stage 1 (Europe) and to participants in iNTS-TCV full dose\_2 and Control\_Stage 2 groups in Stage 2 (Africa).
224160073|NCT03649139|DRUG|sublingual immunotherapy drops|artemisia annua (sweet sagewort) allergen extract drops
224160074|NCT03649139|DRUG|Placebo drops|sublingual placebo drops
224160075|NCT01508793|BEHAVIORAL|Optimize Sleep|Children are asked to increase their sleep by approximately 1 1/2 hours/night for the duration of the two month intervention
224160076|NCT04602013|DRUG|Sintilimab|Body weight \<60kg: 3mg/kg IV Q3W; Body weight ≥60kg: 200mg IV Q3W. Every three weeks is a cycle
224160077|NCT04602013|DRUG|Chemotherapy|"Chemotherapy drugs include cisplatin and albumin-bound paclitaxel for injection Paclitaxel for injection (albumin-bound type) dose: 3 dose groups (di=260 mg/m2, di-1=220 mg/m2, di-2=180 mg/m2).~Dosing on the first day, one cycle every three weeks, a total of 2 cycles. Cisplatin (25mg/m2 IV D1-3 Q3W)"
224160078|NCT04602013|RADIATION|Radiation Therapy|The total dose is 60-66 Gy, divided into 30-33 times (2.0 Gy/f, 5 f per week).
223471462|NCT04009616|DRUG|Chlorhexidine mouthwash|rinsing with chlorhexidine mouthwash for 5 days.
223471463|NCT04009616|DRUG|Placebo mouthwash|rinsing with placebo mouthwash for 5 days.
223471464|NCT00583648|OTHER|Urinanlysis|sending a Urine sample to the laboratory for processing
223471465|NCT03794895|DEVICE|Doppler|Doing doppler for women having IUCD associated menorrhagia
223471466|NCT02051296|DRUG|Minocycline|RCT blinded placebo trial
223471467|NCT02051296|DRUG|placebo|RCT blinded placebo trial
223471468|NCT00359879|DRUG|exenatide|subcutaneous injection, 5mcg or 10mcg, twice a day (before lunch and dinner)
223471469|NCT00359879|DRUG|exenatide|subcutaneous injection, 5mcg or 10mcg, twice a day (before breakfast and dinner)
223471470|NCT04237948|DEVICE|transcranial direct current stimulation (tDCS)|cerebellar tDCS consists in the application of a low intensity (1-2 mA) steady current through a surface scalp electrode over the cerebellum
223471471|NCT04237948|BEHAVIORAL|Physical therapy|Hospitalized patients will undergo a 60 minutes physical treatment improving gait and postural instability for four weeks of time
223471472|NCT00746369|BEHAVIORAL|IMARA HIV Prevention Intervention|Three individual sessions- behavioral intervention for incarcerated female adolescents.
223471473|NCT04905043|DRUG|Acalabrutinib|Participants will receive a single oral dose of acalabrutinib 100 mg capsule on Day 1 (Period 1) and Day 4 (Period 2).
223471474|NCT04905043|DRUG|SmartPill®|Participnats will receive a single oral dose of wireless motility/pH capsule (SmartPill®) on Day 1 (Period 1) and Day 4 (Period 2).
223471475|NCT00106002|DRUG|pemetrexed|600 mg/m2, intravenous (IV), every 14 days until complete response or disease progression
223471476|NCT05374096|OTHER|Patient-Chosen Music|Music played into headphones.
223471477|NCT05374096|OTHER|Placebo|Silence into headphones.
223471478|NCT04215835|DRUG|letrozole then misoprostol|"Drug: Letrozole 2.5mg total dose 7.5 mg per day for 3 days~Drug: Misoprostol Misoprosrol 800mcg will be given to all patients for induction of abortion"
223471479|NCT04215835|DRUG|placebo then misoprostol|"Drug: Placebo placebo for 3 days~Drug: Misoprostol Misoprosrol 800mcg will be given to all patients for induction of abortion"
223471480|NCT05899361|DEVICE|Electromagnetic Guided Laparoscopy|Standard Care
223471481|NCT05899361|DEVICE|Ultrasound|Standard Care
223471482|NCT04895501|OTHER|running flexible shoes|21kms of running flexible shoes followed by a time-to-exhaustion run.
223471483|NCT03485586|DEVICE|Traditional ultrasound biometrics|To evaluate the clinical feasibility of using a new optical coherence interferometry ( lenstar ),comparing with traditional ultrasonic biometry and keratometry in the accuracy and characteristics for intraocular lens calculation of cataract after PPV
223471484|NCT03485586|DEVICE|Lenstar|To evaluate the clinical feasibility of using a new optical coherence interferometry ( lenstar ),comparing with traditional ultrasonic biometry and keratometry in the accuracy and characteristics for intraocular lens calculation of cataract after PPV
223471485|NCT02765737|OTHER|Dehydrated Human Amnion/Chorion Membrane|Dehydrated human amnion/chorion membrane (dHACM) product and is regulated as a Human Cells, Tissues and Cellular and Tissue Based Product (HCT/P) under Section 361 of the Public Health Service Act by the Food and Drug Administration (FDA).
223471486|NCT02765737|DEVICE|Mepilex Ag|
223471487|NCT01790399|PROCEDURE|Excision of sentinel node(s)|Excision of sentinel node(s) using SENTIMAG / SIENNA + in addition to the usual method (blue and /or radioactive product)
223471488|NCT04603755|DEVICE|Electrical Impedance tomography|Electrical Impedance tomography recording during 5 minutes every day during 7 days
224160079|NCT02798640|DEVICE|Celliant|100% Celliant garment
224304085|NCT03994601|DRUG|BMS-986288|Specified dose on specified days
223579727|NCT05129514|OTHER|Manual Lymphatic Drainage (MLD)|The participant will be placed in a supine position and manual lymphatic drainage will be performed for 50 minutes. During the three intervening days, daily 50 minute sessions of manual lymphatic drainage will be provided.
223579728|NCT01053013|BIOLOGICAL|RENCA macrobeads|
223579729|NCT01135914|DRUG|ranibizumab|Ranibizumab 0.5 mg fixed loading dose via intravitreal injection, given once per month for 3 consecutive months (Day 1, Month 1 and Month 2). This treatment could be reapllied, depending on symptoms.
223579730|NCT01135914|PROCEDURE|Laser|Laser photocoagulation treatment was administered on Day 1. Subsequent laser treatments could be administered if needed, in accordance with Early Treatment Diabetic Retinopathy Study (ETDRS) guidelines.
223579731|NCT01873053|DRUG|WIN-34B|Patients assigned to Experimental group(1st or 2nd group) take WIN-34B 450mg or WIN-34B 900mg BID for 12weeks
224304086|NCT03994601|DRUG|Nivolumab|Specified dose on specified days
223471489|NCT02173782|DRUG|Berodual® Respimat ® high dose|
223579732|NCT01873053|DRUG|Placebo|
223579733|NCT04367103|DRUG|Norepinephrine|prophylaxis for hypotension
223579734|NCT04367103|DRUG|Phenylephrine|standerd prophylaxis for hypotension
223579735|NCT00232388|PROCEDURE|Blood draw|
223579736|NCT00241514|DRUG|Esomeprazole|
223579737|NCT01433302|PROCEDURE|Punch Biopsy|5 mm punch biopsy specimens from the affected, lymphedematous limb will be obtained just prior to lymphatico-venular bypass and six (6) months after lymphatico-venular bypass. Punch biopsies will be obtained from the radial (lateral) aspect of the upper arm approximately 10cm above the olecranon process. Biopsy specimens will be collected from the contralateral (normal) arm at the exact same location.
223579738|NCT02073838|DRUG|Ribavirin|
223579739|NCT02073838|DRUG|Vismodegib|
223579740|NCT02073838|DRUG|Decitabine|
224160080|NCT02798640|DEVICE|Control|Control Garment
224160081|NCT04872504|DEVICE|Acumen HPI-enabled EV1000 screen|Acumen HPI-enabled EV1000 screen record the incidence of intraoperative hypotension
224304087|NCT03994601|DRUG|Regorafenib|Specified dose on specified days
224304088|NCT05986721|DRUG|AGB101|low-dose levetiracetam, 220 mg, extended release tablet
224304089|NCT05986721|DRUG|Placebo|Placebo oral tablet
224304090|NCT01155024|DEVICE|Traditional fabricated prosthetic socket|A prosthetic socket constructed utilizing traditional techniques. This intervention is a control and the basis for comparison.
224304091|NCT01155024|DEVICE|Direct manufactured (DM) prosthetic socket|A prosthetic socket constructed from direct manufacturing technique. The socket will be tested under both diagnostic and definitive environments. Diagnostic testing will span several hours (4-6 hours) and definitive testing will span several months (3-6 months)
223579741|NCT05223881|DEVICE|13^C Spirulina Platensis Gastric Emptying Breath Test (GEBT)|After an overnight (minimum 8 hours) fast, patients are given a standardized test meal, after which they are administered the GEBT. Patients are asked to hold a glass tube in a comfortable position, take a deep breath and pause momentarily, blow gently into the tube for 5 - 10 seconds, slowly withdraw straw from tube while continuing to breath into tube, and immediately close the tube securely with the cap.
224304092|NCT04585789|DRUG|JNJ-73763989|JNJ-73763989 will be administered subcutaneously once every 4 weeks up to Week 44.
224304093|NCT04585789|DRUG|JNJ-56136379|JNJ-56136379 tablets will be administered orally once daily up to 48 weeks.
223471490|NCT02173782|DRUG|Berodual® Respimat ® low dose|
223579742|NCT00442832|DRUG|TD-1792|TD-1792 2 mg/kg/day IV
223579743|NCT00442832|DRUG|Vancomycin|Vancomycin 1 Gm IV q 12 hrs
224160082|NCT04008667|OTHER|Acupoint application|Acupoint application: The patients start using the acupoint application on the umbilical Shenque point in 2 hours after surgery, 1 or 2 times a day, lasting 5 days.
224160083|NCT04008667|OTHER|Fake acupoint application|Fake acupoint application: The patients start using the fake acupoint application on the umbilical Shenque point in 2 hours after surgery, 1 or 2 times a day, lasting 5 days.
224160084|NCT00948714|BEHAVIORAL|Peer Coach Phone Calls|Subjects will receive 3 phone calls from a trained peer coach over 6 months.
224304094|NCT04585789|DRUG|Entecavir (ETV)|ETV tablet will be administered orally once daily up to 48 weeks as NA treatment.
224304095|NCT04585789|DRUG|Tenofovir disoproxil|Tenofovir disoproxil will be administered orally once daily up to 48 weeks as NA treatment.
224304096|NCT04585789|DRUG|Tenofovir alafenamide (TAF)|TAF will be administered orally once daily up to 48 weeks as NA treatment.
223471491|NCT02173782|DRUG|Berodual® MDI|
223471492|NCT02173782|DRUG|Placebo|
223471493|NCT00501631|DRUG|VIVITROL 380 mg|Administered via IM injection once every 4 weeks.
223471494|NCT00501631|DRUG|Placebo for VIVITROL 380 mg|Administered via IM injection once every 4 weeks.
223471495|NCT03336125|DIETARY_SUPPLEMENT|Vitamin D|Vitamin D (40µg/day) will be compared with placebo
223471496|NCT03336125|DIETARY_SUPPLEMENT|Placebo|120 mg olive oil
223579744|NCT04594460|DEVICE|Hydrogen-Oxygen Generator with Nebulizer, AMS-H-03|the experimental arm will receive hydrogen-oxygen mixed gas inhalation (Hydrogen-Oxygen Generator with Nebulizer, AMS-H-03, output: 3 L/min (hydrogen concentration: 66.7%, oxygen concentration: 33.3%)) ,the treatment duration will be 8 hours per day, for 12 weeks.
223579745|NCT04594460|DEVICE|OLO-1 Medical Molecular Sieve Oxygen Generator|the control arm will receive oxygen inhalation (OLO-1 Medical Molecular Sieve Oxygen Generator, output: 3 L/min (oxygen concentration: 33.3%), Shanghai Ouliang Medical Devices Co., Ltd.)the treatment duration will be 8 hours per day, for 12 weeks.
223579746|NCT04333940|PROCEDURE|periapical surgery|clinical signs and symptoms, probing depth, Clinical attachment level (CAL ), dimensions of lesion, distance from the defect and apex of tooth to the anatomical structures will be measured
223579747|NCT02362204|BEHAVIORAL|therapeutic education and psychological support|Intervention consists of alternate face-to-face consultations (anticipated duration: 60-90 minutes) and telephone consultations (anticipated duration: 15-30 minutes). All interventions will include: i) a focused assessment of physical and psychological symptoms, ii) information about lung cancer (disease) and its treatment, iii) a review of disease-related and treatment-related side effects and strategies to manage these symptoms, and iv) printed listing and review of available support resources.
223579748|NCT01838265|PROCEDURE|Transrectal Ultrasound-Guided Biopsy|Active Surveillance Alone (AS). Transrectal Ultrasound-guided biopsies within 6 months of enrollment and at 1 year intervals thereafter (maximum four biopsies).
223579749|NCT01838265|PROCEDURE|MRI Ultrasound Biopsy|MRI-Managed Active Surveillance (MRI-AS). MRI Ultrasound or MRI-guided biopsies within 6 months of enrollment and at 1 year intervals thereafter (maximum four biopsies)
223579750|NCT01838265|BEHAVIORAL|Expanded Prostate Cancer index Composite Questionnaire|Quality of life questionnaire obtained at Baseline, and at 12, 24 and 36 months after initial biopsy
224160085|NCT00948714|BEHAVIORAL|Health Educator Visits|Subjects will meet 2 times with a trained health educator in the practice
224160086|NCT00948714|OTHER|written materials|Subjects will receive written material and brochures and a cookbook from the American Heart Association addressing healthy lifestyle
224160087|NCT03723408|DEVICE|ClearLine IV (formerly, AirPurge)|Patient safety device that automatically and continuously detects and actively removes air from IV lines - protecting patients from dangerous air burden, air embolism, air infusions.
224304097|NCT04585789|DRUG|PegIFN-alpha-2a (Optional)|PegIFN-alpha-2a injection will be administered subcutaneously once weekly after Week 40 for either 12 or 24 weeks.
223471497|NCT00179140|DRUG|nutritional supplementation|oral administration of protein supplement (Nepro) during hemodialysis; every other day, 3 days per week for 6 months; Nepro is a lactose-free formula that contains a total of 960 kilocalories: 132.8 kilocalories from protein, 412.8 kilocalories from carbohydrates, and 412.8 kilocalories from fat
223471498|NCT00179140|BEHAVIORAL|exercise|either before or during hemodialysis, patients will perform a leg press exercise; every other day, 3 days per week, for 6 months
223471499|NCT04236843|DIETARY_SUPPLEMENT|Feces|Feces from healthy donor
223471500|NCT04717635|BIOLOGICAL|Canakinumab|Provide as 150 mg/1 mL solution for subcutaneous injection and administer 4mg/kg every 4 weeks.
223471501|NCT02837588|DEVICE|Hyperthermy treatment with MJS electrode|30 patients who are diagnosed Pelvic pain with myofascial syndrome by gyneacologist or urologist goes to Pelvic Floor Physiotherapist for 4 session with hyperthermy treatment with MJS electrode at pelvic floor trigger points
223471502|NCT01245101|DRUG|Raltegravir|Raltegravir 400 mg twice daily in addition to subject's antiretroviral therapy.
223471503|NCT01245101|DRUG|Raltegravir|Raltegravir 400 mg twice daily in addition to subject's antiretroviral therapy.
223471504|NCT01005238|DRUG|Lamivudine|
223471505|NCT01005238|DRUG|Telbivudine|
223471506|NCT05025930|DEVICE|endoscopic surgical instrument control system (SP1000: single-port laparoscopy)|The system will be used in conjunction with other equipment during endoscopic surgery to accurately control endoscopic surgical instruments and perform delicate surgical procedures such as grasping, cutting, blunt separation, hemostasis, ligation and suture.
223471507|NCT05025930|DEVICE|endoscopic surgical instrument control system (IS3000: multi-port laparoscopy)|The system will be used in conjunction with other equipment during endoscopic surgery to accurately control endoscopic surgical instruments and perform delicate surgical procedures such as grasping, cutting, blunt separation, hemostasis, ligation and suture.
223471508|NCT05009355|DRUG|Vitamin C|antioxidant
223471509|NCT01014234|DRUG|Cyclosporins|These patients will undergo maintenance immunosuppressive treatment with cyclosporine + mycophenolate + prednisone according to established clinical practice. The dosage of drugs will be based on evaluations of serum trough levels and it will be adjusted when necessary.
223471510|NCT01014234|DRUG|Rapamycin|These patients will undergo maintenance immunosuppressive treatment with rapamycin + mycophenolate + prednisone according to established clinical practice. The dosage of drugs will be based on evaluations of serum trough levels and it will be adjusted when necessary.
223471511|NCT04215367|DIETARY_SUPPLEMENT|High phenolic EVOO intake|During the pilot dietary intervention patients with CLL consumed before their meals, 40 ml/day high phenolic EVOO for 6 months
223471512|NCT04215367|DIETARY_SUPPLEMENT|No High phenolic EVOO intake|Medical record of each patient's was followed during 6 month before dietary the intervention
223471513|NCT03836586|BEHAVIORAL|Cognitive-Behavioral Intervention|This intervention comprises three components: 1) general education about pain (e.g., pain pathways) and a rationale for the intervention (e.g., gate control theory); 2) impact of positive and negative pain-related thoughts on neural process of pain; and 3) a guided imaginal pain exposure exercise.
223471514|NCT03836586|BEHAVIORAL|Pain Education|General information about the neurobiology of pain and knee osteoarthritis will be given to participants assigned to this intervention.
223471515|NCT01225549|DRUG|AZD5423|Suspension for nebulisation once daily 7 days
223471516|NCT01225549|DRUG|Budesonide 200 microgram|Dry powder for inhalation twice daily 7 days
223471517|NCT01225549|DRUG|Placebo|Solution for nebulisation once daily 7 days
223471518|NCT01225549|DRUG|Placebo|Solution for nebulisation once daily 7 days
223471519|NCT04456686|DRUG|LY3016859|LY3016859 given IV.
223471520|NCT04456686|DRUG|Placebo|Placebo given IV.
223471521|NCT00494663|DRUG|DIO-902|150mg tablet once per day for 16 weeks
223471522|NCT00494663|DRUG|DIO-902|300mg tablet once per day for 16 weeks
223471523|NCT00494663|DRUG|DIO-902|450mg DIO-902 tablet once daily for 16 weeks
223471524|NCT00494663|DRUG|DIO-902 placebo|DIO-902 placebo tablet once daily for 16 weeks
223471525|NCT00494663|DRUG|DIO-902|150mg tablet of DIO-902 once daily for 16 weeks
223579751|NCT01838265|BEHAVIORAL|Short-Form 12 of Health Related Quality of Life Questionnaire|Quality of life questionnaire obtained at Baseline, and at 12, 24 and 36 months after initial biopsy
223579752|NCT01838265|BEHAVIORAL|Memorial Anxiety Scale for Prostate Cancer|Quality of life questionnaire obtained at Baseline, and at 12, 24 and 36 months after initial biopsy
223579753|NCT01838265|PROCEDURE|Plasma/Serum Sample for biomarkers|Plasma/Serum Sample for biomarkers obtained at Baseline, and at 12, 24 and 36 months after initial biopsy for correlative studies (CTC, fcDNA, SNPs)
223579754|NCT01838265|PROCEDURE|Urine Sample for Biomarkers|Urine Sample for biomarkers obtained at Baseline, and at 12, 24, and 36 months for correlative studies (hypermethylated DNA)
223579755|NCT01838265|PROCEDURE|Blood Tests for Blood Urea Nitrogen and Creatinine|Blood Tests for Blood Urea Nitrogen (BUN) and Creatinine obtained at 0 - 6 months, and at 12, 24, and 36 months from initial biopsy. This is optional, subject may refuse
223471526|NCT00494663|DRUG|DIO-902|300mg DIO-902 tablet daily for 16 weeks
224160088|NCT03458988|DEVICE|Blood-pressure measuring (Nellcor™ Adult SpO2 Sensor)|Data will be acquired for 10 minutes with a reusable off the shelf adult SpO2 sensor. The Nellcor™ Adult SpO2 Sensor, model DS-100A, is indicated for use when continuous noninvasive arterial oxygen saturation and pulse rate monitoring are required for patients weighing greater than 40 kg.
223471527|NCT00494663|DRUG|DIO-902|450mg DIO-902 tablet for 16 weeks
223471528|NCT00494663|DRUG|DIO-902 placebo|DIO-902 placebo tablet once daily for 16 weeks
223471529|NCT00902863|BEHAVIORAL|YOGA|Patients with chronic pain will undergo a six week course of YOGA
223471530|NCT03670992|PROCEDURE|duodenal-pancreatectomy|surgical removal of metastatic repetitions in pancreas and/or other distal sites
223471531|NCT01252368|BIOLOGICAL|hypertension|patients taking daily ACE inhibitors or sartanes
223471532|NCT02007902|OTHER|Evaluation of the relationship plasma protein levels - neonatal hemodynamics|"* Patient inclusion at birth~* Total plasma protein values measurement on cord blood sample at birth~* Hemodynamic evaluation at 6 hours after birth with colour doppler echocardiography and organ blood flow colour doppler~* Total plasma protein and albumin values measurement on plasma sample at 12 hours after birth~* Blood pressure, heart rate, O2 saturation, capillary refill time, rSO2 \[regional (cerebral and somatic) tissue oxygenation by NIRS - near infrared spectroscopy\] will be monitored over 24 hours after birth."
223471533|NCT00578903|DRUG|Cytoxan|Cytoxan will be given at 50 mg/kg per dose for 4 successive days.
223471534|NCT00578903|DRUG|Campath|Campath will be given at a dose of 3 mg for patients whose weight is between 5 and 15 kg; at a dose of 5 mg for patients whose weight is between 16 and 30 kg; and at a dose of 10 mg for patients whose weight is greater than 30 kg. The last dose of Campath should be 24 hours or more before stem cell infusion.
223579756|NCT01838265|PROCEDURE|Blood Test for Serum PSA|Blood test for Serum PSA obtained at Baseline, at every 6 months up to 36 months from initial biopsy.
223579757|NCT02262819|DRUG|S. aureus|S. aureus, commensal coagulase-negative staphylococcal species, and Gram-negative commensals, such as Roseomonas and Pseudomonas species
223579758|NCT02337972|DRUG|povidone-iodine 4%|Prior to each injection and before the use of povidone-iodine drops, a conjunctival culture will be taken
223579759|NCT02614482|DRUG|Fesoterodine|Administer medication to patients with overactive bladder
223743814|NCT05311371|OTHER|Breathing exercise group|"The exercise was applied in accordance with the Guideline on Breathing Exercise for Reducing Nausea and Vomiting prepared by the researcher in accordance with the literature. In addition, the researcher has a breath coaching certificate. The guideline include the application steps of breathing exercise. First, the researcher will demonstrate to the patients the practice of breathing exercise in accordance with the guideline. In the next step, patients they will be asked to do this application on themselves. The training is planned to take about 15-20 minutes for each patient. This guide will be given to patients after the training. They will be asked to do this breathing exercise correctly and effectively in accordance with the guideline for at least 5 min in case of sensation of nausea and vomiting for 14 days. The researcher will follow up the patients for 14 days by visiting room them every day."
223743815|NCT05311371|OTHER|Control group|No intervention
224160089|NCT03401216|DEVICE|SYNERGY 48 mm|Material: Platinum-Chromium alloy. Stent strut thickness: 0.0029-0.0032 inches. Polymer carrier composed of PLGA (poly(DL-lactide-co-glycolide)). Drug product: Everolimus, 1µg per 1 mm2. Stent diameters available: 2.25; 2.50; 2.75; 3.00; 3.50; 4.00 mm. Stent length: 48 mm. Nominal balloon pressure: 11 atm. (1117 kPa). Manufacturing company: Boston Scientific Corporation (USA)
224160090|NCT03401216|PROCEDURE|PCI|Standard PCI procedure
223471535|NCT00578903|RADIATION|Total Body Irradiation (TBI)|TBI will be given at a dose of 200 cGy for 6/6 HLA match and at a dose of 400 cGy in two fractions of 200 cGy each for 5/6 HLA matched donor.
223471536|NCT00578903|DRUG|FK-506|FK-506 will be given at a dose of 0.03 mg/kg/day via continuous infusion over 24 hours from 4pm on day -2 until engraftment or when patient is able to take by mouth (PO), then 0.03 mg/kg PO every 12 hours.
223471537|NCT00578903|DRUG|Methotrexate|Methotrexate will be administered on day +1, day +3, day +6 and day +11 at a dose of 5 mg/m2. The day +11 dose may be omitted at the discretion of the bone marrow transplant (BMT) in-patient attending physician.
223471538|NCT00578903|PROCEDURE|Stem cell infusion|Where possible patients will receive bone marrow. Marrow will be collected as per National Marrow Donor Program (NMDP) guidelines to provide a volume of 15-20 ml/kg of marrow and/or 2-4 X 10\^8 nucleated cells/kg. In case marrow cannot be collected, peripheral blood stem cell (PBSC) will be substituted. A minimum of 5-6 X 10\^6 CD 34+ cells/kg should be collected, with a target of 10 X 10\^6/kg.
223471539|NCT00891813|DRUG|Zemplar (paricalcitol)|Zemplar (paricalcitol) dose will be calculated mcg=PARATHYROID HORMONE level/100; this will be provided 3 times per week. Dose will be adjusted by 2-4 mcg every 4 weeks according to the parathyroid hormone level.
223471540|NCT00639119|DRUG|Ropinirole|8 + 8 weeks cross-over placebo controlled
223471541|NCT00743210|DRUG|L-citrulline|Oral L-citrulline, 3 grams once per day for 3 weeks.
223471542|NCT00743210|DRUG|Placebo|Placebo, 3 grams once per day for 3 weeks.
223471543|NCT02532036|BIOLOGICAL|Aerosol inhaled MVA85A|
223471544|NCT02532036|BIOLOGICAL|Intramuscular MVA85A|
223471545|NCT02532036|BIOLOGICAL|Intramuscular Saline placebo|
223471546|NCT02532036|BIOLOGICAL|Aerosol inhaled Saline placebo|
223471547|NCT06195085|RADIATION|CT-guided radioactive iodine-125 seed implantation|The CT-guided radioactive iodine-125 seed implantation procedure mainly consisted of preoperative treatment planning, intraoperative seed implantation and postoperative dosimetric evaluation. All procedures were performed as per relevant guidelines and regulations.
223471548|NCT06458348|BEHAVIORAL|Local opera appreciating and Medical gymnastics training|To construct a local opera viewing combined medical gymnastics training program for elderly patients with post-stroke cognitive impairment, and to explore its feasibility, acceptability and safety.
223471549|NCT04974073|DRUG|PHY606|Danggui Buxue Tang is a well-known TCM formula indicated for anemia through immune modulation and increase energy metabolism
223579760|NCT00278330|DRUG|alvocidib|Given by infusion
223579761|NCT00278330|DRUG|vorinostat|Given orally
223579762|NCT05683015|PROCEDURE|Venapuncture|Blood samples will be collected to determine the serum trough levels and anti-drug antibodies of tildrakizumab.
223743816|NCT00391352|DRUG|IFN-β-1a (Rebif®)|44 mcg Three times a week, subcutaneous injection
224160091|NCT03401216|PROCEDURE|3 month OCT follow-up|Optical coherence tomography imaging of target vessel within 3 month after PCI
224160092|NCT03401216|PROCEDURE|6 month OCT follow-up|Optical coherence tomography imaging of target vessel within 5 month after PCI
223471550|NCT01329198|DEVICE|NeuroPace RNS® System Deep Brain Stimulator|Utilizes a signal that the device detects and will respond to with an electrical pre-defined pulse if the signal is encountered.
223471551|NCT04823234|DIAGNOSTIC_TEST|Lung ultrasound|Lung ultrasound signs in Covid 19 positive pregnant patients
223471552|NCT02581592|DRUG|TD-4208|A single inhaled dose of TD 4208 (175 mcg)
223471553|NCT02349555|DIETARY_SUPPLEMENT|Nutritional Supplement Blend|It is to be taken orally at a dose of 4 capsules per day, 2 capsules with breakfast and 2 capsules with dinner.
223471554|NCT01189448|DRUG|Pyrimethamine/Sulfadiazine|"Pyrimethamine + sulfadiazine group : Pyrimethamine 50 mg once daily orally and sulfadiazine 1g tid. orally, with supplemental folinic acid 50 mg once a week.~Follow-up includes clinical and biological tolerance, according to usual recommendations. Monthly fetal ultrasound is performed. Prenatal diagnosis with amniocentesis is offered after 18 weeks gestation, usually 4 weeks after the maternal infection.~Treatment is be stopped or changed in case of toxicity. If prenatal diagnosis shows fetal infection with T. gondii, management is to be determined by the clinicians with the patient. If the prenatal diagnosis is negative the treatment can be stopped in order to reduce the risk of intolerance, providing that the mother receives at least 4 weeks of therapy."
223471555|NCT01189448|DRUG|Spiramycine|"Spiramycin group : spiramycin 1g tid orally Follow-up includes clinical and biological tolerance, according to usual recommendations. Monthly fetal ultrasound is performed. Prenatal diagnosis with amniocentesis is offered after 18 weeks gestation, usually 4 weeks after the maternal infection.~Treatment is be stopped or changed in case of toxicity. If prenatal diagnosis shows fetal infection with T. gondii, management is to be determined by the clinicians with the patient. If the prenatal diagnosis is negative the treatment is continued according to usual procedures"
223471556|NCT03242785|OTHER|Self-monitoring/Self-titration|"The intervention of the ADAMPA trial is not pharmacological but an intervention that modifies usual clinical practice. The intervention of self-monitoring and self-titration of the medication is composed of 3 elements:~1. Education of the patient: information and training on hypertension, its risks, management, the benefits of an adequate control and the generic measures for an optimal control.~2. Training for self-monitoring: Patients will be trained to perform the self-measurement of blood pressure correctly (and recording their values in the sheet enabled for this purpose)~3. Training for self-titration: patients will be instructed on the target BP numbers, individualized for each patient, on the mode of action against specific figures, including self-adjustment of drug treatment."
223471557|NCT00473083|DRUG|Minocycline|Patients will receive prophylactic treatment with minocycline 100 mg orally twice-daily for at least 4 weeks on the initiation of erlotinib therapy. If rash occurs during the 4 week period of minocycline prophylaxis, the minocycline prophylaxis will continue and additional treatment by grade of rash will be according to the Treatment Arm 2 schedule. If rash occurs after the completion of the 4 week prophylaxis period, treatment by grade of rash will be according to the Treatment Arm 2 schedule.
223471558|NCT00473083|DRUG|Clindamycin 2% in hydrocortisone 1% lotion|"Appropriate amounts of clindamycin and hydrocortisone powder are mixed with corresponding amount of Nutraderm® lotion for this mixture.~If preferred, the appropriate amount of clindamycin powder can be mixed with Emo-Cort® lotion (already contains hydrocortisone 1%), available in 60 mL bottles."
223471559|NCT00473083|DRUG|Erlotinib|Erlotinib will be given on an outpatient basis at a fixed dose of either 150 or 100 mg as a single daily oral dose.
223471560|NCT00473083|DRUG|Topical clindamycin 2%, triamcinolone acetonide 0.1% soln|Clindamycin 2% in Triamcinolone acetonide 0.1% solution in equal parts propylene glycol and water
223471561|NCT04833374|DRUG|Methylprednisolone|Patients will receive 0.5g/d methylprednisolone intravenously for 3 consecutive days in the 1st-2nd-3rd or 1st-3rd-5th month, then oral prednisone 0.5mg/kg/d on alternate days for 6 months.
223471562|NCT01976000|PROCEDURE|multi-slice Computed Tomography angiography and three-dimensional reconstruction software|
223471563|NCT03377465|DIAGNOSTIC_TEST|ADMA (asymmetric dimethylarginine) , NTproBNP (N-terminal pro b-type natriuretic peptide), IL-6 (Interleukin 6), Adiponectina, Leptine, Syndecan, Resistin|ADMA, NTproBNP, IL-6, Adiponectina, Leptine, Syndecan, Resistin
223471564|NCT02858401|DRUG|Vesatolimod|Tablet(s) administered orally once every 2 weeks
223471565|NCT02858401|DRUG|Placebo|Tablet(s) administered orally once every 2 weeks
224160093|NCT04476615|DIETARY_SUPPLEMENT|Fasting-Mimicking Diet (ProLon®)|Dietary restriction: Fasting-Mimicking Diet (ProLon®). 5-days cycles spaced at 1-month intervals for 3 months (3 cycles in total).
224160094|NCT04476615|DIETARY_SUPPLEMENT|Placebo bars|"Dietary supplementation: Low-energy bars (L-Nutra®) to integrate the daily nutritional habits - one bar per day.~5-days cycles spaced at 1-month intervals for 3 months (3 cycles in total)."
224160095|NCT04139772|DRUG|Docetaxel|Docetaxel 75 mg/m2 intravenous (iv) infusion every 3 weeks plus oral prednisone 5 mg twice daily for a maximum of 10 cycles.
224160096|NCT04139772|DRUG|Abiraterone Acetate or Enzalutamide|"Patient will receive Abiraterone or Enzalutamide based on previous treatment.~Abiraterone given orally at the dose of 1000 mg daily plus oral prednisone 5 mg twice daily until progression or unacceptable toxicity. One course of therapy corresponds to four weeks of treatment.~Enzalutamide given orally at the dose of 160 mg daily until progression or unacceptable toxicity. One course of therapy corresponds to four weeks of treatment."
223471566|NCT02858401|DRUG|ARV regimen|Participants' current ARV regimen must be used in accordance with their prescribing information and may include the following: nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs), raltegravir, dolutegravir, rilpivirine, and maraviroc.
223471567|NCT02340455|DRUG|Pregabalin_male|Pregabalin 150mg bid 1day Men
223471568|NCT02340455|DRUG|Pregabalin_female|Pregabalin 150mg bid 1day Women
223471569|NCT02340455|DRUG|Placebo_Men|Placebo durg
223471570|NCT02340455|DRUG|Placebo_Women|Placebo\_Women
223471571|NCT00380900|DRUG|AGG-523|
223579763|NCT05683015|PROCEDURE|Patient questionnaires|The study participants will complete the Dermatology Quality of Life (DLQI) and EQ-5D-5L questionnaire at each study visit.
223579764|NCT00921310|DRUG|Pemetrexed|
223579765|NCT00921310|DRUG|Temsirolimus|
224160097|NCT00544505|DRUG|Fluorouracil/Epirubicin/Cyclophosphamide|Phase III Comparison of Preoperative vs Postoperative FEC (Fluorouracil/Epirubicin/Cyclophosphamide) in Women with Operable Breast Cancer
224304098|NCT03198975|DIAGNOSTIC_TEST|Magnetic resonance image|Histologically-diagnosed primary HCC after curative hepatectomy. The magnetic resonance image will be imported into the software ,and the radiomic textural features will be automatically extracted by the Analysis-Kit software.The high-throughput extracted features will be then selected and a prediction model will be developed in the training set in which patients were collected from a retrospective study. In this project, an independent validation set will be collected and used to validate the prediction accuracy of the model.
224160098|NCT03025516|DEVICE|Rapid Biosensor Systems (RBS) TB Breathalyser|Rapid Biosensor Systems (RBS) recently developed a portable, non-invasive, rapid TB diagnostic 'Breathalyser' capable of diagnosing TB in patient breath samples collected while patients cough (Figure 1). The TB Breathalyser comprises a disposable, single-use sample collection tube and a multi-use reader. At the bottom of the collection tube is a glass bio-sensor coated with a biochemical sensor that is formulated to react with TB bacilli. Patients cough into the collection tube after nebulization with 0.9% saline solution. Following sample collection, the tube is placed into the reader, where a diode laser interrogates the biochemical coating in the sample collection tube and reports the presence of TB bacilli. The entire process takes about two minutes.
224160099|NCT03025516|DEVICE|eNose AeonoseTM|The eNose Company has also developed a hand-held, non-invasive rapid TB diagnostic 'electronic nose' (AeonoseTM) for TB detection based upon analysis of exhaled breath. After the device has been calibrated, the patient is instructed to breathe into the device through a mouthpiece for 5 minutes. Within the device is a micro-hotplate, metal-oxide sensor which behaves as a semiconductor at high temperature. Redox-reactions occurring at the sensor surface result in changes in resistance, with results read and interpreted by a phone application to confirm the presence of MTB.
224160100|NCT00075660|DRUG|triapine|
224160101|NCT02177786|DRUG|Selonsertib|Tablets administered orally once daily
224304099|NCT04178070|BIOLOGICAL|GB224 2mg|2mg (100μL), single dose, abdominal subcutaneous injection
223471572|NCT02415530|BEHAVIORAL|Combined home visiting and group intervention|home visit includes pre-discharge meeting with parents; education of appropriate feeding, breastfeeding, sleeping, position of baby, defecation, environment for baby care and resuscitation on emergency situation first visit (5 days after discharge); understanding baby's sign check feeding, sleeping, sanitation, defecation, environment second visit (14 days after discharge); understanding baby's sign and baby's development support parents check feeding, sleeping, sanitation, defecation, environment special situation third visit (4 weeks after discharge) understanding baby's sign and baby's development support parents special situation fourth visit (8 weeks after discharge) same as third visit Group intervention for parental support with baby 12 times during corrected age 3\~6 months
223471573|NCT02415530|OTHER|No intervention|No intervention
224160102|NCT02177786|DRUG|Placebo to match selonsertib|Tablets administered orally once daily
224160103|NCT02180568|PROCEDURE|Lipiodol|Lipiodol-guided lung localization technique
224160104|NCT02180568|PROCEDURE|Hookwire|Hookwire-guided lung localization technique
224304100|NCT04178070|BIOLOGICAL|GB224 5mg|5mg (250μL), single dose, abdominal subcutaneous injection
224304101|NCT04178070|BIOLOGICAL|GB224 10mg|10mg (500μL), single dose, abdominal subcutaneous injection
223471574|NCT00402935|OTHER|laboratory biomarker analysis|Patients undergo blood collection at the same time points for follicle-stimulating hormone, estradiol, and inhibin B levels.
223471575|NCT00402935|PROCEDURE|fertility assessment and management|Patients undergo a transvaginal or transabdominal ultrasound to measure the ovarian volume and count the number of antral follicles.
223471576|NCT00402935|PROCEDURE|management of therapy complications|Patients are also asked to fill out questionnaires on estrogen-depletion symptoms at those times. Patients also keep a calendar of menstrual bleeding and hormonal medications.
223579766|NCT01895244|DRUG|Autologous stemcell transplantation with CD (cluster of differentiation) 34 selected stem cells|If no active alveolitis: mobilisation with 2x1g Cyclophosphamide If active alveolitis: mobilisation with 2x1.5g Cyclophosphamid If cardiac manifestation: Conditioning with CYC 2 x 50mg + thiotepa 2x5mg + ATG If no cardiac manifestation: Conditioning with 4 x 50mg CYC + ATG
223579767|NCT05479123|DRUG|Propranolol three times a day|"Patients with larger (\>2cm) or multiple (\>1) hemangiomas in this arm will get propranolol in the following regimen:~Week 1: 0.5 mg/kg/day divided TID Week 2: 1 mg/kg/day divided TID Week 3: 2 mg/kg/day divided TID. Patients will stay on this dosage until their 3 month follow up visit."
223579768|NCT05479123|DRUG|Propranolol twice a day|"Patients with larger (\>2cm) or multiple (\>1) hemangiomas in this arm will get propranolol in the following regimen:~Week 1: 0.5 mg/kg/day divided BID Week 2: 1 mg/kg/day divided BID Week 3: 2 mg/kg/day divided BID. Patients will stay on this dosage until their 3 month follow up visit."
224160105|NCT02180568|DRUG|Lipiodol|
223579769|NCT05479123|DRUG|Timolol|Patients with a small (\<2cm) isolated infantile hemangioma are prescribed timolol 0.5% ophthalmic drops, a topical beta-blocker(1 drop BID directly onto the hemangioma).
224160106|NCT05601050|OTHER|There is no intervention|There is no intervention
224160107|NCT02798445|OTHER|TAPIRS|Terminal Axial Perforator Interruption Reflux Source plus Adjustable compression system
224160108|NCT02798445|OTHER|CONTROL|Multilayer bandages and wound care
224160109|NCT02055729|BIOLOGICAL|3mm tissue punch biopsy|Bacterial samples will be collected using deep level tissue biopsy using a Steifel punch of 3 mm in diameter (days 0 and 28).
224160110|NCT02055729|BIOLOGICAL|Superficial bedsore sample|Bacterial samples will be taken from the surface of the bedsore via swabbing. (days 0 \& 28)
224304102|NCT04178070|BIOLOGICAL|GB224 15mg|15mg (750μL), single dose, abdominal subcutaneous injection
224304103|NCT04178070|BIOLOGICAL|GB224 20mg|20mg (1mL), single dose, abdominal subcutaneous injection
224304104|NCT04178070|BIOLOGICAL|GB224 30mg|30mg (1.5mL), single dose, abdominal subcutaneous injection
224304105|NCT04178070|OTHER|Placebo, 2mg|2mg (100μL), single dose, abdominal subcutaneous injection
224304106|NCT04178070|OTHER|Placebo, 5mg|5mg (250μL), single dose, abdominal subcutaneous injection
224304107|NCT04178070|OTHER|Placebo, 10mg|10mg (500μL), single dose, abdominal subcutaneous injection
224304108|NCT04178070|OTHER|Placebo, 15mg|15mg (750μL), single dose, abdominal subcutaneous injection
223471577|NCT00402935|PROCEDURE|ultrasound imaging|Patients undergo a transvaginal or transabdominal ultrasound to measure the ovarian volume and count the number of antral follicles.
223471578|NCT00003360|RADIATION|iodine I 131 monoclonal antibody A33|
223579770|NCT01260025|DRUG|PEDylated Recombinant Human Endostatin|The initial dose of PEDylated Recombinant Human Endostatin (M2ES) will be 7.5mg/m2.Dose Escalation to a next higher level will occur when 3 patients in the same dose level complete 28 days of continuous treatment without experiencing a dose-limiting toxicity.
223579771|NCT06907797|BEHAVIORAL|TRIAL Web-Based Application|A web-based application that provides disease and trial education and access to resources provided by the Leukemia and Lymphoma Society (LLS). iPads will be provided to participants for 14 days.
223579772|NCT00001307|DRUG|Oxygen-15 Water|
224160111|NCT02055729|BIOLOGICAL|Stool sample|Stool samples will be collected on days 0 and 28.
224160112|NCT02055729|BIOLOGICAL|Urine sample|Urine samples will be collected on days 0 and 28.
224160113|NCT02706795|BIOLOGICAL|DaxibotulinumtoxinA|Low, mid, and high dose sequential treatments of daxibotulinumtoxinA in dose-escalation safety and efficacy study
224160114|NCT00026039|DRUG|estrogen|
223471579|NCT06343116|DRUG|Nimotuzumab injection|Nimotuzumab will be administered weekly (dose of nimotuzumab depends on part A) until disease progression, unacceptable toxicity, withdrawal of consent or death due to any cause.
223471580|NCT06343116|DRUG|Placebo|Placebo will be administered weekly (dose of placebo depends on part A) until disease progression, unacceptable toxicity, withdrawal of consent or death due to any cause.
223471581|NCT06343116|DRUG|Trifluridine/tipiracil|Trifluridine/tipiracil will be administered (35 mg/m2) twice daily, 5 days a week, with 2 days of rest, for 2 weeks, followed by a 14-day rest.
224160115|NCT05753202|DEVICE|transcranial current direct stimulation|Transcranial electrical stimulation over two different brain regions associated with cognitive training. 15 sesions in 3 weeks (5 days/week)
224160116|NCT02306941|BEHAVIORAL|Internet-delivered CBT|The Internet-delivered exposure treatment is based on the well-established internet-delivered CBT-treatment for IBS in adults, adapted for adolescents with FAP/FD and their parents. Main component in the treatment is exposure for symptoms. The purpose of the treatment is to reduce fearful and anxious responses to symptoms and lessen avoidance of symptoms in the adolescents, and to teach the parents how parental behavior can influence symptoms in children as well as how to support exposure. Detailed behaviour analysis is made for each individual and instruction is given on how to gradually expose to symptoms to lessen fear for symptoms and widen the behavioral repertoire.
224160117|NCT04625088|OTHER|Standardized liquid test meal|During this study visit, a standardized liquid test meal will be administered. Blood samples will be collected at baseline and then every 30 minutes for 4 hours after test meal.
224160118|NCT04625088|DRUG|Atropine + Standardized liquid test meal|During this study visit, 1.0 mg atropine will be administered I.V and then a standardized liquid test meal will be administered. Blood samples will be collected at baseline, following atropine administration, and then every 30 minutes for 4 hours after test meal.
224160119|NCT01074840|OTHER|Peanut flour|Peanut-allergic subjects will be given peanut flour in increasing amounts.
224160120|NCT00030160|BEHAVIORAL|Strength Training|
224160121|NCT01402323|OTHER|time point of tooth extraction|
223471582|NCT04188054|BEHAVIORAL|Change in sleeping position|The new sleeping position requires you to re-position yourself in your bed when lying on your back so that your feet (and ankles) hang over the end of the mattress, i.e. off the end of the bed.
223471583|NCT04188054|BEHAVIORAL|No change in sleeping position|No change to your normal sleeping position
223471584|NCT00749398|BIOLOGICAL|Infliximab|According to local country regulations.
223471585|NCT04915235|BEHAVIORAL|Algorithm|Algorithm
223471586|NCT03226444|DRUG|0.005% Lacripep|One drop (approximately 50 microliters) of 0.005% ophthalmic solution will be administered three times a day (TID) to both eyes for four weeks.
223579773|NCT00001307|DRUG|Capsaicin|
223579774|NCT05661396|BEHAVIORAL|Serious game rehabilitation|Three patients received therapeutic serious game rehabilitation in addition to conventional rehabilitation. The serious game was proposed to be played three times per week for four weeks, for a total of 12 sessions, with 15 min per session (= 45 minutes per week).
223579775|NCT05593614|DRUG|ATX01 10%|A 100 mL bottle of hydrogel formulation containing 10% amitriptyline hydrochloride w/w
223579776|NCT05593614|DRUG|ATX01 15%|A 100 mL bottle of hydrogel formulation containing 15% amitriptyline hydrochloride w/w
223471587|NCT03226444|DRUG|0.01% Lacripep|One drop (approximately 50 microliters) of 0.01% ophthalmic solution will be administered three times a day (TID) to both eyes for four weeks.
223471588|NCT03226444|DRUG|Placebo|One drop (approximately 50 microliters) of placebo solution will be administered three times a day (TID) to both eyes for four weeks.
223471589|NCT05918536|DIAGNOSTIC_TEST|evaluate the quality of surgical margins achievable with the use of navigated Intraoperative CT|Noninterventional, prospective study of patients operated on for musculoskeletal neoplasms designed to evaluate the quality of surgical margins achievable with the use of navigated Intraoperative CT
223579777|NCT05593614|DRUG|Placebo|A 100 mL bottle of hydrogel formulation containing no active substance
223743817|NCT05875857|BEHAVIORAL|Opioid destruction education|Intervention group will receive a specialized handout and patient education on the safe storage of opioid medications, importance of opioid destruction, opioid destruction options and medication destruction (Deterra) bag before discharge.
224160122|NCT00439309|DEVICE|Gelfoam/Thrombin|Gelfoam/Thrombin
224160123|NCT00439309|DEVICE|VascuSeal|VascuSeal
224163747|NCT01522118|DEVICE|ExAblate 2100; InSightec|"Patients with biopsy proven locally non-advanced T2 prostate cancer identified at 3T MR examination including dynamic contrast enhanced (DCE-with time to peak and mean transit time evaluation) and candidate to radical prostatectomy will undergo Magnetic Resonance guided Focused Ultrasound (MRgFUS) ablation. The procedure is carried out either under general anesthesia or spinal block.~MR images allow correct identification of the target as well as vital structure to avoid during energy delivery. Treatment safety and efficacy is monitored in real time using MR thermometry. Adjustments of energy direction and intensity can be made according to the real time monitoring. Pre- and post-ablative MR examinations will serve to analyze differences of DCE features of the neoplastic tissue; therapy-induced alterations will also be compared to histopathology findings from whole section prostate specimens"
224163748|NCT00002675|BIOLOGICAL|filgrastim|
223579778|NCT03333395|DRUG|Nebulized heparin and salbutamol|HS Group medications (study group) (30 patients) which was prepared by adding Heparin 25000 IU in 5ml (5 ampoules of Heparin Sodium 5000 I.U/ML, Nile company for Pharmaceuticals and Chemical Industries-A.R.E.) to Salbutamol 5mg/2.5ml Nebulizer Solution (one Ventolin nebule containing a preservative-free solution of Salbutamol Sulphate BP 2.5mg, GlaxoSmithKline Inc.)
223471590|NCT04942886|DRUG|Baracle Tab.®|The intervention group take entecavir 0.5mg everyday by oral administration for 3 years after hematopoietic stem cell transplantation.
223471591|NCT03093181|OTHER|Washout / Standard Cleanser|Participants will apply standard cleanser (Simple Kind to Skin Moisturising Facial Wash) twice daily (morning and night) with at least 8 hours between product applications. Participants will use the standard cleanser in a 5-7 day washout period and during the test phase of the study
223579779|NCT03333395|DRUG|Nebulized salbutamol|S Group medications (control group) (30 patients) which was prepared by adding Salbutamol 5mg/2.5ml Nebulizer Solution + Na cl 0.9% 5ml.
223579780|NCT03986047|DEVICE|Thermal care|Wearing of a light elastic lower back heating wrap, which heats up to 40°C within 30 minutes and maintains this temperature continuously for 8 hours. Heat wrap will be worn during the day for 8 hours on 7 consecutive days.
223579781|NCT03986047|OTHER|Exercises|In addition of exercises performed with the physiotherapist at the first session, exercises will be performed at home five times over the next 7 days, for approximately 30 minutes each performing day. Three different categories of exercises will be given: 1) Functional activities exposure (sitting, sit-to-stand, lifting, bending, etc.); 2) cognitive contraction of trunk muscles and basic trunk motor control exercises; 3) mobility of the lumbar spine and preferential direction of movement. Exercises will be chosen and adapted for each participant by a physiotherapist, in function of pain presentation and intensity, and response to exercises.
223579782|NCT03986047|DEVICE|Sham|The same lower back wrap as the Thermal care group will be used, but cooled down to room temperature (opened in advance). The wrap will be worn following the same parameters (duration, frequency) than the Thermal care group.
223579783|NCT03986047|BEHAVIORAL|Education for the management of acute low back pain|Participants will receive education on the management of acute low back pain by a physiotherapist . The main topics addressed will be patient reassurance, staying active, avoiding bed rest, activity modification, and sitting and bed postures/transfer. Participants will received a document that details advices covered during the session and the physiotherapist will answer any questions.
223579784|NCT01275092|DEVICE|CorPath robotic-assisted PCI|CorPath 200® robotic-assisted percutaneous coronary intervention
223579785|NCT01344629|DRUG|Telmisartan/Amlodipin FDC|Telmisartan80mg/Amlodipin5mg FDC
223579786|NCT01344629|DRUG|Telmisartan|Telmisartan 80 mg tablet
223579787|NCT01344629|DRUG|Amlodipin|Amlodipin 5mg tablet
224160124|NCT01614275|BEHAVIORAL|Technology-Enhanced Parent Training|"The training for the parents of children with autism assigned to the EIBI group will begin with completion of a structured parent-training program for 6 weeks that includes 16 to 18 sessions (three, 90-minute sessions per week). When a new topic is introduced, the initial training will include viewing a Power Point presentation, with embedded video and audio, that explains, in laymen's terms, the basic principles and processes related to the topic. The second part of the training involves a parent recruiting an adult friend, who will play the role of a child with autism. The adult playing the child with autism will wear a Bluetooth earpiece connected to a computer, which in turn will be connected to a UNMC expert. The expert will guide the actions of the adult playing the role of the child such that this confederate child will exhibit a variety of target behaviors relevant to the target skill, which will provide an opportunity for immediate feedback."
224160125|NCT01614275|BEHAVIORAL|Technology-Enhanced Tutor Training|"The training for the tutors to work with children diagnosed with autism, who were assigned to the EIBI group, will complete a 40-hour structured training program for 4 to 8 weeks that includes approximately 32 sessions. When a new topic is introduced, the initial training will include viewing a PowerPoint presentation, with embedded video and audio, that explains, in laymen's terms, the basic principles and processes related to the topic. The second part of the training involves a tutor recruiting an adult friend, who will play the role of a child with autism. The adult playing the child with autism will wear a Bluetooth earpiece connected to a computer, which in turn will be connected to a UNMC expert. The expert will guide the actions of the adult playing the role of the child such that this confederate child will exhibit a variety of target behaviors relevant to the target skill, which will provide an opportunity for immediate feedback."
224160126|NCT01614275|BEHAVIORAL|Technology-enhanced Early Intensive Behavioral Intervention|After training, the ABA tutor and parents will assist in the implementation of early intervention services that will be tailored to the particular needs of the family's child. These programs could include conducting a paired-stimulus preference assessment, using a natural language program to increase spoken communication, and using matching-to-sample methods to teach categorization skills. We will record and review at least an hour of the ABA tutor's and parents' interactions with the child per week during unstructured and structured teaching situations. The purpose of these observations is to determine whether the parents are implementing the teaching strategies or behavior-management programs as designed (i.e., treatment integrity measures). If the ABA tutor or parent implements a program with less than 80% accuracy across two consecutive observations, an additional scripted role-play will be conducted as a booster session for the targeted skills.
224160127|NCT01614275|BEHAVIORAL|No-Intervention|The ABA tutors, parents/caregivers, and children will be randomly assigned to a wait-list control group.
224160128|NCT03059511|DRUG|Nalbuphine|Opioid Pain Medicine
224160129|NCT00430027|DRUG|Capecitabine|Given 650 mg/m\^2 BID on days of ration therapy, 825 mg/m\^2 day 1-14, day 15-20 off x 4
224160130|NCT00430027|DRUG|Oxaliplatin|Oxaliplatin 30 mg/m\^2, 130mg/m2 IV Q 21 days x 4
224160131|NCT00430027|DRUG|Cetuximab|Initial Cetuximab 400 mg/m\^2 IV starting no earlier than 8 weeks and no later than 10 weeks after surgical resection
224160132|NCT00004833|DRUG|Immune globulin|
224160133|NCT00269295|BIOLOGICAL|Ty800|Live attenuated Ty800 S typhi oral vaccine is co-administered with a sodium bicarbonate buffer solution. Dosages: 5 X 10\^7 cfu, 5 X 10\^8 cfu, and 5 X 10\^9 cfu.
224163749|NCT00002675|DRUG|carboplatin|
224163750|NCT00002675|DRUG|cisplatin|
223471592|NCT03093181|OTHER|Test product|Participants will apply 0.6 gram (g) of Test product (Moisturising Cream with Niacinamide) twice daily (morning and night) with at least 8 hours between product applications. Participants will use the test product during the test phase of the study.
223471593|NCT03093181|OTHER|Positive control cleanser|Participants will apply positive control cleanser (Neutrogena Visibly Clear Spot Clearing Facial Wash) twice daily (morning and night) with at least 8 hours between product applications. Participants will use the positive control cleanser during the test phase of the study.
223471594|NCT03093181|OTHER|Positive control moisturiser|Participants will apply 0.6 g of positive control moisturiser (Vivatinell Acnecinamide Gel Cream) twice daily (morning and night) with at least 8 hours between product applications. Participants will use the positive control moisturiser during the test phase of the study.
223579788|NCT02545816|DEVICE|Bispectral index (BIS) EEG monitoring|The Bispectral Index (BIS) EEG monitor is a simplified EEG monitoring device which was originally designed to monitor the depth of hypnosis during general anesthesia. It does this by analyzing changes in the processed electroencephalogram (EEG) which occur with the hypnotic state and creating a measure (or index) indicative of these changes. A number between 0 and 100 is derived, with values above 70 associated with an awake state. The monitor also provides a single channel EEG, an electromyogram (EMG) and an index of signal quality (SQI), all in real time.
223579789|NCT04386499|DIETARY_SUPPLEMENT|Resveratrol|mixture of trans-resveratrol 150 mg (REVIFAST), folic acid 400 mcg, vitamin D, vitamin B12 and vitamin B6
223471595|NCT01564004|OTHER|Clinical hypnosis or neuro-linguistic programming|20 minutes tape recording intervention
223579790|NCT04386499|DIETARY_SUPPLEMENT|Folic acid|400 mcg of folic acid
223579791|NCT04104659|DRUG|MK 6240|"PET tracer, \[18F\]MK-6240 (an\[18F\]tau imaging agent,CerveauTechnologies)that has high affinity for the human phosphorylated tau deposits in AD brain offers new opportunities to investigate tau pathology.(Hostetler, Walji et al. 2016, Lohith, Bennacef et al. 2016, Walji, Hostetler et al. 2016, Lohith, Bennacef et al. 2017, Neelamegam, Yokell et al. 2017).We will evaluate this imaging agent in individuals from families with a known Autosomal Dominant Alzheimer's Disease (ADAD) mutation.~The planned dosage for \[18F\]MK-6240 is a single intravenous bolus injection of 185 MBq (5.0 mCi) in a large peripheral vein followed by a 10 mL normal saline (0.9% NaCl) flush."
223471596|NCT00349141|BIOLOGICAL|Whole virion, Vero cell-derived influenza vaccine containing H5N1 HA antigen|
223471597|NCT01219582|DRUG|Glucobay M (Acarbose/Metformin, BAY81-9783)|Oral Glucobay-M 25 every 8 hours (Q8H) titrated to Glucobay-M 50 Q8H or as per investigators discretion.
223579792|NCT04174651|BEHAVIORAL|Trier Social Stress Test (TSST)|Participants randomized to receive the acute stress condition will undergo the TSST wherein the participant will be introduced to an upcoming task (i.e., job interview) and allowed to prepare (2 minutes). The participant will then be required to speak (job interview) for 4 minutes in front of 2 experimenters. After completion of the interview, participants will be asked to perform a mental arithmetic task for 4 minutes.
224160134|NCT00269295|DRUG|Placebo|150 mL of the prepared sodium bicarbonate buffer solution. Placebo will look and taste essentially like the study product.
224160135|NCT01957215|DRUG|Indomethacin|Topical indomethacin
224160136|NCT01957215|DRUG|Placebo|Placebo patch
224160137|NCT04376736|OTHER|Home visit|Home visit by medical provider
224160138|NCT01221662|DRUG|Siwu Tang|Siwu Tang 3 g bid(oral) continuously two weeks
223471598|NCT06506123|DEVICE|Artificial Intelligence Detection and Classification of Patient-Ventilator Dyssynchronies|Machine learning algorithm to detect and classify patient-ventilator dyssynchronies, which is integrated in the mechanical ventilator (Fleximag Max, Magnamed, Brazil).
223471599|NCT04210986|DIETARY_SUPPLEMENT|Fisetin|Fisetin will be administered orally at 20 mg/kg for two consecutive days, followed by 28 days off, then 2 more consecutive days.
223471600|NCT04210986|DRUG|Placebo oral capsule|Placebo will be administered orally for two consecutive days, followed by 28 days off, then 2 more consecutive days.
223471601|NCT04620577|OTHER|antibiotic|normal saline
224160139|NCT05799911|DIETARY_SUPPLEMENT|Hydrogen rich water|Hydrogen-rich water with molecular hydrogen concentration 0.9 ppm.
224160140|NCT05799911|DIETARY_SUPPLEMENT|Placebo|Tap water with molecular hydrogen concentration 0.0 ppm.
224160141|NCT00790491|BEHAVIORAL|guidance tool for providers for lifestyle changes|automated guidance tool for medical providers involved in patient encounters addressing lifestyle changes. Addresses dietary and physical activity. Seeks to reduce cardiac disease risk.
224160142|NCT02451865|DRUG|Binimetinib|Given PO
223471602|NCT02740842|BEHAVIORAL|Interpersonal behavioral change communication|This arm includes home visits to mothers with infants and young children. Frontline health workers will counsel and support mothers in relation to breastfeeding and complementary feeding practices
223471603|NCT02740842|BEHAVIORAL|Mass media|A nationwide mass media campaign of TV and radio spots on infant and young child feeding practices will be aired in 2011, 2012 and 2013. All intervention arms will be exposed to this campaign.
224160143|NCT02451865|DRUG|Docetaxel|Given IV
224160144|NCT02451865|OTHER|Laboratory Biomarker Analysis|Correlative studies
224160145|NCT02668328|BEHAVIORAL|Social Cognitive Theory Tailored Behavioral Intervention|The intervention will enhance self-efficacy
224160146|NCT04609215|OTHER|ALECSAT|"Patients will receive concurrent chemotherapy with carboplatin/gemcitabine with cycles repeated every 3 weeks.~During the loading phase, patients will receive ALECSAT at 28 days intervals at weeks 5, 9, and 13. Hereafter (the maintenance phase), ALECSAT will be administered every 12 weeks until disease progression, death, unacceptable toxicity, investigator/patient decision or EOT visit at 18 months."
224160147|NCT01641354|PROCEDURE|Hemiepiphysiodesis|Partial closure of growth plate to correct deformity
224160148|NCT02648867|DEVICE|Continuous Maternal Feedback|The PushCoach device consists of a modification of the standard fetal scalp electrode and a separate apparatus designed to detect movement of the fetal head by detecting movement of an FSE. The PushCoach will be attached to the patient by an adhesive pad over the sacrum and extend between the patient's legs approximately 2-3 inches from the vaginal introitus. It assesses the movement of the FSE attached to the fetal scalp during pushing. The amount of fetal movement will be measured and recorded. The PushCoach device is connected to a laptop computer which will provide optical and auditory feedback to the patient about descent of the fetal head with maternal expulsive efforts.
223471604|NCT01533532|DRUG|KLH-2109|
223471605|NCT01533532|DRUG|KLH-2109|
223471606|NCT01533532|DRUG|KLH-2109|
223471607|NCT01533532|DRUG|placebo|
224160149|NCT02453139|BEHAVIORAL|Exercise|6 month supervised and home based aerobic exercise intervention
224163751|NCT00002675|DRUG|cyclophosphamide|
224163752|NCT00002675|DRUG|etoposide|
223471608|NCT04233879|DRUG|DOR/ISL|100 mg DOR/0.75 mg ISL FDC tablet taken once daily by mouth.
223579793|NCT04174651|BEHAVIORAL|Landscape Video|Participants randomized to receive the control condition will be watching a landscape video for 10 minutes.
223579794|NCT02227836|DEVICE|Allergy Patch Testing|
223579795|NCT05915624|OTHER|telephone counseiling|One day before the operation, information was given about the operation process via tele-nursing and counseling was provided.
223579796|NCT05408507|BEHAVIORAL|ABC123 Framework|This care planning framework aims to implement existing tools in geriatric medicine, palliative medicine, and medical oncology to aid in cancer care planning for older adults with newly diagnosed incurable advanced cancer and to test the delivery of goal-concordant care. This patient-centered intervention is the ABC123 care planning framework in parallel with usual care that includes a physical function assessment, chemotherapy toxicity estimate calculation, and a guided goals of care discussion.
223579797|NCT03634371|DRUG|Drug Levothyroxine 150 mcg|Administration of a 600 mcg levothyroxine dose
223579798|NCT03634371|DRUG|Drug Eutirox 150 mcg|Administration of a 600 mcg levothyroxine dose
223579799|NCT02148432|DRUG|dexmedetomidine infusion rate, 0.5 mcg/kg/hr|continuous infusion of dexmedetomidine at rate of 0.5 mcg/kg/hr
223579800|NCT02148432|DRUG|dexmedetomidine infusion rate, 1.0 mcg/kg/hr|continuous infusion of dexmedetomidine at rate of 1.0 mcg/kg/hr
223579801|NCT01805544|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|20 mg po once daily, which is also the recommended maximum dose. SmPC recommendations are to be followed for renal impairment
224160150|NCT02233491|BEHAVIORAL|Active lifestyle intervention|Active intervention will comprise reviews by a renal dietician, with cognitive behaviour therapy, to provide additional support for lifestyle intervention.
224160151|NCT02233491|OTHER|Control|No additional support other than lifestyle advice by clinician
224160152|NCT03857477|GENETIC|Genetic SNP profiling|Genetic SNP profiling of known prostate cancer predisposition SNPs will be performed on DNA extracted from saliva samples.
224160153|NCT03857477|OTHER|Prostate cancer screening|Prostate cancer screening in the form of PSA testing will be offered to all men who have a benign biopsy result for five years in order to track development of cancer in the future.
223471609|NCT04233879|DRUG|BIC/FTC/TAF|BIC/FTC/TAF 50/200/25 mg FDC tablet taken once daily by mouth.
223579802|NCT02679365|PROCEDURE|lower segment cesarean section and double lock closure of rectus sheath|
223579803|NCT02679365|PROCEDURE|lower segment cesarean section and continuous non-locking closure of rectus sheath|
223579804|NCT06378645|DRUG|General Anesthesia: Propofol|"Transurethral surgery at the Department of Urology (University Hospital Zurich) performed under study arm-specific anesthesia.~Propofol will be administered intravenously using the target-controlled infusion algorithm with effect site concentrations between 1.5-4.0 µg/ml necessary."
223579805|NCT06378645|DRUG|General Anesthesia: Sevoflurane|"Transurethral surgery at the Department of Urology (University Hospital Zurich) performed under study arm-specific anesthesia.~Sevoflurane will be given in gaseous form via the endotracheal tube in concentrations between 1.5-2.5% Vol."
223579806|NCT00457444|DRUG|Pollen|
223579807|NCT01536548|PROCEDURE|Skin drawing|Mark direction and angle for cannulation with a pencil on the skin
223579808|NCT01536548|PROCEDURE|No skin drawing|Standard practice; i.e. no marks on skin to help find correct direction and angle for introducing needles
223579809|NCT00391391|BIOLOGICAL|Split, Inactivated, Trivalent Influenza Vaccine|Vaccine (infant dose)
223579810|NCT00391391|BIOLOGICAL|Split, Inactivated, Trivalent Influenza Vaccine|Vaccine (children dose)
223579811|NCT00391391|BIOLOGICAL|Split, Inactivated, Trivalent Influenza Vaccine ( Fluzone® 2006/2007 Formulation)|Vaccine (infant dose)
223579812|NCT00391391|BIOLOGICAL|Split, Inactivated, Trivalent Influenza Vaccine ( Fluzone® 2006/2007 Formulation)|Vaccine (children dose)
223471610|NCT04233879|DRUG|Placebo to BIC/FTC/TAF|Placebo tablet matched to BIC/FTC/TAF taken by mouth.
223471611|NCT04233879|DRUG|Placebo to DOR/ISL|Placebo tablet matched to DOR/ISL taken by mouth.
223471612|NCT00826839|DRUG|Oral contraceptive pill and microdose lupron|Desogestrel/ethinyl estradiol tablets, 0.15 mg/0.03 mg, one tablet by mouth daily for 14 days Leuprolide acetate 40 µg by subcutaneous injection twice a day during ovarian stimulation (approximately 14 days)
223579813|NCT06264284|PROCEDURE|epidural anesthesia|Emergency cesarean section (red code) with epidural anesthesia
223579814|NCT06264284|PROCEDURE|general anesthesia|Emergency cesarean section (red code) with general anesthesia
223579815|NCT00678548|BEHAVIORAL|Pleasant guided imagery|CD with pleasant guided imagery
223579816|NCT00678548|BEHAVIORAL|Pain diary|Filling out a pain diary
224160154|NCT03857477|PROCEDURE|MRI Scan|MRI scan will be offered to men identified within the top 10% genetic risk score profile.
223471613|NCT00826839|DRUG|E2 patch/antagonist|"Estradiol transdermal system 0.1 mg/day (25 cm2 patch. Patch changed every other day x 3. Final patch left on for about 7 days. Total duration of therapy approximately 14 days.~Gonadotropin-releasing hormone antagonist 0.25 mg subcutaneously every other day for 3 total doses."
223579817|NCT03772418|DRUG|Cream Base|The formulated dosage form without ginkgo biloba or pomegranate will be applied to the 30 aging people who are suffering from wrinkles in the skin male and female. Typically, will be applied on two groups, one man (Group 0a) and one woman were (Group 0b) which they will be used plain cream.
223579818|NCT03772418|DRUG|Pomegrante and Ginkgo biloba group|The extracts of ginkgo biloba and Pomegranate as formulated in topical dosage form will be applied to the 30 aging people who are suffering from wrinkles in the skin male and female. Formulated cream will be applied on two groups, one man (Group Ia)and one woman (Group Ib).
223579819|NCT00199225|DRUG|Rupatadine|
224160155|NCT03857477|PROCEDURE|Prostate biopsy|Transperineal prostate biopsy under local anaesthetic will be offered to men identified within the top 10% genetic risk score profile.
224160156|NCT04594668|DRUG|Senicapoc|The intervention will consist of 50 mg enteral senicapoc administered as soon as possible after randomization and again after 24 hours
224160157|NCT04246346|OTHER|An interactive chatbot for patient decision aid|A chatbot embedded into a mobile application which is able to bidirectionally interact with patients and provide standard general information, quantitative risk information on the possible outcomes of cataract surgery.
224163753|NCT00002675|DRUG|mesna|
224163754|NCT00002675|DRUG|vincristine sulfate|
224160158|NCT04246346|OTHER|Senior ophthalmologists|Senior ophthalmologists would communicate with patients and provide standard general information, quantitative risk information on the possible outcomes of cataract surgery.
224160159|NCT03167125|OTHER|Automated Prompts|This intervention is an automated data-driven program, using automated phone calls, text messages, and/or emails, for delivering FIT kit prompts to patients due for colorectal cancer screening. The specific components of the intervention are forthcoming and will be determined using a community-based participatory research approach known as boot camp translation which seeks input from patients and providers.
224160160|NCT03167125|OTHER|Automated Plus Live Prompts|This intervention is a higher-intensity program, using automated data-driven prompts plus linguistically and culturally tailored live prompts, for delivering FIT kit messages to patients due for colorectal cancer screening. The specific components of the intervention are forthcoming and will be determined using a community-based participatory research approach known as boot camp translation which seeks input from patients and providers.
224160161|NCT00148525|BEHAVIORAL|Social Cognitive Theory|6 mo dietary intervention. This arm received an diet intervention designed to maintain changes in fruit and vegetable consumption. The intervention components were based on social cognitive theory.
224160162|NCT00148525|BEHAVIORAL|goal system theory|This arm received a 6 mo diet intervention designed to maintain changes in fruit and vegetable consumption. The intervention components were based on goal systems theory and delivered by an automated telephone system.
224160163|NCT01407406|DRUG|BIIB023 - low dose IV Dose|
224160164|NCT01407406|DRUG|BIIB023 - high dose IV Dose|
224160165|NCT02978170|PROCEDURE|Cone-Beam Computed Tomography|Undergo CBCT
224160166|NCT00174928|DRUG|Lansoprazole|Lansoprazole 0.5 mg/kg/day suspension, orally, once daily for up to 5 days.
224160167|NCT00174928|DRUG|Lansoprazole|Lansoprazole 1.0 mg/kg/day suspension, orally, once daily for up to 5 days.
224160168|NCT06507228|DIAGNOSTIC_TEST|NWL PEBBLE STT|At home testing for OSA with AcuPebble.
224160169|NCT05045105|OTHER|Time necessary for ICP catheter placement by Intensive Care Physician vs Neurosurgeon following indication|Time necessary for ICP catheter placement by Intensive Care Physician vs Neurosurgeon following indication and complications related to the maneuver between the two cohorts will be evaluated and compared.
224160170|NCT04116190|BEHAVIORAL|Telerehabilitation|Short inpatient multidisciplinary rehabilitation followed by home-based telerehabilitation and a short evaluation period at the end of it.
224160171|NCT04116190|BEHAVIORAL|Conventional inpatient rehabilitation|Multidisciplinary inpatient rehabilitation, no adjustments due to the study.
224160172|NCT00205946|DRUG|Bupropion|150 mg of bupropion administered 5 hours before fMRI scanning
224160173|NCT00205946|DRUG|Placebo|Administered 5 hours prior to fMRI scanning (randomly assigned, double blind)
224160174|NCT05524558|DEVICE|Pulmonary artery catheter|PAC already in place
224160175|NCT05524558|DEVICE|Esophagal pressure|Esophagal pressure already in place
224160176|NCT01604434|PROCEDURE|Incubator-torso bag|While being placed into an incubator, infant will be placed into a plastic bag to his/her axillae and the bag will be folded and taped to itself to prevent it from covering the infant's nose or mouth. The infant will be wrapped in a blanket over the plastic bag and will receive a cloth hat. He/she will remain in the bag for one hour.
224160177|NCT01604434|PROCEDURE|Incubator-no plastic bag|Infant will be placed in the incubator, wrapped in a blanket, with a cloth hat, according to standard protocol.
224160178|NCT02348294|OTHER|Shear- force 19 newton and 3,9 kpa pressure for half an hour|
224160179|NCT02652546|DRUG|Assess Safety|Assess the safety of a 12-week course if CC-1150 in HIV-infected adults who have been on ART for greater than or equal to 1 year and have suppressed plasma viremia
224304109|NCT04178070|OTHER|Placebo, 20mg|20mg (1mL), single dose, abdominal subcutaneous injection
223579820|NCT00199225|DRUG|moxifloxacin|
224160180|NCT02652546|DRUG|Effect of drug on viral load|Evaluate the effect of CC-11050 on plasma HIV-1 RNA levels by both conventional and single copy assay at week 12 and over all evaluable time points
224160181|NCT02652546|DRUG|Effect of drug on T-cell count|Evaluate the effect of CC-11050 on CD4+ T cell counts and percentages at week 12 and over all evaluable time points
224160182|NCT02652546|DRUG|Effect of drug on inflammatory biomarkers|Evaluate the effect of CC-11050 on markers of markers of systemic inflammation (TNF, IL-\^, CRP, IFNg, sCD14, D-dimer) at week 12 and over all evaluable time points.
224304110|NCT04178070|OTHER|Placebo, 30mg|30mg (1.5mL), single dose, abdominal subcutaneous injection
224160183|NCT02111629|DRUG|Fluconazole and Secnidazole|
224304111|NCT01104909|PROCEDURE|Clinical|Each patient will be submitted a clinical evaluation, considering signals of overload.
223471614|NCT00869869|DRUG|melatonin|2.5 mg melatonin, by mouth, 1 per day, for 3-4 weeks
223471615|NCT00869869|DRUG|placebo|placebo
223471616|NCT04851132|RADIATION|Radiotherapy|IMRT (Intensity Modulated RT) or 3D-CRT (three-dimensional conformal radiotherapy); 95% PGTV 59.92Gy/2.14Gy/28f; 95% GTVnd 59.92Gy/2.14Gy/28f; 95% PTV 50.40Gy/1.80Gy/28f; 5 days a week; 6 weeks.
223471617|NCT04851132|DRUG|Durvalumab|Durvalumab 1000 mg, intravenously (IV), on Day 1 of radiotherapy, every 3 weeks for up to 18 administrations.
223471618|NCT03918811|PROCEDURE|Positive Pressure Extubation Technique|Positive-pressure extubation is performed by only one operator. Ventilator parameters are set to pressure support ventilation mode, with an inspiratory pressure of 15 cm H2O and PEEP of 10 cm H2O. Then, the cuff is deflated, and the ETT is removed without endotracheal suction. Once the ETT is removed, a suction catheter is introduced through the mouth to suction secretions drawn to the oropharynx by the air flow from the ventilator passing between the ETT and the larynx.
224160184|NCT04480515|OTHER|in-hospital mortality rate|In-hospital mortality rate during pandemic of 2020 will be compared with the in-hospital mortality rate of the last year's same time period
224304112|NCT01104909|DEVICE|electrical bioimpedance|From electrical bioimpedance data, will be fixed a revised dry weight for each patient.
224304113|NCT00769093|DRUG|Ferumoxytol|2 mg/kg
224304114|NCT02713386|DRUG|Carboplatin|Given IV
224304115|NCT02713386|DRUG|Paclitaxel|Given IV
224304116|NCT02713386|DRUG|Ruxolitinib Phosphate|Given PO
224304117|NCT02713386|PROCEDURE|Therapeutic Conventional Surgery|Undergo TRS
224304118|NCT01753466|DIETARY_SUPPLEMENT|Hydration|
224304119|NCT01371266|DIETARY_SUPPLEMENT|Honey|60.7 grams orally daily times 14 days
224160185|NCT05455307|DEVICE|Allium ureteral stent|observe the effficacy and safety of long-term self expanding ureteral stents for treating refractory ureteral stricture
224160186|NCT04835688|PROCEDURE|Transmyringeal ventilation tube insertion|"In both groups, the tympanic membrane will be anesthetized by local application of topical prilocaine (EMLA) or phenol or by infiltration anaesthesia of the outer ear canal. The choice of method is left to the discretion of the surgeon.~For the experimental group, insertion of a ventilation tube will be performed. An incision is performed, usually in the lower, anterior quadrant of the tympanic membrane and the transmyringeal tube is inserted."
224160187|NCT04835688|PROCEDURE|Sham-treatment|For the control group, the ENT-specialist will touch the tympanic membrane with an alligator ear forceps to simulate getting a paracentesis. In the same procedure, without having made a paracentesis, a ventilation tube is placed on the tympanic membrane and removed again afterwards. The reason for the above-mentioned is to simulate getting a paracentesis and insertion of a ventilation tube.
224160188|NCT03634293|DRUG|Alirocumab Injectable Product|Alirocumab is an human monoclonal antibodies directed against Proprotein convertase subtilisin/kexin type 9 (PCSK9). It is administered once every two weeks subcutaneously.
224160189|NCT03634293|DRUG|Saline Solution|The placebo will be 2 ml' of 0.9% saline injected subcutaneously.
224160190|NCT00012207|BIOLOGICAL|aldesleukin|
224160191|NCT00012207|BIOLOGICAL|therapeutic autologous lymphocytes|
224160192|NCT00012207|DRUG|cyclophosphamide|
224160193|NCT00012207|DRUG|prednisone|
224160194|NCT00012207|DRUG|vincristine sulfate|
224160195|NCT00012207|PROCEDURE|adjuvant therapy|
224160196|NCT02027272|DRUG|Dexamethasone|Intravenous Dexamethasone 12 mg, 2 doses, 12 hours apart
224160197|NCT00003110|BIOLOGICAL|bleomycin sulfate|Patients receive bleomycin by continuous infusion for 72 hours every 3 weeks. Induction therapy consists of 3 cycles. Patients who achieve complete remission receive 2 more cycles. Patients with partial remission or stable disease may continue therapy until disease progression or unacceptable toxicity occurs.
224160198|NCT00064623|DRUG|Capsaicin Dermal Patch|
224304120|NCT01371266|DIETARY_SUPPLEMENT|High Fructose Corn Syrup 55 (HFCS 55)|65.7 gram daily orally times 14 days
224304121|NCT01371266|DIETARY_SUPPLEMENT|CHO (sugar)|50 grams daily orally times 14 days
224304122|NCT00894738|PROCEDURE|Testing (MRS, US, DEXA, blood tests)|Magnetic Resonance Spectroscopy (MRS) of the liver to determine hepatic triglyceride content; ultrasound (US) of the carotid artery to determine intima-media thickness; dual energy X-ray absorptiometry (DEXA) to determine body composition; fasting lipids, fasting insulin, C-reactive protein, liver enzymes and fibrinogen levels.
224304123|NCT00778024|DRUG|fluoxetine HCL 40 mg capsules|
224304124|NCT01383135|DRUG|F18-FPPRGD2|Radiopharmaceutical administered for imaging, up to 14 mCi intravenous (IV).
224304125|NCT00866736|DRUG|dasatinib|100mg QD
224304126|NCT04941521|DRUG|Exenatide 2 mg [Bydureon]|Exenatide will be purchased commercially as Bydureon® for subcutaneous (SC) injection and administered at a dose of 2 mg once a week for a total of 6 weeks. Each single-dose, dual-chamber pen contains 0.65 mg of diluent and 2 mg of exenatide, which remains isolated until mixed.
224304127|NCT04941521|BEHAVIORAL|Drug Counseling|Once weekly drug counseling sessions for cocaine use with trained masters-level therapists.
224304128|NCT04792775|BEHAVIORAL|PE+ER|PE includes the following components: a) psychoeducation about the common reactions to traumatic events and presentation of the treatment rationale b) repeated in vivo exposure to traumatic stimuli, c) repeated, prolonged, imaginal exposure to traumatic memories, and d) relapse prevention strategies and further treatment planning (session 12). DBT Emotion Regulation Skills is integrated as part of this intervention. DBT training provides skills to understand, name, experience and tolerate emotions, as well as skills to change negative emotional responses and to reduce vulnerability to emotion dysregulation (Linehan et al., 2015). The current project includes an adapted 3- session individual emotion regulation skills training intervention to be implemented concurrently with PE which consists of initial teaching/instruction and brief skills review for the remainder of PE treatment.
224304129|NCT06063265|BEHAVIORAL|Integrated Attention Training Program|Integrated Attention Training Program (IATP) specifically aims at training attentional control, which involves the coordination of complex behaviours, such as planning, reasoning, selection and information inhibition.
224304130|NCT05841303|DRUG|Vit C|Vit c is proven to be an anti-inflammatory and antioxidant agent. also play a great role in collagen biosynthesis (collagen type I), as it helps in fibroblasts proliferation. It reduces the potentiality of scaring via inhibiting cross-linking of collagen fibers and fibrosis. It acts as a cofactor in hydroxyproline synthesis to produce collagen type IV and improves endothelial cell vitality and function..
223579821|NCT00199225|PROCEDURE|Continous electrocardiographic register|
223579822|NCT00199225|PROCEDURE|Pharmacokinetic profile|
223579823|NCT01743404|DIETARY_SUPPLEMENT|Inflaminat|
223579824|NCT01743404|DRUG|Placebo|Sugar pill manufactured to mimic Inflaminat 500 mg tablet
224160199|NCT04987424|DIAGNOSTIC_TEST|Development and validation of Lymphedema levels diagnostic|A single intervention was carried out in which the patients were summoned for an interview and anthropometric measurements of the upper limbs, thus calculating the arm volume for a lymphedema primary diagnosis .
224160200|NCT06356415|DRUG|Bupivacaine injection|Group one will receive infraclavicular block using bupivacaine
224160201|NCT06356415|DRUG|Bupivacaine+ Dexamethasone+ Dexmedetomidine|Group two will receive infraclavicular block using dexamethasone and dexmedetomidine added to the bupivacaine
224160202|NCT01936597|OTHER|Therapeutic and preventive strategies|Single set (control Arm)
224160203|NCT01936597|OTHER|Therapeutic and preventive strategies|Controller
224160204|NCT01936597|OTHER|Therapeutic and preventive strategies|Audio
224160205|NCT01643304|BEHAVIORAL|No drug|No drug intervention. The intervention is a questionnaire with quality of life and perception of menstrual bleedings. All subjects will complete both questionnaires.
224160206|NCT00096824|BEHAVIORAL|Neurological assessment|All participants will undergo neurological examinations and neuropsychological assessments.
223471619|NCT03918811|PROCEDURE|Traditional Extubation Technique|Traditional extubation is performed by 2 operators. Without reconnection to the ventilator, the closed suction system catheter is introduced by one of the operators into the ETT and suctioning is initiated. The cuff is immediately deflated by the other operator, and the ETT is removed with continuous endotracheal suction during the whole procedure by the first operator.
223471620|NCT03585270|DRUG|Clazosentan|Clazosentan will be administered as a continuous intravenous infusion at the dose of 15 mg/hour for up to 14 days.
223471621|NCT03585270|DRUG|Placebo|Placebo will be administered at the same infusion rate as clazosentan for up to 14 days.
223579825|NCT00780286|DEVICE|Polymer based lubricating liquid|5 mls of radiolabeled polymer blend of carboxymethylcellulose, polyoxyl 40 stearate, and polyethylene oxide that coats and protects the mucus membrane
224160207|NCT04036513|PROCEDURE|MINST|"For reducing the need of surgical treatment in patients with chronic periodontal disease, we will use specifically designed Hu-Friedy curettes mini five, micro mini five and after five together with piezoelectric device with thin and delicate tips that produce less periodontal trauma than usual Gracey curettes."
224160208|NCT04036513|PROCEDURE|Conventional SRP|Scaling and root planing with conventional instruments.
224160209|NCT04063228|OTHER|Simple Skill Group|will practice the following skills as needed: bed mobility, transfer, walking, and stairs.
224160210|NCT04063228|OTHER|Complex Skill Group|The program will consist of interventions at the impairments level with an emphasis on core strengthening, functional lower extremity strengthening, balance and endurance training, and at the skill acquisition level. Participants will learn pre-running skills (walking, stairs with handrail, walking backward, walking over obstacles, walking on toes, stairs without handrail, bounding), running skills (force generation in vertical plane: hopping, alternate hopping, running in place in gravity minimized position and against gravity; force generation in horizontal plane: bounding, alternate bounding, open chain movement for swing phase, running) and post running skills (running forward, backward, sideways, skipping, hopping).
224160211|NCT01780324|DRUG|Lidocaine|Intervention - intraurethral lidocaine
224160212|NCT04574674|BEHAVIORAL|Flexibility exercise programme|Static passive flexibility exercises.
224160213|NCT04574674|BEHAVIORAL|Resistance exercise programme|Body weight and resistance bands exercises.
224304131|NCT05841303|OTHER|injectable PRF|5 ml of peripheral blood from each patient , blood will be transferred to a glass coated plastic vacutainer tube without anticoagulant. Then this tube will immediately centrifuged at 700 rpm for 3 mins \[Centrifuge Machine 5000rpm.After centrifugation, two fluid layers will formed, upper being yellow fluid layer (i-PRF) while lower layer containing red blood cells. Yellow fluid layer containing i-PRF will be immediately aspirated using micro needle to be injected for management of gingival phenotype
224304132|NCT00222521|DRUG|Glargine insulin|
223471622|NCT06261723|PROCEDURE|non-chirurgical periodontal treatment|The non-chirurgical periodontal treatment (scaling and root planing) is the gold standard procedure in therapy for periodontitis. It involves the mechanical removal of plaque and bacterial deposits, creating a local microbial environment in harmony with periodontal health and promoting the replacement of damaged periodontal tissues with collagen-rich connective tissues. This favors a shift in the composition of the oral microbiota from a community dominated by Gram-negatives to one dominated by Gram-positives.
223471623|NCT06326736|PROCEDURE|Surgery|Tumors of patients with pancreatic cancer must be radiographically resectable, and subjects with histologically confirmed resected ductal pancreatic adenocarcinoma with macroscopic complete resection (R0 and R1) will be selected for neoantigen vaccine creation.
223471624|NCT06326736|DRUG|Camrelizumab|Camrelizumab will be administered 6 weeks post-tumor resection.
223579826|NCT00780286|DEVICE|Moi-Stir|2 sprays (0.35 mL) of the radiolabeled commercial device. A blend of Water, sorbitol, carboxymethylcellulose, sodium, methylparaben, propylparaben, potassium chloride, dibasic sodium phosphate, calcium chloride, magnesium chloride, sodium chloride, flavor.
223579827|NCT04036994|DEVICE|Photobiomodulation therapy|All patients will undergo photobiomodulation therapy sessions three times a week for the total duration of 12 weeks starting at their last CT administration.
223579828|NCT00558532|PROCEDURE|Bariatric Surgery|Open roux-en-Y gastric bypass, open banded sleeve gastrectomy, abdominoplasty, other abdominal surgery
223579829|NCT01828138|DIETARY_SUPPLEMENT|Sodium|supplemental sodium tablets 150-200 mmol/day in 5 days
223579830|NCT01828138|DIETARY_SUPPLEMENT|Placebo|Placebo are given in 5 days
223579831|NCT04311827|OTHER|Serratus Anterior Plane Block|Injection of bupivacaine 75mg above the serratus anterior facial plane in the anterior axillary line
224160214|NCT05335252|DRUG|Dronabinol|5mg 2x daily for 7 days
224160215|NCT05335252|DRUG|Placebo|1 caplet 2x daily for 7 days
224160216|NCT04026646|PROCEDURE|Proprioceptive Neuromuscular Facilitation stretching exercise|Proprioceptive Neuromuscular Facilitation stretching exercises (contract-relax-antagonist-contract method) will be performed 6 repetition and totally 30 seconds stretching for hamstring muscle group will be performed.It will be applied 3 days in a week for 8 week.
224160217|NCT04026646|PROCEDURE|Static stretching exercise|Static stretching exercises will be applied 2 repetition. Totally 30 seconds stretching for hamstring muscle group will be performed. It will be applied 3 days in a week for 8 week.
223471625|NCT06326736|BIOLOGICAL|SJ-Neo006|SJ-Neo006 will be prepared as personalized tumor Vaccines and administered 9 weeks post-tumor resection (+/- 2 weeks).
223471626|NCT06326736|DRUG|Gemcitabine+Abraxane|Gemcitabine+Abraxane regimen will be administered 21 weeks post-tumor resection.
224160218|NCT04037462|DRUG|Dexamthasone|escalating doses of pretreatment dexamethasone in patients who have failed initial immunotherapy to 1. assess changes in FLT PET uptake 2. assess overall response rates of pretreatment dexamethasone (dose from 1) on subsequent immunotherapy re-challenge
224160219|NCT04447625|DRUG|Oral antibiotic administration|per os antibiotic administration as the standard line of strategy for treating CE of doxycycline at a dosage of 100mg twice a day for 14 days and metronidazole of 500mg twice a day for 14 days
224160220|NCT04447625|DRUG|Intrauterine antibiotic infusion|intrauterine infusion of 3ml of ciprofloxacin at a concentration of 200 mg/100 ml
224160221|NCT01962116|DRUG|Citrate 4%|
224160222|NCT01962116|DRUG|unfractionated heparin|
224160223|NCT00634751|DRUG|Oxaliplatin|On days 1 and 15 of each 28 day treatment cycle, patients receive oxaliplatin 85 mg/m2 as a 2-hour IV infusion. Following the infusion of oxaliplatin, the infusion line should be flushed with Dextrose 5% in Water.
224160224|NCT00634751|DRUG|Capecitabine|Each course of oral capecitabine administration will commence following administration of oxaliplatin. Capecitabine 2250 mg/m2 will be given every 8 hours for a total of 6 doses as above, commencing with each cycle of therapy. Because capecitabine is provided in fixed dose forms, rounding will be necessary. Rounding will be to the nearest 150 mg on a per dose basis.
223471627|NCT00761228|DRUG|Apomorphine|Patients will receive an ascending dosing schedule of continuous subcutaneous apomorphine to reach a maximum infusion rate of up to 6 mg/hour for 12 hours a day.
223471628|NCT00761228|DRUG|Placebo|Patients will receive a continues subcutaneous infusion of saline solution.
223471629|NCT05448638|PROCEDURE|the combination of transversus thoracic muscle plane and pectoral nerves blocks|For the pectoral nerves block, 0.375% ropivacaine , 10ml was injected between the pectoralis major and pectoralis minor and 20 ml above the serratus anterior muscle. For the transversus thoracic muscle plane block, ropivacaine 0.375%,15ml was injected between the transversus thoracic muscle and the internal intercostal muscle.
224160225|NCT00634751|DRUG|Sorafenib|"Cohort 1 will receive 200 mg of sorafenib orally twice daily, cohort 2 will receive 400 mg orally twice daily, both beginning on the first day of the first cycle (see section 9.1). If needed, cohort -1 will be used, at 200 mg of sorafenib once daily. Sorafenib should be taken without food (at least 1 hour before or 2 hours after eating).~Cohort I (Dose escalation phase) Agent Dose Route Day Cycle length~Sorafenib 200 mg BID Oral Daily Every 28 days~If 1/3 patients develop a DLT, enroll 3 patients at dose level -1 Sorafenib 200 mg po qd.~Cohort II (Phase II studies at MTD) Agent Dose Route Day Cycle length~Sorafenib 400 mg BID Oral Daily Every 28 days"
224160226|NCT05519124|DEVICE|BTL-785-7|Treatment with the BTL-785-7 applicator to the BTL-785F system.
224160227|NCT02945943|OTHER|High Velocity Low Amplitude mobilization|Mobilizations were performed one time at each joint, prior to completing the exercise protocol during the first three treatment sessions.
224160228|NCT02945943|OTHER|Exercise Protocol|This exercise regimen is a modified version of the balance training program described by McKeon et al.
224160229|NCT00189436|DRUG|Nebulized Budesonide|Subject is treated with nebulized budesonide 0.5 BID for 3 weeks
224160230|NCT00189436|DRUG|Usual care (albuterol with or without oral steroid)|Subject is treated with usual care as prescribed by the doctor (normally albuterol with or without oral steroid)
224160231|NCT04402385|DRUG|Aspirin 81 mg|Participants randomized to 81 mg of Aspirin daily
224160232|NCT04402385|DRUG|Placebo|Participants randomized to placebo daily
224160233|NCT04469556|DRUG|Folfirinox|Chemotherapy
223471630|NCT05448638|PROCEDURE|the pectoral nerves block only|For the pectoral nerves block, 0.375% ropivacaine , 10ml was injected between the pectoralis major and pectoralis minor and 20 ml above the serratus anterior muscle.
223471631|NCT00637013|PROCEDURE|Acromioplasty|Arthroscopic or open acromioplasty
223471632|NCT00637013|PROCEDURE|Physiotherapy|Physiotherapy according to a standardized protocol
223471633|NCT02133157|DRUG|Sulfatinib|Sulfatinib is a capsule in the form of25, 50mg , 100mg; oral, once a day
223471634|NCT01498302|OTHER|diagnostic laboratory biomarker analysis|
224160234|NCT04469556|DRUG|Gemcitabine/nab-paclitaxel|Chemotherapy
224160235|NCT01467024|OTHER|CDPHL Algorithm|Supplemental testing algorithm performed by the CDPHL.
224160236|NCT02490241|DRUG|Lithium|Patients taking lithium as a mood stabilizer during pregnancy are eligible to participate in the study. Their dose and serum concentration levels of lithium will be monitored throughout pregnancy and up to three months postpartum.
224160237|NCT04017624|OTHER|Fresh Truck with stipend|"Linkage to Community Partner Organization~Investigators will partner with a community organization, Fresh Truck, that deploys mobile fresh produce trucks throughout Boston neighborhoods. Participants randomized to the intervention arm will receive a monthly stipend of $80 to purchase fresh produce available at any Fresh Truck mobile market location."
224160238|NCT04017624|OTHER|THRIVE screening and referral|The THRIVE screening tool includes questions to identify eight potentially unmet health-related social needs associated with health outcomes and healthcare utilization: housing and food insecurity, inability to afford medications, need for transportation, trouble paying for heat and electricity, need for employment or education, and difficulty taking care of children or other family members. The survey is written at a 3rd grade reading level, is available in multiple languages, and requires less than five minutes to complete. The paper screener consists of two parts: part one screens patients for health-related social needs in the eight domains. Part two asks patients to indicate the resources they want help accessing across the eight domains. Patients who request resources in one or more domains receive paper guides that describe available hospital and community resources to address the specific domain(s) indicated.
224160239|NCT05389306|DIAGNOSTIC_TEST|MRI Scanning|MRI scanning will be performed with a 3.0-T magnetic resonance imaging system with a head and neck-combined coil employing spin-echo technique. The range of the MRI scanning will be from the suprasellar cistern to the inferior margin of the sternal end of the clavicle. The section thicknesses for the axial plane, the sagittal plane and the coronal plane will be 5 mm, 3 mm and 2 mm, respectively. The intersection gaps will be 1 mm. Before the intravenous injection of the MRI contrast agents, T1 weighted images, T2 weighted images and diffusion weighted images will be obtained in the axial planes, while only T1 weighted images will be obtained in the sagittal and coronal planes. After the intravenous injection of the MRI contrast agents, T1-weighted axial sequence, T1-weighted sagittal sequences and T1-weighted fat-suppressed coronal sequence will be performed.
223471635|NCT01498302|OTHER|flow cytometry|
223471636|NCT05577728|DRUG|New use of semaglutide injection|New use of semaglutide injection dispensing claim is used as the exposure.
223471637|NCT05577728|DRUG|"New initiation of standard of care (SGL2i, 2nd generation SU, DPP-4i and GLP-1 RA except for semaglutide inj or oral)"|"New initiation of standard of care (SGL2i, 2nd generation SU, DPP-4i and GLP-1 RA except for semaglutide inj or oral) dispensing claim is used as the reference."
223471638|NCT06602544|DEVICE|Robotic Apparel|A robotic apparel system is a portable, lightweight textile-based wearable robot that is worn around the waist and thighs. The apparel provides assistive flexion moment about the hip joint during the swing phase of gait by spooling in a cable that connects the thigh wraps to the front of the waist belt. Inertial measurement units embedded in the thigh wraps are used to control the timing of the robotic apparel assistance. Robotic apparel assistance magnitude is delivered as a small percentage of the bodyweight of the wearer.
223579832|NCT04082013|OTHER|Hamstring Flexibility|"The active knee extension test has been proposed as the gold standard for assessment of hamstring flexibility, as it utilizes readily available equipment and offers a quick, reliable, and low-cost alternative for measurement of hamstring flexibility (Connor et al; 2015).~* The subject will be instructed to maintain 90° hip flexion in the supine position.~* Then asked to actively extend the knee joint.~* The degree of achieving active knee extension will be measured using a universal goniometer.~* The average of three active knee extension measurements will be used as the hamstring muscle length for the data analysis (Dong-Kyu Lee, et al; 2018).~  * the procedures will be done with opposite-leg flexed, then repeated with opposite-leg extended."
223579833|NCT04063787|DEVICE|Fist Assist|"The Fist Assist device works by applying pressure to the subject's arm in the area where their arteriovenous fistula will eventually be created. The device is mobile and battery powered.~The Fist Assist device will be assigned to each enrolled subject by randomization code. All subjects will be asked to use their assigned device twice daily, for two 2-hour sessions, once in the morning and once in the evening. Patients will apply the device to the non-dominant arm above the level of the elbow, and to keep a written log to record use, complications and any problems. They will be asked to do this for 3 months, and will come in to be evaluated via study visits at Months 3, 6, 9 and 12."
223579834|NCT00202813|DEVICE|Cook Spectrum Pediatric Central Venous Catheter Anti-microbial Impregnated Polyurethane and Arrow Pediatric Central Venous Catheter|
223579835|NCT00003231|DRUG|cisplatin|
223579836|NCT00003231|DRUG|docetaxel|
224160240|NCT05389306|DIAGNOSTIC_TEST|Contrast-Enhanced Ultrasonography|A sonographer equipped with a 6-15 MHz linear array probe will be adopted for contrast-enhanced ultrasonography examination. Conventional high-frequency ultrasonography will be performed firstly before the intravenous injection of the ultrasound contrast agents. Then the ultrasound contrast agents will be injected intravenously, and contrast-enhanced ultrasonography examination will be performed. The mechanical index of contrast-enhanced ultrasonography examination will be 0.23. The wash-in and wash-out process within the lymph node will be dynamically observed during the arterial phase. During the Kupffer-phase, the degree of enhancement will also be observed.
223579837|NCT00003231|PROCEDURE|surgical procedure|
223579838|NCT00003231|RADIATION|radiation therapy|
223579839|NCT05240768|DIAGNOSTIC_TEST|Fractional flow reserve, instantaneous wave-free Ratio|Clinical outcomes observed for patients with moderate coronary lesions in whom coronary revascularization was deferred due to a negative physiologic study.
224160241|NCT05389306|DIAGNOSTIC_TEST|Ultrasound-guided Lymph Node Aspiration|After the conventional high-frequency ultrasonography and contrast-enhanced ultrasonography examination was finished, ultrasound-guided aspiration of the target lymph node will be performed. The lymph node tissue obtained from ultrasound-guided lymph node aspiration will be subjected to pathologic evaluation. And the diagnostic performance of MRI and contrast-enhanced ultrasonography will be evaluated using the pathologic diagnosis of the lymph node as the gold standard.
224160242|NCT01254786|PROCEDURE|Non-dependent lung ventilation|"the dependent lung will be ventilated with conventional ventilation (OLV) a tidal volume of 6 mL/kg (predicted body weight), whereas FiO2, I: E ratio, PEEP, frequency, peak inspiratory pressures, and a flow of fresh gas will be maintained as during two-lung ventilation for 15 min.~Then the non-dependent lung will be allowed to deflate to a CPAP of 2 cm H2O, which will be connected to the flowmeter of an oxygen cylinder with a flow rate of 5 L/min and FiO2 of 1.0 for 30 min~Then, the non-dependent lung will be connected to a second identical ventilator, 15 min after OLV, using a FiO2 of 1.0, VT 3 mL/kg (predicted body weight), I: E ratio \<0.3 and R.R 60 breaths/min for further 30 min."
224304133|NCT04413864|OTHER|Inflammatory cytokines and chemokines profiles of patients with dexmedetomidine administration|"Assigned Interventions:~* Blood samples collection at inclusion (D0) and follow-up visits (D2, D7 and M6)~* CAM-ICU scores during ICU hospitalisation, neurological questionnaires at M6 (GOAT, GOSE, MOCA, Barthel Index, PTSD, GDS, Rankin score, HADS)"
223579840|NCT04349241|DRUG|favipiravir|pyrazine carboxamide derivative (6-fluoro-3-hydroxy-2-pyrazinecarboxamide), a new type of RNA-dependent RNA polymerase (RdRp) inhibitor
223579841|NCT04349241|DRUG|Standard of care therapy|oseltamivir 75 mg 12 hourly for 5-10 days and hydroxychloroquine 400mg 12 hourly day -1 followed by 200mg 12 hourly daily on day- 2 to day-5-10
223579842|NCT05270226|BEHAVIORAL|The Metacognitive ADHD Telehealth intervention for Work-performance Enhancement (Work-MATE)|"The Metacognitive ADHD Telehealth intervention for Work-performance Enhancement (Work-MATE) is an innovative program that aim to improve occupational performance at work of adults with ADHD, by enhancing their EF abilities, self-awareness, and personal strategy use.~The Work-MATE is a short, synchronous and hybrid teleintervention program of eleven 1-hour weekly individual sessions. It offers a written standardized protocol, which include uniform structure of each intervention session and pool of therapy aids (for self-tailored matching by occupational therapists)."
224304134|NCT01154816|DRUG|Alisertib|Given orally
224304135|NCT01154816|OTHER|Laboratory Biomarker Analysis|Correlative studies
224304136|NCT01154816|OTHER|Pharmacological Study|Correlative studies
223471639|NCT02783898|DEVICE|AliveCor Heart Monitor|Smart phone based ECG event recorder
223579843|NCT02089152|OTHER|An educational programme for prevention of melioidosis|The intervention will be randomly implemented at 10, 10 and 10 diabetic clinics at the end of years 1, 2 and 3, respectively. The education will be conducted using small group education, in which 20 to 25 participants at a time will attend group sessions conducted by the study team.
223471640|NCT04771845|DEVICE|Transcranial Magnetic Stimulation|Magnetic stimulation to alter neural activity
223471641|NCT02567383|RADIATION|Radiation|5-Gy once a week for a subtotal of 10Gy/2fx a week to gross tumors, followed by 40Gy/20fx/4 weeks, total 50Gy/22fx/5weeks
224304137|NCT03397771|DRUG|Litoxetine|oral study medication provided in a dose titration manner
224304138|NCT03397771|DRUG|placebo|placebo medication provided in a dose titration manner
224304139|NCT02936453|PROCEDURE|Device implantation|"* Implantation of Specify 5-6-5 lead or Go-2 lead in epidural space~* Implantation of Activa RC neurostimulator"
223471642|NCT02567383|DEVICE|Hyperthermia; Thermotron RF-8|40 minutes within 2hr after irradiation
223471643|NCT02567383|DRUG|Cisplatin|20mg/m2 per week for 6 weekly cycles before radiotherapy
223471644|NCT02567383|DRUG|Taxotere|10-12mg/m2 per week for 6 weekly cycles before radiotherapy
223471645|NCT00001781|DRUG|CGP 77116|
223471646|NCT01076543|OTHER|Laboratory Biomarker Analysis|Correlative studies
223471647|NCT01076543|DRUG|Lenalidomide|Given PO
223471648|NCT01076543|DRUG|Temsirolimus|Given IV
223471649|NCT04072029|PROCEDURE|Phacoemulsification with intraocular lens implantation|Phacoemulsification (2.2mm coaxial, viscoelastic shield, experienced surgeon) with intraocular lens implantation (acrylic hidrophobic)
223471650|NCT02016989|DEVICE|RGTA OTR4120 (CACICOL20)|
223471651|NCT02016989|DEVICE|physiological salt solution|
223471652|NCT05434455|DEVICE|RIPC induced with 3 cycles of 5 minutes of ischaemia and 5 minutes of reperfusion|RIPC was induced with 3 cycles of 5 minutes of ischaemia and 5 minutes of reperfusion on the upper arm. By using blood pressure cuff inflation, patients in the RIPC group were exposed to a pressure 50 mmHg higher than the systolic radial artery pressure baseline.
224160243|NCT01254786|PROCEDURE|Non-dependent lung ventilation|"the dependent lung will be ventilated with conventional ventilation (OLV) a tidal volume of 6 mL/kg (predicted body weight), whereas FiO2, I: E ratio, PEEP, frequency, peak inspiratory pressures, and a flow of fresh gas will be maintained as during two-lung ventilation for 15 min.~Then, the non-dependent lung will be connected to a second identical ventilator, 15 min after OLV, using a FiO2 of 1.0, VT 3 mL/kg (predicted body weight), I: E ratio \<0.3 and R.R 60 breaths/min for further 30 min.~Then the non-dependent lung will be allowed to deflate to a CPAP of 2 cm H2O, which will be connected to the flowmeter of an oxygen cylinder with a flow rate of 5 L/min and FiO2 of 1.0 for 30 min"
224160244|NCT00655122|DRUG|Dalteparin sodium|Dalteparin sodium was administered at a daily dosage of 5,000 UI anti-Xa by subcutaneous route. The treatment duration was 7 days in a single daily injection throughout the bedridden period.
224160245|NCT00655122|DRUG|Placebo|Placebo was administered with a daily injection of 0.2 mL by subcutaneous route. The treatment duration was 7 days in a single daily injection throughout the bedridden period.
224160246|NCT02259764|DRUG|KUC 7483 CL - single rising dose|
223471653|NCT04144192|DRUG|Lidocaine patch 1.8%|
224160247|NCT02259764|DRUG|Placebo|
224160248|NCT02259764|OTHER|standardized high fat meal|
223471654|NCT04144192|DRUG|Lidocaine 5% patch|
223471655|NCT04144192|DRUG|Lidocaine 2% Injectable Solution|
223471656|NCT01905618|BEHAVIORAL|Web-based curriculum on tobacco dependence treatment|"The University of Massachusetts Medical School's web-based course, Basic Skills for Working with Smokers was adapted for this Randomized Controlled Trial (RCT). The goal is to provide standardized information in the following core tobacco content areas: epidemiology of tobacco use, health consequences of tobacco use, nicotine dependence and withdrawal assessment, and provision of behavioral and pharmacotherapy tobacco treatment. The course is 3 hours in length and can be completed at the student's convenience. The dean and the course director at each medical school required that the first year medical students complete the web-based curriculum prior to the next component of the study, the role play."
223471657|NCT01905618|BEHAVIORAL|Tobacco Counseling Role Play|The goal of the role play is to provide each student with the opportunity to apply what he/she learned in the web-based curriculum (the 5 As and the physician delivered intervention approach). The one hour session begins with a video of a patient-centered counseling approach which incorporates the 5A intervention presented in the web-based course. This is followed by a 30 minute role play session including various scenarios with physician/patient interaction. Students role play either as physician, patient or observer for each scenario.
223471658|NCT01905618|BEHAVIORAL|Preceptor Training and Teaching Medical Students|The goal of this intervention is to train preceptors in the use of the 5As with their patients and to teach and motivate their medical students to use the 5As. The academic detailing approach is used to provide a standardized 30 to 45 minute group training session during the third year clerkship. All preceptors and medical students are encouraged to intervene with patients who smoke. Preceptors are encouraged to model the 5As, observe and give feedback to the medical student in its use. Study-tailored handouts are available for preceptors and students. This component is implemented with the study cohort in their third year of medical school.
223579844|NCT06176495|DIAGNOSTIC_TEST|Educational Text Messages|"The educational content will be targeted about Diabetes Education and will be guideline based with what complies to the standards of care instituted by the American Diabetes Association.~They text messages will comprise content related to general diabetes knowledge, diabetes management and control, coping with diabetes, and guidance on adopting a healthy lifestyle."
223579845|NCT02142881|OTHER|Antihypertensive medication intensification|Antihypertensive medications will be adjusted by study staff based on ambulatory and clinic BP results at baseline and 2 months with a target 24hr systolic blood pressure of \<130 mmHg.
223579846|NCT02142881|OTHER|Usual care|Antihypertensive medications will be adjusted by the participants' providers (usual care).
223579847|NCT03019978|OTHER|PCAMS assessments|This is a longitudinal study, where data will be collected from 54 individuals who are already enrolled in Pennsylvania's ACAP program. Participants will be required to complete online assessments at baseline and then quarterly over a two-year time period.
224160249|NCT05208346|DIETARY_SUPPLEMENT|Mixed meals|Mixed meals enriched with either 25 or 50 g of canola or coconut oil
223579848|NCT05545644|BEHAVIORAL|Brief Family-Involved Treatment for Alcohol Use Disorder|Up to 3 sessions of counseling involving a patient with alcohol use disorder and a concerned family member
224160250|NCT05824611|OTHER|collect movement data from epileptic seizures|non-invasive recording of movement data during care as usual
224160251|NCT03712670|DRUG|Aflibercept|monthly intravitreal injections
224160252|NCT03712670|DRUG|Pranoprofen|0.1% pranoprofen 3 times a day topical eye drops administration
224160253|NCT03712670|DIETARY_SUPPLEMENT|Carotenoids|daily supplementation of nutraceutical tablets containing the AREDS2 formulation
224304140|NCT04968665|DIAGNOSTIC_TEST|gait testing, functional MRI|diagnostic tests including the gait testing and functional MRI
224304141|NCT04602065|DRUG|IBI318(Recombinant human anti-PD1/PD-L1 bispecific antibody)|IBI318, 300mg, Q2W, Intravenous influsion.
224304142|NCT04078126|COMBINATION_PRODUCT|BFF|Treatment with budesonide and formoterol furmate MDI (metered-dose inhaler)
224160254|NCT03731169|GENETIC|Voriconazole genotype-specific dosing|"Those in the intervention arm will receive an experimental dosage regimen of voriconazole based on their genetic status.~URM: 6 mg/kg voriconazole twice on the first day followed by 5 mg/kg twice daily, rounded to the nearest 50mg for oral formulations up to day 4 post-start of voriconazole therapy.~EM: 6 mg/kg voriconazole twice on the first day followed by 4 mg/kg twice daily, rounded to the nearest 50mg for oral formulations up to day 4 post-start of voriconazole therapy.~HEM and PM: 6 mg/kg voriconazole twice on the first day followed by 2 mg/kg twice daily, rounded to the nearest 50mg for oral formulations up to day 4 post-start of voriconazole therapy."
224160255|NCT03731169|DRUG|Standard of Care|Participants are given 6 mg/kg voriconazole twice on the first day followed by 4 mg/kg twice daily, rounded to the nearest 50mg for oral formulations up to day 4 post-start of voriconazole therapy. After TDM is conducted on day 4 for all patients, dosing in both trial arms will adhere to the following in order to reach the target therapeutic window: 1.0-5.5 mg/L.
224160256|NCT02425995|PROCEDURE|Arthroscopic intercondylar and posteromedial portal|Diagnosis of lesions of the Posterior Horn of the Medial Meniscus in Arthroscopic intercondylar and posteromedial portal in addition with standard ACL reconstruction, during the same surgery.
224160257|NCT03089008|OTHER|Eccentric exercises|
224160258|NCT03089008|OTHER|Stretching exercises|
223743818|NCT00380978|PROCEDURE|combined spinal epidural analgesia|Analgesia was initiated in the early group using a standard needle-through-needle technique with intrathecal fentanyl 25 mcg and an epidural test dose of lidocaine 15 mg/ml and epinephrine 5 mcg/ml in 3ml. At the second analgesia request, the cervix was examined. Epidural analgesia was initiated with a dilute bupivicaine/fentanyl solution if the cervix was less than 4 cm. If the cervix was 4 cm or more, epidural analgesia was initiated with bupivicaine 1.25 mg/ml. If no cervical exam was performed at the second request for analgesia, the cervix was assumed to be at least 4 cm dilated. Thereafter, analgesia was maintained in all participants in the early group with patient-controlled epidural analgesia.
224160259|NCT00088595|DRUG|Pasireotide (SOM230)|Open label. Patients received starting dose of 300 µg of study drug subcutaneously (s.c.) twice (total of 600 µg ) daily for three days, which could be increased in 150 µg increments up to 900 µg twice daily (total 1800 µg daily) if control of symptoms was not achieved. Prior sponsor agreement was required for a higher dose. A dose of 2400 µg/day was the maximum allowed. Dose reductions of 300 µg/day were allowed at any time if unacceptable toxicity occurred.
224160260|NCT02465762|DEVICE|ultrashape Fat reduction|Ultrashape Device focused ultrasound to produce localized mechanical motion within fat tissues and cells for the purpose of producing mechanical cellular membrane disruption. It is intended for reduction in abdominal circumference.
224160261|NCT01406730|OTHER|exercise|16 week of periodized progressive running exercise 2-4 times/week
224160262|NCT03511924|BEHAVIORAL|Intradialytic resistance training|Progressive resistance training programme performed during haemodialysis, taking into account subject´s medical review summarizing: A. full medical history, B. clinical examination including cardiovascular assessment, C. detailed medication usage history, D. review of recent biochemistry and haematology records and results of lower extremity muscle strength assessments. Construction of intradialytic training programme followed recommendations published by the Exercise \& Sports Science Australia (Smart et al., 2013).
224160263|NCT02136316|DRUG|ASP7962|Oral
224160264|NCT02136316|DRUG|Placebo|Oral
224160265|NCT00854984|BEHAVIORAL|Living Life to the Full|A nurse-supported, self-help, cognitive behavioural therapy with web, video and booklet formats.
224160266|NCT02058706|DRUG|enzalutamide|Given PO
224160267|NCT02058706|DRUG|bicalutamide|Given PO
224160268|NCT02058706|PROCEDURE|orchiectomy|Undergo orchiectomy or receive LHRH analogue therapy
224160269|NCT02058706|DRUG|leuprolide acetate|Undergo orchiectomy or receive LHRH analogue therapy
224160270|NCT02058706|DRUG|goserelin acetate|Undergo orchiectomy or receive LHRH analogue therapy
224160271|NCT02058706|OTHER|laboratory biomarker analysis|Correlative studies
224160272|NCT02650193|DRUG|HSP-130|Dosage will vary per each cohort: (Five independent cohorts) Cycle 0 Regimen A - 3 mg Cycle 0 Regimen B - 6 mg Cycles 1-4 Regimen B - 6 mg Cycles 1-4 Regimen A (Potential)- 3 mg Cycles 1-4 Regimen C (Conditional)- 12 mg
224160273|NCT01308853|DEVICE|Macrolane|Device: Macrolane Treatment: Initial injection (incl touch-up) of a maximum of 120 ml/breast.
224160274|NCT03643198|DRUG|ANTIBIOTIC (METRONIDAZOLE AND CIPROFLOXACIN)|The control group will receive two types of placebo tablets that look identical to Ciprofloxacin and Metronidazole respectively, with similar doses and frequencies.
224160275|NCT03643198|OTHER|CONTROL|NO treatment
224160276|NCT04285177|PROCEDURE|Strabismus surgery|Resection or recession of the medial or lateral rectus muscle, or inferior oblique myectomy
224160277|NCT04742764|COMBINATION_PRODUCT|Standard medical therapy|Standard medical therapy (according to the Surviving Sepsis Campaign) will include standard monitoring (pulseoximetry, 5-lead ECG, continuous invasive blood pressure monitoring, central venous cannulation and 24 with PiCCO-technology. Norepinephrine as a vasopressor and dobutamine - if needed - as an inotrope will be administered by the attending physician.
224304143|NCT04078126|COMBINATION_PRODUCT|Symbicort Turbuhaler|Treatment with budesonide and formoterol furmate DPI (dry-powder inhaler)
224160278|NCT04742764|DEVICE|Standard medical therapy plus cytokine removal treatment using Cytosorb, with the adsorber changed in every 12 hours|Standard medical therapy, as discussed above will be applied. Furthermore, Cytosorb will be administered as soon as it is possible after randomization but not later than 2 hour (start of the treatment, T0). In a blood pump circuit in pre-haemofilter position, using a kidney replacement device of Fresenius Multifiltrate as a solo therapy or in combination with renal replacement therapy. It will be run in CVVHD, CVVHDF or CVVH mode with a 150 and 200 ml/min blood flow. Anticoagulation will be applied intravenously with heparin, low molecular weight heparin or citrate. The aim of the pump flow rate will be 100-400 mL/min, and the flow rate will be recorded. Possible shock reversal will be assessed by the physician attending. Adsorber cartridges will be changed in every 12 hours. End of the study period (Te): 12 hours after shock reversal, death of the patient, or maximum of five days, whichever happens first.
224160279|NCT04742764|DEVICE|Standard medical therapy plus cytokine removal treatment using Cytosorb, with the adsorber changed in every 24 hours|The standard medical therapy and method of Cytosorb treatment as detailed above will be applied. Adsorber cartridges will be changed in every 24 hours.
224160280|NCT04325919|OTHER|No intervention|No intervention
223471659|NCT01905618|BEHAVIORAL|Booster Session|The last component of the intervention, a small group booster session, occurs during the third year of medical school. A five minute video reviews the use of the 5As and patient-centered counseling strategies. Faculty facilitate a small group discussion after viewing the video.
224160281|NCT04543656|BEHAVIORAL|AI-Based Lifestyle Recommendations|The intervention provides participants with automated and personalized lifestyle recommendations involving a sophisticated analytics engine using advanced statistics and machine learning.
224160282|NCT04543656|OTHER|No Lifestyle Recommendations|The control group receives an identical activity tracker and BP monitor in order to objectively assess the effectiveness of the experimental group intervention.
224160283|NCT03887975|PROCEDURE|Monoplane Occlusion|Monoplane and lingualized occlusion effect on force distribution
223471660|NCT02199769|OTHER|Clinical Decision Support|Investigators will develop and implement an automated Diabetes Detection Tool (DDT) that does data mining on EMR lab data to systematically identify all primary care patients with elevated RPGs who are at high risk of diabetes and in need of further diabetes testing/screening.
223471661|NCT02345005|DEVICE|The Gore® EXCLUDER® ILIAC BRANCH Endoprosthesis.|The Gore IBE device is a newly designed iliac branched device, that is used in combination with the widely accepted C3 Excluder endograft, for the exclusion of common iliac aneurysms and aorto-iliac aneurysms.
223471662|NCT00667641|DRUG|bortezomib|Starting dose level 0.70mg/m2
223471663|NCT00667641|DRUG|paclitaxel|Starting dose level 40mg/m2
223471664|NCT03040232|OTHER|biomechanical assessment|biomechanical and strength assessment of both groups
223471665|NCT05944835|OTHER|Analyzed on the post-operative scanner|Analyzed on the post-operative scanner
223471666|NCT05222880|DEVICE|JJVC Investigational Multifocal Contact Lenses manufactured in senofilcon A C3|TEST Lens
223471667|NCT06139848|OTHER|Traditional Physical Therapy|Conventional therapy include heating therapy for 10 mints, Bridging exercises (10 rep, 3 sets), Paraspinal muscle stretch.
223471668|NCT06139848|OTHER|Posterior-anterior spinal mobilization, prone press up Techniques|"Posterior-anterior spinal mobilization and prone press- ups techniques. Posterior- Anterior glides and prone press up along with conventional therapy. PA Mobilization on lumber spine, grade I if patient feel no pain the therapist will proceed to grade III-IV. 3 sets for 40 seconds. Total time 10 mints.~Prone press-ups will be performed actively by the patients without no reproduction of pain with lumber extension in standing. In prone press-up the patient pelvis stabilized in prone position and asked for active extension. End range time 5 seconds. Total 10 repetitions."
223471669|NCT04726826|DIAGNOSTIC_TEST|Diagnostic and prognostic biomarkers|Observational study of biomarkers predictive of morbidity and mortality in febrile children
223579849|NCT04170270|DRUG|Omeprazole|"Pre endoscopically: all patients will receive 80 mg omeprazole by 30 minute IV infusion.~After performing upper endoscopy (with initial hemostasis), the patient will be randomly allocated into two groups; group A patients will receive oral omeprazole, while group B patients are intended to receive IV omeprazole.~For patients of group A, omeprazole 40 mg will be administrated orally every 12 hours for 72 hours. Regarding group B, continuous infusion of omeprazole will be administrated at a rate of 8 mg/hour, for 72 hours."
223579850|NCT02035956|BIOLOGICAL|IVAC MUTANOME, RBL001/RBL002|Each patient will receive multiple repeated intranodal injections of IVAC MUTANOME vaccine with or without initial treatment with RBL001/RBL002.
223579851|NCT04685629|DIAGNOSTIC_TEST|25 post ICU-patients|patients who were hospitalized in an intensive care unit
223579852|NCT04685629|OTHER|25 post non-ICU patients|patients who were not hospitalized in an intensive care unit
223579853|NCT04502121|BEHAVIORAL|EXPECT: Preoperative optimization of cardiac valve patient's expectations|The psychological, preoperative intervention follows a treatment manual. Patients get a personal intervention one day before surgery (30-40 minutes). It includes the development of an individual, subjectively perceived disease model, the treatment outcome expectations and the personalized outcome expectancy. Additionally they get two booster telephone calls 4 and 8 weeks after the surgery to recall the discussed topics and to talk about their recovery process (10-15 minutes).
224160284|NCT03887975|PROCEDURE|Lingualized occlusion|Monoplane and lingualized occlusion effect on force distribution
224160285|NCT06378606|BEHAVIORAL|cognitive therapy|"intervention : group A: recive computer cognitive traing by rehacom system and omega 3 supplement .~group B: recive smart phone cognitive application and omega 3 supplement . group c recive omega 3 supplement only."
223579854|NCT02745717|DRUG|Thymoglobulin|administration of ATG 3.5mg/kg/d (Thymoglobuline®, Genzyme) intravenously for 5 days
223743819|NCT00380978|PROCEDURE|late analgesia (systemic)|Analgesia was initiated in the late group with hydromorphone 1mg intramuscularly (IM) and 1 mg intravenously (IV). If the cervix was less than 4 cm at the second analgesia request, hydromorphone analgesia was repeated. Epidural analgesia was initiated with bupivicaine 1.25 mg/ml if the cervix was 4 cm or more. At the third analgesia request, epidural analgesia was initiated regardless of cervical dilation. Thereafter, epidural analgesia was maintained with patient controlled analgesia until delivery.
223743820|NCT04146545|BEHAVIORAL|"Community Rx-Dementia CRxD Caregiver Resources"|A tailored list of resources addressing health-related social needs (HRSN) for caregivers and access to an online community resource finder.
224160286|NCT05746000|BEHAVIORAL|Intervention Group (IG)|Three individual diet counselling that includes sugar calculation (sugar exchange) (60 minutes per session) at baseline, week-4 and week-8.
224160287|NCT05746000|BEHAVIORAL|Control Group (CG)|Three individual diet counselling (60 minutes per session) at baseline, week-4 and week-8.
224160288|NCT05863806|OTHER|Mulligan Mobilzation|"Participants were instructed that MWM, including shoulder movement, must be pain-free and should be immediately stopped if any pain is experienced during the treatment.~The single session of MWM technique was last around 20 minutes, in 3 sets of 10 repetitions with a rest interval of 30 seconds between each sets."
224160289|NCT05863806|OTHER|Trasverse Friction Massage|"Deep friction massage was given to rotator cuff tendon with the tip of index finger, which is reinforced by middle finger.~It was given in transverse direction for 10 - 12 minutes. Transverse friction massage was Given twice a week with the gap of days for the first 3 week and then the repetition is increased to 3 to 4 times a week for the rest of duration."
224160290|NCT00320632|DRUG|Desipramine|
223471670|NCT06508255|BEHAVIORAL|Early Time-Restricted Eating|Eat between 8:00 and 16:00 for 2 weeks
223579855|NCT02745717|PROCEDURE|Cord blood|transfusion of one unit of at least 4/6 HLA loci matched cord blood.
223579856|NCT02745717|DRUG|Cyclosporine Oral Product|administration of cyclosporine A 5mg/kg orally, and maintain the trough serum concentration between 200ng/ml to 300ng/ml.
223471671|NCT06508255|BEHAVIORAL|Late Time-Restricted Eating|Eat between 13:00 and 21:00 for 2 weeks
223743821|NCT01729754|DRUG|Tildrakizumab 200 mg|Tildrakizumab 200 mg administered SC. Each pre-filled syringe (PFS) or autoinjector (AI) contains 1 mL of solution, tildrakizumab 100 mg/mL.
224160291|NCT04366089|OTHER|Oxygen-ozone therapy, probiotic supplementation and Standard of care|\- systemic autohemotherapy with Ozone 30 mcg / ml 250ml 2 times / day for 7 days
223471672|NCT03667768|PROCEDURE|Glass ionomer sealant|
224160292|NCT04366089|DIETARY_SUPPLEMENT|SivoMixx (200 billion)|Composition of SivoMixx: Streptococcus thermophilus DSM322245, Bifidobacterium lactis DSM 32246, Bifidobacterium lactis DSM 32247, Lactobacillus acidophilus DSM 32241, Lactobacillus helveticus DSM 32242, Lactobacillus paracasei DSM 32243, Lactobacillus plantarum DSM 32244, Lactobacillus brevis DSM 27961 (NB: DSM n°... : bacterial strain identification code)
224160293|NCT04366089|DRUG|Azithromycin|dose: 500mg 1 cp / day (alternatively lopinavir/ritonavir cps 200/50 mg, 2 cps x 2 / day or darunavir 800 mg 1 cp / day + ritonavir 100 mg 1 cp / day or darunavir/cobicistat 800/150 mg 1 cp / day)
224160294|NCT04366089|DRUG|hydroxychloroquine|dose: 200 mg, 1 cp x 2 / day
224160295|NCT02292524|OTHER|Commercially-available tomato food product|Each of the three tomato food products (juice, soup, sauce) provided 25-35 mg lycopene/day.
224160296|NCT00935467|DRUG|Saxagliptin|Tablets, oral, 2.5 mg, twice daily, 7 days
224160297|NCT00600665|BEHAVIORAL|PAINReportIt|A pain assessment data collection tool
224160298|NCT00600665|BEHAVIORAL|PAINUCope|A multimedia patient education program tailored to the participant's SCD pain management misconceptions
224160299|NCT00600665|BEHAVIORAL|PAINConsultN|A decision support tool for doctors that will provide algorithm-based pain medication therapies tailored to each participant's pain level
224160300|NCT00000995|DRUG|Zidovudine|
224160301|NCT00000995|DRUG|Ganciclovir|
224160302|NCT01125904|DRUG|crizotinib|Oral liquid. Taste assessment of new formulation. Subjects will not ingest the drug.
224160303|NCT00146224|DRUG|Epoetin alfa RB|Receive drug at same frequency and dose as at the time of randomization Change dose by+/- 25% in order to maintain Hb between 10.0 - 13.0 g/dL and within -1.0 to +1.5 g/dL of the subject's baseline Hb.
224160304|NCT00146224|DRUG|Epoetin alfa DT|Receive drug at same frequency and dose as at the time of randomization Change dose by+/- 25% in order to maintain Hb between 10.0 - 13.0 g/dL and within -1.0 to +1.5 g/dL of the subject's baseline Hb.
224160305|NCT06118190|DRUG|Lidocain|All participants treated with procaine and lidocaine injection for treatment.
224160306|NCT01951326|DRUG|RHB-104|95 mg clarithromycin, 45 mg rifabutin, and 10 mg clofazimine
223471673|NCT03667768|BEHAVIORAL|Non-sealant (toothbrushing)|
223471674|NCT01996111|PROCEDURE|Injection of 1.0 cc of 0.9% Saline|Injection of 1.0 cc of 0.9% Saline into affected area
223743822|NCT01729754|DRUG|Tildrakizumab 100 mg|Tildrakizumab 100 mg administered SC. Each PFS or AI contains 1 mL of solution, tildrakizumab 100 mg/mL.
224160307|NCT01951326|DRUG|Placebo|5 placebo capsules administered orally BID
223471675|NCT01996111|PROCEDURE|Injection of 1.0 cc of 10 mg/ml micrograft dHACM suspension|Injection of 1.0 cc of 10 mg/ml micrograft dHACM suspension into affected area
223471676|NCT01996111|PROCEDURE|Injection of 1.0 cc of 20 mg/ml micrograft dHACM suspension|Injection of 1.0 cc of 20 mg/ml micrograft dHACM suspension into affected area
223471677|NCT01996111|PROCEDURE|Injection of 1.0 cc of 40 mg/ml micrograft dHACM suspension|Injection of 1.0 cc of 40 mg/ml micrograft dHACM suspension into affected area
223471678|NCT00484770|DEVICE|Brain Natriuretic Peptide Levels -- Diagnostic testing|
223471679|NCT00484770|OTHER|clinical assessment|
223471680|NCT01348724|DRUG|[14C] NKTR-118|Single 25 mg oral dose administered on Day 1
223579857|NCT04952038|BEHAVIORAL|sleep disorder|ALS patients with or without sleep disorder
223579858|NCT02973191|DRUG|JCAR015|
223579859|NCT01797380|DRUG|Placebo|Placebo daily for duration of double-blind portion of trial
223579860|NCT01797380|DRUG|Escitalopram|Escitalopram 10 mg po daily for duration of double-blind portion of trial
223579861|NCT03386734|PROCEDURE|SLN biopsy only|In experimental arm, SLN dissection only. A full lymphadenectomy will not be performed. The radical hysterectomy or trachelectomy will be done.
223579862|NCT03386734|PROCEDURE|SLN biopsy + PLN dissection|In active comparator arm, SLN dissection + full lymphadenectomy will be performed.
223579863|NCT00159575|DRUG|Metformin / Placebo treatment for 4 months|M: Metformin 2000mg daily- 12-14 weeks of pretreatment + metformin 2000mg daily through conventional IVF ending on the day of pregnancy test; IE. 14 days after embryo transfer. P: Or identical placebo treatment for the same period
223579864|NCT06421402|OTHER|Air quality monitoring at patient's home|"Indoor Air Quality:~\- MICA-INBIOT system: temperature (ºC), humidity (%), CO2 (ppm), total Volatile Organic Ccompounds (VOCs) (ppb), Formaldehyde (µg/m3); and Particulate Matter (PM) 1/2.5/4/10 (µg/m3)~Outdoor Air Quality:~\- Aeris Weather platform: NO, NO2, NOx, SO2, SO3, CO, and PM10, all expressed in µg/m3"
223743823|NCT01729754|DRUG|Tildrakizumab Placebo|Matching placebo to tildrakizumab administered SC
224160308|NCT04744766|PROCEDURE|major duct excision|2 methods of major/central mammary duct excision are compared as regard the outcome
224160309|NCT00648544|DRUG|Pravastatin|Single-dose 80 mg oral immediate-release tablet
224160310|NCT00648544|DRUG|Pravastatin|Single-dose 80 mg oral immediate-release tablets
224160311|NCT02899104|DRUG|Xofigo (Radium-223 dichloride, BAY88-8223)|Xofigo is indicated for the treatment of patients with castration-resistant prostate cancer (CRPC), symptomatic bone metastases and no known visceral metastatic disease.
224160312|NCT04715958|PROCEDURE|Contrast-Enhanced Ultrasound|Undergo CEUS
224160313|NCT04715958|DRUG|Perflutren Lipid Microspheres|Given IV
224160314|NCT04715958|PROCEDURE|Ultrasound|Undergo unenhanced baseline ultrasound
224160315|NCT02990065|DIETARY_SUPPLEMENT|PROTEIN SUPPLEMENTATION|
223471681|NCT01791985|DRUG|AZD4547 / anastrozole or letrozole|"Patients will continue or restart the NSAI which they have progressed\* on: either anastrozole (1mg) or letrozole (2.5mg), orally, once daily but together with twice daily AZD4547 (80mg).~AZD4547 will be given on an intermittent schedule of one week on / one week off.~\*Prior to study entry, patients must have taken anastrozole or letrozole at some stage in their treatment to date for breast cancer; and shown evidence of resistance to this therapy. The NSAI does not have to be the most recent line of treatment."
223579865|NCT06421402|OTHER|Questionnaires: Baseline & every six months|"General surveys:~* PROMs: ICHOM Adult Set; encompassing Patient Reported Outcomes Measurement Information System (PROMIS 10), World Health Organization Wellbeing Index (WHO 5) and World Health Organization Disability Assessment Schedule (WHO-DAS 12) questionnaires.~* PREMs: Patient-Reported Indicator Survey (PaRIS)~Disease specific questionaires:~* COPD: COPD Assessment Test (CAT); modified Medical Research Council (mMRC) Dyspnea scale.~* Asthma: Asthma Control Test (ACT); Test of Adherence to Inhalers (TAI-12); Asthma Quality of Life Questionnaire (mini AQLQ); Sino-Nasal Outcome Test (SNOT-22)."
223743824|NCT01729754|DRUG|Etanercept Placebo|Matching placebo to etanercept administered SC
224160316|NCT06100107|OTHER|Mirror Therapy exercise|Mirror Therapy for the upper limb involves the use of a mirror to create a reflected image of the unaffected arm, making it appear as if both arms are moving symmetrically. During the therapy, the patient places their affected arm behind the mirror and their unaffected arm in front. While focusing on the mirror reflection, the patient performs various movements with the unaffected arm, giving the illusion that the affected arm is moving normally.
224160317|NCT03375762|OTHER|Remote ischemic perconditioning|Five 5-minute inflations/deflations of an automatic device placed on the upper non-paretic arm initiated in the ambulance on the way to hospital in the case of stroke code activation and RACE score \>0 and RACE motor item\>0
224160318|NCT03375762|OTHER|Sham remote perconditioning|Sham five 5-minute inflations/deflations of an automatic device placed on the upper non-paretic arm initiated in the ambulance on the way to hospital in the case of stroke code activation and RACE score \>0 and RACE motor item\>0
224160319|NCT00053014|BIOLOGICAL|therapeutic allogeneic lymphocytes|
224160320|NCT00053014|DRUG|cyclosporine|
224160321|NCT00053014|DRUG|fludarabine|
223471682|NCT03440476|BEHAVIORAL|e-checkup to go|The e-checkup to go substance program is designed to motivate individuals to reduce their consumption using personalized information about their own use and risk factors. The program is a combination of several components including alcohol education, personalized feedback, attitude-focused strategies, and skills training. It is self-guided and requires no face-to-face time with an administrator. It provides tailored feedback regarding quantity and frequency of alcohol use, normative comparisons, physical health information, amount and percent of income spent on alcohol, negative consequences feedback, explanation and advice for how to reach their goals, and resources.
223471683|NCT03440476|BEHAVIORAL|Feedback-only booster|Booster emails will contain normative feedback indicating average consumption for students at the same institution by sex, their perceptions of student drinkers at the same institution, their own reported consumption, and reminders of strategies they can use to protect themselves from alcohol-related harm. The content is clearly automatically generated.
223471684|NCT03440476|BEHAVIORAL|Feedback-plus-personal-contact booster|Booster emails will contain normative feedback indicating average consumption for students at the same institution by sex, their perceptions of student drinkers at the same institution, their own reported consumption, and reminders of strategies they can use to protect themselves from alcohol-related harm. The email is sent from an individual on the research staff.
223471685|NCT02552108|BEHAVIORAL|Behavioural experiments for intolerance of uncertainty (BE-IU)|
223471686|NCT03598400|BEHAVIORAL|high intensity interval training|Participants will complete 6 sessions of high intensity interval training during a 2 week intervention period. The programme involves repeated 1 minute bouts of simple on the spot movements interspersed with 1 minute of rest.
223743825|NCT01729754|DRUG|Etanercept 50 mg|Etanercept 50 mg administered SC
224160322|NCT00053014|DRUG|mycophenolate mofetil|
224160323|NCT00053014|PROCEDURE|peripheral blood stem cell transplantation|
224160324|NCT00053014|RADIATION|radiation therapy|
224160325|NCT05315024|DRUG|Fluarix Tetra|Fluarix Tetra
223471687|NCT03598400|BEHAVIORAL|moderate intensity continous training|Participants will complete 6 sessions of moderate intensity continous training during a 2 week intervention period. Participants will be asked to complete 30 minutes of continuous exercise.
223471688|NCT05734261|PROCEDURE|Airway Oscillation System|After each methacholine dose administred, respiratory function will be measured by forced oscillation
223743826|NCT00690014|DRUG|probenecid|500 mg q 6 hrs
223743827|NCT00773292|DRUG|ciclosporin|Ciclosporin 2.5 - 5mg/kg/day in two equally divided doses. dose adjusted according to trough ciclosporin concentration
223743828|NCT05149846|PROCEDURE|Pre-conditioning|Pre-conditioning by three consecutive 60 seconds balloon inflations, spaced 120 seconds apart followed by 10 minutes rest prior to PCI
223743829|NCT05324995|DRUG|Multimodal Drug|The Multimodal Drug group received morphine, epinephrine, and ketorolac (n=48), The epinephrine group (placebo group) (n=49) received 300 mcg epinephrine (1:1000) (DarouPakhsh, Tehran, Iran) peri-articulary,and the celecoxib group(control group)(n=49) recieved 400mg celecoxib orally
223743830|NCT05324995|DRUG|epinephrine|The second group received 300 mcg epinephrine (1:1000) (DarouPakhsh, Tehran, Iran) peri-articulary
224160326|NCT05315024|DRUG|Imiquimod cream|Imiquimod cream
224160327|NCT02126241|OTHER|NICaS guided CRT optimization|"1. Baseline CO measurement by NICaS~2. AV delay optimization:~   1. AV delay will be changed (increase and decrease) by 30 ms steps , and for each new AV value, the CO will be real-time measured by NICaS~  2. The AV delay yielding the maximal CO, will be considered the optimal AV delay~  3. The device will be programmed using the optimal AV delay~3. VV delay optimization:~   1. After Step 2, the baseline VV delay will be changed (increase and decrease; meaning that we will be pacing alternatively the LV before the RV, then the RV before the LV), by 30 ms steps, and for each new VV value, the CO will be real-time measured by NICaS~  2. The VV delay yielding the maximal CO, will be considered the optimal VV delay~  3. The device will be programmed using the optimal VV delay"
224160328|NCT01473355|DEVICE|OsseoSpeed™ TX|OsseoSpeed™ TX narrow implants (diameter 3 mm) of lengths 11-15 mm
223471689|NCT01309321|BEHAVIORAL|Perinatal Handwashing Promotion|Pregnancy may serve as a unique opportunity to improve maternal handwashing behavior more deeply and sustainably than a handwashing promotion intervention at a different time. Primiparous women will receive an intensive handwashing promotion program delivered at 3 in-home visits between one month prenatal and 1 week post natal. The program will promote handwashing benefits, provide hardware to reduce barriers to handwashing, and educate mothers about the critical times for handwashing. Mothers will also receive an essential neonatal care package with information on clean delivery, hypothermia prevention, breastfeeding counseling, umbilical cord care, and identification of neonatal danger signs.
223471690|NCT01309321|BEHAVIORAL|Neonatal Health Promotion|Mothers will receive an essential neonatal care package with information on clean delivery, hypothermia prevention, breastfeeding counseling, umbilical cord care, and identification of neonatal danger signs.
223471691|NCT04204161|BIOLOGICAL|CAR-T19/CAR-T22|According to tumor burden and other conditions, patients will be treated with cyclophosphamide or fludarabine,then,CAR-T cells will be infused 48-72 hours later.The recommand dose is 1x10\^5/kg-2.5x10\^8/kg .
223471692|NCT02484014|OTHER|Tarang Adolescence Education programme|The comparison arm involves 'usual care' which in the study setting is the Tarang: Adolescence Education Programme comprising of 16 classroom sessions on process of growing-up, prevention of HIV/AIDS and other Sexually Transmitted Diseases (STDs), and prevention of substance and other drug abuse. This programme is delivered by a trained nodal teacher in the school over the academic year.
223471693|NCT02484014|OTHER|SEHER Intervention|"The SEHER intervention will be delivered by a trained teacher, called as Teacher-as-SEHER Mitra (Mitra meaning friend) or lay health worker called as SEHER Mitra being trained to facilitate following activities:~* Awareness generation activities for all stakeholders in school~* Wall-magazine~* Speak-out box~* Competitions~* School Health Promotion Committee~* School health policies~* Peer groups of students of standard IX~* Workshops and talks for all the students from standard IX, and for teachers~* Counselling and referral services for all the students in the school This intervention will be delivered in each school over the academic year."
223743831|NCT05324995|DRUG|celecoxib|The third group administered celecoxib (200 mg) orally immediately before the surgery
223471694|NCT04014530|DRUG|Ataluren + Pembrolizumab|Ataluren and Pembrolizumab combination therapy
223471695|NCT01155817|DRUG|Nilotinib|200, 400, 800, oral
223471696|NCT03754920|BEHAVIORAL|prolonged fasting|"Fasting for 5 days: Fasting with some fitness regimen, such as meditation and mild physical exercise;~Feeding for 3 days: Gradually distribute participants with rice flour, porridge and juice."
223743832|NCT03742609|OTHER|ii) the reminder|Participants assigned to the prompt group were received instruction to use their hearing aid box as a physical prompt to remind participants to use their hearing aid(s)
223743833|NCT03742609|OTHER|ii) written behavioural plan|Participants assigned to this group were received instruction to create at least one written plan for hearing aid use. Specifically, participants were asked to plan where and when to use their hearing aid(s).
223743834|NCT03742609|OTHER|iv) all materials|i) provision of written information regarding consequences of using a hearing aid and not using a hearing aid, ii) the provision of a physical prompt for the purpose of prompting or cueing the behavior (hearing aid use) development, and iii) creation of a written behavioural plan for hearing aid use.
224160329|NCT05648123|BEHAVIORAL|Supportive Psychotherapy|Supportive psychotherapy is a treatment that uses direct measures to ameliorate symptoms and to maintain, restore or improve self-esteem, ego function, and adaptive skills
224304144|NCT04793048|DEVICE|a noninvasive intraoral electrotherapy device|a noninvasive intraoral electrotherapy device to treat periodontal disease at-home for 20 minutes a day
223471697|NCT05430165|OTHER|Standard mHealth screening (triage) tool|"Standard mHealth triage tool administered to eligible trauma patients by phone at 2 weeks, 1 month, 3 months, and 6 months post-hospital discharge. The mHealth triage tool is a survey that includes a 7-item questionnaire to identify their need for follow-up care.~The need for follow-up care at any of the 4 follow-ups is defined as a flagged response to ≥1 question on the 7-item screening survey."
223743835|NCT02794103|DEVICE|Virtual Reality Distraction|VR prototype developed by the SAT will be used as the experimental intervention. It has a wide screen installed at the end of the hydrotherapy tank offering a 150-degree field view, on which appears a game allowing the child to have the immersive entertainment experience without the need to wear a helmet or 3D glasses. The child or a proxy, depending on age and burn site, will have the opportunity to interact with the game. The interactive component is not mandatory for the immersive and distractive experiences provided by the prototype. Video games tailored to the child's age and injury, different from the commercially available ones, will be adapted to each age-group of children recruited with control over the speed of movement to avoid motion sickness.
223743836|NCT02417012|BEHAVIORAL|U-TURN|Participants in this group will receive individual and group based interventions on obtaining and maintaining a healthy lifestyle, while having the pharmacological treatment regulated
223743837|NCT02417012|BEHAVIORAL|Standard care|Standard individual diabetes support
224160330|NCT00744731|DRUG|placebo|placebo for 1 week
224160331|NCT00744731|DRUG|carisbamate|400 mg/day to 1,200 mg per day
224160332|NCT04065815|OTHER|Resistance Training|"Conventional Resistance Training:~Nutritional therapy (individualized, protein-rich nutritional therapy and counseling; targeted protein intake/day: 1.2 - 1.5 g per kg bodyweight) during a study period of 12 weeks combined with a resistance training program consisting of five exercises: exercises (chest, upper/lower back, abdominals, legs)~* 1 set per exercise~* time-effort per session: \~20 min~* 2 training sessions per week"
224304145|NCT04793048|DEVICE|a sham device|a sham device to be used at-home for 20 minutes a day
223471698|NCT05418465|DRUG|Huangqi Guizhi Wuwu decoction|Huangqi Guizhi Wuwu decoction, 100ml at a time, 2 times a day. Oral administration.
223471699|NCT05418465|DRUG|Dapagliflozin|Dapagliflozin, 10mg at a time, once a day. Oral administration.
223471700|NCT01937897|OTHER|Bi-lateral massage|Unilateral massage on the left side of the body.
223471701|NCT04151511|PROCEDURE|Continuous Erector Spinae Plane Block|"1. Continuous Thoracic Epidural Thoracic Epidural Analgesia~2. Continuous Erector Spinae Plane Block"
223471702|NCT01552486|OTHER|Chiropractic Spinal Manipulative Therapy|Patients will receive a course high-velocity low-amplitude thrust spinal manipulation 3 times per week for 4 weeks.
223471703|NCT01552486|OTHER|Usual Care|Patients will be under the care of the their general physician and will be allowed the following medications: gabapentin, pregabalin, nortriptyline, amitriptyline.
223471704|NCT01565577|BIOLOGICAL|MenbVac|Blood test
223471705|NCT02578017|BEHAVIORAL|Mobile DOT|Mobile DOT is a multi-dimensional tool that uses automated reminders, adherence feedback messages, incentives, and video observation of medication administration.
223579866|NCT06421402|DIAGNOSTIC_TEST|Lung function Testing: Baseline & every six months & during exacerbations|"* Forced Spirometry: Forced Vital Capacity (FVC) and Forced Expiratory Volume in 1 second (FEV1)~* Forced Oscillation Technique: Impedance, resistance and reactance.~Ancillary measurements: Systemic arterial pressure and pulse oximetry."
223579867|NCT06421402|OTHER|EMR & registry data|"Electronic Medical Records (EMRs): Updated every twelve months to track clinical events from Hospital and Primary Care databases.~Registry data: from the Catalan Health Surveillance System (CHSS)."
223579868|NCT06421402|DEVICE|Communication channel - Health Circuit Mobile App (Herranz C. JMIR 2023)|Health Circuit: chat, short questionnaires (Likert scale). As needed.
223579869|NCT06421402|DEVICE|Physiological data - Beat One Watch|Enhanced with real-time physiological data tracking (heart rate, steps walked and Heart Rate Variability (HRV))
223579870|NCT06421402|DEVICE|Patient Empowerment|Mobile App Health Circuit: follow-up of the personalized action plan agreed with the patient \& reference doctor
223579871|NCT06421402|OTHER|Characteristics of exacerbations|Health Circuit: home-based oscillometry, daily disease-specific questionnaire during the acute episode and continuous assessment of physiological variables.
223579872|NCT02884375|OTHER|Extensive GA|"GA includes an evaluation of nine domains according to international recommendations :~* functional status (six-item Activities of Daily Living (ADL) score, Instrumental Activities of Daily Living (IADL))~* mobility (timed get-up-and-go test, one-leg standing balance test, history of fall)~* nutritional status (French National Authority of Health guidelines, weight loss body mass index (BMI), Mini Nutritional Assessment, albumin )~* cognitive status (Mini-Mental State Examination (MMSE), history of dementia, confusion)~* mood (Mini-Geriatric Depression Scale (Mini-GDS), symptoms of anxiety, depression (DSM V))~* comorbidities (CIRS G)~* polypharmacy (number of medications)~* social environment (primary caregiver, support at home, friends , family, living alone)~* urinary and/or fecal incontinence"
223579873|NCT03990805|BIOLOGICAL|JOINTSTEM|JOINTSTEM Autologous Adipose Tissue derived MSCs 1x10\^8cells/(saline), 1 time injection
224160333|NCT04065815|OTHER|WB-EMS|"Whole-Body Electromyostimulation (WB-EMS):~Nutritional therapy (individualized, protein-rich nutritional therapy and counseling; targeted protein intake/day: 1.2 - 1.5 g per kg bodyweight) during a study period of 12 weeks combined with WB-EMS training:~* Stimulation protocol: Frequency of 85 Hz, pulse duration of 0.35 ms, stimulation period of 6 sec, resting period of 4 sec; patients perform simple exercises during the stimulation period following a video tutorial~* time-effort per session: \~20 min~* 2 training sessions per week"
224160334|NCT04065815|OTHER|High-intensity interval training (HIIT)|"HIIT:~Nutritional therapy (individualized, protein-rich nutritional therapy and counseling; targeted protein intake/day: 1.2 - 1.5 g per kg bodyweight) during a study period of 12 weeks combined with high-intensity interval training (HIIT):~* supervised cycle-ergometer training at at 80-95% HRmax~* time-effort per session: \~15 min~* 2 training sessions per week"
224160335|NCT04065815|OTHER|Combined HIIT and Resistance Training (Combi)|"HIIT combined with conventional Resistance Training:~Nutritional therapy (individualized, protein-rich nutritional therapy and counseling; targeted protein intake/day: 1.2 - 1.5 g per kg bodyweight) during a study period of 12 weeks combined with a combined HIIT and resistance training program:~HIIT:~* supervised cycle-ergometer training at at 80-95% HRmax~* time-effort per session: \~15 min~* 1 training session per week~Resistance Training:~* five exercises: exercises (chest, upper/lower back, abdominals, legs)~* 1 set per exercise~* time-effort per session: \~20 min~* 1 training session per week"
223471706|NCT03142945|OTHER|Traditional Physical Therapy|Physical therapy-based interventions
223471707|NCT03142945|OTHER|MDT based physical therapy|MDT based physical therapy
223471708|NCT05403645|DIAGNOSTIC_TEST|Movement With Mobilization|with the help of Movement With Mobilization technique
223579874|NCT03990805|DRUG|saline|saline, 1 time injection
223579875|NCT00840580|DRUG|Moxifloxacin 0.5% ophthalmic solution (Vigamox)|One drop 4 times a day in study eye for one week prior to surgery, followed by one drop 4 times a day for two weeks beginning Day 1 post surgery.
223579876|NCT00840580|DRUG|Levofloxacin 0.5% ophthalmic solution (Cravit)|One drop 4 times a day in study eye for one week prior to surgery, followed by one drop 4 times a day for two weeks beginning Day 1 post surgery.
223579877|NCT02801890|BIOLOGICAL|Intravenous injection|Intravenous injection of stem cell or placebo to the patients with The patients with ultra filtration failure (UFF) .
223579878|NCT02267954|OTHER|Menu edited|The menu is edited to change price label to 50% of actual value and calorie label to 50% of the actual value, along with other changes.
223471709|NCT05403645|DIAGNOSTIC_TEST|Exercise Therapy|with the help of Exercise Therapy technique
223471710|NCT01404910|DEVICE|Apheresis using Liposorber LA-15 System|The Liposorber LA-15 Device is a dextran sulfate cellulose column, one of several currently approved in Europe and United States for pheresis of lipoproteins in the treatment of familial hypercholesterolemia. Such devices have been in use for over 30 years. Published experience in pregnant women with familial hypercholesterolemia suggests that lipoprotein pheresis can be safely used in pregnancy after appropriate individual benefit/risk assessment for both mother and fetus is considered. The Liposorber LA-15 system selected for this trial has been evaluated for its ability to efficiently and selectively remove sFlt-1 in vitro.
223579879|NCT03816280|PROCEDURE|Elective cardiopulmonary bypass (CPB)|All groups undergo elective cardiopulmonary bypass (CPB)
223471711|NCT01458067|DRUG|GSK2636771|Oral capsules
223471712|NCT03447548|BEHAVIORAL|Neurofeedback processing speed training|Processing speed training on tablets that incorporates changes in pupil size to titrate the learning algorithm
223471713|NCT03447548|BEHAVIORAL|Active control|Commercially available games on tablet
223471714|NCT04157361|DIAGNOSTIC_TEST|Collection of breath condensate|Breath condensate will be collected from the patients involved in study.
223471715|NCT06428435|DIAGNOSTIC_TEST|Vision Test|Remote vision testing via digital screen
223471716|NCT06352814|OTHER|Activities-based locomotor training (physical therapy)|AB-LT is implemented through a combination of partial body weight supported treadmill training, overground walking, and play-based activities.
223471717|NCT03977012|DRUG|Buprenorphine|5\~20 mcg
223471718|NCT06014060|PROCEDURE|24 Months DAPT|All subjects will receive co-administration of aspirin (100 mg/day) and clopidogrel (75 mg/day) for 12 months after randomization. The DAPT will last for 24 months after PCI.
223471719|NCT06014060|PROCEDURE|12 Months DAPT|All the subjects will receive aspirin (100 mg/day) + a placebo that is exactly the same in size, color, smell, taste and appearance as clopidogrel for 12 months after randomization. The DAPT will last for 12 months after PCI.
223471720|NCT06367075|DRUG|Cadonilimab|injectable solution
223471721|NCT06367075|DRUG|Adriamycin|injectable solution
223471722|NCT02956382|DRUG|Ibrutinib|Ibrutinib is dispensed as a capsule.
223471723|NCT02956382|DRUG|Venetoclax|Venetoclax is dispensed as a tablet.
223471724|NCT04213014|BEHAVIORAL|Guys/Girls Opt for Activities for Life (GOAL)|The 4 month (16-wk) GOAL intervention has 3 components: (1) After-school GOAL Club: 26 events (2 days/week; 120 min/event/day; 13 weeks due to no club during 3 school break weeks) for boys and girls to engage in physical activity and healthy eating and cooking activities; (2) Three parent-adolescent meetings (1st meeting at each school for parents and adolescents \[Zoom option if needed\]; 2nd and 3rd meetings delivered virtually and asynchronously for parents): to empower parents to assist adolescents with physical activity and healthy eating and cooking; and (3) GOAL social networking website: private website for parents to share with each other how they helped their adolescent increase physical activity and diet quality each week.
223471725|NCT06490055|DRUG|Paclitaxel|Gastric cancer second-line Chemotherapy (paclitaxel plus ramucirumab)
223471726|NCT04094311|BIOLOGICAL|CTL019|A single intravenous (i.v.) infusion of CAR-positive viable T cells.
223471727|NCT06404970|OTHER|Screening intervention|Intervention to improve identification and management of functional impairment among older Veterans in VA primary care settings. Intervention includes 5 components: (1) routine, standardized functional status measurement; (2) nursing screening followed by follow-up primary care provider assessment; (3) electronic tools and templates to facilitate screening, assessment, and documentation; (4) interprofessional educational session; (5) tailored reports on functional status
223579880|NCT03816280|PROCEDURE|Alpha-stat acid-base management|Acid-base status during CPB will be maintained using the alpha-stat regime
223579881|NCT03816280|PROCEDURE|pH-stat acid-base management|Acid-base status during CPB will be maintained using the pH-stat regime
224160336|NCT04838795|BIOLOGICAL|To monitor the effectiveness of the single dose Ad26.COV2.S COVID-19 vaccine|To monitor the effectiveness of the single dose Ad26.COV2.S COVID-19 vaccine among health care workers (HCW) as compared to the general unvaccinated population in South Africa
223471728|NCT06404970|OTHER|Standard bundle of implementation strategies|Standard strategies include champions plus system-level audit and feedback
223471729|NCT06404970|OTHER|Enhanced bundle of implementation strategies|Enhanced strategies include technical assistance plus clinician-level audit and feedback
223579882|NCT04798040|OTHER|cold application|To reduce pain, cold application is applied around the drain before the drain is removed.
223579883|NCT04798040|OTHER|lavender oil inhalation|To reduce pain, lavender oil is inhaled prior to drain removal.
223579884|NCT04798040|OTHER|oxygen administration|To reduce pain, oxygen is inhaled prior to drain removal.
223579885|NCT02606760|DRUG|P-3073|
223579886|NCT02606760|DRUG|Vehicle of P-3073|
223579887|NCT01881022|BEHAVIORAL|Psychosexual Intervention|Couples will complete six weekly psychosexual counselling sessions. Each session will focus on areas relevant to sex therapy and sexual dysfunction in couples facing breast cancer (e.g. education, communication, body imagery, sensate focusing, and problem solving). Sessions will be one hour in length (Note: Session 1 will be 1.5 hours), during which couples will meet with a facilitator via videoconferencing.
223579888|NCT03909451|DRUG|Sotagliflozin (SAR439954)|"Pharmaceutical form: tablet~Route of administration: oral"
223579889|NCT03909451|DRUG|Placebo|"Pharmaceutical form: tablet~Route of administration: oral"
223579890|NCT06000306|DIAGNOSTIC_TEST|Digital Droplet PCR|Measurable residual disease Monitoring by Digital Droplet PCR in the Early Posttransplant Period
223579891|NCT00025116|DRUG|gefitinib|
224160337|NCT04459078|DRUG|Camrelizumab|Intravenous administration of (200mg/3weeks)
224160338|NCT04459078|DRUG|Albumin Paclitacxel|intravenous administration of Albumin Paclitacxel (135mg/m2, d1, d8/3w, 4-6 cycles)
223579892|NCT00554099|DRUG|Mesalamine|6 - 400 mg tablets once daily
223579893|NCT00554099|DRUG|Probiotic|Once capsule daily Bifidobacterium infantis 35624 added at Visit 2 (Day 10 + 4 days)
223579894|NCT00554099|DRUG|Placebo|6 placebo tablets for first 10 (+4) days followed by once daily placebo tablets.
223579895|NCT00554099|OTHER|Dietary Advice|Dietary advice
223579896|NCT00554099|DRUG|Antibiotic for Diverticulitis|Physician recommended antibiotic for Diverticulitis taken for 10-14 days. Antibiotic not specified for study.
223579897|NCT00841399|BIOLOGICAL|E75 + GM-CSF vaccine|Dose escalation scheme involving three patients each receiving injection of 100, 500, or 1,000 mcg E75 + GM-CSF monthly for 6 months. HLA-A2 and HLA-A3 status determined. HLA-A2+ and HLA-A3+ patients receive the vaccine; HLA-A2- and HLA-A3- enrolled to the control arm.
223579898|NCT03920059|DRUG|Mycophenolate Mofetil|"Description Each capsule contains Mycophenolate mofetil 250 mg. Presentation / Packing Cap 250 mg (white to off white powder, light blue/peach hard gelatin, imprinting with MMF on cap and 250 on body) x 10 x 10's.~Storage Store below 30 degree Celcius."
223579899|NCT02168972|DEVICE|Global mapping and ablation device|During the procedure the Globe catheter will be delivered via standard femoral vein access and transseptal puncture. Anatomical and electrophysiological mapping of the LA will be followed by pulmonary vein isolation (PVI) by RF ablation. Additional lesions will be created as deemed appropriate by the investigator.
223579900|NCT05640206|PROCEDURE|i-PRF|Arthrocentesis performed with two-needle technique, and then injection of i-PRF intra-articularly
224160339|NCT04459078|DRUG|Apatinib|Patients will be given oral of Apatinib (250mg Qd po for 5 days, take rest for 2 days every week)
224160340|NCT05081089|DRUG|Artemether-lumefantrine|Tablets containing 20/80 mg artemether and 120/480 mg lumefantrine will be administered according to weight as per manufacturer guidelines.
224160341|NCT05081089|DRUG|Primaquine Phosphate|The single dose of 0.25mg/kg PQ will be administered in an aqueous solution, according to a standard operating procedure (SOP) provided by the manufacturer.
223471730|NCT06363266|BEHAVIORAL|TEMPO|"Stage 1 interventions (weeks 1-12): TEMPO.~After 12 weeks, the benefit of the initial assignment will be assessed. Benefit is defined as a score \< 3 on the ESAS-r anxiety item (range 0-10) or a decrease \>= 2 points from eligibility screening. If both dyad members had anxiety symptoms at recruitment, both must meet the benefit criterion. If one member no longer meets the criterion, the dyad is considered did not benefit.~Stage 2 interventions (weeks 13-25): TEMPO or lay guidance.~1. TEMPO responders will continue with TEMPO. Dyads who did not benefit will be re-randomized to:~   1. Stepping up to lay guidance (8 x 20-minute calls via phone or Teams). Guides will receive TEMPO training and conduct semi-structured exit interviews.~  2. More time with TEMPO for dyads who benefited from it.~2. Non-responders to usual care in Stage 1 will be stepped up to TEMPO."
223471731|NCT06363266|OTHER|Active Monitoring dyads' anxiety|"Stage 1 interventions (week 1-12): Patients will receive usual care throughout the study. Dyads in this group will not receive any information resources from the research team but will have access to all of those available at their participating center (sites will be asked to provide a description of usual care practices).~Stage 2 interventions (week 13-25): Dyads not responding to active monitoring will be stepped up to TEMPO; responders to active monitoring will only be invited to complete the follow-up measures."
223471732|NCT06312800|DRUG|Acamprosate|Randomized allocation of treatments will guide the dispensation of treatments in one of 6 possible sequences--ex, M (methazolamide)- P(placebo)-A (Acamprosate); or PAM or MAP or PMA or AMP or APM. Biostatistician will devise medication randomization strategies and investigators and staff will be blinded.
223471733|NCT06312800|DRUG|Placebo|Randomized allocation of treatments will guide the dispensation of treatments in one of 6 possible sequences--ex, M (methazolamide)- P(placebo)-A (Acamprosate); or PAM or MAP or PMA or AMP or APM. Biostatistician will devise medication randomization strategies and investigators and staff will be blinded.
223471734|NCT06312800|DRUG|Methazolamide|Randomized allocation of treatments will guide the dispensation of treatments in one of 6 possible sequences--ex, M (methazolamide)- P(placebo)-A (Acamprosate); or PAM or MAP or PMA or AMP or APM. Biostatistician will devise medication randomization strategies and investigators and staff will be blinded.
223471735|NCT05315440|OTHER|graston tecnique|Graston technique involves the use of steel tools that are used non-invasively on the skin to identify and treat areas that have stiffness or inflammation. These areas can be located with greater precision than the manual technique precisely because the instruments do not compress in contact with the patient's skin, as is the case with the physiotherapist's fingertips. Thanks to the instruments it is therefore possible to detect the areas of altered consistency and to treat them by pressing a minimum pressure.
223471736|NCT05315440|OTHER|Conventional rehabilitation|30 minutes of passive and active assisted mobilization guided by the therapist, 30 min of Continous passive movement in flexion and abduction and 30 minutes of electrostimulation.
223471737|NCT01190917|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|The CBT social skills curriculum is manualized and anchored in CBT strategies, such as problem identification, affective education, performance feedback, and weekly homework activities to facilitate generalization. The curriculum is a compilation of lessons targeting key social deficits in children with ASD, such as nonverbal communication, emotion recognition, and theory of mind. Structured teaching includes defining skills, breaking them down into simple, concrete steps, modeling the skill through role-play, and introducing a game or activity to practice the target skill. The approach to the parent group will be psychoeducational with a focus on reviewing target skills, rationale for teaching target skills, homework, progress or obstacles, and identifying strategies to promote generalization. Parent information handouts will be provided.
223471738|NCT01190917|BEHAVIORAL|Play Therapy|The social play group is manualized, led by a trained clinician and support staff, follows a specific routine, and contains a parent group component. Group leaders will follow participants' interests and suggestions for games. Group leaders utilize strategies such as reflective functioning statements on the child's behaviors to build emotion-focused play skills. The therapeutic setting incorporates play designed to encourage emotion-focused play including make-believe (dolls, houses), sensory (e.g. play-doh), and cooperative play (e.g. board games) toys. The approach to the parent group will be supportive rather than psychoeducational. Parents will set the agenda for discussion, facilitated by the group leader.
223471739|NCT04630028|DRUG|Ustekinumab Dose Based on BSA and Body Weight|As per BSA and body weight Ustekinumab will be administered SC and IV.
223471740|NCT04630028|DRUG|Matching Placebo|Placebo will be administered subcutaneously.
223579901|NCT05640206|PROCEDURE|Arthrocentesis|Arthrocentesis performed with two-needle technique
223579902|NCT04035746|OTHER|Observation of microcirculation and plasticity of the brain|Assessment of microcirculation, brain plasticity and clinical function
223579903|NCT04825067|DEVICE|Respiratory Sensor measurements|The participant will receive 2 Respiratory Sensors and 1 gateway with wireless compatibility and a welcome packet with instructions for use, a reminder description of the study purpose and procedures, and research staff contact information. Research staff will contact participants to ensure appropriate setup of the Respiratory Sensor and training on proper use. Research staff will ask the subject to place the Respiratory Sensor on the top left-side of the chest. The Respiratory Sensor continuously collects and monitors respiratory data. The participant will be instructed to change each Respiratory Sensor after 24-48 hours. Subjects will be asked to charge each Respiratory Sensor once it is removed. Subjects will exit the study upon completion of the 90-day follow-up.
223579904|NCT04907435|PROCEDURE|simultaneous operations|simultaneous operations
224160342|NCT05081089|DRUG|Sulphadoxine-pyrimethamine with amodiaquine|Sulfadoxine/pyrimethamine tablets contain 500mg sulfadoxine and 25mg pyrimethamine. Amodiaquine tablets contain 150mg amodiaquine (as hydrochloride). Tablets will be administered according to weight as per manufacturer guidelines.
223579905|NCT00139763|PROCEDURE|Educational Materials|
224160343|NCT05081089|DRUG|Tafenoquine|100mg tafenoquine tablets are prepared into a 1mg/mL solution in water. Solution will be given according to weight as indicated per treatment arm in 5kg bands.
223579906|NCT05489900|DRUG|Dexmedetomidine Hydrochloride|"Dexmedetomidine is a specific and potent α2-adrenergic agonist. By acting directly on the sympathetic nervous system, they can exert beneficial effects on the immune system through neuroimmune interactions. Its administration can induce an anti-inflammatory response due to different central (increase parasympathetic tone, promoting control of the inflammatory condition) and peripheral effects (stimulating innate immunity).(MILLER, 2015).~Venous blood samples were collected at three times (T1, T2 and T3): Before anesthetic induction with collection in the preoperative environment on the day of surgery or during venoclysis before anesthetic induction (sample 1, T1); 6 hours after starting orifice closure and completion of drug or placebo infusion (sample 2, T2); and the last blood sample will be collected by me on the morning after the postoperative period, close to hospital discharge - 24h (sample 3, T3)."
223579907|NCT00771121|DRUG|urea/lactic acid|new emulsion type
223579908|NCT00771121|DRUG|Placebo|only emulsion base
223579909|NCT06055816|DRUG|Endostar and Envafolimab|Neoadjuvant therapy consisting of gemcitabine (1000mg/m2 d1,8) , endostar (150mg 3-day continuous infusion) and envafolimab (240mg d1) was given every 3 weeks for 3 cycles. Endostar, administered every 3 weeks (150mg 3-day continuous infusion), was given concurrently with intensity-modulated radiotherapy.
223471741|NCT03988140|DEVICE|Dental Implant Placement and subsequent prosthetic reabilithation|Surgeries to dental implant placement were performed. All patients received 3.5 mm diameter dental implants - surface blasted with TiO2 particles and machined collar of 1mm - in the interforaminal region of the mandible. The surgical sequence followed the protocol described by the implant company.A two stages protocol was used and the prostheses were placed at 4 months.The prosthetic retention system used in rehabilitation with overdentures was the O'ring and the capture of this component was done directly in the patient's mouth. After 7 and 14 days, the patients returned to occlusal adjustments and verification of prosthetic adaptation. The prostheses were made entirely of acrylic resin without metallic reinforcement and the antagonist of the patients were total edentulous and rehabilitated with muco-supported prostheses.
223471742|NCT05554497|BEHAVIORAL|Mindfulness-based stress reduction curriculum|Standard 8-week mindfulness-based stress reduction curriculum
223471743|NCT04156126|OTHER|Blood Collection|Blood Collection
223579910|NCT00306644|DRUG|Rosiglitazone|study drug
223579911|NCT03002623|DRUG|CUDC-907|60 mg (2 capsules of 30 mg capsules) will be given orally once a day 5 days on and 2 days off.
223579912|NCT03386747|BEHAVIORAL|Home visits to improve parenting behaviors|Caregivers will be visited twice per month starting from the third trimester in pregnancy up to age three to discuss important health and development behaviors.
223579913|NCT03386747|BEHAVIORAL|Center based parenting groups|Caregivers will be invited to early childhood development groups. Groups will meet at nearby centers twice per month. Caregivers will be invited to participate starting from the third trimester up to age 3 of the child.
223579914|NCT01196845|DEVICE|cPAP|Patients are randomised in 2 arms : cPAP or sham cPAP
224160344|NCT00249912|DRUG|Lapaquistat acetate and rosuvastatin|Lapaquistat acetate 50 mg, tablets, orally, once daily and stable Rosuvastatin therapy (10 or 20 mg) for up to 24 weeks.
224160345|NCT00249912|DRUG|Lapaquistat acetate and rosuvastatin|Lapaquistat acetate 100 mg, tablets, orally, once daily and stable Rosuvastatin therapy (10 or 20 mg) for up to 24 weeks.
224160346|NCT00249912|DRUG|Rosuvastatin|Lapaquistat acetate placebo-matching tablets, orally, once daily and stable Rosuvastatin therapy (10 or 20 mg) for up to 24 weeks.
224160347|NCT04457661|DIETARY_SUPPLEMENT|Bacillus coagulans TCI711|Using Bacillus coagulans TCI711 for one month and implementing alcohol testing at weeks 0, 1, and 4.
223471744|NCT05556980|PROCEDURE|totally laparoscopic distal gastrectomy|all the surgical procedure would be finished under laparoscopy
223471745|NCT02354612|DRUG|TRC105|
223579915|NCT01196845|DEVICE|cPAP|Patients are randomised in 2 arms : cPAP or Sham cPAP
223579916|NCT01196845|DEVICE|cPAP|Patients are randomised in 2 arms : cPAP or sham cPAP
223743838|NCT04608500|DRUG|FMX103 minocycline foam 1.5%|Dosage form description: Foam containing minocycline HCl 1.5%. Once daily application of a sufficient amount of foam to cover the entire face. Estimated maximum is 0.5 g of drug product containing 7.5 mg (1.5% active) of minocycline. Participants will apply a small amount of the drug as a thin layer over all areas of the face. Participants should apply the drug at approximately the same time each day, about 1 hour before bedtime.
224160348|NCT05933993|OTHER|Elective cesarean section|The study does not contain an intervention in itself, but women are included if they undergo an elective cesarean section
224160349|NCT04850885|DRUG|inj dexamethasone 4mg/ml and inj lignocaine 20mg/ml|The modified technique of classical IANB was to be selected to avoid failure as described by Clark and Homes (1959). The patients were requested to keep their mouth wide open and an occlusal plane parallel to the floor. Palpation of anatomical landmarks was done properly and the guide finger was positioned at the retromolar fossa. A 5 ml syringe equipped with a 24 gauge needle length of 3.6 cm was used, it was been advanced from premolar on the opposite side into the tissue just above the fingernail until hitting the bone. The body of the syringe was redirected over the lower central incisors and kept parallel to the molars in a horizontal plane at the same time. The needle was inserted another 2 cm deep into the tissue and 3.5 ml of solution X was deposited 1 cm higher than the usual after multiple aspirations (90 degrees two planes). Further, 1 ml solution X was deposited after the withdrawn needle in pterygomandibular space.
223471746|NCT02354612|DRUG|Bevacizumab|companion therapy selection depends on companion therapy used in the parent study
223579917|NCT01196845|DEVICE|cPAP|Patients are randomised in 2 arms : cPAP or sham cPAP
223579918|NCT01342744|DRUG|Metformin|Metformin(850 mg) 1tab oral twice aday
223579919|NCT01342744|DRUG|Placebo|Placebo 1 tab oral twice a day
224160350|NCT01467089|OTHER|Two way video assessment|Participants will be assessed extrapyramidal symptoms and tardive dyskinesia
224160351|NCT01979380|DRUG|KD101|200mg (1casule), 600mg (3 capsule), 1000mg (5 capsule), 1400mg (7 capsule) PO, once in the morning
224160352|NCT01979380|DRUG|placebo|PO, once in the morning
224160353|NCT00727350|RADIATION|Fractionated stereotactic body radiation therapy|For centrally located T1 and T2 lesions 4 x 15 Gy over 2 weeks will be delivered. Lesions located peripherally will be treated with 3 x 20 Gy, also delivered within 2 weeks. For both schedules, there should be a minimum of 40 hours and a maximum of 8 days between 2 separate fractions. There should be a maximum of 2 fractions per week.
224160354|NCT01126281|PROCEDURE|Laparoscopic Cholecystectomy|Laparoscopic cholecystectomy
223579920|NCT02182609|DRUG|Kit for the Preparation of 99mTc-rhAnnexin V-128|Kit for the Preparation of Tc-99m Recombinant Human Annexin V-128 for Injection
223471747|NCT02354612|DRUG|Axitinib|companion therapy selection depends on companion therapy used in the parent study
223471748|NCT02354612|DRUG|Pazopanib|companion therapy selection depends on companion therapy used in the parent study
223471749|NCT02354612|DRUG|Capecitabine|companion therapy selection depends on companion therapy used in the parent study
223471750|NCT06108999|DEVICE|Connettivina BIO cream and gauze|Connettivina Bio cream and gauze-pad efficacy and tolerability will be evaluated in the management of acute or chronic wounds of different etiology, according to instruction for use. Only one wound per patient will be considered for the treatment according to the study protocol. The schedule treatment will consist on a daily medication changes, according to the instruction for use and the clinical practice, for a maximum of 7 Visits.
223471751|NCT01255215|DRUG|Inhaled Nitric Oxide|Form: Gas (inhalational) Dose: 80 ppm Dosing schedule: Continuous Treatment period: Maximum 72 hours (may be discontinued earlier if patient recovers and no longer tolerates face mask)
223471752|NCT04232839|DRUG|BI 894416 Reference Formulation|R1 - 60 milligram (6 x 10 milligram tablets) BI 894416 Reference Formulation, immediate release (IR) tablets taken orally with 240 mL of water after an overnight fast of at least 10 hours.
223471753|NCT04232839|DRUG|BI 894416 Formulation A2|T1 - One single dose of 62.5 milligram (1 tablet) BI 894416 Formulation A2, extended release (ER) tablet (fast release rate, FRR) taken orally with 240 mL of water after an overnight fast of at least 10 hours.
223579921|NCT04911712|DIETARY_SUPPLEMENT|a hospital formula of normal protein liquid diet supplementation|group 1 (control group) who will get a hospital formula of normal protein liquid diet supplementation (40 grams per 1000 mL)
224160355|NCT01822015|DRUG|Sirolimus|Given PO
223471754|NCT04232839|DRUG|BI 894416 Formulation C2|"T2 - One single dose of 62.5 milligram (1 tablet) BI 894416 Formulation C2, extended release (ER) tablet (slow release rate, SRR) taken orally with 240 mL of water after an overnight fast of at least 10 hours.~and T5 - One single dose of 62.5 milligram (1 tablet) BI 894416 Formulation C2, extended release (ER) tablet (slow release rate, SRR) taken orally with 240 mL of water following a high-fat high-calorie breakfast."
223471755|NCT04232839|DRUG|BI 894416 Formulation D2|T3 - One single dose of 62.5 milligram (1 capsule) BI 894416 Formulation D2, extended release (ER) capsule (fast release rate, FRR) taken orally with 240 mL of water after an overnight fast of at least 10 hours.
223579922|NCT04911712|DIETARY_SUPPLEMENT|a hospital formula of high protein liquid food supplementation|group 2 (intervention group) will get a hospital formula of high protein liquid food supplementation (60 grams per 1000 mL) as much as 2 bottles (each bottle contains 200 mL)
223579923|NCT05445206|DEVICE|CardioPulmonary Management Device (CPM)|CPM device is used in tangent with reference capnography device.
223579924|NCT00493636|DRUG|Gemcitabine|Gemcitabine will be administered 1000 mg/m2 pm Days 1 and 8 of a 21 day cycle
223579925|NCT00493636|DRUG|Sorafenib|Sorafenib will be administered (400 mg; 2 tablets x 200 mg) orally twice daily (approximately every 12 hours)
223579926|NCT00493636|DRUG|Placebo|Placebo will be administered (400 mg; 2 tablets x 200 mg) orally twice daily (approximately every 12 hours)
223579927|NCT00493636|DRUG|Capecitabine|Capecitabine will be administered orally at a dose of 1,000 mg/m2 twice daily, within 30 minutes after a meal, for 14 days followed by a 7 day rest period (without capecitabine).
223579928|NCT00690287|DRUG|AZD6370|Oral single doses a+b+c, o.d., suspension
223579929|NCT00690287|DRUG|AZD6370|Oral single dose, o.d., b.i.d. and q.i.d., suspension
223743839|NCT04608500|DRUG|Vehicle foam|Dosage form description: Foam containing minocycline vehicle foam. Once daily application of a sufficient amount of foam to cover the entire face. Estimated maximum is 0.5 g of drug product containing 0.0 mg (vehicle) of minocycline. Participants will apply a small amount of the drug as a thin layer over all areas of the face. Participants should apply the drug at approximately the same time each day, about 1 hour before bedtime.
224160356|NCT01822015|DRUG|Idarubicin|Given IV
224160357|NCT01822015|DRUG|Cytarabine|Given IV
224160358|NCT06310785|DRUG|Esketamine|The esketamine group used esketamine as an analgesic during induction and maintenance of anesthesia.
224160359|NCT06310785|DRUG|Sufentanil|In the opioid group, sufentanil was used as an analgesic during anesthesia induction and remifentanil was used as an analgesic during anesthesia maintenance.
224160360|NCT00602069|BEHAVIORAL|Helping to Overcome PTSD through Empowerment (HOPE)|HOPE includes a maximum of 16 sessions of cognitive behavioral therapy. The sessions will emphasize stabilization and empowerment, both of which are identified as important goals by the theoretical and empirical literature on abused women and PTSD.
223471756|NCT04232839|DRUG|BI 894416 Formulation F2|"T4 - One single dose of 62.5 milligram (1 capsule) BI 894416 Formulation F2, extended release (ER) capsule (slow release rate, SRR) taken orally with 240 mL of water after an overnight fast of at least 10 hours.~and T6 - One single dose of 62.5 milligram (1 capsule) BI 894416 Formulation F2, extended release (ER) capsule (slow release rate, SRR) taken orally with 240 mL of water following a high-fat high-calorie breakfast."
223471757|NCT03217591|DRUG|IW-1973|Oral Tablet
223471758|NCT03217591|DRUG|IW-1973|Oral Tablet
223471759|NCT03217591|DRUG|Placebo|Oral Tablet
223579930|NCT00690287|DRUG|Placebo|Placebo
223579931|NCT04336527|BEHAVIORAL|Home Treatment with Peer Support|After allocation participants receive a combination of Home Treatment by a multiprofessional team and Peer Support.
223579932|NCT04336527|BEHAVIORAL|Home Treatment without Peer Support|After allocation participants receive professional-led Home Treatment by a multiprofessional team without Peer Support (treatment as usual).
223579933|NCT06077370|DEVICE|deep TMS|Deep Transcranial magnetic stimulation on anterior Cingulate cortex and medial prefrontal cortex. 20 Hz.
223743840|NCT00263146|PROCEDURE|recruitment maneuver|
224160361|NCT00602069|BEHAVIORAL|Treatment as usual|Treatment as usual includes standard shelter services for abused women.
224160362|NCT01119963|DRUG|17-alpha-hydroxy-progesterone caproate, Makena®|Intramuscular (IM) injection of 17P,Makena® (250mg) beginning as early as 23w0d administered weekly until 34w0d, documented fetal lung maturity at 32w0d - 33w6d, or delivery which ever comes first.
224160363|NCT01119963|DRUG|Castor Oil (Placebo)|IM injections of Placebo (castor oil) beginning as early as 23w0d administered weekly until 34w0d, documented fetal lung maturity at 32w0d - 33w6d, or delivery which ever comes first.
224069243|NCT02564315|BEHAVIORAL|Preparation Phase Behavioral Reduction Counseling|Participants randomized to receive this treatment receive manual-based counseling calls and visits over the course of 11 months. The ultimate goal will be smoking that is reduced in amount and location. Case managers and participants will collaboratively identify a set of steps to progressively reduce smoking. The primary vehicles for change are to encourage substitution of the nicotine mini-lozenge for cigarettes and to reduce the contexts in which smoking occurs. Counseling will counter post-lapse demoralization by emphasizing participants' progress, the value of smoking reduction as a transitional goal, and the critical value of ongoing treatment engagement. Evidence of progress in reduction of smoking, and smoking contexts will be used to build self-efficacy.
224069244|NCT02564315|BEHAVIORAL|Preparation Phase Recycling Counseling|Participants randomized to receive this treatment condition will be encouraged to commit to a new quit date as soon as they feel ready. In the counseling sessions, participants will be encouraged to discuss reasons for and concerns about quitting as well as barriers to setting a quit date.
223471760|NCT05324306|DEVICE|combat application tourniquets (CAT)|"CAT tourniquets have been indicated for use in emergency situations revolving around a wounded limb, such as hemorrhage control.22-23 CAT tourniquets are the official tourniquet of the US Army since in 2005.~We will deploy well-studied and FDA approved combat application tourniquets (CAT) on both thighs of volunteer healthy adult subjects while measuring blood pressure in the upper extremities."
223471761|NCT00244049|BEHAVIORAL|counseling|Physicians discussed high-risk/binge drinking with college-aged individuals in a health care setting.
223471762|NCT00244049|OTHER|Brief Intervention|Physicians discussed effects of high-risk/binge drinking with college-aged individuals in a health care setting.
223471763|NCT02313051|DRUG|Everolimus|mTOR inhibitor
223471764|NCT02313051|DRUG|Goserelin|
223471765|NCT02313051|DRUG|Letrozole|
223471766|NCT04332263|OTHER|Neuromuscular Electrical Stimulation - NMES|NMES will be applied through an alternating biphasic current, with a stimulation frequency of 80 Hz and 1 ms pulse duration. Tetanic evoke forces (EF) at a 50% level of a supra-maximal single-pulse peak EF (i.e., 10-12% of a maximal voluntary isometric contraction) will be used. NMES protocol will be performed five times a week, lasting 20 minutes. Muscle fatigue will be evaluated every 5 min of the intervention, and will be used to determine the NMES protocol termination. A 10 % decrease in the single-pulse evoked torque between the evoked force produced pre- and during the NMES protocol will be used to terminate the fatigue protocol.
223471767|NCT05444816|DEVICE|Personalised Neurofeedback training at home|"The already available Brain Hero® EEG device will be mailed to the subject's home, along with clear video instructions regarding its use (within the app), as previously established in a beta usability study with optimal results.~All game training will take place at home, while the caregivers of patients will receive instructions either online or telephonically from the investigating team. The team is also ready with tips and tricks to keep the child motivated and facilitate the flight of the game hero in the direction of interest.~Patients will be instructed to play a minimum of 20 min for four times a week, under supervision by their caregiver(s). Patients will be provided with a training plan, including all planned months of training and advanced examinations. Instructions will also be provided, verbally and written, and the investigating team will engage in video sessions or direct meetings with the parents to make sure all instructions are properly followed."
223579934|NCT06077370|DEVICE|Sham TMS|Sham Transcranial magnetic stimulation on anterior Cingulate cortex and medial prefrontal cortex. 20 Hz.
223579935|NCT01893359|DRUG|riboflavin ophthalmic solution, 0% dextran|
223579936|NCT01893359|DEVICE|UVA Irradiation (30 mW/cm2 for 2 minutes continuous UVA)|
223579937|NCT01893359|DEVICE|UVA Irradiation (30 mW/cm2 for 3 minutes pulsed UVA with an on/off cycle of 2 seconds UVA on/1 second UVA off)|
223579938|NCT01893359|PROCEDURE|Laser-assisted in situ keratomileusis|
223579939|NCT01394887|DRUG|Metformin|850 mg of metformin twice daily over 12 weeks
223471768|NCT00159315|PROCEDURE|Inhalation Challenge with ATP|
223743841|NCT00542919|DRUG|enzastaurin|1125 mg loading dose then 500 mg, oral, daily until progressive disease
223743842|NCT00655967|DRUG|Acamprosate (Campral)|"During the course of the study patients will be supplied with 333mg tablets of acamprosate provided by the Sponsor. The study medication will be administered at a dose of 666mg (=two tablets) three times a day for patients with a creatinine clearance \>50. The dose will be 333mg three times a day for patients with a creatinine clearance in the range of 30-50.~Treatment compliance will be monitored by counts of returned medication. Records of all concomitant medications will be taken at each study visit as well as reports of adverse events (as shown above)."
223743843|NCT00655967|DRUG|Acamprosate|During the course of the study patients will be supplied with 333mg tablets of acamprosate provided by the Sponsor. The study medication will be administered at a dose of 666mg (=two tablets) three times a day for patients with a creatinine clearance \>50. The dose will be 333mg three times a day for patients with a creatinine clearance in the range of 30-50.
224069245|NCT02564315|BEHAVIORAL|Preparation Phase Control Treatment|Participants randomly assigned to the Preparation Phase Control Treatment condition will continue to receive the Initial Cessation usual care treatment (8 weeks of nicotine patch; two coaching sessions), but will also be told that they can receive additional treatment at no cost from the Wisconsin Tobacco Quitline (WTQL).
224160364|NCT05373316|RADIATION|Ultrahypofractionated MR-guided radiotherapy boost|External beam MR-guided (MR-linac) radiotherapy to the prostate and seminal vesicles of 5x7Gy (once weekly) with an isotoxic integrated focal boost up to 50Gy to the intraprostatic tumor as visible on multiparametric MRI.
223471769|NCT00159315|PROCEDURE|Inhalation Challenge with AMP|
223579940|NCT01394887|DRUG|placebo|850 mg gel capsules with starch (6.8 calories)as placebo
223579941|NCT01109771|DEVICE|permanent mesh fixation|Permanent mesh fixation will be used.
223579942|NCT01109771|DEVICE|absorbable mesh fixation|Absorbable mesh fixation will be used.
223579943|NCT00201123|DRUG|Aerosol Interferon-Gamma|Participants will receive aerosol interferon-gamma.
223579944|NCT00201123|DRUG|Subcutaneous interferon-gamma|Patients will receive subcutaneous interferon-gamma
223579945|NCT00201123|OTHER|Placebo|
223579946|NCT04275609|OTHER|AI generated report|After the endoscopic procedure, the physicians click the structured reporting button of computer to automatically complete the report through the structured diagnostic report generation system. The physicians only make minor corrections to the report.
224160365|NCT02278224|BEHAVIORAL|Group based rumination focused CBT|The RFCBT is a group trans-diagnostic manual based psychotherapy for depression and anxiety. RFCBT focuses on increasing effective behaviour - i.e., not stopping rumination but making it functional. It's grounded within the core principles and techniques of CBT for depression with two adaptations: (1) a functional-analytical perspective using Behavioural Activation (BA) approaches, (2) an explicit focus on shifting processing style via imagery and experiential approaches.
223471770|NCT03962621|RADIATION|Fotona 4D 1064 nm laser|The 1064 nm laser can penetrate deep into the skin to explode pigment particles, destroy blood vessels and heat the dermal collagen by targeting melanin and haemoglobin.(1) Frac3®: 30-35 J/cm2, 1.6 ms pulse width, 4mm spot size, unilaterally accumulated 2000 shots; and (2) PIANO®: 160 J/cm2, 5s pulse width, spot size 9mm, unilaterally accumulated 20000 shots, to increase and maintain facial skin temperature to 39-40oC.
224160366|NCT02278224|BEHAVIORAL|Group based CBT|The control group is gold standard group based CBT based on Becks manual for CBT for depression.
224160367|NCT05515445|DRUG|Chiglitazar|Oral single dose 48 mg
223471771|NCT03962621|RADIATION|Fotona 4D 2940 nm laser|Er:YAG 2940nm have been considered as a good treatment of facial aging, especially in wrinkles.(1) Smooth®: 9-10 J/cm2, 7mm spot size, which is sequentially delivered to upper and lower labial mucosa and buccal mucosa to unilaterally accumulate 5000 shots; (2) SupErficial™: 0.5-1.0 J/cm2, 7mm spot size, a single pass
223471772|NCT01705938|DRUG|SP-333|
223471773|NCT03830268|DIETARY_SUPPLEMENT|No MCT intake with breakfast, no lunch|Water given with a regular standardize breakfast and water given at noon without lunch.
223471774|NCT03830268|DIETARY_SUPPLEMENT|No MCT intake with lunch, no breakfast|Water given in the beginning of the metabolic study day without breakfast and water given at noon with a regular standardize lunch.
223471775|NCT03830268|DIETARY_SUPPLEMENT|10g of Betaquik|BQ10 given with a regular standardize breakfast and BQ10 given at noon without lunch.
223471776|NCT03830268|DIETARY_SUPPLEMENT|10g of Betaquik with low-carbs breakfast|BQ10 given with a low-carbs standardize breakfast and BQ10 given at noon without lunch.
223471777|NCT03830268|DIETARY_SUPPLEMENT|20g of Betaquik|BQ20 given with a regular standardize breakfast and BQ20 given at noon without lunch.
223471778|NCT03830268|DIETARY_SUPPLEMENT|10g of Betaquik with lunch, no breakfast|BQ10 given in the beginning of the metabolic study day without breakfast and BQ10 given at noon with a regular standardize lunch.
223471779|NCT02806440|DRUG|Low dose naltrexone|Active comparator
223471780|NCT02806440|DRUG|Placebo|Placebo comparator
224160368|NCT04737161|BIOLOGICAL|T regulatory cells|T regulatory cells isolated by immunomagnetic selection; donor cells collected through large volume apheresis.
223471781|NCT05927532|DEVICE|Argyle Safety Fistula Cannula with Anti-Reflux Valve|The Argyle Safety Fistula Cannula with Anti-reflux Valve will be used 3x a week for 12 weeks in subjects with an arteriovenous fistulae (AVF) fistula
223471782|NCT03707834|BEHAVIORAL|Antenatal Obesity Treatment (AO)|Participants in the treatment (AO) arm will receive a 4-component intervention: 1)Behavior change goals; 2)Self-monitoring; 3)Tailored skills training; and 4)WIC provider counseling Both treatment and usual care arms will receive the current standard of care offered to postpartum mothers at WIC.
223471783|NCT00914134|DRUG|Levodopa infusion|Naso-duodenal infusion line is inserted in fluoroscopy control. Levodopa infusion is then tested approximately 5 days. If patient responds favorably to the treatment, PEG-infusion line is inserted in gastroscopy control and patient is followed in hospital for 2 to 4 days to ensure stability of the infusion line. The dosage is individually adjusted, starting dose is estimated from earlier oral levodopa dose.
223471784|NCT00714974|DEVICE|BIS|Sedation dosing based on BIS value, oer treating physician discretion.
223471785|NCT03718715|DRUG|Metformin|Receiving Metformin is no study intervention. The investigators have no influence on the Metformin treatment. All participants receive Metformin provided by the health care system. The individual case determine dose and frequency of the treatment as part of the usual therapy guidelines.
223471786|NCT05916898|DEVICE|PCI with support of Shockwave Intravascular Lithotripsy|Coronary artery angioplasty of the primary lesion or optimization of the previously implanted stent with the support of Shockwave Intravascular Lithotripsy device
223471787|NCT02610517|BEHAVIORAL|Provider Training|All providers will receive an online survey about alcohol pharmacotherapy, and an on-site training on alcohol pharmacotherapy will be offered at UAB and UW. The training will cover the most commonly prescribed alcohol pharmacotherapy. Some medications (ex: Zofran) have been used clinically for alcohol pharmacotherapy but have not yet received FDA approval for this indication. Research has shown these medications are beneficial as alcohol pharmacotherapy and are more frequently used by doctors due to the more favorable side effects. Providers in this study will use their clinical judgment in prescribing alcohol medications per their normal standard of care and using any new information gained from the alcohol pharmacotherapy training.
223579947|NCT04275609|OTHER|physicians writing report|After the endoscopic procedure, the physicians writing the report in computer according the procedure.
223579948|NCT05504668|DIETARY_SUPPLEMENT|Turmeric Brainwave|A multiingredient herbal supplement with Turmeric as its most abundant single ingredient.
223579949|NCT00078065|DRUG|Xcellerated T Cells|
223579950|NCT03947528|DRUG|Sarpogrelate HCL 300mg|a single oral dose administration in healthy volunteers under fed condition
223579951|NCT00987493|BIOLOGICAL|rituximab|day 1 at a fixed dose of 375mg/m2
223579952|NCT00987493|DRUG|bendamustine hydrochloride|Bendamustine at day 1 and 2 according to the dose escalation in phase I, and at the recommended dose in phase II: 70mg/m2.
224160369|NCT03272971|DEVICE|Radio-frequency Ablation|The intervention consists of a bronchoscopic approach to ablate lung tumors with radiofrequency.
224160370|NCT03835988|DEVICE|Geniculate Artery Embolization|Embolization is a procedure completed by an Interventional Radiologist in which abnormal blood vessels are blocked for treatment purposes. In the case of geniculate artery embolization, abnormal blood vessels which supply your knee joint are blocked in an effort to reduce inflammation and subsequently and reduce pain and improve joint function.
224160371|NCT03304652|DRUG|Zaleplon|Sleep Aid; 10mg; Oral; Single Use
224160372|NCT03304652|OTHER|Natural Sleep|Natural Sleep without medication
223471788|NCT02610517|BEHAVIORAL|Patient Intervention|Eligible participants will be screened using the Audit and Mini instruments that are routinely asked during regular clinic visits. Once a participant consents, they will be shown 2 computerized brief interventions (CBIs) - one after enrollment (visit 1) and one 3-6 months after enrollment (visit 2). Participants will interact with the touch-screen computer via Peedy the Parrot, a three dimensional animated character. The intervention emphasizes personal responsibility for change, uses empathy as a counseling style, and enhances self-efficacy. At the end of both visits, patients will complete a patient satisfaction survey with questions related to ease of use of CBI and satisfaction with program content. Providers will have the opportunity to prescribe pharmacotherapy at visit 1 and 2.
223579953|NCT00987493|DRUG|lenalidomide|Lenalidomide at days 1-21 according to the dose escalation in phase I, and at the recommended dose in phase II: 10mg
223579954|NCT00215514|DRUG|Epirubicin|Epirubicin (Day 1), Cisplatin (Day 1), 5-FU (Days 1-21)--\> One-week rest --\> External Beam Radiation Therapy plus 5-FU CI --\> Four-week rest --\> Epirubicin (Day 1), Cisplatin (Day 1), 5-FU (Days 1-21)--\> Epirubicin (Day 1), Cisplatin (Day 1), 5-FU (Days 1-21).
223579955|NCT00215514|DRUG|Cisplatin|Epirubicin (Day 1), Cisplatin (Day 1), 5-FU (Days 1-21)--\> One-week rest --\> External Beam Radiation Therapy plus 5-FU CI --\> Four-week rest --\> Epirubicin (Day 1), Cisplatin (Day 1), 5-FU (Days 1-21)--\> Epirubicin (Day 1), Cisplatin (Day 1), 5-FU (Days 1-21).
223579956|NCT00215514|DRUG|5-Fluorouracil (5-FU)|Epirubicin (Day 1), Cisplatin (Day 1), 5-FU (Days 1-21)--\> One-week rest --\> External Beam Radiation Therapy plus 5-FU CI --\> Four-week rest --\> Epirubicin (Day 1), Cisplatin (Day 1), 5-FU (Days 1-21)--\> Epirubicin (Day 1), Cisplatin (Day 1), 5-FU (Days 1-21).
223579957|NCT00215514|PROCEDURE|Radiation|Epirubicin (Day 1), Cisplatin (Day 1), 5-FU (Days 1-21)--\> One-week rest --\> External Beam Radiation Therapy plus 5-FU CI --\> Four-week rest --\> Epirubicin (Day 1), Cisplatin (Day 1), 5-FU (Days 1-21)--\> Epirubicin (Day 1), Cisplatin (Day 1), 5-FU (Days 1-21).
223579958|NCT01341626|BEHAVIORAL|Treatment Foster Care (TFCO)|Youth placed individually in well-trained and supervised foster homes. Basic components: (a) daily telephone contact with TFCO parents; (b) weekly foster parent group meetings focused on supervision, training in parenting practices, and support; (c) an individualized behavior management program implemented daily in the home by foster parent; (d) individualized skills training for the youth; (e) family therapy for aftercare family focused on parent management strategies; (f) close monitoring of school attendance, performance, and homework completion; (g) case management to coordinate TFCO, family, peer, and school settings; (h) 24-hour on-call staff availability to TFCO and biological parents; and (i) psychiatric consultation. Services typically last approximately 6 months.
224160373|NCT06329713|PROCEDURE|Group I: 30 Min Interval Time|10 ml of a solution containing 0,1% of bupivacaine and 2 mcg/ml fentanyl through the epidural cathether, maintained by programmed intermittant epidural (PIE) boluses of 7,5 ml of the same solution once in every 30 minutes, starting 1 hour after the loading dose. patient controlled epidural analgesia (PCEA) will be programmed so that 8 ml of the same solution with a lock-time of 15 minuts may be administered
223471789|NCT02260960|DIETARY_SUPPLEMENT|Omega-3 (Triglyceride form)|
223471790|NCT02374320|DRUG|liposomal bupivacaine|injected as an axillary block
223471791|NCT06835556|BEHAVIORAL|Cognitive Behavioral Therapy|Individuals will be assessed for which psychological factors are maintaining paranoia in their daily lives. They will collaboratively identify one maintenance factor to focus on (e.g. worry, anomalous experience, self-confidence, PTSD) for 8 weeks of individual therapy. Then, all participants will transition to 8 weeks of individual therapy focused on dropping safety behaviors and re-engaging in everyday life.
223471792|NCT06835556|BEHAVIORAL|TAU|Individuals will continue treatment as usual (TAU). In addition they will have contact with a study therapist weekly via phone to provide information on what treatment they received. Phone check-ins will last approximately 5-10 minutes.
223471793|NCT03991533|OTHER|multiparametric MRI|preoperative multiparametric MRI
223579959|NCT01341626|BEHAVIORAL|Group Care|Group Care is the usual service for youth placed in out-of-home care for chronic delinquency in Oregon. These programs represented typical services for girls being referred to out-of-home care by the juvenile justice system and had 2-51 youth in residence (M = 21) and 1-50 staff members (Mdn = 2); most also had onsite schooling. Although the programs differed somewhat in theoretical orientations, 86% reported that they endorsed a specific treatment model, of which the primary philosophy was a behavioral (70%), eclectic (26%), or family-style therapeutic approach (4%). Services typically last approximately 6 months.
224160374|NCT06329713|PROCEDURE|Group II: 60 Min Interval Time|10 ml of a solution containing 0,1% of bupivacaine and 2 mcg/ml fentanyl through the epidural cathether, maintained by programmed intermittant epidural (PIE) boluses of 15 ml of the same solution once in every hour, starting 1 hour after the loading dose. patient controlled epidural analgesia (PCEA) will be programme
224160375|NCT00236613|DRUG|topiramate|
224160376|NCT02532413|DRUG|Poly IC|Poly IC can induce innate immune responses.It may enhance the antiviral efficacy of Entecavir.
224160377|NCT02532413|DRUG|Entecavir|Entecavir can inhibit the replication of HBV.
224160378|NCT05194215|DEVICE|Ada WRA|The Ada WRA is a study-only device based on the Ada mobile app. The patient will use this device to answer questions regarding their symptoms but will not be given any feedback by the app.
223471794|NCT02357459|DRUG|FX006|Single 5 mL IA injection
223471795|NCT02357459|DRUG|Placebo|Single 5 mL IA injection
223471796|NCT02357459|DRUG|TCA IR 40|Single 1 mL IA injection
223471797|NCT04025216|BIOLOGICAL|CART-TnMUC1|Single intravenous administration of genetically modified autologous T cells engineered to express a TnMUC1-Targeted Genetically-Modified Chimeric Antigen (CAR)
223471798|NCT04025216|DRUG|Cyclophosphamide|Patients will receive cyclophosphamide and fludarabine lymphodepletion chemotherapy followed by the investigational product, CART-TnMUC1
223471799|NCT04025216|DRUG|Fludarabine|Patients will receive cyclophosphamide and fludarabine lymphodepletion chemotherapy followed by the investigational product, CART-TnMUC1
223471800|NCT05162456|DIAGNOSTIC_TEST|assessment of the anti-SARS-CoV-2 IgG antibody titer in 3-dose schedule|evaluation of anti-SARS-CoV-2 IgG antibodies in patients after 2-dose vaccination schedule willing to receive a 3rd dose of vaccine
223471801|NCT05162456|DIAGNOSTIC_TEST|assessment of the anti-SARS-CoV-2 IgG antibody titer in 2-dose schedule|evaluation of anti-SARS-CoV-2 IgG antibodies in patients after 2-dose vaccination schedule unwilling to receive a 3rd dose of vaccine
224069246|NCT02564315|BEHAVIORAL|Cessation Phase Supportive Counseling|Supportive Counseling will be consistent with the Public Health Service (PHS) Clinical Practice Guideline (Fiore et al., 2008) and will involve encouragement, a focus on short-term goals, discussion of participant values (what the participant feels would be good and healthy for them in the long run) and how these values are congruent with cessation, emphasis on the patient and the counselor being a team, encouragement for the participant to generate a quitting strategy with the message that smokers often have a good sense of what will work for them, and prompts for the participant to explore his/her feelings about quitting and feelings of optimism and concern (i.e., to use the counselor as a sounding board).
224069247|NCT02564315|BEHAVIORAL|Cessation Phase Skill Training Counseling|"Skill training Counseling will: 1) carefully assess smoking cue contexts and opportunities to smoke, to identify problems encountered in the prior quit attempt; 2) develop specific plans for avoiding such contexts and identify skills for coping with them; 3) develop plans for negotiating with others who smoke; 4) develop lifestyle changes to reduce future smoking opportunities and contexts; and 5) assign homework and assess execution of assigned skills. Participants will receive coping menus that provide personalized coping/avoidance options and coping reports that assess coping execution over time and troublesome contexts and cues around which counseling will be focused. There will be praise for any progress and a collaborative determination of barriers to skill execution."
223471802|NCT05112978|DIAGNOSTIC_TEST|MRI|MRI genu non contrast
223471803|NCT03136575|BEHAVIORAL|Qigong|a 30 minutes exercise program, 3 times a week and lasts for 6 weeks during radiotherapy course
223471804|NCT03136575|BEHAVIORAL|Wait-list control|patients enrolled in this group are informed orally to have exercise only and are arranged in a waiting list
223471805|NCT01548599|OTHER|Multi-sectoral agricultural intervention|Participants in the intervention arm will receive a micro-finance loan and training on financial management and marketing skills. With the loan, each participant will receive vouchers to purchase the following items: the Money Maker hip pump, 50 feet of hosing, fertilizer, and government certified seeds. Participants in the intervention group will also receive training on the use of the Money Maker hip pump, a portable, low-cost, human-powered water pump developed by KickStart. Participants in the intervention group will also receive training from Kickstart on the use of the pump as well as complementary training in best horticultural practices.
224069248|NCT02564315|BEHAVIORAL|Cessation Phase Brief Information|Participants randomized to receive Brief Information will receive brief (generic) information about the importance of taking the cessation medication, how to use the medication, information about side effects/safety, and what to do in case of problems, and will also be given encouragement to quit smoking.
224069249|NCT02564315|DRUG|Cessation Phase Nicotine Patch + Nicotine Mini-Lozenge|All participants will receive 8-weeks of combination NRT (nicotine patch + nicotine mini-lozenge). Nicotine patch dosing will be based on current cigarettes smoked per day, per package insert: for those who currently smoke \>10 cigs/day=4 weeks of 21 mg, 2 weeks of 14 mg, and 2 weeks of 7 mg nicotine patches, along with nicotine mini-lozenges; for those who currently smoke \<=10 cigs/day=6 weeks of 14 mg and 2 weeks of 7 mg nicotine patches along with mini-lozenges. Mini-lozenge dosing will be based on how soon participants currently smoke after waking before their initial quit attempt and will be consistent with the package insert (4 mg for participants who smoke within 30 minutes of waking and 2 mg for participants smoke more than 30 minutes after waking).
224069250|NCT03325673|DEVICE|TrueTear|TrueTear Device (Intranasal Tear Neurostimulator) was used intranasally on CL wear days; it was also used on non-CL wear days if the participant chose. The number of applications was determined by participant.
223471806|NCT03310567|DRUG|Epacadostat + pembrolizumab|Each patient would be administered epacadostat orally twice a day and pembroluzimab by infusion once in a cycle of 21 days
223471807|NCT04394325|BEHAVIORAL|Digital information tool|The patients randomized to group A will receive verbal and written information regarding the digital information tool and how to use it, as well as verbal and written information about the study. They will also receive information about the different instruments and surveys they will be asked to answer at different occasions during the RT treatment period. The applied instruments for data collection will be administrated in person or by post at the baseline collection and by post (including pre-paid return envelope) on consecutive collections. Approximately 30 patients (in group A) will be asked to make regular notes in a notebook during the waiting period prior start of RT as well as during RT treatment period. Following completion of the RT treatment period individual in-depth and telephone interviews will take place with 10-12 patients that accept participation.
223471808|NCT01474343|GENETIC|SAF-301|The treatment plan consists on a direct injection of the investigational medicinal product SAF-301 to both sides of the brain through 6 image-guided tracks, with 2 deposits per track, in a single neurosurgical session.
223471809|NCT00453908|DRUG|Alfuzosin|
223471810|NCT05630196|DRUG|LY3857210|Administered orally
223471811|NCT05630196|DRUG|Placebo|Administered orally
223471812|NCT05258552|PROCEDURE|enema|preoperative enema
223471813|NCT00976365|DIETARY_SUPPLEMENT|THL-P|20ml/bottle, TID, 24weeks
223471814|NCT03438266|DEVICE|JUVÉDERM VOLUMA® XC injectable gel with cannula|Participants had 1 cheek treated with JUVÉDERM VOLUMA® XC injectable gel with cannula.
223471815|NCT03438266|DEVICE|JUVÉDERM VOLUMA® XC injectable gel with needle|Participants had 1 cheek treated with JUVÉDERM VOLUMA® XC injectable gel with a needle.
223471816|NCT00878865|DRUG|Alprazolam|1 mg tablet one oral dose
223471817|NCT00878865|DRUG|Alprazolam|1 mg tablet
223471818|NCT00352118|BIOLOGICAL|filgrastim|subcutaneously on Days 5-14, repeating every 3 weeks for 2 courses.
223471819|NCT00352118|BIOLOGICAL|pegfilgrastim|If applicable on day 5, repeating every 3 weeks for 2 courses.
223471820|NCT00352118|DRUG|cisplatin|Intravenous over 1 hour on day 1, every 3 weeks for 3 courses.
223471821|NCT00352118|DRUG|docetaxel|Intravenous over 1 hour on day 1.
223471822|NCT00352118|DRUG|fluorouracil|Intravenous continuously on days 1-4.
223471823|NCT00352118|PROCEDURE|conventional surgery|As appropriate, neck dissection.
223471824|NCT00352118|RADIATION|radiation therapy|60 Gy 5 days/week x 6 weeks with cisplatin
223471825|NCT05320471|OTHER|This is an observational study|This is an observational study
223579960|NCT05589883|BEHAVIORAL|EMPOWER-Latinx|EMPOWER-Latinx will be delivered in Spanish by videoconferencing (i.e., Zoom, WebEx) with a trained study interventionist. Intervention modules will be audio- and video-recorded (videorecording optional).
223471826|NCT00276302|DRUG|IPI-504|"IV administration of IPI-504 for 21-day cycles. Two different schedules of treatment will be tested. On Schedule A, doses occur on Days 1, 4, 8, and 11 followed by 10 days with no study drug administration. On Schedule B, doses occur on Days 1, 4, 8, 11, 15, and 18, or twice weekly for 3 weeks continuously.~For both Schedule A and B doses will be administered ≥ 72 hours apart."
223471827|NCT00613795|DIETARY_SUPPLEMENT|Lactobacillus GG|Every 12 hours, the contents of a single capsule containing Lactobacillus GG will be suspended in 3 ml of water-soluble jelly. The suspension will be applied to the oropharyngeal mucosa via sterile syringe. The contents of a second capsule will be suspended in 10 ml of sterile water and pushed through the NG tub followed by 10 mL of air to ensure complete administration.
223471828|NCT00613795|DIETARY_SUPPLEMENT|placebo|Every 12 hours, the contents of a single identical placebo capsule containing the inert plant carbohydrate inulin will be suspended in 3 ml of water-soluble jelly. This suspension will be applied to the oropharyngeal mucosa via sterile syringe. The contents of a second placebo capsule will be suspended in 10 ml of sterile water and pushed through eh NG tube followed by 10 mL of air to ensure complete administration
223579961|NCT00600769|DRUG|Clarithromycin|Dosage dependent on clinical factors such as age, weight and patient-specific health status
223579962|NCT02541136|BEHAVIORAL|Aerobic Exercise|"Each exercise class consisted of a warm-up, an aerobic and a cool-down phase, supervised by a physiotherapist. The warm up and cool down phases consisted of 5-7 minutes of low intensity aerobic exercise, \< 40% Heart Rate Reserve (HHR), to allow the cardiopulmonary and musculoskeletal systems to adapt and recover, respectively.~The aerobic component initially consisted of 21 minutes at an intensity of 40-59% HRR and was progressed to 42 minutes at 55-75% HRR by week 8 until programme completion. All participants worked at the same intensity and duration at the various time points throughout the study. Continuous, rhythmic exercise using large muscle groups was prescribed using treadmills, cycle ergometers and other aerobic exercise that increased heart rate to its prescribed level."
223579963|NCT04287686|DRUG|Recombinant human angiotensin-converting enzyme 2 (rhACE2)|In this study, the experimental group will receive 0.4 mg/kg rhACE2 IV BID for 7 days.
223579964|NCT01521910|DIETARY_SUPPLEMENT|low protein diet|"An iso-caloric low protein diet of 0.6 g/kg/day was prescribed during the whole study duration.~The same dietician gave nutritional advices at least every three months during the whole study period. Patients were also seen by the same doctor during each visit for the whole study period.~Supplementation of Calcium of 500mg/day.~Urine albumin losses \>= 2 g/day wre replaced by increasing dietary protein on a gram-for-gram basis, only if the patient was compliant with the prescribed low-protein diet."
223579965|NCT01521910|DIETARY_SUPPLEMENT|normal protein diet|"The patients pre-study diet during the whole study period~Patients were also seen by the same doctor during each visit for the whole study period."
223579966|NCT05462808|DRUG|High viscosity glass ionomer cement|High viscosity glass ionomer cement
223579967|NCT05462808|DEVICE|Stainless steel crown|Stainless steel crown
223579968|NCT05094817|OTHER|Brain Health Assessment|BHA is a free, self-administered online cognitive screening test developed in Toronto at Baycrest (www.cogniciti.com). BHA has been validated against a gold standard neuropsychological assessment for detecting amnestic MCI (aMCI) - the most common type of MCI - in community dwelling older adults. BHA has high sensitivity (.78), specificity (.78), PPV (.82), NPV (.74), and was better than MoCA for identifying aMCI. ROC curves showed an AUC of 0.75 for detecting aMCI from normal subjects. BHA measures memory and executive attention processes sensitive to subtle cognitive changes associated with normal aging and MCI. BHA can be completed from a patient's home or can be self-administered in hospital.
223579969|NCT05094817|OTHER|Demographics questionnaire|To compare the sociodemographic characteristics of patients completing Cogniciti's BHA vs. those who are not able to complete the BHA.
223579970|NCT05094817|OTHER|PHQ-2|PHQ-2 is a shortened version of PHQ-9 which is originally a component of the longer Patient Health Questionnaire. The tool incorporates DSM-IV depression criteria and other leading major depressive symptoms into brief self-reported instruments. PHQ-2 inquires about the degree to which an individual experiences depression and anhedonia (inability to feel pleasure) over the past two weeks. The tool is not for final diagnosis of depression or monitoring its severity but only for the purpose of screening for the condition.The questionnaire comprises of the first two questions from PHQ-9, each item is scored 0-3. Therefore, the PHQ-2 score ranges from 0-6.
223579971|NCT05094817|OTHER|AFT|AFT is a free, rapid cognitive assessment commonly used to assess semantic language ability. Language is one of the earliest functions affected by AD and naming and semantical knowledge seems to be particularly affected. The identification of language deficits may pick up signs of neurological decline preceding the appearance of clinical symptoms. Milder forms of cognitive impairment such as MCI may also show language deficits if language is one of the domains affected.
223743844|NCT02670655|DRUG|lidocaine/prilocaine (5%) application|For AFL pre-treatment, lidocaine/prilocaine (5%) cream (EMLA; Astra Pharmaceuticals, LP, Westborough, MA, USA) was applied to the treatment area under occlusion for 30 min
224069251|NCT03325673|DEVICE|TrueTear Sham Control|TrueTear sham device, which is not electrically active and has limited tip insertion depth, was used intranasally on CL wear days; it was also used on non-CL wear days if participant chose. The number of applications was determined by participant.
224069252|NCT03678805|PROCEDURE|Corticotomy|Perforations in the areas close to the impacted canines will be performed in order to accelerate tooth movement.
224069253|NCT03678805|PROCEDURE|Traditional withdrawal techniques|The impacted canines will be withdrawn using elastic modules.
224069254|NCT04002011|DRUG|Warfarin|It will be started on postoperative day 1 or later when oral anticoagulation is secondary indicated. Daily dose will be adapted to obtain an international normalized ratio of \[2.0-3.0\]. Other anticoagulants will be not administrated.
223471829|NCT02990000|BEHAVIORAL|Scientific Match|We have developed an innovative, personalized Match System based on provider track records determined with a multidimensional outcomes tool - the Treatment Outcome Package (TOP). Specifically, patients are assigned to therapists with previously established strengths (i.e., being historically effective) in treating their primary problems (e.g., depression, anxiety).
223471830|NCT06391411|DIETARY_SUPPLEMENT|a micronutrient mix containing lutein (10 mg), zeaxanthin (2 mg), saffron (20 mg), vitamin C (80 mg), vitamin E (12 mg) and zinc (10mg)|In this three-arm randomized, controlled trial, with one arm represented by healthy subjects, eligible participants were randomly divided into two groups. Fifteen patients were randomly allocated to the intervention group and received, for 6 months, intravitreal injections of anti-VEGF (Aflibercept 2 mg, 0.05 ml) at a fixed regimen and daily supplementation with a micronutrient mix containing lutein (10 mg), zeaxanthin (2 mg), saffron (20 mg), vitamin C (80 mg), vitamin E (12 mg) and zinc (10mg). The other fifteen patients was assigned to the control group and only received the intravitreal anti-VEGF treatment at a fixed regimen for 6 months
223471831|NCT06391411|DRUG|anti-VEGF treatment|Intravitreal injections of anti-VEGF (Aflibercept 2 mg, 0.05 ml) at a fixed regimen for six months
223471832|NCT01966783|DRUG|Budesonide 2 mg suppository|per day
223471833|NCT01966783|DRUG|Budesonide 4 mg suppository|per day
223471834|NCT01966783|DRUG|Mesalazine 1 g suppository|per day
223471835|NCT01966783|DRUG|Budesonide 2 mg suppository/Mesalazine 1 g suppository|per day
223471836|NCT00108446|DRUG|dextromethorphan|
223471837|NCT00108446|DRUG|naloxone|
223579972|NCT05094817|OTHER|GAI-SF|GAI-SF is a 5-item questionnaire derived from the original 20-item Geriatric Anxiety Inventory (GAI).In the population of community dwelling older women GAI-SF was developed in, a cut-off score of 3 yields a specificity of 87% and sensitivity of 75%. This highly accessible questionnaire is suitable for everyday use in a range of health-care settings. It has been employed amongst older adults in primary care settings, nursing homes, geriatric psychiatry patients and amongst clinical geriatric participants with co-morbid anxiety and unipolar mood disorder and their controls.
224069255|NCT04002011|DRUG|Dabigatran|It will be started when patients will be discharged from our center. Our pharmacist referent will validated the drug and its daily dose. Other anticoagulants will be not administrated.
224160379|NCT06086782|OTHER|autogenic inhibition|Group 1 will receive AI-MET with conventional treatment. AI include stretching of the affected muscle and performing isometric contraction with 50% of the total patient's effort in the same muscle that will being stretched and position hold for 10 seconds, with 5 seconds of rest after every repetition. This procedure will repeat 5 times.
223471838|NCT00108446|DRUG|fentanyl|
223471839|NCT00108446|DRUG|lidocaine|
223471840|NCT02308046|DRUG|Terconazole|
223471841|NCT02308046|DRUG|Placebo|
223471842|NCT05497752|OTHER|cervical rehabilitation program|"(Positional release technique on trapezius muscle): The subject was supine The therapist applied Pressure by pinching the trapezius muscle between the thumb and fingers.~Suboccipital muscle release):~The patient will be in a Supine lying position therapist places both his palms at suboccipital region with upward pressure causing a stretch and distraction for 30 seconds. This technique was performed 3 times in one session with a rest interval of 1 minute after each time.~(Stretching of pectoralis muscle):. once daily Stretching with repetition of five, three times a day for 1week"
223471843|NCT05497752|OTHER|control group|Relax shoulders and neck sufficiently look down turn face to the right turn face to the left incline head to the right incline head to the left turn shoulders round and round slowly raise hands fully then lower them. patients were asked to perform five repetitions of each stretching exercise, three times per day (morning, afternoon, and evening).
223471844|NCT05658939|OTHER|Phone/Internet survey|A questionnaire about the current symptoms and satisfaction for received treatment will be conducted over the phone/internet for patients.
223471845|NCT04577066|OTHER|GA2|15 volunteers will receive 50 GA2-infected mosquito bites. The GA2 parasite is a new genetically attenuated Plasmodium falciparum parasite, which arrests development in the liver and should not be able to cause malaria in humans.
223471846|NCT04577066|OTHER|GA1|10 volunteers will receive 50 GA1-infected mosquito bites. The GA1 parasite is a genetically attenuated Plasmodium falciparum parasite, which arrests development in the liver and is not able to cause malaria in humans.
223471847|NCT04577066|OTHER|Placebo|5 volunteers will receive 50 uninfected mosquito bites.
223471848|NCT02392780|DRUG|Cannabidiol|Oral cannabidiol at a dose of 150 mg BID up to 90 days.
223471849|NCT02392780|DRUG|Methylprednisolone|IV methylprednisolone 2 mg/kg/day
223471850|NCT02392780|DRUG|Calcineurin inhibitor|cyclosporine with dose adjusted based on drug trough levels (200-400 ng/ml) or tacrolimus with dose adjusted on drug trough levels (5-15 ng/ml)
223471851|NCT05889975|DEVICE|interdental brush|cleaning the inter dental areas after manual tooth brush twice daily by the patient for 30 days
223471852|NCT05889975|DEVICE|single tufted brush|cleaning the inter dental areas after manual tooth brush twice daily by the patient for 30 days
223471853|NCT05889975|DEVICE|water irrigator|using water irrigator after manual tooth brushing twice daily with 300ml distal water placed in its container. The patients instructed to use the entire 300ml during each irrigation for 30 days
223471854|NCT04830735|DRUG|Dasatinib Anhydrous|Given PO
224069256|NCT04002011|DRUG|Rivaroxaban|It will be started when patients will be discharged from our center. Our pharmacist referent will validated the drug and its daily dose. Other anticoagulants will be not administrated.
224069257|NCT04002011|DRUG|Apixaban|It will be started when patients will be discharged from our center. Our pharmacist referent will validated the drug and its daily dose. Other anticoagulants will be not administrated.
224069258|NCT04002011|DRUG|Edoxaban|It will be started when patients will be discharged from our center. Our pharmacist referent will validated the drug and its daily dose. Other anticoagulants will be not administrated.
224069259|NCT03652532|BEHAVIORAL|Alternate Day Fasting|"During the 8-week intervention, participants consumed 25% of their daily recommended energy intake (approximately 500 kcal) on each fast day (24 h), and consumed food ad libitum on each feed day (24 h). The fast day and feed day were repeated every other day, and the fast day occurred 3 days per week."
224069260|NCT03652532|BEHAVIORAL|Exercise|During the 8-week intervention, participants visited the research center gym at least three times per week and received exercise logs. Each exercise session began with 5 minutes of warm-up and ended with 5 minutes of cool-down. Resistance training was performed using weight training machines, barbells, and dumbbells for 40 minutes. Aerobic exercise was performed on motorized treadmills for 20 minutes.
224069261|NCT01751217|BEHAVIORAL|Functional Family Tx|
224069262|NCT01751217|BEHAVIORAL|Services as Usual|
223471855|NCT04830735|DRUG|Placebo Administration|Given PO
223471856|NCT05553327|BEHAVIORAL|Multimodal prehabilitation|"* Physical state: individualised physical status will be evaluated by a physiotherapist. A specific training program and pelvic floor exercises sessions will be led by a physiotherapist.~* Nutritional state: individual nutritional status will be evaluated by a nutritionist and intervention will be done if applicable. A nutrition group session will be held.~* Mental health: mindfulness group sessions led by psychologists will be held."
223471857|NCT00419705|DEVICE|NeuroThera® Laser System|Transcranial delivery of laser therapy or sham (no laser therapy) to the scalp
223471858|NCT03768193|PROCEDURE|Deep serratus anterior plane block|Deposition of local anaesthetic in the space between the serratus anterior muscle and the external intercostal muscle, at the level of the 4th-5th rib, in the midaxillary line. Procedure performed under ultrasound guidance. Catheter - based infusion of local anaesthetic into this space for 48 hours.
223471859|NCT03768193|PROCEDURE|Surgically-placed paravertebral block|Surgically-placed paravertebral block catheters for continuous local anaesthetic infusion of 0.125% levobupivacaine at 8-12mls/ hr for 48 hours.
223471860|NCT03318185|PROCEDURE|gasless single-port laparoscopic surgery|The single-port laparoscopic surgery is performed when the maneuvering room is provided by external suspension system.
223471861|NCT03318185|PROCEDURE|conventional laparoscopic surgery|The multi-port laparoscopic surgery is performed when the belly is inflated with carbon dioxide to provide maneuvering room.
223471862|NCT04309513|BEHAVIORAL|PAI score to motivate physical activity|Participants will be encouraged to work up to and maintain the highest PAI score possible, with 100 being the ideal, as measured by a wearable device. Their devices and an accompanying app will provide them with an ongoing real time calculation of the PAI score.
223471863|NCT04309513|BEHAVIORAL|Step Counter to motivate physical activity|Step Counter to motivate physical activity
223471864|NCT06262984|OTHER|Therapeutic Play|The researcher will demonstrate the nasopharyngeal swabbing process on the doll with the children who have chosen a therapeutic play group, using a therapeutic play method, and play with the child. The Children's Emotional Manifestation Scale (CEMS) will be evaluated and scored by the researcher and the observing nurse.
223471865|NCT06069388|PROCEDURE|diaphragm technique|The patient will be placed in a supine position with knees bent on a cushion. The therapist will position himself oriented from the patient's head towards his feet. The therapist will make contact with the ulnar edge of his hands on the lower edge of the last ribs. It will be pulled cephalad during the inspiratory time, opening the rib cage laterally. Traction will be maintained during expiratory time and repeated during a cycle of 10 breaths.
223471866|NCT06069388|PROCEDURE|conventional therapy|The patient will be placed in a supine position with knees bent on a cushion. The therapist will position himself oriented from the patient's head towards his feet. The therapist will make contact with the ulnar edge of his hands on the lower edge of the last ribs. It will be pulled cephalad during the inspiratory time, opening the rib cage laterally. Traction will be maintained during expiratory time and repeated during a cycle of 10 breaths.
223471867|NCT02617537|DRUG|EE20/DRSP(YAZ,BAY86-5300)|0.02 mg EE (β-CDC)/3 mg DRSP for 24 days and placebo tablets for 4 days per 28-day intake cycle
223471868|NCT02617537|DRUG|Placebo|Matching placebo tablets for 28 days per 28-day intake cycle
223471869|NCT03599596|DRUG|Sulphadoxine-pyrimethamine|Sulphadoxine-Pyrimethamine 500mg of Sulphadoxine and 25mg of Pyrimethamine 3tablets monthly until delivery
224069263|NCT06457581|OTHER|Dry Needling|Group A will undergo dry needling sessions twice a week over eight weeks, specifically targeting trigger points and tender points. Simultaneously, a consistent dosage of selective serotonin reuptake inhibitor (SSRI) will be administered and maintained throughout the entire duration of the study.
223471870|NCT03599596|DRUG|Sulphadoxine-pyrimethamine|Sulphadoxine-Pyrimethamine 500mg of Sulphadoxine and 25mg of Pyrimethamine 3tablets twice before delivery
223471871|NCT02267941|OTHER|observation|Data were collected by a disigned form. Statistic software was used to analyze clinical data.
223471872|NCT03740464|DRUG|long-acting granulocyte colony stimulating factor|A 6 mg of polyethylene glycol granulocyte colony stimulating factor will be given to patients of study group
223471873|NCT03740464|DRUG|Short-term granulocyte colony stimulating factor|Short-term granulocyte colony stimulating factor will be given to all patients according to the severity of myelosuppression
223471874|NCT02313402|DEVICE|EOL (Eye On Line)|the intervention consists in training program allowing a gradual acquisition of the eye-writing
223471875|NCT01549574|DRUG|crizotinib|Each subject in Treatment A will receive a 250 mg single oral dose of crizotinib administered in a fasted state as 1x 250 mg Formulated Capsule on Day 1 and each subject in Treatment B will receive a 250 mg single oral dose of crizotinib administered in a fasted state as 1x 250 mg Formulated Capsule on Day 5
223471876|NCT01549574|DRUG|esomeprazole|Each subject in Treatment B will receive 40 mg daily dose of esomeprazole from Day 1 to Day 5
223471877|NCT05076227|DRUG|IM injection of vaccination (mRNA vaccination)|mRNA vaccination
223471878|NCT05076227|DRUG|IM injection of vaccination (vector based vaccination)|vector based vaccination
223471879|NCT01244867|BIOLOGICAL|20 micrograms dose H5 VLP|2 doses given 21 days apart of 20 micrograms of H5 VLP vaccine mixed with Alhydrogel
224069264|NCT06457581|PROCEDURE|Trigger points injections|Group B will undergo a comprehensive intervention involving trigger point injections administered biweekly over eight weeks. These injections will specifically target trigger points. Additionally, a control measure will be implemented through simulated needling at non-specific points.
224069265|NCT06457581|DRUG|serotonin reuptake inhibitor (SSRI)|serotonin reuptake inhibitor (SSRI)
224069266|NCT00782457|PROCEDURE|RECTAL CANCER RESECTION|
224069267|NCT01759758|OTHER|Plaster Ulnar Gutter Splint|Patients are placed in a plaster ulnar gutter splint, molded in the safe position.
224069268|NCT01759758|OTHER|Thermoplastic Splint|Thermoplastic Splint is heat moulded to the patient's hand, stabilizing the metacarpal heads, but not immobilizing any joints. This is done by our occupational therapist.
224069269|NCT04572269|OTHER|No Intervention|This protocol does not involve an intervention of drug/device, diet, exercise or PAP compliance.
224069270|NCT03698006|DRUG|Ropivacaine 0.5% Injectable Solution|Tibial nerve block with 10ml of Ropivacaine 0.5%
224069271|NCT03698006|DRUG|Ropivacaine 0.2% Injectable Solution|Infiltration with 25ml of Ropivacaine 0.2% in the posterior knee capsule
223471880|NCT01244867|BIOLOGICAL|30 micrograms dose H5 VLP|2 doses given 21 days apart of 30 micrograms of H5 VLP vaccine mixed with Alhydrogel
223579973|NCT05094817|OTHER|pain VAS|The VAS is a unidimensional measure of pain intensity. The VAS tries to measure a continuous characteristic or attitude signifying the intensity or frequency of symptoms. The scale ranges from 0-10, with 0 = no pain to 10 = worst pain.
223471881|NCT01244867|BIOLOGICAL|45 micrograms dose H5 VLP|2 doses given 21 days apart of 45 micrograms of H5 VLP vaccine mixed with Alhydrogel
223471882|NCT01244867|BIOLOGICAL|45 micrograms non-adjuvanted H5 VLP|2 doses given 21 days apart of 45 micrograms of H5 VLP vaccine
223471883|NCT01244867|BIOLOGICAL|Placebo|2 doses given 21 days apart of the placebo
223471884|NCT00356018|BEHAVIORAL|Compliance|
223471885|NCT06514287|BEHAVIORAL|Individualized intervention|It is a pragmatic intervention where three priorities were identified for physical activities in daily routines, considering the difficulty of the goal, the family's daily routines, opportunities for practice, and time available for practice. The therapist is a consultant, sharing information, educating, and instructing in ways that encouraged engagement of participants in the intervention process. The intervention plan was implemented via online consultation using WhatsApp text, audio, and video messaging for asynchronous and synchronous communication. The focus of intervention was incorporating practice of goals into daily activity routines.
223579974|NCT05094817|OTHER|IADL|Instrumental activities such as preparing meals or managing finances allow individuals to maintain their health while living on their own. The IADL measures the ability of older adults to manage their daily activities, as well as the impact, if any, cognitive decline would have on these activities. Scores range from 0-5 for men, and 0-8 for women, with higher sores being more independent and higher functioning.
223579975|NCT05094817|OTHER|FAM CAM|FAM-CAM was derived from the CAM instrument in order to screen for delirium by interviewing family members or caregivers of the patient. They are asked specific questions about any new or sudden changes in the patient's activity, behavioural or cognitive status. FAM-CAM showed good sensitivity and specificity in the original study where caregivers of elderly patients with pre-existing cognitive impairment were interviewed.
223579976|NCT05094817|OTHER|4AT|The 4AT is a rapid tool for delirium detection that has previously been used in a surgical setting. The 4Ats test for the patient's alertness, mental state, attention, and signs of acute change. Across 17 studies, the pooled sensitivity and specificity of 4AT was 0.86 and 0.89. The 4AT will be administered after the patient has completed surgery, prior to discharge.
223579977|NCT05094817|OTHER|BHA Usability Survey|The survey aims to assess system usability and acceptability based on standard questions adapted from the validated System Usability Scale. The questions evaluate satisfaction, experience with technology, and comfort level, as well as questions targeting usability concerns typically experienced by older adults, such as typeface and font size, consistent navigation, and writing style.
223579978|NCT05094817|OTHER|Clinical Frailty Scale|CFS is a 9-item scale that uses clinical descriptors and pictographs and is an easily applicable tool to stratify older adults according to level of vulnerability. The CFS divides patients into 9 classes from very fit (CFS = 1) to terminally ill (CFS = 9). It is easy to use and may readily be administered in a clinical setting, an advantage over the tools previously developed. The scale helps in objective early identification of older adults with frailty in acute care units and helps to target interventions to prevent complications and to implement effective discharge planning.
223579979|NCT02012686|DEVICE|TENS|transcutaneous electric nerve stimulation frequency of 100 Hz pulse duration of 200 µs wih stimulation intensity of feeling strong but non-painful paresthesia in the upper trapezius
223579980|NCT00612508|DRUG|Desogen (ethinyl estradiol and desogestrel)|1 tablet every day; each tablet contains 0.15mg desogestrel and 0.03mg ethinyl estradiol
223579981|NCT00612508|DRUG|NuvaRing (ethinyl estradiol and etonogestrel)|Place the ring in the vagina for 3 weeks, remove for one week. Repeat with new Ring
223579982|NCT02184429|DRUG|PF-06669571|Single ascending doses of PF-06669571 as extemporaneously prepared solution/suspension, once week in a cross over study: 0.2 mg 0.4 mg, 0.75 mg, 1.50 mg and placebo
223579983|NCT02184429|DRUG|PF-06669571|Single ascending doses of PF-06669571 as extemporaneously prepared solution/suspension, once week in a cross over study: 3 mg 6 mg, 10 mg, 3 mg (fed) and placebo
223579984|NCT02184429|DRUG|PF-06669571|Oral dosing of 0.15 mg PF-06669571 as extemporaneously prepared solution/suspension or powder in capsule formulation for 14 days
224069272|NCT03673683|BEHAVIORAL|SANDWICH protocol|A protocol based intervention incorporating co-ordinated care with greater nursing involvement; patient-relevant sedation plans linked to regular assessment using the COMFORT scale; regular assessment of ventilation parameters with a higher than usual trigger for undertaking an extubation readiness test; a spontaneous breathing trial (SBT) on low levels of respiratory support to test extubation readiness
224069273|NCT03673683|BEHAVIORAL|Usual care|Usual sedation and weaning management that is not protocol based
224069274|NCT05162482|BIOLOGICAL|BIBP (CNBG, Sinopharm) WIV|BIBP (CNBG, Sinopharm) WIV (Whole Inactivated Virus in a single dose, prefilled syringe with a storage temperature of 2-8°C)
224069275|NCT05162482|BIOLOGICAL|CanSinoBIO|CanSinoBIO (Viral Vector in a single dose, prefilled syringe with a storage temperature of 2-8°C)
223471886|NCT00526474|DRUG|Vorapaxar|2.5-mg tablet daily for at least 1 year
224069276|NCT05162482|BIOLOGICAL|AstraZeneca ChAdOx|AstraZeneca ChAdOx (Viral Vector in a multi-dose vial consisting of 10 doses with a storage temperature of 2-8°C)
224069277|NCT00590590|DRUG|Lidocaine/Diphenhydramine|semi solid, twice weekly, 4 months
223471887|NCT00526474|DRUG|Placebo|matching tablet daily for at least 1 year
223471888|NCT01587885|DRUG|Omeprazole 20 mg + Sodium Bicarbonate 1100 mg|Capsules, orally
223471889|NCT01587885|DRUG|Omeprazole 20 mg|Tablets, orally
223471890|NCT02517619|DRUG|Dexamethasone Phosphate Ophthalmic Solution|40 mg/mL
223471891|NCT02517619|DRUG|Prednisolone Acetate Ophthalmic (1%)|Prednisolone Acetate (1%)
224069278|NCT00590590|DRUG|lidocaine|semi solid, twice weekly for 4 months
224069279|NCT00590590|DRUG|placebo|semi solid, twice weekly for 4 months
223471892|NCT02975596|OTHER|Awareness|Awareness: Conduct an awareness campaign throughout Alachua County to alert the community in general to the significance of Serogroup B meningococcal disease in the United States. To inform the material included in the awareness campaign and the education materials, semi-structured interviews with members for each of the key stakeholder groups: students, parents, and medical practitioners will be conducted.
223471893|NCT02975596|OTHER|Education|Education: This component will be both web-based and in-person to meet the individual needs of the learners. There will be parent and a student (18-23 years old) version of the educational curriculum. National resources of patient -focused materials and guidelines will be adapted. There will be pre- and post-education surveys to assess knowledge and vaccine decision-making.
223471894|NCT02975596|OTHER|Empowerment|"Empowerment: A guided program for adolescents and young adults on Decision-Making for your Health will be offered on the vaccination days to assist youth in assessing and utilizing health information to guide their personal decision-making for vaccines."
223471895|NCT02975596|OTHER|Accessibility|Accessibility: MenB vaccine will be offer on the high school and university campuses through a collaborative program between the local schools, university and department of health. We will offer students booster shots of Men ACWY and HPV at the same time. All vaccines will be offered free of charge. Each vaccine administered will be recorded in Florida SHOTS.
223471896|NCT01346865|DRUG|Cilostazol|Cilostazol 100mg bid
223471897|NCT01346865|DRUG|Placebo|Placebo 1tablet bid
223471898|NCT03020485|OTHER|Isomaltulose|Isomaltulose is a disaccharide made up of one molecule glucose and fructose with a (α1-6) linkage.
223471899|NCT03020485|OTHER|Sucrose|Sucrose is normal table sugar
223471900|NCT05130424|DRUG|Herombopag|Herombopag in the treatment of thrombocytopenia-related diseases Non-interventional clinical research.Do not interfere with the dosage and market of Hetrobopar Oral medication
223471901|NCT06235112|DEVICE|Electronic health record-based notification of Nanox.AI Coronary Artery Calcification Assessment|The intervention involves electronic health record, email, or letter notification about the presence of coronary artery calcification on chest CT and recommendation of preventive therapy. This is based on results of the automatic detection of coronary artery calcification from AI device (software).
223471902|NCT01429090|PROCEDURE|blood sampling|blood sampling before and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 16 hours after administration of study medication
223471903|NCT01429090|DRUG|Vagantin®|administration of 2 coated tablets Vagantin® (coated tablets of 50 mg methantheline bromide)
223471904|NCT01429090|DRUG|methantheline solution|administration 100 ml methantheline solution (100 mg methantheline bromide)
223471905|NCT01429090|PROCEDURE|Measurement of salivation|"Volume of salivary gland secretion was measured by chewing a 5 x 5 cm piece of PARAFILM M® (American Can Company, UK) for 5 min. Saliva was collected in glass tubes and the amount of the stimulated saliva was measured by weighing"
223471906|NCT01429090|PROCEDURE|Measurement of accommodation|Accommodation was measured with the optometer according to Schober (Velhagen 1972)
223471907|NCT01429090|PROCEDURE|Pupillometry|Pupil function was assessed with the pupillograph (Compact Integrated Pupillograph, AMTech, Weinheim, Germany). The following data were obtained: pupil diameter, response to defined flash stimuli
223471908|NCT01596569|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|Daily rTMS treatment for one week. Sham TMS participants receive the same study procedures as patients receiving active TMS.
223471909|NCT01596569|BEHAVIORAL|Cognitive Intervention|"Cognitive intervention designed specifically to address the most common cognitive deficits (executive function and memory) in bTBI.~All participants receive weekly cognitive treatment sessions for 10 weeks."
223579985|NCT02184429|DRUG|PF-06669571|Oral dosing of 0.5 mg PF-06669571 as extemporaneously prepared solution/suspension or powder in capsule formulation for 14 days
223579986|NCT02184429|DRUG|PF-06669571|Oral dosing of 1.5 mg PF-06669571 as extemporaneously prepared solution/suspension or powder in capsule formulation for 14 days. This dose may be reached by a titration scheme
223579987|NCT02184429|DRUG|PF-06669571|Oral dosing of 4.5 mg PF-06669571 as extemporaneously prepared solution/suspension or powder in capsule formulation for 14 days. This dose may be reached by a titration scheme
223579988|NCT02184429|DRUG|PF-06669571|Oral dosing of 9.0 mg PF-06669571 as extemporaneously prepared solution/suspension or powder in capsule for 14 days. This dose may be reached by a titration scheme
223579989|NCT03344198|BEHAVIORAL|Circuit Training exercise & Modified Mediterranean diet|Participants will receive circuit training program and a modified Mediterranean diet program. Educational sessions, serving size training, and portion containers will be provided. Participants will also receive individualized support throughout the 6 week intervention.
223579990|NCT06414330|BIOLOGICAL|Ringer acetate based Del Nido cardioplegia|All patients will receive hypothermia 29 - 32 ℃ and cardioplegia will be injected between the aortic valve and aortic cross clamp in a pressure not less than 50 mmHg above systolic pressure. After removal of aortic cross clamping, the heart will be monitored for ventricular arrhythmias, early recovery, and postoperative 24 hours serum troponin and new changes in echocardiography.
223579991|NCT06414330|BIOLOGICAL|HTK|Giving HTK instead of Del Nido
223579992|NCT02008357|DRUG|Placebo|Administered IV
223579993|NCT02008357|DRUG|Solanezumab|Administered IV
224069280|NCT01514682|DRUG|Anti-inflammatory Combination Therapy|"1. salsalate: target dose 4 gm/day, administered in two divided doses of 2 gm in the morning and 2 gm in the evening~2. fluvastatin: target dose 40 mg/day, administered in a single evening dose~3. combined omega-3-fatty acid preparation of EPA and DHA; target dose EPA 2 gm/day and DHA 2 gm/day administered in a single evening dose"
224069281|NCT01514682|DRUG|Placebo|Non-medication pills; To be taken in morning and evening intervals.
224069282|NCT05766995|DEVICE|Waterpik Water Flosser|A pulsating water flosser and jet tip designed to clean between the teeth and below the gingival margin.
224069283|NCT05766995|DEVICE|Oral-B Water Flosser|A water flosser and specialized tip that delivers water with microbubbles of air
224069284|NCT05766995|DEVICE|Waxed Dental Floss|Nylon string used to clean between the teeth manually
224069285|NCT00132132|BEHAVIORAL|Behavioral education program|Monthly 4 hr session which incorporates: exercise, empowerment, education, and incentives
224069286|NCT02025426|DRUG|Phenylephrine|
224069287|NCT02025426|DRUG|Ephedrine|
224069288|NCT00406770|DEVICE|Light therapy|
224069289|NCT05136937|BIOLOGICAL|Oncolytic Virus Injection(RT-01)|Administered by intratumoral injection for 3 dose cohorts: 1×10\^7 TCID50/mL, 1×10\^8 TCID50/mL and 7×10\^8 TCID50/mL
224069290|NCT01210339|DRUG|Clopidogrel|Clopidogrel
224069291|NCT01210339|DRUG|Esomeprazole/ASA|20 mg/81 mg once daily for five days (Day 5-9)
223471910|NCT02779491|BEHAVIORAL|5-a-day fruit and vegetable mobile phone application|5-a-day fruit and vegetable mobile phone application
223471911|NCT03309553|OTHER|Current Primary Care Referral Process|Children who screen positive for hearing loss will receive the same method each school had been using previously. This process involves a letter home to the parents, either sent with the child or by mail, requesting that the parent/caregiver bring the child to village health clinic for an evaluation.
223471912|NCT03309553|OTHER|Telemedicine Referral Process|In villages randomized to the expedited telemedicine intervention, parents of children who screen positive will receive a phone call from the school or the clinic on the day of screening notifying them of the day and time of their child's telemedicine consultation appointment. Appointments will be made same-day or next-day, with community health aides (CHAs) who have dedicated time blocked off to perform telemedicine consults. Participating children screening positive will be transported to clinic for their appointment with adult chaperones. Parents are encouraged but not required to attend, except for children grades 2 and younger, for whom parental participation will be required. Nonparticipating children in communities assigned to the expedited telemedicine intervention arm will receive standard referral following the current school primary care referral process.
223471913|NCT06144255|DRUG|Intranasal insulin|"Enrolled Participants for this trial will come for 3 study visits. The doses will be administered in varying order: participants will be randomized to one six possible permutations of the intranasal study doses (0, 500, 1000 U) of intranasal insulin at each visit.~Participants will undergo a fMRI scan before and after receiving intranasal doses. Additionally, participants will have blood samples taken."
223471914|NCT04117022|DIETARY_SUPPLEMENT|DVS supplementation|Oral supplement. Each subject will be given the carotenoid supplement of DVS formula. The DVS formula consists of vitamins C, D3 and E (d-α tocopherol), zinc oxide, eicosapentaenoic acid, docosahexaenoic acid, α-lipoic acid (racemic mixture), coenzyme Q10, mixed tocotrienols/tocopherols, zeaxanthin, lutein, benfotiamine, N-acetyl cysteine, grape seed extract, resveratrol, turmeric root extract, green tea leaf, and Pycnogenol (patented French Maritime Pine Bark extract, sp Pinus pinaster, Horphag Research, Geneva, Switzerland). Supplements bottles will be labelled with a unique identification number for each subject and supplied by ZeaVision, LLC, Chesterfield, Missouri, USA. To assure that the participants do not have any issues with the vitamin supplement and to ensure adequate adherence to schedule of vitamin intake the participants will get regular phone calls from the study investigators (once every two weeks).
223471915|NCT02018133|DRUG|Vitamin D 2mg daily for 2 weeks oral paricalcitol|vitamin D 2 capsules daily
223471916|NCT02018133|DRUG|Placebo|placebo 2 capsule daily
223471917|NCT00028717|BIOLOGICAL|filgrastim|
223471918|NCT00028717|BIOLOGICAL|rituximab|
223471919|NCT00028717|DRUG|cyclophosphamide|
223471920|NCT00028717|DRUG|doxorubicin hydrochloride|
223579994|NCT05544630|DEVICE|computerized dynamic posturography (sensory orgnization test)|assess of an individual's ability to maintain static and dynamic stance. The assessment is composed of a battery of tests that are similar to everyday conditions of daily living. There are four main components to CDP that are used clinically: the Sensory Organization Test (SOT),
223579995|NCT00060814|OTHER|Combined intervention|300 mg bupropion plus 4mg nicotine gum ad lib plus motivational interviewing counseling
223579996|NCT04294316|DIAGNOSTIC_TEST|Sonovue|Twice dose of 2.4ml of Sulphur hexafluoride microbubbles contrast Sonovue administration to evaluate brain microcirculation
223579997|NCT02584387|BEHAVIORAL|3D Video Virtual Reality Exposure Therapy|The 3D video exposure therapy treatment will be administered using an oculus rift virtual reality headset. The oculus rift is a new, affordable virtual reality headset, which uses two different spherical lenses to induce a sense of stereoscopic 3D. Ortho-stereoscopic 3D refers to 3D videos that are designed to mimic the natural depth we normally see, as opposed to exaggerating it (i.e. Commercial 3D movies). To create these 3D videos, the UT 3D Department shot videos of live spiders using a stereoscopic 3D dual camera rig, which simultaneously shoots footage with two cameras positioned apart from each other in a way that mimics the natural pupillary distance between our right and left eyes. To create a sense of 3D depth, the footage of the right and left cameras is then projected on the two different lenses of the oculus rift, creating a sense of depth to the viewer through retinal disparity.
223579998|NCT06390787|DRUG|Metoclopramide and Vitamin B6|We gave a combination of vitamin B6 (pyridoxine) and metoclopramide as a treatment for managing nausea and vomiting.
223579999|NCT06390787|DRUG|Vitamin B6|We gave only vitamin B6 (pyridoxine) as a treatment for managing nausea and vomiting.
223580000|NCT06390787|DRUG|Ondansetron|We gave only Zofran as a treatment for managing nausea and vomiting.
223471921|NCT00028717|DRUG|prednisone|
223471922|NCT00028717|DRUG|vincristine sulfate|
223471923|NCT04927910|OTHER|Ture self-acupressure|8-week intervention of self-acupressure on acupoints
223471924|NCT04927910|OTHER|Sham self-acupressure|8-week intervention of self-acupressure on non-acupoints
223471925|NCT04927910|OTHER|Usual care|routine care by hospitals
223471926|NCT05635903|PROCEDURE|Continuous nebulisation 0.9% saline Aerogen Solo vibrating mesh Nebuliser|Continuous nebulisation of 0.9% saline using the Aerogen Solo vibrating mesh nebuliser
223580001|NCT06390787|DRUG|Metoclopramide|We gave only Metoclopramide as a treatment for managing nausea and vomiting.
223580002|NCT02479581|PROCEDURE|ERAS group|Intravenous infusion of flucloxacillin sodium 1g an hour before operation
223580003|NCT02479581|PROCEDURE|ERAS group|"1. No routine bowel preparation;~2. Normal eating 1 days before the operation;~3. No drinking 2h and solid food 6h before the operation;~4. Drink 10% glucose 250ml 3h before operation ;~5. Gastric mucosal protective agent was given 3 days before operation(Esomeprazole Magnesium Enteric-coated tablets 40mg/d);"
223580004|NCT02479581|PROCEDURE|ERAS group|Emphasize the preoperative psychological preparation for patients.
223580005|NCT02479581|PROCEDURE|ERAS group|Received subcutaneous recombinant human erythropoietin (rhEPO)150（international unit/kg） once very two days from 2 days after hospital admission to 5 days postoperatively；
223580006|NCT02479581|PROCEDURE|ERAS group|No scopolamine and morphine before surgery; No midazolam; No anti - choline drugs;
223580007|NCT02479581|PROCEDURE|ERAS group|Solu-Medrol®:5mg/kg intravenous infusion during the surgery;
223471927|NCT05635903|PROCEDURE|Intermittent nebulisation 0.9% saline Aerogen vibrating mesh Solo Nebuliser|Intermittent nebulisation of 0.9% saline using the Aerogen Solo vibrating mesh nebuliser
223471928|NCT05635903|PROCEDURE|Intermittent standard intermittent nebulisation of 0.9% saline Intersurgical Cirrus 2 self sealing Jet Nebuliser|standard intermittent nebulisation of 0.9% saline using the Intersurgical Cirrus 2 self-sealing Jet Nebuliser
223471929|NCT01224379|DEVICE|Topping off system|"The intervention group will receive a topping off system (PLIF -posterior intervertebral fusion- connected with a flexible pedicle screw system above the fusion)."
223471930|NCT01224379|DEVICE|monosegmental PLIF|The control group receives a monosegmental PLIF. This is the current standard therapy for many pathologies in the lumbar spine (e.g. Spondylolisthesis)
223471931|NCT03572712|OTHER|No Interventional study|every patient will be monitored with a blood gase, a nocturnal oximetry and a transcutaneous capnography
223471932|NCT01248897|OTHER|This study is non-interventional study, so this section is not applicable.|This study is non-interventional study, so this section is not applicable.
223471933|NCT03961867|DRUG|Docetaxel|"S-1 (BSA \<1.25m2, 80 mg; 1.25 to 1.5m2, 100 mg; \>1.5m2,120 mg) divided into two doses /day after breakfast and dinner, 14 days / 3 weeks, totally 16 cycles.~Docetaxel 40mg/m2/3w from the second to the seventh cycles."
223471934|NCT03961867|DRUG|Oxaliplatin|"S-1 (BSA \<1.25m2, 80 mg; 1.25 to 1.5m2, 100 mg; \>1.5m2,120 mg) divided into two doses /day after breakfast and dinner, 14 days / 3 weeks, totally 16 cycles.~Oxaliplatin 130mg/m2/3w from the first to the eight cycles."
223471935|NCT04458896|BEHAVIORAL|Stand When You Can|"Intervention strategies can be customized to different environments based on consultation with management. Some strategies will be mandatory:~* Education session: group information session during the first week of the intervention (30min) to discuss sedentary time (ST), health risks, strategies to reduce ST, goal setting, \& the identification of barriers and motivators to reducing ST. Group discussion will be encouraged to increase self-motivation and self-efficacy. An information workbook will be given to each attendee for their personal use and goal setting.~* Point of decision prompts (ie: signs that encourage standing; see attachments) will be placed in common areas of the facility, and/or given as pamphlets to residents.~* An intervention package will be provided to the Activity Coordinator and Manager of the facility. This package will provide an introductory letter along with materials to promote reduced sedentary time in the facility"
223471936|NCT02227641|BIOLOGICAL|CMV/EBV specific T-cell|Peptide stimulated allogeneic T-cells with dual specificity for CMV and EBV
223471937|NCT04716244|OTHER|interview/focus group/questionnaire|"Prior to the meetings, participants will be asked to fill in a questionnaire with demographic data including age, family status, number of pregnancies, number of children, education, and employment, history of preeclampsia or GDM, family history of CVD, and self-reported height and weight We will conduct up to 8 groups or until we reach saturation of themes. For the teleconference focus groups, the number of participants will be limited to 6 women per group, as recommended from previous research on teleconference focus groups51. The face to face focus groups will include up to -12 women. The expected duration of each group, will last 1-2 hours.~We will conduct up to 36 in-depth interviews. The expected duration of each interview will last 30 minutes to -1.5 hours.~Participants will be asked for their consent to record the meetings, audio only. The discussions will be then transcribed. An interview guide will be followed."
223471938|NCT05671081|DRUG|Dexmedetomidine|patients will receive combined general anesthesia and bilateral bilevel at T5 \&T10 Erector spinae plane block with 20mL of bupivacaine 0.125 %. plus 0.5 μg/kgof Dexmedetomidine for each injection
223471939|NCT05671081|DRUG|Magnesium sulfate|patients will receive combined general anesthesia and bilateral bilevel at T5 \&T10 Erector spinae plane block with 20mL of bupivacaine 0.125 %. plus 2 mg/kg Magnesium sulfate for each injection
223580008|NCT02479581|PROCEDURE|ERAS group|"1. Apply Transesophageal Echocardiography（TEE）after anesthesia induction;~2. Goal-directed fluid management."
223580009|NCT02479581|PROCEDURE|ERAS group|"1. Infusion of Human Albumin Grifol®20% 50ml;~2. Ultrafiltration(TERUMO CARDIOVASCULAR SYSTEMS (TERUMO®));~3. Shorten the Cardio-pulmonary Bypass line；~4. Continuous near infrared spectrum monitoring of cerebral oxygen saturation(MNIR-P100（chongqingmingxi®）)"
223471940|NCT05671081|DRUG|Narcotic Analgesics|patients will receive general anesthesia and conventional intraoperative and postoperative analgesia
223471941|NCT00383526|BIOLOGICAL|Inactivated, split-virion influenza vaccine|Vaccine
223471942|NCT00383526|BIOLOGICAL|Inactivated, split-virion influenza vaccine|Vaccine
223471943|NCT02930785|DRUG|BAY987517|"Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.~(Formulation Code:Z46-104)"
223471944|NCT00000755|BIOLOGICAL|rgp120/HIV-1MN|
223471945|NCT00000755|DRUG|Zidovudine|
223580010|NCT02479581|PROCEDURE|ERAS group|Monitor urine volume closely, over 0.5ml/kg·h.
223580011|NCT02479581|PROCEDURE|ERAS group|Protective ventilation strategy：Low tidal volume about 6\~8ml/kg and positive end expiratory pressure（PEEP） combined with lung recruitment maneuver
223743845|NCT02670655|DEVICE|2940-nm Er:YAG AFL pretreatment|After the anaesthetic cream was removed, AFL therapy was performed using a 2940-nm Er:YAG AFL (Joule; Sciton Inc., Palo Alto, CA, USA) at 300-550 µm ablation depth, level 1 coagulation, 22% treatment density and a single pulse
223743846|NCT02670655|DRUG|MAL application|Immediately after AFL treatment, an approximately 1-mm-thick layer of MAL (Metvix, PhotoCure ASA, Oslo, Norway) was applied to the lesion and on 5 mm of surrounding normal tissue.
224160380|NCT06086782|OTHER|reciprocal inhibition|Group 2 receive RI-MET with conventional treatment. The RI also include stretching of the affected muscle but contrary to AI, isometric contraction of the antagonist muscles with the 50% of total patient's effort will follow. This position holds for 10 seconds, while agonist's muscle will still in the stretched position, with 5 seconds of rest after every repetition. This procedure will repeat 5 times too.
223471946|NCT05945095|OTHER|Gum chewing group|The mothers in the experimental group, on the other hand, will chew sugar-free gum for at least 15 minutes, starting from the second hour after the surgery.
223471947|NCT00052104|BEHAVIORAL|Cognitive-Behavioral Family Systems Intervention|
223471948|NCT02731196|BEHAVIORAL|Exercise Intervention|Early versus later stabilization and neurodynamic exercise intervention following a post-op lumbar microdiscectomy
223471949|NCT00231790|DRUG|MK-0634 50 mg|one capsule orally, once daily in morning
223471950|NCT00231790|DRUG|MK-0634 125 mg|one or three capsules orally, once daily in morning
223471951|NCT00231790|DRUG|Placebo for MK-0634|one, two, three or four capsules orally once daily in morning
224160381|NCT04645576|DEVICE|Face correction with injectable fillers|Injection of hyaluronic acid-based fillers
223471952|NCT05232227|DRUG|Primaquine double dose over 14 days|Primaquine Phosphate tablets New Drug Application (NDA): 008316 Company: SANOFI AVENTIS US Chloroquine Phosphate tablets
223471953|NCT05232227|DRUG|Primaquine single dose over 14 days|Primaquine Phosphate tablets New Drug Application (NDA): 008316 Company: SANOFI AVENTIS US
223471954|NCT00695227|DIAGNOSTIC_TEST|Screening for Barrett's Esophagus|
223471955|NCT06238414|OTHER|Early psychotherapeutic intervention|The case group will receive an 8-session early psychological intervention The intervention consists of eight face-to-face sessions that include techniques from the dialectical behavioral (DBT), mentalization based therapy orientation (MBT), and narrative approach, concretely an adaptation from the ASSIP therapy. The sessions will be conducted by a clinical psychologist with expertise in psychotherapy. There will be two 60-minutes sessions per week.
223471956|NCT06450769|OTHER|Aronia juice|100% aronia juice, 100 mL/day, twelve-week follow-up
223471957|NCT06450769|OTHER|Mediterranean diet|An individually planned nutrition program suitable for the energy-restricted Mediterranean diet
223471958|NCT06450769|OTHER|Low-fat diet|An individually planned nutrition program suitable for the energy-restricted low-fat diet
223471959|NCT03027947|DEVICE|Spinal cord stimulator|Spinal cord stimulator leads (2-3 leads) will be placed in the lumbar epidural space of lower limb amputees to determine if the patient experiences any pain reduction from spinal cord stimulation.
223471960|NCT04232007|DEVICE|closed-loop system for vasopressor administration|closed-loop system for vasopressor administration
223471961|NCT04345276|DRUG|Danoprevir+Ritonavir|Danoprevir 100mg , one tablet each time , twice per day, up to 10 days. Ritonavir 100mg, one tablet each time , twice per day, up to 10 days.
223471962|NCT01658280|DEVICE|EBUS-TBNA|Patients allocated in the intervention group will undergo EBUS-TBNA procedure, performed in a bronchoscopy suite by the same operator under conscious sedation Three needle passes for each approachable station will be performed. The samples obtained will be examined on-site by experienced blinded cytopathologist.All specimens obtained will be send to definitive cytological and histological evaluation and the final diagnosis will be collected and reported on CRFs
223471963|NCT03474224|DEVICE|Ev1000 Clinical Platform from Edwards Lifesciences|The EV1000 Hemodynamic monitoring platform will be used to guide fluid administration following a volume-based parameter such the stroke volume.
223471964|NCT02035566|OTHER|Telehome Care Monitoring|Telehome care monitoring over a 60-day period wherein patients transmit health measurements to their health care professional on a daily basis
223471965|NCT02191826|DRUG|SOM0226|Oral
223471966|NCT03211065|DRUG|20% subcutaneous immunoglobulin|Subcutaneous Immunoglobulin
223471967|NCT06323759|OTHER|educational intervention|In antenatal breastfeeding education: Theoretical contributions on BF (physiology of lactation, frequency complications), hands-on workshop, Provision of educational tools to promote the learning environment: breastfeeding booklet, educational video on breastfeeding, link to a BF specific platform, access to a telephone platform. In short-term postnatal breastfeeding education: Three systematic fallow-up at home or at midwives' office are planned. During these visits, a time of systematic discussion is planned with the nursing mothers. Their knowledge and ability to manage their breastfeeding are checked. The physiology of lactation, the gestures of breastfeeding and the occurrence of common complications are systematically recalled by the liberal midwife. In long-term postnatal breastfeeding education: Invitation of nursing mothers to breastfeeding information meetings at 2nd and 4th month after birth. These meetings will be facilitated either by the liberal midwives.
223471968|NCT05263362|OTHER|no intervention|At one timepoint patients will get physical examination of the breasts, medical photographs will be taken, and they will fill in five questionnaires about satisfaction of the breasts, quality of life and general health.
223471969|NCT05493826|OTHER|No intervention|Non-interventional study based on secondary use of hospital medical record
223471970|NCT00001566|BIOLOGICAL|therapeutic autologous dendritic cells|3 syringes containing 1 x 10\^6peptide pulsed dendritic cells
223471971|NCT00001566|DRUG|indinavir sulfate|Oral dose, 350 mg/m\^2 administered every 8 hours. Maximum dose is 800 mg every 8 hours.
223471972|NCT00001566|PROCEDURE|peripheral blood stem cell transplantation|Harvested autologous T cells, minimum dose 1 x 10\^6/kg will be thawed rapidly in 37 degree water bath and infused sequentially over 5-15 minutes.
223471973|NCT01088087|DIETARY_SUPPLEMENT|colostrum|colostrum, 2g, 2 times a day, for 3 weeks
223471974|NCT05885932|PROCEDURE|Drug-eluting stenting plus aspirin and clopidogrel or ticagrelor|All the participants in this group will be performed with extracranial vertebral artery sirolimus-eluting stenting plus medical therapy including aspirin 100mg per day + clopidogrel 75mg per day or ticagrelor 90mg twice per day for 6 months and mono anti-platelet therapy thereafter.
223471975|NCT05885932|DRUG|Aspirin and clopidogrel or ticagrelor|All the participants in this group will be given medical therapy including aspirin 100mg per day + clopidogrel 75mg per day or ticagrelor 90mg twice per day for 6 months and mono anti-platelet therapy thereafter.
223471976|NCT05885932|PROCEDURE|mono anti-platelet therapy|mono anti-platelet therapy
223471977|NCT00383799|DRUG|iv Amiodarone|
223471978|NCT00383799|DRUG|iv Procainamide|
223471979|NCT02903979|OTHER|HVGIC|In experimental group, the researches will be performed a restoration, after partial caries removal, with high viscosity glass ionomer cement in the teeth with deep caries lesion.
223471980|NCT02903979|OTHER|Indirect pulp capping|In control group, the researches will be performed a indirect pulp capping with calcium hydroxide cement and high viscosity glass ionomer cement in the teeth with deep caries lesion.
223743847|NCT02670655|DEVICE|Iontophoresis application|In Group A, ionotophoresis was performed on MAL-applied sites. We used iontophoresis (vitaliont II®, ITC Inc, Korea) with a patch. The active electrode was the anode, and 0.50-mA/cm2 current was applied to each AK lesion for 10 min.
224160382|NCT02603172|DRUG|GSK3039294|GSK3039294 will be provided as white, opaque capsules. A single capsule or multiple capsules (20 mg to 200 mg), depending on the dosage required, will be taken orally with water.
224160383|NCT03076203|DRUG|Niraparib|Given orally
224160384|NCT03076203|RADIATION|Radium Ra 223 Dichloride|Given intravenously
223471981|NCT02745288|PROCEDURE|inferior alveolar nerve block|"A long acting local anaesthetic agent Inj Bupivacaine hydrochloride 0.5% (2 ml) will be given after induction by open mouth technique by landmark method.~The mucobuccal fold will be palpated and traced till coronoid notch. The finger will be moved medially across the retromandibular trigone on internal oblique ridge. The 25G needle will be inserted till bone is felt. 2 ml of 0.5% bupivacaine will be injected slowly after withdrawing needle by 1mm and confirming negative aspiration of blood."
223471982|NCT00787826|BIOLOGICAL|Live Francisella Tularensis Vaccine|"Approximately 0.0025 mL of vaccine will be administered percutaneously with a bifurcated needle using 15 pricks on the volar surface of the forearm. Vaccination may be repeated up to two times within the year if successful vaccination is not demonstrated by a positive take reaction and a MA titer of ≥ 1:20."
223471983|NCT05398107|BEHAVIORAL|Experimental: Building Emotion Awareness and Mental Health (BEAM)|The BEAM Program is based on best-practices in telehealth and science-based program design aimed at promoting maternal mental health and supportive parenting. The BEAM Program app is hosted on the University of Manitoba secure servers and is designed/managed by Tactica Interactive. The weekly group telehealth sessions will be led by clinical coaches (a mental health professional or Doctoral-Level Clinical Psychology Student) and will use the secure videoconferencing platform Zoom (Healthcare license). Parent coaches will be mothers who have recently participated in a prior iteration of the BEAM program. Parent coaches will engage with participants on the community peer support forum and will also attend weekly telehealth sessions. The therapeutic aims of the BEAM program are to improve symptoms of anxiety and depression as well as parenting skills, and will emphasize self-compassion, effective communication practices, and social support networks.
223471984|NCT05398107|BEHAVIORAL|Control: MoodMission|"MoodMission will be used as our Standard of Care control group. MoodMission is an app based on CBT principles which creates tailored missions for mothers. These missions are based on self-reported mood and are aimed to improve mental health symptoms."
223471985|NCT02917746|DRUG|Imiquimod|Patients in this group are treated with vaginal imiquimod cream during 16 weeks. A control colposcopy with diagnostic biopsies will be performed after 10 weeks to rule out disease progression. A final colposcopy with diagnostic biopsies will be performed after 20 weeks to evaluate disease efficacy.
223580012|NCT02479581|PROCEDURE|ERAS group|"1. Bilateral thoracic paravertebral block before induction of anesthesia;~2. Fast channel anesthesia:~   * Induction use Sufentanil 0.5\~1ug/kg, Vecuronium for Injection 0.15mg/kg and Etomidate 0.2\~0.6mg/kg; ②. Maintain use Remifentanil Hydrochloride for Injection 0.1\~0.4ug/kg·min, Propofol Injection 2\~6mg/kg·h, Sevoflurane 0.5\~1.5（minimum alveolar concentration） and Infusing Dexmedetomidine which load dose 0.5μg/kg in 10min then changed into 0.5-1.0μg/kg·h,Vecuronium 0.06\~0.12mg/kg·h; ③. Intravenous hydromorphone Hydrochloride Injection 0.15mg/kg before surgery over."
223580013|NCT02479581|PROCEDURE|ERAS group|"1. Drink water after 6h, 200ml once, 2\~3 times / day，~2. early ambulation，mobilization within 48 h,~3. Intravenous the conventional antiemetic drugs Tropisetron hydrochloride Injection 12mg qd；~4. Intravenous the lansoprazole 30mg q12h."
223471986|NCT02917746|PROCEDURE|Large Loop Excision of the Transformation Zone|Patients in this group are treated with LLETZ.
223471987|NCT01153919|BIOLOGICAL|romiplostim|Given subcutaneously
223471988|NCT01153919|DRUG|ribavirin|Given orally
223471989|NCT01153919|OTHER|placebo|Given subcutaneously
223471990|NCT01153919|BIOLOGICAL|PEG-interferon alfa-2a|Given subcutaneously
223580014|NCT02479581|PROCEDURE|Conventional control group|Routine preoperative psychological preparation for patients.
223580015|NCT02479581|PROCEDURE|ERAS group|After operation use Ropivacaine 100mg infiltrating intercostal wound and self-controlled intravenous analgesia pump is applicable(Sufentanil 0.05ug/kg·h combine with Ketamine 40ug/kg·h).
223580016|NCT02479581|PROCEDURE|Conventional control group|"1. Routine bowel preparation;~2. Liquid food eating 2 days before the operation;"
223471991|NCT01153919|OTHER|laboratory biomarker analysis|Correlative studies
223580017|NCT02479581|PROCEDURE|Conventional control group|Intramuscular injection of scopolamine 0.3mg combined with morphine 10mg before surgery;
223580018|NCT02479581|PROCEDURE|Conventional control group|"1. Induction use Sufentanil 0.5\~1ug/kg, Vecuronium 0.15mg/kg and Etomidate 0.2\~0.6mg/kg,Midazolam0.05\~0.1mg/kg ;~2. Maintain use Sufentanil 1\~2ug/kg·h, Propofol 4\~12mg/kg·h, Sevoflurane 1\~3(minimal alveolar concentration)， Vecuronium 0.06\~0.12mg/kg·h;"
223471992|NCT06317012|PROCEDURE|Le Fort I osteotomy using CAD CAM surgical guide and 3Dcustomized plate|"Le Fort I osteotomy will be performed with the aid of a surgical guide through the mucosal incision at the maxillary vestibule region, providing adequate surgical exposure.~The planned position will be obtained using a customized titanium plate for precise maxillary position and fixation as planned virtually on the software."
223471993|NCT03361046|DEVICE|Transcatheter Aortic Valve-in-Valve Implantation (ViV-TAVI)|Patients with failed aortic valve bioprostheses qualified for TAVI due to coexisting illnesses
223471994|NCT02914834|OTHER|Acupuncture|Standardized acupuncture treatment administered for 30 minutes each session
223580019|NCT02479581|PROCEDURE|Conventional control group|Use self-controlled intravenous analgesia pump containing Sufentanil 0.07ug/kg·h
223580020|NCT02479581|PROCEDURE|Conventional control group|Intravenous infusion of dexamethasone 20mg during the surgery
223580021|NCT02479581|PROCEDURE|Conventional control group|Intravenous infusion of flucloxacillin sodium 1g before the operation
223580022|NCT04551001|PROCEDURE|Cold forcep polypectomy|Removal of appropriate polyps using cold forceps until no polyp visible under white light. Two additional biopsies performed at margins of polypectomy site.
223580023|NCT04551001|PROCEDURE|Cold snare polypectomy|Removal of appropriate polyps using cold snare until no polyp visible under white light. Two additional biopsies performed at margins of polypectomy site.
223580024|NCT01442064|DRUG|Ranibizumab 0.5 mg|Ranibizumab intravitreal injection 0.5 mg in a single-dose regimen given on an as needed basis no more frequently than every 30 days (no more than 12 injections per year).
223580025|NCT01969617|DRUG|Nalmefene 18 mg, then placebo|One single oral dose Nalmefene on Day 1 and Placebo on Day 8
223580026|NCT01969617|DRUG|Placebo, then Nalmefene 18 mg|One single oral dose Placebo on Day 1 and Nalmefene on Day 8
223471995|NCT02914834|OTHER|Non-pain related video health education|Attention control group will watch health education videos the equivalent of 10 hours from randomization up to study completion.
223580027|NCT04363593|BIOLOGICAL|Serological test|Serological testing is performed for patients with confirmed COVID-19 infection by RT-PCR.
223580028|NCT04363593|BIOLOGICAL|Serum test|Use of the serum taken from patients consulted for suspicion of COVID-19 before the beginning of the trial
223580029|NCT04644744|DEVICE|Hypothermic oxygenated perfusion (HOPE)|HOPE for 1 hour via the portal vein in a recirculating and pressure controlled system (2-3 mm Hg), 0.1 ml/g liver/min, perfusion volume 3-4 L, Belzer (UW) machine perfusion solution, perfusate temperature 10 °C, perfusate oxygenation pO2 of 60-80 kPa
223743848|NCT02670655|DEVICE|irradiation with red light-emitting diode lamp|After incubation for 2 (Group A and B) or 3 hours (Group C), the dressing and cream were removed, and the area was cleansed with saline. The area was irradiated with a red light-emitting diode lamp (Aktilite CL 128; PhotoCure ASA, Oslo, Norway) with peak emission at 632 nm, placed 5 cm away from the skin surface, and a total light dose of 37 J/cm-2. All patients wore protective goggles during illumination.
224160385|NCT04377126|DRUG|Ghrelin|Ghrelin is a peptide and hormone that is primarily produced by P/D1 cells of the gastric fundus and circulates in both acylated and unacylated forms. This pilot trial will gather preliminary evidence to test investigators hypothesis that unacylated ghrelin improves walking performance and prevents mobility loss in older patients with PAD.
224160386|NCT04377126|DRUG|Placebo|Placebo will consist of saline- no active ingredient.
224160387|NCT04290260|OTHER|Use of breast bra|Patients will use a breast from admission to hospital discharge
224160388|NCT04290260|OTHER|Usual care (not use of bra)|
223471996|NCT00117390|PROCEDURE|Measurement of inulin clearance|
223471997|NCT03060473|DRUG|Azithromycin|Azithromycin 1 gm PO once
223471998|NCT03060473|DRUG|Erythromycin|Erythromycin 250 mg IV every 6 hours for 48 hours followed by 500 mg PO every 8 hours for 5 days.
223471999|NCT03060473|DRUG|Ampicillin|Ampicillin 2 gm IV every 6 hours for 2 days
223472000|NCT03060473|DRUG|Amoxicillin|Amoxicillin 500 mg PO every 8 hours for 5 days (Azithromycin ARM) Amoxicillin 250 mg PO every 8 hours for 5 days (Erythromycin ARM)
223472001|NCT05748899|BEHAVIORAL|Ujjayi pranayama|this group will receive home-based daily ujjayi pranayama for six weeks (fifteen minutes in the morning and 15 min in the evening, this training will be online supervised).
223472002|NCT02172976|DRUG|Gemcitabine|
223472003|NCT02172976|DRUG|Oxaliplatin|
223472004|NCT02172976|DRUG|5-Fluorouracil|
223472005|NCT02172976|DRUG|Irinotecan|
223472006|NCT02172976|DRUG|Natriumfolinate|
223580030|NCT04644744|DEVICE|Normothermic machine perfusion (NMP)|End-ischemic NMP will be continued throughout the recipient hepatectomy and until the transplanting team is ready to implant the liver. The minimum protocol-stipulated NMP duration is 4 hours, the time needed for ATP repletion in animal studies. Total NMP preservation time will be according to the official recommendations of the manufacturer (4-24 hours) and at the discretion of the local transplant centre. The liver allograft will be disconnected from the OrganOx metra® device immediately prior to transplantation and flushed with three litres of HTK via the hepatic artery and the portal vein.
223580031|NCT00769249|OTHER|questionnaire administration|Patients and their caregivers complete three questionnaires that will take approximately 20 minutes either by mail or telephone. The questionnaires comprise of demographic and psychosocial correlates of posttraumatic growth including age, ethnicity, socioeconomic status, education, anxiety, relationship quality, coping style, social support, and cultural beliefs about caring for elders.
223580032|NCT00769249|OTHER|study of socioeconomic and demographic variables|Patients and their caregivers complete three questionnaires that will take approximately 20 minutes either by mail or telephone. The questionnaires comprise of demographic and psychosocial correlates of posttraumatic growth including age, ethnicity, socioeconomic status, education, anxiety, relationship quality, coping style, social support, and cultural beliefs about caring for elders.
223743849|NCT06429462|DIAGNOSTIC_TEST|smartphone camera sensor tool|The study will involve the development and validation of a computer vision-based approach (using cameras to assess movements) to monitor knee flexion and extension, and a walking pattern assessment.
224069292|NCT02235532|OTHER|Foramen Herbal Aloe toothpaste|use of aloe-vera toothpaste for 30 days in the test group.
224069293|NCT02235532|OTHER|fluoride toothpaste|use of signal toothpaste once a day for 30 days in the control group.
224069294|NCT05381064|DEVICE|artificial intelligence assistance system|A deep learning-based bile duct scanning system that can prompt endoscopists to scan standard stations, identify bile ducts and stones in real time
224069295|NCT05562986|DIAGNOSTIC_TEST|GCF (gingival crevicular fluid) collection|Prior to GCF (gingival crevicular fluid) sampling, supragingival plaque was removed by sterile curets and, after air drying, the surfaces were isolated by cotton rolls. Filter paper strips (periopaper, proflow Inc., Amityville, NewYork, USA) were placed in sulcus for 30s. Care was taken not to avoid mechanical trauma and strips contaminated with blood or saliva were discarded. The absorbed GCF volume was estimated by a calibrated instrument (periotron 8000, proflow Inc., Amityville, NY, USA). Then, the strips were sealed into sterile tubes before freezing at -80 0C. The readings were converted to an actual volume (μl) by reference to the standard curve.
224069296|NCT02684214|BEHAVIORAL|Prevention Plus +|Families will receive 6 monthly newsletters and meet with a BHC at the clinic for 30 minutes during months 1, 3, and 5. Child height and weight will be taken. Families will receive feedback about growth and the weight status of their child. The session materials will be reviewed and behavioral parenting strategies will be encouraged to aid with changing two dietary and two leisure-time activity (energy balance) behaviors of the child. The caretaker will also change the same energy balance behaviors as the child, as adult caretakers can then model healthy behaviors. The caretaker and child will be encouraged to change and self-monitor energy balance behaviors with the use of the picture-based diaries. During months 2, 4, and 6, BHCs will complete a 20-minute phone call with the caretaker. Caretakers will be asked to measure the height and weight of their child, calculate BMI and plot it on the BMI-for-age growth chart prior to the call. The BHC will provide feedback.
224069297|NCT02684214|BEHAVIORAL|Prevention Plus -|This condition will be identical to PP+ except that caretakers will not receive any energy balance behavior goals. Additionally, the caretaker will not self-monitor energy balance behaviors. The focus will be on all other behavioral parenting strategies to assist the child with making changes in the targeted behaviors.
223472007|NCT05115799|OTHER|Manual Therapy, Physiotherapy, Kinesiology, Scar Massage|"The physiotherapist performs passive kinesitherapy on the mastectomized patient with lymphatic thrombus, and scar massage when the arm maintains its greater range of mobility.~The patient will never present pain during the rehabilitation session above 5 in Pain Scale Analog Scale."
223472008|NCT05115799|OTHER|Kinesiotherapy, Physiotherapy, Health Education|These users will be instructed in hygienic-postural care and active auto-kinesitherapy assisted to perform daily for 30 minutes. The investigators will value following the instructions every 30 days
223472009|NCT04443335|BEHAVIORAL|continous feeding|At the beginning, all the patients received continuous feeding. After achieving ≥80% of the nutrition target calories (25-30 kcal/kg/d) through continuous feeding, the patients were randomly assigned into the sequential feeding (SF) group or the continuous feeding (CF) group with a random number table. Patients in the CF group received continuous feeding with constant velocity by enteral feeding pump over one day.
223472010|NCT04443335|BEHAVIORAL|sequential feeding|At the beginning, all the patients received continuous feeding. After achieving ≥80% of the nutrition target calories (25-30 kcal/kg/d) through continuous feeding, the patients were randomly assigned into the sequential feeding (SF) group or the continuous feeding (CF) group with a random number table. In the SF group, continuous feeding was changed into time-restricted feeding. The total daily dosage of enteral nutrition was equally distributed during three time periods at 7-9:00, 11-13:00 and 17-19:00. Other times of the day were fasting times. Enteral nutritional suspension in each time period was administered at a uniform rate within two hours by an enteral feeding pump.
223472011|NCT00345085|DEVICE|Wavefront and Contrast Sensitivity|
223472012|NCT00254371|PROCEDURE|Androgen Replacement|
223472013|NCT00975416|BEHAVIORAL|Cognitive Behavioral Therapy|Intranasal oxytocin given in the context of cognitive behavioral therapy
223472014|NCT00975416|DRUG|Intranasal Oxytocin|Intranasal oxytocin given in the context of cognitive behavioral therapy
223472015|NCT00975416|DRUG|Placebo|Placebo given in the context of cognitive behavioral therapy
223472016|NCT00109096|DRUG|Pemetrexed|
223472017|NCT03962400|PROCEDURE|Reinforcement Learning|New computer based procedure for determining dose using a decision support tool
223472018|NCT03962400|PROCEDURE|Heath Care Provider|Warfarin dose will be determined by a qualified health care provider
223472019|NCT03017092|BEHAVIORAL|Tablet-guided tobacco intervention|This intervention, as guided by a tablet computer, is a brief (20 minute) counseling intervention designed to increase motivation to quit smoking and to increase knowledge of methods of quitting.
223472020|NCT03927443|DRUG|SDP-133|one drop
223472021|NCT03927443|DRUG|Lumigan|one drop
223580033|NCT00769249|PROCEDURE|psychosocial assessment and care|Patients and their caregivers complete three questionnaires that will take approximately 20 minutes either by mail or telephone. The questionnaires comprise of demographic and psychosocial correlates of posttraumatic growth including age, ethnicity, socioeconomic status, education, anxiety, relationship quality, coping style, social support, and cultural beliefs about caring for elders.
223580034|NCT05478668|OTHER|visual analog scale|In all patients, the assessment of anesthetic risk was carried out according to the ASA scale. The basic tool for pain intensity research was a visual analog scale. Intervals between analgesia were also studied. The study of the neuropathic component of pain was carried out using the Didier Bouhassiraa neuropathic pain diagnostic questionnaire. Study of the presence of an acute stress reaction The Hospital Anxiety and Depression Scale. Research on the presence of post-traumatic stress disorders was carried out using the Mississippi scale of post-traumatic stress disorders (military version). Satisfaction with treatment results was studied using the Chaban Quality of Life Scale.
223580035|NCT02513758|OTHER|sample|Men will have blood sampling tubes of 10 ml each, a saliva sample and a sample of sperm Women will have a two blood sampling tubes of 10 ml each, a saliva sample and a sampling cervicovaginal secretions
223580036|NCT00682136|PROCEDURE|US-Guided Ropivacaine TAP Block|Bilateral injection of local anaesthetic into the Transversus Abdominis plane, guided by ultrasound.
223580037|NCT00755534|DRUG|Irinotecan|Irinotecan (IV) 150 mg/m2 on day 1 every two weeks until progression
223580038|NCT00755534|DRUG|Capecitabine|Capecitabine (p.o) 2000 mg/m2 (1000 mg/m2 x 2) on day 1-7 every 2 weeks until progression
223580039|NCT00755534|DRUG|Cetuximab|Cetuximab(IV) 500 mg/m2 on day 1 every two weeks until progression
223580040|NCT00755534|DRUG|Oxaliplatin|Oxaliplatin (I.V) 85 mg/m2 on day 1 every two weeks until progression
223580041|NCT02338934|DRUG|Combination Cinacalcet with Vitamin D analogue|Depending on the iPTH level and the serum calcium level they will be started on Cinacalcet 25mg OD and active Vitamin D will be adjusted. If Serum Cal \<2.4 mmol/L - Start Cinacalcet 25mg OD \& Increase active Vit D by 1 mcg/dose 3x/week Increase active Vit D by 1 mcg/dose 3x/week or Serum Ca 2.4-2.54 mmol/L- Start Cinacalcet 25mg OD and Maintain active Vit D dose OR if \>2.54 mmol/L - Start Cinacalcet 25mg OD \& Maintain active Vit D dose. Then they will go to maintenance phase.
223472022|NCT06227169|BEHAVIORAL|JJ-COPES Training|• The JJ-COPES training is derived from an empirically supported CBT manual designed for outpatient treatment of suicidal adolescents. JJ-COPES training focuses on teaching 4 primary treatment strategies plus a caregiver session to community-based clinicians.
223472023|NCT00374010|BEHAVIORAL|Patient-Centered Advance Care Planning|"The PC-ACP is a scheduled interview with the dyad, delivered by a trained nurse facilitator. It consists of 5 stages and lasts about an hour:~1. Representational assessment (10 - 15 minutes);~2. Exploring concerns related to planning for future medical decision-making (10 - 15 minutes);~3. Creating conditions for conceptual change (5 minutes);~4. Introducing replacement information using a disease-specific Statement of Treatment Preferences document (15 minutes); and~5. Summary (3 - 5 minutes)"
223472024|NCT04041817|OTHER|Trigger setting of pressure support ventilation|Trigger variations will be performed following increasing steps of 3 L/min every 15 minutes, from 0.2 to 15 L/min (0.2 - 3 - 6 - 9 - 12 - 15).
223472025|NCT04753034|DRUG|TER-101|Active Comparator
223472026|NCT04753034|DRUG|Vehicle|Placebo Comparator
223472027|NCT04896216|BEHAVIORAL|Stigma Reduction Intervention|Care providers will complete the Stigma Reduction Intervention curriculum. This study uses a modified Zelen design. Control arm participants will be aware that they are part of an observational study but not that they are in the control arm of an intervention study. This avoids artificially inducing changes to the standards of medical care in facilities randomization to the control arm, a common consequence in RCTs to evaluate population based services.
223472028|NCT04382534|COMBINATION_PRODUCT|Respiratory rehabilitation|Health education and energy saving techniques, chest activity training, local lung dilation techniques, breathing training, airway clearance training, aerobic exercise, resistance training
223472029|NCT04372368|BIOLOGICAL|COVID-19 Convalescent Plasma|1-2 units of COVID-19 convalescent plasma will be administered over 1 to 2 hours (rate of 100 to 200 mL/hr)
223472030|NCT06313463|DRUG|Carrellizumab + Capecitabine|Capecitabine 1000-1250mg/m2 PO bid D1-14（Q3W）+ Carrellizumab 200mg IV D1（Q3W），8 cycles in total
223472031|NCT06313463|DRUG|Placebo + Capecitabine|Capecitabine 1000-1250mg/m2 PO bid D1-14（Q3W）+ Placebo 200mg IV D1（Q3W），8 cycles in total
223472032|NCT00672802|DRUG|Ramelteon and Placebo|Ramelteon 16 mg, tablet, orally, once daily for Periods 1 or 2 and ramelteon placebo-matching tablets, orally, once daily for Periods 1 or 2.
223472033|NCT01653275|OTHER|Mediterranean Diet|Subjects will receive key foods (olive oil, walnuts, frozen portions of high n-3 LCPUFA fish) and instructed in the quantity to consume each week. Olive oil : minimum of 3 tablespoons per day. Walnuts:10.5 oz/week (1.5 oz/day). High n-3 LCPUFA fish: 3 or more fish meals per week. Additional guidelines for altering diet include incorporation of fruits, vegetables, legumes, and whole grains to replace sweets, white bread and starches, red meat and highly processed foods.
223472034|NCT02097498|OTHER|Directed feedback|Group will receive feedback from an airway management expert while the paramedic review their baseline simulation scenario through recorded video
223472035|NCT02097498|OTHER|Basic Videolaryngoscopy Videos|Group will watch a series of educational videos related to common airway management errors.
223472036|NCT01249131|DRUG|Cobimetinib|Cobimetinib 20 mg will be given orally as tablet formulation in fasted or fed state, or as capsule formulation in fasted state.
223472037|NCT00137709|DRUG|Sodium valproate|Week 1 \& 2 - 200mg twice daily Week 3 onwards - 400mg twice daily
223472038|NCT00137709|DRUG|Lamotrigine|Week 1 - 25mg mane Week 2 - 25mg twice daily Week 3 - 25mg mane, 50mg nocte Week 4 onwards - 50mg twice daily
223472039|NCT04301973|OTHER|Stool collection|There is no intervention with a product in this study. The healthy subject has just to come 2 times in the clinical trial unit for clinical exam including urinary pregnancy test, fill life habits and diet questionnaires, and provide one stool sample for the 2nd visit, after 2 weeks of alimentary restrictions.
223472040|NCT05058963|BEHAVIORAL|Mantram repetition program|"Week 1: Define and describe the characteristics of a mantram as taught by Eknath Easwaran and how it relates to posttraumatic stress (PTSD) Week 2: Identify ways to choose and use mantram repetition for training attention and targeting craving.~Introduction to substance craving and identify triggers for use. Week 3: Describe the relationship between the PTSD/stress response, mantram repetition and the relaxation response Week 4: Describe at least two benefits of slowing down versus automatic pilot for stress reduction Week 5: Describe at least two benefits of one-pointed attention versus multitasking for stress reduction Week 6: Demonstrate how one-pointed attention and slowing down complement each other for making healthy choices Week 7: List at least five strategies for making mantram repetition a part of your life Week 8: Discuss applications of mantram repetition, one-pointed attention and slowing down for overall health and substance use"
223472041|NCT01219608|DIETARY_SUPPLEMENT|Glutamine 0.5 g/kg/day|Glutamine 0.5 g/kg/day
223472042|NCT01219608|DIETARY_SUPPLEMENT|Glutamine 1 g/kg/day|Glutamine 1 g/kg/day
223472043|NCT01219608|DIETARY_SUPPLEMENT|Enteral Nutrition|Ordinary Enteral Nutrition
223580042|NCT06455410|DRUG|GP|gemcitabine + cisplatin
223580043|NCT06455410|DRUG|Adebrelimab|a PD-L1 inhibitor
223580044|NCT06455410|DRUG|concurrent chemoradiotherapy (CCRT)|concurrent chemoradiotherapy (CCRT)
223580045|NCT02945553|DEVICE|Neuromuscular electrical stimulation|Neuromuscular electrical stimulation (NMES) will be performed 5 times/week for one hour each day. NMES will start within 1 week of injury and continue till 3 weeks following surgery.
223580046|NCT02945553|DEVICE|Microstimulation|Microstimulation will be performed 5 times/week for one hour each day. Microstimulation will start within 1 week of injury and continue till 3 weeks following surgery.
223580047|NCT04710914|DRUG|Prolonged sedation with isoflurane|"Adult patients admitted to the surgical intensive care unit at the Rouen University Hospital for septic shock and requiring sedation for more than 3 days and a maximum of 10 days will be randomised in two groups.~The experimental group will receive sedation by inhaled isoflurane The control group will receive sedation by intravenous midazolam"
223580048|NCT04710914|DRUG|Prolonged sedation with midazolam|"Adult patients admitted to the surgical intensive care unit at the Rouen University Hospital for septic shock and requiring sedation for more than 3 days and a maximum of 10 days will be randomised in two groups.~The experimental group will receive sedation by inhaled isoflurane The control group will receive sedation by intravenous midazolam"
223580049|NCT03553498|DRUG|IV acetaminophen|acetaminophen given intravenously
223580050|NCT03553498|DRUG|IV placebo|given intravenously
223580051|NCT03553498|DRUG|hydromorphone|hydromorphone given intravenously
223580052|NCT04941807|DEVICE|Platelet-rich plasma|Blood will be drawn from a vein in the patient's arm into an 11 ml Eclipse platelet-rich plasma Tube. The blood is processed using a centrifuge machine from eclipse medical. After centrifugation, the platelet poor portion will be separated from the platelet-rich portion. The proximal nail folds are cleansed with alcohol. Using a 1ml syringe and 30g needle, 0.1-0.2 ml of platelet-rich plasma is injected into 8 proximal nail folds.
223580053|NCT04941807|DEVICE|Platelet-poor plasma|Blood will be drawn from a vein in the patient's arm into an 11 ml Eclipse platelet-rich plasma Tube. The blood is processed using a centrifuge machine from eclipse medical. After centrifugation, the platelet poor portion will be separated from the platelet-rich portion. The proximal nail folds are cleansed with alcohol. Using a 1ml syringe and 30g needle, 0.1-0.2 ml of platelet-poor plasma is injected into 2 proximal nail folds.
223580054|NCT04239794|DRUG|Propofol|General anesthesia during the laparoscopic colorectal surgery is achieved by using a target-controlled intravenous infusion of propofol.
223580055|NCT04239794|DRUG|Sevoflurane|General anesthesia during the laparoscopic colorectal surgery is achieved by using an inhalation agent (Sevoflurane).
223580056|NCT05309213|BIOLOGICAL|IM19 CAR-T cells|IM19 CAR-T cells will be administered at dose level:5 x 10\^4 CAR+ T cells/kg,1x 10\^5 CAR+ T cells/kg,3 x 10\^5 CAR+ T cells/kg,1 x 10\^6 CAR+ T cells/kg
223580057|NCT01618617|DIETARY_SUPPLEMENT|High dose Multistrain probiotic, 100 billion cfu/day|100 billion cfu live bacteria (60 billion cfu bifidobacterium cultures and 40 billion lactobacillus cultures).
223472044|NCT06342232|BEHAVIORAL|Neurofeedback mindfulness|The participants used a portable EEG headband to complete 10 minutes of neurofeedback mindfulness practice for 8 weeks. While being seated comfortably, they could modify their brains rates based on the audio neurofeedback they received.
223472045|NCT06342232|BEHAVIORAL|Simple attention controlled task|The controlled group of this project also received an intervention which included an audiobook. While wearing the headband, the controlled participants muted their neurofeedback sounds and only focused on an audiobook while remaining relaxed. A summary of their brain states was given to them when completing their practice every day.
223472046|NCT04069117|DRUG|letrozole 2.5mg (Femara; Novartis Pharma Services, Basel, Switzerland)|letrozole /antagonist protocol
223580058|NCT01618617|DIETARY_SUPPLEMENT|Low dose Multistrain probiotic, 15 billion cfu/day|15 billion cfu live bacteria (9 billion cfu bifidobacterium cultures and 6 billion lactobacillus cultures).
223580059|NCT02741570|BIOLOGICAL|Nivolumab|
223580060|NCT02741570|BIOLOGICAL|Ipilimumab|
223580061|NCT02741570|DRUG|Cetuximab/Erbitux|
223580062|NCT02741570|DRUG|Cisplatin/Platinol|
223580063|NCT02741570|DRUG|Carboplatin/Paraplatin|
223580064|NCT02741570|DRUG|Fluorouracil/Adrucil|
223580065|NCT01100567|DEVICE|Low-magnitude mechanical stimulation platform|Low-magnitude mechanical stimulation platform
224160389|NCT02912949|DRUG|zenocutuzumab (MCLA-128)|full length IgG1 bispecific antibody targeting HER2 and HER3
224304146|NCT03056157|BEHAVIORAL|Adaptive Disclosure for Moral Injury and Loss|AD-MIL is a manualized, 12-session individual psychotherapy designed to improve functioning and to reduce PTSD symptoms by facilitating Veterans doing corrective things in their life to heal and repair traumatic loss and moral injuries. The change agents are: (1) emotional-processing of traumatic loss and moral injuries and motivating a healing and action plan by writing therapeutic letters (e.g., to a lost unit member, to victims of personal transgressions, to people who transgressed); (2) skills training and behavioral contracting to improve functioning and targeting moral injury- and traumatic loss-related psychological and behavioral obstacles to positive and potentially habilitative engagements in occupational, relationship, and family roles; and (3) teaching self- and other-compassion and mindfulness. The goal is to redress the functional impact of moral emotions (anger, shame).
224304147|NCT03056157|BEHAVIORAL|Present Centered Therapy|Participants randomized to the PCT arm will receive 12 sessions of therapy focused on day-to-day functional problems with no focus on trauma or re-visiting past experiences
223580066|NCT01738113|OTHER|Open Kinetic Chain exercise|"1. Hamstrings strengthening exercise~2. Quadriceps strengthening exercise~3. Hamstrings stretch~4. Hip extensors and abductors strengthening~5. Calf-muscles stretching~6. Strength exercise of ankle dorsiflexors \& plantar flexors"
223580067|NCT01738113|OTHER|Closed kinetic chain exercise|"1. Foot sliding from sitting~2. Seated Toe Raises~3. Hamstrings and quadriceps co-contraction from sitting~4. Bridging exercise~5. Sitting-to-standing~6. Side-to side, forward and backwards weight shifting~7. Lunge exercise~8. Squatting exercise~9. Standing Toe Raises~10. Standing Hamstrings Stretch"
223580068|NCT04557475|DRUG|Aspirin|Two tablets daily with dinner
223580069|NCT02316210|DEVICE|electrical stimulation|
223580070|NCT01005212|DRUG|Definity|An intravenous line will be placed and 1.3 mL of the ultrasound contrast agent DEFINITY® will be added to 50 mL sterile saline. Flow will be initiated at 4.0 mL/minute and adjusted for optimal imaging. A maximum of 1.3 mL or one vial of ultrasound contrast will be used per patient per session according to the manufacturer's guidelines.
223580071|NCT03039894|OTHER|Gradebook Game|Students in the intervention group will spend time meeting as teams to review their scorecards, and do team-building activities, all of which will occur during non-content periods at school (Advisory and Enrichment).
223580072|NCT05649592|DIAGNOSTIC_TEST|Magnetic Resonance Hydrolipid Separation Imaging|"MRHS was used to measure different muscle percent fat of core muscles. MRHS, also called Dixon imaging, mainly used the different resonant frequency between the hydrogen nuclei in water and in fat to perform the data acquisition at different echo times (TE). The Dixon sequence basically acquires two images, one image with water and fat signals in-phase and the other with water and fat signals out-of-phase: the sum and subtraction of the two images allow the production of a water-only image and a fat-only image. Scanning equipment: 3.0T superconducting Siemens Skyra Scanner.~Scanning parameters: TR5.36ms, TE1.24ms, Flip Angle 9°, number of layers was 44-60, thickness of layer was 5.0 mm, layer interval 1.0mm, FOV50cm×50cm, the scanning time was 12s×5."
224160390|NCT05364112|DEVICE|Compreflex|The Compreflex standard calf and foot (with basic liner) from Sigvaris (St. Gallen, Switzerland) is an easy-to-use interlacing Velcro wrap device with adjustable compression levels.
224304148|NCT02077439|DEVICE|Hand Robotic Training|Training for 20 sessions for one hour, 3-5 times per week.
223472047|NCT06473441|BEHAVIORAL|Tele-Rehabilitation Therapy|Twice-weekly sessions with remote supervision and guidance from therapists.
223472048|NCT06473441|BEHAVIORAL|Health Education|Health education based on individual assessments.
223472049|NCT06473441|BEHAVIORAL|Exercise Prescription|Exercise prescription tailored to individual needs.
223472050|NCT06473441|BEHAVIORAL|Home Exercise Equipment Use|Use of a home exercise bike, resistance bands, respiratory muscle training device, and a portable heart rate monitor.
223472051|NCT06473441|BEHAVIORAL|Exercise Log|Logging daily exercise intensity and duration in a rehabilitation diary
223580073|NCT05252221|OTHER|ATC Intervention|The ATC intervention offers convenient access to specialty consultation for PCPs and offers patients direct access to addiction treatment in a non-stigmatized primary care setting
224160391|NCT02444806|OTHER|Full polysomnography|Full sleep and respiratory monitoring with EEG
224160392|NCT02444806|OTHER|Oximetry-capnography|Limited monitoring with nurse observation and continuous oximetry-capnography overnight for NIV titration.
224160393|NCT04154761|PROCEDURE|Resection of inferior vena cava and reconstruction|Resection of inferior vena cava and reconstruction with primary repair, resection with autologous or prosthetic patch repair, and circumferential resection with graft replacement
224160394|NCT01528995|DEVICE|Medtronic Interstim II-3058|impulse generator
224160395|NCT01528995|PROCEDURE|Anal bulking injection|"Permacol injection:~four submucosal injections are administered at the 12, 3, 6 and 9 o'clock positions, above the level of the dentate line. The injection produces a bulge in the mucosa"
224304149|NCT02077439|DEVICE|Hand and Arm Robotic Training|Training for 20 sessions for one hour, 3-5 times per week.
223472052|NCT06473441|BEHAVIORAL|Follow-Up Calls|Regular follow-up calls to monitor progress and address any issues.
223472053|NCT02227095|BEHAVIORAL|Exercise|Heart rate monitors worn by each child at each session
223580074|NCT00624416|DRUG|Prednisolone synthetic cortisone and Isoproterenol together|Approximately 0.2 to 0.4cc of isoproterenol-prednisolone solution (0.04 - 0.08 mg isoproterenol and 0.07 - 0.14 mg prednisolone) in one or more sites in the lipoma depending on its size, 5 days a week for 4 weeks.
223580075|NCT01058512|DRUG|NOV-205|"There will be 4 treatment Groups with 10 patients in each group:~* Group A: 30 mg NOV-205 daily subcutaneous administration for 49 days~* Group B: 30 mg NOV-205 daily subcutaneous administration for 98 days~* Group C: 60 mg NOV-205 daily subcutaneous administration for 49 days~* Group D: 60 mg NOV-205 daily subcutaneous administration for 98 days"
223580076|NCT00160199|DRUG|PROMETRIUM® 300 mg|300 mg (3x100mg capsules) by mouth once daily at bedtime for 10 days X 3 cycles
223580077|NCT00160199|DRUG|PROMETRIUM® 400 mg|400 mg (4x100mg capsules) by mouth once daily at bedtime for 10 days X 3 cycles
224160396|NCT01769625|DRUG|placebo/celecoxib 400 mg and cholecalciferol 400 IU/cholecalciferol 2,000 IU|Take 1 capsule from each bottle (1 bottle containing either placebo/celecoxib and 1 bottle containing either cholecaliferol 400 IU/cholecaliferol 2,000 IU) for 30 days
223472054|NCT02227095|BEHAVIORAL|After-school program|Supervised recreational program with token economy
223472055|NCT02824445|DEVICE|individualized Transcranial Magnetic Stimulation|
223580078|NCT05209308|DRUG|Zandelisib|Zandelisib taken orally for 7 days of each 28 day cycle
223580079|NCT05209308|DRUG|Rituximab|Rituximab IV for 6 cycles
223580080|NCT05209308|DRUG|Venetoclax|Orally - Ramp up weeks 1-5
223580081|NCT05908708|DEVICE|Medtronic 780G® hybrid closed loop|"Medtronic 780G® hybrid closed loop system uses the commercial auto-mode with an insulin pump and continuous glucose monitoring."
223580082|NCT00821249|DRUG|ARRY-520, KSP(Eg5) inhibitor; intravenous|Part 1: multiple dose, escalating; Part 2: multiple dose, single schedule; Part 3: multiple dose, single schedule.
223580083|NCT00821249|DRUG|Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous|Part 1: standard of care; Part 2: standard of care; Part 3: standard of care.
223580084|NCT00821249|DRUG|Dexamethasone, steroid; oral|Part 3: standard of care.
223580085|NCT00768404|DRUG|Topirmate and Phentermine|A single oral dose of the combination product VI-0521 (15 mg phentermine and 92 mg topiramate) will be administered with 240 mL of water at hour 0.
223580086|NCT03003078|DEVICE|OncoSil™|The implantation of OncoSil™
223472056|NCT06422039|DRUG|HRS-7535（D）Tablets|One HRS-7535（D）Tablet is administered to healthy subjects.
223472057|NCT06422039|DRUG|HRS-7535（C）Tablets|Two HRS-7535（C）Tablets is administered to healthy subjects.
223472058|NCT04971603|OTHER|Acupuncture|"All acupuncture operations were done by registered Chinese medicine practitioner. Sterile, disposable acupuncture needles (0.25mmin diameter and 40mmin length) were used, which were purchased from HuaTuo acupuncture instrument.~Principal points: Neiguan (PC 6) \*, Sanyinjia (SP 6) \*, Weizhong (BL 40) \*, Baihui (GV 20), Shuigou (GV 26) \*, Zusanli (ST 36) \*, Quchi (LI 11) \*, Waiguan (TE 5) \*, Hegu (LI 4) \*, Huantiao (GB 30) \*, Yanglingquan (GB 34)\* (Grading of recommendation: C, level of evidence: IV).~Supplementary points: If upper limbs hemiplegia occurs, add Jianliao (TE 14) and Shousanli (LI 10); if lower limbs hemiplegia occurs, add Xuanzhong (GB 39) and Taichong (LR 3); if a deviation of the mouth or tongue occurs, add Dicang (ST 4) and Jiache (ST 6)."
223580087|NCT04674501|PROCEDURE|Cardiac evaluation and blood sampling|"Patients in this cohort will undergo cardiac evaluation before and after thoracic irradiation.~The dose-volume parameters for each cardiac substructures will be estimated using artificial intelligence-based auto-segmentation of the heart in CT images. Dose-volume parameters that predict cardiotoxicity will be analyzed.~The patients who developed cardiotoxicity will undergo blood sampling to establish cardiomyocytes derived from induced pluripotent stem cells, which will be used for identifying the mechanisms of radiation-induced cardiotoxicity and therapeutic targets."
223580088|NCT00493428|DRUG|Baclofen|Patients will receive an initial dose of: 5 mg tid to be increased as tolerated to a maximum dose of 20 mg qid. This dose range and schedule reflects that suggested for the drug's muscle relaxant properties in human.
223580089|NCT04220437|OTHER|no interventin|Our stusy analysed the images obtained from ISR patients, no extra intervention was given based on this study.
223580090|NCT03371173|DRUG|Ferric maltol 30 mg (Feraccru®)|Feraccru® 30 mg hard capsules will be used. Each capsule contains 30 mg iron (as ferric maltol), 91.5 mg of lactose, 0.5 mg of Allura Red AC (E129) and 0.3 mg Sunset Yellow FCF (E110) as excipients with known effects
224160397|NCT00047008|DRUG|cisplatin|100 mg/m\^2 intravenously on days 1, 22
224160398|NCT00047008|RADIATION|Standard fractionation RT|Radiation will be delivered in 2 Gy per fraction, five fractions a week. The primary tumor and clinically/radiologically involved nodes will receive 70 Gy in 7 weeks and uninvolved nodes will receive 50 Gy in 5 weeks. The anterior lower neck field will be treated with 2 Gy per fraction at 3-cm depth to a total dose of 50 Gy.
224160399|NCT00047008|RADIATION|Accelerated fractionation radiation therapy|Radiation to the initial target volume encompassing the gross and subclinical disease sites will be delivered in 1.8 Gy per fraction, five fractions a week to 54 Gy in 30 fractions over 6 weeks. At 32.4 Gy/18 Fx (i.e., latter part of week 4), the boost volume covering gross tumor and clinically/radiologically involved nodes will receive boost irradiation of 1.5 Gy/Fx as second daily fraction (at least 6 h interval) for a total of 12 treatment days (18 Gy total). The primary tumor and clinically/radiologically involved nodes will receive 72 Gy in 42 fractions over 6 weeks and uninvolved nodes will receive 54 Gy in 6 weeks. Clinically/radiologically negative posterior neck should receive a minimum dose of 50.4 Gy at 3 cm. The anterior lower neck field will be treated with 1.8 Gy per fraction at 3-cm depth to a total dose of 50.4 Gy in 28 fractions in 5.6 weeks.
224304150|NCT02077439|OTHER|Conventional therapy|Training for 20 sessions for one hour, 3-5 times per week.
223580091|NCT00494910|BEHAVIORAL|Meaning Centered Group Psychotherapy|this eight-week (1 ½ hour weekly sessions) Session 1 - Concepts of Meaning and Sources of Meaning Session 2 - Cancer and Meaning Session 3 - Meaning and Historical Context of Life Session 4 - Storytelling, Legacy Project (optional) Session 5 - Limitations and Finiteness of Life Session 6 - Responsibility, Creativity, Deeds Session 7 - Experience, Nature, Art, Humor Session 8 - Transitions, Goodbyes, Hopes for the Future
223472059|NCT02378662|BIOLOGICAL|MDGN201 TARGTEPO|MDGN201 TARGTEPO secreting EPO
223472060|NCT00542893|DRUG|Genasense® (G3139, oblimersen sodium)|
223472061|NCT00542893|DRUG|Genasense followed by DTIC; then DTIC alone|Cycle 1: Genasense 7 mg/kg/day for 5 days followed by DTIC 1000 mg/m2 Cycle 2: DTIC 1000 mg/m2
223472062|NCT00542893|DRUG|DTIC alone; then Genasense followed by DTIC|Cycle 1: DTIC 1000 mg/m2 Cycle 2: Genasense 7 mg/kg/day for 5 days followed by DTIC 1000 mg/m2
224160400|NCT00047008|PROCEDURE|Conventional surgery for select patients|"Surgical removal (salvage resection) of the primary tumor should be performed if biopsy-proven cancer remains more than three months after completion of therapy. The nature of the surgical resection should be dictated by the extent of tumor at the initial evaluation. The operation should be conducted using accepted criteria for primary surgical treatment of the cancer.~A planned neck dissection for patients with multiple neck nodes or with lymph nodes exceeding 3 cm in diameter (N2a, N2b, N3) is mandatory, regardless of the clinical and/or radiographic response. A neck dissection is required for patients with N1 disease if a palpable or worrisome radiographic abnormality persists in the neck six weeks after completion of therapy. Surgery should be performed within 2 weeks once the decision for neck dissection is made."
224160401|NCT03599544|BEHAVIORAL|Robot-Assisted Therapy (RT)|Highly intensive robot-assisted therapy for the paretic arm with the Armeo exoskeleton (1 hour sessions, 3x week for 3 weeks) followed by robot-assisted therapy for hand motions with Amadeo robot (3x week for 3 weeks).
224160402|NCT03599544|BEHAVIORAL|Robot + Active Learning Program(RT-ALPS)|Highly intensive robot-assisted therapy for the paretic arm with the Armeo exoskeleton (1 hour sessions, 3x week for 3 weeks) followed by robot-assisted therapy for hand motions with Amadeo robot (3x week for 3 weeks). In addition, participants will receive training in active problem solving, analysis of performance and goal setting focused on home action plan activities to assist with carry-over and generalization to every day activities.
224160403|NCT02971527|DEVICE|Oste-scan 500A|The investigators will detect the same calcaneus of each subject by experimental ultrasound bone strength device. Experimental ultrasound bone strength device's model number is Oste-scan 500A and report number is Z-Y-2009-2014, Z-E-0530-2014(G).
224160404|NCT02971527|DEVICE|SONOST3000|The investigators will detect the same calcaneus of each subject by control ultrasound bone strength device. Control ultrasound bone strength device's model number is SONOST3000.
224160405|NCT01762527|RADIATION|Adaptive Radiotherapy|CTCAE scoring baseline, every 2'nd week during RT, 2 weeks, 3, 12 and 24 month after RT cineMR (time resolved MR) baseline and weekly during RT for intra fractional motion
224160406|NCT00550992|BIOLOGICAL|anti-thymocyte globulin|
224160407|NCT00550992|DRUG|asparaginase|
224160408|NCT00550992|DRUG|busulfan|
224160409|NCT00550992|DRUG|cyclophosphamide|
224160410|NCT00550992|DRUG|cyclosporine|
224160411|NCT00550992|DRUG|cytarabine|
224160412|NCT00550992|DRUG|daunorubicin hydrochloride|
224160413|NCT00550992|DRUG|etoposide|
224160414|NCT00550992|DRUG|leucovorin calcium|
224160415|NCT00550992|DRUG|melphalan|
224160416|NCT00550992|DRUG|mercaptopurine|
224160417|NCT00550992|DRUG|methotrexate|
224304151|NCT04811586|PROCEDURE|coronary revascularization|to improve the blood supply for coronary arteries by using either percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG)
224304152|NCT00130455|DRUG|escitalopram|
223472063|NCT00487903|DRUG|PB127 for Injectable Suspension|0.062 mg/kg continuous IV (100-250 mL/hr) during echocardiogram, single dose, infusion not to exceed 60 minutes.
223472064|NCT04322032|DRUG|Reference drug|D759 Tab. 1 Tab. and D308 Tab. 1 Tab.(Total 2 Tab.), Single oral administration under fasting condition.
223472065|NCT04322032|DRUG|Test drug|CKD-389 Tab. 1 Tab.(Total 1 Tab.), Single oral administration under fasting condition.
223472066|NCT01774591|DRUG|Azilsartan medoximil|All subjects were randomized to 80mg azilsartan medoxomil (azilsartan) daily or placebo and followed for six months.
223472067|NCT01774591|DRUG|Placebo|All subjects were randomized to 80mg azilsartan medoxomil (azilsartan) daily or placebo and followed for six months.
224160418|NCT00550992|DRUG|mitoxantrone hydrochloride|
224160419|NCT00550992|DRUG|pegaspargase|
224160420|NCT00550992|DRUG|prednisolone|
224160421|NCT00550992|DRUG|prednisone|
224160422|NCT00550992|DRUG|therapeutic hydrocortisone|
224160423|NCT00550992|DRUG|thioguanine|
224160424|NCT00550992|DRUG|vincristine sulfate|
224160425|NCT00550992|PROCEDURE|allogeneic bone marrow transplantation|
224160426|NCT00550992|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
224160427|NCT00550992|PROCEDURE|umbilical cord blood transplantation|
224304153|NCT02286310|OTHER|Kinetic Chain Exercises|Exercises include kinetic chain segments.
224304154|NCT02286310|OTHER|Traditional Exercises|Stretching, strengthening exercises.
224304155|NCT02669758|DRUG|ALKS 3831|Tablets were administered for daily dosing
223472068|NCT01701245|DEVICE|GammaCore|vagal stimulation
223472069|NCT02400801|DRUG|triptorelin|gonadotropin-releasing hormone (GnRH) agonist
223472070|NCT02400801|DRUG|ethinylestradiol + dienogest|oral oestroprogestogen
224160428|NCT03136900|DIETARY_SUPPLEMENT|Nutrilon without lactose® fortified by concentration|enteral diet with cow milk protein-based infant formula without lactose 20% in place of 14%
224160429|NCT03136900|DIETARY_SUPPLEMENT|Nutrilon without lactose® fortified by Maltodextrin and oil supplementation|enteral diet with cow milk protein-based infant formula without lactose 14%
224160430|NCT00429572|DRUG|Fludarabine|30 mg/m\^2 intravenously Daily for 5 Days
224160431|NCT00429572|DRUG|Melphalan|70 mg/m\^2 intravenously Daily for 2 Days
224160432|NCT00429572|PROCEDURE|Stem Cell Infusion|Stem Cell Infusion on Day 0.
224160433|NCT01366534|BIOLOGICAL|Crucell's replication deficient adenovirus type 35 circumsporozoite malaria vaccine (Ad35.CS.01)|One dose will be administered intramuscularly at Study Day 0.
224160434|NCT01366534|BIOLOGICAL|GSK Biologicals' malaria vaccine 257049 (2 doses)|Two doses will be administered intramuscularly at monthly intervals
224160435|NCT01366534|BIOLOGICAL|GSK Biologicals' malaria vaccine 257049 (3 doses)|Three doses will be administered intramuscularly at monthly intervals
223580092|NCT00494910|BEHAVIORAL|Supportive Group Psychotherapy|The eight weekly 1 ½ hour sessions will focus on group discussion on a set of specific themes that emerge for patients coping with cancer. The session themes or topics will include such issues as: the discussion of strategies for coping with medical issues and procedures, communication with health care providers and issues related to family, friends, and occupational life.
223580093|NCT04589143|DRUG|Agomelatine|Oral tablets of agomelatine at a dose of 25-50 mg/d for 8 weeks
223580094|NCT04589143|DRUG|Placebos|Oral tablets of placebos at a dose of 25-50 mg/d for 8 weeks
223580095|NCT00190047|DRUG|DP-b99|
223580096|NCT01130090|DEVICE|Adjustment of back-up respiratory rate on bi-level ventilator|"3 consecutive nights in randomized order, in either S (Spontaneous) mode, ST (Spontaneous/Timed) mode with a back-up rate under spontaneous respiratory rate of the patient, or in ST (Spontaneous/Timed) mode with a back-up rate at least 2 cycles/minute above spontaneous nocturnal respiratory rate. Each assessment will include complete polysomnographic recording (sleep study) as well as SpO2, PtcCO2, pneumotachograph (flow), mask pressure, quantitative assessment of patient-ventilator synchronisation, central or obstructive apnea and hypopnea, data of built-in software, and rating of patient comfort"
223580097|NCT03352453|DRUG|Rapastinel|Rapastinel pre-filled syringes for weekly IV injections.
223580098|NCT03352453|DRUG|Placebo|Placebo-matching rapastinel pre-filled syringes for weekly IV injections.
223580099|NCT02367391|BEHAVIORAL|Motivational Text Messages|Usual care plus motivational text messages sent via Mobile Phone. All participants receive the active medication, Varenicline.
223580100|NCT02367391|BEHAVIORAL|Control|Usual Care. All participants receive the active medication, Varenicline.
223580101|NCT04828291|BEHAVIORAL|Benign Behavioral Interventions|This project will use a Randomized Control Trial (RCT) design and Daily Reconstruction Method (DRM8) to model the effects of the OMI on dynamic changes in first-year undergraduate and graduate students' well-being over time. The intervention will take place over the course of 46 days, with a 7- day follow up assessment taking place one month after the intervention. People will complete surveys through an online link leading to Qualtrics.com.
224160436|NCT01366534|OTHER|Sporozoite challenge|Subjects were challenged with sporozoite-infected mosquitoes to determine whether immune protective response had been induced by vaccination.
224160437|NCT02387450|DRUG|Sildenafil|100 mg per day
224160438|NCT02387450|DRUG|Placebo|Placebo with same presentation as the active drug
224160439|NCT02748525|OTHER|Milk|Milk, in the form of 8 oz. half and half, administered after CCK scan, and patient is rescanned and ejection fraction measured to determine if ejection fraction is low.
224160440|NCT02748525|BIOLOGICAL|CCK|CCK is standard of care, used in HIDA scans for gallbladder function evaluation. It is given intravenously to cause the gallbladder to contract. The usual dose of CCK is 0.02mg/kg slowly over 3 minutes as per standard.
224160441|NCT01047436|DRUG|Quinine|20 mg/kg intravenous quinine loading dose, followed by 10 mg/kg intravenously every 8 hours until resumption of normal oral therapy
224160442|NCT01047436|DRUG|Artemether|Artemether sublingual spray 3 mg/kg at protocol specified timepoints until resumption of normal oral therapy
223580102|NCT05133713|DEVICE|Catheter directed therapy|Thrombectomy
223580103|NCT05133713|DRUG|Systemic anticoagulation|Conservative therapy
223580104|NCT02904122|OTHER|teleconsultation|Determine the interest of teleconsultation in dentistry tool for the diagnosis of caries. Ie whether oral teleconsultations are of the same quality as conventional consultations for the diagnosis of caries ..
223580105|NCT02146677|OTHER|Osteopathic manipulative treatment|
223580106|NCT02146677|OTHER|Sham therapy|
223580107|NCT02146677|OTHER|Usual care|
223580108|NCT04988997|DRUG|Vurolenatide 50mg/PBO|Vurolenatide - 50 mg biweekly SC administration, PBO alternate weeks
224160443|NCT05462691|PROCEDURE|tuberosity suture|to suture or not suture the tuberosities in reverse shoulder arthroplasty because of a proximal humeral fracture
224160444|NCT02769013|OTHER|Pre-treatment follow up|No active intervention; medical support provided if needed
224160445|NCT02769013|OTHER|S. haematobium treatment|Praziquantel-treatment for S. haematobium positive volunteers
224160446|NCT02769013|OTHER|Post treatment follow up|No active intervention; medical support provided if needed.
223580109|NCT04988997|DRUG|Vurolenatide 100mg/PBO|Vurolenatide - 100 mg biweekly SC administration, PBO alternate weeks
223580110|NCT04988997|DRUG|Vurolenatide 50/50 mg|Vurolenatide - 50 mg weekly SC administration
223580111|NCT04988997|DRUG|Placebo|PBO - weekly SC administration
223580112|NCT03343080|DRUG|1.8% lidocaine plus 0.76% sodium bicarbonate|At the time of intubation, the endotracheal tube cuff will be inflated with a solution containing 1.8% lidocaine plus 0.76% sodium bicarbonate until loss of air leak at a positive pressure of 20 cm of water. This solution will remain in situ through the duration of cardiac surgery, transportation to the intensive care unit, and continued to the time of extubation.
223580113|NCT03343080|OTHER|Air|At the time of intubation, the endotracheal tube cuff will be inflated with air until loss of air leak at a positive pressure of 20 cm of water. The air will remain in situ through the duration of cardiac surgery, transportation to the intensive care unit, and continued to the time of extubation.
223580114|NCT02893826|DRUG|EG-1962 (nimodipine microparticles)|
223580115|NCT02893826|DRUG|Enteral Nimodipine|
223580116|NCT04940897|OTHER|Use of CareSens ketone meter|Use of CareSens ketone meter to identify blood ketone levels and delivery of fluid therapy to those patients at high risk of DKA
224160447|NCT02769013|OTHER|Olfactometer experiment|No active intervention; medical support provided if needed.
224160448|NCT06340776|OTHER|Acupressure|For the acupressure application, planning was made to adjust the temperature, light and silence of the environment and to pay attention to privacy. 5 points that positively affect gastrointestinal functions and pain were selected (SP6, ST36, PC6, HT7 AND LI4). The duration of the session was determined to be approximately 18-20 minutes, depending on the preparation and pressure time to be applied on the 5 selected points (a total of 10 points were applied since each point will also be applied to its counterpart in the other extremity). Acupressure application was applied to each point for 1.5 minutes (1.5\*10=15 minutes).
224160449|NCT01900405|DRUG|Dexmedetomidine|
224160450|NCT03885609|DEVICE|ToothWave|RF-utilizing powered toothbrush for teeth whitening
224160451|NCT03885609|DEVICE|powered toothbrush|regular powered toothbrush with no RF
223472071|NCT01159574|DRUG|dexamethasone|40mg will be given on days 1, 8, 15, 22 of a 28-day cycle
223472072|NCT01159574|DRUG|clarithromycin|orally at a dose of 500 mg twice a day on days 1-28 of a 28 day cycle
223472073|NCT01159574|DRUG|Pomalidomide|orally 4mg daily for days 1-21 of each 28 day cycle
223472074|NCT06106750|DEVICE|Endoscopic nasobiliary duct cutting|Endoscopic retrograde cholangiopancreatography and endoscopic nasobiliary duct placement and drainage are conducted first. Upon achieving a postoperative state marked by satisfactory nasobiliary duct drainage and overall patient stability, the procedure entails the employment of endoscopic scissors. The tools are applied to make an incision on the external segment of the nasobiliary duct, positioned beyond the aperture of the primary duodenal papilla. Then extracting the severed nasobiliary duct and retaining the portion inside the duct.
223472075|NCT06106750|DEVICE|Bilateral plastic stent|Standard protocol for the placement of bilateral biliary plastic stents in the management of malignant hilar biliary tract stenosis
223472076|NCT05276791|OTHER|EMR|Endoscopic mucosal resection, according to standard care
223472077|NCT05276791|OTHER|ESD|Endoscopic submucosal dissection, according to standard care
223472078|NCT01081197|OTHER|Psychiatric and somatic examinations and ,if clinical indicated, treatment|Patients referred to the clinic will be given optimal treatment for revealed psychiatric and/or somatic disease including conversational therapy, and if indicated therapeutic interventions with respect to any kind of disease.
223472079|NCT03369574|DRUG|Reslizumab|reslizumab administration
223472080|NCT02897557|DEVICE|Insulet Artificial Pancreas (AP) System|
223472081|NCT01940822|OTHER|Energy Drink|
223580117|NCT02989051|OTHER|Restrictive fluid regimen|In this treatment arm, patients will receive a maximal daily fluid intake of 70% of normal requirements (for a healthy child).
223580118|NCT02989051|OTHER|Liberal fluid regimen|This is considered current standard clinical treatment, wherein patients will receive a fluid regimen of \>85% of normal fluid recommendations (for a healthy child).
223580119|NCT01241760|DRUG|Ribavirin|Ribavirin (RBV) 1000-1200 milligram (mg) per day (weight dependent) twice daily regimen oral tablets for 24 or 48 weeks depending on the patient's treatment response at week 4
223580120|NCT01241760|DRUG|Telaprevir|1125 mg (3 oral tablets) twice a day (every 10-14 hours) for 12 weeks
223580121|NCT01241760|DRUG|Pegylated interferon alfa-2a|180 microgram (µg) per week, subcutaneous injection, for 24 or 48 weeks Pegylated interferon alfa-2a 180 microgram (µg) per week subcutaneous injection for 24 or 48 weeks depending on the patient's treatment response at week 4
223580122|NCT01241760|DRUG|Telaprevir|750 mg (2 oral tablets) every 8 hours for 12 weeks
223580123|NCT01388751|PROCEDURE|night splinting|splint finger at night for 4 weeks
223580124|NCT05162053|DRUG|vicagrel Capsules|Oral administration for 7 days under fasting
223472082|NCT01940822|OTHER|Placebo Drink|
223580125|NCT05162053|DRUG|Clopidogrel Tablets|Oral administration for 7 days under fasting
223472083|NCT05812248|DIAGNOSTIC_TEST|Perioperative cardiac biomarker measurement|High-sensitivity cardiac troponin T is measured within 7 days prior to surgery and at day 1 and day 2 after surgery. N-terminal pro-B-type natriuretic peptide is measured within 7 days before surgery.
223472084|NCT01690663|DRUG|Bupivacaine 0.25%|
223580126|NCT00670891|PROCEDURE|oxygen (Hyperbaric Oxygen Therapy)|"Current Accepted Applications of HBOT (2008) Jan 2003, ANDI International~1. Air or Gas Embolus~2. Decompression Illness~3. Carbon Monoxide poising~4. Clostridial Myonecrosis (Gas Gangrene)~5. Necrotizing Fasciitis~6. Crush Injury (Compartment syndromes)~7. Selected Problem Wounds~8. Compromised Skin Flaps or Grafts~9. Refractory Osteomyelitis~10. Exceptional Anemia due to Blood loss~11. Osteoradionecrosis~12. Thermal Burns and Radiation Tissue Damage~13. Diabetic Wounds~14. Intra-Cranial Abscess~15. Brain Injury and other Head Trauma~16. Cerebral Palsy~17. High Altitude Sickness~18. Lyme disease"
223580127|NCT02368912|DRUG|ASP1707 single dose of dose levels 1 -7|Oral, dose escalation
223580128|NCT02368912|DRUG|Placebo single dose of dose levels 1-7|Oral, dose escalation, healthy young male
223580129|NCT02368912|DRUG|ASP1707 single dose fasted|Oral, healthy young male
223580130|NCT02368912|DRUG|ASP1707 single dose fed|Oral, healthy young male
224160452|NCT05440344|DRUG|Imlunestrant|Administered orally.
223580131|NCT02368912|DRUG|ASP1707 multiple dose of dose levels 1-4|Oral, multiple dose escalation, healthy elderly male
223580132|NCT02368912|DRUG|Placebo multiple dose of dose levels 1-4|Oral, multiple dose escalation, healthy elderly male
223580133|NCT02368912|DRUG|ASP1707 multiple dose of dose levels 1-2|Oral, multiple dose escalation, healthy pre-menopausal female
224160453|NCT00608803|DRUG|ZIO-201-T and doxorubicin|ZIO-201-T given for 3 consecutive days every 3 weeks. Doxorubicin is given once every 3 weeks. This is a dose escalation arm.
224160454|NCT00786461|PROCEDURE|silver nitrate application to the Bartholin´s cyst|5 mm in diameter and 5 mm in length crystalloid silver nitrate stick is inserted into the cyst or abscess cavity.
223472085|NCT01690663|DRUG|Dexamethasone|
223472086|NCT01690663|DRUG|normal saline|placebo
223472087|NCT03555149|DRUG|Regorafenib|Regorafenib will be administered orally on Days 1-21 of each 28-day cycle.
223472088|NCT03555149|DRUG|Atezolizumab|Atezolizumab will be administered by intravenous (IV) infusion every 3 weeks (Q3W) on Day 1 of 21-day cycles, with the exception of the Atezolizumab + Selicrelumab + Bevacizumab, Atezolizumab + Idasanutlin, Atezolizumab + Regorafenib and Atezolizumab + Regorafenib + AB928 arms where the Atezolizumab will be administered by IV infusion every 2 weeks (Q2W) on Days 1 and 15 of each 28-day cycle.
223472089|NCT03555149|DRUG|Imprime PGG|Imprime PGG will be administered by IV infusion weekly on Days 1, 8, and 15 of each 21-day cycle.
223472090|NCT03555149|DRUG|Bevacizumab|Bevacizumab will be administered by IV infusion on Day 1 of each 21-day cycle for the Atezolizumab + Imprime PGG + Bevacizumab arm, and on Day 1 and Day 15 of each 28-day cycle for the Atezolizumab + Selicrelumab + Bevacizumab arm.
223580134|NCT02368912|DRUG|Placebo multiple dose of dose levels 1-2|Oral, multiple dose escalation, healthy pre-menopausal female
223580135|NCT02368912|DRUG|ASP1707 parallel multiple dose of dose levels 1-3|Oral, multiple dose, healthy pre-menopausal female
223580136|NCT02368912|DRUG|Placebo parallel multiple dose|Oral, dose escalation, healthy pre-menopausal female
224304156|NCT02323516|DRUG|Acetylsalicylic acid + loperamide|In case of inefficiency in one month, according to predefined criteria, acetylsalicylic acid will be stopped and replaced by diosmectite.
223472091|NCT03555149|DRUG|Isatuximab|Isatuximab will be administered on Day 1, 8 and 15 of cycle 1 and on day 1 of all subsequent cycles. Cycles will be 21 days long.
223472092|NCT03555149|DRUG|Selicrelumab|Selicrelumab will be administered by subcutaneous (SC) injection on Day 1 of cycles 1-4 and every third cycle thereafter. Cycles will be 28 days long.
223472093|NCT03555149|DRUG|Idasanutlin|Idasanutlin will be administered orally on Days 1-5 of each 28-day cycle.
223472094|NCT03555149|DRUG|AB928|AB928 will be administered orally once daily on Days 1-28 of each 28-day cycle.
223472095|NCT03555149|GENETIC|LOAd703|LOAd703 will be administered by intratumoral injection on Day 1 of each 21-day cycle.
223580137|NCT01911312|DEVICE|Thermal-aided muscle stimulation|Thermal-aided muscle stimulation is applied to subject quadriceps (one leg) with Niveus Medical Muscle Stimulation System 110
223472096|NCT04189016|DEVICE|Inhalation from a salt particle inhaler with or without content|Inhalation from inhaler with (active) or without (placebo) content
223580138|NCT01911312|DEVICE|Body Temperature Stimulation|Body temperature stimulation is applied to subject quadriceps (one leg) with Niveus Medical Muscle Stimulation System 110
223580139|NCT03728491|DEVICE|Simulator|US Mentor simulator, lung module, provided by 3D Healthcare Systems
223580140|NCT03728491|DEVICE|Healthy figurants|Medical students or volunteers without any pathology in thorax
223580141|NCT05834491|DEVICE|minimal shoes and foot strengthening and flexibility exercises|Flexible shoes that do not provide support and exercises aimed at increasing the strength of plantar intrinsic and extrinsic foot muscles along with foot flexibility exercises aimed at increasing the range of motion of the foot and ankle
223580142|NCT05834491|DEVICE|Supportive Footwear, foot orthotic device and foot flexibility exercises|sturdy supportive shoes fitted with supportive foot orthotic devices and foot flexibility exercises aimed at increasing the range of motion of the foot and ankle
223580143|NCT00514020|DRUG|fluorouracil|Given through a vein over 5 minutes and then continuously over 46 hours on days 1 and 15.
223580144|NCT00514020|DRUG|leucovorin calcium|through a vein over 2 hours on days 1 and 15.
223580145|NCT00514020|DRUG|oxaliplatin|500 ml D5W through a vein over 2 hours on days 1 and 15.
223580146|NCT00514020|GENETIC|gene expression analysis|Blood collection
223580147|NCT00514020|GENETIC|polymorphism analysis|Blood collection
223580148|NCT00514020|GENETIC|protein expression analysis|Blood collection
223580149|NCT00514020|OTHER|pharmacological study|Blood collection
223580150|NCT01044316|BIOLOGICAL|Haemophilus influenzae type b (Hib) vaccine|Comparator study of two commercially available Haemophilus influenzae type b (Hib) vaccines - a monovalent glycoprotein-conjugated (diptheria toxin - CRM197) vaccine and a tetanus toxoid-conjugated vaccine.
224304157|NCT02323516|DRUG|diosmectite + loperamide|In case of inefficiency in one month, according to predefined criteria, diosmectite will be stopped and replaced by acetylsalicylic acid.
224304158|NCT02336035|PROCEDURE|Volar plate|Flexor carpi radialis (FCR)-approach. Standard surgical procedure with a volar locking plate
224304159|NCT04638335|BIOLOGICAL|Blood test|blood test for Anti-HAV antibodies
223472097|NCT01627548|BEHAVIORAL|Structured Approach Therapy|The SAT treatment is provided in 12 weekly 50-minute sessions and is fully manualized. First, couple-based exposure techniques are used to address anxiety about intimacy, increasing the traumatized person's ability to engage in social and relational behaviors that promote bonding and satisfaction. Second, as anxiety decreases, couple-based techniques are also used to increase the positive experiences the couple is having. These activities expose the traumatized person to positive feelings instead of anxiety, so that he/she may become desensitized to the anxiety caused by the closeness, and more comfortable engaging in intimate behaviors.
223472098|NCT02965924|DRUG|Phenylephrine 2.5%|Instilling phenylephrine 2.5% eye drop
223472099|NCT03343548|DRUG|magnesium sulfate|2cc of magnesium sulfate ( 50%) will be administered epidurally
223472100|NCT03343548|DRUG|normal saline|2cc of normal saline will be administered epidurally
223472101|NCT02282462|OTHER|Reg Pressure|Regulated Suction using the Thopaz+ digital chest drainage device
223472102|NCT02282462|OTHER|Unreg Pressure|Unregulated Suction using a traditional system (multi-chambered system e.g. Pleur-Evac, Atrium-Maquet or similar device as is routine at each institution)
223472103|NCT02282462|OTHER|Active Suction (Dig)|Thopaz+ digital chest drainage device set at -20cmH2O at the patient
223472104|NCT02282462|OTHER|Active Suction (Trad)|Pleur-Evac, Atrium-Maquet or similar set at -20cmH2O at the device.
223472105|NCT02282462|OTHER|Passive Drainage (Dig)|"Thopaz+ digital chest drainage device set at -8cmH2O at the patient (physiologic)"
223472106|NCT02282462|OTHER|Passive Drainage (Trad)|"Pleur-Evac, Atrium-Maquet or similar set by gravity (water-seal')"
223580151|NCT01898104|RADIATION|preoperative radiation therapy|25 Gy in 5 fractions over 1 week
223580152|NCT01898104|DRUG|Valproic Acid|
223580153|NCT01898104|DRUG|Capecitabine|
223580154|NCT04034940|OTHER|Dosing Oxidative stress biomarkers & hFABP in STEMI pPCI patients|Dosing oxidative stress biomarkers and hFABP in STEMI pPCI
223580155|NCT03512431|DIAGNOSTIC_TEST|Micro sampling|Compare finger prick micro samples with venous blood samples for measuring whole blood tacrolimus concentrations
223580156|NCT03089944|DRUG|Glecaprevir/Pibrentasvir|Tablet
223580157|NCT01636713|DRUG|GSK573719/VI 62.5/25|Inhalation via Novel Dry Powder Inhaler Once a day
223580158|NCT01636713|DRUG|GSK573719/VI 125/25|Inhalation via Novel Dry Powder Inhaler Once a day
223580159|NCT01636713|DRUG|Placebo|Inhalation via Novel Dry Powder Inhaler Once a day
223580160|NCT03780959|DRUG|Etanercept|Administered twice weekly by subcutaneous injection
223580161|NCT03780959|DRUG|Placebo|Administered twice weekly by subcutaneous injection
223580162|NCT04064346|DRUG|Lixivaptan|Oral vasopressin V2 receptor antagonist
223580163|NCT04064346|DRUG|Placebo|Matching placebo
223580164|NCT04268433|OTHER|N/A - Non-interventional study|"Stages:~1. Patient information and written informed consent (3 Copies. To be carried out \>24 hours after receiving the patient information sheet)~2. Physiological recording set up (ECG, BP, sensor and respiratory band)~3. Control period - no music played~4. Series of pieces of music without tempo control~5. Repeat series of pieces of music with tempo control~6. Participant leaves the study"
223472107|NCT02666222|DEVICE|The Esteem Hearing Implant|The Esteem® Hearing Implant is designed to improve hearing in subjects suffering from moderate to severe hearing loss that is sensorineural in origin. The Esteem® has been approved by FDA for the US market under Pre-Market Approval P090018 and this study fulfills the requirement for one of the Post Approval Studies.
223472108|NCT03149536|DIAGNOSTIC_TEST|Pharmacogenetic test|To develop a pharmacogenetic prediction test
223472109|NCT04244136|DEVICE|contrast CT|contrast CT abdomen fir measurement of the volume of expected residual normal renal tissue before surgery
223580165|NCT03958591|DRUG|CSII and thereafter combination therapy, followed up with wearable devices|Short-term continuous subcutaneous insulin infusion and thereafter the combination therapy of basal insulin, metformin and vildagliptin; Wearable devices and smart apps will be used to manage and follow-up the participants.
224160455|NCT00786461|PROCEDURE|silver nitrat stick|The silver nitrate treatment is performed under local anaesthesia on an outpatient basis. A simple vertical incision 1 cm in length is made in the vaginal mucosa and the underlying cyst or abscess wall. A crystalloid silver nitrate stick of 5 mm in diameter and 5 mm in length is inserted into the cyst or abscess cavity.
224160456|NCT04366739|DRUG|CHLORPROMAZINE (CPZ)|"Drug List 1, AMM obtained in 1952, AMM 3400930571187 1952/90, RCP revised 22/08/2019 Administration: oral route, if the clinical condition requires it, intravenous administration.~Initial dosage: 75 mg per day orally (or 37.5 mg per day orally in subjects 75 years of age or older).~Then: titration up to the maximum tolerated dose, with a minimum of 12.5 mg and a maximum of 300 mg per day by the oral administration (or 600 mg per day by the oral in certain exceptional cases which also correspond to the CPM CPM marketing authorization indications); or from 6.25 to 150 mg per day intravenously.~Duration of treatment: until healing criteria are obtained (≥ 8 days from the onset of COVID-19 symptoms AND ≥ 48 hours of apyrexia and absence of dyspnea) or 21 days maximum"
224160457|NCT04366739|COMBINATION_PRODUCT|Standard of Care (SOC)|"In the absence of a reference treatment in COVID-19, the standard of care (SOC) is the comparison arm"
223472110|NCT04781712|BEHAVIORAL|Modular mHealth for Tailored Rehabilitation|an individually tailored self-management through the mHealth app with a smart band worn on the wrist
223472111|NCT01685879|OTHER|Rice|Rice portion containing 50 g total carbohydrate
223472112|NCT01685879|OTHER|Rice|Rice portion that provides 50 g total carbohydrate.
223472113|NCT01685879|OTHER|Rice|Rice portion that provides 50 g total carbohydrate.
224160458|NCT00578396|DIETARY_SUPPLEMENT|grapes|1 pound of seedless red grapes
224160459|NCT00578396|DIETARY_SUPPLEMENT|grapes|2/3 lb/day fresh red grapes
224160460|NCT00578396|DIETARY_SUPPLEMENT|grapes|1/3 lb/day fresh red grapes
224160461|NCT00939341|DRUG|Symbicort (Budesonide/Formoterol)|Turbuhaler 160/4.5 µg delivered dose, twice daily (one inhalation in the morning and one inhalation in the evening) and as need (prn) in response to symptoms
224160462|NCT01890733|DEVICE|Best Repair of torn Rotator Cuff|
224160463|NCT01890733|DEVICE|InSpace™ system|
224160464|NCT04299256|BEHAVIORAL|Benson relaxation combined with music therapy|In the first interview, the patient information delivered a training booklet explaining the definition, purpose, benefits and application techniques of BRT and music therapy to the patients in the intervention group. After patients reviewed the details in the training booklet, a weekly schedule was planned for each patient based on their hemodialysis days. For the initiation of the intervention, patients were invited to the hemodialysis unit at the hospital 45 min prior to their hemodialysis sessions. All the participants wore black eye patches to provide a dim environment and to focus better on their breath and the music piece. Then, the patients information opened the music piece and gave Benson Relaxation Technique comments in a slightly lower voice. Each session lasted for 20 min, and the music piece was switched off as Benson Relaxation Technique ended. The music piece used in the study was Daniel Kobelco's non-verbal classical song.
224160465|NCT00312741|PROCEDURE|empirical versus microbiological guided treatment|
224160466|NCT01834638|DRUG|ABT-126|capsule(s)
224160467|NCT04564690|DIETARY_SUPPLEMENT|QUARTET® hen eggs (enriched in n-3 PUFA, selenium, vitamin E and lutein)|Consumption of three QUARTET® hen eggs (enriched in n-3 PUFA, selenium, vitamin E and lutein) per day for three weeks
224160468|NCT04564690|DIETARY_SUPPLEMENT|Regular hen eggs|Consumption of three regular hen eggs per day for three weeks
224160469|NCT02747329|DEVICE|BuMA Supreme™ stent|
224160470|NCT02747329|DEVICE|Xience V/Prime stent|
223472114|NCT01685879|OTHER|Glucose Beverage|Glucose beverage that provides 50 g total carbohydrate.
223472115|NCT00562406|DRUG|Ranibizumab|intravitreal injection of 0.5 mg ranibizumab after randomisation, at week 4 and 8
223472116|NCT00562406|PROCEDURE|Laser photocoagulation|laser photocoagulation to the retina at the area of edema
223472117|NCT02443623|BIOLOGICAL|Vaccination with ACAM2000|In this study (VA-008), healthy adult male and female volunteers who meet the requirements for source plasma donors and study entry criteria will be vaccinated with the ACAM2000 smallpox vaccine for collection of plasma to be used in the manufacture of VIGIV. There are possible risks associated with ACAM2000 vaccination. To ensure the safety of plasma donors, risk factor screening procedures and the collection of post-vaccination safety data will be assessed throughout the study.
223472118|NCT00706316|BIOLOGICAL|EBV-Specific CTLs and CD45 Mab|"One time infusion (IV) at one of the following dose levels:~Dose level I: 5 x 107 cells/m2~Dose level II: 1 x 108 cells/m2~Dose level III: 2 x 108 cells/m2"
223580166|NCT03958591|DRUG|CSII and thereafter combination therapy, followed up in traditional ways|Short-term continuous subcutaneous insulin infusion and thereafter the combination therapy of basal insulin, metformin and vildagliptin; Traditional ways such as telephone contact will be used for follow up.
223580167|NCT03958591|DRUG|Traditionally upgrading therapy, followed up in traditional ways|The participants will be applied the combination therapy of basal insulin, metformin and vildagliptin for the entire 12 weeks. Traditional ways will be used for follow up.
224304160|NCT04325763|DRUG|TQB2450|TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.
224304161|NCT04325763|DRUG|Anlotinib|a multi-target receptor tyrosine kinase inhibitor
224304162|NCT04325763|DRUG|TQB2450(blank)|Subjects administrated TQB2450 (blank) intravenously (IV) on Day 1 of each 21-day
223472119|NCT05919628|OTHER|ResPsyPark group|Evaluation of the parkinson's disease patient's score over different psychological questionnaires and a therapeutical observance questionnaire
223472120|NCT05480059|OTHER|A questionnaire|A Questionnaire-based Assessment of the Psychiatric Co-morbidities and Health-related Quality of life in Patients with Irritable Bowel Syndrome
223472121|NCT00942136|DRUG|GSK1349572|GSK1349572 250 mg suspension as a single dose. GSK1349572 is an investigational (not approved by the FDA) medication for the treatment of HIV in the class of integrase inhibitors.
223472122|NCT00942136|DRUG|GSK1349572|GSK1349572 50 mg tablets as a single dose on three separate occasions. GSK1349572 is an investigational (not approved by the FDA) medication for the treatment of HIV in the class of integrase inhibitors.
223472123|NCT00942136|DRUG|Placebo|Placebo Suspension as a single dose.
223472124|NCT00942136|DRUG|Omeprazole|Omeprazole 40 mg once a day for 5 days. Omeprazole is approved by the FDA currently to reduce stomach acid, treat stomach ulcers, and gastroesophageal reflux disease.
223472125|NCT03876925|DRUG|CT053PTSA|Patients will received oral CT053PTSA once daily until disease progression or intolerable toxicity or subject's withdrawal from treatment ,each cycle is defined as 28 days
223472126|NCT02841124|OTHER|interviews|face-to-face interviews with the referent oncologist (or hematologist) and his patient (conducted by a physician and a psychologist respectively) as well as interviews with other partners involved in the situation (care staff and relatives)
223472127|NCT00169299|DRUG|Black cohosh|
223472128|NCT00169299|DRUG|Multibotanical preparation|
223472129|NCT00169299|DRUG|Multibotanical preparation + dietary soy counseling|
223472130|NCT00169299|DRUG|Conjugated equine estrogen +/- medroxyprogesterone acetate|
223472131|NCT04032132|DRUG|curcumin paste|curcumin is a herb used for medical purpose
224160471|NCT05379764|OTHER|Embodiment|Embodiment of a real human in a virtual human (avatar) means that the real human feels incarnated in the avatar. This happens when the real human sees the VRscenario from first person perspective, that the real human can make the avatar move (=agency over the avatar), multi-sensorial integration (=there is a link between the brain of the real human and the avatar. Example, when the avatar sits on a chair, the real human will too and he feels that he is sitting on a chair. Or when the avatar is moving the real human is doing the same movement (and of course the brain of the real human is aware of this movement)) and co-location (= avatar and real human have the sane posture).
224160472|NCT05379764|OTHER|Observation|The person is looking at the VR scenario as if s/he was looking at a TV
224160473|NCT00914095|DRUG|methylphenidate|10 mg tablet of methylphenidate 3 times a day (1 mg/kg/day)
223472132|NCT04032132|PROCEDURE|curettage|open flab debridement surgery
223472133|NCT01474486|DRUG|Micronutrients|Thiamin one tablet daily provides 50 milligrams(mg) of thiamin, Vitamin B-50 one tablet daily: provides an additional 50 mg of thiamin, riboflavin, niacin, pantothenic acid and pyridoxine, 100 microgram(mcg folic acid, and 50 mcg cyanocobalamin (B12) and biotin; Vitamin D one 50,000 International Units(IU) tablet of ergocalciferol per week for two months followed by one tablet every other week for four months, and Zinc Sulfate (Zn SO4) one tablet daily at bedtime which provides 50 mg elemental zinc (220 mg Zn SO4)
223472134|NCT00853294|DRUG|Chlorpheniramine polistirex equivalent to 8 mg of chlorpheniramine maleate and hydrocodone polistirex equivalent to 10 mg of hydrocodone bitartrate capsule|Chlorpheniramine polistirex/hydrocodone polistirex extended release capsule, single dose fasting
223472135|NCT00853294|DRUG|5 mL chlorpheniramine (8 mg/5 mL)/hydrocodone (10 mg/5 mL) extended release oral suspension|Tussionex® Pennkinetic® Extended Release Oral Suspension, single dose fasting
223472136|NCT03352284|DEVICE|Straumann Pure Ceramic Implant|The surgical technique begins with the lift of a vestibular mucoperiosteal flap respecting the papillae of the adjacent teeth. After the alveolar bone is exposed, the sequence of drilling and placement of the intra-bone fixation are carried out. In case of fenestrations or dehiscence, they are treated by xenograft and collagen-absorbable membrane. Once the implant is placed, a healing cap or provisional prosthesis is placed depending on the torque achieved. Finally, the flap is replaced and sutured.
223472137|NCT04753866|DEVICE|Facial scanner|The Bellus3D facial scanner will be used to scan the patient before and after implant rehabilitation in order to produce .obj files that allow 3D comparisons and to obtain discrepancy values regarding lip support.
223472138|NCT03839134|DEVICE|DentalVibe® Comfort Injection System|Soft tissue vibration for 10 seconds using DentalVibe®. The device induces approximately 16 soft tissue vibrations of per second. The device will be in touch of oral mucosa (at the site of injection) before and during the local anesthesia injection.
223472139|NCT03839134|DRUG|Lidocaine Epinephrine|Dental local anesthesia injection of 1.8 mL Lidocaine (2%) with Epinephrine (1:80000 w/v).
224160474|NCT00914095|DRUG|placebo|tablets of placebo 3 times a day
224160475|NCT01408732|DRUG|Sclerotherapy|3% Sodium tetradecyl sulfate (STS) is mixed with air at a ratio of 4 parts air to 1 part STS for injection into the affected vessels in the nose. Topical anesthetic is applied to the nasal mucosa prior to injections. Once the mixture is ready for injection, the needle is placed into the vessel, in a submucosal fashion, penetrating 1-2 mm, and very small quantities of foam are injected The amount of foam injected into each lesion varies between 0.1 cc to 0.25 cc. Individual injection amounts vary between lesions, patients and treatment sessions. No more than a total of 3 ml of solution is used in each session. During each session, several lesions can be treated, but the total amount of STS used does not exceed 3 cc.
224160476|NCT01408732|OTHER|Standard Treatment|Normal standard of care followed by Drug interevention
224160477|NCT03186079|DRUG|Xiaojidaozhi Decoction|Mixture of twelve Chinese herbal medicines granule
224160478|NCT03186079|DRUG|Placebo|Mixture of 10% Chinese herbal medicines granule and 90% artificial gum
224160479|NCT03186079|DRUG|Fiberform|Fiberform is a low-phytate wheat fibre which can increase the gastrointestinal motility.
224160480|NCT03186079|BEHAVIORAL|Toilet training|Toilet training has been considered a routine method in treatment of constipation
224160481|NCT00424099|DRUG|Methylphenidate|5 mg (one capsule) orally every two hours as needed up to a maximum of 20 mg per day for a period of 14 days.
224160482|NCT00424099|BEHAVIORAL|Nursing Telephone Intervention|Call from study nurse 3 times weekly to ask about side effects and other symptoms.
224160483|NCT00424099|DRUG|Placebo|One capsule, orally every two hours as needed up to a maximum of 4 capsules per day for a period of 14 days.
223472140|NCT00898937|GENETIC|microarray analysis|tumor specimen will be assessed by microarray analysis
223472141|NCT00898937|PROCEDURE|breast biopsy|A breast biopsy will be done to obtain a tumor specimen
223580168|NCT05082350|DIETARY_SUPPLEMENT|black garlic|Daily consumption of 4 cloves of black garlic, not cooked, during 12 weeks
223580169|NCT00884910|DEVICE|Provox Vega voice prosthesis 22.5 Fr|The patients' current Provox2 voice prosthesis will be removed and the new Provox Vega voice prosthesis will be inserted.
223580170|NCT05314192|DIAGNOSTIC_TEST|salivary test|saliva was assessed for MIP-1 alpha
223472142|NCT05817123|OTHER|Questionnaires|"Administration of the following questionnaires:~* Mutuality scale~* Pittsburgh Sleep Quality Index (PSQI)~* Epworth Sleep Scale (ESS)~* Sleep Condition Indicator (SCI)~* International Physical Activity Questionaire (IPAQ)~* Mediterranean diet score (MDS)~* Quality of Life SF 12~* Hospital Anxiety and Depression Scale (HADS)"
223580171|NCT05314192|DIAGNOSTIC_TEST|salivary test|saliva was assessed for IL-6
223580172|NCT04642924|DRUG|SGM-101|Fluorescence-guided surgery
223580173|NCT05754060|OTHER|Saint-Louis Lille Battery (SSLIB)|"Saint-Louis Lille Battery (SSLIB) composed of three tests studying the speed of cognitive processing and proposed to the subjects on a tactile tablet. These three tasks are:~(a) Reaction time tasks specifically developed for this study b) A digital adaptation of the WAIS-IV code subtest c) A digital version of the Trail Making Test (A and B)"
223580174|NCT06139562|BEHAVIORAL|Time-Restricted Feeding|Time-restricted feeding (TRF) is a dietary approach that includes a fasting protocol and a fasting period ranging from 3 to 21 hours during the day . Since there is no standard definition of TRF, fasting/feeding periods vary. In this study, 12-hour fasting and 12-hour feeding period defined by Pureza et al.(11) were taken as the TRF model. In the first 4-week arm of the study, applied a time-restricted feeding program from sunrise to sunset. The daily energy requirements of the participants were calculated individually to lose 5% of their initial weight and the distributions of macronutrients were 45-60% of total energy from carbohydrates, 10-20% as protein and less than 35% from fat.
223580175|NCT06139562|BEHAVIORAL|Extended-Time Feeding|Extended-time feeding program was suggested that allows them to eat at any time of the day. During dietary interventions, a weight loss diet was applied to the participants. The daily energy requirements of the participants were calculated individually to lose 5% of their initial weight and the distributions of macronutrients were 45-60% of total energy from carbohydrates, 10-20% as protein and less than 35% from fat.
223580176|NCT03689244|DRUG|Selexipag|oral tablets containing 200 µg of selexipag. Depending on the iMTD, participants will receive 1 to 8 tablets at each administration
223580177|NCT03689244|DRUG|Placebo|Oral tablets without active compound
223580178|NCT01705158|DRUG|carboplatin and liposomal doxorubicin|Carboplatin AUC5 and liposomal doxorubicin 40 or 50 mg/m2, IV (in the vein) on day 1 of each 28 day cycle. Number of Cycles: 6 or until progression or unacceptable toxicity develops.
223580179|NCT01213823|OTHER|Does not apply|This is a non-interventional study, therefore the intervention type / name do not apply
223580180|NCT01213823|OTHER|Does not apply|This is a non-interventional study, therefore the intervention type / name do not apply
223580181|NCT01846559|BIOLOGICAL|Endotoxin|E.coli Endotoxin Day 7 - 2 ng/kg
224069298|NCT05875870|BEHAVIORAL|Daylight exposure combine walking|"1. Out-door of bright-light exposure in the morning (36 min/day, 7 times/week) for six weeks.~2. Tailored to the individual patient with moderate intensity of walking (3 sessions/week) for six weeks. Duration of each session depends on one-on-one exercise consultation via communication software (LINE App). The duration of walking in week 1 is 15 minutes, then increasing 5 minutes each week if the patient has tolerance. If the patient cannot tolerate the duration, the coach will instruct to keep the same duration for the following week. Basically, the goal of duration in week six is 40 minutes.~3. Weekly exercise consultation via communication software (LINE App).~4. Teaching strategy includes one-on one instruction (hard-copy of teaching manual), video, and webpage."
223472143|NCT04534309|BEHAVIORAL|Written Weight Loss Material|Participants will receive written weight loss material by email.
223472144|NCT04534309|BEHAVIORAL|Weight Loss App|Participants will receive written weight loss material as well as instructions for using a free weight loss app on their phone or computer.
223472145|NCT04534309|BEHAVIORAL|Behavioral Lifestyle Weight Loss Intervention (Coaching)|Participants will receive weekly coaching phone calls to encourage regular dietary, exercise, and self-monitoring practices which encourage gradual, healthy weight loss.
223580182|NCT01846559|DRUG|Clopidogrel|Clopidogrel (tablet) over 8 days Day 1: 300 mg loading dose Day 2-7: 75 mg orally once daily
223580183|NCT01846559|DRUG|Ticagrelor|Ticagrelor over 8 days (tablet) Day 1: 180 mg loading dose Day 2-7: 90 mg orally twice daily
223580184|NCT02700165|DEVICE|The ZELTIQ CoolSculpting System|The CoolSculpting device will be used to perform the treatments.
223580185|NCT05847413|DRUG|Verapamil|Subjects will receive oral verapamil for 12 weeks
223580186|NCT00378248|BEHAVIORAL|Combined psychotherapy|18 weeks day hospital treatment followed by long-term outpatient combined group-and individual psychotherapy
224160484|NCT00424099|BEHAVIORAL|Non NTI|Non NTI are calls from research staff 3 times weekly.
223580187|NCT00378248|BEHAVIORAL|Outpatient individual psychotherapy|Eclectic individual psychotherapy in private practice
223580188|NCT04902651|DEVICE|HM242-Gel|HM242-Gel compared to Intrasite Gel in patients with a venous leg ulcer
223580189|NCT04902651|DEVICE|Intrasite Gel|HM242-Gel compared to Intrasite Gel in patients with a venous leg ulcer
223580190|NCT00053547|DRUG|paricalcitol injection|
223580191|NCT00595933|OTHER|sugar-free chewing gum|Chew gum 4 times a day with additional allowances for as needed. Fill out daily questionaire and an end of week.
223580192|NCT00595933|OTHER|chewing gum|Chew gum 4 times a day with additional allowances for as needed. Fill out daily questionaire and an end of week.
223580193|NCT00595933|OTHER|mouth rinse|Rinse mouth 4 times a day with additional allowances for as needed. Fill out daily questionaire and an end of week questionaire
224160485|NCT03377452|BEHAVIORAL|Acceptance and the Behavioral Changes to Treat Sleep Apnea (ACB-SA)|Six session manual-based program using acceptance-and commitment therapy (ACT) framework, behavior change strategies and sleep apnea/PAP education. Sessions delivered in individual format, either in-person or via telehealth.
223472146|NCT03797859|PROCEDURE|Apneic ventilation|Ventilation by THRIVE
223472147|NCT03504917|DRUG|Balovaptan|Participants will receive 10 mg of oral administration balovaptan once a day (QD).
223472148|NCT03504917|DRUG|Placebo|Participants will receive matching placebo.
223472149|NCT05791617|DIAGNOSTIC_TEST|cardiac PET/MRI|Patients will undergo cardiac PET/MRI scanning at 30±5 days and at 90±5 days post-stroke.
223472150|NCT05791617|DIAGNOSTIC_TEST|Inflammatory markers|Measurement of a panel of 92 systemic inflammatory markers on patients' blood samples at 30±5 days and at 90±5 days post-stroke
223472151|NCT05791617|DIAGNOSTIC_TEST|Diagnostic Test: NT-proBNP|NT-proBNP is useful both in the diagnosis and prognosis of heart failure and is considered to be a gold standard biomarker in heart failure. Measurement of NT-proBNP on patients' blood samples at 30±5 days and at 90±5 days post-stroke
223472152|NCT04219189|OTHER|Vaping condition|Participants will be asked to use a JUUL device to vape 20 puffs over 20 minutes. Participants will use JUUL pods with \~5% nicotine by weight. The anticipated amount of nicotine that will be absorbed with 20 puffs is approximately 1.6 mg, which is equal to approximately 1.5 cigarettes.
223580194|NCT00595933|OTHER|mouth rinse|Rinse mouth 4 times a day with additional allowances for as needed. Fill out daily questionaire and an end of week.
223580195|NCT00595933|DRUG|mouth spray|Spray mouth with mouth spray 4 times a day with additional allowances for as needed. Fill out daily questionaire and an end of week
223580196|NCT00595933|DRUG|mouth spray|Spray mouth 4 times a day with additional allowances for as needed. Fill out daily questionaire and an end of week
223580197|NCT03627169|DEVICE|MATRx plus|The MATRx plus device will be used in its capacity as a Level III home sleep apnea test (HSAT). Note: MATRx plus is approved for use in Canada; therefore, the study does not involve any investigational devices.
223580198|NCT01638104|DRUG|ANX-042|Reconstituted in Sterile Water for Injection, United States Pharmacopeia (USP) and administered by 12 hour continuous intravenous infusion with 5% dextrose in water (D5W), United States Pharmacopeia (USP)
223580199|NCT01638104|DRUG|Placebo|Administered once by 12 hour continuous intravenous infusion with D5W (USP)
223472153|NCT04219189|OTHER|Control condition|Participants will have access to an uncharged JUUL device with an empty pod for 20 minutes.
223472154|NCT01381497|DRUG|Combination therapy of sumatriptan and naproxen sodium (SumaRT/Nap)|This is an observational study and patients were prescribed this medication before study start
223472155|NCT01381497|DRUG|Triptan monotherapy|This is an observational study and patients reported a previous triptan monotherapy prescription. Drugs of interested included naratriptan, sumatriptan, rizatriptan, frovatriptan, almotriptan, eletriptan, zolmitriptan
223580200|NCT02273570|DRUG|standard care|Standard care. Patients allocated to this study arm will be treated with all drugs available for PTH control (at the investigator discretion) to obtain a iPTH of 300-540 pg/ml.
223580201|NCT02273570|DRUG|Optimal (I. iPTH control: Zemplar®,Mimpara®; phosphorous control: Renvela®, Phoslo®, Osvaren®, Foznol®,Maalox®; calcium control: calcium and vitamin D|Optimal care. Patients allocated to this study arm will be treated with all drugs available for PTH control (at the investigator discretion - see therapeutic algorithm) to obtain a iPTH of less than 300 pg/ml.
223580202|NCT01680627|BEHAVIORAL|CASI|
223580203|NCT00385398|DRUG|erlotinib hydrochloride|Erlotinib will be administered orally on at a dose of 200 mg/day on Days 1-23 of each 28 day cycle.
223580204|NCT00385398|DRUG|temozolomide|Temozolomide will be administered orally at a dose of 150 mg/m2 on Days 1-5 for Cycle 1 then increased to 200 mg/m2 for Cycle 2 forward.
223580205|NCT00385398|RADIATION|stereotactic radiosurgery|Stereotactic radiosurgery will be performed prior to chemotherapy.
223472156|NCT04870996|DEVICE|tDCS|tDCS was applied using the StarStim 8 (NeuroElectrics, Barcelona, Spain). tDCS with strength of two milliamps for 20 minutes was applied based on montage recommended (Hoy et al., 2014). The stimulation electrode was applied according to international EEG system 10-20. The anode was applied at the left dorsolateral prefrontal cortexDLPFC, which was located at F3; the cathode was applied at the right dorsolateral prefrontal cortexDLPFC, which was located at F4. In the tDCS group, the participants received 'ramp-up' of 30 seconds, followed by active stimulation with a steady current of two milliamps for 20 minutes, then 'ramp-down' of 30 seconds. In the sham group, the current was only delivered in the 30-second 'ramp-up' and 30-second 'ramp-down' period.
223580206|NCT00797680|OTHER|72 hours hypothermia|72 hours mild hypothermia (33 +/1 1 degree Celsius)
223580207|NCT00797680|OTHER|24 hours hypothermia|24 hours mild hypothermia (33 +/1 1 degree Celsius)
223580208|NCT05570890|DEVICE|electrical noise stimulation|The intensity of electrical noise stimulation will be set at 90% of the sensory threshold of each participant.
223580209|NCT05570890|DEVICE|Sham stimulation|Participants will not receive stimulation.
223580210|NCT05570890|DEVICE|Foam|The foam will be used to make an unstable surface.
223580211|NCT04222855|DRUG|Diltiazem|Puerperal patients was administered (60 mg) orally every 8 hours with diltiazem (tables).
223580212|NCT03845972|PROCEDURE|SSFTB|Patients who underwent major knee surgery and had already planned to perform subsartorial femoral triangle block (SSFTB) were included in the study. They were measured the outcomes the night before surgery. The saphenous nerve and nerve to vastus medialis were blocked at the subsartorial femoral triangle level by experienced anesthesiologists. After standard monitor, the distal femoral triangle was identified 2 cm proximal to the opening of adductor canal by ultrasound guidance. At this level, The location of nerve to vastus medialis was confirmed by nerve stimulator and it was blocked with 0.5% levobupivacaine 5 ml. Then, 0.5% levobupivacaine 10 ml would be injected perifemoral artery. The outcomes were re-assessed 30 min after block.
223580213|NCT05996614|PROCEDURE|PRP in skin grafts|topical application of platelet rich plasma before resurfacing with STSG in Post burn raw areas
223580214|NCT05996614|PROCEDURE|conventional methods in skin grafts|fixation of the graft with stitches and staplers
223580215|NCT00139256|DRUG|Betamethasone|Betamethasone injection
223580216|NCT02011490|DRUG|sugammadex|sugammadex 4 mg/kg IV bolus
223580217|NCT03783104|DIETARY_SUPPLEMENT|B12 Supplement|Differential doses of vitamin B 12 supplementation in a two-armed randomised controlled trial
223580218|NCT00162279|DRUG|Abatacept|
223580219|NCT01244633|DRUG|Ecopipam|50 or 100 mg tablets given once per day for eight weeks
223580220|NCT01363583|DRUG|epoprostenol versus normal saline|0.5 ng/kilogram/minute during 4 days
223580221|NCT01363583|DRUG|normal saline|0.5-1.5 ml/hour during 4 days
223580222|NCT06453603|DRUG|PRP injection|Receive pes anserinus PRP injection
223580223|NCT06453603|DRUG|corticosteroid injection|Receive pes anserinus corticosteroid injection
223472157|NCT04870996|BEHAVIORAL|Cognitive Training|All participants received the same program of cognitive training in the app 'the Peak' on a hand-held portable iPad (https://www.peak.net/science/). The traditional Chinese version with Cantonese instructions was selected. The progress, the errors, and the sum scores were stored in the personal profile for interactive feedback on adjusting the difficulty level. The participants performed the tasks in pseudorandomized order during each session. Each training session lasted for 20 minutes, concurrent with either active or sham tDCS stimulation.
223472158|NCT05939687|PROCEDURE|mesh|We'll use mesh repair for prevention of stoma-site hernias in the study group.
223472159|NCT05939687|PROCEDURE|non-mesh|We'll use the layered ligature suturing of the abdominal wall without mesh implantation in the control group.
223580224|NCT00221975|DRUG|Divalproex|Once a therapeutic blood level of lithium was achieved, Divalproex was initiated at 250 mg twice daily and increased slowly over 5 weeks to a minimum blood level of 50 μg/mL.
223580225|NCT00221975|DRUG|Lamotrigine|Lithium monotherapy was initiated at 450 mg once daily and titrated slowly over 3 weeks to a minimum blood level of 0.5 mEqlL.
223580226|NCT00221975|DRUG|Lithium|Subjects who did not respond to the combination of Lithium and Divalproex were then randomly assigned in a 1:1 ratio to adjunctive lamotrigine versus placebo after stratification by illness type (bipolar I versus bipolar II), historical response to lithium (response versus oon-response), and the length of current exposure to the combination treatment with lithium and divalproex (\<2 months versus ≥2 months).
223580227|NCT03697993|DRUG|Fosfomycin tromethamine|Administered orally as 3-gram single-dose sachet into 3-4 ounces (1 / 2 cup) of cool water; each dose must be taken immediately after dissolving in water. Hot water should not be used to dissolve fosfomycin. It may be taken either with or without food for normal kidney function. If Creatinine Clearance (CrCl) is less than 20 mL/min, fosfomycin should be taken as 3 grams every other day.
223580228|NCT03697993|DRUG|Levofloxacin|750 mg is administered orally as one tablet once daily with or without food for normal kidney function. If Creatinine Clearance (CrCl) is 20-49 mL/min, 750 mg should be taken every other day. If on subsequent testing post-randomization, the Creatinine Clearance (CrCl) is less than 20 mL/min, followed by the dose is 500 mg every other day.
223580229|NCT04412213|OTHER|Stuttering severity instrument for school-age children (SSI-3 Arabic version)|Stuttering severity instrument for school-age children (SSI-3 Arabic version) for measuring stuttering severity Stanford Binet test version 4 to evaluate the mentality (IQ)
223580230|NCT02111291|BIOLOGICAL|Collagenase SANTYL® Ointment|Daily application directly to the ulcer bed, approximately 2 mm thick.
223472160|NCT00352183|DRUG|Fenofibrate/Simvastatin|Combination of Fenofibrate and Simvastatin 40mg
223580231|NCT02111291|BIOLOGICAL|Hydrogel (if needed) and foam dressing|Daily application of hydrogel directly to the ulcer bed (if necessary), covered with foam dressing
223580232|NCT01565564|BEHAVIORAL|Shared glycaemic control care within the local three-tier's antenatal care network|"* Individualized dietary and physical activity consultation plus group diabetes education~* Self blood glucose monitoring~* Insulin therapy if indicated~* Self blood glucose monitoring~* Insulin therapy institutions if indicated;"
223580233|NCT03971604|DRUG|Vitamin A|treated with Vitamin A
223580234|NCT03971604|DRUG|Vitamin E|treated with Vitamin E
223472161|NCT00352183|DRUG|Simvastatin|Simvastatin 40mg
223580235|NCT06119438|OTHER|Aromatherapy|Aromatherapy is a TAT (Tapas Acupressure technique) method in which essential oils created from fragrant parts of plants are absorbed from the body and show their effects. The therapeutic, disease-relieving or preventive properties of essential oils are utilized
223580236|NCT02698371|DEVICE|G1-Control: Futurabond®DC-SE (FBDC_SE)|Futurabond®DC (FBDC) adhesive by self-etch (SE) mode bonding in NCCls restorations, was randomly assigned to premolar or molar teeth ensuring that this adhesive/mode is only apllied once in each participant.
223580237|NCT02698371|DEVICE|G2-Control: Futurabond®DC_SE_EE|Futurabond®DC adhesive by self-etch mode with selective enamel etching (FBDC-SE-EE) bonding in NCCls restorations, was randomly assigned to premolar or molar teeth ensuring that this adhesive/mode is only apllied once in each participant.
223472162|NCT02381236|DRUG|G-202|G-202 administered by intravenous infusion on Days 1, 2 and 3 of each 28-day cycle for up to 3 cycles
223472163|NCT05654038|BIOLOGICAL|Anti-CD19 UCAR-NK cells|"The trial includes two portions. The first portion is a3+3dose escalation study, in which three dose groups are set three different dose levels of UCAR-NK cells:Dose level one: 5-10×10\^6/kg; Dose level two:1-2×10\^7/kg; Dose level three:2-5×10\^7/kg."
223472164|NCT02935920|BEHAVIORAL|Individualized, tailored follow-up program|Individualized follow-up in the context of shared decision making, with the use of PRO-data to evaluate the patient needs of consultations.
223580238|NCT02698371|DEVICE|G3: Futurabond® U - ER (FBU_ER)|FuturabondU® (FBU) adhesive by etch-and-rinse (ER) mode, bonding in NCCls restorations, was randomly assigned to premolar or molar teeth ensuring that this adhesive/mode is only apllied once in each participant.
224069299|NCT05875870|BEHAVIORAL|Stretching exercise|"The stretching exercise includes two movements for the upper body and two movements for the lower body, 10 minutes each time, three times a week, for 6 weeks.~The researcher will explain to the participants about how to perform the stretching exercise, according to an instruction manual (hardcopy) for the exercise regimen.~A video is shown to the participants (the content same as hardcopy of education manual)."
224069300|NCT03023943|OTHER|Instrument Assisted Soft Tissue Mobilization|Intervention will be 10 minutes of GT1 instrument application at anterior thigh using sweep technique.
224069301|NCT00737867|DRUG|Vinorelbine|Day 1: Vinorelbine capsules 60 mg/m2 Day 8: Vinorelbine capsules 60 mg/m2
224069302|NCT00737867|DRUG|Gemcitabine|Day 1: Gemcitabine infusion 1000 mg/m2 Day 8: Gemcitabine infusion 1000 mg/m2
224069303|NCT00737867|DRUG|Vinorelbine|Day 1: Vinorelbine capsules 60 mg/m2 Day 8: Vinorelbine capsules 60 mg/m2
224069304|NCT00737867|DRUG|Carboplatin|Day 1: Carboplatin infusion AUC = 5 (Calvert's formula)
224069305|NCT00992316|DRUG|PF-04531083|solution. doses to be selected based upon safety/tolerability/PK at preceeding dose
224069306|NCT03826693|DRUG|Nitrous Oxide|OCD participants in this arm will receive 50%oxygen/50% nitrous oxide admixture for 60 minutes.
223472165|NCT05322096|DRUG|RGH-706|"Capsules~Oral administration"
223472166|NCT05322096|DRUG|Placebo|"Capsules~Oral administration"
224069307|NCT03826693|DRUG|Nitrogen|OCD participants in this arm will receive 50%oxygen/50% nitrogen admixture for 60 minutes.
223472167|NCT03473405|DEVICE|Air Barrier System|The Air Barrier System is a device that uses localized clean air flow to shield a surgery site from ambient airborne microorganisms that are shed into the air from people present in the operating room.
223472168|NCT03473405|OTHER|Control|The Air Barrier System will be deployed onto the surgical field, but the airflow will not be activated, so this is a sham control comparator.
223472169|NCT03101020|OTHER|Active Visceral Manipulation|Visceral manipulation techniques consists of deep manual pressure in certain points of the abdomen and the amount of pressure will be respected according to the participant discomfort or pain. It will be performed cardia mobilization, pylori mobilization, Oddi's sphincter mobilization, duodenum-jejunum valve mobilization, ileocecal valve mobilization, global technique for the liver, global hemodynamic technique. Each technique will last 1 minutes, with the two last ones repeated 10 times.
223472170|NCT03101020|OTHER|Standard care physiotherapy|The care includes advice for correct postures to perform daily activities; abdominal, pelvic and lumbar muscles re-training and strengthening; and advice to perform at least 20 minutes' walk three times a week. The therapist will treat the participants once a week for a 5-week period. All treatment session will last 40 minutes.
223472171|NCT03101020|OTHER|Placebo Visceral Manipulation|The placebo intervention involves light touch at the same regions of the techniques the active visceral manipulation, and no intention on the part of the therapist to impart any therapeutic technique
223472172|NCT02228252|OTHER|Whey protein|
223472173|NCT02228252|OTHER|Casein|
223472174|NCT02228252|OTHER|Gluten protein|
223472175|NCT05810701|OTHER|Comprehensive geriatric assessment and individualised physical training|Comprehensive geriatric assessment and relevant intervention (including medical and pharmacological optimisation, nutritional, social and psychological intervention, among others), and individualised physical training
223472176|NCT00328705|DEVICE|Implantable Cardioverter Defibrillator|
223472177|NCT05817669|BIOLOGICAL|Efgartigimod|Patients receiving efgartigimod infusions
224069308|NCT03878511|DIETARY_SUPPLEMENT|Lactose|Lactose monohydrate 810 mg, silicon dioxide 20 mg, and magnesium stearate 14 mg
224069309|NCT03878511|DIETARY_SUPPLEMENT|Placebo|Dextran 40 EP 671 mg, silicon dioxide 20 mg and magnesium stearate 14 mg
224069310|NCT00951730|OTHER|Polysomnography|Polysomnography is the method of choice for the diagnosis of sleep apnea. This test lasts for one night in hospital.
224160486|NCT03377452|BEHAVIORAL|Non-directive sleep apnea education control|Six session sleep apnea and PAP education program. Sessions delivered in individual format, either in-person or via telehealth.
224160487|NCT04741204|DRUG|Metformin Extended Release Oral Tablet|initial dose of metformin of 750 mg Q.D. (with dinner) for 3-4 weeks. They then will be increased to the final dose of 750 mg BID (breakfast and dinner) until the end of the study.
224160488|NCT06391970|DEVICE|Cognitive screening|The cognitive abilities of participants will be assessed using two different interventions: the first utilizing the new digital device, and the second employing the gold standard method.
223472178|NCT05817669|BIOLOGICAL|Placebo|Patients receiving placebo infusions
223472179|NCT02040714|PROCEDURE|Osteotomy + Long Term Non-Weight Bearing|Surgical procedure that improves femoral head containment, plus a post-operative protocol that requires patient to maintain non-weight bearing for 6 months.
223472180|NCT02040714|PROCEDURE|Osteotomy + Short Term Non-Weight Bearing|Surgical procedure that improves femoral head containment, plus a post-operative protocol that allows early return to function after 6 weeks of non-weight bearing.
223472181|NCT02040714|PROCEDURE|Nonoperative Observation|Group will not undergo any surgical or invasive procedures during course of treatment.
223472182|NCT02040714|PROCEDURE|Multiple Epiphyseal Drilling|Multiple epiphyseal drilling is a procedure that creates small holes in the femoral head growth plate to increase blood flow into the femoral head.
223472183|NCT00003837|DRUG|nelarabine|
223472184|NCT00381212|BIOLOGICAL|AGS-004|Four intradermal injections of AGS-004-001 immunotherapeutic, 4 weeks apart.
223472185|NCT04583982|OTHER|T-Detect™ SARS-CoV-2 Assay|T-Detect™ SARS-CoV-2 Assay is an investigational device that is indicated to assess T-cell immune response to SARS-CoV-2 via the testing of blood samples from patients with signs and symptoms of suspected COVID-19. These results will not be shared with the participant.
224069311|NCT00432978|DRUG|Bosentan administration|
224069312|NCT04651387|DIETARY_SUPPLEMENT|Ozonized oil (HOO|"In addition to the routine standard treatments for COVID-19, in the intervention group, combined use of HOO capsules and HOO oropharyngeal and nasal spray will be administered 3 times per day (after breakfast, lunch, dinner, possibly with a delay of one hour from the routine treatment) and will be prescribed for 2 weeks (14 days).~Posology: 3 HOO capsules plus 3 HOO intranasal administrations for each naris plus 3 HOO oropharyngeal administrations."
224160489|NCT01524809|DRUG|biphasic insulin aspart 30|Dose individually adjusted. Administrated subcutaneously (s.c., under the skin) three times a day for 15 days in each treatment period. A wash-out period of 2-8 weeks will take place between treatment periods.
223472186|NCT01868659|BEHAVIORAL|Diagnostic checklist|Diagnostic checklist used before patient discharged
223472187|NCT01868659|BEHAVIORAL|Usual care with no diagnostic checklist|Patient receives usual care with no research intervention
223472188|NCT02948647|OTHER|Standard of care plus sugar-reduction education|This is a 12-week intervention where subjects will be educated on how to monitor their added sugar consumption. They will be asked to eliminate consumption of sweetened beverages for the 12-week period and will be receiving a weekly delivery of water bottles to their homes to displace the sweetened beverages in their home environment.
223472189|NCT03303495|BIOLOGICAL|Bevacizumab|5 mg/kg intravenously administered over 90 minutes (can be reduced to 30 minutes at the minimum) on day 1 of a 2-week cycle.
223472190|NCT03303495|DRUG|CPT-11|180 mg/m2 intravenously administered over 90 minutes on day 1 of a 2-week cycle
224160490|NCT01524809|DRUG|biphasic insulin aspart 70|Dose individually adjusted. Administrated subcutaneously (s.c., under the skin) three times a day for 15 days in each treatment period. A wash-out period of 2-8 weeks will take place between treatment periods.
223472191|NCT03303495|DRUG|5-FU Bolus|400 mg/m2 intravenous bolus on day 1 of a 2-week cycle.
223472192|NCT03303495|DRUG|5-FU Infusion|2400 mg/m2 continuous infusion over 46 hours on day 1 and 2 of a 2-week cycle.
223472193|NCT03303495|DRUG|l-LV (dl-LV)|200 (dl-LV: 400) mg/m2 intravenously administered over 120 minutes on day 1 of a 2-week cycle.
224160491|NCT04904640|DEVICE|Hip stem|In every hip (with appropriate CT scan), 3 different stem designs will be positioned using a 3D Ct based software for surgical pre-operative planning.
224160492|NCT03273868|OTHER|High velocity low amplitude manipulation|The researcher manually applies a preload force on the T5/T6 level followed by a single posterior to anterior thrust.
223472194|NCT05733663|DIAGNOSTIC_TEST|Endoscopic procedure with duodenal biopsy|"* In all patients the investigators will analyse coeliac serology, DQ-genotype, and results of two duodenal biopsy sampling (one at diagnosis before starting the GFD and another sampling during follow-up with GFD) for assessment of both histopathology and intraepithelial lymphocyte subpopulations by T-cell flow cytometry. In addition, clinical, serological, and histological response to GFD will be evaluated.~* T-cell flow cytometry assay is performed as previously described by our group in previous studies. In all patients, an additional duodenal biopsy sample is taken from the second-third portion of the duodenum at the same endoscopic procedure that for histopathology. The normal cut-off values for the IEL cytometric pattern in our laboratory are CD3+TCRγδ+ IEL ≤8.5% (≤mean + 2SD) and CD3- IEL ≥10% (10th percentile). The cut-offs define four intraepithelial lymphogram patterns: normal, isolated decrease in CD3- cells, isolated increase in TCRγδ+ cells, and the coeliac lymphogram."
223472195|NCT05654571|DIAGNOSTIC_TEST|mammography|All patients are checked for mammography every year after surgery.
223472196|NCT00603031|OTHER|glucagon like peptide -1|continuous infusion 1,2 pmol pr. kg pr minute at 120 minutes
223472197|NCT00603031|OTHER|NaCl|infusion with NaCl for 120 minutes as placebo-arm
223472198|NCT00603031|OTHER|glucose dependent insulinotropic polypeptide|continuous infusion with GIP-1 (3,6pmol/kg/min) at 120 minutes.
223472199|NCT02117258|DRUG|Z-360|Gemcitabine (1,000 mg/m\^2) will be given by 30-minute intravenous infusion on Day 1, 8, and 15 followed by a one week rest in all 28-day Cycles, while Z-360 (60, 120 or 240 mg) will be taken orally, twice daily (BID) after a meal. Dosing will continue until the patient fulfills the withdrawal criteria.
223472200|NCT02117258|DRUG|Placebo|Gemcitabine (1,000 mg/m\^2) will be given by 30-minute intravenous infusion on Day 1, 8, and 15 followed by a one week rest in all 28-day Cycles, while placebo will be taken orally, twice daily (BID) after a meal. Dosing will continue until the patient fulfills the withdrawal criteria.
223472201|NCT03292016|DRUG|APL-130277|APL-130277 sublingual thin film
223472202|NCT03292016|DRUG|APO-go|Subcutaneous APO-go
223472203|NCT03292016|DRUG|Apokyn|Subcutaneous APOKYN
223580239|NCT02698371|DEVICE|G4: Futurabond® U - SE (FBU_SE)|FuturabondU® (FBU) adhesive by self-etch (SE) mode, bonding in NCCls restorations, was randomly assigned to premolar or molar teeth ensuring that this adhesive/mode is only apllied once in each participant.
224160493|NCT03273868|OTHER|Sham manipulation|The researcher manually applies a preload force on the right scapula followed by a single lateral thrust.
224160494|NCT03880006|BEHAVIORAL|Case management|Case management intervention is a multi-step process to coordinate care and provide a family-like support system for people living with HIV. Individuals are assigned to a specific case manager who will provide support throughout the study. The case management approach has five key components: 1) initial meeting between person living with HIV and case manager; 2) follow up meeting between case manager and participant; 3) biweekly automatic text messages sent to participant; 4) monthly phone calls from case manager; and 5) face-to-face meetings between case manager and participant every 6 months.
224160495|NCT00796003|DRUG|JNJ-30979754 15 mg/m2|JNJ-30979754 (decitabine) 15 mg/m2 will be administered once daily by 1-hour intravenous infusion from Day 1 to 5 of 4-Week (28-day) Cycle 1.
223472204|NCT01330082|OTHER|Adjunctive Photodynamic Therapy|using Light-emitting diod(LED) (625-635nm,200mw/cm2 ,30 s for each site, fotoson CMS Dental ,Denmark) in the presence of toluidine blue O (TBO)
223472205|NCT01330082|OTHER|Light-emitting diod Irradiation|625-635nm,200mw/cm2 ,30 s for each site, fotoson CMS Dental ,Denmark
223472206|NCT01330082|OTHER|applying Photosensitizer|toluidine blue O is applied at the bottom of each periodontal pocket
223472207|NCT01042626|OTHER|Oral peptones load|Enrolled subjects will receive 10 g Liebig meat extract diluted in 250ml of 0.9% saline
223472208|NCT05283746|DRUG|Epetraborole|Epetraborole hydrochloride 250 mg tablets for oral administration
223472209|NCT04268355|BEHAVIORAL|Mindfulness Training for Primary Care|MTPC is a referral-based, insurance-reimbursable 8-week program delivered as group psychotherapy by Patient-Centered Medical Home-integrated behavioral clinicians or as an 8-week primary care group visit delivered by a primary care provider. MTPC groups are 2 hours for 8 weeks with a 7-hour weekend day of silent practice. MTPC emphasizes mindfulness-oriented skills for self-regulation, self-management of chronic illness, and health behavior change. All participants complete an action plan during Week 7. Participants are called every two weeks for the first eight weeks for 5-10 minute engagement calls which focus helping participants cultivate a relationship with study staff, giving participants a place to ask questions, and supporting participants in completing study visits.
223472210|NCT01951716|DRUG|Graded Glucose Infusion with Placebo|"Starting at 0 minutes, glucose infusion rates will be increased to 1, 2, 3, 4, 6, and 8 mg/kg/min every 40 minutes.~Starting at 0 minutes, a primed-continuous intravenous infusion of saline containing 1% human albumin will continue for 240 minutes.~The study is finished at 240 minutes."
223472211|NCT01951716|DRUG|Graded Glucose Infusion with GIP Alone|"Starting at 0 minutes, glucose infusion rates will be increased to 1, 2, 3, 4, 6, and 8 mg/kg/min every 40 minutes.~Starting at 0 minutes, a primed-continuous intravenous infusion of GIP in saline containing 1% human albumin will continue for 240 minutes.~The study is finished at 240 minutes."
223472212|NCT01951716|DRUG|Graded Glucose Infusion with xenin-25 alone|"Starting at 0 minutes, glucose infusion rates will be increased to 1, 2, 3, 4, 6, and 8 mg/kg/min every 40 minutes.~Starting at 0 minutes, a primed-continuous intravenous infusion of xenin-25 in saline containing 1% human albumin will continue for 240 minutes.~The study is finished at 240 minutes."
223580240|NCT02698371|DEVICE|G5: Adhese® Universal - ER (ADU_ER)|Adhese®Universal (ADU) adhesive by etch-and-rinse (ER) mode, bonding in NCCls restorations, was randomly assigned to premolar or molar teeth ensuring that this adhesive/mode is only apllied once in each participant.
223580241|NCT02698371|DEVICE|G6: Adhese® Universal - SE (ADU_SE)|Adhese®Universal (ADU) adhesive by self-etch (SE) mode, bonding in NCCls restorations, was randomly assigned to premolar or molar teeth ensuring that this adhesive/mode is only apllied once in each participant.
223472213|NCT01951716|DRUG|Graded Glucose Infusion with GIP plus xenin-25|"Starting at 0 minutes, glucose infusion rates will be increased to 1, 2, 3, 4, 6, and 8 mg/kg/min every 40 minutes.~Starting at 0 minutes, a primed-continuous intravenous infusion of GIP plus xenin-25 in saline containing 1% human albumin will continue for 240 minutes.~The study is finished at 240 minutes."
223472214|NCT01951716|DRUG|Meal Tolerance Test with Placebo|"At 0 minutes, a liquid mixed meal (Boost Plus) plus acetaminophen will be ingested.~Starting at 0 minutes, a primed-continuous intravenous infusion of saline containing 1% human albumin will continue for 300 minutes.~The study is finished at 300 minutes."
223472215|NCT01951716|DRUG|Meal Tolerance Test with xenin-25|"At 0 minutes, a liquid mixed meal (Boost Plus) plus acetaminophen will be ingested.~Starting at 0 minutes, a primed-continuous intravenous infusion of xenin-25 in saline containing 1% human albumin will continue for 300 minutes.~The study is finished at 300 minutes."
223472216|NCT04061785|OTHER|Judo4Balance - 12 week judo inspired exercise program|12 weeks x 45 minute judo inspired exercise in lead by instructor in a group setting.
224160496|NCT00796003|DRUG|JNJ-30979754 20 mg/m2|Phase I: JNJ-30979754 (decitabine) 20 mg/m2 will be administered once daily by 1-hour intravenous infusion from Day 1 to 5 of 4-Week (28-day) Cycle 1. Phase II: JNJ-30979754 (decitabine) 20 mg/m2 will be administered once daily by 1-hour intravenous infusion from Day 1 to 5 of 4-Week (28-day) cycles until the decitabine was expected to be effective in participants.
224160497|NCT05904938|DEVICE|Lenodiar Pediatric|Medical Device made of natural substance
224160498|NCT05904938|OTHER|Placebo|Product appearance similar to verum without clinical efficacy
224160499|NCT00776373|DRUG|Rapamycin + high dose etoposide and cytarabine|Rapamycin,by mouth, loading dose followed by a single daily dose for 8 days (dose level 1 = load of 9 mg followed by 3 mg daily doses, dose level 2 = 12 mg with daily doses of 4 mg; Etoposide 500 mg/m2/day IV and Cytarabine 2000 mg/m2/day IV every 24 hours for 4 days.
224160500|NCT02727504|DEVICE|Electrocardiogram|ECG at inclusion and M12
224160501|NCT02727504|DEVICE|2D and 3D echocardiography|2D and 3D echocardiography at inclusion and M12
224160502|NCT02727504|DEVICE|Dobutamine stress echocardiography|dobutamine stress echocardiography at inclusion
224160503|NCT02727504|BIOLOGICAL|Blood tests|Blood test electrolytes, creatinine, hemoglobin, NT-proBNP, CRP, ST-2 at inclusion and M12
224160504|NCT02727504|DEVICE|Cardiac MRI|Cardiac MRI at inclusion
224160505|NCT02727504|DEVICE|Cardiac scanner|Cardiac scanner at inclusion
224160506|NCT02727504|OTHER|6-minutes walking test|6-minutes walking test at inclusion and M12
224160507|NCT02727504|OTHER|Duke Activity Score|Duke Activity Score at inclusion and M12
224160508|NCT04569760|DRUG|50:2 mg(CBD:THC)/ml - Cannabinoid Oil Oral Preparation- titrated as tolerated up to a maximum 8mls twice daily (200 mg- 800 mg total dose)|Oral cannabinoid oil preparation dosed in 1ml increments
224160509|NCT04569760|DRUG|Placebo Oil|Oral MCT Oil Preparation - No cannabinoids- titrated as tolerated up to a maximum of 8mls twice daily (equivalent to 200 mg- 800 mg total dose of the active product)
223472217|NCT02819713|OTHER|ultrasound gel|
223472218|NCT02819713|OTHER|Instillagel|
223472219|NCT02750995|BIOLOGICAL|NPMW-peptide vaccine|Peptide vaccine against long peptide sequences from NY-ESO-1, PRAME, MAGE-A3, WT-1.
224160510|NCT03687476|DRUG|VTS-270|VTS-270 200 mg/mL administered as described in the arm group description.
224160511|NCT02155504|DRUG|ASP3700|oral
224160512|NCT02155504|DRUG|itraconazole|oral
223472220|NCT02750995|DRUG|Azacitidine|Standard therapy. All participants receive azacitidine 6 months prior to inclusion, which continues during the study period.
223472221|NCT03220022|DRUG|Cyclophosphamide|Given IV
223472222|NCT03220022|DRUG|Doxorubicin Hydrochloride|Given IV
223472223|NCT03220022|DRUG|Etoposide|Given IV
223472224|NCT03220022|BIOLOGICAL|Filgrastim|Given SC
223472225|NCT03220022|DRUG|Ibrutinib|Given PO
223472226|NCT03220022|OTHER|Laboratory Biomarker Analysis|Correlative studies
223472227|NCT03220022|BIOLOGICAL|Pegfilgrastim|Given SC
223472228|NCT03220022|OTHER|Pharmacological Study|Correlative studies
223472229|NCT03220022|DRUG|Prednisone|Given PO
223472230|NCT03220022|BIOLOGICAL|Rituximab|Given IV
223472231|NCT03220022|DRUG|Vincristine Sulfate|Given IV
223472232|NCT06960928|DRUG|Low-dose sirolimus|"Participants will take sirolimus, at home, for 12 weeks (3 months).~* 1 pill once a week for 2 weeks (1mg)~* 2 pills once a week for 2 weeks (2mg)~* 4 pills once a week for 8 weeks (4mg)"
224160513|NCT02155504|DRUG|Placebo|oral
224160514|NCT03163940|BEHAVIORAL|Laughter Yoga|A LY group will be composed of 8-12 participants. Each sessions will include 4 essential elements steps of laughter yoga, laughter meditation and grounding exercises. The 4 steps of laughter yoga are 1) warm up exercise, 2) deep breathing exercises, 3) childlike playfulness and 4) laughter exercises. The laughter meditation is a deeper experience of unconditional laughter in which laughter often comes in natural waves and it becomes infectious and set off a chain reaction to infect other people. The grounding exercises allow individuals to ground the energy of laughter and relax. The LY intervention will be facilitated by a certified lead LY trainer.
224160515|NCT05844774|DEVICE|HPI (using HemoSphere) - guided algorithm|Treatment of hypotension guided by the hypotension prediction index. Patients will receive treatment following the predetermined HPI-algorithm when the HPI exceeds 85%.
224160516|NCT05844774|DEVICE|Treatment of hypotension following standard of care|Patients receive standard of care treatment for hypotension, with a goal-mean arterial pressure (MAP) of 65mmHg.
224160517|NCT03749668|OTHER|non applicable|no intervention in this observational study
224160518|NCT05179057|DRUG|Posoleucel|Administered as 2-4 milliliter infusion, visually identical to placebo
224160519|NCT05179057|DRUG|Placebo|Administered as 2-4 milliliter infusion, visually identical to Posoleucel
224160520|NCT03745404|DRUG|Lidocaine 5% medicated Plaster|
224160521|NCT03745404|DRUG|Placebo Plaster|
224304163|NCT04325763|DRUG|Anlotinib(blank)|Subjects administrated anlotinib (blank) in fasting conditions, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21)
224304164|NCT03218059|PROCEDURE|Methotrexate Combined With Transvaginal Surgery|The methods of treatment of CSP
224304165|NCT06033300|BIOLOGICAL|blood sample|blood sample
224304166|NCT00331240|DRUG|travoprost/timolol fixed combination|
224160522|NCT06250504|DRUG|APRETUDE (cabotegravir) 600 mg\3 mL|choice of 2-monthly injectable long acting cabotegravir. The initial visit will be followed by planned visit for the first injection, one month visit for second injection, and then 2-monthly CAB LA injections with repeat HIV testing and pregnancy testing, and referral to peer navigators for adherence and retention support. We will conduct HIV testing, STI testing, Hep B, Hep C, and safety bloods (Full Blood Count, Creatinine, Liver Function Tests) at baseline, HIV testing two monthly, and annual safety bloods, alongside annual STI testing.
223472233|NCT06960928|DRUG|Placebo|"Participants will take a matching placebo, at home, for 12 weeks (3 months).~* 1 pill once a week for 2 weeks (0mg)~* 2 pills once a week for 2 weeks (0mg)~* 4 pills once a week for 8 weeks (0mg)"
223472234|NCT05630872|DRUG|Dolutegravir (DTG) 50 mg orally BID (~12 hours apart) plus TDF/3TC|Dolutegravir (DTG) 50 mg orally BID (\~12 hours apart) plus TDF/3TC, from study week 6 until 2 weeks after completion of TB treatment: Morning dose DTG 50 mg QD plus TDF/3TC from study-supplied ARV regimen. Evening dose: DTG 50 mg orally QD from study-supplied source.
223472235|NCT05630872|DRUG|DTG 50 mg orally QD plus TDF/3TC|DTG 50 mg orally QD plus TDF/3TC from two weeks after completion of TB treatment to end of study (week 48).
223472236|NCT05630872|DRUG|2HPZM|Daily rifapentine-moxifloxacin plus isoniazid and pyrazinamide regimen
223472237|NCT05630872|DRUG|2HPM|Daily rifapentine-moxifloxacin plus isoniazid regimen
223472238|NCT04623710|DRUG|ALXN2050|ALXN2050 (120 milligrams) will be administered orally twice daily on Days 1 through 3, with an additional dose (120 milligrams) administered orally on the morning of Day 4.
223472239|NCT03195439|DEVICE|TTP|TTP™ allows to continuously measure body temperature using a new non-invasive method, and was cleared for marketing by US FDA (K150160) for as a temperature monitoring system intended to measure and monitor core body temperature of patients of all ages, by applying a sensor unit on the forehead.
223472240|NCT05963399|DEVICE|CAREUP platform|The Experimental Group will test the CAREUP platform at home for 12 months.
223472241|NCT05220488|OTHER|Assessment|Parameters such as physical activity and fear of covid will be evaluated in asthmatic and healthy children and adolescents.
223472242|NCT02506387|DEVICE|mitraclip|The decision to implant mitraclip is not part of this observational study but is made by the heart-team.
223472243|NCT02305264|DRUG|18F-DPA-714 and 18F-FDG|"Positron emission tomography (PET) imaging following the injection of 2 radiotracers (here considered as the drugs): 1) 18F-DPA-714 ii) 18F-FDG. PET -18F-DPA-714, dose 5mCi (185MBq), will be injected via an arm intravenous catheter.~18F-FDG , dose 5mci(185MBq), will be injected via an arm intravenous catheter."
224160523|NCT06250504|DRUG|DAPIRING (Dapivirine) 25mg Vaginal Ring|The initial visit is followed by a 7-day phone call, 3-monthly follow-up. Each follow-up will include repeat HIV testing (POCT x2 and dry blood spots for HIV ELISA) and pregnancy testing, syndromic management of STIs, and referral to peer navigators for adherence support and PrEP/ART and if applicable contraception refills. Safely bloods (full blood count, creatinine, liver function tests) will follow national guidelines. Currently we aim to do baseline and annual safety bloods, alongside annual STI testing
223472244|NCT04500951|OTHER|Optimized resting environment|"Alarms from feeding pumps will be relayed to the nurse call system for all intervention periods. Alternatively meals will be timewise reorganized to not interfer with the intervention resting periods. Signs reminding staff not to disturb will be posted for all intervention periods.~For each patient the close team of rehabilitation professionals will agree upon a guideline suggesting the optimal resting environment for the specific patient. The guideline wil be based on knowledge gathered from relatives on pre-injury preferences. Furthermore, the guideline will be developed based on a toolbox of possible intervention representing best practice. The toolbox has been designed according to the categories of the International Classification of Functioning.~The intervention will designed individually for each patient."
223472245|NCT04500951|OTHER|Standard resting environment|The control condition, standard resting environment, will consist of a basic positioning either reclined in bed or reclined in wheelchair according to regular procedures of the ward. Pressure ulcers and positioning believed to induce pain will be avoided.
223472246|NCT03971760|OTHER|Suction drain removal|Removal of negative pressure suction drain left in place to drain the surgical space after a neck surgery
223472247|NCT05339958|DIETARY_SUPPLEMENT|Nutrafol® Men Hair Growth Nutraceutical|Nutrafol® Men contains patented Synergen Complex® is a blend of proprietary formulation of botanicals with potent anti-inflammatory, anti-stress adaptogenic, antioxidant and DHT-inhibiting properties - combined to synergistically combat the multiple underlying factors that compromise hair growth and health. These ingredients include Sensoril Ashwagandha, BCM-95 BioCurcumin, USPlus Saw Palmetto, EVNolMax 20% Tocotrienol/Tocopherol complex, Bioperine (piperine), Cynatine HNS (solubilized keratin), and Capsimax (capsaicin).
223472248|NCT05339958|OTHER|Placebo Supplement|The placebo capsules contain no active ingredients.
223580242|NCT05697666|OTHER|Modulation of the depth of the neuromuscular blockade|"Analysis of the respiratory mechanics at two times:~* Facial train of four = 0, indicating a deep neuromuscular blockade~* Facial train of four \> 0, indicating a intermediate to light neuromuscular blockade"
223580243|NCT00227513|DRUG|bortezomib|Given IV
223580244|NCT00227513|DRUG|vorinostat|Given orally
223580245|NCT03738007|DEVICE|HA IDF II|Treatment with HA IDF II (YVOIRE volume)
223580246|NCT03738007|DEVICE|Perlane|Treatment with Perlane
223580247|NCT02359214|DIETARY_SUPPLEMENT|Vitamin D3|5000IU (125mcg) vitamin D3 tablet daily over 8 weeks (56 days).
224160524|NCT06250504|DRUG|tenofovir disoproxil and emtricitabine|The initial visit is followed by a 7-day phone call, 3-monthly follow-up. Each follow-up will include repeat HIV testing (POCT x2 and dry blood spots for HIV ELISA) and pregnancy testing, syndromic management of STIs, and referral to peer navigators for adherence support and PrEP/ART and if applicable contraception refills. Safely bloods (full blood count, creatinine, liver function tests) will follow national guidelines. Currently we aim to do baseline and annual safety bloods, alongside annual STI testing
224304167|NCT00331240|DRUG|placebo (artificial tears)|
224304168|NCT00072592|DRUG|Rituximab|
224304169|NCT03527381|DRUG|Nitric Oxide|40 ppm of exogenous gaseous nitric oxide is supplied directly to the oxygenator in the cardiopulmonary bypass circuit during cardiac surgery.
224304170|NCT03527381|OTHER|Standard CPB|Standard CPB protocol of delivery of air gas mixture to the cardiopulmonary bypass circuit during cardiac surgery.
224304171|NCT02740387|DRUG|OTO-104|
223580248|NCT02359214|OTHER|Placebo|100% Lactose tablet daily over 8 weeks (56 days).
223472249|NCT04490408|PROCEDURE|long surgical bypass|long surgical bypass and hybrid approaches in patients with multilevel critical lower limb ischemia.
223472250|NCT04490408|PROCEDURE|Hybrid approach|Hybrid approach including bypass and endovascular revascularization
223472251|NCT06550323|DEVICE|Group using virtual reality glasses|Group using virtual reality glasses: During the procedure, individuals will wear glasses.
223472252|NCT03786380|DRUG|Relamorelin 10 μg|Relamorelin 10 μg injected subcutaneously twice daily.
223472253|NCT04690465|BEHAVIORAL|Resistance training|"Participants will receive a 16-week resistance training program, with 3 times a week (a total of 48 training sessions) and 60 minutes per session intervention, which is adopted from the 12-week resistance training program introduced in the book Growing Stronger: Strength Training for Older Adults (Seguin et al., 2002), with minor modifications under the advice of Physical Fitness Association of Hong Kong, China (PFA)."
224160525|NCT06250504|DRUG|Tenofovir Disoproxil, Lamuvidine and Dolutegravir|The initial visit is followed by a 7-day phone call, 3-monthly follow-up. Each follow-up will include repeat HIV testing (POCT x2 and dry blood spots for HIV ELISA) and pregnancy testing, syndromic management of STIs, and referral to peer navigators for adherence support and PrEP/ART and if applicable contraception refills. Safely bloods (full blood count, creatinine, liver function tests) will follow national guidelines. Currently we aim to do baseline and annual safety bloods, alongside annual STI testing
224160526|NCT01929512|DRUG|HCP1201 750/20mg|750mg Metformin/20mg rosuvastatin fixed dose combination tablet orally in the morning on day1 or day8.
224160527|NCT01929512|DRUG|Metformin SR 750mg|Co-administration of Metformin 750mg and Rosuvastatin 20mg orally in the morning on day1 or day8.
224160528|NCT01929512|DRUG|Rosuvastatin 20mg|Co-administration of Metformin 750mg and Rosuvastatin 20mg orally in the morning on day1 or day8.
223472254|NCT04690465|BEHAVIORAL|Eight-form Yang-style Tai Chi program|The active concurrent control group will receive Eight-form Yang-style Tai Chi program which has been confirmed feasible and will be taught by the qualified coach.
223472255|NCT03539978|OTHER|SM-THINk|Patients will receive the SM-THINk enhanced discharge method.
223472256|NCT04477369|DRUG|DWJ1439|300mg single dose
223472257|NCT04477369|DRUG|DWJ1464|300mg single dose
223472258|NCT04477369|DRUG|DWC202003|300mg single dose
223472259|NCT04477369|DRUG|DWC202004|300mg single dose
223472260|NCT02115984|DRUG|Panagen|
223472261|NCT02115984|DRUG|Placebo|
223580249|NCT00199667|DRUG|Mycophenolate Mofetil|
223580250|NCT04928729|OTHER|Pursed Lip Breathing|PLB with frequency of three times daily for First 3 days of week for a duration of 5-10 mins is perform.
224160529|NCT02374359|OTHER|follow-up|
224160530|NCT01897259|DRUG|Placebo Injection|Participants in the placebo group will recieve placebo injections (1cc 1% lidocaine and 1cc normal saline).
224160531|NCT01897259|BEHAVIORAL|Physical Therapy|Subjects participating in the physical therapy group will attend physical therapy and be prescribed to NSAIDS. No prolotherapy or corticosteroid injections.
224160532|NCT01897259|DRUG|Corticosteroid Injections|Participants in the corticosteroid group will recieve corticosteroid injections (1 cc Kenalog 10 mg). They will also recieve anesthetic of 1 ml 1% lidocaine.
224160533|NCT01897259|DRUG|Prolotherapy|Subjects participating in the prolotherapy group will recieve 1 cc 50% Dextrose and Sodium Morrhuate 1 cc injections.
224160534|NCT04409691|DRUG|prednison and Sirolimus|If the intravenous prednisolone 4 mg / kg / d (one time in the morning and one time in the evening, 2mg / kg body weight each time) is effective, it will be gradually reduced to 2mg / kg / D (one time in the morning and one time in the evening, 1mg / kg body weight each time), gradually converted to oral prednisone of equal dose, and the hormone will be removed within 4-6 weeks. At the same time, the dosage of sirolimus oral liquid is 0.8 mg / m2 twice a day, with an interval of 12 hours, maintaining the blood concentration of 8-15 ng / ml. if there is no intolerable side effect, the treatment will last for 6 months
224160535|NCT04409691|DRUG|prednison|Prednison is taken at a dose of 4mg/kg/d. If the hormone treatment is effective, it will be gradually reduced to 2mg / kg / d (one time in the morning and one time in the evening, 1 mg / kg body weight each time), and repeated after 2 months of continuous treatment and 1 month of drug withdrawal.
224160536|NCT03376776|PROCEDURE|Vitrectomy|
224160537|NCT00529646|DRUG|APD791|
224160538|NCT00696540|DRUG|Inhalation of salbutamol diluted in hypertonic saline|The first of 3 nebulizations of 0.5 mg of Salbutamol is diluted in 3.5 ml of hypertonic (3%) saline. The second and the third are diluted in normal (0.9%) saline.
224160539|NCT00696540|DRUG|Inhalation of salbutamol diluted in normal saline|The 3 nebulizations of 0.5 mg of Salbutamol are diluted in 3.5 ml of normal (0.9%) saline.
224160540|NCT03356795|BIOLOGICAL|Cervical cancer-specific CAR-T cells|1 infusion, for 1x10\^6\~1x10\^7 cells/kg via IV
224160541|NCT06002997|OTHER|Pregnancy and/or delivery complications|Analysis of post-delivery reports for pregnancy and/or delivery complications.
224160542|NCT06002997|OTHER|Periodontal disease|Measuring clinical periodontal parameters for assessing presence of periodontal disease.
224160543|NCT02365324|BEHAVIORAL|Peer-Education Family Fitness Program (PE-FFP)|The proposed integrated project will be implemented by peers and will evaluate the effects of an evidence-based extension education program, grounded in Stages of Change Learning Theory and guided by Social Cognitive Theory (SCT), having 2 arms for the study (with and without a peer-education mode of delivery) on balancing calories to manage body weight (BW), reducing certain foods and food components, increasing selected foods and nutrients, building healthy eating patterns \[i.e., fundamental principles of the Dietary Guidelines for Americans (DGAs), 2010\] and SCT variables.
224160544|NCT02365324|BEHAVIORAL|Family Fitness Program (FFP)|The proposed integrated project will be implemented by adults and will evaluate the effects of an evidence-based extension education program, grounded in Stages of Change Learning Theory and guided by Social Cognitive Theory (SCT), having 2 arms for the study (with and without a peer-education mode of delivery) on balancing calories to manage body weight (BW), reducing certain foods and food components, increasing selected foods and nutrients, building healthy eating patterns \[i.e., fundamental principles of the Dietary Guidelines for Americans (DGAs), 2010\] and SCT variables.
224304172|NCT02069431|DRUG|Intranasal Oxytocin spray|Intranasal OT (24 IUs) self-administration will take place twice a day over a 28-day period.
224160545|NCT04726124|DEVICE|Microwave Ablation Therapeutic Apparatus|The selected and qualified subjects with primary lower extremity varicose veins were randomly treated with microwave ablation equipment or laser treatment equipment. Subjects in the two groups were returned to the hospital for follow-up at 7 days, 3 months, 6 months, 12 months after surgery, respectively, for ultrasound examination and questionnaire evaluation, medication status and adverse events were recorded, and target lesion closure rate and subject satisfaction were evaluated.
224160546|NCT04420065|DEVICE|Preferential left ventricular pacing|Activation of an algorithm attempting to provide preferential left ventricular pacing in an anticipatory manner, thus potentially preventing iatrogenic, pacing-related, right ventricular dysfunction, and improving coupling and outcomes in dyssynchronous heart failure patients
224160547|NCT04420065|DEVICE|Biventricular pacing|Standard biventricular pacing, with V-V delay programmed based on stroke volume maximization, and A-V delay delegated to the device
224304173|NCT02069431|OTHER|Intranasal Placebo spray|placebo (containing all of the inert ingredients except for the oxytocin) self-administration will take place twice a day over a 28-day period.
224304174|NCT01267721|PROCEDURE|Blood sampling|Blood sampling at various time points. Additional 92 mL blood.
224304175|NCT02118090|DRUG|Chloroquine sulfate|Chloroquine sulfate (NIVAQUINE) - 30 mg/kg for 3 days
224304176|NCT02118090|DRUG|DHA-PP|DHA-PIP (Duo-Cotecxin®, DHA 40 mg and PP 320 mg, Zhejiang Holley Nanhu Pharamaceutical Co. Ltd, Jiaxing, Zhejiang province, China): one tablet of DHA-PIP contains 40 mg of dihydroartemisinin (DHA) and 320 mg piperaquine (PIP). It is an oral administration, one dose a day for 3 consecutive days. An adult dose (≥40 kg to 60kg body weight or more than 15 years old) consisted of three doses of 3 tablets over consecutive days (Total dose 9 tablets). The approximate total adult dose was 2-4 mg/kg for DHA and 20mg/kg for PP.
224304177|NCT05084703|OTHER|Functional tests|"* Symmetry indices between the two limbs obtained thanks to the scores of the functional tests : Y balance test~* Muscle endurance index obtained from functional test scores : Closed Kinetic Chain Upper Extremitie Stability test"
224304178|NCT01775852|BEHAVIORAL|ACT-IM|1 hour discussion about migraine management (IM) and 5 hours of group therapy based on Acceptance and Commitment Therapy (ACT). IM covers symptoms and triggers for worsening of migraine symptoms, how to use migraine medications, medication overuse headache, etc. The ACT intervention includes: 1) Behavioral Change Training and; 2) Mindfulness and Acceptance Training emphasizing new ways of managing troubling thoughts, feelings, and physical sensations.
224304179|NCT04317859|BEHAVIORAL|Behavioural Activation|Behavioural Activation (BA) is a therapy previously shown to be effective in depressive disorders. This form of therapy involves modification of activities in order to change perceptions of specific situations, thereby improving mood. The BA treatment program will consist of 18 two-hour visits over 14 weeks (twice weekly group visits for the first 8 weeks, followed by two individual visits over 6 weeks).
224304180|NCT05967052|DRUG|Pregabalin|Pregabalin pharmacotherapy
224304181|NCT05967052|BEHAVIORAL|Independent walking training|Independent walking training
224304182|NCT05967052|DRUG|Placebo|Placebo
224304183|NCT05967052|BEHAVIORAL|Gradual movement therapy in the ward|Gradual movement therapy in the ward
224304184|NCT05967052|BEHAVIORAL|Telerehabilitation|Telerehabilitation
224304185|NCT05967052|BEHAVIORAL|Psychotherapy|Psychotherapy
224304186|NCT03462849|OTHER|increase in positive end expiratory pressure|increase in positive end expiratory pressure from 5 to 10 then 15 cmH2O then at the value for trans pulmonary end expiratory pressure amounting to 3 cmH2O
224304187|NCT05136300|BEHAVIORAL|Pulmonary rehabilitation|"Patients in the intervention group will receive physical therapy, scheduled pain monitoring and coaching by a social worker.~The intensity of the rehabilitation training program will be determined separately for each patient by a steepramp and 1-repetition test within 3 weeks post-operative. The intervention group will be trained and educated in 2 sessions of 2 hours per week, for a period of 3 months."
223472262|NCT02115984|PROCEDURE|Chemotherapy|Chemotherapy course includes 500 mg/m2 cyclophosphan, 50 mg/m2 doxorubicin, and 500 mg/m2 fluorouracil administered intravenously in one day.
223472263|NCT04771910|OTHER|Topical cream with live probiotic bacteria|Application of the probiotic cream once a day, for approximately 8 weeks on one side of the body (elbow or knee cavity; decided by doctor in advance, same as placebo cream). Assessment before product use (T0), after 4 and 8 weeks of product use (T4w and T8w, respectively) and after 4 weeks without product use (T12w).
223472264|NCT04771910|OTHER|Placebo cream|Application of the placebo cream (same formulation as probiotic cream except live probiotic bacteria) once a day, for approximately 8 weeks on one side of the body (elbow or knee cavity; decided by doctor in advance, same as probiotic cream). Assessment before product use (T0), after 4 and 8 weeks of product use (T4w and T8w, respectively) and after 4 weeks without product use (T12w).
224160548|NCT05092347|DRUG|Vonsetamig|Administered by intravenous (IV) infusion
224160549|NCT03345342|DRUG|PP6M|Participants will receive intramuscular injection of PP6M.
224160550|NCT03345342|DRUG|PP3M 350 mg eq.|Participants will receive intramuscular injection of PP3M 350 mg eq.
224304188|NCT04319185|OTHER|Assistance to perform Peritoneal Dialysis (PD) at home|The patient receives assistance of up to one visit per day for three months depending on the patient's needs, as assessed by the interdisciplinary team, the nephrologist, and the primary investigator or delegate.
224304189|NCT02826837|DRUG|LEAC-102 500mg capsule and FOLFOX + Bevacizumab/Cetuximab|"The subjects will be administered FOLFOX + Bevacizumab/Cetuximab by intravenous infusion.~Cycles repeat every 2 weeks. Dose and schedule modifications may be made at the treating physician's discretion.~A standard 3+3 trial design will be used for LEAC-102 dose escalation cohorts.The dosing of LEAC-102 will be divided into 3 cohorts, the subjects will receive LEAC-102 every day~Cohort 1: LEAC-102 500 mg capsule, 3 capsules, three times per day for 24 weeks (oral), Cohort 2: LEAC-102 500 mg capsule, 4 capsules, three times per day for 24 weeks (oral), Cohort 3: LEAC-102 500 mg capsule, 5 capsules, three times per day for 24 weeks (oral)"
224160551|NCT03345342|DRUG|PP3M 525 mg eq.|Participants will receive intramuscular injection of PP3M 525 mg eq.
224160552|NCT03345342|DRUG|PP1M|Participants will receive intramuscular injection of PP1M 50 to 150 mg eq.
224160553|NCT03345342|OTHER|Placebo|Participants will receive matching placebo.
224160554|NCT02437162|DRUG|Placebo|Participants will receive Placebo subcutaneous (SC) injection at Weeks 0, 4, and 16 in Group 1 and at Week 24 in Group 2 and Group 3.
224304190|NCT00441506|DRUG|daily interruption of sedatives|
224304191|NCT03779737|BEHAVIORAL|Muscular Resistance training|
224304192|NCT03779737|BEHAVIORAL|Cardiorespiratory training|
224160555|NCT02437162|DRUG|Ustekinumab 45 mg|Participants will receive Ustekinumab 45 mg SC injection at Weeks 24 and 28 followed by every 12 weeks (q12w) dosing, with the last administration of study agent at Week 100 in Group 1. Participants will start with ustekinumab 45 mg SC injection at Weeks 0 and 4, followed by q12w dosing, with the last administration of study agent at Week 100 in Group 2.
224304193|NCT03779737|BEHAVIORAL|Habitual training|
224304194|NCT01633411|DEVICE|Focal Cryoballoon Ablation System - 6 seconds|"Ablation of Barrett's Esophagus using a Focal Cryoballoon ablation catheter. The System is a Class II device intended to be used as a cryosurgical tool for the destruction of unwanted tissue in the field of general surgery, specifically for endoscopic applications."
224304195|NCT01633411|DEVICE|Focal Cryoballoon Ablation System - 8 seconds|"Ablation of Barrett's Esophagus using a Focal Cryoballoon ablation catheter. The System is a Class II device intended to be used as a cryosurgical tool for the destruction of unwanted tissue in the field of general surgery, specifically for endoscopic applications."
224304196|NCT01633411|DEVICE|CryoBalloon Focal Ablation System - 10 seconds|"Ablation of Barrett's Esophagus using the Focal CryoBalloon Ablation System. The System is a Class II device intended to be used as a cryosurgical tool for the destruction of unwanted tissue in the field of general surgery, specifically for endoscopic applications."
224160556|NCT02437162|DRUG|Ustekinumab 90 mg|Participants will receive Ustekinumab 90 mg SC injection at Weeks 24 and 28 followed by q12w dosing, with the last administration of study agent at Week 100 in Group 1. Participants will start with ustekinumab 90 mg SC injection at Weeks 0 and 4, followed by q12w dosing, with the last administration of study agent at Week 100 in Group 3.
224160557|NCT02437162|DRUG|Golimumab 50 mg|Participants who meet EE criteria (less than \[\<\] 10 percent \[%\] improvement from baseline in both total back pain and morning stiffness measures at both Week 12 and Week 16) will be administered open-label golimumab 50 mg SC administrations at Week 16 and every 4 weeks (q4w) thereafter through Week 52 in Groups 1, 2 and 3.
224160558|NCT00414505|DEVICE|Intradermal Acupuncture Treatment|
224160559|NCT01268943|DRUG|Capecitabine|oral pills, 1000mg/m2/d, split in two times, d1-14, d22-35 combined with concurrent pelvic radiation.
224160560|NCT01268943|DRUG|Capecitabine|oral pills, 1200mg/m2/d, split in two times, d1-14, d22-35 combined with concurrent pelvic radiation.
224160561|NCT01268943|DRUG|Capecitabine|oral pills, 1400mg/m2/d, split in two times, d1-14, d22-35 combined with concurrent pelvic radiation.
224160562|NCT01268943|DRUG|Capecitabine|oral pills, 1500mg/m2/d, split in two times, d1-14, d22-35 combined with concurrent pelvic radiation.
224160563|NCT04338321|DRUG|Esketamine 28 mg|Esketamine will be self-administered at a dose of 28 mg as nasal spray.
224160564|NCT04338321|DRUG|Esketamine 56 mg|Esketamine will be self-administered at a dose of 56 mg as nasal spray.
224160565|NCT04338321|DRUG|Esketamine 84 mg|Esketamine will be self-administered at a dose of 84 mg (maximum uptitrated dose) as nasal spray.
224160566|NCT04338321|DRUG|Quetiapine XR 50 mg|Quetiapine XR will be administered at an initial dose of 50 mg/day and may be further increased to 300 mg/day based on individual participant evaluation.
224160567|NCT04338321|DRUG|Quetiapine XR 100 mg|Quetiapine XR will be administered at a dose of 100 mg/day and may be further increased to 300 mg/day based on individual participant evaluation.
224160568|NCT04338321|DRUG|Quetiapine XR 150 mg|Quetiapine XR will be administered at a dose of 150 mg/day and may be further increased to 300 mg/day based on individual participant evaluation.
224160569|NCT04338321|DRUG|SSRI/SNRI|Participants will continue to take SSRI/SNRI that is approved for use in depression in their country of participation; off-label use of any SSRI/SNRI is not permitted. The continuing SSRI/SNRI dosage may be optimized throughout the study, at the investigator's discretion and based on the SmPC (or local equivalent, if applicable).
224160570|NCT03375203|DRUG|Placebo|Matching placebo will be administered once daily based upon dosing group.
224160571|NCT03375203|DRUG|JNJ-42847922, 5 mg|JNJ-42847922 will be administered as 5 mg (2\*2.5 mg capsule) oral capsules once daily.
224160572|NCT03375203|DRUG|JNJ-42847922, 10 mg|JNJ-42847922 will be administered as 10 mg oral capsule once daily.
224160573|NCT03375203|DRUG|JNJ-42847922, 20 mg|JNJ-42847922 will be administered as 20 mg oral capsule once daily.
224160574|NCT03375203|DRUG|Zolpidem|Zolpidem will be administered as 5 mg or 10 mg (2\*5mg capsule) oral capsule once daily based upon the local labeling information.
224160575|NCT03107793|DRUG|Ustekinumab|Participants will receive IV induction treatment with ustekinumab on a weight-tiered basis at a dose of approximately 6 milligram per kilogram (mg/kg) IV. At Week 8, all participants will receive a 90 mg SC injection of ustekinumab. During the routine care maintenance treatment period, in case of clinical worsening reported by the participant, consistent with disease flare in the investigator's judgment, clinical assessments of disease flare will be performed at the investigator's discretion.
224160576|NCT03321526|DRUG|JNJ-42847922|Participants will receive JNJ-42847922 capsule orally.
224160577|NCT03321526|DRUG|Placebo Matching to JNJ-42847922|Participants will receive placebo capsule matching to JNJ-42847922 orally.
224160578|NCT03321526|DRUG|Quetiapine XR|Participants will receive quetiapine XR capsule orally.
224160579|NCT03321526|DRUG|Placebo Matching to Quetiapine XR|Participants will receive placebo capsule matching to quetiapine XR orally.
224160580|NCT03321526|DRUG|Selective Serotonin Reuptake Inhibitor (SSRI)|Participants will receive SSRI antidepressant (such as, citalopram, escitalopram, fluvoxamine, fluoxetine, paroxetine, sertraline, vilazodone or vortioxetine) as a part of background therapy (at the same dose, without change, every day and at approximately the same time as prior to entering the study) throughout the screening, double-blind, and follow-up phases (approximately up to Week 26).
224160581|NCT03321526|DRUG|Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)|Participants will receive SNRI antidepressant (such as duloxetine, milnacipran, levomilnacipran, venlafaxine, desvenlafaxine) as a part of background therapy (at the same dose, without change, every day and at approximately the same time as prior to entering the study) throughout the screening, double-blind, and follow-up phases (approximately up to Week 26).
224160582|NCT06122909|DRUG|Group VTI|Group VTI will receive resuscitation guided by LVOT-VTI variation after PLR test.
224160583|NCT06122909|DRUG|Group IVC|Group IVC will receive resuscitation guided by IVC diameter variation after PLR test.
224163755|NCT06598163|DEVICE|Five Lives MED|"Five Lives MED is a mobile application that can be installed on smartphones and tablets using the Android and/or iOS operating systems for use at home.~The app offers structured sessions that can be completed once per day. Once the session is completed, the app also offers optional access to additional cognitive training exercises and educational articles.~The intervention sessions begins with a Habit Quest, a physical activity habit building tool delivered through a chat bot. Following the Habit Quest, the participant is guided through a series of gamified cognitive training exercises aimed at improving attention, memory, language and executive function."
223472265|NCT04102826|DEVICE|Functional electrical stimulation (FES)|Functional electrical stimulation combined with mobile arm support to restore upper limb function.
223472266|NCT00566488|BIOLOGICAL|Thymus/Parathyroid Transplantation|Thymus tissue, thymus donor, mother of thymus donor, \& parental parathyroid donor screened for transplant safety. Depending on T cell phenotype \& function, subjects were given 1 of 2 immunosuppression regimes. All received rabbit anti thymocyte globulin pretransplantation. Others also received cyclosporine pre \& post-transplantation. The thymus dose was over 0.2 grams/kg recipient weight. Thymus transplant occurred in operating room; thymic slices were placed in quadriceps. Parathyroid harvest was done under general anesthesia. One parathyroid gland was minced and placed in quadriceps muscle. There was no dose in mg. An open biopsy of thymus allograft was done 2-3 months post-transplant. Biopsy tissue was examined by immunohistochemistry to evaluate for thymopoiesis \& graft rejection.
223472267|NCT02973828|PROCEDURE|Imaging|This is an observational study only, with no interventions. Volunteers will undergo MRI imaging on the MR Linac, however this will not affect, change or initiate any intervention, or change to their care path.
223472268|NCT01664091|RADIATION|post-mastectomy radiation therapy (PMRT)|
223472269|NCT01664091|DEVICE|tissue expander (TE)|
223472270|NCT01664091|DEVICE|acellular dermal matrix (ADM)|
223472271|NCT02143232|DEVICE|remote patient monitoring (Telus RPM)|All joint replacement patients in the study will use the same type of remote patient monitor for 4 days post operation at home.
223472272|NCT05861375|DIAGNOSTIC_TEST|Fibroscan|Fibroscan is a non-invasive device that allows liver exploration painlessly, quickly (a few minutes) and with immediate results. A probe placed on the skin generates an elastic wave completely painlessly and the device measures its speed of propagation in the liver. Liver stiffness is calculated from this speed.
223472273|NCT01464268|DRUG|Riboflavin|Administration of riboflavin every 2 minutes for the duration of UV exposure.
223472274|NCT01464268|DRUG|Riboflavin|Administration of riboflavin every 1 minute for the duration of UV exposure.
223472275|NCT02414698|PROCEDURE|Percutaneous Hydrodiscectomy|The HydroD uses a thin supersonic stream of water to cut, ablation, remove disc material percutaneously via a skin puncture.
223472276|NCT02414698|DRUG|TESI|Transforaminal epidural steroid injections given in the lumbar spine.
223472277|NCT00225745|PROCEDURE|Blood draw|One blood draw prior to first treatment
223472278|NCT03057886|DEVICE|Comparative thermometers to compare with a new device|The made up for the choice of the thermometer to be to general anesthesia the oral and new device (Spot On thermometers) before anesthesia induction, after anesthesia induction the Spot On, and oral, and esophageal thermometers and after surgery in PACU the Spot On and oral thermometer. In group submitted to spinal anesthesia the made up for the choice of the thermometer to be the oral and Spot On thermometers before anesthesia induction, after anesthesia induction the Spot On and oral thermometers and after surgery in PACU the Spot On and oral thermometer.
223472279|NCT02536911|DRUG|eliglustat|"Pharmaceutical form: capsule~Route of administration: oral"
223472280|NCT05931263|DRUG|C-BEAM Regimen|Chidemide，carmustine, etoposide, cytarabine, and melphalan
223472281|NCT05931263|DRUG|BEAM Regimen|carmustine, etoposide, cytarabine, and melphalan
223472282|NCT04550299|OTHER|Surgical technique combined with a specific choice of the material for the ligament reconstruction|The surgical procedure is done as standard of care. The intervention is to randomize the participant into the study arms, which none of those has been proved yet to be a superior choice
223472283|NCT01804088|DEVICE|Formula™ 535 Iliac Balloon-Expandable Stent|Treatment of symptomatic vascular disease of the iliac arteries
223472284|NCT01909804|DRUG|SOF|400 mg tablet administered orally once daily
223472285|NCT01909804|DRUG|VEL|Tablet administered orally once daily
223472286|NCT01909804|DRUG|RBV|200 mg tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
223472287|NCT03160040|DRUG|Minocycline IV|This study is an observational study. All participants were administered minocycline IV prior to enrollment in this study.
223472288|NCT06301789|DRUG|Effect of adding Mg sulfate as an adjuvant to bupivacain in U/S guided QLB for postoperative analgesia in lower abdominal cancer surgeries|Bilateral ultrasound-guided transmuscular (anterior) quadratus lumborum block will be performed Each patient will be placed in the lateral position. the transducer will be placed in a transverse orientation on the flank just cranial to the iliac crest, then slide posteriorly to obtain an image of the quadratus lumborum muscle.echogenic needle will be inserted in-plane with the ultrasound beam in a posterior-to-anterior direction through the quadratus lumborum muscle until the ventral fascia of the muscle penetrated. At this point, the needle directed toward the fascial plan between the quadratus lumborum and the Psoas muscle; the correct position of the needle tip will be confirmed by injecting 3 mL of saline to separate the fascial layers at the lateral aspect of the quadratus lumborum muscle. Thereafter, the needle will be advanced more posteriorly between the quadratus muscle and psoas major muscle
223472289|NCT01038687|DRUG|A3309|A3390, a bile acid transport inhibitor was provided in either 15 mg or 20 mg oral tablets
223472290|NCT01038687|DRUG|placebo|placebo
223472291|NCT01938196|DRUG|KWA-0711|
223472292|NCT01938196|DRUG|Placebo|
223472293|NCT06065644|DEVICE|CTMA|Induced displacement of the Sacroiliac joint
223472294|NCT03292510|OTHER|GO-OUT Group|Following a baseline assessment, eligible participants will be stratified by site, and randomly assigned to receive the 1-day educational workshop and 3-month outdoor mobility program (GO-OUT intervention). Follow-up evaluations will occur at 3, 5.5 and 12 months from baseline.
223472295|NCT03292510|OTHER|Workshop Group|the 1-day workshop plus reminders. Follow-up evaluations will occur at 3, 5.5 and 12 months from baseline
223472296|NCT00000694|DRUG|Interferon alfa-2b|
223472297|NCT00000694|DRUG|Zidovudine|
223472298|NCT00000694|DRUG|Sargramostim|
223472299|NCT05030649|DEVICE|Smart glasses|The real-time ultrasound image is displayed through head-mounted display Moverio BT-300 (Epson Inc., USA) during the radial arterial cannulation.
223472300|NCT05030649|DEVICE|Control|The real-time ultrasound image is displayed by the ultrasound machine's monitor during the radial arterial cannulation.
223472301|NCT02480738|BEHAVIORAL|Computerized Cognitive Training Apparatus|"CoCoTA was developed through collaborative research with the Korean Institute of Science and Technology (KIST) and Primpo Co. Ltd. (www.primpo.com). It was designed to stimulate numerous cognitive domains simultaneously by using sounds and objects familiar to Korean elderly. Training themes and scenarios were developed and evaluated by six board-certified neurologists and three neuropsychologists who specialize in dementia.~Each subject participated in a total of 24 sessions of cognitive training, which consisted of 40 minutes of training, twice per week. To assure the consistency of cognitive training, trained personnel stayed nearby the subjects to help throughout the training process."
223472302|NCT05057221|DRUG|Uproleselan|Uproleselan 20 mg/kg BID up to maximum dose of 2500 mg, infused IV over 20 minutes on days 1-7 or until hospital discharge. It should be administered intravenously (IV) into a peripheral line, a central catheter, or a peripherally inserted central line catheter (PICC). Infusion should take place at a steady rate over a period of 20 minutes ±2 minutes using a syringe pump or IV pump.
223472303|NCT02039258|DRUG|CANA/MET XR FDC|Canagliflozin/extended release Metformin (CANA/MET XR) fixed dose combination (FDC) tablet of 150 mg/1,000 mg
224160584|NCT06685484|BEHAVIORAL|Modified Mindfulness Training Program (MMTP)|"The intervention, designed as a Modified Mindfulness Training Program (MMTP), aims to reduce antenatal depression and perceived stress among pregnant women, especially those with a preference for a male child. This program is adapted to address culturally specific stressors relevant to these women, promoting mental health and resilience during pregnancy.~The intervention is based on Nola Pender's Health Promotion Model and structured using the ADAPT-ITT framework, which includes Assessment, Decision, Adaptation, Production, Topical Experts, Integration, Training, and Testing phases. This phased approach ensures cultural relevance and feasibility within the target population of pregnant women in Pakistan.~Duration and Frequency: The intervention consists of six weekly sessions, each lasting two hours, held in a serene, controlled environment within a seminar room at Sindh Govt. Qatar Hospital, Karachi."
224160585|NCT02808507|OTHER|Active TB case finding|Active TB case finding (ACF) refers to any number of strategies used to identify individuals with active TB disease, outside of passive case finding. In passive case finding, individuals with symptoms present at health centers for diagnosis. In active case finding, the health system makes an effort to identify TB cases before they present passively.
223472304|NCT04849793|OTHER|Acupressure|Before starting the application, the students will be asked to rub the area around the area to be pressed for 20-30 seconds with their palms. With the gentle rubbing of the surrounding tissue, the tension and tissue sensitivity in the area of warming, relaxing and preparatory will be reduced and the tissue will be relieved. . The students will be asked to press the designated point manually with their thumb, index or middle finger for 5 seconds with a depth of 1-1.5 cm, rest for 2 seconds and continue the practice for 2 minutes
223472305|NCT06373341|BEHAVIORAL|VR training for arm and hand rehabilitation|The intervention group will participate in training with a VR-exergame for 4 weeks after inclusion. For this training a Meta Quest VR-headset with a game specifically designed for and with ICU patients that was previously pilot tested for feasibility and safety will be used under supervision of a researcher or caregiver until the patient feels ready to practice alone.
223472306|NCT02067520|DRUG|intrathecal hydromorphone (IT hydromorphone)|
223472307|NCT03502538|DEVICE|Curaprox 5460 Ultra Soft|The toothbrush Curaprox 5460 Ultra Soft will be the tested toothbrush model, in order to asses its efficacy in plaque removal. Therefore, the study participants should brush their teeth using this toothbrush model, following the instructions of the investigator. From the data collect related in plaque removal the results will be arrived at.
223472308|NCT03502538|DEVICE|Oral-B Indicator Plus|Following the same method of the Curaprox group intervention, the participants should brush their teeth using the Oral-B Indicator Plus toothbrush and based on the data collect, the results will be compared with the first group of intervention.
223472309|NCT02143219|DRUG|Oxaliplatine|Oxaliplatine : 85mg/m², 2-hours IV infusion (D1),
223472310|NCT02143219|DRUG|Folinic acid|Folinic acid (FA): 400 mg/m² , 2-hour IV infusion (D1),
223472311|NCT02143219|DRUG|Irinotecan|"Irinotecan (at the dosage determined by the UGT1A1 status), 90 min IV infusion starting 30 min after the FA starts~* Homozygous 6/6 or 6/7: irinotecan will start at 150 mg/m², then will be increased according to clinical/biological tolerance by 10% steps, at each cycle, up to 180 mg/m² at max.~* Homozygous 7/7: irinotecan will start at 130 mg/m² in the first cycle then be increased up to a max of 150 mg/m², by 10% steps, according to tolerance."
223580251|NCT04928729|OTHER|Pursed Lip Breathing +DB|PLB+DB with frequency of three times daily for Last three days of week for a duration of 10-15 mins is perform.
223580252|NCT04928729|OTHER|Conservative care|Participants will be having different dose as per tolerance 5 times daily.
223580253|NCT00288314|PROCEDURE|Magnetic Resonance Imaging, Functional|Structural and functional MRI
224160586|NCT06667401|DEVICE|The ScanNav, a novel artificial intelligence device designed to assist in Ultrasound guided regional anesthesia|The ScanNav, a novel artificial intelligence device designed to assist in Ultrasound guided regional anesthesia.We also aim to see of how it enhances teaching and training of residents by experienced regional anesthesia providers. We intend to use surveys/questionnaires of both resident and regional anesthesia provider as they utilize the device in real time.
224160587|NCT03198286|OTHER|Informational Intervention|Receive treatment summary and survivor care plan
224160588|NCT04248192|BIOLOGICAL|DD HST-NEETs|HIV-infected individuals following Allogeneic Bone Marrow Transplantation (alloBMT) will be treated with DD HST-NEETS therapy. Participants and donors will be screened for eligibility. Eligible donors will undergo a blood draw of up to 300mL to allow production of allogeneic DD HST-NEETs. Participants, who meet specified inclusion criteria including neutrophil recovery post-transplant and for whom donor products have passed release testing, will receive DD HST-NEETs at a dose of 2x107/m2 within 30 days of screening visit.
224160589|NCT01989572|OTHER|Laboratory Biomarker Analysis|Correlative studies
224160590|NCT01989572|OTHER|Placebo|Given GM-CSF placebo SC
224160591|NCT01989572|OTHER|Placebo|Given peptide placebo SC
223472312|NCT02143219|DRUG|5-FU|"5-FU (according to the DPD pharmacogenetic status), continuous IV infusion of 46 hours, starting at the end of FA infusion:~* If no DPD deficiency, 5-FU start at 1600 mg/m² and can be modulated according to clinical/biological tolerance after each course, i.e., 1800 mg/m² the 2nd course and 2000 mg/m² the 3rd one~* If partial DPD deficiency: 5-FU start at 1200 mg/m² and can be increased up to 1800, then 2000 if the clinical/biological tolerance are good at the 2nd and 3rd course."
224160592|NCT01989572|BIOLOGICAL|Sargramostim|Given SC
224160593|NCT01989572|BIOLOGICAL|Tyrosinase Peptide|Given SC
223472313|NCT03416439|OTHER|lifestyle intervention|lifestyle intervention program carried out by trained professionals
223472314|NCT01393145|DRUG|Combination Fluticasone /Formoterol 12/250 μg|Capsules containing Fumarate formoterol 12 µg + fluticasone propionate 250 µg dry powder for inhalation with aerocaps®
223472315|NCT01393145|DRUG|Seretide Diskus (salmeterol/fluticasone) 50/250 μg|Capsules containing salmeterol xinafoate 72.5 µg (equivalent to 50 µg of salmeterol) presented as powder for aspiration, packed in a plastic device in disk format, containing 60 doses
223472316|NCT03119597|DIETARY_SUPPLEMENT|Wild Blueberry Powder-13g|Formulation containing approximately 250mg of anthocyanin+ 4.79g Fructose+ 4.52g Glucose+ 45mg Vitamin C
223472317|NCT03119597|DIETARY_SUPPLEMENT|Placebo|Formulation containing approximately 4.79g Fructose+ 4.52g Glucose+ 45mg Vitamin C
223472318|NCT04880434|DRUG|Fludarabine|Administered intravenously
223472319|NCT04880434|DRUG|Cyclophosphamide|Administered intravenously
223472320|NCT04880434|BIOLOGICAL|Brexucabtagene autoleucel|A single infusion of brexucabtagene autoleucel (KTE-X19) anti-CD 19 CAR T cells
223472321|NCT03601169|DIETARY_SUPPLEMENT|Low Dose MMFS-205-SR|Twice daily, oral 500mg tablets
223472322|NCT03601169|DIETARY_SUPPLEMENT|High Dose MMFS-205-SR|Twice daily, oral 500mg tablets
223472323|NCT03601169|DIETARY_SUPPLEMENT|Placebo|Twice daily, oral
223472324|NCT04056208|DRUG|Pistachio|Unsalted pistachios
223472325|NCT04056208|OTHER|Usual care|Advice and resources will be provided
223472326|NCT01741415|BEHAVIORAL|SIDI|
224160594|NCT06322017|PROCEDURE|Rhythm control by Pulmonary Vein Isolation (PVI) procedure|"The PVI procedure involves the creation of a circumferential lesion around the ostium of the four pulmonary veins.~The choice of the type of energy to insure the lesion will be left to the discretion of the investigator, according to the center's habits and the patient's anatomy found on the scanner."
223472327|NCT01741415|BEHAVIORAL|SC|
223472328|NCT05245383|OTHER|ten products (S01~S10) and two blank (BK1, BK2)|"S01 Functional Peptides Recovering Essence EX S02 Advanced Revitalizing Eye Cream S03 Advanced Revitalizing Lotion S04 NB-1 Anti-Sensitive Repair Activator S05 NB-1 Anti-Sensitive Repair Toning Extract S06 Ginseng Vitality Serum S07 Ginseng Revitalizing Age-defense Essence Cream S08 Ginseng Age-defense Eye Cream S09 Revital Energy Balance Gel S10 Revital Energy Tightening Body Lotion BK1 Water BK2 Blank ten products and two blank, 24 hours single application patch test on the back."
223472329|NCT03727490|OTHER|Repair|The subscapularis will be repaired.
223472330|NCT03727490|OTHER|Standard Treatment|No repair will be performed
223472331|NCT05518123|DRUG|Rimegepant|Rimegepant 75 mg Oral Disintegrating Tablet (ODT) taken every other day during Double-blind Treatment (DBT) phase
223472332|NCT05518123|DRUG|Placebo|Matching placebo with every other day dosing during DBT phase
223472333|NCT04256980|DRUG|Pemigatinib|Pemigatinib will be self-administered at 9mg Or 13.5mg as a QD oral treatment on a 2-week-on therapy and 1-week-off therapy schedule
223472334|NCT05802017|OTHER|Allergen-specific substitute diet|Substitution of IgG4 allergen-specific reactive foodstuffs for equivalent foodstuffs with similar nutritional value.
223472335|NCT05690880|DEVICE|Foresee Home|The ForeseeHome Monitoring System, a non-significant risk device, is prescribed by eye care providers to patients as part of their clinical care. Notal Vision Monitoring Center (NVMC) is an independent diagnostic testing facility responsible for clinical monitoring of FSH data. The NVMC communicates with the patients (for training on the use of the device, troubleshooting of device issues, adherence monitoring, etc.) and with the patients' eyecare providers (for reporting FSH alerts, monitoring of clinical outcomes to assess device functionality and ongoing need for the device, etc.).
224160595|NCT06322017|DRUG|Conventional care by antiarrhythmic drugs (flecainide, sotalol, amiodarone) or bradycardic drugs (all betablocker or calcium channel blocker therapy, digoxin)|"Ventricular rate control is carried out using negative chronotropic agents (e.g. beta-blockers, calcium channel blockers, digitalis, etc.) according to current recommendations. If this fails, ablation of the atrioventricular junction with placement of a permanent pacemaker can be carried out according to current recommendations. As part of this research, the choice of bradycardic drugs and interventions will be left to the discretion of the investigator according to the center's practices and current recommendations.~Rhythm control aims to reduce AF by cardioversion (if it persists) to restore sinus rhythm and subsequently maintain it by introducing anti-arrhythmic treatment. Several antiarrhythmic drugs (flecainide, sotalol or amiodarone) can be used in this setting. As part of this research, the choice of antiarrhythmic drugs will be left to the discretion of the investigator according to the center's practices and current recommendations."
224160596|NCT03009149|OTHER|Aerobic exercise|Aerobic exercise will perform 3 days per week
224160597|NCT01665976|DRUG|RO4917838|film coated tablet, single dose
223472336|NCT03994913|BIOLOGICAL|CAR-CD19 T Cells|"The CAR- CD19 T cells (study drug) used in this study are chimeric antigen receptor specifically expressing T cells targeting CD19.~Fludarabine and Cyclophosphamide are used for lymphodepletion."
223472337|NCT05650203|DRUG|JS009 as a monotherapy and JS009 as a Triple Combination Therapy in Combination with Toripalimab and JS006|"1. JS009 as Monotherapy in first cycle of dose escalation and as the triple combination therapy will be administered in subsequent cycles：JS009,18mg/60mg/180mg/600mg/1200mg, JS006, fixed dose 600mg, Toripalimab injection fixed dose 240mg,IV infusion, every 3 weeks (q3w).~2. Triple combination therapy in dose expansion：JS009, 1 or 2 specific dose, with fixed dose of JS006 and Toripalimab Injection, IV infusion, every 3 weeks (q3w).~3. Triple combination therapy in indication expansion：JS009, 1 specific dose, with fixed dose of JS006 and Toripalimab Injection, IV infusion, every 3 weeks (q3w)."
224160598|NCT01665976|DRUG|RO4917838|oral suspension, single dose
224160599|NCT01665976|DRUG|RO4927838|hard gelatin capsule, single dose
224160600|NCT00467012|DRUG|bevacizumab|10mg/kg，Day1, 15 of 1 cycle(4 weeks)
223472338|NCT02831582|DIETARY_SUPPLEMENT|Omega-3 Fatty Acid|Given PO.
224160601|NCT00467012|DRUG|Paclitaxel|90mg/ m2，Day1, 8, 15 of 1 cycle(4 weeks)
224160602|NCT03644381|OTHER|Oral Immunotherapy|Starting from a very low level and over a period of several months, participants in the treatment group receive escalating doses of milk. Participants will also have blood and saliva draws to assess parameters of their immune system as well as skin prick testing
224160603|NCT04689217|DRUG|intrathecal drug injection|"All patients will be put in the sitting position and lean forward. After sterilization, Dural puncture will be performed at L4-L5 interspace or L3-L4 with a 25 gauge Quincke spinal needle.~The patients will be divided equally into 3 groups according to the additive (fentanyl, nalbuphine or placebo), and all patients will receive the local anesthetic dose of 0.5% heavy bupivacaine according to weight and height"
224160604|NCT03246711|BEHAVIORAL|Fasting|Totally or partially fasting the holy month of ramadan for muslims
223472339|NCT02831582|OTHER|Placebo|Given PO.
223472340|NCT04625335|OTHER|No Massage Protocol|Participants did not receive therapeutic massage prior to completing the Cold Pressor Test.
224160605|NCT06009575|DIETARY_SUPPLEMENT|Iron Supplement Tablets|The intervention group received IST and local culture-based nutrition education
224160606|NCT00826384|PROCEDURE|balloon catheter|transcatheter arterial chemoembolization therapy with balloon catheter
224160607|NCT01455155|OTHER|Creative therapy (art and music therapy)|Creative therapy composed of groups of activities relating to music and art sciences 8 sessions (2 sessions per week for 4 weeks) These activities emphasized on stimulating of cognition, physical, emotion, communication, social relationship, and spiritual domains.
224160608|NCT01455155|OTHER|Physical therapy|Physical therapy composed of a series of physical therapy program including types of exercises and gait training if possible (5 times/week).
224160609|NCT02777164|DEVICE|MIRA device imaging|MIRA Device imaging for adjunctive detection of breast cancer
224160610|NCT00632515|BEHAVIORAL|Questionnaire|Questionnaire regarding awareness of screening tests and attitudes toward colorectal cancer screening, taking 30-45 minutes to complete.
224160611|NCT05537961|BEHAVIORAL|Mindfulness-Oriented Recovery Enhancement|Mindfulness instruction incorporated in classroom-based curriculum
224160612|NCT01386190|OTHER|Exercise/Social Behavioral|Both the control and the intervention groups will be guided in implementing structured social interaction. In the intervention group, the structured interaction will incorporate augmented physical activities, while in the control group, the structured interaction will consist of predominantly social activities such as the caregiver reading or singing to the baby. The duration of the structured activities for both groups will be the same.
224160613|NCT00521118|OTHER|Laboratory Biomarker Analysis|Correlative studies
224160614|NCT00521118|PROCEDURE|Therapeutic Conventional Surgery|Undergo second curettage
224160615|NCT03718468|BIOLOGICAL|GC FLU Quadrivalent|A single dose administration of GC FLU Quadrivalent will be through intramuscular injection.
224160616|NCT03718468|BIOLOGICAL|Fluarix Tetra|A single dose administration of Fluarix Tetra will be through intramuscular injection.
224160617|NCT02047708|DRUG|Zibotentan|Selective endothelin-A antagonist
224160618|NCT04449718|DIETARY_SUPPLEMENT|Vitamin D|200,000 IU on admission
224160619|NCT04449718|DIETARY_SUPPLEMENT|Placebo|200,000 IU on admission
224160620|NCT02280096|DRUG|4-aminopyridine|Each patient will take two capsules every 8 hours after meals, for a total of 6 capsules/day. The 4-aminopyridine dosage will increase 10 mg/4 weeks by substitution of placebo instead of 4-aminopyridine capsules; such that patients will receive from 40 to 60 mg. distribute in 6capsules/day throughout the study.
224160621|NCT02280096|DRUG|Placebo|The placebo arm will include Microcrystalline Cellulose placebo
223472341|NCT04625335|OTHER|Prophylactic Therapeutic Massage|Participants received a 5 minute prophylactic therapeutic massage prior to completing the Cold Pressor Test. The massage was completed distally-to-proximally in the following order: superficial strokes to the entire forearm, deep strokes to the entire forearm, one-handed palmar kneading of the entire forearm with participant's forearm stabilized by the massager's the other hand, bilateral thumb kneading of the forearm in strips until the entire forearm was addressed, bilateral transverse thumb motions over palmar surface of the hand, single thumb kneading of thenar and hypothenar eminences simultaneously, bilateral thumb kneading to the dorsum of hand, deep stroking to the entire forearm, and superficial stroking to the entire forearm.
223472342|NCT05867758|OTHER|Psychosocial group intervention|"The psychosocial group intervention is composed of 8 weekly sessions of 90 minutes each and the receiving of self-help digital materials. Both organized as following: 2 on isolation, loneliness and social connection, 2 on well-being, 2 on the use of digital tools, 2 on the fostering of socialization with peers.~To evaluate the effects of the blended intervention and of the two conditions we will ask participants to fulfill the following clinical questionnaires: ULS-6 (Russell et al. 1980), MSPSS (Zimet et al., 1988), GAD-7 (Spitzer et al., 2006), PHQ-9 (Kroenke, Spitzer \& Williams, 2001), SWLS (Diener et al., 1985), MLQ (Steger et al., 2006) before starting the intervention in presence and online (T0), at the end of that period (T1) and 2 months after (T2)."
223472343|NCT04470973|DRUG|Cefuroxime|Patients receive cefuroxime as part of standard care.
224160622|NCT01129414|DRUG|Clopidogrel|"Pharmaceutical form: tablet~Route of administration: oral"
224160623|NCT01129414|DRUG|Placebo|"Pharmaceutical form: matching tablet~Route of administration: oral"
224160624|NCT01129414|DRUG|Omeprazole|"Pharmaceutical form: delayed-release capsule~Route of administration: oral"
224160625|NCT04427410|DIAGNOSTIC_TEST|Salivary test|Salivary test for measured of oxytocin levels
224160626|NCT02296905|DRUG|ABT-493|Up to 2 single doses of ABT-493 will be given orally in combination with ABT-530.
224160627|NCT02296905|DRUG|ABT-530|Up to 3 single doses of ABT-530 will be given orally alone or in combination with ABT-493.
224160628|NCT05934890|BIOLOGICAL|Walvax PCV13-TT|"PCV13-TT is supplied as 0.5 mL prefill syringe (PFS), with 0.5 mL suspension for intramuscular injection. After shaking, the vaccine is a homogenous, white suspension. Each dose (0.5 mL) of PCV13-TT contains pneumococcal polysaccharide serotypes 1, 3 4, 5, 6A 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F which are conjugated to TT carrier protein individually.~The vaccine is formulated in phosphate-buffered saline containing 4.25 mg/dose sodium chloride (NaCl), 44.35 μg/dose sodium dihydrogen phosphate (NaH2PO4), 19.0 μg/dose disodium hydrogen phosphate (Na2HPO4), and contains 0.5 mg/dose of aluminum phosphate as an adjuvant; no preservatives added."
224160629|NCT05934890|BIOLOGICAL|Pfizer PCV13|PCV13 is a suspension for intramuscular injection available in 0.5 mL single-dose prefilled syringes. Each 0.5 mL dose of PCV13 is formulated to contain approximately 2.2 μg of each of S. pneumoniae serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F polysaccharides, 4.4 μg of 6B polysaccharides, 34 μg 26 CRM197 carrier protein, 100 μg polysorbate 80, 295 μg succinate buffer and 125 μg aluminum as aluminum phosphate adjuvant.
224160630|NCT00410345|DRUG|Mifepristone|
223472344|NCT04470973|DRUG|Amikacin|Patients receive amikacin as part of standard care.
224160631|NCT04946760|OTHER|Sham Manipulation|The sham protocol will consist of examination of the subject's active and passive range of motion in the spine and extremities, in the joints that would have been treated with OMT. The subject will be positioned in sitting, supine and lateral recumbent in a similar manner to that of the OMT group, but without providing an active intervention.
224160632|NCT03930394|DIAGNOSTIC_TEST|Contrast ultrasound perfusion imaging|Contrast ultrasound perfusion imaging for microvascular perfusion, and carotid ultrasound data on intima-media thickness (or plaque size) will be serially assessed in subjects started on ponatinib.
224160633|NCT04308109|BEHAVIORAL|Simulation|Simulation involves the use of a highly realistic tracheostomy mannequin and audiovisual devices which will be used to replicate emergent clinical situations. If home invasive ventilation is anticipated, a home ventilator will be used. The simulation will last approximately 2 hours and will end with reviewing the taped session as part of debriefing. Both active arms will occur in the simulation center or sleep lab and replicate the same clinical situations by the same simulation instructor.
224160634|NCT05737485|DRUG|RCT1100|RCT1100 mRNA therapy supplied as varying dose strengths administered via oral inhalation using nebulizer
224160635|NCT04084080|BIOLOGICAL|Red Blood Cell|Red blood cell exchange transfusions will be performed every 3-6 weeks to maintain a target post-transfusion hemoglobin S level of \<20% and a pre-transfusion hemoglobin S of \<30%.
224160636|NCT04084080|OTHER|Standard of care|NHLBI/ASH/ATS Expert Panel recommended guidelines
224160637|NCT06154993|OTHER|static opening with slider+ Conventional PT|"Patient supine Maintaining neck flexion + contralateral flexion and rotation and applying median nerve slider mobilization while maintaining the neck static in mentioned position.~Frequency: 3 sets of 10 reps with 5 sec hold for 3 times/week for 4 weeks Conventional PT includes hot pack for 10 mins and cervical isometrics. Frequency: 3 sets of 10 reps with 5 sec hold for 3 times/week for 4 weeks.~Duration: 30-40 mins"
224160638|NCT06154993|OTHER|dynamic opener with slider + Conventional PT|"Patient supine Neck flexion + contralateral flexion and rotation. And sliding the median nerve along with neck movement from contralateral flexion+rotation to neutal position in repetitive manner, by releasing tension from median nerve when bringing neck in neutral to ease tension from affected side.~Conventional PT includes hot pack for 10 mins and cervical isometrics. Frequency: 3 sets of 10 reps with 5 sec hold for 3 times/week for 4 weeks.~Duration: 30-40 mins"
224304197|NCT02605993|BIOLOGICAL|Ravulizumab|All treatments were given as IV infusions.
224304198|NCT01454271|PROCEDURE|Total Hip Arthroplasty Replacement|Total Hip Arthroplasty Replacement
223472345|NCT03113370|DIETARY_SUPPLEMENT|Fish Oil|Fish Oil capsules
223472346|NCT03113370|DIETARY_SUPPLEMENT|Placebo|Olive Oil
223472347|NCT01201642|DRUG|Prednisolone|Prednisolone as 5 mg tablets will be given as a single dose of 40 mg daily for 10 days; the dose will then be reduced by 10 mg per 5 day, with a total treatment time of 20 days.
223472348|NCT01201642|DEVICE|acupuncture|The acupuncture points used were Dicang (ST4), Jiache (ST6), Yangbai (GB14), Xiaguan (ST7), Taiyang (EX-HN5), Quanliao (SI18) and Yifeng (TE17) on the affected side, and Hegu (LI4) bilaterally. For acute stages acupuncture, shallow puncturing is used at facial acupoints and routine puncturing is used at other acupoints. For resting stage acupuncture, penetrative needling is used from Dicang (ST4) to Jiache (ST6) and from Taiyang (EX-HN5) to Quanliao (SI18) 2-3 cun, and routine puncturing is used at other acupoints. Filiform needles (33 - 49.5 mm, 0.32 mm) will be used with moderate stimulation to get an acupuncture sensation, and the needles were retained for 30 minutes, once a day, five times a week, for a total period of four weeks.
223472349|NCT01201642|OTHER|other treatment|common medicine or other physical treatment which are different from those 5 Arms Previously.
223472350|NCT03464760|DIETARY_SUPPLEMENT|3.5g of spirulina per day in 1% silicone|5 tablets of 700mg per day
223472351|NCT03464760|DIETARY_SUPPLEMENT|placebo|5 tablets per day of potato-based placebo
223472352|NCT00260988|DRUG|Fragmin (dalteparin)|200 IU/Kg/Day administered subcutaneously for three days prior to but not including the day of the surgery
223472353|NCT00260988|DRUG|Innohep (tinzaparin)|175 IU/kg/Day administered subcutaneously for three days prior to but not including the day of the surgery
223472354|NCT00003677|DRUG|Dolastatin 10|IV bolus once every 21 days.
223743850|NCT01430481|DIETARY_SUPPLEMENT|Rosehip powder|The trial is a patient and physician blinded, 12-week, randomized controlled trial (1:1:1). Participants will be randomized into one of 3 groups: 'Standard rosehip powder' (A), 'New rosehip formulation' (B), or 'New rosehip formulation in half dose' (C). Personnel responsible for data collection will be blinded to group assignment. The patients will report on their symptoms every four weeks.
224304199|NCT02603393|DRUG|QVA149|QVA149 will be supplied in a capsule form in blister packs for use in the Novartis Concept 1 SDDPI
223472355|NCT04829071|BEHAVIORAL|Explicit motor learning|Participants will be provided with visual feedback of their right and left step lengths on a screen in front of a treadmill.
223472356|NCT04829071|BEHAVIORAL|Implicit motor learning|Participants will walk on a treadmill that drives their right and left legs to move at two different speeds.
223743851|NCT03727503|OTHER|PPV from the capstesia|we will challenge the application by doing 2 maneuvers: the first one is to increase the PEEP level from 5 to 15 cmH2O and the second one is the infusion of a mini-fluid challenge (100 ml) followed by the other 400 ml.
223743852|NCT03790839|DRUG|Sitagliptin|Sitagliptin (Januvia® 100 mg tablets for oral administration)
223743853|NCT03790839|DRUG|Dorzagliatin|Glucokinase activator currently under development
224160639|NCT06642311|PROCEDURE|Empty bladder group|Patients in the empty bladder group will be instructed to empty the bladder immediately before the procedure. A colleague will perform transabdominal ultrasound to confirm that the bladder is empty. All the procedures will be performed using the vaginoscopic technique. A rigid 2.9-mm hysteroscope with a 30° lens and a 5-mm outer sheath (Karl Storz GmbH, Tuttlingen, Germany) will be used in all procedures.
223472357|NCT01331811|OTHER|Development of a diagnosis algorithm|"At entry in the study, HIV infected children with suspected tuberculosis will undergo a complete evaluation including:~* interview on anamnesis~* clinical examination~* evaluation of HIV infection stage~* hematology and biochemistry tests~* CD4 count~* HIV viral load~* IGRA~* chest radiograph~* Abdominal ultrasonograph to detect abdominal lymphadenopathy~* Tuberculin skin test~* gastric aspirates, sputum and string tests according to the age of children~* nasopharyngeal aspirate~* stool sample~* lymph node fine needle aspirate or other specimen collection if applicable~Diagnosis and treatment of all participating children will be done according to national guidelines. The children will be followed-up for 6 months until the end of their anti-TB treatment. For the analysis of data and the validation of the algorithm, children will be randomized into 2 groups. Data from Group I will be used to develop the algorithm; data from Group II will be used to validate it."
223472358|NCT01563523|DRUG|activated recombinant human factor VII|Standard therapy in conjunction with three single doses of rFVIIa administered over a 3 hour period. Administered once the subject has received 8 units of PRBC
223472359|NCT01563523|DRUG|placebo|Standard therapy in conjunction with three single doses of placebo administered over a 3 hour period. Administered once the subject has received 8 units of PRBC
223472360|NCT03444558|DIETARY_SUPPLEMENT|Natural supplement containing chlorogenic acid and luteolin|50 eligible subjects will receive natural supplement as the oral pills at a fixed dose of 1 pill/day (450 mg/day) for 6 months, as add-on therapy to the ongoing treatment, maintained at fixed doses for the entire study.
223472361|NCT03444558|OTHER|Placebo (without any active ingredients)|50 eligible subjects will receive placebo (without any active ingredients) at a fixed dose of 1 pill/day for 6 months, as add-on therapy to the ongoing treatment, maintained at fixed doses for the entire study.
223472362|NCT00068276|DIETARY_SUPPLEMENT|cholecalciferol|
223472363|NCT05944939|PROCEDURE|Surgical extraction of impacted third molar|After surgical extraction of mandibular impacted teeth concentrated growth factor placed in socket closure done with help of silk 3.0 suture
223472364|NCT04415346|BIOLOGICAL|HU-014 Inj|Clostridium botulinum type A
223472365|NCT05143463|DRUG|NS101 IV infusion|Approximately 1 hour prior to start of study drug infusion, an IV port will be inserted into the antecubital region and a sterile normal saline solution infusion will be initiated at fixed rate in order to keep the vein open. The study drug will be infused over approximately 60 minutes at a constant rate. At the end of the infusion, 3 mL of saline solution will be injected to flush the remaining drug into the IV catheter. The end of infusion will be set to the end of the 3 mL flush. For safety reason (e.g., administration of rescue medication), the IV line will remain opened for approximately 1 hour following completion of infusion.
223472366|NCT06284499|OTHER|measuring tooth stability after orthodontic treatment using a Periotest® device.|The tooth mobility was determined by taking three repeat measurements from each tooth and calculating the average of these measurements, using a Periotest® device.
223472367|NCT03568435|OTHER|Non-Interventional|Non-Interventional
223472368|NCT01612195|PROCEDURE|Anal fistula plug|All patients have a draining seton for at least 6 weeks prior placement of the anal fistula plug. All patients are administered a general anesthetic and are operated in the lithotomy position. The seton is removed, but no curettage or irrigation of the fistula tract is performed. The plug is inserted through the internal opening, and pulled through the external opening until it fit snugly and its base is sutured to the internal sphincter with 2 interrupted 2-0 polyglactin 910 sutures. The tip of the plug is cut at skin level and not sutured. The external opening is left open to allow for drainage. The patient is instructed to restrict physical and sexual activity for 2 weeks postoperatively. Patients are seen in the post-operative clinic at 10 days, 6 weeks and 6 months as per protocol.
223472369|NCT04754893|DEVICE|Healthdot application|Healthdot device is applied on subject's chest after surgery
223472370|NCT02144701|DIETARY_SUPPLEMENT|Lactobacillus rhamnosus GG|Given PO
223472371|NCT02144701|OTHER|laboratory biomarker analysis was not performed because of no differences in the clinical outcomes|Correlative studies
223580254|NCT06508008|PROCEDURE|continuous negative pressure suction|(1) Open the mouth with a tongue depressor; (2) Apply paraffin oil to the front end of the sputum suction tube; (3) Insert a suction tube into the mouth to aspirate phlegm.
223580255|NCT06508008|PROCEDURE|Intermittent negative pressure sputum suction through oral pharyngeal airway|(1) Insert the oropharyngeal airway parallel into the oral cavity; (2) Apply paraffin oil to the front end of the sputum suction tube; (3) The suction tube is inserted into the deep oral cavity through the middle lumen of the oropharyngeal airway; (4) Intermittent negative pressure for suction and suction of sputum
223472372|NCT05824013|DIAGNOSTIC_TEST|thromboelastography (TEG®6s)|blood samples for conventional coagulation test were obtained in vacutainer tubes from an arterial line. Two blood citrate samples (3 ml, sodium citrate solution, Vacuette® Blood Tubes) were also collected for the laboratory conventional coagulation tests (aPTT, INR, D-dimer levels, Antithrombin III) and TEG®6s assessment. The TEG parameters include reaction time (R), clot formation time (K), angle or α (K angle), maximum amplitude (MA), and amplitude at 30 minutes (LY30)
223472373|NCT01492504|DRUG|Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052)|Observational study - No Intervention \[(subjects were previously treated with Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052)\]
223472374|NCT00683423|DRUG|BMS-741672|Tablets, Oral, 100 mg, once daily, 3 weeks
223472375|NCT00683423|DRUG|Placebo|Tablets, Oral, 0 mg, once daily, 3 weeks treatment period, 2 weeks washout, and 2 weeks follow-up
223580256|NCT04539860|DEVICE|Transdermal Optical Imaging|Blood pressure measurements completed by standard assessment methods and Transdermal Optical Imaging
223743854|NCT02308462|BEHAVIORAL|CHIMPS intervention|"CHIMPs intervention (Family-Intervention composed of 8 Topic-related sessions over a period of 6 month, based on the evaluated manual: a preliminary talk with the family, two sessions with the parents, one session with each child, three sessions with the family).~The sessions are semi-structured and cover the topics illness and coping, education, family relationships and trusting attachement figures, social network and support of the Family. A detailed description of the procedure is found in the Manual (Wiegand-Grefe, Halverscheid \& Plass, 2011)."
224069313|NCT00505466|BEHAVIORAL|Genetic Counseling|Genetic counseling conducted in person, by telephone with an M. D. Anderson Genetic Counselor, or with a local Genetic Counselor in conference with the M. D. Anderson Genetic Counselor.
224163756|NCT02128204|DEVICE|lidocaine contained hyaluronate facial dermal filler|HYADERMIS LA Facial Dermal Implant contains 20 mg/ml hyaluronate and 0.3 % lidocaine.
223472376|NCT01307813|DEVICE|Overstitch Endoscopic Suturing System|"Assess the safety and effectiveness of the Apollo endoscopic suturing device (Overstitch) and cinching device for placement of sutures and surgical knots in a segment of colon under laparoscopic or open visualization of the operative area.~Patients will already require resection of segments of colon for treatment of benign or malignant disease and this will therefore be a treat and resect model"
223580257|NCT00858663|RADIATION|intensity modulated radiation therapy|"All patients will receive standard treatment with definitive radiation therapy (IMRT, intensity modulated radiation therapy), administered as one fraction per day (Monday through Friday) over approximately 33 fractions. Patients with resected tumors will be treated to a maximum dose of 66 Gy. Patients with unresected tumors will be treated to a maximum dose of 70 Gy.~Patients will receive daily RAD0001 it will be administered orally or via percutaneous gastrostomy tube (PEG) once daily according to the dose escalation scheme plus cisplatin intravenously once per week (Days 1, 8, 15, 22, 29, 36) according to the dose escalation scheme.~Approximately 3 - 4 months after completion of chemoradiation, radiologic response assessment will be performed. This will include cross-sectional imaging of the primary tumor (with CT scan and/or MRI) as well as a whole body FDG-PET (fluorodeoxyglucose positron emission tomography) scan."
223580258|NCT00858663|DRUG|RAD001 (everolimus) + Cisplatin|"All patients will receive standard treatment with definitive radiation therapy (IMRT, intensity modulated radiation therapy), administered as one fraction per day (Monday through Friday) over approximately 33 fractions. Patients with resected tumors will be treated to a maximum dose of 66 Gy. Patients with unresected tumors will be treated to a maximum dose of 70 Gy.~Patients will receive daily RAD0001 it will be administered orally or via percutaneous gastrostomy tube (PEG) once daily according to the dose escalation scheme plus cisplatin intravenously once per week (Days 1, 8, 15, 22, 29, 36) according to the dose escalation scheme.~Approximately 3 - 4 months after completion of chemoradiation, radiologic response assessment will be performed. This will include cross-sectional imaging of the primary tumor (with CT scan and/or MRI) as well as a whole body FDG-PET (fluorodeoxyglucose positron emission tomography) scan."
223580259|NCT03394690|DIETARY_SUPPLEMENT|green coffee|2 capsuls
223580260|NCT03394690|OTHER|control|2 capsuls
223580261|NCT00313976|DRUG|Interferon beta-1b (Betaferon/Betaseron, BAY86-5046)|250 micrograms every other day, subcutaneously for 104 weeks
223580262|NCT00313976|DRUG|Interferon beta-1b (Betaferon/Betaseron, BAY86-5046)|2x250 micrograms every other day, subcutaneously for 104 weeks
223743855|NCT02747420|DEVICE|NURO TM|The lower extremity will be palpated and a needle insertion site will be identified 5 cm from the medial malleolus and posterior to the tibia. Between the posterior margin of the tibia and the soleus muscle, a 34-gauge acupuncture-like needle will be inserted 3-4 cm to the tibial nerve. A grounding pad will be placed on the bottom of the foot just below the smallest toe. An inactive grounding pad will be placed on top of the foot above the small toe to be consistent with the sham pad placement. The needle and grounding pad will be connected to the stimulator and the stimulation will be increased from 0 to 10 Milli-ampere. The needle will be taped. The electrical current will be set by the subject and the mA will be recorded. A 30 minute stimulation session will be given at 20 Hz.
224160640|NCT06642311|PROCEDURE|Bladder distension group|Patients in the bladder distension group will be instructed to drink one liter of water and to avoid urination during a period of 2 h before the scheduled procedure. A colleague will perform transabdominal ultrasound to confirm that the bladder is distended . All the procedures will be performed using the vaginoscopic technique. A rigid 2.9-mm hysteroscope with a 30° lens and a 5-mm outer sheath (Karl Storz GmbH, Tuttlingen, Germany) will be used in all procedures.
224160641|NCT06575868|DIETARY_SUPPLEMENT|Myo-inositol|Patients would begin taking myoinositol upon recruitment
224160642|NCT06575868|DIETARY_SUPPLEMENT|Myo-inositol placebo|Patients would begin taking placebo upon recruitment
224160643|NCT04066010|OTHER|Mobile application (BP-n-Me)|"The mobile app consisted of a series of features including (1) calendar reminders of when to take medications and the patient's antihypertensive medication regimen (2) a Call your Pharmacist button specific to patient's pharmacy, (3) a BP log in which the patient could enter blood pressure values that were automatically compared to goal values, (4) counseling points for lifestyle and adherence factors individually tailored to each patient and (5) lifestyle and medication adherence surveys."
224160644|NCT04826120|PROCEDURE|PCEA Infusion|Patients of this group Had PCEA during the second stage of labor
224160645|NCT04826120|PROCEDURE|Continuous epidural infusion|Patients of this group Had continuous epidural infusion during the second stage of labor
224160646|NCT01148576|DRUG|entecavir|entecavir 0.5 mg qd for 12 months
224160647|NCT01148576|DRUG|entecavir|entecavir 0.5 mg qd for 12 months
223472377|NCT01491425|DEVICE|rhBMP-2/ACS//LT-CAGE® Device|LT-CAGE® device with recombinant human bone morphogenetic protein-2 ( rhBMP-2) and the absorbable collagen sponge (ACS).
223472378|NCT01491425|DEVICE|Autogenous Bone//LT-CAGE® Device|LT-CAGE® device with autogenous bone taken from the iliac crest.
223472379|NCT04630223|DIAGNOSTIC_TEST|endocan in umbilical cord blood|After taking blood samples from the umbilical cord, centrifugation is applied to all samples for 15 minutes at 1000 rpm. The serum samples with specific identification numbers are going to be stored at -80 °C. After completing the study group, all serum samples will be analyzed using human endocan ELISA kit for the measurement of endocan levels.
223472380|NCT00913341|DRUG|Alprazolam Tablets, 1 mg (Geneva Pharmaceuticals)|
223472381|NCT00913341|DRUG|Alprazolam Tablets, 1 mg (The Upjohn Company)|
223472382|NCT05970250|OTHER|Whole body vibration group|Whole body vibration apparatus (model Power plate -my5tm, made in United States) with frequency 30 - 40 Hz was used for the whole body vibration program by reciprocating vertical displacements on the left and right side of a fulcrum.
223472383|NCT05970250|OTHER|Weight bearing exercises|Electronic treadmill Kettler- marathon model No 7899-800, made in Germany (as form of weight bearing exercises), which was adjusted to the subject's comfortable walking speed. Generally, during the treadmill training, its speed and inclination are electronically adjusted, and it is also provided with a control panel to display the exercise parameters. It allows for the comfortable running without joint or back pains through a perfect combination between aluminium-pertinax running deck, shock absorbers and overall shock-damping design.
223472384|NCT05970250|DRUG|vitamin D supplements and calcium|vitamin D supplements and calcium
224160648|NCT01148576|DRUG|essentiale + entecavir|entecavir 0.5 mg qd for 12 months，Essentiale 2 tablets tid in the first 3 months and 1 tablets tid in the rest 9 months
223580263|NCT03160469|DEVICE|intragastric Elipse Device|"Obesity prevalence is increasing worldwide, and Kuwait is currently considered to be the country with the most obese population1. Accordingly, standardization of the weight loss procedures has been made according to the Body Mass Index (BMI), keeping the more advanced surgeries for class II obesity (BMI 35- 39.9) and above, with consideration of other factors like, for example, obesity-related comorbidities. For those patients whom considered in the category of overweight (BMI = 25- 29.9) \& class I obesity (BMI 30- 34.9), after failure of diet attempts, the weight loss options are limited. Of the highly requested options are the various types of intra-gastric balloons. Conventional endoscopic gastric balloons have proven to be safe and effective, with Excess Weight Loss (%EWL) of 25-50%2. A new swallowable gastric balloon, named Elipse, has been launched recently in Kuwait and became highly popular due to its unique concept of being procedure-less."
223580264|NCT01196494|PROCEDURE|intraoperative colon lavage with primary anastomosis|Patients with obstructive left-sided colonic cancer in wich treatment in one stage procedure is intraoperative colon lavage with primary anastomosis to avoid Hartamnn´s Procedure
223580265|NCT04807803|DIAGNOSTIC_TEST|Assessment of Minimal hepatic encephalopathy (MHE)|Assessment of MHE at the inclusion and 6 months after treatment if diagnosed with MHE: Serum ammonia analysis, psychometric hepatic encephalopathy score (PHES), animal naming test (ANT) and evaluation of abdominal imaging, liver and splenic transient elastography, gastroscopy
223580266|NCT01669408|DRUG|Cold crystalloid infusions, 0.9%NaCl or Ringer's solution|Infusion of 1L cold crystalloid solution (4°C) over 15 minutes
223580267|NCT02448953|PROCEDURE|Two-field lymphadenectomy|Thoracic-upper abdominal two-field lymphadenectomy
223580268|NCT02448953|PROCEDURE|Three-field lymphadenectomy|Cervical-thoracic-upper abdominal three-field completely lymphadenectomy
223580269|NCT01479946|DRUG|Electrochemotherapy|bleomycin together with electroporation
223580270|NCT03926962|DRUG|WCK 4873|100 to 1200 mg in tablets (the 100 mg dose cohort will receive half a tablet; higher dose cohorts will receive 1 or more tablets)
223580271|NCT03926962|DRUG|Placebo Oral Tablet|Visually matching placebo
224160649|NCT01148576|DRUG|Vitamin E + entecavir|entecavir 0.5 mg qd for 12 months, Vitamin E: 100 mg bid for 12 months
224160650|NCT00821782|DRUG|Levofloxacin; Azithromycin|
224160651|NCT02613091|DRUG|Clemastine fumarate|4mg 2x day clemastine fumarate orally.
224160652|NCT00246376|BEHAVIORAL|Diet|ATP-III diet
224160653|NCT00246376|BEHAVIORAL|Exercise|Supervised exercise in study gym
224160654|NCT00246376|DRUG|Niacin|Niaspan, titrated up to 2 grams per day
224160655|NCT00246376|DRUG|Fenofibrate|Tricor, 120 mg per day
224160656|NCT00246376|OTHER|Placebos|Placebos for Niaspan and Tricor
223472385|NCT05355285|PROCEDURE|Glucose Clamp|Subjects receive variable rates of glucose or insulin infusions to adjust and maintain desired plasma glucose or insulin levels.
224160657|NCT03998241|OTHER|No intervention was provided|No intervention given
223472386|NCT02488226|OTHER|Gaze-contingent eye-tracking technology|When participants look away from a prototypical or expected norm, their gaze patterns are redirected to those prototypical locations.
223580272|NCT05976451|COMBINATION_PRODUCT|melatonin with collagen matrix|(CMX) with melatonin in the esthetic zone using Modified Coronally Advanced Tunneling Technique (MCAT)
223580273|NCT05976451|COMBINATION_PRODUCT|connective tissue graft (CTG)|control group connective tissue graft using Modified Coronally Advanced Tunneling Technique (MCAT)
223580274|NCT00002762|BEHAVIORAL|patient interviewing to obtain menstrual history|
224160658|NCT01733524|BEHAVIORAL|Pet Fish|Participants will receive a betta fish and the supplies to care for the fish for a one year time period.
224160659|NCT01733524|BEHAVIORAL|Picture of a fish|Participants will receive a picture of a betta fish.
224160660|NCT01345825|OTHER|Resistance training|Week 1: 2 sets x 12 repetitions at 12 RM Week 2: 3 sets of 12 repetitions with 12 RM Week 3: 3 sets of 10 repetitions with 10 RM Week 4-5: 3 sets of 10 repetitions with 10 RM Week 6: 3 sets of 8 repetitions with 8 RM Week 7: 4 sets of 8 repetitions with 8 RM Week 8: 4 sets of 8 repetitions with 8 RM
223580275|NCT00002762|PROCEDURE|blood sampling|
224160661|NCT02611934|PROCEDURE|Mild Therapeutic Hypothermia (MHT)|The induction with ice packs and infusion of 0.9% sodium chloride (NaCl) at the temperature of 4˚C. MHT will be maintained with a MTH-dedicated catheter introduced into the inferior vena cava through the femoral vein during PCI. MTH will be maintained for at least 12 hours at target temperature of 33˚C. The rewarming phase will be conducted in an actively controlled manner (0.3˚C per hour). The patient's core temperature will be independently measured in the urinary bladder as well as in the lower one third of the oesophagus using a dedicated catheter and tube. All patients treated with MTH will be mechanically ventilated with a concomitant continuous intravenous infusion of propofol and fentanyl for sedation and analgesia.
224160662|NCT06296472|OTHER|Rehabilitation|-the experimental group will carry out a program of eccentric exercises following the infiltration and will also wear the wrist brace for 4 weeks.
224160663|NCT06296472|OTHER|Standard|-the standard group will carry out a program of generic exercises following the infiltration and will also wear the wrist brace for 4 weeks.
224160664|NCT05310669|DEVICE|Nasal pressure assessment|Once the patient is enrolled nasal pressure will be measured through a dedicated pressure line located at the nostril entrance and connected to a dedicated pressure transducer (OptiVentTM, SIDAM, Mirandola, Italy). Measured nasal pressure will be the result of the variation between inspiratory and expiratory pressure (DeltaPnose).
224160665|NCT05303025|OTHER|Survey|Survey to acquire baseline demographic information as well as information regarding professional experience, working environment and attitudes towards artificial intelligence.
223472387|NCT01145664|DRUG|Herbal concentrate-granules plus western therapy|Intervention time: 7-10 days; Follow-up time: 5 days.
223472388|NCT01145664|DRUG|Reduning Injection plus western therapy|Intervention time: 7-10 days; Follow-up time: 5 days.
223472389|NCT01145664|DRUG|Western therapy|Intervention time: 7-10 days; Follow-up time: 5 days.
223472390|NCT00992862|DRUG|Moexipril HCl 15mg Tablets, Paddock Laboratories, Inc.|
224160666|NCT05303025|OTHER|Semi-structured group discussion|Semi-structured group discussion.
224160667|NCT06183554|DIAGNOSTIC_TEST|CXCR4|Patients with clinical suspected primary aldosteronism will receive a CXCR4 PET imaging.
224163757|NCT02128204|DEVICE|hyaluronate facial dermal filler|Hya-Dermis Facial Dermal Implant contains 20 mg/ml hyaluronate.
223472391|NCT00992862|DRUG|Univasc® 15mg Tablets|
223580276|NCT02492256|DEVICE|Pulmonary vein isolation|CARTO- reconstruction LA, preferably during same rhythm as SUMO map (generally sinus rhythm) for use during registration of SUMO map in CARTO. Conventional PVI by circumferential antral ablation according to standard procedures. Exit and Entrance block conformation. Attempt to induce sustained atrial tachycardia. Optional mapping and ablation of post-ablation atrial tachycardia.
223580277|NCT02492256|DEVICE|GP ablation guided by SUMO technology|"CARTO- reconstruction LA, preferably during same rhythm as SUMO map (generally sinus rhythm) for use during registration of SUMO map in CARTO. High frequency stimulation (HFS; 20-Hz frequency, 5-ms pulse duration, and 15-mA output) to access positive vagal response (the heart rate decreasing by 50% at baseline). RF Ablation of SUMO hotspots (in sinus rhythm if AF converts)~• Target a region of 1.0-1.5 cm diameter around the SUMO 'hotspot'. Control HFS. Attempt to induce sustained atrial tachycardia. Optional mapping and ablation of post-ablation atrial tachycardia."
223580278|NCT02492256|DEVICE|ILR implantation|Implantation the ECG loop recorder according to standard procedure
223580279|NCT03765151|DEVICE|low-level laser therapy|LLLT will be performed by a diode gallium-aluminum-arsenide (Ga-Al-As) laser with a 940-nm wavelength (Ezlase; Biolase Technology Inc., Irvine, CA) and delivered by a quadrant-sized probe which cover the region from the central incisor to the first molar on the test side. The laser probe will be 1 cm from the soft tissue around the test tooth at the gingival margin and alveolar mucosa covering the root area using a setting of 800 milliwatt in a continuous wave. Each tooth will receive 30 seconds of exposure, with no more than 8.6 J/cm2 of energy delivered. In addition, a spot-size laser probe will be applied for 30 seconds 5 mm from the cervical dentin with an output power of 700 milliwatt to reduce tooth sensitivity.
223580280|NCT03765151|OTHER|orthodontic retention|All participants included will wear fixed lingual retainer and removable retainers in the post-orthodontic retention period and their previous orthodontic treatment will be carried out by one operator using preadjusted appliances with bonded 0.022×0.028-inch2 brackets/buccal tubes and 0.014-inch Nickel Titanium (NiTi) archwires as the first archwires.
223580281|NCT00513955|DRUG|bortezomib|
223580282|NCT00513955|DRUG|cyclophosphamide|
223472392|NCT03055884|DEVICE|tDCS|active tDCS versus sham tDCS
223580283|NCT00513955|DRUG|doxorubicin hydrochloride|
223580284|NCT00513955|DRUG|prednisolone|
223472393|NCT03055884|BEHAVIORAL|Verbal paired-associate learning task|with or without repeated retrieval practice
223472394|NCT00485862|DRUG|Atomoxetine Hydrochloride|
223472395|NCT00485862|DRUG|Sertraline|
223580285|NCT00513955|DRUG|vincristine sulfate|
223580286|NCT00513955|OTHER|questionnaire administration|
223580287|NCT00513955|PROCEDURE|quality-of-life assessment|
223580288|NCT00167661|DRUG|Campath-1H|two intravenous 20mg/m2/doses, the first on the day of transplant and the second dose on day 1 post transplant
223580289|NCT05818514|DRUG|[11C]AZ14132516|Injection of radioligand for PET examinations
223472396|NCT00485862|DRUG|Placebo|
223580290|NCT01305603|DRUG|Bupivacaine|On both sides of the abdomen 30 ml of bupivacaine 2.5 mg/ml will be injected. This is a total of 60 ml of bupivacaine 2.5 mg/ml.
223580291|NCT01305603|PROCEDURE|Injection|Injection under ultrasound-guidance
223580292|NCT01238978|DRUG|Vildagliptin|
223580293|NCT01238978|DRUG|"Usual Care"|
223580294|NCT03641846|OTHER|DornierAries2 LiST device + 5 mg Tadalafil|All patients will receive shockwave treatment (6 sessions for all subjects, 5000 shockwaves at each session, at energy level 7), twice per week (total of 3 weeks) without treatment interval. Starting at first LiST session and finishing one week after final LiST session, subjects will receive for 4 weeks daily Tadalafil 5mg. Total treatment period = 4 weeks
223580295|NCT03641846|OTHER|DornierAries2 LiST device + Placebo Pill|All patients will receive shockwave treatment (6 sessions for all subjects, 5000 shockwaves at each session, at energy level 7), twice per week (total of 3 weeks) without treatment interval. Starting at first LiST session and finishing one week after final LiST session, subjects will receive for 4 weeks daily Placebo pills. Total treatment period = 4 weeks.
223580296|NCT01243528|OTHER|Laboratory values|Laboratory values which represent nutritional status
224163758|NCT04559997|OTHER|Exercise+FU|6 years intervention, administered daily, targeted postural instability, balance and mobility using at-limit intensity sensorimotor and visuomotor agility training
224163759|NCT04559997|OTHER|Active Comparator group Exercise|After 3 weeks of intensive therapy, we withdrew treatment and monitored their condition for 6 years and received only hospital base treatment
224163760|NCT00023205|BEHAVIORAL|11th grade reading level arthritis materials|
224163761|NCT00023205|BEHAVIORAL|Interactive in-person arthritis education|
223472397|NCT04632004|OTHER|Invitation to participate|Patients, visitors, and staff members of the University Medical Center Goettingen are invited to participate within our survey study. Study participation has no effect on any medical treatment.
223472398|NCT05604898|DRUG|Recombinant Anti-IL-17A Humanized Monoclonal Antibody Injection|608 will be administered subcutaneously.
223472399|NCT05604898|OTHER|Placebo|Participants will receive Placebo to maintain the blinding of the Investigational Medicinal Products.
223472400|NCT05604898|DRUG|Recombinant Anti-IL-17A Humanized Monoclonal Antibody Injection|608 will be provided at pre-specified time intervals.
224163762|NCT01957085|OTHER|observation only|This is an observational only, nonintervention study. There will be no patient contact. This was a de-identified point prevalence study of hepatitis C infection in hospitalized patients in an inner city hospital.
224163763|NCT05243147|DEVICE|nasal stents|using nasal stents after septoplasty
224163764|NCT05243147|DEVICE|merocel|using merocel after septoplasty
224163765|NCT00244777|DRUG|Hypo-osmolar ORS|
224163766|NCT01966276|DRUG|Methyl-P plus Nutrient Formula|"* Week 1 (take the following together twice a day-at breakfast and lunch)~  * One tablet of Methyl-P (5mg)~ * Four tablets of CFS Nutrient Formula~* Week 2 to Week 12 (take the following together twice a day-at breakfast and lunch):~  * Two tablets of Methyl-P (10mg)~ * Four tablets of CFS Nutrient Formula"
224163767|NCT01966276|DRUG|Methyl-P plus Nutrient matched placebos|"* Week 1 (take the following together twice a day-at breakfast and lunch)~  * One tablet of Methyl-P Placebo~ * Four tablets of CFS Nutrient Placebo~* Week 2 to Week 12 (take the following together twice a day-at breakfast and lunch):~  * Two tablets of Methyl-P Placebo~ * Four tablets of CFS Nutrient Placebo"
223580297|NCT04869033|OTHER|Farinelli's Breathing Exercise|after 1 minute of normal breathing, follow this instruction; inhale 2 seconds, suspend 2 seconds, exhale 2 seconds. inhale 3 seconds, suspend 3 seconds, exhale 3 seconds. inhale 4 seconds, suspend 4 seconds, exhale 4 seconds. inhale 5 seconds, suspend 5 seconds, exhale 5 seconds. inhale 6 seconds, suspend 6 seconds, exhale 6 seconds. This cycle lasted 1 minute (60 seconds), called Farinelli's breathing (FB). When participants finished these cycle, repeated it again 4 times. 1 minute of NB + 4 minutes of FB called 1 set. The participants were asked to practice 6 sets/day, 5 days/week (Monday-Friday) for week 1-4, and increased duration to 8 sets/day, 5 days/week for week 5-8.
223580298|NCT04869033|OTHER|Diaphragmatic Breathing Exercise|after 1 minute of normal breathing, inhale 2 seconds and exhale 2 seconds with nasal airway. Continued breathing this pattern until 4 minutes, then back to normal breathing 1 minute . 1 minute of NB + 4 minute of DB called 1 set. The participants were asked to practice 6 sets/day, 5 days/week (Monday-Friday) for week 1-4, and increased duration to 8 sets/day, 5 days/week for week 5-8.
223580299|NCT04438460|BIOLOGICAL|Blood test|"For patient group, blood tests will be performed at day 1-2, day 3-5 and day 60.~For control group, blood test will be performed the day of elective surgery."
223580300|NCT01866033|DRUG|PCI-32765 (Treatment A)|560 mg capsules administered by mouth on Day 1, Period 1
224069314|NCT05796635|OTHER|Herpecin L|Participants in the Herpecin L arm will use the test product daily as a preventive product by applying the product twice daily. Also, participants will be told they can reapply the product if going outside into the cold, wind, or sun. If participants in the Herpecin L arm do experience a cold sore or fever blister, they will be instructed to use the product at the first sign of the cold sore and then at least four more times during the day until the cold sore is gone (they can use the product more often if they plan to go outside into the cold, sun, or wind).
224069315|NCT03300466|DEVICE|GP0045|Hyaluronic acid gel
224069316|NCT03300466|DEVICE|Comparator|Hyaluronic acid gel
224069317|NCT03343132|BEHAVIORAL|Standard locomotor therapy|Typical clinical therapy.
223580301|NCT01866033|DRUG|PCI-32765 (Treatment B)|560 mg capsules administered by mouth (without grapefruit juice) on Day 1 during Period 2 or 3 according to randomization schedule
223580302|NCT01866033|DRUG|PCI-32765 (Treatment C)|140 mg capsule administered by mouth (with grapefruit juice) on Day 1 during Period 2 or 3 according to randomization schedule
223580303|NCT01866033|DRUG|13C6 PCI-32765 (reference)|100 mcg administered intravenously 2 h after study drug
224069318|NCT02797236|BIOLOGICAL|SF2a-TT15 vaccine|
224069319|NCT02797236|BIOLOGICAL|SF2a-TT15 vaccine + adjuvant|
224069320|NCT02797236|BIOLOGICAL|Placebo|
224069321|NCT02797236|BIOLOGICAL|Placebo + adjuvant|
224069322|NCT00625092|DRUG|fluorouracil|Post-operative day 1 and day 2, 600mg/m\^2 intraperitoneal (IP) held for 23 hours
224069323|NCT00625092|DRUG|leucovorin calcium|Day 0 200 mg/m\^2 intraperitoneal held for 2 hours
224069324|NCT00625092|DRUG|oxaliplatin|Day 0 hyperthermic intraperitoneal oxaliplatin held for 30 minutes - assigned dose level: Levels 1 through 7 - 300 to 600 mg/m\^2
224069325|NCT00625092|PROCEDURE|cytoreductive surgery|Day 0 Cytoreductive surgery is a systematic attempt to remove all or nearly all peritoneal nodules.
224069326|NCT01602692|DRUG|Tumescent solution with dilute lidocaine and epinephrine|Tumescent Solution containing both dilute lidocaine (0.05%) and dilute epinephrine (1:1,000,000)
224069327|NCT01602692|DRUG|Tumescent Solution with dilute epinephrine|Tumescent Solution containing dilute epinephrine (1:1,000,000) only
223580304|NCT04393688|COMBINATION_PRODUCT|Combination Product: Tri-wire Peripheral Balloon Dilatation Catheter|"Procedure:~Percutaneous Transluminal Angiography, Percutaneous transluminal angioplasty (PTA) is a procedure that can open up a blocked blood vessel using a small, flexible plastic tube, or catheter, with a balloon at the end of it. When the tube is in place, it inflates to open the blood vessel, or artery, so that normal blood flow is restored."
224069328|NCT02105454|DRUG|Grazoprevir (GZR)|100 mg oral tablet (total daily dose)
224069329|NCT02105454|DRUG|Elbasvir (EBR)|10 mg oral capsule (total daily dose = 5 capsules)
224069330|NCT02105454|DRUG|Ribavirin (RBV)|200 mg oral capsule (total daily dose = 4-7 capsules)
224069331|NCT00428649|DIETARY_SUPPLEMENT|20 µg selenium|20 µg selenium as selenomethionine
224069332|NCT00428649|DIETARY_SUPPLEMENT|40 µg selenium|40 µg selenium as selenomethionine
224069333|NCT00428649|DIETARY_SUPPLEMENT|60 µg selenium|60 µg selenium as selenomethionine
224069334|NCT00428649|DIETARY_SUPPLEMENT|80 µg selenium|80 µg selenium as selenomethionine
224069335|NCT00428649|DIETARY_SUPPLEMENT|100 µg selenium|100 µg selenium as selenomethionine
224069336|NCT00428649|DIETARY_SUPPLEMENT|120 µg selenium|120 µg selenium as selenomethionine
224069337|NCT00428649|DIETARY_SUPPLEMENT|placebo|placebo
224069338|NCT02953535|DRUG|Magicbuvir|1 tablet contains 400 mg sofosbuvir
224069339|NCT02953535|DRUG|Sovaldi (fist dose)|1 tablet contains 400 mg sofosbuvir
224069340|NCT02953535|DRUG|Sovaldi (second dose)|1 tablet contains 400 mg sofosbuvir
224069341|NCT02211274|OTHER|Everyday Competence Assessment and Planning for Community Transitions|The Everyday Competence Assessment and Planning for Community Transitions (ECAP-CT) toolkit will allow CLC interdisciplinary team members to 1) assess the Veteran's everyday competence for safe and independent living; 2) develop personally meaningful rehabilitation goals that facilitate successful transition out of the CLC based on everyday competence; and 3) conduct structured treatment planning to support resident goals around transitioning back into the community. By considering everyday competence and goal-setting in this context, Veterans will have optimal P-E fit upon returning to the community, ensuring a successful transition.
224069342|NCT04940143|DRUG|Botulinum toxin type-A (Onabotulinum toxin type-A)|Botulinum toxin-A (Onabotulinum toxin type-A/Botox®) injection will be administered from three different points, two on the medial head of the gastrocnemius muscle and one point on the lateral head with total 3-6 units/kg dose, under the guidance of electrical stimulation for the detection of the target neuromuscular junction.
224069343|NCT04940143|OTHER|Physical Therapy|After the botulinum toxin-A injection, the patients will be included in the comprehensive physiotherapy program thrice a week for a total of 12 weeks. The physiotherapy program will be consisted of the ankle range of motion and stretching, strengthening of the antagonist muscles, proprioception exercises, functional walking training and static and dynamic balance training.
224163768|NCT02650167|BIOLOGICAL|Colostrum feeding|
224160668|NCT03953040|DIAGNOSTIC_TEST|intracoronary imaging (IVUS, OCT)|Patients presenting with non STE-ACS will be subjected after performing PCI of the culprit lesion to intracoronary imaging with the help of IVUS and OCT of the non-culprit lesions to detect and image the so-called vulnerable plaques
224160669|NCT05845411|BEHAVIORAL|Mindful Eating|Nutritional advice through expository content, group discussion, and exchange of experiences on self-knowledge, food awareness, and relationship with food and the body.
224160670|NCT05845411|OTHER|Standard dietary treatment|Hypocaloric dietary prescription and nutritional education.
224160671|NCT06181643|BEHAVIORAL|Survivorship Sleep Program with Individual Delivery + No Booster Sessions|4 weekly SSP sessions delivered to individual participants (session durations approximately 45 min/session). No booster sessions.
224160672|NCT06181643|BEHAVIORAL|Survivorship Sleep Program with Group Delivery + No Booster Sessions|4 weekly SSP sessions delivered to groups of participants (session durations approximately 90 min/session). No booster sessions.
224304200|NCT02603393|DRUG|Tiotropium|Tiotropium will be supplied as commercially available blisters, delivered via HandiHaler®
223472401|NCT05604898|OTHER|Placebo|Participants will receive Placebo at pre-specified time points to maintain the blinding of the Investigational Medicinal Products.
223472402|NCT01218802|DRUG|Rosuvastatin 10 mg. daily for 96 weeks|Participants will take Rosuvastatin 10 mg. daily for 96 weeks.
223472403|NCT01218802|DRUG|Placebo|participants will take a sugar pill daily for 96 weeks
223472404|NCT02979704|DRUG|Rosuvastatin|45 patients will be treated with rosuvastatin at a dose of (5-10) mg orally once daily dose for 08 weeks
223472405|NCT02979704|DRUG|Atorvastatin|45 patients will be treated with atorvastatin at a dose of (10-20) mg orally once daily dose for 08 weeks
223472406|NCT01350219|DEVICE|Stem Cell Educator|For the treatment, commonly the left (or right) median cubital vein, a patient's blood is passed through a Blood Cell Separator that isolates the lymphocytes from the blood according to the recommended protocol by manufacture; consequently, the collected lymphocytes were transferred into the Stem Cell Educator and treated by CB-SC; after that, the educated cells return the blood back to the patient via a dorsal vein of hand. During the MCS+ collection, the whole blood flow rate was maintained at 35 mL/min. The whole procedure was scheduled for 8 \~ 9 hrs.
223472407|NCT01483638|DRUG|axitinib|5 mg BID taken orally with food continuously on Day 1 of the study. One cycle corresponds to 28 days.
224069344|NCT04788979|DRUG|Melatonin 5Mg Oral Tablet|"1. control without treatment~2. obese periodontitis patients treated only by scaling and root planning~3. obese periodontitis patients treated with scaling and root planning with daily dietary supplementation of 5 mg melatonin (NOW-USA)"
224069345|NCT01002378|DRUG|Regorafenib (Stivarga, BAY73-4506)|A single dose of regorafenib will be administered immediately following a high fat breakfast
224069346|NCT01002378|DRUG|Regorafenib (Stivarga, BAY73-4506)|A single dose of regorafenib will be administered immediately following a low fat breakfast
224069347|NCT01002378|DRUG|Regorafenib (Stivarga, BAY73-4506)|A single dose of regorafenib will be administered following an overnight fast
224069348|NCT02721355|DIETARY_SUPPLEMENT|GastimunHP|Health food supplement containing specific IgY against urease of H. pylori
224160673|NCT06181643|BEHAVIORAL|Survivorship Sleep Program with Individual Delivery + 3 Booster Sessions|4 weekly SSP sessions delivered to individual participants (session durations approximately 45 min/session). 3 monthly booster sessions.
224160674|NCT06181643|BEHAVIORAL|Survivorship Sleep Program with Group Delivery + 3 Booster Sessions|4 weekly SSP sessions delivered to groups of participants (session durations approximately 90 min/session). 3 monthly booster sessions.
224160675|NCT02418585|DRUG|Esketamine|Participants will self-administer either 56 mg or 84 mg of esketamine, intranasally, twice per week as a flexible dose regimen in the Double-Blind Induction Phase.
224160676|NCT02418585|DRUG|Placebo|Participants will self-administer matching placebo, intranasally, twice per week for 4 weeks as a flexible dose regimen in the Double-Blind Induction Phase.
224160677|NCT02418585|DRUG|Duloxetine (Oral Antidepressant)|Duloxetine could be selected as the oral antidepressant medication by the investigator based on review of Massachusetts General Hospital - Antidepressant Treatment Response Questionnaire (MGH-ATRQ) and relevant prior antidepressant medication information. The minimum therapeutic dose is 60 milligram per day (mg/day).
224163769|NCT02650167|BIOLOGICAL|formula for preterm infants|
224163770|NCT01168375|DRUG|conventional therapy plus umbilical cord serum eye drop|chloramphenicol and betamethasone eye drops every 6 hours, cycloplegic (homatropine) eye drop every 8 hours plus umbilical cord serum eye drop 20% every 4 hours
224163771|NCT01168375|DRUG|conventional therapy|chloramphenicol and betamethasone eye drops every 6 hours, cycloplegic (homatropine) eye drop every 8 hours
224163772|NCT04247321|DEVICE|Licox® Brain Tissue Oxygen Monitoring System|Invasive brain tissue oxygenation monitoring
224163773|NCT04247321|DEVICE|Near-infrared spectroscopy (NIRS)|Non-invasive approach to monitoring brain tissue oxygenation which uses two wavelengths of near infrared light and takes measurements of the ratio of oxyhemoglobin to total hemoglobin
224163774|NCT01556789|BIOLOGICAL|ONT-10|ONT-10 a liposomal synthetic glycolipopeptide antigen formulated with PET Lipid A adjuvant.
224163775|NCT00407641|DRUG|Tinzaparin administration|Patients will receive tinzaparin during the HD session
224163776|NCT00407641|DRUG|Heparin administration|Patients will receive Heparin as an anticoagulant during the HD session.
223472408|NCT01483638|DRUG|placebo|will be administered orally with the same schedule of axitinib
223472409|NCT03327324|BEHAVIORAL|Sleep Using Mentored Behavioral and Environmental Restructuring|SLUMBER is a non-pharmacological intervention program, delivered by providing mentoring to facility staff who work directly with residents. SLUMBER focuses on detecting sleep-disruptive factors including: nighttime noise and patient behaviors associated with poor sleep quality; disruptions caused by nighttime caregiving; daytime inactivity; and limited light exposure. In this model, staff-delivered interventions to improve these factors improve sleep quality thereby creating opportunities to test the impact of improving sleep quality (measured by actigraphy) on mood (depression and anxiety), pain, cognitive function, functional ability, and observed activity levels.
223472410|NCT00160511|DRUG|Levetiracetam|
223472411|NCT00133198|DRUG|Pramipexole|
224069349|NCT05552911|PROCEDURE|Pretreatment strategies before drug balloon therapy|Preconditioning strategies for the treatment of in de novo coronary lesions using drug-coated balloons.
223472412|NCT06177288|COMBINATION_PRODUCT|DEBIRI Combined With Chemotherapy and Bevacizumab|After dissolving 100 mg of irinotecan in water for injection or 4ml of 5% glucose water.use 2mL of 70μm uniform particle size microspheres for loading and adsorption for 5minutes. Then mixed with non-plasma contrast agent to embolize the tumor feeding artery.
223472413|NCT01927094|DIETARY_SUPPLEMENT|Probiotic|Comparison of probiotics vs. ORS
223472414|NCT01927094|DIETARY_SUPPLEMENT|ORS|ORS ad libitum
223472415|NCT00771368|DRUG|Nitric Oxide|1 % Gaseous Nitric Oxide, delivered for 30 minutes daily for 3 consecutive days
223472416|NCT03874442|OTHER|CliniPup serious game|"The interactive game is played at home by the children on a computer or tablet before the surgery. The SERES Pain in Children-game is created with realistic scenarios based on scientific literature about perioperative pain and fear in children. The primary goal of the game is to provide the children insight in the impact of their personal choices on their well-being and on their environment by giving the children information about the day of the surgery. The ultimate aim of the game is to create a change in behaviour, enhance children's coping strategies and reduce the burden of pain and fear in the children and parents."
223472417|NCT05589974|DRUG|Verteporfin|Chronic CSC are receiving one treatment before the observation period.
223472418|NCT00848523|DRUG|Panobinostat|30 mg, three times a week, patients will continue with treatment until they experience unacceptable toxicity that precludes further treatment, disease progression, and/or at the discretion of the investigator.
223472419|NCT04511325|OTHER|Potato Regimen|100 grams cooked white russet potato with the skin
223472420|NCT04511325|OTHER|Refined Grain Regimen|75 grams of cooked long-grain white rice
223472421|NCT02358057|DRUG|Dexmedetomidine|
223472422|NCT02358057|DRUG|Alfentanil|
223472423|NCT00417196|DRUG|QAX576|
223472424|NCT00480844|DRUG|Sertindole|Oral (tablets), 16-24 mg QD (once a day) for 12 weeks.
223580305|NCT04591249|BEHAVIORAL|Physical activity intervention|Participants will 1) receive Fitbit, 2) be enrolled in a secure electronic platform to access Fitbit data, 3) receive 8-week remote counseling by a physical therapist that will include motivational interviewing and creating SMART goals (1 session per week) through a web-based teleconference platform, and 4) receive usual postoperative care directed by their surgeon. The first session will be 45 minutes and sessions 2-8 will be 30 minutes each. During the sessions, participant's confidence in meeting daily step goals will be assessed using a 0-10 scale. If self-reported confidence to meet their goal is \<8, the physical therapist will help participants modify their goal using techniques such as problem-solving, positive statements and affirmations. Progression will be made only if daily steps goals are met for at least 4 out of 7 days a week. If this weekly step goal is not met, a physical therapist will help the participant identify solutions for realistic progression.
223580306|NCT04591249|OTHER|Usual care|Participants will receive postoperative care as determined by their treating surgeon. This includes lifting restrictions, advice to stay active, and oral analgesics as needed. Physical therapy referral will be at the discretion of the surgeon. However, physical therapy is not typically started until 12 weeks after surgery.
223580307|NCT01335529|DRUG|Boceprevir, Peg-interferon alfa 2b and Ribavirin|"* Screen period from Week-8~* Standard treatment from day 0 to week 4 (W4)~* Three-drug-regimen (Boceprevir introduction) from W4 to W8~* HCV RNA determination at W8 determines treatment group and participation duration:~  * If undetectable HCV RNA at W8, it is a complete virological response: 3 drug-regimen is continued until W48, then there is a follow-up period up to W72 and SVR analysis,~ * If HCV RNA ≤ 1000IU/mL at W8, it is an incomplete virological response. The 3-drug-regimen is continued until W72, when another analysis is done."
224160678|NCT02418585|DRUG|Escitalopram (Oral antidepressant)|Escitalopram could be selected as the oral antidepressant medication by the investigator based on review of MGH-ATRQ and relevant prior antidepressant medication information. Escitalopram will be titrated upto a dose of 20 mg/day, but if not tolerated the dose can be reduced to the minimum therapeutic dose of 10 mg/day.
224160679|NCT02418585|DRUG|Sertraline (Oral Antidepressant)|Sertraline could be selected as the oral antidepressant medication by the investigator based on review of MGH-ATRQ and relevant prior antidepressant medication information. Sertraline will be titrated upto a dose of 150 mg/day, but if not tolerated the dose can be reduced to the minimum therapeutic dose of 50 mg/day.
224160680|NCT02418585|DRUG|Venlafaxine Extended Release (XR) (Oral Antidepressant)|Venlafaxine Extended Release could be selected as the oral antidepressant medication by the investigator based on review of MGH-ATRQ and relevant prior antidepressant medication information. Venlafaxine Extended Release will be titrated upto a dose of 225 mg/day, but if not tolerated the dose can be reduced to the minimum therapeutic dose of 150 mg/day.
224160681|NCT02040857|DRUG|Palbociclib|CDK 4/6 inhibitor
223472425|NCT00480844|DRUG|Risperidone|Oral (tablets), 4-8 mg QD (once a day) for 12 weeks.
223472426|NCT01065012|DRUG|Udenafil 50 mg|Tablets via oral administration before an attempt at sexual intercourse. All subjects started at 100 mg and titrated up to 150 mg or down to 50 mg per Investigator and subject.
223472427|NCT01065012|DRUG|Udenafil 100 mg|Tablets via oral administration before an attempt at sexual intercourse. All subjects started at 100 mg and titrated up to 150 mg or down to 50 mg per Investigator and subject.
223472428|NCT01065012|DRUG|Udenafil 150 mg|Tablets via oral administration before an attempt at sexual intercourse. All subjects started at 100 mg and titrated up to 150 mg or down to 50 mg per Investigator and subject.
223472429|NCT01065012|DRUG|Placebo Matching 50 mg Udenafil|Tablets via oral administration before an attempt at sexual intercourse. All subjects started at 100 mg and titrated up to 150 mg or down to 50 mg per Investigator and subject.
223472430|NCT01065012|DRUG|Placebo Matching 100 mg Udenafil|Tablets via oral administration before an attempt at sexual intercourse. All subjects started at 100 mg and titrated up to 150 mg or down to 50 mg per Investigator and subject.
223472431|NCT01065012|DRUG|Placebo Matching 150 mg Udenafil|Tablets via oral administration before an attempt at sexual intercourse. All subjects started at 100 mg and titrated up to 150 mg or down to 50 mg per Investigator and subject.
223472432|NCT03708471|PROCEDURE|Hybrid ablation|This intervention including thoracoscopic surgical ablation, percutaneous catheter ablation and cardiovascular risk control.
223472433|NCT03708471|PROCEDURE|Thoracoscopic surgical ablation|This intervention including thoracoscopic surgical ablation and cardiovascular risk control.
223472434|NCT04586049|DEVICE|MRI|Participants will undergo an MRI scan while participating in a breathing test to measure brain blood flow.
224069350|NCT05552911|PROCEDURE|Different types of in-stent restenosis were treated with drug-coated balloons|A new classification method of ISR lesions was proposed to observe the clinical prognosis of different ISR lesions treated with drug-coated balloon.
224069351|NCT01002807|DRUG|Dapagliflozin|Tablets, Oral, 10 mg, Single Dose
223472435|NCT04586049|DEVICE|Transcranial Doppler Ultrasound|Participants will undergo a TCD scan while participating in a breathing test to measure brain blood flow.
223472436|NCT04586049|OTHER|Sympathetic Nerve Activity|Participants will undergo sympathetic nerve activity testing while participating in a breathing test.
223472437|NCT06460233|PROCEDURE|Bariatric surgery - sleeve gastrectomy|Laparoscopic sleeve gastrectomy performed according to the current surgical standards
223472438|NCT04840472|DRUG|111I-n panitumumab|Imaging Agent
223472439|NCT04840472|PROCEDURE|Single photon emission computed tomography/computed tomography (SPECT/CT) scans|Day 1 to 5 (Day of Surgery inclusive)
223472440|NCT06683911|DRUG|non Opioids|It is planned to avoid opioid side effects by applying opioid-free anesthesia during the perioperative period.
223472441|NCT06683911|DRUG|Opioid|Routine general anesthesia in cardiac surgery
223472442|NCT03058354|DRUG|Propofol|Patient undergoing surgery at Queen Mary Hospital, Hong Kong between 2014 to 2016 using intraoperative TIVA with propofol.
223472443|NCT03058354|PROCEDURE|general anaesthesia|Patient undergoing surgery at Queen Mary Hospital, Hong Kong between 2014 to 2016 using general anaesthesia methods other than intraoperative TIVA with propofol.
223472444|NCT05549180|DRUG|BIKTARVY 50Mg-200Mg-25Mg Tablet and Dovato placebo|The patients randomized to experimental arm will be randomized to Biktarvy + Dovato placebo
223472445|NCT05549180|DRUG|Dovato 50Mg-300Mg Tablet + Biktarvy placebo|The patients randomized to comparador arm will be randomized to Dovato + Biktarvy placebo
223472446|NCT00361452|DRUG|nebulized epinephrine and nebulized albuterol|
223472447|NCT02368132|BEHAVIORAL|Group Delivered TEP|All TEP modules will be in a group format. Each call will take 1.5-2 hours. Each group will be comprised of 5-8 CGs who will call into a teleconference line at a pre-specified time. Groups will include spouse/partner-only or adult child-only CGs. The content of the calls will mirror those in the individual TEP delivered program. In addition to the group calls, they will receive individual care management.
223472448|NCT02368132|BEHAVIORAL|Individual Delivered TEP|Two mandatory modules that cover the stages of dementia and provide a brief introduction to problem solving techniques, action plan development, and coping skills, plus a menu of additional modules covering various content areas evaluated during the course of the monthly assessments (e.g., communication skills, behavioral management techniques, stress management and coping skills, longterm planning, etc.). Each individual TEP session will begin with reviewing education related to the selected module. The remainder of each session will involve coaching the caregiver on emotion-focused and problem focused coping strategies. The care manager will also discuss problem solving with the CG to reinforce the action plan and the educational component of the intervention.
223472449|NCT02543047|DEVICE|Angioshield|Angioshield is applied to vein graft to provide Mechanical Support for Vein Grafts Used in CABG Surgery
224069352|NCT01002807|DRUG|Metformin XR|Tablets, Oral, 1000 mg, Single Dose
224160682|NCT02040857|DRUG|Aromatase Inhibitor|Endocrine Therapy
223472450|NCT02134093|DRUG|Induction of anesthesia,midazolam ,sufentanil,etomidate and rocuronium|Anesthesia induction:midazolam (0.03\~0.05 mg/kg), sufentanil(0. 5\~0.8 μg/kg), etomidate ( 0.2\~0.6mg/kg) and rocuronium(0.6mg/kg)
223472451|NCT02134093|DRUG|Dexmedetomidine|Continuous pump infusion dexmedetomidine at 0.5μg/kg （low dose group）or 1μg/kg （high dose group）for 15 minutes before anesthesia induction，then followed by a continuous pump infusion at 0.2 μg/kg/h（low dose group）or 0.4μg/kg/h（high dose group） until the end of surgery.
223472452|NCT02134093|DRUG|Normal saline|Continuous pump infusion normal saline with identical volume of dexmedetomidine.
223472453|NCT02134093|DRUG|Maintenance of anesthesia , propofol, remifentanil,vecuronium|Continuous infusion of propofol （3\~6 mg/kg/h）, remifentanil （0.05\~0.3 μg/kg/min）is required to maintain Entropy within 40\~60,Mean Arterial Blood Pressure more than 20% of baseline level , Oxygen Saturation more than 90% , airway pressure less than 40 cm H2O, intermittent injection vecuronium （0.05\~0.1mg/kg） as needed to maintain muscle relaxation.
223472454|NCT02314728|DRUG|Misoprostol|Patients who are randomized to receive misoprostol will have 25mcg placed vaginally. Repeated dosing of misoprostol is based on clinical exam and clinical judgment of the provider.
223472455|NCT02314728|DRUG|Oxytocin|Patients who are randomized to receive oxytocin alone will receive intravenous administration of oxytocin as designated by the hospital protocol. Protocol begins with 2 milliunits of oxytocin that is then titrated over time. Titration is based on clinical exam and clinical judgment of the provider and is continued until there are adequate uterine contractions.
224069353|NCT01002807|DRUG|Glucophage|Tablets, Oral, 1000 mg, Single Dose
224069354|NCT02535182|OTHER|Blood Draw|"Lab will draw one tube of blood to be stored in 8 mL Becton Dickinson (BD) Vacutainer Cell Preparation Tube (CPT) tubes at three study time points as described in Table 4.7b. These time points include baseline, Day -2 (immediately prior to transplant, central line placement, or administration of any conditioning regimen), and Day +28.~Peripheral blood mononuclear cells (PBMCs) will be isolated from the whole blood samples collected from patients at the three designated time points (Baseline, Day -2, and Day +28). The lab will conduct western blotting on the cytosolic and membrane fractions of isolated PBMCs to determine the distribution of Rap1 in the different fractions, and the status of Rap1 prenylation in the cells."
224069355|NCT04222595|OTHER|Fluenz Tetra nasal spray suspension|Prophylaxis of influenza in children and adolescents from 24 months to less than 18 years of age. Single dose vaccine, administered as a nasal spray (0.2 ml administered as 0.1 ml per nostril).
224069356|NCT00356278|DRUG|D-Cycloserine|D-Cycloserine doses will be 50 mg. There will be 5 pills total during study, each given 30 minutes prior to each VRE session.
224069357|NCT00356278|DRUG|Alprazolam|Alprazolam doses will be 0.25 mg. There will be 5 pills total during study, each given 30 minutes prior to each VRE session.
224069358|NCT00356278|BEHAVIORAL|Virtual Reality Exposure Therapy|VRE includes viewing scenes of virtual Iraq via a head mounted display. Other stimuli presented include sounds, smells and vibration. Each session will be 60 minutes with approximately 30 to 45 minutes of that wearing head mounted display.
224304201|NCT02603393|DRUG|Salmeterol/fluticasone|Salmeterol/fluticasone propionate dry inhalation powder delivered via Accuhaler™
223580308|NCT00829491|BEHAVIORAL|CVD risk reduction program|Participants will be selected through review of the DH administrative databases or by referral from their primary care provider. After completion of the forms, the navigator and client will discuss potential CVD risk reduction activities and programs available through this program for the client to participate in. Potential activities will include self-monitoring using self-help tools,healthy nutrition and exercise activities, community-based exercise programs using the recreation centers in the community, and referral to the Colorado Quitline for smoking cessation activities. Follow-up questionnaires will be completed at 6 and 12 months after enrollment to assess changes in levels of exercise, dietary patterns, and beliefs and attitudes about behavioral change.
223472456|NCT01791595|DRUG|AZD3965|"Day -7: single dose of 5 mg AZD3965 orally prior to start of continuous treatment.~Cycle 1, Day 1: commenced dosing of 5 mg AZD3965 OD orally for up to 6 28-day cycles.~Trial participants benefitting from treatment could continue beyond 6 cycles for as long as they continued to benefit on agreement between the Investigator and the Sponsor."
223472457|NCT01791595|DRUG|AZD3965|"Day -7: single dose of 10 mg AZD3965 orally prior to start of continuous treatment.~Cycle 1, Day 1: commenced dosing of 10 mg AZD3965 OD orally for up to 6 28-day cycles.~Trial participants benefitting from treatment could continue beyond 6 cycles for as long as they continued to benefit on agreement between the Investigator and the Sponsor."
223472458|NCT01791595|DRUG|AZD3965|"Day -7: single dose of 20 mg AZD3965 orally prior to start of continuous treatment.~Cycle 1, Day 1: commenced dosing of 20 mg AZD3965 OD orally for up to 6 28-day cycles.~Trial participants benefitting from treatment could continue beyond 6 cycles for as long as they continued to benefit on agreement between the Investigator and the Sponsor."
223580309|NCT00350428|PROCEDURE|Laser Preipheral Iridotomy and phacoemulsification|
223580310|NCT00737594|DRUG|Placebo|Matching placebo capsules for oral administration
223580311|NCT00737594|DRUG|Cobiprostone|Cobiprostone capsules for oral administration
224160683|NCT03371212|DEVICE|Dual mobility cohort|Patients will receive the Taperloc femoral stem, ceramic femoral head (size 32mm for acetabular components 48/50mm; size 36mm for acetabular components \> 52mm), polyethylene bearing, and G7 acetabular shell.
224160684|NCT03371212|DEVICE|Conventional cohort|Patients will receive a Taperloc femoral stem, ceramic femoral head (size 32mm for acetabular components 48/50mm; size 36mm for acetabular components \> 52mm), polyethylene bearing, and G7 acetabular shell
223580312|NCT00265070|DRUG|Gefitinib|250 mg tablet oral daily dose
223580313|NCT00459537|DRUG|terbinafine hydrogen chloride|10 % terbinafine hydrogen chloride (HCL)
223580314|NCT00459537|DRUG|amorolfine nail lacquer|5 % amorolfine nail lacquer
223580315|NCT04593459|DIETARY_SUPPLEMENT|Probiotic|See Arm description
224069359|NCT00356278|DRUG|Placebo|Placebo will be administered in the same manner as the active drugs.
223472459|NCT01791595|DRUG|AZD3965|"Day -7: single dose of 30 mg AZD3965 orally prior to start of continuous treatment.~Cycle 1, Day 1: commenced dosing of 30 mg AZD3965 OD orally for up to 6 28-day cycles.~Trial participants benefitting from treatment could continue beyond 6 cycles for as long as they continued to benefit on agreement between the Investigator and the Sponsor."
223580316|NCT04593459|DRUG|Metformin Hydrochloride|See Arm description
223580317|NCT04593459|DIETARY_SUPPLEMENT|Probiotic Placebo|See Arm description
223580318|NCT06542991|OTHER|transcranial magnetic stimulation|During treatment, the patient underwent cTBS targeting the left SMA for 7 consecutive days. Each treatment day comprised six rounds of cTBS, with a 15-minute interval between each. A single cTBS session involved trains of three pulses at 50 Hz, repeated every 200 ms (5 Hz), until reaching a total of 600 pulses, lasting 40s. Stimulation intensity remained at 80% of resting motor threshold. In total, patients received 25,200 pulses throughout the treatment period.
224069360|NCT02341092|BEHAVIORAL|Traumatic brain injury|Collection of the use of expertise relatives of victims of traumatic brain injury
224069361|NCT05453643|BEHAVIORAL|sleep deprivation patterns|Sleep deprivation patterns 1 (SDP1) ; total sleep deprivation for 24 hours followed by early morning sleep and an extended 17 hours wakefulness. Sleep deprivation patterns 2 (SDP2) : Sleep interrupted by two half-hour awakenings
224069362|NCT06344078|PROCEDURE|sigmoid resection and anastomosis / stoma|intestinal resection and recostruction or creation of stoma
224160685|NCT00671398|DRUG|Ramelteon|Ramelteon 8 mg, tablets, orally for one night only.
224160686|NCT00671398|DRUG|Ramelteon|Ramelteon 16 mg, tablets, orally for one night only
223580319|NCT05661266|DEVICE|Eye-Tracking|Eye-tracking technology and algorithms used to successfully capture and track eye movements using an electronic tablet and the embedded camera of the device.
223580320|NCT04243928|OTHER|kinesio taping|apply kinesio taping on dorsi flexors muscles
223580321|NCT01076621|DRUG|0.5 mg estradiol / 0.1 mg norethisterone acetate (NETA)|Data collection of the use of 0.5 mg estradiol and 0.1 mg norethisterone acetate (NETA) in women in connection to a daily clinical practice.
223580322|NCT03705910|OTHER|Perceptive Rehabilitation|"In each session, over one hundred cones will be placed on a rigid wooden base using elastic strips. The patient will be asked to lie down supine on the material. Patients weigh will create pressure and reaction force to his/her body. Treatments will be 2 times a week till 8 weeks.~The therapist will ask the patient firstly to breathe normally and feel the pressure. The patient will then perform breathing exercises and active exercises (including stretching, warming up, and cooling down) under supervision. During the session, the therapist will ask about the pressure of the cones and will correct the patient's posture. At the end of each session, the therapist will photograph the patient's back with the aim of documenting the pressure and hyperaemic areas."
224069363|NCT00609479|PROCEDURE|Osteosynthesis|"1. Micronail osteosynthesis. A cast for the first 14 days, thereafter starting physiotherapy. Control at weeks 1,2,5,12.~2. Hoffmann-II-non-bridging osteosynthesis. Removal of device after 5 weeks. physiotherapy starts at 14 days. Control at weeks 1,2,5,12."
224069364|NCT00599859|DIETARY_SUPPLEMENT|lactose|consumption of 50g lactose/day in 2 divided doses mixed in water.
224160687|NCT00671398|DRUG|Placebo|Ramelteon placebo-matching tablets, orally for one night only
224160688|NCT05342142|BEHAVIORAL|Aerobic and ResistanceExercise|Exercise program consisting of 12 weeks of aerobic and resistance exercises
224160689|NCT02682576|PROCEDURE|Brachial artery ultrasound imaging|
224160690|NCT01137448|BEHAVIORAL|Weight Loss|Subjects will enroll in a weight loss program and participate in weight loss counseling 6 times over the course of 6 months.
224160691|NCT00024674|DRUG|SS1(dsFv)-PE38|
223472460|NCT01791595|DRUG|AZD3965|"Day -7: single dose of 30 mg AZD3965 orally prior to start of continuous treatment.~Cycle 1, Day 1: commenced dosing of 15 mg AZD3965 BD orally for up to 6 28-day cycles.~Trial participants benefitting from treatment could continue beyond 6 cycles for as long as they continued to benefit on agreement between the Investigator and the Sponsor."
223472461|NCT01791595|DRUG|AZD3965|"Day -7: single dose of 20 mg AZD3965 orally prior to start of continuous treatment.~Cycle 1, Day 1: commenced dosing of 10 mg AZD3965 BD orally for up to 6 28-day cycles.~Trial participants benefitting from treatment could continue beyond 6 cycles for as long as they continued to benefit on agreement between the Investigator and the Sponsor."
223472462|NCT01791595|DRUG|AZD3965|"Day -7: single dose of 20 mg AZD3965 orally prior to start of continuous treatment (first 3 trial participants in the Expansion Cohort only; subsequent patients started treatment at Cycle 1, Day 1).~Cycle 1, Day 1: commenced dosing of 10 mg AZD3965 BD orally for up to 6 28-day cycles.~Trial participants benefitting from treatment could continue beyond 6 cycles for as long as they continued to benefit on agreement between the Investigator and the Sponsor."
223472463|NCT05002595|DRUG|H. pylori eradication|Antimicrobial agents for H. pylori eradication
223472464|NCT02599532|DRUG|apixaban|Study subjects will be given a single-dose of apixaban 10 mg.
223472465|NCT03118934|DEVICE|Lotrafilcon B multifocal contact lenses|Contact lenses for near, intermediate, and distance correction worn on a daily wear basis and cared for with participant's habitual lens care solution
223472466|NCT03118934|DEVICE|Nelfilcon A multifocal contact lenses|Contact lenses for near, intermediate, and distance correction worn on a daily disposable basis (removed every night and discarded) with a new pair of study lenses every morning
223472467|NCT03118934|DEVICE|Delefilcon A multifocal contact lenses|Contact lenses for near, intermediate, and distance correction worn on a daily disposable basis (removed every night and discarded) with a new pair of study lenses every morning
223472468|NCT03174444|BEHAVIORAL|Small Media|Bilingual brochures and access to bilingual website
223472469|NCT00842634|BIOLOGICAL|ZFN modified T cells|A single infusion of 5-10 billion ZFN Modified CD4+ T Cells
223472470|NCT00842634|OTHER|Structured Treatment Interruption|Stop Taking HAART Medication for up to 12 weeks (4 weeks after infusion to 16 weeks after infusion)
223472471|NCT03804281|PROCEDURE|Test group|The surgery will be done with the use of 4x magnification loop, the knives are micro blades and micro-sutures 7//0 used with the microsurgical instruments kit
223472472|NCT03804281|PROCEDURE|Control group|esthetic crown lengthening with conventional approach with an internal bevel incision, following CEJ anatomy, this will be followed by an intra-sulcular incision, removal of the strip of outlined marginal gingiva and elevation of a mucoperiosteal ﬂap to the level of the alveolar bone crest.
223472473|NCT01614470|DRUG|Ivacaftor|150 mg tablet, oral use, administered twice a day (q12h)
224069365|NCT00599859|DIETARY_SUPPLEMENT|lactose|consumption of lactose 50g/day in 2 divided doses mixed in water
223472474|NCT01614470|DRUG|Placebo|oral use, administered twice a day (q12h)
223472475|NCT01219543|DRUG|AZD1480 Daily|Oral Dose, Capsule, Daily Dosing
223472476|NCT01219543|DRUG|AZD1480 BID|Oral Dose, Capsule, BID Dosing
223472477|NCT03733808|DEVICE|Repetitive Transcranial Magnetic Stimulation|Non-invasive brain stimulation technique
224069366|NCT06538883|DRUG|Sedation with Ciprofol|During the drug administration period, ciprofol were IV infused at loading doses of 0.1 mg/kg, respectively, over 4 minutes ± 30 seconds depending on the physical condition of each patient. Ciprofol were then immediately administered at an initial maintenance dose of 0.3 mg/kg/hr, with a target sedation depth of RASS +1 to -2, based on the Pain, Agitation/sedation, Delirium, Immobility (rehabilitation/mobilization), and Sleep (disruption) guideline.
224160692|NCT02795065|DRUG|Enoxaparin|Use of enoxaparin 40 mg subcutaneous once daily in high risk intensive care patients as a prophylaxis against venous thromboembolism
223472478|NCT02200146|DRUG|Prednisone|Prednisone per os 0,5 mg/kg/die once/day for 3 months. After 3 months, between responders, prednisone was slowly tapered (5 mg/week maintaining the new reduced dose for one week) to 0,2 mg/kg/die for further 6 months.
223472479|NCT02200146|DRUG|Hydroxychloroquine + Prednisone|Hydroxychloroquine per os 200 mg/die (or adjusted for body weight if less than 61 kg), twice/day + prednisone 0,15 mg/kg per os daily, once/day for 3 months, than for further 6 months between responders.
223472480|NCT00758446|DRUG|BLX-028914|50 mg capsules, p.o, daily, 14 days
223472481|NCT00758446|DRUG|BLX-028914|15 mg capsules, p.o, daily, 14 days
223472482|NCT00758446|DRUG|placebo|capsules, p.o, daily, 14 days
223472483|NCT00972270|DEVICE|Impella LP 2.5|Insertion of the LP 2.5 IMPELLA circulatory support system that can be placed across the aortic valve using a single femoral site. The device pumps blood from the left ventricle into the ascending aorta at 2.5L/min.
223472484|NCT00972270|DEVICE|Intra-Aortic Balloon Pump|The Intra-Aortic Balloon Pump consists of a cylindrical balloon that sits in the aorta and counterpulsates.
223472485|NCT00249834|DRUG|Gonal-f|GONAL-f (follitropin alfa) will be administered subcutaneously based on ART treatment guidelines, which determined the optimal dose of r-hFSH based on subject baseline characteristics/predictors of ovarian response throughout stimulation cycle.
223472486|NCT00249834|DRUG|Recombinant human chorionic gonadotrophin (r-hCG)|When at least 1 follicle greater than or equal to (\>=) 18 millimeter (mm) and 2 follicles \>=16 mm in diameter develop, 250 microgram (mcg) of recombinant human chorionic gonadotrophin (r-hCG) will be administered.
223472487|NCT04813523|DRUG|Pembrolizumab Injection [Keytruda]|Neoadjuvant period: pembrolizumab 200mg IV, Q3W with three cycles. Adjuvant period: pembrolizumab 200 mg IV, Q3W, up to one year, which should be performed within 3-6 weeks after surgery.
223472488|NCT03167554|OTHER|Sham comparator|The electrolysis technique was simulated to be delivered. The guide tube of the needle contacted with the skin, located on the painful area, and the device remained switched on to simulate its functioning.
224160693|NCT02795065|DRUG|Bemiparin|Use of bemiparin 3500 IU subcutaneous once daily in high risk intensive care patients as a prophylaxis against venous thromboembolism
224160694|NCT00780104|DRUG|Rapamycin, Mitoxantrone, Etoposide, Cytarabine|Rapamycin loading dose of 12 mg followed by a single daily dose for 8 days of 4 mg/day + MEC (Mitoxantrone 8 mg/m2/day IV, Etoposide 100 mg/m2/day IV and Cytarabine 1000 mg/m2 IV every 24 hours for 5 days. Starts after 4th dose of sirolimus.
223472489|NCT03167554|OTHER|Experimental group 1|Percutaneous Therapeutic Electrolysis (EPTE®) with monopolar needle, 330 microamps, 1 min 20 sec.
223472490|NCT03167554|OTHER|Experimental group 2|Percutaneous Therapeutic Electrolysis (EPTE®) with bipolar needle, 120 microamps, 1 min 20 sec.
223472491|NCT05667766|DIAGNOSTIC_TEST|Release of Extended Pharmacogenomics Report at Week 1|Whole genome sequencing with reporting on current standard of care (SoC) pharmacogenomic variants (TPMT, NUD15) where applicable (i.e, for patients with diagnosis of acute lymphoblastic leukaemia) by Week 1. Whole genome sequencing on a broader number of actionable variants as per international guidelines for cancer supportive care (identical to study arm) will be reported on at Week 13.
223472492|NCT05667766|DIAGNOSTIC_TEST|Release of Extended Pharmacogenomics Report at Week 13|Whole genome sequencing with reporting on current standard of care (SoC) pharmacogenomic variants (TPMT, NUD15) where applicable (i.e, for patients with diagnosis of acute lymphoblastic leukaemia) and reporting of a broader number of actionable pharmacogenomic variants as per international guidelines for cancer supportive care reported on by Week 1.
223472493|NCT06284421|DEVICE|Shore durometer|The durometer will be held on the exterior of the lower uterine segment and fundus to measure the hardness reading at each location.
223472494|NCT02072642|DEVICE|active light therapy : Light therapy: DayVia lamp 10000 lux|4 weeks of active light therapy with DayVia lamp 10000 lux
223472495|NCT02072642|DEVICE|Placebo light therapy|4 weeks with Placebo light therapy
223472496|NCT05179408|BEHAVIORAL|Targeted-telerehabilitation|Participant-chosen targets: 1) inspiratory muscle training + walking (to reduce dyspnea and improve physical activity/stept count; 2) resistance training (to reduce fatigue and improve role/social function; 3) mindfulness training (to reduce fear of cancer recurrence and anxiety)
223472497|NCT05179408|BEHAVIORAL|Waitlist|8-week waiting period prior to targeted telerehabilitation
223472498|NCT05325996|DIAGNOSTIC_TEST|Standard Automatic Perimetry Humphrey Field Analyzer|Standard Automatic Perimetry (SAP) using the Swedish Interactive Threshold Algorithm (SITA) Standard Strategy measures the visual field in an ophthalmic setting.
223472499|NCT05325996|DIAGNOSTIC_TEST|visuALL H|visuALL H a new portable perimeter measuring the visual field and acuity in a non ophthalmic setting.
223580323|NCT03705910|OTHER|Mobilisation Techniques|"A certified physiotherapist will perform mobilisation techniques. All participants in this group will receive treatment protocol according to the list on below. Treatments will be 2 times a week till 8 weeks.~For this treatment, the participant should lie on a bed and change their position according to the technique (supine, position or side-lying). Also, the therapist will be changing her position according to the technique. All technique will be on the range of motion limit. For releasing techniques the therapist will apply three-dimensional pressures till 3-5 minutes, with the feeling of relaxing therapist will change the limit for the next point."
223580324|NCT02476136|DRUG|paroxetine, duloxetine, fluoxetine or venlafaxine|
223580325|NCT05987436|OTHER|Supervised Aerobic Exercise|Group 1 exercised for six weeks, five sessions per week under the supervision of a medical doctor in the aerobic exercise laboratory.
223580326|NCT04924478|BIOLOGICAL|Mepolizumab|Patients will be receiving this treatment as part of their standard clinical care
223580327|NCT00478309|OTHER|counseling intervention|
223580328|NCT00478309|OTHER|educational intervention|
223580329|NCT04958746|DRUG|Ciprofol|intravenous bolus
223580330|NCT04958746|DRUG|Propofol|intravenous bolus
224160695|NCT00780104|DRUG|Rapamycin + MEC|Rapamycin loading dose of 12 mg followed by a single daily dose for 8 days of 4 mg/day + MEC (Mitoxantrone 8 mg/m2/day IV, Etoposide 100 mg/m2/day IV and Cytarabine 1000 mg/m2 IV every 24 hours for 5 days. Starts after 4th dose of sirolimus.
224160696|NCT04563104|DIAGNOSTIC_TEST|Lung Ultrasound|We will evaluate the role of lung ultrasound on the duration of antibiotics, we hypothesize that ultrasound imaging may have a role, will be correlated with, procalcitonin (PCT). The created database will help in establishing conclusion and recommendations that will help to improve the antibiotics duration and decrease the resistance.
224160697|NCT06380972|DEVICE|Polycaprolactone (PCL) Based Facial Injectable|Polycaprolactone (PCL) Based Facial Injectable
224160698|NCT00005065|DRUG|paclitaxel|Given IV
224160699|NCT00005065|DRUG|carboplatin|Given IV
224160700|NCT00005065|DRUG|motexafin gadolinium|Given IV
223472500|NCT05325996|DIAGNOSTIC_TEST|iCare Home Tonometer|iCare HOME tonometer is a device developed for patients/subjects to measure their eye pressure at home.
223472501|NCT05325996|DIAGNOSTIC_TEST|Spectralis Optical coherence tomography (OCT)|Optical coherence tomography (OCT) is a computerized picture measuring the thickness of the inner layer of the retina that makes the optic nerve.
223580331|NCT04722757|PROCEDURE|ta-IPAA|A trans-anal port (gelpoint path, Applied Medical®) will be used for transanal acces and pneumopelvis will be created. The initial purse string is to be placed approximately 3cm above the dentate line, followed by a rectotomy. The perirectal dissection is then continued and should be pursued for at least 5cm. More proximal dissection can be done by transabdominal access. After completion of the proctectomy, a double purse string anastomosis is performed after creation of the J-pouch. A defunctioning loop ileostomy can be placed according to surgeon's preference.
223580332|NCT04722757|PROCEDURE|tabd-IPAA|Patients in the control group will undergo a rectal dissection by laparotomy, Pfannenstiel incision, (hand-assisted) laparoscopy, single port laparoscopy or robotic surgery, but performed from the abdominal side (tabd-IPAA). Dissection will be performed down to the pelvic floor and include the distal rectum. It is anticipated that most dissection will occur using the TME plane, however, close rectal dissection is also acceptable. Transection of the distal rectum approximately 2 cm above the dentate line will be performed using a linear stapler of the surgeon's choice. After placing the anvil in the J-pouch, a circular stapler will be introduced through the sphincter and a circular anastomosis will be performed. A defunctioning loop ileostomy can be placed according at the surgeon's discretion.
223580333|NCT01999218|DRUG|Ertugliflozin 5 mg|Ertugliflozin, 5 mg, oral, once daily, from Day 1 to Week 104
223580334|NCT01999218|DRUG|Ertugliflozin 10 mg|Ertugliflozin, 10 mg, oral, once daily from Day 1 to Week 104.
224160701|NCT00005065|PROCEDURE|conventional surgery|Undergo complete surgical resection
224160702|NCT00005065|RADIATION|radiation therapy|Undergo radiation therapy
224160703|NCT02474628|DIETARY_SUPPLEMENT|sodium bicarbonate|
223472502|NCT01886508|PROCEDURE|Nerve-spring radical hysterectomy|Nerve-spring radical hysterectomy that is reserve some pelvic autonomic nerves during radical hysterectomy. Reserve hypogastric nerve trunk during dissecting cardinal ligament. Reserve pelvic splanchnic nerve trunk during exsecting uterosacral ligament. Reserve bladder nerve of pelvic plexus during dissecting vesicouterine ligament.
223472503|NCT01886508|PROCEDURE|radical hysterectomy|Radical hysterectomy is Piver III hysterectomy and Q-M classification Type C1 hysterectomy.
223472504|NCT04609683|DEVICE|AleriTM sensors|"AleriTM sensors are worn on the bicep or forearm and communicates through BLETM to a mobile App. The data is sent through the mobile App to web-based system processing where PHI is calculated and sent back to the mobile App.~The AleriTM sensor has a form factor similar to a conventional arm band, with a hockey puck shape of approximately 48mm in diameter and 15mm in thickness the AleriTM sensor is a non-significant risk (NSR) device as it does not meet the definition of significant risk device (21 CFR 812.3(m)) because it is: not an implant; is not purported or represented to support or sustain human life; its use is not of substantial importance in the diagnosis, cure, treatment, mitigation, or prevention of impairment of health; and it does not present a serious risk to the health, safety, or welfare of a subject."
223472505|NCT02895347|BEHAVIORAL|Surgical Simulation Practice Modules|The surgical simulation practice modules simulate surgical settings for suturing.
223580335|NCT01999218|DRUG|Glimerpiride|Glimepiride, oral tablets, initiated at 1 mg daily and titrated up to the maximum approved dose (8 mg daily based on the local country label) or maximum tolerated dose
223580336|NCT01999218|DRUG|Placebo to Ertugliflozin|Matching placebo to ertugliflozin, 5 mg and/or 10 mg, oral, once daily, from Day 1 to Week 104
223580337|NCT01999218|DRUG|Placebo to Glimepiride|Matching placebo to glimepiride, 1 mg or 2 mg, oral, once daily, from Day 1 to Week 104.
223580338|NCT01999218|DRUG|Metformin|Participants are to remain on their stable doses of metformin (oral, \>=1500 mg/day) while receiving blinded investigational product during the double-blind treatment period. Participants on metformin \<1500 at screening are up-titrated to \>= 1500 daily.
223580339|NCT01999218|DRUG|Sitagliptin|Open label, oral, once daily, rescue medication as required.
223580340|NCT06301139|DIETARY_SUPPLEMENT|Goat milk-based infant formula|Infant formula based on goat milk for 4 weeks at volume depending on the infant
223580341|NCT06301139|DIETARY_SUPPLEMENT|Cow's milk-based infant formula with probiotic drops|Infant formula based on cow's milk with probiotic Lactobacillus reuteri drops for 4 weeks at volume depending on the infant
223580342|NCT06537557|OTHER|the early in-hospital temperature management protocol for heat stroke patients|The early in-hospital temperature management protocol for heat stroke includes early identification, selection of cooling methods for rapid cooling, precise target temperature management, and dynamic monitoring. Effective temperature management will be implemented for heat stroke patients to improve their outcomes.
224160704|NCT02474628|DIETARY_SUPPLEMENT|calcium carbonate|
224160705|NCT00260091|PROCEDURE|intrauterine insemination|An assisted reproduction technique which deposits washed sperm directly into the uterus, bypassing the cervix, and allowing the sperm to enter the fallopian tubes where fertilization normally occurs.
224160706|NCT00260091|PROCEDURE|infertility|This procedure involves stimulating the ovaries, retrieving released eggs, fertilizing the eggs, growing the embryos in a laboratory, and then implanting the embryos in the woman's uterus to develop naturally.
224160707|NCT03900663|DEVICE|Anthropometric measures|Measure body weight , height , chest circumference , mid upper arm circumference,skin fold thickness , head circumference
224160708|NCT01085162|DRUG|BMS747158|BMS747158 is a novel PET MPI agent labeled with Fluorine-18.
224160709|NCT00194415|BEHAVIORAL|Safer-sex counseling|Subjects will receive safer-sex counseling during pregnancy
224160710|NCT00194415|PROCEDURE|Type specific serologic HSV testing|Subjects will be testing for HSV by Western Blot
224160711|NCT02463227|BIOLOGICAL|VRC01|"40 mg/kg of VRC01 administered IV in 100 mL of 0.9% sodium chloride for injection, USP.~Administered over about 30 to 60 minutes using a volumetric pump."
224160712|NCT01653756|DRUG|IPI-145, a PI3K Inhibitor|Active drug
224160713|NCT01653756|DRUG|Placebo to match IPI-145|Comparator
223580343|NCT04833959|DRUG|89Zr-panitumumab|Imaging Agent
223580344|NCT01057524|DEVICE|High Frequency Chest Wall Oscillation (HFCWO)|Airway clearance using the high frequency chest wall oscillator device
223580345|NCT01057524|OTHER|Usual airway clearance|Airway clearance treatments using the active cycle of breathing techniques, autogenic drainage, positive expiratory pressure, manual techniques or oscillating positive expiratory pressure
223580346|NCT00885300|DRUG|cloxacillin|cloxacillin 100mg/ml as catheter lock at the end of hemodialysis
224160714|NCT00517725|DRUG|carvedilol|
224160715|NCT00517725|DRUG|bisoprolol|
224160716|NCT00517725|DRUG|Nebivolol|
224160717|NCT02894892|DRUG|(A)Bismuth|
224160718|NCT02894892|DRUG|(B)Bismuth|
224160719|NCT02894892|DRUG|(C)Bismuth|
224160720|NCT02894892|DRUG|(D)Esomeprazole and Bismuth|
224304202|NCT00927693|OTHER|Coronary Artery Calcium (CAC) Scan|A coronary artery calcium (CAC) scan is performed during the baseline clinic visit. The results including the actual images from the scan are viewed by the subject during the risk factor consultation with the nurse practitioner. Results are available for the subjects' physicians upon request.
223580347|NCT00885300|DRUG|heparin|heparin 1000iu/ml as catheter lock at the end of hemodialysis
223580348|NCT05225259|DRUG|LOXO-260|Oral
224160721|NCT02894892|DRUG|(E)Esomeprazole and Bismuth|
224160722|NCT02894892|DRUG|(F)Esomeprazole and Bismuth|
224160723|NCT02894892|OTHER|(G)Control|
224160724|NCT03187795|DRUG|Oxybutynin Chloride IR|Oxybutynin chloride immediate release (IR) 5 mg three times daily for 6 weeks
224160725|NCT03187795|DRUG|Mirabegron|Mirabegron 25 mg tablet once daily for 2 weeks, followed by mirabegron 50 mg once daily for 4 weeks (Note: Placebo twice daily will be included with mirabegron once daily to match the three-time daily dosing of oxybutynin IR in the other intervention).
224160726|NCT02057068|BEHAVIORAL|SLEEP-E Dyads Intervention|Described in arm/group description
224160727|NCT02048774|BEHAVIORAL|Designation of Social Positioning|
224160728|NCT01863706|DRUG|Misoprostol|400µg oral misoprostol
224160729|NCT01863706|DRUG|Oxytocin|20 IU Oxytocin
224304203|NCT00468260|DRUG|Patupilone|
223472506|NCT03421938|OTHER|Walking Exercise|Group 1 will have downhill walking exercises with %10 slope; group 2 uphill walking exercises on the treadmill with %10 slope..
223472507|NCT00142649|BEHAVIORAL|diet|
223580349|NCT02952560|OTHER|Ultrasound scan|Ultrasound scanning examinations will be performed twice (pre-CT scan and post CT-scan). Each examination will be performed by two observers who are blinded to each other's measured values.Patients will be asked to place a small sip of water (20 mL)in their mouth and keep the mouth open during the imaging. A second ultrasound examination of each patient by the two observers will be performed after the CT-scan.
223580350|NCT02032407|DRUG|Dapsone Gel|Dapsone Gel (Aczone®) applied twice daily to the face for 12 weeks.
223580351|NCT02191605|BEHAVIORAL|eSBIRT|A single 20 minute interactive computer-delivered intervention designed to promote motivation to change prenatal marijuana use, without presuming the participant to be currently using marijuana while pregnant.
223472508|NCT00142649|BEHAVIORAL|physical activity|
223472509|NCT02589145|DRUG|Lenalidomide|"Dose Escalation Phase Starting dose of Lenalidomide: 50 mg by mouth on Days -9 to -2.~Dose Expansion Phase Starting Dose: Maximum tolerated dose from Phase I."
223472510|NCT02589145|DRUG|Vorinostat|1000 mg by mouth on Days -9 to -2.
223472511|NCT02589145|DRUG|Gemcitabine|Gemcitabine administered as a loading dose of 75 mg/m2 by vein on Day -8 and 2775 mg by vein on Day -3.
223472512|NCT02589145|DRUG|Busulfan|"Busulfan test dose administered by vein either as outpatient before admission, or as inpatient on day -10. The test dose of 32 mg/m2 based on actual body weight. Doses of days -6 and -5 subsequently adjusted to target an AUC of 4,000 microMol.min-1."
223472513|NCT02589145|DRUG|Melphalan|60 mg/m2 by vein on days -3 and -2.
223472514|NCT02589145|DRUG|Rituximab|Patients with CD20+ tumors receive Rituximab 375 mg/m2 by vein on day -9 in the AM as an inpatient.
223472515|NCT02589145|DRUG|Dexamethasone|8 mg by vein twice a day from Day -8 AM to Day -2 PM.
223472516|NCT02589145|DRUG|Caphosol|Caphosol oral rinses 30 mL four times a day used from Day -8.
224160730|NCT05574712|DRUG|Neoadjuvant treatment|Each drug will be dosed at its respective FDA-approved dose. These dosages are as follows: leuprolide acetate 22.5 mg depot injection x one dose, abiraterone acetate 1000 mg by mouth daily, and belzutifan120 mg administered by mouth once daily. All men will also be treated with prednisone 5 mg by mouth twice daily while on abiraterone acetate in order to blunt its associated mineralocorticoid side effects
223472517|NCT02589145|DRUG|Glutamine|Oral glutamine, 15 g four times a day, swished, gargled and swallowed started on Day -8.
223472518|NCT02589145|DRUG|Pyridoxine|100 mg by vein or mouth three times a day from Day -1
223472519|NCT02589145|DRUG|Enoxaparin|40 mg subcutaneously daily from admission until platelet count drops below 50,000/mm3.
223472520|NCT02589145|PROCEDURE|Stem Cell Transplant|Stem cell transplant performed on Day 0.
223472521|NCT02589145|DRUG|Palifermin|Palifermin per departmental standard of care with 3 doses to be administered prior to starting chemotherapy and 3 doses starting on day 0.
223472522|NCT05148637|DRUG|Maintenance of general anesthesia by Sevoflurane|Anesthesia was maintained by inhalational anesthesia (sevoflurane) titrated by monitoring of patient sensitivity index of the Masimo
223580352|NCT02191605|BEHAVIORAL|Tailored texting|Group text messaging software from Trumpia, Inc. will be used to create the tailored text messages that will be sent to participants assigned to this intervention. Text messages will sent after the initial study participation visit until childbirth or participant opts out of receiving them.
223580353|NCT00584207|PROCEDURE|radiofrequency ablation|Intraoperative RFA of uterine fibroids
223580354|NCT05406609|OTHER|Cost|Costs of operating room, drugs and equipments which are used by anesthesia
223580355|NCT05406609|OTHER|Time|Time of using operating room
224069367|NCT06538883|DRUG|Sedation with Propofol|During the drug administration period, propofol were IV infused at loading doses of 0.5 mg/kg, respectively, over 4 minutes ± 30 seconds depending on the physical condition of each patient. Propofol were then immediately administered at an initial maintenance dose of 1.5 mg/kg/hr, with a target sedation depth of RASS +1 to -2, based on the Pain, Agitation/sedation, Delirium, Immobility (rehabilitation/mobilization), and Sleep (disruption) guideline.
223472523|NCT05148637|DRUG|Maintenance of general anesthesia by Desflurane|Anesthesia was maintained by inhalational anesthesia (desflurane) titrated by monitoring of patient sensitivity index of the Masimo
223472524|NCT05148637|DRUG|Anesthesia was maintained by inhalational anesthesia (total intravenous anesthesia by lidocaine, propfol and fentanyl infusions)|Anesthesia was maintained by inhalational anesthesia (total intravenous anesthesia by lidocaine, propfol and fentanyl infusions) titrated by monitoring of patient sensitivity index of the Masimo
223472525|NCT03621033|PROCEDURE|colonic transendoscopic enteral tubing|The procedure colonic transendoscopic enteral tubing is as follows:The TET tube was inserted into the ileocecal junction through the endoscopy channel at the first time of the cecal intubation after examination and evaluation of the whole colon. Then, the colonoscope was removed from the colon while the TET tube was maintained at the ileocecal junction. Then the endoscopy was inserted into the ileocecum again for affixing the TET tube to cecum with titanium clips.
223472526|NCT04028726|OTHER|Back-squat exercise|Participants begin with a 5 min dynamic warm-up. Then, they will perform two sets of five repetitions at 40-60% of predetermined 1-repetition maximum (1-RM). The clustered bout will be 4 sets of 2 clusters of 5 repetitions with a 30-second intra-set rest between clusters, and 90-second inter-set rest at a load 70% of 1-RM. The traditional bout will be 4 sets of 10 repetitions with a 120-second inter-set rest at a load 70% of 1-RM.
223472527|NCT01542450|DRUG|insulin detemir|Single dose of 0.3 U/kg administered subcutaneously (s.c. under the skin) in each treatment period separated by a washout period of 4-28 days
224069368|NCT03943212|OTHER|Blood Flow Rate Reduction|Hemodialysis blood flow rate will be reduced by 100 mL/min, or to a minimum of 300 mL/min, whichever is higher. Patients will be surveyed regarding their dialysis recovery time and other symptoms weekly.
224069369|NCT03943212|OTHER|Control|No changes will be made to the dialysis prescription. Patients will be surveyed regarding their dialysis recovery time and other symptoms weekly.
224069370|NCT01120665|DRUG|Estradiol valerate|estradiol valerate, 1 mg/day, orally.
224069371|NCT01120665|OTHER|Aerobic training|Aerobic trainin (cycleergometer, 3x/week, moderate intensity, 50 minutes)
223580356|NCT03737877|OTHER|Diet modification|"The parents will have four group sessions with a nutritional therapist, where in depth advice and information about the diet will be provided. Ongoing support will also be provided throughout the study by use of a closed Facebook or WhatsApp group (whichever the parents choose as most appropriate). The diet is based on five main principles:~* Eat at least seven portions of different varieties of fruit and vegetables each day.~* Have a 12 hour overnight break from food (water only during this time).~* Drink a Kefir drink each day - provided free of charge.~* Eat a microbiome friendly, protein rich, breakfast from our menu.~* Reduce sugar and artificial sweeteners."
223580357|NCT02379468|DRUG|Pedyphar Ointment|
224160731|NCT00645515|DRUG|Ziprasidone|Initial dose of 40 mg capsules twice daily on Days 1-3; dose could be flexibly changed within the range of 40 to 80 mg twice daily for the remainder of the study; treatment duration was 24 weeks.
223472528|NCT01542450|DRUG|insulin NPH|Single dose of 0.3 U/kg administered subcutaneously (s.c. under the skin) in each treatment period separated by a washout period of 4-28 days
223472529|NCT05739487|PROCEDURE|selective intra-arterial thrombolysis|IAT introduces rt-PA (50mg) directly into the ophthalmic circulation by super-selective microcatheterization
224160732|NCT00645515|DRUG|Risperidone|Initial dose of 10 mg once daily on Days 1-3; dose could be flexibly changed within the range of 3 to 9 mg twice daily for the remainder of the study; treatment duration was 24 weeks.
224160733|NCT06248944|OTHER|observational-retrospective and prospective|observational-retrospective and prospective
224160734|NCT03577522|DEVICE|Avenir cementless hip stem|Avenir cementless hip stem vs Corail HA-coated hip stem
224160735|NCT03577522|DEVICE|Corail HA-coated hip stem|Avenir cementless hip stem vs Corail HA-coated hip stem
224160736|NCT00060151|DRUG|pazopanib hydrochloride|
224304204|NCT03256331|DRUG|BEL-X-HG|"This study will be carried out in 2 parts:~1. A sequential Dose Escalation Part of four doses following a 3 + 3 design where dose escalation will be made based on DLT, for a single cycle (28 days) of BEL-X-HG treatment~2. A Dose Extension Part of up to 5 cycles (28 days each) at the same dose level (starting dose) of BEL-X-HG treatment~Escalating dose levels of BEL-X-HG in 5 study cohorts and one modified dose will be as follows:~* Cohort 1: Dose level 1 - 0.5 g/day (0.25 g, bid)~* Cohort 2: Dose level 2 - 1.0 g/day (0.5 g, bid)~* Cohort 3: Dose level 3 - 2.0 g/day (1.0 g, bid)~* Cohort 4: Dose level 4 - 4.0 g/day (2.0 g, bid) Modified dose level Cohort 5: Dose level 5 - 1.5 g/day (0.75g bid) This re-escalation is allowed only when dose de-escalates from Dose level 3 to Dose level 2, and 1 DLT in 6 evaluable subjects of Dose level 2."
224304205|NCT00667901|DRUG|riluzole|
223472530|NCT04385433|DRUG|EXPERIMENTAL ARM|"Patients in the experimental arm will receive:~* Daily pravastatin (40mg/d) during 12 months (pravastatin initiation: first day of radiotherapy).~* Standard adjuvant whole breast radiotherapy (50Gy/ 25 fractions to whole breast) followed or not by a boost to tumor bed (16Gy/ 8 fractions)."
223472531|NCT04385433|OTHER|CONTROL GROUP|"Patients in the standard arm will receive:~* Daily placebo during 12 months (placebo initiation: first day of radiotherapy)~* Standard adjuvant whole breast radiotherapy (50Gy/ 25 fractions to whole breast) followed or not by a boost to tumor bed (16Gy/ 8 fractions)."
223472532|NCT04385433|RADIATION|Standard adjuvant whole breast radiotherapy (50Gy/ 25 fractions to whole breast) followed or not by a boost to tumor bed (16Gy/ 8 fractions)|Radiotherapy will last 5 weeks during treatment by Pravastatine or Placebo
223472533|NCT01707888|PROCEDURE|Thoracoscopy/VATS|Patients undergo major lung resection by thoracoscopic surgery or video assisted thoracoscopic surgery.
223472534|NCT03177148|BEHAVIORAL|Intervention by Clinicians|"•Parents will complete surveys after enrollment and at the end of intervention and participate in intervention visits by pediatric clinicians and telephonic counseling with Registered Dietitians (RDs).~Intervention by pediatric clinicians: up to 4 sessions of MI, in-person Intervention by RDs: up to 6 sessions of MI via telephone."
223472535|NCT03177148|BEHAVIORAL|Usual Care|Pediatric clinicians provide care as normal
223472536|NCT01170325|DRUG|Divalproex Sodium|
223580358|NCT02379468|DRUG|Panthenol|Ointment
224160737|NCT01944254|PROCEDURE|Cardiac output measurement at random to respiration|Cardiac output measurement obtained by pulmonary artery catheter thermodilution technique (PAC TD)
224160738|NCT01944254|PROCEDURE|Cardiac output measurement synchronised at start of expiration|Cardiac output measurement obtained by PAC TD
224304206|NCT00667901|GENETIC|protein expression analysis|
224304207|NCT00667901|GENETIC|reverse transcriptase-polymerase chain reaction|
224304208|NCT00667901|GENETIC|western blotting|
224304209|NCT00667901|OTHER|immunohistochemistry staining method|
224304210|NCT00667901|OTHER|laboratory biomarker analysis|
224304211|NCT00667901|OTHER|pharmacological study|
223472537|NCT01170325|DRUG|Placebo Comparator|
224069372|NCT01120665|DRUG|Placebo|lactose powder, corn starch, microcrystalline cellulose, and magnesium stearate
224069373|NCT01120665|OTHER|Control|The control group was advised to maintain their normal habits, and not to begin any physical exercise program during the study period
224069374|NCT03136315|OTHER|INFERNAL Intervention|The intervention consists in serum and urinary dosage (creatinine and Cystatin C) at the beginning and the end of the 110 km race.
224069375|NCT04170517|DIAGNOSTIC_TEST|Measurement of serum progesterone on the day of FET|Measurement of serum progesterone on the day of FET
224069376|NCT03253146|DIAGNOSTIC_TEST|VIM detection|VIM expression in serum and lymphocytes detection
224069377|NCT05284682|DIAGNOSTIC_TEST|Right hearted catheterization|Right hearted catheterization and collection of blood sampels in the coronary sinus, arterial blood and central venous blood for analysis of energy substrate metabolites.
224069378|NCT00242008|DRUG|Rotigotine|
224069379|NCT01652287|DRUG|BB-12 supplemented strawberry yogurt|Bifidobacterium animalis subsp. lactis (B. lactis) strain BB-12 (BB-12) probiotic supplemented yogurt, 4 ounces taken orally for 10 days
224069380|NCT01652287|OTHER|Strawberry flavored yogurt|Placebo, strawberry yogurt, 4 ounces taken orally for 10 days
224069381|NCT02106312|RADIATION|dose reduction of preoperative radiotherapy in MLS|A: The primary sarcoma in case of non-metastatic disease for management is with curative intent (regime to be chosen=18 x 2 Gy) B: In case of oligometastatic patients, the metastasis may also be irradiated to a dose of 36 Gy in order to postpone the time interval to next systemic chemotherapy. These patients are usually not operated upon and the total dose may also be reached in 12 times 3 Gy, for convenience purposes.
223472538|NCT06308471|OTHER|Baby massage was applied to the intervention group (n=20) of the study|The application was applied for 15 minutes every day for ten days, and oral feeding trials were video recorded. Feeding videos were evaluated by expert neonatal nurses using The Oral Feeding Scale without knowing the application group of the babies.
223472539|NCT06308471|OTHER|Oral stimulation|The application was applied for 15 minutes every day for ten days, and oral feeding trials were video recorded. Feeding videos were evaluated by expert neonatal nurses using The Oral Feeding Scale without knowing the application group of the babies.
223472540|NCT04474886|DIETARY_SUPPLEMENT|Fresubin® powder fibre|2 servings per day
223472541|NCT04990193|OTHER|Conventional Physical Therapy Protocol|The conventional physical therapy protocol was designed to improve axial stability and trunk steadiness during standing and walking. The conventional therapeutic protocol for every child was 3 sessions/week for 12 consecutive weeks. Every treatment session was conducted for 2 hours with a 15-minutes rest between the two training hours.
223580359|NCT02248363|OTHER|Multimodal rehabilitation|Multimodal rehabilitation (MMR) distinguishes itself as an interdisciplinary-coordinated (e.g., physician, occupational therapist, physiotherapist, and psychologist) intervention using a bio-psycho-social view of chronic pain. The MMR continues over a lengthy period with a common goal and generally includes patient education, supervised physical activity, simulated work training, and cognitive behavioural therapy (CBT). The exact composition of these MMR components depends on initial evaluations of the patients health status and furhter follow-up testing. The MMR interventional components can act independently and interdependently, resulting in combined effects due to known and unknown mechanisms; the effects are intended to be greater than the sum of its components.
223580360|NCT06104098|DEVICE|D005 vaginal mousse|D005 Vaginal Mousse is class IIa medical device for treatment of Bacterial Vaginosis.
223580361|NCT05067751|DEVICE|hearing aid with directionality|Hearing directionality allows users the ability to focus on voices and other signals of interest, reducing background noises that are unimportant.
223580362|NCT04787055|DEVICE|Receiver-in-canal hearing instrument|Receiver-in-canal hearing instrument
223580363|NCT05874622|DRUG|VC005 tablets|VC005 groups repeat administration for 4 weeks
223580364|NCT05874622|DRUG|VC005 Tablets Placebo|VC005 placebo groups repeat administration for 4 weeks
223580365|NCT04129411|DEVICE|RFA|Radiofrequency ablation of selectively targeted thyroid nodule to treat papillary thyroid cancer.
223580366|NCT03647267|DEVICE|Pneumatic Vitreolysis (C3F8 injection)|Pneumatic Vitreolysis will be performed via an intraocular injection of C3F8 gas. Perfluoropropane (C3F8) is an inert gas under pressure and is administered by injection into the vitreous cavity. It was approved by the FDA in February 1993 (P900066) for the use of placing pressure on detached retina.
223580367|NCT03647267|OTHER|Observation|No intervention; sham injection only
223580368|NCT02432352|BEHAVIORAL|Our Family Our Future|The Our Family Our Future Program is a family preventive intervention that uses resilience and prevention focused strategies to reduce sexual risk behaviors and build mental wellbeing among adolescents.
224160739|NCT01944254|PROCEDURE|Cardiac output measurement timed to instructed exhalation|Cardiac output measurement obtained by PAC TD
224160740|NCT05166551|PROCEDURE|Acupressure|"This study will be conducted in a randomized placebo-controlled research design to investigate the effect of acupressure, to be applied to the Gall Bladder (GB) 31 Fengshi acupuncture point before the vaccinations, on interventional pain in infants (0-1 years) caused by the vaccine."
224304212|NCT00667901|PROCEDURE|neoadjuvant therapy|
224304213|NCT00667901|PROCEDURE|therapeutic conventional surgery|
224304214|NCT05321225|DIAGNOSTIC_TEST|the level of biomarker in bood|Elisa is used to test the level of biomarker in blood.
223580369|NCT03659058|DRUG|silymarin|silymarin 140 three times daily
223580370|NCT03659058|DRUG|Ursodeoxycholic Acid|Ursodeoxycholic Acid 500
223580371|NCT03659058|DRUG|Antioxidants|Beta Carotene - 6Mg Vitamin C - 200Mg Vitamin E - 50Mg
223580372|NCT03659058|DRUG|Colchicine|Colchicine 0.6
223580373|NCT03659058|OTHER|FOLLOW UP|follow up by abdominal ultrasound and fibroscan every 6 month for 1 year
223580374|NCT01904656|BEHAVIORAL|"Get Behind your health"|"Participants are exposed to the Get Behind Your Health! media campaign intervention comprising 3 phases: the media campaign, the medical chart reminder, and a combination of media campaign and chart reminder. Participants also undergo telephone interviews during years 2-4."
223580375|NCT01904656|BEHAVIORAL|Peaches|"Participants are exposed to a Healthy Eating! media campaign intervention comprising 3 phases: the media campaign, the medical chart reminder, and a combination of media campaign and chart reminder. Participants also undergo telephone interviews during years 2-4."
223580376|NCT05107583|BEHAVIORAL|Low-Carbohydrate Pre-Exercise Meal|Sixty minutes of cycling at 60% VO2peak will take place on a stationary bicycle ergometer at 16:00, after having consumed a low-carbohydrate lunch meal (\<10% carbohydrate; 35% estimated energy requirements) 2.5 hours prior.
224304215|NCT04471025|PROCEDURE|USG guided infraclavicular block|USG guided infraclavicular block was applied to patients either by conventional two-person technique or by one person Jedi technique according to the allocated group. On Group I single operator controlled the probe with one hand while controlling the needle and the syringe on the other hand with the Jedi technique. The needle was held between the index finger and the middle phalanx of the middle finger, and the syringe was held with fingers 4 and 5, with the plunger part to the thumb in the palm. On Group II, operator used the probe and needle with different hands while an assistant controlling the syringe to aspirate or inject local anesthetic.
223580377|NCT05107583|BEHAVIORAL|High-Carbohydrate Pre-Exercise Meal|Sixty minutes of cycling at 60% VO2peak will take place on a stationary bicycle ergometer at 16:00, after having consumed a high-carbohydrate lunch meal (\~2.2 g/kg carbohydrate; 35% estimated energy requirements) 2.5 hours prior.
224160741|NCT05166551|PROCEDURE|Placebo Acupressure|Placebo Acupressure
224160742|NCT00235053|DRUG|fluticasone/salmeterol DISKUS 250/50|
224160743|NCT02366247|DRUG|PEG-Tα1|3.2mg/ml, once a week, taken subcutaneously
224160744|NCT02366247|DRUG|Placebo to match PEG-Tα1|1ml, once a week, taken subcutaneously
224160745|NCT02366247|DRUG|Adefovir|10 mg, once daily, taken orally for 48 weeks
223472542|NCT04990193|OTHER|TheraTog orthotic undergarment with its strapping system|TheraTog orthotic undergarment with its strapping system was applied for eight hours every day for twelve consecutive weeks.
224160746|NCT05012514|DEVICE|LLLT RED|"Participants received seven sessions of PBMT LED twice a week, the last session being about twenty minutes before the surgical procedure of bariatric surgery. The therapy was performed on the left side of the abdominal region following the linea alba of all research participants and the right side was considered as control, for application they will receive eye protection, using goggles for safety, the abdomen of the participants will be cleaned by using a neutral cleansing soap. A cluster applicator was used using the parameters described in table 1.~For therapy, the equipment Antares® was used, IBRAMED- Indústria Brasileira de Equipamentos Eletromédicos EIRELI \[EIRELI Brazilian Industry of Electromedical Equipment\], approved by Anvisa Nº 10360310037. Figure 1."
224304216|NCT03995186|BEHAVIORAL|Behavioural activation|4-week programme based on the behavioural activation treatment provided in the NHS IAPT services. The programme includes psychoeducation on the relationship between activity and depression, examining the depressed person's level of activity, helping them identify activities they would like to increase and supporting them in the planning and conduct of those activities.
223472543|NCT02843126|DRUG|Trastuzumab|Pre-dose (0 hours) on Day 1 of Cycles 1 to 8 (cycle length of 21 days)
223472544|NCT02843126|BIOLOGICAL|NK immunotherapy|For each procedure, 10 billion cells will be infused for 4 times
223472545|NCT04522219|DIAGNOSTIC_TEST|Contrast enhanced ultrasound|Acquisition of contrast enhanced ultrasound. Contrast agent: SonoVue®: Hexafluoride (SonoVue®, injectable solution to solubilisate, 8µg/mL) is injected in all patients
223472546|NCT06410651|COMBINATION_PRODUCT|Nimotuzumab with chemoradiotherapy|Radiotherapy, 40-50.4Gy/20-28f. Nimotuzumab 400mg, ivgtt, W2d. Chemotherapy, S-1, 40-60mg/m2, on BSA，orally twice daily on radiotherapy days.
223472547|NCT03724357|DRUG|Vaxchora|One dose. Approximately 100 mL of cold or room temperature purified bottled water is placed into a clean disposable cup. The contents of the buffer sachet are added to the water and stirred. Then the contents of the active (lyophilized vaccine) sachet are added to the water and stirred for approximately 30 seconds. The reconstituted mixture should be completely ingested within 15 minutes.
223472548|NCT00331838|DRUG|Semuloparin sodium|"0.8 mL solution in Type I amber glass vials~Subcutaneous injection"
223472549|NCT00331838|DRUG|Placebo (for Enoxaparin sodium)|"0.4 mL solution in ready-to-use prefilled syringe strictly identical in appearance containing the same volume but without active component~Subcutaneous injection"
223472550|NCT00331838|DRUG|Enoxaparin sodium|"0.4 mL solution in ready-to-use pre-filled syringe~Subcutaneous injection"
223472551|NCT00331838|DRUG|Placebo (for Semuloparin sodium)|"0.8 ml solution in type I amber glass vials strictly identical in appearance containing the same volume but without active component~Subcutaneous injection"
223472552|NCT00254553|DRUG|Testim 1% (testosterone gel)|Testim\_ 100 mg: two tubes of 50 mg of Testim\_per day
223472553|NCT00254553|DRUG|Placebo|two tubes of placebo per day
223472554|NCT05582278|DRUG|D-TACE|CalliSpheres (100-300 µm) loaded with pirarubicin for transarterial chemombolization: Typically, one vial of the beads was loaded with 60 mg pirarubicin. If blushed tumors is still visible after the embolization with one vial of beads, regular microspheres (8spheres) with diameters of 100-700 μm are additionally injected.
223472555|NCT05582278|DRUG|HAIC|FOLFOX-based regimen for hepatic arterial infusion chemotherapy: oxaliplatin, 100 mg/m2 infusion for 2 hours; calcium levofolinate, 200 mg/m2 infusion for 1 hours; and 5-FU, 400 mg/m2 bolus infusion and then 2400 mg/m2 continuous infusion over 46 h.
223472556|NCT05582278|DRUG|Lenvatinib|12 mg/d for bodyweight ⩾ 60 kg or 8 mg/d for bodyweight \<60 kg
223472557|NCT05582278|DRUG|tislelizumab|tislelizumab 200 mg, every 3 weeks.
223472558|NCT03237897|BEHAVIORAL|Preoperative education class|The preoperative enhanced recovery after surgery education class will be offered twice a week in coordination with anesthesia preoperative appointments to minimize inconvenience for patients. Patients will need to attend only one class. All participants will be offered the class. This class will be one hour in duration and will be taught by a surgical advanced care practitioner familiar with the details of colorectal surgery. The class will include detailed information about preoperative care, intraoperative care, and postoperative care.
223472559|NCT03237897|BEHAVIORAL|Pedometer|A pedometer will be affixed to patients in the immediate postoperative period and removed at time of discharge
223472560|NCT02456194|DEVICE|Calcium Sulfate + Antibiotics + Internal Fixation|STIMULAN Rapid Cure, mixed with antibiotic, and prepared in bead form. Must be used in conjunction with internal fixation. Choice of antibiotic is left to the surgeon's discretion.
223472561|NCT02123719|OTHER|Surgery|
223472562|NCT03260608|BEHAVIORAL|Telesupport|In the intervention will be carried out eight weekly phone calls of psychoeducation and support on the disease of the relatives approaching different themes.
223472563|NCT00742911|DRUG|Disulfiram|"Patients will take a pill of disulfiram at a fixed dose of 250 mg with their evening meal. This dose of disulfiram used to treat alcoholism. We will start by administering 2 mg of copper as copper gluconate along with 250 mg disulfiram.~Patients must not consume beverages containing alcohol while taking disulfiram."
223472564|NCT00742911|DRUG|Copper Gluconate|"Commercially available. Copper gluconate has long been manufactured and sold as a food supplement. Copper gluconate should be taken separately from disulfiram, and if possible with breakfast.~Copper gluconate should not be administered to individuals with Wilson's disease or a family history of Wilson's disease.~Patients will receive 2 mg, 4mg, 6mg or 8mg daily"
224069382|NCT00527605|DRUG|Dutasteride 0.5mg capsule|Dutasteride 0.5mg once daily orally
224069383|NCT00527605|DRUG|Dutasteride matched placebo|Dutasteride matched placebo once daily orally
224069384|NCT03697187|DRUG|rhC1INH|Recombinant human C1 inhibitor
224069385|NCT03365466|DRUG|Low dose aspirin|LDA 25mg tid
224069386|NCT03365466|DRUG|Low molecular weight heparin|LMWH 5000u IH qd
224069387|NCT03365466|DRUG|Low dose aspirin plus low molecular weight heparin|LDA 25mg tid + LMWH 5000u IH qd
224069388|NCT03365466|DRUG|no treatment|Patients who did not receive any treatment.
224069389|NCT01481311|DEVICE|medical Body Composition Analyzer seca 514/515|Current of 100 µA
224069390|NCT01481311|PROCEDURE|Deuterium and Sodium Bromide dilution methods|Orally administered to the subject in a solution with 100 ml tap water.
223472565|NCT02848664|DEVICE|Dysphagia retraining with device|Patients used the device for 60 trials of retraining swallowing at home each day and also had the device turned on throughout the day in automatic mode to intermittently trigger every few minutes to trigger a swallow for saliva control
223472566|NCT04554589|DRUG|Glycopyrrolate 0.2 MG|injections
223580378|NCT05107583|BEHAVIORAL|Fasted Exercise|Sixty minutes of cycling at 60% VO2peak will take place on a stationary bicycle ergometer at 16:00, after having skipped lunch, and having consumed nothing other than plain water since breakfast (08:00; 25% estimated energy requirements). Exercise will therefore commence after an 8 hour period of fasting.
223472567|NCT04554589|DRUG|normal saline|normal saline
223472568|NCT01368419|DRUG|Endostar|75mg Endostar in 235mL normal saline, 24h continuous infusion, 6 weeks
223472569|NCT01368419|RADIATION|Radiotherapy|6～15MV X-ray, 2Gy/time，5times/week，6 weeks
223472570|NCT03363971|DRUG|Zhi Kang Capsule|0.3g/capsule, oral, 4 capsules at a time, 3 times a day, half an hour after dinner, warm water delivery; treatment for 6 weeks.
223472571|NCT03363971|DRUG|Simulant agent for Zhi Kang Capsule|0.3g/capsule,oral, 4 capsules at a time, 3 times a day, half an hour after dinner, warm water delivery; treatment for 6 weeks.
223472572|NCT06108908|BEHAVIORAL|Reminder|1\. The reminder is constrained in caring engagement that active engagements, e.g., phone call, or other instant messages, from study nurses to patients.
223472573|NCT04830566|OTHER|Myofascial release technique|Myofascial technique on the thoracolumbar fascia and lumbar paraspinal muscles
223472574|NCT04830566|OTHER|Simulated Myofascial Release technique|Superficial hands contact on the lumbar area
223580379|NCT01350115|DRUG|LDE225|supplied as 100 mg capsules
223580380|NCT01350115|DRUG|Placebo|supplied in capsules
224163777|NCT03748420|OTHER|Adherence Intervention|The adherence enhanced intervention consists of clinical decision support related to cardiovascular risk factors enhanced with external medication adherence information and is delivered at the point of care to the healthcare provider and patient.
223472575|NCT01204671|BIOLOGICAL|Influenza vaccine GSK2321138A|One intramuscular injection
223472576|NCT01204671|BIOLOGICAL|FluarixTM|One intramuscular injection
223472577|NCT01204671|BIOLOGICAL|Influenza vaccine GSK2604409A|One intramuscular injection
223472578|NCT01035749|BIOLOGICAL|GSK Biologicals' Influenza investigational vaccine GSK2340274A|One or two doses administered intramuscularly
223472579|NCT01035749|BIOLOGICAL|GSK Biologicals' Influenza investigational vaccine GSK2340273A|Two doses intramuscularly
223472580|NCT01035749|BIOLOGICAL|Placebo (saline)|One dose intramuscularly
223472581|NCT06521970|DIAGNOSTIC_TEST|The kyphosis angle|The subject was positioned in a neutral standing position. the short side of the phone was placed on the T1-3 spinous process and the protractor was set to 0°. Subsequently, the phone was placed on the T12, and the angular value displayed on the screen was recorded as the kyphotic angle.
223472582|NCT06521970|DIAGNOSTIC_TEST|dynamic postural performance|The test measures spinal alignment deviations during static loading in the 90° shoulder flexion position. The test measurements are made in a standing position with arms 90° flexed, without weight, and after 30 seconds with weight.
223472583|NCT06521970|DIAGNOSTIC_TEST|forward head position|The individual stands with his heels and pelvis in contact with the wall. The severity of kyphosis is interpreted by measuring the distance between the occiput and the wall in cm with the head facing forward. The intensity of kyphosis is classified as mild (≤5 cm), moderate (5.1-8 cm) and severe (\>8 cm)
223580381|NCT05996042|BEHAVIORAL|Time-restricted diet|"On Tuesdays, Thursdays and Saturdays, only eating is allowed between 7am and 3pm. The rest of the time, only drinking pure water is allowed, which is an eight-hour eating window and a 16-hour fasting period.~On Mondays, Wednesdays and Fridays, under the unified guidance of the physical education teachers of the Health Science Department from 6:00 PM to 7:00 PM, the venue is the gymnasium and sports field of Peking University Health Science Center. The exercise items include aerobics, yoga and comprehensive physical training."
223580382|NCT05079477|BEHAVIORAL|Exposure to sugar-sweetened beverage warning labels|Graphic images of the amount of sugar (randomly assigned teaspoons, packets, or cubes) and text warning labels
223580383|NCT05079477|BEHAVIORAL|Exposure to calorie information|Calories for all beverages and foods
223580384|NCT03053869|DRUG|Benzodiazepine - limited use strategy|"1. No routine use of any intraoperative benzodiazepines.~2. Accepted benzodiazepine use in the case of seizure, alcohol withdrawal, or known benzodiazepine dependence.~3. Accepted benzodiazepine use in patients who are hemodynamically unstable and/or have cardiac anatomy that puts them at high risk of developing ischemia on induction of anesthesia."
223580385|NCT03053869|DRUG|Benzodiazepine - Ad libitum strategy|"1. Administration of some benzodiazepine to most patients undergoing cardiac surgery.~2. Accepted lack of benzodiazepine use in patients who have contraindications to the administration of these medications (e.g. documented allergy)."
223580386|NCT05122299|PROCEDURE|Negative control group|No intervention after extraction then delayed implant insertion at the site of extraction after three months
224163778|NCT02891252|PROCEDURE|outpatient procedure|
224163779|NCT00373880|DRUG|Aripiprazole + Cocaine|Participants received aripiprazole (15mg/day) in conjunction with a dose-response of cocaine (0, 12, 25, 50 mg).
224163780|NCT00373880|DRUG|Placebo + Cocaine|Placebo (0 mg/day) in conjunction with a dose-response of cocaine (0, 12, 25, 50 mg).
223472584|NCT03049878|DRUG|Paracetamol Codeine|preoperative administration
223472585|NCT03049878|DRUG|Placebo Oral Tablet|preoperative administration
223472586|NCT00492726|DRUG|Moxifloxacin (Avelox, BAY12-8039)|Moxifloxacin, 400mg, administered intravenously once daily
223472587|NCT00492726|DRUG|Ertapenem intravenous|Active treatment: Ertapenem 1.0g, administered intravenously once daily
223472588|NCT04386902|DEVICE|Neurosteer Aurora system|The system is composed of hardware and software modules that facilitate the capture and interpretation of electrophysiological data as well as enable viewing the processed data in real time and offline. An electrode patch is attached on the subject's forehead to capture the electrophysiological signal. The signal is sent via low energy Bluetooth to an EEG Monitor. The signal is then sent via Wi-Fi to the cloud where the data is stored on a HIPAA compliant server. Data analysis performed in the cloud transforms the electrophysiological signal into easily readable data of brain activity, which is accessible via any web interface.
223472589|NCT01896063|PROCEDURE|Electroacupuncture|
224163781|NCT00302770|DRUG|quetiapine|
223580387|NCT05122299|PROCEDURE|Postive control|Application of collagen only in the socket after extraction then delayed implant insertion at the site of extraction after three months.
223580388|NCT05122299|PROCEDURE|Study group|Application of acombination of CoQ10 and collagen hydrogel in the socket after extraction then delayed implant insertion at the site of extraction after three months.
223472590|NCT04767464|OTHER|Compass Course|The Compass Course is an 8-session group course designed to address purpose in life of those with Breast Cancer. Enrollment in this arm will involve participation in the Compass Course virtually.
223472591|NCT02404545|DEVICE|Ethicon Physiomesh|Ethicon Physiomesh will be paced at the time of radical cystectomy and ileal conduit.
223580389|NCT05657873|RADIATION|L-SABR|L-SABR will be delivered in a week during which the patient receives no chemotherapy. L-SABR can be on the same week or even day as anti-PD-(L)1 therapy.
223580390|NCT05657873|BIOLOGICAL|Anti-PD-(L)1 based immunotherapy|Standard of care treatment (anti-PD-(L)1 based immunotherapy +/- platinum based chemotherapy
223580391|NCT05657873|DRUG|Platinum based chemotherapy|Standard of care treatment (anti-PD-(L)1 based immunotherapy +/- platinum based chemotherapy
224160747|NCT06387277|OTHER|RV1551P GB3224|"RV1551P GB3224 Approximately 2 mg/cm² of product is applied to the Z1 or Z3 study areas (randomization).~From D1 to D2, a single product application is done at the study center by the subject in the presence of the clinical research technician (CRT) after epidermal ablation with an erbium YAG laser. After application, a dressing is placed on the measurement area and removed the following day at the center on D2 and D3 by the CRT before measurements.~From D3 to D18, two product applications are done with a minimum 4-hour interval:~* On visit days (D3, D5, D8, D10, D12, D15): an application is done at the study center by the subject in the presence of the CRT after measurements. A second application is done at home in the evening.~* On non-visit days (D4, D6, D7, D9, D11, D13, D14, D16, D17, D18): the subject applies 2 product applications at home (morning and evening).~Subjects receive the product at the end of visit 3 and return it at the last visit (visit 9)."
224160748|NCT00176878|PROCEDURE|Stem cell transplant|Stem cell transplant on Day 0 - healthy marrow from an unrelated individual. A minimum of 1.0 x 10\^9/kg nucleated cells/kg ideal body weight will be collected with a goal of 2.0 x 10\^9/kg.
224160749|NCT00176878|DRUG|Fludarabine monophosphate|fludarabine 175 mg/m\^2 (total) on Days -6 through -3.
224160750|NCT00176878|PROCEDURE|Total lymphoid irradiation|Dose 500 cGy radiation therapy to specific areas of the body
224160751|NCT00176878|DRUG|Busulfan|Busulfan 8 mg/kg (total) on Days - 8 and -7 (orally or through the catheter),
224160752|NCT00176878|BIOLOGICAL|anti-thymocyte globulin|anti-thymocyte globulin (ATG) 15 mg/kg on days -2 and -1 via catheter
224160753|NCT01131845|DRUG|UT-15C SR (treprostinil diethanolamine)|Single dose, 1 mg UT-15C SR
224160754|NCT04252261|DRUG|sulforaphane|To evaluate the effects of sulforaphane on the cognitive improvement of patients with frontal brain damage
223472592|NCT01661738|BIOLOGICAL|Group ACYW135 Meningococcal Polysaccharide Vaccine|360 subjects were divided into three groups (120 subjects in each group), children (2\~6 years of age), early youth (7\~15 years of age) and adult (16\~30 years of age) to receive Group ACYW135 Meningococcal Polysaccharide Vaccine, 0.5 ml, one dose regime
223472593|NCT04078971|OTHER|Western diet|Subjects in this intervention will follow a normal western diet
223472594|NCT04078971|OTHER|ketogenic diet|Subjects in this group will follow a low carbohydrate ketogenic diet
223472595|NCT06297070|BEHAVIORAL|Whole Health Lifestyle Care for Reproductive Well-being pilot program|The program consists of an individual Integrative Health and Medicine (IHM) consultation with a CWH IHM provider, 4 Shared Medical Appointments (SMA), and 4 individual Health and Wellness Coaching (HWC) sessions. The SMA sessions occur at the UH CWH Beachwood office conference and movement rooms. The HWC sessions are virtual. The consultations are either virtual or in person at UH CWH Beachwood.
223472596|NCT00952666|DEVICE|TRUS-RALRP|During surgery, and part of this research study, the ultrasound probe (TRUS) will be placed in the rectum. Then, using the mechanical support arm to hold and adjust the probe we will take ultrasound images during a portion of the robotic LRP surgery. The ultrasound probe will then be removed, and we will complete the LRP surgery as we usually do. We expect this to add approximately 20 minutes to the regular surgery time; the maximum added time will be 30 minutes.
223472597|NCT02911454|OTHER|Infant formula|
223580392|NCT06387836|DRUG|Isoflurane 0.8 MAC|Patients in this group will be anesthetized using isoflurane with the depth of 0.8\~1.0MAC during the operation.
223580393|NCT06387836|DRUG|Desflurane 0.8MAC|Patients in this group will be anesthetized using desflurane with the depth of 0.8\~1.0MAC during the operation.
223580394|NCT05828667|OTHER|Incorporation of CT and/or c-MRI derived myocardial scar with 3D electroanatomical mapping (EAM).|CT and/or c-MRI derived myocardial scar will be merged with 3D electroanatomical mapping (EAM) prior to the ablation to allow for readily localization and characterization of VT substrates and potential re-entry circuits to be ablated. This is done with the intent to limit the repeated number of inductions and prolonged point-by-point voltage mapping that often result in hemodynamic instability.
224160755|NCT04252261|DRUG|placedo|To evaluate the effects of sulforaphane on the cognitive improvement of patients with frontal brain damage
224160756|NCT01158638|BEHAVIORAL|Web Mediated Step Intervention|The testing of a web mediated step intervention designed to set weekly step targets, and channel participants through a series of motivational screens depending on compliance or non-compliance with set step goals.
224160757|NCT00004141|DRUG|Cisplatin|
224160758|NCT00004141|DRUG|dacarbazine|
224160759|NCT00004141|DRUG|Granulocyte-macrophage colony-stimulating factor|
224160760|NCT02098148|DRUG|Xenon|
224160761|NCT02098148|DRUG|Placebo|
224160762|NCT02236650|BEHAVIORAL|Primary Care Stepping Stones Triple P (PC-SS Triple P)|PC-SS Triple P is a parenting and family support strategy that aims to prevent and treat behavioral problems in children by enhancing parental resilience.
224160763|NCT02236650|OTHER|Treatment as Usual|Treatment as Usual for 4 weeks
224160764|NCT05118750|DRUG|ALTO-300 oral (PO) tablet|One tablet daily
224160765|NCT00531895|DRUG|duloxetine|duloxetine 60 mg/d
224160766|NCT01052636|OTHER|Interdisciplinary intervention program|The intervention program developed for this study included three components: geriatric consultation service, rehabilitation program, and discharge-planning service.
224163782|NCT02233608|BEHAVIORAL|Advanced Pelvic Floor Muscle Exercise (APFX)|
223472598|NCT05691101|OTHER|CISB with IV PCA group|"Ultrasonography guided interscalene brachial plexus block was done with a 5 cm block needle and catheter was inserted. (Stimuplex®A, B Braun Medical, Bethlehem, PA). 10 mL 0.375 % ropivacaine was injected through the catheter.~0.2 % ropivacaine 4 ml/hour was injected through the continuous brachial plexus block catheter. IV-PCA with fentanyl (basal flow 0 ml with patient selected bolus 14 mcg, lockout 10 minutes) was started."
223472599|NCT05691101|OTHER|CISB group|"Ultrasonography guided interscalene brachial plexus block was done with a 5 cm block needle and catheter was inserted. (Stimuplex®A, B Braun Medical, Bethlehem, PA). 10 mL 0.375 % ropivacaine was injected through the catheter.~0.2 % ropivacaine (4 ml/hour with patient selected bolus 5 ml, lockout 60 minutes) was injected through the continuous brachial plexus block catheter."
223472600|NCT01064271|DRUG|Risperidone|Risperidone Tablets 1 mg
223472601|NCT05569798|DIAGNOSTIC_TEST|Whole body point of care ultrasound scan|"The INSIGHT Scan is a whole-body PoCUS scan which comprises imaging the following windows:~1. subcostal~2. inferior vena cava cardiac view~3. left hemidiaphragm~4. bladder~5. right hemidiaphragm~6. six major central veins (left/right internal jugular/ subclavian/ femoral veins)~The scan should take no more than 10 minutes to perform. Simple yes/no questions are asked for each window to identify any significant abnormalities. For example, is the left ventricle bigger than the right ventricle; is there a pleural effusion; is the bladder distended etc.~The scan is reported in the intensive care online medical notes and reviewed by the clinical team as soon as possible."
223580395|NCT06137729|DRUG|PF-07899895|Participants will receive oral ascending doses.
223580396|NCT06137729|DRUG|Placebo|Participants will receive matching placebo.
223580397|NCT05987488|BIOLOGICAL|ShigETEC live, attenuated, oral vaccine|"Vaccine will be delivered orally.~Stage 1:~Adults (18-45 years) will intake the vaccine 3 times 14 days apart in a dose escalating setting with two different doses.~Stage 2:~Children (2-5 years), Toddlers(12-23 months), Younger children (6-11 months) will intake the vaccine 3 times 14 days apart in a dose escalating setting with three different doses."
223580398|NCT05987488|OTHER|Placebo|"Placebo will be delivered orally.~Stage 1:~Adults (18-45 years) will intake the placebo 3 times 14 days apart~Stage 2:~Children (2-5 years), Toddlers(12-23 months), Younger children (6-11 months) will intake the placebo 3 times 14 days apart."
223580399|NCT06437626|DRUG|Mexidol|50 mg/ml IV solution, 250 mg tablets
223580400|NCT06437626|DRUG|Placebo|Placebo IV solution, Placebo tablets
223580401|NCT03460548|DEVICE|Remogen|instil 1 drop of the product in each eye, 4 times per day
223580402|NCT03460548|DEVICE|Cationorm|instil 1 drop of the product in each eye, 4 times per day
223580403|NCT01820052|DRUG|Oral Iron|230 mg of elemental oral iron tablets will be administered daily for 3 months
223580404|NCT01820052|DRUG|Oral Placebo|Oral tablets matching oral iron will be administered daily for 3 months
223580405|NCT00734071|DRUG|Vortioxetine|Encapsulated vortioxetine immediate-release tablets
223580406|NCT00734071|DRUG|Placebo|Vortioxetine placebo-matching capsules
223580407|NCT00373945|DRUG|Observational Study|
223472602|NCT00308945|DRUG|travoprost 0.004% (drug)|local drop application
223580408|NCT03769987|OTHER|observation|observe patients every 6 months
223580409|NCT05648019|BIOLOGICAL|Anti-CD19 CAR T-cells|A target per-protocol dose of vi able CD19 CAR transduced T-cells will consist of a single infusion of 0.2 to 5.0 x 10e6 lentiviral-transduced viable 41BB-CD19 CAR T-cells per kg body weight.
223580410|NCT06065891|PROCEDURE|PALN resection|Resection of paraaortic lymph nodes in pancreatic cancer
223580411|NCT05714137|BEHAVIORAL|Evaluation of the Effect of Proximal Massage and Fist Clenching in Reducing the Risk of Phlebitis From Peripheral Venous Catheter|"Proximal massage: For a total of 5 to 10 minutes, twice daily for 4 days, between 30 seconds- 1 minute in sessions of approximately 20 strokes, a light massage is administered utilizing the palm surfaces of the fingers.~Fist Clenching : Under the researcher's supervision, participants in the activity known as palm fisting squeeze a soft palm ball 20 times in each of 2 days a day for four days, lasting between 30 seconds - 1 minute."
223580412|NCT01545427|DRUG|Imatinib mesylate|200 mg bid for 6 months
223580413|NCT01545427|OTHER|Placebo|Placebo coated to match appearance of Gleevec identically.
223580414|NCT00960479|DRUG|Ribavirin 200 mg Oral Capsule (Geneva Pharmaceutical, U.S.A.)|
223472603|NCT00308945|DRUG|latanoprost 0.005% (drug)|local drop application
223472604|NCT00232700|DRUG|Escitalopram|
223580415|NCT00960479|DRUG|Rebetol 200 mg Oral Capsule (Schering Corporation, U.S.A.)|
223580416|NCT03219411|DIETARY_SUPPLEMENT|Cinnamon|Cinnamon burmannii administered orally as 500-mg capsules three times a day over 12 weeks
223580417|NCT03219411|OTHER|placebo|Placebo administered orally as capsules three times a day over 12 weeks
224160767|NCT00654420|DRUG|Dalotuzumab|Dalotuzumab 20 mg/mL in sterile solution. Intravenous (IV) infusion over 60 minutes at 5 mg/kg, administered weekly at dosage according to treatment group.
223580418|NCT06587685|DRUG|PG-011Gel|Twice daily for 52 weeks or 44 weeks
223580419|NCT06587685|DRUG|Vehicle|Vehicle Gel twice daily for 8 weeks
223580420|NCT03519295|DRUG|MPDL3280A|MPDL3280A administered every 2 weeks at 800 mg for 12 months.
223580421|NCT03519295|DRUG|mDCF|8 cycles of mDCF (docetaxel 40 mg/m2 day 1, cisplatin 40 mg/m2 day 1 and 5-FU at 1200 mg/m2/day for 2 days) every 2 weeks
223580422|NCT02384434|DEVICE|THOR Laser System for Low Level Laser Therapy (LLLT)|Non-invasive, a cold laser output treatment.
223580423|NCT03301116|BEHAVIORAL|Healthy Moves for Aging Well (Healthy Moves)|A safe physical activity program which consists of a brief motivational enhancement and three movements to be performed in a seated position. The intervention will be delivered by home care aides for their clients.
224160768|NCT00654420|DRUG|Erlotinib|Open-label erlotinib administrated orally (tablets) by mouth (PO) at 150 mg daily.
224160769|NCT05122013|BEHAVIORAL|A comprehensive remote multidisciplinary intervention for weight regain after sleeve gastrectomy|A remote 3-months multidisciplinary intervention for weight regain after sleeve gastrectomy including bi-monthly remote consultations with a registered dietitian, physical activity consultant and sleep consultant, combined with weekly text messages meant to enhance happiness and subjective wellbeing.
224160770|NCT05122013|BEHAVIORAL|Control group|Standard nutritional care: One frontal meeting with the study's registered dietitian at the clinic, including nutritional and behavioral assessment and recommendations, followed by guidance to to continue follow up in order to support healthy lifestyle.
223472605|NCT06655987|OTHER|Unrestrained Femoral Internal Rotation (UFIR) manipulation|This is the primary intervention applied to the experimental group. It involves a high-velocity, low-amplitude thrust at the greater trochanter of the affected hip, intended to improve joint mobility and potentially address neuromuscular dysfunction contributing to hip pain and weakness.
223472606|NCT06655987|OTHER|Sham manipulation|This serves as the control intervention. It involves gentle hand placement over the affected hip\&#39;s external rotators for a brief duration. This is intended to mimic the physical contact of the UFIR manipulation without actually delivering the therapeutic thrust.
223580424|NCT03301116|BEHAVIORAL|Active Mind for Aging Well (Active Mind)|A word puzzle program which consists of a brief motivational enhancement and word search activities. The intervention will be delivered by home care aides for their clients.
223472607|NCT05320835|BEHAVIORAL|HIV, HCV and overdose prevention|HIV, HCV and overdose prevention
223472608|NCT02479074|DRUG|Montelukast (High FeNO group)|Montelukast 10 mg film-coated tablet contains montelukast sodium equivalent to 10 mg montelukast patients to take (oral use) one tablet per day for 28 days
223472609|NCT02479074|DRUG|Prednisolon, Montelukast (High FeNO)|Prednisolone 5 mg, patients to take 4 tablets per day for 14 days then take Montelukast 10 mg tablet per day for another 14 days.
223472610|NCT02479074|DRUG|Montelukast (Low FeNO group)|Montelukast 10 mg film-coated tablet contains montelukast sodium equivalent to 10 mg montelukast patients to take one tablet per day for 28 days
223472611|NCT02764801|DRUG|Ultrasound contrast agent (Contrast-enhanced ultrasound)|Intravenous injection of ultrasound contrast agent followed by saline flush though an angiocatheter in the arm or hand.
223472612|NCT02764801|DEVICE|Logiq E9 Scanner (Contrast-enhanced ultrasound)|Ultrasound scanning using a commercial scanner with a C1-5-D broad-spectrum convex transducer followed by a RAB2-5-D broad-spectrum real-time 4D transducer.
223472613|NCT01088633|OTHER|Exhaled particle analysis|"At visit 2, the exhaled particle analysis will be performed. Subjects will be asked to breath through the device and to perform several breathing maneuvers such as deep breathing, shallow breathing, rapid breathing, slow breathing. These measurements will be repeated after 2 hours on the same day.~Visit 3:~After a baseline exhaled particle analysis, the subjects will inhale nebulized saline (2.5 ml of a 0.9 % NaCl-solution). Aerosol generation and transport will be recorded immediately after the end of inhalation as well as 2 hours and 4 hours after the start of inhalation using the same techniques as in visit 2."
223472614|NCT00058253|DRUG|tanespimycin|Given IV
223472615|NCT00058253|DRUG|docetaxel|Given IV
223472616|NCT06458985|BEHAVIORAL|Disclosing Recovery: A Decision Aid and Toolkit|The Disclosing Recovery intervention is designed to help people in treatment for opioid use disorder (1) make key decisions regarding disclosure, including whether, why, what, how, and when to disclose, and (2) build skills to disclose, including planning what to say, practicing disclosure, and preparing for negative responses.
223472617|NCT06612814|DRUG|Fluzoparib|Parp inhibitor
223472618|NCT06612814|DRUG|Dalpiciclib|CDK4/6 inhibitor
223472619|NCT06612814|DRUG|Fulvestrant/AI|Endocrine therapy
223580425|NCT06208345|BEHAVIORAL|Life-Style app|The modules of the Life-Style app are introduced and unlocked sequentially during the first weeks of the intervention phase. Afterwards the modules are fully available. Duration and frequency of app-use is not limited. The parents are accompanied by a coach through the app, who gives regular structured feedback and individual inputs. The coach has access to all data collected in the app.
223580426|NCT03348995|DEVICE|Bridge-Enhanced ACL Restoration (BEAR)|In the BEAR Procedure, surgery is performed to sew the ACL back together and a scaffold is placed between the torn ends at the time of repair.
223580427|NCT06360341|BEHAVIORAL|Emergency Department Digital Pain Self-Management Intervention (EDPSI)|The EDPSI is a developed supplemental digital video for patients presenting to the emergency department with acute low back pain (aLBP). The content consists of self-management approaches for diverse adult patient preferences including biopsychosocial contributors to pain and clinical practice guidelines to self-management options. Highlights of the discharge instructions summary include follow-up with provider, red flag warnings, and medication safety. Actor demonstration of ergonomics and range of motion movements provide application of Physical Therapy (PT)-based preventative strategies. Combination therapies including PT counseling, complementary alternative medicine (acupuncture, massage, yoga, or Pilates), and use of and safety with ice or heat thermal therapies. Active participation, stress management, and involvement of support systems are addressed.
223580428|NCT06360341|OTHER|Routine Discharge Care|Routine Discharge Care
224160771|NCT03849014|PROCEDURE|Dynamic Hip Screw|Dynamic Hip Screw fixation: Fracture will be reduced under image intensifier. The incision will be made 7-10 cm with a lateral approach. The fascia lata will be incised and the vastus lateralis muscle will be splited along the axis of the femur, without stripping the periosteum. A135° angle guide will be inserted in the lower half of the femoral neck. The barrel of the plate will be guided to the hip screw by direct palpation to minimize the soft-tissue injury. After the insertion of the cortical screw, soft tissue will be protected with 4.5mm drill sleeve during drilling and tapping.
223472620|NCT05499091|PROCEDURE|Skin biopsy, blood sample, urine sample|blood samples, urine samples, skin samples.
223472621|NCT07048236|DIAGNOSTIC_TEST|Specimen and clinical data collection|Check total bilirubin, urinary heavy metals,CRP, serum tumor marker, pulmonary function test,Questionnaire
223472622|NCT00054496|DRUG|erlotinib hydrochloride|
223472623|NCT06378177|BIOLOGICAL|LVGN6051 Monoclonal Antibody Injection|LVGN6051 Monoclonal Antibody Injection:1 mg/kg or 2 mg/kg, every 3 weeks(Q3W) , on the first day of the treatment cycle for up to 2 years.
223472624|NCT06378177|BIOLOGICAL|toripalimab Injection|toripalimab Injection: 240mg fixed dose,Q3W, on the first day of the treatment cycle for up to 2 years.
223472625|NCT06378177|DRUG|Paclitaxel injection|paclitaxel Injection:5ml:100 mg/m2(80 mg/m2 or 60 mg/m2 can be used if necessary),Q3W,on the first and eighth day of the treatment cycle for up to 2 years
223472626|NCT05571813|DRUG|CKD-341|A single dose of 1tablets under fasting condition
223472627|NCT04818775|DEVICE|HemaClear|HemaClear Model A
224163783|NCT01561040|DIETARY_SUPPLEMENT|Omega 3, Vitamins A, D3 and E|omega 3 1480 mg vitamin A 1,000 IU vitamin D3 2,000 IU vitamin E 60 IU
224304217|NCT03995186|BEHAVIORAL|Activity monitoring|4-week programme where participants simply monitor their general daily activities in a diary.
223472628|NCT04818775|DEVICE|Pneumatic Tourniquet|Pneumatic Tourniquet
223472629|NCT03710954|DIAGNOSTIC_TEST|Experimental Group|All volunteers were evaluated by numerical pain scale and Fuzzy scale. This procedure was performed to compare the efficacy of the Fuzzy Scale demonstrating greater accuracy of quantification of skeletal muscle pain
223580429|NCT06416722|OTHER|Cognitive-Motor Dual Task Activities|Patients included in this group will be given additional cognitive tasks (e.g. counting months, subtracting 5 from 100) in accordance with the physiotherapist's commands simultaneously with balance and large amplitude functional activities (such as stepping forward-sideways-backwards, sitting and standing).
223580430|NCT06416722|OTHER|Motor-Motor Dual Task Activities|Patients included in this group will be given additional motor tasks (e.g. passing the ball from the right hand to the left hand while standing on a soft surface, clapping) in accordance with the physiotherapist's commands simultaneously with balance and large amplitude functional activities (such as stepping forward-sideways-backwards, sitting and standing).
223580431|NCT06416722|OTHER|Cognitive-Motor & Motor-Motor Dual Task Activities|Simultaneously with balance and large amplitude functional activities (such as stepping forwards-sideways-backwards, sitting and standing), patients included in this group will be given additional cognitive (e.g. counting while standing with feet closed) and motor (e.g. passing the ball from the right hand to the left hand while standing on a soft surface) tasks in accordance with the physiotherapist's commands.
223580432|NCT05432388|DRUG|remibrutinib|oral tablets
224163784|NCT04722380|PROCEDURE|periodontal regenerative surgery|Procedure/Surgery: open flap debridement Open flap for removal of diseased periodontal tissues and necrotic cementum , using xenogenic bone graft with or without Nigella Sativa oil extract
223472630|NCT01965873|DIETARY_SUPPLEMENT|Enteral nutrition|Same as arm description
223472631|NCT04947891|PROCEDURE|Intensive recovery management|Intensive recovery management includes 3 parts: (1) Preoperative analgesia and airway evaluation. (2) The protection and reconstruction of the musculo-ligamentous complex during the surgery, the safe intubation, and the local infiltration anesthesia during surgery. (3) Collar free, multimodal analgesia, airway management, and early recovery after surgery.
223472632|NCT01712516|DRUG|QVA149|QVA149 was supplied in a capsule form in blister packs for use in the Novartis Concept1 SDDPI
223472633|NCT01712516|DRUG|QAB149|QAB149 was supplied in capsule form in blister packs for use in the Novartis Concept1 SDDPI.
223472634|NCT01712516|DRUG|NVA237|NVA237 was supplied in capsule form in blister packs for use in the Novartis Concept1 SDDPI.
223472635|NCT01712516|DRUG|Placebo|Placebo was supplied in capsule form in blister packs for use in the Novartis Concept1 SDDPI.
223472636|NCT00968487|BIOLOGICAL|Lyophilized Plasma|Lyophilized Plasma is serves as a source of plasma proteins for subjects who are deficient in plasma proteins. The donor and recipient are the same person, therefore the process is autologous. HemCon's lyophilized plasma originates from FFP from screened individual donors to significantly reduce the risk of bloodborne disease transmission and undesired transfusion-associated reactions. Each single-donor unit is tested (per required of the blood supply) to reduce the risk of transmission of infectious agents and hence, maximize subject safety.
223472637|NCT00968487|OTHER|Fresh Frozen Plasma|The fluid portion of one unit of human blood that has been centrifuged, separated, and frozen solid at -18 °C (-0.4 °F) (or colder) within 6 hours of collection.
223472638|NCT01181167|DRUG|edoxaban|
223472639|NCT01181167|DRUG|enoxaparin sodium|
223472640|NCT00161213|DRUG|gemcitabine hydrochloride|
223472641|NCT00161213|DRUG|imatinib mesylate|
223472642|NCT03042845|DEVICE|Tiger cardiac catheter|Tiger cardiac catheter
223472643|NCT03042845|DEVICE|Judkins 3.5L/4R cardiac catheters|Judkins 3.5L/4R cardiac catheters
223472644|NCT02433769|DEVICE|TOFscan|"Data from the TOFscan will be compared to simultaneously measured data from the TOF-Watch-SX (gold standard)"
223472645|NCT02433769|DEVICE|TOF-Watch-SX|Data from the TOF-Watch-SX will be compared to simultaneously measured data from the TOFscan
223472646|NCT01042795|DRUG|Sunitinib|Sunitinib 37.5 mg daily X 16 weeks
223472647|NCT02402400|DRUG|Sub Lingual Ticagrelor|180mg sub-lingual ticagrelor
223472648|NCT03107429|DRUG|Acetazolamide|Acetazolamide tablets were placed in capsules to make them look similar to placebo.
223472649|NCT03107429|DRUG|Placebo|Placebo was a sugar based placebo placed in a capsule.
223472650|NCT03107429|OTHER|Trendelenburg Position|Placed in Trendelenburg Position
223472651|NCT03456661|DRUG|Levobupivacaine|Infiltration with 0.25% 29,5ml + 0,5ml physiologic serum (total volume 30ml), US guided, using pectoralis block technique.
223472652|NCT03456661|DRUG|Levobupivacaine + Dexmedetomidine|Infiltration with chirocaine 0.25% 29,5ml + 0,5ml dexmedetomidine (50µg) (total volume 30ml), US guided, using pectoralis block technique.
223472653|NCT04322136|PROCEDURE|Pleurodesis via Video-assisted thoracoscopic surgery|Video-assisted thoracoscopic surgery is a type of key-hole surgery performed under general anaesthetic and usually single lung ventilation by a cardio-thoracic surgeon. This is expected to take about 1 hour. Between one and three ports are used to insert a camera and instruments into the chest cavity. Adhesions can be broken down if present and the lining of the lung (visceral pleura) can sometimes be removed (decortication) to facilitate lung re-expansion. The surgeon can then perform either mechanical abrasion or talc poudrage to induce inflammation and subsequent pleurodesis. A chest drain is left in situ post-operatively and is removed when the fluid draining is below a certain volume depending on local practice.
223580433|NCT05432388|DRUG|placebo|oral tablets
223580434|NCT04715646|DRUG|Brivaracetam|"Brivaracetam (BRV) tablets or oral solution will be administered twice daily (bid) in 2 equally divided doses.~Tablet strengths: 10 mg, 25 mg, 50 mg Route of administration: oral~Oral solution Concentration: 10 mg/ml Route of administration: oral"
223580435|NCT06030180|DEVICE|EsoGuard|EsoGuard is a set of genetic assays and algorithms for the assessment of specific methylation patterns of DNA encoding the genes vimentin (VIM) and cyclin A1 (CCNA1)
223580436|NCT06481566|RADIATION|stereotactic ablative body radiotherapy|The residual primary lung lesions after first-line Almonertinib will be delivered stereotactic ablative body radiotherapy.
223580437|NCT06059716|BEHAVIORAL|Gluten detection technology|Portable technology to sense gluten after ingestion
223580438|NCT06059716|BEHAVIORAL|Continuous telemedicine monitoring|Regular follow-up with an expert dietitian
223580439|NCT05306288|OTHER|Blood Sample Collection|Subjects enrolled in DELFI-L201 will have blood specimens collected (\~30 mL) at enrollment or up to 30 days after enrollment.
223472654|NCT04322136|DEVICE|Indwelling pleural catheter (with talc pleurodesis if suitable)|Once the indwelling pleural catheter is inserted, the pleural fluid will be evacuated as completely as possible. If the lung fully re-expands, 4-5g of sterile graded talc will be instilled via the IPC. The participant will then be discharged on a daily drainage regimen for 14 days. At review in clinic on day 14, the participant will be assessed for spontaneous pleurodesis (\<50ml drainage on 3 consecutive drainage attempts). If pleurodesis has occurred and there is no residual symptomatic effusion, arrangements will be made for IPC removal. Otherwise the participant will switch to a symptom-guided drainage regimen. If the lung does not fully re-expand following complete fluid evacuation, they will be discharged on a symptom-guided regimen without instillation of talc. The drainage regimen will continue for the duration of the study and beyond if pleurodesis has not occurred and pleural fluid continues to accumulate.
223472655|NCT05184855|DIETARY_SUPPLEMENT|Blueberry|Blueberry powder intake
223472656|NCT05184855|DIETARY_SUPPLEMENT|Placebo|Placebo powder intake
224160772|NCT03849014|PROCEDURE|Proximal Femoral Nail|Proximal Femoral Nail fixation: Fracture will be reduced under image intensifier. The incision 2-3 cm with a lateral approach that extended from the cranial part to the tip of the greater trochanter. After palpating the greater trochanter tip, the nail will be then introduced manually into the femoral shaft. The guide wire of the anti-rotational hip blade then introduced. The hip blade should be introduced in the direction of the lower half of the femoral neck. Drilling will be performed under soft-tissue protection with a retractor. The blade will be inserted, and a distal static locking screw and end cap will be inserted under soft tissue protection with a drill sleeve.
224304218|NCT04689919|DRUG|Rivaroxaban 20 MG Oral Tablet|The subjects randomly received single oral dose of Rivaroxaban 20 MG Tablet.
223472657|NCT03053739|DRUG|Sildenafil 20mg and Bosentan 62.5mg|Sildenafil 20 mg three times a day and bosentan 62.5mg two times a day
223472658|NCT03053739|DRUG|Sildenafil 20mg and Placebo|Sildenafil 20 mg three times a day and placebo (matched for bosentan)two times a day
223472659|NCT05440032|DIAGNOSTIC_TEST|Semi-quantitative electrochemical leukocyte esterse test strip|Electrochemical assay to detect level of leukocyte esterase in sample
223472660|NCT05440032|DIAGNOSTIC_TEST|Roche Chemstrip|Urinalysis chemstrip
223472661|NCT02678117|DRUG|Pregabalin & Placebo|
223472662|NCT02678117|DRUG|Magnesium sulphate & Placebo|
223472663|NCT02678117|DRUG|Pregabalin & Magnesium sulphate|
223472664|NCT02678117|DRUG|Placebo|
223472665|NCT00374634|DRUG|rFSH drug dose|"Individual rFSH dose (50, 75 or 100 IU rFSH/day)"
223472666|NCT00374634|DRUG|"Standard rFSH dose"|"Standard rFSH dose was 75 IU/day"
223472667|NCT04946812|OTHER|Split-belt treadmill training|18 sessions of SB-TM training, where the velocity of the belt will be adjusted to the over-ground speed of the subject, and will be reduced on the least affected side by 25%.
223472668|NCT02683109|DRUG|FDC of tiotropium + olodaterol|Fixed Dose Combination of tiotropium + olodaterol
223472669|NCT02683109|DRUG|Placebo|
223472670|NCT02683109|DRUG|Tiotropium|
223472671|NCT02683109|DRUG|Olodaterol|
223472672|NCT02417025|BEHAVIORAL|PE|Prolonged Exposure
223472673|NCT00798005|DRUG|XRP0038 (NV1FGF)|
223472674|NCT01099644|BIOLOGICAL|131 I-8H9|Patients will be administered therapeutic dose of IP 131I-8H9 per the dose escalation regimen. 131I-8H9 pharmacokinetics will be studied by serial blood draws from indwelling venous lines. 131I-8H9 biodistribution will be studied by a single gamma camera scan about 5 days after IP injection where feasible.
223472675|NCT00539396|DRUG|Technosphere Insulin|
223472676|NCT01762488|PROCEDURE|Ablation of the renal arteries|Catheter-based renal denervation by applying low power radiofrequency to the renal artery using the EnligHTN Catheter, introduced by femoral artery access.
223472677|NCT01762488|PROCEDURE|Renal angiography|Renal angiography by femoral access
223472678|NCT04137198|DRUG|Sufentanil|intranasal administration of Sufentanil Forte 0,5mcg/kg as first dose and 0,3mcg/kg as titration doses
223472679|NCT00546403|DRUG|Modafinil|Adjunctive treatment with titrated dose of modafinil
224071658|NCT07143149|DEVICE|the Intelligent Lipid Management Decision-support System|Doctor's Side: Long-term lipid management support based on guidelines/consensus• Provides lipid management pathways based on guidelines/consensus to ensure clinical decisions align with the latest standards.• Combines individualized patient data to offer intelligent lipid management and medication suggestions.• Provides medical education support to enhance doctors' awareness of guidelines, consensus, and management strategies.Patient's Side: Personalized lipid risk assessment and regular reminders• Based on the lipid test reports uploaded by patients via photos, provides lipid test reports tailored to the patient's risk stratification.• Uses digital tools to regularly remind patients, optimizing follow-up adherence and medication compliance.
224160773|NCT04246489|DRUG|Bintrafusp alfa|Participants received an intravenous infusion of 1200 milligrams (mg) bintrafusp alfa once every 2 weeks until confirmed disease progression, death, unacceptable toxicity and study withdrawal.
223472680|NCT00546403|DRUG|Placebo|Adjunctive treatment with placebo
223472681|NCT00553774|DIETARY_SUPPLEMENT|Cocoa Flavanols|Cocoa Flavanols (BD for 21 - 28 days)
223472682|NCT00553774|OTHER|Placebo|Placebo (BD 21 - 28 Days)
223472683|NCT04626323|PROCEDURE|Roux-en-Y gastric bypass|"1. Pneumoperitoneum closed with Veress needle~2. Identification of Treitz angle~3. Measurement of biliary loop (50 cm)~4. Bowel transection with linear stapler (white load)~5. Measurement of the alimentary limb (100 cm)~6. Laterolateral Entero-anastomoses (white load)~7. Construction of gastric pouch distant about 3 cm from the esophageal-gastric junction with stomach section in the small curvature.~8. Linear cutting anastomosis (gastrojejunostomy) from about 1 to 1.2 cm~9. Anastomosis integrity evaluation by methylene blue test and/or perioperative air.~Expected surgical time: 60 minutes"
223472684|NCT04626323|DRUG|Best medical treatment|Patients will also receive standard of care medical therapy for DKD (ACEI or ARB + SGLT2i) and T2DM (metformin, glitazones, incretin therapy - DPP4 inhibitor and GLP-1 analogs - and insulin, if necessary).
223472685|NCT05314309|DIAGNOSTIC_TEST|Comparison of two tests (FIT and mtFIT) in the same bowel movement|Invitees for the Dutch National CRC screening program will be randomly selected by the Screening Organization and invited to participate in this study, where next to the current FIT, participants will also perform the mtFIT in one bowel movement. Both tests will be analysed and if one of the two test results is positive, the individual will be referred for colonoscopy.
224160774|NCT03352869|DRUG|Exenatide|Use Exenatide for 3 months to treat PCOS
223472686|NCT00183430|DRUG|Prazosin|Prazosin capsules 1 to 25 mg are taken orally twice per day in divided doses at 10 am and bedtime.
224160775|NCT03352869|DRUG|Metformin|Use Metformin for 3 months to treat PCOS
224160776|NCT02826876|DRUG|Topical use|Topical use of Ropivacaine in laparoscopic surgery
223580440|NCT04687033|DEVICE|Transcranial direct current stimulation|This instrument will be used to induce post-stroke motor recovery, two different monocephalic montages are typically used to restore excitability in the lesioned hemisphere and to down-regulate excitability of the non-lesioned hemisphere and rebalance Interhemispheric inhibition. each participant will undergo a 20-minute period of tDCS, applied at 2 mA through a pair of saline-soaked surface sponge electrodes (35 cm2).
223580441|NCT06546072|OTHER|MRI|
223580442|NCT04341688|DRUG|Gargle/Mouthwash|"There will be 50 patients in six study groups. Group A (n=10) patients on 10 ml gargle and nasal lavage using 0.2% Povidone-Iodine (Betadiene®) for 20-30 seconds, thrice daily for 6 days.~Group B (n=10) patients will be subjected to 10 ml gargle and nasal lavage using 1% Hydrogen peroxide (ActiveOxy®) for 20-30 seconds, thrice daily for 6 days.~Group C will comprised of (n=10) subjects on 10ml gargle and nasal lavage using Neem extract solution (Azardirachta indica) formulated locally) for 20-30 seconds, thrice daily for 6 days.~Group D (n=10) patients will use 2% hypertonic saline (Plabottle®) gargle and nasal lavage for a similar time period.~Group E (n=10) will serve as positive controls. These will be given simple distilled water gargles and nasal lavage for 20-30 seconds, thrice daily for six days Whereas Group F (n=5) will comprise of negative controls, who will not use any gargles or nasal lavage during study period."
223472687|NCT00183430|DRUG|Placebo|Placebo capsules are taken orally twice per day at 10 am and bedtime.
223472688|NCT00183430|BEHAVIORAL|Psychotherapy|All participants will undergo psychotherapy during medication treatment period.
223580443|NCT01918514|DRUG|Adding Magnesium Sulfate to the standard epidural and interscalene blocks for chronic pain|
224160777|NCT02826876|OTHER|laparoscopic repair of inguinal hernia|intra-operative treatment with ropivacaine Vs placebo in laparoscopic repair of inguinal hernia
224160778|NCT02826876|OTHER|laparoscopic bariatric surgery|intra-operative treatment with ropivacaine Vs placebo in laparoscopic bariatric surgery
224160779|NCT04477525|PROCEDURE|Ultrasound Guided Erector Spinae Plane (ESP) Nerve Block|The planned intervention is a bilateral erector spinae nerve block for patients undergoing bariatric surgery. This intervention will be performed in the PACU for patients with an NRS pain score \>5. All eligible candidates who have consented for this study will be present in the PACU, have all standard ASA monitoring placed. The patient will then be placed in a sitting position. The patient will then be prepped with chlorhexidine in the thoracic region and draped in a sterile fashion. The ultrasound will be brought in over the patient and the T7 Transverse Processes (TP) will be identified. An echogenic needle will be placed under direct ultrasound guidance on the TP. Then, 20 cc of 0.25% bupivacaine will be injected.
224160780|NCT04477525|DRUG|Bupivacaine Injection|20 cc of 0.25% bupivacaine will be injected
224160781|NCT02299804|DRUG|Levophencynonate Hydrochloric|this drug is M receptor inhibitor
223472689|NCT05088265|DEVICE|Bigfoot Unity Diabetes Management System|The Bigfoot Unity System is a wirelessly connected set of hardware and software that is intended for use by people with diabetes mellitus who use disposable insulin pens for self-injection of insulin. Bigfoot Unity consists of the Abbott FreeStyle Libre 2 Sensor, two durable insulin pen caps (one each for specific rapid-acting and long-acting insulin pens) and an iOS-specific mobile App.
223472690|NCT04625036|DIAGNOSTIC_TEST|Single passive leg movement|"The investigation consists of a non-invasive evaluation by ultrasounds performed on the common femoral artery investigating the speed of arterial blood flow \[Leg Blood Flow LBF\] and diameter of vessel with a dedicated ultrasound system (General Electric Medical Systems, Milwaukee, WI) using Doppler method, before and after a passive flexion-extension movement of the knee. A linear probe will be used with a frequency of 5 MHz. Using the diameter of the artery and the average volume (Vmean), the LBF will be calculated every second with the formula=Average volume\*PiGreco\*(vessel diameter / 2)2\*60.~The subject will be placed in a sitting position for 20 minutes before the test. The protocol consists of image acquisition for 60 seconds (basal measurement), followed by a passive flexion-extension of the knee (single passive leg movement). The knee flexion will be performed by health care personnel at a rate of 1 Hz. At the end of the movement, the recording will continue for 60 seconds."
223472691|NCT02124824|DRUG|BQ-123|Endothelin subtype A antagonist
223580444|NCT03755583|DIETARY_SUPPLEMENT|Exclusive Enteral Nutrition|a complete liquid diet of formula for 8 weeks were adminstered in Crohn's Diseas patients ,Nutritional intake was based on the child's estimated energy requirements, no regular table food during 8 weeks treament.
223580445|NCT00478790|DEVICE|ologen™ Collagen matrix implantation in glaucoma filtering surgery|ologen™ treatment is used, the collagen matrix will be placed on top of the scleral flap under the conjunctiva after the trabeculectomy.
223580446|NCT05485142|PROCEDURE|prolotherapy|5% glucose 10ml local injection peripheral to posterior tibial nerve near ankle under ultrasound guidance once a week for 4 weeks.
223580447|NCT04831099|DRUG|Testosterone gel|The route of administration is transdermal.
223580448|NCT04831099|DRUG|Placebo|The route of administration is transdermal
223580449|NCT02743455|DRUG|ISA-720|The vaccine adjuvant ISA 720 will be used with Modified Vaccinia Ankara-Bavarian Nordic-Yellow Fever (MVA-BN-YF) as vaccine adjuvant with a depot effect. This comprises slow release of antigen at the injection site, protection of antigen against degradation and strong stimulation of the immune response.
223580450|NCT02743455|BIOLOGICAL|MVA Smallpox Vaccine|Modified Vaccinia Ankara-Bavarian Nordic Smallpox Vaccine (MVA BN(R)) is a purified live vaccine will be used as an active comparator.
224160782|NCT02299804|DRUG|Placebo|No active ingredient
224160783|NCT04776889|DRUG|Rosuvastatin 20mg|Rosuvastatin 20mg/day for 6 months added to bilateral subcapsular orchiectomy
224160784|NCT04776889|PROCEDURE|surgical castration|bilateral subcapsular orchiectomy
224160785|NCT01951872|BEHAVIORAL|Manual-based treatment for caffeine dependence|Participants will meet with a counselor to discuss plans for caffeine reduction or cessation, and they will receive a manual-based treatment to help guide them through caffeine reduction or cessation.
224160786|NCT00783549|DRUG|an undetermined dose of GSK1292263|GSK investigational product or placebo
224160787|NCT00783549|DRUG|ascending dose of GSK1292263|Ascending dose based on target exposures or placebo
224160788|NCT00783549|DRUG|ascending dose of GSK1292263|An ascending dose based on target exposure
223472692|NCT06134635|DRUG|Statins|Atorvastatin 20mg qn or rosuvastatin 10mg qn or pivastatin 2mg qn, oral
223472693|NCT06134635|DRUG|Evolocumab|Evolocumab 140mg twice a month, subcutaneous injection
223472694|NCT05981924|OTHER|Perioperative Music Therapy|Music therapist will play customized music in the perioperative period on the basis of oxycodone analgesia
223472695|NCT03485625|DRUG|Lidocaine|Two cannulae were placed, one in a vein on the dorsum of the operative hand and the other on the non operative hand for i.v fluids. The operative arm was elevated for 2 min and was then exsanguinated with an elastic bandage. A pneumatic tourniquet was then placed around the upper arm, and the cuff was inflated to 100 mm Hg above systolic BP. Circulatory isolation of the arm was verified by inspection, absence of a radial pulse, and a loss of the pulse oximetry tracing in the ipsilateral index fingers The solutions were prepared by an anesthesiology assistant not involved in any part of the study. The solutions were injected over 90 s by an anaesthesiologist.
223472696|NCT03485625|DRUG|Ketorolac|Two cannulae were placed, one in a vein on the dorsum of the operative hand and the other on the non operative hand for i.v fluids. The operative arm was elevated for 2 min and was then exsanguinated with an elastic bandage. A pneumatic tourniquet was then placed around the upper arm, and the cuff was inflated to 100 mm Hg above systolic BP. Circulatory isolation of the arm was verified by inspection, absence of a radial pulse, and a loss of the pulse oximetry tracing in the ipsilateral index fingers The solutions were prepared by an anesthesiology assistant not involved in any part of the study. The solutions were injected over 90 s by an anaesthesiologist.
223472697|NCT03485625|DRUG|paracetamol|Two cannulae were placed, one in a vein on the dorsum of the operative hand and the other on the non operative hand for i.v fluids. The operative arm was elevated for 2 min and was then exsanguinated with an elastic bandage. A pneumatic tourniquet was then placed around the upper arm, and the cuff was inflated to 100 mm Hg above systolic BP. Circulatory isolation of the arm was verified by inspection, absence of a radial pulse, and a loss of the pulse oximetry tracing in the ipsilateral index fingers The solutions were prepared by an anesthesiology assistant not involved in any part of the study. The solutions were injected over 90 s by an anaesthesiologist.
223472698|NCT05388799|OTHER|Educational intervention|In addition to standard care, brochure-supported education will be given to patients who are scheduled for nose surgery.
223580451|NCT02743455|BIOLOGICAL|MVA-BN Yellow Fever Vaccine|Modified Vaccinia Ankara-Bavarian Nordic-Yellow Fever (MVA-BN-YF) clinical trial material is manufactured in CEF cells derived from Specific Pathogen Free (SPF) eggs in a bioreactor culture using serum free medium.
223580452|NCT02743455|OTHER|Placebo|0.9% Sodium Chloride Injection, USP is a sterile, nonpyrogenic, isotonic solution of sodium chloride and water for injection.
223472699|NCT05170113|DIETARY_SUPPLEMENT|Alpinia galanga formulation|Alpinia galanga formulation capsule- 1 capsule daily
223472700|NCT05170113|DIETARY_SUPPLEMENT|Theacrine formulation|Theacrine formulation capsule- 1 capsule daily
223472701|NCT05170113|DIETARY_SUPPLEMENT|Caffeine formulation|Caffeine formulation capsule- I capsule daily
223472702|NCT05170113|DIETARY_SUPPLEMENT|Placebo|Placebo capsule- 1 capsule daily
223472703|NCT00618501|DRUG|cytarabine|
223472704|NCT00618501|DRUG|daunorubicin hydrochloride|
223472705|NCT00618501|DRUG|etoposide|
223472706|NCT00618501|DRUG|imatinib mesylate|
223472707|NCT00618501|DRUG|leucovorin calcium|
223472708|NCT00618501|DRUG|methotrexate|
223472709|NCT00618501|DRUG|prednisolone|
223472710|NCT00618501|DRUG|therapeutic hydrocortisone|
223472711|NCT00618501|DRUG|vincristine sulfate|
223472712|NCT00618501|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
223472713|NCT00450957|DIETARY_SUPPLEMENT|lycopene|Given orally
223472714|NCT00450957|OTHER|pharmacological study|Correlative studies
223580453|NCT02743455|OTHER|Placebo|0.9% Sodium Chloride Injection, USP is a sterile, nonpyrogenic, isotonic solution of sodium chloride and water for injection.
223580454|NCT02743455|BIOLOGICAL|YF Vax 17D Strain|Yellow Fever Vaccine (YF-VAX) is a vaccine prepared by culturing the 17D-204 strain of yellow fever virus in living avian leucosis virus-free (ALV-free) chicken embryos. Will be used as an active comparator.
223580455|NCT05264116|DEVICE|STRYKER SUSTAINABILITY SOLUTIONS PULSE OXIMETERS|Reprocessed noninvasive pulse oximeter sensors.
223580456|NCT02772588|DRUG|ARN-509|
223580457|NCT02772588|DRUG|Abiraterone|
223580458|NCT02772588|DRUG|Leuprolide|
223580459|NCT02772588|RADIATION|stereotactic, ultra-fractionated radiotherapy|
223580460|NCT04603001|DRUG|LY3410738|Oral LY3410738
223472715|NCT01058447|DRUG|AZD1981|Oral tablet, 250 mg, single dose
223472716|NCT02433847|DRUG|Mosapride|
223472717|NCT03933163|DRUG|Resveratrol|Drug name: Micronised resveratrol. Dosage form: 500mg capsules. Alternate name: 1,3-Benzenediol, 5-\[2-(4-hydroxyphenyl)ethenyl\]-, (E). Ingredients: 99.50% pure trans-resveratrol. Placebo capsules will be identical in terms of taste, smell, and appearance.
223472718|NCT00158353|BEHAVIORAL|GirlPOWER! mentoring program|GirlPOWER! mentoring program includes monthly 3-hour workshops for youth and mentors combined with monthly supplemental activities to be completed independently by youth-mentor pairs.
223472719|NCT00158353|BEHAVIORAL|Traditional mentoring|Traditional mentoring includes a community-based mentoring program, in which the youth-mentor spends time together in activities of their choosing 2 to 4 times a month.
223580461|NCT04603001|DRUG|Venetoclax|Oral venetoclax
223580462|NCT04603001|DRUG|Azacitidine|Subcutaneous or intravenous azacitidine
223580463|NCT03357874|DRUG|Clopidogrel|600 mg loading dose of clopidogrel as pretreatment followed by 75 mg daily for 12 months (52 weeks).
223580464|NCT03357874|DRUG|Ticagrelor|patients will receive a 180 mg loading dose as pretreatment of PCI followed by 90 mg bi-daily for 12 months (52 weeks).
223580465|NCT02808910|BEHAVIORAL|Nudged to eat less added salt and more other seasonings|
223580466|NCT02808910|BEHAVIORAL|Nudged to avoid foods high in salt content, and to choose foods low in salt content|
223580467|NCT02808910|BEHAVIORAL|Nudged to eat more vegetables|
223580468|NCT02808910|BEHAVIORAL|Nudged to eat smaller portions|
223580469|NCT02808910|BEHAVIORAL|Nudged to eat less calorie-dense food|
223580470|NCT02220426|DRUG|Xenon|Inhalation of hyperpolarized xenon gas
224160789|NCT00783549|DRUG|ascending dose of GSK1292263|An ascending dose based on target exposures.
223472720|NCT03318263|DIAGNOSTIC_TEST|next-generation sequencing (NGS)|ESR1, PI3KCA and AKT extensive exon sequencing will be performed using NGS (Miseq Illumina) at the Biopathology department, Institut de Cancérologie de Lorraine (ISO15189 certified lab). Samples taken at baseline (t0), at progression (tp) and 3 months before progression (tp-3) will be systematically analyzed. The intermediate samples will be stored and kept for additional studies. Follow up assessment will be performed according to prescriber's directions.
223472721|NCT05353088|OTHER|scapular stabilization|Scapular stabilization exercise aims to restore scapular position, orientations, motor control of muscles, and movement pattern, thereby attaining stability of scapula for better kinematics of shoulder.scapular stabilization exercises for 4 weeks with 2 sets of 10 repetitions. These exercises comprised of four exercise programs (Scapular retraction; Scapular mobilization, Scapular dynamic stabilization I and Scapular dynamic stabilization II)
223580471|NCT06034652|DEVICE|Integra® Gentrix® Surgical Matrix|Integra® Gentrix® Surgical Matrix is intended for implantation to reinforce soft tissue where weakness exists in patients requiring gastroenterological or plastic \& reconstructive surgery.
223580472|NCT05627219|BEHAVIORAL|Training and Education|Undergo training and education
223580473|NCT05627219|OTHER|Educational Intervention|Receive educational booklet
223580474|NCT05627219|PROCEDURE|Discussion|Attend discussion with peer genetic coach
223580475|NCT06196125|OTHER|Four body positions|Physiological characteristics such as ventilation distribution and lung aeration patterns recorded by the electrical impedance tomography signals and ultrasound imaging will be measured when patients are in a initial supine position, then turned into a lateral positioning on each side then back in supine positioning.
224160790|NCT00783549|DRUG|ascending dose of GSK1292263|An ascending dose based on target exposure
224160791|NCT05955872|DRUG|VX-147|Tablets for oral administration.
224160792|NCT00813267|BIOLOGICAL|mesenchymal stem cell infusion|
224160793|NCT00813267|BIOLOGICAL|bone marrow mononuclear cell infusion|
224160794|NCT06434025|DRUG|Iron Carboxymaltose|Iron Carboxymaltose 500 mg. 2 vials administered IV.
224160795|NCT06434025|DRUG|Dapagliflozin 10mg Tab|Dapagliflozin 10mg Tab, PO, onde a day.
224160796|NCT06434025|DRUG|Placebo of Iron Carboxymaltose|Solution Sodium Chloride 0,9% 100 ml, IV, once.
224160797|NCT06434025|DRUG|Placebo of Dapagliflozin|Equal shape and appearance tab as the tab containing Dapagliflozin 10 mg
224160798|NCT05831514|OTHER|Mobile Application Supported Education Program (G-MUEP)|Parents who meet the inclusion criteria will use the Mobile Application Supported Education Program (G-MUEP).
223580476|NCT06240728|DRUG|NPX887|NPX887 will be administered by IV infusion every 3 weeks until documented disease progression or participant withdrawal for up to 2 years
223580477|NCT05351216|OTHER||No intervention
223580478|NCT06392776|OTHER|Early diagnosis and treatment|Early diagnosis of previously undiagnosed asthma or COPD and subsequent treatment by a primary care practitioner
223580479|NCT06570382|OTHER|Videos: Taste messaging focused|Participants in this intervention will watch the taste focused videos.
223580480|NCT06570382|OTHER|Videos: Health messaging focused|Participants in this intervention will watch the health focused videos.
223580481|NCT06569953|DRUG|Liposomal bupivacaine|Participants randomized to the intervention arm received 266 mg of liposomal bupivacaine for paravertebral block before surgery.(The volume was expanded to 30 mL with normal saline).
224160799|NCT00389129|DRUG|acetylsalicylic acid|
224160800|NCT00471276|DRUG|sunitinib|sunitinib (Sutent), 37.5 mg, daily dosing
224160801|NCT02174328|DRUG|Acetylsalicylic acid|Acetylsalicylic acid once a day until 36 week
224160802|NCT02174328|DRUG|Placebo|Placebo once a day until 36 week
223580482|NCT06569953|DRUG|Bupivacaine Hydrochloride|Participants randomized to the intervention arm received 0.5% 100 mg of bupivacaine hydrochloride for paravertebral block before surgery.(The volume was expanded to 30 mL with normal saline)
223580483|NCT02965885|DRUG|TAS-116|TAS-116 is an oral heat shock protein 90 (HSP90) inhibitor investigated in 3 dosing regimens (QD, QOD, 5 days on 2 days off) in patients with advanced solid tumor and then at one dose schedule in advanced breast and lung cancer.
223580484|NCT04886986|DRUG|225Ac-J591|30 - 40 KBq/kg (dose-escalation) every 8 weeks, for up to 2 cycles. Administered together with 177Lu-PSMA-I\&T. Intravenous administration.
223580485|NCT04886986|DRUG|177Lu-PSMA-I&T|6.8 GBq (fixed dose) every 8 weeks, for up to 2 cycles. Administered together with 225Ac-J591. Intravenous administration.
223580486|NCT04886986|DRUG|68Ga-PSMA-11|\[185 ±74 MBq or 5 ±2 mCi\] intravenous during screening, 12 weeks, 24 weeks. Imaging agent for PSMA PET/CT.
223580487|NCT04901741|DRUG|Olaptesed pegol|400 mg per week as continous infusion until progression or intolerable toxicity
223580488|NCT04901741|DRUG|Pembrolizumab|200 mg every 3 weeks as i.v. infusion until progression or intolerable toxicity or a maximum of 35 administrations
224160803|NCT01614795|BIOLOGICAL|Cixutumumab|Given IV
224160804|NCT01614795|OTHER|Laboratory Biomarker Analysis|Correlative studies
224160805|NCT01614795|DRUG|Temsirolimus|Given IV
224160806|NCT04586296|OTHER|Telemedicine|IVR will consist of a 3 minute call at a decreasing interval from the time of surgery. Questions will assess pain control, signs of infection, prosthesis failure.
224160807|NCT05185817|BIOLOGICAL|Pasocovac vaccine|All enrolled post-Allo-SCT participants who meet the inclusion criteria are recruited to study from 3 to 12 months after Allo-HSCT and vaccinated with 2 doses of Pastucovac, with a 4-week (±7 days) interval and a booster dose at an 8-week (±7 days) interval from the second dose.
224160808|NCT03368599|PROCEDURE|Bronchoscope guided advancement|"During the anesthetic induction for thoracic surgery, Lt. DLT is intubated using the bronchoscope-guided method. The method is as follows.~1. Lt. DLT is intubated through vocal cord using the direct laryngoscopy.~2. Pass the fiberoptic bronschoscope through a bronchial lumen of Lt. DLT.~3. Secure the pathway into the Lt. main bronchus by advancing the bronchoscope into the Lt. main bronchus.~4. Lt. DLT can be advanced through the guide of the bronchoscope into Lt. main bronchus.~5. After the advancement, the position of Lt. DLT can be confirmed using the fiberoptic bronchoscope. If necessary, the depth and direction of Lt. DLT should be modified."
224163785|NCT01207804|DEVICE|ValenTx Endo Bypass System|Patient is implanted with device and followed for 12 weeks
224163786|NCT00474006|DRUG|arm II|Cytarabine 200 mg/m2/d civ x 7 days Daunorubicin 90 mg/m2/d civ x 3 days
224163787|NCT01706120|DRUG|Bevacizumab|• Bevacizumab 15 mg/kg i.v. on Day 1 every 3 weeks up to 22 cycles
223472722|NCT05353088|OTHER|Thoracic extension exercises|Thoracic extension involves concurrent posterior rotation (external torsion) and depression of the posterior ribs with elevation of the anterior ribs. Bending to the side is a combination of spinal segments side bending, ribs on the same come together while ribs on the opposite side separate.Group B performed thoracic extension exercises for 4 weeks with 2 sets of 10 repetitions. These exercises comprised of three exercise programs.
223472723|NCT03322293|DRUG|Aminolevulinic Acid Topical 20% Topical Solution|PDT involves the topical application of aminolevulinic acid (ALA), or one of its derivatives, as a photosensitizing agent. Subjects will receive ALA in all treatment arms (A, B, and C).
223472724|NCT03322293|DEVICE|BLU-U blue light phototherapy illuminator|Depending on the treatment arm, subjects will either receive BLU-U exposure or not. Treatment arms A and B have BLU-U exposure and treatment arm C does not.
223472725|NCT04517682|DIAGNOSTIC_TEST|RT-PCR|The RT-PCR assay will be performed on paired nasopharyngeal and saliva samples
223472726|NCT01178294|BIOLOGICAL|OBI-1|Intravenous infusion
223472727|NCT05580016|DIAGNOSTIC_TEST|Soluble Urokinase Plasminogen Activation Receptor measurement|In addition to the standard of care, Soluble Urokinase Plasminogen Activation Receptor levels will be measured in patients.
223472728|NCT02089347|BIOLOGICAL|Tdap: Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed|0.5 mL, intramuscularly.
223472729|NCT02089347|BIOLOGICAL|Diphtheria and Tetanus toxoids adsorbed|0.1 mL, Subcutaneously
224160809|NCT03368599|PROCEDURE|Conventional advancement|"During the anesthetic induction for thoracic surgery, Lt. DLT is intubated using the conventional method. The method is as follows.~1. Lt. DLT is intubated through vocal cord using the direct laryngoscopy.~2. Rotate Lt. DLT 90 degrees to the left side.~3. Advance Lt. DLT blindly to main bronchus level.~4. After the advancement, the position of Lt. DLT can be confirmed using the fiberoptic bronchoscope. If necessary, the depth and direction of Lt. DLT should be modified."
223472730|NCT02953730|DRUG|PEG-rhG-CSF|
223472731|NCT04825665|OTHER|Continuous force|"A buccally directed continuous tipping force of 150 g is applied to the maxillary first premolar by a cantilever spring made of 0.017 x 0.025 beta-titanium-molybdenum alloy inserted in the tube of the upper first molar, bypassing the second premolar and attaching to the upper first premolar. The buccal tipping force will be checked and reactivated to the original level on the 28th day of the 8 week study period."
223472732|NCT04825665|OTHER|Intermittent force|"A buccally directed tipping force of 150 g is applied to the maxillary first premolar by a cantilever spring made of 0.017 x 0.025 beta-titanium-molybdenum alloy inserted in the tube of the upper first molar and attaching to the upper first premolar. The buccal tipping force will be removed every 21 days for a 7-day rest period, where a passive wire of the same gauge and material of the cantilever spring (0.017 x 0.025 beta-titanium-molybdenum alloy) will be placed instead to maintain the position of the upper first premolar during the rest period."
223472733|NCT02184104|DIETARY_SUPPLEMENT|Caffeine|
223472734|NCT06464627|BEHAVIORAL|Physical activity|16 weeks
223472735|NCT02017002|PROCEDURE|Ivor Lewis|for the patients with lower-to mid third esophageal cancer, some surgeon performed Ivor lewis esophagectomy, which performing the esophago-gastrostomy in the chest after gastric mobilization without cervical incision wound
223472736|NCT02017002|PROCEDURE|Tri-incision|a cervical incision was required for esophagogastrostomy after esophagectomy and gastric mobilization
223472737|NCT00551369|RADIATION|SBRT|SBRT delivered in 3 fractions of 20 Gy/fraction over 1.5 to 2 weeks for a total of 60 Gy
223580489|NCT05649384|DIAGNOSTIC_TEST|European Society of Cardiology hs-cTnT/I 0 h/1 h algorithm|High-sensitivity cardiac troponin (hs-cTn) blood tests are performed at admission (0 h) and 1 hour later in the emergency department.
223580490|NCT05649384|DIAGNOSTIC_TEST|European Society of Cardiology hs-cTnT/I 0 h/3 h algorithm|High-sensitivity cardiac troponin (hs-cTn) blood tests are performed at admission (0 h) and 3 hours later in the emergency department.
223580491|NCT06528288|PROCEDURE|Erector Spinae Plane Block|The erector spinae plane block (ESPB) is a method for injecting local anesthesia to reduce pain related to a surgical procedure. The anesthesia is theorized to spread along the paraspinal fascia and anesthetize a larger area, resulting in patients reporting less pain and using less opioids postoperatively.
223580492|NCT06528288|PROCEDURE|Subcutaneous Anesthesia|Subcutaneous anesthesia injection involves placement of local anesthesia under the skin around the surgical incision. This is thought to reduce pain from the incision site postoperatively.
223580493|NCT05566431|OTHER|ICP|The intervention is a management protocol that includes ICP monitoring for children with severe traumatic brain injury
223580494|NCT05566431|OTHER|CREVICE|The intervention is a management protocol that is based on imaging and clinical examinations without ICP monitoring for children with severe traumatic brain injury
224160810|NCT02661945|DEVICE|Near focus with narrow band imaging|
224163788|NCT01706120|DRUG|Paclitaxel|• Bevacizumab 15 mg/kg i.v. on Day 1 every 3 weeks up to 6 cycles
224163789|NCT01706120|DRUG|Carboplatin|• Carboplatin (AUC 5) on Day 1 every 3 weeks for up to 6 cycles
223580495|NCT00240110|DRUG|Valproate|Valproate with dose titration to achieve blood levels within the therapeutic range
223580496|NCT00240110|DRUG|Placebo|Control arm
223580497|NCT00240110|DRUG|Lithium Carbonate|All participants were started and stabilized on lithium carbonate as a standard treatment for bipolar disorder
223580498|NCT00583791|DEVICE|Device closure with the AMPLATZER Muscular VSD Occluder|Device: AMPLATZER Muscular VSD Occluder
223580499|NCT02433873|DIETARY_SUPPLEMENT|Isomalto-oligosaccharide|Isomalto-oligosaccharide (IMO) is a non-digestible type of oligosaccharide commonly used as a low-calorie sweetener mixed with a variety of other food and beverage products for the purpose of sweetening.
224163790|NCT00626340|DRUG|MDD diagnosis and Estrogen treatment|Treatment for major depressive disorder occurring in the context of the menopause while participating in brain imaging sessions pre and post treatment. Women receiving treatment for depression will be compared to normal controls receiving estrogen only for physical symptoms of menopause.
224163791|NCT00626340|DRUG|MDD diagnosis and Fluoxetine treatment|Menopausal women between the ages of 40-70 diagnosed with Major Depressive Disorder receiving treatment with fluoxetine alone.
224163792|NCT00626340|DRUG|MDD diagnosis with both Estrogen and Fluoxetine treatment|Menopausal women between the ages of 40-70 diagnosed with Major Depressive Disorder receiving treatment with estrogen and fluoxetine combined.
223472738|NCT04768088|OTHER|Falling Training|For the falling training, participants will be instructed to initially land softly with increased knee and hip flexion and then smoothly fall to the direction of the movement while transferring the weight from the feet to the hands and subsequently to the lateral trunk and hip. The training program includes three one-hour training sessions over a week with one or two days between two sessions. Each training session will begin with a warm-up protocol. Participants will progressively increase the task difficulty and decrease the thickness of the mat. For each training session, participants will perform a minimum of one successful practice trial for each task difficulty and each landing direction on the thicker mat and then complete a minimum of three successful practice trials for each task difficulty and landing direction on the thinner mat. The last training session involves falling on a 0.5-inch mat, which is the same as the surface for the post-training and retention assessments.
223472739|NCT01213381|DRUG|Iniparib (SAR240550 - BSI-201)|"Pharmaceutical form:sterile aqueous solution~Route of administration: intravenous"
223472740|NCT01213381|DRUG|Gemcitabine|"Pharmaceutical form:sterile aqueous solution~Route of administration: intravenous"
223472741|NCT01213381|DRUG|Carboplatin|"Pharmaceutical form:sterile aqueous solution~Route of administration: intravenous"
223472742|NCT00597259|DRUG|Pegasys plus Entecavir|Pegasys 180 mcg in 0.5 mL solution administered sc once weekly for 24 weeks plus entecavir (0.5mg mg/capsule) 0.5 mg administered po daily for 24 weeks
223472743|NCT00597259|DRUG|Entecavir|ETV 0.5 mg daily monotherapy for 144 weeks
223472744|NCT02415972|OTHER|Ultrasound perfusion imaging|Dynamic perfusion imaging of brain parenchyma with modern ultrasound is possible with the use of ultrasound contrast media that serve as echo signal amplifier.
223580500|NCT01345565|DRUG|human hepatocytes|"The intrahepatic site for liver cell transplantation has been associated with the best engraftment and function based on animal experiments. Several approaches for access to the portal vein will be considered. The technique used will be determined based on what is considered best for the child based on risk/benefit at the time.~We propose to attempt to infuse approximately 5-10% of the hepatic mass in order to provide improved hepatic function. Since we do not yet know from our experience so far the correct number of cells to transplant in order to improve function, we will continue to infuse hepatocytes as donors become available until the patient improves to the point where they are no longer meet the criteria for organ transplantation. The subject will be evaluated de novo and if they are a candidate for orthotopic liver transplantation they will receive the transplant."
223580501|NCT02476474|PROCEDURE|3 cm start of resection|Investigators will start the resection of the LSG 3 centimeters from the antrum of the stomach.
223580502|NCT02476474|PROCEDURE|6 cm start of resection|Investigators will start the resection of the LSG 6 centimeters from the antrum of the stomach.
223580503|NCT03601559|DIETARY_SUPPLEMENT|Lactobacillus paracasei Lpc-37|Live probiotic bacteria
223580504|NCT03601559|DIETARY_SUPPLEMENT|Placebo|Inert placebo matched for taste and appearance
223580505|NCT05302141|BEHAVIORAL|Wear 3D printing assistive device|"Wear 3D printing aids and engage in functional tasks, including eating, typing, and writing.~At home: use daily, 30 minutes each time; Treatment room: 30 minutes twice a week"
223580506|NCT05302141|BEHAVIORAL|Wear universal cuff device|"Wear universal cuff aids and engage in functional tasks, including eating, typing, and writing.~At home: use daily, 30 minutes each time; Treatment room: 30 minutes twice a week"
223580507|NCT05001841|PROCEDURE|Lung Transplantation|Double lung transplant
223580508|NCT00005875|DRUG|rubitecan|
223580509|NCT03323736|COMBINATION_PRODUCT|Iontophoresis & tube placement|Subjects will receive active Tymbion iontophoresis and will have tubes placed in-office using the Tube Delivery System in all ears indicated for tube placement.
223580510|NCT03323736|DEVICE|Tube placement|Subjects will have tubes placed in the OR using the Tube Delivery System in all ears indicated for tube placement.
223580511|NCT05632276|DEVICE|ConvaFoam|ConvaFoam™ Border, ConvaFoam™ Non-Adhesive, and ConvaFoam™ Silicone dressings are designed to provide a moist wound healing environment. All participants will be assigned a dressing based upon clinical judgement for a maximum of 4 weeks with weekly assessments and dressing changes
223472745|NCT00566085|PROCEDURE|Molecular Breast Imaging|A dual-detector cadmium-zinc-telluride gamma camera system mounted on a modified mammography gantry is used to image the breast. The injection dose of the radiopharmaceutical given to the patient is 28-32 mCi of 99m Tc-sestamibi.
223472746|NCT04752930|DIAGNOSTIC_TEST|ctDNA monitoring|Patients who undergoing radical surgery for colorectal cancer for 6\~12 months and with 2 consecutive positive ctDNA testing results within 1 month will be enrolled, and diagnostic laparoscopy will be performed immediately after enrollment. Patients with positive peritoneal metastasis (PCI score \<20) will be treated with CRS+HIPEC. Tumor markers, endoscopic and imaging examinations, and ctDNA monitoring will be performed every 3 months in patients with negative peritoneal metastasis. Laparoscopy will be performed when imaging suggested peritoneal metastasis (oligometastases). Re-diagnostic laparoscopy will be performed 24 months after radical surgery when there is no radiographic evidence of recurrence or metastasis. Follow-up time will up to 36 months after colorectal cancer surgery.
223580512|NCT04872998|BEHAVIORAL|Step Count Reduction|Subjects reduce daily step counts by approximately 70% through monitoring and recording from step-count monitor
223580513|NCT03353766|DEVICE|Early crossbite correction with Q-H Device|Crossbite treatment in deciduous dentition with Quad-Helix appliance
223580514|NCT00806143|DEVICE|repetitive transcranial stimulation (rTMS)|"Repetitive TMS will be administered using a MAGSTIM rapid magnetic stimulator (Magstim Company, Ltd., Whitland, U.K.) and a 70-mm figure-eight shaped coils.~In monolateral treatment in right DLPFC, three 140-second trains will be applied at 1 Hz and at 110% of RMT. There is a 30 seconds intertrain interval (total of 420 stimuli per session). In sequential treatment, the stimulation will be applied in the first to the right and then to the left dorsolateral prefrontal cortex. In right DLPFC will be applied three 140-second trains at 1 Hz and at 110% of RMT. There will be a 30 seconds intertrain interval (total of 420 stimuli per session). In left DLPFC will be applied twenty 5-second trains were applied at 10 Hz and at 100% of RMT. There will be a 25-second intertrain interval (total of 1000 stimuli per session). Patients will be treated from Monday to Friday, for a total of 15 days."
223580515|NCT00806143|DEVICE|unilateral stimulation|Patients will be treated from Monday to Friday, for a total of 15 days in the same timeframe of the active group right sided low frequency stimulation
223580516|NCT02236416|BEHAVIORAL|Intervention group|Supervised, multimodal physical activity including aerobic, resistance and stretching exercises
223472747|NCT04752930|DIAGNOSTIC_TEST|Imageology|Patients who undergoing radical surgery for colorectal cancer for 6\~12 months and with 2 consecutive positive ctDNA testing results within 1 month will be enrolled. and there will be no need to conduct endoscopic exploration immediately after enrollment. Tumor markers, endoscopic and imaging examinations, and ctDNA monitoring will be performed every 3 months until imaging suggested peritoneal metastasis (oligometastases). Patients with positive peritoneal metastasis (PCI score \<20) will be treated with CRS+HIPEC. Re-diagnostic laparoscopy will be performed 24 months after radical surgery when there is no radiographic evidence of recurrence or metastasis. Follow-up time will up to 36 months after colorectal cancer surgery.
223472748|NCT00259935|DRUG|topotecan|topotecan
223580517|NCT02236416|BEHAVIORAL|Control group|Usual physical activity, generally consisting in long walks and/or stretching, toning and/or balance exercises, or posture education
223580518|NCT05301036|DEVICE|Diadem prototype|Diadem prototype device delivers personalized low-intensity transcranial focused ultrasound stimulation
223580519|NCT00649831|DRUG|Amoxicillin/clavulinic acid|amoxicillin/clavulinic acid 500 mg/62.5 mg tablet; take 2 tablets by mouth twice daily (BID) for 10 days
223580520|NCT00649831|DRUG|Azithromycin|Azithromycin 250 mg tablet; take 2 tablets by mouth on the first day, then 1 tablet by mouth from Days 2 to 5
223743856|NCT02747420|DEVICE|Sham|"A needle will be inserted into the lower extremity approximately 5 cm cephalad from the medial malleolus and posterior to the tibia. A sham needle will be used a the tibial nerve insertion site. This will stimulate needle placement without puncturing the skin. The needle will be taped in place. The grounding pad from the transcutaneous electrical nerve stimulation (TENS) unit device will be placed on the bottom of the foot below the smallest toe. Another electrode will be placed on the top of the foot above the small toe for conduction. The TENS electrode will be connected to the TENS unit, at 20 Hz (the same as the PTNS group). The unit will be turned on and the stimulation will be increased to the subject's first sensory level. The subject will sense stimulation to either the bottom of the foot or the toe. the TENS unit will be on for a 30 minute test period. The TENS unit will be removed and the needle will be discarded."
223743857|NCT06388395|PROCEDURE|Accuracy of full-arch surgical guides|The accuracy of the surgical guides will be assessed by superimposing the pre and post-treatment CBCT scans.
223743858|NCT06388395|PROCEDURE|Survival and complications of the prostheses|Two different prostheses will be assessed (conventional and PEEK). All complications will be recorded for a period of 3 years
223743859|NCT06388395|PROCEDURE|Survival and complications of the implants|The effect of the two different prostheses on implants will be assessed in terms of survival and success rates.
223743860|NCT06388395|PROCEDURE|Conventional (metal-resin) implant-supported prosthesis|Full-mouth implant-supported conventional prosthesis will be constructed and evaluated for up to 3 years.
223743861|NCT06388395|PROCEDURE|PEEK implant-supported prosthesis|Full-mouth implant-supported PEEK prosthesis will be constructed and evaluated for up to 3 years.
223743862|NCT01697865|PROCEDURE|Transfer group|
223743863|NCT01697865|PROCEDURE|Control group|
223743864|NCT00002137|DRUG|Tecogalan sodium|
223743865|NCT01199211|OTHER|Exercise training, women, marathon|Prospective study with no intervention in women who have volunteered to run a full marathon or a half-marathon. Each subject will serve as own control. Each subject will be studies at 3 stages: baseline, after at least 12 weeks of training for the marathon (we will not provide training), 6 weeks after running the marathon.
223743866|NCT03691064|DRUG|LUTATHERA|Labeled dosing regimen: 7.4 gigaBecquerel (GBq) (200 milliCurie \[mCi\]) every 8 weeks for a total of 4 doses.
224069391|NCT06345300|DRUG|Liposomal Irinotecan, Oxaliplatin, 5-Fluorouracil/Calcium folinate in combination with Camrelizumab|"The treatment regimen for this study is as follows:~Intravenous infusion of Oxaliplatin at a dose of 85mg/m2 for 2 hours or according to clinical practice at the research center;~Intravenous infusion of liposomal Irinotecan at a dose of 60mg/m2 for 90 minutes (±30 min);~Intravenous drip of Calcium folinate at a dose of 400mg/m2 for 30 minutes or according to clinical practice at the research center;~Intravenous infusion of 5-Fluorouracil at a dose of 2400mg/m2 (infused for 46-48 hours or according to clinical practice at the research center);~Camrelizumab at a fixed dose of 200mg, administered via intravenous drip, with each infusion lasting no less than 30 min and no more than 60 min. Administered on day 1 of every 2-week cycle (d1, q2w).~Each treatment cycle is 14 days, and all drugs are administered on day 1."
224071659|NCT07142889|PROCEDURE|Low load-BFRt|The participants' two legs will be subjected to 70% arterial occlusion pressure when the physical therapist applies the BFR cuffs. After that, participants will be required to complete eccentric exercises with a maximum repetition count of 30%, such as single leg squat, single leg deadlift, lateral step down, dan single leg calf raise.
224071660|NCT07142889|PROCEDURE|Sham Low load-BFRt|The participants' two legs will be subjected to 10% arterial occlusion pressure when the physical therapist applies the BFR cuffs. After that, participants will be required to complete eccentric exercises with a maximum repetition count of 30%, such as single leg squat, single leg deadlift, lateral step down, dan single leg calf raise.
223580521|NCT06520007|DRUG|Doxycyclin|The drug has been prescribed, as in normal clinical practice, with the National Healthcare System. Patients have been fully informed about interactions, toxicity and posology schedule.
223580522|NCT02737150|DEVICE|CoreValve Evolut R|
223580523|NCT02737150|DEVICE|Edwards Sapien 3|
223580524|NCT02737150|PROCEDURE|Local anesthesia with conscious sedation|
223580525|NCT02737150|PROCEDURE|General anesthesia|
223580526|NCT05663775|DRUG|Mesalamine|Mesalamine, also known as 5-aminosalicylic acid (5-ASA)
223743867|NCT03674060|DRUG|SYO-1644|"100mg: SYO-1644 tablet, PO, 1 100mg tablet~150mg: SYO-1644 tablet, PO, 1 100mg tablet and 1 50mg tablet~200mg: SYO-1644 tablet, PO, 2 100mg tablet"
223743868|NCT03674060|DRUG|Nexavar tab|Nexavar 200mg/tablet, PO, 1 tablet
223743869|NCT03365817|DRUG|Opioids taper off|Decrease of 10% of opioid daily dose every one to two weeks until discontinuation for up to six months.
224071661|NCT07142889|PROCEDURE|High load-Eccentric training|The physical therapist will instruct the participants to complete eccentric exercises at a maximum of 70% repetitions, such as single leg squat, single leg deadlift, lateral step down, dan single leg calf raise.
223580527|NCT04032301|DRUG|Ketamine|Six infusions of intravenous 0.5 mg/kg ketamine hydrochloride solution over 3 weeks.
223472749|NCT01880606|PROCEDURE|colonoscopy with endomicroscopy|Examination will be performed in two steps. On the way from rectum to caecum, mucosa will be evaluated with white light endoscopy and random biopsies will be taken according to the routine standard with minimum of 2 biopsies from each 10 cm of colon. On the way back (from caecum to rectum) mucosa will be stained with indigo carmine and after intravenous fluorescein injection all macroscopically abnormal lesions will be examined by endomicroscopy and biopsied. Additionally, all places where random biopsies were taken will be also examined with endomicrosopy.
223472750|NCT03846869|DIAGNOSTIC_TEST|major cations|blood sample
223472751|NCT02704767|DRUG|Apatinib|a tyrosine kinase inhibitor of VEGF invented by Hengrui pharma in China
223472752|NCT02704767|DRUG|Tarceva|
223472753|NCT02704767|DRUG|Placebo|
223472754|NCT02143817|DIETARY_SUPPLEMENT|L-citrulline supplementation|
223580528|NCT04032301|OTHER|Normal Saline|Six infusions of intravenous normal saline solution over 3 weeks.
223580529|NCT05490186|PROCEDURE|Total Knee Replacement|Surgical technique for Total knee replacement will be standardized with a MicroPort prosthetic knee joint, patella replacement is optional based on the surgeon's assessment. The participants will receive local anesthetic infiltration by the surgeon, and a similar anesthetic technique with spinal anesthesia using epidural morphine and single shot peripheral nerve blocks. They will receive weight based antibiotics and tranexamic acid. Participants will be randomized to one of three groups. 1)Manual adjusted mechanical knee alignment (usual care) involves the surgeon manually. 2) Robot assisted surgery will include using the ROSA© device from Zimmer©. Robot assisted mechanical alignment aims for neutral alignment of the knee joint. 3) Robot assisted restricted kinematic alignment aims to place the knee joint closer to the participant's anatomical positioning.
223580530|NCT04638127|BEHAVIORAL|PREEMIE PROGRESS|PREEMIE PROGRESS is a video-based training program for parents of preterm infants hospitalized in the neonatal intensive care unit (NICU).
223580531|NCT04638127|BEHAVIORAL|Attention Control|usual care and welcome videos
223580532|NCT04414124|OTHER|KB109 + Self Supportive Care (SSC)|KB109 is a novel glycan
223580533|NCT04414124|OTHER|Self Supportive Care (SSC) Alone|Self Supportive Care (SSC) Alone
223580534|NCT02696993|PROCEDURE|Cognitive Assessment|Ancillary studies
223580535|NCT02696993|BIOLOGICAL|Ipilimumab|Given IV
223580536|NCT02696993|OTHER|Laboratory Biomarker Analysis|Correlative studies
223580537|NCT02696993|BIOLOGICAL|Nivolumab|Given IV
223580538|NCT02696993|RADIATION|Stereotactic Radiosurgery|Undergo SRS
223743870|NCT03365817|DRUG|Opioid stable treatment|No changes on prescribed opioids and adjuvant medication for the next six months
223743871|NCT02954510|DRUG|ferumoxytol|ferumoxytol will assess patency of coronary arteries
223743872|NCT01315756|DEVICE|Use of Few Touch Application (FTA)|"The users will receive a Smartphone with the diabetes diary application (the Few Touch application), a self-help tool that consists of five main elements accessible to the user. The five elements are the food habits registration, blood glucose data management system, physical activity registration, personal goals setting and general information. While blood glucose data is automatically transferred to the phone from the blood glucose meter when the user has performed a measurement, activity data and food habits have to be entered manually by the user."
223580539|NCT02696993|RADIATION|Whole-Brain Radiotherapy|Undergo WBRT
224069392|NCT06345300|DRUG|Liposomal Irinotecan, Oxaliplatin, 5-Fluorouracil/Calcium folinate|"The treatment regimen for this study is as follows:~Intravenous infusion of Oxaliplatin at a dose of 85mg/m2 for 2 hours or according to clinical practice at the research center;~Intravenous infusion of liposomal Irinotecan at a dose of 60mg/m2 for 90 minutes (±30 min);~Intravenous drip of Calcium folinate at a dose of 400mg/m2 for 30 minutes or according to clinical practice at the research center;~Intravenous infusion of 5-Fluorouracil at a dose of 2400mg/m2 (infused for 46-48 hours or according to clinical practice at the research center); Each treatment cycle is 14 days, and all drugs are administered on day 1."
223580540|NCT02654236|DRUG|Placebo|1 tablet of placebo, taken orally daily with water, approximately 30 minutes prior to breakfast for 4 weeks.
223580541|NCT02654236|DRUG|10 mg Obeticholic Acid (OCA)|10 mg Obeticholic Acid (OCA) Study medication will be administered orally, once daily, approximately 30 minutes prior to breakfast for 4 weeks.
223580542|NCT02247180|BEHAVIORAL|cognitive rehabilitation|
223580543|NCT02247180|BEHAVIORAL|standardized cognitive training|
223580544|NCT01676519|PROCEDURE|PCI|percutaneous coronary intervention
223580545|NCT01217320|DIETARY_SUPPLEMENT|creatine|5g/d throughout 12 weeks
223580546|NCT01217320|DIETARY_SUPPLEMENT|placebo (dextrose)|5g/d throughout 12 weeks
224069393|NCT02838849|DIETARY_SUPPLEMENT|Fiber|Fiber composed of wheat bran, pectin and green banana flour (total daily amount of 13 g for women and 20 g for men), keeping the usual liquid intake
224069394|NCT02838849|DIETARY_SUPPLEMENT|Fiber and Water|Fiber composed of wheat bran, pectin and green banana flour (total daily amount of 13 g for women and 20 g for men) plus 2 liter of water/day
224069395|NCT00763139|DRUG|Pioglitazone|45 mg by mouth once a day for 8 weeks
224069396|NCT00763139|DRUG|Placebo|By mouth once a day for 8 weeks
224069397|NCT00002553|DRUG|cyclophosphamide|
224069398|NCT00002553|PROCEDURE|allogeneic bone marrow transplantation|
224069399|NCT00002553|RADIATION|low-LET cobalt-60 gamma ray therapy|
223580547|NCT05332418|OTHER|selected exercise program|therapeutic ultrasound, Static neck exercise, Educational postural correction, and Home neck exercise program for patient
223580548|NCT05332418|DEVICE|Electromagenetic Field therapy|Magnetotherapy application the device will be adjusted around the neck and shoulder area at low frequency (50 Hz), with intensity of 2.5 MT, field shape and applicator type rectangular csl60/csp60) , and the application time (10 minutes)
223580549|NCT00869830|OTHER|biofeedback therapy|biofeedback therapy was applied using the surface electromyography (EMG) method with a perianal sensor (Perry, Elan, SRS Medical Systems, Redmond, WA, USA) and biofeedback PC equipment (Orion, Platinum, SRS Medical Systems, Inc., Redmond, WA, USA).
223580550|NCT01655147|DRUG|Abiraterone acetate|Type=exact number, unit=mg, number=1,000, form=tablet, route=oral. Abiraterone acetate administered on Day 1 of Period 1, and Day 14 of Period 2.
223580551|NCT01655147|DRUG|Rifampicin|Type=exact number, unit=mg, number=600, form=capsule, route=oral. Rifampicin administered on Days 8 to 13 of Period 2.
223472755|NCT02143817|OTHER|Whole Body Vibration Training|The Whole body vibration training intervention consists of lower-body exercise in a vibration platform 3 times per wk for 8 wk. The subjects will perform static and dynamic exercises for the legs on the vibration platform. Dynamic exercises will be performed with slow controlled movements starting from an upright position into a 60 degree knee flexion (squat) and maximal heel elevation (toestand). Static exercises will be performed without movement in the joint angles described previously. The training volume will increase progressively over the 12-week training period by increasing the intensity of vibration, duration of the exercise set (30-60 sec), number of sets per exercise, and total duration of the training session, and decreasing the duration of rest periods (30-60 sec).The intensity of vibration and amplitude will also be increased progressively (25-30 Hz of frequency and from low to high amplitude).
223472756|NCT04259333|DRUG|Celecoxib 200mg|Celecoxib tablet
223472757|NCT04259333|DRUG|Acetaminophen, Codeine Drug Combination|acetaminophen-codeine-caffeine tablet
223472758|NCT00560716|DRUG|CYC116|Dose escalation of CYC116
223472759|NCT03037840|DEVICE|Low intensity amplitude-modulated RF EMFs|Low intensity amplitude-modulated radiofrequency electromagnetic fields,the carrier frequency is 27.12MHz with a power of about 100mW
223472760|NCT03656341|BEHAVIORAL|2 Feet 4 Life|2 Feet 4 Life consists of four weekly group intervention sessions of one hour each. 2 Feet 4 Life includes self-management teaching, interactive lecture, and group activities, including instruction and demonstration of routine foot care. The program includes education regarding appropriate footwear and how to find it, evidenced based practices on hygiene, skin care and self-care of the lower extremities, nail trimming and filing, and care of common foot problems.
223472761|NCT00719901|DRUG|obatoclax mesylate|Given IV
223472762|NCT00719901|DRUG|bortezomib|Given IV
223580552|NCT05980338|PROCEDURE|genicular nerve ablation by thermal radiofrequency|"radio-frequency will be done using the Neurotherm NT1100 re-generator. The 3 entry sites will be detected under fluoroscopy then local anesthesia will be performed using lidocaine 2% followed by the insertion of the 3 radiofrequency cannulas (STRYKER 20 G, 9 cm with 1 cm active tip) targeting the 3 main nerves ( superior medial genicular, superior lateral genicular and the inferior medial genicular nerves ) .~A confirmation of the targeted sites is done under fluoroscopy in both A-P and lateral views then a motor stimulation will be done to ensure no undesirable motor response followed by lidocaine 1 % injection and placing of the radiofrequency cables and ablation was done at 80 degrees for 90 seconds . The procedure will be repeated 3 times at different levels in the lateral view separated by 0,5 cm to ensure successful targeting. Then remove the needles."
223743873|NCT01315756|DEVICE|Use of FTA and health counseling based on TTM and CBT|The users will additionally receive health counseling based on TTM and CBT by a diabetes nurse with individualized feedback via SMS from the diabetes nurse which is based on the patient's initiative (via SMS). In addition, the diabetes nurse will call the patients three times during this period and discuss progress. Both the SMS-messages and the calls will be based on CBT according to the TTM-level. The intervention allows information to be given both in an individualized and tailored manner for each particular patient by the nurse, but also in a general way via SMS. The patients need to understand the relationship between areas such as glucose levels, diet, exercises and medicine, in the context of their own lifestyle needs.
223472763|NCT00719901|OTHER|laboratory biomarker analysis|Correlative studies
223472764|NCT00926523|OTHER|Blood Gas|Subject will have both venous and arterial blood draws to assess for the bloods content of MIF
223472765|NCT00926523|OTHER|Pulmonary Exercise Test|Subject will ride exercise bike to assess their pulmonary function level.
223472766|NCT00926523|OTHER|Spirometry|To assess subjects lung function
223472767|NCT00926523|OTHER|Breath Condensate Collector|Subject with use breathing apparatus to allow researchers to collect breath condensate to assess level of MIF in breathe condensate.
223472768|NCT03073772|BEHAVIORAL|Computer-based cognitive training|A total of 36 training sessions, approximately 20 minutes long each. Five different tasks were used in training all tapping different aspects of cognitive control such as updating, shifting, visuo-spatial working memory and episodic memory binding.
223743874|NCT03662542|DRUG|Guselkumab Dose 1|Guselkumab Dose 1 will be administered as IV infusion.
223472769|NCT03073772|BEHAVIORAL|Physical fitness training|A total of 36 training sessions, approximately 40 minutes long each, with physical fitness training performed as group indoor cycling. The participants were instructed to attain a load of approximately 65-80% of their maximum heart rate.
224069400|NCT03556930|DEVICE|AlignRT system (VisionRT LTD, UK)|Pediatric patient will watch age-proper movie during radiation treatment. The motion of pediatric patient will continually be monitored by an AlignRT system (VisionRT LTD, UK). Both movie and radiation beam will be paused if the motion of pediatric patient is beyond positioning accuracy threshold. Movie and beam will be resumed if pediatric patient is positioning with in tolerance.
224069401|NCT04789356|BIOLOGICAL|Adsorbed SARS-CoV-2 (inactivated) vaccine|600 SU/dose; Two doses separated by 28 days (± 7 days). Intramuscular (deltoid) administration.
224069402|NCT03282760|BIOLOGICAL|Human Neural Stem Cells|Allogenic human Neural Stem Cells (hNSCs) in four different dosages (5, 10, 16 or 24 millions). hNSCs are produced by the Laboratorio Cellule Staminali of Terni according to GMP guidelines and are obtained from brain specimens of several fetal human donors from spontaneous miscarriages occurred after the 8th week after conception.
224069403|NCT01592760|DEVICE|air-Q SP|air-Q SP placement for airway maintenance.
224069404|NCT01592760|DEVICE|air-Q|air-Q placement for airway maintenance.
224069405|NCT01592760|DEVICE|i-gel|i-gel placement for airway maintenance.
224069406|NCT04312009|DRUG|Losartan|Losartan; 50 mg daily; oral administration
224069407|NCT04312009|OTHER|Placebo|Placebo (microcrystalline methylcellulose, gelatin capsule); oral administration
224069408|NCT05216965|DRUG|9MW2821|All subjects will receive a single intravenous (IV) infusion of 9MW2821 once weekly for the first 3 weeks of every 4 week cycle (i.e., on Days 1, 8 and 15).
224069409|NCT01008280|DRUG|baclofen|baclofen 10 mg tid
224069410|NCT01008280|DRUG|placebo|placebo pill tid
224069411|NCT04469478|OTHER|Survey and interview|Patients and caregivers will provide information via surveys and interviews regarding their experience viewing diagnostic imaging using conventional methods and using Virtual Reality
224069412|NCT00280410|DRUG|E7337|
223472770|NCT01548963|PROCEDURE|Intensive glycemia control|Blood glucose levels will be maintained by continuous insulin infusion (Actrapid, Novo Nordisk A/S, Bagsvaerd, Danemark - 50 IU/50 ml FR) within normoglycemia limits (4.4 - 6.1 mmol/l)
223472771|NCT05465395|PROCEDURE|Upper Cervical Adjustemnt|Upper cervical adjustement
223472772|NCT05465395|PROCEDURE|Thoracic Adjustemnt|Thoracic adjustment
223472773|NCT04905992|OTHER|Hypertonic saline at 6%|Participants will start the sessions by inhaling a short-acting bronchodilator or an anticholinergic to avoid the presence of bronchospasm during nebulisation. The hypertonic solution (at 6%) will be administered through the Turbo Boy nebuliser (Pari®). The intervention will take place at home.
223472774|NCT04905992|OTHER|Airway clearance techniques (oscillating positive expiratory pressure therapy)|Following nebulisation, participants will perform airway clearance techniques using an oscillating positive expiratory pressure device for at least 15 minutes. The intervention will take place at home
223472775|NCT00516971|DRUG|Esomeprazole 20mg once daily|
223472776|NCT02902926|BEHAVIORAL|Low FODMAPs Diet|Instruct to design and eat Low Fermentable，Oligo-，Di-，Mono-saccharides And Polyols(FODMAPs) Diet
223472777|NCT02902926|BEHAVIORAL|Diet instruction|Answer the doubt and help the patient get the diet knowlege about the IBS.
223472778|NCT04393727|BIOLOGICAL|CONVALESCENT PLASMA|Convalescent plasma will be collected by healthy donors, cured by COVID-19 and, after standard preparation and dosage of neutralizing antibodies, will be administered to patients with SARS-CoV2 pneumonia
223472779|NCT03101306|OTHER|MR scans|Additional imaging using MR scans.
223472780|NCT01256307|OTHER|training and educational program|8 weeks
223472781|NCT01256307|OTHER|educational program|8 weeks
223472782|NCT01122173|DEVICE|Ablation|Atrial fibrillation ablation procedure
223472783|NCT02598674|DRUG|Iodohippurate|An injection of non-radioactive iodohippurate (0.07 mL/kg) will be administered to determine renal plasma flow (RPF)
223472784|NCT02598674|PROCEDURE|24 hour ambulatory Blood Pressure|Ambulatory blood pressure (BP) monitoring will be performed using a commercially available device (TIBA Ambulo 2400) for 24 hours with measurements every 30 minutes while awake and every hour during sleep.
223472785|NCT02598674|PROCEDURE|Peripheral Arterial Tonometry|The peripheral arterial tonometry (PAT) device measures changes in the cutaneous circulation that correlate with flow-mediated dilatation.
223472786|NCT02598674|PROCEDURE|Pulse Wave Velocity|Carotid-femoral and carotid-radial pulse wave velocities (PWV), validated markers of individual cardiovascular risk, will be determined by applanation tonometry using SphygmoCorVx technology (AtCor Medical). PWV is an index of the overall stiffness of a vascular segment between measurement sites 59. Thus, while carotid-femoral PWV is an index of the overall stiffness of proximal (central) arteries, the overall stiffness of peripheral arteries contributes relatively more to carotid-radial PWV.
224160811|NCT05037916|OTHER|laser speckle contrast imaging device|laser speckle contrast imaging device will be used for measurement of burn wound depth en to be compared to the golden standard the laser doppler imaging device
224160812|NCT05795868|DEVICE|Compression stocks|Pregnant women in the compression stockings group will wear the socks given for 3 weeks.
224160813|NCT05795868|OTHER|Knee socks|Pregnant women in the Knee socks group will wear the socks given for 3 weeks.
224160814|NCT00568607|DRUG|IFO, VP-16, DDP, DXM|DXM 40 mg d1-4; IFO 1200mg/m2 d1-4; Mesna 400mg, tid, d1-4; VP-16 75 mg/m2 d1-4; DDP 20mg/m2 d1-4; q3w. Efficacy was evaluated every two cycles. If patients hadn't diseases progression, two more cycles and radiation would be administered.
224160815|NCT01369446|DEVICE|Eeva System Study|The Eeva System will image embryos through cleavage and/or blastocyst stage.
224160816|NCT01603212|DRUG|Vemurafenib|"Phase I Starting dose: 720 mg by mouth twice a day for a 21 day cycle.~Phase II Starting dose: Maximum tolerated dose (MTD) from Phase I."
223472787|NCT02598674|DRUG|Gadolinium|Dotarem Gadolinium (GD)- Gadoterate Meglumine (0.07 to 0.14 mL/kg) will be used to determine GFR.
223472788|NCT05111717|DRUG|Desflurane|Peripheral venous blood samplesof patients will collected at two time points as follows: before the premedication and the induction of anesthesia (T₁): 120 minutes after the beginning of anesthesia (T₂). Anesthesia maintenance will be provided with 40% O₂ and minimum alveolar concentration (MAC) in 60% air with 6% desflurane. DNA will be obtained from blood samples with the help of DNA isolation kit, and global DNA methylation analysis will performed by ELISA method.
223472789|NCT05815966|BEHAVIORAL|The effect of emotion recognition and empathy focused education program|"Emotion recognition and empathy-oriented education program is a group-based, interactive program that includes techniques such as vision development, brainstorming, painting and drawing, recital, role-playing, gamification and information notes, which requires the active participation of children. Within the program; There are trainings aimed at establishing bilateral relations, gaining in-group commitment, expressing emotions comfortably, feeling that they are not alone, and learning new resources that will make them feel good when they feel bad.~The aims of education; children,"
223472790|NCT01184872|DRUG|Daptomycin|"Patients with bacteremia: Daptomycin 6 mg/Kg intravenous once daily for at least 5 days and up to 28 days.~Patients without bacteremia: Daptomycin 4 mg/Kg intravenous once daily for at least 5 days and up to 14 days."
223472791|NCT01184872|DRUG|Vancomycin or Semi-Synthetic Penicillins (SSPs)|"Patients with bacteremia: Vancomycin 1 g intravenous twice daily or Semi-Synthetic Penicillins 2 g intravenous every 4 hours for at least 5 days and up to 28 days.~Patients without bacteremia: Vancomycin 1 g intravenous twice daily or Semi-Synthetic Penicillins 2 g intravenous every 6 hours for at least 5 days and up to 14 days."
223472792|NCT03225430|BEHAVIORAL|Cognitive behavioural treatment for tics|Mainly based on the habit reversal treatment (HRT) and in addition to HRT components, they learn awareness training, relaxation, competing response, contingency management, and generalization training.
223472793|NCT03225430|BEHAVIORAL|Cognitive psychophysiological|Focus on the processes influencing thoughts and behaviors underlying tics.
223472794|NCT02923869|DRUG|Levobupivacaine|Children will receive 0.15 ml/kg of 0.2% Levobupivacaine through bilateral suprazygomatic MNB.
223472795|NCT02923869|DRUG|Bupivacaine|Children will receive 0.15 ml/kg of 0.2% Bupivacaine through bilateral suprazygomatic MNB.
223743875|NCT03662542|DRUG|Guselkumab Dose 2|Guselkumab Dose 2 will be administered as SC injection.
223743876|NCT03662542|DRUG|Golimumab Dose 1|Golimumab Dose 1 will be administered as SC injection.
223472796|NCT00651209|DRUG|Tenofovir|All patients receive 600 mg/day, oral telbivudine for 24 weeks. Patients with non-detectable HBV DNA continue 600 mg/day, oral telbivudine for the remaining treatment period (Sub-group 1) Patients with detectable HBV DNA receive 300 mg/day, oral tenofovir plus 600 mg/day, oral telbivudine for the remaining treatment period (Sub-group 2)
223472797|NCT03794596|DRUG|Avelumab|Colourless odourless aqueous solution for infusion at dose of 10mg/kg
223472798|NCT03794596|DRUG|Aspirin|300mg tablets
223580553|NCT05980338|PROCEDURE|genicular nerve ablation by thermal radiofrequency plus alcohol neurolysis|"radio-frequency will be done using the Neurotherm NT1100 re-generator. The 3 entry sites will be detected under fluoroscopy then local anesthesia will be performed using lidocaine 2% followed by the insertion of the 3 radiofrequency cannulas (STRYKER 20 G, 9 cm with 1 cm active tip) targeting the 3 main nerves of the knee.~A confirmation of the targeted sites is done under fluoroscopy in both A-P and lateral views then a motor stimulation will be done to ensure no undesirable motor response followed by lidocaine 1 % injection and placing of the radio-frequency cables and ablation was done at 80 degrees for 90 seconds . The procedure will be repeated 3 times at different levels in the lateral view. After the radiofrequency is done at each level a 1 ml of 70% alcohol will be injected making a total of 3 ml injection to each nerve Then remove the needles."
223580554|NCT00599690|PROCEDURE|Epi-LASK|10 eyes of 10 patients underwent epi-LASK, epithelial flaps were created with the Amadeus II, epi-LASIK-LASIK microkeratome (Ziemer ophthalmics systems AG, Switzerland). A Visx star 4 system (Visx, Santa Ana, CA, USA) was used to perform the laser ablation in all eyes
223580555|NCT06303245|OTHER|ABDOMINAL BINDERS|will be given abdominal binders along with basic physiotherapy care. Physiotherapy care will include sitting exercises such as deep breathing exercises, protected huffing technique will be performed to improve gases exchange and remove secretion. In supine exercises such as basic ROM, ankle pumps, pelvic rolling, leg sliding will be performed. Each exercise will be of 10 repetition. This exercise will be given for 2 days per week for 6 weeks. Along with these exercises education related postural management and breastfeeding positions will also be guided
223580556|NCT06303245|OTHER|TENS|will receive TENS with high frequency (F=100Hz and T=100μs), intensity according to patient's pain threshold, duration of 30 continuous minutes, 2 cm above and below incision, with electrodes transversally positioned and crossing the incision. Two treatment sessions will be done per week for the period of 6 weeks. This group will be given tens along with abdominal binders with basic physiotherapy care. (23) In this treatment female's abdomen will be measured by a standard inch tape, then, according to the abdominal circumference, the binder will be fastened for 6 weeks. The binder will be placed tightly at the lower abdominal level with the incision positioned at the middle part of the binder. Participants will be asked to note the time to record the duration of binder wearing before taking the break. The binder will be opened between 10 pm and 8 am. This group will be given abdominal binders along with basic physiotherapy care
223472799|NCT03794596|DRUG|Lansoprazole (Proton Pump Inhibitor)|300mg capsule
223472800|NCT03920956|OTHER|ABPM service by Pharmacists|Patients will receive ABPM services provided by a pharmacist and complete a patient satisfaction survey
223580557|NCT04788862|BIOLOGICAL|P. falciparum infected erythrocytes|Chloroquine sensitive P. falciparum 3D7-infected red blood cells, thawed and prepared under strict aseptic conditions, will be used as a challenge agent.
223743877|NCT03662542|DRUG|Golimumab Dose 2|Golimumab Dose 2 will be administered as SC injection.
224160817|NCT01603212|DRUG|IL-2|"Phase I Starting Dose: 7 million IU/m2 by vein on Days 2 - 5 of a 21 day cycle.~Phase II Starting Dose: Maximum tolerated dose (MTD) from Phase I."
224160818|NCT01603212|DRUG|Interferon Alpha-2b|5 million U/m2 subcutaneously on Days 1 - 5 of a 21 day cycle.
224160819|NCT01856803|DRUG|anti thymoglobulin|
224160820|NCT00655811|DRUG|Capsaicin|Topical application, 0.1%, Capzasin HP; Chattem Inc., Chattanooga, TN, U.S.A
224160821|NCT00655811|DRUG|Placebo moisturizing cream|Placebo moisturizing cream with no active ingredient (Cetaphil; Galderma Laboratories LP, Fort Worth, TX, U.S.A.)
224160822|NCT04486612|OTHER|spinal anesthesia|prospective observational study
224160823|NCT00662727|DEVICE|Cardiac Extracorporeal Shockwave Therapy generator (Cardiospec)|Energy Density - 0.09 mJ/mm2
224160824|NCT00662727|DEVICE|Placebo|Placebo
224160825|NCT06025084|DRUG|Egg Shell nanoparticles|Evaluate the effects of egg shell nanoparticles combined with Titanium dioxide nanoparticles in the treatment of dentin hypersensitivity at different time intervals.
224160826|NCT05899894|DEVICE|Neurally Adjusted Ventilatory Assist|NAVA mode will be titrated as per protocol alongside titration of PEEP levels. Peep will be titrated for all NAVA levels in a descending order 10,5,0 NAVA level will be titrated in an ascending order 0.5, 1.0, 1.5, 2.0 at each PEEP level
224304219|NCT01383213|OTHER|Oxygen therapy|patient in group oxygen therapy by Venturi Mask will be treated with oxygen until reaching clinical stability, or criteria of endotracheal intubation
223472801|NCT02576470|BEHAVIORAL|Biofeedback|Motor learning is improvement in movement overtime, followed by retaining what was learned. To determine whether movements are improving, kinematics must be assessed over time, beginning with defining specific kinematic goals, then continually re-evaluating goals throughout rehabilitation while providing the participants with biofeedback. Biofeedback is fundamental in motor learning, because it increases guidance and motivation, supplements losses in intrinsic feedback (proprioception), and facilitates generalization and retention. Biofeedback enhances the training of novel movements and could be essential for training swallowing maneuvers. Biofeedback training will occur 3 times.
223472802|NCT02576470|DEVICE|Transcranial Direct Current Stimulation|Weak direct currents can be applied non-invasively, transcranially and painlessly. Such application leads to transient changes in corticomotor excitability that are fully reversible. There are no known risks of tDCS of the brain, other than mild local discomfort at the electrode sites.The tDCS sessions will be separated by at least 24hrs, the electrode pads will not be used more than 4 times and they will be clean with a sterile saline solution.
223743878|NCT03662542|DRUG|Placebo|Placebo will be administered.
223743879|NCT00006294|DRUG|Chlorthalidone|participant's drug dose will be titrated from 12.5mg to 25mg over the course of the study
223743880|NCT00006294|DRUG|Lisinopril|participant's drug dose will be titrated from 10mg to 40mg over the course of the study
224160827|NCT03082807|DIETARY_SUPPLEMENT|NCDsport|Negative Calorie Diet supplemented with exercise
224160828|NCT03082807|DIETARY_SUPPLEMENT|LCDsport|Low-Calorie diet with exercise
223472803|NCT02576470|BEHAVIORAL|Financial Reward|Motor learning training can be enhanced by adjuvant techniques such as non-invasive neural stimulation and explicit reward. Both influence the primary motor cortex (M1), a key neural substrate of motor skill learning. Non-invasive neural stimulation reduces dysphagia after stroke as measured with subjective swallowing severity scales, however it is unknown whether it could also enhance swallowing maneuver training. Explicit reward (i.e. financial) incentivizes successful gains during motor training. Explicit reward has never been investigated in swallowing rehabilitation. However, it has been shown that increasing stress and financial penalty can reduce swallowing frequency in healthy adults.
223472804|NCT02576470|BEHAVIORAL|targeted dysphagia training maneuver|training swallowing maneuvers or compensatory techniques (referred to as targeted dysphagia training throughout this document) that might reduce their swallowing pathophysiology
223472805|NCT02576470|RADIATION|Videofluoroscopy (VF) and Barium|The videofluoroscopy (VF) and barium will be used to record swallowing in all participant groups. This will capture full resolution VF images of all subjects in real time in the lateral view. From the digital recording, image sequencing will be exported to an image processing computer system and archived. The image intensifier will be focused on the lips, posterior pharyngeal wall, hard palate, and just below the upper esophageal sphincter (UES), providing a full view of the oral cavity and neck. A simultaneously recorded time-code will facilitate frame-by-frame data analysis. VF is the only option for visualizing swallowing kinematics during the pharyngeal swallow.
223472806|NCT02576470|DEVICE|Transcranial Magnetic Stimulation|Transcranial Magnetic Stimulation (TMS) will be used to provide a single-pulse to the brain.
223472807|NCT02576470|DEVICE|Submental Electromyography|Submental Electromyography (sEMG) is used to train participants swallowing maneuvers.
223472808|NCT00965614|OTHER|MCG|Cardiac Arrhythmia,Heart Disease
223472809|NCT02123641|OTHER|Heavy resistance training|Supervised heavy resistance training three times weekly for 52 weeks.
223472810|NCT02123641|OTHER|Moderate intensity training|Moderate intensity training supervised once weekly and home based unsupervised two times weekly for 52 weeks.
223472811|NCT02123641|OTHER|Control|No training
223472812|NCT01988324|OTHER|FDHT-PET scan|
223472813|NCT01988324|OTHER|FES-PET scan|
223472814|NCT01988324|OTHER|CT-scan|
223472815|NCT01988324|OTHER|Bone scintigraphy|
223472816|NCT01988324|OTHER|Tumor biopsy|
223472817|NCT00689065|DRUG|CALAA-01|Subjects with solid tumors who satisfy the eligibility criteria will receive two, 21-day cycles of CALAA-01. A cycle will consist of four (4) 30-minute intravenous infusions administered on days 1, 3, 8, and 10 followed by 11 days of rest. If safe, a second 21-day cycle will be administered consisting of infusions on days 22, 24, 29 and 31 followed by 11 days of rest.
223472818|NCT05946733|PROCEDURE|Group A|After induction of general anesthesia, oblique subcostal TAP blocks will be done(14) under the guidance of Sonosite ,superficial probe ,14-15 MHz ultrasound transducer
223472819|NCT05946733|PROCEDURE|Group B|After induction of general anesthesia, bilateral lateral TAP block will be performed (15) under ultrasonographic guidance with transportable ultrasound device ( Sonosite ,superficial probe ,14-15 MHz)
223472820|NCT05946733|OTHER|Group C|the analgesia will be maintained using a morphine patient-controlled analgesia (PCA) device set to give 1.5 mg bolus administration of morphine without a basic rate and 15 min lock-out time. The total amount of morphine administration will be recorded for the subsequent 24 h
223472821|NCT03877822|BEHAVIORAL|Habitual activity|Two days of habitual physical activity, under normal free-living conditions
223580558|NCT03204890|OTHER|Transcutaneous Posterior Tibial Nerve Stimulation|Three (3) sessions per week for twelve (12) consecutive weeks, with a duration of 30 minutes each, with the application of 20 Hertz with a pulse amplitude of 200 MI sec. in each session. The intensity will be applied individually for each patient depending on the tolerance of the individual. In each session, it is normal to have plantar flexion of the foot and flexion of the first toe, and after the session and particularly during the first sessions there is the possibility of muscle pain, which should be tolerable.
223743881|NCT00006294|DRUG|Amlodipine|participant's drug dose will be titrated from 10mg to 40mg over the course of the study
223743882|NCT00006294|DRUG|Doxazosin|participant's drug dose will be titrated from 2mg to 8mg over the course of the study
224069413|NCT01780610|DRUG|Letrozole and human chorionic gonadotrophin|the follicular development is supported by Letrozole(LE) 2.5mg,once daily is introduced on cycle day 3 .And on cycle day 10 , a Vagina ultrasound is introduced to monitor the development of the follicular ,following by intramuscular gonadotrophin 37.5\~75 IU/d until there is a Luteinizing Hormone(LH) surge or ovulation .On the day appearing Luteinizing Hormone surge，patients is always introduced intramuscular human chorionic gonadotrophin(HCG) 10000 IU.If there is sill no Luteinizing Hormone surge when the follicle is 20-24mm ,the ovulation will be induced by HCG.Then the luteum was supported by HCG 2000-2500 IU/3d.Transfer of thawed embryos will be performed 3 days after ovulation is observed.
224069414|NCT01780610|DRUG|estradiol and progesterone|oral estradiol, 2 mg, once daily, was introduced on cycle day 3 with an increasing doses protocol. If the endometrial thickness was greater than 7mm, progesterone 40-60 mg in oil was administered via intramuscular injection. Transfer of thawed embryos was performed 3 days later
224160829|NCT04339322|OTHER|Follow up|Follow up to assess the outcome until complications, improvement, death or being transferred to another quarantine hospital.
223472822|NCT03877822|BEHAVIORAL|Bed rest|Two days of bed rest, to induce whole-body physical inactivity
223472823|NCT02104687|PROCEDURE|Flow group|After induction, each patient will obtain Transesophageal Dopplerometry probe (CardioQ) in order to monitor the parameters of CI, FTc, PV and SVR.
223472824|NCT02104687|PROCEDURE|Press group|After induction, the parameters of MAP and CVP will be monitored in each of the patients.
223472825|NCT05150574|BEHAVIORAL|Core Health Program|8-week structured stress management and health behaviour change program
223472826|NCT05150574|BEHAVIORAL|Daily resting HRV|Take regular HRV readings in the morning
223472827|NCT05150574|BEHAVIORAL|Momentary HRV feedback|Take regular HRV readings throughout the day when stressed and perform mindfulness activity
223472828|NCT05150574|BEHAVIORAL|Behavioural initiation coaching|15-minute health coaching session in first week of program to help participant set goals and create an action plan
223472829|NCT05150574|BEHAVIORAL|Practice with feedback coaching|15-minute health coaching session in week 2 or 4 of program to help participant review goals and modify action plans if needed
223472830|NCT03467451|PROCEDURE|Endoscopic Mucosectomy|Endoscopic Mucosectomy with anchorage of the tip of the loop
223472831|NCT01005667|DEVICE|BirthTrack|Measurement of cervical dilation and head station
223472832|NCT03217409|DRUG|Rosuvastatin+Ezetimibe|Rosuvastatin 5mg+Ezetimibe 10mg
223472833|NCT03217409|DRUG|Rosuvastatin|Rosuvastatin 5Mg Tablet
223472834|NCT01338896|DRUG|Rotigotine transdermal patch|8 mg/24 h, transdermal patch 8 mg/24 h, 2 days
223472835|NCT02674516|DEVICE|Transcranial direct current stimulation|
223472836|NCT02674516|DEVICE|Sham transcranial direct current stimulation|
223580559|NCT03137628|OTHER|colectomy, GA and MV|"general anesthesia protocol: anesthesia induction (midazolam 0.1mg/kg, sufentanil 0.5ug/kg, etomidate 0.3mg/kg, cisatracurium 0.2mg/kg); anesthesia maintenance \[sevoflurane 1.5-3%, cisatracurium 0.1mg/kg/h, sufentanil is supplemented during the entire surgical procedure according to patients' anesthetic situation, dexmedetomidine（used conditionally）0.4ug/kg/h\].~mechanical ventilation protocol: tidal volume 6-8 ml/kg, positive end-expiratory pressure 5 cmH2O, oxygen concentration 40%; respiratory rate 10-15/min, inspiratory/expiratory ratio 1:1.5."
223580560|NCT02763436|PROCEDURE|physiological-based cord clamping|The cord of the newborn infant is clamped after establishing stable breathing efforts. The suspected time ranges from 2-4 minutes.
223472837|NCT04653311|DEVICE|Endomina®|Endoscopic sleeve gastroplasty (Endomina) at J0 with multidisciplinary follow-up for 1 year
223580561|NCT01549873|DRUG|propofol|Propofol adjusted to maintain the bispectral index at 40-60.
223580562|NCT01549873|DRUG|Desflurane|Desflurane adjusted to maintain the bispectral index at 40-60.
223743883|NCT06267404|OTHER|Iliopsoas Positional release therapy|Group A(Iliopsoas Positional release group) Patient supine, with both hips are fully extended .Find a Tender point in Iliopsoas muscle, at the initiation of pain Passively try combination of flexion Adduction/Abduction medial or lateral rotation at hip joint and stop where pain start to diminished. Hold this position of relief for 30 seconds until minimum of 75% of relief is achieved. Apply three times, than passively take lower limb in extension. Administered on both limbs.
223743884|NCT06267404|OTHER|Conventional exercises|Group B (conventional Physical therapy) For Ultra sonic therapy Patient prone lying, Aqua-sonic gel is applied to lumbosacral area and ultrasonic head is moved in circular motion. For TENS Electrodes are placed in crossed pattern, Paravertebral at L1 and L5 (Box Pattern)with circuit crossing at L3 and current is applied for 10 minutes, Hot pack which is kept in hydro-collateral at 70°C and 75°C is, wrapped in several towel layers, applied for 10 minutes.
223743885|NCT03492099|DRUG|buprenorphine|Patients in this study will receive dosages to be determined by a physician that are specific to each patient.
223743886|NCT02631863|DRUG|Aminolaevulinic acid|Aminolaevulinic acid with illumination
223743887|NCT02631863|DRUG|Placebo|Placebo with illumination
224304220|NCT01383213|OTHER|Helmet CPAP|patient in group CPAP will be treated with CPAP until reaching clinical stability, or criteria of endotracheal intubation
223472838|NCT02879214|RADIATION|Simultaneous boost along with chemo|Prior studies have utilized a sequential boost to deliver a total dose of 55 - 60 Gy to the pelvic sidewall (covering the lower pelvic lymph nodes), including 8-10 Gy that is usually delivered with brachytherapy (1-3), the studies often use single drug. This study treatment plan will use dose intensify in both chemotherapy and radiation. The chemotherapy have two drugs regimens of mitomycin with cisplatin or taxol with cisplatin along of radiation dose escalate, the RT dose escalation to biological GTV defined by PET scan to dose of 57.50 Gy in 25 fx while the elective volumes are held constant at 45 Gy.
223472839|NCT06520956|BEHAVIORAL|Video based exercise group|In each session, 2 videos will be applied and each will be repeated 2-3 times, with a 3-minute rest break between each video. The total session will last an average of 20-30 minutes and 16 sessions of physical activity will be performed twice a week for a total of 8 weeks.
223472840|NCT00270673|PROCEDURE|Early lactate-directed therapy|
223472841|NCT00439972|DRUG|Ortho-Cyclen (R)|The first 21 tablets contain 35 micrograms ethinyl-estradiol and 250 micrograms norgestimate per tablet. The last 7 tablets contain no hormones. Ortho Cyclen (R) is taken for 1-2 months during the screening phase and for 2 months during the treatment phase of the study.
223472842|NCT00439972|DRUG|Ortho Evra (R)|Ortho-Evra® contains 0.75 mg ethinyl estradiol and 6 mg norelgestromin in each 20 cm square patch. The dosing schedule is to apply one patch each week for 3 weeks and no patch the 4th week. Ortho Evra (R) is taken for 2 months during the treatment phase of the study.
223472843|NCT00439972|DRUG|extended use of Ortho Evra (R)|The extended use regimen of Ortho Evra (R) contains 0.75 mg ethinyl estradiol and 6 mg norelgestromin in each 20 cm square patch. The dosing schedule for Ortho-Evra (R) is to apply one patch each week for 7 weeks and no patch the 8th week. Extended use Ortho Evra (R) is taken for 2 months during the treatment phase of the study.
223472844|NCT02116868|DEVICE|Pupillometry guided analgesia (PP)|Analgesia is guided by pupillary reflex provided by the pupillometer (AlgiScan). The anesthesiologist in charge must adjust the peroperative remifentanil dose (Target controlled infusion) during surgery according to the algorithm proposed (Tailored remifentanil controlled infusion). Administration of antihypertensive drugs or vasopressors is also guided.
223472845|NCT02116868|DRUG|Tailored remifentanil controlled infusion|The anesthesiologist in charge must adjust the peroperative remifentanil dose (Target controlled infusion) during surgery according to the algorithm proposed
223472846|NCT02116868|DRUG|Tailored antihypertensive drug administration|Administration of antihypertensive drugs or vasopressors is guided by the results of the pupillary reflex.
223472847|NCT01023204|DRUG|Paclitaxel|Solution, IV, 100 mg/m², weekly for 6 of 7 weeks, until disease progression or unacceptable toxicity became apparent
223472848|NCT06115655|DIAGNOSTIC_TEST|cfDNA methylation detection|Extract cfDNA from bile and plasma, and perform methylation detection.
223743888|NCT01217060|DRUG|Docetaxel|20 mg/m2 given by vein (IV) over 1 hour once a week for up to 5 1/2 weeks.
223743889|NCT01217060|DRUG|5-FU|300 mg/m2 given by vein, continuously for 96 hours a week for about 5 1/2 weeks.
223743890|NCT01217060|RADIATION|Radiotherapy|50.4 Gy (1.8G/Fx/day) for about 5 1/2 weeks, Monday through Friday.
223743891|NCT01217060|PROCEDURE|Esophagectomy|Surgery to remove part of esophagus and nearby lymph nodes, approximately 8 to 10 weeks after completing chemoradiation.
223743892|NCT01217060|DRUG|Dexamethasone|10 mg IV 30 minutes prior to weekly Docetaxel.
223472849|NCT02889068|OTHER|Blood sample|
223580563|NCT04097977|OTHER|An educational support model called RENEW (Rehabilitation for Empowerment, Natural Support, Education and Work) targeting young people with mental health difficulties.|"An educational support model called RENEW (Rehabilitation for Empowerment, Natural Support, Education and Work).~Intervention The RENEW-S intervention consists of two key elements: collaborative networking and a youth group.~Network meetings The RENEW-S network meetings is fundamental for this approach. First meeting between the young person and the facilitator is about what the young person can expect, and information about the principles and ideas behind RENEW-S. The RENEW-S process consists of 4 general phases: 1) a mapping process 2) the development of a team to support goal attainment 3) implementing the plans 4) preparation for exiting RENEW.~Youth group The group is structured around the same agenda each time, starting with a presentation round, followed by an activity within the topic of the day, and finishing with sharing experiences of the activity in plenum. The young people can find inspiration regarding themes and exercises in the RENEW manual."
223580564|NCT05702086|OTHER|SPARX (Smart, Positive, Active, Realistic, X-Factor thoughts)|SPARX (Smart, Positive, Active, Realistic, X-Factor thoughts) is a psychoeducational serious game (an e-intervention that utilizes gaming for serious purposes) that teaches established cognitive behavioural therapy strategies and techniques across seven levels or modules. The game is designed to address depressive symptoms in youth by helping them cope with negative thoughts and feelings, represented in the game as GNATs-Gloomy Negative Automatic Thoughts. SPARX was originally designed and developed at the University of Auckland with the specific needs of certain underserved groups of youth in mind, including Māori rangatahi, the Indigenous young people of Aotearoa, New Zealand.
223580565|NCT05811117|DIAGNOSTIC_TEST|There will be no intervention as we will study patients that undergo autopsy after CAR T cell infusion.|We will study patients that undergo autopsy after CAR T cell infusion.
223580566|NCT05518708|DRUG|BI 3032950|BI 3032950
223472850|NCT03348449|OTHER|Collection of data|Outcome of patients will be collected from charts to evaluate primary and secondary objectives
223472851|NCT04989673|OTHER|Biological sampling and collection (serum)|Detection of the dengue virus during the next scheduled biological assessment as part of normal pregnancy monitoring (additional tube of blood) among women from GNES and GNEF groups
223472852|NCT04989673|OTHER|Biological sampling and collection (placenta)|Detection of dengue virus in the placenta of GE patients (additional tube of placenta)
223472853|NCT04989673|OTHER|Questionnaire|Questionnaire on the patient's socio-economic conditions (10-minute interview with the Clinical Research Associate, CRA).
223472854|NCT04989673|OTHER|Data collection|Case Report Form will be completed by a Clinical Research Associate (CRA) from the medical file of the patient concerned and of her child at the 3 visits carried out (Pre inclusion V0 or Inclusion V1, Childbirth V2 and Maternity leave V3).
223472855|NCT00601055|BEHAVIORAL|Problem Solving-Rx Adherence (PSA)|In PSA, a therapist teaches the participant to identify problems related to depression, functioning, and treatment adherence; to generate multiple solutions; and to choose and implement one or more of those solutions.
223580567|NCT05518708|DRUG|Placebo|Placebo
223580568|NCT01263145|DRUG|Akt Inhibitor MK2206|Given PO
223580569|NCT01263145|OTHER|Laboratory Biomarker Analysis|Correlative studies
223580570|NCT01263145|DRUG|Paclitaxel|Given IV
223580571|NCT01263145|OTHER|Pharmacological Study|Correlative studies
223580572|NCT04897763|DRUG|89Zr-TLX250 PET/CT|Pretherapeutic 89Zr-TLX250 PET/CT
224069415|NCT05466214|BEHAVIORAL|Conjoint Behavioral Consultation (CBC)|Within the treatment group, CBC will be integrated into how a school-based specialist works with families and teachers of children with or at risk of severe emotional disturbance.
223472856|NCT00601055|BEHAVIORAL|PID-C|In PID-C, a therapist identifies obstacles to treatment adherence and helps the participant overcome those obstacles.
223472857|NCT05024279|DEVICE|Left bundle branch area pacing|"Left bundle branch area pacing will be applied as established in the literature using commercially available equipment.~In case of unsuccessful application of left bundle branch area pacing, cross-over to right ventricular pacing is allowed."
223472858|NCT05024279|DEVICE|Right ventricular pacing|Right ventricular pacing as the standard, established form of pacing will be applied in the control group. No cross-over to the intervention arm is anticipated.
223580573|NCT01133119|DRUG|Standard of Care|Subjects will have femoral sheaths removed under general anesthetic but without subcutaneous infiltration of bupivacaine.
223580574|NCT01133119|DRUG|Standard of Care plus bupivacaine|"Subcutaneous dose of 0.25% bupivacaine infiltrated around the entry site of the femoral artery/vein sheath, just prior to sheath removal.~Participants will receive a dose of up to 0.8mL/kg (up to 2.0 mg/kg) of 0.25% bupivacaine, with the final amount at the discretion of the physician."
223580575|NCT00889889|BIOLOGICAL|Cell-Derived Trivalent Subunit Influenza Vaccine|surface antigen, inactivated, prepared in cell cultures
224069416|NCT01748344|DRUG|Cetirizine|10mg tablets
224069417|NCT01748344|DRUG|High dose ONO-4053|Experimental
223580576|NCT00889889|BIOLOGICAL|Placebo|Placebo
223580577|NCT05077462|DRUG|C52R1M Tab. and C52R2 Tab.|Single oral dose C52R1M(FDC, Valsartan/Amlodipine) 160/5 mg tablet and C52R2(Chlorthalidone) 25 mg tablet taken together
223580578|NCT05077462|DRUG|AJU-C52H|Single oral dose AJU-C52(Valsartan/Amlodipine/Chlorthalidone) 160/5/25 mg FDC tablet
223743893|NCT01854905|OTHER|No Treatment|Patients attending consultation for LASIK on Day 1. No intervention or treatment is administered during the study.
223743894|NCT01047956|DRUG|Methadone; NAC|Methadone NAC
223743895|NCT01047956|DRUG|Methadone|Methadone
223743896|NCT03535428|DIAGNOSTIC_TEST|VENOUS exploration|venous echo doppler ultrasound and abdo pelvic scanner in the 48h before surgery
223743897|NCT00006209|DRUG|Tucaresol|
224069418|NCT01748344|DRUG|Low dose ONO-4053|Experimental
224069419|NCT01748344|DRUG|Placebo|None active
224160830|NCT03432572|DRUG|Pyridium|a urine discoloration agent
224160831|NCT03432572|DRUG|Riboflavin|a urine discoloration agent
224160832|NCT03432572|DRUG|Thiamine|active placebo not known to cause urine discoloration
223472859|NCT06429865|DIAGNOSTIC_TEST|cytosponge|Use of cytosponge as a tool to patients who need surveillance after endoscopic submucosal dissection for esophageal squamous cell carcinoma
223472860|NCT00138528|DRUG|Fluvastatin|
223743898|NCT05403242|DRUG|RC48-ADC|2.0 mg/kg, IV, d1, every 2 weeks; or 2.5 mg/kg, IV, d1, every 2 weeks
223743899|NCT05403242|DRUG|S-1|40-60 mg, bid po, d1-10, every 2 weeks
223743900|NCT04031833|DRUG|MAT2203|Encochleated amphotericin B
223743901|NCT04031833|DRUG|Amphotericin B|Intravenous amphotericin B
224069420|NCT04930575|OTHER|Muscle Energy Technique|A biomechanical correction approach can lead to the normalization of spinal curvatures and a decrease in the compressional and tensional stress on joints and soft tissues of the body.
224069421|NCT04930575|OTHER|Mulligan Technique|"* The patient will be in a supportive low back chair, thus cervical region will be in a vertical position (Weight-bearing position) with the therapist position will be behind the patient.~* Then the therapist will move the spinous process up in the direction that must follow the apophyseal joint plane under treatment, that is, toward the eye ball. While sustaining this pain-free accessory glide, the patient will be instructed to actively perform the physiological movement gradually until the end ROM with over pressure at the end of the range."
224069422|NCT02490085|OTHER|24-hour intervention with multiple daily injections|Subjects will be admitted at the research clinical facility at 20:00. A cannula will be inserted into an arm or a hand vein for blood sampling purposes. The subjects will carry on with their normal insulin therapy. Two periods of walking of 15 minutes will be performed at 10:00 and 15:00. Meals will be served at 8:00, 12:00 and 17:00. The CHO content of meals will be adapted to subject's usual CHO intake. Venous blood samples (4 ml each) will be obtained for the measurement of the plasma glucose and insulin. Plasma glucagon and C-peptide will be measured every hour. Blood samples will be drawn every 20 minutes.
224069423|NCT02490085|OTHER|24-hour intervention with closed-loop strategy|Subjects will be admitted at the research clinical facility at 20:00. A cannula will be inserted into an arm or a hand vein for blood sampling purposes. A cartridge containing subject's usual fast acting insulin analog will be placed in the insulin pump. Closed-loop strategy will start at 21:00 until 21:00 the next day. Neither basal nor prandial insulin injections will be given. Two periods of walking of 15 minutes will be performed at 10:00 and 15:00. Meals will be served at 8:00, 12:00 and 17:00. The CHO content of meals will be adapted to subject's usual CHO intake. Venous blood samples (4 ml each) will be obtained for the measurement of the plasma glucose and insulin. Plasma glucagon and C-peptide will be measured every hour. Blood samples will be drawn every 20 minutes.
224069424|NCT02490085|DRUG|Insulin|Subject's usual insulin analog will be used.
224160833|NCT06067932|RADIATION|Foot X rays|Radiographs of ankle and foot anteroposterior/dorsoplantar were taken in standing position with a centralized beam on the ankle joint.
224160834|NCT06067932|DIAGNOSTIC_TEST|Clinical examination + scores|The American Orthopedic Foot and Ankle Society Score (AOFAS- midfoot section and 1st Forefoot ray, Forefoot ray 2-5) and the foot function index (FFI) were assessed
224160835|NCT00546507|DRUG|TDS-943 (topical diclofenac sodium 4% spray)|
224160836|NCT00546507|DRUG|celecoxib|
224160837|NCT00546507|OTHER|placebo|
224160838|NCT00814307|DRUG|CP-690,550|5mg CP-690,550 BID PO for 6 months
223472861|NCT02662569|BIOLOGICAL|Evolocumab|Administered by subcutaneous injection
223472862|NCT02662569|DRUG|Atorvastatin|Administered orally once a day
223472863|NCT02662569|OTHER|Placebo|Placebo to evolocumab administered by subcutaneous injection
223472864|NCT00197678|DIETARY_SUPPLEMENT|Multivitamins-Multiples of RDA|20 mg B1, 20 mg B2, 25 mg B6, 50 mcg B12, 100 mg niacin, 500 mg C, 30 mg E, 0.8 mg folic acid taken orally once per day until 6 weeks after delivery
223472865|NCT00197678|DIETARY_SUPPLEMENT|Multivitamins-Single RDA|1.4 mg B1, 1.4 mg B2, 1.9 mg B6, 50 mcg B12, 100 mg niacin, 70 mg C, 10 mg E, and 0.4 mg folic acid taken orally once per day until 6 weeks after delivery
223472866|NCT05341024|OTHER|Pelvic Floor Muscle Training in female CrossFit and functional fitness exercisers|The intervention will consist of a home-based PFM training program with weekly follow-up by phone by a physiotherapist. Before commencing PFM training, the participants in the intervention group will have an individual session with a physiotherapist including thorough teaching on how to perform a correct PFM contraction (clinical exams of pelvic floor muscle function by observation and vaginal digital palpation) and instructions on how to perform the training program. The program consists of 3 sets of 8-12 maximum contractions per day. An electronic app (Athlete monitoring) will be used to assess adherence to the program. The participants will be asked to register their training sessions in a personal account. A reminder to adhere to the program will be sent by phone. The training period will be 16 weeks and the exercises will take approximately 10 minutes per day to perform.
223472867|NCT02711462|DRUG|PF-06687234|PF-06687234 will be administered via the SC or the IV route and in either single dose or multiple doses
224160839|NCT00814307|DRUG|CP-690,550|10 mg CP-690,550 BID PO for 6 months
223472868|NCT02711462|DRUG|Placebo|In Cohorts 1 and 2, up to 1 subject will receive placebo. In all other Cohorts (Cohorts 3 to 11), up to 2 subjects will receive placebo.
223472869|NCT02991274|PROCEDURE|genomic testing of T790M mutation|patients will need to have genomic testing of T790M mutation at hospital laboratories and in central laboratory.
223472870|NCT00572689|DRUG|Exenatide|10 microgram injected sub-cutaneously once
223472871|NCT00572689|GENETIC|Buccal/blood Sample Collection|Buccal/blood Sample collection for TCF7L2 polymorphism genetic testing
223472872|NCT05982327|PROCEDURE|ORIF|fixation of scapular fractures by plate and screws
223472873|NCT01279746|DEVICE|Ultrasound compression of femoral and popliteal veins|Bedside ultrasound compression of femoral and popliteal veins.
223472874|NCT00003686|DRUG|pilocarpine hydrochloride|Pilocarpine 5 mg po qid x 4 weeks
223472875|NCT00003686|DRUG|Placebo|Placebo 5 mg po qid x 4 weeks
223472876|NCT00000575|DRUG|Placebo|Two 100 Og puffs budesonide placebo bid + two 90 Og puffs albuterol prn OR four 2 mg puffs nedocromil placebo bid + two 90 Og puffs albuterol prn.
223472877|NCT00000575|DRUG|Nedocromil|Four 2 mg puffs bid + two 90 Og puffs albuterol prn
223472878|NCT00000575|DRUG|Budesonide|Two 100 Og puffs bid + two 90 Og puffs albuterol prn.
223472879|NCT03002896|BEHAVIORAL|Pep-Pal|Pep-Pal is designed to complement the utilization of other resources, provide support when no other resources can be obtained, or provide support in the interim until greater resources can be obtained. In this way, Pep-Pal is a resource for our most hard to reach caregivers.
223472880|NCT03002896|OTHER|Treatment as Usual|
223472881|NCT05284175|DRUG|Orelabrutinib|Orelabrutinib, orally, 50 mg QD
223472882|NCT06330714|OTHER|Symptoms of chronic illness.|"The patient is advised to monitor BP and body weight daily in a standardized fashion as described below:~* Body weight should be measured in the morning without clothes or shoes after emptying the urinary bladder but before breakfast.~* BP should be measured in the morning preferably using the right arm, sitting comfortably in a chair after 5 minutes of rest in the seated position."
223472883|NCT06222801|DRUG|Tumor necrosis factor alpha|Antitumor agent. Immunomodulatory agent.
223472884|NCT06222801|DRUG|Interferon gamma|Immunostimulating agent.
223472885|NCT01367197|BEHAVIORAL|exercise training|group based exercise training
223472886|NCT00003819|BIOLOGICAL|QS21|
223472887|NCT00003819|BIOLOGICAL|TF(c)-KLH conjugate vaccine|
223472888|NCT00003819|BIOLOGICAL|Thomsen-Friedenreich antigen|
223472889|NCT00003819|BIOLOGICAL|keyhole limpet hemocyanin|
223472890|NCT03863353|BEHAVIORAL|Educational Intervention|This intervention provides scenario-tailored opioid risk message feedback immediately following interactive analgesic decision-making exercises.
223472891|NCT05715619|BIOLOGICAL|VRELysin™|A cocktail of lytic Enterococcus-specific bacteriophages orally administered with sodium bicarbonate solution
223472892|NCT05715619|OTHER|Placebo|Placebo orally administered with sodium bicarbonate solution
223472893|NCT06580223|DRUG|Aspirin 100mg|Aspirin, enteric coating of tablets, oral administration
224160840|NCT00814307|DRUG|Placebo|Placebo patients advance to 5mg CP-690,550 BID at Month 3 visit
224160841|NCT00814307|DRUG|Placebo|Placebo patients advance to 10mg CP-690,550 BID at Month 3 visit
223472894|NCT06580223|DRUG|Rivaroxaban 10mg|Rivaroxaban, tablets, oral administration.
223472895|NCT05647187|DIAGNOSTIC_TEST|Serum Interleukin 17 levels|Serum Interleukin 17 levels will be measured pre and post treatment by NB-UVB by performing an enzyme-linked immune sorbent assay (ELISA)
223580579|NCT04928209|OTHER|Speech-Language Teletherapy|Access to speech-language teletherapy will be provided as a supplement to Usual Care for subjects randomized to this group. Access is provided by way of 1) direct referral by the clinical team to a teletherapist; 2) availability of a teletherapy slot. All teletherapy providers will be licensed speech-language pathologists (SLPs) and/or credentialed teachers of the deaf (TODs) with specialized training to work with children who are D/HH using an LSL approach. Fluent English and Spanish speaking providers will be matched to the child's home, native language. Teletherapy itself is within routine clinical care and is not considered a research activity. Children who randomize to the Low TT study arm will receive access to an 18-month course of weekly teletherapy, in accordance with the centers' standard of care. The exact details of the therapy course and frequency will be determined based on individual family needs.
223580580|NCT06075992|OTHER|experimental group|An experimental application will not be made to premature babies in this group.
223580581|NCT01838785|DRUG|18F-DTBZ AV-133|
223580582|NCT03234296|DRUG|Ertapenem|Intravenous antibiotic followed by per oral antibiotics
223472896|NCT05647187|RADIATION|NB-UVB|patients will be exposed to narrow band UVB twice weekly for three months
223472897|NCT01299584|DRUG|Remifentanil|Basically there is no treatment allocation. Subjects who would be administered of remifentanil at their physicians' discretion will be enrolled. Dosage regimen will be recommended according to the prescribing information. Subjects will be enrolled consecutively.
223472898|NCT01166919|DEVICE|Matrix Radiofrequency|Matrix Radiofrequency Treatment of Port Wine Stain Birthmarks
223472899|NCT01389778|DRUG|Metformin ER|Metformin ER 1500 mg for 12 weeks
223472900|NCT01389778|DRUG|Metformin|
223472901|NCT02121977|DEVICE|Elevate Anterior and Apical|
223472902|NCT02121977|PROCEDURE|Native Tissue Repair for pelvic organ prolapse|
223472903|NCT02005796|OTHER|Dietary intervention|
223472904|NCT00448656|PROCEDURE|ablation of pulmonary veins by video assisted thoracic surgery|epicardial ablation using HIFU
223472905|NCT03972033|BEHAVIORAL|EMDR|"Treatments will be independent and blinded to the clinical psychologists conducting the clinical assessments. EMDR and CBT treatments will be provided for 16 weeks, each comprising 16 weekly individual sessions. Interventions will be conducted according to published treatment manuals. All treatment sessions will be video recorded for fidelity rating and supervision.~As a safety criterion, if severe worsening of symptoms is observed, patients are withdrawn from their assigned treatment arm."
223472906|NCT03972033|BEHAVIORAL|CBT|"Treatments will be independent and blinded to the clinical psychologists conducting the clinical assessments. EMDR and CBT treatments will be provided for 16 weeks, each comprising 16 weekly individual sessions. Interventions will be conducted according to published treatment manuals. All treatment sessions will be video recorded for fidelity rating and supervision.~As a safety criterion, if severe worsening of symptoms is observed, patients are withdrawn from their assigned treatment arm."
223472907|NCT02806167|OTHER|Clinical algorithm|Patients presenting with suspected acute CES will be assessed in accordance with the algorithm previously outlined.
223472908|NCT03273062|DRUG|Tolcapone 200 MG|Tolcapone 200 MG TID
223472909|NCT03273062|OTHER|Placebo|Placebo, TID Placebo will be in capsules that are identical in appearance to intervention drug, Tolcapone.
223472910|NCT02618746|OTHER|Telerehabilitation|
223472911|NCT02618746|OTHER|Hospital based Rehabilitation|
223580583|NCT03234296|OTHER|Placebo|Intravenous placebo followed by per oral placebo
224160842|NCT03942237|PROCEDURE|single-injection QLB(quadratus lumborum block)|"Inject 0.4ml/kg 0.5% ropivacaine between quadratus lumborum and psoas major muscle~Device: The curved (C1-5) probe of Ultrasound Scanner Philips CX50 is used for scan~Drug: single dose ropivacaine 0.4ml/kg 0.5% ropivacaine is given immediately after the correct position of needle tip is verified."
224160843|NCT03942237|PROCEDURE|Placebo Control|"Inject 0.4ml/kg saline between quadratus lumborum and psoas major muscle~Device: The curved (C1-5) probe of Ultrasound Scanner Philips CX50 is used for scan~Drug: single dose 0.4ml/kg 0.9% NS is given immediately after the correct position of the needle tip is verified"
224160844|NCT00740363|DRUG|sitagliptin|Once daily sitagliptin. If GFR\>50 ml/min/1.73m2: 100 mg/day. If GFR from 25 to 49 ml/min/1.3m2: 50 mg/day
224160845|NCT00740363|DRUG|placebo|No active sitagliptin treatment for 4 weeks
224160846|NCT03043261|BEHAVIORAL|Williams LifeSkills|Online multi-media interactive training modules which address 10 core skills to improve coping, stress management and interpersonal relationships.
224160847|NCT03529370|RADIATION|optic nerve ultrasound|sonograhy of the optic nerve sheath diameter
223472912|NCT05012267|OTHER|16-hour PP|PP according to previous study
223472913|NCT02747927|DRUG|Placebo|TDV placebo-matching SC injection.
224160848|NCT03039192|DRUG|Esketamine|Intranasal esketamine solution 84 milligram (mg)
224160849|NCT03039192|OTHER|Placebo|Intranasal Placebo solution
223472914|NCT02747927|BIOLOGICAL|Tetravalent Dengue Vaccine (TDV)|TDV SC injection.
223472915|NCT03240419|DIETARY_SUPPLEMENT|Probiotics|Bifidobacterium BB12 and Lactobacillus Rhamosus LGG (50%:50%) capsules.
223472916|NCT03240419|DIETARY_SUPPLEMENT|Placebo|capsule manufactured to mimic probiotic capsules.
223472917|NCT03884335|PROCEDURE|laparoscopic radical prostatectomy|The surgery was carried out by laparoscopy. Intraoperative anesthetic maintenance was performed with TCI of propofol infusion for bispectral index between 40 and 60, restrictive administration of fluids or goal-directed parenteral fluid administration, normothermia, normotension and optimal intraoperative analgesia were maintained following the criteria of ERP. Afterwards, patients were awoken from general anaesthesia and transferred to the post-anaesthesia care unit (PACU) for a 6-hour follow-up prior to transfer to conventional ward.
223472918|NCT00411320|DRUG|oral steroid-dexamethasone|2 week steroid trial
223472919|NCT05572203|DIETARY_SUPPLEMENT|Intrinsically labelled protein|It is a protein drink that includes Intrinsically labelled Casein ( from Arla Foods), 13C/2H-labelled Spirulina (from CK Isotopes), and 13C/2H-labelled amino acids (from CK Isotopes)
223472920|NCT00773617|BEHAVIORAL|ICAT|ICAT is a new manual-based psychotherapy treatment for bulimia nervosa (BN) that focuses on emotions and bulimic behavior.
223472921|NCT00773617|BEHAVIORAL|CBT|CBT is a highly structured, manual-based psychotherapy that has been shown to be effective in the treatment of BN. CBT focuses on cognitions and bulimic behavior.
224160850|NCT03039192|OTHER|Standard of Care|The standard of care antidepressant treatment (antidepressant monotherapy or antidepressant plus augmentation therapy) will be determined by the treating physician(s) based on clinical judgement and practice guidelines prior to randomization, and the treatment will be initiated on Day 1.
223472922|NCT01434446|BEHAVIORAL|Sound stimulation|Listening to sound stimuli at the lowest audible level.
223472923|NCT01891214|OTHER|Validation of the French Version of the Inflammatory Bowel Disease Questionnaire (IBDQ)|
223472924|NCT03955172|DRUG|Everolimus|Patients will received everolimus (CERTICAN), oral form, at the necessary dose to obtain trough levels between 6 and 8 ng/ml, during 6 months. Everolimus will replace the anti-proliferative drug they have before (azathioprine or mycophenolic acid). Everolimus will be associated with corticosteroids (prednisolone) and a calcineurin inhibitor (tacrolimus or cyclosporin).
224160851|NCT02324738|DRUG|Mefloquine and Dihydroartemisinin-piperaquine|2 tablets of mefloquine and 3 tablets of dihydroartemisinin-piperaquine single dose
223472925|NCT06405893|BEHAVIORAL|Mindful breathing exercise|Participants do a 10 minute guided mindful breathing exercise or participants do listen to a 10 minute control recording
223472926|NCT02333253|DRUG|cetrotide|0.25 cetrotide S.c was added on when leading follicle reach \>12 mm
223472927|NCT03470077|DRUG|IV nalbuphine 0.1 mg/kg with induction of anesthesia.|"Group A: 40 patients will receive IV nalbuphine 0.1 mg/kg with induction of anesthesia.~."
223472928|NCT03470077|DRUG|IV nalbuphine 0.1 mg/kg at the end of surgery.|Group B: 40 patients will receive IV nalbuphine 0.1 mg/kg at the end of surgery just before discontinuation of anesthesia.
223472929|NCT02679976|DEVICE|etafilcon A|Marketed Multifocal Contact Lens
223472930|NCT04735042|DRUG|Empagliflozin / Linagliptin or Dapagliflozin/Saxagliptin Pill|association between SGLT2-inhibitor and DPP4-inhibitor
223472931|NCT04735042|DRUG|Empagliflozin or Dapagliflozin Pill|SGLT2-inhibitor: diabetic oral drug with diuretic properties.
223472932|NCT05658068|BEHAVIORAL|SAFE Spaces training and coaching|Staff in facilities assigned to the intervention are eligible to receive evidence-based programming in suicide detection and prevention (Shield of Care; SOC) and wellness skill-building (Skills for Life) through training and personalized coaching. Multiple training sessions will be offered to small groups of staff in-person in residential facilities and paired with personalized in-person and virtual coaching.
223472933|NCT06501521|DIAGNOSTIC_TEST|Diagnostic test|No intervention among the arms. The diagnostic, prognostic, predictive and follow-up value of tested biomolecules will be analyzed.
223472934|NCT06550778|BEHAVIORAL|Mindfulness-based emotional regulation intervention|"The intervention was conducted once a week for 6 weeks, with each session lasting 90-120 minutes, including a 30-minute parenting course each week. The intervention program was divided into 6 themes, including Entering mindfulness, feeling the connection between emotions and the body, Dealing with negative emotions, Moderate emotional expression, Mindfulness to relieve anxiety, Learning to be grateful and Embrace future life. The intervention content integrates mindfulness training, parental mindful parenting exercises and emotion regulation skills. For details, refer to Greenland's Mindfulness Games, Bögels' Mindful Parenting Manual, mindful breathing and meditation in MBSR and MBCT, as well as emotion regulation skills. The intervention location was the activity room of the child and adolescent psychology unit of the hospital."
223472935|NCT00072449|BIOLOGICAL|rituximab|
223472936|NCT03810183|DRUG|QAW039|QAW039 (fevipiprant) 450 mg once daily for 6 weeks administered orally as a tablet + Standard of Care
223472937|NCT03810183|DRUG|Placebo|Placebo once daily for 6 weeks administered orally as a tablet + Standard of Care
223472938|NCT02064556|DRUG|Amlodipine 10mg|Amlodipine 10mg 1T, PO, QD for 9days
223472939|NCT02064556|DRUG|Amlodipine 10mg/Candesartan 32mg|Amlodipine 10mg 1T, PO, QD for 9days/Candesartan 32mg 1T, PO, QD for 9days
223580584|NCT02262078|DRUG|Sodium Nitrite Inhalation Solution|90mg of (nebulized) inhaled sodium nitrite will be administered (by inhalation) to participants prior to exercise.
223580585|NCT02262078|OTHER|Placebo|Normal saline will be administered (by inhalation) to participants prior to exercise.
223580586|NCT03529097|DRUG|0.9% Sodium-chloride|2 liters of 0.9% NaCl IV fluids
223580587|NCT03529097|DRUG|Placebos|2 liters of 0.9% NaCl bag covered with black bag so the participant could not tell the fluids are not dripping to his vain
224160852|NCT02324738|OTHER|Wash-out period|
224160853|NCT02324738|DRUG|Mefloquine|2 tablets of Mefloquine single dose
224160854|NCT06429397|DRUG|Anlotinib and Benmelstobart|Enrolled patients received a treatment cycle every 21 days: 200mg of piamprizumab was given intravenously on the first day of treatment, and 12mg of anrotinib hydrochloride capsule was given continuously for 14 days and suspended for 7 days.
223580588|NCT03529097|DRUG|Optalgin, Voltaren, Morphine|Oral and IV Optalgin, Voltaren IM (intramuscular), Morphine IV. All according to the pain intensity and with concordance to the physician.
223580589|NCT02194322|DRUG|BIBN 4096 BS - in single rising doses|
223580590|NCT02194322|DRUG|Placebo|
223580591|NCT01688739|DRUG|Erenumab|Administered by subcutaneous injection or intravenous injection
223580592|NCT01688739|DRUG|Placebo|Administered by subcutaneous injection or intravenous injection
223580593|NCT00011011|BIOLOGICAL|ALVAC(2)120(B,MN)GNP (vCP1452)|
223580594|NCT04172467|OTHER|non-interventional retrospective epidemiological observational study|non-interventional retrospective epidemiological observational study
224069425|NCT02490085|DEVICE|Insulin pump Accu-Chek Combo|During closed-loop intervention, the Accu-Chek Combo (Roche) insulin pump will be used
224069426|NCT02490085|DEVICE|Dexcom G4 Platinum|In both visits, glucose levels will be measure with the Dexcom G4 Platinum (Dexcom)
224069427|NCT04813029|PROCEDURE|Straight leg raise maneuver|With the patient in supine position, one leg is raised to form an angle of at least 45 degrees with the bed. The patient will be asked to keep that position for at least 5 seconds. The maneuver will be repeated after 20-30 seconds. The first adequate maneuver will be considered for the study. Intra-esophageal and intra-abdominal pressure will be analyzed both during baseline and SLR maneuver. Intra-esophageal pressure is measured as peak and mean over 5 seconds, 1 cm and 5 cm above the proximal margin of the LES. Intra-abdominal pressure will be measured as peak and mean over 5 seconds 1 cm below the distal margin of the diaphragm notch.
224069428|NCT01315379|BEHAVIORAL|Prolonged Exposure Therapy|This intervention comprises 12-18 sessions of cognitive behavior therapy for PTSD with the components (a) Psychological education, (b) in vivo exposure (c) prolonged imaginal exposure, (d) cognitive restructuring (e) summary and relapse prevention.
224069429|NCT03340844|PROCEDURE|No Touch (NT)|Tumor resection by No-touch technique: dissection of hepatic hilum, dissection of superior mesenteric vein (SMV) in caudal aspect of pancreas, section of antrum, pancreatic neck section. Section-ligation of veins of duodenopancreatectomy part of SMV and portal. Then Kocher-uncrossing maneuver of the jejunal loop and final section of the retro-portal (back of the portal vein) blade.
224160855|NCT02345044|DRUG|CS-3150|
224160856|NCT02345044|DRUG|placebo|
224160857|NCT02345044|DRUG|eplerenone|
223580595|NCT03454516|OTHER|telemonitoring|the follow-up of the patient will be performed with Telemonitoring
223580596|NCT00812903|BEHAVIORAL|Exercise|Training exercises chosen with background in knowledge of intelligent training
223580597|NCT02270723|DRUG|"5% Human Albumin  Behring"|Intravenous infusion of 5% Human Albumin during major surgery
223580598|NCT02270723|DRUG|Lactated Ringer|Intravenous infusion of Lactated Ringer during major surgery
223580599|NCT02559414|DRUG|Aspirin|
223580600|NCT02559414|DRUG|Clopidogrel|
224160858|NCT05786976|OTHER|Lotion BNO 3732|Crem body lotion twice daily
224160859|NCT05786976|OTHER|Body Lotion Benchmark product|Crem body lotion twice daily
224160860|NCT00435357|DEVICE|mobile-bearing TKA|
224160861|NCT00435357|DEVICE|fixed- bearing TKA|
224160862|NCT00777257|BIOLOGICAL|T dap + Meningococcal Polysaccharide Diphtheria Toxoid Conj.|Day 0: 0.5 mL (T dap)+ Placebo, Intramuscular; Day 28: 0.5 mL (Menactra®) Intramuscular
224160863|NCT00777257|BIOLOGICAL|Tdap + Meningococcal Polysaccharide Diphtheria Toxoid Conj.|Day 0: 0.5 mL (T dap) + 0.5 mL (Menactra®) Intramuscular; Day 28: Placebo 0.5 mL Intramuscular
224160864|NCT00777257|BIOLOGICAL|Meningococcal Polysaccharide Diphtheria Toxoid Conj. + T dap|Day 0: 0.5 mL (Menactra®)+0.5 mL Placebo, Intramuscular; Day 28: 0.5 mL (T dap) Intramuscular
224160865|NCT02267902|DRUG|DA-1229|
224160866|NCT03023319|DRUG|Bosutinib|100mg daily for 4 cycles (21 days per cycle)
224160867|NCT03023319|DRUG|Pemetrexed|500 mg/m2 every 21 days for 4 cycles
224160868|NCT00364468|DRUG|pegfilgrastim|
224160869|NCT02113644|OTHER|Lifestyle intervention|
224160870|NCT00098865|DRUG|temozolomide|The lower 150/m2 Temozolomide dose was for patients who had previously received significant therapy to the bone marrow (chemotherapy or radiation) or cranial spinal raditation.
224160871|NCT00098865|DRUG|thalidomide|Calculated dose was rounded down to the nearest 50mg, or up to 50mg if calculated dose was less than 50mg. Patients increased the daily dose by 50mg (one capsule) on a weekly basis unitl either unacceptable toxicity or a maximum dose.
224160872|NCT03268057|DRUG|VX15/2503 + avelumab|Dose escalation will begin at 5 mg/kg of VX15/2503 and will increase up to 20 mg/kg with a constant dose of avelumab at 10 mg/kg. A recommended phase II dose of VX15/2503 will be determined and then utilized in the expansion phase with 10 mg/kg of avelumab.
224160873|NCT03812198|DRUG|LEO 32731 modified release tablet|At each dosing, subjects will swallow the appropriate number of tablets with approximately 240 mL of water at room temperature.
224160874|NCT03812198|DRUG|LEO 32731 blend, hard capsule|At each dosing, subjects will swallow the appropriate number of capsules with approximately 240 mL of water at room temperature.
224160875|NCT03812198|DRUG|LEO 32731 API, hard capsule|At each dosing, subjects will swallow the appropriate number of capsules with approximately 240 mL of water at room temperature.
224160876|NCT03812198|DRUG|LEO 32731 soft capsule|At each dosing, subjects will swallow the appropriate number of capsules with approximately 240 mL of water at room temperature.
224160877|NCT03812198|DRUG|LEO 32731 gastro-resistant capsule|At each dosing, subjects will swallow the appropriate number of capsules with approximately 240 mL of water at room temperature.
224160878|NCT03812198|DRUG|LEO 32731|At each dosing, subjects will swallow the appropriate number of tablets or capsules with approximately 240 mL of water at room temperature.
224160879|NCT03812198|OTHER|Placebo|At each dosing, subjects will swallow the appropriate number of tablets or capsules with approximately 240 mL of water at room temperature.
224160880|NCT00054860|BIOLOGICAL|EP HIV-1090|
224160881|NCT05375656|OTHER|Cross-over study|Traditional Inuit Diet and Western Diet.
224160882|NCT05977374|OTHER|experimental and conventional group|Static stretchings of the lower limb, Ultrasound 1 MHz 1.5W/cm2 7 mins, knee isometrics, open chain activities, knee mobilizations grade 1 and 2, and home care plan.
224160883|NCT04120350|DRUG|Methotrexate|3.5g/m2 intravenous infusion for 4 hours in d1, every 21 days for 1 cycle. 6 cycles will be prescribed as protocol
223580601|NCT01660100|PROCEDURE|Pulmonary vein antrum isolation (PVAI)|In this group, only standard PVAI will be performed during the primary procedure. Three months later, a 2nd procedure will be performed in all subjects regardless of the recurrence of atrial arrhythmias. Subjects in whom pulmonary vein antrum remains isolated will enter follow-up; however, patients who have pulmonary vein-left atrium reconnection will undergo an re-isolation. Patients who have pulmonary vein antrum re-isolation are subject to a 3rd procedure 3 months later to check the status of pulmonary vein-left atrium connection. Patients will enter follow-up for long-term outcome only after permanent PVAI is confirmed by a repeat procedure.
223472940|NCT06960993|BEHAVIORAL|Intervention website|Website that includes experiential information, stress and coping resources, educational content, and links to trusted websites with additional educational content and links to psychosocial resources for transplant recipients and caregivers.
223472941|NCT06960993|BEHAVIORAL|Enhanced Usual Care (Control) Website|Website that includes stress and coping resources, educational content, and links to trusted websites with additional educational content and links to psychosocial resources for transplant recipients and caregivers.
223472942|NCT00323063|DRUG|gemcitabine hydrochloride|Given IV
223472943|NCT00323063|DRUG|imatinib mesylate|Given orally
223472944|NCT02499562|DRUG|Hydronidone|The investigational products in the test groups and control group shall be orally taken 30 minutes before meals for 52 continuous weeks. There are respectively 60 cases in the test group I, II, III and the control group, totally 240 cases.
223472945|NCT02499562|DRUG|Placebo|
223472946|NCT02499562|DRUG|Entecavir|
223472947|NCT00764218|DEVICE|Positive airway pressure treatment|Positive airway pressure treatment as long as necessary
223472948|NCT00764218|OTHER|No positive airway pressure treatment|No treatment
224160884|NCT04120350|DRUG|Rituximab|375mg/m2 intravenous infusion d1, every 21 days for 1 cycle. 6 cycles will be prescribed as protocol
224160885|NCT04120350|DRUG|Lenalidomide|"In phase 1b study, a 3+3 design dose- escalation will be taken. 3 levels should be tested, 15/20/25mg orally d1-14, every 21 days for 1 cycle. 6 cycles will be prescribed as protocol.~\[update 02-Jun-2020: the phase Ib trial has finished,and no MDT was obsevered in 25mg group. So the recommanded phase II dose was 25mg.\] In phase II study, 25mg daily is considered as an experiment dose for the induction cycles.~In both phase Ib and II study, the does of lenalidomide maintenance is fixed to 25mg orally d1-21 every 28 days for 1 cycle. The duration of maintenance is 2 years."
224160886|NCT05487976|DRUG|Recombinant human activated coagulation factor VII for injection|Human coagulation factor VII is a vitamin K-dependent serine endogenous protease, and its activated form plays an important role in the coagulation process. Recombinant human activated coagulation factor VII is an activated state coagulation factor VII obtained by recombinant means.
224304221|NCT04234932|DRUG|Netarsudil Ophthalmic|Topical instillation of commercial preparations of netarsudil 0.02% ophthalmic solution (Rhopressa and Roclatan)
223472949|NCT02457975|DEVICE|670nm PBM|Battery operated, hand-held, 10 cm2 Light Emitting Diode (LED) array designed to deliver 50 mW/cm2 of light for 90 seconds resulting in a light dose of 4.5 Joules/cm2
223472950|NCT02457975|DRUG|intravitreous VEGF-inhibitors|Threeintravitreous VEGF inhibitors - aflibercept (Eylea, Regeneron Pharmaceuticals), bevacizumab (Avastin, Genentech), and ranibizumab (Lucentis, Genentech) - are commonly used for the treatment of diabetic macular edema causing vision impairment and have been shown to be beneficial and relatively safe. Study participants in the anti-VEGF group will be treated with intravitreous injections of one of these agents: afibercept (2.0 mg), bevacizumab (1.25 mg) or ranibizumab (0.5 mg) at appropriate intervals as determined by the treating ophthalmologist.
223472951|NCT00423046|BIOLOGICAL|GSK Biologicals HPV 16/18 vaccine 580299 (CervarixTM)|Three doses administered intramuscularly at months 0, 1 and 6
223472952|NCT00423046|BIOLOGICAL|Gardasil ® (Merck & Co. Inc)|Three doses administered intramuscularly at months 0, 2 and 6
223472953|NCT00423046|BIOLOGICAL|Placebo|One dose administered intramuscularly at month 1 to maintain blinding
223580602|NCT01660100|PROCEDURE|PVAI plus left atrial posterior wall (LAPW) isolation|In this group, PVAI will be extended to the entire LAPW to achieve LAPW isolation during the primary ablation. Three months later, a 2nd procedure will be performed in all subjects regardless of the recurrence of atrial arrhythmias. Subjects in whom pulmonary vein antrum and LAPW remain isolated will enter follow-up; however, patients who have pulmonary vein antrum and/or LAPW reconnection will undergo a re-isolation. Patients who have pulmonary vein antrum and/or LAPW re-isolation are subject to a 3rd procedure three month later to check the presence of pulmonary vein antrum and/or LAPW re-connection. Patients will enter follow-up for long-term outcome only after PVAI and LAPW isolation are proven by a repeat procedure.
224160887|NCT03613168|DRUG|Trastuzumab|Trastuzumab plus gemcitabine/cisplatin
224160888|NCT00858975|PROCEDURE|cryotherapy|Placing 4-6 cryotherapy probes into the renal tumors and conducting two cycles of freezing and thawing
224160889|NCT02145754|OTHER|MKP media|one half of skin specimen was put in MKP media
224160890|NCT02145754|OTHER|BSK-H media|one half of skin specimen was put in BSK-H media
224304222|NCT03472417|DEVICE|Active partial rebreathing device|
224304223|NCT03472417|DEVICE|Dummy partial rebreathing device|
224304224|NCT00668161|BEHAVIORAL|Exercise|60 minutes/session of aerobic exercise, 6 d/week at 50-50% HHR. All sessions will begin with 10 minutes of stretching and 5 minutes of warm-up, and will end with 5 minutes of cool down.
223472954|NCT00423046|BIOLOGICAL|Placebo|One dose administered intramuscularly at month 2 to maintain blinding
223472955|NCT04713072|BIOLOGICAL|ABY-035|ABY-035 solution for injection
223472956|NCT04713072|BIOLOGICAL|Placebo|Placebo to ABY-035 solution for injection
223472957|NCT03487770|DRUG|Aripiprazole Oral Solution|Aripiprazole 2\~15 mg/day (2\~15 mL/day)
223472958|NCT03487770|DRUG|Placebo Oral Solution|Placebo 2\~15 mg/day (2\~15 mL/day)
223472959|NCT03776448|DIETARY_SUPPLEMENT|Sativa Nigra oil Softgels|Nigella sativa, a flowering plant native to southwest Asia, is considered one of the most important healing medicinal plants in Islamic culture. The use of its richly colored black seeds has been recommended in the prophetic medicine. It's also known by various other names amongst different cultures. Importantly, its seed is known in Arabic as 'habat al Baraka' which translates literally to 'the seed of blessing'.The active ingredient is believed to be thymoquinone richly present in the oil extract of its seeds. Apart from mild occasional gastrointestinal disturbance, black seed oil has no side effects and is considered very safe. .
223472960|NCT03776448|DIETARY_SUPPLEMENT|Activated Charcoal Softgels|This supplement is manufactured by \[Arkopharma Pharmaceutical Laboratories\] and is available commercially. The use of activated charcoal softgels as a placebo is documented in several other clinical trials. The single most relevant characteristic of charcoal is its minimal if any gastrointestinal absorption. As a result, it does not undergo any metabolism and is excreted completely in feces. This makes charcoal an attractive placebo choice for small trials or when manufacturing a specific placebo is not feasible. Charcoal softgels are black in color and resemble black seed oil softgels to a great extent.
223472961|NCT00830128|DRUG|pregabalin (Lyrica)|Dosage: 300-450 mg/day (150-225 mg twice daily), oral administration, Treatment duration: 52 weeks
223472962|NCT01572402|OTHER|Bagueutte Cheese Gourmet (Crocodille)|180g, energy 452.8 Kcal/1895.7 kJ, composition: carbohydrates 49,2 g (44,55%), proteins 18,5 g (16,74%), lipids 18,8 g (38,7%), of which saturated 6,8 g, monounsaturated 6,0 g, polyunsaturated 5,0 g.
223472963|NCT01572402|OTHER|Cous-cous sandwich|235 g, energy 455,88 Kcal /1907,4 kJ, composition: carbohydrates 59,54 g (52,24%), proteins 12,47 g (10,57% %), lipids 18,85 g (37,31%), of which saturated 6,2 g, monounsaturated 11,49 g, polyunsaturated 28,26 g
223472964|NCT01572402|OTHER|McCountry sandwich (McDonald's)|150g, 455 kcal/1903,72 kJ, composition: carbohydrates 31 g (27,25%), proteins 24 g (21,1%), lipids 26 g (51,43%), of which saturated 10 g (38,45%)
223472965|NCT02244671|PROCEDURE|fat, PRP, botulinum toxin|fat injection with platelet-rich-plasma (PRP) after immobilizing the extraocular muscles with botulinum toxin
223472966|NCT02244671|DRUG|botulinum toxin|botulinum toxin used to immobilize extra-ocular muscles prior to fat injection.
223472967|NCT02244671|DEVICE|PRP|autologous PRP is prepared with a dedicated centrifuge at the time of fat harvesting
223472968|NCT06044103|DRUG|PDB + PCS|Pudendal nerve block (PNB) with ropivacaine AND Patient-controlled sedation with propofol by the participant
223580603|NCT05917132|OTHER|Nutritionnal intervention|Participants will be provided with meals corresponding to each diet during the week. Participants will be required to eat only the meals provided.
223580604|NCT03369431|DIETARY_SUPPLEMENT|Vivomixx|Multi-strain probiotic containing 450 billion lyophilized bacterial cells per sachet belonging to 8 probiotic strains. The probiotic strains contained in the intervention are Streptococcus thermophilus, Bifidobacterium breve, Bifidobacterium longum, Bifidobacterium infantis, Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus paracasei, Lactobacillus delbrueckii subsp. bulgaricus.
223580605|NCT03369431|DIETARY_SUPPLEMENT|Placebo|4.4 grams of maltose and silicon dioxide per sachet
223580606|NCT01973608|DRUG|MSB0010445 (0.3 milligram per kilogram [mg/kg])|MSB0010445 will be administered at a single dose of 0.3 mg/kg as intravenous (IV) infusion over approximately 1 hour every 3 weeks (q3w) for the first 12 Weeks as a part of induction phase followed by maintenance dose of 0.3 mg/kg drug every three weeks until significant clinical progression, occurrence of unacceptable toxicity, or withdrawal of consent. The first administration of MSB0010445 will be performed 3 days after the last dose of Stereotactic Body Radiation Therapy (SBRT) to the targeted reference lesion.
224160891|NCT02282774|DRUG|2% lidocaine and 0.5% bupivacaine|Under general anesthesia and the operating microscope, a Lieberman lid speculum was placed and the conjunctiva was cleaned with 4% povidone iodine solution. The surgeon then created a fornix-based incision through conjunctiva and tenon's tissue inferonasally midway between the insertions of the medial and inferior rectus muscles, with blunt Wescott scissors to expose the scleral surface before tunneling posteriorly with curved Stevens scissors to create a small channel to the posterior subtenon space. A blunt-tipped subtenon cannula was then inserted into the posterior subtenon space, 4mL of 2% lidocaine and 0.5% bupivacaine (50:50) mixture versus saline was introduced and the drug solution was injected slowly into the subtenon space. After administration of local anesthetic mixture, the eyelid was gently taped down, and no ocular massage was performed
223743902|NCT05902039|OTHER|MRI|All participants underwent an MR examination on a 3T whole-body Prisma MRI system (Siemens, Erlangen, Germany) with a 64-channel head coil, and a 7T whole-body MAGNETOM MR system (Siemens, Erlangen, Germany) using a 32-channel receive/birdcage transmit head coil (NOVA medical). DP-pCASL, Multi-delay pCASL (MD-pCASL) was acquired to evaluate BBB function and cerebral perfusion. T1-weighted magnetization-prepared rapid gradient echo (T1w-MPRAGE) was scanned at both 3T and 7T for registration in the post-processing workflow. T2-weighted fluid-attenuated inversion recovery (T2w-FLAIR) and T2\*-weighted gradient echo (T2\*w-GRE) were acquired at 7T for high-resolution structural images and evaluation of lesions.
223743903|NCT00982813|OTHER|Periodontal screening|"Periodontal screening in all patients giving birth between 24 and 37 gestational weeks.~Bacteriological sampling in the periodontal pocketing. Search for specific cytokines in the periodontal pocketing. Professional prophylaxis and oral hygiene instruction."
223743904|NCT05872581|BEHAVIORAL|Hand scanner instant feedback|Participants will be informed about their hand scanner results of the first hand washing attempt to get individualized feedback about their hand wash performance.
224160892|NCT02282774|DRUG|Sham subtenon block|
224160893|NCT03020797|DRUG|Perampanel|
224160894|NCT03020797|DRUG|Placebo Oral Tablet|
224160895|NCT03213106|DEVICE|Transcranial Magnetic Stimulation (TMS)|Low frequency (1Hz) transcranial magnetic stimulation aimed to the dentate nucleus contralateral to the most symptomatic side.
224304225|NCT05316883|DRUG|Clozapine|clinical doses adjusted to sideeffects and clinical effect
223472969|NCT00549393|DRUG|2% Chlorhexidine gluconate cloth|Daily bathing
223472970|NCT00623675|DIETARY_SUPPLEMENT|Mineralox C|Mineralox C 2 capsules three times a day.
223472971|NCT02183363|DRUG|BI 1356 - Tablet TFII|
223472972|NCT02183363|DRUG|BI 1356 - Tablet iFF|
223472973|NCT02183363|DRUG|BI 1356 - Tablet TFIIb|
223472974|NCT04600349|BEHAVIORAL|Identity Oriented Psychotrauma Therapy|The method will be presented to the group at the beginning of the first group session. Then every person from the experimental group will set an Intention connected to the emotional or physical difficulties they experience in their lives. Then the person will choose for every word in their Intention, a representative from the support group who will resonate with that word. The focus of every Intention should be the current illness and the traumatic or stressful events which happened before the disease onset.
223472975|NCT04600349|DRUG|Treatment as Usual|The participants randomised in this group will continue taking the classical treatment prescribed for Hashimoto (Levothyroxine)
223472976|NCT02980315|OTHER|CAR-T cells|the patients treat with CAR-T cells
223472977|NCT01048424|DEVICE|RESPeRATE|"RESPeRATE is a commercially available, walkman-like device manufactured by Intercure, Ltd. that measures chest/abdominal excursion during respiration using an elastic belt with a sensor placed around the torso over clothing. The device senses respiration and uses musical tones keyed to inhalation and exhalation to help the user slow respiration and prolong exhalation to a recommended goal of less than 10 breaths per minute. RESPeRATE is approved by the FDA for treatment of mild hypertension and has also been shown to decrease self-reported anxiety and stress, oxygen consumption, and respiratory rate."
223580607|NCT01973608|DRUG|MSB0010445 (1.0 mg/kg)|MSB0010445 will be administered at a single dose of 1.0 mg/kg as IV infusion over approximately 1 hour q3w for the first 12 Weeks as a part of induction phase followed by maintenance dose of 0.3 mg/kg drug every three weeks until significant clinical progression, occurrence of unacceptable toxicity, or withdrawal of consent. The first administration of MSB0010445 will be performed 3 days after the last dose of SBRT to the targeted reference lesion.
223580608|NCT01973608|DRUG|MSB0010445 (1.8 mg/kg)|MSB0010445 will be administered at a single dose of 1.8 mg/kg as IV infusion over approximately 1 hour q3w for the first 12 Weeks as a part of induction phase followed by maintenance dose of 0.3 mg/kg drug every three weeks until significant clinical progression, occurrence of unacceptable toxicity, or withdrawal of consent. The first administration of MSB0010445 will be performed 3 days after the last dose of SBRT to the targeted reference lesion.
223580609|NCT01973608|DRUG|MSB0010445 (2.4 mg/kg)|MSB0010445 will be administered at a single dose of 2.4 mg/kg as IV infusion over approximately 1 hour q3w for the first 12 Weeks as a part of induction phase followed by maintenance dose of 0.3 mg/kg drug every three weeks until significant clinical progression, occurrence of unacceptable toxicity, or withdrawal of consent. The first administration of MSB0010445 will be performed 3 days after the last dose of SBRT to the targeted reference lesion.
223580610|NCT01973608|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|SBRT will be administered using a dose and schedule recommended based upon the data showing the best abscopal effect using multiple fractions if one site will be targeted subject received 3 fractions (1 per day) of 8 Gray (Gy) each (total: 24 Gy). If the target lesion will be located in the thorax, the maximum total dose administered will be 18 Gy (3 x 6 Gy).
223580611|NCT01560455|DEVICE|single stent|single stent
223580612|NCT01560455|DEVICE|two stent|culotte
223580613|NCT01207349|BEHAVIORAL|Secondary prevention intervention trial|Close follow-up by nurses, exercise physiologist and dieteticians
223580614|NCT01207349|BEHAVIORAL|standard follow up|
223580615|NCT01113580|BIOLOGICAL|CSL's 2010/2011 Formulation of Enzira® Vaccine|45 mcg of HA antigen in 0.5 mL administered by intramuscular injection into the deltoid region of the arm on Day 0
223580616|NCT00695552|BEHAVIORAL|Aerobic exercise|Aerobic exercise on stationary bikes. Three sessions/week for 3 three months. First month the workload is equivalent to 65% of HRmax, the second month the workload is equivalent to 70% of HRmax, and the third month the workload is equivalent to 75% of HRmax
223580617|NCT00695552|BEHAVIORAL|Low impact exercise|Participants meets 3 times/week for 3 months. They will engage in low impact activities such as stretching exercises
223580618|NCT03113695|DRUG|Obinutuzumab|obinutuzumab 1000 mg x 8 doses (first dose split on Cycle 1 days 1 100mg and 2 900mg; then day 8 and 15 of cycle 1; then day 1 of cycles 2-6, each cycle being 28 days long)
223580619|NCT03113695|DRUG|lenalidomide|lenalidomide PO daily. The starting dose of lenalidomide is 5 mg PO daily. Starting on C2D1, the dose increases every 2 weeks in 5 mg increments to a maximum of 25 mg PO daily. Patients will continue lenalidomide until disease progression, unacceptable toxicity, or subsequent therapy.
223580620|NCT03113695|DRUG|HDMP|methylprednisolone 1000 mg/m2 (ie HDMP) on days 1-5 of cycles 1-4
223580621|NCT05149560|DRUG|Ticagrelor 90mg|All patients will be prescribed ticagrelor as monotherapy
223580622|NCT04587154|OTHER|low-fat vegan diet with 1/2 cup soybeans daily|Weekly instructions will be given to the participants in the intervention group about following vegan diet with 1/2 cup of soybeans daily.
223580623|NCT04873037|DEVICE|BTL Emsella Chair|The Emsella Chair is a novel high-intensity focused electromagnetic (HIFEM) technology for the treatment of pelvic floor related disorders. HIFEM technology induces deep pelvic floor muscle contractions designed to deliver the equivalent of 11,200 Kegel exercises over 28 minutes. The treatment paradigm consists of 3 different phases. The phases consist of an intense stimulation of the pelvic floor muscles (PFM), which consists of stimulation and relaxation. The repetition of the phases and focused electromagnetic energy delivery leads to pelvic floor stimulation, adaptation, and remodelation.
223472978|NCT01048424|OTHER|Urinary Incontinence Pamphlet|The urinary incontinence pamphlet will provide information about classification, pathophysiology, and management of urinary incontinence, including management strategies such as timed urination and pelvic muscle exercises.
223472979|NCT02125890|DRUG|Tranexamic Acid|two doses of Tranexamic Acid will be given to patients with rupture abdominal aortic aneurysms
223580624|NCT04873037|DEVICE|Sham BTL Emsella Chair|The sham treatment will provide some sensation without active HIFEM technology. The programming for the sham treatment will have an amplitude limitation, with the setting below therapeutic level (less than 10%) power.
223580625|NCT02978703|DRUG|COPD Pharmacologic Substance|COPD patients treated by Fluticasone / Salmetrol via Elpenhaler device
223743905|NCT05872581|BEHAVIORAL|Video training|Participants will watch a training video about the 7 steps of hand washing after the first hand washing attempt.
223472980|NCT03795506|DEVICE|Nocturnal Temperature controlled Laminar Airflow (TLA) Treatment|12 weeks of overnight treatment with active TLA device
223743906|NCT01959542|DEVICE|MRI|
223743907|NCT01959542|OTHER|PSA Blood Test|Serum PSA will also be subsequently checked on the same day as each follow-up MR is performed, i.e. TP 1, 2 and 3, and right after finishing EBRT. 1-2 mls of blood will be sampled per blood test.
224160896|NCT03213106|DEVICE|Sham Stimulation|The stimulation coil will be placed in the same spot as the TMS stimulation, but coil will not be attached to the TMS machine.
223472981|NCT03795506|DEVICE|Placebo TLA Device|12 weeks of overnight use of placebo TLA device
223472982|NCT04249427|DRUG|Erenumab Prefilled Syringe|140mg Erenumab, pre-filled syringe given by subcutaneous injection
223472983|NCT04249427|OTHER|Placebo|Placebo, pre-filled syringe given by subcutaneous injection
223472984|NCT01673178|OTHER|Placebo|0.9% w/v sodium chloride injection, United States Pharmacopeia (USP), once a week for 4 weeks
223472985|NCT01673178|DRUG|25 mg PF-05231023|25 mg IV once a week for 4 weeks
224160897|NCT05424744|BEHAVIORAL|Telemedicine Management of Hypertension|Telemedicine Management of high blood pressure using home blood pressure monitoring and telemedicine based hypertension self- management support and pharmacotherapy. This will be supplemented by support from community health workers.
223472986|NCT01673178|DRUG|50 mg PF-05231023|50 mg IV once a week for 4 weeks
223472987|NCT01673178|DRUG|100 mg PF-05231023|100 mg IV once a week for 4 weeks
223472988|NCT01673178|DRUG|150 mg PF-05231023|150 mg IV once a week for 4 weeks
223472989|NCT02361775|DEVICE|Paravertebral catheter|A catheter is placed ultrasound guided at the T5 paravertebral level
223472990|NCT02361775|DEVICE|opioid iv pca|opioid pca consisting of hydromorphone
223472991|NCT02361775|DRUG|Ropivacaine|0.2% ropivacaine infused through paravertebral catheter
223472992|NCT02361775|DEVICE|Elastomeric Pump|Elastomeric pump connected to paravertebral catheter
223472993|NCT05199792|DIAGNOSTIC_TEST|Dotarem|(Dotarem) (0.4 ml/kg (0.2 mmol/kg))
223472994|NCT05923047|DRUG|Mepolizumab|Patients in the Mepolizumab arms will receive 100 mg of subcutaneous mepolizumab every 4 weeks for a total of 12 doses in addition to daily topical corticosteroid treatment
223472995|NCT05923047|PROCEDURE|Polypeptomy|This group will undergone in-office nasal polypectomy.
223472996|NCT01419314|DEVICE|Splinting application to the lower extremities|Walkabout™ splints (Don Joy Orthopedics, Vista, CA, USA) will used in the splinting treatment. The Walkabout splint is a one-piece injection molded walking boot fitted with a rocker bottom allowing for ambulation. The participants will be fitted and instructed to wear the bilateral LE splints to sleep for the duration of the study (6 weeks).
223472997|NCT01419314|DEVICE|Splint liner application|The liner or protective sheath from the Walkabout™ splint will be applied to the LEs, with the structural frame of the splint removed by the researcher in advance, patients will be blinded to this arm of the study (6 weeks).
223472998|NCT01439035|DEVICE|MGH OFDI Imaging|Imaging of Duodenum with OFDI system
223472999|NCT05185466|BEHAVIORAL|Nurse-Supported Self Management Programme|Training and incentives to improve nutrition habits and sleep health.
223473000|NCT01945983|DRUG|Early norepinephrine|Initiation of norepinephrine, a strong vasoconstrictor, at the initiation of septic shock management, together with fluid resuscitation.
223473001|NCT01945983|DRUG|Placebo|5% dextrose water intravenous drip in the same rate of calculated norepinephrine for the patient's body weight
223473002|NCT00965237|DEVICE|lotrafilcon B multifocal contact lens|Commercially marketed, silicone hydrogel, multifocal contact lens for daily wear use
223473003|NCT00965237|DEVICE|lotrafilcon B single vision contact lens|Commercially marketed, silicone hydrogel, single vision contact lens for daily wear use
223473004|NCT00965237|OTHER|Over-reader spectacles|Reading glasses worn over single vision contact lenses for near vision work on an as-needed basis
223473005|NCT05798715|DRUG|Gleptomet 50/1000(Metformin HCl & Sitagliptin)|Test drug
223473006|NCT05798715|DRUG|Janumet 50/1000(Metformin HCl & Sitagliptin)|Reference drug
223473007|NCT06080009|GENETIC|exome sequencing (retrospective) and exome and methylome sequencing (prospective)|"Three to nine sections will be used as the source of DNA for each tumor. The pathologist will identify and separate tumor tissue from normal tissue, and the two DNAs will be sequenced separately. Variants obtained from tumor and normal tissue will be compared, with different outcomes. Expected in this way are 1) somatic/tumor-specific variants (which are absent in normal tissue), 2) variants lost during tumor evolution due to segmental chromosomal deletion or other mechanisms that cause loss of heterozygosity. Using these two classes of variants, a clustering analysis will be performed at the end of the sequencing project to better define the phenotype and molecular signature of the tumors. In the prospective part of the project, the new tumors will be frozen fresh. This resource will allow methyloma analysis to be performed."
223580626|NCT03238118|OTHER|Attention bias modification training|"Participants will complete the assigned attention-training task three times a week for two weeks (six sessions), yielding 960 trials. Each session consists of three parts: evaluating the individual baseline, training and testing. Participants will also be required to complete a self-report assessment before and after each session. Participants will be evaluated at baseline, the end of week 1 and at the end of week 2 by blind investigators.~Psychoeducation Participants will receive psychoeducation once a week for two weeks. Participants will also be required to complete a self-report assessment before and after each session of psychoeducation. Participants will be evaluated at baseline, the end of week 1 and at the end of week 2 by blind investigators."
223743908|NCT01220479|BEHAVIORAL|Exercise training program|"Exercise Diabetic and Healthy groups perform a similar training program including two exercise sessions per week, of 90 minutes each, during 9 months (excluding holidays) under supervision by physical education teachers and pediatricians. Sessions comprise various weight-bearing activities: rope skipping, jumping, ball games and gymnastics.~Control groups are relatively inactive."
224160898|NCT01594086|DIETARY_SUPPLEMENT|green tea powder|Consuming 2 g/day of green tea powder in three times divided for 3 months
224160899|NCT05992935|BIOLOGICAL|mRNA-1403|Sterile liquid for injection
224160900|NCT05992935|BIOLOGICAL|mRNA-1405|Sterile liquid for injection
224160901|NCT05992935|BIOLOGICAL|Placebo|0.9% sodium chloride (normal saline) injection
224160902|NCT02958085|DRUG|NNC0174-0833|Doses of NNC0174-0833, dosed either once daily or once weekly
224160903|NCT02958085|DRUG|Placebo|Dosed either once daily or once weekly
224160904|NCT00688623|DRUG|Everolimus|Everolimus 5 mg tablets were supplied in blister packs
224160905|NCT02667236|DRUG|A-101 Solution|Active Drug
224160906|NCT02667236|OTHER|Vehicle Solution|Placebo
224160907|NCT00464620|DRUG|Dasatinib|oral agent, continuous dosing, Cycles = 28 days
224160908|NCT04347252|DRUG|Glucagon|Intravenous infusion of glucagon at fasting or elevated glycemia. Blockade of the GLP-1 receptor during hyperglycemia with and without glucagon.
224160909|NCT05326906|DRUG|PD-1/PD-L1 inhibitors|PD-1/PD-L1 inhibitors (the dosage calculation according to dosing instructions)
224160910|NCT02796079|BIOLOGICAL|mesenchymal stem cells|stem cell acquisition, processing and reinfection, to evaluate the efficacy by using autologous bone marrow stem cell
223473008|NCT02926963|OTHER|samples collection : hair and skin biopsy|
223473009|NCT06085521|DRUG|LNK01001 Dose A|Capsules taken orally
223473010|NCT06085521|DRUG|LNK01001 Dose B|Capsules taken orally
223473011|NCT06085521|DRUG|placebo|Capsules taken orally
223473012|NCT05208996|DRUG|siCoV/KK46|"The modified phase I 3 + 1+1 study design was used in dose escalation from low dose to high dose to determine the maximum daily dose. Sequential assignment of Patient cohorts to one of three dose levels of inhaled siCoV/KK46: 3.7 mg, 11.1 mg, 22.2 mg."
223473013|NCT05947669|DRUG|Infliximab|Infliximab is available in vials of 100 mg with pharmaceutical form of concentrate for solution for infusion. Participating sites will ensure availability of infliximab as part of the hospital's standard supply for use in the study.
223743909|NCT04093778|OTHER|Low dose high frequency training and Safe Delivery Phone Application|The intervention period is a 9-month period where we will facilitate a quality improvement cycle using Low Dose High Frequency training with the Safe Delivery App as an anchor point and facilitate the integration into clinical practice through our Safe Delivery Focal Points at each hospital. All staff in maternity, paediatric wards and outpatient clinics will receive training and be encouraged to use the Safe Delivery App on a weekly basis.
224160911|NCT02796079|BIOLOGICAL|saline|saline injections
224160912|NCT01879475|DEVICE|032-11|Topical haemostat
224160913|NCT01879475|DEVICE|Floseal (R)|Topical haemostat
223473014|NCT05947669|DRUG|Methylprednisolone|Methylprednisolone is available in vials of 40 mg. Methylprednisolone is a drug used for standard treatment first line for ir-colitis or diarrhoea CTCAE grade ≥ 3. Participating sites will ensure availability of methylprednisolone for use in the study as part of the hospitals standard supply.
224160914|NCT02308553|DRUG|Nintedanib|Nintedanib (150 mg or 200 mg BID)
224160915|NCT02308553|DRUG|Nintedanib-Placebo|Placebo (150 mg or 200 mg BID)
224160916|NCT02308553|DRUG|Paclitaxel|Paclitaxel as 90mg/mw infusion day 1, 8, 15 q28 (6 cycles)
224160917|NCT00469976|DRUG|bevacizumab|
224160918|NCT00469976|DRUG|carboplatin|
224160919|NCT00469976|DRUG|enzastaurin hydrochloride|
224160920|NCT00469976|DRUG|gemcitabine hydrochloride|
224160921|NCT04653727|OTHER|Cross-sectional survey|No intervention.
224160922|NCT05091073|DRUG|NNC0385-0434|All participants will be dosed with 40 mg oral NNC0385-0434 once-daily for 10 consecutive days
224160923|NCT05490381|OTHER|Iodixanol|Given via injection
224304226|NCT01868893|DRUG|Obinutuzumab|
223473015|NCT05947669|DRUG|Prednisolone|Prednisolone is available in tablets of 25 or 5 mg. Oral corticosteroids are internationally recommended as initial treatment for ir-colitis and ir-diarrhoea CTCAE grade 2 \[24-27\]. Participating sites will ensure availability of prednisolone for use in the study as part of the hospitals' standard supply.
223473016|NCT05504096|DEVICE|Actxa BGM Tracker (GLO2)|Wrist-worn wearable
223473017|NCT05504096|DEVICE|SVT In-Ear Prototype (IEP)|In-Ear wearable
223473018|NCT00402727|DRUG|Moxifloxacin (Avelox, BAY12-8039)|Moxifloxacin (Avelox, BAY 12-8039) 400 mg intravenous (IV) once daily followed by Moxifloxacin 400 mg oral tablets once daily for a minimum of 7 days and a maximum of 21 days. Oral phase was not always mandatory.
223473019|NCT00402727|DRUG|Piperacillin/Tazobactam & Amoxicillin/Clavulanic acid|Piperacillin/Tacobactam 4.0/0.5 g (PIP/TAZ) administered intravenous three times daily followed by Amoxicillin/Clavulanic acid (AMC) oral tablets 875/125 mg twice daily for a minimum of 7 days and a maximum of 21 days. Oral phase not always mandatory.
223473020|NCT04550078|DIETARY_SUPPLEMENT|Calcium Carbonate|Subjects receive a single-dose of 800 mg calcium as calcium carbonate provided in 6 capsules with a standardized breakfast served in the morning.
223473021|NCT04550078|DIETARY_SUPPLEMENT|Calcium Permeate|Subjects receive a single-dose of 800 mg milk calcium as calcium permeate provided in 6 capsules with a standardized breakfast served in the morning.
223473022|NCT04550078|DIETARY_SUPPLEMENT|Placebo|Subjects receive a single-dose of 0 mg calcium as placebo with maltodextrin provided in 6 capsules with a standardized breakfast served in the morning.
223473023|NCT03580070|BIOLOGICAL|Immunotherapy|Patients with primitive head and neck squamous cells carcinoma diagnosed on surgical resection or biopsic sample, between 2008 and 2015. They were included when expressing p16 as assessed by immunochemistry and positive HPV DNA by in situ hybridation or positive HPV PCR
223473024|NCT04996420|DEVICE|Clearsight non invasive hemodynamic monitoring|Goal directed fluid therapy fuided by Clearsight monitoring
223473025|NCT03546712|OTHER|Tactile Localization|tactile localization is help to assess touch sensation
223473026|NCT03474796|BEHAVIORAL|Eye-tracking|Visualisation of 4 photographic scenarios (surgical situations), questionnaire, eye-tracking
223473027|NCT03529253|DRUG|Alirocumab 75 MG/ML [Praluent]+ Rosuvastatin 10mg/daily|Alirocumab group receive Alirocumab75mg/2week subcutaneous injection plus Rosuvastatin10mg/daily by oral for 9 months.
223473028|NCT03529253|DRUG|Rosuvastatin calcium10mg|Rosuvastatin10mg/daily by oral for 9 months.
223473029|NCT00004002|DRUG|bortezomib|
223473030|NCT04951089|DEVICE|i-gel Supraglottic device insertion|i-gel insertion for oxygenation
223473031|NCT04951089|DEVICE|Air-Q SP 3G Supraglottic device insertion|Air-Q SP 3G insertion for oxygenation
223473032|NCT03620799|PROCEDURE|Manual therapy|A manual intervention technique is employed to the intervention group based on a roller treatment.
223473033|NCT04022330|OTHER|Blood sampling|The blood sampling will be done just before surgery
223473034|NCT00510614|DRUG|tinidazole|1 gram twice weekly for 12 weeks
223473035|NCT00510614|DRUG|Placebo|one pill twice weekly for 12 weeks
223473036|NCT01405898|DIETARY_SUPPLEMENT|beetroot juice|Beetroot juice 4 weeks 250ml daily
223473037|NCT01405898|DIETARY_SUPPLEMENT|Nitrate-free beetroot juice|Nitrate-free beetroot juice 4 weeks 250ml daily
223473038|NCT05032144|DRUG|STSA-1002 injection|Intravenous injection
223473039|NCT05032144|DRUG|Placebo|Intravenous injection
223473040|NCT05032144|DRUG|STSA-1002 injection|Intravenous injection
223473041|NCT05032144|DRUG|Placebo|Intravenous injection
223473042|NCT05032144|DRUG|STSA-1002 injection|Intravenous injection
223473043|NCT05032144|DRUG|Placebo|Intravenous injection
223473044|NCT05032144|DRUG|STSA-1002 injection|Intravenous injection
223473045|NCT05032144|DRUG|Placebo|Intravenous injection
223473046|NCT05032144|DRUG|STSA-1002 injection|Intravenous injection
223473047|NCT05032144|DRUG|Placebo|Intravenous injection
223473048|NCT03800316|DEVICE|Video Consultation|Video consultation with emergency medicine physicians for patients that are critically ill prior to arrival in the ED
223580627|NCT03238118|OTHER|Attention Control Training|"Attention Control Training Participants will complete the assigned attention-training task three times a week for two weeks (six sessions), yielding 960 trials. Each session consists of three parts: evaluating the individual baseline, training and testing. Participants will also be required to complete a self-report assessment before and after each session. Participants will be evaluated at baseline, the end of week 1 and at the end of week 2 by blind investigators.~Psychoeducation Participants will receive psychoeducation once a week for two weeks. Participants will also be required to complete a self-report assessment before and after each session of psychoeducation. Participants will be evaluated at baseline, the end of week 1 and at the end of week 2 by blind investigators."
223580628|NCT03238118|OTHER|Psychoeducation|Participants will receive psychoeducation once a week for two weeks. Participants will also be required to complete a self-report assessment before and after each session of psychoeducation. Participants will be evaluated at baseline, the end of week 1 and at the end of week 2.
223580629|NCT02537405|DRUG|Rivaroxaban (BAY 59-7939)|Rivaroxaban granule 10mg for one day
223580630|NCT02537405|DRUG|Rivaroxaban (Xarelto, BAY 59-7939)|Rivaroxaban tablet 10mg for one day
223580631|NCT01352637|DRUG|DCS (D-Cycloserine ) + Prolonged Imaginal Exposure|50mg DCS (taken once a week on the day of the therapy session) + Prolonged Imaginal Exposure
223580632|NCT01352637|DRUG|DCS (D-Cycloserine ) + Virtual Reality Exposure|50mg DCS (taken once a week on the day of the therapy session) + Virtual Reality Exposure
223580633|NCT01352637|DRUG|Placebo + Prolonged Imaginal Exposure|Placebo (taken once a week on the day of the therapy session) + Prolonged Imaginal Exposure
223580634|NCT01352637|DRUG|Placebo (sugar pill) + Virtual Reality Exposure|Placebo (taken once a week on the day of the therapy session) + Virtual Reality Exposure
223580635|NCT00002254|DRUG|Alovudine|
224160924|NCT05490381|PROCEDURE|Angiogram|Undergo diagnostic cerebral angiogram
223473049|NCT03188055|OTHER|Best Case/Worst Case communication tool|"The communication tool promotes dialogue and patient deliberation, and supports shared decision making in the context of life-limiting illness. Building on a conceptual model of shared decision-making proposed and the practice of scenario planning our intervention is designed to lead to a discussion of patient preferences and consideration of outcomes.~The surgeon verbally describes the best case, worst case, and most likely outcomes for each treatment option-incorporating rich narrative from clinical experience and translation of probabilistic information-while drawing a diagram of those options. The surgeon also writes details about each option on the diagram. The narrative and graphic help family and patients formulate and express preferences."
223473050|NCT01148394|OTHER|Multimodal rehabilitation|
223473051|NCT04020211|DEVICE|Senza HF10 Therapy|Senza 10kHz Spinal Cord Stimulation
223473052|NCT03479112|BEHAVIORAL|Flashcards|Participants will be provided with Flashcards depicting how to correctly apply a tourniquet to an extremity wound.
223473053|NCT03479112|BEHAVIORAL|Audio-kit|Participants will be provided with an audio-kit with accompanying visual cues describing and depicting how to correctly apply a tourniquet to an extremity wound.
223473054|NCT03479112|BEHAVIORAL|B-Con training|Participants will undergo the Bleeding control for the injured (B-Con) basic course.
223473055|NCT03479112|BEHAVIORAL|B-Con training retention|Evaluation of retention of Bleeding Control for the injured basic course
223580636|NCT02189278|BEHAVIORAL|Psychosocial Intervention|Telephone-based psychosocial intervention involving six telephone encounters. Each encounter focuses on teaching skills for improving adherence and overcoming barriers to obtaining recommended surveillance.
224160925|NCT05490381|PROCEDURE|Arterial Embolization|Undergo tumor vessel embolization
223473056|NCT02141906|OTHER|Oncozene-DEB-TACE|ONCOZENE microspheres are the newly available microspheres for DEB-TACE. It appears (based on the preliminary bench tests) that these microspheres may allow more efficient drug loading, and slow elution and equivalent vascular occlusion(12). In this pilot study, we aim to assess the safety of these microspheres when used for chemoembolization of unresectable hepatocellular carcinoma.
223473057|NCT04083560|DRUG|Vit B12|Vitamin B12 250mcg
223473058|NCT02894333|BEHAVIORAL|behavioral observation|
223473059|NCT00002935|DRUG|porfimer sodium|
223473060|NCT03698292|DRUG|Itopride|Prokinetic Drug
223473061|NCT03698292|DRUG|Metoclopramide 10mg|Prokinetic Drug
223473062|NCT00302978|BEHAVIORAL|Behavior therapy|
223473063|NCT05862051|PROCEDURE|Local Ablative Therapy|LAT modalities allowed include surgical resection, stereotactic radiotherapy (SRT), laparoscopic or percutaneous thermal ablation \[radiofrequency ablation (RFA) or microwave ablation (MWA)\]. The LAT modalities will be delivered by specialists in the field (surgeons, radiation oncologists and/or interventional radiologists). The precise mode of delivery and number of times the LAT modality is delivered is case-dependent and is determined at a multi-disciplinary meeting (MDM).
223473064|NCT05862051|PROCEDURE|Standard first-line systemic treatment|Standard of care as determined by the treating clinician. The following standard chemotherapy regimens are allowed: single agent fluoropyrimidine, CAPOX, FOLFOX, FOLFIRI, CAPIRI or FOLFOXIRI. Treatment with a biologic is allowed including bevacizumab or an anti-EGFR antibody (cetuximab or panitumumab). For patients receiving a doublet or triplet regimen, treatment may be de-escalated to maintenance fluoropyrimidine +/- biologics or anti-EGFR monotherapy at any point after trial entry at clinician discretion.
223580637|NCT03974737|DEVICE|CRI device (non-invasive vitals sign measurement)|Survey administration, Orthostatic vital measurements
223580638|NCT06965192|BEHAVIORAL|Visual|Physician participants will view the visual decision support before entering the patient's room during the intervention period, with the option to share with the patient.
223580639|NCT06965192|OTHER|No intervention|No intervention
223580640|NCT05639751|DRUG|PRT3789|PRT3789 will be administered by intravenous infusion
223580641|NCT05639751|DRUG|Docetaxel|Docetaxel will be administered by intravenous infusion
223743910|NCT05750927|PROCEDURE|Transcatheter aortic valve intervention (TAVI) and percutaneous coronary intervention (PCI)|TAVI and PCI to be administered as per physician's indication and choice, in one or more stages
224160926|NCT05490381|DRUG|Polyvinyl Alcohol|Given via catheter
224160927|NCT05490381|DRUG|Ethiodized Oil|Given via catheter
224160928|NCT05490381|PROCEDURE|Computed Tomography|Undergo head and neck CT scans
224160929|NCT05490381|OTHER|Chart Abstraction|Ancillary studies
224304227|NCT01868893|DRUG|Chlorambucil|
223473065|NCT02084511|DRUG|Placebo to BI 1026706 solution|Placebo to BI 1026706 solution
223473066|NCT02084511|DRUG|BI 1026706|BI 1026706
223473067|NCT02084511|DRUG|Placebo to BI 1026706 tablet|Placebo to BI 1026706 tablet
223473068|NCT02084511|DRUG|Celecoxib|Celecoxib capsule
223580642|NCT05082259|DRUG|ASTX660|ASTX660 will be supplied as capsules. Each hydroxylpropyl methylcellulose (HPMC) capsule contains either 30 mg or 90 mg of ASTX600 free-base equivalents, suitable for oral administration. Bottles are labelled with the capsule strength (ie, 30 mg or 90 mg) and are further distinguished by different-colored labels. Each bottle contains 14 capsules and an oxygen-absorber (not to be consumed).
223580643|NCT05082259|DRUG|Pembrolizumab|"Pembrolizumab Solution for Infusion 100 mg/vial is a liquid drug product supplied as a clear to opalescent solution, essentially free of visible particles, in Type I glass vials and manufactured using the fully formulated drug substance with L-histidine as buffering agent, polysorbate 80 as surfactant, and sucrose as stabilizer/tonicity modifier.~Pembrolizumab Solution for Infusion can be further diluted with normal saline or 5% dextrose in the concentration range of 1 to 10 mg/mL in IV containers made of polyvinyl chloride (PVC) or non-PVC material."
223580644|NCT05153070|DRUG|Cyclosporin|• Ciclosporin: 5mg/kg, twice a day, oral, between Day 1 and Day 60
223580645|NCT05153070|DRUG|ILT101|• ILT-101: 1MIU/day in a volume of 1 ml; subcutaneous injection every day during 5 consecutive days and then every week between Day 63 and Day 354.
223580646|NCT05153070|DRUG|Placebo|• Placebo with an identical formulation and regimen of injections i.e. Subcutaneous injection every day (5 consecutive days) then then every week between Day 63 and Day 354.
223580647|NCT05925088|OTHER|Focus group|Participants will take part in a 1 hour focus group.
223580648|NCT06107816|BEHAVIORAL|Usual Care|Visit with a primary care provider and referral for diabetes self-management education and support (DSME/S) sessions
223580649|NCT06107816|BEHAVIORAL|F&V Rx alone|Usual Care plus four F\&V prescriptions that are independent of DSME/S attendance
223580650|NCT06107816|BEHAVIORAL|F&V Rx plus DSME/S|Usual Care plus four F\&V prescriptions that are dependent on DSME/S attendance
223580651|NCT02020876|OTHER|DECIPHER Questionnaire|Participants are asked to complete a questionnaire to assess the impact of Decipher on physicians' treatment recommendation. All participants use the same data collection instrument. Each participant opinion is collected based on a random selection of cases.
223580652|NCT01236872|DIETARY_SUPPLEMENT|Beetroot juice|250ml once of beetroot juice
223580653|NCT01236872|DIETARY_SUPPLEMENT|Water|250ml once of low-nitrate mineral water
223580654|NCT05491421|DRUG|ZT002|"Participants will receive a single subcutaneous (SC) ZT002 dose of 0.03, 0.09, 0.18, or 0.3 mg/kg respectively, for SAD Cohorts 1 to 4 under fasted conditions.~Participants will MAD Cohorts will receive a single subcutaneous (SC) ZT002 in following doses under fasting conditions-~* Cohort 1: 7.0mg, 10mg, 20mg;~* Cohort 2: 10 mg, 20mg, 40mg;~* Cohort 3: To be decided post safety review meetings"
223580655|NCT05491421|OTHER|Placebo|"Participants will receive same volume as of the study drug of 0.03, 0.09, 0.18, or 0.3 mg/kg respectively, for SAD Cohorts 1 to 4 under the fasted condition.~Participants in MAD cohorts will receive same volume as study drug in the following cohorts under fasted condition-~* Cohort 1: 7.0mg, 10mg, 20mg;~* Cohort 2: 10 mg, 20mg, 40mg;~* Cohort 3: To be decided post safety review meetings"
223580656|NCT03826680|PROCEDURE|Flexible fiberoptic laryngoscopy|Patients who will undergo thyroidectomy will be evaluated by awake flexible fiberoptic laryngoscopy and during surgery by direct laryngoscopy under general anesthesia
224160930|NCT04830657|OTHER|Distant reiki|In order to determine the sample size of the study, it is planned to study with a total of 62 patients, including at least 31 patients in each group, in the power analysis based on the statistics of the statistician and previous studies. The remote reiki group will be given remote reiki 3 times a week for 4 weeks by the researcher who has a reiki application certificate. Remote reiki sessions will be performed by the reiki practitioner the night before the hemodialysis day of the patient, and the session duration will take approximately 36-40 minutes. After the individuals receive 12 sessions of remote reiki (1 month later), the questionnaire will be filled in for the second measurement. In order to determine whether reiki has an effect in the long term, 4 weeks (1 month) after the second measurement, the questionnaire for the third measurement will be completed and the research will be completed.
223473069|NCT00295165|DRUG|Sargramostim (Leukine)|Sargramostim 6 mcg/kg subcutaneously once daily
223580657|NCT03826680|PROCEDURE|Direct laryngoscopy|Patients who will undergo thyroidectomy evaluated before by ENT physician, will be evaluated by anesthesiologist in means of MCL score by direct laryngoscopy during surgery under general anesthesia
223473070|NCT00295165|DRUG|Placebo|Placebo subcutaneously once daily
223580658|NCT02154685|BEHAVIORAL|Retrieval-Extinction|A relatively brief exposure to cues prior to conducting more protracted cue exposure. This is referred to as retrieval-extinction training.
223580659|NCT02154685|BEHAVIORAL|Non-Retrieval Extinction|Neutral cue exposure.
223473071|NCT03606564|OTHER|study of fasting time among pediatric patients undergoing day care surgery|parents of children undergoing day care surgery were given a questionnaire to be filled containing questions regarding time of fasting that was instructed and
223473072|NCT06323785|DEVICE|Active whole-body hyperthermia|Active water-filtered infrared whole-body hyperthermia as described in Janssen et al. (2016)
223473073|NCT06323785|DEVICE|Sham whole-body hyperthermia|Sham water-filtered infrared whole-body hyperthermia as described in Janssen et al. (2016)
223473074|NCT02749344|OTHER|FET after endometrial preparation|Patients included in the protocol will begin progesterone supplementation 48 hours before scheduled embryo transfer once it has been established that the endometrium is at least 7 mm and there is a leading follicle.
223580660|NCT01510171|DRUG|Prasugrel|25 patients with STEMI undergoing PPCI with bivalirudin (GP IIb/IIIa not allowed ) will be enrolled to receive 60 mg Prasugrel loading dose before PPCI. The loading dose will be performed as soon as possible in the Emergency Room or in the Cath Lab. In the case of vomit in the 2 hours after drug loading dose a new loading dose will be administered.
223580661|NCT01510171|DRUG|Ticagrelor|25 patients with STEMI undergoing PPCI with bivalirudin (GP IIb/IIIa not allowed ) will be enrolled to receive 180 Ticagrelor loading dose before PPCI. The loading dose will be performed as soon as possible in the Emergency Room or in the Cath Lab. In the case of vomit in the 2 hours after drug loading dose a new loading dose will be administered.
223473075|NCT01555658|DRUG|Bivalirudin|Enrolled patients will be randomized 1:1 in the catheterization laboratory, after the decision to perform PCI by means of planned implantation of stents\>33 mm in length in the same coronary vessel, to IV bivalirudin (0.75 mg/kg intravenous bolus followed by 1.75 mg/kg during procedure and 1.25mg/Kg infusion)
223473076|NCT01555658|DRUG|Unfractioned Heparin|Enrolled patients will be randomized in the catheterization laboratory, after the decision to perform PCI by means of planned implantation of stents\>33 mm in length in the same coronary vessel, to IV UFH (60 IU/kg intravenous bolus followed by boluses with target activated clotting time 200-250 s)
223473077|NCT01328964|DRUG|Fluticasone propionate|fluticasone propionate 44 mcg
223473078|NCT01328964|DRUG|Budesonide|budesonide
223473079|NCT01328964|DRUG|Montelukast|montelukast
223473080|NCT01561417|DRUG|activated recombinant human factor VII|One single dose administration, injected i.v. (into the vein)
223580662|NCT02300519|OTHER|blood sampling|Samplings will be taken on 4 citrated S-monovette tubes, 3 citrated tubes and 1 EDTA tube, namely 36.5 ml for each volunteer
223580663|NCT05135481|PROCEDURE|phrenectomy|The qualification for phrenectomy in group 1 will be made based on the Amir scale, i.e. a score of 4 and fewer points for the language function (2).
223580664|NCT05135481|OTHER|Increased lactation support|Management in group 2 will include increased lactation care both during hospital stay and post discharge.
223580665|NCT03808337|RADIATION|Stereotactic Body Radiotherapy/SBRT|Radiation to each metastatic site should be delivered to a minimum dose of 30 Gy in 5 fractions (BED of 48 Gy10). The exact dose of radiotherapy will be determined by the treating radiation oncologist. Preferred regimens for lung metastases include 50 Gy in five fractions, 48 Gy in four fractions, or 54 Gy in three fractions, although lower doses may be employed to respect dose limits to critical structures such as the esophagus. Recommended SBRT dosing for other sites includes 27 to 30 Gy in three fractions or 24 Gy in one fraction for bone metastases.
223580666|NCT03808337|DRUG|Systemic Therapy/Standard of Care|Standard of care systemic therapy, including chemotherapeutics, targeted therapies, immunomodulatory agents, and hormonal therapies will be delivered at the discretion of the treating oncologist. For patients randomized to receive SBRT, systemic therapy can be continued during SBRT at the discretion and concensus of treating physicians (medical oncologist and radiation oncologist). If the treating physicians recommend discontinuing systemic therapy during SBRT, general guidelines for stopping and reinitiating systemic regimen are as follows: Hormonal therapies and immunotherapy can be continued during SBRT. Consideration can be given to holding cytotoxic chemotherapy beginning 3 to 7 days prior to the initiation of SBRT until 3 to 7 days after the completion of SBRT. Similarly, consideration can be given to holding biologic agents during SBRT and for 0 to 3 days before and after.
223580667|NCT03908736|DRUG|Zinc Picolinate 15 Mg|zinc picolinate, 15 mg/day for 6 months
223580668|NCT05921188|BEHAVIORAL|VAULT Phase 4|Children will receive an input-based word learning treatment that is designed based on principles of statistical learning.
223580669|NCT03573349|DRUG|Ketamine|We will enroll 20 adults (aged 18-65 years) with treatment-resistant depression and will provide two i.v. ketamine infusions (0.5 mg/kg, infused over 40 minutes) and measure their depressive symptom responses. Biomarkers will be developed using blood samples from study subjects, taken prior to (predictive biomarkers), and following ketamine treatment (change biomarkers). This will be an open-label feasibility trial.
223580670|NCT03093493|DIAGNOSTIC_TEST|Genotyping|Genotyping by next generation sequencing
223473081|NCT01561417|DRUG|activated recombinant human factor VII|One single dose administration, injected i.v. (into the vein)
223473082|NCT01733277|OTHER|Magnetic Resonance Imaging (MRI)|All participants from both arms will be subjected to MRI
223473083|NCT00763789|OTHER|local anaesthesia and remifentanil sedation|
223473084|NCT00763789|OTHER|total intravenous anaesthesia|
223473085|NCT01859182|DRUG|selumetinib|Given PO
223473086|NCT01859182|DRUG|Akt inhibitor MK2206|Given PO
223473087|NCT01859182|OTHER|laboratory biomarker analysis|Correlative studies
223580671|NCT04152499|DRUG|SKB264|SKB264 is an Antibody Drug Conjugate (ADC) targeting TROP2 expressing cancer cells.
224160931|NCT04262557|DIAGNOSTIC_TEST|Sunrise® solution|Type II medical device with the CE label. It is a chin sensor associated to an integrated and connected platform.
224160932|NCT04262557|DIAGNOSTIC_TEST|Polysomnography|Gold standard method to diagnose SAS used as comparator
224160933|NCT06460935|BEHAVIORAL|sexual health training|The 20-hour sexual health training will be given online for 5 weeks. Case discussions using the Plissit Model will be held in the training content.
223473088|NCT01859182|OTHER|pharmacogenomic studies|Correlative studies
223473089|NCT01859182|PROCEDURE|quality-of-life assessment|Ancillary studies
223473090|NCT04454424|DRUG|BAY1817080|Study intervention BAY1817080 will be administered orally with tablet(s).
223473091|NCT04454424|DRUG|Midazolam|Midazolam will be administered intravenously with dose of 0.1 mg on Day 1.
223473092|NCT01954849|DIETARY_SUPPLEMENT|Probiotic formulation|
223473093|NCT01562977|DRUG|Rituximab, Gemcitabine, Oxaliplatin, Dexametasone|until progression or unacceptable toxicity develops, 8 cicles max Rituximab: 375 mg/m2, IV, day 1. Gemcitabine: 1000 mg/m2, IV, day 2. Oxaliplatin: 100 mg/m2, IV, day 2. Dexametasone: 20 mg/day, days 1-3, oral.
223473094|NCT04313517|OTHER|Yoga|Each yoga session included warm-up practices (for the large joints, spine, and extremities), Simple postures (Asana), breathing exercises (pranayama) and meditation/relaxation. All the yoga participants were given handouts to practice everyday at work as its feasible
223473095|NCT01754519|PROCEDURE|Therapeutic Conventional Surgery|Undergo wide local excision breast surgery
223473096|NCT01754519|RADIATION|Radiation Therapy|Undergo SFRT
223473097|NCT01754519|OTHER|Laboratory Biomarker Analysis|Correlative studies
223473098|NCT01754519|OTHER|Quality-of-Life Assessment|Ancillary studies
223473099|NCT01032564|OTHER|The elastography (elasticity imagery)|This diagnosis mean use the ultrasonography to measure the tissues answer under pressure
223473100|NCT02630810|OTHER|Early oral hydration|starting oral hydration 1 hour following Cesarean Section using 100 ml clear water
223473101|NCT02630810|OTHER|Delayed oral hydration|starting oral hydration 6 hours following Cesarean Section using 100 ml clear water
223473102|NCT01548807|DRUG|Everolimus (RAD001)|
223473103|NCT02701621|OTHER|MIRT-AT|Aquatic therapy
223473104|NCT02701621|OTHER|MIRT|Land-based Therapy
223473105|NCT06160336|OTHER|Transcutaneous Electrical Nerve Stimulation|"Phase 1: Participants undergo a comprehensive assessment in a single experimental session (mapping session) aimed at mapping the regions and sensations that can be electrically stimulated. This mapping protocol is conducted on both the intact and amputated limbs.~Phase 2: This phase comprises a 4-week experimental protocol, including:~1. four mapping sessions conducted at the onset of each week, where the protocol is randomly applied to the participant's intact and amputated limb.~2. three stimulation sessions held over three consecutive days in the initial week to assess the participant's ability to discern stimuli of varying intensities.~3. ten sessions utilizing an end-effector gait rehabilitation robot, aiming to train the participant in walking using the proposed sensory feedback restoration system based on TENS under controlled and repeatable experimental conditions."
223473106|NCT03427710|DRUG|CiVi007|cholesterol lowering drug
223473107|NCT03427710|OTHER|Placebo|matching placebo to CiVi007
223473108|NCT02964130|OTHER|No name|
223473109|NCT04125979|OTHER|In minimally invasive surgery，Vagus nerve preservation|In minimally invasive surgery for lung cancer, the experimental group retained the pulmonary branches of vagus nerve
223473110|NCT04125979|OTHER|In minimally invasive surgery，Vagus nerve is not preserved|In minimally invasive surgery for lung cancer, the control group did not retain the vagus nerve.
223473111|NCT05943353|OTHER|Pentoxifylline|Prominently, Pentoxyfilline (PTX) is a methylxanthine derivative, is an inhibitor of phosphodiesterase activity and increases intracellular cAMP levels, which play an important role in sperm motility. The ability of PTX to improve sperm motility was first recognized in the study of Turner et al (1978). One of the advantages of PTX is that it significantly reduces the time to find and select motile sperm in cases of completely immotile sperm. In recent years, many studies have demonstrated the effectiveness of PTX for the group of spermatozoa, sperm carrying severe abnormalities. Therefore, the use of a sperm motility inducer such as PTX is a potential method to replace traditional ICSI sperm selection methods. Therefore, we performed this study with the aim to evaluate the effectiveness of PTX to select sperm in ICSI on the group of sperm that were completely immotile after ejaculation and obtained from the procedure.
223473112|NCT04247516|BEHAVIORAL|Online-intervention group I (IGI)|Narrative-based online intervention program to promote self-regulatory competences.
223580672|NCT06013137|OTHER|Therabot|The participants assigned to the experimental group will interact with an artificial intelligence therapy chatbot to alleviate symptoms associated with depression, anxiety, and eating disorders. The control group will not have access to this smartphone chatbot app.
223473113|NCT04247516|BEHAVIORAL|Online-intervention group II (IGII)|Narrative-based online intervention program to promote self-regulatory competencies plus gamification strategies.
223580673|NCT06203756|DEVICE|Omnibotics Robotic-assisted Total Knee Arthroplasty with Apex UC|Robotic-assisted total knee arthroplasty in femur and tibial first workflows using the BalanceBot to characterize soft tissue balance, and the Apex UltraCongruent (UC) knee implant type
223580674|NCT06203756|DEVICE|Omnibotics Robotic-assisted Total Knee Arthroplasty with Apex PS|Robotic-assisted total knee arthroplasty with a tibial first workflow using the BalanceBot to characterize soft tissue balance, and the Apex PosteriorStabilized (PS) knee implant type
223580675|NCT06203756|DEVICE|Omnibotics Robotic-assisted Total Knee Arthroplasty with Apex Revision|Robotic-assisted total knee arthroplasty with a tibial first workflow using the BalanceBot to characterize soft tissue balance, and the Apex Revision knee implant type
223580676|NCT06504524|DRUG|Elranatamab|BCMA-CD3 bispecific antibody
223580677|NCT06504524|DRUG|Standard of Care|control arm
223580678|NCT01969877|DRUG|cetuximab|
223580679|NCT01969877|DRUG|cisplatin|
223580680|NCT06981013|OTHER|balance based torso weighting|The intervention in this study is the Balance-Based-Torso-Weighting (BBTW) which will be applied on individuals with MS and healthy controls. It involves the strategic placement of weights based on the assessment of the loss of balance in three dimensions: anterior-posterior, lateral, rotational to counteract the balance loss.4 The BBTW Evaluation Tool Kit will be used to determine the location of the weights. It consists of an adjustable testing vest; rigid orthotic; five pounds worth of weights divided into 1/16, 1/8, 1/4, 1/2 lb. increments; and exam evaluation forms (www.motiontherapeutics.com).
223580681|NCT05681195|DRUG|Pemetrexed|Participants will receive 900 mg/m\^2 via IV infusion over 10 minutes every 3 weeks x 4-8 induction cycles (21 days per cycle) as part of the induction therapy.
223580682|NCT05681195|DRUG|Zanubrutinib|"Participants will receive 320 mg PO daily or dose-adjusted when given concomitantly with CYP3A4 inhibitor on Days 3-19 of each induction cycle x 4-8 cycles (21 days per cycle) as part of the induction therapy.~For those on maintenance therapy, participants will receive 320 mg PO daily or dose-adjusted when given concomitantly with CYP3A4 inhibitor on Days 1-28 of each maintenance cycle (28 days per cycle) until the transplant (if applicable) or disease progression."
223580683|NCT05681195|PROCEDURE|Autologous Stem Cell Transplant (ASCT)|ASCT will occur in participants who are candidates for this procedure according to standard of care institutional protocols
224069430|NCT03340844|PROCEDURE|Superior Mesenteric Artery First (SMA)|Tumor resection by SMA technique: Kocher maneuver extends to the left renal vein (LRV). Dissection above the LRV of the SMA (refer to vessel-loop). Then, SMA will be identified on the caudal side of the pancreas (mesenterial root) and progressive dissection until its origin in the aorta artery (previously referenced with vessel loop).
224069431|NCT01146678|DRUG|Insulin glargine HOE901|"Pharmaceutical form:solution for injection~Route of administration: subcutaneous"
224069432|NCT01146678|DRUG|Lixisenatide AVE0010|"Pharmaceutical form:solution for injection~Route of administration: subcutaneous"
224069433|NCT01968460|DRUG|P2B001 once daily (pramipexole 0.6 mg / rasagiline 0.75 mg),|Fixed Dose Combination of pramipexole 0.6 mg and rasagiline 0.75 mg once daily
224069434|NCT01968460|DRUG|Placebo|placebo
224069435|NCT01968460|DRUG|P2B001 once daily (pramipexole 0.3 mg / rasagiline 0.75 mg),|Fixed Dose Combination of pramipexole 0.3 mg and rasagiline 0.75 mg once daily
224071662|NCT07143916|PROCEDURE|bonded anterior bite turbos|Sixty patients with anterior deep bite malocclusion were treated with composite bite turbos bonded to the maxillary central incisors. A questionnaire form using the Likert scale with 5 responses (very unpleasant, unpleasant, acceptable, pleasant and very pleasant) was used by patients to document their satisfaction and feedback regarding the bite turbos after 1 week and 1 month.
224071663|NCT07142915|OTHER|light-blocking lenses|Subjects will be instructed to wear light-blocking lenses full-time for 12 months.
223473114|NCT04845334|BEHAVIORAL|RR intervention|"The short psychological intervention consists of a narrative interview and a psychocorporeal intervention. Narrative interview: this is an interview aimed at exploring the experience and awareness of illness. The sharing of the dimension of pain and suffering, the verbalization of emotions, the narration of the history of illness, expectations and fears related to the intervention will be aimed at an emotional and cognitive restructuring of the experience of illness, improving the perception of internal resources and resilience.~Psycho-corporeal intervention:it is a training to the psychophysiological technique of the Relaxation Response (R.R.) of Hebert Benson (Mind-Body Medical Institute of Havard), aimed at stress management and consequently at reducing the perception of pain"
223473115|NCT00944710|DRUG|Atropine|Weekend atropine 1%
223580684|NCT05681195|RADIATION|Whole Brain Radiation Therapy (WBRT)|WBRT will occur in participants who are candidates for this procedure but not candidates for ASCT according to standard of care institutional protocols
223580685|NCT06980701|BEHAVIORAL|AI OHI group|The participants will receive personalized OHI such as toothbrush and interdental cleaning to specific areas provided by AI. An mHealth system will be used to detect intraoral photograph of anterior teeth and analysis of the photograph and label the gum condition as Healthy (green)/questionable (yellow)/diseased (red) within 2 minutes by AI. Then specific OHI to each particular site would be provided by AI according to tested results on the photograph
223580686|NCT06980701|BEHAVIORAL|Dental professionals OHI group|ll participants will receive personalized OHI by dental professionals. This instruction includes brushing and interdental cleaning in each particular dental site. If they have any personal concern or unclear points regarding oral hygiene practice, they can ask.
223580687|NCT02603445|DRUG|BCL201|
223580688|NCT02603445|DRUG|Idelalisib|
223580689|NCT06981000|BEHAVIORAL|Locally adapted nature-based health intervention|"The locally adapted NBHIs are organized according to the following structure:~* Duration of the program: Minimum 10 weeks, once a week, 1.5-2.5 hours per session~* Group composition: Across conditions: mild to moderate anxiety, depression, and/or stress~* Group size: 8-12 participants in a closed group~In the locally adapted programs, activities in nature are based on three main mechanisms of change (nature interaction and sensory experiences, social communities, and physical activity and movement)."
223580690|NCT06980909|DRUG|QLC1101|QLC1101 is an innovative small molecule inhibitor targeting KRAS G12D with independent intellectual property rights developed by Qilu Pharmaceutical Co., Ltd.QLC1101 can prevent GTP/GDP nucleotide exchange and/or the formation of KRAS G12D/GTP/RAF1 complex and inhibit mutant KRAS-dependent signal transduction by specifically binding to the KRAS G12D target, thereby inhibiting the generation of KRAS G12D mutant tumors.
223580691|NCT06980909|DRUG|QLC1101|QLC1101 is an innovative small molecule inhibitor targeting KRAS G12D with independent intellectual property rights developed by Qilu Pharmaceutical Co., Ltd.QLC1101 can prevent GTP/GDP nucleotide exchange and/or the formation of KRAS G12D/GTP/RAF1 complex and inhibit mutant KRAS-dependent signal transduction by specifically binding to the KRAS G12D target, thereby inhibiting the generation of KRAS G12D mutant tumors
223580692|NCT06980909|DRUG|QLC1101|QLC1101 is an innovative small molecule inhibitor targeting KRAS G12D with independent intellectual property rights developed by Qilu Pharmaceutical Co., Ltd.QLC1101 can prevent GTP/GDP nucleotide exchange and/or the formation of KRAS G12D/GTP/RAF1 complex and inhibit mutant KRAS-dependent signal transduction by specifically binding to the KRAS G12D target, thereby inhibiting the generation of KRAS G12D mutant tumors.
223580693|NCT06174116|DRUG|Lumateperone|Subject will take lumateperone (Caplyta) for 12 weeks, in addition to their regular medications.
223580694|NCT06174116|DRUG|Placebo|Subject will take placebo for 12 weeks, in addition to their regular medications.
223580695|NCT06981572|PROCEDURE|Modified Enhanced Recovery After Surgery Protocol|This study is to determine the comparison of the effectiveness of the ERAS modification protocol with the standard protocol in reducing length of stay and improving postoperative outcomes for pediatric patients at RSCM who underwent major gastrointestinal surgery using the ERAS modification method. This study is a single-blind clinical trial. Research subjects will be randomly divided into two groups, namely the group who underwent surgery with the ERAS modification protocol and the group who underwent surgery without the ERAS modification protocol. Modified ERAS protocol will be applied during perioperative
223580696|NCT06450613|DEVICE|radiofrequency ablation|HCC Radiofrequency ablation
223580697|NCT06450613|OTHER|percutaneous ethanol injection|HCC percutaneous ethanol injection
224304228|NCT03002129|OTHER|fluid challenge|At two pre-defined time points during the procedure, enrolled patients will receive a fluid bolus of 5 ml/kg during 5 minutes
223473116|NCT00944710|DEVICE|Plano lens|plano lens over the sound eye
223473117|NCT00944710|DRUG|Atropine|Weekend atropine 1%
223473118|NCT05813756|OTHER|Post-diagnosctic psychoeducational intervention|Participants are randomized to the intervention group. In this group, the participant receives 10 one-hour individual sessions of psychoeducational intervention, bi-monthly, with an evaluation at mid-term (T1:T0+\~2.5 months), at the end of the intervention (T2 : T0+\~5 months) and 3 months after the intervention (T3 : T0+\~8 months). At the same time psychological questionnaires and scales will be completed
223473119|NCT00887484|DRUG|BENZOYL PEROXIDE/ CLINDAMYCIN|Commencing at baseline, subjects will apply once daily both treatment arm #1 and treatment arm #2 in a bilateral split-face fashion (allocation to left and right side randomly assigned) for an initial 2 weeks. At 2 weeks, subjects will apply benzoyl peroxide/clindamycin gel to the entire face for an additional 6 weeks.
224071664|NCT07142915|OTHER|single-vision lenses|Subjects will be instructed to wear single-vision lenses full-time for 12 months.
224071665|NCT07142746|PROCEDURE|Digital intra oral scanning|One groups prepared teeth will be scanned by a digital intra oral scanner.
224304229|NCT00967291|DRUG|ifosfamide|2,500 mg/mq on days 1-3 every 28 days
224304230|NCT00967291|DRUG|mitomycin C|8 mg/mq on day 1 every 28 days
224304231|NCT01905748|OTHER|Laboratory tests|Laboratory tests: erythrocyte sedimentation rate (ESR), Blood Count, C reactive Protein, Protein C activity, Protein S activity,Antithrombin II activity, Coagulation Factor VIII and IX,Con Willebrand Factor, prothrombin time (PT), activated partial thromboplastin time (aPTT), Fibrinogen, D Dimer and Prothrombin Fragments F1 and F2.
224304232|NCT03244501|OTHER|Active tSMS|A cylindrical neodymium magnet is placed above the scalp.
224304233|NCT03244501|OTHER|Sham tSMS|A cylindrical piece of nonferrous metal (brass). This is not attracted to magnets, and is identical in weight and appearance to active magnets.
224160934|NCT04495322|DRUG|TG-1000|Subjects will receive one single oral dose of TG-1000 on day 1 following protocol requirements.
223473120|NCT00887484|DRUG|BENZOYL PEROXIDE/ ADAPALENE|Commencing at baseline, subjects will apply once daily both treatment arm #1 and treatment arm #2 in a bilateral split-face fashion (allocation to left and right side randomly assigned) for an initial 2 weeks. At 2 weeks, subjects will apply benzoyl peroxide/clindamycin gel to the entire face for an additional 6 weeks.
223473121|NCT00288652|DRUG|[S,S]-Reboxetine|
223473122|NCT03687632|BIOLOGICAL|ST266|1X ST266 applied in a dose of one drop (30-50 µL) in the study eye for 28 days (112 doses total will be administered).
223580698|NCT07018583|BEHAVIORAL|Pharmacist's Counseling and Self-Management Application Program|This interventional study is structured around established counseling principles and self-management theory, consisting of six sequential stages: Initial Disclosure, Problem Assessment, Commitment to Action, Skill Enhancement, Monitoring, and Follow-up and Evaluation. These stages are delivered through both in-person pharmacist counseling and a dedicated mobile application. The intervention follows a repeated-measures design, with assessments conducted at 3 and 6 months after enrollment.
223580699|NCT07018583|BEHAVIORAL|Usual Care|Usual care or Standard pharmacy practices such as medication reviews, patient education during the initial visit or when medication changes occur, and counseling upon patient request. No additional structured counseling or self-management tools are provided.
223580700|NCT07015229|PROCEDURE|septorhinoplasty|To provide scientific contribution to more effective and timely pain management strategies in the postoperative period by evaluating the time-dependent course of pain scores and the effect of analgesic intervention timing on clinical outcomes in patients who underwent septorhinoplasty and who are followed in the postanesthetic care unit.
223580701|NCT06868836|DRUG|JS207|JS207 (10 mg/kg or 15 mg/kg, IV, d1)
223580702|NCT06868836|DRUG|Pemetrexed|Pemetrexed (500 mg/m², IV, d1)
223580703|NCT06868836|DRUG|Carboplatin or cisplatin|Platinum-based chemotherapy (carboplatin: AUC5, d1 or cisplatin 75 mg/m², d1) every 3 weeks (Q3W) for a total of 4 cycles
224069436|NCT03177733|PROCEDURE|Evaluation of a breast double block|"we made an association of the serratus block and the PIF block, which allows for a complete block of both the laterals branches of intercostal nerves (with the serratus block) and of anterior branches of intercostal nerves (with the PIF block). Therefore, this association of blocks may lead to a complete analgesia of the breast, while the serratus block alone only allows for an analgesia of the lateral part of the breast.~The objective is to analyze this technique through a collection form that evaluates the satisfaction and post-operative morphine consumption of women receiving this association before a general anesthesia for a unilateral mastectomy with homolateral total lymphadenectomy.~This is a purely observational study that assesses our current practice in this type of surgery."
224069437|NCT00711633|DIETARY_SUPPLEMENT|Milk with probiotic and prebiotic activities|Comparison of two different formula for preterm infants
224069438|NCT00711633|DIETARY_SUPPLEMENT|Milk without probiotic and prebiotic activities|Comparison of formula for preterm infants
224069439|NCT05855512|OTHER|Nursing Educational Intervention|Nursing Educational Intervention
224069440|NCT01864408|OTHER|"Usual practice counseling"|
224160935|NCT04495322|DRUG|Placebo|Subjects will receive one single oral dose of placebo on day 1 following protocol requirements.
224160936|NCT04453618|DRUG|FE-SYHA1402 100mg|in either a fasted state or with a meal
224160937|NCT04453618|DRUG|SYHA1402-25mg|SYHA1402 25mg, oral tablets
224160938|NCT04453618|DRUG|Placebo-25mg|Matching placebo tablets
224160939|NCT04453618|DRUG|SYHA1402-50mg|SYHA1402 50mg, oral tablets
224160940|NCT04453618|DRUG|Placebo-50mg|Matching placebo tablets
224160941|NCT04453618|DRUG|SYHA1402-150mg|SYHA1402 150mg, oral tablets
224160942|NCT04453618|DRUG|Placebo-150mg|Matching placebo tablets
224160943|NCT02315794|DEVICE|SPI®ART|implant prothetic restoration using a yttrium oxide stabilized zirconia abutment
224160944|NCT02315794|DEVICE|SPI®EASY|implant prosthetic restoration using a commercially pure titanium grade 4 abutment
224160945|NCT01031108|DRUG|Placebo|"For the placebo product, SRT2104 drug substance will be replaced by microcrystalline cellulose (Avicel® PH 105) to match the SRT2104 investigational product.~Eight placebo capsules are stored in a dosing bottle and provided to all participating subjects for oral ingestion."
224160946|NCT01031108|DRUG|SRT2104|SRT2104 investigational product is a size 00 Swedish Orange opaque hard gelatin capsule containing 0.25 g of SRT2104, a new chemical entity which is supplied as a micronized, yellowish/amber powder. Eight SRT2104 capsules are stored in a dosing bottle and provided to all participating subjects for oral ingestion.
224160947|NCT04367740|DIAGNOSTIC_TEST|To assess for development of IgG antibodies against SARS-CoV2|Swabs will be collected to assess for COVID-19 if PPE supplies allow.
224160948|NCT04102410|OTHER|Sprints|"Two sprints of 8 seconds on a cycle ergometer will be performed for determine Force/Velocity Profile (FVP).~Realized at inclusion and 2 months after."
224160949|NCT04102410|OTHER|Vertical jumps|"Two vertical jumps will be performed. Height of theses vertical jumps will be measured by application My jump 2 to determine muscle power.~Realized at inclusion and 2 months after."
224160950|NCT04102410|OTHER|Questionary Short Form-12 (SF-12)|"Questionary Short Form-12 (SF-12) will be performed to evaluate quality of life. It is composed of 12 questions.~Realized at inclusion and 2 months after."
224160951|NCT04102410|DEVICE|activity actigraph|"Activity actigraph will be wearing by patient during 7 consecutive days. It measures the level of physical activity and the sedentary lifestyle of patients.~Realized at inclusion and 2 months after."
224160952|NCT04102410|OTHER|Program composed of two 2 training strategies|"Program composed of two 2 training strategies according to the initial Force/Velocity Profile (FVP) will be realized at the inclusion.~There are :~* Strategy experimental-speed: speed training strategy for subjects with a force-speed profile (PFV) in favour of force~* Strategy experimental-force: force training strategy for subjects with a force-speed profile (PFV) in favour of speed."
224160953|NCT04102410|OTHER|Program of usual practice|Program composed of training in force and speed independently of the initial Force/Velocity Profile (FVP).
224160954|NCT04460391|BEHAVIORAL|Intensive rehabilitation|Early standing training and routine rehabilitation
224160955|NCT02894294|OTHER|implementation of seasonal malaria chemoprevention|administration of therapeutic doses of antimalarials (Sulfadoxine-pyrimethamine \[SP\] + Amodiaquine \[AQ\]) at monthly intervals during the high malaria transmission season in children 3-59 months of age.
223473123|NCT01288313|DIETARY_SUPPLEMENT|nutritional intervention|Each diet will last 30 days. During the first period of 15 days, the mothers will receive mediterranean diet based on olive oil. Then, lactating women will receive 30gr/day rapeseed oil. Human milk will be collected during the first breastfeeding of the day (10 ml) at three times : Days 0 corresponding to the usual diet , at day 15 after the Mediterranean diet and at day 30, after the study diet.
223473124|NCT01288313|DIETARY_SUPPLEMENT|nutritional intervention|Each diet will last 30 days. During the first period of 15 days, the mothers will receive mediterranean diet based on olive oil. Then, lactating women will receive diet associating 30gr/day of rapeseed oil and n-3 margarine. Human milk will be collected during the first breastfeeding of the day (10 ml) at three times : Days 0 corresponding to the usual diet , at day 15 after the Mediterranean diet and at day 30, after the study diet.
223473125|NCT01288313|DIETARY_SUPPLEMENT|nutritional intervention|Each diet will last 30 days. During the first period of 15 days, the mothers will receive mediterranean diet based on olive oil. Then, lactating women will receive with 30gr/day n-3 margarine. Human milk will be collected during the first breastfeeding of the day (10 ml) at three times : Days 0 corresponding to the usual diet , at day 15 after the Mediterranean diet and at day 30, after the study diet.
223473126|NCT01288313|DIETARY_SUPPLEMENT|nutritional intervention|Each diet will last 30 days. During the first period of 15 days, the mothers will receive mediterranean diet based on olive oil. Then, lactating women receive 30gr/day olive oil (standard group. Human milk will be collected during the first breastfeeding of the day (10 ml) at three times : Days 0 corresponding to the usual diet , at day 15 after the Mediterranean diet and at day 30, after the study diet.
223473127|NCT02943772|OTHER|Local hypothermia|Cooled brick
223473128|NCT02943772|OTHER|Control|Control brick
223473129|NCT03728062|BEHAVIORAL|Mindfulness meditation|Guided mindfulness meditation focused on breath sensations, thoughts and emotions.
223473130|NCT03728062|BEHAVIORAL|Physical exercise|Cardio exercise at gym like rowing, eliptical, cycling, or running outside.
223473131|NCT00898066|GENETIC|cytogenetic analysis|marrow and peripheral blood
223580704|NCT04786587|DIAGNOSTIC_TEST|blood test|"Each pregnant woman completes the self-report during her prenatal consultation and will have a unique blood sampling for dosage of phosphatidylethanol after she returned her self-report to the practitioner and if she is included in the study (informed consent given).~the blood test for dosage of phosphatidylethanol will be offered to all eligible pregnant women in each maternity clinic of the study during the recruitment period. There will not be different arms in this study."
224069441|NCT01864408|OTHER|"Standard usual practice clinical counseling with the pelvic organ prolapse web-based tool (iPad)."|"After a new patient history and physical exam, with POP-Q exam, the subjects specific exam findings are entered into the Interactive Pelvic Organ Prolapse Quantification (POP-Q) Program. The program then constructs a cartoon of the subjects physical exam findings. This image is then used in counseling in addition to standard usual practice counseling."
224069442|NCT03347877|PROCEDURE|autologous osteo-periosteal cylinder graft transplantation|Autologous osteo-periosteal cylinder graft transplantation is a novel treatment for Hepple V osteochondral lesions of the talus.
224069443|NCT03347877|PROCEDURE|autologous osteochondral graft transplantation|Autologous osteochondral graft transplantation is the most common treatment for Hepple V osteochondral lesions of the talus.
223473132|NCT00898066|GENETIC|fluorescence in situ hybridization|marrow and peripheral blood
223473133|NCT03044314|DRUG|Iloprost and nitric oxide administration|Iloprost will be administered by the I-neb ultrasonic nebulizer (Respironics, Cedar Grove, New Jersey) with a disposable attachment that allows for administration to a supine patient at a concentration of 10 µg/ml with a 10 minute dose of 2.5 µg and then repeated to a cumulative dose of 5.0 µg if tolerated.
223473134|NCT04213664|OTHER|prognosis|cancer and overall survival cancer specific survival cancer and recurrence-free survival cancer and disease-free survival lymphocyte to monocyte ratio in non-metastatic renal cancer and progression-free survival
223473135|NCT01298947|DEVICE|Laser Atherectomy (Spectranetics CE marked peripheral laser atherectomy catheters (including Turbo Elite®), Turbo-Booster® and Turbo Tandem™ Systems|comparing the use of a Paclitaxel-eluting angioplasty balloon (PTX PTA) with initial photoablation to the use of PTX PTA alone in the treatment of instent lesions in femoropopliteal arteries
223473136|NCT04226417|DEVICE|Transcranial direct current stimulation|Dual/ Sham tDCS will be applied in 2 mA, 20 mins before the home-based exercise program in 3 times per week for 4 weeks (12 sessions)
223473137|NCT04523012|OTHER|Seroprevalence of SARS-CoV-2 infection in patients with HIV infection|On inclusion, after information and collection of the non-objection, a blood sample (D0) will be taken during the assessment of the HIV infection (no unplanned sample will be taken) and a control to determine the appearance or the Persistence of antibodies will be made at M6 and M12 always as part of the assessment of HIV infection.
224069444|NCT03347877|DEVICE|autologous osteo-periosteal cylinder graft|Autologous osteo-periosteal cylinder graft is taken from ilium.
224069445|NCT04720820|OTHER|Early Supported discharge with home based Rehabilitation|Treatment by Physiotherapist and occupational therapist at least 30 minutes each, per week provided at home.
224069446|NCT04720820|OTHER|Conventional rehabilitation|Treatment will be provided according to current hospital's stroke rehabilitation program.
224069447|NCT01075061|OTHER|healthy volunteers|morphological and functional brain MRI; transcranial magnetic stimulation
224069448|NCT01075061|OTHER|Kallmann|morphological and functional brain MRI; transcranial magnetic stimulation
224069449|NCT01075061|OTHER|Congenital Mirror Movement|morphological and functional brain MRI; transcranial magnetic stimulation
224071666|NCT07142746|PROCEDURE|Conventional impression|One group will recieve impressions conventionally in a tray with dental impression polyvinly siloxane.
224071667|NCT07144644|DEVICE|Adjusting intraocular pressure (IOP) settings|Investigating whether adjusting IOP settings near physiologic levels during cataract surgery could potentially lead to better surgical outcomes
224071668|NCT07144254|DRUG|Tegavivint|Tegavivint will be administered second, IV over 4 hours, on days 1, 8, and 15 at the dose level assigned at study entry Cycle length will be 21 days. A cycle may be repeated for a total of 17 cycles, up to a total duration of therapy of approximately 12 months.
224071669|NCT07144254|DRUG|Gemcitabine|Gemcitabine will be administered first, intravenously (IV) over 60 minutes, on days 1 and 8 at a fixed dose of 1000 mg/m2
224071670|NCT07143890|OTHER|Meal A|Iron chlorophyllin + water
223473138|NCT05909540|PROCEDURE|Posterior facet distraction and fusion|With the patient in prone position, cervical traction was only intraoperatively after anesthesia with weights of approximately 5-8 kg during surgery. Monitoring of the spinal cord with motor evoked potential and somatosensory evoked potential were used throughout the surgery. Using a posterior midline incision, the occiput to the C2 spinous process was surgically exposed, separated to the lateral edge of the C1-2 joint, and cut off at the C2 nerve root to expose the C1-2 articular surface Quantitative reduction techniques included the following steps .1) Facet joint release and cage implantation technique 2)Adjusting POCA by cantilever and occipitocervical fixation technique.
223473139|NCT00691522|DRUG|Xerecept|
223473140|NCT05267210|OTHER|Questionnaire|"1. Back Pain and Body Posture Assessment Instrument for Adults (BackPDE-Y) This questionnaire assesses pain and risk factors associated with back pain. The questionnaire includes questions that include demographic, socio-economic, hereditary and behavioral risk factors. The questionarie consists of 20 questions in total.~2. Musculoskeletal Health Questionnaire (CIS-SS) The questionnaire included pain/stiffness (during the day and night), physical function (walking and dressing), physical activity level, involvement of symptom-related work/daily life and social activities/hobbies, difficulty sleeping, fatigue, emotional well-being, diagnosis and It consists of a total of 14 questions evaluating the understanding of the treatment and the overall effect of the disease."
223473141|NCT05256823|DRUG|Celecoxib|Patients will be treated with Celecoxib twice daily for 48 weeks.
223473142|NCT05256823|DRUG|nucleos(t)ide analogue|Patients will continue ongoing nucleos(t)ide analogue (Entecavir or Tenofovir Disoproxil Fumarate or Tenofovir Alafenamide Fumarate) therapy for 48 weeks
223473143|NCT00264147|DRUG|etoricoxib|Period I: Arm 1: etoricoxib 10 mg tablet once daily. 12 weeks of treatment.
223473144|NCT00264147|DRUG|etoricoxib|Period I: Arm 2: etoricoxib 30 mg tablet once daily. 12 weeks of treatment.
223473145|NCT00264147|DRUG|etoricoxib|Period I: Arm 3: etoricoxib 60 mg tablet once daily. 12 weeks of treatment.
223473146|NCT00264147|DRUG|etoricoxib|Period I: Arm 4: etoricoxib 90 mg tablet once daily. 12 weeks of treatment.
223473147|NCT00264147|DRUG|Comparator: placebo|Period I: Arm 5: Pbo tablet once daily. 12 weeks of treatment.
223473148|NCT00264147|DRUG|etoricoxib|Period II: Arm 1: etoricoxib 90 mg tablet once daily. 12 weeks of treatment.
223473149|NCT00264147|DRUG|Comparator: diclofenac|Period II: Arm 2: diclofenac 75 mg tablet twice daily. 12 weeks of treatment.
223473150|NCT03508778|DEVICE|FluidVision AIOL|Investigational implantable medical device intended for long-term use over the lifetime of the cataract subject
223473151|NCT03508778|DEVICE|AcrySof IQ PanOptix Trifocal IOL|Commercially available implantable medical device intended for long-term use over the lifetime of the cataract subject
223473152|NCT03508778|PROCEDURE|Cataract surgery|Cataract surgery per investigator's standard practice
223473153|NCT04827277|PROCEDURE|Reverse Total Shoulder Replacement|Participants will be randomized to a reverse total shoulder replacement
223473154|NCT04827277|PROCEDURE|Anatomic Total Shoulder Replacement|Participants will be randomized to an anatomic total shoulder replacement
224160956|NCT03990922|PROCEDURE|Continuous Paravertebral block with ropivacaine|Inject 25 ml 0.5% ropivacaine in the T8 paravertebral space followed with catheter insertion and continuous 0.2% ropivacaine infusion(infusion rate: 0.125ml/kg/pulse,1pulse/h).
224160957|NCT03990922|PROCEDURE|"Continuous Paravertebral block with saline"|Inject 25 ml 0.9% saline in the T8 paravertebral space followed with catheter insertion and continuous 0.9% ropivacaine infusion(infusion rate: 0.125ml/kg/pulse,1pulse/h).
223473155|NCT03234465|BIOLOGICAL|AG013|AG013 is made up of genetically modified (GM) bacteria called Lactococcus lactis (L. lactis). Wild type L. lactis are commonly used to produce dairy products including cheeses and milk. To make AG013, the DNA of L. lactis has been changed in the laboratory to secrete a protein called human Trefoil Factor 1 (hTFF1). hTFF1 is normally secreted in saliva and intestines. Trefoil factors have been shown to be important in protecting and healing mucosal tissues, such as the tissue in the mouth, when these tissues are damaged by cancer therapies such as chemotherapy and radiation therapy.
223473156|NCT03234465|OTHER|Placebo|Subjects assigned to the placebo group will receive appearance- and taste-matched placebo powder.
223473157|NCT03880747|PROCEDURE|Vagus nerve-preserving distal gastrectomy|Laparoscopic distal gastrectomy with the preservation of the celiac and hepatic branch of the vagus nerve.
223473158|NCT03464435|DRUG|Tacrolimus|All the patients will be treated with 0.1% tacrolimus suspension two times daily, LE/T eye drops four times daily for 1 month. 0.1% tacrolimus will be continued for the last 5 months.
223473159|NCT04040517|DIAGNOSTIC_TEST|Evoked potential audiometer|The ASSR \[ steady state response\] test stimuli are modulated pure tones with insert earphone..
224160958|NCT03990922|DRUG|Patient-controlled analgesia with morphine|Morphine given as intravenous patient-controlled analgesia bolus: 2mg, lock time: 5min, 1h limitation: 8mg
224160959|NCT04984876|DRUG|ligelizumab|Subcutaneous injection once every 4 weeks
223473160|NCT00986414|DRUG|AFQ056|
223473161|NCT00986414|DRUG|AFQ056|
224160960|NCT04984876|DRUG|Placebo|Subcutaneous injection once every 4 weeks
224160961|NCT02444936|DRUG|ZOSTAVAX|Shingles vaccine
224160962|NCT00852423|DRUG|Dihydroartemisinin-piperaquine|DHA-PQ tablets are green film coated intended for oral use and contain 20/160mg or 40/320mg of dihydroartemisinin (DHA) and piperaquine phosphate (PQ) respectively. In this trial the 40/320mg for adults will be used. Developed by Sigma Tau in partnership with Medicines for Malaria Venture.
224163793|NCT00626340|DRUG|No depression and estrogen treatment|Control participants with no MDD diagnosis received estrogen only for the treatment of physical symptoms of menopause.
224163794|NCT02245880|DEVICE|Glidescope|videolaryngoscope
223473162|NCT00986414|DRUG|AFQ056|
223473163|NCT00986414|DRUG|AFQ056|
223473164|NCT00986414|DRUG|AFQ056|
223473165|NCT00986414|DRUG|Placebo|
223743911|NCT03202264|OTHER|TAPER|"The intervention is medication reduction. This arm is comprised of:~* Medication reconciliation~* Identification of patient priorities for care~* Identification of medications that are potentially appropriate for discontinuation/dose reduction~* Linked pharmacist/family physician consultations with patient to discuss medication with intention to reduce~* Identification of medications for trial of discontinuation/dose reduction (shared decision making)~* Pause of medication and clinical monitoring"
224163795|NCT02245880|DEVICE|ILMA|handling of the device till the optimal ventilation achieved
223473166|NCT03854331|BEHAVIORAL|Resilience program|The resilience program consists of different modules that are based on research on mentalization, mindfulness, parent management training, improving self-control and self-efficacy, cognitive behaviour therapy, social learning theory and neuroscience. The MyResilience program is also informed by cognitive bias modification and self-control training research. These techniques have been found to be effective in improving engagement in health behaviours and reducing symptoms and negative behaviours in clinical groups
223473167|NCT04801251|DIAGNOSTIC_TEST|Echocardiographic examination|Each patient included will undergo full cardiac physical examination and echocardiographic examination
223473168|NCT03854942|DRUG|Placebo|Placebo oral tablet daily
223473169|NCT03854942|DRUG|Naltrexone|Naltrexone (Nemexin) oral tablet 50 mg daily for 2 days, Naltrexone (Nemexin) oral tablet 100 mg daily for 5 days
223580705|NCT04786587|OTHER|self-administered questionnaire|"Each pregnant woman completes the self-report during her prenatal consultation and will have a unique blood sampling for dosage of phosphatidylethanol after she returned her self-report to the practitioner and if she is included in the study (informed consent given).~A self-report, including the T-ACE, is the usual prenatal consultation procedure in the three maternities of the study. The specific procedure for the study is to perform a blood test for dosage of phosphatidylethanol in eligible pregnant women after informed consent."
223580706|NCT07032454|OTHER|High Caffeine Consumption|Individuals consuming 300 mg or more of caffeine daily, meeting DSM-5/ICD-10 criteria for caffeine dependence.
223580707|NCT07032454|OTHER|Low Caffeine Consumption|Individuals consuming caffeine within recommended levels (20-200 mg/day).
223580708|NCT07040826|DRUG|Xiidra|Administered on Day 1 to subjects in Group B, and on Day 8 to subjects in Group A as part of a crossover study design.
223580709|NCT07040826|DRUG|Lifitegrast|Administered on Day 1 to subjects in Group A, and on Day 8 to subjects in Group B as part of a crossover study design.
224071671|NCT07143890|OTHER|Meal B|Soy hemoglobin + water
224071672|NCT07143890|OTHER|Meal C|FeSO4 (negative control) + water
224071673|NCT07143890|OTHER|Meal D|Porcine hemoglobin (positive control) + water
224304234|NCT02878122|PROCEDURE|Cancer treatment|Chemotherapy and laparoscopic surgery
223473170|NCT02493972|PROCEDURE|GelPort|Manual exploration of the peritoneal carcinosis by the system GelPort ® with calculation of peritoneal cancer index for evaluation of the resectability
223473171|NCT02493972|PROCEDURE|laparotomy|laparotomy will be performed if indication confirmed by manual exploration
223473172|NCT00449163|BIOLOGICAL|Bevacizumab|
223473173|NCT00449163|DRUG|Floxuridine|
223473174|NCT00449163|DRUG|Irinotecan|
223473175|NCT00449163|DRUG|Leucovorin|
224071674|NCT07143890|OTHER|Meal E|Iron chlorophyllin + maize porridge
223473176|NCT03106077|BIOLOGICAL|Mirvetuximab Soravtansine|Given IV
223473177|NCT03627104|DIETARY_SUPPLEMENT|Normoprotein diet with animal protein|Each patient will be attended for 1 month through 4 weekly visits. Weekly menus will be delivered according to diet with percentage of standard protein (12-18%) with a predominance of animal protein (60%). Regardless of the type of protein, menus will contain the same amount of energy and concentration of carbohydrates, fats and saturated fats (less than 7%).
223473178|NCT03627104|DIETARY_SUPPLEMENT|Normoprotein diet with vegetable protein|Each patient will be attended for 1 month through 4 weekly visits. Weekly menus will be delivered according to diet with percentage of standard protein (12-18%) with a predominance of vegetable protein (60%). Regardless of the type of protein, menus will contain the same amount of energy and concentration of carbohydrates, fats and saturated fats (less than 7%).
223473179|NCT03627104|DIETARY_SUPPLEMENT|High-protein diet with animal protein|Each patient will be attended for 1 month through 4 weekly visits. Weekly menus will be delivered according to diet with high-protein percentage (25-35%) with a predominance of animal protein (60%). Regardless of the type of protein, menus will contain the same amount of energy and concentration of carbohydrates, fats and saturated fats (less than 7%).
223473180|NCT03627104|DIETARY_SUPPLEMENT|High-protein diet with vegetable protein|ach patient will be attended for 1 month through 4 weekly visits. Weekly menus will be delivered according to diet with high-protein percentage (25-35%) with a predominance of vegetable protein (60%). Regardless of the type of protein, menus will contain the same amount of energy and concentration of carbohydrates, fats and saturated fats (less than 7%).
223473181|NCT03548077|BEHAVIORAL|POWERPLAY|"All men from participating worksites are invited to completed surveys prior to and following implementation of a workplace wellness program (called POWERPLAY)"
223473182|NCT00541242|DRUG|bimatoprost 0.03% eye drops|Open-labeled latanoprost 0.005% 1 drop into each eye every evening for 6 weeks followed by a masked randomized treatment of bimatoprost 0.03% 1 drop every evening for 12 weeks
223473183|NCT00541242|DRUG|latanoprost 0.005% eye drops|Open-labeled latanoprost 0.005% 1 drop into each eye every evening for 6 weeks followed by a masked randomized treatment of latanoprost 0.005% 1 drop every evening for 12 weeks
223473184|NCT04547855|DRUG|anlotinib combined with dose-dense temozolomide|Temozolomide Capsule 150mg, p.o., qd, d1-7,15-21,4 weeks one cycle; Anlotinib hydrochloride capsule 12mg, p.o., qd, D1-D14; 3 weeks one cycle.
224071675|NCT07143890|OTHER|Meal F|Soy hemoglobin + maize porridge
224071676|NCT07143890|OTHER|Meal G|FeSO4 (negative control) + maize porridge
224071677|NCT07143890|OTHER|Meal H|Porcine hemoglobin (positive control) + maize porridge
224071678|NCT07144774|DEVICE|Fitbit wrist-worn Inspire 2® activity tracker (Fitbit Inc., San Francisco, CA, USA)|Visual feedback of the physical activity level
224071679|NCT07143175|OTHER|Comprehensive Assistance and Resources for Effective Diabetic Foot Navigation|"The CARE-D-FOOT-Nav (Comprehensive Assistance and Resources for Effective Diabetic Foot Navigation) program is a patient navigator intervention that aims to increase access to guideline-concordant multidisciplinary DFU care to improve DFU healing.~CARE-D-Foot-Nav is a diabetes educator who will serve as a dedicated Diabetic Foot Ulcer (DFU) patient navigator. The navigator will assist the subjects with diabetic foot ulcer care.~Based on community input, navigators will conduct 30-to 60-minute encounters, either by phone or in person, at least once a week during the 20-week program. Additional contact may be warranted to coordinate appointments and transportation. Participants can call the navigator with DFU-related concerns at any time during the navigator's working hours. The overarching goal of the navigator is to help patients access the four key pillars of DFU care, thereby optimizing the chances of DFU healing."
223473185|NCT04309032|PROCEDURE|retrograde bladder filling with 0.9% normal saline 250cc prior to removal of foley catheter|0.9% NS 250cc was introduced before foley catheter removed for discharge
223473186|NCT04119934|BEHAVIORAL|Smoking Cessation Intervention Tool|A personalized smoking cessation infographic is provided to the physician/NP alongside the patient's regular spirometry report.
223473187|NCT00606307|DRUG|ITF2357|50 mg b.i.d. PO every day. More precisely, ITF2357 was supplied as 50 mg hard gelatine capsules for oral administration.
223473188|NCT00900939|BEHAVIORAL|Low-fat, vegan diet|Participants in the intervention group will be asked to follow a low-fat, vegan diet for the full 16 weeks of the study. They will also be guided to favor foods with a low glycemic index. The diet consists of whole grains, vegetables, legumes, and fruits, with no restriction on energy intake. Animal products, added oils, and added sugars will be excluded.
223473189|NCT00900939|BEHAVIORAL|Control|Participants assigned to the control group will be instructed to follow their usual diets for the full 16 weeks of the study.
223473190|NCT06378424|OTHER|Cold Application|Before peripheral intravenous catheterization, heat of approximately 40-42 o C was applied for 1 minute to the area of the procedure using a hot pack, which is one of the dry heat application methods. The heat application pack has a feature that it can maintain its temperature when taken out of hot water and does not disturb the person when it comes into direct contact with the skin. In order to apply heat to the individuals in this group, a pack of 11 x 19 cm is used. This pack is covered with cloth and contains a non-toxic gel, and is placed in hot water to prepare it for use. Because this pack is reusable, it was disinfected before and after each use.
223473191|NCT06378424|OTHER|Heat Application|Before peripheral intravenous catheterization, heat of approximately 40-42 o C was applied for 1 minute to the area of the procedure using a hot pack, which is one of the dry heat application methods. The heat application pack has a feature that it can maintain its temperature when taken out of hot water and does not disturb the person when it comes into direct contact with the skin. In order to apply heat to the individuals in this group, a pack of 11 x 19 cm is used. This pack is covered with cloth and contains a non-toxic gel, and is placed in hot water to prepare it for use. Because this pack is reusable, it was disinfected before and after each use.
223473192|NCT06378424|OTHER|Vibration Application|With individuals in this group, the Buzzy® device was used to provide vibration. The Buzzy® device, at room temperature, was placed by the researcher on the peripheral intravenous catheterization application area before the application was performed. For one minute before the application, a slight, non-discomforting vibration was applied to the intervention area. As the Buzzy® device can be used more than once, it was disinfected after each use and before being used with another individual. In this study, the body of the device was used, and only vibration was applied to the individuals in this group.
223473193|NCT05681117|OTHER|multi-component nutrition education|"Classroom-based nutrition education 40 minutes once a week for 4 weeks~SMS Reminders SMS reminders containing healthy nutrition tips 2 times a week, 1 weekday, 1 weekend, starting with nutrition education and throughout the education (4 weeks)~Brochure Distribution Brochures prepared in accordance with the content of classroom-based nutrition education were distributed immediately after the nutrition education.~Controversial Supermarket Tour Nutrition label reading activity aimed at gaining the ability to evaluate product contents, in line with the information explained in module 4, in the supermarket tour planned to be organized once with an appropriate number of student groups (maximum 7 people) after the nutrition education"
223473194|NCT04881812|DEVICE|Drug-Coated Balloons|Percutaneous coronary intervention of residual disease adjacent to a chronic total occlusion with a paclitaxel drug-coated balloon (minimal stenting strategy).
223473195|NCT04881812|DEVICE|Drug-Eluting-Stent|Percutaneous coronary intervention of the chronic total occlusion and residual coronary artery disease with an everolimus-eluting platinum chromium coronary stent (complete stenting strategy).
223473196|NCT01274533|DRUG|Lenalidomide|25mg or 10mg (based on creatinine clearance) once daily for days 1-21 of a 28 day cycle
223473197|NCT00597272|BIOLOGICAL|KLH conjugates with GD2L and GD3L|6 vaccinations (on weeks 1, 2, 3, 8, 20 and 32) which will contain the same KLH conjugates with GD2L and GD3L. All vaccines contain KLH conjugates containing 30mcg of GD2L and 30mcg of GD3L and QS-DG or OPT-821. The initial 8 patients will receive the same QS-DG or OPT-821 vaccine dose in all of their vaccines. This dose will be 50 mcg for the first patient, 75 mcg for the second patient and 100 mcg for the third through eighth patients. In all subsequent patients the 1st, 4th and 5th vaccinations will include 150 mcg of OPT-821. The 2nd and 3rd vaccinations will contain 100 mcg of OPT-821 and the 6th vaccination will contain 200 mcg of OPT-821.
223473198|NCT03781726|DRUG|glecaprevir/pibrentasvir treatment|combination treatment with glecaprevir and pibrentasvir fixed dose tablet.
223473199|NCT02008526|BEHAVIORAL|Text Messages Transmitted by Peer Health Educators (TXT-PHE)|"Participants receive five gay-specific, theory-based pre-written messages per day sent on a predetermined schedule. Participants who respond to the pre-written text messages or initiate queries or requests for support (pull) are sent additional real-time messages back from the PHE. Text messages are transmitted and responded to in real time, at the peak hours of high-risk activities. During the 8-week intervention, participants receive a brief weekly text-based assessment on their methamphetamine use and HIV sexual behaviors in the previous seven days."
223473200|NCT02008526|BEHAVIORAL|Text Messages Transmitted by Automation (TXT-Auto)|Participants receive five gay-specific, theory-based pre-written messages per day sent on a predetermined schedule. During the 8-week intervention, participants receive a brief weekly text-based assessment on their methamphetamine use and HIV sexual behaviors in the previous seven days.
223473201|NCT05247762|DEVICE|Acupuncture|The stainless steel needles are used to insert into the two points of Jingming and the Qiuhou, and der-qi, once a week, once for 20 minutes, for 24 consecutive weeks.
223473202|NCT01892332|DRUG|epidural block with lidocaine and fentanyl|"The study method was a step-up/step-down sequence model where the dose for following patients was determined by the outcome of the preceding block. The starting concentration of lidocaine was 1.5 % mixed with fentanyl 75 ug. All patients receive 13mL of lidocaine with fentanyl 75ug. The concentration of lidocaine for subsequent patients is determined by the outcome in the previous patient according to up and down sequential allocation in 0.1% increments. In the case of block failure, the concentration of lidocaine was increased by 0.1%.~Conversely, block success resulted in a reduction in concentration by 0.1%."
223580710|NCT07030244|BEHAVIORAL|Moodpep|See arm description
223473203|NCT05261165|PROCEDURE|hysterectomy|Hysterectomy as primary surgical treatment of endometrial cancer. Abdominal laparotomy approach was performed without intrauterine manipulator (NonManip). Endoscopic - total laparoscopic hysterectomy, laparoscopic assisted vaginal hysterectomy or robotic hysterectomy was performed with use of intrauterine manipulator (Manip). It was Hegar dilatator (ManipHe) or Koh-Rumi device (ManipKoRu).
223473204|NCT04991714|DRUG|Lactisole|sweet taste inhibitor (decreases sweetness)
223473205|NCT04991714|DRUG|Rebaudioside M|Sweetener (increases sweetness)
223473206|NCT04991714|OTHER|Sucrose|10% Sucrose corresponding to a regular soft drink
223580711|NCT07041489|DIETARY_SUPPLEMENT|Active Comparator- Xtressé™ Supplement and Serum|"Participants will receive 3 month supplies 3 times during the study. Participants will apply serum and take supplements daily.~Participants in the Intervention group will receive Xtressé™ Supplements and Serum in Part A and Part B of the study.~Participants in the Placebo Group will receive Xtressé™ Supplement and Serum in Part B of the study only."
223580712|NCT07041489|DIETARY_SUPPLEMENT|Placebo Comparator- Placebo Supplement and Serum|"Participants will receive 3 month supplies 3 times during the study. Participants will apply serum and take supplements daily.~Participants in the Placebo Group will receive Placebo Supplement and Serum in Part A of the study only."
223580713|NCT07041892|OTHER|Prebiotic Supplement + Synbiotic Supplement + Topical Lotion + Unscented Soap|"The intervention includes 4 products:~1. An oral prebiotic dietary supplement~2. An oral synbiotic dietary supplement~3. A topical lotion~4. An unscented bar of soap"
223580714|NCT07040254|BEHAVIORAL|Father-Inclusive Antenatal Education Program|A structured six-week antenatal education program designed for pregnant women and their spouses. The program included sessions on pregnancy care, labor, breastfeeding, newborn care, and postpartum health. Fathers in the intervention group attended the program alongside their partners and were actively engaged in discussions and learning activities related to breastfeeding support. The goal was to enhance paternal awareness and involvement to improve maternal breastfeeding adaptation and both maternal and paternal breastfeeding self-efficacy. No additional materials were provided beyond the scheduled sessions.
223580715|NCT07040618|PROCEDURE|Ultrasound-guided Rhomboid Intercostal Block|This intervention involves an ultrasound-guided injection of 20-25 mL of 0.25% bupivacaine into the fascial plane between the rhomboid major and intercostal muscles. The patient is positioned laterally, and the block is performed at the T5-T6 level using a high-frequency linear ultrasound probe. The goal is to anesthetize the lateral cutaneous branches of the intercostal nerves to provide postoperative thoracic analgesia.
223580716|NCT07040618|PROCEDURE|Ultrasound-guided Erector Spinae Plane Block|This intervention consists of an ultrasound-guided injection of 20-25 mL of 0.25% bupivacaine into the plane deep to the erector spinae muscle at the T4-T5 transverse process level. The patient is positioned sitting or in lateral decubitus, and the procedure uses a curved or linear ultrasound probe. This block targets the dorsal and ventral rami of thoracic spinal nerves to manage postoperative pain after thoracotomy.
223580717|NCT07040865|DRUG|Gadobutrol (Gadovist/Gadavist)|Magnetic resonance acquisition without contrast agent followed the same acquisition 60 s and 15 min after gadobutrol contrast injection.
223580718|NCT07040865|DRUG|Gadopiclenol|Magnetic resonance acquisition without contrast agent followed the same acquisition 60 s and 15 min after gadopiclenol contrast injection.
223580719|NCT07040813|DRUG|CGRP mAbs and onabotulinumtoxin A|CGRP mAbs given subcutanously every 4th week and onabotulinumtoxin A 155 given once intramuscularly according to adjusted PREEMPT protocol in the 12 week period of study intervention.
223580720|NCT07040813|DRUG|CGRP mAbs and placebo|CGRP mAbs given subcutanously every 4th week and placebo once intramuscularly according to adjusted PREEMPT protocol in the 12 week period of study
223580721|NCT06887296|OTHER|women answer a questionnaire|Sexual Function and Distress Assessment in Women with Polycystic Ovary Syndrome (PCOS) Using Standardized Questionnaires
223580722|NCT07040631|DEVICE|Endotra Gel|Endotra Gel is a hyaluronic acid-based, water-soluble wound dressing gel approved by the Korean Ministry of Food and Drug Safety. In this study, it is applied to the cuff of the endotracheal tube before intubation to evaluate its effect on reducing postoperative sore throat and hoarseness.
223743912|NCT04415632|OTHER|low glycemic index diet|• Three-day cycle menu of LGI diet will be designed and supplied to each participant in an amount designed to meet their estimated energy requirements. The percentage energy from protein, fat and carbohydrate will be the same in the two diets. Each diet period of the trial will last for two weeks.
223743913|NCT04415632|OTHER|High glycemic index diet|Three-day cycle menu of HGI diet will be designed and supplied to each participant in an amount designed to meet their estimated energy requirements. The percentage energy from protein, fat and carbohydrate will be the same in the two diets. Each diet period of the trial will last for two weeks.
223743914|NCT03388138|COMBINATION_PRODUCT|etafilcon A with ketotifen|Etafilcon A with ketotifen
224160963|NCT00852423|DRUG|Artesunate-mefloquine|MQAS will be provided as a fixed-dose ACT. There are 2 strengths (AS25+MQ55mg and AS100+MQ220mg) and dosing regimen is calculated according to 12 mg/kg AS and 24mg/kgMQ total dose over three days. Pregnant women will receive 2 tablets/day for 3 days. It is developed by Farmanguinhos with the Drugs for Neglected Diseases Initiative. To be noted: if the FDCs will not get the WHO pre-qualification before the start of recruitment, the separate AS and MQ will be used
224160964|NCT00852423|DRUG|Artesunate-amodiaquine|AQAS, developed by teh DNDi with Sanofi-Aventis and manufactured by Sanofi-Aventis, has been pre-qualified by the WHO in 2008 and is available in several African countries, including those involved in this trial. AQ-AS tablets are round, yellow on one side and white-slightly yellow on the other, with a breaking bar, AS engraved on one side and either 25, 50 or 100 on the other side. Tablets to be used in this trial are those 100mg/270mg AS/AQ, containing 100 mg of artesunate, 352.640 mg of amodiaquine hydrochloride corresponding to 270mg of amodiaquine base.
224160965|NCT00852423|DRUG|Artemether-lumefantrine|AL (tablets containing a FDC of 20 mg of artemether and 120 mg of lumefantrine) is manufactured by Novartis and has been extensively used in Africa for the treatment of uncomplicated malaria. AL was registered in Switzerland in 1999, has since received marketing authorisation in several endemic and non-endemic countries and it is WHO pre-qualified.
224160966|NCT01048255|DRUG|VX-765|300mg Oral Tablet, 900mg TID
224160967|NCT00003613|DRUG|O6-benzylguanine|Given IV
223473207|NCT01118052|OTHER|Laboratory Biomarker Analysis|Correlative studies
223473208|NCT01118052|BIOLOGICAL|PEG-PEI-cholesterol Lipopolymer-encased IL-12 DNA Plasmid Vector GEN-1|Given intraperitoneally
223580723|NCT07041970|OTHER|Exergame|The training program will focus on strength and functional movements. It requires a Nintendo Switch console, a Ring-Con (a Pilates ring that the user holds or ring holder), wireless Joy-Con controllers (the right Joy-Con, connected to the Ring-Con; and the left Joy-Con, attached to the strap around the player's thigh) and a screen. In adventure mode, women will move through the game by performing physical activities such as jogging or doing squats. To minimize risk, knee-assist mode will be used, which makes the game more accessible. Activating knee assist mode provides support when women perform exercises that require walking, kneeling or squatting, making these activities easier for pregnant women, increasing the fitness benefits of the game. In battle mode women will perform aerobic activities, strength training and yoga exercises that involve the whole body to advance in the game.
223580724|NCT07041255|PROCEDURE|Cold endoscopic mucosal resection|3-4 ml of solution is injected into the submucosal layer under the formation. The formation with the surrounding mucous membrane (at least 1 mm from the edge of the formation) is captured with a specialized or standard polypectomy loop available to the operator (depending on the randomization result). The formation is removed by mechanical cutting without using electric current.
223580725|NCT07041255|PROCEDURE|Hot endoscopic mucosal resection|"3-4 ml of solution is injected into the submucosal layer under the formation. The formation with the surrounding mucous membrane (at least 1 mm from the edge of the formation) is captured with a specialized or standard diathermic polypectomy loop available to the operator (depending on the randomization result). The formation is removed using electric current in the Endocat mode (or its analogue, providing alternating cutting and coagulation under the control of a processor built into the electrical unit).~After the formation is removed, the resection site is examined in white light, then virtual chromoscopy (NBI), and then an examination with magnification. The examination results are recorded in the scientific protocol separately, and are assessed as a whole. The criteria for visual removal of the formation within healthy tissues are the absence of visible fragments of the formation. The time of complete cessation of capillary bleeding is recorded."
223473209|NCT02757157|BEHAVIORAL|Water-based walking|"Participants will walk in the water for 15 minutes at an intensity rating of five on the modified Borg scale for dyspnoea or perceived exertion, whichever is the highest. Walking intensity will be measured every three minutes during each walking session. If the intensity level is reported as below five, participants will be encouraged to increase the intensity by increasing their walking speed.~During walking in water, VO2 and VE will be measured breath-by-breath using the Oxycon mobile. Every three minutes during the walking, heart rate, oxygen saturation, dyspnoea and exertion will be measured."
223580726|NCT07040722|OTHER|Baseline|During the baseline, children will carry out their standard paper-and-pencil exercises for writing difficulties (that their perform during usual rehabilitation).
223580727|NCT07040722|OTHER|Intervention|During the intervention, they will carry out usual exercises and they will use VR 15 minutes during each session
223580728|NCT06736093|DRUG|Vitamin D3|Vitamin D3 60,000 IU given once weekly Pre Liver Transplant atleast for 6 weeks
223580729|NCT06736093|DRUG|Placebo|Placebo capsules once weekly for atleast 6 weeks pre liver transplant
223580730|NCT06776549|PROCEDURE|Temperature control|Procedure: Temperature control at 33-34 °C In the hypothermia group, patients receiving ECPR will be immediately cooled to 33ºC-34ºC with ECMO using a heat exchanger. After reaching this targeted temperature, the maintenance phase will start, and the target temperature will be kept at 33ºC-34°C. The maintenance phase will end 24 h after reaching this targeted temperature. Subsequently, rewarming to 36ºC-37ºC will be conducted in 24 h. After the rewarming, the temperature will be kept in the range of 36ºC-37.5ºC for 24 h after rewarming or until the end of ECMO, and should not exceed 37.5ºC. Other interventions, such as sedation, administration of neuromuscular blocking agents, antipyretics, and catecholamines, as well as mechanical circulatory support, are optional and performed at the patient's discretion.
223580731|NCT06776549|PROCEDURE|Temperature control|Procedure: Temperature control at 36 °C In the normothermia group receiving ECPR, the temperature of 36ºC will be immediately reached with ECMO using a heat exchanger. After reaching this targeted temperature, the maintenance phase will start, and the target temperature will be maintained at 36ºC. The maintenance phase will end 24 h after reaching this targeted temperature. Then, rewarming to 36ºC-37ºC will be conducted in 24 h. After the rewarming, the temperature will be kept in the range of 36ºC-37.5ºC for 24 h after rewarming or until the end of ECMO, and should not exceed 37.5ºC. Other interventions, such as sedation, administration of neuromuscular blocking agents, antipyretics, and catecholamines, as well as mechanical circulatory support, are optional and performed at the patient's discretion.
223580732|NCT06609928|BIOLOGICAL|FOLR1 CAR T-cells|Given IV
223580733|NCT06609928|PROCEDURE|Biospecimen Collection|Undergo CSF and blood sample collection
224069450|NCT06536335|DEVICE|Biomax Nuvola aligners|All patients will be treated with Biomax Nuvola aligners built based on the individual patient's characteristics. The number of aligners and the number/type of attachments will be chosen on the basis of the individual malocclusions. In this group the attachments will be bonded at the beginning of first aligner. Two different questionnaires will be administered to the enrolled subjects: the italian version of the adapted OHIP-14 questionnaire, and a customized questionnaire. The questionnaires will be completed at different stages of orthodontic treatment, as following: 24 hours after the delivery of the first aligner - start of orthodontic treatment; 3 days after the start of orthodontic treatment; 7 days after the start of orthodontic treatment; 24 hours after delivery of the third clear aligner; 3 days after delivery of the third clear aligner; 7 days after delivery of the third clear aligner.
224069451|NCT06536335|DEVICE|Biomax Nuvola aligners|All patients will be treated with Biomax Nuvola aligners built based on the individual atient's characteristics. The number of aligners and the number/type of attachments will be chosen on the basis of the individual malocclusions. In this group the attachments will be bonded at the beginning of third aligner, approximately one month after the start of orthodontic treatment. Two different questionnaires will be administered to the enrolled subjects: the italian version of the adapted OHIP-14 questionnaire, and a customized questionnaire. The questionnaires will be completed at different stages of orthodontic treatment, as following: 24 hours after the delivery of the first aligner - start of orthodontic treatment; 3 days after the start of orthodontic treatment; 7 days after the start of orthodontic treatment; 24 hours after delivery of the third clear aligner; 3 days after delivery of the third clear aligner; 7 days after delivery of the third clear aligner.
224069452|NCT03258567|BIOLOGICAL|Nivolumab|Nivolumab, 480 mg IV every 4 weeks for up to 2 years in subjects with responding disease with clinical benefit if they are tolerating treatment
223473210|NCT02757157|BEHAVIORAL|Land-based walking|"Participants will walk on land for 15 minutes at an intensity rating of five on the modified Borg scale for dyspnoea or perceived exertion, whichever is the highest. Walking intensity will be measured every three minutes during each walking session. If the intensity level is reported as below five, participants will be encouraged to increase the intensity by increasing their walking speed.~During walking on land, VO2 and VE will be measured breath-by-breath using the Oxycon mobile. Every three minutes during the walking, heart rate, oxygen saturation, dyspnoea and exertion will be measured."
223473211|NCT05423834|DRUG|Tenofovir alafenamide|Chronic hepatitis B patients who are receiving TAF as antiviral therapy for CHB, who were previously treatment naïve.
223473212|NCT05423834|DRUG|Entecavir|Chronic hepatitis B patients who are receiving ETV as antiviral therapy for CHB, who were previously treatment naïve.
223473213|NCT01171378|DRUG|Ofatumumab|"1000mg vials (50ml @ 20mg/ml), or 100mg vials (5ml @20mg/ml), to be given as an Intravenous (IV) infusion.~Ofatumumab will be infused intravenously on day 1 (300 mg), day 8 (1000 mg) and day 15 (1000mg) in the first cycle, followed by infusions every 3 weeks of 1000 mg on the first day of each cycle for a total of 6 cycles. Maintenance treatment will start 4 weeks after day 1 of cycle 6 in week 20 and consists of six infusions of ofatumumab every 8 weeks"
223473214|NCT04188600|DIETARY_SUPPLEMENT|Libicare|"The main ingredients of Libicare® are:~* Trigonella Foenum-graecum (Trigonella)~* Tribulus Terrestris (Tribulus)~* Turnera Diffusa (Damiana)"
223473215|NCT04188600|DIETARY_SUPPLEMENT|active control|Selenium and vitamins B complex
223473216|NCT05696951|OTHER|Transamine 200mg iv|In the intervention group, intravenous TXA (Transamine) 1000 mg dissolved in 100 mL 0.9% sodium chloride was administered intravenously within 10 minutes as a loading dose within the first 30 minutes at the end of the surgery. After the end of the loading dose, a maintenance dose of 120mg/hour TXA was infused in 500ml (60ml/hour) SF. The placebo group was given 100ml of saline in the first 30 minutes, followed by a maintenance dose of 60ml/hour of saline for 8 hours.
223473217|NCT05859607|PROCEDURE|laparoscopic cholecystectomy|conventional laparoscopic cholecystectomy with calculation of difficulty scorings
223473218|NCT02232204|BEHAVIORAL|CBT for Insomnia in ICD Patients (CBT-I-ICD)|Participants will complete 4 weekly therapy sessions focused on improving sleep and reducing ICD-related stress. A multicomponent CBT-I-ICD (Cognitive Behavioral Therapy for Insomnia in ICD Patients) protocol will involve: sleep hygiene, stimulus control, sleep restriction, relaxation, cognitive restructuring, ICD education and recall information, shock planning, and quality of life-improvement recommendations.
223473219|NCT02949947|DRUG|Ferric Carboxymaltose|15 mg/kg by vein (up to 750 mg) over 15 min infusion. Dose repeated 1 week later.
223473220|NCT02949947|DIETARY_SUPPLEMENT|Iron Supplements|Participants take iron supplements by mouth every day for up to 3 months.
223473221|NCT02949947|BEHAVIORAL|Questionnaire|Health questionnaire completed at Baseline and at Weeks 4, 8, 12, and 24.
223473222|NCT05994547|DRUG|Byfavo|For induction and maintenance of sedation
223473223|NCT05994547|DRUG|Midazolam|For induction and maintenance of sedation
223473224|NCT04321772|OTHER|High Intensity Interval Resistance Training|Subjects trained one leg with HIIRT
223473225|NCT04321772|OTHER|Traditional Resistance Training|Subjects trained the other leg with HIIRT
223473226|NCT03993483|BEHAVIORAL|Unilateral resistance exercise|The participants performed three sets of their unilateral resistance exercise (biceps curls and knee extensions) three times per week for 10 weeks.
223473227|NCT02349035|DEVICE|Compare control of multifunction transradial prosthesis|Subjects practice control methods using a VR system. EMG data and virtual games are used and provide data to assess control methods without prosthesis. Subjects are fit with commercially available multifunctional hand system. They receive 1-3 days of training for conventional or pattern recognition control. They return home for an 8 week trial. They use the prosthesis for 2 hours a day across the 8 week trial. They keep a log of use and check with a therapist about usage and performance. After the 8 week trial, data from the prosthesis is downloaded. The subject will complete 1-3 days of outcomes testing. They perform a series of tests and data is recorded. The subject will repeat the 1-3 days of training, 8 week home trial, and 1-3 days of outcomes testing with either type of control.
223580734|NCT06609928|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
223580735|NCT06609928|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
223580736|NCT06609928|DRUG|Cyclophosphamide|Given IV
223580737|NCT06609928|PROCEDURE|Echocardiography|Undergo ECHO
223580738|NCT06609928|DRUG|Fludarabine|Given IV
224069453|NCT06205121|DRUG|OATD-01|OATD-01 is an oral inhibitor of chitinase-1 (CHIT1)
224069454|NCT06205121|DRUG|Placebo|Matching placebo tablets
224069455|NCT00416962|DRUG|amantadine hydrochloride|
224069456|NCT00416962|DRUG|oseltamivir phosphate|
223580739|NCT06609928|PROCEDURE|Pheresis|Undergo apheresis
223580740|NCT06609928|PROCEDURE|Positron Emission Tomography|Undergo PET
223580741|NCT06226805|DRUG|BB-031|Solution for injection
223580742|NCT06226805|DRUG|Placebo|0.9% sodium chloride for injection
223580743|NCT04401345|DRUG|Glycopyrrolate 0.2 MG/ML|In this group, the patients will receive glycopyrrolate 0.2 mg in 1 ml
223580744|NCT04401345|DRUG|Normal saline|In this group, the patients will receive 1 ml of 0.9% normal saline
223580745|NCT03397992|OTHER|Changing dialysate temperature|Patients had SLED with low dialysate temperature (around 35°C) compared with high dialysate temperature (around 37°C)
223743915|NCT03388138|DEVICE|1-Day ACUVUE|1-Day ACUVUE
223743916|NCT00621881|DRUG|naproxcinod|750 mg bid
224069457|NCT04188418|DRUG|Fentanyl Citrate Buccal Tablet|Given transmucosally
224069458|NCT04188418|DRUG|Morphine|Given PO
224069459|NCT04188418|OTHER|Physical Performance Testing|Complete shuttle walk test
224069460|NCT04188418|OTHER|Placebo Administration|Given PO
224069461|NCT04188418|OTHER|Quality-of-Life Assessment|Ancillary studies
224069462|NCT04188418|OTHER|Questionnaire Administration|Ancillary studies
224071680|NCT06687746|DEVICE|Bili-ruler|The noninvasive test will be conducted by aligning the bili-ruler with the infant's nose and choosing the color on the ruler which most closely matches the yellow discoloration on the skin.
224071681|NCT07142941|DIETARY_SUPPLEMENT|HMB|Participants were instructed to take active products including 3000 mg calcium-HMB per day
224160968|NCT00003613|DRUG|carmustine|Given topically
224160969|NCT00003613|OTHER|laboratory biomarker analysis|Correlative studies
223580746|NCT01637389|OTHER|Basic Safe Water Program|The intervention is community promotional meetings followed by household installations of a UV-based drinking water disinfection system (Mesita Azul). Households can opt-in at the meetings, or when the organization returns for installations in that community (\~2 weeks later). Mesita Azul utilizes a 15-watt UV lamp to disinfect water and a closed mouth collection container for safe storage. The system utlizes UV-Tube technology developed as a method to disinfect water in low- and middle-income communities. The Basic Safe Water Program receives: the community meeting; installation of a Mesita Azul; a six month technical guarantee; one safe-storage container; training of one household member in operation and basic maintenance of the technology; training of at least one local resident in repair and system maintenance; and follow up after four to six months of the installation date.
224071682|NCT07142941|BEHAVIORAL|Exercise|Participants allocated to the exercise programs were provided 45 min of supervised sessions on 2 nonconsecutive days per week
223473228|NCT02349035|PROCEDURE|Perform TMR surgery and evaluate transradial TMR pattern recognition control of multifunctional prostheses.|Subject has Targeted Muscle Reinnervation surgery. The surgery transfers median nerve to flexor digitorum superficialis muscle and ulnar nerve to flexor carpi ulnaris muscle. Two weeks after surgery, exercises start for muscle recovery. Then return to prosthesis from Phase 1 for 6 months. If they have pattern recognition control, usage and performance will be tracked for 6 months. If they return to conventional control, they will not complete tests, track usage, or performance. Six months after surgery, they return to pattern recognition control. Receive 1-3 days of training. Take prosthesis home for 8 week trial. Log use of device, note issues, and follow up with therapist. After home trial, 1-3 days of outcomes testing are completed and usage data downloaded. Continue using their prostheses for an additional 3-4 months. At 12 months after surgery, a final round of 1-3 days of testing and data are downloaded.
223473229|NCT00380263|DRUG|PACAP38|10 pmol/kg/min given one time
223473230|NCT01187316|DEVICE|Transcutaneous electrical nerve stimulation|Sensors were positioned on anterior temporal and masseter muscles bilaterally, and the stimulation was used for 20 minutes at 150 Hz and 100 µs of pulse width; intensity was adjusted individually.
223473231|NCT01187316|OTHER|Physiotherapy|Massage and stretching of the anterior temporal and masseter muscle were performed by an experienced professional for 20 minutes.
223473232|NCT00020657|DRUG|dolasetron mesylate|
223473233|NCT00020657|DRUG|granisetron hydrochloride|
223473234|NCT00020657|DRUG|ondansetron|
223473235|NCT00020657|DRUG|prochlorperazine|
223473236|NCT00020657|PROCEDURE|quality-of-life assessment|
223473237|NCT00193375|DRUG|Irinotecan|50mg/m2 days 1 \& 8 each 21-day cycle 1 \& 2, 28-day cycle 3 \& 4
223473238|NCT00193375|DRUG|Carboplatin|AUC 5
223473239|NCT00193375|DRUG|Bevacizumab|10mg/kg IV every 2 weeks for 10 doses starting week 16
223473240|NCT00193375|RADIATION|Radiation|
223473241|NCT00254514|DRUG|somatropin|
223473242|NCT02343861|BEHAVIORAL|Tailored leaflet group|Parents in intervention group will receive an patient education leaflet and watch an educational video about lifestyle recommendations, and the use of emollients. In addition to general information, parents in intervention group will also receive the tailored leaflet including the estimated amount of emollients based on the body surface area.
224071683|NCT07142941|DIETARY_SUPPLEMENT|Placebo|Participants were instructed to take active products including equal in quality resistant dextrin per day
224071684|NCT07142941|OTHER|Education|Participants were given health education and educational manuals
224160970|NCT03654560|DEVICE|HemoStyp|During elective surgical procedure (non-laparoscopic thoracic, cardiac, abdominal, or vascular surgery) subject has mild to moderate soft tissue, vascular or parenchymal bleeding present at target bleeding site after primary standard conventional surgical hemostatic methods are proven to be ineffective or impractical will have Hemostyp applied in accordance to instructions for use.
224160971|NCT03654560|DEVICE|Surgicel|During elective surgical procedure (non-laparoscopic thoracic, cardiac, abdominal, or vascular surgery) subject has mild to moderate soft tissue, vascular or parenchymal bleeding present at target bleeding site after primary standard conventional surgical hemostatic methods are proven to be ineffective or impractical will have Surgicel applied in accordance to instructions for use.
223473243|NCT02343861|BEHAVIORAL|Control group|Participants (parents of children with atopic dermatitis) in control group will receive an patient education leaflet and watch an educational video about lifestyle recommendations, and the use of emollients.
223473244|NCT00828711|DRUG|MVI 100|Dose reservoir of 100 mcg of misoprostol in a hydrogel polymer vaginal insert within a retrieval system. The MVI 100 will be kept in place for up to 24 hours or will be removed earlier if one of the following occur: onset of active labor, intrapartum adverse event necessitating discontinuation of the study drug, other reasons including maternal request.
224071685|NCT06516913|DEVICE|Harvard Apparatus syringe pump|Used to administer buffer solution with hyaluronic acid SC.
224071686|NCT00380328|DRUG|neratinib|HKI-272
224160972|NCT00395616|DRUG|Botox (drug)|
224160973|NCT04713670|DRUG|(A) T-V14|vonoprazan(vocinti)-based triple therapy for 14 days (T-V14)
224160974|NCT04713670|DRUG|(B) T-V7|vonoprazan(vocinti)-based triple therapy for 7 days (T-V7)
224160975|NCT04713670|DRUG|(C) D-V14|vonoprazan(vocinti)-based dual therapy for 14 days (D-V14)
224160976|NCT04713670|DRUG|(D) HD-V14|vonoprazan(vocinti)-based high dose dual therapy for 14 days (HD-V14)
224160977|NCT04713670|DRUG|(E) BQ-V14|vonoprazan(vocinti)-based bismuth quadruple therapy for 14 days (BQ-V14)
224160978|NCT04713670|DRUG|(F) RH-V14|vonoprazan(vocinti)-based reverse hybrid therapy for 14 days (RH-V14)
224160979|NCT04713670|DRUG|(G) BQ-L14|lansoprazole(takepron)-based bismuth quadruple therapy for 14 days (BQ-L14)
224160980|NCT04713670|DRUG|(H) T-L14|lansoprazole(takepron)-based triple therapy for 14 days (T-L14)
224160981|NCT00995813|BIOLOGICAL|Rotarix|A rotavirus vaccine (Rotarix) will be administered in two doses, 8 weeks apart, in infants between 6 and 14 weeks of age. The standard dosage is 1 mL administered orally or per gastrostomy tube.
224160982|NCT00209092|DRUG|Docetaxel|"Sequential Therapy: Docetaxel will be given at 100 mg/m\^2 Intravenously (IV)Day 1 every 3 weeks for 4 cycles.~Concurrent Therapy: Docetaxel will be given at 50 mg/m\^2 IV Day 1."
224304235|NCT06633822|DIAGNOSTIC_TEST|Digital planning|The digital methodology will consist of obtaining a digital scan and a computed tomography (CBCT) that will be aligned using a digital program for the elaboration of a digital wax-up and fabrication of a printed surgical template.
223473245|NCT00828711|DRUG|MVI 150|Dose reservoir of 150 mcg of misoprostol in a hydrogel polymer vaginal insert within a retrieval system. The MVI 150 will be kept in place for up to 24 hours or will be removed earlier if one of the following occur: onset of active labor, intrapartum adverse event necessitating discontinuation of the study drug, other reasons including maternal request.
223473246|NCT00828711|DRUG|MVI 200|Dose reservoir of 200 mcg of misoprostol in a hydrogel polymer vaginal insert within a retrieval system. The MVI 200 will be kept in place for up to 24 hours or will be removed earlier if one of the following occur: onset of active labor, intrapartum adverse event necessitating discontinuation of the study drug, other reasons including maternal request.
223473247|NCT01618968|DRUG|MTX|"* Treatment A - 1 dose (4, 6, 8 or 10 tablets respectively to make up 10 mg, 15 mg, 20 mg or 25 mg MTX - per subject's dose group)~* Treatment B - SC injection using VIBEX MTX device into abdomen (VIBEX MTX device pre-filled with 10 mg, 15 mg, 20 mg or 25 mg MTX)~* Treatment C - SC injection using VIBEX MTX device into thigh (VIBEX MTX device pre-filled with 10 mg, 15 mg, 20 mg or 25 mg MTX)"
223473248|NCT05213299|PROCEDURE|AURICULAR ACUPUNCTURE|Auricular acupuncture is a method for diagnosing and treating physical and psychosomatic dysfunctions by stimulating a specific point in the ear. To conducting this intervention, the investigators use press tack needles to perform auricular acupuncture.
223580747|NCT01637389|OTHER|Enhanced Safe Water Program|The intervention is community promotional meetings followed by household installations of a UV-based drinking water disinfection system (Mesita Azul). Households can opt-in at the meetings, or when the organization returns for installations in that community (\~2 weeks later). Mesita Azul utilizes a 15-watt UV lamp to disinfect water and a closed mouth collection container for safe storage. The system utlizes UV-Tube technology developed as a method to disinfect water in low- and middle-income communities. The Enhanced program complements the Basic version with: a water quality analysis and presentation of results to households at the community meeting; a six-month money back guarantee; the provision of two safe-storage containers to facilitate access to disinfected water at different locations within the household; training of two household members in operation and basic maintenance of the technology; an additional follow up visit about two weeks after the installation date.
223473249|NCT05213299|OTHER|PLACEBO|For this intervention, instead of needles, the investigators use four pieces of tape.
223473250|NCT06188117|OTHER|'Digital Game Addiction Awareness Training'|"Experimental Group The 'Digital Game Addiction Awareness Training' program will be implemented in 2 sessions in 1 day for a total of 2 hours.~The training program will be implemented in line with the headings 'Digital Game Addiction Definition, Diagnostic Criteria, Frequency, Symptoms, Physical, Psychological and Social Problems Caused by Excessive Digital Game Playing, Recommendations for Parents to Prevent Digital Game Addiction'."
223473251|NCT01494636|DRUG|GSK2339345 (solution)|3, 6, 15, 30, 60 and 120 micrograms (proposed doses). 2 alternating cohorts of 6 subjects. Each subject to receive 3 ascending doses with washout of at least 48 hours between doses. Rinse, Gargle and Spit.
223473252|NCT01494636|DRUG|GSK2339345 (nebulised)|25, 100, 250, 1000 and 2000 micrograms (proposed doses). Subjects randomised to receive three ascending doses (with each dose given on two consecutive days). Washout of at least 6 days between treatment periods. Nebulised.
224304236|NCT06633822|DIAGNOSTIC_TEST|Analogic planning|The analog wax-up will be elaborated based on a silicone impression and periapical radiographs with parallel technique, which will allow us to elaborate an essix-type surgical splint.
223473253|NCT01494636|DRUG|Placebo (0.9% sodium chloride solution)|Administered on Day 1 of one of the treatment periods in part B. Randomised. Nebulised.
223473254|NCT01494636|DRUG|Lidocaine|40mg dose. Administered on Day 2 of one of the treatment periods in part B. Randomised. Nebulised.
223473255|NCT03778008|DRUG|Recombinant bovine basic fibroblast growth factor|Recombinant bovine basic fibroblast growth factor is prescribed at the beginning of radiotherapy for free. Patients are asked to start application of recombinant bovine basic fibroblast growth factor at the onset of radiotherapy, four times a day (after meals and before bedtime), until completion of their radiotherapy. All patients will receive conventional health education and medical care for prevention and treatment of radiation-induced oral mucositis. When grade \> 3 OM happened, other interventions, such as prophylactic or therapeutic antibacterial therapy, will be used, and radiotherapy should be interrupted.
223473256|NCT03778008|COMBINATION_PRODUCT|Quadruple mixture, composed of dexamethasone, gentamicin, vitamin B12, and lidocaine composition|Quadruple mixture is prescribed at the beginning of radiotherapy. Patients are asked to start application of quadruple mixture at the onset of radiotherapy, four times a day (before meals and before bedtime), until completion of their radiotherapy. All patients will receive conventional health education and medical care for prevention and treatment of radiation-induced oral mucositis. When grade \> 3 OM happened, other interventions, such as prophylactic or therapeutic antibacterial therapy, will be used, and radiotherapy should be interrupted.
223580748|NCT04146961|DEVICE|Alcon PanOptix or PanOptix Toric IOL|Patients who previously underwent cataract surgery with the Alcon PanOptix or PanOptix Toric IOL in both eyes.
223580749|NCT02614040|OTHER|0.9% Saline|0.9% Saline will be used whenever an isotonic crystalloid is ordered
223580750|NCT02614040|OTHER|Physiologically-balanced isotonic crystalloid|Lactated Ringers or Plasma-Lyte© A will be used whenever an isotonic crystalloid is ordered
224304237|NCT04364425|DRUG|Triamcinolone Acetonide|ultrasound guided steroid injection using 1ml of 10mg or 4ml of 40mg triamcinolone acetonide
224304238|NCT04364425|DRUG|lidocaine hydrochloride|Ultrasound guided injection using 4ml of 2% lidocaine hydrochloride (Xylocaine)
224304239|NCT04364425|DRUG|Normal saline|Ultrasound guided injection using 15ml or 12 ml of normal saline
224304240|NCT03056586|DEVICE|vaginal pessary|A vaginal pessary will be inserted at the end of the operation, for genital prolapse, and will be sutured to the vaginal wall. The pessary will stay in the vagina for 4 weeks.
224304241|NCT01783548|DRUG|BDP Nasal Aerosol|
224304242|NCT01783548|DRUG|Placebo|
224304243|NCT02141425|DRUG|ASP015K|oral
224304244|NCT02141425|DRUG|Placebo|oral
224304245|NCT03009630|PROCEDURE|RFA|Patients diagnosed with early-stage NSCLC and signing the informed consent will be performed RFA under the guidance of ENB.
223580751|NCT04507451|PROCEDURE|inspiratory and expiratory muscle training|inspiratory muscle training using threshold IMT device expiratory muscle training using a bottle filled of water
223580752|NCT04507451|PROCEDURE|inspiratory and expiratory exercises|inspiratory exercise using fractionated inspirations expiratory exercise using a bottle filled with water at a minimum level
223580753|NCT06903780|OTHER|Survey using a questionnaire.|A short 23-item survey concerning patients' experiences of their biologic treatments for their severe asthma.
223580754|NCT02785458|BEHAVIORAL|EMC2 Strategy|The intervention includes 1) distribution of simplified one-page medication guide summaries, 2) an automated follow-up call to assess medication safety and problematic side effects and 3) summary reports of call to providers with any concerns flagged for clinic follow-up.
223580755|NCT00733135|DEVICE|SilverHawk™ LS-C, TurboHawk™ LS-C, TurboHawk™ LX-C plaque excision systems and SpiderFX™ embolic protection device|Catheter-based excision of moderate to severely calcified plaque located in the SFA and/or popliteal artery.
223580756|NCT04542460|PROCEDURE|PCI|"A loop recorder is implanted i all patients in both study groups to investigate:~* Prevalence and severity of cardiac arrhythmias.~* Effect on detected arrhythmia, in particular ventricular tachyarrhythmia, of optimal medical therapy vs. coronary revascularization by PCI.~* Prevalence and severity of cardiac arrhythmias in CTO-patients with failed PCI.~* Indication for prophylactic ICD implantation in CTO-patients treated conservatively or by PCI and after failed PCI.~* Relation of arrhythmias to angina pectoris symptoms (CCS class), Quality of life questionnaire results and presence of myocardial reversible perfusion defects by CMRI."
223580757|NCT03153072|BIOLOGICAL|Assess the absorption of oral amiodarone|Evaluate the pharmacokinetics of oral amiodarone solution at 15 mg / mL after oral administration
223580758|NCT00824005|BIOLOGICAL|Adult stem cells|Single procedure of intramyocardial electromechanical-guided injection of approximately 100 million bone marrow mononucleated cells (BM-MNCs), administered in 15 different injection sites
223580759|NCT00824005|BIOLOGICAL|Placebo|Single procedure of intramyocardial electromechanical-guided needle insertions and injection of 5% human serum albumin and saline in 15 different injection sites
223580760|NCT02696408|DEVICE|Laser treatment|"Patients randomized to the experimental arm receive in addition to mouthwash, preventive treatment of mucositis by LLLT performed by nurses consisting of daily scanning the entire oral cavity for 2 minutes with a power of 250 mW, starting with conditioning and ongoing until the onset of mucositis of grade 1.~If the mucositis is localised, preventive laser will be kept on the healthy zones, and curative laser will be performed on painful zone. If the mucositis is general (more than 1 site), preventive laser is stopped for curative laser only."
223580761|NCT02696408|DEVICE|Placebo|"Patients randomized to the Placebo arm receive in addition to mouthwash fictive laser treatment performed by nurses until the onset of mucositis of grade 1.~If the mucositis is localised, fictive laser will be kept on the healthy zones, and curative laser will be performed on painful zone. If the mucositis is general (more than 1 site), fictive laser is stopped for curative laser only."
223580762|NCT02223611|DRUG|S1 capsule|Within four weeks after the completely resection, S-1 was administered orally twice a day, after meals on days 1 to 14. The actual dose of S-1 was selected as follows: in a patient with body surface area (BSA)\<1.25 m2 40mg twice a day, 1.25 m2≤BSA\<1.5 m2 50mg twice a day, and 1.5 m2≤BSA 60mg twice a day. Cisplatin (75 mg/m2) was administered intravenously on day 1 The treatment regimen was repeated every 3 weeks, totally 4 cycles unless disease progression or unacceptable toxicity occurred.
223580763|NCT02223611|DRUG|Vinorelbine|Vinorelbine (25 mg/m2) is administered intravenously on day 1, and day 8. Cisplatin (75 mg/m2) is administered intravenously on day 1. The treatment regimen is repeated every 3 weeks, totally 4 cycles unless disease progression or unacceptable toxicity occurred.
223580764|NCT06089213|OTHER|real-time intervention|An individual exercise program will be carried out at home, supervised remotely via videoconference.
223473257|NCT06254989|OTHER|Aerobic Exercise|"Participants will engage in aerobic exercise at HNH fitness at a minimum of 2 days a week for 12 weeks. Participants will have their daily step count collected via the Fitbit during this period. VO2 measurements will also be collected during active intervention using the UNCCRI protocol.~The structured aerobic exercise program (Weeks 3-14) will entail 30 minutes of aerobic activity, 3 days a week, on the treadmill, at a goal of between 50 to 70% of predicted VO2 maximum heart rate. All structured aerobic program sessions will take place at Holy Name Health (HNH) Fitness and will be overseen by our collaborator and Director of Human Performance (Reg Grant). Exercise data will be recorded in the Technogym MyWellness cloud. Participants who drop out or discontinue attendance (defined as 4 consecutive sessions missed without notification of absence) before completion of the 12-week study intervention period will be replaced."
223580765|NCT03732365|COMBINATION_PRODUCT|Ultrasonic Drug Delivery|A maximum dose of 2 grams cefazolin in a solution of 1 gram/100 mL sterile saline will be injected into the affected area, followed by a 3-minute application of external ultrasound delivered at an acoustic intensity equal to 3 watts/square centimeter of surface area.
223580766|NCT03732365|DRUG|Standard of Care Antibiotic Treatment|Antibiotic treatment according to the antibiotic package insert instructions for the particular gram-positive pathogen over a period of no more than 14 days.
223580767|NCT03458702|BEHAVIORAL|YogaFit|For YogaFit Vinyasa Flow (referred to as YogaFit in this manuscript)\], participants followed, via digital versatile disc, a standardized YogaFit format choreographed by an American Council of Exercise Certified and Registered Yoga Teacher (RYT). YogaFit was performed in the same laboratory setting and lasted 30 min. YogaFit is a westernized version of yoga that does not use Sanskrit terms (Shaw 2009). Breath was an integral part of every movement with specific breath rates for each phase of the session. The objective was to move the body with intention and purpose and be present in the body.
223580768|NCT03458702|BEHAVIORAL|Quiet Rest|Participants completed 30 min of quiet rest
223580769|NCT01390779|DEVICE|SENSIMED Triggerfish|Contact lens-based device intended to continuously record the timing of relative changes in IOP for up to 24 hours
223580770|NCT00780637|DRUG|Bradykinin|Patients receive 0, 10, 20, and 40 ng/100cc forearm volume/min of bradykinin intrabrachial.
224071687|NCT02396589|BEHAVIORAL|Education Group|Attention will be provided to the control group to ensure they experience the same effects of time and attention but no effect on the outcome of interest.
224304246|NCT03009630|DEVICE|ENB|ENB will be used to guide bronchoscope into the accurate location of the lesion during RFA.
224304247|NCT02923986|DRUG|BP1001 (varying dose)|BP1001 (varying dose)
223473258|NCT04012528|OTHER|ERAS program|ERAS program
223473259|NCT01608880|DRUG|nitroglycerin ointment|Nitroglycerin ointment will be applied to mastectomy skin flaps at the end of surgery. A maximum of 7.5cm strip of 2% Nitroglycerin ointment will be applied (equivalent to a maximal dose of 45mg)
223473260|NCT01608880|DRUG|Polysporin ointment|Polysporin ointment will be applied as the control ointment on the mastectomy flap skin at the end of surgery. A maximum of 7.5cm strip of ointment will be applied to the skin.
223473261|NCT04308863|DRUG|Chitosan scaffold/ MTA pulp dressing material|Chitosan 3-D porous scaffold will be prepared. The chitosan scaffolds will be examined with the Scanning electron microscopy (SEM) to analyze the surface of the chitosan scaffolds. The scaffolds will be sterilized by Ethylene oxide and stored until further use. A piece of 2-mm thick chitosan scaffold will be gently placed onto the pulp chamber floor and covering the canal orifices, and then a 2-3 mm thick layer of fast setting EndoCem Zr MTA will be applied onto the chitosan scaffold and will be gently condensed with moistened cotton pellet to attain adequate thickness which will be confirmed radiographically. MTA will be allowed to set for 4-5 mins.
223473262|NCT04308863|DRUG|MTA pulp dressing material|MTA will be gently placed over the fresh pulp wound using an MTA carrier to a thickness of 2-3 mm. It will be condensed lightly with moistened cotton pellet to attain adequate thickness and confirmed radiographically. MTA will be allowed to set for 4-5 mins.
224069463|NCT05768672|BEHAVIORAL|Experimental Task|The main task is an olfactory version of a traditional Go/No-Go task (Albayay et al., 2019): it includes the delivery of either an odour or clean air prior to the presentation of a visual target Moreover, all participants will be assessed with the italian version of the Stroop color and word test (Caffarra et al., 2004) to evaluate inhibition, together with selective and sustained attention. This neuropsychological test consists of three tables, showing color words (W), colored circles (C), and color words printed in incongruent ink (i.e., red printed in blue ink, CW), respectively. The Stroop effect consists of a delayed response when words have to be named according to the color of the ink, ignoring the meaning of the printed word.
224069464|NCT03522324|DRUG|Cannabis Edible|Self-Directed Use (ad-libitum)
224069465|NCT06353451|BEHAVIORAL|Digital Detox|In the intervention group, smartphone screen time will be reduced to less than 2 hours for 3 consecutive weeks.
224069466|NCT05550311|OTHER|Robot-assisted rehabilitation|In addition to conventional treatment, an upper extremity robot-assisted rehabilitation program. Range of motion exercises will display on the monitor as a game form. There are 4 games available on the computer (airplane game, rabbit shooting game, ball game, and shopping game) and these games can provide exercises for three joints (shoulder, elbow wrist). There are also 3 different levels of resistance apparatus for each joint. People with a full range of motion can do these exercises with resistance. Before starting the rehabilitation, which joint and which movement to do is determined. To the person; After explaining the desired movement and how to play the game shown on the monitor, the exercises are started. The exercises last 45 minutes, during which exercises are performed for the shoulder, elbow, and wrist.
224069467|NCT05550311|OTHER|Conventional rehabilitation|The conventional Rehabilitation Program consists of; range of motion exercises, strengthening exercises, stretching exercises, balance, and walking exercises and Bobath based neurophysiological approaches.
224069468|NCT03825874|OTHER|Amikacin|A first anorectal swab will be performed before starting any antibiotic treatment Three to four days after the start of antibiotic treatment, patients will be seen again and a new anorectal swab will be performed.
224069469|NCT03825874|OTHER|usual antibiotic treatment|A first anorectal swab will be performed before starting any antibiotic treatment Three to four days after the start of antibiotic treatment, patients will be seen again and a new anorectal swab will be performed.
224069470|NCT06081907|DRUG|IBI363|"IBI363 is based on the 3+3 model with a dose of 1 mg/kg Q3W. IBI325, 20 mg/kg Q3W."
224069471|NCT06081907|DRUG|IBI363|"IBI363 is based on the 3+3 model with a dose of 1.5 mg/kg Q3W. IBI325, 20 mg/kg Q3W."
224069472|NCT06081907|DRUG|IBI363|"IBI363 is based on the 3+3 model with a dose of 600 μg/kg Q2W. Lenvatinib, 8mg QD."
224069473|NCT06081907|DRUG|IBI363|"IBI363 is based on the 3+3 model with a dose of 1000 μg/kg Q2W. Lenvatinib, 8mg QD."
224069474|NCT06081907|DRUG|IBI363|The recommended dosages for IBI363, IBI325, and Lenvatinib in Phase Ib will be determined based on a comprehensive assessment of safety, efficacy, and other data obtained from the safety introduction portions of both Phase Ia (Part A) and Phase Ib (Part B).
224069475|NCT05802719|OTHER|Blood sampling|"The procedure consists of collecting 4 additional tubes of blood (20mL) at each visit for research purposes, in order to perform the immunological assays.~Blood samples at the inclusion, 3 month and 6 month after initiation of anti-TNF therapy"
224304248|NCT02923986|DRUG|BP1001 (fixed dose)|BP1001 (fixed dose)
224069476|NCT01892358|BEHAVIORAL|SKIN Intervention|
224069477|NCT01892358|OTHER|Treatment as Usual|
224069478|NCT02396732|DRUG|Aspirin|Daily dose is 81 mg oral tablet
224069479|NCT02396732|DRUG|Enoxaparin|Daily dose is by subcutaneous injection and weight based at the discretion of the treating clinician.
224069480|NCT05909202|DEVICE|Sham VR|Nature-based non-immersive VR program
224069481|NCT05909202|DEVICE|Active VR|Nature-based immersive VR program
224069482|NCT05151107|DIAGNOSTIC_TEST|"The radiographic images were collected through a software called PACS which combined with a viewer for image processing, that allows the calculation of the residual stomach area (RSA)."|Upper gastrointestinal radiographie
224069483|NCT00179309|DRUG|Docetaxel|35 mg/m\^2 intravenous 30-60 minutes once a week for 3 consecutive weeks with 1 week off drug.
224069484|NCT00179309|BIOLOGICAL|PANVAC-V|2 x 10\^8 PFU
224304249|NCT02923986|DRUG|Dasatinib|Dasatinib
224304250|NCT04221139|BEHAVIORAL|Virtual Reality games|Participants will play the following four virtual reality games for 15 minutes each: Beat Saber, Holopoint, Hot Squat, and Relax Walk.
224304251|NCT01097525|PROCEDURE|WFG PRK|
224304252|NCT01097525|PROCEDURE|WFG LASIK|
224304253|NCT01097525|PROCEDURE|WFO PRK|
224069485|NCT00179309|BIOLOGICAL|PANVAC-F|1 x 10\^9 PFU
224069486|NCT00179309|BIOLOGICAL|Sargramostim|Given subcutaneously under the skin, usually in the thigh on the day of vaccination and daily for the next 3 days.
224069487|NCT00814229|BIOLOGICAL|H9N2 whole virus vaccine, IM, 1.5microg|influenza H9N2 vaccine whole virus containing 1.5microg haemagglutinin by intramuscular injection
224304254|NCT01097525|PROCEDURE|WFO LASIK|
224304255|NCT05760586|DRUG|Tovorafenib|Oral RAF inhibitor provided as an immediate-release tablet (100 mg) or powder for reconstitution (25 mg/mL)
223473263|NCT05311826|PROCEDURE|STANDARD PHYSIOTHERAPY TREATMENT|"The standard postoperative rehabilitation process starts from the first postoperative day. Two sessions are provided daily, with the exception of Sunday and Saturday afternoon. A single physiotherapy session, lasting 30 minutes, can include bed exercises for upper and lower limbs and recovery of autonomy (sitting position, standing and ambulation). In this phase, the sessions are characterized by educational and counseling activities.~The patient will be encouraged to carry out the activities independently."
223473264|NCT05311826|PROCEDURE|EXPERIMENTAL diaphragmatic breathing exercise|The subjects in the intervention group (EXP) will receive, in addition to standard physiotherapy treatment, diaphragmatic breathing exercise. Four exercises in different position (supine and side lying) will be provided for each physiotherapy session by a senior physiotherapist. Patients will be instructed to perform the same exercises independently to achieve relaxation and relief of pain symptoms.
223473265|NCT02646683|DRUG|vedolizumab|
223473266|NCT03521557|BEHAVIORAL|Gaze and Postural Stability|The duration and content of the GPS intervention is specifically designed to focus on gradually increasing difficulty of gaze and postural stability exercises.
223473267|NCT03521557|BEHAVIORAL|Standard Care Control|The Standard Care Control intervention is specifically designed to be focused on improving overall endurance and lower extremity muscular strength.
223473268|NCT00483535|DRUG|GW273225|GW273225 will be available as 25 milligram tablets.
223473269|NCT00483535|DRUG|COC|COC will consist of Microgynon 30 which is available as ethinylestradiol 30 micrograms/levonorgestrel 150 micrograms beige color, sugar-coated tablets.
223473270|NCT02230891|DRUG|Carvedilol|Carvedilol is a non selective beta blocker
223473271|NCT02230891|DRUG|Spironolactone|Spironolactone is an aldosterone antagonist and can lower blood pressure/ is used in heart failure
223473272|NCT02230891|OTHER|Usual care|standard care as per primary care provider
223473273|NCT04347772|DIETARY_SUPPLEMENT|Oral Nutrition Support|Intensive Nutrition Intervention
223473274|NCT04782817|OTHER|Recommendation for high flow nasal cannula oxygen therapy order set|Participants will be assigned post extubation physician order set which recommends the administration of oxygen therapy via HFNC. HFNC is a heated and humidified system that allows prescribed fraction of inspired oxygen (FIO2) levels to be delivered at very high flow rates.
223580771|NCT01874275|DEVICE|VECTTOR|"The VT-200, or VECTTOR system, delivers electrical stimulation via electrodes on the acupuncture points of a patient's feet/legs and hands/arms to provide symptomatic relief of chronic intractable pain and/or management of post-surgical pain.~Once these electrodes are placed, the machine determines the appropriate choice of stimulation by automatically measuring body temperatures through the use of thermistors placed on the fingers during a testing sequence."
223473275|NCT04782817|OTHER|Provider choice standard care order set|Participants will receive order set with provider choice of standard care therapy.
223473276|NCT02473185|DRUG|Methylphenidate|Cross-over
223473277|NCT02821494|BIOLOGICAL|Hespecta|A dose escalation of Amplivant® conjugated peptide
223473278|NCT05637983|PROCEDURE|US-guided femoral puncture vs Fluoroscopy-guided puncture|US-guided femoral puncture and Perclose ProGlide®/Prostyle implantation compared to Fluoroscopy-guided puncture and Perclose ProGlide®/Prostyle in TAVR
223580772|NCT04697186|DRUG|Berberine|berberine , amoxicillin and rabeprazole triple therapy group: given for 14 days at a dose of berberine 100 mg 3 tablets TID, amoxicillin 500 mg 2 capsules BID ，rabeprazole 10 mg BID.
223580773|NCT04697186|DRUG|Amoxicillin|berberine , amoxicillin and rabeprazole triple therapy group: given for 14 days at a dose of berberine 100 mg 3 tablets TID, amoxicillin 500 mg 2 capsules BID ，rabeprazole 10 mg BID.
223580774|NCT04697186|DRUG|Rabeprazole|berberine , amoxicillin and rabeprazole triple therapy group: given for 14 days at a dose of berberine 100 mg 3 tablets TID, amoxicillin 500 mg 2 capsules BID ，rabeprazole 10 mg BID.
224069488|NCT00814229|BIOLOGICAL|H9N2 whole virus vaccine, IM, 5microg|influenza H9N2 vaccine whole virus containing 5microg haemagglutinin by intramuscular injection
224069489|NCT00814229|BIOLOGICAL|H9N2 whole virus vaccine vaccine, IM, 15microg|influenza H9N2 vaccine whole virus containing 15microg haemagglutinin by intramuscular injection
224069490|NCT00814229|BIOLOGICAL|H9N2 whole virus vaccine, IM, 45microg|influenza H9N2 vaccine whole virus containing 45microg haemagglutinin by intramuscular injection
224069491|NCT00814229|BIOLOGICAL|H9N2 whole virus vaccine, alum, IM, 1.5microg|influenza H9N2 vaccine whole virus adjuvanted with alum hydroxide containing 1.5microg haemagglutinin by intramuscular injection
224069492|NCT00814229|BIOLOGICAL|H9N2 whole virus, alum, IM, 5microg|influenza H9N2 vaccine whole virus adjuvanted with alum hydroxide containing 5microg haemagglutinin by intramuscular injection
224069493|NCT00814229|BIOLOGICAL|H9N2 vaccine, whole virus, alum, IM, 15 microg|influenza H9N2 vaccine whole virus adjuvanted with alum hydroxide containing 15microg haemagglutinin by intramuscular injection
224069494|NCT00814229|BIOLOGICAL|H9N2 vaccine, whole virus, alum, IM, 45microg|influenza H9N2 vaccine whole virus adjuvanted with alum hydroxide containing 45microg haemagglutinin by intramuscular injection
224304256|NCT03499886|DRUG|Ketamine Hydrochloride 50Mg/1mL Solution for Injection|In the intervention group, ketamine 1% was administered rapidly at a dose of 0.5 mg / kg (within 5 seconds), and in the control group, ketamine 1.5 mg / kg was slowly injected for 30 to 60 seconds.
224069495|NCT00814229|BIOLOGICAL|H9N2 virosome vaccine, IM, 1.5microg|influenza H9N2 vaccine virosomal containing 1.5microg haemagglutinin by intramuscular injection
224069496|NCT00814229|BIOLOGICAL|H9N2 virosomal vaccine, IM, 5microg|influenza H9N2 vaccine virosome containing 5microg haemagglutinin by intramuscular injection
224069497|NCT00814229|BIOLOGICAL|H9N2 virosomal vaccine, IM, 15microg|influenza H9N2 vaccine virosome containing 15microg haemagglutinin by intramuscular injection
224069498|NCT00814229|BIOLOGICAL|H9N2 virosomal vaccine, IM, 45microg|influenza H9N2 vaccine virosome containing 45microg haemagglutinin by intramuscular injection
224069499|NCT00814229|BIOLOGICAL|H9N2 whole virus vaccine, ID, 5microg|influenza H9N2 vaccine whole virus containing 5microg haemagglutinin by intradermal injection
224069500|NCT00814229|BIOLOGICAL|H9N2 whole virus vaccine, ID, 15microg|influenza H9N2 vaccine whole virus containing 15microg haemagglutinin by intradermal injection
224160983|NCT00209092|DRUG|Capecitabine|Sequential Therapy: administration of capecitabine 1000 mg/m\^2 twice a day by mouth Day 1-14 every 3 weeks for 4 cycles (total 8 cycles) Concurrent Therapy: capecitabine 1000 mg/m\^2 twice a day by mouth Day 1-7 every 2 weeks for 8 cycles (total 16 weeks).
224160984|NCT06177015|DRUG|Darolutamide continuous|standard of care
224160985|NCT06177015|DRUG|Darolutamide intermittent|experimental group
224160986|NCT05399160|BEHAVIORAL|Nurse-led Supportive Care|Nurse-led supportive care was given to women who had breast surgery and planned to receive chemotherapy. Nurse-led supportive care was applied to women for eight weeks in the form of face-to-face clinic and telephone interviews.It took an average of 30 minutes to interview women with breast cancer at the clinic, and 15 minutes on average by phone.
224160987|NCT02929368|DEVICE|PICC implantation under fluoroscopy|PICC Catheter implantation
224160988|NCT02929368|DEVICE|PICC Implantation under Sherlock System|PICC Catheter implantation
223473279|NCT04577105|DIAGNOSTIC_TEST|Simple chest tomography|The images were acquired with a Siemens 256-slice multidetector tomograph (SOMATOM DEFINITION FLASH 128x2) following the recommended parameters for low-dose simple chest tomography. The chest topogram was acquired using 35 mA, 100 Kv, and 6 mm slices, then the chest tomographic slices holding inspiration in a cephalocaudal direction with 80 mA, 100 Kv, a duration of 2.24 seconds, a pitch of 1, and slices 1 mm with a total of 110 DLP, which is calculated with the conversion factor for thorax a total of 1.5 mSv. Multiplanar reconstructions with Kernel filters B26f, B50f, and B70 for mediastinum and lung, respectively, at 1 mm slices.
223473280|NCT04778852|DEVICE|Experimental: EksoGT|EksoGT is an overground wearable gait trainer. The therapy will be carried out 3 days a week for 4 weeks.
223473281|NCT04778852|OTHER|Functional kinematic training|Device: No device. The functional kinematic training will be delivered as comparator treatment and will be carried out 3 days a week for 4 weeks.
223473282|NCT05359471|DEVICE|Bone densitometry|It is the standard method for diagnosing osteoporosis. In the central DXA examination, which measures bone density of the hip and spine, the patient lies on a padded table.
223473283|NCT05359471|OTHER|Questionnaires|Smoking and drug related questionnaires will be used as variable to see dependence, how it impacts participants activities/health or determining whether they are light/moderate/heavy smoker
223473284|NCT05359471|DEVICE|Review of medical chart|History of previous liver diseases including hepatitis B, C, and HIV
223473285|NCT06294288|BIOLOGICAL|LP-003 Dose 1 (Single)|A single dose of LP-003 (Dose 1) was administered intravenously.
223473286|NCT06294288|BIOLOGICAL|LP-003 Dose 2 (Single)|A single dose of LP-003 (Dose 2) was administered intravenously.
223473287|NCT06294288|BIOLOGICAL|LP-003 Dose 3 (Single)|A single dose of LP-003 (Dose 3) was administered intravenously.
223473288|NCT06294288|BIOLOGICAL|LP-003 Dose 4 (Single)|A single dose of LP-003 (Dose 4) was administered intravenously.
223473289|NCT06294288|BIOLOGICAL|LP-003 Dose 5 (Single)|A single dose of LP-003 (Dose 5) was administered intravenously.
223473290|NCT06294288|BIOLOGICAL|Placebo (Single)|A single dose of placebo was administered intravenously.
223473291|NCT06294288|BIOLOGICAL|LP-003 Dose 6 (Multiple)|LP-003 (Dose 6) was administered multiple times subcutaneously.
223473292|NCT06294288|BIOLOGICAL|LP-003 Dose 7 (Multiple)|LP-003 (Dose 7) was administered multiple times subcutaneously.
223473293|NCT06294288|BIOLOGICAL|LP-003 Dose 8 (Multiple)|LP-003 (Dose 8) was administered multiple times subcutaneously.
224160989|NCT00584779|DRUG|Gabapentin|CLcr:14-5 mL/min
223473294|NCT06294288|BIOLOGICAL|Placebo (Multiple)|Placebo was administered multiple times subcutaneously.
223473295|NCT06055413|OTHER|Remote patient monitoring (RPM) bundle|"Patient-families will be given a remote patient monitoring (RPM) bundle with tools to measure objective and subjective information about the child at home that are shared with the home ventilator provider team through an electronic dashboard. The tools include a device to measure carbon dioxide, a digital tablet, a digital weight scale, and a digital application that connects to the child's electronic health record. Each child will be assigned an individualized remote monitoring schedule (timing and data type) based on their indication for ventilation and ventilator regimen at enrollment."
223473296|NCT06025292|OTHER|Lean Pork vs Plant-Based Protein|Participants will eat prepared study meals for three days that have either protein sourced from lean pork or plant-based sources.
223473297|NCT04347408|DIAGNOSTIC_TEST|Covid-19 Antibody testing (IgG and IgM)|Antibody testing for previous exposure to Covid-19
223473298|NCT04347408|OTHER|Blood Storage|Storage of blood for multi-omics analysis
223473299|NCT04687852|OTHER|Conservative and Non-conservative treatments|This program includes Focused Pelvic Floor with Motor Imagery Technique Group ,Nonsteroidal Anti-Inflammatory Drug Group, Diosmin Group, Acupressure Group (LI-4 (Bilateral), CV-6, CV-4, SP-6 (Bilateral). It is aimed to determine the most effective treatment among these groups.
223473300|NCT02370511|DEVICE|Transcatheter Mitral Valve Replacement|Implantation of a balloon expandable Edwards SAPIEN XT or SAPIEN 3 transcatheter heart valve in the mitral position.
223473301|NCT03175887|DEVICE|TMS|Transcranial magnetic stimulation (TMS) is a noninvasive procedure that uses magnetic fields to stimulate nerve cells in the brain to improve symptoms of depression.
223473302|NCT04327921|BEHAVIORAL|Peer navigation social support for smoking cessation|Standard guidelines will be used for brief advice for smoking cessation based on the 5A's. Also, motivational interviewing/guidance will also be used to determine whether enhanced treatment (using a Peer Navigator to navigate smoking cessation, obtain medication and treatment, improve adherence to treatment, and provide social support for quitting) will increase participant's quit attempts and smoking cessation rates.
224160990|NCT00584779|DRUG|Gabapentin|CLcr: 29-15 mL/min
224160991|NCT00584779|DRUG|Gabapentin|Hemodialysis
224160992|NCT00584779|DRUG|Gabapentin|CLcr: 29-30 mL/min
224160993|NCT03726541|OTHER|physiotherapy|Physiotherapy program includes breathing exercises, incisive spirometer study, grade ambulation. Oxygen saturation, heart rate and blood pressure values will be recorded before and after the session. Changes in the follow-up parameters will be discussed.
224163796|NCT01899768|DRUG|GSK2339345|Clear colorless solution in clear glass vial for oral inhalation via aqueous droplet inhaler with unit dose strength of 1000 microgram (mcg) inhaled in two actuations.
224163797|NCT01899768|DRUG|Placebo|Clear colorless solution of 0.9% sodium chloride for oral inhalation via aqueous droplet inhaler inhaled in two actuations.
223580775|NCT04697186|DRUG|Amoxicillin|Bismuth-containing Quadruple Therapygroup: given for 14 days at a dose of amoxicillin 500 mg 2 capsules BID ，clarithromycin 500mg BID ,rabeprazole 10 mg BID and bismuth 110 mg 2 capsules BID
223580776|NCT04697186|DRUG|Clarithromycin|Bismuth-containing Quadruple Therapygroup: given for 14 days at a dose of amoxicillin 500 mg 2 capsules BID ，clarithromycin 500mg BID ,rabeprazole 10 mg BID and bismuth 110 mg 2 capsules BID
224160994|NCT02792036|DRUG|Carboplatin|"Carboplatin will be given intravitreally. Participants are eligible to receive up to 8 injections per eye (once approximately every 14 days) based on lack of toxicity and evidence of tumor response. An injection of consolidation will be given once a complete response is observed. If further regression of stable seeds is noted, additional injections (up to 8 maximum per eye) will be provided at the discretion of the treating team. Injections could be repeated if vitreous recurrence occurs from another source (and patient has not reached 8 max limit per eye)."
224160995|NCT02792036|DRUG|Maxitrol®|Maxitrol® contains neomycin and polymyxin B sulfates and dexamethasone ophthalmic suspension and is for topical ophthalmic use only. It will be given for continued use for five days following the carboplatin injection to prevent infection.
224160996|NCT02792036|PROCEDURE|Focal Therapy|Simultaneously with intravitreal carboplatin, focal therapy will be applied as needed to eradicate the retinal source of the seeding as well as all epiretinal and subretinal active tumors at the discretion of the treating ocular oncologist.
224160997|NCT02792036|PROCEDURE|Plaque Radiotherapy|Participants who have developed progressive disease despite focal (non-irradiative) therapy will receive brachytherapy determined by consensus between the treating ophthalmologist and radiation oncologist.
224160998|NCT04506385|DIETARY_SUPPLEMENT|probiotics|In the first phase: 10 subjects have added in the diet a daily dose of 1 billion of freeze-dried LDD01 probiotics (A arm), 12 individuals are supplemented with a daily dose of 1 billion of the DLBL mix (B arm). In the second phase: 10 individuals are supplemented with a daily low dose of probiotics blend (C arm) and 10 individuals are supplemented with a daily high dose of probiotics blend (D arm).
224160999|NCT01711437|DEVICE|PEG-4000 with citrates and simethicone|1-4 bisacodyl 5-mg tablets (Lovoldyl) at 16:00, followed 2-3 hours later by 50 ml/kg (maximum 2 L) of PEG-CS solution. The patients were instructed to drink all solution in about 2-3 hours.
224161000|NCT01711437|DEVICE|polyethylene glycol 4000 solution with simethicon|patients received a polyethylene glycol 4000 solution with simethicon (Selg Esse) starting at 3:00 p.m. the day before the colonoscopy at a dose of 100 ml/Kg (maximum 4 L). The patients were instructed to drink all solution in about 4-6 hours.
224161001|NCT01711437|DEVICE|polyethylene glycol 3350 hyper-osmotic solution with ascorbic acid|patients received a polyethylene glycol 3350 hyper-osmotic solution with ascorbic acid (Moviprep) a dose of 50 ml/Kg (maximum 2 L) with 25 ml/kg additional clear fluid after completing solution intake.
224161002|NCT01711437|DEVICE|sodium picosulphate plus magnesium oxide and citric acid|patients received two sachets of sodium picosulphate plus magnesium oxide and citric acid (Picoprep), each diluted in 150 ml of water, at 14:00 and 6 hours later in the evening prior to the colonoscopy. Intake of at least 40-50 ml/kg of clear fluids
224161003|NCT03581565|OTHER|zinc polycarboxylate (with the requirements of ISO 9917)|intraoral cementation of single-tooth implant crowns with three different technique, intraoral removal of cement excess upon setting
224161004|NCT05894486|DRUG|Lutetium[177Lu] Oxodotreotide Injection|Lutetium\[177Lu\] Oxodotreotide InjectionFour administrations of 7.4 GBq (200 mCi) Lutetium\[177Lu\] Oxodotreotide Injection administered at 8 +/- 1-week intervals, which could be extended up to 16 weeks to accommodate resolving acute toxicity
224161005|NCT03928509|OTHER|No intervention|No intervention
224161006|NCT01959269|DRUG|Regorafenib (Stivarga, BAY 73-4506)|As determined by the treating physician
224163798|NCT02092506|DRUG|10 day triple therapy|10 day triple therapy
224163799|NCT02092506|DRUG|10 day sequential therapy|10 day sequential therapy
224163800|NCT02092506|DRUG|10 day concomitant therapy|10 day concomitant therapy
224163801|NCT00291746|DRUG|Esomeprazole|
223473303|NCT04327921|BEHAVIORAL|Standard Condition|Standard guidelines will be used for brief advice for smoking cessation based on the 5A's.
223473304|NCT01162733|DRUG|Vancomycin|15mg/kg
223473305|NCT01162733|DRUG|Vancomycin|30mg/kg
223473306|NCT02091700|OTHER|Indocyanine Green ICG|
223473307|NCT04966286|OTHER|multimedia education|The MLEP intervention was based on a literature review of prior research on the content and format of self care related multimedia education programmes
223473308|NCT03912740|DRUG|Dexmedetomidine|Patients in the dexmedetomidine-remifentanil group will receive an infusion of 0.6 mcg/kg in half an hour followed by an infusion of 0.6 mcg/kg/hour.
223473309|NCT03912740|DRUG|sodium chloride|Patients in the remifentanil group will receive an infusion of 0.9% sodium chloride instead of dexmedetomidine (identical infusion rate)
223473310|NCT03912740|DRUG|Remifentanil|Both groups will have remifentanil analgesia guided by the Nol-Index
223473311|NCT04301856|DRUG|CFTR Modulators|CFTR modulators as recommended in routine care by the french health authorities
223473312|NCT06802913|DRUG|Inhaled Melatonin (100 μg)|An orally inhaled formulation of melatonin delivered by pressurised metered dose inhaler (pMDI) to be taken before bedtime. The pMDI will deliver a total of 100 μg of inhaled melatonin (2 x 50 μg/actuation). The investigational product is produced under Good Manufacturing Practice by Ab Initio Pharma Pty Ltd, a GMP certified manufacturer of pharmaceutical products.
223473313|NCT06802913|DRUG|Oral Melatonin (4 mg)|Two orally ingested tablets each containing 2 mg of melatonin (4 mg total) to be taken before bedtime. The investigational product is manufactured under Good Manufacturing Practice and is compliant with the TGA Therapeutic Order #101 that stipulates quality control requirements for capsule and pill-based products used in Australia.
223473314|NCT00733278|DEVICE|Copper IUD ( ParaGard Intrauterine Contraceptive Device)|Intraoperative placement of copper IUD at time of C-section
223473315|NCT06855576|DRUG|Paracetamol ODT|Experimental Paracetamol 500 mg ODT
223580777|NCT04697186|DRUG|Rabeprazole|Bismuth-containing Quadruple Therapygroup: given for 14 days at a dose of amoxicillin 500 mg 2 capsules BID ，clarithromycin 500mg BID ,rabeprazole 10 mg BID and bismuth 110 mg 2 capsules BID
223580778|NCT04697186|DRUG|Bismuth|Bismuth-containing Quadruple Therapygroup: given for 14 days at a dose of amoxicillin 500 mg 2 capsules BID ，clarithromycin 500mg BID ,rabeprazole 10 mg BID and bismuth 110 mg 2 capsules BID
223473316|NCT06855576|DRUG|Alvedon film-coated tablet|Marketed Paracetamol 500 mg film-coated tablet
223473317|NCT06855576|DRUG|Panadol film-coated Tablet|Marketed Paracetamol 500 mg film-coated tablet
223580779|NCT03411109|DRUG|Hydromorphone Hydrochloride|All intrathecal injections were performed preoperatively using a 22g or 25 g Whitacre or 24g Sprotte spinal needle. The IA regimen, medication(s) and dose(s), was at the discretion of the attending anesthesiologist, and consisted of one of the following regimens: (1) hydromorphone + local anesthetic (IA-L), or (2) hydromorphone only (IA-O). In patients receiving IA, no other interventional locoregional analgesic techniques (such as rectus sheath blocks or transversus abdominis plane blocks) were utilized.
223473318|NCT05994963|DRUG|sisunatovir|Administered as either capsules in fasted state or tablet in fasted or fed state.
223580780|NCT00168103|BIOLOGICAL|C1 Esterase Inhibitor|Single application of C1-INH administered intravenously by slow injection or infusion at a recommended rate of 4mL/min.
223473319|NCT00988702|BEHAVIORAL|Dan Tian Breathing|Dan Tian Breathing for one month
223473320|NCT00988702|BEHAVIORAL|Progressive muscle training|Progressive muscle training for one month
223473321|NCT05252637|PROCEDURE|Laparoscopic Fascial Posterior Vagina Duplication|Laparoscopic Fascial Posterior Vagina Duplication with absorbable sutures for posterior prolapse (plus standard Sacral Colpopexy)
223473322|NCT01288300|BEHAVIORAL|Picture good health/Imaginate una buena salud|Diabetes education, self-empowerment training, exercise, patient navigator
223473323|NCT01288300|BEHAVIORAL|Diabetes lecture|Diabetes self-management lecture
223473324|NCT04964115|OTHER|Cohort study|This cohort study does not involve an intervention
223473325|NCT06231641|DRUG|Lemborexant 5 MG [Dayvigo]|Lemborexant 5 mg will be taken orally once per day just prior to initiating laboratory-supervised daytime sleep episodes, for three consecutive days, within a few minutes before going to bed, with at least seven hours remaining before the planned time of awakening.
223473326|NCT06231641|OTHER|Matching Placebo|Matching placebo will be taken orally once per day just prior to initiating laboratory-supervised daytime sleep episodes, for three consecutive days, within a few minutes before going to bed, with at least seven hours remaining before the planned time of awakening.
223473327|NCT06607575|OTHER|Control group|"1. The procedure for heel blood collection will be performed.~2. Pain assessment will be performed with the N-PASS scale during and after the procedure."
223473328|NCT06607575|OTHER|Warming|"1. The cotton sock will be warmed under the heater for 3 minutes. The sock will be put on the newborn and taken off after 3 minutes.~2. The procedure for heel blood collection will be performed.~3. Pain assessment will be performed with the N-PASS scale during and after the procedure."
223473329|NCT06607575|OTHER|Vibration|"1. A rechargeable toothbrush will be prepared for the newborn to whom vibration will be applied. The vibration process will be applied to the midline of the gastrocnemius muscle for 3 minutes.~2. The procedure for heel blood collection will be performed.~3. Pain assessment will be performed with the N-PASS scale during and after the procedure."
223473330|NCT06607575|OTHER|Warming and vibration|"1. After the socks are warmed, they will be put on the newborn\&#39;s feet and both warming and vibration will be applied for 3 minutes.~2. The procedure for heel blood collection will be performed.~3. Pain assessment will be performed with the N-PASS scale during and after the procedure."
223580781|NCT00168103|BIOLOGICAL|Placebo|Single application of physiological saline solution equivalent to the volume calculated for subjects in the C1-INH 20 U/kg bw arm.
223580782|NCT01127555|DRUG|5-fluorouracil, leucovorin, oxaliplatin|D1 Oxaliplatin 85mg/m2 D1, 2 LV 30mg/m2 IV push D1, 2 5-FU 1500mg/m2 CIV over 24hrs Every 2 weeks
223580783|NCT03208920|DIETARY_SUPPLEMENT|Pro-Omega|Pro-Omega (Nordic Naturals, Watsonville, CA, USA). Each Pro-Omega capsule is 550 mg. Must take 4400 mg/day x 6 months.
223580784|NCT03208920|OTHER|ProOmega Placebo|Placebo Comparator: soybean (Nordic Naturals, Watsonville, CA, USA). Each soybean capsule is 550 mg. Must take 4400 mg/day x 6 months.
223580785|NCT00195000|DRUG|Mylotarg|6 mg/m2 on day 1
223580786|NCT00195000|DRUG|Cytarabine|100 mg/m2 given as continuous infusion daily for 7 days.
223580787|NCT03677479|PROCEDURE|socket preservation procedure|socket preservation of post extraction site using bone xenografts
223580788|NCT03624426|DEVICE|Automated Somatosensory Evoked Potential device (EPAD@)|After commencement of general anesthesia and during patient positioning, stimulating sensors will be applied to patient wrists and a recording sensor is applied at base of neck posteriorly (at C5 level), forehead and the bilateral wrists. The monitoring will be continued throughout the surgery.
223473331|NCT03311308|DRUG|Pembrolizumab Injection [Keytruda]|200mg, IV, every three weeks, up to two years; After the first three doses, dosing can be changed to 400mg IV every 6 weeks, at the treating physician's discretion.
223473332|NCT03311308|DRUG|Metformin|500 mg, by mouth, twice a day for nine weeks.
223473333|NCT06596291|DRUG|EG110A|Participants treated with EG110A
223580789|NCT06050668|COMBINATION_PRODUCT|Essential Amino Acid Supplementation|Powdered supplement that can be mixed into beverage of choice. Ingredients: Zinc, Vitamin A, Vitamin C, Whey Protein, Leucine, Calcium, Vitamin D, Glutamine, Boron, Turmeric, Bioperine, Iron, β-hydroxy β-methylbutyrate (HMB)
223580790|NCT04235569|DRUG|Warfarin Sodium 5 MG|warfarin sodium 5mg tablets
223580791|NCT04235569|DRUG|Warfarin Sodium 3 MG|warfarin sodium 3mg tablets
223473334|NCT06821035|BEHAVIORAL|Garnering Resilience in Traumatized youth and families (GRIT)|Dyads randomly assigned to Garnering Resilience in Traumatized youth and families (GRIT) will receive a community health worker delivered psychoeducational intervention that includes 6 weekly sessions focused on: 1) supportive health coaching to garner resilience via psychoeducation and the promotion of buffering protective factors in both youth and caregivers and 2) facilitating self-regulation using heart rate variability (HRV) biofeedback.
223473335|NCT06821035|BEHAVIORAL|Digital Citizenship Curriculum (DCC)|Dyads randomly assigned to DCC will receive a community health worker-delivered, school grade-specific intervention that includes 6 weekly sessions focused on helping youth navigate the complexities of living in a digital world.
223473336|NCT00103948|DRUG|Aricept|
223473337|NCT06612892|DEVICE|Virtual reality games in immersive VR modality|virtual reality involved three characters: a muscular boxer, a superhero, and a rock climber, with patients performing tasks in standing or sitting. Each experience takes 6 minutes, with 5-minute intervals between. Experimenters will instruct users on hand controls and virtual body observation.
224163802|NCT00291746|PROCEDURE|Bravo technique|
223473338|NCT06612892|DEVICE|Virtual reality show in passive VR modality:|In this modality the patient was asked to have a comfortable seat wearing the head set without holding the controllers , the therapist will play a relaxing show as a nature view or colorful scene as a sort of relaxation and mind distraction for around 20 minutes while asking the patient to perform upper limb muscle ROM exercise in active or active assisted form.
223473339|NCT06612892|OTHER|traditional physiotherapy|Includes stretching exercise for upper limb muscles affected by burn, scar tissue release , and splinting technique.
223473340|NCT06612021|PROCEDURE|Beautibond universal adhesive|HEMA free universal adhesive
223473341|NCT06612021|PROCEDURE|Tetric N universal bond|HEMA containing universal bond
223473342|NCT01471977|OTHER|education,counseling, default tracers,quality of care|these interventions were administered along with standard treatment i.e. DOTS at the time of standard follow up of patients at clinic
223473343|NCT00003039|DRUG|alvocidib|
223473344|NCT06992882|DRUG|Capecitabine|capecitabine (1000-1250mg/m2, orally, bid, D1-14, q3w) and trastuzumab (first dose 8mg/kg, q3w; Follow-up maintenance 6 mg/kg, q3w, subcutaneous or intravenous for 1 year)
223473345|NCT06992882|DRUG|Paclitaxel|paclitaxel (80mg/m2, qw, D1, 8, 15, intravenous, q3w) trastuzumab (first dose 8mg/kg, q3w; Follow-up maintenance 6mg/kg, q3w, subcutaneous or intravenous for 1 year)
223473346|NCT03882918|DRUG|OV101|Each subject will be titrated to his or her maximal tolerated daily dose, up to a maximum daily dose of 15 mg at bedtime.
223473347|NCT00481884|OTHER|RadiaPlexRx Gel|RadiaPlexRx Gel: The treated breast is divided into two vertical halves during the simulation using skin marker (medial and lateral halves). Patients are given detailed instructions to apply RadiaPlexRx gel topically 3 Times Daily to one half of the irradiated breast skin and the control, Aquaphor gel, to the other half of irradiated breast skin. This is determined through randomization process.
223473348|NCT00481884|OTHER|Aquaphor Gel|Aquaphor Gel: The treated breast is divided into two vertical halves during the simulation using skin marker (medial and lateral halves). Patients are given detailed instructions to apply Aquaphor gel topically 3 Times Daily to one half of the irradiated breast skin and the experimental, RadiaPlexRx gel, to the other half of irradiated breast skin. This is determined through randomization process.
223473349|NCT01645150|BEHAVIORAL|Progressive strength training|12 weeks of supervised progressive strength training
223473350|NCT06996184|DRUG|Vamifeport (PR formulation)|Vamifeport will be administered orally
224069501|NCT04358679|OTHER|Conventional Treatment|"Conventional Treatment:~* Deep breathing: 10-15 reps, twice a day (BD)~* Assisted coughing 10-15 reps, BD~* range of motion (ROM)+ stretching 10 reps, BD~* Tilt table standing"
224069502|NCT04358679|OTHER|Upper Limb ergometer training|Conventional Treatment + upper limb (UL) ergometry exercise UL ergometry exercise 15 to 20 mints , 2 times ,five days per week for 6 weeks.
224069503|NCT03790683|DEVICE|EnsoETM|Patients having major surgery will have the EnsoETM device placed after induction of general anesthesia. Addition of standard of care surface warming was specified as optional after first 7 patients.
224069504|NCT03790683|DEVICE|Surface Warming|Forced air warming device will be placed on the patient according to standard practice.
224069505|NCT04947488|DIETARY_SUPPLEMENT|Bioarginina C|Dietary supplement vials
224161007|NCT05974891|OTHER|Pilot application|"Pilot application will be carried out with at least 10 students. A pre-test will be applied to the experimental group. After the scales are applied, the experiment will be applied to the experimental group with the Geriatric Medication Game simulation.~Students simulating the elderly patient role during this simulation will gain a better understanding of age-related health problems and how older adults feel when confronting them. After the application, debriefing, which is the last stage of the simulation training, will be done to evaluate the application. After the application and analysis session is completed, the post-test will be applied to the experimental group. A 3-week clinical practice will be planned for the students in the experimental groups in order to evaluate the continuation of the acquired skills and acquired awareness. In this application, students will be asked to care for the elderly patient and the pre-test will be repeated at the end of the application."
224161008|NCT02461849|DRUG|Imatinib|Imatinib 400mg qd daily
224161009|NCT03517735|DEVICE|EasyTiva (algorithm is the property of Medsteer SAS)|Propofol and Remifentanil are administered automatically using a closed-loop system. Bispectral index is used as the input signal and an algorithm defines the appropriate concentrations of propofol and remifentanil. Adequate postoperative sedation is defined by a bispectral index between 55 and 75.
224161010|NCT03517735|DRUG|Propofol|The dosage is modified automatically by the device or according to the new medical prescription.
224161011|NCT03517735|DRUG|Remifentanil|The dosage is modified automatically by the device or according to the new medical prescription.
224161012|NCT02717026|DEVICE|Optical coherence tomography|Sections including the retinal vasculature will be taken.
224161013|NCT02717026|DEVICE|Fluorescein angiography|Video fluorescein angiography from one eye of each subject will be performed
224161014|NCT02717026|DEVICE|Fundus photography|30 and 50 degree fundus images
224161015|NCT03042585|RADIATION|Total body irradiation|When radiation is given in a way to cover the whole body, it is called total body irradiation.
224161016|NCT01392014|DRUG|dihydroartemisinin-piperaquine|This study used fixed-dose tablets of 40 mg dihydroartemisinin and 320 mg piperaquine for each tablet (D-ARTEPP®, Guilin Pharmaceutical Co., Ltd, China. The regimen is based on weight for 3 days (D0, D1 and D2) with maximal dose of 1 x 3 tablets for patients weighing ≥ 41 kg; 1 x 2 tablets for patients weighing 31 - 40 kg, 1 x 1.5 tablets for patients weighing 18 - 30 kg, and 1 X 1 tablet for patients with body weight of 11 - 17 kg.
224161017|NCT01392014|DRUG|dihydroartemisinin-piperaquine + primaquine|For DHP, treatment was as for Arm dihydroartemisinin piperaquine. A single dose PQ of 0.75 mg/kg BW was provided on Day-3 using 15 mg base PQ tablets (local product by PT Pharos Indonesia, batch no 15306002, produced on 30/05/2008 and expiring on May 2012). The maximal dose was 3 tablets for subjects weighing ≥ 60 kg. The dose range for subjects weighing 10 - 13 kg was 0.5 tablet; 14 - 18 kg was 0.75 tablet; 19 - 23 kg was 1 tablet, 24 -30 kg was 1.5 tablet; 31 - 40 kg was 2 tablets; 41- 49 kg was 2.25 tablet; 50 - 59 kg was 2.5 tablet and ≥ 60 kg was 3 tablets.
224161018|NCT01984359|OTHER|Obtaining Human tissue|
224161019|NCT00912496|BIOLOGICAL|MF-59|Doses of A/Anhui/05 vaccine (A) will be administered with or without MF59 adjuvant.
224161020|NCT00912496|BIOLOGICAL|A/Anhui/05|Monovalent inactivated surface antigen influenza A/H5N1 (modified Hemagglutinin and Neuraminidase of A/Anhui/01/2005) vaccine supplied in 5mL multi-dose vials with thimerosal \[0.01%(w/v)\] as a preservative. Each dose level includes both unadjuvanted and MF59C.1 adjuvanted formulations: 7.5, 15, 30, or 60 micrograms (mcg) of H5 Hemagglutinin per milliliter (mL) with MF59C.1, and 7.5, 15, 30, or 60 micrograms (mcg) of H5 Hemagglutinin per milliliter (mL) without MF59C.1 adjuvant.
224304257|NCT03499886|DRUG|Ketamine Hcl 50Mg/Ml Inj|In the intervention group, ketamine 1% was administered rapidly at a dose of 0.5 mg / kg (within 5 seconds), and in the control group, ketamine 1.5 mg / kg was slowly injected for 30 to 60 seconds.
224304258|NCT04589416|OTHER|Dental adhesive materials.|It is used to bond the composite resin to the dental tissues. That is, it is used to bond dental filling materials to dental tissues.
224304259|NCT01140555|DEVICE|GYNECARE GYNOCCLUDE™|GYNECARE GYNOCCLUDE™ Doppler Guided Uterine Artery Occlusion Device
224304260|NCT00149812|BEHAVIORAL|Family Functioning Intervention|
224304261|NCT02599038|DIETARY_SUPPLEMENT|Serine supplementation|Serine supplementation (200 mg/kg/day)
224304262|NCT03598335|DEVICE|Ultrasound|Ultrasound imaging of women arriving at clinic for routine care
224304263|NCT04605224|BEHAVIORAL|Culinary class|This hands-on, optional course teaches students how to measure and weigh ingredients, read and follow recipes, apply various food preparation, cooking and assembly techniques, as well as prepare meals, as per the provincial curriculum
224304264|NCT03682458|GENETIC|Study of Neurodegenerative Diseases Induced Stem Cells|The aim of this study is to generate iPS-induced stem cell lines from patients with neurological and neurodegenerative diseases to differentiate into neurons and glial cells to study the pathological cellular and molecular processes of these diseases. These in vitro cultures will also be used to validate molecules or experimental therapeutic approaches. IPS cells will be generated by the reprogramming of isolated 10-mL cells of peripheral venous blood.
224304265|NCT03321435|OTHER|placenta previa patient|women had placenta previa either major or minor degree
224304266|NCT03321435|OTHER|normal women|those women had not placenta previa
224304267|NCT03804502|DEVICE|TearCare|The TearCare System warms the eyelids to melt the meibum by applying heat to the external surface of the eyelids for 15 minutes. Following completion of the thermal portion of the procedure, the clinician performs manual expression of each of the eyelids.
224304268|NCT04333108|DRUG|Masitinib|Masitinib 6 mg/kg/day
224304269|NCT04333108|OTHER|Placebo|Matching placebo
224304270|NCT04333108|OTHER|Best Supportive Care|Optimal concomitant symptomatic treatments. Includes: H1- and H2-antihistamines, proton pump inhibitors (PPI), sodium cromoglycate, antidepressants, leukotriene antagonists and corticosteroids.
224304271|NCT06107504|DRUG|Sucralfate|2g of sucralfate powder and 1g of tranexamic acid powder will be sprayed after EST
224304272|NCT00988442|BEHAVIORAL|Enhanced nursing telephone support|Weekly phone calls by study nurses for 8 weeks and then calls every 2 weeks for 40 weeks; nurses could schedule more frequent calls at their discretion. Calls provided information, motivational enhancement, problem-solving skills, and affective support.
224304273|NCT00988442|BEHAVIORAL|Standard care|Usual ACTG site care.
224304274|NCT04167293|RADIATION|stereotactic body radiotherapy|Patients will receive stereotactic body radiotherapy (SBRT) using volumetric arc therapy. The prescribed dose is 30-54 Gy in 3-6 fractions over 1-2 weeks.
224304275|NCT04167293|DRUG|Sintilimab|Sintilimab is administered intravenously at 200 mg every 3 weeks for up to 1 year. The first course of sintilimab will be given within 4-6 weeks after completion of SBRT.
224304276|NCT01894035|DRUG|Iloprost (Ventavis, BAYQ 6256)|Patients Diagnosed with Pulmonary Arterial Hypertension, Functional Class NYHA/WHO III, for whom was prescribed inhaled Iloprost.
223473351|NCT07002554|DEVICE|Bright light therapy|the Verilux® HappyLight® Lumi Plus light therapy box, which delivers UV-free, full-spectrum LED light at an intensity of 10,000 lux
223473352|NCT07002554|DEVICE|dim red light|The control group will use the same light box device, configured to emit dim red light. This will be achieved by setting the box to its lowest brightness setting and overlaying a translucent red filter over the light display. This setup is intended to maintain the appearance and experience of light exposure while minimizing any therapeutic effect.
223473353|NCT07006987|DEVICE|A non-invasive blood-based (HerResolve)|A non-invasive blood-based test can detect endometriosis as compared to diagnostic laparoscopy
223473354|NCT06615102|DRUG|Angiotensin II|Intravenous infusion through a central line according to the patient's situation. Once an infusion is established, the dose will be titrated as frequently as every 5 minutes, as needed, depending on the patient's condition and target MAP.
223580792|NCT04235569|DRUG|Enoxaparin Sodium 100 MG/ML Prefilled Syringe|"Clexane® Syringes 2,000 IU (20 mg)/0.2 ml solution for injection in pre-filled syringes.~Clexane® Syringes 4,000 IU (40 mg)/0.4 ml solution for injection in pre-filled syringes.~Clexane® Syringes 6,000 IU (60 mg)/0.6 ml solution for injection in pre-filled syringes.~Clexane® Syringes 8,000 IU (80 mg)/0.8 ml solution for injection in pre-filled syringes.~Dose was determined individually for each patient as 1mg/kg every 12 hours."
223580793|NCT00989235|DRUG|Abatacept|IV solution, IV, 10 mg/Kg, Once monthly, 1 year
223580794|NCT00989235|DRUG|Abatacept|IV solution, IV, 5 mg/Kg, Once monthly, 1 year
223580795|NCT02111135|BIOLOGICAL|b-OPV|
223580796|NCT02111135|BIOLOGICAL|m-OPV2|
224161021|NCT00912496|DRUG|Placebo|Sterile normal saline for injection (0.9% Sodium Chloride Injection, USP Preservative-Free).
224304277|NCT01103622|DRUG|AZD1656|Oral tablet bd, step-wise increased dosage
224304278|NCT01103622|DRUG|Digoxin|Oral tablet od on Day 4
224304279|NCT01103622|DRUG|Placebo|Oral tablet bd, step-wise increased dosage
224304280|NCT05658978|OTHER|Neuromuscular training|Neuromuscular training Length: 12 weeks; Training duration: 90 minutes; Intensity: 70-95%; 3 days per week. The intensity of the training is increasing in the first 20 minutes, and the intensity is gradually decreasing in the next 5 minutes; Rest: 30 seconds rest between exercises and 1-minute rest between sets.
224304281|NCT05658978|OTHER|Control group|The Control group continues previous regular exercises for 12 weeks with a duration of 90 minutes and three days per week.
224304282|NCT02776579|OTHER|Girls-only resistance training|
224304283|NCT05690503|DRUG|CI-581a|Medication infusion intravenously over 90 minutes.
224304284|NCT05690503|DRUG|CI-581b|Medication infusion intravenously over 90 minutes.
224161022|NCT01726504|DEVICE|electro-acupuncture|Procedure: electro-acupuncture; Points:Tianshu (ST25) Fujie(SP14), Shangjuxu (ST37).Pierced the skin, needles are inserted 30to70mm into bilateral ST25 and SP14 vertically until piercing the abdominal muscle layer.Electric stimulator is applied to bilateral ST25 and SP14 with dilatational wave, 10/50 Hz and electric current 0.1-1.0mA. The participant's abdominal muscle twitching mildly is the appropriate dose. Bilateral ST37 are inserted 25-30mm and then twirling lifting and thrusting for 3 times.Local sour and heavy feeling is appropriate dose. Steady small twirling lifting and thrusting 3 times in all. 30 min/per day/per session.During the 8 weeks treatment, the first 2 weeks,5 sessions per week, and 3 sessions per week in the rest 6 weeks,28 sessions for each patients in total.
223580797|NCT02111135|BIOLOGICAL|m-IPV HD|
223580798|NCT02111135|BIOLOGICAL|t-IPV|
223580799|NCT00545532|DRUG|oseltamivir|Dose ranging between 30 to 150 mg orally administered as syrup or capsules (depending on participant's age and weight) po twice daily for 10 days
223473355|NCT06615102|DRUG|Noradrenalin|Intravenous infusion through a central line according to the patient's situation. Once an infusion is established, the dose will be titrated as frequently as every 5 minutes, as needed, depending on the patient's condition and target MAP.
223473356|NCT06613022|OTHER|Instrument Assisted Soft Tissue Mobilization first Control second|Instrument assisted soft tissue mobilization was utilized first on day one and wait-control was completed on second day.
223473357|NCT06613022|OTHER|Control first Instrument Assisted Soft Tissue Mobilization second|This intervention involved waiting for 20 minutes between pre-test and post-test on day one and having Instrument Assisted Soft Tissue Mobilization on day two.
223580800|NCT00545532|OTHER|placebo|Placebo matched to oseltamivir po twice daily for 10 days
223473358|NCT03025373|OTHER|Visuo-acoustic stimulation|Controlled visual and acoustic stimulation in a virtual reality setting
223473359|NCT07011472|OTHER|Decision-Aid with 2-options|This decision aid offers 2 options for post-operative analgesic: a non-opioid combination (ibuprofen/acetaminophen) or an opioid (hydrocodone).
223473360|NCT07011472|OTHER|Decision aid with 3 options|"This decision aid offers 3 options for post-operative analgesic: a non-opioid combination (ibuprofen/acetaminophen), an opioid (hydrocodone), or a non-opioid combination with a just-in-case opioid prescription."
223473361|NCT06629506|DEVICE|MicroMatrix® Flex|MicroMatrix® Flex is intended for the management of wounds including: partial and full-thickness wounds, pressure ulcers, venous ulcers, diabetic ulcers, chronic vascular ulcers, tunneled/undermined wounds, surgical wounds (donor sites/grafts, post-Mohs surgery, post-laser surgery, podiatric, wound dehiscence), trauma wounds (abrasions, lacerations, partial thickness burns, skin tears), draining wounds. The device is intended for one-time use.
223473362|NCT06629506|DEVICE|MicroMatrix® UBM Particulate|MicroMatrix® UBM Particulate is intended for the management of wounds including: partial and full-thickness wounds, pressure ulcers, venous ulcers, diabetic ulcers, chronic vascular ulcers, tunneled/undermined wounds, surgical wounds (donor sites/grafts, post-Moh's surgery, post-laser surgery, podiatric, wound dehiscence), trauma wounds (abrasions, lacerations, second-degree burns, skin tears), and draining wounds. The device is intended for one-time use.
223580801|NCT00002514|BIOLOGICAL|sargramostim|
223580802|NCT00002514|DRUG|asparaginase|
223580803|NCT00002514|DRUG|cyclophosphamide|
223580804|NCT00002514|DRUG|cytarabine|
223580805|NCT00002514|DRUG|daunorubicin hydrochloride|
223580806|NCT00002514|DRUG|dexamethasone|
223580807|NCT00002514|DRUG|etoposide|
223580808|NCT00002514|DRUG|imatinib mesylate|
224161023|NCT01726504|DEVICE|sham electro-acupuncture|Procedure:sham electro-acupuncture;Points:Sham Tianshu(ST25),sham Fujie(SP14),sham Shangjuxu (ST37).Sham points location:20mm away from ST25,middle of Spleen and Stomach Channel;30mm from SP14,middle of Spleen and Stomach Channel; one point beside ST37,middle of Stomach and Gallbladder Channel; Performance:The needle is inserted with needle of 0.30×25mm by 3-5mm. No twirling lifting and thrusting. The electric stimulator is applied to bilateral sham ST25 and sham SP14 with dilatational wave,10/50 Hz and electric current 0.5mA.The mental wire has been cut off with a same outlook as the treatment group.The electric stimulator is looked normal but with no current output. Length of Treatment and the treatment sessions are the same as treatment group.
224161024|NCT02436915|OTHER|Real tDCS|Transcranial direct current stimulation (tDCS) enables noninvasive, selective and sustained modulation of cortical activation. tDCS works by sending low-level currents between two or more scalp electrodes, which alters brain polarity and thus, perfusion and cortical excitability.
223580809|NCT00002514|DRUG|leucovorin calcium|
223580810|NCT00002514|DRUG|mercaptopurine|
223580811|NCT00002514|DRUG|methotrexate|
223580812|NCT00002514|DRUG|prednisone|
223580813|NCT00002514|DRUG|thioguanine|
223580814|NCT00002514|DRUG|vincristine sulfate|
223580815|NCT00002514|PROCEDURE|allogeneic bone marrow transplantation|
223580816|NCT00002514|PROCEDURE|autologous bone marrow transplantation|
223580817|NCT00002514|PROCEDURE|peripheral blood stem cell transplantation|
223580818|NCT00002514|RADIATION|radiation therapy|
223580819|NCT00334581|DRUG|Irbesartan|Administration throughout the study period
223580820|NCT00334581|DRUG|Irbesartan|Administration throughout the study period
223580821|NCT02404922|DRUG|CTP-730|
223580822|NCT02404922|DRUG|Placebo for CTP-730|
223580823|NCT04088084|DIETARY_SUPPLEMENT|palmitoylethanolamide (PEA) 600 mg|PEA 600 mg was added to topical therapy
223580824|NCT03505489|PROCEDURE|Deep inhalation technique|Use of deep inhalations for administration of inhalant
223580825|NCT03505489|PROCEDURE|Tidal breathing technique|Use of tidal breathing for administration of inhalant
223580826|NCT03505489|DRUG|Methacholine|Methacholine direct bronchoconstrictor used for bronchoprovocation challenge
223580827|NCT03505489|DRUG|Mannitol|Mannitol indirect bronchoconstrictor used for bronchoprovocation challenge
223580828|NCT00292838|DRUG|fluticasone 25, 50, 100, 200 mcg|
223580829|NCT00459693|DRUG|[11C]PBR28|
223580830|NCT03205852|OTHER|questionnaire|fulfillment of questionnaire
223580831|NCT04202510|PROCEDURE|Glaucoma and Cataract Surgery|Patients requiring combined cataract and glaucoma surgery will be randomized to either iStent, iStent Inject or Hydrus (to lower intraocular pressure) combined with Phacoemulsification (to remove cataract and insert intraocular lens) Eye Surgery
223473363|NCT06629506|DEVICE|Cytal® Wound Matrix 2-Layer|Cytal® Wound Matrix is intended for the management of wounds including: partial and full-thickness wounds, pressure ulcers, venous ulcers, diabetic ulcers, chronic vascular ulcers, tunneled/undermined wounds, surgical wounds (donor sites/grafts, post-Moh's surgery, post-laser surgery, podiatric, wound dehiscence), trauma wounds (abrasions, lacerations, second-degree burns, skin tears), and draining wounds. The device is intended for one-time use.
224161025|NCT02436915|OTHER|Sham tDCS|For sham tDCS, current will only be applied for the first 60 seconds of each 20 minute session. This is a reliable sham control as sensations arising from tDCS diminish considerably after the first minute of stimulation.
224161026|NCT05120375|DRUG|BAT6021|Ⅳ infusions
224161027|NCT04948840|BIOLOGICAL|Blood sampling|Blood sample of 7 mL whole venous blood in an EDTA citrate tube (4.5 mL) and a PAXgene Blood RNA tube (2.5 mL).
224161028|NCT00864539|DIETARY_SUPPLEMENT|fortified milk|daily intake of milk fortified with 100 IU vitamin D and 500 mg calcium/200 ml package for 10 weeks
224161029|NCT00864539|DIETARY_SUPPLEMENT|plain milk|daily intake of 200 ml plain milk
224161030|NCT00864539|DIETARY_SUPPLEMENT|fortified orange juice|daily intake of orange juice fortified with 100 IU vitamin D and 500 mg calcium/250 ml package
224161031|NCT00864539|DIETARY_SUPPLEMENT|plain orange juice|daily intake of 250 ml plain orange juice
224161032|NCT00864539|DIETARY_SUPPLEMENT|calcium-vitamin D supplement|daily calcium-vitamin D supplement (500 mg calcium + 200 IU vitamin D)
224161033|NCT00864539|DIETARY_SUPPLEMENT|Placebo|daily placebo
224161034|NCT04584866|PROCEDURE|Endonasal endoscopic pituitary surgery in semi-sitting position|Patients will be placed in semi-sitting position. To achieve the semi-sitting position, the patient is placed in supine position. The operating table is then separated and flexed to elevate the torso (angle of 30°). The head, which is fixed in a head clamp, is slightly flexed to bring the floor of the sella right in front of the surgeon and gently rotated toward the operating team.
223473364|NCT06030154|BEHAVIORAL|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy
223473365|NCT06030154|BEHAVIORAL|Amplification of Positivity Therapy|Amplification of Positivity Therapy
223473366|NCT06030154|BEHAVIORAL|Surveys and Interviews|Participants will answer questions regarding their mental and physical health as well as their substance use on the computer and in an interview format.
223473367|NCT06388967|DIAGNOSTIC_TEST|PANcreatic cancer Exosome Early detectiON (PANXEON)|This test will utilize quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) to quantify the expression levels of 5 cell-free and 8 exosome-miRNAs in plasma samples obtained from patients with pancreatic ductal adenocarcinoma and from individuals without it
223473368|NCT01450020|OTHER|educational intervention|Receive ACS material
223473369|NCT01450020|OTHER|questionnaire administration|Ancillary studies
223473370|NCT01450020|OTHER|counseling intervention|Undergo PN session
223473371|NCT01450020|OTHER|survey administration|Ancillary studies
223473372|NCT01450020|PROCEDURE|quality-of-life assessment|Ancillary studies
223473373|NCT06338943|DIAGNOSTIC_TEST|Echocardiography|Echocardiography to diagnose HFpEF
223473374|NCT06338943|OTHER|Questionnaire|Questionnaire to determine the presence of adverse pregnancy outcomes history
223473375|NCT05455333|OTHER|Questionnaires|Sends and returns questionnaires to families.
223473376|NCT03122392|DEVICE|AMS 800|AMS 800 Artificial Urinary Sphincter
223473377|NCT06699615|OTHER|Once time de-identified Qualtrics survey|Once time de-identified Qualtrics survey
223473378|NCT04720989|PROCEDURE|Bathing With Baby Cleanser and water|Late preterm and term newborns, whose informed consents are obtained by their parents to participate in the project, will be given their first baths according to the intervention group they are assigned to. Before the first bath / after birth, preterm newborns in all groups will be wiped only once with a clean towel without removing the vernix caseosa. Newborns who were bathed before the application of the study will be excluded from the study. As the most appropriate time for bath time, 30 minutes after the end of the feeding and treatment of the newborns, the bath application will be made at any time between 9 pm and 3 pm.
223473379|NCT04720989|PROCEDURE|Bathing With only Water|Preterm infants will have their first baths only with water.
223473380|NCT04020419|DRUG|PediaBerry|PediaBerry or placebo will be mixed with a cream vehicle for topical administration or with water for oral administration
223473381|NCT04788095|BEHAVIORAL|Behavioral Intervention|Participate in an app-based mindfulness program
223473382|NCT04788095|OTHER|Quality-of-Life Assessment|Ancillary studies
223473383|NCT04788095|OTHER|Questionnaire Administration|Ancillary studies
223473384|NCT03828955|DIETARY_SUPPLEMENT|Soybean peptides|Subjects receive two bags soybean peptides per day for 8 weeks of a stage. Anthropometric measurements such as blood pressure (systolic blood pressure \[SBP\] and diastolic blood pressure \[DBP\]), body weight, body fat, waistline, hipline and blood biochemical parameters including FBG, albumin, TC, TG, HDL-C, LDL-C, Cr, BUN, AST and ALT were measured every four weeks.
223473385|NCT03828955|DIETARY_SUPPLEMENT|Placebo|Subjects receive two bags of starch placebo of similar appearance per day for 8 weeks of a stage. Anthropometric measurements such as blood pressure (systolic blood pressure \[SBP\] and diastolic blood pressure \[DBP\]), body weight, body fat, waistline, hipline, and blood biochemical parameters including FBG, albumin, TC, TG, HDL-C, LDL-C, Cr, BUN, AST, and ALT were measured every four weeks.
223473386|NCT00929838|BEHAVIORAL|Diabetes Knowledge/Information|This group will receive telephone-delivered diabetes knowledge/information lasting 30 minutes for 12 weeks.
224161035|NCT04584866|PROCEDURE|Endonasal endoscopic pituitary surgery in supine position|Patients will be operated in the standard supine neutral position
224161036|NCT05595213|DEVICE|Wrist cooling device with cooling plate|This device is worn like a watch and pressing the button activates the cooling function to begin to col the wrist skin temperature to 47 degrees. Pushing the device button again cools the skin to 60 degrees and a third time to 77degrees.
224161037|NCT05595213|DEVICE|Wrist fan activating device without cooling plate|This device is worn like a watch and pressing the button activates the cooling fan for 5 minutes.
224161038|NCT05595213|OTHER|Hot Flash Diary|Participants will be instructed to daily document each hot flash experience and indicate if it was mild, moderate, or severe and whether they activated the wrist cooling device.
224161039|NCT02437968|BEHAVIORAL|Camp Cope-A-Lot (Computer-assisted CBT program)|Camp Cope-A-Lot is a computer-assisted program that includes psychoeducation and clinician guided exposure tasks for anxious children.
224161040|NCT03054025|DEVICE|Smart Phone Monitoring Device|Use activity tracker application
224161041|NCT03856086|BEHAVIORAL|Baseline questionnaire|Baseline questionnaire on the day of the patient's surgery.
224161042|NCT03856086|BEHAVIORAL|NCCN Problem List|NCCN Distress Thermometer
224161043|NCT03856086|BEHAVIORAL|FACT-GP|Greater overall quality of life
224304285|NCT04515082|DIAGNOSTIC_TEST|Stool-based SDC2 and SFRP2 DNA methylation test|A diagnostic device measuring syndecan 2 (SDC2) and secreted frizzled-related protein 2 (SFRP2) methylation status in stool DNA to detect colorectal cancer
224304286|NCT04515082|DIAGNOSTIC_TEST|FIT|Fecal immunochemical test
224304287|NCT03456583|DEVICE|Brevera Breast Biopsy System|The Brevera Breast Biopsy System with CorLumina imaging technology is a vacuum-assisted biopsy device, which is used to remove breast tissue in a minimally invasive manner using stereotactic or tomosynthesis imaging. A breast biopsy is a test that removes tissue or sometimes fluid from the suspicious area. The removed cells are examined under a microscope and further tested to check for the presence of breast cancer. A biopsy is a diagnostic procedure that can definitely determine if the suspicious area is cancerous.
224304288|NCT01557361|OTHER|Accelerated RRT initiation|A dialysis catheter will be placed and RRT initiated as soon as possible and within 12 hours of eligibility. This 12 hour window includes the time needed to obtain consent.
224304289|NCT01557361|OTHER|Standard RRT initiation|"Patients will be carefully followed over a period of 7 days to identify potential indications for RRT. The trial team will ask that the clinical team consider RRT initiation if there are:~I. Criteria for persistent AKI (serum creatinine has not declined by more than 50% from value recorded at time of eligibility) AND~II. At least one of the following indications for RRT initiation:~1. Serum potassium ≥6.0 mmol/L, or~2. Serum bicarbonate ≤ 10 mmol/L, or~3. Evidence of severe respiratory failure, based on a PaO2/FiO2 \<200 and bilateral infiltrates on the chest x-ray, or~4. By 72 hours after randomization, creatinine has not declined by more than 50% from that recorded at the time of randomization"
224304290|NCT02507544|DRUG|TRX-818 capsules|
224304291|NCT05121792|BEHAVIORAL|Web Based Therapist Tutorial on Prolonged Grief Disorder Therapy|The tutorial consists of 10 online modules following the main procedures of the Prolonged Grief Disorder Therapy (formerly known as Complicated Grief Treatment). Each module includes didactic information and interactive activities and videos, and takes approximately 30 minutes to review. Participants can study the material at their own pace.
224304292|NCT06344936|DRUG|HRS-1780 tablets; Itraconazole capsules; Rifampicin capsules|Treatment PartⅠ: Itraconazole capsule, 200mg QD, 7 times; HRS-1780 tablets, 10mg QD, twice Treatment PartⅡ: Rifampicin capsules, 600mg QD, 14 times; HRS-1780 tablets, 10mg QD, twice
223473387|NCT00929838|BEHAVIORAL|Motivation/Behavioral Skills|This intervention consists of patient activation, patient empowerment, and behavioral skills training delivered via telephone lasting 30 minutes every week for 12 weeks.
223473388|NCT00929838|BEHAVIORAL|Combined Intervention|This group will receive all components of the diabetes knowledge/information and the motivation/behavioral skills interventions via telephone lasting 30 minutes every week for 12 weeks.
223473389|NCT00929838|BEHAVIORAL|Usual Care|This group will receive telephone-delivered general health education lasting 30 minutes for 12 weeks to control for attention and content.
223473390|NCT05619471|DEVICE|VIO Imaging|Skin conditions that are candidates for skin biopsies
224069506|NCT02072473|PROCEDURE|Coronary sinus / left-sided slow pathway ablation|"Patients with unsuccessful right-sided slow pathway ablation attempt will undergo a stepwise:~1. coronary sinus slow pathway ablation, which, if unsuccessful, will be followed by~2. left-sided slow pathway ablation, using trans-septal approach."
224069507|NCT03907852|BIOLOGICAL|gavo-cel|gavo-cel
224069508|NCT03907852|DRUG|fludarabine|lymphodepletion chemotherapy
224069509|NCT03907852|DRUG|cyclophosphamide|lymphodepletion chemotherapy
224069510|NCT03907852|DRUG|Nivolumab|immuno-oncology agent
224069511|NCT03907852|DRUG|Ipilimumab|immuno-oncology agent
224069512|NCT05144607|OTHER|Muscle Pressure curve (Pmus)|The intervention will be the display of an additional curve - the estimated inspiratory muscle pressure waveform generated using an artificial intelligence algorithm.
224069513|NCT01259609|PROCEDURE|Pars Plana Vitrectomy|25-gauge three-port pars plana vitrectomy
224069514|NCT05195008|DRUG|BIIB113|Administered as specified in the treatment arm.
224069515|NCT05195008|DRUG|BIIB113-Matching Placebo|Administered as specified in the treatment arm.
224069516|NCT05195008|DRUG|11^C]BIO-1819578|Administered as specified in the treatment arm.
224069517|NCT04369365|DRUG|Azithromycin 500 milligram (mg) oral Tablet|weekly oral use
224069518|NCT04369365|DRUG|Placebo|weekly oral use
224069519|NCT01678144|DEVICE|Mitral valve repair using the Medtentia Annuloplasty Ring (MAR)|
224069520|NCT01626898|BEHAVIORAL|HOLA en Grupos|HOLA en Grupos consists of four 4-hour group sessions that combine presentations by facilitators who are trained Latino MSM community members, activities, and scenes from a DVD, and is delivered over a period of two weeks to groups of about 10 participants. HOLA en Grupos is designed to increase HIV prevention knowledge, condom use and mastery, decrease barriers to risk reduction (e.g., health-compromising aspects of machismo), enhance sexual negotiation skills, and increase use of HIV testing, counseling, and treatment services among intervention participants.
224069521|NCT01626898|BEHAVIORAL|General Health intervention (comparison intervention )|The Spanish comparison condition consists of four Spanish-language 4-hour group sessions designed to increase participants' knowledge about cancer, diabetes, alcohol abuse, and cardiovascular disease, and is delivered over a period of two weeks to groups of about 10 participants.
224069522|NCT06156579|DRUG|Decitabine|Decitabine 20 mg/m\^2, i.v., once daily, 10 days
224069523|NCT06156579|DRUG|Venetoclax|Venetoclax, 400 mg, p.o., once daily, 28 days
224161044|NCT03856086|BEHAVIORAL|HADS|Lower anxiety and depression
224161045|NCT03856086|BEHAVIORAL|CSS-CG|web-based CSS-CG
223580832|NCT02111655|DEVICE|Second generation surveillance of AVF|"Doppler ultrasound and transonic dilution method technique will be performed in the experimental group quarterly.~QA will be measured by both techniques and haemodynamic repercussion stenosis will be evaluated by doppler ultrasound."
223580833|NCT02111655|PROCEDURE|vital signs|Effective blood flow, venous pressure, arterial pressure, at the beginning and at the end of the dialysis session
223580834|NCT02111655|PROCEDURE|physical examination of AVF|Predialysis physical examination of AVF every dialysis session.
223580835|NCT02111655|PROCEDURE|ktv test|Weekly ktv measurement using biosensors. In patients who have been dialyzed in monitors with no biosensors, ktv will be measured monthly using monocompartimental Daugirdas equation
223580836|NCT02111655|PROCEDURE|urea method|Quarterly recirculation with urea method.
223580837|NCT03790436|DIETARY_SUPPLEMENT|Betaquik|"Study dietitian will advise each participant on target volume of Betaquik (45g MCT, 225mL Betaquik). Consuming too much MCT too quickly may cause gastrointestinal discomfort such as abdominal pain or diarrhea, this is related to its assimilation to the body. Any symptoms that do occur normally resolve in the majority of patients, and with time and persistence, GI tolerance is usually established.~Therefore the study dietitian will advise on a gradual systematic introduction to minimize any adverse effects. The daily-tolerated amount will be divided into 3-4 equal portions, taken regularly throughout the day. subjects will be advised to always take Betaquik with food, as part of meals and snacks, to help promote gastrointestinal tolerance. The goal is within the first 4 weeks participants will have reached their tolerated target volume of Betaquik."
223580838|NCT04015583|BEHAVIORAL|exergaming group|Exergame is 'exercise + game'. Treadmill exercise is traiditional aerobic exercise
223580839|NCT03630302|DEVICE|DBS|Deep Brain Stimulation
223580840|NCT04542668|OTHER|Cycling then running|Ergometer cycling Treadmill running
223473391|NCT01369459|BEHAVIORAL|MIP Protocol|We intend for MIP to be a 5-session, family-based protocol delivered during the early portion of ASU treatment. MIP will contain three elements deemed essential for integrating pharmacological interventions into outpatient behavioral treatment for youth: (1) standardized psychiatric assessment and family-focused psychoeducation about the target problem; (2) an approved medication regimen with demonstrated efficacy for comorbid populations; (3) family-based interventions for medication acceptance and coordination of psychiatric and behavioral services. MIP will incorporate research-proven interventions from each of these core areas.
223473392|NCT00975728|DIETARY_SUPPLEMENT|Alixir - Pomegranate, apple and Açai drink / Placebo|250 ml/day Alixir/Placebo for Group 2 for 8 weeks 500 ml/day Alixir/Placebo for Group 1 for 8 weeks
223473393|NCT00901043|DIETARY_SUPPLEMENT|Walnut supplementation|Eight weeks of walnut supplementation
223473394|NCT00901043|DIETARY_SUPPLEMENT|Ad lib diet|Eight weeks without walnut supplementation
223580841|NCT04542668|OTHER|Running then cycling|Treadmill running Ergometer cycling
223580842|NCT04542668|OTHER|Inotropy|Adrenaline induced inotropy
223473395|NCT07060638|DRUG|IL-22|F-652 (IL-22) is a fusion protein of human IL-22 with IgG2 fragment, and has anti-inflammatory effects
223473396|NCT07060638|DRUG|Prednisone|Prednisone is an adrenal glucocorticoid with anti-inflammatory effects
223580843|NCT04542668|OTHER|Resting|Subjects must be minimally physically active
223580844|NCT04431310|OTHER|Serial seroconversion measurements in hospital employees during the COVID-19 pandemic|The aim of this study is to apply serology testing methods for SARS-CoV2 antibodies in samples collected from HCWs in an acute hospital.
223580845|NCT04006301|DRUG|JNJ-74699157|Participants will receive JNJ-74699157 orally.
223580846|NCT05265884|DEVICE|Kinesiotaping|The tape is waterproof, porous, and adhesive. The width is 5 cm and thickness of 0.5 mm will be used in this study. This tape is with elastic core wrapped within cotton and capable of stretching up to 140-150%, applies heat-sensitive acrylic adhesive to avoid risk of latex allergy .The tape without medicinal properties is water resistant and can remain on the skin for 3 to 5 days. It will be applied two times per week for one month
223580847|NCT05265884|BEHAVIORAL|traditional therapy intervention|traditional treatment (ROM exercises, stretching exercises, and Deep friction message) 3 times per week for one month.
223580848|NCT05507632|COMBINATION_PRODUCT|Donafenib plus Sintilimab in combination with transarterial chemoembolisation|Donafenib plus Sintilimab in combination with transarterial chemoembolisation (TACE)
224069524|NCT06351995|DRUG|Combination of Neostigmine and Glycopyrrolate|Intravenous or transdermal
224069525|NCT06351995|DEVICE|I-Box by Dynatronics|Electric field conducting drugs through the skin without compromising its integrity
224069526|NCT06063109|DRUG|THP-00101 (Dapagliflozin) 10mg|Dapagliflozin 10mg Tablet / 5 days in period 1 and period 2 will be given to Arm A Dapagliflozin 10mg Tablet / 5 days in period 2 will be given to Arm B
224069527|NCT06063109|DRUG|THP-00102 (Telmisartan) 80mg|Telmisartan 80mg Tablet / 5 days in period 1 and period 2 will be given to Arm B Telmisartan 80mg Tablet / 5 days in period 2 will be given to Arm A
224069528|NCT02438709|DRUG|COX-2 inhibitor|oral COX-2 inhibitor intake 60mg qd
224069529|NCT04230174|DRUG|11C-PBR28|This study will evaluate, serially, functional and structural tissue changes in the cortex and WM of subjects with RRMS and progressive disease under Ocrelizumab using 11C-PBR28 MR-PET imaging at baseline and at approximately 12-month follow up.
224069530|NCT05355142|BEHAVIORAL|PM+|"1 Brief introduction to PM+ \& NDA (5 min) Assessment-based review with PSYCHOLOPS (psychopomps psychology ) assessment (10 min) What is PM+ (20 minutes) Understanding Adversity (30 minutes) Stress Management (20 minutes) Closing the meeting (5 minutes)~2 General Review (5 min) Issue management (70 minutes) Stress management (10 minutes) Closing the meeting (5 minutes)~3 General Review (5 minutes) Problem Management (35 minutes) Take action and be consistent (35 minutes) Stress management (10 minutes) Closing the meeting (5 minutes)~4 General Review (5 minutes) Issue Management (20 minutes) Take action and be persistent (20 minutes) Strengthening Social Support (30 minutes) Stress management (10 minutes) Closing the meeting (5 minutes)~5 General Review (20 minutes) Staying Healthy (30 minutes) Imagining how to help someone (20 minutes) Looking ahead (15 minutes) Closing the de-briefing (5 minutes)"
224071688|NCT02396589|BEHAVIORAL|Home Modifications Group|The standardized components include assessment, identification of five problematic activities (and environmental barriers), identification of three solutions (for each problem), implementation of a solution set selected by the participant, training, and active practice of daily activities in one's own home and community.
224071689|NCT03899987|DRUG|EC Aspirin|Given PO
223473397|NCT07060638|DRUG|Acamprosate|Acamprosate is a propane-1 sulfonic acid with anti-ethanol dependency effects
223473398|NCT07060638|DRUG|Prednisone placebo|Matching placebo
223473399|NCT07060638|DRUG|IL-22 (F-652) Placebo|Matching Placebo
223473400|NCT07060638|BEHAVIORAL|Motivational Interviewing (MI)|MI is an evidence-based counseling style to overcome ambivalence to treatment in AUD patients
223473401|NCT07060638|BEHAVIORAL|Motivational Enhancement Therapy (MET)|MET is an MI-based approach that includes 2-4 behavioral treatment sessions based on the Platform Treatment Manual
223473402|NCT07060638|BEHAVIORAL|Usual Care|defined as a brief intervention with advice not to drink alcohol-containing beverages and referral to a 12-step program
223473403|NCT03863847|PROCEDURE|Neurofeedback|The patients will receive neurofeedback on pain related brain-activity, and through training, learn to control said brain-activity.
223473404|NCT03863847|PROCEDURE|Sham|The patients will receive sham neurofeedback on non-pain related brain-activity, and through training, learn to control said brain-activity.
223473405|NCT04235400|DIAGNOSTIC_TEST|No Dye BreakUp Time|Measurement without dye of the tear meniscus height (TMH) which give an rapid hint on the quantity of tears present on the ocular surface, the measure in real time of the tear osmolarity and, at last, the analysis of the thickness of the tear's layer by interferometry (measurement of the light fringes reflected by the tears when illuminated with polarized light, whereby the complete layer or the lipid layer alone can be evaluated separately depending on the machines used) and of the assessment of the quality of the Meibomian glands (non-contact imaging by infrared illumination).
223473406|NCT04022317|BIOLOGICAL|Biocon Insulin R|Biocon Insulin R is a short-acting human insulin, produced by recombinant deoxyribonucleic acid (rDNA) technology utilizing Pichia pastoris (yeast).
223473407|NCT04022317|BIOLOGICAL|Humulin®R|Humulin® R is a polypeptide hormone structurally identical to human insulin synthesised through recombinant deoxyribonucleic acid (rDNA) technology in a non-pathogenic laboratory strain of Escherichia coli bacteria.
223473408|NCT02100124|BEHAVIORAL|Reproductive Life Planning (RLP)|
223473409|NCT02100124|BEHAVIORAL|Contraceptive Action Planning|
224161046|NCT03889522|DIAGNOSTIC_TEST|Bioelectrical Impedance Analysis|BIA is a radiation-free and clinically accessible measure of body composition \[47, 49\]. An electrode is placed on the youth's extremities and they are asked to sit for 10 minutes. The youth's height and weight is manually inputted and the measure is obtained (approx. 90 seconds to complete). BIA sends a low level of electrical current through the body and measures the impedance to the current based on fat, muscle, bones providing a measure of body composition.
223473410|NCT02100124|BEHAVIORAL|Contraception information|
223473411|NCT07056686|DIAGNOSTIC_TEST|Mammogram|Each patient will undergo a mammogram and echo of the breast used to detect early signs of cancer, such as tumors or calcifications, before symptoms appear.
223473412|NCT04360265|OTHER|No Investigational Product|No investigational product will be administered in this follow-up trial.
223473413|NCT04360265|DRUG|Adjuvant Immunomodulatory (IM) Therapy|The Principal Investigator and/or caregiver, in consultation with the medical monitor, will determine whether to initiate adjuvant IM therapy. Not all participants may receive IM therapy.
223473414|NCT06761339|DIETARY_SUPPLEMENT|Azka Nasal and Throat for Children|Azka Nasal and Throat for Children is provided as a liquid oral preparation, designed with a pleasant flavor to ensure compliance in pediatric patients. The intervention involves administering 7.5 ml per dose three times daily, taken orally 30 minutes before meals, for a duration of 7 days. The supplement is intended to alleviate symptoms of nasal and throat irritation, reduce phlegm, and improve overall respiratory comfort. Azka Nasal and Throat for Children has been widely used in clinical and community settings, with a favorable safety profile and reported effectiveness in pediatric respiratory care.
223473415|NCT06761339|DRUG|Prospan cough Syrup|The active comparator, Prospan Cough Syrup is a plant-based herbal medicinal product containing the active ingredient Hedera helix (ivy leaf extract), standardized to ensure consistent pharmacological efficacy. The syrup is formulated as an oral liquid preparation with a pleasant taste suitable for pediatric and adult use. The intervention involves administering 2.5 ml per dose three times daily, taken orally 30 minutes before meals, for a duration of 7 days.
223473416|NCT07061548|OTHER|No Intervention: Observational Cohort|No intervention
223473417|NCT06758583|DRUG|Dapiglutide 7.5 mg|Single dose administration of 7.5 mg dapiglutide administered s.c. with two drug product concentrations, 10 mg/mL and 25 mg/mL.
223473418|NCT07072221|DRUG|BCL regimen|"Induction therapy period (28 days\*6)~Bendamustine; Specification: 100mg per vial; 90mg/m2 d1-2, ivgtt.; for age≤70 years; 70mg/m2 d1-2, ivgtt.; for age\>70 years;~Chidamide; Specification: 5mg per tablet; 20mg biw for 2 weeks, po.; for age≤70 years; 15mg biw for 2 weeks, po.; for age\>70 years;~Lenalidomide Specification:10mg per tablet; 10mg qd d1-d21, po.; for age≤70 years; 10mg qd d1-d14, po.; for age\>70 years;"
223473419|NCT07072221|PROCEDURE|Cohort 1 (ASCT-eligible)|"Autologous hematopoietic stem cell transplantation~SEAM conditioning~Simustine 250mg/m2 orally, d1;~Etoposide 200mg/m2 intravenous infusion, d2-d5;~Cytarabine 400mg/m2 intravenous infusion, d2-d5;~Metformin 140mg/m2 intravenous infusion, d6;"
223473420|NCT07072221|DRUG|Cohort 2 (ASCT--ineligible)|"Maintenance therapy period (2 years)~Chidamide; Specification: 5mg per tablet; 15mg biw for 2 weeks per 3 weeks, po.;"
223473421|NCT06826313|BIOLOGICAL|VRT106|Intravenous drip administration
223473422|NCT04417062|DRUG|Olaparib|Olaparib is taken by mouth, twice daily through out the 28 day study cycle.
223473423|NCT04417062|DRUG|Ceralasertib|Ceralasertib is taken by mouth, twice daily on days 1-14 of the study cycle.
223473424|NCT06769594|DEVICE|Investigational CT Scan|All pre-contrast testing and administration of supporting medications shall be done according to the hospital's SOC. Images will then be compared with the previously acquired imaging conducted as standard of care. The investigational scan takes between 10-30 minutes.
224071690|NCT03899987|PROCEDURE|Radical Prostatectomy|Undergo radical prostatectomy
224071691|NCT03899987|BIOLOGICAL|Recombinant Interferon Alfa-2b|Given IV
224071692|NCT03899987|DRUG|Rintatolimod|Given IV
224071693|NCT05794828|DRUG|Bupivacaine Injection|Bucivacaine will be administered intramuscularly according to package insert directions after first numbing the area with lidocaine subcutaneously
224161047|NCT03889522|DIAGNOSTIC_TEST|Total Body Dual-energy X-ray Absorptiometry|The DXA total body scan provides measurements of percent body fat, lean and fat free mass throughout the body. Youth lay on a table while the machine moves around them. The process takes about 3 minutes and 20 seconds.
224161048|NCT03889522|DIAGNOSTIC_TEST|Blood draw|Blood will be drawn to assess the following labs: HbA1c, leptin, lipid panel and comprehensive metabolic panel.
223473425|NCT06924502|OTHER|Protective Balm|The test product will be applied in addition to an additional washing product in the test area.
223473426|NCT06828679|OTHER|Acupuncture|Patients will receive 12 weeks of acupuncture with 3 half-hour sessions weekly. Acupoints will include (1) a basic formula of 8 Bo's abdomen acupoints (paretic side, 0.5cm depth vertically) \[66\]; (2) 12 conventional acupoints (bilateral, opposite to paretic side first, 1-4 cm depth vertically) \[67\]; and (3) 3 scalp acupoints (opposite to paretic side, 0.5-cm depth at 15-30 degrees) \[68\]At most 3 additional supplementary acupoints will be included, depending on the clinician's professional judgement. Sterile needles will be used after skin disinfection. Manual rotating manipulation \[69\] will be performed every 10 minutes on the conventional acupoints to achieve De-qi sensation \[70\]. Abdomen and scalp acupoints do not require De-qi. Subjects will be monitored throughout the course of therapy with face-to-face assessments by blinded and trained clinicians after 0, 4, 8, 12 weeks of intervention. Clinical scales will also be recorded at 0 (A0), 8 (A½), and 12 weeks (A1).
223473427|NCT06828679|OTHER|control group|Subjects in this group will receive the typical post-stroke care offered to stroke survivors of Hong Kong. This care emphasizes restoring function and independence through a comprehensive approach. Physical therapy focuses on improving mobility with exercises and training; occupational therapy helps patients relearn essential daily living skills, facilitating a smooth transition back to everyday life. Speech therapy is integral for addressing communication challenges, and psychological support is provided to help patients manage the emotional impact of stroke. All subjects will receive the above care for 8 weeks (≥3 hourly sessions per week). Clinical scales will be recorded at 0 (A0), 4 (A½), and 8 weeks (A1).
223473428|NCT06828679|DEVICE|Robotic Training|For this treatment group, CMC (corticomuscular coherence)-EMG-triggered control will assist wrist extension with hand open and wrist flexion with hand close alternately by mechanical pneumatic support \[60\]. During wrist-hand extension, the pneumatic fingers will assist a hand-open motion with constant inflation till the inner pressure reaches 90kPa; during the wrist-hand flexion, the pneumatic fingers will deflate constantly to assist a hand-close motion. To trigger ENMS assistance, two criteria must be met: (1) the average EMGs of target muscles exceed a pre-defined threshold, and (2) a significant CMC peak value with peak frequency in the beta band is captured. Here, the target muscle groups will be the extensor digitorum and extensor carpi ulnaris (ED-ECU) and flexor digitorum and flexor carpi radialis (FD-FCR), and the EMG and CMC will be evaluated during sustained contraction of these muscles over a 3-sec window.
224161049|NCT01117181|DRUG|Methylphenidate|The target dose is 20 mg per day provided as two 10 mg doses administered orally. Patients will start by taking 10 mg daily (two 5 mg over-encapsulated tablets) for three days, at which time the dose will be increased to 20 mg per day (four 5 mg over-encapsulated tablets). In the event of significant side-effects, the dose will be reduced to a minimum of 10 mg per day. The study drug will be administered for 6 weeks.
224161050|NCT01117181|DRUG|placebo|Patients will start with two capsules of placebo for three days, at which time the dose will be increased to four capsules. The dose may be reduced to a minimum of two capsules per day if there appears to be significant side-effects. Placebo will be administered for 6 weeks.
224161051|NCT01117181|OTHER|Psychosocial intervention|"The psychosocial intervention will consist of three components: a counseling session, the provision of education materials, and 24-hour availability for crises.~The counseling session, in which a trained study clinician will counsel the primary caregiver, lasts approximately 20-30 minutes, and consists of the following elements:~* Review and adjustment of the patient and caregiver supportive care plans~* Emotional support and opportunity to ventilate feelings~* Counseling regarding specific caregiving skills~* Assistance with problem solving of specific issues that the caregiver brings to the sessions~* Answers for questions regarding the educational materials~The educational materials will consist of a copy of the book The 36-Hour Day"
224161052|NCT04078269|BIOLOGICAL|Dendritic cell immunotherapy|Intravenous infusions of MIDRIXNEO-LUNG DCs every 2 weeks, using an intra-patient dose escalation scheme progressing along the following range: 10 x10E6 DCs (minimal dose), 20 x 10E6 DCs, 40 x 10E6 DCs, 80 x 10E6 DCs, 100 x 10E6 DCs (maximal dose), until exhaustion of the batch or occurrence of grade ≥3 toxicity event
224161053|NCT04078269|BIOLOGICAL|Antigen-specific DTH|Intradermal injection of 1 x 10E6 MIDRIXNEO-LUNG DCs at baseline and after completion of all i.v. DC vaccination rounds. This is used for assessment of induction of antigen-specific immune responses as part of in vivo immunomonitoring (delayed-type hypersensitivity cutaneous reaction as test read-out)
224161054|NCT04078269|BIOLOGICAL|Control DTH|Intradermal injection of 1 x 10E6 MIDRIX-CTRL DCs at baseline and after completion of all i.v. DC vaccination rounds. This is used for assessment of background (i.e. non-antigen-specific) reactivity (delayed-type hypersensitivity cutaneous reaction as test read-out)
224161055|NCT00149110|PROCEDURE|Sleep deprivation|3 days with a normal night between
224161056|NCT00149110|PROCEDURE|Light therapy|Daily light therapy for 29 weeks
224161057|NCT00149110|PROCEDURE|Diurnal rhythms|Keeping the day-night cycle constant by use of educational measures
224161058|NCT00149110|BEHAVIORAL|Exercise|Moderate intensity daily exercise for 30 minutes at least
223473429|NCT06828679|DEVICE|Neuromuscular Electrical Stimulation Group|For this treatment group, constant NMES (70V, 40Hz, 0-300µs square wave bursts \[63\]) will be delivered to the ED-ECU and FD-FCR muscles to assist in wrist-hand extension and flexion, respectively. The pulse width of NMES will be individually adjusted to achieve the maximum muscle contraction with the minimum stimulation intensity. The control strategy of CMC-EMG-triggered NMES will be the same as that used in the robot.
223473430|NCT06833333|PROCEDURE|Central venous catheter|Central venous catheter will be introduced to measure central venous pressure
224161059|NCT00149110|DRUG|duloxetine|60 mg daily
224161060|NCT00149110|DRUG|duloxetine|60 mg daily
224161061|NCT00432263|DRUG|Genotropin (PN-180,307) Somatropin|
224161062|NCT00675844|DRUG|Elvucitabine|10 milligrams (mg) elvucitabine daily as part of an ART regimen
224161063|NCT03249701|DEVICE|Transcutaneous Electrical Acupoint Stimulation|The intervention will be administered by electrical acupoint machine, the brand is Great Wall.
224304293|NCT01265433|BIOLOGICAL|Galinpepimut-S + Montanide + GM-CSF|Patients will receive 6 injections over 12 weeks. Treatment will be administered on weeks 0, 2, 4, 6, 8, and 10. All patients will receive Sargramostim (GM-CSF) (70 mcg) injected subcutaneously on days 0 and -2 of each vaccination. Patients may self administer the Sargramostim (GM-CSF) on day -2 if they have been appropriately instructed on SQ injection administration. Patients will be informed of the expected reactions such as irritation at the injection site. Patients will keep a logbook noting the time and placement of the injection. Patients will also receive 1.0 ml of emulsion with Montanide alone or with WT-1 peptides plus Montanide. It will be administered by a nurse (it may not be self administered) subcutaneously to the same anatomical site as the GM-CSF. This site will be marked by the patient or treating healthcare professional by a permanent marker pen.
224304294|NCT01265433|BIOLOGICAL|Montanide + GM-CSF|Patients will receive 6 injections over 12 weeks. Treatment will be administered on weeks 0, 2, 4, 6, 8, and 10. All patients will receive Sargramostim (GM-CSF) (70 mcg) injected subcutaneously on days 0 and -2 of each vaccination. Patients may self administer the Sargramostim (GM-CSF) on day -2 if they have been appropriately instructed on SQ injection administration. Patients will be informed of the expected reactions such as irritation at the injection site. Patients will keep a logbook noting the time and placement of the injection. Patients will also receive 1.0 ml of emulsion with Montanide alone or with WT-1 peptides plus Montanide. It will be administered by a nurse (it may not be self-administered)subcutaneously to the same anatomical site as the GM-CSF. This site will be marked by the patient or treating healthcare professional by a permanent marker pen.
224161064|NCT03249701|DEVICE|Electroacupuncture|The intervention will be administered by electrical acupoint machine, the brand is Great Wall.
224304295|NCT05420870|BEHAVIORAL|exercise|"Six weeks of exercise intervention~To meet weekly 150 min of moderate to vigorous physical activity and twice weekly strength exercise General description of the exercise program~Main goal of the supervised exercise (1 hour per session, twice a week) are three folds. 1) Instruct participants to correctly perform prescribed exercises. 2) Encourage participants to be compliant to exercise program. 3) Participants were encouraged to hand in their exercise diary~Main goal of the home-based exercise is to perform calisthenics exercise daily. Participants were encouraged to perform at least one set of exercise (8-12 different exercises) and stretching (At least 3 days per week, but preferably most of the days) daily~Basic 8 exercises which increase ROM and strength of shoulder, lower back, Hip, Knee and ankle Additional 4 exercise to increase core strength and stability"
223473431|NCT06833333|DIAGNOSTIC_TEST|IVC collapsibility index|In supine position, IVC will be assessed in the anteroposterior plane in the subxiphoid view using two-dimensional mode till an optimal view of IVC entering the right atrium will be obtained. Then, measurement of its collapsibility will be done.
223473432|NCT06502847|OTHER|Exosome profile study|Neonatal serum and maternal exosome profiles will be studied in all groups.
223473433|NCT06173284|DRUG|611|subcutaneous injection
223473434|NCT06173284|DRUG|Matching placebo|subcutaneous injection
223473435|NCT00196599|DRUG|emtricitabine, FTC (drug)|
223473436|NCT00196599|DRUG|didanosine, ddI (drug)|
223473437|NCT00196599|DRUG|efavirenz (drug)|
223473438|NCT00788333|DRUG|BMS-754807|Tablets, Oral, Dose escalation to MTD, then MTD to response/EOT, once daily, Varies - treatment is continued to disease progression or MD/subject/Sponsor decision to stop
223473439|NCT00788333|DRUG|trastuzumab (Herceptin®)|IV solution, IV, 4mg/kg Day 1 loading dose, 2mg/kg once weekly, Varies - treatment is continued to disease progression or MD/subject/Sponsor decision to stop
223473440|NCT00154388|DRUG|Imatinib mesylate|
223473441|NCT00564980|PROCEDURE|Wafer Procedure|A dorsal approach to the distal ulna is used dividing the extensor retinaculum between the 5th and 6th compartments. The ulnar head is exposed through a transverse capsulotomy. Cartilage and bone are resected to result in slight negative ulnar variance based on the preoperative pronated grip view. The ulnar styloid and TFCC attachments are preserved. The dorsal capsule and retinaculum are repaired in separate layers.
223473442|NCT00564980|PROCEDURE|Ulnar shortening osteotomy|A longitudinal incision of approximately 8 cm is made at the distal third of the ulna along the ulnar border of the forearm. The interval between the flexor carpi ulnaris is used. The ulna is exposed at its distal third preserving the periosteum. Care is taken to protect the sensory branches of the lunar nerve. An oblique osteotomy is performed using a reciprocating saw, removing enough bone to result is slight negative ulnar variance. Fixation and compression at the osteotomy site is achieved using a 5 or 6 hole titanium LC-DCP plate.
223473443|NCT00964704|DRUG|bevacizumab [Avastin]|15mg/kg iv every 3 weeks
223473444|NCT00964704|DRUG|capecitabine [Xeloda]|added at time of disease-progression, 1000mg/m2 bid po days 1-14 of every 3-week cycle
223473445|NCT00964704|DRUG|docetaxel|background therapy at time of disease progression, 100mg/m2 iv every 3 weeks
224161065|NCT03249701|DEVICE|sham Transcutaneous Electrical Acupoint Stimulation|The intervention will be administered by transcutaneous electrical acupoint machine, even no truly actualized.
224161066|NCT04264494|PROCEDURE|PRP intra articular injection|Fifty RA patients were injected intra-articularly with 3 doses of PRP at 4 weeks intervals for the joints with only tenderness (arthralgia without swelling or effusion) and revaluated at 3 and 6 months post the last injection regarding the same evaluating tools.
223473446|NCT00964704|DRUG|trastuzumab [Herceptin]|8mg/kg iv on day 1 of the first 3-week cycle, followed by 6mg/kg every 3 weeks
223473447|NCT01402856|OTHER|Education|An educational program targeting HS students on the risks of distracted driving that was 60-min long \& utilized: a 5-10 min DVD on a teenager's real-life experience of the devastating effects of distracted driving, other videos placing the viewer in the driver's seat, power point presentations of state and national statistics related to seat belt usage, mortality, and substance use, overview of state laws, demonstrations of the physics of an accident, \& interactive games simulating distracted driving.
223473448|NCT04832217|OTHER|Pyrenees´ Beef diet|24 participants were randomly assigned to a Pyrenees' beef diet, 3 serving per week during of 8 weeks.
223473449|NCT04375124|BIOLOGICAL|Biological/Vaccine: Angiotensin peptide (1-7) derived plasma|angiotensin peptide (1-7) derived plasma will be given to COVID-19 positive participants
224161067|NCT04264494|PROCEDURE|NACL intra articular injection|and 50 patients who serve as a control and injected intra-articularly with 3 doses of placebo (NaCl saline) at 4 weeks intervals for the joints with only tenderness (arthralgia without swelling or effusion) and revaluated at 3 and 6months post last injection regarding the same evaluating tools.
223473450|NCT04364490|DEVICE|Copernicus noVF|Advanced gait training sessions by the computerized BWS system, named Copernicus®, without visual feedback.
223473451|NCT04364490|DEVICE|Copernicis VF-Plus|Advanced gait training session with the addition of visual feedback ensuring a real-time interactive control of locomotor performance.
223473452|NCT04364490|OTHER|Control group|Usual care
223473453|NCT00480116|BIOLOGICAL|Adjuvanted Hepatitis B vaccine Lot 1|20 µg, IM, month 0 and 1
223473454|NCT00480116|BIOLOGICAL|Adjuvanted Hepatitis B vaccine Lot 2|20µg, IM, month 0 and 1
223580849|NCT01789138|BEHAVIORAL|Situated Optimal Adherence Intervention|Situated Optimal Adherence Intervention consists of 3 individual sessions (during consecutive medication pick-up visits to the clinic) -- patient-centered, non-judgmental, Motivational Interviewing- and theory-based, semi-structured, brief, candid conversations with a trained clinical care nurse using the Next Step Counseling approach. The intervention targets: accurate information about ART (mechanisms of HIV and antiretrovirals) and the development of mental imagery around it; promotion of perceived sense of ease and efficacy in working the ART regimen into the context of one's daily life and circumstances that may challenge drug use persistence; identification and refinement of skills that promote ease of adhering to one's ART regimen across the diverse and challenging contexts.
224161068|NCT01440504|OTHER|culture ex vivo with exposure to different therapeutic agents alone or in combination.|When tumor resection, tumor specimens of ovarian cancer will be made towards a culture ex vivo with exposure to different therapeutic agents alone or in combination.
223580850|NCT02949388|DRUG|Placebo|Two capsules (both containing Placebo enclosed) taken twice a day and approximately 12 hours apart
223580851|NCT02949388|DRUG|400 mg (200 mg BID)|Two capsules (both containing two 50mg tablets enclosed) taken twice a day and approximately 12 hours apart
224161069|NCT02276794|OTHER|Thrust Manipulation|After positioning patients in right side-lying, a rotational TM technique will be addressed at the L4-L5 lumbar segments. The treating therapist will have up to two attempts to apply the TM.
224161070|NCT02276794|OTHER|Non-thrust manipulation (NTM)|A grade III rotational non-thrust manipulation will be addressed at the L4-L5 lumbar segments. Thirty oscilations will be performed.
224161071|NCT00883649|DIETARY_SUPPLEMENT|Hydroeye|2 Capsules BID
224161072|NCT00883649|OTHER|Inactive Capsule|2 Capsules BID
223473455|NCT00480116|BIOLOGICAL|Adjuvanted Hep B vaccine Lot 3|20µg, IM, month 0 and 1
223473456|NCT00190034|DRUG|N-Acetylcysteine 600mg/tab|
223473457|NCT03813108|BIOLOGICAL|CPS-immunization|Subjects will be immunized 3 times by exposure to the bites of P. falciparum NF135.C10 infected mosquitoes while taking mefloquine prophylaxis.
223473458|NCT03813108|BIOLOGICAL|malaria challenge infection, P. falciparum NF135.C10|Subjects will receive bites from 5 Anopheles mosquitoes infected with Plasmodium falciparum NF135.C10 sporozoites.
223473459|NCT03813108|BIOLOGICAL|malaria challenge infection, P. falciparum NF54|Subjects will receive bites from 5 Anopheles mosquitoes infected with Plasmodium falciparum NF54 sporozoites.
223473460|NCT03813108|BIOLOGICAL|CPS-immunization (A/L)|Subjects will be immunized 3 times by exposure to the bites of P. falciparum NF135.C10 infected mosquitoes and receive presumptive treatment with artemether/lumefantrine initiated on day 7 after each immunization.
223473461|NCT03813108|DRUG|Atovaquone / Proguanil Oral Tablet [Malarone]|All participants will be treated with atovaquone/proguanil (1000/400 mg (= 4 tablets) 1×/day during 3 consecutive days) when they develop a malaria infection or on day 28 after malaria challenge infection.
223580852|NCT02949388|DRUG|300 mg (150 mg BID)|Two capsules (one containing 50mg tablet and one containing two 50 mg tablets) taken twice a day and approximately 12 hours apart
224161073|NCT01518309|DRUG|pimavanserin tartrate (ACP-103)|Tablets taken once daily by mouth at 20, 40, or 60 mg doses
224161074|NCT00878813|PROCEDURE|Sampling of 15ml blood|On admission, 2 x 7.5ml blood tubes will be drawn during the first routine blood sampling
224161075|NCT00878813|PROCEDURE|Blood-Sampling|On day 1 after intra-arterial thrombolysis, 2 x 7.5ml blood tubes on the following routine blood-sampling will be drawn.
224161076|NCT02277236|RADIATION|DXA scanning|Exposure: Participants will undergo DXA scanning in the supine position per manufacturer guidelines to estimate absolute and percentage of total lean body mass (LBM) and body fat (BF).
224161077|NCT02277236|RADIATION|CT imaging|Exposure: Estimates of intramuscular adipose tissue (IMAT) will be obtained with CT imaging. This measure will be restricted to a single leg (dominant side) in the mid-femur region, using a single 10mm axial image slice (120 kVp, 200 to 250 mA).
224161078|NCT00863317|DRUG|montelukast sodium|4mg granules daily for 14 days
224161079|NCT00863317|OTHER|sucrose|table sugar as placebo daily for 14 days
224161080|NCT06188728|DIETARY_SUPPLEMENT|effect of 10 gm psyllium husk fiber twice a day, 30 minutes before breakfast and dinner|comparing the effect of psyllium husk fiber and lifestyle modification alone with the combined effect of psyllium husk fiber on metabolic health of centrally obese school teachers
224161081|NCT06188728|BEHAVIORAL|Effect of life style modification (Diet, Behavior and physical activity)|To assess the effect of life style modification (Diet, Behavior and physical activity) on centrally obese school teachers
223473462|NCT03344471|OTHER|Passation of questionnaires|Specific questionnaires (Perinatal PTSD Questionnaire evaluating the Post-Traumatic Stress Disorder) and (NEO-FFI evaluating personality)
223473463|NCT04685954|DEVICE|Filtek Bulk-Fill Posterior|Bulk-fill restorative composite
223473464|NCT04685954|DEVICE|Filtek Ultimate Universal|Incremental restorative composite
224161082|NCT06188728|COMBINATION_PRODUCT|Combined effect of 10 gm Psyllium husk fiber and lifestyle modification|To evaluate the combined effect of 10 gm psyllium husk fiber in gel form, 30 minutes before breakfast and dinner along with dietary, behavioral and physical activity modification on centrally obese school teachers
223473465|NCT00870727|DRUG|Aripiprazole oral product|Minimum dose of 2 mg per day to a maximum dose of 20 mg per day over 8-weeks of treatment.
223473466|NCT00870727|DRUG|Placebo oral capsule|Placebo will be identical in size and appearance to study drug.
223473467|NCT00879853|BEHAVIORAL|Interpersonal Therapy|
223473468|NCT04038827|DIAGNOSTIC_TEST|D-CEC counting|By means of preliminary bulk separation step with the CellSearch system, single CEC will be sorted
223473469|NCT06053229|DEVICE|percussive massage|30 minutes of percussive massage will be administered twice per day during the 10 day immobilization period using a percussive massage device
223473470|NCT06053229|COMBINATION_PRODUCT|Leg Immobilization|All subjects will have their left leg immobilized using an immobilization brace for 10 days
223473471|NCT06167057|DRUG|Mitomycin/Gemcitabine|UTUC treatment
223473472|NCT06167057|DRUG|Saline|UTUC treatment
223473473|NCT03337412|OTHER|Adapted physical activity|"Patients will be asked to complete questionnaires about their physical activity, diet and quality of life prior to hospital care.For an evaluation of the chronological evolution of their physical activity, they will be invited to complete the Physical Activity Questionnaire GPAQ 2.0 every 2 months, for the duration of the Research.At 6 months during a telephone contact and at 12 months, during a consultation, the food and quality of life questionnaires will also have to be informed. The evolution of weight, body mass index and metabolic biological factors will also be collected.~Employees will benefit from a life-health awareness program, accompanied by an APA educator, they are offered the opportunity to participate in physical activity workshops on a regular basis (12 workshops minimum over 6 months), adapted to their abilities and personalized.They will be invited to fill, from their home or on the website Fleury Michon, the same type of questionnaire"
223473474|NCT04270773|BIOLOGICAL|Human Papillomavirus 9-valent Vaccine, Recombinant|Vaccine administrated
223473475|NCT01020422|PROCEDURE|Reduction mammaplasty|Sexual function of patients undergoing reduction mammaplasty will be assessed by the Female Sexual Function Index (FSFI) preoperatively and 3 and 6 months postoperatively.
223473476|NCT00869414|DRUG|Evening only administration of insulin glargine|Evening only administration of insulin glargine, with normal saline injection administered in the morning.
223473477|NCT00869414|DRUG|Morning only administration of insulin glargine|Morning only administration of insulin glargine, with normal saline injection administered at night.
223473478|NCT00869414|DRUG|split dose insulin glargine|split dose of insulin glargine, half administered in the morning, half administered in evening
223473479|NCT05027854|OTHER|TMS or tES|Transcranial magnetic or electric stimulation
223473480|NCT05027854|OTHER|sham TMS or tES|Sham transcranial magnetic or electric stimulation
223473481|NCT00327158|PROCEDURE|Transesophageal transducer|One time use of reamer during surgery
223473482|NCT00327158|PROCEDURE|echocardiography|takes photos of right atrium during the reaming processes
223473483|NCT04755010|DEVICE|Linq II implantable cardiac monitor|Implantation of Linq II implantable cardiac monitor
223473484|NCT04600869|OTHER|Naturalistic Decision-Making Model-based Oncofertility Care Education|We designed the education program according to Klein's NDM model, which explored the reasoning mechanism behind decision-making (Klein, 1993). It depends on the on-the-job training date in each unit. The education program consisted of the following: (1) Information accumulation: explanations of common cancer therapies related to subsequent infertility, psychological and mental change in cancer survivors with infertility, the necessity and method of early determination of fertility intention, and type of fertility preservation. (2) Sense-making: situational case sharing, emphasis on the guidance interaction between experienced and novice nurses to understand the patient's situation. (3) Decision-making: how to provide support, how to correspond, and attitudes toward people with strong fertility intention.
223473485|NCT04149340|DRUG|Cataract surgery|Patient's satisfaction and surgeon's satisfaction was assessed by four Lickert's scales, ranging from one to four. hemodynamic parameters before incision, 10 min post-incision and at the end of the surgery
223473486|NCT03928366|DRUG|Propofol|sedation
223580853|NCT03658070|DRUG|XY0206|Dosage form:Tablet;Single dose treatment:Take the drug once on day 1,each time 1 tablet. Multiple dose phase:Take the medicine once a day,1 tablet at a time.4 weeks of continuous medication is one course of treatment. After the first course of treatment, the subjects can continue to receive the experimental drug treatment until they meet the criteria for stopping treatment or determine the duration and interval of treatment according to the accumulated condition after multiple dose.
223580854|NCT02642146|DRUG|Calcium Channel Blockers|
223580855|NCT02642146|DRUG|Phosphodiesterase Inhibitors|
223580856|NCT02642146|DRUG|Endothelin receptor blocker|
223580857|NCT02642146|DRUG|Prostanoids|
223473487|NCT03928366|DRUG|Remifentanil|remifentanil
223473488|NCT06285500|OTHER|Patient-specific treatments|Treatment will be decided specifically for the patient based on biomarker test results.
223473489|NCT01384877|DRUG|Lidocaine|10mg/kg by subcutaneous infusion over 5.5 hours
223473490|NCT01384877|DRUG|Placebo (D5W)|Same volume as for lidocaine infusion, identical clear liquid in appearance, given in same device over same time period (5.5 hrs)
223473491|NCT03938571|PROCEDURE|Duodenal Switch|
223473492|NCT05412277|OTHER|VIA Disc Nucleus Pulposus Allograft|A single dose, intradiscal injection of 100mg of VIA Disc NP mixed with 2ml sterile saline administered to the affected 1 to 3 levels, L1-S1.
223473493|NCT02388451|DEVICE|Feuerstein Program|The IE activity is administered by instructors in groups of 10 to 15 participants. The intervention comprises 30 twice weekly meetings of 90 minutes duration per group.
223580858|NCT02642146|DRUG|Other vasodilator|
223473494|NCT03630393|OTHER|Pneumoperitoneum Pressure 6 mmHg|A pneumoperitoneum insufflation pressure of 6 mmHg will be used during robotic assisted laparoscopic prostatectomy (RALP).
223473495|NCT03630393|OTHER|Pneumoperitoneum Pressure 15 mmHg|A pneumoperitoneum insufflation pressure of 15 mmHg will be used during robotic assisted laparoscopic prostatectomy (RALP).
223580859|NCT00931801|DRUG|atazanavir/raltegravir|Atazanavir/r 300/100mg once daily plus raltegravir 400mg twice daily
223580860|NCT00931801|DRUG|atazanavir/raltegravir|Atazanavir 300mg twice daily plus raltegravir 400mg twice daily
223580861|NCT00931801|DRUG|atazanavir/tenofovir/emtricitabine|Continue baseline regimen of atazanavir/r 300/100mg once daily plus tenofovir and emtricitabine
223580862|NCT03462186|OTHER|Healthfinder invitation|Invitation to use healthfinder (healthfinder.gov/myhealthfinder
223580863|NCT02506686|DRUG|Meropenem|Meropenem i.v.
223580864|NCT02822300|DRUG|Coppertone (BAY987517)|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation: SR15-74\_R84-086)
223580865|NCT02002468|OTHER|Test result sent by letter|
224161083|NCT06188728|OTHER|Control|No intervention
224304296|NCT03361475|BEHAVIORAL|SME App|"The features in the App could be used in the future by linking with some platforms / existing services so that more SME messages can be sent to the students for sharing. One school workshop will be held to promote SME and introduce the function of SME App for students to download and use immediately to connect family members.~SME App promotes SME via:~* Express gratitude to family members (sharing)~* Deliver positive messages regularly (mind)~* Record physical and other joyful activities (enjoyment)~* Increase knowledge and understanding of adolescent mental health problem (in particular the anxiety disorders)"
224304297|NCT02430285|PROCEDURE|Endoscopic Ultrasound|Endoscopic Ultrasound
224304298|NCT02430285|DEVICE|Olympus 180 series echoendoscope|
224304299|NCT04832893|DIAGNOSTIC_TEST|steady intensity aerobic test of 30 minutes long|the use of different type of masks during an aerobic exercise
224304300|NCT05174494|DIAGNOSTIC_TEST|Evaluation of serum CRP and NT-proBNP|All patients were evaluated to 6-months post-treatment reduction of serum CRP and NT-proBNP
224304301|NCT00151138|DRUG|Atenolol (drug), Lisinopril (drug)|
224304302|NCT01735955|DRUG|Nilotinib|Patients who were on nilotinib treatment in a Novartis-sponsored study (parent study) and were benefiting from nilotinib treatment met the criteria for enrolment into the CAMN107A2409 study and to receive continued nilotinib treatment. The starting dose of nilotinib in the CAMN107A2409 study should have been the same as the last dose administered in the parent study. After the starting dose, the dose of nilotinib was based on the investigator's judgement. The dose of nilotinib should have been ≤ 800 mg/day for adult patients, 230mg/m2 body surface area (BSA) and ≤ 800 mg/day for pediatric patients.
224304303|NCT04896814|PROCEDURE|Transcutaneous tibial nerve stimulation|The participant will be placed in the supine position with the soles of the feet together and the knees flexed and abducted at 90º. Two adhesive electrodes will be used for each leg. First one: 32 mm of diameter that will be placed in the posterior tibial nerve, that is, 4-5 cm cranial to the internal malleolus, between the posterior edge of the medial border of the tibia and the soleus tendon. Second one: 50x50 mm to be placed in the ipsilateral calcaneus. The electrodes will be connected to the NeuroTracTM PelviTone stimulation device. The stimulation range will be selected according to the tolerable pain limit for the patient, between 0.5 and 20 mA (adjustable in 1 mA levels).The intensity elevation will be allowed each time the patient perceives the fading of the previous sensation due to accommodation. Under no circumstances should the stimulation cause a painful feeling.
224304304|NCT04896814|PROCEDURE|Placebo|The participant will be placed in the same position. Two 50 x 50 mm adhesive electrodes will be placed on the external face of the thigh, on a single leg. This area is outside the territory of the posterior tibial nerve. A discontinuous current at 2Hz frequency and a pulsed frequency of 50 µs, with 2 seconds of work and 10 seconds of pause will be applied. This simulated current being considered to be insufficient to achieve therapeutic effects in the body and to be outside of the usual ranges described in electrotherapy manuals regarding pain management. The intensity will be selected according to the paint limit level of the patient, between 0.5 and 60 mA (adjustable in 0.1 mA levels), where a low or moderate sensation of the patient will be sought, without muscle contraction.
224304305|NCT00357123|DRUG|Rosuvastatin|20 mg 10 days daily since abdominal sepsis diagnosis
224304306|NCT02276014|DIETARY_SUPPLEMENT|Beta-carotene|
224304307|NCT02971735|OTHER|mobile technology of e-learning (M-TEL)|UME students learn the Top 10 emergent ORL-HNS disorders using the M-TEL including the IM module or the PPS module.
223473496|NCT00618293|DRUG|Haemate HS|intravenous infusion of Haemate (dosage dependent on body weight)
223580866|NCT02002468|OTHER|Test result conveyed by general practitioners|
224161084|NCT06379880|DEVICE|CONTINUUM+ CONNECT remote monitoring|"CONTINUUM+ CONNECT is a web platform, accessible via the internet, which contains the digital medical device (DMN) Continuum+ alert module. This is a medical software intended for the interpretation of clinical constants, symptoms, adverse events and pain, generating alerts with a view to improving the monitoring of patients undergoing anticancer treatment. The Continuum+ Alert Module version 1.0.0 dated 30 April 2021 is CE-marked and will be used in accordance with the manufacturer's instructions for use by patients in the experimental group."
224161085|NCT02253394|DRUG|Ambrisentan plus Spironolactone|Cardiopulmonary fitness
224304308|NCT03194841|OTHER|Heart failure application|A mobile phone application that allowed for input of physiologic data, qualitative question input and education retrieval along with SMS use.
224304309|NCT03317834|DEVICE|Navio ™ Robotic-assisted Surgical System|Total Knee Replacement
224304310|NCT05084716|BEHAVIORAL|Enhanced PrEP provision|At the intervention site during healthcare facility outreach events, all community members will be offered the opportunity to attend intervention workshops where they can learn basic facts about PrEP and be taught skills about how to advocate for PrEP in their community. Check-in reminder calls will be conducted systematically with PrEP users. Healthcare facility staff will encourage PrEP initiators to select an adherence supporter.
224304311|NCT04271579|PROCEDURE|Salvage Lymphnode dissection|"A salvage lymphnode dissection is performed in all study patients (both arms)using standard surgical techniques (openly or DaVinci).In patients who were randomized to the bilateral pelvic lymphnode dissection group, a salvage lymphadenectomy was also performed on the opposite side with resection of the corresponding fields that were removed on the PSMA-PET positive side (th Blinding must be guaranteed during pathological assessment)"
224304312|NCT02890654|OTHER|First time measure|"* Initial Interview~* Initial Survey,~* Quality of life Scale~* Kinesitherapy Review~* Anxiety Scale"
223473497|NCT00618293|OTHER|NaCl-solution|intravenous infusion of 0.9%NaCl-Solution
223473498|NCT00712452|OTHER|Biology and ultrasonography after chemotherapy|Study of markers of ovarian reserve: Estradiol, LH, FSH and progesterone levels and ultrasonographic antral follicle count (no made in current practice)
223473499|NCT00712452|OTHER|Biology and ultrasonography after chemotherapy|Study of markers of ovarian reserve: Estradiol, LH, FSH and progesterone levels and ultrasonographic antral follicle count (no made in current practice)
223580867|NCT03747900|DRUG|Botulinum Toxin Type A|200 U Botulinum toxin type A injection in the spastic biceps brachii muscle.
224161086|NCT02253394|DRUG|Ambrisentan plus Placebo|Placebo is a sugar pill manufactured to resemble spironolactone 50 mg Cardiopulmonary fitness
224304313|NCT02890654|OTHER|Second time measure|"* Kinesitherapy review~* Second survey including numeric scale of pain~* Anxiety scale~* Scoliosis Research Society 22 quality of life scale"
223473500|NCT00712452|OTHER|Biology and ultrasonography after chemotherapy|Study of markers of ovarian reserve: Estradiol, LH, FSH and progesterone levels and ultrasonographic antral follicle count (no made in current practice)
224161087|NCT02485067|DRUG|THVD-201|Combination of Tolterodine 2mg and Pilocarpine 9mg
223473501|NCT00408499|DRUG|cetuximab|Cetuximab will be administered intravenously weekly at the maximum tolerated dose (determined in Phase I portion of the study) on a 28 day cycle. Participants will be in this study for at least 2 cycles (8 weeks). If the evaluations show that this treatment has been effective against the participant's cancer, he/she will continue the therapy.
223473502|NCT00408499|DRUG|erlotinib|Erlotinib will be taken by mouth daily on a 28 day cycle. It is in tablet form. The dose will be determined in Phase I portion of the study. Participants will be in this study for at least 2 cycles (8 weeks). If the evaluations show that this treatment has been effective against the participant's cancer, he/she will continue the therapy.
223580868|NCT03747900|COMBINATION_PRODUCT|Botulinum Toxin Type A and dry needling.|Dry needling for 4 times in total in the spastic biceps brachii muscle after the Botulinum toxin type A injection.
223473503|NCT00039403|DRUG|7-hydroxystaurosporine|Given IV
223473504|NCT00039403|DRUG|gemcitabine hydrochloride|Given IV
223580869|NCT03990207|DEVICE|PowerSpiral Enteroscopy System|Motorized spiral enteroscopy system
223580870|NCT00494377|DRUG|duloxetine|
223580871|NCT01390324|DRUG|Fixed-dose combination of naratriptan+naproxen|Tablets containing naratriptan 2,5 mg + naproxen 500 mg
224161088|NCT02485067|DRUG|Placebo(For THVD-201)|
224161089|NCT02485067|DRUG|Detrusitol 2mg tablet|Tolterodine 2mg
224161090|NCT02485067|DRUG|Placebo(For Detrusitol 2mg tablet)|
223473505|NCT00039403|OTHER|pharmacological study|Correlative studies
223580872|NCT01390324|DRUG|Naratriptan|Tablets containing naratriptan 2,5 mg
223580873|NCT01390324|DRUG|Naproxen|Tablets containing naproxen 500 mg
223580874|NCT00933244|DIETARY_SUPPLEMENT|High Dose Vitamin D3|Yellow gel-cap vitamin D3 at 50,000 International Units daily for 15 days then two times a month for 350 days. Daily white placebo pills.
224069531|NCT06208020|OTHER|Functional near-infrared spectroscopy (fNIRS) detection|fNIRS( NirScan Danyang Huichuang Medical Equipment Co. Ltd., China) will be used to detect changes in HbO and HbR during rest and voluntary swallowing. The swallowing procedure will be used consisted of three phases of manipulations: 30-s resting state periods, 30-s swallowing periods and 30-s resting state periods. A pre-collection will be conducted before the formal collection so that the subjects could understand the test process. After the pre-collection, the subjects will take a rest for 5 minutes before the formal collection.
224069532|NCT03185390|PROCEDURE|ERCP guided biopsy or brush cytology|ERCP guided biopsy or brush cytology
224069533|NCT04671849|DRUG|SIM1803-1A|SIM1803-1A will be administered orally as tablets at a given dose once daily in continuing 21-days cycles.
224069534|NCT05337254|DRUG|Dihydroergotamine|Dihydroergotamine intranasal powder
224069535|NCT05337254|DRUG|Dihydroergotamine|Dihydroergotamine intramuscular injection
224069536|NCT05337254|DRUG|Dihydroergotamine|Dihydroergotamine intranasal spray
224161091|NCT05363618|DIETARY_SUPPLEMENT|Panosyl-isomaltooligosaccharides (PIMO) 1g (1.4 ml)|Active study product
223473506|NCT00039403|OTHER|laboratory biomarker analysis|Correlative studies
224069537|NCT02368717|DRUG|Mesalazine Enema|
224069538|NCT02368717|DRUG|Placebo Enema|
224069539|NCT01659645|DRUG|FACBC|Drug FACBC will be given intravenously (IV) over 2 minutes prior to performing the PET scan
223473507|NCT00435071|PROCEDURE|Carpal Tunnel Release Surgery|Patient will have large incision size during carpal tunnel release surgery.
223473508|NCT00435071|PROCEDURE|Carpal tunnel release surgery|Patient will have a small incision size during carpal tunnel release surgery.
223473509|NCT01077492|OTHER|Virtual Bronchoscopy Navigation|Use of dedicated virtual bronchoscopy navigation software using 4D CT-PET scan spacial data.
223473510|NCT00524433|DRUG|tezosentan|tezosentan delivered i.v. at 20 mL/h (5 mg/h) for 30 min followed by 4 mL/h (1 mg/h) for 23.5 to 71.5 h (24 to 72 h in total)
223473511|NCT00524433|DRUG|placebo|
223473512|NCT01586195|DRUG|Vemurafenib|Vemurafenib 960 mg BID
223473513|NCT02273401|DRUG|BI 11054 CL|
223580875|NCT00933244|DIETARY_SUPPLEMENT|Low Dose Vitamin D3|White gel-cap vitamin D3 at 800 International Units to take orally, daily for 365 days. Intermittent yellow placebo pills.
223580876|NCT00933244|DIETARY_SUPPLEMENT|Placebo|Yellow gel-cap placebo pills to take orally, daily for 15 days then two times a month for 350 days. White gel-cap placebo pills once daily for 365 days.
223580877|NCT03270267|OTHER|Questionnaires|
223580878|NCT05857449|DRUG|LPM3480392|Intravenous infusion
223580879|NCT01522144|BEHAVIORAL|Computerized Decision support|Using a clustered randomized method, computerized decision support, embedded in the electronic health record, was offered to selected primary care practices and outcomes of asthma care were compared to those practices without the computerized decision support.
223580880|NCT00514228|DRUG|sunitinib malate|"* Starting dose: 37.5 mg 3 x 12.5 mg capsule~* Reduced dose: 25 mg 2 x 12.5 mg capsule"
223580881|NCT00817648|DRUG|Quetiapine|Quetiapine fumarate, 25mg/200 mg, the dose titration is carried in week 1. flexible doses(600-750 mg/d) from week 2 to week 6. If a patient is intolerant, the doses can be adjusted as judged by investigator.
223580882|NCT00817648|DRUG|risperidone|risperidone, 1mg/tablet, the dose titration is carried in week 1. flexible doses(3-6 mg/d) from week 2 to week 6. If a patient is intolerant, the doses can be adjusted as judged by investigator.
223580883|NCT01826266|DRUG|PER977, Placebo|
223580884|NCT02266875|DRUG|hypertonic saline|
223580885|NCT02266875|DRUG|standard saline|
224069540|NCT04813471|DRUG|Endothelial Protocol|Endothelial Protocol
224069541|NCT05779982|PROCEDURE|Sentinel lymph node biopsy followed by axillary lymph node dissection|This is a retrospective study to determine the feasibility of sentinel lymph node biopsy (SLNB) after neoadjuvant systemic therapy (NAST) according to response to NAST and breast cancer subtypes. All patients received SLNB followed by axillary lymph node dissection after NAST.
224069542|NCT00963274|DRUG|Bortezomib|Starting dose: 1.3 mg/sq m
224069543|NCT00963274|DRUG|Romidepsin|Starting dose: 8 mg/sq m
224161092|NCT05363618|OTHER|Placebo 1.4 ml|Placebo
224304314|NCT02890654|OTHER|Third time measure|"* Scoliosis Research Society 22 quality of life Scale~* Anxiety scale~* Numeric scale of pain~* Kinesitherapy review"
224304315|NCT02476240|BEHAVIORAL|Parkinson's disease Sensory Attention Focused Exercise|The first half of the exercise class will include walking exercises that include large magnitude and coordinated movements. All walking will be performed slowly. Walking exercises will be followed by balance, stretching, and coordination exercises while sitting in, or standing near, standard office chairs, utilizing latex Thera-bands®. To ensure that balance and coordination are constantly challenged throughout the intervention, the exercise program progresses each week, increasing in difficulty. Depending on the task, the first set of each exercise will be performed with 'eyes-open' to familiarize participants with the task, and subsequent sets will be performed with 'eyes-closed'. If there is only one set for a specific exercise, the first half of the repetitions will be performed with 'eyes-open' and the second half with 'eyes-closed'.
224304316|NCT01930565|OTHER|LFCO application|Application of LFCO (Lactobacillus fermented Chamaecypris obtusa ) containing creams to one randomly selected face of patients to monitor its effectiveness and safety of acne treatments.
223473514|NCT02273401|DRUG|Placebo|
223473515|NCT00997334|DRUG|Erlotinib|
223473516|NCT00702780|DRUG|escitalopram|5 mg/day for 2 weeks, 10 mg/day for 2 weeks and 20 mg/day for 48 weeks (maintaining donepezil at the previous stable dose during the whole trial period)
223580886|NCT06020846|OTHER|Soleus Pushup Exercise|"Patient will be seated on a chair, his legs at 90 degrees to the floor, keep the toes, and feet flat on the ground, and move his heels up and down continuously.~4 sets of 15 minutes each,1hour total intervention time"
223580887|NCT06020846|OTHER|treadmill walk group 2|The patient will do treadmill walk at normal walking speed, 4 sets of treadmill walk for 15 minutes each, 1hour total intervention time
223473517|NCT00702780|DRUG|placebo|5mg/day for 2 weeks, 10mg/day for 2 weeks and 20mg/day for 48 weeks (maintaining donepezil at the previous stable dose during the whole trial period)
223473518|NCT02828865|DEVICE|Irreversible Electroporation (IRE) System|
223473519|NCT01694693|DRUG|Orencia|No Intervention
223473520|NCT05883865|DRUG|Fenofibrate|Fenofibrate is orally administrated daily with food for at least 1 week during pregnancy
223473521|NCT05588258|OTHER|Participants were given the 10% urea cream purchased in pharmacy or supermarket as appropriate after randomisation and their foot skin quality was assessed by validated questionnaire.|Participants agreed to the interventions after allocation to each arm according to randomisation and after signing an informed consent form. The creams tested in this study provided to participants are authorised for sale within the European Union but are not considered drugs or medical devices. The main purpose of the interventions was based on the care and assessment of the quality of the skin of the participants' feet.
223473522|NCT04785417|OTHER|touch screen tablet|traditional occupational therapy in addition to games on tablet
223580888|NCT04072107|DRUG|sintilimab|Investigate whether capecitabine would be able to improve prognosis in patients at high risk groups
223580889|NCT04072107|DRUG|Capecitabine|Investigate whether capecitabine would be able to improve prognosis in patients at intermediate risk groups
223580890|NCT05778773|PROCEDURE|TAVR (Transcatheter Aortic Valve Replacement)|Percutaneous aortic valve replacement, also known as percutaneous aortic valve implantation, transcatheter aortic valve implantation or transcatheter aortic valve replacement, is the replacement of the aortic valve of the heart through the blood vessels.
223580891|NCT05778773|PROCEDURE|AVR (Aortic Valve Replacement)|Aortic valve replacement is a procedure whereby the failing aortic valve of a patient's heart is replaced with an artificial heart valve through an open-heart surgery.
223580892|NCT04132635|DEVICE|artificial dermis|artificial dermis will be used after fully debridement of the wound
223580893|NCT04132635|OTHER|growth factor|growth factor
223580894|NCT05510661|DEVICE|Export Catheter|Manual thrombus aspiration with the use of export catheter during primary PCI
223580895|NCT05510661|DEVICE|Balloon catheter|Predilatation with balloon catheter
224069544|NCT03687216|PROCEDURE|HVPG-guided therapy|"The baseline HVPG measurement is performed. According to the result, patients with an HVPG over 20 mmHg will be receive transjugular intrahepatic portocaval shunt (TIPS) .~Patients with an HVPG below 20 mmHg will be treated by endoscopic variceal ligation (EVL) plus nonselective beta blocker (NSBB) propranolol until treatment fails."
224069545|NCT03687216|PROCEDURE|Routing Therapy|Without HVPG measurement, patients receive endoscopic variceal ligation (EVL) plus nonselective beta blocker (NSBB) propranolol.
224069546|NCT03716869|OTHER|Universal Screening Arm|"Students with PHQ-9 score \>10, corresponding to a positive MDD screen, will proceed through the same SAP triage process as students referred by traditional means.~SAP triage will determine MDD identification. As SAP triage is not diagnostic, MDD identification is based on SAP recommendations for MDD related school or community services.~Treatment engagement will be tracked per current SAP processes.~To immediately identify and address suicidal intent, the survey will flag a positive response to PHQ-9 question 9 in real time. A suicidal student would proceed directly to management through the school crisis plan.~Students in the intervention arm will also be tracked for behavior concerning for MDD at any point in the school year prompting SAP triage referral."
224069547|NCT02363686|PROCEDURE|FEES|A thin, flexible endoscope designed for assessment of laryngeal structures is passed through the nose to the oropharynx, visualizing the laryngeal structures, and the base of tongue and the pharynx. If needed 4% topical lidocaine and/or oxymetazoline (Afrin) will be administered. Swallowing will then be evaluated directly with six food boluses of 5 ml each. All patients will be allowed to swallow spontaneously without a verbal command to swallow. Video of the examinations will be recorded and presence of dysphagia will be designated independently by 3 different observers (one pulmonary physician and two speech language pathologists (SLPs)). This procedure will take 5-10 minutes. The camera will then be removed.
224304317|NCT01930565|OTHER|TTO application|Application of TTO (Tea tree oil) containing creams to the other side of face of patients to monitor its effectiveness and safe compared with LFCO.
223473523|NCT01376869|DIETARY_SUPPLEMENT|Hops Extract|All 150 participants will complete 1 study visit; receiving either of the 4 hops doses or placebo (silica). Computer generated random numbers will be used to allocate treatments to participant identification numbers. Treatment will be administered in capsule form and in a double blind manner.
223580896|NCT00539617|DRUG|Erlotinib|Tarceva single agent therapy: 150 mg/day PO
223473524|NCT01376869|OTHER|Placebo (silica)|All 150 participants will complete 1 study visit; receiving either of the 4 hops doses or placebo (silica). Computer generated random numbers were used to allocate treatments to participant identification numbers. Treatment will be administered in capsule form and in a double blind manner.
223473525|NCT03356717|BEHAVIORAL|educational intervention with observer tool|To assess if the use of an observer tool by observers during high fidelity simulation improves learning outcomes
223473526|NCT03356717|BEHAVIORAL|educational intervention|without observer tool
223473527|NCT02078544|OTHER|Integrated Molecular Analysis|
223473528|NCT03946059|DEVICE|iTBS then cTBS|repetitive transcranial magnetic stimulation applied with intermittent theta-burst stimulation protocol applied in week 1 and continuous theta-burst stimulation protocol applied in week 2.
223473529|NCT03946059|DEVICE|cTBS then iTBS|repetitive transcranial magnetic stimulation applied with continuous theta-burst stimulation protocol applied in week 1 and intermittent theta-burst stimulation protocol applied in week 2.
223473530|NCT00114556|DRUG|zoledronic acid|
223473531|NCT04630548|DEVICE|Intrauterine copper device|The obstetrical team will identify subjects who present in labor who meet the criteria and express interest in intrauterine contraception. Immediately after cesarean delivery, consented subjects will be randomized to immediate post placental IUD placement within 10 minutes or IUD placement at their routine standard postpartum visit (6 to 8 weeks postpartum).
223473532|NCT00495053|DRUG|hMaxi-K|Two dose levels (5000 µg/90 mL intravesical instillation and 10000 µg/90 mL intravesical instillation)
223473533|NCT00495053|OTHER|Placebo|Matching placebo (PBS-20% sucrose)
223473534|NCT02654678|DRUG|Enalapril Orodispersible Minitablet|Weight-dependent long-term treatment scheme with enalapril ODMTs of 0.25 and/or 1 mg strength
223473535|NCT00730184|DIETARY_SUPPLEMENT|potassium bicarbonate|90 mmol/d given as 4 tablets after each meal, with a full glass of water
223473536|NCT00730184|DIETARY_SUPPLEMENT|Placebo (microcrystalline cellulose)|Given as 4 tablets after each meal, with a full glass of water
223580897|NCT00539617|DRUG|5-fluorouracil|5-FU bolus: 400 mg/m2 IV once every 2 weeks for 16 weeks 5-FU infusion: 2400 mg/m2 IV over 46-48 hours, once every 2 weeks for 16 weeks
223580898|NCT00539617|DRUG|Leucovorin|400 mg/m2 IV once every 2 weeks for 16 weeks
224069548|NCT02363686|PROCEDURE|BSE|Following the FEES, a speech language pathologist (SLP) will perform a noninvasive bedside swallow evaluation (BSE). The SLP will be blinded to the results of the FEES, and the name of the SLP performing the BSE will not be recorded. No other identifying information will be collected regarding the SLP performing the test.
224069549|NCT02952222|DRUG|Dexmedetomidine|Patients in Group DP will receive 0.5 mcg/kg Dexmedetomidine (DEX) administered over 1 minute followed by an infusion of 0.15 mcg/kg/hr. Following the 0.5 mcg/kg DEX bolus, propofol will be administered with the identical protocol (with same endpoint of Bispectral Index (BIS) 40-50) of the P Group. Propofol infusion will be started at 200 mcg/kg/min and will be titrated throughout the procedure to maintain a BIS 40-50. Propofol may be administered prn in 10-20 mg increments for any abrupt patient movement which may compromise the continuity of the procedure.
224069550|NCT02952222|DRUG|Propofol (Group P)|Patients in Group P will receive intravenous propofol in bolus increments (2.0 mg/kg bolus over one minute then 0.5 mg/kg bolus q 1 minute titrated to a BIS of 40-50). These patients will be maintained with a continuous intravenous infusion of propofol starting at 200 mcg/kg/min and will be titrated to an endpoint of maintaining a BIS level of 40-50.
224069551|NCT02952222|DRUG|Propofol (Group DP)|Patients in Group DP will receive 0.5 mcg/kg DEX administered over 1 minute followed by an infusion of 0.15 mcg/kg/hr. Following the 0.5 mcg/kg DEX bolus, propofol will be administered with the identical protocol (with same endpoint of BIS 40-50) of the P Group. Propofol infusion will be started at 200 mcg/kg/min and will be titrated throughout the procedure to maintain a BIS 40-50. Propofol may be administered prn in 10-20 mg increments for any abrupt patient movement which may compromise the continuity of the procedure.
224069552|NCT00562549|DRUG|SLx-2101|
224069553|NCT05409339|DRUG|Caffeine|150 mg caffeine, 3 times/day (wakeup + 45 min, +255 min, and +475 min)
224069554|NCT05409339|DRUG|Placebo|Mannitol, 3 times/day (wakeup + 45 min, +255 min, and +475 min)
224069555|NCT05525117|BEHAVIORAL|covivio (additional to treatment as usual)|Covivio is a dialogue-based online psychological intervention for patients with type 2 diabetes. This intervention includes elements that address disease literacy, physical activity and exercise, dieting and nutritional principles, coping with depression, etc. Content is adapted to users needs using interactive dialogues, illustrations and audio files. Participants may also continue with their usual treatment.
224069556|NCT05525117|OTHER|treatment as usual|Participants may continue with any treatment that they require (treatment as usual)
224069557|NCT04934761|PROCEDURE|Fluid challenge strategy|Patients received 2ml/kg of succinylateol gelatin within 10 min for fluid shock therapy after grouping, taking SVV as the management target. If SVV\< 13% after shock therapy, the shock therapy was stopped and the infusion was maintained with 4ml/kg/h of crystal solution. If SVV ≥ 13% and ΔSV \<10%, the individual would be excluded from the experiment. If SVV ≥ 13% but ΔSV≥10%, 2ml/kg of succinylateol gelatin was given again within 10 min for liquid shock therapy until SVV\<13%, and 4ml/kg/h of crystal solution was maintained after reaching the target. If SVV≥ 13% after two shock treatments, they were excluded from the experiment. We excluded patients whose intraoperative bleeding ≥400ml and operative time ≥5 hours from the group.
224069558|NCT04934761|PROCEDURE|conventional strategy|4ml/kg/h of crystal solution was maintained. We excluded patients whose intraoperative bleeding ≥400ml and operative time ≥5 hours from the group.
224069559|NCT00057473|DRUG|carboplatin + irinotecan|Solution, IV, Carbopaltin AUC 4 mg/ml.min every 21 days; irinotecan 12 mg/m2/day x 10 days , Minimum of two cycles of chemotherapy projected to be up to 6.
224069560|NCT00057473|DRUG|irinotecan|Solution, IV, irinotecan 12 mg/m2/day x 10 days, minimum of two cycles of chemotherapy projected to be up to 6.
224069561|NCT06422741|DIETARY_SUPPLEMENT|grape seed proanthocyanidin extract|250 mg of product presented in capsule form will be given.
224069562|NCT06422741|DIETARY_SUPPLEMENT|Placebo|165 mg of cellulose will be given presented in capsule form.
224069563|NCT02750462|OTHER|Immediate coronary angiography|Immediate coronary angiography in survivors of out-of-hospital cardiac arrest without ST-segment elevation
224069564|NCT02750462|OTHER|Delayed/selective coronary angiography|Initial intensive care evaluation to further stratify the etiology of out-of-hospital cardiac arrest with delayed/selective coronary angiography if indicated
224161093|NCT01737138|PROCEDURE|RSD|Contrast renal angiography(iodixanol) was performed to localize and assess the renal arteries for accessibility and appropriateness for RSD. Once the anatomy was deemed acceptable, the internally irrigated radiofrequency ablation catheter(Celsius Thermocool,Biosense Webster, Diamond Bar, California) was introduced into each renal artery. then was maneuvered within the renal artery to allow energy delivery in a circumferential, longitudinally staggered manner to minimize the chance of renal artery stenosis. About six to nine ablations at 10 W for 1 min each were performed in both renal arteries. During ablation, the catheter system monitored tip temperature and impedance, altering radiofrequency energy delivery in response to a predetermined algorithm.
224161094|NCT01737138|DRUG|medicine|Angiotensin converting enzyme inhibitors, angiotensin receptor antagonist, calcium antagonists, diuretic, beta adrenoceptor blocking agent, statins, platelet aggregation inhibitor, anticoagulants and so on.
223473537|NCT05182944|DRUG|A：non-pCR patients|"After 2 cycles of neoadjuvant therapy（Camrelizumab+Albumin Paclitaxel+Cisplatin）, non-pCR patients adjuvant treatment（2-4 cycles Camrelizumab+Albumin Paclitaxel+Cisplatin and Camrelizumab maintenance treatment）~Camrelizumab, 200 mg，Intravenous injection，q3W continuous medication Albumin Paclitaxel, 125 mg/m2, Intravenous injection d1,8 q3W continuous medication Cisplatin: 75mg/m2, Intravenous injection,d1, q3W continuous medication"
223473538|NCT05182944|DRUG|B：non-pCR patients|"After 2 cycles of neoadjuvant therapy（Camrelizumab+Albumin Paclitaxel+Cisplatin）, non-pCR patients adjuvant treatment（Camrelizumab maintenance treatment）~Camrelizumab, 200 mg，Intravenous injection，q3W continuous medication Albumin Paclitaxel, 125 mg/m2, Intravenous injection d1,8 q3W continuous medication Cisplatin: 75mg/m2, Intravenous injection,d1, q3W continuous medication"
223473539|NCT05182944|DRUG|A：pCR patients|"After 2 cycles of neoadjuvant therapy（Camrelizumab+Albumin Paclitaxel+Cisplatin）, pCR patients adjuvant treatment（Camrelizumab maintenance treatment）~Camrelizumab, 200 mg，Intravenous injection，q3W continuous medication Albumin Paclitaxel, 125 mg/m2, Intravenous injection d1,8 q3W continuous medication Cisplatin: 75mg/m2, Intravenous injection,d1, q3W continuous medication"
223580899|NCT00539617|DRUG|Oxaliplatin|85 mg/m2 IV once every 2 weeks for 16 weeks
223580900|NCT00204867|OTHER|CTC surveillance|In vivo CTC surveillance of 6-9 mm polyp
223580901|NCT00875056|DRUG|Vorinostat|Two 100 mg oral capsules of vorinostat, twice daily (400 mg/day), on Days 1 through 14 of each 21 day cycle
223580902|NCT02699268|OTHER|Lung function measurement|The infants will be exposed to lung function measurements performed by a new metod (Volusense Pediatrics) and a validated method (EcoMedics Exhalyzer D). The two Methods will be compared. This is not an intervential study, but a study aiming to validate a New Method versus an old method
223580903|NCT05918627|DRUG|Belumosudil mesylate|Pharmaceutical form: capsule; Route of administration: oral
223580904|NCT05918627|DRUG|Placebo|Pharmaceutical form: capsule; Route of administration: oral
223580905|NCT02459275|OTHER|PEP uP Protocol|Semi-elemental tube feeds are started at the hourly goal rate as determined by the 24 hour volume goal. Protein supplements will be started at the initiation of tube feeds to target a daily delivery of 2 g/kg/day.
223580906|NCT02459275|DRUG|Metoclopramide|Metoclopramide 10mg Intravenous (IV) every 6 hours (q6h) or 5mg IV q6h for renal failure will be started empirically concomitant with EN initiation. Gastric Residual Volume (GRV) will be checked every 4 hours and will be reinfused to the patient each time it is checked.
224161095|NCT00038142|DRUG|Vincristine|2.0 mg/m\^2 (max 2.0 mg) IV x 1 repeated every 3 weeks X 6.
224161096|NCT00038142|DRUG|Doxorubicin|90 mg/m\^2 IV over 30 min x 1 repeated every 3 weeks X 6.
224161097|NCT00038142|DRUG|Cyclophosphamide|2.0 g/m\^2 IV daily x 2 days repeated every 3 weeks X 6.
224161098|NCT00038142|DRUG|Dexrazoxane|900 mg/m\^2 IV (30 min prior to doxorubicin) repeated every 3 weeks X 6.
224161099|NCT00038142|BIOLOGICAL|ImmTher|900 mcg/m\^2 IV over 1 hour every week x 50-52 weeks.
224161100|NCT03531762|DRUG|Tepotinib|Participants received single oral dose of 500 mg Tepotinib in Treatment A, B and C.
224161101|NCT03531762|DRUG|Omeprazole|Participants received omeprazole alone on Day 1 to 4 and co-administration of omeprazole with Tepotinib on Day 5 in Treatment B and C.
224161102|NCT00032110|DRUG|erlotinib hydrochloride|Given orally
224304318|NCT03503526|BEHAVIORAL|Receptive music therapy|12 weekly trauma-focused Group therapy sessions of a length of 2.5 hours. The core element is receptive music psychotherapy with music listening, art making, and other art based methods.
223473540|NCT05182944|DRUG|B：pCR patients|"After 2 cycles of neoadjuvant therapy（Camrelizumab+Albumin Paclitaxel+Cisplatin）, pCR patients adjuvant treatment（Best Supportive Care）~Camrelizumab, 200 mg，Intravenous injection，q3W continuous medication Albumin Paclitaxel, 125 mg/m2, Intravenous injection d1,8 q3W continuous medication Cisplatin: 75mg/m2, Intravenous injection,d1, q3W continuous medication"
224161103|NCT00032110|OTHER|pharmacological study|Correlative studies
224304319|NCT00879957|DRUG|heparin|Heparin will be added to PICC infusions at a dose of 0.5 units heparin per milliliter of intravenous fluid/parenteral nutrition.
223580907|NCT00236392|DRUG|rabeprazole|
223580908|NCT02312765|BEHAVIORAL|AirCare App|Tablet software to encourage adherence and support
223580909|NCT05104619|PROCEDURE|tongue surgery|In squamous cell carcinoma of the tongue, complete surgical resection of the tumor
223580910|NCT02481713|BEHAVIORAL|motivational interviewing|motivational interviewing
223580911|NCT02481713|BEHAVIORAL|learning style interviews|interview and feedback about learning style
223580912|NCT01920152|BIOLOGICAL|PRP|Each PRP preparation requires a total of 36 ml of peripheral blood. This will be obtained via venapuncture and collected in four 9 ml extraction tubes containing 3.8% sodium citrate. The tubes are then centrifuged at 640 rpm for 8 minutes at room temperature. The 1ml plasma fraction located above the buffy coat is aspirated from each tube and dispensed into the fractioning tube. The entire PRP process takes place under laminar airflow. Immediately prior to injection, calcium chloride is is drawn up from the activator ampoule with the activation syringe and is added to the PRP fractioning tube. The activated PRP is then injected in its entirety into the hip joint under strict aseptic technique.
223580913|NCT01920152|DEVICE|Hyaluronic Acid|Hyaluronic acid is supplied as a non-pyrogenic solution in 2.5 ml pre-filled syringes and is administered by intra-articular injection using a 22-23 gauge needle. The full 2.5 ml is injected in one joint under strict aseptic administration.
223580914|NCT04401839|DRUG|Oxytocin IV shot|Oxytocin 10 IU I.V shot administered at the time of delivery of the anterior shoulder of the baby
223580915|NCT04401839|DRUG|Oxytocin IV drip|administration of oxytocin 5 IU units IM (WHO GDG recommendations,2012) and waiting for signs of placental separation
223580916|NCT04401839|PROCEDURE|Amr maneuver|sustained traction downward and posteriorly was applied to anterior and posterior lips of the cervix using ovum forceps for approximately 90 seconds
223580917|NCT04500236|OTHER|General anesthesia|Surgery under general anesthesia with the use of propofol
223580918|NCT04500236|OTHER|Hypno-analgesia|Surgery under Hypnosis session and analgesics
223580919|NCT03755232|DIETARY_SUPPLEMENT|scFOS|Fossence™ (short chain Fructo-oligosaccharides (scFOS)
223580920|NCT03755232|OTHER|Control|water or dextrose or white bread
223580921|NCT04150692|BIOLOGICAL|Dara-SC|-Subcutaneous daratumumab and hyaluronidase-fihj
223580922|NCT04150692|PROCEDURE|Blood for research assessments|-Cycle 1 Day 1, Cycle 3 Day 1, and at progression or end of study (whichever is first)
224161104|NCT00032110|OTHER|laboratory biomarker analysis|Correlative studies
223473541|NCT01324297|OTHER|skin test|four patches of 2 x 3cm thin blotting paper will be soaked with an equivalent amount (0.1 mL) of aqueous methyl nicotinate in four different concentrations: 0.1, 0.01, 0.001, 0.0001 M. The four patches will then be applied at the same time to the inner forearm for 60 seconds.
223580923|NCT04150692|PROCEDURE|Bone marrow for research assessments|-Cycle 1 Day 1, Cycle 3 Day 1, and at progression or end of study (whichever is first)
224161105|NCT06407336|DIAGNOSTIC_TEST|Contrast sensitivity|Contrast sensitivity will be assessed by using two different techniques of refraction on is Cylinderical lens and other is Spherical equivalent
224161106|NCT06407336|OTHER|Refraction|Refraction will be performed and contrast sensitivity will be assessed to assess patient comfort level and compliance.
224161107|NCT05345704|OTHER|cardiopulmonary resuscitation (CPR)|Data from observation and collected from simulation mannequin during simulated CPR of an infant and child.
223580924|NCT00677755|DRUG|mifepristone combined misoprostol|women received a single dose of mifepristone (Mifepristone tablets; Xianju Pharmacy, Zhejiang, China) 200mg orally on day 1, and then returned to the clinic on day 3 and were given misoprostol (Cytotec tables; Searle,A Division of Monsanto.P.L.C, England )0.8mg orally
223473542|NCT03294915|DIETARY_SUPPLEMENT|Resistant Starch|Addition of 42g per day of green banana flour (10g / day resistant starch) to the usual diet of study participants
223473543|NCT03294915|DIETARY_SUPPLEMENT|Placebo|Addition of 42g per day of mixture of guar gum, maltodextrin and cellulose to the usual diet of study participants
223580925|NCT00677755|DRUG|misoprostol alone protocol|patients were only administered 0.8 mg of misoprostol orally on day 3.
223580926|NCT01883648|DRUG|Coconut Oil Beverage|There are 2 treatment arms: Fuel for Thought™ and placebo, with a treatment allocation of 1:1. After 3 months of treatment in one group, subjects will have a 3-5 day wash-out period before receiving the alternate (opposite) treatment for 3 months.
223580927|NCT01883648|OTHER|Placebo Beverage|There are 2 treatment arms: Fuel for Thought™ and placebo, with a treatment allocation of 1:1. After 3 months of treatment in one group, subjects will have a 3-5 day wash-out period before receiving the alternate (opposite) treatment for 3 months.
224161108|NCT01486940|DRUG|insulin detemir|Individually adjusted dose administered subcutaneously (s.c., under the skin) twice daily
224161109|NCT01486940|DRUG|insulin aspart|Individually adjusted dose administered subcutaneously (s.c., under the skin) prior to meals
223473544|NCT03159143|DRUG|Docetaxel|Docetaxel (28) is a semi-synthetic taxane which blocks mitosis by preventing microtubule depolymerization. It mediates its actions by binding to a different set of microtubule-associated proteins than paclitaxel. It is administered every 3 weeks as a 30 minute infusion at doses between 60 to 75 mg/m\^2.
223473545|NCT03159143|DRUG|Oxaliplatin|Alkylating antineoplastic agent. It is administered on day 1 of each cycle at a dose of 110 mg/m\^2
223580928|NCT01706042|OTHER|legume meal|
223580929|NCT01706042|OTHER|white bread|
223580930|NCT00570934|DIETARY_SUPPLEMENT|Cholecalciferol|2000IU Cholecalciferol P.O. Q.D.
223580931|NCT00570934|DIETARY_SUPPLEMENT|Calcium|1 gm calcium as calcium carbonate
223580932|NCT00570934|DIETARY_SUPPLEMENT|Calcium and cholecalciferol|2000IU cholecalciferol and 1 gm calcium P.O. Q.D. for 6 months
224161110|NCT01486940|DRUG|insulin NPH|Individually adjusted dose administered subcutaneously (s.c., under the skin) twice daily
224304320|NCT00879957|DRUG|No heparin|In the no heparin group, the subjects will not receive heparin as an additive to their PICC infusions.
223580933|NCT00570934|DRUG|Placebo|Placebo
223580934|NCT04375397|DRUG|Ibrutinib|Capsules were to be administered orally with water once daily. For participants who required nasogastric tube (NGT) placement while on study, capsules may have been administered by opening the capsules, mixing with water, and flushing down the NGT.
223580935|NCT04375397|DRUG|Placebo|Capsules were to be administered orally with water once daily. For participants who required nasogastric tube (NGT) placement while on study, capsules may have been administered by opening the capsules, mixing with water, and flushing down the NGT.
223580936|NCT04841603|DEVICE|Mindshift CBT|A tablet with the Mindshift CBT app installed. Mindshift CBT is a free, evidence based app developed by Anxiety Canada, designed to help users reduce symptoms of anxiety and distress.
223580937|NCT04841603|DEVICE|Treatment as Usual|Treatment as usual. A tablet identical to the intervention group, but without the Mindshift CBT app is available for patients to use during their inpatient stay.
223580938|NCT04292990|DRUG|Fentanyl|Patch releasing drug at the rate of 25 µg/hour, increasing by 25 µg/hour increments to maintain the NRS score≤3 after the frst 24 hours according to no change in pain control. The maximum dose allowed in this study is 300 µg/hour.
224161111|NCT01486940|DRUG|human soluble insulin|Individually adjusted dose administered subcutaneously (s.c., under the skin) prior to meals
224161112|NCT03128255|OTHER|Assessment of already preacquired I-124 PET/US|Assessment of preacquired I-124 PET/US by review of anonymous digital case files
224161113|NCT01231672|BIOLOGICAL|Routine biological analyses|Bilirubinemia (total and conjugated), hematology, hemogram, SOFA score
224161114|NCT02000544|DEVICE|Modular Cardiopulmonary Bypass Circuit|Open heart surgery with a novel hybrid modular extracorporeal circulation circuit which is a closed cardiopulmonary bypass circuit with enhanced safety as it can be instantly converted to an open circuit.
224161115|NCT05759104|DRUG|Infliximab|Drug
224161116|NCT05759104|PROCEDURE|Stomy|Surgery
223473546|NCT02613130|DRUG|Stannous fluoride toothpaste|
223473547|NCT02613130|DRUG|Potassium nitrate toothpaste|
224161117|NCT00779818|DEVICE|Electrical acupuncture|Treatment by electrical acupuncture
224304321|NCT03373773|PROCEDURE|Foley catheter removal|After reinsertion of the Foley catheter, both groups of women will be given instructions on urinary catheter and bag management, this will be done by an RN as per standard protocol. Prior to discharge, every subject from the home removal group as well as their significant other/caregiver/family member will receive a standardized education session and written and illustrated instructions on Foley catheter removal from RN, per standard protocol. They will be provided with the syringe for catheter removal, urine collection pan, and a diary to record their voiding quality and quantity. Both groups of women will have the catheter removal in 2 days.
223473548|NCT03350386|DRUG|FYU-981|Single administration
223473549|NCT03350386|DRUG|Oxaprozin|Repeated administration
223473550|NCT00872547|DEVICE|DePuy ASR™ Hip System|Resurfacing system
223473551|NCT00872547|DEVICE|DePuy ASR™ XL Head / ASR™ Acetabular Cup System|Large Metal-on-Metal Total Hip Replacement
223473552|NCT05426590|DEVICE|Specular biomicroscopy|Specular microscopy will be done before and 3 weeks after cataract surgery
223473553|NCT05888519|OTHER|FID123300 ocular lubricant|Investigational ocular lubricant
223473554|NCT05888519|OTHER|FID123301 ocular lubricant|Investigational ocular lubricant
224161118|NCT00779818|DEVICE|Laser|Treatment by laser
223473555|NCT05888519|OTHER|FID122505 ocular lubricant|Comparator ocular lubricant
223473556|NCT03895801|DRUG|IFX-1|intravenously administered
223473557|NCT03895801|DRUG|Placebo-IFX-1|intravenously administered
223473558|NCT03895801|DRUG|Glucocorticoid (GC)|orally administered
223473559|NCT03895801|DRUG|Placebo-Glucocorticoid (Placebo-GC)|orally administered
223473560|NCT03885973|DRUG|Lactobacillus plantarum|Fermented milk containing probiotic Lactobacillus plantarum for three weeks
223473561|NCT03885973|DRUG|Placebo|Fermented milk containing placebo for three weeks
223473562|NCT03405311|DEVICE|Rivanna Accuro 3D Ultrasound Device|The treatment group (Group 1: Ultrasound and Epidural) will receive epidural analgesia using ultrasound pre-procedural scan with the ACCURO device
223473563|NCT03405311|OTHER|Palpation|The control group (Group 2: Epidural) will receive the 'Blind approach/palpation', which is using palpation in administering labor epidural analgesia. Additionally, anesthesiologist will scan patient's back with Accuro device in turned off mode
223473564|NCT05029661|DIAGNOSTIC_TEST|Carotid ultrasound|"* Ultra-COMPASS measurements (longitudinal + cross-sectional) Shear wave elastography: plaque stiffness Strain elastrogaphy: plaque deformation B-mode visualization: geometry~* Intima-media thickness~* Pulse wave velocity"
224161119|NCT00809614|BIOLOGICAL|AIN457|The investigational drug, AIN457 50 mg lyophilizate vials was prepared by Novartis. Reconstitution of AIN457 with 1.2 mL SWFI produced a 47 mg/mL concentrate solution for infusion from which at least 1 mL was useable. The AIN457 concentrate was diluted in 5% glucose bags for infusion through a 0.2 micron in-line filter.
224161120|NCT00809614|BIOLOGICAL|Placebo|Matching placebo to AIN457
224161121|NCT04514406|DEVICE|APERTO OTW DCB|Drug Coated Balloon Angioplasty
224304322|NCT00001110|PROCEDURE|Bronchoalveolar lavage|
224304323|NCT05854810|PROCEDURE|fertilized embryo Insertion|insertion of single fertilized embryo through IVF
223473565|NCT00279084|DRUG|GROUP A: if necessary, martial treatment and / or erythropoietin treatment to achieve the goal of haemoglobin level from 110 to 129 g/L.|
223473566|NCT00279084|DRUG|GROUP B: martial treatment and / or erythropoietin treatment to achieve the goal of haemoglobin level from 130 to 149 g/L|
223473567|NCT03885557|OTHER|Group I Experimental DOS|After the application of hot pack treatment of 7-10 minutes, dynamic oscillatory stretch(DOS) technique (30 repetitions each of 2 seconds stretch duration in one session) was applied to DOS group. An experienced orthopedic manual physical therapist provided these techniques to patients .
223473568|NCT03885557|OTHER|group II SS group|After the application of hot pack treatment of 7-10 minutes , Static stretching (2 repetitions each of 30 seconds in one session) was applied to SS group. An experienced orthopedic manual physical therapist provided these techniques to patients .
223473569|NCT05385406|DIAGNOSTIC_TEST|HPV genotyping|Genotyping will be obtained by the Xpert system which uses 5 color channels containing primers and probes for the detection of specific genotypes or pooled results as follows: i) HPV 16, ii) HPV 18/45 in pooled result, iii) HPV types 31, 33, 35 52, or 58, in pooled result, iv) HPV types 51 or 59, in pooled result, and v) HPV types 39, 56, 66 or 68 in pooled result.
223473570|NCT05385406|DIAGNOSTIC_TEST|Visual inspection after application of acetic acid|"After application of acetic acid and Lugol's iodine, the cervix will be assessed using simplified ABCD criteria (A= acetowhite lesion within the transformation zone, B = spontaneous bleeding or upon slight touch, C (optional) = Lugol-positive coloring of acetowhite lesions, D = diameter \> 5mm of acetowhite lesion)."
223473571|NCT02543840|OTHER|Replicating Effective Programs plus External Facilitation|Packaging, training and technical assistance according to the Replicating Effective Programs model plus External Facilitation
223473572|NCT02543840|OTHER|Educational Materials|Dissemination of educational materials on the collaborative chronic care model for 4 or 8 months prior to cross-over to REP-F
223473573|NCT00581217|OTHER|Aquacel Ag|Aquacel Ag will be applied to one donor site.
223473574|NCT00581217|OTHER|Glucan II|Glucan II to be applied to a donor site on same patient for comparison
224161122|NCT03185325|OTHER|bone marrow puncture and venous blood samples|bone marrow and peripheral blood samples are collected in non hodgkin lymphoma patients
224161123|NCT03185325|OTHER|venous blood samples|venous blood samples are collected in healthy voulnteers
224161124|NCT01080625|DRUG|phenylephrine|100 mcg of phenylephrine (volume 10 ml) iv at the time of reperfusion
224161125|NCT01080625|DRUG|epinephrine|10mcg of epinephrine (volume 10 ml) is administered iv at the time of reperfusion
224161126|NCT01080625|DRUG|placebo control|10ml of normal saline is administered at the time of reperfusion
224161127|NCT03482336|OTHER|Four FOP label designs|"Color (present and absent) were crossed with facial icon (present and absent) for a total of four FOP label treatments. For each trial, both packages had the same FOP treatment, but one appeared at a healthy level while the second unhealthy. Subjects were asked to choose the healthier option as quickly as possible. Accuracy and speed to correct selection both served as dependent variables."
224161128|NCT03563586|OTHER|Bowel Preparation plus antibiotics|Preoperative oral antibiotic therapy with rifaximin 400 mg plus metronidazole 500mg the day prior to surgery at 2:00, 3:00 and 10:00 pm, with mechanical bowel preparation (2 vials sodium phospate 45ml at 1:00 and 7:00 pm)
224161129|NCT03563586|OTHER|Bowel Preparation|Mechanical Bowel Preparation (2 vials sodium phospate 45ml at 1:00 and 7:00 pm) alone Both groups will receive iv antibiotics (cefoxitin 2 gr plus metronidazole 500gr) perioperatively and discontinuation within 24 hours
224161130|NCT00740428|PROCEDURE|Pregnants for receive the physical therapy guide|pregnants for the first time who will receive the physical therapy guide, perform the exercises under the supervision of a physical therapist, and complete an exercise compliance form and a log with information on urinary losses.
223473575|NCT01592214|OTHER|Placebo|Placebo: 4% Klucel® gel formulation, concentration 0, total daily volume 1.8 ml, 3 doses 8 hours apart on Day 1 and 1.2 ml, 2 doses 12 hrs apart on Days 2 to 5.
224161131|NCT05499689|DRUG|Bupivacaine Hydrochloride|2.5 cc bupivacain injection will be administered by approaching the greater occipital nerve under ultrasound guidance.
224304324|NCT05854810|PROCEDURE|fertilized embryo Insertion|insertion of double fertilized embryo through IVF
224304325|NCT01846910|BEHAVIORAL|Tooth Whitening|1\. A dental check-up will ensure the absence of contraindications to tooth whitening (cavities, soft tissue pathology, severe periodontitis) 2. Removal of calculus, plaque, or stains with a dental polishing 3. Treatment time is approximately 1 hour total4. Lips are retracted, tongue protector is placed and protective eyewear used 5. Saliva is suctioned and teeth are air dried 6. A liquid rubber dam material is applied to protect gums and cured by visible light. 7. The bleaching material is placed on the enamel surface of the involved teeth and is replaced if drying occurs 8. After 15 minutes, the bleach is suctioned, mouth rinsed and process repeated 9. Three to four applications are typically used
223473576|NCT01592214|DRUG|XF-73 in 2% Klucel gel|XF-73 in a modified 2% Klucel® gel formulation: Part 1, #1: concentration 0.5 mg/g, twice a day in volume 0.3 mL/naris/dose, total dose 0.6 mg; Part 1, #2: 2.0 mg/g concentration, twice a day in volume 0.3 mL/naris/dose, total dose 2.4 mg; Part 2, #1: Concentration 0.5 mg/g, 3 doses 8 hours apart on Day 1, total volume 1.8 ml, total dose 0.9 mg, 2 doses 12 hours apart on Days 2-5, total volume 1.2 ml and total dose 0.6 mg ; Part 2, #2: 2.0 mg/g, 3 doses 8 hours apart on Day 1, total volume 1.8 ml, total dose 3.6 mg, 2 doses 12 hours apart on Days 2-5,total volume 1.2 ml and total dose 2.4 mg.
223473577|NCT01592214|DRUG|XF-73 in 4% Klucel gel|XF-73 in a 4% Klucel® gel formulation: Part 2 #3: concentration of 0.5 mg/g and volume of 0.3 mL/naris/dose in 3 doses 8 hours apart on Day 1 and 2 doses, 12 hours apart on Days 2 to 5. Total daily volume of 1.8 ml on Day 1 and 1.2 ml on Days 2 to 5; and total daily dose of 0.9 mg on Day 1 and 0.6 mg on Days 2 to 5.
223473578|NCT00980876|DRUG|Cipro HC|Cipro HC (Ciprofloxacin HCl and Hydrocortisone)
223473579|NCT00980876|DRUG|Ciprofloxacin HCl and Hydrocortisone|Ciprofloxacin Hydrochloride and Hydrocortisone
223473580|NCT00283179|DRUG|Aripiprazole|
223473581|NCT00283179|DRUG|Risperidone|
223473582|NCT01955811|DRUG|Administration of platelet concentrate and taking blood samples|Patient with the need of a platelet transfusion, will have 4 intervention points. 1. directly before the start of the transfusion a blood sample will be drawn. 2. Patient receives the platelet transfusion. 3. One hour after the end of transfusion a second blood sample will be drawn. 4. 24 h after the end of the platelet transfusion a further bloos sample will be collected. The first two samples will be (beside blood cell counts) spiked in-vitro with different amounts of Human fibrinogen and blood clotting tests will be performed. The same with the 3. blood sample, but without spiking steps.
223473583|NCT03964948|DIAGNOSTIC_TEST|Kidney MRI|An MRI examination will be completed per research MRI protocol.
223473584|NCT03953742|DRUG|CPI-200|CPI-200 will be administered via intravenous infusion on Day 1 of a 21-Day cycle
223473585|NCT05572580|OTHER|questionnaire|the patients are asked to fill in a questionnaire
223473586|NCT01525953|DRUG|Chemotherapy|Chemotherapy according to standard
223473587|NCT01525953|RADIATION|Radiotherapy|Radiotherapy according to local standard
224069565|NCT02981771|BEHAVIORAL|Balance activity program|Participants will take part in a biweekly, 12 week physical activity program that will include balance and coordination exercises
224069566|NCT02981771|BEHAVIORAL|Strength activity program|Participants will take part in a biweekly, 12 week physical activity program that will include traditional strength exercises
224069567|NCT06296862|OTHER|Dietary Approaches to Stop Hypertension Diet|The DASH diet is a heart-healthy eating pattern that is focused on adequate consumption of fruits, vegetables, whole grains, low-fat dairy, fish, poultry, beans, nuts, and vegetables oils while emphasizing limited intake of foods containing saturated fat, such as fatty red meats, full-fat dairy products, and tropical oils, such as coconut, palm kernel, and palm oils, as well as sugar-sweetened beverages and sweets. The chosen 4 week intervention duration phase is consistent with previous research showing positive effects of consuming a sodium-reduced dietary intervention on volume status and is longer than in other studies showing positive effects of DASH diet consumption on cardiac outcomes among HF patients. Potential carryover effects are minimized by a washout period of 4 weeks. The meal plan has been previously developed based on NHLBI guidelines for the DASH diet.
224069568|NCT00586573|DRUG|memantine hydrochloride|tablet, 5-20 mg, twice daily, by mouth, 12 weeks
224069569|NCT01941407|DRUG|Eribulin|Eribulin: 1,23mg/m² d1, d8, IV Bevacizumab: 15mg/kg d1, IV
224069570|NCT00556660|DRUG|[123I] AV-151|To assess the dynamic uptake and washout of 123-I AV151, a potential imaging biomarker for β-amyloid burden in brain, using single photon emission computed tomography (SPECT) in similarly aged healthy controls and Alzheimer's (AD) subjects
224069571|NCT06401161|OTHER|3T Pu'er tea|Two types of Pu-erh tea with different levels of theabrownin content.
224069572|NCT01496885|OTHER|Observational study|This was an observational study and no study drug was administered.
224069573|NCT03657901|BEHAVIORAL|Music listening|Guided music listening for 30 minutes before sleep onset
224069574|NCT03657901|BEHAVIORAL|Slow breathing|Guided slow breathing for 30 minutes before sleep onset
224069575|NCT05011708|DEVICE|I-DROP MGD|I-DROP MGD are eye drop produced by I-MED PHARMA for the management of moderate to severe Dry Eye Disease.
224069576|NCT05011708|DEVICE|Thealoz Duo|I-DROP MGD are eye drop produced by Laboratoires Thea for the management of Dry Eye Disease.
224304326|NCT01846910|BEHAVIORAL|Motivational Counseling|Normally three counseling sessions. Session #1: Introductions; discuss habits, feelings, pros and cons of smoking; degree of addiction; previous quit attempts and relapse; reinforce patient confidence; open-ended questions to illicit self-efficacy; homework includes Pack-Track and Why Test. Session #2: Discuss smoking patterns, triggers, and risk situations; discuss methods to resist triggers, need for medications; prepare environment and back-up plan; discuss quit date; homework to review self-help workbook. Session #3: Reinforce previous concepts; review resistance plan; discuss and arrange pharmaceutical cessation aids; set quit date; homework to finalize all self/home preparations; offer tooth polishing on quit date; follow-up by telephone or appointment.
224304327|NCT02176408|BEHAVIORAL|Behavioral Activation|Behavioral Activation Therapy (BA). All participants will receive a standard behavioral activation treatment based on the manualized treatment described by Lejuez et al., 2011. Treatment will be delivered in 60-minute weekly sessions over a 6-week period followed by 3 biweekly booster sessions. Behavioral activation includes scheduling activities the patient will enjoy and find important with the purpose of improving mood.
224304328|NCT02176408|BEHAVIORAL|Exercise Intervention|Exercise Intervention (EX). The exercise intervention will immediately follow each of the first six weekly BA sessions. Each EX session will comprise 30 minutes of either providing rationale for the program or reviewing the previous week's progress. As part of the intervention, participants will be asked to perform 40 minutes of aerobic exercise at 60-75% of maximum heart rate on three days each week, with 5 minute stretching warm up and cool down. We will help all participants initiate and plan their at-home program of exercise.
224304329|NCT02176408|BEHAVIORAL|Stretching Intervention|Stretching Intervention (STR). The stretching intervention will also follow each of the first six weekly BA sessions. These sessions will comprise 30 minutes of providing rationale for the stretching program or reviewing the previous week's progress. As part of the intervention, participants will be asked to perform 50 minutes of stretching on three days each week. Participants in this condition will be provided with a 50-minute DVD of stretching exercises and will work with the therapist to plan their at-home stretching exercises.
224304330|NCT03204708|DEVICE|catheter|catheter was placed under clavipectoral fascia by open technique by surgeon at the 1/3 lateral part of clavicula neighbourhood of nervus thoracicus longus, nervus thoracodorsalis, nervus pectoralis lateralis, nervus pectoralis medialis
223473588|NCT06399601|OTHER|Drug allergy training program|Two identical didactic courses on drug allergy were designed. Each course will last 12 hours and conducted over 2 consecutive days (6 hours each day). All candidates will attend physically and on-site. Various aspects of drug allergy with pre-set learning objectives will be taught in-person by instructors (physicians or nurses specializing in drug allergy nominated by the University of Hong Kong). Course materials and instructors will be identical for each course.
223580939|NCT04292990|DRUG|Morphine|Tablets taken orally, twice daily, morning \& evening with preferably 12 hours (not less than 6 hours) between doses. Titration phase: starting at 30 mg, increasing at a minimum of 3 days intervals by 20 mg, with a maximum dose of 100 mg. Maintenance phase: continuing on dose level established in titration phase.
223580940|NCT01777945|DRUG|capecitabine|Participants received capecitabine according to individualized physician-prescribed regimen.
223580941|NCT01777945|DRUG|docetaxel|Participants received docetaxel according to individualized physician-prescribed regimens.
223580942|NCT02165462|OTHER|Patients with haemophilia|Assessment of bilateral deficit phenomenon during dynamic plantar flexion task with a force platform (Kistler 9286 BA model, Kistler Instruments, Amherst, NY, USA)
224161132|NCT05499689|OTHER|Transcutaneous pulsed radiofrequency qurrent|Pulsed radiofrequency current will be applied through transcutaneous pads adhered over the greater occipital nerve trace on the nape.
224161133|NCT04324268|DRUG|lirentelimab (AK002)|Lirentelimab (AK002) is a humanized non-fucosylated immunoglobulin G1 (IgG1) monoclonal antibody directed against Siglec-8.
224161134|NCT04324268|OTHER|Placebo|Placebo
224304331|NCT03204708|DRUG|iv analgesia|patients were given 100 ml of tramadol 30 minutes before extubation
224304332|NCT00650208|DRUG|Lamotrigine Tablets 25 mg|2x25mg, single dose fasting
224304333|NCT00650208|DRUG|Lamictal® Tablets 25 mg|2x25mg, single dose fasting
223580943|NCT01276444|DEVICE|Swan-Ganz catheter|the data s=derived from PAC included pulmonary artery occlusion pressure etc
223580944|NCT01276444|DEVICE|transpulmonary thermodilution + central venous saturation|Described in details above
224161135|NCT04225312|DRUG|Personalized extended interval dosing of natalizumab|Personalized extended interval dosing of natalizumab with a schedule from every 6 weeks, which will be further extended if the trough level exceeds 10 ug/ml.
223580945|NCT03490149|DEVICE|Electroconvulsive Therapy|Series of electroconvulsive therapy for major depressive disorder
223580946|NCT03490149|DRUG|Medication - Treatment as usual|Medication only sample - Treatment as usual
223580947|NCT03894384|DIAGNOSTIC_TEST|Trefoil factor family 3 (TFF3),Pepsinogen 1(PG1)|Diagnostic Test: A) CBC . B) FBG. C)KFT. D) LFT. A)CBC: Complete blood count. B)FBG: Fasting blood glucose. C)KFT: Kidney function tests. D)LFT: Liver function tests.
224069577|NCT03434405|BEHAVIORAL|SocialMind|SocialMind is a mindfulness-based intervention including elements such as radical acceptance, decentering or meditation-techniques. It is designed to target social cognition, defined as the ability to recognize, understand and benefit from social stimuli.
224069578|NCT03434405|BEHAVIORAL|Psychosocial treatment|Treatment as usual delivered by patient's practitioner
224069579|NCT03434405|DRUG|Psychotropic treatment|Treatment as usual delivered by patient's practitioner
224161136|NCT04225312|DRUG|Standard interval dosing|Standard interval dosing in control group and historic group
224069580|NCT01404299|DIETARY_SUPPLEMENT|Nutritional Supplementation|\- Providing two 200mL per day of commercial liquid formula cans for 12 weeks (additional 400kal of energy, 25g of protein, 9.4g of essential amino acids (60.2% leucine), 400mL of water, and micronutrients per day)
224069581|NCT01404299|OTHER|Control|\- No intervention, except monthly home visits
224069582|NCT00085371|DRUG|triapine|Given IV
224069583|NCT03380910|BEHAVIORAL|Pharmacy and Behavioral Health Team|An interdisciplinary approach using medications through pharmacy support and counseling through behavioral health team members will be used to improve smoking cessation rates.
224069584|NCT03380910|BEHAVIORAL|Motivational Interviewing|Patients not ready to quit will be offered motivational interviewing to increase readiness to quit.
223580948|NCT04754685|DRUG|Intra-articular injection of platelet-rich plasma|The patient was put in 20 degree flexion in supine position with the knee. Under aseptic conditions, a 21-gage needle was used to inject 5 mL of PRP into the suprapatellar knee joint pouch, using a superolateral method. Local anesthetics were not used. Patients were instructed after the injection to refrain from physical exercise for at least 24 hours but no restriction was specified regarding activities of daily living. Three IA-PRP injections were administered at 2-week intervals. The same physician who was engaged in selecting and testing participants did the injections
223580949|NCT05440136|DRUG|LY3462817 (SC)|Administered SC.
223580950|NCT05440136|DRUG|Placebo (SC)|Administered SC.
223580951|NCT05440136|DRUG|LY3462817 (IV)|Administered IV.
223580952|NCT05440136|DRUG|Placebo (IV)|Administered IV.
223580953|NCT05400629|OTHER|Training program|12-week strength training program of the lower limbs consisting of 5 different exercises: Leg extension, leg press, hip abduction, squat and plantar flexion. All exercises will be perform between 6 and 8 maximal repetitions.
223580954|NCT04213170|DRUG|sintilimab|Sintilimab 200mg d1 and Bevacizumab 15mg/kg d1 q21d
223580955|NCT02568449|DRUG|Nintedanib|Given PO
223580956|NCT04527523|DIAGNOSTIC_TEST|Optical Coherence Tomography|OCT is an imaging method that uses light waves to create images of the retina.
223580957|NCT00610441|DRUG|MK-8777|
224161137|NCT01092364|BEHAVIORAL|Behavioral weight loss intervention|Behavioral lifestyle intervention for weight loss, compared to advice-only control.
224304334|NCT05428410|OTHER|IL-4R|IL-4R was injected subcutaneously.
224304335|NCT05428410|OTHER|Placebo|Placebo was injected subcutaneously.
224304336|NCT03934411|DRUG|Tramadol|The subjects will orally ingest 100 mg tramadol retard actavis
224304337|NCT03934411|OTHER|Placebo|The subjects will orally ingest 100 mg calcium powder
224304338|NCT06132932|DRUG|WX390|Participants will receive WX390 1.1 mg tablet orally once a day for a continuous 28-day cycle.
224304339|NCT04229173|DIAGNOSTIC_TEST|MRI acquisition|MRI acquisition
224304340|NCT04229173|DIAGNOSTIC_TEST|DAT-SPECT|Imaging with DAT SPECT (Dopamine Transporter, Single Photon Emission Computed Tomography)
224304341|NCT04229173|DIAGNOSTIC_TEST|blood sample, cerebrospinal fluid (optional)|blood sample, cerebrospinal fluid
224304342|NCT04229173|BEHAVIORAL|Evaluations about motor abilities, depression, cognition and lifestyle|Evaluations about motor abilities (UMSAR scale), depression (BDI scale), cognition (MoCA scale) and lifestyle (MSA- QoL)
224304343|NCT04229173|BEHAVIORAL|Evaluation about depression cognition|Evaluations about depression (BDI scale), cognition (MoCA scale)
224304344|NCT00123474|DRUG|dasatinib|Tablets, Oral, 50 mg BID, indefinitely, survival study
224304345|NCT00123474|DRUG|dasatinib|Tablets, Oral, 70 mg BID, indefinitely, survival study
224304346|NCT00123474|DRUG|dasatinib|Tablets, Oral, 100 mg QD, indefinitely, survival study
224304347|NCT00123474|DRUG|dasatinib|Tablets, Oral, 140 mg QD, indefinitely, survival study
224304348|NCT05568901|BEHAVIORAL|Lethal means counseling|"Lethal means counseling is a type of safety education that advises securement or removal of potentially hazardous household items such as medications, knives, and firearms. Counseling provided by study team was derived from the Suicide Prevention Resource Center's Counseling on Access to Lethal Means training module and the Store It Safe campaign from the Ohio Chapter of the American Academy of Pediatrics (AAP). Guidance focused on securement of dangerous items in the household, such as medications and firearms, with locking devices-or more preferably removing these items from the home, even if temporarily."
224304349|NCT05568901|BEHAVIORAL|Provision of Cable-style gun locks|Caregivers were provided 2 (two) SnapSafe Cable Padlock (Item No. 75281), advised on how to use these devices to store firearms safely (including instructions from within the package of the provided gun locks) and were advised to store keys away from the firearm in a location that children would not have access
223580958|NCT00610441|DRUG|Placebo|
223580959|NCT04053595|DIAGNOSTIC_TEST|Dynamic parameters of fluid responsiveness protocol|Dynamic parameter of fluid responsiveness (pulse pressure variation/stroke volume variation) are used to optimize hemodynamics intraoperatively and during the first 6 hours postoperatively when appropriate. A cutoff of 12% is used to predict an increase of stroke volume \>10% after fluid administration.
224304350|NCT04708548|OTHER|Health-related Quality of Life|Health-related quality of life (HRQOL) is an individual's or a group's perceived physical and mental health over time.
224304351|NCT04708548|OTHER|Psychological Distress|Measured of the distress experienced by patients
224304352|NCT04708548|OTHER|Fatigue|Measure of the extreme tiredness resulting from mental or physical exertion or illness
224304353|NCT04708548|OTHER|Cognitive Functioning|Cognitive functioning refers to multiple mental abilities, including learning, thinking, reasoning, remembering, problem solving, decision making, and attention. This will be measured through self-report and cognitive testing.
224304354|NCT03514849|PROCEDURE|prophylactic cranial irradiation (PCI)|Patients in the control group are enrolled in the follow-up, and the patients in research group will receive prophylactic cranial irradiation （PCI） by 25 gy/10 fx.
224304355|NCT03514849|PROCEDURE|lobectomy + mediastinal lymph node dissection or systematic lymph node sampling|lobectomy + mediastinal lymph node dissection or systematic lymph node sampling
223580960|NCT04053595|DIAGNOSTIC_TEST|Estimated oxygen extraction protocol|Oxygen extraction is estimated by the difference of arterial oxygen saturation and central venous oxygen saturation divided by arterial oxygen saturation. A cutoff of 27% is used as a marker of inadequate tissue perfusion requiring hemodynamic optimization.
224161138|NCT02412527|OTHER|Patch III heart rate sensor|
224161139|NCT03946644|DEVICE|EVLA with keeping of securuty distance|The EVLA will be performed with the 1470nm diode laser and a radial fibre (Leonardo® - 1470 nm/15W, Biolitec). The exact position of the catheter tip will be fixed under ultrasound guidance 2 cm below the SFJ.
224161140|NCT03946644|DEVICE|EVLA without keeping a distance|The EVLA will be performed with the 1470nm diode laser and a radial fibre (Leonardo® - 1470 nm/15W, Biolitec). The exact position of the catheter tip will be fixed under ultrasound guidance without keeping a distance to the SFJ.
224161141|NCT00364832|DRUG|methoxy polyethylene glycol-epoetin beta [Mircera]|Differing doses and frequencies of sc administration
224161142|NCT03696849|OTHER|polished emax Press|lithium disilicate glass ceramic crowns subjected to polishing only
224304356|NCT03514849|DRUG|postoperative adjuvant chemotherapy|If the postoperatively pathological examination of the patient is confirmed to be in pT1-2N0 stage, a single postoperative adjuvant chemotherapy (combining etoposide with cisplatin) is recommended. If patients are difficult to tolerate the side effects of cisplatin, we can replace cisplatin by carboplatin in the adjuvant chemotherapy scheme.
223580961|NCT05484817|DIAGNOSTIC_TEST|Assessment of cardiovascular risk factor, endocrine hormones and related biomarker|Cardiovascular risk factors: glycated hemoglobin/C-peptide/continuous glucose monitoring/blood pressure, blood lipids, uric acid, microalbumin test, etc. Endocrin hormones: bone metabolism, sex hormones, adrenal and pituitary hormones, and related biomarkers
223580962|NCT02564861|DRUG|DS-1971a|DS 1971a is supplied as a powder or crystals and will be given as an oral suspension
223580963|NCT02564861|DRUG|Placebo|Placebo matching DS-1971a suspension
223580964|NCT02680210|OTHER|Questionnaires and cognitive measures|
223580965|NCT06414421|OTHER|Transcuten Electriacal Nerve Stimulation|In TENS group patients, 4 electrodes of the TENS device were placed 3-5 minutes before the biopsy procedure, and the application was started and TENS was applied throughout the procedure. continued. TENS was applied again for 30 minutes 2 hours after the procedure.
223580966|NCT01995552|DEVICE|External Loop Recorder|
223580967|NCT05751889|BEHAVIORAL|Serious Game|Serious Game embedded with healthcare information regarding HCV and safe sexual practice.
224161143|NCT04024735|DIAGNOSTIC_TEST|Spirometry, Forced Oscillation Technique, Step-counter, sputum and blood samples|We will be collecting demographic and clinical information including daily physical activity level, lung function, blood and sputum samples. These measurements will be collected at patient admission, discharge and at follow-up of 30 and 90 days.
224161144|NCT03885076|PROCEDURE|Blood collection and bone marrow aspirate|Blood and bone marrow samples will be collected for the trial alongside routine tests.
224161145|NCT05601765|OTHER|Standard communication pathways after discharge|Standard communication pathways after discharge
223580968|NCT05751889|BEHAVIORAL|Traditional Health Education|Reading materials regarding HCV and safe sexual practice.
223580969|NCT05551624|DRUG|Atorvastatin 40 Mg Oral Tablet + N-acetylcysteine 400 mg Oral tablet|Oral tablets administered daily, atorvastatin once a day and N-acetylcysteine every 8 hours
224069585|NCT05439499|DRUG|FCN-437c, Letrozole or anastrozole, Goserelin acetate|FCN-437c：available in 25mg and 100mg capsules for oral administration on an empty stomach. 200mg once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment until progressive disease。Letrozole or anastrozole：Letrozole 2.5 mg or anastrozole 1 mg once daily；Goserelin acetate：premenopausal /perimenopausal patients should be coadministered with 3.6mg, Subcutaneously at every 28 days until progressive disease。
224069586|NCT05439499|DRUG|Placebo, Letrozole or anastrozole, Goserelin acetate|"Placebo：available in 25mg and 100mg capsules, and is administered in the same way as FCN-437c。~Letrozole or anastrozole：Letrozole 2.5 mg or anastrozole 1 mg once daily；~Goserelin acetate：premenopausal /perimenopausal patients should be coadministered with 3.6mg, Subcutaneously at every 28 days until progressive disease。"
224069587|NCT05075538|BIOLOGICAL|Spikevax|Booster dose, if a booster dose is administered during the study per local / national health policy guidelines.
224069588|NCT05075538|BIOLOGICAL|Comirnaty|Booster dose, if a booster dose is administered during the study per local / national health policy guidelines.
224069589|NCT05075538|BIOLOGICAL|Spikevax bivalent Original/Omicron BA.1|Booster dose, if a booster dose is administered during the study per local / national health policy guidelines.
224069590|NCT05075538|BIOLOGICAL|Spikevax bivalent Original/Omicron BA.4-5|Booster dose, if a booster dose is administered during the study per local / national health policy guidelines.
224069591|NCT05075538|BIOLOGICAL|Comirnaty Original/Omicron BA.1|Booster dose, if a booster dose is administered during the study per local / national health policy guidelines.
224069592|NCT05075538|BIOLOGICAL|Comirnaty Original/Omicron BA.4-5|Booster dose, if a booster dose is administered during the study per local / national health policy guidelines.
224069593|NCT05075538|BIOLOGICAL|Comirnaty Omicron XBB.1.5|Booster dose, if a booster dose is administered during the study per local / national health policy guidelines.
224069594|NCT05075538|BIOLOGICAL|Spikevax Omicron XBB.1.5|Booster dose, if a booster dose is administered during the study per local / national health policy guidelines.
224161146|NCT05601765|OTHER|Digital team-based communication after discharge|Standard communication pathways plus digital team-based communication after discharge
224161147|NCT02148601|OTHER|Fecal Microbiota Transplantation|
224161148|NCT02148601|DRUG|Standard Antibiotic Therapy|
224161149|NCT02148601|DRUG|Vancomycin (before randomization)|Vancomycin will be administered in all patients for 5 days before randomization. Then, patients will be randomized in FMT Group or Standard Antibiotic therapy Group. Patients in the FMT Group will stop vancomycin 24 hours before the fecal microbiota transplantation. Patients in the Standard Antibiotic Therapy Group will continue vancomycin.
224304357|NCT00405886|DRUG|Neramexane|Oral tablets, duration: 16 weeks
224161150|NCT03432208|PROCEDURE|GI consult|
224304358|NCT00405886|DRUG|Placebo|Oral tablets, duration: 16 weeks
224304359|NCT04380363|DEVICE|Honda Walk Assist (HWA) device|Use of HWA for 2 months in the home setting
224304360|NCT04380363|OTHER|SRALab fitness center membership|Membership to Shirley Ryan AbilityLab fitness center for 2 months
224304361|NCT01434186|DRUG|Placebo matching with Saxagliptin|Tablet, Oral, 0.0 mg, Daily, Day 1 through week 52
224304362|NCT01434186|DRUG|Metformin IR|Tablet, Oral, 1000 mg -2000 mg, Daily , Day 1 through week 52
224304363|NCT01434186|DRUG|Metformin XR|Tablet, Oral, 1000 mg -2000 mg, Daily, Day 1 through week 52
224304364|NCT01434186|DRUG|Saxagliptin|Saxagliptin Tablet, 2.5 mg, or Saxagliptin Tablet, 5 mg, (based on subject's weight)
224304365|NCT03599830|OTHER|Cognitive test passations|"Tests :~MoCA2 Hopkins verbal learning test WAIS-IV Trail Making test Stroop Verbal fluences"
224304366|NCT00831766|DRUG|Idarubicin|Intravenous infusion of Idarubicin as outlined in Phase I and Phase II Treatment Arms.
224304367|NCT00831766|DRUG|Cytarabine|Intravenous infusion of Idarubicin as outlined in Phase I and Phase II Treatment Arms.
224304368|NCT00831766|DRUG|Lenalidomide (Revlimid®)|Lenalidomide as outlined in Phase I and Phase II Treatment Arms.
223473589|NCT05828342|PROCEDURE|Endotracheal tube cuff inflation with the loss of resistance syringe method|The cuffs of the endotracheal tubes will be inflated with the epidural loss of resistance syringe, the syringe piston will be released, the syringe piston will be pushed back with oscillation, and then the cuff pressures will be measured and recorded with a cuff manometer (VBM Cuff Pressure Gauge) and an electronic injector that measures cuff pressure (AG Cufill). A three-way vein valve will be used when making this measurement. During the measurement, an epidural resistance loss injector will be attached to one valve, a cuff manometer attached to another valve, and an electronic injector (AG Cufill) measuring cuff pressure to the third track. With this technique, the possibility of leakage due to insertion and removal during measurements will be eliminated.
223473590|NCT04745351|DRUG|Remdesivir|Administered as Intravenous (IV) infusion once daily
223473591|NCT04745351|DRUG|RDV Placebo|Administered as IV saline once daily
223473592|NCT04745351|DRUG|Standard of Care|Standard of Care Treatment for COVID-19 Infection
223473593|NCT03963440|OTHER|Exercise Adherence Rating Scale (EARS)|"Inclusion and first questionnaires period (10 questionnaires), after geting consent, during normal patient consultation schedule for functional restoration program of the lumbar spine (1 to 3 weeks hospital in day care).~Second questionnaire period at 48h (Only EARS questionnaire) Third questionnaires period (10 questionnaires) at the end of the restoration program hospital care.~Fourth and last questionnaires period (10 questionnaires) at 3 months during a normal patient follow-up consultation No additional appointments."
223580970|NCT05553275|PROCEDURE|Usual Care|"Blood sugar evaluation (accuchecks) every four hours in latent labor and every 2 hours in active labor.Participants will be routinely managed with maintenance fluids of lactated ringers during latent labor and lactated ringers with dextrose 5% in active labor. Blood sugars of more than 110 mg/dl at any time point in labor will be treated with an insulin drip as follows:~Regular insulin (100 units) in 100cc of normal saline, with Lactated Ringers with 5% dextrose at 125cc/hour. If blood sugar 111-140, insulin drip at 1 unit/hour will be given and continued if blood sugar is 111-140.If blood sugar is 141-180, then drip will be changed to to 1.5 unit/hour and if blood sugar is 181-220, drip will be changed to 2.0 units/hour and MD will be called if blood sugar is more than 221 mg/dl"
223580971|NCT05553275|PROCEDURE|Permissive intrapartum glucose control|"Blood sugar evaluation (accuchecks) every four hours in latent labor and every 2 hours in active labor.Participants will be routinely management with maintenance fluids of lactated ringers during latent labor and lactated ringers with dextrose 5% in active labor.Blood sugars of more than 180 mg/dl at any time point in labor will be treated with an insulin drip as follows:~Regular insulin (100 units) in 100cc of normal saline, with Lactated Ringers with 5% dextrose at 125cc/hour.If blood sugar is 181-200, insulin drip at 1 unit/hour will be given. If blood sugar is 201-220, then drip will be changed to 1.5 units/hour. If blood sugar is 221 - 250, then drip will be changed to 2.0 units/hour and if blood sugar is more than 251 MD will be called."
224304369|NCT04020757|DEVICE|variation in dialysis bicarbonate|35 mEq/L dialysate bicarbonate for one week, followed by 30 mEq/L for one week, followed by 35mEq/L for one week with nutritional supplement during dialysis
224304370|NCT04020757|DIETARY_SUPPLEMENT|Zone Perfect bar|16g protein supplement given during first 30 mins of dialysis on last testing day
223580972|NCT02864173|GENETIC|Whole genome small nucleotide polymorphism genotyping|
223580973|NCT01968057|DRUG|Baricitinib|Administered orally
223580974|NCT01968057|DRUG|Ciclosporin|Administered orally
223580975|NCT03109691|DRUG|bupivacaine|group 1
223580976|NCT03109691|DRUG|Dexamethasone|group 2
223580977|NCT03109691|DEVICE|ultrasound|in all groups
223580978|NCT02819960|DRUG|Probio-Tec® BG-VCap-6.5|Each capsule contents: 2 lyophilized probiotic strains, total amount of minimum 2,7x10 9 CFU/cps, ratio LGG®: BB-12® = 50% : 50% (Culture percentages are based on cell concentration and are approximate) Lactobacillus rhamnosus GG® (ATCC 53103) Bifidobacterium animalis subsp. lactis BB-12® (DSM 15954) Additives: maltodextrin, microcrystalline cellulose, silicium dioxide, magnesium stearate
223580979|NCT02819960|DRUG|Placebo|Maltodextrin
223580980|NCT03223467|PROCEDURE|Bariatric surgery|Bariatric surgery includes several different types of surgical procedures used to achieve weight loss.
223580981|NCT05443282|DIAGNOSTIC_TEST|Prolidase Level|Measurement of venous blood serum level of prolidase enzyme level by ELISA method.
223580982|NCT05443282|DIAGNOSTIC_TEST|Follicle Stimulating Hormone Level|Measurement of venous blood serum level of follicle stimulating hormone level.
223580983|NCT05443282|DIAGNOSTIC_TEST|Estradiol Level|Measurement of venous blood serum level of estradiol hormone level.
223580984|NCT05443282|DIAGNOSTIC_TEST|Proline Level|Measurement of venous blood serum level of proline level.
223580985|NCT05443282|DIAGNOSTIC_TEST|Hydroxyproline Level|Measurement of venous blood serum level of hydroxyproline level.
223580986|NCT05443282|DIAGNOSTIC_TEST|Anti-mullerian Hormone Level|Measurement of venous blood serum level of anti-mullerian hormone level.
224069595|NCT04378803|BEHAVIORAL|Mindfulness training (MT) Connect|MT Connect will involve instructor-led weekly sessions and mindfulness exercises over a 4-week interval for a total of 8 to 10 hours. There will be one instructor-led session per week that will last between 2 and 2.5 hours. Participants will also be asked to complete three categories of mindfulness exercises (formal and informal mindfulness exercises, and reflective practices) as part of their daily 'out-of-class' homework. The daily homework will require between 10 to 30 minutes to complete.
224069596|NCT06541223|OTHER|Standard informed consent procedure|Face-to-face informed consent procedure supported by informational brochure
224069597|NCT06541223|OTHER|Multimedia video|Multimedia presentation on implant-based reconstruction
224069598|NCT03826927|OTHER|treatment with NOACs or VKAs|treatment with NOACs or VKAs initiated or continued for prevention of ischemic events
224069599|NCT02672566|DRUG|Enoxaparin|Enoxaparin will be delivered to the patients every day at the dose of 4 000 Ui.
224069600|NCT02672566|OTHER|Usual care|Patients will all benefit from the usual care
224069601|NCT05388539|PROCEDURE|Theta Burst Stimulation|3 TBS sessions per day, with an offer of 1200 pulses per session and a 30-minute interval between sessions. This protocol will be applied to patients for 15 days, totaling 45 stimulation sessions. The stimulations will be directed to the left dorsolateral prefrontal cortex (F3 obtained by the Beam method) and will be performed in a Magventure MagPro R30 device.The stimulation will be delivered at 100% of the motor threshold and will last for 6 minutes.
224304371|NCT00971776|DEVICE|AB Portable Driver System|Evaluate the safety and performance of the AB Portable Driver System in home environment.
224304372|NCT04300140|DRUG|Batiraxcept|Batiraxcept is experimental drug
224304373|NCT04300140|DRUG|Cabozantinib (Cabo)|Cabozantinib is standard of care as monotherapy and in combination with nivolumab in ccRCC
224304374|NCT04300140|DRUG|Nivolumab|Nivolumab is standard of care in the first line treatment of ccRCC
224304375|NCT01162746|DRUG|Intravitreal dexamethasone and intravitreal ranibizumab|"Patients will receive intravitreal dexamethasone using a special drug delivery system and same day intravitreal ranibizumab.~Study medications are initially given at the baseline visit. At each subsequent monthly follow-up visit, ranibizumab is administered if further visual decrease or persistence of sub-/intraretinal fluid is detected in the examination. At month 3, 6, 9 and 12 further treatments with intravitreal dexamethasone in combination with intravitreal ranibizumab are given if leakage is detected in fluorescein or indocyanine green (FLA or ICG) angiography, in case of further vision decrease or persistence of sub-/intraretinal fluid in OCT."
223473594|NCT05325359|BEHAVIORAL|L test|"It is an expanded version of the TUG and is designed to assess advanced functional ambulation with more detail available elsewhere. It is recorded when the participant gets up from the chair, walks 3 m to a cone, turns 90° to the right, continues to walk 7 m to the next cone, turns 180° left around the cone, then returns to the chair the same way. The test time is recorded, starting with the word go and ending with the participant's back touching the back of the chair."
223473595|NCT04937790|BEHAVIORAL|Core stabilization group(CSG)|Exercises training of this group occurs from 3 stages. In the stage 1 covering the first two weeks, core stabilization exercises are going to be applied 3 sets of 10 repetitions except side plank. Side plank is going to be performed 3 sets of 10 seconds. Stage 2 is going to include from 3 to 5 weeks. In this stage, exercises are going to be performed 3 sets of 12 repetitions except bride dog, plank and side plank. These exercises are going to be applied 3 sets of 15 seconds. Patients are going to perform exercises of stage 3 from 6 to 8 weeks. Exercises of stage 3 are going to be practiced 3 sets of 15 repetitions except bride dog, side plank and plank exercises which are going to be applied 3 set of 20 second. All stages include the same exercises except modified push-up exercise includes instead of plank exercise in stage 1. All of the exercises are going to practiced 3 days a week for 8 weeks. One of the sessions is estimated to take approximately 45-60 minutes.
223580987|NCT05443282|DIAGNOSTIC_TEST|Antral Follicle Count|Ultrasonographic evaluation of antral follicle count to determine ovarian reserve.
223580988|NCT05443282|DIAGNOSTIC_TEST|Prolactine Level|Measurement of venous blood serum prolactine hormone level.
223580989|NCT05443282|DIAGNOSTIC_TEST|Thyroid Stimulating Hormone Level|Measurement of venous blood serum thyroid stimulating hormone level.
223580990|NCT05671796|GENETIC|Mesenchymal stem cell transplantation|Patients will undergo two autologous bone marrow stem cell transplantation into the lesion area
224161151|NCT04781725|DRUG|INT230-6|INT230-6 is a formulation of two well known chemotherapeutic agents, cisplatin (0.5mg/mL) and vinblastine sulfate (0.1mg/mL), combined with 2-hydroxybenzoylaminooctanoate (also known as SHAO-FA or SHAO as a sodium salt at 10mg/mL).
224161152|NCT04781725|OTHER|Saline injection|Standard 0.9 % NaCl Normal Saline
224161153|NCT01174589|OTHER|Strength training|to compare if there is a difference between 6 or 12 weeks of physical strength training
224304376|NCT01162746|DRUG|Intravitreal ranibizumab|Patients will receive intravitreal ranibizumab monotherapy (cohort 3). Study medications are initially given at the baseline visit. At each subsequent monthly follow-up visit, ranibizumab is administered if further visual deterioration or persistence of sub-/intraretinal fluid is detected in the examination
224304377|NCT06483568|BEHAVIORAL|Pathways to Happiness Intervention|Four weeks of activities including a gratitude journal, random acts of kindness, self-compassionate letter, and capitalizing on positive events activities.
224304378|NCT06483568|BEHAVIORAL|Personal Organization Activities|"Four weeks of activities including a completed tasks journal, weekly task burst, productivity letter, and talking to others about task activities."
224304379|NCT02852720|DRUG|Levobupivacaine|After the block procedure, 2 ml blood samples will be taken in defined times to determine the plasma blood levels of levobupivacaine.
223743917|NCT05812521|PROCEDURE|Paravertebral block with methylene blue|The paravertebral space is identified under ultrasound guidance and after negative aspiration a 3 ml test dose of anesthetic is injected. After observing widening of the paravertebral space and anterior pleural displacement to confirm the correct needle positioning, a bolus dose of 20 mL 0.5% ropivacaine with a solution of 1 ml 1% methylene blue and 4 ml of saline will be injected in the paravertebral space. At the start of the surgery, the spread of the solution of anesthetic and methylene blue will be assessed through visualization in thoracoscopy and if necessary the block will be repeated. After the surgery, intravenous acetaminophen will be administered 3 times daily and tramadol 50 mg will be prescribed as rescue analgesic.
224304380|NCT02852720|PROCEDURE|Spinal anesthesia|Spinal anesthesia in the L3-L4 or L4-L5 interspace with hyperbaric bupivacaine 0,75% 1,4 ml plus 20 ug fentanyl to achieve a bilateral anesthetic level of T4 determined by pinprick.
224304381|NCT02852720|PROCEDURE|Peripheral vein canulation|An intravenous (18-gauge) catheter will be placed under local anesthesia for co hydration and a second IV catheter for venous sampling
224304382|NCT02852720|PROCEDURE|Ultrasonography|TAP blocks will be performed using a ultrasound Sonosite M-Turbo US machine (Sonosite Inc, Washington) with an L38x 10-5 megahertz (MHz), 38-mm broadband linear array probe.
224304383|NCT02852720|DEVICE|Holter|A portable 12-lead Holter (NorthEast Monitoring®, Boston, USA) will record continuously the electrocardiogram (ECG) after the TAP block, for 24 hrs.
223580991|NCT05671796|OTHER|Placebo|Patients will undergo two subcutaneous injections of 1 ml of glycophysiological solution into the lesion area by sham procedure
223580992|NCT01363934|DRUG|GC1113|"Each Group volunteers (n=10) will be administered GC1113 0.3ug/kg to 5ug/kg or Placebo (GC1113:placebo=8:2) once intravenously.~Each Group volunteers (n=10) will be administered GC1113 1ug/kg to 8ug/kg or Placebo (GC1113:placebo=8:2) once subcutaneously."
224161154|NCT03229876|BIOLOGICAL|CD19-UCART|A conditioning therapy with cyclophosphamide and fludarabine will be conducted before CD19-UCART injection. VP16 can be added to the conditioning therapy.
224161155|NCT05544110|DEVICE|Active transcranial magnetic stimulation|The coil parallel to the scalp is placed on the target for real and effective stimulation.
223473596|NCT04937790|BEHAVIORAL|Wobble board group (WBG)|Patients in this group are going to perform exercise on computerized wobble board. This device is going to provide unstable surface to patient and offer visual feedback about their movement qualities. The 8 weeks program consists of 3 stages and each stage includes six exercises. In the first stage covering the first two weeks, repetitive exercises are going to be practiced 3 sets of 10 repetitions; time controlled exercises are going to be practiced 3 sets of 20 seconds. Stage 2 is going to include from 3 to 5 weeks. In this stage, repetitive exercises are going to be performed 3 sets of 12 repetition and time controlled exercises are going to be performed 3 sets of 25 seconds. Stage 3 is going to last from 6 to 8 weeks. In this stage, repetitive exercises are going to be practiced 3 sets of 15 repetitions and time controlled exercises are going to be practiced 3 sets of 30 seconds. One of the sessions is estimated to take approximately 45-60 minutes.
223580993|NCT01363934|DRUG|Darbepoetin alfa|Each Group volunteers (n=8) will be administered Darbepoetin alfa by IV or SC.
223580994|NCT04801888|BIOLOGICAL|Two doses of inactivated SARS-CoV-2 vaccine at the schedule of day 0,28 and one dose Quadrivalent Influenza Vaccine on day 0 or day 28.|The inactivated SARS-CoV-2 vaccine was manufactured by Sinovac Research \& Development Co., Ltd., with a antigen content of 600SU/0.5ml. The Quadrivalent Influenza Vaccine manufactured by Sinovac Biotech Co.,Ltd. including 4 antigens H1N1, H3N2, BV and BY, 15μg for each, 0.5ml per dose.
223580995|NCT04801888|BIOLOGICAL|Two doses of inactivated SARS-CoV-2 vaccine at the schedule of day 0,28 and one dose Quadrivalent Influenza Vaccine on day 14.|The inactivated SARS-CoV-2 vaccine was manufactured by Sinovac Research \& Development Co., Ltd., with a antigen content of 600SU/0.5ml. The Quadrivalent Influenza Vaccine manufactured by Sinovac Biotech Co.,Ltd. including 4 antigens H1N1, H3N2, BV and BY, 15μg for each, 0.5ml per dose.
223580996|NCT02279836|DEVICE|SC20 Colonoscope|Single Arm Post-Marketing Study of SC20 Colonoscope
223580997|NCT01011933|OTHER|Diagnostic Laboratory Biomarker Analysis|Correlative studies
223743918|NCT05812521|PROCEDURE|Thoracic Epidural Anesthesia|The epidural catheter will be placed using the loss of resistance technique, and after ruling out intravenous or intrathecal catheter placement with a negative aspiration test dose, an initial dose of 10 mL 0.25% bupivacaine will be injected. Continuous infusion will be started with with 0.125 % bupivacaine + fentanyl 0.5 mcg/ ml at 6-10 ml/hour will be started based on the patient weight for 48 hours postoperatively. After the surgery, intravenous acetaminophen will be administered 3 times daily and tramadol 50 mg will be prescribed as rescue analgesic.
223743919|NCT01268111|DRUG|Ergocalciferols|ERgocaclciferol 50,000 units weekly for 8 weeks
223743920|NCT01268111|DRUG|Placebo|matching placebo
223743921|NCT01528072|DEVICE|Dynesys Spinal System|Dynesys Spinal System will be used for all subjects
223743922|NCT02164305|OTHER|Strengthening group|Open-chain exercise for rotator cuff and scapular muscles
223743923|NCT02164305|OTHER|Neuromuscular group|Closed-chain exercise for shoulder muscles
223743924|NCT02164305|OTHER|Control|No exercise training
223743925|NCT06224842|DRUG|mitoxantrone liposome 16 and azacitidine|The mitoxantrone liposome will be intravenous infused at a dose of 16mg/m\^2 on day1 , combined with subcutaneous injection of azacitidine at a dose of 75 mg/m\^2 on days 1-7, with each cycle lasting 4 weeks (28 days).
223743926|NCT06224842|DRUG|mitoxantrone liposome 18 and azacitidine|The mitoxantrone liposome will be intravenous infused at a dose of 18mg/m\^2 on day1 , combined with subcutaneous injection of azacitidine at a dose of 75 mg/m\^2 on days 1-7, with each cycle lasting 4 weeks (28 days).
223743927|NCT06224842|DRUG|mitoxantrone liposome 20 and azacitidine|The mitoxantrone liposome will be intravenous infused at a dose of 20mg/m\^2 on day1 , combined with subcutaneous injection of azacitidine at a dose of 75 mg/m\^2 on days 1-7, with each cycle lasting 4 weeks (28 days).
224069602|NCT05388539|PROCEDURE|Sham Stimulation|The placebo will consist of a sham stimulation activity. A noise generator, which makes the same noise as active stimulation, and a surface electrode placed over the patient's eyebrow, mimicking the tactile sensory effects of TBS. It will also occur three times a day, with a duration of 6 minutes. The interval time between procedures will be of 30 minutes. It will take place for the same 15 weekdays, totalizing 45 sham stimulations.
224069603|NCT01124487|DIETARY_SUPPLEMENT|The acute effects of dietary fat on lipid profile, insulin sensitivity and inflammatory markers|
224304384|NCT02767882|DRUG|Dexamethasone|Bolus injection of different dose of dexamethasone will be given intravenously prior to incision.
223580998|NCT01011933|DRUG|Selumetinib|Given PO
223580999|NCT00928278|DRUG|Treatment A|Inhaled, 300/150, single dose
223581000|NCT00928278|DRUG|Treatment B|Inhaled, 300/150, single dose
223581001|NCT00928278|DRUG|Treatment C|Inhaled, 300/150, single dose + oral activated charcoal block
223581002|NCT00928278|DRUG|Treatment D|Inhaled, 300/150, single dose + oral activated charcoal block
223581003|NCT01439074|DEVICE|Mepilex Ag|Dressing
223581004|NCT01439074|DRUG|Silver Sulphadiazine Ag cream|A cream used on burnt areas.
223581005|NCT02639338|DRUG|SOF/VEL/VOX|400/100/100 mg FDC tablet administered orally once daily with food
223581006|NCT02639338|DRUG|SOF/VEL|400/100 mg FDC tablet administered orally once daily without regard to food
223743928|NCT04482504|DIAGNOSTIC_TEST|3 tests: Posturography, Questionnaire, vitamin D|Posturography platform Kistler 9281B Questionnaire focused on exercise activities and self-evaluation of postural stability The investigators also determine level of vitamin D in the blood.
223581007|NCT05922072|PROCEDURE|Nasogastric aspiration for measurement of Residual Gastric Volume|The patients enrolled in this study undergoing elective general anesthesia,their mean gastric residual volume will be measured by taking Nasogastric tube aspirate.
223743929|NCT02746211|BIOLOGICAL|High Titre Influenza virus|High Titre Influenza virus
223743930|NCT02746211|BIOLOGICAL|Medium - High Influenza virus|Medium - High Influenza virus
223743931|NCT02746211|BIOLOGICAL|Medium Low Titre Influenza virus|Medium Low Titre Influenza virus
223743932|NCT02746211|BIOLOGICAL|Low titre|Low titre
223743933|NCT01123109|PROCEDURE|3-D Endoanal Ultrasound|The subject will be placed in the supine position with their feet in the stirrups and a drape will be used, exposing only the anus and perineum in order to introduce the probe. In order to prevent and minimize any potential discomfort, the lubricated ultrasound probe will be gently inserted into the anal canal up to the anal verge, with minimal manipulation of the probe once inserted. The scan lasts approximately two minutes and the entire exam will take no more than five minutes.
223473597|NCT05802433|DIETARY_SUPPLEMENT|Vitamin D3 supplement|10µg vitamin D3 supplement per day for 90 days
223473598|NCT04805268|DIAGNOSTIC_TEST|18F FDG PET/CT|18F FDG PET/CT imaging (fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography).
223473599|NCT01244477|BEHAVIORAL|Group CPT-C|Participants will be randomly assigned to participate in CPT-C or a 12 week waitlist control group. Waitlist control subjects will participate in CPT-C after the 12 weeks.
223473600|NCT05090644|GENETIC|DNA analysis|GWAS
223473601|NCT06071416|PROCEDURE|Lateral sinus floor augmentation|maxillary sinus floor augmentation by lateral approach
223473602|NCT06071416|DRUG|Biphasic Calcium Phosphate|appliaction of BCP bone substitute
223473603|NCT06071416|PROCEDURE|Injectable platlets rich fibrin|centrifuge 10 ml of patient blood to get I-PRF that applied to the bone substitute
223473604|NCT00571675|DRUG|AT-101, prednisone and docetaxel|docetaxel (75mg/m2 intravenously over 1 hour on day 1, every 21 days \[one cycle\]), oral prednisone (5mg BID on days 1-21), and oral AT-101 on cycle days 1-3
223473605|NCT00571675|DRUG|placebo, prednisone and docetaxel|docetaxel (75mg/m2 intravenously over 1 hour every 21 days \[one cycle\]), oral prednisone (5mg BID on days 1-21), and oral placebo on cycle days 1-3
223473606|NCT01863771|DRUG|Golimumab|Participants will receive 200 mg golimumab at Week 0 and 100 mg golimumab at Week 2 as a subcutaneous (SC) (under the skin) injection in the induction phase. Participants who have a clinical response in the induction phase and are randomly allocated to golimumab in the maintenance phase will receive 100 mg SC every 4 weeks through Week 52. Participants who do not have a clinical response in the induction phase will receive 100 mg of golimumab SC at Week 4 and will continue with 100 mg of golimumab SC every 4 weeks through Week 52 only if a response is obtained by Week 8.
223473607|NCT01863771|OTHER|Placebo|Participants who have a clinical response to golimumab in the induction phase and are randomly allocated to placebo in the maintenance phase will receive SC placebo every 4 weeks through Week 52. However, participants receiving placebo and who will lose clinical response any time during the study will be eligible to receive 100 mg golimumab SC every 4 weeks through Week 52.
223473608|NCT01715246|OTHER|Infant Formula|
223473609|NCT02719977|DRUG|CX5461|
223473610|NCT03281044|DRUG|Fecal microbiota capsules|Patients will receive FMT capsules DE containing the fecal microbiota drug substance within a gelatin capsule shell. The drug substance is fecal microbiota from a single donor.
223473611|NCT03281044|DRUG|Placebo oral capsule|The control condition is a placebo FMT capsule. The FMT placebo capsule is identical in appearance to active capsules, but does not contain human feces, the active pharmaceutical ingredient. Placebo capsules will contain an autoclaved solution of glycerol and saline, contained in an identical gelatin capsule as the active product, including the same enteric polymer coating
223473612|NCT03627676|PROCEDURE|Cryoablation|Two percutaneous cryoprobes would be used for all patients. The 17-Gauge cryoprobes is introduced into the masses under US guidance. Mean distance to the skin has to be 5mm at least. Although US guidance is used, a non-enhanced CT scan may be used to assess the position of the cryoprobes before ablation, and to obtain a baseline examination in order to avoid thermal injuries to adjacent tissues such as the bowel during the ice growth. No ice extension to the skin has to be observed during cycles assessed by real-time US monitoring. Each cryoablation procedure involves 3 successive cycles: 10 minutes freeze with Argon gas, followed by 9 minutes passive and 1 minute active thawing with Helium gas, followed by a second 7 minutes freeze. The ice covered the entire targeted lesion on the short axes is visualize by US or CT-scan performed at the end of the three cycles or after repositioning. At the end of the cryoablation procedures, the probes are removed through active thawing.
223473613|NCT05181072|BEHAVIORAL|Enhanced in-person peer-motivation smoking cessation|Tobacco cessation classes will be offered in-person for a total of five sessions delivered weekly for five weeks and will utilize the CEASE Today Tobacco This is a seven-week tobacco cessation program and will be offered in-person weekly for seven weeks and will utilize the CEASE Today Tobacco Cessation Manual.
223581008|NCT05922072|PROCEDURE|Nasogastric Aspiration for Measurement of Gastric pH|The patients enrolled in this study undergoing elective general anesthesia,their mean gastric gastric PH will be measured by taking Nasogastric tube aspirate.
223743934|NCT02996864|OTHER|Healthy Detours App|"The app features:~* Immediate and relevant feedback at the point of decision-making to reinforce healthy lifestyle behaviors within a population making crucial lifestyle choices.~* User-centered and location-specific tailored information to provide users with information to improve future decision-making through activity tracking.~* Multiple health-tracking features (i.e., diet and PA tracking, and accelerometry for PA and sleep) that will aid in self-monitoring."
223743935|NCT02996864|OTHER|Fat Secret App|Freely available app for weight loss and nutrition. Includes food and exercise diaries; calorie counting.
223743936|NCT04354207|DIAGNOSTIC_TEST|Peripheral vein punction|Vitamin D level, vitamin D receptor genetic polymorphisms, allergen specific IgE and total IgE will be measured in peripheral blood
223743937|NCT04354207|DIAGNOSTIC_TEST|Stool collection|Gut microbiome will be investigated in stool samples.
224304385|NCT02767882|DRUG|Saline|Bolus injection of 4ml 0.9% saline will be given intravenously prior to incision.
223581009|NCT00576030|OTHER|hab cof with water|habitual coffee drinker provided with water
223581010|NCT00576030|OTHER|hab cof with dec espresso|habitual coffee drinkers given decaffeinated espresso
223743938|NCT03471195|DIAGNOSTIC_TEST|Total Salivary Cytokine profile|Saliva will be collected using the passive drool technique and stored in a deep freezerat-60C.
223743939|NCT02372669|DEVICE|Chitosan nerve tube in addition to gold standard therapy|Primary microsurgical repair of traumatic lesion of sensory nerves of the hand with use of an chitosan nerve tube in addition. Clinical Follow-up will be performed after 3,6,12 and 24 months.
223743940|NCT02372669|PROCEDURE|Gold standard Primary microsurgical repair|Primary microsurgical repair of traumatic lesion of sensory nerves of the hand. Clinical Follow-up will be performed after 3,6,12 and 24 months.
223743941|NCT00123539|DRUG|Estrogen Replacement Therapy|
223581011|NCT00576030|OTHER|hab cof with caf espresso|habitual coffee drinkers given caffeinated espresso
223581012|NCT00576030|OTHER|non-hab cof with water|non-habitual coffee drinkers given water
223581013|NCT00576030|OTHER|non-hab cof with dec espresso|non-habitual coffee drinkers given decaffeinated espresso
223581014|NCT00576030|OTHER|non-hab cof with caf espresso|non-habitual coffee drinkers given caffeinated espresso
223473614|NCT05181072|BEHAVIORAL|Virtual peer-motivation smoking cessation|This is a seven-week tobacco cessation program and will be offered virtually (except first two sessions: orientation and technology set-up) weekly for seven weeks and will utilize a newly developed website with smoking cessation modules that mirrors lessons of the CEASE Today Tobacco Cessation Manual
223581015|NCT05050396|PROCEDURE|Cooled versus thermocoagulant Radiofrequency Ablation in pain relief of knee osteoarthritis|Radiofrequency (RF) ablation, or modulation of the sensory innervation surrounding the knee, specifically the genicular nerves (GNs), has emerged as a therapeutic option to treat chronic knee OA pain for patients who are unresponsive to conservative treatments or are unsuitable candidates for total knee arthroplasty (TKA). \[16, 17\] Similar to conventional RFA, water-cooled radiofrequency (CRF) ablation is a novel technology that utilizes thermal ablative mechanisms; however, CRF gives the ability to create a greater local neuronal lesion to increase the changes of effective denervation \[20\]
223581016|NCT00002742|DRUG|amphotericin B deoxycholate|
223581017|NCT00002742|DRUG|nystatin|
224161156|NCT05544110|DEVICE|Sham transcranial magnetic stimulation|The coil is placed perpendicular to the scalp above the target for ineffective stimulation.
224161157|NCT01246024|DEVICE|ERG|scotopic and photopic ERG
223581018|NCT05251532|OTHER|Kinesio Taping|In addition to Kinesio Tex tape distortion taping, conventional rehabilitation is applied.
224161158|NCT02286752|DRUG|Neostigmine|for reversal of neuromuscular block: 0,05 mg kg-1 neostigmine + 0,025 mg kg-1 atropine
224161159|NCT02286752|DRUG|sugammadex|for reversal of neuromuscular block: sugammadex 2 mg kg-1
224161160|NCT05727527|PROCEDURE|Local Anesthesia 1|Local anesthesia injection after applying a candy flavor
224161161|NCT05727527|PROCEDURE|Local Anesthesia 2|Local anesthesia injection after applying sterile water
223581019|NCT05251532|OTHER|Conventional Rehabilitation|Conventional rehabilitation practices are carried out
223581020|NCT00895960|DRUG|Dasatinib|Starting dose of 150 mg/day administered by mouth daily on Days 1 to 28 of every 28 day cycle, beginning on the first day of RT.
223473615|NCT06098989|PROCEDURE|Radio frequency ablation|Radio frequency ablation
223581021|NCT00895960|RADIATION|RT (Radiotherapy)|As a part of standard of care, receive 60 Gy radiation therapy Monday-Friday for a total of 30 radiation treatments (about 6 weeks).
223743942|NCT00123539|PROCEDURE|Surgery|
223743943|NCT02560337|DRUG|Cabazitaxel|
224304386|NCT02188186|DRUG|Initial triple combination|Initial triple combination arm
224304387|NCT02188186|DRUG|Conventional treatment|Conventioanl treament with dose escalation
224304987|NCT00963781|DEVICE|Medtronic Endeavor Stent|The study population was to consist of 900 consecutive, eligible patients with ischemic heart disease scheduled to undergo elective percutaneous coronary revascularization and amenable to treatment with an Endeavor drug-eluting stent with reference vessel diameter between 2.5 and 4.0 mm. Patients will be assigned to 6 month duration of post-procedure thienopyridine treatment with indefinite aspirin (minimum 81 mg daily) according to protocol. Recruitment was terminated early due to difficulty recruiting patients and difficulty achieving patient compliance with the six month anti-platelet protocol.
223473616|NCT02106481|DRUG|Femoral Nerve Catheters|"Catheter will be bolused with 0.5 % ropivacaine around the femoral nerve and occlusive dressing applied over the catheter.~Patients with CFNB will receive ropivacaine 0.2% infusion (the infusion rate will be dependent on the clinical judgement of the anaesthesiologist)"
223473617|NCT02106481|DRUG|Single Shot Femoral Nerve Blocks|The group with SSFNB will receive a femoral nerve block before the surgery in the pre-operative area guided by a nerve stimulator and ultrasound. A bolus of 0.5 % ropivacaine will be injected around the femoral nerve.
223581022|NCT00895960|DRUG|TMZ (Temozolomide)|75 mg/m\^2 capsules daily by mouth for up to a maximum of 7 weeks beginning first day of RT until RT end followed by 4 weeks off then 150 mg/m\^2 daily on Days 1-5 of each 28 day study cycle and 200 mg/m\^2 daily of subsequent cycles.
223473618|NCT06132971|BEHAVIORAL|New Beginnings Program|
223581023|NCT00944463|DRUG|Gemcitabine+simvastatin|Gemcitabine and simvastatin
223581024|NCT00944463|DRUG|Gemcitabine+Placebo|Gemcitabine plus Placebo
223581025|NCT00787202|DRUG|CP- 690 550|Administration via oral route twice daily for the duration of treatment
223581026|NCT00787202|DRUG|CP- 690 550|Administration via oral route twice daily for the duration of treatment
223743944|NCT01246947|PROCEDURE|Tricuspid valve repair|Randomized to receive Tricuspid valve repair using a rigid 3-dimensional annuloplasty ring using standard techniques, during Mitral surgery.
223743945|NCT01246947|OTHER|Mitral surgery alone|Randomized to Mitral surgery alone
223743946|NCT03815097|PROCEDURE|Mapleson circuit and nasal trumpet|The Mapleson Circuit is a breathing system used to deliver oxygen and remove carbon dioxide during anesthesia. It consists of fresh oxygen flow, a reservoir bag, an expiratory valve, tubing, and a connection to the patient. There are different types of Mapleson circuits depending on the different arrangements of its components. We plan to use a Mapleson D circuit attached to a nasal trumpet via a connector.
224161162|NCT03986476|DIETARY_SUPPLEMENT|Probiotics|5x10\^8 colony forming units (CFU) of each probiotic strain, two capsules per day over six weeks
224161163|NCT03986476|OTHER|Placebo|Similar in shape and taste to intervention capsules but without the probiotic components, two capsules per day over six weeks
224161164|NCT00438724|BEHAVIORAL|Information, counseling and support|
224161165|NCT01525745|RADIATION|Radiosurgery/SBRT|1, 3 or 5 SBRT treatments
224161166|NCT01525745|RADIATION|External Beam Radiation Therapy|10 consecutive days of standard radiation
224161167|NCT00478595|DRUG|Rimonabant|Tablet, oral administration
224161168|NCT00478595|DRUG|Placebo (for Rimonabant)|Tablet, oral administration
224161169|NCT00478595|DRUG|Anti-diabetic monotherapy|Previous treatment with Sulfonylurea or α-glucosidase inhibitor continued at stable dose during the study period
224161170|NCT01037751|BEHAVIORAL|Interview|1-on-1 interview with study doctor or staff member, during regularly scheduled, standard of care clinic visit taking 30 minutes.
224161171|NCT01037751|BEHAVIORAL|Survey|Complete 3 Questionnaires during clinic visit, about 10 minutes to complete all.
224161172|NCT04709250|PROCEDURE|interscalene block|The patient will be put in the supine position, with the arm adducted a high-frequency linear ultrasound probe is oriented transversely across the lateral neck. When visualizing the ''stoplight sign,''15 to 30 mL of 0.25% bupivacaine will be injected
223473619|NCT06432387|OTHER|Patients undergoing complex thoraco-abdominal aortic aneurysm repair|Patients undergoing complex thoraco-abdominal aortic aneurysm repair
223581027|NCT00787202|DRUG|CP- 690 550|Administration via oral route twice daily for the duration of treatment
223581028|NCT00787202|DRUG|CP- 690 550|Administration via oral route twice daily for the duration of treatment
223581029|NCT00787202|OTHER|placebo|Administration via oral route twice daily for the duration of treatment
223581030|NCT05781958|DRUG|Cadonilimab+Gem/Cis|Cadonilimab (500mg, iv, Q3W, Day1) with gemcitabine(1000mg/m\^2, iv, Q3W, Day1and Day8) plus cisplatin(25mg/m\^2, iv, Q3W, Day1and Day8) up to 8 cycles followed by cadonilimab (500mg, iv, Q3W, Day1) plus capecitabine（1000 mg/m\^2 orally according to Body Surface Area (BSA)，BID，Q3W，on Days 1-14）as maintenance therapy until disease progression or other discontinuation criteria, up to 24months.
223581031|NCT05061654|DRUG|Ceftolozane-tazobactam IV|Empiric Ceftolozane-tazobactam IV 3g over 1 hour every 8 hours. The dose will be reduced to 1.5g 8 hourly in patients with CrCl of 30-50 ml/min, and to 750mg every 8 hours in those with CrCl of 15-29 ml/min. Patients on hemodialysis will receive 2.25g loading dose followed by 450mg every 8 hours.
223581032|NCT00979355|DEVICE|GP-D-SPECT|The D-SPECT system uses a solid-state detector, made of an alloy of Cadmium, Zinc, and Telluride, eliminating the need for thick crystals and large PMTs. As a result, the system is significantly miniaturized, and ergonomically optimized to both user and patient.
223581033|NCT04451824|DEVICE|CL-100|Red Light LED device for circumferential reduction
223581034|NCT00114023|DRUG|Imiquimod 5% cream|
223581035|NCT03291262|OTHER|Follow up for death and recurrence|Patients are followed up to determine the specific date of diagnosis, recurrence and death.
223581036|NCT06497335|DIAGNOSTIC_TEST|non invasive hemoglobin measure|non invasive hemoglobin measure
224069604|NCT01070160|DRUG|Endometrin (progesterone 100mg vaginal inserts)|once a day, 6-8 days as specified (prior to each EMBx)
224069605|NCT01070160|DRUG|Metformin|per clinical care guidelines
224069606|NCT00539695|BIOLOGICAL|IL-2|"IL2 Administration:~Patients will be given a fixed dose (1x10e5 units/m2/dose) of IL-2 given as a subcutaneous injection three times weekly (separated by at least one day) for 6 weeks beginning no earlier than day +7 after HSCT but beginning no later than 30 days after HSCT. If the patient has not developed \>grade I side effects to IL-2 and has not developed \>grade I GVHD then the patient may continue the IL-2 for 6 additional weeks. Time will be measured as 'week beginning with first IL-2 injection."
224161173|NCT04709250|PROCEDURE|selective nerve block|"the patient will be put in the sitting position, linear 38-mm high frequency 10-12 MHz transducer will be placed first on the scapula to view of the suprascapular nerve. 5-8 mL of 0.25% bupivacaine is injected to block the SSN.~The ultrasound probe put on the posterior aspect of the shoulder to view the circumflex artery, 10 mL of 0.25% bupivacaine this will lead to loss of sensation over the deltoid.lateral pectoral nerve block (LPNB) will be done by injecting a volume of 8 ml of a 0.25% bupivacaine The probe will be moved towards the biceps muscle until the musculocutaneous nerve is seen and 8 ml of 0.25% bupivacaine will be injected."
224161174|NCT04709250|DRUG|bupivacaine|bupivacaine
224161175|NCT04481945|DRUG|bioceramic sealer|pre-mixed bioceramic obturation material. It is dispensed using a syringe in cases of root canal obturation and with either a syringe or as a putty when doing root repair and retrograde fillings.
224161176|NCT00862498|OTHER|Written Disclosure|Five sessions, each spaced 1 week apart, during which participants are asked to write about their motor vehicle accident for 30 minutes. The first session of the intervention also involves a description of common reactions to a motor vehicle accident and the rationale for this treatment.
224161177|NCT00921570|DRUG|Amlodipine|calcium channel blocker (Amlodipine 10 mg) during 12 weeks
224161178|NCT00921570|DRUG|Valsartan|AII receptor blocker inhibitor (Valsartan 160 mg) during 12 weeks
224161179|NCT06234085|OTHER|VCA feedback report available|Access to feedback report described in the intervention
224161180|NCT05591430|PROCEDURE|Ganglion Impar Neurolysis|block of Ganglion Impar by neurolytic drug
224161181|NCT05591430|PROCEDURE|Bilateral S2, S3 and S4 Pulsed radiofrequency|Bilateral S2, S3 and S4 Pulsed radiofrequency
224161182|NCT03734770|DRUG|Subcutaneous Progesterone|Subcutaneous progesterone (Pleyris, IBSA Farmaceutici, Italia) 25 mg one time per day (every day at the same time, according to patient's availability and preference).
224161183|NCT03734770|DRUG|Vaginal progesterone|Micronized vaginal progesterone (Progeffik, EFFIK Spa, Italia) 200 mg three times per day (every 8 hours).
224161184|NCT04258904|COMBINATION_PRODUCT|Skin Care Program|The intervention consists of a Skin Care Program including neat information regarding dermatological complications to the device use, prevention of these and moisturizer to keep healthy skin.
224161185|NCT03237390|DRUG|Gemcitabine Hydrochloride|Given IV
224161186|NCT03237390|OTHER|Laboratory Biomarker Analysis|Correlative studies
224161187|NCT03237390|OTHER|Pharmacological Study|Correlative studies
224304988|NCT00963781|DRUG|Reduced duration (6 months) DAPT|
223473620|NCT04642989|OTHER|Sham Treatment|All movements of facial effleurage except applying pressure
223473621|NCT04642989|OTHER|Facial Effleurage|Facial massage to remove any lymphatic blockages
223473622|NCT04642989|DRUG|Antibiotics|"Appropriate standard-of-care antibiotics as determined by the physician."
223473623|NCT03845894|DRUG|Liposomal bupivacaine|Interscalene brachial plexus blockade using liposomal bupivacaine (expanded with plain bupivacaine)
223473624|NCT03845894|DRUG|Bupivacaine with adjuvants|Interscalene brachial plexus blockade using plain bupivacaine with adjuvants: clonidine, epinephrine, buprenorphine, dexamethasone.
223581037|NCT04933760|DIAGNOSTIC_TEST|Cytovale IntellipSep test|The Cytovale IntelliSep test measures a series of physical properties that indicate activation of leukocytes obtained from a venous K2-EDTA anti-coagulated whole blood sample.
223581038|NCT01428336|PROCEDURE|1 ug ACTH stimulation test|1 ug cortrosyn dose
223581039|NCT01428336|PROCEDURE|250 ug ACTH stimulation test|ACTH stimulation test will be done using 250 ug cortrosyn dose
224069607|NCT04276584|DEVICE|Positive expiratory pressure|Three blocks of 10 deep inspiration followed by expiration against a positive airway pressure device of 10-15 cm of water pressure. Repeated three times. Estimated time of 3 minutes time.
224069608|NCT04276584|OTHER|Speaking loudly during about 3 minutes|A specified swedish text
224304989|NCT01480843|DRUG|Glargine|Use of glargine with/without other glucose lowering agent to simplify insulin regimen in older adults
224161188|NCT03237390|DRUG|Ribociclib|Given PO
224161189|NCT01440972|OTHER|partial blood flow restriction (PBFR)|low intensity resistance training with partial blood flow restriction 3 times/week for 4 weeks.
223473625|NCT05232552|DRUG|Anlotinib hydrochloride|anlotinib was administered orally 12mg daily for 14 days concurrent with inductive chemotherapy (TP ) for 3 cycles and definitive chemoradiation for additional 2 cycles
223473626|NCT05232552|DRUG|induction chemotherapy|docetaxel 75mg/m2 d1 plus DDP 75mg/m2 d1 for 3 cycles every 21days
223473627|NCT05232552|RADIATION|concurrent chemoradiation|definitive IMRT (GTV\>66Gy) concurrent with 2 cycles of DDP (100mg/m2 d1) and anlotinib (12mg d1-14) every 21 days
223473628|NCT04942704|OTHER|Non interventional Imaging - MRI|MRI Scanning using short protocols
223473629|NCT02328508|DEVICE|Hyperbaric oxygen therapy|HBOT was carried out in a hyperbaric chamber for 120-min per session, five days a week for four consecutive weeks (20 treatment sessions).
223473630|NCT03809390|PROCEDURE|Vaginal seeding|The same as that stated in arm descriptions.
223473631|NCT02987881|BEHAVIORAL|Home-based aerobic exercise and nutritional counseling|Moderate walking and running with nutritional counseling at study visits.
223473632|NCT02171351|DEVICE|effect of neuromuscular electrostimulation (NMES)|Each subject (type 2 diabetes and control) will be assessed with plethysmography during a single session of neuromuscular electrostimulation (NMES).
223473633|NCT02171351|DEVICE|effect of neuro electrostimulation (NES)|Each subject (type 2 diabetes and control) will be assessed with plethysmography during a single session of neuro electrostimulation (NES)
223473634|NCT02171351|OTHER|effect of voluntary contractions (VC)|Each subject (type 2 diabetes and control) will be assessed with plethysmography during a single session of voluntary contractions (VC)
223473635|NCT00879190|DRUG|Unasyn|Unasyn 3 grams intravenously every 6 hours, plus intravenous normal saline placebo dose every 8 hours until 24 hours post delivery.
223473636|NCT00879190|DRUG|Ampicillin/gentamicin|Gentamicin 1.5mg/kg intravenously every 8 hours plus ampicillin 2 grams intravenously every 6 hours until 24 hours post delivery.
223473637|NCT01248455|DRUG|(Anti-KIR)|Patients will receive anti-KIR(IPH2101) (1mg/kg) every other month for 6 cycles
223473638|NCT03169569|PROCEDURE|Endo-clot™ (EndoClot Plus, Unc., Santa Clara, CA, USA) group|For patients in the study group, after hemostasis on the post-resection ulcer using conventional method and removal of specimen, Endo-clot™ (EndoClot Plus, Unc., Santa Clara, CA, USA) was applied immediately onto the post-resection surface.
223473639|NCT03169569|PROCEDURE|Hemostatic forceps Only (Coagrasper®, Olympus, Japan) group|All ESDs were performed according to the standard procedure sequence in the hemostatic group and control group except hemostatic powder application.
223581040|NCT01428336|PROCEDURE|25 ug Cortrosyn stimulation test|ACTH stimulation test using a 25 ug cortrosyn dose
223581041|NCT01428336|PROCEDURE|Insulin tolerance test|subjects will undergo an insulin tolerance test
223581042|NCT02423122|DRUG|VX-745|Orally-Active Selective P45 MAP Kinase inhibitor
223581043|NCT02248740|PROCEDURE|Ablation of the incompetent small saphenous vein|For each patient, the Small Saphenous Vein (SSV) will be accessed from the midcalf. After liberal use of tumescent anesthesia, ablation of the incompetent small saphenous vein will be performed. Half the patients will have this procedure performed using the Laser Ablation device and half will be performed using the Radiofrequency Ablation device. They will be randomly assigned to treatment.
223581044|NCT05363540|PROCEDURE|pre-incisional parasternal intercostal block|LA will be administrated by the anesthesiologist under ultrasound guidance and before surgical incision On either side of thorax, 2 cm lateral to sternal edge from 2nd to 6th intercostal space, A volume of (4 mL) of 0.25% bupivacaine will be used
223581045|NCT05363540|PROCEDURE|post-incisional parasternal intercostal block|LA will be administered by the cardiac surgeon before the sternal closure. injection will introduced 2 cm lateral to sternal edge from 2nd to 6th intercostal space and volume (4 mL) of 0.25% bupivacaine will be used.
223581046|NCT04069923|OTHER|Magnesium-based Bone Void Filler|Given intraoperatively
223581047|NCT02525094|BIOLOGICAL|MEDI9929|Participants will receive 6 subcutaneous doses of MEDI9929 280 mg every 2 weeks for 12 weeks, with the last dose at Week 10.
223581048|NCT02525094|BIOLOGICAL|Placebo|Participants will receive 6 subcutaneous doses of placebo every 2 weeks for 12 weeks, with the last dose at Week 10.
223581049|NCT02138240|BEHAVIORAL|Social network intervention|The intervention combined a social network approach with strategies that address public housing residents' challenges related to the built environment to improve dietary habits. Given the frequent intake of sugar-sweetened beverages (SSB) in this population, the intervention focused on reducing added sugar intake through the reduced consumption of SSB.
223473640|NCT04116333|DEVICE|Endotracheal tube introducer|Use of endotracheal tube introducer with the Macintosh laryngoscope on a manikin during continuous chest compressions with mechanical compression device.
223473641|NCT04116333|DEVICE|Macintosh laryngoscope|Use of the Macintosh laryngoscope on a manikin during continuous chest compressions with mechanical compression device.
223473642|NCT00426270|DRUG|Octagam 10%|Octagam 10% was supplied as a ready-to-use solution in glass bottles.
223473643|NCT06064240|OTHER|We do not have any intervention type|We do not have any intervention type
223473644|NCT02880423|PROCEDURE|tubal ligation group II|"Every woman , who is eligible to enter the study in terms of the above criteria , will receive a detailed explanation of the study and will review the consent form , and then be asked whether she agrees to participate in . If so , the participant will stamped on the informed consent form .~The control group will be women who undergo tubal ligation method BTL during cesarean section . All women will be invited to follow up about three months after surgery. The women will answer questionnaire to quantify the symptoms of menopause by NAMS , blood test for AMH and sonar and Doppler examination of both the ovaries"
223473645|NCT02880423|PROCEDURE|salpingectomy group I|women who agreed to participate in the study and assigned randomly to this group will have salpingectomy during cesarean section for sterilization.
224161190|NCT01440972|OTHER|low intensity resistance training|low intensity resistance training without partial blood flow restriction
224161191|NCT02811081|PROCEDURE|Passive Deflation|In the control group, residual carbon dioxide gas was evacuated by the routine method using passive exsufflation through the port site at the end of surgery.
223473646|NCT04956809|DRUG|Dapagliflozin 10Mg Tab|This will be a single-center randomized, placebo controlled, double-blind, 2-treatment, 2-phase cross-over trial in 27 HFrEF subjects: (A) Dapa 10 mg daily; (B) Placebo.
223473647|NCT04956809|DRUG|Placebo|This will be a single-center randomized, placebo controlled, double-blind, 2-treatment, 2-phase cross-over trial in 27 HFrEF subjects: (A) Dapa 10 mg daily; (B) Placebo.
223473648|NCT02209064|DEVICE|Pericardial access|Access to the pericardium to enable further treatments.
223473649|NCT05623800|OTHER|PREM-Kit|The PREM-Kit, which was created based on the Information-Motivation-Behavioral Skills model, is used in a series of HIV education sessions as part of the intervention. Over the course of three sessions, there will be a total of six weeks (one session for every two weeks). Three sub-modules, namely HIV facts and information, motivation for HIV preventive behavior, and behavioral skills for HIV prevention, will be emphasized in each session to the participants via flip chart and health educational videos. Additionally, participants will receive a QR code that gives them access to the PREM-Kit's e-flip chart, which they can see at a later time.
223473650|NCT01117870|OTHER|Pulsed Radiofrequency|120 seconds at 42 degrees celsius
223473651|NCT01117870|OTHER|Placebo|Needle will be continuously stimulated at a low voltage to give a sensation of PRF application.
223473652|NCT00272402|BEHAVIORAL|Cognitive Behavioral Intervention|Intervention consists of simulated case based learning for physicians.
223473653|NCT00272402|BEHAVIORAL|Office System Redesign Intervention|Intervention consists of clinical decision support within the electronic medical record.
223473654|NCT01669239|DRUG|Liposomal Doxorubicin|"Six cycles of:~* Trastuzumab 4 mg/kg loading dose on Day 1 of the first cycle, then 2 mg/kg on Days 8 and 15 of the first cycle and on Days 1, 8, and 15 of the subsequent cycles, every 3 weeks~* Pertuzumab 840 mg loading dose on Day 1 of the first cycle, then 420 mg on Day 1, every 3 weeks~* Liposomal doxorubicin 50 mg/m2 on Day 1, every 3 weeks~* Paclitaxel 80 mg/m2 on Days 1, 8, and 15, every 3 weeks"
223473655|NCT04135534|DRUG|group A|mutonpain 0.05 mg/kg
223473656|NCT04135534|DRUG|group B|mutonpain 0.1 mg/kg
223473657|NCT04135534|DRUG|group C|mutonpain 0.2 mg/kg
223473658|NCT05944796|OTHER|Diathermy|The patients belonging to the experimental group will undergo 10 diathermy sessions. The control group will have the same sessions but in athermy (placebo)
223473659|NCT05944796|OTHER|Placebo|The patients belonging to the placebo group will undergo 10 placebo sessions (athermya)
223473660|NCT02841696|DEVICE|Cardiac echography|The exam is in the left lateral decubitus position. 4 electrodes are applied to the patient's chest for a synchronization with the Electrocardiogram (ECG). The examination is conducted as standard with acquisition loops of records in parasternal long axis parasternal short axis, apical 4-cavities, 2-cavities and aorta 2 cavities.
223473661|NCT05409391|DEVICE|Insulin Titration System|A noval insulin titration system, which is based on deep learning
224161192|NCT02811081|PROCEDURE|Normal Saline Instillation|In the normal saline instillation group, in addition to the routine method, the patients were placed in the Trendelenburg position (30°), isotonic normal saline (20 ml/kg of body weight) was infused in the sub-diaphragmatic region at the end of surgery.
223473662|NCT04942067|DRUG|APG-2575+ Pd|APG-2575 + Pomalidomide 4mg QD x 21 days + dexamethasone (40 mg for patients ≤ 75 years old or 20 mg for patients \> 75 years old) on Days 1, 8, 15, and 22 of a repeated 28-day cycle
223473663|NCT04942067|DRUG|APG-2575 + DRd|APG-2575+ Lenalidomide administered at a dose of 25 mg orally (PO) on Days 1 through 21 of each 28-day cycle, dexamethasone will be administered at a dose of 40 mg (or 20 mg for patients \> 75 years old) once weekly, and daratumumab will be administered intravenously at a dose of 16 mg/kg (or 1800 mg administered subcutaneously if commercially available) weekly in cycles 1 and 2 and then every 2 weeks in cycles 3 to 6 and every 4 weeks thereafter.
223473664|NCT02057770|DRUG|busulfan|
223581050|NCT00314301|DEVICE|loaded sit-to-stand training|
224161193|NCT02811081|PROCEDURE|Normal Saline Instillation + Pulmonary Recruitment|In the combined intervention group, in addition to the routine method, the patients were placed in the Trendelenburg position (30°), and a pulmonary recruitment maneuver was performed after instillation of isotonic normal saline (20 ml/kg of body weight) in the sub-diaphragmatic region at the end of surgery.
223473665|NCT02057770|DRUG|fludarabine phosphate|
223473666|NCT02057770|RADIATION|total-body irradiation (TBI)|
223473667|NCT02057770|PROCEDURE|Stem cell transplant|
223581051|NCT03294070|COMBINATION_PRODUCT|Fimasartan plus amlodipine besylate|Fimasartan 60 mg plus amlodipine besylate 5 mg or Fimasartan plus 12.5 mg HCTZ plus one 5 mg amlodipine besylate
223473668|NCT02057770|DRUG|cyclophosphamide|
223473669|NCT02057770|DRUG|tocilizumab|
223473670|NCT01260909|DEVICE|Real-time kV/MV Prostate Imaging|The kV images will be acquired using onboard kV X-Ray imaging system existing in the clinical linear accelerator (LINAC).
223473671|NCT00489242|PROCEDURE|Procedure / Percutaneous angioplasty|
223473672|NCT05415306|BEHAVIORAL|Attention Bias Modification|Attention bias modification (ABM) is a procedure for treatment of depression, with the intention of supplementing cognitive behavioural therapy (CBT) or as a treatment on its own. ABM procedures modify attention biases in emotional disorders, resulting in subjects learning to deploy their attention toward the more positive stimuli (Jonassen et al., 2018). A computerized attention bias modification intervention for depression involves repeatedly redirecting the attention of the subject away from emotionally relevant threat cues, and towards neutral (non-threatening) stimuli (Amir et al., 2009). The location of the probe will replace the relatively positive stimulus in the pair with 100% probability.
223581052|NCT00699218|DEVICE|Magnetic Stimulator Rapid2 made by Magstim Company Ltd. U.K.|High frequency repetitive TMS given daily on weekdays for 3 weeks
223581053|NCT01228292|DRUG|Unfractionated heparin|dose 5-10 IU/kg/hrs adaptations of infusion rate upon APTT measurements during hemodialysis
223581054|NCT01228292|DRUG|Citrasate|Citrasate is infused as a dialysate
223581055|NCT04731207|DEVICE|Optovue®|Optical coherence tomography and optical coherece tomography angiography
223743947|NCT05463185|OTHER|Stretching exercises|Stretching exercises along with manual lymphatic drainage
224304990|NCT04430478|DIAGNOSTIC_TEST|Volume flow guided angioplasty|Volume flow measurements using DUS will be obtained at the end of each balloon dilation, at 24 hours, 6 months, and one year after index procedure.
224304991|NCT04607161|OTHER|no intervention|no intervention
224304992|NCT02048930|DEVICE|Budesonide Easyhaler|
224304388|NCT03963986|DEVICE|STIMUL group|The STIMUL Group participants in the Adaptive Physical Activity Focus (APA) program receive access to an online digital Platform, as well as a starter kit consisting of a connected pedometer measuring several physical activity indicators including the number of steps, number of so-called active minutes, sleep time, and distance travelled; a tape measure and a starter guide. They then conduct a remote assessment and motivational interview by videoconference or telephone, followed by 15-20 minute support interviews (month 1, month 3, month 6). Between these interviews, during months 1, 2, and 3, participants exchange weekly written messages with an educator on their platform. A planner of their physical activity objectives is provided.
224304389|NCT05563376|DIAGNOSTIC_TEST|Univentricular Hearts|Prevention when factors are recognized
224304390|NCT04098900|DIAGNOSTIC_TEST|Click Sexual Health Test|The Click Device is a single-use (disposable), fully integrated, rapid, compact, device containing a polymerase chain reaction (PCR)-based nucleic acid amplification test (NAAT) for accurate, qualitative detection and differentiation of deoxyribonucleic acid (DNA) for Neisseria gonorrhea (NG), Trichomonas vaginalis (TV), and Chlamydia trachomatis (CT) organisms.
224304391|NCT00714961|DRUG|Clopidogrel (SR25990)|plus acetylsalicylic acid (ASA)
223581056|NCT05895903|DEVICE|Screw expander|threadform screw expanders with special condensing burs for lateralization and compaction of bone
223581057|NCT05895903|DEVICE|Osseodensification drills|special drills to expand narrow alveolar ridges.
223581058|NCT03327168|DRUG|Adenosine|Intravenous infusion of adenosine (0.14 mg/kg) is administered for 5 minutes during PET/CT scan.
223581059|NCT03327168|OTHER|Cold exposure|Controlled cold exposure is performed before and during PET/CT scan.
223581060|NCT00868673|DIETARY_SUPPLEMENT|low fructose|"patients will receive a low fructose diet to evaluate possible changes in weight loss after a 6 week period of receiving a caloric intake (proteins, fats and carbohydrates) based on their healthy-desired weight. Participants will be randomized to a 1500, 1800 or 2000 kilocalories diet calculated by Harris Benedict equation, thermic effect of foods and energy (without exercise). low fructose arm: a 2 week period of low fructose diet (less than 10 grams/day ) followed by a 4 week period of healthy fructose diet levels (less than 20 grams/day).Baseline measurements and weekly monitoring of somatometry parameters (BMI, %body fat, waist and hip Index, blood pressure), lipid profile and uric acid levels will be done."
223581061|NCT00868673|DIETARY_SUPPLEMENT|Normal fructose arm|patients will receive a normal fructose diet to evaluate possible changes in weight loss after a 6 week period of receiving a caloric intake (proteins, fats and carbohydrates) based on their healthy-desired weight. Participants will be randomized to a 1500, 1800 or 2000 kilocalories diet calculated by Harris Benedict equation, thermic effect of foods and energy (without exercise). Normal fructose arm: participants will receive a 6 week period of normal fructose diet between 50 to 70 grams/day. Baseline measurements and weekly monitoring of somatometry parameters (BMI, %body fat, waist and hip Index, blood pressure), lipid profile and uric acid levels will be done.
223581062|NCT01495520|DRUG|Ranolazine|os, pill, 750 mg, b.i.d., 30 days
223581063|NCT01495520|DRUG|Placebo|os, pill, b.i.d., 30 days
223581064|NCT04905355|DEVICE|Virtual reality|The VR used during the ambulatory orthopedic surgery allows immersive experience in HD-2D virtual environment. Patient can choose among movies, cartoons, entertainments offered for visualization during the surgery
224069609|NCT06962787|DRUG|BL-B01D1|Administration by intravenous infusion for a cycle of 3 weeks.
224069610|NCT06962787|DRUG|axitinib|Oral administration, and twice daily with an interval of 12 hours.
224069611|NCT06962787|DRUG|pembrolizumab|Administration by intravenous infusion for a cycle of 3 weeks.
224069612|NCT01707407|DRUG|Pomalidomide|4 mg pomalidomide capsule administered orally once in the morning
224069613|NCT01707407|DRUG|Ketoconazole|200 mg Ketoconazole tablet administered orally twice a day on Days 1-7.
224069614|NCT01707407|DRUG|Fluvoxamine|50 mg Fluvoxamine tablet administered orally twice a day on Days 1-7.
224069615|NCT01707407|DRUG|Carbamazepine|"100 mg Carbamazepine tablet administered orally once in the evening on Day 1~100 mg Carbamazepine tablet administered orally twice daily on Days 2-3~200 mg Carbamazepine tablet administered orally twice daily on Days 4-11"
224069616|NCT05956041|DRUG|Pembrolizumab|400mg Intravenously
224069617|NCT05956041|DRUG|Mogamulizumab|1mg/kg Intravenously
224069618|NCT05493475|BEHAVIORAL|Fentanyl Test Strips|A brief fentanyl test strip (FTS) education intervention will be given to participants at court sites in the intervention arm after enrollment and collecting baseline data. It will be offered one-on-one with participants and will include the purpose, benefits, and limitations of FTS testing, and information on how to use FTS, interpret the results, what to do if the FTS is positive, and how to use FTS for different drug delivery methods. Participants will practice and demonstrate use of the FTS, and the short video on how to interpret the FTS will include an on-camera statement on the importance of testing for fentanyl. The video will be accessible to participants after study enrollment. Participants will be advised of the possibility of both false positive/negative results, and that the drugs may be mixed with other substances not detectable with FTS. Participants will be encouraged to practice other harm reduction strategies.
224069619|NCT05215340|DRUG|Datopotamab Deruxtecan|Dato-DXd will be administered as an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle.
224069620|NCT05215340|DRUG|Pembrolizumab|Pembrolizumab will be administered as an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle.
224069621|NCT05879419|BIOLOGICAL|Recombinant Herpes Zoster Vaccine (RZV)|RZV comprise 50 μg of recombinant VZV glycoprotein E and the liposome-based AS01B adjuvant system (which contains 50 μg of 3-O-desacyl-4'-monophosphoryl lipid A \[MPL\] and 50 μg of Quillaja saponaria Molina, fraction 21 (QS21, licensed by GSK from Antigenics, a subsidiary of Agenus)). Vaccine will be administered (0.5 ml) into the deltoid muscle at inclusion and 6 weeks (two doses).
224069622|NCT05879419|OTHER|MTX Discontinuation|Evaluation of discontinuation of the use of methotrexate (MTX) for 2 weeks after each vaccine dose in ARD patients: patients using MTX at a stable dose for at least 12 weeks, prednisone maximum dose of 5 mg/day, in association or not with other drugs except rituximab will be consecutively evaluated at outpatient clinics regarding disease activity. Those considered to be at stable disease (at remission or low disease activity according to specific standardized disease activity indexes) will be randomized (1:1) into two arms: one that will withhold MTX for 2 weeks after each vaccine dose (MTX-withhold) and other that will maintain stable therapy (MTX-maintain).
224161194|NCT04222673|BEHAVIORAL|Peer Specialist Suicide Prevention|The intervention will last 3-months, a time frame that overlaps with the typical duration of a VA suicide high risk flag. Meetings will be 30-45 minutes and occur primarily in the community, home, or by telephone. Session content will be rooted in Peer Specialists (PSs) offering nonjudgmental empathic support, active listening, and constructive disclosure and role modeling. A primary focus will be helping patients with flags to identify and strengthen connections with informal supports and participation in activities in their community that will enable them to feel more worthwhile as individuals and hopeful about their future.
224161195|NCT05010395|BEHAVIORAL|Letter intervention|Letter intervention
224161196|NCT00954473|OTHER|laboratory biomarker analysis|Correlative studies
224161197|NCT02766049|BIOLOGICAL|DC|Autologous dendritic cells (3x10e7)
224161198|NCT02766049|BIOLOGICAL|DC10e6+HIV-AT2|Autologous dendritic cells (3x10e6), pulsed with chemically inactive autologous HIV
224161199|NCT02766049|BIOLOGICAL|DC10e7+HIV-AT2|Autologous dendritic cells (3x10e7), pulsed with chemically inactive autologous HIV
224161200|NCT00068822|DEVICE|Percutaneous vertebroplasty|Placement of polymethylmethacrylate (PMMA) into vertebral compression fracture
224161201|NCT00068822|PROCEDURE|Sham vertebroplasty|Participants, following local anesthesia with lidocaine and bupivacaine, were given verbal and physical cues such as pressure on the back, but the needle was not placed.
224161202|NCT04944758|DEVICE|Light therapy|Light therapy
224161203|NCT00617162|DEVICE|Deep Brain Stimulation, Libra Deep Brain Stimulation System|DBS Active Treatment Group - implanted with investigational device and activated for stimulation
224161204|NCT00617162|DEVICE|Deep Brain Stimulation, Libra Deep Brain Stimulation System|implanted with investigational device, but will not receive active stimulation for the first 6 months of the study
224161205|NCT03881644|DRUG|Imigran|All patients will undergo this intervention on one of two study days
224161206|NCT03881644|OTHER|Isotonic Saline|All patients will undergo this intervention on one of two study days
224161207|NCT03881644|OTHER|Pituitary adenylate cyclase-activating peptide-38|All patients will undergo this intervention on both study days
224161208|NCT00489502|BEHAVIORAL|Brief Counseling|
224161209|NCT00489502|DEVICE|REE Assessment|
224161210|NCT00735072|DRUG|Placebo|Dose based on current medications in regimen: 150mg PO BID for those on a protease inhibitor-based regimen other than Tipranavir; 600mg PO BID for efavirenz-containing regimens; or 300 mg PO BID for all other regimens.
224161211|NCT00735072|DRUG|Maraviroc|Dose based on current medications in regimen: 150mg orally (PO) twice daily (BID) for those on a protease inhibitor-based regimen other than Tipranavir; 600mg PO BID for efavirenz-containing regimens; or 300 mg PO BID for all other regimens.
224161212|NCT02330471|PROCEDURE|Spray|surgical method to achieve intraoperative hemostasis by a superficial electrocoagulation of 80 Watt voltage
224161213|NCT02330471|PROCEDURE|Forced|surgical method to achieve intraoperative hemostasis by a deep tissue electrocoagulation of 80 Watt voltage
224161214|NCT03227094|DIAGNOSTIC_TEST|Standard OGTT|Standard-OGTT Plasma glucose : 0, 30, 60, 90, 120 minutes Complete biochemical profile, weight and size (body mass index), drugs list, pulmonary function by spirometry (FEV, etc.) Questionnaires CGMS training \& delivery of Jelly-Bean/75g glucose beverage
224161215|NCT03227094|DIAGNOSTIC_TEST|Home-based OGTT (Beverage)|In a random order Candy-OGTT (Jelly-Bean) or 75 g glucose beverage Glycemia every 15 minutes from CGMS collection; standardized condition (fasting + rest) Questionnaires
224161216|NCT03227094|DIAGNOSTIC_TEST|Home-based OGTT (Candy)|In a random order Candy-OGTT (Jelly-Bean) or 75 g glucose beverage Glycemia every 15 minutes from CGMS collection; standardized condition (fasting + rest) Questionnaires
224304392|NCT00714961|DRUG|Placebo|plus acetylsalicylic acid (ASA)
224304393|NCT03671616|BIOLOGICAL|IPV-Al SSI|IPV-Al contains the reduced dose of IPV to be administered intramuscularly to the anterolateral of the right thigh. A single dose of the IPV-Al SSI will be given to infants age 15-18 months.
224304394|NCT01381666|DRUG|INS316 solution for inhalation|inhalation via nebulizer given for 2 doses for 60 minutes each
224304395|NCT01381666|DRUG|hypertonic saline 3% sodium chloride solution|inhalation via nebulizer given for 2 doses for 60 minutes each
224304396|NCT06002841|BIOLOGICAL|intravenous treatment with EVs|intravenous treatment with extracellular vesicles
224304397|NCT06002841|BIOLOGICAL|intravenous treatment with placebo solution|intravenous treatment with placebo solution (without extracellular vesicles)
224304398|NCT05668130|PROCEDURE|Sacrospinous ligament fixation|Women with stage II or higher pelvic organ prolapse with apical compartment involvement planned for surgical management will be randomised to either sacrospinous ligament fixation arm or uterosacral ligament suspension arm. those raandomized to sacrospinous ligament fixation arm will undergo unilateral (right) sided sacrospinous ligament fixation of apex as a part of pelvic organ prolapse surgery.
224304399|NCT05668130|PROCEDURE|Uterosacral Ligament Suspension|Similarly women randomised to uterosacral ligament suspension arm will undergo modified high uterosacral ligament suspension of apex. Both arms will be followed up in 6 months and 12 months for anatomical and functional outcome.
224304400|NCT05910112|PROCEDURE|Pleural interventions|eg thoracocentesis, chest drain, indwelling pleural catheters, thoracoscopy
224304993|NCT02048930|DEVICE|Budesonide dry powder inhaler|
224161217|NCT03638362|DIETARY_SUPPLEMENT|Placebo|Participants consumed placebo beverage for 4 weeks.
224161218|NCT03638362|DIETARY_SUPPLEMENT|Tart cherry juice|Participants consumed tart cherry juice (8 ounces; 240 mL) per day for four weeks.
224161219|NCT03871764|DIAGNOSTIC_TEST|blood sample , doppler of uterine vessel and placenta|blood sample for factor V and doppler examination of uterine arteries , placenta pathology post partum
224161220|NCT02837809|RADIATION|Low dose CT|annual CT vs biennial CT
224161221|NCT06149741|PROCEDURE|Defunctioning left-sided loop colostomy|Descending or left transverse double-barrelled loop colostomy in left iliac fossa after complete splenic flexure mobilisation, mesorectal excision, and anastomosis.
224161222|NCT03938025|PROCEDURE|Gastric volume resected in sleeve gastrectomy|Misure of resected gastric volume and outcome
224161223|NCT05939076|DEVICE|Pulmonary vein isolation|Arctic Front™ Cryoballoon Advance, Medtronic, for pulmonary vein isolation
224161224|NCT05939076|DRUG|dronedarone - Multaq™ OR flecainide - Tambocor™ OR propafenone - Rytmonorm™ OR sotalol - Sotacor™|Antiarrhythmic drugs
224161225|NCT00003304|DRUG|temozolomide|
223473673|NCT05415306|BEHAVIORAL|Deep-breathing training|In most deep breathing studies, participants are required to alter their breathing pattern to a specific frequency for a specific duration of time. In the present study, participants will be required to perform deep-breathing at a rate of 6 breaths per minute for 9 minutes.
223473674|NCT05415306|BEHAVIORAL|Sham Training|This condition is identical to the Attention Bias Modification condition with the except of the location of the probe, which replaces the positive, negative, and neutral stimuli with equal probability. This control procedure is not expected to modify any underlying biases present.
223473675|NCT06297512|DRUG|Radiotherapy, Temozolomide, Doxorubicin|"Radiation treatment Concomitant TMZ: 75mg/m2/day per OS for 7 days per week, from the first day of radiotherapy to the last (maximum cumulative dose 3150mg/m2), with possibility of earlier initiation on clinician's judgment.~After 1 month (4-5 weeks ± 7 days) from the end of RT/TMZ treatment they will receive:~Adjuvant TMZ: 2 cycles at increasing doses (150-180 mg/m2) per OS for 5 consecutive days 28 days apart~After 3 months (12 weeks ± 7 days) from the end of RT/TMZ treatment they will receive:~Dox 4 cycles with 37.5mg/m2/day by continuous infusion over 48 hours (2 days) every 28 days (maximum cumulative dose 300mg/m2)~And after 4 weeks ± 7 days from the end of Dox treatment they will receive:~TMZ adjuvant 12 cycles at increasing doses (150-180 mg/m2) by OS for 5 consecutive days 28 days apart (maximum cumulative dose 16200 mg/m2);"
223581065|NCT01571869|OTHER|1- Low fat drinkable fermented dairy product enriched with 1.6g of plant sterol (as free equivalent) per unit|1-Intervention with test product (morning, evening or snack)
223581066|NCT01571869|OTHER|2- Low fat drinkable fermented dairy product without plant sterols (control)|2 - Intervention with control product (morning and/or evening)
224161226|NCT02934061|DEVICE|Tizaspray® administered intranasally|0,5 mg Tizaspray® administered intranasally
223473676|NCT02783612|OTHER|glucose buddy application|
223473677|NCT05190627|DRUG|Loratadine|Loratadine 10mg/day added to rapamycin for 12 months
223473678|NCT05190627|DRUG|Placebo 10mg/day added to rapamycin for 12 months|Placebo in the same type of capsule than the experimental drug
223473679|NCT03102762|DRUG|Botulinum Toxin Type A|Drug: Botulinum Toxin Type A The treatment group will be injected with 100 units BTX-A one day following penile colour doppler assessment.
223473680|NCT03102762|DRUG|Normal saline|The treatment group will be injected with 1 ml normal saline one day following penile colour doppler assessment.
223473681|NCT00958074|DRUG|vorinostat|Given PO
223473682|NCT00958074|OTHER|flow cytometry|correlative study
223473683|NCT00958074|OTHER|laboratory biomarker analysis|correlative study
223473684|NCT02709746|DRUG|Vortioxetine 10 mg/day|10 mg/day, encapsulated tablet (with addition of lower initial dose levels). Based on tolerability the dose may be reduced by 5 mg/day. No dose increase will be allowed
223473685|NCT02709746|DRUG|Vortioxetine 20 mg/day|20 mg/day, encapsulated tablet (with addition of lower initial dose levels). Based on tolerability the dose may be reduced by 5 mg/day. No dose increase will be allowed
223473686|NCT02709746|DRUG|Fluoxetine 20 mg/day|20 mg/day, encapsulated tablet (with addition of lower initial dose levels). Based on tolerability the dose may be reduced by 10 mg/day. No dose increase will be allowed
223473687|NCT02709746|OTHER|Placebo|Encapsulated tablet
223473688|NCT06029764|PROCEDURE|extended one-level interbody fusion|For patients who have vacuum signs in the intervertebral disc adjacent to the surgical segment but are asymptomatic and not unstable, the intervertebral fusion surgery is extended to one segment and followed up immediately after surgery, 3 months, 6 months, and annually within 1 to 5 years. Take lumbar spine MR to determine the degree of degeneration progression of adjacent segments and whether revision surgery is needed. Take X-rays of the lumbar spine in frontal and lateral + flexion and extension positions, and CT-three-dimensional reconstruction to judge the bony fusion of the intervertebral fusion.
223473689|NCT03962608|DEVICE|Yaq-001|Study patients will be dosed daily with 8g of product Yaq-001 for a period of 48 weeks. The product will be provided as beads packed in individual sachets intended each for one oral administration. For each patient, the study duration will be up to 54 weeks, including the screening (up to 45 days), treatment (48 weeks) and 7-day follow up period.
223473690|NCT03962608|DEVICE|Placebo|Study patients will be dosed daily with a quantity of placebo equivalent to 8g of product Yaq-001 for a period of 48 weeks. The product will be provided as beads packed in individual sachets intended each for one oral administration. For each patient, the study duration will be up to 54 weeks, including the screening (up to 45 days), treatment (48 weeks) and 7-day follow up period.
223473691|NCT00190268|DRUG|3,4-diaminopyridine|3,4-diaminopyridine
223581067|NCT03396055|OTHER|specific rehabilitation exercise|specific rehabilitation exercise for patients with cervical myelopathy
223581068|NCT03306641|DEVICE|Test Contact Lens|Daily disposable contact lens
223581069|NCT03306641|DEVICE|Nelfilcon A|Focus Dailies All Day Comfort contact lens (nelfilcon A)
223581070|NCT05764668|DRUG|Zihua Wenfei Zhisou Granule|14 daily- doses of Zihua Wenfei Zhisou Granule，one bag at a time (15 g/bag), three times/day
223581071|NCT05764668|DRUG|Placebo|14 daily- doses of placebo，one bag at a time (15 g/bag), three times/day
223581072|NCT06198855|DEVICE|QMon-20 device|Automatic Blood pressure measurement with QMon-20 device in the waiting room for 20 minutes every 5 minutes.
223581073|NCT03365141|DRUG|Triamcinolone acetonide 0.4mg/cc|"* Intralesional injection of dilute triamcinolone acetonide with 2% lidocaine (400mg/20 mL) would be performed to reduce pain when injecting the drug.~* Once weekly, for a total of 12 weeks"
223581074|NCT03365141|DEVICE|Phototherapy (NBUVB or excimer laser)|NBUVB or excimer laser treatment weekly
223581075|NCT03365141|DRUG|Topical tacrolimus|Application of topical tacrolimus ointment twice a day
224161227|NCT02934061|DRUG|Sirdalud® 2 mg tablets administered|Sirdalud® 2 mg tablets administered in patients with acute low back pain
224161228|NCT00029341|BEHAVIORAL|Treatment Interruption|
224161229|NCT02261311|OTHER|Quality of Life|All participants recruited will complete a questionnaire prior to their breast biopsy and then again approximately one week before their surgery. The questionnaire is focused on the level of anxiety patients experience during the wait time between diagnosis and surgery. Additional tissue will be collected at the time of the diagnostic biopsy.
224304401|NCT02906761|DRUG|Aspirin|Aspirin 600 mg (2 tablets of 300 mg) twice daily for 6 months
224304402|NCT02906761|DRUG|Placebo|Placebo (2 tablets) twice daily for 6 months
224161230|NCT01886404|DRUG|Efavirenz|"HIV-infected subjects currently receiving efavirenz (EFV) containing antiretroviral therapy (ART) will be asked to provide plasma samples. In addition to blood samples for determination of EFV concentrations, we will collect whole blood samples for functional Single Nucleotide Polymorphism (SNP) discovery within known candidate genes of interest in drug metabolism and transport.~Subjects will be at steady state for efavirenz when blood samples are collected. EFV is usually taken during the evening hours. The study consists of 2 blood draws at 12 and 18 hours post EFV dose. At the first blood draw, venous blood will be obtained by venous puncture for plasma concentrations of EFV and pharmacogenetics. At 18 hours post EFV dose , a second blood draw by venous puncture will be obtained for EFV plasma concentrations.~Demographics and clinical parameters will be collected at the time of the first visit, Neuropsychological tests and questionnaires completed as well."
223473692|NCT03123081|PROCEDURE|Umbilical Cord Milking|At birth the cord of a depressed newborn is clamped immediately and cut 30 cm from the umbilicus. After completion of initial steps, if required, positive pressure ventilation (PPV) is given for 30 seconds, along with UCM. The cord is untwisted and held in a vertical position. It is milked 3 times towards the baby at a speed of 10 cm/s and then clamped 3 cm from the umbilicus. After completion of PPV along with UCM, if the baby requires further resuscitation, the NRP 2015 guidelines will be followed. Depressed newborns who respond to initial steps of resuscitation with normal breathing and heart rate of 100 bpm or higher, will receive UCM after this.
224161231|NCT01581905|PROCEDURE|Conventional Laparoscopic Hysterectomy (LH)|Patients assigned to this intervention will undergo conventional laparoscopic hysterectomy, either total or supracervical.
224161232|NCT01581905|PROCEDURE|Robot Assisted Hysterectomy|Patients assigned to this group will undergo Robot-Assisted Laparoscopic Hysterectomy, either total or supracervical.
224161233|NCT02329145|PROCEDURE|renal denervation|
224161234|NCT04955509|OTHER|MRI|conventional MRI and diffusion MRI
224161235|NCT00978133|PROCEDURE|Dermabond ProPen (2-octylcyanoacrylate)|Application of 2 layers of Dermabond to abdominal wounds after closure of deep layers
223581076|NCT06942598|BEHAVIORAL|Produce prescription|Participants randomized to this arm will receive $10 worth of fruits and vegetables from Help Our People Eat (H.O.P.E) of Winston Salem each week. H.O.P.E is a local non-profit that distributes nutritious meals and fruits and vegetables to neighborhoods throughout Forsyth County to help families with FI. H.O.P.E also collaborates with local farmers to provide a Neighborhood Produce Market that provides low-cost produce. Participants will have the produce delivered to their home each week for 3 months.
223581077|NCT06942598|BEHAVIORAL|Medically tailored meals|Medically-tailored meals will be provided by Second Harvest Food Bank of Northwest NC. During the 3 months, participants will receive 10 medically-tailored refrigerated or frozen meals (5 lunches and 5 dinners) delivered to their home weekly. All meals are planned by a registered dietitian. Meals have minimal preparation time, can be heated by stove, oven, or microwave. Because the meals are medically-tailored, participants are asked not to share them.
223581078|NCT00494715|DRUG|Benazepril|Patients satisfying the inclusion/exclusion criteria will be randomly given equivalent doses (half the standard doses recommended by the manufacturer for blood pressure control) of benazepril (10 mg/day) or valsartan (160 mg/day) or one fourth of the standard doses of both agents in combination (benazepril 5 mg/day and valsartan 80 mg/day).If well tolerated, treatment will be up-titrated to full dose of benazepril (20 mg/day) or valsartan (320 mg/day) or one half of the standard doses of both agents in combination (benazepril 10 mg/day and valsartan 160 mg/day).
224161236|NCT00978133|PROCEDURE|Skin closure with skin staples|Skin closure with skin staples
224161237|NCT03146403|BIOLOGICAL|GEN-003|HSV-2 protein subunit vaccine consisting of 2 recombinant T cell antigens: internal fragment of the immediate early (IE) protein ICP4 and glycoprotein D
224161238|NCT03146403|BIOLOGICAL|Matrix-M2|Matrix-M2 is derived from fractionated Quillaja saponins, phosphatidylcholine, and cholesterol.
224161239|NCT03146403|OTHER|0.9% normal saline|Placebo
224161240|NCT02217683|DRUG|Nitric Oxide|Nitric oxide at 80 part per million will be administrated by inhalation for approximately 1 hour during the blood transfusion
224161241|NCT01024920|DRUG|BIBF 1120|VEGF inhibitor
224161242|NCT01024920|DRUG|sunitinib|VEGF inhibitor
223473693|NCT03114293|BEHAVIORAL|Smartphone App|The app includes an EBPI and physical activity feedback
223473694|NCT02755753|DRUG|Lansoprazole|Oral administration of Lanston® (lansoprazole) 30 mg, 1 capsule, PO, qd, 30 min before breakfast
223743948|NCT05463185|OTHER|Soft tissue mobilization|Soft tissue mobilization along with manual lymphatic drainage
223743949|NCT01859494|DEVICE|NINJA 3 Investigational Blood Glucose Monitoring System|Untrained subjects with diabetes self-tested capillary fingerstick and palm blood using the NINJA 3 Investigational Blood Glucose Monitoring System. Study staff tested subject fingerstick blood. All BG results were compared to reference method results obtained from subject capillary plasma.
224161243|NCT00077922|DRUG|LMB-2|40 micrograms/kg every other day (QOD) x 3 every 4 weeks
224161244|NCT06168890|DIAGNOSTIC_TEST|PET/CT with choline in the restaging phase of prostate cancer.|PET/CT with choline in the restaging phase of prostate cancer in patients suffering from prostate cancer with biochemical recovery of the disease during hormonal therapy.
224161245|NCT04917250|DRUG|Gemcitabine|1000mg/㎡，d1,4 ivdrip
224161246|NCT04917250|DRUG|Pegaspargase|2500IU/㎡, maximum dose less than 3750IU
224161247|NCT04917250|DRUG|Etoposide|100mg/㎡，d1-3 ivdrip
224161248|NCT04917250|DRUG|Dexamethasone|20mg/d d1-4 ivdrip
224161249|NCT06055049|OTHER|Intervention (Kinesio Taping) group|It is the group to which Kinesio Taping applied.
224161250|NCT04606407|DEVICE|LungFit™|Patients will receive inhalations of 150 ppm for 40 min 4 times a day, up to 7 days (maximum 28 treatments)
224161251|NCT06705842|DRUG|PVI|After removal of the appendix from the patient's abdomen and attainment of hemostasis, 10 mL/kg of 1% PVI (up to a maximum of 1,000 mL) will be used to irrigate the pelvis and right upper and lower quadrants. The solution will be left to dwell for 1 minute and then suctioned out
224161252|NCT06705842|DRUG|Usual Care|Surgeons may utilize local irrigation with saline if deemed necessary, defined as instillation of a small volume (\<100 mL) of liquid followed by aspiration, for the purpose of confirming hemostasis or suctioning thick fluid. Some surgeons may utilize large volume irrigation with saline solution, if that is consistent with their usual practice. Patients in the usual care arm will not receive PVI irrigation.
224161253|NCT00127816|PROCEDURE|Permanent prostate implant|
223473695|NCT02755753|DRUG|Rebamipide|Oral administration of Mucosta (rebamipide) 100 mg, 1 tablet, PO, tid, 30 minutes before breakfast, lunch, and dinner
223473696|NCT02755753|DRUG|Rebamipide-placebo|Oral administration of Mucosta®-placebo, 1 tablet, PO, tid, 30 minutes before breakfast, lunch and dinner
223473697|NCT01816321|DRUG|Corifollitropin alfa|Corifollitropin alfa 150μg on day 2 of the menstrual cycle (stimulation day 1)
223581079|NCT00494715|DRUG|Valsartan|Patients satisfying the inclusion/exclusion criteria will be randomly given equivalent doses (half the standard doses recommended by the manufacturer for blood pressure control) of benazepril (10 mg/day) or valsartan (160 mg/day) or one fourth of the standard doses of both agents in combination (benazepril 5 mg/day and valsartan 80 mg/day).If well tolerated, treatment will be up-titrated to full dose of benazepril (20 mg/day) or valsartan (320 mg/day) or one half of the standard doses of both agents in combination (benazepril 10 mg/day and valsartan 160 mg/day).
223581080|NCT00494715|DRUG|Benazepril/Valsartan|Patients satisfying the inclusion/exclusion criteria will be randomly given equivalent doses (half the standard doses recommended by the manufacturer for blood pressure control) of benazepril (10 mg/day) or valsartan (160 mg/day) or one fourth of the standard doses of both agents in combination (benazepril 5 mg/day and valsartan 80 mg/day).If well tolerated, treatment will be up-titrated to full dose of benazepril (20 mg/day) or valsartan (320 mg/day) or one half of the standard doses of both agents in combination (benazepril 10 mg/day and valsartan 160 mg/day).
223581081|NCT03927352|BIOLOGICAL|SCT630|Administered by subcutaneous injection
223581082|NCT03927352|BIOLOGICAL|Adalimumab|Administered by subcutaneous injection
223581083|NCT01751776|DRUG|Placebo matching BI 655064|Placebo matching BI 655064 injected subcutaneous.
223581084|NCT01751776|DRUG|BI 655064|BI 655064 injected subcutaneous
223581085|NCT03033342|DRUG|Oral single doses of MRX-4|Oral single escalating doses of MRX-4
223581086|NCT03033342|DRUG|Oral multiple doses of MRX-4|Multiple ascending doses of MRX-4 given twice daily for 10 days
223581087|NCT03033342|DRUG|MRX-4 co-administered with omeprazole|MRX-4 given orally on Day 1 and Day 7, co-administered with omeprazole on Day 3 through Day 7
223581088|NCT03033342|DRUG|Oral single doses of placebo|Single doses of placebo to match MRX-4
223581089|NCT03033342|DRUG|Oral multiple doses of placebo|Oral placebo given twice daily for 10 days to match the oral MRX-4
223581090|NCT03033342|DRUG|Placebo co-administered with omeprazole|Placebo given orally on Day 1 and Day 7, co-administered with omeprazole on Day 3 through Day 7
223581091|NCT00581451|DRUG|bifeprunox|oral tablet once daily
223581092|NCT04825990|DRUG|Pembrolizumab|200 mg pembrolizumab every 3 weeks plus 300 mg olaparib twice a day (BID) every day starting from Day 1 of Cycle 1.
223581093|NCT02483949|BEHAVIORAL|Healthy Eating and Active Living for Diabetes - Gestational Diabetes Mellitus|
223581094|NCT06448819|OTHER|Diet|Patients received Crohn's disease exclusion diet or Mediterranean diet
223581095|NCT01902459|BIOLOGICAL|EVARREST™ Fibrin Sealant Patch|EVARREST™ Fibrin Sealant Patch is a sterile, bio-absorbable combination product, comprised of two biological components (human plasma-derived fibrinogen and thrombin) embedded in a flexible composite patch component.
223581096|NCT01902459|OTHER|Standard of Care|Standard of Care will be manual compression (MC) with or without a topical absorbable hemostat (TAH) or any other adjunctive hemostasis technique that is deemed by the surgeon to be his/her standard of care.
223581097|NCT01122108|DRUG|Cholestyramine|Cholestyramine 12 grams, one time dose
223581098|NCT01122108|DRUG|Colesevelam HCl|Colesevelam HCl, 4 grams, one time dose
223581099|NCT05654701|DRUG|Palopegteriparatide (TransCon PTH)|The investigational drug Palopegteriparatide (TransCon PTH) is supplied as a solution with a concentration of 0.3 mg PTH(1-34)/mL in a single-patient-use prefilled pen intended for subcutaneous injection.
223581100|NCT02303899|DRUG|Gemcitabine|infusion drug
223581101|NCT02303899|DRUG|Imatinib mesylate|oral drug
223581102|NCT06064123|DIAGNOSTIC_TEST|Cell-free DNA|Donor-derived cell-free DNA relation to recipient-derived cell-free DNA is compared to histopathological rejection grade from the same time frame.
223581103|NCT05301738|OTHER|Plyometric Exercises|The plyometric exercise group received a 12-week plyometric training program. Each session lasted 45 minutes and was repeated two times a week. The training was conducted in conformity with the National Strength and Conditioning Association guidelines and American Academy of Pediatrics safety standards. The plyometric exercise program consisted of ten unilateral and bilateral lower limb plyometrics in the form of hopping/bounding/jumping activities. The Iplyometric workout was proceeded by a 5-minute warm-up and ended up with a 5-minute cool-down
224161254|NCT01608529|DEVICE|Feel Breathe, restriction device ventilatory nasal|The Feel Breathe (FB) consisted of a small adhesive strip that is placed across the bridge of the nose during exercise. The FB was place following procedures for placement as indicated by the manufacturer's directions, while the placebo nasal, was placed over the nostrils of the subject, without interfering nasal breathing; thus, nasal airflow resistance was not increase. Each subject was required to perform three identical submaximal exercises with intensity at 50% VT1-VT2 under different breathing conditions. The breathing conditions were: oronasal, nasal and FB breathing. All participants performed three trials of stable load (50% VT1-VT2) for 10 minutes in the three conditions mentioned above, setting the cadence at 70-75 rpm, and controlling the same in all three exercise conditions.
223473698|NCT01816321|DRUG|recombinant FSH|recombinant FSH 300IU/daily from day 2 of the cycle (stimulation day 8)until day of ovulation triggering
223473699|NCT01816321|DRUG|Ganirelix|Ganirelix 0.25mg/daily from day 7 of the cycle(stimulation day 6) until day of ovulation triggering
223473700|NCT01816321|DRUG|hp HMG|hp HMG 300IU/daily from day 9 of the cycle (stimulation day 8)until day of ovulation triggering
223473701|NCT01206465|DRUG|pralatrexate|Given IV
223473702|NCT01206465|DRUG|fluorouracil|Given IV
223473703|NCT01206465|OTHER|laboratory biomarker analysis|Correlative studies
223473704|NCT01206465|GENETIC|DNA analysis|Correlative studies
223473705|NCT01206465|OTHER|high performance liquid chromatography|Correlative studies
223473706|NCT01206465|GENETIC|polymerase chain reaction|Correlative studies
223581104|NCT05301738|OTHER|Standard Physical Therapy|The control group received their usual physical rehabilitation program for 45 minutes, twice/week for 12 consecutive weeks. The program comprised advanced balance training, and gait training exercises, postural and flexibility exercises, strength training exercises.
223743950|NCT00862186|BEHAVIORAL|'Fatigue Facts & Fixes'|"'Fatigue Facts \& Fixes' is an evidence based educational resource for adolescents with cancer. It is a bright colored laminated 8.5x11 double sided page. One side features information on cancer-related fatigue: Why am I so tired? (description of cancer-related fatigue); What causes fatigue? (contributing factors - environmental, personal/behavioral, cultural/family/other, and treatment-related); and What can help me to not be so tired? (alleviating factors - environmental, personal/behavioral, cultural/family/other, and treatment-related). The other side is a 'Do Not Disturb' sign with a pillow graphic which adolescents can use in the hospital or at home when they need some quiet time and which may also serve to attract their interest to the resource."
223473707|NCT01206465|GENETIC|nucleic acid sequencing|Correlative studies
223473708|NCT01206465|OTHER|pharmacological study|Correlative studies
223581105|NCT03984630|BEHAVIORAL|Dietary Fiber Intervention|Intervention included weekly group-based phone counseling with a Registered Dietitian (RD) to encourage consumption of a high fiber diet (≥30 g/day). All women reported their body weight weekly.
223581106|NCT02909855|OTHER|No intervention|Participants in this study will not receive any interventions as part of the study.
223581107|NCT02030990|DRUG|Mitomycin-C|0.01% applied to cornea with a sponge during PRK
223581108|NCT02030990|DRUG|Fluorometholone 1% topical ocular steroid|topical steroid drops applied to the cornea after PRK
223581109|NCT02728531|DRUG|Bendamustine|
223581110|NCT02728531|DRUG|Rituximab|
223581111|NCT02728531|DRUG|Cytarabine|
223581112|NCT02728531|DRUG|Pegfilgrastim|
223581113|NCT02728531|PROCEDURE|Leukapheresis|
223581114|NCT02728531|DRUG|Filgrastim|
223581115|NCT02728531|PROCEDURE|Autologous stem cell transplant|
223581116|NCT01910870|DRUG|Cisplatin|25 mg/m² I.V. (day 1 to day 3) Total dose : 75 mg/m² every 3 weeks
223581117|NCT01910870|DRUG|Metronomic Cyclophosphamide|150 mg per os from day 1 to day 14 (total dose = 2100 mg) every 3 weeks
223581118|NCT01813123|BEHAVIORAL|RealTeen|A web-based, gender-specific program intended improve girls' cognitive and behavioral skills. Each of the 9 sessions requires approximately 20 minutes. After initial intervention, girls will receive two annual booster sessions (i.e., a 20-minute review of previously learned material indexed to new age).
223581119|NCT00831701|DRUG|Tamsulosin|0.4 mg Tamsulosin once daily for 21 days
223581120|NCT00831701|DRUG|Placebo|One placebo pill per day for 21 days or until stone expulsion
223743951|NCT00365196|BEHAVIORAL|CBT Hostility Reduction Program|
223743952|NCT06846671|DRUG|BGB-16673|Administered orally
224069623|NCT05879419|OTHER|MMF Discontinuation|Evaluation of discontinuation of the use of mycophenolate mofetil (MMF) for one week after each vaccine dose in ARD patients: patients using MMF at a stable dose for at least 12 weeks, prednisone maximum dose of 7.5 mg/day, not associated with other immunosuppressive therapy, will be consecutively evaluated at outpatient clinics regarding disease activity. Those considered to be at stable disease (at remission or low disease activity according to specific standardized disease activity indexes) will be randomized (1:1) into two arms: one that will withhold MMF for 2 weeks after each vaccine dose (MMF-withhold) and other that will maintain stable therapy (MMF-maintain).
224069624|NCT05879419|OTHER|Placebo|Patients with ARDs who received the placebo at study entry (P2). ARD patients will be randomly assigned in a 1:1 ratio, with the use of an automated Web and telephone system, to one of two subgroups: P1, patients allocated to receive vaccine right after randomization (at D0 and D42), and P2, patients allocated to receive placebo at D0 and D42. Subsequently, blindness will be broken at D84 and P2 patients will receive vaccine doses at the D84 and D126.
224161255|NCT02804373|DRUG|Oxytocin (OXT) continuous|Administration of 24 IU of oxytocin daily during 28 days
223473709|NCT01206465|OTHER|pharmacogenomic studies|Correlative studies
223473710|NCT01206465|GENETIC|polymorphism analysis|Correlative studies
223473711|NCT03802552|DRUG|Cefadroxil|oral one-time dose of cefadroxil
223473712|NCT03802552|DRUG|Cephalexin|oral one-time dose of cephalexin
223473713|NCT01939912|DRUG|Adenosine|Antiarrhythmic agent.
223473714|NCT01607658|DRUG|Placebo|placebo intranasal gel administered prn, 2-8 hours before a planned sexual event
223581121|NCT01805388|DRUG|Experimental: Regeneration Treatment Group|Regenerative Root Canal Therapy using Triple Antibiotic Paste study drug
223581122|NCT01805388|PROCEDURE|Control Non-Study Drug Group|Endodontic RTC with no study drug
223581123|NCT03481621|DEVICE|Acupuncture|Needle size: #32(0.22 mm), 1-1.5 inch(30-40 mm long); Acupuncture time and frequency: 45 min per session, once or twice per week, for 6-12 sessions total (in 6 weeks).
223581124|NCT03481621|OTHER|Standard care|PT, pain medications, nerve block, etc
223581125|NCT02437786|DRUG|GRAZAX|GRAZAX
223581126|NCT04720768|DRUG|Binimetinib|MEK inhibitor
223581127|NCT04720768|DRUG|Encorafenib|BRAF inhibitor
223581128|NCT04720768|DRUG|Palbociclib|CDK4/6 inhibitor
223581129|NCT04462991|DIAGNOSTIC_TEST|corneal topography|In all patients, TCT will be measured first by WaveLight® Oculyzer™II Pentacam HR and second by The Optovue AS-OCT .
223581130|NCT02301481|RADIATION|SIB-IMRT|45.1Gy and 40.04Gy in 22 fractions using intensity-modulated radiotherapy with a simultaneous integrated boost (SIB-IMRT) to primary tumor
223581131|NCT02301481|DRUG|S-1|40mg/m2, orally twice daily every weekday concurrently with radiotherapy treatment
223581132|NCT02301481|PROCEDURE|Surgery|Surgery, preferred D2 lymphadenectomy
223581133|NCT02301481|DRUG|SOX|SOX (S-1: 40\~60mg, orally twice daily on days 1 to 14, oxaliplatin 130mg/m2 intravenously on day 1, 21 days per cycle)
223581134|NCT05113667|OTHER|Clinical Pharmacist-led Appropriate Acid Suppression Therapy Stewardship Program|Clinical pharmacist provided medication reconciliation and medication review during the hospital stay.
223581135|NCT01329744|DRUG|mecasermin|a subcutaneous injection twice a day
223581136|NCT01329744|DRUG|Placebo control|Subcutaneous injection given twice per day of placebo compound, for 24 weeks
223581137|NCT00123773|PROCEDURE|Positron Emission Tomography|
223743953|NCT06846671|DRUG|Bendamustine|Administered intravenously
223743954|NCT06846671|DRUG|Idelalisib|Administered orally
223743955|NCT06846671|DRUG|Rituximab|Administered intravenously
223743956|NCT06846671|DRUG|Venetoclax|Administered orally
223743957|NCT01027481|DRUG|Lucentis|intravitreally administration of 0.05 ml Lucentis
223473715|NCT01607658|DRUG|Low dose TBS-2|Low dose testosterone intranasal gel administered prn 2-8 hrs before a planned sexual event
223473716|NCT01607658|DRUG|Medium dose TBS-2|Medium dose testosterone intranasal gel administered prn 2-8 hrs before a planned sexual event
223473717|NCT01607658|DRUG|High dose TBS-2|High dose testosterone intranasal gel administered prn 2-8 hrs before a planned sexual event
223473718|NCT05269329|DRUG|XC8, film-coated tablets, 20 mg/day|20 mg/day (1 tablet twice a day)
223473719|NCT05269329|DRUG|XC8, film-coated tablets, 40 mg/day|40 mg/day (2 tablets twice a day)
223473720|NCT05269329|DRUG|XC8, film-coated tablets, 80 mg/day|80 mg/day (4 tablets twice a day)
223473721|NCT05269329|DRUG|Placebo|1, 2, or 4 tablets twice a day
223473722|NCT00914121|DRUG|SKI-606|
223473723|NCT00914121|DRUG|Placebo|
223473724|NCT00914121|DRUG|Moxifloxacin|
223473725|NCT03588117|BEHAVIORAL|Physician-supervised nonsurgical weight management program|Participants of a physician-supervised nonsurgical weight management program were observed as they received weekly in-person coaching sessions with licensed clinicians. In-person coaching sessions were focused on educating participants on strategies to manage their weight and adopt a healthy lifestyle. Prescribed diets were individualized based on each participant's behavior, level of physical activity, and total energy expenditure. Supplements, appetite suppressant medications, and compounded injections were used to control appetite and/or boost energy during a period of low-caloric intake. The program was generally divided into three phases: Acute, Short-Term Maintenance, and Wellness.
223473726|NCT05555680|OTHER|Ferriman-Gallwey Score|The Ferriman-Gallwey score is used to evaluate hirsutism. The examiner scores the subjects on a scale of 0-4 for terminal hair growth on eleven different body areas according to the Ferriman-Gallwey scoring system. A Ferriman-Gallwey score of 8 or more was considered diagnostic of hirsutism
223581138|NCT02210091|BIOLOGICAL|Antihemophilic Factor (Recombinant) - Plasma/Albumin Free Method|Pharmacokinetic (PK) analysis of ADVATE
223581139|NCT02210091|BIOLOGICAL|PEGylated Recombinant Factor VIII|Pharmacokinetic (PK) analysis of BAX 855
223743958|NCT02210936|OTHER|Educational Intervention|"The design is primarily a pre-post, non-equivalent comparison group test of program effectiveness. If final sample size permits, we will examine program effects for each practice environment separately. For measures that require interview data there will be no comparison group data.~We will construct matched comparison groups of physicians for each environment for which only secondary data analysis will be conducted. The matched comparison group will be constructed using prescription data from the DoD's pharmacy data transaction system (MACH and DORN VAMC) and from SCRIPTS (community-based physicians and VA prescribers)."
224161256|NCT02804373|DRUG|Placebo|Placebo daily during 28 days
223473727|NCT02142842|BIOLOGICAL|Autologous adipose tissue stromal vascular fraction and platelet rich plasma|
223473728|NCT03426345|DRUG|Placebo|Placebo injected subcutaneously twice daily.
223581140|NCT02210091|BIOLOGICAL|PEGylated Recombinant Factor VIII|Prophylaxis treatment
223581141|NCT01613352|OTHER|Ambulatory surgery|Sentinel node mapping was done on the previous day and the patients were operated on first in the morning.
223581142|NCT01268215|DRUG|Infasurf|Endotracheal instillation of Infasurf once per week for three weeks
223581143|NCT01268215|DRUG|Pulmicort|Endotracheal instillation, once per week for three weeks
223743959|NCT04073758|DRUG|Dexmedetomidine|Comparing effects of remifentanil versus dexmedetomidine
223581144|NCT01268215|OTHER|Sham|None instilled through the endotracheal tube
223581145|NCT02290938|BEHAVIORAL|MICUNAY|MICUNAY is a three session workshop focused on discussions about how to make healthy choices using motivational interviewing, and providing a cultural activity.
223581146|NCT02290938|OTHER|Community Wellness Gathering|a monthly gathering focused on making healthy choices and learning about Native American culture
223581147|NCT03362697|DIETARY_SUPPLEMENT|Probiotics|The Probiotic group will receive Sachet 1 - contains an instant cranberry drink, consisting of xylitol, monosodium citrate, cranberry aroma, cranberry extract, grape-skin extract, xanthan gum, acesulfame potassium and zinc gluconate and Sachet 2 - contains a total of 5\*10\^8 CFU of Lactobacillus reuteri DSM 16666/ATCC 55845 \& Lactobacillus reuteri DSM 17938, mixed with maltodextrin. Both Sachets should be administered Day 1-14, twice per day This group will also receive for Placebo for Antibiotic treatment day 1-7, twice per day
223581148|NCT03362697|DRUG|Antibiotics|Patient in this group will receive for 7 days Amoxicillin + clavulanic acid (500 mg twice daily) for seven days in patients with negative nitrites in dipstick or oral nitrofurantoin (200mg twice per day) for patients with positive nitrates in dipstick. This group will also receive for placebo for probiotics 2 sachets for 14 days
223581149|NCT02578342|DEVICE|MRI|Functional Magnetic Resonance Imaging technique measures brain activity by detecting associated changes in blood oxygenation level dependency
223743960|NCT03897452|DRUG|Fentanyl (5 microgram/ml) prediluted ampoules|"Bolus; Fentanyl (5 microgram/ml) 0,5 microgram/kg (0.1 ml/kg) is administered over 1 min starting 3-5 min before the lighter skin breaking procedure.~Fentanyl (5 microgram/ml) 2 microgram/kg is administered over 10 min before the start of the more painful procedur ( pleura drainage or tracheal intubation)."
224161257|NCT02804373|DRUG|Placebo continuous|Placebo administration the following 2 days after each OXT administration, during 28 days.
224161258|NCT02804373|DRUG|Oxytocin|Administration of 24 IU of oxytocin every 3 days during 28 days.
224161259|NCT04517110|DRUG|Pregabalin 300 mg|Pregabalin 300 mg, capsule
224161260|NCT04517110|DRUG|Pregabalin 75 mg|Pregabalin 75 mg twice daily, capsules
224161261|NCT04517110|DRUG|Pregabalin 300 mg Placebo|Placebo, matching Pregabalin 300 mg capsule
224161262|NCT04517110|DRUG|Pregabalin 75 mg Placebo|Placebo, matching Pregabalin 75 mg capsules
224161263|NCT04517110|OTHER|Usual Care|Usual Care
223473729|NCT03426345|DRUG|Relamorelin|Relamorelin 10 μg injected twice daily for 12 weeks.
223473730|NCT03594006|BEHAVIORAL|CCI; cancer care coordination instrument|Designed to assess cancer patients' perceptions of care coordination
223473731|NCT05581563|PROCEDURE|total knee arthroplasty(TKA)|Knee replacement, also called knee arthroplasty or total knee replacement, is a surgical procedure to resurface a knee damaged by arthritis. Metal and plastic parts are used to cap the ends of the bones that form the knee joint, along with the kneecap. This surgery may be considered for someone who has severe arthritis or a severe knee injury.
223473732|NCT03534024|DIETARY_SUPPLEMENT|nanomicielle curcumin|Participants will be selected from those referring to endocrinology clinics of Shohadaye YaftAbad and Pars Hospital (Tehran, Iran) who meet the inclusion criteria. Each subject will give informed written consent to participate in the study. 10 cc fasting blood samples will be collected from each subject at baseline and at the end of trial. Anthropometric parameters will be measured.In order to control the confounding factors in patients, they will be randomly assigned to receive either nanomicelle curcumin or placebo. nanomcelle curcumin and placebo supplements will be provided from the Elixir Nano Sina Company the patients will advise not to change their lifestyle during the study.
223473733|NCT03534024|DIETARY_SUPPLEMENT|placebo|Participants will be selected from those referring to endocrinology clinics of Shohadaye YaftAbad and Pars Hospital (Tehran, Iran) who meet the inclusion criteria. Each subject will give informed written consent to participate in the study. 10 cc fasting blood samples will be collected from each subject at baseline and at the end of trial. Anthropometric parameters will be measured.In order to control the confounding factors in patients, they will be randomly assigned to receive either nanomcielle curcumin or placebo. nanomcelle curcumin and placebo supplements will be provided from the Elixir Nano Sina Company the patients will advise not to change their lifestyle during the study.
223581150|NCT00906269|DRUG|Sildenafil therapy plus post-NSRRP HBO2T|Sildenafil (Viagra) 50 mg - PO QHS for 12 months beginning the first evening they return home from surgical hospital stay PLUS Post-NSRRP hyperbaric oxygen therapy (90 minutes of 100% oxygen at 2.2ATA (equivalent to the pressure exerted at a depth of approximately 40 feet below sea level). There will be 5 or 10 treatments. The full treatment cycle will be completed within 2 weeks.
223581151|NCT00906269|DRUG|Sildenafil therapy plus sham post-NSRRP HBO2T|Sildenafil (Viagra)50 mg - PO QHS for 12 months beginning the first evening they return home from surgical hospital stay PLUS Post-NSRRP sham hyperbaric oxygen therapy - 90 minutes at 2.2ATA but instead of 100% oxygen, they will receive air administered via the oxygen hoods, as if they were being administered oxygen. Participants in this group will receive 5 or 10 sham treatment sessions. Full treatment cycle will be completed within 2 weeks.
223581152|NCT06397508|DRUG|AGMB-129|Each participant will receive 3 study interventions, 1 in each intervention period
223581153|NCT04507165|PROCEDURE|Paravertebral block+Anterior serratus plane block|"Paravertebral block will be performed at T3 and T7 level on the surgical side using out-of-plane approach under ultrasound-guided, with 0.5% ropivacaine 10ml at each injection site. Anterior serratus plane block will be performed at the 4th rib level on the surgical side under ultrasound-guided, with 0.5% ropivacaine 15ml. The blocking range is measured by ice cube method 15 minutes after the procedure."
223581154|NCT04507165|DRUG|opioid free anesthesia|"Anesthesia induction: Dexmedetomidine 1µg/kg (intravenous infusion within 10min), propofol 1.5-2mg/kg (intravenous bolus), lidocaine 1.5-2mg/kg (intravenous bolus), cisatracurium besylate 0.15-0.3mg/kg (intravenous bolus before tracheal intubation), methylprednisolone 40mg (intravenous bolus), esmolol 1mg/kg (intravenous bolus), and 0.5% tetracaine 5ml for surface anesthesia of the throat.~Maintenance of anesthesia: Continuous infusion of propofol and dexmedetomidine \[0.4μg/(kg.h)\]. The infusion rate of propofol was adjusted according to bispectral index value. Cisatracurium besylate was given as needed. Flurbiprofen 50mg was given intravenously before the skin incision and suture respectively.~Remedy: If blood pressure rises (more than 30% of the mean arterial pressure after induction), and heart rate increases (more than 30% of heart rate after induction) during skin incision, lidocaine 1.5mg/kg will be given intravenously and then be continuously infused at a rate of 1.5mg/(kg.h)."
223743961|NCT02381418|BIOLOGICAL|Trivalent influenza subunit vaccine Influvac|"3x 15mcg HA per 0.5 ml,trivalent one injection at Day 1 "
223743962|NCT00003681|BIOLOGICAL|epoetin alfa|
223743963|NCT00003681|DRUG|amifostine trihydrate|
223743964|NCT02270164|DIETARY_SUPPLEMENT|Artichoke Leaf Extract|Capsule
223743965|NCT02270164|OTHER|Placebo|Capsule
223743966|NCT00424138|RADIATION|FDG|
223743967|NCT01903304|OTHER|Olive Oil|3 months intervention
223743968|NCT04458753|OTHER|Lumbar focused exercises|Transersus abdominis activation Multifidus activation Back extension exercise Curl up abdominal exercise
223743969|NCT04458753|OTHER|Knee focused exercises|Strengthening of quadriceps Stretching of calf and Hamstring muscles
223743970|NCT01879228|DRUG|Sitagliptin|The GPA test as described in the primary outcome section will be performed at baseline and after 6 months of therapy in the Sitagliptin and placebo arms. Furthermore, evaluation of endogenous GLP-1 levels will be assessed by a mixed meal tolerance test compared at baseline and 6 months.
224069625|NCT05879419|OTHER|MTX maintain|MTX dose will be held stable after the two vaccine doses for comparison of vaccine immunogenicity and disease activity with the MTX-withhold group.
224069626|NCT05879419|OTHER|MMF maintain|MMF dose will be held stable after the two vaccine doses for comparison of vaccine immunogenicity and disease activity with the MMF-withhold group.
224069627|NCT02008656|DRUG|Oxaliplatin (OXAL)|
224069628|NCT02008656|DRUG|5-Fluorouracil (5-FU)|
224069629|NCT02008656|DRUG|Leucovorin|
224069630|NCT02008656|DRUG|Capecitabine (Xeloda®)|
224069631|NCT02008656|RADIATION|intensity modulated radiotherapy (IMRT)|
224069632|NCT02008656|BEHAVIORAL|Quality of Life Questionnaires|
224069633|NCT02008656|PROCEDURE|DRE-Endoscopy|
224069634|NCT06570304|PROCEDURE|iCount Device|"Designed as single use. Intended purpose - To be used to count swabs and tampons after surgery in an objective manner. This is intended to be used in patients during and just after surgery.~This is a device accessory."
224069635|NCT05010005|DRUG|Ruxolitinib|Ruxolitinib 20mg BID
224069636|NCT05010005|DRUG|Duvelisib|Duvelisib 25mg, 50mg, or 75mg BID
224069637|NCT03988439|DRUG|IDP-118 Lotion|Topical
224069638|NCT06388187|DRUG|Cagrilintide|Participants will receive once-weekly cagrilintide subcutaneously.
224069639|NCT06388187|DRUG|Semaglutide|Participants will receive once-weekly semaglutide subcutaneously.
224069640|NCT06388187|DRUG|Placebo|Participants will receive once-weekly placebo matched to cagrilintide and semaglutide subcutaneously.
224069641|NCT00832728|OTHER|Standard of Care|Standard hospital protocol for the treatment of acute liver failure
224069642|NCT00832728|DEVICE|ELAD®|ELAD therapy
224161264|NCT05015322|DRUG|bupivacaine and methylprednisolone|5 mL of 0.25% bupivacaine containing 20 mg methylprednisolone was administered to the subacromial area
223473734|NCT02463383|DRUG|Ibuprofen Tab 400 MG|400mg ibuprofen is provided and an alcohol challenge (0.4g/kg bw) is given 30min later
223473735|NCT02463383|DRUG|Placebo tab|A placebo tablet is provided and an alcohol challenge (0.4g/kg bw) is given 30min later
223473736|NCT01448733|DRUG|Benzoyl peroxide 2.5%/clindamycin phosphate 1.2% in the morning with with tretinoin 0.05% gel in the evening|Green pea sized amount of Benzoyl peroxide 2.5%/clindamycin phosphate 1.2% in the morning in combination with a green pea sized amount of tretinoin 0.05% gel in the evening
224161265|NCT05015322|DRUG|bupivacaine and methylprednisolone|5 mL of 0.25% bupivacaine containing 20 mg methylprednisolone was administered to the subacromial area for the subacromial+acromioclavicular joint injection. In addition, 2 mL of 20 mg methylprednisolone and the same concentration of local anaesthetic were injected into the acromioclavicular joint
223473737|NCT03139539|DEVICE|Ioban|
224161266|NCT05015322|DRUG|bupivacaine and methylprednisolone|suprascapular nerve block was administered with a mixture of 10 mL of 0.25% bupivacaine and 40 mg methylprednisolone
224161267|NCT00422357|DRUG|Urtica Dioica (Tea bag)|
224161268|NCT01547962|DEVICE|Gintuit|"Gintuit is prepared in a S fold and trimmed to fit the prepared wound bed, with a standardized width of 5 mm and sutured in place with a 5/0 gut suture."
224161269|NCT01547962|OTHER|autologous Free Gingival Graft (FGG)|Autologous FGG harvested from the subject's palate, the width of the FGG will be 5 mm and sutured in place with a 5/0 gut suture.
223473738|NCT05722691|DRUG|Double-Stranded RNA sodium salt|Once intramuscular injection 5 mg (1 vial)
223473739|NCT05722691|DRUG|Placebo|Once intramuscular injection (1 vial)
223581155|NCT04507165|DRUG|opioid based anesthesia|"Anesthesia induction: Propofol 1.5-2mg/kg (intravenous bolus), sufentanil 0.3μg/kg (intravenous bolus), cisatracurium besylate 0.15-0.3mg/kg (intravenous bolus before tracheal intubation), methylprednisolone 40mg (intravenous bolus), esmolol 1mg/kg (intravenous bolus).~Maintenance of anesthesia: Continuous infusion of propofol and remifentanil. The infusion rate of propofol was adjusted according to BIS value. The infusion rate of remifentanil was 0.1-0.5µg/(kg.min) and adjusted according to the change of heart rate and blood pressure. Cisatracurium besylate was given as needed. Sufentanil 0.1μg/kg and flurbiprofen 50mg were given intravenously before the skin incision and suture respectively."
223581156|NCT06113575|DEVICE|NeuroStar TMS|NeuroStar TMS treatment - 90-120% of Observed MT, 3 pulses/burst, 5 bursts/sec, 2 sec stimulation, 20 msec interval, 20 trains, 600 total pulses/session for 36 treatments in 5 days. 6 treatments on day 1, 8 treatments on days 2, 3, and 4, 6 treatments on day 5.
223581157|NCT05794711|PROCEDURE|Surgical resection|Surgical resection of lung adenocarcinoma. Wedge resection, segmentectomy or lobectomy will be performed according to each patients' condition.
223581158|NCT02170909|DRUG|BIBR 1048 MS low dose|
223581159|NCT02170909|DRUG|BIBR 1048 MS medium dose|
223581160|NCT02170909|DRUG|BIBR 1048 MS high dose|
223581161|NCT05069207|OTHER|POWER breathe K5|Maximum inspiratory pressure (MIP) and volume (Volume (V)) parameters will be evaluated with the POWER breathe K5 to evaluate
223581162|NCT01231815|RADIATION|15O-H2O PET -|Assessment of coronary reserve using PET
223581163|NCT01231815|RADIATION|MRI|Assessment of coronary reserve using MRI
223581164|NCT03159104|DRUG|Tenoten for children|Tablet for oral use.
223581165|NCT03159104|DRUG|Placebo|Tablet for oral use.
223581166|NCT00507273|OTHER|GIST Registry|Internet based data registry about how different physicians treat and manage patients with gastrointestinal stromal tumors.
223581167|NCT03985007|DRUG|CDIAG regimen|Chidamide 30mg orally twice every week for 2 weeks on days 1, 4, 8, 11, decitabine 20mg/m2 intravenously daily for 5 days (d1-d5) and IAG regimen (cytarabine, 10 mg/m2 subcutaneously every 12 h on days 4-17; idarubicin, 5mg intravenously every other day on days 4, 6, 8, 10, 12, 14; and concurrent granulocyte colony-stimulating factor, 200mg/m2/day subcutaneously daily on days 3-17.
223581168|NCT06523062|DEVICE|blood pressure measurement|automated blood pressure measurement on 3 occasions at each consultation, twice with one month apart
223581169|NCT00242307|DRUG|Roflumilast|
223581170|NCT00456599|DRUG|gemcitabine|Gemcitabine 1000mg/m2 will be infused over 30 minutes on days 1, 8, and 15 of a treatment cycle.
223581171|NCT00456599|DRUG|oxaliplatin|Oxaliplatin 85mg/m2 will be infused following gemcitabine over approximately 90 minutes on days 1 and 15 of a treatment cycle.
223581172|NCT00456599|PROCEDURE|Radiation|The total dose in a three week treatment block will be 30 Gy in 2.0 Gy fractions.
223581173|NCT05173935|PROCEDURE|Percutaneous endoscopic gastrostomy|Gastrostomy tube placement using an endoscopic camera inserted via the mouth into the stomach to place the tube.
223581174|NCT05173935|PROCEDURE|Radiologically-inserted gastrostomy|Gastrostomy tube placement using a temporary nasogastric tube placed from nose to stomach and fluoroscopy (x-rays).
224161270|NCT02785666|DRUG|grazoprevir/elbasvir, ribavirin|To investigate the virological efficacy and safety of grazoprevir/elbasvir ±ribavirin for HIV/HCV-coinfected MSM with a GT 1 and/or 4 infection
224161271|NCT02785666|BEHAVIORAL|Behavioural Intervention|To counsel the targeted population with a behavioral intervention regarding the reduction of sexual risk behaviour and recreational drug use.
224161272|NCT06201923|DRUG|Honey Mouthwash|0.2% thyme honey mouth rinse
224161273|NCT06201923|DRUG|Normal saline|0.9% sodium chloride
224161274|NCT02456454|DRUG|Risperidone|Liquid risperidone
224161275|NCT02456454|DRUG|Valproic Acid|Liquid valproic acid
223473740|NCT02446691|BIOLOGICAL|MenACWY|Four Intramuscular doses of MenACWY vaccine at 2, 4, 6 and 12 months of age followed by two blood samples at 13 and 24 months of age.
223473741|NCT05475639|OTHER|Axillary Diclofenac phonophoresis|axillary diclophenac phonophoresis (voltaren gel) will be received three times per week for four weeks
223473742|NCT05475639|OTHER|Post isometric facilitation|Post isometric facilitation exercise will be received three times per week for four weeks
223473743|NCT05475639|OTHER|Traditional physiotherapy|Traditional physiotherapy will be received three times per week for four weeks
223473744|NCT03650647|PROCEDURE|Carious dentin removal|Carious tissue removal and managing deep cavitated carious lesions in primary teeth.
223473745|NCT02497469|DRUG|Vedolizumab|Vedolizumab infusion
223473746|NCT02497469|DRUG|Adalimumab placebo|Adalimumab placebo-matching injection
223473747|NCT02497469|DRUG|Adalimumab|Adalimumab injection
223473748|NCT02497469|DRUG|Vedolizumab placebo|Vedolizumab placebo-matching infusion
223473749|NCT06228404|DRUG|Enhanced autologous PSMA-CAR T|"3 escalated dosing cohorts are designed to explore safety and efficacy of enhanced autologous PSMA-CAR T:~cohort A： CART-PSMA cells 0.25×106/kgBW, following lymphodepleting chemotherapy with cyclophosphamide 300 mg/m2/day and fludarabine 30 mg/m2/day given according to protocol;~cohort B： CART-PSMA cells 0.75×106/kgBW，following lymphodepleting chemotherapy with cyclophosphamide 300 mg/m2/day and fludarabine 30 mg/m2/day given according to protocol;~cohort C： CART-PSMA cells 2×106/kgBW，following lymphodepleting chemotherapy with cyclophosphamide 300 mg/m2/day and fludarabine 30 mg/m2/day given according to protocol;"
223473750|NCT02818504|OTHER|Wize Mirror|Interactive mirror which integrates contactless sensors and a touch screen interface to derive a semeiotic model of the face with reference to cardiometabolic risk in healthy subjects
223473751|NCT04906798|DRUG|CKD-385|Test Drug
223473752|NCT04906798|DRUG|D744|Reference Drug
223473753|NCT00051701|DRUG|alemtuzumab|
223473754|NCT04549194|BIOLOGICAL|Blood collection|A blood sample will be collected before during and after the treatment.
223473755|NCT04549194|DRUG|L-Tyrosine 500 Mg|The participants will be administered 4 capsules of L-Tyrosine 500 mg per oral route daily over 1 month.
223473756|NCT04549194|BEHAVIORAL|Psychological questionnaires|"The participants will fill in several psychological questionnaires before, during and after treatment administration:~* Life Event Checklist~* Moral injury~* Posttraumatic Checklist~* Burnout Assessment Tool~* State-Trait Anger Expression Inventory-2~* Ruminative Response Scale - Reconsidered~* Deployment Risk and Resilience Inventory-2~* Questionnaire about tobacco use"
223473757|NCT04549194|DEVICE|Photoplethysmography|Photoplethysmography recording will be performed before during and after the treatment.
223473758|NCT04549194|DRUG|Placebo|The participants will be administered 4 capsules of Lactose 500 mg (placebo) per oral route daily over 1 month.
223473759|NCT04489368|RADIATION|Neo-Adjuvant Radiotherapy|Neo-Adjuvant Radiotherapy via any technique, delivered concurrently with Neo-Adjuvant Chemotherapy.
223473760|NCT04489368|DRUG|Neo-Adjuvant Chemotherapy|Neo-Adjuvant Chemotherapy, delivered concurrently with Neo-Adjuvant Radiotherapy.
223473761|NCT04489368|PROCEDURE|Esophagectomy|Esophagectomy, performed 4-6 weeks after completion of Neo-Adjuvant Concurrent ChemoRadiation
223473762|NCT03916588|BEHAVIORAL|Individualized Care Plan|Medical, neuropsychological, and social assessment of patient's cognitive, behavioral, medical, and environmental needs with a focus on improving quality of life, reducing health care utilization, and improving staff/family caregiving burden along with a specific plan to address and monitor identified patient and staff/facility needs
223473763|NCT00840125|DRUG|erlotinib|150mg tablet daily
223473764|NCT00840125|DRUG|docetaxel|30 mg/m2 days 1,8 of 22 days cycles, up to 6 cycles
223473765|NCT02963480|PROCEDURE|Cardiac Surgery|
223473766|NCT05397652|DRUG|Tranexamic Acid Injectable Product|Patients from the experimental group will receive 10 minutes before the procedure 1 g of tranexamic acid in 100 ml of saline intravenously unlike the patients in the control group who will receive just sterile saline.
223473767|NCT05397652|DRUG|Placebo|Patients from experimental group will receive 10 minutes before the procedure 1 g of tranexamic acid in 100 ml of saline intravenously unlike the patients in the control group who will receive just sterile saline.
223473768|NCT04081688|DRUG|Atezolizumab 1200 MG in 20 ML Injection|Given IV every 3 weeks (cycle is 21 days)
223473769|NCT04081688|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT between cycle 1 and cycle 2 (each cycle is 21 days)
224069643|NCT01687764|OTHER|Attentional Bias Modification Treatment (ABMT) - Active|The ABMT consists of 160 trials (120 angry-neutral and 40 neutral-neutral presentations). In the ABM condition, the target appears at the neutral-face location in all angry-neutral trials. Probe type (\< or \>) is not factorially counterbalanced but appears with equal probability for each of the following: angry-face location, probe location, or actor.
224069644|NCT01687764|OTHER|Attentional Bias Modification Treatment - Placebo|The Placebo protocol consists of 160 trials (120 angry-neutral and 40 neutral-neutral presentations). In the placebo condition, angry-face location, probe location, and actor are fully counterbalanced in presentation.
224069645|NCT01687764|BEHAVIORAL|Cognitive Behavioral Group Therapy|"FRIENDS for Life Australian protocol for the treatment of anxiety disorders in children"
224069646|NCT01687764|BEHAVIORAL|Psychoeducational Control Intervention|Psychoeducational control intervention provides only brief psychoeducational information about anxiety associated with general educational activities
224069647|NCT03798821|DIETARY_SUPPLEMENT|Lactobacillus rhamnosus, Lactobacillus casei y Bifidobacterium longum (100MG)|six weeks of consumption
224069648|NCT03798821|DIETARY_SUPPLEMENT|Lactobacillus rhamnosus, Lactobacillus casei y Bifidobacterium longum (300MG)|six weeks of consumption
224069649|NCT03798821|DIETARY_SUPPLEMENT|maltodextrin and sucrose (PLACEBO)|six weeks of consumption
224069650|NCT02246062|BEHAVIORAL|info|the relative received leaflet containing information about the anesthetic procedure one day before the surgery at ward.
224069651|NCT02246062|BEHAVIORAL|smartphone|the child received smartphone application immediately before entering the operating room
224069652|NCT02776488|DRUG|Sodium Lactate|Infusion of exogenous sodium lactate
224069653|NCT02776488|DRUG|Placebo|Infusion of normal saline
224069654|NCT02037737|DRUG|Abatacept|
224069655|NCT04429620|DIAGNOSTIC_TEST|Immunfluorescence|Serum indirect immunofluorescent (IIF) method is used, analysis is performed under an automated microscope.
224069656|NCT00000896|DRUG|Indinavir sulfate|
224069657|NCT00000896|DRUG|Lamivudine/Zidovudine|
223473770|NCT04081688|DRUG|Varlilumab 3 mg/kg|Given IV every 3 weeks (cycle is 21 days)
224069658|NCT00000896|BIOLOGICAL|Hepatitis A Vaccine (Inactivated)|
224069659|NCT00000896|DRUG|Interleukin-12|
224069660|NCT00000896|DRUG|Nevirapine|
224069661|NCT00000896|DRUG|Stavudine|
224069662|NCT00000896|DRUG|Sargramostim|
224069663|NCT00006366|DRUG|fluorouracil|
224069664|NCT00006366|DRUG|irinotecan hydrochloride|
224069665|NCT00006366|PROCEDURE|conventional surgery|
224069666|NCT00006366|RADIATION|radiation therapy|
224069667|NCT05458414|DEVICE|Intra-operative Navigation System|In the experimental group，a navigation technology was used to identify tumor margins during the surgery.
224161276|NCT02456454|DRUG|Placebo|
223473771|NCT03798236|DRUG|PBF-1650 oral capsules|Adenosine A3 receptor (AA3R) antagonist
223473772|NCT03798236|DRUG|Placebo oral capsule|solid microcrystalline cellulose
223473773|NCT06379126|DIAGNOSTIC_TEST|Test thrombin-antithrombin complex（TAT）, α2-plasmin inhibitor-plasmin complex（PIC）, tissue plasminogen activator-inhibitor complex（tPAI·C） and thrombomodulin（TM）|Test TAT, PIC, tPAI·C and TM of blood of SIC patients.
224161277|NCT01956058|RADIATION|brachytherapy remedial|brachytherapy remedial will be performed with injection of hyaluronic acid gel to interface prostate / rectum to push the rectum back and protect it from radiation.
224161278|NCT04630210|DRUG|Letrozole|Letrozole 2.5 mg/day oral until surgery
224161279|NCT04630210|DRUG|Atezolizumab|Atezolizumab 840 mg intravenous (IV) single-dose 14 days (+/- 4 days) before surgery
224161280|NCT05467605|DIETARY_SUPPLEMENT|probiotics( Lactobacillus acidophilus, lactobacillus delbruekii and lactobacillus fermentum 10 billions),|therapeutic intervention, Children will be randomized into two groups using sealed envelopes on admission after meeting inclusion criteria, group ONE will receive multi strain probiotic product which contains(Lactobacillus acidophilus, lactobacillus delbruekii and lactobacillus fermentum 10 billions),
224161281|NCT05467605|OTHER|maltose dissolved in distilled water|the other group placebo (GROUP TWO ) will receive maltose dissolved in 10 ml distilled water .
224161282|NCT05551910|DRUG|Esketamine|The patients in the test group were given esmketamine (50mg / 2ml \* branch, Jiangsu Hengrui Pharmaceutical Co., Ltd.) 0.15-0.5mg/kg H was pumped intravenously. Two minutes after the administration, the pain was scored with the cpot pain observation scale. The target cpot was \< 3 points. The dose of esketamine was adjusted according to the cpot score.
224161283|NCT05551910|DRUG|Remifentanil|Patients in the control group were given remifentanil (1mg / branch, Yichang humanwell Pharmaceutical Co., Ltd.) 0.05-2ug/kg Minutes after administration, the analgesic score was measured with cpot pain observation scale. The target cpot was less than 3 points, and the dose of remifentanil was adjusted according to the cpot score.
224161284|NCT05551910|DRUG|propofol|propofol
224161285|NCT05526092|OTHER|Dietary intervention|Changes in metabolism, microbiota, vitality and comprehensive health after 6 week consumption of oat / rice.
224161286|NCT03954249|PROCEDURE|Erecto Spinae nerve block|The ESPB is a myofascial block alternative to the paravertebral block. It is performed by injecting local anesthetic in the plane between the erector spinae muscle and the spinal transverse process. The ESPB is thought to be safer than the paravertebral block because the transverse process acts as a barrier to the pleura. It has been postulated that local anesthetic spread reaches the paravertebral space and in fact, cadaveric studies have shown dye spreading to involve the ventral and dorsal rami of spinal nerves.
224161287|NCT03954249|PROCEDURE|Multimodal Analgesia|Patients in the control group will receive standard 100mg pregabalin PO, midazolam 2mg IV, fentanyl 100mcg IV.
224161288|NCT03356808|BIOLOGICAL|Lung cancer-specific T cells|1 infusion, for 1x10\^6\~1x10\^7 cells/kg via IV
224161289|NCT05344612|RADIATION|CT Coronary Angiography|Upfront ct-coronary angiography
224161290|NCT04649190|DEVICE|TAVI|Coronary access for PCI after TAVI
224161291|NCT05427175|RADIATION|Narrowband ultraviolet B|Patients will receive 8 sessions of NB-UVB per month for 3 successive months
224304403|NCT03570671|DIAGNOSTIC_TEST|Spasm positive|"Investigators define the positive criteria for VSA on MDCTA as follows:~1. Significant stenosis (≥ 50%) with negative remodeling but no definite evidence of plaques, which completely dilated on IV nitrate CT, or~2. Diffuse small diameter (\< 2mm) of a major coronary artery with beaded appearance which completely dilated on IV nitrate CT."
223473774|NCT02986776|BEHAVIORAL|Inpatient Care|21 days of inpatient substance misuse treatment
223473775|NCT02986776|BEHAVIORAL|Outpatient Care|21 days of outpatient substance misuse treatment
223473776|NCT03479554|OTHER|Early antihypertensive treatment|"The CATIS 2 trial is designed to test BP reduction strategies-early antihypertensive treatment vs. delayed antihypertensive treatment-rather than test the efficacy of individual antihypertensive drugs. Several antihypertensive agents, including angiotensin-converting enzyme inhibitors, calcium channel blockers, and diuretics will be used in the trial.~BP-lowering treatment will start immediately after randomization in the early antihypertensive treatment group. The target treatment goals are:~* Step 1 (within 24 hours after randomization): To lower systolic BP by 10-20% with an average of 15% (but systolic BP not lower than 130 mmHg and diastolic BP not lower than 80 mmHg) within the first 24 hours after randomization based on the participant's admission BP levels.~* Step 2 (within 7 days after randomization): To achieve systolic BP below 140 mmHg (but not lower than 120 mmHg) and diastolic BP below 90 mmHg (but not lower than 70 mmHg) and maintain this BP level afterward."
223581175|NCT02431390|DEVICE|RAPAELⓇ Smart Glove digital treatment system|The RAPAELⓇ Smart Glove digital treatment system is constituted for stroke rehabilitation. For use, stroke patients wear the gloves and play the games or puzzle for rehabilitation of upper limbs. The system provides biofeedback to user.
223581176|NCT02431390|BEHAVIORAL|Additional occupational therapy|30 minutes of additional conventional occupational therapy session composed of hand dexteriy training
223581177|NCT00040807|DRUG|docetaxel|
223581178|NCT00040807|DRUG|irinotecan hydrochloride|
223581179|NCT01086176|DEVICE|NMT (a device that can do neurostimulation and can record the response on the stimulation by Datex)|on one side, we do a post-tetanic count, on the other side we don't, after, we do train-of-four on both sides and check the difference
223581180|NCT04429399|OTHER|decrease the positive end expiratory pressure (PEEP)|decrease the PEEP going from high (according to ExPress Trial) to low level
223581181|NCT04429399|OTHER|mechanical features assessment|evaluation of the mechanical features of respiratory system
224161292|NCT05427175|DRUG|Methotrexate|Patients will receive 25 mg/1ml of methotrexate vial per week for 3 successive months
224161293|NCT00250497|BEHAVIORAL|New Moves|The New Moves intervention is an all girls physical education class that provides a supportive environment for girls. Girls participate in noncompetitive physical activities. They also receive lessons on nutrition and social support. After the class is over, girls continue to receive intervention messages through weekly lunch meetings. Girls meet individually with a personal coach.
224304404|NCT03570671|DIAGNOSTIC_TEST|Spasm negative|Suspected vasospastic angina subjects with negative MDCTA-derived VSA are considered as reference modality.
224304405|NCT04709211|PROCEDURE|Facia Iliaca block|patients will receive Ultrasound-guided Facia Iliaca block using 50 ml 0f Bupivacaine 0.25%
224304406|NCT04709211|PROCEDURE|Anterior Quadratus Lumbroum block|patients will receive Ultrasound-guided Anterior Quadratus Lumbroum block using 50 ml 0f Bupivacaine 0.25%
224304407|NCT04709211|DRUG|bupivacaine|bupivacaine
224304408|NCT03893565|DRUG|GSK2831781 - Double Blind Phase|GSK2831781 will be administered intravenously in the double blind induction phase and subcutaneously in the double blind ETP (both according to randomization).
223473777|NCT03479554|OTHER|Delayed antihypertensive treatment|All home antihypertensive medications will be discontinued in the first seven days after randomization. Study participants will receive antihypertensive treatment on day eight after randomization and will target systolic BP \<140 mmHg (but not lower than 120 mmHg) and diastolic BP \<90 mmHg (but not lower than 70 mmHg) in two weeks. A BP check-up visit will be conducted in two weeks. If BP treatment goal is not achieved, antihypertensive medication will be titrated or a new medication will be added.
223473778|NCT01755299|OTHER|"Regular 5-hour Energy"|Amount equivalent to the package commercially packaged and sold (1.93 fl. oz.)
223473779|NCT01755299|OTHER|"Decaf 5-hour Energy"|"Commercially available 5-Hour Energy Decaf product in the amount that is packaged (1.93 fl. oz.)"
223473780|NCT01755299|OTHER|Compounded concentrated caffeine liquid|"Concentrated caffeine liquid has been used to compound a 135 mg/2 ounce caffeine product, which contains the same amount of caffeine as a regular 5-hour Energy"
223473781|NCT01755299|OTHER|Flavored bottled water|Bottled water will be flavored and colored to serve as a placebo product for this trial.
223473782|NCT01026493|DRUG|temozolomide 60 mg x 21 days|Temozolomide 60 mg/m2 x 21 days, with a 28-day cycle. Treatment will continue until progressive disease unless toxicity or the discretion of the treating physician precludes further therapy.
223473783|NCT01026493|DRUG|temozolomide 75 mg x 21 days|Temozolomide 75 mg/m2 x 21 days, with a 28-day cycle. Treatment will continue until progressive disease unless toxicity or the discretion of the treating physician precludes further therapy.
223473784|NCT01026493|DRUG|ABT-888 20 mg x 21 days|20 mg bid x 21 days, with a 28-day cycle. Treatment will continue until progressive disease unless toxicity or the discretion of the treating physician precludes further therapy.
223581182|NCT04429399|OTHER|shunt assessment|evaluation of the pulmonary shunt during two different ventilation setting
224069668|NCT02825095|PROCEDURE|Talc Pleurodesis|chest tube type PIGTAIL 10 - 14 Fr will be inserted to the pleural space. In case of fluid discharges less than 250 cc/24, talc pleurodesis will be performed
224069669|NCT02825095|PROCEDURE|Indwelling Pleural Catheter|Indwelling Pleural Catheter type PLEURAX will be inserted to the pleural space. the patients will be discharged with the pleural catheter.
224069670|NCT02825095|PROCEDURE|chest ultrasound|All insertion of a chest drain will be guided by ultrasound
223473785|NCT01026493|DRUG|ABT-888 40 mg x 21 days|40 mg bid x 21 days/28-day cycle. Treatment continues until progressive disease unless toxicity or the discretion of the treating physician preclude further therapy
223473786|NCT01026493|DRUG|Temozolomide 150 mg x 5 days|150 mg/m2 x 5 days (up to 200 mg/m2 after 2nd cycle)\*, with a 28-day cycle; dose reduction to 125 mg/m2 if necessary. Treatment continues until progressive disease unless toxicity or the discretion of the treating physician preclude
223473787|NCT01026493|DRUG|ABT-888 40 mg x 5 days|40 mg bid x 5 days/28-day cycle. Treatment continues until progressive disease unless toxicity or the discretion of the treating physician preclude
223473788|NCT02838745|DRUG|Pemetrexed|
223473789|NCT02838745|DRUG|Cisplatin|
223473790|NCT06216418|DEVICE|BRFS-18G-S100WH|A facial tissue fixation material made of polydioxanone (PDO).
223473791|NCT06216418|DEVICE|MINT Lift FINE+|A facial tissue fixation material made of polydioxanone (PDO).
223473792|NCT01472055|DRUG|Fludarabine|"1. Fludarabine 40 mg/m\^2 once a day intravenous administration over 30 min~2. Development of sampling-minimized analysis method through individualized pharmacokinetics Sampling time: 0hr (pre-dose), 30 min (post-dose), 1hr, 3hr, 5hr, 8hr, 24hr~3. Population pharmacokinetics analysis~4. Comparative analysis of population pharmacokinetics in pediatric and adult patients~5. Analysis of population pharmacokinetics, toxicity, engraftment rate, survival rate"
223473793|NCT02455128|OTHER|Therapeutic listening|Method of responding to others in order to encourage better communication and clearer understanding of personal concerns.
223473794|NCT00289211|BIOLOGICAL|C1 esterase inhibitor [human] (C1INH-nf)|
223473795|NCT00289211|DRUG|Placebo (saline)|
223473796|NCT05719168|DEVICE|Body Surface Gastric Mapping|64-channel electrode array placed on the outer abdomen
223473797|NCT05912868|DEVICE|Endoscopic Mini/Less Open Sublay Repair|The traditional techniques are open sublay or transabdominal intraperitoneal onlay mesh (IPOM) repair. In order to avoid the risks -large trauma to the abdominal wall with pain and infection, lesion of intraabdominal organs - a new hybrid technique - small skin incision, wide endoscopic dissection of the retrorectus space with implantation of a large mesh - was developed (EMILOS -Endoscopic Mini/Less Open Sublay).
223581183|NCT00235911|DRUG|budesonide/formoterol Turbuhaler|
223581184|NCT00006268|BIOLOGICAL|cintredekin besudotox|
223581185|NCT00006268|DRUG|isolated perfusion|
223581186|NCT00006268|PROCEDURE|conventional surgery|
223581187|NCT00783081|DRUG|K-134|K-134 is given as low dose mid dose and high dose tablets for 26 Weeks.
223581188|NCT00783081|DRUG|Cilostazol 100 mg BID|Cilostazol 100mg BID for 26 weeks.
224069671|NCT02825095|DRUG|Local anesthesia|Inserting a chest drain will be after local anesthesia with 10-20 mL of Lidocaine hydrochloride 20MG/ML - Esracain injection 2%
224069672|NCT02825095|PROCEDURE|Chest Tube|chest tube type PIGTAIL 10 - 14 Fr will be inserted to the pleural space. In case of fluid discharges less than 250 cc/24, talc pleurodesis will be performed
224069673|NCT02997995|DRUG|Immune-attractant|The first cohort patients will receive tremelimumab (3 mg/kg, single infusion) as immune-attractants combined with exemestane (25 mg daily).
224304409|NCT03893565|DRUG|Placebo|Placebo (commercial saline solution) will be administered intravenously in the double blind induction phase and subcutaneously in the double blind ETP (both according to randomization).
224304410|NCT03893565|DRUG|GSK2831781 - Open Label phase|GSK2831781 will be administered intravenously in the open label induction phase and subcutaneously in the open label ETP.
224304411|NCT02707445|DRUG|Clopidogrel|Administration of conventional dual anti-platelet treatment (aspirin 100mg and clopidogrel 75mg daily) for minimum 3 months after percutaneous coronary intervention
223473798|NCT00630916|DEVICE|Mitroflow Aortic Heart Valve|Replacement of the native aortic valve or a previously implanted prosthetic aortic valve
223743971|NCT01879228|DRUG|Placebo|The GPA test as described in the primary outcome section will be performed at baseline and after 6 months of therapy in the Sitagliptin and placebo arms. Furthermore, evaluation of endogenous GLP-1 levels will be assessed by a mixed meal tolerance test compared at baseline and 6 months.
223743972|NCT01609920|DRUG|Gadofosveset enhanced MRL of axillary lymph nodes|A MRL of the axilla will be performed before and after administration of a single IV bolus injection of gadofosveset of an equivalent of 0.03 mmol Gd/kg body weight at an injection speed of 1.5 mL/sec., followed by a saline flush of 25 mL at an injection speed of 1.5 mL/sec.
223743973|NCT04287504|DIAGNOSTIC_TEST|SavvyCheck Vaginal Yeast Test|Point-of-care test for the detection of vaginal candidosis
223473799|NCT00243243|DRUG|Recombinant Factor VIIa|intravenous infusion of Factor VIIa
223473800|NCT00243243|DRUG|Placebo|intravenous infusion of placebo (sterile water)
223473801|NCT04053582|BEHAVIORAL|AMT|The session will be done on an individual basis. AMT group will receive neurofeedback training from the PCC while focusing on the physical sensations of the breath. The session will last one hour, including 3 neurofeedback runs during which subjects will undergo three conditions across three consecutive blocks: Rest (30s), Describe (view an adjective and decide whether the word describes them; 20s), and Focus on the Breath with neurofeedback (70s).
223473802|NCT04053582|BEHAVIORAL|Sham|The session will be done on an individual basis. Sham group will receive artificial neurofeedback while focusing on the physical sensations of the breath. The session will last one hour, including 3 sham neurofeedback runs during which subjects will undergo three conditions across three consecutive blocks: Rest (30s), Describe (view an adjective and decide whether the word describes them; 20s), and Focus on the Breath with artificial neurofeedback (70s).
223473803|NCT04703413|DEVICE|LoFric® OrigoTM and LoFric® SenseTM|The investigational device is either a CE-marked LoFric® OrigoTM , 40 cm, CH12/CH14 or LoFric® SenseTM, 15 cm, CH12. They are all intermittent urinary catheters with a Nelaton tip from a more sustainable manufacturing process. All subjects will use the investigational device for 30 days each.
223473804|NCT01556217|DRUG|JNJ-39393406|Type= exact number, Unit= mg, Number= 200, Form= oral suspension, Route= oral administration. Oral suspension to be taken once with 240 mL (8 ounces of water) between 8:00 AM and 10:30 AM.
223581189|NCT00783081|DRUG|Placebo|Placebo BID for 26 weeks.
223581190|NCT01765725|BEHAVIORAL|Patient education program|Patient education program, 8 meetings, every other week, 2,5 hours per meeting.
223581191|NCT06829641|PROCEDURE|Tislelizumab Combined with Chemotherapy,|Tislelizumab Combined with Chemotherapy as Induction Therapy
223581192|NCT04465968|DRUG|Cisplatin|Cisplatin 60 mg/m2, IV, day 1
223581193|NCT04465968|DRUG|S1|80 - 120 mg/day, PO, day 1-14
223581194|NCT04465968|RADIATION|concurrent radiotherapy|66 Gy/33 Fr
223581195|NCT04465968|DRUG|Durvalumab|preoperative durvalumab therapy within 28 days after chemoradiotherapy. Two courses are given every two weeks.
223581196|NCT04465968|PROCEDURE|Surgery|Surgery will be performed between day 15 and day 42 of the second course of preoperative durvalumab therapy after confirming that all surgical operation criteria are met.
223581197|NCT04465968|DRUG|Durvalumab|"(For resectable SST) Postoperative durvalumab therapy will be started between day 28 and day 63 with the day of surgery as Day 1. Twenty-two courses are given as a 2-week course.~Drug: Durvalumab 10 mg/kg/body, IV, day 1 (For unreectable SST) Additional durvalumab therapy between day 15 and day 28 of the second course of preoperative durvalumab therapy.~Twenty-two courses are given as 2-week course. Drug: Durvalumab 10 mg/kg/body, IV, day 1"
223581198|NCT02315482|PROCEDURE|pneumoperitoneum insufflation and steep trendelenburg|the sequence of pneumoperitoneum insufflation and steep trendelenburg positioning is randomized
223581199|NCT00151372|BEHAVIORAL|Treatment Adherence Intervention|The care management intervention aims at facilitating adherence to a treatment algorithm based on the Agency for Health Care Policy and Research (AHCPR) guidelines. The investigators hypothesize that this intervention, in comparison to usual care, will increase the prescription of adequate antidepressant treatment by physicians, enhance treatment adherence by patients, and reduce depressive symptoms, suicide ideation, and disability.
223581200|NCT00151372|BEHAVIORAL|Enhanced Care|For subjects in the Enhanced Care group, physicians providing aftercare will receive no clinical instructions by the research team, but will be informed in writing of the patients' diagnosis and will be provided with a copy of the Agency for Health Care Policy and Research (AHCPR) guidelines for the treatment of depression in primary care with an addendum updating the tables describing Selective Serotonin Reuptake Inhibitors (SSRI) side effect and dosage profiles. The investigators expect that these physicians will continue to base their practice on clinical judgment about how best to treat depression in chronic obstructive pulmonary disease patients.
223581201|NCT05276310|BIOLOGICAL|IMC-002|Part 1: Dose escalation IMC-002 5, 10, 20, and 30 mg/kg over 3 hours (±30 minutes) intravenous (IV) infusion every 2 weeks Part 2: Expansion cohort IMC-002 20 mg/kg over 3 hours (±30 minutes) IV infusion at the first cycle, if the first infusion is tolerated, then over 1 to 1.5 hours (±10 minutes) IV infusion at all following cycles every 3 weeks In hepatocellular (HCC) Cohort, Lenvatinib 8 mg once daily (body weight of \< 60 kg), or 12 mg once daily (body weight of ≥ 60 kg) In triple negative breast cancer (TNBC) Cohort, Paclitaxel 175 mg/m2 IV infusion on Day 1 of each cycle, or Gemcitabine 1,000 mg/m2 followed by Carboplatin AUC 2 IV infusion on Day 1 and Day 8 of each cycle In biliary tract cancer (BTC) Cohort, Lenvatinib 8 mg once daily (body weight of \< 60 kg), or 12 mg once daily (body weight of ≥ 60 kg) In B-cell lymphoma Cohort, Rituximab 375 mg/m2 IV infusion on Day 1 of each cycle
223581202|NCT04300036|DIETARY_SUPPLEMENT|longan syrup|Subjects will take 15 ml of longan syrup once a day for 3 months
223581203|NCT04300036|DIETARY_SUPPLEMENT|Placebo syrup|Subjects will take 15 ml of placebo syrup once a day for 3 months
223581204|NCT04251975|DEVICE|CPAP treatment|In this group of patients (CPAP group) will be prescribed CPAP treatment at an optimal pressure. It will be performed a CPAP titration with an automatic or manual CPAP according to usual clinical practice
223581205|NCT04732949|DRUG|SNG001|SNG001 nebuliser solution, 2 syringes each containing 0.65 mL once a day
223581206|NCT04732949|DRUG|Placebo|Placebo nebuliser solution, 2 syringes each containing 0.65 mL solution containing excipients of the SNG001 solution
223473805|NCT01556217|DRUG|Placebo|Form= oral suspension, Route= oral administration. Oral suspension to be taken once with 240 mL (8 ounces of water) between 8:00 AM and 10:30 AM.
223473806|NCT00400244|PROCEDURE|Wheelchair skills traing program|
223473807|NCT05338463|DRUG|Fespixon Cream|"1. Name : Fespixon Cream~2. Dosage form: Topical cream, 15 g ointment per tube~3. Active ingredients: 1.25% extracts of Plectranthus amboinicus (PA-F4, 0.25%) and Centella asiatica (S1, 1%)~4. Dose(s): Apply 1 cc per 5 cm\^2 ulcer size (not exceeding 2 mm in thickness)~5. Dosing schedule: Apply twice a day~6. Duration: up to 20 weeks"
223473808|NCT05198141|DRUG|Letrozole tablets|GI: Patients who were undergoing laparoscopic salpingectomy GII: patients who medically treated with 5 mg d-1 of letrozole using two tablets (2.5 mg of Femara) every day for 10 d GIII patients who medically treated with 10 mg d-1 of letrozole using four tablets (2.5 mg of Femara) every day for 10 d (group III)
223473809|NCT05198141|PROCEDURE|laparoscopic salpingectomy|laparoscopic salpingectomy
223581207|NCT05691374|PROCEDURE|Ultrasound (US) examination|"Shear-Wave Elastography (SWE) measurements of operated shoulder (quality, elasticity of repaired tendon) compared to healthy contralateral side. Parameters documented by regular US: Diameter of repaired tendon/ tendon thickness (mm), Rotator cuff muscle fatty infiltration (Grade 0-4), Signs of suture cut-through (yes \| no), Signs of anchor displacement and location (lateral\|medial row), Location of defect (at the foot print\|medial cuff failure), Status of long biceps tendon (intact\|in continuity\|defect). Tissue elasticity measured by SWE in longitudinal orientation (in passive state and with active tension): Trapezius and Deltoid muscle: uninjured superficial muscle for individual patient muscle quality, SSP muscle and tendon: anterior and posterior part, SSC muscle and tendon: cranial and caudal part, ISP muscle and tendon, Biceps muscle and tendon: native (intraarticular) or subpectoral tenodesis (extraarticular)"
223473810|NCT06095908|DRUG|Bupivacain|Bupivacain administered with two different ways to the patients, postoperative pain recorded
223473811|NCT01932385|DRUG|Sorafenib|
223473812|NCT01932385|OTHER|Best Supportive Care|
223473813|NCT02425306|BIOLOGICAL|6MHP|6 melanoma helper vaccine comprised of 6 class II MHC-restricted helper peptides
223473814|NCT02425306|DRUG|Montanide ISA-51|Montanide ISA-51 (Incomplete Freund's Adjuvant), local adjuvant
223581208|NCT05691374|PROCEDURE|Clinical examination|Clinical examination for shoulder range of motion and strength measurement
223581209|NCT06419166|DRUG|GC012F injection|"Each subject will receive GC012F injection (CD19-BCMA CAR-T cells) once by intravenous infusion on Day 0.~Other Name: CD19-BCMA CAR-T cells"
223581210|NCT05796973|BEHAVIORAL|Guided physical exercise|Patients will be participating in guided physical exercise program regularly two times / week at a sports facility and guided by a professional trainer. They will participate in aerobic and resistance exercises during the sessions.
223581211|NCT05796973|DRUG|Atorvastatin|Patients will be participating in guided physical exercise program regularly two times / week at a sports facility and guided by a professional trainer. They will participate in aerobic and resistance exercises during the sessions. In addition to the exercise program they will be given atorvastatin 40 mg QD medication.
223581212|NCT05796973|OTHER|Independent exercise|The control group is advised of the benefits of physical exercise and they get an exercise program to follow. Participants in the control group exercise on their own.
223581213|NCT03737721|COMBINATION_PRODUCT|Avelumab and Radical radiotherapy|A single-arm, interventional study combining Avelumab with radical radiotherapy. Avelumab will be delivered on a 14-day cycle, with the first cycle administered 14 days in advance of the radiation therapy start date; 63-66 Gy radiation will be delivered over 30 daily fractions concurrent with an additional 4 cycles of Avelumab
223743974|NCT04287504|DIAGNOSTIC_TEST|OSOM BVBLUE Test|Point-of-care test for the detection of bacterial vaginosis
223743975|NCT05164900|PROCEDURE|pterygium excision with sutures fixed conjunctival auto-graft|Pterygium excision with vicryl 8/0 fixed conjunctival auto-graft under local anesthesia. During the follow up period, indicators of ocular irritation were assessed.
223743976|NCT04091503|DRUG|Intranasal Modified Temozolomide|"Intranasally Modified Temozolomide is administered to patients at a dose of 75/150/200 mg / M2 for five days continuously. After the 5-day course, patients do not take treatment for two days, and they will be examined on an outpatient basis (blood tests, kidney and liver tests, visually mucous membranes of the mouth, nasal cavity, olfactory rapid tests, including the University of Pennsylvania test, etc.).~After 30 days after the first intranasal administration of Modified Temozolomide (IM-TMZ), all patients undergo an MRI of the brain with perfusion and ultrasound of the abdominal cavity as an outpatient, after which the results are evaluated"
224304412|NCT02811432|OTHER|Kangaroo mother care|Skin-to-skin care (target: at least 18 hours per day)
223473815|NCT02425306|DRUG|polyICLC|polyICLC, local adjuvant
223473816|NCT02425306|DRUG|Cyclophosphamide|Cyclophosphamide, systemic adjuvant
223743977|NCT04720326|DRUG|Tacrolimus Pill|Envarsus® tablets dosed to achieve and maintain whole blood trough levels of tacrolimus within a patient-specific therapeutic range (interval of 3 ng/ml) that lies within a wider reference range of 3-12 ng/ml.
224304413|NCT02811432|OTHER|Standard care|Incubator or radiant warmer until neonate meets stability criteria; once stable (WHO indication for KMC certain), the baby can transition to routine (intermittent) KMC
224304414|NCT02332837|BEHAVIORAL|Intervention A: Questionnaire accuracy|Participants will be tested by questionnaire to measure how well consent is understood
224304415|NCT02332837|BEHAVIORAL|Intervention B: Questionnaire speed of completion|Time to complete questionnaire from time of presentation
223473817|NCT04451018|OTHER|evaluation of arterial anomalies in upper limbs|evaluation of arterial anomalies in upper limbs with doppler ultrasound
223473818|NCT02978469|OTHER|Life style changing: reducing sedentary behavior|"The program includes 23 meetings held once per week (with holiday breaks). Each meeting lasts 90 minutes, consisting of exercise training.~the group will meet for information providing and discussion. Participants are guided in the process of creating a focussed individualized activity plan.~In the group setting they will experience a variety of activities enabling them to explore activities they prefer: each participant receive three personal consultation meetings. The group will experience sport and recreational activities with persons with physical impairments. Also activities in sport in community facilities."
223473819|NCT03386526|DRUG|APG-1387 for Injection|Multiple dose cohorts, 30 minute IV infusion, once weekly for 3 weeks of a 21-day cycle
223473820|NCT04023201|OTHER|Nocturnal symptoms|Parkinson's disease patients with or without nocturnal symptoms
223473821|NCT02295644|DEVICE|Ultrasound Sonicator 740|Therapeutic ultrasound (Ultrasound Sonicator 740) used on masseter muscle, 1MHz, 5 minutes
224161294|NCT05566327|BEHAVIORAL|De-implementation Bundle|"A multicomponent intervention directed at the drivers of low value preoperative testing.~An administrative change will be implemented whereby medically necessary preoperative tests for patients undergoing scheduled surgery will be ordered at the discretion of a consulting anaesthesiologist only. Workshops will be delivered to surgical, internal medicine, and anaesthesia divisions. The workshop program will include rationale for the policy, discussion of perceived local barriers to implementation and mitigation strategies.The clinical departments will commit to supporting the change in policy. Nurses will be coached to feel comfortable calling the anesthesiologist about any preoperative tests ordered, and the PAC nurses will have the authority to cancel tests. Check boxes will be removed from surgeons' and family physicians' order forms to reduce to ease of ordering the tests."
224161295|NCT01427127|DRUG|Ramosetron|Patients received intravenous ramosetron 0.3 mg at end of surgery and 24hr after surgery.
223473822|NCT00838071|DRUG|Specific intravenous anti-hepatitis B immunoglobulin|Monthly doses of 5000 IU administered intravenously during 6 consecutive months
223473823|NCT03945513|DRUG|LPRI424 (dienogest/ethinylestradiol)|One LPRI424 tablet once per day for 24 days followed by 4 placebo tablets for 4 days equals one cycle.
223473824|NCT04365335|BEHAVIORAL|Assessment of work-related stress|Assessment of burnout, mindfulness, interoceptive awareness, anxiety, post-traumatic stress disorder, coping flexibility and sleep through questionnaires.
223473825|NCT04365335|BIOLOGICAL|Saliva sample collection|Saliva sample is collected before and after emotional stimulation in order to measure resting-state allostatic load biomarkers: DHEA, cortisol and chromogranine A levels
223473826|NCT04365335|OTHER|Cardiac and electrodermal recordings|Electrocardiogram and electrodermal activity (tonic and phasic) is collected at rest and after emotional stimulation.
223473827|NCT04365335|BEHAVIORAL|Assessment of behavioral response to emotional stimulation|"Emotional stimulation involves asking the participants to remember a recent event related to the COVID-19 crisis that has been emotionally difficult for them.~Perceived stress, situational awareness and emotions is assessed after emotional stimulation through questionnaires."
223473828|NCT02108301|DRUG|tacrolimus-cyclosporine A|conversion of immunosuppression from tacrolimus to cyclosporine A in hepatitis C-positive renal transplant recipients
223473829|NCT01075776|DRUG|C-type natriuretic peptide (CNP)|360 pmol/min for 15 minutes intra-arterially
223473830|NCT01075776|DRUG|Saline|Sodium Chloride 0.9% intra-arterially 0.5ml/min
223473831|NCT01075776|DRUG|Acetylcholine|2 stepped infusions for a total 9min per limb, totalling 1.05micromoles per limb
223473832|NCT01995916|BEHAVIORAL|Mindfulness Intervention|The Mindfulness Group will meet once a week for 2.5 hours for 8 weeks with a half day retreat.
223473833|NCT01995916|BEHAVIORAL|Social Support Group|The Social Support Group will meet once a week for 2.5 hours for 8 weeks with a half day retreat.
223473834|NCT00324155|DRUG|Ipilimumab|"Intravenous solution; intravenous; 10mg/kg; one dose every 3 weeks for 10 weeks then one dose every 12 weeks starting at Week 24, until disease progression, unacceptable toxicity or withdrawal of consent~In Maintenance phase: Only Ipilimumab: 10mg/kg, every 12 weeks will be continued until disease progression"
223473835|NCT00324155|DRUG|Placebo|Intravenous solution; intravenous; 0 mg; one dose every 3 weeks for 10 weeks then one dose every 12 weeks starting at Week 24; until disease progression, unacceptable toxicity or withdrawal of consent
223473836|NCT00324155|DRUG|Dacarbazine|Intravenous solution; intravenous; 850 mg/m\^2; one dose every 3 weeks for 22 weeks, until disease progression, unacceptable toxicity or withdrawal of consent
223581217|NCT06579846|DRUG|Cytisinicline and exercise|"Doctors will provide brief, personalized counseling anti-smoking plan. This counseling will support smokers in the determination-action phase of behavior change.~Physicians will administer cytisine as follows: 1 tablet every 2 hours (maximum 6 per day) from days 1-3; every 2.5 hours (maximum 5 per day) from days 4-12; every 3 hours (maximum 4 per day) from days 13-16; every 5 hours (maximum 3 per day) from days 17-20; and 1-2 tablets per day (maximum 2 per day) from days 21-25.~Participants will follow a combined aerobic and strength exercise program. This includes at least 150 minutes of moderate-intensity aerobic physical activity per week, or 75 minutes of vigorous-intensity aerobic activity, or an equivalent combination of both. Aerobic activity should be performed in sessions lasting at least 10 minutes."
223581218|NCT06579846|DRUG|Cytisinicline|Same intervention as the experimental group without directed exercise prescription
224161296|NCT01197781|DRUG|FOSTAMATIN|Oral tablets - single dose
224161297|NCT01197781|DRUG|Verapamil|Oral tablets - administered 3 times daily over 4 days
224161298|NCT00760890|DIETARY_SUPPLEMENT|Fer-In-Sol (ferrous sulfate)|7.5 mg/day in the form of 0.3 ml once each day
224161299|NCT00760890|DIETARY_SUPPLEMENT|Iron fortified cereal|1 jar each day of one of three wet pack cereals manufactured by the Gerber Company: Each jar provided 7 mg of ferrous sulfate.
224161300|NCT02219672|DRUG|Triplitode|"Drug: Triptolide Triptolide Wilfordii is a Chinese old herb which is widely used as a remedy for rheumatic diseases and nephropathy in China. It is approved that it can play a role as an immune modular.~Other Name: Tripterygium Wilfordii Hook F (TwHF) Drug: cART Participants who will be enrolled in this Triplitode group would be treated with Tenofovir plus lamivudine plus Lopinavir / ritonavir plus raltegravir ."
224161301|NCT02219672|DRUG|Tenofovir plus lamivudine plus Lopinavir / ritonavir plus raltegravir|Participants who will be enrolled in this trial would be treated with Tenofovir plus lamivudine plus Lopinavir / ritonavir plus raltegravir.
224161302|NCT03428295|DEVICE|Dose Safety AP system|Device will be used to automatically dose insulin
224161303|NCT00529412|OTHER|Seprafilm|two sheets per body
224304416|NCT02332837|BEHAVIORAL|Intervention C: Questionnaire Completion rate|Number of participants who complete the questionnaire
223473837|NCT04817878|COMBINATION_PRODUCT|Developmental assessment|Physical development assessment (head circumference, length, weight), Neurodevelopment assessment at 36 to 40 weeks of correction (GMS assessment, NBNA assessment), neurodevelopment assessment at 18 months, 24 months, and 36 months (ASQ scale, Language assessment, Wei-style scale), audiovisual screening, etc.
223473838|NCT04397978|RADIATION|Stereotactic radiotherapy|Local ablative therapy with SRT
223473839|NCT00113477|DRUG|Q10|
223473840|NCT00113477|DRUG|Selen|
223473841|NCT02768987|BEHAVIORAL|Bright 1 Bodies|A 12-week intensive lifestyle program utilizing group exercise classes adapted for this population, supplemented with coping skills training and diabetes self-management education.
223473842|NCT01310283|OTHER|xylitol mints and fluoride varnish|Subjects in the intervention group will receive additional diet, oral hygiene handouts, more frequent professional fluoride application, and xylitol mints based on their caries risk levels.
223581219|NCT05773963|DEVICE|Irilens; Iridina; Afomill Lubricating Eye Drops|"* Irilens (with 0.4% HA as key ingredient);~* Iridina (with 0.4% HA as key ingredient);~* Afomill Lubricating Eye Drops (with 0.2% HA as key ingredient and distilled water of Chamomile)."
223581220|NCT05725018|BIOLOGICAL|EB-101 Surgical application of RDEB wounds|"EB-101 autologous RDEB keratinocytes isolated from skin biopsies and transduced with a recombinant retrovirus containing a full-length COL7A1 expression cassette for C7~Other Names:~• LZRSE-Col7A1 Engineered Autologous Epidermal Sheets \[LEAES\]"
223581221|NCT03980821|DRUG|AZD4635|AZD4635 taken orally
223581222|NCT01209663|OTHER|Postoperative Intermediate Care|Comparison of postoperative Intermediate Care versus Ward Care.
223581223|NCT01762254|PROCEDURE|incisionless laparoscopic colectomy|Arm 1:Incisionless Laparoscopic Colectomy Laparoscopic colectomy is being performed in the same manner as conventional laparoscopic colectomy, except that at the end of procedure, the TEO device with the outer diameter of 4cm is inserted into the anus for the delivery of specimen and insertion of anvil instead of creating a small wound as in the conventional laparoscopic colectomy. Finally, intra-corporeal anastomosis is performed in the same manner with the TEO device removed.
223581224|NCT01762254|PROCEDURE|conventional laparoscopic colectomy|Arm 2: Conventional Laparoscopic colectomy The operation is completed by laparoscopic instruments using video laparoscopy. At the end of the procedure, pneumoperitoneum is abolished and a small wound was created for the delivery of bowel and insertion of anvil of the circular stapler. Finally, pneumoperitoneum is re-created for intra-corporeal anastomosis
223581225|NCT00684827|DRUG|Levalbuterol HFA MDI followed by Racemic albuterol HFA MDI|"1. Subjects will receive both treatments: (a) levalbuterol HFA MDI; 45 micrograms (16 cumulative doses); followed by (b) racemic albuterol HFA MDI; 90 micrograms (16 cumulative doses)~2. Arm #A~3. Xopenex HFA MDI, Pirbuterol HFA MDI"
223581226|NCT00684827|DRUG|Racemic Albuterol followed by levalbuterol HFA MDI|"1. Subjects will receive both treatments: (a) racemic albuterol HFA MDI; 90 micrograms (16 cumulative doses) followed by (b) levalbuterol HFA MDI; 45 micrograms (16 cumulative doses)~2. Arm #B~3. Pirbuterol HFA MDI, Xopenex HFA MDI"
223581227|NCT00109356|DRUG|AQ4N (Chemotherapy)|
223581228|NCT00007267|BEHAVIORAL|Cognitive behavioral therapy|
223581229|NCT00007267|BEHAVIORAL|Disease/health education|
223581230|NCT00007267|BEHAVIORAL|Self-help cognitive behavioral intervention facilitated by a psychologist|
223581231|NCT03261206|OTHER|5-ASA Withdrawal|Withdrawal of 5-ASA therapy
224161304|NCT04783714|DIETARY_SUPPLEMENT|Swisse Nutra+ Cholesterol Balance|Swisse Nutra+ Cholesterol Balance is a multi-ingredient nutraceutical composition contained in a brown soft-gel capsule format. Three capsules are required per dose.Swisse Nutra+ Cholesterol Balance is a multi-ingredient formulation containing artichoke extract, bergamot juice extract, hydroxytyrosol, an antioxidant derived from olive oil and sunflower oil-derived phytosterols. All ingredients target cholesterol reduction by different and complementing mechanisms, as evidenced by human clinical trials. These ingredients have been chosen to work synergistically to alleviate hypercholesterolemia and/or dyslipidemia through multiple pathways, whereby each ingredient works via a different mechanism to lower LDL-cholesterol in the body.
224161305|NCT04783714|DIETARY_SUPPLEMENT|Placebo|Matched brown soft-gel capsule placebo containing olive oil and palm olein - no therapeutic benefit.
224161306|NCT04336111|PROCEDURE|retrolaminar block|will receive real bilateral bilevel ultrasounded guided retrolaminar block at T4 and T10 after induction of anaesthesia in prone position. The total desired volume used in the whole injection will be 40 ml containing 3mg / kg bupivacaine with adrenaline 2.5 2 µg/ml. The total 40 ml volume will be divided into 10 ml for each injection.
223581232|NCT04195386|PROCEDURE|Dental Restoration with Chemically activated Composite resin Alkasite|Selective removal of dental caries with manual instruments, under relative isolation, application of universal adhesive system and restoration with chemically activated composite resin Alkasite.
223743978|NCT04720326|DRUG|Tacrolimus capsule|Advagraf® capsules dosed to achieve and maintain whole blood trough levels of tacrolimus within a patient-specific therapeutic range (interval of 3 ng/ml) that lies within a wider reference range of 3-12 ng/ml.
223473843|NCT06369636|PROCEDURE|Thyroid Surgery|EGRI scores and airway ultrasonographic values will be recorded in patients who undergo thyroid surgery.
223473844|NCT05412134|DEVICE|Pro2 - 75% of participant's MIP|"Each participant will be provided a PrO2™ device and trained on its use as well as its accompanying PrO2 Fit™ app. The PrO2™ is a flow-resistive device that provides inspiratory resistance via a fixed 2mm orifice and has Bluetooth connectivity to most IOS/Android devices or Mac/Windows computers. The PrO2™ device and app allows for both 100% adherence monitoring and immediate user biofeedback.~Participants will be instructed to inspire forcefully through PrO2™ until the device signals that the user has achieved the target resistance (via audible alarm and visible light signal). The research team will implement biofeedback signals at a specific inspiratory resistance to provide precise and individualized training target. Successful IMR repetitions will require that subjects achieve a pressure target that is 75% of their MIP."
223581233|NCT04195386|PROCEDURE|Dental Restoration with Resin-Modified Glass ionomer Cement|Selective removal of dental caries with manual instruments, under relative isolation, application of polyacrylic acid and restoration with resin-modified glass ionomer cement.
223581234|NCT03242356|OTHER|Questionnaire to assess of the application of the current French guidelines as to fasting during labor.|"Questionnaire focuses on :~* oral intake of clear fluid during the labor~* oral intake of solid meal during the labor~* fasting duration for solid and liquids~* instruction received as to fasting during labor, nature of these instructions, and who given the instruction (midwife, nurse anesthetist, …)~* discomfort related to thirst during labor~* discomfort related to hunger during labor~We will also record several medical data as to the course of pregnancy and delivery, analgesia technique, history and characteristics of the parturient."
223581235|NCT03747120|DRUG|Paclitaxel|All subjects will receive Paclitaxel weekly for 12 weeks
223581236|NCT03747120|DRUG|Trastuzumab|All subjects will receive Trastuzumab every 3 weeks
223743979|NCT05425901|OTHER|biopsy|endoscopy biopsies (6)
223473845|NCT05412134|DEVICE|Pro2 - 15% of participant's MIP|Participants in the control intervention will also use the same PrO2™ device but at a reduced peak resistance of 15% MIP. The research team will implement biofeedback signals at a specific inspiratory resistance to provide precise and individualized training target. Successful IMR repetitions will require that subjects achieve a pressure target that is 15% of their MIP for each repetition. Participants will perform 3 sets of 50 inspiratory breaths 3 times per week.
223473846|NCT01656044|PROCEDURE|wound care management|Receive SSD
224161307|NCT00964249|DRUG|GW642444|Long acting Beta 2 agonist
223473847|NCT01656044|PROCEDURE|wound care management|Receive NPT
223473848|NCT02009943|DRUG|Ferric carboxymaltose|One time dosing
223473849|NCT02009943|DRUG|Iron sucrose|Goal-directed dosing
223473850|NCT03228901|DRUG|Oxytocin|Administration of the hormone oxytocin
223473851|NCT03228901|DRUG|Placebos|
223581237|NCT03747120|DRUG|Pertuzumab|Arm A and Arm B subjects will receive Pertuzumab every 3 weeks
223473852|NCT03881436|DIAGNOSTIC_TEST|MRI with DTI sequence|"At the end of the planned sequence, but before any contrast agent injection:~* Acquisition of a an additional anatomical T2 SPACE sequence~* Acquisition of a tractography DTI sequence"
223581238|NCT03747120|DRUG|Pembrolizumab|Arm B and Arm C subjects will receive Pembrolizumab every 3 weeks
223581239|NCT06326749|OTHER|Modified Graded Motor Imagery and Conventional Treatment Group|A modified form of graded motor imagery training and conventional rehabilitation will be applied.
223581240|NCT06326749|OTHER|Graded Motor Imagery and Conventional Treatment Group|Graded motor imagery training and conventional rehabilitation will be applied.
223581241|NCT06326749|OTHER|Conventional Treatment Group|conventional rehabilitation will be applied.
223581242|NCT02878044|OTHER|Thyroid Decision Aid|The Thyroid Decision Aid is a tool designed to help clinicians and patients discuss treatment options for thyroid nodules.
223473853|NCT03167242|DRUG|KAF156|KAF156 comes in 100 mg tablets for oral administration. KAF156 was administered in combination with LUM-SDF once daily (QD) for 1, 2 or 3 days at 200 mg, 400 mg or 800 mg doses.
223473854|NCT03167242|DRUG|Coartem|Coartem comes as 20/120 mg dispersible tablets or 80/480 mg tablets for oral administration. Coartem was administered twice daily for 3 days as active comparator.
223473855|NCT03167242|DRUG|Lumefantrine Solid Dispersion Formulation|LUM-SDF comes in 240 mg or 480 mg sachets for oral administration. LUM-SDF was administered in combination with KAF156 once daily (QD) for 1, 2 or 3 days at 480 mg or 960 mg doses.
223473856|NCT03211507|OTHER|Computer-assisted telephone interview|Occupational history
223473857|NCT03211507|GENETIC|Genetic analysis|To include analysis of known susceptibility markers
223473858|NCT02253264|DRUG|Rituximab|
223473859|NCT06433167|OTHER|Pedobarographic analysis|During the pedobarographic analysis, the patient takes steps on the platform at a regular walking speed, with arms relaxed at the sides, following a natural gait. In static analysis, measurements are taken while the patient remains stationary on the platform with arms in a relaxed position beside the body. Five measurements are separately recorded for both feet during the phases of stepping, heel strike, and toe lift. These measurements capture the highest pressures on the back of the foot, the middle part of the foot, and the inner, middle, and lateral sides of the front of the foot, including the toes. The pressure, force, and pressure-time integral corresponding to each area are then used to determine how and for how long these areas are exposed to pressure.
223473860|NCT04119648|BEHAVIORAL|CAMS-4Kids|The Collaborative Assessment and Management of Suicidality (CAMS-Jobes, 2006; 2016) is an evidence-based, therapeutic framework for addressing suicide risk in the adult population. CAMS-4Kids, the research intervention used in this study, is a 10-session developmentally-sensitive adaptation of CAMS for children ages 5 - 11 years old.
223581243|NCT04460859|OTHER|Specific lung recruitment maneuvers|Specific lung recruitment maneuvers will be performed to measure the potential for lung recruitment at different levels of positive end-expiratory pressure (PEEP) provided by the mechanical ventilator. Electrical impedance tomography signals, synchronized signals of airway pressure and flow, esophageal pressure (if available), and volumetric capnography (if available) will be recorded continuously, during the time span of the protocol for offline analysis.
224161308|NCT00964249|DRUG|Placebo|Matching placebo
224161309|NCT05642065|OTHER|Hip muscle activation home exercise program|Participants will perform a home exercise program consisting of five hip muscle activation exercises with the use of a resistance band. The program will be eight weeks in duration, and participants will perform the exercises twice weekly.
224161310|NCT02909582|PROCEDURE|Cohen Incision|This is a straight transverse incision through the skin, 3 cm below the level of the anterior superior iliac spines (higher than the Pfannenstiel incision). Should a pannus exist, the pannus should be left in the physiologic location (not retracted) to allow placement of the incision.
223581244|NCT00270660|BEHAVIORAL|biopsy, audiometry, ET function test, ear swab culture, DNE|
223581245|NCT05796115|PROCEDURE|Procalcitonin/Presepsin guided antibiotic prophylaxis for EOS|Infants will receive antibiotic prophylaxis for EOS on the basis of Procalcitonin and Presepsin values measured within the first 3 hours of life.
223581246|NCT05796115|PROCEDURE|Antibiotic prophylaxis for EOS|Infants will receive antibiotic prophylaxis for EOS.
223581247|NCT04545437|OTHER|Admission to ICU|Exposure is admission to an Intensive Care Unit
223581248|NCT06318611|OTHER|sleep, chronotype|Our objectives were to compare sleep health composite dimensions, and chronotype in children and adolescents with and without T1D, and to explore relationship between sleep and glycemic variability in T1D.
223581249|NCT00434798|BIOLOGICAL|Campylobacter jejuni strains CG8421 and BH-01-0142|Campylobacter jejuni strains CG8421 and BH-01-0142 at a single dose. Dosing will be based on attack rate, to achieve a 75% attack rate. Anticipate use of 10\^6-10\^9 CFU
223581250|NCT04248894|OTHER|Exercise training of High Intensity|High intensity
223581251|NCT04248894|OTHER|Exercise training of Moderate Intensity|Moderate intensity
223581252|NCT04248894|OTHER|Untraining|Sedentary
223581253|NCT00832494|DRUG|DMXAA in combination with carboplatin and paclitaxel|Administered every 21 days
224161311|NCT02531503|OTHER|Clinical asthma remission|Clinical asthma remission was defined as having no asthma symptoms and no use of medication during the past 12 months.
224304994|NCT02492880|DEVICE|Precision Spectra™ SCS system programming features|Precision Spectra™ SCS system programming features using the CoverEdge surgical lead.
224304995|NCT02675439|DRUG|ADU-S100|
223473861|NCT01105052|BEHAVIORAL|Self-help CBT-I|Comparison between Bibliotherapy with and without support to a wait-list control group
223473862|NCT02709317|BEHAVIORAL|Prevention Intervention|
223473863|NCT02709317|BEHAVIORAL|Brief Intervention|
223581254|NCT02151331|BEHAVIORAL|External Facilitation|Non-responding sites randomized to receive external facilitation
223581255|NCT02151331|BEHAVIORAL|External + Internal Facilitation|Non-responding sites randomized to receive both internal and external facilitation
223581256|NCT02187315|DEVICE|Chrono-chemotherapy pump:Melodie|
223581257|NCT02187315|DEVICE|Routine intravenous drip|
223581258|NCT02187315|DRUG|induction chemotherapy|
223581259|NCT02187315|DRUG|cisplatin chrono-chemotherapy|
223581260|NCT02187315|RADIATION|intensity-modulated radiation therapy|
223581261|NCT02187315|DRUG|cisplatin routine-chemotherapy|
223581262|NCT03551756|OTHER|Biomarker Assessment|Exploratory Biomarker Analysis for cardiac patients versus healthy adults
223581263|NCT01410812|BEHAVIORAL|Control|Receive weekly emails asking participants about their exercise and receive cash.
223581264|NCT01410812|BEHAVIORAL|Suggested Tying Intervention|Participants receive 4 iTunes audio novels for their own iPods to listen to only at the gym
223581265|NCT01410812|BEHAVIORAL|Forced Tying Intervention|Participants receive cash and also 4 iTunes audio novels for a loaned iPod accessible only at the gym to listen to only at the gym.
223581266|NCT06492473|DEVICE|ECHO|type and size of ventricular septal defect
223581267|NCT04788056|PROCEDURE|Parasternal Subpectoral Plane Block|Nerve block catheter inserted into plane between rib cartilages and pectoralis muscle.
223581268|NCT00697437|DRUG|Docetaxel|70mg q3wx 1 dose
223581269|NCT00697437|DRUG|Ketoconazole|6 doses of oral ketoconazole 200mg bid starting 2 days before, and with 1 dose to be completed after, docetaxel infusion
224161312|NCT04246541|DRUG|Ketorolac|Patients will receive IV ketorolac during surgery followed by 3 days of oral ketorolac (10 mg every 6 hours) for pain control. Patients will also be given oxycodone-acetaminophen (5mg-325mg) PRN for pain not controlled with ketorolac.
224161313|NCT04246541|DRUG|Oxycodone-Acetaminophen|Patients will be discharged with oxycodone-acetaminophen (5mg-325mg) PRN for pain control after surgery.
223473864|NCT02716740|DIETARY_SUPPLEMENT|Leucine-enriched amino acid supplementation and 30 minutes of physical training 3 times per week|After 3 months of obesity-surgery, if patients lost more than 15% of muscular weight, they will take a leucine-enriched amino acid supplementation during 3 months added with a regular physical training (30 minutes, 3 times/week). Arm A will take 2.46g/day of leucine-enriched amino acid supplementation and arm B 4g/day.
223473865|NCT02629978|PROCEDURE|CT-guided percutaneous radiofrequency ablation|Percutaneous radiofrequency ablation (RFA) is a minimally invasive technique will be performed in patients with malignant pulmonary nodules in this group. RFA kills the tumors by causing coagulation necrosis via tissue heating. The electrode delivers thermal energy will be inserted into the target tissues under the CT guidance to ensure the area of ablation should cover the targets and the lung tissues 0.5-1.0 cm around the tumors. Post-operative scan and laboratory test will be conducted in time.
223581270|NCT05093803|BEHAVIORAL|CONTROL GROUP|Intervention based on measurements of health parameters before and after providing participants with personalized dietary and physical activity recommendations.
223581271|NCT05093803|BEHAVIORAL|HEALTH APP GROUP|"Use of a mobile application based on machine learning with the aim of improving health parameters and body composition.~Specific diet program and moderate physical activity, all guided and mediated by a mobile application. As well as the recording and monitoring of periodic evaluations of health indicators."
223581272|NCT04566653|DRUG|Calcium Polystyrene Sulphonate 15g/60 mL water|K+ binder, not for treatment but for tasting (sip-and-spit taste test)
223581273|NCT04566653|DRUG|Lokelma® 5 g/45mL water|K+ binder, not for treatment but for tasting (sip-and-spit taste test)
223581274|NCT04566653|DRUG|Lokelma® 10 g/45 mL water|K+ binder, not for treatment but for tasting (sip-and-spit taste test)
223581275|NCT04566653|DRUG|Veltassa® 8,4 g/80mL water|K+ binder, not for treatment but for tasting (sip-and-spit taste test)
223581276|NCT04566653|DRUG|Sodium Polystyrene Sulphonate 15g/60 mL water|K+ binder, not for treatment but for tasting (sip-and-spit taste test)
223581277|NCT02667756|OTHER|Non-interventional|
223581278|NCT01331928|DRUG|Capecitabine (Xeloda, Roche), Oxaliplatin (Sanofi-Aventis), Docetaxel (Sanofi-Aventis)|capecitabine orally 1000 mg/m2 twice daily, day1 to day 10, every 2 weeks plus oxaliplatin 85mg/m2 (2hrs IV infusion)on day1, every 2 weeks for 6 cycles, then shift to docetaxel 30 mg/m2(over 30-minute intravenous infusion) on day 1 and day 8 plus oral capecitabine 825 mg/m2 twice daily on day 1 to 14, every 3 weeks for 4 cycles.
223581279|NCT00002506|BIOLOGICAL|recombinant interferon alfa|
223581280|NCT00002506|DRUG|isotretinoin|
223581281|NCT01984450|PROCEDURE|ACIC|"Autologous Collagen Induced Chondrogenesis (ACIC):~ACIC is a single stage arthroscopic procedure. It is done as a day case procedure. The cartilage defect is debrided and implanted with a collagen + fibrin gel mixture under CO2 insufflation."
223581282|NCT01984450|PROCEDURE|MCIC|"Mesenchymal Cell Induced Chondrogenesis (MCIC):~MCIC is a single stage arthroscopic procedure. It is done as a day case procedure. BMAC is harvested intraoperatively and concentrated. It is then mixed with a fibrin gel and implanted under CO2 insufflation."
223581283|NCT01984450|DEVICE|implant with a collagen + fibrin gel mixture|
223581284|NCT01660620|DRUG|Betaxolol|
223581285|NCT01660620|DRUG|topical betaxolol|given topically
223581286|NCT04180566|OTHER|Ultrasound Examination|Includes a regular growth ultrasound examination.
224161314|NCT04825249|PROCEDURE|traditional suture bridge technique|(A) Limbs of the sutures from the medial anchor were passed through torn tendon (B) the suture limbs were tied in a horizontal mattress suture pattern (C) the lateral row pressed the free tails of the knotted line on the greater tubercle of the humerus (D) the effect after completion of the TSB technique
224161315|NCT04825249|PROCEDURE|modified suture bridge technique|(A) Limbs of the sutures from the medial anchor and 2 tendon sutures were passed through the same position of torn tendon (B) the lateral row pressed free tails of the two tendon lines on the greater tubercle of the humerus (C) after examination of sufficient tension and stable fixation, sutures of medial row was knotted (D) the effect after completion of the MSB technique
224161316|NCT03034109|DEVICE|Transcranial Direct Current Stimulation|TDCS involves sending a weak electrical current to the brain to modulate brain functions.
223473866|NCT06050681|BEHAVIORAL|Mindfulness Training|Participants will be asked to complete 21 mindfulness sessions within the Calm app on their own time and at a location of their choosing. They will be instructed to complete the '7 Days of Calm' program within the first two weeks of the intervention, the '7 Days of Managing Stress' program during weeks 3 \& 4 of the intervention, and the 'Letting Go of Anxiety' program during the final two weeks of the intervention. The sessions have a mean run time of 11.76 minutes. Each 7-day program will be completed within a 2-week period, which equates to about one session every other day, but can be completed at any interval within those 2 weeks. All 21 sessions will be completed within a 6-week period.
223581287|NCT04180566|OTHER|Antenatal Testing (biophysical profile)|Includes weekly ultrasounds with a biophysical profile, which measures fetal tone, fetal movements, fetal breathing and amount of amniotic fluid (water around baby).
224161317|NCT00026975|PROCEDURE|Hyperbaric Oxygen|
223581288|NCT02101489|OTHER|Foley Catheter|20 with intraoperative Foley catheter measurement of the urethral length and 20 without
223581289|NCT01659099|DRUG|GA101|in GA-ACBVP or in GA-CHOP 1000 mg on D1 and D8 (D8 in cycle 1 and 2)
223581290|NCT01659099|DRUG|Rituximab|in R-ACBVP or in R-CHOP 375 mg/m² on D1
223581291|NCT01659099|DRUG|Doxorubicin|in ACBVP : 75 mg/m² on D1 in CHOP : 50 mg/m² on D1
223581292|NCT01659099|DRUG|Cyclophosphamide|in ACBVP : 1200 mg/m² on D1 in CHOP : 750 mg/m² on D1
224161318|NCT04847739|PROCEDURE|Seton Placement|This treatment consists of inserting a seton (a soft flexible tube or nonabsorbable string) into the subject's perianal fistula. The seton will be removed by a study doctor at study visits as applicable.
224161319|NCT04847739|DRUG|AVB-114|AVB-114 consists of stem cells taken from a subject's fat tissue seeded into a bioabsorbable plug. AVB-114 will be inserted into the subject's fistula by a study doctor on Day 0.
224161320|NCT02955368|DRUG|DP-R212|DP-R212 + C1-R212 placebo + C2-R212 placebo
224161321|NCT02955368|DRUG|C1-R212|DP-R212 placebo + C1-R212 + C2-R212 placebo
224161322|NCT02955368|DRUG|C2-R212|DP-R212 placebo + C1-R212 placebo + C2-R212
223581293|NCT01659099|DRUG|Prednisone|in ACBVP : 60 mg/m² from D1 to D5 in CHOP : 40 mg/m² from D1 to D5
224161323|NCT05110404|OTHER|The high-volume HIIT|patients will undergo a warm up at 65%-70% of HRpeak for 5 minutes, and then they will walk on a treadmill for 4 intervals of 4 min each at an intensity corresponding to 85%-90% of HRpeak with 3 min active recovery interval interval in between at 65%-75% of HRpeak. Finally, a 3-min cool-down period will be permitted. The speed and the inclination of the treadmill will be adjusted between intervals to ensure that all patients are exercising at the desired target heart rate monitored by Pulse Oximeter.
224161324|NCT05110404|OTHER|The low-volume HIIT|Each session will start with a 5-minute warm up at 65-70% of peak HR. Then they will walk on a treadmill for 4 intervals of 2 min each at an intensity corresponding to 85%-90% of HRpeak with three intervals of active recovery in between for 2 min at 65%-75% of HRpeak. Finally, a 3-min cool-down period will be permitted.
224161325|NCT04125381|OTHER|Exposure to Arsenic by drinking water|People residing in municipalities with Arsenic drinking water concentrations over legal threshold (10 µg/L), were considered as exposed.
224161326|NCT00838370|DRUG|Capecitabine, 5-fluorouracil|"Patients to treat with capecitabine/5-FU will be screened prior to start of therapy for DPYD\*2A. Patients heterozygous or homozygous mutant for DPYD\*2A receive dose reductions of capecitabine/5-FU of at least 50% in the first two courses. In case this dose is tolerated well, doses will be increased.~In addition, the pharmacokinetics of capecitabine/5-FU and their metabolites will be assessed in these patients."
224161327|NCT00926185|DRUG|Lifitegrast|Ophthalmic Solution
224161328|NCT00926185|DRUG|Placebo|Ophthalmic Solution
224161329|NCT04599972|DRUG|CSF-1|One drop bilaterally twice daily for approximately 2 weeks.
223581294|NCT01659099|DRUG|Bleomycin|in ACBVP 10 mg from D1 to D5
223581295|NCT01659099|DRUG|Vindesin|in ACBVP 2 mg/m² from D1 to D5
223581296|NCT01659099|DRUG|Vincristine|in CHOP 1,4 mg/m² on D1
223581297|NCT04271475|DRUG|Macitentan|Participants will receive Macitentan film-coated tablets orally od.
224161330|NCT04599972|DRUG|Vehicle|One drop bilaterally twice daily for approximately 2 weeks.
224161331|NCT06031376|DRUG|Fruquintinib|5mg once daily for 14 days on/7 days off, over a 21-day cycle
224161332|NCT06031376|DRUG|PD-1 inhibitors|The anti-PD-1 antibody was administered intravenously on day 1, and its recommended dosage was as follows: nivolumab: 240 mg, every 2 weeks; pembrolizumab, camrelizumab, and sintilimab: 200 mg every 3 weeks; and toripalimab: 240 mg every 3 weeks.
224304996|NCT02675439|BIOLOGICAL|ipilimumab|
223581298|NCT04271475|DRUG|Placebo|Participant will receive matching placebo tablets orally od.
223581299|NCT00114088|PROCEDURE|hysterectomy|
223581300|NCT00114088|PROCEDURE|endometrial ablation|
223581301|NCT06477796|DEVICE|Morning Bright Light Therapy|Morning bright light: Sitting in front of a lightbox for 60 minutes every morning within 120 minutes of waking up.
223581302|NCT06477796|DEVICE|Negative Ion Generator|Negative ion generator: Sitting in front of a modified negative ion generator for 60 min every morning within 120 minutes of waking up.
223581303|NCT05011877|DEVICE|High-flow nasal cannula therapy|High-flow nasal cannula therapy (HFNC) (from 25 - 60 L/min based on patient's tolerance) will be used in 21 participants during one additional sleep study to investigate its acute impact on reducing sleep abnormalities. Inspired fraction of oxygen will be titrated to maintain patient SpO2 similar to the levels during standard oxygen therapy.
223581304|NCT01549119|BIOLOGICAL|VAC-3S|Comparison of different doses of vaccine. Liquid form Volume: 0.5 mL - 2 X 0.5 mL for double-dose arm 3 vaccinations at one month apart
223581305|NCT01549119|BIOLOGICAL|Placebo|Comparison with experimental vaccine
223743980|NCT06008119|DRUG|Tunlametinib plus Vemurafenib|12mg BID Tunlametinib+720mg BID Vemurafenib
223743981|NCT06008119|DRUG|Doublets Chemotherapy ± Bevacizumab or Doublets Chemotherapy ± Cetuximab|According to investigators' suggestion
224161333|NCT06031376|DRUG|Trifluridine/Tipiracil|TAS-102 35 mg/m²orally twice a day on days 1-5 and 8-12, every 28 days
224161334|NCT06031376|DRUG|Bevacizumab|Bevacizumab 5 mg /kg, intravenously on days 1,15,every 28 days
224161335|NCT02885272|PROCEDURE|Computed Tomography|Undergo PET/CT scans
224161336|NCT02885272|RADIATION|Fludeoxyglucose F-18|Given IV
224304997|NCT03533738|OTHER|Food sequence 1|Vegetables first then meat \& rice together
223473867|NCT02910232|DEVICE|bone void filler|Bone void filler device prepared from porous starch-hydroxyapatite composites for bone regeneration
223473868|NCT03153670|OTHER|fMRI|DBS patients will undergo fMRI scanning. For each patient, scans will be performed using a selection of DBS settings. fMRI responses will be analysed to evaluate brain responses on different DBS settings. These results will be provided to the programming clinician to guide them choose the optimal setting for each patient at the clinician's discretion.
223473869|NCT05720819|DEVICE|Combined biofeedback-virtual reality device|The study's biofeedback-VR device was developed in collaboration with students and faculty at the University of Washington Global Innovation Exchange program. The system included an Oculus Go mobile VR headset (wireless, portable, head-mounted display, with screen providing a 101° field of view with 2560 x 1440 resolution at a 60-72 Hz frame rate; Oculus VR, LLC, Menlo Park, CA/USA) and with built-in speaker, in addition to a Polar H10 heart rate monitor (electrocardiogram, or ECG, to measure heart rate; Polar Electro Inc., Bethpage, NY/USA), with customized software programmed for the study using the Unity3D game engine (Unity Technologies, Bellevue, WA/USA). Individuals in the experimental arm are asked to use this device for 10 minutes daily, on at least 3 days per week.
223473870|NCT00599560|GENETIC|vasopressin, V2 receptor and cyclic AMP|plasma vasopressin, V2 receptor, cyclic AMP
223473871|NCT01963468|BEHAVIORAL|Early language intervention|Parents will practice the specific set of strategies (visual, interactive, tactile, responsive) during sessions that occur weekly and last 1 hour for a total of 26 sessions, over 6 months. Each session will include four segments: (a) the therapist will review the intervention strategies taught in the workshop (10 min), (b) the therapist will model the intervention strategy with the child (10 min), (c) the parent will practice the strategy with her child with coaching from the therapist across four different routines and activities of the parent's choice (30 min), and (d) the therapist will provide feedback to the parent, summarize the session, and answer the parent's questions (10 min).
223473872|NCT01578772|DRUG|Telmisartan|80mg tablets po daily for 6 weeks
223473873|NCT00705419|DRUG|Vicriviroc maleate|Follow-up for subjects who previously received 30 mg tablet administered once daily according to the parent protocol.
223473874|NCT00705419|DRUG|Vicriviroc maleate|Follow-up for subjects who previously received 20 mg tablet administered once daily according to the parent protocol.
223473875|NCT00705419|DRUG|Placebo|Follow-up for subjects who previously received placebo tablet administered once daily according to the parent protocol.
223473876|NCT00705419|DRUG|Emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg|Follow-up for subjects who previously received active control consisting of emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg combination tablet administered once daily according to the parent protocol.
223473877|NCT04182958|DRUG|(14C)-OPC-61815|On the morning of Day 1, all subjects will receive a single IV infusion of (14C) OPC-61815
223473878|NCT03432481|PROCEDURE|Unicompartmental Knee Arthroplasty Surgery|Unicompartmental Knee Arthroplasty Surgery using the Bodycad Unicompartmental Knee System (BUKS)
223473879|NCT03432481|DEVICE|Bodycad Unicompartmental Knee System (BUKS)|Unicompartmental Knee Arthroplasty Surgery using the Bodycad Unicompartmental Knee System (BUKS)
223473880|NCT05401565|DRUG|Balovaptan|Intervention of oral administration of 10mg balovaptan QD for 12 weeks followed by two weeks of follow-up period
223473881|NCT05401565|DRUG|Placebo|Matching placebo
223473882|NCT04463134|DRUG|NTM drug treatment|NTM drug treatment according to guideline and sensitivity test results
223581306|NCT06585709|DEVICE|Active repetitive Transcranial Magnetic Stimulation (rTMS)|Active rTMS will be delivered with a MagVenture MagPro X100 rTMS device with a Cool-B65-AP coil. rTMS will be applied to a personalized treatment target within the Left-Dorsolateral Prefrontal Cortex using a Localite Neuronavigation device.
224161337|NCT02885272|PROCEDURE|Magnetic Resonance Imaging|Undergo standard of care MRI
224161338|NCT02885272|PROCEDURE|Positron Emission Tomography|Undergo PET/CT scans
224161339|NCT02500472|DIETARY_SUPPLEMENT|Kava|3 doses equaling 250 mg kavalactones per day. Participants will take 1 capsule three times daily at 8:00 (± 2 hours), 14:00 (± 2 hours) and 20:00 (± 2 hours) for 7 consecutive days.
224161340|NCT02597985|OTHER|Prehabilitation|Supervised exercise training intervention will include three sessions per week for four weeks at a Mayo Clinic system cardiac rehabilitation facility. The Rochester, Minnesota Cardiac Rehabilitation Program will provide guidance and oversight. Modes of aerobic exercise will include treadmill walking (the primary mode of training) supplemented with non-weight-bearing activities such as stationary cycling and combination arm/leg recumbent exercise (NuStep device), as needed. Intensity will be set using Borg Perceived Exertion Scale (RPE) ratings of 12-14 (somewhat hard), keeping patients below the threshold for more than mild angina.
224161341|NCT02597985|OTHER|Usual Care|
224161342|NCT01379729|OTHER|Transplantation of encapsulated beta cells.|Implantation of a therapeutical dose of encapsulated beta cells.
223473883|NCT02886923|DEVICE|Hioxifilcon A Test|contact lens made with hioxifilcon A material
223473884|NCT02886923|DEVICE|Hioxifilcon A With Cosmetic Ring Control|contact lens made with hioxifilcon A material with a cosmetic ring on the lens
223473885|NCT02461537|DRUG|HAM|High-dose cytarabine 1 - 3 g/m2 (days 1-3)/Mitoxantrone 20 mg/m2 (days3-5)
223473886|NCT02461537|DRUG|LDAC and/or Mitoxantrone|Low-dose cytarabine 20 mg/m2 (days 1-10) and/ or mitoxantrone 10mg/m2 (max 3 doses)
223473887|NCT01560247|PROCEDURE|Mechanical thrombectomy|Mechanical thrombectomy using a MindFrame device
223473888|NCT02862301|BIOLOGICAL|blood sample|
223473889|NCT00726609|DRUG|Posaconazole|The usual dose of NOXAFIL® is 400 mg twice daily (10 mL) at meals or with 240 mL of a food supplement. For patients unable to take meals or food supplements, NOXAFIL® is administered at a dose of 200 mg (5 mL) four times daily.
223473890|NCT02405819|OTHER|'My Care Plan'|'My Care Plan' is a patient-initiated survivorship care planning tool.
223473891|NCT02405819|OTHER|'Survivorship Care Plan Builder'|'Survivorship Care Plan Builder' is a provider-initiated survivorship care planning tool.
223473892|NCT06180057|DRUG|Chenodeoxycholic acid|Two capsules were administered orally
223473893|NCT06180057|DRUG|Chenodeoxycholic acid leadiant|Two capsules were administered orally
223473894|NCT06454786|OTHER|Simulation Method|Management of cardiogenic shock scenario on an advanced simulation mannequin
223473895|NCT00808340|DEVICE|balafilcon A|multifocal contact lens
223473896|NCT00808340|DEVICE|senofilcon A production|multifocal contact lens
223473897|NCT00808340|DEVICE|senofilcon A test|multifocal contact lens
223473898|NCT05939908|OTHER|Using Jamar Dynamometer for Grip Strength.|Hand grip strength as a marker by using JAMAR hand grip dynamometer in patients with T2DM.
223473899|NCT02402374|DEVICE|Autologous platelet rich plasma gel|PRP gel application to exuding wounds, such as leg ulcers, pressure ulcers, and diabetic foot ulcers and for the management of mechanically- or surgically-debrided wounds
223473900|NCT02402374|DEVICE|Placebo|Placebo control arm will be receiving commercial formulations of pre-prepared saline gel.
224161343|NCT01379729|OTHER|Transplantation of encapsulated beta cells.|Implantation of a therapeutical dose of encapsulated beta cells.
224161344|NCT03949621|DRUG|Vedolizumab SC|Vedolizumab SC liquid.
224161345|NCT05146037|OTHER|CO2 and saline flushing|TAVI valves will be prepared by flushing with CO2 to displace any retained air during manufacturing and preparation. The valves will then be flushed with saline as per IFU.
224161346|NCT05146037|OTHER|Saline flushing|TAVI valves will be flushed with saline only as per IFU.
224161347|NCT05305976|OTHER|Telerehabilitation|The 8 week exercise program with telerehabilitation
224161348|NCT06252740|OTHER|No intervention|Comare the difference in batting mechanics, hip and thoracic spine mobility, and muscle stiffness in baseball players with and without a history of low back pain
224161349|NCT04189640|DRUG|Postoperative analgesia management|Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit. Postoperative patient evaluation will be performed by an anesthesiologist blinded to the procedure. If the VAS score will be ≥ 4, 0.5 mg/ kg tramadol IV will be administered.
224161350|NCT04443894|OTHER|PECS block|PECS block is performed at the side of surgery (II) before incision with ropivacaine 0,375%.(30 ml). General anesthesia is induced and maintained with midazolam, fentanyl, propofol and rocuronium. Pain is assessed postoperatively according to protocol (24 hours and after 3 months).
224161351|NCT04443894|OTHER|local infiltration|local infiltration of the surgical wound before incision with πwith ropivacaine 0,375%.(30 ml). General anesthesia is induced and maintained with midazolam, fentanyl, propofol and rocuronium. Pain is assessed postoperatively according to protocol (24 hours and after 3 months).
223473901|NCT06516120|BEHAVIORAL|RGS-app|Participants use the RGS-app on a smartwatch once for 1.5 hours during the measurement. The RGS-app consists of augmented reality games to provoke upper limb movement.
223581307|NCT06585709|DEVICE|Sham repetitive Transcranial Magnetic Stimulation (rTMS)|Sham rTMS in an identical fashion to the active-rTMS condition will be delivered via the built-in e-sham system in the MagVenture device.
223581308|NCT06585709|DIAGNOSTIC_TEST|High Ventral Striatal Reactivity|We will test for ventral striatal reactivity using a Reassessment of Craving MRI task and define high ventral striatal reactivity as having \>mean voxels in the ventral striatum activate
223581309|NCT06585709|DIAGNOSTIC_TEST|Low Ventral Striatal Reactivity|We will test for ventral striatal reactivity using a Reassessment of Craving MRI task and define low ventral striatal reactivity as having \<mean voxels in the ventral striatum activate
223581310|NCT06098534|BEHAVIORAL|Hospi'Senior|The Hospi'Senior room is equipped with conventional furnishings (same bed and same armchair as a conventional room) to which have been added technological innovations and innovations in furnishings. Innovative technologies cover bed equipment, patient mobility (autonomous and assisted), lighting, communication and social space.
223581311|NCT06098534|BEHAVIORAL|Conventional room|"The conventional room is a classic hospital room not equipped with the innovative technologies found in the Hospi'Senior room.~The room is equipped with a bed, bedside table, adjustable bed table with castors and an armchair."
223581312|NCT05621239|BIOLOGICAL|BNT162b2|BNT162b2 half dose and full dose
223581313|NCT06454149|OTHER|MALT lymphoma|New diagnosis with gastric MALT lymphoma
223581314|NCT06980844|OTHER|No intervention: no treatment|translationnal study: Only blood sampling and imaging will be performed on two groups of ILD patients.
223581315|NCT06815003|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic HCT
223581316|NCT06815003|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223581317|NCT06815003|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
223581318|NCT06815003|PROCEDURE|Computed Tomography|Undergo CT
223581319|NCT06815003|DRUG|Cyclophosphamide|Given IV
223581320|NCT06815003|PROCEDURE|Echocardiography|Undergo ECHO
223581321|NCT06815003|DRUG|Fludarabine|Given IV
223581322|NCT06815003|DRUG|Melphalan|Given IV
223581323|NCT06815003|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
224304417|NCT02697240|DRUG|Intravenous citrulline|Intravenous citrulline at a bolus dose of 20 mg/kg over 5 minutes and then continuous at a rate of 7 mg/kg/hour for the next 23 hours for the first 7 participants, and depending on safety and pharmacokinetic profile, increase or decrease the continuous rate to 9 or 5 mg/kg/hour for the next 7 participants.
224304418|NCT05008601|DEVICE|Wrist-word optical heart rate and ECG measurement device|Aino ECG: wrist-word optical heart rate and ECG measurement device
223473902|NCT03617887|OTHER|Experimental group|"Plank exercise, Lateral plank exercise, Bird dog exercise, Pelvic drop exercise, and Stabilization of the middle gluteus in the knee valgus.~The intervention consisted of sessions of approximately 20 minutes, taking place 2 days a week, for 8 weeks. The exercises were performed at the beginning of the training session, and consisted of a work of the abdominal region in the control group, and a specific work of gluteus medius, added to the previous one, in the experimental group."
223473903|NCT03617887|OTHER|Control group|Plank exercise, Lateral plank exercise and Bird dog exercise. The intervention consisted of sessions of approximately 20 minutes, taking place 2 days a week, for 8 weeks. The exercises were performed at the beginning of the training session, and consisted of a work of the abdominal region.
223473904|NCT02622243|DRUG|Tiotropium|long acting muscarinic antagonist
223473905|NCT02622243|DRUG|glycopyrronium|long acting muscarinic antagonist
223473906|NCT02622243|DEVICE|Respimat|inhaler device used to deliver active tiotropium or placebo
223473907|NCT02622243|DEVICE|Breezehaler|inhaler device used to deliver active glycopyrronium or placebo
223473908|NCT01516138|DRUG|GIK|Intravenous solution was started at about 10 minutes before general anesthesia, running at a rate of 1 mL/kg/h for 12.5 hours.
223473909|NCT01516138|DRUG|Control|Intravenous solution was started at about 10 minutes before general anesthesia, running at a rate of 1 mL/kg/h for 12.5 hours.
223473910|NCT01007799|DIETARY_SUPPLEMENT|vitamin D placebo|12 weeks of placebo
223473911|NCT01007799|DIETARY_SUPPLEMENT|Vitamin D|12 weeks supplementation based on serum vitamin D levels
224161352|NCT01517906|BEHAVIORAL|Identity Intervention Program|Cognitive behavioral strategies will be used by trained nurse-therapists to facilitate the participant's: a) identification of a small collection of personally meaningful and feasible desired possible selves, b) prioritization of the desired possible selves as short and long-term goals, c) identification, elaboration, implementation and evaluation of cognitive and behavioral strategies to achieve the desired possible self selected as the goal, and d) identification of internal and external barriers that interfere with achieving the possible self goal and utilization of active problem solving strategies to overcome the barriers.
224161353|NCT01517906|BEHAVIORAL|Supportive Psychotherapy for the Eating Disorders|SPI is a 20-week program with a one-hour individual psychotherapy session scheduled each week. The SPI is organized in three stages: 1) Stage 1 (Sessions 1-8) including assessment of the current and past ED history, collection of personal and family history, and identification of problems contributing to the ED; 2) Stage 2 (Sessions 9-16) aims include exploration of underlying emotional problems, increased self-disclosure and expression of feelings, and fostering independence; and 3) Stage 3 (Sessions 17-20) includes continued exploration of underlying problems and implications for future behaviors and termination.
224161354|NCT04313504|DRUG|Niraparib|Niraparib \& Dostarlimab combination
224161355|NCT04313504|DRUG|Dostarlimab|Niraparib \& Dostarlimab combination
223473912|NCT01394289|BIOLOGICAL|Lolium allergen extract|"This is an open, unblinded and non randomized biological as proposed by the Nordic Guidelines.~Four concentrations of Lolium perenne allergen extract, together with a positive and negative control, using 10 mg/ml histamine dihydrochloride solution and a glycerinated phenol saline solution, respectively, will be tested in every patient in duplicate on the volar surface of the forearm. This test will be referred to as the Titrated Skin Prick test."
223581324|NCT06815003|OTHER|Questionnaire Administration|Ancillary studies
223581325|NCT06815003|DRUG|Tacrolimus|Given IV or PO
223581326|NCT06815003|BIOLOGICAL|Vedolizumab|Given IV
223581327|NCT06979908|DRUG|Fruquintinib+Sintilimab+Chidamide|"Fruquintinib: 5 mg orally once daily on days 1-14 of each 21-day cycle (Q3W).~Sintilimab (anti-PD-1): 200 mg intravenously on day 1 of each cycle (first infusion over 60 minutes, subsequent infusions over 30-60 minutes, Q3W).~Chidamide: 30 mg orally twice weekly (BIW; e.g., Monday \& Thursday or Tuesday \& Friday, with ≥3 days between doses), taken 30 minutes after meals."
223581328|NCT06980142|BIOLOGICAL|CM512|Administered SC
224161356|NCT01909986|DRUG|[14C]ONO-4053|Single dose \[14C\]ONO-4053
224161357|NCT00605358|BEHAVIORAL|Open Door intervention|"Open Door intervention subjects will:~1. receive an evaluation~2. receive a referral to a local mental health provider~3. identify barriers, set goals and problem-solve to achieve a mental health evaluation using available resources."
223581329|NCT06980142|DRUG|Placebo|Administered SC
224161358|NCT00111891|DRUG|niacin (+) laropiprant|
224161359|NCT00111891|DRUG|Comparator: placebo (unspecified)|
224161360|NCT02861118|OTHER|No Intervention|
223473913|NCT00909168|DRUG|FLAIMy - Fluda, Ida, Ara-C, Mylotarg|"FLUDARABINE: 25 mg/m2/day, 250 FS in 30', start h 9 - 1, 2, 3, 4, 5~ARABINOSYL-CYTOSINE (Cytarabine): 2 g/m2/day, 500 FS in 3 h, start h 13 - 1, 2, 3, 4, 5~IDARUBICIN: 10 mg/m2/day, 100 FS in 1 h, start h 16 - 1, 3, 5~GEMTUZUMAB OZOGAMICIN (Mylotarg): 5 mg, single dose 500 FS in 4 h - 6"
223473914|NCT03257748|RADIATION|Laser Therapy|The groups will be submitted to 12 sessions of phototherapy held twice a week for six weeks, during which only the researcher in charge of programming the phototherapy device will be aware of which treatment is being employed. However, the programmer will not participate in the execution of the treatments, evaluations or data analysis.
223473915|NCT03257748|RADIATION|LED therapy|The groups will be submitted to 12 sessions of phototherapy held twice a week for six weeks, during which only the researcher in charge of programming the phototherapy device will be aware of which treatment is being employed. However, the programmer will not participate in the execution of the treatments, evaluations or data analysis.
223473916|NCT02855489|BEHAVIORAL|Attitudes Only|
223473917|NCT02855489|BEHAVIORAL|Norms Only|
223473918|NCT02855489|BEHAVIORAL|Perceived Behavioral Control Only|
223581330|NCT02745847|RADIATION|Re-irradiation with SBRT|Patients previously treated with SBRT with relapsed pancreatic cancer will be re-irradiated with SBRT.
223581331|NCT06102811|OTHER|Low Concentration Local Anesthetic Fascia Iliaca Compartment Block|Fascia iliaca block with Ropivacaine 0.075% (50 mL)
223581332|NCT06102811|OTHER|High Concentration Local Anesthetic Fascia Iliaca Compartment Block|Fascia iliaca block with Ropivacaine 0.25% (50 mL)
224161361|NCT03674294|DRUG|Aprepitant|Aprepitant is manufactured by Merck \& Co. for prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV) and for prevention of postoperative nausea and vomiting. It was approved by the FDA in 2003
224161362|NCT03674294|DRUG|Palonosetron|Palonosetron is a 5-HT3 antagonist used in the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV). It is used for the control of delayed CINV-nausea and vomiting and there are tentative data to suggest that it may be more effective than granisetron.
224161363|NCT03674294|DRUG|Dexamethasone|Dexamethasone is a type of corticosteroid medication. It is used in the treatment of many conditions, including rheumatic problems, a number of skin diseases, severe allergies, asthma, chronic obstructive lung disease, croup, brain swelling, and along with antibiotics in tuberculosis.
224161364|NCT03674294|DRUG|Placebo Oral Tablet|In the current clinical trial, placebo oral tablet is provided as a substance for Aprepitant with no active therapeutic effect.
224161365|NCT01679340|DRUG|S-1|Mode of administration: orally (capsules) Dosing schedule:80mg/m2, Bid,D1-14,every 3 week,for 8-10cycles
224161366|NCT01679340|DRUG|oxaliplatin|Mode of administration: intravenously Doseing schedule: 65 mg/m2 D1,D8,every 3 week, for 6 cycles
223581333|NCT05425810|DEVICE|Apply ENABLE sensing pad|The developed ENABLE system is integrated into the standard prosthetic liner and measures the pressure distribution during locomotion. Using the ENABLE system may lead temporary increase in the temperature inside the prosthetic socket and it is expected that the total exposition during the experimental procedure will be less than 10 min.
223473919|NCT02855489|BEHAVIORAL|Intentions Only|
223473920|NCT02855489|BEHAVIORAL|Three Constructs|
223473921|NCT02855489|BEHAVIORAL|Four Constructs|
223473922|NCT00499811|DRUG|vorinostat|Given orally
223473923|NCT00499811|OTHER|pharmacological study|Correlative studies
223473924|NCT04264208|DRUG|68-Ga RM2.|PET radiopharmaceutical
223473925|NCT04264208|DRUG|68-Ga PSMA11|PET radiopharmaceutical
223473926|NCT04264208|DEVICE|PET/MRI|PET/MR scanner by GE healthcare
223473927|NCT05966233|DRUG|R-DHAP|"* Rituximab 375 mg/m2 IV on D0 or D1~* Dexamethasone 40 mg/day IV or PO on D1-4~* Ara-C 2 g/m2 IV on D2 (2 doses every 12h) or D2 and D3~* Cisplatin 100 mg/ m2 IV on D1"
223473928|NCT05966233|DRUG|Pola-R-DHAP|"* Polatuzumab Vedotin 1.8 mg/kg IV on D1~* Rituximab 375 mg/m2 IV on D0 or D1~* Dexamethasone 40 mg/day IV or PO on D1-4~* Ara-C 2 g/m2 IV on D2 (2 doses every 12h) or D2 and D3~* Cisplatin 100 mg/ m2 IV on D1"
223473929|NCT06123702|BEHAVIORAL|Fear extinction|Extinction of conditioned fear response
223473930|NCT06123702|DRUG|Cannabidiol Cap/Tab|12 50-mg capsules
223473931|NCT06123702|DRUG|Placebo|12 placebo capsules
223473932|NCT05202834|DEVICE|UltraClear|Evaluation of the UltraClear Laser Workstation for Skin Treatment - Histology Study of Laser Ablation on human skin
223473933|NCT04168034|BEHAVIORAL|iParent2Parent Program|In addition to standard care, parents in the experimental group will receive the iParent2Parent program. The iParent2Parent program is a tailored peer mentorship program that provides modeling and reinforcement by peers (trained parents of children with JIA) to parents of children diagnosed with JIA.
223581334|NCT05425810|DEVICE|Insert small pads at pressure tolerant locations|To change the pressure distribution inside the socket, four fitting conditions are introduced by adding small pads at patella tendon (PT), lateral tibial crest (LTC), medial tibial crest (MTC), and popliteal fossa (PF) respectively. Including the no pads scenario, totally of five fitting conditions are simulated.
223581335|NCT04511117|OTHER|Control group|ProTaper Next rotary system and iRoot SP sealer with composite restorations.
223581336|NCT04511117|OTHER|Endocrown group|ProTaper Next rotary system and iRoot SP sealer with endocrown restorations.
224161367|NCT01679340|DRUG|cisplatin|Mode of administration: intravenously Dosing schedule: 75mg/m2 D1,every 3 week,for 6 cycle
223473934|NCT04168034|BEHAVIORAL|Waitlist Control|The control group will receive standard care but without the iParent2Parent program
223473935|NCT05731310|DRUG|Angong Niuhuang Pill|Take Angong Niuhuang pill half a pill/day； Angong Niuhuang pill combined with music scalp acupuncture group These operations last for 4 weeks
224161368|NCT06323499|PROCEDURE|Induction of atypical atrial flutter|Electrophysiological study with induction of atypical atrial flutter. When the induction was successful, ablation of arrhythmia was performed similar to the control group.
223473936|NCT02060357|DEVICE|Optical coherence tomography|
223473937|NCT00032773|DRUG|pentostatin for injection|
223473938|NCT04500444|OTHER|exercise training|An aerobic exercise program with blood flow restriction will be applied 4 times a week for a total of 6 weeks. The aerobic exercise training consists of a warm up period for 5 minutes, walking on treadmill at 4 km per hour speed for 20 minutes and cooling down for another 5 minutes.
223473939|NCT02778217|PROCEDURE|Culture media renwal|
223473940|NCT03019484|BEHAVIORAL|Breastfeeding support|Self-efficacy
223473941|NCT06415461|BIOLOGICAL|PremierMaxCB®-Platinum (CFL001);|Stem Cell: Human cell, tissue, and cellular or tissue-based product (HCT/P) manufactured from umbilical cord blood
223473942|NCT03458520|DIAGNOSTIC_TEST|PET/MR imaging|undergo PET/MR imaging
223473943|NCT03458520|DIAGNOSTIC_TEST|MR imaging|Undergo MR imaging
223473944|NCT03458520|DIAGNOSTIC_TEST|PET/CT imaging|Undergo PET/CT imaging
223473945|NCT06357624|OTHER|Mulligan mobilization|The SNAGS technique was applied to 3 sets of 10 repetitions with 15-30 seconds rest between sets while the participants were in a sitting position. A physiotherapist applied passive motion to facet joints at each spinal level. The participant was questioned in which direction he/she felt pain during cervical ROM and the application was carried out in the painful/limited directions.
223473946|NCT06357624|OTHER|Self-Mobilization|For the self-mobilization technique, each participant was asked to extend a pain-free while pushing upwards from the transverse processes of the treated vertebra with the thumbs of both hands. In addition, the middle or index finger of the right hand was asked to pull the treated vertebra to the right side, while at the same time, left rotation was asked at the pain limit. Self-mobilization was applied every day, twice a day, five times.
223473947|NCT03080935|DRUG|Evolocumab|Subjects will receive Evolocumab 140 mg every 2 weeks (Q2W) or 420 mg monthly (QM), according to the subject's preference.
223473948|NCT04157010|DRUG|Tocilizumab|
223473949|NCT04157010|DRUG|Methotrexate|
223473950|NCT02175121|DRUG|Placebo|Tablet, once daily for 28 days
223473951|NCT02175121|DRUG|PF-06291874|Tablet, 15 mg, once daily for 28 days
223473952|NCT02175121|DRUG|PF-06291874|Tablet, 35 mg, once daily for 28 days
223581337|NCT06396221|DRUG|Estetrol 15 mg/Drospirenone 3 mg (24/4)|Completing a pack (28 pills) of Estetrol 15 mg/Drospirenone 3 mg (24/4), starting on day 7-9 of menstrual cycle
223581338|NCT06396221|DRUG|Ethinylestradiol (EE) 20 mcg/Gestodene 75 mcg (21/7)|Completing a pack (28 pills) of Ethinylestradiol (EE) 20 mcg/Gestodene 75 mcg (21/7), starting on day 7-9 of menstrual cycle
223581339|NCT05982444|PROCEDURE|water vapor thermal therapy (Rezum) for prostate|all patients underwent rezum therapy for bph are evaluated for its effectiveness for long period
224161369|NCT02099292|DRUG|Rituximab and DexaBEAM|combination treatment
223473953|NCT02175121|DRUG|PF-06291874|Tablet, 75 mg, once daily for 28 days
223473954|NCT02175121|DRUG|PF-06291874|Tablet, 150 mg, once daily for 28 days
223473955|NCT04010279|PROCEDURE|preoxygenation with 100% O2, fresh gas flow rate 12 L/minute|volunteers will be placed in supine position, fresh gas flow rate will be set at 12 L/min and delivered oxygen concentration will be set at 100%.
223473956|NCT04726553|DRUG|Anifrolumab|Anifrolumab is a monoclonal antibody which inhibits the Interferon alpha beta receptor (IFNAR) which is the main transducer of signals from Type I interferons.
223473957|NCT04726553|DRUG|Standard of Care|Standard of Care treatments for Systemic Lupus Erythematosus
223473958|NCT01776086|BEHAVIORAL|Neurological testing|
223473959|NCT05802888|DRUG|Tetracycline 500mg tid|Amoxicillin 1000mg bid +Tetracycline 500mg tid +Bismuth+Esomeprazole 40mg bid
223473960|NCT05802888|DRUG|Tetracycline 500mg qid|Amoxicillin 1000mg bid +Tetracycline 500mg qid +Bismuth+Esomeprazole 40mg bid
223743982|NCT00878007|DRUG|Intermittent screening and treatment for malaria|All children will be screened for malaria using rapid diagnostic tests (RDTs) once a term (thrice yearly). Children (with or without clinical malaria symptoms) found to be RDT-positive will be treated with artemether-lumefantrine according to national guidelines. Screening and treatment will be administered by district public health staff once a school term, observed by the evaluation research team.
223743983|NCT00878007|BEHAVIORAL|Teacher training on literacy instruction|Education intervention designed to improved early grade literacy instruction, focusing on phonological awareness \& vocabulary and relationship between letters and sounds in a systematic and explicit fashion. Specific interventions will include training on (i) how to monitor students' progress in large classes (ii) developing and using instructional materials for reading (iii) lesson planning for explicit teaching of letter-sound relationships (iv) instructional techniques for large classes.
223473961|NCT03821038|BIOLOGICAL|CYT107|IV twice a week at 10µg/kg for 3 weeks
223473962|NCT03821038|DRUG|Placebos|IV twice a week at the same volume for 3 weeks
223473963|NCT03665337|BEHAVIORAL|mTranS-C|MOBILE HEALTH
223581340|NCT06471530|DRUG|TE-8105 SAD Cohort 1|Each participant will receive one dose of TE-8105 0.5 up to 1.5mg injection via subcutaneous (SC) injection into the abdomen administered on Day 1.
223581341|NCT06471530|DRUG|TE-8105 SAD Cohort 3|Each participant will receive one dose of TE-8105 1.5 mg or less than or equal to 2.5 mg injection via subcutaneous (SC) injection into the abdomen administered on Day 1.
223473964|NCT03665337|BEHAVIORAL|Control|MOBILE HEALTH
223743984|NCT00878007|OTHER|IST plus literacy instruction programme|Schools will receive both IST and the literacy instruction programme
223581342|NCT06471530|DRUG|TE-8105 SAD Cohort 5 (Adaptive cohort)|Each participant will receive one dose of TE-8105 less than or equal to 6 mg injection via subcutaneous (SC) injection into the abdomen administered on Day 1.
223581343|NCT06471530|DRUG|TE-8105 MAD Cohort 1|Each participant will receive 0.5mg up to 1.5mg of TE-8105 injection via SC injection into the abdomen on Day 1 and then once every 2 weeks for 5 doses.
223743985|NCT01575496|DEVICE|BrainSTIM Transcranial Stimulator|Cathodal stimulation of the auditory cortex with an anode (reference electrode) over the prefrontal cortex. Stimulation will be applied for 20 minutes at 2 mA.
224161370|NCT04078074|DEVICE|Maxillary OSS|Maxillary OSS will be a night guard for the top teeth. Digital impressions will be taken at the first appointment. After delivery appointment the patient will take home a sleep test monitor and bruxism monitor to record respiration and muscle activity during sleep.This will be a 2 night sleep study (Night A will be without splint and Night B will be with splint). Therefore, the patient will sleep with the mouth guard one night and the monitoring device two nights. Subjects will also undergo cone beam computed tomography (CBCT) airway imaging with and without splint.
224304419|NCT00513136|BEHAVIORAL|Group based mind body medicine intervention|Small groups of women (5-15) will participate in 10 weekly sessions that will include learning relaxation and yoga techniques, principles of exercise and nutrition, cognitive behavioral therapy and exploration of common issues and concerns
224304998|NCT03533738|OTHER|Food sequence 2|Meat first then vegetables \& rice together
223473965|NCT02758418|OTHER|TAO|"TAO is a self-applied online treatment program and consists on the computerized version of the traditional CBT protocol for Adjustment Disorders.~The treatment protocol comprises different therapeutic components (see section Intervention) which are presented to the patients through 7 modules (one of them introductory). The Internet platform allows audiovisual resources (videos, illustrations, music and exercises that provide quick feedback) to be included, that makes the program more interactive."
223473966|NCT03329885|DRUG|BMS-986251|Escalating oral dose
223473967|NCT03329885|OTHER|Placebo|Escalating oral dose
223581344|NCT06471530|DRUG|TE-8105 MAD Cohort 2|Each participant will receive 9 doses of TE-8105 injection via SC injection into the abdomen starting from Day 1 every 2 weeks. Dose will be titrated up by 0.5mg every 4 weeks, with dose levels of 1.5mg (2 doses), 2.0 mg (2 doses), 2.5 mg (2 doses) and 3.0 mg (3 doses)
223581345|NCT06471530|DRUG|TE-8105 SAD Cohort 2|Each participant will receive one dose of TE-8105 0.75mg injection via subcutaneous (SC) injection into the abdomen on Day 1.
223581346|NCT06471530|DRUG|TE-8105 SAD Cohort 4|Each participant will receive one dose of TE-8105 3 mg or less than or equal to 5 mg injection via subcutaneous (SC) injection into the abdomen administered on Day 1.
223581347|NCT06053398|DRUG|Phenylephrine|Intraoperative phenylephrine infusion Phenylephrine infusion to be titrated as needed to target a mean arterial pressure (MAP) \> 65 mm Hg.
223581348|NCT06053398|DRUG|Norepinephrine|Intraoperative norepinephrine infusion Norepinephrine infusion to be titrated as needed to target a MAP \> 65 mm Hg.
223743986|NCT01575496|DEVICE|BrainSTIM Transcranial Stimulator|Sham tDCS sessions will last 20 minutes.
223743987|NCT06387732|OTHER|Aerobic exercise|This will be delivered by coaches in a small group class format. Participants will complete the trial in staggered cohorts, with no more than six participants per class. Intervention activities will be tailored to each individual's own ability and fitness level.
223743988|NCT06387732|OTHER|Stretching and relaxation|This will be delivered by coaches in a small group class format. Participants will complete the trial in staggered cohorts, with no more than six participants per class. Intervention activities will be tailored to each individual's own ability and fitness level.
223743989|NCT03210610|DIAGNOSTIC_TEST|colchicine level measurement|levels of colchicine will be measured in FMF patients taking colchicine
223473968|NCT03622450|DRUG|Colistin|Polymyxins are bactericidal drugs that bind to lipopolysaccharides (LPS) and phospholipids in the outer cell membrane of gram-negative bacteria.
223473969|NCT03622450|DRUG|Carbapenem + Aminoglycoside/ Quinolone|Dual antipseudomonal given as IV for ventilator associated pneumonia for patients with Multi-drug resistant bacteria risk factors
223473970|NCT00521183|DRUG|Cytochlor|The study's starting dose of CldC is 50 mg/m2/day. The dose of CldC will be escalated / de-escalated for patients. Patients will receive CldC+H4U on 3 days (Wed, Thr, Fri) in week 1, which precedes the initiation of radiation therapy. Patients will receive H4U and CldC IV by bolus infusion. Treatment with CldC+H4U will then continue for 5 days (Mon-Fri) during each of weeks 2 and 3, and will be accompanied by radiation therapy at 3 Gy/fraction initiated 3-4 h after bolus infusion of CldC+H4U. Treatment with CldC+H4U and radiation will then stop at the end of week 3.
223473971|NCT00521183|DRUG|Tetrahydrouridine|A fixed dose of H4U at 720 mg/m2/day will be used, regardless of the dose of CldC administered. H4U will be delivered by an IV bolus infusion over a period of 5 minutes, followed 5 minutes later by an IV bolus infusion of CldC. Patients will receive CldC+H4U on 3 days (Wed, Thr, Fri) in week 1, which precedes the initiation of radiation therapy. Patients will receive H4U and CldC IV by bolus infusion. Treatment with CldC+H4U will then continue for 5 days (Mon-Fri) during each of weeks 2 and 3, and will be accompanied by radiation therapy at 3 Gy/fraction initiated 3-4 h after bolus infusion of CldC+H4U. Treatment with CldC+H4U and radiation will then stop at the end of week 3.
223473972|NCT00521183|RADIATION|Radiation Therapy|One treatment of 3 Gy will be given daily 5 days per week (10 fractions) for a total of 30 Gy over two weeks.
223581349|NCT07041788|DRUG|Iparomlimab and Tuvonralimab Injection|"Induction Therapy:~Spatially Fractionated Radiotherapy: Administer 10-20 Gy in a single fraction to the tumor.~Chemotherapy + Immunotherapy:~Docetaxel 75 mg/m² IV on Day 1. Cisplatin 25 mg/m² IV on Days 1-3. Iparomlimab and Tuvonralimab Injection 5 mg/kg IV on Day 1. Cycles: Every 3 weeks (Q3W) for 3 cycles.~Maintenance Therapy:~Begin 4-6 weeks after radiotherapy completion.~Iparomlimab and Tuvonralimab:~Dose: 5 mg/kg diluted in 100 mL 0.9% NaCl or 5% glucose. Administration: IV infusion over ≥20 minutes (total duration including flushing ≤60 minutes).~Cycles: Q3W for 14 cycles (maximum 1 year).~Iparomlimab and Tuvonralimab Injection:~Continue until disease progression, intolerable toxicity, initiation of new anti-tumor therapy, withdrawal of consent, or investigator decision to discontinue.~Maximum treatment duration: 1 year."
223581350|NCT07038980|OTHER|Observational Assessment|"Participants in both groups undergo a one-time diagnostic evaluation consisting of:~Smartphone Addiction Scale - Short Form (SAS-SF)~Neck Disability Index (NDI)~MyotonPRO measurement of cervical muscle tone, stiffness, and elasticity~Pressure pain threshold measurement using a handheld algometer~Social Media Addiction Scale (SMAS)~No therapeutic or behavioral intervention is applied. All procedures are non-invasive and conducted for observational purposes only."
224161371|NCT04078074|DEVICE|Mandibular OSS|Mandibular OSS will be a night guard for the bottom teeth.Digital impressions will be taken at the first appointment. After delivery appointment the patient will take home a sleep test monitor and bruxism monitor to record respiration and muscle activity during sleep.This will be a 2 night sleep study (Night A will be without splint and Night B will be with splint). Therefore, the patient will sleep with the mouth guard one night and the monitoring device two nights. Subjects will also undergo CBCT airway imaging with and without splint.
224161372|NCT04078074|DEVICE|Modified farrar splint|Modified farrar splint will be a night guard for the top teeth that positions and maintains the lower jaw in a more forward position.Digital impressions will be taken at the first appointment. After delivery appointment the patient will take home a sleep test monitor and bruxism monitor to record respiration and muscle activity during sleep. This will be a 2 night sleep study (Night A will be without splint and Night B will be with splint). Therefore, the patient will sleep with the mouth guard one night and the monitoring device two nights. Subjects will also undergo CBCT airway imaging with and without splint.
223581351|NCT07041710|OTHER|experimental in day hospital|multidisciplinary day hospital
223581352|NCT07041710|OTHER|taste and smell disorders questionnaire|Answer to the home-made questionnaire at inclusion and at 6 months
223581353|NCT07041645|DIETARY_SUPPLEMENT|Vitamin K|each participant will recive one dose of each of the four vitamin K vitamers but in different orders (4 different orders).
223581354|NCT07040982|DRUG|Asciminib|Given PO
223581355|NCT07040982|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223581356|NCT07040982|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
224161373|NCT03718273|DRUG|Ivabradine|"Ivabradine 5 mg, twice a day the first month administered by mouth. If the tolerance is good, the dose will be increased to 7.5 mg on month 2 and will continue until the third month.~Patients with 75 or more years of age will receive an initial dose of 2.5 mg / twice a day, which can be increased to 5 mg / twice a day in week 7 and to 7.5 mg in month 1 if the tolerance has been good"
224161374|NCT03718273|DRUG|Digoxin|The initial dose will be based on whether there are factors such as age over 80 years, weight less than 60 kg and creatinine clearance \<60ml / min, if there is no factor, the oral dose will be 0.25mg / 24h. If there are 2 factors, the dose will be 0.15 mg / 24 h. and if there are 2 or 3 factors, the dose will be 0.10 mg / 24 h.
224161375|NCT05116111|DRUG|SYHA1402 tablets|SYHA1402 tablets, oral, twice daily
223581357|NCT07040982|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
223581358|NCT07040982|PROCEDURE|Echocardiography Test|Undergo echocardiography
223581359|NCT07040982|OTHER|Survey Administration|Ancillary studies
223581360|NCT07040280|DRUG|Sulforaphane (broccoli sprout extract)|Sulforaphane - Three tablets of Avmacol® Extra Strength \[Nutramax\] by mouth, once daily, for 12 months.
223581361|NCT07040280|DRUG|Placebo|Three tablets by mouth, once daily, for 12 months
223581362|NCT07040280|DEVICE|Derma-AI|Photographs of lesions as part of the clinical exam at baseline, three (3) months, and twelve (12) months. These photographs will be submitted for assessment by a software called Derma-AI, which tracks moles over time for changes in size, number, and appearance
223581363|NCT07041138|BEHAVIORAL|cognitive behavioural programme with physical training|Participants will receive 7 sessions of cognitive behavioural programme over 8 weeks and have physical training at home for 8 weeks.
223581364|NCT07041138|BEHAVIORAL|health education with physical training|Participants will receive 7 sessions of health education over 8 weeks and have physical training at home for 8 weeks.
223581365|NCT07041138|BEHAVIORAL|Usual Care|Participants will maintain their usual life and activities for 8 weeks.
223581366|NCT07041476|OTHER|Exercise|Tele-rehabilitation methods can provide an important advantage for patients who cannot receive hospital services due to pain, mobility limitations, and distance to the hospital
223581367|NCT07041476|OTHER|telemedicine|Tele-rehabilitation will be achieved through a video conference (VC) via the internet platform Zoom at the time and day 29 decided upon with the therapist
223581368|NCT07040891|BEHAVIORAL|Just ASK training|"Just ASK™ is a web-based training designed to help providers understand the impact of assumptions about their patients' interest in cancer clinical trials. The training framework aims to increase clinical trial discussions with all cancer patients."
223581369|NCT06924177|OTHER|Telehealth with dietician|9 weeks of telehealth visit with dietician using the DPP diet modules
223581370|NCT07041502|OTHER|Aut-CARE|There is no intervention
223473973|NCT02144870|BEHAVIORAL|Habit Reversal Training|awareness training, competing response training
223473974|NCT02144870|BEHAVIORAL|Resources activation|
223473975|NCT02037893|DRUG|Antipyrine and Benzocaine otic solution|antipyrine 54 mg and benzocaine 14 mg
223581371|NCT07040384|DEVICE|Knee Extensors Activation (KEA) Device|A portable, non-electric device consisting of an inflatable cushion, pressure gauge, and digital counter. It provides objective feedback during isometric quadriceps exercises after ACL reconstruction. The device encourages full contraction by only counting repetitions that exceed a preset pressure threshold and return to baseline.
223581372|NCT07040384|OTHER|Conventional Towel-Based Exercise|Standard rehabilitation method using a rolled towel under the knee during quadriceps setting exercises. Patients perform isometric contractions without feedback or objective measurement. Repetitions are manually counted by the physiotherapist.
223581373|NCT07040579|DEVICE|transcatheter closure of outlet VSDs with bioabsorbable occluders|Transcatheter closure of outlet ventricular septal defects using a bioabsorbable occluder (Shape Memory Alloy Ltd, Shanghai, China). Implantation is performed via femoral/transthoracic approach under echocardiographic guidance following standard interventional protocols.
223581374|NCT06726863|DRUG|Vamifeport IRF|Vamifeport IRF will be administered orally as per the dosing levels and formulations for respective treatment periods.
223581375|NCT06726863|DRUG|Vamifeport PR1|Vamifeport PR1 will be administered orally as per the dosing levels and formulations for respective treatment periods.
223581376|NCT06726863|DRUG|Vamifeport PR2|Vamifeport PR2 will be administered orally as per the dosing levels and formulations for respective treatment periods.
223581377|NCT07041879|PROCEDURE|maxillary anterior teeth atraumatically extracted with piezotome extraction kit, and subsequent immediate implant placement|piezotome extraction kit,
223581378|NCT07041879|PROCEDURE|maxillary anterior teeth atraumatically extracted with periotome, and subsequent immediate implant placment|periotome
223581379|NCT07040410|PROCEDURE|Aromatherapy|Fifteen minutes before the PD session and during the first outflow and inflow phases, aromatherapy will be administered via inhalation. Five drops of 100% pure organic lavender oil
223743990|NCT04071730|DIETARY_SUPPLEMENT|Immulina Dietary Supplementation|Immulina Dietary Supplementation is a highly standardized extract derived from various preparations of Spirulina, a cyanobacterium, marketed as a dietary supplement and has been utilized in several clinical studies describing its immunopotentiating properties.
223743991|NCT05095987|PROCEDURE|Laparoscopic Appendectomy|Laparoscopic Appendectomy for acute uncomplicated appendicitis in children
223743992|NCT01516957|DRUG|AMG 827 140|140 mg AMG 827 SC (subcutaneous)
223743993|NCT01516957|DRUG|Placebo|Placebo SC (subcutaneous)
223743994|NCT01516957|DRUG|AMG 827 280|280 mg AMG 827 SC (subcutaneous)
223743995|NCT01516957|DRUG|AMG 827 210|210 mg AMG 827 SC (subcutaneous)
223743996|NCT05443191|DRUG|Semaglutide|Participants will be treated with commercially available oral semaglutide according to local label and to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available oral semaglutide has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician based on local label before and independently from the decision to include the participant in this study.
224161376|NCT05116111|DRUG|Placebo|Placebo, oral, twice daily
224161377|NCT05027776|BIOLOGICAL|2-doses Group among 9-14 years|Subjects were planned to receive two doses of the study vaccine administered intramuscularly according to a 0, 6 month vaccination schedule.
224161378|NCT05027776|BIOLOGICAL|3-doses Group among 9-19 years|Subjects were planned to receive three doses of the study vaccine administered intramuscularly according to a 0, 2, 6 month vaccination schedule.
223473976|NCT02037893|DRUG|Antipyrine Otic Solution|Antipyrine 54 mg and glycerine dehydrated to 1.0 mL
223473977|NCT02037893|DRUG|Benzocaine Otic Solution|benzocaine 14 mg and glycerine dehydrated to 1.0 mL
223473978|NCT02037893|DRUG|Placebo Otic solution|Placebo otic solution will be glycerin that is dehydrated
223473979|NCT05458986|OTHER|Media Intervention|Watch an educational video
223473980|NCT05458986|OTHER|Best Practice|Receive usual care
223473981|NCT05458986|OTHER|Questionnaire Administration|Ancillary studies
223581380|NCT07040410|PROCEDURE|Music Therapy|Fifteen minutes before the PD session and during the first outflow and inflow phases, music chosen by the child or parent will be played. Pain and vital signs will be assessed as in the control group.
223581381|NCT07040410|PROCEDURE|Control|"Peritoneal dialysis treatment will be started with discharge first, and then the amount of dialysate fluid determined by the physician's request will be filled. In the clinical routine, nonpharmacological pain treatment method is not applied during excretion and filling. Nonpharmacological pain treatment method will not be applied to the control group. The Wong-Baker Facial Expressions Rating Scale and Life Signs Evaluation Form will be filled in by the researcher at the 0th and 1st minutes of the first discharge and at the 0th and 1st minutes of the first filling."
223581382|NCT07041671|DEVICE|ColdZyme|"ColdZyme is a medical device classified as a Class III device, certified according to the European Medical Devices Regulation (2017/745/EU) (MDR). It has been CE-marked since 2013.~ColdZyme is a mouth spray that protects against upper respiratory tract viruses causing common cold and flu-like symptoms. ColdZyme forms a protective moisturizing barrier on the mucous membrane of the oral cavity and throat. The viscous barrier catches the virus and thereby the contact between the virus and the epithelial cells are reduced and avoided, thus the barrier disables the viruses' ability to spread and multiply."
223473982|NCT06404437|DIAGNOSTIC_TEST|Auscultation|Auscultation at five auscultation points using a digital stethoscope and a smartphone
223473983|NCT04627636|OTHER|Myofascial trigger points pressure (MTrP) release|Myofascial trigger points pressure (MTrP) release technique, the initial step was to recognize and find the trigger points (TP) , and The second step after TP palpation was the MTrP release technique, as follow, by one or both hands, the thumbs or four fingers of the therapist applied a maintained pressure, pushing internal toward the middle
223473984|NCT04627636|OTHER|Shockwave therapy application|The JEST-2000 (JOEUN Medical, Dae-Jeon, South Korea) was used for the ESWT. The application of pressure pulses of ESWT was centered around the flexor muscles with hypertonia
223473985|NCT04627636|OTHER|conventional therapy|Passive ROM exercises performed by the therapist and Bobath Neurodevelopmental Approach (prolonged stretch): The Intervention methods for Bobath involved the activation of key points of control for the reduction of tone
223473986|NCT02039934|OTHER|High intensity interval training|"The intervention consists of 30 minute sessions of high-intensity interval training on a bicycle ergometer three times per week.~Training program: After 5 minutes of warm-up the subject cycles for 10 intervals of 60 s. at 90 % maximum effort separated 60 s at 20% maximum effort, based on a previously performed spiroergometry, followed by 5 minutes of cool-down."
223473987|NCT04673773|BEHAVIORAL|A Massive Open Online Course|Same as intervention
223473988|NCT01566110|DIETARY_SUPPLEMENT|Gluten Free Diet|Subjects assigned to the intervention group will receive a standardized dietary education intervention that will inform subjects and family members of the effects of gluten on the gastrointestinal tract and emphasize the need to adhere to a diet that is gluten-free. This intervention will be delivered by a dietician who is trained in celiac disease and gluten free diet.
223473989|NCT04775030|DRUG|CBD occlusal appliance|Occlusal appliance manufactured with CBD molecules released from material to patients oral cavity during sleep time
223473990|NCT04775030|DEVICE|Acrylic resin occlusal appliance|Acrylic resin occlusal appliance during sleep time
223473991|NCT05593588|DRUG|Fisetin|20 mg per kilogram (kg) of body weight supplied in 100 mg capsules and administered orally on days 0, 1, 28, and 29
223473992|NCT05593588|DRUG|Placebo|Looks exactly like the study drug, but it contains no active ingredient. Administered orally on days 0, 1, 28 and 29
223473993|NCT00537888|DRUG|fluconazole|Intravenous or oral 400 md/d
223473994|NCT02936375|DRUG|Iguratimod|25mg twice a day, orally administrated
223473995|NCT02936375|DRUG|Cyclophosphamide|1g/m², every 4 weeks, intravenous
223473996|NCT02936375|DRUG|Azathioprine|2mg/kg·d, once a day, orally administrated
223473997|NCT02936375|DRUG|Steroids|Prednisone, methylprednisolone or prednisonlone, once a day, orally administrated. Steroids should be 1mg/kg·d in the beginning four weeks, then tapered 5-10mg/d every two weeks till 30mg/d, then tapered 2.5-5mg/d every two weeks. After 24 weeks of follow-up, a patient should receive steroids no more than 10mg/d. Patients may receive temporal high dose of steroids (1mg/kg·d) because of symptoms outside of kidney, for no more than two weeks. All the dosage of steroids above is calculated by prednisone.
223473998|NCT01251042|DEVICE|Sangvia|The Sangvia® Blood Salvage System used to collect blood intra-operatively.
223473999|NCT00269152|DRUG|pemetrexed|500 milligrams per square meter (mg/m\^2), intravenous (IV), every 21 days x 4 cycles
223474000|NCT00269152|DRUG|cisplatin|75 mg/m\^2, intravenous (IV), every 21 days x 4 cycles
223474001|NCT00269152|DRUG|carboplatin|area under the curve (AUC) 5 milligrams per milliliter\*minute (mg/ml\*min), intravenous (IV), every 21 days x 4 cycles
223474002|NCT03886272|DRUG|BI 730357 (Test)|tablet
223474003|NCT03886272|DRUG|BI 730357 (Reference)|tablet
223474004|NCT06415435|DEVICE|Radiofrequency Microneedling|Sylfirm X radiofrequency microneedling device
223474005|NCT04001556|DIAGNOSTIC_TEST|Minor Salivary gland Biopsy|Minor salivary gland biopsy with injection of lidocain
223474006|NCT04001556|DIAGNOSTIC_TEST|ARFI|Acoustic Radiation Force Impulse on Major Salivary Glands
223474007|NCT04001556|DIAGNOSTIC_TEST|MSG US|Ultrasonography of Major Salivary Glands
223581383|NCT07040371|OTHER|Health Promotion Behavior Intervention Program|The intervention program is structured around a three-step framework: ① building motivation and providing opportunities; ② reinforcing motivation, enhancing capabilities, and providing opportunities; and ③ sustaining motivation, strengthening capabilities, and providing opportunities. The process involves assessing the current state of health-promoting behaviors among elderly migrants, implementing interventions to promote these behaviors, and evaluating the effectiveness of the interventions. The program spans 12 weeks and is carried out by a team of researchers and nursing students. Key intervention components include: ① helping elderly migrants recognize their health issues, analyzing the impact of migration on health-promoting behaviors, and emphasizing the importance of such behaviors through comparisons of negative and positive case studies; ② conducting thematic training on health habits, dietary nutrition, exercise safety, oral hygiene, and other topics through health lectures,
223474008|NCT03779347|DRUG|Praziquantel|Praziquantel to treat schistosomiasis during pregnancy
223474009|NCT03779347|DIAGNOSTIC_TEST|UCP-LF CAA|UCP-LF CAA to diagnose Schistosomiasis during pregnancy
223474010|NCT03779347|DIAGNOSTIC_TEST|composite diagnostic|composite diagnostic reference test based on extensive egg microscopy, serology, qPCR on egg DNA, and POC-CCA to diagnose Schistosomiasis during pregnancy
223474011|NCT02926105|BEHAVIORAL|T&E Home-based exercise programme|"T\&E exercises programme consists of home-based individually tailored balance and functional strength tests and exercises performed 3x a week over 12 months, accompanied by eight in-home visits of physiotherapists during the first six months."
223474012|NCT02926105|BEHAVIORAL|Otago|Otago exercises programme consists of home-based individually tailored balance, strength and walking exercises performed 3x a week over 12 months, accompanied by eight in-home visits of physiotherapists during the first six months.
223474013|NCT02926105|BEHAVIORAL|Helsana booklet|Helsana programme consists of a booklet with recommendations and 10 exercises performed 3x a week over 12 months.
223474014|NCT05908396|DRUG|IGM-2644|IGM-2644 is an engineered, bispecific IgM antibody directed against CD3 and CD38. IGM-2644 is designed to bind to CD38 to selectively target and kill myeloma cancer cells through both T-cell dependent cellular toxicity (TDCC) and complement dependent cytotoxicity (CDC) activities.
223474015|NCT03025633|OTHER|PEARL|PEARL, is a commercially available PC-based tool that provides a realistic and functional 3D model of a linac and, having uploaded example treatments it can demonstrate the treatment procedure and also relevant anatomical information.
223474016|NCT00098241|DRUG|Certican|
223474017|NCT03950453|BEHAVIORAL|Parenting Mindfully for Health Nutrition (PMH)|"PMH will include included the following components:~1. mindfulness strategies as outlined in the MBSR manual,~2. mindful parenting concepts,~3. mindful eating and awareness of family choices;~4. self and child monitoring of food intake, PA and emotional reactivity;~5. utilizing mindfulness for emotion regulation and distress tolerance,~6. behavioral strategies of goal setting and implementing increasing frequency of healthy food intake and physical activity (PA)"
223474018|NCT03950453|BEHAVIORAL|Contact Control Nutrition (C+N)|Contact Control Group where parents engage in a quiet, relaxing, but stimulating activity and also nutrition counseling.
223474019|NCT03950453|OTHER|Non-randomized historical control (WLC) assessment only|Non-randomized, historical control group with only assessments during intervention and follow-up period.
224161379|NCT05027776|BIOLOGICAL|3-doses Group among 20-26 years|Subjects were planned to receive three doses of the study vaccine administered intramuscularly according to a 0, 2, 6 month vaccination schedule.
224161380|NCT03542292|DIAGNOSTIC_TEST|placental drainage|
224161381|NCT03803449|DRUG|50-200mg propofol|participants in both groups are given standard regimen including 50-200mg propofol.
223474020|NCT03053882|OTHER|mouthwash|mouthwash containing herbal peppermint or green tea
223474021|NCT02576392|BEHAVIORAL|Intervention|Intervention consisted of a mailing 2 weeks prior to surgery, another 2 weeks post surgery, and a pharmacist intervention if a refill of opioid medication was requested within 90 days of surgery.
223474022|NCT01119690|DIETARY_SUPPLEMENT|Cold-pressed turnip rapeseed oil (CTPRO)|"1. In the dietary period of 6 to 8 weeks: CTPRO 37 ml/day.~2. In the 5-hour oral glucose and fat tolerance test: glucose and CTPRO."
223474023|NCT01119690|DIETARY_SUPPLEMENT|milk fat|"1. In dietary period of 6 to 8 weeks: 37.5 grams of butter.~2. In the 5-hour oral glucose and fat tolerance test: glucose and cream"
223474024|NCT00250822|DRUG|Gemcitabine and Oxaliplatin|"Dose:~Gemcitabine 1000 mg/m2 - IV in about 60 minutes on days 1 \& 15. Oxaliplatin 100 mg/m2 - IV over 2hr on days 2 \& 16"
223474025|NCT02557399|DRUG|Duac® fixed dose combination gel|Duac® fixed dose combination gel containing clindamycin phosphate 1.2% and benzoyl peroxide 3%.
223474026|NCT02557399|DRUG|ADA 0.1% gel|ADA 0.1% gel containing 0.1% of adapalene.
223474027|NCT02557399|DRUG|CLDM 1% gel|CLDM 1% gel containing clindamycin phosphate 1.2% (1% as clindamycin).
223581384|NCT07040371|OTHER|receiving routine community care and management only|It primarily included distributing health manuals, conducting regular health education sessions, and performing follow-ups. Researchers and community nurses collected and addressed health-related inquiries raised by the elderly migrants. Additionally, to ensure scientific rigor and equity in the study, compensatory interventions (such as providing equivalent intervention opportunities or distributing relevant intervention materials) were offered to participants based on their actual needs upon completion of the research project.
223474028|NCT00689689|DEVICE|Fully coated Prodigy stem|Total hip arthroplasty with fully coated Prodigy stem
223474029|NCT00689689|DEVICE|Cemented Endurance Stem|total hip arthroplasty with cemented endurance stem
223474030|NCT01350817|DRUG|Erlotinib + docetaxel|docetaxel :75 mg/m² IV day 1 every 3 weeks with erlotinib:150 mg/d per os d2-d16
223474031|NCT01350817|DRUG|Docetaxel|docetaxel :75 mg/m² IV day 1 every 3 weeks.
223474032|NCT02712957|DRUG|NEO6860|TRPV1 antagonist
223474033|NCT02712957|DRUG|NEO6860 placebo|Inactive substance
223581385|NCT06732453|OTHER|Seated Yoga Skills Training in Functional Dyspepsia and Gastroparesis (FD-GP)|Two one-hour chair-based yoga sessions that will include gentle movements, breathing practices, and meditation, along with home practice.
223581386|NCT06823297|OTHER|Total mesorectal excision|Direct surgery without receiving neoadjuvant chemoradiotherapy
223581387|NCT06823297|OTHER|Neoadjuvant Chemotherapy followed by total mesorectal excision|Neoadjuvant chemoradiotherapy treatment regimens (including conventional chemoradiotherapy/radiotherapy/chemotherapy regimens or total neoadjuvant chemoradiotherapy regimens) before surgery
223581388|NCT06718140|DEVICE|Transcranial Focused Ultrasound|Using MRI-guided targeting, we will administer focused ultrasound to one of the 4 brain locations
223743997|NCT04387851|BEHAVIORAL|Placebo induction|The placebo interventions of interest are experimental learning methods (e.g. verbal suggestion, conditioning), used to induce placebo effects on somatosensory sensations.
224069674|NCT02997995|DRUG|Durvalumab|Durvalumab (lymphocyte activation) will be administrated at a dose of 1500 mg Q4W (equivalent to 20 mg/kg Q4W) IV, combined with exemestane (25 mg daily), for six months
224069675|NCT02997995|PROCEDURE|Biopsy|After three weeks (+/- 3 days) of immune-attractants, a tumor biopsy will be done. Patients who present \>10% CD8+ cells in the tumor after 3 weeks will receive the Durvalumab
224069676|NCT03246737|OTHER|monitoring|
224069677|NCT05930262|DEVICE|TCM acupuncture therapy|TCM acupuncture therapy: Zusanli, Quchi, Hegu, Taichong, Feishu and Fenglong were selected as the main acupoints, and the auxiliary acupoints were selected according to the symptoms, including Fengchi, Dazhui, Lieque, Tiantu, Shenshu, Zhongfu, etc.
223474034|NCT02712957|DRUG|Naproxen|NSAID
223474035|NCT02712957|DRUG|Naproxen placebo|inactive substance
223474036|NCT06436989|OTHER|hot purified water|Hot purified water,drink once a workday,almost 360mL.Buy from regular channels.
223474037|NCT01844037|DEVICE|OneShot Ablation System|Renal denervation
224069678|NCT05930262|DRUG|Conventional drug therapy|Antibiotics were selected based on drug sensitivity test results. Patients with body temperature \> 38.5℃ were treated with physical cooling and antipyretic drugs. In patients whose sputum was thick and difficult to cough up, nebulization and inhalation therapy was given, as well as effective coughing and patting the back to expel phlegm were guided.
224069679|NCT05930262|BEHAVIORAL|Rehabilitation therapy|Comprehensive training for hemiplegic limbs included a joint range of motion training, bridging exercise, turnover training, balance training, gait training, hand function training and self-care ability training, 40 min/d, 6 times/w.
224069680|NCT05930262|BEHAVIORAL|Breathing training|Training was conducted daily in the morning, or after symptom relief in the case of fever or other discomforts, once a day, 30-40 min/time.
224069681|NCT00961883|BIOLOGICAL|NYVAC-B|New York Vaccinia (NYVAC) vector for HIV-1, delivered intramuscularly by injection at a dose of 1 x 10 \^7 PFU
224069682|NCT00961883|BIOLOGICAL|Placebo|Sodium Chloride for injection, delivered intramuscularly
224069683|NCT00961883|BIOLOGICAL|rAd5|Recombinant adenoviral serotype 5 (rAd5) vector vaccine, delivered by injection intramuscularly at a dose of 1 x 10\^10 PFU
224069684|NCT00961883|BIOLOGICAL|rAd5|Recombinant adenoviral serotype 5 (rAd5) vector vaccine, delivered by injection intramuscularly at a dose of 1 x 10\^9 PFU
224069685|NCT00961883|BIOLOGICAL|rAd5|Recombinant adenoviral serotype 5 (rAd5) vector vaccine, delivered by injection intramuscularly at a dose of 1 x 10\^8 PFU
224069686|NCT02373280|DRUG|10 day sequential therapy (Esomeprazole, amoxicillin, clarithromycin, metronidazole)|In this group, patients will receive the 10 day sequential regimen for eradication of H. pylori. 10 day sequential regimen is like follows; Esomeprazole 40 mg bid 10 days (D1-D10)+amoxicillin 1 g bid 5 days (D1-D5)+clarithromycin 500 mg bid 5 days (D6-D10)+metronidazole 500 mg tid 5 days (D6-D10).
223474038|NCT00931632|DRUG|Inhaled Nitric Oxide|Inhaled Nitric Oxide will be administered continuously starting at 20ppm into the inspiratory limb of the ventilator circuit in mechanically ventilated subject using an INOvent delivery system of by nasal cannula as needed for 24 days of therapy.
224161382|NCT03803449|DRUG|50ug fentanyl|participants in fentanyl group are given intervention regimen: 50ug fentanyl.
223474039|NCT00931632|DRUG|Placebo|Nitrogen gas will be administered in the same manner as the experimental drug.
223474040|NCT05778474|OTHER|Healthy subjects|"Participants' ground spontaneous speed overground will be tested by means of the 10-meter walking test. Participants will be tested for their foot dominance by means of the Waterloo footedness questionnaire-revised. Participants will walk on a treadmill mounted on force sensors. The test sequence will be the following:~1. Familiarization. Participants will walk on the treadmill with the belt running at increasing velocities up to their spontaneous walking velocity . Speed will be increased of 0.2 m s-1 every 30 s. A brief pause of around 1 minute will follow.~2. Walking. Participants will walk at 0.4 m s-1 and 1.2 m s-1 for at least 30 seconds.~3. Walking with a rigid ankle-foot orthosis. Participants will walk at 0.4 m s-1 and 1.2 m s-1 for at least 30 seconds with an ankle-foot orthosis on the dominant lower limb.~Participants will repeat the last point (n°3) with the ankle-foot orthosis on the non-dominant lower limb. A 3-min pause will follow each section."
224161383|NCT03803449|DRUG|1 mg midazolam|participants in both groups are given standard regimen including 1 mg midazolam.
223474041|NCT05778474|OTHER|Pathologic group|"Participants will walk on a treadmill mounted on force sensors. They will walk freely, under tight supervision, but without hanging to any support. The test sequence will be the following:~4\. Familiarization. Participants will walk on the treadmill with the belt running at increasing velocities up to their spontaneous walking velocity . Speed will be increased of 0.1 m s-1 every 30 s. A brief pause of around 1 minute will follow.~5\. Walking. Participants will walk at 0.4 m s-1 for at least 30 seconds. Participants will be informed a few seconds before the changes in belts' velocities with a verbal warning."
223474042|NCT02569892|DEVICE|Pascal Retinal Laser Photocoagulator|Sub-threshold macular laser treatment with Pascal laser Endpoint Management System
223474043|NCT01121510|DEVICE|closure device|the invasive specialist must carefully manage the difficult balance of patient anticoagulation and coagulation for stopping the bleeding at the femoral artery puncture site. the QuickClose design 9 system is designed to benefit the patients and the medical staff by improving the process. the risks to patients associated with this study are considered reasonable in comparison to the anticipated benefits to the subjects, and the scientific knowledge that can be gained from the study.
223474044|NCT01784874|BIOLOGICAL|Purified Vero Rabies Vaccine (VRVg) - Serum Free|0.5 mL, Intramuscular
223474045|NCT01784874|BIOLOGICAL|Imovax® Rabies: inactivated rabies vaccine|1.0 mL, Intramuscular
223474046|NCT05868538|DIAGNOSTIC_TEST|Serum calprotectin and IMA concentrations|Serum calprotectin and IMA concentrations were compared among active BD cases, inactive BD cases and control subjects.
223581389|NCT07040904|BEHAVIORAL|mindfulness|MBSR: Mindfulness Program A novel and culturally-adapted version of the well-validated mindfulness-based stress reduction (MBSR) course will be used for the intervention. The adapted program curriculum embeds core MBSR principles and practices within a culturally responsive didactic framework developed directly from community focus-group feedback. The course will be delivered via a group meeting across 8 weeks, with weekly classes held at a local community center. All classes will be held in hybrid format, with most participants attending in person, but with a live-stream option offered via Zoom.
223581390|NCT07041372|DIAGNOSTIC_TEST|FDG-PET|The participants undergo whole-body FDG PET once their neurological status has stabilized after stroke.
223474047|NCT01904890|BEHAVIORAL|CRC Prevention and Screening Education|Refer to Arm Description
223474048|NCT01904890|BEHAVIORAL|Nutrition Education|Refer to Arm Description
223474049|NCT02923700|BIOLOGICAL|Leukocyte-rich PRP intra-articular injections|
223474050|NCT02923700|BIOLOGICAL|Leukocyte-poor PRP intra-articular injections|
223474051|NCT03045939|DEVICE|cervical ripening device|insertion of the double balloon device for 12 hours (standard care) vs 6 hours, following oxytocin IV infusion according local protocol guidelines as mentioned above
223474052|NCT00099112|GENETIC|microarray analysis|
223474053|NCT00099112|PROCEDURE|biopsy|
223474054|NCT00099112|PROCEDURE|evaluation of cancer risk factors|
223581391|NCT03756311|DRUG|NanoPac (sterile nanoparticulate paclitaxel) Powder for Suspension|
223743998|NCT04387851|BEHAVIORAL|Control|Placebo and nocebo effects should be measured relative to a control group (between-subjects design). In the case of within-subjects designs, these will be included to the extent possible (in a separate analysis or descriptively depending on the number of results).
223743999|NCT04387851|BEHAVIORAL|Nocebo|The nocebo interventions of interest are experimental learning methods (e.g. verbal suggestion, conditioning), used to induce nocebo effects on somatosensory sensations.
224161384|NCT04716049|OTHER|Powerade©, CHP, CJ, FR, CWI|"Combination of recovery strategies including dietary, neuromuscular and physiological as follows:~Powerade©: players will drink 500 mL during the game~Carbohydrate and protein (CHP): players will drink 250 mL of water with CHP within 30 minutes after the end of the game.~Tart cherry concentrate (CJ): players will drink 30 mL of CJ within 30 minutes after the end of the game.~Foam roller (FR): players will follow FR protocol using a polyvinylchloride pipe roller. They will begin with the FR at the most proximal portion of the muscle and to roll as much body mass as tolerable back and forth at a cadence of 1 second superior and 1 second inferior for 45 seconds followed by a 15-second rest for each muscle group (quadriceps, adductors, hamstrings, abductors and calf) in each extremity and repeated once.~Cold Water Immersion (CWI): will be the last strategy used. Players will immerse their lower body to the level of hips for 10 minutes in cold water (13-14°C)."
223474055|NCT00526422|PROCEDURE|Dental Preventive|
223474056|NCT04037124|PROCEDURE|Cervical procedure|simple hysterectomy, radical hysterectomy or fertility sparing surgery
223474057|NCT01655316|DRUG|Verapamil|
223474058|NCT05562869|DRUG|Belatacept 250 Milligram Intravenous Powder for Solution|"Phase 1 (from 3 to 12 months post transplantation): conversion to belatacept (IV, 5mg/Kg days 1, 15,30, 45, 60 then every months) and CNI withdrawal.~Phase 2 (from 12 to 18 months post transplantation) : belatacept arrest and CNI resumption (tacrolimus target 6 ng/ml)"
223474059|NCT04645563|OTHER|Sending thorax ct video images via smartphone applications|Video images of the patients will be sent via smartphone application to infectious disease specialist for consulting.
224161385|NCT04716049|OTHER|Powerade©, CHP, STR, ICWI|"Combination of recovery strategies including dietary, neuromuscular and physiological as follows:~Powerade©: players will drink 500 mL of Powerade© during the game~Carbohydrate and protein intake (CHP): players will drink 250 mL of water with CHP within 30 minutes after the end of the competition.~Stretching (STR): players will perform 10-min of static stretching, involving 2 unilateral repetitions of 30 seconds held stretches to the quadriceps, adductors, hamstrings, abductors and calf muscles.~Intermittent Cold-Water Immersion (ICWI): will be the last strategy used. It will consist of five 2 min intermittent immersions of the lower limb (up to the iliac crest) in a cold-water bath (13-14ºC), separated by 2 min rest in ambient air. Ice will be added to the bath at regular intervals to maintain water temperature at 13-14ºC. Players will be instructed to stand in the bath, with as little movement as possible."
224161386|NCT05238558|BIOLOGICAL|FMPV-1|Intradermal administration
224161387|NCT05238558|BIOLOGICAL|GM-CSF (as adjuvant)|Intradermal administration
224161388|NCT01594411|DIAGNOSTIC_TEST|Corus CAD|Age/Sex/Gene Expression Score (ASGES)
224161389|NCT06505681|PROCEDURE|Pharmacopuncture|"The selection of acupoints, depth of insertion, and other parameters will be determined based on the clinical judgment of the Korean medicine practitioner, considering the patient's symptoms, imaging results, and degree of improvement. All acupoints where pharmacopuncture is administered will be recorded at the time of treatment.~The type and dosage of pharmacopuncture solution to be used during treatment will be determined entirely based on the clinical judgment of the Korean medicine practitioner performing the pharmacopuncture. Retrospective chart reviews will be conducted to record the type of pharmacopuncture solution used and the total amount administered (in ml).~The treatment will be administered twice a week for a total of 3 weeks, and all sessions will be documented for accurate evaluation."
224161390|NCT06505681|PROCEDURE|Physical therapy|"The selection of physical therapy methods, treatment areas, and treatment duration will be determined based on the clinical judgment of the physician, considering the patient's symptoms, imaging results, and degree of improvement. The type, frequency, and areas of prescribed and administered physical therapy will be recorded.~The treatment will be administered twice a week for a total of 3 weeks, and all sessions will be documented for accurate evaluation."
224161391|NCT00911066|DRUG|MLN4924|"MLN4924 intravenous (IV) on a 21-day cycle on one of the following schedules:~* Days 1, 3, and 5, followed by a rest period of 16 days (Schedule A)~* Days 1, 4, 8, and 11, followed by a rest period of 10 days (Schedule B)~* Continuous weekly dosing on Days 1, 8, and 15 (Schedule C)~* Days 1, 4, 11, 15 for Cycle 1 only; Days 1, 4, 8, 11 for all subsequent cycles (Schedule D)~* Dosing on Days 1, 3, and 5 in patients with high-grade MDS or AML (Schedule E)"
224161392|NCT00911066|DRUG|Azacitidine|Azacitidine will be administered (IV or subcutaneous (SC)) on Days 8 to 12 and Days 15 and 16 in Cycle 1, and on Days 1 to 5 and Days 8 to 9 (Schedule D)
224161393|NCT01698073|BEHAVIORAL|mCOL|
224161394|NCT01698073|OTHER|AS+|
224161395|NCT02144376|DIETARY_SUPPLEMENT|Ispaghula|
224161396|NCT02144376|DIETARY_SUPPLEMENT|Maltodextrin|
224161397|NCT04338542|GENETIC|Tumor biobsies analysis|Analysis on archived tumor biopsies
224161398|NCT04238689|BIOLOGICAL|TB31F|Monoclonal antibody
224161399|NCT00079820|BIOLOGICAL|ACAM3000 MVA Vaccine|Two subcutaneous injections of MVA3000 smallpox vaccine, separated by 28 days
224161400|NCT04449276|BIOLOGICAL|CVnCoV Vaccine|Participants will receive an intramuscular injection by needle in the deltoid area.
224161401|NCT04449276|DRUG|Placebo|Participants will receive an intramuscular injection by needle in the deltoid area.
224161402|NCT02970539|DRUG|Oraxol|Oraxol (Paclitaxel and HM30181A) will be dosed orally. Paclitaxel will be supplied as capsules and HM30181A will be supplied as tablets.
224161403|NCT02970539|DRUG|Ramucirumab|Ramucirumab will be administered by iv infusion and supplied as a solution at a concentration of 10 mg/mL
224161404|NCT01633229|PROCEDURE|Bone Marrow Stromal Cell Infusion|
224161405|NCT00655057|DRUG|S-citalopram|Participants will take 10 to 30 mg of s-citalopram daily for 12 weeks.
224161406|NCT00655057|BEHAVIORAL|Cognitive behavioral therapy (CBT)|Participants will attend twice weekly CBT sessions for 2 weeks and then once weekly sessions for 10 weeks. Sessions will focus on modifying thoughts and behaviors that may contribute to depression.
223474060|NCT00015002|DRUG|Betamethasone|"coded study medication is 12 mg of betamethasone (or placebo) given as 2 ml intramuscular injection in 2 doses, 24 hours apart (the Course). Patients administered weekly courses for 4 weeks, until 33 weeks 6 days gestation or delivery, whichever occurs first."
223581392|NCT06736132|DEVICE|High-flow nasal oxygen|In this study, we will use high-flow nasal oxygen for preoxygenation in patients undergoing elective anaesthesia. Preoxygenation with high-flow nasal oxygen is most often performed at flow rates of \<50 l/min. In this study, patients will be randomised to preoxygenation using high-flow nasal oxygen and flow rates of 45 l/min, 70 l/min or 95 /min.
223581393|NCT02965690|PROCEDURE|Zimmer Biomet NexGen CR|Total Knee Replacement
223581394|NCT02965690|PROCEDURE|Medacta International GMK Sphere|Total Knee Replacement
223744000|NCT00587483|DRUG|Lidocaine|Lidocaine is a class I (sodium channel block) antiarrhythmic drug
224304999|NCT03533738|OTHER|Food sequence 3|Vegetables first then meat followed by rice
224305000|NCT03533738|OTHER|Food sequence 4|Vegetables first followed by meat and rice together
223744001|NCT00587483|DRUG|Amiodarone|300 mg
223744002|NCT00587483|DRUG|Placebo|Saline
223474061|NCT02764437|BIOLOGICAL|Whole lung antigen challenge, segmental allergen challenge|Whole lung antigen challenge with housedust mite, short ragweed or cat hair allergen extracts. Segmental allergen challenge with housedust mite, short ragweed or cat hair allergen extracts.
223474062|NCT01687218|DRUG|Oral FTC/TDF (Daily Emtricitabine/Tenofovir Disoproxil fumarate Tablet)|
223474063|NCT01687218|DRUG|Rectal Daily TFV RG 1% gel (Rectally applied Tenofovir Reduced Glycerin 1% Gel)|
223581395|NCT05888662|PROCEDURE|Endo-epicardial ablation|Endo-epicardial ablation of ventricular tachycardia
223581396|NCT05888662|PROCEDURE|endocardial ablation only|endocardial-only catheter ablation of ventricular tachycardia
223581397|NCT06727552|BIOLOGICAL|Barzolvolimab|Subcutaneous Administration
223744003|NCT02769247|DRUG|Naproxen|Oral naproxen vs placebo
223744004|NCT02769247|DRUG|Lidocaine|Intrauterine lidocaine vs normal saline
223744005|NCT02769247|DRUG|placebo|either normal saline or empty oral capsule
224161407|NCT00655057|PROCEDURE|TRODAT-1 single photon emission computed tomographic (SPECT) imaging|Participants' striatal dopamine transporter (DAT) levels will be measured using \[99mTc\]TRODAT-1 SPECT with magnetic resonance imaging (MRI) co-localization on two separate occasions. Participants with depression will undergo TRODAT-1 SPECT imaging immediately before and after 12 weeks of their assigned treatment. Healthy participants will undergo TRODAT-1 SPECT imaging at baseline and 12 weeks later.
224161408|NCT02449772|OTHER|No intervention|No intervention
224161409|NCT00910728|DRUG|AZD1480|Oral capsule 2.5 mg, 10 mg and 40 mg
223474064|NCT01687218|DRUG|Rectal RAI-associated TFV RG 1% gel (Receptive Anal Intercourse Associated rectally applied Tenofovir Reduced Glycerin 1% Gel)|
223474065|NCT04806269|DEVICE|Fitbit and Glandy|Data collection from wearable devices (Fitbit Inspire 2 TM) and a mobile app (Glandy TM) Fitbit collects user's heart rate, activity, and sleep data. Glandy collects user's subjective symptom scores.
223581398|NCT06727552|DRUG|Matching placebo|Subcutaneous Administration
223581399|NCT05066646|DRUG|CT103A|CT103A consists of autologous T lymphocytes transduced with anti-BCMA CAR lentiviral vector that containing a unique CAR structure with a fully human single-chain variable fragment (scFv).
223581400|NCT06506006|BIOLOGICAL|Covid infection|outcome with and without covid infection
223581401|NCT04556032|DIETARY_SUPPLEMENT|L-Ergothioneine 10 mg/d|L-Ergothioneine 10 mg/d
223581402|NCT04556032|DIETARY_SUPPLEMENT|L-Ergothioneine 25 mg/d|L-Ergothioneine 25 mg/d
223581403|NCT04556032|OTHER|Placebo|0 mg/d L-Ergothioneine
223581404|NCT03692481|RADIATION|18FDG-PET scan|18FDG PET scan will be performed in each patient before initiation of pirfenidone and after 12 weeks of treatment
223581405|NCT00159913|DRUG|Sildenafil citrate|oral; 20mg, 40mg and 80 mg; 3 times a day(TID)
223581406|NCT00159913|DRUG|Sildenafil citrate|oral; 10mg, 20mg and 40mg; 3 times a day(TID)
223581407|NCT00159913|DRUG|Placebo|oral; 3 times a day(TID)
223581408|NCT00159913|DRUG|Sildenafil citrate|oral; 10 mg; 3 times a day(TID)
223581409|NCT02816203|DEVICE|Hemostatic Intra-Uterine suction cup|The hemostatic intra-uterine suction cup is introduced to the uterine cavity and a negative pressure is applied into the device.
224161410|NCT02384304|BEHAVIORAL|Choice|A self help program consisting of 8 modules and access to therapist guidance either through messages or through chat sessions
224161411|NCT02384304|BEHAVIORAL|Messages|A self help program consisting of 8 modules and access to therapist guidance through messages
224161412|NCT02384304|BEHAVIORAL|Self help|A self help program consisting of 8 modules
223474066|NCT01835912|OTHER|Sodium Citrate Dihydrate|Dose sodium citrate dihydrate through 2 dosing protocols (Acute and Chronic)
223474067|NCT03301636|DRUG|Pembrolizumab|Pembrolizumab will be administered intravenously every 3 weeks starting on day 1.
224161413|NCT00023712|DRUG|bortezomib|Given IV
224161414|NCT00023712|OTHER|laboratory biomarker analysis|Correlative studies
224161415|NCT00023712|OTHER|pharmacological study|Correlative studies
224161416|NCT05074862|DIETARY_SUPPLEMENT|KetoneAid KE4 Pro Monoester|A dietary supplement containing ketone monoester.
224161417|NCT05074862|DIETARY_SUPPLEMENT|Maltodextrin and fat-based placebo|Dosis isocaloric to the KetoneAid Arm
224161418|NCT02866604|PROCEDURE|Sterofundin|
224161419|NCT02866604|PROCEDURE|0.9% saline|
223474068|NCT03301636|DRUG|Nivolumab|Nivolumab will be administered intravenously every 2 weeks starting on day 1.
223474069|NCT03301636|DRUG|Indoximod|Indoximod will be administered orally every 12 hours starting at Day 1
223474070|NCT03139552|OTHER|Apple Crisp|Subjects tasted the three recipes (full sugar recipe, reduced sugar recipe, and reduced sugar plus spice recipe) of apple crisp in a randomized sequence schedule. Tastings for each test item (apple crisp, tea and oatmeal) were done during separate weeks. Subjects tasted each recipe of an item at one sitting (ie: subject completed apple crisp tastings during one seating during first week, oatmeal tastings during one seating the next week and tea tastings during one seating the next and final week).
223474071|NCT03139552|OTHER|Tea|Subjects tasted the three recipes (full sugar recipe, reduced sugar recipe, and reduced sugar plus spice recipe) of tea in a randomized sequence schedule. Tastings for each test item (apple crisp, tea and oatmeal) were done during separate weeks. Subjects tasted each recipe of an item at one sitting (ie: subject completed apple crisp tastings during one seating during first week, oatmeal tastings during one seating the next week and tea tastings during one seating the next and final week).
223581410|NCT05203367|DRUG|BAR502|"Single oral doses of BAR 502/placebo will be administered as film-coated tablets, in the morning of Day 1, with 240 mL of water, after an overnight fasting of at least 8 hours.~BAR 502 film-coated tablets are available at dose strengths of 10, 50 and 150 mg. A maximum of 4 dose levels are pre-planned (10 mg, 50 mg, 150 mg, 300 mg)."
223581411|NCT05203367|DRUG|Placebo|Matching BAR 502 placebo film-coated tablets will be given to 2 out of 8 subjects in each cohort using the same regimen as outlined for the active study treatment
223581412|NCT05300685|DRUG|Standard Buccal Harvest|Our institutions current anesthetic regimen. Comparison group
223581413|NCT05300685|DRUG|Basic buccal procedure + Long acting local|Addition of long-acting local anesthetic to the wound bed following the oral graft harvest.
223581414|NCT05300685|DRUG|Basic buccal procedure + Buccal block|Addition of long-acting local anesthetic as a buccal block after oral graft harvest
223581415|NCT02508740|DRUG|bevenopran|Single oral dose
223581416|NCT02933567|OTHER|CSC OnDemand|CSC OnDemand is a multifaceted online learning product that includes four levels: 1) an online readiness tool and CSC Learning Hub; 2) dynamic multimedia core curriculum on first episode psychosis and CSC; 3) live faculty-led online courses; and 4) ongoing support, including an online community of practice to support peer-to-peer learning.
223581417|NCT01292083|DRUG|azacitidine|Given IV
223581418|NCT01292083|OTHER|laboratory biomarker analysis|Correlative studies
223581419|NCT01292083|OTHER|immunohistochemistry staining method|Correlative studies
223581420|NCT01292083|GENETIC|polymerase chain reaction|Correlative studies
223581421|NCT01292083|GENETIC|western blotting|Correlative studies
223581422|NCT01292083|GENETIC|nucleic acid sequencing|Correlative studies
223581423|NCT01292083|PROCEDURE|therapeutic conventional surgery|Undergo definitive breast surgery
224161420|NCT02918955|PROCEDURE|up-front neck dissection|
224161421|NCT02918955|RADIATION|radiotherapy|70 Gy in 35 fractions to the macroscopic disease 50 Gy in 25 fractions (if sequential boost) or 56 Gy in 35 fractions (if simultaneous integrated boost) to the elective volumes 66 Gy in 35 fractions to the post-operative region with lymphatic extracapsular extension (Arm B only)
224161422|NCT02918955|DRUG|Chemotherapy (Cisplatin)|"100 mg/m2 every three weeks during radiotherapy~In Arm B, chemotherapy can be omitted in case of a cT1-2 primary and a surgical downstaged pN0-1 neck without lymphatic extracapsular extension."
224161423|NCT02918955|PROCEDURE|Early Salvage Neck Dissection in case of less than cCR (Arm A only)|"Early salvage neck dissection in case of residual lymph node disease will be performed based on the response evaluation by MRI and PET/CT performed 3 and 4 months after the end of (chemo)radiotherapy, respectively (and additional diagnostic modalities if clinically indicated by the physician) and not more than 3 weeks after this post-radiotherapy evaluation.~In Arm A, a successful early salvage neck dissection without the operation of the primary tumor in case of less than clinical complete response (cCR) will be considered a component of the multimodality treatment and not as a failure."
223474072|NCT03139552|OTHER|Oatmeal|Subjects tasted the three recipes (full sugar recipe, reduced sugar recipe, and reduced sugar plus spice recipe of oatmeal in a randomized sequence schedule. Tastings for each test item (apple crisp, tea and oatmeal) were done during separate weeks. Subjects tasted each recipe of an item at one sitting (ie: subject completed apple crisp tastings during one seating during first week, oatmeal tastings during one seating the next week and tea tastings during one seating the next and final week).
223581424|NCT02256410|DEVICE|Stimulation|The Nervomatrix device first measures skin impedance, and then creates a digital pain matrix map of the back. Regions with low resistance are then selected for brief electric stimulation, thus targeting the treatment to specific peak pain regions. Preliminary evidence supports the effectiveness of this device in reducing pain and disability over 6 sessions
223581425|NCT02256410|OTHER|Sham|The Nervomatrix device first measures skin impedance, and then creates a digital pain matrix map of the back. Regions with low resistance are then selected for brief mechanical pressure.
223581426|NCT04709484|DRUG|USG-guided steroid injection|In the palpation-guided group, the most painful point will be found by palpation on the calcaneus boIn the USG-guided group, steroid injection will be made to the area where the fascia is thickened under USG guidance. The content of the steroid solution will be 1 ml of 1% Lidocaine + 1 ml (40 mg) methylprednisolone.ne and steroid injection will be made to that part. The content of the steroid solution will be 1 ml of 1% Lidocaine + 1 ml (40 mg) methylprednisolone.
224161424|NCT01857024|DRUG|sevelamer carbonate (Renvela®)|800 mg tablets or 2.4 g powder for oral suspension should be administered as instructed in the Renvela® SmPC.
224161425|NCT02727517|PROCEDURE|Early (≤ 60 seconds) cord clamping|If the infant don't breathe, the umbilical cord is clamped (≤ 60 seconds) and cut and resuscitation will be provided at a resuscitation table
224161426|NCT02727517|PROCEDURE|Delayed (≥ 180 seconds) cord clamping|If the infant don't breathe, the umbilical cord is not clamped and cut until after 180 seconds. Initial resuscitation will be provided bedside to the mother
224161427|NCT03020264|DEVICE|glycemic sensor FREESTYLE Libre Pro|Collection of hypoglycemia episodes with glycemic sensor FREESTYLE Libre Pro
224161428|NCT06268483|DIETARY_SUPPLEMENT|HA 100 mg, CS 400 mg, N-Acetylglucosamine 200 mg and vitamin C 80 mg + cranberry, D-mannose, propolis extract, tumeric and Boswellia|Group I: an oral preparation (capsule) of HA 100 mg, CS 400 mg, N-Acetylglucosamine 200 mg and vitamin C 80 mg once a day in the morning plus an oral preparation of cranberry, D-mannose, propolis extract, tumeric and Boswellia twice a day for three months.
224161429|NCT06268483|DIETARY_SUPPLEMENT|cranberry, D-mannose, propolis extract, tumeric and Boswellia|Group C: an oral preparation of cranberry, D-mannose, propolis extract, tumeric and Boswellia twice a day for three months.
224161430|NCT06430645|DRUG|Esketamine|Sufentanil(0.1ug/kg) and flurbiprofen axetil(50mg) are administered before induction. Propofol (10 mg/ml) is infused via target-controlled infusions (TCIs). Esketamine hydrochloride (0.3mg/kg total body weight) single intravenous injection after stable plasma concentration of propofol deep sedation.
224161431|NCT06430645|DRUG|Esketamine|Sufentanil(0.1ug/kg) and flurbiprofen axetil(50mg) are administered before induction. Propofol (10 mg/ml) is infused via target-controlled infusions (TCIs). Esketamine hydrochloride (0.6mg/kg total body weight) single intravenous injection after stable plasma concentration of propofol deep sedation.
224161432|NCT06430645|DRUG|Saline|Sufentanil(0.1ug/kg) and flurbiprofen axetil(50mg) are administered before induction. Propofol (10 mg/ml) is infused via target-controlled infusions (TCIs). The same volume of 0.9% saline instead of esketamine will be given to the control group after stable plasma concentration of propofol deep sedation.
224161433|NCT02046382|DRUG|IV Acetaminophen|1000mg dose of IV acetaminophen in 100mL solution every 8 hours for 48 hours. The first dose will be administered intraoperatively following delivery of the baby. A total of 6 doses will be given.
223474073|NCT00623532|BEHAVIORAL|Mind-body exercises|
223581427|NCT04709484|DRUG|Palpation-guided steroid injection|In the palpation-guided group, the most painful point will be found by palpation on the calcaneus bone and steroid injection will be made to that part. The content of the steroid solution will be 1 ml of 1% Lidocaine + 1 ml (40 mg) methylprednisolone.
223581428|NCT03165214|DEVICE|coil|microcoils
223581429|NCT03165214|DEVICE|hystoacryl glue|hystoacryl mixed with lipidol
223581430|NCT01731730|DRUG|Placebo Injection|3mL solution for intrathecal injection; Vehicle formulation designed to mimic AYX1 Injection (with no active drug)
223474074|NCT00623532|BEHAVIORAL|Adapted Tai-chi|
223581431|NCT01731730|DRUG|AYX1 Injection 110 mg|3mL solution for intrathecal injection with 110 mg of AYX1
223581432|NCT01731730|DRUG|AYX1 Injection 330 mg|3mL solution for intrathecal injection with 330 mg of AYX1
223581433|NCT00002849|BIOLOGICAL|recombinant interferon alfa|first 2 years
223581434|NCT00002849|DRUG|dexamethasone|40 mg\*/d PO 1 - 4, 9 - 12, 17-20 q 35 days for 3 cycles\*
223581435|NCT05639153|DRUG|DR30303|DR30303 dose level of escalation IV every 3 weeks (Q3W) Day 1, as well as dose expansion with recommended dose level from dose escalation.
223581436|NCT02523625|DEVICE|Ultrasound of temporal and axillary arteries|Each patient will have a clinical assessment and ultrasound examination of both temporal and axillary arteries
223581437|NCT04909502|DRUG|EHP-101 25 mg OD|25 mg OD during the first 28 Days of the trial
223581438|NCT04909502|DRUG|EHP-101 25 mg BID|25 mg BID during the first 28 Days of the trial
223474075|NCT04321577|PROCEDURE|Radical surgery|Radical surgery is proposed to participants with pT1b, pT2 or pT3 tumors in the cholecystectomy specimen without evidence of disseminated disease with staging imaging techniques. A resection of the gallbladder bed or an anatomic resection of the hepatic segments IVb/V is performed. A lymphadenectomy of the hepatic hilum is associated in all cases. Common bile duct resection is performed in patients with involvement of the cystic margin.
223474076|NCT04512807|DIAGNOSTIC_TEST|AMH|AMH \& PREGNANCY
223474077|NCT01257347|BEHAVIORAL|Disclosure of adherence report to clinician|During clinical visits with patients with uncontrolled hypertension, clinicians will be provided with a quantitative summary of their patients' electronically-monitored adherence to antihypertensive medications. The summary will be in the form of a report that fits onto one page and lists the percent of days patients correctly adhered to each of the monitored BP medications and the mean adherence to the whole regimen. Adherence data will be provided for the 7-days and 1-month prior to the clinic visit. The report will also show the number of days patients exceeded the recommended number of pill container openings. Clinicians in the intervention arm will get a brief training (\<10 minutes) in the interpretation and use of the report at the time of enrollment.
223474078|NCT01257347|DEVICE|MedSignals pillbox|(Non-experimental) Patients will be given an electronic pillbox. The device records the date and time when each compartment is opened. Adherence to each BP medication was calculated as the percent of doses taken as prescribed. Patients are informed that their adherence was recorded by the electronic pillbox and might be shared with their clinician depending on randomization.
223474079|NCT03204643|BEHAVIORAL|BH-VPN|A bundle of usual care components, applied consistently and completely, along with access to behavioral health specific patient navigators and navigation services.
223474080|NCT00380172|DEVICE|Rheopheresis blood filtration|
223474081|NCT01768325|DEVICE|EUS-TCB needle (QuickCore) standard of care|"* The number of needle passes requiring to acquire adequate specimen were tallied.~* Length of core tissue obtained~* Diagnostic contribution of immunohistochemical staining~* Rates of complications"
224161434|NCT02046382|DRUG|Placebo|100 mL of Normal Saline every 8 hours for 48 hours. The first does will be administered intraoperatively following delivery of the baby. A total of 6 doses will be given.
224161435|NCT00565812|DRUG|SD-6010|200 mg tablets once a day for 2 years
223474082|NCT01768325|DEVICE|EUS-Guided biopsy needle (ProCore)|"* The number of needle passes requiring to acquire adequate specimen were tallied.~* Length of core tissue obtained~* Diagnostic contribution of immunohistochemical staining~* Rates of complications"
223474083|NCT05316064|BIOLOGICAL|probiotic|oral administration of probiotic at 9 log CFU/day for 12 weeks to reduce vaginal abundance of HPV in women compared to placebo via the use of vaginal self-swab.
223474084|NCT05316064|OTHER|placebo|oral administration of primarily carrier without the probiotic for 12 weeks
223474085|NCT02351947|OTHER|upper limb rehabilitation for chronic stroke|subjects in this group will receive upper limb motor learning rehabilitation and undergo fMRI/EEG testing as well as testing of motor function (AMAT and FM).
223581439|NCT04909502|DRUG|EHP-101 50 mg OD|After 28 Days of treatment with 25 mg OD, patients will escalate to 50 mg OD up to the end of the trial
223581440|NCT04909502|DRUG|EHP-101 50 mg BID|After 28 Days of treatment with 25 mg BID, patients will escalate to 50 mg BID up to the end of the trial
223581441|NCT01394614|BIOLOGICAL|A/H1N1 vaccine|Verify if exposure to Arepanrix vaccine increase risk of developing narcolepsy in 16 weeks post-vaccination.
223581442|NCT03835884|DRUG|AR-13503 Implant 10.6 Dose|AR-13503 Implant 10.6 Dose (10.6 µg) administered as an intravitreal implant into a single eye
224161436|NCT00565812|DRUG|SD-6010|50 mg tablets once a day for 2 years
224161437|NCT00565812|DRUG|Placebo|Placebo tablets once a day for 2 years
224161438|NCT05246475|DIAGNOSTIC_TEST|PET-MRI|Simultaneous PET-MRI measurement
224161439|NCT01887756|DEVICE|Tele Rehabilitation|
223474086|NCT04260516|DRUG|N-acetyl cysteine|Mucolytic and antioxidant drug
223474087|NCT06019572|PROCEDURE|Spine decompression and fixation surgery|Surgery is performed by either an anterior or posterior approach. Anterior approach is performed with either discectomy or corpectomy accompanied fusion, while the posterior approach consist in a bilateral laminectomy accompanied by fusion.
223474088|NCT00221013|PROCEDURE|"augmented CRRT regimen"|We randomly assigned critically ill patients with acute kidney injury to receive CRRT in the form of post-dilution continuous veno-venous hemodiafiltration (CVVHDF) at 25 ml/kg/hr (lower intensity) or 40 ml/kg/hr (higher intensity) of effluent flow.
223474089|NCT03604939|DIAGNOSTIC_TEST|Evaluation of social, cultural and behavioral factors|Evaluation of the social, cultural and behavioral factors that impact the uptake of the NCD prevention and control services among women, using the RARE methodology
223474090|NCT03604939|DIAGNOSTIC_TEST|Evaluation of the feasibility and acceptability of delivery of early detections services|Evaluation of the feasibility and acceptability of delivery of the NCD early detections services by the trained community health workers at home settings
223581443|NCT03835884|DRUG|AR-13503 Implant 21.2 Dose|AR-13503 Implant 21.2 Dose (21.2 µg) administered as intravitreal implants into a single eye
224161440|NCT03926260|OTHER|ctDNA analysis|blood sample at Baseline, 3weeks, 9 weeks after treatment, at progression if applicable
224161441|NCT04425460|DRUG|Favipiravir|Favipiravir combined with supportive care recommended in the current National/Local guidelines. Favipiravir dosage and method of administration: Day 1 1800 mg x2; Day 2 up to a maximum of 14 days 600 mg x 3
224161442|NCT04425460|OTHER|Placebo|Placebo combined with supportive care recommended in the current National/Local guidelines. Placebo dosage and method of administration: Day 1 1800 mg x2; Day 2 up to a maximum of 14 days 600 mg x 3
224161443|NCT00317057|PROCEDURE|Patient education and disease management|
224161444|NCT03790540|DEVICE|DentalVibe|It is a vibrotactile device that aids in reducing pain during local anesthesia injection in pediatric patients
224161445|NCT03790540|DRUG|Topical Benzocaine 20%|Topical benzocaine 20% gel on the mucosal injection site prior to injection
224161446|NCT05693103|DEVICE|High-Intensity Focused Electromagnetic therapy|"The HPM-6000UF is a non-invasive therapeutic device. The device produces electromagnetic field that interacts with the tissues of the human body.~The electromagnetic field delivered in the muscular or neuronal tissue area is triggering the stimulation and tonisation."
224305001|NCT03533738|OTHER|Food sequence 5|Rice first followed by vegetables \& meat together
224305002|NCT01560650|DEVICE|CRRT|Difference dose of CRRT
223474091|NCT01820663|OTHER|Modified Atkins Diet|A high fat, high protein, low- carbohydrate diet
223474092|NCT01820663|OTHER|Control diet|The control diet is a diet determined by the attending physician caring for the patient and may consist of either a low sodium diet, a low sodium/ low cholesterol diet, a regular diet or a diabetic diet.
223474093|NCT03717103|DRUG|IBI188|Part A: 0.1 mg/kg IV QW, 0.3 mg/kg IV QW, 1 mg/kg IV QW. Part B: 1mg/kg IV D1+3, 10, 20, 30 mg/kg IV D8 QW or 45mg/kg D8 IV Q3W.
223474094|NCT02485665|DEVICE|Extracorporeal biofeedback device (Any Kegel)|Prostate cancer patients of intervention group will received extracorporeal biofeedback device (Any Kegel) for pelvic floor muscle exercise (PFME) to improve the post-prostatectomy incontinence after robot-assisted laparoscopic radical prostatectomy. Enrolled patients in intervention group should be performed PFME regularly, based on following protocols: total exercise time (10 minutes/day), intensity (1.2 kgf), tension duration (10 sec/ 1 contraction), total exercise number (4 times/day)
223474095|NCT03017222|DRUG|Ondansetron|Ondansetron also has been reported as effective prophylactic and therapeutic 5-HT3 receptor antagonist for the treatment of PONV. Ramosetron has been shown to have a very strong effect for preventing PONV in previous meta-analyses, but in recent report, its clinical significance may be questioned to request for additional study.
223474096|NCT03017222|DRUG|Ramosetron|Ramosetron is a newly developed selective 5-HT3 (5 hydroxytryptamine 3) receptor antagonist with longer duration of action up to 48hours and higher receptor affinity, than its previously developed congeners, including ondansetron.
223474097|NCT00261105|DRUG|telithromycin|
223474098|NCT01505283|DRUG|NaCl 0.9%|epidural administration of 6 ml of NaCl 0.9%
223474099|NCT01505283|DRUG|Sufentanil|epidural administration of sufentanil 10 µg
223474100|NCT01505283|DRUG|lidocaine|epidural administration of lidocaine 50 mg
223474101|NCT01102309|DEVICE|Robot therapy (NeReBot)|Rehabilitation therapy of the affected arm with NeRebot for five weeks, five times weekly for 40 minutes, plus 80 minutes of conventional therapy
223474102|NCT01102309|OTHER|Conventional therapy|Conventional rehabilitation therapy of the affected arm for five weeks, five times weekly for 120 minutes
223474103|NCT03368807|DEVICE|Continuous Glucose Monitoring|Commercially available
223474104|NCT03368807|DRUG|Insulin Lispro|As prescribed.
223474105|NCT03912389|BIOLOGICAL|BCD-100|Anti-PD-1 monoclonal antibody, IV infusion
223474106|NCT03912389|DRUG|Pemetrexed|IV infusion
223474107|NCT03912389|DRUG|Cisplatin (or carboplatin)|IV infusion
223474108|NCT03912389|OTHER|Placebo|IV infusion
223474109|NCT00264212|DRUG|irbesartan and irbesartan-hydrochlorothiazide|
223474110|NCT05217030|OTHER|Animal assisted therapy|Patients in AAT group had handler place dog on bed and patient's hand was placed on dog. Bedside RN measured GCS, RLAS, LoCmds before and after intervention
223474111|NCT03035448|BEHAVIORAL|Questionnaires|"Participants complete 3 assessment questionnaires during an already-scheduled office visit. These questionnaires should take about 9 minutes to complete.~Participant completes 3 questionnaires after watching the second video about whether they think 1 of the videos was better than the other, and about their attitude toward psychology services. These questionnaires should take about 4 minutes to complete."
224161447|NCT06071390|BEHAVIORAL|Animated- assisted video|"For the experimental group, 15 minutes prior to the endoscopy, the researcher provided insight into the procedure by showing them a 3-minute animated video titled Endocan. This video, crafted by Köse in 2019 for his doctoral dissertation, offers a succinct overview of the endoscopy procedure."
224161448|NCT01733836|DRUG|Metformin|
224161449|NCT01733836|DRUG|placebo|
224304420|NCT00513136|BEHAVIORAL|Group-based mind body medicine intervention + family focus|In addition to the 10 weekly group-based sessions, women and their key family members will meet twice with a cognitive therapist and family members will participate in selected aspects of the 10 week program.
223474112|NCT03035448|OTHER|Video Presentation|Participant watches 2 videos showing actors playing a doctor, counselor, and patient, discussing psychology service options.
223474113|NCT00045266|BIOLOGICAL|ziv-aflibercept|
223474114|NCT03220308|OTHER|MYmind mindfulness training|The MYmind mindfulness training uses a standardised protocol based on mindfulness-based cognitive therapy. It consists of 8 weekly group sessions of 90 minutes for youth with ADHD, and parallel mindful parenting training for the parents. Eight weeks after the last session there is a single 90 minutes booster session.
223474115|NCT03220308|OTHER|Care-as-usual for children (8-16 years old) with ADHD|According to the Dutch Multidisciplinary guidelines for the diagnosis and treatment of ADHD, care-as-usual for children aged 8-16 years with ADHD consists of psycho-education and the prescription of medication approved for ADHD and/or evidence-based parent and/or teacher-administered behaviour therapy, preferably both medication and behaviour therapy. First-line option for medication is a psychostimulant, second-line option is atomoxetine, and third-line options are alpha-2 presynaptic agonists or tricyclic antidepressants (imipramine).
223474116|NCT01984957|PROCEDURE|Muscle biopsy|open muscular biopsy of the deltoid under local anaesthesia
223474117|NCT05107661|BEHAVIORAL|Telephone Prompt|Scripted messaging to remind subjects to complete their colorectal screening (colonoscopy or fecal test)
223474118|NCT03618875|OTHER|ice pack|ice pack was placed on eyelid 5 minutes prior to IVIT
223474119|NCT03618875|OTHER|room temperature pack|room temperature pack was placed on eyelid 5 minutes prior to IVIT
223474120|NCT06003361|DEVICE|Digital CBT|An app-based intervention based on principles from cognitive behavioral therapy for depression.
223474121|NCT06003361|OTHER|Waitlist|Participants will wait for 5 weeks prior to receiving the intervention
223474122|NCT01198912|DRUG|placebo|during 56 days
223474123|NCT01198912|DRUG|doxycycline 100 mg|during 56 days
223474124|NCT03748134|BIOLOGICAL|Sintilimab|For weight \<60kg, 3mg/kg IV Q3W day 1, and for weight≥60kg, 200mg IV Q3W day 1
223474125|NCT03748134|DRUG|Cisplatin|75mg/m\^2 IV Q3W day 1
223474126|NCT03748134|DRUG|Paclitaxel|87.5 mg/m\^2 IV Q3W day 1, day 8 for first cycle and 175mg/m\^2 IV Q3W day 1 after first cycle
223474127|NCT03748134|DRUG|Fluorouracil|800 mg/m\^2 IV continuous infusion over 24 hours daily on Days 1-5 Q3W
223474128|NCT03748134|DRUG|Placebo|For weight \<60kg, 3mg/kg IV Q3W day 1, and for weight≥60kg, 200mg IV Q3W day 1
224305003|NCT05331196|DIAGNOSTIC_TEST|Preoperative cardiopulmonary exercise tetsing|Patients underwent a cardiopulmonary exercise test prior to surgery.
223474129|NCT02833896|GENETIC|surgery|
223474130|NCT05371561|DEVICE|reusable respirators|Dentist wearing reusable respirator will examin the patient
223474131|NCT03380286|DEVICE|Firehawk|Firehawk stent
223474132|NCT04668417|BEHAVIORAL|Portal Reminders for Second Dose of Influenza Vaccine with Direct Scheduling Link|Patient proxy receives reminder/recall messages via the patient portal to get a second dose of influenza vaccine with a direct scheduling link included, enabling the patient to directly schedule a flu vaccination only visit
223474133|NCT04668417|BEHAVIORAL|Portal Reminders for Second Dose of Influenza Vaccine without Direct Scheduling Link|Patient proxy receives reminder/recall messages via the patient portal to get a second dose of influenza vaccine with no direct scheduling link included
223474134|NCT01973218|BIOLOGICAL|Meningococcal B Recombinant vaccine rMenB+OMV NZ|Subjects were randomized to one of two treatment groups to receive intramuscular (IM) vaccination with two doses of rMenV+OMV NZ vaccine (0.5 mL) in the non-dominant arm, one month apart. Subjects were followed for two months.
223474135|NCT01973218|BIOLOGICAL|Placebo|Subjects were randomized to one of two treatment groups to receive intramuscular (IM) injection of saline solution followed by one dose of MenACWY-CRM vaccine (0.5 mL), one month apart. Subjects were followed for two months.
223474136|NCT01973218|BIOLOGICAL|Meningococcal ACWY-CRM conjugate vaccine|Subjects were randomized to one of two treatment groups to receive intramuscular (IM) injection of saline solution followed by one dose of MenACWY-CRM vaccine (0.5 mL), one month apart. Subjects were followed for two months.
223474137|NCT03172598|DRUG|MT-8554 low dose|Capsule
223474138|NCT03172598|DRUG|MT-8554 middle dose|Capsule
223474139|NCT03172598|DRUG|MT-8554 high dose|Capsule
223474140|NCT03172598|DRUG|Placebo|Capsule
223474141|NCT02247466|DRUG|Rocuronium and Sugammadex|
223474142|NCT02001571|DRUG|Abiraterone acetate|On the morning of Day 1, each participant was given four 250 mg tablets of abiraterone acetate with 240 mL of room temperature tap water. Dosing followed at least a 10-hour fast from food (not including water).
223474143|NCT05062096|OTHER|Blood samples|Blood samples at each protocol visit, T and NK cell analysis
223474144|NCT05062096|OTHER|Skin biopsy|Biopsy of the skin lesion (optional)
223474145|NCT06183034|OTHER|Very Low Calorie Diet|Participants will receive a very low calorie diet as described in the arm/group
223474146|NCT00221819|DEVICE|heated humidifier (device)|
223474147|NCT00221819|DEVICE|Heat and moisture exchanger (device)|
223474148|NCT05718349|OTHER|Biospecimen sampling|From the patients participating in the study i) blood, ii) tissue from resected material, iii) bile, iv) stool, v) urine, vi) jejunal content and vii) information on the itch severity will be collected.
223474149|NCT03242317|DRUG|Mitomycin C|The surgical procedure includes a low dose, short duration MMC treatment on the exposed stromal bed of the non-dominant eye, before the unilateral implantation of the corneal inlay. This treatment is at a concentration of 0.2 mg/mL (0.02%) applied for 10 to 30 seconds on the stromal bed as well as the stromal side of the corneal flap or pocket.
223474150|NCT03242317|DEVICE|Raindrop Near Vision Inlay|The surgical procedure includes the unilateral implantation of the Raindrop Near Vision Inlay in the non-dominant eye for the improvement of uncorrected near vision.
223474151|NCT01414244|DRUG|Glutamine|Drug
223474152|NCT05034549|DEVICE|Noninvasive ventilation|The non-invasive ventilator at home (≥5h/ night)
223474153|NCT02193841|PROCEDURE|Curettage with puncture (C & P)|A curette will be inserted to scrape the contents of the cyst (curettage) and a hole in the cyst wall will be made (puncture) near the bone marrow cavity
223474154|NCT02193841|DEVICE|Curette|A small surgical instrument with a rounded edge designed for scraping
223581444|NCT03835884|DRUG|AR-13503 42.4 Dose|AR-13503 Implant 42.4 Dose (42.4 µg) administered as intravitreal implants into a single eye
223581445|NCT03835884|DRUG|AR-13503 63.6 Dose|AR-13503 Implant 63.6 Dose (63.6 µg) administered as intravitreal implants into a single eye
223581446|NCT05259644|DEVICE|laparoscopic sleeve gastrectomy|Surgical procedure - laparoscopic sleeve gastrectomy.
223581447|NCT05259644|OTHER|conservative treatment of obesity|Diet and exercise
223581448|NCT05259644|DEVICE|endoscopic gastric plication|Endoscopic procedure - endoscopic gastric plication
223581449|NCT00002039|DRUG|Foscarnet sodium|
223474155|NCT02193841|DEVICE|Vitoss morsels|A bone substitute intended for use as a filler for voids or gaps in bones
223474156|NCT05794815|DIETARY_SUPPLEMENT|Probiotic|Bifidobacterium infantis YLGB-1496 at 1x10 log CFU/day for 12 weeks
223474157|NCT05794815|DIETARY_SUPPLEMENT|Placebo|Intervention consists of daily administration of 2g of maltodextrin, administered daily for 12-weeks)
223474158|NCT00456872|DRUG|lidocaine|
223474159|NCT01039766|DRUG|Oxytocin|A single intranasal administration of 40 IU of oxytocin will be given to patients up to 6 hours after a traumatic event, with consecutive follow up for 13 months.
223474160|NCT01039766|DRUG|placebo - saline nasal spray|A single intranasal administration of saline will be given to patients up to 6 hours after a traumatic event, with consecutive follow up for 13 months as the control to the oxytocin arm
223581450|NCT01582048|DRUG|immunosuppression|Conditioning with treosulfan 14 g/m2 day -6 to -4, fludarabine 30 mg/m2/24h day-6 to -2, ATG-Fresenius 20 mg/kg day -4 to -2, rituximab 500 mg/m2 day -1. Unmanipulated PBSC day 0. Postgrafting immunosuppression with mycophenolate mofetil (15 mg/kg TID) and sirolimus (2 mg QD).
223581451|NCT05532267|DRUG|Ciprofloxacin 750 mg|an immediate release film-coated tablet containing 750 mg Ciprofloxacin
223581452|NCT05532267|DRUG|Ciproxin 750 mg|an immediate release film-coated tablet containing 750 mg Ciprofloxacin
223581453|NCT05308524|DIAGNOSTIC_TEST|ICU scoring system in covid 19|The intensive care unit (ICU) at Assiut University Hospital, which is supervised by the staff members of the Chest Diseases Department and designated to deal with critically ill Covid 19 patients.
223581454|NCT00404170|DRUG|B-CIT and SPECT imaging|Optional ongoing B-CIT SPECT imaging scans at follow-up visits
223581455|NCT01318070|DRUG|Alogliptin and pioglitazone|Alogliptin 12.5mg, tablets, orally, once daily and Pioglitazone 15 or 30 mg, tablets orally once daily for up 12 weeks.
223581456|NCT01318070|DRUG|Alogliptin and pioglitazone|Alogliptin 25 mg, tablets, orally, once daily and Pioglitazone 15 or 30 mg, tablets orally once daily for up 12 weeks.
223581457|NCT01318070|DRUG|Pioglitazone|Pioglitazone 15 or 30 mg, tablets orally once daily for up 12 weeks.
224161450|NCT01128166|DEVICE|COGNIS CRT-D|"Patients with existing or newly implanted COGNIS® CRT-D pulse generators (PG)are enrolled in the study. PG is modified by the download of investigational software called Sensor Research Device-1™ (SRD-1). The goal of the SRD-1 system is to collect sensor data without affecting the delivered CRT-D therapy. This is accomplished through the conversion of an implanted COGNIS PG into a SRD-1 PG by downloading investigational software. Only a market approved COGNIS model N119/N120/P107/P108 device may be converted to a SRD-1 investigational device. There will be no PG hardware changes resulting from the conversion."
223474161|NCT01259947|DRUG|Lippia alba (Mill.) N. E. Brown ethanolic extract|1-2 drops per kilogram per day, PO, twice a day
224161451|NCT02536157|DEVICE|Thermoplastic splinting|
223474162|NCT05637034|DIAGNOSTIC_TEST|68Ga-DOTA-F2 PET/CT and 18F-FDG|Each subject receive a single intravenous injection of 68Ga-DOTA-F2 and 18F-FDG, and undergo PET/CT imaging within the specified time.
223474163|NCT05652127|OTHER|Mightier|Mightier is an app-based biofeedback video game that utilizes heart rate (HR) monitoring during game play to teach and facilitate practice of emotional regulation skills in children ages 6-14
223474164|NCT02952651|PROCEDURE|Pulse oximeter|When there are clinical signs of hypovolemia, such as hypotension, decreased urine output and central venous pressure less than 5 mmHg, POP waveforms are obtained from each index finger, which pulse oximeter sensor is applied by increasing contact force (from 0 to 1.4N, being increased by 0.2-0.3N). Then intravenous crystalloid 10 mL/kg is infused for 15 min.
223474165|NCT04533256|PROCEDURE|CytoSorb|three consecutive sessions of hemoadsorption in patients with sepsis
223474166|NCT03342729|BEHAVIORAL|Intervention|Participants receive the AMP 10-week program immediately
223474167|NCT03342729|BEHAVIORAL|Control|Participants will not received the AMP 10-week program immediately, rather will wait 3-months
223474168|NCT02033759|DEVICE|Bio-Impedance Testing|Participants in the BIA Arm will also undergo bio-impedance testing with this device.
223474169|NCT02033759|OTHER|Anxiety Questionnaire|21 item questionnaire
223474170|NCT02033759|OTHER|Traditional Circumferential Measurements|
223474171|NCT04865588|PROCEDURE|rotational atherectomy|angioplasty with rotational atherectomy - a rotating instrument used to break up the calcification
223474172|NCT04865588|DEVICE|cutting balloon|a balloon with microsurgical blades on its outer surface which make longitudinal incisions in the calcified area in order to open resistant clogs
224161452|NCT02121444|DRUG|Interferon beta-1b (Betaferon, BAY 86-5046)|
224161453|NCT02121444|DEVICE|BETACONNECT auto-injector.|
224161454|NCT01505972|OTHER|Six and three time schedule|Invitation letter sent 6 weeks and reminder 3 weeks before a pre-specified screening colonoscopy appointment date.
224161455|NCT01505972|OTHER|Four and two time schedule|Invitation letter and reminder sent 4 and 2 weeks before pre-specified screening colonoscopy appointment date.
224304421|NCT04380090|DRUG|Propylene Glycol|Patients in the propylene glycol arm will receive one standard dose of the drug on postoperative day one prior to discharge with the aim of decreasing rates of postoperative constipation for patients following single total knee replacement surgery
224161456|NCT06103019|OTHER|conventional complete denture|conventional complete denture. The succession of complete denture insertion was randomized to reduce the impact of the order of the complete denture on patient satisfaction outcomes. Each denture was used for 3 months followed by 2 weeks rest period without wearing the denture then the other type of denture was delivered and used for another 3 months and vice versa.
224304422|NCT04380090|DRUG|Docusate Sodium|Patients in the docusate sodium arm are receiving the current standard of care for prevention of postoperative constipation following single total knee replacement surgery, docusate sodium one pill twice a day by mouth for 28 days
223474173|NCT04865588|DEVICE|plain old balloon|current standard treatment of stent placement
223474174|NCT03985683|OTHER|agility tests|In control group athletes will perform T-Test, Illinois agility test, 30 meter run test and Agility Compass drill test, before and after 6 days of intervention.
223474175|NCT03985683|DIETARY_SUPPLEMENT|Nutritional Interventional|Athletes were given 50 % carbohydrate in first 3 days and 70 % in next 3 days respectively.T-Test, Illinois agility test, 30 meter run test and Agility Compass drill test, before and after 6 days of intervention.
223474176|NCT03573037|DRUG|Oral anticoagulant|1:1 randomization to 1-month anticoagulation or 2-month anticoagulation after radiofrequency catheter ablation of paroxismal atrial fibrillation
223474177|NCT01776970|DRUG|Cannabis Sativa extract Oromucosal spray|Comparison between active drug (Cannabis Sativa extract Oromucosal spray, containing THC (27 mg/ml):CBD (25 mg/ml) vs placebo
223474178|NCT03497871|DEVICE|HeartMan system|The HeartMan system uses wristband sensors to monitor patients' physical activity and physiological parameters. These data are connected to a decision support system, providing medical advice to patients concerning physical exercise, nutrition, medication intake, clinical measurements, environment management, and mental support. The decision support system is based on predictive models, clinical care guidelines and expert knowledge. The advice will be personalized according to each individual patient's medical and psychological profile, and will be presented to the patient through the user interface of a mobile application on a smartphone.
223474179|NCT02559037|DEVICE|Acupuncture and moxibustion|"Acupuncture acupoints: CV12, bilateral ST36, ST37, SP6, SP9, SP4, LR3 and LI3. Disposable acupuncture auxiliary device and 0.30\*40mm or 0.30\*25mm acupuncture needles (hwato, suzhou medical supplies factory co., LTD.) were used. The needles were directly inserted 20-30mm into the skin and elicited a de-qi sensation. The needle was kept for 30 min.~Moxibustion acupoints: bilateral ST25 and ST36. Using mild-warm moxibustion, The surface temperature of acupoints were maintained at 43 ℃ ± 1 ℃, 30min for each acupoint. Moxibustion and acupuncture were performed at the same time, once every other day, three times a week, a total of 12 weeks of treatment. After the treatment, subjects were followed up in the weeks 24, 36 and 48."
223581458|NCT02956850|OTHER|Placebo|Placebo matching to RO7020531 will be administered as per schedule specified in the respective arm.
223581459|NCT02956850|DRUG|RO7020531|RO7020531 will be administered as per schedule specified in the respective arm.
223581460|NCT01278316|BEHAVIORAL|Control|Participants will be asked to perform computerized tasks that involve auditory and verbal performance one hour each day, five days per week for 8-10 weeks. Six tasks requiring auditory and verbal information will be presented.
223474180|NCT02559037|DEVICE|Sham acupuncture and moxibustion|"The acupoints used are same to the experimental group. Same disposable acupuncture auxiliary device and 0.35 \* 40mm acupuncture needle (flat and blunt needle tip, Hwato, Suzhou Medical Supplies Factory Co., Ltd.) was selected. When the needle was pricked to the acupoint, it did not penetrating into the skin. The subject only felt slight pain and do not have the de-qi sensation.~Sham moxibustion : by using the same moxa stick, The surface temperature of acupoints were maintained at 37 ℃ ± 1 ℃, 30min for each acupoint. Sham acupuncture and sham moxibustion were performed at the same time. They were treated once every other day, three times a week, a total of 12 weeks. After the treatment, subjects were followed up in the weeks 24, 36 and 48."
223474181|NCT04356937|DRUG|Tocilizumab|"Patients will receive the standard treatment for COVID-19 per MGH guidance and also be randomized (2:1) to one of the following arms:~1. Tocilizumab 8mg x 1 (n=185)~2. Standard of care/Placebo (n=93)"
223474182|NCT04356937|DRUG|Placebos|"Patients will receive the standard treatment for COVID-19 per MGH guidance and also be randomized (2:1) to one of the following arms:~1. Tocilizumab 8mg x 1 (n=185)~2. Standard of care/Placebo (n=93)"
223474183|NCT01835106|PROCEDURE|Epidural catheter is used postoperatively|
223474184|NCT01835106|PROCEDURE|Fascia iliaca compartment catheter is used postoperatively|
223474185|NCT06555445|OTHER|BREATHING EXERCISE|Participants will be guided to adopt a deep breathing practice by emphasizing the use of the diaphragm muscle, thereby minimizing the contribution of accessory muscles during inspiration. This approach fosters the efficiency of respiratory mechanics, aiding in the mitigation of dyspnea symptoms. Participants are directed to undertake these exercises 2-3 times per day, dedicating 15-20 minutes per session, consistently over a period of 2 months. Pursed-Lip Breathing .This technique involves exhaling through semi-closed lips, creating a resistance that helps control the rate of exhalation and, thus, optimizes lung volumes and capacities. This exercise is recommended to be performed similarly to diaphragmatic breathing, 2-3 times daily for 15- 20 minutes per session for a period of 2 months
223474186|NCT06555445|OTHER|BREATHING EXERCISE REGIMEN COUPLED WITH BREATHER DEVICE|The resistance on the BREATHER device will be adjusted to match each participant's abilities and progression. The resistance level will be challenging yet manageable, ensuring participant comfort. Each daily session will consist of 15-30 minutes with the BREATHER device and can be split into two shorter sessions if necessary. The total duration of this treatment protocol will span 2 months. The BREATHER device will be employed for both inspiratory and expiratory muscle training. Alongside the device usage, specific breathing exercises, such as diaphragmatic and pursed lip breathing, will be performed
223474187|NCT03533751|BIOLOGICAL|Etokimab|Humanized monoclonal antibody, administered by subcutaneous injection
223744006|NCT04020133|PROCEDURE|saphenous nerve block|"The skin is disinfected and the saphenous nerve is located via Ultrasound . the transducer is placed anteromedially, approximately at mid-thigh level a high-frequency linear probe 5Y12 MHz prepared in a sterile fashion (Phillips HD11) .~The block needle (Stimuplex; Braun Medical, Bethlehem, Pa), is inserted in plane in a lateral-to-medial orientation and advanced toward the femoral artery .Once the needle tip is visualized anterior to the artery and after careful aspiration, 1-2 mL of local anesthetic is injected to confirm the proper injection site . When injection of local anesthetic does not appear to result in its spread around the femoral artery, additional needle repositions and injections may be necessary."
223744007|NCT04020133|PROCEDURE|popliteal plexus block|After doing saphenous nerve block , we will move distally with the artery in the adductor canal until it moves away from the sartorius muscle to enter adductor hiatus . here , we will inject L.A above artery and so , popliteal plexus block will be accomplished
224161457|NCT06103019|OTHER|3D complete denture|3D complete denture. The succession of complete denture insertion was randomized to reduce the impact of the order of the complete denture on patient satisfaction outcomes. Each denture was used for 3 months followed by 2 weeks rest period without wearing the denture then the other type of denture was delivered and used for another 3 months and vice versa.
224161458|NCT04743271|OTHER|High-Fat Diet|The diet will consist of a breakfast, lunch, dinner, and snack
223744008|NCT04020133|DRUG|Plain bupivacaine|15ml of plain bupivacaine 0.5% will be given in both blocks
224161459|NCT04743271|OTHER|Low-Fat Diet|The diet will consist of a breakfast, lunch, dinner, and snack
224161460|NCT04968353|DEVICE|Incisally-beveled attachment|Incisally-beveled attachments will be bonded to teeth before or during orthodontal treatment with clear aligners
224161461|NCT04968353|DEVICE|Gingivally-beveled attachment|Gingivally-beveled attachments will be bonded to teeth before or during orthodontal treatment with clear aligners
224161462|NCT04968353|DEVICE|Optimized attachment|Optimized attachments will be bonded to teeth before or during orthodontal treatment with clear aligners
224161463|NCT04968353|DEVICE|Horizontal attachment|Horizontal attachments will be bonded to teeth before or during orthodontal treatment with clear aligners
224161464|NCT01425645|OTHER|FDD program|FDD is a 12 month lifestyle intervention and behavioural support program delivered in the context of the surrounding family
223474188|NCT03533751|DRUG|Placebo|Administered by subcutaneous injection
223474189|NCT06985199|BEHAVIORAL|Enhanced Usual Care Group|A culturally-adapted mobile health platform will be used in the intervention to enable participants to record blood pressure and heart rate readings at home and store data in the mobile platform. Providers will have access to the store data using a provider-facing app.
223474190|NCT06607406|RADIATION|Accelerated radiotherapy|6 fractions per week, BID fractions one day per week
223474191|NCT06607406|RADIATION|Conventional radiotherapy|5 fractions per week, daily M-F
223744009|NCT04020133|DRUG|0.05 mg epinephrine|0.05 mg epinephrine will be added to bupivacaine in both blocks to prolong their duration
224161465|NCT05229419|OTHER|complete blood count|complete blood count will be done for corrosive cases
224161466|NCT03595449|DRUG|Lidocaine jelly|lidocaine 2% jelly applied during Mohs surgery
224161467|NCT03595449|DRUG|Surgilube|surgilube (placebo) applied during Mohs surgery
224161468|NCT02169713|DRUG|Mirabegron|Oral
224161469|NCT02169713|DRUG|Solifenacin succinate|Oral
224161470|NCT02169713|DRUG|Tamsulosin HCl|Oral
224161471|NCT02169713|DRUG|Placebo|Oral
224161472|NCT04266158|DEVICE|Myoelectric UE Device-UE Orthosis-No Device|all subjects receive 2 education sessions, during which they are trained on the donning and use of the MyoPro 2 Motion-G, orthosis, and no device, all on the affected UE. The presentation and training on these interventions is non-randomized and administered to all subjects.
224161473|NCT03999385|BEHAVIORAL|Mindful Self-Compassion (MSC)|The MSC program was developed by Christopher K. Germer, PhD and Kristin Neff, PhD.
223581461|NCT01278316|BEHAVIORAL|Cognitive Training|Participants will be asked to perform the Brain Fitness (PositScience) cognitive training tasks an hour each day, five days per week for 8-10 weeks. Six tasks manipulating auditory and verbal information will be presented, and stimuli from all tasks are presented auditorily. All tasks are designed to begin with the lowest level of difficulty required to attain 85% accuracy, and as performance improves, difficulty increases to maintain 85% accuracy, with difficulty decreasing if accuracy decreases.
223581462|NCT03059771|BEHAVIORAL|Mobile Enhancement of Motivation (MEMS)|The MEMS group will engage in a goal-setting session and then receive personalized text-messages to support goal attainment.
223474192|NCT03980067|OTHER|Virtual Reality Game|The virtual reality headset, device, and software, created by Stanford's Childhood Anxiety Reduction through Innovation and Technology (CHARIOT)program/Weightless Studio, LLC will be utilized in this study. Children in the VR intervention group will be allowed to select a distraction-based game to play with active VR content featuring interactive avatars and interactive experiences tailored to the pediatric population that allow players to do things such as control penguins sliding down a mountain while collecting pebbles for points, control puppies running in space to collect treats to the rhythm of music, and control an asteroid miner exploring an asteroid belt and collecting points based on color of asteroids collected. The game will last a minimum of 5 minutes in duration, provided participant tolerance. The participant may play longer if desired prior to receiving procedural sedation and the total length of activity played will be documented.
223474193|NCT00419536|DRUG|LBH589|
223581463|NCT03059771|BEHAVIORAL|Control|The control group will only engage in a goal-setting session.
224161474|NCT03412123|BEHAVIORAL|group lifestyle-integrated functional exercise|Manualized teaching of balance and strength principles and integration of exercises and physical activity into daily routine during 7 sessions in a group of 8 to 10 participants with 2 trainers. The pilot intervention group will undergo the same strength and balance exercises and learn about the same physical activity enhancement strategies as described in the LiFE programme by Clemson et al. (BMJ 2012;345:e4547). However, instead of 7 home visits, gLiFE participants will attend seven group sessions (1 session/week). In these, LiFE contents are adapted to the group setting and enhanced by health psychological and behaviour change strategies fitting to the social structure and modalities of a group.
224161475|NCT03718676|PROCEDURE|Ferric sulphate|Teeth were pulpotomized with ferric sulphate in this group.
224161476|NCT03718676|PROCEDURE|Ortho-MTA|Teeth were pulpotomized with Ortho-MTA in this group.
223474194|NCT02112253|DEVICE|Deep brain stimulator ventral electrode up to 2 mA|
223474195|NCT02112253|DEVICE|Deep brain stimulator ventral electrode up to 3 mA|
223474196|NCT02112253|DEVICE|Deep brain stimulator dorsal electrode up to 2 mA|
223474197|NCT02112253|DEVICE|Deep brain stimulator dorsal electrode up to 3 mA|
223474198|NCT02112253|DEVICE|Deep brain stimulator empirical programming|
223474199|NCT06661525|DEVICE|Free Flap NIRS|Monitoring of tissue oxygenation after Free Tissue Transfer (FTT) surgeries.
223474200|NCT04398719|RADIATION|[11C]PBR28|The radiotracer, \[11C\]PBR28, will be administered at the beginning of each PET scan
223474201|NCT04398719|DRUG|Low-dose lipopolysaccharide|Subjects will receive intravenous lipopolysaccharide.
223474202|NCT04398719|DRUG|Intradermal Capsaicin|A small dose of capsaicin will be administered by intradermal injection.
223474203|NCT06612996|DRUG|Tramadol|Intravenous tramadol
223474204|NCT06612996|DRUG|Magnesium sulphate|Intravenous magnesium sulphate
223474205|NCT06612996|OTHER|Saline|Normal saline
223474206|NCT06314152|PROCEDURE|Lightweight mesh fixation in 3 points or 1 point|Lightweight mesh fixation in 3 points
223474207|NCT05117060|DRUG|LEO 152020 tablet|LEO 152020 is a small drug molecule which can bind to the histamine 4 receptor (H4R) and prevent histamine from binding to the receptor. LEO 152020 is a tablet for oral administration.
223474208|NCT05117060|DRUG|LEO 152020 placebo tablet|LEO 152020 placebo tablet contains the same excipients in the same concentration as LEO 152020 tablet, except that it does not contain the medical ingredient LEO 152020. LEO 152020 placebo is a tablet for oral administration.
223474209|NCT02440893|DIAGNOSTIC_TEST|Corus CAD (ASGES)|
223474210|NCT04703985|DIETARY_SUPPLEMENT|Enteral Nutrition|Protocol of Enteral Nutrition adapted to the conditioning autograft (BEAM or Melphalan 200)
223581464|NCT05601661|DEVICE|Active VNS|An implantable system consisting of an implantable neurostimulator (model 1001 Implantable Pulse Generator (IPG)) and an implantable lead and electrode (Model 30000 VNS lead) will be used. An external system consisting of an external controller (Model 2000 Wireless Transmitter) and an external software system (computer and Model 4001 Microtransponder SAPS® software) will provide clinical control of settings for the implantable pulse generator (IPG) . All VNS devices (Vivistim System® ) will be provided as a donation by Microtransponder Inc. The device is programmed to stimulate for 0.5s on each button push. After surgical recovery, participants will receive five stimulations in reducing strength (starting at 0.8mA and then reducing to 0.1mA each step) at the beginning of each therapy session, followed by stimulation (0.8 mA)
223581465|NCT05601661|DEVICE|Sham VNS|An implantable system consisting of an implantable neurostimulator (model 1001 Implantable Pulse Generator (IPG)) and an implantable lead and electrode (Model 30000 VNS lead) will be used. An external system consisting of an external controller (Model 2000 Wireless Transmitter) and an external software system (computer and Model 4001 Microtransponder SAPS® software) will provide clinical control of settings for the implantable pulse generator (IPG) . All VNS devices (Vivistim System® ) will be provided as a donation by Microtransponder Inc. The device is programmed to stimulate for 0.5s on each button push. After surgical recovery, participants will receive five stimulations in reducing strength (starting at 0.8mA and then reducing to 0.1mA each step) at the beginning of each therapy session, followed by stimulation (0 mA)
223581466|NCT05601661|OTHER|Arm rehabilitation|. The rehabilitation therapy involves arm and hand exercises with objects. The therapist will select these exercises based on movement abilities. Tasks will be selected from six functional task categories: reach and grasp, gross movement, object flipping, simulated eating tasks, inserting objects, and opening containers. Approximately 30-50 repetitions will be performed in each category. On average, 300-500 repetitions will be performed during each session within 1.5-2hours.
223744010|NCT06238479|DRUG|LY4101174|Intravenous
224161477|NCT03718676|PROCEDURE|Retro-MTA|Teeth were pulpotomized with Retro-MTA in this group.
223474211|NCT01124812|OTHER|131I-L19SIP Radioimmunotherapy (RIT) in Combination With External Beam Radiotherapy (EBRT) and Concurrent Chemotherapy|"Lung tumor irradiation with a total dosage of between 60-66 Gy, fractionated in combination with the following concurrent chemotherapy options:~1. Cohorts 1, 2 \& 3a is composed of cisplatin i.v. 80 mg/m2 on day 1, and vinorelbine i.v. 25 mg/m2 on day 1, 8, 15 for cycle 1 \& 4. For patients with significant comorbidities, the dose of vinorelbine is reduced to 12.5 mg/m2 during cycles 2 \& 3. Treatment cycles will be repeated every 28 days.~2. Protocol A (suggested for patients with comorbidities: Carboplatin 70 mg/m2, over 30 min iv, (Day 1-5 ) + Vinorelbine 12.5 mg/m2 as a 5-min bolus iv or short iv-infusion (Day 1, 8, 22), repeated on Day 28.~3. Protocol B (suggested for patients in good clinical condition): Paclitaxel 50 mg/m2 1 hour iv (Day 1, 15, 22, 29, 36, 43, 50) + Carboplatin AUC 2, 30 min iv on (Day 1, 15, 22, 29, 36, 43, 50).~   * Total treatment duration is 8-16 weeks"
223474212|NCT01911416|DRUG|LDE225|
224161478|NCT03215667|DEVICE|easy-graft CLASSIC (beta-Tricalcium Phosphate)|easy-graft will be grafted to a single extraction socket and covered by polylactide membrane to facilitate regeneration of new bone in order to preserve alveolar ridge dimensions.
224161479|NCT00260195|BEHAVIORAL|School-based cognitive behavioral support group|
224161480|NCT03352128|DIETARY_SUPPLEMENT|Creatine|Participants will have to supplement themselves with creatine for 7 days (20g/day).
224161481|NCT03352128|DIETARY_SUPPLEMENT|Calcium lactate|Participants will have to supplement themselves with calcium lactate for 7 days (elemental calcium: 0.780g/day).
224161482|NCT06118762|DRUG|Fruquintinib|Fruquintinib capsule is taken orally once a day, 5 mg each time, and taken for 2 weeks and stopped for 1 week, every 21 days (3 weeks) for a cycle. Raltitrexed: 3 mg/m2 intravenously, on the first day of each cycle, for a treatment cycle of 3 weeks. Combination treatment until toxicity becomes intolerable, disease progression, or death.
224161483|NCT04208880|BEHAVIORAL|TBH Brain Workout 1.0|TBH Brain Workout program with easy challenge activities.
224161484|NCT04208880|BEHAVIORAL|Brain Health Book Club|Each week a new chapter will be read that contains new information to enhance brain health.
224161485|NCT04208880|BEHAVIORAL|TBH Brain Workout 2.0|TBH Brain Workout program with moderately difficult challenge activities.
224161486|NCT04208880|BEHAVIORAL|TBH Memory 1.0|TBH Memory program with easy challenge activities.
224161487|NCT04208880|BEHAVIORAL|TBH Memory 2.0|TBH Memory program with moderately difficult challenge activities
223474213|NCT01419535|DRUG|Mifepristone|Mifepristone 50mg tablet by mouth every six hours for nine days.
223474214|NCT01419535|DRUG|Placebo|Placebo (matching mifepristone 50mg tablet) by mouth every six hours for nine days.
223474215|NCT03213847|DEVICE|Superb microvascular imaging (SMI) (Toshiba)|to determine whether there is a correlation between the increased intraneural flow as measured using Doppler US and SMI methods and the severity of CTS as measured by nerve conduction studies, we designed this study
223474216|NCT02344316|DRUG|Melatonin|Taken at 9 PM or 1 hour before bedtime, whichever is earlier
223474217|NCT02344316|OTHER|Placebo|Matching placebo taken at 9 PM or 1 hour before bedtime, whichever is earlier
223474218|NCT03842904|DRUG|Trimbow pMDI|Clinical Trial of an Investigational Medicinal Product (CTIMP)
223474219|NCT03842904|DRUG|Fostair pMDI|Clinical Trial of an Investigational Medicinal Product (CTIMP)
223474220|NCT02354768|DRUG|Effects of lanreotide with current anti-diarrheal treatments (diosmectite and loperamide)|
223474221|NCT02354768|DRUG|Effects of current anti-diarrheal treatments (diosmectite and loperamide) alone|
223474222|NCT06778486|OTHER|Artificial Intelligence Chatbot|The intervention is a generative artificial intelligence large language model chatbot that has a structured prompt with fill-in-the-blank style questions that the participant will complete.
223474223|NCT03210532|DRUG|Telmisartan + Amlodipine + Rosuvastatin|Telmisartan + Amlodipine + Rosuvastatin + Telmisartan placebo
223474224|NCT03210532|DRUG|Telmisartan + Amlodipine|Telmisartan + Amlodipine + Rosuvastatin placebo + Telmisartan placebo
223474225|NCT03210532|DRUG|Telmisartan + Rosuvastatin|Telmisartan + Amlodipine placebo + Rosuvastatin + Telmisartan placebo
223474226|NCT02273947|DRUG|BMS-955176|Single dose by mouth for each treatment specified
223474227|NCT03912636|BEHAVIORAL|Diaphragmatic breathing|Subjects will perform Diaphragmatic breathing after the test meal.
223474228|NCT03912636|BEHAVIORAL|Deep Slow Breathing|Subjects will perform Deep Slow Breathing after the test meal.
223474229|NCT03912636|BEHAVIORAL|Normal breathing|Subjects will perform Normal Breathing (as a control) after the test meal as a control.
223474230|NCT04278352|BEHAVIORAL|Mindfulness Based Relapse Prevention|The intervention is a group skills training program that is delivered once weekly for eight weeks. Content focuses on mindfulness and cognitive-behavioral relapse prevention skills, including psychoeducation, experiential exercises, and between session homework assignments.
223474231|NCT05739916|DRUG|DA-1229_01 5/1000mg (Before)|single dose administration (one tablet once a day)
223474232|NCT05739916|DRUG|DA-1229_01 5/1000mg (After)|single dose administration (one tablet once a day)
223474233|NCT00718601|DRUG|Imetelstat Sodium (GRN163L)|25% dose escalation infused over 2 hours weekly
223474234|NCT02528032|OTHER|Echographic evaluation of heart function|Echocardiographic data collection and analysis, not fully exploited at present
224161488|NCT01810380|DRUG|Placebo|Once daily as tablets and capsules, orally
224161489|NCT01810380|DRUG|Brexpiprazole|2-4 mg/day, once daily, tablets, orally
224161490|NCT01810380|DRUG|Quetiapine extended release|400-800 mg/day, once daily, encapsulated tablets, orally
224161491|NCT00614991|DRUG|Raltegravir|400mg BID
224161492|NCT00614991|DRUG|Fosamprenavir|1400mg BID, 700 mg BID or 1400 mg QD
224161493|NCT00614991|DRUG|Ritonavir|100 mg BID or QD
224161494|NCT00578422|OTHER|Ivus (Intravascular Ultrasound) of Amputation Specimens|Human lower extremity arterial segments will be obtained at autopsy and from amputation specimens. All imaging studies and vessel fixation will be undertaken immediately upon vessel procurement; in most cases this will occur within 2 hours of dissection and within 24 hours of death. The ex vivo portion of the study will make use of 150 excised vessels obtained over a 48-month period from randomly selected autopsy cases. From these vessels we expect to collect data from a minimum of 560 plaques
223474235|NCT01351636|DRUG|Arotinolol Hydrochloride|Antihypertensive medications plus arotinolol hydrochloride, dosage of arotinolol hydrochloride from 2.5mg bid, 2 days later increased to 5mg bid or 10mg bid, for 18 months
224304423|NCT04585880|OTHER|Virtual Collaborative Care Clinic|The vCCC will operate under a collaborative care agreement with the Primary Care Physicians as an extension (and not a replacement) of their care. Trained clinical pharmacists will monitor blood pressure and prescribe and adjust medications under the license of, and in communication with, the patient's Primary Care Physician. As part of the Primary Care Physician's team and per Primary Care Physician's directions, the pharmacists may coordinate blood pressure management with other clinicians such as cardiologists or nephrologists co-managing patients blood pressure.
223474236|NCT01351636|DRUG|Non arotinolol group|Antihypertensive medications without arotinolol for 18 months
223474237|NCT01987115|PROCEDURE|Fascial manipulation|Group will receive fascial manipulation at 3 centers of coordination (C.C) at: 1. C.C above the pronator teres muscle. (M.F unit of INTRA-CUBITUS), 2. C.C above proximal part of pronator quadratus muscle, between the palmaris longus and the flexor carpi radialis tendons (M.F unit of INTRA-CARPUS), 3. C.C in the mid-palmar region between metacarpus 3-4 (M.F unit of INTRA-DIGIT).4. C.C. over the muscle belly of Ext. Digit and Ext. Pollicis Longus (M.F unit of EXTRA-CARPUS).
223474238|NCT01987115|PROCEDURE|Traditional physiotherapy|Group will receive U.S. treatment delivered to the A1 pulley area (3 Megahertz, over 1cm², for 5 minutes), Metacarpophalangeal and Proximal interphalangeal joint mobilization (for 5 minutes), eccentric stretching, and self exercises at home (self-stretch and self-massage).
223474239|NCT05627115|DRUG|Tislelizumab, AVD, Radiotherapy|"GROUP A: Early stage disease without adverse features in CMR: 2 further cycles tislelizumab then radiotherapy then 200mg IV tislelizumab once every 3 weeks until a maximum of 2 years total treatment. PET-CT (PET2) 12 weeks after radiotherapy.~GROUP B: Early stage disease with adverse features in CMR: 2 cycles of AVD plus tislelizumab then radiotherapy. PET-CT (PET2) 12 weeks after the completion of radiotherapy.~GROUP C: All early stage disease not in CMR: 4 cycles of AVD plus tislelizumab then PET-CT and radiotherapy. PET-CT 12 (PET2) weeks after radiotherapy.~GROUP D: Advanced stage disease in CMR: 4 cycles of AVD plus tislelizumab then radiotherapy at investigator's discretion. PET-CT (PET2) 12 weeks after radiotherapy.~GROUP E: Advanced stage disease not in CMR: 6 cycles of AVD plus tislelizumab then PET-CT then radiotherapy at investigator's discretion. PET-CT (PET2) 12 weeks after radiotherapy."
223474240|NCT02873689|DRUG|Dexlansoprazole|Dexlansoprazole delayed-release capsule
223581467|NCT05805748|BEHAVIORAL|serious game rehabilitation|The SG rehabilitation was proposed to be played four times per week for three weeks, for a total of 12 sessions, with 15 min per session (= 60 minutes per week). Conventional rehabilitation comprised five sessions of 45 min of neuropsychological rehabilitation using classical exploration training (= 225 minutes per week).
224161495|NCT00578422|PROCEDURE|IVUS (Intravascular Ultrasound)|Standard diagnostic arteriographic images will be obtained. Appropriate oblique views will be acquired at the common femoral bifurcation. Next, IVUS will be performed obtaining ultrasound data from a 10 cm lower extremity artery.
224161496|NCT06216106|PROCEDURE|Prepectoral breast reconstruction with polyurethane implants|Breast reconstruction in the prepectoral plane without elevate the pectoralis major muscle. We choose this type of reconstruction only in patients with mastectomy flap thickness of plus then 0.5 cm. We usally use silicone implants covered by an external layer of polyurethane so not to put directly in contact the silicone with the subcutaneus tissue.
224161497|NCT04202276|OTHER|diet assessment|Food frequency questionnaire to investigate differences in diet of children and adolescents with GERD compared to the age- and sex matched control group.
224161498|NCT03975530|BEHAVIORAL|Precision Family Spirit|Family Spirit home-visiting sites from the Inter-Tribal Council of Michigan (ITC of MI) will be selected based on comparability and randomized to provide either Standard Family Spirit or Precision Family Spirit to their clients. Both groups will receive educational Family Spirit lessons. Each lesson will take about 60 minutes. Participants will receive a customized version of Family Spirit that is unique to your circumstances. The two sites randomized to provide the Precision approach will receive additional training on how to provide it.
224304424|NCT05659693|BEHAVIORAL|digital literacy education specific to menopause|Education; It is planned as 5 sessions in the form of presentation, homework, scenario and sending reminder messages. The training is planned to last approximately 20 minutes with a power point presentation prepared by the trainer. The survey will be evaluated in the first session. Women will be told what digital literacy is, why it is important, how to verify information and resources, security of accounts, resources, money and devices, access to information, understanding and valuing information. A screening and access to information session will be held with a scenario prepared on menopausal symptoms, taking into account the variables of information and resource security, access to information, understanding and valuing information, with examples on the digital platform. The woman will be given a scenario homework on menopausal symptoms. Interim evaluation will be made in the fourth week of the training. The final evaluation will be made in the fifth session.
224304425|NCT05301153|DIAGNOSTIC_TEST|real time PCR , ELISA|Real-time RT PCR will be performed on complementary DNA produced from 250 ng total RNA using the following primers Interleukin 37, F: 59-CAGTGAGGTCAGCGATTAGGAA-39 R: 59-TTAGTGAGCAGGTTTGGTGTTTT-39 b-actin, F: 59-CACCATTGGCAATGAGCGGTTC-39 R 59-AGGTCTTTGCGGATGTCCACGT-39. Detection of autoantibodies to muscle specific kinase (MuSK) and low-density lipoprotein receptor-related protein 4 (LRP4) serum levels by ELISA
223474241|NCT02873689|DRUG|Placebo|Dexlansoprazole placebo-matching capsules
223474242|NCT00350545|DRUG|Rituximab|375 mg/m2;IV infusion once weekly for four doses (days 1,8,15,22); option for second 4-week course at week 9
223474243|NCT00350545|DRUG|Prednisone|1 mg/kg; po per day with taper
223474244|NCT00350545|DRUG|Cyclosporine A|trough 200-300 or lower; po
223474245|NCT00350545|DRUG|tacrolimus|trough 5-10 or lower; po
223474246|NCT03470467|OTHER|No intervention|No intervention planed
223474247|NCT03925155|DRUG|EZ scrub vaginal chlorhexidine 4% solution|Patients will be randomized to receive one of two solutions. Either chlorhexidine 4% solution or standard of care 10% provodine-iodine vaginal solution
223581468|NCT02663141|DRUG|Losartan|
223581469|NCT02663141|DRUG|Intravitreal bevacizumab|
223581470|NCT02663141|DRUG|Placebo|
223581471|NCT01173029|DRUG|Anti-hypertensive drug treatment|Anti-hypertensive drug treatment was non-investigational. Drug regimen, including which drug and the number of drugs prescribed, was left at discretion of the physician who carried primary assistance.
223474248|NCT03925155|DRUG|10% provodine-iodine vaginal preparation|Patients will be randomized to receive one of two solutions. Either chlorhexidine 4% solution or standard of care 10% provodine-iodine vaginal solution
223474249|NCT05992441|OTHER|SCALE DEVELOPMENT STUDY|"The study to be carried out is a scale development study. The steps to be followed for the scale development study are as follows;~1. Creating an item pool by making use of the literature review on the subject,~2. Questioning the relevance of the prepared question pool to the subject to be measured with the Expert Evaluation Form by experts in the field,~3. Pilot application,~4. Switching to the main study after the pilot application,~5. After the factor and item analyzes, the final arrangements regarding the item and form of the scale will be completed.~As a result of this study, an awareness scale related to physiotherapy will be created for individuals with breast cancer."
223474250|NCT03772223|DRUG|Treatment A (Budesonide/Albuterol Sulfate metered dose inhaler)|Randomized participants will receive a single-dose (2 inhalations, 2 x 80/90 µg).
223581472|NCT05356338|BEHAVIORAL|Pilot Intervention to reduce SSB consumption in children and families enrolled in WIC|"A 6-month intervention based on the use of 5 components: 2 educational videos, provision of a water-promotion toolkit, a mobile phone application (app), a series of 14 computerized interactive voice response (IVR) phone calls to parents and 2 counseling sessions by a WIC nutritionist to compare families' SSB's consumption behaviors"
223581473|NCT02177019|OTHER|Personalized health plan|
223581474|NCT03028987|BIOLOGICAL|Fluzone®|Fluzone® Quadrivalent (IIV4; inactivated influenza virus vaccine)
223581475|NCT03028987|BIOLOGICAL|FluMist®|FluMist® Intranasal Spray (quadrivalent, live, attenuated influenza vaccine)
223581476|NCT03420105|OTHER|Neuropsychological, psycho-pathological and quality of life assessments|Patients and Healthy volunteers perform neuropsychological, psycho-pathological and quality of life assessments, and sleep tests
223581477|NCT03420105|DRUG|Hormonotherapy|Adjuvant hormone therapy
223581478|NCT01287195|DRUG|Oral OKT3|1 mg or 2 mg Oral OKT3 will be given orally to participants once daily for 30 days
223581479|NCT01287195|DRUG|Omeprazole|20 mg Omeprazole will be given orally to participants once daily for 30 days
223581480|NCT03562793|BEHAVIORAL|Communication and Activation in Pain to Enhance Relationships and Treat Pain with Equity (COOPERATE)|. COOPERATE seeks to improve patient activation in minority Veterans with chronic pain by focusing on two major skill sets: 1) goal clarification and prioritization, and 2) communication skills (Table 1). By understanding, clarifying, and prioritizing goals, and having the skills to communicate their goals, priorities, and preferences to providers, Veterans will gain knowledge, confidence, and skills to be actively involved in managing their chronic pain. The intervention consists of 6 total sessions delivered individually over 12 weeks: 4 sessions focused on teaching skills related to goal clarification/prioritization and communication (30-minutes each), delivered weekly for the first 4 weeks, plus 2 booster sessions (20-25 minutes each) delivered once per month for the next 2 months.
223581481|NCT04033094|DRUG|MorphaBond ER|This was a retrospective, non-interventional study. Previous users of branded and generic products (tablets or capsules) with ER and immediate release (IR) release type formulations of oxycodone, oxymorphone, hydromorphone and morphine (except MorphaBond).
223581482|NCT04033094|DRUG|Comparator Drug|This was a retrospective, non-interventional study. Previous users of the MorphaBond ER brand of ER morphine sulfate with A-D labeling, by prescription or non-prescription.
223581483|NCT06103318|BEHAVIORAL|ICOgnition|"The ICOgnition intervention for breast cancer patients consists of three levels:~Level 1: Monthly assessments using FACT-Cog PCI and Cognifit. Scores \<54 (PCI) or ≤250 (Cognifit) escalate to Level 2.~Level 2: Specialized content includes Cognitive Psychoeducation, validating experiences and improving health literacy; Behavioral Guidance, offering practical strategies for daily tasks; and Embracing Cognitive Deficits, promoting self-compassion and acceptance through mindfulness and metaphors.~Level 3: Online cognitive training focuses on enhancing cognitive skills through gaming exercises, completing the comprehensive intervention approach."
223581484|NCT02474537|DRUG|INC280|Single 200 mg dose INC280
223581485|NCT05700253|DEVICE|Cooled Radiofrequency Ablation|Image-guided genicular nerve ablation will be performed with the Coolief System (COOLIEF\* CRFA; Avanos Medical).
223581486|NCT05700253|DEVICE|Hyaluronic Acid Injection|Synvisc-One (\[Hylan G-F 20\]; Sanofi) will be administered as a single intra-articular dose (6 mL).
223581487|NCT00506597|DRUG|Erwinase|If allergic to E.Coli Asparaginase = 1 Dose (20,000 Units/m\^2) Daily; If allergic to Pegylated Asparaginase = 6 Doses (25,000 Units/m\^2) Daily Every Other Day. Received as an injection through a needle in vein, under the skin, or in muscle.
223581488|NCT04425785|OTHER|Physical Exercise Program|A structured exercise program
223581489|NCT04425785|BEHAVIORAL|Cognitive Behavioural Therapy|A structured cognitive behavioural therapy program
223581490|NCT03926312|DEVICE|Smart device-based cardiac rehabilitation|A smart device coupled with remote monitoring will be used to increase physical activity of patients after myocardial infarction with a history of low physical activity.
223581491|NCT03328416|DEVICE|Augmented Reality|The neurointerventional radiologist will have imaging information projected on a headset in addition to on the conventional monitors that hang from the procedure suite ceiling.
224161499|NCT03975530|BEHAVIORAL|Standard Family Spirit|Family Spirit home-visiting sites from the Inter-Tribal Council of Michigan (ITC of MI) will be selected based on comparability and randomized to provide either Standard Family Spirit or Precision Family Spirit to their clients. The investigators will select four sites and randomize two of them to Standard Family Spirit and two to Precision Family Spirit.Both groups will receive educational Family Spirit lessons. Each lesson will take about 60 minutes. Participants will receive Family Spirit lessons based on a standard program schedule.
223474251|NCT03772223|DRUG|Treatment B (Budesonide metered dose inhaler)|Randomized participants will receive a single-dose (2 inhalations, 2 x 80 µg).
223581492|NCT00870194|DRUG|exenatide and sitagliptin|exenatide-subcutaneous injection, 5mcg (4 weeks) followed by 10mcg (16 weeks), twice a day; sitagliptin-100mg tablet orally once a day
223581493|NCT00870194|DRUG|exenatide and placebo|exenatide-subcutaneous injection, 5mcg (4 weeks) followed by 10mcg (16 weeks), twice a day; placebo-tablet orally once a day
223581494|NCT00506194|DRUG|Insulin|
223581495|NCT00506194|DRUG|OAD|Gliclazide-MR, Metformin, Glimepiride
223581496|NCT02322190|PROCEDURE|Extracorporeal Photopheresis (ECP)|Twice weekly for 1 month or Twice every other week for 2 months or Twice during one week per month for 4 months for a total of up to 7 months of treatment.
224161500|NCT05651984|DEVICE|Comparison between communication board and eye tracking|The comparison between the communication board and eye tracking, conducted as a crossover, generates a randomization of the patients (from the cross-sectional part) into two groups and the communication interfaces were divided into two time periods: group A received eye tracking/communication board sequence and group B received communication board/eye tracking sequence.
224161501|NCT05834699|BIOLOGICAL|HER2 expression of circulating tumor cells|Detect HER2 expression of circulating tumor cells dynamically during ADC-based treatment in HER2-low ABC
224161502|NCT03823430|DIAGNOSTIC_TEST|Pupillometry|Pupillar diameter variation measurement
223474252|NCT03772223|DRUG|Treatment C (Albuterol Sulfate metered dose inhaler)|Randomized participants will receive a single-dose (2 inhalations, 2 x 90 µg).
223581497|NCT02322190|DRUG|Methoxsalen|Sterile solution used in conjunction with photopheresis procedure.
223581498|NCT04787068|BEHAVIORAL|Occupational Therapy support|Intervention include (a) didactic education about diseases; (b) the use of errorless techniques to improve assistance for CR's Activities of Daily Living (ADL), Instrumental ADL, and communication tasks; (c) the use of incentives (e.g., providing a favorite scented shampoo); (e) use of a schedule/calendar on a computer, cell phone and/or blackboard in CR's home to coordinate caregiving tasks for family members; (f) suggesting more frequent PACE daycare visits or use of a nearby PACE, having a snack or short game to prevent going to bed right after dinner); (d) use of the Buffalo Functional Exercise for strengthening ( a home-based exercise developed for PACE by the PI and shown to be effective in preventing falls)
223581499|NCT00252460|DEVICE|Computed Tomography Scan and Magnetic Resonance Imaging|
223581500|NCT04167215|PROCEDURE|superior gluteal artery flap and lumbar artery falp|Doppler ultrasound will be used to confirm location of the superior gluteal artery perforators or lumbar perforators . Flaps will be designed to allow deepithelialization and dissection . After complete sketolization of the flap it will be analyzed for viability and trimmed to achieve the desired bulk.
223581501|NCT04167215|PROCEDURE|The gluteal pocket|pocket will be created by undermining in a plane just superficial to the gluteal muscle from the lower body lift line inferiorly extending to within 5 cm of the inferior gluteal crease. should extend only over the medial half of the buttock.
223581502|NCT04167215|PROCEDURE|infragluteal dermal lifiting flap|dermal flap will be performed for lifting the ptotic buttocks with ill-defined infragluteal fold. This deepithelialized dermal flap allows for the creation of a well-defined stable infragluteal fold through an incision of the infragluteal fold and exposure of ischial tuberosity and anchor it to the ischial tuberosity.
223581503|NCT03854890|DRUG|Indocyanine Green|Indocyanine Green will be injected to the submucosal layer around the lesion one day before surgery.
223581504|NCT00990145|DRUG|EDP-322|
223581505|NCT05978635|BEHAVIORAL|Group A Standard 4 deep breaths measured in milliliters from the ventilator.|Tidal volume breath measured in milliliters
223581506|NCT05978635|BEHAVIORAL|Group B Coached 4 deep breaths measured in milliliters from the ventilator|Coached tidal volume breath measured in milliliters
223581507|NCT01656629|DRUG|Teriparatide|20 mcg subq daily for 3 months
223581508|NCT01656629|DRUG|Alendronate|70 mg weekly for 3 months
223581509|NCT01656629|DIETARY_SUPPLEMENT|calcium and vitamin D|
223581510|NCT03304067|BEHAVIORAL|Tueo Program|The asthma management solution utilizes devices (2 to attach on the child's bed and 1 for data transmission), which collect various metrics for a tailored smartphone application experience. The smartphone application provides access to view metrics from the devices, educational and clinical context content, and an asthma coach.
223581511|NCT06358560|OTHER|Therapeutic exercises|Rehabilitation exercises designed to achieve the treatment goal
224161503|NCT01985386|DIETARY_SUPPLEMENT|GDS capsule with meal|GDS capsule with meal
223581512|NCT01778322|PROCEDURE|Intracranial aneurysm embolization|Treatment of intracranial aneurysms
224161504|NCT01985386|DIETARY_SUPPLEMENT|Ferrous sulfate with meal|Ferrous sulfate with meal
224161505|NCT04907812|DRUG|Tranexamic acid|Patients will receive 1 gram dose of intravenous (IV) tranexamic acid mixed with 50cc 0.9% sodium chloride before your surgery and 1 gram dose of intravenous (IV) tranexamic acid mixed with 50cc 0.9% sodium chloride 3-6 hours after your first dose on the day of your surgery
224304426|NCT02387983|DRUG|Posaconazole|Posaconazole 300 mg solid oral tablet
223474253|NCT03143023|DRUG|arginine toothpaste|acid neutralizer toothpaste
223474254|NCT03143023|DRUG|fluoride toothpaste|bactericidal toothpaste
223474255|NCT01794702|DRUG|Decitabine|Phase I and II - 20 mg/m2 by vein daily for 5 days (days 1-5)
223474256|NCT01794702|DRUG|Idarubicin|Phase I and II - 10 mg/m2 by vein daily for 3 days (days 6-8)
223581513|NCT04896203|PROCEDURE|rotational thromboelastometry|Viscoelastometric method useful to study the kinetics of clot formation and fibrinolysis, providing a global information of both the cellular component and the pro and anticoagulant proteins, as well as the interactions between both components.
223744011|NCT02063516|DEVICE|Guardian Laryngeal Mask|Guardian Laryngeal Mask: The Guardian Laryngeal Mask (Ultimate Medical Pty Ltd, Richmond, Vic, Australia) is a new silicone-based single-use extraglottic airway device that forms a seal with the glottis for ventilation and with the hypopharynx for airway protection, and provides a gastric drainage port. In addition, it has a port for suctioning material from the hypopharynx and a pilot balloon valve that constantly monitors intracuff pressure. In the following randomized, non-crossover study, the investigators test if oropharyngeal leak pressures differed between the Guardian Laryngeal Mask and the LMA proseal in paralysed, anaesthetised patients.
223744012|NCT02063516|DEVICE|Proseal Laryngeal Mask Airway|Proseal Laryngeal Mask Airway: Silicon based, reusable, modified dorsal cuff and drainage tube
224305004|NCT00554190|DEVICE|AdvaCoat sinus gel|A sterile,viscoelastic, bioresorbable gel composed of highly purified hyaluronan, a naturally occurring constituent of tissues in the body
224305005|NCT00554190|DEVICE|Merogel Injectable|Bioresorbable hyaluronic acid product
224305006|NCT00616798|DRUG|RO4917838|10mg po daily
224305007|NCT00616798|DRUG|RO4917838|30mg po daily
223474257|NCT01794702|DRUG|Cytarabine|Phase I and II - 1 g/m2 by vein daily for 5 days (days 6-10)
223474258|NCT01794702|DRUG|Clofarabine|"Phase I Starting Dose - 15 mg/m2 by vein daily for 4 days (days 6-9)~Phase II Starting Dose - Maximum tolerated dose from Phase I (number of days selected based on Phase I portion)."
223474259|NCT00775879|DRUG|Induction with Sevoflurane|
224305008|NCT00616798|DRUG|RO4917838|60mg po daily
223474260|NCT01729195|PROCEDURE|A ciprofloxacin containing bioabsorbable PLGA bone screw|The syndesmosis injury will be fixed the antibiotic releasing bioabsorbable bone screw or a standard metal screw. After surgery, the ankle will be immobilized in a cast for 6 weeks. The metal screw will be surgically removed at 8 weeks. The bioabsorbable screw will be left in place.
223474261|NCT00948545|OTHER|Observational study - there is no intervention|Observational study - there is no intervention
223474262|NCT04908618|OTHER|digital impression for normal abutment|Accuracy of scan body impression
223474263|NCT04908618|OTHER|open tray impression|Accuracy of open tray impression
223474264|NCT04908618|OTHER|closed tray impression|Accuracy of closed tray impression
223474265|NCT04059250|DEVICE|Nobio composite|Nobio has developed a bactericidal composite, which does not leak out the bactericidal nano fillers
223474266|NCT04059250|DEVICE|traditional composite|traditional composite which has no bactericidal activities
223474267|NCT01341704|BIOLOGICAL|MSP3-LSP/AlOH|"30 µg of test vaccine MSP3-LSP/AlOH, administered by subcutaneous route according to the following schedule:- Primary administration: Three doses administered at 4 weeks interval: D0, D28 (± 2 days), D56 (± 4 days)~Secondary administration (Boost):~Year 1: One dose 3 months after the third dose Year 2: Two doses, given exactly one year after the date corresponding to the third dose and the first boost given during Year 1"
223474268|NCT01341704|BIOLOGICAL|Verorab Vaccine|The Verorab rabies vaccine will be given as control for the primary series of the experimental vaccine. It consists of inactivated rabies virus produced in vero cells (Wistar Rabies PM/W138 1503-3M (inactivated). Manufacturer SANOFI PASTEUR SA. Presentation is 0.5 ml per dose in a pre-filled syringe.
223474269|NCT01341704|OTHER|0.9% NaCl/Normal Saline|0.5 ml per dose; to be given as control for the secondary/booster doses of experimental vaccine
223474270|NCT02265523|OTHER|Cycle ergometer|The Viscus V1.5 is a kinetic flywheel cycle ergometer that will allow participants' pedal revolutions to be tracked as well as time of use.
223474271|NCT03191968|BEHAVIORAL|Supervised Physical Activity Plus Behavioral Counseling|In addition to supervised physical activity, behavioral counseling sessions will be delivered with a PA specialist based on the Multi-process Action Control (M-PAC) framework and include behavior change techniques addressing information regarding the consequences, social support, goal setting, self-monitoring, cues and prompts, barrier identification, intention formation, planning, and habit and identity formation
223474272|NCT03191968|BEHAVIORAL|Supervised Physical Activity Plus Exercise Counseling|In addition to the supervised exercise sessions, standard exercise counseling will be delivered by a PA specialist to teach proper PA and resistance training techniques, how to monitor intensity, and to progress PA safely and effectively to achieve the public health PA guideline.
223474273|NCT02327455|PROCEDURE|Stress Dobutamine Echocardiographic using 4DE System|Subjects will undergo their clinically indicated stress dobutamine echocardiographic studies using our standard clinical graded dobutamine stress imaging protcol, employing the iE33 4DE system.
223474274|NCT00434629|DRUG|Bexxar|"Day 0: Tositumomab, IV (in the vein) followed by test dose of 131I-Tositumomab, IV (in the vein) to determine treatment dose of 131I-Tositumomab.~1-2 weeks after Day 0: Tositumomab, IV (in the vein) followed by therapeutic dose 131I-Tositumomab (in the vein)."
223581514|NCT05558215|OTHER|Otago Exercise Program|"The Otago Exercise Program (OEP) is a CDC endorsed evidence-based falls prevention program for older adults. It has not been well studied with individuals with dementia. It is comprised of a brief warm up/flexibility series, lower extremity strengthening, and balance exercises. The same menu of exercises is used for all participants, but exercises are progressed based upon individual performance. For the purposes of this study, three 25-minute video recorded versions of OEP will be rotated for use, all of which include brief flexibility activities, strengthening, and balance exercises. Strengthening exercises will be limited to body weight resistance for ease of instruction, safety, and consistency. Balance exercises involve changes in base of support in static and dynamic contexts, with challenge progressively increased by decreasing arm support during training (from 2-hands, to 1-hand, to no hands)."
223581515|NCT02675335|DRUG|Sitagliptin|
223581516|NCT02675335|DRUG|Placebo|
223581517|NCT01685983|DRUG|Abiraterone acetate|Type=exact number, unit=mg, number=250, form=tablet, route=oral. Patients will receive 4 tablets of abiraterone acetate at least 1 hour before a meal or 2 hours after a meal any time up to 10 pm every day.
223581518|NCT01685983|DRUG|Prednisolone|Type=exact number, unit=mg, number=5, form=tablet, route=oral. Patients will receive 1 tablet of prednisolone twice daily.
223744013|NCT05897073|BEHAVIORAL|Time-restricted eating intervention|Participants will be asked to reduce their daily eating time window to a maximum of 8 hours/day. They can choose when to begin their eating window but will be advised that the last meal should be completed before or at 20:00 hours. No calorie-containing food or beverage intake will be allowed outside the 8 hours eating window.
224069687|NCT02373280|DRUG|7 day tailored PPI triple therapy (clarithromycin-containing triple therapy)|the participants received PPI based triple therapy\[Esomeprazole 40 mg bid 7 days (D1-D7)+amoxicillin 1000mg bid 7 days (D1-D7)+clarithromycin 500mg bid 7 days (D1-D7)\]
223474275|NCT05907265|BEHAVIORAL|Behavioral: ONCOBrain_ImmersiveVR|A multimodal and digitally-based cognitive training, physical exercise and mindfulness intervention delivered face to face and through 360MK Virtual Reality technology
223474276|NCT05907265|BEHAVIORAL|Behavioral: Control_Condition|Traditional paper or pdf format multimodal intervention that will combine cognitive, mediation and physical activities.
223474277|NCT00413023|DRUG|GW679769|
223474278|NCT04127370|PROCEDURE|Bariatric Surgery|The Role of Bariatric Surgeries in Management of Nonalcoholic Fatty Liver Disease
224069688|NCT02373280|DRUG|7 day moxifloxacin based triple therapy [Esomeprazole, Moxifloxacin, Amoxicillin]|moxifloxacin triple therapy \[Esomeprazole, 40 mg bid 7 days (D1-D7)+Moxifloxacin, 400 mg qd 7 days (D1-D7)+Amoxicillin 1 g bid 7 days (D1-D7)\].
224069689|NCT02373280|DRUG|7 or 14 days tailored EBMT therapy group (bismuth quadruple therapy)|bismuth quadruple therapy \[Esomeprazole, 40 mg bid 7 days (D1-D7)+amoxicillin 1 g bid 7 days (D1-D7)+clarithromycin 500mg bid 7 days (D1-D7)\], bismuth quadruple therapy \[Esomeprazole, 40 mg bid 7 days (D1-D7)+Tri potassium dicitrate bismuthate, 300 mg qid 7 days (D1-D7)+Metronidazole, 500 mg tid 7 days (D1-D7)+Tetracycline 500 mg qid 7 days (D1-D7)\] If there was no metronidazole resistance, the treatment was 7 days in duration. If metronidazole resistance was evident, treatment duration was 14 days.
224069690|NCT02905786|DEVICE|Cobas h232 (Roche Diagnostics)|NT-proBNP point-of-care test
223474279|NCT01697241|OTHER|Supervised exercise|Patients in the exercise groups will receive two types of exercise, delivered on separate days. One type of exercise is individualized, goal-based neuromuscular training (NEMEX-TJR) in groups with progression guided by the patient's neuromuscular function. The other type of exercise is individualized, intensive resistance training (RT) in groups with each exercise progression guided by load. Each of the two types of exercise will be offered weekly during the 12 week intervention period in sessions lasting 60-70 minutes. Thus, the entire exercise intervention consists of 24 sessions
223474280|NCT01697241|OTHER|Patient education|The patient education program is designed to educate the patients about hip osteoarthritis during 3 sessions of 90 min. duration
223581519|NCT06179316|PROCEDURE|Robot Assisted Radical Prostatectomy|Performing radical prostatectomy operation using robotic equipment while preserving bilateral nerve bundles
223581520|NCT06246071|DRUG|TYK-00540|TYK-00540 PO, BID
224161506|NCT04907812|PROCEDURE|Surgery|This will include regional anaesthesia, tourniquet inflation to 250mmHg and perioperative antibiotics. At the conclusion of the procedure hemostasis will be achieved followed by standard closure technique. There will be three separate surgical groups that will undergo the outlined study protocol: 1) Distal radius fractures will be treated with open reduction from a volar approach only technique 2) Mild dupuytren's: a. Low: i. MCP joints \<50 contracture ii. PIP joints \<40 contracture b. 1-2 fingers involved 3) Severe dupuytren's a. High: i. MCP joints \>50 degree contracture ii. PIP Joints \>40 degrees contracture b. \>2 fingers involved
224161507|NCT06166290|PROCEDURE|CO2 LASER Vaporisation|The CO2 LASER vaporization procedure is described as follows. Patient positioning will be done, and patient will be anesthetized. Local infiltration with 2% lidocaine, nerve block or general anesthesia will be given. The surgical field will be disinfected and draped. The perianal and anal area will be investigated for lesion. CO2 LASER from 20 cm distance in a continuous wave mode and 20 W power will be applied. After warts melts, necrotic tissue will be removed. After the operation was completed, residual debris will be wiped away with a piece of moist gauze. Bacitracin cream applied over the treated areas. Upon discharge acetaminophen 1-gram q8 and Ibuprofen 600 q8 for pain.
224161508|NCT06166290|PROCEDURE|Electrosurgical Fulguration|The procedure is described as follows. Patient will be administered regional or general anesthesia, placed in prone jack-knife position. Prepping and draping will be done. The perianal and anal area will be investigated for lesion. The lesions will be excised, and the bases will be fulgurated. Electrosurgery device will be used in monopolar setting (30 Cut mode, 30 Coag mode). After procedure local analgesics total MERCAINE/EPI 0.25% 20 ml on both sides of the lesion. Bacitracin cream applied over the treated areas. Upon discharge 1000 mg of Tylenol every 8 hours along with 600 mg of ibuprofen every 8 hours.
224161509|NCT01054612|OTHER|Tissue Sectioning via Electro Erosion Process|Focused RF energy can be used to produce consecutive thin sections of fresh tissue for immunohistochemical and nucleic acids analysis by electro-dissociation without thermal damage, ultimately allowing high resolution reconstruction of gene and protein expression patterns of large tissue specimens in 3D.
224161510|NCT01238952|DRUG|NK012 and carboplatin|NK012 and carboplatin via infusion once every 28 days
224161511|NCT02590640|DEVICE|Repetitive transcranial magnetic stimulation, MagStim Rapid2|"This study plans to learn more about the way an experimental technique called transcranial magnetic stimulation (TMS) affects a specific part of the brain, called the insula. Some research suggests that this part of the brain plays an important role in craving. The investigators plan to study the effects of TMS using standard surveys and magnetic resonance imaging (MRI) of subjects' brain."
224305009|NCT00616798|DRUG|Placebo|po daily
223474281|NCT03653741|DRUG|Perampanel 6 MG|Perampanel is a drug approved and marketed in the USA for the treatment of epilepsy to prevent recurrent seizures. In a previous study, healthy volunteers have tolerated a single dose of perampanel at 6 mg quite well.
223474282|NCT02757196|DRUG|Rituximab plus methylprednisolone|rituximab （1000mg IV day1, week 3, week 17 , and week 19）
223474283|NCT02757196|DRUG|methylprednisolone|1mg/kg, oral or IV; begin to reduce at week 4, reduce 8mg every 2 weeks, then another 8 weeks later reduce 2-4mg every 2-4 weeks
223581521|NCT00686842|DRUG|VEGF inhibitor PTC299|20 mg capsules to be taken by mouth BID. Three dose levels will be evaluated: 40 mg, 80mg, and 100mg BID. Subjects will receive PTC299 in consecutive 28-day cycles for a maximum of 12 cycles.
223581522|NCT00686842|GENETIC|gene expression analysis|To describe the effects of PTC299 on viral gene expression and cellular gene transcription in KS tumor biopsies using real-time QPCR-based profiling.
223581523|NCT00686842|GENETIC|polymerase chain reaction|To describe the effects of PTC299 on viral gene expression and cellular gene transcription in KS tumor biopsies using real-time QPCR-based profiling.
223581524|NCT00686842|GENETIC|protein expression analysis|To describe the effects of PTC299 on viral gene expression and cellular gene transcription in KS tumor biopsies using real-time QPCR-based profiling.
223581525|NCT00686842|OTHER|immunohistochemistry staining method|To describe the effects of PTC299 on KS tumor biopsies with respect to expression of VEGF, the VEGFR-2 and -3, phospho-Akt, p53, HIF-1α and proliferation, measured by Ki-67 staining.
223581526|NCT00686842|OTHER|laboratory biomarker analysis|To describe the effects of PTC299 on KS tumor biopsies with respect to expression of VEGF, the VEGFR-2 and -3, phospho-Akt, p53, HIF-1α and proliferation, measured by Ki-67 staining.
223581527|NCT00686842|OTHER|pharmacological study|To describe the pharmacokinetics of PTC299 in patients with HIV-associated KS. To describe the effects of PTC299 on circulating VEGF, VEGFR and cytokine levels in patients with HIV-associated KS.
223581528|NCT00686842|PROCEDURE|biopsy|To describe the effects of PTC299 on KS tumor biopsies with respect to expression of VEGF, the VEGFR-2 and -3, phospho-Akt, p53, HIF-1α and proliferation, measured by Ki-67 staining.
223581529|NCT01443130|DRUG|Chloroquine|Chloroquine tablets contain 300 mg chloroquine base per tablet. Dosages: Chloroquine 1,500 mg base over 3 days twice during pregnancy or Chloroquine 600 mg loading dose followed by 300 mg orally once per week. Intermittant preventative treatment in pregnancy (IPTp) doses will be administered between weeks 20-28 and weeks 28-34 gestation, 4 weeks apart. Participants randomized to IPTp with chloroquine will require their second and third doses of chloroquine after the initial dose given in the clinic and those assigned to chloroquine chemoprophylaxis will require weekly doses.
223581530|NCT01443130|DRUG|Sulfadoxine-pyrimethamine|Sulfadoxine-pyrimethamine 3 tablets (1,500 mg sulfadoxine and 75 mg pyrimethamine) twice during pregnancy. Intermittant preventive treatment in pregnancy (IPTp) doses will be administered between weeks 20-28 and weeks 28-34, 4 weeks apart.
224161512|NCT02590640|DEVICE|Sham repetitive transcranial magnetic stimulation|Sham repetitive transcranial magnetic stimulation will be applied to the insula in smokers.
223581531|NCT05947630|DEVICE|Ankle Foot Orthosis (AFO)|3D treatment (AFO will be printed) versus traditional made AFO
223581532|NCT05947630|DEVICE|Knee Ankle Foot Orthosis (KAFO)|3D treatment (KAFO will be printed) versus traditional made KAFO
223581533|NCT03430271|OTHER|Physical Activity Intervention|Participants in this arm will complete exercise sessions 1 time per week for 24 weeks. An optional, second PA session will also be offered to PA participants. The exercise sessions will be multimodal and involve walking, lower extremity strengthening exercises, flexibility and balance training.
223581534|NCT03430271|OTHER|Healthy Aging Intervention|Participants will attend health education workshops on topics of relevance to older adults. Workshops will be offered weekly in a group setting, and participants will be required to attend biweekly.
223581535|NCT00189943|BIOLOGICAL|MVA-BN|
224161513|NCT04297410|RADIATION|177Lu-PSMA-I&T Radionuclide|Each patient will receive two single doses of 7.4 GBq 177-Lu-PSMA-I\&T treatments. The treatments will be given intravenously, 2 weeks apart starting 12 weeks prior to radical prostatectomy.
223581536|NCT06441292|PROCEDURE|AI-assisted|utilize advanced deep learning models that integrate multi-modal image fusion from multi-parameter ultrasound and MRI to guide the biopsy process
224161514|NCT03375723|OTHER|Information on anatomy and physiology, and breathing technique|The patients in the treatment group receive information about what acute PE is regarding anatomy and physiology, a review of what causes the respiratory associated pain in acute PE and also a review of the breathing technique to manage their respiratory associated pain. The given information is standardized and the patient also receives written information with both text and pictures. Patients in the treatment group will meet the physiotherapist at day 1, 2 and the patients also has an opportunity to see the physiotherapist or talk to her at the phone if there are any questions concerning the study.
223581537|NCT06441292|PROCEDURE|Non-AI-assisted|undergo standard prostate biopsy procedures without additional technological assistance
223581538|NCT03301064|BEHAVIORAL|Motivational Enhancement Therapy and Strengths Based Case Management (MET/SBCM)|Key objectives of the intervention are as follows: (1) identify health and personal goals and develop discrepancies between goals and current actions, (2) provide feedback related to risks associated with the participant's drinking (e.g., driving after drinking, liver disease), (3) provide normative feedback about the participant's pattern of drinking to alcohol use in the US among Latinos in the participant's age and gender group, (4) discuss reasons for drinking (e.g., feeling isolated from family, machismo, low status employment), (5) weigh the pros and cons of drinking and reasons to reduce drinking (e.g., to better provide for the family, improving family relationships), (6) negotiate a plan for reducing drinking and/or seeking help, (7) recognize personal strengths in the process of change (e.g., religiosity, desire to provide for family), and (8) identify needed social and health services and explore potential barriers (e.g., transportation).
223581539|NCT03301064|OTHER|Alcohol education brochure|The alcohol education brochure will address health risks associated with alcohol use and will provide information on low-risk drinking.
223581540|NCT05874349|BEHAVIORAL|General variables|Variables evaluated: age, sex, location, extent, and phenotype of IBD according to the Montreal classification, smoking habit, therapeutic requirements (immunosuppressants, biologics, steroids, salicylates, drugs that cause enteropathy such as olmesartan, valsartan, non-steroidal anti-inflammatory drugs, etc, ...).
223581541|NCT05874349|BEHAVIORAL|Clinical activity|Clinical activity was evaluated using the Harvey-Bradshaw index (HBI) (cut-off values: \<5, remission; 5-7, mild activity; 8-16, moderate activity; and \>16, severe activity).
223581542|NCT05874349|PROCEDURE|Laboratory data|Laboratory data: blood count, renal function and C-reactive protein, anti-transglutaminase antibodies, genetic study of celiac disease DQ2.5, DQ8, and DQ2.2, study of parasites, fecal calprotectin.
223581543|NCT05874349|PROCEDURE|Endoscopic and histology data|"Endoscopic signs suggestive of CD in UDT (presence of canker sores, ulcers, ...) and colon inflammatory activity was evaluated when available in patients with active disease using the Simple Endoscopic Score for CD (SES-CD: 0-2, remission; 3-6, mild endoscopic activity; 7-15, moderate endoscopic activity; and \>15, severe endoscopic activity).~Duodenal biopsies were assessed by 2 pathologists and were evaluated according to Marsh classification modified by Ensari \[Marsh 0, 1, 2 or 3\], the limit of normality for intraepithelial lymphocytes (IELs) per 100 enterocytes is set at 25, gastric biopsies (determination of H. Pylori by immunohistochemistry) and esophageal biopsies was recorded too.~Percentage of lymphocyte subpopulations are assessed by flow cytometry."
224161515|NCT03375723|OTHER|Usual care treatment|Usual care treatment given to patients with respiratory associated pain in acute PE, which is treatment with analgesics. The information on anatomy and physiology in acute PE is the usual information given by the physician at the ward that the patient is treated.
223581544|NCT01016314|DEVICE|Aspen Spinous Process System|Aspen Spinous Process System is an interspinous process fixation device
223581545|NCT01016314|DEVICE|Pedicle Screw Fixation|Pedicle Screws are used for the fixation of the spine
223581546|NCT00927615|DRUG|abciximab|0.25 mg/kg body weight (intracoronary)
223581547|NCT00927615|DRUG|abciximab|0.25 mg/kg body weight (intravenous)
223581548|NCT00084175|BEHAVIORAL|Behavior Therapy|
223581549|NCT02228343|OTHER|Ayurveda|Ayurveda includes meditation, yoga, breathing exercises, herbs
223581550|NCT05741047|OTHER|a2Milk skim milk powder|a2Milk skim milk powder (1L) containing A2 β-casein only
224161516|NCT04129086|DRUG|Ketamine plus usual care|Bolus of .35 mg/kg Infusion start @ 0.15 mg/kg/hr; titrate range is 0.1 - 0.25 mg/kg/hr for 24 to 48 hours after admission and each subsequent major surgery plus multi-modal pain therapy considered as standard of care. Standard of care medications include Acetaminophen 1000 mg po q6 hours, Naproxen 500 mg po q12 hours, Gabapentin 300 mg po q8 hours and Lidocaine patch q 12 hours.
224161517|NCT04129086|DRUG|Usual Care|Standard of care medications include Acetaminophen 1000 mg po q6 hours, Naproxen 500 mg po q12 hours, Gabapentin 300 mg po q8 hours and Lidocaine patch q 12 hours.
224305010|NCT00616798|DRUG|Standard antipsychotic therapy|As prescribed
224305011|NCT04820530|DRUG|Iptacopan (LNP023)|Taken orally b.i.d. Dosage supplied: 200mg Dosage form: Hard gelatin capsule Route of Administration: oral
223474284|NCT04085640|OTHER|Obturator nerve block with ropivacaine 0.2%.|20 milliliters of ropivacaine 2 mg/mL will be injected in the interfacial plane between the pectineus and external obturator muscles.
223474285|NCT04085640|OTHER|Obturator nerve block with isotonic saline|20 milliliters of isotonic saline will be injected in the interfacial plane between the pectineus and external obturator muscles.
223474286|NCT01493817|OTHER|laboratory biomarker analysis|Correlative studies
223474287|NCT03473990|OTHER|High-intensity interval training|2 minute warm up, followed by 5x1min HIT intervals separated by 90 seconds active recovery (walking on the spot) and then a 2 minute recovery period. The high intensity bouts will be a pyramid of exercises (star jumps, mountain climbers and on-the-spot sprints)
223474288|NCT04089722|DRUG|Deoxycholic Acid|The active ingredient in KYBELLA® is synthetic deoxycholic acid. Deoxycholic acid is a naturally occurring molecule in the body that aids in the breakdown and absorption of dietary fat.
223474289|NCT00720278|DRUG|0.15% azelastine hydrochloride 1644 mcg daily|0.15% azelastine hydrochloride 1644 mcg daily
223474290|NCT00720278|DRUG|0.1% azelastine hydrochloride 1096 mcg daily|0.1% azelastine hydrochloride 1096 mcg daily
223474291|NCT00720278|DRUG|Placebo|0 mcg Placebo daily
223474292|NCT02729857|DIETARY_SUPPLEMENT|SFA muffin|Muffin rich in saturated fat.
223474293|NCT02729857|DIETARY_SUPPLEMENT|PUFA muffin|Muffin rich in polyunsaturated fat.
223474294|NCT04656613|BIOLOGICAL|Gam-COVID-Vac|the Gam-COVID-Vac is combined 2 -component vector vaccine against the SARS-СoV-2-induced coronavirus infection
223474295|NCT04656613|OTHER|placebo|Placebo Comparator
223474296|NCT06017271|DIAGNOSTIC_TEST|CTPA (computed tomography pulmonary angiography)|The CTPA diagnosis suggest or did not suggest pulmonary embolism.
223474297|NCT04447859|DRUG|Semaglutide|Slow semaglutide titration group vs. label recommended titration group (16-week flexible vs. 8-week semaglutide titration)
223474298|NCT04447859|OTHER|label recommended titration|label recommended titration
223474299|NCT04364516|DRUG|Anticoagulation|Study of prognostic impact according to oral anticoagulation therapy (Vitamin K Antagonists or Direct Oral Anticoagulants)
223474300|NCT03103958|DIETARY_SUPPLEMENT|Probiotic|"Probiatop is a live microbial preparation saches containing 1g of the formulation composed by Lactobacillus acidophilus NCFM, 10⁹, Lactobacillus rhamnosus HN001 10⁹, Lactobacillus paracasei LPC-37 10⁹, Bifidobacterium lactis HN019 10⁹ combined with Polydextrose.~Subjects will take two sachets per day after diluting them in 100 ml of water"
223581551|NCT05741047|OTHER|Yili skim milk powder|Yili skim milk powder (1L) containing A1 and A2 β-caseins
223581552|NCT01107561|OTHER|Seldinger technique|Involves blind needle insertion through the skin into the cricoid membrane followed by insertion of the guide-wire and subsequent insertion of the tube over the guidewire
223581553|NCT01107561|DEVICE|Surgical Airway Approach|The classical open or surgical technique involves a vertical skin incision with blunt dissection and identification of the anatomy followed by incision of the cricoid membrane and tube insertion.
223581554|NCT05766033|OTHER|Enamel conditioning with a novel etchant paste|The maxillary and mandibular incisors, canines, and premolars for each patient will be conditioned using the Novel etchent paste on one side (experimental), while the other side (control) conditioned with a phosphoric acid gel 37% . Both systems use identical brackets and adhesive system (differ only with regard to the etching system).
223581555|NCT01950585|DRUG|Hydroxyurea|
223474301|NCT03103958|DIETARY_SUPPLEMENT|Placebo|"The placebo sachets were prepared by substituting equivalent amounts of Maltodextrin for the probiotic powder.~Subjects will take two sachets per day after diluting them in 100 ml of water"
223474302|NCT00368251|OTHER|Placebo|"* Pharmaceutical Form: Tablet~* Concentration: 2.5 mg, 25 mg and 50 mg~* Route of Administration: Oral use"
223474303|NCT00368251|DRUG|BRV 2.5 mg|"* Pharmaceutical Form: Tablet~* Concentration: 2.5 mg~* Route of Administration: Oral use"
223474304|NCT00368251|DRUG|BRV 25 mg|"* Pharmaceutical Form: Tablet~* Concentration: 25 mg~* Route of Administration: Oral use"
223474305|NCT00368251|DRUG|BRV 50 mg|"* Pharmaceutical Form: Tablet~* Concentration: 50 mg~* Route of Administration: Oral use"
223474306|NCT03699592|BEHAVIORAL|Reach Home and Read Toolkit|The toolkit currently includes one age-appropriate book along with a set of educational pamphlets explaining the importance home literacy. These educational materials focus on appropriate literacy milestones and descriptions of how parents can engage with their children around books. In addition, we will create an information sheet outlining zipcode-specific community literacy resources, including location and information on how to access the library, where to obtain low-cost books, and a schedule of literacy promotion activities in their community (e.g. community reading sessions). All materials will also be translated into Spanish by a certified interpreter, and will be reviewed to ensure that they are written at a fifth grade reading level. Additionally, EDCI families receiving this intervention will also receive an additional new book at each home visit conducted during the study period.
223474307|NCT05333211|DRUG|Ortho-R/PRP|Ortho-R® is a freeze-dried drug/biologic combination product containing a chitosan component and trehalose, a disaccharide that acts as a lyoprotectant during the lyophilization process and calcium chloride, which acts as a PRP coagulation agent.
223474308|NCT02281708|DRUG|vinorelbine plus cisplatin|"Drugs will be administered for 4 cycles, and should be administered at scheduled day +/- 3 days~* vinorelbine 25mg/m2 IV (Day 1, 8) q 3wks cisplatin 75mg/m2 IV (Day 1) q 3wks"
223581556|NCT04214886|DRUG|Fludarabine|Fludarabine is an anti-cancer drug acting as an antimetabolite that is used to treat leukemia and lymphoma cancers.
223581557|NCT04214886|DRUG|Cyclophosphamide|Cyclophosphamide is is an anti-cancer drug acting as an alkylating agent that is used to treat leukemia and lymphoma cancers.
223581558|NCT04214886|BIOLOGICAL|CD19-CD34 CAR transduced T cells|CD19-CD34 CAR transduced T cells are the subject's own immune cells that target B cell markers on cancer cells.
223581559|NCT00332865|BEHAVIORAL|Swallowing Exercises|Daily exercises
223581560|NCT06008483|DRUG|153-Sm-DOTMP (Samarium-153-DOTMP)|This is an open-label, unblinded, multi-center, dose-finding study of 153Sm-DOTMP (CycloSam®) to identify the MTD of 153Sm- DOTMP, given as a tandemly administered pair of doses to subjects with solid tumors visible on bone scan.
223581561|NCT01328340|OTHER|High-speed power training|exercised 3 times per week for 12 weeks. Each training session will consist of 3 sets of 12 to 14 repetitions at 40% of maximal strength
223474309|NCT03759925|OTHER|Nutritional Support|Weekly nutritional components: Month 1: equivalent of 3 meals/day in the form of 14 frozen meals, and breakfast bag with items to prepare 7 breakfast meals. Month 2: equivalent of 3 meals a day in the form of 7 frozen meals, grocery bags, and breakfast bags with items to prepare 7 breakfast meals. Month 3: the equivalent of 2 meals a day in the form of 7 frozen meals and grocery bags. Month 4: Participant choice to receive either 7 frozen meals or grocery bag with equivalent food for 1 meal a day. Month 5: Grocery bag with equivalent food for 1 meal a day Nutritional counseling component: Individual counseling with Registered Dietician monthly
223474310|NCT00313690|DRUG|Bortezomib, Docetaxel and Cisplatin|
223474311|NCT04457856|BIOLOGICAL|TJ003234 injection|Intravenous administration, single dose (0.3-1-3-10mg/kg) or multiple dose (1-3-6mg/kg, once every week, for 8 weeks)
223474312|NCT01627132|DRUG|Dasatinib|100mg QD
223474313|NCT01156519|OTHER|Salivary Cortisol|"* Day 1: 1st salivary cortisol at 23 hours~* Day 2: 2nd salivary cortisol at 23 hours and administration of dexamethasone (for overnight 1-mg dexamethasone suppression test)~* Day 3: serum cortisol at 8 am~* Between Day 4 and Month 3: if serum cortisol at 8 am \> 18ng/mL:~* Cortisol for 24 hours~* dexamethasone suppression test (2mg/j during 2 days)~* Cortisol and ACTH cycle~* Noriodocholesterol scintigraphy"
223581562|NCT01328340|OTHER|Slow-speed strength training|exercised 3 times per week for 12 weeks. Each training session will consist of 3 sets of 8 to 10 repetitions at 80% of maximal strength
224069691|NCT02905786|OTHER|Clinical audit and feedback|Clinical audit and feedback to detect previously unrecognized HF patients and inform GPs about their current quality of HF care
223474314|NCT04031495|DEVICE|central vein cannulation|central vein cannulation
223474315|NCT03312738|DRUG|Everolimus|Everolimus was formulated as tablets of 5 mg strength and was packaged into blister packs . Everolimus (two 5 mg tablets daily) was administered in a blinded manner by continuous oral daily dosing.
223474316|NCT03312738|DRUG|Exemestane|Commercially available exemestane was supplied as 25 mg tablets. Exemestane was administered as continuous oral daily dose of 25 mg tablets.
223474317|NCT03312738|DRUG|Everolimus Placebo|Placebo was formulated to be indistinguishable from the everolimus tablets. Matching placebo (two tablets daily) was administered in a blinded manner by continuous oral daily dosing.
223474318|NCT01130844|DRUG|MMX Mesalamine|30 mg/kg/day of MMX Mesalamine tablets, dosed once daily for 7 days.
223474319|NCT01130844|DRUG|MMX Mesalamine|60 mg/kg/day of MMX Mesalamine tablets, dosed once daily for 7 days.
223474320|NCT01130844|DRUG|MMX Mesalamine|100 mg/kg/day of MMX Mesalamine tablets, dosed once daily for 7 days.
223474321|NCT02633774|DRUG|Propafenone|AAD(antiarrhythmic drug)
223474322|NCT02633774|DRUG|Apixaban|anti-coagulation
223474323|NCT01450735|DEVICE|MANOS CTR™|The MANOS device is a carpal tunnel blade used to release the transverse carpal ligament in order to provide relief for Carpal Tunnel Syndrome.
223474324|NCT06183138|GENETIC|Genomic sequencing|Both sick and high-risk newborn un-randomized to receive genomic sequencing will receive a Genomic Newborn Sequencing Report which will include pathogenic or likely pathogenic variants identified in genes associated with childhood-onset disease.
223474325|NCT00003062|DRUG|temozolomide|
223474326|NCT04597567|PROCEDURE|Metal removal|Implant removal after fracture consolidation after posterior fixation of thoracolumbar spine fractures
223474327|NCT03175211|DRUG|BI 456906|single dose
223474328|NCT03175211|DRUG|Placebo|single dose
223474329|NCT02466399|DRUG|POLAT-001|Subconjunctival injection
223474330|NCT02466399|DRUG|Latanoprost ophthalmic solution|Latanoprost ophthalmic solution q.d., evening
223474331|NCT04670211|DEVICE|maxillary distractor|the type of maxillary distractor: tooth-borne, bone-borne or hybrid distractor
223474332|NCT00064311|DRUG|ravuconazole|
223474333|NCT06329167|DRUG|Daphnetin|150mg tid (3 capsules/time, 3 times daily) and gradient compression stockings.
223474334|NCT06329167|DRUG|Aescuven|150mg (2 capsules/time, 2 times daily) and gradient compression stockings.
223474335|NCT01123330|BEHAVIORAL|Motivational Interviewing|
223581563|NCT05236985|DRUG|Oxytocin bolus or oxytocin infusion|"On the day of surgery, the patients will be randomized to either bolus or infusion administration of oxytocin.~On the day of the procedure, periprocedural data and patient satisfaction (single question) will be recorded."
224069692|NCT02905786|OTHER|Assistance by a specialized HF nurse|Assistance by a specialized HF nurse in general practice for education of patients, advice in diagnosis and treatment, transition of care
223581564|NCT00494559|DRUG|Pioglitazone|Actos 15mg once a day before breakfast
223581565|NCT00494559|DRUG|Placebo|Placebo drug with the same appearance as actos
223581566|NCT02145871|OTHER|standard fluid management|
224069693|NCT03516760|DRUG|GEM333|infusion of GEM333; administered intravenously and continuously over 10 days
224069694|NCT04136431|OTHER|Programed cryotherapy and continuous passive motion|The intervention group started to use a CPM machine and applied programed cryotherapy intermittently within one hour while returning to the ward on the day of surgery.
224069695|NCT04136431|OTHER|Unrogramed cryotherapy and continuous passive motion|A CPM machine and cryotherapy were not applied on the day of surgery while returning to the ward
224069696|NCT00785330|DRUG|standard GVHD prophylaxis|Application of tacrolimus from day -1 with a goal of tacrolimus serum concentration of 10 ng / ml Aplication of mycophenolat mofetil from day +1 to day +28 in a dose of 2 x 1g per day
224069697|NCT00785330|DRUG|rituximab|Patients receiving 375 mg/ m2 of rituximab at weeks 3, 4, 5, 6, 25, 26, 27, 28 after allogeneic stem cell transplantation in addition to standard GVHD prophylaxis (tacrolimus with aimed serum level of 10 ng / ml and mycophenolat mofetil 2 x 1 g p.o. day 1 to 28 after allogeneic SZT
224069698|NCT03187600|PROCEDURE|Mucosa/submucosa Pharyngeal Flap|Included in study arm description
224069699|NCT03187600|PROCEDURE|Standard of Care Pharyngeal Flap|Included in study arm description
224069700|NCT02882295|OTHER|Validation of a handwriting scale|
224069701|NCT00453271|DRUG|NB-002|
224069702|NCT00453271|DRUG|Vehicle control|
224069703|NCT04370327|OTHER|Pain Free Exercise (PF)|Patients will exercise until the onset on claudication (1 on the rating scale)
224069704|NCT04370327|OTHER|Moderate Claudication Pain Exercise (MOD-P)|Patients will exercise until they experience moderate claudication pain (2 on the rating scale)
223474336|NCT02686996|DIETARY_SUPPLEMENT|carnosine|Carnosine capsules (2g) twice per day for 14 weeks
223581567|NCT02145871|OTHER|fluid management guided by the EV1000|
223581568|NCT02880813|OTHER|Infusion|infusion of nutrients
223581569|NCT00239954|DRUG|Escitalopram|
223581570|NCT01167907|DEVICE|0.2% ropivacaine|0.2% ropivacaine by elastomeric infusion pump at 5ml/h started within 6h of catheter placement
223581571|NCT01167907|DRUG|saline|saline (control) by elastomeric infusion pump at 5ml/h started within 6h of catheter placement
223581572|NCT00531297|PROCEDURE|endoscopic posterior mesorectal resection|6 weeks after local excision of a T1 rectal cancer a rectum sparing endoscopic removal of the dorsal part of the mesorectum by EPMR is performed.
223581573|NCT02749383|DRUG|PAC-14028 cream 0.3%|Topical application
223581574|NCT02749383|DRUG|PAC-14028 cream 1.0%|Topical application
223474337|NCT02686996|OTHER|Placebo|Placebo (methylcellulose) capsules for control group identical to intervention capsules and dose
223474338|NCT05276739|BEHAVIORAL|Bright Light|6.5-hour 10,000 lux light pulse (4100K fluorescent light) centered within the 16-hour wake episode (start 4.75 hour after wake and end 11.25 hour after wake).
223474339|NCT05276739|BEHAVIORAL|Time-restricted eating|6.5-hour restricted meal window (4 meals at 4.75, 6.9, 9.1, 11.25 hours after waking) centered within the 16-hour wake episode.
223474340|NCT05276739|BEHAVIORAL|Dim light|dim light (\<3 lux) throughout the 16-hour wake episode
223744014|NCT05897073|BEHAVIORAL|Exercise intervention|The exercise intervention will include 2 days/week of supervised moderate-high intensity resistance training (rating perceived exertion \>7, circuit-training, upper and lower body exercises involving major muscle groups) and high-intensity interval training (4 sets of 4-minute intervals at \>85% peak heat rate with 4-minute of active recovery at 50-65% peak heat rate, uphill treadmill walking). This intervention has already been tested previously in our lab. Moreover, participants will receive an individualized moderate-intensity goal-setting aerobic (walking) program consisting of increasing 15% daily steps per week.
224069705|NCT04370327|OTHER|Maximal Claudication Pain Exercise (MAX-P)|Patients will exercise until they experience maximal claudication pain (4 on the rating scale)
223474341|NCT05276739|BEHAVIORAL|12-h meal window|12-hour restricted meal window (4 meals at 2, 6, 10, and 14 hours after waking) centered within the 16-hour wake episode.
223474342|NCT03984929|BEHAVIORAL|Conexion Localized|The localized version of Conexion is an online health information resource on diabetes and depression tailored for the target community.
223474343|NCT03984929|BEHAVIORAL|Conexion Generic|The generic version of Conexion is an online health information resource on diabetes and depression.
223474344|NCT02889913|OTHER|No intervention only description|No intervention only description
223581575|NCT02749383|DRUG|PAC-14028 cream vehicle|Topical application
223581576|NCT00321997|DRUG|Pegaptanib sodium|
223581577|NCT05788705|DIETARY_SUPPLEMENT|"apigenin and glycyrrhizin"|"apigenin will be administered as capsule (10mg,eq 200mg Matricaria chamomilla L extract) two times daily. Also, glycyrrhizin  will be administered as capsule(50 mg eq 250 mg licorice extract) two times daily. The two types of capsules administration will be continue for 6 months"
223581578|NCT05788705|DIETARY_SUPPLEMENT|"glycyrrhizin and boswellic acid"|"boswellic acid will be administered as capsule (200mg,eq 250mg Boswellia serrata extract) two times daily. Also, glycyrrhizin  will be administered as capsule(50 mg eq 250 mg licorice extract) two times daily. The two types of capsules administration will be continue for 6 months"
223581579|NCT05788705|DIETARY_SUPPLEMENT|"placebo"|"Placebo capsule will be administered two times daily for 6 months"
223581580|NCT00900185|GENETIC|mutation analysis|
223581581|NCT00900185|GENETIC|polymerase chain reaction|
224069706|NCT01472497|DRUG|Pioglitazone|pioglitazone (15mg) once a day for 24 weeks
224069707|NCT06392880|OTHER|Floss Band|A floss band will be applied to the ankle joint and the participant will practice various weight-bearing active ankle motions simultaneously.
224069708|NCT06392880|OTHER|Mulligan Mobilization|Mulligan mobilization will be applied to the ankle joint and the participant will practice various weight-bearing active ankle motions simultaneously.
224069709|NCT06392880|OTHER|Control|Participants will practice various weight-bearing active ankle motions simultaneously.
224069710|NCT02491294|BEHAVIORAL|School|students receive Cooking With Kids (CWK) - Colorado cooking \& tasting lessons, SPARK active recess, and Cafeteria Connections
224069711|NCT02491294|BEHAVIORAL|Family|students receive the FFF family component - family nights, parent blog, and action packs that go home after each CWK-Colorado lesson
224069712|NCT02491294|BEHAVIORAL|About Eating|parents who completed the parent survey are invited to access the 6 lesson online About Eating program
224069713|NCT02465073|DEVICE|NXTSC wound gel|Subjects will receive NXTSC wound gel only.
224069714|NCT02465073|DEVICE|NXTSC wound gel plus Standard of Care|Subjects will be randomized to the NXTSC wound gel plus Standard of Care of only.
224069715|NCT02465073|DEVICE|Standard of Care Group|Subjects will receive Standard of Care only.
224069716|NCT01914562|DRUG|OCA 10 mg|OCA 10 mg tablet oral
224069717|NCT01914562|DRUG|OCA 25 mg|OCA 25 mg tablet oral
224069718|NCT01517477|DEVICE|iStent|Implantation of One iStent through a small temporal clear corneal incision.
224069719|NCT01517477|DEVICE|iStent|Implantation of Two iStents through a small temporal clear corneal incision
224069720|NCT01517477|DEVICE|iStent|Implantation of Three iStents through a small temporal clear corneal incision
224069721|NCT01999283|OTHER|Yoga Group Exercise|Yoga poses and postures modified to diminish stress on the cervical region and improve flexibility. Breathing and mind-body focus to address stress-related discomfort. A general Hatha yoga style will be used with components from Ashtanga Yoga. Intensity and range of motion will be progressively increased as tolerated.
224069722|NCT01999283|OTHER|Pilates Group Mat Exercise|The Pilates mat exercises focus on both spinal muscle activation and stability, progressive endurance of the stabilizing muscles with arm and leg challenges and dynamic mobility. The exercises are progressed from more supported to anti-gravity position, slow increases in arm weights and flexibility.
224069723|NCT02971878|BIOLOGICAL|Acetyl-L-carnitine (ALC), N-acetyl-L-cysteine (NAC) and α-lipoic acid (ALA)|Human embryos will be cultured in media that contains 3 antioxidants (Acetyl-L-carnitine (ALC), N-acetyl-L-cysteine (NAC) and α-lipoic acid (ALA)) that can be found in the in vivo Environment.
223474345|NCT00607893|DEVICE|Continuous Positive Airway Pressure (CPAP)|Participants will use the higher pressure CPAP, as determined by an in-laboratory attended titration study, every night for 12 weeks.
223744015|NCT05897073|BEHAVIORAL|Time-restricted eating plus exercise intervention|Participants will be asked to reduce their daily eating time window to a maximum of 8 hours/day. They can choose when to begin their eating window but will be advised that the last meal should be completed before or at 20:00 hours. No calorie-containing food or beverage intake will be allowed outside the 8 hours eating window. The exercise intervention will include 2 days/week of supervised moderate-high intensity resistance training (rating perceived exertion \>7, circuit-training, upper and lower body exercises involving major muscle groups) and high-intensity interval training (4 sets of 4-minute intervals at \>85% peak heat rate with 4-minute of active recovery at 50-65% peak heat rate, uphill treadmill walking). This intervention has already been tested previously in our lab. Moreover, participants will receive an individualized moderate-intensity goal-setting aerobic (walking) program consisting of increasing 15% daily steps per week.
223581582|NCT00900185|GENETIC|polymorphism analysis|
223744016|NCT02595931|DRUG|Berzosertib|Given IV
224161518|NCT03783338|COMBINATION_PRODUCT|Aerobic exercises and Vitamin D supplementation|"Aerobic exercises:~Children in groups B and C will receive aerobic exercises in the form of bicycle ergometer and treadmill training for 15 min 3 days/week for 12 weeks. The procedure and goals of exercise will be explained to all children before starting the exercise program. The child will stop exercising immediately if he feels pain, fainting or shortness of breath.~Vitamin D supplementation:~Children in group C only will receive vitamin D supplementation in the form of an oral daily dose of vitamin D3 1000 IU (Cholecalciferol) for 12 weeks."
223581583|NCT05801406|DEVICE|Tornado (Cook)|Fiducial marker endobronchial positioning under augmented fluoroscopy to mark ground glass opacities.
223581584|NCT03026478|DRUG|Betamethasone Dipropionate|
223744017|NCT02595931|PROCEDURE|Biopsy Specimen|Undergo biopsy
223744018|NCT02595931|PROCEDURE|Biospecimen Collection|Correlative studies
223744019|NCT02595931|PROCEDURE|Computed Tomography|Undergo CT
224161519|NCT00045487|DRUG|OSI-774|OSI-774 is an orally active, potent, selective inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase.
224161520|NCT03527771|DEVICE|Video-assisted CPR|Emergency call using a Software capable of video Transmission for Video assistance in CPR
224161521|NCT03527771|DRUG|telephone-assisted CPR|Emergency call with telephone assistance in CPR
224161522|NCT03209362|COMBINATION_PRODUCT|SI-613|SI-613 will be repeated intra-articularly administered.
224161523|NCT03209362|COMBINATION_PRODUCT|Placebo|Placebo will be repeated intra-articularly administered.
224161524|NCT02844673|DRUG|Hydroxyurea|Patients will receive fixed dose Hydroxyurea therapy (15 mg/Kg/day) with standard monitoring
223581585|NCT03026478|DRUG|Clobetasol Propionate|
223581586|NCT04580706|OTHER|this is an observational study with none intervention|this is an observational study with none intervention
224161525|NCT02844673|DEVICE|Mobile Directly Observed Therapy|Mobile DOT will consist of a web based medication adherence monitoring system that includes direct video confirmation of adherence using the patient's personal cellular telephone. Patients will receive alerts on their cell phone at pre-arranged times to remind them to take their medications.
224161526|NCT02511275|PROCEDURE|Renal microdialysis|Renal microdialysis is an innovative and promising technique in the monitoring of renal ischemia. Its sterile nature enables intraoperative use to give us real-time reflection of the in situ metabolism. In Patients who participated in clinical research with this microinvasive technique, no complications including bleeding has been reported.
223581587|NCT05030064|DRUG|Intestinal flora capsule|"This research group has independently researched and created a human intestinal flora capsule based on intestinal bacteria transplantation: Intestinal flora capsule, which has been declared a national invention patent (patent number: 2015103040414)."
223581588|NCT05030064|PROCEDURE|placebo capsule|Each placebo capsule is the two-layer empty capsule shell of the Intestinal flora capsule, which is made of titanium dioxide and iron oxide yellow. It is non-toxic and has the same appearance as the authentic Intestinal flora capsule.
223581589|NCT00180297|DEVICE|Endotak Reliance G|Reliance G is a defibrillation lead to be placed in the right ventricle.
223581590|NCT03077698|DRUG|Sodium Cridanimod|The study will investigate the efficacy of Sodium Cridanimod in conjunction with progestin therapy in a population of subjects with endometrial cancer, who have failed progestin monotherapy or who have been identified as PrR negative.
223581591|NCT03077698|DRUG|progestin therapy|The study will investigator the use of progestin therapy in conjunction with Sodium Cridanimod
223744020|NCT02595931|DRUG|Irinotecan Hydrochloride|Given IV
223474346|NCT00607893|DEVICE|Sham CPAP|Participants will use the lower pressure CPAP every night for 8 weeks.
223474347|NCT04096690|DRUG|Pegaspargase|Pegaspargase 3750IU administered by intramuscular injection on Day 1 of each 21-day cycle for 6 cycles in induction treatment
223474348|NCT04096690|DRUG|Anti-PD-1 monoclonal antibody|Anti-PD-1 antibody 200mg administered intravenously (IV) on Day 2 of each 21-day cycle for 6 cycles in induction treatment Anti-PD-1 antibody 200mg administered intravenously (IV) on Day 1 of each 21-day cycle for up to 28 cycles in maintenance treatment
223581592|NCT03461406|BIOLOGICAL|Fibrin Sealant Grifols|The FE Grifols solution was applied topically via drip or spray application.
223581593|NCT03461406|BIOLOGICAL|EVICEL|The EVICEL solution was applied topically via drip or spray application.
223581594|NCT00004705|DRUG|amiloride|
223581595|NCT00004705|DRUG|uridine|
223581596|NCT06430190|DRUG|Peginterferon α-2b injection|Participants receive CO2 laser treatment followed by local injection of 36mcg of Peginterferon α-2b directly into the base of each treated wart, repeated weekly for 12 weeks, and then followed for another 12 weeks.
223744021|NCT03854617|DRUG|Oral NVB Metronomic|50mg three times weekly on Mondays (or Tuesdays), Wednesdays (or Thursdays) and Friday (or Saturdays). A cycle is a 3 weeks period.
223744022|NCT03854617|DRUG|Oral NVB Weekly|60mg/m2 weekly for cycle 1 and 80mg/m2 weekly for subsequent cycles in the absence of grade 3 or 4 toxicity. A cycle is a 3 weeks period
223744023|NCT04167917|DRUG|NTX-301|oral hypomethylating agent
223744024|NCT05916729|DRUG|Miconazole|Protocol for active control groups includes use of Miconazole Oral gel for 14 days with frequency of four time per day.
223474349|NCT03220503|PROCEDURE|endometrial injury|single induced injury will be done on the posterior endometrium on day 7 of the transfer cycle by using modified Cook catheter.
223474350|NCT06102551|BEHAVIORAL|Recurrence after surgery|Recurrence after repair was the main outcome
223474351|NCT03097601|DIAGNOSTIC_TEST|ELR+CXCL cytokines levels are of sunitinib response|Demonstrate on independent cohorts of patients that ELR+CXCL cytokines levels are of sunitinib response
223474352|NCT02669849|DRUG|VX-210|
223474353|NCT02669849|DRUG|Placebo|
223474354|NCT03170713|DRUG|arveles|800 mg ibuprofen and 50 mg dexketoprofen in 150 cc normal saline before operation will be given in 30 minutes. The edema size, mouth opening (trismus) will be recorded in all patients in the preoperative period, postoperative period, postoperative 48th hour and 1 st week.
223581597|NCT06430190|DRUG|Peginterferon α-2b injection|Participants undergo CO2 laser treatment and then receive a weekly subcutaneous injection of 180mcg of Peginterferon α-2b for 12 weeks, and then followed for another 12 weeks.
223581598|NCT06430190|OTHER|CO2 laser|On the day (baseline), CO2 laser treatment was performed to remove all warts, and the treatment range was 0.2cm around the lesion and the depth was up to the dermis. Wound disinfection after laser. Participants are treated with CO2 laser therapy only and are observed for 12 weeks, followed by another 12-week observation period without any additional adjuvant therapy.
223581599|NCT00220493|DRUG|Ritalin|
223581600|NCT03710239|DEVICE|Dilapan-S|Synthetic osmotic dilator
223581601|NCT03710239|DEVICE|Laminaria|Seaweed-based osmotic dilator
223581602|NCT05482659|BEHAVIORAL|Health education on healthy nutrition and regular physical activity based on the transtheoretic model|An announcement was made by visiting all the faculties at Nuh Naci Yazgan University, stating the content of the research and the duration of the research. Among the volunteer students, students who met the inclusion criteria were included in the study. Afterwards, the students were assigned to the groups by the statistician using a simple randomization method. As a result of the pre-test, it was determined which change stage each student was in according to the Transtheoretic model (TTM). The students were not given information about which group they were in and what stage they were in according to TTM. Health education was given to university students once a week by online education method and it took 4 weeks-30 days to complete the research. The average duration of the health education given to each student is 30-45 minutes. When the training process was over, the post-test questions were sent to the students by the online survey method.
223581603|NCT00005647|DRUG|paclitaxel|Patients receive paclitaxel IV over one hour on day 1. Treatment continues weekly in the absence of disease progression or unacceptable toxicity.
223581604|NCT00005647|DRUG|semaxanib|Patients receive SU5416 IV over one hour on days 1 and 4. Treatment continues weekly in the absence of disease progression or unacceptable toxicity.
223581605|NCT00023751|DRUG|fluorouracil|
223581606|NCT00023751|DRUG|leucovorin calcium|
223581607|NCT00023751|PROCEDURE|conventional surgery|
223581608|NCT00023751|RADIATION|radiation therapy|
223744025|NCT05916729|DIETARY_SUPPLEMENT|CandBerrol® lozenges|Protocol for experimental groups includes use of Miconazole Oral gel and CandBerrol® lozenges for 14 days with frequency of four time per day
223744026|NCT02702440|OTHER|Liquid calories from sugars|
223744027|NCT01462084|DEVICE|Adaptive servo-ventilation (ASV)|Adaptive servo-ventilation (ASV) is a form of positive airway pressure (PAP) that is delivered based on the needs of the individual.
223744028|NCT01462084|DEVICE|Bi-Level PAP|Bi-Level PAP delivers therapy at 2 pressures IPAP and EPAP that are fixed.
223474355|NCT03170713|DRUG|intrafen|800 mg ibuprofen in 150 cc normal saline before operation will be given in 30 minutes.The edema size, mouth opening (trismus) will be recorded in all patients in the preoperative period, postoperative period, postoperative 48th hour and 1 st week.
223474356|NCT03170713|OTHER|placebos|150 cc normal saline before operation will be given in 30 minutes.The edema size, mouth opening (trismus) will be recorded in all patients in the preoperative period, postoperative period, postoperative 48th hour and 1 st week.
223474357|NCT04689542|OTHER|Sit-To-Stand test|The 1-minute sit-to-stand test will be realized with or without a surgical facemask covering the face of the patient with COVID-19
223474358|NCT02208908|OTHER|Evaluation of the oral conditionand proper care|An accurate assessment of the oral condition and proper care will be carried out on day 2 (J2) of hospitalization and repeated on the day of hospital discharge by the nurse detached service, regardless of caregivers.
223474359|NCT02915939|BEHAVIORAL|The Residential Care Transition Module|Residential Care Transition Module sessions focus on the experiences of the caregiver, the care recipient, and (potentially) other family members immediately following residential long-term care (RLTC) admission. The sessions are designed to establish a therapeutic rapport with the caregiver and the family; provide a safe environment to explore stressors; examine family relational dynamics as they relate to the RLTC placement decision itself as well as the roles different family members play in the life of the caregiver and relative in RLTC; identify new modes of communication to facilitate more effective interactions with other family members and care staff; and identify effective ways to advocate for improved quality of care for and quality of life of their relatives in RLTC.
223474360|NCT03408899|DRUG|PC-1005 gel|PC-1005 (0.002% MIV-150/0.3% zinc acetate in 3.0% carrageenan gel) in 4 mL, 16 mL, and 32 mL doses administered rectally.
223474361|NCT00348257|DEVICE|Hair removal by laser/IPL device|
223474362|NCT00606008|DRUG|Sunitinib Malate|Initially, patients were started on sunitinib at a dose of 50 mg daily. If 50 mg daily resulted in unacceptable toxicity, 2 dose modifications were allowed (to 37.5 and to 25 mg daily, if necessary). Study patients who could not tolerate 25 mg daily of sunitinib were taken off study.
223474363|NCT01248416|DRUG|Aromatase Inhibitor|
223474364|NCT01248416|DRUG|Growth Hormone|
223474365|NCT01248416|DRUG|Aromatase Inhibitor and Growth Hormone|
223744029|NCT00150072|DRUG|imatinib|
223744030|NCT05089682|DEVICE|DBS Stimulation during sleep|Open and closed-loop electrical modulation triggered and based on ongoing sleep staging by researcher as well as automated closed-loop algorithm for stimulation.
223744031|NCT04484233|DEVICE|iAnemia Decision Support System|iAnemia permits to display the appropriate guideline using several inputs about a patient: age, type and delay of the surgery, gender, hemoglobin level, and iron deficiency status.
223744032|NCT02909452|DRUG|Entinostat|HDAC (histone deacetylase) inhibitor
223744033|NCT02909452|DRUG|Pembrolizumab|A selective humanized monoclonal antibody (mAb)
223474366|NCT01055990|BIOLOGICAL|split-virion, non-adjuvanted H1N1 vaccine of 15 μg|The influenza A (H1N1) 2009 monovalent, (Split-virion)inactivated vaccine was developed by Shanghai Institute of Biological Products, and the seed virus was prepared from reassortant vaccine virus A/California/7/2009,distributed by the Centers for Disease Control and Prevention in the United States. This strain was recommended by the World Health Organization and obtained from the Chinese Food and Drug Administration.The vaccine adopted the assessment of experts, and formally accessed to the approval document number of production and new drug certificate issued by the Chinese Food and Drug Administration.
224161527|NCT03048357|DEVICE|Freedom Bed|Fully Integrated Lateral Rotation Bed System that automatically turns the patient to a specific angle in degrees between from 15-25 with dwell times between 1-120 minutes.
224161528|NCT03048357|OTHER|Standard hospital bed|Caregiver turning patients to one side then the other every 2 hours for pressure relief over bony prominence's.
223474367|NCT01055990|OTHER|blood fix|The blood fix with a hemagglutination-inhibition titer of 1:80 or more than was collected from healthy persons who are inoculated with specific H1N1 vaccine
223474368|NCT06452342|DRUG|Tranexamic acid|Tranexamic acid 1.5 grams, orally, three times a day during menstrual cycle for the 3 month study period
223474369|NCT06452342|OTHER|No Tranexamic acid|Routine clinical care without Tranexamic acid
223474370|NCT00596492|DRUG|DYME|2ml of 0.05 mg/ml BBG 250 in sterile ophthalmic solution
223474371|NCT00596492|DRUG|DYME|2ml of 0.25 mg/ml BBG 250 in sterile ophthalmic solution
223474372|NCT06293742|DRUG|ECC5004|ECC5004 tablet will be administered orally.
223474373|NCT06293742|DRUG|Midazolam|Midazolam will be administered orally.
223474374|NCT06293742|DRUG|Rosuvastatin|Rosuvastatin will be administered orally.
223474375|NCT06293742|DRUG|Digoxin|Digoxin will be administered orally.
223474376|NCT06293742|DRUG|Atorvastatin|Atorvastatin will be administered orally.
223474377|NCT00300196|BIOLOGICAL|Ancrod (Viprinex)|0.167 IU/kg/hr IV for 2-3 hours
223474378|NCT00300196|DRUG|Placebo|0.6 mL/kg/hr
223474379|NCT04867759|PROCEDURE|Endometrial Biopsy|On outpatient basis, we will take a uterine sample on mid-luteal phase day 21 by Novac curette or pipelle aspirator. Samples of endometrium will be kept in formaline solution and will be sent to National Institute of research and medical sceinces at Alexandria University to be tested for uNK Cells CD56.
223474380|NCT02014272|DRUG|RIN 150|Each subject will receive a single oral dose of 4 fixed dose combination tablets (RIN 150) each contains 150 rifampicin and 75 mg isoniazid.
223474381|NCT02014272|DRUG|reference drugs|Each subject will receive a single oral dose of 4 x 150 mg rifampicin capsules and 3 x 100 mg isoniazid capsules.
223474382|NCT04621331|DRUG|Roxadustat|HIF-PH inhibitor for treatment of anemia in CKD
223474383|NCT00480714|BIOLOGICAL|BCG (SSI Strain)|
223474384|NCT03499795|BIOLOGICAL|VGX-3100|One milliliter (1 mL) VGX-3100 (deoxyribonucleic acid \[DNA\] plasmids encoding E6 and E7 proteins of HPV types 16 and 18) will be injected IM and delivered by EP using CELLECTRA™ 5PSP on Day 0, Week 4 and Week 12, and potentially Week 40.
223474385|NCT03499795|DEVICE|CELLECTRA™ 5PSP|IM injection of VGX-3100 is followed by EP with the CELLECTRA™ 5PSP device.
223474386|NCT02014623|OTHER|Grass pollen sublingual immunotherapy tablet|
223474387|NCT02014623|DRUG|Control|
223474388|NCT03636256|DRUG|NanoDoce (direct injection)|Subjects will receive NanoDoce injected into the index tumor resection site on the bladder wall, immediately following transurethral resection of the bladder tumor (TURBT)
223474389|NCT03636256|DRUG|NanoDoce (intravesical instillation) - Visit 2 Instillation|All subjects will receive an initial intravesical instillation within 2 hours of direct injection.
223474390|NCT03636256|OTHER|Institutional Standard of Care|Group 2 (MIBC) will receive institutional standard of care treatments after the Visit 2 intravesical instillation.
223474391|NCT03636256|DRUG|NanoDoce (intravesical instillation) - Induction and Maintenance Instillations|Group 1 (NMIBC) will receive intravesical instillations in an Induction Period and a Maintenance Period.
223474392|NCT02741284|DRUG|Room air|
223474393|NCT02741284|DRUG|10L Oxygen by nonrebreather mask|
223474394|NCT05807282|OTHER|Interventions to Decrease Heat Stress among Latinx Farmworkers in Idaho|The interventions will be developed in collaboration with our study partners and will include increasing access to shade at the workplace, providing hydration packs to participants, and providing education regarding the signs and symptoms of occupational heat stress.
223474395|NCT04615000|DIAGNOSTIC_TEST|SARS-CoV-2 serological assessment (IgG)|Periodic assessment of the serology status (SARS-CoV-2 specific IgG) with a 3 to 6 month interval
223474396|NCT00132886|DRUG|tolvaptan|
223474397|NCT00488397|OTHER|In-vitro testing|This is an in-vitro study thus only one group in the study and there is no intervention treatment nor procedure involved in this study.
223474398|NCT05540431|DRUG|Activated Charcoal|RCT
223474399|NCT05540431|DIETARY_SUPPLEMENT|Probiotic|RCT
223474400|NCT05540431|OTHER|No intervention|RCT
223474401|NCT01218308|BIOLOGICAL|FluLaval® Quadrivalent|One intramuscular dose for primed subjects. Two intramuscular doses for unprimed subjects.
224161529|NCT01176188|OTHER|Comfort Care|The intervention will consist of two parts: (1) A 15-20 minute period of parental soothing at the bedside comprised of calming activities which the child and parents are familiar with; (2) A quiet period will follow, in which earmuffs are applied over the child's ears to block auditory stimulation. The intervention will take place twice/24 hours, up to a maximum of 72 hours. Total time of first (daytime) intervention will be 2 hours, and of second (night-time) intervention will be 7 hours.
223474402|NCT01218308|BIOLOGICAL|Havrix™|Two intramuscular doses for primed subjects. Three intramuscular doses for unprimed subjects.
223474403|NCT00930020|DRUG|Minocycline (Borymycin)|oral dose, 200 mg once a day for 5 days
223474404|NCT00930020|DRUG|Matched placebo|matched placebo (cornstarch) once a day for 5 days
223474405|NCT04931615|DRUG|ARTISS 4mL Fibrin Sealant Topical Solution (Frozen)|Wound sealant
223474406|NCT04931615|OTHER|no ARTISS|Wound closed without sealant
223474407|NCT02937376|DRUG|N-acetyl cystein|A trial of exercise before and after 4 weeks of N-acetyl cystein (NAC) supplementation.
223474408|NCT02937376|OTHER|Placebo|A trial of exercise before and after 4 weeks of placebo administration.
223744034|NCT01977508|DEVICE|ePTFE vascular access grafts|
224161530|NCT01176188|OTHER|Usual care|Usual nursing care for the child in the Pediatric Intensive Care Unit, including usual parental involvement and usual exposure to unit noise levels.
223474409|NCT00183339|DRUG|Fluoxetine|Between 2 mg per day and 20 mg per day of liquid fluoxetine will be given in the morning using a flexible dosing strategy, following a 36-week dose titration schedule.
223474410|NCT00183339|DRUG|Placebo|Between 0.5ml per day and 5ml per day of liquid placebo will be given in the morning using a flexible dosing strategy, following a 36-week dose titration schedule.
223474411|NCT02424825|BEHAVIORAL|Cooking Course|This is a month-long online cooking course, aimed at promoting a low-fat, plant-based diet.
223474412|NCT05761847|OTHER|Pediatric Medication Therapy Management (pMTM)|The pMTM intervention is comprised of 3 activities: comprehensive review of the medication regimen; optimization of the medication regimen; and creation of the medication action plan.
223474413|NCT02548871|BEHAVIORAL|Teen Outreach Program|TOP® is a positive youth development and service learning program for youth ages 12 to 17, and its Changing Scenes curriculum is separated into age appropriate levels. The program uses an approach that involves a caring adult, positive self-efficacy, future planning and goal setting and life management skills to to reduce risky sexual behavior and improve school outcomes. TOP® is designed to be delivered in weekly sessions over 9 months and includes community service learning.
223474414|NCT00547339|RADIATION|stereotactic body radiation therapy (SBRT)- 45 Gy|Dose of SBRT - 45 Gray (Gy) in five fractions
223474415|NCT00547339|RADIATION|stereotactic body radiation therapy (SBRT) - 47.5 Gy|Dose of SBRT - 47.5 Gray (Gy) in five fractions
223581609|NCT04791059|DRUG|S-ketamine|S-ketamine 50 mg is included in the mixture for patient-controlled analgesia.
223581610|NCT04791059|DRUG|Dexmedetomidine|Dexmedetomidine 200 microgram is included in the mixture for patient-controlled analgesia.
223581611|NCT04791059|DRUG|Sufentanil|Sufentanil 4 microgram/kg (maximum 250 microgram) is included in the mixture for patient-controlled analgesia.
223581612|NCT02926092|DIAGNOSTIC_TEST|Observation|Observation of progression of disease over time
223581613|NCT06073639|PROCEDURE|Autogenous dentin graft|Dentin graft is made from the participant extracted tooth by using Kometa Smart Dentin Grinder
223581614|NCT02679625|DEVICE|Ultrasound and NICOM|All patients enrolled will have all three ultrasound-based modalities for fluid responsiveness performed, as well as have NICOM data to serve as the comparison standard.
223581615|NCT02467920|DRUG|glargine + exenatide|glargine ( once-daily subcutaneous injection at bedtime) combination with exenatide (subcutaneous injection, twice-daily)
223581616|NCT02467920|DRUG|aspart 30|aspart 30 ( subcutaneous injection, twice daily)
223581617|NCT01309022|DRUG|Sirolimus|Obtained by prescription and given at doses used in ClinicalTrials.gov record NCT00014911.
223581618|NCT01309022|DRUG|Tacrolimus|Obtained by prescription and given at doses used in ClinicalTrials.gov record NCT00014911.
223581619|NCT01309022|DRUG|Mycophenolate mofetil|Obtained by prescription and given at doses used in ClinicalTrials.gov record NCT00014911.
223581620|NCT01309022|DRUG|Mycophenolic acid|Obtained by prescription and given at doses used in ClinicalTrials.gov record NCT00014911.
223581621|NCT02419170|PROCEDURE|Standard of care surgery|
223744035|NCT05773144|BEHAVIORAL|Aerobic exercise|Moderate- to vigorous-intensity aerobic exercise
223744036|NCT05773144|BEHAVIORAL|Progressive stretching|Static stretching of eight major muscle groups
224161531|NCT03982745|DEVICE|bonfils|bonfils intubation
223474416|NCT00547339|RADIATION|stereotactic body radiation therapy (SBRT) - 50 Gy (Phase 1)|
224161532|NCT06725264|DRUG|Deucravacitinib|6 mg twice daily
223581622|NCT02419170|PROCEDURE|Apheresis|
223581623|NCT02419170|DRUG|Cyclophosphamide|
224161533|NCT04184505|DRUG|Azacitidine|75mg/mq/day subcutaneously for 7 days every 28 days
224161534|NCT04184505|DRUG|Standard Chemotherapy|"1. cycle (induction): i.v. 3+7 (Citarabine 200 mg/m2 iv continuous infusion (24 h) for 7 days, Daunorubicine 60 mg/mq iv day 1-3)~2. cycle (consolidation): i.v. 3+7 (Citarabine 200 mg/m2 iv continuous infusion (24 h) for 7 days, Daunorubicine 45 mg/mq iv day 1-3)"
223474417|NCT00547339|RADIATION|stereotactic body radiation therapy (SBRT) - 50 Gy (Phase 2)|
223474418|NCT02961842|DRUG|500 mL Colloid Preload|6% hydroxyethyl starch 130/0.4 in 0.9% sodium chloride (voluven®) 500 mL will be rapidly infused before spinal anesthesia
223474419|NCT02961842|PROCEDURE|Spinal Anesthesia|Performed at the L3-L4 or L4-L5 interspace using 27- or 25-gauge spinal needle
223474420|NCT02961842|DRUG|Intrathecal Bupivacaine|Bupivacaine 12.5 mg (2.5 mL 0.5%) will be administered in the subarachnoid space
223474421|NCT02961842|DRUG|Intrathecal Fentanyl|Fentanyl 15 µg will be administered in the subarachnoid space
223581624|NCT02419170|BIOLOGICAL|Personalized mature dendritic cell vaccine|
223581625|NCT04800068|DIAGNOSTIC_TEST|[Ga-68] PSMA-11 PET/CT|Imaging scan
223581626|NCT04800068|DIAGNOSTIC_TEST|[Ga-68] PSMA-11 PET/MR|Imaging scan
223581627|NCT01059383|DRUG|VECAM 40/300|1 capsule, orally, once daily at bedtime.
223581628|NCT01059383|DRUG|Esomeprazole 20 mg|1 capsule, orally, once daily 30-60 min. before dinner
223581629|NCT04498351|DRUG|Control Test|"Spermatic cord block by18ml levobupivacaine 0.5% plus 2 ml normal saline in total volume of 20 ml.~The procedure is repeated on the contralateral side."
223581630|NCT04498351|DRUG|Dexmedetomidine|Spermatic cord block by total of 18ml levobupivacaine 0.5% plus 1 μg/kg dexmedetomidine in 2 ml in total volume of 20 ml The procedure is repeated on the contralateral side.
223581631|NCT04498351|DRUG|Dexmedetomidine and magnesium sulphate|"Spermatic cord block by total of 18ml levobupivacaine 0.5% plus 1 μg/kg dexmedetomidine and 100 mg magnesium sulphate in 2 ml in total volume of 20 ml .~The procedure is repeated on the contralateral side."
223744037|NCT04950569|DRUG|levosimendan|On the basis of standard conventional anti-heart failure treatment, levosimendan was used for 24 hours. The first load was 12 μg/kg, intravenous injection for 10 minutes, followed by intravenous infusion of 0.1 μg/Kg/min for 24 hours.
223744038|NCT01996826|DRUG|Avastin® (bevacizumab)|One time subconjunctival injection of 0.1 mL (2.5 mg) bevacizumab followed by topical treatment with 1% solution bevacizumab four times a day for four weeks.
223744039|NCT01996826|DRUG|0.9% NaCl & Refresh Liquigel|One-time subconjunctival injection of 0.1mL 0.9% NaCl followed by topical treatment with Refresh Liquigel four times a day for four weeks.
223744040|NCT00695396|DRUG|Placebo|Matching volume 2 mLfor 48 weeks
224161535|NCT04184505|PROCEDURE|Allogeneic stem cell transplantation|Allogeneic stem cell transplantation
224161536|NCT02663180|BEHAVIORAL|Educational program|Educational strategies: 2 Lecture about depression 30 minutes supported by group discussion, brochures and display of posters with mental-health slogans on depression in the schools.
224161537|NCT02663180|BEHAVIORAL|Video contact|Contact strategies: Investigators will show a video of a young male who had been diagnosed with depression. The video presented information that was moderately disconfirming of prior stereotypes by balancing the individual's difficulties resulting from Depression, with his ability to live a normal life.
224161538|NCT01531361|DRUG|Crizotinib|Given PO
224161539|NCT01531361|OTHER|Laboratory Biomarker Analysis|Correlative studies
224161540|NCT01531361|OTHER|Pharmacological Study|Correlative studies
224161541|NCT01531361|DRUG|Sorafenib Tosylate|Given PO
224161542|NCT01531361|DRUG|Vemurafenib|Given PO
224161543|NCT06189248|BEHAVIORAL|Resourcefulness intervention|Teaching personal and social resourcefulness skills.
224161544|NCT06925802|OTHER|visceral manipulation|The procedure begins with the patient lying in a comfortable supine position to ensure relaxation and access to the abdominal region. Gentle palpation is used to assess tissue mobility and identify any restrictions or tension points. The practitioner applies light, rhythmic pressure to the gastroduodenal junction to stimulate movement and improve coordination between the stomach and duodenum. Attention is then given to the sphincter of Oddi, where soft, sustained pressure is employed to facilitate the release of bile and pancreatic juices, aiding digestive processes. Moving to the duodenojejunal flexure, the therapist uses gentle stretching and mobilization techniques to alleviate any obstructions, promoting smoother passage of intestinal contents. Finally, the sigmoid colon is manipulated with circular and oscillatory pressures to enhance peristalsis and relieve constipation.
223474422|NCT02961842|DRUG|500 mL Crystalloid Coload|Ringer acetate 500 mL will be rapidly infused immediately after intrathecal injection
223474423|NCT02961842|DRUG|1000 mL Crystalloid Coload|Ringer acetate 1000 mL will be rapidly infused immediately after intrathecal injection
223474424|NCT02961842|PROCEDURE|Cesarean Delivery|Lower segment cesarean section using the Pfannenstiel incision
223474425|NCT02961842|RADIATION|Ultrasound Assessment of the Inferior Vena Cava|The inferior vena cava largest and smallest diameters will be measured proximal to the opening of the hepatic veins in the longitudinal axis with the M-mode using a 5-2 MHz curved array ultrasound probe placed longitudinally in the subxiphoid region
223474426|NCT02961842|DRUG|Intravenous Ephedrine|Intravenous ephedrine 3, 5, and 10 mg will be administered when Systolic blood pressure decreases below 90%, 80%, and 70% of baseline, respectively.
223474427|NCT04639882|BEHAVIORAL|Personalized normative feedback|Information presenting perceived and actual drinking norms.
223474428|NCT03843996|DEVICE|Treatment - Stratamed|To determine if Stratamed is more effective than standard of care therapy in limiting severity and duration of signs and symptoms of acute inflammation post follicular harvesting procedure.
223474429|NCT03163628|BIOLOGICAL|Diagnostic performances of a combination of biomarkers|"3 ml of blood will be drawn at inclusion at the same time of the venipuncture prescribed for standard care. The dosage of the 7 biomarkers will be performed in a central laboratory. The adjudication committee will classify patients in 6 groups, based on their clinical data. The committee will not be aware of the biological results. The analysis of Train Set data will aim to identify the most effective combination of markers in response to the primary objective of identifying biomarkers for the diagnosis of severe bacterial infections. The best combination selected will then be applied to the Test Set data (approximately the other half of patients), in order to obtain its real and unbiased performance.~The calculation of positive and negative likelihood ratios will be performed.~The targeted performances are:~* A positive likelihood ratio (LR +) of 5.67 minimum, ideally greater than 8.5.~* A negative likelihood ratio (LR-) of 0.5 maximum, ideally less than 0.3."
223474430|NCT02849028|BEHAVIORAL|sleep disorder|The study is to investigate whether exist the relationship between sleep disorder and circadian rhythm of patients with TBI or not.
223474431|NCT05139355|COMBINATION_PRODUCT|Effects of Oat and Oat Components on Cardiometabolic risk variables|Oat and oat bioactive components consumed as breakfast meal.
223474432|NCT01516216|DRUG|FOLFOX + bevacizumab|
223474433|NCT01516216|DIETARY_SUPPLEMENT|Vitamin D|
223581632|NCT04498351|DRUG|magnesium sulphate|Spermatic cord block by total of 18ml levobupivacaine 0.5% plus 100 mg magnesium sulphate in 2 ml in total volume of 20 ml
223581633|NCT04867694|BEHAVIORAL|BCC|Behavior change communication on Nutrition, Health \& Hygiene, including (but not limited to) awareness of dietary diversification from 6 months of age and adequate complementary feeding; and raising awareness of good water and hygiene practices.
224161545|NCT06728800|BEHAVIORAL|FBT 2.0|FBT 2.0 is a translation of Family-Based Behavioral Treatment (FBT) into an e-health intervention product for families with a child/adolescent with obesity. FBT is an evidence-based obesity intervention that takes a family-centered approach to weight management that includes training in behavioral skills for the family, such as self-monitoring, stimulus control, problem solving, pre-planning, and impulse control. Youth with obesity, along with one participating caregiver, will be introduced to the evidence- based Traﬃc Light Eating Plan and behavioral skill training appropriate for their developmental age, while the caregiver learns positive parenting approaches to help shape and support their child's weight change efforts in addition to their own weight management goals. The ﬁnal product will consist of eight modules, each aligned with evidence-based FBT skills and competencies.
223474434|NCT05396690|DRUG|Remimazolam Injection [Byfavo]|Induction dose: 6 mg/kg/h with sufentanil Maintenance dose: 1\~2 mg/kg/h with sufentanil If arousal occurs during surgery, rapidly increase the infusion rate of remimazolam to 12 mg/kg/h and infuse for 1 minute. If the patient's arousal persists after these measures, stop remimazolam infusion and replace with another drug.
223744041|NCT00695396|DRUG|Epoetin alfa|40,000 IU subcutaneously once every week (1 mL dose) for 48 weeks
223744042|NCT00695396|DRUG|Placebo|Matching volume 1 mL for 48 weeks
223744043|NCT00695396|DRUG|Epoetin alfa|80,000 IU subcutaneously once every week (2 mL dose) for 48 weeks
223474435|NCT05396690|DRUG|Sevoflurane|Induction dose: 2\~3 mg midazolam with sufentanil Maintenance: Adjust the concentration to be BIS 35-65 based on 0.5 mac If arousal occurs during surgery, raise the concentration of sevoflurane to 1.5 MAC (increase the total gas flow rate to 8 l/min) and if arousal persists after 1 minute, administer midazolam 2-3 mg.
223474436|NCT04784130|BEHAVIORAL|Physical Activity|Respondents will complete activity logs (step count, using pedometer) and surveys (two items from the Summary of Diabetes Self-care activities measure) for physical activity.
223474437|NCT04784130|BEHAVIORAL|Medication Adherence|Respondents will provide information on their medication adherence using a survey (questionnaire - MMAS-8).
223474438|NCT04784130|BEHAVIORAL|Dietary Modification|Respondents will complete food logs and surveys (three items from the Summary of Diabetes Self-care activities measure) for dietary intake.
223474439|NCT03299985|OTHER|Diaphragmatic myofascial release|Subjects in this arm will receive different myofascial release techniques aimed to normalize the myofascial tension of the diaphragmatic muscle
223474440|NCT03299985|OTHER|Sham myofascial release|Subjects in this arm will receive the same manual techniques of the diaphragmatic myofascial release group, but without the myofascial stimulus
223581634|NCT04867694|DIETARY_SUPPLEMENT|Preventive supplement|Monthly delivery of a nutritional supplement: enriched flour (CSB++), at a dose of 3 kg/month/beneficiary child. The nutritional supplement is limited to \[6-11\] months old children diagnosed as non-wasted (green MUAC); or children \[12-59\] months old for 6 months after discharge from a CMAM treatment or consolidation program.
223581635|NCT04867694|DIETARY_SUPPLEMENT|MNP|Delivery of micronutrient powders to \[12-23\] months old children (30 sachets per month for 2 months, every 6 months, according to international recommendations).
223581636|NCT04867694|OTHER|Water purification input|Monthly delivery of a water purification input: bleach or flocculant/decontamination sachets for the potabilization of the water of the whole household. The water treatment input is limited to households with \[6-11\] months old children, or children \[12-59\] months old enrolled in a CMAM treatment program and for 6 months after discharge.
223744044|NCT04564456|DRUG|Fluticasone propionate 500 mcg and salmeterol xinafoate 50 mcg/Respirent|2 inhalations of Test oproduct in one study period
224161546|NCT06728800|BEHAVIORAL|Information-and-referral|Caregiver-youth dyads randomized to the information-and-referral control intervention will be given written educational materials. Prior to starting the intervention trial, dyads will meet for 20 minutes with a trained researcher who will provide them with educational materials used in investigators' prior studies which teaches about the impact of eating and activity behaviors on weight. Caregivers will be asked to monitor their health by using daily paper-and-pencil diaries to record eating and activity behaviors. Youth without a medical provider will be given referrals to a primary care provider in their community.
224161547|NCT03625804|GENETIC|PNS+AO+Training|Electrical stimulation was applied to the radial and ulnar nerve (PNS) of the paretic arm for 60 minutes. During the last 30 minutes of PNS, action observation (AO) was introduced in which subjects were required to watch a series of video clips. After one hour's PNS+AO, the subjects then proceeded to a 30-minute period of motor training of paretic hand.
224161548|NCT03625804|GENETIC|PNS+AOsham+Training|PNS was given as described before. During the last 30 minutes of the PNS, subjects were shown different photos illustrating a letter, a number or a hand as AOsham. The protocol of motor training was the same as described before.
224161549|NCT03625804|GENETIC|PNSsham+AOsham+Training|The 1-hour PNSsham was conducted with the electrical stimulation unit turned on but without current output. The protocols for AOsham and motor training were the same as those described before.
224304427|NCT05403255|OTHER|evaluation of the quality of life with questionnaires|"Questionnaire data will be collected among patients and their parents during follow-up consultations.~Children's quality of life will be evaluated using the Kidscreen-10 questionnaire (for children and parents) and PedsQL multidimensional fatigue scale. Psychosocial indicators (standard of living, schooling, recreation activities, social and family relationships, perceived health status and physical appearance) will be gathered using a questionnaire based on the HBSC (Health Behaviour in School-Aged Children) questionnaire (INPES 2010), and compared with data from the general population of elementary-, middle-and high-school children in France."
223474441|NCT03759080|PROCEDURE|mental practice|training of mental practice to do the pattern of proprioceptive neuromuscular facilitation
223581637|NCT04867694|BEHAVIORAL|Family MUAC|"One-time delivery of a mid-upper arm circumference (MUAC) measuring tape and training of families in its use, and actions to be taken based on the results. This will involve distributing Shakir bands to all households with \[6-59\] months old children and training mothers/guardians, or any other family members who express an interest, in screening for wasting using the MUAC criteria, and explaining the procedure to follow if the child tests positive in the family.~Formative supervision of MUAC measurement in families. The training will be carried out by the members of the care groups and at each home visit, they will be able to ensure that the MUAC measurement technique is well mastered by the mother (or another member) and correct the technique if necessary."
223744045|NCT04564456|DRUG|ADVAIR DISKUS® 500/50|2 inhalations Reference product in one study period
224304428|NCT02974647|DRUG|Ruxolitinib|
224304429|NCT04636242|PROCEDURE|Skin Biopsy|A Biopsy of the skin where the arthroscopic instrument will be placed, will be taken and sent to the microbiology lab for analysis
224304430|NCT04636242|DRUG|5 Aminolevulinic Acid + Phototherapy|5 aminolevulinic acid solution will be placed on the skin of the shoulder and the participant will receive Photodynamic therapy on the morning of surgery
223474442|NCT03759080|PROCEDURE|proprioceptive neuromuscular facilitation|upper limb Pattern: Flexion -Abduction- External rotation
223474443|NCT01712282|BEHAVIORAL|physical activity, 2 x 30 minutes/day|weight-bearing treadmill, pulse reserve increase of 50%
223474444|NCT03092427|DIETARY_SUPPLEMENT|VSL#3|Dietary Supplement
223474445|NCT03092427|OTHER|Placebo|Placebo
223474446|NCT03197636|DRUG|Pembrolizumab|Pembrolizumab is already approved for treatment of malignant melanoma in advanced stages. We will investigate if sPD-1 or vitamin D status is changed in patients receiving pembrolizumab.
223581638|NCT04867694|BEHAVIORAL|Screening by care group|"Monthly screening by the care group volunteers of the children they follow, using the MUAC.~Referral to the health center of \[6-59\] months old children screened as malnourished (result of MUAC orange or red), and follow-up on referral to confirm child was enrolled"
224161550|NCT01186003|DRUG|Detemir|Detemir 0.25 units per kg body weight given subcutaneously every 24 hours while patients are receiving intravenous (IV) standard insulin drip therapy
224161551|NCT04344262|DRUG|Atracurium Besylate regular dose|"Intubating dose of muscle relaxant will be atracurium 0.5 mg/kg~Maintenance doses of muscle relaxant will be given throughout the intraoperative period~to maintain the Train-of-four values continuously less than 2"
223474447|NCT05529537|OTHER|manual lymphatic drainage|In addition to conventional treatment for 4 weeks, manual lymph drainage will be applied to the patients.
224161552|NCT04344262|DRUG|Atracurium Besylate minial dose|atracurium boluses of muscle relaxant given only upon complain of the surgeon and after a bolus dose of propofol 0.5 mg/kg. When required, 20% of the initial dose of muscle relaxant will be provided as a bolus to achieve this goal
224161553|NCT00251589|DRUG|Vorinostat|Vorinostat 200 mg twice a day for 3 days a week.
224161554|NCT00251589|DRUG|Vorinostat|Vorinostat 300 mg once a day for 3 days a week.
224304431|NCT03227614|BEHAVIORAL|Support Person Intervention|The patient participant will have a support person of her choice accompany her during her abortion procedure.
224304432|NCT03107143|DEVICE|Q2 System|
224161555|NCT00251589|DRUG|Vorinostat|Vorinostat 300 mg twice a day for 3 days a week.
224161556|NCT00251589|DRUG|Vorinostat|Vorinostat 400 mg once a day for 21 out of 28 days.
224161557|NCT00251589|DRUG|erlotinib|erlotinib 150 mg once a day.
224161558|NCT01082341|BIOLOGICAL|Immunization with P. vivax irradiated sporozoites|"Anopheles albimanus mosquitoes will be infected by artificial membrane feeding using blood from P. vivax infected donors. Once mosquitoes are positive will be irradiated at 15000 cGy and kept in boxes until use.~14 Fy(+) human volunteers in the experimental group will be immunized with 1,000-2,000 P. vivax irrad-spz bites. Seven Fy(+) volunteers in the control group will be exposed to non-infected mosquito bites. Six Fy(-) volunteers will be exposed to infective mosquito bites. For the challenge both the immunized and control groups will be exposed to 3 ± 1 infective mosquito bites. Volunteers will be closely monitored post infection and will be treated with antimalarials."
224161559|NCT02109068|BEHAVIORAL|Weight Loss Counseling- Phone|"The intervention will be based on the Diabetes Prevention Program weight loss program, which uses a combination of reduced caloric intake, increased physical activity, and behavior therapy. The content of the weight loss program will be similar for the in-person and telephone interventions, but the approach will vary (i.e., in-person vs. telephone counseling). The weight loss intervention will be conducted by a Registered Dietitian, who has training in exercise physiology and behavior modification.~During the 6-month intervention, participants will receive weekly (month 1), then bi-weekly (months 2 and 3), then monthly (months 4, 5, and 6) individualized counseling sessions. An advantage of tapering the frequency of visits from weekly to every other week and then monthly works as a process tool to help transfer the work or responsibility onto the participant for life long change and maintenance of behavior change."
224304433|NCT03724526|BEHAVIORAL|Text messaging|"Intervention-Text messaging: Participants will receive regular text messages for 12 months. Each participant will receive 6 text messages per week. They will receive one general education about diabetes and CVD messages, one glucose control message, one blood pressure control message, one healthy eating message, one medication adherence message and one physical activity message per week.~Control: The control group will receive the usual care."
224304434|NCT04752046|PROCEDURE|maxillary cancer resection|patient with maxillary cancer will resected and reconstructed
223474448|NCT05529537|OTHER|excersize|upper extremity normal joint range of motion exercise, strengthening exercise, tendon gliding exercises
223474449|NCT00187408|DRUG|Low Molecular Weight Heparin (dalteparin)|
223474450|NCT05213091|OTHER|Otago Exercise Programme|The first four weeks will be Otago Exercise Programme training and practice. For the next weeks, there will be institution visits and telephone interviews. Individuals will be given an Otago Exercise Programme training booklet, exercise chart and exercise diary to better manage this process. The research will be conducted in small groups (average 6-8).
223474451|NCT03777501|BEHAVIORAL|non-random whole body vibration|Each participant will receive the treatment about one hour after the administration of medicine. For non-random whole body vibration group, participants will be required to maintain the erect standing position on the vibratory platform and the frequency and amplitude of vibratory stimuli will be 6Hz and 3mm respectively. Each treatment includes five sessions and each session is composed of one minute whole body vibration and one minute rest.
223474452|NCT03777501|BEHAVIORAL|occupational therapy|Participants will receive the occupational therapy including dynamic balance training and functional ambulatory training.
223474453|NCT01458587|DRUG|Aminolevulinic Acid PDT (ALA)|20% ALA applied to upper extremities for 3 hours prior to 10 J/cm2 blue light
223474454|NCT01458587|DRUG|Vehicle PDT (VEH)|Levulan Kerastick containing vehicle ingredients only. Vehicle solution applied to upper extremities 3 hours prior to 10 J/cm2 blue light
223474455|NCT01603602|BIOLOGICAL|botulinum toxin Type A|Intramuscular injections of botulinum toxin Type A into specified muscles of the upper limb on Day 1.
223474456|NCT01603602|DRUG|Normal Saline (Placebo)|Intramuscular injections of normal saline (placebo) into specified muscles of the upper limb on Day 1.
223474457|NCT01079780|BIOLOGICAL|cetuximab|Given IV
223744046|NCT03532919|DIAGNOSTIC_TEST|Serum Tropinin|Blodsamples will be taken 4 times from preoperatively to 2 Days postoperatively
223744047|NCT00930995|DRUG|Candesartan|16mg po daily
223744048|NCT00930995|DRUG|Placebo|once daily
223744049|NCT00159640|DRUG|PD-217,014|
223744050|NCT00441844|DRUG|Simvastatin|
223744051|NCT04746703|RADIATION|Magnetic Resonance Imaging|Pancreatic MRI will be performed in severe-obese patients with a planned bariatric surgery, before and 6 months after bariatric surgery.
224304435|NCT02440568|DRUG|Cytarabine|Cytarabine (100mg/m\^2/day) in 1000ml NS as a continuous IV infusion over 24 hours x 7 days.
224304436|NCT02440568|DRUG|Idarubicin|Idarubicin (12 mg/m\^2/day) IVPB in 100 mL NS over 15 minutes daily from Days 1 to 3.
224304437|NCT02440568|DRUG|Omacetaxine mepesuccinate|Omacetaxine administered subcutaneously Q12 hours Days 1 to 7. Dose level 0.625mg/m\^2
224304438|NCT02440568|DRUG|Omacetaxine mepesuccinate|Omacetaxine administered subcutaneously Q12 hours Days 1 to 7. Dose level 1.25mg/m\^2
224304439|NCT02440568|DRUG|Omacetaxine mepesuccinate|Omacetaxine administered subcutaneously Q12 hours Days 1 to 7. Dose level 2.0mg/m\^2
224161560|NCT02109068|BEHAVIORAL|Weight Loss Counseling- In-Person|"The intervention will be based on the Diabetes Prevention Program weight loss program, which uses a combination of reduced caloric intake, increased physical activity, and behavior therapy. The content of the weight loss program will be similar for the in-person and telephone interventions, but the approach will vary (i.e., in-person vs. telephone counseling). The weight loss intervention will be conducted by a Registered Dietitian, who has training in exercise physiology and behavior modification.~During the 6-month intervention, participants will receive weekly (month 1), then bi-weekly (months 2 and 3), then monthly (months 4, 5, and 6) individualized counseling sessions. An advantage of tapering the frequency of visits from weekly to every other week and then monthly works as a process tool to help transfer the work or responsibility onto the participant for life long change and maintenance of behavior change."
224161561|NCT02692976|BIOLOGICAL|mDC vaccination|Intranodal mDC vaccination
224161562|NCT02692976|BIOLOGICAL|pDC vaccination|Intranodal pDC vaccination
224161563|NCT02692976|BIOLOGICAL|mDC and pDC vaccination|Intranodal mDC/pDC vaccination
224161564|NCT02450500|BEHAVIORAL|Lifestyle counselling|This will consist of a web-based lifestyle app and personalised behaviour modification advice by a registered dietitian delivered via messaging. Participants will be issued with a pedometer and instructed to wear this daily. Participants will access web-based material on prediabetes through the lifestyle app. Contact between the dietitian and participants will consist of weekly messaging to facilitate changes in diet and activity behaviour through motivational and cognitive behavioural strategies. Changes in diet and activity levels will be recorded as personalised goals which will be monitored and reviewed by both the participants and dietitian. In addition participants will be encouraged to complete a food diary to self-monitor their progress against dietary recommendations.
224161565|NCT03723499|OTHER|Medical data collection|Medical data collection by medical record will be collected: demographics data, medical history, clinical symptoms, smoking, type of endoscopic method, complete treatment or not, type of surgeries if yes, anatomopathology of the injury and recurrence if yes
224161566|NCT00323427|BEHAVIORAL|The Living Well with Hearing Loss Workshop|Interactive group session modeled on Patient-Centered medicine and Adult Learning principles; the participants are partners with the Group Facilitator who is a hearing rehabilitation professional
224304440|NCT02440568|DRUG|Omacetaxine mepesuccinate|Omacetaxine administered subcutaneously Q12 hours Days 1 to 7. Dose level 3.0mg/m\^2
224304441|NCT02550730|BEHAVIORAL|Birth Sisters Best Beginnings for Babies|Birth Sisters Best Beginnings for Babies support during Pregnancy, Labor and Delivery and six weeks postpartum. Participants assigned to the Birth Sister group receive community doula services with consultation from the Medical Legal Partnership when indicated beginning at 24 weeks. Participants receive up to 8 two-hour prenatal home visits; continuous support through labor and birth, and up to 4 two-hour postpartum home visits through 6-8 weeks postpartum.
224304442|NCT02550730|OTHER|Usual maternity care|Usual prenatal, intrapartum and postpartum maternity care
224304443|NCT03392493|BEHAVIORAL|Robot-assisted hand rehabilitation|Robot-assisted hand rehabilitation: 20 minute of worm-up exercise and 40 minute of robot-assisted hand exercise. Robot-assisted hand exercises include passive range of motion of hand, bilateral hands task and robot-assisted task.
223474458|NCT01079780|BIOLOGICAL|ramucirumab|Given IV
223474459|NCT01079780|DRUG|irinotecan hydrochloride|Given IV
223474460|NCT05496023|DEVICE|Percutaneous coronary intervention|"1. Pre-PCI angio-FFR was calculated and virtual pullback was generated~2. Automated algorithm to calculate delta angio-FFR per unit length and co-registered onto coronary angiogram was developed~3. PCI was performed using 2nd generation DES"
223474461|NCT02696889|PROCEDURE|ROSE-1 Protocol|A bone marrow aspiration will be performed under anesthesia in preparation for a diagnostic laparoscopy for full evaluation of the pelvic anatomy. Following laparoscopy, injection of BMSCs into the right ovary will occur.
223474462|NCT01392599|PROCEDURE|SUBCUTANEOUS VENOUS SYMPATHECTOMY (RSVS)|After incision of the skin a subcutaneous area of approximately 16 cm² (2.5 square inches) will be en block removed between dermis and muscle fascia. All prior detected and marked veins in the operating field will be ligated or coagulated precisely.The tissue defect generated by this operation will be closed by a full thickness or a meshed skin graft which arises during the preparation.
223474463|NCT02081989|PROCEDURE|Renal denervation|Renal denervation
223474464|NCT02948816|BEHAVIORAL|Facebook|Participants will spend 30 minutes on a Facebook page that is primarily non-food related posts.
223474465|NCT02948816|BEHAVIORAL|Facebook + Food|Participants will spend 30 minutes on a Facebook page that is food related posts.
223474466|NCT02948816|BEHAVIORAL|Colouring|Participants will spend 30 minutes colouring quietly.
223744052|NCT04911283|OTHER|Brucella serology test|MCs type 1 and type 2 patients were examined in terms of Brucella serology by using agglutination with Coombs test.
223744053|NCT04911283|OTHER|Medical history for brucellosis|Both of the MCs groups and healthy controls were investigated for their medical history regarding brucellosis.
223744054|NCT00005010|DRUG|Irbesartan|
223474467|NCT02783066|DEVICE|Offloading boot: PulseFlow|A new offloading boot, which may enhance balance, gait, and lower extremity blood flow
223744055|NCT00005010|DRUG|Pravastatin|
223744056|NCT04823039|OTHER|Blood sample taken|For patients with sepsis who require vaccination during hospitalization, we will analyze the immunogenicity of pneumococcal conjugate vaccine (PCV13) by taking blood samples
223744057|NCT02428660|GENETIC|Pharmacogenetic testing|Genetic testing for 2D6, 2C9, 2C19, 3A4, 3A5 polymorphisms
223474468|NCT05052580|OTHER|COVID-19 Testing|Participants who consent to participate in this study will be tested at days 1, 3, 5, and 7 following a known COVID-19 exposure on day 0. If the COVID-19 tests are negative, the participant will remain in the school environment. A positive COVID-19 test or the development of symptoms on any day after exposure would require isolation according to school, local and state guidelines.
223474469|NCT05334667|OTHER|Routine management|Routine management
223744058|NCT02428660|OTHER|Software-based drug & gene interaction risk analysis|By assessing a patient's medication list along with the frequencies of variant phenotypes in the population, YouScript is able to identify whether a patient might be at risk for an adverse drug event and suggest when testing might be appropriate.
223744059|NCT02428660|OTHER|MTM|Medication Therapy Management
223474470|NCT05334667|DEVICE|CRRT|Prisma-flex (Gambro-Swedan) machine will be used to carry out both CRRT and PPH sessions. Each CRRT session continue for 72 hours, while PPH session continue for 4 hours.
223474471|NCT05334667|DEVICE|PPH|Prisma-flex (Gambro-Swedan) machine will be used to carry out both CRRT and PPH sessions. Each CRRT session continue for 72 hours, while PPH session continue for 4 hours.
223474472|NCT03176485|OTHER|Solar Simulator|A Multiport UV Solar Simulator Model 600 (Solar Light Co., Inc., Philadelphia, PA) will be used to administer Solar Simulated Light (SSL) exposures to formerly unexposed buttock skin.The device is equipped with six 8mm liquid light guides (LLG), allowing for 6 simultaneously conducted exposures.A large 3x2 endplate places the LLGs several centimeters apart and is specifically designed for Sun Protection Factor (SPF) and photo patch testing. The dose of emission from each LLG can be precisely regulated and the spectrum of emission can be limited to UVA (320-390 nm) or UVB+UVA (290-390 nm). The operator can select between UVA only and a combined Ultraviolet-A (UVA)/ Ultraviolet-B (UVB) spectrum by placement of an optical filter. The spectral output (indicated below) follows the distribution of sunlight from 290 to 390 nm.
223474473|NCT03736252|DEVICE|Orthosis provision|Hely and Weber CMC controller
223474474|NCT05251597|OTHER|green exercise with aerobic exercise|Green exercise is a type of exercise done outdoors. It is an advantageous type of exercise in benefiting from sunlight and reducing anxiety. It is mostly applied in the form of brisk walking in the open air.
223474475|NCT01300403|OTHER|Flutter valve|Flutter valve is a physiotherapy device commonly used for the treatment of pulmonary hypersecretive conditions. The patients is taught to exhale through the device, producing positive expiratory pressure and flow oscillations. In this study the intervention took 15 minutes. During this period the patients were free to cough.
223474476|NCT01300403|OTHER|expiration with the glottis open in lateral posture (ELTGOL)|This technique is a maneuver of slow expiration with the glottis open, with the subject in lateral posture. The patients performed three sets of 10 repetitions in left and right lateral decubitus.
223474477|NCT01300403|OTHER|Control|Patients were instructed to stay comfortably seated during 15 minutes. After this period they were stimulated to cough during a five minutes period.
223474478|NCT04894058|PROCEDURE|Ureteroscopic lithotripsy|"After combined spinal and epidural anesthesia, patients were subjected to low pressure perfusion; The semirigid ureteroscope was passed through the urethra to the bladder, after which both ureteral orifices were observed. A 0.035 soft-tipped guidewire was sent through the ureter orifice and reached the renal pelvis. Subsequently, the patients were placed in the reverse trendelenburg position by leaning 10 ° or 20 ° with their head up and hips down or standard lithotomy position. The ureter stone was accessed with a semirigid ureteroscope. A 273 micron Holmium: yttrium-aluminum-garnet (Ho: YAG) laser was applied as an energy source set at 1.0 J and a speed of 8-10 Hz."
223474479|NCT06147934|DIAGNOSTIC_TEST|Diagnostic Test: Transient elastography (TE) and 2D-shear wave elastography (2D-SWE)|"Index test: TE examination will be completed by experienced nurses, requiring fasting for more than 4 hours before the examination and an interval of no more than 1 week from the abdominal ultrasound and 2D-SWE examination. The report will be considered highly reliable only if IQR/med is ≤ 30%, at least 10 successful acquisitions are obtained, and the success rate is at least 60%. Abdominal ultrasound and 2D-shear wave elastography (2D-SWE) will be completed by a sonographer, the interval between ultrasonic examination and laboratory tests should be less than a week, and the patients should fast for at least 4 hours before the examination.~Reference standard: Liver biopsy will be conducted by experienced interventionists and reported by pathologists. There should be a maximum interval of no more than 1 month between the liver biopsy and ultrasound examination, and the length of specimen should be more than 1.0cm."
223474480|NCT03248297|DRUG|Azithromycin|Azithromycin tablet
223474481|NCT03248297|DRUG|Azithromycin and amoxicillin|azithromycin and amoxicillin
224161567|NCT00323427|DEVICE|hearing aid services|Standard VA audiological hearing aid dispensing services
224161568|NCT04963634|OTHER|Biobanking|For patients included in BRADYDIAG study, 2 blood samples will be collected at enrollment (for group 1: bradykinin angioedema and for group 2: histamine-mediated angioedema) and at 1 year visit (for group 1 only: bradykinin angioedema).
224304444|NCT03392493|BEHAVIORAL|Standard treatment|Standard treatment only group: 60 min standard treatment. 20 minute of worm-up exercise and 40 minute of traditional occupational therapy. Traditional occupational therapy include spasticity-reducing activity, bilateral hands activity and hand training task.
223474482|NCT03248297|DRUG|Placebo|Placebo tablet
223474483|NCT05789966|GENETIC|Genetic Risk Estimate+Health Coaching|The genetic risk information includes individual remaining-lifetime and 10-year genetic risk estimates for CHD as well as a dichotomized genetic risk category: 'increased genetic risk' (if their genetic risk is higher than the average population risk) or 'no increased genetic risk' (if their genetic risk is not higher than the average population risk). Health coaching will be incorporated through phone or Zoom calls to provide an explanation of each participant's own genetic risk of CHD as well as lifestyle modification measures.
223744060|NCT05144724|PROCEDURE|Volume targeted ventilation|Positive pressure ventilation will be provided using a set tidal volume
223744061|NCT05144724|PROCEDURE|Pressure targeted ventilation|Positive pressure ventilation will be provided using a set peak inflation pressure
223744062|NCT05304754|BIOLOGICAL|NK cells stimulated ex vivo with IL-15|When patient and donor are KIR-HLA match, the patient submits all HLA class I molecules, or in the absence of any, your donor does not have this molecule, or having it lacks the corresponding KIR receiver. For more information detailed information on the product under investigation, reference is made to the Dossier of the Research Product (IMPD): PEI 09-008
224161569|NCT05289154|OTHER|self- applied acupressure plus Qigong course plus advice literature|daily self applied acupressure over 20min plus 2 times per week online live Qigong course of each 45min- both over 8 weeks.
224161570|NCT05289154|BEHAVIORAL|advice literature with naturopathy|advice literature with naturopathic remedies will be handed out and application will be supported with dairies and phone calls
224161571|NCT04829942|BEHAVIORAL|positive health behavior|Training on nutrition, physical activity, first aid, individual hygiene, violence and bullying will be provided to the initiative group.
224161572|NCT06794697|OTHER|Questionnaire including APAIS scale|Patients will complete a questionnaire in two stages : upon admission and just before leaving for the operating room
224304445|NCT03695861|DIAGNOSTIC_TEST|Whole-body 18F-FDG PET-CT scan|A 18F-FDG PET-CT will be performed within 5 days of the beginning of the patients care with infectious endocarditis at the University Hospital center of Bordeaux.
223474484|NCT05789966|DEVICE|Genetic Risk Estimate + Fitbit Functions+Health Coaching|"Intervention: Device: Genetic Risk Estimate + Fitbit Functions The genetic risk information includes individual remaining-lifetime and 10-year genetic risk estimates for CHD as well as a dichotomized genetic risk category: 'increased genetic risk' or 'no increased genetic risk'.~The two unique Fitbit functions are step goal setting and prompts. Individualized daily step goals will be set to be 10% higher than participants' own baseline Fitbit step counts. The 'Reminder To Move' function of Fitbit will be used as a prompt to remind participants to reduce sedentary time and walk at least 250 steps/hour within a specified timeframe (i.e., from 9am to 10pm in the proposed research). If the user has not accumulated at least 250 steps/hour, a reminder (for example, 150 steps to go) will appear on the Fitbit screen at 10 minutes before the hour (for example, at 10:50 a.m.) and cause the device to vibrate. Health coaching will be incorporated as well"
223474485|NCT04206865|DRUG|Sacubitril-Valsartan|Patient's will be randomized to ICU initiation of sacubitril-valsartan vs. alternate oral vasodilator therapy in 1:1 fashion
223474486|NCT04206865|DRUG|Standard Oral Vasodilators|Patient's will be randomized to ICU initiation of sacubitril-valsartan vs. alternate oral vasodilator therapy in 1:1 fashion. Alternate vasodilators will include ARBs, hydralazine and isosorbide dinitrate, and ACEi
223474487|NCT04554472|DIAGNOSTIC_TEST|Intraoperative ultrasound|During the surgery, the standard AP and lateral x-rays will be performed. Additional projections (lateral 30 degrees tilt, and dorsal tangential view) will also be registered. Finally an intraoperative ultrasound of the wrist extensor tendons will be taken, checking the compartments individually in order to detect invasion of the dorsal cortex by the screws. In case of no protrusion, the patient will be registered as a correct fixation. Otherwise, it will be specified which position of the plate and which compartment the screw/s protrude. A screw with a correct measurement will then be replaced and implanted and recorded as a measurement error.
223744063|NCT05304754|BIOLOGICAL|Alloreactive NK cells|When the patient lacks the HLA class I molecule and his donor has this molecule and also the donor NK cells have the KIR receptor that recognizes the absence of the corresponding HLA class I ligand
223744064|NCT01312818|DRUG|Bortezomib|1.3 mg/m\^2 by intravenous pyelogram (IVP) over 3-5 seconds on days 1, 4, 8 and 11.
223744065|NCT01312818|DRUG|Vorinostat|180 mg/m\^2 (max dose 400mg) by mouth (PO) divided twice a day (BID) on days 1-14
224069724|NCT00881777|PROCEDURE|Radiofrequency heating of the myocardial infarct scar|Radiofrequency energy is applied to the epicardial surface of the heart using an external generator and a hand-held probe to heat myocardial infarction scar.
224069725|NCT00881777|PROCEDURE|Coronary Artery Bypass Grafting (CABG) surgery|A standard surgical procedure performed to relieve angina and reduce the risk of death from coronary artery disease. Arteries or veins from elsewhere in the body are grafted to the coronary arteries to bypass atherosclerotic narrowings and improve the blood supply to the coronary circulation supplying the myocardium.
224069726|NCT03420950|OTHER|Rapid sequence intubation: sedative first|Sedative first
224069727|NCT03420950|OTHER|Rapid sequence intubation: paralytic first|Paralytic first
224069728|NCT02560610|DRUG|OC000459|
224069729|NCT02560610|DRUG|Placebo|
224069730|NCT02215603|BEHAVIORAL|Breaking prolonged sitting with physical activity|
224069731|NCT00739414|DRUG|LBH589|10, 15, 20 mg/m2, i.v. on day 1 and 8 of each 21 day cycle
224069732|NCT02452580|OTHER|Family Centered Care|Neonatal intensive care toward premature infants and their parents in a unit physically and culturally optimized for parent-infant interaction 24 hours a day 7 days a week from birth to discharge.
224069733|NCT04607733|DRUG|Mirikizumab Prefilled Syringe|Administered SC by prefilled syringe
224069734|NCT04607733|DRUG|Mirikizumab Autoinjector|Administered SC by autoinjector
224069735|NCT02482675|OTHER|Glucose|Following baseline measurements, participants will consume a 75 g glucose solution within five minutes.
224069736|NCT02482675|OTHER|Glucose with Non-fat Milk|Following baseline measurements, participants will consume 75 g glucose dissolved in two cups of non-fat milk within five minutes.
224069737|NCT02482675|OTHER|Glucose with Whey Protein Isolate|Following baseline measurements, participants will consume 75 g glucose and whey protein isolate dissolved in 2 cups water within five minutes.
224069738|NCT02482675|OTHER|Glucose with Sodium Caseinate|Following baseline measurements, participants will consume 75 g glucose and sodium caseinate dissolved in 2 cups water within five minutes.
224069739|NCT00300638|PROCEDURE|Magnetic Resonance Imaging (MRI)|We present emotional words and pictures on a computer screen, and using MRI scans, we observe how the brain works when people purposefully respond to the words and pictures. Additionally, we are comparing brain structure and activation patterns in men and women, because there may be gender differences in responses to emotional stimuli.
224069740|NCT00300638|BEHAVIORAL|Interviews, cognitive tests, and emotional measurements|We present emotional words and pictures on a computer screen, and using MRI scans, we observe how the brain works when people purposefully respond to the words and pictures. Additionally, we are comparing brain structure and activation patterns in men and women, because there may be gender differences in responses to emotional stimuli.
224069741|NCT04276714|OTHER|Socket without Revofit system|All the tests are evaluate during one week with the classical type of fittings
224069742|NCT04276714|OTHER|Socket with Revofit system|All the tests are evaluate during one week with the adjustable type of fittings (that is to say with Revofit system)
224069743|NCT02501265|BEHAVIORAL|Varenicline Standard Protocol|"4 weeks pre-TQD: Start Placebo Varenicline~1 week prior to TQD: Switch to Active Varenicline~1 week prior to TQD: Start Placebo Bupropion Varenicline + Placebo Bupropion to 12 weeks post TQD"
224069744|NCT02501265|BEHAVIORAL|Nicotine Patch Standard Protocol|"4 weeks pre-TQD: Start Placebo Nicotine Patch TQD: Start active Nicotine Patch~1 week prior to TQD: Start Placebo Bupropion Nicotine Patch + Placebo Bupropion to 12 weeks post TQD"
224069745|NCT02501265|DRUG|Varenicline Adaptive Protocol|"VARENICLINE RESPONDER 4 weeks pre-TQD: Start Varenicline 2 weeks pre-TQD: DOES reduce cigs/day by \> 50% 1 week pre-TQD: Start Placebo Bupropion Varenicline + Placebo Bupropion to 12 weeks post TQD~VARENICLINE NON-RESPONDER 4 weeks pre-TQD: Start Varenicline 2 weeks pre-TQD: DOES NOT reduce cigs/day by \> 50%~1 week pre-TQD: Start active Bupropion Varenicline + Bupropion to 12 weeks post TQD"
224161573|NCT04493463|DRUG|Methylprednisolone 40 mg + Ropivacaine + Saline|To infiltrate the study solution, the surgeon will inject the incision site with a 10 cm long, 22-gauge needle before the closing of the incision site. A standard volume of 10 ml in each level will be injected, based on the study by Milligan et al., with a total of 5ml study solution injected laterally into the erector spinae muscle and 5 ml subcutaneously along both margins of the incision. This standardization will be on the basis of the number of levels to be treated, and will be consistent in each patient. The depth of penetration will include the subcutaneous tissues, paravertebral muscles, along with the deep muscles surrounding the spinous process, lamina, transverse process and facet joints; the epidural space and intrathecal space will be spared. The local infiltration solution in the treatment group will consist of a total of 30 ml study solution, containing 1 ml of 40 mg methylprednisolone plus 15ml of 1% ropivacaine and 14 ml saline.
224304446|NCT01019928|DRUG|AZD1386|95 mg, oral solution, single dose
223474488|NCT03894358|DIETARY_SUPPLEMENT|FeFum and 7.5 g prebiotic mixture|"The 3 weeks intervention will consist of 24 g of wheat-based instant cereal and 90 ml of water per portion and will contain 3.6 mg FeFum and AA (molar ratio Fe:AA between 2.5 and 3) plus 7.5 g prebiotics mixture~The absorption study test meals will consist of 24 g wheat-based instant cereal and 90 ml of water per portion and additionally:~Test meal 1 will be composed of: 3.6 mg of Fe as 57FeFum and 0 g prebiotic mixture added extrinsically.~Test meal 2 will be composed of: 3.6 mg of Fe as 1.5 mg iron as 58FeFum, 2.09 mg iron as 56FeFum and 7.5 g prebiotic mixture added extrinsically."
223474489|NCT03894358|DIETARY_SUPPLEMENT|FeFum and 3 g prebiotic mixture|Standard wheat-based instant cereal containing 3.6 mg FeFum and AA (molar ratio Fe:AA between 2.5 and 3) plus 3 g prebiotics mixture per portion
223474490|NCT03894358|DIETARY_SUPPLEMENT|Fefum and no prebiotic mixture|Standard wheat-based instant cereal containing 3.6 mg FeFum and AA (molar ratio Fe:AA between 2.5 and 3) per portion.
223474491|NCT05379920|BEHAVIORAL|High Volume Aerobic Exercise|Aerobic exercise is completed for 30 minutes, 5 days a week. Exercise intensity is adjusted weekly to 90% of the heart rate threshold. Exercise interventions for all participants are adjusted to the 90% Heart rate threshold (HRt) collected on the BCTT.
223474492|NCT05379920|BEHAVIORAL|Low Volume Aerobic Exercise|Aerobic exercise is completed for 20 minutes, 3 days a week. Exercise intensity is adjusted weekly to 90% of the heart rate threshold. Exercise interventions for all participants are adjusted to the 90% Heart rate threshold (HRt) collected on the BCTT.
223474493|NCT03176771|DRUG|MT-5199|MT-5199 40 mg capsules
223474494|NCT03176771|DRUG|Placebo|MT-5199 placebo capsules
223474495|NCT03030521|DIAGNOSTIC_TEST|the aortic delamination test|The aortic delamination test will be performed in the dissected tissue of all patient. The processes of this test has been descripted in the summary.
223474496|NCT06440928|BEHAVIORAL|mobilization|mobilization and exercise to be applied to patients with chronic lateral epicondylitis
223474497|NCT06440928|OTHER|standard treatment|standard treatment
223474498|NCT06440928|OTHER|deep friction|deep friction
223474499|NCT02879292|OTHER|Spinal anesthesia|Spinal Anesthesia
223581639|NCT04867694|BEHAVIORAL|CMAM compliance|"Weekly follow-up of \[6-59\] months old children under treatment and for 6 months after discharge from the national treatment and consolidation program : care group volunteers follow children under treatment until they recover and for the whole duration of their consolidation (for children cured of severe emaciation) through weekly home visits.~They monitor treatment adherence (i.e., families follow the planned schedule of visits and receive inputs for treatment or consolidation) and treatment compliance (i.e., the malnourished or consolidating child receives the planned dose of therapeutic or supplementary food each day)."
223581640|NCT05577949|OTHER|Structured aerobics exercise|A 12 week structured aerobics exercise program will be offered. The patient has to perform exercise five times a week , 30 minutes a day
224163803|NCT06367049|DIAGNOSTIC_TEST|Methylation-specific PCR|"Methylation-specific PCR is the simplest and quickest method for qualitative detection of methylation status.~The unmethylated C base is converted to U by bisulfite conversion, which is subsequently amplified by PCR with primers (methylation-specific and non-methylation-specific primers) and subsequently detected by agarose gel electrophoresis or a probe. The key to MSP is to design PCR primers for specific gene regions. The research team of this project has previously found the sequence sites of methylation of H4C6, Septin9 and RASSF1A genes in nasopharyngeal carcinoma tissues through methylation sequencing, and designed specific MSP amplification primers and probes accordingly, which can perform methylation detection easily and quickly."
224304447|NCT01019928|DRUG|Placebo to AZD1386|Placebo, oral solution, single dose
224304448|NCT03450395|OTHER|Hot Cereal|Intervention involves consumption of one hot cereal in the beginning of each day
223474500|NCT02445469|OTHER|MRI exam of the brain|MRI exam of the brain
223474501|NCT03530293|DRUG|Valbenazine|vesicular monoamine transporter 2 (VMAT2) inhibitor
224304449|NCT02214784|DEVICE|Active Neurotech Vital|12 weeks treatment for 30 minutes per day, 5 days out of 7.
224304450|NCT02214784|DEVICE|Modified Neurotech Vital Device|12 weeks treatment for 30 minutes per day for 5 days out of 7.
223474502|NCT03530293|DRUG|Placebo oral capsule|non-active dosage form
223474503|NCT02069795|OTHER|Voice recording|
223474504|NCT04326257|DRUG|Nivolumab+Relatlimab|IV administration of both Nivolumab and Relatlimab
223581641|NCT03715296|DRUG|Lenalidomide 25mg|Lenalidomide 25mg/d PO d1-10 Plus Rituximab 375 mg/m2 IV d1, Cyclophosphamide 750mg/m2 IV d2, Doxorubicin 50mg/m2 IV d2, Vincristine 1.4 mg/m2 IV d2, Prednisone 60 mg/m2 PO d2-6 OR Ifosfamide 1500mg/m2/d iv d1-3, Carboplatin 5\*\[GFR(ml/min)+25\]mg/d iv d2, Etoposide 100mg/m2/d iv d1-3,
223474505|NCT04326257|DRUG|Nivolumab+Ipilimumab|IV administration of both Nivolumab and Ipilimumab
223474506|NCT00000948|DRUG|Aldesleukin|Il-2
223744066|NCT01312818|DRUG|Dexamethasone|6 mg/m\^2 by mouth (PO) divided twice a day (BID) on days 4-15.
223744067|NCT01312818|DRUG|Methotrexate|Intrathecal Methotrexate at age based dose on day 1 (repeat on day 15 or 16 for CNS positive patients only)
223744068|NCT01312818|DRUG|Imatinib mesylate|"For Ph+ acute lymphoblastic leukemia (ALL) patients only:~Imatinib Mesylate is allowable at 340 mg/m2 PO once a day (rounded to the nearest 100 mg) for age ≤18 years and 400 mg for \>18 years on Days 1-16."
223474507|NCT00000948|DRUG|ART|antiretroviral therapy for the treatment of HIV
224304451|NCT02352545|DRUG|Montelukast|Patients in experimental treatment arm were given Montelukast Sodium Tablets (p.o., 10mg, q.d.) .
223581642|NCT05190055|DEVICE|bone graft delivery system/wiltrom interbody fusion system/wiltrom spinal fixation system|After receiving prophylactic antibiotics according to the local hospital protocol, the patients were generally anesthetized in a prone position. Paramedian or midline posterior sections were conducted, exposing the lumber vertebras encompassing the facet joints. The facet joints were removed, and decompression was performed. The diseased disc nucleus was then excised before filling in the bone substitutes. In the case of the device group, a novel filler tube with an integrated threaded rod, which can be connected to a surgical drill, A PEEK interbody fusion cage was then placed into the disc space followed by fixation with pedicle screws.
224161574|NCT04493463|DRUG|Ropivacaine + Saline|To infiltrate the study solution, the surgeon will inject the incision site with a 10 cm long, 22-gauge needle before the closing of the incision site. A standard volume of 10 ml in each level will be injected, based on the study by Milligan et al., with a total of 5ml study solution injected laterally into the erector spinae muscle and 5 ml subcutaneously along both margins of the incision. This standardization will be on the basis of the number of levels to be treated, and will be consistent in each patient. The depth of penetration will include the subcutaneous tissues, paravertebral muscles, along with the deep muscles surrounding the spinous process, lamina, transverse process and facet joints; the epidural space and intrathecal space will be spared. The local infiltration solution in the control group will consist of a total of 30 ml study solution, containing 15 ml of 1% ropivacaine and 15ml saline.
224161575|NCT02707679|OTHER|Mulligan's Straight leg-raise with traction|Mulligan's Straight leg raise technique was performed on patients with patellofemoral pain syndrome. The extremity on which the practice would be performed in supine position was grasped from the ankle level and was, then, subjected to traction longitudinally. Afterwards, the knee was lifted up passively while in extension and was kept for waiting for a few seconds at the point where tension was felt and was, then, returned to its initial position. The practice was repeated 10 times, and 3 sets of practice at 1-minute-intervals were performed.
224161576|NCT02707679|OTHER|Mulligan's Mobilization with Movement|Mulligan's Mobilization with Movement technique was performed on patients with patellofemoral pain syndrome. Each patient was tested in every direction in the course of the active knee flexion-extension movement so as to find out the best pain-free tibial gliding direction (medial-lateral part of the tibia, anterior-posterior, internal-external rotation). At the time of the active movement of the knee, the tibial gliding direction where pain was felt at the least was selected as the treatment direction of mobilization technique along with movement. The practice was performed by doing 10 repetitions for 3 sets and by providing 1-minute-resting time between the sets.
224161577|NCT02707679|OTHER|Kinesiotaping|Kinesiotaping was applied on patient with patellofemoral pain syndrome. To maintain proprioceptive stimulation in the quadriceps (from origo towards insertio) and to alleviate the tension of hamstring muscle, a 'Y''-shaped kinesiotape was applied by using the muscle technique.
224161578|NCT02707679|OTHER|Exercise|All the patients were provided with several exercises within the scope of the home exercise program, such as hamstring muscle stretching, quadriceps isometric exercises, 4-way-strengthening with exercise elastic bands for the muscles of the hip, knee locking on foot and mini-squatting exercises. They were asked to do these exercises in 3 sets a day along with 10 repetitions for a period of 6 weeks.
224161579|NCT02376478|DRUG|TNF-alpha inhibitors|therapy for at least 6 months
224161580|NCT02376478|DRUG|Alternative/no medication|therapy for at least 6 months or no therapy
224161581|NCT02376478|OTHER|Alternative/no medication|phototherapy for at least 6 months
224161582|NCT02376478|DRUG|Purine/folic acid analogues|therapy for at least 6 months
223581643|NCT05190055|DEVICE|wiltrom interbody fusion system/wiltrom spinal fixation system|After receiving prophylactic antibiotics according to the local hospital protocol, the patients were generally anesthetized in a prone position. Paramedian or midline posterior sections were conducted, exposing the lumber vertebras encompassing the facet joints. The facet joints were removed, and decompression was performed. The diseased disc nucleus was then excised before filling in the bone substitutes. For the control group, the bone substitutes were filled in the disc space manually using a bone grafting funnel. A PEEK interbody fusion cage was then placed into the disc space followed by fixation with pedicle screws.
224161583|NCT01924741|PROCEDURE|ALPPS|Other procedures related to ALPPS like banding of the parechyma with portal vein ligation etc.
224161584|NCT02451033|DRUG|standard medical therapy|diuretics, albumin infusion, antibiotics, nutrition, and variceal banding wherever needed
224161585|NCT02451033|DRUG|G-CSF|G-CSF at the dosage of 5 µg/Kg subcutaneously every 12 hr for five consecutive days then every 3 monthly for 3 days till 1 year
224161586|NCT02451033|DRUG|Growth Hormone|Growth Hormone in low dose of 1unit sc daily for 1 year
224161587|NCT01915017|BEHAVIORAL|Cognitive Behavior Therapy for Psychosis|The CBT manual to be used for the present study was based upon the work of Kingdon and Turkington (2005) and Granholm et al., (2005) a group-delivered CBT skills training). Available manuals were modified to improve ease of training and to better accommodate the delivery of the full CBT treatment in the home environment. Supervision will be provided throughout the study by D. Turkington and S. Tai world renowned experts in CBT for psychosis. Training will be held for 1-2 weeks annually and supervision will proceed weekly via SKYPE. All therapists will be certified prior to providing treatment for the trial. Sessions are conducted weekly by master's and doctoral level therapists.
224161588|NCT01915017|BEHAVIORAL|Cognitive Adaptation Training|CAT supports are established and maintained on weekly home visits by bachelor's and master's level staff. Regular supervision will be provided by the PI who developed CAT.
224161589|NCT01915017|BEHAVIORAL|Multi-modal Cognitive Therapy|A manual driven intervention combining CBT and CAT. Weekly sessions delivered in the home focus on altering cognitive biases using CBT and bypassing cognitive deficits using environmental supports
224161590|NCT01915017|OTHER|Treatment as Usual|Standard medication follow up and limited case management
224161591|NCT06020833|DRUG|Roxadustat in combination with retinoic acid|Roxadustat 150mg po qod combined with retinoic acid 20mg po bid
224161592|NCT02571972|DRUG|Dorzolamide-timolol|On enrollment, eligible patients will be started on topical dorzolamide-timolol in the study eye twice daily for the study duration
224161593|NCT01070238|DIETARY_SUPPLEMENT|Isomaltulose|
224161594|NCT01502358|BIOLOGICAL|Tetravalent Dengue Vaccine (TVDV)|Low dose delivered intramuscularly on Study Days 0, 30 and 90
224163804|NCT00432640|PROCEDURE|Endoscopic ultrasound staging|Endoscopic ultrasound staging with both EUS-FNA and EBUS-TBNA
224161595|NCT01502358|BIOLOGICAL|Tetravalent Dengue Vaccine (TVDV) with Vaxfectin® (low-dose)|Low dose: TVDV formulated with Vaxfectin®; 1.0 mL volume delivered intramuscularly on Study Days 0, 30 and 90
224304452|NCT06152952|PROCEDURE|The rhomboid flap approach|"The rhomboid flap Approach :~The flap will be dissected deep to the gluteal fascia (subfascial level) so as to raise thick a fasciocutaneous flap. This will assure good vascularity of the flap without dead space. The rhomboid flap (CDEF) will be mobilized from the gluteal fascia and sutured without tension in three layers~The deep suturing approach :~A vertical elliptical incision encompassing all pilonidal pits will be made and excision of the sinus will be carried out down to the level of the sacrococcygeal fascia. T then the deep fascia will be approximated and the wound will be closed"
223474508|NCT04925102|OTHER|Standardized treatment protocol for cerebral palsy|Passive and active range of motion (ROM) exercises of all joints, prone positioning, slow prolonged manual stretching (30 minutes daily), standing frame for children with GMFCS IV-V, supported sitting, supported walking, lower limb serial casting (if needed), active strength training, progressive resistance training, functional exercises, sensory integration: therapeutic activities to organize sensation from the body and environment, bimanual training: repetitive task training in the use of two hands together, context-focused therapy: changing the task or the environment, the occupational therapy, cognitive behaviour therapy and home programmes.
223474509|NCT00626288|DRUG|Mesalazine|Mesalazine 800mg t.i.d. 12 weeks
223474510|NCT00626288|DRUG|Placebo|Placebo cpr, t.i.d. 12 weeks
223474511|NCT00687934|DRUG|STA-9090|This is a dose-escalation study. The first cohort will consist of three patients who will receive STA 9090 (ganetespib)during a 1-hour infusion once per week for three consecutive weeks followed by a 1 week dose-free interval. Subsequent cohorts will receive higher amounts of STA-9090 (gantespib) provided that the previous dose was well tolerated during cycle 1 (week 1 - 4). Dose escalation will continue until the maximum tolerated dose (MTD) is determined.
223474512|NCT02024061|BEHAVIORAL|Peer support|
224304453|NCT04016441|OTHER|Survey|Participants will complete a survey online
223474513|NCT02024061|BEHAVIORAL|Regular treatment|The participants in this arm will receive the regular obesity treatment provided by the hospital and university (interactive sessions and physical activity).
223474514|NCT03385733|OTHER|inspiratory muscle training|The treatment group received IMT. Patients were trained using an inspiratory threshold-loading device
223474515|NCT03541993|DIETARY_SUPPLEMENT|Resveratrol|
223474516|NCT03541993|OTHER|Placebo|
224161596|NCT01502358|BIOLOGICAL|Tetravalent Dengue Vaccine TVDV with Vaxfectin® (High Dose)|High dose: TVDV formulated with Vaxfectin®; 1.0 mL volume delivered intramuscularly on Study Days 0, 30 and 90
223474517|NCT02059707|DEVICE|LARIAT RS Suture Delivery Device|LARIAT RS Suture Delivery Device
224304454|NCT02302859|DRUG|Nicotine Patch|Participants receive an 8 week supply of Nicotine patches.
223474518|NCT03276208|OTHER|Prenatal Massage|We will utilize moderate pressure Swedish massage (SM) that utilizes long slow strokes known as effleurage and kneading strokes known as petrissage. A specific routine will be performed on each participant with focus on low back, upper back, shoulders, and neck musculature. Consistent moderate pressure, which is lighter than deep tissue massage but deeper than brush strokes, will be used.
223474519|NCT03276208|OTHER|Mindfulness|The intervention and control group will be enrolled in the Craving to Quit® program, a 21-day mindfulness-based program delivered via a smartphone application (https://www.cravingtoquit.com/). This program uses a mindfulness-based approach to train people to recognize and be aware of their tobacco cravings. The program includes videos, online exercises to complete, and a virtual support community.
223474520|NCT01997125|DEVICE|Neural Bridge System|Implanted device
223474521|NCT04550117|PROCEDURE|Insertion of Intraspinal pressure monitor|A fiberoptic pressure monitoring wire will be placed into the subarachnoid space at the site of traumatic spinal cord injury
223474522|NCT01514916|DEVICE|mechanical anastomosis without suture|The Vascular Join device is intended to be used to create sutureless end-to-end anastomosis between an artery and a venous or synthetic graft conduit. Any type of e-PTFE and Dacron conduits can be used.
223474523|NCT05805449|PROCEDURE|Surgery|Control patients will receive usual standard of care surgical repair of their complex fistula by LIFT or advancement flap technique without any biologic adjunct.
223581644|NCT03399656|DIETARY_SUPPLEMENT|Avmacol tablets|The active components of Avmacol® are ground broccoli seeds that provide glucoraphanin and freeze-dried broccoli sprouts that provide a stabilized form of the enzyme myrosinase, which converts glucoraphanin to sulforaphane.
223581645|NCT03399656|DIETARY_SUPPLEMENT|Placebo tablets|MCC 90M Emcocel
223581646|NCT01612455|BEHAVIORAL|LINC Case Management|The 1st case management (CM) session will be at the Narcology Hospital and will follow a modified strengths-based case management curriculum. As part of this first session, the CM will show a 10 minute video clip produced by a Russian NGO of HIV-infected patients talking about accessing HIV care. The CM will also tell the patient what his/her CD4 cell count is and discuss what it means with the patient. The case manager will help the client identify the outpatient HIV clinic on a map and will discuss basic drug harm reduction ideas with the client. The remaining 4 CM sessions will happen over the following 6 months. Sessions may happen at the HIV clinic, NGOs, or in the community. The HIV CM helps the client understand the importance of HIV care, identify barriers to care acquisition and recognize one's own strengths, abilities and assets to reduce self-identified barriers to care. The HIV CM's primary aim is to have the client attend an appointment at the HIV outpatient clinic.
223581647|NCT02845076|OTHER|Protocol for weaning of noninvasive ventilation|3 protocols for weaning of noninvasive ventilation will be compared
223581648|NCT05324423|DRUG|Colchicine|Colchicine0.5 mg Oral Tablet Day-7\~Day25 qd；Febuxostat 40 mg Oral Tablet Day1 and Day14 qd；XNW3009 0.5 mg Oral Tablet Day8 and Day21 qd
224161597|NCT04843943|DRUG|Sintilimab|Sintilimab: 200mg IV Q3W D1
224161598|NCT04843943|DRUG|Bevacizumab Biosimilar|Bevacizumab biosimilar: 15mg/kg, IV, Q3W, D1
224161599|NCT03137017|DRUG|Norco 5Mg-325Mg Tablet|Single oral dose in one of the four cross-over trial periods.
224304455|NCT02302859|BEHAVIORAL|Questionnaires|Questionnaire completion at baseline on laptop, then weekly for 8 weeks on smartphone, then 3 months after smartphone intervention.
224304456|NCT02302859|OTHER|Pamphlet|Pamphlet given to participant describing health and financial reasons to quit smoking.
223474524|NCT05805449|OTHER|Platelet-rich plasma (PRP)|Participants will have 40-50cc of peripheral whole blood drawn into a syringe pre-loaded with acid citrate dextrose (ACD) anticoagulant and concentrated PRP harvested by double centrifugation technique using the manufacturer's kit and benchtop centrifuge. This typically yields 5-8cc of PRP that is 18-times more concentrated than baseline.
223474525|NCT05805449|DEVICE|Matrix|"Participants will receive 200g of paste matrix and 200g injected at the following sites: the internal opening closure site at level of the sphincter muscle, within the walls of the fistula tract along its length, and within the tissue of an advancement flap particularly at areas of tissue apposition."
223474526|NCT03805334|OTHER|Touchpoints|Touchpoints are worn on either the wrists or ankles. They deliver a low level vibration in an alternating fashion to the skin.
223474527|NCT00306254|DRUG|PD 0348292|
223474528|NCT00306254|DRUG|Enoxaparin|
223581649|NCT06376071|DIAGNOSTIC_TEST|functional endoscopic sinus surgery|functional endoscopic sinus surgery for diagnosis the disease
223581650|NCT05410262|OTHER|Evaluation of CT images|A helicoidal CT scanner will be used (Aquilion CXL, Toshiba, Japan), with AIDR 3D technique (Adaptive Iterative Dose Reduction 3D) in order to minimize exposure to X-rays. Two complete thorax CT scans will be performed, one of them in expiratory pause (PEEP) and the other in inspiratory pause (PPlat). Esophageal pressure shall be measured (FluxMed GrT, Argentina) and transpulmonary pressure will be calculated at the end of inspiration (Ppl-insp) and expiration (Ppl-exp).
223581651|NCT01272791|BIOLOGICAL|bavituximab|Patients who qualify for enrollment into the study will be randomized in a 1:1 ratio to receive study treatment of gemcitabine alone or gemcitabine with weekly 3 mg/kg bavituximab. Treatment for each patient will begin on Study Day 1. Gemcitabine (1000 mg/m2) will be given on Days 1, 8 and 15 of each 28 day cycle (4 weeks) until disease progression or unacceptable toxicities. Patients randomized to receive bavituximab will be treated weekly beginning on Day 1 of each cycle. Study visits are scheduled to occur every 7 (± 2) days for bavituximab administration (for patients randomized to receive bavituximab); gemcitabine administration will occur every 7 (± 2) days for the first 3 weeks of each 4-week cycle
223581652|NCT01272791|DRUG|Gemcitabine|Gemcitabine (1000 mg/m2) will be given on Days 1, 8 and 15 of each 28 day cycle (4 weeks) until disease progression or unacceptable toxicities
223581653|NCT02570243|DRUG|High dose of Unfractionated Heparin|Unfractionated Heparin 100IU/Kg
223581654|NCT02570243|DRUG|Standard dose of Unfractionated heparin|Unfractionated heparin 50IU/Kg
223581655|NCT01650714|OTHER|Full thickness gastric biopsy|
223581656|NCT01650714|PROCEDURE|Full thickness gastric biopsy|
223581657|NCT01634529|DRUG|V158866|Single ascending oral doses of V158866 and Placebo
223581658|NCT01634529|DRUG|V158866|Multiple ascending oral doses of V158866 and Placebo
223581659|NCT03123614|DRUG|Loteprednol Etabonate 0.5% Oph Gel|
224069746|NCT02501265|DRUG|Nicotine Adaptive Protocol|"NICOTINE PATCH RESPONDER 4 weeks pre-TQD: Start Patch 2 weeks pre-TQD: DOES reduce cigs/day by \> 50% 1 week pre-TQD: Start Placebo Bupropion Patch + Placebo Bupropion to 12 weeks post TQD~NICOTINE PATCH NON-RESPONDER 4 weeks pre-TQD: Start Patch 2 weeks pre-TQD: DOES NOT reduce cigs/day by \> 50%~1 week pre-TQD: Start Bupropion Patch + Bupropion to 12 weeks post TQD"
223474529|NCT05728476|PROCEDURE|Vitrectomy combined with ILM peeling|Standard 25-gauge PPV will be performed by an experienced surgeon under retrobulbar anesthesia. After clearing the central vitreous, a complete posterior vitreous detachment (PVD) will be achieved with aspiration to remove the tightly attached posterior hyaloid. The vitreous will be removed by a high-speed vitrectomy surgical system (Constellation Vision System, Alcon Laboratories, Fort Worth, Texas, USA). The ILM stained with indocyanine green (ICG) will be peeled up to the vascular arcades. In case of need, panretinal photocoagulation (PRP) can be performed during surgery. The vitreous cavity will be filled with balanced salt solution (BSS) at the end of the procedure.
223474530|NCT05728476|DRUG|Conbercept intravitreal injection|Patients will receive three monthly intravitreal injections of 0.5 mg Conbercept (Chengdu Kanghong Biotech Co.) with a 30-gauge syringe needle approximately 3.5-4 mm posterior to the corneal limbus under topical anesthesia.
224069747|NCT04856553|OTHER|Acute effects of handgrip exercise|The participants will be randomized into three sessions, handgrip exercise in the morning, handgrip exercise in the afternoon, and control performed in the morning to analyze the acute effects of handgrip exercise on blood pressure and vascular function at different times of the day. After the morning sessions, ambulatory blood pressure will also be measured for 24 hours.
224069748|NCT06005870|DRUG|Zanubrutinib plus RCHOP|Rituximab 375mg/m2 D1; cyclophosphamide 750mg/m2 D2; adriamycin 50 mg/m2 D2 vincristine 1.4mg/m(Max 2mg) D2; prednisone 100mg/d D2-6; Zanubrutinib 160 mg, the bid D1-21
224069749|NCT00689572|DRUG|Ondansetron|4 mg twice a day + Cognitive Behavioral Therapy + Brief Behavioral Enhancement Therapy
224069750|NCT00689572|DRUG|Placebo|twice a day + Cognitive Behavioral Therapy + Brief Behavioral Enhancement Therapy
224069751|NCT06195722|OTHER|simulation|parenteral drug simulation
224069752|NCT02298829|DRUG|Subjects Previously Treated with AA4500|no treatment to be administered - observational only
223474531|NCT00231023|DRUG|Peribulbar Triamcinolone Acetonide|
223581660|NCT03123614|DRUG|Prednisolone Acetate 1% Oph Susp|
223581661|NCT00633789|DRUG|brivanib|Tablets, Oral, 800 mg, once daily, until progression
223581662|NCT00633789|DRUG|Placebo|Tablets, Oral, 0 mg, once daily, until progression
223581663|NCT01367392|DEVICE|biopsy or ablation|biopsy or ablation performed as in standard of care with assistance of ActiSight Needle Guidance system
223581664|NCT04109833|DRUG|ABT|any antibiotic therapy in the first week of life
223581665|NCT03030339|OTHER|High VA intake, recent VAS|Children who are exposed to multiple VA programs, have received a high-dose VA supplement (VAS; 200,000 IU) in the past month, and are identified as being likely to have chronic excessive dietary VA intake.
223581666|NCT03030339|OTHER|High VA intake|Children who are exposed to multiple VA programs, have received a high-dose VA supplement (200,000 IU) in the past 3-6 months, and are identified as being likely to have chronic excessive dietary VA intake.
224069753|NCT03303794|DRUG|Exparel|1.3 % liposomal Bupivacaine in patients undergoing total knee arthroplasty
224069754|NCT03303794|DRUG|0.25% bupivacaine|0.25% bupivacaine in patients undergoing total knee arthroplasty
224161600|NCT03137017|DRUG|GRT7014 - Abuse Deterrent Tablet|Single oral dose in one of the four cross-over trial periods.
224161601|NCT00695500|DRUG|Varenicline|Varenicline tablets, 2 mg per day for 3 weeks
223474532|NCT04229823|DIAGNOSTIC_TEST|Video-oculography|Eye movement parameters will be measured in all of the subjects using video-oculography device (EyeSeeCam, InterAcoustics). Measurement sessions consist of the study subject wearing a goggle attached to a camera that detects the pupil and eye position and velocity. Evaluation start with vestibulo-ocular reflex testing, with video head impulse test. Afterwards, saccades, smooth pursuit and fixation are evaluated.
223474533|NCT04229823|DIAGNOSTIC_TEST|Clinical Scales|All subjects are examined by an investigator in order to score clinical scales for ataxia, including Scale for the Assessment and Rating of Ataxia (SARA), International Co-operative Rating Scale (ICARS), Neurological Examination Scale for SCA (NESSCA), Inventory of Non-ataxia Symptoms (INAS), SCA Functional Index (SCAFI) and Composite Cerebellar Functional Severity Score (CCFS).
223474534|NCT04229823|DIAGNOSTIC_TEST|Genotyping|Individuals at 50% risk (offspring of subjects with molecular diagnosis of SCA3/MJD) will be genotyped in a double-blind manner so that they can be divided into pre-ataxic carriers and related controls (non carriers)
223474535|NCT02016846|DRUG|Liraglutide|
223474536|NCT02016846|DRUG|Placebo|
224161602|NCT00695500|DRUG|Placebo|Placebo tablets, 0 mg per day for 3 weeks
223474537|NCT01812187|BEHAVIORAL|SHIFT Cognitive Behavioral Therapy|Manualized, evidence-based, cognitive behavioral therapy for the treatment of substance abuse disorders
223474538|NCT06436716|RADIATION|MRI|Every patient needs an MRI to assess spinal cord injury. This is one of the clinically necessary examinations.
223474539|NCT01082419|DEVICE|ARFI measurement|"ARFI values are measured during a standard liver ultrasound examination, with patient lying on his back and performing a light apnea.~For group A the measurement is made by a second and a third investigator during the same examination."
223581667|NCT03030339|OTHER|Low/adequate VA intake|Children who are not exposed to multiple VA programs, have received a high-dose VA supplement in the past 3-6 months, and are identified as being likely to have chronic low to adequate dietary VA intake.
223581668|NCT00973102|DRUG|Premarin IV|One time dose of Premarin IV
223581669|NCT00973102|DRUG|Placebo|One time dose of placebo.
224069755|NCT03070158|BEHAVIORAL|Attachment Promotion|"Attachment Promotion consists of:~1. Education session about newborn and mother care.~2. Training in multisensory stimulation using the ATVV Intervention (auditory, tactile, visual and vestibular)~3. Two domiciliary visits to follow up and to give education about newborn care and ATVV Intervention.~4. Daily Phone follows up."
224304457|NCT02302859|BEHAVIORAL|Phone Counseling Sessions|"Standard Treatment (ST) Group: Participants receive 8 phone counseling sessions (one session per week) for support in quitting smoking. The calls should last about 15 minutes.~Automated Treatment (AT) Group: Participants receive brief video clips with advice on how to quit smoking over smartphone, as well as interactive text and picture messages once a week for 8 weeks. The video clips will be about 5 minutes long.~Participants also have access to additional counseling content on the smart phone, which can be used at any time."
224304458|NCT02302859|OTHER|Saliva Test|Participants complete saliva cotinine test 3 months after intervention.
223474540|NCT01082419|DEVICE|ARFI measurement|"ARFI values are measured during a standard liver ultrasound examination, with patient lying on his back and performing a light apnea.~For all other groups (B, C, D, E) ARFI is measured only once."
223474541|NCT01082419|DEVICE|ARFI measurement|"ARFI values are measured during a standard liver ultrasound examination, with patient lying on his back and performing a light apnea.~For groups F and G : ARFI is measured again after clinical healing."
223581670|NCT03514680|BEHAVIORAL|CIPN Assessment and Management Algorithm|The revised algorithm incorporates evidence-based CIPN assessment and management strategies and standardized CIPN/pain patient-reported outcomes measures. In terms of processes, trained study staff will administer the screening questionnaires (e.g., PRO-CTCAE, 0 - 10 numerical rating scale of worst CIPN pain intensity) to consented patients before their clinician visit (e.g., in the waiting room). Following patient completion of the screening questionnaires, study staff will provide the clinicians with a color-coded summary of the patients' responses to the screening questionnaires and the CIPN assessment and management algorithm. Clinicians may then use the algorithm at their discretion to guide the assessment and management of their patients' CIPN symptoms
223581671|NCT03331783|OTHER|Standard hydrocolloid adhesive patch|This patch is made of a standard hydrocolloid adhesive
223581672|NCT03331783|OTHER|LT-2|This patch is made of a new adhesive
223581673|NCT03331783|OTHER|LT-21|This patch is made of a new adhesive
224161603|NCT01391338|DRUG|ASP3652|Oral
224161604|NCT01391338|DRUG|Placebo|Oral
224161605|NCT01359852|DRUG|[11C] JNJ-42491293|Part B:\[11C\] JNJ-42491293 (300 to 370 MBq) will be dosed as an i.v. bolus injection, have a 90 minute PET scan and have arterial and venous blood sampling.
223474542|NCT02732639|DRUG|Pegylated Interferon (PEG-IFN) alfa-2a|Participants received pegylated interferon (PEG-IFN) alfa-2a 180 microgram (mcg) subcutaneously (SC) weekly for 48 weeks.
223474543|NCT05762575|OTHER|knotting methods|The volunteers in experimental group study new knotting technology.
223474544|NCT02730962|DRUG|Vancomycin|Vancomycin 3 times a day for 7 days
223581674|NCT03331783|OTHER|33-20|This patch is made of a new adhesive
223581675|NCT05289583|BEHAVIORAL|Dialectical Behavior Therapy|DBT is a cognitive-behavioral treatment program that was developed to treat suicidal Patients with BPD (Linehan, 1993).
223581676|NCT03118830|DRUG|Triptorelin|daily SC injection of Triptorelin 0.1 mg started at day 21 of the cycle prior to stimulation cycle and continued till the day of hCG triggering.
224161606|NCT01359852|DRUG|[11C] JNJ-42491293 + JNJ-40411813|Part C:\[11C\] JNJ-42491293 (300 to 370 MBq) will be dosed as an i.v.bolus injection. Volunteers will be pre-treated with JNJ-40411813 between 1.5 to 3 hours prior to the second and prior to the third PET scan
224161607|NCT01359852|DRUG|[11C] JNJ-42491293 + JNJ-40411813|"Part D:\[11C\] JNJ-42491293 (300 to 370 MBq) will be dosed as an i.v. bolus injection.~Volunteers will be treated with a single dose of up to 500 mg JNJ-40411813 prior to the second scan and will have a third scan at least 2 hours later to evaluate the rate of clearance of JNJ-40411813 from the brain"
224161608|NCT01359852|DRUG|[11C] JNJ-42491293|Part A: \[11C\] JNJ-42491293 (300 to 370 MBq) will be dosed as an i.v. bolus injection and have a 120 minute PET scan.
224161609|NCT01770756|BEHAVIORAL|Self-Care Training|
223474545|NCT02730962|OTHER|Placebo|Placebo pills identical in appearance to each antibiotics to be taken on the same schedule as each antibiotic
223474546|NCT02730962|DRUG|Neomycin|Neomycin 3 times a day for 1 day
223474547|NCT02730962|DRUG|Clindamycin|Clindamycin 3 times a day for 5 days
223474548|NCT02730962|PROCEDURE|Fecal Microbiota Transplantation|FMT conducted via colonoscopy
223474549|NCT03980119|OTHER|HITSystem 3.0|The HITSystem 3.0 is a web-based intervention that aims to improve pediatric ART retention and adherence, and viral suppression. The HITSystem 3.0 is accessed online through a computer, using mobile broadband modems that respond to a cellular signal. The primary components include: (1) action alerts to complete time-sensitive interventions; (2) real time communication of HIV PCR results to hospitals to reduce turn-around time; (3) continuous follow-up for timely ART initiation among HIV-infected infants; (4) promotion of retention in EID care via SMS text messaging and/or patient tracing; and (5) an automated and individualized SMS text messaging component to communicate with mothers. The HITSystem has a unique dashboard that proactively monitors time-sensitive interventions along the EID cascade of care, alerting clinics, laboratories and mothers when an intervention has been missed.
223474550|NCT02860936|DRUG|Lenvatinib|Lenvatinib will be self orally administered at 24 mg daily, on a continuous basis in 4 week cycles until tumour progression, unacceptable toxicity or other criteria for discontinuation is met. Study drug should be taken at approximately the same time each morning.
223474551|NCT02265510|DRUG|INCB052793|Initial cohort dose of INCB052793 monotherapy at the protocol-specified starting dose, with subsequent cohort escalations based on protocol-specific criteria.
223474552|NCT02265510|DRUG|gemcitabine|Gemcitabine administered intravenously over 30 minutes at the protocol-specified dose and frequency.
223474553|NCT02265510|DRUG|nab-paclitaxel|nab-paclitaxel administered intravenously over 30 minutes at the protocol-specified dose and frequency.
223474554|NCT02265510|DRUG|dexamethasone|Dexamethasone administered orally at the protocol-specified dose and frequency.
223581677|NCT03118830|DRUG|cetrorelix|Flexible GnRH antagonist protocol was done with daily s.c administration of cetrorelix 0.25 mg started when one or more of the following criteria were achieved: (i) one or more follicle reached 14 mm diameter; (ii) The level of serum E2 reached 600 pg/ml; and (iii) The level of serum LH levels reached 10 IU/l .
223581678|NCT03118830|DRUG|Recombinant Follicle Stimulating Hormone|Daily sc rFSH (Gonal-f; Merck Serono , Darmstadt, Germany) injections was started on 2nd day of the cycle in the antagonist protocol. Continuation of rFSH and GnRH antagonist daily until triggering day was done.
223581679|NCT04226976|DEVICE|Otoband|Participants with AUV will wear the Otoband set at normal power (effective) during vestibular test battery and outcome measurements will be recorded by the investigator during site visit.
223581680|NCT04226976|DEVICE|Placebo Device|Participants with AUV will wear the placebo device set at low power during vestibular test battery and outcome measurements will be recorded by the investigator during site visit.
223581681|NCT03375372|PROCEDURE|Scaling and Root Planing (S&RP)|dental Scaling and Root Planing and oral hygiene regimen
224069756|NCT05993624|DEVICE|virtual reality|The BeCure Balance Assessment System protocol used in this study; It was planned to determine the amount of change in the center of gravity in the x and y axes and the position of the center of gravity of the body with images during standing and balancing for 15 seconds on the board with eyes open. In order to support the balanced development of the participants with the Becure system; Balance surfing, balance adventure, balance bowling and traffic games were played. uBall, gates, smartclean and SmartBubblePop games with Kinect for the upper extremity; KneeUp game was played on the lower extremity.
223474555|NCT02265510|DRUG|Carfilzomib|Carfilzomib administered intravenously at the protocol-specified dose and frequency.
223474556|NCT02265510|DRUG|bortezomib|Bortezomib administered intravenously or subcutaneously at the protocol-specified dose and frequency.
223581682|NCT04503590|DEVICE|Minimally Invasive Micro Sclerostomy (MIMS)|The System is a surgical device, designed to create a drainage channel at the sclera-corneal junction . The drainage channel is created by a Stainless Steel surgical tool.
224163805|NCT00432640|PROCEDURE|Surgical staging|Surgical staging
224163806|NCT04142840|DRUG|Dexmedetomidine|a selective α-2 adrenoceptor agonist which is widely used as an adjuvant to general anesthesia
223474557|NCT02265510|DRUG|lenalidomide|Lenalidomide administered orally at the protocol-specified dose and frequency.
223474558|NCT02265510|DRUG|azacitidine|Azacitidine administered subcutaneously at the protocol-specified dose and frequency.
223474559|NCT02265510|DRUG|INCB052793|INCB052793 tablets administered orally at the protocol specified dose strength and frequency.
223474560|NCT02265510|DRUG|pomalidomide|Pomalidomide administered orally at the protocol-specified dose and frequency.
223474561|NCT02265510|DRUG|INCB050465|INCB050465 tablets administered orally at the protocol specified dose strength and frequency.
223474562|NCT02265510|DRUG|INCB039110|INCB039110 tablets administered orally at the protocol specified dose strength and frequency.
223474563|NCT02499588|DEVICE|Esteem Plus with ConvaTec Moldable Technology|
223474564|NCT02499588|DEVICE|Natura with ConvaTec Moldable Technology|
223474565|NCT02499588|DEVICE|Natura Accordion with ConvaTec Moldable Technology|
223474566|NCT02499588|DEVICE|Esteem synergy Plus with ConvaTec Moldable Technology|
223474567|NCT05376501|DIETARY_SUPPLEMENT|Astaxanthin|8 mg Astaxanthin per capsule, taken once a day with meal
223474568|NCT05376501|OTHER|Placebo|Modified food starch
223474569|NCT01668797|DRUG|Brexpiprazole|Brexpiprazole tablets 1 to 4 mg /day
223474570|NCT01668797|DRUG|Placebo|Placebo comparator for 52 weeks
223474571|NCT02987010|DRUG|IDH305|Isocitrate Dehydrogenase 1 inhibitor
223474572|NCT03706846|PROCEDURE|fasting|fasting before gastrointestinal endoscopy
223474573|NCT01004614|DRUG|Amlodipine|3rd OD 5 mg tablet single oral dose administered with water
223474574|NCT01004614|DRUG|Amlodipine|2nd OD 5 mg tablet single oral dose administered with water
223474575|NCT01004614|DRUG|Amlodipine|3rd OD 5 mg tablet single oral dose administered without water
223474576|NCT01004614|DRUG|Amlodipine|2nd OD 5 mg tablet single oral dose administered without water
223474577|NCT00677638|DEVICE|Ventor Embracer|Implantation of Ventor Embracer
223474578|NCT03387293|OTHER|LGI-LII Breakfast|This test meal with low GI and low FII amounts were served as a breakfast after 12-hours fasting and participants were asked to consume the meal in full, within 15 min.
223474579|NCT03387293|OTHER|LGI-HII Breakfast|In crossover design, this test meal with low GI and high FII amounts were served as a breakfast to compare the LGI-LII Breakfast.
223474580|NCT04075448|OTHER|Control|100 grams breakfast cereal
223474581|NCT04075448|OTHER|50 g Walnut|50 grams walnuts mixed with 50 gram breakfast cereal.
223474582|NCT02530385|OTHER|Placebo Capsules|Placebo capsules contain powdered cocoa and gelatin
223474583|NCT02530385|BIOLOGICAL|FMT Capsules|Capsules will be generated as per FDA-approved procedures
223474584|NCT03044418|OTHER|Application of ET laser tube in propofol anesthesia|The special ET laser tube covered by aluminum tape is used during anesthesia of endolaryngeal laser surgery.
223474585|NCT01569022|DEVICE|CPAP|CPAP Treatment for 12 weeks
223474586|NCT01569022|DEVICE|MAD|MAD Treatment for 12 weeks
223474587|NCT03613493|DIAGNOSTIC_TEST|HPV self-sampling kit|The HPV self-sampler kit will include the collection swab and the vial for collecting and storing the specimen, and an instructional sheet that visually depicts the steps for self-sampling.
223474588|NCT03613493|BEHAVIORAL|Culturally-targeted Fear Appeal Message|Participants will receive culturally-targeted and fear appeal messages in a graphically designed kit.
223474589|NCT03613493|BEHAVIORAL|Fear Appeal Message|Participants will receive fear appeal messages (only) in a graphically designed kit.
223474590|NCT03613493|BEHAVIORAL|Interview|Participants will be interviewed about experiences using the self-sampling tool (qualitative).
223474591|NCT05238662|PROCEDURE|pedicle screw fixation on one side and intervertebral cage on the other sided|pedicle screw fixation on one side and intervertebral cage on the other sided
223474592|NCT05238662|PROCEDURE|pedicle screw fixation and interbody cage on the same side|pedicle screw fixation and interbody cage on the same side
223474593|NCT01149941|DRUG|Ibuprofen|Ibuprofen 200 mg gel capsules of Dr. Reddy's Laboratories Limited
223474594|NCT06266013|OTHER|inspiratory muscle training|The subjects will perform deep inspirations against a threshold device with varying resistances to observe the effect on the diaphragm and the musculature of the lower limbs.
223474595|NCT01135342|BEHAVIORAL|Diet and exercise|Standardized instruction to eat less and exercise more to create an energy balance deficit to promote weight loss (16 classes)
223474596|NCT01135342|BEHAVIORAL|Cognitive Behavioral Therapy|Standardized cognitive behavioral therapy for insomnia (8 classes)
223474597|NCT01135342|BEHAVIORAL|Passion and Balance|Attention-match sessions of general interest, but unrelated to diet, exercise, or sleep (8 sessions)
223744069|NCT06256419|DRUG|GLP-1 receptor agonist|Eligible patients with T2DM were required to have received GLP-1RA as monotherapy or in combination with other antidiabetic agents. GLP-1 RA was injected subcutaneously at standard dose and frequency for consecutive 6 months in patients with T2DM.
224069757|NCT01443104|DEVICE|Sirolimus-eluting stent with a bioresorbable polymer (Orsiro)|Percutaneous coronary intervention with implantation of a sirolimus-eluting stent with a bioresorbable polymer for coronary artery disease
224069758|NCT01443104|DEVICE|Everolimus-eluting stent with a durable polymer|Percutaneous coronary intervention with implantation of an everolimus-eluting stent with a durable polymer for coronary artery disease
224069759|NCT05030870|DEVICE|Capnography monitoring|Standard monitoring and capnographic monitoring.
224069760|NCT05030870|DEVICE|Standard monitoring|Standard monitoring but no capnographic monitoring
224069761|NCT00707070|DRUG|efalizumab plus placebo|1 mg/kg/week subcutaneous for 24 weeks
224069762|NCT00707070|DRUG|efalizumab plus acitretin|1 mg/Kg/week for 24 weeks plus oral acitretin 0.4 mg/kg/day
223474598|NCT00253942|PROCEDURE|Injecting bee venom as a treatment for OA|
223474599|NCT02818543|DRUG|LYC-30937|
223474600|NCT05151913|OTHER|Exploratory|Fecal microbiome
223474601|NCT02111083|BIOLOGICAL|Insulin Lispro|LY275585 administered SC.
223474602|NCT06420739|DIAGNOSTIC_TEST|Gastric Ultrasound|Bedside Gastric Ultrasound to determine the volume and nature of gastric content in patients before their surgery.
223474603|NCT00116142|DRUG|Docetaxel|60 mg/m² q 3 weeks for 3 cycle at the start of treatment followed by weekly Docetaxel at 20 mg/m² per week beginning at week one of radiation therapy and continuing for seven weeks.
224069763|NCT03099486|DRUG|Regorafenib|The dose of Regorafenib is 160 mg PO daily D1-D21 of 28-day cycle or last tolerated dose while on Regorafenib monotherapy.
224069764|NCT03099486|DRUG|5-FU|5-FU dose D1 and D15 of 28 day cycle i400 mg/m2 bolus over 10 mins followed by 2400 mg/m2 continuous infusion over 46 hours
223474604|NCT00116142|DRUG|Androgen Hormonal Suppression and Radiation|Total Androgen Ablation and external beam radiation therapy
223474605|NCT00116142|DRUG|Androgen Suppression Therapy and Radiation Therapy|Total Androgen Ablation and External Beam Radiation Therapy
223474606|NCT00433836|DRUG|Valsartan|Weight stratified dosages given by mouth, once daily, of valsartan 80/160/320 mg.
223474607|NCT00433836|DRUG|Enalapril|Weight stratified dosages given by mouth, once daily, of enalapril 10/20/40 mg.
223474608|NCT00644059|BIOLOGICAL|Adjuvanted trivalent inactivated subunit influenza vaccine|Either two intramuscular (IM) injections of half dose or one IM injection of full dose, depending on age of subject, were administered in the deltoid muscle preferably of the non-dominant arm.
223474609|NCT00644059|BIOLOGICAL|Non-adjuvanted trivalent inactivated subunit influenza vaccine or non-adjuvanted trivalent inactivated split influenza vaccine|For both vaccines, either two intramuscular (IM) injections of half dose or one IM injection of full dose, depending on age of subject, were administered in the deltoid muscle preferably of the non-dominant arm.
223474610|NCT00644059|BIOLOGICAL|Meningococcal C conjugate vaccine or tick-borne encephalitis vaccine|"1. Meningococcal vaccine: two IM injections~2. Tick-borne encephalitis vaccine: two IM injections"
223474611|NCT01163799|DRUG|Alefacept (ASP0485)|Withdrawal of calcineurin inhibitor at 30 days post-transplant. Administer Alefacept 7.5 mg post-op day 0, post-op day 2 given IV; Alefacept 15 mg SQ X 12 weeks, then monthly until Month 12.
223474612|NCT05601336|DRUG|Dapagliflozin 5 MG|SGLT2 inhibitor
224069765|NCT03099486|DRUG|Leucovorin|D1 and D15 of 28 day cycle Leucovorin 400 mg/m2 over 2 hours,
224069766|NCT01764074|BEHAVIORAL|Brief Sleep Intervention|Participants will meet with a therapist for three sessions to try to improve sleep problems (hypersomnia or insomnia, depending on the problems the participant has).
224069767|NCT01681420|BEHAVIORAL|HIV Counseling and Testing|HIV counseling and testing in lieu of blood donation.
223474613|NCT05601336|DRUG|Metformin Hydrochloride 1000 MG|metformin
223474614|NCT05601336|DRUG|Dapagliflozin/Metformin|SGLT2 inhibitor and metformin HCl extended-release
223581683|NCT05045170|DRUG|Influence of propofol sedation on memory consolidation and 'working memory'|Spinal anesthesia is performed by anesthesiologist. Memory testing is conducted immediately prior to propofol sedation (stage 1), 5-10 minutes after the start of propofol sedation (stage 2), 10 minutes after propofol sedation is finished and consciousness is restored (stage 3). Five emotionally neutral words are heard by the patients twice at each stage to assess the impact of sedation on memory consolidation. The patients repeat the memorized words after each audition. To assess the effect of sedation on the 'working memory', anesthesiologist asked the patient to remember and reproduce the memorized words five minutes after learning in the second stage. Approximately, 24 hours after the end of anesthesia, recall and recognition of the experimental words are tested. The number of words in recall and recognition testing is recorded by researcher.
223744070|NCT06256419|DRUG|responders group and nonresponders group|"For all the patients with type 2 diabetes who were initially enrolled in the study, blood samples were obtained for genotyping before the administration of GLP-1 receptor agonists. Patients were re-screened according to whether they had used GLP-1 RA continuously for more than 6 months and had completed the specified follow-up tasks.~Patients were divided according to the type of T2DM susceptibility genes. Or all were divided into responses group and nonresponses group according to whether they had glycemic response (△HbA1c↓ ≥1.0%) and weight response (△weight↓ ≥3.0%) after taking GLP-1 receptor agonist for 6 months.~According to the above grouping, the variables that can predict the efficacy of the drug were identified, and the weight of the influence of these variables on the efficacy was evaluated."
223744071|NCT04015245|DRUG|Stronger Neo-Minophagen C|intravenous injection after TACE
224161610|NCT03519399|DEVICE|Monica AN24|Monica AN24 will be used to record maternal and fetal ECGs. The Zephyr will be used to determine maternal lie.
224161611|NCT01146548|DRUG|FLUOXETINE|20mg/d, oral administration for 6 weeks, then 40mg/d for 4 months.
224161612|NCT02493868|DRUG|Esketamine|Open-label induction phase: Direct entry participants start at a dose of 56 mg on Day 1. On Day 4, the dose may be increased to 84 mg or remain at 56 mg. From Day 8 to 22, dose may be increased to 84 mg, remain the same or be reduced to 56 mg from 84 mg per protocol, at investigator's discretion based on efficacy and/or tolerability. On Day 25, a dose reduction from 84 mg to 56 mg is permitted but no dose increase is permitted. Optimization Phase: Direct-entry and transferred-entry participants will self-administer intranasal esketamine (same dose) for first 4 weeks, then individualized to either once weekly or once every other week based on depressive symptoms. Maintenance Phase: All participants assigned to esketamine will self-administer intranasal esketamine once weekly or once every other week based on depressive symptoms.
224161613|NCT02493868|DRUG|Placebo|Optimization Phase: Transferred-entry participant will self-administer intranasal placebo at weekly treatment sessions for the first 4 weeks of this phase, then individualized to either once weekly or once every other week based on depressive symptoms. Maintenance Phase: Direct-entry and transferred-entry participants assigned to placebo will self-administer matching intranasal placebo once weekly or once based on depressive symptoms.
224161614|NCT02493868|DRUG|Duloxetine (Oral Antidepressant)|Duloxetine could be selected as the oral antidepressant medication by the investigator based on review of Massachusetts General Hospital - Antidepressant Treatment Response Questionnaire (MGH-ATRQ) and relevant prior antidepressant medication information. The minimum therapeutic dose is 60 milligram per day (mg/day).
224161615|NCT02493868|DRUG|Escitalopram (Oral antidepressant)|Escitalopram could be selected as the oral antidepressant medication by the investigator based on review of MGH-ATRQ and relevant prior antidepressant medication information. Escitalopram will be titrated upto a maximum dose of 20 mg/day, but if not tolerated the dose can be reduced to the minimum therapeutic dose of 10 mg/day.
224161616|NCT02493868|DRUG|Sertraline (Oral Antidepressant)|Sertraline could be selected as the oral antidepressant medication by the investigator based on review of MGH-ATRQ and relevant prior antidepressant medication information. Sertraline will be titrated upto a maximum dose of 200 mg/day, but if not tolerated the dose can be reduced to the minimum therapeutic dose of 50 mg/day.
224161617|NCT02493868|DRUG|Venlafaxine Extended Release (XR) (Oral Antidepressant)|Venlafaxine Extended Release could be selected as the oral antidepressant medication by the investigator based on review of MGH-ATRQ and relevant prior antidepressant medication information. Venlafaxine Extended Release will be titrated upto a maximum dose of 225 mg/day, but if not tolerated the dose can be reduced to the minimum therapeutic dose of 150 mg/day.
223474615|NCT05355155|DRUG|Bevacizumab Biosimilar IBI305|Patients received bevacizumab and FOLFOX4 every two weeks
223474616|NCT02054780|BEHAVIORAL|Trauma-Focused Cognitive Behavioral Therapy|We propose using TF-CBT to address stress related problems (SRP) and reduce HIV risk behaviors. OVC lack behavioral and cognitive skills and intention necessary to use the available information and resources to prevent HIV. For example, internalizing problems are related to HIV risk through low self-efficacy, poor assertiveness skills, and reduced ability to negotiate safe sex. Given evidence on the link between abuse/trauma and elevated HIV risk, researchers have called for overlap between evidence-based mental health treatments like TF-CBT and HIV prevention programs. Some studies have found that skills-oriented interventions reduced HIV-risk behaviors among minority and troubled youths. An intervention study using CBT increased condom use and decreased high-risk sexual behaviors among runaway youths in a short-term follow-up evaluation. However, these studies were done in Western countries; their relevance to OVC in Africa is unproven.
223744072|NCT06530342|OTHER|The same evaluation methods were used for both groups.|No treatment applied to participants and same evaluation methods used in all athletes.
223744073|NCT03382119|DEVICE|Ultrasound with ARFI (acoustic radiation force impulse)|This technology uses sound waves to measure the stiffness of tissue.
223744074|NCT03382119|DEVICE|Ultrasound with backscatter imaging|This ultrasound tool gathers data from the waves returning from imaged tissue.
223744075|NCT03622346|PROCEDURE|Semi-constrained total knee arthroplasty|Semi-constrained total knee arthroplasty
224069768|NCT01681420|BEHAVIORAL|Blood Donation|Blood donation without HIV counseling
224069769|NCT00484497|DRUG|cyclamax|
224069770|NCT00024115|DRUG|BL22 immunotoxin|
224069771|NCT00024115|PROCEDURE|antibody therapy|
224069772|NCT00024115|PROCEDURE|biological response modifier therapy|
224069773|NCT00024115|PROCEDURE|immunotoxin therapy|
224161618|NCT02407236|DRUG|Placebo IV|Placebo will be administered as intravenous infusion.
224161619|NCT02407236|DRUG|Placebo SC|Placebo will be administered Subcutaneously.
223474617|NCT02054780|BEHAVIORAL|Psychosocial Counseling|"The curriculum Psychosocial Care and Counseling was developed for HIV Infected Children and Adolescents. The goal is to enable health care providers to provide safe supportive counseling and support services to HIV infected youth and their families. The course materials are designed to be adapted to different cultures and needs. The 14 modules cover child development, family systems, communicating with children, disclosure and adherence and legal/ethical issues. The course teaches basic counseling skills with children such as listening and play. It explores and challenges barriers to care such as caregivers' fear and reluctance to disclose an HIV positive diagnosis to a child, discussing adolescent sexuality, and practical issues such as inadequate legislation governing child rights. The curriculum was adapted for Zambia and endorsed by the MoH."
223474618|NCT03368417|OTHER|Usual Care|"Participants will be advised to measure their BP at least 3 times a week and record their results on a form. The participants will be educated on how to interpret their BP according to standard self-monitoring practice guidelines.~As part of the study, participants without a HBPM will be provided with the Omron HEM 7130. Adherence to hypertensive medicines will be monitored using the medication event monitoring system eCAP™. In addition, the participants will be asked to undertake ambulatory blood pressure monitoring (using the Welch Allyn ABPM 7100 monitor) at Baseline and Month 6 for a duration of 12 hours, during their waking hours."
223474619|NCT03368417|OTHER|Wireless HBPM System|"BP will be monitored using the iHealth KN-550BT wireless HBPM and transmitted to the study application via the iHealth mobile application.~The Wireless HBPM System consists of:~i) Instant BP feedback: Classification of each BP reading with feedback SMS. CRC will call the patient in case of alarming BP readings.~ii) Weekly HBPM adherence feedback: Participants receive praise, encouraging, or reminder SMSes.~iii) Continuous assessment: Based on average BP over the last 4 weeks, participants will be categorized and flagged for the CRC to follow clinical protocols. Protocols include asking patients to immediately come to the clinic, checking for alarm symptoms and discussing adherence over the phone, remote titration, and cancelling 1 clinic visit in case of good BP control."
224069774|NCT02014064|DRUG|Atomoxetine|"MA Group: Dispense 1 cap @ 8 AM on Treatment day 9 and 10 (total daily dose 40mg or 0); 1 cap SID @ 8 AM and 4 PM on day 11,12, and 13 (total daily dose 80mg or 0); 1 cap @ 8 AM on day 14 (total daily dose, 40mg or 0).~Control Group Schedule:~* Day 1: 40mg @ 8:00am~* Day 2: 40mg @ 8:00am~* Day 3: 40mg @ 8:00am, 40mg @ 8:00pm~* Day 4: 40mg @ 8:00am, 40mg @ 8:00pm~* Day 5: 40mg @ 8:00am, 40mg @ 8:00pm~* Day 6: 40mg @ 8:00am = Testing day (fMRI scan \& cognitive testing session)"
224069775|NCT02014064|OTHER|Placebo|Control Group: Day 1: 40mg @ 8am Day 2: 40mg @ 8am Day 3: 40mg @ 8am, 40mg @ 8pm Day 4: 40 mg @ 8am, 40mg @ 8pm Day 5: 40mg @ 8am, 40 mg @ 8pm Day 6: 40 mg @ 8am = Testing day (fMRI scan \& cognitive testing session)
224161620|NCT02407236|DRUG|Ustekinumab IV|Ustekinumab will be administered as intravenous infusion at Week 0 or Week 8 in Induction Study.
224161621|NCT02407236|DRUG|Ustekinumab SC|Ustekinumab will be administered as subcutaneously.
224161622|NCT03725449|OTHER|Best Practice|Receive standard of care
224161623|NCT03725449|BEHAVIORAL|mySmartCheck|Receive access to mySmartcheck program
224161624|NCT03725449|OTHER|Survey Administration|Ancillary studies
224161625|NCT03461185|DRUG|EGFR-TK Inhibitor|EGFR-TKIs include but are not limited erlotinib, gefitinib
224069776|NCT06351943|DIAGNOSTIC_TEST|Fracture classification annotations provided by the Turin group|Fracture classification annotations provided by the Turin group: fracture vs non-fracture, and, if fracture, the Arbeitsgemeinschaft für Osteosynthesefragen (AO, in English, Association for the Study of Internal Fixation)/Orthopedic Trauma Association (OTA) classification.
224069777|NCT06351943|DIAGNOSTIC_TEST|Fracture classification annotations provided by the AO expert surgeon group|Fracture classification annotations provided by the AO expert surgeon group: fracture vs non-fracture, and, if fracture, the AO/OTA classification.
224069778|NCT03482414|OTHER|traditional wooden checkerboard|upper limb training with traditional wooden checkerboard
224069779|NCT03482414|OTHER|gaming board with single-player games|upper limb training with a LED-based interactive gaming board equipped with single-player games
224069780|NCT03482414|OTHER|gaming board with two-player games|upper limb training with two LED-based interactive gaming boards equipped with two-player competitive games
224069781|NCT01527214|RADIATION|CT scan and education|GPs get direct access to chest CT scans for their patients. The GPs will be offered special training related to the diagnosis of lung cancer in general practice.This will be done by offering training sessions and written material. The training will include risk groups, alarm symptoms, symptom complexes and interpretation of CT scan descriptions.
224069782|NCT02202876|OTHER|Oral Glucose Tolerance Test|1.75 gm/kg to a maximum of 75 gm of an oral glucose solution
224069783|NCT02202876|OTHER|High Glycemic Index Meal|"isocaloric breakfasts - set the high glycemic index to 80~The nutrient composition of each meal will be 10 kcal per kg, 50% kcal from carbohydrates, 20% kcal from protein, and 30% kcal from fat"
224069784|NCT02202876|OTHER|Low Glycemic Index Meal|"isocaloric breakfasts - set the low glycemic index to 30~The nutrient composition of each meal will be 10 kcal per kg, 50% kcal from carbohydrates, 20% kcal from protein, and 30% kcal from fat"
224161626|NCT03461185|DRUG|Anti-Angiogenic Drugs|Anti-Angiogenic Drugs contain endostatin, apatinib and anlotinib
224161627|NCT02299271|DRUG|Ropivacaine|0.375% ropivacaine as a one-time, 60 milliliter injection
224161628|NCT02299271|DRUG|Saline|Saline as a one-time, 60 milliliter injection.
224161629|NCT06460831|DEVICE|Microcatheter|The microcatheter group undergoes alcohol ablation using a microcatheter.
224161630|NCT06460831|DEVICE|OTW|The OTW group undergoes alcohol ablation using an OTW balloon.
224161631|NCT00868361|DRUG|Talampanel (non-radiolabeled), [14C] Talampanel|50 mg capsule single dose
224161632|NCT00355329|PROCEDURE|Tongue Acupuncture (Procedure)|
224161633|NCT03771989|BIOLOGICAL|autologous, micro-fragmented adipose tissue|"The active treatment is an intra-articular injection with autologous, microfragmented adipose tissue prepared using the Lipogems system.~Implantation of the graft is performed with the patient supine using two injections sites in order to reduce the risk of extra-articular injection."
224161634|NCT03771989|OTHER|Saline|The placebo is an injection with saline
224161635|NCT06905483|DRUG|Budesonide/Glycopyrronium/Formoterol (BGF)|Each patient received 4 weeks of treatment with either BGF or FUV followed by a 1-week washout period, and then 4 weeks of treatment with the other drug.
224161636|NCT06905483|DRUG|Fluticasone Furoate/Umeclidinium/Vilanterol (FUV)|Each patient received 4 weeks of treatment with either BGF or FUV followed by a 1-week washout period, and then 4 weeks of treatment with the other drug.
224161637|NCT03976518|DRUG|Atezolizumab|Atezolizumab will be administered on Day 1 every 21 days (+/- 3 days).
224161638|NCT04010162|OTHER|Mesh debate awareness survey|"A web-based questionnaire with questions about recent discussions of mesh in urogynecology.~10 questions. Average survey completion time: 1 minute"
224161639|NCT00108836|DRUG|XBD173|
224161640|NCT06926647|DRUG|Nucleos(t)ide Analogues|Administer NAs \[LAM, ETV, TDF, TAF (TAF preferred for those aged 6 years and older)\] continuously for 48 weeks based on age.
224161641|NCT06926647|DRUG|Interferon alfa|IFNα monotherapy for 48 weeks (select conventional IFNα for ages ≥1 and \<3 years, select PEG-IFNα-2b for ages ≥3 years)
224304459|NCT02302859|DEVICE|Smart phone|"Standard Treatment (ST) Group: Participants receive proactive phone counseling (8 sessions) over the 8-week period for support in quitting smoking. The call will last about 15 minutes.~Automated Treatment (AT) Group: Participants receive brief advice to quit smoking (tailored video clips) and an 8-week automated intervention (interactive text messages and graphical messages) for support in quitting smoking via smartphone."
224304460|NCT03915730|OTHER|Initial periodontal therapy|Scaling and root planing and polishing with specific curettes were performed to patients with CP and oral hygiene education was provided to each patient.
224304461|NCT03003949|DRUG|Estradiol Patch, 0.1 Mg/24 Hours Weekly Transdermal Film, Extended Release|Transdermal Estradiol worn daily for 16 weeks (patch changed every 7 days).
223581684|NCT05045170|DRUG|Influence of dexmedetomidine sedation on memory consolidation and 'working memory'|Spinal anesthesia is performed by anesthesiologist. Memory testing is conducted immediately prior to dexmedetomidine sedation (stage 1), 5-10 minutes after the start of dexmedetomidine sedation (stage 2), 10 minutes after dexmedetomidine sedation is finished and consciousness is restored (stage 3). Five emotionally neutral words are heard by the patients twice at each stage to assess the impact of sedation on memory consolidation. The patients repeat the memorized words after each audition. To assess the effect of sedation on the 'working memory', anesthesiologist asked the patient to remember and reproduce the memorized words five minutes after learning in the second stage. Approximately, 24 hours after the end of anesthesia, recall and recognition of the experimental words are tested. The number of words in recall and recognition testing is recorded by researcher.
223581685|NCT05045170|DRUG|Influence of spinal anesthesia on memory consolidation and 'working memory'|Spinal anesthesia is performed by anesthesiologist. Memory testing is conducted immediately prior to operation (stage 1), 5-10 minutes after the start of operation (stage 2), 10 minutes before the end of operation (stage 3). Five emotionally neutral words are heard by the patients twice at each stage to assess the impact of sedation on memory consolidation. The patients repeat the memorized words after each audition. To assess the effect of sedation on the 'working memory', anesthesiologist asked the patient to remember and reproduce the memorized words five minutes after learning in the second stage. Approximately, 24 hours after the end of anesthesia, recall and recognition of the experimental words are tested. The number of words in recall and recognition testing is recorded by researcher.
223581686|NCT01615601|DRUG|darunavir (PREZISTA)|Form = tablet, route = oral, Units = mg, number = 800 administered once daily
224161642|NCT06926647|DRUG|NAs combined with IFNα|Receive NAs combined with IFNα treatment for 48 weeks.
224161643|NCT06926647|OTHER|comparative observation|Blank control observation for 48 weeks.
224161644|NCT06926647|OTHER|drug withdrawal observation|This group is the drug withdrawal observation group, which will strictly monitor virological indicators and biochemical results, and will reinitiate antiviral treatment if necessary based on antiviral treatment standards and the willingness of the child (or family members)
224161645|NCT00006968|BIOLOGICAL|filgrastim|
223581687|NCT01615601|DRUG|etravirine (INTELENCE)|Form = tablet, route = oral, Unit = mg, number = 200, administered twice daily
223581688|NCT01615601|DRUG|ritonavir|Form = tablet/capsule, route = oral, Units = mg, number = 100 administered once daily
224161646|NCT00006968|DRUG|cyclosporine|
224161647|NCT00006968|DRUG|pentostatin|
224161648|NCT00006968|PROCEDURE|allogeneic bone marrow transplantation|
224161649|NCT00006968|PROCEDURE|peripheral blood stem cell transplantation|
224161650|NCT00890669|OTHER|Treadmill walking training with additional body load|"The training program was divided into three phases (A1-B-A2):~* treadmill training with additional body load (A1),~* control condition (conventional physical therapy group) (B). and~* treadmill training with additional body load again (A2).~Each phase lasted six weeks, totaling 18 weeks. Both evaluations and training were performed during on-phase of the medication cycle."
224161651|NCT05218538|DIAGNOSTIC_TEST|Fibroscan (non interventional)|An elastography test that includes an ultrasound wave imaging of the liver to estimate liver fatness, in combination with a proprioty examination of the liver stiffness.
224161652|NCT02881671|GENETIC|genetic blood analysis|patients will undergo a blood sample (15 ml) to analyse their genetic profile
224161653|NCT06148350|OTHER|Stroke Rehabilitation|Both the groups received interventions three days/week for 30-60 minutes for four weeks
224304462|NCT03003949|DRUG|Placebo Patch|Matching placebo patches to be worn every day for 16 weeks (patch changed every 7 days).
224304463|NCT03003949|DRUG|Progesterone Capsule|Micronized progesterone (200 mg) will be administered every day for 12 days during the 9th week of randomization and again following randomization at the 17th week
224304464|NCT03003949|DRUG|Placebo Oral Capsule|Matching placebo capsules will be administered orally every day for 12 days during the 9th week of randomization and again following randomization at the 17th week.
224304465|NCT05813314|COMBINATION_PRODUCT|BMN 111 administration via Injector Pen|BMN 111 Injection will be given using an injector pen
224304466|NCT05813314|DRUG|BMN 111 administration via vial and syringe|BMN 111 Injection will be given using vial and syringe
224161654|NCT00643448|DRUG|AZD1305|AZD1305 loading dose 250 mg + 125 mg evening dose on Study Day 1, maintenance dose 125 mg twice daily from Study Day 2
224161655|NCT00643448|DRUG|AZD1305|AZD1305 loading dose 500 mg + placebo evening dose on Study Day 1, maintenance dose 125 mg twice daily from Study Day 2
224304467|NCT05735041|BEHAVIORAL|Multi-domain cognitive digital therapy|Patients in the cognitive digital therapy group received multi-dimensional targeted cognitive function training electronically, involving attention, memory, executive function, thinking, processing speed and perception. The system will adjust the training difficulty and training plan adaptively according to the patient's current training time and performance, and train the patient's weak cognitive ability as far as possible. The patients had the same total amount of training each day.
223474620|NCT03368417|BEHAVIORAL|BP Monitoring Incentives|"Participants will receive an intervention identical to those in the Wireless HBPM System, with financial incentives for BP monitoring. This arm is further randomly subdivided into the Instant Reward and Health Capital arms in a 1:1 ratio.~Instant Reward sub-arm:~* Participants receive SGD 3 for each day they measure their BP, up to three times per week.~* Participants do not receive financial incentive if they do not measure their BP.~Health Capital sub-arm:~* Participants receive an initial health capital of SGD 72~* Participants' health capital increases by SGD 6 on each week where they measure their BP on at least 3 different days and decreases weekly by 10% per missing BP reading."
223474621|NCT01499485|DRUG|Acetazolamide|"Daily morning ABGA:~* If actual bicarbonate \> 26 mmol/L and pH \> 7.35: administration of enteral capsule of acetazolamide 500 mg .~* If actual bicarbonate \> 26 mmol/L and pH \<= 7.35, increase minute ventilation to reach pH \> 7.35 and then administer enteral capsule of acetazolamide 500 mg.~* If actual bicarbonate \<= 26 mmol/L: omit treatment that day."
223474622|NCT01499485|DRUG|Placebo|"Daily morning ABGA:~* If actual bicarbonate \> 26 mmol/L and pH \> 7.35: administration of enteral capsule of placebo.~* If actual bicarbonate \> 26 mmol/L and pH \<= 7.35, increase minute ventilation to reach pH \> 7.35 and then administer enteral capsule of placebo.~* If actual bicarbonate \<= 26 mmol/L: omit treatment that day."
223474623|NCT02431598|DRUG|gadoxetate disodium|
223474624|NCT02431598|DRUG|gadoterate dimeglumine|
223474625|NCT02431598|DRUG|Saline|
223474626|NCT01877798|PROCEDURE|volume resuscitation, vasoactive drug|
223474627|NCT01780623|DEVICE|Bright white light|
223474628|NCT01780623|DEVICE|Dim red light|
223474629|NCT00472420|DRUG|rituximab [MabThera/Rituxan]|375mg/m2 iv every 3 weeks
223581689|NCT01615601|DRUG|Other antiretroviral medications|Given as per Canadian Product Monograph
223581690|NCT03349866|DRUG|apatinib|apatinib：250mg qd po
223581691|NCT03349866|DRUG|Capecitabine|1000mg/m2 bid d1-14
223581692|NCT03349866|DRUG|Oxaliplatin|130 mg/m2 Ivgtt d1 q3w
223581693|NCT03349866|RADIATION|Radiotherapy|45Gy/25f （1.8Gy/f/d，5 f/w）
223744076|NCT01514760|OTHER|Mobile-based Asthma Action Plan|"The participant will be distributed a mobile phone (iPhone or Android) at the time of consent. The mobile-based Asthma Action Plan application will be provided on the mobile device. The mobile phone based application features will include ambulatory peak flow and asthma symptoms diary, individualized treatment plan for routine care and during episodes of acute asthma symptoms, and education components to reinforce asthma self-management concepts. Participants will receive 3 daily messages from the Asthma Action Plan mobile application. A fourth rotating message will be sent twice weekly."
224161656|NCT00643448|DRUG|Placebo|Placebo corresponding to AZD1305 loading dose + evening dose on Study Day 1, maintenance dose twice daily from Study Day 2
224161657|NCT00360672|DRUG|Revlimid|25 mg/day, orally for 21 days with 7 days rest (28 day cycle).
224161658|NCT04359225|OTHER|3D Telemedicine|Telemedicine using 3D broadcast to clinician
223474630|NCT00472420|DRUG|First line chemotherapy|As prescribed
223474631|NCT01339312|BIOLOGICAL|Purified inactivated rabies vaccine, serum free|0.5 mL, Intramuscular
223474632|NCT01339312|BIOLOGICAL|Purified inactivated rabies vaccine, serum free|0.5 mL, Intramuscular
223474633|NCT01339312|BIOLOGICAL|Purified Vero Rabies Vaccine|0.5 mL, Intramuscular
223474634|NCT01339312|BIOLOGICAL|Purified Vero Rabies Vaccine|0.5 mL, Intramuscular
223474635|NCT03144232|DEVICE|Active rTMS|rTMS will be delivered via a MagPro double blinded rTMS Research System (MagVenture, Denmark) with a Cool-B65 Butterfly Coil (a combined active and sham coil). We will use a standard resting motor threshold (rMT) determination to determine the TMS dose. Study-treatment will be delivered at 120% rMT. Each active rTMS study-treatment will consist of a total of 4000 pulses of 10Hz stimulation (5s-on,10s-off). Study-treatments will be delivered at the EEG coordinate for F3 (which approximates the left DLPFC), and will be found using the Beam-F3 method.
223474636|NCT03144232|DEVICE|Sham rTMS|Sham sessions will be delivered using an electronic sham system consisting of a coil that mimics the appearance and sound of rTMS, combined with a TENS device which produces a small electric shock mimicking the feeling of active rTMS. This type of sham has been demonstrated to be indistinguishable from active rTMS.
223474637|NCT03022006|DRUG|elbasvir, grazoprevir|
223474638|NCT00000442|DRUG|naltrexone (Revia)|
223474639|NCT01168895|DRUG|Cipro Inhale (Ciprofloxacin, BAYQ3939)|32.5 mg ciprofloxacin corresponding to 50 mg Ciprofloxacin Pulmosphere inhalation powder will be given as single dose inhalation
223474640|NCT01168895|DRUG|Cipro Inhale (Ciprofloxacin, BAYQ3939)|48.75 mg ciprofloxacin corresponding to 75 mg Ciprofloxacin Pulmosphere inhalation powder will be given as single dose inhalation
223474641|NCT04023578|DEVICE|RHEO KNEE XC|Microprocessor controlled knee using Magneto-Rheologic techonology.
223581694|NCT00568477|DRUG|MabThera|"Rituximab (MabThera):~375 mg/m² as IV infusions over \>=6h each at time point 0 and 2 weeks. Initial infusion rate of 50 mg/h, stepwise rise is possible after 30 minutes"
223581695|NCT00272688|DRUG|Levodopa (drug), intraduodenal administration|
223581696|NCT05242666|DIAGNOSTIC_TEST|3T MR Imaging of the cervical spinal cord|Patients will undergo either Magnetic Resonance Imaging of the Spinal Cord
223581697|NCT05242666|OTHER|Positron Emission Tomography using [11C]PIB|Patients will undergo combination MRI/PET using a \[11C\]PIB radiotracer
223581698|NCT05242666|OTHER|3T MR Imaging of the Brain|3T MR Imaging of the Brain
223581699|NCT05242666|OTHER|7T MR Imaging of the Spinal Cord|7T MR Imaging of the Spinal Cord
224161659|NCT04359225|OTHER|2D Telemedicine|Standard care with 2D telemedicine
224161660|NCT01969305|BEHAVIORAL|Kazakhstani Family Together|Adolescent-caregiver pairs will receive three 45-minute interactive multi-media sessions with avatars customized to participants' gender that will focus on risk reduction self-efficacy, resistance to peer pressure, decision-making skills and caregiver-adolescent communication, support and monitoring to strengthen youth's relationships with caregivers and reduce youth's risks of drug use and sexual risk behaviors. Through the multimedia tool, participants will confront a series of sexual risks and substance use related situations and will practice their listening, empathy, assertiveness, refusal, and other interpersonal skills. Each caregiver-youth pair will work jointly and engage in discussions, exercises, and behavioral rehearsal as directed by the program.
223474642|NCT00313235|BIOLOGICAL|DC Vaccine and Cyclophosphamide|"Autologous dendritic cells (DC) are derived from PBMC, cultured with cytokines, pulsed ex vivo with irradiated allogeneic (Colo 829) melanoma cells. About 15 x 10\^6 dendritic cells will be injected subcutaneously, in 3 separate sites (3.3 ml/site).~Patients will receive a total of 7 doses of the vaccination. Each individual dose will be administered at weeks: 0, 2, 4, 6, 11, 14, and 18. Patients with SD, PR according to RECIST criteria may receive 4 more vaccines at 36, 48, 60 and 72 weeks. Patients with CR will receive 4 additional vaccines at 36, 48, 72, and 96 weeks.~CPA will be administered 300mg/m2, intravenously over a 2-hour infusion 24 hours prior to DC vaccinations # 1, 3, 5, 6 and 7. Frequency of CPA administration might be increased based on their T cell measure."
224163807|NCT04142840|DRUG|Propofol|a short -acting medication that result in a decreased level of consciousness and lack of memory for events,widely used including the starting and maintenance of general anesthesia.
223474643|NCT03457857|OTHER|Cleanser|Cosmetic Baby Cleanser/Shampoo
223474644|NCT03457857|OTHER|Cleanser and Lotion|Cosmetic Baby Cleanser/Shampoo and Baby Lotion
223474645|NCT03430739|OTHER|No intervention|No intervention
223581700|NCT01859845|OTHER|Smartphone|"Our team of dermatologists and biomechanical engineers led by the PI developed a simulation skills training prototype device using a smartphone. Software was developed to teach dermoscopic evaluation of pigmented lesions using the three-poin checklist of dermoscopy. The software used in the smartphone presentation of the educational intervention also provides a decision tree of clinical management options and best-practices feedback. No patients are involved in this research."
223581701|NCT00853840|DRUG|Maraviroc|Maraviroc 300 mg twice daily for 3 - 4 days plus a single oral dose of Vardenafil 20 mg.
223581702|NCT00853840|DRUG|Vardenafil|Maraviroc 300 mg twice daily for 3 - 4 days plus a single oral dose of Vardenafil 20 mg.
223581703|NCT00853840|DRUG|Maraviroc|Maraviroc 300 mg twice daily for 3 - 4 days plus a single oral dose of Placebo.
223744077|NCT02092662|OTHER|stroke|task-oriented therapy: physical and occupational therapy emphasizing integration of the patients needs, environment and context
224163808|NCT04043416|OTHER|Motivating reminiscence technology|The jDome BikeAround uses Google Street View, a stationary bike and a domed screen. Residents are seated in front of the screen; their destination is typed into the computer and when loaded the image appears on the screen. Using pedals on the bike they can propel themselves down the street, steer and change direction as they wish.
224163809|NCT06092840|DIETARY_SUPPLEMENT|Transform Burn|Study product Transform Burn contains dihydrocapsiate, red pepper (Capsicum annuum) fruit extract, citrus (Citrus spp) peel extract, coleus (Coleus forskholi) root extract, and african mango (Irvingia gabonensis) seed extract.
224163810|NCT03236506|DRUG|Elbasvir/Grazoprevir 50 MG-100 MG Oral Tablet|Drugs will be given to participants to treat hepatitis C infection
223474646|NCT03846934|DEVICE|Ultrasonography thoracic|Thoracic ultrasonography will be performed as soon as possible after admission to the ED, without delaying the start of treatment and in addition to routine thoracic radiography.
223474647|NCT04324749|OTHER|Roasted peanuts (group A)|After 2 weeks following a peanut-free diet, the participants of this group consume 25 g/ day of whole skin roasted peanuts (RP) within the habitual diet during 6 months.
223474648|NCT04324749|OTHER|Peanut butter (group B)|After 2 weeks following a peanut-free diet, the participants of this group consume 2 tbsp/ day (32 g/ day) of peanut butter (PB) within the habitual diet during 6 months.
223474649|NCT04324749|OTHER|Control (group C)|After 2 weeks following a peanut-free diet, the participants of this group consume 2 tbsp/ day (32 g/ day) of control supplement (containing the same proportion of macronutrients as peanuts and peanut butter) within the habitual diet during 6 months.
223474650|NCT03129932|DIETARY_SUPPLEMENT|gluten phase|2 cakes containing 9g of vital gluten/each will be consume during the 4 weeks of intervention
223474651|NCT03129932|DIETARY_SUPPLEMENT|placebo phase|2 cakes without gluten will be consume during the 4 weeks of intervention
223474652|NCT00984412|PROCEDURE|Allogeneic hematopoietic stem-cell-transplantation|2 allogeneic BMTs 6 weeks apart
223474653|NCT03319771|BEHAVIORAL|Treadmill Walking Exercise Training|12-weeks of supervised, progressive treadmill walking exercise training
223474654|NCT03319771|BEHAVIORAL|Stretching-and-toning Exercise Training|12-weeks of supervised, stretching-and-toning exercise training
223474655|NCT03636399|BEHAVIORAL|Standard GIST|13 group modules will be administered to outpatients in 12 x 2,5-3 hours sessions. Manualized intervention; In every group session a new topic is presented, discussed and practiced in group exercises. Homework assignments between sessions.
223474656|NCT03636399|BEHAVIORAL|Intensive GIST|13 group modules will be administered to inpatients during 4 weeks in hospital. Participants is admitted to a hospital unit for cognitive rehabilitation treating patients in acute and/or cronic phase. The participants are given extended leave every weekend to work on homework Assignments between each treatment week.
223474657|NCT00125008|BIOLOGICAL|Typhoid Vi vaccine|single 0.5ml dose (25ug of purified Vi polysaccharide of S. typhi)
223474658|NCT00125008|BIOLOGICAL|Hepatitis A vaccine|720 EL.U. of inactivated hepatitis A viral antigen for children 1440 EL.U. of inactivated hepatitis A viral antigen for adults
223581704|NCT00853840|DRUG|Placebo|Maraviroc 300 mg twice daily for 3 - 4 days plus a single oral dose of Placebo.
223581705|NCT03571165|BEHAVIORAL|My Tools 4 Care - In Care|Self-administered web-based transition toolkit (My tools 4 Care - In Care) contains interactive activities and resources to help carers through transitions.
223581706|NCT06334757|DRUG|Serplulimab|300 mg，IV，Q3W
223744078|NCT02092662|OTHER|Healthy controls|no treatment
223744079|NCT06063577|DEVICE|Stratafix suture|Stratafix symmetric suture
223474659|NCT02347046|DRUG|FYU-981, (Oral single dosing)|FYU-981, (Oral single dosing)
223474660|NCT02597413|PROCEDURE|Catheterization|Women in this group will be systematically catheterized before leaving the delivery room.
223474661|NCT01795443|OTHER|Calibration|"Subjects will be seated on a table, feet dangling, blindfolded, arms crossed over the chest and held in place by bandages to minimize the visual and proprioceptive inputs that may contribute to the realization of the task.~The investigator uses an electronic goniometer to measure the maximal extension and flexion during a pelvic pivot. These measures will be used to determine a target position midway along the pelvic movement range."
223474662|NCT01795443|OTHER|Practice|"Propioception test: The movement required is flexion - extension of the lumbar spine without moving the shoulders; it is a pelvic rocking motion. The patients will be helped to the target position by the investigator. After keeping the target position for 5 seconds, they will be asked to completely pivot the pelvis to a forward position, then return to the target position.~Each subject will have three (non-measured) tries at the proprioception test without vibration, then three tries with low frequency vibration (20 Hertz), and then three tries with high frequency vibration (60 Hertz). Between each series of tries, a 2-minute rest period with walking is required."
223474663|NCT01795443|OTHER|Measures - no vibration|"The movements required are performed without vibration.~The movement required is flexion - extension of the lumbar spine without moving the shoulders; it is a pelvic rocking motion. The patients will be helped to the target position by the investigator. After keeping the target position for 5 seconds, they will be asked to completely pivot the pelvis to a forward position, then return to the target position. This test is repeated five times.~The investigator measures the lumbar angle using an electronic goniometer twice during each of the five tests: once after the patient is helped to the target angle, and once after the patient tries to remember the target angle by his/herself."
223474664|NCT01795443|OTHER|Measures - low vibration|"The movements required are performed with low frequency vibration (20 Hertz on following device: VIBRALGIC 5; manufacturer = Electronique Conseil).~The movement required is flexion - extension of the lumbar spine without moving the shoulders; it is a pelvic rocking motion. The patients will be helped to the target position by the investigator. After keeping the target position for 5 seconds, they will be asked to completely pivot the pelvis to a forward position, then return to the target position. This test is repeated five times.~The investigator measures the lumbar angle using an electronic goniometer twice during each of the five tests: once after the patient is helped to the target angle, and once after the patient tries to remember the target angle by his/herself."
223474665|NCT01795443|OTHER|Measures - high vibration|"The movements required are performed with low frequency vibration (20 Hertz on following device: VIBRALGIC 5; manufacturer = Electronique Conseil).~The movement required is flexion - extension of the lumbar spine without moving the shoulders; it is a pelvic rocking motion. The patients will be helped to the target position by the investigator. After keeping the target position for 5 seconds, they will be asked to completely pivot the pelvis to a forward position, then return to the target position. This test is repeated five times.~The investigator measures the lumbar angle using an electronic goniometer twice during each of the five tests: once after the patient is helped to the target angle, and once after the patient tries to remember the target angle by his/herself."
223474666|NCT05089214|DEVICE|Intra oral cameras|Diagnostic comparison of two intra oral cameras
223474667|NCT00305162|DRUG|Cangrelor (P2Y12 inhibitor)|IV bolus (30 mcg/kg) \& infusion (4 mcg/kg/min) initiated prior to PCI, as soon as possible following randomization (after need for PCI is confirmed) but not more than 30 minutes prior to placement of arterial access. Infusion is to continue for at least 2 hours, or until the end of the PCI, whichever is longer with the option to extend up to 4 hours maximum (per investigator discretion).
223474668|NCT00305162|DRUG|clopidogrel (oral P2Y12 inhibitor)|600 mg active clopidogrel administered as soon as possible following randomization (after need for PCI confirmed), but not more than 30 minutes prior to the placement of the arterial access.
223474669|NCT00305162|DRUG|Placebo bolus & placebo infusion|placebo bolus (30 mcg/kg) \& placebo infusion (4 mcg/kg/min) administered from randomization for at least 2 hours, or until the end of the PCI, whichever is longer with the option to extend up to 4 hours maximum (per investigator discretion)
223474670|NCT00305162|DRUG|Placebo capsules - end of infusion|Placebo capsules given at the end of infusion to mimic 600mg clopidogrel dosing
223474671|NCT00305162|DRUG|Placebo capsules - as soon as possible after randomization|Placebo capsules given as soon as possible after randomization to mimic 600mg clopidogrel dosing
223474672|NCT04525521|OTHER|Hand sanitizer and hand washing|All subjects will cleanse their hands with hand sanitizer, followed by hand washing with soap and water
223474673|NCT02679664|DRUG|Rosuvastatin|20 mg tablet of rosuvastatin
224304468|NCT05735041|BEHAVIORAL|Basic cognitive therapy|The training content of the positive control group was cognitive training tasks with weak difficulty or no difficulty change. The patients underwent cognitive function training with fixed programs, including 15 training items, and the internal difficulty of the training items remained constant without change. The system presents the training content randomly according to the training scheme. The patients had the same total amount of training each day.
223581707|NCT06334757|DRUG|Bevacizumab Biosimilar HLX04|7.5 mg/kg，Q3W
224304469|NCT04601610|DRUG|KN046 （PD-L1/CTLA4 BsAb）|KN046 5mg/kg Q3W
223581708|NCT06334757|DRUG|Pemetrexed|500 mg/m2，IV，Q3W
223581709|NCT06334757|DRUG|Carboplatin|AUC=5，IV，Q3W
223581710|NCT04070196|DIAGNOSTIC_TEST|Periplex|Periplex test strip will be used to examine the PD effluent for peritonitis, in addition to the routine leucocyte testing of PD effluent
223581711|NCT01341691|OTHER|chewing gum|single piece of chewing gum containing specified amount of chitosan with or without extender chewed twice daily for 14 days
223581712|NCT03455439|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|As prescribed by the treating physician
223581713|NCT00966719|OTHER|Lactation Consultant support|Meeting with lactation consultant once while in hospital and up to 3 times after discharge, in addition to current standard of care for jaundice.
223581714|NCT00246506|PROCEDURE|intrauterine insemination|An assisted reproduction technique which deposits washed sperm directly into the uterus, bypassing the cervix, and allowing the sperm to enter the fallopian tubes where fertilization normally occurs.
223744080|NCT06063577|DEVICE|Standard of care suture|Standard of care suture
223744081|NCT02686879|DEVICE|Multifocal contact lenses|
223744082|NCT02686879|DEVICE|Single vision contact lenses|
223744083|NCT01091389|PROCEDURE|Totally Thoracoscopic PV isolation|Surgery is performed through three ports bilaterally in the intercostal spaces. PVI is performed with a bipolar radiofrequency clamp and confirmed with a custom made multi-electrode probe with closely spaced (1mm) electrode terminals. Additional left atrial ablation lines are created and conduction block is verified in patients with persistent and permanent AF.
224161661|NCT01969305|BEHAVIORAL|Usual Care Alone|"Adolescents from both study arms will receive the usual care, a health education program about how to prevent drug use and HIV/STIs (sexually transmitted infections). The health education curriculum is delivered in a group format by trained peer educators and outreach workers. The curriculum consists of three 45-minute sessions that include lectures and interactive quizzes about drugs and HIV. These three sessions include information on the following topics:~1. Facts and Myth about HIV. HIV/STIs modes of transmission;~2. Prevention of HIV. Abstinence and Safe Sex. Attitudes and values about sexuality, sexual risk behaviors, and condom use;~3. Knowledge, attitudes and beliefs about drinking and drug use. Risks and consequences of drug use."
224161662|NCT04709874|OTHER|Paravertebral block|Paravertebral block using nerve stimulator guidance will be done at C7-T1
223474674|NCT06163118|DIAGNOSTIC_TEST|Deglut'G test|"Two tests to assess swallowing disorders using the Deglut'G tool will be carried out by a nurse or a caregiver from the Geriatric Short-Stay Unit, at visit 1.~The tests can be taken successively, or spaced apart by a time defined by the medical team, and will be taken blind to each other.~The average test administration time will be measured during the study, but the test should not exceed 10 minutes depending on the patients.~The Deglut'G tool consists of an initial administration of gelled water (1 to 3 teaspoons), to identify if a cough occurs. In the event of a cough, the oral treatment is stopped; if the cough is absent, a new step this time consists of the administration of water (1 to 3 sips). In case of cough, the food will be mixed, the liquids thickened, and the medicinal treatments crushed. If there is no cough, foods and liquids can be taken as normal."
223474675|NCT06163118|DIAGNOSTIC_TEST|SLP swallowing test|"At visit 1, 1 to 2 hours after the last Deglut'G test, a second swallowing test will be carried out by a SLP according to his skills and according to his usual practice, independently of the Deglut'G tool.~This test should not exceed 20-30 minutes depending on the patient."
223474676|NCT06163118|DIAGNOSTIC_TEST|ENT doctor swallowing test|"At Visit 2 (day 7 +/- 3 days after the inclusion), still as part of the short-stay hospitalization, the patient will meet an ENT doctor who will carry out an examination aimed at detecting swallowing disorders, according to his usual practice, of independent of the Deglut'G tool.~The examination should not exceed 20-30 minutes depending on the patient."
223474677|NCT01787552|DRUG|LDE225|
223474678|NCT01787552|DRUG|INC424|
223581715|NCT00246506|PROCEDURE|in vitro fertilization|This procedure involves stimulating the ovaries, retrieving released eggs, fertilizing the eggs, growing the embryos in a laboratory, and then implanting the embryos in the woman's uterus to develop naturally.
223581716|NCT01228994|DRUG|Baclofen 30 mg/day|Baclofen 30 mg/day for 8 weeks with 2 week induction and 2 week decrease
223581717|NCT01228994|DRUG|placebo pill|placebo pill
223581718|NCT01228994|DRUG|Baclofen 60 mg/day|baclofen 60 mg/day for 8 weeks with 2 week induction and 2 week decrease
223581719|NCT04175067|DIAGNOSTIC_TEST|Disulphide(μmol/L)|Aforementioned oxidative stress markers will be measured via Cobas c501(Roche Diagnostics, Indianapolis, IN, USA) used with sphectrophotometry
223581720|NCT04175067|DIAGNOSTIC_TEST|Total Oxidant Capacity(μmolH2O2Equiv/L)|Aforementioned oxidative stress markers will be measured via Cobas c501(Roche Diagnostics, Indianapolis, IN, USA) used with sphectrophotometry
223744084|NCT00045279|BIOLOGICAL|PEG-interferon alfa-2b|
223744085|NCT01754233|DEVICE|755nm Alexandrite Laser|755nm Alexandrite Laser for epidermal and dermal pigmented lesions
223744086|NCT06180291|OTHER|PRECOP program|"PRECOP program is the first program combining early detection of cerebral palsy with implementation of early interventions following the latest international recommendations (multidisciplinary program at home, with the possibility of intensive courses, coaching parental, in the first 2 years of life).~This comprehensive monitoring is implemented as soon as the infant arrives at home, by a multidisciplinary team and continues during the child's first 2 years. It includes:~* Follow-up organized primarily at home~* Monitoring of psychomotor development~* Screening for possible cerebral palsy~* Comprehensive support for the child's development: weight, diet, sleep...~* Reeducation, implementation of SMART type objectives (Specific, Measurable, Achievable, Achievable, Timely defined) determined with parents~* Creation of equipment if necessary: early seating installation in particular~* Parental support and guidance for optimizing early care~* Parental psychological support."
223744087|NCT06001554|BEHAVIORAL|Interaction Competencies with Children - for Teachers (ICC-T)|Core training components include teacher-student interaction, maltreatment prevention, effective discipline strategies, identifying and supporting burdened students and implementation of the training materials into the school setting
223744088|NCT06793488|DRUG|Disulfiram 250 mg|Disulfiram will be used in Participants with Alcohol Use Disorder only to facilitate abstinence.
223744089|NCT06793488|DIAGNOSTIC_TEST|functional MRI|Participants will undergo fMRI scanning. Participants with alcohol use disorder will undergo scanning after 1 week and 3 months of disulfiram maintenance. Healthy volunteer participants will undergo scanning once.
223744090|NCT03797209|DEVICE|EUS-guided fistulization AXIOS|By using a convex type ultrasonic endoscope to form a fistula by gastrointestinal puncture, to perform various drainage.
223744091|NCT02418507|DIETARY_SUPPLEMENT|Proprietary Probiotic Blend|A proprietary probiotic blend: Lactobacillus acidophilus, Bifidobacterium lactis, Bifidobacterium longum, and Bifidobacterium bifidum at 56.75 mg
224161663|NCT04709874|OTHER|Suprascapular block|Paravertebral block using nerve stimulator guidance will be done
224161664|NCT00888680|DRUG|BGC20-1531|BGC20-1531 administered orally
224161665|NCT00888680|DRUG|Lactose|Placebo administered orally
224161666|NCT05979155|BIOLOGICAL|NWY001|Part 1: Participants will be given a single-dose of NWY001 intravenously once every 3 weeks until a discontinuation criteria was met during treatment period.
224161667|NCT05979155|BIOLOGICAL|NWY001|Part 2: Participants will be given RP2D of NWY001 intravenously once every 3 weeks until a discontinuation criteria was met during treatment period.
224161668|NCT00616772|DRUG|ABT-335|Capsule
224161669|NCT00616772|DRUG|Placebo|Capsule
224161670|NCT00616772|OTHER|Atorvastatin|Capsule
223474679|NCT05265702|DEVICE|Non-invasive Neuromodulation|The electrodes will be placed with the help of gloves and adapted socks for 1 hour, twice a week, until 12 intervention sessions are completed. In addition, depending on the session, an adhesive electrode will be placed at the level of C7. Characteristics of microcurrents: pulsed monophasic rectangular wave with a pulse of 1.3 s and pause of 300 ms, voltage 3 millivolt and intensity 0.5 μA.
223474680|NCT04174066|OTHER|blood sample|blood sample during planned in the follow-up of patients.
223474681|NCT04174066|OTHER|tissue sample|tissue sample during planned in the follow-up of patients.
223581721|NCT06915636|OTHER|DPL|Half of the face was randomly treated with DPL, with an energy of 6-8 J/cm2, at an interval of 10 days, for a total of 8 treatments.One randomly assigned half of the face was treated with a large-spot, low-energy 1064nm laser at an energy of 0.8-1 J/cm², administered at 10-day intervals, for a total of 8 treatment sessions.
223581722|NCT03618914|BIOLOGICAL|Dultavax and Vaxigrip|All the women got an influenza/DTP vaccine in order to induce acute inflammation
223744092|NCT02418507|OTHER|Placebo|The placebo is administered to randomized healthy participants
223744093|NCT05411237|DRUG|Pegylated liposomal doxorubicin|PLD 20 mg/m2 on Day 1 of every 21-day cycle
223744094|NCT05411237|DRUG|Paclitaxel|PTX 100 mg/m2 on Day 1 of every 21-day cycle
223744095|NCT04122092|DIAGNOSTIC_TEST|The level of plasma cfDNA CINs|The extracted cfDNA from PB will be analyzed by UCAD to determine the level of CINs
223744096|NCT00304499|DRUG|Oxybutynin|
223744097|NCT02814123|OTHER|24-hour inpatient intervention|Subjects will be admitted at the research facility at 7:30. A cannula will be inserted into an arm or a hand vein for blood sampling purposes. Each 24-hour intervention visit includes 3 standardized meals (8:00, 12:00, and 17:00), an evening snack (21:00) and an overnight stay. The glucose level as measured by the real time sensor will be entered manually into the computer every 10 minutes. The insulin and pramlintide pumps' infusion rates will then be changed manually based on the computer generated recommendation, while still maintaining the ratio. The computer generated recommendations are based on a predictive algorithm.
223744098|NCT01729507|OTHER|tDCS|Stimulation will be performed with a DC stimulator MC Location of stimulation: Anode over the left dorsolateral cortex, corresponding with F3 (in 10-20 EEG system); cathode over the right temporal cortex Intensity: 2 mA Total duration: Constant stimulation for 20 minutes
224161671|NCT02846857|OTHER|15-week intervention with sensor-augmented pump|A sensor will be inserted on the day before the start of the intervention by the participant. The participant will also have to install the study insulin pump. Participants will be advised to continue with study intervention at home for the next 15 weeks. Participants will have been previously shown how to use the study insulin pump.
224161672|NCT02846857|OTHER|15-week intervention with single-hormone closed-loop|A sensor will be inserted on the day before the start of the intervention by the participant. On the first day of the intervention, participants will be admitted to the clinical research facility anytime between 8:00 am and 11:30 am. Training on connection and disconnection of the system, meal boluses, etc. will be given. Only participants demonstrating competency on use of study devices will be allowed to continue to the home study phase. Participants will be advised to continue with study intervention at home for the next 15 weeks.
224161673|NCT02846857|OTHER|15-week intervention with dual-hormone closed-loop|A sensor will be inserted on the day before the start of the intervention by the participant. On the first day of the intervention, participants will be admitted to the clinical research facility anytime between 8:00 am and 11:30 am. Training on connection and disconnection of the system, meal boluses, etc. will be given. Only participants demonstrating competency on use of study devices will be allowed to continue to the home study phase. Participants will be advised to continue with study intervention at home for the next 15 weeks. Participants will have to reconstitute glucagon everyday.
223474682|NCT04174066|OTHER|excreta|urine sample during planned in the follow-up of patients.
223474683|NCT02005107|DRUG|Venlafaxine IR and Venlafaxine XR|
223474684|NCT03423069|DIETARY_SUPPLEMENT|Diet low in FODMAPs|A strict restriction of all high FODMAP foods for the time of observation. All these foods will be identified by appropriate nutritional visits and alternatives will be suggested to ensure the diet is nutritionally adequate.
223474685|NCT03423069|DIETARY_SUPPLEMENT|Specific dietary advice for IBS|Dietary recommendations such as limitation of alcohol, spicy food and fatty foods, caffeine, carbonated drinks; avoidance of chewing gums and sweeteners containing polyols; small and frequent meals; avoidance of stressful conditions and eating slowly.
223474686|NCT00282217|DRUG|Sirolimus|
223474687|NCT06170710|DRUG|Anti-PD-1 monoclonal antibody|"Postoperative CCRT followed by any anti-PD-1 monoclonal antibody of the following:~Pembrolizumab, 200mg, Q3W or Nivolumab, 3mg/kg, Q2W or Tislelizumab，200mg，Q3W or Camrelizumab，200mg，Q3W or Sintilimab，200mg，Q3W or Toripalimab，240mg，Q3W"
223474688|NCT06170710|OTHER|Postoperative CCRT|Postoperative chemoradiotherapy
223474689|NCT01108939|DRUG|Antimalarial treatment|
223474690|NCT01108939|OTHER|Observation|
223474691|NCT01380366|DRUG|Somatropin|Patients are given somatropin (growth hormone) for their short bowel syndrome for 28 days at a dose of 0.1 mg/kg subcutaneously daily to a maximum of 8 mg daily.
223581723|NCT01892761|DRUG|Renal transplant recipients were allocated to TCL/MMF or to CyA/MMF groups|
223581724|NCT03720600|BEHAVIORAL|MAB Intervention|The intervention is a 60-minute voice-recorded PowerPoint presentation on a mindfulness- and acceptance-based (MAB) intervention adapted from Eustis et al. (2017). This adaptation was informed by research on MAB therapies and other approaches to coping with discrimination (e.g., Watson, Black, \& Hunter, 2016), as well as clinical experience providing an in-person workshop on MAB strategies for coping with racism-related stress.
223581725|NCT03048838|BEHAVIORAL|Risk reduction behavioral intervention|
223581726|NCT03048838|BEHAVIORAL|Wellness Promotion Intervention|
223744099|NCT01729507|BEHAVIORAL|standardised behavioural therapy|"The standardised behavioural therapy will be performed according to the certified Smoke-free programme' of the of the Institute for Therapy Research ('Institut für Therapieforschung', IFT). The course leaders' manual specifies that the ideal number of participants is 8-12.~1 group session for 90 minutes/week for 7 weeks, 2 telephone calls of 10 minutes each, first after the fourth session 3 days after collective smoking cessation, second on day 3 after the last session."
223744100|NCT04528082|DRUG|Apremilast|Participants will receive apremilast orally.
223744101|NCT04528082|DRUG|Placebo|Participants will receive the matching placebo orally.
223474692|NCT01380366|PROCEDURE|Seven Day Food Diary|Subjects are asked to fill out a seven day food diary the week prior to their inpatient appointment, prior to receiving rHGH treatment for their short bowel syndrome. Subjects will be asked to repeat the use of a food diary after completing the administration of the growth hormone.
223474693|NCT01380366|PROCEDURE|Blood Tests (standard of care)|Blood tests are taken (standard of care) to evaluate the potential hepato-protective effects of improving intestinal barrier function on those receiving human growth hormone for short bowel syndrome. Per clinical protocol to test liver function i.e. Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline phosphatase (ALP), Gamma-glutamyl transpeptidase (GGT), Total Bilirubin). A complete blood count (CBC) with platelets (PLTS) and white-count differential (WBC with diff) is performed to check for anemia and infection. These tests will be taken at baseline (before fasting) and repeated again on the 28th day (last dose) of the growth hormone. Blood is also taken at clinical visit over the next two years (approximately every two months).
223581727|NCT04784312|COMBINATION_PRODUCT|9MW1411 injection|9MW1411 injection
224161674|NCT02846857|DEVICE|Insulin pump|MiniMed® Paradigm® Veo™, Medtronic
224161675|NCT02846857|DEVICE|Continuous glucose monitoring system|Enlite sensor®, Medtronic
224161676|NCT02846857|DRUG|Insulin|Participant's usual fast-acting insulin analog will be used: Lispro (Humalog), Aspart (NovoRapid) or Glulisine (Apidra)
224161677|NCT02846857|DRUG|Glucagon|Glucagon (Eli Lilly) will be used during dual-hormone closed-loop strategy.
224161678|NCT01186094|DEVICE|Cypher|Sirolimus-eluting stent
224161679|NCT01186094|DEVICE|Endeavor Resolute|Zotarolimus-eluting Stent
224161680|NCT05316519|OTHER|Transcutaneous Vagus Nerve Stimulation|Visuomotor task training with transcutaneous stimulation targeting landmark that activates biomarker
224161681|NCT06939465|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|The participants will undergo a 6-week cognitive behavioral therapy (CBT) guided by a psychologist, with one session per week, each lasting 1 hour.
224161682|NCT06939465|BEHAVIORAL|Lifestyle management (sham control)|The participants will undergo a 6-week lifestyle management (sham control) guided by a psychologist, with one session per week, each lasting 1 hour.
224161683|NCT05286268|DIAGNOSTIC_TEST|Ischemia Modified Albumin|"Blood sampling at admission for measurement of IMA and suPAR levels and at day 10 from symptom onset (peak of symptoms) for IMA level. Samples will be collected in blood collection tubes containing K2EDTA as anticoagulant and serum separation gel tubes for SuPAR and IMA assays respectively. The samples will be centrifuged (at 3000 x g for 10 minutes) within the first 3 hours of sampling. Then, both plasma and serum samples will be placed in Eppendorf tubes and stored at -80oC. IMA levels will be determined according to the principles of the ACB assay, using the commercially available Ischemia Modified Albumin Assay Kit method (Abbexa LTD, Cambridge, UK), on the Architect c8000 automatic analytical system (Abbott, USA). SuPAR levels will be determined by the suPARnostic TurbiLatex quantitative turbidimetric immunoassay (ViroGates A/S, Denmark), also on the Architect c8000 automatic analytical system."
224161684|NCT03688893|DEVICE|Laser Application for Dental Bleaching|The Laser used was the Whitening Lase II (DCM EQUIPMENTS).
224161685|NCT06944444|DRUG|SSS59|A humanized antibody targeting MUC17
224304470|NCT04601610|DRUG|Ningetinib Tosylate（multi-target TKI）|ningtinib QD, dose will be decided by investigator
224304471|NCT04376762|DRUG|Fibrinogen|Fibrinogen Concentrate (Human) Injection \[Fibryga\] (dose: 70 mg/kg; intervention group). in-whom fibrinogen supplementation after separation from CPB is indicated, based on the presence of clinically-significant bleeding and documentation of low fibrinogen level on viscoelastic point-of-care testing (MCF \< 10 mm on the FIBTEM assay of ROTEM).
224304472|NCT04376762|DRUG|Cryoprecipitate|Cryoprecipitate group (dose: 10 ml/kg; active control group) in-whom fibrinogen supplementation after separation from CPB is indicated, based on the presence of clinically-significant bleeding and documentation of low fibrinogen level on viscoelastic point-of-care testing (MCF \< 10 mm on the FIBTEM assay of ROTEM).
224304473|NCT04671186|DIETARY_SUPPLEMENT|Culturelle (Lactobacillus rhamnosus strain GG)|Culturelle probiotics are typically sold over the counter as dietary supplements Probiotics group will take 1 capsule of probiotics orally once daily
224304474|NCT04671186|OTHER|Placebo|Placebo group will take 1 capsule of placebo orally once daily
224304475|NCT01798355|BEHAVIORAL|Cognitive Behavioral Therapy|The treatment group is offered cognitive behavior therapy(CBT) by psychologists/psychotherapists. CBT is offered according to a treatment manual and consists of 10- sessions during 12-15 weeks.
223581728|NCT04784312|COMBINATION_PRODUCT|9MW1411 injection placebo|9MW1411 injection placebo
223581729|NCT04254874|DRUG|Abidol hydrochloride|0.2g once, 3 times a day,two weeks
223581730|NCT04254874|DRUG|Abidol Hydrochloride combined with Interferon atomization|Abidol Hydrochloride:0.2g once, 3 times a day,two weeks; Interferon(PegIFN-α-2b) atomization:45ug, add to sterile water 2ml, twice a day,two weeks
223581731|NCT02970526|DRUG|Oxaliplatin|Intensity of neuropathy induced by oxaliplatin evaluated by the QLQ-CIPN20 Questionnaire (EORTC).
223581732|NCT02166541|PROCEDURE|BCSK|"The BCSK is a specific technique of polysegmental spinal manipulation developed by Professor Kozyavkin based on applying quick short impulse aimed on moving intervertebral joints outside restrictive barrier."
223581733|NCT02166541|PROCEDURE|Traditional spinal manipulation|Spinal manipulation by traditional technique is a mild mobilization without impulse, based on applying gentle repetitive force without crossing restrictive barrier.
223744102|NCT01895660|BEHAVIORAL|Variations in Pediatric Constraint-Induced Movement Therapy (P-CIMT) versus usual and customary rehabilitation|Types of constraint and dosage amounts will be varied.
224161686|NCT02794025|DRUG|Esmolol|"patients in the esmolol group received continuous infusion of esmolol via a micro-pump through a catheter placed in the superior vena cava. The initial dose was 0.05 mg/kg/min and was adjusted based on heart rate (HR) (target HR: 70 bpm \< HR \< 100 bpm within 72 hours).~Control group also received natural saline via a micro pump, in the same way the esmolol group received esmolol."
224161687|NCT02794025|DRUG|natural saline|Control group also received natural saline via a micro pump,
224161688|NCT06350357|OTHER|punching closure|The hole clamping and the grooves hold the metal clips better
224161689|NCT06350357|OTHER|Conventional clipping|Metal lip closure is one of the most commonly used closure methods
223474694|NCT01380366|OTHER|Fasting|Eight hour overnight fast prior to being given sucralose, mannitol, lactulose, and sucrose. This is done at baseline (day one) and repeated again after the last dose of growth hormone and prior to sugar permeability urine tests.
223474695|NCT01380366|OTHER|Sugar Permeability Test|Subject will be given 4 capsules of sucralose (250mg per capsule), 2.0 grams of mannitol, 7.5 grams of lactulose, and 40 grams of sucrose in 150 mL of water. This will be given on the second day of the study after an 8-hour overnight fast and repeated within 72 hours of the last dose of growth hormone.
223474696|NCT01380366|OTHER|Urine Collection|Urine will be collected for the following five hours after subject has been given combination of sucralose, mannitol, lactulose, and sucrose to complete the intestinal sugar permeability test looking at urine ratio of lactulose to mannitol (L/M ratio). Tests include urinalysis (UA) and a blood urea nitrogen (BUN)/creatinine (Cr).
223474697|NCT00121004|BEHAVIORAL|Advance Directive Selection|
223474698|NCT03056924|BIOLOGICAL|Pneumococcal Pneumonia vaccine|Vaccination for pneumococcal pneumonia will be carried out with either the PSV-23 (Pneumovax, Merck, Whitehouse Station, NJ) or the PCV-13 (Prevnar 13, Pfizer, Philadelphia, PA). Either vaccine is administered in a single dose of 0.5 mL intramuscularly.
223474699|NCT03056924|BIOLOGICAL|Influenza vaccine|Influenza vaccination will be carried out with the 2017-2018 trivalent component vaccine (Afluria, Seqirus USA Inc., King of Prussia, PA) or for patients over 65 years of age (Fluzone, Sanofi Pasteur, Swiftwater, PA). Both of these vaccines are administered in a single dose of 0.5 mL intramuscularly.
223474700|NCT03056924|BIOLOGICAL|Hepatitis B vaccine|Hepatitis B vaccination with be carried out with a single antigen, recombinant hepatitis B vaccine (Energix B, GlaxoSmithKline, Research Triangle Park, NC). This vaccine is administered in a three dose series with 1.0 mL given intramuscularly at 0, 1, and 6 months. For patients receiving a booster, a single intramuscular dose of 1.0 mL will be given.
223474701|NCT02820662|OTHER|RETCAM|
223474702|NCT02820662|BIOLOGICAL|Blood samples|
223474703|NCT06369480|PROCEDURE|Resection/Ablation of tumor|Curative treatment
223474704|NCT06369480|PROCEDURE|Palliative chemotherapy|Chemotherapeutic medications
223474705|NCT06369480|PROCEDURE|Neoadjuvant chemotherapy|Chemotherapeutic medications after surgery
223474706|NCT06369480|PROCEDURE|Stereotatic radiotherapy|Radiotherapy
223474707|NCT06369480|PROCEDURE|Best supportive care|Symptomatic treatment, non-curative treatment
224161690|NCT06949930|OTHER|Optimized package of child essential health and nutrition services|Optimized package of child essential health and nutrition services
223474708|NCT00650962|OTHER|cardiopulmonary resuscitation|10 cycles of 30:2 cardiopulmonary resuscitation before rhythm analysis by AED
223474709|NCT00650962|OTHER|Rhythm analysis|Rhythm analysis as soon as AED is ready
223474710|NCT03915743|OTHER|palliative care|complex and multi-faceted individualized palliative care
223474711|NCT00580320|DRUG|Dacarbazine and bortezomib|Level 0: Dacarbazine 190 mg/m2 + Bortezomib 1.0 mg/m2; Level 1: Dacarbazine 250 mg/m2 + Bortezomib 1.0 mg/m2; Level 2: Dacarbazine 250 mg/m2 + Bortezomib 1.3 mg/m2; Level 3: Dacarbazine 250 mg/m2 + Bortezomib 1.6 mg/m2; Level 4: Dacarbazine 330 mg/m2 + Bortezomib 1.6 mg/m2; Level 5: Dacarbazine 440 mg/m2 + Bortezomib 1.6 mg/m2; Level 6: Dacarbazine 580 mg/m2 + Bortezomib 1.6 mg/m2
223474712|NCT03377439|OTHER|Platelet function tests|Platelet reactivity was measured by flow cytometry, filopodia detection and the platelet aggregation analyzer.
223474713|NCT05821049|OTHER|UPI65 (Low Dose)|Red colored Capsules
223474714|NCT05821049|OTHER|UP165 (High Dose)|Red colored Capsules
223474715|NCT05821049|OTHER|Placebo|Red colored Capsules
223474716|NCT04079790|DRUG|Gepotidacin|Tablets containing gepotidacin mesylate with a unit dose of 750 mg will be administered orally with 240 milliliter (mL) of water.
223474717|NCT04079790|DRUG|Placebo|Tablets containing unit dose of placebo matching of gepotidacin will be administered orally with 240 mL of water.
223474718|NCT02204189|DRUG|TongFuSan|TongFuSan 1g
223474719|NCT02531685|OTHER|Placebo|Placebo: 0.9% Sodium Chloride injection.
224161691|NCT06949930|OTHER|Standard package of essential child and nutrition services|Standard package of essential child and nutrition services
223474720|NCT02531685|BIOLOGICAL|Recombinant Double Mutant Heat-Labile Toxin LT(R192G/L211A) (dmLT) Oral enterotoxigenic Escherichia coli (ETEC) Vaccine|LT(R192G/L211A), or dmLT is formulated as a freeze-dried (lyophilized), white to off-white cake, containing 700mcg of vaccine protein in a 3 ml, multi-dose.
223474721|NCT05964062|DEVICE|active rTMS treatment|Participants will receive 10 sessions per day of 1800 pulses per session, lasting for 5 days. Individualized targets will be generated using the pBFS method.
224161692|NCT06949358|DRUG|Olipudase alfa|Pharmaceutical form:Powder for concentrate for solution for infusion-Route of administration:intravenous infusion
223474722|NCT05964062|DEVICE|sham rTMS treatment|The parameters in the sham arms are the same as the active stimulation groups. Stimulation was delivered by the same device as the active group fitted with a sham coil.
223474723|NCT00390689|DRUG|Pramipexole 0.125 mg tablet|
223474724|NCT00390689|DRUG|Pramipexole 0.5 mg tablet|
223474725|NCT03021915|OTHER|OvaPrime Treatment|The treatment is based on identified EggPC cells in the outer-most layer of the ovary. During OvaPrime, the EggPC cells are isolated from biopsy tissue obtained from the outer layer of the ovary. OvaScience separates the EggPC cells and these isolated cells are then returned to the IVF clinic - there is no culture or expansion of the EggPC cells during this process. Upon receipt of the autologous EggPC cells, the clinic initiates the process of reintroducing the cells into the follicular development zone of the woman's own ovary using a laparoscopic procedure. Once in the ovary, the EggPC cells have the opportunity to develop and mature into fertilizable eggs naturally or with controlled ovarian hyperstimulation (when stimulated by exogenous gonadotropins) using standard IVF protocols.
224161693|NCT06174961|DRUG|Unfractionated heparin|15,000 units of unfractionated heparin administered in the thigh
224161694|NCT06174961|BEHAVIORAL|Double-legged cycle ergometer exercise|One hour of double-leg cycle ergometer exercise
224161695|NCT06174961|BEHAVIORAL|Single-legged cycle ergometer exercise, with unfractionated heparin injection in the exercising leg|One hour of single-leg cycle ergometer exercise, after unfractionated heparin injection in the ipsilateral leg
224161696|NCT06174961|BEHAVIORAL|Single-legged cycle ergometer exercise, with unfractionated heparin injection in the non-exercising leg|One hour of single-leg cycle ergometer exercise, after unfractionated heparin injection in the ipsilateral leg
224161697|NCT06174961|BEHAVIORAL|No exercise|No exercise
224161698|NCT06949020|DRUG|JMKX003142 Injection|JMKX003142 injection for experimental groups once daily for five days.
224161699|NCT06949020|DRUG|JMKX003142 Injection|JMKX003142 injection for experimental groups once daily for five days.
224161700|NCT06949020|DRUG|JMKX003142 Injection|JMKX003142 injection for experimental groups once daily for five days.
223474726|NCT01253161|DRUG|Pasireotide Long Acting Release (LAR)|Pasireotide will be administered as an intramuscular injection at the beginning of every cycle which is defined as 28 days (+/- 3 days). Study treatment should begin within 14 days following enrollment into the study and continue until disease progression, unacceptable toxicity, or withdrawal of consent.
223474727|NCT00075075|DRUG|Infliximab|
223474728|NCT03871556|DIAGNOSTIC_TEST|LOGIQ P6 Diagnostic Ultrasound|Ultrasound measurements of subcutaneous fat thickness
223474729|NCT05976789|DEVICE|Sound therapy using low-level background sound|"This study will use an FDA-regulated device, a tinnitus masker, as one of the sound therapy options in Aim 2.~The tinnitus masker will provide low-level background sound for hyperacusis relief."
223474730|NCT05976789|BEHAVIORAL|Remote counseling using HAT-Online|This study will implement Hyperacusis Activities Treatment-Online, a four-week remote counseling program in Aim 1.
223474731|NCT05976789|OTHER|Sound therapy using successive approximations|This study will use the approach of successive approximations with the participants' bothersome sounds in Aim 2.
223581734|NCT02166541|PROCEDURE|INRS|"The INRS is a treatment program developed at the International Clinic of Rehabilitation where the spinal manipulation is one of several components. There may be some variation in treatment depending on the clinical situation. All children receive the main treatment components which are massage, physical therapy, warm wax and paraffin applications and low electro stimulation with a special portable device as a part of treatment called Reflexotherapy."
223581735|NCT01998191|OTHER|Explicit case note review checklist (nurse)|"A checklist to be used to screen notes for features of avoidable death used by nurses.~to be compared with 'Implicit Case note review (physician)' 'Implicit Case note review (MDT)' 'Implicit Case note review (nurse)' and the other two intervention arms."
223581736|NCT01998191|OTHER|Explicit case note review checklist (physician)|"A checklist to be used to screen notes for features of avoidable death, used by a nurse.~to be compared with 'Implicit Case note review (physician)' 'Implicit Case note review (MDT)' 'Implicit Case note review (nurse)' and the other two intervention arms."
224069785|NCT02202876|OTHER|Test Soda|Test soda containing 60% fructose and 40% glucose at a dose of 1.75 grams per kilogram body weight to a maximum of 75 grams.
224069786|NCT02202876|OTHER|Fruit juice|Fruit juice containing a combination fructose, glucose, and sucrose at a dose of 1.75 grams per kilogram body weight to a maximum of 75 grams
224069787|NCT00416247|BEHAVIORAL|Hypnosis|Hypnosis
223474732|NCT01924533|DRUG|Olaparib|Tablets-at a dose of 100mg orally twice daily, throughout each cycle (28 days); Once paclitaxel dosing is stopped, the planned monotherapy olaparib dose will be 300mg twice daily.
223474733|NCT01924533|DRUG|Paclitaxel|IV infusion over 1 hour at 80 mg/m2 weekly on days 1, 8 and 15 of a 28 days schedule.
223474734|NCT01924533|DRUG|Placebo|Tablets-at a dose of 100mg orally twice daily, throughout each cycle (28 days); Once paclitaxel dosing is stopped, the planned monotherapy placebo dose will be 300mg twice daily.
223474735|NCT06144372|DEVICE|Electroconductive and Electrohydraulic types|The patients were randomly assigned to two types of lithotripter.
223474736|NCT00006022|BIOLOGICAL|aldesleukin|
223474737|NCT00006022|DRUG|bryostatin 1|
223474738|NCT00417066|DRUG|Ganirelix 0.25mg (Orgalutran, Organon, The Netherlands)|
223474739|NCT00417066|DRUG|Arvekap 0.1mg (Triptorelin, Ipsen, France)|
223474740|NCT04800497|PROCEDURE|Hepatic resection|Hepatic resection for HCC
223474741|NCT05363228|BEHAVIORAL|Therapy by Dance and Movement|Therapy by dance and movement is based on the principals of movement-analysis by Rudolf Laban and Irmgard Bartenieff. Participants will attend sessions twice a week (90 minutes each) for the duration of three months.
223474742|NCT05363228|BEHAVIORAL|Tai Chi|Tai Chi is based on somatic approach. Participants will attend sessions twice a week (90 minutes each) for the duration of three months.
223744103|NCT02490722|OTHER|Patient education|Four times two hours group based patient education
224069788|NCT06281860|DRUG|Cisplatine Teva®|PITHAC: Cisplatin (Cisplatine Teva®) at a dose between 7.5 and 70 mg/m2 of body surface at a temperature of 39±1°C
224069789|NCT05230888|OTHER|Questionnaires about symptoms|The CGA and VES-13 questionnaires will be conducted at baseline. Immune-related adverse events (irAEs) will be investigated at 3 and 6 months using a Patient Knows Best symptom tracker form (local Trust created).
224069790|NCT00193895|DRUG|Carboplatin|Carboplatin will commence with a dose calculated to target an AUC of 2.0. A maximum of 6 doses of weekly Carboplatin will be given. Carboplatin will be administered intravenously over 20-30 minutes prior to radiation therapy.
224069791|NCT00193895|RADIATION|Radiotherapy|60 Gy OR 66Gy in 2Gy/fraction 5days/week
224069792|NCT00075504|DRUG|triapine|Given IV
224069793|NCT00075504|DRUG|gemcitabine|Given IV
224161701|NCT06949020|DRUG|JMKX003142 placebo|JMKX003142 placebo for placebo groups once daily for five days.
224161702|NCT06949046|OTHER|nursing-led communication support|nursing-led communication support program using mobile health information
224161703|NCT06949046|OTHER|Nursing routine treatment|Nursing routine treatment
224161704|NCT01039311|DEVICE|Optical Coherence Tomography|Obtain OCT images.
224161705|NCT05628402|OTHER|Semi-structured interview|The semi-structured interview will take place during a standard follow-up appointment with the therapist already treating the patient after the patient has agreed to participate in the study.
224161706|NCT04628598|BEHAVIORAL|Antenatal care and prenatal education with a home visit|Providing prenatal education and care by home visits to pregnant women
224161707|NCT00517205|PROCEDURE|Non-contrast helical computerized tomogram (NCHCT)|
224163811|NCT03236506|BEHAVIORAL|Psychological intervention|"Participants randomised to fortnightly pick-up with psychological intervention will have an interview with the study nurse designed to aid their compliance with the drug regimen. During the intervention participants will be guided by their trial nurse in the completion of a personalised booklet, Hepatitis C and Me. The booklet uses the principles of node-link mapping to structure the intervention."
223474743|NCT00017251|BIOLOGICAL|oblimersen sodium|Given IV
223474744|NCT00017251|DRUG|carboplatin|Given IV
223474745|NCT00017251|DRUG|etoposide|Given IV
223474746|NCT00017251|OTHER|pharmacological study|Correlative studies
223474747|NCT00017251|OTHER|laboratory biomarker analysis|Correlative studies
223474748|NCT05246254|DIAGNOSTIC_TEST|Frailty index scale|There are clinically common scales for assessing weakness and delirium.
223474749|NCT05677399|OTHER|aquatic exercise and peloidotherapy|Treatment group received 30 minutes of aquatic exercise by a physiotherapist in a warmed up to 33° C tap water and 30 minutes of mud pack treatment at 42°C on both knees 5 weekdays for 2 consecutive weeks (totally 10 sessions).
223474750|NCT05720403|OTHER|pilates group|Pilates, which lasts for eight weeks, three days a week for 1 hour, will be carried out by Australian Pilates and Physiotherapy Institute certified and experienced Ph.D. Physiotherapist Halil Ibrahim Bulguroglu. Microsoft Teams program will be used to implement the online practice method. The individuals in both pilates exercise groups will be divided into six small groups of 3 or 4 people to make the exercises more effective. In this study, the program will be 15 minutes of warm-up, 30 minutes of pilates, and 15 minutes of cool-down and stretching exercises. The exercises will be performed in ten repetitions. The same exercises will be applied in online pilates and face-to-face pilates training.
223581737|NCT01998191|OTHER|Explicit case note review checklist (MDT)|"A checklist to be used to screen notes for features of avoidable death used by a nurse and an expert physician.~to be compared with 'Implicit Case note review (physician)' 'Implicit Case note review (MDT)' 'Implicit Case note review (nurse)' and the other two intervention arms."
223581738|NCT02008409|DEVICE|EndoLift Liver Retractor|"During the surgery, the surgeon will use the new internal liver retractor device. The device will retract the liver out of the way and help the surgeon see better during the surgery. The device is placed inside the abdomen during the surgery. It is clipped onto 2 safe surfaces inside the abdomen. The device is removed before the surgery ends."
223581739|NCT00002363|DRUG|Peptide Construction 3, Synthetic|
223581740|NCT02460341|DRUG|ondansetron|Ondansetron 8mg, 16mg, 24mg
223581741|NCT02460341|DRUG|placebo|placebo pill
224161708|NCT06948877|BEHAVIORAL|ARMOR Online|"The online version of ARMOR comprised three core components. The first was an MI-based relationship check-up with a brief relationship assessment. In the second component, SMs chose relationship improvement domains from a list of 10 topic areas or modules and watched a short (5-7 minute) video on their chosen area providing (a) evidence-based or evidence-informed psychoeducation, (b) modeling of skills, and (c) practice of the skills. For the third component, SMs were asked MI's key question (i.e., What's the next step? Miller \& Rollnick, 2023) and, if desired, completed a planning module where they were given the opportunity to create a personalized action plan (specifying how they might test any planned changes to see if they had the desired impact)."
224161709|NCT03396640|PROCEDURE|Unicondylar Knee Arthroplasty|"Incision will be midline incision, as with a TKA, for maximum security of blinding.~Standard operative technique will hereafter be used, with minor individual preferences for each surgeon as to whether tourniquet/not, drain or not."
224161710|NCT03396640|PROCEDURE|Total Knee Arthroplasty|Incision will be midline incision, as standard. Standard operative technique will hereafter be used, with minor individual preferences for each surgeon as to whether tourniquet/not, drain or not.
224161711|NCT05166603|OTHER|TeleGRACE|Patients receive a virtual home visit and care from the GRACE team
224161712|NCT03529890|DRUG|Nivolumab|"Experimental intervention:~Immunotherapy with 4 cycles of Nivolumab: 240 mg intravenously every 2 weeks, starting one week before radiotherapy (week1, d1), last infusion on week 7, d1"
224161713|NCT03529890|RADIATION|Radiation therapy of the pelvis|Neoadjuvant radiation therapy of pelvis with 45+5,4 Gy for 6 weeks: 28 x 1.8 Gy including a boost of bladder with 5.4 Gy, starting with week 2 (d1)
224161714|NCT03529890|PROCEDURE|Radical cystectomy with standardized pelvic lymphadenectomy|Radical cystectomy with standardized bilateral pelvic lymphadenectomy: performed between week 11 - 15 (Aim: week 13)
224304476|NCT01798355|BEHAVIORAL|Treatment As Usual|Treatment as usual consist of strategies such as habituation, tell-show-do, premedication with midazolam, nitrous oxide sedation and general anesthesia. All offered by dentists and dental hygienist and/or dental assistants.
223474751|NCT02928484|DIETARY_SUPPLEMENT|Probiotic mix CBP-004019/C|One capsule per day of the probiotic mix CBP-004019/C during one month.
223474752|NCT02928484|DIETARY_SUPPLEMENT|Placebo|One capsule per day of the placebo (maltodextrin) during one month.
223581742|NCT02559661|OTHER|Training on a virtual simulator in eye surgery|
224161715|NCT04505878|DRUG|Vitamin C|Vitamin C is a first-line antioxidant that directly scavenges free radicals, inhibits reactive oxygen species (ROS) producing enzymes and recovers other cellular antioxidants
224161716|NCT02778373|DIETARY_SUPPLEMENT|Vitargo ®, Swecarb AB, Karlskrona, Sweden|
224161717|NCT02778373|DIETARY_SUPPLEMENT|DE15 maltodextrin, Matrin® M160, Grain Processing Corporation, Muscatine, IA|
223474753|NCT03072186|DEVICE|near-infrared light nasal endoscope used with ICG|Using the near-infrared light nasal endoscope with ICG will identify anatomical landmarks and and tumor characteristics to provide a clear demonstration of the blood supply.
223474754|NCT03120611|OTHER|Virtual Reality Exercise|Game developed by the Kinect, adapted to the lying position of participants.
223474755|NCT03120611|OTHER|Conventional exercise intradialysis|Aerobic exercise (cycling) and strengthening exercise for lower limbs using elastic bands and gravity
223474756|NCT01482559|DRUG|Dopamine hydrochloride|Active drug substance 1.5 mg in 1 mL IV Infusion Minimum dose = 5mcg/kg/min Maximum dose = 20mcg/kg/min
224161718|NCT02778373|OTHER|Placebo: Water|
224161719|NCT06434090|DRUG|Liposomal irinotecan|Liposomal irinotecan will be given biweekly at a dose from 70mg/m2 to 90mg/m2.
223474757|NCT01482559|DRUG|Dextrose 5%|IV Infusion Minimum dose = 5mcg/kg/min Maximum dose = 20mcg/kg/min
224161720|NCT06434090|DRUG|Bevacizumab|bevacizumab will be given biweekly at a dose of 5mg/m2
224161721|NCT01562145|PROCEDURE|Blood sampling|Four mL venous blood samples were collected from all study participants after inclusion
224161722|NCT03048409|OTHER|Enteral Formula|Enteral feeding with a peptide-based formula.
224161723|NCT01111721|BEHAVIORAL|Project POWER HIV Risk-reduction Intervention|Nine session group-based behavioral intervention for incarcerated female adults.
223474758|NCT00915174|DRUG|Neramexane|25 mg q.d., 3 days 2 x 25 mg b.i.d., 11 days
223744104|NCT03911895|DEVICE|Stent more than 26 mn length|stent length in patients undergoing PCI (Drug Eluting Stent)
224161724|NCT01111721|BEHAVIORAL|NC DOC Standard of Care for STIs|Standard North Carolina Department of Correction intake STI testing and counseling.
224161725|NCT01734278|OTHER|No intervention|This is a non-interventional study.
224163574|NCT06370338|OTHER|Delphi Questionnaire|Experts will be approached to participate in the research via email. If the experts agree to participate they will check 'yes' in the email with the informed consent and will be directed to the Qualtrics survey. If the expert decides to decline consent they will check 'no' in the email and will not be enrolled. Subjects who agree to participate will undergo 2 phases of questions with three rounds of the same questions in each phase. This Delphi survey research involves Phase 1 and Phase 2 of questioning, each phase involves up to 3 rounds of questions to determine agreement or disagreement. Each round will take approximately 20 minutes to complete, and your responses will remain completely confidential. For both phases, the questions will either be 7-point Likert or multiple choices. For both phases, the group of questions will be sent up to three times until we obtain agreement (up to 80% of agreement consensus). Questions that have obtained agreement will be removed in each round.
224304477|NCT04713150|OTHER|No Intervention|No Intervention
224304478|NCT03021109|DEVICE|Measurement of inferior vena cava diameters with ultrasound|The patient is placed in the supine position. Curvilinear probe is used. Subxiphoid view is obtained. The IVC is visualized in the longitudinal plane as it enters the right atrium. The diameter of the IVC for calculation of the caval index is measured 2 cm from where it enters the right atrium
224163575|NCT05450445|DEVICE|myHealthHub|myHealthHub is a multimodal patient engagement platform delivered on bedside terminals to provide hospital inpatients with social connection, meal ordering services, entertainment (TV, etc.), and access to medical care team.
224163576|NCT05450445|DEVICE|TV-only|myHealthHub device equipped with the TV-only entertainment option.
224304479|NCT05437926|DEVICE|Arrhythmia Analysis Software (software) which runs on a mobile application (Huawei Phone) and uses input from a wearable device (smart watch or smart band).|Subjects with or without cardiac arrhythmias and of light skin tone (melanin index \<150) or dark skin tone (melanin index \>350). Subjects will be divided based on their heart rhythm in three groups: approximately 1/3 with normal sinus rhythm, 1/3 with atrial fibrillation and 1/3 with premature beats
224163577|NCT05572541|DIAGNOSTIC_TEST|Fonseca questionnaire|Fonseca questionnaire for the evaluation of temporomandibular dysfunction
224163578|NCT03775603|DEVICE|TOFscan|comparison of TOFscan over TOF-Watch SX
224163579|NCT04976309|DRUG|Lu AG09222|Single dose
224304480|NCT03415061|DRUG|Regular Insulin, Human 100 UNT/ML|40 IU of Humulin-R to be administered via nose using metered nasal dispenser prior to surgery, and up to 7 days after surgery.
224304481|NCT03415061|DRUG|Normal Saline Flush, 0.9% Injectable Solution|Normal Saline to be administered via nose using metered nasal dispenser prior to surgery, and up to 7 days after surgery
223474759|NCT06312982|DRUG|Tislelizumab|Enrolled patients will receive tislelizumab 3 times after initiation of radiotherapy.
224304482|NCT04948164|DRUG|sumatriptan 85mg and naproxen sodium 500mg|Subjects took 1 tablet of the study drug (each containing sumatriptan 85mg and naproxen sodium 500mg) within 1h of an acute migraine attack of mild severity, and if the headache progressed to moderate severity within 2 hours, they could take the remedial drug phenol chai (each containing acetaminophen 500mg and caffeine 65mg).
224304483|NCT04948164|DRUG|Placebo|"subjects were given one tablet of placebo within 1 h of an acute migraine attack with mild severity, and if the headache progressed to moderate severity within 2 hours, they were given the remedial drug phenol chai (each tablet contains acetaminophen 500 mg and caffeine 65 mg)."
223474760|NCT06523179|OTHER|quantify the impact of genetic risk factors|the impact of genetic risk factors for the development of NAFLD-HCC and their interaction with acquired risk factors, on the incidence of the disease in a prospective cohort of patients at risk, through a score capable of predicting NAFLD-HCC and selecting patients for whom screening is cost-effective.
223474761|NCT01339065|DRUG|Ketamine|determining the effect of low dose sub anesthetic doze of ketamine and placaebo on post operative patients
223474762|NCT04643886|DRUG|GEM103|Biological
223474763|NCT01549158|DRUG|torasemide-PR|Single oral dose of torasemide PR 10 mg
224163580|NCT04976309|DRUG|Placebo|Single dose
224163581|NCT02325089|DEVICE|Mandibular advancement device|Use of a mandibular advancement device every night during one year. Device will be titrated to reduce or - if possible - eliminate snoring and sleep apnea.
224163582|NCT02325089|DEVICE|Placebo|Placebo oral appliance will be identical to the mandibular advancement device without, however, the attachemnt to allow mandibular advancement. It will be used every night during one year.
224163583|NCT01922466|PROCEDURE|Bee Venom Acupuncture|"Bee Venom 1:20,000 under BVA Increment Protocol~\- Increment Protocol as~* 1st week - SC 0.2cc/day, 2 days/week~* 2nd week - SC 0.4cc/day, 2 days/week~* 3nd week - SC 0.8cc/day, 2 days/week"
224163584|NCT01922466|DRUG|Loxoprofen|60 mg/Tab, pers os 1Tab tid, for 3 weeks
224163585|NCT02353325|DIETARY_SUPPLEMENT|non-encapsulated FeSO4|
224163586|NCT02353325|DIETARY_SUPPLEMENT|encapsulated FeSO4, before cooking|
223474764|NCT01549158|DRUG|Furosemide-IR|Single oral dose of furosemide IR 40 mg
223474765|NCT01549158|DRUG|torasemide-IR|Single oral dose of torasemide IR 10 mg
223474766|NCT01441986|DRUG|Dextromethorphan hydrobromide|Dextromethorphan hydrobromide•1 H2O; 30 mg; hard capsules; single, oral dose.
223474767|NCT01441986|DRUG|Amantadine|Amantadine hydrochloride 100 mg; tablets; single, oral dose.
223474768|NCT01441986|DRUG|Pacebo 1 (placebo for Amantadine)|Talets for oral use; single dose.
223474769|NCT01441986|DRUG|Placebo 2 (fo Dextromethorphan)|Capsles for oral administration; single dose.
223474770|NCT03546465|DRUG|ropeginterferon alfa-2b|6 subjects in each cohort will receive a single dose by subcutaneous injection
223744105|NCT03911895|DEVICE|Stent equal to or less than26 mn length|stent length in patients undergoing PCI (Drug Eluting Stent)
223744106|NCT00818428|BEHAVIORAL|Speech Production Intervention|Individual speech therapy directed at teaching the child to articulation specific speech sounds or word shapes accurately using traditional procedures such as phonetic placement and imitated and spontaneous speech production practice with feedback from the clinician about accuracy of articulatory gestures and knowledge of results.
223474771|NCT02332265|OTHER|Support to Able-Bodied Vulnerable groups to Achieve Food Security (SAFE)|The SAFE program was developed \& implemented from Jan. 2008-Dec. 2010 by CARE-Malawi, a country office of CARE International, a large NGO. SAFE participants were selected by CARE-Malawi. SAFE was designed to address intertwined structural issues contributing to HIV susceptibility: food insecurity, poverty, gender inequity and ineffective governance. SAFE was implemented in 3 geographic subdivisions (Njombwa, Kaomba, \& Mwase) of Kasungu District, located in west-central Malawi. It was funded primarily by the European Commission \& partially by the Austrian Development Cooperation. SAFE had 4 main components: 1) improving farming practices \& sustainable agriculture through Farmer Field Schools, 2) increasing access to savings and investment through Village Savings \& Loans Groups, 3) building capacity of local governance structures \& 4) integrating HIV education \& gender empowerment into programs through training \& education. Details: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4082534/.
223474772|NCT02390232|BIOLOGICAL|liver biopsy|A small needle is inserted into the liver to collect a tissue sample
223581743|NCT00755469|PROCEDURE|Post-conditioning|The post-conditioning protocol consists of performing 4, 30-second PTCA balloon occlusions followed by 30 seconds of reperfusion for a total of 4 minutes. The first balloon inflation occurs immediately after an angioplasty guidewire is placed through the obstruction in the artery and flow is restored. Following this protocol the vessel will be stented as part of usual practice for treatment of acute MI.
223581744|NCT03205904|DIETARY_SUPPLEMENT|Diet|Nutrition booklet with guidelines on types of fats and glycemic index
223581745|NCT02845778|DRUG|Melatonin|Each sachet contains 0.5 g
223581746|NCT00566865|DRUG|placebo for gemfibrozil|mitiglinide + placebo for gemfibrozil 600 mg bid
223581747|NCT00566865|DRUG|gemfibrozil|Mitiglinide + 600 mg gemfibrozil bid
223581748|NCT01887119|DRUG|Eplerenone|
223744107|NCT00818428|BEHAVIORAL|Speech Perception Intervention|Individualized intervention in which the Speech Assessment and Interactive Learning System is used to teach the child to identify recordings of words as either correct or incorrect pronunciations of the target word. In the event that the child is completely unable to pronounce the target speech sounds or word shapes focused stimulation activities are used to provide the child with further auditory exposure to the target forms. If the child stimulable for the target forms, the child is given opportunities the produce the target speech sounds or word shapes in the context of minimal pair games in which the child receives feedback about the communicative effectiveness of his or her attempts to produce the target words.
223474773|NCT02390232|BIOLOGICAL|collection of stools|collection of stools
223474774|NCT02390232|BIOLOGICAL|blood sample|collection of blood sample
223474775|NCT05512117|DEVICE|Midline insertion|Midline catheter insertion
223474776|NCT03307174|DRUG|Bupivacaine|
223474777|NCT03307174|DRUG|Fentanyl|
223474778|NCT02173613|OTHER|procalcitonine|"The recommendations will be based on the level of PCT: 4 levels of advice will be given:~* It is highly recommended to stop antibiotics if PCT \<0.1ng/ml, and the recommended stop if 0.1ng/ml \<PCT \<0.25 ng / ml.~* It is recommended to continue treatment if 0.25 ng / ml \<PCT ng / ml.~* Finally, if the initial PCT greater than 10 ng / ml, a stop will be advised in case of reduction to less than 10% of baseline level."
223474779|NCT00971113|DIETARY_SUPPLEMENT|sc-FOS and Sideritis euboea extract|"dietary supplement: jelly with 5g sc-FOS and 0.3g Sideritis euboea extract per daily portion for 30 days~placebo food: jelly with no sc-FOS and Sideritis euboea"
223474780|NCT01923519|PROCEDURE|bronchofiberscopy|
223581749|NCT01887119|OTHER|Placebo|Eplerenone-matched placebo
223581750|NCT00200538|DRUG|memantine|
223581751|NCT02258555|DRUG|GS-9901|GS-9901 tablets administered orally
223581752|NCT04861246|DEVICE|Laser|The device will be used to do Laser treatment. To compare the therapeutic effect to laser treatment before and post treatment for 14 and 60 days.
223581753|NCT04861246|DEVICE|ApolloVue® S100 Image System|The device is an in vivo non-invasive optical coherence tomography and will be used to obtain OCT images before and after laser treatment of skin.
223581754|NCT04861246|DEVICE|VISIA®|The device is skin analysis system and will be used to obtain before and after images of laser treatment.
224163587|NCT02353325|DIETARY_SUPPLEMENT|encapsulated FeSO4, after cooking|
224163588|NCT02353325|DIETARY_SUPPLEMENT|non-encapsulated FeSO4 + ascorbic acid|
224163589|NCT02353325|DIETARY_SUPPLEMENT|encapsulated FeSO4 + ascorbic acid, before cooking|
224163590|NCT02353325|DIETARY_SUPPLEMENT|encapsulated FeSO4 + ascorbic acid, after cooking|
224163591|NCT05270967|DIAGNOSTIC_TEST|F-18 FDG PET/CT imaging|Oncological imaging
224163592|NCT05270967|BIOLOGICAL|Pfizer/biontech mRNA vaccine|COVID-19 vaccine
224163593|NCT05715840|DRUG|SG001 injection|360 mg，Q3W，IV infusion
224163594|NCT05715840|DRUG|Paclitaxel|175 mg/m\^2，Q3W，IV infusion
224163595|NCT05715840|DRUG|Cisplatin|50 mg/m\^2，Q3W，IV infusion
224163596|NCT05715840|DRUG|Carboplatin|AUC=5，Q3W，IV infusion
224163597|NCT05715840|DRUG|Bevacizumab injection|15 mg/kg，Q3W，IV infusion
224163598|NCT05715840|DRUG|SG001 placebo|Q3W，IV infusion
224163599|NCT02647892|DRUG|lidocaine|local anesthesia
224163600|NCT02647892|DRUG|sodium bicarbonate|additional drug added to lidocaine
224163601|NCT02840734|OTHER|Kinesio taping|This study was conducted in a randomized crossover double-blind design. Each subject was tested for muscular power, strength, endurance, and fatigue of the lower extremities under three conditions: 1) NT (no taping), 2) PT (placebo taping, 3M tape) and 3) KT (Kinesio taping). For allocation of treatment sequence, the participants drew straws for which treatment first (each treatment indicated different numbers).
224163602|NCT05431738|DEVICE|Gastroesophageal stent placement|A gastroesophageal stent is placed during a digestive endoscopy performed under general anesthesia, under endoscopic and fluoroscopic control
224163603|NCT04548479|DEVICE|PEP bottle|PEP bottle: it will be performed with a bottle of distilled water and a plastic tube, where the patient breathes against a resistance during expiration.
224163604|NCT04510155|BEHAVIORAL|Overnight fasting duration|Subjects will adhere to overnight fasting protocol for 1 day
224163605|NCT02855086|BIOLOGICAL|Cetuximab|Administered intravenously (IV)
224163606|NCT02855086|DRUG|Cetuximab-IRDye 800CW|Administered intravenously (IV)
224163607|NCT02855086|PROCEDURE|Tumor resection|Standard of care treatment
224161726|NCT05370560|OTHER|Plasma transthyretin concentration|Plasma transthyretin concentrations were measured by BS 200 Autoanalyser (Mindray, Shenzhen, China) using immunoturbidimetric method.
224304484|NCT05802732|DIAGNOSTIC_TEST|Stool Antigen test|Correlation between the result of endoscopic biopsy and stool antigen test
224161727|NCT04953663|BIOLOGICAL|it-hMSC|Different doses of it-hMSC
223474781|NCT04275336|DRUG|EMLA application|A thick layer of cream (lidocaine and propiocaine 2.5%/2.5%) will be applied on a 1x1 cm2 area of skin on the cannulation site. The transparent dressing will be left in place for 30 minutes, then remove and clean with a sterile cotton swab. Then nurse perform IV cannulation for them.
224161728|NCT01992900|DRUG|Eurartesim dispersible oral tablet|The first dose of Eurartesim dispersible oral tablet will be administered immediately after randomization. the other two doses will be administered with an interval of 24 hours. Eurartesim tablet will be dispersed in about 10 mL of water.
224161729|NCT01992900|DRUG|eurartesim film coated tablet|The first dose of Eurartesim film coated tablet will be administered immediately after randomization. the other two doses will be administered with an interval of 24 hours. tablet will be crushed and dispersed in a few amount of water (about 10 ml).
224304485|NCT01470495|OTHER|RFA + Sorafenib|combined RFA and Sorafenib to treat recurrent HCC
223474782|NCT04275336|BEHAVIORAL|Distraction techniques|Multiple distractions including toy whistles, cartoon books, a TV showing cartoons, and various electronic products with video games will be provided for the children to choose and play with. They will also be taught breathing exercises (i.e. inhaling through the nose for 3 seconds and exhaling for 5 seconds, while they are counting) if they are willing. A play therapist play with the children for 5 min. prior to and throughout the venipuncture procedure.
224304486|NCT01470495|OTHER|RFA|treat Recurrent HCC with RFA
224304487|NCT04953572|GENETIC|autologous peripheral blood mesenchymal stem cell|Transplantation of autologous peripheral blood mesenchymal stem cell
224304488|NCT04953572|PROCEDURE|Microfracture|Microfracture
223474783|NCT04275336|OTHER|EMLA cream and distraction techniques|both EMLA cream and distraction techniques will be used. EMLA cream will be applied on the pre-puncture site for 30 minutes as the EMLA group, then 5 minutes before the venipuncture, the play therapist encourage them to choose their favorite toys to play with or to learn breathing exercises. During IV cannulation the play therapist will also continue distracting the child with toys.
224304489|NCT04953572|COMBINATION_PRODUCT|Microfracture + collagen membrane|Microfracture plus collagen membrane transplantation
224304490|NCT04953572|PROCEDURE|Autologous osteochondral transplantation|Autologous osteochondral transplantation
224304491|NCT00735605|OTHER|BFD|The investigators used pressure based biofeedback training, using a perfused eight-channel polyvinyl catheter with a compliant balloon at the tip
223474784|NCT03691636|DEVICE|Eyelash prostheses|Eyelash prostheses are essentially specialized eyelash extensions
223474785|NCT03691636|DEVICE|5.0% Lifitegrast Ophthalmic Solution|5.0% Lifitegrast Ophthalmic Solution
224304492|NCT00735605|PROCEDURE|PDPR|A 2-3 cm curved incision is made on either side of the anal canal along its posterolateral aspect, each about 2.5 cm distance from the anal verge Fig(2). After that dissection in ischiorectal fossa was done till reaching the puborectalis sling from outside i.e. extrasphincteric approach . Using a right angle forceps the puborectalis sling is lifted up, guided by the contralateral index finger in the anal canal Fig(3). Nearly the inner half of puborectalis sling was divided on each side by using a scalpel NO. 11 Fig(4). Complete haemostasis was followed by skin closure without drain
224304493|NCT00735605|OTHER|BTX A|A vial of Dysport, 500 u, (Dysport, Ipsen, United Kingdom) is dissolved in 2.5 ml isotonic saline Fig(1). A volume of 0.5 ml of dissolved toxin, i.e., 100 u Dysport, is injected in each patient
223474786|NCT05017844|DRUG|KSR-001-04|One drop to both eyes four times a day for 12 weeks
223474787|NCT05017844|DRUG|KSR-001-02|One drop to both eyes four times a day for 12 weeks
224304494|NCT03290703|DRUG|GDC-0853|Participants will receive different formulations of GDC-0853 tablet.
223474788|NCT05017844|DRUG|KSR-001-03|One drop to both eyes four times a day for 12 weeks
223474789|NCT05484830|PROCEDURE|Individualized HDR-approach|"Heparin concentration necessary to achieve target ACT \> 480 sec. calculated based on individual HDR-curve.~If HDR slope ˂80 s/IU/mL (reduced sensitivity to heparin), 1000 IU of AT concentrate (Antitrombin III Baxalta®, Takeda Pharma, Vallensbæk Strand, DK). Whole blood concentration of circulating heparin assessed by heparin assays. Additional heparin given as required. After weaning, protamine necessary to reverse circulating heparin calculated according to heparin-protamine titration measurement. After protamine, heparin reversal evaluated with low-range heparin-protamine titration cartridge and additional protamine given as required."
223474790|NCT05484830|PROCEDURE|Conventional ACT-approach|"Initial Heparin 400 IU/kg (500 IU/kg if treated with heparin prior to surgery). ACT Assessment with Hemochron® Signature Elite (ITC, International Technidyne Corp., Edison, NJ, USA).~Additional heparin until ACT \> 480 sec. If ACT \< 480 sec. after despite repeated heparin supplement with 1000 IU of AT III concentrate. Target ACT \> 480 sec. during normothermic CPB, and target ACT \> 700 seconds during hypothermia After weaning, protamine 10mg/mL (0.7 mg of protamine/ 100 IU total heparin administered). Heparin reversal is evaluated with an activated partial thromboplastin (APTT). If APTT \> 40 seconds, additional protamine (25-50 mg i.v.)."
224161730|NCT03157999|BEHAVIORAL|Intervention group (CAST)|"Intervention duration is expected to be 6 months. A full-time registered nurse (RN) will function as a Care Transitions Coordinator (CTC) who works collaboratively with one local hospital and other health and non-health representatives to deliver the intervention, which includes:~* care coordination and system navigation (including facilitating timely primary care follow-up);~* medication management;~* assessing the needs and risk of the participants (including in-depth assessment of depressive symptoms);~* evidence-based management of depressive symptoms and other chronic conditions to prevent the onset and worsening of other chronic conditions;~* patient and caregiver education; and goal setting and problem-solving therapy."
224161731|NCT02481440|BIOLOGICAL|human umbilical cord mesenchymal stem cells (hUC-MSCs)|Four times of intrathecal administrations of hUC-MSCs
224161732|NCT06819189|DRUG|Ethanol|IV Ethanol
224161733|NCT04623931|OTHER|Quality-of-Life Assessment|Ancillary studies
224161734|NCT04623931|OTHER|Questionnaire Administration|Ancillary studies
224304495|NCT03290703|DRUG|Rabeprazole|Participants will receive rabeprazole 20 mg twice daily (BID) for three days prior to GDC-0853 administration and a single dose coadministered with GDC-0853.
223474791|NCT06014177|BEHAVIORAL|STIckER|"STIckER is an interactive and personalized intervention based on the principles of SDM that has been designed with input from the AYA ED patients and providers. STIckER guides AYA patients through a series of steps, beginning with scanning your STIckER. Participants complete risk assessments, SDM modules, and conclude with an anonymous final digital infographic that informs an SDM conversation with the medical provider. This decision aid seamlessly integrates into the ED workflow, recommending appropriate STI testing for high-risk individuals and using SDM concepts for those at intermediate risk."
223474792|NCT06014177|OTHER|Control|"After enrollment but before the start of their clinical visit, AYA participants assigned to a provider in the control arm will scan a QR code. They will receive a prompt stating, If you would like to be tested for a sexually transmitted infection today, please tell your medical doctor."
223474793|NCT03055936|DRUG|Levodopa|Levodopa 50 mg or 100 mg or 150 mg
223474794|NCT03055936|DRUG|Carbidopa|Carbidopa 12.5 mg or 25 mg or 65 mg
223474795|NCT03055936|DRUG|ODM-104|ODM-104 50 mg or 100 mg
223474796|NCT04664205|OTHER|High Intensity Interval Exercise|One session of high intensity interval exercise
223474797|NCT04664205|OTHER|Moderate Intensity Continuous Exercise|One session of calorically matched moderate intensity exercise
223474798|NCT04664205|OTHER|Control|No exercise, resting measures
223581755|NCT04239183|DEVICE|Stomatherapy|Demonstrate improvement of quality of life (difference of at least 5 points in the StomaQoL questionnaire (21)) among descending colostomy patients, establishing the following comparisons.
223581756|NCT03781219|DRUG|HL-085|HL-085 ( Capsule) is one MEK inhibitor.
223581757|NCT03781219|DRUG|Vemurafenib|Vemurafenib ( Tablet) is BRAF inhibitor,
223581758|NCT01895933|DEVICE|5ml surgishield|"in the case of active, apply solution type adhesion barrier to merocel and pack 5ml of adhesion inhibitor Surgi Shield on the surgical site~merocel in the inflated state maintained for 36\~48 hours, remove packing then solution type adhesion inhibitor is to be injected in to the surgical site"
223581759|NCT01083498|DEVICE|Ablative fractional laser therapy|10,600 nm ablative fractional laser Irradiance: 10 mJ/microbeam. Coverage: 35-45%. Number of treatment sessions: 3
223581760|NCT01710527|DRUG|Metformin 500mg|EVALUATE BIOEQUIVALENCE BETWEEN METFORMIN 500 MG TABLETS MANUFACTURED BY SAVIPHARM J.S.C, VIETNAM AND GLUCOPHAGE® 500 MG TABLETS MANUFACTURED BY MERCK SANTE S.A.S.2, RUE DU PRESSOIR VERT-45400 SEMOY-FRANCE AND BE REGISTERED IN VIETNAM IN HEALTHY, ADULT, HUMAN MALE SUBJECTS UNDER FASTING CONDITION
223581761|NCT01710527|DRUG|Glucophage 500mg|EVALUATE BIOEQUIVALENCE BETWEEN METFORMIN 500 MG TABLETS MANUFACTURED BY SAVIPHARM J.S.C, VIETNAM AND GLUCOPHAGE® 500 MG TABLETS MANUFACTURED BY MERCK SANTE S.A.S.2, RUE DU PRESSOIR VERT-45400 SEMOY-FRANCE AND BE REGISTERED IN VIETNAM IN HEALTHY, ADULT, HUMAN MALE SUBJECTS UNDER FASTING CONDITION
223581762|NCT00579046|DRUG|Darbepoetin alfa|"Dosage form: injection (to store between 2 and 8 °C). Dosage: various dosages are available (10, 15, 20, 30, 40, 50, 60, 80, 100, 150 or 300 µg/ml).~Frequency: every week for 2 months: 8 injections"
224161735|NCT04623931|RADIATION|Radiation Therapy|Undergo radiation therapy
224161736|NCT04623931|DRUG|Temozolomide|Given PO
224161737|NCT01116661|DRUG|5-Aminolevuline Acid (ALA)|Given orally at a dose of 20 mg/kg body weight 3hrs before anesthesia prior to surgery
223474799|NCT00128128|DRUG|Cranberry juice cocktail|Participants will consume 4 or 8 ounces of Cranberry Juice Cocktail or Placebo daily for 6 months.
223474800|NCT04059718|BEHAVIORAL|SCI Thrive Peer-Led Online Self-Management Program|6 week online course in self-management for individuals with spinal cord injuries. This was developed by a team using principles of cognitive behavioral techniques.
223474801|NCT01464567|PROCEDURE|"T Tube Spontaneous Breathing Trial"|"T Tube ventilation for 30 minutes"
223474802|NCT01464567|PROCEDURE|Pressure Support Ventilation|Pressure-Support Ventilation for 30 minutes
223474803|NCT02125240|DRUG|Icotinib|125 mg three times daily (375 mg per day) by mouth
223474804|NCT02125240|DRUG|Placebo|1 tablet three times daily by mouth
223474805|NCT01203696|DRUG|Amlodipine|For patient with suboptimal angina control: oral 2.5-10mg daily
223474806|NCT01203696|DRUG|Amlodipine|For patient with suboptimal BP control: 2.5-10mg daily po
223474807|NCT02552927|DEVICE|Chest shield with aluminum foil (CALF)|
223581763|NCT03159364|BIOLOGICAL|pathogen-specific CTLs|Patients will receive approximately 1x10\^5\~1x10\^6 CTLs/kg as a single infusion via IV injection and may receive additional infusions.
223581764|NCT04161378|DIAGNOSTIC_TEST|Cardiac imaging|"* Transthoracic echocardiography~* Late gadolinium enhancement CMR"
223581765|NCT04161378|DIAGNOSTIC_TEST|Laboratory analysis|"* complete blood count~* biochemistry~* hs-CRP, MMPs, IL6, NT-pro-BNP"
223581766|NCT05066945|OTHER|Observation|observe the association of ctDNA with efficacy of treatment
223744108|NCT00818428|BEHAVIORAL|Articulation Parent Group|Parents are taught to carry out home practice activities that focus on the child's ability to correctly articulate target speech sounds and word shapes.
223744109|NCT00818428|BEHAVIORAL|Dialogic Reading Parent Group|Parents are taught to read to their children using interactive techniques that help their children acquire new vocabulary, verbal reasoning abilities, and preliteracy skills.
223744110|NCT01909908|DEVICE|ECM|ECM in saline applied to wound
224161738|NCT00854867|DRUG|Whole Brain Radio Therapy (WBRT) with sequential Depocyte|
223474808|NCT02552927|DEVICE|SHIELD|
224161739|NCT00854867|DRUG|Whole brain radiotherapy (WBRT) with concomitant Depocyte|
224161740|NCT01872273|OTHER|Moderate Physical Exercise|This intervention is comprised of two separate visits at least one week apart. The purpose of visit 1 is to determine the cycle ergometer workload that produces a moderate exercise intensity of 60% heart rate reserve to be used on visit 2. The purpose of visit 2 is to determine changes in platelet reactivity in response to moderate exercise.
224161741|NCT01649752|BIOLOGICAL|Differentiated stem cells to endometrium is deposited in the uterine cavity through an IUI catheter|
224161742|NCT01649752|BIOLOGICAL|Undifferentiated MSC is deposited in the uterine cavity through an IUI catheter.|
224161743|NCT03286634|DRUG|Daunorubicin|Given IV
224161744|NCT03286634|DRUG|Prednisolone|Given PO or IV
224161745|NCT03286634|DRUG|Vincristine|Given IV
224161746|NCT03286634|DRUG|Epirubicin|Given IV
224161747|NCT03286634|DRUG|E-coli L-asparaginase|Given IM or IV
224161748|NCT03286634|DRUG|6-Mercaptopurine|Given PO
224161749|NCT03286634|DRUG|Methotrexate|Given IV, PO or IT
223474809|NCT04547400|OTHER|assessment|Assessments of balance, gait, lower extremity position sense, and foot sole sense
223474810|NCT03886909|BEHAVIORAL|Exercise|The exercise intervention is at least 2 weeks lasting (till the day transplant is taking place) 5-times weekly resistance training intervention combined with aerobic exercise (mostly walking).
223474811|NCT03886909|BEHAVIORAL|Prehabilitation Education|Participant will receive a prehabilitation and stem cell education class which will be held at the Penn State Cancer Institute.
223474812|NCT02542969|DRUG|Simvastatin|
223474813|NCT02542969|DRUG|Rosuvastatin|
223474814|NCT02542969|DRUG|MGL-3196|
223474815|NCT05143424|DRUG|Morphine Sulfate|Morphine sulfate 30 mg tablets as a single dose twice
223474816|NCT03179358|DEVICE|C-REX Ring-locking Procedure|"The C-REX Ring-locking Procedure is a method based on adaptive anastomosis, in which intestinal ends adapt to each other after resection due to tumor, injury, or other disease.~The investigational devices comprised of two components, i.e. C-REX LapAid and C-REX DMH/DMHC"
223581767|NCT05586698|PROCEDURE|Auricular acupressure|We conducted auricular acupressure at zero acupoints on the left ear with Vaccaria ear seed (Group A) or removed seed (Group B) in 20 minutes, with 2 times of auricular acupressure. The stimulation was performed for 30 seconds each time, with two pressure movements per second, resulting in a total of 60 pressure movements per stimulation.
223581768|NCT03923582|BEHAVIORAL|Comprehensive sexual health curriculum|"This is a randomized, controlled, single blinded, trial, stratified by health profession, of the intervention versus waitlist control assessing knowledge, attitude change and skill development. At the end of the intervention as compared with waitlist controls.~The intervention was a 4-day, Afrocentric, comprehensive sexual health curriculum. Tanzanian faculty wrote the curriculum in English and Kiswahili to address the most common sexual health challenges clinicians experience in Tanzania. The 4-day curriculum covers sexual health across the lifespan, LGBT and sexual violence, clinical skills training, ethics and policy writing, and community resources and cultural considerations."
224161750|NCT03286634|DRUG|Hydrocortisone|Given IT
224161751|NCT03286634|DRUG|Cytarabine|Given IV, IT or SC
223474817|NCT01494207|BEHAVIORAL|Wellness counseling|Each participant will receive up to six counseling sessions where the counselor will employ motivational interviewing techniques. The first and last session will be face-to-face with the remaining four sessions being telephonic.
223474818|NCT05024383|OTHER|Chemical sensitivity|Chemical sensitivity will be evaluated with paper taste strips embedded with varying concentrations of capsaicin solutions (activates TRPV1) and allyl isothiocyanate solutions (activates TRPA1) applied to the tongues of healthy subjects and site of cancer in oral cancer patients.
223474819|NCT05024383|OTHER|Mechanical sensitivity|Mechanical sensitivity will be evaluated via von Frey filaments applied to the tongues of healthy subjects and and site of cancer in oral cancer patients.
223474820|NCT05233813|BEHAVIORAL|Active Body and Mind|The intervention group attended three 45-min group exercise lessons per week and wore a Fitbit activity tracker during the weekdays for 12 weeks combined with weekly feedback and personalized activity goals.
223474821|NCT05948085|DRUG|Zavegepant 10 mg IN|All participants will receive zavegepant 10 mg IN spray in period 1 and a butterscotch candy + zavegepant 10 mg IN spray in period 2
223474822|NCT03639168|DRUG|Chidamide combined with cisplatin|Chidamide combined with cisplatin
223474823|NCT03113045|OTHER|seated time|Pt will be seated for a predetermined time period. All Patients will receive intrathecal bupivacaine and morphine.
223474824|NCT00748202|DRUG|C1-Esterase Inhibitor|1000 I.E.
223474825|NCT00049816|BEHAVIORAL|Walking exercise|30 minutes/day, 3 times/week for 52 weeks
223474826|NCT00049816|BEHAVIORAL|Cycling Exercise|30 minutes/day, 3 times/week for 52 weeks
223474827|NCT05516303|GENETIC|Genetic polymorphism|One blood tube will be taken for genetic testing
223474828|NCT05516303|DIAGNOSTIC_TEST|Measurement of fingolimod and fingolimod-phosphate concentrations|Measurement of fingolimod and fingolimod-phosphate concentrations before usual drug administration time
223474829|NCT01836237|DEVICE|Alexis - a wound protector|Alexis is a double ring, self-retaining circumferential device that is designed to protect incision site during surgical manipulation.
223474830|NCT00709189|DRUG|Norgestimate/Ehinyl Estradiol; Folic acid.|
223474831|NCT02073786|DEVICE|Conventional lightwand intubation|Conventional lightwand intubation technique will perform during intubation
223474832|NCT02073786|DEVICE|Rigid video stylet|Rigid video stylet will inserted through endotracheal tube before induction. After induction with propofol and remifentanil using TIVA infusion pump, rocuronium 0.6mg/kg were used to facilitate intubation. After 2minutes, board-certificated anesthesiologist perform intubation using Optiscope.
223474833|NCT04519424|BIOLOGICAL|CSL324|Recombinant anti-granulocyte colony-stimulating factor (G-CSF) receptor monoclonal antibody
223474834|NCT04519424|DRUG|Placebo|Normal saline (0.9% sodium chloride)
223474835|NCT01760902|BEHAVIORAL|Diet and Physical Activity|The group will convene weekly for 12 consecutive weeks and monthly thereafter for 9 consecutive months. Thus, there will be a total of 21 group-based sessions over the one-year period
223581769|NCT02635347|PROCEDURE|Remote Ischemic Conditioning (RIC)|Each RIC intervention will comprise three cycles of 5 minutes of inflation followed by 5 minutes of deflation of a pneumatic tourniquet placed in mid-thigh.
224161752|NCT03286634|DRUG|Cyclophosphamide|Given IV
224161753|NCT00645190|DRUG|Galantamine HBr|
224161754|NCT03013426|DRUG|NVX-508|Administration of NVX-508 emulsion intravenously
224161755|NCT02550860|DRUG|soybean oil (SO)-based IVFE (Medialipide)|The soybean oil (SO)-based IVFE will be allocated for a 3-month period, allowing sufficient timeframe for epidermal complete renewal.
224161756|NCT02550860|DRUG|fish oil (FO)-containing IVFE (Lipidem)|The fish oil (FO)-containing IVFE will be allocated for a 3-month period, allowing sufficient timeframe for epidermal complete renewal.
223474836|NCT00158808|BIOLOGICAL|Diphteria, tetanus, whole-cell pertussis, hepatitis B & Hib|
224161757|NCT04030819|BEHAVIORAL|schema therapy|The intervention is the schema therapy focuses on the management of anxiety and is based on self-efficacy, self-management . It consists of 20 once-weekly sessions of 90 minutes (with a 15 Min break), with homework activities between the sessions
224161758|NCT02880930|DIETARY_SUPPLEMENT|Fultium-D3 drops (Internis)|Oral daily doses of vitamin D3 (400 IU for 3 months; and 1,000 IU for an additional 3 months)
223474837|NCT06017245|DEVICE|whole-body vibration to Control|Whole-body vibration (WBV) will be applied while standing upright. During this position, he will be asked not to voluntarily contract the calf muscles and to remain relaxed. The vibration will be applied with the PowerPlate® Pro5 WBV (London UK) device. The vibration amplitude will be 2 mm. The vibration frequency will be 30, 33, and 36 Hz. Each vibration frequency will be applied for 45 seconds. A 5-second rest period will be applied between vibrations of 45 seconds.
223474838|NCT01334294|DEVICE|ForeseeHome|The ForeseeHomeTM device, was designed to identify central and paracentral irregularities (vision abnormalities) in the visual field, most commonly associated with exudative macular degeneration.
223474839|NCT06508086|PROCEDURE|laser ablation technique in the treatment of pilonidal sinus|group (A) will include patients with pilonidal sinus disease who will be operated by sinus tract ablation procedure using 1470 nm Diode laser
223474840|NCT06508086|PROCEDURE|Karydakis technique in the treatment of pilonidal sinus|group (B) will include patients with pilonidal sinus disease who will be operated by Karydakis technique
223474841|NCT05621161|DRUG|Postoperative analgesia management|Intravenous paracetamol 1 gr and a dose of 0,5 mg/kg-1 tramadol intravenously will be performed on all patients 30 min before the end of the surgery for postoperative analgesia. Patients will be administered paracetamol 1 gr IV every 8 hours in the postoperative period. A patient-controlled device prepared with 5 mg/ ml tramadol will be attached to all patients with a protocol including 10 mg bolus without infusion dose, 10 min lockout time, and 4-hour limit. If the VAS score will be ≥ 4, 0,5 mg/kg-1 meperidine IV will be administered.
223474842|NCT03962361|OTHER|Concentration of circulating microparticles.|The microparticles contained in the blood sample will be isolated by ultracentrifugation and quantified by flow cytometry. The microparticles concentration will be determined by the number of microparticles per uL of plasma, based on the volume of the sample, the flow rate of the cytometer and the number of fluorescent events.
223474843|NCT03991039|RADIATION|Gamma knife|Microvascular decompression
223474844|NCT02346734|DEVICE|Multiple Sclerosis Home Automated Telemanagement (MS HAT) system|
223474845|NCT05594082|DRUG|Trastuzumab Deruxtecan|Trastuzumab Deruxtecan, 5.4 mg/kg ivgtt q3w
223474846|NCT02707497|DRUG|rhTPO|Recombinant Human Thrombopoietin，TPIAO®, Shenyang Sunshine Pharmaceutical Company Limited \[SUNSHINE\], Shenyang, China）， 15000u/d, qd, subcutaneous injection, daily for no more than 7 consecutive days
223474847|NCT02707497|DRUG|Placebo|The control group will not use any platelet-increased drugs.
223474848|NCT00496561|BIOLOGICAL|subcutaneous immunotherapy (House Dust Mites)|subcutaneous immunotherapy (House Dust Mites)
223474849|NCT00496561|OTHER|placebo of subcutaneous immunotherapy (House Dust Mites)|placebo of subcutaneous immunotherapy (House Dust Mites)
223474850|NCT02436863|PROCEDURE|Surgical performance|Two different surgical performances
223474851|NCT02343224|DRUG|Pegylated interferon alpha-2b|PEG-Intron 1mcg/kg/dose weekly through an injection under the skin on the same day each week
223581770|NCT02635347|DEVICE|Pneumatic tourniquet|Portable Tourniquet System(PTSii, Delfi Medical Innovations, Inc.) used to perform RIC interventions.
224161759|NCT02204410|DIETARY_SUPPLEMENT|Omega-3 Fatty Acid|
224161760|NCT02204410|DRUG|ADHD Medication|
224304496|NCT00157079|BIOLOGICAL|Immune Globulin Intravenous (Human), 10%|
224304497|NCT02654860|DRUG|Paracetamol 3%|Investigate the efficacy and safety of a single intrathecal injection of paracetamol,for post-operative analgesia of hip replacement surgery
224304498|NCT02654860|DRUG|Placebo injection containing Saline solution 0.9%|Injection containing sterile solution of Saline Solution 0.9 %. Study part 2 will be placebo-controlled. Each patient will be allocated to a treatment arm (one of the three paracetamol doses or placebo) according to a computer-generated randomisation list.
223474852|NCT05123573|BEHAVIORAL|Clinical Skills|evaluate the students' ability to demonstrate essential clinical skills, clinical reasoning and problem-solving skills, management of life-threatening medical conditions, management of common medical problems, and placing the patients' needs and safety at the center of the care process.
223581771|NCT04835376|DEVICE|Percussion Palm Cup: Safety and Usability of Newly Designed Products in Infants and Children with Cystic Fibrosis|Patients/guardians/caregivers will be given 3 percussor palm cups to use over the course of 6 days. Each cup will be trialed for 2 days, allowing for equal time dedicated to each.
223581772|NCT04306289|DEVICE|transcranial direct current stimulation|Transcranial direct current stimulation (tDCS) is a noninvasive technique of neuronal modulation that has been used in different neurological conditions, neuropathic pain.
223581773|NCT05158985|OTHER|phonophoresis|treatment
224304499|NCT02654860|DRUG|Hyperbaric Bupivacaine HCl 0.5%|NIMP, spinal anaesthetic before the surgical procedure
223581774|NCT05158985|OTHER|exercises|treatment
223581775|NCT02144155|DRUG|Oxytocin: 24IU - 168 IU|Oxytocin: 24IU - 168 IU
223581776|NCT02144155|DRUG|Placebo|placebo drug
223581777|NCT02995044|DRUG|BAY987521|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation Code: Z09-180)
224161761|NCT05109078|DRUG|[14C]- Rongliflozin|Patients will receive single dose of orally \[14C\]- Rongliflozin on Day 1
224161762|NCT01462045|BEHAVIORAL|Mindfulness-based exercise|8-week program of mindfulness-based stretching and breathing exercises
224161763|NCT02579863|BIOLOGICAL|Pembrolizumab|IV infusion
224161764|NCT02579863|DRUG|Lenalidomide|oral capsules
224161765|NCT02579863|DRUG|Dexamethasone|oral tablets
224161766|NCT04344015|OTHER|Plasma Donation|Previously infected COVID-19 patients will be recruited to donate convalescent plasma.
224161767|NCT04461613|OTHER|Original IPAQ followed by a revised one.|Comparing two questionnaires (a revised version and an original International Physical Activity Questionnaire short form) with an activity diary.
224161768|NCT04461613|OTHER|Revised IPAQ followed by an original one.|Comparing two questionnaires (a revised version and an original International Physical Activity Questionnaire short form) with an activity diary.
224161769|NCT01679704|DIETARY_SUPPLEMENT|Food products|
224161770|NCT05525065|DRUG|GlucoCorticoid|Glucocorticoid as calculated in prednisone oral equivalents.
224304500|NCT00040768|DRUG|bortezomib|Given IV
224304501|NCT01442428|DRUG|Dexamethasone|Dexamethasone: 4 mg 3x daily for 2 weeks, then 2x daily for 1 week, then once daily for 1 week
223474853|NCT04217291|DRUG|SY-004|Take orally once a day
223581778|NCT02995044|DRUG|SPF Control|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.
223581779|NCT02482857|DRUG|Acetylsalicylic acid|To compare BID dosing with OD dosing with clinically used aspirin dosages.
223581780|NCT02124772|DRUG|Trametinib|Trametinib was administered orally, once daily. It was available in tablets (0.125 mg, 0.5 mg, 2 mg dose) as well as in powder form for oral solution (0.05 mg/mL dose).
223581781|NCT02124772|DRUG|Dabrafenib|Dabrafenib was administered orally, twice daily. The daily dose was divided into two equal doses. It was available in capsules (50 mg and 75 mg), dispersible tablets (10 mg) and powder for oral suspension (10 mg/mL dose).
223581782|NCT03518346|BEHAVIORAL|Virtual Reality|Samsung VR Go (VR head set), Samsung S7 (phone), and programmed distraction
223581783|NCT03518346|BEHAVIORAL|Standard of Care|Books, movies, TV
223581784|NCT02718014|OTHER|scaling and root planing (srp)|
223744111|NCT01909908|BIOLOGICAL|Blood Products|Autologous blood product applied to wound, with saline cleanse on alternating weeks
223744112|NCT01909908|DEVICE|ECM in Blood Products|Alternating treatments of ECM in saline and ECM in autologous blood products, applied to wound
224161771|NCT04634318|OTHER|Respiratory rehabilitation program (RR).|"Patients in the RR group will follow the respiratory rehabilitation program during a 4-week hospitalization in the respiratory diseases department of Renée Sabran hospital (Hyères, France).~The program includes for each week:~One medical consultation Four 40-min sessions of aerobic exercises on an ergocycle Four 1-hour sessions of walking in Renée Sabran Hospital's park Three 1-hour sessions of muscle strengthening exercises One 1-hour session of sophrology One 1-hour session of occupational therapy One 1-hour session of psychomotricity"
224161772|NCT04634318|OTHER|Respiratory tele-rehabilitation program (TRR).|Patients in the TRR group will realize the 4-week respiratory tele-rehabilitation program at home. The TRR program for each week includes the same sessions as RR program. But, medical consultation, sophrology, occupational therapy, psychomotricity and muscle strengthening sessions are carried out through live videoconferences. Additionally, aerobic and walking sessions are carried out outside home. The intensity of each session will be controlled by heart rate monitor.
224161773|NCT05032287|DRUG|Tamsulosin|Tamsulosin 0.4 mg once daily
224161774|NCT05032287|DRUG|Placebo|Placebo once daily
224161775|NCT03394196|DIAGNOSTIC_TEST|HIV-2 Genotypic Drug Resistance Testing using DBS|Real time HIV-2 genotypic drug resistance testing using dried blood spots and consensus sequencing.
224161776|NCT03394196|DRUG|2nd line ART ( Zidovudine 300mg BID + Lamivudine 150mg BID or Tenofovir DF 300mg QD + Lamividine 300mg QD or Emtricitabine 200mg QD + Lopinavir/Ritonavir 400/100mg BID)|1\. No resistance: Continue Current ART: Zidovudine 300mg BID + Lamivudine 150mg BID or Tenofovir DF 300mg QD + Lamividine 300mg QD or Emtricitabine 200mg QD + Lopinavir/Ritonavir 400/100mg BID (AZT/3TC or TDF/3TC or TDF/FTC + LPV/r) + Enhanced Adherence Counseling
224163812|NCT03236506|DRUG|Sofosbuvir 400 MG|Drugs will be given along with Zepatier to participants to treat genotype 3hepatitis C infection
224163813|NCT03616470|DRUG|Uproleselan|A rationally designed E-selectin antagonist used to inhibit binding of cells to E-selectin
224163814|NCT03616470|DRUG|Placebo|Saline, 0.9% Sodium Chloride
223474854|NCT04217291|OTHER|SY-004 matching placebo|Take orally once a day
223474855|NCT06088641|DIAGNOSTIC_TEST|preoperative BNP value|preoperative BNP value
223474856|NCT01317563|DIETARY_SUPPLEMENT|Vitamins A, E, C & Selenium|daily dose = Vitamin A 10000 IU (beta carotene), Vitamin E 400 IU, Vitamin C 1200mg, and Selenium 300mcg.
223474857|NCT01317563|DIETARY_SUPPLEMENT|Placebo|total daily dose = 1200mg whey protein, 800mg microcrystalline cellulose
223474858|NCT05545475|DRUG|Low molecular weight heparin|Anticoagulants were given. When using warfarin, international normalized ratio (INR) was detected every 3-4 days and adjusted carefully by 0.75mg dosage until achieve the target level of 2-3.
223474859|NCT00699868|OTHER|Sampling of blood, phenotypic analysis sub-populations NK by cytometric of stream in multiple markings|Sampling of blood
223581785|NCT03964753|DRUG|Nab-paclitaxel and Cisplatin|Nab-paclitaxel,125mg/m(2), d1,d8, Cisplatin,75mg/m(2), d1, 3 week, 2 cycles.
223581786|NCT03964753|PROCEDURE|surgery|surgery
223581787|NCT00280345|PROCEDURE|Trabeculectomy|A surgical procedure used in the treatment of glaucoma to relieve intraocular pressure by removing part of the eye's trabecular meshwork
223581788|NCT00280345|PROCEDURE|Trabeculectomy and cataract surgery|A surgical procedure used in the treatment of glaucoma to relieve intraocular pressure by removing part of the eye's trabecular meshwork and the removal of the cataract
223581789|NCT00280345|PROCEDURE|Cataract surgery|Removal of the cataract from the eye
223581790|NCT02350387|PROCEDURE|High Intensity Short Duration Exercise|Participants randomized to this group will perform 4 sets of 8-15 repetitions of eccentric exercise using the Eccentron set at 50-80% of the participant's one repetition maximum.
223581791|NCT02350387|PROCEDURE|Low intensity Long Duration Exercise|Participants randomized to this group will perform 5-20 minutes of continuous eccentric exercise using the Eccentron set at 50% of the participant's one repetition maximum.
223581792|NCT00780273|DEVICE|Ankylos Implants|ANKYLOS Implant System vs Certain PREVAIL Implant
223581793|NCT00780273|DEVICE|Biomet 3i Prevail Implants|
223581794|NCT05606991|OTHER|CPAP Withdrawal|Complete withdrawal of continuous positive airway pressure (CPAP) therapy for a 2-week period.
223581795|NCT04214431|BEHAVIORAL|Mindfulness-Based Childbirth Education|8-week mindfulness-based childbirth education
223581796|NCT03504566|DRUG|Linagliptin|Linagliptin
223581797|NCT03504566|DRUG|Empagliflozin|Empagliflozin
223581798|NCT03504566|DRUG|Telmisartan|Telmisartan
223581799|NCT03504566|DRUG|Sulodexide|Sulodexide
223581800|NCT05497856|OTHER|Integrated neuromuscular inhibition technique|Ischemic compression will be applied for 90 seconds followed by the SCS technique with a reduction in pain of at least 70%. it will be held for 20-30 sec followed by the Muscle energy technique in which the isometric contraction will be held for 7-10 sec and then the stretch will be held for 30 sec. This will be repeated 5 times per session with a 30-second rest interval in between each repetition Session will be held 3 times per week for 2 consecutive weeks
223744113|NCT00212823|DRUG|almotriptan malate|
223474860|NCT00699868|OTHER|Sampling of blood, phenotypic analysis sub-populations NK by cytometric of stream in multiple markings|Sampling of blood
223474861|NCT06202859|DEVICE|MIE|Two sequences separated for 1 min of 6 cycles each of MI-E(Cough Assist E70, Respironics Philips.
223474862|NCT03786835|OTHER|Protein supplementation and regular physical activity|To determine if high protein diet and/or regular physical activity improves muscle and bone health
223474863|NCT00244439|DRUG|MALG|30 minute application
223474864|NCT00244439|DRUG|Ovide (malathion) lotion 0.05%|8-12 hour application
223474865|NCT00244439|DRUG|Permethrin 1%|10 minute application
223474866|NCT06045117|DEVICE|CardioPumlonary Management System (CPM)|The CPM Device measures and trends a variety of physiologic parameters including thoracic impedance, respiration rate, tidal volume, ECG (electrocardiogram), heart rate, and diastolic heart sounds, all in an unobtrusive patch form factor.
223474867|NCT03188575|BEHAVIORAL|SilverCloud Internet-delivered Cognitive Behavioural Therapy|SilverCloud Health is a leading provider of online therapeutic solutions to support and promote positive behavior change and mental wellness. SilverCloud delivers interventions for all of the anxiety disorders (panic disorder, social anxiety, phobias, GAD, health anxiety, OCD), depression and also comorbid depression and anxiety. The programs for the treatment of depression and anxiety employ several innovative engagement strategies for improving the user experience. These are divided into several categories: personal, interactive, supportive, and social. Research on the SilverCloud interventions has yielded significant clinical outcomes (Richards et al., 2015).
223474868|NCT03188575|OTHER|Waiting List|8 week waiting list period.
223581801|NCT05497856|OTHER|Myofascial Release|Deep sustained pressure on the trigger points will be applied with thumb in 5-7/10 pain tolerance and maintained for 60 seconds and then will be released in a vertical direction followed by stretch of the rhomboid muscle held for 30 sec. This Sustained manual pressure will be applied for 3 times each followed by a stretch per session with a 30 sec rest interval in between .Session will be held 3 times per week for 2 consecutive weeks.
224161777|NCT03394196|DRUG|2nd line ART (Tenofovir DF 300mg QD + Lamividine 300mg QD or Emtricitabine 200mg QD + Lopinavir/Ritonavir 400/100mg BID + Raltegravir 400mg BID )|2\. NRTI resistance only: Tenofovir DF 300mg QD + Lamividine 300mg QD or Emtricitabine 200mg QD + Lopinavir/Ritonavir 400/100mg BID + Raltegravir 400mg BID (TDF/FTC or TDF/3TC + LPV/r + RAL) + Enhanced Adherence Counseling
224161778|NCT03394196|DRUG|2nd line ART (Tenofovir DF 300mg QD + Lamividine 300mg QD or Tenofovir DF 300mg QD + Emtricitabine 200mg QD + Darunavir 600mg BID-Ritonavir 100mg BID +Raltegravir 400mg BID)|3\. NRTI-PI resistance: Tenofovir DF 300mg QD + Lamividine 300mg QD or Tenofovir DF 300mg QD + Emtricitabine 200mg QD + Darunavir 600mg BID-Ritonavir 100mg BID +Raltegravir 400mg BID (TDF/FTC or TDF/3TC +DRV/r2 + RAL) + Enhanced Adherence Counseling
223474869|NCT03874611|OTHER|electrophysiological data from DBS|For each selected patient, the evaluation of cognitive or sensory-motor functions by electrophysiology will be conducted in the operating room, preoperatively the week before implantation and post-operatively within five days between the implantation of deep electrodes and the setting of the stimulator.
223474870|NCT02886351|DRUG|Nitrous Oxide|Nitrous Oxide at 60%-70% concentration administrated by mask, to achieve cooperation in Pediatric dentisry
223474871|NCT02760888|DRUG|Tramadol|Women will receive a oral Tramadol 100mg 1 hour before the procedure
223474872|NCT02760888|DRUG|Diclofenac|Women will receive oral Diclofenac 100mg 1 hour before the procedure
223474873|NCT02760888|DRUG|Placebo|Women will receive a Placebo 1 hour before the procedure
223474874|NCT04575870|OTHER|waiting period|amount of time between clinical procedure and modified functional endoscopic exam of swallowing
223474875|NCT01036802|DRUG|Warfarin|Patients on the active treatment arm will receive warfarin to achieve a target international normalized ratio of between 2 and 3
223744114|NCT02395796|PROCEDURE|Epidural Pressure Waveform|When loss of resistance occurs, a high-pressure tubing extension will be connected to the needle and the pressure will be transduced and the waveform, recorded. An epidural catheter will then be passed through the needle and connected to a high-pressure tubing extension and the pressure will be transduced and recorded. A test dose of 3 mL of 2% lidocaine with epinephrine 1:200.000 will then be given to exclude potential spinal or intravascular injection. After 3 minutes, a loading dose of 10 mL of 0,125% bupivacaine will be given for labor analgesia and the presence or absence of a bilateral sensorial block at T10 or higher at 30 min will be assessed.
223744115|NCT02507635|DRUG|Levocetirizine|administration of Levocetirizine 5 mg/day for 4 weeks
223744116|NCT02507635|DRUG|Desloratadine|administration of Desloratadine 5 mg/day for 4 weeks
224161779|NCT04974944|DRUG|Camrelizumab|IV injection
224161780|NCT04974944|DRUG|Apatinib|Oral
224161781|NCT04974944|DRUG|Paclitaxel|IV injection
224161782|NCT04974944|DRUG|Cisplatin|IV infusion
224161783|NCT04974944|DRUG|Carboplatin|IV infusion
223474876|NCT01036802|DRUG|Placebo|
223474877|NCT02025608|DRUG|Pramipexole|
223474878|NCT02025608|DRUG|Placebo|
223474879|NCT03826251|PROCEDURE|Nasogastric tube removal|Nasogastric tube was removed immediately after surgery
223474880|NCT02789371|PROCEDURE|the first pass is made with 5ml suction technique|the first pass is made with 5ml suction technique, then modified wet suction technique / 5ml suction technique/ modified wet suction technique is operated successively.
224161784|NCT04974944|DRUG|Bevacizumab|IV infusion
224304502|NCT01442428|DRUG|Atorvastatin|Atorvastatin: 80 mg once daily (equivalent to 30mg ± 10mg with rifamycin co-administration in this TB population)
224304503|NCT01442428|DRUG|Naproxen|Naproxen: 250 mg 3x daily for 2 weeks, then 2x daily for 1 week, then once daily for 1 week
223474881|NCT02789371|PROCEDURE|the first pass is made with modified wet suction technique|the first pass is made with modified wet suction technique, then 5ml suction technique/ modified wet suction technique/ 5ml suction technique is operated successively.
223474882|NCT03974282|BEHAVIORAL|Psychological task|Participants will complete a psychological task that evokes antisocially- and prosocially-motivated empathic responding
223581802|NCT04947306|DEVICE|Tetragraph® (Senzime, Uppsala, Sweden)|The Tetragraph® is a recently marketed electromyographic neuromuscular monitor that uses a disposable electrode array (TetraSens) that combines stimulating and recording electrodes
223581803|NCT04947306|DEVICE|TOF Watch® SX (Organon Teknika B.V., Boxtel, Holland)|The TOF Watch® SX is a common used neuromuscular monitor
223474883|NCT02797028|DIETARY_SUPPLEMENT|Anthocyanidins capsule|Continuous intervention for 1 years, detect the indicators in the intervention of 0,6,12 months
223474884|NCT02797028|DIETARY_SUPPLEMENT|Placebo capsule|Continuous intervention for 1 years, detect the indicators in the intervention of 0,6,12 months
223474885|NCT02797028|DRUG|Allopurinol|Continuous intervention for 1 years, detect the indicators in the intervention of 0,6,12 months
223474886|NCT02204670|OTHER|Acute release of irisin after a single exercise session.|We will determine the amount of Irisin secreted after a single bout of resistance exercise. Participants will be stratified into 3 groups based on the degree of Irisin release during this acute bout of resistance exercise. The metabolic adaptations to the 4 weeks of resistance training will be compared between youth stratified according to the amount of Irisin released during the acute bout of resistance exercise.
223581804|NCT02061046|DEVICE|CPAP therapy|8 weeks of CPAP therapy
223581805|NCT04418336|PROCEDURE|Endoscopic Pilonidal sinus treatment (EPSIT) versus Sinus Laser Closure (SiLaC) versus lay open technique|Endoscopic Pilonidal sinus treatment (EPSIT) versus Sinus Laser Closure (SiLaC) versus lay open technique in sacrococcygeal Pilonidal sinus treatment
223581806|NCT00913614|DRUG|Eplivanserin (SR46349)|Oral administration
223581807|NCT00430001|DRUG|docetaxel|
223581808|NCT00430001|DRUG|vinorelbine|
223581809|NCT00430001|DRUG|trastuzumab|
223581810|NCT00024310|DIETARY_SUPPLEMENT|folic acid|
223581811|NCT00024310|DRUG|lometrexol|
223581812|NCT00024310|DRUG|paclitaxel|
224161785|NCT05393544|BEHAVIORAL|Digitally assisted peer recovery coach|The certified peer recovery coach utilized an existing care coordination smartphone app to provide support to the patient during and after an inpatient detoxification treatment for alcohol use disorder. The coach utilized the telephone or text messages to send daily motivational messages, remind about upcoming appointments, and checked-in if responses were concerning. Follow-up by the coach continued for 30 days.
224161786|NCT04857840|DRUG|Firibastat (QGC001) Period 1|1000 mg (2 x 500 mg) tablets QD per Os
224161787|NCT04210232|DEVICE|TECNIS® TORIC II Intraocular Lens (IOL)|Surgeons will perform standardized, small-incision, cataract surgery and implant in one or both eyes the study lenses.
224161788|NCT02658149|DRUG|Ropivacaine with NaCl|50 mL (40 mL of 0.2% Ropivicaine and 10 mL of 0.9% NaCl) are administered into the psoas compartment
223474887|NCT04014010|OTHER|Blood pressure|"Systolic Blood Pressure (SBP)~1. Maximum change from preoperative SBP, in a) absolute change (mmHg), and b) relative change (%)(emergency and elective cases analyzed separately)~2. Cumulative duration (minutes) \>=20% below preoperative SBP~3. Longest single episode (minutes) below a) 80, b) 90, and c)100 mmHg~4. Cumulative duration (minutes) below a) 80, b) 90, and c)100 mmHg~Mean Arterial Pressure (MAP)~1. Maximum change from preoperative MAP, in a) absolute change (mmHg), and b) relative change (%) (emergency and elective cases analyzed separately)~2. Cumulative duration (minutes) \>=20% below preoperative MAP~3. Longest single episode (minutes) below a) 60, b) 65, c) 70, and d) 80mmHg~4. Cumulative duration (minutes) below a) 60, b) 65, c) 70, and d) 80mmHg"
223581813|NCT05666232|DIAGNOSTIC_TEST|renal resistive index and myocardial performance index|"Transthoracic echocardiography and transabdominal ultrasonography will be performed before induction of anesthesia, after termination of operation and before transmission to ICU and then daily for the early seven postoperative days.~RRI = (peak systolic velocity - end diastolic velocity) ∕ peak systolic velocity: Then, we will obtain the mean RRI from the above three measurements.~We will consider RRI ≥0.7 as abnormal and define it as subclinical AKI.~Myocardial performance index (using tissue doppler) =~(isovolumetric contraction time + isovolumetric relaxation time) / ejection time. We will consider MPI ≥0.4 as abnormal and define it as subclinical LV dysfunction."
224161789|NCT02658149|DRUG|Epinephrine|"0.15 mg Epinephrine are injected as part of the drug cocktail"
224161790|NCT02658149|DRUG|Morphine|"4 mg Morphine are injected as part of the drug cocktail"
223581814|NCT04445623|DRUG|Prasugrel Hydrochloride 10 MG Oral Tablet|administration of prasugrel daily for 15 days
223581815|NCT04445623|DRUG|Placebo|administration of placebo daily for 15 days
223581816|NCT02225912|OTHER|PrevinC|
223581817|NCT02225912|DRUG|placebo|
223581818|NCT05549310|DEVICE|CPAP|At the beginning of the experiment we will choose the most suitable pressure and flow for the patient by titration，
223581819|NCT05549310|DEVICE|high-flow nasal canula oxygen therapy|At the beginning of the experiment we will choose the most suitable pressure and flow for the patient by titration，
223581820|NCT02032342|DEVICE|Endobronchial double lumen tube|Endobronchial double lumen tube for one lug ventilation
223581821|NCT02032342|DEVICE|Arndt® blocker|Arndt® blocker for selective lobar deflation
223581822|NCT02032342|DEVICE|Cohen blocker|Cohen blocker for selective lobar deflation
223581823|NCT02032342|DEVICE|Fuji Uni-blocker|Fuji Uni-blocker foe selective lobar deflation
223581824|NCT01688921|BIOLOGICAL|AFLURIA vaccine (2012-2013 formulation)|Patients will receive a single 0.5 mL injection of AFLURIA vaccine in the deltoid region.
223581825|NCT01688921|DEVICE|Needle-Syringe|
223581826|NCT01688921|DEVICE|Stratis needle-free injection device|
223581827|NCT02358044|DRUG|Sofosbuvir|400 mg tablets, taken orally (PO) every day (QD) for 12 weeks.
223581828|NCT02358044|BIOLOGICAL|PegIntron|PegIntron administered subcutaneously every week (QW) at 1.5 mcg/kg for 12 weeks.
223581829|NCT02358044|DRUG|Ribavirin|Capsule and/or tablet administered PO twice daily (BID) based on weight (1000 - 1200 mg) for 12 weeks.
223581830|NCT02358044|DRUG|Grazoprevir/Elbasvir (100 mg/50 mg) FDC|Grazoprevir/Elbasvir (100 mg/50 mg) FDC, taken PO QD for 12 weeks.
223581831|NCT02607540|OTHER|2 cycles cisplatin-5-fluorouracil|2 cycles cisplatin-5-fluorouracil(PF 2 cycles): cisplatin: 75mg/m2 d1，29; 5-fluorouracil：750mg/m2 CIV24h d1-4，d29-32.
223581832|NCT02607540|OTHER|4 cycles cisplatin-5-fluorouracil|4 cycles cisplatin-5-fluoroura(PF 4 cycles): cilcisplatin: 75mg/m2 d1，29, 57, 85; 5-fluorouracil：750mg/m2 CIV24h d1-4，d29-32, d57-60, d85-88.
223581833|NCT02607540|RADIATION|Radiotherapy|concurrent radiotherapy： 50Gy in total，2 Gy/d，5d/w，Until disease progression or unacceptable toxicity
223581834|NCT04488744|DRUG|Nicotine 0.2mcg/kg/s and 1.0mcg/kg/s|Nicotine infusion 0.2 mg nicotine delivered over 2.5 minutes (5 pulsed-nicotine deliveries), 0.2mg nicotine delivered over 10 min (20 pulsed-nicotine deliveries), 1.0 mg nicotine delivered over 2.5 minutes (5 pulsed-nicotine deliveries) and 1.0 mg nicotine delivered over 10 min (20 pulsed-nicotine deliveries).
223474888|NCT04014010|OTHER|Heart rate|"1. Maximum change (beats per minute, BPM) from preoperative heart rate (positive and negative)~2. Relative change (%) from preoperative heart rate (positive and negative)~3. Maximum pulse variation (maximum heart rate minus minimum heart rate)~4. Longest single episode (minutes) a) below 60, and b) above 100BPM~5. Cumulative duration (minutes) a) below 60, and b) above 100BPM"
224161791|NCT02658149|DRUG|Ketorolac Tromethamine|"30 mg morphine are injected as part of the drug cocktail"
224161792|NCT02658149|DRUG|Ropivacaine|"30 mL 0.5% Ropivicaine are injected as part of the drug cocktail"
223474889|NCT04014010|OTHER|Use of hemodynamic medications (i.e. special medications for blood pressure)|"1. Vasopressor/inotrope use (yes vs. no): phenylephrine, norepinephrine, epinephrine, vasopressin, dobutamine, or milrinone~2. Infusion of any vasopressor/inotropes above (yes vs. no) (identified by unit of weight over time)~3. Phenylephrine/ephedrine bolus (yes vs. no) (identified by unit of weight only)~4. Vasodilator use (yes vs. no): labetalol, esmolol, nitroglycerin, nitroprusside~5. Infusion of any vasodilator above (yes vs. no) (identified by unit of weight over time)"
223474890|NCT04014010|OTHER|Oxygen saturation by pulse oximetry (SpO2)|"1. Longest single episode (minutes) below a) 88, and b) 90%~2. Cumulative duration (minutes) below a) 88, and b) 90%"
223474891|NCT04014010|OTHER|End-tidal Carbon dioxide (EtCO2)|"1. Longest single episode (minutes) a) below 30, and b) above 45mmHg~2. Cumulative duration (minutes) a) below 30, and b) above 45mmHg"
223581835|NCT04944368|BIOLOGICAL|SARS-CoV-2 recombinant spike protein + Advax-SM adjuvant|SARS-CoV-2 recombinant spike protein (25 µg) with Advax-SM adjuvant (15 mg) in two doses with a 21-day interval administered with intramuscular injections in the non-dominant arm
223581836|NCT04944368|BIOLOGICAL|Saline placebo|0.9% sodium chloride (1 mL) injection in two doses with a 21-day interval administered with intramuscular injections in the non-dominant arm
223581837|NCT02761577|DRUG|Sodium bicarbonate|3 mL/kg/hour of Sodium bicarbonate, an hour prior to angiography and 1 mL/kg/hour, within six hours after angiography
223581838|NCT02761577|DRUG|N-acetylcysteine|N-acetylcysteine (1200 mg twice a day, IV (in vein) ) one day before angiography, on the day of the angiography, and one day after the diagnostic procedure
224161793|NCT05022693|DRUG|BIO89-100|Subcutaneous Injections
224161794|NCT02869685|RADIATION|radiotherapy|radiotherapy
224161795|NCT04358991|DRUG|Ceftazidime-avibactam|collection of blood samples around clinical dosing immediately pre-dose, then at the following times thereafter: 1, 2, 4, 6, 8, and 12 hours and EMR review.
224161796|NCT01397513|DRUG|Aspirin|Tablets, 75 or 320mg once daily for 4 weeks. A 4-week wash-out period separated the two treatment periods.
224161797|NCT02458352|DEVICE|Ultra low dose non-contrast enhanced CT|Non-contrast enhanced CT for CACS and AC using a novel protocol for ultra low dose radiation dose exposure
223474892|NCT05965596|OTHER|a psycho educational intervention program|The program was developed by the researcher herself based on recommendations derived from a systematic review of psychoeducational interventions to improve the quality of Life and psychological outcomes in gynecological cancer patients. Also guided by the program adopted by chow et all in 2014(28) to test the feasibility of implementing a psychoeducational intervention program for gynecological cancer patients.
223474893|NCT05965596|OTHER|the routine care|the routine care provided for all gynecological cancer patients in the study setting
223474894|NCT03435588|PROCEDURE|EUS|Radial endoscopic ultrasound. A special endoscope uses high-frequency sound waves to produce detailed images of the lining and walls of the digestive tract , and allows to take samples from abnormal areas.
223581839|NCT02437604|DRUG|Treatment A: Fp MDPI|Fp MDPI 200 mcg, 1 inhalation
223581840|NCT02437604|DRUG|Treatment B: FS MDPI|FS MDPI 200/12.5 mcg, 1 inhalation
223581841|NCT02437604|DRUG|Treatment C Flovent|FLOVENT DISKUS 250 mcg, 2 inhalations
223581842|NCT02437604|DRUG|Treatment D: Advair|ADVAIR DISKUS 500/50 mcg, 1 inhalation
223581843|NCT06147687|DIAGNOSTIC_TEST|Self reported data collection|ML assessement of colleceted data
223581844|NCT01007422|BEHAVIORAL|telephone-based intervention|
223581845|NCT01007422|OTHER|communication intervention|
223581846|NCT01007422|OTHER|intervention by caregiver|
223581847|NCT01007422|OTHER|medical chart review|
223581848|NCT01007422|OTHER|survey administration|
223744117|NCT01959620|BEHAVIORAL|1-Session Exposure Therapy|One exposure therapy session lasting one hour
224161798|NCT02458352|DEVICE|Standard dose non-contrast enhanced CT|Clinically indicated non-contrast enhanced CT for CACS and AC according to routine protocol
223581849|NCT01007422|PROCEDURE|end-of-life treatment/management|
223581850|NCT01007422|PROCEDURE|pain therapy|
223581851|NCT01007422|PROCEDURE|psychosocial assessment and care|
223581852|NCT03202108|DIETARY_SUPPLEMENT|Krio|"Krio is a ready to eat, chocolate-flavoured, solid bar containing 20g fat per 28g bar. It contains protein and carbohydrate with added sweetener and flavourings. It does not contain any added micronutrients. Krio is not for use as a sole source of nutrition.~It has a fat to protein and carbohydrate ratio of 3 to 1, making it suitable for use in all versions of the ketogenic diet.~This product is to be consumed daily under the direction of a dietitian."
223744118|NCT01959620|BEHAVIORAL|3-Session Exposure Therapy|Three exposure therapy sessions lasting one hour each, delivered one week apart
224161799|NCT05181215|DRUG|Monomethyl Fumarate 190 Mg|2 x oral 95 mg capsules, delayed-release
224161800|NCT05181215|DRUG|Diroximel Fumarate 462 mg|2 x 231 mg capsules, delayed-release
224161801|NCT04331210|DRUG|Diclofenac Sodium|Group 1 will take oral diclofenac sodium and group 2 will take Rectal diclofenac sodium as an analgesic
224161802|NCT06179108|DRUG|LB-102|LB-102 is a dopamine D2/3 and 5HT7 antagonist.
224161803|NCT04228107|DEVICE|Medication monitoring|This is an observational study of medication use patterns. The propeller health device has reminders for controller medication use and gives feedback regarding medication use to the participant, their guardian and their asthma provider
224161804|NCT03209011|DRUG|Peginterferon Alfa-2a|patients untreated in immune-active phase were given subcutaneous injection of Peginterferon Alfa-2a with starting dose of 180 mg/weekly in experiment group.
224161805|NCT00668850|DRUG|Generex Oral-lyn™|Generex Oral-lyn™ spray in a split-dose fashion (half the dose immediately prior to the meal and half the dose immediately after the meal) + BID NPH insulin AM and PM as pre-randomization dose
224161806|NCT00668850|DRUG|Regular human insulin|Regular human insulin 30 minutes before meals + BID NPH insulin AM and PM as pre-randomization dose.
223474895|NCT03435588|PROCEDURE|FNA with ROSE|Endoscopic ultrasound guided biopsy of the pancreas with the traditional fine needle aspirate needle with the addition of rapid on-site cytopathology (cytopathologist looking at each biopsy samples as they are taken): The sampling is done with a small needle called fine needle aspiration needle or FNA. FNA alone is sometimes limited due to inadequate acquisition of cells for proper diagnosis under the microscope, which can lead to need for repeat endoscopic procedures and delay in diagnosis and possibly treatment. Rapid on-site evaluation of cytopathology (ROSE) is where a cytopathologist is next to the physician doing the endoscopic procedures and evaluates each sampling performed.
223474896|NCT03435588|PROCEDURE|FNB alone|Endoscopic ultrasound guided biopsy with a novel core biopsy needle without on-site cytopathology: New needles called core needles (fine needle biopsy, FNB) have recently been developed which not only acquires cells but also the entire tissue structure (histology).
224161807|NCT03053401|PROCEDURE|Adductor Canal Block|Under guidance of a linear ultrasound transducer probe (General Electric; GE). Performed using a 22-gauge 2-inch Stimuplex A needle ( B. Braun Medical Inc., Melsungen, Germany).Solution to be injected will be a combination of Ropivacaine 0.2 % ( 0.5 ml/kg, maximum of 30 ml) and methylprednisolone acetate 1 mg/kg ( maximum of 40 mg ).
224161808|NCT03053401|PROCEDURE|Femoral Nerve Block|Under guidance of a linear ultrasound transducer probe (General Electric;GE).Block will be performed using a 22-gauge 2-inch Stimuplex A needle ( B. Braun Medical Inc., Melsungen, Germany).Solution to be injected will be a combination of Ropivacaine 0.2 % ( 0.5 ml/kg, maximum of 30 ml) and methylprednisolone acetate 1 mg/kg (maximum of 40 mg ).
224161809|NCT03053401|DEVICE|Ultrasound|Use of linear ultrasound transducer probe (General Electric;GE) to guide needle placement for both Adductor Canal Block and Femoral nerve Blocks
223581853|NCT03303118|OTHER|Hypoxia|No drug or product will be used in this study. No medication will be give to the participants. No arm will be used for product administration.
223581854|NCT05749354|OTHER|electroacupuncture|"Electroacupuncture (EA) is a method of treating diseases by inserting a needle (usually a filiform needle) into the skin or tissue of a patient at a certain Angle, and then passing through the needle (sensing) micro-current waves of human bioelectricity to stimulate specific parts of the human body (acupoints).~1. Disposable sterile acupuncture filiform needle (0.16mm×13mm, 0.30mm×25mm, 0.30mm× 40mm), Guizhou Andi Medical Equipment Co, LTD, Guizhou Food and Drug Supervision and Equipment Production Xu 20170011.~2. Electroacupuncture apparatus: SDZ-Ⅱ electroacupuncture apparatus of Huatuo brand, Suzhou Medical Supplies Factory Co., LTD., Registration No. : 20172270675.~For non-acupoint group,the internal wire of the electroacupuncture instrument will be interrupted, no current passed through."
223581855|NCT04498377|BIOLOGICAL|F-652|IL-22 fusion protein administered intravenously
223581856|NCT04498377|BIOLOGICAL|Placebo|Placebo administered intravenously
223581857|NCT02001896|DRUG|gemcitabine; cisplatin or carboplatin; erlotinib|
223581858|NCT02001896|DRUG|erlotinib|
223581859|NCT01739803|BEHAVIORAL|Behavioral Contract|Intervention activities were performed by a study clinical pharmacist. Behavioral contract goal was achieving and maintaining IST adherence. Other components of the contract addressed: (a) motivation(s) or positive reinforcement for achieving IST adherence; (b) problems or barriers that may interfere with achieving IST adherence and possible solutions to overcome problems/barriers; (c) social support available to the RTR such as a significant other who may assist the RTR in following the IST dosing schedule; (d) tools/strategies the RTR may use to remind himself/herself to follow the IST dosing schedule; and (e) possible consequences of IST nonadherence (e.g., graft loss).
223581860|NCT02230371|DRUG|Granisetron|If the patient does not have any pain after the first or second injection of granisetron (Kytril®; 1 mg/mL, Roche, Stockholm, Sweden), there will be no more injections but the patient will still come for the follow ups.
223581861|NCT02230371|DRUG|Control (placebo)|If the patient does not have any pain after the first or second injection of granisetron (isotonic saline (NaCl); 0.9 mg/mL, Fresenius Kabi, Uppsala, Sweden), there will be no more injections but the patient will still come for the follow ups.
223581862|NCT01248871|DRUG|procedure:sevoflurane-remifentanil/sufentanil|Active Comparator
223581863|NCT01248871|DRUG|volatile agent only during reperfusion|Active Comparator
223581864|NCT01248871|DRUG|propofol-remifentanil/sufentanil|Active Comparator
224161810|NCT03053401|DEVICE|Stimuplex A needle|22-gauge 2-inch Stimuplex A needle ( B. Braun Medical Inc., Melsungen, Germany) used to perform both Adductor Canal Block and Femoral nerve Blocks.
224304504|NCT01442428|DRUG|Placebo|Atorvastatin placebo
223474897|NCT00004102|DRUG|FOLFOX regimen|
223581865|NCT05045677|OTHER|digital DBT skills intervention|The digital intervention consists of 6 modules that will be delivered over 6 to 10 days. The modules cover mindfulness skills, emotion regulation skills and distress tolerance skills.
223581866|NCT05045677|OTHER|Standard Care|Standard inpatient care includes a multi-disciplinary team approach including daily psychiatric review, medication management and in-person psychosocial interventions (social work, nursing).
223581867|NCT02645617|DRUG|Varnish|Topical application to the teeth
223474898|NCT00004102|DRUG|fluorouracil|
223474899|NCT00004102|DRUG|leucovorin calcium|
223581868|NCT05451680|DEVICE|Negative pressure device|Negative-pressure therapy postoperatively on the full-thickness skin graft
223744119|NCT04738110|OTHER|MRI|Structural MR (T2, FLAIR, T1 and T1+C), DCE, DSC
224161811|NCT03053401|DRUG|local anaesthetic injection|Ropivacaine 0.2 % ( 0.5 ml/kg, maximum of 30 ml) for either Adductor Canal Block and Femoral nerve Blocks.
224161812|NCT03053401|DRUG|Steroid Drug|Methylprednisolone acetate 1 mg/kg (maximum of 40 mg ) for either Adductor Canal Block and Femoral nerve Blocks.
224161813|NCT01973972|BEHAVIORAL|Weight management|Weight management group visits using low-carbohydrate diet followed for weight management.
224161814|NCT01973972|BEHAVIORAL|Shared medical appointments (SMA)|Diabetes management group visits for diabetes management.
224161815|NCT00257322|DRUG|GM-CSF|250ug/m\^2 SQ QD with a cap of 500mcg SQ QD
224161816|NCT01519336|DRUG|danoprevir|100 mg q12h
224161817|NCT01519336|DRUG|darunavir|600 mg q12h
224161818|NCT01519336|DRUG|ritonavir|100 mg q12h
224161819|NCT04248556|OTHER|Health care product|Health care product (gel) - to be applied on the participant's skin
224161820|NCT03797885|OTHER|No treatment given|No treatment is administered to the participants for this study
224161821|NCT01738074|BIOLOGICAL|trivalent rotavirus genetic reassortment vaccine|
223474900|NCT00004102|DRUG|oxaliplatin|
224161822|NCT01738074|BIOLOGICAL|Placebo|
223474901|NCT00086671|DRUG|ABT-874/Human monoclonal antibody against IL-12|
223474902|NCT00086671|DRUG|Placebo|
223474903|NCT01082744|DRUG|Ropivacaine + Sufentanil|Sufentanil at 0.25 µg/ml added to ropivacaine at 2 mg/ml at a perfusion rate of 0.15 ml/kg/h for continuous paravertebral block over 48 hours
223474904|NCT01082744|DRUG|Ropivacaine|Ropivacaine at 2 mg/ml at a perfusion rate of 0.15 ml/kg/h for continuous paravertebral block over 48 hours
223474905|NCT00000363|DRUG|Antihistamine|
223581869|NCT05451680|PROCEDURE|Conventional care|Conventional dressing postoperatively on the full-thickness skin graft
223581870|NCT04988282|DRUG|Methylprednisolone Tablet|Methylprednisolone, oral, 0.5 mg/kg/day, 4 weeks
223744120|NCT06477601|OTHER|Assigning cooling agent type cigarettes|This study is intended to help understand what people who smoke menthol cigarettes would do in a scenario where the Food and Drug Administration bans menthol cigarettes but allows cooling agent cigarettes.
223744121|NCT06477601|OTHER|Assigning traditional tobacco type cigarettes|This comparison group is intended to help understand what people who smoke menthol cigarettes would do in a scenario where the Food and Drug Administration bans menthol and cooling agent cigarettes.
224304505|NCT06050161|DEVICE|Articulating laparoscopic instrument|The Artisential articulating laparoscopic instrument will be evaluated for efficacy and safety in suturing during minimally invasive gynecologic surgery.
223744122|NCT06477601|OTHER|Assigning menthol type cigarettes|This comparison group is for where the Food and Drug Administration does not ban menthol cigarettes.
223744123|NCT02418468|DRUG|Indacaterol|Indacaterol 150µg capsules for inhalation daily
223744124|NCT02418468|DRUG|Placebo|Matching placebo indacaterol capsules for inhalation daily
223474906|NCT00000363|DRUG|Corticosteroid|
223474907|NCT04190355|OTHER|Irrigant type|The success of endodontic treatment is directly related to infection control. In successful endodontic treatment, it is necessary to perform an ideal irrigation both in order to gain a better understanding of the complex anatomical structure of the root canals and to increase the efficiency of the instruments and methods used during the canal preparation. Sodium hypochlorite (NaOCl) solution is the standard irrigation agent for cleaning and disinfection of root canal. In this study, the effect of NaOCI on postoperative pain using different uniforms will be evaluated.
223474908|NCT04190355|DRUG|5.25% NaOCl|5.25% NaOCl solution
223474909|NCT04190355|DRUG|5.25% Cloraxid gel/ distilled water|5.25% Cloraxid gel/ distilled water
223474910|NCT06265831|OTHER|Hand-fan application to the face|Hand fan application is one of the applications recommended in managing dyspnea in evidence-based guidelines. Hand fan application effectively reduces shortness of breath by stimulating cold airflow to the 2nd and 3rd trigeminal nerve branches, mucosa, and skin.
223474911|NCT03372798|PROCEDURE|ICE/IVUS imaging during atrial fibrillation ablation|Intravascular ultrasound imaging of the left atrial wall thickness with ICE/IVUS during atrial fibrillation ablation
223474912|NCT02526485|PROCEDURE|Blood Draw|A one time blood draw of 150 milliliters will be performed using a vein in the participants arm. Existing venous access will be used for the blood draw in preference of new venipuncture.
223474913|NCT04149717|DIETARY_SUPPLEMENT|Energy Drink Ingredients and Exercise|"Subject will ingest 500 mL of one of three test solutions:~A) sucrose (150g) B) sucrose (150g); caffeine (400 mg) C) sucrose (150g); caffeine (400 mg); taurine (4,000 mg); carnitine (400 mg) 3. 30 min later, subject will exercise on a treadmill using the Bruce Protocol maximum exercise test (https://www.aopa.org/go-fly/medical-resources/health-conditions/heart-and-circulatory-system/bru...). For one additional session, subjects will receive test solution C without exercise.~4\. Each stage will last 3 minutes. Stage 1 = 1.7 mph at 2% Grade Stage 2 = 2.5 mph at 4% Grade Stage 3 = 3.4 mph at 6% Grade Stage 4 = 4.2 mph at 8% Grade Stage 5 = 5.0 mph at 10% Grade Stage 6 = 5.5 mph at 12% Grade Stage 7 = 6.0 mph at 14% Grade Stage 8 = 6.5 mph at 15% Grade Stage 9 = 7.0 mph at 15% Grade. The test will end when subjects reach exhaustion.~5\. 1, 2, and 4 hrs following ingestion, HR, BP, and EKG will be recorded."
223474914|NCT04823312|DEVICE|Experimental prospective single arm evaluating the Medtronic Duo Extended Set|Subjects will be using 4 Duo extended sets that will serve as an exploratory pilot study to assess the 7-day survival of the Duo Extended set.
223581871|NCT02786680|BEHAVIORAL|stroop test in condition DBS off|Patients were evaluated in DBS Off
223581872|NCT02786680|BEHAVIORAL|stroop test in condition DBS on|Patients were evaluated in DBS On
223581873|NCT00819455|BEHAVIORAL|Experimental|Active Life style modification-motivation by I.T technology
223581874|NCT00819455|BEHAVIORAL|Control arm (usual care/standard care arm)|Life style modification only once
223581875|NCT01166061|BIOLOGICAL|Placebo|Solution resembling active solution but without peptides
223581876|NCT01166061|BIOLOGICAL|ToleroMune Grass|1 x4 administrations 4 weeks apart
223581877|NCT03296631|OTHER|collection of diapers with fresh stools|collection of diapers with fresh stools
223581878|NCT00848341|DEVICE|GUIDANT ICD SYSTEM|
223581879|NCT00969436|BIOLOGICAL|GSK Biological's investigational MMRV vaccine 208136|Subcutaneous injection
223744125|NCT02914769|DRUG|Ayahuasca|patients will receive a single dose of ayahuasca.
223744126|NCT02914769|DRUG|placebo|patients will receive a single dose of a passive placebo.
223744127|NCT02488655|DEVICE|Echopulse|HIFU Under ultrasound guidance
224161823|NCT00728195|DRUG|JNJ-37822681|Participants will receive JNJ-37822681 capsule 10 mg orally twice a day for 12 consecutive weeks.
223581880|NCT00969436|BIOLOGICAL|Priorix™|Subcutaneous injection
224161824|NCT00728195|DRUG|JNJ-37822681|Participants will receive JNJ-37822681 capsule 20 mg orally twice a day for 12 consecutive weeks.
224161825|NCT00728195|DRUG|JNJ-37822681|Participants will receive JNJ-37822681 capsule 30 mg orally twice a day for 12 consecutive weeks.
224161826|NCT00728195|DRUG|Olanzapine|Participants will receive olanzapine 10 mg capsule alone or in combination with olanzapine 5 mg capsule orally for 6 or 12 weeks.
224161827|NCT00728195|DRUG|Placebo|Participants will receive matching placebo capsules orally for 12 weeks.
224304506|NCT06050161|DEVICE|Conventional laparoscopic instrument|Conventional laparoscopic instruments will be evaluated for efficacy and safety in suturing during minimally invasive gynecologic surgery.
223744128|NCT04176276|OTHER|no interventions required.|The study does not require any interventions.
223474915|NCT05056961|OTHER|Multiparametric mesurements|Multiparametric assessments will necessitate the use of a plastic belt to record electro-impedancemetry tomography data; and a nano-gatsric tube fitted with esophageal and gastric low pressure balloons
223474916|NCT00871156|DRUG|Chloroquine, Tafenoquine|Chloroquine and Tafenoquine
223744129|NCT02838056|DRUG|epidural injection|drug combination: 2% lidocaine 17 ml + 2 ml alfentanil (544 mcg x 2 = 1088 mcg) + 7% sodium bicarbonate 2.3 ml (1.9 mEq) + 0.1mg epinephrine (1:200000)
223474917|NCT00871156|DRUG|Placebo|Placebo
223474918|NCT02779140|BIOLOGICAL|NTM-1632|Monoclonal antibody mixture of XB10, XB18, and XB23
223474919|NCT02779140|OTHER|Placebo|Placebo
223474920|NCT00333567|DRUG|Lumiracoxib|
223744130|NCT01592344|DEVICE|StimRouter - active stimulation|"The stimulation program settings for this arm are as follows:~Stim Settings~* Waveform: Symmetric or Asymmetric~* Phase Duration: 100-250 µsec~* Pulse Rate: 50-100 Hz~* Intensity: 0-30mA Time Settings~* Constant Stim: On~* Total Time: 6 hour"
223744131|NCT01592344|DEVICE|StimRouter - Control|"The stimulation program settings for this arm are as follows:~Stim Settings~* Waveform: Symmetric or Asymmetric~* Phase Duration: 200 µsec~* Pulse Rate: 1 Hz~* Intensity: 0 mA Time Settings~* Constant Stim: On~* Total Time: 6 hour"
223744132|NCT06361862|DEVICE|Active alarms from WARD software|Wireless continuous vital sign monitoring with real time staff alerts
223744133|NCT00099437|DRUG|Fulvestrant|intramuscular injection
223744134|NCT05619276|DEVICE|Standard serving utensil toolkit|Serving a meal using standard kitchen utensils (100% of subjects experiment with these tools first)
223744135|NCT05619276|DEVICE|Optimsed portion-control toolkit|Serving a meal using optimised, portion-control utensils (100% of subjects experiment with these tools second)
223744136|NCT03782428|DIETARY_SUPPLEMENT|Probiotic|30 billions colony-forming unit (CFU) of a mixture of six viable strains including 107 mg of Lactobacillus acidophilus BCMC® 12130, Lactobacillus lactis BCMC® 12451, Lactobacillus casei subsp BCMC® 12313, Bifidobacterium longum BCMC® 02120, Bifidobacterium bifidum BCMC® 02290 and Bifidobacterium infantis BCMC® 02129
223744137|NCT03782428|OTHER|Placebo|Placebo samples produced were identical to the probiotics in term of taste and texture without live microorganisms.
223744138|NCT06646276|BIOLOGICAL|BMS-986489 (BMS-986012+Nivolumab)|Specified dose on specified days
223744139|NCT06646276|BIOLOGICAL|Atezolizumab|Specified dose on specified days
224161828|NCT03541590|PROCEDURE|Percutaneous transhepatic biliary drainage|When ERCPs failed or was not possible to be performed due to an altered anatomy in patients with malignant extrahepatic bile duct obstruction, PTBD was performed next in all patients. Percutaneous bile duct puncture was guided by Color Doppler ultrasound. The further procedure was guided by fluoroscopy. A self-expandable metal stent (SEMS) was inserted into the obstructed bile duct by endoscopic luminal guidance in the first session. After successful SEMS implantation, the percutaneous external catheter was removed at the end of the procedure.
224161829|NCT00865995|PROCEDURE|Tracheal Lavage|Tracheal Lavage will be performed on the control population patients and the tracheal fluid obtained from this procedure will be used as the research sample.
224161830|NCT04216511|DIAGNOSTIC_TEST|Tumor autoantibody detection|Level of a set of autoantibodies potentially relative with lung cancer will be tested for each of the participants.
224161831|NCT03933215|DRUG|Cladribine|Participants received cladribine tablets as per investigator discretion and as per United States approved label: 3.5 milligram/kilogram (mg/kg) body weight over 2 years, administered as 1 treatment course of 1.75 mg/kg per year.
224161832|NCT02964182|DRUG|Cigarette|Smoke usual brand of cigarettes
224161833|NCT02964182|DRUG|Nicotine Replacement|Received NRT (Electronic Cigarette - ECIG-Hi)
223474921|NCT04545073|DEVICE|PanOptix|Trifocal IOL with ORA in post refractive patients
223474922|NCT00502567|DRUG|AZD2171|oral tablet once daily
223744140|NCT06646276|DRUG|Carboplatin|Specified dose on specified days
223744141|NCT06646276|DRUG|Etoposide|Specified dose on specified days
223744142|NCT02083731|BIOLOGICAL|MSCs|
223744143|NCT04582110|DIAGNOSTIC_TEST|Optical coherence tomography angiography|Each subject underwent Optical coherence tomography angiography (a non-invasive, fast, diagnostic imaging technique)
223744144|NCT03513484|DRUG|Azacitidine|Given IV or SC
223474923|NCT00502567|DRUG|FOLFOX|intravenous infusion
223474924|NCT00502567|DRUG|Pemetrexed|intravenous infusion
223474925|NCT00502567|DRUG|Irinotecan (administered with & without Cetuximab)|intravenous injection
223474926|NCT00502567|DRUG|Docetaxel|intravenous infusion
223474927|NCT02037672|DRUG|metformin|
223474928|NCT02037672|DRUG|metformin and roflumilast|
223744145|NCT03513484|OTHER|Laboratory Biomarker Analysis|Correlative studies
223744146|NCT03513484|DRUG|Nintedanib|Given PO
223744147|NCT02478242|DRUG|Nafamostat mesilate|nafamostat mesilate use for anticoagulation
223744148|NCT02478242|DRUG|Normal saline|
223744149|NCT04969224|DRUG|ELX/TEZ/IVA|Fixed dose combination (FDC) tablet for oral administration.
223744150|NCT04969224|DRUG|IVA|Tablet for oral administration.
223744151|NCT02726074|DRUG|Perampanel|
223474929|NCT03209479|DRUG|Glatiramer acetate|Copaxone subcutaneous injection syringe
223474930|NCT03936569|DRUG|Marketed Toothpaste|Marketed stannous fluoride (0.454%) toothpaste
223474931|NCT03936569|DRUG|Marketed Cavity Protection Toothpaste|Marketed sodium monofluorophosphate (0.76 %) toothpaste
223474932|NCT00094991|DRUG|Muraglitazar|
223474933|NCT04824807|OTHER|Yoga|"The yoga classes included a progression of low-impact, modified poses, stretching and isometric exercises focused on the shoulders, arms, and chest, and meditation. Breathing and poses to drain the lymphatic system were incorporated throughout the yoga practice to assist with lymphatic flow.~Exercises: sitting down badrasana, ardha navasana, dhanurasan, setu bandhasana, Urdhva Dhanurasana, Urdhvamukha Svanasana, Virabhadrasana, Warrior Virasana, Supta Virasana, Surya Namaskar, Mayurasana, Padmasana, Bharadvajasana."
223744152|NCT05063110|DRUG|Itacitinib|Administration of 300 mg of ITACITINIB per os every day for 30 days.
223744153|NCT02236429|BIOLOGICAL|vaginal flora transplant|
223744154|NCT01136304|DRUG|Imiglucerase|Imiglucerase intravenous infusions regardless of dose or schedule of administration.
223474934|NCT04824807|OTHER|Clinical Pilates|"before starting the clinical Pilates exercise program, the patients were trained on Pilates exercises and postures. During training, the patients were taught how to create lumbopelvic stability (core stabilization), which is the basis for Pilates exercises, and spinal stabilization and appropriate posture techniques.~Exercises: cork screw, toy soldier, kleopatra, the saw,breast stroke preparation, swimming, diamond press - arm openings, scapula isolations, open book, scissors, shoulder bridge."
223474935|NCT04824807|OTHER|An educational booklet|Only educational booklets will be given to the control group
223474936|NCT02694133|PROCEDURE|Smart Phone Based Assistive Speech Therapeutic System|use the mobile device, which with the camera and speaker, for patients to practice the naming training at home, and assess the speech ability every 2-4weeks by speech therapist via telerehabilitation platform. Concise Chinese Aphasia Test (CCAT) will be used as the assessment tool for evaluation speech ability and functional ability.
223474937|NCT02694133|PROCEDURE|Mobile phone-based tele rehabilitation program|Mobile phone-based tele rehabilitation program
223474938|NCT02171546|DRUG|Dabigatran etexilate capsules|
223581881|NCT00969436|BIOLOGICAL|Varilrix™|Subcutaneous injection
223581882|NCT00499902|DRUG|alfimeprase|Alfimeprase will be given as a single bolus of 1mg/2mL, or a split bolus of 5mg/2mL or 10mg/2mL in a three-tier dose escalation format. The 5mg and 10mg doses will be administered as split doses with 1/2 of the total dose given initially and 1/2 of the total dose given 30 minutes after the initial dose.
223581883|NCT00627536|DRUG|Avotermin|A single intradermal injection of avotermin administered at the dose to both margins of a full-thickness incision immediately following closure.
223581884|NCT00627536|DRUG|Placebo|Matched to avotermin dosage strength
223581885|NCT05205369|BEHAVIORAL|10-week home-based Yi Jin Bang exercise program|Each participant in this group will do a home-based Yi Jin Bang exercise program four times a week for ten consecutive weeks, which consists of ten minutes of warm-up, 18 minutes of Yi Jin Bang exercise (ten exercises), and ten minutes of cool-down. To learn how to conduct the home-based exercise session, each participant will be invited to one introductory session before starting the prescribed exercise program. Two experienced Yi Jin Bang instructors will lead the introductory session. Besides, in order to monitor participants' adherence and help them to conduct self-training, we will use the Zoom Meeting application. Zoom can capture and record participants' movements through the webcam. During the introduction sessions, we will teach participants how to use Zoom. Furthermore, we will provide support for adherence to the home exercise sessions through telephone calls or e-mail every two weeks.
224161834|NCT02964182|DRUG|Nicotine Replacement|Received NRT (Electronic Cigarette - ECIG-Hi)
224161835|NCT02964182|OTHER|Questionnaire Administration|Ancillary studies
224161836|NCT02964182|OTHER|Survey Administration|Ancillary studies
224161837|NCT02964182|DRUG|Very Low Nicotine Content Cigarette|Smoke very low nicotine content cigarette
224161838|NCT02964182|DEVICE|ECIG-Hi|Patients smoke ECIG-Hi for 3 weeks and then ECIG-Lo for 3 weeks.
223474939|NCT02171546|DRUG|Quinidine sulfate tablets|
223474940|NCT02171546|DRUG|Fexofenadine tablets|
223474941|NCT00072111|BIOLOGICAL|anakinra|
223474942|NCT04422938|OTHER|Manuel chest compressions handled by clinicians|Compressions will be handled by human efforts
223474943|NCT04422938|DEVICE|LUCAS™ 2 Chest Compression System|LUCAS-2 model piston-based mechanical chest compression device was used for mechanical chest compressions
223474944|NCT00461734|OTHER|RV lead placement site|Patients randomised to RV apical or high septal lead placement site
223474945|NCT02236000|DRUG|Neratinib|"Dose-Escalation Phase (Part 1) - Neratinib Dose-escalation will proceed on the basis of DLT during Cycle 1 starting at 120 mg/day.~Dose level 1: 120 mg/day; Dose level 2: 160 mg/day; Dose level 3: 200 mg/day; Dose level 4: 240 mg/day~Dose-evaluation Phase (Part 2) - Patients will receive the highest dose of neratinib with T-DM1 found in Phase I as study therapy"
223474946|NCT02236000|DRUG|T-DM1|"Dose-Escalation Phase (Part 1) - Trastuzumab emtansine (T-DM1) will be given at 3.6 mg/kg IV Day 1 every 21 days.~Dose-evaluation Phase (Part 2) - Trastuzumab emtansine (T-DM1) will be given at 3.6 mg/kg IV Day 1 every 21 days."
223474947|NCT03723434|DEVICE|Single-pulse transcranial magnetic stimulation (spTMS)|Single-pulse TMS (spTMS) will be delivered with a TMS stimulator (MagPro X100 w/ MagOption, MagVenture, Farum, Denmark) and a figure-of-eight TMS coil. 80 spTMS will be repeated at 0.2 Hz. An MRI-based TMS navigation system will be used to navigate the TMS coil (Localite, St Augustin, Germany).
223744155|NCT05380401|DIETARY_SUPPLEMENT|Enfamil® DHA & ARA Supplement for Special Dietary Use|Dosage: 60 mg/kg/day of DHA and 120 mg/kg/day of ARA. Route of administration: enteral tube or by oral syringe
223744156|NCT03771469|OTHER|Sleep study|Sleep study
223744157|NCT05782283|DEVICE|ACE (AI-Cirrhosis-ECG) 2.0|An electrocardiogram (ECG) based artificial intelligence (AI) powered tool for detection of undiagnosed cirrhosis in primary care practices. And email alert is sent to providers which will display whether the ACE 2.0 result is positive or negative for the likelihood of advanced liver disease.
224161839|NCT02964182|DEVICE|ECIG-Lo|Patients smoke ECIG-Lo for 3 weeks and then ECIG-Hi for 3 weeks
224161840|NCT06513130|OTHER|Geriatric assessment in the 7 days following ICU discharge.|ICU survivors will be assessed by a geriatric physician, in a global (clinical, physical, psyochological and social) approach at the end of the ICU stay or in the 7 days following ICU discharge.
224161841|NCT06513130|OTHER|No geriatric assessment in the 7 days following ICU discharge.|No geriatric assessment in the 7 days following ICU discharge.
224161842|NCT04369222|OTHER|Observational|Maternal consumption of mild analgesics
224161843|NCT00732706|PROCEDURE|Sartorius Muscle Twitch|Stimulation of the femoral nerve branch responsible for activating the Sartorius Muscle fascia with the lowest possible current.
224161844|NCT00732706|PROCEDURE|Quadriceps Muscle Twitch|Stimulation of the femoral nerve branch responsible for activating the Quadriceps Muscle fascia with the lowest possible current.
224161845|NCT02352090|DRUG|Ethinyl estradiol / dienogest|One tablet orally for 9 weeks, continuous use
224161846|NCT02352090|DRUG|Estradiol valerate / dienogest|One tablet orally for 9 weeks, continuous use
224161847|NCT02352090|DRUG|Dienogest|One tablet orally for 9 weeks, continuous use
224161848|NCT06071923|DEVICE|Fibroscan|Scan the liver for metabolic fatty changes
224161849|NCT01006694|OTHER|Behavioral Activation + Medication|Psychoeducation, behavioral activation therapy, and medication delivered within a collaborative care model.
223474948|NCT03723434|DEVICE|Paired associative stimulation (PAS)|Paired associative stimulation (PAS) will be applied with two TMS stimulators (MagPro X100 w/ MagOption, MagVenture, Farum, Denmark) and two TMS coils. The pulses from each stimulator/coil will be repeated at 0.2 Hz, duration of run 15 minutes (180 pulses for each stimulator/coil). In different sessions, we will deliver PAS with different asynchrony values to examine their effects on effective connectivity. Coils will be navigated using an MRI-based TMS navigation system (Localite, St Augustin, Germany).
224161850|NCT01006694|DRUG|Guideline Antidepressant Medication|Guideline Antidepressant Medication, following the VN National Mental Health plan.
224161851|NCT00917137|PROCEDURE|TBNA + transbronchial lung biopsy + bronchial washing|
224161852|NCT01199497|DRUG|Group 1|fixed dose combination of diphenhydramine + dropropizine + pseudoephedrine (Notuss® syrup).
224161853|NCT01199497|DRUG|Group 2|placebo
224161854|NCT00279266|DRUG|Thiamine|
223474949|NCT03723434|DEVICE|Repetitive transcranial magnetic stimulation (rTMS)|Repetitive TMS (rTMS) will be applied at 1 and 20 Hz with a TMS stimulator (MagPro X100 w/ MagOption, MagVenture, Farum, Denmark) and a figure-of-eight TMS coil. 300 rTMS pulses will be delivered during 1 and 20 Hz stimulation. An MRI-based TMS navigation system will be used to navigate the TMS coil (Localite, St Augustin, Germany).
223474950|NCT03538080|DEVICE|ACCUVEIN plus ultrasound|"Intervention is marking of the saphenous veins with ACCUVEIN system. The AccuVein® AV400 vein illumination system is a laser imaging system that detects superficial veins up to 10 mm deep and digitally displays, through a projected red light, a map of the vascularization on the surface of the skin. in real time, allowing clinicians to check vein permeability and position.~This system is portable and lightweight. It can be easily cleaned, and requires no calibration or adjustment. It does not require any contact with the patient. Second time is completion of marking by ultrasound if necessary"
223581886|NCT05205369|BEHAVIORAL|10-week home-based usual exercise therapy program|Among exercise therapy in the treatment of SAPS, stretching and strengthening protocols are often used . Therefore, participants in this group will do a standardized home-based stretching and strengthening exercise program four times per week for ten weeks, which is set up according to a previous study. This program has been demonstrated that can be effective in reducing pain and improving function in patients with SAPS. For strengthening exercises, elastic bands will be used. To learn how to conduct the self-training program, each participant in this group will also be invited to one introductory session before starting the prescribed exercise training. Two certificated physiotherapists will lead the introductory session. In addition, a video demonstration clip will be given to each participant to provide a home reference, and the Zoom Meeting application will be used to help monitor the exercise.
223581887|NCT01295736|DRUG|Sildenafil|Sildenafil 20 mg TID per os during 90 days
223744158|NCT06214650|OTHER|Radiofrequency|"Experimental group will receive the common exercise program associated with a radiofrequency treatment using INDIBA® (INDIBA Activ 7, Barcelona, INDIBA S.A.) at a frequency of 448 hertz. It will use the capacitive electrode as a method of preparation and vascularization of the superficial tissues and immediately, within the same session, the resistive electrode to stimulate deep tissues. This treatment is based on the protocols established by INDIBA® S.A.~It will consist of one weekly diathermy session of thirty minutes during ten weeks. The use of diathermy will not be interrupted throughout the session.~The common exercise program consist in a ten abdominal exercises (including recti abdominis, transversus and obliques). It will practised at home only just three days at week."
224161855|NCT05907005|BEHAVIORAL|iCBT-based EMI|Consists of brief iCBT for psychological support (mandatory), stroke care education (optional), and nurse-led real-time chat-based support messages, delivered according to participants' preferences.
224161856|NCT02837055|DEVICE|VivaSight intubation|patients are intubated with an endotracheal tube with an integrated camera
224161857|NCT02837055|DEVICE|conventional intubation|patients are intubated with a conventional endotracheal tube
224161858|NCT01960179|DRUG|lixisenatide AVE0010|Pharmaceutical form:solution Route of administration: Subcutaneous injection
224161859|NCT05270265|BIOLOGICAL|Pvs25-IMX313/Matrix-M1|Three doses of Pvs25-IMX313 in Matrix-M1 at different concentrations
224161860|NCT00911144|BIOLOGICAL|GSK Biologicals' Synflorix™ (Pneumococcal vaccine GSK1024850A)|Intramuscular injection, administered as a single dose
224161861|NCT00911144|BIOLOGICAL|Wyeth-Lederle's Prevenar™|Intramuscular injection, administered as a single dose
224161862|NCT00911144|BIOLOGICAL|GSK Biologicals' Hiberix™|Intramuscular injection, administered as a single dose
224161863|NCT06205680|DEVICE|NAA for topical anaesthesia of the nasal cavity|NAA for topical anaesthesia of the nasal cavity
224161864|NCT01191957|DRUG|Busulphan plus Cyclophosphamide|"I.V. Bu (Busilvex), 12.8 mg/kg:~Day -9: 0.8 mg/kg/dose x 4 doses Day -8: 0.8 mg/kg/dose x 4 doses Day -7: 0.8 mg/kg/dose x 4 doses Day -6: 0.8 mg/kg/dose x 4 doses Day -5: Rest~Followed by:~Cyclophosphamide, 120 mg/kg iv:~Day -4: 60 mg/kg Day -3: 60 mg/kg"
224304507|NCT06050161|DEVICE|Robotic surgical instrument|Robotic surgical instruments will be evaluated for efficacy and safety in suturing during minimally invasive gynecologic surgery.
223474951|NCT03538080|DEVICE|Ultrasound only|Intervention is marking with ultrasound imaging as in usual practice.
223474952|NCT01085643|DRUG|Lubiprostone|24mcg PO taken once
223474953|NCT01085643|DRUG|Placebo|24mcg placebo capsule taken once
223581888|NCT01295736|DRUG|placebo|Placebo pills TID per os during 90 days
223581889|NCT03766269|DRUG|Dronabinol|Dronabinol coadministered with patient's existing Baseline Opioid.
223581890|NCT02446873|OTHER|Egg supplementation|A weekly supply of eggs will be given to the mother in the egg supplementation group with instructions to give the child one egg per day.
224304508|NCT04012151|OTHER|Physical measurement|Parturients of gestational week \>= 32 weeks will have their arms and fingers measured to generate the conicity index.
224304509|NCT04012151|OTHER|Cuff size fitting|Fit on arm cuff and finger cuff as selected by investigators based on the measurement.
224304510|NCT05459454|DEVICE|A digital health program for patients with Breast Cancer|A digital solution that supports healthy lifestyle changes, provides disease and side effect education as well as daily tasks for patients diagnosed with breast cancer.
224304511|NCT04760392|BEHAVIORAL|Goal-directed mobilization|"* A short educational intervention with handout of a leaflet on GDM.~* Definition of personal mobility goal level.~* Communication of the mobility goal level to involved stakeholders.~* Regular reassessment of the mobility goal level and booster sessions by physiotherapists."
223474954|NCT03561194|DIETARY_SUPPLEMENT|Omegaven|After the diagnosis of PNALD is made, patients who are followed by the Neonatal Intensive Care Unit, NICU, will contact Dr. Honrubia and Dr. Swarup. Cases may also include referrals of patients with PNALD from other healthcare facilities or self-referrals. If the patient's parents or guardians agree to participate in the study, informed consent will be obtained. The history of present illness and past medical history will be reviewed with the guardian and pertinent demographic and medical information will be recorded on data collection forms. This form will be used to record all laboratory results, nutritional history, and descriptions of any liver biopsies performed.
223474955|NCT00381628|PROCEDURE|epithelial cells and blood lymphocyte extraction|Nasal curettage will be performed from each nostril to obtain nasal epithelial cells. Venipuncture will be performed and up to 60-ml of blood will be obtained from which neutrophils will be isolated.
223474956|NCT01612663|DEVICE|Pain relief by Acupuncture needle at non-specific site|
223474957|NCT01612663|DEVICE|Acupuncture needle|
223474958|NCT01612663|DEVICE|Acupuncture needle|
223474959|NCT01612663|DEVICE|Acupuncture needle|
223474960|NCT04381065|DEVICE|Personal KinetiGraph® (PKG®) System|"The Personal KinetiGraph (PKG®) System consists of the following:~* A wrist-worn movement recording device known as the PKG® Watch, designed to acquire data on the kinematics of movement disorder symptoms over a 6-10 day period~* Proprietary algorithms to translate raw movement data collected by the PKG® Watch~* Data-driven report known as the PKG®~The PKG® provides continuous, objective, ambulatory assessment of the treatable and disabling symptoms of Parkinson's disease including tremor, bradykinesia and dyskinesia. The PKG® also provides an assessment of daytime somnolence and an indication of propensity for impulsive behaviors."
223474961|NCT04381065|DEVICE|Personal KinetiGraph® (PKG®) Watch|"The Personal KinetiGraph (PKG®) System consists of the following:~* A wrist-worn movement recording device known as the PKG® Watch, designed to acquire data on the kinematics of movement disorder symptoms over a 6-10 day period~* Proprietary algorithms to translate raw movement data collected by the PKG® Watch"
223474962|NCT02371681|DRUG|Treatment|Different Drug combinations
223474963|NCT02371681|RADIATION|PET/CT Scan|PET/CT Scans
223474964|NCT02371681|PROCEDURE|Sample Collection|Sample Collection
223474965|NCT05023122|DIETARY_SUPPLEMENT|vitamin D3|vitamin D3 (cholecalciferol) 800 IU QD
223474966|NCT05023122|DIETARY_SUPPLEMENT|calcium|calcium citrate 600 mg QD
223474967|NCT03247777|OTHER|Traditional strengthening|dead lifts, bench press, wrist curls, and lat pulldowns as examples
223474968|NCT03247777|OTHER|Functional Strengthening|diagonal chops, one leg deadlifts, lateral plyometrics as examples
223474969|NCT00465530|DRUG|Saline|Intranasal Saline
223474970|NCT00465530|DRUG|Gentamycin|Intranasal irrigation
223474971|NCT00949442|DRUG|Insulin Glargine (HOE901) [Lantus]|100 Units/ml solution for injection in a pre-filled pen SoloStar® (3 ml)
224161865|NCT01191957|DRUG|Busulphan plus Fludarabine|"I.V. Bu (Busilvex), 12.8 mg/kg:~Day -6: 0.8 mg/kg/dose x 4 doses Day -5: 0.8 mg/kg/dose x 4 doses Day -4: 0.8 mg/kg/dose x 4 doses Day -3: 0.8 mg/kg/dose x 4 doses plus:~Fludarabine, 4 x 40 mg/m² iv:~Day -6: 40 mg/m² Day -5: 40 mg/m² Day -4: 40 mg/m² Day -3: 40 mg/m²"
224161866|NCT03312361|DRUG|15% oxygen|Participants will inhale 15% oxygen for 2 hours to see how it affects them.
223474972|NCT00949442|DRUG|Glimepiride|tablets of 1 and 2 mg
223474973|NCT00949442|DRUG|human insulin [NPH]|100 IU/ml suspension for injection in a prefilled pen OptiSet® (3 ml)
223474974|NCT02577536|OTHER|No Interventions|No Interventions will be conducted under this study.
223581891|NCT01195688|DRUG|BI 638683 or placebo|oral doses given to 6 subjects per dose group
223581892|NCT01195688|DRUG|Placebo solution|oral doses given to 2 subjects per dose group
224161867|NCT00498641|PROCEDURE|computer program and patching|
223581893|NCT01579487|DEVICE|The Zeltiq System|This is a follow-up study from the initial treatments performed in 2010. No additional treatments will be performed.
223581894|NCT06162533|BIOLOGICAL|Vaccination against SARS-CoV-2|Interventions are either a vaccination against SARS-CoV-2 or an infection with SARS-CoV-2
223581895|NCT04772144|BEHAVIORAL|behavioural and cessation aids|information, motivational interview, refferal to healty life-centers, free cessation aids
223581896|NCT02789410|DRUG|Morphine|Morphine is administered as part of spinal anesthesia for post-operative pain relief.
223581897|NCT02789410|DRUG|Hydromorphone|Hydromorphone is administered as part of spinal anesthesia for post-operative pain relief.
224161868|NCT00748865|OTHER|Systane Ultra Lubricant Eye Drops|Systane Ultra Lubricant Eye Drops 1 drop each eye one time
224304512|NCT00168311|DEVICE|Transcranial Magnetic Stimulation|Participants were sequentially randomly assigned to either 15 active bilateral treatments or 15 sham bilateral treatments that were administered on a daily basis, five days per week.
224304513|NCT00168311|DEVICE|sham TMS|
224304514|NCT02353052|OTHER|follow up|The patients were followed up for 3 years about their survival conditions and tumor status (eg. recurrence and metastasis).
223474975|NCT02238366|DRUG|triptorelin|This is an observational study. Thus, the treatment selection with triptorelin (Diphereline® or Diphereline PR®) is at investigator's discretion based on the current practice principles and guidelines/protocols, in accordance with the Summary of Product Characteristics (SmPC) approved in Romania by the National Medicines Agency.
223474976|NCT04688632|DRUG|Ampreloxetine <Dose A>|Ampreloxetine \<Dose A\> will be administered as 1 tablet of \<Dose A\> and 3 tablets of Ampreloxetine Placebo.
223474977|NCT04688632|DRUG|Ampreloxetine <Dose B>|Ampreloxetine \<Dose B\> will be administered as 4 tablets of \<Dose A\>
223474978|NCT04688632|DRUG|Ampreloxetine Placebo|Ampreloxetine Placebo will be administered as 4 tablets of placebo. The placebo tablet will match (in appearance) the ampreloxetine \<Dose A\> tablet.
223474979|NCT04688632|DRUG|Moxifloxacin|Moxifloxacin will be administered orally as a single tablet.
223581898|NCT05744726|BIOLOGICAL|A-PRF|0.5 to 1g of Advance Platelet-Rich Fibrin (A-PRF) clot for each dental socket.
224161869|NCT00748865|OTHER|Systane Lubricant Eye Drops|Systane Lubricant Eye Drops 1 drop each eye one time
224161870|NCT04525560|OTHER|PEG-ELS-S|2/3 dose of PEG-ELS was taken orally from the evening on the day before colonoscopy, and the remaining 1/3 dose of PEG-ELS was orally administered in the morning of the next day.
224304515|NCT02158312|DEVICE|Magstim Eldith DC-stimulator(Magstim Co., Whitland, UK)|2 mA for 20 minutes transcranial direct current stimulation
223474980|NCT04688632|DRUG|Moxifloxacin Placebo|Moxifloxacin placebo will be administered orally as a single tablet. The placebo tablet will match (in appearance) the moxifloxacin tablet.
223474981|NCT02909062|DEVICE|Electronic Activity Monitoring (EAM)|All registered patients will receive a wearable EAM device that will measure their physical activity. Patients will wear this device around their wrist for the designated period of assessment. The EAM device has the potential to measure active minutes, number of steps, distance walked and number of floors climbed. For the purpose of this study the EAM data captured will focus on daily step count.
224161871|NCT04525560|OTHER|PEG-ELS-L|PEG-ELS is given orally on the day before colonoscopy, which is divided into 10-12 portions and taken one portion every hour. If half of the total amount is not completed at afternoon ward round the day before colonoscopy, nasogastric feeding is recommended.
224304516|NCT00004450|DRUG|glyceryl trierucate|
223474982|NCT02909062|BEHAVIORAL|Daily Questionnaire|Participants will be asked to complete this self-administered, paper-based questionnaire each day that they are expected to wear the EAM device. The questionnaire was designed specifically for the purpose of this study. It consists of 5 items that ask about the patient's perceived level of physical activity and fatigue in each 24 hour period that they have worn the EAM device. The daily questionnaires will be optional; however each participant will be encouraged to complete them.
223474983|NCT01164761|DRUG|Ramipril|Ramipril 10 mg Capsules of Dr. Reddy's Laboratories Limited
223581899|NCT05744726|COMBINATION_PRODUCT|Bone-wax|0.5 to 1g of Bone-wax for each dental socket
223581900|NCT05108597|DRUG|Misoprostol|400ug misoprostol will be administered through rectal route, 1 hour before surgery to assess its effect on intra-operative blood loss during myomectomy
223581901|NCT00536887|DRUG|atorvastatin|atorvastatin 10 mg versus 40 mg during the 8 months of follow-up
223581902|NCT04433013|DRUG|Lianhua Qingwen|The LHQW capsules will be administered to trial participants 4 capsules, 3 times a day, after meal
223581903|NCT04433013|DRUG|Placebo|The placebo capsules will be administered to trial participants 4 capsules, 3 times a day, after meal
224304517|NCT00004450|DRUG|glyceryl trioleate|
224304518|NCT00004450|DRUG|interferon beta|
224304519|NCT00004450|DRUG|thalidomide|
224304520|NCT01557738|DIETARY_SUPPLEMENT|High Flavanol Trial|The experimental trial (high flavanol content) will involve the consumption of a beverage containing about 1000mg of cocoa flavanols.
224304521|NCT01557738|DIETARY_SUPPLEMENT|Low Flavanol Trial|The placebo trial (low flavanol content) will involve the consumption of a beverage containing 75 mg of cocoa flavanols.
224304522|NCT01557738|DIETARY_SUPPLEMENT|High Flavanol Trial; long-term|The experimental trial (high flavanol content) will involve the daily consumption of a beverage containing about 1000mg of cocoa flavanols for 4 weeks. Subjects will be provided with 28 packets of the beverage to take home with them.
223474984|NCT01164761|DRUG|Altace|Altace@ 10 mg capsules of Kings Pharmaceuticals, USA
223474985|NCT01033838|PROCEDURE|rectosigmoid resection|
223474986|NCT03641976|DRUG|A-FOLFOXIRI|"Arm I (A-FOLFOXIRI)~Biological: bevacizumab Given IV~Drug: fluorouracil Given IV~Drug: irinotecan hydrochloride Given IV~Drug: leucovorin calcium Given IV~Drug: oxaliplatin Given IV"
223474987|NCT03641976|DRUG|Arm II (A-FOLFOX/A-FOLFIRI)|"Arm II (A-FOLFOX/A-FOLFIRI)~Biological: bevacizumab Given IV~Drug: fluorouracil Given IV~Drug: irinotecan hydrochloride Given IV~Drug: leucovorin calcium Given IV"
223581904|NCT05085912|PROCEDURE|Circumferential pulmonary vein isolation + linear ablation + bi-atrial mapping + driver ablation|Patients receive circumferential pulmonary vein isolation and linear ablation (ablation of a roof line and a mitral isthmus line) combined with bi-atrial mapping and driver ablation.
223581905|NCT05085912|PROCEDURE|Circumferential pulmonary vein isolation + linear ablation + posterior wall box isolation|Patients receive circumferential pulmonary vein isolation and linear ablation (ablation of a roof line and a mitral isthmus line) combined with posterior wall box isolation.
223581906|NCT05085912|PROCEDURE|Circumferential pulmonary vein isolation + linear ablation + vein of Marshall ethanol infusion|Patients receive circumferential pulmonary vein isolation and linear ablation (ablation of a roof line and a mitral isthmus line) combined with vein of Marshall ethanol infusion.
223581907|NCT02274259|DRUG|Aflibercept|Aflibercept injection is given at every visit. Time to next treatment according to presence of macular edema
223581908|NCT02274259|DRUG|Ranibizumab|Ranibizumab injection is given at every visit. Time to next treatment according to presence of macular edema
224161872|NCT05588713|PROCEDURE|Brief assessment protocol|The intervention constitutes of a brief assessment protocol for assessing ADHD.
224161873|NCT05588713|PROCEDURE|Comprehensive assessment protocol|The intervention constitutes of a comprehensive assessment protocol for assessing ADHD.
224161874|NCT02111707|DRUG|Rectal indomethacin 100mg one time before or after ERCP|Patients will receive rectal indomethacin suppository 30 minutes before or immediately after ERCP for prevention of post-procedure pancreatitis. Patients will be randomized to the timing of administration.
224304523|NCT01557738|DIETARY_SUPPLEMENT|Low Flavanol Trial; long-term effects|The placebo trial (low flavanol content) will involve the daily consumption of a beverage containing 75 mg of cocoa flavanols for 4 weeks. Subjects will be provided with 28 packets to take home with them.
224304524|NCT04405895|OTHER|Breakfast Diet|Breakfast Diet (3Mdiet) consist on high-energy breakfast and reduced in energy and carbohydrate (CH) dinner. Participants fasting serum to provide serum to for the in ex-vivo cell studies, will be collected at fasting (8:00), at start (day 0), after 2 weeks and at the end of 3Mdiet intervention (12 weeks). The participants serum is added to culture medium (as serum conditioned medium) to treat during 48 hours the cultured hepatocytes. After 48 hours of serum treatment, the mRNA extraction for the assessment of SIRT1 and Clock Gene expression will be performed at 00:00, 06:00, 12:00 and at 18:00 to assess SIRT1 and the Clock Genes circadian oscillation in hepatocytes. The 3Mdiet efficacy on reducing the overall glycemic excursions is assessed with continuous monitoring system at baseline after 2 weeks month of diet intervention.
224161875|NCT03990441|DEVICE|TENS|TENS application using the TensMed S82 (Enraf Nonius). Current parameters: balanced symmetric biphasic square waveform, continuous stimulation, frequency 80 Hz, pulse duration modulated between 250 and 290 μs, modulation time 5 seconds. Self-adhesive electrodes of 50 x 90 mm applied paravertebrally to 2 cm. of the spinous apophysis. Use of two channels with independent intensity (mA): electrodes of the first channel applied at level T10-L1 and second channel ones at level S2-S4. Maximum intensity without reaching pain, increasing the intensity throughout the application to maintain this level. Start of the intervention when the woman expresses pain. End of the intervention when neuraxial anesthesia is applied (if the woman demands it) or after delivery.
224161876|NCT03990441|DEVICE|TENS Placebo|Same application as Intervention, but using 0,1 mA as fixed intensity on both channels.
224161877|NCT00987727|DRUG|carboxymethylcellulose 0.5% , glycerin 0.9% (OPTIVE® MD)|One drop in each eye three to six times daily, as needed
224161878|NCT00987727|DRUG|sodium hyaluronate 0.18% (VISMED® Multi)|One drop in each eye three to six times daily, as needed
224161879|NCT01678313|DRUG|Doxazosin 4 mg daily plus Celecoxib 200 mg every day (QD)|Study group
224161880|NCT01678313|DRUG|Doxazosin 4 mg every day (QD)|Control group
224161881|NCT00591162|DRUG|Tetracycline|Two courses of IV Tetracycline(10mg./kg./day for two days)separated by a two week interval.
224304525|NCT04405895|OTHER|Allday Diet|Allday Diet (6Mdiet) consist in 6 small meals: breakfast, lunch and dinner and 3 snacks, with calories and carbohydrates (CH) evenly distributed throughout the day. Participants fasting serum to provide serum to for the in ex-vivo cell studies, will be collected at fasting (8:00), at start (day 0), after 2 weeks and at the end of 6Mdiet intervention (12 weeks). The participants serum is added to culture medium (as serum conditioned medium) to treat during 48 hours the cultured hepatocytes. After 48 hours of serum treatment, the mRNA extraction for the assessment of SIRT1 and Clock Gene expression will be performed at 00:00, 06:00, 12:00 and at 18:00 to assess SIRT1 and the Clock Genes circadian oscillation in hepatocytes. The 6Mdiet efficacy on reducing the overall glycemic excursions is assessed with continuous monitoring system at baseline after 2 weeks month of diet intervention.
224304526|NCT02027675|OTHER|High fat poor micronutrient meal|The meal will be prepared by a team of nutritionist in order to comply with the demand characteristics of an high fat poor micronutrient meal.
224304527|NCT02027675|OTHER|Mediterranean meal|The meal will be prepared by a team of nutritionist in order to comply with the demand characteristics of an Mediterranean meal
224304528|NCT03565458|DRUG|Gemigliptin|zemiglo 50mg,LG Chem
224304529|NCT03565458|DRUG|Dapagliflozin|forxiga, dapagliflozin 10mg
224304530|NCT03565458|DRUG|Empagliflozin|jardiance 25mg, empagliflozin
224304531|NCT00273390|DRUG|Remicade (infliximab)|
224304532|NCT04857463|OTHER|Nutritional supplement drink|At the intervention period (0th to 12th week of the experiment), In addition to nutrition and health education, subjects were provided with 2 bottles of commercially available oral nutritional supplements (Meiji Mei Balance, Meiji Co., Ltd., Tokyo, Japan) every day, between lunch and dinner and before bedtime.
224304533|NCT04857463|OTHER|Nutritional education|At the intervention period (0th to 12th week of the experiment) , subjects will be given regular nutrition education by a qualified clinical dietitian to ensure the effectiveness of nutrition education, in order for the nutrition education group to benefit from participating in this trial, the subjects will also be provided with the same nutritional products after the trial
224304534|NCT02468752|DRUG|Oxygen|
224304535|NCT02468752|OTHER|Air|
223474988|NCT00948090|DRUG|IV Busulfan, Cyclophosphamide and Etoposide (BuCyE Regimen)|Pk-directed IV Busulfan (based on test dose method) for 4 days followed by Etoposide 1400mg/m2 QD for one day and Cyclophosphamide 2.5 g/m2 QD for two days followed by autologous stem cell transplant.
223474989|NCT00910234|DRUG|recombinant human erythropoietin (rhEpo)|rhEpo is administered 3000 U/kg, iv at 3 to 6 hours after birth, and at 24 hours interval for another 2 doses.
223474990|NCT00910234|DRUG|recombinant human erythropoietin (rhEpo)|rhEpo is administered 100 U/kg, iv at 3 to 6 hours after birth, and at 24 hours interval for another 2 doses.
223474991|NCT00910234|DRUG|Normal saline|normal saline is administered 0.5/kg, iv at 3 to 6 hours after birth, and at 24 hours interval for another 2 doses.
223474992|NCT01510405|OTHER|Tissue Collection|Tissue sample collection
223474993|NCT03307421|OTHER|debriefing without instructor|"The randomization will focus on the allocation of the debriefing method: group without instructor versus group with instructor (AI). It will be stratified by center and performed before the first simulation session. The randomization will be carried out by the clinical methodology center of the Besançon University Hospital.~The sequence of scenarios for each binomial will also be determined by randomization."
223474994|NCT03307421|OTHER|debriefing with instructor|The randomization will focus on the allocation of the debriefing method: group without instructor versus group with instructor (AI). It will be stratified by center and performed before the first simulation session. The randomization will be carried out by the clinical methodology center of the Besançon University Hospital.
223581909|NCT02072395|PROCEDURE|Plication|Plication of the stomach will be performed in conjunction with placement of a gastric band.
223581910|NCT03216759|PROCEDURE|Ischemic preconditioning|After the anesthesia induction and before surgery,the patient's left upper limb was subjected to ischemic preconditioning then patients received ischemic preconditioning.
224161882|NCT00591162|RADIATION|Duel Energy X-Ray Absorptiometry (DEXA)|DEXA before discharge from acute admission and again one year post burn.
224304536|NCT01321619|DRUG|Daflon|Drug B (Daflon): Administered one tablet two times daily (oral), the main meals (breakfast and dinner)for 30 days.
224304537|NCT01321619|DRUG|Varicell placebo|Drug C (Varicell placebo) : Administered one tablet three times a day,(oral), the main meals (breakfast, lunch and dinner)for 30 days.
224304538|NCT01718548|DIETARY_SUPPLEMENT|Cordyceps Sinensis (CS) and Lingzhi|
224304539|NCT01718548|DIETARY_SUPPLEMENT|Tea and Flour|Placebo
224304540|NCT00920894|DIETARY_SUPPLEMENT|plant stanol ester|the effect of plant stanol esters on plasma lipids
224304541|NCT01859767|DRUG|[123I]MNI-672 SPECT|Subjects will be dosed by intravenous injection to a target dose of 5 mCi and not to exceed 5.5 (not \>10% of 5 mCi limit) I-123 MNI-672 prior to the SPECT scan.
223474995|NCT03273855|OTHER|Fecal microbiota transplantation|The intervention treatment is fecal microbiota transplantation made of frozen donor feces. The FMT is transferred as rectal enema where we use a rectal probe with a balloon to prevent leakage and keep the solution long enough in the colon. The patient will stay on the bench in different positions for 20 minutes. We will encourage the participant to keep the solution in the colon as long as possible and give them four pills of loperamide before the procedure in order to reduce bowel motility.
223474996|NCT03273855|OTHER|Placebo: fecal microbiota transplantation|The placebo group get fecal microbiota transplantation made of their own feces. The FMT is transferred as rectal enema where we use a rectal probe with a balloon to prevent leakage and keep the solution long enough in the colon. The patient will stay on the bench in different positions for 20 minutes. We will encourage the participant to keep the solution in the colon as long as possible and give them four pills of loperamide before the procedure in order to reduce bowel motility.
223474997|NCT04040686|DRUG|Injection of 99mTc-NM-02|Patient will be injected with microdose (\<100ug) of 99mTc-NM-02 radiotracer
223474998|NCT00721799|DRUG|18F-Fluorothymidine PET scan|18F-Fluorothymidine (0.04 - 0.08 mCi / kg to a maximum dose of 5 mCi) administered once intravenously for a positron emission tomography (PET) scan.
224161883|NCT00591162|PROCEDURE|Bone Biopsy|Bone biopsy to be taken in the operation room at the last skin grafting operation at the site of the iliac crest. A second bone biopsy will be taken one year later post discharge from the acute admission.
223474999|NCT05383742|DRUG|Rifampicin (RIF)|Rifampicin 35 mg/kg
223475000|NCT05383742|DRUG|Isoniazid (INH)|Isoniazid 10 or15 mg/kg
223475001|NCT05383742|DRUG|Linezolid (LZD)|1200 mg
223475002|NCT05383742|DRUG|Pyrazinamide (PZA)|25 mg/kg
223475003|NCT05383742|DRUG|ethambutol (EMB)|20 mg/kg
224161884|NCT00981292|DIETARY_SUPPLEMENT|EGCG|Acute oral administration of capsules containing either: 0mg, 135mg or 270mg. One dosage administered on each of three separate study days.
224161885|NCT00981292|DIETARY_SUPPLEMENT|Placebo|Pharmaceutical grade silica was utilized as placebo
224161886|NCT04694794|OTHER|Educational Brochure|Participants will be provided with Education Brochure developed by the study team to provide information to patients about managing side effects related to chemotherapy
224161887|NCT05565066|DEVICE|FNB group|Fine-needle-biopsy (Echotip ProCore Needle)
224161888|NCT05565066|DEVICE|FNA group|Fine-needle-aspiration (Echotip Needle)
224161889|NCT04691349|DRUG|CAR-T|The basic design of car includes a tumor associated antigen binding region (usually derived from scFv segment of monoclonal antibody antigen binding region), transmembrane region and intracellular signal region.
224161890|NCT01131130|DEVICE|Investigational contact lens|After one week of wearing the first lens type, the participants will crossover to the second lens type for one week, and then crossover to the third lens type.
224161891|NCT01131130|DEVICE|Acuvue Oasys Contact Lens|After one week of wearing the first lens type, the participants will crossover to the second lens type for one week, and then crossover to the third lens type.
224304542|NCT04950959|DEVICE|Hands-free, user-controlled robotic system intended to assist in the planning and advancement of an instrument during CT guided percutaneous procedures. T|The system is used for trajectory planning and is intended to assist the physician in the positioning of an instrument, such as a needle, where CT imaging is used for target trajectory planning and intraoperative tracking. The XACT ACE Robotic System uses a computerized quantitative guidance system, which provides real-time, accurate needle guidance, including advancement and steering of the needle from the entry point on the subject's body to the target point within the body.
223475004|NCT05383742|DRUG|Rifampicin|10 mg/kg
223581911|NCT03216759|DRUG|Dexmedetomidine|At the beginning of anesthesia induction, 3 ug/kg/h of dexmedetomidine was infused and adjusted to 0.3 ug/kg/h after 10 min of infusion until 30 minutes before the end of the procedure.
223744159|NCT06214650|OTHER|Control|Control group will receive a weekly INDIBA® session in the abdominal area with the same protocol as the experimental group in athermic mode (placebo treatment) and the common exercise program. The session will last thirty minutes and will be carried out by the research physiotherapist during ten weeks.
223744160|NCT00613015|DRUG|Guanfacine|
224304543|NCT05291832|OTHER|Brain.fm Music|Experimental arm
223475005|NCT05383742|DRUG|Isoniazid|5 mg/kg
223475006|NCT01845779|DRUG|DCF regimen|
223475007|NCT02958579|OTHER|No intervention will be done. Participants are on standard care and the treatments will be recorded because of observational nature of this study.|
223475008|NCT02785198|DEVICE|Passive knee extensor machine|The passive training machine, moves both legs from flexion to extension and back, 60 times per minute in 1 hour, 3 times per week. ROM is 60 degrees
223475009|NCT04391478|DRUG|Milrinone|milrinone lactate, 1mg/ml, for intra venous use only
223475010|NCT04391478|DRUG|Sildenafil|50mg sildenafil citrate/tablet, crushed in water taken by nasogastric tube
223475011|NCT01331317|DRUG|Paricalcitol|capsule, 1-2 micrograms daily for 90 days
223475012|NCT07026890|OTHER|Evaluation visits|"3 assessment visits (initial (V1), intermediate (V2) and final (V3).~A series of motor assessments carried out by the physiotherapist:~* Timed Up and Go Test (TUG)~* 10 m walk test (TM10)~* Functional Reach Test (FRT)~* Minimum Motor Test (TMM)~* 10 m walk test combined with a verbal task such as naming different animals"
223475013|NCT07026890|OTHER|Rehabilitation sessions|Usual treatment: 4 to 5 rehabilitation sessions per week, each lasting 45 minutes.
224161892|NCT01131130|DEVICE|Air Optix Aqua|After one week of wearing the first lens type, the participants will crossover to the second lens type for one week, and then crossover to the third lens type.
224161893|NCT01188785|DRUG|siG12D LODER|"Phase 0 - subjects diagnosed with an operable adenocarcinoma of the pancreas will have 8 siG12D LODER placed in tumor. The siG12D LODER will be placed in the subject's tumor using an EUS biopsy needle.~Phase I - subjects diagnosed with locally non-operable advanced adenocarcinoma of the pancreas. These subjects will have one of three different siG12D LODERs dose levels placed in tumor - Either 1 siG12D LODER, 2 siG12D LODERs or 8 siG12D LODERs. The siG12D LODER/s will be placed in the subject's tumor using an EUS biopsy needle."
224161894|NCT00648973|DRUG|Diphenhydramine 50 mg|"Three times daily: two diphenhydramine 25 mg capsules~Twice daily: one pseudoephedrine-matching placebo tablet"
224304544|NCT05291832|OTHER|Spectrally-matched Noise|Active control arm
224161895|NCT00648973|DRUG|Diphenhydramine 25 mg|"Three times daily: one diphenhydramine 25 mg capsule and one diphenhydramine-matching placebo capsule~Twice daily: one pseudoephedrine-matching placebo tablet"
224161896|NCT00648973|DRUG|Pseudoephedrine 120 mg|"Three times daily: two diphenhydramine-matching placebo capsules~Twice daily: one pseudoephedrine 120 mg tablet"
224161897|NCT05267145|COMBINATION_PRODUCT|blood preservation solution III|Blood bag added blood preservation solution III
224161898|NCT03464136|BIOLOGICAL|Placebo for Ustekinumab|Participants will receive placebo as SC injection to blind adalimumab.
224161899|NCT03464136|BIOLOGICAL|Placebo for Adalimumab|Participants will receive placebo as IV infusion to blind ustekinumab.
224161900|NCT03464136|BIOLOGICAL|Ustekinumab (6 mg/kg)|Participants will receive ustekinumab 6 mg/kg (weight based dosing) as IV infusion.
224161901|NCT03464136|BIOLOGICAL|Ustekinumab (90 mg)|Participants will self-administer SC injection of ustekinumab 90 mg.
224161902|NCT03464136|BIOLOGICAL|Adalimumab (40 mg)|Participants will self-administer multiple SC injections of adalimumab (each 40 mg) and will receive total dose of 160 mg at Week 0, 80 mg at Week 2, and 40 mg q2w from Week 4 to 56.
224161903|NCT03412565|DRUG|Daratumumab|Daratumumab will be administered at a dose of 1800 mg by SC injection in Cycles 1 to 4 in D-VRd cohort and until documented progression of disease, unacceptable toxicity, or end of study for D-VMP, D-Rd and D-Kd cohorts.
224161904|NCT03412565|DRUG|Bortezomib|Bortezomib will be administered as 1.3 mg/m\^2 SC injection in Cycles 1 to 4 in D-VRd cohort and in Cycles 1 to 9 in D-VMP cohort.
224304545|NCT06214533|DRUG|Ropivacaine 0.5%|Prior to the end of the laparoscopic surgery and any additional procedures, the bilateral celiac plexus block will be performed by the surgeon after identification of the aorta at the superior border of body of pancreas. A 22-gauge spinal needle will be inserted into the retroperitoneal fat on either side of the aorta under direct vision. Needle aspiration will be performed to exclude entry into vessels before administration of the interventional drug. The block will contain 20 mL of 0.5% ropivacaine hydrochloride + 1:400000 adrenaline.
224304546|NCT06214533|DRUG|Normal Saline|Prior to the end of the laparoscopic surgery and any additional procedures, the bilateral celiac plexus block will be performed by the surgeon after identification of the aorta at the superior border of body of pancreas. A 22-gauge spinal needle will be inserted into the retroperitoneal fat on either side of the aorta under direct vision. Needle aspiration will be performed to exclude entry into vessels before administration of the interventional drug. The block will contain 20 ml of 0.9% normal saline + 1:400000 adrenaline.
224304547|NCT03842579|OTHER|Resistance training|Supervised progressive explosive type heavy-resistance training two times per week
224304548|NCT03842579|OTHER|High-protein diet|Daily supplementation with milk-based protein-rich products
224304549|NCT03842579|OTHER|Recommendations|Provided with the official national recommendations on nutrition
224304550|NCT05701644|DRUG|C1K 150mg|Subcutaneously administrate C1K 150mg at Day 1, Day 8, Day 15
223475014|NCT07026890|OTHER|Virtual reality sessions|3 virtual reality sessions per week, each lasting 30 minutes.
223475015|NCT07026890|OTHER|Additional rehabilitation sessions|3 additional rehabilitation sessions per week. These sessions correspond to standard rehabilitation sessions.
223475016|NCT03141359|RADIATION|SBRT|Primary tumor SBRT
223475017|NCT03141359|DRUG|Carboplatin|concurrent chemotherapy
224161905|NCT03412565|DRUG|Lenalidomide|Lenalidomide will be administered as 25 mg capsule orally in Cycles 1 to 4 in D-VRd cohort and in all Cycles until documented progression of disease, unacceptable toxicity, or end of study in D-Rd cohort.
224161906|NCT03412565|DRUG|Dexamethasone|Dexamethasone will be administered as 20 mg orally or intravenously in Cycles 1 to 4 in D-VRd cohort; 40 mg orally or intravenously in all cycles and thereafter until documented progression of disease, unacceptable toxicity, or end of study in D-Rd and D-Kd cohort.
224161907|NCT03412565|DRUG|Melphalan|Melphalan will be administered as 9 mg/m\^2 orally in Cycles 1 to 9.
224161908|NCT03412565|DRUG|Prednisone|Prednisone will be administered as 60 mg/m\^2 orally in cycles 1 to 9.
224161909|NCT03412565|DRUG|Carfilzomib|Carfilzomib will be administered as 20 mg/m\^2 IV on Day 1 of Cycle 1 only then 70 mg/m\^2 IV on Days 8 and 15 of Cycle 1 and Days 1, 8 and 15 of Cycle 2 and thereafter until documented progression of disease, unacceptable toxicity, or end of study in D-Kd cohort.
224161910|NCT06243315|DEVICE|Ellansé-S|It is indicated for subcutaneous implantation to correct moderate-to-severe NLFs
224161911|NCT05566574|DRUG|RP-3500|RP-3500 on Days 1-5.
224161912|NCT05566574|RADIATION|External Beam Radiotherapy (EBRT)|Palliative radiation therapy (4Gy x 5 fractions) to a metastatic site on Days 1-5
223475018|NCT03141359|DRUG|Paclitaxel|concurrent chemotherapy
223475019|NCT03141359|DRUG|cis Platinum|concurrent chemotherapy
224161913|NCT03066310|DIAGNOSTIC_TEST|Next generation sequencing|The obtained DNA from the urine, blood and tumor (optional) will be tested by next generation sequencing for each arm.
224161914|NCT06478550|DRUG|Semaglutide|Participants will be treated with commercially available semaglutide subcutaneously (s.c.) according to routine clinical practice and according to local label at the discretion of the Health Care Providers (HCP). The decision to initiate treatment with semaglutide s.c. is independent from the decision to include the participant in the study.
224161915|NCT00449995|PROCEDURE|confocal laser microscopy|
224161916|NCT04026945|DRUG|Lidocaine|Sustained-release lidocaine injection
224304551|NCT05701644|DRUG|C1K 300mg|Subcutaneously administrate C1K 300mg at Day 1, Day 8, Day 15
224304552|NCT05701644|DRUG|Placebo with the same volume of C1K 300mg|Subcutaneously administrate placebo with the same volume of C1K 300mg at Day 1, Day 8, Day 15
224304553|NCT05701644|DRUG|C1K 600mg|Subcutaneously administrate C1K 600mg at Day 1, Day 8, Day 15
224304554|NCT05701644|DRUG|Placebo with the same volume of C1K 600mg|Subcutaneously administrate placebo with the same volume of C1K 600mg at Day 1, Day 8, Day 15
223475020|NCT03141359|DRUG|Etoposide|concurrent chemotherapy
223475021|NCT03141359|RADIATION|IMRT|mediastinal radiation
223475022|NCT03141359|DRUG|Durvalumab|adjuvant immunotherapy
223475023|NCT04227717|DIAGNOSTIC_TEST|MRI with custom MRI spine coil|Participants will undergo MRI with custom MRI spine coil
223744161|NCT00613015|DRUG|Modafinil|
224161917|NCT03003429|OTHER|Heart rate monitor|The intervention consist in monitoring the heart rate variability during one night by using a heart rate monitor and a Polar RS800CX
223475024|NCT01466738|BIOLOGICAL|HRV-16 (100 TCID50)|Each volunteer will receive a single administration of 100 TCID50 of HRV-16 in a total volume of approximately 1.0 mL administered via 4 intranasal instillations.
223475025|NCT01466738|BIOLOGICAL|HRV-16 (1000 TCID50)|Each volunteer will receive a single administration of 1000 TCID50 of HRV-16 in a total volume of approximately 1.0 mL administered via 4 intranasal instillations.
223475026|NCT01081626|DRUG|Recombinant FSH (follitropin alpha)|A starting dose of 75 IU and a first adjustment on Day 14 or Day 7 of stimulation in Group I and II respectively, if no ovarian response is observed.
223581912|NCT03216759|PROCEDURE|Patient-controlled epidural analgesia|Before the induction of anesthesia, the steel wire epidural catheter was placed in the T8-9 or T10-11 gap.The first volume of morphine 2mg + 0.2% ropivacaine + 0.9% saline 6ml, maintenance dose of morphine 18mg + 0.1% ropivacaine + 0.9% saline total 150ml. PCEA work with a continuous background dose of 2 ml/h with a single dose of 2ml/time, load 2ml, locking time 15min.
223581913|NCT03472690|BIOLOGICAL|QBECO-SSI|Subcutaneous injection
223581914|NCT03472690|OTHER|Placebo|Subcutaneous injection
223581915|NCT02840786|DEVICE|plaque excision system|
223581916|NCT02840786|DEVICE|balloon and Stent|
223581917|NCT05275530|BEHAVIORAL|Active FIT Choice|The investigators will send randomized participants a message via MyChart indicating the benefits of CRC screening, along with tailored information about FIT as a screening strategy. At the end of the message, participants will complete a survey asking them to indicate if they would like to be screened for CRC with a FIT, or if they prefer no screening whatsoever. The investigators will then ask follow-up questions to better understand the reason patients made their respective choices.
223581918|NCT05275530|BEHAVIORAL|Active Colonoscopy Choice|The investigators will send randomized participants a message via MyChart indicating the benefits of CRC screening, along with tailored information about colonoscopy as a screening strategy. At the end of the message, participants will complete a survey asking them to indicate if they would like to be screened for CRC with a colonoscopy, or if they prefer no screening whatsoever. The investigators will then ask follow-up questions to better understand the reason patients made their respective choices.
223581919|NCT05275530|BEHAVIORAL|Active Dual Choice|The investigators will send randomized participants a message via MyChart indicating the benefits of CRC screening, along with tailored information about FIT Kit and Colonoscopy screening. At the end of the message, participants will complete a survey asking them to indicate if they would like to be screened for CRC with either a FIT or Colonoscopy, or if they prefer no screening whatsoever. The investigators will then ask follow-up questions to better understand the reason patients made their respective choices.
223581920|NCT03241004|OTHER|Sleep Mask|sleep mask applied for two separate 60-minute periods during anesthesia
224161918|NCT02622048|BEHAVIORAL|Triple P Positive Parenting Programme|10 week self-directed (guided) parenting intervention promoting self-belief, parenting confidence/self-efficacy and problem solving skills.
224161919|NCT04031924|OTHER|Assessment of: 1. Functional Capacity 2. Physical Fitness 3. Physical Activity Level 4. Balance 5. Kinesiophobia 6. Psychological Status 7. Fatigue Severity|All liver transplantation patients who underwent transplant at least one year ago and healthy subjects were evaluated the first day they came.
223475027|NCT04158219|BEHAVIORAL|Behavioral activation for health and depression (BA-HD)|Consistent with successful BA manuals, we plan to conduct up to 10 sessions of treatment over 12 weeks (the recommendation will be at least 8 sessions; scheduling of sessions will be flexible and conform to patient preference). The initial two sessions will be about 50 minutes long and later sessions will be 20-30 minutes long. Sessions can be done on site or over the phone; home visits will be offered for sessions 1-2 if a participant cannot travel. Treatment sessions will use behavioral activation techniques to assess participant values and link these values to behavior change. Goal-setting will focus on sequential, idiographic behavior change (tobacco use, medication adherence, physical activity, and diet) and be accompanied by educational materials and commercially available tools (e.g. activity trackers, pillboxes).
223475028|NCT01503983|DRUG|Trastuzumab|Trastuzumab: 8 mg/kg day 1 followed by 6 mg/kg every 3 weeks (i.v.)
223475029|NCT01503983|DRUG|Capecitabine|Capecitabine: 1000 mg/m2/12h/days 1 - 14 every 3 weeks (v.o.)
223475030|NCT01503983|DRUG|Oxaliplatin|Oxaliplatin: 130 mg/m2 in 2 h, day 1 / (i.v.) /every 3 weeks
223475031|NCT03048045|PROCEDURE|Supportive Periodontal Treatment (SPT)|Assessment of Gingival Bleeding Index and Plaque Control Record, re-instruction and re-motivation to effective individual plaque control, professional tooth cleaning, application of a fluoride gel. Twice a year a periodontal charting with probing pocket depths (PPD) and vertical attachment Level (PAL-V) are obtained at 6 sites per tooth. Thirty seconds after probing bleeding on probing (BOP) is recorded. Sites exhibiting PPD = 4 mm and BOP as well as sites with PPD \>/= 5 mm are scaled subgingivally. Assignment of SPT intervals is performed according to the periodontal risk assessment (PRA).
223475032|NCT02074514|DRUG|Sofosbuvir|400 mg tablet administered orally once daily
223475033|NCT02074514|DRUG|RBV|200 mg tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
223475034|NCT03546673|BEHAVIORAL|Self-Regulation Condition|
223475035|NCT03546673|BEHAVIORAL|Emotional Disclosure Condition|
223475036|NCT04281329|PROCEDURE|Magnetic resonance imaging|Cardiac magnetic resonnance imaging before catheter ablation.
223581921|NCT02704611|DEVICE|Real tDCS|Real tDCS (2mA for 25 minutes on 5 consecutive days/week for 2 weeks with the anode centered over M1 bilaterally. Anodal tDCS for 20 minutes at 1.5mA (15 s ramp in and 15 s ramp out) will be applied daily for 10 consecutive days (5 sessions/week). The anodal electrode 24 cm² with current density of 0.08 mA (2mA/24 cm²) will be placed over the left primary motor area in group I, and the reference electrode (24 cm² will be fixed over the contralateral arm (extracephalic).
223744162|NCT00613015|DRUG|Placebo|
224161920|NCT00996541|BEHAVIORAL|STRIVE family intervention|Adolescent and parent attend a 5-session family-oriented cognitive-behavioral intervention aimed at giving runaway youths and their parents the tools to effectively deal with conflict.
224161921|NCT03633513|DIAGNOSTIC_TEST|LBT-3627|Immunomodulatory agent
224161922|NCT03633513|DIAGNOSTIC_TEST|Immunological profiling|Comprehensive profiling of inflammatory and anti-inflammatory markers (incl. cellular, molecular) including cellular functional assays
224161923|NCT01766245|DRUG|semaglutide|For subcutaneous (s.c., under the skin), single dose administration at two separate dosing visits.
224161924|NCT02295436|DRUG|minodronic acid|comparison of different doses, ages and medication conditions
224161925|NCT04085692|BEHAVIORAL|Low-Dose, High-Frequency Simulation-Based Training|"Twelve weeks of LDHF training~The simulation-based training sessions take place at the EMDC, at extra workstations set-up as ordinary EMD workstations in an out-of-the-way area. Before each session, the EMD is informed about the simulation call and receives instructions concerning technical differences from a regular call. The instructor acts as a standardised caller, guided by a computer program. This program, the Danish version of Resuscitation Quality Improvement for Telecommunicators (Laerdal Medical AS, Stavanger, Norway), is a training program for DA-CPR based on the simulation platform Laerdal Learning Application. This modified version of the RQI-T program has, one test scenario, one data collection scenario and six different cardiac arrests scenarios as well as a feedback checklist based on the Danish dispatcher protocol Danish Index for Emergency Care.~Each simulation session takes approximately 20 minutes, including introduction and feedback"
223475037|NCT06942897|DIETARY_SUPPLEMENT|Melissa officinalis supplement|This intervention consists of a standardized oral dietary supplement containing 400 mg of Melissa officinalis extract formulated in phospholipids. The supplement is administered once daily for 3 weeks to evaluate its potential effects on mood, stress perception, and cortisol levels in healthy adults.
223475038|NCT06940648|DEVICE|The study is to evaluate the use of the Virtuoso Endoscopy System to perform safe and effective bladder lesion excisions.|This study is to evaluate the use of the Virtuoso Endoscopy System (VES), which is a robotic enhanced system, to perform safe and effective bladder lesion excisions.
223475039|NCT06955169|DRUG|[177Lu]Lu-DOTATATE|The treatment regimen consists of 4 (+2 optional) administrations of \[177Lu\]Lu-DOTATATE. The recommended interval between infusions is 4 weeks (+ 7 days).
223475040|NCT06955169|OTHER|Standard of Care treatments|Treatments will occur at the discretion and based on clinical judgement of the local and treating investigator. Local SOC therapy with one of the following agents: bevacizumab, everolimus, hydroxyurea, or sunitinib.
223475041|NCT03999047|DIAGNOSTIC_TEST|PRISMA score|Screening for frailty using PRISMA-7
223475042|NCT04765787|DRUG|Combination of Paracetamol 650mg + Orphenadrine 50mg|In routine practice for pain , combination of Paracetamol 650 mg + Orphenadrine 50mg prescribed for 7-10 days with follow up and as per physician discretion
223475043|NCT02097732|DRUG|Ipilimumab|Ipilimumab 3mg/kg given intravenously over 90 minutes, every 3 weeks for a total of 4 doses.
223581922|NCT02704611|DEVICE|Sham tDCS|Sham tDCS will be applied using the above described parameters in group. For sham tDCS, the placement of the electrodes, current intensity, and ramp time was identical to real tDCS stimulation group; however, the stimulation lasted only for 30 Sec. However, since none of the patients have been experienced tDCS previously, they were unaware of which stimulation is real and which sham is. The investigator responsible for delivering tDCS had no contact with the patients.
223581923|NCT05618093|DEVICE|Non-invasive hemodynamic measurements|A patient profile will be set up in the Edwards EV1000 clinical platform by inputting the patient's demographic information. One or two Edwards ClearSight finger cuffs will be placed on the index, middle, and/or ring finger on one hand of the patient. A pressure controller will be secured by a forearm strap where the finger cuffs will be connected to the pressure controller. The pressure controller will be connected to the Edwards EV1000 clinical platform monitor. A heart reference sensor (HRS) will be connected to the pressure controller, a finger cuff, and to the patient at heart level. The Edwards EV1000 clinical platform will calibrate the finger probes, then record measurements for 10-30 seconds. If two finger probes are available, measurements will alternate between fingers.
223581924|NCT02450968|DRUG|Dexamethasone|
223581925|NCT02450968|DRUG|Placebo|
223581926|NCT03024138|RADIATION|Repeat CT scan|
223581927|NCT03300297|OTHER|Cervical Spine Thrust Joint Manipulation|High velocity, short amplitude thrust to the cervical spine
223581928|NCT03300297|OTHER|Cervical Spine Sham Manipulation|Manipulative hold position shy of end range without a thrust
223581929|NCT03300297|OTHER|Home Program|therapeutic exercise program and education
223581930|NCT03300297|OTHER|Suboccipital Release|suboccipital soft tissue mobilization
224161926|NCT05394207|DIETARY_SUPPLEMENT|L. casei DG® (Lactobacillus paracasei CNCM I-1572)|L. casei DG® (Lactobacillus paracasei CNCM I-1572) containing 8 billion of live cells daily + Vitamin D 4.000 U.I. daily.
224161927|NCT05394207|OTHER|placebo|The comparator product is an identical matching placebo daily + Vitamin D 4.000 U.I. daily.
224161928|NCT01849562|DRUG|Sovaprevir|Nonstructural protein 3/4A protease inhibitor.
224161929|NCT01849562|DRUG|ACH-3102|Nonstructural protein 5A inhibitor.
224161930|NCT01849562|DRUG|Ribavirin|
224161931|NCT01849562|DRUG|Placebo|
224161932|NCT04403841|OTHER|patient education and self-management intervention in a low-resource setting on diabetes knowledge and levels of blood glucose control|The intervention consisted group education on type 2 diabetes, including, in addition to usual diabetes care: information on diet, exercise, drug therapy, and adherence
224161933|NCT04403841|OTHER|Usual diabetes care alone|Usual diabetes care was consistent with the ADA guidelines (15) and comprised standard dietary and exercise advice in addition to antidiabetes treatment
223475044|NCT02097732|PROCEDURE|Stereotactic Radiosurgery|Stereotactic radiosurgery is a type of focused radiation therapy. It requires the placement of a metal frame on the head for several hours.
223581931|NCT01605942|DRUG|Dexamethasone Drug Delivery System|Dexamethasone Drug Delivery System administered into the study eye at the conclusion of cataract surgery on Day 1.
223581932|NCT01605942|DRUG|Placebo Drug Delivery System|Placebo Drug Delivery System administered into the study eye at the conclusion of cataract surgery on Day 1.
223581933|NCT01534949|BIOLOGICAL|rituximab|375 mg/m2 by intravenous \[IV\] infusion
223581934|NCT03474081|DRUG|FF/UMEC/VI|A single inhaler triple therapy of FF/UMEC/VI will be provided via ELLIPTA DPI. FF/UMEC/VI will be available as dry white powder with dosing strengths of 100/25/62.5 mcg per blister.
223581935|NCT03474081|DRUG|Tiotropium|Tiotropium will be provided as a hard gelatin capsule for oral inhalation containing 18 mcg tiotropium bromide blended with lactose, administered via HANDIHALER DPI.
223581936|NCT03474081|DRUG|Albuterol/salbutamol|Albuterol/salbutamol will be provided as an inhalation via MDI with a spacer or nebules and will be given as a rescue medication throughout the study.
223744163|NCT00142571|DRUG|Gemcitabine|
223744164|NCT00142571|DRUG|Docetaxel|
223475045|NCT02855255|BEHAVIORAL|NHS 1-1 smoking cessation programme.|Smoking cessation using cognitive behavioural therapy/motivational interviewing
223475046|NCT02855255|BEHAVIORAL|Group smoking cessation programme|Smoking cessation using Allen Carr's Easyway method being delivered in a spoken form.
223475047|NCT04166214|OTHER|Imaging using intraoral cameras|The SOPROCARE is intended for clinical practice of general dentistry, as an aid in the diagnosis of pit and fissure caries, as an aid to highlight dental plaque and gingival inflammations and as intra-oral camera to visualize anatomical details that are invisible to the naked eye or with a mirror. In CARIO mode, the camera helps the dental practitioner to highlight carious warning on pits and fissures of the occlusal side of the teeth. In DAYLIGHT mode, the camera enables you to visualize anatomical details invisible to the naked eye or with a mirror. In PERIO mode, the camera helps the dental practitioner to see the presence of dental plaque but also to highlight gingival inflammations . This mode offers to the dentist and/or hygienist a tool for an improved communication, motivation and education of his/her patients, who will then become aware of their oral health condition.
223475048|NCT04518696|PROCEDURE|suprachoroidal buckling|"Location, marking and freezing of the retinal tear on the scleral side . Subretinal fluid is released from the outside of the sclera as needed. In the quadrant of the retinal tear, the spherical conjunctiva was opened and the radial full-thickness scleral incision (3mm)was made about 8-13mm away from the retinal tear. After the choroid was exposed, a pocket is formed by injecting some viscoelastic agent into the posterior edge of the sclera and separating the choroid from the sclera using the Healon packaged cannula (No.27 Rycroft cannula). The Healon 5 syringe was connected with a 450-um special tube . The cannula is inserted into the supragromal space under microscopic and was scaned by iOCT . Once confirmed in accord with the needle position, sodium hyaluronate injection, usually need 0.2 mL to 0.5 mL, application of anterior chamber puncture or subretinal fluid stable intraocular pressure. Exit the duct and close the incision with scleral presutures."
223475049|NCT05786859|DRUG|Rifaximin 200 mg|Rifaximin Treatment Group:on the basis of comprehensive treatment of liver failure, Rifaximin will be added, three times a day, 400mg each time, for a total of 4 weeks, and we will observe until 12 weeks after withdrawal.
223475050|NCT05786859|OTHER|Standard Treatment without Rifaximin|The standard treatment group (control group), which will receive routine comprehensive treatment for liver failure without Rifaximin.
223475051|NCT02337764|DRUG|TVP-1012 1mg|TVP-1012 1mg Tablets
223475052|NCT06238739|OTHER|Control - Standard Strategies for hypothermia prevention|Standard temperature management. Patients underwent one-hour pre- and post-operative warming with hot-air warming blankets at 38°C, without any other preoperative or intraoperative thermal protection measure.
223475053|NCT06238739|OTHER|Fluid warming before infusion and infiltration|Passive Measures: Patients underwent one-hour preoperative warming with hot air warming blankets at 38°C (100.4°F), operating room (OR) temperature was maintained at a minimum of 21°C (69.8°F), aseptic/antiseptic solutions along with infiltration fluid were all warmed to 38°C (100.4°F), and surgical fields were kept as dry as possible.
223475054|NCT06238739|DEVICE|Thermal convection blanket by water flow (Blanketrol)|Blanketrol: Patients underwent continuous intra-operative temperature protection, using a thermal convection blanket by water flow (Blanketrol®) at 40°C (104°F).
223475055|NCT06238739|DEVICE|Conductive fabric electric warming device (HotDog)|HotDog: Patients underwent permanent intra-operative thermal protection measures with conductive fabric electric warming device (HotDog®) at 40°C (104°F).
223475056|NCT00745888|OTHER|Chemiluminescence Analyzer|measure reactive oxygen species
223475057|NCT06522321|BIOLOGICAL|i-PRF and FDBA|"A mucoperiosteal flap will be raised and atraumatic extraction will be done. An immediate implant with FDBA and I-PRF (experimental group) will be placed according to the standard protocol.~An immediate implant with FDBA( comparative group) will be placed according to the standard protocol .~The surgical wound closure will be coapted with sutures"
223475058|NCT00000220|DRUG|Buprenorphine|
223475059|NCT05259631|DRUG|Sevoflurane|Patients are to be sedated by sevoflurane inhalation. For this purpose, any certificated devices are suitable - AnaConDa or Mirus evenly. Starting dose of sevoflurane is to be 2 ml/h and may be modified at the discretion of the attending intensivist to achieve and maintain the target level of sedation
223475060|NCT05259631|DRUG|Propofol|Patients of this group will receive an intravenous infusion of propofol with starting dose of 1 mg/kg/h. The precise dose to maintain the desired level of sedation is left at the discretion of the attending intensivist and may be revised at any time. The upper dose limit for propofol is 4 mg/kg/h. In case of tolerance to propofol infusion, midazolam or antipsychotics (haloperidol) can be added to achieve the desired level of sedation
223475061|NCT00532623|DRUG|Gemcitabine plus Vinorelbine|Gemcitabine, 1,000mg/m2 and Vinorelbine, 25mg/m2, on day 1 and day 8, every 3 week cycles
223475062|NCT00532623|DRUG|Sequential|"Gemcitabine monotherapy followed by Vinorelbine monotherapy:~-Gemcitabine: 1,200 mg/m2, intravenously, on day 1 and day 8 in 3 week cycles. Vinorelbine: 30 mg/ m2, intravenously, on day 1 and day 8 in 3 week cycles."
223475063|NCT04208893|BEHAVIORAL|Exercise training|See description of Arms
223475064|NCT01967199|DEVICE|Everolimus-eluting balloon expandable stent|Everolimus-eluting balloon expandable stent (Xience Prime or Xience Xpedition or Xience Alpine)
223581937|NCT03474081|DRUG|Placebo to match FF/UMEC/VI|Placebo matching FF/UMEC/VI will be available as a dry white powder of lactose or magnesium stearate, administered via ELLIPTA DPI.
223581938|NCT03474081|DRUG|Placebo to match tiotropium|Placebo will be given as hard gelatin capsule for oral inhalation containing lactose, administered via HANDIHALER DPI.
223581939|NCT03474081|DEVICE|ELLIPTA inhaler|ELLIPTA DPI will contain two individual blister strips with 30 blisters per strip. FF/UMEC/VI and placebo to match FF/UMEC/VI will be administered to the subjects using ELLIPTA DPI.
223581940|NCT03474081|DEVICE|HANDIHALER|Tiotropium and placebo to match tiotropium will be administered to the subjects using HANDIHALER DPI.
223581941|NCT03474081|DEVICE|MDI|Albuterol/salbutamol will be provided as a rescue medication throughout the study using MDI.
224161934|NCT03489538|PROCEDURE|laparoscopic long limb roux-en-Y gastric bypass|standard laparoscopic roux-en-Y gastric bypass (biliopancreatic limb 40 to 60 cm, alimentary limb 150 cm)
224161935|NCT00113711|BEHAVIORAL|smoking cessation|
224161936|NCT00113711|BEHAVIORAL|reducing diet|
224304555|NCT05701644|DRUG|C1K 900mg|Subcutaneously administrate C1K 900mg at Day 1, Day 8, Day 15
223475065|NCT01967199|DEVICE|paclitaxel eluting balloon|paclitaxel eluting balloon (SeQuent Please)
223475066|NCT00105430|PROCEDURE|Deep Brain Stimulation|
223475067|NCT04140448|DRUG|Ranibizumab 0.5 MG/0.05 ML Intraocular Solution [LUCENTIS]|Intravitreal injection of Ranibizumab 0.5 MG/0.05 ML
223475068|NCT04140448|DEVICE|Ultra-wide Fluorescein Angiography|Ultra-wide-field Fluorescein Angiography can clearly observe the peripheral retina
223475069|NCT01170585|DRUG|Rosuvastatin|All patients will be uptitrated from an initial start dose of 5mg to 20mg rosuvastatin. This will be given once a day for 2 years.
223475070|NCT01170585|DRUG|Placebo|Placebo
223475071|NCT03598296|OTHER|Large size tube|Patients in Group A are inserted the large size tube (28F).
223475072|NCT03598296|OTHER|Drainage ball|Patients in Group B are inserted the small-bore tube connects with a negative pressure ball(drainage ball).
223475073|NCT01490411|DRUG|Placebo|The drug tested in this study (rBet v1-FV) was given as a subcutaneous (just under the skin) injection. Patients received at least 10 injections of Placebo or rBet v1-FV, administered in increasing doses weekly for 10 weeks, up to one of the maximum concentrations.
223475074|NCT01490411|BIOLOGICAL|rBet v1-FV|The drug tested in this study (rBet v1-FV) was given as a subcutaneous (just under the skin) injection. Patients received at least 10 injections of Placebo or rBet v1-FV, administered in increasing doses weekly for 10 weeks, up to one of the maximum concentrations.
223744165|NCT05263700|DRUG|68Ga-FAPi-46|FAPI-46 is a small molecular radiopharmaceutical that binds to the fibroblast activated protein on cancer associated fibroblasts. Gallium-68 (68Ga) is a positron-emitting isotope with a half-life of 68 minutes.
224161937|NCT02480062|OTHER|mWELLCARE|mWELLCARE intervention arm will include a software application loaded on a tablet computer that will be used by Nurse Care Coordinators (posted in community health centers) in the course of their jobs to register patients with hypertension or diabetes, to generate clinical decision support recommendations, to track these patients over time and to improve follow-up care. Decision support recommendations will be printed and given to a doctor, who will make the final call on the management plan that will be used for the patient. Registered patients will also receive customized messages on their mobile phone. In addition, at sites where network connectivity permits, the doctor may also be equipped with a doctor's app on a tablet that will be largely the same as the NCC app.
224161938|NCT02480062|OTHER|Usual Care|Usual care at the community health centers
224161939|NCT01554189|DRUG|MK-8325|MK-8325 capsules, orally, once per day for 5 days, at a dose determined by panel assignment (10-200 mg)
224161940|NCT01554189|DRUG|Placebo|Placebo to match MK-8325 capsules, orally, once per day for 5 days
224161941|NCT01983449|DRUG|Dexamethasone Sodium Phosphate Injection, USP|Adventitial infusion of dexamethasone after angioplasty or atherectomy-based revascularization of the superficial femoral or popliteal artery.
224161942|NCT00626769|DIETARY_SUPPLEMENT|aglycone genistein|2 capsules per day containing 27 mg of aglycone genistein, calcium carbonate (500 mg) and vitamin D (400 IU), for a 3-year period.
224304556|NCT05701644|DRUG|Placebo with the same volume of C1K 900mg|Subcutaneously administrate placebo with the same volume of C1K 900mg at Day 1, Day 8, Day 15
224304557|NCT05701644|DRUG|C1K 1200mg|Subcutaneously administrate C1K 1200mg at Day 1, Day 8, Day 15
224161943|NCT00626769|DIETARY_SUPPLEMENT|placebo|2 capsules per day containing calcium carbonate (500 mg) and vitamin D (400 IU), for a 3-year period.
223475075|NCT01490411|BIOLOGICAL|rBet v1-FV|The drug tested in this study (rBet v1-FV) was given as a subcutaneous (just under the skin) injection. Patients received at least 10 injections of Placebo or rBet v1-FV, administered in increasing doses weekly for 10 weeks, up to one of the maximum concentrations.
223475076|NCT01490411|BIOLOGICAL|rBet v1-FV|The drug tested in this study (rBet v1-FV) was given as a subcutaneous (just under the skin) injection. Patients received at least 10 injections of Placebo or rBet v1-FV, administered in increasing doses weekly for 10 weeks, up to one of the maximum concentrations.
223475077|NCT01490411|BIOLOGICAL|rBet v1-FV|The drug tested in this study (rBet v1-FV) was given as a subcutaneous (just under the skin) injection. Patients received at least 10 injections of Placebo or rBet v1-FV, administered in increasing doses weekly for 10 weeks, up to one of the maximum concentrations.
223475078|NCT02674724|OTHER|Gym Group|"Patients from Gym Group will perform a strengthening program of 45 minutes sessions, twice a week in a 12-week period.~The initial load is established as 60% of one-repetition maximum strength test (1RM) applied for each exercise at the beginning of program. Patients will be encouraged to perform 3 sets of 8 to 12 repetitions. All subjects will be instructed to rest for 30-60 second intervals between sets."
223744166|NCT05263700|PROCEDURE|PET/CT imaging|PET with the investigational tracer 68Ga-FAPI-46 with accompanying low-dose CT for anatomical localisation
223744167|NCT06132178|DRUG|Psilocybin|A psychedelic drug found in certain mushrooms. It will be in a capsule of 25mg psilocybin (COMP360).
223744168|NCT06132178|DEVICE|Accelerated intermittent theta burst (aiTBS) rTMS treatment|A form of non-invasive brain stimulation that delivers a series of quick magnetic pulses to the scalp and a portion of the brain. It will be targeted to a functional magnetic resonance imaging (fMRI) functional connectivity-guided personalized left dorsolateral prefrontal cortex target using neuronavigation and delivered over 10 sessions daily for 5 consecutive days at 90% of coil-to-target depth-corrected resting motor threshold.
224161944|NCT01789710|DRUG|Bupropion|All participants who are medically eligible to take Bupropion will receive this study medication one week prior to their smoking quit date.
224161945|NCT01789710|DRUG|Nicotine replacement therapy|All participants will receive two forms of nicotine replacement therapy - nicotine patches and a rescue method (either gum or lozenge).
224304558|NCT05701644|DRUG|Placebo with the same volume of C1K 1200mg|Subcutaneously administrate placebo with the same volume of C1K 1200mg at Day 1, Day 8, Day 15
224304559|NCT04952636|PROCEDURE|arthroscopic Cuistow|peforming the Cuistow Procedure under arthroscopy
224304560|NCT04952636|PROCEDURE|open Cuistow|peforming the Cuistow Procedure with the traditional open process
224304561|NCT02540759|DIETARY_SUPPLEMENT|Buglossoides oil|
224304562|NCT02540759|DIETARY_SUPPLEMENT|High Oleic Sunflower Oil|
224304563|NCT05114382|PROCEDURE|EP Procedure|Intracardiac signals will be passively recorded using CathVision Cube® System in parallel with the commercial (CE marked) EP recording system during a scheduled electrophysiology procedure
224304564|NCT01157897|BIOLOGICAL|VMP001|Plasmodium vivax malaria protein 001 (VMP001) with GSK Biologicals' Adjuvant System AS01B
223475079|NCT02674724|OTHER|Free Weights Group|Patients from Free Weights Group will perform a strengthening program of 45 minutes sessions, twice a week in a 12-week period. The program aim to recruit the same muscles requested in Gym Group. Investigators will apply six different exercises with patients lying supine,standing in stance, sitting and in four points kneeling. All exercises aim to strengthen abdominal muscles, trunk extensors, gluteus, quadriceps and scapula adductors. Patients will perform 3 sets of 8 to 12 repetitions, the load will be offered with dumbbells, elastics with different resistances and anklets.
223475080|NCT02674724|OTHER|Control Group|All three groups will be instructed to perform stretching exercises of trunk, leg and shoulder muscles, according to an illustrated booklet. Only the Control Group patients will be instructed to perform stretching exercises at home in the same 12-week period.
223475081|NCT02471443|PROCEDURE|Surgery for severe endometriosis|Consecutive patients undergoing excisional surgery for severe endometriosis with bowel involvement
223475082|NCT02623192|OTHER|Patients who have performed the ARDS pulmonary function test|
223475083|NCT00917696|PROCEDURE|Comparator: Iontophoresis and Laser Doppler with ATP|Iontophoresis treatments with 10 mM ATP (adenosine triphosphate) solution and a current of 0.8 or 1.2 mA. Iontophoresis treatments will last 4 minutes. Laser doppler will be used during the iontophoresis treatments to measure dermal blood flow.
223475084|NCT00917696|PROCEDURE|Comparator: Iontophoresis and Laser Doppler with Saline|Iontophoresis treatments with 20 mM saline solution and a current of 0.8 or 1.2 mA. Iontophoresis treatments will last 4 minutes. Laser doppler will be used during the iontophoresis treatments to measure dermal blood flow.
223475085|NCT04606303|DRUG|Toripalimab combination with platinum-containing dual-drug chemotherapy.|"cisplatin + paclitaxel/ albumin-bound paclitaxel/ gemcitabine/ Pemetroxel+ Toripalimab (cisplatin 75mg/m2 (D1), paclitaxel 175mg/m2 (D1), or albumin-bound paclitaxel 260mg/m2 (D1), or gemcitabine 1250mg/m2 (D1, D8), or Pemetroxel 500mg/m2 (D1)), Toripalimab 240mg D1, Q3W.~If the patient is SD or PD, Toripalimab combined with platinum-containing dual-drug chemotherapy in the third cycle will continue, and a total of 4 cycles can be carried out at most, and the therapeutic effect will be evaluated after each cycle of treatment. If the patient is PR or CR at any time during the treatment (after treatment in the third or fourth cycle), the surgical treatment will be entered. If PR or CR is still not reached after treatment in the fourth cycle, the endpoint of the trial will be reached, theobservation of the patient will be finished, and the subsequent treatment will be decided by the clinician."
223475086|NCT01030146|DRUG|NeilMed® Sinus Rinse™ System with Isotonic Saline|NeilMed® Sinus Rinse™ System with Isotonic Saline twice a day
223475087|NCT05424341|OTHER|Muscle Energy Technique|For Gastrocnemius muscle, subject will be in supine position keeping knee fully extended and therapist on affected side in walking position. The subject's ankle joint will be dorsiflexed until a resistance feel and will ask to hold this position and exert 20% of force towards plantar flexion for a period of 5 to 7 seconds. Resistance will be released and relaxation of 5 seconds will be given during which the ankle will was passively dorsiflexed to a new barrier. 5 repetitions will be given.
223581942|NCT02955680|PROCEDURE|recorded maternal voice|"A voice recording will be performed before the operation. At a preoperative visit or preoperative clinic, informed consent was obtained before the recording. On a calm environment, the mother was asked to speak following sentences.~ OO (first name of child), wake up\~. Let's go home with mommy. OO, wake up\~. Open your eyes. Take a deep breath.  At the end of surgery, the recorded maternal voice was delivered to the child every 15 seconds until he/she wakes up."
223581943|NCT02955680|PROCEDURE|recorded stranger's voice|"A voice recording will be performed before the operation. On a calm environment, a blinded female investigator was asked to speak following sentences.~ OO (first name of child), wake up\~. Let's go home with mommy. OO, wake up\~. Open your eyes. Take a deep breath. "
223581944|NCT05450627|DRUG|Pancreatic Enzyme|Registry of pancreatic enzyme therapy prescribed to included patients
223581945|NCT02610491|DIETARY_SUPPLEMENT|Hesperidin|Citrus peel extract
223581946|NCT02610491|DIETARY_SUPPLEMENT|Placebo|Cellulose
223581947|NCT01730404|DRUG|CHF6001 DPI|
223581948|NCT01730404|DRUG|Roflumilast|
223581949|NCT01730404|DRUG|Placebo|
223581950|NCT06385535|BEHAVIORAL|Habit Reversal Training (HRT)|Habit Reversal Training (HRT) is a multicomponent treatment package developed to treat a repetitive behaviors. HRT includes (1) increasing awareness of discrete occurrences of tics and associated premonitory urges (PMUs; i.e., awareness training), (2) teaching the patient to suppress tics by engaging in behaviors that are physically incompatible with target tics (i.e., competing response \[CR\] training), and (3) prompting and reinforcing between-session patient engagement with therapeutic techniques and homework (i.e., providing social support).
224161946|NCT01789710|BEHAVIORAL|Contingency Management|All participants will be asked to provide home carbon monoxide monitoring with equipment that is loaned to them. When participants provide readings that are low enough to suggest abstinence from smoking, they are provided monetary reinforcement (i.e., money).
224161947|NCT00171002|DRUG|valsartan/amlodipine|
224161948|NCT04306666|OTHER|Regional anesthesia|Injection of local anesthetics by a regional anesthesia named Walant block (Wide Awak Local anesthesia No Tourniquet)or by axillary brachial plexus block.
224304565|NCT01157897|OTHER|P. vivax sporozoite challenge|P. vivax sporozoite challenge
223581951|NCT06377709|OTHER|ProACTive|ProACTive intervention, a talking therapy utilising acceptance and commitment therapy (ACT) techniques.
223581952|NCT01390207|OTHER|16mm triggering|"Final oocyte maturation will be achieved by administration of 10.000 IU of hCG (Pregnyl®). Randomization will be into 2 groups:~• Group A (early hCG group): hCG will be administrated as soon as ≥ 3 follicles ≥ 16mm were present on ultrasound."
224161949|NCT04114045|DIETARY_SUPPLEMENT|Experimental:Whey protein|Each participant in the protein group received 2 protein drinks immediately following exercise. The supplement was given using a relative quantity of whey protein isolate (0.3g/kg) and was chocolate flavoured.
224161950|NCT04114045|DIETARY_SUPPLEMENT|Active Comparator: Isoenergetic control - Carbohydrate|Each participant in the carbohydrate group received 2 drinks immediately following exercise. The supplement was given using a relative quantity of maltodextrin (0.3g/kg), non-caloric chocolate flavouring was added to mask the drinks contents.
224304566|NCT03734666|BEHAVIORAL|Mindfulness Based Relapse Prevention - Smoking and Alcohol|Mindfulness Based Relapse Prevention (MBRP) is a treatment for preventing relapse in addictive disorders that integrates mindfulness meditation with standard relapse prevention practices.
224304567|NCT03734666|BEHAVIORAL|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy (CBT) is a form of therapy that aims to help individuals modify problematic emotions, behaviors, and thoughts.
223475088|NCT05424341|OTHER|Counterstrain Technique|Therapist places thumb on tender point at plantar fascia insertion while patient in supine position with ipsilateral knee flexed. Plantar flex the toes and ankle while monitoring sore site with thumb, curling around tender point until monitoring thumb feels symptomatic relief. Supination/pronation of foot will be added if necessary. The position of ease will be maintained for 90 secs until tissues beneath monitoring thumb softens. Tender spot is re-evaluated once the foot is returned to neutral without moving the thumb. It will be repeated 3 times for 30 secs resting interval in-between
223475089|NCT01176929|OTHER|Usual treatment and Prevention program|"Prevention program of recurrent suicidal acts includes three interventions:~* A series of three telephone calls ( the second week , one month and three months after discharge from hospital )~* A systematic telephone contact with the referring physician~* A telephone helpline for people who made a suicide attempt and referring physicians."
223475090|NCT01176929|OTHER|Usual Treatment|Usual Treatment
223475091|NCT00304629|DRUG|galantamine|
224304568|NCT00001026|BIOLOGICAL|gp160 Vaccine (Immuno-AG)|
223475092|NCT02641054|DRUG|CVXL-0107|
223475093|NCT02641054|DRUG|Placebo|
223475094|NCT02641054|DRUG|Levodopa|
223475095|NCT00910598|DRUG|glatiramer acetate|20 mg daily s.c. for 1 year
223475096|NCT00666250|DIETARY_SUPPLEMENT|Xocai Activ drink|proprietary blend of cocoa powder and extracts of acai, grape and blueberry
223475097|NCT01040819|DRUG|Pioglitazone|Patients will receive PIO 15 mg/d for one month, then 55 patients continue with the same dose for one additional month, and in 55 patients the dose will be increased to 30 mg/d for an additional one month. Other non-diabetes drugs should not be changed. Other hypoglycemic agents, including insulin may be adjusted, if clinically indicated. NSAID, COX2 inhibitors, aspirin \>162 mg/d, steroids and prostaglandin analogs will be prohibited.
223475098|NCT03851289|COMBINATION_PRODUCT|platelet-rich fibrin and calcium sulfate|
223475099|NCT03851289|COMBINATION_PRODUCT|platelet-rich fibrin and xenograft|
223475100|NCT06064448|DRUG|Sildenafil|Subjects were given sildenafil citrate, 25mg/capsule, once a night, one capsule each time, for 4 weeks.
223475101|NCT06064448|DRUG|Ningmitai capsule|The subjects took Ningmitai capsule, 0.38 g/capsule, 3 times a day, 4 capsules each time, after meals, and continued to treat for 4 weeks.
223475102|NCT06064448|DRUG|Ningbitai capsule + sildenafil|The subjects took Ningmitai capsule orally, 0.38 g/capsule, 3 times a day, 4 capsules each time, and took it after meals. Sildenafil citrate, 25mg/capsule, once a night, one capsule each time, was taken orally for 4 weeks.
223581953|NCT01831817|DRUG|5% calcium sodium phosphosilicate/ sodium monofluorophosphate dentifrice|Calcium sodium phosphosilicate dentifrice (5% w/w) and 1500 ppm F as sodium monofluorophosphate
223581954|NCT01831817|DRUG|0% calcium sodium phosphosilicate/ sodium monofluorophosphate dentifrice|No calcium sodium phosphosilicate and 1500 ppm F as sodium monofluorophosphate
223581955|NCT01831817|DRUG|Sodium monofluorophosphate dentifrice|Sodium monofluorophospate dentifrice (1000 ppm F)
223475103|NCT04748718|OTHER|Exercise-based injury prevention program|\~10-minute, 4+ times/week exercise-based injury prevention program. Includes flexibility, strengthening, balance, agility and plyometric exercises.
223475104|NCT03073707|BEHAVIORAL|Sample collection|Stool samples will be collected from household members of children diagnosed with NTS infection. In addition stool samples of animals and rats will be collected as well as samples of the water supply of the household.
223475105|NCT03056053|DRUG|Zolpidem|Commercially available tablets of zolpidem (5 or 10 mg) for oral use
224304569|NCT00001026|BIOLOGICAL|rgp120/HIV-1IIIB|
224304570|NCT00001026|BIOLOGICAL|rgp120/HIV-1MN|
224304571|NCT00001026|BIOLOGICAL|rgp120/HIV-1 SF-2|
224304572|NCT00001026|BIOLOGICAL|HIVAC-1e|
224304573|NCT02991170|PROCEDURE|unipolar or bipolar radiofrequency ablation+CABG|Patients with myocardial infarction related potential malignant ventricular arrhythmia undergoing unipolar or bipolar radiofrequency ablation and Coronary Artery Bypass Grafts at the same time
223475106|NCT04738383|PROCEDURE|Version 1: Paramedic|Instead of a physician, who is constantly present, a paramedic is present next to the instructor during the sessions, who can give first aid in case of an emergency and bridge the time until the ambulance arrives on site. The physician still acts as a supervisor visiting the group roughly every six weeks.
223475107|NCT04738383|PROCEDURE|Version 2: Physician-on-call|This version implicates that a physician is not physically present but is on call during the sessions and must be constantly accessible by phone and able to arrive within three minutes in case of an emergency. To ensure this, version two should be implemented in facilities, which are linked to cardiac or rehabilitation center.
223581956|NCT01831817|DRUG|Sodium Fluoride dentifrice|Dentifrice containing 1100ppm F as sodium fluoride
223581957|NCT04608734|DRUG|Buccal midazolam|The drug was sprayed in the buccal vestibule across the area between the primary first and second molars in all four quadrants to maximize the absorption through wide area of the buccal mucosa.
223581958|NCT04608734|DRUG|Intranasal midazolam|Half of the dose was sprayed in the right nostril and the other half in the left nostril to double the absorptive surface area by short and quick puffs.
223581959|NCT05505604|PROCEDURE|PENG|patients will receive an ultrasound-guided Pericapsular Nerve Group Block with 20mL of 0.25% bupivacaine (not to exceed 2mg/kg)
223581960|NCT05505604|PROCEDURE|FICB|Patients will receive an ultrasound-guided Fascia Iliaca Compartment Block with 20 mL of 0.25% bupivacaine (not to exceed 2 mg/kg) diluted to total volume of 40 mL of injectate
223581961|NCT00911573|DRUG|Tigecycline|50 mg IV every 12 hours up to 14 days
224304574|NCT02991170|PROCEDURE|CABG|Patients with myocardial infarction related potential malignant ventricular arrhythmia undergoing Coronary Artery Bypass Grafts
224304575|NCT04173299|PROCEDURE|early tips|patients with early tips
224304576|NCT02459548|OTHER|Follow up in Sleep Unit Group|Compare the results of a program of treatment and follow-up by Primary Care in patients with obstructive sleep apnea on CPAP treatment, versus the usual practice of control by the Sleep Unit.
224304577|NCT02459548|OTHER|Follow up in Primary Care Group|Compare the results of a program of treatment and follow-up by Primary Care in patients with obstructive sleep apnea on CPAP treatment, versus the usual practice of control by the Sleep Unit.
223475108|NCT04738383|PROCEDURE|Version 3: Trained instructor|The sessions take place with the instructor only, who receives a comprehensive emergency training before and during the model phase and replaces the constantly present physician. Just like in the previous versions the physician still acts as a supervisor visiting the group roughly every six weeks.
223475109|NCT01951300|OTHER|Gallium-68 citrate|Single intravenous bolus injection of 200 MBq of Gallium-68 citrate radiopharmaceutical
223744169|NCT06132178|DRUG|Low-dose psilocybin|A psychedelic drug found in certain mushrooms. It will be in a low-dose form of the experimental dose as a 1mg capsule of psilocybin (COMP360).
224161951|NCT04114045|OTHER|Placebo|Each participant in the water group received 2 drinks immediately following exercise. The water was provided in a similar volume using the same non-caloric chocolate flavouring as the other drinks.
223475110|NCT01592955|DEVICE|EYEOP1|Cyclocoagulation using High Intensity Focused Ultrasound with EYEOP1 device
223475111|NCT01065818|DRUG|Fluoro-L-Thymidine|4D-PET/CT imaging with an injection of Fluoro-L-Thymidine at pre-Neoadjuvant Therapy and post-3 weeks Neoadjuvant Therapy prior to surgery.
223581962|NCT00911573|DRUG|Clindamycin (or Vancomycin if needed)|For clindamycin 10mg/kg (not to exceed 900mg) IV every 8 hours up to 14 days. For vancomycin 15mg/kg (not to exceed 2g/day and adjusted as needed for renal impairment) IV every 8 hours
223581963|NCT04787380|DEVICE|Heartfelt device|"The Heartfelt device uses a system of cameras in a compact device to generate 3D images of the feet and lower legs with a view to detecting early volume changes. The device can be installed on the wall or as a free standing unit; however, given the COVID-19 pandemic, only the free standing option will be available to participants, so as to avoid the necessity of an installer visiting the patient. For the measurements to take place, the participant walks in the field of view of the device. Participants are not expected to change anything to their routine. The device can also take measurements in the dark.~The switch between 'full data analysis' and 'technical checks only' modes can be done remotely, making the cross-over seamless.~In the event that an alert is generated by the device, a medical assessment will take place either by phone or face to face appointment to evaluate the participant's condition."
224161952|NCT05007262|DRUG|Tangningtongluo tablets|Four pills each time and three times a day after meals.
224161953|NCT05007262|DRUG|Calcium dobesilate capsules|1 capsule at a time, tid,po.(morning, midday, and evening), used on an empty stomach.
224304578|NCT04472247|DIAGNOSTIC_TEST|Continuous EEG and EMG monitoring, with derived variables|All patients are monitored during their ICU stay by frontal EEG and EMG measuring devides, which are already in clinical use.
224304579|NCT00242736|DRUG|Esomeprazole|
224304580|NCT03276221|BEHAVIORAL|Abstinence|Cannabis users randomized to this condition will be enrolled in a contingency management intervention for 30 days of cannabis abstinence.
223475112|NCT02186041|DEVICE|Sacral Nerve Modulation|
223475113|NCT01450813|DRUG|Saline 0.06 ml/kg|IV Infusion x1 prior to laryngoscopy
223744170|NCT06132178|DEVICE|Sham Accelerated intermittent theta burst (aiTBS) rTMS treatment|The sham version is meant to look and feel like the active SAINT rTMS, but the main difference is that the brain is not being stimulated like the active condition.
224161954|NCT06087731|DRUG|Tocilizumab|Tocilizumab (8mg/kg) every 4 wekks
224161955|NCT02219737|DRUG|Carboplatin|Given IVPB
224161956|NCT02219737|DRUG|Etoposide|Given IVPB
224161957|NCT02219737|DRUG|Ibrutinib|Given PO
224161958|NCT02219737|DRUG|Ifosfamide|Given IV
224161959|NCT02219737|OTHER|Laboratory Biomarker Analysis|Correlative studies
224161960|NCT02219737|OTHER|Pharmacological Study|Correlative studies
224161961|NCT02219737|BIOLOGICAL|Rituximab|Given IV
224161962|NCT04246424|BEHAVIORAL|Fibit + Coaching|This intervention is a combination of the coaching and fitbit interventions
224304581|NCT00026364|DRUG|fluorouracil|
224304582|NCT00026364|DRUG|gefitinib|
224304583|NCT00026364|DRUG|irinotecan hydrochloride|
224304584|NCT00026364|DRUG|leucovorin calcium|
224304585|NCT00671138|BIOLOGICAL|Necator americanus|10 necator americanus larvae will be inoculated at week 0 with a further 5 larvae inoculated at week 12
224304586|NCT00671138|OTHER|Sham inoculation|A diluted amount of McIlhenny \& Co Tabasco Pepper Sauce will be applied via a gauze dressing at weeks 0 and 12.
224304587|NCT05528835|PROCEDURE|Frozen embryo transfer|All women in both groups will receive oral estradiol valerate 8 mg/ day from the second day of the menstrual cycle. Endometrial thickness will be assessed by vaginal ultrasonography at the tenth day of treatment. When endometrial thickness reached ≥ 7 mm all subjects, in addition to estrogen, they will receive progesterone vaginal suppositories 400 mg twice daily and 100 mg of progesterone intramuscularly daily. Frozen thawed embryo transfer will be at day 6 of progesterone. Estrogen and progesterone will be continued until 9-10 weeks of gestation
223475114|NCT01450813|DRUG|Rocuronium 0.2 mg/kg|IV Infusion x1 prior to laryngoscopy
223475115|NCT01450813|DRUG|Rocuronium 0.4 mg/kg|IV Infusion x1 prior to laryngoscopy
223475116|NCT01450813|DRUG|Rocuronium 0.6 mg/kg|IV Infusion x1 prior to laryngoscopy
223475117|NCT02090881|OTHER|Ultrasound scan|Trans cranial Doppler ultrasound examination of cerebral arterial blood flow
223744171|NCT04305834|DRUG|Abemaciclib|Given PO
223744172|NCT04305834|OTHER|Questionnaire Administration|Ancillary studies
223744173|NCT06497465|DRUG|Dolutegravir 50mg Tab|Participants will receive Dolutegravir 50mg
224161963|NCT04246424|BEHAVIORAL|Coaching|"Coaching Participants who are assigned coaching group will receive telephone coaching. Coaches follow a guide developed by Kelly Glazer Baron, Jennifer Duffecy, Kathryn Reid, and Lauren Caccamo. The first session is an approximately 30 minute engagement session, with the purpose of getting to know the participant to increase likelihood for participation. The end goal is to have participants express Desire, Ability, Reason, Need, Can (DARN-C) to make changes in sleep). The remainder calls (week 2-6) are follow-up calls lasting about 5 minutes. The goal of these calls is to keep participants motivated and address any issues with the Fitbit hard or software.~Participants will also receive weekly email lessons to their personal email address for 1-6 weeks."
223475118|NCT01935089|DRUG|Pegylated Interferon alpha 2b|1µg/kg/week
223475119|NCT01994213|DRUG|Famitinib|Famitinib 25 mg p.o. qd
223475120|NCT02052362|DRUG|ABT-450/r/ABT-267|ABT-450, ABT-267 and ritonavir
223475121|NCT05301439|PROCEDURE|Restoration with Resin|"Prophylaxis with prophylactic paste and rubber cup. Relative isolation (lip retractor, cotton roll and saliva sucker). Selective removal of carious tissue with dentin spoons at the dentin-enamel junction.~Cleaning the cavity with water. Application of the Universal Adhesive System (Shofu). Excess removal. Application of a new layer of adhesive system. Light rubbing and excess removal. Photoactivation - 20s. Insert Bulk Fill Resin (Shofu) in 4mm increments. Photoactivation for 20. Preservation. Clinical and radiographic control at 1, 3, 6 and 12 months."
223475122|NCT05301439|PROCEDURE|Hall Technique|"Prophylaxis with prophylactic paste and rubber cup. Relative isolation (lip retractor, cotton roll and saliva sucker). Clinical evaluation through inspection of the texture of the remaining dentin with a rounded exploratory probe.~Cleaning the cavity with water. Take drying. Proof of the steel crown. Relative isolation. Filling the inner part of the crown with bioactive resin cement or glass ionomer cement for cementation.~Clinical and radiographic control at 1, 3, 6 and 12 months."
223475123|NCT05301439|PROCEDURE|Conventional Steel Crown|"* Prophylaxis;~* Relative isolation;~* The preparation of the tooth will be performed conventionally with reduction of the occlusal, mesial and distal surface of 1 to 1.5 mm and selective removal of the decayed tissue;~* Cleaning the cavity with water;~* Slight drying;~* Trial of steel crown;~* Relative isolation;~* Filling the inner part of the crown with bioactive resin cement or glass ionomer cement for cementation.~* Clinical and radiographic control at 1, 3, 6 and 12 months."
223475124|NCT01400048|DIETARY_SUPPLEMENT|Aloe vera effervescent tablet (AVH200)|250 mg aloe vera and 60 mg ascorbic acid, Aloe Life®
223475125|NCT01400048|DIETARY_SUPPLEMENT|Placebo control|60mg Ascorbic acid
223475126|NCT00208364|DEVICE|Pinnacle Acetabular Cup System|A cementless acetabular cup with metal liner for use in total hip replacement
223475127|NCT04236284|DEVICE|Home-based tDCS|tDCS is a non-invasive neuromodulation technique that has been used to improved cognitive functions. It will be administered with a constant current intensity of 2 mA57 for 20 min per session/ 10 sessions total daily for 2 weeks (Monday to Friday). The device is a Soterix 1x1 tDCS mini-CT Stimulator (Soterix Medical Inc., NY) with headgear and 5 \_ 7 cm saline-soaked surface sponge electrodes.
223581964|NCT04114799|PROCEDURE|Hemodynamic management based on invasive fluid responsiveness parameters|In case of hypotension (reduction of MAP for more than 15% of individual blood pressure) the SPV value more than 8% will be used as a trigger for the bolus of 2 ml/kg of Plasmalyte (Baxter)
223581965|NCT04114799|PROCEDURE|Hemodynamic management based on noninvasive cardiac output and SVV measurement|In case of hypotension (reduction of MAP for more than 15% of individual blood pressure) the systemic vascular resistance (SVR) value will be used to trigger norepinephrine infusion. In patients with low SVR norepinephrine infusion will be started. In patients with high SVR value either fluid bolus (in patient with SVV value above 8%), or dobutamine infusion (in patients with SVV value below or equal 8%) will be used.
223581966|NCT05578638|COMBINATION_PRODUCT|Aloe Vera rosemary tropical application|10 ml of the Aloe Vera rosemary spray will be rubbed two times per day during the skin care on the areas at risk for PIs, including the patient's sacrum area, hip areas and heels area. This action will continue for 10 days
223581967|NCT05578638|COMBINATION_PRODUCT|aloevera tropical application|10 ml of the Aloe Vera spray will be rubbed two times per day during the skin care on the areas at risk for PIs, including the patient's sacrum area, hip areas and heels area. This action will continue for 10 days
223581968|NCT05578638|COMBINATION_PRODUCT|rosemary tropicalapplication|10 ml of the rosemary spray will be rubbed two times per day during the skin care on the areas at risk for PIs, including the patient's sacrum area, hip areas and heels area. This action will continue for 10 days
223581969|NCT05296980|BEHAVIORAL|REMINDER|The REMINDER program is a therapist-mediated manualized neuropsychological intervention, involving training skills to stimulate cognitive reserve, socialization and personal development, to diminish the risk of cognitive decline.
223581970|NCT05296980|BEHAVIORAL|Brain health Psychoeducation|Delivery of psychoeducation sessions about dementia modifiable risk factors, brain health solutions and lifestyle change tips.
223581971|NCT00206934|DRUG|Escitalopram|Either 10 mg of escitalopram or placebo will be administered to a group of healthy volunteers
223581972|NCT00206934|DRUG|escitaolpram|Either 15 mg of escitalopram or placebo will be administered to healthy volunteers
223581973|NCT06064773|DIAGNOSTIC_TEST|thoracic USG|the confirmation of double lumen tube placement with thoracic USG in thoracic surgery operations with one lung ventilation.
223581974|NCT03716752|PROCEDURE|Modified connective tissue graft wall with wing technique|the usage of bone graft and collagen barrier to treat recession defects accompanied vertical bony defcets in posterior teeth
223581975|NCT02155530|DRUG|Atorvastatin 40mg|homogenous neointimal pattern at baseline OCT and randomized to atorvastatin 40 mg group
223744174|NCT06497465|DRUG|Dolutegravir/Lamivudine 50 MG-300mg Oral Tablet [DOVATO]|Participants will receive Dolutegravir/Lamivudine 50 MG-300 MG Oral Tablet \[DOVATO\]
224161964|NCT04246424|BEHAVIORAL|Fitbit|Fitbit Participants in the fitbit group will receive a Fitbit Charge 3 black, and asked to wear it for 1-6 weeks. Participants will monitor their sleep through the sleep section in the Fitbit app on the smartphone. Participants will be provided login information so that researchers can access this data and asked to keep Bluetooth on. After week 6, participants can choose to continue to wear the device for the duration of the study (12 weeks). Though wear at weeks 7-12 is not required, researchers will still use any data that was collected from the fitbit during that time. At the completion of their participation, researchers retain the login information and the device is switched to a personal login of the participants choice.
224161965|NCT01916187|DRUG|Imetelstat|
223475128|NCT04236284|BEHAVIORAL|Prolonged Exposure Therapy|Prolonged Exposure Therapy is a treatment for PTSD that includes the following components: a) psycho-education about the common reactions to traumatic events and presentation of the treatment rationale (sessions 1 and 2), b) repeated in vivo exposure to traumatic stimuli (in vivo exercises are assigned as homework during sessions 3 through 11), c) repeated, prolonged, imaginal exposure to traumatic memories (imaginal exposure is implemented during sessions 3 through 11; patients listen to session audiotapes for homework between sessions), and d) relapse prevention strategies and further treatment planning (session 12).
223475129|NCT00218907|PROCEDURE|Educational video|
223581976|NCT02155530|DRUG|pravastatin 20 mg|Intervention description : homogenous neointimal pattern at baseline OCT and randomized to pravastatin 20 mg group
224161966|NCT03121807|OTHER|Oliclinomel N4 Per bag 1.5 L|Home parenteral nutrition with 910 kcal/day , including 33 g amino acid/day, 120 g glucose/day, 30 g lipid/day and electrolyte, micro-element and vitamin according to the nutritional status of subjects and followed the standard procedure of the hospital (Oliclinomel N4 Per bag 1.5 L), was infused continuously daily in an infusion time ranged between 18-24 hours.
224161967|NCT03121807|DRUG|Oxaliplatin|
224304588|NCT04644874|DIAGNOSTIC_TEST|Geriatric 8|The G8 is an eight-item screening tool, developed for older cancer patients. The G8 score ranges from 0 (heavily impaired) to 17 (not at all impaired), with a cut-off for potential frailty of ≤14.
224304589|NCT04644874|DIAGNOSTIC_TEST|modified Geriatric 8|The mG8 is a modified version of the Geriatric 8 screening tool, consisting of 6-items. The mG8 score ranges from 0 (not at all impaired) to 35 (heavily impaired), with a cut-off for potential frailty at ≥6.
223475130|NCT04483414|DRUG|68Ga PSMA-11 injection|Injection of 68Ga PSMA-11
223475131|NCT04483414|PROCEDURE|Positron Emission Tomography/Computed Tomography|PET/CT scan after 68Ga PSMA-11 injection
223475132|NCT02147171|DIETARY_SUPPLEMENT|VisionAce|
223475133|NCT02147171|DIETARY_SUPPLEMENT|Placebo|
223475134|NCT02271451|DEVICE|Q collar|collar worn around neck
223581977|NCT00337584|PROCEDURE|Pre-surgical screening|
223581978|NCT06054256|BEHAVIORAL|Group CBT-I|The group-based intervention will consist of 6 weekly sessions (90-min, 5-8 pregnant women in each group). The treatment components aim to address the behavioural, cognitive and physiological factors perpetuating insomnia with the followings: psycho-education about sleep and sleep hygiene (e.g., psychoeducation about sleep during pregnancy and normal development and patterns of infant sleep, psychoeducation on ways of improving infant sleep, strategies to limit the development of unwanted sleep associations, etc.), stimulus control, sleep restriction, relaxation training, structured worry time, cognitive restructuring (targeting sleep-related dysfunctional cognitions), and relapse prevention.
223581979|NCT06054256|BEHAVIORAL|App-based CBT-I|The smartphone app-based intervention will consist of 6 weekly sessions. The app-based intervention will involve a self-paced, fully automated digital programme with interactive components. The structure of the app involves six sequential modules (comparable to the six treatment sessions delivered in groups) with different elements to engage the users, such as animated videos, case vignettes, narration, quizzes, and homework assignment. Each module will be unlocked and released to the participants every week after the previous module has been completed. Personalised feedback will be provided by the app following the completion of sleep diary each week. Automated messages will be sent to the participants regularly via phone to remind them of implementing learned strategies after each module, as well as timely completing the treatment modules and sleep diaries.
223581980|NCT06054256|OTHER|Health related psychoeducation|The control group will receive 6 sessions of group-based health-related psychoeducation, a format that has been adopted in the previous research, in order to provide the credibility of the intervention to the participants, and to control for the potential effects of attention and nonspecific components.
223581981|NCT01133015|DEVICE|Fractional flow reserve|Fractional flow reserve measured by pressure wire
223581982|NCT01133015|DEVICE|IVUS|intravascular ultrasound
223581983|NCT00342706|PROCEDURE|Community based intervention|
223581984|NCT03507075|BEHAVIORAL|Contingency management: Contingent incentives|Monetary incentives are delivered to participants contingent upon on-time breathalyzer submissions and verified abstinence from alcohol.
223744175|NCT06497465|DRUG|Dolutegravir plus Tenofovir disoproxil fumarate (TDF)/ lamivudine (3TC)|Participants will receive Dolutegravir plus Tenofovir disoproxil fumarate (TDF)/ lamivudine (3TC)
223744176|NCT04434365|DRUG|Berberine|Berberine 100 mg twice daily for 4±1 weeks (Stage 1); then, 200 mg twice daily for 4±1 weeks (Stage 2); then, 300 mg twice daily for 4 weeks (Stage 3).
223744177|NCT04434365|DRUG|Aspirin|Aspirin 100 mg once daily for 12±1 weeks.
223744178|NCT04434365|DRUG|Clopidogrel|Clopidogrel 75 mg once daily for 12±1 weeks.
224304590|NCT04644874|DIAGNOSTIC_TEST|30 second chair stand test|Repetitions within 30 seconds
224304591|NCT04644874|DIAGNOSTIC_TEST|Handgrip Strength Test|Measured in kilograms
224304592|NCT01592305|DRUG|atazanavir|multiple oral doses
223475135|NCT06021327|PROCEDURE|Erector spinae plane block|Under aseptic precautions, the ultrasound transducer will be placed on the patient's back in a longitudinal paramedian orientation approximately 3 cm from the midline. A short-bevel, 80 mm 22-gauge insulated nerve block needle will be inserted using an in-plane approach to contact the tip of the T4 transverse process , After negative aspiration of blood, a total of 20 mL of 0.25% bupivacaine will be injected through the needle. Adequacy of the block will be confirmed by ultrasonographic visualization of fluid spread (seen as a lifting of the erector spina muscles in both block) and after 15 min, documenting the sensory blockade will be done by using a piece of ice or cold object. If the desired sensory level fails to be achieved (T4 - T8), patients will be excluded from the study.
223475136|NCT06021327|PROCEDURE|Retrolaminar block|Under aseptic precautions, the ultrasound transducer will be placed on the patient's back in a longitudinal paramedian orientation approximately 1 cm from the midline. A short-bevel, 80 mm 22-gauge insulated nerve block needle will be inserted using an in-plane approach to contact T4 lamina of the vertebra , After negative aspiration of blood, a total of 20 mL of 0.25% bupivacaine will be injected through the needle. And after 15 min, documenting the sensory blockade will be done by using a piece of ice or cold object. If the desired sensory level fails to be achieved (T4 - T8), patients will be excluded from the study.
223475137|NCT02337491|DRUG|Pembrolizumab|
223475138|NCT02337491|DRUG|Bevacizumab|
223475139|NCT00723229|DRUG|acyclovir|Acyclovir 400 mg PO BID for 28 days
223475140|NCT00703235|DRUG|Bevacizumab|
223475141|NCT03455517|DRUG|Venetoclax|Venetoclax and rituximab association
223475142|NCT03455517|DRUG|Rituximab|Venetoclax and rituximab association
223744179|NCT04434365|DRUG|Statin|Statins once daily for 12±1 weeks.
224161968|NCT03121807|DRUG|5Fluorouracil|
224161969|NCT03121807|DRUG|Leucovorin|
224161970|NCT01465451|PROCEDURE|curative resection for colorectal cancer|right hemicolectomy for right colon cancer, transverse colectomy for transverse colon cancer, left hemicolectomy for left colon cancer, sigmoid colectomy for sigmoid colon cancer, and anterior resection or abdominal-perineal resection for rectal cancer.
224304593|NCT01592305|DRUG|danoprevir|multiple oral doses
224304594|NCT01592305|DRUG|ritonavir|multiple oral doses
224161971|NCT01465451|DRUG|intra-operative 5-FU chemotherapy|"5-FU, 1000 mg/m2, injection into bowel lumen at the beginning of resection 5-FU, 200 mg/m2, injection into portal vein via mesentery vein at the end of tumor removal and bowel reconstruction.~5-FU, 300 mg/m2, left in abdominal cavity before incision closure. surgical procedures will be the same as described in ARM A."
224161972|NCT01091142|DRUG|NP001|Cohort 1: 0.3 mg/kg NP001(6:2 active:placebo) Cohort 2: 1.1 mg/kg NP001(6:2 active:placebo) Cohort 3: 2.1 mg/kg NP001(6:2 active:placebo) Cohort 4: 4.3 mg/kg NP001(6:2 active:placebo)
224161973|NCT01091142|DRUG|Placebo|Cohort 1: placebo Cohort 2: placebo Cohort 3: placebo Cohort 4: placebo
224161974|NCT00365742|DRUG|simvastatin|
224161975|NCT00365742|DRUG|red yeast rice|
224304595|NCT01592305|DRUG|tenofovir disoproxil fumarate|single oral doses
223475143|NCT03261076|BEHAVIORAL|Strategies Enhancing Reading in Older Underperf. Students|Strategies for Enhancing Reading in Older Underperf. Students (SERIOUS) combines two scientific, research based intervention programs, each meeting specific need of youth in detention: (1) Stevenson Reading Program, manualized and uniquely suited to students with phonological awareness, attention, and memory difficulties that may impact reading; and (2) Dr. Sharon Vaughn's well-documented, validated program, explicitly designed for older, severely reading-impaired students. SERIOUS also includes: (3) metacognitive strategies for self-regulated learning, and (4) A gamified extension of the intervention on a SmartPhone, designed to reinforce word-level skills (e.g., decoding, automaticity, and vocabulary), and including features efficacious for learning.
223475144|NCT04320498|BIOLOGICAL|prp injection|PRP was injected locally in the anal fissure area and glyceryl trinitrate was administered twice daily in the perianal region as in the control group.
223475145|NCT04320498|DRUG|Anrecta|self-administered topical glyceryl trinitrate (anrecta), in the perianal area twice a day
223475146|NCT04320498|BEHAVIORAL|sitz bath|participants were told to take a hot water sitz bath once a day
223475147|NCT04320498|DIETARY_SUPPLEMENT|nutrition regulation|The study participants were told to eat a fiber-rich diet and to drink least 2 liters of water daily
223475148|NCT00354315|BEHAVIORAL|Continuous medical education (CME)|The intervention will be held over a 6 months period. DECISION+ is a multifaceted intervention program that includes: Interactive workshops (3x180 min), reminders of expected behaviours and feedback.
223475149|NCT01368510|BEHAVIORAL|Intensive Cognitive Behavioral Therapy (CBT)|Nondrug psychotherapy administered daily 5 days/week for 4 weeks
223475150|NCT01368510|BEHAVIORAL|Waitlist|Minimal contact waitlist weekly for 4 weeks
223475151|NCT04213443|OTHER|Analysis of a patient registry|Analysis of a patient registry.
223475152|NCT05846750|DRUG|Obinutuzumab|"Induction (6 cycles, every 28 days/cycle): 1000 mg each time, administered on Days 1, 8, and 15 of Cycle 1, and on Day 1 of Cycles 2-6 ( 8 total infusions)；~Maintenance(12 cycles, every 2 months/cycle): 12 infusions of 1000 mg every 2 months for 2 years or until disease progression"
223475153|NCT05846750|DRUG|lenalidomide|"Induction( 6 cycles, every 28 days/cycle): 20 mg/day, oral, Dosing on Days 2-22, every 28 days/cycle of Cycles 1-6；~Maintenance(12 cycles, every 28 days/cycle):10 mg on Days 2-22 of each 28-day cycle, 12 cycles for 1 year or until disease progression"
223475154|NCT03848559|DEVICE|Airway management with a submerged model|Airway management with a submerged manikin using different airway devices in randomized order
223475155|NCT03106688|DIAGNOSTIC_TEST|fMRI imaging|Using blood oxygenation level dependent (BOLD) echo-planar imaging, fMRI will be used for characterising individual differences in the brain circuits.
224161976|NCT00365742|DRUG|pharmaceutical grade fish oil|
224161977|NCT00365742|BEHAVIORAL|therapeutic lifestyle changes|
224161978|NCT00504192|DRUG|Gemcitabine and Oxaliplatin|gemcitabine 1000mg/m2 IV on day 1 and oxaliplatin 85mg/m2 on day 2 every 2weeks
224161979|NCT04816370|DIAGNOSTIC_TEST|FSFI|2 group and 2 subgroup
224161980|NCT04346277|BIOLOGICAL|IC14, a monoclonal antibody against CD14|IC14 is a recombinant chimeric anti-human monoclonal antibody directed against human CD14. It recognizes both membrane-bound CD14 and soluble CD14.
224161981|NCT01098032|DEVICE|RenalGuard system|The RenalGuard™ System (PLC Medical Systems, Inc.) is a real-time measurement and real time matched fluid replacement device designed to accommodate the RenalGuard Therapy. The RenalGuard Therapy is based on the concept demonstrated by clinical data that high urine output is beneficial to patients with impaired baseline renal function who receive intravascular iodinated contrast medio (CM). The RenalGuard System seems to be ideal for the prevention of CI-AKI, by allowing an optimal urine flow rate \>300 ml/h. It is known that excessive diuresis can cause dehydration which increases the risk to the kidneys from CM. The RenalGuard System should allow the patient to achieve high urine output safely by maintaining the intravascular blood volume and avoiding the risk of over-or-under-hydration.
224161982|NCT01098032|DRUG|Systemic alone therapy|Patients allocated to the Systemic alone therapy group will receive 154 mEq/l of sodium bicarbonate in dextrose and H2O, according to the protocol reported by Merten et al. The initial intravenous bolus was 3 ml/kg per hour for 1 hour immediately before contrast injection. Following this, patients will receive the same fluid at a rate of 1 ml/kg per hour during contrast exposure and for 6 hours after the procedure. All patients will receive NAC (Fluimucil, Zambon Group SpA, Milan, Italy) orally at a dose of 1200 mg twice daily on the day before and on the day of administration of the contrast agent (total of 2 days)
224161983|NCT02262013|BEHAVIORAL|Parents as Coaches|Adolescents will receive lifestyle intervention (TEENS) and parents will receive parents as coaches (PAC) intervention.
224161984|NCT02262013|BEHAVIORAL|Parent Weight Loss|Adolescents will receive lifestyle intervention (TEENS) and parents will receive parent weight loss (PWL) intervention.
224161985|NCT03003013|PROCEDURE|Biphasic Bone Graft Material (BGM) in Combination With Autologous Platelet-rich Fibrin (PRF)|
224304596|NCT03303183|DEVICE|Standard Impression technique|Silicone impression technique
224304597|NCT03303183|DEVICE|Direct Ear Scanner|Direct Ear Scanner to scan the ear anatomy
224304598|NCT00681590|DIETARY_SUPPLEMENT|cholecalciferol (vitamin D)|400 IU daily (low dose)
224304599|NCT00681590|DIETARY_SUPPLEMENT|cholecalciferol (vitamin D)|2000 IU daily (high dose)
224304600|NCT00424775|DRUG|MK0683, vorinostat|vorinostat 300 mg or 400 mg once daily consecutive days (14 days) followed by 11 days of rest in the first cycle or 7 days of rest in the second or later cycle.
224304601|NCT04439773|DRUG|placebo|the control group will be given the same volume of saline.
224161986|NCT03136913|DEVICE|Cytoplast® TXT-200|Non-resorbable membrane
224161987|NCT03136913|DEVICE|MinerOss® Cortical and Cancellous Chips (FDBA)|Mixture of allograft mineralized cortical and cancellous chips
224161988|NCT03136913|PROCEDURE|Open Flap Technique|After extraction, the socket wound is left open to heal by secondary intention
224161989|NCT03136913|PROCEDURE|Closed Flap Technique|After extraction, the socket wound is closed by primary closure
223475156|NCT03106688|DIAGNOSTIC_TEST|[11C]carfentanil PET scan|\[11C\]carfentanil is used to measure μ-opioid receptor (MOR) availability in brain.
224161990|NCT03562520|BEHAVIORAL|Behavior change counseling|"Core modules: 1 psychoeducation session at week 0; 4 behavior change counseling (BCC) sessions will occur at weeks 0, 4, 8, and 12; phone calls and/or texting sessions (weeks 1-3, 5-7, 9-11, and booster calls and/or texts on weeks 16 and 20) from therapists.~Optional modules: Exercise coaching sessions; family involvement options will include participation in any aspect of the intervention; peer support options will include: group exercise classes on site, online Fitbit groups where adolescents can participate in competitions with each other and provide motivational support, and fitness support groups facilitated by registered social workers."
223475157|NCT03106688|DIAGNOSTIC_TEST|[18F]FMPEP-d2 PET scan|\[18F\]FMPEP-d2 is used to measure cannabinoid receptor type 1 (CB1) availability in brain and body.
223475158|NCT03106688|DIAGNOSTIC_TEST|[18F]-FDG PET scan|Brain and body insuin stimulated glucose uptake is measured with radioligand \[18F\]-FDG.
224161991|NCT02182999|DEVICE|Wound infiltration catheter|Wound catheter with multiple and laterally aligned holes is inserted through the intact skin via an 16G iv catheter 2 cm proximal-laterally from the proximal end of the dorsomedial skin incision and placed subcutaneously through the wound and medially around the first metatarsal so that the tip projects into the interdigital space 1/2.
223475159|NCT03106688|DIAGNOSTIC_TEST|Physical activity measures and fitness tests|Physical activity will be measured over one week following the screening check-up, before the PET measurement days. For the measurement, subjects will wear Polar M600 GPS Sports Watch for the measurement period. The fitness tests will be performed at the Paavo Nurmi Centre.
224161992|NCT02182999|DRUG|NaCl 0.9%|The catheter is connected to the perfusor line filled with saline 0.9% to allow continuous wound infiltration at a rate of 2 ml/h for 24 hours.
224304602|NCT04439773|DRUG|Lidocaine|the experimental group will be given 1-1.5mg/kg lidocaine and then 2mg/kg/h
223475160|NCT03106688|DIAGNOSTIC_TEST|Laboratory measurements|Weight, height, blood pressure, medical history, and current medication are determined. Body fat percentage will be assessed using BodPod plethysmograph.
224161993|NCT02182999|DRUG|Ropivacaine 0.2%|The catheter is connected to the perfusor line filled with Ropivacaine 0.2% to allow continuous wound infiltration at a rate of 2 ml/h for 24 hours.
224161994|NCT06386536|DEVICE|Intelligent stationary bike|A stationary motorized bike prototype that can evaluate lower limb functions such as strength, coordination, range of motion, and tonus. Based on the evaluation results, the iBike proposes a training program that is specific to each individual needs. Moreover, the intelligent bike offers diverse pedaling modes such as forward and backward pedaling, assisted pedaling, isotonic pedaling and pedaling with sensory stimulations.
224161995|NCT06386536|DEVICE|Conventional stationary bilke|A conventional stationary bike that can be found in gyms or rehab centers.
224161996|NCT02762123|DRUG|BMS-986142 200mg|
224161997|NCT02762123|DRUG|BMS Drug-drug interaction cocktail (montelukast, flurbiprofen, omeprazole, midazolam, and digoxin)|
224161998|NCT02762123|DRUG|BMS-986142 350mg|
224161999|NCT03216395|DEVICE|Over-the-scope Clips|Over-the-scope Clips is mounted onto a transparent cap, which is attached to the tip of the endoscope. To deploy the claw device, a cogwheel at the scope head is turned pulling a trip string. This in turn retracts the cap releasing the OTSC onto tissue.
224162000|NCT03216395|DEVICE|Hemo-clipping|Hemo-clipping \<=20 clips
224162001|NCT03216395|DEVICE|thermo-coagulation|contact thermo-coagulation \< = 8 pulses
224162002|NCT03216395|DRUG|Epinephrine|epinephrine injection (diluted 1:1000) beneath peptic ulcer \<20 mls
224162003|NCT03228992|DRUG|Ibuprofen 400 mg|Subjects will receive 4 doses of oral ibuprofen over a 24 hour period.
224304603|NCT01791153|DRUG|Tocilizumab|Tocilizumab will be administered at a dose of 162 mg as SC injection qw or q2w for 52 weeks in Part 1 of the study and at a dose 162 mg as SC injection qw for 104 week at the discretion of the investigator in Part 2 of the study.
224304604|NCT01791153|DRUG|Prednisone|Prednisone will be administered at tapering oral doses as tablets daily for 26 or 52 weeks according to the protocol-defined schedule in Part 1 of the study. Prednisone will also be administered as escape therapy to treat disease flares in an open-label manner during Part 1 at a dose and duration selected by the investigator.
223475161|NCT03106688|DIAGNOSTIC_TEST|Questionnaires|All the participants will complete a self-administered questionnaire at baseline, and at 12 months, for assessment of leisure-time physical activity (LTPA). The following questionnaires will be completed: Behavioural inhibition / activation, Dutch Eating Behaviour Questionnaire, Yale Food Addiction Scale, PCL-Revised, Food craving State / Trait (FCS-FCST) questionnaires, Autism Spectrum Quotient, State-Trait Anxiety Questionnaire and Pain Sensitivity Questionnaire.
223475162|NCT03106688|DIAGNOSTIC_TEST|Hyperinsulinemic euglycemic clamp|Low-dose hyperinsulinemic euglycemic clamp technique will be used to promote glucose uptake and measure insulin sensitivity of the subjects. In the clamp study subjects are administered intravenous insulin at a steady rate of 0.25 mU/kg/min and normoglycemia is maintained using a variable rate infusion of 20 % glucose based on plasma glucose measurements, which are performed every 5-10 min from arterialized venous blood.
223581985|NCT03507075|BEHAVIORAL|Contingency management: Noncontingent incentives|Monetary incentives are delivered to participants contingent upon on-time breathalyzer submissions only with no contingency on alcohol use.
223581986|NCT00156169|DRUG|Dunaliella|
223581987|NCT05293678|DRUG|REGN15160 (IV)|Administered in single intravenous (IV) dose
223581988|NCT05293678|DRUG|Matching Placebo (IV)|Administered in single IV dose
223581989|NCT05293678|DRUG|REGN15160 (SC)|Administered in single subcutaneous (SC) dose
223581990|NCT05293678|DRUG|Matching Placebo (SC)|Administered in single SC dose
223581991|NCT00418054|DRUG|Nitazoxanide plus peginterferon alfa-2b|
223581992|NCT00418054|DRUG|Peginterferon alfa-2b|
224162004|NCT03228992|OTHER|Placebo|Subjects will receive 4 doses of placebo over a 24 hour period.
224162005|NCT06138392|DEVICE|Dental implant (ELEMENT RC INICELL, Thommen Medical)|Dental implant
224304605|NCT01791153|DRUG|Tocilizumab Placebo|Tocilizumab placebo will be administered as SC injection qw or q2w for 52 weeks in Part 1 of the study.
223581993|NCT03346577|DEVICE|stent or balloon|Endovascular treatment with stent or balloon according to current practice
224162006|NCT05241288|COMBINATION_PRODUCT|Albuterol eMDPI DS|"Albuterol sulfate electronic multidose dry powder inhaler (Albuterol eMDPI) Digital System (DS) with 3 component devices:~Device 1: Albuterol eMDPI Device 2: Albuterol eMDPI Patient-facing smart device application (App) Device 3: Digital Health Platform (DHP, Cloud solution)"
224162007|NCT02252588|DRUG|Chlorhexidine|Oral Rinse
224162008|NCT02252588|OTHER|Placebo|Oral Rinse
224162009|NCT02521168|DRUG|Oral triiodothyronine|Oral triiodothyronine is given peri-operatively through naso-gastric tube
224162010|NCT02521168|DRUG|Placebo|Placebo consist of saccharin lactis that has the same appearance as Tetronine
224162011|NCT02616536|OTHER|Teaching methods|the two teaching methods will be given to two groups of students and their knowledge gain will be analysed
224304606|NCT01791153|DRUG|Prednisone Placebo|Prednisone placebo will be administered as tablets orally daily according to the protocol-defined schedule (from Week 26 to Week 52) in Part 1 of the study.
223475163|NCT03885947|BIOLOGICAL|Cord blood stem cells|CD34 selected VPA expanded umbilical cord blood cells used in combination with or without unmanipulated umbilical cord blood .
223475164|NCT03885947|DRUG|Valproic Acid|Valproic Acid (VPA) expanded cord blood stem cells
223475165|NCT03885947|DRUG|Fludarabine|Fludarabine 150 mg/m2
223475166|NCT03885947|DRUG|cytoxan|Cytoxan 50 mg/m2
223475167|NCT03885947|DRUG|Thiotepa|Thiotepa 10 mg/m2
223475168|NCT03885947|BIOLOGICAL|TBI|TBI 400cGy
223475169|NCT01057355|PROCEDURE|EUS and/or ERCP with ethanol injections of pancreatic cyst|Lavage of cyst with 80% ethanol
223475170|NCT04474340|DRUG|COVID-19 Convalscent Plasma|The source convalescent plasma is typically collected from individuals who have recovered from COVID-19 which contains antibodies titer against SARS-CoV-2 and is administered to patients with COVID-19. Donor eligibility criteria and qualification are based on American Accredited Blood Banks ( AABB) standards , including questionnaires and relevant transfusion-transmitted infections testing are performed. Furthermore, pathogen inactivation will be performed for each unit, CCP was only collected from individuals who meet all donor eligibility requirements (21 CFR 630.10 and 21 CFR 630.15). Donors must be found positive at a diagnostic test of nasopharyngeal swab at the time of illness and positive serological test for SARS-CoV-2 antibodies after recovery. All donors should have negative HLA antibodies.
223475171|NCT04383197|BEHAVIORAL|Endurance exercise training|Ergometer cycling at 70 % of VO2 max, 45 minutes, 3 times a week
223475172|NCT04383197|DRUG|Semaglutide|3 months of therapeutic treatment with semaglutide
223475173|NCT04951141|BIOLOGICAL|anti-GPC3 CAR-T cells|A single arm, open-label pilot study is designed to determine the safety and efficacy of anti-GPC3 CAR-T cells in patients with GPC3-positive advanced liver cancer.
223475174|NCT00839124|BIOLOGICAL|Clinical Center Reference Endotoxin (CCRE)|inhalation challenge with 20,000 EU CCRE
223475175|NCT00839124|BIOLOGICAL|Clinical Center Reference Endotoxin (CCRE)|inhalation of 20,000 EU CCRE
223475176|NCT04082052|BEHAVIORAL|Single Session Interventions|A single session intervention either active (for self-dislike) or placebo (feelings disclosure)
223475177|NCT02896166|OTHER|microwave ablation|eligible patients will be treated with microwave ablation in the primary tumor sites
223475178|NCT02025075|DRUG|Rocuronium|Rocuronium 0.6 - 1.2 mg/kg with the dose adjusted to achieve 1-2 post-tetanic counts (Deep NMB) or 1-2 twitches in the train-on-four (Moderate NMB).
223475179|NCT01064544|PROCEDURE|light therapy with the device: EnergyLight|2 hr of light therapy during each hemodialysis session
223475180|NCT03766035|DEVICE|SpyGlass DS I - II|The SpyScope™ DS Access and Delivery Catheter (SpyScope™ DS Catheter) is a sterile, single-use endoscope that enables access and delivery of accessories to targeted pancreaticobiliary anatomy and displays live video when connected to a Spy Glass DS Digital Controller.
223475181|NCT03073486|DRUG|Olumacostat Glasaretil Gel, 5.0%|Gel containing Olumacostat Glasaretil
223475182|NCT03073486|OTHER|Olumacostat Glasaretil Gel, Vehicle|Vehicle (placebo) gel
223475183|NCT02391831|OTHER|Strength, function and activity measurements|
223475184|NCT02391831|OTHER|Muscle MRI|
223475185|NCT02391831|OTHER|Electrophysiology measurements|
223475186|NCT02391831|OTHER|Blood sampling for biomarker analysis|
223475187|NCT03236454|DEVICE|DC-Stimulator MC, NeuroConn|20 minutes of 2 mA anodal stimulation; Electrode placement: left dorsolateral prefrontal cortex (F3, EEG 10/20 system), return electrode at the right upper arm.
223475188|NCT01120262|GENETIC|gene expression analysis|
223475189|NCT01120262|GENETIC|polymorphism analysis|
223475190|NCT01120262|OTHER|laboratory biomarker analysis|
223475191|NCT04960215|DRUG|Coenzyme Q10|Coenzyme Q10 (myoquinon) capsule 100mg, 5 capsules a day.
223475192|NCT04960215|DRUG|Placebo|A soft gelatin capsule containing soy oil, 5 capsules a day.
223475193|NCT03469115|DIAGNOSTIC_TEST|Serum blood|Serum blood test for laboratory analysis to determine level of alpha defensin
223475194|NCT00239148|DRUG|E1 and G1|
223475195|NCT06525116|OTHER|MRD|Calculate the 3-year EFS based on the MRD status (MRD positive and negative groups)
223475196|NCT02763774|OTHER|Walking exercise|Participants will be sumitted to progressive exercises and supervised by a physiotherapist, active-assisted to free active exercise in upper and lower limbs, stationary running and walking. The intensity of walk will be determined by the Borg's sujective effort perception scale - (modified from zero to 10). On first postoperative day, participants will perform exercises in supine position. From the second to the fifth postoperative day, they will perform progressive walking.
223475197|NCT02763774|OTHER|Stationary cycling exercise|Participants will be sumitted to progressive exercises and supervised by a physiotherapist, active-assisted to free active exercise in upper and lower limbs. From the first to the fifth postoperative day, they will perform progressive cycling exercise.The intensity of cycling will be determined by the Borg's sujective effort perception scale - (modified from zero to 10).
224162012|NCT04027036|BIOLOGICAL|Inactivated poliovirus vaccine in reduced doses|"contains the following excipients: 2-phenoxyethanol (2.5 mg), water for injection and diluent solution and phosphate buffer having the following composition: sodium phosphate, sodium chloride, potassium chloride, magnesium sulfate, phenol red and calcium chloride.~dosage:0,1ml duration: first dose: month 2 of age; second dose: month 4 of age"
224162013|NCT03723785|DRUG|Insulin icodec|Participants will receive single dose of Insulin 287 subcutaneously (under the skin) on Day 1
223475198|NCT02763774|OTHER|Neuromuscular electrical stimulation|Participants will be sumitted to progressive exercises and supervised by a physiotherapist, active-assisted to free active exercise in upper and lower limbs. From the first to the fifth postoperative day, quadriceps and gastrocnemius muscles will be percutaneous stimulated with the following parameters: Synchronic mode, 50Hz, 400uS, time on 10s, time off 20s, intensity as tolerated by the patient.
223475199|NCT03671070|DRUG|Epinephrine|IV Low dose Boluses
223475200|NCT03671070|DRUG|Traditional management of shock|"1. Initial resuscitation: Push boluses of 20 cc/kg isotonic saline or colloid up to and over 60 cc/kg until perfusion improves or unless rales or hepatomegaly develop~2. Fluid refractory shock: Begin inotrope IV/IO. Use atropine/ketamine IV/IO/IM to obtain central access and airway if needed. Reverse cold shock by titrating central dopamine or, if resistant, titrate central epinephrine. Reverse warm shock by titrating central norepinephrine.~3. Catecholamine resistant shock: Begin hydrocortisone if at risk for absolute adrenal insufficiency."
223475201|NCT03173417|BIOLOGICAL|IM19 CAR-T|T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor
224162014|NCT05374291|DRUG|Dapagliflozin 10 mg/day (oral)|Patients take 10 mg dapagliflozin or matching placebo once daily in the morning
224162015|NCT05374291|DRUG|Placebo|Patients take 10 mg dapagliflozin or matching placebo once daily in the morning
224162016|NCT05782348|BEHAVIORAL|Cognitive behavioral intervention|A six-session CBI Intervention component will be used with the TEST GROUP I. This will examine a cognitive behavioral intervention designed to improve tooth brushing and oral hygiene. The components include oral health education, values-based activities, motivational interviewing, goal setting, problem solving skills, cognitive restructuring, verbal reinforcement and stress management.
224162017|NCT05782348|OTHER|Colgate smart toothbrush|A Colgate smart toothbrush that provides the user with details on toothbrushing habits and frequency
224162018|NCT03039790|BIOLOGICAL|NoV Vaccine|NoV vaccine injection administered.
224162019|NCT01520688|DRUG|Fluticasone, Budesonide, Beclomethasone|Fluticasone 100 mcg bid Budesonide 180 mcg bid Beclomethasone 80 mcg bid
224162020|NCT01520688|DRUG|Fluticasone, Beclomethasone, Budesonide|Fluticasone 100mcg BID Beclomethasone 80 mcg BID Budesonide 180 mcg BID
224162021|NCT01520688|DRUG|Budesonide, Fluticasone, Beclomethasone|Budesonide180 mcg BID Fluticasone 100 mcg Beclomethasone 80 mcg BID
224162022|NCT01520688|DRUG|Budesonide, Beclomethasone, Fluticasone|Budesonide 180 mcg BID Beclomethasone 80mcg BID Fluticasone 100mcg BID
223475202|NCT03173417|DRUG|fludarabine and cyclophosphamide|Two days before cell infusion,all patients will be treated with fludarabine and cyclophosphamide for 3 days
224162023|NCT01520688|DRUG|Beclomethasone, Fluticasone, Budesonide|Beclomethasone 80 mcg BID Fluticasone 100mcg BID Budesonide 180 mcg BID
224162024|NCT01520688|DRUG|Beclomethasone, Budesonide, Fluticasone|Beclomethasone 80mcg BID Budesonide 180 mcg BID Fluticasone 100mcg BID
224162025|NCT04912661|DIETARY_SUPPLEMENT|Ferinject|intravenous iron carboxymaltose
224162026|NCT01619813|DRUG|Docetaxel, Reolysin and Prednisone|Docetaxel 75 mg/m2 will be delivered as a 1-hour infusion q 3 weekly beginning on day 1, cycle 1. Reolysin will be delivered as a 1-hour infusion days 1-5. On day 1 of each cycle, when both agents are given, the docetaxel will be given first. Prednisone 5 mg BID will be given beginning day 1. Each cycle is 3 weeks in length.
224162027|NCT01619813|DRUG|Docetaxel and Prednisone|Docetaxel 75 mg/m2 will be delivered as a 1-hour infusion q 3 weekly. Prednisone 5mg BID will be given beginning Day 1. Each cycle is 3 weeks in length.
224162028|NCT04328441|DRUG|BCG Vaccine|Intracutaneously 0.1ml BCG vaccine, which accounts for 0.075mg of attenuated Mycobacterium bovis
224162029|NCT04328441|DRUG|Placebo|Intracutaneously 0.1ml NaCl 0,9%
224162030|NCT01498536|BEHAVIORAL|aerobic exercise|3 times per week for 12-weeks
224162031|NCT05001568|DEVICE|Immediate in-brace correction: Conventional Brace|The trunk surface will be scanned to reconstruct a numerical model of the patient's trunk, this reconstruction will help to produce the optimized brace. The patient skeletal will also be reconstructed from a bilateral radiograph using an EOS imaging system. Each patient will try both the control and the test brace. Radiographic (supine position) and patient-reported data will be gathered and analyzed to observe changes between the immediate correction of the braces. The SRS-22r will be collected. The study protocol requires no additional visits beyond the standard of care. There will be one additional radiograph compared to the standard of care.
223475203|NCT01483118|DRUG|Cinnamon Extract|Purified aqueous abstract of cinnamon in 125mg capsules, which would be taken orally before each meal, for a total of 1,500mg/day for 6 months.
224162032|NCT05001568|DEVICE|Immediate in-brace correction: Optimized Brace|The trunk surface will be scanned to reconstruct a numerical model of the patient's trunk, this reconstruction will help to produce the optimized brace. The patient skeletal will also be reconstructed from a bilateral radiograph using an EOS imaging system. Each patient will try both the control and the test brace. Radiographic (supine position) and patient-reported data will be gathered and analyzed to observe changes between the immediate correction of the braces. The SRS-22r will be collected. The study protocol requires no additional visits beyond the standard of care. There will be one additional radiograph compared to the standard of care.
224304607|NCT01791153|DRUG|Corticosteroids|Participants without sustained remission at Week 52 will receive corticosteroids at a dose and schedule at the discretion of the investigator for a maximum of 104 weeks.
224304608|NCT01791153|DRUG|Methotrexate|Participants without sustained remission at Week 52 will receive methotrexate at a dose and schedule at the discretion of the investigator for a maximum of 104 weeks.
223475204|NCT01483118|DIETARY_SUPPLEMENT|Placebo|Placebo capsules containing ground cereal.
223475205|NCT02791256|DRUG|Ribavirin|
223475206|NCT02791256|DRUG|peginterferon alfa-2a|
224162033|NCT05001568|DEVICE|Long-term bracing: Conventional Brace|After comparing the immediate correction of the braces, each patient will be using either the test or the control brace for a period of two years. There will be follow-up visits, between 6 months and 1 year depending on the patient growth. The brace will be renewed using the same procedure to adapt to the patient's growth. The study protocol requires no additional visits beyond the standard of care. There will be no additional radiograph compared to the standard of care. Compliance monitors are installed in each brace.
223475207|NCT03518359|BEHAVIORAL|Enhanced Stress Resilience Training (ESRT)|ESRT involves six weekly 90-minute group classes and one 2 - 4 hour retreat. Classes focus on developing mindfulness skills (i.e. sustained attention, open monitoring, emotional regulation, meta-cognition) in the context of skills and concepts for managing stress, particularly in practicing medicine. Homework consists of 20 minutes per day of mindfulness exercises following guided meditation CDs or videos of movement-based practice, and practice will be reported periodically by text. A 3-hour outdoor retreat occurs at week six. The central exercises of ESRT are the body scan, sitting meditation, chi gong and yoga. For both arms, the weekly teaching sessions occur on a workday morning during protected time at Parnassus, Mission Bay or Zuckerberg San Francisco General Hospital campus.
224162034|NCT05001568|DEVICE|Long-term bracing: Optimized Brace|After comparing the immediate correction of the braces, each patient will be using either the test or the control brace for a period of two years. There will be follow-up visits, between 6 months and 1 year depending on the patient growth. The brace will be renewed using the same procedure to adapt to the patient's growth. The study protocol requires no additional visits beyond the standard of care. There will be no additional radiograph compared to the standard of care. Compliance monitors are installed in each brace.
224304609|NCT01483859|OTHER|preoperative liver stiffness measurement|Liver stiffness measurement (LSM) using Fibroscan is a newly introduced noninvasive tool that generates an elastic wave using a vibrator applied to the thoracic wall at the level of the right lobe of the liver and measures the prolongation velocity of the wave, which is directly associated with liver stiffness (LS).
224304610|NCT04557306|BIOLOGICAL|CBT101 cells, every 2 weeks|CBT101 cells, every 4 weeks
223581994|NCT02552862|DRUG|Vivomixx®|Vivomixx® is a probiotic mixture of 8 proprietary strains, namely Streptococcus thermophilus DSM 24731, bifidobacteria (B. breve DSM 24732, B. longum DSM 24736, B. infantis DSM 24737) and lactobacilli (L. paracasei DSM 24733, L. acidophilus DSM 24735, L. delbrueckii subsp bulgaricus DSM 24734, L. plantarum DSM 24730). The active agent will be supplied as a 4.4g sachet at a dose of 450 billion live bacteria per sachet with maltose and silicon dioxide as excipients.
223581995|NCT02552862|DRUG|Placebo|Placebo will be formulated as identical in appearance and administered according to the same schedule as the active agent. Placebo contains maltose and silicon dioxide as inactive agent.
223581996|NCT05152810|OTHER|Transcranial Magnetic Stimulation sessions|"* 10 sessions daily from Monday to Friday (2 sessions/day, 15 minutes apart) during the 1st week = attack phase~* 2 weekly maintenance sessions the following week (S2), then 1 weekly maintenance session the following 4 weeks (S3, S4, S5 and S6) = maintenance phase"
223581997|NCT05152810|OTHER|Evaluations|"Before the first stimulation session, just after the 10th session, at 6 weeks, at 12 weeks and at 24 weeks.~The assessment included the collection of AEs/EIGs, the TAC, the VAS on desire to smoke, the TCQ, the QSU, BDI-II (except at S1), the CO tester, GoNoGo, the PQI and the ISI."
223581998|NCT05549154|DRUG|High-dose vitamin D2 softgels|5000U/capsule of vitamin D2 soft capsule; High-dose VD group 50,000 U/week, 5 vitamin D2 softgels given twice a week each time; 25(OH)D \> 80ng/ml after 3 months of intervention or within 3 months in both groups, changed to 5,000 U/ weekly maintenance until the full 6 months of intervention. To prevent unmasking, the maintenance dose was still given twice weekly (the first time 1 vitamin D2 capsule + 4 placebo capsules were given and the second time 5 placebo capsules were given)
223581999|NCT05549154|DRUG|low-dose vitamin D2 softgels|5000U/capsule of vitamin D2 soft capsule; low-dose VD group 25,000 U/week, 3 vitamin D2 softgels + 2 placebo in the first dose, 2 vitamin D2 softgels + 3 placebo in the second dose, 25(OH)D \> 80ng/ml after 3 months of intervention or within 3 months in both groups, changed to 5,000 U/ weekly maintenance until the full 6 months of intervention. To prevent unmasking, the maintenance dose was still given twice weekly (the first time 1 vitamin D2 capsule + 4 placebo capsules were given and the second time 5 placebo capsules were given);
223582000|NCT05549154|DRUG|placebo|placebo was filled with excipients (aniseed ether, refined vegetable oil), and the shape and size were the same as vitamin D2 soft capsule.the control group was given placebo, 5 placebo capsules twice weekly for 6 months of the intervention. The medication was dispensed by a designated person (not the investigator) in advance and independently according to the patient's medication number (only the drug number was provided on the outer packaging).
223582001|NCT06229054|DRUG|Dexmedetomidine|Dexmedetomidine (DEX), an α2-agonist with more promising pharmacokinetic and pharmacodynamic characteristics than clonidine has been proved to have a positive effect on postoperative pain intensity and to reduce opioid consumption
223582002|NCT06229054|DRUG|Bupivacaine Hydrochloride|local anesthesic which works through blocking sodium channels
223582003|NCT01326832|DEVICE|Primoris|Total hip arthroplasty with the new Primoris femoral component
223744180|NCT06071715|DEVICE|ACTIVE cryoneurolysis|Cryoneurolysis of the major nerves of the thigh (or their distal counterparts) in the residual limb: The cryoneurolysis device will be triggered using 1 cycle of 5.5-minute argon activation followed by a 30-60 second defrost period with helium Initial treatment: Cryoneurolysis of the major nerves of the thigh (or their distal counterparts) in the residual limb: The cryoneurolysis device will be triggered using 1 cycle of 5.5-minute argon activation followed by a 30-60 second defrost period with helium (Varian) or 2 cycles of 2-minute gas activation with an active probe separated by a 30-60 second defrost (Epimed). For active treatment, the gas will be deployed to the probe tip where a drop in temperature will result in cryoneurolysis.
224304611|NCT04557306|BIOLOGICAL|CBT101 cells, every 4 weeks|CBT101 cells, every 4 weeks
224304612|NCT06989840|DRUG|TVB-3567|Orally administered capsule
224304613|NCT06989840|DRUG|Placebo|Orally administered capsule
224304614|NCT00975286|DRUG|Lixisenatide (AVE0010)|Self administered by subcutaneous injections once daily within the hour preceding breakfast.
224304615|NCT00975286|DRUG|Placebo|Self administered by subcutaneous injections once daily within the hour preceding breakfast.
224304616|NCT00975286|DRUG|Insulin glargine|Dose to be adjusted to maintain a fasting SMPG between 100 and 80 mg/dL (5.6 and 4.4 mmol/L), inclusive.
223582004|NCT04215432|DEVICE|Gel containing propolis extract, nanovitamin C and nanovitamin E|The patient had to use the gel as a toothpaste and apply it with an interdental brush in mesial and distal aspects of the implant with peri-implant mucositis. during 1 month.
223582005|NCT04215432|DEVICE|Placebo|The patient had to use the gel as a toothpaste and apply it with an interdental brush in mesial and distal aspects of the implant with peri-implant mucositis.
224162035|NCT00498368|DRUG|Intravenous Rituximab|"Rituximab Therapy \[27 Patients\]~* Rituximab 1 gm IV on Treatment Day 1~* Rituximab 1 gm IV on Treatment Day 15~* Rituximab 1 gm IV on Treatment Day 168~* Rituximab 1 gm IV on Treatment Day 182"
224162036|NCT00498368|DRUG|ACE/ARB|ACE inhibitors and /or ARBs will be used to achieve a blood pressure goal of \<130/80 millimeters of mercury (mmHg). Patients not attaining the target blood pressure with an ACE inhibitor or ARB alone should be treated with the combination of ACE inhibitor (ACEi) + ARB
224304617|NCT00975286|DEVICE|Pen auto-injector|Lantus® SoloStar® OptiClik®
224304618|NCT00975286|DRUG|Metformin|Metformin to be continued at stable dose (at least 1.5 gram per day) up to Week 24.
224304619|NCT00975286|DRUG|Thiazolidinedione (TZD)|TZD (either rosiglitazone or pioglitazone) if given, to be continued at stable dose up to Week 24.
224304620|NCT00027079|DRUG|ondansetron (Zofran)|
224304621|NCT00027079|DRUG|naltrexone (ReVia)|
224304622|NCT00027079|BEHAVIORAL|Cognitive Behavioral Therapy|
224304623|NCT01487070|DRUG|Macugen (Pegaptanib Sodium)|"Pegaptanib sodium drug substance is a pegylated (40 kDa branched PEG molecule consisting of two 20 kDa PEG arms) anti-VEGF aptamer. It is formulated in phosphate buffered saline at pH 6-7. Sodium hydroxide or hydrochloric acid may be added for pH adjustment.~Pegaptanib sodium is formulated at 0.3mg/90µl and presented in a USP Type I glass barrel syringe sealed with a bromobutyl rubber stopper. A 30-guage needle is fixed to the end of the syringe after removal of the rubber stopper. The syringe comes in a sealed foil pouch, and the 30-gauge needle is added to the sterile injection field separately. The drug product is preservative-free and intended for single use by intravitreous injection only."
223475208|NCT03518359|BEHAVIORAL|Active Control|Control group participants will meet for 6 weeks, 90 minutes each week, for classes focuses on stress management through rest and exercise, with equivalent protected time and small group bonding but without the use of contemplative practices. Topics will include the history of surgery, patient perspective, the physician personality, technical mastery, fallibility and limits, balancing compassion and detachment and knowing when not to operate. For daily practice, control participants will be asked to devote 20 min per day to stress management through rest and exercise again reported daily by text.
223475209|NCT03785028|BEHAVIORAL|working memory and attention|working memory and attention tasks
223475210|NCT02932657|OTHER|Non interventional study|First individual interviews will be set up with teenagers of Nantes University Hospital . Then, focus group will be conduct with patients and professionals in Nantes and Foch University Hospital.
223475211|NCT03098316|DIAGNOSTIC_TEST|Metabolomics analysis of patient samples|Metabolomics analysis of patient samples by mass spectrometry and nuclear magnetic resonance spectroscopy.
223475212|NCT01746719|DRUG|Etodolac Capsules USP 300 mg|300 mg capsule once a day
223475213|NCT01746719|DRUG|Etodolac|500 mg tablet once a day
223475214|NCT03757416|OTHER|Data collection|If it has been determined that the patient will be undergoing flexor tenosynovectomy for the treatment of recurrent carpal tunnel syndrome, the patient will be asked to participate in this data collection study.
223475215|NCT02870491|BEHAVIORAL|Free Distribution|Caretakers of children under 5-years-old will have access to free ORS and zinc
223475216|NCT02870491|BEHAVIORAL|Preemptive Delivery|Caretakers of children under 5-years-old will have ORS and zinc delivered to their home
223475217|NCT05704816|OTHER|Spinal anesthesia application|The success of the needles with different tip designs and thicknesses used in spinal anesthesia application
223582006|NCT06422637|DIAGNOSTIC_TEST|Liquid Biopsy Early Screening|An early screening model for lung cancer aids in identifying individuals with early-stage lung cancer. Those with positive indications of lung cancer will subsequently undergo confirmatory clinical assessments using Low-Dose Computed Tomography (LDCT) in sequence. Ultimately, a definitive diagnosis of lung cancer is established through surgical and pathological examination.
223582007|NCT03890328|PROCEDURE|radiofrequency ablation|apply RF therapy to the treatment of splenic trauma
223582008|NCT02757612|RADIATION|laser diode|laser diode
224162037|NCT00498368|DIETARY_SUPPLEMENT|Omega-3 Fatty Acid Fish Oil Supplement|Omega-3 Fatty Acid Fish Oil Supplement 3.6 gm eicosapentaenoic acid (EPA)/day
223475218|NCT02104440|BIOLOGICAL|"Sequential infusion of allogeneic mesenchymal stem cells expanded in vitro"|
223475219|NCT03844841|DRUG|Propofol|At minimum 5 minutes before start of sedation for atrial fibrillation ablation a bolus of fentanyl (20-50 µg) will be administered. Thereafter, sedation is induced via the continuous infusion of propofol using a target-controlled infusion (TCI) pump. The effect-site propofol concentration will be initially set to 1.5 µg/ml, unless the patient is already sedated by fentanyl. Subsequently, an effect-site propofol concentration of 1 µg/ml will be chosen adjusted stepwise (using steps of 0.3 µg/ml) to reach a target score of 2-3 on the MOAA/S scale. In case of pain fentanyl can be administered bolus-wise (10-30 µg) at the cardiologists discretion.
224304624|NCT02373670|BEHAVIORAL|Promotion of positive deviance behaviors|Using locally derived positive deviance findings to inform a behavioral intervention
224304625|NCT02373670|BEHAVIORAL|Promotion of healthy behaviors|Using standardized healthy behavior education (EatPlayGrow curriculum from NHLBI)
224304626|NCT02357342|DRUG|Sirolimus|intravitreal injection
224304627|NCT02357342|DRUG|Standard of Care intravitreal injections of anti-VEGF|intravitreal injections of anti-VEGF
224304628|NCT02620215|DEVICE|Cervical Ripening Balloon|Cook® Cervical Ripening Balloon with Stylet Order number G19891 Reference Part Number J-CRBS-184000 Catheter (Fr) 18.0 Length (cm) 40 Balloon Volume (mL) 80
224304629|NCT02620215|DRUG|Prostin|Prostin E2 vaginal tablets contain the active ingredient dinoprostone, which is a naturally occuring female hormone also known as prostaglandin E2. Prostaglandins are involved in naturally starting labour. Dose of Prostin is 3 mg vaginally.
224162038|NCT01716949|RADIATION|Radiotherapy|45 up to 50.4 Gy; daily dose 1,8 Gy, 5 days per weeks
224162039|NCT01716949|PROCEDURE|Hyperthermia|10 sessions, therapeutic time 60 min
224162040|NCT01716949|DRUG|5-Fluorouracil|250 mg/m\^2/d as continuous i.v. infusion on d1-14, 22-35 (may be preplaced by Capecitabine)
223475220|NCT03844841|DRUG|Dexmedetomidine|At minimum 5 minutes before start of sedation for atrial fibrillation ablation a bolus of fentanyl (20-50 µg) will be administered. Thereafter, sedation is induced with a loading dose of dexmedetomidine (0.8 µg/kg) over 10 minutes. The maintenance dexmedetomidine dose is adjusted to the appropriate sedation criteria for CA (0.4 µg/kg/h) and for a target score of 2-3 on the MOAA/S scale. In case of pain, additional fentanyl can be administered bolus-wise (10-30 µg) at the cardiologists discretion.
223582009|NCT01024192|DRUG|ZOLPIDEM SL800750|"Pharmaceutical form: Zopidem 12.5 mg tablets~Route of administration: Oral~Dose regimen:One tablet at bed time and as needed (the patients choose which night they take the tablet without limit of number of nights)"
224162041|NCT01716949|DRUG|Capecitabine|1650 mg/m\^2/d oral intake d1-14, 22-35 (may be replaced by 5-Fluorouracil)
224162042|NCT01716949|DRUG|Oxaliplatin|50 mg/m\^2/d as 2-hour bolus infusion on d2, 9, 23, 30
224162043|NCT00964769|BIOLOGICAL|pneumococcal polysaccharide vaccine|single intramuscular injection of 0.5 ml Pneumo23® (Sanofi-Aventis, Lyon France)
224162044|NCT02266004|DEVICE|Transcranial Direct Current Stimulation (tDCS)|Anodal tDCS will be applied for the duration of the walking training at 2 milliamps with IOMED Phoresor.
223475221|NCT01126892|DRUG|Nilotinib|
223582010|NCT01685021|DRUG|MOR00208 (formerly Xmab5574)|
223582011|NCT06398925|DRUG|OCT461201 50 mg|Oral capsule
223475222|NCT01093768|DRUG|Oxytocin|
223582012|NCT06398925|DRUG|OCT461201 100 mg|Oral capsule
223582013|NCT06398925|DRUG|OCT461201 150 mg|Oral capsule
223582014|NCT06398925|DRUG|OCT461201 450 mg|Oral capsule
223582015|NCT06398925|DRUG|Placebo|Placebo capsule
223582016|NCT06484361|DRUG|68Ga-PSMA|all patients will undergo PET/MRI with 68Ga-PSMA and 68Ga-RM2 prior to surgical intervention
223582017|NCT06484361|DRUG|68Ga-RM2|all patients will undergo PET/MRI with 68Ga-PSMA and 68Ga-RM2 prior to surgical intervention
223582018|NCT02198235|DRUG|Dexamethasone|
223582019|NCT02198235|DRUG|Buprenorphine|
223582020|NCT01742065|OTHER|Auto Plus|Clinics randomized to the Auto-Plus arm will engage in all activities in the Auto arm (send an introductory letter to participants, then a FIT Kit, then a reminder letter encouraging the return of the FIT Kit) in addition to one other outreach effort.
223582021|NCT03693911|BEHAVIORAL|Acceptance and Commitment Therapy|6 digital and gamified session prevention program based on Acceptance and Commitment Therapy
223475223|NCT01093768|DRUG|Vasopressin|
223475224|NCT02158897|OTHER|Prolon diet|3 cycles of a 5-day Prolon diet very month
223582022|NCT02264548|RADIATION|Radio-Ablation|Level I 20Gy/5 Level II 25Gy/5 Level III 30Gy/5 Level IV 35Gy/5 Level V 40Gy/5
223582023|NCT00498888|PROCEDURE|tolterodine|Detrusitol SR 4 mg, 1 capsule for a day, 3 months.
223582024|NCT00498888|PROCEDURE|bladder training|Four visits in 3 months with pelvic floor physical therapist, who is trained in the procedure, for educate and schedule voiding regimen.
223582025|NCT00498888|PROCEDURE|pelvic floor muscle training|Four visits in 3 months with pelvic floor physical therapist, who is trained in the procedure, for reinforced pelvic floor muscles.
223582026|NCT00498888|PROCEDURE|pelvic floor rehabilitation|The Pelvic floor rehabilitation protocol based on bladder training protocol and PFMT and lifestyle advice and information about good bladder and bowel habits. Four visits in 3 months was made with pelvic floor physical therapist, who is trained in the procedure.
223582027|NCT04619277|DEVICE|drug-coated balloon|drug-coated balloon
223582028|NCT00354666|DRUG|GSK159797|
224162045|NCT02266004|OTHER|locomotor training|An individualized dual-task walking program for approximately 30 minutes.
224162046|NCT03935490|PROCEDURE|emergency transrectus sheath pre-peritoneal mesh repair (e-TREPP)|"The Trans REctussheath PrePeritoneal mesh repair (TREPP) was developed in 2006 as an open preperitoneal technique to reduce CPIP. In short: a 4-5 centimeters (cm) transverse incision is made about 1 cm above the localization of the deep inguinal ring. The anterior rectus sheath is opened. After retracting the rectus muscle medially, the preperitoneal space (PPS) is bluntly dissected and a complete overview can be achieved. All possible hernia orifices can be visualized such as: a direct, indirect, pantaloon, and/or femoral hernia. A self-expandable mesh is then positioned in the PPS. Due to the upstream principle no mesh fixation is necessary."
224162047|NCT01791465|DRUG|extended-release exenatide|Single arm study - 2mg Bydureon every 7 days x 16 weeks
224162048|NCT03289052|DEVICE|Restylane Volyme|Subcutis injection
223582029|NCT00596115|DRUG|R(+) pramipexole dihydrochloride monohydrate|20 mg tid per day orally
223582030|NCT01651091|OTHER|Meditation Awareness Training|Psychotherapy Intervention
223582031|NCT01651091|OTHER|Treatment as usual|
223582032|NCT04573881|DEVICE|HistoSonics System|The HistoSonics System - intended for the destruction of liver tissue using histotripsy, a non-thermal, mechanical process using focused ultrasound.
223582033|NCT00126984|BIOLOGICAL|Conjugated meningococcal ACWY-TT (vaccine)|One intramuscular dose during the primary vaccination
223582034|NCT00126984|BIOLOGICAL|DTPa/Hib containing vaccine|One intramuscular dose during the primary vaccination study in subjects of 12-14 months of age
224162049|NCT03174808|BEHAVIORAL|Mindfulness-Based Stress Reduction (MBSR)|Participants will attend weekly 2.5-hour group sessions (of 10-14 persons) based on the standard MBSR protocol.
224162050|NCT00934713|DRUG|montelukast|montelukast 4mg once per day for 8 weeks period
224162051|NCT00537771|DRUG|Anastrozole|1 mg once daily oral dose
224162052|NCT00537771|DRUG|Tamoxifen|20 mg once daily oral dose
224162053|NCT05312268|DRUG|Rasburicase|Rasburicase 1.5 mg/day for 3 consecutive days at scheduled times.
224162054|NCT00063388|BIOLOGICAL|Cetuximab|Cetuximab 400 mg/m2 intravenously (IV) (over 120 minutes) on Day 1 of Cycle 1. followed by weekly doses of 250 mg/m2 (over 60 minutes).
224162055|NCT04346004|DRUG|Normal saline|"Participants in Control group are administered IV 100cc normal saline \& IM normal saline (1cc) 1 day before surgery."
224162056|NCT04346004|DRUG|Iron isomaltoside|"Participants in Iron isomaltoside group are administered IV Iron maltoside diluted in 100 cc normal saline (20mg/kg, maximum dose: 1g) \& IM Vitamin B12 (1mg) 1 day before surgery."
224162057|NCT03099798|OTHER|Questionnaires|"All patients will complete a number of questionnaires at different time points.~* SF-12, WHOQoL-Bref, EQ-5D-5L, iPCQ, iMCQ~* 1 week, 1 month, 3, 6 and 12 months after treatment"
224162058|NCT03099798|DIAGNOSTIC_TEST|MRI abdomen|Patients who were treated with splenic artery embolization will also undergo an MRI one month and one year after treatment.
224162059|NCT00873704|OTHER|supplemental postoperative oxygen|
224162060|NCT01986517|BEHAVIORAL|No feedback|Therapists will receive no feedback.
224162061|NCT01986517|BEHAVIORAL|Feedback after every fourth session|
224162062|NCT01681290|DRUG|CBX129801|
224162063|NCT04253470|OTHER|embryo transfer|Step of the assisted reproduction in which embryos are placed into the uterus in order to obtain a pregnancy
223475225|NCT03435055|DRUG|Nitrous Oxide Gas for Inhalation|Each volunteer will participate in one scanning visit in which simultaneous functional magnetic resonance imaging (fMRI) and electroencephalogram (EEG) data will be collected wherein they receive placebo (20 minutes) followed by inhaled nitrous oxide at subanesthetic levels (35% inhaled concentration) over 40 minutes.
223475226|NCT04630743|BEHAVIORAL|Cognitive and Behavioral intervention for the Management of Episodic Breathlessness|The cognitive and behavioral brief intervention comprises two parts: In a first module, the intervention and the study team is introduced, the definition of episodic breathlessness is given and the individual characteristics of breathlessness episodes are recorded. Goals of the intervention are discussed. In a subsequent module on patient education and the strategies, the patient and intervention executor discuss the patients' assumptions about episodic breathlessness including triggers and already used management strategies for breathlessness episodes. This follows the presentation of the non-pharmacological strategies: movement of air/ handheld fan, forward lean, diaphragmatic breathing, distraction, pursed lips breathing, long breaths out and relaxation training. The patient selects 2-3 strategies and trains them with the intervention executor.
223475227|NCT01937988|OTHER|Doula Arm|
223475228|NCT03908346|OTHER|Decision Aid for Surrogate Decision Makers of Comatose Survivors of Cardiac Arrest|a decision aid has been created that is a four page document meant to support surrogate decision makers for comatose survivors of cardiac arrest
223475229|NCT02431689|PROCEDURE|IVF/ICSI|controlled ovarian hyperstimulation with various protocols, follow up till stimulated follicles measure from 18-20 mm, then ovum pickup followed by embryo transfer is done.
223475230|NCT04325997|DEVICE|laryngoscope with mouth opener|Double-lumen tube combined with mouth gag for laryngoscope intubation
223475231|NCT04325997|DEVICE|video laryngoscope with mouth opener|Double-lumen tube combined with mouth gag for video laryngoscope intubation
223475232|NCT05463965|BIOLOGICAL|QM1114-DP|Intramuscular injection
223475233|NCT05463965|BIOLOGICAL|OnabotulinumtoxinA|Intramuscular injection
223475234|NCT05463965|BIOLOGICAL|Placebo|Intramuscular injection
223475235|NCT04999241|COMBINATION_PRODUCT|exclusive enteral nutrition|Administration of a liquid formula diet with the exclusion of all other regular food for 8 weeks, then patients can administration of regular food.
224162064|NCT02558985|PROCEDURE|Casting|Serial casting is used to partially correct the deformity before beginning bracing. A cast can be considered a full-time brace which cannot be removed.
224162065|NCT02972593|BIOLOGICAL|Blood and blood products for transfusion|Randomization would not occur until the patient's Hgb dropped below 7 g/dL. If the patient is randomized to the liberal arm, they would be transfused to keep their Hgb \>7 g/dL. If the patient is randomized to the conservative arm, they would not be transfused until their Hgb drops below 5.5 g/dL. If the patient's Hgb does not drop below 7.0 g/dL, randomization will not be done.
224162066|NCT02950441|DIETARY_SUPPLEMENT|Nicotinamide Riboside|
224162067|NCT02950441|OTHER|Placebo|
224162068|NCT04319770|DEVICE|enamel matrix derivative (EMD)|periodontal regenerative surgery with enamel matrix derivative (EMD) (control)
224162069|NCT04319770|DEVICE|hyaluronic acid (HA)|periodontal regenerative surgery with hyaluronic acid (HA) (test)
224162070|NCT00693693|DRUG|hydrocortisone 17-butyrate 0.1% Cream preparation|Apply medication twice a day to affected areas of atopic dermatitis
224162071|NCT00693693|DRUG|hydrocortisone 17-butyrate 0.1% Ointment preparation|Apply medication twice a day to affected areas of atopic dermatitis
223475236|NCT04999241|COMBINATION_PRODUCT|regular food|Administration of regular food in the induction phase and the later time.
223475237|NCT01876095|PROCEDURE|Multidisciplinary medication review|"Consists of the following steps:~* 1\. Elderly care physician and nursing staff evaluate with the patient the experience of taking medicines, adverse drug reactions and patient's preferences.~* 2\. Pharmacist reviews medication to identify drug related problems using START/STOPP en Beers criteria.~* 3/4. Meeting of elderly care physician, pharmacist. Possibilities to discontinue prescribed medication will be examined resulting in pharmaceutical care plan that optimizes the patient's medication i.e. which inappropriate medication should be discontinued following a prioritization and time schedule.~* 5\. Execution of pharmaceutical care plan according to agreed schedule."
223475238|NCT02121197|DRUG|Ozurdex|
224162072|NCT00693693|DRUG|hydrocortisone 17-butyrate 0.1% Lipocream preparation|Apply medication twice a day to affected areas of atopic dermatitis
224162073|NCT00823160|PROCEDURE|Sternotomy|Sternotomy performed after finding blood in the pericardial sac
224162074|NCT00823160|PROCEDURE|Subxyphoid window|Subxyphoid window performed after the finding of blood in the pericardial sac
224162075|NCT02069704|DRUG|Bevacizumab biosimilar (BEVZ92)|"Active ingredient Bevacizumab 25 mg/mL (strength = 100 mg/4 mL). 30-minute\* IV infusion (5 mg/kg) every 2 weeks, prior to chemotherapy (Folfox any or Folfiri).~FOLFIRI = Folinic Acid + Fluorouracil + Irinotecan FOLFOX = Folinic Acid + Fluorouracil + Oxaliplatin Treatment will continue until disease progression, unacceptable toxicity, patient withdraws consent or death (whichever occurs first).~\*The first infusion will be given over 90 minutes. If it is well tolerated, the second infusion can be given over 60 minutes. If it is well tolerated, subsequent infusions can be given over 30 minutes.~The FOLFOX (any) or FOLFIRI regimen will be chosen as per investigator's criteria based on the hospital standard of care."
224305012|NCT06083012|DEVICE|Cardiac mapping|"All patients enrolled are treated for their atrial fibrillation/tachycardia via a catheter ablation procedure using VX1/Volta AF-Xplorer/Volta AF-Xplorer II software (used in accordance with its approved indication as per of its IFU) during the mapping phase to identify areas of interest specific to the patient.~The ablation approach is free and chosen by the operator according to his standard practice. The two main phases of the ablation procedure are:~* 3D mapping of the atria and location of areas of interest;~* Catheter ablation at the operator\&amp;#39;s discretion."
223744181|NCT06071715|DEVICE|SHAM cryoneurolysis|SHAM cryoneurolysis of the major nerves of the thigh (or their distal counterparts) in the residual limb: The cryoneurolysis device will be triggered using 1 cycle of 5.5-minute argon activation followed by a 30-60 second defrost period with helium (Varian) or 2 cycles of 2-minute gas activation with a sham probe separated by a 30-60 second defrost (Epimed). However, for sham treatment, the gas is NOT deployed to the probe tip and therefore there is NO drop in temperature with NO resulting cryoneurolysis.
224162076|NCT02069704|DRUG|Avastin® (bevacizumab, reference product)|"Active ingredient: Bevacizumab 25 mg/mL (strength: 100 mg/4 mL). 30-minute\* IV infusion (5 mg/kg) every 2 weeks, prior to administration of chemotherapy. Treatment will continue until disease progression, unacceptable toxicity, patient withdraws consent or death (whichever occurs first).~\*The first infusion will be given over 90 minutes. If the first infusion is well tolerated, the second infusion can be given over 60 minutes. If this infusion is well tolerated, subsequent infusions can be given over 30 minutes.~The FOLFOX (any) or FOLFIRI regimen will be chosen as per investigator's criteria based on the hospital standard of care."
223475239|NCT03913962|OTHER|indirect calorimetry|Patients will be separated in different subgroups. Subgroups will be constituted according the disease status (i.e. active vs inactive) to assess the impact of the pathology on physical fitness and according to treatments to assess the effect of treatment on physical fitness.
223475240|NCT04722562|DRUG|Vericiguat (BAY1021189)|Oral single dose of 2.5 mg (2 x 1.25 mg immediate release tablet)
223475241|NCT05620524|DRUG|Extra blood samples for determining exposure to 5-FU|Extra blood samples for determining exposure to 5-FU
223475242|NCT03712280|DRUG|MNK6106|1 gram tablet of MNK6106 for oral administration
223475243|NCT03712280|DRUG|Rifaximin|550 mg tablet of rifaximin for oral administration
223475244|NCT01235988|DRUG|Eltrombopag|Eltrombopag 50mg \& standard of care
223475245|NCT01235988|DRUG|Placebo|Placebo + standard of care
223475246|NCT00586560|DRUG|Kareniticin and cyclophosphamide|"An accelerated titration dose escalation design will be used in this study. Dose escalation will function independently for each stratum. Patients in both strata will receive Karenitecin and cyclophosphamide administered as an IV infusion each day for 5 consecutive days. In addition, patients in Stratum 1 will receive prophylactic G-CSF starting 24 hours after completion of the fifth dose of Karenitecin and cyclophosphamide (and continuing daily until the ANC is over 1500/mm3 after nadir). The regimen will be repeated every 21 days (1 treatment cycle).~Treatment may continue for up to 20 cycles, provided there is continued evidence of clinical benefit and absence of unacceptable toxicity."
223475247|NCT04818099|DRUG|Vortioxetine 10 mg|Vortioxetine will be used with a dosage of 10mg once a day, for 2 months.
223475248|NCT04818099|OTHER|Placebo|Placebo will be used with a dosage of one tablet once a day for 2 months.
223475249|NCT03797352|OTHER|Multicomponent exercise|To identify frailty and other potential health issues, and determine if Multicomponent exercise helps at-risk elderly to have better health outcomes.
223475250|NCT00236743|DRUG|topiramate|
223475251|NCT04268693|OTHER|urine collection|Collect three urine samples either in the clinic or at home. This will occur prior to starting neoadjuvant chemotherapy, and again at the end of the scheduled course of neoadjuvant chemotherapy.
223475252|NCT05847608|DIETARY_SUPPLEMENT|Omega-3|Daily consumption of 500 mg DHA and 750 mg EPA in liquid form
223475253|NCT05847608|DIETARY_SUPPLEMENT|Placebo|Oleic Acid, Linoleic Acid
223475254|NCT05751551|OTHER|Personalized, home-based motor-cognitive training|"The simultaneous motor-cognitive training in this study will be conducted in form of exergames (interactive video games) using Senso hardware (DIV-SENSO-H, Dividat GmbH, Schindellegi, Switzerland) - a stepping platform with 5 pressure sensitive plates which is connected to a screen. For the home-based training, a more mobile version of the Dividat Senso will be used: a foldable pressure-sensitive mat. In both devices, stimuli of exergames appear on the screen and the participants have to react by stepping in one of 4 directions (front, back, left, right).~The motor-cognitive training approach allows targeting different cognitive functions such as attention, executive functions, memory, and visuo-spatial functions as well as balance, and strength.~FITT-VP principles will serve as a guideline but based on the functional status of each participant (physical and cognitive), the training sessions will be personalized in terms of training content, intensity and duration."
223475255|NCT01066234|RADIATION|concurrent chemoradiotherapy|weekly paclitaxel 50mg/m2 plus weekly cisplatin 25mg/m2 5times with concurrent radiotherapy (5000rad/25fx) for 5 weeks followed by 2 cycles of 3-weekly paclitaxel (175mg/m2) plus cisplatin 80mg/m2.
223475256|NCT01066234|DRUG|chemotherapy only|four cycles of 3-weekly paclitaxel (175mg/m2) and carboplatin (AUC5.5).
223475257|NCT01873014|DRUG|chinese herbs-I|two agent per day, twice a day
223475258|NCT01873014|DRUG|chinese herbs-II|two agent per day, twice a day
223475259|NCT00733967|DRUG|Varenicline|Varenicline (oral capsule): 0.5 mg once daily for 3 days; 0.5 mg twice daily for 2 days; 1 mg twice daily for one day; 1 mg once daily for one day.
223475260|NCT00733967|DRUG|Placebo|Matching oral placebo capsules as control.
223475261|NCT02479841|OTHER|Self management program|
223475262|NCT02700399|DEVICE|Erigo® Hocoma|Robotics assisted tilt table, without functional electrical stimulation
223475263|NCT02700399|DEVICE|Traditional tilt table from Rehab-Care|Traditional tilt table
223475264|NCT05608057|OTHER|Vitamin C mesotherapy|Vitamin C intra-mucosal injection; in which the site of interest will be anesthetized using a topical anesthetic agent (lidocaine gel or xylocaine gel) or infiltration anesthesia, followed by intra-mucosal field injections of 1-1.5 ml Cevarol (L-Ascorbic acid 1000 mg/5 ml
223475265|NCT05608057|RADIATION|Diode laser|Diode laser ablation: in which the site of interest will be anesthetized using infiltration anesthesia, followed by laser ablation. 980nm Diode laser will be applied using the following setting parameters: continuous mode with 980nm wavelength at 1.5 W output power.
223475266|NCT03528421|BIOLOGICAL|IM19|CAR-T cells
224304630|NCT03959215|BEHAVIORAL|Back in the Game|"A six-month programme of cognitive-behavioural therapy delivered by smartphone application. The intervention commences in the first week after ACL reconstruction. The smartphone app is delivered in parallel with usual rehabilitation care.~Usual rehabilitation care: all participants will be referred to physiotherapy following ACL reconstruction. Overall treatment aims, content and progressions of rehabilitation will follow current clinical guidelines. The choice of specific therapies, exercises and the number of treatment sessions needed to achieve the treatment aims is at the clinical discretion of the treating physiotherapist."
223475267|NCT03528421|DRUG|Fludarabine|Two days before cell infusion, all patients will be treated with fludarabine for 3 days
223475268|NCT03528421|DRUG|Cyclophosphamide|Two days before cell infusion, all patients will be treated with Cyclophosphamide for 3 days
223475269|NCT01559441|DIETARY_SUPPLEMENT|Beetroot Juice with oral fat load|140mL (9.6 mmol nitrate) beetroot juice (Beet It, James White drinks Ltd)
223475270|NCT01559441|DIETARY_SUPPLEMENT|Carbohydrate control drink with oral fat load|140 mL (low-nitrate) carbohydrate control drink
223475271|NCT01267279|DRUG|Zoledronic acid|Zoledronic acid per protocol
223475272|NCT01267279|OTHER|Placebo|Placebo
224162077|NCT01236768|DRUG|AG200-15|"Contraception; AG200-15 is applied and replaced every 7 days for 3 weeks, followed by a 1-week patch free period."
224162078|NCT01236768|DRUG|Levora|One tablet of Levora will be taken each day for a 28 day cycle.
224162079|NCT00638690|DRUG|Placebo|Four tablets once daily until disease progression
224162080|NCT00638690|DRUG|Abiraterone acetate|Four 250-mg tablets once daily until disease progression
224069794|NCT04441229|BEHAVIORAL|ABMT mobile application|"After consent/assent, participants will complete 1 hour-long, in-person or remote, baseline study visit at the Multiple Sclerosis Comprehensive Care Center. During this visit, participants will complete baseline study surveys and a brief computerized attention bias assessment and be trained on the use of the ABMT mobile application. Participants will then complete at-home game play 4 days a week, for 30 days, using an iOS mobile device, approximately 10-15 minutes each day. Subjects will complete weekly online study surveys via REDCap or MyCap (Mobile REDCap Application). At the conclusion of participation, participants will complete online end of study surveys via REDCap or MyCap.~Parents of participants will complete surveys at the baseline visit, followed by online surveys at Week 2 and at the end of study. For participants who are 18 years old or older, parental participation will not be required."
224162081|NCT00638690|DRUG|Prednisone/prednisolone|5 mg twice daily until disease progression
223475273|NCT04786769|DRUG|Ferric carboxymaltose|Intravenous ferric carboxymaltose according to baseline weight and hemoglobin
223475274|NCT00906126|DRUG|Misoprostol|Oral misoprostol
223582035|NCT00126984|BIOLOGICAL|Meningitec|One intramuscular dose during the primary vaccination study in subjects of 12-14 months of age
223582036|NCT00126984|BIOLOGICAL|Mencevax ACWY|One subcutaneous dose during the primary vaccination study in subjects of 3-5 years of age (group E) and subcutaneous administration of 1/5 dose during the booster vaccination study in subjects of 12-14 months of age (group C, group E)
223582037|NCT02313883|DRUG|PerioSept(r)|Taurolidine is derived from the amino acid taurine and has antimicrobial and immune modulating properties
223582038|NCT02411786|BIOLOGICAL|pTVG-AR|Given ID
223582039|NCT02411786|BIOLOGICAL|gm-csf|Given ID
224162082|NCT03456180|DEVICE|Haemoadsorption with Cytosorb cartridge|microcirculatory monitoring in septic shock patients requiring renal replacement therapy for acute renal failure and haemoadsorption with Cytosorb cartridge
223475275|NCT04614506|DEVICE|Transcranial Magnetic Stimulation (TMS)|Transcranial magnetic stimulation (TMS) is a method for noninvasive electrical cortical stimulation, where small intracranial currents are generated by a powerful, fluctuating, extracranial magnetic field. TMS is unique in its capacity for experimental, diagnostic, and therapeutic utility. Single pulse (spTMS) and paired-pulse TMS (ppTMS) have been used extensively to study, measure, and modulate cortical excitability and plasticity.
223475276|NCT04614506|DEVICE|Electroencephalogram (EEG)|These will be an ambulatory EEG recordings that span 24 hours and done without sedation. Recordings will be performed using electrode locations specified by the international 10-20 system for standard clinical practice.
223582040|NCT02382848|DRUG|Prazosin|A starting dose of Prazosin (1mg capsule) will be given at Week # 1 of this arm. Symptoms will be reassessed and medication will be adjusted by 1-2 mg increments every 7 days for 3 weeks based on clinical response and severity of night mares, to achieve maximum therapeutic benefit while monitoring adverse effects using side effects scale on weekly basis (psychiatrist will be using the scale at every visit). The end point for capping the Prazosin dose will be 6 mg daily.
223582041|NCT02382848|DRUG|Placebo|Prazosin-matched placebo pill
224069795|NCT02342015|DRUG|Atorvastatin|Atorvastatin 40mg/day for three months
224069796|NCT02274103|BEHAVIORAL|BFST|Family-based skills training.
224069797|NCT01692301|DRUG|LCZ696|200 mg tablet
224069798|NCT01692301|DRUG|Olmesartan|20 mg and 40 mg capsules
224162083|NCT03859804|PROCEDURE|Standard transrectal 12 core biopsy|TRUS-guided SPB was performed by obtaining 12 core samples in each patient. 6 cores from left and right. the cores labeled as, apex, mid, base, apex far lateral, mid far lateral and base far lateral
224162084|NCT03859804|PROCEDURE|MRI- US fusion prostate biopsy (FPB)|FPB was performed by obtaining 10-12 core samples in each patient, followed by the acquisition of 2-4 core samples for each suspected lesion detected on MpMRI (combined biopsy)
224162085|NCT01181297|OTHER|Extensively Hydrolyzed Formula with a Probiotic|
224162086|NCT01181297|OTHER|Extensively Hydrolyzed Formula without a Probiotic|
224162087|NCT00115544|DRUG|Stanate|Intramuscular injection of stannsoporfin at 0.75 or 1.5mg/kg for treatment of severe hyperbilirubinemia to prevent exchange transfusion
224162088|NCT00725829|DRUG|simvastatin|Simvastatin 40mg/d
224162089|NCT00725829|DRUG|ezetimibe|ezetimibe 10mg/d
224162090|NCT00725829|DRUG|placebo|placebo
224162091|NCT04949828|DRUG|CREON|Oral Capsules
224162092|NCT02454894|DRUG|lidocaine|surface anesthesia with lidocaine
224162093|NCT02454894|PROCEDURE|postoperative management|lying without the pillow for half an hour after lumbar puncture
224162094|NCT02607462|BIOLOGICAL|PRP|
224162095|NCT02607462|OTHER|Placebo|
223475277|NCT02980016|DRUG|rifapentine + isoniazid|Rifapentine + isoniazid Once weekly rifapentine (at a dose of 900 mg) plus isoniazid (at a dose of 900 mg), with adjustment for participants weighing ≤50 kg
223475278|NCT02980016|DRUG|Isoniazid|Daily self-administered isoniazid (at a dose of 300 mg/daily), with adjustment for participants weighing ≤24 kg
223475279|NCT02365883|DEVICE|Photoacoustic Imaging System|manufactured by Endra
223475280|NCT04741048|DEVICE|CI624 Slim 20 Electrode|Cochlear Ltd CI624 cochlear implant with Slim 20 Electrode
223475281|NCT01753349|BIOLOGICAL|Botulinum toxin type A|Investigators were free to prescribe any BoNT A preparation, including Dysport, Botox and Xeomin.
223475282|NCT06157450|DRUG|ZSP1273|Participants receive ZSP1273 orally.
223475283|NCT00609817|DRUG|GCS-100|GCS-100 160mg/m2 IV (in the vein) on Study Days 1, 4, 8 and 11 for up to 12 consecutive 21-day treatment cycles. Three patients will be assigned to each cohort until maximum tolerated dose is reached. The dose levels: 1) 160 mg/m2; 2) 210 mg/m2; 3) 280 mg/m2; 4) 370 mg/m2
223475284|NCT00609817|DRUG|Bortezomib/Dexamethasone|Bortezomid 1.3 mg/m2 and dexamethasone 20 mg/day plus an additional 20 mg of dexamethasone on the day following each of the GCS-100/bortezomib and dexamethasone dosing. GCS-100/bortezomib and dexamethasone dosed on Study Days 1, 4, 8 and 11 of each 21-day cycle after disease progression is noted.
223475285|NCT04676204|DRUG|Cladribine|Cladribine is a purine antimetabolite indicated for the treatment of relapsing forms of multiple sclerosis, to include relapsing-remitting disease and active secondary progressive disease, in adults.
223582042|NCT02382848|DRUG|Prazosin|A starting dose of Prazosin (1mg capsule) will be given at Week # 5 of this arm. Symptoms will be reassessed and medication will be adjusted by 1-2 mg increments every 7 days for 3 weeks based on clinical response and severity of night mares, to achieve maximum therapeutic benefit while monitoring adverse effects using side effects scale on weekly basis (psychiatrist will be using the scale at every visit). The end point for capping the Prazosin dose will be 6 mg daily.
223744182|NCT06493305|BEHAVIORAL|Neurolinguistic programming|In the NLP application protocol, the visual, auditory and/or tactile representation system that the woman uses most frequently will be determined. Then, using the anchoring technique, the internal reactions and external reactions created by the woman's current symptoms and emotions and thoughts regarding the urination process will be combined using the anchoring technique. Existing negative emotions will be reduced and positive emotions will be reinforced. Then, with the swish technique, the intensity of the woman's existing negative emotions will be erased from the most frequently used visual, auditory or tactile representation system. Then, taking into account the representation system that the woman uses most frequently, the belief change model will be used in her negative thoughts about the current symptom, and her negative feelings and thoughts will be replaced by positive feelings and thoughts and reinforced.
223744183|NCT04256785|DIETARY_SUPPLEMENT|VSL#3|sachets containing probiotic
223744184|NCT04256785|DIETARY_SUPPLEMENT|Placebo|sachets containing placebo
223744185|NCT01738854|PROCEDURE|intracuff pressure by cuff pressure manometer|36 patients are randomly allocated according to random sequence of the intracuff pressure 40, 60 and 80 cmH2O. After insertion of LMA supreme, we confirm adequate ventilation. And then we measure OLP and leakage volume at intra-cuff pressure 40, 60 and 80 cmH2O adjusted by cuff pressure manometer according to random sequence of the intracuff pressure.
223475286|NCT04676204|DRUG|Dimethyl fumarate|Dimethyl fumarate is indicated for the treatment of relapsing forms of multiple sclerosis, to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults
223475287|NCT04676204|DRUG|Fingolimod|Fingolimod is a sphingosine 1-phosphate receptor modulator indicated for the treatment of patients with relapsing forms of multiple sclerosis to reduce the frequency of clinical exacerbations and to delay the accumulation of physical disability.
223475288|NCT04676204|DRUG|Teriflunomide|Teriflunomide is a pyrimidine synthesis inhibitor indicated for the treatment of patients with relapsing forms of multiple sclerosis.
223475289|NCT04676204|DRUG|Ozanimod|Ozanimod is a sphingosine-1-phosphate receptor modulator indicated for the treatment of patients with relapsing forms of multiple sclerosis.
223475290|NCT04676204|DRUG|Diroximel fumarate|Diroximel fumarate is indicated for the treatment of relapsing forms of multiple sclerosis, to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
223475291|NCT03022409|DRUG|Ceralasertib|"Ceralasertib is an oral agent and will be dosed at 160 mg. Ceralasertib tablets should be taken at the same time each day, approximately 12 hours apart (maximum ± 2 hour window) with one glass of water.~Ceralasertib is a potent, selective inhibitor of the serine/threonine-specific protein kinase, ataxia telangiectasia and Rad3-related protein (ATR), with good selectivity against other phosphatidylinositol 3-kinase-related kinase (PIKK) family members."
223582043|NCT02382848|DRUG|Placebo|Prazosin-matched placebo pill
223582044|NCT01858753|BIOLOGICAL|Autologous fibroblasts|
223582045|NCT01858753|BIOLOGICAL|placebo sterile saline|
223582046|NCT04151849|DRUG|GLP-1 receptor agonist|Treatment with GLP-1 agonist for up to 1 year.
223744186|NCT04043091|PROCEDURE|percutaneous coronary intervention (stenting)|percutaneous stent implantation in coronary artery
223744187|NCT04034173|DRUG|Panitumumab|"Panitumumab 6 mg/kg BW as 60-min i.v. infusion\* D1~\*If the 1st infusion is well tolerated, all subsequent infusions can be applied over 30-60 minutes."
223744188|NCT04034173|DRUG|Irinotecan|Irinotecan 180 mg/m² BSA i.v., 30 - 90 min D1
223582047|NCT04151849|DRUG|SGLT2 inhibitor|Treatment with SGLT2 inhibitor for up to 1 year
223582048|NCT02631265|OTHER|Exercise 1|Participants will be admitted at IRCM at 14:00. At 15:30, participant's insulin basal rate will be reduced by 80% and participants will perform a 45-minute exercise on the ergocycle at 60% of VO2 peak (moderate intensity). At 16:15, the participant's usual insulin basal rate will be set in the insulin pump and a standardized snack (30g CHO) will be served. At 16:45, the participant will be discharged and will be asked to eat a standardized dinner at home (60g CHO for females and 80g CHO for males).
223582049|NCT02631265|OTHER|Exercise 2|Participants will be admitted at IRCM at 14:00. At 15:10, participant's insulin basal rate will be reduced by 80%. At 15:30, participants will perform a 45-minute exercise on the ergocycle at 60% of VO2 peak (moderate intensity). At 16:15, the participant's usual insulin basal rate will be set in the insulin pump and a standardized snack (30g CHO) will be served. At 16:45, the participant will be discharged and will be asked to eat a standardized dinner at home (60g CHO for females and 80g CHO for males).
223582050|NCT02631265|OTHER|Exercise 3|Participants will be admitted at IRCM at 14:00. At 14:50, participant's insulin basal rate will be reduced by 80%. At 15:30, participants will perform a 45-minute exercise on the ergocycle at 60% of VO2 peak (moderate intensity). At 16:15, the participant's usual insulin basal rate will be set in the insulin pump and a standardized snack (30g CHO) will be served. At 16:45, the participant will be discharged and will be asked to eat a standardized dinner at home (60g CHO for females and 80g CHO for males).
223744189|NCT04034173|DRUG|Folinic acid|Folinic acid (racemic) 400 mg/m²BSA i.v., 120 min D1
223582052|NCT00083486|DRUG|epoetin alfa|
223744190|NCT04034173|DRUG|5-FU|5-FU 400 mg/m² BSA, bolus, D1 5-FU 2400 mg/m² BSA i.v. infusion over a period of 46 h D1-2
224162096|NCT06353867|OTHER|Group Exercise|The children with special needs included in the study were included in group exercises for 45 minutes 2 days a week in groups of 10 children each. Group exercises were planned as balance and coordination exercises including warm-up and cool-down periods. In the warm-up and cool-down periods, counting in place and balance exercises were performed. The exercises included tasks such as side walking, tandem walking, walking on a balance board, walking in a figure 8, walking over obstacles, throwing a ball to the person next to him/her while passing through cones, and throwing a ball by jumping while passing through cones.The exercises were made more difficult by following a progressive method every 2 weeks. The exercises were performed in 3 sets of 5 repetitions under the supervision of a physiotherapist.
223475292|NCT03022409|DRUG|Olaparib|"Olaparib is available as a green film-coated tablet containing 100 mg or 150 mg of Olaparib. Patients will be administered Olaparib orally twice daily at 300 mg bid. The Olaprib tablets should be taken at the same time each day, approximately 12 hours apart with one glass of water.~Olaparib (AZD2281, KU-0059436) is a potent Polyadenosine 5'diphosphoribose \[poly (ADP ribose)\] polymerisation (PARP) inhibitor (PARP-1, -2 and -3) that is being developed as an oral therapy, both as a monotherapy (including maintenance) and for combination with chemotherapy and other anti-cancer agents."
223475293|NCT02944292|PROCEDURE|Deepening of sedation|Deepening of sedation will be achieved with a bolus and subsequent continuous infusion of propofol.
223582053|NCT04162522|DRUG|Escitalopram|Participants are given escitalopram for 8 weeks. At week 8, those classified as responders will continue on escitalopram until the end of study.
223582054|NCT04162522|DRUG|Brexpiprazole|Participants who are classified as non-responders are given 8 weeks add-on brexpiprazole, in addition to escitalopram, for the remainder of the study.
223744191|NCT06229366|DRUG|[Ac-225]-PSMA-62 (mCRPC)|"Phase Ia: Administered intravenously per dose escalation scheme. Patients will receive a single dose of \[Ac-225\]-PSMA-62 on Day 1 of each 6-week cycle for up to 4 cycles.~Phase Ib: Administered intravenously at MTD or one dose level below MTD. Patients will receive a single dose of \[Ac-225\]-PSMA-62 on Day 1 of each 6-week or 4-week cycle, for a total of 4 cycles."
223744192|NCT06229366|DRUG|[Ac-225]-PSMA-62 (OmHSPC)|"Phase Ia: Administered intravenously per dose escalation scheme. Patients will receive a single dose of \[Ac-225\]-PSMA-62 on Day 1 of each 8-week cycle for up to 2 cycles.~Phase Ib: Administered intravenously at MTD or one dose level below MTD. Patients will receive a single dose of \[Ac-225\]-PSMA-62 on Day 1 of each 8-week cycle, for a total of 2 cycles."
224162097|NCT01147367|BEHAVIORAL|3 month physical activity intervention|3 month physical activity intervention involving moderate intensity walking and strength training with resistance bands
224162098|NCT05589740|BEHAVIORAL|Culturally tailored healthy eating advice|Culturally-tailored education includes strategies for healthy eating, preferences for traditional healthy foods, recommendations for limiting unhealthy traditional foods, portion sizes, etc.
224162099|NCT05589740|BEHAVIORAL|Standard healthy eating advice|Standard healthy eating education includes strategies, foods, portions, and cooking and eating tips for general dietary recommendations from USDA My Plate
224162100|NCT00625014|DRUG|Haloperidol|Haloperidol 3 mg/day for 8 days
224162101|NCT01720472|GENETIC|Biomarker studies|
224162102|NCT01452191|BEHAVIORAL|Injury Prevention Briefing Plus facilitation|Injury Prevention Briefing (IPB) to provide best evidence on what works to reduce house fire injuries, and activities to get the evidence into practice. This arm will receive facilitation to support the implementation of the information in the IPB
224162103|NCT01452191|BEHAVIORAL|Injury Prevention Briefing|Children's centres will receive the Injury Prevention Briefing only.
223475294|NCT02944292|DRUG|Propofol|"Propofol will be dosed according to lean body weight (LBW) for bolus administration and according to total body weight (TBW) for continuous infusion.~All patients will receive a bolus of propofol 1 mg/kg LBW as a rapid infusion during one minute. Measurements will be made one minute after the ending of bolus infusion. Continuous infusion of propofol at a rate of 3 mg/kg/h will be started immediately following completion of measurements, not later than 5 minutes after bolus administration. The propofol infusion rate is decreased in case of hemodynamic instability by 1 mg/kg/h and until a minimum of 1 mg/kg/h, if needed. Maximum total dose of infusion of 5 mg/kg/h will not be exceeded (bolus not considered)."
223475295|NCT06013566|DEVICE|SSVEP|Non-invasive, non-interventional SSVEP EEG device
223475296|NCT04151394|PROCEDURE|Duodenojejunostomy|Resection of duodenal lesions and reconstruction by duodenojejunostomy
223475297|NCT02130440|DRUG|Resveratrol nasal spray|
223582055|NCT03098225|RADIATION|Orbital radiotherapy|A high-voltage linear accelerator will be used and a cumulative radiation dose of 20 Gy will be delivered to each eye in 10 fractionated doses over a period of 2 weeks. All patients will be treated in both eyes.
223582056|NCT03098225|DRUG|Methylprednisolone|Methylprednisolone pulse therapy for 12 weeks as follows: 500 mg IV once weekly for 6 weeks, then 250 mg IV once weekly for a further 6 weeks. Cumulative dose 4.5 g.
223582057|NCT05490966|OTHER|isometric trunk extensor muscles fatigue|Participants will perform three sets of intermittent isometric efforts between 50 and 60 percents of their maximal isometric strength. A padded force sensor will be placed approximately at the level of the 7th thoracic vertebrae. The first two sets will last six minutes each, while the third set will last three minutes. Between each set participants will rest for two minutes.
223744193|NCT06260007|DRUG|Tribulus terrestris|Tribulus terrestris
223744194|NCT06260007|OTHER|Placebo|Placebo
223744195|NCT01042327|DEVICE|ELISIO dialyzer|3 x week dialysis using ELISIO dialyzer for 12 weeks
224162104|NCT03378973|DRUG|Dexmedetomidine|Patients will randomly assigned to received Arm 1 anesthesia or Arm 2 anesthesia during surgery.
223475298|NCT02859883|DEVICE|gastroscope FUSE™|All patients undergoing a diagnostic gastroscopy are eligible. Using the FUSE endoscope with side screen, the duodenal and accessory papilla are monitored. Data are collected by each operator. Clinical examination of patients is performed before they leave the centre.
223475299|NCT02415946|PROCEDURE|Sinus floor augmentation (lateral)|
223475300|NCT02415946|PROCEDURE|Sinus floor augmentation (transcrestal)|
223475301|NCT05192642|DRUG|Larotrectinib(Vitrakvi, BAY2757556)|Clinical trials
223582058|NCT05231798|DRUG|[18F]-FEOBV Radiotracer|Participants will be administered an \[18F\]-fluoroethoxybenzovesamicol (FEOBV) radiotracer for diagnostic imaging purposes (PET scan).
223582059|NCT05536856|DRUG|a new effervescent mixture 5-florouracil formula|30 patients will apply a new effervescent mixture 5-florouracil formula prepared at faculty of pharmacy (Girls) - Al-Azhar university
223582060|NCT05536856|DRUG|5-Fluorouracil plain powder|30 patients will apply the 5-florouracil plain powder on the selected patch followed by 3 milliliters of water till complete dissolution of the powder
223582061|NCT05499624|DEVICE|MicroTrend System|The hands-free device measures oral mucosal carbon dioxide pressure (POMCO2) and functions outside of the body and does not require a surgical procedure or any significant deviation from standard practice to operate.
223582062|NCT00187070|DRUG|Doxorubicin, Cotrimoxazole, Carboplatin, Ifosfamide, Dexamethasone, Prednisone, Vincristine, Cytarabine, Methotrexate, Etoposide, Cyclophosphamide, Vinblastine|See Detailed Description section for details of treatment interventions.
223582063|NCT00187070|PROCEDURE|Stem cell transplant,|See Detailed Description section for details of treatment interventions.
223582064|NCT00187070|RADIATION|Radiation Therapy|See Detailed Description section for details of treatment interventions.
223582065|NCT05845671|DRUG|Amivantamab 1050mg|"Amivantamab is a bispecific antibody that binds to the extracellular domains of EGFR and MET.~In in vitro and in vivo studies amivantamab was able to disrupt EGFR and MET signaling functions through blocking ligand binding and, in exon 20 insertion mutation models, degradation of EGFR and MET. The presence of EGFR and MET on the surface of tumor cells also allows for targeting of these cells for destruction by immune effector cells, such as natural killer cells and macrophages, through antibody-dependent cellular cytotoxicity (ADCC) and trogocytosis mechanisms, respectively."
223744196|NCT01042327|DEVICE|Fresenius FX100 dialyzer|
223744197|NCT06471985|COMBINATION_PRODUCT|Music and pain|In both arms of the study the participant will take the same pain test. They will either listen to Enya or slayer, depending on the arm
223744198|NCT03393546|BEHAVIORAL|Auricular Point Acupressure|It includes 4 weekly auricular point acupressure treatments.
223744199|NCT01335581|DEVICE|Q-Switched Nd:YAG Laser (RevLite)|Laser treatment added to a microdermabrasion and topical lightening agent regimen
223744200|NCT01335581|DRUG|Retin-A and microdermabrasion|Microdermabrasion and topical lightening agent regimen
223744201|NCT01899300|DEVICE|Metal Stent (WallFlex™ Esophageal RX)|
223744202|NCT03762824|BIOLOGICAL|13-valent pneumococcal conjugate vaccine|Pneumococcal conjugate vaccination during antirheumatic treatment
223744203|NCT03762824|BIOLOGICAL|23-valent pneumococcal polysaccharide vaccine|Pneumococcal polysaccharide vaccination during antirheumatic treatment
224069799|NCT01692301|DRUG|LCZ696 matching placebo|LCZ696 Matching Placebo tablet
224069800|NCT01692301|DRUG|Olmesartan matching placebo|Olmesartan matching placebo capsule
224069801|NCT01692301|DRUG|amlodipine|amlodipine 2.5 mg or 5 mg tablets
224069802|NCT01692301|DRUG|hydrochlorothiazide|hydrochlorothiazide 6.25mg, 12.5mg, or 25 mg tablets
224069803|NCT02789865|DRUG|Ertapenem, Levofloxacin and Metronidazole|The patients will be treated with intravenous broad-spectrum antibiotics (Ertapenem 1g/d) for 3 days and oral antibiotics (Levofloxacin 500mg once daily and Metronidazole 500mg 3 times per day) for 7 days. If patients in the antibiotic group deteriorate during the hospital stay (suspicious perforation or any symptoms of peritonitis) patients will be operated.
224069804|NCT02789865|PROCEDURE|Endoscopic retrograde appendicitis therapy (ERAT)|The procedures of ERAT will be performed as below：1.Cannulation of the appendiceal lumen. 2.Endoscopic retrograde appendicography (ERA). 3.Irrigation and appendicolith removal. 4.Stenting for drainage.
223475302|NCT05192642|DRUG|Data on other treatments|Real word data
223475303|NCT04506736|OTHER|ARM|"The ARM is performed by setting the peak inspiratory pressure to 45 cmH₂O then changing the mode of ventilation to pressure controlled ventilation (PCV) with the inspiratory pressure set to give a tidal volume equal to that given during VCV, I:E ratio of 1:1 and a PEEP of 5 cmH₂O. The PEEP level is then increased in 5 cmH₂O steps every minute till it reaches 20 cmH₂O and inspiratory pressure is increased to get an airway opening pressure (inspiratory pressure + PEEP) of 40 cmH₂O which is maintained for one minute after which the ventilation returned to the original setting except for the PEEP level which is kept at 20 cmH₂O.~The titration of individualized PEEP is done by decremental reduction of the 20 cmH₂O PEEP level in 2 cmH₂O steps every 2 minutes and measuring static compliance of the respiratory system (CRS) at each step."
223475304|NCT04506736|OTHER|spontanous ventilation|volume controlled ventilation (7ml/kg tidal volume) with addition of 5 cm H₂O fixed PEEP till the end of the surgery .
223744204|NCT05244577|DRUG|Olanzapine Tablets|Olanzapine,Ondansetron,Dexamethasone,Fosaprepitant
223744205|NCT05244577|DRUG|Placebo|Placebo,Ondansetron,Dexamethasone,Fosaprepitant
223744206|NCT03352986|BIOLOGICAL|biological analysis|biological analysis will be performed in the 6 groups of patients
223744207|NCT03352986|OTHER|peripheral arterial tonometry|peripheral arterial tonometry will be performed in the 6 groups of patients
224069805|NCT02789865|PROCEDURE|Appendectomy|The patients will receive laparoscopic appendectomy according to standard routines.
224069806|NCT03764852|PROCEDURE|outpatient laparoscopic|The intervention is a outpatient laparoscopic sacrocolpopexy with robotic assistance.
224069807|NCT03764852|PROCEDURE|outpatient laparoscopic|The intervention is a outpatient laparoscopic sacrocolpopexy without robotic assistance.
224069808|NCT04073771|DEVICE|Continuous renal replacement therapy with oXiris|Continuous renal replacement therapy with oXiris in patient with septic shock
224069809|NCT01052584|DRUG|Chloroquine- P. vivax|Total of 25mg base per kg over 3 days (10 mg base/kg on Days 1 and 2, and 5 mg base/kg on Day 3)
224069810|NCT01052584|DRUG|Artemether-Lumefantrine: P. vivax|administered twice daily for three days as tablets containing 20 mg of artemether plus 120 mg of lumefantrine in a fixed dose combination at a dosage
224304631|NCT03959215|OTHER|Usual rehabilitation care|Following ACL reconstruction, as per routine clinical practice, all participants will be referred to physiotherapy. Overall treatment aims, content and progressions of rehabilitation will follow current clinical guidelines. The choice of specific therapies, exercises and the number of treatment sessions needed to achieve the required treatment aims is at the clinical discretion of the treating physiotherapist.
224304632|NCT03359577|DIETARY_SUPPLEMENT|Psorax35|This is a randomized, 32 weeks, single center, placebo controlled, double blind study to investigate Psorax35 supplementation in patients with mild to moderate Psoriasis. Groups of patients will be block randomized using randomly selected block sizes, and stratified according to gender.
224305013|NCT06355011|DEVICE|Total Elbow Replacement|Total elbow replacement is a procedure that involves replacing the elbow joint with an implanted device to alleviate pain and improve function.
223475305|NCT00614835|DRUG|Docetaxel plus Gemcitabine|Gemcitabine 900 mg/m2 IV over 90 minutes day 1 Gemcitabine 900 mg/m2 IV over 90 minutes day 8 + Docetaxel 75 mg/m2 IVPB day 8 Dexamethasone 8 mg po bid days 7-9 GCSF 150 ug/m2 (round to nearest vial size: 350 ug or 480 ug) SQ days 9-15 Repeat every 21 days for total of 4 cycles
223475306|NCT01562899|DRUG|MEK162|Supplied as tablets of dosage strength 15 mg in high-density polyethylene bottles with child-resistant closure.
223475307|NCT01562899|DRUG|AMG 479|Supplied as sterile liquid for intravenous infusion in vials in boxes. Until April 2013 a frozen formulation with a concentration of 30 mg/ml was used; from May 2013 onwards a refrigerated formulation with a concentration of 70 mg/ml was used.
224069811|NCT01052584|DRUG|Artemether-lumefantrine: P. falciparum|administered twice daily for three days as tablets containing 20 mg of artemether plus 120 mg of lumefantrine in a fixed dose combination at a dosage
224069812|NCT02474966|DEVICE|Deep Transcranial Magnetic Stimulation (dTMS)|Patients will present on two consecutive days in order to receive dTMS followed by dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI). Subjects will be randomized into two groups: the first group will be treated before with real-dTMS (the first day) and after with sham-dTMS (the second day); the second group will be treated before with sham-dTMS (the first day) and after with realTMS (the second day). At the end of each session of dTMS the patients will undergo by MRI exams.
224069813|NCT04360902|OTHER|Anemia Controller|"Model Predictive Controller software (called Anemia Controller) that utilizes our physiology-based erythropoiesis model to provide ESA dosing recommendations in order to guide a patient's Hgb level towards a predefined target value."
224069814|NCT03304015|BEHAVIORAL|Behavioral Change Communications|HERrespect is developed by Business for Social Responsibility (BSR) and Change Associates. HERproject is one of BSR's numerous initiatives for improving women's lives through enhancement of access and knowledge (BSR, 2015). The factory-based component of HERrespect will be implemented by Change Associates. The intervention group will receive training (group session), research and consultancy services to the corporate and development sectors. HERrespect proposes to use the workplace as an incubator of dialogue among men and women to tackle underlying issues which allow violence against women and girls. Workplace offers a unique platform and environment to engage women who are gaining financial independence to reduce intimate partner violence and workplace violence.
224069815|NCT01568593|DEVICE|T2750|1 drop in each eye 3 to 6 times daily during 84 days
224069816|NCT01568593|DEVICE|Vismed|1 drop in each eye 3 to 6 times daily during 84 days
224069817|NCT00865865|PROCEDURE|Computer aided total knee arthroplasty|Use of computer aided surgery to balance soft tissue tension in total knee arthroplasty
224069818|NCT00865865|PROCEDURE|Conventional total knee arthroplasty|Conventional method of total knee arthroplasty
224069819|NCT03212833|DIAGNOSTIC_TEST|fasting serum insulin|fasting serum insulin in chronic hepatitis C patients
224069820|NCT06398041|OTHER|Blood flow restriction training|standard physiotherapy 45 minutes per day, 5 day a week (GAPP) + 2 extra sessions of blood flow restriction training
224069821|NCT06398041|OTHER|Opinions|Healthcare workers in the geriatric rehabilitation ward and patients will be asked on their opinions on GAPP+Care concerning blood flow restriction training
224069822|NCT03242837|BEHAVIORAL|Army Resilience Training|The Army Resilience Training consists four training sessions of 90 minutes each. Participants learn to reflect their stress management (including thinking, emotions, behavioral consequences; coping strategies) and build resilience using specific strategies.
224069823|NCT03242837|OTHER|Diversity Management Training|Diversity Management Training consists four training sessions of 90 minutes each. Participants learn about diversity and social awareness reflecting different situations and settings.
224069824|NCT01727609|DIETARY_SUPPLEMENT|Milk feed (breast milk or formula milk)|
224069825|NCT04739046|DRUG|Theragene arm|Theragene®,Ad5-yCD/ mutTKSR39rep-ADP with radiation therapy
224069826|NCT04422249|PROCEDURE|laparoscopic middle hepatic vein guidance anatomic hemihepatectomy|95 patients with primary HCC were divided into the middle hepatic vein guidance group(n=45) and the traditional group(n=45) according to the odd and even Numbers, and sealed into envelopes.Outcomes were monitored and evaluated during the 3-year follow-up period
224069827|NCT04854837|DRUG|Remdesivir|Remdesivir treatment
224069828|NCT02138032|BEHAVIORAL|Gains Framed Message|
224069829|NCT02138032|BEHAVIORAL|Loss Framed Message|
224069830|NCT04755049|DIAGNOSTIC_TEST|The Chinese version of the American Shoulder and Elbow Surgeons standardized shoulder assessment form questionnaire|The Chinese version of the American Shoulder and Elbow Surgeons standardized shoulder assessment form questionnaire
224069831|NCT04659460|DEVICE|Remote Ischemic Conditioning|RIC interventions will be applied to the upper extremity calibrated to induce four, ten-minute cycles of five-minutes-ischemia and five-minutes-perfusion for a total of 20 cumulative minutes of limb ischemia, at a pressure of 250 mmHg.
224069832|NCT02109484|BIOLOGICAL|P2-VP8 Subunit Vaccine 10mcg|10 mcg
224069833|NCT02109484|BIOLOGICAL|P2-VP8 Subunit Vaccine 30 mcg|30 mcg
224069834|NCT02109484|BIOLOGICAL|P2-VP8 Subunit Vaccine 60mcg|60 mcg
224069835|NCT02109484|OTHER|Placebo|
224069836|NCT00006112|DRUG|chemotherapy|
224069837|NCT00006112|DRUG|fluorouracil|
224069838|NCT00006112|DRUG|leucovorin calcium|
224069839|NCT00006112|DRUG|mitomycin C|
224069840|NCT05186142|OTHER|Ultrasonography / Ultrasound elastography|Ultrasonography / Ultrasound elastography
224069841|NCT04204733|BEHAVIORAL|Mobile application|Mobile application that incorporates biosensor feedback, teleconsultation, and online group physical activity classes
223744208|NCT05797558|PROCEDURE|Unilateral adrenalectomy|Minimally invasive surgery is performed via the lateral transperitoneal approach or the posterior retroperitoneal approach, with or without robotic assistance, according to the surgeon's preference.
223744209|NCT05797558|DRUG|Medical treatment (eplerenone)|The initial dose of eplerenone is 25 mg twice daily. The dose will be increased by 50 mg every fourth week until systolic blood pressure of 140 mmHg and diastolic blood pressure of 90 mmHg or lower has been reached and biochemical control (plasma renin above the middle of the reference range, i.e \> \~20 mIU/L) is attained and/or hyperkalemia develops. The maximal dose of eplerenone is 300 mg twice daily.
223744210|NCT00112593|DRUG|fludarabine phosphate|Given IV
223744211|NCT00112593|RADIATION|total-body irradiation|Undergo TBI
223744212|NCT00112593|PROCEDURE|peripheral blood stem cell transplantation|Undergo allogeneic bone marrow or peripheral blood stem cell transplantation
224162105|NCT02635685|OTHER|Clinical Decision Support tool|Automatized support tool for identification of patients with a diagnosis of atrial fibrillation without appropriate anticoagulant therapy for stroke prevention.
224304633|NCT03359577|DIETARY_SUPPLEMENT|MCT oil|This is a randomized, 32 weeks, single center, placebo controlled, double blind study to investigate Psorax35 supplementation in patients with mild to moderate Psoriasis. Groups of patients will be block randomized using randomly selected block sizes, and stratified according to gender.
224304634|NCT05755152|OTHER|polyphenol-lecithin precipitate (PLP)|Chewing gum made with material produced from patented technology to rapidly isolate polyphenols from fruit juice (PLP).
223582066|NCT05845671|DRUG|Amivantamab 1400mg|"Amivantamab is a bispecific antibody that binds to the extracellular domains of EGFR and MET.~In in vitro and in vivo studies amivantamab was able to disrupt EGFR and MET signaling functions through blocking ligand binding and, in exon 20 insertion mutation models, degradation of EGFR and MET. The presence of EGFR and MET on the surface of tumor cells also allows for targeting of these cells for destruction by immune effector cells, such as natural killer cells and macrophages, through antibody-dependent cellular cytotoxicity (ADCC) and trogocytosis mechanisms, respectively."
223582067|NCT05845671|DRUG|Amivantamab (to be determined)|"Amivantamab is a bispecific antibody that binds to the extracellular domains of EGFR and MET.~In in vitro and in vivo studies amivantamab was able to disrupt EGFR and MET signaling functions through blocking ligand binding and, in exon 20 insertion mutation models, degradation of EGFR and MET. The presence of EGFR and MET on the surface of tumor cells also allows for targeting of these cells for destruction by immune effector cells, such as natural killer cells and macrophages, through antibody-dependent cellular cytotoxicity (ADCC) and trogocytosis mechanisms, respectively.~Dose will be determine after the Safety Lead-In"
223582068|NCT05845671|DRUG|Amivantamab (to be determined)|"Amivantamab is a bispecific antibody that binds to the extracellular domains of EGFR and MET.~In in vitro and in vivo studies amivantamab was able to disrupt EGFR and MET signaling functions through blocking ligand binding and, in exon 20 insertion mutation models, degradation of EGFR and MET. The presence of EGFR and MET on the surface of tumor cells also allows for targeting of these cells for destruction by immune effector cells, such as natural killer cells and macrophages, through antibody-dependent cellular cytotoxicity (ADCC) and trogocytosis mechanisms, respectively.~Dose will be determine after the Safety Lead-In"
223744213|NCT00112593|DRUG|cyclosporine|Given IV or PO
223744214|NCT00112593|DRUG|mycophenolate mofetil|Given IV or PO
223744215|NCT00112593|OTHER|laboratory biomarker analysis|Correlative studies
223744216|NCT00646529|DRUG|budesonide/formoterol (Symbicort)|
223744217|NCT00646529|DRUG|budesonide (Pulmicort)|
223744218|NCT00265954|BEHAVIORAL|internet, in-person and internet+in-person|All participants receive an 18 month behavioral weight loss program that meets weekly for the first 6 months and monthly for the next year.
224162106|NCT05287269|DIAGNOSTIC_TEST|Ocular Coherence Tomography|OCT images were recorded as a fast macular radial line scan with captured on either Heidelberg Spectralis (Heidelberg Engineering GmbH, Germany) or Topcon DRI Triton (Topcon Medical Systems inc. USA).
224162107|NCT00252876|DRUG|tesaglitazar|
224304635|NCT05755152|OTHER|control formulation|Chewing gum made with material produced from conventional technology (e.g cranberry extract).
224304636|NCT00503711|DRUG|Vandetanib|100 mg every other day, 100mg once daily
224304637|NCT00503711|DRUG|Vandetanib 300 mg|300mg once daily
223744219|NCT00231335|DRUG|escitalopram|
224162108|NCT00357240|DRUG|Atazanavir|Capsules, Oral, 400 mg, once daily, 6 days.
224162109|NCT00357240|DRUG|Atazanavir/Ritonavir|Capsules/capsules, Oral, 300/100 mg, once daily, 10 days.
224162110|NCT00357240|DRUG|Atazanavir/Ritonavir+Omeprazole|Capsules/capsules + Capsules, Oral, 300/100 mg + 20 mg, once daily in PM + once daily in AM, 7 days.
224304638|NCT04917718|DRUG|Conversion from IR Tacrolimus to XR Tacrolimus|All participants will be consented to the study on IR Tacrolimus. After their baseline visit, they will be converted to XR Tacrolimus
224304639|NCT00004890|BIOLOGICAL|aldesleukin|
224304640|NCT00004890|DRUG|Biomed 101|
224162111|NCT00357240|DRUG|Atazanavir/Ritonavir+Omeprazole|Capsules/capsules + Capsules, Oral, 400/100 mg + 20 mg, once daily in PM + once daily in AM, 7 days.
224162112|NCT00357240|DRUG|Atazanavir|Capsules, Oral, 400 mg, once daily, 6 days.
224162113|NCT00357240|DRUG|Atazanavir/Ritonavir|Capsules/capsules, Oral, 300/100 mg, once daily, 10 days.
224304641|NCT00944749|DRUG|h-ATG (ATGAM )|
224304642|NCT00944749|DRUG|Cyclosporine (Gengraf )|
224304643|NCT06412237|DEVICE|RELab tenoexo|The RELab tenoexo is a fully wearable and portable RHO developed at the Rehabilitation Engineering Laboratory (RELab) at ETH Zurich.
224304644|NCT03052413|DIETARY_SUPPLEMENT|Nutrafol|Eligible subjects will receive Nutrafol® to take daily for 180 days
224304645|NCT03052413|DIETARY_SUPPLEMENT|placebo|Eligible subjects will receive Placebo to take daily for 180 days
224304646|NCT01613950|DRUG|AUY922|AUY922 is a non-geldanamycin inhibitor of the heat shock protein 90 (HSP90).
224304647|NCT01613950|DRUG|BYL719|BYL719 is an oral α-specific phosphatidylinositol-3-kinase (PI3K) inhibitor.
224304648|NCT03697265|DRUG|Sepranolone (UC1010) low dose|Subcutaneous (SC) administration
224304649|NCT03697265|DRUG|Sepranolone (UC1010) high dose|Subcutaneous (SC) administration
224304650|NCT03697265|DRUG|Placebo|Subcutaneous (SC) adminstration
224304651|NCT02038231|BEHAVIORAL|Parenting Mindfully Program|see Arm Description.
224162114|NCT00357240|DRUG|Atazanavir/Ritonavir+Omeprazole|Capsules/capsules + Capsules, Oral, 400/100 mg + 20 mg, once daily in AM + once daily in AM, 7 days.
224162115|NCT00357240|DRUG|Atazanavir/Ritonavir+Omeprazole|Capsules/capsules + Capsules, Oral, 400/100 mg + 20 mg, once daily in AM + once daily in PM, 7 days.
224162116|NCT01987752|DRUG|brimonidine tartrate/timolol maleate Ophthalmic Solution|brimonidine tartrate/timolol maleate (Combigan®) Ophthalmic Solution as per local standard of care in clinical practice.
224162117|NCT01359527|DEVICE|Hip Resurfacing|
223475308|NCT05540119|PROCEDURE|Surgery|Patients who undergo surgery are separately assessed
223475309|NCT06201091|BEHAVIORAL|Systematic simple swallowing training|"Systematic simple swallowing training includes the following:~Warm-up: including joint activities, chest expansion exercise, etc., totally 5 minutes.~Cognitive swallowing training: play video of food programs for five minutes. Lip training: Bounce the upper and lower lips to make a bo sound. 30-60 seconds.~Tongue training: Do the upper, lower, left, and right four-directional movements of the tongue muscle. 30-60 seconds.~Mandibular training: slowly open r mouth to the maximum, then slowly close it. 30-60 seconds.~Soft palate training: Make the sounds of g, k, and h for 1-2 minutes. Cheek puffing training: Close lips tightly and puff cheeks. 30-60 seconds. Swallowing training: We require the elderly to swallow small amounts of water intermittently and forcefully for 2-5 times.~Completing the above content in succession is called a round, and each training session includes 2-3 rounds. 2 sessions a day. Five days a week."
223475310|NCT04695561|OTHER|Self Myofascial Relaxation|Total of 12 times for 6 weeks
223582069|NCT05084014|OTHER|Deep Stripping|The deep longitudinal stripping can be applied on adhesions and knots in muscles. The lengthening stokes are parallel to muscle fiber and applied in an oblique direction with the help of the thumbs of hands/ elbow/ knuckles
223744220|NCT06202391|PROCEDURE|Autogenic Inhibition-MET|Autogenic Inhibition-MET protocol: 3-5 repetitions of post isometric relaxation (PIR) (30- 50% isometric contraction of the muscle to be stretched for 5-10 seconds, followed by rest period of 5 seconds and then a stretch of 20-30 seconds' hold. A total of 12 sessions, four times a week, for three consecutive weeks.
224304652|NCT02038231|OTHER|Parent Education Program|See Arm Description.
223475311|NCT04695561|OTHER|Instrument Assisted Soft Tissue Mobilization|Total of 12 times for 6 weeks
223475312|NCT04695561|OTHER|Only Exercise (Control)|Every day for 6 weeks
223475313|NCT04595058|DEVICE|Double pigtail plastic stent through lumen-apposing metal stent|Biliary drainage guided by endoscopic ultrasound: Addition or not, of a axis-orienting plastic stent, mostly, double-pigtail stent through the lumen of a lumen-apposing metal stent
223475314|NCT04595058|DEVICE|Lumen-apposing metal stent without double pigtail plastic stent|Endoscopic ultrasound-guided transmural biliary drainage is with lumen-apposing metal stent is a formal indication according to the instruction forms of the manufacturer.
223582070|NCT05084014|OTHER|Kneading|kneading lifts the muscle in circular movements with the help of the hands. It lifted, rolled, and squeezed muscle
223744221|NCT06202391|PROCEDURE|Reciprocal Inhibition-MET protocol|Reciprocal Inhibition-MET protocol: 3-5 repetitions of Reciprocal Inhibition (RI) MET (30- 50% isometric contraction of the muscle opposite to the muscle to be stretched for 5-10 seconds, followed by rest period of 5 seconds and then a stretch of 20-30 seconds' hold A total of 12 sessions, four times a week, for three consecutive weeks
223744222|NCT01518010|BEHAVIORAL|Play game|Participants engage in non-game activity (establish baseline) 7 \* 1 hr weekly; play single-player game 7 \* 1 hr weekly; play multi-player game 7 \* 1 hr weekly.
223582071|NCT00541346|DRUG|Methylphenidate Transdermal System|10mg for one week, with weekly stepwise increases to 15mg, 20mg, and 30mg for additional 7 weeks, if symptom reports remained elevated. Titration decreased one stepwise dosage
223582072|NCT04966923|OTHER|No intervention in this study|Analyses of pathogenic variant TP53 and variants in genetic test
223744223|NCT03437720|DRUG|SAR425899|"Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous injection"
223744224|NCT03437720|DRUG|Placebo|"Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous injection"
223744225|NCT01818154|OTHER|LED phototherapy|
223582073|NCT02920723|OTHER|Training|
223744226|NCT01818154|OTHER|narrowband UVB phototherapy|
224162118|NCT01359527|DEVICE|Total Hip Arthroplasty|
224162119|NCT01478581|DRUG|PCI-32765|
224162120|NCT01478581|DRUG|Dexamethasone|
224162121|NCT00621244|DRUG|LBH589|
224162122|NCT06446895|DIAGNOSTIC_TEST|Coronariography|Patients were classified as MICAD or MINOCA by the presence or absence of an epicardial vessel with ≥50% stenosis after performing a coronariography.
224162123|NCT05941910|DRUG|Q10|240mg of Q10 orally, every day
224162124|NCT03188302|OTHER|Collection of stool samples|The subjects collect stool samples to be used for validation of a new direct measurement of stool consistency. Every stool sample produced during 2 collection periods of approximately 60 hours each have to be collected using the Commode Specimen Collection System (Medline Industries, Inc.). Each collection period starts preferably in the evening (20h00) and ends 3 days later in the morning (08h00). The collected samples must be stored at subject's home in a refrigerator provided by the sponsor until handover to the site staff.
223582074|NCT02920723|OTHER|Control|
223582075|NCT00003252|DRUG|amifostine trihydrate|
223744227|NCT05302544|OTHER|Mixed Reality training|Mixed Reality training: Mixed Reality game with appearance of virtual balloons in the game area that the subject must find and pierce with finger
223744228|NCT05302544|OTHER|motor activities|motor activities usually performed
224162125|NCT05655728|DRUG|Metformin|The participants will receive treatment of metformin (initial dose of 500 mg/day, within 2 weeks reaching the maximum tolerated dose \[maximum: 1500 mg/day\]).
224162126|NCT05655728|OTHER|Placebo|The participants will receive treatment of placebo.
224162127|NCT05711511|PROCEDURE|conventional obturation technique|cold lateral condensation ,this technique involves placing a single cone of gutta-percha (GP) with sealer in the prepared root canal and adding secondary GP cones that are compacted together with the use of a spreader. The cones stay together due to frictional grip and the presence of a sealer
224304653|NCT02943967|PROCEDURE|CXL + PRK group|Corneal cross-linking with subsequent photorefractive keratotomy after 6 months was performed in one eye
224304654|NCT02943967|PROCEDURE|PRK group|Photorefractive keratotomy alone was performed in contra lateral eyes
223475315|NCT04260633|DEVICE|Dental Monitoring assisted aligner change, 12-hour tray wear time and VPro+ are the interventions for the trial.|"The current standard of care for clear aligner use as suggested by Invisalign is unclear as to how frequently aligners should be changed. We suspect that the frequency for aligner change as determined by the orthodontist using Dental Monitoring will be variable for every participant.~Vpro+ is an adjunctive therapeutic tool for clear aligner treatment. It is proposed to deliver high frequency vibrations to reduce treatment time and pain associated with clear aligners.~Align Technology suggests 22-hour wear time for clear aligner therapy. Participants in two arms of the study will be asked to wear the trays for about half the recommended wear time to assess whether night-time aligner wear will be sufficient for successful treatment."
223475316|NCT01352039|BIOLOGICAL|Heparin Sodium - Eurofarma|Heparin Sodium will be given during 5 to 7 days each 8 hours on dosis 5,000 UI
223475317|NCT01352039|BIOLOGICAL|Heparin Sodium - APP Pharmaceuticals|Heparin Sodium will be given during 5 to 7 days each 8 hours on dosis 5,000 UI
223475318|NCT00282932|DRUG|Detrol LA|
223475319|NCT05321537|OTHER|Therapeutic exercises|A somatosensory training and an endurance-strength training protocol
223475320|NCT05230901|OTHER|Standard of Care|Patients with CMR-derived ECV% levels ≥25.9% will be treated with standard of care according to current guidelines (Control group).
223744229|NCT02153112|BIOLOGICAL|GI.1/GII.4 (15/15)|Norovirus GI.1/GII.4 (15 μg/15 μg) bivalent VLP vaccine combined with 500 μg aluminum hydroxide for IM injection
223582076|NCT01073475|OTHER|There is no intervention associated with the parent MNHR study. For the MNHR COVID sub-study, participants will be asked to provide a blood specimen at or near delivery.|"There is no intervention associated with the parent MNHR study~For the MNHR COVID sub-study, each woman will be asked to provide a blood specimen of approximately 3-5 cc at or near delivery (at delivery or 14 days after) to be tested for COVID-19 antibodies. The person collecting the specimen will be a trained member of the registry staff. The ZEUS ELISA SARS-CoV-2 IgG Test System will be used and run at each site. RTI International will provide central quality support of the analyses."
223582077|NCT05756608|DIAGNOSTIC_TEST|68Ga-FAPI and 18F-AlF-FAPI PET-MR|Hybrid Cardiac PET-MR with 68Ga-FAPI and 18F-AlF-FAPI radiotracer
223582078|NCT04097379|DRUG|LRX712|LRX712 intra-articular injections
223582079|NCT04097379|DRUG|Placebo|Placebo intra-articular injections
223582080|NCT02448589|DRUG|TAS-119|
223582081|NCT06508983|DRUG|SG301 Injection|Dosage form: solution for infusion Route of administration: intravenous Frequency: weekly intervals (QW) for 8 weeks, then every 2 weeks (Q2W) thereafter.
223582082|NCT06508983|DRUG|SG301 placebo|Dosage form: solution for infusion Route of administration: intravenous Frequency: weekly intervals (QW) for 8 weeks, then every 2 weeks (Q2W) thereafter.
223744230|NCT02153112|BIOLOGICAL|GI.1/GII.4 (15/50)|Norovirus GI.1/GII.4 (15 μg/50 μg) bivalent VLP vaccine combined with 500 μg aluminum hydroxide for IM injection
223582083|NCT06508983|DRUG|pomalidomide|Dosage form: capsule Route of administration: oral Dosage: 4 mg Frequency: once daily on Days 1 through 21 of each 28-day cycle.
223744231|NCT02153112|BIOLOGICAL|GI.1/GII.4 (50/50)|Norovirus GI.1/GII.4 (50 μg/50 μg) bivalent VLP vaccine combined with 500 μg aluminum hydroxide for IM injection
223744232|NCT02153112|BIOLOGICAL|GI.1/GII.4 (50/150)|Norovirus GI.1/GII.4 (50 μg/150 μg) bivalent VLP vaccine combined with 500 μg aluminum hydroxide for IM injection
223744233|NCT02153112|DRUG|Placebo|Placebo saline solution
223744234|NCT06536803|OTHER|high load strength training and Tissue-specific plantar fascia stretching exercise for 12 weeks|high load strength training and Tissue-specific plantar fascia stretching exercise for 12 weeks
223744235|NCT06536803|OTHER|high-load strength training with routine physiotherapy|high load strength training with routine physiotherapy for 12 weeks
223582084|NCT06508983|DRUG|dexamethasone|Dosage form: tablets or solution for infusion Route of administration: oral or intravenous Dosage: 40 mg (participants with BMI \< 18.5 kg/m2 received 20 mg dexamethasone) Frequency: once daily on Day 1, 8, 15, 22 of each 28-day treatment cycle.
223744236|NCT01067014|DEVICE|Baxano iO-Flex® System|Decompressive lumbar surgery using Baxano iO-Flex® System
223744237|NCT03774277|BEHAVIORAL|Packed Promise for a Healthy Heart|"Voucher for fresh vegetables and fruits (referred to as a fresh check); Home delivered food boxes that contain Dietary Approaches to Stop Hypertension (DASH)-approved ingredients for preparing low-salt, and traditional healthy Chickasaw meals; Heart-healthy recipes (available at getfreshcooking.com) that are tailored to traditional Chickasaw diet and culture; Educational materials; Personalized invitation to attend local cooking demonstrations; Assistance to link the Fitbit and AYA app"
223744238|NCT04425707|DRUG|Ivermectin|use of Ivermectin in the treatment of COVID 19 patients, in comparison to and in addition to the standard care of treatment of COVID 19 in Egypt
224069842|NCT00265538|BEHAVIORAL|Patient educational letter to engage provider in hypertension rx discussion|Patients will receive a customized/tailored letter (education) including most recent clinic blood pressure, current blood pressure medications and suggested htn medication(s). All the intervention arms (A, B and C) receive the letter.
224069843|NCT00265538|BEHAVIORAL|Financial incentive (Arms B and C) and health educator phone call (Arm C)|Patients may receive a financial incentive for discussing the intervention letter with their provider and 6 months copay reimbursement and/or the financial incentive discussion incentive, 6 months copay reimbursement as well as a phone call reminder 1-2 days prior to their primary care appt. The Financial incentive is part of both Arms B and C. The health educator phone call is only in Arm C.
224162128|NCT05711511|DEVICE|Obtura II|"is a popular warm gutta-percha technique that uses a gun to warm and inject the gutta-percha filling into the root canal.Obtura 2 system: The gutta-percha is heated from temperature range of 160C to 200C which is then injected through the needle"
223582085|NCT02651480|DIETARY_SUPPLEMENT|Plant-based diet|Weekly instructions will be given to the participants in the intervention group about following vegan diet.
223744239|NCT02176850|DRUG|Micardis®|
223582086|NCT02651480|DIETARY_SUPPLEMENT|Control Group|Unrestricted diet with no instruction.
223582087|NCT06579690|DRUG|8.4% sodium bicarbonate solution|Sodium bicarbonate infusion 8.4% solution The study drug will be contained in identical 25 mL glass vials (Neon Laboratories Ltd, Mumbai, India), administered intravenously as a single bolus dose.
223744240|NCT04039412|DRUG|Hybrid regimen|two-step (dual-quadruple) treatment
224069844|NCT03003208|OTHER|Pulmonary rehabilitation|An exercise and education program
223475321|NCT05230901|DRUG|Spironolactone 25mg|"Patients with CMR-derived ECV% levels ≥25.9% in Arm Spironolactone will receive spironolactone 25 mg/d in addition to standard of care medication ."
223475322|NCT05230901|DRUG|Dihydralazine|"Patients with CMR-derived ECV% levels ≥25.9% in arm Spironolactone + Dihydralazine will receive spironolactone 25 mg/d + dihydralazine (2x12.5 mg/d p.o. in slow acethylators, and 2x25mg/d p.o. in fast acethylators, confirmed by genetic testing)"
223475323|NCT01302899|DRUG|Aliskiren|Aliskiren 150 mg (Tablet)
223475324|NCT01302899|DRUG|Placebo to Aliskiren|Aliskiren 150 mg Matching Placebo (Tablet)
223475325|NCT01302899|DRUG|Hydrochlorothiazide (HCTZ)|HCTZ 25mg (Capsule)
223475326|NCT01302899|DRUG|Placebo to Hydrochlorothiazide (HCTZ)|HCTZ 25mg (Capsule) Matching Placebo
223582088|NCT06579690|OTHER|0.9% Normal Saline|The comparision group will receive 50 mls of 0.9% Normal Saline
223582089|NCT03350906|DRUG|n3-PUFA|The DHA/EPA softgels will each contain \~465mg of EPA and \~375mg of DHA for a total daily dosage of 3.4g/day. Additionally, each capsule will contain SCI's proprietary Advance Lipid TechnologiesTM (ALTTM) containing the surfactants polysorbate 80, NF (\~381 mg) and poloxamer 237, NF (\~8.8 mg).
223582090|NCT03350906|DRUG|Placebo|Looks exactly like the study drug but contains soybean oil with no active ingredient.
223582091|NCT03350906|PROCEDURE|Biopsy|Two muscle biopsies from the upper part of one leg. A small (\~1cm) incision will be made through the skin, and a needle will then be used to remove the muscle.
223582092|NCT03350906|DIAGNOSTIC_TEST|Body Composition Scan|Measure of body fat percentage, skeletal muscle mass, body water, and visceral fat.
223582093|NCT01877577|DIETARY_SUPPLEMENT|Vitamin D3|Study patients who took 2,000 IU daily of vitamin D3 will be compared to those who took 4,000 IU daily to determine the different effects of vitamin D3 dose on quality of life, disease activity, and the laboratory tests in this study.
223582094|NCT06089941|OTHER|circulating tumoral DNA detection|blood samples taken at diagnosis, mid-treatment, end of treatment and in the event of relapse
223582095|NCT03468972|DRUG|Immunosuppressive treatment|At 3 months after randomization, patients in the corticosteroid arm who have persistent proteinuria of ≥ 1.0 g/g creatinine, or fast decline in eGFR ≥ 15% from the baseline value, will additionally receive cyclosphosphamide during the following 3 months. Patients who have substantial decreased amount of proteinuria \< 1.0 g/g creatinine at 3 months will continue protocol-based corticosteroids during the same period. At 6 months after randomization, patients who receive add-on cyclophosphamide will switch to azathioprine as a maintenance therapy and those who receive corticosteroids alone will discontinue the treatment and will be followed up during 24 months thereafter. Assessment of outcome will be done at 6 months and at 36 months.
223582096|NCT03468972|OTHER|intensive supportive care|During 3-6 months before the enrollment, all patients will receive maximal supportive care including the use of RAS blockers, blood pressure control with a target of \<130/80 mmHg, and protein restriction diet. If proteinuria does not decrease \< 1.0 g/g creatinine, patients will be randomly assigned to continue supportive care, or to receive corticosteroids.
223582097|NCT04590209|OTHER|Blood sampling|Recruited patients will be subjected to 2 blood samples of 7 mL at day 0 for serological analysis and cell collection and to an additional blood sample of 7 mL at day 15 for serological analysis
223582098|NCT04590209|OTHER|Skin biopsy|Recruited patients will be subjected to a single skin biopsy at day 0 for histological and transcriptomic analysis
223582099|NCT02792023|OTHER|Immunochemical fecal occult blood test|Participants will be provided with a single immunochemical fecal occult blood test. Participants will introduce a small sample of feces inside and bring the test to the hospital
223582100|NCT02792023|DEVICE|Colonoscopy|A colonoscopy (procedure performed using a scope design to examine the large bowel) will be offered to the participants
223744241|NCT04039412|DRUG|Reverse hybrid regimen|one-step two-phase (quadruple-dual) treatment
223475327|NCT01302899|DRUG|Ramipril|Ramipril 10mg (Tablet)
223475328|NCT04361058|DRUG|Nivolumab|At Day +50 (±10 days) post-allogeneic SCT, participants will be treated with Nivolumab. Nivolumab will be administered intravenously once every two weeks for a total of 4 treatments. Participants will initially receive nivolumab at a significantly reduced starting dose of 0.25 mg/kg. This dose was determined based on the incidence of increased aGVHD, which was noted after treatment post-SCT in previous studies. Nivolumab IV will be given every 2 weeks for 4 cycles. One dose of nivolumab is equivalent to one cycle. The first administration will be at Day +50 (±10 days), assuming the participant has not had any evidence of Grade II-IV aGVHD after allogeneic SCT and does not have any current evidence of any grade of aGVHD at the day of first application of nivolumab. Depending on emerging safety data, dose escalation cohorts will explore higher dose levels of nivolumab at 0.5 mg/kg and 1 mg/kg.
223744242|NCT04039412|DRUG|Levofloxacin quadruple regimen|non-Clarithromycin non-Bismuth quadruple therapy
223475329|NCT00424242|DRUG|Pemetrexed|Orally beginning at 500 mg/m2 every 3 weeks until disease progression
223475330|NCT05724290|GENETIC|EGR2|We investigated the expression of EGR2 in patients with nasal polyps through immunohistochemistry.
223475331|NCT00855348|OTHER|All eligible subjects will provide blood for SEPT9 biomarker testing|A single blood sample per participant selected according to analysis plan is tested for evidence of methylation of a specific DNA sequence, SEPT9.
223475332|NCT02834975|DRUG|Pembrolizumab|Pembrolizumab on Day 1 of each cycle.
223475333|NCT02834975|DRUG|Paclitaxel|"* NACT: Paclitaxel on Day 1 of each cycle;~* ACT: Paclitaxel same as NACT OR; dose-dense option weekly per protocol."
223475334|NCT02834975|DRUG|Carboplatin|Carboplatin IV on Day 1 of each cycle.
223475335|NCT00023231|DRUG|Daclizumab|1 mg/kg/dose at study entry and Weeks 2, 4, 6, and 8
223475336|NCT00023231|DRUG|Methylprednisolone/prednisone|Dosage is dependent on weight and varies throughout study. Refer to protocol for more information.
223744243|NCT00014677|BIOLOGICAL|interleukin-4 PE38KDEL cytotoxin|
223744244|NCT00014677|PROCEDURE|conventional surgery|
223744245|NCT00130221|DRUG|2% chlorhexidine gluconate impregnated cloth|
223744246|NCT00130221|OTHER|Daily bathing with Bar soap|bathed daily with bar soap (Dial Corp., Scottsdale, AZ), warm water, and cotton washcloths.
223744247|NCT01709851|DEVICE|Vascular microdialysis using the GMD-system|Glucose levels will be monitored by means of vascular microdialysis using the GlucoMen(R)Day system
223475337|NCT00023231|DRUG|Mycophenolate mofetil|Solution or oral tablet taken daily. Dosage depends on body surface area.
223744248|NCT01709851|DEVICE|Vascular and subcutaneous microdialysis using the GMD-system|Glucose levels will be monitored by means of vascular and subcutaneous microdialysis using the GlucoMen(R)Day system
224162129|NCT00338429|BEHAVIORAL|FHP Sleep Program|Cognitive-Behavioral Intervention
224162130|NCT00175318|BEHAVIORAL|Motivational Interviewing|Beginning at 12 months of age, regular application of fluoride varnish will be an option that a mother in the MI group may choose for her child. Control families will receive dental health information from a pamphlet, and will have access to fluoride varnish at local dental clinics.
224162131|NCT03612674|PROCEDURE|Standard colonoscopy|Current standard of care colonoscopy.
224162132|NCT03612674|DEVICE|ARC Endocuff Vision|Subjects randomized to undergo a colonoscopy procedure with ARC Endocuff Vision will have this device placed on the top of the colonoscope used during their procedure.
224162133|NCT05847556|OTHER|video game hearing tests|Video game hearing tests (as a non-medical device) used to monitor ototoxicity
224162134|NCT05847556|OTHER|Audio-training|Audio-training (as a non-medical device) used to determine if it can improve spatial hearing perception.
224162135|NCT05148429|OTHER|Ultrasound exam|Ultrasound exam
224162136|NCT05148429|OTHER|Fetal MRI|Fetal MRI
224162137|NCT05148429|OTHER|Postnatal abdominal ultrasound|Postnatal abdominal ultrasound
224162138|NCT05148429|OTHER|Pediatric Follow up|Pediatric Follow up
224304655|NCT04171024|DEVICE|Sham electrical stimulation|A non invasive sham diaphragm electrical stimulation using transcutaneous thoracic probes
224304656|NCT04171024|DEVICE|Transcutaneous diaphragm electrical stimulation|A non invasive diaphragm electrical stimulation using transcutaneous thoracic probes
223475338|NCT00023231|DRUG|Sirolimus|Oral tablet taken once prior to transplant. Dosage dependent on body surface area.
223475339|NCT00023231|DRUG|Bactrim|Oral tablet taken three times per week. Dosage is dependent on weight.
223475340|NCT00023231|DRUG|Ganciclovir|Oral tablet taken daily. Dosage is dependent on weight.
223475341|NCT00023231|DRUG|Lipitor|Oral tablet taken daily
223475342|NCT03164642|BEHAVIORAL|LENA with Feedback|The LENA with Feedback intervention will involve mothers running the Language ENhancement Assessment/intervention system, an audiorecorder language pedometer that records adult speech centered on the child, child vocalizations, and parent-child reciprocal turn-taking conversations. During their regular EI providers will use a standardized feedback protocol that includes emphasizing the mother's strengths, reviewing the LENA visual output from the previous recording, and asking questions to elicit how the mother can increase her child-centered and reciprocal communications during daily routines. The conversation will include concrete examples of how the mother can increase the language exchanges, encouragement, and practical ways to individually tailor the strategies to the family.
223475343|NCT03164642|BEHAVIORAL|LENA no feedback|The LENA with Feedback intervention will involve mothers running the Language ENhancement Assessment/intervention system, an audiorecorder language pedometer that records adult speech centered on the child, child vocalizations, and parent-child reciprocal turn-taking conversations
223475344|NCT02667899|DEVICE|deep brain stimulation|Deep brain stimulation means stimulate the brain with DBS.
223475345|NCT02667899|DEVICE|transcranial magnetic stimulation|Transcranial magnetic stimulation means stimulate the brain with magnetic stimulation.
223475346|NCT02667899|OTHER|Routine treatment|Means without above additional treatment.
223475347|NCT01741077|DIETARY_SUPPLEMENT|folic acid|subjects take multivitamin supplement containing folic acid. Women were enrolled based on whether or not they were taking supplements.
223582101|NCT02792023|DEVICE|Upper endoscopy|An upper endoscopy (procedure performed using a scope to examine the upper digestive tract) will be offered to the participants
223582102|NCT03908918|OTHER|Mindfulness app|Mobile app-delivered mindfulness intervention delivered over 4 weeks.
223582103|NCT02054884|DRUG|Arm A: F16IL2 in combination with paclitaxel|"Intravenous (i.v.) 1 hour infusions of paclitaxel 90 mg/m\^2 followed, after 30 min pause, by 3 hour i.v. infusions of F16IL2 35 Mio IU on days 1, 8, 15 of each 28 day cycle.~Patients will receive 4 week cycles of study therapy for a maximum of 24 weeks, or until disease progression, unacceptable toxicity or withdrawal of consent."
223582104|NCT02054884|DRUG|Arm B: Paclitaxel|"Intravenous (i.v.) 1 hour infusions of Paclitaxel 90 mg/m\^2 on days 1, 8, 15 of each 28 day cycle.~Patients will receive 4 week cycles of study therapy for a maximum of 24 weeks, or until disease progression, unacceptable toxicity or withdrawal of consent."
223582105|NCT02215343|DIETARY_SUPPLEMENT|Wheat bran extract|Patients will be provided with 15g of wheat bran extract (WBE) (Cargill R\&D Centre Europe).
223582106|NCT02215343|DIETARY_SUPPLEMENT|Fish oil|Patients will be provided with a fish oil supplement (capsules), containing 3-4g of N-3 fatty acids (Axellus A/S, Ishøj, Denmark).
223582107|NCT04441008|DEVICE|Accelerated Intermittent Theta Burst (aiTBS)|High-dose intermittent theta burst administered at a treatment frequency 10x per day, with each treatment session duration 3x standard TMS (1800 pulses). Delivering 50 sessions in 5 days.
223582108|NCT04441008|DEVICE|Electroconvulsive therapy (ECT)|ECT as per standard clinical care and management.
223582109|NCT05160766|BIOLOGICAL|Comirnaty (BTN162b2)|Single booster shot (3rd dose in Part A and 4th dose in Part B)
223582110|NCT05160766|BIOLOGICAL|Spikevax (mRNA-1273)|Single booster shot (3rd dose in Part A and 4th dose in Part B)
223582111|NCT02991469|DRUG|Sarilumab SAR153191 (REGN88)|"Pharmaceutical form: Solution~Route of administration: Subcutaneous"
223582112|NCT02773771|DIETARY_SUPPLEMENT|beta-hydroxy-beta-methylbutyrate|HMB is a leucine metabolite that may also be a potent mediator of anabolic processes in skeletal muscle; subjects will not receive \>3g of HMB/ day.
223582113|NCT02773771|DIETARY_SUPPLEMENT|Placebo|The placebo is cornstarch and will be mixed in with Vital HP. The solution will look identical to the intervention arm.
223582114|NCT02773771|DIETARY_SUPPLEMENT|Vital HP®|Vital HP® is a form of enteral nutrition a part of the Massachusetts General enteral formulary
223582115|NCT04886700|DRUG|SG001|Subjects will receive intravenous infusion of SG001 at the dose of 240 mg every 2 weeks until disease progression, unacceptable toxicity, meeting the suspension or termination criteria, or up to 24 months in patients without disease progression.
223582116|NCT05845463|DEVICE|Cerebro endoscopy quality control tool|The AI provides feedback via a separate screen to the endoscopists to inform them which part of the upper GI tract have been adequately visualised.
223582117|NCT02853435|DRUG|Gepotidacin RC Tablet|The tablet is a capsule shape white film coated tablet with no identifying markings. This is an immediate release tablet containing gepotidacin 750 mg (free base) and inactive formulation excipients administered orally with 240 mL of water. Up to an additional 100 mL of water may be given to assist in swallowing tablets.
223582118|NCT02853435|DRUG|Gepotidacin HSWG Tablet|The tablet is an oval shape white film coated tablet with no identifying markings. This is an immediate release tablets containing gepotidacin 750 mg (free base) and inactive formulation excipients administered orally with 240 mL of water. Up to an additional 100 mL of water may be given to assist in swallowing tablets.
223582119|NCT02853435|DRUG|Gepotidacin Capsule|It is a pink gelatin size 00 capsule with no identifying markings containing slightly agglomerated pale yellow to grayish yellow to yellowish gray powder. This is an immediate release capsules containing gepotidacin 500 mg (mesylate salt) and inactive formulation excipients administered orally with 240 mL of water. Up to an additional 100 mL of water may be given to assist in swallowing capsules.
223582120|NCT05696093|DRUG|cotrimoxazole|Use of cotrimoxazole therapy for enterobacterial VAP
223582121|NCT05696093|DRUG|standard antibiotic therapy|Use of standard antibiotic therapy for enterobacterial VAP
223582122|NCT04467671|COMBINATION_PRODUCT|Tissue Engineered Vascular Grafts|Patients will undergo EC TCPC interposition grafting with a tissue engineered vascular graft and serial magnetic resonance imaging (MRI)
223582123|NCT06258057|OTHER|Not applicable / database analysis|Not applicable / database analysis
223582124|NCT00996801|DRUG|MK-5442|MK-5442 tablets (randomized to a dose of 5, 7.5, 10 or 15 mg) taken orally, once-daily, for 12 months
223582125|NCT00996801|DRUG|Placebo to MK-5442|Matching placebo to MK-5442 taken orally, once-daily, for 12 months
223582126|NCT00996801|DRUG|Alendronate Sodium|Alendronate tablets 70 mg, taken orally, once-weekly, for 12 months
223582127|NCT00996801|DRUG|Vitamin D3|Vitamin D3 (cholecalciferol) administered orally, at a dose of 5600 IU (two tablets, 2800 IU each), once-weekly for 12 months
223582128|NCT00996801|DRUG|Calcium carbonate|Participants who qualify (those who have a calcium intake of less than 1200 mg/day) will receive oral supplemental calcium carbonate, at a dose of either 400 mg or 500 mg, once-daily, for 12 months
223582129|NCT00996801|DRUG|Placebo to Alendronate|Placebo to alendronate once-weekly for 12 months
223582130|NCT00439452|OTHER|Telemedicine-Based Collaborative Care|Off-site depression care team (telephone nurse care manager, telephone pharmacist, tele-psychologist and tele-psychiatrist) works collaboratively with on-site primary care providers. Telephone nurse care manager activities include promoting patient activation and self management, assessing symptoms and comorbidities, and monitoring adherence, side-effects and treatment response. Telephone pharmacist activities include documenting medication histories and conducting medication management. Tele-psychologist activities include providing cognitive behavioral therapy via interactive video. Tele-psychiatrist activities include conducting patient consultation via interactive video.
223582131|NCT00439452|OTHER|Practice Based Collaborative Care|One-site nurse care manager works collaboratively with on-site primary care providers. Nurse care manager activities include promoting patient activation and self management, assessing symptoms and comorbidities, and monitoring adherence, side-effects and treatment response.
223582132|NCT04118790|OTHER|Clinical Assessment|"1. Medical history and details of the vascular incident will be collected from the patient and the medical journal. (Duration: 1hr)~2. Neuropsychological measures collected using test measures and questionaries (duration approx 45-60 min)."
223582133|NCT04118790|PROCEDURE|MRI scan|1\. MRI scan session, which includes Structural, Quantitative, Functional and Diffusion MRI sequences. (maximum duration: 90 min).
223582134|NCT01737294|DRUG|Qutenza exposure|Cutaneous patch
223744249|NCT05783362|BEHAVIORAL|Conditioned Pain Modulation (CPM)|Participants will receive a testing stimulus of pressure applied per ascending intensity at the web space of the foot until the pain reaches 40 out of 100, then discontinued. After testing the stimulus, participants will then receive a conditioning stimulus by immersing the non-dominant hand into the water-cooled by refrigeration unit with a temperature of 6 degree Celsius (males) or 8 degree Celsius (females) for 60 seconds. Subjects will be asked to rate the cold pain during the four 60-second trials. Participants completely removed their hand from the cold pressor for 30 seconds following each of the four 60-second immersions, during which time the testing stimulus will be re-applied per the sequential paradigm to the web space of the foot. Participants complete four 60-second periods of immersion. Conditioned pain modulation will be calculated as the average pain ratings of the second testing stimulus series minus the average pain ratings of the first testing stimulus series.
223744250|NCT02046460|DRUG|Acetylsalicylic acid|Acetylsalicylic acid, 300mg o.p.d.
223744251|NCT02046460|DRUG|Vitamin K antagonist|Vitamin K-antagonists, target INR 2.0-3.0
223744252|NCT04484363|DRUG|Pevonedistat|Pevonedistat 20 milligram per square meter (mg/m\^2), intravenous infusion, on Days 1, 3, and 5 of repeated 28-day cycles.
224162139|NCT04422197|BIOLOGICAL|Botox|effect of botox injection in abdominal wall muscle post major abdominal surgery in terms of postoperative pain, incidence of incisional hernia.
224162140|NCT04422197|PROCEDURE|surgery without botox injection|surgery without botox injection
224162141|NCT03052699|PROCEDURE|vaginal Cesarean Section|follow-up to patients operated for vaginal Cesarean Section
224162142|NCT00717951|DRUG|docetaxol, cisplatin, capecitabine|docetaxol(75mg/m2 d1 every 21 days) combined with cisplatin(75mg/m2 d1 every 21 days) VS docetaxol( 75mg/m2 d1 every 21 days) combined with capecitabine(2000mg/m2 d1-14 every 21 days)
224162143|NCT05234190|DRUG|QEL-001|QEL-001 is an autologous therapy that is composed of engineered regulatory T cells transduced with a lentiviral vector containing a CAR directed against HLA-A2. Treatment will be given via an IV infusion.
223582135|NCT03993223|BEHAVIORAL|Upper trapezius muscle fatigue|Isometric contraction of scapular elevation
223582136|NCT00518674|PROCEDURE|local infiltration analgesia|local wound infiltration with 30 ml ropivacaine 0.2 % (60 mg)
223582137|NCT03041142|BEHAVIORAL|Interdisciplinary intervention|Physical Activity, nutrition and Psychological
223582138|NCT03041142|OTHER|Routine|The participants continued to maintain their routine
223582139|NCT02804750|DRUG|CORT125134|
223582140|NCT01073917|OTHER|Spontaneous Breathing|
223582141|NCT01073917|OTHER|Pressure Controlled Ventilation|
223582142|NCT01073917|OTHER|Pressure Support Ventilation|
223475348|NCT00962286|DRUG|Furosemide|"Subjects will receive 300 mg of lithium carbonate at 22.00 the day before the renal function tests.Intravenous catheters will be placed in each upper limb for infusion of clearance markers and blood sampling.A priming dose of inulin (50 mg/kg) and p-aminohippuric acid (8 mg/kg) will be administered. Thereafter, inulin and p-aminohippuric acid will be infused continuously. A 200-300 ml water load will be given during the first 60-min prime.~Subjects will be started on furosemide p.o. 20 mg every 12 hours, starting on day 1 at 15.00 after the renal function studies. Nine doses will be taken, the last dose on day 4 at 7 am.~In case the blood pressure does not decrease following 20 mg bid furosemide administration, the study will be repeated after 4 weeks using a dose of 40 mg p.o. bid."
223475349|NCT03558516|DRUG|Magnesium group|We will dilute magnesium 6 gram with 0.9% sodium chloride to 30 ml. The patient will receive magnesium sulfate 40 mg/kg infuse over 30 min started at skin incision and continuous drip 10 mg/kg/hr until the dura is closed. Anesthesia is standardized with propofol, fentanyl, cisatracurium and sevoflurane. Vasopressor or antihypertensive drug are used to control hemodynamics.
223475350|NCT03558516|DRUG|Normal saline group|The patient will receive 0.9% sodium chloride the same amount of magnesium sulphate infuse over 30 min started at skin incision and continuous drip until the dura is closed. Anesthesia is standardized with propofol, fentanyl, cisatracurium and sevoflurane. Vasopressor or antihypertensive drug are used to control hemodynamics.
223475351|NCT05989425|DRUG|surufatinib|Surufatinib is a tablet in the form of 50mg, oral, once a day.
223475352|NCT05541705|BEHAVIORAL|Treadmill Oscillation Walking|Each participant with stroke will partake in 18 training sessions. Training sessions will be for one hour three times a week for 6 weeks. During training, participants will walk at their self-selected walking speed on the treadmill that moves side-to-side for 1 cm in a sinusoidal pattern. The sinusoidal oscillation frequency will match each participant's natural stride frequency calculated from baseline evaluation. Subjects will be instructed to respond naturally and maintain continuous walking. Participants will wear a safety harness with no body weight support. For each training session, six 6-minute bouts of treadmill oscillation trials will be performed (Hsiao et al. 2016) and rest period will be provided between bouts. Because lower extremity muscle activity increases with increasing oscillation frequency, the treadmill oscillation frequency will be increased by 5% each week to continue to drive progressive adaptive changes (25% over 6 weeks) (Pohl et al. 2002).
223475353|NCT06231524|OTHER|Analyse pathologic slides|HE-stained whole slide images were used for the validation of the PSN-AI model.
223475354|NCT02861313|DEVICE|CM LOC attachment|CM LOC attachment
223475355|NCT02861313|DEVICE|ball attachment|Ball attachment
223582143|NCT04144959|DEVICE|Indigo Aspiration System|Indigo Aspiration System
223582144|NCT02582047|BIOLOGICAL|Influenza vaccination with PPV23|GCflu and Pneumovax-23
223582145|NCT02582047|BIOLOGICAL|Influenza vaccination with PCV13|GCflu and Prevenar-13
223582146|NCT05674799|BEHAVIORAL|NDPP-NextGen|"NDPP-NextGen will incorporate content on preconception/prenatal health into standard NDPP. Participants will be encouraged to make sustainable improvements in diet and activity, but without pre-set goals to better accommodate diverse, low-income populations. Upon pregnancy, recommendations will adjust to support appropriate GWG, breastfeeding, and postpartum weight loss. We will provide education on diet and activity during pregnancy/postpartum, including sufficient energy intake and exercise safety to support the growing fetus. NDPP-NextGen will include 3 strategies to better engage young women. (1) Pre-sessions to increase knowledge of diabetes risks, self-efficacy, and readiness to change using motivational interviewing techniques. (2) Delivering classes remotely (via phone- and video-conference) to facilitate participation regardless of inclement weather, dependent care, illness, transportation, etc. (3) Offering classes specially for young women to increase personal relevance."
223582147|NCT05533372|DRUG|IA-14069|IA-14069 for oral administration.
223582148|NCT05533372|DRUG|Placebo|Placebo for oral administration.
223582149|NCT05533372|DRUG|Methotrexate|Methotrexate for oral or SC administration.
224069845|NCT06428578|OTHER|FBM-In person|Participants will receive two home visits by a CHW. Each home visit will last about 30 minutes, during which the CHW will assist the woman with community resources and help with enrolling in any state or federal nutrition and medical programs. Furthermore, the participants will be given access to a private Facebook group for nutrition, health education, and social support. Home visits will occur during the second and fifth weeks of the study.
223582150|NCT05533372|DRUG|Methotrexate|Methotrexate for oral administration.
223582151|NCT06339515|BEHAVIORAL|Universal Design Model|Universal design-based learning is based on the application of universal design approach principles to education. Universal design-based learning considers three broad networks of the brain to enable learning. These are recognition networks, strategic networks and affective networks. Universal design-based learning is a student-centered approach and curricula are designed to appeal to all students. Curricula consist of objectives, teaching methods, teaching materials and assessment and evaluation elements. Students' interests, needs and abilities are taken into consideration when designing curricula. Students' learning disabilities are identified and alternative practices are planned to eliminate these disabilities. All students are given equal opportunity to learn
223582152|NCT02158208|OTHER|Blood sample drawn into a 5 mL dry tube at the diagnosis and after 3 months of treatment|
223582153|NCT02158208|OTHER|16 blood samples drawn into 6 mL heparinized tubes at the diagnosis and after 3 months of treatment|
223582154|NCT02158208|OTHER|Blood sample drawn into a 5 mL dry tube|
223582155|NCT02158208|OTHER|16 blood samples drawn into 6 mL heparinized tubes|
223582156|NCT03166111|DRUG|lidocaine gel|syringe filled with 5 ml gel to be self-administered vaginal 10 minutes prior to insertion
223582157|NCT03166111|DRUG|placebo gel|syringe filled with 5 ml gel to be self-administered vaginal 10 minutes prior to insertion
223582158|NCT05036707|DEVICE|Xenodiagnosis Ticks|Larval ticks will be obtained from Dr. Sam Telford from a laboratory maintained tick colony at Tufts Veterinary School. These ticks are hatched from eggs laid by ticks that have fed only on specific pathogen free laboratory animals that were purchased from established vendors.
223582159|NCT05036707|PROCEDURE|skin biopsy|2-3 mm skin punch biopsies will be performed.
224305014|NCT04903951|DEVICE|Adaptive Servoventilation (ASV) therapy|Patients assigned to the active group will receive ventilatory support with ASV (DreamStation BiPAP autoSV®) during diurnal and nocturnal sleep, from study randomization until clinically indicated
223582160|NCT05036707|PROCEDURE|blood draw|Peripheral blood draws will be performed.
223582161|NCT00843154|DRUG|Candesartan and standard chronic heart disease therapy|Candesartan 4mg, tablets, orally, once daily and stable dose therapy for chronic heart disease for two weeks; then Candesartan increased up to 32mg, tablets, orally, once daily and stable dose therapy for chronic heart disease for up to 48 weeks.
224162144|NCT00659906|BEHAVIORAL|Resistance Exercise|60 minute sessions 3 times a week of moderate-vigorous lower and upper body free-weight strength training plus impact training (jumps). Two of the three sessions are conducted in a supervised setting at a university fitness facility and the third session is a modified version of the exercise program performed at home. Participants are in the exercise program for 12 months
224162145|NCT00659906|BEHAVIORAL|Flexibility Training|60 minute session 3 times a week focusing on whole body flexibility (stretching) and relaxation (progressive neuromuscular relaxation, focused breathing) exercises. Exercises are selected to be non-weight bearing and require minimal muscle strength in order to provide a contrast to the intervention arm. Two sessions are conducted in a supervised setting at a university fitness center and the third is a home-based version of the program performed at home.
223582162|NCT00843154|DRUG|Standard chronic heart disease therapy|Candesartan placebo-matching tablets, orally, once daily and stable dose therapy for chronic heart disease for up to 48 weeks.
224162146|NCT00997828|DEVICE|everolimus-eluting stent|Xience V stent
224162147|NCT00997828|PROCEDURE|coronary artery bypass graft surgery|coronary artery bypass graft surgery
224162148|NCT01662986|DRUG|tiotropium bromide|18 mcg once a day (QD)
224162149|NCT01662986|DRUG|Placebo|Once a day (QD)
224162150|NCT00482365|OTHER|biologic sample preservation procedure|biologic sample preservation procedure
224162151|NCT00482365|OTHER|medical chart review|review of patients' medical records at study entry and every 6 months
224162152|NCT00482365|OTHER|Patient interview|Elicit demographic data as well as information about personal habits such as drinking and smoking.
224162153|NCT02809846|DEVICE|Quell|
224162154|NCT02809846|DEVICE|Sham Quell|
224162155|NCT05875012|OTHER|action observation physical training|Action observation training 3 sessions per week for 3 successive months
224162156|NCT05875012|OTHER|Traditional physical therapy training|Traditional physical therapy training 3 sessions per week for 3 successive months
224162157|NCT05321589|OTHER|impression techniques for implant used for maxillary screw retained hybrid prosthesis|"conventional splinted open tray impression technique was done for maxillary implants to fabricate screw retained hybrid prosthesis and digital intra oral impression was done for the same patients after screwing scan bodies to the implants intra orally.~evaluation of accuracy and 3D deviation between the two techniques was done"
223582163|NCT05755815|PROCEDURE|retrolaminar block|A high-frequency 12 MHz linear ultrasound probe will be used, patients will receive bilateral ultrasound-guided retrolaminar plane block with 20 mL of bupivacaine 0.25%. Their spines will be palpated from the vertebra prominens caudally to T7 and point will be marked to identify the spinous processes, which will be confirmed by ultrasound through counting from T12 with the characteristic last rib attached to its transverse process upward to the T7 lamina. The linear high frequency transducer (6-13 MHz) will be placed in the parasagittal plane one cm lateral to the midline. The needle will be inserted in the in-plane view of the ultrasound probe and will be advanced from downward to upward to target the T7 posterior lamina surface at an angle of 90˚ to the skin until the needle tip will be contacted the posterior surface of targeted lamina . After negative aspiration, 20 mL of bupivacaine 0.25% will be injected. The procedure was repeated following the same steps on the other side.
224069846|NCT06428578|OTHER|FBM-Virtual|Participants will receive access to a virtual platform which will have information on national, state, and local food and medical resources, as well as local community resources, and will have access to a private Facebook group for nutrition, health education, and social support.
224069847|NCT06428578|OTHER|home delivered food boxes|Participants will receive weekly deliveries of a box containing fresh produce and staple goods (approximately 5 meals a week), culturally tailored meals (6 meals a week), and prepared fruit, vegetable and grain-forward meal kits (4 units a week) plus standard nutrition education materials consisting of recipes inside of the boxes. Each participant will receive one box for eight consecutive weeks.
224069848|NCT05559229|PROCEDURE|laparoscopic whole-layer cholecystectomy|laparoscopic whole-layer cholecystectomy.
224069849|NCT00892632|PROCEDURE|ERCP and Confocal imaging|A major new advancement in cancer imaging is the development of a probe-based confocal endomicroscopy (pCLE) system capable of cellular and sub-cellular imaging of the biliary tree.
224069850|NCT05821803|OTHER|Using Insoles|FootBalance %100 Control Orthopedic insoles used for 4 weeks.
224069851|NCT05821803|OTHER|Foot Core Exercises|4 weeks including
224069852|NCT03445091|DEVICE|SANKOM Patent Socks|Using compression socks to ease symptoms of patients with chronic venous insufficiency
224069853|NCT04735094|DIAGNOSTIC_TEST|Endobronchial biopsy with the use of a balloon attached to the echo-bronchoscope|A small balloon made of latex can be attached to the tip of echo-bronchoscope which is then inflated with water or saline for better apposition of the echo-endoscope and the airway wall. This may improve ultrasound image quality and aid better visualization of the lymph nodes.
224069854|NCT03020732|PROCEDURE|test groups|Coronally advanced flap procedure is a mucogingival surgery technique that was used to prepare recipient sites. Concentrated growth factor(CGF) membranes were placed over the exposed root surface. The flap was advanced 1 mm coronally from CEJ to completely cover.
224069855|NCT03020732|PROCEDURE|control groups|Coronally advanced flap procedure is a mucogingival surgery technique that was used to prepare recipient sites. Subepithelial connective tissue graft was placed over the exposed root surface. The flap was advanced 1 mm coronally from CEJ to completely cover.
224069856|NCT03651596|BEHAVIORAL|mHealth Messaging Intervention Group|The newly developed intervention messages will be sent to individuals assigned to the intervention group during the study.
224069857|NCT03651596|BEHAVIORAL|Standard mHealth Messaging Group|Standard mHealth messages will be sent to individuals assigned to the active control group during the study.
224069858|NCT00023374|DRUG|Rifampin|6mos REZ intermittent
224162158|NCT01442090|DRUG|Everolimus|Everolimus will be administered orally at a 10 mg daily dose.
224162159|NCT01442090|DRUG|GDC-0980|GDC-0980 will be administered orally at a 40 mg daily dose.
224162160|NCT00596895|DIETARY_SUPPLEMENT|Isoflavone|Ingested 47 mg of isoflavone in three 8 oz servings per day
223475356|NCT03733964|PROCEDURE|Manual therapy|Manual therapy - the mobilisation of joint segments L4-L5 and L5-S1 and mobilisation techniques for soft tissues (functional massage of soft tissues and skin relaxation using the methods of stretching).
223475357|NCT03733964|PROCEDURE|PNF|The PNF method - the movement patterns of the scapulae and the pelvis were used (anterior and posterior elevations and depression) along with the patterns of upper extremities (e.g. bending, abduction, outward rotation) and lower extremities (e.g. bending, abduction, inward rotation with bending of the knee joint).
223582164|NCT05755815|PROCEDURE|Peritoneal block|before giving an incision for the ports, 20 ml of 0.25% bupivacaine will be infiltrated subcutaneously over the port sites (6 ml will be infiltrated around each midline port site and 4 ml will be infiltrated around at the lateral port sites) and at the end of surgery and before the removal of trocars, 20 ml of 0.25% bupivacaine diluted in normal saline will be instilled by the surgeon intraperitoneally at gallbladder bed and under domes of both diaphragms under direct vision with a separate catheter passed through one of the trocars.. The pressure of the gas insufflation was kept within 10-12 mm Hg in all patients. At the end of surgery, CO2 was evacuated, and intraperitoneal anesthetic solution was left in situ.
223744253|NCT04484363|DRUG|Azacitidine|Azacitidine 75 mg/m\^2, intravenous or subcutaneous infusion, on Days 1 to 5, Days 8 and 9 of repeated 28-day cycles or Days 1 through 7 of repeated 28-day cycles.
224162161|NCT01620593|DRUG|Placebo|All eligible subjects will be randomized in a 1:l manner to receive a bottle containing sufficient 500mg tablets of placebo after castration, blinded to the patient and the study team.
224162162|NCT01620593|DRUG|Metformin|All eligible subjects will be randomized in a 1:l manner to receive a bottle containing sufficient 500mg tablets of metformin after castration, blinded to the patient and the study team.
224162163|NCT03054740|DRUG|Gebauer Ethyl Chloride|Will be administered according to manufacturers recommendations which is to spray the aerosol can for 4-10 seconds from a distance of 3 to 9 inches. Do not spray longer than 10 seconds.
224162164|NCT03054740|DRUG|Nature's Tears|Sterile water mist will be administered 1-2 sprays prior to intravenous access
224162165|NCT05946707|DRUG|restrictive oxygen supply|Oxygen supply will be limited to guarantee normoxia at the beginning of OLV.
224304657|NCT01040884|OTHER|ActiSight Needle Guidance System|ActiSight™ Needle Guidance System is comprised of several sub-system components: a computer, a disposable ActiSensor optical sensor, and the disposable ActiSticker, which provides a reference for the insertion of the tool and for the camera
224162166|NCT05946707|DRUG|liberal oxygen supply|Oxygen supply will be maximized to 100% at the beginning of OLV
224162167|NCT00901589|DIETARY_SUPPLEMENT|marine n-3 polyunsaturated fatty acids|Four capsules daily containing 2.2 g marine n-3 polyunsaturated fatty acids in total
224304658|NCT03088618|PROCEDURE|Nasal septoplasty|Type of surgery
224162168|NCT00901589|DIETARY_SUPPLEMENT|thistle oil|four capsules a day
224162169|NCT00901589|DIETARY_SUPPLEMENT|marine n-3 polyunsaturated fatty acids|Four capsules daily, 2.2 g marine n-3 PUFAs in total
224162170|NCT00901589|DIETARY_SUPPLEMENT|Thistle oil|Four capsules daily
224162171|NCT03403855|DEVICE|Rocket® IPC- Long External Length|Rocket® IPC- Long External Length Intervention. Evaluation of Long and Short External Length Rocket® Pleural Catheters in Terms of Quality of Life, Feasibility and Satisfaction in Patients Being Treated for Recurrent Malignant Pleural Effusions
224162172|NCT03403855|DEVICE|Rocket® IPC- Short External Length|Rocket® IPC- Short External Length Intervention. Evaluation of Long and Short External Length Rocket® Pleural Catheters in Terms of Quality of Life, Feasibility and Satisfaction in Patients Being Treated for Recurrent Malignant Pleural Effusions
224162173|NCT00006030|DRUG|tamoxifen citrate|
224162174|NCT00006030|PROCEDURE|conventional surgery|
224162175|NCT00006030|RADIATION|radiation therapy|
224162176|NCT01398228|BEHAVIORAL|quality improvement initiatives|A six component quality improvement intervention will be implemented. These components include: establishment of a quality improvement team, hospital performance audit and feedback, implementation of a clinical pathway, training of physicians and nurses, online technical support and patient education.
224162177|NCT00845845|DRUG|Omega-3-acid ethyl esters (Lovaza)|4 milligrams daily omega-3-acid ethyl esters (Lovaza) with dietary counseling for 24 weeks.
224304659|NCT03512951|OTHER|Digital signal processing algorithms|The intervention consists in applying five processing on some recorded speech signals. In particular, the processing performed by one specific algorithm is compared against the four other. The applied processing is supposed to restore sound externalization (expected audio-visual fusion).
223475358|NCT03733964|PROCEDURE|Manual therapy + PNF|Combination therapy - Manual therapy and Proprioceptive Neuromuscular Facilitation
223475359|NCT03733964|PROCEDURE|Kinesiotherapy|Traditional kinesiotherapy in the form of active slow exercises of back muscles, abdominal and gluteal muscles on a mat. The patients participated in a uniform treatment programme consisting of ten exercises. Each of the exercises was performed in a number of 20 repetitions.
223475360|NCT04272229|DIAGNOSTIC_TEST|Cognition|Cognition tests will be performed with questionnaires, which will be applied to the main investigator. Stroop Color test, digit symbol substitution test, Addenbrooke's cognitive examination 3, mini-mental state examination, Montreal Cognitive Assessment, Trail Making Test A e B and Reaction time test will be performed to check the cognition in all volunteers.
224162178|NCT00845845|DRUG|Placebo|Daily placebo with dietary counseling for 24 weeks.
224162179|NCT05606380|DRUG|HLX60|HLX60(anti-GARP Monoclonal Antibody）have 5 dose cohorts: 0.5, 2, 5, 15, 25mg/kg, intravenous infusion, every 3 weeks.
224162180|NCT03455062|OTHER|Questionnaire about fertility|"Recruitment of participants through the list of cardiac, renal, hepatic, pancreatic or pulmonary transplant patients collected from the the Organ Transplant Unit.~A letter from the the Organ Transplant Unit will initially be sent to patients informing them of the study and if they do not wish to participate they can report their opposition by email.~A fertility questionnaire will be send and that will have to be returned by the patient in order to be included in the study.~The questionnaires, anonymous, will be numbered according to their order of return."
224304660|NCT03489161|DRUG|Buprenorphine|buprenorphine/naloxone 4mg/1 mg for Clinical Opioid Withdrawal Scale (COWS) scores between 8 and 12, or 8mg/2mg S/L ≥ 12 by the sublingual route
224305015|NCT04903951|OTHER|Best medical treatment|Best medical treatment for stroke, including rehabilitation
224305016|NCT03244644|DRUG|RBX2660|RBX2660 is a rectally administered microbiota suspension
223475361|NCT04272229|DIAGNOSTIC_TEST|Sympathetic Nervous System|The sympathetic activation will be evaluated by heart rate variability. Volunteers will have their hear rate recorded by a frequencymeter and the R-R interval will be analyzed to ch check the central nervous system activation during all cognitive tests.
223475362|NCT04272229|DIAGNOSTIC_TEST|Concentratio and Attention|Concentration and attention measures will be recorded with the MindWave headset during all cognitive tests. The EEG will be recorded with the MindWave and then alfa wave will be analized to check the attention and concentration levels.
223475363|NCT02640079|BEHAVIORAL|Cognitive behavioral therapy|
223475364|NCT04582617|DIETARY_SUPPLEMENT|Cocoa Extract|2 capsules each day containing a total of 500 mg cocoa flavanols, including 80 mg (-)-epicatechin, and 50 mg theobromine
223582165|NCT05433415|BEHAVIORAL|Black Girls Move|Goal setting and monitoring. All BGM daughters will self-monitor their progress towards PA goals using a PA device, Fitbit®. Additionally, BGM daughters will self-monitor their progress towards diet goals using a mobile application, Start Simple with My Plate®. Further, all BGM mothers will use Fitbit® and Start Simple with My Plate® for self monitoring, however, mothers' data will not be analyzed for this study. Since the daughter/ mother relationship is critical to achieving behavioral change, BGM mothers will utilize Fitbit® and Start Simple with My Plate® as a mechanism to communicate, problem solve and support daughters' behavioral goals.BGM is situated within the contexts of environmental, cultural, interpersonal, and developmental factors impacted by structural racism. Intentionally engaging mothers and daughters in an asset based program provides a framework for mothers to model responses to structural racism i.e. racial socialization.
223475365|NCT04582617|DIETARY_SUPPLEMENT|Cocoa Extract Placebo|Cocoa extract placebo
223475366|NCT04582617|DIETARY_SUPPLEMENT|Multivitamin|Multivitamin
223475367|NCT04582617|DIETARY_SUPPLEMENT|Multivitamin placebo|Multivitamin placebo
223582166|NCT06083584|OTHER|RNA sequencing|RNA-Seq (Sureselect XT HS2 RNA) from patient blood sample
223475368|NCT00929669|DRUG|pasireotide LAR|pasireotide LAR 80 mg IM once a month
224069859|NCT00023374|DRUG|Pyrazinamide|6mos REZ intermittent
224069860|NCT00023374|DRUG|Ethambutol|6mos REZ intermittent
224069861|NCT00023374|DRUG|REZ|Rif+PZA+EMB given 2 or 3 times weekly for 6 months
223475369|NCT04285463|DIAGNOSTIC_TEST|Transbronchial Lung Cryobiopsy (TBLC)|TBLC is a relatively new endoscopic technique used to obtain lung parenchyma specimens. It is a minimally invasive technique performed with a flexible or rigid bronchoscope under deep sedation or general anesthesia. Flexible cryoprobes of either 1.9 or 2.4 mm in diameter are introduced into a bronchoscope and a compressed gas, most commonly carbon dioxide or nitrous oxide, is released at high flow at the tip of the probe. As the tissue rapidly freezes, it adheres to the probe and is avulsed and extracted with a quick pullback movement followed by immediate extraction of samples.
223475370|NCT01658839|DRUG|Travoprost ophthalmic solution, 0.004% (new formulation)|Travoprost ophthalmic solution, 0.004%, new formulation
223475371|NCT03236792|DRUG|Ixazomib|3 mg or 4mg of Ixazomib will be taken orally on days 1, 8, and 15 of a 28-day cycle
224069862|NCT02111993|DEVICE|Standard Defibrillation Testing|Once the ICD is implanted, Standard Defibrillation Threshold (DFT) testing will begin. A low energy shock will be delivered to the heart at the peak of the T wave to induce ventricular fibrillation (VF). Once VF is induced, a rescue shock of 25J will be delivered to restore sinus rhythm. This process will be repeated once more after 5 minutes.
224069863|NCT02111993|DEVICE|Upper Limit of Vulnerability Testing|Once the ICD is implanted, Upper Limit of Vulnerability (ULV) testing will commence. An 18 J shock will be delivered will at different points from the t-wave. If VF is not induced with any of these shocks, then the ULV will be considered to be 18J. If VF is induced, then a 25 J rescue shock will be delivered.
223475372|NCT03236792|DRUG|Cyclophosphamide|300, 400, or 500 mg of oral Cyclophosphamide on days 1, 8, and 15 of a 28-day cycle
223475373|NCT03236792|DRUG|Dexamethasone|20 mg of oral Dexamethasone on days 1, 8, 15, 22 in a 28-day cycle
224069864|NCT03671031|PROCEDURE|isolated roux loop|Isolated roux loop reconstruction following pancreaticoduodenectomy
224069865|NCT03671031|PROCEDURE|single loop|Conventional single loop reconstruction following pancreaticoduodenectomy
224069866|NCT00293579|DRUG|Pemetrexed|500 mg/m2 IV every 3 weeks for 6 cycles
224069867|NCT05797701|DRUG|SAR443820|Tablet by oral administration
224069868|NCT05797701|DRUG|SAR443820|Capsule by oral administration
224069869|NCT05987111|BEHAVIORAL|Pilates|Pilates exercises were applied twice a week for 4 weeks in both groups. The sessions were supervised by an Australian Physiotherapy and Pilates Institute (APPI) certified physiotherapist as 5 minutes of warm-up, 45 minutes of exercise and 5 minutes of cool-down periods.
224069870|NCT02538068|BEHAVIORAL|Daily Surveys|Participants complete 28 daily surveys of daily meaning, mood, and physical activities.
224069871|NCT02538068|BEHAVIORAL|Random Surveys (8)|Participants complete 8 random surveys of activities over the past 24 hours during the first 4 weeks.
224069872|NCT03223545|BEHAVIORAL|MBCT-T|This 8-week program combines mindfulness training with cognitive therapy and is delivered to small groups of patients by telephone using a conference line. Each weekly session is 1 hour long and is comprised of a check-in period, teaching on the week's topic, group discussion, a skill-building exercise, and a home-based practice assignment.
224069873|NCT03223545|BEHAVIORAL|Usual Care|"Treatment guidelines recommend counseling patients with prehypertension on the importance of lifestyle modification to reduce BP. Because of variability in counseling across primary care practices, the study team will provide all participants with NHLBI print educational materials to ensure exposure to lifestyle recommendations: Your Guide to Lowering Blood Pressure; and Facts about the DASH Eating Plan."
224069874|NCT04074928|BIOLOGICAL|QIVc|Previously vaccinated subjects received a 0.5 mL intramuscular dose of QIVc on Day 1; not previously vaccinated subjects received a 0.5 mL intramuscular dose of QIVc on Day 1 and Day 29.
224069875|NCT04074928|BIOLOGICAL|Comparator QIV|Previously vaccinated subjects received a dose of Comparator QIV on Day 1; not previously vaccinated subjects received a dose of Comparator QIV on Day 1 and Day 29. Subjects 6 months through 35 months of age received a 0.25 mL intramuscular dose of Comparator QIV; subjects 36 months through 47 months of age received a 0.5 mL intramuscular dose of Comparator QIV.
224069876|NCT01309178|DRUG|Amitriptyline|2 x 12,5 mg capsules for oral use in the first two weeks, the higher dose of 50 mg (2 x 25 mg) will be adapted after 2 weeks of treatment.
223475374|NCT02602951|OTHER|Pilot MRI program|Pilot MRI program
223475375|NCT02602951|OTHER|MRI with 4D Flow sequence|MRI with 4D Flow sequence
223475376|NCT03306199|DEVICE|Laser Atherectomy|The Turbo-Power is a laser atherectomy catheter designed for treatment of de novo or restenotic lesions in native infrainguinal arteries and for the treatment of femoropopliteal artery in-stent restenosis (ISR) in bare nitinol stents with adjunctive percutaneous transluminal angioplasty (PTA).
223475377|NCT03108612|DIAGNOSTIC_TEST|Análisis de carga de trabajo (ACT)|Semi-structured interview for detecting possible occupational etiology of an upper limb musculoskeletal disease that has been reported (by the worker) as possibly of occupational origin. The instrument is called Workload Analysis Instrument (WAI) or Análisis de Carga de Trabajo (ACT).
223582167|NCT01670565|DRUG|Belimumab|Belimumab (Benlysta®) decreases B-Cell survival and has been FDA approved for the treatment of systemic lupus erythematosus, another rheumatic autoimmune disease. Belimumab is a recombinant, fully human monoclonal antibody; it binds to the soluble human B lymphocyte stimulator (BLyS) with high affinity and inhibits its biologic activity. Prior research provides a robust rationale for the investigation of belimumab in combination with MMF (Cellcept ®) for the treatment of early diffuse cutaneous systemic sclerosis.
223582168|NCT01670565|DRUG|Mycophenolate Mofetil|Patients received background MMF therapy, some who were naive to MMF were titrated up to 1,000 mg twice daily and others had been receiving MMF at \<2,000 mg/day for \<3 months. MMF was chosen so that background therapy would be uniform and not a further source of variability in the small study.
223582169|NCT01670565|OTHER|Placebo Infusion|Infusion of normal saline
223475378|NCT03675217|OTHER|PE|Physical exercise program for familiy caregivers. 36 session physical exercise (3 sessions/week) performed by physioterapist. It incluided exercices to improve coordination, aerobic capacity, control motor and strenght
223475379|NCT03675217|OTHER|Usual Care|Usual Programe in primary care for family caregivers. 4 session (2 session/week). It incluides: ergonomy, postural hygiene, mobilitation of patients and self-care.
223475380|NCT04976816|PROCEDURE|peri-levator betamethasone injection|The injection dose was 1 ml of betamethasone suspension (1 ml contains 5 mg betamethasone dipropionate \&2 mg betamethasone sodium phosphate). The needle was introduced percutaneously superior to the globe and advanced towards the orbital roof to a depth of approximately 15 mm where the injection was delivered. The injection was repeated every 4 weeks according to the clinical response up to 5 injections.
223475381|NCT04976816|PROCEDURE|peri-levator triamcinolone injection|The needle was introduced percutaneously superior to the globe and advanced towards the orbital roof to a depth of approximately 15 mm where 1ml (40mg/ml) triamcinolone acetate was injected. The injection was repeated every 4 weeks according to the clinical response up to 5 injections.
223475382|NCT04976816|PROCEDURE|peri-levator and retrobulbar betamethasone injection|In addition to peri-levator betamethasone injection for UER, a retrobulbar injection for proptosis was given with the needle introduced through the skin of the lateral one-third of the lower eyelid and passed posteriorly, medially, and upward to reach the retrobulbar space.
223475383|NCT04976816|PROCEDURE|peri-levator and retrobulbar triamcinolone injection|In addition to peri-levator triamcinolone injection for UER, a retrobulbar injection for proptosis was given with the needle introduced through the skin of the lateral one-third of the lower eyelid and passed posteriorly, medially, and upward to reach the retrobulbar space.
223475384|NCT00607217|BIOLOGICAL|influenza vaccine|Intramuscular injection of one 0.5-mL dose of influenza vaccine
223475385|NCT00607217|BIOLOGICAL|placebo for influenza vaccine|Intramuscular injection of one 0.5-mL dose of placebo for influenza vaccine
223475386|NCT00607217|BIOLOGICAL|influenza vaccine|Intramuscular injection of one 0.5-mL dose of influenza vaccine
223475387|NCT00605683|DRUG|Safinamide (as add-on therapy)|Safinamide, (S)-(+)-2-\[4-(3-fluorobenzyloxy) benzylamino\] propanamide methanesulfonate, is an a-aminoamide derivative
223582170|NCT03566017|DRUG|pegunigalsidase alfa|Recombinant human alpha galactosidase A
223582171|NCT04311398|DIAGNOSTIC_TEST|New QIAstat-Dx fully automatic multiple PCR detection platform|We use the New QIAstat-Dx fully automatic multiple PCR detection platform to test the enrolled patients
223582172|NCT05924477|PROCEDURE|Sulcus tube placement|GDD implantation surgery with tube placement in the ciliary sulcus
223582173|NCT05924477|PROCEDURE|Anterior chamber (AC) tube placement|GDD implantation surgery with tube placement in the anterior chamber
223744254|NCT06155942|PROCEDURE|7 Tesla MRI|Patients will have a 7T MRI and questionnaires
223744255|NCT00944450|DRUG|Sitagliptin phosphate anhydrous formulation|Single dose sitagliptin 100 mg tablets (anhydrous form) in one of two treatment periods.
223475388|NCT00605683|DRUG|Safinamide (as add-on therapy)|Safinamide add-on therapy with subjects with IPD treated with single dopamine agonist
223475389|NCT00605683|DRUG|Safinamide (as add-on therapy)|Safinamide add-on therapy with subjects with IPD treated with single dopamine agonist
223475390|NCT01925443|OTHER|Low level laser therapy|Will be performed irradiation with low-intensity laser in quadriceps muscle
223475391|NCT04112576|DEVICE|Wearable cardiac monitor|Participants will be fitted with a wearable cardiac monitor placed on the skin that measures physiologic signals.
223475392|NCT01192321|DEVICE|Toric T3 - T9|Bilateral implantation of Alcon AcrySof Toric Intraocular Lens (IOL) models SN60T3 through SN60T9 following cataract removal.
223475393|NCT01192321|DEVICE|Monofocal|Bilateral implantation of any monofocal Intraocular Lens (IOL) following cataract removal.
223475394|NCT04486664|BEHAVIORAL|Mediterranean Diet|Diet instruction and menu samples from the dietitian on following the Mediterranean Diet.
223744256|NCT00944450|DRUG|Comparator: sitagliptin phosphate monohydrate form|Single dose sitagliptin 100 mg tablets \[monohydrate Final Market Image (FMI) form\] in one of two treatment periods.
224069877|NCT01309178|DRUG|Mannite|Mannit capsules daily in two doses (2 x 12,5 mg). After 2 weeks of treatment the higher dose of 50 mg (2 x 25 mg) will be given
224069878|NCT00427609|DRUG|Bicillin L-A|Bicillin L-A administered intramusculary in a dose of 2.4 million units every three weeks or normal saline injection administered intramusculary in a dose of 3 cc every three weeks
224069879|NCT01024998|BIOLOGICAL|AAV2-sFLT01|2 x 10\^8 vector genomes (vg) AAV2-sFLT01. Single intravitreal injection to a single eye, using a fixed volume of 100 μL.
224069880|NCT01024998|BIOLOGICAL|AAV2-sFLT01|2 x 10\^9 vector genomes (vg) AAV2-sFLT01. Single intravitreal injection to a single eye, using a fixed volume of 100 μL.
224304661|NCT02083237|BEHAVIORAL|Behavioural Intervention Program|People with MCI and their close family member (80% spouses) participate jointly in the first hour, which provides education about MCI, lifestyle influences on cognitive health, and community resources. During the second hour, family members participate in a separate psychosocial group intervention, while the individuals with MCI participate in memory training. The first 6 of the 8 sessions occur weekly, the 7th occurs as a 1-month follow-up session and the 8th as a 3-month follow-up session. These follow-up sessions provide support to sustain positive outcomes and provide further assistance with resolving continued challenges.
223475395|NCT01183923|OTHER|Broccoli Sprouts|Broccoli Sprouts will be eaten daily in a sandwich form during the intervention period for broccoli sprouts.
223475396|NCT01183923|OTHER|Alfalfa Sprouts|Alfalfa sprouts will be eaten daily in a sandwich form during the intervention period for alfalfa sprouts.
223475397|NCT04900311|DRUG|pyrotinib + trastuzumab + nab-paclitaxel|patients will be treated every 3 weeks for four cycles prior to surgery at following doses: pyrotinib: 400 mg/day, orally, qd trastuzumab: IV infusion on Day 1 every 3 weeks with loading dose of 8 mg/kg in Cycle 1, and 6 mg/kg in Cycles 2-4 nab-paclitaxel: 260 mg/m2 IV infusion on Day 1 every 3 weeks, or 125 mg/m2 IV infusion on Days 1, 8 and 15 every 3 weeks (the nab-paclitaxel administration cycle was determined by investigator at each site)
223475398|NCT04900311|DRUG|pertuzumab + trastuzumab + nab-paclitaxel|patients will be treated every 3 weeks for four cycles prior to surgery at following doses: pertuzumab: IV infusion on Day 1 every 3 weeks with loading dose of 840 mg for Cycle 1, followed by 420 mg for Cycles 2-4 trastuzumab: IV infusion on Day 1 every 3 weeks with loading dose of 8 mg/kg in Cycle 1, and 6 mg/kg in Cycles 2-4 nab-paclitaxel: 260 mg/m2 IV infusion on Day 1 every 3 weeks, or 125 mg/m2 IV infusion on Days 1, 8 and 15 every 3 weeks (the nab-paclitaxel administration cycle was determined by investigator at each site)
224304662|NCT02852642|OTHER|Exercise|Plyometric training
223475399|NCT04494646|DRUG|Bardoxolone Methyl|Once-daily administration of bardoxolone methyl (20mg)
223475400|NCT04494646|DRUG|Placebo|Once-daily administration of matching placebo
223475401|NCT02506920|DIETARY_SUPPLEMENT|Six different types of fat in a meal in random order|Oral fat tolerance test
223475402|NCT00286182|DRUG|Erythropoietin alpha|Erythropoietin alpha is administered weekly by subcutaneous injection using a pre-specified dosing algorithm. The dosing algorithm is designed to make adjustments based on the rate of rise (ROR) of the hemoglobin over a one week period, as well as the absolute hemoglobin value. Subjects initially received active treatment with 7,500 units of erythropoietin given weekly by subcutaneously injection. Subjects are carefully monitored (e.g. every week) to avoid rapid increases in hemoglobin/hematocrit and/or increasing blood pressure control. Dose adjustments are made if the hemoglobin rises too rapidly (greater than 0.3 g/dL) in any given weekly interval.
223475403|NCT00286182|DRUG|Placebo|Placebo
223475404|NCT03818152|OTHER|Functional strength assessment|Functional strength exercises to assess strength in lower limbs.
223475405|NCT02785939|DRUG|Docetaxel|Given IV (arm II closed to accrual 12/18/2015)
223475406|NCT02785939|OTHER|Laboratory Biomarker Analysis|Correlative studies
223475407|NCT02785939|DRUG|Palbociclib|Given PO
223475408|NCT02668003|BEHAVIORAL|Cognitive Behavioural Therapy|The CBT intervention, delivered by telephone, will consist of an initial assessment, 6 weekly sessions, and then booster sessions at 3 and 6 months. The intervention will be delivered by trained and accredited therapists. Participants will be supported by a self-management CBT manual. There will be a patient-centred assessment by the therapist for problem identification, risk assessment and development of a shared formulation of the current health problem. The sessions will involve education about musculoskeletal pain, somatic symptoms and specific CBT techniques such as pacing of activity, behavioural activation, diary keeping, identifying and challenging negative and unhelpful thinking patterns and the development of a longer term management plan.
223475409|NCT03786640|RADIATION|3T MRI scan|A clinically indicated 3T MRI scan will be performed per standard procedures for the radiology department. Cardiac monitoring during the MRI scan is recommended to include Pulse Oximetry and/or ECG.
223475410|NCT05033132|DRUG|Balstilimab|Anti-programmed cell death protein 1 (anti-PD-1) monoclonal antibody
223475411|NCT05033132|DRUG|Balstilimab + Zalifrelimab|An anti-PD-1 monoclonal antibody in combination with a cytotoxic T-lymphocyte antigen-4 (CTLA-4) antibody
223475412|NCT05543304|DIAGNOSTIC_TEST|radiological evaluation|All patients with advanced HCC receive imaging evaluation before and after systemic treatments to assess the development of diseases.
223475413|NCT02147626|BEHAVIORAL|Web-based educational and motivational modules|
223582174|NCT05780918|OTHER|Best Case/Worst Case-ICU Communication Tool|"This intervention uses scenario planning and a daily report of the interplay between major events and prognosis to illustrate a range of long-term outcomes and treatment experiences. By using a graphic aid to illustrate what we are hoping for, what we are worried about, and the evolution of the patient's story over time, the tool aims to facilitate dialogue among older adult trauma patients, their families, and the trauma team. Because the tool delivers critical prognostic information over the longitudinal course of care, subsequent treatment decisions can be made within the context of the patient's overall health status. This information alerts patients and families to the life-limiting nature of serious injury and provides an entrée for them to consider how comfort-focused strategies might better align with patients' end-of-life goals.~All clinicians will be trained to create, use, and/or reference the graphic aids with patients depending on their roles in the trauma ICU."
224304663|NCT00005965|DRUG|bryostatin 1|
224304664|NCT00005965|DRUG|cisplatin|
223475414|NCT02147626|BEHAVIORAL|Information and Screening Group|
223475415|NCT05461040|PROCEDURE|optic capture|optic capture of Intraocular lens without anterior vitrectomy
223475416|NCT05461040|PROCEDURE|In-the-bag implantation of Intraocular lens|in-the-bag implantation of Intraocular lens with anterior vitrectomy
223475417|NCT02415985|DRUG|Lopinavir/r will be supplied by NHSO/GPO|200/50 mg tablet LPV/rtv
223475418|NCT02415985|DRUG|Rifabutin|
223475419|NCT05899530|DEVICE|Invisalign|Expansion using Invisalign versus conventional expander
223475420|NCT05899530|DEVICE|Conventional expander|conventional expander
223475421|NCT00394641|BEHAVIORAL|listening to music / stories via stereophonic headphones|
224305017|NCT03244644|DRUG|Placebo|Placebo is normal saline solution administered rectally
223475422|NCT01244464|BIOLOGICAL|IMOVAX Polio™-Inactivated types 1, 2, and 3 poliovirus D vaccine|0.5 mL, at 2, 3, and 4 months; Intramuscular
223582175|NCT06269705|DRUG|ZILRETTA|IA injection of 32 mg ZILRETTA
223475423|NCT04562974|DEVICE|MRI-scanner|Only one group of 30 participants is constituted. All participants will perform perception and memory tasks inside a MRI-scanner. Functional activity (BOLD signal) will be registered, as well as anatomical and behavioural data.
223582176|NCT06269705|DRUG|TCA-IR|IA injection of 40 mg TCA-IR
223582177|NCT06269705|OTHER|Placebo|IA injection of placebo (normal saline)
224162181|NCT02635529|PROCEDURE|OFD+ DFDBA|After Phase I therapy, patient's were assigned for OFD+DFDBA group. Mucoperiosteal flap were reflected.After Open Flap Debridement (OFD), DFDBA graft was placed for the treatment of intrabony defects.
224162182|NCT02635529|PROCEDURE|OFD+ DFDBA+ AM|After Phase I therapy, patient's were assigned for OFD+DFDBA + AM group. Mucoperiosteal flap were reflected. After Open Flap Debridement (OFD). DFDBA and AM was placed for the treatment of intrabony defects.
224162183|NCT03472963|DRUG|Single dose of Genvoya® and a single 800 mg dose of Darunavir®|Men will be instructed to take Single dose of Genvoya® and a single 800 mg dose of Darunavir® per oral
223582178|NCT05913102|DRUG|PDLLA|Administer PDLLA/saline every 2 weeks for 2.5 months
223582179|NCT01989611|DRUG|emtricitabine / tenofovir 200/300 mg|Fixed dose combination of emtricitabine / tenofovir 200/300 mg once daily orally during one year
224162184|NCT04212936|PROCEDURE|Intraabdominal pressure|Limited intraabdominal pressure during laparoscopic cholecystectomy between 8 and 10 mmHg.
224162185|NCT04841213|PROCEDURE|Dental implantation|Traditional 2-stage dental implantation according to surgical protocols of dental implant systems (Straumann (Institut Straumann AG, Switzerland), Astra Tech (Dentsply Implant Manufacturing GmbH, Germany), Xive (FRIADENT GmbH, Germany), Alpha Bio (Alpha Bio Tec Ltd., Israel) for different types of bone tissue
223475424|NCT00941551|DRUG|levothyroxine|levothyroxine 75-125 ug/day
223582180|NCT01657760|DRUG|citalopram|citalopram, 40 mg IV, vs. saline control, each to be administered in a double-blinded, within-subjects design.
223582181|NCT01694108|BIOLOGICAL|BCG-vaccine (SSI)|
223582182|NCT00044187|DRUG|Sibutramine|
223582183|NCT03409510|RADIATION|UVB radiation|"UVB treatment regimen:~Week 1-2: 0.85 kilo Joule/m2 twice per week Week 3-7: 0.85 kilo Joule/m2 three times per week Week 8-9: 1.4 kilo Joule/m2 three times per week"
223582184|NCT02506660|DRUG|Bupivacaine|
223582185|NCT02506660|DRUG|Perineural dexamethasone|Dexamethasone in nerve block
223582186|NCT02506660|DRUG|Intravenous dexamethasone|
223582187|NCT02506660|DRUG|Intravenous saline|
223582188|NCT02506660|DRUG|Perineural saline|Saline in nerve block
224162186|NCT00663338|DRUG|Rotigotine|Rotigotine 9.0mg patch (equivalent to 4mg/24hr transdermal absorption) once daily during the treatment phase.
224162187|NCT05845008|DRUG|Acetaminophen/Naproxen Sodium Fixed Combination|Acetaminophen/naproxen sodium fixed combination tablets, oral.
223475425|NCT00941551|DRUG|no levothyroxine|observation only without prophylactic levothyroxine
223475426|NCT00572832|BIOLOGICAL|Quadrivalent human papillomavirus vaccine on-time administration|The vaccine is given in three doses: Dose 1; dose 2 given 60 days later; dose 3 given six months after dose 1.
223475427|NCT00572832|BIOLOGICAL|Quadrivalent human papillomavirus vaccine delayed administration|The vaccine is given in three doses: Dose 1; dose 2 given 60 days later; dose 3 given 12 months after dose 1.
223475428|NCT00966433|PROCEDURE|Spontaneous ventilation|The patient will breathe spontaneously (on their own)while under general anesthesia throughout the duration of the surgery.
223582189|NCT05716204|OTHER|High force lateral distraction|High force lateral distraction on the affected hip.
223582190|NCT05716204|OTHER|Placebo distraction group|Placebo lateral distraction on the affected hip.
223582191|NCT00940485|DRUG|entecavir|0.5mg po daily for 8 weeks
223582192|NCT00940485|DRUG|entecavir|0.5mg po daily for 48 weeks
223582193|NCT00940485|DRUG|peginterferon alfa-2a [Pegasys]|180 micrograms sc/week for 48 weeks
224162188|NCT06512831|DRUG|Isoniazid|Those with risk factors were recommended a 6-month prophylaxis regimen, consisting of INH (300 mg/d) and pyridoxine (10 mg/d to prevent INH-related neurotoxicity).
224162189|NCT03126279|PROCEDURE|Total Knee Replacement Surgery|All chronic knee osteoarthritis patients will be recruited as they are on the NHS waiting list for a total knee replacement. Only this group will undergo the procedure
223475429|NCT00966433|DEVICE|Pressure support Ventilation|The patient will breathe on their own and with a little assistance from the anesthesia machine while under general anesthesia throughout the duration of the surgery.
223582194|NCT05455502|DRUG|VX-548|Tablet for oral administration.
223582195|NCT04803955|DRUG|16mg，KB|16mg,Q8h±3min,Day1-Day7
223582196|NCT04803955|DRUG|Placebos|16mg,Q8h±3min,Day1-Day7
223582197|NCT06441474|BEHAVIORAL|Presentation of personal breast cancer risk estimate|All participants will be presented with their personal breast cancer risk estimate, calculated using the Gail Model
223582198|NCT03584243|PROCEDURE|A crosslinking with oxygen treatment|"A supplemental oxygen system during the cross linking will be used to apply filtered, humidified oxygen across the surface of the eye through a mask. The oxygen flow will be turned on immediately prior to initiation of irradiation, and will continue through the irradiation period. The supplemental oxygen flow will be shut off following completion of the programmed irradiation time.~All subjects will be evaluated at screening, day 3, and 1, 3, 6, 12 and 24 months after treatment. At the same time all the potential adverse effects will be relieved."
223582199|NCT02961946|DRUG|Nitroglycerin|Patients grouped in sublingual administration (group 1 and 2) will receive Nitroglycerin during the cCTA scan by the MD after the Calcium scoring scan and 5 minutes before the actual cCTA scan. Patients categorized to transdermal administration will receive Nitroglycerin 1 hour before the CT examination. The patch will be placed on the chest or the upper arm.
223582200|NCT00086099|DRUG|Idarubincin and Amufostine (Ethyol)|Starting doses of Idarubincin(12,18 mg/m2 to 21 mg/m2), ara-C, plus amofostine (N-36)
223582201|NCT00086099|DRUG|Idarubincin|Idarubincin (12mg/m2) and ara-C(N-18)
223582202|NCT04555837|DRUG|Alisertib|Given PO
223582203|NCT04555837|BIOLOGICAL|Pembrolizumab|Given IV
224304665|NCT04156620|DRUG|Secukinumab|The subjects will receive secukinumab 6 mg/kg i.v. at randomization (Baseline (BSL) visit), followed by the administration of secukinumab 3 mg/kg i.v. every four weeks starting at Week 4 through Week 48 (exposure through Week 52)
223475430|NCT00966433|DEVICE|Pressure control ventilation|The patient's ventilation will be completely supported by the anesthesia machine while under general anesthesia throughout the duration of the surgery.
223582204|NCT05632783|DRUG|Chondroitin Sulfate Sodium|Chondroitin sulfate 800 mg tablets
223582205|NCT05632783|OTHER|Placebo|Placebo tablets
223582206|NCT05773976|DEVICE|Afomill Refreshing Soothing, Afomill Anti-redness Eye Drops, Iridil|"At baseline visit (V0), as per clinical practice, only one of the below reported IPs products can be dispensed to the enrolled subject, depending on investigator clinical evaluation and decision:~* Afomill Refreshing Soothing~* Afomill Anti-redness Eye Drops~* Iridil"
223582207|NCT03542279|PROCEDURE|Plasma exchange (PE)|PE is performed every other day using a multi-filtrate apheresis device (Fresenius, Bad Homburg, Germany), and 5 times in total for each course. The plasma removed during PE is replaced with an equal volume of substitution (half 5% albumin with normal saline and half plasma). The plasma volume to be replaced was estimated according to the following formula: plasma volume (L) = 7.5%×weight (kg)×(1-hematocrit)×1000ml. Heparin was added to the exchange circuit to prevent blood clotting. The exchange rate was monitored, recorded, and balanced to prevent cardiovascular instability. Blood pressure and other vital signs were closely monitored every 15 minutes throughout the exchange.
223582208|NCT03542279|DRUG|intravenous immunmoglobulin (IVIG), intravenous methylprednisolone (IVMP)|IVIG is given 0.4 g/kg/d for each course for 5 days. IVMP is 1,000 mg or 500 mg methylprednisolone for 3 or 5 days, and the dosage of glucocorticoid will gradually decrease.
224069881|NCT01024998|BIOLOGICAL|AAV2-sFLT01|6 x 10\^9 vector genomes (vg) AAV2-sFLT01. Single intravitreal injection to a single eye, using a fixed volume of 100 μL.
224069882|NCT01024998|BIOLOGICAL|AAV2-sFLT01|2 x 10\^10 vector genomes (vg) AAV2-sFLT01. Single intravitreal injection to a single eye, using a fixed volume of 100 μL.
224304666|NCT04156620|DRUG|Placebo|The subjects will receive i.v. placebo at randomization (BSL visit), Weeks 4, 8, and 12 , followed by the administration of secukinumab 3 mg/kg i.v. at Week 16 and every four weeks through Week 48 (exposure through Week 52)
223475431|NCT03925896|DRUG|LMP2 Antigen-specific TCR T cells|All enrolled subjects will be infused with EBV TCR-T cells. The project which enrolls 27 patients, according to the patient's HLA subtypes will be divided into HLA-A2, HLA-A11, HLA-A24 three groups, 9 patients in each group. Using a dose climbing method, each group will be divided into three dose subgroups. In the first dose subgroup, 5×106/kg TCR-T cells will be returned, and in the second dose subgroup, 1×107/kg TCR-T cells will be returned. The third dose subgroup 5 x 107/kg TCR-T cells will be returned.
223475432|NCT01031290|DEVICE|Repetitive Transcranial Magnetic Stimulation|daily sessions for 5 days
223475433|NCT03735615|BEHAVIORAL|sprint interval training|Each training session will be performed 3 times per week for 3 weeks. Each session consists of 3-5x20 sec all-out cycling efforts against a load corresponding to 0.05-0.07 kg/kg body mass, separated by 3-5 min of low intensity cycling (20-50 W), on a lode bicycle ergometer (Excalibur Sport V2.0, Groningen, the Netherlands). All training sessions includes a 5 min warm-up and 3 min cool-down.
224069883|NCT02014636|DRUG|Pazopanib|Pazopanib is an orally administered 200 mg tablet available in the dose range of 400 to 800 mg
224069884|NCT02014636|DRUG|MK-3475|MK 3475 is an intravenously administered 100 mg/ 4mL solution available in the potential dose range of 1 to 10 mg/kg.
224069885|NCT03993184|BEHAVIORAL|Hot Yoga|Bikram or hot yoga is a standardized series of 26 postures with two breathing exercises. Classes will be performed at local yoga studios in Austin, Texas and participants will be required to sign in for each session. All participants will receive 12 weeks of free classes for their participation.
224069886|NCT02950220|DRUG|Ibrutinib|Given PO
224069887|NCT02950220|OTHER|Laboratory Biomarker Analysis|Correlative studies
224069888|NCT02950220|BIOLOGICAL|Pembrolizumab|Given IV
224069889|NCT01311700|DRUG|Injectable (i.v.) metoprolol tartrate (up to 15 mg).|"Patients are randomized to active intervention (early metoprolol initiation strategy) or no treatment (delayed metoprolol initiation strategy).~Patients randomized to early metoprolol initiation strategy receive up to three 5mg i.v. dosages (2 minutes apart) before reperfusion.~Patients randomized to delayed metoprolol initiation strategy receive no active treatment before reperfusion.~Patients in both groups receive oral metoprolol tartrate treatment (25-100mg/12h), starting 12-24 hr post-reperfusion."
224069890|NCT02685709|DRUG|Octreotide capsules|
224069891|NCT00821639|BEHAVIORAL|Counseling, educational pamphlet and a sticker|Infants exposed to secondhand smoke will be recruited and randomized based on parents to receive or not receive counseling, an educational pamphlet and a sticker on SHS.
224069892|NCT01701570|BEHAVIORAL|Placebo Attention Control|The placebo attention control group will receive weekly phone calls to monitor their blood glucose levels.
224069893|NCT01701570|OTHER|Supervised Exercise Training|The 20-week aerobic exercise training intervention provides supervised exercise training sessions 3 times weekly following the HERITAGE study training model that was feasible in prior studies with older, sedentary overweight adults (55%maximal oxygen uptake (VO2max) for 30 minutes per session at study entry with progressive titration to 70-80% VO2max for 50 minutes).
224069894|NCT06417619|BEHAVIORAL|Mindfulness-Based Psychoeducation|The Effect of Mindfulness-Based Psychoeducation on Depression Level of Depression Patients
224069895|NCT02394873|BIOLOGICAL|ALLO-ASC-DFU|Dressing for second-degree burn wound.
224069896|NCT04161430|DRUG|DBPR108; Placebo matching sitagliptin|"Phase A (Weeks 1-24): DBPR108 100 mg once daily under fasted conditions for 24 weeks; Placebo matching sitagliptin 100 mg once daily under fasted conditions for 24 weeks.~Phase B (Weeks 25-52): Drug: DBPR108 100 mg once daily under fasted conditions for 28 weeks."
224069897|NCT04161430|DRUG|Placebo matching DBPR108; Sitagliptin; DBPR108|"Phase A (Weeks 1-24): Placebo matching DBPR108 100mg once daily under fasted conditions for 24 weeks; Sitagliptin 100 mg once daily under fasted conditions for 24 weeks.~Phase B (Weeks 25-52): Drug: DBPR108 100 mg once daily under fasted conditions for 28 weeks."
224069898|NCT04161430|DRUG|Placebo matching DBPR108; Placebo matching sitagliptin; DBPR108|"Phase A (Weeks 1-24): Placebo matching DBPR108 100 mg once daily under fasted conditions for 24 weeks; Placebo matching sitagliptin 100 mg once daily under fasted conditions for 24 weeks.~Phase B (Weeks 25-52): Drug: DBPR108 100 mg once daily under fasted conditions for 28 weeks."
224162190|NCT02667392|PROCEDURE|Gait Training with Biofeedback|"Intervention (12, 60-minute sessions, 3X/week for four weeks) will occur in an outpatient research setting. Participants will be supervised by a licensed physical therapist and wear a gait belt during all activities. The therapist will choose from a standardized bank of gait activities, suitable to each participant's ability level. The goal for total walking time for each session will be 50 minutes: 5, 10-minute bouts with a 2-minute rest between bouts. This is the typical length and intensity of outpatient rehabilitation sessions for ambulatory patients discharged from inpatient rehabilitation.~Biofeedback Group: Biofeedback (external-focus feedback) will be provided as an adjuvant to therapist-provided feedback during the intervention. Participants will be instructed that a tone will sound when they push off with their (paretic) leg to swing it forward when the participant-specific pre-programmed threshold is exceeded."
223475434|NCT03583281|DIETARY_SUPPLEMENT|Capsules containing flax oil|Capsules containing flax oil to provide 4 grams ALA per day for 4 weeks
224162191|NCT02667392|PROCEDURE|Gait Training with Verbal Feedback|"Intervention (12, 60-minute sessions, 3X/week for four weeks) will occur in an outpatient research setting. Participants will be supervised by a licensed physical therapist and wear a gait belt during all activities. The therapist will choose from a standardized bank of gait activities, suitable to each participant's ability level. The goal for total walking time for each session will be 50 minutes: 5, 10-minute bouts with a 2-minute rest between bouts. This is the typical length and intensity of outpatient rehabilitation sessions for ambulatory patients discharged from inpatient rehabilitation.~Verbal Feedback Group: Therapist-provided internal-focus feedback (directed towards components of body movement) will be used to instruct participants on achieving and/or maintaining appropriate movement patterns that contribute to propulsion generation."
224162192|NCT01999712|PROCEDURE|Echocardiography|Patients will undergo an echocardiogram at baseline (preoperative) and at 30 and 90 days after LVAD implantation
224162193|NCT02033850|BEHAVIORAL|Attention Process Training-II|Rehabilitation of attention using the Attention Process Training-II
224162194|NCT01250743|DIETARY_SUPPLEMENT|ascorbic acid (vitamin C)|intravenous vitamin C, 25 to 100 grams, once or twice a week, for five months
224162195|NCT06179706|DIAGNOSTIC_TEST|11C-choline PET/CT|In our study we evaluated the efficacy of high-dose RT guided by 11C-Choline PET/CT on bone metastases in prostate cancer patients with a limited number of metastases.
224162196|NCT01920971|RADIATION|infrared therapy|wavelength = 890 nm, radiant power output = 6.24 W, power density = 34.7 milliWatts/cm2 for 40 min, total energy 83.2 J/cm2
224162197|NCT00650312|DRUG|Metformin Hydrochloride ER Tablets 500 mg|500mg, single dose fasting
224162198|NCT00650312|DRUG|Glucophage® XR Tablets 500 mg|500mg, single dose fasting
224162199|NCT04951180|OTHER|Demographic data and MRI images extraction|The data were retrospectively extracted pre- and postoperatively after hip arthroscopy. The prognosis of the surgery was evaluated through MRI images.
224162200|NCT02820038|BEHAVIORAL|Medication Guides|The investigators will compare the effectiveness of two types of written prescription drug information targeted for patients: (1) Medication Guides mandated by the Food and Drug Administration, and (2) Drug Facts Boxes, developed by Woloshin and Schwartz.
224162201|NCT02820038|BEHAVIORAL|SMART Program|The investigators will determine if the effectiveness of written medication information can be increased by Gist Reasoning Training, delivered via the SMART Program, which is designed to enhance patients' ability to extract meaningful gist from complex information.
224162202|NCT02820038|BEHAVIORAL|Drug Facts Boxes|The investigators will compare the effectiveness of two types of written prescription drug information targeted for patients: (1) Medication Guides mandated by the Food and Drug Administration, and (2) Drug Facts Boxes, developed by Woloshin and Schwartz.
224162203|NCT04679714|DEVICE|Transcatheter mitral valve repair (PLAR Implant and Delivery System)|The PLAR Implant is placed on the mitral valve posterior annulus using its delivery system via femoral vein access and a transeptal puncture
224162204|NCT02998255|DRUG|Single dose of 2L PEG|Patients at average risk for inadequate BP were given instructions for bowel preparation through phone call a day before scheduled colonoscopy. Patients began to drink 2 L of PEG 4-6 hours before colonoscopy at a rate of 250 mL every 15 minutes.
224162205|NCT02998255|DRUG|Split dose of 4L PEG|All patients at average risk for inadequate BP were given instructions for bowel preparation through phone call a day before scheduled colonoscopy. the participants began to drink the first 2 L of PEG at 7:00-9:00 PM on the day before colonoscopy at a rate of 250 mL every 15 minutes. On the day of the procedure, patients took the remaining 2 L 4-6 hours before colonoscopy.
224162206|NCT01886755|DIETARY_SUPPLEMENT|ORS rehydration solution|
224162207|NCT01886755|DIETARY_SUPPLEMENT|placebo|
224162208|NCT03374761|OTHER|Families First Home Visiting Program|10 group sessions and 4 home visits with community facilitators emphasizing positive parenting
224304667|NCT05444322|DRUG|RD14-01 cell infusion|Autologous CAR T cells
224304668|NCT00560430|DRUG|telmisartan|80 mg per day, orally, weeks 1-14
223475435|NCT03583281|DIETARY_SUPPLEMENT|Capsules containing DHA-enriched fish oil|Capsules containing fish oil to provide 4 grams DHA per day and 0.8 grams EPA per day for 4 weeks
223475436|NCT00522665|DRUG|Irinotecan|Irinotecan 125 mg/m2 IV days 1 and 8
223475437|NCT00522665|BIOLOGICAL|Cetuximab|Cetuximab 250mg/m2 IV days 1, 8 and 15
223475438|NCT00522665|BIOLOGICAL|RAD001|Patients on Arm A will crossover and receive RAD001 at disease progression
223582209|NCT06250738|BEHAVIORAL|Mindfulness-based Stress reduction program: Virtual|Through mindfulness meditation and a series of carefully crafted exercises, MBSR equips individuals with powerful tools to manage stress, reduce anxiety, and enhance their overall well-being. Participants will complete 4 weekly virtual sessions covering topics like introduction to stress and its consequences, awareness of sensations, and thoughts, mindful eating, and mindful walking.
224304669|NCT00560430|DRUG|telmisartan|80 mg per day; orally, weeks 1 and 2; 160 mg per day; orally, weeks 3-14
223475439|NCT03359746|DRUG|Grazoprevir/Elbasvir|Medication for treatment of patient
223475440|NCT03233074|OTHER|Bone marrow analyses|This is a non-interventional study for the constitution of a biobank of bone marrows, in order to further investigate in vitro the cellular properties of bone marrow-isolated mesenchymal stromal cells.
223475441|NCT03720561|DRUG|Ibrutinib|Participants in this observational study with confirmed diagnosis of CLL receiving ibrutinib in routine clinical practice settings will be observed approximately for 3 years.
223475442|NCT01704261|DRUG|Omarigliptin|Omarigliptin 25 mg capsule administered orally once a week
224162209|NCT02408926|BIOLOGICAL|Boostrix|Pregnant women will be vaccinated with an acellular pertussis containing vaccine between 27 and 36 weeks of gestation.
224162210|NCT02408926|BIOLOGICAL|Infanrix hexa|Children from group A will be vaccinated with an acellular pertussis containing vaccine according to the official recommendations in Thailand at 2, 4, 6 and 18 months.
223475443|NCT01704261|DRUG|Matching placebo to Omarigliptin|Matching placebo to omarigliptin capsule administered orally once a week
224162211|NCT02408926|BIOLOGICAL|Quinvaxem|Children from group B will be vaccinated with a whole cell pertussis containing vaccine according to the official recommendations in Thailand at 2, 4, 6 and 18 months.
224162212|NCT02408926|BIOLOGICAL|OPV|Children from group B will be vaccinated with OPV vaccine according to the official recommendations in Thailand at 2, 4, 6 and 18 months.
224162213|NCT01311739|DRUG|Cyanocobalamin|
224162214|NCT02253940|DRUG|BILR 355 - Treatment A (current tablet formulation)|
224162215|NCT02253940|DRUG|BILR 355 - Treatment B (new tablet formulation)|
224162216|NCT02253940|DRUG|BILR 355 - Treatment C (new capsule formulation)|
224162217|NCT02253940|DRUG|BILR 355 - Treatment D (current tablet formulation)|
224162218|NCT02253940|DRUG|BILR 355 - Treatment E (new capsule formulation)|
224162219|NCT02253940|DRUG|Ritonavir|
223475444|NCT01704261|DRUG|Glimepiride|Open-label glimepiride tablet(s) administered orally once daily for a total daily dose \>=4 mg. In the event of hypoglycemia, the glimepiride dose may be down-titrated to a minimum dose of 1 mg daily.
223475445|NCT01704261|DRUG|Metformin|Open-label metformin tablet(s) administered orally once or twice daily for a total daily dose \>=1500 mg
223475446|NCT04845230|BEHAVIORAL|FreshRx Nourishing Healthy Starts|This is a field experiment study that incorporates referrals to public programs, food supplementation and nutrition education, or integrative care services provided by a Licensed Masters Social Worker.
223475447|NCT01012050|DEVICE|NV|Noninvasive ventilation coupled with nebulization(Nebulization containing salbutamol (2.5mg) and ipratropium bromide (0.25mg)plus oxygen flow in 7Lpm)
223475448|NCT01012050|OTHER|NEB group|Nebulization containing salbutamol (2.5mg) and ipratropium bromide (0.25mg)plus oxygen flow in 7Lpm
223475449|NCT01096940|DRUG|AZD1656|Oral tablet, BID dose
223475450|NCT01096940|DRUG|simvastatin|Oral tablet, single dose
223475451|NCT02137798|DEVICE|Radio-frequency catheter ablation|Radio-frequency atrial fibrillation catheter ablation includes circumferential PV isolation and voltage-map guided substrate modification, which means low voltage zone (amplitude \< o.5 mV) will also be ablated.
223475452|NCT06243445|DIAGNOSTIC_TEST|Transthoracic echocardiography for central venous catheter tip location|Measure of time between injection of echographic contrast in the distal lumen of a central venous catheter, inserted via supra/infra clavicular right veins, and visualization, using transthoracic echocardiography, of micro bubbles in right atrium with the catheter tip positioned under transesophageal ultrasound control in four different positions: right atrium, cavo-atrial junction (CAJ), at 4 centimeters proximal to CAJ, in superior vena cava and at 8 centimeters proximal to CAJ
223475453|NCT03196141|DIAGNOSTIC_TEST|StO2 and EndoPAT|"* StO2 probe is a lightweight plastic probe that will be applied over the brachioradilalis muscle (anterolatereal aspect of the forearm) where there is less subcutaneous fat and taped in place.~* The EndoPAT probe will be place on a finger on the same arm.~* Pulse oximeter probes will be connected to a finger on each hand."
223475454|NCT02722967|DRUG|Aripiprazole + IEM (Ingestible Event Marker)|Oral aripiprazole (2, 5, 10, 15, 20, or 30 mg) with an ingestible event marker in a single daily dose for duration of the trial.
223475455|NCT05861908|OTHER|Filtek™ Bulk Fill restoration|restoration of class II caries with different bulk-fill technique
223475456|NCT05861908|OTHER|Heated Filtek™ Bulk Fill restoration|restoration of class II caries with different bulk-fill technique
223475457|NCT05861908|OTHER|G-aenial™ BULK Injectable restoration|restoration of class II caries with different bulk-fill technique
223475458|NCT05861908|OTHER|Sonicfill3 restoration|restoration of class II caries with different bulk-fill technique
223475459|NCT02596048|OTHER|Iomeron|Iomeron or Imeron which is a iomeprol injection, hereafter referred to as iomeprol is an injectable solution of iomeprol, a non-ionic hydrosoluble iodinated compound used as a medical imaging contrast agent for radiological examinations.
223582210|NCT06250738|BEHAVIORAL|Home exercises|Following each virtual session, participants will be given home exercises like practicing awareness of breathing, awareness of thoughts, and awareness of eating.
224162220|NCT02918539|DRUG|florbetapir F 18 PET scan|For those patients who do not have an existing amyloid scan, each will receive an IV injection, 370 MBq (10 mCi), single dose of florbetapir F 18 followed by a Positron Emission Tomography (PET) Scan to determine amyloid status
224162221|NCT02067572|OTHER|Saline mouthwash|
224162222|NCT02067572|OTHER|Salvia mouthwash|
224162223|NCT03029767|OTHER|Aerobic exercise .|The aerobic exercise group will perform brisk walking. Intensity of the aerobic exercise program will be progressively increased throughout the 16-week program. Intensity of aerobic exercise will be 40-65% of maximum heart rate , which is low to moderate.Duration of each session will be 45 minutes. Aerobic exercise will be performed 3 days per week.
223475460|NCT01834547|DRUG|Drugs use: methylphenidate|40 mg tablets
223475461|NCT01834547|DRUG|Drug use: modafinil|40 mg tablets
223475462|NCT01834547|DRUG|caffeine|400 mg
223475463|NCT01834547|DRUG|placebo|placebo
224162224|NCT03029767|OTHER|Resistance exercise|"The resistance exercise group will perform 8 different exercises. Frequency of exercises per week is 3 days and duration of each exercise session is 45minutes. Interval rest among different exercises is 1minute.The intensity and repetition of resistance exercises is progressive. Participants will be exercised at 30% intensity (low intensity) for upper body and 50% intensity (moderate intensity) repetition voluntary maximum for lower body.~Progressive, dynamic and rhythmical, alternative to upper-body and lower-body works and circuit resistance training of low to moderate intensity exercises will be executed."
224162225|NCT03029767|OTHER|Aerobic and resistance exercise|The aerobic and resistance exercise group will perform 23 minutes aerobic exercises and 22 minutes resistance exercises. The exercises will be performed three days per week . Intensity of aerobic and resistance exercise group for aerobic and resistance exercises are similar with intensity of aerobic group and resistance group exercises respectively.
224162226|NCT02235168|PROCEDURE|six minute walking test|
224162227|NCT03771781|DRUG|Empagliflozin Tablets|Observe the safty and PK after subjects receiving a single dose of Empagliflozin Tablets.
224162228|NCT03771781|DRUG|Empagliflozin Tab 25 MG|Observe the safty and PK after subjects receiving a single dose of Empagliflozin Tablets( Jardiance®）.
223475464|NCT00773357|DRUG|guanfacine|3 mg/day, with 3-week lead-in medication period. The starting dose is 0.5 mg/day for days 1-3, followed by 1.5mg/day for days 4-7, followed by 2 mg/day for days 8-12, followed by 2.5 mg/day for days 13-15, followed by 3 mg/day from day 16 to remainder of study. 5-day taper at end of study.
223475465|NCT00773357|DRUG|placebo|placebo
223475466|NCT00846053|DIAGNOSTIC_TEST|FDG-PET|All subjects underwent FDG-PET and low-dose volumetric CT imaging. After completing a transmission scan, \[18F\]FDG was injected intravenously at the start of dynamic scan acquisition. Regions of interest were drawn over multiple tomographic slices to determine average whole-lung and regional lung tissue \[18F\] FDG uptake. Patlak graphical analysis was used to determine the rate of \[18F\]FDG uptake from the blood input function and lung tissue activity curves, measured as the influx constant Ki (slope of the linear regression from the Patlak plot). Corrected Ki (i.e., Ki divided by the initial volume of distribution). Lung density was calculated from the attenuation image by standard methods.
223475467|NCT00111761|DRUG|Irinotecan|Part 1: 125 mg/m\^2 IV infusion once a week on weeks 1 through 4 of each 6-week treatment cycle. Part 2: 180 mg/m\^2 IV infusion every other week until disease progression or unable to tolerate.
223475468|NCT00111761|BIOLOGICAL|Panitumumab|Intravenous (IV) infusions of panitumumab 2.5 mg/kg once a week delivered in 6-week cycles.
223475469|NCT00111761|DRUG|5-Fluorouracil|Part 1: IV bolus 500 mg/m\^2 on weeks 1 through 4 of each 6-week cycle. Part 2: IV bolus 400 mg/m\^2 and infusional 2400-3000 mg/m\^2 over 46 hours once every other week until disease progression or unable to tolerate.
224162229|NCT02732249|DRUG|Esomeprazole|Given 30 min before morning and evening meals
223475470|NCT00111761|DRUG|Leucovorin|Part 1: IV bolus 20 mg/m\^2 on weeks 1 through 4 of each 6-week cycle. Part 2: 400 mg/m\^2 every other week until disease progression or unable to tolerate.
224162230|NCT02732249|DRUG|Bismuth Potassium Citrate|Given 30 min before morning and evening meals
224304670|NCT00560430|DRUG|placebo|placebo; orally weeks 1-14
223475471|NCT02361866|BIOLOGICAL|GC1107|0.5 ml, Intramuscular, single dose(day0)
223475472|NCT02361866|BIOLOGICAL|Tetanus and Diphtheria(Td vaccine)|0.5ml, Intramuscular, single dose(day0) only applicable step1
224162231|NCT02732249|DRUG|Clarithromycin|Given 30 min after morning and evening meals
223475473|NCT04862338|DIETARY_SUPPLEMENT|Nicotinamide mononucleotide (NMN-C)|Nicotinamide mononucleotide (NMN-C) at 400 mg/day for 28 days in total
224162232|NCT02732249|DRUG|Metronidazole|Given 30 min after meals or at bedtime
223475474|NCT04918862|DRUG|Granisetron|210 patients were enrolled, divided into two groups \[Granisetron 1 mg: 105 patients received 1mg granisetron, Granisetron 3 mg: 105 patients received 3mg granisetron\]. The two groups were compared in demographic characteristics (age, gender, weight, and height), hemodynamic parameters (MAP and HR), and duration of surgery
223475475|NCT00563771|DRUG|Rasburicase|
223475476|NCT00153426|BEHAVIORAL|West Virginia WISEWOMAN|Print-based tailored health communications and computer-based interactive nutrition program
223475477|NCT06478641|DRUG|Tafenoquine|Tafenoquine will be self-administered orally as 2 x 100 mg dark pink coated tablets once daily (total daily dose 200 mg) with food on Days 1, 2, 3 \& 4 then weekly thereafter (starting on day 11) until the patient has two consecutive negative PCR tests for Babesia parasites and symptoms of babesiosis have resolved.
223475478|NCT01763541|DRUG|leuprolide acetate|Given to both arms to induce hypogonadism
223475479|NCT01763541|DRUG|Anastrozole|Given to men to prevent conversion of administered testosterone to estradiol.
223475480|NCT06517992|OTHER|Health education for cadre (communicated project)|The investigators perform health education to cadre in order to support their role in providing care for metastatic breast cancer living in the community using a module. The module consists of text (written information) and some videos as education medias.
223475481|NCT00706563|BIOLOGICAL|Fluarix™|Single intramuscular dose on Day 0
224162233|NCT06306352|OTHER|Vibrotactile feedback|The ABLE exoskeleton is accompanied by a vibrotactile feedback belt which users wear around their chest to receive real-time feedback during the double support phase. This feedback can assist them in their weight shift during the double support phase.
224162234|NCT04930952|DRUG|Ethanol-amine Oleate Sclerotherapy Injection|Intralesional Sclerotherapy Injection
224162235|NCT02530099|PROCEDURE|CN-group|Time limited simulation based training on camera navigation tasks on a virtual reality-simulator.
224162236|NCT02530099|PROCEDURE|Procedure-group|Time limited simulation based training on laparoscopic procedure on a virtual reality-simulator.
224162237|NCT05154071|OTHER|Collection of medical data|Collection of adverse events, of mortality, length of hospitalization
224162238|NCT04295707|DEVICE|orthokeratology|Nightly wear of orthokeratology lenses to correct vision in the daytime
224162239|NCT04295707|DEVICE|Menicon Progent A+B|Menicon Progent A+B is a commercially available protein remover for rigid lenses. It has received FDA clearance and been launched in Hong Kong for over a decade. The product contains two separate sterile solutions, one with sodium hypochlorite and the other with potassium bromide. By mixing the two solutions in a special vial, it can clean and remove protein deposits on the lenses. Parents of subjects assigned to use weekly protein remover will be required to soak the cleansed lenses in the solution mixture for not more than 30 mins every week. All lenses must be rinsed thoroughly with saline and cleansed with daily cleaner again before daily disinfection.
224162240|NCT02699671|DEVICE|Bioresorbable Vascular Scaffold|
224162241|NCT00033371|DRUG|Celecoxib|Given 400 mg PO twice a day
224162242|NCT00033371|OTHER|Placebo|Given PO to match DFMO
224162243|NCT00033371|DRUG|eflornithine|Given PO at 0.5 gm/m\^2/day rounded down to the nearest 250 mg dose (BSA of \< 1.4 = 500 mg/day; BSA of 1.5 - 2.0 = 750 mg/day; BSA of 2.1 - 2.5 = 1000 mg/day; BSA of \> 2.6 = 1,250 mg/day).
224162244|NCT00033371|OTHER|Laboratory biomarker analysis|Correlative studies
224162245|NCT00033371|OTHER|Questionnaire administration|Ancillary studies
224305018|NCT03244644|DRUG|Open label RBX2660 (only for confirmed CDI recurrence)|RBX2660 administered as a second treatment after confirmed CDI recurrence following the initial dose of placebo or RBX2660
223475482|NCT04127617|OTHER|Osteopathic Manipulative Treatment|"Osteopathic treatment~Dural system:~L5-S1 decompression; sacred decompression among the iliacs; occipital-sphenoid approach; decongestion of occipital condyles~Fascial system:~fascial techniques in the abdominal region: right hypochondrium, epigastrium, left hypochondrium, right side, mesogastrium, left side, right iliac area, hypogastrium, left iliac area; relationship with corresponding vertebral levels (eg, hypogastrium); fibro scar adhesions treatment.~Biomechanical system:~diaphragm rebalancing with respect to anatomical insertions; passive mobilization of dysfunctional areas. Nursing education as described in Standard Treatment"
223475483|NCT04127617|OTHER|Nursing Educational Care|"Nursing education~* assessment of the best personal evacuation strategy concerning the quality of life, individual resources, and level of autonomy;~* assessment of the correct execution of the identified evacuation manoeuvre (digital stimulation, manual removal, reflex stimulation, transanal irrigation, use of micro-enemas or suppositories;~* identification of the best postural strategies during evacuation;~* nutrition and proper hydration education;~* education in completing the evacuation diary;~* colonic massage training;~* verification of the correct hiring of any previously prescribed laxative drugs."
223475484|NCT05216484|BIOLOGICAL|SARS-CoV-2 Vaccine, Inactivated (Vero Cell)|the third dose immunization schedule of SARS-CoV-2 inactivated vaccine
223475485|NCT04265677|OTHER|Telemedicine FCR|Parents/guardians will be able to join family centered rounds using telemedicine (audio and visual)
223475486|NCT04265677|OTHER|Standard of care|Parents/guardians will not be able to join family centered rounds using telemedicine (audio and visual)
223475487|NCT03201991|OTHER|Resistance Exercise Program|The resistance exercise program will involve three sets of 10 repetitions of each exercise in levels 1 and 2 every day. Participants will be given instructions to follow.
224162246|NCT01505660|BEHAVIORAL|Care management|The intervention will include healthcare delivery team notification of patient reported outcomes (PROs) including medication adherence and adherence barriers such as depression symptoms along with intervention recommendations and targeted care management using a stepped care approach. Patients will receive structured calls from their care manager 2 and 6 weeks after enrollment. An assessment including depression, adherence, and substance use will be completed at the beginning of each call. After the 2nd call, a stepped care approach will be used where patients with a greater need based on adherence and depression will receive more intensive interventions based on the PEARL intervention. The components include: a) problem solving treatment, b) social and physical activation, c) pleasant events scheduling, d) patient support and education regarding medication use, and e) medical and psychiatric consultation. Patients will also receive follow-up calls at \~9 and 12 months after enrollment.
224162247|NCT02198560|DEVICE|RS-3000 Lite|
223582211|NCT05838573|DRUG|Metformin treatment|Participants assigned to the metformin group will receive 500mg metformin three times daily (tid) for 24 weeks. The initial dose will be 500 mg orally in the evening for the first two days, followed by an increase to 500mg twice a day for the subsequent two days. By day 5, the dosage will be further increased to 500mg tid. The highest tolerated dosage will be maintained for participants who could not tolerate the maximum dosage.
223582212|NCT05838573|DRUG|Placebo treatment|Parallel-dose adjustments will be made for the placebo group to maintain consistency in dosing between the two groups.
223582213|NCT05838573|OTHER|Baseline assessments|Schizophrenic participants who don't meet any of the diagnostic criteria for metabolic syndrome will only accept baseline evaluations.
224162248|NCT00253929|DRUG|Intra-arterial infusion of adenosine|
223582214|NCT05838573|OTHER|Volunteer assessments|Apart from psychiatry scales(Hamilton Depression Scale, Young Mania Rating Scale and Self-reporting Inventory-90), other assessments for the healthy subjects are the same as the baseline for sczhiophrenic participants.
223582215|NCT05785182|PROCEDURE|Open Fracture|Patients 18 years of age or older with open fracture. Provision of informed consent.
223744257|NCT03644745|BEHAVIORAL|VM @ Home Usability|Our primary outcome measures will be use of the coaching system features, level of daily physical activity, mood, self-efficacy, and user satisfaction. Secondary outcomes that will inform our further development and be important outcomes in subsequent trials include user adherence to their coaching goals, physical function and level of socialization. For the pilot study, we plan to assess physical function and level of socialization at baseline and at the end of 3 months. For the other outcome measures, we will be able to integrate the data collection into the VM@Home platform and coaching process.
224162249|NCT00253929|DRUG|intra-arterial infusion of caffeine|
224162250|NCT00253929|DRUG|intra-arterial infusion of acetylcholine|
224162251|NCT00253929|DRUG|intra-arterial infusion of sodium nitroprusside|
224162252|NCT00253929|PROCEDURE|Occlusion of arm-circulation by inflation of upper-arm cuff to 200mmHg for 2, 5 and 13 minutes|
223475488|NCT01220791|OTHER|In vitro fertilization treatment for infertility|IVF treatment
223475489|NCT02246933|OTHER|PUFA Diet|The 7-day diet will consist of 50% carbohydrate, 15% protein, and 35% fat. 21% of total energy will be poly-unsaturated fatty acids, 9% mono-unsaturated fatty acids, and 5% saturated fatty acids.
223475490|NCT02246933|OTHER|Control Diet|The 7-day diet will consist of 50% carbohydrate, 35% fat, and 15% protein. Furthermore, 7% of total energy will be poly-unsaturated fatty acids, 15% of total energy will be mono-unsaturated fatty acids, and 13% of total energy will be saturated fatty acids.
223475491|NCT01092767|DEVICE|Valiant Thoracic Stent Graft with the Captivia Delivery System|All subjects will be implanted with this device
224162253|NCT02894255|DEVICE|Coronary artery bypass grafting|
224162254|NCT02894255|PROCEDURE|Percutaneous coronary intervention|
224162255|NCT03874195|BEHAVIORAL|Access to PCforMe for review|Intervention Arm subjects will receive access to PCforMe.
224162256|NCT03874195|BEHAVIORAL|Access to three nationally-recognized Palliative Care websites for review|Subjects in the Active Control arm will receive a list of three nationally-recognized websites to receive information on palliative care
224162257|NCT02923050|BEHAVIORAL|Simple Suppers|Theory-based 10-week family meals program
224162258|NCT03123484|DRUG|β-elemene|β-elemene：400-600mg + 5%GS 500ml,ivgtt,qd, continuously 45days
224162259|NCT03123484|DRUG|EGFR-TKIs(Erlotinib, Gefitinib and Icotinib)|EGFR-TKIs(Erlotinib, Gefitinib and Icotinib) as usual
223475492|NCT02702544|DEVICE|CardioScreen 1000 - Haemodynamic Measurement System, Medis|Impedance cardiography (ICG)
224162260|NCT02914197|OTHER|Full information|Patients will be randomized to receive full information or standard information at the study start. The second wave will follow the same randomization process 6 months following the study start.
224162261|NCT03799627|DRUG|Vadadustat|Vadadustat Tablets 150 mg
224162262|NCT03799627|DRUG|Epoetin Alfa|Epoetin Alfa
224162263|NCT03799627|DRUG|Vadadustat TIW|Oral Vadadustat
224162264|NCT00776698|DRUG|bevacizumab [Avastin]|7.5mg/kg every 3 weeks for 3 cycles (cohort 1) or 15mg/kg every 3 weeks for 3 cycles (cohort 2). Preferred dose every 3 weeks for 9 cycles (cohort 3).
224162265|NCT00776698|DRUG|cisplatin|80mg/m2 iv every 3 weeks for 3 cycles
224162266|NCT00776698|DRUG|etoposide|100mg/m2 iv for 3 consecutive days, every 3 weeks for 3 cycles
224162267|NCT02883426|BIOLOGICAL|H3N2v MN 2010/AA ca live attenuated influenza vaccine (LAIV)|Approximately 10\^7.0 Fluorescent Focus Units (FFU) per 0.2 mL dose; administered intranasally
224162268|NCT02883426|BIOLOGICAL|H3N2v inactivated subvirion influenza vaccine|15 μg; administered intramuscularly
224162269|NCT02883426|BIOLOGICAL|Placebo|Administered by nasal spray
224162270|NCT02666040|DEVICE|ULTRAPRO® meshes|The inguinal hernia repair has to be performed with the Lichtenstein technique, with standardized prosthesis fixation and no use of plug.
224162271|NCT02666040|DEVICE|"Prolene® meshes"|The inguinal hernia repair has to be performed with the Lichtenstein technique, with standardized prosthesis fixation and no use of plug.
224162272|NCT02666040|PROCEDURE|Detecting the mode of admission to hospital|Ordinary admission or day surgery
224162273|NCT02666040|PROCEDURE|Duration of surgery|Time operating room
224162274|NCT02666040|PROCEDURE|Anesthesia volume and type used|Anesthesias used: infiltration, followed by spinal, general, epidural.
224162275|NCT06153914|PROCEDURE|Sequential Adult Left Lateral Liver Transplantation|Hemihepatectomy combined with orthotopic left lateral lobe liver transplantation is performed first, and residual liver resection is performed after the graft has grown to a sufficient functional liver volume. After the two-stage surgery, we will follow up on all subjects for one year.
224162276|NCT01211119|OTHER|No PRF|Group B (n=6), implantation of PRF after partial menisectomy and suture; Group (n=6), partial menisectomy only
224162277|NCT02512276|BEHAVIORAL|Telepharmacist intervention|The intervention consists of a brief telephonic consultation with a clinical pharmacist using behavioral interviewing techniques tailored to patient's level of health activation and progress reports of medication-taking and disease control. Based on the barriers identified during the initial telephone consultation, patients will be offered more intensive support including reminder and motivational text-messages, video visits and pillboxes.
224162278|NCT04019392|DEVICE|Game Ready® device|The half leg boot sleeve of the Game Ready® device (CoolSystems, Inc., Alamda, CA) will be applied to each participants' lower leg and ankle for 30 minutes set on the medium pressure setting (5-50 mmHG).
224162279|NCT04019392|OTHER|Wetted Ice Bag with Elastic Wrap|A standard ice bag filled with 2000 mL of cubed ice and 300 mL of 5˚C water will be applied using an elastic wrap to each participants' lower leg for 30 minutes. An elastic wrap applied at approximately 75% percent tension starting distal to the treatment area and moving proximally overlapping by half will be applied over the wetted ice bag.
224162280|NCT03065725|PROCEDURE|late FDG|In addition to regular FDG-PET/CT 60 minutes post injection, an extra scan 180 minutes post injection is made.
224162281|NCT05793112|DRUG|INF108F probiotic|Oral suspension
224162282|NCT05793112|DRUG|Placebo|Oral suspension
224304671|NCT02722148|DEVICE|Novel Allergen-Specific Immune Signature Directed Approach to Dietary Elimination Therapy|A novel assay developed by the investigator to diagnose food allergens. Results from the assay are used to guide food elimination therapy for the treatment of Eosinophilic Esophagitis (EoE).
224304672|NCT03961022|DIETARY_SUPPLEMENT|Polyherbal supplement: ReWin(d) vs Placebo|Supplementation during 4 weeks + 72 hours post acute exercice
223475493|NCT02702544|DEVICE|SCHILLER, BR-102 plus - Ambulatory Blood Pressure Monitoring System|Blood pressure monitoring every 1 min during leg elevation
224069899|NCT02331082|OTHER|Structured Quality Improvement|For structured quality improvement, trained healthcare providers (primarily doctors from referral hospital) will serve as mentors to mid-level providers. The mentors will facilitate on-site trainings of primary care with mid-level providers at the district hospital. Mentors will also travel monthly to the healthcare facilities themselves to provide training both in the direct context of clinical care and to provide feedback based upon surveillance and monitoring data. The focus will be on the techniques from the Institute for Healthcare Improvement's Model for Improvement, including Plan-Do-Study-Act cycles, run charts, and root cause analyses. Finally, they will work with the clinical healthcare staff to identify resource needs from the local government for maintenance, water, electricity, and supplies. These resource needs will be addressed through an integrated supply chain management system across the tiers of the healthcare system.
224162283|NCT03385434|DEVICE|Endorings-2|292 patients with an indication for screening colonoscopy will be included. 146 patients will receive a standard colonoscopy and 146 patients will receive an Endorings-2 assisted colonoscopy (1:1 standard colonoscopy vs Endorings-2-assisted colonoscopy).
224162284|NCT04212546|OTHER|Synbiotic test drink|In a healthy male population, participants consumed a synbiotic test drink containing 200 mL milk + 16 g inulin + Lactobacillus casei431 \[\>106cfu/mL\] per day for 21 days with their habitual diet.
223475494|NCT03252626|DRUG|Alprostadil|"Alprostadil injection USP for intravascular infusion contains 500 micrograms Alprostadil, more commonly known as prostaglandin E1. Vasodilation, inhibition of platelet aggregation are among the most notable of these effects.~2ml Alprostadil injection added into 10ml 0.9% saline."
223475495|NCT03252626|DRUG|Normal saline|2ml normal saline injection added into 10ml 0.9% saline.
223475496|NCT01445249|PROCEDURE|Landmark guided ankle block.|25-30mls 0.5% levobupivacaine will be infiltrated to provide a landmark guided ankle block.
223475497|NCT01445249|PROCEDURE|PNS guided block.|This group will have 25-30mls of 0.5% levobupivacaine infiltrated as directed by peripheral nerve stimulation.
223475498|NCT03310216|PROCEDURE|Order I of visual inspection|Participants in group I are provided AI visual inspection system first and EDTRS later.
224162285|NCT04212546|OTHER|Control drink|In a healthy male population, participants consumed a synbiotic test drink containing 200 mL milk + 16 g maltodextrin per day for 21 days with their habitual diet.
224162286|NCT04151719|DRUG|Methylnaltrexone bromide (MNTX)|Methylnaltrexone bromide will be administered per dose and schedule specified in the respective arm.
224162287|NCT01424319|DRUG|Atrasentan low dose group|Subjects will take two tablets daily of one of those which are atrasentan low dose, atrasentan high dose or atrasentan placebo for 12 weeks during the treatment period.
223475499|NCT03310216|PROCEDURE|Order II of visual inspection|The participants in Group II are provided EDTRS first and AI visual inspection system later.
223475500|NCT00467519|BIOLOGICAL|Tdap (Tetanus Toxoid Reduced Diphtheria Toxoid/Acellular Pertussis)|0.5 mL, IM
223475501|NCT00467519|BIOLOGICAL|DTaP (Diphtheria & Tetanus Toxoids & Acellular Pertussis Adsorbed)|0.5 mL, IM
223475502|NCT01028781|DRUG|Thalidomide|Pill form, 50mgs with increasing dosage up to a maximum of 250 mg qd based on pain reports, taken once daily for 14-16 weeks with one 6 month follow-up appointment.
223475503|NCT00747214|DRUG|CRx-102|
223475504|NCT00747214|DRUG|Placebo|
223475505|NCT00747214|DRUG|DMARD Therapy|DMARD therapy can include methotrexate or other DMARD therapy
223475506|NCT04030312|DIETARY_SUPPLEMENT|Bottle Supplementation--Commercially-Sterilized Donor Human Milk|Supplementation by bottle with 20-calorie-per-ounce commercially-sterilized donor human milk (up to 15 ml, up to two times) for infants meeting hypoglycemia criteria and randomized to this treatment arm.
223582216|NCT05785182|PROCEDURE|Infected Fracture|Patients 18 years of age or older with infected fracture. Provision of informed consent.
223582217|NCT03493607|DRUG|AMO-01|Subjects will receive a single 6-hour intravenous infusion for a total dose administration or 120 mg/m2 of AMO-01.
223582218|NCT04163367|BEHAVIORAL|Safer Kids|A behaviorally based parent training program with the purpose to reduce or prevent child abuse.
223582219|NCT04163367|OTHER|Intervention as usual (IAU)|Everything that's included in the social service units' regular handling of cases; such as the formal investigation and family treatment. The units cannot offer Safer Kids as a part of IAU.
223582220|NCT02936284|BEHAVIORAL|Music Enhancement|
223744258|NCT00916747|DRUG|Lonafarnib, Zoledronic Acid, and Pravastatin|"Lonafarnib: Lonafarnib dosing will begin at 150 mg/m2 by mouth twice daily. Lonafarnib will be orally administered without planned breaks, approximately every 12 hours, for a period of 24 months. For patients unable to swallow capsules, the capsules can be opened and dissolved into Ora Blend SF or Ora-Plus.~Zoledronic Acid: Zoledronic acid will be administered intravenously at week one, and months 6, 12, 18 and 24 of this treatment trial. Treatment will consist of one infusion over a 30 minute period.~Pravastatin: Pravastatin will be orally administered once daily without planned breaks, approximately every 24 hours, for a period of 24 months. The drug may be taken with meals. For patients unable to swallow pills, pills can be crushed into food. Pravastatin will be dosed according to the patient weight. Patients less than 10 kg will receive 5 mg pravastatin orally, once daily. Patients weighing 10 kg or greater will receive 10 mg pravastatin daily."
224069900|NCT02331082|OTHER|Chronic Care Model|Senior physicians trained in mentorship of non-physician mid-level providers will provide decision support for mid-level providers in the current district healthcare system with specific protocols for target conditions. We will add the following elements: focus on mid-level, non-physician providers as the primary clinicians within the intervention; intensive Community Health Worker (CHW) outreach for detection, screening, follow-up of patients, and encouragement of patient self-care and behavior change; and focused effort on the seamless care coordination of patients across the tiers of the system. Through trainings of CHWs, much of patient self-management comes in the form of home visits that reinforce clinic and hospital counseling, including risk management and prevention. CHWs will be trained in the counseling of each target condition, with counseling largely occurring in the patients' homes, where much of the challenges of chronic disease management and behavior change lie.
224069901|NCT02331082|DEVICE|Integrated Electronic Medical Record|Clinical information systems. We are developing a system for tracking patients that integrates across each of the tiers using an electronic medical record. This is a key technology in supporting each of the above delivery system design elements.
224069902|NCT02331082|DEVICE|Solar-powered electrical supply|As a component of our comprehensive healthcare systems strengthening intervention, we are installing solar panels at community-level clinics to ensure continuous electrical supply for medical devices and technology.
224069903|NCT02331082|BEHAVIORAL|Performance-based financing|As part of our healthcare systems strengthening intervention, we have established a performance-based financing agreement with the Government of Nepal that conditionally funds healthcare delivery based on population-level health outcomes and quality healthcare service delivery. In this arrangement, the Government serves as a regulator of healthcare delivery rather than a primary provider of healthcare services.
224069904|NCT02331082|OTHER|Existing healthcare system|This is the current rural, district-level public sector healthcare infrastructure of rural Nepal that is not strengthened during the study.
224069905|NCT00332995|DRUG|dapivirine (TMC120) vaginal ring|
223582221|NCT02936284|BEHAVIORAL|Play Date|
223582222|NCT05369832|DRUG|Ozanimod|Specified dose on specified days
223582223|NCT05021549|DEVICE|nasal prong|apneic preoxygenation group (30 patients), will receive 10 L/ min of O2 via nasal prong during preintubation apnia
224069906|NCT00784654|DRUG|Lisdexamfetamine dimesylate (LDX)|LDX 30, 50, or 70mg capsule once per day (open-label and double-blind periods)
224069907|NCT00784654|DRUG|Placebo|Placebo capsule once per day (double-blind period)
224069908|NCT04002635|DRUG|Letrozole|Letrozole ovulation induction
224069909|NCT04002635|DRUG|estradiol valerate|hormonal replacement therapy
224069910|NCT03458208|DRUG|Metformin|"First aIntervention Period:~Single administered dose of Metformin (1 000 mg tablet immediate release) in a fasting condition"
224069911|NCT03458208|DRUG|Glucophage®|"Second Intervention Period:~Single administered dose of Glucophage® (1 000 mg tablet immediate release) in a fasting condition"
224069912|NCT03458208|DRUG|Metformin|"Third Intervention Period:~Single administered dose of Metformin (1 000 mg tablet immediate release) in a fed condition"
223475507|NCT04030312|DIETARY_SUPPLEMENT|Bottle Supplementation--Standard Infant Formula|Supplementation by bottle with 20-calorie-per-ounce standard infant formula (up to 15 ml, up to two times) for infants meeting hypoglycemia criteria and randomized to this treatment arm.
223475508|NCT00171093|DRUG|valsartan + simvastatin|
224069913|NCT03458208|DRUG|Glucophage®|"Fourth Intervention Period:~Single administered dose of Metformin (1 000 mg tablet immediate release) in a fed condition"
224162288|NCT01424319|DRUG|Atrasentan high dose group|Subjects will take two tablets daily of one of those which are atrasentan low dose, atrasentan high dose or atrasentan placebo for 12 weeks during the treatment period.
224162289|NCT01424319|DRUG|Atrasentan placebo group|Subjects will take two tablets daily of one of those which are atrasentan low dose, atrasentan high dose or atrasentan placebo for 12 weeks during the treatment period.
224162290|NCT02983513|BEHAVIORAL|Early Intervention|
224162291|NCT02417675|OTHER|Community-based Adherence Clubs|"Women in the AC arm are prescribed 2 months of their current ART medication (compared to 1 month in the SOC) and will be advised to go to the AC office immediately, where they will be scheduled for their first session. Women will attend AC meetings every two months. At these meetings, women will receive a 2 month supply of medication, health education and peer-support. A trained Community Health Worker (CHW) will also collect blood samples, weight, and current signs/symptoms from women.~Each participant has 5 working days after their AC session to come and collect her medication. Those who have defaulted will be followed up by the CHW via phone calls and, possibly, home visits. If reached, women will be told to return immediately to the main ART facility for receipt of ART care."
224304673|NCT04751292|OTHER|Exposure to high altitude|permanence at high (\>2500 m) altitude; permanence is defined as being born and living at high altitude with the total time spent at lower altitudes not exceeding 2 years in the past 10 years
223475509|NCT05968105|PROCEDURE|Lateral Sagittal Infraclavicular Block|Patients will be in the supine position and after aseptic conditions are provided, the axillary artery of the patient will be visualized in the craniocaudal plane, in the infraclavicular region and in the lateral sagittal position with the help of an 8-12 mHz linear probe. After the brachial plexus cords around the axillary artery are identified, a local anesthetic mixture will be applied in-plane between the posterior cord and the artery. During the block, patients will routinely be given a mixture of 0.25% bupivacaine + 0.5% lidocaine 0.5 mL/kg.
223475510|NCT05968105|PROCEDURE|Inferior vena cava diameter >1.5 cm and Vena Cava Inferior Collapsibility Index (VCI-CI) < 50%|While the patients are lying in the supine position, the vena cava will be determined 2 cm before the inferior heart entrance with the help of a 3.5-5 mHz convex probe. M-mode ECHO will be used to determine the fluctuation rate of the VCI between inspiration and expiration. After determining the farthest and closest points in M-mode ECO, their ratios to each other will be calculated.
223475511|NCT05968105|DIAGNOSTIC_TEST|Inferior vena cava diameter <1.5 cm and Vena Cava Inferior Collapsibility Index (VCI-CI) > 50%|While the patients are lying in the supine position, the vena cava will be determined 2 cm before the inferior heart entrance with the help of a 3.5-5 mHz convex probe. M-mode ECHO will be used to determine the fluctuation rate of the VCI between inspiration and expiration. After determining the farthest and closest points in M-mode ECO, their ratios to each other will be calculated.
223475512|NCT00310986|BEHAVIORAL|Breathing Meditation|
223475513|NCT02783638|DRUG|YHD1119|2 by 2
224162292|NCT02417675|OTHER|Standard of Care for Mothers|Women will be referred immediately from the maternity ART clinic to their nearest adult ART clinic at their first postpartum clinic visit. At referral, they receive an initial 1-month supply of their current ART medication. At the first appointment after transfer into the general ART service, patients undergo clinical history and examination by a doctor or clinical nurse practitioner. Laboratory investigations are ordered according to standard protocols or based on clinician discretion. For the 1st 4 months in the new service, stable patients are dispensed 1 month of ART; subsequent visits are 2-monthly for medication refill, with clinician review 6-monthly; patients with particular clinical or psychosocial concerns may be reviewed more regularly, or referred to higher levels of care.
224304674|NCT00395174|BIOLOGICAL|Influenza Vaccination|0.5mL dose for intramuscular injection
224304675|NCT02872363|OTHER|Intervention A - Behavioural Regulation|"SMS reminder with 'Behavioural Regulation' message:~'Don't forget to make a diary note of your screening mammogram apt at (time)(date) at (site). Call 02033136644 to rearrange'"
224304676|NCT02872363|OTHER|Intervention B - Priority|"SMS reminder with 'Priority' message:~'Is your breast screening appointment on your priority list? Apt at (time), (date) at (site). Call 02033136644 to rearrange.'"
223475514|NCT02783638|DRUG|Lyrica|2 by 2
223582224|NCT04877236|DEVICE|Green Sun Medical Brace|"All patients in the study will receive the Green Sun Medical Whisper Brace. Each GSM brace will be custom-fabricated via computer-assisted design using the 3D torso scans and a treatment plan (e.g. placement of corrective forces) devised by the treating orthotist as inputs. The brace components are then assembled. Once fabricated, the GSM brace will be fit to the subject by representatives of the manufacturer and in consultation with the treating orthotist.~The GSM brace will be prescribed for the same number of hours per day as was the TLSO (generally 18-22 hours per day, individualized based on patient characteristics). Subjects and the family will be shown how to don and doff the brace, how to clean the brace cover, how to remove the temperature monitor, and how to remove the iButton and how to replace batteries in the GSM sensor board."
223582225|NCT04487171|OTHER|Questionnaire|The mothers were administrated three questionnaires, (i) the Edinburgh Postnatal Depression Scale (EPDS), (ii) the State-Trait Anxiety Inventory (STAI-YA), and (iii) the Mother-to-Infant Bonding Scale (MIBS) in two stages, on days 2-3 after delivery and during a phone call between days 25-35.
223582226|NCT00547950|DRUG|:Deng Zhan Sheng Mai Capsule|capsule，0.18g，2＃，po，Bid\*1year.
223582227|NCT04356794|OTHER|Acupuncture needle with electrical stimulation|EA is treated for 4 weeks, 3 times per week.
223582228|NCT04356794|OTHER|Sham electroacupuncture|Sham EA is treated for 4 weeks, 3 times per week.
223582229|NCT04732104|DRUG|Lidocaine topical|intranasal spray anesthesia will be administered for achieving pulpal local anesthesia of maxillary anterior and premolar teeth. Xylometazoline OTC decongestant will be used to prolong the duration of anesthesia
223582230|NCT04732104|DRUG|Lidocaine Hydrochloride|injectable local anesthesia will be administered to achieve pulpal local anesthesia of maxillary anterior and premolar teeth
223582231|NCT00606983|DRUG|Tamsulosin|oral administration of Tamsulosin
223582232|NCT04645745|DIETARY_SUPPLEMENT|myo-inositol, alpha-lactalbumin, folic acid|Evaluating the improvement vs the baseline after three and six months of treatment
223582233|NCT06292104|DIAGNOSTIC_TEST|multimodal diagnostic testing|Serological testing, cardiac MRI, skin biopsy, cardiovascular testing, blood volume measurements
223744259|NCT04988711|DIAGNOSTIC_TEST|Hb Oxymeter|Measurement of Hb Oximeter
224304677|NCT06167590|DIAGNOSTIC_TEST|GAPsy protocol|Each participant will undergo a 7 T multimodal neuroimaging session, including T1-weighted, 1H-MRS and fMRI. Each participant will also be assessed through a structured clinical interview (SCID-I e SCID-II) and will be administered scales such as HAM-A, HAM-D, BPRS and MADRS.
223744260|NCT01136850|DRUG|chloroquine, sulphadoxine pyrimethamine, LLIN|"\> 50Kg: chloroquine base 150 mg 4 tablets daily for 3 days, plus sulphadoxine pyrimethamine 1500/75 mg single dose.~\< 50 Kg: chloroquine base 150 mg 3 tablets daily for 3 days, plus sulphadoxine pyrimethamine 1500/75 mg single dose.~Given at enrolment, 14-26 weeks gestation, by mouth."
223475515|NCT01627665|DRUG|D->R->C+R|one oral dose DABIGATRAN 300 mg -\> RIVAROXABAN 40 mg -\> 1g/day CLARITHOMYCINE with RIVAROXABAN 40 mg
223475516|NCT01627665|DRUG|D->R->C+D|one oral dose DABIGATRAN 300 mg -\> RIVAROXABAN 40 mg -\> 1g/day CLARITHOMYCINE with one oral dose DABIGATRAN 300 mg
223475517|NCT01627665|DRUG|R->D->C+D|RIVAROXABAN 40 mg -\> one oral dose DABIGATRAN 300 mg -\> 1g/day CLARITHOMYCINE with one oral dose DABIGATRAN 300 mg
223475518|NCT01627665|DRUG|R->D->C+R|RIVAROXABAN 40 mg -\> one oral dose DABIGATRAN 300 mg -\> 1g/day CLARITHOMYCINE with RIVAROXABAN 40 mg
223475519|NCT05618223|DRUG|Dapagliflozin|Dapagliflozin 10 mg once daily in addition to standard therapy
223475520|NCT01806181|OTHER|Exercise|
223475521|NCT00671268|BIOLOGICAL|AL0704rP|strict subcutaneous
223475522|NCT00671268|BIOLOGICAL|Placebo|strict subcutaneous
223475523|NCT05549596|DEVICE|Ceragem Master V6 Traction|Ceragem Master V6 Traction for L2\~L3
223475524|NCT05549596|DEVICE|Physical therapy with standard traction device|Physical therapy with standard traction device
223582234|NCT05825235|DRUG|Pramipexole|6 months of treatment with add-on Pramipexole
223582235|NCT06562595|BEHAVIORAL|Education Intervention|Training will be provided to the participants, with the objective of determining the most accurate training method on HPV and cervical awareness.
223582236|NCT00419315|BEHAVIORAL|Alcohol Care Management|Care management for alcohol dependence with a focus on pharmacotherapy
223582237|NCT00419315|BEHAVIORAL|Usual Care|Usual care included a referral to a specialty addiction treatment program.
223582238|NCT06175351|DRUG|9MW1911|Participants will receive IV 9MW1911 every 4 weeks.
223582239|NCT06175351|DRUG|Placebo|Participants will receive IV placebo every 4 weeks.
223582240|NCT02036762|OTHER|Stretching Exercises|The group submitted to stretching exercises in the respiratory muscles and treadmill exercises
223582241|NCT06080100|DRUG|Xenon|inhalation of xenon in a sub-narcotic dosage
223582242|NCT06080100|OTHER|premedication hydroxyzine 25 mg|taking anxiolytic 30 minutes before surgery
223582243|NCT06779669|OTHER|Questionnaire CAM|Selected patients will answer a questionnaire about their practice and habits with regard to alternative and complementary medicines. Of these patients, 12 will also complete an additional qualitative questionnaire.
223582246|NCT04175769|DIETARY_SUPPLEMENT|Nutritional supplement|Subjects will orally consume two gelatin capsules of nutritional supplement (1 gram), 2 times per day with meals, and 1 capsule at one additional meal or snack, totaling five capsules per day beginning the first day of treatment and continuing for the duration of their treatment.
223582247|NCT04175769|OTHER|Placebo|Subjects will orally consume two gelatin capsules of placebo (1 gram), 2 times per day with meals, and 1 capsule at one additional meal or snack, totaling five capsules per day beginning the first day of treatment and continuing for the duration of their treatment.
223582248|NCT05696782|DRUG|Durvalumab|Participants will receive Durvalumab 1500 mg intravenously every two weeks for 60 minutes. Each treatment is called a cycle and lasts for four weeks (or 28 days).
223582249|NCT05696782|OTHER|the EORTC Core Quality of Life Questionnaire (EORTC QLQ-C30)|Participants will be asked to answer all 30 items on the EORTC Core Quality of Life questionnaire (EORTC QLQ-C30). This patient-reported outcome measure is designed to measure cancer patients' physical, psychological and social functions. The measure can be completed using a paper form, by verbally providing answers to the study team, or by entering the answers online into REDCap using a computer or mobile device. The total time to complete the questionnaire is approximately 11 minutes (
223582250|NCT05696782|DIAGNOSTIC_TEST|COPD Assessment Test (CAT)|Participants will be asked to answer all items on the COPD assessment test (8 items) and the patient-reported outcome measures designed to measure respiratory function. The measures can be completed using a paper form, by verbally providing answers to the study team, or by entering the answers online into REDCap using a computer or mobile device. The total time to complete the questionnaire is less than 5 minutes.
224069914|NCT00273104|PROCEDURE|Bariatric surgery|Bariatric surgery as a part of public health service offered treatment seeking morbidly obese patients.
224069915|NCT00273104|BEHAVIORAL|Intensive lifestyle intervention|Intensive lifestyle intervention as a part of public health service offered treatment seeking morbidly obese patients.
224069916|NCT03740971|DEVICE|Remote Ischemic Conditioning treatment|Remote Ischemic Conditioning is given twice a day with 200mmHg pressure.
224069917|NCT03740971|DRUG|Guideline-based therapy|Guideline-based therapy
224069918|NCT06147479|BEHAVIORAL|CS-ADL (Cognitive stimulation in Activities of Daily Living)|CS-ADL sessions are delivered once weekly, for seven weeks. Sessions last approximately 2 hours. Sessions are themed around domains of everyday activities, for example 'Morning routine', ' Domestic Activities', 'Leisure'. Activities in each session follow this theme. A typical session begins with introductions, reality orientation, a group song and discussion of the news of the week. This is followed by a physical activity/game and ADL-focused cognitive stimulation activities. These activities include the identification and categorization of everyday items, discussion, reminiscence, planning and sequencing of ADLs and the completion of everyday writing/calculation tasks. This is followed by practice of an ADL. Examples of activities include making a breakfast, a simple gardening activity or sorting laundry. The session then ends with a summary and repeat of the group song, and a plan for the next session.
224069919|NCT02989064|GENETIC|Autologous genetically modified MAGE A10ᶜ⁷⁹⁶T cells|Infusion of autologous genetically modified MAGE A10ᶜ⁷⁹⁶T on Day 1
224069920|NCT01001000|PROCEDURE|Ultrasound (Pressure measurement)|cut-off value for non maturationg fistulas
224069921|NCT02698488|PROCEDURE|Morphology|
224069922|NCT02698488|PROCEDURE|Morphology and Mass Spectroscopy|
224162293|NCT02417675|OTHER|Standard of Care for Infants|All infants will receive care at their nearest primary care clinic. Following national protocols, all HIV-infected mothers are issued a 6-week supply of nevirapine syrup after delivery and counselled on daily nevirapine prophylaxis. Infant follow-up takes place within 1 week postpartum with the mother (at the MOU) and then at 6 weeks postpartum (at the nearest primary care clinic) when HIV PCR testing of the infant is carried out. Following national protocols, infants who are breastfed beyond 6 weeks receive HIV PCR testing 2-4 weeks after the cessation of breastfeeding, again conducted at the nearest City of Cape Town primary care clinic.
224162294|NCT00766064|DRUG|Paliperidone|"Paliperidone will be gradually increased to a final dose between 3 - 6 mg/day according to the following schedule:~Weeks 1 - 3: 3 mg daily, Weeks 4 - 5: flexible dosing according clinical situation, dose range between 3 mg - 6 mg daily\*, Week 6: fixed dose,~\*Criteria to increase the dose from 3 mg to 6 mg daily are 1\] absence of any side effects, 2\] patients not showing a sufficient response to 3 mg paliperidone can be increased to 6 mg daily. Response is defined as change in depression and anxiety ratings of at least 30% compared to baseline."
224162295|NCT03600870|DRUG|Midodrine|Midodrine is an oral alpha-1 agonist that increases vascular tone. It is administered orally. The initial starting dose will be midodrine 5mg orally three times a day. After 7-10 days, patients will increase the dose to 10mg three times a day as tolerated if no adverse effects occur. Treatment duration will be 6 months.
224162296|NCT02959697|DRUG|Subcut. + Subconj. Xylocaine|Patient will receive the standard subcutaneous local anesthetic as well as an additional subconjunctival injection of local anesthetic (Xylocaine).
224162297|NCT02959697|DRUG|Subcut. + Sham Subconj. Injection|Patient will receive the standard subcutaneous local anesthetic as well as a subconjunctival sham injection of Normal Saline.
224162298|NCT02959697|PROCEDURE|Blepharoptosis Repair|Patients will undergo blepharoptosis repair using an anterior approach.
224162299|NCT05300854|PROCEDURE|Standard anesthesia in addition to serratus plane block|a US-guided SPB was performed after induction of general anesthesia with the patient lying supine.
224162300|NCT05300854|PROCEDURE|Standard anesthesia in addition to para-vertebral block|Standard anesthesia in addition to para-vertebral block
224162301|NCT02091193|DIETARY_SUPPLEMENT|Krill Oil (Supplement A)|
224162302|NCT02091193|DIETARY_SUPPLEMENT|Placebo (Supplement B)|
224162303|NCT03907592|DIETARY_SUPPLEMENT|L-carnitine supplementation|Supplementation of 1000 mg L-carnitine-L-tartrate in combination with 3000 mg L-leucine per day throughout the study period.
224162304|NCT03907592|DIETARY_SUPPLEMENT|Leucine supplementation|Supplementation of 4000 mg L-leucine per day throughout the study period.
224162305|NCT03907592|PROCEDURE|Resistance training|Resistance training at the gym, twice a week for 24 weeks (48 training units in total).
224162306|NCT01922739|DRUG|Hydrocodone ER|Participants were instructed to take hydrocodone ER tablets orally with a glass of water on an empty stomach at least 1 hour before or 2 hours after eating.
224162307|NCT01922739|DRUG|Placebo|During the double-blind titration period used in the original protocol, placebo tablets matching each dose of hydrocodone bitartrate ER tablets (active drug) were used to maintain the blind but not for purposes of comparison.
224162308|NCT02619058|BIOLOGICAL|NKT cells|autologous natural killer T cell
224162309|NCT01176890|DRUG|GLP-1|"1.2 pmol/kg/min GLP-1 will be infused intravenously during the four hour meal test (100 g Ny NAN1 and 1.5 g paracetamol dissolved in 300 ml water) ingested over 10 minutes.~After four hours an ad libitum meal will be supplied"
224162310|NCT01176890|OTHER|Saline|"Saline (isotonic NaCl) will be infused intravenously during the four hour meal test (100 g Ny NAN1 and 1.5 g paracetamol dissolved in 300 ml water) ingested over 10 minutes.~After four hours an ad libitum meal will be supplied"
224162311|NCT06228443|DRUG|Leflunomide 20 mg Film-coated Tablet|Leflunomide 20 mg Film-coated Tablet (Test Drug)
224162312|NCT06228443|DRUG|ARAVA® 20 mg Film-coated Tablet|ARAVA® 20 mg Tablets (Reference Drug)
224162313|NCT03150199|BEHAVIORAL|Positive Psychology + Motivational Interviewing|Participants randomized to PP-MI will receive a treatment manual. For each session, a PP exercise will be described in the manual, with instruments and space to write about the exercise and its effects. Next, an MI section will outline specific MI-based topics (e.g., pros/cons, managing slips) and facilitate physical activity goal-setting. Following randomization, participants will engage in weekly, 30-minute phone calls over the next 8 weeks. Participants will independently complete PP exercises and MI-based goals between phone sessions and review them during phone sessions. PP and MI components will be delivered step-wise within sessions (rather than intertwined).
224162314|NCT03150199|BEHAVIORAL|MI-based Health Education Intervention|Each week, participants will learn about a different health behavior topic related to diabetes health. As an attentional control, this condition has a parallel structure to the experimental arm with a treatment manual, weekly assignments, and weekly calls to review assignments. Motivational interviewing topics (e.g., pros and cons of behavior change, importance and confidence of behavior change, identification of barriers and resources to change) will be presented related to each health behavior.
224162315|NCT02395289|BEHAVIORAL|Cognitive-Based Compassion Training (CBCT)|"Cognitive-Based Compassion Training (CBCT) is composed of secular, didactic instruction and meditation practices. CBCT includes the meditative practices of developing one-pointed concentration and mindfulness. CBCT will be one class per week, 2 hours each, for 8 weeks, for a total of 16 hours during the study. Each meditation class will include a didactic and discussion session that will describe the meditative technique introduced during the week and a practice meditation session. The training protocol is highly iterative and techniques introduced early in training are practiced daily. All participants will be asked to meditate approximately 30 minutes a day at home and will be given a meditation diary to record amount of time spent meditating per week."
224304678|NCT05056610|OTHER|food antigens on duodenal mucosa|Administration of food antigens on duodenal mucosa and determining the response through confocal laser endomicroscopy
224304679|NCT00862238|BEHAVIORAL|Art Messaging|4-session educational group which utilizes art, photography, film, painting to portray a message to reduce drug use, and prevent hepatitis A, B, \& C
224304680|NCT00862238|OTHER|Health Promotion|4 session education which offers basic information about the prevention of hepatitis A, B, \& C
223744261|NCT01136850|DRUG|azithromycin, sulphadoxine pyrimethamine, LLIN|"sulphadoxine pyrimethamine (1500 mg/75 mg as single dose) plus azithromycin (1 g twice daily for 2 days).~Given three times by mouth at monthly intervals, commencing at between 14 and 26 weeks gestation."
224162316|NCT02395289|BEHAVIORAL|Health discussion|Health discussion therapy is one class per week, 2 hours each, for 8 weeks. Each class will use interactive teaching methods to present the health material in an engaging and relevant manner. Representative weekly topics that will be covered include healthy diet, the role of exercise in emotional health, and the importance of sleep and relaxation. It is important to note that the material presented in the health discussion group, although intended to be beneficial to participants, does not include a contemplative component and is not iterative in nature.
224162317|NCT01494025|BEHAVIORAL|Diet and Exercise|Subjects underwent a diet regimen targeted to elicit a 10% weight loss. Diets were designed based on the US Dietary Guidelines with caloric deficits individualized for each subject. Aerobic exercise was monitored over approximately 14 weeks, several times per week, to elicit significantly increased VO2max.
224162318|NCT03623906|PROCEDURE|Carbon dioxide insufflation colonoscopy|Carbon dioxide insufflation colonoscopy
224162319|NCT03623906|PROCEDURE|Air insufflation colonoscopy|Room air insufflation colonoscopy
224162320|NCT05076331|DIAGNOSTIC_TEST|PI-2620 tracer for Tau PET scan|Tau PET scans are obtained using PI-2620 tracer provided by Life Medical Imaging.
224162321|NCT01793090|DRUG|Epi-743|EPI- 743 in capsule or formulation comprised of USP/NF Sesame Oil at a potency of 100 mg EPI-743/ 1 mL total volume. Mode of Administration: Oral with meal or G-Tube infusion with food.
224162322|NCT01793090|OTHER|Placebo supplementation|Placebo will be administered in the same formulation as the active comparator
224162323|NCT03148795|DRUG|Talazoparib|1 mg daily
224162324|NCT02949557|PROCEDURE|Decortication + bone grafts|
224162325|NCT01898962|PROCEDURE|Complete Surgical Removal|
224162326|NCT01898962|RADIATION|Stereotactic Radiosurgery|
224162327|NCT01898962|RADIATION|Ablative external beam radiation dose|
224162328|NCT01898962|PROCEDURE|Subtotal surgical removal plus ablative radiation dose|Residual tumor or close/positive margins should be followed by ablative radiation doses (by either stereotactic radiosurgery or convential EBRT) to constitute definitive locoregional treatment
224304681|NCT00309764|BEHAVIORAL|Telemedicine|
223475525|NCT04045756|DEVICE|Procedure/Surgery: Transperineal Focal Laser Ablation (TPLA)|The intervention will take place in an ambulatory setting of the interventional radiology department using the combined Echolaser XVG system. The treatment consists of a local anesthesia to the perineal region. Within each needle, an optic fiber of 300um will be inserted. Each ablation lasts 6 minutes and each fiber ablates 1800J at a power of 2-3W. At the end of the ablation there is a pull-back of about 1cm from the original ablation location. According to the dimension of the middle lobe of the prostate, multiple pullbacks can be used. The total ablation is 3600J for 2 fibers (1800J/ fiber) at the power of 2-3W for a total duration of about 30minutes. At the end of the treatment, a 20mg bollous of i.v. corticosteriods () is given for anti-edema and anti-inflammatory effects. Antibiotic therapy (Cirpofloxacin 500mg and gastroprotective therapy is given for 5 days. After an adequate amount of time for observation, the patient is dismissed.
223582251|NCT05696782|DIAGNOSTIC_TEST|Modified Medical Research Council (mMRC) dyspnea scale|Participants will be asked to answer the modified medical research council dyspnea scale (1 item), and the patient-reported outcome measures designed to measure respiratory function. The measures can be completed using a paper form, by verbally providing answers to the study team, or by entering the answers online into REDCap using a computer or mobile device. The total time to complete the questionnaire is less than 5 minutes.
223744262|NCT02474992|BEHAVIORAL|Microclinic|Individuals randomized to this arm will be invited to recruit members of their social network to form a health team, or microclinic. These groups will proceed through a discussion-based health education curriculum led by local community health workers. Topics will include HIV biology, medications, the importance of social support, and community outreach for reducing HIV stigma. The curriculum will conclude with an opportunity for all group members to disclose their HIV status to one another.
223744263|NCT06415409|OTHER|Water|Plain water
223744264|NCT06415409|OTHER|Gatorade|Sport Drink Gatorade
223744265|NCT06415409|OTHER|BodyArmor|Sport Drink BodyArmor
223744266|NCT06415409|OTHER|GoodSport|Sport Drink GoodSport
224162329|NCT01898962|RADIATION|Radioembolization|radioembolization of the liver with Y-90 microspheres or other site-appropriate techniques
224162330|NCT01995422|OTHER|Physical activity program|One hour sessions of active walking occurring three times a week during three months
224162331|NCT00625040|OTHER|Oral glucose tolerance test (OGTT), isoglycemic iv. clamp, liquid meal test, gastric emptying rate|"OGTT: The test is performed with 50 g of glucose deluded in 300 ml water~Isoglycemic iv. clamp: Iv. glucose infusion mimicking the glucose response curves from the OGTT~Liquid Meal test: The test is performed with 100g of formula milk deluded in 300 ml. water~Gastric Emptying Rate: Paracetamol absorption test."
224162332|NCT00159614|DRUG|KW-3902IV|
224162333|NCT04836923|BEHAVIORAL|"LIver FrailTy intervention (LIFT)"|Novel physical therapy intervention to decrease frailty in pre-transplant patients
224162334|NCT04836923|BEHAVIORAL|"Realistic Effort Action Planning intervention (REAP)"|This intervention is an interactive behavioral interviewing process to engage patients in their care
224162335|NCT03536273|OTHER|Pilates Group Exercises|For 12 weeks, 3 repetitions per week
224304682|NCT00626314|BIOLOGICAL|myoblast|autologous myoblast
224304683|NCT00626314|BIOLOGICAL|sham|sham injection procedure
223475526|NCT02845674|DRUG|OTX-101 0.09%|0.09% cyclosporine nanomicellar solution
223582252|NCT01068249|DRUG|Letrozole|2.5 mg daily by mouth every day, at same time as Everolimus.
223582253|NCT01068249|DRUG|RAD001 (Everolimus)|10 mg by mouth daily
223744267|NCT02496247|OTHER|Canned Herring|Families with children in this study arm will receive a weekly ration of herring throughout the 8-10 week study period (2 cans herring/day per study child).
223744268|NCT02235142|OTHER|Blood sample|
224162336|NCT04185662|DIETARY_SUPPLEMENT|sucralose|daily intake different dose of artificial sweeteners sucralose or placebo
224162337|NCT04489940|DRUG|Bintrafusp alfa|Participants received an intravenous infusion of 1200 milligrams (mg) bintrafusp alfa once every 2 weeks until confirmed disease progression, unacceptable toxicity, study withdrawal or death.
224162338|NCT02725268|DRUG|Paclitaxel|Paclitaxel intravenous solution.
224304684|NCT05161806|DRUG|SOK583A1 (40 mg/mL)|SOK583A1 provided in a Prefilled Syringe (PFS), which includes 2 mg aflibercept in 0.05 mL for IVT administration
224162339|NCT02725268|DRUG|Sapanisertib|Sapanisertib capsules.
224162340|NCT02725268|DRUG|MLN1117|MLN1117 capsules.
224162341|NCT04498468|DRUG|Sustained Release Dexamethasone, 0.4 mg|dexamethasone 0.4mg lacrimal insert
224162342|NCT04498468|OTHER|E-Caprolactone-L-Lactide copolymer (PCL) punctal plug|Control eye will receive a tear duct plug without the dexamethasone (EXTENDED WEAR SYNTHETIC ABSORBABLE PUNCTAL PLUG made of E-Caprolactone-L-Lactide copolymer (PCL). Absorbs in 60 to 180 days. Size 0.5mm which is comparable to the study treatment)
224162343|NCT01638169|DEVICE|adding a heel|walking with and without heels on the gaitrite system
224162344|NCT04843072|DEVICE|Evolut R/PRO bioprosthesis|To compare Evolut R/PRO versus Sapien S3/Ultra in failing surgical bioprostheses
223475527|NCT01550133|BEHAVIORAL|Learned: Non-nutritive beverage to Non-nutritive beverage|For the learning phase of the experiment, random allocation will assign about 15 participants to consume a beverage product made with non-nutritive sweetener everyday for two weeks.Half of these participants will then be tested against a non-nutritive beverage.
223475528|NCT01550133|BEHAVIORAL|Learned: Nutritive solid to Nutritive solid|For the learning phase of the experiment, random allocation will assign about 15 participants to consume a solid food product made with nutritive sweetener everyday for two weeks. Half of these participants will then be tested against a nutritive solid.
223475529|NCT01550133|BEHAVIORAL|Learned: Nutritive beverage to Nutritive beverage|For the learning phase of the experiment, random allocation will assign about 15 participants to consume a beverage product made with nutritive sweetener everyday for two weeks. Half of these participants will then be tested against a nutritive beverage.
223582254|NCT05139797|OTHER|EchoNet-LVH screening for cardiac amyloidosis|An AI algorithm identifies LVH, low voltage, and high suspicion for cardiac amyloidosis. The intervention is the suspicion score. Patients with high suspicion score will be referred to specialty clinic for standard of care evaluation, screening, and treatment as determined by physicians.
224162345|NCT04843072|DEVICE|Edwards Sapien S3/Ultra bioprosthesis|Edwards Sapien S3/Ultra bioprosthesis
224162346|NCT04737967|DRUG|Venlafaxine|Patients will receive will receive Venlafaxine extended release (37.5 mg) tablets once daily(Zimmerman et al., 2016)
224162347|NCT04737967|DRUG|Memantine|Patients will receive memantine (10 mg) once daily (Morel et al., 2016)
224162348|NCT00668772|DRUG|Tiotropium/Salmeterol|Tiotropium/Salmeterol Inhalation Powder, Hard Polyethylene Capsule
224162349|NCT00668772|DRUG|Tiotropium/Salmeterol QD + Salmeterol|Tiotropium/Salmeterol Inhalation Powder, Hard Polyethylene Capsule, plus Salmeterol Inhalation Powder, hard PE capsule
224162350|NCT00668772|DRUG|Placebo|Placebo Inhalation Powder, hard PE capsule / hard gelatine capsule
224162351|NCT00668772|DRUG|Salmeterol|Salmeterol Inhalation Powder, hard PE capsule
224162352|NCT00668772|DRUG|Tiotropium|Tiotropium Inhalation Powder, hard gelatine capsule (Spiriva®)
224162353|NCT03186872|BEHAVIORAL|Digital behavioral program app|mobile app utilizing cognitive behavioral techniques to help alleviate anxiety
224162354|NCT03696004|DRUG|FEC-100|Patients will recieve six cycles of FEC-100 and Breast conservative surgery after 4-6 weeks
224162355|NCT04862741|DRUG|NX-13 250mg IR|Subjects will take study drug by ingesting one tablet per day, recommended at the same time in the morning for consistency. Subjects in a NX-13 group will receive either 250 mg or 500 mg of NX-13 in an immediate release or modified release tablet and subjects in the placebo group will receive matched placebo.
224162356|NCT04862741|DRUG|NX-13 500mg IR|Subjects will take study drug by ingesting one tablet per day, recommended at the same time in the morning for consistency. Subjects in a NX-13 group will receive either 250 mg or 500 mg of NX-13 in an immediate release or modified release tablet and subjects in the placebo group will receive matched placebo.
223475530|NCT01550133|BEHAVIORAL|Not Learned: Non-nutritive solid to Nutritive solid|For the learning phase of the experiment, random allocation will assign about 15 participants to consume a solid food product made with non-nutritive sweetener everyday for two weeks. Half of these participants will then be tested against a nutritive solid.
223475531|NCT01550133|BEHAVIORAL|Not Learned: Nutritive beverage to Non-nutritive beverage|For the learning phase of the experiment, random allocation will assign about 15 participants to consume a beverage food product made with nutritive sweetener everyday for two weeks. Half of these participants will then be tested against a non-nutritive beverage.
223582255|NCT05572398|BEHAVIORAL|STAC-T|Middle school participants will complete online modules to learn about anti-bullying techniques and bystander intervention.
223582256|NCT06973811|DRUG|Methotrexate|400ug intravitreal injection every week for 4 doses in the induction phase, every 2 weeks for 2 doses as consolidation, then every month for 10 doses
223582257|NCT06973811|DRUG|Rituximab (R)|Rituximab 375mg/m2 intravenous infusion d1, every 21 days for 1 cycle. 6 cycles will be prescribed as protocol
223582258|NCT06973811|DRUG|Zanubrutinib|160mg Bid, oral. 21-day cycle for 6 cycles in the induction phase and for 2 years in the maintenance phase
224162357|NCT04862741|DRUG|NX-13 500mg MR|Subjects will take study drug by ingesting one tablet per day, recommended at the same time in the morning for consistency. Subjects in a NX-13 group will receive either 250 mg or 500 mg of NX-13 in an immediate release or modified release tablet and subjects in the placebo group will receive matched placebo.
224162358|NCT04862741|DRUG|Placebo|Subjects will take study drug by ingesting one tablet per day, recommended at the same time in the morning for consistency. Subjects in a NX-13 group will receive either 250 mg or 500 mg of NX-13 in an immediate release or modified release tablet and subjects in the placebo group will receive matched placebo.
224162359|NCT00863941|DRUG|Abrika Bupropion 150 mg XL Tablet, single dose|A: Experimental Subjects received Abrika formulated products under fasting conditions
224162360|NCT00863941|DRUG|Wellbutrin XL® 150 mg Tablet, single dose|B: Active comparator Subjects received GlaxoSmithKline formulated products under fasting conditions
224162361|NCT05280236|DRUG|Propofol TIVA|Patients will receive propofol-based TIVA with propofol and remifentanil TCI (target controlled infusion)
224162362|NCT05280236|DRUG|Remimazolam TIVA|Patients will receive remimazolam-based TIVA with remimazolam infusion and remifentanil TCI
224162363|NCT05892536|PROCEDURE|dental regenerative endodontics|regenerative procedures performed in necrotic mature permanent teeth
224162364|NCT04024449|OTHER|Group A|ovarian function test in control group
224162365|NCT00006190|DRUG|Nelfinavir mesylate|
224162366|NCT00006190|DRUG|Stavudine|
224162367|NCT00006190|DRUG|Lamivudine|
223475532|NCT01550133|BEHAVIORAL|Not Learned: Non-Nutritive solid to Non-nutritive solid|For the learning phase of the experiment, random allocation will assign about 15 participants to consume a solid food product made with nutritive sweetener everyday for two weeks. Half of these participants will then be tested against a non-nutritive solid.
224162368|NCT00006190|DRUG|Efavirenz|
224162369|NCT01947647|BEHAVIORAL|Transdiagnostic Behavior Therapy|A new transdiagnostic CBT protocol for the depressive/anxiety disorders was developed and revised through two demonstration studies and one focus group. The resulting protocol involves several primary components, including psychoeducation on the symptoms of depression and anxiety (session 1), assessment of motivation and setup of treatment plans (session 2), exposure therapy (sessions 3-15), and relapse prevention (final session). In addition to these primary components, optional modules are included to supplement exposure therapy later in treatment to address secondary symptoms (e.g., anger, sleep, hypervigilance, drinking to cope). The goal of these modules is to allow providers to tailor treatment to specific symptoms that may be present in any single or set of diagnoses that may be reducing the effects from the primary exposure approach. Session will be weekly for 45-60 minutes with homework assignments to be completed between sessions.
224162370|NCT01947647|BEHAVIORAL|Behavioral Activation Therapy|To provide an evidence-based comparison for the transdiagnostic CBT condition, a second group of participants will receive manualized BAT. In general, BAT involves teaching patients to monitor their mood and daily activities with the goal of increasing pleasant, reinforcing activities and reducing unpleasant events. In the present study, the BAT condition will be manualized, following an existing protocol in the literature. BAT will be structurally equivalent to the transdiagnostic CBT with the same session length (45-60 minutes), frequency of sessions (weekly), duration of treatment (12-16 sessions), and amount of homework.
224162371|NCT03844139|DEVICE|Feeding pump and glycerin syringe|The continuous group use feeding pump and the intermittent group use syringe to give dysphagia patients after stroke prescribed nutrition through nasogastric tube.
224162372|NCT04826029|OTHER|Standard strategy|In the standard arm, patients will complete CA 125 (+/- HE4) at 3 months, 6 months, 12 months, 18 months and 24 months (+/- 15 days), complete the HAD and EQ5D self-questionnaires, and be managed according to INCa 2018 recommendations. If clinical symptoms, marker elevation, and/or imaging workup occur, the patient will be referred to the multidisciplinary consultation meeting (MDC) for management according to INCa 2018.
224162373|NCT04826029|OTHER|Follow-up strategy|In the interventional arm, patients will perform at 3 months, 6 months, 12 months, 18 months and 24 months (+/- 15 days) a CA125 assay (+/- HE4 assay), a thoracoabdominal CT scan after contrast injection and a whole body MRI (T2, DW and T1 sequences after fat saturation before and after gadolinium injection) with a maximum delay of 15 days between the two examinations, and will complete the HAD and EQ5D self-questionnaires. A senior radiologist from each center will perform a prospective reading of each of the images. For any suspicious anomaly identified, the following criteria will be analyzed: Size, location, number, evolution, contrast after injection, MRI signal (T2, Diffusion, Dynamic Enhancement Curve). The RECIST criteria (version 1.1) will be applied.
224162374|NCT03135639|OTHER|NeuroConn Plus Stimulator tACS|Transcranial alternating current stimulation (tACS) is a novel, noninvasive brain stimulation approach in which weak electric currents are applied to the scalp. The electric currents that are applied to the scalp are in a sine-wave pattern.
223582259|NCT06973811|DRUG|Methotrexate (MTX)|Methotrexate 3.5g/m2 intravenous infusion d1, every 21 days for cycle 5 and 6 only.
224162375|NCT03135639|OTHER|NeuroConn Plus Stimulator Sham|For sham stimulation, the participant receives up to 1 minute of tACS stimulation until the stimulation fades. This mimics the same skin sensations that a participant would experience during a tACS session.
224162376|NCT01755338|DRUG|Methylprednisolone|Methylprednisolone 15mg/kg
224162377|NCT01755338|DRUG|Placebo|Placebo
224162378|NCT03619850|DRUG|Ferumoxytol|Each 20 mL single-use vial contains 17 mL of ferumoxytol that consists of iron at a concentration of 30 mg Fe/mL, coated with polyglucose sorbitol carboxymethylether and formulated with mannitol, at a concentration of 44 mg/mL, in a black to reddish brown sterile, aqueous, colloidal, isotonic solution.
224162379|NCT03619850|DRUG|Iron sucrose|Each mL contains 20 mg of elemental iron as iron sucrose in water for injection. The 5 mL single-use vial contains 100 mg of iron per 5 mL. The drug product contains approximately 30% sucrose (300 mg/mL).
224304685|NCT05161806|DEVICE|Prefilled Syringe (PFS)|Prefilled Syringe (PFS)
223582260|NCT06797895|BEHAVIORAL|VR assisted mobility|Commercially-based VR experience used to help move upper extremities to music, similar to dancing or Tai-Chi.
223582261|NCT06975137|BEHAVIORAL|Zithandani Stepping Stones and Creating Futures|Delivered to heterosexual couples. 14 group based sessions, with each session lasting approximately 3 hours. Sessions are delivered by two trained facilitators. Intervention focused on transforming gender norms, strengthening communication, reducing symptoms of poor mental health and improving relationship dynamics. Mixture of couples focused, same-gender discussions, and whole group discussions.
223582262|NCT04023227|DRUG|Sacubitril/valsartan|50 (24/26) mg, 100 (49/51) mg and 200 (97/103) mg will be available for dose adjustments.
223582263|NCT04023227|DRUG|Enalapril|5 mg and 10 mg will be available for dose adjustments.
223582264|NCT02928991|OTHER|MRD-BMT with Fludarabine-based RIC for Acquired AA|"Fludarabine: Dose: 30mg/m2/day (\<10kg will receive 1mg/kg/day) Days: -7, -6, -5, -4, -3~Cyclophosphamide: Dose: 60mg/kg/day Days: -5, -4~Thymoglobulin: Dose: 3mg/kg/day Days: -4, -3, -2~Bone marrow infusion: Day 0"
223582265|NCT02928991|OTHER|MRD-BMT with Fludarabine-based RIC for iBMF with trilineage aplasia|"Fludarabine: Dose: 30mg/m2/day (\<10kg will receive 1mg/kg/day) Days: -7, -6, -5, -4, -3~Cyclophosphamide: Dose: 10 mg/kg/day Days: -6, -5, -4, -3~Thymoglobulin: Dose: 3mg/kg/day Days: -4, -3, -2~Bone marrow infusion: Day 0"
223475533|NCT01550133|BEHAVIORAL|Not Learned: Non-nutritive beverage to Nutritive beverage|For the learning phase of the experiment, random allocation will assign about 15 participants to consume a beverage food product made with non-nutritive sweetener everyday for two weeks. Half of these participants will then be tested against a nutritive beverage.
223475534|NCT01550133|BEHAVIORAL|Not Learned: Non-Nutritive solid to Non-Nutritive Solid|For the learning phase of the experiment, random allocation will assign about 15 participants to consume a solid food product made with non-nutritive sweetener everyday for two weeks. Half of these participants will then be tested against a non-nutritive solid.
223475535|NCT02643875|DEVICE|Orthokeratology|It is a kind of rigid permeable lens.
223744269|NCT03314155|DIAGNOSTIC_TEST|Cerebral neuroinflammation evaluation|Pet scan following an injection of the radiotracer (\[18F\]DPA-714), to evaluate the neuroinflammation. MRI to evaluate functional and structural integrities. Blood test to analyze various inflammation marker (IL-6, Tumor Necrosis Factor (TNF) alpha, CRPus, and TSPO). And psychological scales to assess the depressive symptoms.
224162380|NCT03903913|DRUG|S-1226|The drug product S-1226 has two components delivered by inhalation. It is a mixture of perfluorooctylbromide (PFOB) nebulized with a medical gas mixture containing CO2. The PFOB component remains the same but the medical gas component contains 4%, 8% or 12% CO2.
224162381|NCT03256136|DRUG|Carboplatin|Chemotherapy
224162382|NCT03256136|DRUG|Nivolumab|will allow the body's immune system to work against tumor cells
224162383|NCT03256136|DRUG|pemetrexed|Chemo therapy
224162384|NCT03256136|DRUG|Ipilimumab|will allow the body's immune system to work against tumor cells
224162385|NCT04011306|DEVICE|Lumina24 BLU|Lumina24 BLU is the technology used to deliver continuous low-irradiance phototherapy for the treatment of acute burns
224162386|NCT00722475|DRUG|Intravenous immunoglobulin|Intravenous infusions, 25-35 g each time, 4th to 15th gestational week
224162387|NCT00722475|DRUG|Human albumin|Repeated infusions of Human Albumin 5%, 250-350 ml between 4th and 15th gestational week
224162388|NCT03929406|DEVICE|Brain Tissue Imprint|"Brain Tissue Imprint procedure (BTI) is performed during DBS surgery. Before the implantation of the electrode, the surgeon uses a dilator. It is a rigid stylet with a blunt end, intended to prepare the way for the final electrode. This dilator is lowered gently through the cerebral parenchyma up to the target then removed to be replaced by the electrode.~In our BTI study, the standard dilator used in DBS surgery will be replaced by a CE marked Medical Device. This brain imprint kit will be used for each hemisphere. The procedure is the following:~* The guide tube with the first stylet is set up to the target~* Withdrawal of the first stylet and insertion of the second stylet for one minute to have a spontaneous and adequate tissue adhesion~* Withdrawal of the guide tube containing the stylet. This last step will prevent contamination of the harvested material on the stylet during the removal."
224162389|NCT04973085|DEVICE|Cold circulated water|Cold water was circulated through an adhesive wrap applied to the front of the neck, overlying the carotid arteries, for 120 minutes. MR thermometry was used to measure core brain temperature in 1-minute intervals throughout the intervention. On a different day, subjects crossed over and repeated the intervention in the other study arm (i.e., cold went to body-temperature, and vice-versa).
224162390|NCT04973085|DEVICE|Body-temperature circulated water|Body-temperature water was circulated through an adhesive wrap applied to the front of the neck, overlying the carotid arteries, for 120 minutes. MR thermometry was used to measure core brain temperature in 1-minute intervals throughout the intervention. On a different day, subjects crossed over and repeated the intervention in the other study arm (i.e., cold went to body-temperature, and vice-versa).
224162391|NCT02048852|OTHER|Reduced Nicotine Content- Non Menthol|Switch from own brand of cigarette to a research cigarette with a Reduced Nicotine Content of 0.07mg nicotine yield without menthol.
224162392|NCT02048852|OTHER|Reduced Nicotine Content- Menthol|Switch from own brand of cigarette to Reduced nicotine level of each research cigarette to 0.07mg nicotine yield with Menthol
224162393|NCT02048852|OTHER|Conventional Nicotine Content- Menthol|Allow own brand of Conventional Nicotine-Menthol Cigarette
224162394|NCT02048852|OTHER|Conventional Nicotine Content- Non Menthol|Switch from own cigarette to a research cigarette which contains Conventional Nicotine yield.
224162395|NCT00029289|DRUG|Lutein (10 or 30 mg/day) capsules|
224162396|NCT02947334|BIOLOGICAL|Bococizumab|Bococizumab PFS
224162397|NCT02947334|DRUG|Placebo|Placebo
224162398|NCT04818489|DRUG|Colchicine 0.5 MG|colchicine 0.5 mg (2 tablets: 1 mg) twice per day as a loading dose, followed by one tablet 0.5 twice per day for three weeks in addition to the standard protocol
223475536|NCT02866656|OTHER|Conventional conservative treatment|Treatment last for 4 weeks, three times a week,
223475537|NCT02866656|DEVICE|therapeutic ultrasound|Treatment last for 4 weeks, three times a week, stimulation was given 8 minutes every time, location of treatment were lower limb ischemia area and its surrounding tissues；
223475538|NCT05470452|OTHER|The reading process is assisted by ENDOANGEL|Diagnosis of benign and malignant lesions with the help of ENDOANGEL
223475539|NCT05470452|OTHER|No ENDOANGEL assistance during the reading process|Diagnosis of benign and malignant lesions without the help of ENDOANGEL
223475540|NCT03951519|OTHER|oral administration of water|Volume expansion via 500 mL of water administered by the patient's nasogastric tube
223475541|NCT03951519|OTHER|administration of saline solution|Volume expansion via 500 mL of saline (Nacl 0.9%) administered by the venous route
223475542|NCT03710512|PROCEDURE|Bilateral sagittal split osteotomy|Bilateral sagittal split osteotomy of the mandible is a surgical procedure used to correct dentofacial discrepancies
223475543|NCT00975936|DRUG|[14C]-GSK706769|50µg \[14C\]-GSK706769 containing 250 nCi
223475544|NCT00975936|DRUG|Ketoconazole|200 mg Ketoconazole (Q12)
223475545|NCT03905733|DEVICE|Optiflow|supply of oxygen at 2 L / min/ kg through Optiflow
223475546|NCT02460016|DRUG|AK0529|AK0529 pellets for oral administration
223475547|NCT00861133|DEVICE|Sleuth AT Implantable ECG Monitoring System|The study device provides monitoring only. It cannot provide intervention or treatment.
223475548|NCT00843492|DRUG|Fondaparinux sodium|After randomization (Day 1), subjects will receive subcutaneously once daily fondaparinux 2.5 mg \[0.5mL\] (1.5 mg \[0.3mL\] in patients with creatinine clearance between 30 and 50 mL/min) for at least 21 Days, up to complete mobilization, corresponding to cast or brace removal. The maximal duration of treatment is 45 days.
223475549|NCT00843492|DRUG|Nadroparin|After randomization (Day 1), subjects will receive subcutaneously once daily nadroparin 2850 anti-Xa IU (0.3 mL) for at least 21 Days, up to complete mobilization, corresponding to cast or brace removal. The maximal duration of treatment is 45 days.
223475550|NCT05724342|DRUG|rhTNK-tPA Thrombolysis|rhTNK-tPA Thrombolysis
223475551|NCT04482634|OTHER|Remote controlled exercise|Breathing, aerobic, posture, stretching, upper and lower extremity strengthening exercises.
223475552|NCT04482634|OTHER|Home exercise|Breathing, aerobic, posture, stretching, upper and lower extremity strengthening exercises.
223475553|NCT02110979|BEHAVIORAL|Use of a PDA to assist shared decision making|
223475554|NCT02553343|BIOLOGICAL|High-dose quadrivalent influenza virus vaccine|0.5 mL, Intramuscular (IM), injected into the deltoid area
223475555|NCT02553343|BIOLOGICAL|High-dose influenza virus vaccine|0.5 mL, Intramuscular (IM), injected into the deltoid area
223475556|NCT02553343|BIOLOGICAL|High-dose trivalent inactivated influenza vaccine|0.5 mL, Intramuscular (IM), injected into the deltoid area
223475557|NCT02553343|BIOLOGICAL|High-dose trivalent inactivated influenza vaccine|0.5 mL, Intramuscular (IM), injected into the deltoid area
223475558|NCT01378208|BEHAVIORAL|Intermittent fasting - the effect on glucose metabolism, body composition and cognitive function|"Each of the 10 subjects must through a period of monitoring (four weeks) before the study period (four weeks). Before, during, and after both the monitoring period and the study period, the subjects will undergo tests at Rigshospitalet.~DAY 1: Inclusion and exclusion of subjects DAY 1 to DAY 28: Monitoring period (usual lifestyle)~* 28 days of dietary monitoring~* 28 days measurement by pedometer DAY 1, DAY 28 \& DAY 56: Test 1~* Oral glucose tolerance test with stable isotopes~* Fat and muscle biopsies DAY 2, DAY 29 \& DAY 57: Test 2~* DXA scanning~* Resting Metabolic Rate Measurement~* VO2max test on bicycle~* Cognitive testing~* MRI of the brain and abdomen DAY 9, DAY 19, DAY 38 \& DAY 48: Test 3~* Actiheart for 3 days~* 72-hour blood glucose monitoring with CGMS System DAY 29 to DAY 57: INTERVENTION~* Fasting from 7am - 9pm~* 28 days of dietary monitoring~* 28 days measurement by pedometer"
223475559|NCT05660096|DEVICE|Cionic Neural Sleeve NS-100|Sleeve applies neuromuscular stimulation as patients walk to help contract appropriate muscles at appropriate times.
223475560|NCT00921323|BEHAVIORAL|Goal-setting group|This intervention group will be advised to increase their daily steps by at least 20% gradually over 3 months
223475561|NCT00921323|BEHAVIORAL|Control|The control group will be advised to continue to be physically active and record daily steps
223475562|NCT04346316|DRUG|SHR0302|Oral tablets taken once daily (QD)
223475563|NCT01677741|DRUG|Dabrafenib|Dabrafenib is available as 50 mg or 75 mg capsules and as oral suspension (10 mg/mL for subjects unable to swallow capsules). Dabrafenib (either formulation) will be administered orally as a single dose on Day 1 and twice daily from Day 2, based on weight at the appropriate study dose level.
223475564|NCT04329429|DRUG|RC48-ADC|The eligible patients will be treated with RC48-ADC, an antibody-drug conjugate, 2.5 mg/kg, once every two weeks until investigator-assessed loss of clinical benefit, unacceptable toxicity, investigator or participant's decision to withdraw from therapy, or death (whichever occurs first)
223475565|NCT04400461|OTHER|Data collection and clinical testing of subjects|"Clinical Testing: muscle strength. Muscle strength, as a component of physical function, will be assessed with the Medical Research Council sum score (MRC- SS) at discharge from the ICU and at discharge from the hospital.~Clinical testing: physical function. The Functional Status Score for the ICU (FSS-ICU) will be used to evaluate 5 functional tasks at discharge from hospital."
223475566|NCT01450488|DRUG|masitinib|masitinib 3 mg/kg/day
223475567|NCT01450488|DRUG|masitinib|masitinib 6 mg/kg/day
223475568|NCT00720499|DRUG|BI 1744 CL plus tiotropium bromide|BI 1744 CL plus tiotropium bromide fixed dose combination; Solution for inhalation via Respimat® Inhaler (A5); Oral inhalation
223475569|NCT00720499|DEVICE|Respimat® Inhaler|
223475570|NCT02060500|PROCEDURE|Cardiaplication|
223475571|NCT00061581|DEVICE|Isolex 300i Stem Cell Selection|
223582266|NCT02928991|OTHER|MRD-BMT with Fludarabine-based RIC for iBMF without trilineage aplasia|"Fludarabine: Dose: 30mg/m2/day (\<10kg will receive 1mg/kg/day) Days: -6, -5, -4, -3, -2~Busulfan: Dose: every 6 hours for a total of 12 doses with dosing adjustments to achieve a steady state concentration of 900-1200ng/mL OR daily for a total of 3 doses targeting AUC 3600-6000 (micromole/liter)\*minute Days: -7, -6, -5, -4~Thymoglobulin: Dose: 3mg/kg/day Days: -10, -9, -8~Bone marrow infusion: Day 0"
223582267|NCT06980103|BEHAVIORAL|Decision Aid|The study intervention is a web-based decision aid (DA) developed by the study team. The Radioactive Iodine Decisions decision aid is designed as an educational tool to help patients have information about Radioactive Iodine and encourage them to talk with their medical team about this treatment decision.
223582268|NCT06980103|BEHAVIORAL|Usual Care|Patients randomized in the Usual Care Condition arm will receive a link for the American Cancer Society website on Radioactive Iodine (Radioiodine) Therapy for Thyroid Cancer as our comparison.
223582269|NCT06602063|PROCEDURE|surgery/chemotherapy|secondary cytoreductive surgery followed by 6 cycles of post-operative chemotherapy
223582270|NCT06602063|DRUG|Iparomlimab/Tuvonralimab|Iparomlimab/tuvonralimab will be administered at a dose of 5 mg per kilogram IV every 21 days. Treatment will continue until disease progression confirmed by RECIST criteria v1.1, intolerable toxicity or withdrawal of consent.
223582271|NCT06980467|OTHER|Large Language Model|An artificial intelligence system generating clinical recommendations using prompts, designed to simulate clinical advisory outputs. The protocol focuses on structured medical language generation.
223744270|NCT02360384|DRUG|Linaclotide|Linaclotide 290mcg po od in all patients with irritable bowel syndrome with constipation.
224069923|NCT01962233|BIOLOGICAL|mesenchymal stem cells|"Procedure: On the basis of conventional therapy, at the same time, selected patients were given by intravenous infusion of umbilical cord blood stem cells 100-800 million. All patients before treatment, after treatment for 15days, 90days and 180 days were evaluated respectively the curative effect.~Intravenous infusion of umbilical cord derived mesenchymal stem cells"
224069924|NCT00262873|DRUG|bortezomib|
224069925|NCT03448250|BEHAVIORAL|Optimune|Optimune is a web-based psychological intervention developed for women with breast cancer.
224069926|NCT03448250|OTHER|Care-As-Usual|Participants are free to continue to engage with any treatment they require (i.e., CAU).
224069927|NCT00844753|DRUG|atomoxetine|atomoxetine
224069928|NCT00844753|DRUG|Placebo|Placebo + parent management treatment
224069929|NCT00844753|BEHAVIORAL|Parent Management Training|
224069930|NCT06046144|DIAGNOSTIC_TEST|Fluorescence-Advanced videodermatoscopy|"Datas collected : Presence or absence of atypical roundish cell, dendritic cell, atypical nests, points, folliculotropism, blue homogenous zone, regular honeycomb pattern.~Between 10 and 60 images taken by a hand-held camera set directly on the skin lesion, with an oily interface."
224162399|NCT04818489|OTHER|the standard protocol only|the local standard protocol for COVID19
224162400|NCT06287931|DRUG|Ursodoxycholic acid group|Ursodoxycholic acid, 250mg po tid x 6 months
223475572|NCT01492348|BEHAVIORAL|STEPS UP|"The STEPS UP intervention enhances RESPECT-Mil in several ways:~1. Adds care manager training in motivational enhancement, problem solving, and behavioral activation strategies to improve patient engagement.~2. Adds preference-based stepped care (i.e., order of steps determined by symptom severity, patient preference, \& primary care recommendation) to existing options of pharmacotherapy that includes web-based self-management programs; flexible, modularized telephone-delivered CBT; and individual face to face psychotherapy by specialist.~3. Adds option for centralized, telephone-based care management to improve fidelity of intervention delivery, continuity of care, and access to care during off-hours.~4. Adds a centralized care team using an electronic symptom registry to provide staffing to care managers, track patients longitudinally, develop stepped-based treatment recommendations, and monitor intervention components."
223475573|NCT01492348|BEHAVIORAL|OUC|"Service members randomized to Optimized Usual Care (OUC) will get usual treatment at the site. OUC is RESPECT-Mil, a voluntary, primary care-based implementation program based on the three-component model where, with the assistance and collaboration of a psychiatrist and an on-site nurse-level care manager, service members with symptoms of PTSD and depression are screened, tracked, and treated within the primary care system. Components of the RESPECT-Mil program include (1) equipping and training primary care clinics to screen each visit and use symptom severity tools for diagnosis and assessment; (2) using nurse care managers to assist patients and primary care clinicians; and (3) increasing access to a mental health specialist, often using a clinic specialist."
223582272|NCT06981312|BEHAVIORAL|Acceptance and Commitment Therapy|Participants receive a 9-week internet-delivered intervention: 2 weeks of Pain Neuroscience Education (PNE) based on the PSE curriculum, followed by 7 weeks of Acceptance and Commitment Therapy (ACT) targeting psychological flexibility. In addition to value-oriented behavioral activation, the ACT content includes classical exposure. The treatment is mainly text-based, supported by multimedia content, and delivered on a secure digital platform. Communication with a clinician occurs at least weekly. Parents receive a parallel program based on PSE, ACT, and behavioral principles to support flexible and effective parenting.
223582273|NCT06981312|BEHAVIORAL|Pain Science Education|Participants receive 9 weeks of internet-delivered Pain Science Education (PSE), based on the PSE curriculum but with more detailed content, including extended examples, reflection exercises, and behavioral experiments. The aim is to reduce the threat value of pain by promoting a reconceptualization of pain. Parents receive a parallel program with tailored content. The intervention is text-based with multimedia components and delivered via a secure platform. Clinician support is provided asynchronously at least once weekly.
223582274|NCT06981286|OTHER|A dataset comprising participants withT2D will be used to evaluate the classification performance of various machine learning techniques.|A dataset comprising participants with T2D will be used to evaluate the classification performance of various machine-learning techniques.
223582275|NCT06980493|DRUG|Amphotericine in liposome (Ambisome®)|The aim of the study will be to evaluate the efficacy and safety of topical amphotericin B solution in treatment of non-inflammatory type of tinea capitis after resistant response to oral systemic treatment
223582276|NCT06657378|OTHER|No Intervention|This is a non-interventional study.
223582277|NCT05570071|DEVICE|physical therapy|medical treatment of pelvic floor
223582278|NCT01495468|BIOLOGICAL|PEG-somatropin|drug:pegylated somatropin 0.2mg/(kg.w), once per week for 6 months drug: Jintropin AQ, 0.25mg/(kg.w), once per day for 6 months
223582279|NCT06980714|BEHAVIORAL|Powered|The intervention involves the use of the Oral-B iO6 powered toothbrush, which provides oscillating-rotating brushing action with personalized feedback via its smart pressure sensor and app integration. Participants in this group are instructed to brush for at least two minutes twice daily. The toothbrush is designed to ensure consistent brushing performance, with real-time feedback on brushing technique and duration, allowing for improved oral hygiene habits. The intervention aims to standardize brushing duration and technique, eliminating potential variations found with manual brushing.
223744271|NCT02360384|DIETARY_SUPPLEMENT|FODMAP diet|Patients with irritable bowel syndrome with alternating bowel habit will be commenced on the either the low FODMAP diet or a control healthy eating diet.
223744272|NCT01754844|DRUG|AZD7624|Single dose inhaled IMP via a nebulizer
223744273|NCT01754844|DRUG|Placebo to match|Single dose inhaled Placebo via a nebulizer
224069931|NCT06046144|DIAGNOSTIC_TEST|Reflectance confocal microscopy|"Datas collected : Presence or absence of atypical roundish cell, dendritic cell, atypical nests, points, folliculotropism, blue homogenous zone, regular honeycomb pattern.~Between 10 and 60 images taken by a hand-held camera set directly on the skin lesion, with an oily interface."
224069932|NCT06046144|DIAGNOSTIC_TEST|Super-high magnification dermoscopy|"Datas collected : Presence or absence of atypical roundish cell, dendritic cell, atypical nests, points, folliculotropism, blue homogenous zone, regular honeycomb pattern.~Between 10 and 60 images taken by a hand-held camera set directly on the skin lesion, with an oily interface."
224069933|NCT02890810|OTHER|Real Acupuncture with Electrical Stimulation|Acupuncture is a therapy commonly used in East Asian countries, where the practitioner insert thin needles at specific body sites in order to relieve pain and illnesses. Recent studies found low frequency electricity applied through acupuncture needles can lead to profound pain relief by increasing endorphin levels in the central nervous system. Electroacupuncture will thus be used as the active intervention to treat chronic low back pain in this clinical study.
224069934|NCT02890810|OTHER|Simulated Acupuncture with Electrical Stimulation|This intervention serves as the placebo control of the active intervention. Sterile acupuncture needles and the ITO electrical stimulators will be used in this intervention. But special care will be taken to have this intervention mimic the real treatment yet remaining as physiologically inert as possible.
224069935|NCT01550562|DEVICE|Boston Scientific Precision Plus spinal cord stimulation therapy|Epidural spinal cord stimulation (SCS) using the Boston Scientific Precision Plus SCS system
224069936|NCT01477242|DRUG|Ondansetron|2mg (5mL) in \< 15 kg and 4mg (10mL) in 15kg to 30kg
224069937|NCT03119909|OTHER|First session of fMRI: localization of the premotor areas of the medial frontal cortex|Subjects should perform simple tasks to map the premotor areas of the medial frontal cortex. In this context, they will have to perform hand, tongue, ocular movements for about 20s. Additionally, as part of a control condition, they will need to perform eye fixation on a cross shown at the center of the screen for about 20s.
224162401|NCT06287931|DRUG|Bifidobacterium group|Bifidobacteria, 210 mg po tid x 6 months
224162402|NCT04483752|OTHER|CHEST CT SCAN|Chest CTscan at 3 and 12 months
224304686|NCT01753336|BIOLOGICAL|Botulinum toxin type A|Dysport® (intramuscular injection), Up to 500 units (U)/vial using 2mL dilution, 3 treatment cycles
224304687|NCT05957419|PROCEDURE|Transapical beating-heart septal myectomy|We have invented a beating-heart myectomy device.Through a minimally invasive intercostal incision, septal myectomy could be accomplished via a transapical access in the beating heart using the device. The whole process of resection is monitored, navigated, and evaluated by real-time transesophageal and transthoracic echocardiography. Left ventricle outlet tract gradient and the grade of mitral regurgitation are evaluated each time after resection. Multiple resections are performed to tailor the muscular resection for sufficient relief of left ventricle outlet tract obstruction and mitral regurgitation, while preventing iatrogenic injuries.
223475574|NCT03651141|OTHER|Neurodynamic Sliding|Subjects in the neurodynamic sliding group perform 2 movements; 1) movement 1 involves sitting on the edge of the treatment table the bringing their neck to their chest along with bending their knee and pointing their ankle to the ground. Movement 2 is performed by facing their head towards the ceiling and straightening their knee while pointing their ankle towards their nose. Subjects will alternate these 2 active movements for 60s and repeated 5 times, with rest period of 15s between sets. A metronome will be set at 30 beats per minute for 15 full slides per minute to standardize the amount of slides per session.
223582280|NCT06980714|BEHAVIORAL|Manual|The intervention involves the use of the TePe Select Soft manual toothbrush, which features soft bristles for gentle yet effective plaque removal. Participants in this group are instructed to brush for at least two minutes twice daily, with guidance on proper brushing technique. To ensure compliance with the brushing duration, participants are required to use a smartphone app that tracks and records their brushing sessions. The manual toothbrush allows for participant control over brushing pressure and technique, with no additional oral hygiene aids allowed during the study period.
223582281|NCT06981117|OTHER|12 hr Respite Service|12 hours of respite service within 3 months will be provided by volunteers. Volunteers will provide elderly-sitting service (accompany the care recipient) during the service session, and provide cognitive training or physical training to the care recipient if situation allows.
223582282|NCT06981117|OTHER|36 hr Respite Service|36 hours of respite service within 3 months will be provided by substitute caregivers. Substitute caregivers will provide elderly-sitting service (accompany the care recipient) during the service session, and provide cognitive training or physical training to the care recipient if situation allows.
223582283|NCT06980363|DRUG|traditional inferior alveolar nerve block by articaine|use articaine for inferior alveolar nerve block with buccal infiltration to anesthetized lower molar teeth
223582284|NCT06980363|DRUG|hyaluronidase plus articain buccal infilteration|use of articain plus hyaluronidase enzyme buccal infiltration to anesthetized lower molar teeth
223582285|NCT06825910|DEVICE|LMA igel|adults allocated to the LMA igel group, an LMA igel device will be inserted intraoperatively
223582286|NCT06825910|DEVICE|LMA protector|adults allocated to the LMA protector group, an LMA protector device will be inserted intraoperatively
223582287|NCT06997887|OTHER|CH2 vaginal gel|12-week intervention with CH2 vaginal gel
223582288|NCT06997887|OTHER|vaginal rehabilitation exercises|12-week intervention with vaginal rehabilitation exercises
223582289|NCT02092402|OTHER|Fecal transplantation|
223582290|NCT07007364|DRUG|Adebrelimab Combined With Albumin Paclitaxel|Eligible patients received neoadjuvant low-dose radiotherapy combined with Adebrelimab and monotherapy with albumin paclitaxel for two cycles. Radical surgical resection is planned to be carried out 3 to 4 weeks after neoadjuvant therapy. Patients who obtain PCR after evaluation by the researchers after the operation will be maintained for 6 cycles of immunomonotherapy
223582291|NCT04056780|OTHER|Sample collection study|Sample collection and collection of laboratory values
224069938|NCT03119909|OTHER|Second fMRI session|The subjects will position their left and right thumbs on response buttons. Each trial will begin with the appearance of one of 2 possible indexes. It will be an unknown abstract visual stimulus). After a variable delay of 0.5 to 6s (average = 2s), a blue or yellow circle will appear on the left or right of the screen.
224069939|NCT03119909|OTHER|Third fMRI Session|This session is identical to the second session but the subject will have to respond by performing saccadic ocular responses.
224069940|NCT03119909|OTHER|Training fMRI session|The training session will consist in training the subject to carry out the different behavioral tasks that he will then have to perform during the sessions of fMRI.
223582292|NCT06687824|OTHER|Black Tea Extract|Sterile gauze is impregnated into 5ml of black tea-extract solution with tannin concentration 18.67mg/ml
223582293|NCT06687824|OTHER|0.5% Povidone Iodine Impregnated Sterile Gauze|Diluted povidone-iodine act as negative control is added into sterile gauze to color blind the involved subject and the operator
223582294|NCT02596191|OTHER|Clinical evaluation|
223582295|NCT02596191|OTHER|electrophysiological record|
223582296|NCT02596191|OTHER|Muscle MRI|
223582297|NCT02596191|OTHER|blood samples analysis|
223582298|NCT07032623|PROCEDURE|Spinal Manipulation|The spinal manipulation will target the sacroiliac joint using the global pelvic manipulation technique. Participants will be positioned in lateral decubitus with the ACL-reconstructed limb placed uppermost. The therapist will apply progressive rotation and flexion at the hip and knee joints to increase tissue tension. To establish contact, the therapist's knee will be placed against the participant's flexed knee. A high-velocity, low-amplitude thrust will then be delivered to optimize joint motion, with cavitation being monitored throughout the procedure.
223582299|NCT07033026|DRUG|NGM120 Q4W|NGM120 given subcutaneously every 4 weeks
223582300|NCT07033026|DRUG|NGM120 Q8W|NGM120 given subcutaneously every 8 weeks
223582301|NCT07033026|DRUG|Placebo given|Placebo given subcutaneously every 4 weeks
223582302|NCT07033351|PROCEDURE|Dental implant placement without PRF|Standard dental implant placement procedure with flap elevation and suturing, without the application of any PRF membrane over the implant site.
224069941|NCT03119909|OTHER|Pilot behavioral study|In a pilot study, 30 subjects will participate in a behavioral study (2 sessions of 2 hours each) aimed at establishing the learning characteristics of the different types of rare events unrelated to actions (visual and sensorimotors on the hand).
224069942|NCT03119909|OTHER|fMRI Study|Each subject will participate in 2 fMRI sessions of about 2 hours each: a first session in which a first version of the task will be presented and a second session in which the second version of the task will be presented.
223475575|NCT03651141|OTHER|Myofascial Decompression|For the group receiving the cupping treatment, the subject will lay on their stomach and their affected hamstring will be exposed. Cocoa butter will be applied to the hamstring prior to the application of the cups. 5 cups will be placed along the hamstring and calf muscles. Using a handheld suction pump, each cup will be pumped so that skin fills up half of the cup. The cups will stay in place for five minutes and the clinician will instruct the subject to perform 5 repetitions of active quad sets and 5 repetitions of ankle pumps .
223475576|NCT03651141|OTHER|Diathermy|The control group will receive a sham heat (diathermy treatment). The subjects will be asked to sit and relax for five minutes and the machine will not be turned on with a timer timing the treatment.
223475577|NCT00800358|DRUG|Paricalitol|oral paricalcitol variable daily dosing based on intact PTH level for 6 months
223475578|NCT00800358|DRUG|Calcitriol|oral calcitriol variable daily dosing based on intact PTH level for 6 months
223475579|NCT00344695|DRUG|bupropion SR|
223475580|NCT01270477|OTHER|Hyperbaric oxygen treatment|Hyperbaric oxygen treatment for 2,5 hours at maximum 14 meters (standard table in Norway).
223475581|NCT04448119|DRUG|Favipiravir|Favipiravir is the experimental drug. The dosage for favipiravir to be used in this study for prophylaxis is 1600 mg (8 x 200 mg tablets) orally twice daily on day 1 followed by 800 mg (4 x 200 mg tablets) orally twice daily on days 2-25. The dose of favipiravir for treatment is 2000 mg orally twice daily on day 1, the 1000 mg orally twice daily for 13 additional days.
223475582|NCT04448119|DRUG|Favipiravir Placebo|Favipiravir Placebo is the placebo drug. For chemoprophylaxis, the dosage of favipiravir placebo is 8 tablets orally twice daily on day 1, followed by 4 tablets twice daily from days 2-25. The dosage of favipiravir placebo for treatment is 10 tablets orally twice daily on day 1, followed by tablets twice daily from days 2-14.
223475583|NCT06491498|DIAGNOSTIC_TEST|Supraclavicular Brachial Plexus Blockade|Hemidiaphragmatic Paralysis Following Ultrasound-Guided Supraclavicular Brachial Plexus Blockade in patients undergoing upper limb surgery
223475584|NCT04541355|DRUG|Cisplatin|Given IV
223475585|NCT04541355|OTHER|Hearing Handicap Inventory for Adults - Screening|Patient self-assessment questionnaire to measure probability of hearing impairment
223475586|NCT04541355|RADIATION|Radiation Therapy|Radiation therapy will be delivered according to the standard of care
223582303|NCT07033351|BIOLOGICAL|Single-layer PRF membrane application|PRF membrane prepared via centrifugation is applied as a single layer over the implant site following implant placement before flap closure.
223475587|NCT04541355|DRUG|Sodium Thiosulfate|Given IV
223475588|NCT00433472|DEVICE|magnetic resonance imaging (MRI)|MRI scan to be complete to look at RSR13 on measurement of T2 and T2\* on MRI
223475589|NCT05171322|DEVICE|WARD|"The following monitoring devices are included in the WARD monitoring system (as intervention):~Isansys Life Touch patch: Measures heart rate (HR), respiratory rate (RR) and electrocardiogram (ECG)~Wearable, wireless Pulse Oximeter (Model 3150 WristOx from Nonin): Measures peripheral oxygen saturation of arterial hemoglobin (SpO2) and pulse rate (PR)~Blood pressure monitor (Meditech BlueBP-05): Measures BP every 30 minutes during daytime and every 60 minutes during the night~All included patients are set up with the monitoring devices after surgery when they are back at their ward (with a maximum of 24 hours postoperative). Afterwards they wear the devices for up to 5 days. All measurements are sent through bluetooth to a tablet serving as a gateway which in turn sends data to a central server where the algorithmic processing ensures."
223475590|NCT04911348|OTHER|none (observational)|no intervention
223475591|NCT03021746|BEHAVIORAL|Diabetes Self Management Support (DSMS)|
223582304|NCT07033351|BIOLOGICAL|Triple-layer PRF membrane application|Three autologous PRF membranes prepared via centrifugation are stacked and applied as a 3-layer membrane over the implant site before flap closure.
224069943|NCT05543564|PROCEDURE|PRP|Single session prophylactic early Pan-retinal Photocoagulation
224069944|NCT04414800|DRUG|Placebo|Distilled water
224069945|NCT04414800|DRUG|Ketamine|1 mg/kg intranasal ketamine
223475592|NCT01418443|DRUG|Torrent's Pantoprazole Sodium Delayed - Release Tablets|
223475593|NCT03638323|OTHER|Speech therapy|During a 1-hour speech-language consultation, a lack of word evaluation will be conducted and patient will answer a Hearing Difficulty Questionnaire
223582305|NCT07036068|DEVICE|IceMagic™ CryoAblation Catheter|IceMagic™ CryoAblation Catheter is available in two diameters: 23 mm and 28 mm. Each diameter has two types of balloon outer surfaces: with or without multi-channel tissue temperature measurement function. The catheter length is 140 cm, and the tube diameter is 10.5 F. Doctors can choose according to the size of the target pulmonary vein.
223744274|NCT01879774|OTHER|Neuropsychological and motoric tests|"1. Neuropsychological tests~   * Mini Mental Status Test~  * Dem-Tect~  * Rey-Osterrieth Complex Figure Test~  * Trailmaking Test~  * Beck Depression Inventory~  * d2-R (optional)~2. Motoric tests~   * modified UPDRS (Unified Parkinson Disease Rating Scale) Part III~  * Timed-up-and-go Test~  * Halstead Fingertapping Test~  * AIMS (Abnormal involuntary movement scale)~3. EEG (only in patients with hyponatremia)~4. MRI (only in patients with hyponatremia)"
223744275|NCT03451318|DRUG|Mometasone Furoate Nasal Spray|Mometasone Furoate Nasal Spray NASONEX
224069946|NCT04414800|DRUG|Fentanyl|1μg/kg intranasal fentanyl
224069947|NCT02282943|DEVICE|Laser|Vapourisation/excision of endometriosis AFS stages I-III using CO2 laser
224069948|NCT02282943|DEVICE|Harmonic scalpel|Excision of endometriosis using Harmonic scalpel
224069949|NCT00953368|PROCEDURE|remote ischemic preconditioning|Remote ischemic preconditioning will be induced by four 5-min cycles of upper limb ischemia and 5-min reperfusion with a blood-pressure cuff inflated to 200 mmHg and be performed before and after the coronary anastomosis
224069950|NCT02882659|BIOLOGICAL|Dendritic Killer Cell (DKC)|DKC is a hybrid cell type capable of dual functionality, i.e. cytotoxicity and antigen presentation, similar to NK cells and DCs, respectively.
224069951|NCT04755634|DEVICE|Hyaluronic Acid|Injectable
224069952|NCT03539250|RADIATION|IMRT|IMRT with and without chemotherapy
224162403|NCT00071214|BIOLOGICAL|S. aureus Type 5 and 8 Capsular Polysaccharide Conjugate Vaccine|
224162404|NCT03534713|DRUG|Carboplatin|carboplatin aera Under curve 5 on day 1, every 21 days during 3 cycles
224162405|NCT03534713|DRUG|Paclitaxel|paclitaxel 175 mg/m² on day 1, every 21 days during 3 cycles
224162406|NCT03534713|DRUG|Cisplatin|Cisplatin 40mg/m² given once a week during 5 weeks
224162407|NCT03534713|RADIATION|Radiotherapy|45 gray to the pelvis and para aortic area over 5 weeks + intracavitary brachytherapy alone or prior to surgery, depending on response to treatment according to the current guidelines
224162408|NCT00903994|DRUG|Ketoprofen Topical Patch 20%|Ketoprofen is a pressure-sensitive adhesive material containing 20% Ketoprofen which is applied to a polyester textile and covered with a foil release liner.for the treatment of mild to moderate acute pain associated with Tendonitis or Bursitis of the shoulder, elbow or knee
224162409|NCT02224274|DRUG|Clopidogrel|
224162410|NCT02224274|DRUG|Ticagrelor|
224162411|NCT01333462|BIOLOGICAL|NB-1008|NB-1008 is composed of Fluzone containing 4 micrograms (mcg) or 10 micrograms of strain-specific hemagglutinin (HA) and 5%, 10%, 15%, or 20% W805EC adjuvant.
224162412|NCT01333462|OTHER|Control|The controls include PBS placebo control as well as Fluzone IN and IM active controls.
224162413|NCT04556201|DEVICE|SOLTIVE™ Premium SuperPulsed Laser Fiber System|SOLTIVE™ SuperPulsed Laser Fiber System and SOLTIVE™ Laser Fibers for single-use only
224162414|NCT02745041|DRUG|Fibrinogen Concentrate|"Fibrinogen Replacement using Fibrinogen Concentrate as per ROTEM guided treatment algorithm \[FIBTEM ≤ A5 10mm\]~FIBTEM A5 0mm (Flat Line) = 6g FC FIBTEM A5 1 - 4mm = 5g FC FIBTEM A5 5 - 6mm = 4g FC FIBTEM A5 7 - 8mm = 3g FC FIBTEM A5 9 - 10mm = 2g FC"
223475594|NCT04245774|DRUG|Levobupivacaine (as Levobupivacaine Hydrochloride) 75 Mg/10 mL Solution for Injection Ampoule|7,5 mg (1.5 mL) of 0,5% hyperbaric levobupivacaine (1 mL 0.75% isobaric levobupivacaine (Chirocaine® 75 mg/10mL ampoule Abbott/Turkey, Nycomed Pharma/Norway) plus 0.24 mL 50% Dextrose (dextrose 120 mg) (Eczacıbaşı/Turkey) and 0.26 mL distilled water) injected into the intrathecal space in sitting position through L4-L5 or L5-S1 intervertebral space in 30 seconds. All patients kept in sitting position for 5 minutes with aid after intrathecal injection and than layed in supine position, finally they positioned in prone jack-knife.
223475595|NCT04245774|DRUG|Bupivacaine/Dextrose|7,5 mg (1.5 mL) of 0,5% hyperbaric bupivacaine (dextrose content 80 mg/mL) injected into the intrathecal space in sitting position through L4-L5 or L5-S1 intervertebral space in 30 seconds. All patients kept in sitting position for 5 minutes with aid after intrathecal injection and than layed in supine position, finally they positioned in prone jack-knife.
223475596|NCT01769547|DRUG|Dovitinib|Treatment continued until Disease Progression, Toxicity, or patient withdrawal.
223475597|NCT01004939|DRUG|fondaparinux|fondaparinux
223475598|NCT01621009|DRUG|Active bupropion + counseling|"Medications-Pre-quit: 150 mg bupropion per day 7 days before quit attempt, then 150 mg twice daily for 4 days before quit attempt; then 150 mg bupropion twice daily for eight weeks.~Counseling-Pre-quit: two 10 minutes sessions before quit date; eight 10-minute sessions post quit date."
223475599|NCT01621009|DRUG|Active bupropion, No counseling|"Medication - 150 mg bupropion per day starting week before quit day, then 150 mg twice daily 3 days before quit day, then 150 mg twice daily for eight weeks after quit day.~Counseling: No cessation counseling, only medication checks"
223475600|NCT01621009|DRUG|Placebo medication + counseling|"Placebo bupropion once daily 7 days before quit day, then twice daily 4 days before quit attempt, then twice daily for 8 weeks after quit day.~Counseling: Two 10-minutes sessions before quit day, then eight 10-minutes sessions for eight weeks after quit day."
223475601|NCT01621009|DRUG|Placebo medication, No counseling|"Pre-quit: Placebo medication once daily 7 days before quit day, then twice daily before quit day, then twice daily for 8 weeks after quit day.~Counseling: No counseling, just medication checks"
223582306|NCT07039032|DEVICE|FireMagic™ Magbot Ablation Catheter 、FireMagic™ TrueForce™ Ablation Catheter|"1. The pressure-sensing catheter primarily consists of electrodes, a catheter body, and a control handle. The catheter body comprises a high-torque body and a flexible tip, divided into an adjustable bending segment and a main segment. By pushing or pulling the handle at the proximal end of the catheter, the internal traction wire at the catheter tip can be activated to control the bending of the tip. The adjustable bending segment is fixed with four electrodes at regular intervals, including one tip electrode and three ring electrodes.~2. The disposable star-shaped magnetoelectric positioning catheter is specifically designed for cardiac electrophysiological mapping. The distal end of the catheter has multiple 3F branches, each with multiple platinum-iridium electrodes for collecting cardiac electrophysiological signals. The distal end of the catheter features an adjustable bend design; pushing the button on the catheter forward will cause the distal end of the catheter to bend."
223582307|NCT07040137|DRUG|KPS-0373|Oral administration
223582308|NCT07040137|DRUG|Placebo|Oral administration
223582309|NCT07042113|DRUG|new formulations of 611|Subjects will receive new formulations of 611 300mg once subcutaneous injection on D1
223582310|NCT07042113|DRUG|existing formulations of 611|Subjects will receive existing formulations of 611 300mg once subcutaneous injection on D1
223582311|NCT00293436|DRUG|celecoxib|
224162415|NCT02745041|OTHER|Cryoprecipitate|"Fibrinogen replacement using Cryoprecipitate as per ROTEM guided treatment algorithm \[FIBTEM A5 ≤ 10mm\]~FIBTEM A5 0mm (Flat Line) = 20 Units Cryo FIBTEM A5 1- 4mm = 16 Units Cryo FIBTEM A5 5 - 6mm = 14 Units Cryo FIBTEM A5 7 - 8mm = 10 Units Cryo FIBTEM A5 9 - 10mm = 8 Units Cryo"
224162416|NCT00187044|BIOLOGICAL|PolyEnv1 vaccine|administered subcutaneously as 10\*7 pfu in 0.8 mL
224162417|NCT02422394|DRUG|Eltrombopag|
224162418|NCT01976624|DRUG|bimatoprost/timolol|Bimatoprost/timolol (Ganfort®) treatment for open-angle glaucoma or ocular hypertension as per local standard of care in clinical practice.
224162419|NCT03931980|PROCEDURE|Robotic-assisted rectal cancer resection and Laparoscopic rectal cancer resection|we perform robotic surgery using the da Vinci Robot System Si version and laparoscopic surgery to treat rectal cancer
223582312|NCT00293436|DRUG|erlotinib hydrochloride|
223582313|NCT00293436|PROCEDURE|adjuvant therapy|
224162420|NCT03054298|BIOLOGICAL|huCART-meso cells|Intravenous administration or local delivery of lentiviral transduced huCART-meso cells in 7 cohorts with or without lymphodepletion..
224162421|NCT05106335|DRUG|camrelizumab + famitinib|camrelizumab for intravenous injection; famitinib malate capsules for oral administration
224304688|NCT01501136|OTHER|DDGP(cisplatin,dexamethasone,gemcitabine,pegaspargase)|DDP 20 mg/m2,ivgtt（intravenously guttae）, d1-4;DEX 15mg/m2,ivgtt,d1-5;GEM 800mg/m2,ivgtt,30min,d1,8;Pegasparaginase,im,2500IU/m2 d1.Every 21 days for one cycle and three cycles are required. Completion of chemotherapy is followed by radiotherapy 50Gy.Efficacy was evaluated every two cycles.
223744276|NCT03451318|PROCEDURE|tonsillar adenoidectomy|tonsillar adenoidectomy
223475602|NCT05544097|OTHER|Recording of the bowel sounds|Recording of the bowel sounds before and after enteral feeding three times a week with an electronical stethoscope
223475603|NCT06194916|OTHER|Education|A 4-WEEK SELF-MANAGEMENT TRAINING WILL BE PROVIDED THROUGH THE WEB-BASED TRAINING SITE.
223475604|NCT06194916|OTHER|CONTROL GROUP|THEY WILL RECEIVE THE ROUTINE CARE GIVEN TO PATIENTS WITH EPILEPSY.
223475605|NCT04509271|DIAGNOSTIC_TEST|MicRNAs battery kits|Novel peripheral blood diagnostic biomarker for MCI due to AD.
223475606|NCT03661775|DRUG|Magnesium sulfate administration|controlled group : administration of magnesium sulfate is 4 grams for loading dose in 15 minutes, followed by 2 grams for maintenance dose per hour Experimental group : administration of magnesium sulfate is 4 grams for loading dose in 15 minutes, followed by 2.5 grams for maintenance dose per hour
224069953|NCT07029620|DEVICE|Balance and postural rehabilitation using sensor-based stabilometric platform (GEAMASTER) under static and dynamic conditions|This intervention consists of a structured postural rehabilitation program supported by the GEAMASTER stabilometric platform. The device provides real-time feedback on center-of-pressure shifts and enables both static and dynamic balance training through interactive visual tasks. Exercises include multi-directional weight shifting, stability control, and task-specific balance strategies. The platform integrates sensor-based tracking and allows fine-grained analysis of postural parameters, distinguishing it from conventional physiotherapy by its precision, adaptability, and real-time feedback mechanisms.
224069954|NCT07029620|OTHER|Conventional balance and gait rehabilitation program|This intervention consists of a standardized physiotherapy program aimed at improving postural control and gait in patients with peripheral neuropathy. The rehabilitation protocol includes stretching, weight-shifting exercises, balance training on foam or unstable surfaces, and obstacle navigation. Unlike the experimental intervention, this program does not use any technological or sensor-based feedback systems. The content, frequency, and duration of the sessions are matched to those of the experimental arm to allow for comparative analysis of clinical outcomes.
224069955|NCT07029620|OTHER|Stabilometric assessment in healthy volunteers|This intervention involves a non-interventional assessment of healthy adult volunteers using the GEAMASTER stabilometric platform. The objective is to generate normative data for stabilometric parameters and to assess test-retest reliability of the device under static and dynamic conditions. Participants do not undergo any rehabilitation program or therapeutic intervention. The data collected will serve as a reference for interpreting pathological findings in patients with peripheral neuropathy.
224069956|NCT07028359|BEHAVIORAL|Printed Instructions with Phone Reminders|Participants received paper-based instructions for perioperative care, including medication, fasting, and follow-up logistics. Automated phone calls were sent before surgery to reinforce preparation. Participants used a printed checklist to self-report eye drop adherence.
224069957|NCT07028359|BEHAVIORAL|Sharp Health Companion App (CareKit)|The Sharp Health Companion App delivered interactive digital perioperative checklists, medication adherence prompts, COVID-19 protocol reminders, symptom tracking, and educational videos via iPhone. Participants logged their medication use in real time on the Sharp Health Companion App. Printed instructions were provided as a backup.
224069958|NCT07039396|OTHER|NeoThelium FT (HCT/P 361)|NeoThelium FT (HCT/P 361) is a dehydrated wound covering derived from donated human placental tissue. NeoThelium FT is a dual-layer membrane with amnion and chorion combination layers.
224069959|NCT07049692|OTHER|Hyperbaric Oxygen Therapy|1.6 atmosphere absolute (1.6 ATA), HBO treatment administrated via mask or hood, one 60 minutes session, once daily, 10 sessions per course, inter-session intervals of fewer than 48 hours.
224069960|NCT07049692|OTHER|High-flow oxygen therapy|1 atmosphere absolute (1 ATA), high-flow oxygen delieved at 10L/min (100%) via mask or hood, one 60 minutes session, once daily, 10 sessions per course, inter-session intervals of fewer than 48 hours.
224069961|NCT06744673|OTHER|No Intervention|This is a non-interventional study.
224069962|NCT06742957|DRUG|Tapinarof Cream 1%|Cream
224069963|NCT06742957|DRUG|VTAMA®|Cream
224069964|NCT06742957|DRUG|Placebo|Cream
224069965|NCT07142928|OTHER|light-blocking lenses|The eye with higher hyperopia will be fitted with light-blocking lenses for full-time wear, while the fellow eye with lower hyperopia will be fitted with conventional single-vision lenses for full-time wear, over 12 months
224069966|NCT07142928|OTHER|single-vision lenses|Both eyes of the subjects will be fitted with conventional single-vision lenses for full-time wear over 12 months.
224069967|NCT07143279|DRUG|Sustanon 250|Sustanon 250® (1 ml, IM) every 10 days
224069968|NCT07144189|DIAGNOSTIC_TEST|AI diagnostic test for severe low-gradient aortic stenosis|All participants will undergo standard transthoracic echocardiography performed for clinical indications. Echocardiographic images will be analyzed both by experienced physicians and by the investigational AI model. Additional diagnostic tests (such as cardiac CT, low-dose dobutamine stress echocardiography or transesophageal echocardiography) may be performed if clinically indicated, according to current guideline recommendations. The AI-derived results will not influence clinical decision-making.
224069969|NCT07144761|DEVICE|Ziplyft|Ziplyft™ is a Class 1, 510(k) Exempt device for removing excess unwanted eyelid skin using a novel surgical device called Ziplyft™.
224069970|NCT05630716|DEVICE|NICOM|non-invasive monitor capable of measuring cardiac output (CO) and cardiac index (CI), and stroke volume (SV) and stroke volume index (SVI) based on heart rate. The NICOM technology will be implemented by the Rapid Response Team providers (Advanced Practice Providers) and ICU nurses at FSH, most of whom are already trained and familiar with its use.
224069971|NCT05110300|DEVICE|Body weight support system control group|Participants will complete the physical therapy exercises as described previously, without experiencing, therapist induced, balance perturbations.
224069972|NCT05110300|DEVICE|Body weight support system with balance perturbations|Participants will complete the physical therapy exercises as described previously, while experiencing intermittent, therapist induced, balance perturbations aimed at training the participant's balance-control and balance-reactions. With the ZeroG BWSS integrated TRiP module, therapist's are able to induce safe lateral, anterior, or posterior perturbations via a Wi-Fi-enabled handheld device. The force, or level, of perturbation can be adjusted from 1 (least amount of force) up to 10 (highest amount of force) using the same handheld device,
224069973|NCT01359774|OTHER|31P-MR spectroscopy|Brain energy deficit is quantified using 31P-MR spectroscopy
224069974|NCT01359774|OTHER|31P-RMN spectroscopy|Brain energy deficit is quantified using 31P-RMN spectroscopy
223582314|NCT07041749|DRUG|Bleomycin|);will be treated with combination of microneedling and topical bleomycin .
223582315|NCT07041749|DEVICE|Microneedling alone|' Microneedling will be performed on each wart using dermapen supplied with 12 needles arranged in rows. Topical anesthetic cream will be applied for 60 min before the procedures. Microneedling will be performed on each wart using dermapen. The penetration depth will be adjusted at 2-mm, endpoint is pinpoint bleeding and the dermapen will be held by the hand in a vertical direction on the warts.
223582316|NCT07041749|DRUG|5 fluorouracil|);will be treated with combination of microneedling and topical 5-flurouracil .
223582317|NCT07040449|BEHAVIORAL|Montreal Imaging Stress Task|Psychosocial stress procedure consisting of completing sections of mental arithmetic that are 5.5 minutes in length, during which the individual receives neutral and negative evaluative feedback about their performance relative to their peers.
223582318|NCT07040449|BEHAVIORAL|Trier Social Stress Test for Children|Psychosocial stress procedure in which the individual tells a story for 5 minutes in front of two neutral judges and performs mental arithmetic in front of the judges for 5 minutes.
224069975|NCT04909125|RADIATION|Hypofractionated radiotherapy VS Standard/Conventional fractionation radiotherapy|The purpose of this study is to investigate toxicity following standard conventional fractionation versus moderately hypofractionated radiotherapy to the breast, chest wall and regional lymph nodes
224069976|NCT03983850|DRUG|Busulfan|Busulfan should be administered intravenously via a central venous catheter as a three-hour infusion every 24 hours.
224069977|NCT03983850|DRUG|Fludarabine|Fludarabine will be infused by IV over 60 minutes.
224069978|NCT03983850|DRUG|Cyclophosphamide|IV cyclophosphamide will be administered over 2 hours. Slower rates of infusion may be used to decrease side effects. A fluid intake of greater than 2 L/day is recommended during and for 1 to 2 days after cyclophosphamide administration.
224069979|NCT03983850|DRUG|Mycophenolate Mofetil|Any oral formulation should be taken on an empty stomach, 1 hour before or at least 2 hours after meals. Oral formulations should not be administered simultaneously with antacids. Avoid inhalation or direct contact with skin or mucous membranes of dry powder contained in capsules or suspension. IV solutions should be administered over at least two hours through either a peripheral or central vein and should not be administered by rapid or bolus injection.
224069980|NCT03983850|DRUG|Sirolimus|Oral tablets should be administered approximately 4 hours after cyclosporine administration. Sirolimus is administered orally, once daily, without food. Patients unable to tolerate tablets may take the oral solution formulation.
224069981|NCT05763745|DIAGNOSTIC_TEST|Point of Care Ultrasound|Use Point of Care Ultrasound to evaluate the gastric content/bleed prior to upper endoscopy
224069982|NCT03004378|BEHAVIORAL|Activity Tracker|Fitbit Alta
224069983|NCT01203384|DRUG|CHF5074 1x|oral tablet, 1x, once a day in the morning for 14 days
224069984|NCT01203384|DRUG|CHF5074 2x|oral tablet, 2x, once a day in the morning for 14 days
224069985|NCT01203384|DRUG|CHF5074 3x|oral tablet, 3x, once a day in the morning for 14 days
224069986|NCT01203384|DRUG|Placebo|oral tablet, placebo, once a day in the morning for 14 days
224162422|NCT05106335|DRUG|famitinib|famitinib malate capsules for oral administration
223582319|NCT07040163|DRUG|ketamine|This is the experimental intervention to be used as an alternative sedation method to the other comparator intervention (fentanyl).
223582320|NCT07040163|DRUG|fentanyl|This is the traditional (comparator) intervention used in interventional radiology procedure sedation.
223582321|NCT07040163|DRUG|Midazolam|Adjuvant administered in combination with either fentanyl (comparator) or ketamine (experimental).
223582322|NCT07040215|DEVICE|Freewalk lower limb Robotic Assistive Gait Training|"Participants in this group will receive robotic-assisted gait training three times per week (every other day) for 30 minutes per session, using the FREE Walk exoskeleton device (FREE Bionics, Taiwan). The device assists with walking, standing, and sitting. A physical therapist will help the participant wear the exoskeleton and supervise the training, adjusting the level of robotic support and intensity based on the participant's ability. In addition to RAGT, participants will receive conventional stroke rehabilitation therapy (including sit to stand, balance and gait training) on the remaining weekdays (2 days/week), 30 minutes per session.~Intervention Duration: 4 weeks."
223582323|NCT07040215|OTHER|Physiotherapy|Participants in this group will receive conventional stroke rehabilitation therapy (including sit to stand, balance and gait training) 5 days/week, 30 minutes per session. Intervention Duration: 4 weeks.
223582324|NCT07040995|OTHER|Swift follow-up|Swift and structured follow-up on-demand for 6 months at a disease-specific outpatient clinic following hospitalization for heart failure among older adults
223582325|NCT07041060|DIETARY_SUPPLEMENT|EOLO|Eolo, a nutraceutical blend of sodium alginate, sodium bicarbonate, palmitoylethanolamide (PEA), and herbal extracts
223582326|NCT07041060|DRUG|PPI (proton pump inhibitor)|Received a half-dose of PPIs for 24 weeks
223744277|NCT03451318|PROCEDURE|Maxillary expander plus Twin-Block|Twin-block appliance combined with maxillary expander
224162423|NCT05106335|DRUG|docetaxel|docetaxel for intravenous injection
224162424|NCT02840526|PROCEDURE|Paravertebral blockade (PVB)|preoperative ThPVB performed unilaterally at Th10 level
224162425|NCT02840526|DRUG|Sopodorm|midazolam 0,1 mgkg-1 intravenously (anesthesia induction)
224162426|NCT02840526|DRUG|Propofol WZF|propofol 2 mgkg-1intravenously (anesthesia induction)
224162427|NCT02840526|DRUG|Nimbex|cis-atracurium 0,15 mgkg-1 intravenously (anesthesia induction)
224162428|NCT02840526|DRUG|Fentanyl WZF|fentanyl 1,5 µgkg-1 intravenously (anesthesia induction)
224162429|NCT02840526|DRUG|Sevorane|sevoflurane in 1 MAC (Minimal Alveolar Concentration) - anesthesia maintenance
224162430|NCT02840526|DEVICE|Intubation|Intratracheal intubation with a single lumen endotracheal tube
224162431|NCT02840526|DRUG|Oxynorm|1 mgml-1 concentration oxycodone solution intravenously
224162432|NCT02840526|DRUG|Paracetamol Kabi|1g paracetamol intravenously every 6 hours
224162433|NCT02840526|DRUG|Ketonal|100 mg ketoprofen intravenously every 12 hours
224162434|NCT02840526|DRUG|Bupivacaine WZF|0,3 ml kg-1 0,5% plain bupivacaine (regional anesthesia - paravertebral blockade)
224162435|NCT04203017|BIOLOGICAL|allogeneic fecal microbiota|All patients receive autoHSCT with RIC (Cyclophosphamide, Antithymocyte globulin, Rituximab). After immune system reconstitution (approximately starting D+60 up to D+120), patients will receive FMT from healthy donor via po capsules.
223475607|NCT06550921|PROCEDURE|ablation of oligometastasis|The oligometastasis of hepatocellular carcinoma are ablation completely by ablation (including microwave ablation, radiofrequency ablation, and cryoablation)
223475608|NCT01589315|DEVICE|focal ECT|FEAST, ECT, unidirectional stimulation
223475609|NCT02147301|DEVICE|LC Bead|"Doxorubicin Eluting Bead Transarterial Chemoembolization (DEB-TACE):~Doxorubicin-loaded LC Beads® are administered via a co-axially placed commercially available hepatic artery catheter into hepatic arteries targeted for treatment. Procedure is performed under direct fluoroscopic visualization until stasis of arterial flow is achieved or until a total of 4 ml of microspheres have been administered, whichever occurs first."
223475610|NCT01625468|BEHAVIORAL|Educational print materials and a coaching call|Intervention group participants receive three sets of mailed educational materials about making their home smoke-free and one coaching call.
223475611|NCT00151944|DRUG|SPD476 (mesalazine)|
223744278|NCT04552392|OTHER|No intervention|No intervention
224162436|NCT05008458|DIAGNOSTIC_TEST|von willebrand factor and copeptin|biomarkers increase in children with febrile seizures
224304689|NCT01501136|OTHER|VIPD（cisplatin，Etoposide，Ifosfamide， dexamethasone，Mesna）|DDP,33mg/m2,ivgtt（intravenously guttae）,d1-3；VP-16,100mg/m2,ivgtt,d1-3；IFO,1.2g/m2,ivgtt,d1-3；DEX,40mg,ivgtt,d1-4；Mesna,0、4、8h after IFO,240mg/m2,iv,d1-3.Every 21 days for one cycle and three cycles are required. Completion of chemotherapy is followed by radiotherapy 50Gy.Efficacy was evaluated every two cycles.
224304690|NCT01501136|OTHER|gemcitabine,pegaspargase,cisplatin,dexamethasone|Radiotherapy 50Gy is followed by chemotherapy(DDP 20 mg/m2,ivgtt（intravenously guttae）,d1-4;DEX 15mg/m2,ivgtt,d1-5;GEM 800mg/m2,ivgtt,30min,d1,8;Pegasparaginase,im,2500IU/m2 d1.Every 21 days for one cycle and three cycles are required ).Efficacy was evaluated every two cycles.
223475612|NCT00144599|DRUG|MRA(Tocilizumab)|
223475613|NCT00144599|DRUG|placebo|
223475614|NCT04746638|DIAGNOSTIC_TEST|whole body study and SPECT with 99mTc-RM26|One single intravenous injection of 99mTc-RM26, followed by gamma camera imaging after 2, 4, 6 and 24 hours.
223475615|NCT03400449|OTHER|Video counseling|Video counseling
223475616|NCT03400449|OTHER|Conversational counseling|Conversational counseling
223475617|NCT00004233|DRUG|fluorouracil|
223475618|NCT00004233|DRUG|leucovorin calcium|
223475619|NCT00004233|DRUG|triacetyluridine|
223475620|NCT03641508|DRUG|Triamcinolone|Triamcinolone acetonide (Kenalog; 10 mg/mL; insoluble). This will be mixed with 1% lidocaine without epinephrine
223744279|NCT05507255|OTHER|Relaxation training|Relaxation training in the form of deep breathing exercises
223475621|NCT03641508|DRUG|Dexamethasone|dexamethasone sodium phosphate (Decadron; 4 mg/mL; soluble). Again, this will be mixed with 1% lidocaine without epinephrine
223475622|NCT03642990|DRUG|Nicotinamide Riboside|Capsule
223475623|NCT03733236|DEVICE|ISS Active Stimulation|ISS SPG stimulation and standard of care
223475624|NCT05235438|DRUG|IMM27M|IMM27M injection
223475625|NCT03658551|DIAGNOSTIC_TEST|Fluorescein|Measurement of intensity in the gastrointestinal mucosa after intravenous administration of fluorescein by confocal endoscopy
224162437|NCT04752943|OTHER|Tips By Text Messages|Texts sent to caregivers meant to increase parent child interaction around literacy, sent to participants 3 x a week for 7 months
224162438|NCT00001827|BIOLOGICAL|aldesleukin|
224162439|NCT00001827|BIOLOGICAL|incomplete Freund's adjuvant|
224162440|NCT00001827|BIOLOGICAL|p53 peptide vaccine|
223475626|NCT05355558|DIAGNOSTIC_TEST|[18F]FLT-PET/MRI body scan|"\[18F\]FLT-PET/MRI body scan will be done at~* Visit 2 (Baseline-Pre-Treatment FLT-PET/MRI) which will occur between 1 to 28 days prior to initiation of radiotherapy.~* Visit 3 (During Treatment FLT-PET/MRI) which will occur between week 4 to week 5 of External Beam Radiotherapy (before brachytherapy).~At these visits:~* Obtain vital signs and weight in kg before FLT administration.~* Record the dose of FLT received and injected. (\*\*specify dose: 1mCi per 10kg. Maximum injected dose: \< 10mCi per patient.)~* Place one (1) IV catheters into the participant's arm vein to inject the bolus of FLT.~* Perform a saline flush following the FLT injection.~* Body PET/MRI will be performed after FLT injection.~* Time of injection of FLT and time of scan will need to be recorded."
223475627|NCT04572373|DIETARY_SUPPLEMENT|SMOFlipid|
223475628|NCT00855218|DRUG|Sorafenib (Nexavar, BAY43-9006)|800 mg sorafenib (4 tablets) will be taken daily (400mg b.i.d. \[twice daily\], 2 tablets). Transarterial Chemoembolization (TACE) using DC Bead
223475629|NCT00855218|DRUG|Placebo|4 tablets of placebo will be taken daily (2 tablets b.i.d). TACE using DC Bead
223475630|NCT04063839|DRUG|Elbasvir / Grazoprevir Oral Tablet|HCV treatment according to Norwegian guidelines
223475631|NCT04005040|PROCEDURE|Mobile X-ray|Evaluating the effect of mobile x-ray compared to x-ray at the Hospital
223475632|NCT01542827|OTHER|Biofreeze|The gel will be applied at 2.5 ml per 500 cm2 to the upper trapezius and neck muscles by a gloved technician
223475633|NCT01542827|OTHER|Placebo|The gel will be applied at 2.5 ml per 500 cm2 to the upper trapezius and neck muscles by a gloved technician
223582327|NCT07041060|DIETARY_SUPPLEMENT|Group C: Eolo|Eolo, a nutraceutical blend of sodium alginate, sodium bicarbonate, palmitoylethanolamide (PEA), and herbal extracts for 24 weeks
223582328|NCT07042204|PROCEDURE|Group I (extended platelet-rich fibrin)|mucoperiosteal flap will be raised through sulcular incisions Debridement of granulation tissue from the osseous defect and furcation will be filled with (ePRF) at the first group
223582329|NCT07042204|PROCEDURE|Group II (bioactive glass nanoparticles mixed with extended platelet-rich fibrin)|bioactive glass nanoparticles mixed with extended platelet-rich fibrin (BGn+ePRF)
223582330|NCT07042204|PROCEDURE|Group III (bioactive glass nanoparticles and covered by a collagen membrane)|bioactive glass nanoparticles and covered by a collagen membrane
223582331|NCT07042087|BEHAVIORAL|Mindfulness Yoga|A structured 9-month program integrating physical yoga postures (asanas), breathing techniques, sound, and meditation. Sessions are conducted twice weekly (90 minutes each) and focus on enhancing physical health, stress regulation, and cognitive performance. Delivered by certified instructors.
224162441|NCT00001827|BIOLOGICAL|sargramostim|
224162442|NCT00001827|BIOLOGICAL|therapeutic autologous dendritic cells|
224162443|NCT00001827|PROCEDURE|in vitro-treated peripheral blood stem cell transplantation|
224304691|NCT01501136|OTHER|cisplatin,Etoposide,Ifosfamide,dexamethasone,Mesna|Radiotherapy 50Gy is followed by chemotherapy(DDP,33mg/m2,ivgtt（intravenously guttae）,d1-3；VP-16,100mg/m2,ivgtt,d1-3；IFO,1.2g/m2,ivgtt,d1-3；DEX,40mg,ivgtt,d1-4；Mesna,0、4、8h after IFO,240mg/m2,iv,d1-3.Every 21 days for one cycle and three cycles are required ).Efficacy was evaluated every two cycles.
224304692|NCT01501136|RADIATION|Radiotherapy|Suitable type intensity-modulated radiation therapy(IMRT)50Gy
224304693|NCT03025490|DEVICE|Capnographic monitoring|Capnographic monitoring is used during the sedation.
224304694|NCT03896984|DRUG|Radium-223 (Xofigo, BAY88-8223)|Ra-223 was approved by the FDA in May 2013 for the treatment of patients with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastatic disease.
224304695|NCT03896984|DRUG|Abiraterone|Abiraterone is a CYP17 inhibitor. It was approved by the FDA for the treatment of patients with mCRPC in 2011, and for patients with metastatic high-risk castration-sensitive prostate cancer in 2018.
223582332|NCT07042087|BEHAVIORAL|Time-Restricted Eating with nutritional counseling promoting a flexitarian dietary pattern|Participants follow a 16:8 time-restricted eating schedule (16 hours fasting / 8 hours eating window) for 9 months, with nutritional counseling promoting a flexitarian dietary pattern. The intervention is designed to support metabolic health and reduce risk factors for neurodegeneration.
223582333|NCT07042087|BEHAVIORAL|Cognitive Training|A 9-month structured program of twice-weekly cognitive training sessions (90 minutes each), targeting memory, attention, executive function, and social cognition using both paper-based and computer-based tasks. Supervised by trained therapists.
223582334|NCT07042087|BEHAVIORAL|Stretching|A twice-weekly stretching routine performed over 9 months (90-minute sessions), led by physiotherapists. This intervention provides low-intensity physical activity to control for physical engagement across study arms.
223582335|NCT07041346|OTHER|Education|"1. Objectives of the Training Program To increase students' knowledge and awareness of gender concepts, gender roles, and gender inequality.~   To help students develop more conscious and critical thinking skills regarding social norms and gender-based discrimination.~   To promote the development of gender-sensitive attitudes and contribute to positive attitude changes following the training.~2. Duration and Structure of the Training Total Duration: 2 weeks~   Weekly Duration: 2 hours~   Training Format: In-person~   Training Methods: Presentations, group discussions, surveys, brainstorming, Q\&A sessions, debates~3. Training Content and Modules Week 1 Topic 1: Fundamental Concepts, Gender Roles, and Inequality~Introduction and Training Objectives~Gender and Social Norms: Definition of gender norms and their impact on individuals"
223582336|NCT07041112|DRUG|Biologic therapy for psoriasis|Exposure to systemic biologic drugs for psoriasis, including TNF inhibitors (etanercept, adalimumab, infliximab, certolizumab), IL-12/23 inhibitors (ustekinumab), IL-17 inhibitors (secukinumab, ixekizumab, brodalumab), and IL-23 inhibitors (guselkumab, risankizumab, tildrakizumab). Treatments were prescribed as part of routine clinical care.
223582337|NCT07035405|DRUG|Colchicine 0.5 mg|Oral colchicine will be initiated with a dose of 0.5 mg per day.
223582338|NCT07035405|DRUG|Placebo colchicine|Oral placebo colchicine will be initiated with a dose of 0.5 mg per day.
223582339|NCT07042061|DEVICE|Mobile external automated defibrillator|A single-use, hand-held, chocolate bar sized portable AED
224162444|NCT00278551|BIOLOGICAL|Immune ablation and hematopoietic stem cell transplant|Autologous Hematopoietic Stem Cell Transplant
224162445|NCT03878225|DIETARY_SUPPLEMENT|H.V.M.N. Ketone Ester|The ketone mono ester will be ingested 5 times daily for 3 days (72 hours). Please see above for details.
224162446|NCT03878225|OTHER|Placebo|The placebo will be ingested 5 times daily for 3 days (72 hours). Please see above for details.
224162447|NCT05597241|DRUG|apimostinel|N-methyl-D-aspartate (NMDA) receptor modulator
224162448|NCT05597241|DRUG|Placebo|Placebo
224162449|NCT00225888|BEHAVIORAL|Digital Photography of meals/snacks and group discussion|Digital Photography of meals/snacks and group discussion
224162450|NCT04262791|DEVICE|Wrist Actigraphy Device|Wrist Actigraphy Device
224162451|NCT04262791|DEVICE|Sleep Headband|Sleep Headband
224162452|NCT00125437|DRUG|spironolactone|
224162453|NCT06425263|BIOLOGICAL|adipose tissue fragmented|harvested from the case form buccal pad of fat
224304696|NCT03896984|DRUG|Enzalutamide|Enzalutamide is an androgen receptor inhibitor. It was approved by the FDA for the treatment of patients with mCRPC in 2012, with warning and precautions added in 2017 regarding the risk of seizure and encephalopathy.
224304697|NCT05884879|BEHAVIORAL|Tinnitus simulation|The control group will perform speech perception tests and listening effort tests in the absence and presence of a simulated tinnitus percept using a bone vibrator.
224304698|NCT02103270|DRUG|Peanut Protein 4,000mg|"Arm A will be defined as clinically tolerant if there is no clinical reactivity at the Week 104 and Week 117 DBPCFC. Clinical reactivity is defined as any reaction ≥ Grade 1 based on the Bock's Criteria (Appendix 4). Individuals in Arm A who meet the definition of clinically tolerant will continue to avoid peanut protein (i.e. continue on 600 mg per day of oat flour) as long as each subsequent DBPCFC (performed every 13 weeks until end of study) shows no clinical reactivity."
224162454|NCT06436820|PROCEDURE|Lumbar puncture|Lumbar puncture procedure performed within a clinical setting
224162455|NCT03385525|DRUG|BIIB074|Administered as specified in the treatment arm
224162456|NCT03385525|DRUG|Valproic Acid|Administered as specified in the treatment arm
224304699|NCT02103270|DRUG|Oat Flour|"Arm C will be defined as natural loss of responsiveness if they show no clinical reactivity at DBPCFCs (week 117 to end of study)."
224304700|NCT02103270|DRUG|Peanut Protein 300 mg|"Arm B will be defined as desensitized to a minimum of 300 mg per day of peanut protein if they show no clinical reactivity at DBPCFCs (week 117 to end of study)."
224304701|NCT03605654|BIOLOGICAL|MDR-102|Enriched CD34+ hematopoietic stem cells and defined dose of CD3+ T-cells
224304702|NCT03605654|DRUG|Immunosuppressive Agents|Standard Anti-Rejection Medications that would be given to kidney transplant recipients who are outside the study
224304703|NCT05210244|DIETARY_SUPPLEMENT|Beetroot Juice (BJ) acute supplementation|One serving of 70 mL of BJ (6.4 mmol of NO3) 3h before initiating the testing session
224304704|NCT05210244|DIETARY_SUPPLEMENT|Placebo Juice (PLA) acute supplementation|One serving of 70 mL of juice (0.005 mmol of NO3) 3h before initiating the testing session
223475634|NCT06036472|PROCEDURE|Standard periodontal therapy (steps 1 & 2)|participant will receive standard periodontal treatment consisting of two sessions of supra- and subgingival debridement (steps 1 and 2) under local anesthesia following current guidelines for periodontal therapy in patients with periodontitis (Herrera et al., 2022; Sanz et al., 2020). The use of chlorhexidine (0.12%) and cetylpyridinium chloride (0.05%) mouthwash will be prescribed twice a day for 15 days (Perio-Aid®, Dentaid, Barcelona, Spain). If needed, hopeless teeth might be extracted during this step.
223475635|NCT06036472|PROCEDURE|supragingival debridement with anesthesia (step 1)|periodontal treatment consisting of two sessions of supragingival debridement with anesthesia (step 1) and administration of a placebo mouthwash (FluorAid®, Dentaid, Barcelona, Spain), twice a day for 15 days.
223475636|NCT04173819|BIOLOGICAL|3BNC117-LS-J|300mg
223475637|NCT04173819|BIOLOGICAL|10-1074-LS-J|300mg
223475638|NCT04173819|BIOLOGICAL|Combination 3BNC117-LS-J and 10-1074-LS-J|30mg/kg of each
223475639|NCT04173819|BIOLOGICAL|Combination 3BNC117-LS-J and 10-1074-LS-J Ratio 1|Total \~300 mg (\< 2.5 ml) combined of 3BNC117-LS-J and 101074-LS-J - Dosage ratios chosen will be those considered worthy of further investigation based on the safety and preliminary PK observed in groups 1-2
223475640|NCT04173819|BIOLOGICAL|Combination 3BNC117-LS-J and 10-1074-LS-J Ratio 2|Total \~300 mg (\< 2.5 ml) combined of 3BNC117-LS-J and 101074-LS-J - Dosage ratios chosen will be those considered worthy of further investigation based on the safety and preliminary PK observed in groups 1-2
223582340|NCT06887387|DEVICE|Wearable device|This is an observational study that does not impact routine clinical care for participants
223582341|NCT07042074|BEHAVIORAL|Augmented Reality (AR) / Virtual reality (VR) Exposure Therapy + Cognitive Behavioral Therapy (CBT) Exposure Therapy|AR/VR (Apple Vision Pro or Meta Quest 3) will be used together with Cognitive Behavioral Therapy (CBT) Exposure Therapy
223582342|NCT07042074|BEHAVIORAL|Cognitive Behavioral Therapy (CBT) Exposure Therapy|Participant will experience the traditional CBT exposure therapy only
223744280|NCT05507255|OTHER|An aerobic exercise program|An aerobic exercise program of a moderate intensity, based on the target heart rate (THR) that will be calculated in accordance with Karvonen's equation, using resting heart rate (HRrest), maximal heart rate (HRmax) and training fraction. THR = HRrest (bpm) + (HRmax (bpm) - HRrest (bpm)) × training fraction.The exercise session will have three phases, warming up, active phase and cooling down.
224162457|NCT00435149|PROCEDURE|Carpal tunnel release surgery|Patient will have carpal tunnel release surgery and will be put in a splint after surgery.
223744281|NCT04385823|DEVICE|patients receiving nasal high flow|patients admitted to the ICU for Covid-19-related acute hypoxemic respiratory failure treated with nasal high flow
224162458|NCT00435149|PROCEDURE|Carpal tunnel release surgery|Patient will have carpal tunnel release surgery and will have a bandage placed over the incision site after surgery.
224162459|NCT00550290|DRUG|Cefazolin PostOperatively|Cefazolin 1 gram IV every 8 hours for a total of 3 doses. Patients in both arms will receive an initial pre-operative 2 gram dose of Cefazolin within 30 minutes prior to incision. In penicillin/cephalosporin allergic patients, the substitute of Clindamycin 900 mg IV q 8 hrs will be used.
224162460|NCT00550290|DRUG|Cefazolin Preoperatively|Patients in active comparator arm will receive an initial pre-operative 2 gram does of Cefazolin within 30 minutes prior to incision. In penicillin/cephalosporin allergic patients, the substitute of Clindamycin 900 mg IV will be used.
224162461|NCT01802541|DIETARY_SUPPLEMENT|diacylglycerol oil|
224162462|NCT01802541|DIETARY_SUPPLEMENT|triacylglycerol oil|
223475641|NCT04173819|BIOLOGICAL|Combination 3BNC117-LS-J and 10-1074-LS-J Ratio 3|Total \~300 mg (\< 2.5 ml) combined of 3BNC117-LS-J and 101074-LS-J - Dosage ratios chosen will be those considered worthy of further investigation based on the safety and preliminary PK observed in groups 1-2
223475642|NCT04173819|BIOLOGICAL|Placebo|0.9% Saline
223475643|NCT04173819|BIOLOGICAL|Placebo|Buffer Solution
223475644|NCT00764790|BIOLOGICAL|Fluarix|One (Day 0) or two (Day 0 and Day 28) doses by intramuscular injection. Two different doses are tested.
223475645|NCT00764790|BIOLOGICAL|Fluzone|One (Day 0) or two (Day 0 and Day 28) doses by intramuscular injection.
223475646|NCT03191552|DEVICE|SPIO|"SPIO (stabilizing input pressure orthosis) 2 hours will receive conventional exercise therapy with the garment on during 2 hours. SPIO 6 hours group wore the SPIO 4 hours more in addition to 2 hours during therapy.~SPIO 6 hours group will wear the SPIO 4 hours more in addition to 2 hours during therapy.~(conventional exercises :range of motion, strengthening, trunk control and strengthening exercises and exercises to improve fine and gross motor skills"
223475647|NCT03191552|OTHER|conventional exercises|range of motion, strengthening, trunk control and strengthening exercises and exercises to improve fine and gross motor skills
223475648|NCT03847961|DEVICE|hemoperfusion with cytokine adsorption column (CA330)|Hemoperfusion treatments are performed using a perfusion machine via centrally inserted standard dialysis catheters at a prescribed blood flow rate of 100-300ml/min. In the beginning, lower flow rate is recommended, if there is no discomfort, then gradually increases. Each patient received 2 hemoperfusion treatments within 24 hours with a target duration for each treatment of 120-180 minutes (minimum of 120 minutes). The shorter the interval between the two hemoperfusion is, the better. It is suggested that the second hemoperfusion be performed within 0-5 hours after the first one.
223475649|NCT01441973|BIOLOGICAL|Elotuzumab (BMS-901608; HuLuc63)|
223475650|NCT04993209|BIOLOGICAL|NDV-HXP-S 1μg|NDV-HXP-S 1μg 0.5mL 2 doses intramuscular (deltoid) 28 days apart
223475651|NCT04993209|BIOLOGICAL|NDV-HXP-S 3μg|NDV-HXP-S 3μg 0.5mL 2 doses intramuscular (deltoid) 28 days apart
223475652|NCT04993209|BIOLOGICAL|NDV-HXP-S 10μg|NDV-HXP-S 10μg 0.5mL 2 doses intramuscular (deltoid) 28 days apart
223582343|NCT07041593|OTHER|Inspiratory Muscle Training and Traditional Physiotherapy|Participants in this group will undergo inspiratory muscle training (IMT). The resistance to be applied at the start of IMT has been set at 30% of the maximum inspiratory pressure (MIP) value. The MIP value will be remeasured every week, and the training load will be updated according to 30% of the new value obtained. IMT will be carried out twice a week with a physiotherapist and on the remaining days as a home programme, for a total of eight weeks, five days a week, 15 minutes a day. Participants in the experimental group will receive traditional physical therapy treatments for cerebral palsy in the same manner as the control group. In this context, traditional physical therapy methods based on neurodevelopmental principles will be applied and designed according to the individual's needs.
224162463|NCT03044470|OTHER|cryotherapy|Role of cryotherapy in reduction of post operative pain
224162464|NCT02293941|DRUG|JKB-122 5mg|Participants were randomized to receive JKB-122 5mg for 12 weeks
224162465|NCT02293941|DRUG|JKB-122 15mg|Participants were randomized to receive JKB-122 15mg for 12 weeks
223475653|NCT04993209|OTHER|Adsorbed inactivated COVID-19 vaccine (CoronaVac)|Adsorbed inactivated COVID-19 vaccine 600 SU/0.5 mL 2 doses intramuscular (deltoid) 28 days apart
224162466|NCT02293941|DRUG|JKB-122 35mg|Participants were randomized to receive JKB-122 35mg for 12 weeks
223475654|NCT02391025|DRUG|Gallium-68 citrate|Given via IV at time of imaging
223475655|NCT02391025|PROCEDURE|Positron Emission Tomography (PET)|Imaging procedure
223475656|NCT00632567|PROCEDURE|caesarean section|caesarean section for second delivery if the first had to be traumatic after forceps with anal sphincter rupture diagnosed with anal endosonography.
224162467|NCT02293941|DRUG|Placebo|Participants were randomized to receive comparable placebo for 12 weeks
223475657|NCT00632567|PROCEDURE|vaginal delivery|vaginal delivery for second delivery if the first had to be traumatic after forceps with anal sphincter rupture diagnosed with anal endosonography.
223582344|NCT07041593|OTHER|Traditional Physiotherapy|Participants in the control group will undergo a neurodevelopmental-based traditional physiotherapy programme for 8 weeks, with two 40-minute sessions per week under the supervision of a physiotherapist; on other days, they will be asked to continue the exercises taught to their families at home.
223582345|NCT07040878|BEHAVIORAL|Antigravity Treadmill Training|Antigravity treadmill training uses air pressure to reduce effective body weight during walking, minimizing joint load while preserving gait mechanics. The 6-week intervention includes five sessions per week within a 120-minute daily kinesitherapy program. Treadmill speed is individualized at baseline and increased by 0.5 km/h every two weeks. Unloading is progressively reduced: 60% support in weeks 1-2, 40% in weeks 3-4, and 20% in weeks 5-6, allowing gradual adaptation to full weight-bearing.
224162468|NCT03954977|DIAGNOSTIC_TEST|PICC line ultrasound|NICU patient's with PICC lines will be enrolled and blinded ultrasound operators will scan the neonate to find the PICC tip location. This will be compared to the location on the patient's chest x-ray. This process will be repeated each time the patient has a chest x-ray.
223475658|NCT02187549|DEVICE|HYMOVIS|Intra-articular injection
223475659|NCT02187549|DEVICE|Placebo|Intra-Articular Injection
223475660|NCT00528307|DEVICE|HIS buldle ablation|HIS bundle ablation, followed by implant of a biventricular pacemaker
223475661|NCT01149655|DRUG|Aripiprazole|Aripiprazole (2-mg, 5-mg, 10-mg, 15-mg, 20-mg, 25-mg or 30-mg)
223475662|NCT01149655|DRUG|Aripiprazole|Aripiprazole (10-mg, 15-mg, 20-mg, 25-mg or 30-mg)
223744282|NCT02725242|DRUG|Budesonide/formoterol (160/4.5 μg/d)|After the patients who have all criteria, they will be randomization to take Budesonide/formoterol (160/4.5 μg/d)
223744283|NCT02725242|DRUG|Budesonide (400μg/d)|After the patients who have all criteria, they will be randomization to take Budesonide (200 ug) twice daily
223744284|NCT05947201|DRUG|Cadonilimab Combined Albumin-paclitaxel, Cisplatin and Fluorouracil|If the addition of Cadonilimab to neoadjuvant chemotherapy further improve the efficiency for locally advanced esophageal squamous cell carcinoma
223744285|NCT03295253|PROCEDURE|Autologous adipose tissue harvesting/grafting using Lipogems|Adipose tissue harvesting and grafting in the urethra using fat micro-fragmentation and processing device Lipogems
224162469|NCT04298931|OTHER|Series of ventilator settings|"Before a planned fluid administration, the investigators will apply a series of 10 ventilator settings for 30 seconds each.~The settings are the following combinations of respiratory rate (RR) and tidal volume (TV):~RR (min\^-1), TV (ml/kg predicted body weight)~31, 6~31, 8~24, 6~24, 8~17, 6~17, 8~10, 4~10, 6~10, 8~10, 10~(the order of the respiratory rates: 17 to 31, will be randomized. 10/min will always be last. Tidal volume is always applied from lowest to highest for each respiratory rate)."
224162470|NCT02078661|DRUG|PG101|A topical gel containing either 1% or 0.25% PG101 active.
224162471|NCT01085656|DRUG|OXi4503|"Two safety cohorts treating two (2) patients at a dose of 2.5 mg/m2 followed by two patients at 3.75 mg/m2 will be completed prior to beginning at the dose level of 5 mg/m2.~Dosing of OXi4503 will be an intravenous infusion (IV) over 10 minutes on Days 1, 8, 15, and 22 of each 28 day cycle.~Dose escalations and de-escalations of 25% will be made until the maximum tolerated dose is reached.~Number of cycles: After Cycle 1, subjects who achieve stable disease (SD) or greater response may continue to receive additional cycles of treatment until either disease progression (defined as greater than 25% increase in leukemia myeloblasts in the bone marrow compared to baseline examination) or unacceptable toxicity due to the investigational agent."
223744286|NCT00832585|DRUG|Alefacept|Alefacept 15mg IM every week for 12 weeks
223475663|NCT02031523|DRUG|Sanjie analgesic capsule|Oral, four each time, 3 times a day, on the first day of menstruation to start taking, taking three consecutive menstrual cycle.or follow the doctor's advice.
223475664|NCT02031523|DRUG|placebo|oral，four each time, 3 times a day, on the first day of menstruation to start taking, taking three consecutive menstrual cycle. Or Follow the doctor's advice.
223475665|NCT01890655|DRUG|MT-1303-Low|
223475666|NCT01890655|DRUG|MT-1303-Middle|
223475667|NCT01890655|DRUG|MT-1303-High|
223475668|NCT02823353|DRUG|Fenofibrate|Fenofibrate 200mg/day
223744287|NCT00136305|BEHAVIORAL|Pictorial asthma action plan|
223475669|NCT02823353|DRUG|UDCA|UDCA 13-15mg/kg/day
223475670|NCT03720678|DRUG|etrumadenant|Etrumadenant is an A2aR and A2bR antagonist.
223475671|NCT03720678|DRUG|mFOLFOX|Oxaliplatin, Leucovorin and 5-fluorouracil given as part of standard mFOLFOX chemotherapy regimen
223475672|NCT03874832|DRUG|Dihydroergotamine|Dihydroergotamine is a semi-synthetic derivative of ergotamine tartrate.
223475673|NCT02664142|PROCEDURE|BIS Group|BIS monitoring will be used in the BIS Group patients. The BIS value will be known to the anaesthetist, who will be able to act accordingly.
223475674|NCT02664142|PROCEDURE|Non-BIS Group|BIS monitoring will be used in the Non-BIS Group patients. The BIS value will NOT be known to the anaesthetist and will be observed by a trained co-investigator, with subsequent evaluation.
223475675|NCT02664142|DRUG|Anaesthetics|Anaesthetics will be administered in both experimental groups, in order to maintain the required general anaesthesia.
223475676|NCT04195711|DIAGNOSTIC_TEST|"objective pediatric vision screen, blinq,"|hand-held birefringent screener for simultaneous foveation
223475677|NCT06482164|DIAGNOSTIC_TEST|Dry Eye Disease|Corneal sensitivity in patients who also have dry eye.
223475678|NCT01298830|DRUG|GLP-1 CellBeads|GLP-1 CellBeads are alginate microcapsules containing allogenic mesenchymal cells, transfected to secrete Glucagon like peptide-1. By implantation into brain tissue cavity after surgical evacuation of the hematoma, a volume of 500μl GLP-1 CellBeads which equals approximately 2330 GLP-1 CellBeads resulting in a total number of approximately 7.8 million cells is administered to the patient. The cells are removed by second surgery after a 14 days treatment period.
223475679|NCT05576311|OTHER|Focus Group|Focus Groups to capture information about the need for innovation in the diagnosis and monitoring of urinary symptoms.
223475680|NCT00624988|PROCEDURE|Vibration Therapy|Treatment will consist of 10 sessions of 60 seconds each with one minute intervals in between at 50 Hz frequency three times per week for three months.
223475681|NCT04716985|DIETARY_SUPPLEMENT|MOLECULAR HYDROGEN|Magnesium Tablet
223475682|NCT04716985|DIETARY_SUPPLEMENT|PLACEBO MAGNESIUM|Magnesium carbonate tablet
223582346|NCT07040878|BEHAVIORAL|Body Weight-Supported Treadmill Training|Body weight-supported treadmill training uses a harness-based system to partially offload body weight, promoting safe ambulation and gait normalization in early postoperative rehabilitation. The 6-week intervention includes five sessions per week within the 120-minute daily kinesitherapy program. Treadmill speed is individualized at baseline and increased by 0.5 km/h every two weeks, depending on tolerance. The unloading level remains constant and is individually adjusted to ensure safety.
224163608|NCT06442085|OTHER|Teaching of trauma resuscitation by using virtual reality simulation|"The intervention was teaching of trauma resuscitation by using VRS. Following welcome and a video lecture by Advance Trauma Life Support certified physician, the intervention group participants were orientated (15 minutes) to the VRS environment, head-mounted display (Oculus Rift S or Oculus Quest, Oculus, USA) and hand controllers by playing game First Steps (Oculus, USA). Then the participants were training by using the Internal Hemorrhage scenario in Trauma Simulator."
224163609|NCT06442085|OTHER|Teaching of trauma resuscitation by using mannequin based simulation|Volunteers were trained in groups of three or four by using mannequin-based rapid cycle deliberate practice simulation facilitated by a critical care physician. Next, the volunteers had 50 min training of the same trauma scenario as the intervention group. The simulation facility was set-up as close as possible to the virtual reality environment.
223582347|NCT07040878|BEHAVIORAL|Conventional rehabilitation|Conventional rehabilitation follows standard postoperative protocols after hip or knee arthroplasty. The 6-week program includes five weekly sessions. Gait training is conducted in hospital corridors under physiotherapist supervision, using assistive devices as needed (crutches, walkers). Daily therapy includes 120 minutes of kinesiotherapy (general exercises and gait training), 30 minutes of ergotherapy to improve functional independence, and three individualized physical therapy procedures (laser therapy, magnetic therapy, or electrotherapy) tailored to patient needs.
223744288|NCT00136305|BEHAVIORAL|Written asthma action plan|
223744289|NCT02360592|DRUG|Entecavir|In arm 1, Entecavir is used for 48 weeks and the follow up 24 weeks as conventional control, In arm 2 and 3, Entecavir is used for 8 weeks.
223744290|NCT02360592|DRUG|Interferon alfa-2b|In arm 2 and 3, interferon alfa-2b is used for 48 weeks
223744291|NCT02360592|DRUG|Interleukin 2|In arm 3, Interleukin 2 is used for 12 weeks
224163610|NCT05608200|DRUG|Lenvatinib, sintilimab plus TACE|Lenvatinib 12mg (body weight ≥60kg) or 8mg (body weight \<60kg) P.O. qd and sintilimab (200mg I.V. q3w) will be started at 3-7 days after the first TACE. TACE will be repeated if clinically indicated. Treatment of sintilimab will last up to 24 months. Patients will be allowed to have lenvatilib or sintilimab as a sigle agent and will be still considered on study when the other drug cause intolerable toxicity.
223475683|NCT03477656|PROCEDURE|Large volume specific immunoadsorption|1 to 2 sessions of large volume specific immunoadsorption using GLYCOSORB®-ABO column
223744292|NCT02360592|DRUG|Hepatitis B Vaccine|In arm 3, Hepatitis B Vaccine is used for 48 weeks
223744293|NCT04418999|DRUG|dexamethasone ophthalmic insert 0.4 mg, for intracanalicular use|Experimental
223744294|NCT04418999|DRUG|Loteprednol Etabonate 0.38% Ophthalmic Gel/Jelly|Active Comparator
224163611|NCT05608200|DRUG|Lenvatinib plus TACE|Lenvatinib 12mg (body weight ≥60kg) or 8mg (body weight \<60kg) P.O. qd will be started at 3-7 days after the first TACE. TACE will be repeated if clinically indicated. The interruption, dose reduction and discontinuation of lenvatinib depended on the presence and severity of toxicities according to the drug directions.
224163612|NCT02209259|OTHER|PROMIS Upper Extremity Function|
223475684|NCT03477656|PROCEDURE|Double Filtration Plasmapheresis|1 to 5 sessions of double filtration plasmapheresis
223475685|NCT04640922|DEVICE|Gedea Pessary pHyph|Vaginal tablet
223475686|NCT04640922|DEVICE|Placebo|Vaginal tablet
223475687|NCT00471484|BIOLOGICAL|recombinant interferon alfa-2b|
223475688|NCT00471484|DRUG|doxorubicin hydrochloride|
223475689|NCT00471484|DRUG|fluorouracil|
223744295|NCT02784210|DRUG|Methylprednisolone|3 days of corticosteroids (intravenous methylprednisolone at 1000 mg/day
224163613|NCT02209259|OTHER|Pain intensity|
224163614|NCT02209259|OTHER|PROMIS depression|
224163615|NCT02209259|OTHER|Positive affect negative affect scale (PANAS)|
224163616|NCT02209259|OTHER|standard PCS|
224163617|NCT02209259|OTHER|positively-adjusted version of the PCS|
224163618|NCT03878160|OTHER|Individual Interview|Individual Interviews will focus on exploring (a) changes after ACS, such as psychosocial changes and health behavior changes; (b) specific preferences for the MBCT intervention; and (c) potential barriers and facilitators of group videoconferencing and (d) blood spot data collection. Individual interviews will use a semi-structured interview guide. Individual interviews will be conducted until thematic saturation is reached. Individual interviews will be audio-recorded for transcription and data analysis.
224163619|NCT02763267|OTHER|Oral glucose tolerance test|75 gram oral glucose tolerance test (fasting) at: Visit 1 (pregnant \[4-14 weeks gestation\] and nonpregnant women); Visit 2 (pregnant subjects only at 24-28 weeks gestation); Visit 3 (pregnant subjects only at 6-12 weeks postpartum)
223475690|NCT00471484|DRUG|oxaliplatin|
223475691|NCT00471484|OTHER|diagnostic laboratory biomarker analysis|
223475692|NCT00471484|OTHER|immunoenzyme technique|
223475693|NCT00471484|OTHER|immunohistochemistry staining method|
223582348|NCT07041827|DIAGNOSTIC_TEST|Cardiovascular assessment|A cardiovascular assessment will be performed to screen for (sub)clinical cardiovascular diseases and to compare the prevalences in survivors of non-Hodgkin lymphoma and a control group.
223582349|NCT07041073|DEVICE|Active swLORETA Z-score Neurofeedback|Participants receive 10 sessions (25 minutes each, twice per week for 5 weeks) of EEG-based neurofeedback using the NeuroGuide® software and a 24-channel EEG recording system (eego™, ANT Neuro). The neurofeedback protocol is based on real-time swLORETA Z-score training targeting brain regions involved in emotion regulation. Feedback is provided via gamified visual displays when EEG activity moves toward normative patterns. This is an operant conditioning-based protocol designed to enhance emotional self-regulation.
223582350|NCT07041073|DEVICE|Yoked-sham swLORETA Z-score Neurofeedback|"Participants receive 10 sessions identical in appearance and duration to the active neurofeedback condition. However, the feedback provided is not based on their own EEG activity. Instead, it is pre-recorded data from a matched participant in the active group (yoked design), ensuring no real-time neurophysiological modulation occurs. The same EEG equipment and visual feedback interface are used to maintain blinding."
223582351|NCT07042126|DRUG|611|Double blind treatment period : 611 600 mg/450 mg at day 1，then 300 mg subcutaneous injection Q2W thereafter until week 16 Maintenance treatment period : 611 300 mg subcutaneous injection Q2W/Q3W until week 52.（The subjects in the placebo group during the double-blind treatment period need to be given a loading dose at week 16.）
223582352|NCT07042126|DRUG|Matching placebo|Double blind treatment period : placebo subcutaneous injection Q2W until week 16.
223582353|NCT07040436|DRUG|OPM-101|"OPM-101 will be administered in combination with an authorized regimen of Pembrolizumab.~Pembrolizumab will be administered by IV infusion either at a dose of 200 mg every 3 weeks or at a dose of 400 mg every 6 weeks, as per Principal Investigator's decision."
223582354|NCT07040709|OTHER|Opioid Analgesic (tramadol hydrochloride)|For postoperative pain management, a patient-controlled analgesia (PCA) pump will be routinely applied to the patient in our clinic. An infusion of an opioid (tramadol hydrochloride) at an appropriate dose will be administered via intravenous route through the pump, and the patient will be provided with detailed information about its use. Instead of continuous infusion, the device will deliver intermittent bolus doses when the patient's numeric rating scale (NRS) score is 4 or higher.
223744296|NCT02784210|DRUG|Prednisone|3 days of corticosteroids (oral prednisone at 1250 mg/day
223744297|NCT04511793|DEVICE|Medtronic Synchromed II pump|The pump will be placed during surgery and the pump will be filled with a combination of floxuridine (FUDR), dexamethasone, heparin, and saline.
223744298|NCT03525210|BIOLOGICAL|9-valent HPV vaccine|Vaccination
223475694|NCT00471484|PROCEDURE|adjuvant therapy|
223475695|NCT00471484|PROCEDURE|biopsy|
223475696|NCT00471484|PROCEDURE|neoadjuvant therapy|
223475697|NCT00471484|PROCEDURE|therapeutic conventional surgery|
223475698|NCT01738100|DRUG|Ticagrelor|
223475699|NCT01738100|DRUG|Clopidogrel|
223475700|NCT01738100|DRUG|Morphine Sulfate|
223475701|NCT01738100|DRUG|Saline|
223744299|NCT05418192|OTHER|Enriched Environment|Enriched Environment (EE) consisted of motor and sensory enriched play environment to promote participant's self-generated movements, exploration and task success. EE also included positioning in a graded manner. Visual stimulus and level appropriate vestibular stimulus was also given. Dosing of positioning and sensory inputs was done throughout the therapy. Primary Intervention will be given for 20 to 25 minutes intermittently for period of 4-5 hours a day, 5 days a week for 24 weeks.
223475702|NCT00000347|DRUG|Risperidone|
223475703|NCT00743756|DIETARY_SUPPLEMENT|home-delivered meals|3 diabetic meals per day, 7 days per week for 12 months
224069987|NCT00107237|DRUG|AEE788|AEE788 was available in the form of a hard gelatin capsule of 50 mg or 100 mg strengths and packaged in bottles.
224069988|NCT00107237|DRUG|everolimus|Everolimus was formulated as tablets of 2.5 mg and 5 mg strength and supplied in blister packs.
224069989|NCT05723614|BEHAVIORAL|TRUE HAVEN|The two components of the TRUE HAVEN intervention are: housing support for recently incarcerated people as well as family members of currently incarcerated people, and mental wellness training for neighborhood residents to participate in trauma-informed care training sessions.
224069990|NCT03368170|DRUG|Mesdopetam (IRL790)|Mesdopetam (IRL790) capsule
224069991|NCT02587533|OTHER|Hypoxia without dopamine|Target hemoglobin oxygen saturation (SpO2) 80%.
223475704|NCT00743756|DIETARY_SUPPLEMENT|home-delivered meals|diabetic meals 3 times per day, 7 days a week for six months
223475705|NCT00743756|BEHAVIORAL|diabetes education for 12 months|subjects in this group received diabetes education for 12 months
223475706|NCT03557593|OTHER|Educational|Multi component educational intervention in long-term care
223475707|NCT06612632|DRUG|research drug in combination with Toripalimab|research drug in combination with Toripalimab
223475708|NCT06612632|DRUG|Toripalimab|Toripalimab
224069992|NCT02587533|OTHER|Hypoxia with dopamine|Target hemoglobin oxygen saturation (SpO2) 80%. Dopamine dose 3 µg/kg/min.
224069993|NCT02587533|OTHER|Hyperoxia without dopamine|Nearly complete hemoglobin oxygen saturation.
224069994|NCT02587533|OTHER|Hyperoxia with dopamine|Nearly complete hemoglobin oxygen saturation. Dopamine dose 3 µg/kg/min.
224069995|NCT05672342|DRUG|Cannabidiol|Given PO
224069996|NCT05672342|DRUG|Delta-8-Tetrahydrocannabinol|Given PO
224069997|NCT05672342|DRUG|Placebo Administration|Given PO
224069998|NCT05672342|OTHER|Questionnaire Administration|Ancillary studies
224069999|NCT03591081|OTHER|Intellin smart phone application|This feasibility study will explore if creating an electronic platform Intellin smart phone application can promote and support timely self-referral for individuals with a recently healed DFU. It will explore the software applications acceptance and ease of use for patients.
224070000|NCT03041558|BEHAVIORAL|SafeCare+ (SC+)|SafeCare intervention with the additional Healthy Relationships (HR) module
223475709|NCT06380920|DEVICE|"AI Mindful Eating App"|"The investigators propose on design of an AI Mindful Eating App, to enhance individual's healthy lifestyle with subsequent weight-loss. Based on gut-brain axis, this is anticipated to be achieved by using CBT, in place of medication, to alleviate food addiction and proper nutrition intake during proper metabolic conditions and time, which are coordinated via AI."
223475710|NCT06380920|BEHAVIORAL|Outpatient regular follow-up|Outpatient regular follow-up
223475711|NCT04833894|BIOLOGICAL|Efgartigimod IV|Intravenous infusion of Efgartigimod
223475712|NCT00550342|DRUG|rituximab|375 mg/m2 intravenously for 4 doses
223475713|NCT06612697|OTHER|Radiology|A retrospective analysis was conducted using systematic records from the Department of Radiation Oncology at our hospital. The study included patients diagnosed with nasopharyngeal carcinoma through endoscopic pathological reports from January 1, 1984, to December 31, 2022. Eligible patients had baseline imaging (CT or MRI) prior to treatment, received definitive radiotherapy at our institution, and were followed up long-term with complete medical records.
223475714|NCT01118078|GENETIC|DNA methylation analysis|Undergo DNA methylation analysis
223475715|NCT01118078|GENETIC|gene expression analysis|Undergo gene expression analysis
223475716|NCT01118078|GENETIC|microarray analysis|Undergo microarray analysis
223475717|NCT01118078|GENETIC|reverse transcriptase-polymerase chain reaction|Undergo RT-PCR
223475718|NCT01118078|OTHER|diagnostic laboratory biomarker analysis|Correlative studies
223582355|NCT07040709|OTHER|Prophylactic analgesia (intravenous paracetamol)|All patients will receive routine prophylactic analgesia with 1 gram of intravenous paracetamol every 6 hours (which may be skipped if the patient's pain score is 2 or below and they do not request pain relief).
223582356|NCT07040709|OTHER|Rescue analgesia (intramuscular diclofenac sodium)|If the pain persists despite the administered analgesics and the patient's pain score remains 4 or above, rescue analgesia with intramuscular diclofenac sodium, which is routinely used in our clinic, will be administered.
223582357|NCT07040462|BEHAVIORAL|Child-Parent Psychotherapy (CPP)|CPP is a structured, evidence-based dyadic therapy designed for children aged 0-6 exposed to trauma and their caregivers. The intervention involves weekly joint sessions emphasizing safety, emotional expression, and caregiver reflective functioning. Delivered by trained psychologists either online or in person.
223582358|NCT07041190|DRUG|Abrysvo|Maternal RSV Vaccine (MV). RSV bivalent recombinant vaccine with subgroup A and B stabilised prefusion F antigens, single intramuscular injection of 0.5 mL, administered once, in pregnancy.
223582359|NCT07041190|DRUG|Nirsevimab|Infant RSV monoclonal antibody (mAb). For infants \<5kg: 50mg (0.5mL in pre-filled syringe), for infants ≥5kg: 100mg (1mL in pre-filled syringe), administered as a single intramuscular injection.
223582360|NCT06733558|PROCEDURE|Electroconvulsive Therapy|Electroconvulsive therapy (ECT) is a medical treatment that uses controlled electrical stimulation to induce a brief, generalized seizure in the brain. This intervention is performed under general anesthesia with muscle relaxants to ensure patient comfort and safety. ECT is typically used to treat severe depression, bipolar disorder, and other mental health conditions when other treatments, such as medication and psychotherapy, have not been effective.
223582361|NCT07041801|DRUG|hUC-MSCs treatment (low dose)|patients will receive conventional therapy plus low dose hUC-MSCs treatment,The dosage is 1E6 cells/kg.
223582362|NCT07041801|BIOLOGICAL|hUC-MSCs treatment (medium dose)|patients will receive conventional therapy plus medium dose hUC-MSCs treatment,The dosage is 3E6 cells/kg.
223582363|NCT07041801|BIOLOGICAL|hUC-MSCs treatment (high dose)|patients will receive conventional therapy plus high dose hUC-MSCs treatment,The dosage is 5E6 cells/kg.
223744300|NCT05418192|OTHER|Traditional Physcial Therapy|Participants of this group received traditional physical therapy based NDT. No additional dosing guidance was given to this group. No home program was specifically assigned to this group. No specific environmental modifications were made for this group.
223744301|NCT01648855|OTHER|Biological samples|To measure the levels of sFlt1, angiogenic and antiangiogenic factors at birth in maternal blood, umbilical cord blood and in the amniotic fluid
223744302|NCT03809507|OTHER|Qualtrics survey questions|"Qualtrics Survey:~For each of the scenarios, practitioners will be asked whether opioids are prescribed or not, and the type(s) of other analgesic medications that would be prescribed, the strength in mg, and the number of doses for each medication"
223475719|NCT05897671|OTHER|retrospective data analysis|Macular hole closure rate, visual acuity and OCT
223475720|NCT05812950|BEHAVIORAL|GST|Outpatient eating disorder treatment (5 individual pre-group sessions followed by 26 weekly group sessions + 8 optional individual sessions)
223475721|NCT05812950|BEHAVIORAL|CBT-E|Outpatient eating disorder treatment (20-40 weekly individual sessions)
223475722|NCT02969785|OTHER|G1: exercises for lumbar stabilization|Specific exercises for lumbar stabilization. The Group 1 (G1) will perform therapy with specific exercises for lumbar stabilization whith the Swiss ball as a therapeutic resource, including warming; stretching of hamstrings, paraspinals, trapezes; phasic perineal exercise; tonic perineal exercise; pelvic lumbar synergism; trunk mobility; mobility of the shoulder girdle; balance; and slow pelvic balance.
223582364|NCT07041801|DRUG|Placebo|patients will receive conventional therapy plus Placebo
223582365|NCT07041801|BIOLOGICAL|hUC-MSCs treatment （Double dose）|Double dosing is selected by the investigators and the sponsor based on the data from the single-dose part of the study. One superior dose is chosen for multiple dosing (tentatively set at 3E6 cells/kg, administered twice with an interval of 4 weeks; the actual dose, frequency and interval of multiple dosing can be adjusted according to the available data). During the trial, stable standard treatment is allowed.
223582366|NCT06893978|DRUG|Placenta organoids treatment|Placenta organoids in vitro treatment with heparin, aspirin, IVIG, filgrastim and metformin
223475723|NCT02969785|OTHER|G2: back strengthening exercises|Specific back exercises. The Group 2 (G2) will perform therapy including back strengthing exercise on a Roman chair machine to perform flexion and extension of trunk with load progressive training.
223475724|NCT03255356|OTHER|Survey|An anonymised questionnaire will be answered for each includable consecutive patient after verifying the absence of exclusion criteria.
223475725|NCT05550168|DEVICE|Low Level Laser therapy|The participants in the intervention group experienced a total of 7 session laser applications on their randomly determined molar region during the 12-week clinical trial period.
224304705|NCT01946191|BEHAVIORAL|24 months of personalized coaching through the EHR patient portal, with 24 scheduled contacts.|Participants were assigned to a specific coach, who contacted the participants via the EHR weekly for 1 month, biweekly in months 2 to 6, monthly in months 7 to 12, and quarterly in months 13 to 24, for a total of 24 scheduled contacts. Coaching group participants received brief questionnaires relevant to weight management, including a text field where they could discuss questions or barriers. On the basis of participant responses and self-monitoring data in the EHR flow sheets, coaches wrote a brief personalized note with advice on questionnaire topics and responses to any queries or barriers mentioned by the participant. Coaching participants who did not complete questionnaires or log information into the flow sheet for 2 weeks were considered inactive and were contacted by telephone or e-mail and invited to reengage at any time. Coaching participants were able to send secure messages to the coach.
223475726|NCT07025629|DRUG|Dapagliflozin 10 MG Oral Tablet [Farxiga]|One tablet of dapagliflozin 10 mg will be administered once daily from randomization and for 12 months period +/- 15 days..
223475727|NCT07025629|DRUG|One tablet of placebo of dapagliflozin 10 mg|One tablet of placebo of dapagliflozin 10 mg will be administered, per os, once daily from randomization and for 12 months period ± 15 days.
223475728|NCT06593418|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|Stereotactic body radiation therapy, which delivers precise, high-dose radiation non-invasively to generate thermal scarring to myocardial targets causing VT
223475729|NCT06798207|DRUG|TQB2102 for injection|TQB2102 for injection is a HER2 dual-antibody-drug Conjugate (ADC).
223582367|NCT06747455|DRUG|BCG for Therapeutic Use|After the subjects after transurethral bladder tumor resection were screened and randomly enrolled, the subjects were given intravesical infusion (experimental drug) within 2\~12 weeks after surgery, and perfused once a week for 6 consecutive times during the induction period; During the intensive phase, perfusion is given once every two weeks, 3 times in a row; During the maintenance period, perfusion was given once every 4 weeks, for a total of 19 perfusions, and the perfusion time continued until 1 year after surgery.
223582368|NCT06747455|DRUG|BCG for Therapeutic Use ( BI SAI JI )|After the subjects after transurethral bladder tumor resection were screened and randomly enrolled, the subjects were administered intravesical infusion (control drug) within 2\~12 weeks after surgery, and perfused once a week for 6 consecutive times during the induction period; During the intensive phase, perfusion is given once every two weeks, 3 times in a row; During the maintenance period, perfusion was given once every 4 weeks, for a total of 19 perfusions, and the perfusion time continued until 1 year after surgery.
223582369|NCT06756256|DEVICE|Customized insole|Participants will wear the produced customized insoles during daily activities and interventions for six weeks under the guidance of physical therapists working at Miso Hospital in Iksan City. As their continuation of their rehabilitation program, they will receive a conservative physiotherapy treatment five times a week for six weeks.
223582370|NCT06748703|DEVICE|CPAP Treatment|CPAP therapy will be administered to patients for 3 months. The CPAP device will be set to deliver a continuous flow of air at a prescribed pressure to keep the patient's airway open during sleep.
223582371|NCT05055310|DIAGNOSTIC_TEST|MicRNAs test|plasma micRNAs concentration
223582372|NCT00623168|DRUG|Ribavirin|7 Day multiple dosing regime based on weight and dosage day
223582373|NCT03921554|DRUG|Baricitinib|Baricitinib will be taken by mouth or via gastrostomy feeding tube or nasogastric tube as directed by the study doctor. Baricitinib will be dosed by patient age, weight range and estimated glomerular filtration rate (eGFR). Dosing formulations in use in this study will include 1 mg and 2 mg tablets and will be used without splitting. Dispersion will be permitted to aid in swallowing.
224304706|NCT01946191|BEHAVIORAL|Online self-monitoring|Participants were encouraged to log in daily and enter data on weight, diet, and physical activity.
224304707|NCT01946191|BEHAVIORAL|Real-time updates to Primary Care physicians|Referring PCPs of coaching group participants received regular support, including real-time progress reports with counseling tips delivered via the EHR, notification of weight change in increments of at least 10 pounds, and annual progress reports at 12 and 24 months.
224304708|NCT01629966|DRUG|Placebo|Matching 10 mg and 20 mg placebo tablets, once per day, oral administration,
224304709|NCT01629966|DRUG|Vilazodone|Vilazodone, 20mg, oral administration once per day.
223475730|NCT07043556|OTHER|Artificial Intelligence-Based ROTEM Interpretation|A structured artificial intelligence-based evaluation system that analyzes ROTEM (Rotational Thromboelastometry) parameters and provides treatment recommendations. ROTEM case data are converted into standardized clinical scenarios and evaluated by AI models using a predefined template. The AI output is compared to the consensus of expert clinicians regarding the presence and type of coagulopathy and the need for therapeutic intervention (e.g., fibrinogen, protamine, platelets, PCC, plasma). This intervention does not involve any patient-facing activity and is performed on de-identified data only.
223475731|NCT06725147|BEHAVIORAL|AI enabled wellness chatbot|Elomia uses generative AI to respond to user input about psychological stress and distress. It was trained on the responses of real therapists with expertise in cognitive-behavioral therapy. It provides an array of wellness interventions including exercises for calming; • exercises for falling asleep; • grounding techniques; • exercises to reduce anxiety; • breathing exercises; • exercises to improve self-esteem.
223475732|NCT06725147|BEHAVIORAL|Penn Digital Wellness Resources|This active control intervention consists of a variety of digital wellness and stress management resources that are freely available to all Penn students.
223475733|NCT05079321|DEVICE|Hydra-PEG|Zen™ RC scleral lenses (Hydra-PEG coated)
223475734|NCT05079321|DEVICE|Uncoated|Zen™ RC scleral lenses (non-coated)
223582374|NCT06900543|DRUG|NRT6003 Injection|Patients will be administered NRT6003 Injection via Intra-arterial infusion, and subsequently they will be assessed by PET/CT imaging within 24 hours for its distribution in the chest and upper abdomen, including extrahepatic shunts, intrahepatic distribution, and target lesion distribution as expected.
223582375|NCT06900543|DRUG|cTACE|Patients will receive cTACE treatment. And the investigators will select one or more chemotherapy drugs in combination with embolic materials for administration, based on the specific condition of the patient.
224070001|NCT03041558|BEHAVIORAL|SafeCare (SC)|SafeCare intervention as usual
224304710|NCT01629966|DRUG|Vilazodone|Vilazodone, 40mg, oral administration once per day.
224304711|NCT03936673|PROCEDURE|Percutaneous nephrostomy|
224304712|NCT03138226|PROCEDURE|uterus transplantation|
223475735|NCT06726460|DIAGNOSTIC_TEST|Nova Stat Profile pHOx Ultra Analyzer System(Nova)|This group involves the use of Nova for measuring serum and whole blood samples. The results from Nova will be compared with those obtained from P1.
224304713|NCT04866277|OTHER|Fast-track referral for reference services|Activation of fast-track referral for specialized units and care programs for the four psychosocial and behavioural risk factors under study.
224304714|NCT06231394|OTHER|multimodal pelvic floor rehabilitation|A multimodal pelvic floor rehabilitation program will be performed on all children for 10 weeks, two days a week and approximately 45 minutes. A multimodal pelvic floor rehabilitation will include education, bladder and bowel training, manual techniques, exercise training (diaphragmatic breathing exercise, pelvic floor muscle training, trunk stabilization exercises based on developmental kinesiology) and a home program. The home program will be given on other days of the week.
223475736|NCT06726460|DIAGNOSTIC_TEST|Novel POCT dry electrolyte analysis system(P1)|This group involves the use of P1 for measuring serum and whole blood samples. The results from P1 will be compared with those obtained from Nova.
223475737|NCT04610138|DRUG|CNM-ZnAg|ZnAg liquid solution
223582376|NCT04505267|OTHER|Hafnium Oxide-containing Nanoparticles NBTXR3|Given IT or intranodally
223582377|NCT04505267|RADIATION|Radiation Therapy|Undergo RT
223582378|NCT06664866|DIAGNOSTIC_TEST|EchoNet-LVH Assessment|The AI algorithm is previously described (Duffy et al. JAMA Cardiology 2022) and will remain unchanged throughout the course of the study. A pre-determined threshold based on prior experiments and analysis has been decided prior to the study. From each site, approximately 100,000 echocardiogram studies will be reviewed by EchoNet-LVH for approximately 500 patients to be flagged.
223582379|NCT06930677|DEVICE|embolization therapy|MSK embolization
223582380|NCT00534287|DRUG|meropenem|Empirical antibiotic therapy with 3 x 1 g intravenous meropenem. Dosage is adjusted in case of renal dysfunction. Recommended duration of therapy is 7 days but can be extended up to 14 days.
223582381|NCT00534287|DRUG|meropenem, moxifloxacin|Empirical antibiotic therapy with 3 x 1 g intravenous meropenem plus 1 x 400 mg intravenous moxifloxacin. Dosage of meropenem is adjusted in case of renal dysfunction. Recommended duration of therapy is 7 days but can be extended up to 14 days.
223582382|NCT02703688|BEHAVIORAL|Healthy Homes|The Healthy Homes Behavioral Intervention (HHBI) will be delivered during 8 sessions over 10 weeks using home visitations. The first 6 sessions occur weekly and provide education about healthy dietary intake including caloric recommendations for preschool aged children, healthy sleep goals, active play and screen time limits, and family routines and organization. Each session will include a parent-child interaction component to teach child behavior management skills related to intervention goals. Two final sessions occur every other week to provide problem solving and planning for maintenance of treatment effects.
223582383|NCT02703688|OTHER|Usual Care|A pediatrician with experience delivering weight management treatment to children will deliver a single session, 1-hour treatment to families. Content to be delivered during the session will include lifestyle recommendations currently recommended by the AAP.
223582384|NCT06903286|DRUG|SPG302|Open label SPG302 to be self-administered daily by eligible participants for 52 weeks.
223582385|NCT03859739|DRUG|MK-8558|Single dose of MK-8558 administered as a tablet at a dose up to 1600 mg.
223582386|NCT00970450|DRUG|Paracetamol|Paracetamol 1 g i.v. once
223582387|NCT00970450|DRUG|Tropisetron|Tropisetron 5 mg i.v. once
224070002|NCT02977169|RADIATION|PORT|3-dimensional conformal or intensity-modulated radiotherapy, total dose of 50.4 Gy, 1.8 Gy once daily over 5.5 weeks, following the standard and consistent PORT CTV delineation guideline
224304715|NCT04269564|DEVICE|stepwise PEEP|"* a PEEP of 4 cmH2O will be used after intubation till 5 minutes after pneumoperitonium, and adjusted in a step wise approach after lung ultrasound by adding 2 cmH2O, repeating ultrasound 5 minutes after every change in peep till no lung collapse is detected by lung ultrasound with a maximal peep of 10 cmH2O, or if hemodynamic instability occurs.~* Lung ultrasound examination will be performed at a minimum three times in each patient; the first will be performed 1 min after starting mechanical ventilation of the lungs, 5 minutes after pneumoperitonium, 5 min after every peep increase in stepwise peep group and the last time at the end of the surgery.~We define anaesthesia-induced atelectasis to be significant if any region has a consolidation score of ≥ 2."
223475738|NCT04610138|DRUG|Placebo|Water
223475739|NCT02003144|BIOLOGICAL|eculizumab|
223582388|NCT00970450|DRUG|Placebo|Saline
223582389|NCT02818348|DRUG|darunavir/cobicistat|800/150 mg, once daily during 35 days + etravirine 400 mg, once daily during 14 days
223582390|NCT02818348|DRUG|etravirine|400 mg, once daily during 28 days + darunavir/cobicistat 800/150 mg, once daily during 7 days
223582391|NCT05665400|DEVICE|Bloomlife Lovelace FT|Bloomlife Lovelace FT is a non-invasive, wireless, external measurement system used to measure accelerometer and electrophysiological signals on pregnant women with a singleton pregnancy, by acquiring biopotential signals from abdominal surface electrodes.
223582392|NCT05366491|DIAGNOSTIC_TEST|Il-38 serum level|measurement of serum levels of IL-38
223582393|NCT06194955|DRUG|GIP(1-42)|Infusion
223582394|NCT06194955|DRUG|GLP-1|Infusion
223582395|NCT06194955|DRUG|GLP-2|Infusion
223582396|NCT06194955|OTHER|Placebo|Saline
223582397|NCT01882517|DIETARY_SUPPLEMENT|Yogurt that contains plant stanol esters|
223582398|NCT01882517|DIETARY_SUPPLEMENT|Placebo yogurt|
223582399|NCT03023254|OTHER|Hydrotherapy|3-week Avène hydrotherapy
223582400|NCT03062618|DRUG|PRCL-02|Oral tablet(s) administered with water
223582401|NCT03062618|DRUG|Placebo Oral Tablet|Administered with water
223582402|NCT01146652|DRUG|SAR153191 (REGN88)|"Pharmaceutical form: solution~Route of administration: subcutaneous"
223582403|NCT00941369|DRUG|Insulin Glargine (HOE901)/NPH Insulin|"Arm 1: Subcutaneous injection of Insulin Glargine with the TactiPen® injector pen once daily at any time, but each day at the same time~Arm 2: Subcutaneous injection of Protamine Hagedorn basal insulin with the TactiPen® injector pen once or twice daily at the discretion of the treating physician~The starting dose is 10 I.U. (NPH basal insulin) resp. 10 U (insulin glargine) per day.~The dose adjustments will be based on the results of self-monitoring."
223582404|NCT03919227|PROCEDURE|empty bladder before inserting UAS|In group 1, investigator empty the bladder of urine with a catheter before inserting UAS, so that we can see if the empty bladder is easier for inserting UAS.
223582405|NCT03919227|PROCEDURE|do not interfere with the filling degree of bladder|In group 2, investigator does not interfere with the filling degree of bladder before inserting UAS, so that we can see if the filling degree of bladder has impact on the insertion of UAS.
223582406|NCT01711281|DEVICE|Intracardiac Impedance Measurement Algorithm (integrated in CRT-D device)|
223582407|NCT03395301|DEVICE|Coil|Fiber platinum coil were inserted into the interstitial part of the tubes of patients in hydrosalpinx through hysteroscopy
223582408|NCT03373032|OTHER|Stiper|"Stiper silicon tablets, for acupunture's stimulation of meridian points, the Stiper's chemical composition is nothing more than SiO 2 - (silicon dioxide) the shape of the quartz stone (silicon rich).They will perform the treatment with the Stiper silicon inserts, which will be applied and fixed by plasters at the acupuncture points, duration of 05 minutes."
223582409|NCT03373032|OTHER|Acupuncture|Treatment with a systemic needle to stimulate meridian acupuncture points, treatment begins with asepsis with 70% alcohol-soaked cotton in the region of the acupoints and then sterile and disposable needles (0.25 mm x 30 mm) will be inserted in both limbs, will be placed in the following regions: shoulders, thorax, legs and feet with the puncture order from bottom to top,duration of 30 minutes.
223582410|NCT03373032|OTHER|Exercise|Will perform pre-defined kinesiotherapy based on the stretching of cervical musculature and scapular waist, lumbar spine and lower limbs with exercises for WM and upper limb (MS) and lower limb (MI) strength with a duration of 30 minutes.
223582411|NCT03373032|OTHER|Follow Up|Use of the therapeutic massager, in hands and feet, to stimulate region's sensitivity, women who were submitted to the chemotherapy treatment with Taxane and continued with changes in sensitivity. Once in each dermatome, adding time of 5 minutes of application on average.
223582412|NCT03373032|OTHER|Observation|The waiting room (observation) group did not receive any intervention. Conduct evaluations of the research protocol as groups A, B and C.
223582413|NCT05562349|DRUG|Clavulanic Acid Only Product|Drug will be given in 250mg capsules
223582414|NCT05562349|DRUG|Placebo|Capsule with no active medication - identical to drug capsule
223582415|NCT04485689|DRUG|Capsaicin Topical - alone|5x7 cm2 capsaicin patch applied on the dorsal area of the hand and left in place for 24 hours
223582416|NCT04485689|DRUG|Placebo - alone|5x7 cm2 patch applied on the dorsal area of the hand and left in place for 24 hours
223582417|NCT04485689|DRUG|Capsaicin Topical - ice|5x7 cm2 capsaicin patch applied on the dorsal area of the hand and left in place for 24 hours. Ice will be applied on top of the patch 1.5 hrs post patch application and left in place for 1 hr.
223582418|NCT04485689|DRUG|Placebo - ice|5x7 cm2 patch applied on the dorsal area of the hand and left in place for 24 hours. Ice will be applied on top of the patch 1.5 hrs post patch application and left in place for 1 hr.
223582419|NCT05908968|DIETARY_SUPPLEMENT|ELO water|Drinking 1.5 litres daily of ELO water for 12 weeks
224162472|NCT06904183|COMBINATION_PRODUCT|LEN+SIN+DEB-TACE+HAIC|"For DEB-TACE, superselective catheterization is performed and DEBs loaded with pirarubicin is use for chemoembolization. The embolization end point was blood stasis of the tumor-feeding arteries. In order to reduce the risk of complications, the embolization end point was not achieved in the initial TACE but in the second or third TACE session. After each chemoembolization, the microcatheter is reserved at the main hepatic tumor-feeding artery. The FOLFOX-based regimen is intra-arterially administered. During follow-up, the treatment of DEB-TACE and/or HAIC will be repeated for viable tumors based on the evaluation of the follow-up laboratory and imaging examination.~Lenvatinib 12mg (body weight ≥60kg) or 8mg (body weight \<60kg) P.O. qd and sintilimab 200mg I.V. q3w will be started with 7 days after the first DEB-TACE+HAIC."
224304716|NCT04840966|DIAGNOSTIC_TEST|Flavor test|A simplified self-administrable flavor test has been proposted to all the enrolled subjects
224304717|NCT04840966|OTHER|Self-assesment questionnaire|"Questionnaire to score subjective chemosensory function (smell and flavor) before and after COVID-19 using a 0-10 scale with 0 corresponding to no smell/flavor perception and 10 corresponding to excellent smell/flavor perception."
224304718|NCT04568031|DRUG|AZD1222|For subjects in part 1 will have that route of Administration as Intramuscular, 5 × 1010 vp (nominal, ± 1.5 × 1010 vp) on V2
224304719|NCT04568031|DRUG|0.9% (w/v) saline|For subjects in placebo will have that route of Administration as Intramuscular 0.9% (w/v) saline on V2 and V6.
224304720|NCT01180439|DEVICE|Adjustment of ventilator settings (device)|Decrease in pressure support, increase in respiratory back-up rate, increase in expiratory positive airway pressure (EPAP) to counteract effect of PEEPi, and adjustment of cycling (at higher percentage of peak inspiratory flow)
224304721|NCT05918224|DRUG|Streptococcus salivarius K12|The patients in intervention group were treated with Streptococcus salivarius K12 lozenges three times a day after gargling from the first day of radiotherapy up to 1 week after the end of treatment. Streptococcus salivarius K12 is dissolved in the mouth and then swallowed.
224304722|NCT05918224|DRUG|Streptococcus salivarius K12 simulants|Patients in control group were treated with Streptococcus salivarius K12 simulants, and its use method and use time are the same as intervention group.
224304723|NCT05320341|PROCEDURE|TIVA|During the anesthesia maintenance of the TIVA group, 3 μg.kg-1 fentanyl, 0.01-0.05 mg.kg-1 midazolam, and 0.2 mg.kg-1 rocuronium bromide were applied throughout the operation to keep BIS between 40 and 60, approximately once every 45 minutes.
224304724|NCT05320341|PROCEDURE|SEVO|During the anesthesia maintenance of the SEVO group, 2-3% sevoflurane (1-2 MAC), 3 μg.kg-1 fentanyl and 0.2 mg.kg-1 rocuronium bromide were applied throughout the operation to keep BIS between 40-60.
224304725|NCT02567318|DEVICE|MRI-scan|Magnetic resonance imaging scan of the brain
224304726|NCT05068375|DIAGNOSTIC_TEST|Thrombophilia screening|Genetic thrombophilia and acquired thrombophilia screening
224304727|NCT04154306|DIETARY_SUPPLEMENT|Red clover|2 weeks of Red clover
224304728|NCT04154306|DIETARY_SUPPLEMENT|Placebo|2 weeks of Placebo
224304729|NCT00819975|DIETARY_SUPPLEMENT|Casein|
224304730|NCT00819975|DIETARY_SUPPLEMENT|Whey Isolate|
224304731|NCT00819975|DIETARY_SUPPLEMENT|Whey Hydrolysate|
224304732|NCT00819975|DIETARY_SUPPLEMENT|Alphalact-Albumin|
224304733|NCT02240342|DRUG|Bone marrow transplant into ovarian artery|Bone marrow progenitors mobilized to peripheral blood, obtained by plasmapheresis and infused into the ovarian artery
224304734|NCT00545675|DRUG|Abilify(aripiprazole)|Abilify and Depakote in 24-week treatment of mania in patients with bipolar disorder
223475740|NCT06119165|BEHAVIORAL|Environmental nudges|Participants will view protein, frozen meal, and snack products with eco-labels applied. For each category, they will then be instructed to select 1 item from that category they wish most to purchase. Categories will be shown in random order. If a participant selects a product with a red eco-label, they will be shown a peer comparison message and will be given an opportunity to switch to a product with a yellow or green eco-label.
223475741|NCT06894277|BEHAVIORAL|iTRAC-HERO|"iTRAC-HERO will consist of eight, approximately 45-minute, gamified digital modules of 4-6 activities (games, videos, etc.). No instruction is needed to use the program. Content will use gender- and sexuality-inclusive language and avoid heteronormative descriptions of risk. This content will include strategies for (and practice with) recognizing and managing emotions, particularly in relation to sexual health situations, to enhance the likelihood that the emotion regulation and sexual health education provided can be applied to experiences that are emotionally arousing and lead to risk."
223475742|NCT05965752|OTHER|BrainHQ/Active Comparator Activity|BrainHQ platform provides a set of cognitive activities, like puzzles and games, that are cognitively stimulating and actively engage participants but do not continuously and adaptively challenge them. These activities are designed to be a face-valid, active comparison approach to cognitive therapy, thus participants are blinded, attention time is matched, and overall user experience is identical to the active arms.
223475743|NCT05965752|OTHER|BrainHQ|BrainHQ is an online cognitive training program, and has been used to improve cognitive function among persons with cognitive impairment based on principles of neuroplasticity.
224162473|NCT06904183|COMBINATION_PRODUCT|LEN+SIN+DEB-TACE|"For DEB-TACE, superselective catheterization is performed and DEBs loaded with pirarubicin is use for chemoembolization. The embolization end point was blood stasis of the tumor-feeding arteries. In order to reduce the risk of complications, the embolization end point was not achieved in the initial TACE but in the second or third TACE session. During follow-up, the treatment of DEB-TACE will be repeated for viable tumors based on the evaluation of the follow-up laboratory and imaging examination.~Lenvatinib 12mg (body weight ≥60kg) or 8mg (body weight \<60kg) P.O. qd and sintilimab 200mg I.V. q3w will be started with 7 days after the first DEB-TACE."
223744303|NCT04748133|DEVICE|acupuncture needles|"Site of acupuncture points:~* Du 26: At junction of the upper and middle third of philtrum.~* Ren 17: On the midline level with the 4th intercostal space midway between the nipples.~* LI4 (Large Intestine 4): On the dorsum of the hand, between the 1st and 2nd metacarpal bones~* HT7 (Heart 7): On the ulnar end of the transverse crease of the wrist, in the small depression between the pisiform and ulna bones~* LV3 (Liver 3): On dorsum of the foot in a depression distal to the junction of the 1st and 2nd metatarsal bones.~* ST36 (Stomach 36): Antero-lateral leg, 1 middle-finger breadth next to the anterior crest of tibia, 3 cun under the depression lateral to the patellar ligament.~* PC6 (Pericardium 6): Palmar aspect of the forearm, between the tendons, 2 cun away from the transverse crease of the wrist"
223582420|NCT03476876|COMBINATION_PRODUCT|Dermacell|Subject will receive treatment for one non-healing deep diabetic foot ulcer using one Dermacell acellular matrix. Subject will be followed up to 16 weeks post treatment, or until wound has closed, whichever comes first.
223582421|NCT03476876|COMBINATION_PRODUCT|Integra|Subject will receive treatment for one non-healing deep diabetic foot ulcer using one Integra bilayer cross-linked matrix. Subject will be followed up to 16 weeks post treatment, or until wound has closed, whichever comes first.
224304735|NCT00545675|DRUG|Depakote (divalproate)|Placebo and Depakote in 24-week treatment of mania in patients with bipolar disorder
223582422|NCT02499692|DEVICE|SYNERGYTM Coronary Stent System|SYNERGYTM MONORAILTM Everolimus-Eluting Platinum Chromium Coronary Stent System
224304736|NCT03801382|DEVICE|IntelliSpace Cognition (ISC)|Philips ISC is a Class-II Medical Device in the US and provides objective data regarding cognition via scoring algorithms that HCPs can use to inform diagnostic decision making and treatment planning. It enables tracking cognition over time and offers the possibility of new outcome measures. ISC can be used in a variety of healthcare environments such as neurology and neuropsychology practices.
223582423|NCT06521073|BEHAVIORAL|education|"Patient Information Form (HBF): This form, prepared by scanning the literature, includes the patient\&#39;s age, gender, marital status, education level, profession, social security, place of residence, presence of caregivers in the family, from whom he/she receives care, chronic diseases, the side on which knee prosthesis is applied, knee prosthesis. It is a form consisting of questions about your training status, who you received your training from, and your satisfaction with the training.~Barthel Index (BI): Barthel activities of daily living index is an evaluation scale used to measure an individual\&#39;s performance in daily living activities. The index is used for activities of daily living in 10 domains. The Turkish validity and reliability of the Barthel index, developed by Barthel and Mahoney (1965), was determined by Küçükdeveci et al. (17)."
223582424|NCT01198457|DRUG|Clodronate (Bonefos, BAY94-8393)|Random group of patients in oncology clinic
223582425|NCT04453813|DRUG|Toripalimab plus concurrent chemo-radiotherapy|"1. Toripalimab: 240 mg, intravenous injection over 60 minutes (Q3W); 2 cycles of toripalimab are concurrently used during radiotherapy and other 9 cycles of toripalimab are used after the end of radiotherapy. (A total of 11 cycles).~2. Concurrent cisplatin chemotherapy: cisplatin is given at a dose of 100 mg/m2 via a continuous intravenous infusion during radiotherapy and starts on the 1st day of radiotherapy for 2 cycles. 1 cycles per 3 weeks.~3. IMRT: PTVnx#60.0Gy/27Fr/2.22Gy; PTVnd# 60-64Gy/27Fr/2.22-2.37Gy; PTV1#54Gy/27Fr/2.00Gy"
223744304|NCT04748133|OTHER|placebo|no treatment
223744305|NCT01374087|DRUG|Triptorelin 22.5 mg|Triptorelin: A single, intramuscular injection (22.5 mg), preferably 2 months before brachytherapy.
223744306|NCT01374087|RADIATION|Brachytherapy|Brachytherapy: Low or high dose rate.
224304737|NCT03801382|DIAGNOSTIC_TEST|Paper-Pencil Tests|The same cognitive tests that are on the ISC platform are performed using paper and pencil (rather than digitally) as is the case in standard clinical practice.
224304738|NCT01233921|BIOLOGICAL|palifermin|Given IV
223744307|NCT03830944|DIAGNOSTIC_TEST|Blood sampling|Assessment of complete blood count, biochemistry, inflammatory biomarkers, adhesion molecules
224162474|NCT03074318|DRUG|Avelumab|Given IV
224162475|NCT03074318|DRUG|Trabectedin|Given IV
224304739|NCT01233921|OTHER|flow cytometry|Correlative studies
224304740|NCT01233921|OTHER|laboratory biomarker analysis|Correlative studies
224304741|NCT01233921|OTHER|pharmacological study|Correlative studies
224304742|NCT05971654|DRUG|azithromycin|azithromycin.:500 mg PO once for 5 days every month
223475744|NCT05965752|OTHER|PASC CoRE|PASC CoRE is a manualized, adaptable cognitive rehabilitation intervention adapted from Goal Management Training and other evidence based programs that improve attention and executive functions, among other cognitive domains.
224162476|NCT02275520|DEVICE|NIO Adult device|IO access-1
223475745|NCT05965752|DEVICE|tDCS-active|"Transcranial direct current stimulation (tDCS) will use a device specifically for home-based use. This device delivers a weak electrical current of 2.0 mA passed through two electrodes placed on the scalp to target the dorsolateral prefrontal cortex region of the brain. The electrodes are single-use for each session and can be attached to a headset by snapping into place.~The device has a user-friendly interface and a large-button keypad, making it is easy to use at home."
223744308|NCT03830944|DIAGNOSTIC_TEST|transthoracic echocardiography|Assessment of the ventricular anatomy, size, function, speckle tracking, myocardial strain, valvular function.
223744309|NCT03830944|DIAGNOSTIC_TEST|Late Gadolinium-Enhancement Cardiac Magnetic Resonance|Assessment of the ventricular anatomy, function, viability, degree of fibrosis, quantification of infarct size, mass.
223744310|NCT03830944|DIAGNOSTIC_TEST|Coronary Angio Computed Tomography|Assessment of coronary plaque anatomy, morphology, vulnerability features, quantification of epicardial adipose tissue
223744311|NCT00004159|DRUG|gemcitabine hydrochloride|
223744312|NCT00004159|DRUG|paclitaxel|
223744313|NCT01380509|DRUG|Metronidazole|Capsules, single-dose, fasting
223744314|NCT01380509|DRUG|Flagyl|Capsules, single-dose, fasting
223744315|NCT03011307|DRUG|Oxytocin|spinal injection of oxytocin
223744316|NCT03011307|DRUG|Placebo|spinal injection of placebo
224162477|NCT02275520|DEVICE|Bone Iniection Gun|IO access-2
224162478|NCT02275520|DEVICE|EZ-IO|IO access-3
224162479|NCT02275520|DEVICE|Jamshidi Intraosseous Needle|IO access-4
224162480|NCT02275520|DEVICE|Cook Intraosseous Needle|IO access-5
223475746|NCT05965752|DEVICE|tDCS-sham|tDCS devices used in the sham arm will be pre-programmed to deliver the same ramp up/down at the beginning/end of the 30-minute period as the active arm, except with no current otherwise delivered during the session.
223475747|NCT06339775|DRUG|Blinatumomab|"patients with positive MRD were treated with Blinatumomab 28μg×5-15 days, followed by DLI treatment.~(MNC infusion is about 5×10\^7/kg\~1×10\^8/kg). Patients with hematologic recurrence were given Blinatumomab 9μg D1-4,11.66μg d5-7,28μg Starting from d8 （8 to 21 days in total）, followed by DLI treatment (infusion of MNC approximately 5×10\^7/kg\~1×10\^8/kg)."
223475748|NCT03934671|DEVICE|Antioxidant dressing (active product)|"Antioxidant dressing (active product), covered with secondary dressing. Compression bandage if necessary.~Device: Reoxcare®"
223475749|NCT03934671|DEVICE|Usual care dressing that create a moist environment (standard clinical practice)|Usual care dressing; moist environment dressing chosen from the study centres' formulary (hydrocolloid, alginate, polyurethane foam dressings, silver dressings). Compression bandage if necessary
223475750|NCT04354935|DEVICE|rTMS basic|1 session per day, for 4 or 6 weeks.
223475751|NCT04354935|DEVICE|rTMS VIIT|5 sessions per day, for 2 weeks.
223475752|NCT04354935|DEVICE|rTMS SAINT modified|8 sessions per day, for 1 week.
223475753|NCT04354935|DEVICE|rTMS SAINT|10 sessions per day, for 1 week.
223475754|NCT04039620|OTHER|Observational study, no interventions expected|No interventions are planned
223475755|NCT05098327|DRUG|Pioglitazone 30 mg|pioglitazone 30 mg dose 1 tab daily will be given for 12 weeks
223475756|NCT05098327|DRUG|Placebo|placebo pills containing cellulose 1 pill daily will be given for 12 weeks
223475757|NCT00006320|PROCEDURE|determine blood levels of anti-HIV drugs|
223475758|NCT00198991|DRUG|Cyclophosphamide|Cytostatic drug
223475759|NCT00198991|DRUG|Dexamethasone|Antileukemic drug
223475760|NCT00198991|DRUG|Vincristine|Cytostatic drug
223744317|NCT01185119|DRUG|native glp-1 (7-36)|During hyperglycemic clamp and GLP-1 versus placebo infusion 10 men will be CNS-PET scanned
223744318|NCT00271947|BIOLOGICAL|Autologous Stem Cell Transplantation|Autologous Stem Cell Transplantation will be performed after conditioning regimen
223744319|NCT04816695|DEVICE|VOC analysis|VOC analysis in exhaled air with e-noses and mass spectrometry.
223744320|NCT02157155|BIOLOGICAL|LPS|LPS is endotoxin from gram negative bacteria. It is used scientifically to mimic infection lasting 4-8 hours.
223744321|NCT03305328|DEVICE|Transcranial Alternating Current Stimulation|Transcranial Alternating Current Stimulation passes a weak, 2 mA sinusoidal current through the scalp to the cortex at a specified frequency. Previous evidence suggests this exogenous sinusoidal stimulation interacts with the endogenous, cortical sinusoidal oscillatory activity, resulting in modulations of cortical oscillations. The intervention is non-invasive and virtually painless with no lasting adverse side-effects.
223744322|NCT06203925|DIAGNOSTIC_TEST|Hepatitis C virus self-test (oral fluid HCVST)|"The participant will be able to choose between oral-fluid or blood-based HCVST. The package will include an HCV OraQuick ® HCV Self-Test kit, (OraSure Technologies, Inc, Bethlehem, PA) or a Wondfo® HCV Self-Test (Guangzhou, P.R. China) at Primary Study.~At Ancyllary study, the individuals attending PrEP consultations at INI/FIOCRUZ will be invited to perform HCVST using blood-based and oral-fluid kits."
224070003|NCT02977169|DRUG|Platinum-based two drug chemotherapy (cisplatin/carboplatin + vinorelbine or cisplatin/carboplatin + pemetrexed regimen)|Cisplatin/ carboplatin + vinorelbine regimen for squamous cell lung carcinoma Cisplatin/carboplatin + pemetrexed regimen for lung adenocarcinoma
224070004|NCT01469910|DRUG|Simotinib Hydrochloride|Single ascending doses: 25 mg、50 mg、100 mg、150 mg、225 mg、300 mg、400 mg、500 mg、600 mg、750 mg
224070005|NCT01469910|DRUG|Placebo|Single ascending doses: 150 mg、225 mg、300 mg、400 mg、500 mg、600 mg、750 mg
224070006|NCT06541405|DRUG|NK520|The number of NK520 cell infused for each dosing should be calculated base on the body weight of subject. NK520 will be administered through intravenous infusion.
224070007|NCT04669834|OTHER|a traditional therapeutic knee rehabilitation program|mini-squatting exercise and clamshell exercise
224070008|NCT04669834|OTHER|core stability exercise|the principles of core stability will be explained to patients before initiation of treatment and patients will be asked to comply with these principles during exercise. These principles include learning how to activate transversus abdominus by abdominal bracing without allowing pelvis tilting and ensure neutral spine and diaphragmatic breathing during exercise.
224162481|NCT00093756|RADIATION|3-dimensional conformal radiation therapy|
223475761|NCT00198991|DRUG|Daunorubicin|Cytostatic drug
224162482|NCT00093756|DRUG|bortezomib|Given IV
223475762|NCT00198991|DRUG|Asparaginase|Cytostatic drug
223744323|NCT06203925|DIAGNOSTIC_TEST|Hepatitis C virus self-test (blood-based HCVST)|The participant will be able to choose between oral-fluid or blood-based HCVST. The package will include an HCV OraQuick ® HCV Self-Test kit, (OraSure Technologies, Inc, Bethlehem, PA) or a Wondfo® HCV Self-Test (Guangzhou, P.R. China) at Primary Study. At Ancylary Study, the individuals attending PrEP consultations at INI/FIOCRUZ will be invited to perform HCVST using blood-based and oral-fluid kits.
224070009|NCT01662440|BIOLOGICAL|Rabies|Subjects received three doses of Rabies, whole virus vaccine (inactivated, Germany).
224070010|NCT01662440|BIOLOGICAL|Japanese Encephalitis|Subjects received two doses of Japanese Encephalitis vaccine.
224070011|NCT01662440|OTHER|Placebo|Subjects received either two, three, four or five doses of normal saline, 0.9% w/v sodium chloride depending on the vaccine group.
224162483|NCT00093756|DRUG|paclitaxel|Given IV
224162484|NCT00093756|DRUG|carboplatin|Given IV
223475763|NCT00198991|DRUG|Methotrexate|Cytostatic drug
223475764|NCT00198991|DRUG|Cytarabine|Cytostatic drug
223475765|NCT00198991|DRUG|Mercaptopurine|Cytostatic drug
223475766|NCT00198991|DRUG|G-CSF|Growth factor
223475767|NCT00198991|DRUG|Vindesine|Cytostatic drug
223475768|NCT00198991|DRUG|Etoposide|Cytostatic drug
223475769|NCT00198991|DRUG|Prednisolone|Antileukemic drug
223475770|NCT00198991|DRUG|Adriamycin|Cytostatic drug
223475771|NCT00198991|DRUG|Thioguanine|Cytostatic drug
223475772|NCT00198991|DRUG|Teniposide|Cytostatic drug
223475773|NCT00198991|PROCEDURE|CNS irradiation|Cytostatic drug
223475774|NCT00198991|PROCEDURE|Mediastinal Irradiation|Irradiation
223475775|NCT00198991|PROCEDURE|Stem cell transplantation (SCT)|Stem cell transplantation
223475776|NCT00198991|DRUG|Idarubicin|Cytostatic drug
223475777|NCT00198991|DRUG|Fludarabine|Cytostatic drug
223475778|NCT00198991|DRUG|Cladribine|Cytostatic drug
223475779|NCT05031442|DEVICE|RH1 (low waist)|Investigational product variant 1 low waist
223475780|NCT05031442|DEVICE|Reference variant 1 (low waist)|Reference product variant 1
223475781|NCT05031442|DEVICE|RC2 (high waist)|Investigational product variant 2 high waist
223475782|NCT05031442|DEVICE|Reference variant 2 (high waist)|Reference product variant 2
223475783|NCT01324947|DRUG|pomalidomide|Oral pomalidomide 4 mg on Days 1-21 of 28-day cycle until progressive disease (PD) or unacceptable toxicity
223475784|NCT04401332|OTHER|mobile health app|asthma symptom monitoring via a clinically integrated mobile health (mHealth) app installed on patients' smartphones
223475785|NCT05628753|DIAGNOSTIC_TEST|Lung Ultrasound (LUS)|LUS performed 30 mins prior to and 120 minutes after planned extubation with a linear high frequency probe longitudinal approach was used in all three zones Repeated third scan will be done prior to re-intubation (if required) The ultrasound total execution cut-off time expected to be less than 5 minutes
223475786|NCT02675205|DRUG|Clopidogrel|clopidogrel: efficacy and safety in cerebral aneurysm stenting
223475787|NCT02675205|DRUG|Ticagrelor|ticagrelor:efficacy and safety in cerebral aneurysm stenting
223475788|NCT02675205|DRUG|aspirin|
223475789|NCT03620513|DRUG|Decongestant (oxymetazoline 0.05%)|As described in arm/group
223475790|NCT03620513|DRUG|Anesthesia (Lidocaine 15%)|As described in arm/group
223475791|NCT03620513|DRUG|Decongestants and Anesthesia (oxymetazoline and lidocaine)|As described in arm/group
223475792|NCT03620513|DRUG|Normal saline|Spray of normal saline as premedication
223475793|NCT00037986|DEVICE|Hearing Aids|Hearing aid use
223475794|NCT06128018|PROCEDURE|Surgical gastrojejunostomy (S-GJ)|Surgical gastro-jejunostomy
223475795|NCT06128018|PROCEDURE|EUS-guided gastrojejunostomy (EUS-GJ)|Endoscopic Ultrasound guided gastro-jejunostomy
223475796|NCT01274351|DRUG|Nilotinib|administered orally at a dose of 300 mg twice daily for 24 months
223475797|NCT03228030|DIETARY_SUPPLEMENT|Thiamine|Capsules
223475798|NCT03228030|DIETARY_SUPPLEMENT|Placebo|Identical capsules
223475799|NCT00216593|DRUG|galantamine hydrobromide|
223475800|NCT00535613|DRUG|Propofol|IV, single bolus at completion of anesthetic, 0.1 ml/kg
223475801|NCT06204497|PROCEDURE|Stent-based Diverting Technique|The stent-based diverting technique (SDT) contains two parts to achieve feces diversion One is a degradable solid intestinal stent to be implanted 20 cm from the terminal ileum and could be gradually degraded within 3-4 weeks. Another part is a drainage tube to be placed at the proximal 5-10 cm of the aforementioned stent. Given this SDT, intestinal contents could be diverted through the drainage tube, and the stent prevents the feces from entering the distal intestinal. After removing the drainage tube after 3-4 weeks, intestinal contents will freely access the distal intestinal space following the degradation of the stent. For patients, stoma reversal is avoided.
223475802|NCT00042913|BIOLOGICAL|epratuzumab|
223475803|NCT02669706|DRUG|Pentamidine|Pentamidine is an antimicrobial medication given for prevention and treatment of Pneumocystis pneumonia (PJP) caused by Pneumocystis jirovecii
223475804|NCT04441346|RADIATION|Echocardiography|test that uses high frequency sound waves (ultrasound) to make pictures of your heart.
223475805|NCT04454359|DIETARY_SUPPLEMENT|Multi-nutrient supplement|
223475806|NCT04454359|DIETARY_SUPPLEMENT|Placebo|
223475807|NCT04176224|DRUG|MT-1186|Suspension
223475808|NCT04378335|OTHER|completion of questionnaire|parents have to complete 2 questionnaires: demographic questionnaire and Montréal questionnaire when they come on allergy consultation.
223475809|NCT01296412|DRUG|sitagliptin|100 mg tablet, orally, once daily.
223475810|NCT01296412|DRUG|liraglutide|0.6 mg by subcutaneous (pen) injection, once daily, on Days 1-7; up-titrated on Day 8 to 1.2 mg daily. At Week 12, dose may be increased to 1.8 mg once daily for participants who did not meet protocol-specified glycemic goals.
223475811|NCT01296412|DRUG|glimepiride|starting dose of 1 mg tablet (up-titrated as needed), once daily, as needed, after Week 12.
223475812|NCT01296412|DRUG|metformin|metformin tablets at a dose of ≥1500 mg per day
223475813|NCT00776880|OTHER|ASA scale|ASA scale evaluation before operation
223475814|NCT00776880|OTHER|PPS scale|PPS scale evaluation before operation
223475815|NCT02461212|PROCEDURE|Magnetic Resonance Imaging (MRI)|A MRI scan which will include magnetic resonance spectroscopy (MRS) of the liver to determine hepatic triglyceride content, a hepafat scan to measure volume fraction of fat in liver tissue, and a MRI for detection of liver fibrosis. The scan will last approximately 15 minutes.
224162485|NCT01627782|DRUG|Placebo|Form= intravenous infusion, route= intravenous (IV) use. IV infusions of placebo 2 times weekly or IV infusions of placebo 3 times weekly.
223475816|NCT02078258|BEHAVIORAL|ABMT|During a two-week period, 8 sessions of a modified dot probe task for attentional bias modification training (ABMT) condition, 8 sessions of a classic dot probe task for placebo training (PT) condition.
223475817|NCT02632617|OTHER|Computed tomographic angiography|Preoperative examination is needed in patients with valvular disease. The invasive coronary angiography is used for patients in ICA group, while the computed tomographic angiography is used as a gatekeeper and invasive coronary angiography is selectively used for patients in CTA group.
223475818|NCT02160626|DRUG|A-101 Vehicle|Placebo control
223475819|NCT02160626|DRUG|A-101 (40) Topical Solution|A-101 (40) Topical Solution - high dose
223475820|NCT02160626|DRUG|A-101 (32.5) Topical Solution|A-101 (32.5) Topical Solution - low dose
223475821|NCT03918317|DEVICE|AirXpanders AeroFormtissue expander|The AeroFormdevice will be placed in an immediate fashion at the time of mastectomy in a submuscular, prepectoral or dual-plane approach. The tissue expander will be minimally inflated intraoperatively to minimize dead space and while facilitating tension free closure. Participants will undergo standard postoperative management, and will be given instructions on utilization of the device, including daily expansion until desired volume is reached as determined b surgeon and participant agreement.
223475822|NCT01340690|DIETARY_SUPPLEMENT|ω-3 fatty acids suspension|2 bags of Esprico(R) suspension given orally once daily in the morning for 84 days
223475823|NCT01340690|DIETARY_SUPPLEMENT|placebo suspension|suspension to mimic verum Esprico (R) suspension. 2 bags of Esprico(R) placebo suspension given orally once daily in the morning for 84 days
223475824|NCT02888054|DRUG|lesinurad/allopurinol 200/300 FDC tablet|
223475825|NCT02888054|DRUG|lesinurad 200 mg|
223475826|NCT02888054|DRUG|allopurinol 300 mg|
223475827|NCT04559984|DEVICE|JUVÉDERM VOLUX®|JUVÉDERM VOLUX® injectable gel
223582426|NCT04453813|DRUG|Concurrent chemo-radiotherapy|"1. Concurrent cisplatin chemotherapy: cisplatin is given at a dose of 100 mg/m2 via a continuous intravenous infusion during radiotherapy and starts on the 1st day of radiotherapy for 2 cycles. 1 cycles per 3 weeks.~2. IMRT: PTVnx#60.0Gy/27Fr/2.22Gy; PTVnd# 60-64Gy/27Fr/2.22-2.37Gy; PTV1#54Gy/27Fr/2.00Gy"
223582427|NCT03481803|DRUG|MS1819-SD|Patient will receive increasing doses from the lowest dose of MS1819-SD to a maximum dose of MS1819- SD. The total treatment phase will range from 48 days to 60 days.
223582428|NCT04104685|COMBINATION_PRODUCT|FCD105|Experimental combination
223475828|NCT05944640|PROCEDURE|Intraocular surgery|Pars plana vitrectomy or cataract surgery.
223744324|NCT05537077|OTHER|Prolotherapy|DPT was applied as a total of 3 sessions at 0, 3 and 6 weeks. In each session, intra-articular 5 ml and periarticular 10 ml dextrose injections were administered to the knee. Periarticular injection was applied to 10 points as 1 ml in each region. The regions were determined as medial and lateral coronary ligaments, proximal and distal medial and lateral collateral ligaments, pes anserinus region, proximal and distal patellar tendon, quadriceps tendon attachment area.
223744325|NCT05537077|OTHER|Home based exercise program|Knee ROM, isometric and isotonic quadriceps strengthening exercises were given as 2 sets of 10 repetitions per day for 12 weeks.
224162486|NCT01627782|DRUG|Ketamine|Type= exact number, unit= mg/kg, number= 0.5, form= intravenous infusion, route= intravenous (IV) use. IV infusions of ketamine 0.50 mg/kg, 2 times weekly or IV infusions of ketamine 0.50 mg/kg, 3 times weekly.
224162487|NCT04813978|OTHER|Music|For the interventional group, in addition to normal nursing care, patients will listen to instrumental relaxing music genre consist of pitch, rhythm and tone color for 30 minutes pre-operatively, using mp3 player and over-ear headphones to reduce outside interference, at a volume of the patient's preference.
224305019|NCT01931696|DEVICE|Verum acupuncture|100 patients receive verum acupuncture treatment once every other day,choosing Dazhui(GV14), Fengmen(BL12), Feishu(BL13), needles retention for 30 minutes and no moxibustion or electrical stimulation. Patients receive verum acupuncture once every other day with a total of 20 sessions in 6 weeks. The needle brand is Hwato®™ Sterile Acupuncture Needles for Single Use.
223744326|NCT05537077|OTHER|Hotpack therapy|Hotpack treatment was applied for 20 minutes at 0, 3 and 6 weeks.
223475829|NCT01822444|OTHER|Biomarker analysis|
223475830|NCT02215850|DRUG|SLC-0111|
223475831|NCT03451396|DRUG|Lifitegrast|All subjects meet dry eye inclusion and will be treated with Lifitegrast gtts BID
223475832|NCT02172027|DEVICE|Immunomagnetic Detection|Analysis of pleural effusion through immunomagnetic detection device.
223475833|NCT04371016|OTHER|Verticalization (bed)|"The use of a dedicated bed (Total Lift Bed™, VitalGo Systems, Inc., Arjo AB) allows the verticalization of patients under sedation and mechanical ventilation up to 90°. The procedure foresees the gradual verticalization of the patients of 0°, 30°, 60° and 90° by steps of 30 minutes.~At the end of each position step (0°, 30°, 60° and 90°), measurement of end-expiratory lung impedance (EELI) and chest electrical impedance tomography (EIT) parameters, measurement of esophageal pressures, collection of ventilatory parameters on the ventilator, collection of Swan-Ganz catheter hemodynamic data, measurement of lung shunt by mixed venous and arterial blood gas analyses and measurement of end-expiratory lung volume (EELV) by the N2 washin-washout method"
223582429|NCT04104685|DRUG|3% Minocycline Foam|Active Comparator
223582430|NCT04104685|DRUG|0.3% Adapalene Foam|Active Comparator
223582431|NCT04104685|OTHER|Vehicle Foam|Placebo
223582432|NCT02836782|PROCEDURE|Blood sample withdrawal|Blood withdrawal for HIV-DNA or HCV resistance test
223582433|NCT03455829|DRUG|G1T38|CDK 4/6 inhibitor
223582434|NCT03455829|DRUG|Osimertinib|EGFR TKI; 80 mg
223582435|NCT02086201|BEHAVIORAL|Problem Solving Therapy|PST is a behavioral intervention for depression that is delivered by trained therapists over a 9 week period. It consists of a process to help patients understand and then solve the problems in their lives they feel is contributing to their depression.
223475834|NCT05959928|DEVICE|Continuous wearable thermometer placed on patient's armpit to monitor body temperature remotely|The HaH team will place Viture Device on the patient's armpit and train the patient and/or caregiver. They will ask to complete control STMs between 3 and 6 times a day on the same arm where the Viture Device is placed and record the measuring data in the Home data collection notebook (HDCN)
224162488|NCT06451276|DEVICE|Nasoalveolar molding in unilateral cleft lip and palate|compare the effectiveness of adhesive nasoalveolar molding (GS-NAM) and conventional nasoalveolar molding on the alveolar ridge, nasal, and labial growth in children with unilateral cleft lip and palate
223475835|NCT04798157|RADIATION|transcranial doppler|Transcranial Doppler ultrasonography will be done using the ultrasound machine by placing a transducer over the relatively thinner temporal and occipital bones in order to visualize and evaluate the velocities at the circle of Willis.
223475836|NCT00032591|PROCEDURE|Weekly patient self-testing of prothrombin time|
223475837|NCT00032591|OTHER|High quality anticoagulation management (HQACM) with conventional monthly testing|HQACM with testing every 4 weeks and as indicated for out of range values, medication/clinical changes.
223582436|NCT02086201|BEHAVIORAL|Engage|Engage is a weekly behavioral intervention that is delivered over a 9 week period of time by trained therapists. The focus of Engage is to help patient reconnect with activities that they have lost interest in pursuing due to depression.
223475838|NCT00367926|DRUG|American ginseng root / polysaccharides|
223582437|NCT03446053|BIOLOGICAL|N-Rephasin® SAL200|continuous intravenous infusion over 60 minutes
223475839|NCT05625243|OTHER|Bulk-fill ormocer (Admira fusion x-tra, Voco, Cuxhaven, Germany) with Precontoured circumferential matrix system (Palodent 360, Dentsply Caulk, Millford DE, USA)|A suitable size precontoured circumferential matrix band (Palodent 360, Dentsply Caulk, Millford DE, USA) will be selected and placed. Teeth separation will be acquired with a suitable size wedge (Palodent V3, Dentsply Caulk, Millford DE, USA) and a separation ring (Palodent V3 universal ring, Dentsply Caulk, Millford DE, USA). Then the bulk-fill ormocer (Admira fusion x-tra, Voco, Cuxhaven, Germany) will be applied and light cured according to the manufacturer instructions.
223582438|NCT03446053|OTHER|INT200-Placebo|Formulation buffer except active ingredient for continuous intravenous infusion over 60 minutes
223744327|NCT02677987|DEVICE|Intervention systematic light exposure|Bright light using Litebook device.
223475840|NCT05625243|OTHER|Bulk-fill ormocer (Admira fusion x-tra, Voco, Cuxhaven, Germany) with Precontoured sectional matrix systym (Saddle matrix, TORVM, Moscow, Russia)|A suitable size precontoured sectional matrix band (Saddle matrix, TORVM, Moscow, Russia) will be selected and placed. Teeth separation will be acquired with a suitable size wedge (fixing wooden wedges, TORVM, Moscow, Russia) and a separation ring (Delta ring, TORVM, Moscow, Russia). Then the bulk-fill ormocer (Admira fusion x-tra, Voco, Cuxhaven, Germany) will be applied and light cured according to the manufacturer instructions.
223475841|NCT05625243|OTHER|Bulk-fill resin composite (X-tra fill, Voco, Cuxhaven, Germany) with Precontoured circumferential matrix system (Palodent 360, Dentsply Caulk, Millford DE, USA)|A suitable size precontoured circumferential matrix band (Palodent 360, Dentsply Caulk, Millford DE, USA) will be selected and placed. Teeth separation will be acquired with a suitable size wedge (Palodent V3, Dentsply Caulk, Millford DE, USA) and a separation ring (Palodent V3 universal ring, Dentsply Caulk, Millford DE, USA). Then the bulk fill resin composite (X-tra fill, Voco, Cuxhaven, Germany) will be applied and light cured according to the manufacturer instructions.
223475842|NCT06122558|DIETARY_SUPPLEMENT|Probiotic|Probiotic Lactobacillus plantarum at 9 log CFU/day for 8 weeks
223475843|NCT06122558|DIETARY_SUPPLEMENT|Placebo|Intervention consists of daily administration of 2g of maltodextrin, administered daily for 8-weeks)
223582439|NCT02707211|BIOLOGICAL|Anti-oxLDL IgM antibody|Immunization
223582440|NCT01651832|BEHAVIORAL|SCAN|The Supportive Cancer Care Networkers intervention (SCAN) consists of an additional telephone support and symptom-related out-patient care management through Oncology Nursing. The SCAN intervention assesses patients' resources and barriers in utilizing health care services in order to meet their individual needs adequately and supports maintenance of therapy compliance. Thus, the SCAN offers a comprehensive mirroring the patients' medical and psychosocial care needs across changing sectors of health care.
223582441|NCT04790487|DRUG|CPM|one spray dose (\~100 µL of the solution containing 1.25 mg CPM) per nostril twice a day
223582442|NCT04790487|DRUG|Placebo|Saline
223582443|NCT01305655|DRUG|Glucarpidase|Patients treated with Glucarpidase if the 24 hour levels of MTX is \>250 µM, 36 hour levels \>30 µM or 42 hours levels \>10 µM together with a reduced kidney function will be compared with patients in just below the tricking values.
223744328|NCT02677987|DEVICE|Comparison systematic light exposure|Dim light using modified Litebook device.
223744329|NCT03006744|BEHAVIORAL|Phonological awareness training|Training on specific ways to improve children's phonological awareness by making them more aware of the sound structure of words.
223744330|NCT03006744|BEHAVIORAL|Reading enjoyment training|Training on how to make reading enjoyable for children.
224070012|NCT03012373|PROCEDURE|Ear acupressure alone|The magnet pellets were placed with adhesive tape at shenmen point of both ears and were pressed 5 times every 5 minutes for 15 minutes then were attached until next treatment and change now one. The patients received this treatment 2 times a week for 4 weeks.
224070013|NCT03012373|PROCEDURE|Electroacupuncture plus ear acupressure|Acupuncture included Hegu (LI 4) and Zusanli (ST 36) on both hands and legs with electrical stimulation was conducted. The frequency of electrical stimulation was 5 Hz and wave form was adjustable. The intensities of the stimulation were increased in 1 mA increments to maximal tolerable intensity. At the same time, The magnet pellets were placed with adhesive tape at shenmen point of both ears and were pressed 5 times every 5 minutes for 15 minutes. After 15 minutes treatment, acupuncture needles were removed and magnet pellets were attached until next treatment and change now one. The patients received this treatment 2 times a week for 4 weeks.
224070014|NCT01084187|DRUG|Vardenafil|vardenafil 20 mg on demand or vardenafil daily or placebo
224070015|NCT05314244|PROCEDURE|Pylorus resecting pancreaticoduodenectomy|The patients in pylorus resection group will underwent pylorus resecting procedure during pancreaticoduodenectomy
224070016|NCT02116010|DRUG|E. coli Phages cocktail|Use of Pherecydes Pharma Phages cocktail to treat respectively E. coli burn wound infection
224070017|NCT02116010|DRUG|Standard of care : Silver Sulfadiazine|Use of Standard of care : Silver Sulfadiazine, to treat E. coli or P. aeruginosa infected burn wound
223582444|NCT03166579|BEHAVIORAL|Dialectical Behaviour Therapy|Dialectical Behaviour Therapy (DBT) is a psychological intervention which was originally developed for women with Borderline Personality Disorder. DBT is delivered by a team of multidisciplinary mental health professionals, and comprises of individual therapy sessions for each patient, group skills training sessions, phone coaching and consultation meetings for the clinicians on the DBT team. Group skills are delivered in blocks of three modules which teach mindfulness, distress tolerance, emotion regulation and interpersonal effectiveness. The three modules are delivered over a 24-week period and are then repeated.
223475844|NCT03767712|DIAGNOSTIC_TEST|Comparison of the levels of antinuclear antibodies (ANA) by indirect immunofluorescence on a Hep-2 cell line.|To analyse whether patients with pertrochanteric femoral fracture with consecutive gamma-nailing develop any laboratory signs of transient autoimmunity (comparison of the levels of ANA; in order to overcome the problem of subjective semiquantitative evaluation, the novel method of automated digital fluorescence microscopy will be used)
223582445|NCT02876874|DRUG|indocyanine green(ICG)|ICG will be injected into the dorsal of hand/foot
223582446|NCT02340390|DEVICE|G7|The Biomet G7™ Acetabular System has been designed to provide more options to surgeons for treatment of patients needing total hip arthroplasty, while concurrently simplifying the surgical process with well-designed, modular components and corresponding instruments. The G7™ Acetabular System includes three liner types; ArComXL highly-crosslinked or E-1 Vitamin E-infused polyethylnene and a Biolox Delta (Ceramtec, Plochingen, Germany) ceramic liner.
223582447|NCT02340390|DEVICE|Exceed ABT|The Exceed ABT Acetabular System has been designed for cementless fixation and consists of an acetabular shell and an acetabular insert. The acetabular insert/bearing includes a tapered outer geometry that matches the inner geometry of the acetabular shell and an inner hemispherical geometry to suit the varying modular head diameters. Inserts/bearings are inserted into the acetabular shell intra-operatively and are available in varying sizes to match the acetabular shell diameters. The insert/bearings are available in Biolox Delta ceramic (CeramTec AG).
223475845|NCT04239924|BEHAVIORAL|Paramedic Coaching|The intervention is an adaptation of the evidence-based REACH program, specific coaching content is delivered by paramedics in 1-2 hour in-home sessions and over the phone throughout a 12-month period.
223475846|NCT04267497|DRUG|Amphotericin B Liposomal 50 MG|Amphotericin B 50 mg powder for infusion diluted in 12 ml of sterile water. It will be administered by nebulized route 25 mg (6 ml), 3 times a week, for 6 weeks.
223475847|NCT04267497|OTHER|Placebo|Sterile water for injection. It will be administered by nebulized route: 6 ml, 3 times a week for 6 weeks.
223582448|NCT02098811|DEVICE|1064nm Laser|Patient will be treated with 1064nm Laser prior to abdominoplasty
223582449|NCT02098811|DEVICE|940nm Laser|Patient will be treated with 940nm Laser prior to abdominoplasty
223475848|NCT07073560|PROCEDURE|Anthropometric Measurements|"1. Assessment of the accuracy of sex determination from hand indexes using anthropometric hand measurements.~2. Assessment of the accuracy of sex determination from the length of the metacarpals using x-ray radiographs on the same hand.~3. Determination of the best and least costly method for sex identification by comparing the effectiveness of the previous two methods."
223582450|NCT00005056|DRUG|bryostatin 1|
223582451|NCT04536922|DRUG|Cyclophosphamide|Days -7 and -6: Cyclophosphamide 60 mg/kg/day x 2 days IV in 250 mL D5W infused simultaneously with mesna 15 mg/kg /day over 1 hour x 2 days.
223582452|NCT04536922|DRUG|Fludarabine|Days -7 to -3: Fludarabine 25 mg /m2/day IVPB daily over 30 minutes for 5 days.
223582453|NCT04536922|DRUG|Aldesleukin|Aldesleukin 720,000 IU/kg IV (based on total body weight) over 15 minutes approximately every 8 hours beginning within 24 hours of cell infusion and continuing for up to 4 days (maximum 10 doses).
223582454|NCT04536922|DRUG|Pembrolizumab (KEYTRUDA(R))|Pembrolizumab 2 mg /kg IV over approximately 30 minutes on Days -2, 21, 42, and 63.
223582455|NCT04536922|BIOLOGICAL|Individual Patient TCR-Transduced PBL|Day 0: Cells will be infused at a dose not to exceed 1.5e11 in 400 mL intravenously on the Patient Care Unit over 20-30 minutes (2-4 days after the last dose of fludarabine).
223582456|NCT00714766|PROCEDURE|Intravascular volume administration|Infusion of colloid to reestablish CVP under heat stress
223582457|NCT01063842|DRUG|tramadol hydrochloride /acetaminophen|1 tablet of tramadol hydrochloride/acetaminophen three times daily without titration for 14 days.
223475849|NCT05519865|DRUG|Tucidinostat|30mg orally BIW
223475850|NCT05519865|DRUG|Tislelizumab|200 mg intravenously (IV) Q3W
223475851|NCT06748157|DEVICE|CardiaCare RR2|CardiaCare has developed a wrist band that delivers non-invasive neuromodulation to the median nerve to elicit a vagal response (Median-Vagus nerve stimulation-mVNS). The device is in the post-prototype development stage and is ready for human clinical trials. The CardiaCare RR2 device has already been approved by the IRB of the Chaim Sheba Medical Center, IL and the IL MOH (Ministry of Health) in an already completed pilot clinical trial for modulating AF.
223475852|NCT06748157|DEVICE|Sham Device|Sham device will be dispensed, which will create a sensation but not provide therapy
223582458|NCT01063842|DRUG|tramadol hydrochloride / acetaminophen and placebo|1 tablet of tramadol/acetaminophen in the morning, 1 tablet of placebo in the afternoon and evening for 3 days, then 1 tablet of tramadol/acetaminophen in the morning, evening and 1 tablet of placebo in the afternoon for 4 days, then 1 tablet of tramadol/acetaminophen 3 times daily for next 7 days
223582459|NCT04326855|OTHER|Incremental shuttle walking protocol (ISWT)|Patients will perform an incremental shuttle walk test to the limit of tolerance to establish peak walking speed. The test will be developed in a 10-m course corridor, and it will be externally-paced via a recorded metronome that gives a signal for each stride. The walking pace will be increased every minute and the test will be terminated when the individual is no longer able to keep up the pace. Pulmonary variables will be recorded breath-by-breath. Cardiac output will be assessed every min. Arterial oxygen saturation will be measured by a pulse oximeter. Patients will score the intensity of their breathlessness and leg discomfort using the 1-10 Borg's scale every minute.
223744331|NCT06039423|PROCEDURE|The M-TAPA block|A high frequency (6-12 MHz) US linear probe was placed in the sagittal plane on the 10 th costal margin in the midline. The probe was then angulated deeply to visualize the lower surface of the costal cartilage. Via in plane technique, a 21 gauge Tuohy needle was inserted cranially between the lower fascia of the costal cartilage and upper fascia of the transversus abdominis muscle by moving the needle tip towards the posterior aspect of the 10 th costal cartilage and 20 mL bupivacaine (0.25 %) was injected.
223744332|NCT06039423|DRUG|Ketorolac|conventional general anaesthesia receiving multimodal analgesia
223744333|NCT01531712|DRUG|Gemcitabine|1000mg/m2 / / 40mg/m2
223744334|NCT01531712|RADIATION|Radiotherapy|50.4 Gy
223475853|NCT06909240|OTHER|Progressive gait training|The focus of the intervention is on exercises that can improve venous return, and consists of progressive gait training at moderate and high intensity as well as guidance on progressive gait training. The training program is inspired by the WHO's recommendations for physical activity. The training program consists of a 14-day introductory period based on an initial interview with a physiotherapist, where the aim is to obtain 30 mins/day of gait training at moderate intensity. After 14 days, the patient receives physiotherapist guidance via telephone on progressive gait training and is introduced to the next period of 14 days, where the activity level is maintained, and the goal is to further achive 2 x 20 mins/week of muscle-strengtening activities at moderate or greater intensity. After one and two months of training, the patient will be guided via telephone on maintaining their current level of physical activity or possibly on further progression.
223475854|NCT06909240|OTHER|Standard Care (in control arm)|Standard care encompasses standard diagnostics with compression ultrasound examination, and a treatment procedure with anticoagulant medication, and compression stockings class III. Standard care also involves visits to the outpatient anticoagulation clinic, where patients with DVT are required to attend treatment sessions within the first 14 days and 90 days after diagnosis. Standard care will serve as a comparator to reflect the current treatment regimen.
223475855|NCT05498389|DRUG|EMB-01|EMB-01 is a bispecific antibody against epidermal growth factor receptor (EGFR) and the receptor tyrosine kinase Met (cMET).
223475856|NCT05498389|DRUG|Osimertinib|Osimertinib is an approved, third-generation EGFR tyrosine kinase inhibitor
223582460|NCT04326855|OTHER|Endurance shuttle walking (ESW) protocol|Subsequently, during the second visit all patients will perform the continuous endurance shuttle walk (ESW) protocol to the limit of tolerance at a walking speed corresponding to 85% of VO2 peak derived by the ISWT (visit 1). During the ESW protocol patients will receive standardized instructions to walk for as long as possible although there will be a predetermined 6 minute maximum point. No further encouragement will be provided during the exercise performance. The test will be terminated when the individual is no longer able to keep up the pace or stops due to intolerable exertional symptoms. Gas exchange and cardiorespiratory variables will be assessed as per visit 1.
223744335|NCT01531712|DRUG|Tarceva|100mg/day
223744336|NCT01531712|DRUG|Oxaliplatin|100mg/m2 (only in QT)
223744337|NCT04959942|OTHER|scapular stabilization exercise|In the supine position, the subject will instruct to take a deep breath to relax the body. In croock-lying position, the subject will raise his dominant arm to 90° shoulder flexion with full elbow extension and scapular protraction. In the quadruped position, the subject lifts up his arms alternatively with shoulder abduction and 120 ° flexion. In a sitting position with 90° knee flexion on a stool or bed without back support, the subject held a pair of dumbbells (2 kg) in each hand and laterally lifted them up while maintaining the height of scapulae below 80°. Each stage will instruct to be held for 10 seconds before returning to the starting position and three laps of 10 repetitions with a 30-second break in between will perform. In the sitting position, a mirror will place in front of the patient. The subject will instruct to check and correct his posture by him
224070018|NCT02116010|DRUG|P. Aeruginosa, Phages cocktail|Use of Pherecydes Pharma Phages cocktail to treat P. aeruginosa burn wound infection
223744338|NCT04959942|OTHER|postural correction exercise|The program consisted of two strengthening (deep cervical flexors and scapular retractors) and two stretchings: cervical extensors (sub-occipital muscles) and pectoral muscles). The program was based on a program by Harman and Kendall.
223744339|NCT04959942|OTHER|advice|all subjects will be instructed to maintain normal alignment of the cervical vertebry
223744340|NCT01786954|DEVICE|Icare rebound tonometry|
223744341|NCT01786954|DEVICE|Tonopen applanation|
223744342|NCT01786954|DEVICE|Goldmann applanation|
223744343|NCT02968303|DRUG|Vemurafenib and Cobimetinib|Combination of Vemurafenib with Cobimetinib in BRAF V600E/K mutated melanoma patients to normalize LDH and optimize immunotherapy with Nivolumab and Ipilimumab
224070019|NCT02766829|PROCEDURE|Cross leg sitting position|Subjects were set on cross leg sitting position before spinal anesthesia begun.
224070020|NCT02766829|PROCEDURE|Traditional sitting position|Subjects were set on traditional sitting position before spinal anesthesia begun.
224070021|NCT05303051|DEVICE|Application Validation|After creating accounts, participants in both groups will download the Azumio Instant Diabetes Test and provide a Photoplethysmography (PPG) waveforms by placing their index finger over their smartphone camera for 20 seconds to provide PPG waveform data for the study .
224070022|NCT03723382|OTHER|SECRET structured 5 bundles of standard healthcare services|THE 5 BUNDLES OF Stroke SERVICE They the mix of the services for stroke patient which are available at the SS EVT bundle: is the availability of the Endovascular services Telemedicine core bundle : is the ability to guide or guided via tele-medicine for decision making for stoke patients tPA core bundle : the availability of all infrastructure to administer tPA in the first 3 hours of onset (NNT=8) DISMAST bundle : which refer to the availability of Dysphagia detection and management ,Aspirin in hyper acute phase , The Mobilization plans and programs for the patients, anticoagulant and statin prescription for selected patients for secondary prophylaxis programs Process of care bundle : like registering patients and morphology of the disease, screening programs for risk factors , following primary prevention plans all bundles should be judged by the 8M approach
224070023|NCT00110773|DRUG|S-Caine™ Peel (lidocaine and tetracaine topical cream 7%/7%)|S-Caine Peel, composed of a 1:1 (w:w) eutectic mixture of 7% lidocaine and 7% tetracaine, applied topically. S-Caine Peel applied at approximately 1 mm in thickness and remained on the treatment area for 20 minutes (±2 minutes).
224070024|NCT00110773|DRUG|Placebo Peel|Placebo Peel applied topically at approximately 1 mm in thickness and remained on the treatment area for 20 minutes (±2 minutes).
224070025|NCT02229552|OTHER|Standardized Assessments|Children were asked to attend appointments without consuming study foods 24 hours previously, as habituation measurements are sensitive to recent consumption. Children were provided access to snack prior to completing questionnaires or cognitive assessments. Habituation to food, questionnaires and cognitive assessments were re-measured at 1-year and 2-year follow up.
224070026|NCT04872101|DRUG|Delgocitinib cream|Cream for topical application
223475857|NCT06275737|OTHER|Prehabilitation program|"Cohort 1 - Prehabilitation program will be implemented during the last cycles of neoadjuvant chemotherapy (cycle 5 - cycle 6 or cycle 6 - cycle 8) and the weeks preceding surgery (planned 3-4 weeks after the last chemotherapy cycle)~Cohort 2 - Prehabilitation program will be implemented during the last cycles of neoadjuvant chemotherapy (cycle 2 - cycle 4) and the weeks preceding surgery (planned 3-4 weeks after the last chemotherapy cycle)"
223475858|NCT01860859|PROCEDURE|Closure of the hysterotomy at the time of primary cesarean|
223475859|NCT06757010|DRUG|NE3107|NE3107 20 mg BID
223582461|NCT04326855|OTHER|First Intermittent shuttle walking protocol|All patients will perform an intermittent shuttle walking protocols to the limit of tolerance (visit 3) by alternating 1-min walking bouts sustained at a walking speed equivalent to 85% peak (equivalent to the continuous ESW protocol) with 1-min rest periods.The test will be terminated when the individual is no longer able to keep up the pace or stops due to intolerable exertional symptoms although there will be a predetermined 20 minute maximum point.Gas exchange and cardiorespiratory variables will be assessed as per visit 1.
223582462|NCT04326855|OTHER|Second Intermittent shuttle walking protocol|To obtain test re-test reliability in terms of distance walked, of cardiorespiratory and symptoms responses this intermittent shuttle walking protocol will be repeated on a different day (visit 4). The test will be terminated when the individual is no longer able to keep up the pace or stops due to intolerable exertional symptoms although there will be a predetermined 20 minute maximum point. Gas exchange and cardiorespiratory variables will be assessed as per visit 1.
223582463|NCT04326855|OTHER|Focus group study|Semi-structured interviews to explore patients' preferences of undertaking the intermittent or continuous ESW protocols and healthcare professionals' perceived factors affecting the implementation of these protocols in the PR setting. These semi-structured interviews consist of questions in some degree predetermined order but still ensures flexibility in the way issues are addressed to the patients. Conversation is sustained in an informal tone and lasts for about an hour. Participants are allowed for an open response in their own words.
223582464|NCT00313547|DRUG|Quinapril 40 mg|
223582465|NCT00313547|DRUG|Quinapril 10 mg and amlodipine 5 mg|
224162489|NCT03177967|BEHAVIORAL|Sleep Restriction Therapy/Stimulus Control|Sleep Restriction Therapy focuses on forcing your available sleep time into a fixed window. The sleeper sets a bedtime and wake-up time and sticks to those times closely. The time allocated for being allowed in bed is determined from an estimate of how long the patient in average has been sleeping during the night, in the week before treatment. The goal is to have the patient sleeping the entire time he or she is in bed by making this period so restricted that the patient has no chance of sleeping enough. Once this goal is achieved, the time allocated for bed can be slowly increased, for example by 15 minutes at a time. After enough iterations, an equilibrium is achieved that the patient can keep maintaining after treatment has completed.
223582466|NCT00096018|DRUG|fludarabine phosphate|Given IV
224162490|NCT03177967|OTHER|Discussions about adverse cognitions about sleep|Group discussions about insomnia, CBT-i treatment and it's effects
223475860|NCT06757010|DRUG|Placebo|Placebo BID
223475861|NCT04729231|PROCEDURE|Nasalis Sling Flap|The nasalis sling flap involves alteration of the nasalis muscle to create a myocutaneous pedicle flap that will be used to fill in the wound.
223475862|NCT04729231|PROCEDURE|Lobed Transposition Flap|Lobed flap reconstruction involves the use of cutaneous tissue located adjacent to the nasal tip to fill in the wound. The flap will undergo a 90-degree arc to approximate the desired position.
223475863|NCT07129096|BEHAVIORAL|Applied Relaxation|Applied relaxation method developed by psychologists from progressive relaxation is used. The method is trained using a web application (Relappy.app), which contains step-by-step instructions with self-instructed exercises and exercise diaries, in which the examinee records his/her level of tension before and after the exercise (on a scale of 0-100, where 0 means a completely relaxed state, 50 a normal state (neither relaxed nor tense) and 100 maximum tenseness.
223475864|NCT07129096|DEVICE|Occlusal splint|The splint group is treated with occlusal splint, which is a conventional treatment method in cases where the implementation of information and self-care methods has not given a sufficient treatment response. The splint is prepared for night use and controlled according to the usual protocol.
223582467|NCT00096018|DRUG|thalidomide|Orally
223582468|NCT00252772|DRUG|Tesaglitazar|
223582469|NCT00252772|BEHAVIORAL|Dietary and Lifestyle counseling|
223475865|NCT06948279|PROCEDURE|The endoscopic retrograde cholangiopancreatography (ERCP) with insertion of a plastic stent.|A plastic stent was placed during the initial ERCP, with elective stone removal scheduled 8-12 weeks later.
223475866|NCT06948279|PROCEDURE|The endoscopic retrograde cholangiopancreatography (ERCP) with immediate stone extraction attempts.|Immediate ERCP for stone removal, utilizing conventional techniques such as basket, balloon, or mechanical lithotripsy as needed.
223475867|NCT06955325|DRUG|Icotinib|Oral icotinib tablets (125 mg) administered three times daily (TID) for up to 1 year or until disease recurrence or unacceptable toxicity. Icotinib is an EGFR tyrosine kinase inhibitor targeting EGFR-sensitizing mutations.
223475868|NCT06955325|DRUG|Rezivertinib|Oral rezivertinib capsules (100 mg) taken once daily (QD) for up to 1 year or until disease recurrence or unacceptable toxicity. Rezivertinib is an EGFR tyrosine kinase inhibitor targeting EGFR-sensitizing mutations.
223475869|NCT06955325|DRUG|Ensartinib|Oral ensartinib capsules (225 mg) taken once daily (QD) for up to 1 year or until disease recurrence or unacceptable toxicity. Ensartinib is an ALK/ROS1 tyrosine kinase inhibitor designed to inhibit ALK/ROS1 fusion-driven NSCLC.
223582470|NCT02458547|DRUG|Desflurane|Inhalation anesthesia with desflurane at age-adjusted MAC of 0.8\~1.0
224162491|NCT03177967|OTHER|Psychoeducative advice about how to improve sleep|Learning about sleep and sleep hygiene tips. It also includes learning about stimulus control and sleep restriction.
224162492|NCT04340960|OTHER|Home Monitoring|Patients in this group will receive home monitoring for NIBP (non-invasive blood pressure), SPO2 (pulse oximetry), and pain scores. These will be monitored 4 times a day for 2 weeks following surgery.
224162493|NCT05656391|DIETARY_SUPPLEMENT|Treatment vs control bread|Consumption of 200 grams per day of either treatment or control bread for eight weeks
224162494|NCT06916338|RADIATION|18F-FAPI-04 PET scan|FAPI-04, labeled with PET radio-nuclide 18F will be used as a molecular imaging tracer for PET scan. All participants will undergo 18F-FAPI-04 PET scan.
223475870|NCT06955325|DRUG|Benmelstobart|Intravenous infusion of bemosumab 1200 mg every 3 weeks (Q3W). Treatment continues for up to 4 cycles initially, and may be extended (maintenance) for up to 3 years or until disease recurrence or unacceptable toxicity. Bemosumab is a monoclonal antibody under investigation for immunotherapy in NSCLC.
223475871|NCT06951009|DEVICE|Colli-Pee|The Colli-Pee device is a first void urine self-sampling device. Participants will collect urine samples with this device three times during one week of study participation. Urine sample collection with this device will occur either in Week 1 or Week 2 of study participation, depending on the Participant's Arm assignment.
223475872|NCT06951009|DEVICE|standard of care 60 mL urine cup|Participants will collect clean catch urine samples with this device three times during one week of study participation. Urine sample collection with this device will occur either in Week 1 or Week 2 of study participation, depending on the Participant's Arm assignment.
223475873|NCT06951009|DIAGNOSTIC_TEST|Urinalysis|Participant samples will be analyzed by urinalysis to evaluate for leukocyte esterase (LE).
223582471|NCT02458547|DRUG|Propofol|Total intravenous anesthesia with propofol target controlled infusion
223582472|NCT02458547|DRUG|Bupivacaine|Spinal anesthesia with 0.5% bupivacaine
223582473|NCT04927793|DRUG|EDP-938|\[14C\]EDP-938
223582474|NCT02896036|PROCEDURE|Veress needle entry with concomitant CO2|The Veress will be connected to the CO2 tubing, and a skin incision will be made with the scalpel, followed by starting the CO2 gas insufflation and insertion of the Veress needle.
223582475|NCT02896036|PROCEDURE|Veress needle entry with subsequent CO2|A skin incision will be made with the scalpel. The Veress needle will be inserted until intraperitoneal location obtained. This will be followed by starting CO2 gas insufflation until the standard 15 mmHg.
223582476|NCT00337792|DRUG|oxycodone + lorazepam versus fentanyl + midazolam|
223582477|NCT03689712|DRUG|GC4419 90mg|60 minute IV infusion
223582478|NCT03689712|DRUG|Placebo|60 minute IV infusion
223582479|NCT02519569|OTHER|Internet-based cognitive-behavioral therapy|The intervention consists of ten writing assignments
223582480|NCT01981681|DRUG|PF-06263726|Subjects will receive dose strength of 2% PF-06263276 (1.14 mg) and matching placebo in topical formulation (2.5 µL/cm2) to be applied twice daily to two separate contralateral 20 cm2 areas on the back.
223582481|NCT01981681|DRUG|PF-06263726|Subjects will receive dose strength of 4% PF-06263276 (2.28 mg) and matching placebo in topical formulation (2.5 µL/cm2) to be applied twice daily to two separate contralateral 20 cm2 areas on the back.
223582482|NCT01981681|DRUG|PF-06263726|Subjects will receive dose strength of 2% PF-06263276 (11.4 mg) in topical formulation (2.5 µL/cm2) to be applied twice daily to a 200 cm2 area on the back.
223582483|NCT01981681|DRUG|Placebo|Subjects will receive dose strength of 2% PF-06263276 (11.4 mg) matching placebo in topical formulation (2.5 µL/cm2) to be applied twice daily to a 200 cm2 area on the back.
223582484|NCT01981681|DRUG|PF-06263726|Subjects will receive dose strength of 4% PF-06263276 (22.8 mg) in topical formulation (2.5 µL/cm2) to be applied twice daily to a 200 cm2 area on the back.
223582485|NCT01981681|DRUG|Placebo|Subjects will receive dose strength of 4% PF-06263276 (22.8 mg) matching placebo in topical formulation (2.5 µL/cm2) to be applied twice daily to a 200 cm2 area on the back.
223582486|NCT04373473|DRUG|PRIM-DJ2727|Fecal Microbiota Transplantation (FMT) product manufactured as PRIM-DJ2727 capsules consists of lyophilized microbiota suspension from well-screened donors. Microbiota from three donors will be combined to make the product.
223582487|NCT04373473|DRUG|Placebos|Placebo capsule will be identical to PRIM-DJ2727 but will not contain intestinal bacteria.
223582488|NCT00386555|DRUG|docetaxel|
224162495|NCT02177812|DRUG|GSK2879552|GSK2879552 capsules contain 0.25 mg, 0.5 mg, 2 mg or 5 mg of GSK2879552 as parent. The initial dosing regimen will be continuous oral daily dosing.
224162496|NCT02177812|DRUG|ATRA|ATRA (Tretinoin) will be supplied as a 10 mg capsule for oral administration. The initial dosing regimen will be continuous oral twice daily dosing
224162497|NCT06032572|PROCEDURE|VRS100 robotic-assisted PCI|The VRS100 is intended for use in the remote delivery and manipulation of guidewires and rapid exchange balloon/stent catheters, and remote manipulation of guide catheters during percutaneous coronary intervention (PCI) procedures.
223582489|NCT00386555|DRUG|CP-868,596 + docetaxel|
223582490|NCT00386555|DRUG|AG-013736 + docetaxel|
224162498|NCT06032572|PROCEDURE|Manual PCI|Use the traditional technique of manually advancing intracoronary guidewires, balloons, and stents at the patient's tableside.
224162499|NCT00089999|DRUG|Lapatinib|
223582491|NCT00386555|DRUG|CP-868,596 + AG-013736 + docetaxel|
223582492|NCT01545973|OTHER|Skin Moistening, Skin Denuding|Application of normal saline to skin and Tape stripping of the superficial skin
223582493|NCT04465565|PROCEDURE|9% Sodium Chloride (NaCl) IV|9% Sodiun Chloride (NaCl) ( 20cc/kg) adminstrated intravenously
223582494|NCT01186107|DEVICE|Endeavor Resolute stent|zotarolimus-eluting stent
223582495|NCT01186107|DEVICE|Cypher stent|sirolimus-eluting stent
223582496|NCT00689793|DRUG|Ferrous sulphate|"Volunteers will receive 80 mg/day oral ferrous sulphate (Tardyferon®) for four weeks. Visual analogical scales and questionnaires will be performed at day 0 and 30 to quantify fatigue ( Fatigue Severity Scale). We will also check depression and anxiety symptoms ( Prime MD ) and health survey ( SF-12 ). An evaluation of the menstruation ( Pictorial Bleeding Assessment Chart  of Jansen) will be performed at day 0 to detect a possible hypermenorrhea (appendix 1-4). A physical test will be performed (Chester Step Test) to assess the VO2 max. Every side effect will be written on follow-up notes."
223582497|NCT00689793|DRUG|Placebo|"Volunteers will receive 1 pill/day oral placebo for four weeks. Visual analogical scales and questionnaires will be performed at day 0 and 30 to quantify fatigue ( Fatigue Severity Scale). We will also check depression and anxiety symptoms ( Prime MD ) and health survey ( SF-12 ). An evaluation of the menstruation ( Pictorial Bleeding Assessment Chart  of Jansen) will be performed at day 0 to detect a possible hypermenorrhea (appendix 1-4). A physical test will be performed (Chester Step Test) to assess the VO2 max. Every side effect will be written on follow-up notes."
223744344|NCT01522365|DEVICE|Abutment-supported XiVE CAD/CAM bridge|One side will be provided with a XiVE CAD/CAM bridge placed directly on an abutment
224162500|NCT02370550|DRUG|Cyclosporin A|CsA 2-3 mg/kg/d, BID PO
223475874|NCT06951009|DIAGNOSTIC_TEST|Sysmex UP-5000|Participant samples will be analyzed by the Sysmex UP-5000 to evaluate for white blood cells (WBCs) per microliter.
223475875|NCT03708146|DRUG|BIA 5-1058|"25 mg and 100 mg tablets; Oral, once-daily, from Day 1 to Day 10. In Cohorts 1, 3, 5, 7 and 9 (fasted), BIA 5-1058 will be orally administered in the morning after a minimum of 8 h fast. Subjects will remain fasted until 4 h post-dose and will receive lunch approximately 4 h after dosing.~In Cohorts 2, 4, 6, 8 and 10 (fed), BIA 5-1058 will be orally administered in the morning after a moderate breakfast (containing approximately 550 kcal with fat contributing approximately 150 kcal). The meal should be consumed over a maximum period of 25 min, with dosing occurring 30 min after the start of the meal.~Each dose will be administered with 240 mL water."
223582498|NCT02526108|OTHER|HIFT|Workout alternates short periods of intense exercise using varied, multiple-joint movements, with less-intense active recovery periods. Workout sessions will be led by a trained instructor.
223582499|NCT02212171|OTHER|TRIAP|"The primary healthcare professionals organised in healthcare mini-teams, composed of 2 doctors, 2 nurses and 1 member of the administrative staff.~1. Administrative staff:~   Following a flow chart, they will refer patients with mild self-limiting illnesses as well as consultations regarding chronic disorders in adults to the nurses. They will also perform administrative tasks such as the printing of prescriptions, sick leave reports and medical notes (justifying absence), etc.~2. Nursing staff:~   They will carry out activities focused on health promotion, self-management and de-medicalisation during visits from patients with mild self-limiting illnesses as well as appointments for chronic diseases in adults.~3. GP:~They will develop the new portfolio of services: health promotion, joint review of patient medical records by doctors and nurses to improve the management of certain groups of patients, and organization of minor surgery services, etc."
223582500|NCT04767165|DIAGNOSTIC_TEST|MRI|Dynamics of Bone marrow fat fraction by mDixon-quant (%)
223582501|NCT04799691|PROCEDURE|Invasive ventilation strategy|Use of an invasive ventilatory support strategy
223582502|NCT04799691|PROCEDURE|Non-invasive ventilation strategies|Use of non-invasive ventilatory support strategies
223582503|NCT01117935|RADIATION|intensity modulated external beam radiation therapy|"Low risk - 69.6 Gy in 2.4 Gy fractions to prostate~Intermediate risk - delivered in 30 fractions with neoadjuvant and concurrent androgen deprivation therapy: 72 Gy in 2.4 Gy fractions to prostate + 60 Gy in 2 Gy fractions to seminal vesicles +/- 50.4 Gy in 1.68 Gy fractions to lymph nodes~High risk - 30 fractions with neoadjuvant, concurrent, and long term adjuvant androgen deprivation therapy: 72 Gy in 2.4 Gy fractions to prostate + 60 Gy in 2 Gy fractions to seminal vesicles +/- 50.4 Gy at 1.68 Gy fractions to lymph nodes"
223582504|NCT03968159|DRUG|Pimavanserin|Pimavanserin 34 mg (provided as 2×17 mg tablets) administered orally as a single dose once daily
223582505|NCT03968159|DRUG|Placebo|Placebo (2×placebo tablets \[size- and color-matched to pimavanserin\]) administered orally as a single dose once daily
223582506|NCT03577392|DRUG|oxaliplatin + capecitabine (XELOX chemotherapy)|Oxaliplatin(130mg/m2 over 2h)was intravenously administated for at least 2h on day 1. Capecitabine(1000mg/m2 twice daily)was oral administrated from the evening of day 1 to the morning of day 15.
223582507|NCT03577392|DRUG|rebombniant human endostatin|Endostar is a recombinat human endostatin with antiangiogenic properties that has been useful in treating a wide range of cancers and shows promise for use in combination treatment for advanced colorectal cancer. The dose of Recombinant human endostatin on day -5 was calculated according to the patients's body surface area, to provide a CIV 7 days' dose in physiological saline to 240mL volume.
223582508|NCT01604655|PROCEDURE|Coronary CT Angiography|CCTA
223582509|NCT01604655|PROCEDURE|Stress Test|Stress Test
223582510|NCT03283150|DRUG|Remifentanil|Remifentanyl will be administered for 10 -15 minutes before initiating the MER phase and the patient will be allow to wake up and the bispectral index (BIS) values to normalize to awake level for the MER.
223582511|NCT03283150|DRUG|Propofol|Propofol will be administered for 10 -15 minutes before initiating the MER phase and the patient will be allow to wake up and the BIS values to normalize to awake level for the MER.
223582512|NCT03283150|DRUG|Dexmedetomidine|Dexmedetomidine will be administered for 10 -15 minutes before initiating the MER phase and the patient will be allow to wake up and the BIS values to normalize to awake level for the MER.
223582513|NCT05004506|DRUG|Adductor Canal Block|The anesthesia provider will identify the adductor canal using ultrasound guidance and inject 15ccs of 0.5% marcaine with epinephrine around the saphenous nerve.
223582514|NCT05004506|DRUG|Intra-articular Injection|receive 20ccs of 2% lidocaine with epinephrine as an intra-articular injection
223582515|NCT01009749|BEHAVIORAL|Motivational Enhancement System for Adherence (MESA)|MESA is designed to increase motivation for adherence to Highly Active Antiretroviral Therapy (HAART) among youth newly recommended to begin medications.
224162501|NCT02370550|DRUG|Prednisone|Prednisone 0.5mg/kg/d QD PO starting at Week 0. After 2-4 weeks, the initial dose is gradually tapered by 2.5 mg each week until a maintenance dosage of 5-7.5 mg/d through week 52 (visit 6). The initial and maintenance doses are determined by the investigators of each center depending on the patients.
224162502|NCT02370550|DRUG|Placebo|Placebo tablet 2-3 mg/kg/d, BID PO
224162503|NCT02370550|DRUG|Calcium carbonate D|Calcium carbonate D 600 mg, QD PO
223582516|NCT01009749|BEHAVIORAL|Motivational Enhancement System for Health (MESH)|Motivational Enhancement System for Health (MESH) is an attentional control providing information on nutrition and exercise.
223582517|NCT05389501|BEHAVIORAL|Social policy intervention to support women of reproductive years|"The project team will attempt to address this challenge by delivering the following interventions through social workers in underdeveloped primary healthcare settings to promote maternal and child health:~1. Developing a database on a digital app of participants in the study and use the data for development of an Index for Maternal Health and Wellbeing~2. Conducting a Community Assessment Needs~3. Conduct a psychosocial needs assessment~4. Develop interprofessional health workforce collaboration~5. Measure basic clinical health indicators~6. Provide health awareness and literacy training to participants"
223582518|NCT02515201|DRUG|Taurolidine|taurolidine in central catheter lumen
223582519|NCT02515201|DRUG|Heparin|heparin in central venous catheter lumen
224162504|NCT03389269|OTHER|Meal test|240 min mixed meal test with aspiration using AspireAssist.
224162505|NCT00453323|DRUG|Paclitaxel|paclitaxel 80mg/m2 iv on day 1 and 8, every 3 weeks
224162506|NCT00453323|DRUG|Capecitabine|capecitabine 900mg/m2 bid po on day 1\~14, 1 weeks rest, until disease progression
223475876|NCT03708146|DRUG|Placebo|"matching placebo tablet; Oral, once-daily, from Day 1 to Day 10. In Cohorts 1, 3, 5, 7 and 9 (fasted), placebo will be orally administered in the morning after a minimum of 8 h fast. Subjects will remain fasted until 4 h post-dose and will receive lunch approximately 4 h after dosing.~In Cohorts 2, 4, 6, 8 and 10 (fed), placebo will be orally administered in the morning after a moderate breakfast (containing approximately 550 kcal with fat contributing approximately 150 kcal). The meal should be consumed over a maximum period of 25 min, with dosing occurring 30 min after the start of the meal.~Each dose will be administered with 240 mL water."
223582520|NCT04097496|BEHAVIORAL|Act Out! Intervention|Data included in the description of the intervention arm.
223582521|NCT06243055|OTHER|questionnare|laval questionnare
223475877|NCT01915316|OTHER|prostate biopsy|Measurements of Zinc concentration along fresh Specimens taken during Trans-Perineal saturated repeat Prostate Biopsy before Specimens are sent to Pathology.
223475878|NCT00434252|DRUG|bevacizumab|15 mg/kg by intravenous (IV) infusion on the first day of each 3-week cycle (dose was based on patient's weight at screening and remained the same throughout study)
223582522|NCT06243055|OTHER|questionnare|Obese-Specific Quality of Life
223582523|NCT06243055|OTHER|questionnare|SF-12 Quality of Life scale
223582524|NCT00864851|BIOLOGICAL|Replagal|Intravenous (IV) infusion for 12 months
223582525|NCT03425721|OTHER|No Intervention|No Intervention is administered in this study.
223582526|NCT05041569|OTHER|MRI sequences|perform additional sequences added by research
223582527|NCT05588037|PROCEDURE|FLACS +PPV+IOL + air|The procedures are combined the FLACS +PPV+IOL + air.
223582528|NCT05588037|PROCEDURE|FLACS +PPV+IOL + epiretinal membrane peeling + Ozurdex|The procedures are combined the FLACS +PPV+IOL + epiretinal membrane peeling + Ozurdex.
223582529|NCT05588037|PROCEDURE|FLACS + PPV+IOL + internal limiting membrane peeling + air|The procedures are combined the FLACS + PPV+IOL + internal limiting membrane peeling + air.
223744345|NCT01522365|DEVICE|Implant-supported XiVE CAD/CAM bridge|One side will be provided with a XiVE CAD/CAM bridge fixed directly on the implant
223744346|NCT03320772|DRUG|TMVP1-ICG|Detection of SLN
223475879|NCT00434252|DRUG|carboplatin|Dose based on patients' creatinine clearance (Calvert formula) and administered by intravenous (IV) infusion on the first day of each 3-week cycle, for a maximum of 10 cycles
223744347|NCT03320772|DRUG|ICG|Detection of SLN
224070027|NCT04872101|DRUG|Cream vehicle|The cream vehicle is similar to the delgocitinib cream except that it does not contain any active ingredient.
224070028|NCT02269527|OTHER|Live music|Providing 1-hour live music 5 days/ week.
224070029|NCT02029287|OTHER|Hospital-Community-Family-Care Management Platform Online|Hospital-Community-Family-Care Management Platform Online: the remote monitoring service platform on line based on community and family for subjects with CHF under the guidance of the regional central hospital
223475880|NCT00434252|DRUG|paclitaxel|175 mg/m\^2 by IV infusion on the first day of each 3-week cycle (dose was based on patient's weight and could be adjusted for weight change)
223582530|NCT05588037|PROCEDURE|FLACS + PPV+IOL|The procedures are combined the FLACS + PPV+IOL.
223582531|NCT01790555|DRUG|Namisol|
223582532|NCT01790555|DRUG|Diazepam/placebo|
223582533|NCT05810714|OTHER|Best Practice|Receive usual care
223582534|NCT05810714|OTHER|Fecal Immunochemical Test|Receive FIT kit
224070030|NCT02029287|OTHER|Subjects with CHF via conventional clinic visit according to the latest relevant guidelines|Subjects with CHF via conventional clinic visit according to the latest relevant guidelines
223582535|NCT05810714|BEHAVIORAL|Health Education|Receive audio brochure
223582536|NCT05810714|BEHAVIORAL|Health Education|Receive video brochure
223582537|NCT05810714|OTHER|Scheduled Notification|Receive scheduled reminder
223582538|NCT05810714|OTHER|Survey Administration|Ancillary studies
223582539|NCT05291559|DIETARY_SUPPLEMENT|Enterade|Enterade is a glucose-free, amino acid-based medical food containing specific amino acids (aspartic acid, valine, serine, threonine and tyrosine) in addition to electrolytes and a non-sugar sweetener.
223582540|NCT05291559|DIETARY_SUPPLEMENT|Placebo|The placebo is an identical product to Enterade except without added amino acids.
223582541|NCT01842581|DRUG|Rifaximin|Rifaximin will be administered per the dose and schedule specified in the arms.
223582542|NCT01842581|DRUG|Lactulose|Laculose will be administered per the schedule specified in the respective arm.
223582543|NCT00940784|DRUG|Clopidogrel (Plavix)|Clopidogrel, aspirin plus hydroxyurea 75mg qd (Plavix) + 81 - 100 mg qd (aspirin) + hydroxyurea
223582544|NCT00940784|DRUG|Placebo|Placebo, aspirin (81-100 mg qd) plus hydroxyurea
223582545|NCT00940784|DRUG|Aspirin|81-100 mg qd
223582546|NCT05736939|OTHER|Out-patient Pulmonary Rehabilitation|Pulmonary Rehabilitation (PR) programme consisting of 30 minutes interval aerobic exercise on cycle ergometers at 100% of peak work rate (WRpeak) and resistance exercises for the upper body. Dyspnoea and leg discomfort were recorded on the modified 1-10 Borg scale, whereas heart rate (HR) and oxygen saturation (SpO2%) were monitored by a pulse oximeter. Based on symptoms of breathlessness and fatigue reported at the end of each session, the exercise intensity was increased by 5-10% of the baseline WRpeak in the next session. The remote 24 home-based PR sessions consisted of 30 minutes walking with an individualised target of steps, recorded via the mobile app installed in the patients' mobile phone. The steps, leg discomfort and dyspnoea were reported by the patient via a physical activity diary on a weekly basis. If dyspnoea and fatigue were both \<4 at the Borg scale the weekly target of steps was increased by 5-10% by the assessors.
223744348|NCT00673179|DRUG|Doxorubicin|Pre-Surgery, Regimen 1: IV Over 15 Minutes on Day 1 of Weeks 1 and 6; Post-Surgery, Regimen 1: IV on Day 1 of Weeks 16, 21, and 26; Pre-Surgery, Regimen 2: IV over 15 Minutes on Day 1 of Weeks 1, 4, and 7. Dose 90 mg/m\^2.
223744349|NCT00673179|DRUG|Cisplatin|Pre-Surgery, Regimen 1: IV Over 48 Hours, on Days 1 and 2 of Weeks 1 and 6; Post-Surgery, Regimen 1: IV Over 48 Hours, on Days 1 and 2 of Weeks 16, 21, and 26. Pre-Surgery, Regimen 2: Infusion through an artery over 4 hours on Day 1 of Weeks 1, 4, and 7. Dose 60 mg/m\^2/day for 2 days continuous infusion.
223744350|NCT00673179|DRUG|Methotrexate|Pre-Surgery, Regimen 1: IV Over 4 Hours on Day 1 of Weeks 4, 5, 9, and 10; Post-Surgery, Regimen 1: IV Over 4 Hours on Day 1 of Weeks 14, 15, 19, 20, 24, 25, 29, and 30; Post-Surgery, Regimen 2: IV Over 4 Hours on Day 1 of Weeks 14, 15, 20, 21, 26, 27, 32, 33, 38, and 39. Dose 12 gm/m\^2, max 20 gm over 4 hours.
223475881|NCT00434252|DRUG|placebo|Administered by IV infusion on the first day of each 3-week cycle
223475882|NCT02442908|DIETARY_SUPPLEMENT|Nutrifriend Cachexia|2 daily for 12 weeks
223475883|NCT02442908|DIETARY_SUPPLEMENT|Isocaloric placebo|2 daily for 12 weeks
223475884|NCT05175625|BIOLOGICAL|SARS-CoV-2 recombinant spike protein + Advax-SM adjuvant|SARS-CoV-2 recombinant spike protein (25 µg) with Advax-SM adjuvant (15 mg); a single intramuscular injection into the deltoid muscle of the non-dominant arm
223475885|NCT05175625|BIOLOGICAL|Saline placebo|0.9% sodium chloride (1 mL); a single intramuscular injection into the deltoid muscle of the non-dominant arm
223582547|NCT00967759|DRUG|Bronpheniramine and fenilefrine (Decongex Plus)|Oral Solution: Bronpheniramine (2mg/ml) and fenilefrine (2,5mg/ml) 2 drops/kg/day divided into 3 doses; maximum of 60 drops/day QID, during 5 days.
223582548|NCT00967759|DRUG|Bronpheniramine isolated|Oral Solution: Bronpheniramine (2mg/ml) 2 drops/kg/day divided into 3 doses; maximum of 60 drops/day QID, during 5 days.
223582549|NCT00967759|DRUG|Fenilefrine isolated|Oral Solution: Fenilefrine (2,5mg/ml) 2 drops/kg/day divided into 3 doses; maximum of 60 drops/day QID, during 5 days.
223582550|NCT00353873|DRUG|Fluticasone propionate|200μg twice daily
223582551|NCT00353873|DRUG|Fluticasone propionate/salmeterol|50/100μg twice daily
223582552|NCT00487643|PROCEDURE|Tear Collection|The tear sample will be collected from the left eye of each subject. Subjects wearing contact lenses will be instructed to remove their lenses and wait at least 5 minutes before proceeding with the tear collection procedure. The patient will then be instructed to sit with eyes gently closed for two minutes after instilling one (1) drop of 0.5% proparacaine on the cornea and conjunctiva. Tear collection was accomplished by using a polyester fiber rod wick. This wick will be placed in contact with the tear fluid at the lower cul-de-sac for a minimum time to obtain fluid without irritating the subject's eye approx. for 3 to 5 minutes.
223582553|NCT04049929|DRUG|YY-20394|YY-20394 is a new type of PI3K-δ selective inhibitor which differs structurally from idelalisib and its analogs, showing high potency against PI3Kδ, but with markedly improved selectivity (\>1,000-fold selectivity for PI3K-δ versus PI3Kγ). This higher selectivity for PI3Kδ may decrease the risk of serious infection seen with idelalisib and especially with duvelisib due to strong immune suppression.Preclinical evaluation has demonstrated improved efficacy and safety for YY-20394 compared to idelalisib.
223582554|NCT03837288|PROCEDURE|Cerclage|Cervical cerclage under effect of spinal anaesthesia
223582555|NCT01848470|DRUG|CG400549 640mg|multiple oral doses of 640 mg CG400549 (n=6) BID for 5 days (Days 1-5) and a final dose on Day 6 in the fed state
223582556|NCT01848470|DRUG|CG400549 320 mg|multiple oral doses of 320 mg CG400549 (n=6) QD for 5 days in the fed state
223475886|NCT01899092|DRUG|TT-034|The study drug will be given as a single dose IV infusion on Day 1. 5 different dose levels corresponding to the 5 cohorts of the study will be given.
223582557|NCT01848470|DRUG|CG400549 640 mg|multiple oral doses of 640 mg CG400549 (n=6) QD for 5 days in the fed state
223582558|NCT01848470|DRUG|CG400549 960 mg|multiple oral doses of 960 mg CG400549 (n=6) QD for 5 days in the fed state
223582559|NCT01848470|DRUG|Placebo 640mg|multiple oral doses of 640 mg placebo (n=2) BID for 5 days (Days 1-5) and a final dose on Day 6 in the fed state
223582560|NCT01848470|DRUG|Placebo 320mg|multiple oral doses of 320 mg placebo (n=2) QD for 5 days in the fed state
223582561|NCT01848470|DRUG|placebo 960 mg|multiple oral doses of 960 mg placebo (n=2) QD for 5 days in the fed state
223582562|NCT01848470|DRUG|Placebo 640mg|multiple oral doses of 640 mg placebo (n=2) QD for 5 days in the fed state
224162507|NCT03091426|DRUG|Omiganan|Omiganan 1%
224162508|NCT03091426|DRUG|Omiganan|Omiganan 1.75%
224162509|NCT03091426|DRUG|Omiganan|Omiganan 2.5%
223475887|NCT03811938|PROCEDURE|Low voltage ablation|Catheter ablation of low voltage areas in the left atrium and catheter ablation aiming for the electrical isolation of the pulmonary veins.
223475888|NCT03811938|PROCEDURE|Pulmonary Vein Isolation|Catheter ablation aiming for the electrical isolation of the pulmonary veins.
223475889|NCT05395507|DRUG|Recombinant Interferon Alpha|Recombinant Interferon Alpha, with an initial dose of 300 wu three times a week. Other interferons that have been listed can be used if Recombinant Interferon Alpha (300 wu) is not available.
223582563|NCT00110487|DRUG|ERB-041|
224070031|NCT02115464|DRUG|Metformin plus Chemo-radiotherapy|Metformin 2000 mg a day for 12 months plus cisplatin-based chemotherapy with or without consolidation with standard radiotherapy of 60-63 Gy for 6 weeks.
224070032|NCT02115464|RADIATION|Chemo-radiotherapy|Cisplatin-based chemotherapy with or without consolidation with standard radiotherapy of 60-63 Gy for 6 weeks.
224070033|NCT03907332|OTHER|Home visits|An experimental design, a cluster randomized controlled trial (RCT) will be used. A total of 20 clusters will be randomized with block randomization of electoral areas with a) resident staff midwives and b) resident Community Health Nurse midwifes. All women residing in an electoral area will receive the same intervention for practicality and to prevent contamination.
224070034|NCT04057625|DEVICE|transthoracic ultrasound|using transthoracic ultrasound in the diagnosis and follow up of vap,measuring the largest area of consolidation according to intercostal space and the direction of the probe.
224070035|NCT03807713|DEVICE|Minimally Invasive Ponto Surgery|Minimally Invasive Ponto surgery is used for hearing rehabilitation using Ponto Wide Implants in patients indicated and counselled for Bone Anchored Hearing Systems.
224162510|NCT03091426|DRUG|Placebo|Vehicle
224162511|NCT00588757|DEVICE|Optease IVC filters|IVC filters will be implemented and evaluated for retrieval after 2-3 weeks.
224162512|NCT00588757|DEVICE|Gunter-Tulip IVC filters|IVC filters will be implemented and evaluated for retrieval after 2-3 weeks.
223475890|NCT05395507|DRUG|Pegylated interferon alfa-2b|Pegylated Interferon Alfa-2b, with an initial dose of 135 ug at week 0 , and then 180 ug once a week from week 1 to week 52.
223475891|NCT03351270|OTHER|Standardized strength, respiratory and motor function assessments|Standardized assessments will be adjusted by the age, the ambulant status and the respiratory status of the patient. The visit frequency will also be adjusted according to the age and to the time spent in the study varying between quarterly to yearly.
223475892|NCT00066456|RADIATION|3-Dimensional Conformal Radiation Therapy|
223475893|NCT00066456|DRUG|Chemosensitization/Potentiation Therapy|
223475894|NCT00066456|DRUG|Docetaxel|Given IV
224162513|NCT06932133|DIAGNOSTIC_TEST|Point-of-care ultrasound|Point-of-care ultrasound will be performed on symptomatic breast patients. The images will be analysed by AI
223475895|NCT04852822|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
223475896|NCT04852822|OTHER|Electronic Health Record Review|Medical records are reviewed
223475897|NCT04675879|DEVICE|Shoulder arm bandage|Three different shoulder-arm bandage types
224162514|NCT06286267|DIAGNOSTIC_TEST|imaging|Patient medical imaging materials including ultrasound, mammography, CT, MRI
224162515|NCT06234072|DRUG|Astragalus + Gemcitabine|Participants will receive Astragalus combined with Gemcitabine. Astragalus, a traditional Chinese medicine, exhibits promising potential in cancer treatment. Studies suggest its role in regulating immune responses, suppressing tumors, and improving overall treatment outcomes in cancer patients. Astragalus combined with chemotherapeutic drug such as Gemcitabine is a popular complementary and alternative therapy used for cancer patients because it can increase therapeutic effects and decrease side effects. This synergistic approach holds potential for more effective and targeted therapeutic outcomes in pancreatic cancer patients.
223475898|NCT02130219|DEVICE|Non-invasive intracranial pressure measurement|The noninvasive ICP measurement device Vittamed 205 aICP meter used in this study has been developed in Lithuania. The method is based on two-depth transcranial Doppler technique for simultaneously measuring flow velocity pulsatilities in the intracranial and extracranial segments of the ophthalmic artery (OA). These measurements are made while applying a series of small pressure steps to the tissues surrounding the eye-ball. The intracranial segment of the OA is compressed by ICP and the extracranial segment of the OA is compressed by the externally applied pressure Pe. Blood flow pulsatility parameters in both of these OA segments are monitored.Pulsatilities are approximately the same when Pe = ICP. Two-depth TCD device is used as an indicator of the pressure balance point.
223475899|NCT02130219|DEVICE|Brain MRI/CT|"1.5 T MRI using T1 and T2 regimes, brain MRI angiography, performed for selected patients to analyze anatomical features of ophthalmic artery and optical nerves sheath diameter.~Brain CT performed to evaluate hemorrhage and stroke volume."
223475900|NCT02130219|PROCEDURE|Lumbar puncture and cerebrospinal fluid pressure measurement|Lumbar puncture performed in lateral decubitus position while knees and head flexed. After local antiseptics and anesthesia puncture in lumbar 3/4 or 4/5 intervertebral space performed. As CSF appears legs and head are relaxed and slightly straightened. Spinal manometer graded 0-40 cm H₂O with stopcock connected to the needle. CSF pressure monitored for 10 minutes and recorded. CSF collected for diagnostic test. Spinal needle Number 22 and Rocket Spinal Manometer Set (No. R55990) used for this study.
223475901|NCT03150043|DEVICE|Masimo Rainbow Pulse CO-oximeter|Masimo Rainbow Pulse CO-oximeter will be used to measure hemoglobin values of pregnant women during primary cesarean delivery
223475902|NCT03736018|DIAGNOSTIC_TEST|CTCA|Computed Tomography Cardiac angiography (CTCA) performed prior to invasive coronary angiogram (ICA).
223475903|NCT02733419|DRUG|Enfuvirtide|Participants will receive 90 mg enfuvirtide subcutaneously (SC) b.i.d.
223475904|NCT02733419|DRUG|Optimized background antiretroviral regimen (OB)|Participants will receive OB (nucleoside and or non-nucleoside reverse transcriptase inhibitor and protease inhibitor) as per investigator's discretion. Protocol does not specify any particular OB drugs.
223475905|NCT05104593|OTHER|Intervention tested (CAREPATH)|The intervention tested will be the CAREPATH system. CAREPATH consists of an integrated, patient-centred, flexible and modular system that will provide a viable solution for the improvement of the management of multimorbid elderly patients with Mild Cognitive Impairment or mild dementia, with the help of clinicians. CAREPATH will act on patients and their informal caregivers, and its main objective is to empower multimorbid patients with MCI or mild dementia to manage their health condition together with their informal caregiver by providing assistance and reinforcement to follow their individual care plans, so independence and quality of life will increase for both of them. The intervention will provide a personalized care plan and activities proposal (treatment, activities proposal, lifestyle changes, referrals etc.) to patients and caregivers, considering the various sources of patient data available through the CAREPATH platform, and with the help of clinicians.
223475906|NCT06133166|DRUG|EG017 ointment|Apply once a night on the skin side of both eyelids at bedtime, approximately 100 mg/eye per dose, for 8 weeks
223475907|NCT06133166|DRUG|EG017 ointment placebo|Apply once a night on the skin side of both eyelids at bedtime, approximately 100 mg/eye per dose, for 8 weeks
223475908|NCT02868944|DRUG|experimental group : sequential combined spinal epidural with local anesthetic injection (chirocaine) associated with morphine (sufentanil).|
223475909|NCT02868944|DRUG|control group : sequential combined spinal epidural with local anesthetic injection (chirocaine) alone.|
223475910|NCT01029756|DEVICE|Macintosh Laryngoscope|Device used to gain a direct view of the vocal cords, to enable an endotracheal tube to be passed into the trachea at induction of anaesthesia.
223475911|NCT01029756|DEVICE|Pentax AWS Videolaryngoscope|Self-contained video laryngoscope with an integral colour-viewing screen mounted on the handle. A camera at the tip transmits an indirect image, which obviates the need to obtain a direct view of the vocal cords, when passing an endotracheal tube on induction of anaesthesia.
223475912|NCT04938050|DIAGNOSTIC_TEST|Ultrasound|Ultrasound evaluation, with grayscale and color Doppler imaging.
223475913|NCT00566826|BEHAVIORAL|Patient support sessions|Patient support sessions aim to enhance patient self-care for independent exercise and physical activity.
223475914|NCT00566826|BEHAVIORAL|Treatment as usual|Treatment as usual includes standard care for TKR surgery rehabilitation.
223475915|NCT05029492|OTHER|Low-calorie diet|Low-calorie diet of 1200 kcal for 3 months, modified every two weeks.
223475916|NCT05029492|OTHER|Visceral manipulation with diet|Visceral manipulation to the pelvic organs and their related structures (8 sessions, once per week in the first month then once every other week for two months) added to the same low-calorie diet as the group (A).
223475917|NCT01100788|DIETARY_SUPPLEMENT|Short chain fructo-oligosaccharide (scFOS) 5 g|"Dietary Supplement: scFOS 5 g~Novel fiber administered in two 5 g doses--the first in a beverage and the second in a solid chew."
224162516|NCT06234072|DRUG|Gemcitabine alone|Gemcitabine is a potent chemotherapy drug widely employed in treating various cancers, including pancreatic cancer. As a nucleoside analog, it disrupts DNA synthesis, impeding cancer cell proliferation. Gemcitabine is administered intravenously and has shown efficacy in alleviating symptoms, improving survival rates, and enhancing the quality of life for patients undergoing cancer treatment.
223475918|NCT01100788|OTHER|Placebo|Treatment without scFOS fiber
223475919|NCT01100788|DIETARY_SUPPLEMENT|Short chain fructooligosaccharide (scFOS) 8 g|Novel fiber administered in two 8 g doses--the first in a beverage and the second in a solid chew.
223475920|NCT00906321|BEHAVIORAL|Web-Based Decision Support|
223475921|NCT02431013|DRUG|Simvastatin|Simvastatin 40 mg on Day 1 \& Day 8.
223475922|NCT02431013|DRUG|Pravastatin|Pravastatin 20 mg on Day 1 \& Day 8.
223475923|NCT02431013|DRUG|Cilostazol|Cilostazol 100 mg twice a day for 6 days \& on Day 8 with statin.
223475924|NCT00300157|DEVICE|Percutaneous coronary intervention with Taxus stent|
223475925|NCT02997163|DRUG|Talazoparib|Daily oral doses of talazoparib 0.5 mg
223582564|NCT01986972|OTHER|Toothbrushing With Dentifrice|The participants were instructed to interrupt any chemical and/or mechanical oral hygiene procedure for 72 hours. Dental plaque was stained by a 2% erithrosin solution, followed by a mouth rinsing with water for 1 minute. Next, the set of dental quadrants (1-3 and 2-4) were randomly allocated to experimental groups by the flip of a coin. One of the sets was brushed with multi bristle brush without the use of dentifrice and the second set was brushed with multi bristle brush using dentifrice. Toothbrushing was performed by the individual's regular technique timed. Two minutes was used for each set. After toothbrushing, the dental biofilm was again stained and evaluated by the same examiner, who was blind to the quadrants brushed with or without dentifrice.
223582565|NCT01986972|OTHER|Toothbrushing Without Dentifrice|The participants were instructed to interrupt any chemical and/or mechanical oral hygiene procedure for 72 hours. Then, dental plaque was stained by a 2% erithrosin solution, followed by a mouth rinsing with water for 1 minute. Next, the set of dental quadrants (1-3 and 2-4) were randomly allocated to experimental groups by the flip of a coin. One of the sets was brushed with multi bristle brush without the use of dentifrice and the second set was brushed with multi bristle brush using dentifrice. Toothbrushing was performed by the individual's regular technique timed. Two minutes was used for each set. After toothbrushing, the dental biofilm was again stained and evaluated by the same examiner, who was blind to the quadrants brushed with or without dentifrice.
223582566|NCT04367467|OTHER|Kidney Function Test|Cystatin-C measurement
223582567|NCT03946865|OTHER|Reiki Therapy|Reiki is a healing practice that originated in Japan. Reiki practitioners place their hands lightly on or just above the person receiving treatment, with the goal of facilitating the person's own healing response.
223582568|NCT01189305|BEHAVIORAL|Behavioral Couples Therapy|Behavioral Couples Therapy
223582569|NCT01189305|BEHAVIORAL|Individual Drug Counseling|Individual Drug Counseling
223475926|NCT04735614|DEVICE|Posthorax Thoraxbelt|The patients will be assisted to put on the ThoraxBelt after the surgery by our research member and will be asked to keep it on except for during showering through the whole study period.
223475927|NCT01059331|DRUG|Pregabalin|150 mg x 2 daily for 2 days
223475928|NCT01059331|DRUG|Sugar pill|1 tablet x 2 daily, for 2 days
223475929|NCT05053490|OTHER|Static Stretching|Static stretches are those in which you stand, sit or lie still and hold a single position for a period of time.
223475930|NCT05053490|OTHER|dynamic stretching|Dynamic stretching involves making active movements that stretch the muscles to their full range of motion.
223475931|NCT02931461|PROCEDURE|Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration|
223744351|NCT00673179|DRUG|Leucovorin|Pre- and Post-Surgery, Regimen 1: IV Over 5 minutes on the day after each methotrexate dose and then by mouth every 6 hours; Post-Surgery, Regimen 2: IV Over 5 minutes on the day after each methotrexate dose and then by mouth every 6 hours. Dose 10 mg IV, with 10 mg orally every 6 hours.
224162517|NCT01655940|DEVICE|Somanetics cerebral oximeter|Somanetics cerebral oximeter
224162518|NCT01655940|DEVICE|CASMED cerebral oximeter|CASMED cerebral oximeter
223475932|NCT02470741|DRUG|Letrozole|
223475933|NCT02470741|OTHER|Placebo|
223475934|NCT05478109|DRUG|[14C]XZP-3287|360 mg suspension containing 50µCi of \[14C\] XZP-3287
223475935|NCT01446705|OTHER|Active Health Information Exchange|Patients selected to share data between the VA \& external healthcare agencies.
223475936|NCT01446705|OTHER|Non-Active Health Information exchange|Patients not selecting to share data
224162519|NCT00354939|DRUG|Insulin glargine|
224162520|NCT06506851|OTHER|AR-based Training with Microsoft HoloLens 2®|Practical nurses in this group receive AR-based training using Microsoft HoloLens 2®. This training method incorporates augmented reality technology to provide immersive and interactive learning experiences, enhancing their proficiency in device utilization.
224162521|NCT06506851|OTHER|Traditional Guideline-based Self-Learning|Practical nurses in this group follow traditional guideline-based self-learning methods without augmented reality technology. They rely on conventional educational materials and guidelines for learning device utilization skills.
224162522|NCT02072746|DIETARY_SUPPLEMENT|Zinc|
224162523|NCT02072746|DIETARY_SUPPLEMENT|Placebo|
224162524|NCT03872557|DIETARY_SUPPLEMENT|Tyrosine (TYR) Supplementation|L-Tyrosine dietary supplement will be provided as 500 mg capsules and 4 (four) 500 mg capsules are to be given before OGTT. The capsules are formed from animal gelatin, and the contents are formulated with magnesium stearate as a flow agent, but without binders, coatings or colorings and also have no added flavorings, sugars, salt, artificial sweeteners, preservatives or salicylates. The capsules are to be administered with less than eight ounces of water to minimize dilution of gastric acidity.
223475937|NCT02880501|DEVICE|proximal femoral nail antirotation|Twenty patients with intertrochanteric femoral fracture scheduled to undergo proximal femoral nail antirotation (PFNA) implantation.
223475938|NCT06066775|OTHER|Observation study without intervention|Observation study without intervention
223475939|NCT04238741|OTHER|Audio-recording of consent for anaesthesia for elective caesarean section|Antenatal women will be invited to attend 5-15 days before their caesarean section for an anaesthetic consent discussion with audio-recording. Participants will complete a questionnaire immediately following the recorded discussion and again within the 48 hours following their surgery, to establish their views on the process of audio-recording of consent and the potential usefulness/acceptability of the audio-recording.
223475940|NCT01680263|DEVICE|Kinesiotaping|"Use of kinesiotaping on the painful area in the form of space correction. Kinesiotaping was repeated for 3 weeks with 1week interval"
223475941|NCT01680263|PROCEDURE|NSAIDs/Physical therapy|Use of non-steroidal anti-inflammatory drugs and 10 sessions of daily physical therapy.
223475942|NCT04814797|OTHER|Capnography data included in Lung Clearance Index measurement|Capnography data included in Lung Clearance Index measurement (a pulmonary function test included in routinely yearly follow-up of cystic fibrosis children) will be collected and analyzed
223475943|NCT05798312|OTHER|Customizable support material|Customizable support material will enable patients to identify their personal breast cancer information.
223475944|NCT05798312|OTHER|Non-customizable support material|Non-customizable support material will include general breast cancer information.
223475945|NCT00021164|BIOLOGICAL|aldesleukin|
223475946|NCT00021164|BIOLOGICAL|incomplete Freund's adjuvant|
223475947|NCT00021164|BIOLOGICAL|telomerase: 540-548 peptide vaccine|
223475948|NCT00140439|BEHAVIORAL|Emergency Department based asthma follow-up clinic|"The clinical activities of the intervention followed a fully specified protocol and provided education and care in three domains:~1. Asthma self-monitoring and management: Educators first reviewed the basic physiology of asthma with emphasis on its chronicity. After evaluating asthma severity and treatment history, the physician completed an individualized medical action plan (MAP) and provided any necessary device teaching.~2. Environmental modification and trigger control: After evaluation of potential environmental triggers in the home, each family was educated on their control. Each child was provided hypoallergenic bed encasings.~3. Linkages and referrals to ongoing primary care: Clinic staff stressed the importance of longitudinal asthma care by a PCP. A full report of the clinic visit was mailed to each child's PCP. In addition, the asthma educator scheduled a follow-up appointment with the PCP within 4 weeks"
223475949|NCT01949545|DRUG|Carfilzomib|Carfilzomib was administered by IV injection over 30 minutes
223582570|NCT03625752|DEVICE|Active Comparator: Active tDCS + Active TUS|Device: transcranial Direct Current Stimulation (tDCS) Subjects will receive 20 minutes of either active or sham tDCS at intensity of 2mA. The anodal electrode will be placed over the primary motor cortex contralateral to the most painful side, and the cathodal electrode will be placed over the contralateral supraorbital area. In the sham group, the tDCS device will not be active for the full 20 minutes. Device: Transcranial Ultrasound (TUS) Subjects will receive 20 minutes of either active or sham TUS. During active stimulation the ultrasound will be active for the full 20 minutes- however, during sham stimulation the ultrasound will not be active for the full 20 minutes.
223582571|NCT03625752|DEVICE|Sham|Device: SHAM Comparator Device: transcranial Direct Current Stimulation (tDCS) Subjects will receive 20 minutes of either active or sham tDCS at intensity of 2mA. The anodal electrode will be placed over the primary motor cortex contralateral to the most painful side, and the cathodal electrode will be placed over the contralateral supraorbital area. In the sham group, the tDCS device will not be active for the full 20 minutes. Device: Transcranial Ultrasound (TUS) Subjects will receive 20 minutes of either active or sham TUS. During active stimulation the ultrasound will be active for the full 20 minutes- however, during sham stimulation the ultrasound will not be active for the full 20 minutes.
223582572|NCT02717130|DRUG|Aripiprazole|
223582573|NCT02257723|DRUG|Herbal medicine|Herbal medicine was taken 3 times daily in dried powder (2g) and water-base decoction form (120ml) (Ostericum koreanum, Eucommia ulmoides, Acanthopanax sessiliflorus, Achyranthes bidentata, Psoralea corylifolia, Peucedanum japonicum, Cibotium barometz, Lycium chinense, Boschniakia rossica, Cuscuta chinensis, and Atractylodes japonica).
223582574|NCT02257723|PROCEDURE|Acupuncture|Acupuncture treatment was administered 1-2 times daily using mainly Ah-shi points and local acupuncture points.
224162525|NCT06948552|DRUG|5-Aminolevulinic acid Hydrochloride (Gliolan®)|Participants will receive a single oral dose of 5-aminolevulinic acid (20 mg/kg) approximately 2 to 4 hours prior to surgery. The goal is to evaluate the feasibility of using fluorescence cystoscopy with blue light to improve tumor detection and visualization during ureteroscopic resection of upper tract urothelial carcinoma.
224162526|NCT06949293|OTHER|Hand massage with lavender oil|Each hand of the patient will be massaged with lavender oil for 5 minutes before and during cystoscopy. Before the application, 5% lavender oil will be applied to a small part of the hand and this area will be monitored for signs of allergic reaction such as swelling and redness. If no allergic reaction is observed, the study will continue.
224162527|NCT06949293|OTHER|Classic hand massage|Each hand of the patient will be massaged with baby oil for 5 minutes before and during the cystoscopy procedure.
223475950|NCT01050153|DRUG|Dalteparin sodium|Dalteparin sodium injection 5000IU subcutaneously daily until fully ambulatory
223475951|NCT01050153|DRUG|Dalteparin sodium/aspirin|Dalteparin sodium (2500-10,000IU sc daily), aspirin (81-325mg daily) po.
223475952|NCT03631641|BIOLOGICAL|Nivolumab|Given IV
223475953|NCT03520010|BEHAVIORAL|Externally-facilitated implementation|NHs randomized to the externally-facilitated arm will attend the same kickoff meetings and have access to the same online resources as the control arm but will also be assigned a clinical coach and will have the opportunity to participate in a series of hosted peer-to-peer learning opportunities. The clinical coach will meet regularly with NH staff to guide the facility through implementation of the Wisconsin UTI Improvement Toolkit.
223475954|NCT03520010|BEHAVIORAL|Internally-driven implementation|Study NHs randomized to the control arm will participate in kickoff meetings introducing the different UTI toolkit components. The meeting will also cover topics on how to assemble a change team, how to use the different tools in the UTI toolkit, and how to track process and outcome measures to monitor progress. NHs assigned to the control arm will have access to a web-based data tracking tool that will allow them to trend a number of study outcomes (e.g., number of monthly urine cultures and UTI treatment events) in their facility over time. Instructions and educational tools will be made available as an online resource but otherwise NHs in the control arm will be expected to implement the Wisconsin UTI Improvement Toolkit using existing internal resources.
223744352|NCT00673179|DRUG|Dexrazoxane|Dose 900 mg/m\^2 IV Push with doxorubicin. Pre-Surgery, Regimen 2: IV Over 15 minutes on Day 1 of Weeks 1, 4, and 7.
223744353|NCT00673179|DRUG|Ifosfamide|Post-Surgery, Regimen 2: IV continuously over 5 days each time, on Weeks 16, 22, 28, and 34. Dose 2.8 gm/m\^2. Dose 2.8 grams m\^2/day.
223744354|NCT00673179|BEHAVIORAL|Questionnaire|Questionnaires to be completed on 5 different days during the study.
224162528|NCT06949293|OTHER|Lavender inhalation|Before and during the cystoscopy procedure, 2-3 drops of 5% lavender oil will be poured onto a 5x5 cm sterile gauze. It will be placed 10 cm away from the patient's nose and sniffed for 10 minutes.
223475955|NCT06199739|BEHAVIORAL|Early-Weight bearing|The patients began early weight bearing under attending physician and physiotherapist surveillance within 48 hours after surgery. Patients were instructed to stand up near the bed, and muscle power, gait stability, and pain tolerance were recorded. The physiotherapist instructed the patients to perform early mobilization and weight bearing as tolerable by self-adjustment of body weight distribution over the bilateral lower extremities, and walking assistance was used to prevent repeat falling accidents.
223475956|NCT05641571|BEHAVIORAL|The home-based extremity exercise program|Participants have to perform a total of 50 minutes of exercise including the Ten Skilled Hand exercise fourth a day, 5 minutes each time and Buerger Allen exercise twice a day, 15 minutes each time before chemotherapy to the completion of chemotherapy.
223475957|NCT02169882|DRUG|Placebo|"Patients receiving 450 mg rifampicin will receive additional 2 placebo tablets, while those who receive 900 mg rifampicin will receive 1 placebo tablet.~Patients receiving 1350 mg rifampicin will not receive any placebo tablet.~With this arrangement, every subject will receive 3 tablets of study drugs."
223475958|NCT02169882|DRUG|Rifampicin|"Patients in experimental arms will receive either 1 or 2 additional tablets of rifampicin.~Placebo tablets will be added accordingly, so that every study subject will receive 3 tablets of rifampicin plus placebo as described in the Arms section."
223475959|NCT02169882|DRUG|Other TB drugs|"Along with study drug and placebo, patients will receive other oral TB drugs (INH, Ethambutol, and Pyrazinamide) and pyridoxin, in accordance to National TB Program guidelines for 6 months.~Unconscious subjects will receive oral drugs via nasogastric tubes (NGT)"
223475960|NCT02169882|DRUG|Adjuvant dexamethasone|Patients will receive dexamethasone in decreasing dose (in 6-8 weeks, according to TBM severity grade on admission)
223475961|NCT02280434|DRUG|CBP-307|
223582575|NCT02257723|PROCEDURE|Pharmacopuncture|Select ingredients similar to those included in the oral herbal medicine (Ostericum koreanum, Eucommia ulmoides, Acanthopanax Sessiliflorus, Achyranthes bidentata, Psoralea corylifolia, Peucedanum japonicum, Cibotium barometz, Lycium chinense, Boschniakia rossica, Cuscuta chinensis, and Atractylodes japonica) were freeze dried into powder form after decoction, then diluted in normal saline and adjusted for acidity and pH to be used in injections. The pharmacopuncture injections were injected once daily to the amount of 1 cc and Ah-shi points and local acupuncture points (CPL, 1 cc, 26G x 1.5 syringe, Shinchang medical co., Korea).
223582576|NCT02257723|PROCEDURE|Bee venom pharmacopuncture|Bee venom pharmacopuncture was applied after confirming a negative reaction to the hypersensitivity skin test. Diluted bee venom (saline:bee venom ratio, 10,000:1) was injected at 4-5 acupoints at the physician's discretion. Each acupuncture point was injected with approximately 0.2 cc to a total of 0.5-1 cc using disposable injection needles (CPL, 1 cc, 26G x 1.5 syringe, Shinchang medical co., Korea).
223582577|NCT02257723|PROCEDURE|Chuna manipulation|Chuna was administered 3-5 times a week. Chuna is a Korean version of spinal manipulation that incorporates conventional spinal manipulation techniques for mobilization involving high-velocity, low amplitude thrusts to joints slightly beyond the passive range of motion and gentle force to joints within the passive range of movement.
223582578|NCT03255876|DIETARY_SUPPLEMENT|Enriched pomegranate juice|Pure pomegranate juice enriched with grape seed and apple peel extract (200 ml) to be consumed with 109 g of bread
223582579|NCT03255876|DIETARY_SUPPLEMENT|Placebo beverage|Beverage containing the same type and amount of carbohydrates as pomegranate juice and similar flavor (200 ml) to be consumed with 109 g of bread
223582580|NCT04254029|DIETARY_SUPPLEMENT|MOROLSTEVER1|The intervention consisted of a daily consummation of 425 ml of drink containing the extracts of 1,38mg of leaves extracts of moringa oleifera and 23,46 mg of stevia rebaudiana Bertoni leaves extracts lasting 45 days.
223582581|NCT01508845|DIETARY_SUPPLEMENT|cholecalciferol|800 IU vitamin D3, 1 dose; 800 IU deuterated vitamin D3, 1 dose
223582582|NCT01508845|DIETARY_SUPPLEMENT|cholecalciferol|50,000 IU vitamin D3, 1 dose; 800 IU deuterated vitamin D3, 1 dose
223582583|NCT01508845|DIETARY_SUPPLEMENT|cholecalciferol|50,000 IU vitamin D3, 1 dose; 800 IU vitamin D3, 1 dose
223582584|NCT01508845|DIETARY_SUPPLEMENT|cholecalciferol|50,000 IU vitamin D3, 1 dose; 800 IU deuterated vitamin D3, 1 dose
223582585|NCT00073463|GENETIC|tgAAVCF|
223582586|NCT02184832|DRUG|Metformin|2 doses of 500 mg metformin given approximately 12 hrs apart
224163620|NCT04193605|BEHAVIORAL|Mindfulness|The traditional MBSR intervention consists of the following: (1) a series of eight weekly session of 2.5 to 3 hours; (2) a silent retreat during the sixth week; (3) daily home assignments including formal and informal mindfulness practices; and (4) didactic presentations on stress and the consequences of stress. We are culturally tailoring the intervention with the goal of maintain fidelity.
223475962|NCT02280434|DRUG|Placebo|
223475963|NCT04699539|RADIATION|SBRT|SBRT: in 5-6fractions with Cyberknife.
223582587|NCT02184832|OTHER|Low tryptophan diet|
223582588|NCT02184832|OTHER|High tryptophan diet|
223582589|NCT00763945|OTHER|data collection|The data of patients is collected from their hospital documentation The follow-up of all patients is done via phone calls in order to collect data about the outcome of each patient
223582590|NCT01767272|DRUG|fexofenadine|fexofenadine brand name
223582591|NCT03624452|OTHER|rIPC + Exercise|The interventions consist of exercise training on a static bike three times per week and/or three bouts of rIPC per week for 8 weeks. A single bout of rIPC consists of cycles of upper arm cuff inflation for 5 minutes, followed by 5 minutes cuff deflation repeated 4 times.
223582592|NCT03624452|OTHER|rIPC only|Three bouts of rIPC per week for 8 weeks. A single bout of rIPC consists of cycles of upper arm cuff inflation for 5 minutes, followed by 5 minutes deflation repeated 4 times.
223582593|NCT00106691|DRUG|Toremifene 20 mg|The subject takes one dose by mouth of the 20mg Toremifine Citrate tablet once a day for the length of the trial (360 days).
223475964|NCT04699539|DRUG|Chemotherapy|Gemcitabine (1000mg/m2，d1, 8) + albumin-bound paclitaxel (125mg/m2，d1, 8) or single-agent oral S-1 (60-120 mg/ daily, d1-14) , repeat every 3 weeks.
223475965|NCT01675609|DRUG|Placebo|1 drop in each eye daily for up to 35 days
223475966|NCT01675609|DRUG|Brimonidine tartrate 0.025%|1 drop in each eye for up to 35 days
223475967|NCT04198168|DRUG|IV crystalloid fluid bolus|The participant receives IV fluid as a standardised bolus of 7 ml/kg (ideal body weight).
223475968|NCT00081003|GENETIC|gene expression analysis|
223475969|NCT00081003|GENETIC|protein expression analysis|
223475970|NCT00081003|OTHER|cytology specimen collection procedure|
223475971|NCT00081003|OTHER|laboratory biomarker analysis|
223475972|NCT00081003|OTHER|physiologic testing|
223582594|NCT00106691|DRUG|Placebo|The subject takes a placebo tablet identical in appearance to the toremifene 20mg tablet, administered by mouth daily for 360 days.
223582595|NCT02122809|DRUG|Chiauranib|Take orally
223582596|NCT00530920|DRUG|tipranavir|
223582597|NCT00530920|DRUG|ritonavir|
223582598|NCT04432805|DEVICE|Performing of lung ultrasound|Performing of lung ultrasound at bedside in labor ward or in COVID unit
223582599|NCT04320511|DEVICE|CT-V|CT-V is an image processing-based modality that recovers changes in local tissue volumes, induced by respiratory motion, from an inspiration-expiration CT (IE-CT) scan or a standard non-contrast 4D CT scan
223582600|NCT03345524|OTHER|Peer-Buddy System|"2-4 30-minute in person sessions with Peer Buddy (2 before and 2 after receiving CPAP)~Standard of care CPAP educational training~8-10 phone conversations with Peer Buddy over 3 month period~Subsequent 3 months use of phone system to contact Peer Buddy as needed"
223582601|NCT03345524|OTHER|Usual Care|"Standard of care CPAP educational training~Educational Brochures and DVD videos mailed to participants (12 times)"
223582602|NCT05117021|DRUG|Caudal Epidural Block using 0.25% plain bupivacaine dose 1 ml / kg and Ultrasound Guided Transversus Abdominis Plane Block using 0.25% plain bupivacaine dose 0.5 ml / kg|Caudal Epidural Block and Ultrasound Guided Transversus Abdominis Plane Block using 0.25% plain bupivacaine
224162529|NCT06948188|DIAGNOSTIC_TEST|Infrared exposure test|"Patients will undergo a standardized infrared exposure test (this test is specifically for research purposes) to evaluate the occurrence of cholinergic urticaria reaction.~IR exposure test with non-invasive core body temperature measurements, evaluate the occurrence of cholinergic urticaria up to 10 minutes after the end of the test, stop the test at the first clinical signs of urticaria.~Desk lamp with infrared bulb, switched on 20cm vertically from the forearm posteriorly for 3 minutes. Reading up to 10 minutes after end of exposure test: diagnosis of cholinergic urticaria flare-up if presence of pruritic micropapules on erythematous background of trunk +/- limbs. Stop the test as soon as urticarial lesions appear."
224162530|NCT06949891|DIETARY_SUPPLEMENT|Ketogenic diet|A eucaloric ketogenic diet (30-40 g carbohydrate per day) for 3 months, followed by a less strict ketogenic diet (50-60 g carbohydrate per day) for another 3 months.
224305020|NCT01931696|DEVICE|Sham acupuncture|100 patients receive sham acupuncture treatment once every other day, choosing Jinsuo(DU08), Ganshu(BL18), Danshu(BL19), needles retention for 30 minutes and no moxibustion or electrical stimulation. Patients receive sham acupuncture once every other day with a total of 20 sessions in 6 weeks. The needle brand is Hwato®™ Sterile Acupuncture Needles for Single Use.
224305021|NCT01811316|OTHER|Probiotics|
224305022|NCT04241315|DRUG|OTL38 for Injection|Folate analog ligand conjugated with an indole cyanine-like green dye as a solution in vials containing 3 mL at 2 mg/mL
223475973|NCT00081003|PROCEDURE|breast duct lavage|
223582603|NCT01483209|DRUG|Injection of botulinum toxin A|One-time injection of 100 units of botulinum toxin into hand to perform full chemical digital sympathectomy
223582604|NCT04957758|DRUG|OC-01 (varenicline) nasal spray 1.2 mg/ml|OC-01
223582605|NCT04957758|DRUG|Placebo (vehicle) nasal spray|Placebo (vehicle)
223475974|NCT00081003|PROCEDURE|endoscopic biopsy|
223475975|NCT00081003|PROCEDURE|study of high risk factors|
223475976|NCT04149418|OTHER|Yogurt|Low-fat flavored yogurt
223475977|NCT04149418|OTHER|Control food|Low-fat flavored soy pudding
223475978|NCT00623181|BIOLOGICAL|Fluzone: Influenza virus vaccine|0.1 mL, Intradermal Right deltoid, 0.5 mL, Intramuscular Left deltoid
223475979|NCT00623181|BIOLOGICAL|Fluzone: Influenza virus vaccine|0.5 mL, Intramuscular Right deltoid, 0.1 mL, Intradermal Left deltoid
223475980|NCT01677286|DRUG|Doxycycline 100 mg po bid x 12 months|100mg by mouth twice daily for 1 year.
223475981|NCT05200169|DRUG|14C-AB1010|Oral solution of 14C radiolabelled AB1010 (200 mg per subject)
223475982|NCT01855958|PROCEDURE|DIMST|The investigators used electro acupuncture of 2 Hz during 30 minutes.
223475983|NCT01855958|PROCEDURE|Placebo-sham|Electro acupuncture with rubber electrodes, without current passing.
223475984|NCT00320047|DRUG|Baclofen|Participants will take baclofen 3 times a day, before meals, for 10 weeks. Baclofen dosages will be low to begin, followed by a gradual increase over a 2-week period. Upon reaching the maximum tolerated dose of baclofen, participants will continue at this dosage level until Week 11, at which time the dose will be gradually decreased. If any serious side effects occur, baclofen dosage will be decreased to the previous tolerated dosage level.
223475985|NCT00296244|DRUG|Steroids|Patients randomized to Control group shall be administered steroids as methylprednisolone (Solumedrol) 1000 mg IV during the anhepatic phase. Methylprednisolone will be continued according to the following taper schedule: 50 mg IV every 6 hrs on day 1; 40 mg IV every 6hrs on day 2; 30 mg IV every 6 hrs on day 3; 20 mg IV every 6 hrs on day 4; 20 mg IV every 12 hrs on day 5; and Prednisone 20 mg by mouth or Naso-gastric tube (NGT) on day 6. Prednisone shall be tapered slowly starting at 1 month post-OLT and weaned off completely by 6 months post-OLT.
223475986|NCT00296244|DRUG|Basiliximab|Basiliximab shall be given as induction therapy at 20 mg IV bolus intra-operatively and on the 4th day after transplantation.
223475987|NCT00296244|DRUG|Tacrolimus|Tacrolimus shall be used as the main maintenance immuno-suppressive drug. It will be given at a dose of 0.15mg/ kg/ day by mouth or through a naso-gastric tube (NGT), starting not earlier than 24 after the transplant but within 48 hrs after reperfusion. The dose shall be adjusted to achieve a trough level of 10-15 ng/ml during the first 30 days after transplantation and lowered to 5-10 ng/ml, thereafter.
223582606|NCT00487448|DRUG|Fludarabine|
223582607|NCT00487448|DRUG|Cytarabine|
223582608|NCT00487448|DRUG|G-CSF|
223582609|NCT00487448|DRUG|Idarubicin|
223582610|NCT00487448|PROCEDURE|Peripheral blood stem cell transplantation|
223582611|NCT00487448|PROCEDURE|Bone marrow transplantation|
223582612|NCT01901965|BEHAVIORAL|Neuromuscular electrical stimulation|
223582613|NCT01901965|BEHAVIORAL|eccentric training|
223582614|NCT00707746|DRUG|mipomersen|
223582615|NCT00707746|DRUG|placebo|
223744355|NCT00673179|DRUG|Gemcitabine|IV over 1 hour, every other week.
224162531|NCT06949891|DIETARY_SUPPLEMENT|Mediterranean diet|The control group will receive a eucaloric diet according to the national healthy food guidelines/Mediterranean diet.
223475988|NCT00296244|DRUG|Enteric-coated Mycophenolic acid (EC-MPA)|This drug may be given in combination with calcineurin inhibitors (tacrolimus) and steroids for maintenance immuno-prophylaxis to prevent rejection. They are particularly useful in recipients with renal dysfunction and neurotoxicity, when there is a need to reduce dose or delay introduction of calcineurin inhibitors. This drug is given at 720 mg PO BID for 3 months.
223475989|NCT00053326|DRUG|fenretinide|Given orally
223475990|NCT00053326|OTHER|pharmacological study|Optional correlative studies
223475991|NCT03433235|DRUG|Edoxaban|"1-3-6-12 rule\*~Anticoagulation in patients with acute ischemic stroke and atrial fibrillation can be initiated from the following days after stroke event.~After 1 day: transient ischemic attacks~After 3 days: mild ischemic strokes (NIHSS \<8)~After 6 days: moderate ischemic strokes (NIHSS 8-16)~After 12 days: severe ischemic strokes (NIHSS \>16)~\- NIHSS: National Institute of Health Stroke Scales"
223475992|NCT01077557|OTHER|No Antiretroviral (ARV) Drug Exposure|No pharmacy dispensing of an ARV drug
223582616|NCT03802045|PROCEDURE|Electroacupuncture|"The interventions will be performed by acupuncture specialists with at least 3 years of clinical experience, who will receive prior training to ensure that they rigorously follow the study protocol and are familiar with the types of treatments, including details such as acupuncture points and manipulation of electroacupuncture parameters.~After the randomization, the acupuncturist will sequentially open the envelopes, and the individuals will be randomly assigned to one of five treatment groups: Low frequency EA (LF), high frequency EA (HF), alternating frequency EA (AF), control group (C) and placebo group (P), each containing 25 participants. The acupuncture points will be located and described according to the WHO Standard Acupuncture Locations. Based on the beneficial effects of previous clinical trials, the acupoints selected for this study will be: BL23, BL25, BL40, SP6 and KI3."
223582617|NCT03802045|DEVICE|Needle|Sterile and disposable 0.25mm x 30mm stainless steel needles (Dong Bang Acupuncture Inc., Seoul, Korea) will be used.
223582618|NCT03802045|DEVICE|Adhesive Moxa|In the placebo group an adhesive moxa will be placed on each acupoint and the needle will be inserted over it.
223582619|NCT00435526|BIOLOGICAL|anti-CFA/I bovine IgG, and anti-CfaE bovine IgG|
223582620|NCT00495378|DRUG|epoetin alfa|
223582621|NCT01259453|BIOLOGICAL|Vaccination to prevent hepatitis B virus infection|Standard dosing with Twinrix; comparison of standard and acceleration dosing schedule
223582622|NCT00586443|DRUG|bevacizumab, everolimus, panitumumab|"Cohort # subjects Bevacizumab Everolimus Panitumumab~* 3 3-6 5 mg/kg IV Q2 weeks 5 mg PO QoD 3.6 mg/kg IV Q2 weeks~* 2 3-6 5 mg/kg IV Q2 weeks 5 mg PO QoD 4.8 mg/kg IV Q2 weeks~* 1 3-6 10 mg/kg IV Q2 weeks 5 mg PO QD 4.8 mg/kg IV Q2 weeks~  1. 3-6 10 mg/kg IV Q2 weeks 10 mg PO QD 4.8 mg/kg IV Q2 weeks~ 2. 3-6 10 mg/kg IV Q2 weeks 10 mg PO QD 6 mg/kg IV Q2 weeks 3a 10 RPTD\* RPTD\* RPTD\* 3b 10 RPTD\*\* RPTD\*\* RPTD\*\*~     * Panitumumab and RAD001 started on Day 1, bevacizumab started on Day 15. \*\*Bevacizumab and RAD001 started on Day 1, panitumumab started on Day 15."
223582623|NCT05006209|OTHER|One visit root canal treatment|
223582624|NCT05006209|OTHER|Two visit root canal treatment|
223582625|NCT00866671|DRUG|nelarabine|Nelarabine is a prodrug of 9-β-D-arabinofuranosylguanine (ara-G), a deoxyguanosine analogue.
224162532|NCT01570452|PROCEDURE|colonic or colorectal resection|standard laparotomic resection of colon-rectum including right hemicolectomy, left hemicolectomy, sigmoidectomy, anterior resection
224162533|NCT06948734|DIAGNOSTIC_TEST|Clinical and radiographic examination|In order to evaluate the pulpal and periapical health of natural teeth adjacent to dental implants at specific time intervals, percussion, palpation, and pulpal diagnostic tests were performed, and the presence of any pathological changes was monitored using radiographic examinations.
224162534|NCT06949059|DRUG|Hydromorphone|Hydromorphone 1mg was given intravenously and conventional treatment was performed at the same time.
223582626|NCT04904809|DEVICE|Perclose ProGlide SMC System and/or Perclose ProStyle SMCR System|The Perclose ProGlide SMC and Perclose ProStyle SMCR in this study will be used for multiple access site closures in a single vein in the ablation procedure.
223582627|NCT02418988|DRUG|TACE plus rAd-p53 artery injection|Trans-catheter chemo-embolization (TACE) with rAd-p53 injection will be given every 21 days
223582628|NCT02418988|DRUG|TACE|Trans-catheter chemo-embolization (TACE) without rAd-p53 injection will be given every 21 days
223582629|NCT05157347|OTHER|Robot-assisted Training|The gait training in this study uses an exoskeletal wearable robot (Product name: ANGEL LEGS M20, Angel robotics, Co., Ltd.) consisting of a wearable part, a hip or knee joint gear providing the auxiliary force, and a controller backpack. This product is a powered orthopedic device for gait rehabilitation and treatment such as the lower limb muscle reconstruction and joint motion recovery in patients or handicapped individuals. The product consists of a power part, a controller part and a gear part, while the device is powered by an electric motor and the device motion induces the gait posture to support the lower limbs and allow the gait training to be performed.
223582630|NCT05157347|OTHER|Conventional Therapy|The conventional gait rehabilitation has been performed as a 1:1 training session between the therapist and a stroke patient.
223582631|NCT03024645|BEHAVIORAL|Be A Mom|The Be a Mom program is a web-based self-guided cognitive-behavioral intervention to prevent postpartum depression, targeting postpartum women. It consists of 5 weekly modules, each module targeting a specific thematic content, and providing women with both information and specific therapeutic strategies (with a strong focus on cognitive-behavioral techniques) to address each thematic content. Modules are sequential.
223582632|NCT03024645|OTHER|Treatment as usually (TAU)|performed in primary care settings
223475993|NCT01077557|DRUG|Any Antiretroviral (ARV) Drug Exposure|Pharmacy dispensing claim for any ARV drug
223475994|NCT03052894|DEVICE|Hydraulic Monitoring Device|"The hydraulic monitoring device externally measures the pressure associated with thumb strength applied to the device to determine the depth of neuromuscular blockade during general anesthesia.~This will be compared to measurements using a current monitoring device in the same patient."
223475995|NCT03052894|DEVICE|Standard EMG Monitoring Device|"Standard and in current usage, the electromyographic monitoring (EMG) device externally measures the action potential of the muscles of the thumb to determine the depth of neuromuscular blockade during general anesthesia.~This will be used as the clinical monitoring device and as a comparator."
223744356|NCT00673179|DRUG|Sargramostim|Inhaled aerosol (5 mcg/kg, maximum dose 300 mcg) twice a day for 7 days on, 7 days off, beginning the day receive gemcitabine.
223744357|NCT00673179|PROCEDURE|Surgery|Planned limb salvage surgery after 3 courses of doxorubicin + cisplatin (IV) and High-dose methotrexate - at approximately week 12.
224162535|NCT06949761|DRUG|QLC1101+QL1203|QLC1101 is an innovative small molecule inhibitor targeting KRAS G12D with independent intellectual property rights developed by Qilu Pharmaceutical Co., Ltd.；QL1203, developed by Qilu Pharmaceutical Co., Ltd., is a recombinant anti-EGFR fully human monoclonal antibody injection and a biosimilar to Vectibix®
224162536|NCT06949761|DRUG|QLC1101+QL2107|QLC1101 is an innovative small molecule inhibitor targeting KRAS G12D with independent intellectual property rights developed by Qilu Pharmaceutical Co., Ltd.；QL2107 developed by Qilu Pharmaceutical Co., Ltd. is a potential biosimilar to Pembrolizumab (Keytruda®)
224162537|NCT06949761|DRUG|QLC1101+QL1706|QLC1101 is an innovative small molecule inhibitor targeting KRAS G12D with independent intellectual property rights developed by Qilu Pharmaceutical Co., Ltd.；QL1706 Injection (QL1706) is a combination antibody developed by Qilu Pharmaceutical Co., Ltd. It consists of two full-length immunoglobulin G (IgG) antibodies: anti-PD-1 monoclonal antibody (hereafter referred to as anti-PD-1) and anti-CTLA-4 monoclonal antibody (hereafter referred to as anti-CTLA-4)
224162538|NCT06949761|DRUG|QLC1101+docetaxel|QLC1101 is an innovative small molecule inhibitor targeting KRAS G12D with independent intellectual property rights developed by Qilu Pharmaceutical Co., Ltd.；Docetaxel is a tubulin binding agent that prevents cell division by stabilizing microtubule structure and leads to apoptosis
223582633|NCT03939078|RADIATION|CO2 fractional ablative laser|3 intravaginal fractional ablative CO2 laser sessions, with one month interval between them.
223582634|NCT04218071|DRUG|Ruxolitinib|Ruxolitinib at protocol-specified doses for given platelet count
223582635|NCT04218071|DRUG|9-ING-41|9-
224162539|NCT06240793|PROCEDURE|unilateral transforaminal epidural steroid block|unilateral transforaminal epidural steroid block
224162540|NCT06240793|PROCEDURE|bilateral transforaminal epidural steroid block|bilateral transforaminal epidural steroid block
224162541|NCT01167153|DRUG|Valsartan/Amlodipine|Valsartan/Amlodipine 80/5mg single pill combination (SPC)
224162542|NCT01167153|DRUG|Nifedipine|Nifedipine GITS (Gastro-Intestinal Therapeutic System ) 30 mg
224162543|NCT06066853|DRUG|MDMA|MDMA-assisted psychotherapy
223475996|NCT01781897|DEVICE|acupuncture|sterile, disposable needles with a length of 40 mm and a diameter of 0.25 mm (Dongbang® Acupuncture Inc, Korea)
223475997|NCT01781897|DRUG|mosapride|Mosapride Citrate tablet（5mg），Dainippon Sumitomo pharmaceutical Co.Ltd,Japan
223475998|NCT02378272|OTHER|care manager for depression|District nurse (care manager for depression) providing clinical services ( in cooperation with GP) as patient information and education on patient's preferred treatment, development of care plan, assessment of patient's depressive symptoms and regular telephone contacts.
223475999|NCT04367298|BEHAVIORAL|Chronoprevention|Preventive measures will be focused on organizational, educational and behavioural elements related to older people and healthcare professionals
223476000|NCT01905696|DRUG|Oral N-acetylcysteine|
223476001|NCT01973751|DRUG|Budesonide|Inhaled powder of inhaled corticosteroid, 2 puffs (200mcg) twice a day for 8 weeks
223476002|NCT02815371|PROCEDURE|Needle Acupuncture|See above
223476003|NCT02815371|PROCEDURE|Laser Acupuncture|See above
223476004|NCT02815371|PROCEDURE|Sham Laser Acupuncture|See above
223476005|NCT05241301|OTHER|one to one interviews|one to one interviews to explore the perspective of family carers of older adults of Turkish and Moroccan origin in Flanders and Brussels, Belgium, concerning advance care planning (ACP)
223582636|NCT05260333|DEVICE|Butterfly iQ transperineal ultrasound exam|Transperineal ultrasound
223582637|NCT00612625|DRUG|glucagon-like peptide-1|continuous infusion of GLP-1 (1½ pmol/kg/min)
223582638|NCT00612625|DRUG|Saline|continuous infusion of saline
223582639|NCT00685373|DRUG|Canakinumab (ACZ885)|6 mL glass vial containing 150 mg lyophilized Canakinumab reconstituted with water for a subcutaneous injection every 8 weeks. Dosage based on body weight.
223744358|NCT00673179|DRUG|Mesna|IV continuously over 6 days each time, on Weeks 16, 22, 28, and 34. Dose 2.8 gm/m\^2/day.
223744359|NCT05387733|DRUG|10 mg CBL-514 per injection|"The total injection volume per lipoma will be based on the lipoma size, as determined by ultrasound. Dosing sceme is presented as below:~Lipoma diameter of ≥1.0cm and ≤2.0cm - 1 injection (2 mL each); total of 10 mg CBL-514.~Lipoma diameter of \>2.0cm and ≤3.5cm - 2 injections (2 mL each); total of 20 mg CBL-514.~Lipoma diameter of \>3.5cm and ≤5.0cm - 3 injections (2 mL each); total of 30 mg CBL-514.~Lipoma diameter of \>5.0cm and ≤6.0cm - 5 injections (2 mL each); total of 50 mg CBL-514."
223744360|NCT05387733|DRUG|15 mg CBL-514 per injection|"The total injection volume per lipoma will be based on the lipoma size, as determined by ultrasound. Dosing sceme is presented as below:~Lipoma diameter of ≥1.0cm and ≤2.0cm - 1 injection (3 mL each); total of 15 mg CBL-514.~Lipoma diameter of \>2.0cm and ≤3.5cm - 2 injections (3 mL each); total of 30 mg CBL-514.~Lipoma diameter of \>3.5cm and ≤5.0cm - 3 injections (3 mL each); total of 45 mg CBL-514.~Lipoma diameter of \>5.0cm and ≤6.0cm - 5 injections (3 mL each); total of 75 mg CBL-514."
223744361|NCT04234035|BEHAVIORAL|Decision Aid|Decision aid to facilitated shared decision-making
223744362|NCT04234035|OTHER|Standardized Educational Material (informational pamphlet)|Pamphlet with information about kidney stones
223476006|NCT05793658|PROCEDURE|Standard capnography|Patients undergoing colonoscopy under sedation were randomly assigned to receive standard capnography monitoring or modified capnography monitoring which can be achieved by tucking capnography probe under the face mask.74 patients were enrolled. Patient characteristics were well balanced between the two groups 37 patients in each group.
223582640|NCT01335750|OTHER|Multipurpose Solution #1|B\&L Renu Fresh Multipurpose Solution
223744363|NCT05836064|DEVICE|GastroBot|An artificial intelligence-developed and WhatsApp-based software bot. It will send the instructions to the patient through the WhatsApp application, guided by the software bot with multiple and personalized alternative instructions according to results.
223744364|NCT05836064|OTHER|Conventional explanation|Patients will receive in writing detailed explanation about bowel preparation with polyethylene glycol
223744365|NCT01843764|DEVICE|HRP2 and LDH based rapid diagnostic tests for P.falciparum|
223476007|NCT05793658|PROCEDURE|Modified capnography|If Respiratory rate below 14 b/m: more sedation isn't not advised and the patient may develop airway obstruction and needs airway intervention ( like jaw thrust or oral airway) If respiratory rate more than 20 b/m it means this patient is prone to awake or to move and this patient in need for incremental dose of sedative drug ( e.g 20 to 30 mg propofol) Also roughly speaking respiratory rate from 16 to 18 b/m is the target
223476008|NCT05084391|DEVICE|stereotactic ablative radiotherapy (SABR)|is safe for treating heart arrhythmias (irregular heartbeat
223476009|NCT05084391|OTHER|Standard of Treatment|Standard of care
223476010|NCT06233786|DEVICE|Transcutaneous Electrical Nerve Stimulation (TENS)|This intervention is performed using a TENS with an asymmetric biphasic wave of 200 µs width, frequency of 100Hz and maximum intensity tolerated by the participant, adapting to avoid accommodation. The intervention will be carried out for 30 minutes, once a day, and 2 days a week, with 48-72 hours between both interventions. Regarding the electrodes, 4 adhesive electrodes (5.0x5.0) will be placed, 2 in the lower lumbar region and two in the parasacral region (S2-S4).
223476011|NCT03632824|DRUG|Tranexamic Acid|"One gram( 2 ampules ) of tranexamic acid was received by the participant intravenously twice daily for 48 hours followed by 500 mg tranexamic acid tablet three times daily for 5 days .~follow up of the patient was done by recurrence of the bleeding latter on during pregnancy . the course of treatment was repeated again ."
223744366|NCT04495127|DRUG|Selumetinib|Selumetinib 25 mg/m2 BID
223744367|NCT01492322|RADIATION|TRODAT|Smoker will receive a TRODAT injection
224162544|NCT06949540|DIETARY_SUPPLEMENT|Blue Burn Tincture|Participants will complete self-assessments and provide weight and blood measurements during the study.
224162545|NCT06948305|BEHAVIORAL|instant messaging software|instant messaging software
224162546|NCT03186261|DRUG|Nano silver fluoride solution|Nano silver fluoride that composed of silver nanoparticles, chitosan and fluoride that combines preventive and antimicrobial properties.
223476012|NCT05766241|BEHAVIORAL|Sensory Strategies Training|In SST, participants will be introduced to the concept of sensory processing in the context of PTSD and will learn about the ways in which difficulties in this area can impact their affective, cognitive, and functional outcomes. Participants will learn about the effects of PTSD symptoms on their ability to regulate stressful situations and engage in social interactions, as well as the benefits of physical activity and proper sleep hygiene. Participants will also identify functional goals (e.g., reduce sensation-avoiding, better regulate physical and emotional reactions to trauma reminders, increase sensory sensitivity, etc.) which they will aim to achieve with the knowledge and resources gained from SST. Throughout the program, participants will learn various strategies to help with movement, sleep, and interacting with others, and will have opportunities to practice the strategies identified as being relevant to their specific needs during their baseline sensory assessment.
224162547|NCT03186261|DRUG|Cavity Cleanser|Moistens dentin surface after cavity preparation using a micro brush.
224162548|NCT00797706|DRUG|CHRONSEAL|Cream (1.4/2.8 g depending on ulcer size) topical administration, every 2nd day at 3 occasions
224162549|NCT00633802|DRUG|Risperidone|1 mg/d risperidone for 10 weeks or placebo
224162550|NCT01203124|DRUG|AZD8848|The subjects are dosed with a range of intranasal doses of AZD8848 on 2, 3, 4 or 7 days of the 7 days treatment period. On the other days the subjects receive placebo.
224162551|NCT01203124|DRUG|Placebo|Placebo
224162552|NCT00048009|DRUG|Dual Integrin Antagonist|
224162553|NCT00024128|BIOLOGICAL|anti-thymocyte globulin|
223476013|NCT03367000|DIETARY_SUPPLEMENT|Ceprolac|The supplement was packed into two \~15g sachets in powder form of a 90-94% whey protein isolate and hydrolysed whey. The protein powder was dissolved in 75-100ml water at room temperature and was ingested post meal once daily.
223476014|NCT03367000|OTHER|Dietary counseling (DC)|Received standard dietary counseling at baseline and month 6.
223476015|NCT00427934|DRUG|Maraviroc|300 mg (2- 150 mg tablets) are administered by mouth twice a day (BID) for 12 weeks.
223476016|NCT00427934|DRUG|Maraviroc Placebo|Placebo tablets to match active drug. Two tablets are administered by mouth twice a day (BID) for 12 weeks.
223476017|NCT04168957|DRUG|Oraxol|"Oraxol (oral paclitaxel + oral HM30181AK-US)~Paclitaxel: supplied as capsules HM30181 methanesulfonate monohydrate: supplied as HM30181AK-US tablets"
223476018|NCT05037604|OTHER|Questionnaire about associated factors|Questionnaire about age, prolonged sun exposure, intake of anticoagulants / antiplatelets, intake of oral steroids, chronic kidney disease. Maternal age\> 40 years in their last child , time of lactation per pregnancy and cumulative time of lactation. Age of the first pregnancy and age of menopause onset.
223476019|NCT05037604|DIAGNOSTIC_TEST|Self questionnaire diagnostic tool|Self questionnaire of physical characteristics
223744368|NCT04325958|DRUG|Cannabis|750mg cigarette of plant material
223744369|NCT04325958|DRUG|Placebos|750mg cigarette of plant material
223744370|NCT05945654|PROCEDURE|Anastomotic Leak after Ivor Lewis Oesophagectomy|Surgical resection of the esophagus with oesophagogastrostomy. Groups depend on postoperative complication
223744371|NCT02466555|BEHAVIORAL|Music Therapy|During the educational music therapy intervention, member(s) of the Adult Sickle Cell Disease team will share with the patients the medical information pertinent to the appointment, ask health related questions of the patients and respond to any pertinent inquiries. The Music Therapist will then engage the patients and member(s) of the Adult Sickle Cell Disease team in a music therapy intervention designed to teach and reinforce the skills and knowledge presented. These music therapy interventions may include but are not limited to original songs/rap/instrumental playing, vocal and/or instrumental improvisation, patient-contributed lyrics, mnemonics, and stress and pain reducing strategies. The music therapy interventions will be tailored to best convey the educational message.
223744372|NCT03006159|DRUG|SHR0534|
223744373|NCT03006159|DRUG|Placebo|
223744374|NCT04170348|DRUG|Daily oral vitamin D3, 3,333 IU|Oral vitamin D3, 3,333 IU, will be administered daily.
224162554|NCT00024128|BIOLOGICAL|therapeutic allogeneic lymphocytes|
224162555|NCT00024128|DRUG|cyclophosphamide|
224162556|NCT00024128|DRUG|cyclosporine|
224162557|NCT00024128|PROCEDURE|peripheral blood stem cell transplantation|
224162558|NCT00024128|RADIATION|radiation therapy|
224305023|NCT04241315|DEVICE|Near infrared camera imaging system|Near infrared camera imaging system
223476020|NCT05037604|OTHER|Physical Examination|Physical Examination made by a dermatologist
223476021|NCT06258252|OTHER|Effect of BCAAs metabolic dysfunction on cardiac function in sepsis|Effect of BCAAs metabolic dysfunction on cardiac function in sepsis
223476022|NCT04576000|DRUG|Janus Kinase Inhibitor|Janus Kinase inhibitor induction therapy will be administered according to Standard Of Care (SOC)
223476023|NCT03540459|DIAGNOSTIC_TEST|sleep polygraphy|sleep polygraphy (one night) in all included patients
223476024|NCT03673891|DEVICE|Life Flow|LifeFlow device will be used to administer intravenous fluids in this group. LifeFlow is a FDA approved device to administer IV fluids. Subject will have a bedside ultrasound performed by the study investigator after receiving 500 ml of intravenous fluid bolus. The images will be recorded on ultrasound machine hard drive for future review. If the bedside ultrasound findings determine that the subject is not fluid responsive, subjects will be excluded from the study. If the subject is determined to be fluid responsive, the above listed outcome measures will be collected. Ultrasound will be repeated after every 500 ml bolus if the patient continues to receive IV fluids which will be determined by the treating physician. Ultrasound measurements and other parameters listed above will be collected throughout the ED and hospital stay.
223476025|NCT03355144|DIETARY_SUPPLEMENT|Daily Supplementation with Coffee|"At the beginning of study week 2 (study day 8), two coffee machines (one Nespresso Inissia and one Hamilton Beach 46205 12 Cup Programmable Coffee Maker) will be installed in the resident work rooms at each site.~Subjects will be provided with free coffee beans, milk, cream, sugar and sweetener"
223476026|NCT03966989|BEHAVIORAL|Performance Feedback|Performance feedback offline that benchmarks providers' own performance to that of their peers
223476027|NCT03389165|DEVICE|Wearable hip assist robot|All participants climbed stairs from the first basement level to the fourth floor of the Proton Therapy Center, Samsung Medical Center, Korea with and without a wearable hip assist robot. During climbing stairs, the metabolic energy expenditure of all participants was measured using a portable cardiopulmonary metabolic system (Cosmed K4b², Rome, Italy).
223476028|NCT00134134|DRUG|efalizumab|
223476029|NCT00499122|DRUG|Cyclophosphamide|
223476030|NCT00499122|DRUG|Docetaxel|
223476031|NCT00499122|DRUG|Doxorubicin|
223476032|NCT00499122|DRUG|NOV 002|
223476033|NCT04399681|DEVICE|Bedside lung ultrasound|Point of care ultrasound will be used as bedside lung ultrasound to determine the patients if they have a COVID-19 pneumonia.
223582641|NCT01335750|OTHER|Multipurpose Solution #2|Optifree Replenish Multipurpose Solution
223582642|NCT01335750|OTHER|Mutlipurpose Solution #3|Ciba ClearCare Multipurpose Solution
223582643|NCT01335750|OTHER|Multipurpose Solution #4|Saline Solution
223582644|NCT02642965|DRUG|Cytarabine|Given IT or IV
223582645|NCT02642965|BIOLOGICAL|Filgrastim|Given SC or IV
223476034|NCT05152121|OTHER|Carb and fat counting|In the 7 days leading up to the study, participants were contacted to review blood glucose levels with CGMS, food and activity diary. basal rates and insulin carbohydrate ratio and sensitivity factor were changed according to the CGMS values and normoglycemia was achieved.In the study day same meals were served which included high fat, high energy density test meal containing 80 gram carbohydrate (34%), 70 gram fat (66%) and 35 g protein (14%).The participants had to have no glucose fluctuations 2 hours before study entry based on CGMS, no correction boluses for at least 4 hours before the test meal consumption and fasting glycemia in the range of 70-180 mg/dL on both study days.The participants received the test meal calculating insulin dose by CC on the first study day and calculating insulin dose by and fat/protein counting in the second study day. The test meal consumption was completed in 20 minutes under supervision by a caregiver and a dietician of the research team
223476035|NCT03699423|DRUG|0.01% atropine eye drops|0.01% atropine sulphate
223476036|NCT03699423|DRUG|0.02% atropine eye drops|0.02% atropine sulphate
223582646|NCT02642965|DRUG|Fludarabine Phosphate|Given IV
223582647|NCT02642965|OTHER|Laboratory Biomarker Analysis|Correlative studies
223582648|NCT02642965|DRUG|Liposome-encapsulated Daunorubicin-Cytarabine|Given IV
223582649|NCT02642965|OTHER|Pharmacological Study|Correlative studies
223476037|NCT03699423|DRUG|0.03% atropine eye drops|0.03% atropine sulphate
223476038|NCT04996030|DRUG|SY-2101|SY-2101 will be administered per dose and schedule specified in arm description.
223582650|NCT02023021|DRUG|nab-paclitaxel|Patients firstly receive nab-paclitaxel 100 mg/m\^2 (iv, 30 minutes) on days 1, 8, and 15 for 3 weeks, followed by one week without treatment. Treatment repeats every 4 weeks for up to 6 circles in the absence of disease recurrence or unacceptable toxicity.
223582651|NCT02023021|DRUG|gemcitabine|Patients secondly receive gemcitabine 1000 mg/m\^2 (iv, 30 minutes) on days 1, 8, and 15 for 3 weeks, followed by one week without treatment. Treatment repeats every 4 weeks for up to 6 circles in the absence of disease recurrence or unacceptable toxicity.
223582652|NCT01473095|DRUG|ARQ 092|Subjects in this study will receive ARQ 092 orally at dose levels specified for their respective dose cohorts. Dosing will begin at 10 mg every other day (QOD) and will escalate until the MTD or RP2D is determined. Cycles will be repeated in four-week (28 day) intervals until progression of disease, unacceptable toxicity, or another discontinuation criterion is met. In the case of toxicity, dose adjustment will be permitted.
223582653|NCT05890378|OTHER|Testing water|Using existing secondary data available on the research communities as well as qualitative inquiry, we will purposefully select 40 water sources for the water analysis across from the communities selected for the implementation research (up to 30 communities with a maximum of 5 water sources per community). The selection of water sources will be stratified by type of water sourceand near the route for long-term animal migration. For each water source, we will aim to have a water sample collected at all water sources twice a day (morning and later afternoon) once a week for four weeks, varying the day of the week. Thus, we will collect a total of 320 water samples in the course of four weeks at the end of the dry season before the rains start.
223582654|NCT06026956|OTHER|Tele-Assessment|Tele-Assessment
223582655|NCT01603381|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia (CBT-I)|Behavioral management of insomnia
223582656|NCT00701636|DRUG|daptomycin|Subjects enrolled in the intervention group will receive a single intravenous administration of daptomycin 8 mg/kg 30-60 minutes prior to surgery (incision). The 500 mg vial will be reconstituted with 10 mL of 0.9% normal saline (NS) and further diluted in 50 mL of 0.9% NS to be given over a 30 minute infusion.
223582657|NCT02635334|DRUG|Montelukast 10 mg orally|
223582658|NCT02635334|OTHER|Placebo|
223476039|NCT04996030|DRUG|Arsenic Trioxide|IV ATO will be administered per dose and schedule specified in arm description.
223476040|NCT04168242|DEVICE|Scalp cooling Paxman Orbis II system|The experimental arm will have scalp cooling that starts 30 minutes before the chemotherapy, continues throughout the infusion of the chemotherapy, and lasts for 20-90 minutes more depending on the type of regimen.
223582659|NCT05639322|DRUG|Ketamine Hydrochloride|Ketamine-HCL IV 1mg/kg (up to 100 mg) over 2 hours, on weeks 2, 7, and 12.
223582660|NCT05639322|BEHAVIORAL|Cognitive Behavioral Therapy|Cognitive Behavioural Therapy/ Mindfulness Based Meditation therapy (CBT/MM) remotely for 16 hours between weeks 1 to 16 inclusive + in-person sessions on weeks 2, 7 and 12
223582661|NCT05639322|OTHER|Ketamine + Cognitive Behavioral Therapy|Ketamine-HCL + CBT/MM according to the same directions specified in Arm 1 and Arm 2.
223582662|NCT03693313|BEHAVIORAL|CrossFit Kids exercise program|Participants will be actively participating in a 14 week twice weekly CrossFit Kids exercise program.
223582663|NCT00137826|DRUG|Erlotinib|Taken orally once daily. Participants may continue on study treatment until disease progresses or they experience serious side effects.
223582664|NCT00137826|DRUG|Bevacizumab|Given intravenously over 30-90 minutes, on day 1 of each 21-day cycle. Participants may continue on study treatment until disease progresses or they experience serious side effects.
223582665|NCT01175200|DRUG|Clopidogrel|antiplatelet agent
223582666|NCT01175200|DRUG|Prasugrel|antiplatelet agent
223582667|NCT01175200|DRUG|Lansoprazole|proton pum inhibitor
223582668|NCT01175200|DRUG|Placebo|placebo comparator similar to lansoprazole
223582669|NCT03839836|OTHER|Backpack child's body weight|Children are asked to walk naturally, facing forward, with their hands out of pockets; wearing light, comfortable clothes, with the BP placed correctly. As the children start walking, the researchers select the foot of the first step inside the bars, in the Optogait software. After being instructed to 'walk slowly at a comfortable speed', the children walk from a point two metres in front of the bar and stop at a point two metres behind the last bar, to minimize effects of acceleration and deceleration . A three-minute interval occurs between individual assessments to transmit the data, as well as to prepare for the next assessment. Only steps in the sensor areas are included in the analysis. Recording six to eight strides is reported as sufficient to obtain representative data for unimpaired adults. Subsequently, five experimental conditions are measured: without BP, BP loads of 5%, 10%, 15%, and 20% of body weight. The order of these loaded conditions are random.
223582670|NCT01829282|BEHAVIORAL|Risk Reduction|
223582671|NCT01480011|DRUG|lactobacillus CD2 lozenges|The study drug contains not less than 2x109 (2 billion) viable cells of Lactobacillus CD2 as active ingredient
223582672|NCT05953012|DRUG|PMC-403|PMC-403 will be administered Intravitreal.
223582673|NCT01605487|DRUG|Rupatadine|Rupatadine in Tab 10mg: 4 Tab.(2 Tab. of Rupatadine + 2 Tab. of Placebo) once daily during 7 days, then 14 days washout period; Placebo 4 Tab once daily during 7 days, then 14 days washout period; Rupatadine in Tab. 10mg, 4 Tab. once daily during 7 days
223582674|NCT01605487|DRUG|Rupatadine|Rupatadine in Tab 10mg: 4 Tab.(2 Tab. of Rupatadine + 2 Tab. of Placebo) once daily during 7 days, then 14 days washout period; Rupatadine in Tab. 10mg, 4 Tab. once daily during 7 days,then 14 days washout period; Placebo 4 Tab once daily during 7 days
223582675|NCT01605487|DRUG|Rupatadine|Placebo 4 Tab once daily during 7 days, then 14 days washout period; Rupatadine in Tab 10mg: 4 Tab.(2 Tab. of Rupatadine + 2 Tab. of Placebo) once daily during 7 days, then 14 days washout period; Rupatadine in Tab. 10mg, 4 Tab. once daily during 7 days
223582676|NCT01605487|DRUG|Rupatadine|Rupatadine in Tab. 10mg, 4 Tab. once daily during 7 days,then 14 days washout period; Placebo 4 Tab once daily during 7 days, then 14 days washout period; Rupatadine in Tab 10mg: 4 Tab.(2 Tab. of Rupatadine + 2 Tab. of Placebo) once daily during 7 days
223582677|NCT01605487|DRUG|Rupatadine|Placebo 4 Tab once daily during 7 days, then 14 days washout period; Rupatadine in Tab. 10mg, 4 Tab. once daily during 7 days, then 14 days washout period; Rupatadine in Tab 10mg: 4 Tab.(2 Tab. of Rupatadine + 2 Tab. of Placebo) once daily during 7 days
223582678|NCT01605487|DRUG|Rupatadine|Rupatadine in Tab. 10mg: 4 Tab. once daily during 7 days, then 14 days washout period; Rupatadine in Tab 10mg: 4 Tab.(2 Tab. of Rupatadine + 2 Tab. of Placebo) once daily during 7 days, then 14 days washout period; Placebo 4 Tab once daily during 7 days
223582679|NCT03167489|BEHAVIORAL|Lifestyle Plus Emotional Regulation|Group intervention over 5 months, integrating the Mediterranean Diet into a lifestyle intervention and emotional regulation skills.
223476041|NCT04168242|OTHER|Standard treatment|The control arm will not have scalp cooling before, during and after chemotherapy.
223582680|NCT03378648|DRUG|CHF6366|"Drug: CHF6366 (Part 1 - SAD) Single doses of CHF6366 at each period (for up to 3 periods per subject)~Drug: CHF6366 (Part 2 - MAD) Once daily doses of CHF6366 for 7 days~Drug: CHF6366 (Part 3) Single dose of CHF6366"
223582681|NCT03378648|DRUG|Placebo CHF6366|"Drug: Placebo (Part 1 - SAD) Single doses of placebo matching CHF6366 at each period (for up to 3 periods per subjects)~Drug: Placebo (Part 2 - MAD) Once daily dose of placebo matching CHF6366 for 7 days~Drug: Placebo (Part 3) Single dose of placebo matching CHF6366"
223582682|NCT03378648|DRUG|umeclidinium bromide and vilanterol trifenatate|Part 3 Single dose
223582683|NCT02320851|BEHAVIORAL|SVD-tailored Integrative Psychotherapy (IPT)|(see description of corresponding study arm)
224163621|NCT02026934|DEVICE|CliniMACS CD34 Reagent System|Following screening and enrollment, peripheral blood or bone marrow collection will be performed on the donor followed by subsequent CD34+ cell selection using the Miltenyi CliniMACS device. There is no limit to the number of CD34+ progenitors that can be administered. The CD34+ selected cells will be infused within 12 hours of the initiation of processing.
223476042|NCT04955756|DIAGNOSTIC_TEST|mNGS|Participants will be randomized to receive mNGS or multiplex PCR for diagnosis at enrollment.
223476043|NCT04955756|DIAGNOSTIC_TEST|Multiplex PCR|Participants will be randomized to receive mNGS or multiplex PCR for diagnosis at enrollment.
223476044|NCT00038662|DRUG|Atrasentan|
223476045|NCT00881166|DRUG|MP-470 + topotecan|Topotecan 1.5 mg/m2 IV infusion over 30 minutes on Days 1-5
223476046|NCT00881166|DRUG|MP-470 + docetaxel|Docetaxel 75 mg/m2 IV infusion over 1 hour on Day 1
223476047|NCT00881166|DRUG|MP-470 + erlotinib|150 mg PO once daily at least 1 hour before or 2 hours after eating
223582684|NCT02320851|BEHAVIORAL|Self-help group (SHG)|(see description of corresponding study arm)
223582685|NCT03099148|DRUG|Reference Formulation (R)|Administered PO
223476048|NCT00881166|DRUG|MP-470 + paclitaxel/carboplatin|Paclitaxel 200 mg/m2 IV infusion over 3 hours followed by carboplatin IV infusion over 1 hour to a target AUC of 6 mg∙min/mL on Day 1
223476049|NCT00881166|DRUG|MP-470 + carboplatin/etoposide|Carboplatin IV infusion over 1 hour to target AUC of 5 mg min/mL on Day 1 followed by etoposide 100 mg/m2 IV infusion over 2 hours on Days 1-3
223476050|NCT03031925|OTHER|ANXA2|serum and urinary concentration
223476051|NCT03309618|DRUG|low-dose combination of fluvastatin (10 mg) and valsartan (20 mg) (low-flu/val)|
223476052|NCT03309618|DRUG|placebo|
223476053|NCT02638792|BEHAVIORAL|Internet-based exposure therapy (I-ET)|"The internet-based exposure therapy (I-ET) group receives a ten-week Internet-based CBT treatment, which is an extended version of the self-help book Sluta älta och grubbla med kognitiv beteendeterapi (How to quit worrying and ruminating with Cognitive behavior therapy) by licensed psychologist Olle Wadström (2007). The main focus of the book is to expose to the frightening word/image and refrain from using neutralizing thoughts. This is supposed to lead to the extinction of upsetting words/images."
223476054|NCT02638792|BEHAVIORAL|Internet-based stress management therapy|The I-SMT group receives a ten-week Internet-based CBT treatment focused on stress and how to manage stressful situations. This protocol is based on current evidence based recommendations for worry and has shown to be effective when delivered via the internet for irritable bowel syndrome and hypochondric worries.
223476055|NCT05285839|DRUG|Dupixent|dupilumab 300mg
223476056|NCT03968809|DIAGNOSTIC_TEST|CardioFlux Magnetocardiography|All patients enrolled and receiving standard screening tests for CAD will undergo a 2 minute scan with MCG. It will be determined if MCG scanning can provide equal or superior accuracy to predict MACE than standard testing.
223476057|NCT02305316|DRUG|BIA 9-1067 non-micronized|
223476058|NCT02305316|DRUG|BIA 9-1067 micronized|
223476059|NCT00299039|DRUG|acetaminophen plus codeine|capsules four times daily until pain free or for a maximum of seven days
223582686|NCT03099148|DRUG|LY3337641 (T1)|20 mg PO
223582687|NCT03099148|DRUG|LY3337641 (T2)|20 mg PO
223582688|NCT04082910|DRUG|Metoprolol|Metoprolol was given in patients who received CAR T cell therapy for CRS control or CRS precaution.
223582689|NCT04082910|DRUG|metoprolol, infliximab, etanercept, tocilizumab and/or other agents|During the term of metoprolol use, antibodies (infliximab, etanercept and tocilizumab) and/or other agents were not completely limited to be used under the consideration of clinical requirement for sufficient control of continuously progressed CRS.
223582690|NCT05122117|DEVICE|Methylene blue mediated Photodynamic therapy|Methylene blue (MB) with a concentration of 10 mg/mL was delivered inside the periodontal pocket. MB was injected inside in the selected periodontal pockets 4 - 6 mm with the help of a blunt needle and left for 1 min. Later, the periodontal pockets were flushed with distilled water for 3 min to remove the excess MB. The diode laser HELBO® TheraLite - Bredent Medical, Germany) of diameter 200 µm was used to deliver the light to initiate the disinfection process. Each participant underwent single session of laser exposure. The laser parameters such as wavelength, spot area, power output and laser energy were set at 660 nm, 0.028 cm2, 60 mW/cm2, and 150 mW, respectively. The laser was subjected for a period of 30 s in each pocket.
223582691|NCT05122117|PROCEDURE|Non-surgical periodontal therapy|A single session of full-mouth ultrasonic scaling using a sterilized scaler was rendered to the control group. Deep pockets were additionally approached and cleaned by using manual 'After Fives' Gracey curette for root planning (Hu Friedy Gracey After Five Vision curette; HuFriedy, Chicago, USA). This session was followed by a polishing session. A motivational session was conducted where the patients were educated on the importance of maintaining a good oral hygiene by brushing their teeth twice daily followed by the regular use of dental floss and chlorhexidine mouth wash twice daily, respectively.
223476060|NCT00299039|DRUG|acetaminophen plus ibuprofen|capsules four times daily until pain free or for a maximum of seven days
223476061|NCT06201104|OTHER|Patient empowerment education|"After the pre-test is administered to the patients in the experimental group, patient empowerment training (intervention) will be given. Patients will be divided into groups of 15 people and the training will be given in a total of 6 sessions, all in one session. The Patient Empowerment Handbook prepared by the researchers will be used during the training. The training was planned to last 1 hour (45 minutes of theoretical training, 15 minutes of question and answer). The training was planned to be carried out in an interactive manner (question and answer method, sharing of patient experiences, group discussion). The Patient Empowerment Handbook will be delivered to patients after the training for them to read whenever they want. How to use the manual will be explained to patients."
223476062|NCT03707002|DIETARY_SUPPLEMENT|scFOS|daily intake for 6 weeks
223476063|NCT03707002|DIETARY_SUPPLEMENT|Maltodextrin|daily intake for 6 weeks
223476064|NCT00903968|DRUG|Plerixafor|
223476065|NCT00903968|DRUG|bortezomib|
223476066|NCT00903968|DRUG|Dexamethasone|
223476067|NCT00001132|DRUG|Abacavir sulfate|
223476068|NCT00339053|DRUG|Immunonutrition ( Impact)|
223476069|NCT04539275|DRUG|Convalescent Plasma|Convalescent plasma from persons recovered from SARS-CoV-2 is being used to treat hospitalized individuals with complicated COVID-19 infection.
223476070|NCT04539275|OTHER|Masked Saline Placebo|0.9% saline solution will be used as the Masked Saline Placebo
223476071|NCT00189930|BIOLOGICAL|MVA-nef|3 imm.: 5E8\_TCID50 MVA-nef, 1E8\_TCID50 MVA-nef in non-dominant upper arm
223476072|NCT00189930|BIOLOGICAL|IMVAMUNE|3 immunizations: 1E8\_TCID50 IMVAMUNE
223476073|NCT03176914|BEHAVIORAL|prevention and management of childhood illnesses at community level|provision of critical health education and targeted promotion services to the participants in their locality
223476074|NCT03176914|BEHAVIORAL|conventional community interventions|community health programs as the sole source of health education
223582692|NCT05229796|DRUG|Empagliflozin 10 mg Tab|The Empagliflozin 10 mg Tab were administered orally. The plasma concentrations of empagliflozin were determined using an HPLC-MS/MS method. Tolerability and safety were assessed throughout the study. This study included 26 subjects, 26 in each fasting and fed group.
223582693|NCT02916459|DEVICE|21G EBUS-TBNA needle|
223582694|NCT02916459|DEVICE|Flexible 19G EBUS-TBNA needle|
223582695|NCT04239300|BEHAVIORAL|Delivery in water|Participants delivery in water
223582696|NCT01703065|DRUG|Cabozantinib|Given orally once a day
223582697|NCT01576328|DRUG|Mesenchymal Precursor Cells (MPCs)|Single intravenous infusion of MPCs Dose 1
223476075|NCT02243748|OTHER|Palliative Therapy|Receive individualized palliative care
223476076|NCT02243748|OTHER|quality-of-life assessment|Ancillary studies
223476077|NCT02243748|OTHER|questionnaire administration|Ancillary studies
223582698|NCT01576328|DRUG|Mesenchymal Precursor Cells (MPCs)|Single intravenous infusion of MPCs Dose 2
223582699|NCT01576328|DRUG|Mesenchymal Precursor Cells (MPCs)|Single intravenous infusion of MPCs Dose 3
223582700|NCT01439126|DRUG|clonidine hydrochloride|KAPVAY™ (clonidine hydrochloride) 0.1 mg, 0.2 mg, 0.3 mg, or 0.4 mg from Weeks 11-36
223582701|NCT01439126|DRUG|Placebo|KAPVAY™ (clonidine hydrochloride) 0.1 mg, 0.2 mg, or 0.3 mg at Week 11; KAPVAY™ 0.1 mg, KAPVAY™ 0.2 mg, or placebo at Week 12; KAPVAY™ 0.1 mg or placebo at Week 13; placebo from Weeks 14-36
223476078|NCT02318199|PROCEDURE|Anesthesia recovery after intracranial surgery|Intracranial surgery for brain tumor, traumatic brain injury, intracranial hemorrhage, subarachnoid hemorrhage and infection.
223476079|NCT02957552|BIOLOGICAL|Mesenchymal Stem Cells|Donor-specific, bone marrow derived mesenchymal stem (stromal) cells
223476080|NCT01373164|DRUG|Galunisertib|Administered orally
223476081|NCT01373164|DRUG|Gemcitabine|Administered intravenously
223476082|NCT01373164|DRUG|Placebo|Administered orally
223476083|NCT04948918|PROCEDURE|Anatomically optimized distal renal denervation|Bilateral radiofrequency renal denervation will be performed using Symplicity Spyral renal denervation system. Generally, at least two separate applications of radiofrequency energy will be performed in each segmental branch of renal artery. Each application will be done through 4 electrodes deployed in helical manner according to the design of the catheter
223476084|NCT03061942|OTHER|Arthroscopic rotator cuff repair without synovectomy|30 subjects will undergo conventional arthroscopic rotator cuff repair without synovectomy.
223476085|NCT03061942|OTHER|Arthroscopic rotator cuff repair with synovectomy|30 subjects will undergo arthroscopic rotator cuff repair with synovectomy. Synovectomy is an operation performed to remove inflamed synovial membrane of a joint. Arthroscopic synovectomy will be performed with the use of a shaver and a cautery device through the portals for arthroscopic rotator cuff repair.
223476086|NCT02474836|BIOLOGICAL|Skin Prick Test - Atopic subjects|Skin prick test of 4 concentrations of each allergenic source, together with a positive and negative control, using 10 mg/ml histamine dihydrochloride solution and a glycerinated phenol saline solution, respectively, will be tested in every patient in duplicate on the volar surface of the forearm. Assessment of the wheal size after 15 minutes.
223476087|NCT02474836|BIOLOGICAL|Skin Prick Test - Non Atopic subjects|Skin prick test of 4 concentrations of each allergenic source, together with a positive and negative control, using 10 mg/ml histamine dihydrochloride solution and a glycerinated phenol saline solution, respectively, will be tested in every subjects in duplicate on the volar surface of the forearm. Assessment of the wheal size after 15 minutes.
223476088|NCT02474836|BIOLOGICAL|Skin Prick Test - Allergic subjects|Skin prick test of 4 concentrations of each allergenic source, together with a positive and negative control, using 10 mg/ml histamine dihydrochloride solution and a glycerinated phenol saline solution, respectively, will be tested in every patient in duplicate on the volar surface of the forearm. Assessment of the wheal size after 15 minutes.
223476089|NCT00612235|DRUG|Lamotrigine|Subjects had at least 3 months on a stable dosage of lamotrigine monotherapy.
223476090|NCT00612235|DRUG|Levetiracetam|Subjects had at least 3 months on a stable dosage of levetiracetam monotherapy.
223476091|NCT00612235|DRUG|Carbamazepine|Subjects had at least 3 months on a stable dosage of carbamazepine monotherapy.
223476092|NCT00612235|OTHER|No Intervention|No intervention was given
223476093|NCT05222867|PROCEDURE|lower back massage|Lower back massage performance: In the study, Linda Kimber's massage protocol was used. First, the researcher ensured that the patient was holding the bed, squatting, or bent over on the bed, which is suitable for the massage, between two contractions. The pregnant woman was instructed to breathe deeply and exhale audibly when her contractions began. Gloves were worn during the massage and liquid Vaseline, which does not contain any active substance, was used to provide lubricity. The circular hip massage was applied at the beginning of the contraction, and lower lateral area and sacral pressure massage was applied towards the end of the contraction as per the massage protocol, and simultaneously with the inhaling sound of the pregnant woman
223476094|NCT00049231|DRUG|EF5|
223476095|NCT00049231|OTHER|immunohistochemistry staining method|
223476096|NCT00049231|PROCEDURE|biopsy|
223582702|NCT05088993|OTHER|Antigravity treadmill training|This group received antigravity treadmill training 100% weight bearing
223582703|NCT05088993|OTHER|Conventional exercise program|This group received the conventional exercise program only.
223476097|NCT02254642|PROCEDURE|Ischemic preconditioning during aortic clamping|Ischemic preconditioning during aortic clamping
223476098|NCT02254642|PROCEDURE|Procedure/Surgery: usual surgery|Procedure/Surgery: usual surgery
223476099|NCT02526238|DEVICE|TMS and trunk rotation|TMS and trunk rotation
223476100|NCT02526238|DEVICE|Sham TMS and trunk rotation|Sham TMS and trunk rotation
223476101|NCT05072808|OTHER|View PACCI-ED and referral recommendations|Results of parent completed PACCI-ED and referral recommendations
223582704|NCT02721108|BEHAVIORAL|Mindfulness meditation|The meditation content is a structured and progressive course, layering in new techniques and concepts over successive sessions. The course was created and narrated by a former monk - Andy Puddicombe - drawing on a secularised version of the techniques he was taught over 10 years' experience in monasteries around the world. The first 30 days cover basic techniques, assuming no previous experience of meditation. The second 30 days focus specifically on the use of these techniques with respect to pain. The duration of individual sessions builds over time. Days 1-10 are 10 minutes in duration, days 11-20 are 15 minutes in duration, and days 21-60 are 20 minutes in duration.
223582705|NCT02721108|BEHAVIORAL|Relaxation app|The Active Control group will use the same app, but the app will be configured so that they will hear a series of non-meditative progressive muscle relaxation instructions, also narrated by Andy Puddicombe. These sessions will be identical every day, except that their duration will increase to mirror the increasing duration of the meditation content being listened to by the Intervention group.
223582706|NCT04267731|DIETARY_SUPPLEMENT|VMK223|Heat killed and purified Bifidobacterium breve polysaccharide-based extract
223476102|NCT01799941|DRUG|Nuedexta (DM 20 mg/Q 10 mg)|Single Arm, Open-Label Dosing with Nuedexta (DM 20 mg/Q 10 mg)
224162559|NCT06569160|DEVICE|Upper-room UVGI (Ultra-Violet Germicidal Irradiation)|"Nursing homes are equipped with UVGI devices in all common living places. UVGI devices can be deactivated by installing an invisible internal filter. The inactivation filters will be installed by a technical team independent of the investigation team. Inactivation will therefore be carried out blind to the care givers and the investigation team. The centers included will be randomized into two arms. In arm A: the UVGI device will be left active during period 1, and filtered/deactivated during period 2. In arm B: the UVGI device will be filtered/deactivated during period 1 and left active during period 2.~The two periods will last 7 months each, and will take place two years in a row on the same dates (October 1 to April 30). They will be separated by a 5-month wash-out period (May 1 to September 30), during which all UVGI equipments will be switched off in both arms."
223582707|NCT04267731|DIETARY_SUPPLEMENT|Cellulose|Bulking agent in food production without probiotic properties
223582708|NCT03715192|BIOLOGICAL|LY3462817 IV|Administered IV
223582709|NCT03715192|BIOLOGICAL|LY3462817 SC|Administered SC
223582710|NCT03715192|DRUG|Placebo|Administered IV
223582711|NCT05677503|DIAGNOSTIC_TEST|CBC|measurement of CBC will be performed at the time of admission and by the time of discharge
224162560|NCT05444829|DEVICE|specific screw holes locating surgical guide and pre-bent plates|Put the specific screw holes locating device in place and drill the screw holes, remove the screw holes locating device and mobilize the segments then apply the pre-bent plates and fix it with screw for passive reduction of the segments. Then suture the mentalis muscle then the mucosa.
224162561|NCT05444829|DEVICE|classical reduction and internal fixation.|mobilize the broken segment first, Arch bar was made to achieve proper occlusion put the compression plate on the inferior border and remove it for further bending using plate pliers for further accommodation of the plate on the inferior border the fix it in place using compression and tension plate.
224162562|NCT01807676|DEVICE|ET View Double Lumen Tube|
223582712|NCT05677503|DIAGNOSTIC_TEST|(NT-proBNP)|measurement of serum NT-proBNP levels will be performed at the time of admission and by the time of discharge
223582713|NCT05677503|DIAGNOSTIC_TEST|(cTnT)|measurement of cTnT levels will be performed at the time of admission and by the time of discharge
223582714|NCT03033953|DIETARY_SUPPLEMENT|Native whey|
223582715|NCT03033953|DIETARY_SUPPLEMENT|Milk|
223582716|NCT03033953|OTHER|Strength training|
223582717|NCT02654418|PROCEDURE|Endoscopic Mucosal Resection of large colon polyps (greater than or equal to 20 mm in size)|
223582718|NCT03110445|BIOLOGICAL|rVV-740CTA|non replicating recombinant vaccinia virus expressing 7 Cancer Testis Antigen (CTA) epitopes together with CD80 and CD154(40L)
223582719|NCT04533399|BIOLOGICAL|SARS-CoV-2 rS/Matrix-M1 Adjuvant|Alternating intramuscular (deltoid) injections of SARS-CoV-2 rS co-formulated with Matrix-M1 adjuvant (0.5 mL) on Days 0 and 21.
223582720|NCT04533399|OTHER|Placebo|Alternating intramuscular (deltoid) injections of placebo (0.5 mL) on Days 0 and 21.
224162563|NCT01807676|DEVICE|conventional Double Lumen Tube|
224162564|NCT04815226|DEVICE|Peristeen Transanal Irrigation|Using Peristeen Transanal Irrigation twice per week for 12 weeks
224162565|NCT01177826|PROCEDURE|Sample collection|Stool sample
224162566|NCT06032429|OTHER|Shared Medical Appointments|SMA is a subset of such clinics and are defined by groups of patients meeting over time for comprehensive care for a defining chronic condition or health care state, which involved both a person trained or skilled in delivering patient education or facilitating patient interaction.
224162567|NCT03290586|DEVICE|Flower Cube|single use, sterile disposable fixation construct
224162568|NCT02138162|DRUG|enzalutamide|oral
223582721|NCT01707589|DEVICE|The new sensor is not on the market. We have named it Elfi-sensor.|Participating subjects will be monitored for one hour with a noninvasive sensor.The noninvasive sensor, the size of a penny, will be affixed to the skin, above the umbilicus, with pediatric adhesive tape. The monitor will record continuously the heart rate, cardiac rhythm, respiratory rate and body motion.
223582722|NCT03776773|OTHER|Pollution exposure|Pollution exposure and sleep data will be recorded by pollution sensor and polysomnography respectively. In order to compare the variations according to the pollinisation season and the allergic rhinitis status of the patients.
223582723|NCT05530889|DEVICE|TEST Lens|ACUVUE® Theravision® with Ketotifen
224162569|NCT05493436|DIAGNOSTIC_TEST|MII pH-meter|using multichannel impedance pH-meter
224162570|NCT00065351|DRUG|CC-5013|CC-5013 - oral - 30mg daily on days 1-21 every 28 days
224162571|NCT00032305|DRUG|Visilizumab|
224162572|NCT01902654|OTHER|Cardiovascular risk factors diagnoses collection.|We look over patient medical record and we collect the diagnoses associated with cardiovascular risk factor as hypertension, obesity, dislipidemia and diabetes.
224162573|NCT01902654|OTHER|History of cardiovascular disease|In all patient we collect the history of cardiovascular disease.
224162574|NCT01902654|OTHER|Cardiovascular risk factors association|We have defined two groups according to grouping of none, 1 or 2 cardiovascular risk factors or 3 or more.
224162575|NCT04254575|OTHER|None, observational study only (no interventions)|None, observational study only (no interventions)
223582724|NCT05530889|DEVICE|CONTROL Lens|1-DAY ACUVUE® MOIST.
223582725|NCT06135363|DRUG|SC1011|SC1011 tablet
223582726|NCT06135363|DRUG|Placebo tablet|SC1011-matching placebo tablet
223582727|NCT03467672|OTHER|Diagnosis of bacterial infection|use of eosinopenia in the diagnosis of bacterial infection
223582728|NCT06337578|BEHAVIORAL|Telephone-based neuropsychological assessment - ALS|"ALS patients will be administered the following TBCS tests:~* ALS Cognitive Behavioral Screen-Phone Version;~* Telephone-based Frontal Assessment Battery;~* Telephone Language Screener;~* Telephone-based Verbal Fluency Battery;~This group will also undergo a telephone-based, caregiver-reported behavioral and functional assessment via the following scales:~* Activities of Daily Living;~* Instrumental Activities of Daily Living;~* Amsterdam IADL Questionnaire - Short Version;~* Caregiver Behavioral Questionnaire;~* ECAS-Carer Interview."
223744375|NCT04170348|DRUG|Monthly oral vitamin D3, 100,000 IU|Oral vitamin D3, 100,000 IU, will be administered monthly.
224162576|NCT01945190|DEVICE|Electroacupuncture|
224162577|NCT03793283|DEVICE|CSII|Currently receiving CSII therapy during 6 or more months.
224162578|NCT03793283|DRUG|Multiple dose insulin injections|Currently receiving MDI therapy during 6 or more months.
224162579|NCT01193049|DRUG|Prednisone|Prednisone (25 mg) tablets as a single oral dose on Day 1 of each study period
224162580|NCT01193049|DRUG|Placebo|Matching placebo tablets as a single oral dose on Day 1 of each study period
223476103|NCT03394937|BIOLOGICAL|ECI-006|ECI-006 consists of TriMix and 5 tumor associated antigens mRNA. TriMix is a mixture of mRNAs that encodes potent immune stimulating molecules
223476104|NCT00843349|DRUG|Lanthanum Carbonate|Phosphorus binder
223476105|NCT00843349|OTHER|900 mg Phosphate Diet|Amount of phosphorus consumption in a day kept below 900 mg.
223476106|NCT00843349|DRUG|LC Placebo|Placebo for Lanthanum Carbonate
224162581|NCT05187494|OTHER|Conventional local palatine injection|Conventional palatal injection with anesthetic (lidocaine HCL2% with Epinephrine 1:80000, Korea) Then the palatal probe will be performed with a dental probe in contact with the bone to estimate anesthetic effectiveness
223476107|NCT00843349|OTHER|Ad Libitum Diet|Patients continued to eat their usual diet.
223476108|NCT01605903|DRUG|Ibuprofen|Children in the ibuprofen group will be receive grape-flavored ibuprofen 100mg/5 mL. During the postoperative period, ibuprofen 10mg/kg (max dose 600 mg) will be dispensed Q6.
223582729|NCT06337578|BEHAVIORAL|Telephone-based neuropsychological assessment - AD, LBD, FTD and CVD|"AD, DLB, FTD and CVD patients will be administered the following TBCS tests:~* Telephone Interview for Cognitive Status;~* Telephone-based Frontal Assessment Battery;~* Telephone Language Screener;~* Telephone-based Verbal Fluency Battery;~These groups will also undergo a telephone-based, caregiver-reported behavioral and functional assessment via the following scales:~* Activities of Daily Living;~* Instrumental Activities of Daily Living;~* Amsterdam IADL Questionnaire - Short Version;~* Neuropsychiatric Inventory;~* Frontal Behavioural Inventory."
223582730|NCT06337578|BEHAVIORAL|Telephone-based and in-person cognitive screening - NIs|"NIs will undergo the Telephone Interview for Cognitive Status over the telephone and will be additionally administered, in person, the following cognitive screeners:~* Mini-Mental State Examination~* Montreal Cognitive Assessment~* In-Person Telephone Interview for Cognitive Status in person."
224162582|NCT05187494|DRUG|EMLA cream only|Emla cream will be applied at a distance of 1 mm from the palatine gingival edge by cotton buds for 3 minutes within the application area 14\*14 mm and the mouth will be open throughout the procedure and the saliva will be controlled by a saliva absorbent. Then the palatal probe will be performed with a dental probe in contact with the bone to estimate anesthetic effectiveness.
224162583|NCT05187494|DRUG|chemical permeability enhancer DMSO with EMLA cream|Adding 10 g of EMLA cream 5%, 1,026 g of DMSO 100% and it will be applied with cotton bud for a period of 3 minutes while the child is opening his mouth and the saliva is controlled by saliva absorbent. Then the palatal probe will be performed with a dental probe in contact with the bone to estimate anesthetic effectiveness.
224162584|NCT05187494|DRUG|Oral patches with EMLA Cream|EMLA cream 5% will be applied at a distance of 1 mm from the palatal gingival edge using an oral patch 14\*14 mm for 3 minutes and the Mouth will be closed throughout the procedure. Then the palatal probe will be performed with a dental probe in contact with the bone to estimate anesthetic effectiveness
224163622|NCT00469040|DRUG|GW642444M for 14 days|M salt
223582731|NCT01617447|DRUG|Placebo of Aripiprazole|administered orally once daily
223582732|NCT01617447|DRUG|Aripiprazole|Flexibly dose administered orally once daily
223582733|NCT02609945|DRUG|zolmitriptan|Oral Tablet and Nasal Spray
224163623|NCT06411106|DRUG|IMIQUIMOD cream 50mg/g|5 mg imiquimod (100mg Aldara®) per treatment site with a 12mm Finn chamber
223476109|NCT01605903|DRUG|Acetaminophen|During the postoperative period, ibuprofen 10mg/kg (max dose 600 mg) will be dispensed Q6.
223476110|NCT02120404|DRUG|Esmolol administration|"Esmolol will be administered during 24 hours, beginning with a titration period to determine the minimal dose allowing to achieve the randomized heart rate reduction of 10% or 20%, as defined by randomization.~Titration will be performed in sequences of increasing doses, beginning with 5 μg/kg/min as initial dose, and increasing by 5 μg/kg/min each 30 minutes until the target heart rate reduction is obtained. The maximum dose is 200 μg/kg/min.~The titrated dose will be maintained for a total duration of 24 hours."
223476111|NCT05902624|DRUG|Hepatitis B Virus Vaccine(HBV)|Hepatitis B Virus Vaccine(HBV)
223476112|NCT01068236|BEHAVIORAL|Healthy lifestyle managment|Exercise, yoga, food diaries, provider consultation
223476113|NCT01559168|DEVICE|UpholdTM LITE placement|Uphold TM LITE mesh is used for the surgical correction of pelvic organ prolapse.
223476114|NCT00218413|BIOLOGICAL|NicVAX|100 μg, Formulation A, on Days 0, 21, 42, 91 \& 182
223476115|NCT00218413|BIOLOGICAL|NicVAX|200 μg, Formulation A, on Days 0, 21, 42, 91 \& 182
223476116|NCT00218413|BIOLOGICAL|NicVAX|200 μg, Formulation B, on Days 0, 21, 42m 91 \& 182
223582734|NCT02609945|DRUG|CVT-427 (zolmitriptan inhalation powder),|Capsules containing zolmitriptan; dose levels equivalent to estimated fine particle dose (i.e., lung-delivered) zolmitriptan.
223582735|NCT00005053|DRUG|glufosfamide|
223582736|NCT02986113|BEHAVIORAL|MAPS tailored multimedia patient activation program|
223582737|NCT02986113|BEHAVIORAL|Sleep hygiene video|3 minute video on sleep hygiene produced by HealthiNation
223582738|NCT02986113|BEHAVIORAL|Telephone evidence-based follow-up care|3 months of suicide-focused collaborative mental health care, directed by a supervising psychiatrist and implemented by a care manager working with the patient and their primary care provider
223582739|NCT02986113|BEHAVIORAL|Commitment to Living for Primary Care|Brief (30 minutes total time) video modules presenting participating patients' primary care providers with a patient-centered framework for suicide risk assessment and intervention
223476117|NCT00218413|BIOLOGICAL|NicVAX|300 μg, Formulation B, on Days 0, 21, 42, 91 \& 182
223476118|NCT00218413|BIOLOGICAL|NicVAX|400 μg, Formulation B, on Days 0, 21, 42, 91 \& 182
223476119|NCT02037087|BEHAVIORAL|Good household prenatal practice|Knowledge on nutrition, labor, non-medical pain management, breastfeeding and depression
223476120|NCT02037087|BEHAVIORAL|Care seeking|"* Danger-sign recognition~* Reminders for government projects"
223476121|NCT02037087|BEHAVIORAL|Full bank of SMS|"* Danger-sign recognition~* Reminders for government projects~* Knowledge on nutrition, labor, non-medical pain management, breastfeeding and depression"
223476122|NCT04512495|OTHER|Blood samples will be collected at two times :|"* at Baseline,~* after surgery or at the time of post-chemotherapy evaluation."
224162585|NCT05187494|DRUG|Micro-needle patches dissolved with EMLA Cream|EMLA cream 5% will be applied at a distance of 1 mm from the palatal gingival edge using an micro-needle patch 14\*14 mm, 0,25 micron for 3 minutes and the Mouth will be closed throughout the procedure. Then the palatal probe will be performed with a dental probe in contact with the bone to estimate anesthetic effectiveness.
224162586|NCT00076856|DRUG|Temozolomide|
223476123|NCT04828499|PROCEDURE|Progressive Cracking Technique|Performing the cataract surgery with our phaco chop-progressive cracking technique.
223476124|NCT04828499|PROCEDURE|Conventional Chop Technique|Performing the cataract surgery with Conventional Chop Technique.
223476125|NCT04596319|BIOLOGICAL|AP-PA02|Bacteriophage administered via inhalation
223476126|NCT04596319|OTHER|Placebo|Inactive Placebo administered via inhalation
223476127|NCT02609490|DRUG|Azilsartan tablets|20mg/tablet
223476128|NCT02609490|DRUG|Azilsartan placebo tablets|placebo tablet
223476129|NCT02609490|DRUG|Olmesartan medoxomil tablets|20mg/tablet
223582740|NCT01075971|DRUG|Buprenorphine hydrochloride marketed sublingual tablet (Subutex)|8 mg or 16 mg daily, sublingual route on Days 1 and 2
223582741|NCT01075971|DRUG|Buprenorphine hydrochloride fast dissolving tablet (FDT)|8 mg or 16 mg daily, sublingual route on Days 3, 4, and 5
223582742|NCT02995551|PROCEDURE|Arthroscopic meniscal repair or resection|Arthroscopic meniscal repair or resection following standard procedures.
223582743|NCT02995551|BEHAVIORAL|Exercise and education|A 12-week (2 exercise sessions per week) supervised neuromuscular and strengthening exercise program tailored to 18-40 years old patients with a meniscal tear combined with patient education teaching the participants about their disease and how to manage it through exercise and in their daily life.
223582744|NCT03217032|BIOLOGICAL|YUVA-GT-F801|Lentiviral factor VIII gene modified autologous hematopoeitic stem cells and mesenchymal stem cells
223582745|NCT02713529|BIOLOGICAL|AMG820 and pembrolizumab|Treatment with AMG820 and pembrolizumab
223582746|NCT05565768|DRUG|HZN-457|HZN-457 will be given in one subcutaneous administration
223582747|NCT05565768|DRUG|Placebo|Placebo will be given in one subcutaneous administration
223582748|NCT02827500|DRUG|ivabradine|Active Comparator: ivabradine
223582749|NCT02827500|OTHER|Usual Care|Placebo Comparator: usual care
223744376|NCT04170348|DRUG|Placebo oral tablet|Participants randomized to receive once monthly oral bolus of vitamin D3, will receive placebo on all other days of the month.
223744377|NCT01588691|DEVICE|Eon-mini IPG (implantable pulse generator)|programming parameters set at low frequency. Patients will receive this therapy dose for 3 weeks.
223744378|NCT01588691|DEVICE|Eon-mini IPG (implantable pulse generator)|programming parameters set at high frequency. Patients will receive this therapy dose for 3 weeks.
224162587|NCT04737954|DIAGNOSTIC_TEST|Venepuncture|Venous blood draw
224162588|NCT04737954|DIAGNOSTIC_TEST|Fingerstick|Capillary blood draw
224162589|NCT00053105|DRUG|cisplatin|
224162590|NCT00053105|DRUG|cytarabine|
224162591|NCT00053105|DRUG|methylprednisolone|
224162592|NCT00053105|DRUG|pixantrone dimaleate|
224162593|NCT04761575|OTHER|Validation of the FFQ65+ via eNutri app|All participants will provide two eNutri FFQ datasets within a 14-day interval along with three 24-hour dietary recalls and dried blood spot samples.
224162594|NCT03177473|DEVICE|CervicalStim bone growth stimulator|Orthofix CervicalStim bone growth stimulator
224162595|NCT00741741|DRUG|TMC278|
224162596|NCT02828644|DEVICE|EVO|videogame-like digital therapy
223476130|NCT02609490|DRUG|olmesartan medoxomil placebo tablets|placebo tablet
223476131|NCT03437967|DEVICE|LightForce EXPi|LASER photobiomodulation therapy of 15-25 watts of coherent infrared light to affected area for 10 minutes using wand-type probe.
223476132|NCT04192682|DRUG|Anlotinib Hydrochloride|Anlotinib Day 1 to day 14 followed by 7 days off treatment in a 21-day cycle, Combined With Sintilimab 200mg/time，21-day cycle。
223476133|NCT04472572|BIOLOGICAL|Convalescent Plasma|Fresh or frozen plasma will be infused one time to patients with COVID-19 infection
223476134|NCT00171275|DRUG|Fluvastatin|
223476135|NCT03051711|DRUG|GBT440|Capsules which contain GBT440 drug substance in Swedish Orange
223476136|NCT05669157|PROCEDURE|Radiography request by nurse|Intervention group with radiography requested by the IRN instead of the physician. The radiography will be interpreted by the physician afterwards, according to current practice
223476137|NCT05669157|PROCEDURE|Radiography request by physician|The physician prescribed the X-ray, the X-ray technician carries out the imagery and the physician interprets it afterwards
223582750|NCT00487123|DRUG|Valsartan+/- Hydrochlorothiazide|
223582751|NCT04139720|BEHAVIORAL|e-book|sexual harassment prevention via education e-book
223582752|NCT05628051|PROCEDURE|ultrasonographic measurement of carotid artery corrected flow time (FTc)|Ultrasonic measurement of carotid corrected blood flow time: 1. Patient's head turned to the left 30°. Firstly, the 6.0 \~ 13.0MHz linear probe was placed longitudinally on the maternal neck, and the probe marker was oriented towards the maternal head. Real-time B-ultrasound images of the long axis of the right common carotid artery were obtained from the lower margin of the thyroid cartilage. Then, the probe was placed in the center of the carotid lumen, about 2cm from the bifurcation of the carotid artery, to obtain the arterial pulse Doppler flow spectrum and store the carotid flow waveform. 2. Using the caliper function of the ultrasonic instrument, carotid flow time (FT) was obtained by measuring the interval between the systolic ascending stage and the restroke notch. Wodey (W) formula to calculate FTc. FTc= FT+\[1.29× (HR-60)
223582753|NCT01484379|PROCEDURE|unilateral neck exploration|All elderly patients with primary hyperparathyroidism suspected to have a single gland disease will have a unilateral neck exploration following the index gland identification.
223582754|NCT03481712|DIAGNOSTIC_TEST|Diagnostic tests|"Head-to-head comparison between:~* CADScor and Diamond-Foster score~* Rb PET and 3T CMRI~* QFR and ICA-FFR"
223582755|NCT00138112|DRUG|Empirical Vancomycin|
224162597|NCT02493335|DRUG|Budesonide 0.5mg orodispersible tablet twice daily|
224162598|NCT02493335|DRUG|Budesonide 1mg orodispersible tablet twice daily|
224162599|NCT02493335|DRUG|Placebo orodispersible tablet twice daily|
224162600|NCT00198406|PROCEDURE|diagnostic and therapeutic management|
223582756|NCT00138112|DRUG|Prophylactic Vancomycin|
224162601|NCT04283773|COMBINATION_PRODUCT|p16INK4a Recombinant Rabbit Monoclonal Antibody (RM267)|Treatment of slides that cut from paraffin embedded blocks related to groups by immunohistochemical method by p16INK4a Recombinant Rabbit Monoclonal Antibody (RM267).
224162602|NCT04283773|COMBINATION_PRODUCT|Ki67 antibody (DAKO) for malignant cases only|Treatment of slides that cut from paraffin embedded blocks related to malignant case group by immunohistochemical method by Ki67 antibody.
224162603|NCT00004580|DRUG|Lopinavir/Ritonavir|
224304743|NCT04917653|DEVICE|Heart rhythm monitoring with wearable device|"The study compares the ability of lightweight measurement methods to detect different heart rhythms compared to the Holter registration.~1. Faros 360 ECG sensor with wet electrodes. Faros 360 Holter is CE and FDA 510 cleared class 2a medical device, which is attached to the patient's chest with five single-use wet electrodes.~2. Suunto Movesense one-time ECG device (Suunto Oy, http://www.suunto.com Vantaa Finland). Movesense is CE cleared consumer device, which is used with two dry electrodes to the ECG measurement.~3. Empatica E4 activity bracelet (Empatica Ltd http://www.empatica.com Milan, Italy), which is CE cleared consumer device. Empatica E4 is a photopletysmogram which measures optically the amount of blood circulating in the blood vessel."
224304744|NCT04917653|OTHER|Blood samples and biomarkers|"Several blood samples will be collected during the study protocol in pre-defined times before and after the cardioversion intervention.~Atrial peptides and cardiac troponins will be analyzed and kinetics estimated to predict the duration of early-onset AF period."
223476138|NCT06470581|DRUG|Botulinum toxin A|Patients were assigned 1:1 to a control group using only local anesthetics (Group A) and a BTX-A group (Group B). In Phase 1, the needle is inserted near the vertebrae T3 under fluoroscopic guidance. An 1 ml of non-ionized contrast medium is injected to evaluate the diffusion pattern, and 3ml of 0.75% ropivacaine is injected. After identifying a temperature increase in the ipsilateral palm within 20 min in the operating room with the prone position, 3 ml of 0.375% ropivacaine and botulinum toxin type A 75 IU mixed with 3 ml of non-preserved saline solution are injected in the patients in the control and botulinum toxin groups, respectively.
223476139|NCT02491762|PROCEDURE|respiratory function tests|FVC, FEV1, MVV, FRC, RV, TLC, MIP, MEP
223476140|NCT05729958|DIAGNOSTIC_TEST|CT scan|CT scan of the involved ankle
223476141|NCT03804619|DEVICE|Accelerated intermittent theta-burst stimulation (aiTBS)|aiTBS is an effective form of non-invasive brain stimulation which has been FDA-approved for the treatment of Major Depressive Disorder (MDD)
223476142|NCT03563222|DRUG|Smoflipid|"The study drugs will be infused via a dedicated line for parenteral nutrition (PN) into a central vein using a central venous catheter or a peripherally inserted central catheter.~The initial rate of infusion should be no more than 0.05 mL/minute for the first 10 to 15 minutes. If no untoward reactions occur, the rate can be changed to permit infusion of 0.5 mL/kg/hour.~The individual dosage of study drug should be infused at a constant rate for 10 to 24 h/d. The administration flow rate is determined by dividing the volume of study drug by the duration of the infusion. Maximum infusion rate for lipid should not exceed 0.125 g/kg/h lipid.~Study drug infusions should be given 5 to 7 days per week. Study treatment will last for a minimum of 90 consecutive days and as long as PN is indicated, up to 365 consecutive days. If the indication for PN continues after Study Day 365, PN will continue per normal institution policy."
223582757|NCT02308488|RADIATION|Intensity-modulated radiation therapy (IMRT)|Patients will receive 15 daily radiation fractions of 2.7 Gy, Monday to Friday for three weeks, to the entire breast/chest wall and axillary level III and supraclavicular nodes with a daily concomitant boost of 0.5 Gy to the tumor bed, for a total daily dose of 3.2 Gy to the tumor bed (2.7 Gy + 0.5 Gy). The overall dose will be 40.5 Gy to the breast/chest wall, axillary level III and supraclavicular nodes, and 48.0 Gy to the tumor bed.
223582758|NCT01929538|PROCEDURE|ERCP|endoscopic retrograde cholangiopancreatography
223582759|NCT01929538|DEVICE|covered self-expanding biliary metal stent, 12mm in diameter|
223582760|NCT01929538|DEVICE|covered self-expanding biliary metal stent, 10mm in diameter|
223582761|NCT03256786|BEHAVIORAL|Prewarming using forced air warmer, warmed intravenous fluid|Combined modality active warming consisting of preoperative 15 min of surface warming using a forced air warmer before spinal anesthesia and coloading of warmed intravenous fluid in active warming group
223582762|NCT01496911|DRUG|Levocetirizine|a single oral dose of 5 mg
223582763|NCT01496911|DRUG|Hydroxyzine|a single oral dose of 50 mg
223582764|NCT01496911|DRUG|Placebo|a single oral dose
223582765|NCT04147936|DIETARY_SUPPLEMENT|AXA1665|Dietary supplement: AXA1665
223582766|NCT04147936|DIETARY_SUPPLEMENT|Placebo|Placebo
223744379|NCT01588691|DEVICE|Eon-mini IPG (implantable pulse generator)|programming parameters set at lowest settings to deliver minimal power. Patients will receive this therapy dose for 3 weeks.
224162604|NCT00004580|DRUG|Nevirapine|
224162605|NCT06048809|OTHER|Stannous Fluoride Toothpaste (Sensodyne Repair and Protect)|Sensodyne Repair and Protect toothpaste containing 1100 ppm fluoride as SnF2.
224162606|NCT06048809|OTHER|Regular Fluoride Toothpaste (Colgate Cavity Protection)|Colgate Cavity Protection containing 1100 ppm fluoride as SMFP.
224162607|NCT06476795|OTHER|Chardonnay Marc|Food product made from Chardonnay wine grapes
224162608|NCT00225667|DRUG|Irbesartan|
224162609|NCT02283372|DRUG|nab-Paclitaxel|
224162610|NCT02283372|DRUG|Gemcitabine|
224162611|NCT02283372|RADIATION|Intensity modulated radiation|
224162612|NCT06099028|OTHER|no intervention|no intervention
224162613|NCT04003064|DIAGNOSTIC_TEST|Blood|3ml blood
224162614|NCT02672150|BEHAVIORAL|Core|
224162615|NCT02672150|BEHAVIORAL|Enhanced|
224162616|NCT02144090|DEVICE|Fractional flow reserve measurement|Fractional flow reserve measurement
224162617|NCT03030794|DEVICE|Repetitive transcranial magnetic stimulation|A non-invasive method of brain stimulation that emits a magnetic pulse.
224162618|NCT03030794|DEVICE|Repetitive transcranial magnetic stimulation (sham)|No brain stimulation will be administered.
224304745|NCT02584400|DRUG|Injection with the hypoxia tracer [18F]HX4,|The \[18F\]HX4 PET scan will be performed, by administrating 444 MBq (12 mCi) \[18F\]HX4 via a bolus IV injection.
224162619|NCT04179760|BIOLOGICAL|SCM-AGH|SCM-AGH will be administrated 3 times with 2-week intervals by IV infusion to subjects at Weeks 0, 2 and 4 (Visits 2, 3 and 4).
224304746|NCT00786994|DRUG|Oleogel-S10 100 mg/g|topical use once or twice daily
223476143|NCT03563222|DRUG|Intralipid, 20%|"The study drugs will be infused via a dedicated line for parenteral nutrition (PN) into a central vein using a central venous catheter or a peripherally inserted central catheter.~The initial rate of infusion should be no more than 0.05 mL/minute for the first 10 to 15 minutes. If no untoward reactions occur, the rate can be changed to permit infusion of 0.5 mL/kg/hour.~The individual dosage of study drug should be infused at a constant rate for 10 to 24 h/d. The administration flow rate is determined by dividing the volume of study drug by the duration of the infusion. Maximum infusion rate for lipid should not exceed 0.125 g/kg/h lipid.~Study drug infusions should be given 5 to 7 days per week. Study treatment will last for a minimum of 90 consecutive days and as long as PN is indicated, up to 365 consecutive days. If the indication for PN continues after Study Day 365, PN will continue per normal institution policy."
223476144|NCT03736967|DRUG|REGN3500|Administered subcutaneous (SC) every 2 weeks (q2w)
223476145|NCT03736967|DRUG|Dupilumab|Administered SC q2w
223476146|NCT03736967|DRUG|REGN3500 + Dupilumab Combo|Administered SC q2w
223476147|NCT03736967|DRUG|Placebo|Administered SC q2w
223476148|NCT03810443|DIAGNOSTIC_TEST|Hyperventilation test|The elements of the research consist of the Nijmegen questionnaire response, two dyspnea questionnaires (Dyspnea 12, MDP), a quality of life questionnaire (SF36), a psychological disorder screening questionnaire (HAD) and a diagnostic test: the hyperventilation test.
223476149|NCT00259831|DRUG|CVT-E002 (Cold-FX); a natural health product|
223476150|NCT05877989|DRUG|Amino Acid|Amino acid enteral and/or parenteral nutrition either enteral or parenteral to target a total protein delivery of 2.0g/kg/day.
223476151|NCT05877989|PROCEDURE|Physical exercise|The physical exercise intervention will be delivered by trained nursing staff, and started as close to the time of randomization as feasible (within 24hours of randomization). The intervention group will receive exercise sessions, for up to 20 min duration (as tolerated by patient).The implementation of physical exercise intervention will be protocolized to provide passive exercise early before weaning and shift to active exercise after weaning and also graduated resistance during each session and between daily sessions.
223476152|NCT02271178|OTHER|Combined capsule|Combined capsule containing ramipril (5 to 10 mg), atenolol (50 to 100 mg), 100 mg aspirin, 40 mg simvastatin. In follow-up visits doses of atenolol and ramipril capsules may be adjusted according to blood pressure and heart rate.
223476153|NCT02271178|OTHER|Conventional therapy|Usual therapy
223476154|NCT00194376|PROCEDURE|Continuous positive airway pressure ventilation|CPAP ventilation is a therapeutic modality which uses positive pressure of air through a sealed nasal mask to treat a condition known as sleep apnea
223476155|NCT02419807|DRUG|Indocyanine Green Solution|Given subdermally
223476156|NCT02419807|RADIATION|Technetium Tc-99m Sulfur Colloid|Given via injection
223476157|NCT02419807|PROCEDURE|Lymphoscintigraphy|This is a method used to check the lymph system for disease. A radioactive substance that flows through the lymph ducts and can be taken up by lymph nodes is injected into the body. A scanner or probe is used to follow the movement of this substance on a computer screen. Lymphoscintigraphy is used to find the sentinel lymph node (the first node to receive lymph from a tumor), which may be removed and checked for tumor cells. Lymphoscintigraphy is also used to diagnose certain diseases or conditions, such as lymphoma or lymphedema.
223476158|NCT02419807|PROCEDURE|Axillary Lymph Node Biopsy|Undergo biopsy
223476159|NCT05849857|DRUG|Mosunetuzumab|Mosunetuzumab is administered as a subcutaneous injection. The first dose is 5 mg in 0,5 mL volume, subsequent doses are 45 mg in 1,0 mL volume.
223476160|NCT00883727|DRUG|Stem cell|IV infusion of stem cells
223476161|NCT00883727|DRUG|Plasmalyte A|IV infusion
223476162|NCT04732793|DEVICE|Hyruan ONE®|For use as a symptomatic treatment of osteoarthritis (OA) of the knee
223476163|NCT04732793|DEVICE|Durolane®|For use as a symptomatic treatment of osteoarthritis (OA) of the knee
223476164|NCT01655875|DRUG|AMD3100|AMD3100 will first be administered at 240 mcg/kg (the FDA approved dose for mobilization of autologous PBSC) IV once daily prior to conditioning for 3 days (days -6, -5 and -4) in the first group of participants. If toxicity criteria are met, the dosing will be escalated in the second group of participants to 240 mcg/kg IV once daily prior to conditioning for 5 days (days -8, -7, -6, -5 and -4).
224162620|NCT04179760|OTHER|Placebo|Placebo will be administrated 3 times with 2-week intervals by IV infusion to subjects at Weeks 0, 2 and 4 (Visits 2, 3 and 4).
224162621|NCT05386004|OTHER|Birth-Specific Stereogram Cards (BSSC)|Focus on Birth-Specific Stereogram Cards (BSSC) during uterine contractions in latent active and transitional phase
224162622|NCT01942408|PROCEDURE|Repeat PVI|Repeat EP study 8-10 weeks post-initial PVI with re-isolation of PV reconnection
224162623|NCT03391375|BIOLOGICAL|DNA-HIV-PT123 & AIDSVAX B/E|DNA-HIV-PT123 encodes clade C ZM96 Gag and gp140, CN54 Pol-Nef; AIDSVAX®B/E is a subtype B (MN) and subtype E (A244) HIV gp120 glycoprotein adsorbed onto aluminium hydroxide gel adjuvant
223476165|NCT01353534|BIOLOGICAL|A/H5N1 Antigen|A/H5N1 Antigen
223476166|NCT01353534|DRUG|Vaccine Enhancement Patch|Vaccine Enhancement Patch
223476167|NCT03445169|DRUG|Belzutifan|Belzutifan Tablets
223476168|NCT00388999|DRUG|Intravenous Recombinant Human Mannose-Binding Lectin (rhMBL)|Intravenous (i.v.) administration for 4 weeks. Patients will be randomized to one of three cohorts: 0 mg/kg; 0.5 mg/kg, or 1.0 mg.kg
223476169|NCT00388999|DRUG|Intravenous Recombinant Human Mannose-Binding Lectin (rhMBL)|Intravenous (i.v.) administration for 4 weeks. Patients will be randomized to one of three cohorts: 0 mg/kg; 0.5 mg/kg, or 1.0 mg.kg
223582767|NCT06025812|BIOLOGICAL|Omicron BA.4/5-Delta strain recombinant novel coronavirus protein vaccine (CHO cells)|Intramuscular injection of deltoid muscle of upper arm of 25μg/0.5ml/person dose Omicron BA.4/5-Delta strain recombinant novel coronavirus protein vaccine (CHO cells).
223582768|NCT06025812|BIOLOGICAL|Recombinant novel coronavirus protein vaccine (CHO cells)|Intramuscular injection of deltoid muscle of upper arm of 25μg/0.5ml/person dose Recombinant new coronavirus vaccine (CHO cells).
223582769|NCT02337699|DEVICE|Implantation with the commercially available Axium neurostimulator|
223582770|NCT02337699|PROCEDURE|QST Testing|
224162624|NCT02734849|DRUG|AK001 low dose|25 mg AK001 will be administered as multiple doses
224162625|NCT02734849|DRUG|AK001 high dose|250 mg AK001 will be administered as multiple doses
224162626|NCT02734849|DRUG|Placebo|Placebo will be administered as multiple doses
224162627|NCT05452187|DRUG|Assess the effectiveness and safety of DAAs in patients with IBD.|Variables evaluated: age, gender, location, extent, phenotype, and activity of IBD, treatments, anti-HCV and viral load, DAA treatment and duration, fibrosis and hepatic decompensation and adverse effects (AE).
224162628|NCT05452187|DRUG|Evaluate the interaction of DAAs with IBD drugs, particularly immunosuppressants and/or biologics.|Variables evaluated: Interactions.
224162629|NCT05452187|OTHER|Assessment of the impact of DAAs on the course of IBD.|Qualitative variables will be expressed as a percentage and 95% confidence interval and quantitative variables as median and interquartile range. A priori it is difficult to determine which statistical analysis should be performed. It is basically a descriptive study, and the subsequent statistical analysis will depend on the evolution that the patients have presented in relation to the DAA treatment. If the drugs have been well tolerated without adverse effects, further statistical analysis will not be necessary. Instead, if the DAAs trigger activity outbreaks, variables related to the appearance of these outbreaks will be evaluated (type of DAA, immunomodulator, ...). To compare whether there are differences between the established groups, Chi Square (in qualitative independent variables), a t-student or ANOVA or their corresponding non-parametric tests (in quantitative independent variables) will be used. Statistical significance has been set at a probability level of \<0.05.
224162630|NCT03456414|OTHER|Virtual reality exercise during hemodialysis|Subjects will play a virtual reality game specially adapted for subjects undertaking hemodialysis treatment
223476170|NCT00388999|DRUG|Intravenous Recombinant Human Mannose-Binding Lectin (rhMBL)|Intravenous (i.v.) administration for 4 weeks. Patients will be randomized to one of three cohorts: 0 mg/kg; 0.5 mg/kg, or 1.0 mg.kg
224162631|NCT00794469|OTHER|Water|Children will drink 10 cc/kg of cold water(4 degrees centigrade)
224162632|NCT01329068|BEHAVIORAL|individual consult|regular individual consultations
224162633|NCT01329068|BEHAVIORAL|group medical consult|group medical consult
224162634|NCT02163668|OTHER|Yoga Group|8 months of Yoga training
224162635|NCT05129124|DEVICE|kalifilcon A Daily Disposable Toric LD213001 Contact Lenses|kalifilcon A Daily Disposable Toric LD213001 Contact Lenses at different fittings
224162636|NCT05129124|DEVICE|Commercially available Ultra for Astigmatism Contact Lenses|Commercially available Ultra for Astigmatism Contact Lenses at different fittings
224162637|NCT04744883|OTHER|Spinal Manipulation Therapy (SMT)|2 SMT techniques are administered each session, both of which are scripted interactions between the physical therapist (PT) providing the SMT and the subjects: 1) Participants will lie on the SMT table for 20 mins, while the PT sits approximately 6 ft away. As part of the script, the PT will review with subjects the inclusion/exclusion criteria ostensibly to ensure that nothing has changed. 2) The PT will perform the 2 SMT techniques during the next 20 mins. 3) Subjects will sit upright in a chair for the remaining 20 mins, while the PT sits approximately 6 feet away. The PT will review home exercises with participant.
224162638|NCT04744883|DRUG|Naloxone|In randomized order (crossover) across 2 laboratory sessions each approximately 3 days apart, participants will receive either 1) 2 doses of saline placebo (20ml each) or 2) weight-adjusted doses of Naloxone beginning with a dose of 0.11mg/kg followed by a weight-adjusted dose of 0.055 mg/kg
224162639|NCT04744883|DRUG|Placebo|In randomized order (crossover) across 2 laboratory sessions each approximately 3 days apart, participants will receive either 1) 2 doses of saline placebo (20ml each) or 2) weight-adjusted doses of Naloxone beginning with a dose of 0.11mg/kg followed by a weight-adjusted dose of 0.055 mg/kg
224304747|NCT00786994|DRUG|Placebo (petroleum jelly)|topical use once or twice daily
223476171|NCT01006629|BIOLOGICAL|palivizumab|palivizumab 15 mg/kg intramuscularly
223476172|NCT03738280|DIAGNOSTIC_TEST|Endoscopic ultrasound-fine needle biopsy|Patients with non-hypovascular solid pancreatic lesion undergo endoscopic ultrasound-fine needle biopsy
223476173|NCT04742218|DRUG|K-877|K-877 Tablet
223476174|NCT04954872|BEHAVIORAL|Standard Problem Management Plus training (training as usual)|10-day training on Problem Management Plus.
223476175|NCT04954872|BEHAVIORAL|Equip-based Problem Management Plus training|Training and supervision for Problem Management Plus in which the trainers and supervisors use the EQUIP platform for competency assessment and feedback.
223476176|NCT00095329|BIOLOGICAL|sirolimus|
223476177|NCT04148404|PROCEDURE|Normothermic group|"1. Normothermic group (NT group) included patients will undergo CABG under warm bypass using warm blood cardioplegia (Normothermic CBP).~2. Hypothermic group (HT group) included patients will undergo CABG under cold bypass using cold blood cardioplegia (Hypothermic CBP)."
223476178|NCT05255822|DRUG|INNA-051|Liquid for intra-nasal administration
223476179|NCT05255822|OTHER|Placebo|Liquid for intra-nasal administration
223476180|NCT02827539|DEVICE|LessRay|A software device has been developed that combines the benefits of reduced radiation associated with low-dose and/or pulse settings while preserving and possibly offering enhanced resolution. LessRay is a software device that is viewed on a separate monitor next to the fluro screen of the C-arm.
223476181|NCT02827539|DEVICE|Standard Fluoroscopy|For control arm, patients will receive the standard fluoroscopy for imaging.
223476182|NCT03157089|DRUG|Afatinib|Film-coated tablet
223476183|NCT03157089|DRUG|pembrolizumab|Solution for infusion
223476184|NCT00202488|DRUG|H. pylori treatment|
223476185|NCT04942600|DEVICE|MagStim Rapid2 Transcranial Magnetic Simulation|A non-invasive method of brain stimulation
223476186|NCT01506076|DRUG|Levocetirizine DiHCl|Levocetirizine DiHCl Tablets 5 mg
223582771|NCT01283490|DEVICE|DASD Group|Single application of 20% Benzocaine applied for one minute with the DASD ultrasonic and sonic vibration prior to needle puncture.
223582772|NCT01283490|DEVICE|Sonic Vibration (SV)|Single application of 20% benzocaine applied with SV for one minute prior to needle puncture.
223476187|NCT02932943|DRUG|Rapastinel|Rapastinel pre-filled syringes for weekly IV injections.
223476188|NCT02932943|DRUG|Placebo|Placebo-matching rapastinel pre-filled syringes for weekly IV injections.
223476189|NCT04661631|DIAGNOSTIC_TEST|Lung ultrasound|Lung ultrasound during the screening process for SARS-CoV-2 infection in patients with an indication for urgent surgery.
223476190|NCT00487591|DRUG|Omacor (omega-3-acid ethyl esters)plus simvastatin|Omacor(omega-3-acid ethyl esters) - 4/g day (4 one gram capsules) simvastatin - 20 mg/day (1 tablet/20 mg)
223744380|NCT06180590|DRUG|Sofosbuvir / Velpatasvir / Voxilaprevir Oral Tablet [Vosevi]|Evaluate the efficacy of Vosevi in DAAs-experienced patients
224163624|NCT01571167|DRUG|Placebo|Participants will receive varenicline or matched placebo from day 1 through day 7, then the same subjects will return within 2-4 weeks and assigned to each of the two remaining study medication conditions, and undergo the identical procedures (3-phase study).
223582773|NCT01536483|DRUG|Butyrate enemas|"Seven enemas~* Possibility to delay from 24 to 48 hours the procedure in case of clinical poor tolerance(maximum two enemas postponed and delayed at PND12 and PND13)~* The study remains blinded for the investigation team through the intervention of a clinical research nurse~* According to the procedure previously described by Nakaoka et al. (2009), a lubricated Foley catheter Ch 6 will be introduced into the rectum, the balloon will be inflated with 1 ml water for injections. Butyrate solution will be placed in a bag placed 50 cm above the child. Therefore, treatment administration will be performed at a controlled pressure of 50 cm H2O without any manual intervention~* Installation time and retention is setted at 15 minutes~* Treatment units will be directly placed in the incubator 30 min before the procedure to warm the enema to +36°C~* Per-treatment clinical monitoring of the tolerance will be performed by a neonatologist"
223582774|NCT05025696|OTHER|Blacksoap(R)|Blacksoap(R)
223582775|NCT05126628|DRUG|Proxalutamide|Proxalutamide 300mg q.d.(3 tablets of 100mg each) for 14 days.
223582776|NCT05126628|DRUG|Placebo|Placebo 3 tablets q.d. for 14 days
223582777|NCT01918449|OTHER|Clinical follow up by general practitioners in primary care|The study evaluates two different setting to follow up patients with obstructive sleep apnea on CPAP treatment
223582778|NCT02502981|DRUG|Spironolactone|25mg orally once a day for 40 weeks
223582779|NCT02502981|DRUG|Chlortalidone|25mg orally once a day for 40 weeks
223582780|NCT01180608|OTHER|MR Spectroscopy|"During each MR Spectroscopy session, we will measure at regions of interest (rACC, both thalami, dominant DLPC) the levels of the following biochemical substances:~* gamma-aminobutyric acid (GABA)~* glutamate (Glu)~* glutamine (Gln)~* N-acetylaspartate (NAA)~* Choline-containing compounds (Cho)~* Creatine plus phophocreatine (total creatine: Cr)~* Myo-inositiol (Ins)~* Choline (Cho)~* Glucose (Glc)~* Lactate (Lac)"
223582781|NCT05477199|OTHER|Cognitive behavioral principles-based treatment program|The treatment protocol had a total duration of 6 weeks. Two sessions were conducted each week, the first being a group session lasting 1.5 hours and the second an individual session lasting 45 minutes. During the group sessions, emotional disclosure and sharing of the experiences of patients with post COVID-19 syndrome were encouraged. During the individual sessions, a strong relationship was developed between the patient and the healthcare professional, with the healthcare professional helping the patient develop self-efficacy, thought monitoring, helpful self-talk, and reflection on changes in activity levels throughout the program.
223582782|NCT05477199|OTHER|Control intervention|Patients received an informational brochure in a consultation with a health professional. The brochure explained the importance of physical activity to improve the health condition of these patients. Patients had the opportunity to ask any questions to the healthcare professional.
223582783|NCT02242981|DRUG|LY2623091|Administered orally
223582784|NCT02038660|DEVICE|Balloon angioplasty|
223582785|NCT00142623|BEHAVIORAL|Tailored DVDs|Five DVDs aimed at reducing exposure to ETS
223582786|NCT02430324|OTHER|posttraumatic cerebral infarction|the difference between groups refers to the developing of cerebral infarction after traumatic brain injury
223582787|NCT05059964|OTHER|Circuit Training program|"The 4 weeks Circuit Training program, it will be of 3 times per week. Each CT workout includes 6 stations per circuit Training. Before the training period, all participants underwent an exercise familiarization session to ensure proper execution of technique.~The 6 stations will be included as 40 lb. carry for 100 ft., 3-min stair climb, 45 s plank pose, 20 lb. carry with a fast walk for 100 ft., right and left single leg stands for as long as balance was maintained, and a 15 lb. carry up and down 30 stairs"
223582788|NCT05059964|OTHER|Continuous aerobic exercise Group|Continuous aerobic exercise Frequency 3 time per week Intensity 50% of Heart rate reserve Type continuous aerobic exercise Time 40 minutes
223582789|NCT02426151|DRUG|BEPO-A|BEPO-A (Bioreactor manufacturing process)
223582790|NCT02426151|DRUG|REPO-A|REPO-A (Roller bottle manufacturing process)
223582791|NCT00693654|DRUG|Sarna|Active Ingredient: Pramoxine Hydrochloride Inactive ingredients:Benzyl Alcohol, Carbomer 940, Cetyl Alcohol, Dimethicone, Glyceryl Stearate (\&) PEG-100 Stearate, Isopropyl Myristate, Petrolatum, PEG 8 Stearate, Purified Water, Stearic Acid, Sodium Hydroxide
224163625|NCT01571167|DRUG|Varenicline|For varenicline 1 mg, dosing will begin at 0.5 mg once daily (with 0 mg placebo to maintain blind of bid dosing) for days 1-3, will be increased to 0.5 mg twice daily for the days 4-6, and then reduced to 0.5 mg once daily on day 7. No medication is given on Day 8.
223582792|NCT00693654|DRUG|Cetaphil|Purified Water, Glycerin, Hydrogenated Polyisobutene, Cetearyl Alcohol, Ceteareth 20, Macadamia Nut Oil, Dimethicone, Tocopheryl Acetate, Stearoxytrimethylsilane, Stearyl Alcohol, Panthenol, Farnesol, Benzyl Alcohol, Phenoxyethanol, Acrylates/C10-30 Alkyl Acrylate Crosspolymer, Sodium Hydroxide, Citric Acid
223582793|NCT03315169|OTHER|External dressing|Application of external dressing whilst perianal abscess cavity heals.
223582794|NCT03315169|OTHER|Packing of perianal abscess cavity|Internal packing of perianal abscess cavity - standard treatment.
223582795|NCT06108843|OTHER|Myofascial Arm Pull and Active Release Technique|Six weekly sessions of the treatment will be given over the course of four weeks. Baseline treatment includes Ultrasound for 10 minutes.
223582796|NCT06108843|OTHER|Myofacial Arm Pull|Six weekly sessions of the treatment will be given over the course of four weeks. Baseline treatment includes Ultrasound for 10 minutes.
223582797|NCT03364972|DEVICE|Cataract surgery|Conventional small-incision phacoemulsification cataract surgery with insertion of intraocular lens implant
223582798|NCT02774655|DEVICE|Pai APP|prescribed 100 PAI weekly
223582799|NCT02774655|DEVICE|FitBit APP|prescribed 10000 steps daily
223582800|NCT06105359|BEHAVIORAL|Dignity therapy|"Dignity therapy will be applied in the interview room that will be requested in the oncology clinic to protect the confidentiality of information.~The application is planned as five sessions and the sessions will last approximately 40 minutes. Two questions in the dignity therapy protocol will be discussed in each session."
224163626|NCT01571167|DRUG|Varenicline|For varenicline 2 mg, dosing will begin at 0.5 mg once daily for days 1-3 (with 0 mg placebo to maintain blind of bid dosing), will be increased to 0.5 mg twice daily for day 4, and increased to 1 mg twice daily on days 5-6, and then reduced to 1 mg once daily on day 7. No medication is given on Day 8.
224163627|NCT00171613|DRUG|Octreotide|
224162640|NCT04744883|BEHAVIORAL|Mindfulness Based Stress Reduction Therapy (MT)|Each MT session consists of (a) body scan meditation accompanied by awareness of breathing and other bodily sensations while in a lying position, (b) sitting meditation, focusing on awareness of breathing, bodily sensations, thoughts, and emotions (c) gentle movement exercises intended to develop awareness (mindfulness) during movement. In-session activities include suggestions for application of mindfulness as a method for responding positively to stress; dealing with the challenges of pain; and exercises focusing on the challenges and achievements patients experience in integrating mindfulness into their lives and the stressful situations they encounter. Additional discussion will focus on stress reactivity and they will be taught problem-solving skills to develop solutions to meet MT goals. Finally, patients will develop a written maintenance plan that includes a list of short- and long-term goals for applying mindfulness methods and a plan for dealing with possible setbacks.
224162641|NCT04428788|DRUG|CC-94676|Specified dose on specified days
223476191|NCT00487591|DRUG|simvastatin plus placebo|simvastatin 20mg/day (1 tablet 20 mg)plus 4 capsules matching placebo
224162642|NCT04428788|DRUG|CC1083611|Specified dose on specified days
224162643|NCT04428788|DRUG|CC1083610|Specified dose on specified days
223476192|NCT00250484|DEVICE|Transcranial Magnetic Stimulation|1Hz transcranial Magnetic Stimulation for 10 days for 26 minutes each day
223476193|NCT00250484|DEVICE|Sham Transcranial Magnetic Stimulation|Sham procedure of transcranial Magnetic Stimulation for 10 days for 26 minutes each day
223476194|NCT03661918|BEHAVIORAL|In-Person First Session|Conduct first session in person vs. over the phone
223476195|NCT03661918|BEHAVIORAL|Second Caregiver|Have second caregiver participate in three coaching calls
223476196|NCT03661918|BEHAVIORAL|WiFi-enabled Scale|Have participant weigh in weekly on a wifi-enabled scaled vs. regular scale
223476197|NCT03661918|BEHAVIORAL|10 Core Coaching Calls Only|Participant will receive 10 core phone coaching sessions
223476198|NCT06167902|OTHER|Ginseng oligopeptide (Ginseng extract）|The experimental group was given ginseng oligopeptide preparation 1.2g per day orally.
223476199|NCT06167902|OTHER|Maltodextrin|The control group was treated with placebo maltodextrin 1.2g/d
223476200|NCT04710121|OTHER|Virtual Reality Glasses|Virtual Reality Glasses (VRG), one of the methods of distracting attention; widely used in clinical medical care to relieve symptoms by providing the opportunity to create therapeutic environments for the evaluation and treatment of medical conditions. Virtual reality is a computer simulation technique that enables individuals to hear and feel the sounds and corresponding stimuli accompanying the visual image through headphones. The most basic feature that distinguishes virtual reality (VR) glasses from similar applications is that it gives individuals a real feeling. VR has helped to distract patients from mental processing and reduce the amount of pain. Virtual reality glasses, which are inexpensive to apply and use, do not cause side effects, and can be used in the recovery of the individual, are an intervention that can be preferred in nursing practices.
223476201|NCT02453607|DRUG|Infliximab|Drug is prescribed by treating physician and is not a part of the study. This study is non-interventional. Patients, to be elgibile, are being prescribed either monotherapy inlfiximab or combo therapy infliximab with azathiopurine.
223476202|NCT02453607|DRUG|thiopurine|Drug is prescribed by treating physician and is not a part of the study. This study is non-interventional. Patients, to be elgibile, are being prescribed either monotherapy inlfiximab or combo therapy infliximab with azathiopurine.
223582801|NCT06105359|OTHER|standardize care|Patients in this group will receive standard treatment and care in the clinic. No action will be taken other than standard care.
224162644|NCT03887052|DEVICE|ASSURE™ Wearable Cardioverter Defibrillator (WCD)|WCD with shock alarms and shock functionality disabled
224162645|NCT03224156|DIAGNOSTIC_TEST|Cardiac Magnetic Resonance Imaging|Patients undergo baseline characterisation including CMR, ECG, blood samples prior to ICD implantation.
223476203|NCT04015739|DRUG|Bevacizumab, Olaparib and Durvalumab (MEDI 4736) combination|"Patients will receive a combination of these 3 drugs :~Bevacizumab 15mg/kg q3w IV, Olaparib 300mg BD Per Os; and Durvalumab (MEDI 4736) 1.12g IV q3w"
223476204|NCT01088555|DRUG|Sodium thiosulfate|Oral administration of sodium thiosulfate pentahydrate 5% solution (American Regent) 10ml BID x 7 days
223582802|NCT02471768|PROCEDURE|CORONARY ANGIOGRAM AND CENTRAL AORTIC WAVEFORM ANALYSIS|coronary angiogram
224162646|NCT01804842|DRUG|Met DR|metformin delayed-release tablets
224162647|NCT00628134|DRUG|calfactant|single inhaled dose by nebulizer
224162648|NCT00628134|DRUG|isotonic saline|single inhaled dose by nebulizer
224162649|NCT01271595|OTHER|sham acupuncture|12 sessions of sham acupuncture over 8 weeks
223476205|NCT02356120|OTHER|Echocardiogram|Tricuspid annular plane systolic excursion will by measured by emergency physician performed echocardiogram
223476206|NCT01477307|OTHER|Hypocaloric diet|Eurodiet,standardized hypo-caloric diet, during 3 weeks
223476207|NCT00692575|BEHAVIORAL|Problem-solving, education based telephone counseling|Caregivers are contacted every 2 weeks for 16-20 weeks after discharge of TBI survivor home. A caregiver support specialist provides telephone counseling based on a problem-solving, educational model.
223476208|NCT00692575|OTHER|No Intervention|The control group will receive standard of care, i.e., typical resources and/or supports offered to caregivers of persons with TBI.
223476209|NCT01022333|DIETARY_SUPPLEMENT|Diindolylmethane (DIM)|300 mg per day of DIM for six weeks.
224162650|NCT04821297|OTHER|Health Promotion and Education|Receive messages
224162651|NCT04821297|OTHER|Survey Administration|Complete survey
224162652|NCT04821297|OTHER|Interview|Participate in an interview
223476210|NCT00329316|DRUG|Crinone Gel 8%|
223476211|NCT02106273|DEVICE|Bronchial blocker (Coopdech, Arndt)|Using bronchial blocker with LMA
223476212|NCT02106273|DEVICE|LMA-ProsealTM|
223582803|NCT03858504|OTHER|Exercise|The children with enthesitis related arthritis will be randomized into one of the exercise groups as yoga or home exercises and will perform the exercise program for 2 times a week for 8 weeks according to their groups.
223582804|NCT01058941|DRUG|Lipoic acid and fish oil concentrate|Lipoic acid (600 milligrams per day) and fish oil concentrate (3 grams per day) for 18 months
223582805|NCT01058941|DRUG|Placebo|Placebo LA and placebo oil capsules for 18 months
224162653|NCT06306196|BIOLOGICAL|Hecolin® Recombinant Hepatitis E Vaccine|30㎍/dose, 0.5mL administered intramuscularly
224304748|NCT00496535|DRUG|TNFerade biologic|
223476213|NCT00163592|DRUG|Tissucol®|
224162654|NCT06306196|BIOLOGICAL|Isotonic Sodium Chloride injection|0.5mL administered intramuscularly
224162655|NCT04097028|DRUG|Trifluridine and Tipiracil Hydrochloride|Given PO
224162656|NCT04097028|DRUG|Oxaliplatin|Given IV
224162657|NCT05740293|PROCEDURE|VisuMax SMILE procedure for the reduction or elimination of myopia with astigmatism|Bilateral treatment with the approved VisuMax SMILE procedure for the reduction or elimination of myopia with astigmatism.
224162658|NCT03687827|DRUG|Insulin degludec|Participants will receive insulin degludec U100 subcutaneous (s.c.) injection once daily for 36 weeks. Doses will be adjusted according to the fasting self-measured plasma glucose (SMPG) values. Participants earlier treated with one or more allowed oral antidiabetic drug(s) (OAD(s)), should continue their pre-trial OAD(s) treatment throughout the trial.
224162659|NCT03687827|DRUG|Insulin glargine|Participants will receive insulin glargine U100 s.c. injection once daily for 36 weeks. Doses will be adjusted according to the fasting SMPG values. Participants earlier treated with one or more allowed OAD(s), should continue their pre-trial OAD(s) treatment throughout the trial.
224162660|NCT04520308|DRUG|Dupilumab Only Product|SC injections of 300 mg dupilumab every 2 weeks for 24 weeks following a loading dose of 600 mg on day 1
224162661|NCT03073369|DRUG|Ergocalciferol 50000 UNT|Oral Ergocalciferol 50000 IU once daily for 6 weeks
224162662|NCT03073369|DRUG|Placebo|Oral Placebo - one capsule once daily for 6 weeks
224162663|NCT00561301|DRUG|GemDOx|gemcitabine oxliplatin
224162664|NCT01578525|OTHER|Pharmaceutical Care Service|Checking medication under safety considerations (medication at admission, hospitalization, discharge); recommendations for potentially inappropriate medication (PRISCUS-criteria),
224162665|NCT05885373|DIETARY_SUPPLEMENT|SIM01|SIM01 consists of a blend of food-grade Bifidobacterium as active probiotics
224162666|NCT00269958|DRUG|epoetin alfa|
224162667|NCT00164788|DRUG|Intravenous bolus injection of esomeprazole|80mg followed by continuous intravenous infusion of 8mg per hour for 24 hours
223476214|NCT00163592|PROCEDURE|Control: Conventional treatment, i.e. compression with swabs|
223476215|NCT00257452|DRUG|tiotropium 18 mcg or 54 mcg qd|
223476216|NCT00257452|DRUG|placebo matching tiotropium qd|
223476217|NCT00257452|DRUG|moxifloxacin 200 mg|
223476218|NCT04058496|OTHER|Blood sampling|Five Timepoints: baseline (pre-operative), ICU admission, 4 hours after ICU admission, 8 hours after ICU admission, 48 hours after ICU admission
223476219|NCT04453683|DEVICE|Air-Q. ILA insertion of proper size|Success of fiberoptic guided intubation throuhgh Air Q supraglottic airway device
223476220|NCT04453683|DEVICE|ILMA insertion of proper size|Success of fiberoptic guided intubation throuhgh ILMA supraglottic airway device
224162668|NCT00164788|DRUG|Oral esomeprazole|40mg every 12 hours for 24 hours
224162669|NCT02128958|DRUG|CF102|orally q12h
224162670|NCT02128958|DRUG|Placebo|orally q12 hours
224162671|NCT06242106|DEVICE|Glucometer|A glucometer, which is a portable device used to measure blood glucose levels, was used in this study to collect data. It is a dependable and widely used tool for assessing glycemic control in people with diabetes, including gestational diabetes
224162672|NCT02314286|DRUG|Rosuvastatin|Rosuvastatin is a hydrophilic statin, short treatment (hours to days) with this type of statin improved the outcome of patients during acute myocardial infarction, sepsis, contrast-induced nephropathy, hepatic ischemia/reperfusion injury, emphasizing its preferential pleiotropic effects. Currently, the FDA classiﬁes all statins as pregnancy category X and discourages their use during pregnancy due to higher abortion rate and teratogenicity that were observed in animals exposed to hydrophobic statins during pregnancy. Since the use of statins after delivery is allowed, the present study will aim to evaluate whether Rosuvastatin may accelerates preeclampsia resolution following delivery and potentially reduce postpartum preeclampsia complications.
224304749|NCT04275765|BEHAVIORAL|Arm 2:Behavioral Intervention with nudges & Facebook interaction|Participants will receive nudges and be enrolled to Facebook group for self-learning.
224162673|NCT02314286|DRUG|Placebo|
224304750|NCT04275765|OTHER|Arm 3: Community Intervention with individualised teleconferencing sessions and phone calls.|Participants will receive individualised teleconferencing sessions and phone calls by skilled midwives.
223476221|NCT02017301|OTHER|Nutritional assessment|Daily nutritional assessment with bioelectrical impedance vector analysis, phase angle and mid-arm muscle circumference
223476222|NCT05706324|BIOLOGICAL|Recombinant COVID-19 Vaccine (chimpanzee adenovirus vector) for Inhalation|0.2mL/dose, Inhalation using a nebulizer
223476223|NCT00421278|DRUG|MK0633|Single dose MK0633 100mg po in the fed state administered during a 4-wk study.
223476224|NCT02300610|DRUG|Enzalutamide|Enzalutamide orally once a day. Dose Escalation Level 1: 80 mg; Level 2: 160 mg. Dose Expansion at recommended dose level, after dose escalation.
223476225|NCT02300610|DRUG|Cisplatin|Cisplatin at 70 mg/m\^2 IV on day 1, repeated every 21 days for total of 6 cycles.
223476226|NCT02300610|DRUG|Gemcitabine|Gemcitabine at 1000 mg/m\^2 IV on days 1, 8, repeated every 21 days for total of 6 cycles.
224162674|NCT03708484|OTHER|Aerobic Interval Training|"Aerobic Interval Training Patients in this group will perform 6 minutes of cycling followed by 3 minutes of pause and again 6 minutes of cycling followed by 3 minutes of pause and finally 6 minutes of treadmill followed by 3 minutes of rest.~both groups will perform cool down exercises that include again breathing exercises, stretching and active exercises."
224304751|NCT01674127|DRUG|Methyldopa|
224304752|NCT01674127|DRUG|Placebo|
223476227|NCT00095979|DRUG|ixabepilone|Given IV
223476228|NCT04384900|PROCEDURE|Prone position ventilation|Patients are placed in a prone position using specialized equipment.
223476229|NCT01626066|DRUG|LUM015|LUM015 assigned dose given once by IV push
223476230|NCT01995383|OTHER|LS followed by NS diet condition|LS diet period followed by NS diet period
223476231|NCT01995383|OTHER|NS followed by LS diet condition|NS diet period followed by LS diet period
223476232|NCT01995383|DRUG|Placebo|Single oral administrations
223476233|NCT01995383|DRUG|Placebo|2 single oral administrations
223476234|NCT01995383|DRUG|RO6836191|Orally administered, single ascending doses
223476235|NCT01995383|DRUG|RO6836191|2 single oral doses
223744381|NCT01120756|BEHAVIORAL|Goal-oriented attentional self-regulation|This will involve 5-7 weeks of training (20 hours of group training (2 hour sessions, 2 days per week), 3 hours of individual training (1 hour at the beginning, halfway through and at the end of training), and approximately 20 hours of home practice). In brief, the GBSM training protocol is designed to maximize the potential for improving attention regulation skills and the goal-directed functions they support, applying mindfulness-based attention regulation training to practice in redirecting attention to goal-relevant processes especially in the context of distractions is emphasized throughout training. Participants are asked to identify realistic functional goals as feasible individual and group projects, and are then trained in goal management strategies on the functional task(s) of their choice.
223744382|NCT01120756|BEHAVIORAL|Brain Health Education|Brain Health Education (EDU) will involve 5-7 weeks of training (20 hours of group training (2 hour sessions, 2 days per week), 3 hours of individual training (1 hour at the beginning, halfway through and at the end of training), and approximately 20 hours of homework). The EDU intervention involves education in health and brain injury in a classroom format, with study materials for homework.
223744383|NCT03145168|OTHER|High Target Mean Arterial Pressure|High target group (80-85 mm of Hg).
223744384|NCT03145168|OTHER|Low Target Mean Arterial Pressure|Low target MAP group (60-65mm Hg).
223744385|NCT04870333|DRUG|Niclosamide|140μL of a 1% niclosamide ethanolamine solution in each nostril twice daily, equivalent to 1.4mg of niclosamide ethanolamine salt per nostril twice daily, approximately 12 hours apart. Total daily dose 5.6mg niclosamide ethanolamine salt (4.7mg free niclosamide acid). Treatment duration will be 6-9 months or up to 28 days after COVID-19 diagnosis unless hospitalised. Participants hospitalised with a diagnosis of COVID-19 should stop the randomised treatment immediately.
223744386|NCT04870333|DRUG|Placebo|140μL of a matching placebo solution in each nostril twice daily. Treatment duration will be 6-9 months or up to 28 days after COVID-19 diagnosis unless hospitalised. Participants hospitalised with a diagnosis of COVID-19 should stop the randomised treatment immediately.
224162675|NCT03708484|OTHER|Aerobic + Resistive Interval Training|"Aerobic + Resistive Interval Training Patients in this group; first set will perform 3 minute of cycling ,1 set of hand grippers 1.5 to 2.5 lbs (10 to 12 reps) and 1 set of biceps resistive exercises 1 Kg to 3 kg (10 to 12 reps) followed by 3minute of pause. In second set patient will perform 3 minutes of stationary cycling , 1 set of quadriceps resistive exercises 1 to 3 Kg (10 to 12 reps) again followed by 3 minutes of pause and in third set patient will perform 3 minutes of treadmill walk at 1.5 to 4 speed, and 1 set of standing ankle pumps (10 to 12 reps).~both groups will perform cool down exercises that include again breathing exercises, stretching and active exercises."
224304753|NCT03564444|BIOLOGICAL|Bivalent influenza vaccine|A single dose of bivalent vaccine (10\^7±5 fluorescent focus unit of 2 cold-adapted, attenuated, temperature-sensitive, 6:2 reassortant influenza strain) will be administered as intranasal spray on Day 1.
224162676|NCT03277105|DRUG|Dara SC|Participants will receive a fixed dose of Dara SC as 1800 mg daratumumab with rHuPH20 2000 U/mL, once weekly in Cycle 1 and 2, every 2 weeks in Cycle 3 to 6, every 4 weeks in Cycle 7 and thereafter until disease progression, unacceptable toxicity or the end of study.
224162677|NCT03277105|DRUG|Dara IV|Participants will receive Dara IV 16 mg/kg once weekly in Cycle 1 and 2, every 2 weeks in Cycle 3 to 6, every 4 weeks in Cycle 7 and thereafter until disease progression, unacceptable toxicity or the end of study.
224162678|NCT01769638|DRUG|SPO1101|A single-dose of ODF and FCT formulations of sildenafil given orally in a fasted state (dose: 50mg), with a 7-day washout period between the formulations.
224162679|NCT01769638|DRUG|SPO1101D|A single-dose of ODF and FCT formulations of sildenafil given orally in a fasted state (dose: 100mg), with a 7-day washout period between the formulations.
224162680|NCT00262639|DRUG|Flumazenil and Gabapentin|2 mg flumazenil for infusion given slowly over 20 minutes given day 1 and day 2 gabapentin 300 mg increasing to 1200 mg over 4 days and continuing to day 30. Gabapentin 900 mg Day 31 to Day 33 gabapentin 600 mg Day 34 to 36 and gabapentin 300 mg Day 37 to 39.
224162681|NCT00262639|DRUG|Placebo|20 mg Saline infused slowly over 20 minutes. Placebo 1 capsule Day 1, 2 capsules Day 2, 3 capsules Day 3, 4 capsules days 4 to 30; 3 capsules Day 31 to 33; 2 capsules day 34 to 36 and 1 capsule 37 to 39.
224162682|NCT04596072|COMBINATION_PRODUCT|Chinese traditional rehabilitation|Chinese traditional rehabilitation including acupuncture and herbs
224162683|NCT02656524|DRUG|Regorafenib (Stivarga, BAY73-4506)|Product is used in accordance with SmPC
224304754|NCT03564444|OTHER|Placebo|A single dose of placebo matched to bivalent influenza vaccine will be administered as intranasal spray on Day 1.
224304755|NCT01080443|DRUG|Mycophenolate Mofetil Capsule 250 mg|Subjects will be administered either Test Product or Reference Product with 240 mL of water according to randomization schedule
224304756|NCT04625426|DEVICE|3M Cavilon No-Rinse Skin Cleanser and 3M Cavilon Advanced Skin Protectant|Hypoallergenic no-rinse skin cleanser and liquid acrylic tetrapolymer skin protectant
224304757|NCT04625426|DEVICE|Conveen EasiCleanse and Conveen Critic Barrier|Hypoallergenic no-rinse skin cleanser and zinc-oxide barrier cream
224304758|NCT04625426|DEVICE|Standard cleansing and Conveen Critic Barrier|Hospital's standard care for IAD management
224304759|NCT00969631|DRUG|metformin HCl (Cidophage®; CID,Cairo, Egypt), CC (Clomid®; Global Napi Pharmaceuticals,Cairo, Egypt),Cairo, Egypt)|metformin HCl 1500 daily for 6-8 weeks then 100 mg CC for 5 days starting from day 3 of menstruation up to 6 cycles.
224304760|NCT00969631|PROCEDURE|Laparoscopic ovarian diathermy (LOD)|Three-puncture technique. Each ovary was cauterized at four points, each for 4 seconds at 40 W for a depth of 4 mm with a mixed current, using an monopolar electrosurgical needle.
224304761|NCT03775720|BEHAVIORAL|Dietary advice|Based on their genetic risk, participants are given advice to either adhere to general dietary guidelines related to salt intake or to reduce their salt intake to no more than 4 grams per day.
224304762|NCT04776837|BEHAVIORAL|Observational Cohort|Patients will be followed by collecting clinical data, biospecimens, and quality of life assessment
223476236|NCT01995383|DRUG|RO6836191|Intravenous administration
223744387|NCT04870333|DRUG|Ciclesonide|"Participants will be prescribed ciclesonide once daily, administered as follows:~Two puffs (320 μg) inhaled via mouth sequentially One puff (160 μg) inhaled via nose Treatment duration will be 6-9 months or up to 28 days after COVID-19 diagnosis unless hospitalised. Participants hospitalised with a diagnosis of COVID-19 should stop the randomised treatment immediately."
223476237|NCT04245761|DIETARY_SUPPLEMENT|Sonidor®|Sonidor® triple layer release tablets are developed with a specialized process to improve stability and bioavailability of the formulation based on hawthorn, lavender and hop extracts. The hawthorn, lavender and hop extracts used to product Sonidor® have an elevated content of vitexin (3%), monoterpens (4% as linalool) and flavonoids (4%), respectively.
223582806|NCT05135611|DEVICE|4 channel Electrical Stimulation Device|electrical stimulation at muscles which related with sleep apnea,. 4-channel NMES is the protocol that provides sequential electrical stimulation to Rt. suprahyoid m (channel 1), Lt.suprahyoid m (channel 2), bilateral thyrohyoid m (channel 3), and biltateral sternothyroid m (channel 4). At this time, channels 1 and 2 start to contract first and stimulate for 1200ms, and channel 3 starts stimulation 150ms after channels 1 and 2, and applies stimulation for 1050ms. Channel 4 starts stimulation 250ms after stimulation of channels 1 and 2 and stimulates it for 950 ms.
223582807|NCT01274611|DRUG|Botulinum Toxin Type A|Botox will be injected into the underarm, targeting the sweat glands, to stop underarm sweating.
223582808|NCT01274611|DEVICE|Suction-Curettage|The doctor will insert a suction tool into two small incisions in order to suction out the sweat-producing glands. It is similar to liposuction, but instead of suctioning out fat, the doctor suctions out the layer of the deep skin where the sweat glands are located to decrease underarm sweating.
223582809|NCT00955604|DRUG|Group R+AD Rasagiline + Antidepressant|Rasagiline and an antidepressant (SRIs, SNRIs, St. John's wort and/or TCAs) at least 14 days
223582810|NCT00955604|DRUG|Group R Rasagiline|At least 2 months of rasagiline
223582811|NCT00955604|DRUG|Group AD Anti-PD + Antidepressant|An approved dopaminergic medication for PD. (2 months of treatment with an antidepressant medication.
223582812|NCT04588155|DEVICE|Functional assessment|Timed Up and Go Test administration with application of Inertial Measurement Unit for a temporal and kinematic assessment of movement performed during test esecution
223582813|NCT04588155|OTHER|Clinical assessment|"Roland Morris Disability Questionnaire (RMDQ) to assess the level of functional impairment and disability in the activity of daily living~Numerical Pain Rating System (NPRS) administration to quantify level of pain experienced just before the TUG test execution"
223582814|NCT03712111|DRUG|Norepinephrine 6 mcg|An intravenous bolus of norepinephrine 6 mcg will be administered for management of maternal hypotension.
223582815|NCT03712111|DRUG|Norepinephrine 10 mcg|An intravenous bolus of norepinephrine 10 mcg will be administered for management of maternal hypotension.
223744388|NCT04870333|DRUG|Placebo|"Matched placebo: two puffs inhaled via mouth sequentially and one puff inhaled via nose.~Treatment duration will be 6-9 months or up to 28 days after COVID-19 diagnosis unless hospitalised. Participants hospitalised with a diagnosis of COVID-19 should stop the randomised treatment immediately."
224162684|NCT01530373|DRUG|solifenacin|oral solifenacin 5.0 mg daily for 3 weeks
224162685|NCT01530373|DRUG|Clonidine|oral clonidine 0.1 mg daily for 3 weeks
224162686|NCT06587802|DRUG|Triprolizumab|At the end of radiotherapy, 240mg of triplizumab was administered intravenously every cycle (21 days)
224162687|NCT06587802|DEVICE|rodiotherapy|SBRT radiotherapy (radiotherapy dose: 40Gy, 5 times, 8Gy each time, number of metastatic radiotherapy: ≤5)
224162688|NCT04031157|DEVICE|Predictix Antidepressant|Predictix Antidepressant guided treatment
224162689|NCT02304419|DRUG|Galunisertib|Administered orally.
224304763|NCT04128280|PROCEDURE|TUDP|a surgery: transurethral dilation of prostate with a columnar balloon
223582816|NCT03712111|DRUG|Bupivacaine Hydrochloride|Subarachnoid block will be performed using Bupivacaine hydrochloride (2.2 mL) in addition to fentanyl 25 mcg
223582817|NCT03712111|DRUG|Norepinephrine infusion|Prophylactic norepinephrine infusion will be started after subarachnoid block
223744389|NCT04870333|DRUG|Sotrovimab|"There will be a single infusion of sotrovimab administered at the beginning of the study.~500mg of sotrovimab solution (8mL) will be diluted in 42mL of 0.9% sodium chloride and administered by intravenous infusion. 50mLs to be infused over 30 minutes with a 0.2 micrometre inline filter. Four vials will be required for a 2000 mg dose."
223744390|NCT04870333|DRUG|Placebo|There will be a single infusion placebo, in the form of 100mL 0.9% sodium chloride, administered at the beginning of the study.
223744391|NCT01948128|DRUG|Vitamin D3|Participants will take 4 capsules of Vitamin D which equals 40,000 IU by mouth daily during the wait time between diagnosis and surgery.
223744392|NCT01948128|OTHER|Placebo|Participants will take 4 capsules of placebo by mouth daily during the wait time between diagnosis and surgery.
223744393|NCT04026048|BEHAVIORAL|Cognitive Behaviour Therapy for Insomnia (CBT-I)|CBT-I is a manualized multi-component intervention that includes sleep restriction, stimulus control, cognitive restructuring, relaxation training, and sleep hygiene.
224162690|NCT00333424|BIOLOGICAL|pHIS-HIV-AE (DNA vaccine) prime and rFPV-HIV-AE (recombinant fowlpox virus boost) vaccine|6mg pHIS-HIV-AE at weeks 0, 4 and 8; 3 x 10e8 pfu/mL rFPV-HIV-AE at week 12
224162691|NCT00549653|DRUG|GW856553|
224163628|NCT03734133|OTHER|Foot insoles|Different foot insoles of different hardness
224163629|NCT02368730|DRUG|desmopressin|
224163630|NCT02416765|OTHER|15-hour intervention|Interventions will be conducted in outpatient settings. Subject's usual insulin will be used. Meals will not be standardized. Subjects will be allowed to eat whatever and when they want and will be allowed to drink alcohol. Subjects will be allowed to exercise, but they will be asked to do the same amount and intensity of exercise on all intervention visits. Subjects will be accompanied all the time by a member from the research team during closed-loop visits to implement hormonal infusions.
224163631|NCT02416765|DRUG|Insulin (Lispro, Aspart or guilisine)|Patient's usual insulin (Lispro, Aspart or guilisine) will be used in all interventions.
224163632|NCT02416765|DRUG|Glucagon (Eli Lilly)|In the dual-hormone CLS interventions, glucagon (Eli Lilly) will be used.
224163633|NCT02416765|OTHER|Closed-loop strategy|Every 10 minutes, the glucose level as measured by the real time sensor (Dexcom G4 Platinum, Dexcom) will be entered manually into the computer. The pumps' infusion rate will then be changed manually based on the computer generated recommendation infusion rates. The computer generated recommendations are based on a predictive algorithm.
224163634|NCT03188003|OTHER|Exercise Movement Techniques based on mobilization|10 sessions will be held twice a week, with each session taking an average of 50 minutes.
224163635|NCT03188003|OTHER|Exercise Movement Techniques based on stabilization|10 sessions will be held twice a week, with each session taking an average of 50 minutes.
223476238|NCT00968162|DRUG|fludarabine|Conduct a pilot trial using a transplant protocol, in which the standard busulfan, cyclophosphamide and anti-thymocyte globulin conditioning regimen is modified by adding fludarabine, a highly immunosuppressive agent, in order to determine the feasibility of reducing the total dose of cyclophosphamide from its present standard of 200 mg/kg to 90 mg/kg and of busulfan from its present standard of 12.8 mg/kg (IV) to 6.4 mg/kg, using a four step dose de-escalation schema.
223476239|NCT03824431|DIAGNOSTIC_TEST|Endoscopic esophageal biopsies|
223476240|NCT04422886|DEVICE|active transcranial direct current stimulation (tDCS)|20 minutes at 2.0 mA with electrodes positioned at Cz and Fpz (as per 10-20 electrode placement guidelines)
223744394|NCT02742987|DRUG|Ticagrelor|Ticagrelor 90 mg twice daily
223476241|NCT04422886|BEHAVIORAL|Physiotherapy|motor skills based physiotherapy intervention (representative of typical goal-focused intervention in the clinical ABI program at Holland Bloorview), 45 minutes in duration
223476242|NCT04422886|DEVICE|sham transcranial direct current stimulation (sham)|1 minutes at 1.0 mA with electrodes positioned at Cz and Fpz (as per 10-20 electrode placement guidelines) and 19 minutes with unit shut off and electrodes remaining on the scalp
223476243|NCT00270023|DRUG|epoetin alfa|
223476244|NCT01719250|DRUG|Buparlisib|Given PO
223476245|NCT01719250|OTHER|Laboratory Biomarker Analysis|Correlative studies
223476246|NCT01719250|OTHER|Questionnaire Administration|Ancillary studies
223476247|NCT03337516|BIOLOGICAL|Blood sampling|Blood sampling in order to assess cytarabine pharmacokinetics
223476248|NCT03337516|GENETIC|Genetic analysis|Genetic analysis in order to determine genetic polyporphism of Deoxycytidine Kinase and Cytidine Deaminase
223476249|NCT03175497|DRUG|Telatinib Mesylate|Telatinib mesylate tablets will be administrated twice a day orally
223476250|NCT04221334|DEVICE|Electric Toothbrush|Electric Toothbrush used to remove dental plaque and resolve gingivitis
223476251|NCT04221334|OTHER|oral health care application|phone application that shows the user brushing efficiency real time
223476252|NCT00591799|DEVICE|The Jarvik 2000 Ventricular Assist System|Jarvik 2000 Heart implantation is intended for patient's with end-stage heart failure who are approved heart transplant candidates - who meet all of the study's inclusion criteria and none of its exclusion criteria.
223476253|NCT02136381|BEHAVIORAL|LEAP intervention|"LEAP has 5 modules of tools and resources. LEAP is personalised based on information provided at different stages. The user determines the modules to complete (skipping or revisiting modules). Users can choose among 8 animated mentors (4 female; 4 male) to guide them through the intervention.~Users will provide demographic data, health-related information, and current lifestyles in order to tailor the advice to be received.~Advice will focus on adopting elements of a Mediterranean dietary pattern, increase physical activity, and improve social connectedness.~Participants will receive 1) Mediterranean diet recipes; 2) a step counter to monitor physical activity goals; 3) advice in how to enhance social engagement and facilitate social roles"
223476254|NCT02136381|BEHAVIORAL|Control|"Thirty participants will be randomised to a minimal intervention comparator condition, where participants will be emailed a direct link to the National Health Service (NHS) choices 'LiveWell' website (http://www.nhs.uk/LiveWell/Pages/Livewellhub.aspx).~The email will encourage the participants to access the health resources and information on the pages labelled men's health 40-60, men's health 60-plus, women's health 40-60, women's health 60-plus, as appropriate.~Participants in the control group will be assessment after two months."
223476255|NCT04214743|DEVICE|Incident dark field videomicroscope from Braedius|It allows to look at conjunctival microcirculation
223476256|NCT04214743|DEVICE|Fundus camera from Optomed|It allows to monitor retinal microvasculature
223476257|NCT00022477|DRUG|BMS-247550|
223476258|NCT06207474|OTHER|Video + Chatbot|Participants will receive detailed information about the radiation therapy process, potential side effects, frequently asked questions, and aftercare instructions using a combination of educational videos and interactive chatbot sessions.
223476259|NCT06207474|OTHER|Video + Paper|Participants will receive detailed information about the radiation therapy process, potential side effects, frequently asked questions, and aftercare instructions using a combination of educational videos and paper materials.
223476260|NCT06207474|OTHER|Paper + Chatbot|Participants will receive detailed information about the radiation therapy process, potential side effects, frequently asked questions, and aftercare instructions using a combination of paper materials and interactive chatbot sessions.
223476261|NCT06207474|OTHER|Paper + Paper|Participants will receive detailed information about the radiation therapy process, potential side effects, frequently asked questions, and aftercare instructions using paper materials.
223476262|NCT01482611|DRUG|JNJ-47910382|Type = exact number, unit = mg, number = 10, 75, 300, form = suspension, route = oral use.
223476263|NCT01482611|DRUG|JNJ-47910382|Type = exact number, unit = mg, number = 30, 150, 600, form = suspension, route = oral use.
223476264|NCT01482611|DRUG|JNJ-47910382|Type = exact number, unit = mg, number = To be determined, form = suspension, route = oral use.
223476265|NCT01482611|DRUG|JNJ-47910382|Type = exact number, unit = mg, number = To be determined, form = suspension, route = oral use.
223476266|NCT01482611|DRUG|Placebo|Type = exact number, unit = mg, number = equivalent of 10, 75, 300, form = suspension, route = oral use.
223476267|NCT01482611|DRUG|Placebo|Type = exact number, unit = mg, number = equivalent of 30, 150, 600, form = suspension, route = oral use
223476268|NCT01482611|DRUG|Placebo|Type = exact number, unit = mg, number = equivalent dose to be determined, form = suspension, route = oral use.
223476269|NCT01482611|DRUG|Placebo|Type = exact number, unit = mg, number = equivalent dose to be determined, form = suspension, route = oral use
223476270|NCT02779569|DRUG|decitabine|
223476271|NCT02627560|DRUG|Tranexamic Acid|moisten the surgical wound surface with 20 ml tranexamic acid 25 mg/ml
223476272|NCT02627560|DRUG|saline|moisten the surgical wound surface with 20 ml placebo (0.9% saline)
223476273|NCT06293833|RADIATION|Low-dose CT scan|Participants get an annual low-dose CT scan in UZA
223744395|NCT02742987|DRUG|Clopidogrel|Clopidogrel 150 mg once daily
224304764|NCT04128280|PROCEDURE|TUIB|a surgery: transurethral incision of bladder neck
223476274|NCT06293833|BEHAVIORAL|Smoking Cessation|Smoking cessation campagnes
223476275|NCT03181308|DRUG|Carotuximab (TRC105)|Anti Endoglin Antibody
223476276|NCT03181308|DRUG|OPDIVO|Programmed Death Receptor-1
223476277|NCT04054297|BEHAVIORAL|High GI/SFA diet|Subject will adhere to a 2 week high GI/SFA diet.
224162692|NCT01364142|PROCEDURE|endobronchial blocker|After intubation of endotracheal tube, the Uniblocker® was inserted into the endotracheal tube and advanced step by step with inflation of the blocker balloon until the peak inspiratory pressure dropped abruptly.
223476278|NCT04054297|BEHAVIORAL|Low GI/SFA diet|Subject will adhere to a 2 week low GI/SFA diet.
223476279|NCT00912366|PROCEDURE|Lobectomy|Assessment of VATS versus open surgery.
223582820|NCT02139904|DRUG|Vinorelbine|Vinorelbine was first licensed in the UK for Non-Small Cell Lung Cancer (NSCLC) and advanced breast cancer in 1997. Vinorelbine (Navelbine®) is a semi-synthetic, third generation, vinca alkaloid. The cytotoxic effect of vinorelbine is through the disruption of mitotic spindle formation, blocking mitosis at the G2-M stage resulting in cell death.
223582821|NCT02139904|OTHER|Active Symptom Control|
223582822|NCT03770104|PROCEDURE|ETT insertion depth using Spanish recommendations|Infants included in this assignment group will be intubated using the formula 5.5 plus weight, when requiring oral intubation in the delivery room.
223582823|NCT03770104|PROCEDURE|ETT insertion depth using international recommendations|Infants included in this assignment group will be intubated using the formula 6 plus weight, when requiring oral intubation in the delivery room.
223582824|NCT02644356|BEHAVIORAL|Online CE/CME course|Educational modules of a proposed online CE/CME course, module topics consisting of acupuncture, massage, and music-related interventions
223582825|NCT01763294|DEVICE|Nicolet Endeavor CR: 30min|Transcranial direct current stimulation (tDCS) is a safe, non-invasive method that modulates cortical excitability. In direct current polarization, the cerebral cortex is stimulated through a weak constant electric current in a noninvasive and painless manner. This weak current induces focal changes of cortical excitability increase or decrease depending on the electrode polarity- that last beyond the period of stimulation.
223476280|NCT02399332|OTHER|Community pharmacist involvement|Collaborative involvement of the community pharmacists in formulating and following complex care plans
223476281|NCT02484677|DRUG|Cisplatin|Antineoplastic cytostatic. Blood sampling for pharmacokinetic evaluation
223582826|NCT01763294|DEVICE|Nicolet Endeavor CR: 60min|Transcranial direct current stimulation (tDCS) is a safe, non-invasive method that modulates cortical excitability. In direct current polarization, the cerebral cortex is stimulated through a weak constant electric current in a noninvasive and painless manner. This weak current induces focal changes of cortical excitability increase or decrease depending on the electrode polarity- that last beyond the period of stimulation.
223582827|NCT01763294|DEVICE|Nicolet Endeavor CR: 30min for 3 days|Transcranial direct current stimulation (tDCS) is a safe, non-invasive method that modulates cortical excitability. In direct current polarization, the cerebral cortex is stimulated through a weak constant electric current in a noninvasive and painless manner. This weak current induces focal changes of cortical excitability increase or decrease depending on the electrode polarity- that last beyond the period of stimulation.
223744396|NCT02742987|DRUG|Standard medical therapy|Standard medical therapy for patients with coronary artery disease undergoing percutaneous coronary interventions
223476282|NCT02484677|DRUG|Docetaxel|Taxanes. Blood sampling for pharmacokinetic evaluation
223476283|NCT02484677|DRUG|5-Fluorouracile|Antineoplastic and immunomodulating agents. Blood sampling for pharmacokinetic evaluation
224162693|NCT04993755|DRUG|TPN-101, 400 mg/day|400 mg/day of study investigational drug TPN-101 once daily for 24 weeks (double-blind treatment) followed by 400 mg/day TPN-101 for 24 weeks (open-label treatment).
224162694|NCT04993755|DRUG|Placebo|Placebo once daily for 24 weeks (double-blind treatment) followed by 400 mg/day TPN-101 for 24 weeks (open-label treatment).
224162695|NCT02396004|DEVICE|Near Infrared Red Spectroscopy (NIRS)|NIRS using INVOS cerebral/somatic oximeter
223476284|NCT05348252|OTHER|Patient Journey App|The group will receive all information and insctructions on discontinuing PPI use through the Patient Journey App which timely deliveres all information.
223476285|NCT05348252|OTHER|Information folder|The group will receive all information and instructions on discontinuing PPI use through an information folder.
223476286|NCT03530891|PROCEDURE|Computer guided lag screw fixation|Under general anaesthesia: Patient specific pre operative prefabricated surgical guide will be used intra operative for open reduction and internal fixation for anterior mandibular fracture using lag screws.
223476287|NCT03530891|PROCEDURE|Conventional lag screw fixation|Under general anaesthesia: Open reduction and internal fixation for anterior mandibular fracture utilising lag screws.
223476288|NCT05446285|OTHER|Clinical assessment|All participants will be invited to attend their local research facility to undergo a physical and questionnaire assessment as well as an MRI. Assessments include: Expanded Disability Status Scale, 9-Hole Peg Test, MRI scan, Patient Reported Outcome Measures (MSIS-29, neuroQOL and PROMIS), Brief International Cognitive Assessment for MS)
223476289|NCT02607631|DRUG|Pembrolizumab|treated with Pembrolizumab 200 mg every 3 weeks
223476290|NCT03635918|DEVICE|NightOwl HSAT|Patient wears the NightOwl sensor device
223476291|NCT02606812|DIETARY_SUPPLEMENT|Traditional-food|Intake of ethnic local food
223476292|NCT00834184|DRUG|nikkomycin Z|"Multiple rising doses. Doses packaged on a unit dose basis in 250 mg capsules. Subjects take 1-3 capsules per dosing block for 14 days unless ADE or study withdrawal. Dose escalation unless a dose-limiting adverse effect is noted. Subjects assigned to BID dosing will receive 28 doses and subjects assigned to TID dosing will receive 42 doses.~250 mg BID (n=6) vs Placebo capsule BID (n=2), 500 mg BID (n=6) vs Placebo capsule BID (n=2), 750 mg BID (n=6) vs Placebo capsule BID (n=2), 750 mg TID (n=6) vs Placebo capsule TID (n=2) At least 4 subjects complete lower dose before randomization includes next higher dose, thus there are 4 arms for active intervention and corresponding placebos."
223476293|NCT01099046|BEHAVIORAL|Lifestyle|water intake, tympanic tubing, regular sleep
224162696|NCT00058188|DIETARY_SUPPLEMENT|cholecalciferol|Given orally
224162697|NCT00058188|DRUG|calcium gluconate|Given orally
223476294|NCT02360332|BEHAVIORAL|Project SEARCH plus ASD Supports|Project SEARCH program (Rutkowski, Daston, Kuiken, and Riehle, 2006) is a work based learning model for high school transition that was developed at Cincinnati Children's Hospital Medical Center. The model provides complete immersion in the workplace. Students spend their entire school day at the workplace for a full school year. Consistent with principles of work based learning, Project SEARCH facilitates the development of a broad range of high-quality jobs within the employer organization and provides over 700 of supervised work experience. The model also relies on the intensive application of supported employments strategies (task analysis and customization, systematic instruction, ongoing support, etc.) to allow the participation of individuals with extensive support needs.
223476295|NCT04836741|DEVICE|Micro Hand S robot|The surgeries are performed with the Micro Hand S robot
223476296|NCT04836741|DEVICE|Laparoscope|The surgeries are performed with the laparoscope
223476297|NCT05278468|OTHER|PCR test for covid-19|real-time reverse transcription polymerase chain reaction results for severe acute respiratory syndrome coronavirus-19 (COVID-19) infection.
223476298|NCT02924935|DIETARY_SUPPLEMENT|L-Histidine|L-Histidine in 500mg capsules taken at a dose of 50mg/kg to maintain high-normal serum histidine levels
223476299|NCT01663623|BIOLOGICAL|Placebo|Placebo
223476300|NCT01663623|BIOLOGICAL|Belimumab 10 mg/kg|Belimumab 10 mg/kg
223476301|NCT01663623|DRUG|Azathioprine|Azathioprine
223476302|NCT02251275|DRUG|Tolvaptan|Tolvaptan tablets (15 or 30 mg) self-administered orally as split-dose regimens, once upon awakening and another approximately 8 to 9 hours later
223476303|NCT01994200|OTHER|Interdisciplinary Team-Based Approach|Three meetings will be scheduled with the oncology dedicated-nurse. First meeting: information about the physical illness; the emotional impact of being newly diagnosed with thyroid cancer; as well as surgery and its' short- and long-term consequences. Second meeting: information on radioactive iodine treatments and its associated safety precautions, nutrition and dietary considerations. Third meeting: how the cancer diagnosis can be an opportunity to make important lifestyle changes and establish new life-priorities. The dedicated nurse, in collaboration with the Department of Nursing and ENT, will develop and implement an interdisciplinary team-based approached developed for this study according to guidelines of the Programme québécois de lutte contre le cancer (PQLC).
223582828|NCT01763294|DEVICE|Nicolet Endeavor CR: 30min for 5 days|Transcranial direct current stimulation (tDCS) is a safe, non-invasive method that modulates cortical excitability. In direct current polarization, the cerebral cortex is stimulated through a weak constant electric current in a noninvasive and painless manner. This weak current induces focal changes of cortical excitability increase or decrease depending on the electrode polarity- that last beyond the period of stimulation.
223476304|NCT01994200|OTHER|Usual Care Control|Patients in the control group will be provided with usual care, comprised of meetings with surgeons and endocrinologists. All patients in this study will be provided with an information website containing information on their cancer, treatments, and treatment side-effects.
224162698|NCT00058188|DRUG|zoledronic acid|Given IV
223476305|NCT01272206|DRUG|NNC 0128-0000-2011|Administered as one single i.v. (intravenous) injection, 100 mcg/kg
223582829|NCT01763294|DEVICE|Nicolet Endeavor CR: Placebo|The same procedures just that in this case the machine produces only a 60 second stimulus at the beginning so the patient can feel the initial electric stimulus.
223476306|NCT01272206|DRUG|NNC 0128-0000-2021|Administered as one single i.v. (intravenous) injection, 100 mcg/kg
223476307|NCT03096535|PROCEDURE|Cooling|Individualized cooling protocol.
223476308|NCT03096535|PROCEDURE|Thermoneutral|Thermoneutral control day.
223476309|NCT00667511|DEVICE|NxStage System One|Comparison of Nocturnal (NHD) and Short Daily Hemodialysis (DHD) with the NxStage System One
223476310|NCT03447834|OTHER|Selective intracoronary hypothermia + PPCI|Selective intracoronary hypothermia is a new technique, recently tested for safety and feasibility in the SINTAMI trial. The procedure starts by advancing a guidewire beyond the occlusion in the culprit artery, followed by an OTWB that is inflated at the location of the occlusion, at a low pressure (4 atm), to prevent reperfusion. After that, a pressure/temperature wire will be advanced along the inflated OTWB and is placed in the distal coronary artery. Then the guidewire is removed and the lumen is used for infusion of saline. During the 'occlusion phase', saline at room temperature is infused for 10 minutes with distal coronary temperature 6-8°C below body temperature. After that, the balloon of the OTWB is deflated. Simultaneously, infusion is started with saline of 4°C, the so called 'reperfusion phase'. This is continued for 10 more minutes. After that, the OTWB can be retracted and the procedure can continue not different from routine PPCI.
223582830|NCT01621867|DRUG|pGM169/GL67A|5ml Gene Product/Lipid Vector pGM169/GL67A nebulised; 2ml nasal application of pGM169/GL67A in addition to 5ml nebulised gene product (Nasal Subgroup)
223582831|NCT01621867|DRUG|Placebo|5ml Nebulised non-active placebo; 2ml nasal administration of non-active placebo (nasal subgroup)
223582832|NCT01071616|DRUG|Cannabis Cigarette|
223582833|NCT04721522|DIAGNOSTIC_TEST|blood sampling & ultrasound|"Blood sampling:~Serum P4 \& estradiol will be performed on the day of triggering and on the day of embryo transfer. Progesterone/ Estradiol (P4/E2) ratio will be calculated Ultrasound: On triggering day, at time of ovum pick up and on ET day, we will measure~1. Endometrial thickness~2. Endometrial pattern~3. Endometrial compaction: the difference in measurement of endometrial thickness between the day of embryo transfer and the day of triggering.~4. Junctional zone thickness~5. Uterine contraction (peristalsis).~6. Blood flow of uterine vessels: PI of the uterine arteries will be calculated also Endometrial - sub endometrial blood flow"
223582834|NCT03423524|DEVICE|Micropure 1.2.3.|"Implantation of intraocular lens (IOL). Name: MicroPure 1.2.3. It is a monofocal intraocular lens consisting of hydrophobic acrylic material. One IOL per eye will be implanted"
223582835|NCT02364440|DEVICE|Ultherapy™ System|Subjects will receive 20 lines Ultherapy™ System Treatment over their right and left hand with 1.5 and 3.0 probe respectively
223744397|NCT02628795|BEHAVIORAL|PRT + FM|Supervised progressive resistance training + functional mobility training (PRT+FM) 3 days per week for 16 weeks post-surgery.
224162699|NCT05367713|OTHER|patients having had an osteitis of the cranial flap after craniectomy|description of management and failure of cranial flap after craniectomy
224162700|NCT02373566|DEVICE|Novomaix dermal substitute in combination with STSG|Novomaix dermal substitute in combination with STSG
223476311|NCT03447834|OTHER|Standard PPCI|PPCI per routine
223476312|NCT00311051|DRUG|ramatroban|
223744398|NCT02628795|OTHER|Usual Care|Post-surgical usual care activities including any prescribed physical therapy
223744399|NCT00506155|DRUG|Avastin|10 mg/kg by vein over 90 minutes
223744400|NCT00506155|DRUG|Cisplatin|70 mg/m\^2 by vein over 4 hours
223744401|NCT00506155|DRUG|Doxorubicin|30 mg/m\^2 by vein over 15 minutes
223744402|NCT00506155|DRUG|Methotrexate|30 mg/m\^2 by vein over 30 minutes
223476313|NCT00311051|DRUG|montelukast|
223476314|NCT01100385|DIETARY_SUPPLEMENT|Ateronon|Tomato extract (lycopene) capsule, taken once daily for 56 days
223744403|NCT00506155|DRUG|Vinblastine Sulfate|3 mg/m\^2 by vein over 30 minutes
223476315|NCT01100385|DIETARY_SUPPLEMENT|Placebo|Matched placebo capsule, taken once daily for 56 days
223476316|NCT02222662|OTHER|Parent massage tx group|The parent-delivered massage is based on Chinese medicine. There are specific techniques for each area of difficulty, e.g. the head, fingers, and toes. After a few months, massage becomes relaxing and enjoyable, and parent touch comes back into use to effectively help the child self-regulate.
223476317|NCT02222662|OTHER|Parent massage wait-list control group|The parent-delivered massage is based on Chinese medicine. There are specific techniques for each area of difficulty, e.g. the head, fingers, and toes. After a few months, massage becomes relaxing and enjoyable, and parent touch comes back into use to effectively help the child self-regulate.
223476318|NCT00004700|DRUG|insulin-like growth factor I|
223476319|NCT03147326|DIAGNOSTIC_TEST|FDG-PET-CT|scanning method
223476320|NCT03147326|DIAGNOSTIC_TEST|NaF-PET-CT|scanning method
223476321|NCT03147326|DIAGNOSTIC_TEST|Whole-body MRI|scanning method
223582836|NCT04001972|BEHAVIORAL|Brief advice (AWARD model)|"Ask: smoking habit, quit intention and attempt, smoking reduction intention, previous quitting experience including NRT and SC use.~Warn: smokers will be orally warned about the harms of smoking and receive a A5-sized leaflet, which includes some shocking pictures of smoking-related diseases, and SC services information.~Advise: smokers will be advised to quit as soon as possible and use NRT or SC services.~Refer: smokers will be encouraged to seek SC services for free NRT or other SC services. Those who agreed will be actively referred to their preferred SC services. The collected contact information with consent will be sent to the SC services providers for a quick appointment and follow-up.~Do-it-again: Relapsed smokers (identified during follow-ups and IM conversation) will receive the Advise and Refer intervention."
223744404|NCT03760146|BIOLOGICAL|20vPnC|20vPnC
223744405|NCT03760146|BIOLOGICAL|13vPnC|Pneumococcal conjugate vaccine
223744406|NCT03760146|BIOLOGICAL|PPSV23|Pneumococcal polysaccharide vaccine
223744407|NCT03760146|OTHER|Saline|Placebo
223744408|NCT05568784|OTHER|Straight Leg Raise exercise|Patient lying supine will lift leg to the height of the contralateral knee flexed to 90 degrees with the ankle positioned and tested in all three positions (dorsiflexion, neutral, and plantarflexion)
223744409|NCT05796011|DEVICE|hearing aids|Hearing aid(s) fitted for one or two sides of ear.
223744410|NCT05796011|OTHER|without hearing intervention|neither earing aids nor other heaing treatment were applied.
223744411|NCT05796011|OTHER|healthy control|healthy control
223744412|NCT02690610|PROCEDURE|EBUS TBNA of mediastinal lesions or lymph nodes|Through endo-bronchial ultrasound, a transbronchial needle will be introduced to take biopsies from mediastinal lesions under ultrasonic guidance.
223744413|NCT01536314|DRUG|Memantine EBIXA®|The aim of this study is to evaluate if memantine administered during 4 weeks beginning 2 weeks before surgery induces a decrease of painful intensity 3 months after surgery, compared to placebo group.
223744414|NCT01536314|DRUG|Placebo : lactose|The aim of this study is to evaluate if memantine administered during 4 weeks beginning 2 weeks before surgery induces a decrease of painful intensity 3 months after surgery, compared to placebo group.
223744415|NCT03160742|DEVICE|Mespere VENUS 200CVP system|Non-invasive sensor placed on the neck
223744416|NCT02011347|DRUG|Ketamine|
223744417|NCT02011347|DRUG|Placebo|
223744418|NCT04308837|DRUG|Paclitaxel|50 mg/m2 given by intravenous infusion on days 1, 8, 15, 22 and 29.
224070036|NCT04349527|PROCEDURE|Round-block Oncoplastic Breast Conserving Surgeries|We de-epithelize the gap between the double round-lines, and we dissect the dermis from the best localization where we can reach the tumor. If the tumor located close to the skin then we are not performing de-epithelization, we excise it with the skin. We mark every wall of the tumor bed with clips. We dissect the surrounding parenchyma- so called parenchyma pillars- from the pectoral fascia and the skin, and we mobilize it. The line under the skin means, the layer under the subcutis, above the superficial fascia, so gives appropriate blood supply to the skin. After this the incision line should be placed 5 mm from the outer round line, so a dermis pillar should be left, and the skin is dissected from the parenchyma as needed. The outer round line should be tightened with a non-absorbable running Benelli suture to fit the areola then interrupted sutures placed to make tensionless the running intracutaneous suture.
224070037|NCT04349527|PROCEDURE|Retroglandular Oncoplastic Breast Conserving Surgeries|We incise the skin slightly lateral in the IMF, around 7 cm long. We dissect with electrocauther the parenchyma with the pectoral fascia from the pectoralis major muscle at least until the mamilla. We incise the fascia along with the parenchyma which contains the tumor and macroscopically 10 mm safe zone. If the tumor is palpable, we turn the parenchyma slightly inside-out, if not, we localize it at the maximum measurement detected according to the ROLL labeling. After marking the tumor bed, we directly adapt the surrounding parenchyma pillars with absorbable sutures, or inverting sutures, or if it requires, we adapt the tumor bed with so-called dual plane mobilization. After revision, we close the fascia with absorbable running suture over the Redon drain then subcutaneous running suture with absorbable suture and finally intracutaneous skin closure.
223476322|NCT01543165|DRUG|Ketorolac and nefopam balanced analgesia|Sequential intravenous administration of ketorolac and nefopam
224070038|NCT00971945|DRUG|Paclitaxel|Solution, I.V., 100 mg/m2, Weekly for 6 of 7 weeks, Until disease progression or unacceptable toxicity became apparent
224070039|NCT01998828|DRUG|Momelotinib|Momelotinib tablet administered orally once daily
223744419|NCT04308837|DRUG|Carboplatin|Carboplatin AUC = 2 given by intravenous infusion on days 1, 8, 15, 22 and 29.
223744420|NCT04308837|DRUG|Dexamethasone|All patients receiving Paclitaxel will receive institutional standard premedications, which include Dexamethasone (10 mg IVPB)
224162701|NCT00802724|BEHAVIORAL|Classification-directed treatment|People in the Classification-directed treatment will be treated based on their direction-specific LBP classification. Treatment will consist of 3 primary components. The first component of treatment will be analysis and instruction in modification of the person's direction-specific alignment and movement strategies during symptomatic functional activities and activities in which the person uses similar strategies to those displayed with symptomatic functional activities. The second component is education about the principles of tissue injury and healing and the need to keep active. The third component is exercise prescription that consists of practice in performance of modified versions of the direction-specific impairment tests from the exam, with an emphasis on impairments that can be modified to eliminate symptoms.
223476323|NCT01543165|DRUG|Balanced analgesia using ketorolac and morphine|Sequential intravenous administration of ketorolac and morphine
224162702|NCT00802724|BEHAVIORAL|Non-specific treatment|People in the Non-specific treatment will be provided treatment that incorporates treatment commonly cited in the literature for people with chronic LBP. The first component of treatment will consist of training in functional activities based on biomechanical principles. The second component will include general education about low back pain. The third component is exercise prescription that is directed at improving the strength and flexibility of the trunk and limbs.
224162703|NCT03423615|BEHAVIORAL|Comprehensive Health & Hygiene Improvement Program (CHHIP)|CHHIP is an intense, multi-component holistic school health program based on the WHO Health Promoting School framework and designed for implementation by lay fieldworkers.
224162704|NCT02323308|OTHER|blood sampling|
224162705|NCT02575300|DRUG|Ibrutinib|Ibrutinib will be administered orally once daily and each cycle will be defined as 4 weeks duration. Study treatment should begin within 14 days following enrollment into the study and continue until disease progression, unacceptable toxicity, or withdrawal of consent.
224162706|NCT05190757|OTHER|Airway and Ventilation|Insertion of Laryngeal Mask airway for ventilation or use of Face Mask
224162707|NCT03431792|DEVICE|Long Tail Balloon|s. description of experimental Arm
224162708|NCT03144830|DEVICE|Exoskeleton|This is an open study and so all participants involved with be using the exoskeleton to determine the safety and feasibility of its use during the acute rehabilitation phase.
224162709|NCT02736929|BEHAVIORAL|Cognitive Processing Therapy - Cognitive|CPT-C is a brief cognitive behavioral treatment for PTSD. It consists of 2 hours of therapy each week for 6 weeks (i.e., two sessions).
224162710|NCT03068052|BEHAVIORAL|No incentive|Each participant will receive an email describing the importance of colorectal cancer screening and that they have been selected to receive a risk assessment. They will directed to an online platform where they will be asked about age, family history, and prior screening history. Those who are eligible for screening will be offered the VIP access phone number to schedule an appointment.
224162711|NCT03068052|BEHAVIORAL|Incentive|Each participant will receive an email describing the importance of colorectal cancer screening and that they have been selected to receive a risk assessment, for which they will received a loss-framed incentive. They will directed to an online platform where they will be asked about age, family history, and prior screening history. Those who are eligible for screening will be offered the VIP access phone number to schedule an appointment and will receive an additional unconditional pro-social incentive.
224162712|NCT06417398|BIOLOGICAL|T cell injection targeting CD19 chimeric antigen receptor|Intravenous administration, 1 bag each time (depending on individual differences), dose: 1×108-1×109 CD19-CAR-gdT (UTAA09 injection), the investigator can decide whether to reduce or increase the dose and whether multiple infusions are required according to the condition of the subject.
224162713|NCT01438775|DRUG|NX-1207|2.5 mg NX-1207 in 10 mL saline vehicle
224162714|NCT00432185|DRUG|PEP005|0.25% PEP005 Gel
224162715|NCT00052832|DIETARY_SUPPLEMENT|doxercalciferol|
224162716|NCT01968304|OTHER|Iron status follow up|
223476324|NCT01543165|DRUG|Pain control with single analgesics (ketorolac)|This arm do not use balanced analgesia. Instead, ketorolac IV administration followed by 50cc normal saline administration (for blinding) will be used in this group.
223476325|NCT00761098|DRUG|Standard Care|Standard Care: 25% salt poor albumin administered day 1 (1.5g/kg) and day 3 (1.0g/kg)
223476326|NCT00761098|DRUG|Experimental|25% Salt Poor Albumin administered per standard care on day 1 (1.5g/kg). Second dose administered on day 2 only to those individuals with renal insufficiency and risk for renal failure.
223744421|NCT04308837|DRUG|Diphenhydramine|All patients receiving Paclitaxel will receive institutional standard premedications, which include diphenhydramine (50mg IVP)
224070040|NCT03354663|DEVICE|TactiCath SE|Ablation to achieve pulmonary vein isolation.
223476327|NCT02817139|DEVICE|TDCS|
223476328|NCT05246995|DRUG|IBI325+Sintilimab|IBI325 + sintilimab combination does-escalation Patients will receive IBI325 monotherapy on Cycle 1 Day 1 ,and then receive IBI325 and sintilimab combination until progressive disease, intolerability, or other reasons leading to treatment discontinuation
223476329|NCT03738735|DRUG|Hypertonic saline|For the intervention group, the surgical staff will add 120 mL of 23.4% saline to the 3L bags of lactated Ringer's solution, and this new solution will be used for arthroscopic irrigation purposes throughout the rotator cuff repair surgery.
223744422|NCT04308837|DRUG|Famotidine|All patients receiving Paclitaxel will receive institutional standard premedications, which include Famotidine (20mg IVPB)
223744423|NCT04308837|DRUG|Palonosetron|All patients receiving Paclitaxel will receive institutional standard premedications, which include Palonosetron (0.25mg IVP)
224070041|NCT03691974|DRUG|Fasinumab|Subcutaneous (SC) every four weeks (Q4W)
224070042|NCT03691974|OTHER|Placebo|Subcutaneous (SC) every four weeks (Q4W)
224070043|NCT01482364|DEVICE|Integrated hemodynamic management (IHM) - HOTMAN System|Therapeutic approach according to HOTMAN System measurement(ICG)results .
224070044|NCT01482364|DEVICE|Non Integrated Hemodynamic Management (Non-IHM) - HOTMAN System|Therapeutic approach according to 2007 ESH Guidelines, regardeless HOTMAN results.
224070045|NCT00554125|DRUG|sirolimus|given at an initial dose of 3 mg/m2, and adjusted over time to achieve steady-state whole-blood trough levels of approximately 5-8 ng/mL
224070046|NCT01661140|DRUG|Methotrexate (stable dose)|Methotrexate (MTX) was administered weekly according to the subject's pre-study MTX dose
224070047|NCT01661140|DRUG|Tocilizumab|8 mg/kg intravenously every 4 weeks for 72 weeks
223476330|NCT01381120|DRUG|Solifenacin succinate treatment|Dosage form: tablet, film coated Dosage: 5 mg Frequency: daily Duration: three months
223476331|NCT01381120|DRUG|Oxycodone and acetaminophen combination treatment|Dosage form: tablet, film coated Dosage: 10 mg Frequency: every 6 hours Duration: 5 - 8 days (stent inserted)
223476332|NCT04898881|OTHER|Breast Human Milk|Interventional drug is given to the neonates 2 minutes before the heel lance
223476333|NCT04898881|OTHER|24 % Sucrose|0.5 ml of sucrose given once 2 minutes prior to procedure
223476334|NCT06519058|OTHER|self-myofascial stretching|self-myofascial stretching exercise
223476335|NCT06519058|OTHER|conventional physical therapy|conventional physical therapy treatment, including exercises
224162717|NCT03046563|OTHER|Acupressure and Abdominal Massage|Pressing the Hegu (LI 4), Zusanli (ST 36) , Tianshu(ST 25) and abdominal massage for eight minutes
224162718|NCT03046563|OTHER|Pressing the Sham points|Pressing the sham points for eight minutes
224162719|NCT04066699|PROCEDURE|Percutaneous localization of suspicious lung lesion(s) using electromagnetic navigation and tools.|Transthoracic localization of suspicious lung lesion(s) in preparation for subsequent resection.
224162720|NCT06337994|DRUG|Memantine Hydrochloride|Memantine was added to each patient's current medication, with the initial dosage of 5 mg/day (once daily). The dosage was then increased to 10 mg/day after a week and maintained till the end of the study. In the case of intolerance to this increase, the dosage was flexibly adjusted according to the condition of the patient.
223476336|NCT04896463|RADIATION|Abdominal ultrasound (US)|abdominal examination with US device
223476337|NCT02891473|OTHER|Mézières Method|10 sessions of rehabilitative treatment according to the Mézières Method, 2 sessions per week for 5 weeks, each lasting 1 hour.
223476338|NCT02891473|OTHER|Home based exercise program|1 single training session lasting 1 hour for the explication of the rehabilitation program that the patient has to perform independently at home followed by 2 sessions of home based exercises per week for 5 weeks, each lasting 1 hour.
223476339|NCT03314480|DIAGNOSTIC_TEST|Standardized physical examination|Standarized physical examination dedicated to assess a potential fracture in the maxillofacial or mandibular region.
223476340|NCT04337632|DRUG|Doxorubicin Hydrochloride Liposome Injection+carboplatin|Doxorubicin Hydrochloride Liposome Injection 25mg/m2, carboplatin AUC 5, first day, intravenous drip, repeated every three weeks.
223476341|NCT04337632|DRUG|paclitaxel +carboplatin|paclitaxel 175mg/m2, carboplatin AUC 5, day 1, intravenous infusion, repeated every three weeks.
223476342|NCT04172740|DEVICE|Radiesse (calcium hydroxylpatite)|"RADIESSE® injectable implant is a sterile, non-pyrogenic, semi-solid, cohesive implant, whose principle component is synthetic calcium hydroxylapatite (CaHA) suspended in a gel carrier of sterile water for injection, glycerin and sodium carboxymethylcellulose. RADIESSE injectable implant has a CaHA particle size range of 25-45 microns. RADIESSE is available in 1.5cc and 0.8cc pre-filled syringes.~RADIESSE injectable implant is indicated for subdermal implantation for the correction of moderate to severe facial wrinkles and folds, such as nasolabial folds and it is also intended for restoration and/or correction of the signs of facial fat loss (lipoatrophy)."
223476343|NCT00856180|DRUG|Bevacizumab|
223476344|NCT00856180|DRUG|Cyclophosphamide|
223476345|NCT00266318|DRUG|Interferon Alfacon-1 and Ribavirin|
223744424|NCT04308837|RADIATION|3D conformal or intensity modulated radiotherapy|Treatment will be given 5 days per week. Photon beams \>6 MV are required. Treatment may be delivered either by a 3D conformal technique or IMRT. IMRT via dynamically moving MLCs, step-and-shoot with a multileaf collimator, Rapid Arc, binary multileaf collimator, and tomotherapy are allowed. Proton therapy is not allowed.
224070048|NCT01661140|DRUG|Methotrexate (tapering dose)|Tapering doses of methotrexate (MTX) were administered weekly from Week 24 to Week 56. Tapering doses depended on dose administered to the subject during the open label period. First tapering occurred at randomization (Week 24), second tapering at Week 32, third tapering at Week 40 and final tapering at Week 48.
224070049|NCT00176280|DRUG|Leukine|
224070050|NCT00176280|DRUG|Dexamethasone|
224070051|NCT03639714|BIOLOGICAL|GRT-C901|a patient-specific neoantigen cancer vaccine prime
224070052|NCT03639714|BIOLOGICAL|GRT-R902|a patient-specific neoantigen cancer vaccine boost
224070053|NCT03639714|BIOLOGICAL|nivolumab|anti-PD-1 monoclonal antibody
224070054|NCT03639714|BIOLOGICAL|ipilimumab|anti-CTLA-4 monoclonal antibody
224070055|NCT02417272|DEVICE|Surgical treatment of cervical degenerative disc disease (CP ESP®)|
224070056|NCT02417272|DEVICE|Surgical treatment of cervical degenerative disc disease (Axelle®)|Axelle®
224070057|NCT01946321|OTHER|Post-amputation functional rehabilitation (normal clinical practice)|
224070058|NCT04295161|DRUG|Abiraterone Acetate|Abiraterone acetate immediate release formulations
224070059|NCT05772260|PROCEDURE|Per-oral endoscopic myotomy|"Per-oral endoscopic myotomy will be performed under general anesthesia. Per-oral endoscopic myotomy will be performed according to the standard care.~General anesthesia will be conducted according to the standard care in our institution, and standardized as follows.~* Monitoring: ECG, SpO2, noninvasive blood pressure, invasive blood pressure monitoring via radial artery cannulation, advanced hemodynamic monitoring (including cardiac output, cardiac index) uisng EV1000 clinical platform (Edwards Lifesciences, USA), anesthetic depth monitoring by SedLine Sedation monitor (Masimo corporation).~* Anesthetic induction: Target controlled infusion (TCI) of Remifentanil (target 3.0 ng/mL), propofol 2 mg/kg IV, rocuronium 0.8 mg/kg IV~* Anesthetic maintence: sevoflurane 0.9 age corrected MAC and remifentanil TCI (target range 1.0-4.0 ng/mL)"
224070060|NCT04255056|DRUG|Pyrotinib|"Pyrotinib is administered orally at 400 mg daily from day 1 of the first cycle to day 21 of the fourth cycle or to the day of surgery, within 30 minutes after breakfast.~Epirubicin (90 mg/m2), intravenously, every 21 days. Cyclophosphamide (600 mg/m2), intravenously, every 21 days."
224162721|NCT02527902|DEVICE|Holter|measure of ANS in IgAN patients
224162722|NCT03156413|DEVICE|F&P nasal mask|Investigative Nasal Mask to be used for OSA therapy
224162723|NCT04723004|COMBINATION_PRODUCT|Toripalimab combined with Bevacizumab|"Experimental group:~Toripalimab, 240mg, IV infusion, every 3 weeks (q3w). combined with Bevacizumab 15mg/kg, IV infusion, every 3 weeks (q3w), Continuous infusion, in a cycle of 3 weeks (21 days), until occurrence of termination event specified in the protocol."
224162724|NCT04723004|DRUG|Sorafenib|"Control group:~Sorafenib 400mg, po, Bid, continuous administration, until occurrence of termination event specified in the protocol."
224162725|NCT05799547|OTHER|cold group|Application will be made in the form of 10 minutes of application to the cesarean section incision, 20 minutes of break and 10 minutes of application.
224162726|NCT05553262|BEHAVIORAL|Behavioral support|Behavioral support as described under 'Arm description'.
224162727|NCT03486249|OTHER|Repetition of medical examinations performed as part of the care|Cardiac echo, diaphragm ultrasound and phrenic nerves stimulation performed before the spontaneous breathing trial.
224162728|NCT05743725|DRUG|Dexmedetomidine|dexmedetomidine loading 1 microgram/kg bolus in 10 minutes followed by 0.2-1 microgram/kg/hour till the end of surgery
224162729|NCT05743725|DRUG|Magnesium sulfate|2 gm magnesium infusion for 30 minutes
224162730|NCT00674024|DRUG|Pazopanib|
223476346|NCT01515124|BEHAVIORAL|Exercise Intervention|The Exercise Intervention combines the twice-weekly weight-lifting intervention from PAL with the 180 minutes of weekly aerobic exercise from the recently completed WISER trial and the ongoing WISER Sister Trial. Women will be trained by certified fitness professionals in both the PAL weight-lifting intervention and in safely increasing their aerobic exercise activity over 6 weekly sessions, and then monitored through phone contact, and monthly in-person sessions.
223476347|NCT01515124|BEHAVIORAL|Weight Loss Intervention|The Weight Loss Intervention begins with a 24 week intensive phase that includes weekly meetings and provision of all meals and snacks from a commercial manufacturer (NutriSystem, Inc., Fort Washington, PA). Daily caloric intake will be strictly controlled during this first 24 weeks at 1200-1500 calories per day.
223476348|NCT05430906|DRUG|AK104 - Chemotherapy|AK104 10mg/kg then \[paclitaxel (135-175 mg/m²) or docetaxel (75 mg/m²)\] and \[carboplatin (AUC5 or 6) or cisplatin (75mg/m²)\] of each 21-day cycle
223476349|NCT01985178|DIETARY_SUPPLEMENT|Omega-3 Fatty Acid Supplement|
223476350|NCT01979432|OTHER|Cardiovascular evaluation|
223476351|NCT05188105|DEVICE|Alpha tACS (12 Hz) over the occipital cortex|Single session of alpha tACS (12 Hz) over the occipital cortex
223476352|NCT00415467|DEVICE|GliaSite Radiation Therapy System|Radiation delivery system that provides brachytherapy targeted to a specific site in the brain, to see its effects to the surrounding area where the tumor was located.
223476353|NCT03307135|DEVICE|single assessment with the MSPMI|Manually applied stretch with the MSPMI installed on the foot and shank at 3 different velocities on 2 positions (knee flexed and extended)
223476354|NCT03307135|DEVICE|double assessment with the MSPMI with 7 days of interval|Manually applied stretch with the MSPMI installed on the foot and shank at 3 different velocities on 2 positions (knee flexed and extended)
224162731|NCT00674024|DRUG|Pazopanib (GW786034)(GW786034)|
224162732|NCT04703049|OTHER|Blood Viscosity Testing|we calculated WBV using the formula \[(0.12 × hematocrit) + (0.17 × (total protein - 2.07)\]. We defined CIN as the absolute (≥0.5 mg/dl) or relative increase (≥25%) in serum creatinine 48-72 h after exposure to a contrast agent compared with baseline serum creatinine values.
223476355|NCT03307135|DEVICE|double assessment with the MSPMI before and after treatment|Manually applied stretch with the MSPMI installed on the foot and shank at 3 different velocities on 2 positions (knee flexed and extended)
223744425|NCT04308837|PROCEDURE|Surgical resection|Surgical resection will constitute subtotal or total gastrectomy (depending on tumor size and location) and D2 lymphadenectomy.
223476356|NCT00880126|BEHAVIORAL|Community Development Teams|CDTs bring together counties who are implementing a new practice
223476357|NCT02865161|DRUG|NISELAT|NISELAT 600MG BD
223476358|NCT04617821|DRUG|Nab paclitaxel plus gemcitabine|Albumin-bound paclitaxel and gemcitabine are given intravenous infusion, repeated every 4 weeks for 1, 8, and 15 days, for a total of 4 to 6 cycle.
224070061|NCT06223282|OTHER|short inter-set rest resistance exercise|Subjects in short inter-set rest trial performed 3 sets per exercise, 7 repetitions with load of 70%-1RM with 60 sec of rest between sets.
224070062|NCT06223282|OTHER|medium inter-set rest|Subjects in medium inter-set rest trial performed 3 sets per exercise, 7 repetitions with load of 70%-1RM with 120 sec of rest between sets.
224070063|NCT06223282|OTHER|long inter-set rest|Subjects in long inter-set rest trial performed 3 sets per exercise, 7 repetitions with load of 70%-1RM with 180 sec of rest between sets.
224070064|NCT06223282|OTHER|medium inter-set rest with failure|Subjects in long inter-set rest trial performed 3 sets per exercise, repeated to failure with load of 70%-1RM with 120 sec of rest between sets.
223744426|NCT04308837|RADIATION|Adjuvant Chemotherapy|The patient will begin adjuvant chemotherapy 4-12 weeks after surgery. The adjuvant chemotherapy will consist of FOLFOX every 2 weeks for 6 cycles (i.e. 3 months)
224070065|NCT01391000|PROCEDURE|LASER CO2|The therapy is performed with the patient sitting, place the unit high above the shoulder with the following indicators: through a pulsed 40 Hz, distance between device and patient 60 cm, 10x15 cm area of application, power 2W; energy between 10 and 15 J/cm2
224070066|NCT01391000|PROCEDURE|TENS|"Transcutaneous Electrical Nerve Application of Stimulation occurs through the use of No. 3 channels (long head of biceps area (CLB), the supraspinatus muscle area, the area medial border of the scapula.~Duration: Twenty (20) minutes, mpulsi: 70 microsec, frequency: 100 Hz, intensity: between 20 and 40 mA."
224070067|NCT01991782|OTHER|Telemedicine|Patients in the telemedicine cohort will have two follow-up visits (at 6 weeks and 6 months) through video calls.
224070068|NCT00157976|DRUG|Photrex (rostaporfin)|
224070069|NCT02279680|DEVICE|Electroencephalography|
224070070|NCT02279680|BEHAVIORAL|Neuropsychological assesments|
224070071|NCT03766880|PROCEDURE|Transjugular HVPG measurement|By means of catheterization of a hepatic vein with a balloon catheter.
224070072|NCT03766880|PROCEDURE|MR imaging|MR images for the post-processing analysis
224070073|NCT04783636|DRUG|leuprorelin acetate 3.75mg|PT105, PT105R
224070074|NCT04740047|DIAGNOSTIC_TEST|Ion Endoluminal System|Robotic bronchoscopy with c-arm imaging.
224070075|NCT00488891|DRUG|Paliperidone ER|Route = oral. Paliperidone ER will be prescribed to the patients at the investigator's discretion. Patient receive their medication according to usual care in their treatment setting ie, no study drug is provided
224162733|NCT02384785|DEVICE|Transcutaneous Electric Nerve Stimulation|Electric currents: 'Transcutaneous Electric Nerve Stimulation' and Transcranial Direct Current Stimulation will be applied on the back of the patients in parallel to the implanted electrodes. Implanted electrode will measure voltages that generated near the spinal cord tissue.
223744427|NCT04424017|BIOLOGICAL|Specific anti-SARS-CoV-2 antibodies|"A serum sample needs to be collected from each participant upon recruitment into the investigation All samples will be tested by the rapid test (Artron, Artron Laboratories, Burnaby, Canada), IgM / IgG which is an antibody capture Immunochromatografac assay for simultaneous detection of IgM and IgG in serum or plasma for COVID -19 in samples.~All samples will be tested for total Immunoglobulins and IgG in samples for COVID-19 virus by Ortho clinical diagnostics chemiluminescent technique (Ortho, Raritan, USA)."
224162734|NCT04064944|DEVICE|blood purification equipment|The subjects enrolled in this study will undergo blood purification treatment, and will be randomized into either immunoadsorption group or plasma exchange group, and the following indicators will be evaluated: (1) changes in EDSS scores and visual acuity before and after treatment; (2) changes in AQP4-IgG levels; (3) the safety of immunoadsorption treatment.
224162735|NCT02625467|PROCEDURE|Penetrating keratoplasty|Conventional Penetrating keratoplasty technique
224162736|NCT02625467|PROCEDURE|Pachymetry and Excimer laser assisted lamellar keratoplasty|Ablation profile focusing on topography and pachymetry with Schwind Amaris excimer laser
224162737|NCT02625467|DRUG|Treatment posterior to surgery|Fluoroquinolone topical antibiotic (Moxifloxacin, Vigamox) and topical steroid (Prednisolone Acetate Ophthalmic Suspension, Pred Forte)
224162738|NCT05001776|PROCEDURE|Endovenous laser ablation|Laser ablation of the great saphenous vein close to sapheno-femoral junction
224162739|NCT05001776|DRUG|Fondaparinux Sodium|Fondaparinux sodium for 7 days or 45 days
224162740|NCT02844140|PROCEDURE|DE-CT's and SE-CT|Patients included in the trial will receive 3 extra DE-CT's and 3 extra SE-CT's
224162741|NCT04226144|DEVICE|Breath Stacking Group|Lung recruitment technique using manual bag resuscitation with oronasal mask interface
224162742|NCT04226144|DEVICE|Breath stacking and EMT|Lung recruitment technique with one way valve with counter resistance during all expiratory phase
224162743|NCT00003549|DRUG|CMF regimen|
224162744|NCT00003549|DRUG|cyclophosphamide|
224162745|NCT00003549|DRUG|fluorouracil|
224162746|NCT00003549|DRUG|methotrexate|
224162747|NCT00702936|DRUG|TELMISARTAN|80 mg daily
224162748|NCT00702936|DRUG|RAMIPRIL|5 mg daily
224162749|NCT03795636|OTHER|Garlic extract|A 100 gram of garlic cloves has been cleaned, peeled and dried. Ethanol of 70% concentration was added for 60 seconds. The cloves were placed in a laminar airflow chamber for evaporation of residual ethanol. Using a sterile mortar and pestle, cloves were homogenized aseptically and filtered through a double layer paper. The fully concentrated extracted was diluted to the concentration of 25% with distilled water
223476359|NCT04617821|DRUG|mFOLFIRINOX|Intravenous oxaliplatin for 2 hours, day 1;Intravenous infusion of calcium formyl tetrahydrofolate (LV) for 2 h, day 1;Irinotecan intravenous infusion is added 30 minutes later for 90 minutes, day 1;Intravenous infusion of 5-fluorouracil (5-FU) continued for 46 hours.Repeat every 2 weeks for a total of 4-6 cycles.
224162750|NCT03795636|OTHER|NaOCl (COLTENE®)|Sodium hypochlorite
224162751|NCT04863118|OTHER|Strength training in shallow water and dry land|"Dry land: The intervention will last for 60 minutes, consisting of exercises to strengthen the global extensor musculature, that is, involving the upper limbs, trunk and lower limbs. Weights and equipment for strength training will be used. The sessions will start with 10 minutes of warm-up, the central part of exercises to strengthen the extensor muscles and the last part will consist of oriented stretches. In the central part, a typical strength training will be performed (2-6 series; 85% of RM), using submaximal subjective effort and with repetition control.~Shallow water: The intervention performed on dry land will be adapted and produced in an aquatic environment. Aquatic implements will be used for strength training."
224162752|NCT04863118|OTHER|High-intensity training in shallow and deep water|"Shallow water: The intervention will last 60 minutes. The exercises consist of: immersion, balance, strength, agility and displacement in the water. As they will start with 10 minutes of warm-up and the last part will consist of stretches oriented along the edge of the pool and on the depth reduction platform. In the main part of the intervention, different styles of exercises will be performed, with or without the use of implements. Displacements will have varying speeds in the same session, defined by Borg's Scale of subjective sensation of effort.~Deep water: The intervention carried out in shallow water will be adapted with the use of floating belts and reproduced in deep water."
224162753|NCT01347073|DRUG|HPN-100|HPN-100 is a pro-drug of PAA that combines with glutamine to provide an alternative vehicle for waste nitrogen elimination. It is a liquid with minimal taste and odor. Approximately three teaspoons of HPN-100 (\~17.4 mL) delivers an equivalent amount as PBA that 40 tablets of NaPBA.
224162754|NCT02204059|DRUG|hMAb BIWA 4|
224162755|NCT00596349|BEHAVIORAL|questionnaires|study participants complete one-time survey, questionnaires, and cognition testing, comprising the following: QOL-Cancer Survivor FACT-Ovarian SF-36 (general QOL scale) CES-D (depression scale) Impact of Events Scale (anxiety scale) FACT-GOG-NTX (neurotoxicity scale) Female Sexual Functioning Index (FSFI) Cognition Testing Perception of disease chronicity/acuity Concerns about Recurrence Report of surveillance type, frequency, utility Health behaviors Self-report of co-morbidities Self-report of potential unmet needs Background information form List of current medications Patient-defined QoL domains
224163636|NCT02401776|DIETARY_SUPPLEMENT|Monster Energy Drink|Small Dose of Monster energy drink. This will be given at a dose of 2mg caffeine/kg body weight (equivalent to approximately one 16 ounce can of monster energy drink for a person weighing 75 kg).
224163637|NCT02401776|DIETARY_SUPPLEMENT|Monster energy drink|Medium Dose of Monster Energy Drink. This will be given at a dose of 3 mg caffeine/kg body weight (equivalent to approximately one 24 ounce can of monster energy drink for a person weighing 75 kg).
223744428|NCT05481567|OTHER|Questionnaire|A series of 14 questions about with the impact of periodontitis on quality of life.
223744429|NCT02081144|OTHER|Smokefree TXT Program|The SmokeFreeTxt program is a library consisting of \~130 brief messages that can be proactively sent to smokers' cellphones using software developed and maintained by NCI. The message content is informed by principles of cognitive behavioral therapy. They are sent to smokers at random times of day (during normal waking hours), up to 5 messages per day.
223744430|NCT02081144|DRUG|nicotine replacement patches|Subject will be given 4 weeks of Nicotine Replacement Patches, based on the amount he/she is smoking at baseline.
223744431|NCT02081144|DRUG|Nicotine Replacement Gum|Subjects will be given 10 pieces of 2mg Nicotine Replacement Gum x 28 days.
223476360|NCT03599960|DRUG|Chemotherapy|"* Idarubicin 12mg/m2 IV at D1~* Methotrexate at D1 (24H infusion, alkaline hydration, leucovorin rescue):~  * Patients \<65y and albuminemia \>35 g/l and CrCl (MDRD)\>60 ml/min: 3000 mg/m²~ * Patients \<65y and albuminemia \<35 g/l and/or CrCl (MDRD) \<60 ml/min: 1000 mg/m² IV~ * Patients ≥65y and albuminemia \>35 g/l and CrCl (MDRD) \> 60 ml/min : 1000 mg/m²~ * Patients ≥ 65y and albuminemia \< 35 g/l and/or CrCl (MDRD) \< 60 ml/min : 500 mg/m²~* L-asparaginase (SPECTRILA) : 5000 units/m² IV at D2, 5, 8, 11 (switch to Erwinia asparaginase/Cirsantaspase 25 000 U/m² with the same drug regimen in case of hypersensitivity reactions or significant diminution of asparaginase activity)~* Dexamethasone 40mg PO or IV at D1-4 (dose diminution at 20 mg for Age ≥65y)"
224162756|NCT00596349|BEHAVIORAL|questionnaires|study participants complete one-time survey, questionnaires, and cognition testing, comprising the following: QOL-Cancer Survivor FACT-Ovarian SF-36 (general QOL scale) CES-D (depression scale) Impact of Events Scale (anxiety scale) FACT-GOG-NTX (neurotoxicity scale) Female Sexual Functioning Index (FSFI) Cognition Testing Perception of disease chronicity/acuity Concerns about Recurrence Report of surveillance type, frequency, utility Health behaviors Self-report of co-morbidities Self-report of potential unmet needs Background information form List of current medications Patient-defined QoL domains
223476361|NCT02467244|DRUG|Levothyroxine|At first visit, after taking detailed history including baseline symptomatology, clinical evaluation, and laboratory investigation, treatment will be started with levothyroxine (50 microgram/day). The dosage of levothyroxine (LT4) will be adjusted (at 4th and 8th week) in an attempt to keep the serum FT4 and TSH concentrations within the normal range. After 12 weeks, all the patients will be followed up, clinical and laboratory tests will be repeated.
224162757|NCT00596349|BEHAVIORAL|questionnaires|study participants complete one-time survey, questionnaires, and cognition testing, comprising the following: QOL- Cancer Survivor, FACT-Ovarian, SF-36, CES-D, IES, FACT-GOG-NTX, FSFI, Cognition Testing, Perception of disease chronicity/acuity, Report of surveillance type, frequency, utility, Health behaviors, Self-report of co-morbidities, Self-report of potential unmet needs, Background information form, List of current medications,Patient-defined QoL domains
224162758|NCT02740894|DRUG|Gefitinib|
224162759|NCT06471088|DRUG|Dovprela|Daily dose: 200 mg
223476362|NCT05512559|DEVICE|body composition analysis|Body composition analysis by bioelectrical impedance measurement, just before induction of anesthesia.
223476363|NCT05185804|DRUG|Dimolegin|60 mg orally, 1 time per day
223476364|NCT05185804|DRUG|Clexane|40 mg subcutaneously, 1 time per day
223476365|NCT00822848|DRUG|epirubicin hydrochloride|I.V., days 1-3 of each cycle. Epirubicin to be omitted during cycle 2 (concomitant chemoradiation)
223476366|NCT00822848|DRUG|ifosfamide|Over 90 minutes I.V., days 1-3 of each cycle. Administered with hydration and Mesna.
224162760|NCT00494195|GENETIC|rAAV1.tMCK.human-alpha-sarcoglycan- First cohort|"The first cohort of subjects with LGMD2D (alpha-sarcoglycan deficiency) and proven mutations will undergo gene transfer with a minimum of three subjects enrolled into this cohort and will receive a total of 1.5 ml volume of study agent in two to six separate injections into the selected muscle (extensor digitorum brevis) or other muscle if more appropriate upon considering the individual patient. The dose will be 3.25 X 10 to the 11 vg in 1.5 ml.~In each cohort, only one extremity will receive vector with transgene while the opposite extremity will be injected with placebo."
223476367|NCT00822848|DRUG|sorafenib tosylate|P.O. daily beginning 2 weeks before first chemotherapy cycle, held 1 week before and after surgery.
223476368|NCT00822848|OTHER|immunoenzyme technique|
223476369|NCT00822848|OTHER|immunohistochemistry staining method|
223476370|NCT00822848|OTHER|laboratory biomarker analysis|
223476371|NCT00822848|PROCEDURE|adjuvant therapy|Preoperative administration has been the preference at our institution.
224162761|NCT00494195|GENETIC|Genetic: rAAV1.tMCK.human-alpha-sarcoglycan- Second cohort|The second cohort will receive the same dosis of 3.25 X 10 to the 11 vg in 1.5 ml delivered to muscle according to the same paradigm. In each cohort, only one extremity will receive vector with transgene while the opposite extremity will be injected with placebo.
223476372|NCT00822848|PROCEDURE|neoadjuvant therapy|
223582837|NCT04001972|DRUG|NRT-S|One-week free NRT (gum or patch) will be provided with dosage based on time to first cigarette smoking after waking up in the morning and previous NRT use (standard practice and according to specific NRT product instructions). Subjects who have first cigarette \<30 minutes in the morning or have previously used NRT, will receive 4mg nicotine gum or 21mg nicotine patch. Those who have first cigarette \>30 minutes after waking up and have not previously used NRT will receive 2mg nicotine gum or 14mg nicotine patch. NRT use and potential side effects will be briefly explained orally based on standardized script according to the product instructions. An NRT use card containing reminders of NRT use and potential side effects will be given.
223744432|NCT02081144|BEHAVIORAL|Faxed Referral CT Smokers Quitline|A faxed referral will be sent to the CT Smokers Quitline for the subject.
224162762|NCT03709914|DRUG|ZTI-01 100 mg/kg|ZTI-01 intravenous (IV)
224162763|NCT03709914|DRUG|ZTI-01 75 mg/kg|ZTI-01 intravenous (IV)
224162764|NCT05813860|DRUG|Azathioprine|azathioprine in combination with Infliximab, with a dose of 1-2 mg/kg/d.
224162765|NCT05813860|DRUG|Infliximab|5mg/kg for the first dose, and the same dose at weeks 2 and 6 after the first dose and every 8 weeks thereafter. Treatment with single Infliximab or combined azathioprine, respectively.
224162766|NCT02705352|DRUG|5-Fluorouracil|Treatment medication
224162767|NCT02705352|OTHER|Normal saline|Placebo
224162768|NCT01690988|DRUG|Ketamine (0.5 mg/kg)|Low dose (sub-anesthetic) 0.5 mg/kg ketamine following induction of anesthesia or administration of sedative medications.
223476373|NCT00822848|PROCEDURE|therapeutic conventional surgery|Surgery should be planned for 2-4 weeks after the initiation of chemotherapy for cycle 3.
223476374|NCT00822848|RADIATION|hypofractionated radiation therapy|28 Gy (350 centigray (cGy) x 8 fractions in 10 days) beginning at the start of cycle 2. \*Boost: postoperative boost of 12 Gy (200 cGy x 6 fractions) for patients with positive surgical margins only.
223744433|NCT00449644|DRUG|TMC207|TMC207 400mg (4 tablets) once daily for 14 days, 200mg (2 tablets) three times a week for 6 or 22 weeks.
223476375|NCT06406504|OTHER|in-laboratory simulation group|The students in-laboratory group performed the simulation applications in the patient room in the simulation laboratory. One of the Stage 2 and one of the Stage 3 PI was created by the researcher with moulage to the heel and lateral malleolus area of the standardised patient taken to the patient room.
223476376|NCT06406504|OTHER|in-situ simulation group|Students in the in-situ simulation group performed the simulation practices in a patient room in a clinic at a university hospital. One of the Stage 2 and one of the Stage 3 PI was created by the researcher with moulage to the heel and lateral malleolus area of the standardised patient taken to the patient room.
223476377|NCT00686972|DRUG|GLP-1|5 ng/kg/min, IV for 1 hour during each clamp study (7) over 2 year period.
224162769|NCT01690988|DRUG|Normal Saline (placebo)|Normal saline IV following induction of anesthesia or administration of sedative medications
223476378|NCT03749161|DEVICE|Low-add multifocal IOL|Lentis comfort, low-add multifocal, IOL
223476379|NCT03749161|DEVICE|Monofocal IOL|Lentis L-313, monofocal IOL
223476380|NCT04115813|BEHAVIORAL|Project YES! Youth Engaging for Success|Participants in the intervention were offered once a month one-on-one meetings and group meetings with their assigned youth peer mentors over approximately six months. The participant's caregiver could also attend up to 3 caregiver support groups held at the clinic (every other month). In addition, intervention participants in the children's hospital were assessed (clinical and psycho social factors) for physical transition to an adult clinic. After midline data collection, the intervention arm went into a maintenance phase, meeting with the youth peer mentor every other month (3 times). Participants in the comparison arm after midline started the Project YES! intervention as described above. Primary analysis was conducted using midline data.
223476381|NCT04256200|DRUG|Dienogest 2 MG Oral Tablet|Deinogest (Visanne) 2mg/day, orally for 24 weeks versus combined OCP (Yasmin, 0.03mg
223476382|NCT04256200|DRUG|Yasmin|0.03mg Ethinyl Estradiol and 3mg Drospirenone daily for 24 weeks
223476383|NCT05141253|DRUG|RD133|The enhanced MSLN-CAR-T cell design of this study is obtained by co-infecting T cells with two lentiviral vectors. One lentiviral vector expresses CD19-CAR and tEGFR molecular safety switch, and the other lentiviral vector expresses MSLN- CAR and dnTGFβRII receptors. dnTGFβRII receptor without intracellular signal is used to resist the inhibition of T cell function by the immune microenvironment of tumor tissue. In addition, for the safety of CAR-T cell application in vivo, tEGFR is used in the CAR design as a molecular safety switch for CAR-T cells.
224162770|NCT01690988|DRUG|Ketamine (1 mg/kg)|Low dose (sub-anesthetic) 1 mg/kg ketamine following induction of anesthesia or administration of sedative medications.
224162771|NCT00372489|DRUG|peginesatide|Participants received the same initial peginesatide dose as was administered at the end of the previous peginesatide treatment study (NCT00228449) in which the participant was enrolled. The median first dose at study start was 0.087 milligram per kilogram (mg/kg) with an interquartile range of 0.064 to 0.123 mg/kg. Each participant was to receive peginesatide as an injection administered intravenously once every 4 weeks for approximately 54 months in this trial.
224162772|NCT00183261|BIOLOGICAL|MRKAd5 HIV-1 gag/pol/nef|1.5 x 1010 Ad vg/mL, 1.0 mL administered intramuscularly
224162773|NCT00183261|BIOLOGICAL|MRKAd5 HIV-1 gag/pol/nef placebo|1.0 mL administered intramuscularly
223476384|NCT06082232|DRUG|Dexmedetomidine|Under strict aseptic conditions, a lumbar puncture will be performed with selective technique in sitting position at L2-3 or L3-4 interspaces with midline approach using a 25-G Quincke's needle. After achieving the free flow of cerebrospinal fluid, the study drug will be injected into the subarachnoid space, immediately after injection the patient will be asked for supine position.
223476385|NCT06082232|DRUG|Midazolam|1 mg midazolam intrathecal administration
223476386|NCT06082232|DRUG|Bupivacain|20 mg bupivacaine intrathecal administration
223476387|NCT02330341|DIETARY_SUPPLEMENT|Artemisia dracunculus|
223582838|NCT04001972|BEHAVIORAL|IM Apps and Chatbot|Twelve-week personalized behavioral support will be delivered using interactive communication technologies using (1) regular tailored messages on abstinence, and (2) synchronous IM Apps conversation with trained SC advisors, and (3) a Chatbot: A Chatbot will be built using open source NLP and machine intelligence platforms. The unstructured text data from our previous study (ClinicalTrials.gov ID: NCT03182790) will be used to train the proposed Chatbot. We will draft responses for each identified question. The final version will be incorporated with Application Programming Interface (API) integration into user-friendly apps (iOS/Android/web app) with a backend server support and continuous data collection for potential bigdata analysis.
223582839|NCT04001972|BEHAVIORAL|Regular SMS message|Regular SMS messages focus on general health and remind the importance of participating in the follow-up surveys and biochemical validation for quitting
223476388|NCT02330341|OTHER|Placebo|
223744434|NCT00449644|DRUG|Placebo|Placebo 4 tablets once daily for 14 days, 2 tablets three times a week for 6 or 22 weeks.
224162774|NCT00638274|PROCEDURE|Air|3 mls used for identifying epidural space
223476389|NCT06551740|DRUG|HUC2-344|per oral
223476390|NCT06551740|DRUG|HUC2-344-R1, HUC2-344-R2|per oral
223476391|NCT02640560|OTHER|Food allergy questionnaire|The Parents of the cases children will compile a questionnaire including questions about general information on the family, on life and food habits, on indoor environment, on health status, on clinical aspects of the allergy, on the access to diagnostic and treatment resources
223476392|NCT02640560|OTHER|Control Questionnaire|The Parents of the control children will compile a questionnaire including questions about general information on the family, on life and food habits and on indoor environment.
223582840|NCT00099281|DRUG|YMB 1002|
224162775|NCT00638274|PROCEDURE|Saline|3 mls of saline used to identify epidural space
224162776|NCT01465373|DRUG|Endometrin|100 mg per vagina TID
224162777|NCT01465373|DRUG|Progesterone in Oil|50 mg IM injection daily
224162778|NCT01251991|DRUG|Psyllium husks|Oral suspension, oral use, two daily dosages consisting of 5 grams each
224162779|NCT01251991|DIETARY_SUPPLEMENT|Isolated soy protein|Oral suspension, oral use, 30 grams once per day
224162780|NCT01251991|DIETARY_SUPPLEMENT|Isolated whey protein|Oral suspension, oral use, 30 grams once per day
224162781|NCT01251991|OTHER|Microcrystalline cellulose|Oral suspension, oral use, two daily dosages consisting of 5 grams each
224162782|NCT04494477|BEHAVIORAL|The IN•clued program|The INclued program as previously described.
224162783|NCT03634228|DRUG|Cytarabine|Given SC
223476393|NCT02833909|OTHER|surgery|
223476394|NCT06163859|BEHAVIORAL|Intervention Group|FCHVs will undergo a 4-day training program on hypertension management, including screening, counseling, medication adherence, self-care, and referrals. They will then collaborate with healthcare facilities to conduct one-day hypertension screening camps. FCHVs will form self-support groups for individuals with hypertension and hold monthly meetings to discuss control strategies, review BP logs, and promote healthcare visits, including family involvement. They will also maintain regular communication with healthcare facility in-charges to ensure effective collaboration in the 'Hypertension Care Cascade Model'.
223476395|NCT04226157|DEVICE|Home Blood Pressure Monitoring Device (Qardio Arm)|The Home Blood Pressure Device with telemonitoring capability will allow the participants and physician to monitor blood pressure over time and titrate blood pressure medications as needed for persistently elevated blood pressure.
223582841|NCT02320344|BEHAVIORAL|Partners in Care|"The diabetes self-management intervention is titled, Partners in Care, emphasizing that there are many individuals and groups that one can call upon to assist with managing one's diabetes. The content includes practical behavioral strategies to improve diabetes self-management practices. The 12 week curriculum provides a basic overview of diabetes and self-management activities, standards of care recommended by the American Diabetes Association, strategies to improve patient-provider communication, support needed for diabetes self-management, information about diabetes medications, and ways to avoid diabetes-related complications."
223582842|NCT04445376|OTHER|Physical Exercises|Aerobic Training and Breathing Exercises.
223582843|NCT01557881|DEVICE|magnetic resonance imaging with positron emission tomography scanning|University Hospitals Seidman Cancer Center \[SCC\] will house the Philips Ingenuity TF PET/MR, which is a hybrid scanner that merges magnetic resonance imaging with positron emission tomography scanning. University Hospitals is one of only five hospitals in the world with this technology. The PET/MRI system consists of two imaging scanners used sequentially as in PET/CT. The 3Tesla MRI component provides the high resolution that is necessary for soft tissue contrast and functional information on perfusion, diffusion, or metabolism. PET provides information about cellular metabolism and receptor status.
223744435|NCT00449644|DRUG|Background regimen (BR) for MDR-TB (multi-drug resistant tuberculosis)|Background Regimen (BR) of antibacterial drugs used in the treatment of TB according to national TB program and selected at the baseline visit as speciified in the protocol for up to 96 weeks.
223744436|NCT00149981|DRUG|everolimus (RAD)|Everolimus
223744437|NCT05463510|DIAGNOSTIC_TEST|Videodermoscopy|Patients who had records for at least twice with videodermoscopy every 3 months were included.
224162784|NCT03634228|DRUG|Milademetan Tosylate|Given PO
224162785|NCT03634228|DRUG|Venetoclax|Given PO
224162786|NCT04281823|DIAGNOSTIC_TEST|Cardiovascular Magnetic Resonance|Patients will undergo various CMR techniques designed to assess cardiovascular structure and function, tissue characteristics, and flow.
223582844|NCT02534662|DEVICE|ENDOMINA|Endomina will be introduced into the stomach over guide wires and then fixed to the endoscope. The procedure will include the placement of 4-6 transmural anterior-posterior sutures after argon plasma coagulation of the tissue opposition areas in order to ensure persistence of the pouch reduction. Patient will be kept overnight after the procedure.
224162787|NCT01084473|DRUG|Dexmedetomidine|The study subjects will be given a normal loading dose (1 μg/kg in 20 minutes) of dexmedetomidine (dexmedetomidine hydrochloride 100 μg/ml, Precedex® Abbott Laboratories North Chicago, IL 60064, USA) followed by continuous infusion of 0.7 μg/kg/h for 190 min. The administration of the loading dose will be started at t = -30 min (30 min prior to the administration of paracetamol and lactulose).
224162788|NCT01084473|DRUG|Morphine|The study subjects will be given 0.10 mg/kg morphine hydrochloride (morphine hydrochloride 2 mg/ml, Morphin® Nycomed Austria GmbH, St. Peter Strasse 25, A-4021, Linz, Austria) in 20 minutes followed by a placebo infusion for 190 min. The administration of the morphine infusion will be started at t = -30 min (30 min prior to the administration of paracetamol and lactulose).
224162789|NCT01084473|DRUG|Placebo|0.9 % NaCl will be infused.
223744438|NCT01082965|DRUG|Donepezil|5 mg tablets once daily for 7 days and then 10mg on 8th day
223744439|NCT01082965|DRUG|Placebo|matching placebo
224162790|NCT01137006|BIOLOGICAL|IMC-20D7S (Cohort 1A)|"5 mg/kg i.v. every 2 weeks.~Administered every other week on Days 1 and 15 of each treatment cycle.~If no dose-limiting toxicity (DLT) in first 3 participants or 1 DLT in 6 participants, then enrollment into Cohort 2A."
223744440|NCT00868075|PROCEDURE|Chest physiotherapy|Twice daily for 8 weeks
223744441|NCT00868075|PROCEDURE|Chest Physiotherapy + Exercise Program|Twice daily chest physiotherapy and Three times weekly exercise program (two sessions supervised)for 8 weeks
223744442|NCT04000204|DEVICE|HYAJOINT Plus|60 mg / 3 ml cross-linked hyaluronan, SciVision Biotech Inc.
223744443|NCT04000204|DEVICE|Durolane|60 mg / 3 ml cross-linked hyaluronan, Bioventus LLC.
223744444|NCT06213168|OTHER|HFNC|Patients assigned to the control group will be continuously treated by HFNC. HFNC will be initiated within one hour following randomization
223744445|NCT06213168|OTHER|CPAP and HFNC|Patients assigned to the intervention group will receive high flow nasal oxygen plus CPAP sessions
224162791|NCT01137006|BIOLOGICAL|IMC-20D7S (Cohort 2A)|"10 mg/kg i.v. every 2 weeks.~Administered every other week on Days 1 and 15 of each treatment cycle.~If no DLT in first 3 participants or 1 DLT in 6 participants in Cohort 2A, then enrollment into Cohort 3A."
224162792|NCT01137006|BIOLOGICAL|IMC-20D7S (Cohort 3A)|"20 mg/kg i.v. every 2 weeks.~Administered every other week on Days 1 and 15 of each treatment cycle.~If no DLT in first 3 participants or 1 DLT in 6 participants in Cohort 3A, then enrollment into Cohort 4A."
224162793|NCT01137006|BIOLOGICAL|IMC-20D7S (Cohort 4A)|"30 mg/kg i.v. every 2 weeks.~Administered every other week on Days 1 and 15 of each treatment cycle."
223744446|NCT03930446|DRUG|Ethanol|The 0.8 g/kg body weight dose of oral alcohol (190-proof ethanol) will be divided into 4 servings of 0.2 g/kg each. The 0.8 g/kg dose is equivalent to 4 standard drinks, where a standard drink is defined as one 12 oz beer, one 5 oz glass of wine, or one 1.5 oz shot of 80 proof alcohol. Women will receive a reduced dose (0.68 g/kg) to account for sex differences in total body water
223744447|NCT03930446|OTHER|Placebo|The placebo beverage will consist of the cranberry or orange juice plus 1% alcohol added as a taste mask. All beverages will be sprayed with an alcoholic mist to provide a strong alcoholic scent.
223476396|NCT04226157|OTHER|Primary Care Provider Blood Pressure Management|Participant will follow up as would normally do with primary care provider for blood pressure management.
223476397|NCT00002419|DRUG|Abacavir sulfate|
223476398|NCT00002419|DRUG|Amprenavir|
223476399|NCT00002419|DRUG|Efavirenz|
223476400|NCT00002419|DRUG|Adefovir dipivoxil|
223476401|NCT06250114|OTHER|Retreatment|manual k file, carrier based technique, Xrays, tooth build up, provisional and definitive crowns. Post if necessary will be placed
223582845|NCT06458231|DEVICE|Blood Catheters|Central line as a predisposing factor for Blood stream infection
223582846|NCT01631916|DRUG|corticosteroid|Dexamethasone 0.6 mg/kg/day or Methylprednisone 1 mg/kg/day
223582847|NCT00897390|DRUG|Saxagliptin|Tablet, Oral, 2.5 mg, Once Daily, 1 week
223582848|NCT00897390|DRUG|Metformin IR (glucophage)|Tablets, Oral, 1000 mg, Once Daily, 1 week
223582849|NCT00897390|DRUG|Saxagliptin + Metformin IR (FDC)|Tablet, Oral, Saxagliptin 2.5 mg + metformin IR 1000 mg, Once Daily, 1 Week
223582850|NCT05644093|DRUG|SPL026 IV|IV dosing
223582851|NCT05644093|DRUG|SPL026 IM|IM dosing
223582852|NCT05620953|DIAGNOSTIC_TEST|respiratory specimen|nasopharyngeal swab or nasal aspiration or broncho-alveolar lavage
223582853|NCT02162966|DRUG|High Dose Colistin|High Dose Colistin
223582854|NCT02162966|DRUG|Standard Dose Colistin|Standard Dose Colistin
223582855|NCT00052156|BIOLOGICAL|CancerVax vaccine (CANVAXIN)|
223582856|NCT05297526|BEHAVIORAL|Culturally adapted children's book|Tribe-specific children's book celebrating tribal culture with an embedded oral health message
223582857|NCT05297526|BEHAVIORAL|Standard informational brochure on children's oral health|Informational brochure about children's oral health designed by the NIH for American Indian/Alaska Native parents.
223582858|NCT01420419|OTHER|Lanolin|Pea-sized amount of lanolin applied to each nipple after every breastfeeding session (approximately 8-12 times daily) until complete resolution of nipple pain and damage for a maximum of 7 days.
223582859|NCT01420419|OTHER|Standard (usual) in-hospital and community postpartum care|Women randomized to standard care will not receive lanolin or information regarding how to use lanolin. In-hospital standard care may include any of the following pain management measures at the recommendation / discretion of the participant's health care provider, or based on the patient's personal preference: analgesics (such as ibuprofen or acetaminophen); application of cold or warm compresses; application of ice packs; use of breast shields; air drying the nipples; or applying expressed breast milk.
223582860|NCT03561935|DRUG|Propafenone|prescribing propafenone for the management of premature ventricular complex
223582861|NCT03561935|DRUG|Indenol|prescribing indenol for the management of premature ventricular complex
223582862|NCT02410577|DRUG|89Zr-J591|The intervention is the administration of an injection of 18-19mg of unchelated J591 to reach the total administered dose of antibody followed by 5 mCi (+/- 10%) of 89Zr-J591 (1 to 2 mg) . After administration of the experimental tracer, the patient will undergo a Brain PET/CT scan 24 hours, 48 hours post injection and 3-8 days. The 48 hour scan is strongly suggested, but optional.
223744448|NCT04130451|DRUG|PYODINE AND TALC SLURRY|"pyodine Povidone-iodine is a broad spectrum antiseptic for topical application in the treatment and prevention of wound infection. It may be used in first aid for minor cuts, grazes, burns, abrasions and blisters.~TALC a white, grey, or pale green soft mineral with a greasy feel, occurring as translucent masses or laminae and consisting of hydrated magnesium silicate"
223476402|NCT06250114|OTHER|extraction implant|Flapless or flapped techniques, early, delayed and immediate implant insertions. Cement retrained restorations
223476403|NCT01462942|DRUG|Aclidinium Bromide/Formoterol Fumarate|Inhaled Aclidinium/formoterol Fixed Dose Combination (FDC) low dose (400/6 μg), twice per day
223476404|NCT01462942|DRUG|Aclidinium Bromide/Formoterol Fumarate|Inhaled Aclidinium/formoterol FDC high dose (400/12 μg), twice per day
223476405|NCT01462942|DRUG|Aclidinium Bromide|Inhaled Aclidinium 400 μg, twice per day
223476406|NCT01462942|DRUG|Placebo|Inhaled dose-matched placebo, twice per day
223582863|NCT02410577|DEVICE|PET/CT Scan|
223582864|NCT02410577|DEVICE|MRI|
223582865|NCT02410577|OTHER|Blood draw|Bloods samples will be drawn immediately before and approximately 30 minutes after 89Zr-J591 injection.
223582866|NCT03400813|BEHAVIORAL|R-TEP EMDR|Recent Traumatic Episode Protocol Eye-Movement Desensitization and Reprocessing is a early and short adaption protocol of EMDR developed by Shapiro E. EMDR is a psychotherapeutic approach that can rapidly process disturbing experiences adaptively together with the aid of eye movements or other forms of bi-lateral stimulation.
223582867|NCT00317408|BIOLOGICAL|anti-thymocyte globulin|
223582868|NCT00317408|DRUG|busulfan|
223582869|NCT00317408|DRUG|carboplatin|
223582870|NCT00317408|DRUG|carmustine|
224070076|NCT00488891|DRUG|Atypical antipsychotics (AAP)|Route = oral. AAP including quetiapine, risperidone, olanzapine, ziprasidone or aripiprazole. Dosage and administration of antipsychotics will be prescribed at the investigator's discretion
223476407|NCT01462942|DRUG|Formoterol Fumarate|Inhaled Formoterol 12 μg, twice per day
223582871|NCT00317408|DRUG|cyclosporine|
223582872|NCT00317408|DRUG|cytarabine|
223582873|NCT00317408|DRUG|dexamethasone|
223582874|NCT00317408|DRUG|etoposide phosphate|
223582875|NCT00317408|DRUG|idarubicin|
223582876|NCT00317408|DRUG|ifosfamide|
223582877|NCT00317408|DRUG|leucovorin calcium|
223582878|NCT00317408|DRUG|lomustine|
223582879|NCT00317408|DRUG|melphalan|
223582880|NCT00317408|DRUG|methotrexate|
223582881|NCT00317408|DRUG|mitoxantrone hydrochloride|
223582882|NCT00317408|DRUG|prednisolone|
223582883|NCT00317408|DRUG|thiotepa|
223582884|NCT00317408|DRUG|vinblastine sulfate|
223582885|NCT00317408|DRUG|vindesine|
223582886|NCT00317408|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
223582887|NCT00317408|PROCEDURE|autologous hematopoietic stem cell transplantation|
223582888|NCT00317408|PROCEDURE|peripheral blood stem cell transplantation|
223582889|NCT00317408|RADIATION|total-body irradiation|
223582890|NCT05380323|DRUG|LY3541105|Administered SC.
223582891|NCT05380323|DRUG|Placebo|Administered SC.
223744449|NCT02847546|DEVICE|True™ Flow Valvuloplasty Perfusion Catheter|Balloon Aortic Valvuloplasty as preparation step in implantation of a Tanscatheter Aortic Valve Implantation (TAVI).
223744450|NCT04954547|BEHAVIORAL|Subsidy Treatment|Participants will be awarded $50 for reaching the PBF goal at the end of 12 weeks. Regardless of goal-attainment, participants will be reimbursed 50% of approved health-improving expenses up to a cap of $300 in the 12 weeks. The subsidy is voluntary and flexible, with no direct intervention from researchers - participants will submit receipts and simply be reimbursed at the end of the experiment (subject to approval from the research team).
223744451|NCT04954547|BEHAVIORAL|Cash Treatment|Participants will be awarded $350 for reaching the PBF goal at the end of 12 weeks.
223744452|NCT05034107|OTHER|Aromatherapy|Approximately 6-7 drops of Ylang-ylang essential oil will be diffused in a common area estimated to be about 300 square feet with temperature of around 25 - 26 degree Celsius and humidity of 50% - 60%. Water and essential oil will be diffused twice a day, each for a duration of 20 min during the respective phases.
223744453|NCT05350319|RADIATION|A low-dose CT scan of the shoulder|Briefly, a conventional CT scan will be conducted, with scan images representing a reconstruction of simultaneous scans at two sensors. L-CT images will be derived from single source data (ie the scan data gathered by one of the emitters rather than a reconstruction from both).
223744454|NCT04252755|BEHAVIORAL|EEG Neurofeedback|Participants will undergo a baseline (pre) session, then be scheduled for 8 sessions of NFB, and finish with another session (post) after completion of all NFB sessions.
223744455|NCT04476979|DRUG|Tocilizumab|Tocilizumab 8mg/kg D1 and if no response (No decrease of oxygen requirement) a second fixed dose of 400mg wil be administered at D3
223744456|NCT04476979|DRUG|Dexamethasone|Dexamethasone : 10 mg once daily for the first five days (day 1 to day 5) then 5 mg per day for up to 5 days, 2.5mg per day for up to 4 days (or until oxygen supply independency if sooner)
223744457|NCT04902755|OTHER|Questionnaire|validation of the French linguistic version and the cross-cultural adaptation of the NBSS-SF.
224162794|NCT01137006|BIOLOGICAL|IMC-20D7S (Cohort 1B)|"10 mg/kg i.v. every 3 weeks.~Administered every 3 weeks on Days 1 and 22 of each treatment cycle.~If no dose-limiting toxicity (DLT) in first 3 participants or 1 DLT in 6 participants in Cohort 1B, then enrollment into Cohort 2B."
224162795|NCT01137006|BIOLOGICAL|IMC-20D7S (Cohort 2B)|"20 mg/kg i.v. every 3 weeks.~Administered every 3 weeks on Days 1 and 22 of each treatment cycle.~If no DLT in first 3 participants or 1 DLT in 6 participants in Cohort 2B, then enrollment into Cohort 3B."
223744458|NCT03647228|DRUG|IONIS-ENaCRx|Ascending single and multiple doses of IONIS-ENaCRx inhaled or nebulized.
223744459|NCT03647228|DRUG|Placebo|Placebo comparator calculated volume to match active comparator inhaled or nebulized.
223744460|NCT02183831|DEVICE|Insertion of the capsular tension ring|
223744461|NCT01559012|DRUG|Clonidine|transdermal clonidine patch 5 mg q. 5 days
223744462|NCT00243178|DRUG|clopidogrel (SR25990C)|75 mg once daily in combination with aspirin
224070077|NCT04872114|DEVICE|SyMapCath I™ catheter and SYMPIONEER S1™ Stimulator/Generator|Radiofrequency ablation of renal arterial sympathetic nerves
224070078|NCT01436539|DRUG|Adefovir Dipivoxil and polyene phosphatidylcholine|Adefovir Dipivoxil 10 mg once daily for 48 weeks plus Polyene phosphatidylcholine (PPC) 456 mg three times per day for 48 weeks
224070079|NCT01436539|DRUG|Adefovir Dipivoxil|Adefovir Dipivoxil 10 mg once daily for 48 weeks
224070080|NCT04926974|BEHAVIORAL|Low Vision Rehabilitation|Smart phone App
224070081|NCT05661773|DEVICE|the combined use of vacuum assisted suction and heat exchanger warming|Heat causes capillary vasodilation, where warming hands and toes improves blood flow while cooling them causes vasoconstriction. Applying a vacuum across a capillary bed increases the transcapillary gradient increasing the driving force of blood flow into tissues. The combination of these two mechanisms can work synchronously to improve blood flow to ischemic extremities and digits.
224070082|NCT00251537|DRUG|LTB4|
224070083|NCT01961700|OTHER|Physiotherapy|Physiotherapy treatment
224070084|NCT02872766|DEVICE|CXL Myopia|Applying riboflavin 0,22% to 0,25 % up to 20 minutes . Then, the eyes are exposed to UVA light with the KXL II system according to the programmed treatment pattern.
224070085|NCT03607864|DEVICE|coral bone graft and xenograft|"ligible patients will be randomized in equal proportions between control group(immediate implant placement with grafting with xenograft) and study group (immediate implant placement with grafting with coral bone) Patients of both groups will be subjected to standard panoramic radiographs, cone beam ct .~Crestal bone level will measured by cone beam ct. Local anesthesia will be given to the patient. Only sulcular incision line with reflection is used A peritome will be used for a traumatic extraction of remaining roots. The extraction socket will be evaluated for absence of any fenestration or granulation tissues implant will be inserted in extraction socket bodily palatal with grafting with coral bone and xenograft The flap will then be copiously irrigated with saline in preparation for closure.~The flap will then be closed using interrupted 5/0 prolene sutures."
224070086|NCT00767377|DRUG|EOF5|epirubicin 50 mg/m2 day 1, oxaliplatin 130 mg/m2 day 1, and 5-FU 375-425 mg/m2/d day 1 through 5 continuous infusion, repeated every 3 weeks
224070087|NCT00494091|DRUG|Temsirolimus (CCI-779)|20 mg/m2 IV TEMSR weekly (Japan, n=6)
224070088|NCT00494091|DRUG|Temsirolimus (CCI-779)|25 mg IV TEMSR weekly (all other pts)
224070089|NCT03598166|DIAGNOSTIC_TEST|Septin9|Septin9 is a FDA-approved blood test for colorectal cancer screening
224070090|NCT02466061|BEHAVIORAL|Telemedicine Weight Management plus Wi-Fi Scale (Arm A)|Telephonic weight loss counseling by trained interventionists, with guided digital scale measurements of weight, lean mass, and fat mass. Counseling sessions and digital weight recording occur at regularly scheduled intervals over a six-month intervention period.
224070091|NCT02466061|BEHAVIORAL|Text for Diet (Text4Diet) Group (Arm B)|Short Message Service (SMS) text messaging in which participants receive 3-5 text messages each day during a six-month intervention period. The text messages provide tips and reminders to encourage healthy eating and weight loss. Participants on this arm also receive a digital scale to track and report weight as prompted once per week through the text program.
224070092|NCT02466061|BEHAVIORAL|Enhanced Usual Care Group (Arm C)|Participants are provided with handouts based on American Cancer Society guidelines for healthy eating and exercise.
223476408|NCT05696067|BIOLOGICAL|Corfluvec component 1 low dose|Participants will receive single intranasal injection of H3N2 recombinant attenuated influenza vector with modified NS gene coding for the N protein fragment of SARS-CoV-2
223476409|NCT05696067|BIOLOGICAL|Corfluvec component 2 low dose|Participants will receive single intranasal injection of H1N1pdm09 recombinant attenuated influenza vector with modified NS gene coding for the N protein fragment of SARS-CoV-2
223582892|NCT02564978|DRUG|Minocycline|Adult participants will be instructed to take their prescribed IP orally two times a day, once in the morning and once in the evening, approximately 12 hours apart. The capsules will be dispensed to the participant in a tight, light-resistant container as defined in the USP in three-month supply aliquots. Starting at Month 9 and continuing at Month 12, a three-month supply will be dispensed to the participant during the study visit or mailed to the participant. Participants will be given an instruction sheet for taking the prescribed IP. Starting at Month 15 participants will receive two bottles for a six-month supply. The IP should be stored between 15-30 degrees C (or 59-86 degrees F).They should be protected from light, moisture, and excessive heat. Participants will be required to bring their bottles of IP to each appropriate visit for capsule counts for compliance monitoring.
223582893|NCT06339970|OTHER|Slider Nerve Gliding Technique along with Mulligan Spinal Mobilization Technique|In this group 21 patients will perform Slider Nerve Gliding Technique along with Mulligan Spinal Mobilization Technique.Protocol for 4 weeks 12 Sessions (3 sessions in a week) and 10 sec rest between each segment, 3 sets of 10 repetitions. Patient is sitting in the chair / plinth. Therapist's standing behind the patient.
223582894|NCT06339970|OTHER|Tensioners Nerve Gliding Technique along with Mulligan Spinal Mobilization Technique|In this group 21 patients will perform Tensioners Nerve Gliding Technique along with Mulligan Spinal Mobilization Technique.Protocol for 4 weeks 12 Sessions (3 sessions in a week) and 10 sec rest between each segment, 3 sets of 10 repetitions. Patient is sitting in the chair / plinth. Therapist's standing behind the patient.
223582895|NCT00474617|DRUG|Sugammadex|
223582896|NCT00474617|DRUG|Rocurium|intravenous (IV) single bolus dose of 0.6 mg.kg-1
223582897|NCT02870530|PROCEDURE|Single Anastomosis Sleeve Jejunal (SAS-J) Bypass|Single Anastomosis Sleeve Jejunal (SAS-J) Bypass as A treatment for Morbid
223582898|NCT03102060|OTHER|Dietary Intervention|Undergo gluten free diet
223582899|NCT03102060|OTHER|Laboratory Biomarker Analysis|Correlative studies
223582900|NCT05054543|DRUG|Uproleselan|A rationally designed E-selectin antagonist used to inhibit binding of cells to E-selectin
223582901|NCT05054543|DRUG|Placebo|0.9% Sodium Chloride
223582902|NCT05082727|DIETARY_SUPPLEMENT|KOVIR (TD0068) oral softgel|KOVIR (TD0068) is a softgel containing Allium sativum extract 270mg, Colostrum156.4 mg, fine powder mixed herbs 43.6mg
223582903|NCT05082727|DIETARY_SUPPLEMENT|Placebo oral softgel|Placebo
223582904|NCT06231433|DEVICE|CO2 Vaginal Laser|CO2 Vaginal laser
223582905|NCT01502163|DEVICE|Thermoflect [TM] passive insulation|passive insulation in the preoperative phase, befor induction of anesthesia
223582906|NCT01502163|DEVICE|Active prewarming (Thermoflect™/Mistral Air™, TSCI, Amersfoort, NL)|Prewarming Thermoflect™/Mistral Air™, TSCI, Amersfoort, NL before induction of anesthesia
223476410|NCT05696067|BIOLOGICAL|Corfluvec component 1 high dose|Participants will receive single intranasal injection of H3N2 recombinant attenuated influenza vector with modified NS gene coding for the N protein fragment of SARS-CoV-2
223476411|NCT05696067|BIOLOGICAL|Corfluvec component 2 high dose|Participants will receive single intranasal injection of H1N1pdm09 recombinant attenuated influenza vector with modified NS gene coding for the N protein fragment of SARS-CoV-2
223582907|NCT01825941|DRUG|metoclopramide|10 milligrams, administered intravenously over 15 minutes
223582908|NCT01825941|DRUG|diphenhydramine|50 milligrams, administered intravenously over 15 minutes
224070093|NCT00917449|DRUG|L-arginine|Oral L-arginine (3.2 gr bid)for 18 months
224070094|NCT00917449|DRUG|Placebo|Oral Placebo BID for 18 months
224070095|NCT00003385|DRUG|carboplatin|
224070096|NCT00003385|DRUG|paclitaxel|
224070097|NCT00003385|DRUG|pegylated liposomal doxorubicin hydrochloride|
224070098|NCT04248413|DEVICE|Blood Flow Restriction Therapy|The blood flow restriction cuff, which is regulated by the FDA under 878.5910 and is registered under number 9681444, is manufactured by Delfi Medical. The cuff will be used as recommended by the manufacturer and Owens Recovery Science, the company who provides certificating of blood flow restriction training.
224070099|NCT04248413|OTHER|Standard physical rehabilitation|Patients diagnosed with non-operative rotator cuff or biceps tendinopathy will undergo physical rehabilitation under the supervision of the same physical therapists who will be performing the BFR therapy.
224070100|NCT00648375|DRUG|Propanolol|Participants will take a 40-mg dose of propranolol immediately after they experience a traumatic memory associated with strong hyperarousal symptoms. Participants may take up to two doses a day, if the doses are separated by at least 6 hours.
224070101|NCT00648375|DRUG|Placebo|Participants will take a single dose of placebo immediately after they experience a traumatic memory associated with strong hyperarousal symptoms. Participants may take up to two doses a day, if the doses are separated by at least 6 hours.
223476412|NCT05696067|BIOLOGICAL|Corfluvec low dose|Participants will receive two intranasal injections of recombinant attenuated influenza vector with modified NS gene coding for the N protein fragment of SARS-CoV-2 tree weeks apart (H3N2 →H1N1pdm09)
223476413|NCT05696067|BIOLOGICAL|Corfluvec high dose|Participants will receive two intranasal injections of recombinant attenuated influenza vector with modified NS gene coding for the N protein fragment of SARS-CoV-2 tree weeks apart (H3N2 →H1N1pdm09)
223476414|NCT05696067|BIOLOGICAL|Placebo|Participants will receive two intranasal injections of placebo three weeks apart
223476415|NCT01027845|BIOLOGICAL|Pneumococcal vaccine GSK1024850A|Intramuscular injection, 4 doses
224070102|NCT00648375|BEHAVIORAL|Cognitive therapy workbook|Participants will also receive a cognitive behavioral therapy-based workbook in which they will track symptoms and efforts to use cognitive techniques to relieve symptoms each day.
224070103|NCT01965132|DRUG|Biologic or targeted synthetic DMARD|
224070104|NCT03960281|OTHER|Regular dental examination|Regular dental examination, and the patient will be asked to fill a questionnaire
223476416|NCT01027845|BIOLOGICAL|DTPa|Subcutaneous injection, 4 doses
223476417|NCT04573270|BIOLOGICAL|PrimePro|Intravenous Injection
223476418|NCT04573270|OTHER|Placebo|Intravenous Injection
223476419|NCT00368550|DRUG|Sertraline|Sertraline (to a maximum of 200 mg/day) for 14-week treatment period
223476420|NCT00368550|DRUG|Placebo|Placebo for 14-week treatment period
223476421|NCT04568200|DRUG|Durvalumab|Durvalumab 1500mg i.v. day 1-22-43-64
223476422|NCT04568200|DRUG|Carboplatin|Chemotherapy
223476423|NCT04568200|DRUG|Paclitaxel|Chemotherapy
223476424|NCT04568200|RADIATION|Radiotherapy 23 x 1.8 Gy|Radiotherapy 23 x 1.8 Gy
223476425|NCT03489564|BEHAVIORAL|Active|No behavioral intervention included but the exposure is level of physical activity. Individuals in the Active group will be categorized by their own routine physical activity levels.
223476426|NCT03489564|BEHAVIORAL|Sedentary|No behavioral intervention included but the exposure is level of physical activity. Individuals in the Sedentary group will be categorized by their own routine physical activity levels.
223476427|NCT04376281|DRUG|Noradrenaline|Noradrenaline infusion for patients undergoing liver transplantaion from living donor .
223476428|NCT05518721|PROCEDURE|Hallux Rigidus Treatment|Participants will receive either a synthetic cartilage implant or dermal interposition arthroplasty
223582909|NCT01825941|DRUG|placebo|
223582910|NCT03716661|PROCEDURE|ORIF|Open Reduction Internal Fixation
223582911|NCT06256991|DRUG|Patiromer 8400 MG [Veltassa]|Patiromer is a cation-exchanging polymer intended for oral intake that is not resorbed from the gastro-intestinal tract. Patiromer has been approved by the European Medicines Agency (EMA) and is available for clinical use in The Netherlands for the indication of hyperkalemia in adults. It contains calcium-sorbitol complex as a counter-ion. Patiromer increases the faecal excretion of potassium in the gastro-intestinal lumen by exchange with part of the calcium. This results in a lower concentration of free potassium in the gastro-intestinal lumen, reducing in turn plasma potassium concentration. After initiation of patiromer, a clinically significant reduction in plasma potassium can be observed at around 7 hours, the effect persists for approximately 24 hours. Patiromer is excreted by the fecal route, 24-48 hrs after ingestion. Since patiromer is not absorbed or metabolized by the body, other drugs are not expected to influence the efficacy of patiromer.
223582912|NCT06256991|DRUG|Placebo|Placebo is a powder with a similar appearance, smell, and taste as patiromer, but without and clinically detectable effects. It is intended for oral intake.
224070105|NCT00883714|OTHER|Supervised exercise|The patients will carry out a daily exercise program consisting of walking on a treadmill for 30 minutes at an intensity of 80% of the maximum heart rate. The patients will be supervised by medical personnel.
224070106|NCT00883714|OTHER|Exercise Instruction|The patients will receive instructions about exercise and will have access to a bike ergometer to work out. However, they will not receive daily supervision or participate in a structured exercise program.
223476429|NCT00225875|DRUG|Mabthéra|
223476430|NCT00005925|DRUG|Muscimol|
223476431|NCT06472479|BIOLOGICAL|LCAR-M61S cells preparation|"Biological:~LCAR-M61S or LCAR-M61D cells intravenous infusion; Prior to infusion of the LCAR-M61S and LCAR-M61D cell preparation, Subjects will receive a conditioning premedication regimen consisting of cyclophosphamide and fludarabine."
223476432|NCT06472479|BIOLOGICAL|LCAR-M61D cells preparation|"Biological:~LCAR-M61S or LCAR-M61D cells intravenous infusion; Prior to infusion of the LCAR-M61S and LCAR-M61D cell preparation, Subjects will receive a conditioning premedication regimen consisting of cyclophosphamide and fludarabine."
223476433|NCT00486044|DRUG|Simvastatin|40 mg tablet each night for one month, then 80 mg for 8 months
223476434|NCT00486044|DRUG|Placebo|Matching tablet each night for 9 months
223476435|NCT03072550|DEVICE|RenewalNail™ Plasma Treatment System|application of cold atmospheric plasma to a fungal infected toenail
223476436|NCT03715062|OTHER|Dialogue tool|The intervention has two parts: an educational session and a dialogue tool. The educational session consists of 75 minutes of education in diagnosing urinary tract infection. The dialogue tool consists of 1) a checking box for the most important symptoms and observations for urinary tract infection 2) an algorithm to evaluate if urinary tract infection is likely based on the present symptoms and observations 3) a list of reflection points to evaluate with a collegue 4) a specialized ISBAR (communication tool) if long-term care facility staff finds it appropriate to contact the General Practicioner
223476437|NCT01670292|OTHER|HVLA-SM|High Velocity Low Amplitude Spinal Manipulation
223476438|NCT00379106|PROCEDURE|Arm exercises.|Basic active exercise program at home.
223476439|NCT00379106|PROCEDURE|Arm Exercises|Instruction in the same active exercise program along with additional exercises using exercise equipment and stretching exercises
223476440|NCT05001607|DEVICE|Bronchial Blocker|Trial of four methods of pulmonary blockade; one novel method and three published methods.
223476441|NCT00781846|DRUG|ridaforolimus|oral tablets, daily for 5 days/week
223476442|NCT00781846|DRUG|bevacizumab|IV infusion
223476443|NCT03194334|BEHAVIORAL|Vegetarian diet|
223476444|NCT03194334|DIETARY_SUPPLEMENT|creatine|1g creatine/day
223476445|NCT03194334|DIETARY_SUPPLEMENT|Placebo|pills
223476446|NCT03194334|DIETARY_SUPPLEMENT|Beta-alanine|0.8g beta-alanine per day
223582913|NCT05375864|OTHER|Absorption test|Paracetamol's administration (1 gram) - 48 hours after oseltamivir administration.
223582914|NCT00203021|DRUG|Glatiramer acetate|Glatiramer acetate will be administered as per the dose and schedule specified in the respective arms.
223582915|NCT03412253|PROCEDURE|Single-Anastomosis Gastric Bypass surgery (SAGB).|We checked the effect of SAGB on patients suffered from T2DM with BMI 25-30
223582916|NCT02557022|OTHER|GI and/or GL|Randomized controlled trials of equal or more than 12 weeks duration looking at the GI and/or GL of diet as a whole and providing data on body weight
224070107|NCT02236455|BEHAVIORAL|Audio Relaxation Technique|Audio relaxation technique created by an Icelandic Registered Nurse.
224070108|NCT02236455|BEHAVIORAL|Medical Music Intervention|Audio recordings of non-lyrical relaxing music
224070109|NCT02236455|BEHAVIORAL|Nature Therapy without Music|Nature videos of the mountains, desert, Icelandic scenery, and ocean were provided via iPads for surgical patients
223476447|NCT01751282|GENETIC|Stem Cell|
224162796|NCT01137006|BIOLOGICAL|IMC-20D7S (Cohort 3B)|"30 mg/kg i.v. every 3 weeks.~Administered every 3 weeks on Days 1 and 22 of each treatment cycle."
223476448|NCT06550492|DEVICE|smoke filtering electrocautery device|A smoke-filtering electrocautery device was used during surgery.
223476449|NCT06550492|OTHER|double mask|A double-layer mask was used during the operation.
223476450|NCT04420091|DIETARY_SUPPLEMENT|Cartidyss|Oral intake of two tablets of Cartidyss 500 mg, once daily in the morning, preferably during a meal, with water, during 3 months
223476451|NCT00792181|DRUG|Midazolam|Midazolam 1 mg: 70 years or more and less than 70 kg Midazolam 2 mg: under 70 years and 70 kg or more
223476452|NCT00792181|OTHER|Course intervention - a professional development course for caregivers.|The nursing intervention involves a professional development course for caregivers. The course is expected to deepen the caregivers' knowledge about the encounter with patients as well as cardiovascular treatment.
224162797|NCT03696576|DEVICE|EMST|Training of the respiratory system muscles using the EMST device.
224162798|NCT03696576|BEHAVIORAL|PhoRTE|Completing of PhoRTE voice therapy.
224162799|NCT03304392|BEHAVIORAL|Personalized ICBT|An 8-week transdiagnostic internet-delivered cognitive behavioural therapy (ICBT) will be delivered to participants. All clients will receive support from registered social workers, psychologists or supervised graduate students, with experience delivering ICBT, with contact depending upon group allocation. In addition to the online program, therapists, registered social workers, psychologists or supervised graduate students, with experience delivering ICBT will provide support within one business day of client emails. Amount of contact will be personalized to patients' needs.
224162800|NCT03304392|BEHAVIORAL|Standard ICBT|An 8-week transdiagnostic internet-delivered cognitive behavioural therapy (ICBT) will be delivered to participants. All clients will receive support from registered social workers, psychologists or supervised graduate students, with experience delivering ICBT, with contact depending upon group allocation. In addition to the online program, therapists, registered social workers, psychologists or supervised graduate students, with experience delivering ICBT will provide support by email only once a week. Therapist will spend approximately 15 minutes per week/per client.
224162801|NCT00123786|PROCEDURE|Positron Emission Tomography|Positron Emission Tomography
224162802|NCT01922986|DEVICE|active rTMS|10 minutes of real high-frequency (6-Hz) rTMS priming (total priming pulses = 600) plus 10 minutes of low-rate (1Hz) rTMS (total low-rate pulses = 600).
224162803|NCT01922986|DEVICE|sham rTMS|20 minutes of sham rTMS stimulation
224162804|NCT01922986|BEHAVIORAL|conventional stroke therapy|conventional stroke therapy consisting of exercises and physical training
224162805|NCT04106011|DRUG|Gabapentin|Titration of gabapentin will be standardized as 300mg QHS and increased by 300mg every 3 days until taking 1200mg TID or maximum tolerable dose. Subjects will undergo cognitive evaluation prior to initiation of the medication, at 1 week (when titrated to approximately 900mg/day), 3 weeks (when titrated to approximately 2100mg/day), and at 6 weeks (when titrated to 3600mg/day or maximum tolerable dose).
224162806|NCT04106011|DIAGNOSTIC_TEST|BTACT|Cognition measure: Brief Test of Adult Cognition by Telephone
224162807|NCT04106011|DIAGNOSTIC_TEST|BPI|Pain severity and interference at baseline using the Brief Pain Inventory
224162808|NCT04106011|DIAGNOSTIC_TEST|HADS|Assessment of depression and anxiety with the Hospital Anxiety and Depression Scale
224162809|NCT04106011|DIAGNOSTIC_TEST|SLP9|Assessment of Sleep
224162810|NCT04106011|DIAGNOSTIC_TEST|NPSI|Assessment of neuropathic components
224162811|NCT01901367|DIETARY_SUPPLEMENT|nutritional intervention|Receive nutritional intervention
224162812|NCT01901367|BEHAVIORAL|exercise intervention|Receive exercise intervention
224162813|NCT01901367|OTHER|follow-up care|Receive booster follow-up sessions from the nutritionist and exercise physiologist
223476453|NCT00006152|DRUG|Ritonavir|
223476454|NCT00006152|DRUG|Abacavir sulfate|
223476455|NCT00006152|DRUG|Amprenavir|
223476456|NCT00875316|DRUG|Cogane™ (PYM50028)|Orally active neurotrophic factor inducer
223476457|NCT06207955|DRUG|TMJ Arthrocentesis Followed By Injectable Platelet Rich Fibrin And Botulinum Toxin Type A|TMJ Arthrocentesis I-PRF Intra-articular Injection Botulinum Toxin Type A to Lateral Pterygoid Muscle
223476458|NCT06207955|DRUG|TMJ Arthrocentesis Followed By Injectable Platelet Rich Fibrin|TMJ Arthrocentesis I-PRF Intra-articular Injection
223476459|NCT06207955|DRUG|TMJ Arthrocentesis|TMJ Arthrocentesis By Saline
223476460|NCT00918983|DRUG|NX-1207|Single intraprostatic injection of 2.5 mg NX-1207
223476461|NCT00918983|DRUG|Placebo|Single intraprostatic injection of placebo
223476462|NCT05459415|PROCEDURE|Reducing Excision Margins|Reducing Excision Margins After Neoadjuvant Chemoimmunotherapy
223476463|NCT01308619|DRUG|Doxycycline|doxycycline 40 mg (30 mg immediate release / 10 mg delayed release beads) Capsules, oral, one capsule daily in the morning
223476464|NCT01308619|OTHER|Placebo|Placebo, oral, one capsule daily in the morning
223476465|NCT00269724|DRUG|OROS® oxybutynin|
224162814|NCT01901367|BEHAVIORAL|counseling intervention|Receive phone counseling with a trained health coach
224162815|NCT01901367|OTHER|quality-of-life assessment|Ancillary studies
224162816|NCT01901367|OTHER|laboratory biomarker analysis|Correlative studies
224162817|NCT01901367|OTHER|questionnaire administration|Ancillary studies
224162818|NCT02927535|DRUG|TNF blockers monotherapy|
224162819|NCT03978286|DRUG|Vortioxetine|10 mg per day
224162820|NCT03978286|DRUG|Sertraline|75 mg per day
224162821|NCT00552344|BIOLOGICAL|Cimzia|"* Active substance: Certolizumab Pegol~* Pharmaceutical form:first reconstituted, lyophilized powder formulation of CZP and after implementation of Amendment 2 (after 401 subjects were enrolled) prefilled syringe~* Concentration: 200 mg/ml~* Route of Administration: Subcutaneous use"
224162822|NCT01634100|DRUG|Probenecid|Probenecid
224162823|NCT01634100|DRUG|Rifampicin|Rifampicin
224162824|NCT01634100|DRUG|Empagliflozin|BI Drug
224162825|NCT01634100|DRUG|Empagliflozin|BI Drug
224162826|NCT01634100|DRUG|Rifampicin|Rifampicin
224162827|NCT01634100|DRUG|Probenecid|Probenecid
224162828|NCT01634100|DRUG|Empagliflozin (BI 10773)|BI Drug
223582917|NCT05855655|BEHAVIORAL|Mindfulness-Based Queer Resilience (MBQR)|"This work aims to develop an internet-delivered MBI to address minority stress and its negative HIV-related health consequences experienced by young men who have sex with men (YMSM). This aim will examine the feasibility and acceptability of the internet-delivered mindfulness-based intervention (iMBI), called Mindfulness-based Queer Resilience (MBQR), for HIV prevention. The study will enroll and randomize a sample of 60 distressed, high-risk YMSM into one of two groups: MBQR intervention (n=30) or active control condition (n=30)."
223582918|NCT02292004|DEVICE|ACL Repair with MIACH Scaffold|Surgical insertion of the MIACH scaffold to promote ACL healing/repair
223476466|NCT05185063|DIAGNOSTIC_TEST|Point of Care blood test|The pH will be incorporated into the MIRACLE2 score in a pre-hospital setting. The patients will continue to be treated with standard of care.
223476467|NCT04142333|GENETIC|GIA|Patients receive a secure GIA link from their provider and then are able to send their relatives the link to GIA through texting, email, and/or Facebook messenger. Once a relative clicks on the provided link, GIA's platform is structured as a decision tree, allowing family members to construct a personalized conversation about their family member's test results. This can be done either on a smartphone or computer. GIA provides basic genetics education and risk assessment and connects family members with local genetic counseling resources to continue this conversation and/or go forward with genetic testing. At the end of the conversation, the family member has the option of having a transcript sent to them via email for their reference. The objective of the current study is to evaluate the application of GIA for cascade testing in newly identified high risk breast and gynecologic mutation carriers.
223476468|NCT00514085|BIOLOGICAL|recombinant human interleukin-21|"Patients enrolled in Part A will receive treatment daily x 5 on weeks 1, 3, and 5 of an 8 week cycle.~Patients enrolled in Part B will receive treatment daily x 5 on weeks 1, and 3 of a 6 week cycle"
223476469|NCT00514085|OTHER|immunohistochemistry staining method|Cycle 1 Day 1 and Cycle 1 Day 29
223476470|NCT00514085|OTHER|laboratory biomarker analysis|slides will be blocked for 15 minutes in 20% normal goat serum and then incubated in primary antibody
223476471|NCT00514085|OTHER|pharmacological study|Starting dose of 50μg/kg/day as an IV push
223476472|NCT03154086|DRUG|GSK3352589|It will be available in the dose of 1, 5, 25 and 100 mg tablet for oral administration.
223582919|NCT02292004|PROCEDURE|Standard ACL Reconstruction|Standard surgical reconstruction of the ACL with autograft hamstring tendon
223582920|NCT01076413|BEHAVIORAL|skill based exercise|2 times per week for 12 weeks Pre gait and gait activities
223582921|NCT01076413|BEHAVIORAL|aerobic conditioning|2 times per week for 12 weeks. aerobic conditioning exercise consisting of treadmill walking
223582922|NCT03972878|OTHER|control snack|dry fruit snack (200 kcal) + 250 ml water
223582923|NCT03972878|OTHER|control cream|commercial spreadable cocoa and hazelnut cream (200 kcal)+ 250 ml water
223582924|NCT03972878|OTHER|cream version 1|commercial spreadable cocoa and hazelnut cream (200 kcal), version 1+ 250 ml water
223582925|NCT03972878|OTHER|cream version 2|commercial spreadable cocoa and hazelnut cream (200 kcal), version 2+ 250 ml water
223582926|NCT03972878|OTHER|cream version 3|commercial spreadable cocoa and hazelnut cream (200 kcal), version 3+ 250 ml water
223582927|NCT03972878|OTHER|control chocolate bar|commercial chocolate bar (200 kcal)+ 250 ml water
223582928|NCT03972878|OTHER|chocolate bar version 1|commercial chocolate bar (200 kcal), version 1+ 250 ml water
223582929|NCT05863208|DEVICE|Artificial intelligence|ASUS EndoAim AI Endoscopy System (ASUS, Taiwan) is used to help the detection of colon adenoma
223582930|NCT05863208|DEVICE|Endocuff vision|Endocuff vision (Olympus, UK) is used to help the detection of colon adenoma
223582931|NCT05863208|DEVICE|High-definition endoscope|High-definition endoscope (EVIS-EXERA 290 video system, Olympus Optical, Aizu, Japan) is used under white light for the detection of colon adenoma
224070110|NCT02236455|BEHAVIORAL|Nature Therapy with Music|Nature videos of the mountains, forest, Icelandic landscape, and the ocean were provided via iPads for surgical patients
224070111|NCT01017393|DRUG|Ketamine|
224070112|NCT01017393|DRUG|ketamine free|
224070113|NCT03824860|BEHAVIORAL|Yoga|"Participants will attend at least one group class per week (in-person or Zoom) and practice one self-guided yoga video class at home on their own per week, over eight weeks~Participants may choose to attend Flow Yoga and/or Chair Flow Yoga classes. These classes will be videotaped and made available to participants electronically.~Classes consist of:~* guided breathing exercises,~* upper and lower extremity stretching~* structured postures and movements to improve balance and strength"
224070114|NCT04395794|DIAGNOSTIC_TEST|SARS-CoV-2-test|Nasopharyngeal and oropharyngeal testing for SARS-CoV-2
224070115|NCT04395794|OTHER|SARS-CoV-2 questionnaire survey|Questionnaire regarding SARS-CoV-2 symptoms and contact with COVID patients
224070116|NCT00679952|PROCEDURE|closed suction drainage of pancreatic duct|A Fr 5-8 silastic polyethylene pediatric feeding tube with multiple side-holes is inserted 2 cm into the pancreatic duct. The catheter exited via a small enterotomy in the jejunal loop of the distal portion of the hepaticojejunostomy. Totally externalized pancreatic stents were connected to the aspiration bag of a Jackson-Pratt drain to generate negative pressure or to a bile bag for natural drainage.
224070117|NCT00679952|PROCEDURE|natural drainage of pancreatic duct|Natural drainage group
224070118|NCT03638505|OTHER|PSP-QoL|"PSP-QoL is a patient-reported outcome measure for progressive supranuclear palsy (PSP). The Supranuclear Palsy Quality of Life scale (PSP-QoL) may be a helpful patient-reported scale for clinical trials and studies in PSP.~PSP-QoL consists of 28 items scored on a 3- or 5-point Likert scale, with the total score ranging from 0 to 100. Each item is scored from either 0 to 4, with the exception of four items, which are scored from 0 to 2, with higher scores indicating more-severe disability or movement abnormality. Items are in six categories: daily activities (by history); behavior; bulbar; ocular motor; limb motor; and gait/midline. The scale includes comments and/or instructions for each item and word anchors to explain the ratings."
224070119|NCT02012478|BEHAVIORAL|MI- informed SMS program|
223476473|NCT03154086|DRUG|Matching Placebo|It will be available across all strengths to match active drug in the form of tablet for oral administration.
223476474|NCT01603277|BIOLOGICAL|Anti-GM-CSF Monoclonal Antibody 400mg|Anti-GM-CSF Monoclonal Antibody 400mg
223476475|NCT01603277|OTHER|Placebo|Normal Saline
223476476|NCT05393596|BEHAVIORAL|Virtual Reality Software Intervention|Virtual Reality Software Intervention
223476477|NCT02936973|DEVICE|Real catgut implantation at acupoints|"1. Absorbable surgical suture will be embedded in acupoints as below. Group A ：Zhigou (TE 6), Tianshu (ST25), Weishu (BL21), Zhongwan (CV12) and Zusanli (ST36); Group B ：Quchi (LI11), Huaroumen (ST24), Pishu (BL20), Shuifen (CV9), and Fenglong (ST40). Each group will be used alternatively and treated once every 2 weeks.~2. lifestyle intervention :Experienced nutritionists calculated every participant's basal metabolic rate,then designed a proper diet and exercise treatment for them. During the treatment, a diet and exercise diary will be distributed to the patients, and detailed guidance concerning their diet and exercise will be provided according to the diary. The patients should be encouraged to maintain the diet and exercise diary for at least 4 days per week ."
223476478|NCT02936973|DEVICE|sham catgut implantation at acupoints|"Empty needles without catgut will be pushed into the chosen position as below :Group A ：1 cun lateral from the Zhigou (TE 6), Tianshu (ST25), Weishu (BL21), Zhongwan (CV12) and Zusanli (ST36); Group B ：1 cun lateral from the Quchi (LI11), Huaroumen (ST24), Pishu (BL20), Shuifen (CV9), and Fenglong (ST40).Those two groups of acupoints will ultimately be selected for alternative treatment. Each group will be used alternatively and treated once every 2 weeks.~lifestyle intervention :It will be performed as the same as the real catgut implantation at acupoints group."
223476479|NCT00089219|BIOLOGICAL|IFA|vaccine adjuvant
223476480|NCT00089219|BIOLOGICAL|6MHP|melanoma helper peptides
223476481|NCT00089219|BIOLOGICAL|GM-CSF|vaccine adjuvant
223476482|NCT04880109|DRUG|APX-115|Oral administration of APX-115 100 mg capsule once daily for 14 days
223476483|NCT04880109|DRUG|Placebo|Oral administration of placebo capsule once daily for 14 days
224070120|NCT00883337|DRUG|Interferon β-1a|"Sterile preservative-free solution packaged in graduated pre-filled syringes~Subcutaneous injection~Ascending doses from 8.8 to 44 mcg according to local standard for Rebif®"
224070121|NCT00883337|DRUG|Teriflunomide|"Film-coated tablet~Oral administration"
224070122|NCT02230631|OTHER|No treatment given|Two different questionnaires will be applied to patients during a regular clinical visit.
224070123|NCT01578980|DEVICE|Outpatient Control-to-Range|Subjects will spend two nights (\~42 hours) in a local hotel during which the AP Platform will be remotely monitored in an adjacent hotel room for validation that remote system monitoring can successfully occur.
224070124|NCT03451188|DEVICE|Cerecare compression garments|all Cerecare compression garments
224070125|NCT05087069|DRUG|BV100|Rifabutin for Infusion
224070126|NCT05087069|DRUG|Placebo|Saline intravenous infusion
224070127|NCT03582670|BEHAVIORAL|Strategy Training|Participants will attend four strategy training sessions total. In sessions 1 and 2, in addition to teaching about event- and time-based tasks, the trainer teaches the participant specific strategies for each type of task (implementation intentions for event-based and strategic clock-checking for time-based). In sessions 3 and 4, the trainer tells the participant s/he will be practicing both types of tasks in the training games and can support the participant's strategy use if needed. Feedback on accuracy and strategy use are provided after each training game. At the end of each session after completing the training games, the trainer and participant discuss how the strategies can be applied to the participant's real-life prospective memory goals, and the trainer helps the participant develop written action plans to do so. Plans are reviewed (and modified if necessary) at each session.
224070128|NCT03582670|BEHAVIORAL|Process Training|Participants will attend four process training sessions in this group. In sessions 1 and 2, the trainer teaches the participant about event- and time-based prospective memory tasks, respectively. In sessions 3 and 4, the trainer simply tells the participant that s/he will be practicing both types of tasks in the training games. In all sessions, the participant completes the training games with no strategy instruction from the trainer. Feedback on accuracy is provided after each training game. At the end of each session after completing both training games, the trainer reminds the participant of his/her real-life prospective memory goals, provides a handout that lists the goals, and instructs the participant to try to complete them as intended. Of note, even this minimal level of discussion of real-life cognitive tasks is not typical of process training interventions, but we include it to control for that which is occurring in the strategy training group.
224070129|NCT03582670|BEHAVIORAL|Control Group|Participants in this group do not attend any sessions during the time the other groups are participating in the Strategy or Process Training
224070130|NCT02177760|DRUG|Sirolimus|
224070131|NCT01531036|DEVICE|3D Ultrasound elastography by means of shear wave propagation into breast tissue|Aixplorer Supersonic Imagine Ultrasound System with 3D probe for real-time elastography
224070132|NCT00918814|DRUG|LIPO-102|Subcutaneous Injection
224070133|NCT00918814|DRUG|Placebo|Placebo
224070134|NCT03146572|BEHAVIORAL|Sit Down and Play|Sit Down and Play (SDP) is designed to be a brief, low-cost intervention that incorporates key theoretical constructs to elicit positive parenting behaviors. It is intended to be delivered by existing clinical staff, nonprofessionals, or volunteers during each of the eight well-child visits between 2-24 months of age while a family waits to be seen by their pediatrician in the examination room
224070135|NCT03146572|OTHER|Handout|Handout providing written descriptions of strategies to encourage positive parenting behaviors
224070136|NCT02276092|OTHER|antimicrobial stewardship|A member of the antimicrobial stewardship program will prospectively review the patient's medical record and make recommendations to the most responsible physician in the care of that patient
224070137|NCT01582438|DRUG|Access program - sildenafil citrate, Viagra, Revatio|The recommended dose is 20 mg TID for subjects with body weight \> 20 kg and 10 mg TID for subjects with body weight ≤ 20 kg. If subject is 18 years of age or older, the recommended dose is 20 mg TID, regardless of body weight. If a subject was receiving a higher dose in study A1481156 and the investigator believes that the subject requires continued treatment on that dose, or if dose reduction is judged to be associated with pulmonary arterial hypertension (PAH) deterioration in a particular subject, the higher dose may be made available, as judged on an individual basis on discussion with the sponsor.
224070138|NCT04415073|DRUG|SNDX-6352|SNDX-6352
223476484|NCT03225963|RADIATION|Chemoradiation with temozolomide|
223582932|NCT04973696|BEHAVIORAL|Toolkit for Optimal Recovery after Orthopedic Injury|The Toolkit (TOR) is a 4-session, individual, live video, synchronous program developed specifically for patients with orthopedic acute injuries who are at risk for chronic pain and disability. The program teaches evidence-based mind-body skills (e.g., relaxation and mindfulness; myths about pain; activity pacing; acceptance and values based goal setting). Participants gain access to a website downloaded on their phones as an app. The website included explainer videos of skills and recordings of mindfulness and relaxation exercises. In addition, participants will receive usual care as determined by medical team.
223476485|NCT03148262|DEVICE|The Comfort Flo system|The Comfort Flo system will be used for the high flow nasal cannula during procedural sedation
223476486|NCT03148262|DEVICE|The Salter nasal cannula|A Salter nasal cannula will be used at 4L/ minute during the procedural sedation.
223476487|NCT02950701|DEVICE|Observational data collection.|
223476488|NCT05469945|DEVICE|Compressive garments class II|Daily wearing of compressive garments, especially during prolonged standing upright or strenuous activities.
223476489|NCT01515839|DIETARY_SUPPLEMENT|Multivitamin Supplement intervention|"We recommend the following protocol:~1. 2 tablets of a high quality multivitamin BID~2. 2 capsules of omega 3 fish oil BID for a total of 3 grams daily~3. 3 capsules of a brain and memory formula BID which contains Acetyl-L-Carnitine (HCL) 1000 mg, Ginkgo Biloba Extract 120 mg, Alpha-Lipoic Acid (ALA) 300 mg, Huperzine A (Huperzia serrata)150 mcg, N-Acetyl-L-Cysteine (NAC) 600mg, Phosphatidyl Serine (soy) 100 mg, Vinpocetine 15mg~4. Weight loss"
223476490|NCT02522117|DRUG|Atorvastatin|Patients were assigned to two groups; one of them received oral atorvastatin (study group), and the other homologated placebo (control group) for 4 weeks before transplant. Then IL2, IL6, TNFalpha and HLA levels were assessed in the recipient's kidney graft by visual analog scale at prior reperfusion, and after 3 and 12 months.
223476491|NCT02522117|DRUG|Placebo|Patients were assigned to two groups; one of them received oral atorvastatin (study group), and the other homologated placebo (control group) for 4 weeks before transplant. Then IL2, IL6, TNFalpha and HLA levels were assessed in the recipient's kidney graft by visual analog scale at prior reperfusion, and after 3 and 12 months.
223476492|NCT05211934|OTHER|No intervention|No intervention
223476493|NCT02472899|OTHER|Blood sample|Non-interventional study based on blood samples taken at a single study visit
223476494|NCT00550199|DRUG|LBH589, Gemcitabine|Phase I dose escalation: LBH589 will be administered orally twice weekly. Gemcitabine will be administered intravenously over 30 minutes on days 1, 8, and 15 every 28 days.
223476495|NCT02936947|DEVICE|High Frequency Percussive Ventilation|High Frequency Percussive Ventilation
223476496|NCT02936947|OTHER|Free breathing|Free breathing
223476497|NCT02936947|OTHER|Active Breathing Control|Active Breathing Control
224070139|NCT04415073|DRUG|Placebo|Placebo comparator
224070140|NCT03468309|GENETIC|Genecept Assay and G-DIG decision tool|Participating providers will review results of the Genecept Assay using a secure web-based program and will utilize the G-DIG tool in order to determine the optimal medication regime for the patient, based on their individual genetic profile. Genomind will provide training to all investigators prior to the study start regarding the interpretation of the pharmacological assay and the use of the G-DIG tool. Genomind representatives will be available throughout the duration of the study for consultation regarding the interpretation and implementation of the testing results. All final decisions about changing dosage, adding medications, or removing medications will be determined by the provider.
224070141|NCT01004757|OTHER|LOGI diet|diet based on 25% low glycemic index carbohydrates, 30% protein and 45% fat combined with heart rate controlled aerobic exercise for three weeks
223476498|NCT04435496|DEVICE|GYN-CS|placement of the GYN-CS device
223476499|NCT05759572|DRUG|Apatinib|TKI
223476500|NCT05759572|DRUG|Dalpiciclib|CDK4/6 inhibitor
223476501|NCT05759572|DRUG|Fulvestrant/AI|Endocrine therapy
223476502|NCT04465422|BEHAVIORAL|Occupational therapy based on the MOHO theory|"We selected two acute wards in the Songde hospital as the intervention group and the control group. At the same time, the demographic data of the participants were collected, including gender, age, age of onset, marital status, education level, work experience, etc., and the clinical records, including assessment of mental symptoms and medication records, etc. Continuity or categorical information on Occupational performance, personal and social performance, instrumental activities daily living, and clinical performance.~OPHI-II, CGIS, PSP, LIADL, COPM, COTES were tested before and after in the intervention group and the control group to explain the intervention effect of the MOHO theory-based treatment model."
223476503|NCT04465422|BEHAVIORAL|Occupational therapy|The original Occupational therapy. OPHI-II, CGIS, PSP, LIADL, COPM, COTES were tested before and after in the intervention group and the control group to explain the intervention effect of the MOHO theory-based treatment model.
223476504|NCT05052840|OTHER|Muscle endurance training (MET)|Experimental group will be given MET Program, stretching \& strengthening exercises and Hot packs (for 15 minutes). MET program will include warm up, endurance and cool down exercises. The warm up and cool down period will be consisted of 5-minute walking, and 10 repetitions of stretching exercises. Endurance exercises will consist of 4 levels.
224070142|NCT01004757|OTHER|Low Fat diet|traditional low fat diet based on 55% mixed glycemic index carbohydrates, 20% protein and 25% fat for three weeks followed by LOGI diet for two weeks, always combined with heart rate controlled aerobic exercise
224070143|NCT06137118|DRUG|AZD0486|Investigational Product administered via intravenous infusion.
224070144|NCT05966298|OTHER|Core stabilization training|First, while focusing on the activation methods of deep cervical flexor, transversus abdominus and multifidus muscles in individuals; In the next stages, exercises will be performed that will preserve the contraction of the deep cervical flexor, transversus abdominus and multifidus muscles and activate the other muscles of the body.
224070145|NCT05966298|OTHER|Standart Rehabilitation|This treatment includes shoulder exercises and conventional therapy (Infrared, TENS).
224070146|NCT01707472|BIOLOGICAL|Simtuzumab|700 mg intravenously for a total of 12 infusions.
224070147|NCT05131204|DRUG|Cemdisiran|Administered per protocol
224070148|NCT05131204|DRUG|Eculizumab|Administered per protocol
224070149|NCT05131204|DRUG|Pozelimab|Administered per protocol
224070150|NCT05131204|DRUG|Ravulizumab|Administered per protocol
223476505|NCT05052840|OTHER|Conventional Treatment|"Conventional treatment group will be given hot packs (for 15 minutes) and Strengthening \& stretching exercise program including:~STRETCHING EXERCISES (lumbar extensor muscles, iliopsoas muscles, hamstring muscles, gastrocnemius muscles and pectoral muscles).~STRENGTHENING EXERCISES (rectus abdominus crunch, oblique crunch, pelvic elevation, single leg pelvic elevation, lumbal spine extension, on hands and knees position with the raise of one leg, on hands and knees position with the raise of opposite arm and leg). Each exercise will be repeated 10 times."
223476506|NCT02061657|DRUG|Misoprostol|25 patients undergoing myomectomy operation will receive two tablets of misoprostol (400 mcg) rectally two hours before the operation
223476507|NCT02061657|DRUG|Placebo( for misoprostol)|Include 25 patients undergoing myomectomy operation will not receive misoprostol before the operation.
223476508|NCT02391337|DRUG|Bisoprolol|Drug intervention
223476509|NCT02391337|DRUG|Digoxin|Drug intervention
223476510|NCT01824017|OTHER|Blood Draw|
223476511|NCT02386852|DRUG|Placebo|Study subjects received, in a double blind fashion, placebo pills identical to the drug (drug 1-ginseng, group 1; drug 2-ginkgo biloba-group 2)
223476512|NCT02386852|DRUG|Ginseng|The ginseng group received two capsules containing either 1000 mg or 500 mg of Panax Ginseng extract standardized to 3% of ginsenosides (GNC, USA) or similarly looking placebo capsules over a period of three days of testing.
223476513|NCT02386852|DRUG|Ginkgo Biloba|The ginkgo group received two capsules containing either 240 mg or 120 mg of ginkgo biloba extract standardized to 24% ginkgo flavone glycosides and 6% terpene lactones (GBE24/6) or similarly looking placebo capsules over a period of three testing days.
223476514|NCT03779269|OTHER|meditation|meditation effect assessment using assessment tools.
223476515|NCT00746551|DRUG|Ferli-6® (Continental Pharm co., ltd.)|In the O-group, women had to take 3 ferrous fumarate tablets (Ferli-6®) everyday with a total of 200 mg of elemental iron per day from 33 weeks gestation until delivery. Emphasizing and monitoring for compliance to the treatment protocol were carried out.
223582933|NCT04973696|OTHER|Minimally Enhanced Usual Care (MEUC)|The MEUC is educational material, in the form of a physical hard-copy pamphlet and website downloaded as an app on their phones. In addition, participants will receive usual care as determined by medical team.
223582934|NCT02582281|DEVICE|intrauterine device TCu 380A|
223582935|NCT05147714|DEVICE|Surgical Pleth Index (SPI)|SPI data were recorded at one-minute intervals during the last five minutes (6 times in total) until the entropy value reached 60
223582936|NCT04332614|BEHAVIORAL|Less-is-better|Email
223582937|NCT04332614|BEHAVIORAL|Social proof|Email
223582938|NCT04332614|BEHAVIORAL|Endowment / decision staging|Email
223582939|NCT04332614|BEHAVIORAL|Standard email|Email
223582940|NCT04401878|DRUG|Sphenopalatine Ganglion Block using 2% lidocaine|Sphenopalatine Ganglion Block is performed by a hollow culture swab that is connected with a 21-gauge syringe filled with three ml 2% lidocaine, inserted parallel to the floor of the nose until resistance is felt. The swab is at the posterior pharyngeal wall superior to the middle turbinate. The applicator was kept in the nostril for five to ten mins. The same procedure is done also in the second nostril. The patients are then examined by TCD.
223476516|NCT00746551|DRUG|Venofer® (Vifor AG, St. Gallen, Switzerland)|Women in the IV-group received 500 mg iron sucrose (Venofer®, Vifor International AG, St. Gallen, Switzerland) divided into three weekly administrations. Two doses of 200 mg iron sucrose were given at 33 and 34 weeks gestation while the remaining (100 mg) was infused at gestation of 35 weeks. Thereafter, women in this group received no further iron therapy until delivery. In preparation, 200 mg of iron sucrose was diluted into 100 ml of 0.9% saline solution.
223476517|NCT04283318|BEHAVIORAL|12h fasting|12h fasting (overnight)
223476518|NCT04283318|BEHAVIORAL|36h fasting|36h fasting ( one day and two nights fasting)
223476519|NCT03398473|DRUG|Epoetin Hospira SDV|Epoetin Hospira Single Dose Vial
223582941|NCT06583291|DRUG|Allogeneic dopaminergic neural precursor cell(iDAP)|Bilateral implantation
223582942|NCT04007770|OTHER|Acupuncture|10 treatments of acupuncture over the course of 10 weeks with a +/- 7 day window
223476520|NCT03398473|DRUG|Epoetin Hospira MDV|Epoetin Hospira Multi-Dose Vial
223476521|NCT00185315|DRUG|Ventavis (Iloprost, BAYQ6256)|Inhaled iloprost
223476522|NCT04958876|DRUG|SP-104|oral capsule once daily
223476523|NCT04958876|DRUG|Naltrexone immediate release oral capsules|oral capsule once daily
223582943|NCT04007770|OTHER|Sham Acupuncture|10 treatments of sham acupuncture over the course of 10 weeks with a +/- 7 day window. After the 16-week study concludes patients in this group will have the option of receiving up to 10 sessions of real acupuncture; however, these sessions must be completed within 6 months of study conclusion.
223582944|NCT04007770|OTHER|16 week waiting period + optional Acupuncture|Optional real acupuncture after 16 weeks waiting period. This arm is Closed to accrual.
223582945|NCT02535533|DRUG|Selenomethionine (SLM)|SLM administrated orally twice daily for 14 days followed by SLM once daily in combination with Axitinib 5 mg twice daily with titration according to package insert
223582946|NCT02535533|DRUG|Axitinib|Following SLM administrated orally twice daily for 14 days, SLM once daily in combination with Axitinib 5 mg twice daily with titration according to package insert
223582947|NCT02535533|DRUG|Selenomethionine (SLM)|Maximum tolerated dose (MTD) of SLM determined in the Escalation Part 1 (4000 mcg SLM) given orally twice daily for 14 days, followed by SLM once daily in combination with axitinib 5 mg twice daily with titration according to package insert
223582948|NCT02535533|DRUG|Axitinib|Following maximum tolerated dose (MTD) of SLM determined in the Escalation Part 1 (4000 mcg SLM) given orally twice daily for 14 days, SLM once daily in combination with axitinib 5 mg twice daily with titration according to package insert
223582949|NCT02535533|DRUG|Selenomethionine (SLM)|Pilot Phase - Dosing will begin at dose level 3 (4000, 5000 or 6000 mcg SLM calculated based on patients' BSA). SLM will be given orally twice daily for 14 days
224070151|NCT05143840|DRUG|Single Agent Asciminib|taken orally once a day starting cycle 1 day 1 for up to 24 months during the single agent asciminib phase. Asciminib is a potent allosteric inhibitor of BCR::ABL1.
224162829|NCT03914872|BIOLOGICAL|Neoantigen DNA Vaccine|The schedule for vaccination will be weeks 1, 5, 9, 13, 17, and 21. All vaccines will occur within +/- 1 week with at least 3 weeks between vaccines.
224162830|NCT03914872|DEVICE|Integrated electroporation device|"* Ichor Medical Systems~* All study injections will be given intramuscularly using an integrated electroporation device"
223476524|NCT05782153|DEVICE|Intervention A (hearing aid self-fitting with direct adjustment)|The intervention offered is a hearing aid fitting with the Lexie B2 Powered by Bose receiver-in-the-canal hearing aids using a self-fitting strategy with direct adjustment. The hearing aids will be accompanied and operated with the Lexie smartphone application. Participants will complete a hearing screening (at 500, 1000, 2000 and 4000 Hz) called Hearing Check on the Lexie smartphone application, which will be used to tune the hearing aids according to frequency and loudness level. Participants will be able to use two wheels to change the loudness and fine-tune the hearing aids. Participants will wear the hearing aids for four weeks.
223582950|NCT05178381|DEVICE|Continuous theta burst transcranial magnetic stimulation|Participants will receive cTBS (50Hz stimulation at 80% AMT for 40 seconds). Stimulation will be applied to either the target area (frontal pole or IFG) or control area (vertex). Targeting of each region will be achieved using a frameless neuronavigation system with a Polaris Spectra infrared camera that enables stimulation to be centered on specific coordinates in Montreal Neurological Institute space. We will use coordinates \[x,y,z\] = \[35,50,15\] for frontal pole and \[x,y,z\] = \[56,16,22\] for right IFG based on the location of our activations in the young pilot group (Figure 4). The vertex control site is defined as the Cz position of a 10-20 EEG system. After receiving TMS, participants will stare at a white wall for 1 minute before performing the Horizon Task for 45 minutes.
223582951|NCT03075124|DEVICE|External Counter Pulsation|A standard ECP protocol involves 35 one-hour sessions (once per day, 5 days a week) and continuous for 7 weeks. ECP consists of three sets of pneumatic cuffs attached to each of the patient's legs at the calf and lower and upper thigh. The inflation of the cuffs is triggered by a computer, and timing of the inflation is based on the R wave of the electrocardiogram. The ECP therapist adjusts the inflation and deflation timing to provide optimal blood movement per a finger plethysmogram waveform reading.
223582952|NCT04326660|OTHER|SCOPE-Chinese Women|SCOPE-Chinese Women is a smart-phone based intervention that includes a Fitbit tracking device to monitor daily activity, 12-weeks of educational modules delivered by WeChat, and Bi-weekly messages that encourage positive behavioral change. The data will be examined by the research team to assess efficacy of the intervention.
223582953|NCT02125565|OTHER|Injected subcutaneous local (lidocaine) anaesthesia|Trial of technique
223582954|NCT04836988|OTHER|Three months of digitally delivered osteoarthritis treatment|Digitally delivered osteoarthritis management including education and exercise and weight control if needed
223582955|NCT04836988|OTHER|Three months of face-to-face delivered osteoarthritis treatment|Face-toface delivered osteoarthritis management including education and exercise and weight control if needed
223582956|NCT01513681|DRUG|Lamotrigine|Lamotrigine Tablets 200 mg
224070152|NCT05143840|COMBINATION_PRODUCT|Low TKI|"Low dose tyrosine kinase inhibitor (lowTKI) (dasatinib 50 mg daily or imatinib 300 mg daily or nilotinib 300 mg daily) at investigators discretion, may be added to asciminib in the following situations:~* Patients who have treatment failure at any time based on ELN criteria (Appendix 7)~* Patients who have a warning response after 12 months of single agent asciminib based on ELN criteria (Appendix 7)~* Patients who have not achieved MR4.5 after 24 months, but no later than 36 months, of single agent asciminib."
224070153|NCT05143840|OTHER|Elective Free Treatment|Once central eligibility has been obtained the patient should discontinue asciminib and if applicable lowTKI within 14 days.
224070154|NCT01514032|PROCEDURE|Extracorporal shockwave lithotripsy|Extracorporal shockwave lithotripsy
224162831|NCT04121052|DRUG|JNJ-64417184|Participants will receive single dose of JNJ-64417184 as oral tablet.
224162832|NCT02407665|BEHAVIORAL|Tai Chi|Each Tai Chi session will last 60 minutes and will continue twice a week for 12 weeks. Our instructors, who have extensive experience conducting Tai Chi training programs, will follow the standardized Tai Chi protocol. We will also provide the participants with printed materials on FM and the Tai Chi Mind-Body program, including Tai Chi principles, practicing techniques, and safety precautions for participants with FM
224162833|NCT04330456|RADIATION|Preoperative stereotactic radiation therapy in hypofractionation mode|"At the first step patient undergoes preoperative stereotactic radiation therapy in hypofractionation mode. Radiation therapy plan is based on topometric MRI and CT scans. Radiation therapy plan are performed after MRI and CT fusion, contouring of the target and surrounding normal tissues.~At first step only tumor and, if necessary, the surrounding normal tissues, which will be removed during surgery, are exposed to radiation.~GTV - determined in with the boundaries of the tumor visualised by topometric MRI and CT CTV1 - match GTV CTV2 - formed inward (to the tumor center) from GTV by 0.5-1 cm (depending on the proximity of functionally significant normal tissues (neurovascular bundles, bone tissue, skin and subcutaneous fat, etc.) PTV - 3-5 mm indent from CTV1, taking into account the proximity of functionally significant normal tissues and the planned surgery Preoperative radiation therapy is carried in 5 fractions with a single dose on PTV - 5 Gy, a single dose on CTV2 - 7 Gy."
224162834|NCT04330456|PROCEDURE|Surgery|In 14-21 days after preoperative stereotactic radiation therapy radical surgery will be performed
224162835|NCT04330456|RADIATION|Postoperative conformal radiation therapy in normofractionation mode|"In 25-35 days after the surgery postoperative conformal radiation therapy is performed according to the standard protocol GTV (tumor bed) - based on the volume of the primary tumor, including the swelling zone (T2-weighted images on preoperative MRI) СTV - formed with an indent of 4 cm from GTV (without going beyond the boundaries of the involved compartment), in the transverse direction the indent could be reduced to 2 cm.~PTV - formed with an indent of 0.5-1cm from CTV An important condition for planning radiation therapy is to limit the dose absorbed during both stages of radiation therapy in surrounding normal tissues that are not removed during surgery."
224162836|NCT00298285|DRUG|enoxaparin|
224070155|NCT01514032|PROCEDURE|Retrograde intrarenal surgery|Retrograde intrarenal surgery
224162837|NCT02331316|OTHER|Daily extra water intake|"Intervention-A: Timing of assigned daily extra water intake specified~Intervention-B: Daily extra water assigned at any time during 24 hour period"
224162838|NCT02327728|PROCEDURE|Botulinum toxin A injection (5 sites: 12.5U)|
224162839|NCT02327728|PROCEDURE|Botulinum toxin A injection (4 sites: 10U)|
224162840|NCT02327728|DRUG|Botulinum toxin A 12.5U|
224162841|NCT02327728|DRUG|Botulinum toxin A 10U|
223476525|NCT05782153|DEVICE|Intervention B (hearing aid self-fitting with in-situ fitting)|The intervention offered is a hearing aid fitting with the Lexie B2 Powered by Bose receiver-in-the-canal hearing aids using the in-situ audiometry fitting strategy. The hearing aids will be accompanied and operated with the Lexie smartphone application. Participants will complete an in-situ audiogram on the Lexie app, which enables the measurement of hearing thresholds through the hearing aids (at 500, 1000, 2000 and 4000 Hz). The hearing aids will then be self-programmed according to the participant's in-situ audiogram with a proprietary fitting algorithm that is based on NAL-NL2. Participants will wear the hearing aids for four weeks.
223476526|NCT00652444|DRUG|ezetimibe|ezetimibe 10mg. Blood samples were collected again at the end of study treatment, week 6.
223476527|NCT00652444|DRUG|simvastatin|simvastatin 20mg . Blood samples were collected again at the end of study treatment, week 6.
223476528|NCT00652444|DRUG|Placebo (Unspecified)|Matching ezetimibe placebo
223582957|NCT01513681|DRUG|Lamictal®|Lamictal® 200 mg Tablets
223582958|NCT05218525|OTHER|Algorithm|"Participants in the intervention group will receive the general offer of the telehealth intervention including the telehealth system with the implemented COPD prediction algorithm. The participants are asked to measure their vital signs and respond to COPD related questions as usual. As usual refers to fixed days in the week, either Monday or Thursday, where the participants must measure their vital signs. In addition, the participants must weekly measure two oxygen saturation measurements drawn from the fingertip pulse oximeter."
223582959|NCT04461418|DRUG|Glucocorticoid therapy|The study intervention is defined as treatment with either prednisone or dexamethasone as palliative therapy for the control of neurological symptoms; patients with symptomatic brain metastases with a requirement for glucocorticoid therapy will be treated with an available, standard-of-care immune checkpoint inhibitor regimen.
224162842|NCT02022891|BEHAVIORAL|systematic psychological care|Prevention treatment plan that provides systematic medical and psychological care at routine pediatric consultations for SCD. Bio-psychosocial paradigm applied at pediatric consultations.
223476529|NCT03779555|OTHER|Medication Event Monitoring System|-Microchipped bottle cap
223476530|NCT00614510|DEVICE|CardioWest temporary Total Artificial Heart (TAH-t)|The SynCardia CardioWest temporary Total Artificial Heart (TAH-t) system is a pulsatile biventricular device that replaces a patient's native ventricles and valves and pumps blood to both the pulmonary and systemic circulation. The system consists of the implantable CardioWest TAH-t and an external console connected by drivelines.
223476531|NCT06184048|PROCEDURE|Intra-Articular knee injection of LC-PRP|Blood Collection 45mL, Processed Neutrophil-Poor PRP, 2 Injections at day 0 and 3 weeks.
223476532|NCT03931070|DRUG|Ramelteon|Patients assigned to Ramelteon group will receive 8mg of Ramelteon every night throughout the hospitalization or up to 30 days, whichever is sooner.
223476533|NCT03931070|DRUG|Placebo - Cap|Patients assigned to Placebo group will receive placebo pill that is indistinguishable from Ramelteon, every night throughout the hospitalization or up to 30 days, whichever is sooner.
223476534|NCT00833755|DRUG|Ketamine|To compare pain threshold, pain tolerance, and wind up, as measured by QST, before and after a single dose of ketamine infusion under two clinical conditions: chronic pain patients on opioid therapy and chronic pain patients without opioid therapy.
223476535|NCT00833755|DRUG|Placebos|To compare pain threshold, pain tolerance, and wind up, as measured by QST, before and after a single dose of ketamine infusion under two clinical conditions: chronic pain patients on opioid therapy and chronic pain patients without opioid therapy.
223476536|NCT05125445|PROCEDURE|Implants placed at bone crest|"Mid crestal incision will be performed and full-thickness envelope flap will be elevated to expose the alveolar ridge (no releasing incisions will be made).~Implant site will be prepared according to the manufacturer's instructions under sterile copious irrigation Implants will be placed at crestal level"
223476537|NCT05125445|PROCEDURE|Implants placed 1mm Subcrestally|Implants will be placed 1mm subcrestally
223476538|NCT01457794|OTHER|School meals based on the principles of the New Nordic Diet|The study participants are provided with three daily school meals for 3 month
223476539|NCT02439164|DRUG|Midazolam|specific benzodiazepine agonist midazolam will be used titrate to desired sedation level, its specific antagonist flumazenil will also be used
223476540|NCT03366662|DEVICE|Monitoring of frontal electrical muscle activity|Continuous monitoring of frontal electrical muscle activity during general anesthesia simultaneous to burst suppression electroencephalogram
223476541|NCT01776554|BIOLOGICAL|Adjuvanted H5N1 pandemic influenza vaccine|Comparison of two doses of aH5N1c vaccine
223476542|NCT01344135|DIETARY_SUPPLEMENT|Dietary supplementation|"Phase A, Rehabilitation (4 months): 3 nutritional supplements daily~Phase B, Maintenance (8 months): nutritional supplementation on advice (1 supplement daily)~Phase C, Follow-up (3 months): no supplementation"
224162843|NCT00438490|DRUG|Recombinant Human Prolactin|
224162844|NCT05613192|DRUG|Cholecalciferol|patients receive the standard conventional therapy in addition to a single oral dose of cholecalciferol 300,000 IU followed by oral cholecalciferol 800 IU daily for 4 months.
223476543|NCT01344135|DIETARY_SUPPLEMENT|Placebo supplement|"Phase A, Rehabilitation (4 months): 3 placebo nutritional supplements daily~Phase B, Maintenance (8 months): No supplementation~Phase C, Follow-up (3 months): No supplementation"
223476544|NCT01344135|BEHAVIORAL|Nutritional counselling|"Phase A, Rehabilitation (4 months): No counselling~Phase B, Maintenance (8 months): Nutritional counselling (4x)~Phase C, Follow-up (3 months): No counselling~Aim:~1. Optimising dietary intake to physical activity pattern and energy expenditure.~2. Minimize deterioration of dietary intake during acute exacerbations.~3. Optimize dietary lipid profile with respect to total fat intake; trans fatty acids and proportion of poly-unsaturated fatty acids to modulate cardiovascular risk and muscle fatty acid metabolism.~4. Increasing adherence/compliance by addressing issues like taste fatigue, gastro-intestinal symptoms, individual preferences and lifestyle."
224162845|NCT04265092|DRUG|Incobotulinum toxin A|Treatment consisted of 200 IU of incobotulinum toxinA injected into the TS. Outcome measures were assessed before injection, at 6 weeks and 3 months post-injection, using the Goal Attainment Scale (GAS), Twelve Item MS Walking (MSWS-12) Scale, Timed Up and Go (TUG) Test, 6 Minute Walk Test (6MWT). Spatiotemporal gait data was obtained by GAITRite.
224162846|NCT04281108|DRUG|APT-1011|APT-1011 is an orally disintegrating tablet that includes fluticasone propionate as its active ingredient.
224162847|NCT04281108|DRUG|Placebo oral tablet|Placebo orally disintegrating tablet.
223744463|NCT01136096|BEHAVIORAL|Physical activity promoting intervention|"1. An interview with a physiotherapist~2. An exercise video specially designed by this study including warm-up, aerobic, cool-down and stretching exercises, and/or a simple exerciser to use at home~3. An individualized home-based exercise program based on the Health Belief Model and Transtheoretical Model~4. The daily record to check their body weight, exercise mode and duration~5. Proper diet, caloric intake calculation, metabolic risk factors and prevention of diabetes were taught and a guide book was provided that included all the above mentioned details~6. Telephone reminders of healthy lifestyle including the ways of overcoming barriers of regular exercise every 1 to 2 weeks for 3 months, 1-2 calls a month afterwards and no calls for the last month on a tapered off schedule"
223744464|NCT01136096|BEHAVIORAL|General instruction and education|"1. Oral instruction and written general education information about weight control, proper diet and regular exercise in a one-page education brochure that was similar to the way used in the outpatient clinic~2. Telephone reminders of healthy lifestyle every 1 to 2 weeks for 3 months, 1-2 calls a month afterwards and no calls for the last month on a tapered off schedule~3. Without individualized exercise program and interview with a physiotherapist"
223744465|NCT00022828|DEVICE|3-D Laser Imaging Device|
223744466|NCT06970743|DRUG|BGB-16673|Administered orally
223744467|NCT06970743|DRUG|Bendamustine|Administered intravenously
223744468|NCT06970743|DRUG|Rituximab|Administered intravenously
223744469|NCT06970743|DRUG|Methylprednisolone|Administered intravenously
223744470|NCT00229255|OTHER|high frequency of meals|high carbohydrate diet i.e. 65% carbohydrate, 15% protein, 20% fat for 4 weeks.
223744471|NCT00229255|OTHER|twice a day meals|high carbohydrate diet i.e. 65% carbohydrate, 15% protein, 20% fat for 4 weeks.
223744472|NCT03401983|OTHER|Pelvic Floor Muscle Training and Abdominal Training|Pelvic Floor Muscle Training + Abdominal Training program was used in the study. The follow-up measurements of the PFMT+AT group were obtained in the 0th, 4th, and 8th weeks.
223744473|NCT03401983|OTHER|Pelvic Floor Muscle Training|Pelvic Floor Muscle Training program was used in the study. The follow-up measurements of the PFMT group were obtained in the 0th, 4th, and 8th weeks.
223744474|NCT02467569|DRUG|Hemay020|
223744475|NCT02291055|DRUG|ADXS11-001|
223744476|NCT02291055|DRUG|MEDI4736|
223744477|NCT01746927|OTHER|Glidescope Cricoid pressure|The current study test by direct visual evidence the occlusion of esophageal entrance during application CP. The closure of the lumen was further demonstrated by the inability to introduce a GT into the esophagus during CP. using in radimized method : 0 N,10 N, 20N AND 30 N
223476545|NCT01344135|BEHAVIORAL|Feedback on physical activity level|"Phase A, Rehabilitation (4 months): No exercise counselling~Phase B, Maintenance (8 months): Exercise counselling (2x)~Phase C, Follow-up (3 months): No exercise counselling~Aim:~1. Integration of exercise behaviour into daily routine~2. Improvement of self-regulation skills (e.g. self-monitoring, goal setting, action planning)~3. Increasing adherence/compliance by addressing issues like coping with difficult situation, individual preferences and lifestyle"
223476546|NCT02475369|DRUG|pancrelipase|
223476547|NCT02462265|DRUG|Oshadi D & Oshadi R;|Oshadi D (180mg/TID) \& Oshadi R (180mg TID) will be administrated;
223476548|NCT02462265|DRUG|salvage therapy cytosar and mitoxantrone|Salvage therapy - HAM: Hi dose cytosar (5 or 6 days) and mitoxantrone (2 or 3 days)
223476549|NCT06447636|DRUG|Surufatinib|Surufatinib: 250mg qd，d1-21, q3w
223476550|NCT06447636|DRUG|Sintilimab|Sintilimab：200mg ivdrip, d1, q3w
223476551|NCT06447636|DRUG|Oxaliplatin|130mg/m2，iv drip for 2h，d1, q3w
223476552|NCT06447636|DRUG|S1|S1：40\~60mg Bid，d1\~14, q3w
223476553|NCT03424135|DRUG|Naproxen sodium and diphenhydramine hydrochloride soft capsules|Single oral administration of Naproxen sodium 220 mg/DPH HCl 25mg (2 capsules)
223476554|NCT03424135|DRUG|Naproxen sodium and diphenhydramine hydrochloride coated tablets (Aleve PM, BAY98-7111)|Single administration of Naproxen sodium 220 mg/DPH HCl 25mg (2 tablets)
223476555|NCT04386785|DEVICE|Radiofrequency (RF) Thermal Ablation of Incompetent Perforator Veins|The physician operator will access the IPV and advance the device to the target treatment position using ultrasound guidance. After providing local anesthesia to the vein and surrounding tissues, thermal ablation energy is delivered to the vein wall. After treatment is complete, the device is removed and vessel closure confirmed with duplex ultrasound.
223476556|NCT02631681|BEHAVIORAL|Group based exercise|Supervised group based combined aerobic and resistance training for 12 weeks as part of our normal clinical practice.
223476557|NCT04254510|OTHER|Myofascial relaxation technique|"* Before the intervention, the number of days of the last menstrual cycle of all participants, the number of painful days throughout the cycle, pain intensity values according to the Visual Analogue Scale will be recorded, and the scores will be recorded in the participants.~* Technique of direct relaxation of fascia of both psoas muscles to the participants in the myofascial relaxation group since the end of the last cycle, 90-120 sec. It will be applied by the physiotherapist twice a week."
223476558|NCT03717571|DIAGNOSTIC_TEST|Glenohumeral translation assessment|amount of glenohumeral translation under load
223476559|NCT00306176|DRUG|Rosiglitazone|
223476560|NCT04539977|DRUG|TQB2450|Inductive therapy: TQB2450 + EC(4 cycles) Maintenance therapy: TQB2450+EC(2 cycles) followed byTQB2450 (1 year)
223476561|NCT04539977|DRUG|TQB2450|Inductive therapy: TQB2450 + EC(4 cycles) Maintenance therapy: TQB2450+EC(2 cycles) followed byTQB2450 (1 year)
223744478|NCT03022292|DRUG|Aflibercept Ophthalmic|IAI given for active exudative macular degeneration (CNV, SRF, PED) per SOC
223744479|NCT03022292|DEVICE|optovue angiovue|FDA approved Optovue Angiovue will be used to monitor progression and responsiveness of active exudative macular degeneration to IAI.
223744480|NCT01828892|PROCEDURE|Endoscopy exploration and glue application|A forward-viewing fistula-fiberscope (EndoView, Outai Medical Equipment, Shanghai, China), with 15cm length and 5mm width of fiber optical wire, was inserted into the fistula tract to accomplish endoscopic visualization. Briefly, the fistula-fiberscope assisted procedure was carried out percutaneously, allowing the exposure of internal hole and the whole tracts, followed by insertion of this catheter with distal mixing device.
223476562|NCT01369381|PROCEDURE|Endotracheal intubation|Study patients undergo endotracheal intubation using both a conventional direct laryngoscope (Macintosh) and an alternative indirect laryngoscope (Airtraq). The order of intubation (Macintosh then Airtraq--or--Airtraq then Macintosh) is randomized.
223476563|NCT05441007|OTHER|Hypoxic|Hypoxic gas mixture Gas mixture of 10% O2 and 90% N2 for six minutes.
223476564|NCT05441007|OTHER|Hypercapnic|Hypercapnic gas mixture Gas mixture of 21% O2, 5% CO2 74% N2 for six minutes.
223476565|NCT05441007|OTHER|Hypoxic and Hypercapnic|Hypoxic and Hypercapnic gas mixture Gas mixture of 10% O2, 5% CO2 85% N2 for six minutes.
223476566|NCT06082440|BIOLOGICAL|Human Umbilical Mesenchymal Stem Cells|Ntra-articular injection inject a corresponding dose of cells suspension into each joint cavity according to the lesion site.
223476567|NCT04585997|DRUG|Mepolizumab|Mepolizumab 100mg subcutaneous injection monthly for 6 months
223476568|NCT04585997|DRUG|Omalizumab|Omalizumab subcutaneous injection every 2-4 weeks (dosage determined by the Omalizumab nomogram).
223476569|NCT06545305|PROCEDURE|Lensectomy and vitrectomy|Corrections
223476570|NCT02346864|BEHAVIORAL|Three-stair-position|Infants in the TSP group received three-stair-prone position. Implementation steps were as following: 1) produced pad of three-stair-prone position the total height of which should be the same height as the head elevated 15 °. 2) Placed the infants on the pad with head on the highest ladder, chest on the second step and leg on the third step, bending the knees to the chest
223476571|NCT02346864|BEHAVIORAL|Head elevated tilt position group|Infants in the HETP group were allowed head up 15 ° prone position using a protractor with head to one side, arms against the sides of the body naturally bending, knees bent to the chest.
223476572|NCT04170413|DRUG|CeVUS|Contrast enhanced voiding urosonography
223476573|NCT03012737|DEVICE|Trilogy 100 ® (Philips Respironics)|Trilogy 100 ® (Philips Respironics) on MPV mode.
223476574|NCT06006156|PROCEDURE|Dental implants placement|surgery for placement of two one-piece trans gingival implants
223476575|NCT01202500|PROCEDURE|reducing treatment to 3 months|The treatment will be stopped after 3 months
223476576|NCT01202500|PROCEDURE|registered length of treatment|The treatment procedure will follow the actual recommandation
223582960|NCT06522243|BEHAVIORAL|8-week mindful parenting program|The current study adopts the Mindful Parenting program developed by Prof Susan Bögels (Bögels \& Restifo, 2013), which is an application of mindfulness-based intervention which aims to improve parenting by reducing parents' own stress levels, decreasing parental automatic reactivity, increasing open and unbiased attitudes towards children, and decreasing inter-generational dysfunctional parenting (Bögels et al., 2014). The program consists of eight consecutive weeks of parent groups and one follow-up session two months after the last session. Each parent group will include 15-20 participants. The original Mindful Parenting Program will last for around 3 hours for each session, with the longest practice of 40 minutes. Considering parents recruited in the study may have a higher risk of psychiatric conditions than the general population, each session of mindful parenting group will be reduced to 2 to 2.5 hours with the longest mindfulness practice of 30 minutes (Baer et al., 2019).
223582961|NCT06436937|DIETARY_SUPPLEMENT|Single meal containing 20 g of 15N intrinsically labelled protein from honey chlorella|Ingestion of a 15N labeled test meal. Subjects are equipped with a nasoileal tube. 15N is followed in biological fluids (plasma, effluents, urines).
223476577|NCT02174757|DRUG|Inersan|Probiotic
223476578|NCT02174757|DRUG|Doxycycline|Antibiotic
223476579|NCT00727129|DRUG|Divigel|
223476580|NCT01880827|PROCEDURE|Roux-en-Y|Subjects in the intervention group will be divided into two consecutive surgical groups, RYGB or SG. After the surgery, subjects are controlled in hospital ward for approximately three days.
223476581|NCT01880827|DRUG|GIP-infusion|Blood flow and volume during infusion
223476582|NCT01880827|DRUG|GLP-1|Blood flow and volume during infusion
223476583|NCT01880827|DRUG|MMS|Blood flow and volume after meal solution
223476584|NCT01880827|PROCEDURE|Sleeve gastrectomy|as in RYGS group
223476585|NCT03608826|DEVICE|Investigational LINQ™ HF RAMware|The Reveal LINQ™ device and the 2090 programmer are market-released, but once the investigational LINQ™ HF RAMware is downloaded into the devices, they are considered investigational.
223476586|NCT00183079|BEHAVIORAL|Motivationally-focused brief alcohol intervention|Brief, motivationally-focused alcohol intervention
223476587|NCT03817281|DEVICE|Accuryn Monitoring System|The Accuryn Monitoring System is a novel Foley catheter and monitoring device capable of detecting physiologic changes in vital signs via sensors within the catheter system. These data are captured non-invasively, continuously, and at a high frequency.
223476588|NCT03122171|OTHER|Occupational Therapy Treatment|Each occupational therapy treatment will be a one-hour standardized session that will include the following: stretching/strengthening (approximately 20 minutes), bi-manual training (approximately 20 minutes), and activities of daily living (approximately 20 minutes).
223476589|NCT04858152|PROCEDURE|Follicular Unit Extraction via punch biopsy|Follicular unit extraction will be performed using standard 0.7mm - 1mm punch biopsies. The donor site, which will be selected as a vitiligo-free, hair-bearing area that is not visible per patient's preference, will be harvested via punch biopsies and transplanted to the recipient site, which will be the glabrous skin of the hands or feet.
223476590|NCT04346953|BEHAVIORAL|Video based exercise|Individuals (n = 64) to be included in the study group will be grouped according to the levels of physical activity (low, medium, high level) determined by the International Physical Activity Questionnaire. An exercise program will be created for each group based on physical activity levels and videos of these exercise programs will be prepared. The videos will be scheduled for 20 minutes. Individuals will be asked to apply for these programs with video for 20 minutes every day for 6 weeks. Exercise programs will start with pulmonary exercises and warm-up exercises to prepare for exercise. The exercise program will end with cool down exercises. The exercise protocol will be determined as a combination of aerobic and strengthening exercises.
223476591|NCT03035162|DEVICE|Transcranial direct current stimulation|Dual Active/sham tDCS will be applied over the leg motor area (M1) priori to conventional physical therapy (1 hours). Anodal on affected hemisphere, Cathodal on unaffected hemisphere. Each participant will complete two experiments (active/sham tDCS). The interval between two experiments is at least 48 hours. The two experiments will be performed in random order for each subject.
223476592|NCT05926609|DIETARY_SUPPLEMENT|EB-PA|1 capsule to be taken after breakfast once a day
223476593|NCT05926609|DIETARY_SUPPLEMENT|Placebo|1 capsule to be taken after breakfast once a day
223476594|NCT00953030|BEHAVIORAL|COACH|
223476595|NCT00953030|BEHAVIORAL|RealAge|
223476596|NCT06448052|BIOLOGICAL|umbilical cord mesenchymal stem cell|A total of 100 million single cells were suspended in 0.9% sterile saline solution and given intravenously at a 5-ml/min rate for 45 min. All patients will get two intravenous autologous infusions on days 0 (D0) and 90 (D90).
223476597|NCT06171893|BEHAVIORAL|Wavy stress application|"The intervention consists of the application named Wavy. Wavy uses artificial intelligence and the user's feedback to detect stress increasingly more efficient over time. This provides not only real-time feedback on an individual's stress level but also helps the patient to calm down using music guided relaxation. It does so with a music filter, allowing the participant to listen to music where the stress level determines the quality of the music.~Thus, relaxing is rewarded by improving the experience. In this process, implicit learning is used to establish a habit of getting better at recognising increased stress levels and getting familiar with reducing stress levels more and more effectively."
223582962|NCT06436937|DIETARY_SUPPLEMENT|Single meal containing 20 g of 15N intrinsically labelled protein from faba bean meat analogue|Ingestion of a 15N labeled test meal. Subjects are equipped with a nasoileal tube. 15N is followed in biological fluids (plasma, effluents, urines).
223582963|NCT05729009|DIAGNOSTIC_TEST|skin microvascular reactivity|Laser-based method for evaluating non-invasive, operator-independent systemic microvascular function that detects microvascular flow in the skin for the evaluation of systemic vascular endothelial function.
223582964|NCT06366230|DRUG|Urea in the dialysate|Adding urea to the dialysis fluid. Ure-Na 15 grams would be used. It would be added to the acid component of the dialysis fluid. The amount added would depend on the serum BUN concentration and is determined by a simple calculation. It would be available in powder form. Urea would be added just to the first 1-3 dialysis treatments as needed.
223582965|NCT03469011|DRUG|Imatinib Oral Tablet|3+3 trial design. Cohorts of 3-6 patients with escalating imatinib doses. No intra-patient dose escalation allowed.
223582966|NCT05991934|BEHAVIORAL|Smartphone-based intervention messages|Intervention messages in the proposed trial will address specific high-risk situations for smoking and smoking urges. Messages will focus on two key situational triggers for message matching: 1. Stress (high/low) and 2. Presence of other smokers (yes/no). For each situation, characterized by a combination of these characteristics, several messages were developed. To improve user engagement with the intervention, all messages contain visual content in form of pictures.
223582967|NCT06372652|DRUG|TE-8214 - SAD|Cohort 1 - Single subcutaneous dose of 0.6 mg Cohort 2- Single subcutaneous dose of 1.2 mg Cohort 3 - Single subcutaneous dose of 2.0 mg Cohort 4 - Single subcutaneous dose of 3.0 mg or 4.0 mg Cohort 5 (Optional) - Single subcutaneous dose of 6.0 mg
223582968|NCT06372652|DRUG|Placebo|Single subcutaneous dose of matching placebo across the cohorts
223582969|NCT06450106|DRUG|STM-416p|STM-416p monotherapy
223582970|NCT05965401|OTHER|Pharmacogenetic-guided dosing|SSRI dosing based on Clinical Pharmacogenetics Implementation Consortium's SSRI dosing guidelines.
223744481|NCT01828892|PROCEDURE|Endoscopy exploration|A forward-viewing fistula-fiberscope (EndoView, Outai Medical Equipment, Shanghai, China), with 15cm length and 5mm width of fiber optical wire, was inserted into the fistula tract to accomplish endoscopic visualization.
223744482|NCT01828892|DRUG|Antibiotics (ceftazidime, cefotaxime, or meropenem, with or without vancomycin)|Antibacterial therapy in patients with signs of systemic sepsis or local inflammation with pain
224162848|NCT04281108|PROCEDURE|Esophagogastroduodenoscopy|Esophagogastroduodenoscopy (EGD) is a test that involves an endoscope, a lighted camera on the end of a tube, that is passed down a subject's throat to visualize their esophagus.
224162849|NCT04135391|BEHAVIORAL|Aerobic exercise training|All recruited subjects underwent 36 times of moderate-intensity continuous training (MICT) at 60% of peak oxygen consumption (VO2peak) for 30 mins, and 10or had high-intensity interval training (HIIT) at alternative 80% and 40% VO2peak with the same training times and duration.
224162850|NCT03644589|BIOLOGICAL|Pembrolizumab|200mg,Given intravenous (IV) infusion, every 21 days
223476598|NCT05665868|DEVICE|integrated care mode|The information system consists of big data platform and nursing strategy platform. The system includes medical work end, patient operation end and administrator management end. The big data platform can automatically extract patient data from HIS, Medcare and other patient diagnosis and treatment systems, complete registration and establish patient health files according to the preset patient registration standards. By comparing the data input on the patient side with the database set on the platform, the system decision-making module can generate personalized measures and plans for feedback to patients, and can generate patient information overview feedback to the nurse side. Complete intelligent push of symptom management decision model
223476599|NCT05665868|DEVICE|conventional care mode|① The health education manual for patients receiving targeted treatment of gastric stromal tumors will be issued. The patients who need targeted treatment will be identified and followed up in the routine outpatient department (1 month, 3 months, 6 months, 12 months after surgery, and once a year thereafter); ② Telephone follow-up (1 month, 3 months, 6 months, 12 months and once a year thereafter); ③ Patients independently complete disease symptom monitoring, lifestyle adjustment, and other disease self-management.
223582971|NCT05965401|OTHER|GLAD-PC guided dosing|SSRI dosing based on GLAD-PC clinical practice guidelines
223582972|NCT06981273|PROCEDURE|Robotic pancreatoduodenectomy|A Robotic approach pancreatoduodenectomy is performed on patients
223744483|NCT01828892|DIETARY_SUPPLEMENT|Nutrition support|Nutritional replacement and bowel rest via enteral or parenteral nutrition
224162851|NCT03644589|DRUG|Cisplatin|75mg/m2, intravenous (IV) infusion, every 21 days, for 6 cycles Given IV
224162852|NCT04407286|DIETARY_SUPPLEMENT|Vitamin D3|Oral vitamin D3 capsules
224162853|NCT01501162|DRUG|hepatitis, alcohol, probiotics|7 days of probiotics (1500 mg/day)
224162854|NCT01501162|DRUG|alcohol, hepatitis, Placebo|Placebos of the same shape and size were manufactured at Pharmaceutical Corporation.
224162855|NCT03645811|BEHAVIORAL|Music Therapy|Music therapy was applied in the application room. Via a portable computer, students listened to the mahur maqam for 20 minutes under the supervision of the investigators using an MP3 player.
224162856|NCT03645811|BEHAVIORAL|EFT|EFT includes taps, nine gamut sequences, and eye movements on the meridian system, focusing on the individual's inhibiting thoughts, disturbing emotions, or memories. EFT regulates the flow of energy in the meridian system of the individual, causing relaxation in the mind, body, and emotions.
224162857|NCT01934608|BEHAVIORAL|Refill synch|
224162858|NCT03774706|DRUG|Misoprostol|two tablets misoprostol 400 μg sublingual
224162859|NCT03774706|DRUG|Tranexamic Acid|two ampoules of tranexamic acid (1gm in 10 ml) in 100ml saline
224162860|NCT03774706|DRUG|placebo to tranexamic acid|placebo to tranexamic acid (110 ml saline)
224162861|NCT00553618|DRUG|Proleukin and Dacarbazine|"IL-2 (Proleukin), injected just under the skin, at a dose of 12 million units on days 1-4 for each of the six months of therapy.~Dacarbazine, administered as an IV infusion through a freely flowing IV, at a dose of 750 mg, repeated every four weeks."
223582973|NCT06981273|PROCEDURE|open pancreatoduodenectomy|An open approach for pancreatoduodenectomy is performed
223582974|NCT06979739|BEHAVIORAL|reiki|6 week reiki
223582975|NCT06979739|BEHAVIORAL|refleksologia|6 week refleksologia
223582976|NCT06979739|BEHAVIORAL|reiki and refleksologia|6 week reiki and refleksologia
223582977|NCT06979934|BEHAVIORAL|3D printing splint group|Wear 3D printing design splint for position for 60 minutes each time, plus 20 minutes of exercise which including:(1) Raise hands for 5 minutes, and bend and straighten the elbow for 5 minutes for proximal movement exercise;(2) Wear 3D printed design hand splint and change objects according to the ability of grasp, such as hold a cup, handle, eraser, pen, etc.
223582978|NCT06979934|BEHAVIORAL|functional splint group|Wear functional splint for position for 60 minutes each time, plus 20 minutes of exercise which including:(1) Raise hands for 5 minutes, and bend and straighten the elbow for 5 minutes for proximal movement exercise;(2) Grasp the holder according the grasp ability, such as hold a cup, handle, eraser, pen, etc.
223582979|NCT06981130|DEVICE|FebriDx Point of Care Test|Patients self-referring to their GP practice with symptoms of acute respiratory infection (ARI) will receive the FebriDx point-of-care test during their clinical consultation.
224162862|NCT02252328|DRUG|Simvastatin|Simvastatin 80mg once daily
224162863|NCT02252328|DRUG|Placebo|Placebo tablets once daily
224162864|NCT05346861|DRUG|Trastuzumab plus chemotherapy|Trastuzumab: 8 mg/kg loading dose followed by 6 mg/kg, Q3W Chemotherapy regimen is chosen from the following: Vinorelbine, Gemcitabine, taxanes or Eribulin monotherapy Experimental: Pyrotinib +Trastuzumab + chemotherapy
224162865|NCT05346861|DRUG|Trastuzumab in combination with pyrotinib plus chemotherapy|Pyrotinib: 400 mg po QD, Q3W Chemotherapy regimen is chosen from the following: Vinorelbine, Gemcitabine, taxanes or Eribulin monotherapy
223744484|NCT01334203|DRUG|Ranolazine|"Subjects will be randomized to either ranolazine 500 mg twice daily up-titrated on Day 4 to 1000 mg administered orally twice a day or matching placebo for the 12 week treatment period.~Subjects receiving diltiazem or verapamil as their concomitant antianginal medication will receive ranolazine 500 mg or placebo administered orally twice a day."
224162866|NCT03007628|DEVICE|Magpro X100|In addition to treatment as usual (TAU), participants are supposed to receive ten sessions of MST in four weeks, with three sessions per week in the first two weeks and two sessions per week in the following two weeks.
224162867|NCT03007628|DEVICE|ThymatronSystem Ⅳ Electroconvulsive System|In addition to treatment as usual (TAU), participants are supposed to receive ten sessions of modified ECT in four weeks, with three sessions per week in the first two weeks and two sessions per week in the following two weeks.
224162868|NCT03007628|OTHER|Treatment as usual (TAU)|Participants will engage in their intpatient treatment program as-usual.
224162869|NCT04023344|DRUG|Humalog Mix25|Subcutaneus injections Humalog® Mix 25 twice daily during 4 weeks of glucose-level based dose titration, 24 weeks of treatment with stable doses
224304765|NCT06322173|DIAGNOSTIC_TEST|NGS Analysis|An analytical pipeline with NGS technology developed in the GENRES study will be used for the identification of infecting microorganisms and the drug resistance they carry. For this purpose, a sequencing method will be identified and adopted that can obtain gene sequences of approximately 75 bp in length and on the Illumina MiSeq platform. Furthermore, IT software and bioinformatics analyzes with specific quality control parameters (pre- and post-alignment of reads) will be identified and adopted in order to develop an IVD system that includes a complete package of sequencing kits and software.
223582980|NCT06981182|OTHER|Faith-placed intervention to promote breast, cervical, bowel, and AAA screening uptake in Black communities.|The intervention includes a two-hour workshop, delivered in person to the entire congregation, that aims to promote the uptake of breast, cervical, bowel, and AAA screening among Black communities in the North East of England, Leeds and Scotland. However, we will only include effectiveness data (i.e., surveys and screening uptake) from those who meet the study eligibility criteria. The intervention will be a peer-led, multidimensional community workshop. It will incorporate multiple components that tackle barriers to screening and that are present in the existing IMCAN and PROCAN-B interventions, if the PICE group believe these are helpful, such as health education about breast, cervical, bowel and AAA screening delivered by a healthcare provider with an opportunity to ask questions, personal testimonials through survivors' stories, as well as members of the community discussing experiences of screening, and utilising community and peer support and religious leaders.
223744485|NCT00853723|DRUG|Parathyroid hormone related protein (1-36)|PTHrP (1-36) 400 micrograms / day administered subcutaneously for 3 months
223744486|NCT00853723|DRUG|Parathyroid hormone related protein(1-36)|PTHrP(1-36)600 micrograms subcutaneously administered daily for 3 months
223744487|NCT00853723|DRUG|Parathyroid hormone (1-34)|PTH(1-34)20 micrograms subcutaneously administered daily for 3 months
223744488|NCT03839212|BEHAVIORAL|HOLA Component 1|At week 1 and week 8 participants will meet individually with Community Health Worker (CHW) for 30 minutes for a manualized social and physical activation session.
224162870|NCT04023344|DRUG|Insulin Lispro Biphasic 25|"Subcutaneus injections Insulin Lispro Biphasic 25 (Geropharm) twice daily during 4 weeks of glucose-level based dose titration, 24 weeks of treatment with stable doses"
224304766|NCT04831463|BEHAVIORAL|Increasising Health Awareness Program for Immigrant Men|The IHAPIM program is a health promotion intervention. The aim of intervention improve health perception and responsibilitiy
224304767|NCT03753763|DRUG|Safinamide Methanesulfonate|100 mg (free base)
224304768|NCT03753763|DRUG|Safinamide Methanesulfonate matching placebo|100 mg placebo
224162871|NCT01487863|BIOLOGICAL|sipuleucel-T|Sipuleucel-T is an autologous cell product consisting of antigen presenting cells (APCs) loaded with PA2024, a recombinant fusion protein composed of prostatic acid phosphatase (PAP), linked to granulocyte-macrophage colony-stimulating factor (GM-CSF).
224162872|NCT01487863|DRUG|abiraterone acetate|Abiraterone acetate (1000 mg po QD) was administered in combination with prednisone (5 mg po BID) for a total of 26 weeks.
224162873|NCT00486889|BIOLOGICAL|alglucosidase alfa|Dose: 20 mg/kg every 2 weeks; Route of administration: Intravenous infusion
224162874|NCT00893763|PROCEDURE|Pre-intubation CHX|Oral application of 5 ml CHX gluconate 0.12% solution pre-intubation, and 5 ml CHX gluconate 0.12% solution twice a day following intubation.
224162875|NCT00893763|PROCEDURE|Control|No pre-intubation intervention, 5 ml CHX gluconate 0.12% solution twice a day following intubation
223476600|NCT04105179|DEVICE|Zimmer NexGen LPS-Flex|Patients will be randomly assigned to 1 of 2 devices
223476601|NCT04105179|DEVICE|Smith & Nephew Journey II|Patients will be randomly assigned to 1 of 2 devices
223476602|NCT04440501|DEVICE|Virtual Reality Goggles to provide education a regarding the gluten free diet.|To watch and participate in a virtual reality educational experience regarding the gluten free diet.
223476603|NCT02139540|DRUG|Nitrous Oxide|"Patients will receive either up to 50% nitrous oxide/50% oxygen for 1 hour or placebo (50% nitrogen \[inert\]/50% oxygen) in two separate sessions. Both sessions will be 1 week apart."
223476604|NCT02139540|DRUG|Placebo|50% nitrogen \[inert\]/50% oxygen - otherwise completely identical administration and setup
223476605|NCT02139397|DRUG|DFMO|
223476606|NCT02139397|DRUG|Bortezomib|
223476607|NCT00100906|DRUG|IL-2|Immunotherapy with interleukin-2
223476608|NCT00100906|DRUG|ATRA|
223476609|NCT00349336|DRUG|bevacizumab [Avastin]|7.5mg/kg iv on day 1 of each 3 week cycle
223476610|NCT00349336|DRUG|XELOX|As prescribed
224162876|NCT01310192|DEVICE|Fluourine-18 Fluoromethylcholine PET/CT Imaging|Single-dose Study
224162877|NCT00314054|DRUG|HCV-796|HCV-796 1000mg single dose
224162878|NCT01531686|PROCEDURE|Intraosseous delivery of CT contrast dye|Delivery of CT contrast through intraosseous vascular access at the proximal humerus for CT examination.
224162879|NCT03700086|DEVICE|Disposable negative wound pressure device (PICO)|Application of a disposable negative wound pressure device for surgical site infection prevention.
224162880|NCT03700086|DEVICE|OPsite post-op visible standard sterile dressing|Application of a standard sterile wound dressing.
224162881|NCT05221489|OTHER|listening to lullabies or self-selected music|listening to lullabies for lullaby group and listening to music of their choice among various music for mix music group
224162882|NCT03637894|DIETARY_SUPPLEMENT|Feeding infants with fermented formula milk|Infants enrolled were fed either with fermented formula milk or with standard formula during the first four months of life. Breastfed infants were the reference group.
224162883|NCT03637894|OTHER|Feeding infants with standard formula milk|Infants enrolled were fed either with fermented formula milk or with standard formula during the first four months of life. Breastfed infants were the reference group.
224162884|NCT03637894|OTHER|Breastfeeding infants|Reference group
223476611|NCT00349336|DRUG|bevacizumab [Avastin]|5mg/kg iv on day 1 of each 2 week cycle
223476612|NCT00349336|DRUG|FOLFOX-4|As prescribed
223476613|NCT02125552|PROCEDURE|Ultrasound guidance|The ultrasound machine will be used to guide intravenous line placement in patients randomized to the ultrasound guided intravenous line group
223476614|NCT02125552|PROCEDURE|Traditional intravenous access|Placement by experienced nurse using standard IV techniques
223476615|NCT03524716|BEHAVIORAL|Fitbit and Text Messages|Physical activity tracker wristband and daily text messages delivered to the participants' phones.
223476616|NCT05684341|COMBINATION_PRODUCT|Connected Solution with H2S app which connects with blood glucose meter (BGM)|Combination of the Insultrate titration module software, the H2S app for participants, and the H2S platform for healthcare professionals
223476617|NCT00525837|DRUG|fixed dose varenicline|varenicline 0.5 mg po daily for days 1-3, 0.5 twice daily for days 4-7, 1 mg twice daily thereafter for study duration.
224162885|NCT03317366|DRUG|ARQ 092|Open-label expanded access for ARQ 092 capsules
223476618|NCT00525837|DRUG|varenicline|up to 1 mg twice daily
223476619|NCT03500978|BEHAVIORAL|Peer CBT Intervention|Peer specialist delivery of cognitive behavioral therapy intervention over the phone.
223476620|NCT00049244|DRUG|capecitabine|
223476621|NCT00049244|DRUG|ixabepilone|
223476622|NCT03513016|DRUG|UBX0101|Investigational drug intra-articular injection
223476623|NCT03513016|OTHER|Placebo|Diluent intra-articular injection
223476624|NCT00545025|BIOLOGICAL|Influenza Vaccine GSK1247446A|Single dose, Intramuscular injection
223476625|NCT00545025|BIOLOGICAL|Fluarix™|Single dose, Intramuscular injection
223476626|NCT00617279|DEVICE|GORE PROPATEN Vascular Graft|Arterial Occlusion Bypass
223476627|NCT00617279|PROCEDURE|Disadvantaged Autologous Vein Graft|Arterial Occlusion Bypass
223476628|NCT00709332|DRUG|Norgestimate; Ethinyl Estradiol; Folic acid|
223476629|NCT03880474|BIOLOGICAL|MVA-NP+M1|Trial Vaccine
223476630|NCT03880474|DRUG|Saline|Sodium Chloride Placebo
223476631|NCT00921024|DRUG|CXA-101|intravenous
223476632|NCT00921024|DRUG|Ceftazidime|intravenous
223476633|NCT03328988|PROCEDURE|QLB|bilateral single shot block, placed under ultrasound control between the thoracolumbar fascial structures close to the quadratus lumborum muscle
223476634|NCT03412214|DEVICE|Perfusion index detected by pulse oximeter|Perfusion index detected by pulse oximeter
224162886|NCT04511091|PROCEDURE|VATS lobectomy|VATS lobectomy allows surgeons to carry out exactly the same operation within the chest that is performed by thoracotomy, but it is done through 3-4 small incisions without rib spreading rather than the large incision with rib spreading that a thoracotomy entails. The surgeon gains his view inside the chest from a small video camera inserted through one of the small incisions, and the procedure is carried out with long instruments passed through the other small incisions.
224162887|NCT04453605|OTHER|standard treatments|patients were treated according to the good clinical practice recommended by the international guidelines, and followed a six-month or an yearly calendar of follow-up visits
224162888|NCT04827173|PROCEDURE|transcutaneous medium-frequency alternating current|Patients receive nerve block of right forearm through transcutaneous medium-frequency alternating current
223476635|NCT03412214|DEVICE|AAI|The AEP Monitor/2 (Danmeter A/S, Odense, Denmark), a commercialized system for depth of anesthesia monitoring, extracts the middle latency auditory evoked potentials (MLAEP) from the EEG-signal by using an autoregressive model with an exogenous input adaptive method.
223476636|NCT02028598|DRUG|Treatment 1|An oral single dose administration
223476637|NCT02028598|DRUG|Treatment 2|An oral single dose administration
223476638|NCT02028598|DRUG|Treatment 3|Co-administration of oral single doses
223476639|NCT01749956|RADIATION|Radiation|
223476640|NCT01749956|DRUG|Aflibercept|
223476641|NCT01749956|PROCEDURE|Surgery|Abdominoperineal or low anterior resection with total mesorectal excision, per standard treatment guidelines
223476642|NCT01749956|DRUG|FOLFOX6|
223582981|NCT00755547|OTHER|Aerobic Exercise Training|All sessions will be designed to elicit a certain degree of energy expenditure that will progressively increase throughout the trial. Adolescents randomized to the vigorous activity group will perform interval sessions that ensure an average heart rate between 70 and 85% of maximal heart rate reserve while those randomized will perform aerobic activity between 40 and 50% of heart rate reserve. The goal for the trial will be to expend a minimum of 350 kcal. The type of exercise will depend on the preference of each participant however, during the supervised sessions walking/jogging on a treadmill or outdoors will be used to elicit exercise intensities. The three activity sessions held at the YMCA-YWCA facilities in Winnipeg and be supervised by a trained kinesiologist who will record heart rate and perceived exertion for each session.
223582982|NCT06610552|BEHAVIORAL|Powerly|Powerly is a mental well-being mobile app, in which pregnant women can track their mood and level of stress, and receive personalized psychological modules to increase their mental health and well-being. By integrating evidence-based content and cognitive behavioral techniques with insights from pregnant and postpartum individuals and health professionals, Powerly offers a comprehensive psychological support including reappraisal, mental imagery, gratitude, mindfulness, self-efficacy and behavioral activation exercises.
223744489|NCT03839212|BEHAVIORAL|HOLA Component 2|A CHW led 45 minute (10 minutes of stretching and warm up, followed by 30 minutes of walking with a 5 minute cool down) group walk session of six participants at a time done 3 times a week that utilized interval training that slowly gradually increases in intensity.
224162889|NCT02940197|BEHAVIORAL|MediterrAsian diet|no other description
224162890|NCT01751789|BEHAVIORAL|Linkage|
224304769|NCT01104779|DRUG|Cariprazine|Patients who meet eligibility criteria will be administered a once daily oral dose of cariprazine for six weeks. Upon completion of the study or early termination, patients will undergo a two week safety follow-up period.
223476643|NCT02239211|DRUG|BTT1023|IV (in the vein) Investigational Medicinal Product (IMP)
223476644|NCT06661473|DEVICE|Avance Solo Negative Pressure Wound Therapy|Avance Solo NPWT 7-14 days after high-risk revision TKA or THA.
223476645|NCT03434210|OTHER|LAT-treated Community Model|The subjects in experimental group is on 'LAT-treated Community Model'. which means,beside care as usual, subjects will be treated by paliperidone palmitate, Psychiatrists will guide community mental health professinals about the treatment and management. Psychiatrists will give community mental health professinals and patients/ caregiver long acting injection related education information.
223476646|NCT03434210|OTHER|care as usual|Control group will get usual community care, the treatment is identified by doctors, patients and care-giver as usual.
223476647|NCT03415178|DRUG|Alirocumab SAR236553|Pharmaceutical form: Solution for injection Route of administration: Subcutaneous
223744490|NCT03839212|BEHAVIORAL|HOLA Component 3|A CHW led pleasant event discussion, asking each participant to identify a pleasant event. This task is done in conjunction with the cool down of HOLA 2.
223476648|NCT03415178|DEVICE|Current auto-injector device (AI)|"Pharmaceutical form:~Route of administration: Subcutaneous self-administration of alirocumab"
223476649|NCT03415178|DEVICE|New auto-injector device (SYDNEY)|"Pharmaceutical form:~Route of administration: Subcutaneous self-administration of alirocumab"
223476650|NCT03415178|DRUG|Atorvastatin|Pharmaceutical form:tablet Route of administration: oral
223476651|NCT03415178|DRUG|Rosuvastatin|Pharmaceutical form:tablet Route of administration: oral
223476652|NCT00523432|DRUG|Topotecan|Weekly doses via IV infusion. Dose will be assigned based on time of study entry.
223476653|NCT00523432|DRUG|CCI-779 (temsirolimus)|Weekly 25mg dose via IV infusion.
223476654|NCT03062371|BEHAVIORAL|Playgroup|A semi-structured gathering of caregivers and their children in a community setting developed and implemented by a skilled provider.
223476655|NCT06612658|DIETARY_SUPPLEMENT|A novel, proprietary encapsulated form of Capsicum extract in beadlet form standardized to 2% capsaicinoids|This study will investigate the effect of the supplement on exercise performance.
223476656|NCT01138020|BEHAVIORAL|Cognitive Intervention|Cognitive rehabilitation treatment designed specifically to address the most common cognitive complaints in executive and memory function
223476657|NCT01138020|BEHAVIORAL|Educational intervention|Educational intervention is geared at personal management of TBI-related symptoms.
223476658|NCT02471573|PROCEDURE|Freeze-all protocol|Embryos are selected for cryopreservation using vitrification technique. Two vitrified embryos will be warmed and transferred in subsequent cycle.
224162891|NCT01751789|OTHER|Treatment as Usual|
224162892|NCT05076552|DRUG|TACH101|Orally via capsules
224162893|NCT05013099|BIOLOGICAL|zirconium Zr 89 crefmirlimab berdoxam|Up to three zirconium Zr 89 crefmirlimab berdoxam PET scans (up to 1.0 mCi ± 20% at 1.5 mg API per scan, for a total of up to 3.0 mCi ± 20% and 4.5 mg API) as an IV infusion or slow bolus injection as follows: First (PETbaseline) within 14 days prior to the onset of IOT, and a second (PETEOC1) 4 to 6 weeks after start of immunotherapy. The second zirconium Zr 89 crefmirlimab berdoxam administration and scan (PETEOC1) should be completed prior to the start of the third cycle of IOT. Subjects who are determined by the treating physician to have PD on immunotherapy can receive the optional third zirconium Zr 89 crefmirlimab berdoxam PET scan at the principal investigator's (PI's) discretion.
224162894|NCT01512693|DRUG|MK-0822|A single oral dose (50 mg tablet) of MK 0822 will be administered on Day 1 after an overnight fast.
223476659|NCT02471573|PROCEDURE|Fresh transfer protocol|Two embryos are selected and transferred fresh in the same cycle.
223476660|NCT04258072|DRUG|Vactosertib|Vactosertib: 50-mg white round film-coated tablets containing excipients (lactose monohydrate Fastflo 316, microcrystalline cellulose Avicel PH 102, crospovidone Kollidon CL-F, povidone Kollidon 30, magnesium stearate, opadry white) and active pharmaceutical ingredient (N-((4-(\[1,2,4\]triazolo\[1,5-a\]pyridin-6-yl)-5-(6-methylpyridin-2-yl)-1H-imidazol-2-yl)methyl)-2-fluoroaniline), 10% (w/w) of total weight
223744491|NCT03839212|BEHAVIORAL|HOLA Component 4|One booster walking session twice a month for three months post intervention for reinforcement.
223582983|NCT07041086|PROCEDURE|Extracorporeal membrane oxygenation (ECMO)|In extracorporeal membrane oxygenation (ECMO), blood is pumped outside of the body to a heart-lung machine. The machine removes carbon dioxide and sends oxygen-rich blood back to the body. Blood flows from the right side of the heart to the heart-lung machine. It's then rewarmed and sent back to the body.
223582984|NCT04284813|BEHAVIORAL|CRAFT-FT|CRAFT-FT will be delivered via telemedicine. Topics include building motivation, self-care, communication, understanding patterns of behavior, positive reinforcement, and negative consequences. The intervention will be tailored to families of individuals experiencing psychosis and substance use who are enrolled in first episode psychosis outpatient services. Participants will be asked to completed assessments at pre-treatment, mid-treatment (approximately week 3), post-treatment, and a follow-up assessment approximately 3 month post-treatment.
223582985|NCT05211401|DRUG|Active arm 1000 mg|Active arm 1000 mg: 1 bag containing 1000 mg of rituximab\* in 500 ml of NaCl 0.9% \* Mabthera® and all registered biosimilars are likely to be used in this trial
223582986|NCT05211401|DRUG|Placebo arm|Placebo arm: 1 bag of 500 ml of NaCl 0.9%
223582987|NCT02181478|DRUG|cyclophosphamide|All patients will receive a single IV dose of 50 mg/kg of cyclophosphamide on day -6
223744492|NCT01983358|DRUG|JPI-289|PARP-1 inhibitor
223744493|NCT01983358|OTHER|Placebo|Placebo
223744494|NCT00739037|DRUG|Placebo|
224162895|NCT00065715|DIETARY_SUPPLEMENT|Echinacea|Echinacea phytochemical profile Each tablet is comprised of the equivalent of 1275 mg of echinacea root, as follows: A) Echinacea purpurea - 675 mg root yields 112.5 mg dried extract, standardized to contain 2.1mg alkamides. B) Echinacea angustifolia - 600 mg root yields 150 mg dried extract, standardized to contain 2.0 mg alkamides. Each batch of tablets is analyzed by Reversed Phase - High Peformance Liquid Chromatography to determine the levels of alkamides and caffeic derivatives present. Caffeic acid derivative levels are typically as follows: caftaric acid = 0.5 to 2.0 mg/tablet; cichoric acid = 3.4 to 8.5 mg/tablet; chlorogenic acid = \< 0.5 mg/tablet; dicaffeoyl quinic acids (including cynarin) = 0.7 to 2.0 mg/tablet; echinacoside = 1.0 to 1.7 mg/tablet
223476661|NCT03150459|DRUG|Simvastatin 20 mg|Simvastatin 20 mg/day for 12 weeks (Group 1)
223476662|NCT03150459|DRUG|Simvastatin 40mg|Simvastatin 40 mg/day for 12 weeks (Group 2)
223476663|NCT03150459|DRUG|Rifaximin 400 mg|Rifaximin 400 mg/8 hours for 12 weeks (Group 1 and 2)
223476664|NCT03150459|OTHER|Placebo of Simvastatin|Placebo of Simvastatin for 12 weeks (Group 3)
223744495|NCT00739037|DRUG|PAZ-417|
223744496|NCT00482235|DRUG|MK0359|
223744497|NCT01809873|BEHAVIORAL|Performance based incentives|Facilities enrolled in the intervention arm will receive a financial incentive that is based on their diagnosis and prescription practices for malaria over that quarter. The intervention will last 12 months.
223744498|NCT01650038|OTHER|treatment with faecal transplantation (donor faeces)|faecal transplantation
224162896|NCT00065715|OTHER|Blinded placebo|Blinded placebo - Coated tablet
224162897|NCT04326881|DRUG|SHR-1314|single dosing
224162898|NCT01975376|DRUG|bococizumab (PF-04950615)|150 mg, every 2 weeks, subcutaneous. The duration of the treatment period will depend upon reaching the targeted number of adjudicated and confirmed CV outcome events, approximately 3 to 4 years after the entry of first subject into the study.
223476665|NCT03150459|OTHER|Placebo of Rifaximin|Placebo of Rifaximin for 12 weeks (Group 3)
223476666|NCT01872962|DRUG|gemcitabine and cisplatin (Induction chemotherapy)|Patients receive gemcitabine (1000 mg/m² d1,8) and cisplatin (80mg/m² d1) every 3 weeks for 3 cycles before concurrent chemoradiotherapy.
223476667|NCT01872962|RADIATION|IMRT and concurrent cisplatin|Intensity modulated-radiotherapy (IMRT) is given as 2.0-2.30 Gy per fraction with five daily fractions per week for 6-7 weeks to a total dose of 66 Gy or greater to the primary tumor, concurrently with cisplatin 100 mg/m² every 3 weeks for 3 cycles.
223582988|NCT02181478|DRUG|fludarabine phosphate|Given by IV during prep at 40mg/m2 for 5 days
223582989|NCT02181478|RADIATION|total-body irradiation|Undergo single fraction of reduced intensity conditioning (RIC) regimen of 200 cGy TBI without shielding on day -1
223582990|NCT02181478|DRUG|cyclosporine|Initiated in patients on the day -5. Cyclosporine will be administered orally or intravenously at 2 mg/kg/dose every 12 hours for 2-hour period. Cyclosporine will continue until day +100
223744499|NCT01650038|OTHER|treatment with faecal transplantation (own faeces)|faecal transplantation
223744500|NCT02280564|BEHAVIORAL|health coaching with technology support|Intensive behavior change support. Engaging participants to take an active role in their diabetes care using motivational interviewing, technology, family communication, problem solving skills.
223744501|NCT04562285|DIAGNOSTIC_TEST|Serologic immunoassays to SARS-CoV-2 antibodies|Detect and characterize antibodies to SARS-CoV-2
223744502|NCT00445965|GENETIC|DNA analysis|
223744503|NCT00445965|OTHER|immunologic technique|
223744504|NCT00445965|OTHER|pharmacological study|
223744505|NCT00445965|RADIATION|iodine I 131 monoclonal antibody 3F8|
223744506|NCT00445965|RADIATION|131I-3F8|Patients will receive 10mCi intrathecal 131I-3F8 per week. Patients will be pre-medicated with dexamethasone to prevent possible meningeal inflammatory reaction, Liothyronine and SSKI to prevent thyroid accumulation, and acetaminophen and diphenhydramine in anticipation of possible allergic reaction and fever.
224162899|NCT01975376|DRUG|Placebo|Placebo comparator, every 2 weeks, subcutaneous. The duration of the treatment period will depend upon reaching the targeted number of adjudicated and confirmed CV outcome events, approximately 3 to 4 years after the entry of first subject into the study.
224162900|NCT01816542|OTHER|patch tests on healthy skin|Patches will be placed on healthy skin.
223476668|NCT07045584|DEVICE|Transcranial Alternating Current Stimulation|Intervention Group（tACS）: Receive tACS stimulation targeting the temporal pole, with stimulation frequency of 40Hz, using adapter power supply: voltage 9V, current set at 1.5mA, 6 times/day, 20min/session with 20min intervals between sessions, lasting for 5 days;
223476669|NCT07045584|DEVICE|transcranial Temporal Interference Stimulation|Intervention Group（tTIS）: Receive tTIS targeting the temporal pole, with stimulation frequency of 2040/2000HZ, using battery power supply: voltage 12V, current set at 1.5mA, 6 times/day, 20min/session with 20min intervals between sessions, lasting for 5 days;
223582991|NCT02181478|DRUG|mycophenolate mofetil|Given at 1g intravenously or orally twice daily from day -5 to +100, or as clinically indicated.
223582992|NCT02181478|PROCEDURE|umbilical cord blood transplantation|Following RIC, on day T+0, dimethylsulphoxide will be removed from the cord blood cells and given as transplant.
223582993|NCT02181478|PROCEDURE|mesenchymal stem cell transplantation|The total dosage of hMSC will be 2x10\^6cells/kg (+/-20%).
223582994|NCT05256420|DEVICE|Kinesiotape|Application of a kinesiotape bandage on the knee.
223582995|NCT05256420|DEVICE|Sham Bandage|Application of a sham bandage on the knee.
223582996|NCT06902662|DIETARY_SUPPLEMENT|SS-MN4|Participants in the SS-MN4 group will take 2 capsules daily containing a total of 1000 mg/day of Sanghuangporus sanghuang mycelia extract for 42 consecutive days. The capsules are identical in appearance to the placebo.
223582997|NCT06902662|DIETARY_SUPPLEMENT|Placebo|Participants in the placebo group will take 2 capsules daily of an inert substance designed to match the SS-MN4 capsules in color, taste, and appearance. The placebo contains no active ingredients and will be taken for 42 consecutive days.
223582998|NCT00114920|DRUG|Resiquimod|
223582999|NCT00431951|DRUG|ST-246|250 mg, 400 mg or 800 mg capsules given once daily for 21 days
223583000|NCT00431951|DRUG|Placebo|Capsules to match experimental drug
223583001|NCT05187754|OTHER|Mindfulness-based breathing therapy program|Participant caregivers of palliative patients were randomized into the intervention and the control groups. Prior to randomization, participants and nurses were informed online abut the aim of the research and their written consent was obtained. Once the study ended, mindfulness-based breathing therapy were recommended to the patients in the control group. Data were collected online via Google forms survey and the interviews were conducted online via Zoom.
223583002|NCT01146288|DRUG|Furosemide first, then Acetazolamide|Two renal function studies will be performed: one before and after intravenous furosemide and the second before and after intravenous acetazolamide. Subjects will receive 300 mg of lithium carbonate at 22.00 the day before the renal function tests. A priming dose of inulin (50 mg/kg) and p-aminohippuric acid (8 mg/kg) will be administered and a 200-300 ml p.o water load will be given. Thereafter, inulin and p-aminohippuric acid will be infused continuously. After the first 60 minutes, 8 accurately timed urine collections of 30 to 40 minutes will be obtained by spontaneous voiding. After the first 4 timed urine collections, participants will receive intravenous furosemide 2 mg/5min or intravenous acetazolamide 5 mg/kg/5 min.Four other times urine collections will be performed thereafter.
223583003|NCT01146288|DRUG|Acetazolamide first, then Furosemide|Two renal function studies will be performed: one before and after intravenous acetazolamide and the second before and after intravenous furosemide. Subjects will receive 300 mg of lithium carbonate at 22.00 the day before the renal function tests.A priming dose of inulin (50 mg/kg) and p-aminohippuric acid (8 mg/kg) will be administered and a 200-300 ml p.o water load will be given. Thereafter, inulin and p-aminohippuric acid will be infused continuously. After the first 60 minutes, 8 accurately timed urine collections of 30 to 40 minutes will be obtained by spontaneous voiding. After the first 4 timed urine collections, participants will receive intravenous furosemide 2 mg/5min or intravenous acetazolamide 5 mg/kg/5 min.Four other times urine collections will be performed thereafter.
223583004|NCT00385723|DIETARY_SUPPLEMENT|Omega 3 (Fish Oil) Supplementation|1.25 g or 2.496 g daily for 4 months
224070156|NCT03164382|DRUG|FOLFOX regimen|Firstly, the femoral artery was percutaneously punctured using the Seldinger technique. Then, the catheter was inserted into the celiac trunk or superior mesenteric artery for arteriography. When more than one feeding artery of HCC was detected, the smaller arteries were embolized with gelatin sponge particles. A micro-catheter was inserted through the arterial catheter located at the common hepatic artery or proper hepatic arterial branch (feeding artery). When blood flows into the gastroduodenal artery was confirmed by micro-catheter angiography, the route was embolized with a coil or micro-coil to prevent reflux of chemotherapeutic drugs to the stomach and duodenum. The peripheral part of the catheter that was exposed to the outside of the body was covered with medical sterile gauze and fastened on the thigh's skin using medical rubberized fabric and bandage. Catheter insertion was repeatedly performed before every cycle of treatment.
223583005|NCT00385723|DIETARY_SUPPLEMENT|Placebo|matching placebo capsule daily for 4 months
223583006|NCT01547312|DRUG|Peg-Interferon|Polyethyleneglycolated Interferon alfa-2b at 1.5 ug/kg/week, administered subcutaneously, once a week, over the entire course of the study.
223583007|NCT01547312|PROCEDURE|Liver Samples from FNA|Tissue samples are collected at 3 separate visits, with each collection consisting of 3-4 fine needle aspiration (FNA) passes through the liver, guided by ultrasound.
223583008|NCT01547312|PROCEDURE|Liver Samples from CNB|Tissue samples are collected at 1 of six possible visits by core needle biopsy (CNB) of the liver.
224162901|NCT06403358|DIETARY_SUPPLEMENT|YOVIS BIMBI|42 male and female subjects, aged between 3 and 14 years with acute diarrhea will be treated with Yovis BAMBINI. The 42 subjects will be recruited with a competitive enrolment at the involved study sites.
223476670|NCT02377869|OTHER|No intervantion|
223476671|NCT05418803|DRUG|YHP1807 Tab. 2.5mg|Rivaroxaban 2.5mg
223476672|NCT05418803|DRUG|YHR1901 Tab. 2.5mg|Rivaroxaban 2.5mg
223476673|NCT03416348|DRUG|Aluminum Chloride 20% (deodorant)|Aluminum Chloride (deodorant)
223476674|NCT03416348|DRUG|Alcohol|Placebo
223476675|NCT00168948|DRUG|Sulfadoxin (12.5) Pyrimethamine (250 mg)|
223476676|NCT02394769|DRUG|Aspirin|
223476677|NCT02394769|DRUG|Placebo for Aspirin|
223583009|NCT01547312|PROCEDURE|Blood Samples|Blood is collected from multiple blood draws, with the total volume for each participant not expected to exceed 500 ml.
223583010|NCT01547312|DRUG|Ribavirin|Ribavirin, 600-1400 mg administered orally, twice daily, over the entire course of the study.
223583011|NCT01547312|DRUG|800 mg Grazoprevir|800 mg Grazoprevir administered orally, once per day, for 7 consecutive days.
223476678|NCT04630184|BEHAVIORAL|Exposure intervention in virtual reality|6 sessions of 45 minutes weekly and 2 follow-up meetings (3 and 6 weeks after the weekly follow-up) with cognitive restructuring and VR exposure supervised by psychologists
223476679|NCT04630184|BEHAVIORAL|Exercise|Participants will have to go twice a week, for 12 weeks to carry out 2 individual endurance training sessions of 45 minutes (moderate to vigorous intensity), supervised by a kinesiologist. Participants will also have to complete a 3rd 60-minute endurance session at home (or two 30-minute sessions).
223476680|NCT04630184|BEHAVIORAL|Placebo|6 sessions of 45 minutes weekly and 2 follow-up meetings (3 and 6 weeks after the weekly follow-up) Discussion around social physical anxiety, stress management (relaxation and breathing) supervised by psychologists
223476681|NCT04245969|DEVICE|Experimental: 448 kilohertz Capacitive Resistive Monopolar Radiofrequency stimulus|448kilohertz capacitive resistive monopolar radiofrequency will be applied on the shoulder and thoracic area
223476682|NCT04245969|OTHER|Sham comparator|A simulation of 448kilohertz capacitive resistive monopolar radiofrequency will be carried out to make believe the patient to be treated through this equipment.
223476683|NCT04245969|OTHER|No intervention|These participants will be assessed at the same time than the rest of participants. They will not receive any kind of treatment.
223476684|NCT03539094|OTHER|Intermittent fasting|the subjects randomized to this group will do IF by restricting their diet and consuming few calories two days per week. During the days of fasting, subjects will be allowed to drink water, calorie-free beverages, and eat fresh, steamed or roasted non-starchy vegetables.
223476685|NCT01662544|PROCEDURE|Oxygen delivery|
224070157|NCT03164382|DRUG|Sorafenib 200Mg Tab|Sorafenib will be administered orally at the starting dose of 400 mg twice daily (800 mg total daily dose) to patients randomized to Arm S in accordance to its package insert or equivalent documentation. The 400 mg dose will be achieved by administration of 2 x 200 mg film-coated tablets, administered twice daily.
224070158|NCT03833830|DIAGNOSTIC_TEST|Optical Coherence Tomography angiography (OCTA)|There will be an OCTA measurement (observational study) for both groups. Group allocation will be made due to previous anti-VEGF treatments (longterm treatment group \>20 injections and shortterm treatment group \< 5 injections).
224070159|NCT00215384|DRUG|Formoterol Fumarate|
224304770|NCT01104779|DRUG|Placebo|Patients who meet eligibility criteria will be administered a once daily oral dose of placebo for six weeks. Upon completion of the study or early termination, patients will undergo a two week safety follow-up period.
224304771|NCT06309654|BEHAVIORAL|12-week home-based circuit training (HBCT)|Participants in the exercise group performed HBCT three times per week on non-consecutive days for 12 weeks. The first session was conducted at USM Hospital and participants were instructed how to perform the prescribed exercises in a correct form. In each session, participants performed seven exercises (two aerobic- and five resistance-based) in a circuit fashion, using bodyweight movements and adjustable dumbbells for varied weights, activating all the major muscle groups. In weeks 1-6, participants executed 15 repetitions for 2 rounds with 1 min passive rest between exercises and rounds. In weeks 7-12, participants executed 30 repetitions for 4 rounds with the same rest as prescribed in weeks 1-6. Each round lasted 10-15 min and the total session duration was 20-60 min, aiming to help participants adapt gradually to increasing training volume.
224304772|NCT06309654|BEHAVIORAL|Standard of care (CONT)|"Providing education about the nature of OA, its progression, and strategies for symptom management.~Empowering individuals with self-management techniques, such as joint protection strategies, activity modification, and lifestyle changes (e.g., weight management, exercise)."
223476686|NCT04277780|DEVICE|Continuous Glucose Monitoring Sensor|Placement of continuous glucose monitor sensor for 14 days. Instructions on how to peel off the sensor and mail it back to the clinician.
223476687|NCT04277780|OTHER|Diabetes Management Instructions|Instructions on checking fingerstick blood glucose and information on the required equipment including glucose test strips, lancets, and glucometer. Instructions on how to log blood glucose values onto the blood glucose log sheet for 14 days, and how to mail it back to the clinician.
223476688|NCT00001475|DRUG|IL-2 plus Anti-TNF or Thalidomide|
223476689|NCT01866254|DRUG|Hydromorphone|Injection of 100 mcg hydromorphone into the intrathecal space
223476690|NCT01866254|DRUG|Morphine|Injection of 200 mcg of intrathecal morphine
224070160|NCT05168358|PROCEDURE|Overnight Bladder Drainage|Parents or caregivers of the patients will be taught to place an indwelling catheter in the bladder at bedtime for about 8-12 h under a clean technique every night for one year. The catheter will then be allowed to drain freely into a gravity drainage collecting bag or in the diapers. On the next morning, the catheter will be removed and the timed voiding regimen will be resumed.
224070161|NCT04882397|OTHER|Instrument Assisted Soft Tissue Mobilization|Bilateral Instrument assisted soft tissue mobilization application will be applied in a single session to the trapezius and sternocleideomastoideus muscles.
224070162|NCT04882397|OTHER|Sham|Bilateral sham Instrument assisted soft tissue mobilization application will be applied in a single session to the trapezius and sternocleideomastoideus muscles.
224304773|NCT00644449|OTHER|placebo|placebo
223476691|NCT00678457|DRUG|Ondansetron|ondansetron (4 μg/kg b.i.d.)
223476692|NCT00678457|DRUG|Olanzapine|olanzapine (9, 18, and 36 μg/kg)
223476693|NCT00678457|DRUG|Placebo|placebo
223476694|NCT02603133|BEHAVIORAL|Three Good Things|"In this tool participants reflect on good things that happened that day during evenings across 10 days. Participants are also able to voluntarily share their good things and read other participants' good things through the nightly anonymous log. By savoring good moments from earlier that day, participants are thought to shift from the natural focus on what went poorly due to negativity bias1 to an appreciation for what went well. This shift in focus is thought to reduce rumination and depression symptoms. In prior research, 3GTs was found to increase happiness and decrease depression in internet participants.2 In prior cohorts of 3GTs, we saw improvements in burnout, depression symptoms, work-life balance, and happiness. Participants also report benefiting from viewing nightly Three Good Things logs of others."
223476695|NCT02603133|BEHAVIORAL|Gratitude|In this tool participants are offered the opportunity to cultivate gratitude toward others through a guided gratitude letter writing exercise.2 Through expressing gratitude, we learn more about our vital connections to others, often in surprising and meaningful ways. Previous research has found that gratitude interventions increase well-being in a number of ways, particularly in boosting positive affect.
224162902|NCT05257915|DRUG|Perampanel|"For patients ≥12 years old, the initial dose is 2 mg/d, and according to the clinical response and tolerance of the patient, the dose is increased to the minimum clinically effective dose in increments of 2 mg, and the interval between dose increases is not less than 2 weeks.~For patients \<12 years, according to the actual clinical situation, the initial dose and addition plan are judged by the investigator."
223476696|NCT02603133|BEHAVIORAL|Random Acts of Kindess|In this tool, participants report kind acts that they have committed, received, and/or witnessed, each day. By committing random acts of kindness participants experience a boost of positive emotions, and report lower negative affect. Recipients of acts of kindness benefit as well.
223476697|NCT02603133|BEHAVIORAL|Awe|This tool provides participants the opportunity to recount in detail one of their own experiences of awe, and encourages them to be on the lookout for new ones (even minor examples) over a few days. When we experience awe, our sense of time expands, we are kinder to others, we experience higher life satisfaction, and we prefer experiences over material things.
223476698|NCT02603133|BEHAVIORAL|1 Good Chat|This tool uses the latest research on cultivating relationships and increasing social connection. Feeling socially connected is linked to health and well-being outcomes, including longevity.6 The 1 Good Chat tool asks participants to reflect on good conversations and to note the prosocial behaviors that he/she and the other person engaged in
223476699|NCT00502437|DRUG|GRANISETRON|
223476700|NCT00303043|PROCEDURE|Mixed venous saturation monitoring|Mixed venous saturation monitoring
223476701|NCT00592111|DRUG|COPP/ABV|4 courses of COPP/ABV hybrid
223476702|NCT00592111|DRUG|COPP/ABV|6 courses of COPP/ABV hybrid
223476703|NCT00592111|DRUG|intensive chemo with concurrent growth factor|6 cycles (2 courses) of intensive chemotherapy with concurrent growth factor
223476704|NCT04081181|PROCEDURE|Microwave ablation|CT\_guided Microwave ablation is a minimally invasive technique that kill the insitu lung cancer cells, produce large volumes of cellular necrosis with reduced procedure time .According to the preoperative CT image of the patient , we will determine the focal position of the lesion ,it's size and it's relationship with adjacent organs to choose the optimal puncture point , puncture path and proper microwave antenna and to set the power and time of ablation.Then under the guidance of CT , the tip of antenna will be sent into the focus by puncture with ablation power of 60\_80 W .according to tumor size , the ablation time will be determined.Needle track coagulation will be done to prevent seeding of malignant cells. After ablation a CT scan will be done immediately to observe the size ,shape and relation to nearby organ of the lesion and to determine if there is pneumothorax
223583012|NCT01547312|DRUG|100 mg Grazoprevir|100 mg Grazoprevir administered orally, once per day, for 7 consecutive days.
223583013|NCT01547312|PROCEDURE|Liver samples from CNB and FNA|Tissue samples from the liver are collected by CNB as part of standard of care, and also by FNA during a single visit.
224070163|NCT00845442|DEVICE|pacemaker|Placement of pacemaker over the chest wall to stimulate the larynx in the neck via a tunneled electrode
224070164|NCT00170430|DRUG|Fluconazole|
223476705|NCT02441647|DEVICE|KL029 Intimate Lubricant Gel|
223476706|NCT01950702|PROCEDURE|Laryngoscope assisted lightwand intubation|"After standard monitoring(EKG, pulse oximetry, NIBP), participants were induced with remifentanil and propofol continuous infusion, using targe-controlled infusion device with prexoygenation with 100% oxygen.~Manual in-line stabilization was applied with velcro during intubation to maintain neutral head position.~The Macintosh laryngoscope (female: 3rd blade, male: 4th blade) was inserted into the oral cavity to provide direct view of the epiglottis and then the tip of the lightwand was placed below the epiglottis."
223476707|NCT01950702|PROCEDURE|Lightwand intubation|"After standard monitoring(EKG, pulse oximetry, NIBP), participants were induced with remifentanil and propofol continuous infusion, using targe-controlled infusion device with prexoygenation with 100% oxygen.~Manual in-line stabilization was applied with velcro during intubation to maintain neutral head position.~After 2min from administration of rocuronium, the clinician holds the wand similar to a pencil, stands directly behind the patient's head, inserts the device into the side of the mouth and sweeps the tip to the midline. After confirmation of precise location via clear light source on anterior neck, endotracheal tube was inserted and withdrawn lightwand."
223476708|NCT04075175|DRUG|S315|Human monoclonal antibody against Diphtheria Toxin
223476709|NCT04075175|DRUG|0.9% Sodium Chloride (NaCl)|Placebo 0.9% Sodium Chloride (NaCl)
223476710|NCT00068523|BIOLOGICAL|anti-thymocyte globulin|anti-thymocyte globulin IV over 4 hours on days -2 to -1
223476711|NCT00068523|DRUG|cyclophosphamide|cyclophosphamide IV over 1 hour on days -3 to -2
223476712|NCT00068523|DRUG|cyclosporine|oral cyclosporine on days -1 to 100
223583014|NCT01976858|DRUG|PEX168|A injection administered subcutaneously
223583015|NCT03697044|PROCEDURE|Irinotecan Drug-Eluting-Bead Trans Arterial ChemoEmbolisation|Patient Registry to assess the delivery of Irinotecan loaded drug eluting beads for the treatment of colorectal liver cancer metastases.
223583016|NCT01270152|DRUG|Ascorbic Acid|comparing three different doses of ascorbic acid: 50 mg, 100 mg and 200 mg administered inside the catheter and maintained for up to 60 minutes
223583017|NCT00895687|DRUG|Erlotinib Hydrochloride|Beginning dose of 150 mg taken by mouth daily for 21-day cycle.
223583018|NCT00895687|DRUG|Bortezomib|Beginning dose of 1. mg/m\^2 by vein over about 1-5 minutes on Days 1, 4, 8, and 11 of each 21-day cycle.
223583019|NCT05109260|DIAGNOSTIC_TEST|Point-of-Care Immunoassay device|2 POC Immunoassay devices will be used. One will measure D-dimer levels in capillary blood, the other will measure venous.
223583020|NCT03545997|DRUG|Montelukast 10mg|The capsules will be presented in box of 95 capsules packaged in unit blister
223583021|NCT03545997|DRUG|Placebo|Mannitol 350mg The capsules will be presented in box of 95 capsules packaged in unit blister
223583022|NCT03793491|OTHER|TCI scale|TCI scale : Evaluation of the patient's personality with the TCI before that the treatment by continuous infusion started.
223583023|NCT03793491|OTHER|PDQ-39 scale|PDQ-39 scale: Comparison of life quality before and after the starting of he treatment by continuous infusion.
223583024|NCT02990507|OTHER|AVEED: Arm rotation, video display|Participants rotate arm cranks for 5 minutes then rest for 5 minutes.
224070165|NCT00170430|DRUG|Metronizadole|
224070166|NCT02005757|DRUG|Bredinin tablet 150mg|Bredinin 150mg qd vs Bredinin 50mg tid
224070167|NCT02005757|DRUG|Bredinin tablet 50mg|Bredinin 150mg qd vs Bredinin 50mg tid
224304774|NCT00644449|DRUG|azithromycin SR (Zithromax; compound: CP-62,993)|azithromycin 2.0 g by mouth in the form of a slurry for 1 dose
223476713|NCT00068523|DRUG|fludarabine phosphate|fludarabine IV over 30 minutes on days -8 to -4
223476714|NCT00068523|DRUG|methylprednisolone|methylprednisolone (oral or IV) on days 5-15
223583025|NCT02990507|OTHER|AVEED: Arm rotation, without video display|Participants rotate arm cranks for 5 minutes then rest for 5 minutes.
223583026|NCT02990507|OTHER|AVEED: Leg rotation, arm-energy input, video display|Participants rotate leg cranks for 5 minutes then rest for 5 minutes.
223583027|NCT02990507|OTHER|AVEED: Leg rotation, arm-energy input, without video display|Participants rotate leg cranks for 5 minutes then rest for 5 minutes.
223744507|NCT05667038|DRUG|Probiotic|"The probiotics sachet contains a granular powder with 6 microorganism strains (30 × 109 CFU/gram): Lactobacillus acidophilus BCMC®12130, Lactobacillus casei subsp BCMC®12313, Lactobacillus lactis BCMC®12451, Bifidobacterium bifidum BCMC®02290, Bifidobacterium infantis BCMC®02129, and Bifidobacterium longum BCMC®02120.~The drug is consumed orally, two sachets per day, by dissolving the sachet content in a glass of room-temperature water, one before breakfast and one before the last meal, for three months length."
223583028|NCT01221194|BEHAVIORAL|Standard therapy|Standard therapy consisting of education, regular foot care and protective shoes and insoles. The standard therapy group will use the stockings they normally wear.
223583029|NCT01221194|DEVICE|PFC Stockings|A pressure and friction reducing stocking. The novelty of the PFC Sock stems from its innovative double layer structure and technological fibre composition. These simultaneously and significantly reduce both pressure and friction in a format that is practical for everyday wear with therapeutic shoes in high-risk cases.
223744508|NCT05667038|DIETARY_SUPPLEMENT|Placebo|"Placebo:~Subjects in the placebo group will receive the placebo consisting of only the carrier of the probiotic product, that is maize starch and maltodextrins.~The sachet is consumed orally, two sachets per day, by dissolving the sachet content in a glass of room-temperature water, one before breakfast and one before the last meal, for three months length."
224162903|NCT05859581|PROCEDURE|Beyond complete mesocolic excision surgery|If the participants were diagnosed with positive retroperitoneal resection margin (RPRM), they underwent beyond complete mesocolic excision surgery to ensure the R0 resection.
224162904|NCT00491751|DRUG|atorvastatin|atorvastatin 40 or 80 mg/day
224162905|NCT00491751|DRUG|ascorbic acid|ascorbic acid 500 mg/day
223476715|NCT00068523|PROCEDURE|UV light therapy|Patients undergo ultraviolet-B (UVB) light therapy every other day between days -10 and -2 for a total of 3 days. Posttransplantation UVB light therapy: Following PBSC transplantation, patients undergo UVB light therapy twice weekly on week 1 (at least 1 day apart) and three times weekly on weeks 2-4.
223476716|NCT00068523|PROCEDURE|allogeneic bone marrow transplantation|
223476717|NCT00068523|PROCEDURE|peripheral blood stem cell transplantation|Allogeneic peripheral blood stem cell (PBSC) transplantation: Patients undergo PBSC transplantation on day 0.
223744509|NCT03309358|DRUG|Inhaled SNSP113|A single ascending dose of inhaled SNSP113 will be administered to healthy subjects and subjects with stable cystic fibrosis.
223744510|NCT03309358|DRUG|Inhaled Placebo|A single dose of inhaled placebo control will be administered to healthy subjects and subjects with stable cystic fibrosis.
223476718|NCT04538105|OTHER|Control|Saline Articular Nerve Branch Block
223476719|NCT04538105|OTHER|Articular Branch Block (ABB)|0.5% Bupivacaine with epinephrine 1:200,000 (Articular Branch Block)
223583030|NCT04533230|BEHAVIORAL|Educational intervention with prescription feedback|Educational intervention and targeted feedback on prescription of benzodiazepines and benzodiazepine-like hypnotics
223583031|NCT04533230|BEHAVIORAL|Information on treatment guidelines|Written information on treatment guidelines.
223744511|NCT02950077|BEHAVIORAL|mindfulness based stress reduction|The intervention will be delivered in a group setting and the group will meet for 2 hours once per week for 8 weeks. The intervention is based on new neuroscience of stress and resilient adaptive behaviors, mindfulness based stress reduction, therapeutic breath and synchronized yogic movement with a focus on the lower abdomen, integrated with cognitive and behavioral strategies for self-control and healthy decision making.
223744512|NCT05552872|DIAGNOSTIC_TEST|mNGS, IDSeq UltraTM|pathogen detection
224162906|NCT00491751|DRUG|Placebo|matching placebo
224162907|NCT00000199|DRUG|Piracetam|
224162908|NCT03225651|BIOLOGICAL|Stem cell transplantation|Transplantation of Autologous Bone Marrow Mononuclear cells
224162909|NCT03225651|BEHAVIORAL|Psychological therapy and Rehabilitation|Psychological Therapy and Rehabilitation for autism children around 3 months
224162910|NCT04731922|DRUG|TAK-510|TAK-510 solution.
224162911|NCT04731922|DRUG|TAK-510 Placebo|TAK-510 placebo-matching solution.
224162912|NCT05345938|DRUG|Mitoxantrone Hydrochloride Liposome|Intravenous injection (IV), on day 1 of each 28-day cycle (q4w)
224162913|NCT02339441|DRUG|Methotrexate|Immunosuppressant agent. Patients treated with Methotrexate at the entry of the study, either oral or subcutaneous with a target dose of 20-25mg weekly.
224162914|NCT02339441|DRUG|Mycophenolate mofetil|Immunosuppressant agent. Patients treated with Methotrexate at the entry of the study,recommended dose 500 mg twice daily for 2 weeks increasing to 1gm twice daily.
224162915|NCT02339441|DRUG|Cyclophosphamide|Immunosuppressant agent. Patients treated with Methotrexate at the entry of the study, recommend use (i) IV. Minimum monthly dose 500mg/m2 with a recommended duration of 6-12 months. (ii) Oral. 1-2mg/day with a recommended duration of 12 months.
224162916|NCT02564068|DRUG|Oxytocin|"To test that intranasal oxytocin administration blunts the deleterious hypoxia/hypercapnia induced changes in heart rate that occur during nocturnal apnea in patients with OSA, we will examine the changes in heart rate in a group of patients that have recently been diagnosed with OSA. 8 subjects that have recently undergone a standard in the sleep-lab diagnostic polysomnography (per standard of care medical guidelines, and not for research purposes) and have been diagnosed with OSA will be recruited into a study to assess the beneficial effects of oxytocin treatment."
224304775|NCT00644449|OTHER|placebo|placebo
224304776|NCT00644449|DRUG|levofloxacin|500 mg (two 250 mg capsules) by mouth once daily for 7 days
224304777|NCT03632967|DEVICE|Tricinch Coil System Implantation|Patients enrolled in this study with all eligibility criteria confirmed will be implanted with the TriCinch Coil System. This device offers a percutaneous treatment (access through the vein at the groin) to treat the leaking tricuspid valve.
223476720|NCT02936999|DRUG|Cholecalciferol|Cholecalciferol 100,000 IU followed by 4000 IU orally once daily for 30 days.
223476721|NCT00753519|DEVICE|Real iTBS|Real iTBS was performed in 8 sessions over 2 successive weeks, a session/day for 4 consecutive days/week.
223476722|NCT00753519|DEVICE|Sham iTBS|Sham iTBS was performed in 8 sessions over 2 successive weeks, a session/day for 4 consecutive days/week.
223476723|NCT06197490|BIOLOGICAL|Evaluation of the parameters of the lithiasis assessment before and after KAFTRIO initiation|Collection of Uricuria, phosphaturie, calciuria, magnesuria, glycosuria, citraturia, oxaluria, before and after initiation of KAFTRIO
223583032|NCT06905444|COMBINATION_PRODUCT|Myofascial Release Technique|"GROUP A (Multimodal Therapy) Group A was treated with multimodal therapy for 30-45 minutes for 2 sessions per week for 6 weeks. Postural education like correct posture and forward head posture exercises like chin tuck in. Patient was sitting on chair. Therapist was standing on side of patient treated part. Strengthening exercises for the deep cervical flexors, shoulder blade stabilizers, and core muscles with 3 Sets of 3 repetitions with hold for 5 seconds of each exercise. Then breathing exercises for 1 minute. Then grade A (pain free range) cervical spine mobilization 1 Set of 3 repetition. During entire treatment session, the therapist kept close eye on patient's discomfort."
223583033|NCT06905444|COMBINATION_PRODUCT|Multimodal Therapy|Group B (Myofascial Release Technique) Group B was treated with multimodal therapy for 30-45 minutes for 2 sessions per week for 6 weeks. Palpate the muscles and fascia to identify areas of restriction. Apply gentle, sustained pressure to the restricted area using the fingertips or knuckles for Fascial Unwinding. Hold the pressure for 3-5 minutes to allow the fascia to release. Encourage the patient to breathe deeply and slowly to promote relaxation. The stretching of tight muscles 1 set of 3 repetitions. Apply gentle, sustained pressure to release tension of these tight muscles, Suboccipital, Scalene, Pectoralis Major, Trapezius, Levator Scapulae
223583034|NCT04763187|PROCEDURE|Tooth extraction|Tooth extraction and alveolus regeneration with autologous blood concentrate.
223744513|NCT00679263|DRUG|MN-221|Initial dose: 16 μg/min for 15 minutes followed by 8 μg/min for 105 minutes (2-hour infusion with a total dose of 1,080 μg)
223744514|NCT00679263|DRUG|MN-221|Subsequent dose: 30 μg/min for 15 minutes followed by 15 μg/min for 45 minutes (1-hr infusion with a total dose of 1,125 μg).
223744515|NCT00679263|DRUG|Placebo|Placebo intravenous infusion with dosing volume equivalent to active treatment.
223744516|NCT02526940|PROCEDURE|rectal biopsies|6 rectal biopsies
223744517|NCT02526940|OTHER|Blood samples|Blood samples
224162917|NCT05018468|DEVICE|Ventilation|Patients in group 1 undergo ventilation with an anatomical facial mask and 100% oxygen for three minutes. Patients in group 2 undergo ventilation with a nasal mask and 100% oxygen for three minutes. In both groups, ventilation will be performed with the controlled mode of the anesthesia machine with a volume of 8 cc/kg and a speed of 12-20/min.
224162918|NCT02738346|DRUG|Carboplatin|Intravenous administration of Carboplatin AUC 5 at Day 1, Every 3 weeks, maximum 6 cycles
224162919|NCT02738346|DRUG|Etoposide|Intravenous administration of 100mg/m²/day of Etoposide, Day 1 to Day 3 Every 3 weeks, maximum 6 cycles
224162920|NCT02738346|DRUG|Topotecan|Per os administration of 2.3 mg / m2 of Topotecan, Day 1 to Day 5 Every 3 weeks, maximum 6 cycles
224162921|NCT02738346|DEVICE|CT scans|The CT scan evaluations will be conducted during chemotherapy every 6 weeks
224304778|NCT05346783|DRUG|TJO-083|Diquafosol ophthalmic sodium solution, 1 drop 3 times a day
223476724|NCT06197490|DRUG|Collection of Arterial pressure, metabolic data, kidney function, proteinuria and hematuria before and after KATRIO initiation|Arterial pressure, glycemia, glycated hemoglobin, lipid profile, weight, serum and urinary electrolytes, hepatic check, complete blood count, calcium phosphate balance and urinary sediment analysis before and after initiation of KAFTRIO
223476725|NCT03625024|BEHAVIORAL|Cognitive-behavioral therapy|Individual cognitive-behavioral therapy, including homework and behavioral change methods.
223476726|NCT04432480|PROCEDURE|NIPE (Newborn Infant Parasympathetic Evaluation) monitoring|Non invasive monitor connected to standard anesthesia monitor (no part of the device in contact with the patient) during anesthesia.
223476727|NCT03342768|OTHER|Smartphone-based messages|"For the TID arm, the messages' contents include the tobacco industry's (TI's) anti-smoking campaigns that made smoking more grown-up and more appealing to youth; the TI's role in smoking in movies; etc.~For the sugar sweetened beverage (SSB) arm, the messages' contents include the disease conditions linked to SSBs, and the interference of sugar industry in scientific research."
223476728|NCT01136590|DRUG|Tranexamic Acid|A 10-mg/kg dose of tranexamic acid will be administered as a bolus or as a fast, 20-minute intravenous infusion before performing the incision at the start of surgery, followed by perfusion of 2 mg/kg/hour up to the time the surgical wound is closed at completion of surgery.
224162922|NCT02291328|OTHER|High Brassica|Participants consume a minimum of one portion of a Brassica food (84g frozen broccoli, 84g frozen cauliflower, or 300g frozen broccoli and sweet potato soup) each day for 14 consecutive days at their homes.
224162923|NCT02291328|OTHER|Low Brassica|Participants consume one portion of a Brassica vegetable (84g frozen broccoli, or 84g frozen cauliflower) each week for two weeks at their homes.
224162924|NCT03696628|OTHER|Electrocardiogram|heart testing
224162925|NCT03696628|OTHER|physical examination|done by the investigator
224162926|NCT03696628|OTHER|echocardiography|heart testing
224162927|NCT03696628|BIOLOGICAL|blood test|A sample of blood will be taken to each patient or healthy children in order to generate hiPSC-cardiomyocytes
224162928|NCT06949995|DEVICE|Active Recovery with Blood Flow Restriction|10-minute active recovery protocol performed with blood flow restriction using a pneumatic cuff set at 60% of the participant's total occlusion pressure.
224162929|NCT06949995|OTHER|Active Recovery|10-minute active recovery protocol.
224162930|NCT04377789|DIETARY_SUPPLEMENT|Quercetin Prophylaxis|a daily dose of quercetin (500mg) will be taken by non-COVID-19 intervention group 1
224304779|NCT05346783|OTHER|Placebo (vehicle)|1 drop 6 times a day
224304780|NCT05346783|DRUG|Diquafosol ophthalmic sodium solution 3%|Diquafosol ophthalmic sodium solution, 1 drop 6 times a day
224304781|NCT00389831|DRUG|Rotigotine Nasal Spray|Daily single dose of 62µg, 124µg, and 247µg rotigotine delivered as single puff of nasal spray solution
224304782|NCT00389831|OTHER|Placebo Nasal Spray|Daily single dose of placebo delivered as single puff of nasal spray solution
224162931|NCT04377789|DIETARY_SUPPLEMENT|Quercetin Treatment|a daily dose of quercetin (1000mg) will be taken by proven COVID-19 cases intervention group 2
224162932|NCT04603274|PROCEDURE|8 sessions of electroacupuncture to the upper limb with carpal tunnel syndrome|All participants will accept 8 sessions of electroacupuncture, 2 days a week for 1 month by experienced physicians. Acupuncture sterile disposable needles 0,25x 0,25 mm will be inserted for 20 minutes at specific acupuncture points to all patients. Electrical stimulation will be applied at specific acupuncture points for 20 minutes.
224162933|NCT00666055|DRUG|ARV regimen chosen by treating physician|"Women may also be naïve to either NNRTI or PIs and initiating their first, second or third HAART regimen (ARVs to be investigated: zidovudine, lamivudine, emtricitabine, abacavir, tenofovir, efavirenz, lopinavir/ritonavir, atazanavir with or without ritonavir).~Provided the ARV regimens contain one or more of the agents under study they may also include new agents such as maraviroc (CCR5 inhibitor), raltegravir (integrase inhibitor) and/or etravirine (NNRTI)."
224162934|NCT01819194|DEVICE|senofilcon A|
224162935|NCT06869577|OTHER|Project SUGRI: A supportive group intervention for caregivers to patients with a glioblastoma|A 12-week supportive group intervention targeted caregivers to patients with glioblastoma.
224162936|NCT01875705|DRUG|GDC-0994|Escalating doses of GDC-0994 until maximum tolerated dose is reached
224162937|NCT01875705|DRUG|GDC-0994|Recommended dose determined in Stage I-Dose Escalation phase, until disease progression
224162938|NCT00247572|DRUG|NRP104|
224162939|NCT01962857|BEHAVIORAL|Exercise|4-week supervised high intensity shuttle running intervention, 3 sessions per week (12 sessions in total)
224162940|NCT02562950|DRUG|GLPG1837 500 mg|Each subject will receive multiple oral daily doses of GLPG1837 (250 mg b.i.d. for 11 days) from Days 2 to 12.
224162941|NCT02562950|DRUG|Midazolam|Each subject will receive a single oral dose of midazolam (2 mg) on 2 occasions (Days 1 and 12).
224162942|NCT02562950|DRUG|GLPG1837 1000 mg|Each subject will receive multiple oral doses of GLPG1837 (500 mg b.i.d. for 11 days) from Days 2 to 12.
224162943|NCT00005969|DRUG|Chemotherapy|
224162944|NCT00005969|DRUG|Tretinoin Liposome|Liposome by vein (IV) over 30 minutes every other day for 28 days
224162945|NCT05059704|OTHER|Circuit Class Training|Station 1 will include tasks for warm-up specific for upper extremity, station 2 will include shoulder exercises, station 3 will include elbow exercises, station 4 will include wrist exercises and station 5 will include hand activities and functional training. Variables such as speed, or/and resistance will progressively increase in diﬃculty according to each patient's ability.
224162946|NCT05059704|OTHER|Individual Task specific training|Variables such as speed, or/and resistance will progressively increase in diﬃculty according to each patient's ability.
224162947|NCT03442504|DIAGNOSTIC_TEST|FES PET/CT|"There will be no premedication or other treatment before and after PET FES. PET / CT will be performed at the center level on a hybrid PET camera.~* The first TEP FES acquisition begins at the time of injection and continues for 30 minutes,~* The second acquisition of 20 minutes takes place 60 minutes after the injection is a total of 50 minutes of imaging and 1:30 in the service."
224304783|NCT03848247|OTHER|Injection of Isotonic saline|Half the participants will be injected in a neck muscle with isotonic saline (Control group) and the other half will get NGF (Neck pain group).
223476729|NCT01136590|DRUG|fisiologic serum|The placebo will be administered according to the same regimen and infusion time as the medication in the study arm (bolus or 20-minute fast infusion before the incision at the beginning of surgery followed by perfusion of 2 mg/kg/hour until closure of the surgical wound at completion of surgery)
223476730|NCT02898467|OTHER|diabetics|additional blood and urine collection during usual medical care endarterectomy samples during usual medical care
223476731|NCT02898467|OTHER|non-diabetics|additional blood and urine collection during usual medical care endarterectomy samples during usual medical care
223476732|NCT03950804|DRUG|Eculizumab Injection|Patients receive eculizumab as deemed necessary by the primary physician
223476733|NCT04734613|BEHAVIORAL|Tai Chi exercise|Yang style Tai Chi 16 movements
223476734|NCT04734613|BEHAVIORAL|self management|health education and dietary counseling
223476735|NCT02820389|PROCEDURE|Optical colonoscopy|Patients with suspected colorectal cancer in this group will undergo Optical Colonoscopy as the initial imaging modality.
223476736|NCT02820389|PROCEDURE|CTC|Patients with suspected colorectal cancer in this group will undergo Computed Tomography Colonography (CTC) as the initial imaging modality. Subsequent imaging might be required based on the findings from the CTC scan, i.e. patients with medium to large polyps or colorectal cancer will undergo Optical Colonoscopy as the second imaging test.
223476737|NCT05649501|OTHER|Proprioceptive neuromuscular facilitation techniques.|Proprioceptive neuromuscular facilitation stretching which include hold-relax and contract-relax for 6 sec hold, 10 repetitions and 2 min rest in between, for 5 day/week for 4 weeks along with conventional treatment for 40 minutes.
223476738|NCT05649501|OTHER|Traditional physical therapy|Conventional therapy (ROMs, stretching, strengthening) of lower limbs for 40 minutes.
223476739|NCT00747877|DRUG|cyclophosphamide|Given orally
224162948|NCT00331955|DRUG|doxorubicin hydrochloride|Given IV
224162949|NCT00331955|DRUG|vorinostat|Given orally
224162950|NCT00331955|OTHER|pharmacological study|Correlative studies
224162951|NCT00331955|OTHER|laboratory biomarker analysis|Correlative studies
224162952|NCT03156855|DRUG|14-day sequential therapy|D1-D7: (esomeprazole 40mg qid + amoxicillin 500mg qid) for 7 days D8-D14: (esomeprazole 40mg qid + clarithromycin 500mg bid + metronidazole 500mg bid) for another 7 days
224162953|NCT03156855|DRUG|Bismuth quadruple therapy|D1-D10: (esomeprazole 40mg bid + dibismuth trioxide 120mg qid + metronidazole 500mg tid + tetracycline 500mg qid) for 10 days
224162954|NCT01586650|OTHER|aerobic training|The intervention comprises fifty minutes of walking at anaerobic threshold plus stretching exercises 3 times a week for 12 weeks.
224162955|NCT01586650|OTHER|Stretching exercises|Global stretching exercises will be performed for about 20 minutes 3 times a week for 12 weeks with supervision of specialized physiotherapists.
224162956|NCT00110123|DRUG|fotemustine|
224162957|NCT00110123|DRUG|isolated perfusion|
224162958|NCT01320813|PROCEDURE|Robot-assisted thyroidectomy|Patients will have a thyroidectomy via a robot-assisted (da Vinci robot) endoscopic (subclavical entry)surgical technique.
224304784|NCT03848247|OTHER|Injection of NGF|Half the participants will be injected in a neck muscle with NGF (Neck pain group).
223476740|NCT00747877|DRUG|melphalan|Given IV
223476741|NCT00747877|PROCEDURE|autologous hematopoietic stem cell transplantation|Patients undergo autologous hematopoietic stem cell transplantation on day 0.
223476742|NCT01008644|OTHER|Water|The subjects will drink tap water for 2 hours, volume calculated according to weight: 20ml/kg/hour.
223476743|NCT01008644|OTHER|Saline 3%|The subjects will receive saline 3% intravenously for 2 hours, the volume calculated as 0.1 ml/kg/min
223476744|NCT02059109|PROCEDURE|Hands on Assembly of Belmont Rapid Infuser|Participants will work individually or in pairs to assemble the Belmont Rapid Infuser in addition to completing the traditional training methods.
224162959|NCT01320813|PROCEDURE|Open thyroidectomy|Patients will have a conventional (non-endoscopic) thyroidectomy using an open surgical technique
224162960|NCT06220552|DRUG|Sintilimab|Sintilimab 200mg D1, Q3W
223476745|NCT02807259|BEHAVIORAL|Multi-level intervention|At the individual level, the intervention will focus on: (i) structured reflection groups for FSWs to enhance self-esteem, encourage critical reflection around gender norms and violence, and build individual and collective efficacy; (ii) separate sessions for intimate partners to discuss issues around violence and condom use as well as gender, equity, respect and responsibility; (iii) skills building around female condoms (iv) access to individual and couples-based counselling. At the community level, the intervention will focus on: (i) strengthening the supportive crisis management systems so that they are able to address 'domestic' as well as 'work-place' violence among FSWs and (ii) building an environment that encourages action against violence from intimate partners by training male champions and developing folk media troops to generate discussion around gender, masculinity, violence and HIV risk behaviours.
223583035|NCT05718037|BIOLOGICAL|Recombinant Zoster Vaccine|0.5mL, Intramuscular
223583036|NCT05718037|BIOLOGICAL|Placebo|0.5mL, Intramuscular
223583037|NCT05718037|BIOLOGICAL|Zoster Vaccine Recombinant, Adjuvanted|0.5mL, Intramuscular
223583038|NCT00005976|DRUG|carboplatin|
223583039|NCT00005976|DRUG|pyrazoloacridine|
223583040|NCT05015790|DEVICE|virtual reality Bliss Solution|use virtual reality Bliss Solution
223583041|NCT03522727|BEHAVIORAL|Single self-incentivising implementation intention|Participants are asked to form a single self-incentivising implementation intention (if-then plans)
223583042|NCT03522727|BEHAVIORAL|Multiple self-incentivising implementation intentions|Participants are asked to form multiple self-incentivising implementation intentions (if-then plans)
223583043|NCT03522727|BEHAVIORAL|Self-generated self-incentivising implementation intentions|Participants are asked to form a self-incentivising implementation intention (if-then plans) without a drop-down menu
223583044|NCT01100528|BIOLOGICAL|recombinant interferon alfa-2b|Given subcutaneously (SC) 3 times a week for 24 weeks
223583045|NCT01100528|DRUG|dacarbazine|Given IV on days 1 and 29
224162961|NCT06220552|RADIATION|Low-dose Radiotherapy|Radiotherapy 1Gy/1F, D1/D2/D8/D15, Q3W
223476746|NCT03861039|DRUG|Tirzepatide|Administered SC
223476747|NCT03861039|DRUG|Oral antihyperglycemic medication (OAM)|Oral antihyperglycemic medication (OAM): Sulfonylurea, biguanide, alpha-glucosidase inhibitor, thiazolidinedione, glinide, or sodium-glucose cotransporter type 2 inhibitor.
223476748|NCT06424353|PROCEDURE|Endoflas pulpectomy|obturation of root canals of primary molars with Endoflas using pressure seringe and lentilospiral files
223476749|NCT00719667|OTHER|coronary artery bypass grafting|on pump off pump
223476750|NCT04321889|DEVICE|defurocumarinized bergamot loaded in a nanotechnological essential oil release system|Patients will be treated either with placebo cream or with defurocumarinized bergamot loaded in a nanotechnological system of essential oil release in the pharmaceutical form of cream 2 times a day for 4 weeks. The subject will be monitored throughout the treatment and for at least 4 weeks after the end of the treatment.
223583046|NCT01100528|OTHER|laboratory biomarker analysis|Correlative studies obtained prior to therapy, every 8 weeks while on therapy, and then every 6 months during follow-up
223583047|NCT02940782|PROCEDURE|Reciproc single file system|A reciprocating Nickel Titanium single file system used for instrumentation of root canals in endodontic treatment.
223583048|NCT02940782|PROCEDURE|One Shape single file system|A rotary Nickel Titanium single file system used for instrumentation of root canals in endodontic treatment.
223583049|NCT02940782|DEVICE|X-smart Plus, Dentsply Maillefer, Ballaigues, Switzerland|It is a micro-motor designed for performing root canal treatments with the reciprocating, single file technique or traditional continuous rotation file system.
223583050|NCT01504581|BIOLOGICAL|HM10660A|Single dose of HM10660A 1.5, 2.25, 3.0, or 4.0 ug/kg
223583051|NCT01504581|BIOLOGICAL|HM10660A placebo|Single dose of HM10660A Placebo
223583052|NCT01504581|BIOLOGICAL|Pegasys|Single dose of Pegasys 180ug
223583053|NCT03083184|DRUG|Ethanol|An ethanol 40 % v/v - enoxaparin 1000 U/mL (Ethenox) interdialytic lock solution
223583054|NCT03083184|DRUG|enoxaparin|An ethanol 40 % v/v - enoxaparin 1000 U/mL (Ethenox) interdialytic lock solution
223583055|NCT05203159|OTHER|Ocean sound|The experimental group will listen to ocean sound, starting at the 1st minute before the ROP examination and ending at the 5th minute after the ROP examination.
223583056|NCT05203159|OTHER|Routine|No sound will be played before, during and after the ROP examination.
224162962|NCT04683172|DEVICE|Active Transcranial Direct Current Stimulation|"tDCS consists of delivering a low-intensity (1 to 2 milliamperes) direct electrical current by means of a pair of electrodes (anode and cathode) applied to the scalp. Electrodes generally have a diameter (round electrode) or a diagonal (rectangular electrodes) ranging from 2 to 3.5 cm.~To stimulate a given cortical zone, the anode is placed over of the selected zone, generally identified by means of an EEG headset (10/20 System Positioning). For the treatment of pain, the anode is placed over the primary motor cortex (M1) on the contralateral side to the pain or on the left side in patients with diffuse pain. The cathode is placed over a supposedly neutral cortical zone, usually the contralateral supraorbital cortex with respect to the anode. In this study, the stimulation intensity will be 1.5 mA using round sponge electrodes 3.5 cm in diameter."
224163638|NCT02401776|DIETARY_SUPPLEMENT|Monster Energy Drink|Monster energy drink. This will be given at a dose of 3mg caffeine/kg body weight (equivalent to approximately one 24 ounce can of monster energy drink for a person weighing 75 kg).
224163639|NCT02401776|DIETARY_SUPPLEMENT|Coffee|Coffee. This will be given at a dose of 2mg caffeine/kg body weight (equivalent to approximately one 8 ounce cup of coffee drink for a person weighing 75 kg).
223476751|NCT04321889|OTHER|Placebo|nanotechnological system loaded with placebo cream
223476752|NCT05679986|OTHER|no intervention|no intervention
223476753|NCT03816046|DRUG|botulinum toxin A|injection in hair bearing area of armpits
223476754|NCT00737178|DEVICE|CuT380A|Comparison of different timing of IUD insertion
223476755|NCT05029531|COMBINATION_PRODUCT|the risk-adapted choice of therapy and the use of a combination of chemotherapy with immunotherapy and hematopoietic stem cell transplantation for patients with risk factors.|two-stage stratification into risk groups: Initially and According to the results of induction therapy MRD-positive patients receive a course of blinatumomab and HSCT.
223476756|NCT03346239|BEHAVIORAL|Gaze Contingent Music Reward Therapy|Feedback according to participants' viewing patterns, in order to modify their attention.
223476757|NCT03346239|DRUG|Escitalopram|10-20 mg of Escitalopram
224162963|NCT04683172|DEVICE|Sham Transcranial Direct Current Stimulation|"The tDCS device has a Sham mode that allows for true placebo stimulation. A simulated session is thus designed as a real stimulation session without its effects. Sensations similar to tDCS are created by generating currents only at the start of the session.~Same modalities as for the Active tDCS procedure will therefore be put in place: a pair of electrodes (anode and cathode) are applied to the scalp.To stimulate a given cortical zone, the anode is placed over of the selected zone, generally identified by means of an EEG headset (10/20 System Positioning). For the treatment of pain, the anode is placed over the primary motor cortex (M1) on the contralateral side to the pain or on the left side in patients with diffuse pain. The cathode is placed over a supposedly neutral cortical zone, usually the contralateral supraorbital cortex with respect to the anode."
224162964|NCT03043209|GENETIC|Genomic sequencing|Genomic sequencing of DNA in Blood sample and myectomy tissue
223476758|NCT03346239|BEHAVIORAL|Waitlist|Participants will wait for 12 weeks while in touch with the clinic, then receive GC-MRT for 8 weeks.
223476759|NCT04370496|PROCEDURE|Minimally invasive surgery using endoscopic stapler|Radical hysterectomy by minimally invasive surgery (laparoscopic or robotic) will be done with the help of an endoscopic stapler in cutting and suturing the uterine cervix.
223476760|NCT03422185|OTHER|No intervention|No intervention
223476761|NCT05863442|DRUG|Soliris 300 MG in 30 ML Injection|Active Comparator
223476762|NCT05863442|DRUG|TUR03 300 MG in 30 ML Injection|Investigational medicinal Product, eculizumab - Turgut
223583057|NCT04438876|OTHER|Functional Power Training|The exercise intervention encompassed high-velocity movement, balance, and mobility exercises with the use of body weight and resistance bands as resistance. Participants were instructed to move rapidly during the concentric phase and slowly during the eccentric phase when performing the dynamic exercises.
223583058|NCT04438876|OTHER|Usual care|Participants either continued the usual exercise program provided by their respective community senior activity centers or their personal exercise routine.
223476763|NCT05252338|BIOLOGICAL|CVSQIV|Participants will receive an intramuscular injection by needle in the deltoid area.
223476764|NCT01477567|DRUG|LY3009385|
223476765|NCT01477567|DRUG|Placebo|
223476766|NCT04093271|DIETARY_SUPPLEMENT|Rest-ZZZ|A dietary supplement containing melatonin, valerian root, chamomile, passion flower, GABA, hawthorn berry, and lemon balm
223583059|NCT03184610|DEVICE|OCT-scanning|All participants will be scanned with a OCT-device
223583060|NCT05881720|DRUG|Sacubitril / Valsartan Oral Tablet|Group 1 (N = 40) received sacubitril/valsartan (target dose, 100 mg twice daily) in addition to recommended therapy according to physician's judgment.
223583061|NCT05881720|DRUG|Valsartan 80 mg|group 2 received valsartan (N=40, target dose, 80 mg twice daily) in addition to recommended therapy according to physician's judgment.
223583062|NCT02391376|OTHER|moist heat pack; ;|Three sessions of 15 minutes of superficial heat through a moist heat pack-MHP applied on the lower back.
223583063|NCT02391376|OTHER|seed pack|Three sessions of 15 minutes of superficial heat through a seed pack-SP applied on the lower back.
223583064|NCT02391376|OTHER|gel pack|Three sessions of 15 minutes of superficial heat through a gel pack-GP applied on the lower back.
223583065|NCT00004864|DRUG|GEM 231|
223583066|NCT00004864|DRUG|docetaxel|
223583067|NCT01342549|DRUG|Valproate|250mg per day 30 minutes after a meal. Dosages will be increase as tolerated to a maximum recommended dosage of 60 mg per kg per day. Usual dosage is between 1250mg to 2000mg per day
223583068|NCT01342549|DRUG|Naltrexone|25mg per day, taken by mouth for 7 days, then 50mg per day
223583069|NCT05140551|DEVICE|COMPASS: digital CBT|COMPASS is an evidence based digital CBT intervention with guided therapist support, tailored to treat anxiety and/or depression in long term conditions (LTCs). The intervention consists of eleven modules/sessions in which CBT techniques are taught. Users of COMPASS receive guided therapist support from a trained therapist. The guided support aims to help patients identify and apply the CBT skills outlined in COMPASS to meet their individual needs and experiences of living with LTC(s). The support can occur through in-site messaging or via the telephone.
223583070|NCT04065633|DRUG|P3-Fast|200 mg (2 × 100 mg) PF-04965842 Phase 3 tablet formulation under fasted conditions
223583071|NCT04065633|DRUG|Comm-Fast|200 mg PF-04965842 commercial tablet formulation under fasted conditions
223583072|NCT04065633|DRUG|Vari-Fast|200 mg PF-04965842 variant tablet formulation with slower dissolution under fasted conditions
223583073|NCT04065633|DRUG|Comm-Fed|200 mg PF-04965842 commercial tablet formulation under fed conditions
224163640|NCT06317441|DIETARY_SUPPLEMENT|Probiotic|The intervention consists of a probiotic either with a low or high dosage
224163641|NCT00054756|DRUG|TRH (Thyrotropin Releasing Hormone)|
224163642|NCT00762528|DRUG|Triclosan/Copolymer/fluoride toothpaste|Twice daily usage
223476767|NCT04093271|DRUG|Active Comparator - Diphenhydramine HCl|DIN 02229960 encapsulated for blinding purposes
223476768|NCT04093271|OTHER|Placebo|No active ingredients
223476769|NCT00485836|DRUG|Sham injection|Sham injection in a single-dose regimen given every month (Day 0 through the Month 5 visit), for a total of six sham injections.
223476770|NCT00485836|DRUG|Ranibizumab injection 0.3 mg|Ranibizumab injection 0.3 mg in a single-dose regimen given every month (Day 0 through the Month 5 visit), for a total of six injections.
223476771|NCT00485836|DRUG|Ranibizumab injection 0.5 mg|Ranibizumab injection 0.5 mg in a single-dose regimen given every month (Day 0 through the Month 5 visit), for a total of six injections.
223476772|NCT00008697|DRUG|arsenic trioxide|
223476773|NCT06346158|DIAGNOSTIC_TEST|Cognitive testing|Preoperative cognitive battery test
223476774|NCT06346158|DEVICE|electroencephalogram|Preoperative 24 channel EEG
223476775|NCT06346158|DEVICE|High density electroencephalogram|preoperative 128-channel electroencephalogram
223476776|NCT06346158|PROCEDURE|General anesthesia|induction of general anesthesia using propofol 1%
223476777|NCT04686032|OTHER|Advanced early Rehabilitation Program|Patient education, Ambulation, In bed exercises, Deep breathing exercises: (5 rep x 3set), Connective tissue manipulation for intestinal motility (5 min) and TENS\* for incisional pain (30min)
223476778|NCT04686032|OTHER|Early ambulation|Patient education \& Assisted ambulation out of bed including walking away from bedside for at least 15 min gradually moving to Unsupervised ambulation for 30 min
223476779|NCT00901641|DEVICE|CogniFit Personal Coach®|The program provides individually tailored cognitive training based on the results of a baseline evaluation (the Neuropsychological Examination - CogniFit Personal Coach®).7 The program assigns scores to 17 cognitive abilities that are subsequently trained by means of 21 different tasks.
223476780|NCT01686893|DEVICE|Nasal oxygen insufflation with a TNI 20 oxy device|Nasal oxygen insufflation with a TNI 20 oxy device
223476781|NCT01686893|DEVICE|Standard Nasal Insufflation of oxygen|Standard Nasal Insufflation of oxygen
223476782|NCT04233684|DIAGNOSTIC_TEST|rapid urease test|"Rapid urease test is the test for H. pylori infection by detect the change of pH by urease enzyme metabolism.~Pathologic test for H. pylori by H\&E stain and Giemsa stain Gold standard is a immunohistochemistry."
223476783|NCT01737528|PROCEDURE|Transcatheter Aortic Valve Replacement|Minimal invasive implantation of a biological prothesis in Aortic Position
223476784|NCT02359708|PROCEDURE|Surgical hand disinfection.|Bacterial recolonization
224162965|NCT01832857|DRUG|CPI-613|CPI-613 drug product, provided in concentrated form at 50 mg/mL, must be diluted with D5W prior to administration. CPI-613 is to be infused intravenously (IV) via a central venous catheter. CPI-613 will be given 2x weekly, administered on Days 1 and 4 of each of the 3 treatment weeks, followed by a week of rest. The dose of CPI-613 will be 3,000 mg/m2 infused IV over 2 hours (this is the maximum tolerated dosing \[MTD\]), via a central venous catheter with D5W running at a rate of about 125-150 mL/hr.
224162966|NCT02343952|DRUG|Pembrolizumab|Pembrolizumab, 200 mg IV every 3 weeks (until PD, unacceptable toxicity, or after 12 months of therapy with pembrolizumab.
223476785|NCT04562909|DEVICE|Neurocom balance master device|With the Modified Sensory Balance Interaction Clinical Test, the static balance will be examined by measuring the torso oscillation velocities while the eyes are open and the eyes closed on the stable rigid and unstable foam floors, and the dynamic balance will be examined with the sit-stand test, which is the basic motor activity in daily life, and the parameters will be measured on the same device.
223476786|NCT02349438|DEVICE|senofilcon A|A soft spherical contact lens
223476787|NCT02349438|DEVICE|lotrafilcon B|
223476788|NCT03029390|DIETARY_SUPPLEMENT|Berberine|"Berberine capsules, 500 mg, three per day before each meal during 14 weeks.~The patients will have a running period during two weeks:~First week they will receive one 500 mg capsule before breakfast Second week they will receive two 500 mg capsules (before breakfast and meal) From the third week until the end of the study (14 week), they will be receive three 500 mg"
223476789|NCT03029390|DRUG|Metformin|"Metformin capsules, 850 mg, two per day before breakfast and dinner and one placebo capsule before lunch during 14 weeks.~The patients will have a running period:~First week they will receive one 850 mg capsule before breakfast Second week they will receive one 500 mg capsules (before breakfast) and one placebo capsule (before meal).~From the third week until the end of the study (14 week), they will be receive two 850 mg capsules (before breakfast and dinner) and one placebo capsule (before meal)."
223476790|NCT03659344|DRUG|Vicryl plus|Using vicryl sutures which coated with triclosan (antibiotic)
223476791|NCT01258374|DRUG|Raltegravir|Raltegravir, 400 mg bid
223476792|NCT01258374|DRUG|Darunavir|Darunavir, 800 mg QD + ritonavir 100 mg QD
223476793|NCT06399159|PROCEDURE|Thyroidectomy and lymph node dissection|All surgical specimens of thyroidectomy and lymph node dissection were subjected to paraffin-embedded histopathological examination, and postoperative were categorized as with cervical lymph node metastasis and without cervical lymph node metastasis.
224163643|NCT00762528|DRUG|Sodium monofluorophosphate toothpaste|Twice daily usage
224163644|NCT00589602|PROCEDURE|peripheral blood lymphocyte therapy|T-cell depletion will be accomplished using CD34 selection with the Baxter Isolex 300i v. 2.5 device. The desirable T-cell dose will be \>0.5 x 105 but \<1.0 x 105 CD3+ cells per kg. The targeted CD34 cell dose will be \>2 x 106 cells/kg.
224304785|NCT05058534|DEVICE|Multiline Neo®|Multiperfusion neonatal system
223476794|NCT00079976|DRUG|Tigecycline|
223476795|NCT03932708|BEHAVIORAL|CDC Core Elements of Outpatient Stewardship|The intervention is described above and includes components of leadership, action of policy and practice, tracking and reporting, and education and expertise.
223476796|NCT00560963|DRUG|everolimus|
223476797|NCT02957201|OTHER|Blood samples|Blood samples at baseline and 3 timepoints for EPC analysis
223476798|NCT04902781|DRUG|AT-007|Treatment with AT-007 given orally
223476799|NCT04902781|OTHER|Placebo|Placebo given orally
223476800|NCT04936893|BEHAVIORAL|Mindfulness Practice|10-15 mins of daily mindfulness practice using HeadSpace, for 3 weeks
223476801|NCT04936893|BEHAVIORAL|Cognitive training|10-15 mins of cognitive games using Lumosity, for 3 weeks
223476802|NCT04968704|OTHER|3D photography and computer modelling|3D photography is available at our unit department of clinical photography. Photos will be taken and the associated NHS software (Canfield Imaging scientific, inc) used to sit down with the patients and model their reconstruction, thereby reducing anxiety and improving awareness of their treatment plan.
223476803|NCT04064268|DIETARY_SUPPLEMENT|Whey|45 g whey + 20 g maltodextrin
223476804|NCT04064268|DIETARY_SUPPLEMENT|3-OHB + Whey|50 g ketone + 45 g whey + 20 g maltodextrin
223476805|NCT02791269|DRUG|Peginterferon alfa-2a|180 mcg SC injection QW for 48 weeks.
223476806|NCT04831710|DRUG|Sintilimab|Sintilimab,200mg, ivd, d1
223476807|NCT04831710|DRUG|Chidamide|Chidamide,30mg,po,biw,d1-21
223476808|NCT04546763|DEVICE|Study Watch|The Study Watch is a miniaturized wearable device made with biocompatible contact materials containing various sensors capable of measuring physiological and environmental metrics.
224304786|NCT06928025|PROCEDURE|Preoperative Education|animation-based education for elderly patients before coronary artery bypass graft surgery Before coronary artery bypass graft surgery, the scenario prepared based on the literature information including introduction of the service, preparation for surgery, monitoring, drug treatment and applications, deep breathing and cough exercise, spirometer use, operation time, postoperative period and care, patient pain management and intubation process will be given as animation-based video training. The effects of this on postoperative pain, fear, anxiety and self-care management will be evaluated.
224304787|NCT06928584|RADIATION|Conventional Radiotherapy|50Gy/25Fx irradiation or 39Gy/30Fx bid reirradiation (previous pelvic radiation)
224162967|NCT04866095|DEVICE|Transthoracic echocardiogram|Transthoracic echocardiogram (TTE) is a widely used and validated imaging technique which involves the study of the heart and great vessels through multiple examination windows. In particular, the subcostal window represents the gold standard for evaluating the diameter of the inferior vena cava (IVC) and its compliance, allowing the physician to obtain valuable information on the volume status of patients. Acquiring images in the subcostal window with a transthoracic echocardiogram (TTE) can be, in some cases, difficult or impossible due to the presence of drainages or surgical wounds: in such cases an alternative could be represented by the trans-hepatic window. This has not been validated in the scientific litterature.
224304788|NCT06928584|DRUG|Capecitabine|1000mg/m2 d1-14 q3w
224304789|NCT06928584|DRUG|5-fluorouracil|400 mg/m2 (bolus) and 2400 mg/m2 (continuous infusion for 48hr)
224304790|NCT06928584|DRUG|folinic acid|400 mg/m2 q2w
224304791|NCT06928584|DRUG|Oxaliplatin|130 mg/m² q3w or 85 mg/m² q2w
223744518|NCT02964468|RADIATION|3DCRT treatment (sequential boost)|"Radiotherapy:~3DCRT treatment (sequential boost) 25 fractions fraction 1,8Gy by administering a total dose of 45 Gy on tumor and lymph nodes and lymph node chains more pelvic margin determined according to protocol.~3 fractions fraction 1,8Gy by sequentially administering an additional dose of tumor and lymph nodes 5,4Gy on more margin.~Chemotherapy:~According to routine clinical practice of the participating centers."
223744519|NCT02964468|RADIATION|Dose Escalation Intensity Modulated Radiotherapy treatment|"Radiotherapy:~IMRT treatment (concomitant boost technique) 25 fractions fraction 2,15Gy by administering a total dose of tumor and lymph nodes 53,75Gy on more margin. Simultaneously we will proceed to the irradiation of pelvic lymph node chains according to protocol, a division of 1,8Gy per session until a total dose of 45 Gy.~Chemotherapy:~According to routine clinical practice of the participating centers."
224162968|NCT04866095|DEVICE|Clear Sight system|"The Clear Sight System is a non-invasive blood pressure (BP) monitoring system, where the CO is determined analysing the photo-plethysmography curve by a miniaturized pressure cuff and infrared LEDs.~Its main advantage is to assess CO continuously in a completely non-invasive way, following its variations and thereby contributing to the detection of hypovolaemia. Other visualized parameters are: the stroke volume (SV), the systemic vascular resistance (SVR) as well as the BP and the heart rate (HR)."
224162969|NCT06053970|OTHER|Assessing postural responses induced by visual stimulation (Visual Evoked postural responses, VEPR)|"The intervention will last 60 minutes and will include an assessment of the Berg Balance Scale (BBS), the collection of stabilometric data, the collection of the numerical difficulty scale, the Fast Motion Sickness Scale (FMS) and will end with a break after exposure to VR.~The various conditions will be carried out in this order:~* Eyes open with VR headset simulating a static environment~* Eyes closed with VR helmet off~* Eight measurements on a stabilometry platform will be taken for each of the VR signals, in random order"
224304792|NCT06928584|DRUG|Irinotecan|180 mg/m² q2w and 200 mg/m² q3w
224304793|NCT06928584|DRUG|Cetuximab|500 mg/m² q2w
224304794|NCT06928584|DRUG|Bevacizumab|5 mg/kg q2w or 7.5mg/kg q3w
224304795|NCT06928584|RADIATION|Hypofractionated radiotherapy|25-40Gy/5Fx irradiation or 15-30Gy/5Fx reirradiation (previous pelvic radiation)
224304796|NCT06928584|DRUG|PD-1 antibody|200mg IV q3w
224304797|NCT06928064|PROCEDURE|Prediction of Postoperative Pain Severity Using Pain Sensitivity Questionnaire Applied in Preoperative Period in Patients Undergoing Breast-Conserving Surgery (Lumpectomy).|": This study included 74 patients over the age of 18 with American Society of Anesthesiologists (ASA) scores of I, II, or III, who were scheduled to undergo breast-conserving surgery. Ethical approval from the local ethics committee and written informed consent from each patient were obtained. Patient data, including age, ASA score, and comorbidities, were collected, and contact details were recorded for postoperative follow-up.~The PSQ was administered to all patients during the preoperative period to assess their pain sensitivity. Anesthesia induction and maintenance followed a standardized protocol on the day of surgery. The intraoperative analgesic consumption and the duration of the surgery were documented. Postoperative assessments were conducted 24 hours after the surgery in the general surgery ward, where analgesic use and short pain inventory scores were recorded. Patients were followed up one month postoperatively, and their pain levels were assessed using the Numeric Rating"
224304798|NCT06926777|DIAGNOSTIC_TEST|Nerve Conduction Study|"This study involves two diagnostic interventions for evaluating CTS:~Ultrasound Examination (Diagnostic Intervention)~1. A high-frequency ultrasound probe will be used to assess the median nerve at the wrist.~2. Parameters measured include cross-sectional area, flattening ratio, and echogenicity.~The goal is to determine if ultrasound can accurately diagnose CTS compared to NCS.~NCS (Diagnostic Intervention)~1. Surface electrodes will be placed on the skin to stimulate and record median nerve conduction.~2. Parameters such as latency, conduction velocity, and amplitude will be recorded.~3. NCS serves as the gold standard for diagnosing CTS and will be used for comparison with ultrasound results.~Each participant will undergo both ultrasound and NCS, allowing researchers to compare their effectiveness in diagnosing CTS."
224304799|NCT06928805|OTHER|Balloon inflation exercise|Balloon inflation exercise was applied in addition to the forward-leaning position.
224304800|NCT06928805|OTHER|Pursed-lip breathing exercise|The pursed-lip breathing exercise was applied in addition to the forward-leaning position.
224304801|NCT06928805|OTHER|Control (Standard treatment)|Standard practice is implemented in the institution where the study is conducted.
224304802|NCT00249691|DRUG|Topiramate + Cognitive Behavioral Therapy|Topiramate up to 300 mg per day
224304803|NCT00249691|DRUG|Placebo + Cognitive Behavioral Therapy|Placebo twice a day
224304804|NCT03982199|BIOLOGICAL|RSV Vaccine|Participants will receive a single IM injection of an Ad26-based RSV vaccine at a single dose level on Day 1 and revaccination after either 1 year, 2 years, or 3 years.
223744520|NCT02453763|DEVICE|Transcranial direct current stimulation|All participants will receive transcranial direct current stimulation. During the MRI images of the head a battery-powered device pulses a small current between a pair of the electrodes which will be immediately followed by more MRI images. The current pulses will be very short and there should be no feeling from the pulses. The entire imaging period will be at most 90 minutes.
223476809|NCT04546763|DEVICE|Zio XT|The Zio XT Patch, the reference device, is a FDA-cleared single-patient use, continuously recording ECG monitor that can be worn up to 14 days.
223476810|NCT05676658|BEHAVIORAL|Coherent breathing|Guided audio of coherent breathing pre-recorded by trained breathwork facilitator: \~5.5bcpm (with equal inhalation/exhalation durations of \~5.5secs each) for \~10mins/day over four weeks / 28 days. Delivered remotely through audio link.
223583074|NCT01376570|BEHAVIORAL|Abstinence-reinforcing contingency management intervention|The contingency management intervention consists of participants receiving vouchers exchangeable for goods and services contingent on achieving abstinence. When participants are abstinent (urine is free of cocaine, oxycodone and opiates), they will receive a voucher. If participants are not abstinent (cocaine or oxycodone or opiates are in the urine), they will not receive a voucher. The value of vouchers increases with continued evidence of abstinence. When participants have urines with opiates or cocaine, the value of the voucher is reset. The vouchers are part of the intervention, they are not participant compensation.
223744521|NCT02453763|PROCEDURE|MRI|All participants will receive an MRI. During the MRI images of the head a battery-powered device pulses a small current between a pair of the electrodes which will be immediately followed by more MRI images. The current pulses will be very short and there should be no feeling from the pulses. The entire imaging period will be at most 90 minutes.
223744522|NCT03479307|DRUG|Bilastine Ophthalmic Solution 0.6%|1 drop in each eye at 2 separate times during an 8 day period.
223744523|NCT03479307|DRUG|Ketotifen Ophthalmic Solution 0.025% (Zaditen)|1 drop in each eye at 2 separate times during an 8 day period.
223744524|NCT03479307|DRUG|Vehicle of Bilastine Ophthalmic Solution|1 drop in each eye at 2 separate times during an 8 day period.
223744525|NCT00649675|DRUG|Meloxicam Tablets 15 mg|15mg, single dose fed
223476811|NCT05676658|BEHAVIORAL|Placebo coherent breathing|Same audio of coherent breathing but paced at: \~12bcpm (with equal inhalation/exhalation durations of 2.5secs each) for \~10mins/day over four weeks / 28 days.
223476812|NCT01621074|DIETARY_SUPPLEMENT|Sodium bicarbonate|Ergogenic effect
223476813|NCT01621074|DIETARY_SUPPLEMENT|Placebo|Placebo effect
223583075|NCT01376570|BEHAVIORAL|Performance Feedback intervention|Participants will receive performance feedback about their drug use. The research team will provide informational slips of paper indicating results of urine tests and will congratulate participants when urines are drug-free or encourage participants to stop using cocaine and/or opiates when urines are not drug-free.
223583076|NCT04912323|DEVICE|Percutaneous Implantation of the MAGNITUDE® Bioresorbable Arterial Scaffold|Placement of one or more MAGNITUDE® bioresorbable scaffolds using a percutaneous technique at one or more arterial stenoses.
223583077|NCT02674425|DEVICE|Dark Adaptometer|
223583078|NCT04700956|PROCEDURE|primary abdominal closure|The linea alba will be closed to a ratio of 5mm / 5mm. Only the fascia will be sutured ; fat or muscle tissue will be avoided. Subcutaneous tissue will be closed with polyglactin 3/0 suture. The skin will be closed with a stapler.
223744526|NCT00649675|DRUG|Mobic® Tablets 15 mg|15mg, single dose fed
223744527|NCT01464346|DEVICE|Enlite Sensor|This is the Enlite sensor (all subjects)
223476814|NCT02329158|DRUG|6% hydroxyethyl starch|
223476815|NCT04553419|DRUG|Cephalexin|Cephalexin capsule: TEVA Cephalexin Cephalexin suspension: LUPIN Cephalexin
223476816|NCT04553419|DRUG|Placebo|Cellulose capsules or suspension
223476817|NCT02950389|DEVICE|PMMA filter|
223476818|NCT02950389|DEVICE|HFR17 filter|
223476819|NCT02950389|DEVICE|F7 filter|
223476820|NCT01398241|DRUG|RO5267683|Multiple ascending doses
223476821|NCT01398241|DRUG|placebo|Multiple ascending doses
223744528|NCT00311337|DRUG|bortezomib|
223744529|NCT02741908|BEHAVIORAL|Calorie counting diet|
223744530|NCT02741908|BEHAVIORAL|Fixed diet plan|
223744531|NCT03999892|BEHAVIORAL|ACHIEVE|The investigators will test two modules of the adapted video-assisted curriculum format of 45 to 60-minute multipurpose classes, which will include a segment on group weight management (\~20-30 minutes) and group exercise (\~20-30 minutes). Within each module, the group weight management topic varies by week, and within each week the content of the three weight management groups builds gradually and is purposely repeated. Within each module, the group exercise classes will focus on mild to moderate intensity aerobic exercise using an exercise video. In this pilot study, a trained study interventionist will deliver the ACHIEVE-D curriculum.
224163645|NCT00589602|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Allogeneic Hematopoietic Stem Cell Transplantation
224163646|NCT00589602|PROCEDURE|peripheral blood stem cell transplantation|Peripheral blood stem cell transplantation
224163647|NCT00589602|RADIATION|total-body irradiation (TBI)|Treatment will be delivered using 6MV photons twice daily for 3 days
224163648|NCT02870244|BIOLOGICAL|Escalating Doses|"Subjects will receive a single infusion of autologous bulk TIL 13831 TCR transduced T cells supported with low dose IL-2. Autologous bulk TIL 13831 TCR transduced T cells means the infusion will consist of a polyclonal mixture of CD4 + and CD8+ T Cells expressing the TIL 13831 TCR.~Subjects in Cohort 1 will receive 7.5 x 10\^6/kg TIL 1383I TCR transduced T cells.~Subjects in Cohort 2 will receive 2.5 x 10\^7/kg TIL 1383I TCR transduced T cells.~Subjects in Cohort 3 will receive 7.5 x 10\^7/kg TIL 1383I TCR transduced T cells."
224163649|NCT04765657|DRUG|inclisiran sodium|Subcutaneously injected on Day 1, 90 and 270 (Core Part). Subcutaneously injected on Day 360 and every 6 months thereafter until EOS visit (Extension Part)
224163650|NCT04765657|DRUG|Placebo|Subcutaneously injected on Day 1, 90, and 270.
224163815|NCT01832844|PROCEDURE|"Group  with scan prior to infiltration "|Scan will be conducted by the operator performing the gesture. He will examine the lumbar spine from L3 to S1, in longitudinal and cross sections and determine the best surgical approach. This will be defined by the largest interspinous space or better visibility of the epidural space. The depth of the epidural space will be noted. The selected stage will be marked with a skin pen to facilitate its location thereafter
224163816|NCT01832844|PROCEDURE|"Group  without scan "|
224162970|NCT01378299|DRUG|Testosterone Cypionate|"Testosterone cypionate was administered at 200 mg by intramuscular injection every 2 weeks.~DEPo-Testosterone Injection, for intramuscular injection, contains testosterone cypionate which is the oil-soluble 17 (beta)-cyclopentylpropionate ester of the androgenic hormone testosterone.~Testosterone cypionate is a white or creamy white crystalline powder, odorless or nearly so and stable in air. It is insoluble in water, freely soluble in alcohol, chloroform, dioxane, ether, and soluble in vegetable oils. The chemical name for testosterone cypionate is androst-4-en-3-one,17-(3-cyclopentyl-1oxopropoxy)-, (178)-. Its molecular formula is CvH400a, and the molecular weight of 412.61."
224162971|NCT05920070|PROCEDURE|therapeutic mammoplasty|therapeutic oncoplastic surgeries in cases of breast cancer
224162972|NCT05193877|PROCEDURE|autologous bone marrow aspirate concentrate by centrifugation|"50 cc bone marrow aspirates concentrate after centrifugation with final volume up to 7 cc.~Assess total nucleated count and viability. Bone marrow aspirate concentrate is chosen as a source of mesenchymal stem cells, because of safe and easy procedure.~Bone marrow aspiration is done under local or general anesthesia, depending on the individual case. Around 50 cc of bone marrow is aspirated from the posterior iliac crest after proper sterilization using bone marrow aspiration needle (size according to the patient) and collected in heparinized syringes. Mononuclear cells (MNCs) are obtained by centrifugation. The isolated MNCs are checked for viability manually and confirmed on automated cell count machine.~The separated MNCs is administered intra-articularly immediately after centrifugation."
224162973|NCT02702947|DIETARY_SUPPLEMENT|Prunus domestica extract|Prosman 1 capsule twice a day
224162974|NCT00829218|OTHER|Glutamate additive-free diet|All subjects will follow a diet for one month where all foods containing the additive glutamate have been removed. At the end of the one month diet, subjects who have responded positively to the diet will go onto the challenge arms of the study, where they will be randomized to receive placebo (mixed juice alone) for three days on one week, and 5 grams of glutamate in the mixed juice for three days on the other week.
223476822|NCT01138241|OTHER|Tc99mDTPA renal clearance|"Tc99mDTPA renal clearance only for 200 patients~1. Plasma and urine 24 hr for creatinin, glucose, Creatinin clearance, Phosphatemia, uric acid, HCO3, protein, Microalbuminuria, ß2- microglobulinuria~2. serum creatinine prior and during TDF~3. TDF plasma levels ( only TDF use) using a validated high-performance liquid chromatography (HPLC)-mass method and stored PBMC for intracellular TDF levels~4. stored samples (PBMC) for pharmacogenomic study of transporter gene ie Organic Acid Transporter (OAT)~5. serum for cystanin C ( stored sample prior taking ARV and present time)~6. intensive 24 hours pharmacokinetic study of TDF in 20 patients"
223476823|NCT04780399|DRUG|Yangxue Qingnao pills|72 subjects in the Yangxue Qingnao pills group take 7.5g of Yangxue Qingnao pills each time, twice a day, 0.5 hours after breakfast and dinner, taking with warm water.
224162975|NCT00829218|OTHER|Placebo diet|Juice with nothing added.
224304805|NCT03982199|BIOLOGICAL|Placebo|Participants will receive a single IM injection of placebo control on Day 1.
223476824|NCT04780399|DRUG|Yangxue Qingnao pills|72 subjects in the Yangxue Qingnao pills group take 5g of Yangxue Qingnao pills and 2.5g placebo identified to Yangxue Qingnao pills each time, twice a day, 0.5 hours after breakfast and dinner, taking with warm water.
223476825|NCT04780399|DRUG|Placebo|72 subjects in the placebo group take 7.5g placebo identified to Yangxue Qingnao pills each time, twice a day, 0.5 hours after breakfast and dinner, taking with warm water.
223476826|NCT03515408|DEVICE|rTMS|The 10-Hz stimulation is delivered at 100% of the subject's resting motor threshold via 60 trains of 3-s 10-Hz rTMS (30 pulses with 27-s duration per train).
223476827|NCT00818935|DIETARY_SUPPLEMENT|Low-Intermediate-Glycemic Index diets|
223476828|NCT00818935|DIETARY_SUPPLEMENT|High GI diet|
223476829|NCT00420745|BIOLOGICAL|Rotarix™|Two-dose oral vaccination.
223476830|NCT00420745|BIOLOGICAL|Placebo|Two-dose oral administration
223476831|NCT00247234|BEHAVIORAL|Schema Therapy|group based schema therapy
223476832|NCT00247234|BEHAVIORAL|standard care|standard psychiatric out-patient care
223476833|NCT01125930|DRUG|vehicle gel|Topical gel that does not contain active drug. The gel will be applied initially 3 times per week to the face. If no irritation seen at follow up visit, the investigator will consider increasing the frequency of use. This topical medication will not be applied more than once daily. If there is irritation, the subject will be asked to decrease frequency of use.
223476834|NCT01125930|DRUG|Atralin gel|Topical Atralin gel will be applied initially 3 times per week to the face. If no irritation seen at follow up visit, the investigator will consider increasing the frequency of use. This topical medication will not be applied more than once daily. If there is irritation, the subject will be asked to decrease frequency of use. This drug will be used for the duration of the study.
223476835|NCT02111018|DEVICE|CytoSorb Device|
223476836|NCT02111018|PROCEDURE|CVVH|
223583079|NCT04700956|DEVICE|abdominal closure with prophylactic mesh|After the fascia was closed with the same method, 5 cm of subcutaneous tissue will be dissected around the incision. The mesh will be placed in the supra-aponeurotic area (onlay) to a distance of laterally and cranial-caudally 5 cm from the fascia margins. The mesh used will be partially absorbable, light and large porous. After this procedure, the borders of the mesh will be fixed circumferentially on the abdominal wall using polypropylene suture to prevent the intestines from herniating on the mesh. Two subcutaneous drainage catheters will be placed in all patients with mesh.
223583080|NCT01299571|DRUG|Dutasteride|Basically there is no treatment allocation. Subjects who would be administered of dutasteride at their physicians' discretion will be enrolled. Dosage regimen will be recommended according to the prescribing information. Subjects will be enrolled consecutively.
223583081|NCT00088283|DRUG|pegaptanib sodium|
223583082|NCT02124954|DRUG|TA-8995|
223583083|NCT02124954|DRUG|Midazolam|
223583084|NCT02124954|DRUG|Digoxin|
224162976|NCT04589338|OTHER|Endurance training|This group will perform aerobic type exercises. Initially, patients will perform continuous exercises of progressive intensity in order to adapt to this kind of effort. Next, we will introduce interval exercises.
224304806|NCT00594646|DRUG|TRUVADA + Raltegravir|TRUVADA (tenofovir disoproxil fumarate (DF) 300mg + emtricitabine 200mg) + RALTEGRAVIR 400mg
224304807|NCT00000117|DRUG|Immunoglobulin|
224162977|NCT04589338|OTHER|Resistance training|Patients in this group will perform lower limb strengthening exercises to improve the maximum strength of different muscle groups.
223476837|NCT00666770|DRUG|Gabapentin|Gabapentin 250 mg oral capsule 30 minutes prior to bedtime
223476838|NCT00666770|DRUG|Gabapentin|Gabapentin 500 mg oral capsule 30 minutes prior to bedtime
224162978|NCT00456885|DRUG|exenatide|5 microgram twice a day for two week and then 10 mcg for remaining 15 weeks
224162979|NCT00456885|DRUG|Placebo|Twice daily injection of placebo
223476839|NCT00666770|DRUG|Placebo|Matched placebo 30 minutes prior to bedtime
223476840|NCT00150696|DRUG|Risedronate|
223476841|NCT03098979|DRUG|Neladenoson bialanate (BAY1067197)|5 mg orally once daily for 20 weeks
223476842|NCT03098979|DRUG|Neladenoson bialanate (BAY1067197)|10 mg orally once daily for 20 weeks
223476843|NCT03098979|DRUG|Neladenoson bialanate (BAY1067197)|20 mg orally once daily for 20 weeks
224162980|NCT03503812|BEHAVIORAL|Intervention (1) for outdoor exposure reduction - Asthma in Children|"Intervention 1 (I1) aims to reduce exposure to outdoor particles and it will be applied on days with DDS during the follow-up period. This intervention will consist of two recommendations:~1. Reduce time spent outdoors and~2. Reduce physical activity"
224162981|NCT03503812|BEHAVIORAL|Intervention (2) for outdoor and indoor exposure reduction - Asthma in Children|"Intervention 2 (I2) aims to reduce both:~i) exposure to outdoor particles and it will be applied on days with DDS during the follow-up period. This intervention will consist of two recommendations:~1. Reduce time spent outdoors and~2. Reduce physical activity~   ii) indoor particle levels on a continuous daily basis throughout the follow-up DDS period. This intervention will consist of two recommendations for participants' schools and houses:~3. Reduce particle infiltration into residences by keeping windows and doors closed as much as possible and~4. Reduce indoor particle levels by using air cleaners."
224162982|NCT03503812|BEHAVIORAL|Intervention (1) for outdoor exposure reduction - Atrial Fibrillation|"Intervention 1 (I1) aims to reduce exposure to outdoor particles and it will be applied on days with DDS during the follow-up period. This intervention will consist of two recommendations:~1. Reduce time spent outdoors and~2. Reduce physical activity"
224162983|NCT03503812|BEHAVIORAL|Intervention (2) for outdoor and indoor exposure reduction - Atrial Fibrillation|"Intervention 2 (I2) aims to reduce both:~i) exposure to outdoor particles and it will be applied on days with DDS during the follow-up period. This intervention will consist of two recommendations:~1. Reduce time spent outdoors and~2. Reduce physical activity~   ii) indoor particle levels on a continuous daily basis throughout the follow-up DDS period. This intervention will consist of two recommendations for participants' houses:~3. Reduce particle infiltration into residences by keeping windows and doors closed as much as possible and~4. Reduce indoor particle levels by using air cleaners."
224162984|NCT04306978|OTHER|CareLink Express RM system|CareLink Express remote monitoring system consists of implantable pacemaker CareLink Express station for implanted Medtronic cardiac devices and provides remote data transmissions
224162985|NCT04306978|OTHER|Standard follow-up|Follow-up will be provided according to the standard guidelines (HRS/EHRA Expert Consensus on the Monitoring of Cardiovascular Implantable Electronic Devices (CIEDs): Description of Techniques, Indications, Personnel, Frequency and Ethical Considerations; 2008)
224162986|NCT01448707|DRUG|Darunavir|Darunavir (DRV): type = exact number, unit = mg, number = 800, form = tablet, route = oral use
224162987|NCT01448707|DRUG|Ritonavir|ritonavir (rtv): type = exact number, unit = mg, number = 100, form = tablet, route = oral use
224162988|NCT02082028|DEVICE|BGStar|
224162989|NCT02082028|DEVICE|glucose meter|
223476844|NCT03098979|DRUG|Neladenoson bialanate (BAY1067197)|30 mg orally once daily for 20 weeks
223476845|NCT03098979|DRUG|Neladenoson bialanate (BAY1067197)|40 mg orally once daily for 20 weeks
223476846|NCT03098979|DRUG|Placebo|Orally once daily for 20 weeks
223476847|NCT02426684|DRUG|IdeS® (Imlifidase)|0.24mg/kg IdeS
223476848|NCT05598567|OTHER|target controlled infusion - total intravenous general anesthesia|Both interventions are subtypes of general anesthesia.
223476849|NCT05598567|OTHER|sevoflurane based balanced general anesthesia|Both interventions are subtypes of general anesthesia.
223476850|NCT02661308|DEVICE|Litebook|
223476851|NCT02369653|DRUG|Apixaban|
223476852|NCT02369653|OTHER|No systemic anticoagulant prophylaxis|
223476853|NCT05634291|OTHER|Standard of care|Standard of care as prescribed by healthcare provider.
223476854|NCT05634291|DEVICE|Nottingham AR smartphone app with active intervention|AR software treatment delivered by smartphone app and developed by VRx Medical (VRx) using established principles of illusion therapies (e.g. mirror therapy) for pain management.
223476855|NCT03847493|OTHER|Endothelial Glycocalyx|Non-invasive assessment of endothelial glycocalyx dimensions.
223476856|NCT03720587|OTHER|Semi-structured interviews|Semi-struuctured telephone interviews
223476857|NCT05092087|BEHAVIORAL|nutrition counseling|nutrition counseling
223476858|NCT04989933|PROCEDURE|Ultrasound-guided erector spinae plane block|Ultrasound-Guided erector spinae plane block with 0.25% bupivacaine
223476859|NCT02650739|PROCEDURE|Macular hole surgery|Vitrectomy with internal limiting membrane removal and gas tamponade
223476860|NCT00425919|DRUG|PPM-204|
224162990|NCT00428883|DRUG|N-acetylcysteine (NAC)|
224162991|NCT03023605|BEHAVIORAL|Training Intervention for PE Diagnosis|"Focused on the Emergency Department staff and the rotating residents during the months 4 and 5 of 2015, and consisted of:~1. Clinical Update Sessions for staff ED (20 physicians)~2. training sessions for residents that rotate in ED (60 physicians )~3. Development of a triptych, including clinical prediction scales, combination algorithm of scales and D-Dimmer value~4. Development of posters, with brief information~5. Dissemination by e-mail of scientific information~6. Direct reminder during the working day"
224162992|NCT04853277|BEHAVIORAL|Education|Each Patient will undergo a 30 minute telephone visit with a trained Medical Provider outlining the timeline of various common emotional challenges experienced after transplant/CAR-T, as well as coping techniques. A pamphlet with information discussed will also be provided to the patient to review on their own time. The patient will have an opportunity to express any psychosocial/emotional concerns at this time.
224162993|NCT05013294|OTHER|Intervention|Text messages through a basic phone or smart phone
223476861|NCT02362022|DRUG|Morphine|Group Saline (Group S): Received i.v saline 0.9 % in 10 ml volume (n=30) Group Morphine 1 (Group M1): Received i.v morphine 0.1 mg kg-1 in 10 ml volume (n=30) Group Morphine 2 (Group M2): Received i.v morphine 0.2 mg kg-1 in 10 ml volume (n=30)
223476862|NCT04363476|OTHER|SHRED Osteoarthritis program|Combined exercise and education intervention
223476863|NCT05510453|OTHER|Low-intensity online intervention (LiON)|"The LiON in the current study is comprised of three core modules identified to be core areas of stress and needs of participants based on clinical experiences of the research team. The three modules include (1) stress management, (2) sleep and relaxation, and (3) problem-solving skills.~Each module consists of four 1-on-1 sessions which will be conducted through online platforms (such as Zoom) that lasts for 45 minutes. Participants will attend these sessions once a week.~The control group will receive the intervention after a waiting period of 4 weeks."
223476864|NCT00047827|DRUG|Micafungin|IV
223476865|NCT00047827|DRUG|Liposomal Amphotericin B|IV
223583085|NCT03166644|DEVICE|Analgesia Nociception Index (ANI)-guided sufentanil administration|One recent observational study showed that ANI-guided remifentanil administration during vascular surgery resulted in low opioid consumption and low postoperative pain rates.
223583086|NCT01203358|DRUG|Exosurf|Infants received up to four intratracheal doses of the surfactant.
223476866|NCT03587636|DRUG|liposome bupivacaine|interscalene block with liposomal bupivacaine plus bupivacaine
223583087|NCT01203358|DRUG|Survanta|Infants received up to four intratracheal doses of the surfactant.
223583088|NCT00140699|BEHAVIORAL|Balance|
223583089|NCT04764734|DEVICE|NightOwl|The NightOwl is a finger-mounted home sleep apnea testing device
223583090|NCT04152434|DRUG|Erenumab Auto-Injector|Assess synergy of add on medication to Erenumab
223583091|NCT03147313|DEVICE|MTS Medical UG Orthogold 100|300 or 500 pulses, frequency 3Hz, energy 1 (0,1mJ/mm2)
223583092|NCT03147313|DEVICE|Sham|Extracorporeal shock wave treatment will be faked.
223583093|NCT02196480|BIOLOGICAL|anti-TNF|Anti-tumor necrosis factor therapy
223583094|NCT01189292|DRUG|Dexamethasone|8mg (2ml) of dexamethasone (Mephameson®) administered intravenously preoperatively before thyroid surgery
223583095|NCT01189292|OTHER|NaCl 0.9%|2ml of NaCl 0.9% administered intravenously preoperatively before thyroid surgery
223583096|NCT03972410|BEHAVIORAL|EMDR|2-4 sessions individual 60-min-long treatment sessions of EMDR Recent birth trauma protocol
223583097|NCT03972410|BEHAVIORAL|SEDP|2-4 sessions individual 60-min-long treatment sessions of SEDP
223583098|NCT02389205|OTHER|kinesio group|"kinesio group, The kinesio Taping® Method is a definitive rehabilitative taping technique that is designed to facilitate the body's natural healing process while providing support and stability to muscles and joints without restricting the body's range of motion as well as providing extended soft tissue manipulation to prolong the benefits of manual therapy administered within the clinical setting.~The effect of intervention may affected by the varying durations and frequencies of exercise, different state of arthropathy and joint range of motion limitations of ankle , etc."
223583099|NCT03653572|DEVICE|Ultrasound exam|Eligible subjects will be positioned for their ultrasound exam, which will take a similar amount of time and be performed in a similar manner as standard of care ultrasound exams at the site. The type and duration of ultrasound exam will be based on the subject's clinical condition.
223583100|NCT04023617|DRUG|Nivolumab|Nivolumab 300mg + docetaxel 75mg/m2 IV q3w Nivolumab 200mg IV q2w
223583101|NCT00708734|BEHAVIORAL|functional exercise training|twice weekly group sessions for 5 weeks
223583102|NCT01724424|DRUG|Melatonin|20 mg oral single dose
223583103|NCT01724424|DRUG|Melatonin|30 mg oral single dose
223583104|NCT01724424|DRUG|Melatonin|50mg oral single dose
223583105|NCT01724424|DRUG|Melatonin|100mg oral single dose
223583106|NCT06302894|BEHAVIORAL|Self-sufficiency|Rewarding positive behavior and developing alternative behaviors towards obstacles such as feeling restless, depressed or angry if internet use is reduced or controlled.
223583107|NCT05592496|PROCEDURE|Bilateral retromuscular rectus sheath block catheters usage for early postoperative analgesia after laparotomic gastrectomy.|After surgery patients in the Block group receives continuous 0.125% (10-12 mg/h) bupivacaine infusion through rectus sheath catheters for 72 h in addition to fentanyl i/v infusion on postoperative day 0, and ketorolac or trimeperidine injection on postoperative day 1-2 if necessery. Patients in the Control group receives NaCl 0,9% infusion and fentanyl i/v infusion on postoperative day 0 and ketorolac or trimeperidine injection on postoperative day 1-2 if necessery Pain intensity is going to be assessed in both groups using 0-100 mm Visual Analog Scale (VAS) at 24, 48 and 72 hour intervals after surgery at rest and during movement (by asking the patient to bend legs). Postoperative complications, hospital stay, comorbidities, the time taken to start walking after the surgery, bowel movements (time until first stool) were all examined.
224162994|NCT00228189|BIOLOGICAL|CEA-loaded dendritic cell vaccine|Carcinoembryonic antigen (either peptide or mRNA) loaded dendritic cells.
223476867|NCT03587636|DRUG|Bupivacaine|interscalene block with bupivacaine
223476868|NCT03595098|BEHAVIORAL|Family Based Cognitive Behavioural Therapy|Family Based Cognitive Behavioural Therapy (FCBT) focuses on the interrelation between thought, emotion, and behaviour, Exposure and Response Prevention, family involvement, homework assignments, and formulating of specific goals for the child. The important, active components is Exposure and Response Prevention. It involves exposing the child to a feared object, situation or thought, and preventing the child from carrying out compulsions to show the child that distress/anxiety can decrease or disappear without performing rituals.
223476869|NCT03595098|BEHAVIORAL|Family Based Psychoeducation/Relaxation Training|Family-based Psychoeducation/Relaxation Training (FPRT) as an active control matches the experimental intervention as closely as possible, many elements of the control intervention are similar to FCBT. The main and intended difference between the two approaches is the absence of the Exposure and Response Prevention component, which is deemed the most effective treatment for OCD.
224162995|NCT04191213|DIETARY_SUPPLEMENT|Acacia Senegal extract|Oral Digestion of Gum Arabic to be consumed early morning in daily basis for 12 weeks
224162996|NCT04191213|DIETARY_SUPPLEMENT|Pectin|Oral Digestion of Pectin to be consumed early morning in daily basis for 12 weeks
224162997|NCT03242590|DRUG|LPCN 1021|Oral testosterone undecanoate
224162998|NCT01671891|RADIATION|radiation therapy|45-55Gy
223476870|NCT03434262|DRUG|Gemcitabine|Given intravenously (IV).
223476871|NCT03434262|DRUG|ribociclib|Given orally (PO).
223476872|NCT03434262|DRUG|sonidegib|Given PO.
223476873|NCT03434262|DRUG|trametinib|Given PO.
223476874|NCT03434262|BIOLOGICAL|filgrastim|Given subcutaneously (SQ).
223476875|NCT06190366|PROCEDURE|Bloodletting acupuncture at the fossa poplitea|This group is treated with bloodletting acupuncture at the fossa poplitea. The treatment takes place twice a week from week 1 to week 3. This means that 6 treatments of approx. 20 minutes each should be carried out within the 3 weeks.
223476876|NCT06190366|PROCEDURE|Bloodletting acupuncture at the regio glutaea|This group is treated with bloodletting acupuncture at the regio glutaea. The treatment takes place twice a week from week 1 to week 3. This means that 6 treatments of approx. 20 minutes each should be carried out within the 3 weeks.
223476877|NCT05622903|OTHER|Cash Benefit|Spending from the cards was not restricted to food but could be spent on anything and anywhere Visa was accepted. The debit cards were credited with the first payment on November 18th, 2020 and the second payment on December 18th, 2020. The program continued with monthly credits through August 2021.
223476878|NCT05622903|OTHER|No Cash Benefit|No monthly cash benefit.
223476879|NCT06327594|DIAGNOSTIC_TEST|ultrasound scan|The patients with lung cancer who are scheduled to undergo radical resection of lung cancer are examined by ultrasound at multiple sites of the whole body, including muscle and fat.
223476880|NCT06327594|DIAGNOSTIC_TEST|CT/MRI scan|The patients with lung cancer who are scheduled to undergo radical resection of lung cancer are examined by abdominal CT/MRI.
223476881|NCT00345267|DEVICE|Integrated Care Pathway|
223476882|NCT06508814|PROCEDURE|Lower Insufflation Pressure|Participants underwent laparoscopic hysterectomy with an insufflation pressure that is lower than the standard insufflation pressure used in this type of surgery.
223476883|NCT06508814|PROCEDURE|Standard Insufflation Pressure|Participants underwent laparoscopic hysterectomy with a standard insufflation pressure.
223476884|NCT06026436|BIOLOGICAL|Blood samples|12-24 hours after P2Y12 ADP receptor loading dose (LD)
223476885|NCT06026436|BIOLOGICAL|Blood samples|1 month after Percutaneous Coronary Intervention (PCI)
223583108|NCT05592496|DEVICE|Catheter insertion technique by using special tube t|By using special tube, it is possible to locate the catheters in retromuscular space, where they are close to cutaneous nervs
223583109|NCT05592496|PROCEDURE|"Connection of catheters bilateraly to easy pump system,"|"Connection of catheters, which are inserted in to retromuscular space, to ensure continuous receiving of Bupivacaine fluid for analgesia. Easy pump system provides continous receiving of bupivacaine fluid infusion speed - 5ml per hour"
223744532|NCT02295995|BEHAVIORAL|Exercise as an Adjuvant Therapy for Veterans with PTSD|Methods: Approximately 50 Veterans 60 years and older with PTSD will be recruited to participate in a 12-week physical activity program consisting of aerobic and strength-training activities. Participants will be randomized to an intervention arm or usual care wait-list control. Outcomes: Changes in physical function, PTSD symptom severity, and aerobic endurance will be assessed between the two study arms. Secondary outcomes include compliance with the intervention, pain, sleep, and psychological well-being.
223744533|NCT00087451|DRUG|AP23573|ridaforolimus
223744534|NCT04422028|DRUG|Desogestrel 0.075 MG|Test Drug
223744535|NCT04422028|DRUG|Desogestrel 0.075 MG|Reference Product
224304808|NCT06927453|PROCEDURE|Acrylic splint|The HAM particulate material will be packed into the extraction socket then the HAM will be tucked over the extraction socket then the socket plug will be maintained in place with approximating sutures using 5-0 resorbable suture material. The surgical site covered with the custom acrylic splint.
223476886|NCT00546442|DRUG|Metformine|850-2550 mg/daily for 48 weeks
223476887|NCT00546442|OTHER|Placebo of metformine|850-2550 mg/daily for 48 weeks
223476888|NCT03248037|DRUG|Netarsudil|netarsudil opthalmic solution 0.02%
223476889|NCT03248037|DRUG|Placebo|Placebo eye drops
223476890|NCT02517723|BEHAVIORAL|Narrative Exposure Therapy|"Narrative Exposure Therapy (NET) is based on Testimony Therapy in combination with cognitive behavioural exposure techniques and elements of client-centered counselling. The clients can restore their autobiographic memories about their traumatic experiences. In this way fragmentary memories are transformed into a coherent narrative structure. This practice enables the processing of painful emotions and the construction of clear contingencies of dangerous and safe conditions, generally leading to significant emotional recovery. Therapeutic aims are the reduction of PTSD-Symptomload via activation of fear-network and habituation of fear and the placement of traumatic experiences in a reconstructed, detailed and consistent autobiography.~NET will be applied in eight sessions (90-120min/session) in a standardized, manualized manner."
223476891|NCT02517723|BEHAVIORAL|Dialectical Behavior Therapy|"Dialectical behavior therapy is a cognitive behavioral treatment program developed by Marsha Linehan to treat suicidal clients meeting criteria for BPD. It directly targets suicidal behavior, behaviors that interfere with treatment delivery, and other dangerous, severe, or destabilizing behaviors.~Via standard DBT patients improve behavioral capabilities, motivation for skillful behavior, generalization of gains to the natural environment, structuring the treatment environment so that it reinforces functional rather than dysfunctional behaviors. It also targets the therapist capabilities and motivation to treat patients effectively. Patients get weekly individual psychotherapy (1 h/wk), group skills training (3.75 h/wk), a weekly therapist consultation team meetings."
223476892|NCT02517723|BEHAVIORAL|Standard Inpatient Care|Unspecific group therapy that is identical in both groups (music therapy etc.)
223476893|NCT02517723|OTHER|Waiting List|Treatment as usual in the community (no DBT, no exposure of trauma memories)
223476894|NCT03950882|DRUG|PXL770|Oral capsule
223476895|NCT03950882|DRUG|Placebo|Oral capsule
223583110|NCT05592496|DIAGNOSTIC_TEST|VAS scale for pain control|By using Visual Analog scale of pains, the pain score is fixed
223583111|NCT06421272|BEHAVIORAL|APP-based emotion recognition intervention|ASD children were asked to play emotion recognition-related games for eight weeks using iPAD. Two 15-minsute sessions each day was required.
223583112|NCT06421272|BEHAVIORAL|APP-based memory intervention|ASD children were asked to play memory-related games for eight weeks using iPAD. Two 15-minsute sessions each day was required.
224162999|NCT01671891|DRUG|capecitabine (625mg/m2,bid,d1-5 qw)and oxaliplatin (85mg/m2 d1 qw)|radiotherapy concurrent chemotherapy(capecitabine+oxaliplatin)
224163000|NCT03423862|OTHER|Mixed Meal Tolerance Test|"After a 10-hour overnight fast (not eating or drinking anything except water), participants will complete a mixed meal tolerance test (MMTT):~This involves participants drinking a Boost drink, like a milkshake, which will raise participants' blood sugar.~The amount of Boost will be based on participants body weight, up to a maximum of 360 mL or about 1 ½ cups, and should be consumed within 5 minutes.~An IV will be placed in participants arm and blood will be drawn from it. Blood will be drawn from the IV before and then 6 times over the next 2 hours after participants drink the Boost."
224163001|NCT04439812|OTHER|Observation|The primary aim of this study was to evaluate the influence of positive margins on the tumour's recurrence and OS after gastrectomy for GC. The secondary outcome was to analyse the possible confounding factors that could affect the recurrence and OS after gastrectomy.
223476896|NCT03035019|BEHAVIORAL|Lantern|This pilot will evaluate how the availability of a virtual stress management resource can help patients reduce anxiety and improve quality of life.
223476897|NCT05983536|DIAGNOSTIC_TEST|HIV Ag +Ab Assay Kit (Sysmex)|Using the HIV Ag +Ab Assay Kit (Sysmex) to detect the HIV antigen and antibody in serum, then verified by Human Immunodeficiency Virus (HIV 1+2) Antibody Test Kit (Immunoimprinting). The specificity of the HIV Ag +Ab Assay Kit (Sysmex) is calculated according to the specificity calculation formula.
223476898|NCT05828992|OTHER|No intervention administered|Survey only to gather people's experiences, opinions and needs.
223476899|NCT01655160|BEHAVIORAL|MT with low-intensity group (MT-LI)|The MT-LI group will receive a 30-minute MT per session followed by a 30-minute functional training.
223476900|NCT01655160|BEHAVIORAL|MT with moderate-intensity group|The MT-MI group will receive a 60-minute MT per session followed by a 30-minute functional training.
223476901|NCT01655160|BEHAVIORAL|Mirror therapy with high intensity group|The MT-HI group will receive a 90-minute MT per session followed by a 30-minute functional training
223476902|NCT01655160|BEHAVIORAL|Control intervention group|The CI group will carry out a 30-minute conventional stroke rehabilitation training per session followed by a 30-minute functional training.
223476903|NCT00001512|DRUG|Id-KLH Vaccine|
223476904|NCT00001512|DRUG|GM-CSF|
223476905|NCT05841511|BEHAVIORAL|"Chinese handwriting intervention program for children with ASD, named Go Go Handwriting - ASD version"|"The intervention program was developed and finalized by a group of occupational therapist specialists in the pediatric field. Thirty-six 20-minute activities with twelve activities for each handwriting fundamental skill were designed in this program.~All intervention activities were designed based on the characteristic of Chinese characters and included different types of characters.~The activities designed will also be graded according to the following principle: (1) the similarities between the character given, (2) the complexity of the figure or character in the activities, and (3) the frequency and level of therapist assistance.~Furthermore, a playful and interesting intervention context will also be integratedinto the program with the design of the adventure journey of an astronaut to further facilitate the motivation and participation of the participants in our program."
223476906|NCT00002438|DRUG|Itraconazole|
223476907|NCT05648734|DRUG|Corticosteroids alone|(≥ 20 mg prednisolone or its equivalent for ≥ 10 days after hospital discharge)
223476908|NCT05648734|DRUG|Corticosteroids + Colchicine|(≥ 20 mg prednisolone or its equivalent for ≥ 10 days) + Colchicine (1 mg/day for ≥ 10 days)
223476909|NCT05648734|DRUG|Corticosteroids + Pirfenidone|(≥ 20 mg prednisolone or its equivalent for ≥ 10 days) + Pirfenidone (267 mg TID for ≥ 14 days)
223476910|NCT05648734|DRUG|Corticosteroids + Colchicine + Pirfenidone for ≥ 14 days|(≥ 20 mg prednisolone or its equivalent for ≥ 10 days) + Colchicine (1 mg/day for ≥ 10 days) + Pirfenidone (267 mg TID for ≥ 14 days)
223476911|NCT02654509|BIOLOGICAL|Eastern Equine Encephalitis Vaccine, Inactivated, Dried, TSI-GSD 104|Eastern Equine Encephalitis Vaccine, Inactivated, Dried
223476912|NCT02897349|DRUG|placebo|
223476913|NCT02897349|DRUG|linagliptin|
223476914|NCT02897349|DRUG|background therapy|insulin with or without metformin
223476915|NCT05665998|DEVICE|ARC-BSI Cervical system|Unilateral implantation of a 64 channel - ECoG array over the sensory motor cortex combined with an implantation of 32 channel spinal cord stimulation system over the cervical region. The system decodes the motor attempts of the participant and translates those intentions into modulation of electrical stimulation.
223476916|NCT01289522|BIOLOGICAL|cetuximab IV|"* Cetuximab 400 mg/m² over 120 minutes on day 1 of cycle 1 only.~* Cetuximab dose will be 250 mg/m² IV over 60 minutes weekly on subsequent administrations during the four cycles of chemotherapy.~* Cetuximab dose will be 500mg/m2 IV every 2 weeks during the maintenance therapy.~Drug: Cisplatin IV : 75 mg/m2 intravenous every 3 weeks for 4 cycles~Drug: Docetaxel IV : 75 mg/m2 intravenous every 3 weeks for 4 cycles~G-CSF support with lenograstim 150 microg./m2/day is delivered after each cycle of chemotherapy."
223476917|NCT01289522|OTHER|Biopsies|No intervention, only biopsy for translational project.
223476918|NCT06279078|DRUG|Corticosteroid|oral/inhaled corticosteroid
223476919|NCT00207168|BEHAVIORAL|Compliance|
223476920|NCT05279872|DRUG|Zanubrutinib|Zanubrutinib 80mg po qd 6 weeks
223476921|NCT04222543|COMBINATION_PRODUCT|RGD PET/CT|Patients will receive an RGD PET/CT and a CT perfusion scan prior to treatment and during chemoradiotherapy
223476922|NCT03547609|OTHER|No arm intervention|No arm intervention
223476923|NCT01930591|DRUG|Ticagrelor|180 mg bolus followed by 90 mg BID
223476924|NCT01930591|DRUG|Clopidogrel|300 mg bolus followed by 75 mg OD
223476925|NCT05057520|OTHER|Questionnaire|Completion of the questionnaire by the patient after consultation with the general practitioner
223476926|NCT03113955|DEVICE|Tandem Microsphere loaded with Epirubicin|The primary objective of this study is to evaluate the safety and efficacy of transcatheter arterial chemoembolization with Tandem Microspheres loaded with Epirubicin in the treatment of patients with localized hepatocellular carcinoma (HCC)
223476927|NCT05141032|PROCEDURE|Endoscopic Submucosal Dissection with Pathfinder/Overtube device|Removal of gastrointestinal polyps via ESD
223476928|NCT03189082|PROCEDURE|Microbotox|Microbotox is the injection of multiple microdroplets of diluted botulinum toxin into the dermis of the lower face
223476929|NCT02943122|DEVICE|Ambulatory blood pressure monitor|
223476930|NCT01708603|DRUG|210 mg brodalumab|210 mg brodalumab administered SC
223476931|NCT01708603|DRUG|140 mg brodalumab|140 mg brodalumab administered SC
223476932|NCT01708603|DRUG|ustekinumab|45 mg or 90 mg ustekinumab administered SC per the labeled dosing regimen.
223476933|NCT01708603|DRUG|placebo|Placebo administered SC
223476934|NCT00001078|BIOLOGICAL|Hepatitis A Vaccine (Inactivated)|
223476935|NCT04979871|PROCEDURE|Venous bleeding|Blood samples collected 5 times with approx. 2-4 weeks interval
223583113|NCT06280534|DRUG|Test drug XT1061 capsules and placebo,Single dose group|Eight people took capsules of the test drug XT1061 and two people took a placebo.
223583114|NCT06280534|DRUG|Test drug XT1061 capsules and placebo，Multiple dosing group|D1-D7 were administered under fasting conditions for 7 consecutive days, of which D1-D6 were administered BID and D7 was administered once in the morning under fasting conditions only.Eight people took capsules of the test drug XT1061 and two people took a placebo.
223583115|NCT06280534|DRUG|Test drug XT1061 capsules and placebo，Food Impact Group|Eight people in group A took the test drug XT1061 capsules and two people took placebo, and all eight people in group B took the test drug XT1061 capsules.
223583116|NCT00265018|DRUG|Adriamycin|
223583117|NCT00265018|DRUG|Bleomycin|
223583118|NCT00265018|DRUG|Vinblastine|
223583119|NCT00265018|DRUG|DTIC|
223583120|NCT00265018|RADIATION|30 Gy IF-RT|
223583121|NCT00265018|RADIATION|20 Gy IF-RT|
223583122|NCT03519061|DRUG|Budesonide|Nasal saline irrigations with budesonide
223583123|NCT01549795|PROCEDURE|Liver transplantation|Liver transplantation using classic technique and avoiding proximal ilum dissection. The donor hepatic artery will be anastomosed to a jump graft connected to the Aorta. In case of positive margin of the bile duct at a frozen section analysis the liver transplant will be performed after an adjunctive pancreatodudodenctomy
223583124|NCT01549795|RADIATION|45 Gy external radiations|45 Gy in 30 fractions, 1,5 Gy twice a day) and 5-FU iv infusion- 3 week treatment
223583125|NCT01549795|RADIATION|Endoluminal bile duct Brachytherapy|Brachytherapy (20 Gy a 1 cm in 20-25h) - administered 2 weeks after radiotherapy completion
223583126|NCT01549795|DRUG|Capecitabine|Capecitabine - administered till liver transplantation
223476936|NCT04222491|DRUG|Peanut oral immunotherapy|Peanut oral immunotherapy for peanut allergy
223476937|NCT02739893|PROCEDURE|Scope Guide Assist|"Olympus has developed a new instrument which provides physicians a real-time, three dimensional visualization of position and configuration during colonoscopy. The Olympus ScopeGuide technology has received FDA clearance and can be used within the United States. The new technology called the 'scopeguide' has been developed that uses magnetic coils embedded into the scope to create a 3 D image of the shape of the entire scope inside the body that is projected onto the monitor to see. This acts as a GPS and shows the advancement of the scope through bends providing information on loops and thereby eliminating chances of loop formation, helping in loop reduction and also reducing the number of external maneuvers that may be required for the completion of colonoscopy."
223476938|NCT02739893|PROCEDURE|Standard procedure for colonoscopy|
223476939|NCT02230163|BIOLOGICAL|anti-CHIKV hyperimmune immunoglobulins|Anti-CHIKV immunoglobulins (CHIKVIg) were purified after the Tégéline manufacturing process from a pool of 583 plasma samples from donors in the convalescent phase of CHIKV infections. Anti-CHIKV hyper immune intravenous immunoglobulin (50 mg/ml) is prepared as a powder to be reconstituted. The therapeutic regimen will consist of 2 doses of 0.5 g/kg 12 hours apart.
223476940|NCT05122481|DIETARY_SUPPLEMENT|Vitamin C|Vitamin C (also known as ascorbic acid and ascorbate) is a vitamin found in various foods and sold as a dietary supplement.Vitamin C is a water-soluble vitamin, with dietary excesses not absorbed, and excesses in the blood rapidly excreted in the urine, so it exhibits remarkably low acute toxicity. More than one gram may cause indigestion, flatulence and stomach pain.
223583127|NCT01549795|PROCEDURE|Pre liver transplantation laparoscopic hand assisted staging|Pre liver transplantation laparoscopic hand assisted staging for sampling hepatic artery lymph nodes and assessing peritoneal disease.
223583128|NCT03842683|OTHER|CGM|This study seeks to assess CGM accuracy and develop prediction models for hypoglycemia detection and no intervention is therefore applied.
223744536|NCT02447081|DEVICE|Subjects implanted with Amulet Device|Percutaneous Left Atrial Appendage occlusion with successful implant of occlusion device.
223476941|NCT00170443|BIOLOGICAL|rHAO Trivalent Influenza Vaccine|
223476942|NCT01416038|BIOLOGICAL|DPX-Survivac|Vaccine targeting survivin antigen will be administered subcutaneously.
223476943|NCT01416038|DRUG|low dose cyclophosphamide (oral)|Low dose cyclophosphamide will be taken by mouth.
223476944|NCT03773874|OTHER|Assessment|Evaluation
223476945|NCT05069467|DEVICE|Acupuncture|For the active acupuncture group, the acupuncturist chose standard points depending on subjects' preferred positions. In addition, up to four acupuncture points were chosen on the basis of subjects' other presenting symptoms (such as fatigue, insomnia, or erectile dysfunction). The needles (30 or 40 mm and 0.25 mm gauge; Soochow, Hwato) will be inserted and manipulated until De Qi, a sensation of soreness and tingling.
223476946|NCT05069467|DEVICE|Sham Acupuncture|Treatment will be the same for the sham acupuncture, except for the following: the acupuncturist selected the same number of nonacupuncture, nontrigger points. Instead of eliciting De Qi, the needles will be minimally manipulated to avoid eliciting sensations other than initial contact with skin.
223583129|NCT01252524|DRUG|Placebo|Placebo tablet po TID before each meal with 8 oz of water for 6 months
223583130|NCT01252524|DRUG|Calcium polycarbophil|calcium polycarbophil 625 mg po TID before each meal with 8 oz water for 6 months
223583131|NCT03328858|OTHER|Ketogenic Diet|Once tolerance to the diet has been assessed, participants will be placed in the ketogenic diet, followed-up every three months until the one year completion.
223583132|NCT04035096|DRUG|Ascorbic Acid|"1. Start with IVC (intravenous ascorbic acid) 25 g biweekly, 50 g biweekly, and 75 g biweekly. If the target blood level is below 350mg/dl, the dose will titrate up to 100 g/dose or maximal dose of 1.5g/kg/dose to achieve the target level.~2. The final dose will be kept for 12 weeks.~3. Maintenance dose: 75-100g every 2 week will be maintained for additional 12 weeks"
223476947|NCT01612013|DRUG|Sodium bicarbonate plus saline|Sodium bicarbonate solution (Sodium bicarbonate 8.4%, Equiplex, Brazil) was given by adding fifteen ampoules of sodium bicarbonate (150 mEq of sodium) to 1 L of 5% dextrose. Infusion in bolus began 60 min prior to the start of contrast administration at 3.5 ml/Kg/h, decreased to 1.18 ml/Kg/h during the contrast exposure and for the next 6 hours after the procedure. Saline (0.9 percent) was given IV at a rate of 1 ml/Kg/h over 60 min prior to the start of contrast administration and followed at the same rate during and for the next 6 hours after the procedure.
223583133|NCT04035096|OTHER|Control group|"1. Selection of control group: stage IV colon cancer patients match for sex, age and chemotherapy /target therapy drugs~2. Usual care"
223476948|NCT01612013|DRUG|Intravenous NAC plus saline|Acetylcysteine (Flucistein 100 mg/ml, Neo Química, Brazil) was given via IV bolus at a rate of 150 mg/kg in 500 ml dextrose 5% over 60 min immediately before contrast exposure and followed by 50 mg/kg in 500 ml dextrose 5% during the contrast exposure and for 6 hours after the procedure. Saline (0.9 percent) was given IV at a rate of 1 ml/Kg/h over 60 min prior to the start of contrast administration and followed at the same rate during and for the next 6 hours after the procedure.
223476949|NCT01612013|DRUG|NAC plus sodium bicarbonate plus saline|Acetylcysteine was given intravenous at a rate of 150 mg/kg over 60 min before contrast exposure and followed by 50 mg/kg during the contrast exposure and for 6 hours after the procedure. Sodium bicarbonate solution(150 mEq of sodium) was began 60 min prior to the start of contrast administration at 3.5 ml/Kg/h, decreased to 1.18 ml/Kg/h during the contrast exposure and for the next 6 hours after the procedure. Saline was given intravenous at a rate of 1 ml/Kg/h over 60 min prior to the start of contrast administration and followed at the same rate during and for the next 6 hours after the procedure.
223476950|NCT01612013|DRUG|Saline|Saline (0.9 percent) was given IV at a rate of 1 ml/Kg/h over 60 min prior to the start of contrast administration and followed at the same rate during and for the next 6 hours after the procedure.
223476951|NCT01612013|DRUG|NAC plus saline|Acetylcysteine was given via intravenous bolus at a rate of 150 mg/kg over 60 min immediately before contrast exposure and followed by 50 mg/kg during and for 6 hours after the procedure. Saline (0.9 percent) was given intravenous at a rate of 1 ml/Kg/h over 60 min prior and followed at the same rate during and for the next 6 hours the procedure.
223583134|NCT06194500|DRUG|[14C]-LY3549492|Administered as oral solution.
223583135|NCT06194500|DRUG|LY3549492|Administered orally.
223583136|NCT06194500|DRUG|[14C]-LY3549492|Administered as IV infusion.
223583137|NCT04266470|DEVICE|Lara Scan|"Four (4) sensors will be placed prior to the injection of 18 F-fludeoxyglucose (18FDG) at the following sites: 7 cm above injection site; injection site; surface of palpable presumed malignant tissue; palpable carotid artery.~Standard doses of 18-FDG will be injected per Department of Radiology protocols~All injections will be evaluated to insure the total dose of 18-FDG has been injected. Injections resulting in moderate to severe extravasations, as interpreted by Lara software, will be segregated and evaluated on an individual basis.~The sensors will remain in place for 60 minutes during the 18-FDG uptake period with the patient in a reclined chair.~After the uptake time is complete, the sensors will be removed by the technologist and the participant will be released.~The study team will then upload the sensor data to a personal computer in the treatment planning room where it will be coded and processed as a Lara scan."
223583138|NCT04266470|DIAGNOSTIC_TEST|PET/CT Scan - Pre-treatment and Post-treatment|The PET/CT imaging will be conducted according to standard of care. The main alteration to process flow will be the addition of the Lucerno sensors just prior to the injection of the PET material.
223583139|NCT04404270|DIAGNOSTIC_TEST|Anti-SARS-CoV2 Serology|The anti-SARS-CoV2 serological status will be measured on a blood sample collected at Day 0.
223583140|NCT04404270|BEHAVIORAL|Questionnaire|"Epidemiological data will be collected in a questionnaire that will be filled by participants at Day 0 (Visit 1), after 3 months (Visit 2) and after 9 months (Visit 3).~The questionnaire includes:~* medical data (height, weight, smoking, history of intense stress);~* socio-demographic data (age, gender, civil/military status, function/occupation, rank category, army, family status/home composition, housing conditions, etc.);~* clinical data : history of symptoms suggestive of COVID-19 in the last 3 months, current symptoms suggestive of COVID-19;~* use of care, hospitalization, work stoppage in the last 3 months;~* contact with people who are symptomatic or proven COVID-19."
223583141|NCT04404270|DIAGNOSTIC_TEST|Anti-SARS-CoV2 serological controls and serum neutralization|Serological controls and a serum neutralization test will be performed on blood samples collected 3 months (Visit 2) and 9 months (Visit 3) after Day 0, respectively.
223583142|NCT02451891|BIOLOGICAL|MVA-EBO Z|
223583143|NCT02451891|BIOLOGICAL|ChAd3-EBO Z|
223583144|NCT02006069|DEVICE|MPP|"All patients enrolled in the study will be implanted (according to current Guidelines) with an MPP compatible CRT device.~The MPP feature will be evaluated in two study phases. Patients randomized to MPP in Phase I will have MPP programmed per the physician's discretion (no mandated MPP programming) and patients randomized to MPP in Phase II will have MPP programmed per protocol requirements (mandated MPP programming)."
223744537|NCT01787175|OTHER|Integrated Medication Manager|A theory based electronic health record. Half of the provider participants were assigned the IMM to use. The other half were assigned the VA's CPRS EHR to use for the simulation. Providers were randomly assigned to a EHR to use.
223744538|NCT03621852|DEVICE|Endoultrasound guided FNB|EUS FNB with Aquire TM device
223744539|NCT01352299|DEVICE|Macintosh Laryngoscope blade|Laryngoscopy performed with Macintosh Laryngoscope
223744540|NCT01352299|DEVICE|MacCoy|Laryngoscopy performed with MacCoy Laryngoscope
223744541|NCT01352299|DEVICE|Miller|Laryngoscopy performed with Miller Laryngoscope
223744542|NCT01352299|DEVICE|TrueView|Laryngoscopy performed with TrueView laryngoscope
223744543|NCT01148121|OTHER|Skeletal Status Assessment of a Down Syndrome Population|The investigators hypothesize that the bone deficits seen in Down Syndrome patients are similar to the phenotype seen in the down syndrome mouse model (Ts65Dn).The bone turnover markers, CBC, and DXA scan results will be used to assess the skeletal status of the down syndrome patients. This data will form the basis to establish the Ts65Dn as a reasonable proxy for pathogenesis and treatment in humans.
224163002|NCT00205751|DRUG|Thalidomide/Dexamethasone vs Melphalan/Prednisone|
224163003|NCT01255293|PROCEDURE|1000 centistoke silicone oil|Patients who are enrolled in the study and have been identified to have a complex retinal detachment requiring silicone oil tamponade may be randomly assigned to receive 1000 centistoke silicone oil.
223476952|NCT01612013|DRUG|NAC plus sodium bicarbonate plus saline|Acetylcysteine was given intravenous at a rate of 150 mg/kg over 60 min before contrast exposure and followed by 50 mg/kg during and for 6 hours after the procedure. Sodium bicarbonate solution (150 mEq/L of sodium) was given in bolus began 60 min before contrast administration at 3.5 ml/Kg/h, decreased to 1.18 ml/Kg/h during and for the next 6 hours of the procedure. Saline was given intravenous at a rate of 1 ml/Kg/h over 60 min prior to the start of contrast administration and followed at the same rate during and for the next 6 hours after the procedure.
223476953|NCT00671749|DRUG|adapalene gel, 0.3%|Applied once daily at bedtime
224163004|NCT01255293|PROCEDURE|5000 centistoke silicone oil|Patients who are enrolled in the study and have been identified to have a complex retinal detachment requiring silicone oil tamponade may be randomly assigned to receive 5000 centistoke silicone oil
224163005|NCT04904315|OTHER|Mindera Kit|The entire duration of the study, including the screening period, will be approximately 16 weeks. Mindera Kit will be applied with applicator and left on the skin for 5 minutes, and once removed, the investigational product (IP) will be placed in a buffer solution, sealed, labeled and sent to Mindera for processing.
223476954|NCT00671749|DRUG|clindamycin/benzoyl peroxide gel|Applied once daily in the morning
223583145|NCT01560052|DRUG|methylprednisolone|"Original Cohort:~Oral methylprednisolone or placebo 0.8mg/kg/day with a maximum of 48mg/day x 2months, taper by 8mg/day every month, patients will also receive optimal blood pressure control and full dose of ACE inhibitors or ARBs as recommended by guidelines~Low Dose Cohort:~Oral methylprednisolone or placebo 0.4mg/kg/day with a maximum 32mg/day and minimum of 24mg/day then reducing over 6-9months. All the patients will also receive optimal blood pressure control and full dose of ACE inhibitors or ARBs as recommended by guidelines throughout the trial.~Prophylactic trimethoprim/sulfamethoxazole (a single strength tablet daily or half a double strength tablet daily) will be used during the first 3 months after randomisation in the low dose cohort, for the prevention of severe PJP infection, unless there is a documented sulfa allergy."
223583146|NCT01560052|DRUG|Placebo|"Intervention: Drug: Placebo~Original Cohort:~Matching placebo tablets, all the patients will receive optimal blood pressure control and full dose of ACE inhibitors or ARBs as recommended by guidelines throughout the trial.~Low Dose cohort:~Matching placebo will be given reducing over 6-9months. All the patients will also receive optimal blood pressure control and full dose of ACE inhibitors or ARBs as recommended by guidelines throughout the trial.~Prophylactic trimethoprim/sulfamethoxazole (a single strength tablet daily or half a double strength tablet daily) will be used during the first 3 months after randomisation in the low dose cohort, for the prevention of severe PJP infection, unless there is a documented sulfa allergy"
224163006|NCT03658798|PROCEDURE|Functional Electrical Stimulation|Study participants will receive 40 sessions of intervention, 3 to 5 times a week over 2 to 3 months. Each session will be one hour in duration and participant will receive functional electrical stimulation therapy with their customized shirt. During therapy participants will be expected to carry out functional movements with assistance from the FES Garment.Participants will be expected to don, activate, and doff the garment as independently as possible. The exercises conducted will be defined by the investigator based on the functional status of the participant and eventual progress.
224163007|NCT05825092|DRUG|Androgel Topical Product|AndroGel® will be applied daily to the upper arms/shoulders at 9:00 am. The daily dose will be 101.25 mg in men and 20.25 mg in women. AndroGel® will be administered within 24 hours after inclusion for a period of 28 days or until hospital discharge. For patients discharged from ICU before day 28, AndroGel® will be administered in hospital wards to complete the 28 days of treatment or until hospital discharge
224163008|NCT05825092|DRUG|Placebo|Placebo gel will be applied daily to the upper arms/shoulders at 9:00 am. The daily dose will be 101.25 mg in men and 20.25 mg in women. Placebo gel will be administered within 24 hours after inclusion for a period of 28 days or until hospital discharge. For patients discharged from ICU before day 28, Placebo gel will be administered in hospital wards to complete the 28 days of
224304809|NCT06927453|PROCEDURE|No splint|The HAM particulate material will be packed into the extraction socket then the HAM will be tucked over the extraction socket then the socket plug will be maintained in place with approximating sutures using 5-0 resorbable suture material. The surgical site will not be covered
224304810|NCT02984774|PROCEDURE|Cystectomy|Segment of cystic wall from the patients for planned cystectomy was taken after operation and was preserved at -80º Celsius for further analysis
224304811|NCT02984774|PROCEDURE|Endometrial sampling|Endometrial sampling was performed at the same operation with the planned operation for the main indication and was preserved at -80º Celsius for further analysis
224304812|NCT02984774|PROCEDURE|Peripheric blood sampling|4 cc peripheric venous blood was sampled into the EDTA(Ethylenediaminetetraacetic acid)-containing tubes during catheterization for anesthesia was preserved at 4º Celsius for further analysis
224304813|NCT02984774|PROCEDURE|Ovarian tissue sampling|2cm linear tissue sample from ovarian cortex was performed at the same operation with the planned operation for the main indication and was preserved at -80º Celsius for further analysis
224304814|NCT06927960|DRUG|AH-001 or placebo|SAD: Subjects are planned to receive a single dose of AH-001 or placebo once MAD: Subjects are planned to receive a single daily dose of AH-001 or placebo for 7 consecutive days
224304815|NCT06927024|DEVICE|Active taVNS|Active taVNS delivered via the TENS Device 7000.
224304816|NCT06927024|DEVICE|Sham taVNS|Sham taVNS delivered via the TENS Device 7000.
224304817|NCT01124344|DRUG|Placebo|Oral Solution, Oral, 0 mg, Once Daily, 14 days
224304818|NCT01124344|DRUG|BMS-866949|Oral Solution, Oral, 3 mg, Once Daily, 14 days
223476955|NCT05236530|DRUG|Midazolam|Midazolam 2 mg (1 mL of 2 mg/mL oral solution) administered as a single dose in a 4-probe cocktail in the morning in Period 1 on Day 1 and in Period 2 on Day 3.
223476956|NCT05236530|DRUG|Repaglinide|Repaglinide 0.5 mg (1 x 0.5 mg tablet) administered as a single dose in a 4-probe cocktail in the morning in Period 1 on Day 1 and in Period 2 on Day 3.
223476957|NCT05236530|DRUG|Dextromethorphan|Dextromethorphan 15 mg (10 mL of 7.5 mg/5 mL syrup) administered as a single dose in a 4-probe cocktail in the morning in Period 1 on Day 1 and in Period 2 on Day 3.
224304819|NCT01124344|DRUG|BMS-866949|Oral Solution, Oral, 10 mg, Once Daily, 14 days
224304820|NCT01124344|DRUG|BMS-866949|Oral Solution, Oral, 30 mg, Once Daily, 14 days
224304821|NCT01124344|DRUG|BMS-866949|Oral Solution, Oral, 45 mg, Once Daily, 14 days
224304822|NCT01124344|DRUG|BMS-866949|Oral Solution, Oral, 60 mg, Once Daily, 14 days
223476958|NCT05236530|DRUG|Metformin|Metformin 500 mg (1 x 500 mg tablet) administered as a single dose in a 4-probe cocktail in the morning in Period 1 on Day 1 and in Period 2 on Day 3.
223476959|NCT05236530|DRUG|Ganaplacide|Ganaplacide 400 mg (4 x 100 mg tablets) administered q.d. in Period 2 on Days 1 - 3, with the 4-probe cocktail co administered on the morning of Day 3.
223476960|NCT05236530|COMBINATION_PRODUCT|Lumefantrine|Lumefantrine 960 mg (4 x 240 mg sachets) administered q.d. on Days 1 - 3, with the 4-probe cocktail (as a single dose) co administered on the morning of Day 3.
223476961|NCT05236530|DRUG|Rosuvastatin|Rosuvastatin 5 mg (1 x 5 mg tablet) administered as a single dose in a 2-probe cocktail in the morning in Period 1 on Day 1 and in Period 2 on Day 3.
224163009|NCT05825092|DIAGNOSTIC_TEST|Physical performance|"Physical performance at 3, 6 months and 1 year after ICU admission~6 minute walk distance 3 months after ICU admission, at 6 months and at 1 year Percentage of patients with Short Physical Performance Battery \< 10 at 3, 6 months and 1 year Physical component of SF 36 (Medical Outcomes Study 36 Item Short Form Health Survey) at 3, 6 months and 1 year"
223476962|NCT05236530|DRUG|Dolutegravir|Dolutegravir 50 mg (1 x 50 mg tablet) administered as a single dose in a 2-probe cocktail in the morning in Period 1 on Day 1 and in Period 2 on Day 3.
223476963|NCT05236530|DRUG|Ganaplacide|Ganaplacide 400 mg (4 x 100 mg tablets) administered q.d. in Period 2 on Days 1 - 3, with the 2-probe cocktail co administered on the morning of Day 3.
223476964|NCT05236530|COMBINATION_PRODUCT|Lumefantrine|Lumefantrine 960 mg (4 x 240 mg sachets) administered q.d. on Days 1 - 3, with the 4-probe cocktail (as a single dose) co administered on the morning of Day 3.
223476965|NCT02515227|BIOLOGICAL|6MHP|6 melanoma helper vaccine comprised of 6 class II MHC-restricted helper peptides
224163010|NCT05825092|DIAGNOSTIC_TEST|Muscle strength|"Muscle strength at ICU discharge at 3, 6 months and 1 year after ICU admission~Handgrip: Kg and percent of the predicted force Medical Research Council testing (MRC)"
223476966|NCT02515227|DRUG|Pembrolizumab|Humanized monoclonal antibody (mAb) specific for PD-1.
223476967|NCT00896259|OTHER|home based exercise and education program|Individual assessment with physiotherapist with educational information, exercise instruction and prescription provided. Instructed to perform home exercises and walking for 12 weeks. Will be individually tailored to participants, bi-monthly phone calls will be used to monitor and facilitate exercise and walking progression .
223476968|NCT04489342|DEVICE|IMU sensor test|Measurement of maximum range of movement in the spine; Ambulatory observational data while performing standardised functional tests
223476969|NCT05244200|OTHER|Pharmaceutical care and insulin staging.|Pharmaceutical care is a patient-centered practice in which the practitioner assumes responsibility for a patient's drug-related needs and is held accountable for this commitment. Due to the progressive nature of Type 2 Diabetes Mellitus, which requires timely optimization of treatment, leading in a majority of cases to insulin therapy, so that proper use of insulin is one of the critical tools for prevention of long-term complications. From the hundred patients in this study, half of the patients will be the control group without any intervention, and pharmaceutical care and insulin staging will be applied on the remaining. In this research two strategies will be applied including pharmaceutical care process and Insulin Staging approach on patients with T2DM, those who are on end stage treatment.
223476970|NCT00922311|DRUG|Aliskiren|Titrate from 150 mg daily to 300 mg daily
223476971|NCT03265561|DEVICE|Bone allograft|All patients will undergo the same surgical procedure consisting of open surgery, more debridement of infected and devitalized tissue, as well as corresponding bone resection. For the identification of the microorganism, biopsies will be performed by puncture guided by CAT and / or fluoroscopy, and culture and antibiogram will be performed in case of not obtaining enough material for this, at the time of the surgery samples will be sent to perform the same procedure. We will use the appropriate antibiotics, according to infecting microorganism and result of antibiogram. We will include patients with infections with gram positive and negative microorganisms only. This patients will go stabilized with bone allograft only.
223476972|NCT03265561|DEVICE|Bone auto and allograft group|All patients will undergo the same surgical procedure consisting of open surgery, more debridement of infected and devitalized tissue, as well as corresponding bone resection. For the identification of the microorganism, biopsies will be performed by puncture guided by CAT and / or fluoroscopy, and culture and antibiogram will be performed in case of not obtaining enough material for this, at the time of the surgery samples will be sent to perform the same procedure. We will use the appropriate antibiotics, according to infecting microorganism and result of antibiogram. We will include patients with infections with gram positive and negative microorganisms only. This patients will go stabilized with bone autograft plus bone allograft
223476973|NCT01259245|OTHER|Tai chi + PRP|The exercise content was totally identical to PRP group except 15 minutes of 5 Sun Style Tai Chi were substituted to 15 minutes of relaxation exercise
223476974|NCT01259245|OTHER|PRP|Formal pulmonary rehabilitation program consisted of overview of COPD management, aerobic exercises, breathing control exercises, Thera-Band strengthening exercises, safety precautions for physical training and goal setting
223476975|NCT03139500|DRUG|JNJ-61803534|Participants will receive JNJ-61803534 tablets orally.
223476976|NCT03139500|DRUG|Placebo|Participants will receive matching placebo.
223476977|NCT03139500|DRUG|Midazolam|Participants will receive single oral dose of midazolam.
223476978|NCT02258061|PROCEDURE|DDD-80|Basal pacing rate set to 80-bpm. Note:Patients have already pacemaker implanted before this study.
223476979|NCT02258061|PROCEDURE|DDD-60|Basal pacing rate set to 60-bpm. Note:Patients have already pacemaker implanted before this study.
223476980|NCT00858286|OTHER|Spirometry, PEF measurements and diary cards to evaluate control of Asthma|No intervention is made with the existing therapy, but patient will perform spirometry and PEF evaluations together with a registration of control of asthma in diary cards and health economic parameters in questionnaires
223476981|NCT05660876|PROCEDURE|standard fistulotomy|in a standard manner fistula tract was identified and laid open without doing marsupialization
224163011|NCT05825092|DIAGNOSTIC_TEST|Muscular mass|"Muscular mass at 3, 6 months and 1 year after ICU admission~Mid-arm muscle circumference (MAMC)"
224163012|NCT05825092|DIAGNOSTIC_TEST|Test: Functional status|"Functional status at 3, 6 months and 1 year after ICU admission~• Composite score of 11 items of Activities of Daily Living (ADL) and Instrumental Activities of Daily Living (IADL)"
224304823|NCT01124344|DRUG|BMS-866949|Oral Solution, Oral, 90 mg, Once Daily, 14 days
223476982|NCT05660876|PROCEDURE|fistulotomy with marsupialization|in this arm fistulotomy was done in a standard manner and marsupialization was done
224163013|NCT05825092|DIAGNOSTIC_TEST|Oxygen muscular consumption|"Oxygen muscular consumption at ICU discharge and at 3 months after ICU admission~Ventilation free days at day 28 Length of stay in ICU Length of stay in hospital Mortality rate at day 28 Mortality rate at day 90 ICU mortality rate Hospital mortality rate"
224163014|NCT02327312|DEVICE|Stents|Two Trabecular meshwork Micro-Bypass stents into the study eye
223476983|NCT04638062|OTHER|1.Post Isometric Relaxation|"For Upper Trapezius In supine position Neck flexion, contra-lateral full side bending followed by slight ipsilateral rotation will be provided towards the side being treated. while asking the patient to shrug the stabilized shoulder and contraction will be maintained for 7- 10s. Repeating it 3-5 times.~For Levator Scapulae Step One In supine position while lifting the patients neck in full flexion, lateral flexion and rotation with 7-10s isometric contraction away from side to be treated will be provided.~Step Two The patient will be instructed to take head backwards to the table while at the same time asking the patient to slightly shrug the shoulder and resistance will be provided. Repeating it 3-5 times.~2.Neck isometric strengthening exercises Intensity 5 reps Frequency at 1st week one set and second week will progress to 2 sets~3.Cryotherapy will be placed on cervical region for 10 min after the treatment."
224163015|NCT02327312|PROCEDURE|Laser|Laser Trabeculoplasty
224163016|NCT02327312|DEVICE|Laser Trabeculoplasty|
224163017|NCT05094804|DRUG|OR2805|IgG1 monoclonal antibody that binds specifically to the CD163 protein.
223476984|NCT04638062|OTHER|1.Myofascial Release therapy|"For Upper Trapezius In sitting position Myofascial Release of Trapezius will be performed unilaterally with soft fist or elbow sinking and then taking up the line of tension from mid belly of Trapezius, to the acromion process, while the patient drops the head forward and will slowly rotate the head from side to side. While providing the resistance to contralateral side of rotation. Repeating for 2-3 times.~For Levator Scapulae In sitting position applying same unilateral muscle release as Trapezius, but the line of tension will be to the inferior border of Scapulae slightly laterally and will ask the patient to drop the head forward to increase resistance on Levator muscle. Repeating it 2-3 times~2.Neck isometric strengthening exercises Intensity 5 reps Frequency at 1st week one set and second week will progress to 2 sets~3.Cryotherapy will be placed on cervical region for 10 min after the treatment."
224163018|NCT05094804|DRUG|Cemiplimab|IgG4 mAb that binds to PD-1 and blocks its interaction with PD-L1 and PD-L2.
224304824|NCT01124344|DRUG|BMS-866949|Oral Solution, Oral, 3-60 mg, Once Daily, 14 days
223476985|NCT00447083|DEVICE|UVB|UVB exposure by a tanning bed
223476986|NCT00447083|PROCEDURE|Non-UVB|Non-UVB exposure by a tanning bed
223583147|NCT03897894|BEHAVIORAL|Child Friendly Space|Child Friendly Spaces (CFS) are one of the most widely used interventions to provide Mental Health and Psychosocial Support (MHPSS) as well as provide a protective environment for children in humanitarian settings.
223583148|NCT02893124|DRUG|peginterferon alfa|peginterferon alfa-2a 180 micrograms/week or peginterferon alfa-2b 80 micrograms/week, for at most 96 weeks.
223583149|NCT00955149|DRUG|Erlotinib (Tarceva)|Patients with PSC found to be positive for Trisomy 7 on biliary brushings will be treated with Erlotinib (Tarceva) at a dose of 25 mg or 50 mg by mouth once daily for 6 months.
223583150|NCT03169257|BEHAVIORAL|diet plus physical activity|OB subjects will undergo an isocaloric Mediterranen balanced diet plus a daily aerobic training for at least 60 minutes. All the evaluations will be performed at baseline and after 6 and 12 months of this behavioral therapy. To assess food consumption, foods will be divided according to the classic basic food groups by the Italian Institute of Research on Food and Nutrition. Food frequencies questionnaires, validated for a wide range of ages, will be also completed by parents. Physical activity will be recorded by parents daily on a specific questionnaire.
223583151|NCT05713084|OTHER|mandibular setback using BSSRO|mandibular setback using BSSRO
223583152|NCT02066129|DRUG|Fluticasone 44 mcg|Fluticasone is an inhaled corticosteroid
224163019|NCT05094804|DRUG|Docetaxel|An antineoplastic agent that acts by disrupting the microtubular network in cells that is essential for mitotic and interphase cellular functions.
224163020|NCT03702855|DRUG|Tetrabenazine Tablets 25 mg|
224163021|NCT00946023|DRUG|Fludarabine|Days -6 through -2: 30 mg/m\^2 IV daily
224304825|NCT00044980|PROCEDURE|nutritional support|
224304826|NCT00044980|PROCEDURE|quality-of-life assessment|
224304827|NCT03544879|BEHAVIORAL|Yoga Intervention|The 60-minute yoga sessions began with a brief breathing practice led by the instructor. The yoga instructor then led students through yoga poses at a gentle pace using chairs as props as needed. The pace of the class increased slowly over time as students became more familiar and more capable with the poses. Meditation and breathing was followed by chair poses (15-20 minutes), standing poses (10-15 minutes), floor poses (15 minutes), and lastly a supine resting pose (Savasana; 10 minutes). In the Silver Age Yoga method at that time, there were 73 available postures overall including: 35 Chair Postures, 18 Standing Postures, 20 Floor Postures, with a typical class covering 20-25 poses.
223583153|NCT02066129|DRUG|Fluticasone 220 mcg|Fluticasone is an inhaled corticosteroid
224163022|NCT00946023|DRUG|Cyclophosphamide|Days -6 and -5: 14.5 mg/kg IV daily; Days 3 and 4: 50 mg/kg IV daily
224163023|NCT00946023|RADIATION|Total body irradiation|Day -1: 200 centigray (cGy) in a single fraction
224163024|NCT00946023|DRUG|Tacrolimus|Start on Day 5 through Day 180
224163025|NCT00946023|DRUG|Mycophenolate Mofetil|Days 5 through 35: 15 mg/kg PO three times daily (max 3 g/day)
224163026|NCT00946023|DRUG|Rituximab|Day 30 and every week after for 8 total doses: 375 mg/m\^2 IV
224163027|NCT00946023|BIOLOGICAL|Allogeneic Bone Marrow Transplant (BMT)|Day 0: Donor bone marrow infusion
224163028|NCT06120933|DIETARY_SUPPLEMENT|Hair Nutra Growth Supplement & Hair Nutra Boost Supplement|"Study Initiation (Week 0) to Week 8:~Each participant will take both the Hair Nutra Growth capsules and the Hair Nutra Boost capsules.~Participants should take 2 capsules of Hair Nutra Growth daily, one in the morning and one in the afternoon, with food or after a meal. The capsules should be taken with water.~Participants should take 1 capsule of Hair Nutra Boost daily with food or after a meal. These capsules should also be taken with water."
224163029|NCT06120933|DIETARY_SUPPLEMENT|Hair Nutra Growth|"From Week 9 to Week 12:~Participants should ONLY take the Hair Nutra Growth. Participants should take 1 capsule of Hair Nutra Boost daily with food or after a meal. These capsules should also be taken with water."
223476987|NCT04271215|OTHER|Chemotherapy protocol used|Chemotherapy protocol used in each participating hospital
223476988|NCT06228339|DRUG|Alfuzosin Hydrochloride 10 mg Prolonged-release Tablets|Alfuzosin Hydrochloride 10 mg Prolonged-release Tablets (Test Drug)
223476989|NCT06228339|DRUG|Xatral® XL 10 mg|Xatral® XL 10 mg (Reference Drug)
223476990|NCT01856933|DRUG|PSMA ADC|2.5 mg/kg, IV, over 60 minutes every 3 weeks
224163030|NCT02457299|PROCEDURE|Two Stage Esophagectomy|Patients will undergo laparoscopic staging and ischemic gastric conditioning and pyloric Botox injection 7-10 days prior to an esophagectomy with gastric pull-up reconstruction
224163031|NCT02457299|PROCEDURE|One Stage Esophagectomy|Patients will undergo an esophagectomy with gastric pull-up reconstruction without any preconditioning.
223476991|NCT02171624|DRUG|dabigatran etexilate|
223476992|NCT02171624|DRUG|quinidine|
223476993|NCT05327582|DRUG|Durvalumab|Administered intravenously, 1000 mg on day 1 in a 3-week cycle
223476994|NCT05327582|DRUG|Lenvatinib|Administered orally, 8mg/d once daily in a 3-week cycle
223476995|NCT05327582|DRUG|Nab paclitaxel|Administered intravenously, 180-220 mg/m2 on day1 in a 3-week cycle
223476996|NCT00217490|BEHAVIORAL|dietary counseling via computer|An interactive computer program that addresses dietary change, barriers to change and possible solution to barriers to develop an action plan
223476997|NCT00217490|BEHAVIORAL|dietary counseling via nutritionist|A one on one counseling sessions to addresses dietary change, barriers to change and possible solution to barriers to develop an action plan
223476998|NCT00217490|BEHAVIORAL|combined computer and nutritionist|An interactive computer program plus one on one nutrition counseling that addresses dietary change, barriers to change and possible solution to barriers to develop an action plan
224304828|NCT03544879|BEHAVIORAL|Healthy Aging Education|The health education comparison intervention consisted of once weekly, 90-minute health information workshops conducted in group format. The 90-minute sessions generally consisted of a 60-minute lecture followed by 30 minutes of questions and discussion. The lecture titles for Weeks 1-10 were as follows: Introduction/ Exploring Communication, The Science of Successful Aging, Acupuncture 101: How it Works \& What it is Good for, Quality of Life/Quality of Well Being, Fighting Cancer With Your Fork, Forgiveness via Shakespeare's: A Winter's Tale, Better Eyesight in Minutes a Day, Brain Fitness, The Importance of Organic Foods/ Organic Gardening, How Dementia Can Be Modified. Lectures were provided by a mix of credentialed experts (physicians/psychologists, etc) and other clinicians. Instructors were asked not to talk about yoga or medication in their lectures. Content was not otherwise closely monitored.
224304829|NCT00125411|DRUG|satraplatin and docetaxel|"Satraplatin - oral administration within 2 hours of docetaxel infusion. Subsequent dosing will be on days 2-5 at approximate 24 hour intervals.~Docetaxel will be administered as intravenous infusion over 1 hour followed by saline flush."
224304830|NCT03485053|DRUG|IOP Injection / MPB-1514|Dilute with 5% Dextrose solution (D5W)
224304831|NCT05486455|DIAGNOSTIC_TEST|Low-dose chest CT scan|baseline, 1-year, 3-year and 5-year low-dose CT scan
223476999|NCT00217490|OTHER|physical activity counseling via computer|An interactive computer program that addresses increase to physical activity, barriers to change and possible solution to barriers to develop an action plan
223477000|NCT03363906|DRUG|Dulaglutide (Reference)|Administered SC
223477001|NCT03363906|DRUG|Dulaglutide (Test)|Administered SC
223477002|NCT01513655|DEVICE|LTNIV|LTNIV with the ventilator and the settings and pressures which reversed the respiratory failure and the hypercapnic acidosis. We know the patients are able to tolerate these settings. The ventilators are Philips A30. The patients must use the ventilator for a minimum of six hours a night.
223477003|NCT06179459|PROCEDURE|Endoscopic management of pancreatic fluid collections|Patients with pancreatic fluid collections will be undergoing EUS-guided drainage and/or endoscopic necrosectomy
223477004|NCT03282864|DEVICE|Bedroom air filtered by an air filtration device to remove airborne pollutants|The air in the bedroom of study subjects in the active comparator arm was processed by an air filtration device which pulled air through a pre-filter, a high efficiency particular air (HEPA) filter and an active carbon filter continuously. The air in the bedroom of subjects in the placebo arm was processed by a placebo air filtration device that looked identical to the real air filtration device but did not possess the HEPA filter and the active carbon filter. Each subject was assigned to the active comparator arm and the placebo arm in a randomized order with a two-week washout period scheduled in-between. The subjects, their guardians and the study staff that assessed the health indicators of the subjects were blinded to this order till the end of the study.
223477005|NCT03764605|DRUG|Metformin|Patieny will be treated by using Metformin from 500 mg a day to 500 mg thrice a day.
223477006|NCT03764605|DRUG|Tolvaptan|Patients will be treated with tolvaptan from 45 mg + 15 mg a day to 90 mg + 30 mg a day
223477007|NCT03261999|DRUG|Leuprolide Mesylate|Subcutaneous injection of 25mg Leuprolide Mesylate
223477008|NCT02714153|DEVICE|Bridge Balloon|The Bridge Balloon will be used in a non-emergent setting to allow for evaluation of how best to integrate this new technology into the investigators clinical practice. The study will focus on the effect of the Bridge balloon on the patient preparation clinical workflow, ease of insertion/positioning/deployment, and the ability to recognize proper inflation and vein sealing under fluoroscopy.
223583154|NCT06505486|DRUG|Gemcitabine-Oxaliplatin Regimen|Hepatic arterial infusion chemotherapy (HAIC) of gemcitabine and oxaliplatin (GEMOX) plus systemic gemcitabine chemotherapy (GEM-SYS) combined with lenvatinib and programmed cell death protein-1 (PD-1) inhibitor.
223477009|NCT02363088|OTHER|Neutral text message reminder|"Your cervical smear test is due. To book please call \<xxxxxxxxxxx\>"
223477010|NCT02363088|OTHER|Messenger text message reminder|"\<GP NAME\>: Your cervical smear test is due. To book please call \<xxxxxxxxxxx\>"
223477011|NCT02363088|OTHER|Social Norms A reminder|"Last year in Hillingdon 7 out of 10 women took part in cervical screening. Your cervical smear test is due. To book please call \<xxxxxxxxxxx\>"
224163032|NCT03898388|PROCEDURE|Bone Marrow Concentrate treatment|Correlate patient outcomes 6 months after receiving the Regenexx SD treatment with measurements of synovial fluid collected before treatment
224163033|NCT00735098|OTHER|KBA exercise|KBA exercise protocol, 3 times per week for 8 weeks
223477012|NCT02363088|OTHER|Social Norms B reminder|"Last year 12000 women in Hillingdon took part in cervical screening. Your cervical smear test is due. To book please call \<xxxxxxxxxxx\>"
224163034|NCT00735098|OTHER|strength training exercise|strength training exercise, 3 times per week for 8 weeks
223477013|NCT02363088|OTHER|Framed Gain text reminder|"Cervical cancer screening saves 4500 lives in England every year. Your cervical smear test is due. To book please call \<xxxxxxxxxxx\>"
223477014|NCT02363088|OTHER|Framed Loss text reminder|"Failing to attend cervical screening could lead to 4500 avoidable deaths in England each year. Your cervical smear test is due. To book please call \<xxxxxxxxxxx\>"
223477015|NCT02196129|DRUG|Sinbaro-3|1cc administered to site of pain(ashi acupoints), once and once only before any other intervention/if pain in both low back and extermities, the site of most pain
223477016|NCT02196129|DRUG|Hwangryun|1cc administered to site of pain(ashi acupoints), once and once only before any other intervention/if pain in both low back and extermities, the site of most pain
223477017|NCT03271697|DRUG|Astragalus Membranaceus|This research is trying to see if AM can enhance the clinical prognosis for spontaneous aneurysm ruptured subarachnoid hemorrhage patients.
223477018|NCT03271697|DRUG|Placebo|as a comparator comparing with AM group
223477019|NCT03130413|DEVICE|Ambu Aura Gain supraglottic airway|Anesthesia is induced with sevoflurane in oxygen. The anesthesia plane is gradually deepened by increasing the inspired concentration of sevoflurane (2-8%) till the loss of eyelash reflex. After intravenous (IV) cannula is inserted and intravenous fentanyl 1mcg/kg and rocuronium 0.6mg/kg are administered. Use of neuromuscular blocking agent is to minimize the risk of reflex activation of the airway. After 3 minutes, the appropriate size (depending upon body weight) of Ambu Aura Gain is lubricated with water soluble lubricant (KY jelly) is inserted by investigator based on manufacturer recommendation with the patient's head in neutral position. The cuff then is inflated to an intra-cuff pressure of 40 cm H20, measured using a digital cuff pressure monitor.
223477020|NCT03130413|DEVICE|Air-Q supraglottic airway|Anesthesia is induced with sevoflurane in oxygen. The anesthesia plane is gradually deepened by increasing the inspired concentration of sevoflurane (2-8%) till the loss of eyelash reflex. After intravenous (IV) cannula is inserted and intravenous fentanyl 1mcg/kg and rocuronium 0.6mg/kg are administered. Use of neuromuscular blocking agent is to minimize the risk of reflex activation of the airway. After 3 minutes, the appropriate size (depending upon body weight) of Air-Q supraglottic airway is lubricated with water soluble lubricant (KY jelly) is inserted by investigator based on manufacturer recommendation with the patient's head in neutral position. The cuff then is inflated to an intra-cuff pressure of 40 cm H20, measured using a digital cuff pressure monitor.
223477021|NCT00516646|DRUG|ALT-711|200 mg bid
223477022|NCT00516646|DRUG|Placebo|bid
223477023|NCT03453294|DEVICE|Apnoeic oxygenation using THRIVE|Apnoeic oxygenation using THRIVE
223477024|NCT03453294|DEVICE|Endotracheal intubation and mechanical ventilation|Endotracheal intubation and mechanical ventilation
223477025|NCT00485823|DRUG|Olanzapine Hydrochloride|
223477026|NCT00485823|PROCEDURE|Weight Management Program|
223477027|NCT02936765|DEVICE|Anterior cervical discectomy with prosthetic disc replacement / ESP.|Anterior cervical discectomy, with the use of the ESP prosthesis (Manufacturer: FH orthopedics, Mulhouse, France) for the disc replacement.
223477028|NCT02936765|DEVICE|Anterior cervical discectomy with prosthetic disc replacement / Squale.|Anterior cervical discectomy, with the use of the Squale spacer (Manufacturer: OSD, Avignon, France) for the disc replacement.
223477029|NCT02192788|RADIATION|Stereotactic Body Radiation Therapy for Oligometastases|
223477030|NCT04599231|DIAGNOSTIC_TEST|Quality of Recovery -15|The investigators plan to evaluate patients' quality of recovery at postoperative day (POD) 1, 2, and 3.
223477031|NCT05363202|DRUG|Fluticasone propionate Inhalation Aerosol 44 mcg|Dosage Form: Metered dose Inhalation Aerosol Dosage Frequency 44 mcg (two inhalations; twice daily (i.e. morning \& evening approximately. 12 h apart, Mode of Administration: Oral inhalation
223477032|NCT05363202|DRUG|FLOVENT HFA 44 mcg|Dosage Form: Metered dose Inhalation Aerosol Dosage Frequency 44 mcg (two inhalations; twice daily (i.e. morning \& evening approximately. 12 h apart, Mode of Administration: Oral inhalation
223477033|NCT05363202|DRUG|Matching Placebo inhaler|Dosage Form: Metered dose Inhalation Aerosol Dosage Frequency 44 mcg (two inhalations; twice daily (i.e. morning \& evening approximately. 12 h apart, Mode of Administration: Oral inhalation
224163035|NCT00735098|OTHER|KBA and strength training|KBA and strength training exercise, 3 times per week for 8 weeks
223477034|NCT03798743|DRUG|Sintilimab Combined With Docetaxel|Sintilimab 200mgi.v q3w Docetaxel 75mg/m2 i.v q3w
223583155|NCT05329870|OTHER|SNP array|SNP arrays for known bleeding SNPs to compare genetics of patients with normal colonoscopy and normal qFIT vs raised qFIT
223583156|NCT04861428|OTHER|IQOS|IQOS is a heat-not-burn tobacco product (consisting of an electronic heating device and Heatstick tobacco rods).
224163036|NCT00735098|OTHER|Control group|8 week control group
224163037|NCT04925947|DRUG|KN046|KN046 will be given intravenously at 5 mg/kg every 2 weeks. A cycle is defined as 2 treatments (28 days). Treatment will be given until progression, excessive toxicity, or up to two years.
224163038|NCT04379947|PROCEDURE|Fractional Flow reserve|Measurement of fractional flow reserve in the preoperative work-up for oronary artery bypass surgery
224163039|NCT00441480|DIETARY_SUPPLEMENT|Plant sterols esters|1.6g phytosterols and 1.3g omega-3 fatty acids per day
224163040|NCT00441480|DIETARY_SUPPLEMENT|placebo|4 gr of corn oil
224163041|NCT03771495|OTHER|Joint Mobilization|Manual Therapy Intervention, commonly used by physiotherapists
224163042|NCT03771495|OTHER|Laying on of Hands|Sham Hip Joint Mobilization
224163043|NCT01956994|DIETARY_SUPPLEMENT|Whey protein supplement|Supplements will be provided in powder form and mixed into beverages to be consumed twice per day (after breakfast and after dinner).
224163044|NCT01956994|DIETARY_SUPPLEMENT|Carbohydrate supplement|Supplements will be provided in powder form and mixed into beverages to be consumed twice per day (after breakfast and after dinner).
224163045|NCT02561780|BEHAVIORAL|Curriculum|A mental health educational resource delivered in the classroom by trained educators
224163046|NCT02561780|BEHAVIORAL|eLearning Follow-up|An online mental health education module that students access individually
223477035|NCT02532504|OTHER|CBT|"8 sessions of CBT based intervention called change your life with seven sheets of paper by Prof. Chris Williams. These sheets cover key skills of CBT that are;~1. Five Areas vicious circle~2. Bad thought spotter~3. Amazing Bad thought Busting Programme (ABTPB)~4. Easy 4 Step plan~5. Things you do that mess you up/Confidence sheet~6. Happy List/ Things you do that boost how you feel sheet~7. Planner and Review sheets"
223477036|NCT01869309|DRUG|Prasugrel|Patients will discontinue ticagrelor treatment and start 10 mg prasugrel daily while continuing 81 mg of aspirin daily.
223477037|NCT01869309|DRUG|Ticagrelor|Patients will be given 180 mg of Ticagrelor followed by 90 mg twice a day while continuing 81 mg of aspirin daily).
223477038|NCT04186156|DRUG|KA2507|KA2507, an orally-active new chemical entity, is a potent and selective inhibitor of the HDAC6 enzyme, with potential clinical utility in the treatment of melanoma and other solid tumors. KA2507 has been shown to display potent in vitro activity in a range of cancer cell lines, including melanoma cell lines. KA2507 exerts potent in vivo efficacy in a syngeneic model of B16 melanoma. Here, the combination of the agent's direct tumor growth inhibition and metastasis suppression, coupled with its immunotherapeutic activity - demonstrated by decreased expression of STAT-3 and PD-L1 and increased expression of acetylated tubulin, gp100 and MHC Class I in tumors - have been observed.
223477039|NCT03442452|OTHER|Electronic Decision Aid Tool|The AML Decision Aid tool consists of ten video modules, approximately 3 minutes each, containing content regarding key areas such as an explanation of what AML is, treatment choices, and things to consider when determining a treatment path.
223477040|NCT05951634|DEVICE|PerQseal ELITE|"Percutaneous ELITE Arterial Closure Device~The term PerQseal Elite used singularly refers to the closure system comprising the closure device and Introducer. These individually are referred to as: PerQseal Elite VCD or PerQseal Elite closure device and/or PerQseal Elite Introducer."
223477041|NCT04179682|PROCEDURE|40-hour constraint-induced movement therapy|Participants were randomly allocated to 1 of 2 CIMT programs (40 hours): a 2-week 4-hours/day CIMT program and a 4-week 2-hours/day CIMT program. One CIMT program was performed 1 month after a BoNT-A injection, and then the second program was implemented with the next injection.
223477042|NCT02346318|DRUG|Compound Kushen Injection|Compound Kushen Injection 20ml i.v.drip qd, synchronize with radiotherapy, total dosage is 400ml.
223477043|NCT02760303|BEHAVIORAL|Cognitive Behavioral Therapy|Participants will attend group therapy sessions, once a week for 9 weeks. The focus of these sessions will be the thought-emotion-behavior linkages as outlined by cognitive-behavioral theory. Activities will illustrate how thoughts affect emotions and behaviors, the application of these activities to current stressors, and strategies to apply these new skills to future stressors.
223477044|NCT02760303|BEHAVIORAL|Mindfulness Based Stress Reduction|Participants will attend group therapy sessions, once a week for 9 weeks. The focus of these sessions will be understanding how to gain control over one's thoughts and feelings using relaxation, meditation, and other mindfulness-based techniques. Activities will focus on the instruction and practice of mindfulness techniques, such as meditation and yoga, and the application of these practices to everyday activities.
223477045|NCT02760303|BEHAVIORAL|Diabetes Support and Education|Participants will attend group therapy sessions, once a week for 9 weeks. Participants will receive diabetes education via a support group format. The focus of these sessions will be peer group social support and non-adherence diabetes education topics (e.g., emergency preparedness, smoking and diabetes).
223477046|NCT02423408|DRUG|TNX-201|TNX-201 capsule
223477047|NCT02423408|DRUG|Placebo|Placebo capsule
223477048|NCT04479046|OTHER|PMMA crowns|New type of pediatric crowns
223477049|NCT02655874|BIOLOGICAL|Influenza vaccine|Administered at day 1
223477050|NCT02655874|BIOLOGICAL|Influenza vaccine|Administered at day 180
223477051|NCT02655874|BIOLOGICAL|Tetanus-diphtheria-pertussis vaccine|Administered at day 180
223477052|NCT02774083|BEHAVIORAL|Feuerstein Program|Mediated learning cognitive enhancement program
223477053|NCT02774083|BEHAVIORAL|Adler Program|Social and emotional group program
223477054|NCT01687699|DRUG|Spironolactone|
223477055|NCT05362201|PROCEDURE|therapeutic position of the anterior repositioning splints|the ADDWR paricipants will be allocated into 2 grounps and treated with anterior repositioning splints determined by traditional and digitial method respectively.
223583157|NCT04861428|OTHER|Smoking as Usual|Cigarette smoking
223583158|NCT05418595|OTHER||
223583159|NCT03930992|DRUG|Colaren in HIV positive|1 Arm (HIV+): will receive Zoledronic acid 4mg and colaren ® (vitamin D, magnesium, phosphate, calcium).
223583160|NCT03930992|DRUG|standard treatment in HIV positive|2 Arm (HIV+): will receive Zoledronic acid 4mg and standard treatment (vitamin D and calcium carbonate)
224163047|NCT05823792|DIAGNOSTIC_TEST|Non-invasive diagnosis of ileocolic intussusception by ultrasound with indication for surgery|Non-invasive diagnosis of ileocolic intussusception by ultrasound with indication for surgery
224163048|NCT03785444|OTHER|WHODAS 2.0|WHO Disability Score
224163049|NCT03785444|OTHER|EQ5D|Health related quality of life measured with European Quality of Life 5 Dimensions 5 Level
224304832|NCT01176214|PROCEDURE|Early tracheostomy|"Patients with supratentorial ICH who require mechanical ventilation, fulfill the inclusion criteria, and have been randomized to the treatment arm will receive an early tracheostomy within 72h after symptom onset."
223583161|NCT03930992|DRUG|Colaren in HIV negative|3 Arm (HIV-): will receive Zoledronic acid 4mg and colaren ® (vitamin D, magnesium, phosphate, calcium).
223583162|NCT03930992|DRUG|standard treatment in HIV negative|4 Arm (HIV-): will receive Zoledronic acid 4mg and standard treatment (vitamin D and calcium carbonate)
223583163|NCT03255759|DIAGNOSTIC_TEST|Multiplex molecular diagnostic assay|To assess the added value and acceptability of a multiplexed molecular diagnostic assay in the identification of pathogens in patients presenting with bacteremia at hospitals in LMICs, and to assess health care providers' satisfaction with the assay.
224163050|NCT03785444|OTHER|IADL|The Lawton Instrumental Activities of Daily Living
224163051|NCT03785444|OTHER|Barthel-Score|Barthel Score of the patient
224163052|NCT03785444|OTHER|SF-36|Short Form Health 36
224163053|NCT03785444|OTHER|MoCA Blind|Montreal Cognitive Assessment
224163054|NCT02705222|PROCEDURE|D&C|Cervical dilatation and fractional endometrial curettage will be done in operation theatre and the curetting will be sent for histopathological examination
223477056|NCT06424808|OTHER|Consolidating content on a single website and providing access to it via QR codes in a brochure format|The group assigned to the experimental group will receive information in the same manner as current patients do, with the addition of receiving a brochure once when moving to a general ward after surgery. Afterward, they are free to use the brochure. The control group will receive information only in the manner currently provided to patients.
223477057|NCT05612321|DEVICE|Vacuum application|vacuum-assisted delivery
224304833|NCT01176214|PROCEDURE|Late tracheostomy|"Compared to the early tracheostomy-group, those patients who have been randomized to late tracheostomy will undergo conventional tracheostomy between day 12 - 14 if extubation fails"
223477058|NCT04020562|OTHER|Mild Resistive Expiratory Technique|"Mild Resistive Expiratory Technique (EMST150- five-week training protocol):~The EMST requires the participant to forcibly blow into the device for 5 seconds with sufficient pressure to open the one-way valve. Each blow is one repetition. The device will be set at a resistance of 30 cmH2O. Participants will be instructed to complete five sets of five repetitions (total of 25 times and approximately 20 minutes per day), any five days per week, for five weeks. Whole exercise will be done in sitting position. Rest between repetitions will be given according to comfort level of patient."
223583164|NCT01479582|DRUG|Access to unlicensed cord blood units|
223583165|NCT06262256|BEHAVIORAL|High-intensity interval training|supervised exercise conducted on stationary bikes after individualized intensity prescription.
223583166|NCT02787590|DRUG|Simvastatin|
223583167|NCT02787590|DRUG|Matched Placebo (for Simvastatin)|
224070168|NCT05798260|DIAGNOSTIC_TEST|Agilent Seahorse XF Cell Mito Stress Test|The Agilent Seahorse XF Cell Mito Stress Test measures key parameters of mitochondrial function by directly measuring the oxygen consumption rate (OCR) of cells on the Seahorse XFe and XF Extracellular Flux Analyzers. It is a plate-based live cell assay that allows to monitor spare respiratory capacity (SRC), basal respiration, ATP production-coupled respiration, maximal respiration, and non-mitochondrial respiration in real time before and after ketone monoester
223477059|NCT04020562|OTHER|Conventional Training|"Breathing exercise: Deep breathing 10-15 repetitions twice a day. Assistive Coughing: 5-6 repetitions twice a day. ROM Exercises: Both active and passive limb ROM exercises 10-15 repetitions twice a day.~Sustained stretching: Both upper and lower limbs, 10 repetitions, held for 5 seconds, twice a day.~Splinting: According to patient's injury level Bracing: According to patient's injury level Functional Mobility: Mobilizing patient according to injury level Tilt table standing: 10-15 minutes once a day"
223477060|NCT02891512|OTHER|ELF|Very low frequency magnetic fields (ELF) at intensity of 100 mT and a frequency of 1-80 Hz. Protocol (antiedema-antinflammatory): 12 sessions, 3 times a week for 4 consecutive weeks, each session lasted 30 minutes.
223477061|NCT02891512|OTHER|Xinepa®|2 tablets of Xinepa daily (morning and evening) for 1 month.
223583168|NCT03867019|DIAGNOSTIC_TEST|Heart rate variability parameters monitoring|"No intervention- only additional monitoring of heart rate, physical tests and filling of questionnaires:~Heart rate variability parameters monitoring- by wearing a Polar watch (RS800CX).~Isometric grip test- by using a Jamar Hand Held Dynamometer.~Questionnaires:~1. Dizziness Handicap Inventory (DHI) - hebrew version.~2. Stait-Trait Anxiety Inventory (STAI)"
223583169|NCT05969717|DRUG|GD-iExo-001|One drop (about 50 μL) of GD-iExo-001 was given to the affected skin area of 2-4 cm2 for 14 consecutive days, twice per day.
223583170|NCT05969717|OTHER|normal saline|One drop (about 50 μL) of normal saline was given to the affected skin area of 2-4 cm2 for 14 consecutive days, twice per day.
223583171|NCT04095689|DRUG|Docetaxel|Microtubule-targeting drug (inhibits microtubule depolymerization)
223583172|NCT04095689|DRUG|Pembrolizumab|Programmed cell death-1 (PD-1) inhibitor
223583173|NCT04095689|DRUG|IL-12 gene therapy|Adenoviral-mediated IL-12
223583174|NCT06013280|OTHER|Progresive Muscle Relaxation and Breathing Exercise|"Intervention protocol contains 40 minuntes sessions, which involved tensing and relaxing the body along with deep breathing.~Protocol consisted with; Warm-up (5 minutes breathing exercise) Progressive Muscle Relaxation Exercises (The participants performed PMR for each body part in a particular order, beginning with the face muscles and head, followed by neck, shoulders, chest, abdomen, legs, and feet. This muscle tensing and relaxing procedures were performed in accompaniment with deep breathing.) Cool-down (5 minutes breathing exercise)"
223583175|NCT01961960|BIOLOGICAL|ASP7374|intramuscular
223583176|NCT03694743|DEVICE|2Shape rotary system|root canal preparation
223583177|NCT01403376|DRUG|teriflunomide|"Film-coated tablet~Oral administration"
223583178|NCT01403376|DRUG|Interferon-β-1|Powder for reconstitution, of any licensed strength for either intramuscular or subcutaneous injection
224070169|NCT01608412|DRUG|Tacrolimus|TACROLIMUS (C0 = 5-10 ng/mL) + MPS 1440 mg + Pred
224070170|NCT01608412|DRUG|Everolimus|Everolimus (C0 = 6-10 ng/mL) + MPS 1440 mg + Pred
224070171|NCT03446885|DRUG|Lisdexamfetamine Dimesylate 40 MG|Lisdexamfetamine Dimesylate 40 MG administered orally
224070172|NCT03446885|DRUG|Placebo|Placebo capsule administered orally
224070173|NCT02801214|OTHER|fMRI|
224070174|NCT05726318|DRUG|Antibiotics|Participants will be provided either nitrofurantoin 100 mg oral twice a day for 5 days, trimethoprim/sulfamethoxazole 875/125 oral twice a day for 3 days, fosfomycin 3g once oral, ciprofloxacin 250 mg oral twice a day for 5 days or cephalexin 500 mg oral twice a day for 5 days
224070175|NCT06075095|DRUG|BGF MDI HFO 320/14.4/9.6μg|Study interventions will be administered orally via MDI as 2 inhalations BID (every morning and evening, approximately 12 hours apart)
224070176|NCT06075095|DRUG|BGF MDI HFA 320/14.4/9.6 μg|Study interventions will be administered orally via MDI as 2 inhalations BID (every morning and evening, approximately 12 hours apart):
224070177|NCT06075095|DRUG|Placebo MDI HFA|Study interventions will be administered orally via MDI as 2 inhalations BID (every morning and evening, approximately 12 hours apart)
224070178|NCT05468697|DRUG|Belzutifan|40 mg tablet administered orally at a dose of 120 mg.
224070179|NCT05468697|DRUG|Palbociclib|75, 100, or 125 mg tablet administered orally according to randomized dose for 21 days consecutive days followed by 7 days off.
224070180|NCT06076408|OTHER|SNAGS with Pilates|Patients will Receive Sustained Natural Apophyseal glides and Pilates Technique. Pilates Exercises focusses on five main areas (breath control, pelvic lumbar region, chest, shoulder positioning, head and neck positioning) a special session was organized for each patient
223477062|NCT02891512|OTHER|Placebo Xinepa®|2 tablets of Xinepa placebo daily (morning and evening) for 1 month.
223477063|NCT04593381|RADIATION|Stereotactic body radiotherapy|All patients accrued will be treated with SBRT to all sites of active metastatic disease as per CT scan or PET/CT and/or MRI. A range of schedules and doses are provided, it is advised that the maximum dose that can be achieved whilst meeting the organs at risk planning constraints is prescribed.
223477064|NCT03918057|BEHAVIORAL|Cognitive Behavioural Therapy for Insomnia|Cognitive behavioural therapy for insomnia (CBT-I) is an evidence-based psychotherapeutic intervention that combines cognitive and behavioural principles. Specifically, this therapy provides psychoeducation about thoughts contributing to the maintenance of sleep problems, and instruction in behavioural techniques to help decrease sleep onset latency and promote effective sleep maintenance.
223477065|NCT03918057|OTHER|Active Control|Participants will receive regular obstetric care and will be placed on a wait-list for CBT-I treatment after their final assessment. All activities women try for improving their own sleep problems between assessments will be recorded and coded for.
223477066|NCT00318695|DIETARY_SUPPLEMENT|Probiotics|Bifidobacterium longum \[BL999\] and Lactobacillus rhamnosus \[LPR\]
223477067|NCT00318695|OTHER|Placebo|Commercially available cow's milk based infant formula without probiotic supplementation
223477068|NCT01100424|DEVICE|Opti-Free RepleniSH|Commercially available contact lens solution used for pre-soaking balafilcon A contact lenses overnight prior to lens insertion.
224163055|NCT02705222|PROCEDURE|Hysteroscopy|Hysteroscopy will be done in operation theatre and hysteroscopic-guided curettings will also be taken and sent for histopathological examination
223583179|NCT01403376|BIOLOGICAL|Influenza vaccine|"Inactivated, split-virion influenza vaccine 2011-2012~One administration by intramuscular or intradermal route as per product specification"
223583180|NCT01897545|PROCEDURE|Circumferential PV isolation|The left atrium (LA) and pulmonary veins (PVs) are explored through a transeptal approach. Real-time 3D LA maps are reconstructed by using a nonfluoroscopic navigation system. The ipsilateral left and right PVs are encircled in one lesion line by circumferential PV isolation. Radiofrequency energy is delivered at 43°C, 35 W, 0.5 cm away from the PV ostia at the anterior wall, and is reduced to 43°C, 30 W, 1 cm away from the PV ostia at the posterior wall, with a saline irrigation speed of 17 mL/min. Each lesion is ablated continuously until the local potential amplitude decreased by \>80% or RF energy deliveries exceeded 40 s. The endpoint of circumferential PV isolation is PV isolation. Additional ablation lines are created by connecting the left inferior PV to the mitral annulus (mitral isthmus) and the roof of the LA between the two superior PVs. After the end of the procedure the implantable loop recorder is implanted in the parasternal area of the chest.
223583181|NCT01897545|PROCEDURE|PV isolation+renal denervation|"The procedure of AF ablation is the same like in the circumferential PV isolation.~After AF ablation procedure, the angiogram of both renal arteries is performed via femoral access. After that the treatment catheter is introduced into each renal artery and is applied discrete, radiofrequency ablations lasting up to 2 min each and of 8 watts or less to obtain up to six ablations separated both longitudinally and rotationally within each renal artery. During ablation, the catheter system monitored tip temperature and impedance, altering radiofrequency energy delivery in response to a predetermined algorithm. After the procedure the control arterial angiogram should be done."
223583182|NCT03090347|OTHER|Overconsumption of specific dietary nutrient|Subjects will be studied before and then after the consumption of a diet where specific nutrients are provided in excess.
223583183|NCT05231447|OTHER|Environmental survey|"Exposure to environmental factors, drugs or individual toxicity during the periconceptional period and at the beginning of the pregnancy will be investigated by means of a questionnaire administered to the parents. This questionnaire, drawn up by the Aquitaine Reproduction Enfance Maternité et Impact Santé-environnement (ARTEMIS) centre and completed by both members of the couple, will constitute an initial assessment that will make it possible to collect environmental exposures for the parents of cases identified by the register."
223583184|NCT00316888|BIOLOGICAL|cetuximab|Given IV
224070181|NCT06076408|OTHER|SNAGS|Patients will Receive Sustained Natural Apophyseal glides
224070182|NCT06451913|DRUG|Amoxicillin + Saccharomyces boulardii CNCM I-745|At inclusion visit (V1), the Investigator will dispense and ask the subject to take Amoxicillin 1000 mg bid for 14 days + Saccharomyces boulardii 250 mg x 2 twice a day for 21 days
224070183|NCT06451913|DRUG|Amoxicillin + Placebo|At inclusion visit (V1),the Investigator will dispense and ask the subject to take Amoxicillin 1000 mg bid for 14 days + a matching placebo bid for 21 days
223477069|NCT01100424|DEVICE|ReNu MultiPlus|Commercially available contact lens solution used for pre-soaking balafilcon A contact lenses overnight prior to lens insertion.
223477070|NCT01100424|DEVICE|Balafilcon A|Commercially available silicone hydrogel contact lenses removed from blister pack and soaked overnight in Opti-Free Replenish, ReNu MultiPlus, or Unisol 4, then applied to the eye and worn for 2 hours.
223477071|NCT01100424|OTHER|Unisol 4|Commercially available non preserved sterile saline solution used for pre-soaking balafilcon A contact lenses overnight prior to lens insertion.
223477072|NCT00087178|DRUG|cyclophosphamide|Arm 1: cyclophosphamide 600 mg/m2 IV every 21 days for 4 cycles; Arm 2: cyclophosphamide 500 mg/m2 IV every 21 days for 6 cycles
223477073|NCT00087178|DRUG|adriamycin|adriamycin 60 mg/m2 IV every 21 days for 4 cycles
223477074|NCT00087178|DRUG|epirubicin|epirubicin 100 mg/m2 IV every 21 days for 6 cycles
223477075|NCT00087178|DRUG|fluorouracil|fluorouracil 500 mg/m2 IV every 21 days for 6 cycles
223583185|NCT00316888|DRUG|cisplatin|Given IV
223583186|NCT00316888|DRUG|fluorouracil|Given IV
223583187|NCT00316888|RADIATION|radiotherapy|Given once daily 5 days a week for 5 weeks
223583188|NCT01369186|DRUG|Morphine|i.v. bolus injection
223583189|NCT01369186|DRUG|Placebo|i.v. bolus injection
223583190|NCT02680470|DEVICE|Virtual observed therapy|Virtual Observation of participants taking their medication
224070184|NCT06451913|OTHER|Stool samples|"The subject will be asked to collect thanks to four OMNIgene® •GUT OMR-200 kits :~* an initial stool collection when returning home at D1 (in any case before any intake of amoxicillin and of the investigational medication and up to 1 day after D1).~* a stool collection at home after the phone call 1, Day 7 (stool collection up to Day 7 + 1 day)~* a stool collection at home after the phone call 2, Day 14 (stool collection up to Day 14 + 1 day)~* at home the day of the Visit 2, Day 21 (stool collection up to Day 21 + 1 day)"
223744544|NCT04730245|DRUG|sodium phosphate enema, oral rifaximin and polyethylene glycol|Patients were hospitalized for 4-5 hours to receive two saline colon enemas with sodium phosphate Fleet®, 2 to 3 hours apart, appropriate hydration was provided during the procedure. If signs of fecal impaction were observed, the stools were removed manually prior to the first enema. Patients were discharged with oral treatment consistent with rifaximin 200 mg three times a day for 7 days and polyethylene glycol-3350, 17 gr per day in water for 10 days, but it was continued if necessary. Importantly, no modifications in time and dose of dopaminergic therapy or anti-dyskinetic medication (i.e. amantadine) were done at baseline or during the study
223477076|NCT04527588|OTHER|Questionaire Michigan|Patient-Reported Outcome Measures (PROMs) are important clinical items for evaluating injuries and recovery of the hand. The Michigan Hand Questionnaire is one of the most important.
223583191|NCT04463849|DIAGNOSTIC_TEST|Stimulation test with arginine infusion in order to verify the possible existence of damage to the beta cell function induced by COVID-19 infection|"All participants will be subjected to the collection of glycemic data through continuous professional retrospective monitoring of blood glucose for seven days, positioned on the day the test will be performed. During the entire recording period, parameters such as mean glucose, estimated glycosylated hemoglobin, peak glucose and nadir, blood sugar levels above the limit of 140 mg / dL, average glucose values at 60 and 120 minutes after meals, standard deviation and variability coefficient.~The evaluation of insulin secretion will be evaluated by performing the stimulus test with arginine infusion according to validated protocols."
223583192|NCT01837667|DRUG|LB-100 for Injection|Part 1 and Part 2: LB-100 for Injection infusion on Days 1,2,3 of each 21 day cycle.
223583193|NCT01837667|DRUG|Docetaxel|Part 2: Docetaxel infusion on Day 2 of each 21 day cycle.
223744545|NCT03310554|PROCEDURE|26cm suspended overlength biliary stents|The test group will be placed 26cm suspended overlength biliary stents in introhepatic bile duct in ERCP
223744546|NCT03310554|PROCEDURE|30cm suspended overlength biliary stents|The test group will be placed 30cm suspended overlength biliary stents in introhepatic bile duct in ERCP
223744547|NCT03310554|PROCEDURE|ordinary plastic biliary stents|The control group will be placed ordinary plastic biliary stents in bile duct in ERCP
223744548|NCT02406651|DRUG|Recombinant Human Interleukin-22 IgG2-Fc (F-652)|IV infusion of reconstitution lyophilized F-652.
223744549|NCT02406651|DRUG|Systemic Corticosteroids|Prednisone (or equivalent) at the time of the onset of clinical symptoms consistent with GI and/or liver aGVHD, as per the standard of care. Prednisone (or equivalent) will be given at a dose of 2 mg/kg/day and tapered as needed.
224163056|NCT00133172|DRUG|Tacrolimus|IV
223477077|NCT00746005|DIETARY_SUPPLEMENT|fish oil|3 g fish oil (3078 mg) total EPA 1512 mg and total DHA 1026 mg
223744550|NCT05995158|PROCEDURE|Metagenomic testing of the subgingival plaque samples|sampling, extraction and sequencing of the oral microbiome in the samples
223744551|NCT02946047|DRUG|Ixazomib 1 MG|1 mg on days 1, 8 and 15 for three 28 days cycles, then be reviewed by DSMB and based upon their recommendation patients will receive ixazomib once weekly for 12 weeks or ixazomib 1 mg on days 1, 8 and 15 for three 28 days cycles. Visits 3-15 will have a window of ± 3 days.
223744552|NCT02946047|DRUG|Ixazomib 2 MG|2mg on days 1, 8 and 15 for three 28 days cycles, then be reviewed by DSMB and based upon their recommendation patients will receive ixazomib once weekly for 12 weeks or ixazomib 2 mg on days 1, 8 and 15 for three 28 days cycles. Visits 3-15 will have a window of ± 3 days.
224163057|NCT00133172|DRUG|mycophenolate mofetil|IV
224163058|NCT00133172|DRUG|Prednisone|IV
224304834|NCT06927570|DRUG|HS-20122（Phase 1a：Dose Escalation）|Intravenous (IV) administration of HS-20122 ; Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and confirmed disease progression.
224304835|NCT06927570|DRUG|HS-20122（Phase 1b：Dose Expansion ）|travenous (IV) administration of HS-20122 ; Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and confirmed disease progression.
224163059|NCT03476967|PROCEDURE|Panretinal photocoagulation|In cases of proliferative diabetic retinopathy (PDR), panretinal photocoagulation (PRP) is the first-line treatment. Although PRP reduces the risk of severe vision loss, it has been shown that laser energy can cause destruction to all layers of retina including the ganglion cells and the retinal nerve fiber layer (RNFL), and therefore generate visual field defects similar to that observed in glaucomatous damage. In such cases, visual field testing can be less helpful to evaluate glaucomatous damage in PDR patients treated with PRP.
224304836|NCT06928090|DRUG|DTG + 3TC FDC|None(Non-interventional, retrospective chart review, single-arm study )
224304837|NCT06929052|DEVICE|ADL-018 Autoinjector|Test product (A): ADL-018 Injection 150 mg/mL solution in a single dose pre-filled autoinjector manufactured/supplied by Kashiv BioSciences LLC, USA.
223477078|NCT00746005|DIETARY_SUPPLEMENT|placebo, sunflower oil|3 g of sunflower oil
223477079|NCT00226369|DRUG|CY-1503|
223477080|NCT01012427|PROCEDURE|percutaneous cryoablation|All patients will have percutaneous image guided core biopsies of the treatment site and CT or MR imaging at approximately 5-7 months following the cryoablation. They will have repeat imaging every 5-7 months for a period of two years, and if there is evidence of recurrence (ablation zone increase \> 5 mm or increased enhancement 15 HU), then repeat biopsy will be obtained. Imaging follow-up past the two year point will be at the discretion of the patient's physicians.
223477081|NCT01841372|OTHER|Second Life|Second Life is an online virtual reality environment.
223477082|NCT01841372|BEHAVIORAL|Group Phone Conference Call|
223583194|NCT01972685|PROCEDURE|Cryobiopsy biopsy|Cryobiopsy vs. Transbronchial vs. VATS biopsy
223583195|NCT01972685|PROCEDURE|Transbronchial Biopsy|
223583196|NCT01972685|PROCEDURE|VATS biopsy|
223583197|NCT02177409|DRUG|Telmisartan|
223583198|NCT02177409|DEVICE|Amlodipine|
223583199|NCT02177409|DRUG|Placebo|
223744553|NCT02946047|DRUG|Ixazomib 3 MG|3 mg on days 1, 8 and 15 for three 28 days cycles, then be reviewed by DSMB and based upon their recommendation patients will receive ixazomib once weekly for 12 weeks or ixazomib 3 mg on days 1, 8 and 15 for three 28 days cycles. Visits 3-15 will have a window of ± 3 days.
224163060|NCT04585672|OTHER|Ammonia infusion|Ammonia metabolism investigated in healthy individuals and patients with cirrhosis with and without ammonia lowering agent: glycerolphenylbutyrat (healthy) and Lactulose + Rifaximin (Cirrhosis)
223477083|NCT04149080|PROCEDURE|SIM + polypropylene membrane|After tooth extraction the socket will be filled with 1.2% simvastatin gel and covered with polypropylene membrane, which will be intentionally exposed.
223583200|NCT02584361|PROCEDURE|Round window approach|In this group the insertion of the electrode into cochlea will be performed through an incision in the membrane (paracentesis) of the round window (round window approach = RWA).
223583201|NCT02584361|PROCEDURE|Cochleostomy|In this group the insertion of the electrode into cochlea will be performed by drilling a hole in cochlea (cochleostomy).
223583202|NCT00967161|PROCEDURE|Total Knee Arthroplasty|Total Knee Arthroplasty
223583203|NCT00967161|PROCEDURE|Motion analysis|Motion analysis (Gait/EMG during walking and functional tasks)
223583204|NCT05458661|DEVICE|Clinical Prototype BioBase (SN 07 and SN 08)|Scheimpflug- or OCT based corneal tomographers with the ability to measure anterior and posterior corneal curvature maps \>6mm diameter and corneal pachymetry maps \>6mm.
223583205|NCT05123521|DIAGNOSTIC_TEST|urine analysis|Urine was then tested for evidence of substance abuse using the multi-drug screen panel dip steak ABONtm (Abon Biopharm (Hangzhou) CO., Ltd) which is a lateral flow chromatographic immunoassay . It allowed for qualitative detection of multiple drugs in a single run. This kit was chosen for its ability to detect the most commonly abused substances in Egypt, namely: opioids, benzodiazepines, hashish, and tramadol. A single coloured line at region C for of a specific drug indicated a positive result, whilst two coloured lines at both regions C and T indicated a negative result. The absence of coloured lines was an indication of the invalidity of the particular kit, and the kit was discarded.
223583206|NCT02300597|OTHER|Internet based support and coaching|Young people between age 15 and 25 with ADHD and/or autism spectrum disorders are offered internet-based support and coaching during eight weeks (chat and e-mail). Data is collected before and after the intervention and six months after end of treatment using self-report questionnaires pertaining to sense of coherence, self-esteem, quality of life, depressive and anxiety symptoms and socioeconomic status. Parents complete an assessment scale for the next of kin. After treatment the young people are interviewed regarding the quality of the intervention.
223583207|NCT05364736|DIETARY_SUPPLEMENT|Highland barley β-glucan dietary supplement|100 mL oral liquid mainly containing highland barley β-glucan once daily for 12 weeks
223583208|NCT05364736|OTHER|Placebo controls|Placebo with a similar appearance and taste to highland barley β-glucan supplement
223583209|NCT03254277|DRUG|3BNC117-LS|Intravenous infusion of 3BNC117-LS
224070185|NCT06451913|OTHER|BSFS : Bristol Stool Form Scale|All included subjects will have to complete a stool diary BSFS (Bristol Stool Form Scale) daily and at each bowel movement, from Day 1 until the end of study treatment (Day 21). The patient will fill the form with the date, the time, and the stool texture.
224070186|NCT06451913|OTHER|GSRS : Gastrointestinal Symptom Rating Scale|All included subjects will have to complete a GSRS (Gastrointestinal Symptom Response Score) questionnaire weekly from Day 1 until the end of the study treatment (Day 21).
224070187|NCT06395324|OTHER|High arabinose diet|Participants will consume a high arabinose diet for 18 consecutive days.
223477084|NCT04149080|PROCEDURE|Placebo|After tooth extraction the socket will be filled with gel and covered with polypropylene membrane, which will be intentionally exposed.
223477085|NCT00622765|DRUG|placebo|Placebo capsule twice daily
223477086|NCT00622765|DRUG|R256918|5 mg capsule twice daily
223477087|NCT00622765|DRUG|R256918|10 mg capsule twice daily
223477088|NCT00622765|DRUG|R256918|15 mg capsule twice daily
223477089|NCT03017859|DEVICE|High flow nasal cannula|We shall use the Airvo 2 device to administer humidified and warmed air at high flow during sleep.
223477090|NCT02219256|DRUG|TAK-079|TAK-079 solution
223477091|NCT02219256|DRUG|Placebo to TAK-079|Placebo to TAK-079 solution
223477092|NCT02678819|DEVICE|Digital cognitive aid|Digital cognitive aid during anesthesia and intensive care crises.
223477093|NCT01710462|DRUG|Pantoprazole + Domperidone|
223477094|NCT01710462|DRUG|Pantozol®|
223477095|NCT06233708|DRUG|Non-Selective Beta-Adrenoreceptor Agonists for Systemic Use|Non-selective blocker including Propranolol, Carvedilol PO was prescribed
223477096|NCT03893786|DEVICE|Robotic Rehabilitation|"Fifteen patients with Parkinson's Disease will perform ten 45-minute training sessions of the upper limb bilaterally with the Armeo®Spring, an electromedicad device aimed at improving force and coordination in neurologically affected patients.~The device was built to sustain the forearm during the upperlimb training and is equipped with a VR screen with which the patient may interact during the playful and motivating rehab."
223477097|NCT01427140|OTHER|Polyunsaturated fatty acid group|Addition of polyunsaturated fatty acids to the diet in the form of pastries
223477098|NCT01427140|OTHER|Saturated fatty acid group|Addition of saturated fatty acids to the diet in the form of pastries
223477099|NCT00998153|BEHAVIORAL|Risk Reduction through Family Therapy|Component based intervention based on existing empirically supported treatments
223477100|NCT00833326|DRUG|ARRY-334543, EGFR/ErbB2 inhibitor; oral|multiple dose, escalating
223477101|NCT00833326|DRUG|Docetaxel, mitotic inhibitor; intravenous|multiple dose, single schedule
223477102|NCT00833326|DRUG|Prophylactic growth factors; subcutaneous|standard of care
223477103|NCT00988182|OTHER|dietary intervention|whey protein
223477104|NCT00988182|OTHER|water control|
223477105|NCT00005649|DRUG|capecitabine|
223477106|NCT00005649|DRUG|paclitaxel|
223477107|NCT02667639|BIOLOGICAL|RPH-104|Anti-IL-1 Mab
223477108|NCT02667639|OTHER|Sodium chloride Sterile Injection 0.9% w/v|Sterile saline solution
223477109|NCT01692119|BEHAVIORAL|Regular, pharmacy based intervention|"Regular, pharmacy-based intervention conducted in cooperation with the treating physician:~* Medication review at baseline: recording of all medicines currently taken (prescribed medication and self-medication), check for drug-related problems, consolidation of a medication plan.~* Regularly (weekly): dose-dispensing of the medication (weekly dosing aid), discussion and counseling regarding medication, adherence, potential side effects, and signs and symptoms of cardiac decompensation; blood pressure and pulse measurement. If required: contact with patients' physician."
223477110|NCT00997893|DIETARY_SUPPLEMENT|Soy Phytoestrogen|Novasoy® pill (55 mg)
223477111|NCT00997893|DRUG|Estradiol|Estradiol pill (1 mg)
224163061|NCT00004604|BIOLOGICAL|CEA RNA-pulsed DC cancer vaccine|carcinoembryonic antigen RNA-pulsed dendritic cells
224163062|NCT02371018|DIETARY_SUPPLEMENT|Nepro|Patients will be asked to consume a single 8 oz can of Nepro
223477112|NCT00997893|DRUG|Medroxyprogesterone Acetate (MPA)|medroxyprogesterone acetate (MPA) (10mg)
223477113|NCT00997893|DRUG|Soy Placebo|oral placebo pill (0mg Soy Phytoestrogen)
223477114|NCT00997893|DRUG|MPA Placebo|oral placebo pill (0mg MPA)
223477115|NCT02989974|BEHAVIORAL|KY LEADS Survivorship Care|"Survivor: Survivor questionnaire 1 at enrollment; KY LEADS Survivorship Care Program; survivor questionnaire 2 one week after program completion; survivor questionnaire 3 six months after enrollment.~Caregiver: Caregiver questionnaire 1 at enrollment;KY LEADS Survivorship Care Program; caregiver questionnaire 2 one week after program completion; caregiver questionnaire 3 six months after enrollment"
223477116|NCT00598091|DRUG|gemcitabine|1000mg/m2, Days 1, 8, 15
223477117|NCT00598091|DRUG|dasatinib|50mg, PO, QD
223477118|NCT00598091|DRUG|gemcitabine|1000mg/m2, days 1, 8, 15
223477119|NCT00598091|DRUG|dasatinib|50mg, PO, BID
223477120|NCT02500498|DRUG|Nulojix|
223477121|NCT03444207|BEHAVIORAL|Endurance training|The women in group A underwent endurance exercise on cycle ergometers (Schwinn Evolution, Schwinn Bicycle Company, Boulder, Colorado, USA). Exercise sessions consisted of a five-minute warm-up (stretching exercise) at low intensity (50%-60% of maximum heart rate), a 45-minute exercise (at 50%-80% of maximum heart rate), five minutes of cycling without a load, and five minutes of closing stretching and breathing exercise of low intensity.
223583210|NCT03254277|DRUG|Placebo|Placebo
223583211|NCT01928823|BEHAVIORAL|CBT|12 sessions of CBT (cognitive behavioral therapy) with psychoeducation and in-vivo exposure
223583212|NCT01928823|DRUG|D-Cycloserine|Administered for three times (50mg, oral) directly after exposure
223583213|NCT05768243|DRUG|Hyaluronic acid|hyaluronic acid is used as an adjunctive treatment to scaling and root planing
224163063|NCT02411513|DEVICE|CEFALY|
223583214|NCT05768243|PROCEDURE|red injectable platelet rich fibrin (i-prf)|injecting red i-prf into the pocket after scaling and root planing
223583215|NCT04478032|DEVICE|deep transcranial magnetic stimulation with H7 coil|low frequency(1Hz) deep transcranial magnetic stimulation on ACC .Duration:20 days.
223477122|NCT03444207|BEHAVIORAL|Endurance-strength training|Group B performed endurance-strength exercise consisting of a five-minute warm-up (stretching exercises) of low intensity (50%-60% of maximum heart rate), a strength component, an endurance component, 5 minutes cycling without a load, and a 5 minutes closing stretching and breathing exercise of low intensity. The 20-minute-long strength component was performed using a neck barbell and a gymnastic ball. Directly after the strength exercise, the women took part in a 25-minute endurance exercise on cycle ergometers (Schwinn Evolution, Schwinn Bicycle Company, Boulder, Colorado, USA) at 50%-80% of maximum heart rate.
223477123|NCT05572931|DEVICE|Fu's Subcutaneous Needling(FSN)|"Insertion points are both sides of 1) inferior edge of the scapula; 2)the midpoint of inferior edge of the posterior superior iliac spine and the ischial tuberosity.~FSN (Trocar Acupuncture Needle, Nanjing FSN Medical Co. , Ltd, China.) ) is a solid needle with plastic cannula tube on the outside. Add on swaying movement (SM) and reperfusion approach (RA) after the needle inserting into the subcutaneous layer. The SM is a horizontal fan sway movement with the base of the needle for the fulcrum, The SM speed is 200 times in 2 minutes. Apply RA when performing SM. RA movement is hip extension in prone position with resistance by physician's hand for 10 seconds. And then rest for 10 seconds. Repeat 3 cycles. The same RA is performed over the other three insertion point."
223477124|NCT05572931|DEVICE|fine acupuncture needle|(36G, 0.5 inch, Wujiang city cloud \& dragon medical device Co.,Ltd.) Only inserted to skin, not into the subcutaneous layer. No SM and RA.
224070188|NCT06798597|BEHAVIORAL|Health4Life app|Health4Life is a program based on the anticipatory guidance approach aiming to support parents create healthy lifestyle behaviours starting in early infancy. The intervention consists of ten themes over a 16 month period and incorporates interactive features such as quizzes.
224070809|NCT07143760|DEVICE|Gengigel|Free gingival graft (FGG) surgery leaves an open wound at the palatal donor site, which heals by secondary intention and can cause patient discomfort. Various adjunctive materials, such as stents, collagen sponges, platelet-rich fibrin, and hyaluronic acid (HA), have been explored to improve healing. HA is a naturally occurring glycosaminoglycan with hydrating, anti-inflammatory, and pro-regenerative properties that support fibroblast and keratinocyte activity and promote angiogenesis. These qualities make HA a promising adjunct for enhancing wound healing in periodontal surgery. However, few studies have assessed its clinical impact on palatal donor site healing after FGG, and in existing studies HA was applied only once by the operator rather than used consistently by patients. This study evaluates daily, patient-applied HA gel to address this gap and compare outcomes in smokers and non-smokers.
224070810|NCT07143331|DRUG|Part 1 KS101|Six doses of oral KS101 will be administered to participants.
223477125|NCT04158609|DIAGNOSTIC_TEST|Doppler flow indices assessment|Doppler flow indices, UA-PI, MCA-PI and CPR values, assessment performed prior to induction of labor
223477126|NCT03641027|OTHER|Increased physical activity|"Preoperatively~Individual coaching by a physical therapist to:~* increase physical activity 30 minutes/day (At least 150 min/week)~* decrease time spent sitting/lying~Telephone follow up one week after the intervention starts~At the hospital~-Frequent mobilization~After discharge~A telephone follow up one week postoperatively with coaching by a physical therapist to:~* increase physical activity 30 minutes/day (At least 150 min/week) until 8 weeks postoperatively~* decrease time spent sitting/lying~The intervention includes a prescribed FaR (Fysisk aktivitet på recept) with frequency, duration and intensity of the activity corresponding 12-15 on the BORG-RPE scale."
223477127|NCT03641027|OTHER|Standard care|
223477128|NCT04970082|DIAGNOSTIC_TEST|FFR DWP|FFR will be measured twice in the same lesion : One with the standard method and the other with the DWP method.
223583216|NCT03770247|PROCEDURE|Intraoperative celiac plexus neurolysis|neurolysis of celiac plexus by intraoperative techniques
223583217|NCT03770247|PROCEDURE|CT guided celiac plexus neurolysis|Neurolysis of celiac plexus percutaneously by CT guidance
224163064|NCT00351806|DRUG|Erigeron breviscapus injection|
223583218|NCT05892640|OTHER|Low-Salt Diet|Low-salt diet (LS diet) according to DASH eating plan, with sodium intake of 1500 mg (3.75 g of salt), within the period of 14 days
224163065|NCT00351806|DRUG|hua tuo zai zao wan (a herbal medicine pill)|
223583219|NCT00553007|PROCEDURE|Periodontal therapy|Normal periodontal therapy is performed.
223477129|NCT04970082|DIAGNOSTIC_TEST|FFR|FFR will be measured twice in the same lesion : One with the standard method and the other with the DWP method.
223477130|NCT02247388|BEHAVIORAL|Computerized Alcohol Screening|iPad based automated alcohol screening
223477131|NCT02247388|BEHAVIORAL|Brief Negotiated Interview|iPad based automated brief negotiated interview (BNI)
223477132|NCT00293592|DRUG|Dexamethasone|1 mg per kg as a single dose before initiation of cardiopulmonary bypass
223477133|NCT06265311|PROCEDURE|IDUS examination|for patients with high risks of bile duct stones recurrence using IDUS during ERCP
223477134|NCT04861792|BEHAVIORAL|Michigan SPARC Quality Improvement Intervention|Practice facilitation, electronic health record (EHR) support, performance monitoring and feedback combined with alcohol-related continuing medical education (CME) and maintenance of certification (MOC) and tools to support alcohol related care including a decision aid for shared decision making about alcohol use disorder (AUD).
223477135|NCT04287348|DRUG|Brolucizumab 6 mg solution for intravitreal injection|All consenting, enrolled patients (irrespectively of maximum recurrence-free interval under aflibercept pretreatment) will receive an intravitreal injection of brolucizumab 6 mg at baseline (week 0), at week 4 and each of the following treat and extend visits. At each visit all patients will undergo an OCT assessment. For all patients extension of treatment intervals is only possible 2-week-stepwise, e.g. 4, 6, 8 weeks etc.
223477136|NCT01707524|PROCEDURE|Randomized left versus right radial artery approach|Randomized left versus right radial artery approach
223477137|NCT03998631|PROCEDURE|Carbon Dioxide and Saline Flush|The TEVAR or TAVI device will be flushed with approximately 1.2L of medical grade carbon dioxide using a 60mL syringe and connecting tubing. The reservoir will then be flushed with at least 60mL of standard saline prior to deployment to minimize bubbles in the saline.
223477138|NCT03998631|PROCEDURE|Standard Saline Flush|Standard of care flushing of the TEVAR or TAVI device with normal saline.
223477139|NCT02165527|PROCEDURE|Lunar iXDA scan|Subject will receive a total body scan taken by the Lunar iXDA. This scan will take approximately 8 minutes to complete. Following the scan, the computer of the Lunar iXDA will calculate the bone length.
223477140|NCT06147674|DEVICE|VQm Pulmonary Health Monitor™|"The VQm Pulmonary Health Monitor™ (may be referred to as the VQm PHM™) is a a Class IIa, Health Canada approved medical device used as an adjunct monitor and is non-life supporting, providing clinicians with measurements of pulmonary function parameters of mechanically ventilated adult patients. The measurements provided are:~* Pulmonary Blood Flow (PBF)~* Shunt Fraction (Qsi)~* Dead space (VD):~* Functional Residual Capacity (FRC)"
223477141|NCT02830139|PROCEDURE|Hyperthermic intraperitoneal chemotherapy (HIPEC)|Normal saline 3000ml-4000ml, Cisplatin 60mg/m2, 5-Fu 1500mg/m2, 43°C, 60min, During surgery and 7 days after surgery.
223583220|NCT02773654|OTHER|Healthy Volunteers|Scapula static position of subjects with and without shoulder symptoms will be recorded utilizing a mobile phone application placed on their scapula by either the examiner's hands or with a handle, held by the examiner.
223583221|NCT02773654|OTHER|Symptomatic Volunteers|Scapula static position of subjects with and without shoulder symptoms will be recorded utilizing a mobile phone application placed on their scapula by either the examiner's hands or with a handle, held by the examiner.
223583222|NCT00182897|BEHAVIORAL|Skills Building for Caregiver Health and Care-recipient|
223583223|NCT01028170|DRUG|furosemide and hypertonic saline solution|250-500 mg furosemide (30 min IV Q 12 hours) with 150 mL of 2.4% NaCl
223583224|NCT01028170|DRUG|furosemide|80-160 mg furosemide (Given over 5 min IV twice a day)
223583225|NCT00857948|DRUG|ivermectin treatment conditioner|Application followed by thorough rinsing of the hair and scalp with water.
223583226|NCT00857948|DRUG|Placebo, vehicle control|Application followed by thorough rinsing of the hair and scalp with water.
223583227|NCT00815191|DEVICE|a forced-air warming cover|A forced-air warming cover will be placed on the subject prior to surgery, remain on the subject during surgery and removed after surgery.
223583228|NCT00815191|DEVICE|vital HEAT (vH2) Temperature Management System|The vital HEAT (vH2) Temperature Management System will be placed on the subjects arm prior to surgery. remain on the arm during surgery and removed after surgery.
224163066|NCT00351806|DRUG|Compound stroke herbal medicine (8 herbal)|
223477142|NCT02830139|PROCEDURE|Radical colorectal resection|radical colorectal resection with lymphadenectomy
223477143|NCT02830139|DRUG|Oxaliplatin , Capecitabine|XELOX postoperative chemotherapy Oxaliplatin 130mg/m2 d1, Capecitabine 1000mg/m2 d1-14.
223477144|NCT02830139|DRUG|Normal saline , Cisplatin , 5-Fu|
224070811|NCT07143331|DRUG|Part 1 Placebo|Six doses of oral matching placebo will be administered to participants.
223477145|NCT04871464|DRUG|Live Combined Bifidobacterium,Lactobacillus and Enterococcus Capsules|Oral
223477146|NCT04871464|OTHER|Placebo|Oral
223477147|NCT04808102|DEVICE|IER AG|The game is a web-based single-player adventure game with 3 levels created with the RPG Maker MV. Playtime is approximately 3 hours.
223477148|NCT04808102|DEVICE|BubbleShooter|A free-to-play arcade browser puzzle game called BubbleShooter.
223583229|NCT02117635|BIOLOGICAL|CTX DP|20 million cell dose administered by surgery to the damaged area of the brain
223583230|NCT02996799|OTHER|Umbilical cord milking|Milking of the umbilical cord at delivery
223583231|NCT00777699|DRUG|XL765 (SAR245409)|Gelatin capsules supplied in 5-mg, 10-mg, and 50-mg strengths; daily dosing
223583232|NCT00777699|DRUG|erlotinib|Tablets supplied in 25-mg, 100-mg, and 150-mg strengths; daily dosing
223583233|NCT00185874|BIOLOGICAL|Intratumoral Dendritic Cell Immunotherapy|
223583234|NCT00185874|BIOLOGICAL|autologous dendritic cells|
223583235|NCT05153707|BEHAVIORAL|Discharge Education Program|medication reconciliation, medication review, individually prepared patient medicine (pill) card, patient education (based on Health Belief Model by using written material and video, and verbally \[by using Teach back method especially for patients with low health literacy\]) and counseling (using behavior change techniques based on The Capability, Opportunity, and Motivation Behavior model).
224070812|NCT07143331|DRUG|Part 2 with Food|KS101 administered with food
224070813|NCT07143331|DRUG|Part 2 without food|KS101 administered without food
224070814|NCT07143331|DRUG|Part 3 KS101|3 multiple doses of KS101
224070815|NCT07144046|OTHER|Micropore covering of the medial half of the scar|3 months of micropore covering of the medial half of the scar
223477149|NCT01258049|DRUG|Artemether Sublingual Spray|Artemether sublingual spray administered at 3 mg/kg (milligrams per kilogram) at specified timepoints
223477150|NCT01258049|DRUG|Quinine|Quinine administered intravenously, 20 mg/kg loading dose followed by 10 mg/kg every eight hours
224163067|NCT02623699|DRUG|Tofersen|Administered as specified in the treatment arm.
224163068|NCT02623699|DRUG|Placebo|Administered as specified in the treatment arm.
223583236|NCT01814670|BIOLOGICAL|botulinum toxin Type A|20 units botulinum toxin Type A (total dose) injected into frown lines on Day 1.
223583237|NCT04043832|DIAGNOSTIC_TEST|quantitative ultrasonic technique|Collection of all quantitative ultrasonic data was performed by one ultrasound physician
223583238|NCT00877721|DEVICE|Self Mobility Improvement in the eLderly by using the SMILING system|The effect of treatment with the SMILING system on postural stability and gait of elderly individuals will be measured using RCT cross over study design
223583239|NCT06917690|DRUG|Oleogel-S10|Topical gel
224163069|NCT00899678|DRUG|Certolizumab Pegol|"400 mg administered subcutaneously at once every 4 weeks for subjects ≥ 40 kg or 200 mg for subjects 20 to \< 40 kg~\*prior to this dosing regimen, subjects will undergo an induction of Certolizumab Pegol administered subcutaneously every 2 weeks (total 3 injections) at of either 400 mg for subjects ≥ 40 kg or 200 mg for subjects 20 to \< 40 kg"
224163070|NCT00899678|DRUG|Certolizumab Pegol|"200 mg administered subcutaneously at once every 4 weeks for subjects ≥ 40 kg or 200 mg for subjects 20 to \< 40 kg~\*prior to this dosing regimen, subjects will undergo an induction of Certolizumab Pegol administered subcutaneously every 2 weeks (total 3 injections) at of either 400 mg for subjects ≥ 40 kg or 200 mg for subjects 20 to \< 40 kg"
224163071|NCT03577951|PROCEDURE|high position space group|The left and right Trocar meet at the level of the sternum angle and begin to establish the operating space.
224163072|NCT03577951|PROCEDURE|low position space group|The left and right Trocar meet under the sternum angle and begin to establish the operating space.
224163073|NCT02150460|PROCEDURE|One-site peribulbar injection|injection into the inferior medial orbital compartment
224163074|NCT02150460|PROCEDURE|Two- site peribulbar injection|Two injections into the infero-temporal and supero-nasal orbital compartments
223583240|NCT02710942|BEHAVIORAL|SPHERE|
223583241|NCT02710942|BEHAVIORAL|PRISM|
223583242|NCT05547529|PROCEDURE|Patients undergoing neoadjuvant chemoradiotherapy plus Ivory-Lewis or McKeown esophagectomy.|Patients undergoing neoadjuvant chemoradiotherapy plus Ivory-Lewis or McKeown esophagectomy.
223583243|NCT05547529|PROCEDURE|Patients undergoing neoadjuvant chemotherapy plus Ivory-Lewis or McKeown esophagectomy|Patients undergoing neoadjuvant chemotherapy plus Ivory-Lewis or McKeown esophagectomy
223477151|NCT02752477|DRUG|Opioid-free general anesthetic|An opioid-free general anesthetic technique utilizing dexmedetomidine, ketamine, and lidocaine infusions
223477152|NCT02752477|DRUG|Traditional general anesthetic|Traditional general anesthetic technique utilizing sufentanil, fentanyl or remifentanil
223744554|NCT02946047|DRUG|Ixazomib 4 MG|4 mg on days 1, 8 and 15 for three 28 days cycles, then be reviewed by DSMB and based upon their recommendation patients will receive ixazomib once weekly for 12 weeks or ixazomib 4 mg on days 1, 8 and 15 for three 28 days cycles. Visits 3-15 will have a window of ± 3 days.
224163075|NCT00510367|DRUG|5-Fluorouracil|500 mg/m\^2 By Vein Daily x 2 Days
224163076|NCT00510367|DRUG|Cyclophosphamide|500 mg/m\^2 By Vein On Day 1
224163077|NCT00510367|DRUG|Doxorubicin|50 mg/m\^2 By Vein Over 72 Hours
224163078|NCT02726048|DEVICE|Simplus/Eson|Released product Simplus and Eson masks
224163079|NCT02699125|DRUG|Guanfacine|Guanfacine 1mg for 2 weeks followed by guanfacine 2mg for 4 weeks.
224163080|NCT02699125|DRUG|Hydrochlorothiazide|Hydrochlorothiazide 12.5 mg for 2 weeks followed by hydrochlorothiazide 25 mg for 4 weeks
224163081|NCT03796195|DRUG|.5% Bupivacaine|Ultrasound guided right sided stelate ganglion block using .5% bupivacaine (5mLs)
223477153|NCT05415878|DEVICE|RCW design form|"Tall RCW= a knee high removable cast walker with an offloading insole~Short RCW= an ankle high (extending up the leg just past the ankle) removable cast walker with an offloading insole, paired with an external shoe lift to be used with a diabetic shoe on the contralateral limb"
223744555|NCT06818695|OTHER|Imaginal Exposure for Anorexia Nervosa|Imaginal exposure aims to use the power of imagining the fearful situation to heighten anxiety and by not engaging in imaginative restriction or other eating disorder behaviours, the individual, in theory, can habituate to the anxiety until it naturally subsides.
224163082|NCT03787095|BIOLOGICAL|Cemiplimab|Administered as an intravenous (IV) infusion
224163083|NCT03787095|BIOLOGICAL|Placebo|Diluent for REGN2810, administered as an IV infusion
224163817|NCT02733887|DEVICE|magnetic resonance imaging|MRI was performed on a 3 Tesla system (GE Discovery 750W). A single-shot,echo-planar imaging-based, spectral adiabatic inversion recovery DWI sequence was obtained with b values of 0,30,50,80,100,150,200,400,600,800 and 1,000.
224163818|NCT02733887|DEVICE|positron emission tomography/computed tomography|18F-FDG-PET/CT was performed using a multidetector PET/CT system (GE Discovery ST16). Patients fasted for 6 hours before imaging.
223477154|NCT01142336|DRUG|Simvastatin|Simvastatin 40mg qHS for 1 year
223477155|NCT01142336|DRUG|Placebo|Placebo 1 tablet qHS for 1 year
223477156|NCT04077892|DRUG|budesonide|SAR patients received treatment of a combination of budesonide and montelukast tablet or only intranasal budesonide randomly for 14 days
223477157|NCT00091078|BIOLOGICAL|oblimersen sodium|Given IV
223744556|NCT06818695|OTHER|Treatment as Usual (TAU)|TAU includes specialist nurse monitoring, occasional medical reviews, and dietetic support (depending on the individual's particular needs)
224163819|NCT02733887|RADIATION|fludeoxyglucose F 18|Patients fasted for 6 h before receiving FDG intravenously. A dose of 5.18-7.4 MBq/kg was used.
224163820|NCT03827967|BIOLOGICAL|PalloV-CC|The PalloV-CC vaccine uses yeast cell wall particles (YCWP) to serve as an efficient vaccine delivery system as they can contain a broad range of antigenic material, they are rapidly phagocytized by antigen presenting cells, and they are inherently immunogenic. The PalloV-CC vaccine utilizes silicate-capped YCWP to deliver allogenic colon cancer tumor lysate. The vaccine will be given to subjects with resectable colon cancers neoadjuvantly shortly before surgery in order to study the effect of the vaccine on the tumor microenvironment using a well-validated immune scoring system for colon cancer and other immunologic tests.
223477158|NCT00091078|DRUG|imatinib mesylate|Given orally
223477159|NCT00091078|OTHER|laboratory biomarker analysis|Correlative studies
223477160|NCT05029908|DIAGNOSTIC_TEST|Jaw Functional Limitation Scale|DC/TMD Axis I TMD Pain Screener Questionnaire and TMD Symptom Questionnaire will be administered to the participants. To determine parafunctional habits and limitation of function, the DC/TMD Axis II assessment tools 'Jaw Functional Limitation Scale-8 (JFLS-8) and Oral Behavioral Checklist (OBC) will be applied. In addition, demographic data (age, gender, education level, occupation) will be questioned.
223477161|NCT02029417|DRUG|cytarabine|Given SC
223583244|NCT04638842|BEHAVIORAL|Online Intervention Grief COVID-19|The online Intervention Grief COVID-19 aims to provide to the target population a self-applied intervention based on Cognitive Behavioral Therapy, Mindfulness, Behavioral Activation Therapy, and Positive Psychology, aimed at the Psychoeducation regarding the manifestations of normal grief, advice and guidance on how to find emotional relief, with the aim that survivors allow themselves to validate their experience of emotional pain and recognize it as a normal part of their process of adaptation to loss, what does grief deprived of rights consist of, specifically from the contingency of COVID-19, establish self-care measures for people in different areas of their life (physical, emotional, cognitive and spiritual), direct the survivor to relocate the died in his life without his memory causing suffering, in addition to beginning to resume his life project, adjusting according to his needs and goals. The sessions will be delivered in a frequency of one session every three days.
223583245|NCT03825692|DRUG|Zhizhu Kuanzhong Capsule|Zhizhu Kuanzhong Capsule, 3 capsules at a time, 3 times a day, taken orally 10-15 min before meals. an 8-week intervention period
223583246|NCT03825692|DRUG|Zhizhu Kuanzhong Placebo Capsule|Placebo, 3 capsules at a time, 3 times a day, taken orally 10-15 min before meals. an 8-week intervention period
223583247|NCT03738059|DRUG|Dexmedetomidine Injection [Precedex]|will receive intravenous Dexmedetomidine
223583248|NCT03738059|OTHER|normal saline 0.9%|will receive intravenous normal saline 0.9%
223583249|NCT01813838|DRUG|ACADESINE 140mg/kg/d|"3 patients will be included at the initial dose of 140mg/kg/d. In absence of toxicity, 3 additional patients will be included at the higher dosage.~In case of 1/3 toxicity, 3 additionnal patients will be included at the same dose level, currently 140mg/kg/d.~In case of toxicity in 2 or more patients, the dose of acadesine will be reduced at the the dose of 85mg/kg/d"
223583250|NCT01813838|DRUG|ACADESINE 210mg/kg/d|"3 patients will be included at the dose of 210mg/kg/d. In absence of toxicity, 3 additional patients will be included at the higher dosage.~In case of 1/3 toxicity, 3 additionnal patients will be included at the same dose level, currently 210mg/kg/d.~In case of toxicity in 2 or more patients, the dose of acadesine will be reduced at the the dose of 140mg/kg/d"
223583251|NCT01813838|DRUG|ACADESINE 315mg/kg/d|"3 patients will be included at the dose of 315mg/kg/d.~In case of 1/3 toxicity, 3 additionnal patients will be included at the same dose level, currently 315mg/kg/d.~In case of toxicity in 2 or more patients, the dose of acadesine will be reduced at the the dose of 210mg/kg/d"
223583252|NCT03514498|PROCEDURE|Dental surgery|All types of dental surgery
223583253|NCT00625612|DRUG|Denufosol Tetrasodium (INS37217) Inhalation Solution|Drug: Denufosol Tetrasodium (INS37217) Inhalation Solution, Denufosol 60 mg is administered as an inhalation solution, three times daily for twelve months.
224163084|NCT06328855|DEVICE|Intermittent Oro-esophageal Tube Feeding|The specific procedure was as follows: the infant was placed in a semi-recumbent or sitting position with the head fixed. Before each feeding, the infant's oral and nasal secretions were to be cleared. An intermittent oro-esophageal tube was appropriately lubricated with water on the head part. The professional medical staff held the tube and slowly inserted it through one side of the mouth into the upper part of the esophagus. The depth of insertion depended on the patient's age and height. After each feeding, the tube was immediately removed, and the patient was held upright for at least 30 minutes in case of reflux.
224163085|NCT06328855|BEHAVIORAL|comprehensive rehabilitation therapy|Both groups were given comprehensive rehabilitation therapy. The main intervention measures included: 1) non-invasive ventilator treatment, generally at least once every night and typically not exceeding continuous daily usage.; 2) attention to feeding and sleeping positions, with a recommended sleeping position of lateral recumbent and the head of the bed raised by 20-30°; 3) swallowing function training, such as tongue muscle stretching training, assisted anterior jaw protrusion training, lemon ice stimulation to the soft palate, pharyngeal wall, etc., generally 5 days per week, twice per day, 5-20 minutes each time; 4) pulmonary ultrashort wave therapy, generally at least 2-3 times a week, and not more than once a day; 5) physical therapy, such as intensive training for gross motor functions including lifting the head, turning over, sitting, crawling, standing, etc., generally 3-5 days per week, 1-2 times per day, 5-20 min each time.
224163821|NCT02428387|BEHAVIORAL|My Tools 4 Care|On-line self-administered (My Tools 4 Care) transition toolkit includes interactive activities and resources to help caregivers deal with their transitions
223477162|NCT02029417|DRUG|omacetaxine mepesuccinate|Given SC
223477163|NCT02029417|DRUG|decitabine|Given IV
223477164|NCT02029417|OTHER|laboratory biomarker analysis|Correlative studies
223477165|NCT03580018|DRUG|Tranexamic Acid Powder|Ten mL of Tranexamic Acid(100 mg/mL) was injected into the joint at the end of the operation.
223583254|NCT00625612|DRUG|Placebo|Placebo - 0.9% w/v sodium chloride solution, three times daily for twelve months.
223583255|NCT04518163|DRUG|Tranexamic Acid|Intravenous 1 gm tranexamic acid in 100 ml saline by slow infusion before skin incision
223583256|NCT04518163|DRUG|placebo to TA|Intravenous 110 ml saline by slow infusion before skin incision
224163822|NCT02177604|OTHER|Wingate HIT|"3 sessions of Wingate based High-Intensity Interval Training (6-8 x 15 second all out sprints on a cycle ergometer interspersed by 2 minutes recovery)"
224163823|NCT02177604|OTHER|Modified HIT|3 sessions of Modified High-Intensity Interval Training (8 x 60 second sprints at approximately 90-95% VO2 peak on a cycle ergometer interspersed by 60 seconds recovery)
224163824|NCT02177604|OTHER|High-fat overfeeding|7 days of high-fat overfeeding (50% excess calories)
224163825|NCT01606332|PROCEDURE|Interscalene block with nerve catheter|Interscalene block with ropivacaine 0.5% 10ml and placement of an indwelling nerve catheter with ropivacaine 0.2% @5ml/hr for 24 hours
224163826|NCT03808844|DRUG|HSK3486|Initial dose of 0.4 mg/kg followed by 0.2 mg/kg if needed.
224163827|NCT03808844|DRUG|Propofol|Initial dose of 2.0 mg/kg followed by 1.0 mg/kg if needed
223477166|NCT03580018|PROCEDURE|Post-anterior cruciate ligament reconstruction (ACLR)|Post-anterior cruciate ligament reconstruction (ACLR)
223477167|NCT03168945|OTHER|GeneXpert MTB/RIF|Screening intervention: novel diagnostic for active case finding (GeneXpert MTB/RIF) for TB collected and performed at point-of-contact in a mobile van
223477168|NCT03168945|OTHER|Smear microscopy|Screening intervention: routine diagnostic test (smear microscopy) for active case finding for TB on sputum collected at point-of-contact in a mobile van but sent to laboratory
223583257|NCT04518163|DEVICE|Bakri Balloon|Bakri balloon was inserted into the lower uterine segment through the uterine incision by passing the balloon shaft through the cervix with an assistant pulling vaginally
224163086|NCT06328855|DEVICE|Nasogastric Tube Feeding|Nasogastric Tube Feeding were used for feeding to provide nutritional support. Each feeding was administered by a nurse using the infant's mother's breast milk through the tube. The amount of each feeding varied from 20 to 100 ml depending on the age of the infant, with feedings given every 2 to 3 hours, approximately 10 times per day. The duration of each feeding procedure ranged from 10 to 20 minutes. The total daily intake ranged from 200 to 1000 ml. Each tube was kept indwelling for 5 to 7 days. When the tube needed to be replaced, it was removed after the last feeding of a day and a new tube was to be inserted through the other nostril on the following morning to continue the nutritional support.
224163828|NCT04739995|DRUG|Low-dose naltrexone|4.5 mg LDN/day for 1 year
223583258|NCT04353700|BEHAVIORAL|Yoga group|During the in-home yoga intervention, participants performed 30 to 50 minutes of yoga postures three to five times a week for 12 weeks, including 5 minutes of warm-up exercise, 15 to 30 minutes of dynamic flow yoga postures, 10 minutes of weight barring standing postures, and 5 minutes of cool-down. These in-home sessions were a repeat of what participants learned during the first week of training session at UML. We progressively increased the intensity of the home practice sessions by adding the number of sun salutation (SS) over the 12 weeks.
223583259|NCT00647114|BIOLOGICAL|V930|V930 - Over a 94 week duration, patients will receive a series of 5 injections (2.5 mg/injection), one every other week. Within 2 minutes of each injection of V930, each patient will be given an EP-IM injection consisting of two 60 msec pulses.
223583260|NCT00647114|BIOLOGICAL|V932|V932 - Over a 94 week duration, patients will receive a series of 5 injections, 6 patients will initially received intramuscular V932 vaccinations at a low dose (0.5x109 vg/injection),and following a safety assessment, up to an additional 35 patients will be treated with the high dose V932 (0.5x1011 vg/injection).
223583261|NCT01143987|DRUG|Cinacalcet|starting with 25 mg daily dose with titration, maximum dose 100 mg daily
223583262|NCT05855343|OTHER|BIDI Stick e-cigarette|The BIDI will be dispensed, and subjects will be instructed to use the BIDI as often as they like during the 12 week period, and to switch completely to the BIDI within 1 week. If, however, they do smoke any CC, they will also be instructed to use the BIDI immediately before each CC to relieve their craving as much as possible before smoking their usual brand. The BIDI will also be the first product that they are instructed to use each morning. Smokers will be told to try to completely substitute BIDI for CCs by the end of the first week of use.
223583263|NCT03443427|BIOLOGICAL|NTHi Mcat investigational vaccine (GSK3277511A)|Two doses administered intramuscularly at Day 1 and Day 61 in the deltoid region of the non-dominant arm and a third dose administered at either Day 181 or Day 361, according to each vaccination scheduling defined per protocol.
223583264|NCT03443427|BIOLOGICAL|Placebo|One dose administered intramuscularly at either Day 181 or Day 361 in the deltoid region of the non-dominant arm.
223583265|NCT03690180|DIAGNOSTIC_TEST|serum magnesium|assessment of serum magnesium in all patients
223583266|NCT00060580|PROCEDURE|Raman scattering spectroscopy|
223583267|NCT02576860|DRUG|CLS001 (Omiganan)|Topical gel
223583268|NCT02576860|DRUG|Vehicle|Vehicle gel
223583269|NCT00322946|BIOLOGICAL|rDEN4delta30-4995|Live attenuated rDEN4delta30-4995 vaccine (one of three doses)
224163829|NCT01599949|DRUG|Ibrutinib|Type=exact number, unit=mg, number=560, form=capsule, route=oral use. 560 mg oral ibrutinib is to be administered once daily continuously until disease progression, unacceptable toxicity, or study end, whichever occurs first. Doses can be held or reduced based on the severity of and the recovery from side effects of the study drug.
223477169|NCT04056169|DRUG|high-dose rosuvastatin|rosuvastatin 20 mg once a day for 6 months
223477170|NCT04056169|DRUG|low-dose rosuvastatin plus ezetimibe|ezetimibe/rosuvastatin 10/5 mg once a day for 6 months
223477171|NCT01254370|DRUG|Latanoprost|0.005%
223477172|NCT01254370|DRUG|Travatan Z|0.004%
223744557|NCT04786223|DRUG|C-11 ER-176|Participants will receive a one-time administration of C-11 ER176 and undergo a PET/CT imaging study. Blood samples for plasma biomarker testing will be obtained as part of the study.
223744558|NCT04786223|DIAGNOSTIC_TEST|Blood Test|Participants will undergo a one time venipuncture blood collection to evaluate the presence of inflammatory and genetic markers.
223477173|NCT04873726|DEVICE|Magnetic Tape® aplication|Magnetic tape® is applied without creating any tension on the lumbar paravertebral skin to assess changes in pupil size
223477174|NCT04873726|DEVICE|Kinesiology Tape|Kinesiology tape is applied without creating any tension on the lumbar paravertebral skin to assess changes in pupil size
223477175|NCT00006126|DRUG|busulfan|
223477176|NCT00006126|DRUG|cyclophosphamide|
223477177|NCT00006126|DRUG|etoposide|
223477178|NCT00006126|DRUG|fludarabine phosphate|
223477179|NCT00006126|PROCEDURE|peripheral blood stem cell transplantation|
223477180|NCT00006126|RADIATION|radiation therapy|
223583270|NCT00322946|BIOLOGICAL|Placebo|Placebo for rDEN4delta30-4995
223583271|NCT02791412|PROCEDURE|percutaneous coronary intervention or coronary-artery bypass graft|
223583272|NCT00990912|DRUG|Carboplatin|IV, Infusion, AUC2 mg/ml.min, Once every 21 days, until progression or unacceptable toxicity
223583273|NCT00990912|DRUG|Irinotecan|IV, Infusion, 12 (9) mg/m²/day, Once daily x 10 days, every 21 days, until progression or unacceptable toxicity
223583274|NCT00990912|DRUG|Irinotecan|IV, Infusion, 10 (18) mg/m²/day, Once daily x 10 days, every 21 days, until progression or unacceptable toxicity
223583275|NCT01989702|OTHER|Fermented blueberry drink|
223583276|NCT01989702|OTHER|Placebo drink|
223583277|NCT01989702|OTHER|Sachets with probiotic bacterial powder|
223477181|NCT04398836|DIETARY_SUPPLEMENT|Exclusive Enteral Nutrition|Mulnourished patients will drink an enteral polymeric formula suited to their energy expenditure calculated by 25-30 kcal/kg and at least 1 gr/kg of protein, a minimum of 1500 ml (1500 kcal, 54 gr of protein). The amount of formula to achieve nutritional requirements are based on body weight, but the average intake is of 6-8 cups of formula (36-48 scoops of formula mixed with 1260-1680 ml of water to achieve a concentration of 1 kcal per ml). During this period patients will be guided to avoid eating and drinking anything but the enteral formula. The formula will be supplied to the patients by the investigators. The formula used for this study will be VITAL - suitable for people with disease-related malnutrition and malabsorption. Vital 1.5kcal is peptide-based, nutritionally complete formulation for the dietary management of active phase of Crohn's disease. VITAL includes all the nutritional macro and micronutrients and can serve as a sole source of nutrition.
223477182|NCT04398836|OTHER|High energy / protein diet.|Mulnourished patients will receive a high energy / protein diet.
223477183|NCT04398836|OTHER|Standard nutrition|Well nurished patients will receive a standard nutrition
223477184|NCT05673395|DEVICE|Electrolyzed alkaline reduced water generator|Participants drink water (10 mL/kg body weight) generated from the device after intensive excercise.
223477185|NCT01141816|OTHER|Contrast-Enhanced Ultrasound|Contrast-enhanced ultrasounds of the kidney will be performed within 7 days of routine CTs or MRIs at 3, 6, 12, 18, and 24 months post-radiofrequency ablation, with Perflutren Lipid Microsphere Injectible Suspension ('Definity') as the contrast agent.
223477186|NCT02444026|BEHAVIORAL|iCBT for Insomnia|Internet-delivered Cognitive Behavioural Therapy for Insomnia
223477187|NCT03297190|BEHAVIORAL|SMS|Receipt of SMS messages on nutrition and health topics
223477188|NCT03297190|BEHAVIORAL|Interpersonal Counselling|Interpersonal counselling on health and nutrition topics
223477189|NCT01894906|DRUG|Soluble Ferric Pyrophosphate|
223583278|NCT01989702|OTHER|Sachets with placebo powder|
223583279|NCT05492760|DEVICE|cryoballoon ablation|Patients with AF will accept cryoballoon ablation.
223583280|NCT05960084|OTHER|screening|screening for colistin resistant E. coli
223583281|NCT02162212|OTHER|Optimized Shoulder Movement Program|"A trained physical therapist will see the participant for a max of 6 visits over the 3 month intervention; for baseline instruction, and at 2, 4, 6, and 8 weeks to progress and check subject adherence before a final check-out and testing visit at 3 months. Participants will perform 3 assigned stretching motions a min of 2 sets of 10 reps each and will be instructed in active shoulder movements with a dose based on the subject's measured activity count at baseline and with enough duration to increase it by 10%. Exercise: 10-15 minutes 2x/day for 3 month duration. Participants will log their activity."
223583282|NCT02162212|OTHER|ADA Guideline Instructed|The ADA guideline instructions are to include: blood sugar control (goal is A1c \< 7.0%), physical activity (150 minutes/week of moderate intensity aerobic activity), foot care (examine feet daily, monofilament testing), and blood pressure control (goal is \<130/80). Participants will receive a logbook to record daily outcomes. The goal of this intervention is to control for personal interactions with investigators and provide useful information for disease management but not provide intervention that likely would improve shoulder joint motion. The control group will be given instruction in the exercise program at the end of the 1 year study period.
223583283|NCT04208048|DEVICE|FLXfit 15TM device|In order to implant the FLXfit 15TM device properly, your study doctor will first prepare the space between the low back bones (vertebrae) and then remove your damaged disc. The FLXfit 15TM device will then be placed into the space between the low backbones, using specific medical instruments, where the damaged disc was removed.
224163087|NCT02302755|DRUG|TP10|All patients will be enrolled through the University of Iowa. This study will follow a patient-specific dose-escalation scheme during the Induction Period and subsequent TP10 dose adjustments based on complement levels during the Maintenance Period.
224163088|NCT01026350|DIETARY_SUPPLEMENT|colostrum enriched with anti flu antibodies|each volunteer will receive six 1.2 g oral tablets (equivalent to 600 mg of bovine colostrum powder each) once a day for two weeks.
224163089|NCT00601679|OTHER|NT-proBNP guided care|knowledge of NT-proBNP results
224163090|NCT00333047|DRUG|Letrozole|
224163091|NCT02394223|PROCEDURE|Full Field Optical Coherence Tomography (FFOCT) procedure|TRUS Prostate biopsy are performed under the care procedure Pathological examination of these prostate biopsy with FFOCT procedure, as compared to standard pathological evaluation
224163092|NCT03944304|DRUG|Paclitaxel|Paclitaxel will be administered at 80mg/m2/day every four weeks at Day 1, Day 8 and Day 15 per cycle. One cycle consists of 4 weeks (28 days).
223744559|NCT06575920|BEHAVIORAL|Breathing excercizes|The intervention comprised six sessions. The first week involved obtaining informed consent, taking measurements and providing a brief introduction to breath and coherent breathing exercises. This was followed by four weekly sessions, each consisting of 90 minutes combining lectures and breathing exercises. At the final session, measurements and feasibility data were collected.
224163093|NCT00259519|PROCEDURE|Induction of delivery|Induction of delivery
223477190|NCT01894906|OTHER|Placebo|
224163094|NCT03395041|DIAGNOSTIC_TEST|cardiac imaging tests|cardiac computed tomography, echocardiography, intravascular ultrasound, optical coherence tomography
224163095|NCT02092324|OTHER|Laboratory Biomarker Analysis|Correlative studies
224163096|NCT02092324|OTHER|Quality-of-Life Assessment|Ancillary studies
224163097|NCT02092324|OTHER|Questionnaire Administration|Ancillary studies
223477191|NCT01785381|OTHER|Added value of coordinator|Added value of coordinator
223477192|NCT06525467|PROCEDURE|radical nephrectomy|open radical nephrectomy and lymph node dissection.
223477193|NCT04460053|PROCEDURE|Neurofilament light protein measurement in Isolated limb perfused patients|A prospective feasibility trial measuring neurofilament light protein in peripheral blood as a biomarker for neurotoxicity after isolated limb perfusion.
224163098|NCT02092324|DRUG|Ruxolitinib Phosphate|Given PO
224163099|NCT02758041|DEVICE|Sebacia Microparticles|
224163100|NCT00000314|DRUG|M-CPP|
223477194|NCT06525792|PROCEDURE|Oxygen|Oxygen and standard therapy were given
223477195|NCT06525792|PROCEDURE|Ozone|Ozone and standard therapy were given
223477196|NCT06525792|PROCEDURE|Standard therapy|Best standard of care
223477197|NCT04194164|OTHER|Fluid intake app|Monitor fluid intake and interdialytic weight gain in patients using the fluid app
223477198|NCT00836732|PROCEDURE|harvest of a small bone marrow sample|harvest of a small bone marrow sample during open chest surgery
223583284|NCT03396510|OTHER|IMPROVED intervention|Patients randomized to IMPROVED will self-report their symptoms each day using a tablet computer. If any patient refuses or is unable to complete the symptom assessment on the computer, the investigators will permit them to use paper versions. At morning rounds each day, the clinical team will view reports detailing their patients' symptom burden. Patients randomized to IMPROVED will have their symptoms presented to their inpatient oncology team, but the investigators will not provide guidance about what actions to take in response to patients' symptoms.
223583285|NCT04615325|DRUG|RO7303359|RO730359 will be administered as a single intravitreal injection.
223744560|NCT06770985|OTHER|Artificial Intelligence|"Ollama (Ollama., 2024, https://ollama.ai/) artificial intelligence program and PYTHON 3 Programming Language and open source libraries will be used for the necessary algorithms for data review and analysis. In case of deficiencies in the data of the patients; the missing data will be edited using Data Imputation techniques. Number of files to be reviewed and/or date range to be covered: Patients who underwent lung resection between January 2023 and October 2024 will be included. An estimated 2000 files are planned to be scanned."
223583286|NCT03400631|DRUG|Dextrose 0|Dextrose injection at time 0
223583287|NCT03400631|DRUG|Aspiration 0|Aspiration only at time 0
223583288|NCT03400631|DRUG|Dextrose 1|Dextrose injection at week 1
223744561|NCT00782145|OTHER|educational intervention|
223744562|NCT00782145|OTHER|informational intervention|
223744563|NCT00782145|OTHER|internet-based intervention|
223744564|NCT00782145|OTHER|questionnaire administration|
223744565|NCT00782145|OTHER|study of socioeconomic and demographic variables|
223744566|NCT00782145|OTHER|survey administration|
223583289|NCT03400631|DRUG|Aspiration 1|Aspiration only at week 1
223583290|NCT01541917|BEHAVIORAL|Web-based coping skills training|This intervention comprises a 12-week interactive, multi-component, multimedia online training that consists of instruction in specific self-management strategies, disease education, and social support. The content is rooted in cognitive-behavioral principles of disease self-management. In addition to the web-based modules, the intervention consists of monthly telephone support for 3 months by a trained bilingual health coach (research nurse) to review material and help enhance motivation.
223744567|NCT00782145|PROCEDURE|psychosocial assessment and care|
223744568|NCT00782145|PROCEDURE|quality-of-life assessment|
223477199|NCT00815152|BEHAVIORAL|coping skills intervention training|The strategies will include ways to improve problem solving, communication skills, and managing activities.
223583291|NCT01541917|BEHAVIORAL|Online disease education|"The online disease education intervention provides access to an online resource center containing links to 12 educational websites about Juvenile Idiopathic Arthritis. Participants will be asked to review one educational website per week over the course of 12 weeks. Participants also will receive three monthly phone calls by a bilingual nurse health coach to discuss the participant's efforts at managing his/her disease."
223583292|NCT00121641|DRUG|Saxagliptin|Tablets, Oral, 2.5 mg, Once daily (24 weeks short term \[ST\], 42 months long term \[LT\])
223583293|NCT00121641|DRUG|Saxagliptin|Tablets, Oral, 5 mg, Once daily (24 weeks ST, 42 months LT)
223744569|NCT00782145|PROCEDURE|standard follow-up care|
223744570|NCT06985238|DEVICE|MRI|Will receive up to 15 minutes of additional MRI scan time during the existing prostate MRI imaging session.
223744571|NCT06981884|OTHER|core stabilization exercises|Participants will be given core stabilization exercises 2 days a week, 45 minutes per session, for 2 months. At the end of 2 months, the outcome measurements will be taken by an evaluator physiotherapist who is not present during the treatment.
223744572|NCT06981884|OTHER|motor imagery training group|core stabilization exercise + motor imagery training group Participants will be given core stabilization exercises and motor imagery training 2 days a week, 60 minutes per session, for 2 months. Motor imagery training will be applied for 15 minutes immediately after the core stabilization exercisesAt the end of 2 months, the outcome measurements will be taken by the same evaluator physiotherapist who is not present during the treatment
223744573|NCT06586177|DRUG|Anti-CD20 antibody|Study participants receive an anti-CD20 antibody according to the summary of product characteristics.
223744574|NCT01928524|DRUG|DOS2w Dose level 1A|Docetaxel (30 mg/m2), Oxaliplatin (70 mg/m2) and S1 (60 mg/2) will be given every 2 weeks. In total there is 5 dose levels and if no patients experience DLT on a given level, next dose level will be administered.
224163101|NCT03594461|DRUG|Aflibercept Injection|Intense Treatment Regimen for Refractory Neovascular Age-Related Macular Degeneration with or without Polypoidal Choroidal Vasculopathy
224163102|NCT01039428|DIETARY_SUPPLEMENT|HS219|Chewing for 30 min three time a day far after meal
223477200|NCT00815152|BEHAVIORAL|usual care|The ususal care at the Preston Robert Tisch Brain Tumor Center
223477201|NCT05120076|DRUG|Dexamethasone 4 Mg/mL Injectable Solution|s. arm/group description
223477202|NCT05120076|DRUG|NaCl 0.9%|s. arm/group description
223583294|NCT00121641|DRUG|Saxagliptin|Tablets, Oral, 10 mg, Once daily (24 weeks ST, 42 months LT)
223583295|NCT00121641|DRUG|Placebo matching Saxagliptin|Tablets, Oral, 0mg, Once daily (24 weeks ST, 42 months LT)
223583296|NCT00121641|DRUG|Metformin|Tablets, Oral, 500 mg, daily (42 months LT)
223583297|NCT00121641|DRUG|Placebo matching Metformin|Tablets, Oral, 0 mg, daily (42 months LT)
223583298|NCT00121641|DRUG|Saxagliptin|Tablets, Oral, 10 mg, Once daily (24 weeks ST, 42 months LT) Open Label
223583299|NCT00121641|DRUG|Metformin|Tablets, Oral, 500-2000 mg (as needed for rescue)
223583300|NCT01365624|DRUG|Ketorolac tromethamine|Single dose of 30 mg of intranasal Ketorolac tromethamine (100 uL of a 15% solution in each nostril)
223744575|NCT01928524|DRUG|DOS2w Dose level 2A|Docetaxel (30 mg/m2), Oxaliplatin (70 mg/m2) and S1 (70 mg/2) will be given every 2 weeks. In total there is 5 dose levels and if no patients experience DLT on a given level, next dose level will be administered.
223744576|NCT01928524|DRUG|DOS2w Dose level 3A|Docetaxel (40 mg/m2), Oxaliplatin (70 mg/m2) and S1 (70 mg/2) will be given every 2 weeks. In total there is 5 dose levels and if no patients experience DLT on a given level, next dose level will be administered.
223477203|NCT05613348|BIOLOGICAL|CD19 CAR T-Cell(CAT19T2)|Drug: Fludarabine， Administered intravenously Drug: Cyclophosphamide， Administered intravenously
223477204|NCT01231269|OTHER|MRI|MRI scan without administration of contrast/without radiation
223477205|NCT02673749|DRUG|RP-G28|Study drug taken orally
223477206|NCT02673749|OTHER|Placebo|Placebo taken orally
223477207|NCT05571111|DRUG|FE 999302|Subcutaneous injection as a single dose. 3 different doses
223477208|NCT05571111|DRUG|Ovitrelle|Subcutaneous injection as a single dose. 250 µg (0.5 mL)
223477209|NCT05571111|DRUG|Novarel|Subcutaneous injection as a single dose. 10,000 IU (1 mL)
223477210|NCT02322996|OTHER|questionnaires|The deep phenotyping of acute pain will be conducted using the oral surgery model. Before surgery, subjects will undergo QST and answer short-form questionnaires related to pain and activities of daily living.
223477211|NCT04543864|DEVICE|Electric intraoral welding device|welding metal framework to the implants in completely edentulous maxilla by electric welding device intraorally
223583301|NCT03112304|BEHAVIORAL|MATCH-ADTC|MATCH - ADTC (Modular Approach to Therapy for Children with Anxiety, Depression, Trauma, or Conduct Problems; Chorpita \& Weisz, 2009) is a psychosocial intervention designed to treat children with multiple disorders and problems encompassing anxiety, depression, post-traumatic stress, and disruptive conduct, including the conduct problems associated with ADHD. It is recommended for children aged 6-15. MATCH is composed of 33 modules-i.e., specific treatment procedures derived from decades of research on EBTs. The various modules can be organized and sequenced flexibly to tailor treatment to each child's characteristics and needs.
223744577|NCT01928524|DRUG|DOS2w Dose level 4A|Docetaxel (50 mg/m2), Oxaliplatin (70 mg/m2) and S1 (70 mg/2) will be given every 2 weeks. In total there is 5 dose levels and if no patients experience DLT on a given level, next dose level will be administered.
224163103|NCT01039428|DIETARY_SUPPLEMENT|Placebo|Chewing for 30 min three times a day far after meal
224163104|NCT01617928|DRUG|veliparib (ABT-888)|Dosing orally twice daily starting Day 1 through day 7 of each cycle. Decisions to move to the next cohort will be based on evaluation of DLTs in the current cohort. Decisions will be made with a discussion between the Sponsor and the principal investigator to dose escalate or de-escalate or add more subjects to the cohort.
224163105|NCT01617928|DRUG|carboplatin|Carboplatin will be administered on Day 3 of each cycle, intravenously.
224163106|NCT01617928|DRUG|paclitaxel|Paclitaxel will be administered on Day 3 of each cycle, intravenously.
224163107|NCT02139267|BIOLOGICAL|GX-188E|DNA vaccine administered via IM route using TDS-IM electroporation device
224163108|NCT01339780|RADIATION|BS, SPECT/CT, PET/CT, MRI|Planar bone scintigraphy (BS), single photon emission computed tomography combined with low-dose computed tomography (SPECT/CT), 18F-fluoride positron emission tomography computed tomography (PET/CT) and magnetic resonance imaging (MRI) will be performed to all patients.
224163109|NCT02262676|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Patients treated by Physicians under approved local prescriptions
224163110|NCT03224260|DRUG|BMS-986177|Oral Suspension
224163111|NCT03224260|OTHER|Matched Placebo|Oral Suspension
223477212|NCT04543864|DEVICE|casting|casting the metal framework
223477213|NCT00877968|DIETARY_SUPPLEMENT|Whole wheat banana bread|"Dose was portioned so that subjects received 50 g available carbohydrate~Portion: 62.8 g Available CHO: 51.7 g"
223477214|NCT00877968|DIETARY_SUPPLEMENT|Whole pea flour banana bread|"Dose was portioned so that subjects received 50 g available carbohydrate~Portion: 67.8 g Available CHO: 52.0 g"
223477215|NCT00877968|DIETARY_SUPPLEMENT|Whole wheat biscotti|"Dose was portioned so that subjects received 50 g available carbohydrate~Portion: 79.8 g Available CHO: 53.1 g"
223477216|NCT00877968|DIETARY_SUPPLEMENT|Whole pea flour biscotti|"Dose was portioned so that subjects received 50 g available carbohydrate~Portion: 86 g Available CHO: 51.7 g"
223477217|NCT00877968|DIETARY_SUPPLEMENT|Whole wheat pasta|"Dose was portioned so that subjects received 50 g available carbohydrate~Portion (Dry): 70 g Available CHO: 51.1 g"
223477218|NCT00877968|DIETARY_SUPPLEMENT|Whole pea pasta|"Dose was portioned so that subjects received 50 g available carbohydrate Pea pasta is 30% whole pea pasta, 70 white wheat durum~Portion (Dry pasta) : 90 g Available CHO: 53.1 g"
223477219|NCT00877968|DIETARY_SUPPLEMENT|White bread|"Dose was portioned so that subjects received 50 g available carbohydrate~Portion: 100 g Available CHO: 50 g"
224163112|NCT05051176|DIAGNOSTIC_TEST|2D usg and 3D/4D usg|IRD distance measured by a linear probe 2D usg. Pelvic floor muscle morphometry measured by 3D/4D usg
223477220|NCT00877968|DIETARY_SUPPLEMENT|Boiled yellow peas|"Dose was portioned so that subjects received 50 g available carbohydrate~Portion: 100 g (dry) --\> 250 g cooked Available CHO: 52.8 g"
223477221|NCT04369937|RADIATION|IMRT (Intensity Modulated Radiotherapy)|Radiation therapy
223477222|NCT04369937|DRUG|Pembrolizumab|A potent and highly selective humanized monoclonal antibody (mAb) of the IgG4/kappa isotype designed to directly block the interaction between programmed cell death protein 1 (PD-1) and its ligands, PD-L1 and PD-L2.
223477223|NCT04369937|DRUG|Cisplatin|Chemotherapy
223477224|NCT04369937|BIOLOGICAL|ISA101b|ISA101b is a therapeutic cancer vaccine that induces specific immune responses to the oncogenic E6 and E7 antigens from HPV16.
223477225|NCT04805528|RADIATION|Acupuncture-Like Transcutaneous Electrical Stimulation (ALTENS)|Twice weekly ALTENS therapy for 12 weeks
223477226|NCT05219162|GENETIC|Gene Profile explore|The tissue and blood sample for this genetic research will be obtained from the participants at baseline(disease progression after 1L Osimertinib). Paired tissue and whole blood sample should be collected per participant for genetics during the study.
223477227|NCT04632108|DRUG|ASKB589 Injection|ASKB589 Injection with dose escalation stage of 0.3mg/kg up to 20mg/kg,as well as dose expansion stage with recommended dose level from dose escalation stage.
223583302|NCT03112304|OTHER|TRAC|"TRAC (Treatment Response Assessment for Children) is a web-based system that provides weekly monitoring of the MATCH modules used and the child's response to treatment. Child's response to treatment is based on caregiver and child reports of (a) changes in problem severity on the standardized Brief Problem Checklist, and (b) changes in severity of the top treatment concerns identified by youths and caregivers. At the end of treatment, TRAC provides a complete record of modules used, and child treatment response, across all the weeks of treatment, as illustrated in the client dashboard."
223583303|NCT02345096|DIETARY_SUPPLEMENT|Saccharomyces cerevisiae|
223583304|NCT02345096|DIETARY_SUPPLEMENT|Placebo|
223477228|NCT04154891|GENETIC|Trio Whole Genome Sequencing|WGS trio analysis will be performed using the genome data of the index case in addition to the genome data of his parents. This analysis will follow a consensus protocol that contains 3 obligatory steps: first of all, de novo variants (SNV, CNV and others SV) will be examined in the whole genome data set; then, a SNV/CNV/other SV analysis will be performed under a AR or X linked Mendelian mode hypothesis in the whole genomic regions of a OMIM extended list (that contains all genes already involved in human genetic diseases). Finally, analysis will focus on inherited pathogenic variants under an AD mode hypothesis (analysis of variations already reported as pathogenic in clinVar or HGMD pro; CNV or truncating variation in OMIM genes, etc). When these 3 steps analysis is completed then variants of interest identified at each step will be recorded until examination by a specific multidisciplinary meeting.
223744578|NCT01928524|DRUG|DOS3w Dose level 1B|Docetaxel (40 mg/m2), Oxaliplatin (100 mg/m2) and S1 (50 mg/2) will be given every 3 weeks. In total there is 5 dose levels and if no patients experience DLT on a given level, next dose level will be administered.
224163113|NCT03743376|BIOLOGICAL|UB-421(25 mg/kg) Q2W|Monoclonal antibody by IV infusion plus standard ART
224163114|NCT03743376|BIOLOGICAL|UB-421(25 mg/kg) Q4W|Monoclonal antibody by IV infusion plus standard ART
224163115|NCT06056401|BEHAVIORAL|record Hemodynamic variables, respiratory variables and arterial blood gas at specific times|Hemodynamic variables, respiratory variables and arterial blood gas were measured and recorded 15 minutes after induction of anesthesia (T1), 15 minutes after establishment of a folding knife position (T2), 30 and 60 minutes after CO2 pneumoconiosis (T3 and T4), and 15 minutes after pneumoconiosis (T5). Hemodynamic variables measured included mean arterial pressure , heart rate , cardiac output, cardiac index, stroke volume index and stroke volume variation. Breathing variables include tidal volume, minute ventilation , respiratory rate , airway frontal pressure , mean airway pressure , plateaus airway pressure , peripheral oxygen saturation , oxygen saturation , and oxygen response . Arterial blood gas variables include pH value, arterial carbon dioxide, arterial oxygen pressure , alkali surplus , alveolar oxygen pressure , and bicarbonate of soda ion concentration .
224163116|NCT00861094|DRUG|cisplatin|
224163117|NCT00861094|DRUG|5-FU|
224163118|NCT00861094|DRUG|oxaliplatin|
224163119|NCT00861094|RADIATION|radiation therapy|
224163120|NCT00861094|DRUG|Folinic Acid|
224304838|NCT06929052|DRUG|ADL-018 Injection|Reference Product (B): ADL-018 Injection 150mg/mL solution in a single dose pre-filled syringe manufactured/supplied by Kashiv BioSciences LLC, USA
223477229|NCT04154891|GENETIC|Simplex Whole Genome Sequencing|This analysis will be performed using only the index case following a similar strategy than the one used for the WGS trio
223477230|NCT04154891|GENETIC|Current French Reference strategy|Actual ANPGM recommendations defined by the following analysis: Fra-X + chromosomal microarray analysis + 44GPS
223477231|NCT05736406|COMBINATION_PRODUCT|5-ALA HCl intraoperative Photodynamic Therapy (PDT) at 200 J/cm^2|5-ALA HCl, 20 mg/kg, is orally administered 4-6 hours before the surgery. Then after resection of tumor tissue is judged maximal, the intraoperative PDT procedure is initiated at 200 J/cm\^2.
223477232|NCT05736406|COMBINATION_PRODUCT|5-ALA HCl intraoperative Photodynamic Therapy (PDT) at 400 J/cm^2|5-ALA HCl, 20 mg/kg, is orally administered 4-6 hours before the surgery. Then after resection of tumor tissue is judged maximal, the intraoperative PDT procedure is initiated at 400 J/cm\^2.
223477233|NCT03506061|DRUG|Trikafta|Participants will take Trikafta which is a combination tablet comprised of 100 milligrams (mg) of elexacaftor, 50 mg of tezacaftor and 75 mg of ivacaftor (2 tablets taken in the morning), and 150 mg of ivacaftor taken in the evening.
223477234|NCT00003261|DRUG|methotrexate|
223477235|NCT00003261|DRUG|zidovudine|
223477236|NCT00003261|PROCEDURE|neoadjuvant therapy|
223477237|NCT00003261|RADIATION|radiation therapy|
223477238|NCT02143687|BEHAVIORAL|Moderate altitude sojourn|Participants will travel from Zurich (490 m) to St. Moritz Salastrains (2048 m) and stay there for 2 days
223477239|NCT02143687|BEHAVIORAL|Low altitude sojourn|Low altitude baseline evaluations will be performed during a stay at Zurich (490)
223477240|NCT02143687|DRUG|Oxygen|Oxygen administration via a nasal cannula at a rate of 3 L/min during nights spent at 2048 m
223477241|NCT02143687|DRUG|Sham oxygen (room air)|Sham oxygen (room air) administration via a nasal cannula at a rate of 3 L/min during nights at 490 m and 2048 m
223477244|NCT02115100|PROCEDURE|procedure|Renal ablation+pulmonary vein isolation OR pulmonary vein isolation only
223477245|NCT00707837|OTHER|Preterm infant formulas and discharge formulas|Preterm infant formulas to be consumed per health care provider orders
223477246|NCT00707837|OTHER|Preterm infant formula with added soluble lipids|Preterm infant formula to be fed per healthcare provider instructions
223477247|NCT04042831|PROCEDURE|Biospecimen Collection|Undergo collection of blood and tissue samples
223477248|NCT04042831|PROCEDURE|Computed Tomography|Undergo CT
223477249|NCT04042831|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223477250|NCT04042831|DRUG|Olaparib|Given PO
223477251|NCT02385786|BEHAVIORAL|Mindfulness-Based Cognitive Therapy|Eight week course in mindfulness meditation training with elements of cognitive behavioral therapy
223477252|NCT04165122|BIOLOGICAL|HDIT101|i.v. Infusion
223477253|NCT04165122|DRUG|Valaciclovir|oral application of encapsulated Valaciclovir tablets
223477254|NCT04165122|BIOLOGICAL|HDIT101 placebo|i.v. Infusion
223477255|NCT04165122|DRUG|Valaciclovir placebo|oral application of encapsulated Valaciclovir placebo tablets
223477256|NCT02429050|DRUG|sustained release morphine|Patients will receive morphine SR 10mg two to three times daily or placebo. Hard gelatin capsules of size AA in Swedish orange containing one morphine SR tablet 10 mg per capsule will be produced. Morphine SR has a marketing authorisation for pain and will be used according to current Dutch and international guidelines for treatment of dyspnea.
223477257|NCT02429050|DRUG|placebo|Patients in the control group will receive placebo, consisting of microcrystalline cellulose (FMC BioPolymer). Hard gelatin capsules of size AA in Swedish orange containing microcrystalline cellulose will be produced.
224304839|NCT05673213|OTHER|Three-stair positioning pillows group|The infant was cared for, fed and treated by the primary nurse responsible for the infant between 08:30 and 08:55. No intervention was made to the preterm infant between 09:00-12:00 and the infant was allowed to rest. Preterm infants were followed for 3 hours (09:00-12:00) with three-stair positioning pillows. Between these hours, the oxygen saturation and heart rate of the preterm infants in were counted by the researcher with a pulse oximeter device and recorded 18 times in 10 minutes. Sleep-wakefulness status was recorded by taking 15-second recordings with the Actigraphy measuring device.
223477258|NCT00171249|DRUG|STI571 400 mg|STI571 capsules and tablets
223477259|NCT00171249|DRUG|STI571 600 mg|STI571 capsules and tablets
223477260|NCT01952652|DRUG|Group N:Naproxen sodium|drug will be given 60 minutes before surgery
223477261|NCT01952652|DRUG|Group NC :naproxen sodium codeine phosphate|drug will be given 60 minutes before surgery
223477262|NCT01041859|DRUG|Tapentadol extended release (ER)|Type= range, unit= mg, number= 100 to 250, form= tablet, route= oral use. Tapentadol ER optimal dose ranging between 100 mg and 250 mg twice daily for 15 weeks.
223477263|NCT01041859|DRUG|Placebo|Form= tablet, route= oral use. Matching placebo twice daily.
223583305|NCT04229836|DRUG|Tildrakizumab 100 mg Solution for Injection|Participants will be treated with tildrakizumab 100 mg.
223583306|NCT00247455|DRUG|Low fibre breakfast cereal (puffed rice/cornflakes)|
224070189|NCT06107972|BEHAVIORAL|Launching! to Adulthood (¡Iniciando! la Adultez) program|The program includes cognitive behavioral and acceptance and commitment therapy, with a focus on developing goals during the transition to adulthood through a values framework. After a combined (parents and young adults) 90-minute introductory group meeting in-person, parents and the transition-aged young adults with ASD attend 9 separate, 90-minute weekly group telehealth meetings. Additionally, young adults have weekly personal coaching meetings for 30-minutes to discuss progress toward goals and barriers encountered. Leaders teach transition-aged young adult's skills through various social activities, as well as other skills (e.g., emotion regulation, cognitive diffusion) to help overcome barriers towards their goals. The treatment targets three core factors (i.e., mental health conditions, social skills, and coping with and adapting to stress). Leaders teach parents new parenting skills, knowledge of ASD, and readiness to support their young adult's transition to independent life.
223477264|NCT00595361|DRUG|salmeterol|salmeterol 50 micrograms twice daily for 2 weeks
224070190|NCT05371886|OTHER|Dose-effect relationship of morphine +/- midazolam administration|Dose-effect relationship of morphine +/- midazolam administration as continuous infusion in neonates undergoing mechanical ventilation through PKPD modelling
224070191|NCT05098197|BIOLOGICAL|Tumor Infiltrating Lymphocyte|Adoptive transfer of 1x10\^9-5x10\^10 autologous TILs to patients i.v. in 30-120 minutes.
224070192|NCT04303858|DRUG|Eciskafusp Alfa|Participants will be administered eciskafusp alfa in different schedules.
223477265|NCT03889392|PROCEDURE|Kidney transplantation and nephrectomy|Bilateral nephrectomy of polycystic kidneys are routinely performed during kidney transplantation in ADPKD patients
223477266|NCT00981617|DRUG|ALKS33 (RDC-0313) (1 mg)|1 mg ALKS33 (RDC-0313) taken once daily for 12 weeks
224070193|NCT04303858|DRUG|Atezolizumab|Participants will be administered 1200 mg of atezolizumab once every 3 weeks.
224070194|NCT05667753|BEHAVIORAL|MINISTOP 3.0|MINISTOP 3.0 is a behavioral changed program with the overall aim to promote healthier lifestyle behaviors (i.e., diet, physical activity, and sedentary behavior) among 2.5/3-year old children. The MINISTOP 3.0 program consists of features such as information, monitoring, and feedback (dietary variables, physical activity, and screen time) and is built around 13 themes over a 6-month period.
224070195|NCT06472011|OTHER|lean steak and potatoes|Participants will be fed \~400 kcal lean steak and potatoes on one occasion to test for changes in blood glucose and insulin levels as well as appetite over a 4-hour period of time.
224070196|NCT06472011|OTHER|lentil and sweet potato chili|Participants will be fed \~400 kcal lentil and sweet potato chili on one occasion to test for changes in blood glucose and insulin levels as well as appetite over a 4-hour period of time.
223477267|NCT00981617|DRUG|ALKS33 (RDC-0313) (2.5 mg)|2.5 mg ALKS33 (RDC-0313) taken once daily for 12 weeks
223477268|NCT00981617|DRUG|ALKS33 (RDC-0313) (10 mg)|10 mg ALKS33 (RDC-0313) taken once daily for 12 weeks
223477269|NCT00981617|DRUG|Placebo|Matching placebo taken once daily for 12 weeks
223477270|NCT04367805|DIAGNOSTIC_TEST|nasopharyngeal Covid 19 RT-PCR|nasopharyngeal Covid 19 RT-PCR
223477271|NCT02075125|DRUG|Prasugrel 60 mg|Patient administer prasugrel 60 mg as loading dose followed by 10 mg/day as maintenance dose.
223477272|NCT02075125|DRUG|Ticagrelor 180 mg|Patients administer ticagrelor 180 mg as loading dose followed by 90 mg bid as maintenance dose.
223477273|NCT01642381|BEHAVIORAL|"Full Motivational Interviewing (FMI)"|Relational and technical technical (directive) strategies in counselling sessions to significantly increase commitment strength to reduce drinking.
223477274|NCT01642381|BEHAVIORAL|"Spirit Only Motivational Interviewing (SOMI)"|Empathic and non-directive counselling based on Rogerian psychotherapy model.
223583307|NCT00247455|DRUG|High fibre cereal (All Bran/Bran Flakes)|
223583308|NCT03801746|DRUG|vadadustat|Oral dose 300 mg
223583309|NCT03801746|DRUG|Rifampin|IV Rifampin
223583310|NCT03801746|DRUG|Probenecid|Oral Probenecid
223583311|NCT03801746|DRUG|Cyclosporins|Oral Cyclosporine
223583312|NCT00047619|PROCEDURE|Pulsatile Lavage|pulsatile lavage to wound bed
223583313|NCT00047619|OTHER|sham pulsatile lavage|pulsatile lavage to not directed at wound or patient
223583314|NCT05167903|OTHER|Normal Diet|All praticipants in ND will perform supervised and monitored RT three time per week for the 10 weeks of intervention. The ND group will consume all meals between 6 am - 10 pm (16 h eating window with 8 h of fasting, ad-libitum).
224163121|NCT06454162|OTHER|Modified Ketogenic Diet|the patients will receive KD after nutritional counseling, patients will instructed to start by limiting carbohydrate intake to just 20 g/day for 4 weeks in order to establish ketosis. Then, patients increase their carbohydrate intake by 5 g each week until they reach their individual maximum (approximately 40 g) to maintain stable ketosis. All carbohydrates relevant for elevating blood glucose are limited to 40-50 g/ day. In addition, the glycemic index and glycemic load of carbohydrates have to be below 50 and 60, respectively. This ketogenic diet is equivalent to a traditional ketogenic diet, but with a liberalized macronutrient composition of 70-80% fats, 15-20% proteins and 5-10% carbohydrates (compared to a traditional ketogenic diet with 90% fat, 6% proteins and 4% carbohydrates)+ exercise program
224163122|NCT06454162|OTHER|exercise program|the patients will receive exercise program in the form of aerobic training (10-30 minutes at moderate intensity) and resistance training (1-3 sets of 8-15 repetition maximum (RM)
224163123|NCT02287662|OTHER|Vancouver 3M Clinical Pathway|
224163124|NCT02393222|OTHER|Observing effect of routine HD|Observing effect of routine HD via transcranial doppler, neurocognitive questionnaires and (in some) brain MRI
224163125|NCT06115057|DIETARY_SUPPLEMENT|Fiber|"Subjects in this study are to consume the study product twice daily during regular meals.~The fiber mix consists of different types of dietary fiber that are individually well tolerated for human consumption."
223583315|NCT05167903|BEHAVIORAL|Time-restricted eating|All participants in TRE will perform supervised and monitored RT three time per week for the 10 weeks of intervention. Participants in the TRE group will be instructed to consume all meals between 12pm to 8pm, and to avoid consumption of food or caloric drinks during the fasting period (8 h eating window with 16 h of fasting).
224163126|NCT03587922|DEVICE|Fantom|Treatment of den ovo coronary lesions
224304840|NCT00121160|BEHAVIORAL|Cognitive Behavioral Stress Management (CBSM) group intervention|Participants will meet in closed, structured groups of 4 to 6 women for ten weekly, 2-hour group sessions. The intervention employs CBSM techniques interwoven with information in a supportive group format. The information portion of the intervention focuses on learning to cope with daily stressors, and learning about optimal use of social support. Group members and group leaders are used as role models for effective coping and the use of social support. The groups also encourage emotional expression and provide an opportunity to practice techniques learned in the group and experience social support. Avoidance coping is discouraged, and acceptance and reframing are instead encouraged as coping responses. Health behavior change, framed as a coping technique, will also be discussed using motivational interviewing techniques. Each week participants also experience a different relaxation technique. The goal of the CBSM intervention is thus to reduce distress through a variety of techniques.
223583316|NCT00659503|DRUG|Ciclesonide|200µg Ciclesonide versus Placebo
224304841|NCT06927752|DEVICE|PelviGYNious|Patient received PelviGYNious implant.
223583317|NCT00659503|DRUG|Placebo|placebo
224304842|NCT06927752|DEVICE|EndoGYNious|Patient received EndoGYNious implant.
224304843|NCT06929000|OTHER|the supine head-lateral position group|the supine head-lateral position group: during the perioperative period, keep the patient's head tilted to the left or right
224304844|NCT06929000|OTHER|the adjustable headrest group|the adjustable headrest group: placing an adjustable pillows on the patient's head to align the patient's external auditory canal horizontally with the sternum
224304845|NCT06929000|OTHER|the supine head-straight position group|the supine head-straight position group: during the perioperative period, keep the patient's head upright
224304846|NCT03907462|BEHAVIORAL|SMART 2.0|SMART 2.0 uses a fully integrated system of modalities that includes: 1) a popular consumer-level wearable, wireless scale, and corresponding app; 2) a highly tailored and interactive text messaging system; 3) multiple social media streams; 4) social network mechanisms of influence; and 5) technology-mediated health coaching.
224304847|NCT06926712|DRUG|Vitamin E|dose of vitamin E in an appropriate dose for age during hospital stay for intervention group
224304848|NCT04262661|DRUG|NNC0472-0147|Part 1: A single dose of NNC0472-0147, dose increased in each cohort. Part 2: Daily doses of NNC0472-0147, dose increased in each cohort.
223583318|NCT06034756|OTHER|TMJ dysfunction|Fonseca's Anamnestic Questionnaire (FAQ) was used for TMJ dysfunction. The diagnostic accuracy of the FAQ was found to be high in identifying pain-related and intra-articular TMDs, and the cut-off point was set as 25 points. A score of 25 and above was accepted as the presence of TMD.
223583319|NCT06034756|OTHER|Maximum pain-free mouth opening (MMO)|The maximum pain-free mouth opening was recorded using a 15 cm ruler
223583320|NCT06034756|OTHER|Forward head posture|Forward head posture was evaluated by CVA using a goniometer. CVA was measured in degrees as the angle between the horizontal plane, the seventh cervical vertebra and the ear hole
223744579|NCT01928524|DRUG|DOS3w Dose level 2B|Docetaxel (50 mg/m2), Oxaliplatin (100 mg/m2) and S1 (50 mg/2) will be given every 3 weeks. In total there is 5 dose levels and if no patients experience DLT on a given level, next dose level will be administered.
223744580|NCT01928524|DRUG|DOS3w Dose level 3B|Docetaxel (60 mg/m2), Oxaliplatin (100 mg/m2) and S1 (50 mg/2) will be given every 3 weeks. In total there is 5 dose levels and if no patients experience DLT on a given level, next dose level will be administered.
223744581|NCT05132829|DRUG|Azithromycin 1 gram IV|Perioperative addition of azithromycin at the time of physical exam indicated cerclage placement.
223744582|NCT05132829|DRUG|Cefazolin and indomethacin|Perioperative standard of care with cefazolin and indomethacin
224163127|NCT03175016|PROCEDURE|TACE|Transcatheter arterial chemoembolization（TACE）is a minimally invasive procedure performed to restrict a tumor's blood supply.
224163128|NCT03175016|DRUG|Irinotecan|Irinotecan hydrochloride is a semisynthetic derivative of camptothecin, an alkaloid extracted from the tree Camptotheca acuminata. Irinotecan hydrochloride trihydrate is a pale yellow to yellow crystalline powder, it is mixed in eluting-beads and injected in the tumor.
224304849|NCT04262661|DRUG|insulin glargine|Part 2: A fixed dose level of 0.5 U/kg insulin glargine will be used in all cohorts.
224304850|NCT04262661|DRUG|Placebo (NNC0472-0147)|Part 1: A single dose of placebo, dose increased in each cohort.
224304851|NCT02182791|DRUG|Nevirapine|
224304852|NCT02182791|DRUG|EE/NET|
224304853|NCT00084448|DRUG|celecoxib|
224304854|NCT00084448|DRUG|paclitaxel|
224304855|NCT05397743|OTHER|Quality of Life|Questionnaire Perceived stress scale (PSS) + Questionnaire Short form 36 (SF-36) + Questionnaire Visual functioning questionnaire 25 (VFQ-25)
223477275|NCT03559816|OTHER|Classification of perineal tears based on new classification|Classifications according to the American College of Obstetricians and Gynaecologists (ACOG) and the Royal College of Obstetricians and Gynaecologists (RCOG) and sub classification of second-degree lacerations based on the assumption that episiotomy involves the same anatomic structures of a second-degree laceration (perineal muscle, mucosa and skin), and divides them in two sub-groups, named A (if spontaneous vaginal tear is smaller than episiotomy) and B (if spontaneous vaginal tear is bigger than episiotomy).
223477276|NCT03559816|PROCEDURE|Selective use of Episiotomy|Standardized selective use of Episiotomy as recommended by guidelines.
223477277|NCT00982345|DRUG|quetiapine (Seroquel XR)|Seroquel XR (starting dose 100mg and increased up to 400 mg as tolerated) treatment.
223477278|NCT02101151|DIETARY_SUPPLEMENT|Vitamin D3(cholecalciferol)|
223477279|NCT02908347|DRUG|MP1032|hard gelatine capsules containing 50 mg MP1032 as active ingredient
223583321|NCT06034756|OTHER|Tongue strength and endurance|Tongue strength and endurance were evaluated with IOPI (Medical LLC, Redmond, WA), which has been clinically validated and reliable
223583322|NCT06034756|OTHER|Static endurance evaluation of the trunk muscles|The Trunk Flexors Endurance Test and the Biering Sorenson Test were used. These static tests are measurements targeting the local core muscles.
223583323|NCT06034756|OTHER|Dynamic endurance evaluation of the core muscles|The Sit-ups and the Modified Push-ups Tests were used. These dynamic tests are measurements targeting the global core muscles.
223583324|NCT01653899|DRUG|IDN-6556|14 day oral treatment of the investigational caspase inhibitor drug IDN-6556 following first islet transplant at 50mg twice daily.
223583325|NCT03220607|OTHER|uterocervical angle|uterocervical angle is the angle between lower segment of uterus and cervix
223583326|NCT02421913|DRUG|S(+)-Ketamine|S(+)-Ketamine 0,3mg/kg/hr intraoperative
223583327|NCT04965961|DRUG|EPO|Please refer to the arm description
223744583|NCT00091351|PROCEDURE|conventional surgery|
223744584|NCT00091351|RADIATION|radiation therapy|
224070197|NCT06472011|OTHER|macaroni and cheese|Participants will be fed \~400 kcal macaroni and cheese on one occasion to test for changes in blood glucose and insulin levels as well as appetite over a 4-hour period of time.
224070198|NCT06472011|OTHER|fish tacos|Participants will be fed \~400 kcal fish tacos on one occasion to test for changes in blood glucose and insulin levels as well as appetite over a 4-hour period of time.
224070199|NCT06472011|OTHER|chicken and pea fried rice|Participants will be fed \~400 kcal chicken and pea fried rice on one occasion to test for changes in blood glucose and insulin levels as well as appetite over a 4-hour period of time.
224070200|NCT06472011|OTHER|pita and hummus|Participants will be fed \~400 kcal pita and hummus on one occasion to test for changes in blood glucose and insulin levels as well as appetite over a 4-hour period of time.
224070201|NCT06472011|OTHER|creamy pork pasta|Participants will be fed \~400 kcal creamy pork pasta on one occasion to test for changes in blood glucose and insulin levels as well as appetite over a 4-hour period of time.
224070202|NCT06381388|DEVICE|cTBS|A single cTBS session delivered to the contralesional primary motor cortex.
224070203|NCT01485627|BEHAVIORAL|Communication training and coaching|Oncologists will receive communication training. Patients will be coached to make the most of the oncologist visit.
223477280|NCT02908347|DRUG|Placebo|hard gelatine capsules without active ingredient
223477281|NCT05392400|DEVICE|Steri3X|This study will initially attempt to recruit pregnant patients at the Regional One Health outpatient obstetrics clinic, at which point they will be randomly assigned to one of two cohorts. Participants who are consented to participate in the study will receive a chart flag in the EMR so that they may receive the proper intraoperative and postoperative treatment(s). Patients randomized to receive the Steri3X wound dressing will have the liquid polymer applied in the operating room after closure of the Cesarean section incision. Participants of both arms will be monitored postoperatively to assess for signs and symptoms of postoperative surgical site infection(s).
223477282|NCT05392400|OTHER|Control|"Device: Steri3X~This study will initially attempt to recruit pregnant patients at the Regional One Health outpatient obstetrics clinic, at which point they will be randomly assigned to one of two cohorts. Participants who are consented to participate in the study will receive a chart flag in the EMR so that they may receive the proper intraoperative and postoperative treatment(s). Patients randomized to receive the control wound dressing will have the current standard of care dressing applied in the operating room after closure of the Cesarean section incision. Participants of both arms will be monitored postoperatively to assess for signs and symptoms of postoperative surgical site infection(s)."
223477283|NCT00393315|DEVICE|paclitaxel coated balloon catheter|
223583328|NCT04965961|OTHER|Control group - saline injection|Please refer to the arm description
223583329|NCT01529736|PROCEDURE|High torque insertion|Osseotite implant placed with high insertion torque forces
224163129|NCT03175016|DEVICE|eluting-bead|The eluting-bead,loaded with irinotecan (DEBIRI) to treat patients with hepatic metastases from colorectal cancer.
224163130|NCT01599819|BIOLOGICAL|Antihemophilic Factor (Recombinant) - Plasma/Albumin Free Method|1 PK infusion of ADVATE (low dose in Cohort 1, high dose in Cohort 2)
224163131|NCT01599819|BIOLOGICAL|PEGylated Recombinant Factor VIII|1 PK infusion of BAX 855 (low dose in Cohort 1, high dose in Cohort 2)
224304856|NCT00240942|DRUG|Letrozole|
223583330|NCT01529736|PROCEDURE|Low torque insertion|Osseotite implant placed with low insertion torque forces
223583331|NCT01014455|BEHAVIORAL|Informing surgical patients about CO monitoring|A brief intervention that recommends preoperative fasting from cigarettes and that informs patients that their smoking status will be checked before surgery using inhaled CO monitoring will decrease their exposure to cigarette smoke prior to surgery
223583332|NCT01014455|BEHAVIORAL|a brief intervention recommending preoperative abstinence from smoking|a brief intervention that recommends fasting but does not mention that CO will be checked
223744585|NCT04204954|OTHER|Tea Tree Oil Shampoo|Twice a day eyelid margin cleansing for three days.
223744586|NCT04204954|DRUG|Ciprofloxacin Ophthalmic Ointment 0.3%|Applied topically in the eyelid margin every four hours for three days.
223744587|NCT04204954|OTHER|Baby shampoo|Twice a day eyelid margin cleansing for three days.
223744588|NCT04204954|OTHER|Blephaclean|Twice a day eyelid margin cleansing for three days.
223477284|NCT06516471|DEVICE|Conventinal Navigation System Group|The preoperative planned model is projected onto the endoscopic display area in 3D using a mixed reality headset, accurately matching the actual anatomical structure and tissue displayed under the patient's endoscope to guide surgical resection of tumors.
223477285|NCT02431429|DRUG|Miltefosine|
223477286|NCT04626505|DRUG|Ziltivekimab|Administered subcutaneously (s.c., under skin) once every 4 weeks for 12 weeks
223477287|NCT04626505|DRUG|Placebo (ziltivekimab)|Administered s.c. once every 4 weeks for 12 weeks
224163132|NCT04833790|BEHAVIORAL|Free distribution of ORS|Provides will receive 3 months supply of ORS at the beginning of the study to dispense to their patients. They will be asked to dispense the ORS at the market rate and not to give it away to other providers.
224304857|NCT04797429|OTHER|Peer Support Intervention via Instant Messaging Service Tool (IMS-Tool)|Peer Support via the IMS-tool increases diabetes self-management, improves self-efficiacy, adherence and glycaemic control
223477288|NCT01367691|DEVICE|CRT reprogramming (Medtronic CRT)|CRT devices will be reprogrammed according to CMR analysis
223477289|NCT03246945|BEHAVIORAL|Instructions on taking photographs provided, see methods|Parent-patient dyads were provided with written 3-step instructions on how best to take a photograph of skin conditions using a smart phone
223477290|NCT05711368|BEHAVIORAL|Distress tolerance training|It consisted of seven sessions. A 90-minute session will be conducted twice a week for four weeks. The first introductory session will be concerned with helping the student learn how to engage in distress tolerance training and define goals of distress tolerance. At the end of the 1st session, a written plan for every session (time, duration and setting) will be scheduled individually with each student.The next six training sessions will cover three core skills which comprised three sets: Crisis Survival Skills, the skills of Reality Acceptance; and the Skills When the Crisis Is Addiction. The distress tolerance training methods will include individualized interactions, demonstration, and rehearsal, psychoeducation, practice exercises and homework assignments. Follow up between sessions will done using telephone calling and messaging in order to encourage performance homework assignments, and provide help and support when needed particularly at the time of stress. .
223477291|NCT00691379|DRUG|Carboplatin|Carboplatin (IV) 2 AUC on day 1,8,15. Treatment repeats every 4 weeks until progression
223583333|NCT05981937|DRUG|ICG solution|ICG-ATT is available at our institute since 2019 using a near-infrared (NIR) light source and special scope and camera equipped with xenon light (CARL STORZ GmbH \& Co. KG, Tuttlingen, Germany); ICG was supplied as a sterile water-soluble lyophilized powder (Diagnostic Green® GmbH). ICG-ATT is routinely used whenever available in daily practice with the following protocol: after the specimen resection the two colonic stumps or colonic and rectal stumps are checked with 5 cc of ICG 25 mg diluted in 10 cc of water sterile solution before fashioned anastomosis. Two laparoscopes with ICG-optic system are nowadays available department and ICG anastomosis control is always performed if ICG device are available (no performed in case of not available ICG instrument for sterilization in case of two consecutive surgery in the same day, concomitant ICG surgery or ICG malfunction).
223583334|NCT03674099|DRUG|Imatinib Mesylate|Tablets 400 mg
223583335|NCT03674099|DRUG|Methylprednisolone|1 g tablets or infusion
223583336|NCT01995955|PROCEDURE|a new non-invasive imaging technique|a new non-invasive imaging technique for evaluation of cardiac microciculation in coronary artery disease
223583337|NCT05896852|BEHAVIORAL|physical activity|Participants will increase their physical activity through walking.
223583338|NCT01544452|PROCEDURE|MR colonography and MR of the liver|Altered planned surgical procedure if MR colonoscopy reveals synchronous cancer or larger polyps
223583339|NCT01544452|PROCEDURE|Standard diagnostic evaluation|Altered planned surgical procedure if MR colonoscopy reveals synchronous cancer or larger polyps
223583340|NCT01519739|DEVICE|MediGuide™|MediGuide™ system will be used to guide CRT implants
223744589|NCT06857422|BEHAVIORAL|Hand Fan Application|Participants in the experimental group will be instructed to use a hand fan to cool their face for 10 minutes each day for a period of 6 weeks. The fan should be held approximately 15 cm from the face, focusing on the middle area. This intervention aims to alleviate symptoms of dyspnea and improve psychological well-being, including anxiety, depression, and illness perception. The participants will receive daily reminders to ensure consistent application of the intervention.
224163133|NCT04833790|BEHAVIORAL|Standardized patient with ORS preference|Providers will receive a visit from an anonymous standardize patient posing a caretaker for a child with diarrhea who requests ORS to treat their child's diarrhea.
224163134|NCT04833790|BEHAVIORAL|Standardized patient with Antibiotic preference|Providers will receive a visit from an anonymous standardize patient posing a caretaker for a child with diarrhea who requests Antibiotics to treat their child's diarrhea.
224163135|NCT04833790|BEHAVIORAL|Standardized patient with no preference|Providers will receive a visit from an anonymous standardize patient posing a caretaker for a child with diarrhea who does not request anything specific to treat their child's diarrhea.
224304858|NCT04797429|OTHER|antidiabetic therapy according to the current guidelines|In contrast, the control group has to manage their diabetes mellitus type 2 with standard support and without online exchange.
224304859|NCT06112431|OTHER|Intervention|Participants randomized to the Intervention Arm and referred to ophthalmology will receive assistance from a Study Coordinator with scheduling in-office eye exam appointment and arranging transportation to these appointments over 2 years at either Columbia Ophthalmology, Harlem Hospital, or their own eye care provider.
223477292|NCT00691379|DRUG|Bevacizumab|Bevacizumab (IV) 10 mg/kg on day 1,15. Treatment repeats every 4 weeks until progression
223477293|NCT00691379|DRUG|Paclitaxel|Paclitaxel (IV) 90 mg/m2,on day 1,8,15. Treatment repeats every 4 weeks until progression
223583341|NCT06230978|BEHAVIORAL|Habit workup|The patient and pharmacist will work together to specify a cue to help them take their medicine every day (e.g. brushing teeth, getting dressed, eating breakfast, making coffee, alarms, visual reminders etc).
223583342|NCT06230978|BEHAVIORAL|Standard Medication Counseling|The pharmacist provides standard counseling on the new medication
223583343|NCT04323293|OTHER|Cold Water Bath|immersion of the hand for 2-5min in 2-10°C water
223583344|NCT04323293|OTHER|Neutral Water Bath|immersion of the hand for 2-5min in 32±2°C water
223477294|NCT06062992|DIAGNOSTIC_TEST|Contrast Enhanced Stereotactic Biopsy|Stereotactic breast biopsy using CEM as targeting modality
223477295|NCT00000498|BEHAVIORAL|diet, sodium-restricted|
223477296|NCT00000498|BEHAVIORAL|diet, reducing|
223583345|NCT06150794|DEVICE|Excimer laser|Excimer laser will be started at a dose of 300 mj/cm2 and increases 50-100 mj/cm2 each session. The aim of treatment is to deliver a dose that induces visible redness in the psoriatic lesion (supra-erythematous dose), but not induce a blister.
223583346|NCT06150794|DRUG|Methotrexate Injection|A ring block with 0.5 mL plain lignocaine (2%) will be administered in the web spaces on either side of the digit, followed by a 2.5-mg intramatrical methotrexate injection into each side of the nail at a point 2.5 mm proximal and lateral to the junction of proximal and lateral nail folds.
223583347|NCT04963907|DEVICE|Active Alpha-Stim CES|Active Alpha-Stim devices will be randomly assigned to participants for use daily for 8 weeks.
223583348|NCT04963907|DEVICE|Sham Alpha-Stim CES|Sham Alpha-Stim devices will be randomly assigned to participants for use daily for 8 weeks.
223583349|NCT02378207|BIOLOGICAL|H4:IC31|H4 contains Mtb antigens Ag85B and TB10.4
223583350|NCT02378207|BIOLOGICAL|H56:IC31|H56 contains Mtb antigens ESAT-6, and Rv2660c
223583351|NCT02378207|BIOLOGICAL|BCG|
223583352|NCT02378207|BIOLOGICAL|Control Sodium Chloride 0.9%|
224070816|NCT07143526|DIAGNOSTIC_TEST|Optical Coherence Tomography Angiography (OCT-A)|Two Optical Coherence Tomography Angiography swept source devices are compared for the detection of large pigment epithelium detachments in age related macular degeneration. The sensitivity of the devices is compared in both the automatic segmentation done by the device and the manual segmentation done by a retina specialist.
224163136|NCT04833790|BEHAVIORAL|Standardized patient with no preference + no financial incentive|Providers will receive a visit from an anonymous standardize patient posing a caretaker for a child with diarrhea who does not request anything specific to treat their child's diarrhea. In addition they will inform the provider that they are not going to purchase anything from the provider because they have an uncle with a drug shop where they can get a discount.
223477297|NCT00000498|BEHAVIORAL|alcohol restriction|
223477298|NCT00000498|DRUG|antihypertensive agents|
223477299|NCT00761878|PROCEDURE|Exposure to plasma energy|Non-invasive exposure to pulsed plasma to the unbroken skin over half of the facial area
223477300|NCT03798418|BEHAVIORAL|elastic band strengthening exercise|2-3days per week(150min per week)
223583353|NCT00094107|DRUG|Axitinib [AG-013736]|VEGFR \[vascular endothelial growth factor Receptor\] and PDGFR \[Platelet-Derived Growth Factor Receptor\] inhibitor: Single agent AG-013736 starting dose 5 mg BID +/- 20% according to toxicity. Treatment until progression or unacceptable toxicity occurs.
224070817|NCT07143071|PROCEDURE|Acute Phase|Patients with acute high-risk type B aortic dissection received endovascular treatment in acute phase (2-14days)
224070818|NCT07143071|PROCEDURE|Subacute Phase|Patients with acute high-risk type B aortic dissection received endovascular treatment in subacute phase (≥14days)
223477301|NCT03798418|DIETARY_SUPPLEMENT|diet counseling|each patients in this group will receive4-5times diet counseling
223477302|NCT05742334|PROCEDURE|Robot-Assisted Radical Prostatectomy with MLG-COMPLETE Allograft Implantation|The intervention will be administered on an inpatient basis. Participants receiving MLG-Complete™ will have it placed around the neurovascular bundle. Placement of the graft should not take more than 5 minutes, therefore, there should be minimal impact to overall surgical time.
223477303|NCT05742334|DEVICE|MLG-COMPLETE Allograft Implantation|The MLG-Complete™ allograft will be placed on each neurovascular bundle (NVB) bilaterally as shown on the above picture after excision of the prostate prior to completing the urethrovesical anastomosis.
223477304|NCT00123344|DEVICE|AT501 pacemaker|
223477305|NCT03245281|DRUG|Diuretic Suspension (DS)|Stop diuretic consumption in the 48h before the follow-up visit
223477306|NCT03245281|DRUG|Diuretic Increase (DI)|Double diuretics dosage in the 48h before the follow-up visit
223583354|NCT04942223|DEVICE|guided bone regeneration|After local anesthesia, the surgery started with a mid-crestal incision with vertical releasing cuts followed by the full-thickness buccal and lingual/palatal flaps raising to expose the bone defect completely. The flaps were coronally extended to assure a complete closure with a passive suture above the titanium. Subsequently, an intra-oral mandibular ramus bone cortical block was harvested in the molar zone. The bone block was milled and mixed with freeze-dried. The particulate graft was put to fill the deficit above the mesh until its perfect stability and unity with the defect's borders. Two or three titanium mini-screws were used to stabilize the device , and the flaps were carefully sutured. Ceftriaxone was administered intravenously at a loading dose of 2 g; together with a non-steroidal analgesic, it was continued at two g/die per os beginning the day after surgery and continuing for six days.
223583355|NCT00259688|DEVICE|CPAP therapy for subjects diagnosed with sleep apnea|CPAP therapy is being offered to women who are diagnosed on Polysomnogram with sleep apnea. However, this is not an intervention study and treatment is not part of the study protocol.
223583356|NCT00951756|OTHER|High fat diet|High fat diet and low fat diet are composed of the same food, but the portion sizes are varied.
223583357|NCT06506994|DRUG|HRS-9057|HRS-9057 injection dose 1
223583358|NCT06506994|DRUG|HRS-9057|HRS-9057 injection dose 2
224070819|NCT07144735|DRUG|Allogeneic γδ T (ABOUT) cells|Allogeneic γδ T cells genetically edited to knockout the ARIH1 and BCL11b genes.
224070820|NCT07143669|OTHER|Screening|After providing informed consent and relevant medical history data, samples will be collected from participants with suspected clonal mast cell disease.
224070821|NCT02589262|DRUG|AUT00206|
224070822|NCT00959816|DRUG|ABT-614|Single dose administered on Study Day 1 in Part 1, daily dose administered on Study Days 1-14 in Part 2.
224070823|NCT06356909|OTHER|Survey of sedo-analgesia practices before laryngoscopy|The survey will evaluate adequation to the French best practice guidelines to improve their dissemination and to identify current practices of premedication before laryngoscopy in neonates in French units (agents, dosing, efficacy, safety)
224070824|NCT04475055|DIAGNOSTIC_TEST|Diagnostisches Interview bei psychischen Störungen (DIPS)|The DIPS is a structured interview which assesses the most frequent psychological disorders. It can be delivered by trained clinicians and takes between 50-120 minutes. Its acceptance with patients is very good.
224070825|NCT00465959|DRUG|trospium chloride inhalation powder (TrIP)|
224070826|NCT00465959|DRUG|Placebo|
223477307|NCT03245281|DRUG|Diuretic and Medication Suspension (DMS)|Stop diuretic and MRA medication consumption in the 48h before the follow-up visit
223477308|NCT06442605|DEVICE|single-channel uterine fibroid morcellation system|Conventional laparoscopic myomectomy is performed with the use of a single-channel uterine fibroid morcellation system for fragmentation and retrieval of the fibroids during the procedure.
223477309|NCT06442605|DEVICE|Multi-channel specimen retrieval bag + conventional laparoscopic uterine fibroid morcellator|In conventional laparoscopic myomectomy, a multi-channel specimen retrieval bag is used during the procedure, along with a conventional laparoscopic uterine fibroid morcellator for fragmentation and retrieval of the fibroids.
223477310|NCT01326871|DRUG|Cisplatin|Intravenous infusion; 3 initial treatment courses and an additional 3 maintenance courses for responders (maintenance revised for Phase II): on day 1 of each course (if given)
223477311|NCT01326871|DRUG|Gemcitabine|Intravenous infusion; 3 initial treatment courses and an additional 3 maintenance courses for responders (maintenance revised for Phase II); on day 1 and 8 of each course
223477312|NCT01326871|BIOLOGICAL|ALT-801|Intravenous infusion; 3 initial treatment courses and an additional 3 maintenance courses for responders (maintenance revised for Phase II): on day 3, 5, 8, and 12 of each course
223477313|NCT01449253|DRUG|Sildenafil|20 mg initially and then increased to 20 mg TDS if there is no fall in BP
223583359|NCT06506994|DRUG|Tolvaptan|Tolvaptan tablets
223583360|NCT04058704|DRUG|Icotinib|125mg Tid/375mg per day
223583361|NCT04058704|RADIATION|SRS/WBRT/HA-WBRT/SMART|\>3 with WBRT/HA-WBRT/SMART or 1-3 with SRS
224163137|NCT04479449|DRUG|SP-8203|SP-8203 80 mg will be intravenously administered as 40 mg/dose twice daily (intervals of 12 hours)
223477314|NCT01449253|DRUG|Bosentan|Bosentan 62.5 mg BD initially for 1 month and then increased to 125 mg BD
223477315|NCT05696600|PROCEDURE|Scaling and root planing and open flap debridement|"Scaling and root planing involves removal of plaque and calculus.~Open Flap debridement involves reflection of full thickness mucoperiosteal flap, thorough debridement of the surgical site and approximation and suturing of the flap at the original position."
223583362|NCT05453994|DRUG|H. pylori eradication|PPIs-based Antimicrobial agents for H. pylori eradication
223477316|NCT02510339|OTHER|Observation|Administration of two questionnairs during post operative visits.
223477317|NCT05324917|DRUG|Rituximab|Chemotherapy for children with lymphoma: rituximab (375mg/m2 BSA) was added intravenously from COPADM1 regimen. once every 3 weeks to 4 weeks, combined with corresponding chemotherapy, a total of 4 times.
223477318|NCT05324917|DRUG|Rituximab (once a week)|"Rituximab (375mg/m2 BSA) was administered intravenously for lymphoproliferative diseases and EB virus-associated B lymphoproliferative diseases after hematopoietic stem cell transplantation. Once a week, a total of 4 times.~ITP and AIHA patients received rituximab (100mg/m2 BSA) intravenously once a week, a total of 4 times."
223477319|NCT05901220|BEHAVIORAL|Healthy lifestyle|An educational programme to promote healthy lifestyle will be performed.
223477320|NCT04150315|DIAGNOSTIC_TEST|Proteome analysis|Evaluation of specific protein levels in tissue and plasma.
223477321|NCT02084823|BIOLOGICAL|cancer stem cell vaccine|
223583363|NCT01444586|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|The patients will be treated according to the routine practice. All the patients meeting the criteria of inclusion and exclusion to whom administration of Xarelto is indicated are fit for participation in this non-interventional study.
223583364|NCT05281770|DRUG|Erenumab|treatment with erenumab as chosen by treating physician
223583365|NCT05281770|DRUG|Fremanezumab|treatment with fremanezumab as chosen by treating physician
223583366|NCT05281770|DRUG|Galcanezumab|treatment with galcanezumab as chosen by treating physician
223744590|NCT06857422|OTHER|Standard Care for COPD Patients|Participants in the control group will receive standard care for chronic obstructive pulmonary disease (COPD) patients. This includes routine management and treatment as prescribed by their healthcare providers, such as medication and lifestyle recommendations. They will not be instructed to use a hand fan or any other cooling device during the study period. The control group will continue their regular care without any additional interventions from the research team.
224070204|NCT04589988|BEHAVIORAL|Removing Environmental Barriers to Independent Living (REBIL)|REBIL is a complex intervention with two essential components: (1) removing environmental barriers and home hazards in the home tailored to the participant's unique abilities and limitations and (2) strategy training with the participant to help participant to be able to identify barriers in the home and community and identify potential resources and strategies to remove the barriers. Treatment includes one assessment session and four 75-minute visits in the home with an occupational therapist over 8 weeks, followed by a 6 -month assessment session by a blinded rater.
224070205|NCT04589988|BEHAVIORAL|Waitlist Attentional Control|The waitlist attentional control group will receive an initial assessment session then four 75 minute interview visits from an occupational therapy graduate assistant, followed by a 6-month assessment session by a blinded rater. After the 6-month follow-up is completed this group will receive the REBIL intervention.
223583367|NCT01184417|DRUG|10 mg/kg IV phenobarbital in 100 ml saline|10 mg/kg IV phenobarbital in 100 ml saline
223583368|NCT01184417|DRUG|placebo|100 m l saline
223583369|NCT05942794|DEVICE|Screening examination|"After an initial clinical visit, all three operators will wear the tissue autofluorescence detection device (GOCCLES®), reporting both observations on their operator-module."
223583370|NCT01611220|BEHAVIORAL|RePAN|The dissonance relapse prevention intervention consists of eight groups conducted by a psychologist who involves participants in interactive activities aimed to prevent relapse after discharge from the inpatient treatment
223583371|NCT00832052|DRUG|PF-04447943|Planned oral dose is PF-04447943, 5 mg q12 hours for 7 days.
223583372|NCT00832052|DRUG|PF-04447943|Planned oral dose is PF-04447943, 15 mg q12 hours for 7 days.
223583373|NCT00832052|DRUG|PF-04447943|Planned oral dose is PF-04447943, 35 mg q12 hours for 7 days. Actual dose may be adjusted based on pharmacokinetic and other data from prior dose cohorts.
223583374|NCT00832052|DRUG|PF-04447943|Planned oral dose is PF-04447943, 35 mg q12 hours for 7 days. Actual dose may be adjusted based on pharmacokinetic and other data from prior dose cohorts.
223583375|NCT00832052|DRUG|PF-04447943|Planned oral dose is PF-04447943, 35 mg q12 hours for 14 days. Actual dose may be adjusted downward based on pharmacokinetic and other data from prior dose cohorts.
223477322|NCT03463083|DRUG|Dexmedetomidine|"All cases of spine surgery will be done under G.A with the patient in prone position. After surgery an epidural catheter will be placed through a separate skin puncture above the incision The catheter will be positioned up to 7 cm from skin entry directing downwards in the epidural space . Once the patient in the post-operative room will be noted to have pain (VAS) of\>4, the study will start. A test dose of 3 ml lignocaine with adrenaline will be injected the following parameters will be noted .~1. The pain score, by using VAS~2. Onset of analgesia (fall of VAS\<4 ).~3. Peak level of analgesia ( VAS score 0).~4. Duration of analgesia (once the patient asks fwith VAS\>4).~5. Monitoring of NIBP, pulse rate, respiratory rate every 30 min.~6. Side-effects such as nausea, vomiting, respiratory depression, Motor blockade Bromage scale\>1 Also deep sedation Ramsay sedation scale\>3 , And shivering and hypotension."
223477323|NCT03463083|DRUG|Bupivacaine|"All cases of spine surgery will be done under G.A with the patient in prone position. After surgury an epidural catheter will be placed through a separate skin puncture above the incision The catheter will be positioned up to 7 cm from skin entry directing downwards in the epidural space . Once the patient in the post-operative room will be noted to have pain (VAS) of\>4, the study will start. A test dose of 3 ml lignocaine with adrenaline will be injected the following parameters will be noted .~1. The pain score, by using VAS~2. Onset of analgesia (fall of VAS\<4 ).~3. Peak level of analgesia ( VAS score 0).~4. Duration of analgesia (once the patient asks fwith VAS\>4).~5. Monitoring of NIBP, pulse rate, respiratory rate every 30 min.~6. Side-effects such as nausea, vomiting, respiratory depression, Motor blockade Bromage scale\>1 Also deep sedation Ramsay sedation scale\>3 , And shivering and hypotension."
223477324|NCT03463083|DRUG|Fentanyl|"All cases of spine surgery will be done under G.A with the patient in prone position. After surgury an epidural catheter will be placed through a separate skin puncture above the incision The catheter will be positioned up to 7 cm from skin entry directing downwards in the epidural space . Once the patient in the post-operative room will be noted to have pain (VAS) of\>4, the study will start. A test dose of 3 ml lignocaine with adrenaline will be injected the following parameters will be noted .~1. The pain score, by using VAS~2. Onset of analgesia (fall of VAS\<4 ).~3. Peak level of analgesia ( VAS score 0).~4. Duration of analgesia (once the patient asks fwith VAS\>4).~5. Monitoring of NIBP, pulse rate, respiratory rate every 30 min.~6. Side-effects such as nausea, vomiting, respiratory depression, Motor blockade Bromage scale\>1 Also deep sedation Ramsay sedation scale\>3 , And shivering and hypotension."
223477325|NCT03289078|OTHER|Spa Treatment|The spa treatments will be realised daily 6 days a week and during 18 days. The care will be provided is : Swimming pool of mobilization by physical therapist (20 minutes daily, Cataplasms (10 minutes daily), Shower in the jet (10 minutes daily), Shower under affusion (10 minutes daily)
223583376|NCT03912701|DIAGNOSTIC_TEST|Vitalpac early warning score (VIEWS)|The Vitalpac early warning score (ViEWS) is an early warning system aimed primarily at prediction of the first 24-hour mortality in emergency patients and has not been used to assess intensive care unit discharge.
223583377|NCT00525824|DRUG|Rosuvastatin (Crestor)|10mg and 20 mg
223583378|NCT00525824|DRUG|Ezetimibe|10 mg
223583379|NCT00525824|DRUG|Simvastatin|40mg and 80 mg
223583380|NCT06508359|DRUG|Norepinephrine|Prophylactic or rescue norepinephrine for spinal anesthesia-induced hypotension
223583381|NCT06508359|DRUG|Phenylephrine|Prophylactic or rescue phenylephrine for spinal anesthesia-induced hypotension
223583382|NCT01943019|DRUG|Linagliptin|
223583383|NCT06508684|DRUG|BTK inhibitor|BTKi can refer to Orelabrutinib, Ibrutinib, Zanubrutinib, and Acalabrutinib
223583384|NCT05737719|BEHAVIORAL|Rehabilitation before knee surgery (prehab)|Physiotherapy strategies for preparing the patient awaiting the surgical procedure
223583385|NCT05737719|BEHAVIORAL|Post-surgery rehabilitation|Physiotherapy strategies to manage post-surgery recovery
223583386|NCT00143780|BIOLOGICAL|The polysaccharide vaccine used is Pneumovax (Merck vaccines)|
223744591|NCT04350788|OTHER|Survivorship Care Plan|Participants visit the NCI prostate cancer website in addition to their standardized post-treatment survivorship care
224163138|NCT04479449|DRUG|Placebo|Placebo will be intravenously administered twice daily (intervals of 12 hours)
224163139|NCT03430336|OTHER|CDSS provides drug-therapy relevant information|External computerized decision support system (CDSS: RpDoc® eMMa Software, RpDoc® Solutions GmbH, Saarbruecken) provides drug-therapy relevant information about participating patients with polypharmacy on demand to the general practitioners (GPs) such as data about diagnoses and treatments. The information is based on claims data gathered from all health care professionals involved in the care of the patient (e.g. specialized physicians, other GPs, psychotherapists as well as data about hospital stays and prescription data from pharmacies).
224163140|NCT03430336|OTHER|Modification of medication|GPs can add and modify patient's data within the CDSS (e.g. remove drugs which are not taken by the patient anymore, add most recent laboratory findings about kidney function etc.) to enrich and update claims data based information.
224163141|NCT03430336|OTHER|Assessment of medication appropriateness|GPs systematically assess the appropriateness of the medication supported by the CDSS, which will alert in case of drug-drug, drug-disease, and drug-age interactions as well as other inappropriateness, such as prescriptions with regard to incorrect dosage or Dear Doctor letters.
223744592|NCT04350788|OTHER|Enhanced Survivorship Care Plan|In addition to their standardized post-treatment survivorship care, participants visit the prostate cancer education resources for couples (PERC) website that was based on scientific evidence and input from stakeholders including PC patients, partners, and cancer care providers. Participants learn about skills and knowledge about how to enhance their positive appraisals of symptoms and self-efficacy in symptom management through information and skills training, fostering healthy behaviors, and facilitating social support
223583387|NCT00143780|BIOLOGICAL|The conjugate vaccine used is Prevnar (Wyeth-Ayerst vaccines)|
223583388|NCT04175925|DRUG|BMS-986322|Specified Dose on Specified Days
223583389|NCT04175925|OTHER|BMS-986322 Placebo|Specified Dose on Specified Days
223583390|NCT04175925|DRUG|famotidine|Specified Dose on Specified Days
223744593|NCT06989658|DEVICE|SCL miniaturized scleral lens positioning|"1. Experimental evaluation:~   1. TESTs withSCL system~      * Before positioning the SCL lens: slit lamp examination~     * After positioning the SCL lens: slit-lamp examination~     * Tests performed on projected screen.~  2. Tests with a conventional oculometer: tests performed on a projected screen.~2. Ophthalmological assessment:~   1. slit lamp examination~  2. An end-of-study follow-up phone call."
223744594|NCT06912997|OTHER|Exercise|The home-based inspiratory muscle training (IMT) protocol will use an inspiratory threshold loading device (PowerBreathe Wellness, Southam, United Kingdom). IMT for experimental group will start with a minimal load (\~9 cmH2O) during the first week, aiming for a familiarization process. During the second week, the IMT targeted a moderate load of 45% of maximal inspiratory pressure (MIP) previously defined, which will be gradually increased by 10% of MIP each week until reaching 75% of MIP in the final week.
223477326|NCT06515288|BEHAVIORAL|Nutrition Goes To School (NGTS) Program Intervention Package|"The NGTS Program intervention package in this project consists of four components:~1. A comprehensive Nutrition Education to improve healthy eating, physical activity, and hygiene-sanitation practices.~   This is a weekly interactive and fun nutrition and health promotion with different kinds of activities.~2. Healthy School Canteen to improve the availability of healthy food in school. This is an effort to strengthen the school canteen referring to the 4 Pillars of a Healthy School Canteen, including School Commitment and Management, Human Resources, Facilities and Infrastructure, and Food Quality.~3. School Garden. This is a gardening activity as a form of school garden as a media for nutrition education, character building, and contribute to supply vegetables during cooking class sessions in school.~4. Entrepreneurship nutrition. Entrepreneurship nutrition aims to foster entrepreneurial potential and skills among school members in providing healthy food at school."
223477327|NCT06515288|BEHAVIORAL|Nutrition Education Capacity Building for Teachers and Management|The intervention schools will receive Nutrition Education Capacity Building for Teachers and School Management, before the above four NGTS components is implemented in the respective school. Three representatives from each school will be invited to attend a 5-day training that include knowledge on adolescent nutrition and health issues, as well as skills in implementing the NGTS Program.
223477328|NCT01200329|DRUG|Gemcitabine|2775 mg/m2 by vein over about 3 hours on days -8 and -3.
223477329|NCT01200329|DRUG|Busulfan|"32 mg/m2 test dose with PKs as outpatient and on day -10 as inpatient~AUC 4,000 by vein over about 3 hours on days -8 to -5."
223744595|NCT06912997|OTHER|Sham Comparator|The Sham group will performer the same training protocol that experimental group, but at 5% of MIP during all weeks. Therefore, the sham group will not increase the training load during the protocol.
223477330|NCT01200329|DRUG|Melphalan|60 mg/m2 by vein over about 30 minutes on days -3 and -2.
223744596|NCT07189611|BEHAVIORAL|A blended online and offline teaching model for internal medicine nursing practice based on generative artificial intelligence|This study will employ a convergent mixed-methods design. Participants will be convenience-sampled undergraduate nursing students from the 2024 cohort (intervention group) and the 2023 cohort (control group) at Changsha Medical University. The intervention group will experience the new blended model, which includes: 1) Optimizing a GAI-assisted clinical case library with progressive scenarios; 2) Utilizing online resources (Learning Terminal platform, virtual simulation experiments with an AI assistant); 3) Engaging in offline interactive sessions (card-based desktop deduction games and scenario simulations). The control group will receive traditional teaching methods. Quantitative data will include course scores (theoretical knowledge and practical skills) and teaching satisfaction questionnaires. Qualitative data will be collected via semi-structured interviews to explore students' experiences deeply.
223583391|NCT05661305|OTHER|Whole Genome Sequencing to compare healthy volunteers genome with that of cardiomyopathies patients.|Egyptian patients and their family members diagnosed with different types hereditary cardiomyopathies.Healthy Egyptian individuals to provide the first of its kind resource on human genetic variation in Egyptians, which is essential for understanding the significance of detected variations in patients with inherited cardiovascular disease and their families.
223583392|NCT03699137|OTHER|No interventions|No interventions
223744597|NCT07190404|BEHAVIORAL|A metacognitive strategy for cognitive rehabilitation called the Multicontext Approach.|The Multicontext Approach is a strategy training approach to cognitive intervention provides ways to maintain daily function despite the presence of cognitive deficits. It involves teaching people to use metacognitive, compensatory, or adaptive techniques to optimize information processing or bypass cognitive limitations and achieve task-related goals. Strategy training is recommended for those with mild (vs. more severe) cognitive deficits because it requires learning, capitalizes on existing cognitive resources, and aims to prevent or delay functional decline.
224304860|NCT06112431|OTHER|Usual Care|Consented participants randomized to the Usual Care Arm will receive all the basic level of services including the eye health screening, optometric exam if they fail the screening, and eyeglasses at no charge. Those who require referral to ophthalmology will be scheduled for the initial in-office eye exam and their outcomes will be tracked. No additional support will be provided the Usual Care participants during the study. The Usual Care Arm represents a realistic choice currently available for participants following eye health screening.
223477331|NCT01200329|PROCEDURE|Stem Cell Transplantation|Infusion of stem cells on Day 0.
223477332|NCT01200329|DRUG|Palifermin|60 mg/kg by vein over 30 seconds daily, Days -12 to -10 and Days 0 to 2.
223477333|NCT03531749|DIETARY_SUPPLEMENT|HIV+ MRPJ|supplemented with (1g/d) MRPJ
223477334|NCT03531749|DIETARY_SUPPLEMENT|HIV+ ascorbic acid|Supplemented with (1g/d) AA
223477335|NCT04000178|DEVICE|polyurethane stent|patients were prospectively enrolled in the study and stratified (non-randomly) into either group A - polyurethane - control group or group B - silicone - experimental group
223477336|NCT04000178|DEVICE|silicone stent|silicone stent
223583393|NCT01825278|DEVICE|ExSpiron Respiratory Volume Monitor (RVM, ExSpiron™, Respiratory Motion, Inc.; Waltham, MA|Monitoring sensors will be applied to patient's right chest and the monitoring device will collect breathing parameters such as breathing rate and volumes before, during and after the procedure until patient is ready to leave the recovery room. At the beginning and at the end of the study investigator will perform a one-time measurement of patient's respiratory parameters using a standard handheld spirometer. This is a non-invasive device that is commonly used in clinical care not related to research.
224304861|NCT06336538|OTHER|MBCT|Mindfulness-Based Cognitive Therapy (MBCT) is a group-based psychological intervention for depression that combines mindfulness training with cognitive therapy.
223477337|NCT00677898|BEHAVIORAL|Patient-centered computerized tool|A brief computer program that provides personalized health information to patients prescribed second-generation antipsychotic medications on adherence to guidelines for screening of metabolic side effects
223477338|NCT00677898|BEHAVIORAL|Written educational materials|Printed information on the metabolic side effects of second-generation antipsychotic medications and general recommendations for screening
223477339|NCT03279042|PROCEDURE|Flapless corticotomy surgical intervention will be conducted|Piezocision will be used to perform the procedure
223477340|NCT03279042|PROCEDURE|Traditional corticotomy|Here the surgery involves elevation of flaps and then conducting the surgical intervention using piezo-surgery cutting saws.
223477341|NCT02852460|OTHER|rapid recovery|
223477342|NCT01528410|DEVICE|ALFApump removal of ascites|Implanted ALFApump, removing produced ascites according to programmed schedule
223583394|NCT04623515|OTHER|REDCap Questionnaires|Once consent is obtained, the participants will be routed to a REDCap secure link. Participants will complete a questionnaires regarding demographics and medical history. Participants will also complete validated questionnaires regarding their lower urinary and bowel tract function and sexual health- International Consultation on Incontinence Questionnaire Female Lower Urinary Tract Symptoms (ICIQ-FLUTS), Modified Manchester Health Questionnaire (MMHQ), PROMIS® v2.0 Brief Profile Sexual Function and Satisfaction (Female) and SF-12 ® .
223477343|NCT01528410|PROCEDURE|Large volume paracentesis for removal of ascites|Large volume paracentesis - standard of care, removing ascites according to patient need
223477344|NCT04659005|OTHER|Nurse-led decision counseling|Provide education, tailored information, decision support, and psychosocial support regarding hepatocellular carcinoma screening
223477345|NCT04659005|OTHER|Usual care|Usual care provided by the hospital, including one-page written education information about diet, medications, and daily exercises
223477346|NCT00029822|DRUG|Alfuzosin (SL770499)|
223477347|NCT04375163|OTHER|Isokinetic intense exercise protocol|The isokinetic protocol included 6 sets of 10 maximum efforts at 60 °/s of one leg with a 2-minute break between the sets.
223477348|NCT04375163|OTHER|Massage treatment|"Massage consisted of stroking (30) and petrissage (50) for muscle relaxation, then friction (10), pincement and clapping (30) to prepare muscles for the next set."
223583395|NCT02610244|OTHER|Modified Cogmed Training|Comparison of outcome measures between treatment-as-usual group and Modified Cogmed Training group after 10 weeks and 3 months follow up.
223583396|NCT04469231|DEVICE|Anterior Cervical Discectomy & Fusion|ACDF
223583397|NCT01355796|DRUG|Xylitol|Aerosolized 15% xylitol, 5 ml twice a day for 2 weeks
223583398|NCT01355796|DRUG|Hypertonic saline|4 ml of 7 % saline aerosolized twice a day for 2 weeks
223583399|NCT03379142|BEHAVIORAL|Faith-Based messages|We will send out faith based text messages on a weekly basis for the one week prior to the start of Ramadan, then twice a day during the Ramadan period that will encourage smoking cessation and continue to encourage change of behavior. The faith-based messages will be incorporated with messages drawn from the Smokefree.gov Mobile Interventions QuitNowTXT Message Library. These messages will be geared towards reminding the smokers that as Ramadan is coming closer they need to consider the effects that smoking may have on their health and should consider taking steps towards quitting.
223583400|NCT06176508|DRUG|HS-10374|Administered orally QD for 16 weeks
223744598|NCT07190404|BEHAVIORAL|Cognitive (Process) Training|This treatment is functional task training, a widely-used approach in neurorehabilitation153,154 that parallels the cognitive training used in PD to-date but with functional cognitive tasks (vs. computer or paper \& pencil tasks) to improve ecological validity. It has the same structure within and across treatment sessions and uses the same treatment activities as the MC intervention. However, the OT does not use mediated learning techniques or explicitly address strategies, metacognition, or transfer/generalization. Rather, participants practice functional cognitive tasks with knowledge of results feedback and cueing by the OT to improve task performance.
224304862|NCT03548064|OTHER|Placebo|Placebo
224304863|NCT03548064|OTHER|Placebo|Placebo
223477349|NCT03517904|PROCEDURE|IVUS-guided angioplasty|Angioplasty using drug-coated balloon (DCB) will be performed in standard manner. IVUS evaluation will be performed before predilation and after DEB treatment. In cases of stent implantation, additional IVUS evaluation will be performed after stenting. All lesions will be predilated using a plain balloon with a diameter 1 mm smaller than vessel size. Selection of DCB diameter will be chosen on the basis of IVUS measurement. Implantation of stents will be left to the operator's decision after reviewing IVUS findings after the DCB treatment. Generally, in presence of ≥ 50% residual stenosis or flow limiting dissections, implantation of stents is recommended.
223477350|NCT03517904|PROCEDURE|Angiography-guided angioplasty|Angioplasty using drug-coated balloon (DCB) will be performed in standard manner. All lesions will be predilated using a plain balloon with a diameter 1 mm smaller than vessel size. Selection of DCB diameter will be chosen on the basis of angiogram. Implantation of stents will be left to the operator's decision after reviewing the angiogram after the DCB treatment. Generally, in presence of ≥ 50% residual stenosis or flow limiting dissections, implantation of stents is recommended.
223477351|NCT01813279|OTHER|the cell therapy|the reinjection of autologous stromal vascular fraction of adipose tissue issue on the fingers of patients with scleroderma.
223477352|NCT01940965|DRUG|lixisenatide AVE0010|Pharmaceutical form:solution Route of administration: Subcutaneous injection
223477353|NCT01940965|DRUG|biguanide|Pharmaceutical form:tablet Route of administration: oral
223477354|NCT01940965|DRUG|TZD|Pharmaceutical form:tablet Route of administration: oral
223477355|NCT01940965|DRUG|alpha-GI|Pharmaceutical form:tablet Route of administration: oral
223477356|NCT01940965|DRUG|glinide|Pharmaceutical form:tablet Route of administration: oral
223477357|NCT02717195|DRUG|Risperidone|4-6 mg/day, encapsulated tablets, orally
223477358|NCT02717195|DRUG|Olanzapine|15-20 mg/day, encapsulated tablets, orally
223477359|NCT02717195|DRUG|Lu AF35700|10 mg/day, encapsulated tablets, orally
223583401|NCT06176508|DRUG|HS-10374-matched placebo tablets|Administered orally QD for 16 weeks
223583402|NCT06176508|DRUG|Tofacitinib 5Mg Tab,Oral|Administered orally BID for 16 weeks
224304864|NCT03548064|OTHER|Placebo|Placebo
223477360|NCT02717195|DRUG|Lu AF35700|20 mg/day, encapsulated tablets, orally
223477361|NCT00973258|DIETARY_SUPPLEMENT|Nutritional Intervention|Each subject in the nutritional intervention group is provided with a commercial liquid formula (Fortisip Multi Fibre, Nutricia), which should be taken every evening for a period of 24 weeks. Subjects are also given one capsule of iron and folate supplement (Sangobion, Merck; consisting of 1 mg folate and 29mg iron), one capsule of Vitamin B6 and vitamin B12 supplement (Neuroforte; consisting of 200mcg B12 and 200mg vit B6) and one tablet of Caltrate with Vitamin D (consisting of 200 IU vitamin D and 600 mg of calcium) for a duration of 24 weeks.
223477362|NCT00973258|OTHER|Physical Exercise|The exercise intervention group comprises a combination of 2 types of exercise: resistance exercise and in-balance exercise. Key components in both programs are balance and strength, because these are the most prominent domains that should be addressed in at risk frail elderly. The first program is administered in the first 6-week, and then followed by the second program for the next 6-week of intervention period. Both exercise programmes are tailored to the functional needs of the participants, maintaining a moderate intensity that focuses on long-term sustainability and enjoyment.
223477363|NCT00973258|OTHER|Cognitive Training|"The proposed cognitive training intervention program comprises:~1. Reasoning training focusing on inductive reasoning, the ability to solve problems that follow a serial pattern and manifest in executive functioning.~2. Memory training focusing on verbal episodic memory, which deals with acquisition and retrieval of information acquired in a particular place at a particular time.~3. Speed training focusing on visual search and the ability to identify and locate visual information quickly in a divided attention format, with and without distractors."
223477364|NCT00973258|OTHER|Combined|Nutritional Intervention + Physical Exercise + Cognitive Training
223477365|NCT00973258|OTHER|Placebo|Participants will receive their usual diet and placeboes.
223477366|NCT03087058|DRUG|Patiromer|4.2 g/day, 8.4 g/day and 16.8 g/day
223477367|NCT03087058|DRUG|Patiromer|2 g/day, 4 g/day and 8 g/day
223583403|NCT00860015|DRUG|Alimta|"500 mg/m2 via IV over 10 minutes~A chemotherapy drug with indications to treat pleural mesothelioma and non-small cell lung cancer."
223583404|NCT00860015|DRUG|Gemcitabine|"1000 mg/m2 via IV over 90 minutes~A nucleoside analog used as chemotherapy."
223583405|NCT00801047|DRUG|Bupivacaine epidural|Bupivacaine 0.1%, fentanyl 1 mic/kg
223583406|NCT00801047|DRUG|Remifentanil|40-50 mic per 1-2 min via PCA
223583407|NCT02580513|BEHAVIORAL|Circadian Misalignment|
223583408|NCT04276688|DRUG|Lopinavir/ritonavir|400mg/100mg twice daily for 14 days
223583409|NCT04276688|DRUG|Ribavirin|400mg twice daily for 14 days
223583410|NCT04276688|DRUG|Interferon Beta-1B|0.25mg subcutaneous injection alternate day for 3 days
223583411|NCT02914288|OTHER|High resolution magnetic resonance imaging for intracranial vessel walls|High resolution magnetic resonance imaging for intracranial vessel walls at initial (optional), 1 month, 3 month, 6 month (optional), and 12 month
223583412|NCT00806442|DRUG|Borage Seed Oil and Echium Seed Oil|2 g/day of borage seed oil and 7 g/day of echium seed oil to provide 1.6 g/day of GLA and 0.9 g/day of SDA.
223583413|NCT00806442|DIETARY_SUPPLEMENT|Corn Oil|9 g/day of corn oil
223583414|NCT02621398|RADIATION|3-Dimensional Conformal Radiation Therapy|Undergo 3D-CRT or IMRT
224304865|NCT03548064|BIOLOGICAL|Recombinant Double Mutant Heat-Labile Toxin LT(R192G/L211A) (dmLT) Oral enterotoxigenic Escherichia coli (ETEC) Vaccine|LT(R192G/L211A), or dmLT is a derivative of wild-type enterotoxigenic Escherichia coli heat-labile enterotoxin that has been genetically modified by replacing the arginine at amino acid position 192 with glycine and the leucine at amino acid position 211 with alanine. These two amino acid substitutions take place in proteolytic cleavage sites which are critical for activation of the secreted toxin molecules.
223477368|NCT03087058|DRUG|Patiromer|1 g/day, 2 g/day and 4 g/day
223477369|NCT03308552|RADIATION|SIB-IMRT|PTV:50.4Gy/28f, PGTV:59.92Gy/28f
223477370|NCT03308552|DRUG|Paclitaxel|45-50 mg/m2, once a week, concurrent with radiotherapy for 5-6weeks
223477371|NCT03308552|DRUG|Platinum-Based Drug|Nedaplatin or Lobaplatin or Cisplatin, 20-25mg/m2, once a week, concurrent with radiotherapy for 5-6weeks
223477372|NCT03308552|DRUG|Paclitaxel|150mg/m2 on day1,every 3 weeks, 4 cycles, 1-3 months after completion of radiotherapy
223477373|NCT03308552|DRUG|Platinum-Based Drug|Nedaplatin or Lobaplatin or Cisplatin, 50-80mg/m2 on day1 (Lobaplatin 50mg on day 1),every 3 weeks, 4 cycles, 1 month after completion of radiotherapy
223477374|NCT05437601|DRUG|Astaxanthin Oral Capsule|12 mg oral astaxanthin daily for 8 weeks
223477375|NCT05437601|OTHER|Placebo|Oral placebo identical to astaxanthin
223477376|NCT02577029|DRUG|ARC-520|ARC-520 will be administered intravenously concomitantly with 0.9% normal saline using an infusion rate of 0.4 mL/min (24 mL/hour) for study treatment and 200 mL/hr for saline.
223477377|NCT02577029|DRUG|entecavir|0.5 mg once daily; oral
223477378|NCT02577029|BIOLOGICAL|pegylated interferon alpha 2a|180 mcg; subcutaneous injection once weekly
223477379|NCT02577029|DRUG|tenofovir disoproxil|300 mg once daily; oral
223477380|NCT02577029|DRUG|antihistamine|All participants will be pre-treated with an oral antihistamine selected by the investigator from the list of approved antihistamines that is available in that country. Acceptable antihistamines are: diphenhydramine 50 mg p.o., chlorpheniramine 8 mg p.o., hydroxyzine 50 mg p.o., or cetirizine 10 mg p.o.
223477381|NCT03912038|OTHER|No intervention.|No intervention
223583415|NCT02621398|DRUG|Carboplatin|Given IV
223583416|NCT02621398|RADIATION|Intensity-Modulated Radiation Therapy|Undergo 3D-CRT or IMRT
223583417|NCT02621398|OTHER|Laboratory Biomarker Analysis|Correlative studies
223583418|NCT02621398|DRUG|Paclitaxel|Given IV
223583419|NCT02621398|BIOLOGICAL|Pembrolizumab|Given IV
223583420|NCT01694719|BEHAVIORAL|Brief Behavioral Activation Treatment for Depression|
223583421|NCT01694719|BEHAVIORAL|Cognitive Control Training|
223583422|NCT02288013|PROCEDURE|Closure of uterine incision at C section|Closure of uterine incision at Cesarean section
223583423|NCT04403594|OTHER|dry needling|dry needling followed by functional electrical stimulation and treadmill training
223583424|NCT01314560|OTHER|Blood sample|Blood sample
223477382|NCT02078817|DRUG|Ketamine|IV infusions of 0.5mg/kg of Ketamine hydrochloride over a 40-minute infusion period. Participants will receive a total of 6 doses over a 2-week period.
223477383|NCT06523712|BEHAVIORAL|Smile Smarts|The interactive oral health care lessons provided to participants in Arm 1 would involve activities and discussions aimed at changing behaviors such as tooth brushing frequency, brushing techniques, and the use of interdental aids. The intervention aims to educate and motivate participants to adopt and maintain optimal oral hygiene habits through behavioral change strategies.
223477384|NCT02980081|OTHER|abdominal plain x-ray|Abdominal plain x-ray as prescribed by the emergency physician
223477385|NCT04344717|DRUG|Apixaban single dose|A single dose of apixaban 2.5 mg and 5 mg (wash out period of at least 7 days) will be administered and PK characteristics will be measured
223583425|NCT02578433|BEHAVIORAL|Mindful Self Compassion|Mindful Self Compassion (MSC) training has its primary focus on developing a friendly relationship with oneself by meditation,conversation with the group and the trainer, informal practice and homework assignments. These relationship is founded on mindfulness; therefore the participants will learn a way concentrate on the present moment. The orginal MSC training by Neff and Germer is well established, this intervention will be a shortened form of the original version and will last for the whole visit of the clinical patients in rehabilitation
223583426|NCT02578433|BEHAVIORAL|Progressive Muscle Relaxation|Progressive Muscle Relaxation by Jacobson is a well known relaxation technique where participants learn to recognize the difference between tension and relaxation by tensing and subsequently relaxing the muscles. The trainingw ill last the wohole stay and the control group will also do homework assignments.
223583427|NCT05551975|OTHER|Control Product|Fed from Study Day 1
223583428|NCT05551975|OTHER|Experimental Product 1|Fed from Study Day 1
223583429|NCT05551975|OTHER|Experimental Product 2|Fed from Study Day 1
223583430|NCT03340194|RADIATION|Radiography|Radiography of the hand and feet (face incident) the day of the inclusion
223583431|NCT03340194|PROCEDURE|Veinous punction|Blood sample to analysis VEGF, endothelin 1, endostatin and P/GF, (ELISA method)
223583432|NCT02249494|OTHER|telehealth|Use the call service offered by the Center for Telehealth Rio Grande do Sul to answer clinic questions with qualified staff and in real time. All physicians who work in Primary Health Care in Brazil can call when they have questions about diagnosis and management of their patients.
223583433|NCT02249494|OTHER|nutritional counseling|Performing routine nutritional counseling in their clinical practice
223583434|NCT02249494|DEVICE|smartphone (mobile app)|Mobile app, designed to provide nutritional recommendations for hypertensive patients, will be use. The recommendations will be based on the DASH diet guidelines appropriate to the patient profile: consumption of whole grains, fruits, vegetables, milk or low fat dairy products, lean meats, poultry and fish, nuts, seeds and legumes, amount of fats, oils and sweets, as well as guidelines for salt intake and alcohol.
223583435|NCT04728594|BEHAVIORAL|Social Proof|Email
223583436|NCT04728594|BEHAVIORAL|Reframing|Email
223583437|NCT04728594|BEHAVIORAL|Scarcity Message|Email
223583438|NCT03791853|DIAGNOSTIC_TEST|Light-CT|Fresh specimen is trimmed into a block with a size not larger than 2.5 cm (Typically not larger than 1.5 cm). Prepared specimen is submitted to Light-CT tests. FF-OCT images are obtained to depict the structure information and DCI images are generated to collect the dynamic information of the cell and tissue. After the imaging detection, specimens are submitted for routine pathological diagnosis to obtain corresponding pathological images.
223583439|NCT03140982|DIAGNOSTIC_TEST|FOUR coma scale and frontal espectrograpy evaluation|systematic evaluation using the validated FOUR coma scale during propofol administration
223583440|NCT00180167|DRUG|randomization between two established Chemotherapies|
223583441|NCT04665115|DRUG|Ibrutinib|Given PO
223583442|NCT04665115|OTHER|Quality-of-Life Assessment|Ancillary studies
223583443|NCT04104074|RADIATION|Radiotherapy|"Arm 1: The single radiotherapy dose was 200cGy, once a day, and the total dose was 5000cGy.~Arm 2: the single dose of radiotherapy was 300 cGy, once a day, and the total dose was 3000 cGy."
223583444|NCT04104074|DRUG|Sintilimab|Sintilimab is a PD-1 inhibitor, intravenously, at a dose of 200 mg, once every 3 weeks
223583445|NCT02871687|DRUG|Simvastatin|Simvastatin 20 mg daily followed by potential increase to 40 mg simvastatin according to dose escalation procedure
224163142|NCT03430336|OTHER|Medication plan|GPs print out the updated medication plan including also recommendations for medication use and reasons for prescription in lay language (also available in foreign languages for patients with migration background) as well as recommendations on drugs to use / to avoid including over-the-counter drugs (OTC) (optional) and hand it out to the patient.
223477386|NCT04344717|DRUG|Apixaban steady-state|Steady-state apixaban PK characteristics will be measured in patients already treated with apixaban
223477387|NCT01420536|PROCEDURE|Occlusal scheme|"Before enrollment, all participants will receive conventional complete dentures adjusted according to the bilateral balanced occlusion concept.~Following randomization, canine guidance will be achieved by adding composite resin (Restorative Z100, 3M Brazil, Sumaré, SP, Brazil) on the lingual surface of the maxillary canines. A sham comparator will also employ the addition of composite, but without changing eccentric contacts."
223583446|NCT02871687|DRUG|Pravastatin|Pravastatin 40 mg daily followed by potential increase to 80 mg pravastatin according to dose escalation procedure
223583447|NCT02871687|OTHER|Placebo|Placebo prepared by Investigation Drug Services at Brigham and Women's Hospital
223583448|NCT05473013|BEHAVIORAL|Behavioral Therapy for Eating Disorders|Standard behavioral therapy for eating disorders aimed at changing behaviors that maintain binge eating (e.g. rigid dietary restriction outside of binge episodes, irregular or chaotic eating patterns).
223583449|NCT05473013|BEHAVIORAL|Skills Monitoring On|Integrates behavioral treatment for eating disorders with a more complex self-monitoring than the self-monitoring protocol with traditional behavioral treatment. Via a smartphone application, participants will be asked to self-monitor skill usage of the skills provided during treatment sessions on top of monitoring their eating patterns, binging, and (if applicable) compensatory behaviors.
224163143|NCT03430336|OTHER|Guidance in medication process|GPs receive guidance via the CDSS (e.g. recommendations addressing certain types of medication errors and high risk prescribing, developed by the German Society for Internal Medicine in collaboration with other scientific medical societies).
223477388|NCT01162200|RADIATION|Stereotactic Body Radiation Therapy|3 dose cohorts. Patients in each dose cohort will all be treated as a single group for dose escalation. The starting dose for the dose escalation portion will be 6 Gy per fraction for 5 fractions (total dose = 30 Gy). Subsequent cohorts of patients will receive an additional 0.5 Gy per treatment (total 2.5 Gy per escalation).
223477389|NCT02650375|DRUG|Metatinib Tromethamine|Patients receive Metatinib orally 200mg once daily (QD) or 100mg twice daily (BID) until disease progression or unacceptable toxicity occurred.
223477390|NCT02283398|OTHER|without RIPC|the cuff will be placed around the left arm without being inflated
224163144|NCT04668547|DEVICE|Hysteroscopic Embryolysis|Hysteroscopic removal of the products of conception for induced abortion using a hysteroscopic morcellator. If this method of induced abortion fails, a traditional Dilation and Curettage procedure is performed
223477391|NCT02283398|PROCEDURE|RIPC|RIPC will be induced with three cycles of inflation of a blood-pressure cuff on the left arm to 200 mm Hg for 5 min, followed by 5 min of reperfusion while cuff deflated
223477392|NCT04352348|OTHER|blood samples|"All arms:~1 blood sample at inclusion (T0)~COVID-19 positive, severe only:~1 blood sample at D3, at D7, in case of transfer to intensive care unit or in case of aggravation of symptoms, eventually, at discharge from hospital if the last blood sample was more than 3 days old, in case of post-COVID-19 follow-up visit scheduled in standard care at 3 to 6 months after hospitalization and in case of post-COVID-19 follow-up visit scheduled in standard care at 11 to 13 months after hospitalization.~Follow-up after COVID-19 hospitalization only:~1 blood sample in case of post-COVID-19 follow-up visit scheduled in standard care at 11 to 13 months after hospitalization"
224163145|NCT05625880|DEVICE|Picterus Jaundice Pro|Use Picterus Jaundice Pro, a smartphone app that is used to take photo of the newborns skin, where the Picterus calibration card is place
223583450|NCT05473013|BEHAVIORAL|Automated Reminder Messages|Integrates behavioral treatment for eating disorders with two randomly time automated push notifications from a smartphone application each week to remind participants about skills they have learned in session to encourage skill use.
223583451|NCT05473013|BEHAVIORAL|JITAIs|Integrates behavioral treatment for eating disorders with push notifications each week from a smartphone application to remind participants about skills they have learned in session to encourage skill use during app-identified moments of need (i.e., JITAIs, just-in-time adaptive interventions).
224163146|NCT00481221|PROCEDURE|Observation of results from laboratory tests|Laboratory data summary only
224163147|NCT04762264|DEVICE|ProFlor inguinal hernia device|Device follow up after inguinal hernia repair with ProFlor
224163148|NCT04672070|OTHER|Selective Caries Removal|"Selective caries are removed only for secure sealing with a direct restoration, without removing deep caries next to the pulp.~If the pulp is exposed, pulpotomy will be performed instead and the tooth will be excluded from further analysis."
223583452|NCT01497613|BEHAVIORAL|PRISM C: Computer Condition|A specialized computer system designed to support social connectivity and access to resources; knowledge and prospective memory
223583453|NCT01497613|BEHAVIORAL|PRISM B: Notebook Condition|Telephone check-in calls and a notebook that contains information about community resources, games; topics of interests to seniors; a calendar and contact list.
223477393|NCT04352348|OTHER|feces samples (COVI-BIOME ancillary study)|"All arms:~1 feces sample at inclusion (T0)~COVID-19 positive, severe only:~1 feces sample at D3, at D7, in case of transfer to intensive care unit or in case of aggravation of symptoms and, eventually, at discharge from hospital"
223477394|NCT04352348|OTHER|sweat samples (COVIDOG ancillary study)|"All arms:~2 sweat samples at inclusion (T0)"
223477395|NCT04352348|OTHER|saliva samples|"All arms:~1 saliva sample at inclusion (T0)~COVID-19 positive, severe only:~1 saliva sample at D7, at discharge from hospital, in case of post-COVID-19 follow-up visit scheduled in standard care at 3 to 6 months after hospitalization and in case of post-COVID-19 follow-up visit scheduled in standard care at 11 to 13 months after hospitalization.~Follow-up after COVID-19 hospitalization only:~1 blood sample in case of post-COVID-19 follow-up visit scheduled in standard care at 11 to 13 months after hospitalization"
223477396|NCT04352348|OTHER|6 minutes walk test|"COVID-19 positive, severe only:~6 minutes walk test in case of post-COVID-19 follow-up visit scheduled in standard care at 3 to 6 months after hospitalization and in case of post-COVID-19 follow-up visit scheduled in standard care at 11 to 13 months after hospitalization.~Follow-up after COVID-19 hospitalization only:~6 minutes walk test at inclusion (T0) and in case of post-COVID-19 follow-up visit scheduled in standard care at 11 to 13 months after hospitalization."
223477397|NCT04352348|OTHER|Phone call|"All arms except COVID-19 negative:~1 phone call 3 months after COVID-19 infection.~All arms except COVID-19 negative:~1 phone call 6 months after COVID-19 infection.~All arms except COVID-19 negative:~1 phone call 12 months after COVID-19 infection."
223583454|NCT01808885|DRUG|olesoxime (TRO19622)|"olesoxime (3 caps: 495 mg, od) will be administered orally as 165 mg soft capsules for 6 months.~Investigational products will be allocated in a 1:1 ratio from Baseline/Visit 0 to Week 24 (Visit 3/Final Visit)."
223583455|NCT01808885|DRUG|placebo|placebo capsule shells with identical appearance as the active compound TRO19622
223583456|NCT00049777|DRUG|Drotrecogin Alfa (Activated)|
223583457|NCT00049777|DRUG|Unfractionated heparin|
223583458|NCT00049777|DRUG|Low molecular weight heparin|
224163149|NCT04672070|OTHER|Pulpotomy|"Complete caries removal and excision of the coronal pulp to the level of the root canal orifices will be performed. After haemostasis, sealing with Biodentine® and restoration.~If the pulp is not exposed after complete caries removal, the tooth will be restored without further excavation and pulp exposure. If the pulp is assessed intra-operatively to be non-vital or not amenable to pulpotomy, root canal treatment will be performed instead. In both cases, the tooth will be excluded from further analyses."
224163150|NCT02418728|OTHER|subcutaneous adipose tissue microdialysis under local beta/alpha blockade|adipose tissue lipolysis under local beta/alpha blockade in abdominal subcutaneous adipose tissue, using microdialysis
224163151|NCT02377908|OTHER|Online Survey|Online questionaire submitted to experts in geriatrics in different European countries. 12-item survey.
223583459|NCT00351182|DRUG|Telithromycin|
224163152|NCT01616069|DRUG|epinephrine and levosimendan|epinephrine (0,06mcg/kg/min), levosimendan (0,2 mcg/kg/min)
224163153|NCT01229280|DRUG|Darifenacin|Single dose 7.5 mg tablets of darifenacin
224163154|NCT01229280|DRUG|Darifenacin|Single dose 7.5 mg tablets of Darifenacin
223477398|NCT04352348|OTHER|Urine samples|"All arms:~1 urine sample at inclusion (T0)~COVID-19 positive, severe only:~1 urine sample at D3, at D7, at discharge from hospital, in case of post-COVID-19 follow-up visit scheduled in standard care at 3 to 6 months after hospitalization and in case of post-COVID-19 follow-up visit scheduled in standard care at 11 to 13 months after hospitalization.~Follow-up after COVID-19 hospitalization only:~1 urine sample in case of post-COVID-19 follow-up visit scheduled in standard care at 11 to 13 months after hospitalization"
223477399|NCT02941640|PROCEDURE|E group|The securing the base of appendix by endoloop.
223477400|NCT02941640|PROCEDURE|S group|The securing the base of appendix by Stapler.
224163830|NCT06313749|DEVICE|Minimally Invasive Micro Sclerostomy Device|During this clinical trial, the Minimally Invasive Micro Sclerostomy (MIMS®) procedure will be performed by investigators using the proprietary MIMS® device developed by Sanoculis Ltd.
223477401|NCT02941640|PROCEDURE|H group|The securing the base of appendix by Hem-o-lok clip.
223477402|NCT02941640|PROCEDURE|DS group|The securing the base of appendix by DS clip.
223477403|NCT02941640|DEVICE|Endoloop|
223477404|NCT02941640|DEVICE|Stapler|
223477405|NCT02941640|DEVICE|Hem-o-lok clip|
223477406|NCT02941640|DEVICE|DS clip|
223477407|NCT04192331|DRUG|nab-paclitaxel regimen1|nab-paclitaxel regimen1 means use abraxine with 125mg/m2 at day 1 and day 8 per 21d.
223477408|NCT04192331|DRUG|nab-paclitaxel regimen2|nab-paclitaxel regimen2 means use abraxine with 125mg/m2 at day 1 and day 8 and day 15 per 28d.
223583460|NCT00351182|DRUG|Doxycycline|
223583461|NCT01616979|PROCEDURE|placing saline bag during cardiac displacement|For grafting to LCX territory, the heart is displaced using positioner and a suction-type epicardial stabiliser is applied to the target area. The degree of cardiac displacement and the LV compression by stabilisers are adjusted for maximal surgical access and minimal haemodynamic instability.
224070206|NCT06599840|BEHAVIORAL|Parent intervention|This is a novel intervention based on established CBT-based parenting strategies that are regularly used to strengthen parent-child cooperation and reduce conflicts. Here, the strategies are adapted to address typical challenges of T1D family life. The program structure consists of six weekly modules and a seventh booster module. Each of the first six modules has a theme with information on a parental strategy associated with the theme, self-reflective questions, and an assignment where parents plan to implement the strategy during the upcoming week. One month later, a seventh session is held to summarize the program and make plans for future progress.
223477409|NCT00405418|DRUG|Insulin glargine|Subcutaneous injection, once a day in the evening
223477410|NCT00405418|DRUG|Insulin Detemir|Subcutaneous injection, twice a day at breakfast and before dinner
223477411|NCT01590108|DRUG|(Pyr1)apelin-13|(Pyr1)apelin-13 will be infused at 30 nanomol/min intravenously. This dose has been used in healthy volunteer and patients groups
223477412|NCT01590108|DRUG|Saline|Saline
223583462|NCT00724113|PROCEDURE|infiltration intra articular|infiltration intra articular at inclusion with XYLOCAINE 1%
223583463|NCT00724113|PROCEDURE|ARTHRO distension plus intensive mobilisation|ARTHRO distension plus intensive mobilisation
223583464|NCT00128713|PROCEDURE|Medium Dose Prophylactic Platelet Transfusions|2.2 x 10\^11 platelets per m\^2 BSA
224070207|NCT03685786|BIOLOGICAL|CART19 cell and auto-HSCT|Phase 1 Clinical Study of CD19-directed Chimeric Antigen Receptor-modified T (CART19) Cells treatment for Adult Patient with Minimal Residual Disease(MRD) of B Cell Malignancies and then Autologous Hematopoietic Stem Cell Transplantation(Auto-HSCT). Subjects will receive 0.5-4 x 10\^8 transduced CAR T cells as a split dose over three days as follows:Day 0, 10% fraction: 0.5-4x10\^7 CART19 cells, Day 1, 30% fraction: 1.5x10\^7-1.2x10\^8 CART19 cells, Day 2, 60% fraction: 3x10\^7-2.4x10\^8 CART19 cells. Auto-HSCT will be made about 6 mouths after CART19 cell is infused back to the patient.
224070208|NCT02476721|OTHER|detection of pulmonary embolism|
224070209|NCT06275503|BEHAVIORAL|Screening invitation mode|Cluster randomized study to compare mode of invitation
224070210|NCT06126302|OTHER|Birth year|we divided the patients according to patients' birth year
224070211|NCT02989415|OTHER|Mechanical Ventilation|Mechanical ventilation during robotic surgery
224070212|NCT05535348|BEHAVIORAL|Relaxation Response Resiliency Program for Father of CYSHCN|Virtually delivered psycho-educational resiliency training program for fathers of CYSHCN
224070213|NCT03587454|DIAGNOSTIC_TEST|Teleglaucoma|Subjects are evaluated through a teleglaucoma protocol then by physical presence in a glaucoma clinic
223477413|NCT00826553|DRUG|Dexmedetomidine|Standard of care sedative. Dosage, frequency, and duration will be determined by the managing clinical team.
223477414|NCT00826553|DRUG|GABA agonist|Patients sedated with GABA agonists (e.g. propofol, benzodiazepines) during mechanical ventilation will be enrolled. Patients randomized to the GABA agonist arm will continue the sedative that is active at enrollment. The specific drug as well as dosage, frequency, and duration will be determined and titrated by the managing clinical team.
223477415|NCT03040401|DRUG|Cohort 1, Ceplene® and Proleukin®|"Patients in Cohort 1 will be administered only Ceplene® during the first treatment cycles and Ceplene® in combination with Proleukin® during treatment cycles 2-4.~IL-2 will be administered s.c., 1 µg/kg (=16400 IU/kg) body weight twice daily (BID) during treatment periods. Ceplene® will be administered s.c. 0.5 mg BID after IL-2."
223583465|NCT00128713|PROCEDURE|Lower Dose Prophylactic Platelet Transfusions|1.1 x 10\^11 platelets per m\^2 BSA
223477416|NCT03040401|DRUG|Cohort 2, Ceplene® and Proleukin®|"Patients in Cohort 2 will be administered Ceplene® in combination with Proleukin® during all treatment cycles 1-4.~IL-2 will be administered s.c., 1 µg/kg (=16400 IU/kg) body weight twice daily (BID) during treatment periods. Ceplene® will be administered s.c. 0.5 mg BID after IL-2."
223583466|NCT00128713|PROCEDURE|Higher Dose Prophylactic Platelet Transfusions|4.4 \* 10\^11 platelets per m\^2 BSA
223583467|NCT03817294|OTHER|Comparison of exercise training modalities|As above
224163831|NCT03080701|BEHAVIORAL|Auto Mailing Plus Money|Participant receives money as a thank you for completing CRC screening within 6 months.
224163832|NCT03080701|BEHAVIORAL|Auto Mailing Plus Lottery|Participant has a 1 in 10 chance of winning money in a lottery for completing CRC screening within 6 months.
224163833|NCT02017067|PROCEDURE|hydraulic resistance circuit training|12 weeks (3 times per week, 40 min circuit) of hydraulic resistance circuit training that consisted of 7 types of equipments for different part of strength training.
224163834|NCT03842761|DRUG|BI 685509|Tablet
223477417|NCT03040401|DRUG|Cohort 3, Ceplene® and Proleukin®|"Cohort 3 will receive either only Ceplene® during treatment cycles 1-4 or Ceplene® in combination with Proleukin® during treatment cycles 1-4. Treatment will be decided by the study committee based on the safety profile of treatment administered to cohort 1 and 2.~IL-2 will be administered s.c., 1 µg/kg (=16400 IU/kg) body weight twice daily (BID) during treatment periods. Ceplene® will be administered s.c. 0.5 mg BID after IL-2."
223477418|NCT00296855|DRUG|Vasovist (BAY86-5283, MS-325)|All patients receive a single IV bolus injection of Vasovist at a dose of 0,03 mmol/kg BW at a flowrate of 0,5 mL/sec, followed by a saline flush of at least 30 mL
223477419|NCT04505852|DEVICE|Embrace|Patients wear Embrace2 to help in seizure reporting and patient care.
223477420|NCT03686553|OTHER|laboratory-based data collection|laboratory-based surveillance of SSI
223477421|NCT00143338|DRUG|Inhaled insulin|
223477422|NCT01265498|DRUG|obeticholic acid|25 mg daily for 72 weeks
223477423|NCT01265498|DRUG|placebo|placebo capsule, 25 mg daily for 72 weeks
223477424|NCT00968461|DRUG|Phenethyl Isothiocyanate (PEITC)|Starting dose 40 mg capsules by mouth, 4 times a day, on Days 1-3 and 8-10 of each cycle.
223477425|NCT01502085|DRUG|Vorinostat, Lenalinomide and Dexamethasone|"Vorinostat: 400 mg po days 1-7 and 15-21 Lenalidomide: 25 mg po days 1-21~\* Lenalidomide dose for patients with renal impairment (CrCL\<50ml/min) has be dose adjusted according to package insert~Dexamethasone: 40mg po days 1, 8, 15 and 22 for patients aged less than 75 years, 20mg for those aged 75 years and above"
223583468|NCT01264770|DRUG|Fostamatinib and placebo injections|Fostamatinib 100mg twice daily and placebo injection once every two weeks
223583469|NCT01264770|DRUG|Fostamatinib and placebo injections|Fostamatinib 100mg twice daily / fostamatinib 150mg once daily and placebo injection once every two weeks
223583470|NCT01264770|DRUG|Fostamatinib and placebo injections|Fostamatinib 100mg twice daily / fostamatinib 100mg once daily and placebo injection once every two weeks.
223583471|NCT01264770|DRUG|Adalimumab and placebo of fostamatinib|Adalimumab 40mg injection once every two weeks and placebo to fostamatinib twice daily.
223583472|NCT01264770|DRUG|Placebo of fostamatinib, fostamatinib, and placebo injections|Placebo injection once every two weeks. Placebo to fostamatinib for six weeks, followed by fostamatinib 100mg twice daily (Group F) / fostamatinib 100mg twice daily then 150mg once daily (Group G).
224070214|NCT02335827|PROCEDURE|irreversible electroporation|Percutaneous (CT-guided and/or US-guided) or open IRE with voltage in level B for renal tumors
224070215|NCT00274521|DRUG|Tiotropium|
223477426|NCT05171907|BEHAVIORAL|Teleobesity|Teleintervention based on Dietary Guidelines for the Brazilian Population during 8 weeks; two subsequent assessments will also be made, in 24th and 48th weeks, to assess the maintenance of weight loss.
223477427|NCT02055586|OTHER|fluorine F 18 fluorothymidine|Undergo FLT-PET/MRI
223477428|NCT02055586|DEVICE|positron emission tomography|Undergo FLT-PET/MRI
223477429|NCT02055586|DEVICE|magnetic resonance imaging|Undergo FLT-PET/MRI
223477430|NCT06359899|DRUG|AK0901 capsule|Active Substance: AK0901, Pharmaceutical Form: Capsule, Route of Administration: Oral
223477431|NCT06359899|DRUG|Placebo|Active Substance: Placebo, Pharmaceutical Form: Capsule, Route of Administration: Oral
223583473|NCT03328923|DIETARY_SUPPLEMENT|500mg brown seaweed powder|
223583474|NCT03328923|DIETARY_SUPPLEMENT|Placebo|
223583475|NCT00196768|DRUG|Arsenic trioxide|
223583476|NCT00196768|DRUG|Trisenox|
224070216|NCT02736669|BEHAVIORAL|Energy Reduction|
223477432|NCT04050033|DEVICE|Evoke Device|Subjects will undergo treatment with Evoke Device
223477433|NCT01652690|BIOLOGICAL|Denosumab|This is an non-interventional study, therefore denosumab is administered as part of routine care and not for purposes of the study.
223477434|NCT03330509|OTHER|SPARK intervention|An integrated model of care (SPARK care) in which the palliative care team co-rounds with the medical oncology team, supporting them in their delivery of basic palliative care, seamlessly stepping in and out to deliver specialist palliative care directly to patients when needed.
223583477|NCT04363450|DRUG|Hydroxychloroquine|Hydroxychloroquine loading 400mg (2 capsules) twice 12 hours apart followed by 200mg (1 capsule) twice weekly
223583478|NCT04363450|DRUG|Placebo|Loading dose of two placebo capsules twice 12 hours apart followed by 1 capsule twice weekly
223583479|NCT02090790|DRUG|iv dexamethasone|2 ml 8 mg iv dexamethasone
223583480|NCT02090790|DRUG|femoral dexamethasone|2ml 8mg dexamethasone administration added 30 ml 0,5 % bupivacain
223583481|NCT02090790|DRUG|serum physiologic|2 ml iv serum physiologic
224070217|NCT03239821|DEVICE|VIPUN Balloon Catheter 0.1 deflated|deflation balloon
224070218|NCT03239821|DRUG|Codeine Phosphate|58.8 mg codeïne phosphate
224070219|NCT03239821|DRUG|Placebo|Sirupus Simplex
224070220|NCT03239821|DEVICE|VIPUN Balloon Catheter 0.1 inflated|VIPUN Balloon Catheter 0.1 inflated
224070221|NCT02575521|DRUG|Propofol-Dexmedetomidine group|Porofol (1.5-2 mg/kg/h) infusion, Dexmedetomidine (0.2-1µg/kg/h) infusion and Fentanyl in repeated doses (50µ) when needed (heart rate or mean arterial blood pressure increase more than 20% of the basal value). Maintenance infusions will start immediately after induction.
224070222|NCT02575521|DRUG|Sevoflurane group|Sevoflurane at a concentration of 2-2.5%., Fentanyl in repeated doses (50µ) when needed (heart rate or mean arterial blood pressure increase more than 20% of the basal value).
224070223|NCT06475144|OTHER|online escape room teaching|here are a total of eight game levels, each accompanied by video instructions or hints. Participants can proceed to the next room based on the level and hints, guiding their reasoning to the correct answers and achieving the learning objectives.
224070224|NCT06475144|OTHER|online video-based teaching|"The study is divided into four units: SIRS Definition, Sepsis Definition and Classification, Sepsis Early Warning Scoring System, and Early Goal-Directed Therapy for Sepsis. Clinical case scenarios are animated for participants to watch, with content identical to the video prompts used in the experimental group's gameplay."
223477435|NCT05551390|OTHER|one-time umbilical cord milking|"Before UCM procedures, in the case of vaginal delivery, the maternity doctor or nurse held the newborn below the level of the introitus. In the case of a cesarean section, the surgeon carries the newborn below the level of the incision.~Then maternity nurse or doctor swiped blood in length 20 centimeters of umbilical cord into the newborn, according to the number of swipes that assigned, then cutting the umbilical cord by the international standard methods. Newborns after birth were cared for and assessed according to the newborn nursing standards of QSMH in the department of pediatrics."
223744599|NCT07190404|BEHAVIORAL|MC Approach Booster Session|MC+B participants will come from the MC Approach group only. They will receive 2 additional treatment sessions with their original OT within the month following their 6mo FU assessment. The OT will review the participant's relevant Post and FU data beforehand for treatment planning purposes. The first session will involve a review of goals, prior learning, and strategies and discussion of successes/challenges related to functional cognitive performance and strategy application since initial treatment. Then the same protocol (treatment activities with metacognitive framework and mediation, strategy bridging discussions, homework action planning and review) will be followed for the rest of the booster treatment to reinforce or re-activate prior learning, address new concerns, and develop supports for maintenance.
223583482|NCT04533074|BIOLOGICAL|Single-visit regeneration protocol|In a single visit, access opening, minimal instrumentation and irrigation will be done. After irrigation and drying, the apical tissue will be irritated to evoke bleeding in the canal, using a precurved K-file 2mm past the apical foramen, with the goal of having the entire canal filled with blood to the level of the cemento-enamel junction. The bleeding will be stopped at a level that allows for 3-4 mm of restorative material. Three millimeters of Biodentine will then be placed directly over the blood clot of each tooth. A 3-4 mm layer of glass ionomer is flowed gently over the capping material. Each access cavity will be restored using composite resin.
223583483|NCT04533074|BIOLOGICAL|Multiple-visits regeneration protocol|In the first visit, access opening, minimal instrumentation and irrigation will be done. The root canal will be then dried and filled with calcium hydroxide paste. The tooth will be sealed with an intermediate restorative material (IRM), and the patient will be dismissed for 1-4weeks. In the second appointment, response to initial treatment will be assessed and the steps will be repeated if symptoms are persistent. If there are no symptoms, evoking bleeding to the level of the cemento-enamel junction will be done followed by Biodentine application over the blood clot with final glass ionomer and composite restorations.
223583484|NCT02018874|DRUG|LY2780301|"LY2780301 will be given orally Q.D. at different dose levels. Because of a favourable safety profile, the different dose levels will be as follow :~* Dose level -1: 300 mg Q.D.~* Dose level -0.5: 400 mg Q.D.~* Dose level 1: 400 mg Q.D.~* Dose level 1.5: 500 mg Q.D.~* Dose level 2 : 500 mg Q.D."
223583485|NCT02018874|DRUG|Gemcitabine|The dose level of Gemcitabine will be fixed (1000 mg/m2). Gemcitabine will be administered over a 30 minutes infusion.
223583486|NCT02839694|DRUG|decitabine (DAC)|Administered IV at increasing frequency or dose from 3-5 times per week for 8-12 weeks
223583487|NCT02839694|DRUG|Tetrahydrouridine (THU)|Administered IV at increasing frequency or dose from 3-5 times per week for 8-12 weeks
223477436|NCT05551390|OTHER|three-times umbilical cord milking|"Before UCM procedures, in the case of vaginal delivery, the maternity doctor or nurse held the newborn below the level of the introitus. In the case of a cesarean section, the surgeon carries the newborn below the level of the incision.~Then maternity nurse or doctor swiped blood in length 20 centimeters of umbilical cord into the newborn, according to the number of swipes that assigned, then cutting the umbilical cord by the international standard methods. Newborns after birth were cared for and assessed according to the newborn nursing standards of QSMH in the department of pediatrics."
223477437|NCT02799147|PROCEDURE|Allogeneic stem cell transplantation|
224070225|NCT02264990|DRUG|Paclitaxel|Administered by Intravenous infusion on Day 1 of each 21-day cycle
224070226|NCT02264990|DRUG|Carboplatin|Administered by Intravenous infusion on Day 1 of each 21-day cycle
224070227|NCT02264990|DRUG|Cisplatin|Administered by Intravenous infusion on Day 1 of each 21-day cycle
224070228|NCT02264990|DRUG|Veliparib|Oral capsule, administered twice daily for 7 days in each 21-day cycle
223477438|NCT02799147|DRUG|Fludarabine monophosphate|
224070229|NCT02264990|DRUG|Pemetrexed|Administered by Intravenous infusion on Day 1 of each 21-day cycle
224070230|NCT03041285|DRUG|idronoxil (NOX66) suppository|"Patients in Group 1 will be given 400mg of Idronoxil suppository (NOX66) (1 suppository) daily from Day 0(1 day before radiotherapy) until 7 days after radiotherapy. Group 2 will be given Idronoxil (NOX66) 800mg (2 suppositories) daily from Day 0 until 7 days after radiotherapy.~All patients will receive one course of Stereotactic Body Radiation Therapy (SBRT), to be delivered in 20 Gray in 5 fractions.~Radiotherapy session will involve irradiation of 1-2 lesions.~."
224070231|NCT03041285|RADIATION|Stereotactic Body Radiation Therapy|All patients (Group 1 and Group 2) will receive one course of Stereotactic Body Radiation Therapy (SBRT), to be delivered in 20 Gray in 5 daily fractions on consecutive days. Radiotherapy session (week 1) will involve irradiation to 1-2 lesions.
224070232|NCT01084265|DRUG|Recombinant human luteinizing hormone (r-hLH)|One r-hLH (75 International Units \[IU\]) injection s.c. once daily.
224070233|NCT01084265|DRUG|Recombinant human follicle-stimulating hormone (r-hFSH)|One r-hFSH (150 IU) injection s.c. once daily.
224070234|NCT01084265|DRUG|Human chorionic gonadotropin (hCG)|After adequate follicular response, ovulation induction was triggered by an injection of 10,000 IU hCG.
223477439|NCT02799147|DRUG|Busulfan|
223477440|NCT02799147|DRUG|Bendamustine|
224070235|NCT00907400|DRUG|PN400|oral tablet
224070236|NCT00907400|DRUG|Naproxen|oral tablet
224070237|NCT02743832|PROCEDURE|Resection for primary lesion and cervical lymph node dissection|Resection for primary lesion and cervical lymph node dissection are performed in the early-stage oral squamous cell carcinoma.
224070238|NCT02743832|PROCEDURE|Resection for primary lesion only|Only resection for primary lesion is performed in the early-stage oral squamous cell carcinoma.
224070239|NCT01134965|DRUG|Flibanserin plus Digoxin|Flibanserin 100 mg once daily for 7 days plus Digoxin 0.5 mg as single dose
224070240|NCT01134965|DRUG|Digoxin|Digoxin 0.5 mg as single dose
223477441|NCT05239663|DRUG|Ganglioside-Monosialic Acid|Standard (neo)adjuvant chemotherapy (Taxanes combined with cyclophosphamide or doxorubicin combined with cyclophosphamide followed by taxanes) plus Ganglioside-Monosialic Acid 100mg+250ml normal saline (NS)
223477442|NCT05239663|DRUG|250ml normal saline (NS)|Standard (neo)adjuvant chemotherapy (Taxanes combined with cyclophosphamide or doxorubicin combined with cyclophosphamide followed by taxanes) plus 250ml normal saline (NS)
223477443|NCT06139926|DRUG|Dexmedetomidine administered intranasally|Intranasal administration of dexmedetomidine (plain) was given at the bedside of the ward as per the pre-tested recommended dose. The patient's vital signs were maintained. On the day of surgery, 30 min before induction of anesthesia, intranasal dexmedetomidine (original solution) was administered in the operating room at the pre-tested recommended dose.
223477444|NCT02842528|BEHAVIORAL|Diagnostic Interview for Genetic Studies|
223477445|NCT02842528|BEHAVIORAL|Family Informant Schedule and Criteria|
223477446|NCT02842528|BEHAVIORAL|Temperament and Character Inventory|
223477447|NCT02842528|BEHAVIORAL|Barratt Impulsiveness Scale|
223477448|NCT02842528|BEHAVIORAL|Wisconsin Card Sorting Test|
223477449|NCT02842528|GENETIC|blood sample withdrawn|
223477450|NCT03225287|DRUG|Zilucoplan (RA101495)|Subjects will continue to receive the final maintenance dose they were receiving in the qualifying study.
223477451|NCT03036267|BEHAVIORAL|BREATHE|Primary care providers (PCPs) randomized to BREATHE will be trained to deliver the 7-minute brief shared decision-making intervention using a 4-step motivational interviewing approach.
223583488|NCT02839694|DRUG|Celecoxib|400 mg orally twice a day every day for while on DAC-THU therapy
224070241|NCT00832507|DRUG|Cicletanine|Cicletanine capsules 150 mg or 300 mg administered orally once or twice daily
224070242|NCT00832507|DRUG|Cicletanine Placebo|Placebo to match cicletanine administered orally once daily, followed by active cicletanine in the blinded extension period
224070243|NCT06198673|DRUG|Antiplatelet Agents|Antiplatelet agents more commonly used at time of percutaneous coronary intervention in patients with chronic coronary syndrome
224070244|NCT06345677|COMBINATION_PRODUCT|ViXe Xombination|Combination of Xeomin and the ultrasound based delivery system (Vibe) for intravesical administration of the drug in a minimally invasive procedure
224070245|NCT06345677|COMBINATION_PRODUCT|Placebo + Sham|Placebo identical in package and appearance to Xeomin together with all steps of Vibe device preparation and activation, but without the actual operation of the ultrasound energy
224070246|NCT00876993|DRUG|Bevacizumab|Bevacizumab 10 mg/kg IV on day 1 and day 15 of a 28 day cycle
224070247|NCT00876993|DRUG|Irinotecan|Irinotecan 125 mg/m2 on day 1 and day 15 of a 28 day course given IV for the first 3 dose levels. If the Maximum Tolerated Dose of temozolomide is not reached at dose level 3, then dose level 4 will be an escalation of irinotecan to 150mg/m2.
224070248|NCT00876993|DRUG|Temozolomide|For the first cohort (dose level 0) of patients, dosing is 75 mg/m2/day day 1-5 of a 28 day course given PO for the first course. Doses will be escalated according to standard phase I dose escalation criteria. Dose levels are as follows (Dose level 1 = 125mg/m2, Dose level 2 = 175mg/m2, Dose levels 3 and 4 = 200 mg/m2)
224070249|NCT01452334|BIOLOGICAL|BMS-936559 (Anti PD-L1)|Injection for infusion, Intravenous (IV), 1, 3 or 10 mg/kg, Every 2 weeks, 48-96 weeks depending on response
224070250|NCT04884230|PROCEDURE|Oversewing|Oversewing of the gastric remnant
224070251|NCT01849172|OTHER|electroacupuncture|Stick adhesive tapes to all points. For ST25, EX-CA1 and RN4, insert the needle vertically through the pads and the skin, and then slowly and vertically penetrate through the layer of fatty tissue, into the muscles of the abdominal wall .For RN4, manipulate the needle with an even lifting, thrusting and twisting method slightly for 3 times. Insert the needle vertically at SP6 to a depth of 1 cm. Manipulate the needle with an even lifting, thrusting and twisting method slightly for 3 times to reach de-qi. Put the electric stimulator on the pair of EX-CA1 and ST25 points with a dilatational wave, 10/50 Hz, 0.5-1.0mA. To turn on the current intensity till the abdomen shivers. The same manipulation methods for RN4 and SP6 will be given every 10 minutes (3 times in all).
224163835|NCT03842761|DRUG|Placebo|Tablet
224163836|NCT03621124|PROCEDURE|Resting Energy Expenditure|During each visit, the participant will be assessed in a resting state in a stable temperature controlled environment, and will undergo tests to find out how the body adjusts its metabolism to different temperatures.
224163837|NCT03621124|OTHER|Thermal Comfort Questionnaire|Patients will be given a questionnaire to assess their thermal response (whether they felt warmer or colder) during each study visit.
224163838|NCT03887325|DRUG|Maxipost|To investigate the role of maxipost on cerebral hemodynamic and headache in healthy volunteers and migraine patients
224163839|NCT03887325|DRUG|Saline|To investigate the role of saline on cerebral hemodynamic and headache in healthy volunteers and migraine patients
223477452|NCT03036267|OTHER|Attention Control Condition|PCPs randomized to the control intervention will not receive any specific training. To control for contact, they will be instructed to engage in a 7-minute diet and exercise discussion as this will not confound results.
223477453|NCT04763993|PROCEDURE|Roux-en-Y-Gastric bypass, Sleeve gastrectomy|RYGBP consists in creating a small gastric pouch along the little curvature of the stomach, followed by the section of the small bowel. The restoration of the gastro-intestinal tract is achieved by performing a gastro-jejunal and a jejuno-jejunal anastomosis, giving this procedure the characteristic aspect of a Y. Also, for RYGBP the laparoscopic approach requires the placement of 5 trocars in the upper part of the abdomen.
223477454|NCT04763993|PROCEDURE|SG|SG consists in removing the fundus and the body of the stomach, along the greater curvature. To perform it with a laparoscopic approach, we create the pneumoperitoneum with Veress needle and place 5 trocars in the upper part of the abdomen. The first step is the dissection of the greater curvature of the stomach, that starts at 6 centimetres from pylorus and it's conducted up to the angle of His, freeing the fundus and exposing the left pillar. A 38 Fr bougie is placed inside the stomach to calibrate its section. After it is carried out, the specimen is removed from the greater trocar site.
223477455|NCT06296511|BEHAVIORAL|Exercise|60 min of treadmill exercise performed at 70% of peak oxygen uptake.
223583489|NCT02699372|DRUG|Placebo|
223583490|NCT02699372|DRUG|RO6889450|
224163840|NCT04327895|BEHAVIORAL|evaluation of the need for training|analyse of results of survey
224163841|NCT01037140|DRUG|Cholecalciferol|oral cholecalciferol tablets of 175 micrograms daily for 6 months
224163155|NCT03237429|DIAGNOSTIC_TEST|bioimpedance spectroscopy|"Bioimpedance spectroscopy-The technique involves attaching electrodes to the patient's forearm and ipsilateral ankle, with the patient in a supine position. The BCM measures the body resistance and reactance to electrical currents of 50 discrete frequencies, ranging between 5 and 1000 kHz. Based on a fluid model using these resistances, the extracellular water (ECW), the intracellular water (ICW) and the total body water (TBW) are calculated. These volumes are then used to determine the amount of fluid.~Carotid-femoral pulse wave velocity-will be determined by arterial applanation tonometry using the Sphygmocor system by sequentially recording ECG-gated carotid and femoral artery waveforms.. Pulse wave signals will be recorded by tonometers positioned at the base of the right common carotid artery and over the right femoral artery."
224163156|NCT05896410|DEVICE|splint (orthosis)|3D printed splint (orthosis) help prevent the joint from shifting during pinch activities. This reduces improper joint loading and helps reduce pain and the progression of degenerative change in patients with OA.
224163157|NCT04771481|DRUG|Metoclopramide|Metoclopramide 10 mg + NSS 10 ml intravenous slowly push in 5min before endoscopy 30-120 min
224163158|NCT04771481|DRUG|Normal Saline 10 mL Injection|Normal saline 10 ml intravenous slowly push in 5min before endoscopy 30-120 min
224163159|NCT00441012|BIOLOGICAL|Comparator: Modified Process Vaccine|Modified process vaccine HBsAg 5 ug/0.5 mL and PRP \[OMPC\] 7.5 ug/0.5 mL in a 3-dose regimen at 2, 4 \& 12 months of age. Duration of treatment is 11 months.
224163160|NCT00441012|BIOLOGICAL|Comparator: COMVAX™|COMVAX™ HBsAg 5 ug/0.5 mL and PRP \[OMPC\] 7.5 ug/0.5 mL in a 3-dose regimen at 2, 4, and 12 months of age. Duration of treatment is 11 months.
224163161|NCT03694067|OTHER|Punch skin biopsy|One 1 mm punch biopsy will be taken from the patients from balding scalp. Another 1 mm punch biopsy will be taken from an area of occipital non-balding scalp of the same individual. Local anesthesia will be injected around the biopsy site beforehand.
224163162|NCT05936372|BEHAVIORAL|Acute intense aerobic exercise|The acute intense aerobic exercise bout (iE) will consist of a 13-minute 20-meter shuttle run. During this exercise bout two speeds, based on a percentage of the estimated maximal oxygen consumption (VO2max), will be combined: a fast-paced speed (fast: 85% of VO2max) and a slow-paced speed (slow: 60% VO2max). A total of 3 series of 3 min of the fast-paced speed will be carried interspersed with 2 series of 2 min of the slow-paced speed. Prior to the iE start, a warm-up protocol consisting of 2 min slow and 1 min fast will be done with the objective to familiarize participants with the iE speeds. A 5-minute rest period will be guaranteed before starting the iE. Transition time between iE and the rotational visuomotor adaptation task (rVMA) will be 4 min.
223477456|NCT05387876|DIETARY_SUPPLEMENT|Vitamin D intervention|Nordic Naturals vitamin D gummies (1000 IUs/gummie), 4 gummies per day for 12 weeks
223477457|NCT05387876|DIETARY_SUPPLEMENT|Placebo intervention|Organic gummie candies (no vitamin D), 4 gummies per day for 12 weeks
223477458|NCT06609122|OTHER|Animal Assisted Intervention|"Animal-assisted intervention (AAI) is a therapeutic approach that involves animals as part of a treatment plan to improve physical, social, emotional, or cognitive functioning in individuals. Animals such as dogs, cats, horses, and even dolphins are commonly used in AAI due to their ability to provide comfort, companionship, and motivation.~AAI can take many forms, including animal-assisted therapy (AAT), where a trained therapy animal works with a licensed healthcare professional to achieve specific treatment goals. Animal-assisted activities (AAA) involve interactions with animals in a more casual and recreational setting, such as visits to hospitals or nursing homes to provide companionship and emotional support."
223477459|NCT02821533|PROCEDURE|TACE|TACE is performed under local anesthesia with right femoral puncture. The feeding lobar hepatic artery is selectively catheterized for drug delivery.
223477460|NCT02821533|DRUG|Cisplatin|Cisplatin will be mixed with a mixture of Lipiodol and ethanol (LEM), which consists of 33% ethanol by volume in Lipiodol, in a ratio of 2mg cisplatin per mL of LEM, and delivered through catheters or microcatheters to the tumors until there is flow reduction at the tumor feeders. The total dose of cisplatin given in each treatment session is limited to 100mg (50mL LEM) in each treatment session. The usual volume of LEM delivered will be 20 - 30 mL.
223477461|NCT06983678|BEHAVIORAL|Smoking as usual fMRI session|Participants in this condition will continue smoking as usual prior to the fMRI session
223477462|NCT06983678|BEHAVIORAL|Abstinent fMRI session|Participants in this condition will be asked to abstain from smoking or using any other tobacco products for 24 hours prior to the fMRI session
223583491|NCT02103374|DRUG|Atrovent + Bricanyl or Atrovent + Ventoline|3 daily inhalations of Atrovent mixture to form Bricanyl or Ventolin form during 48 weeks
223583492|NCT02103374|DRUG|Placebo|1 capsule lactose during 48 weeks
223583493|NCT04039867|DRUG|Oxaliplatin with Gemcitabine|Oxaliplatin will be given as an intravenous infusion over 60 minutes on Days 1 and 14 at a dose of 100 mg/m2 for each cycle. Gemcitabine (1000 mg/m2) will be given on days 1 and 14 as an intravenous infusion over 30 minutes immediately prior to Oxaliplatin.
223583494|NCT05840107|BIOLOGICAL|GC012F injection|GC012F injection is an autologous dual CAR-T targeted BCMA and CD19. A single infusion of CAR-T cells will be administered intravenously
223583495|NCT04548362|OTHER|Meat arm|Randomised sequence of pork, beef, chicken meat, and an egg white/pea combination
223583496|NCT04548362|OTHER|Starchy foods arm|Randomised sequence of boiled potato, fried potato, potato crisps, and boiled white rice
223583497|NCT01260545|DRUG|CA-18C3|2.5 mg/kg, 3.75 mg/kg IV (in the vein) on Day 1 of each 14 day cycle until the subject is no longer benefiting clinically or unacceptable toxicity occurs.
223744600|NCT06007586|DRUG|Aprepitant Injection|Two antiemetic groups use placebo,Dexamethasone and Ondansetron, Three antiemetic groups use Aprepitant,Dexamethasone and Ondansetron.
224163163|NCT01838304|DEVICE|Probability ramp control|Decision support software that calculates propofol doses appropriate for age and weight of the patient
224163164|NCT01838304|DEVICE|Monitoring|Manual recording of drug doses determined by CRNA
224304866|NCT03548064|BIOLOGICAL|Recombinant Double Mutant Heat-Labile Toxin LT(R192G/L211A) (dmLT) Oral enterotoxigenic Escherichia coli (ETEC) Vaccine|LT(R192G/L211A), or dmLT is a derivative of wild-type enterotoxigenic Escherichia coli heat-labile enterotoxin that has been genetically modified by replacing the arginine at amino acid position 192 with glycine and the leucine at amino acid position 211 with alanine. These two amino acid substitutions take place in proteolytic cleavage sites which are critical for activation of the secreted toxin molecules.
224163165|NCT00744640|DRUG|gemcitabine, oxaliplatin, capecitabine|gemcitabine day 1 and 8, oxaliplatin day 1, capecitabine days 1-14, q3weeks
223477463|NCT05978167|DRUG|Methylphenidate|Oral administration of 20 mg Methylphenidate
223477464|NCT05978167|BEHAVIORAL|Memory reconsolidation|Retrieval of drug-cue memories before extinction.
223583498|NCT05052619|DRUG|Preventive use of advanced antibiotics|Treat patients in this group with advanced preventive usage of antibiocs: Sulperazon 3g q8h, in postoperative days 1-5.
223477465|NCT05978167|DRUG|Placebo|Matching placebo pill
223477466|NCT06986148|OTHER|Immediate Antibiotic Prescribing Group Instructions|Children randomized to the immediate antibiotic prescribing group will receive an antibiotic prescription with instructions to fill and administer the antibiotics.
223477467|NCT06986148|OTHER|Safety Net Antibiotic Prescribing (SNAP) Group Instructions|For children randomized to the SNAP group, their parents or guardians will receive a prescription for antibiotics, but will be told not to administer the antibiotic unless their child's symptoms show no improvement at 72 hours or worsen within 72 hours.
223477468|NCT00161655|DRUG|Etanercept|
223477469|NCT00161655|DRUG|Methotrexate|
223477470|NCT03634319|DEVICE|Beacon Aqueous Microshunt|"The Beacon Aqueous Microshunt is an implantable device designed to lower intraocular pressure (IOP) in glaucoma patients by shunting aqueous humor from the anterior chamber of the eye to the surface of the eye.~Because there are no physiologic sources of outflow resistance, the device can be engineered to target an IOP that is low enough to halt the progression to blindness in a patient suffering from glaucoma."
223477471|NCT01628536|DIETARY_SUPPLEMENT|Black cohosh|Remifemin 20 mg tablet orally twice per day x 4 weeks
223477472|NCT06513260|PROCEDURE|Surgical extraction of impacted lower third molars.|Surgical extraction of impacted mandibular third molars in the mesioangular position, according to the Tetsch and Wagner classification
223477473|NCT06993038|DRUG|adenosine|IV adenosine at standard doses for SVT (6 mg, 12 mg)
223477474|NCT06993038|DRUG|diltiazem|IV diltiazem at standard doses for SVT (0.25 mg/kg)
223583499|NCT05052619|OTHER|Routine|Treat patients in this group with routine preventive usage of antibiocs: Cefmetazole 1g q12h, in postoperative days 1-3.
223477475|NCT06996301|DIAGNOSTIC_TEST|Treatment guided by the PCR results|Patients receive treatment prescribed by a blinded clinician, based solely on the PCR diagnostic results
223583500|NCT01537146|DRUG|Ropivacaine|Bolus infusion via catheter/6H for 24H
223583501|NCT01537146|DRUG|Ropivacaine|Intra operational bolus infusion. Bolus infusion via catheter /6H for 24H
223583502|NCT04340440|PROCEDURE|D1 lymphadenectomy|Radical gastrectomy with D1 lymphadenectomy
223583503|NCT04340440|PROCEDURE|D2 lymphadenectomy|Radical gastrectomy with D2 lymphadenectomy
223583504|NCT02037490|BEHAVIORAL|Grow2Gether|"Participants in this intervention will:~Participate in Facebook group of 6-12 peers for about 8 months, led by a professional group mentor.~Complete an intervention video activity approximately weekly:~1. View educational videos addressing topics related to healthy infant growth~2. Create photos/videos modeling healthy behaviors and post them to the group~3. Provide and receive feedback on posts~4. Be encouraged to share information with key caregivers of their child~Attend group party soon after enrollment, to meet peers and group leader in person."
223744601|NCT02734979|DEVICE|Biobridge and lymph node transfer|Biobridge is surgically implanted with conventional vascularized lymph node transfer surgery
223744602|NCT04536155|OTHER|questionnary SF36|"This is a validate questionnary:~Ware et al,1992, McHorney et al, 1993, McHorney et al, 1994 French version : Author : Alain Leplège; et coll. En 2001"
223744603|NCT04536155|OTHER|Hospital Anxiety and Depression Scale|this is a validate scale: author: Zigmond A.S., Snaith R.P. in 1983
223583505|NCT05623111|DRUG|Incobotulinumtoxin-A 100 UNIT Injection|Perineural injection
223583506|NCT05623111|DRUG|Saline|Placebo containing trace amounts of human albumin and sucrose, diluted with 5ml of sterile saline.
223583507|NCT00048750|DRUG|Micafungin|IV
223744604|NCT04536155|OTHER|Chronic Pain Acceptance Questionnaire|"This is a validate questionnaire:~Fish, R., McGuire, B.E., Hogan, M., Stewart, I. \& Morrison, T. (2010)."
223583508|NCT00048750|DRUG|Placebo|IV
223583509|NCT00563823|DRUG|vatalanib|
223583510|NCT04400929|DRUG|Sargramostim|Dosage for IV Leukine® injection: 125mcg/m2/day over a 4-hour period for up to 5 days.
223583511|NCT04400929|OTHER|Normal Saline 0.9%|IV normal saline 0.9% for 5 days
223583512|NCT03802539|DEVICE|Glass Liner|restoration of root caries according to two different protocols
223744605|NCT04536155|OTHER|digital pain scale|this is a validate scale A.N.A.E.S. February 1999
223744606|NCT03698474|DRUG|Natrium picosulfate / Magnesium citrate|bowel preparation formula
223744607|NCT03698474|DRUG|Polyethylene glycol / Ascorbic acid|bowel preparation formula
223744608|NCT03698474|DRUG|Natrium/ Kalium/ Magnesium sulfate|bowel preparation formula
224163166|NCT03365440|DEVICE|esoECG-3D catheter|Recording of esophageal ECGs with the investigational medical device (IMD). Recording of respiration with a commercial breathing sensor.
224163167|NCT00003519|DRUG|cyclophosphamide|
224163168|NCT00003519|DRUG|docetaxel|
224163169|NCT00003519|DRUG|doxorubicin hydrochloride|
224163170|NCT03674541|DRUG|Pyridostigmine Bromide|Pyridostigmine Bromide 60 mg capsule by mouth as a one time dose
224163171|NCT03674541|DRUG|Placebo|Placebo (Cellulose microcrystalline) capsule by mouth as a one time dose
224163172|NCT05706818|OTHER|Validity and reliability study|Validity and reliability assessment of the Community Integration Questionnaire-revised
224163173|NCT02035241|DIETARY_SUPPLEMENT|Spices 1|In this study, subjects are asked to consume 200 ml beverage drinks contain certain amounts of spices 1. Following 10 min. beverage consumption, subjects will be given standardized breakfast corresponding to 50 g carbohydrate.
224163842|NCT01037140|DRUG|placebo|oral placebo tablets similar to active comparator
224163843|NCT00676728|DRUG|JNJ-26481585|In Part 1, Initial dose of JNJ-26481585 4 mg oral capsule is administered once daily on each day of a 21-day cycle. Dose will be escalated or de-escalated until Maximum tolerated dose (MTD) of JNJ-26481585 is determined in Part 1. MTD of JNJ-26481585 will be the initial dose in Part 2.
224163844|NCT00865202|DRUG|L-tryptophan supplementation|L-tryptophan 1 gram enterally TID for a maximum of nine doses or to be discontinued at the time of discharge from the ICU (whichever occurs first)
223477476|NCT06996301|DIAGNOSTIC_TEST|Treatment guided by the C&S results|Patients receive treatment prescribed by a blinded investigator (clinician), based solely on the C\&S diagnostic results.
223477477|NCT03198845|OTHER|video game|20-min per session for 3 times per week for a 4-week duration
223744609|NCT03016247|BEHAVIORAL|TRUST Intervention|The TRUST intervention will be guided by Rotenberg's Framework of Interpersonal Trust 3. The TRUST group will meet with an interventionist trained in weight self-management for eight 90-minute weekly sessions. Each session will include adolescent/parent trust-building exercises (honesty, reliability, emotional connection), didactic content, experiential skills developing (nutrition label reading), behavior-change goal-setting, and problem-solving.
224163174|NCT02035241|DIETARY_SUPPLEMENT|Spices 2|In this study, subjects are asked to consume 200 ml beverage drinks contain certain amounts of spices 2. Following 10 min. beverage consumption, subjects will be given standardized breakfast corresponding to 50 g carbohydrate.
223477478|NCT03198845|OTHER|exercise|20-min per session for 3 times per week for a 4-week duration
223583513|NCT02604758|BEHAVIORAL|The Psychiatric Nursing Approach Based On The Tidal Model|To provide individualized care for patients in the experimental group, the One-to-One Sessions were initiated and interventions were performed in line with the goals of the persons and the aims of the research. The interventions were selected from interventions regarding with coping and self-esteem from the Nursing Interventions Classification(NIC) system.The One-to-One sessions help the person recognize change and focus the person on achievement and goals.Taking into account the basic process of the Tidal Model, care stages, the following interview plan was drawn up, containing the details of the interviews to be carried out with people with alcohol dependency, and the One-to-One Sessions were held in line with this plan two times per week.
223583514|NCT02483390|OTHER|psychosocial intervention|e-health services (e.g. by use of SKYPE) to the psychosocial needs of patients and their families who are getting services through home hospice care. In addition, the attitudes of the hospice staff will be investigated to the use of e-health methods.
223583515|NCT03612323|DRUG|Intra-ligamentary Piroxicam|Piroxicam is a long-acting potent analgesic non selective oxicams derivative, has a half-life of 50 hrs in the plasma.The onset of action of oral piroxicam is 2-4 hrs, but it is anticipated that injectable piroxicam could produce more rapid onset of action. It could favourably overcome the intense pain up to 48 hrs following the treatment
223583516|NCT03612323|DRUG|Intra-ligamentary Articaine|Articaine is a local anesthetic agent , has been reported to be an effective anesthetic in controlling pain during root canal treatment
223583517|NCT04887389|DRUG|Nano Silver Fluoride varnish|Nano Silver Fluoride(5%) is a new experimental formulation containing silver nanoparticles, chitosan and fluoride combines preventive and antimicrobial properties. It is a yellow solution and safe to be used in humans
223583518|NCT04887389|DRUG|nano-hydroxyapatite varnish|nano-hydroxyapatite (10%) has antibacterial effect, higher solubility, surface energy and bioactivity and its structure is similar to dental apatite.
223583519|NCT04887389|DRUG|sodium Fluoride Varnish|Fluoride varnish (5%) applied every six months is effective in preventing caries in the primary and permanent dentition of children and adolescents
223583520|NCT00663299|DEVICE|Endovascular Embolization Device|The TRUFILL DCS and TRUFILL DCS ORBIT Detachable Coils are each an embolic coil system that consists of a platinum detachable coil, a delivery system (delivery tube and coil introducer) and a syringe. Each system has been designed to deliver, position and detach embolic coils in order to embolize intracranial aneurysms
223744610|NCT03016247|BEHAVIORAL|Enhanced Usual Care|Single meeting with a Nutritionist for physical activity and eating counseling.
224163175|NCT02035241|DIETARY_SUPPLEMENT|Spices 3|In this study, subjects are asked to consume 200 ml beverage drinks contain certain amounts of spices 3. Following 10 min. beverage consumption, subjects will be given standardized breakfast corresponding to 50 g carbohydrate.
223477479|NCT01689597|DRUG|Morphine|Comparison of different dosages of drug
223477480|NCT01689597|DRUG|Placebo|
223477481|NCT01042418|OTHER|Effect of breakfasts with whole vs milled rye kernels on appetite|Iso-caloric portions of the three breakfast foods along with identical additional foods are tested in a cross over design
223477482|NCT05356364|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia (CBTI)|cognitive and behavioral treatment for perinatal insomnia.
223477483|NCT05356364|BEHAVIORAL|Perinatal Understanding of Mindful Awareness for Sleep (PUMAS)|Mindfulness and behavioral based therapy for perinatal insomnia.
223477484|NCT04030598|DRUG|Donidalorsen|Donidalorsen administered SC
223477485|NCT04030598|DRUG|Placebo|Placebo matching solution administered SC
224163176|NCT02035241|DIETARY_SUPPLEMENT|Herbs 1|In this study, subjects are asked to consume 200 ml beverage drinks contain certain amounts of herbs 1. Following 10 min. beverage consumption, subjects will be given standardized breakfast corresponding to 50 g carbohydrate.
224163177|NCT02035241|DIETARY_SUPPLEMENT|Herbs 2|In this study, subjects are asked to consume 200 ml beverage drinks contain certain amounts of herbs 2. Following 10 min. beverage consumption, subjects will be given standardized breakfast corresponding to 50 g carbohydrate.
223477486|NCT07005973|BEHAVIORAL|mobile-based mindfulness intervention|"Patients will be provided with usual care by surgeon, anesthetist and perioperative team, and they will be asked to install a validated mindfulness based mobile app during the PAS session. Orientation and teaching on the use of the mobile app will be carried out by research team. Return demonstration by patients will be performed at the end to ensure they are capable to use the app at home independently.~A minimum of 4-week intervention duration with session lengths of 1 min, 3 days per week is set for this study.~Patients will be distributed a dairy log to record the frequency and duration of mindfulness practice and submit to the researcher on the day of admission. Follow up on patient's progress through phone call or whatsapp will be provided by the researcher to ensure patient's adherence to the intervention on a bi-weekly basis."
223477487|NCT03658980|BEHAVIORAL|Health Education Intervention|Face-to-face health education intervention on Diabetic Retinopathy and available services at a tertiary hospital, followed by telephonic reminder at Day 7, 30 and 90.
223744611|NCT04640090|BEHAVIORAL|Smartphone app (Wysa)|The commercially available smartphone application, Wysa, offers evidence-based wellness tools such as supportive listening, deep breathing techniques, guided meditation, yoga, and more. Users can communicate via text to a virtual artificial intelligence (AI) chatbot and/or a human well-being coach.
224163178|NCT02035241|DIETARY_SUPPLEMENT|Control drink|As a control, subjects are asked to consume 200 ml control drinks. Following 10 min. beverage consumption, subjects will be given standardized breakfast corresponding to 50 g carbohydrate.
224163179|NCT03169114|DRUG|Amikacin Injection|Participants allocated to Antibiotic Non-operative Management Strategy will be given intravenous Amikacin 15mg/kg/day divided over 3 doses for first 48 hours and followed by oral ciprofloxacin 500mg bd for 7 days
224163180|NCT03169114|PROCEDURE|Appendicectomy|Patients allocated to Surgery Management Strategy will undergo appendicectomy
224163181|NCT05258981|DIAGNOSTIC_TEST|MRI|Brain MRI
224163182|NCT05560295|PROCEDURE|Naser Al-Husban|uterine surgery
223477488|NCT01383278|BEHAVIORAL|Computer-directed 5 A's intervention for smoking|Computer-directed 5 A's intervention for smoking
223477489|NCT01383278|BEHAVIORAL|Screening and resource provision|Screening and resource provision
223477490|NCT07014137|DRUG|ABSK043 single agent|ABSK043 BID continuously for 28 day cycle
223477491|NCT06686420|DIETARY_SUPPLEMENT|B. longum|On the first day of the intervention period, participants will be instructed to consume two capsules of the live B. longum strain daily with a glass of water before breakfast for the next eight weeks.
223477492|NCT06686420|DIETARY_SUPPLEMENT|Placebo|On the first day of the intervention period, participants will be instructed to consume two capsules, which are without any live bacteria, daily. They should take these before breakfast with a glass of water, for the following eight weeks.
223477493|NCT06094816|DRUG|Furosemide (Diuretic)|The diuretic furosemide will be given during a 3% hypertonic saline infusion to examine blockade of the NKCC2.
223477494|NCT06094816|OTHER|Hypertonic Saline Infusion|3% Hypertonic saline infusion to acutely increase sodium and osmolality
223477495|NCT03251365|DRUG|HIPEC-gemcitabine|• Group II.After a R0 cytoreductive surgery, HIPEC is performed with gemcitabine, 120mg / m2 for 30' + adjuvant treatment with iv gemcitabine , 1000 mg / m2 for at least 4 cycles
223477496|NCT01916200|DRUG|Paroxetine CR|Paroxetine CR will be provided by GlaxoSmithKline (GSK) and be available as 12.5 mg over-encapsulated tablets with the research use only label outside the package. Paroxetine CR should be administered as a single daily dose, with or without food. The recommended initial dose is 25 mg/day. Patients were dosed in a range of 25 mg to 62.5 mg/day in the clinical trials demonstrating the effectiveness of paroxetine CR in the treatment of major depressive disorder. As with all drugs effective in the treatment of major depressive disorder, the full effect may be delayed. Some patients not responding to a 25-mg dose may benefit from dose increases, in 12.5 mg/day increments, up to a maximum of 62.5 mg/day. Dose changes should occur at intervals of at least 1 week.
223477497|NCT05814107|DRUG|CT-996|Capsule of CT-996
223477498|NCT05814107|DRUG|Placebo|Capsule of placebo matching CT-996.
223477499|NCT03908411|PROCEDURE|Paratracheal pressure|Paratracheal pressure is applied by 30N force with the ultrasound transducer.
223477500|NCT03908411|PROCEDURE|Sellick's maneuver|Conventional Sellick's maneuver is applied by 30N force
223477501|NCT07034950|DRUG|Intravenous esketamine using Dixon's up-and-down sequential method|Using Dixon's up-and-down sequential method, esketamine will be titrated intravenously from an initial 0.3 mg∙kg-1 dose with 0.02 mg∙kg-1 adjustments based on intraprocedural responses to pain (Positive: purposeful somatic movement or the complaint of pain; Negative: no movement or no complaint of pain). The titration sequence will continue until six crossover inflection points are observed.
223477502|NCT07034950|DRUG|Intravenous the dose of esketamine ED95|The intervention group will be injected with the dose of esketamine ED95.
223477503|NCT07034950|DRUG|Intravenous fentanyl 1 μg∙kg-1|The control group will be injected with fentanyl 1 μg∙kg-1.
223583521|NCT02927275|BEHAVIORAL|Experimental: Standing Modality|Cognitive performance when standing
223583522|NCT02927275|BEHAVIORAL|Experimental: Biking Modality|Cognitive performance when biking slowly
223583523|NCT02927275|BEHAVIORAL|Experimental: Walking Modality|Cognitive performance when walking at 1mph
223583524|NCT02927275|BEHAVIORAL|No Intervention: Seated Modality|Cognitive performance when sitting.
223583525|NCT01965223|RADIATION|Multi-fraction SABR|Multi-fraction SABR; 48Gy delivered in 4 fractions, delivered over 2 weeks, with each fraction delivered 48 hours apart.
223583526|NCT01965223|RADIATION|Single Fraction SABR|Single fraction SABR; 28Gy delivered in 1 fraction
223583527|NCT00135252|PROCEDURE|nasal cannula oxygen delivery|
223583528|NCT00135252|PROCEDURE|supplemental oxygen delivery by hood|
223583529|NCT04319744|OTHER|other|Our hypothesis is that playing video games may have positive effects on videostile use, but there is no research on this subject Our goal is to compare the performances of anesthesia assistants who have played video games with those who did not.
223583530|NCT04051554|OTHER|Neuromuscular and Proprioceptive Training|Myklebust's training program (floor exercises, mat exercises, and wobble board exercises for 5 weeks)
223583531|NCT04051554|OTHER|Conventional Training|Running, Sprinting, Agility training and Dynamic stretching for five weeks
223583532|NCT01708447|DRUG|L.M.X.4.® cream|A lidocaine topical anesthetic cream
223583533|NCT01708447|OTHER|A placebo cream|Placebo cream containing no anesthetic properties.
223583534|NCT01708447|DEVICE|Ulthera System Treatment|Focused ultrasound energy delivered below the surface of the skin
223583535|NCT05274360|BEHAVIORAL|Mobile evidence-based aphasia therapy|Use of mobile application to practice language for 2 weeks with a recommendation of 2 sessions per day of 20 minutes. The Android application, which is a Unity-based 2D game, will be installed on the patient's own phone, and they will play individually with the support of a family member if needed. The patients are free to start and stop using the application at any time. The application is safe to use, and it consists of therapeutic training methods such as object-matching, word search, writing, and manual voice recordings.
223583536|NCT05274360|BEHAVIORAL|Conventional aphasia rehabilitation|Control Group (conventional aphasia rehabilitation). No therapy as patients are in the chronic stage, where they do not receive healthcare rehabilitation training.
223583537|NCT02142036|DRUG|EMA-approved ATI based targeted therapy|All drugs that may be used in the study are approved by EMA for treatment of disseminated cancer in the palliative setting, but not for the particular tumor type in question.
223583538|NCT06267638|DRUG|Ketamine group|Participants will receive intraoperative ketamine during total knee arthroplasty
224163183|NCT06482255|OTHER|manual therapy and therapeutic exercise|"* Soft tissue massage~* Mobilization of the glenohumeral joint~* Scapular retraining Therapeutic Exercise"
224163184|NCT06482255|OTHER|manual therapy and therapeutic exercise and virtual reality|"* Soft tissue massage~* Mobilization of the glenohumeral joint~* Scapular retraining Therapeutic Exercise~* virtual reality"
223477504|NCT03717597|BEHAVIORAL|Intervention|"Subjects will attend a series of 2 hour classes, once a week for 10 weeks. Topics discussed in group sessions will cover compensation strategies (e.g., calendar, goal setting and task lists, functional zones) and brain health behaviors (e.g., exercise, cognitive activity, stress reduction and mindfulness).~Subjects may be asked to wear an actigraphy monitor (that looks like a wrist watch) and/or heart rate sensor that is designed to collect information regarding physical activity."
223477505|NCT03668210|PROCEDURE|Isokinetic evaluation|Isokinetics is used to measure the peak of strength of quadriceps and hamstrings, in concentric or eccentric, at slow and fast speed to determine a hamstring / quadriceps ratio to highlight a deficit or imbalance.
223477506|NCT03335345|OTHER|maintaining calorie intake|Maintaining enteral caloric intake at the same rate. No aspiration in the gastric tube.
223477507|NCT03335345|OTHER|maximum gastric vacuity|stopping enteral feeding at least 6 hours before extubation. Suction in the gastric tube (if its caliber permits) continuously for 6 hours before extubation
223477508|NCT05401721|DIAGNOSTIC_TEST|Serum copeptin|Blood test
223477509|NCT02097823|DRUG|Olanzapine|
223477510|NCT02097823|DRUG|Aprepitant|
223477511|NCT01941394|BIOLOGICAL|Mesenchymal stem cells|Mesenchymal stem cells infusion
223477512|NCT00173628|PROCEDURE|blood drawing|
223477513|NCT00747916|DEVICE|CryoSpray Ablation (TM) System|Subjects will be treated with spray cryotherapy using the CryoSpray Ablation (TM) System at Day 0 using up to 3 cycles of 10-40 second sprays as the studied dosimetry and will cover the affected area, including the tumor and the parietal pleural surface. If disease exists bilaterally, only one side will be sprayed. Subjects will be assessed 2-5 days from the initial treatment (Day 0) to check for mucosal sloughing, to reassess tumor burden and for additional CSA therapy as needed.
223477514|NCT02025283|PROCEDURE|Group Decompression or Group Nucleoplasty|Group Decompression: Decompression with flexible intradiscal decompression catheter (SpineCATH®, Smith \& Nephew, Memphis, TN) Group Nucleoplasty: Nucleoplasty with radiofrequency-compatible needle (Coblation: Perc DLE SpineWandTM \[ArthroCare Spine, Sunnyvale, CA\]
223477515|NCT02107846|DRUG|PRX-112|
223583539|NCT06267638|DRUG|Placebo group|Participants will receive intraoperative normal saline during total knee arthroplasty
223583540|NCT04073160|DRUG|Tremelimumab|Tremelimumab and durvalumab will be administered in combination during cycles 1 and 2. Tremelimumab will be administered intravenously at a dose of 75 mg on cycle 1 day 1 and cycle 2 day 1. Cycles are 4 weeks long.
224163185|NCT05482555|PROCEDURE|Percutaneous arteriotomy closed using a plug-based arteriotomy closure device|Percutaneous arteriotomy closed using a plug-based arteriotomy closure device (MANTA, Essential Medical Inc., Malvern, Pennsylvania).
224163186|NCT05482555|PROCEDURE|Surgical cut-down and arterial puncture under direct vision|Surgical cut-down and arterial puncture under direct vision.
224163187|NCT05882123|OTHER|cerebral microbleeds|Whether patients with acute ischemic stroke are complicated by cerebral microbleeds
224163188|NCT05579795|PROCEDURE|Detethering of the spinal cord|Release of the tethered spinal cord
223477516|NCT02974933|DRUG|Apatinib combined with pemetrexed|For those pretreated non-squamous non-small cell lung cancer, treat with apatinib 500mg Qd, po.combined with pemetrexed continue until disease progression
223477517|NCT03456245|DEVICE|Vision device validation|Group members had their vision tested with the following devices/methods: Eyenetra NETRA, PlenOptika Quicksee, Right Manufacturing Retinomax K Plus 3, and standard eyesight tests using eye charts, phoropters, and slit lens lamp imaging.
223583541|NCT04073160|DRUG|Durvalumab|"Tremelimumab and durvalumab will be administered in combination during cycles 1 and 2. Durvalumab will be administered intravenously at a dose of 1500 mg on cycle 1 day 1 and cycle 2 day 1. Cycles are 4 weeks long.~Eligible subjects may go on to receive a combination of durvalumab and bladder radiation during cycles 3 and 4. Durvalumab will be administered intravenously at a dose of 1500 mg on cycle 3 day 1 and cycle 4 day 1.~At the completion of radiation, eligible subjects may continue to receive durvalumab for a maximum of one year from the date of their initial dose. Durvalumab will be administered intravenously at a dose of 1500 mg on the first day of each cycle."
223583542|NCT04073160|RADIATION|Bladder radiation|During the durvalumab cycles 3 and 4, eligible subjects will receive 6.5 weeks of radiation to the bladder. Radiation will be administered at a dose of 64 Gy in daily 2 Gy fractions.
223583543|NCT04073160|DRUG|Intravesicular Therapy|Subjects will receive intravesicular therapy, if clinically indicated during cycles 5 and beyond of durvalumab administration. Intravesicular therapy will consist of BCG, gemcitabine, mitomycin or a similar drug, depending on institutional standards and treating provider's discretion.
223744612|NCT04777708|BIOLOGICAL|Nanoplexed Poly I:C BO-112|Given by intratumoral injection
223744613|NCT04777708|BIOLOGICAL|Pembrolizumab|Given IV
224163189|NCT05104749|DRUG|Homeopathic Medication|Homeopathic medicines are prepared according to standardized methods as specified by the Homeopathic Pharmacopoeia of the United States (HPUS), which was mandated by Congress to regulate the manufacture of homeopathic medicines as part of the Food, Drug, and Cosmetics Act of 1939. All homeopathic medicines prescribed in this study must be found in the HPUS. For a complete list of homeopathic medicines, contact the researchers.
224163190|NCT05104749|OTHER|Placebo|Inert lactose pellets
224163191|NCT02980549|OTHER|children's sleep habits questionnaire|survey of children's sleep habits completed by parent
224163192|NCT05225506|BEHAVIORAL|Exercise|Exercise sessions will be one hour in duration and be a combination of resistance, aerobic, and balance exercise, with emphasis on movements specifically targeting common deficits seen in Parkinson's.
224163193|NCT06373536|DIAGNOSTIC_TEST|Thermoacoustic imaging, MRI and Ultrasound imaging|This is a Thermoacoustic imaging exam that will last 10-15 minutes. Distinguishing; assessment of steatosis liver disease in obese and morbidly obese patients.
224163194|NCT04072536|DEVICE|Electric wheelchair with activated assistance module|This evaluation will be carried out in 3 standardized test circuits of increasing difficulty, one week apart. At each session, the patient will perform the circuit 6 times, including 3 with activated assistance
223477518|NCT05817162|DRUG|Ropivacaine injection|Ropivacaine is a local anesthetic that has been synthesized for use in infiltration anesthesia and to produce both peripheral and central block. Unlike one of its analogues, Bupivacaine, Ropivacaine anesthetize the sensory fibers without affecting the without affecting the motor ones. Ropivacaine comes as solution for injection.
223477519|NCT05817162|PROCEDURE|temporomandibular joint arthrocentesis|Temporomandibular arthrocentesis is a minimally invasive surgical procedure, which aims to eliminate the inflammatory mediators from the inside of the TMJ.
223477520|NCT05817162|DRUG|PRP injection|Platelet-Rich Plasma (PRP) is an orthobiological adjuvant treatment. PRP has properties to restore intra-articular hyaluronic acid, increases glycosaminoglycan chondrocyte synthesis and balances joint angiogenesis. It is often used as a viscosupplement in TMJ arthrocentesis
223477521|NCT05817162|DRUG|Ringer's Lactate solution|Ringers lactate solution is used during arthrocentesis to wash out the joint inflammatory cells and to release the stuck disc phenomenon.
223477522|NCT05328960|OTHER|Diagnosed during or not during the pandemic|We will create a group of patients that are diagnosed before and after the pandemic and one group diagnosed during the pandemic
223477523|NCT06107998|OTHER|stethoscope|endotracheal tube cuff will be inflated via stethoscope guidance
223477524|NCT06107998|OTHER|Audible leak/Balloon palpation|endotracheal tube cuff will be inflated via audible leak/balloon palpation method
223477525|NCT02991001|PROCEDURE|Ultrasound-guided hydrodissection|Ultrasound-guided hydrodissection with 5cc normal saline between carpal tunnel and median nerve.
223477526|NCT02991001|PROCEDURE|Placebo ultrasound-guided injection|Ultrasound-guided injection with 5cc normal saline at subcutaneous layer beyond carpal tunnel
223477527|NCT02991001|DEVICE|Ultrasound|
223477528|NCT02991001|DRUG|Normal Saline|
223477529|NCT02511301|DEVICE|Cyrcadia CBR™ device placement for abnormality screening|Cyrcadia CBR™ device, including adhesive patches on both breasts connected to a small recorder, is placed on the study subject for 2 to 24 hours. After the test period, the CBR™ will be removed and the data will be downloaded to a central site for analysis. There are no interventions after the CBR™ is removed from the Study Subject.
223477530|NCT05348304|DIETARY_SUPPLEMENT|EUDIAMET|A combination of myo-inositol and D-chiro-inositol in the 40:1 ratio, Gymnema sylvestre, alpha-lactalbumin and zinc
223477531|NCT03614104|BEHAVIORAL|Mobile Health Technology (short message service)|Health education through mobile technology with Short Message Service (SMS)
223477532|NCT00000972|BIOLOGICAL|MTP-PE/MF59|
223477533|NCT00000972|BIOLOGICAL|Env 2-3|
223744614|NCT05890040|OTHER|questionnaire|assessment of anxiety
224163195|NCT04072536|DEVICE|Electric wheelchair with assistance module not activated|This evaluation will be carried out in 3 standardized test circuits of increasing difficulty, one week apart. At each session, the patient will perform the circuit 6 times, including 3 with no activated assistance
224163196|NCT03870906|BEHAVIORAL|Occupational-specific health talk|Health talk will provide information about hazards of tobacco (active smoking, second- and third-hand smoke), benefits of quitting smoking and methods to quit smoking.
224163197|NCT03870906|BEHAVIORAL|WhatsApp interaction|Individual WhatsApp interactions last 3-month and consist of 2 parts. First part is regular WhatsApp message. The schedule will be adjusted according to the participants' quitting status. Second part is real-time discussion intervention based on participants' socio-demographic characteristics, smoking habit at baseline and updated smoking status obtained during online conversation. At 3-month follow-up, participants who are still smoking are encouraged to join an additional 1-month online group chat moderated by a smoking cessation counselor.
223477534|NCT01953991|DEVICE|Dentures|Removable prosthesis to replace missing teeth
223477535|NCT05892237|PROCEDURE|bronchial artery interventional therapy|After successful anesthesia, right femoral artery puncture was performed by Seldinger method. 5F-Yashrio catheter is chosen to locate the bronchial artery of the diseased side at the level of the thoracic aortotracheal bifurcation. Angiography was performed (Osu 300mg/ml, 3ml/s, total 8ml, 200Psi) to visualize tumor blood supply artery before infusion of chemo+PD-1 inhibitor and embolism.
223477536|NCT05892237|DRUG|Chemotherapy drug|Nano-paclitaxel 260 mg/m2, d1, ivgtt, q3w+Cisplatin 75mg/m2, d1, ivgtt,q3w.
223477537|NCT05892237|RADIATION|IMRT|60Gy/2Gy/30f
223477538|NCT05892237|DRUG|Immunotherapy|PD-1 inhibitor (Tirelizumab) 200mg, d1, ivgtt, 30-60min, q3w.
223477539|NCT00660452|DRUG|Staloral|Sublingual immunotherapy with Staloral dust mites solution
223477540|NCT04494698|DEVICE|Duotherm VibraCool Back Device|Active New multimodal pain device
223477541|NCT04494698|DEVICE|TENS 8-channel unit|LG Smart TENS unit
224163198|NCT03870906|BEHAVIORAL|Phone follow-up/counselling service|The intervention outcomes and participants' smoking status will be followed up regularly via telephone interviews (15 - 30 minutes).
223477542|NCT01320397|DRUG|Rostafuroxin|6 microgram capsules
223477543|NCT01320397|DRUG|Rostafuroxin|50 micrograms capsules
223477544|NCT01320397|DRUG|Rostafuroxin|500 micrograms capsules
223477545|NCT01320397|DRUG|Losartan|Losartan 50 mg once a day
223477546|NCT01150682|GENETIC|RNA analysis|
223477547|NCT01150682|GENETIC|reverse transcriptase-polymerase chain reaction|
223477548|NCT01150682|OTHER|enzyme-linked immunosorbent assay|
223477549|NCT01150682|OTHER|immunohistochemistry staining method|
223477550|NCT01150682|OTHER|laboratory biomarker analysis|
223477551|NCT05417750|DRUG|TIL therapy|A tumor sample is resected from each participant and cultured ex vivo to expand the population of autologous tumor infiltrating lymphocytes injection (GC101 TIL). After lymphodepletion, patients are infused GC101 TIL followed sintilimab.
223477552|NCT05360290|DEVICE|GILUPI CellCollector®|Use of GILUPI CellCollector® to detect CTC
223477553|NCT01765322|DEVICE|ZILOS-TK IVOS Analyzer|The subjects are going to participate the treatment of assisted hatching in vitro fertilization by Zona Infrared Laser Optical System (ZILOS-TK,Hamilton Thorne Biosciences,USA)
223477554|NCT06517199|DRUG|Olanzapine 2.5 MG|olanzapine 2.5 mg/day for 28 days
223477555|NCT06517199|DRUG|Olanzapine 5 MG|olanzapine 5 mg/day for 28 days
223477556|NCT06517199|DRUG|Placebo|placebo 1 tab/day for 28 days
223477557|NCT00959751|DRUG|NXN-188|200 mg capsules, 600 mg, PRN
223477558|NCT00959751|DRUG|Placebo|200 mg capsules with no active ingredient designed to match the NXN-188 capsules
223477559|NCT01735812|DEVICE|IceSense3 system|The IceSense3™ is a modern cryosurgical device that was designed by IceCure Medical for a variety of applications.
223477560|NCT05681988|PROCEDURE|Early minimally invasive image guided endoscopic hematoma evacuation|The intervention group will first receive BMT (as defined below) upon admission and early minimally invasive image guided endoscopic hematoma evacuation as an add-on therapy to BMT. Surgery will be performed within 6-24 hours after SSICH symptom onset. Surgery will be performed in an emergency operating theatre or a hybrid operation theatre equipped with intraoperative CT (in hybrid OR), neuronavigation, and neuro-endoscopy.The position and progress of the trocar towards the hematoma cavity will be monitored with neuro-navigation. The endoscope (LOTTA® system, Karl Storz Endoscopes, Germany; Minop®, BBraun, Tuttlingen, Germany or equivalent) will be inserted into the trocar and tracked using neuro-navigation. Using the pre-planned trajectory, the hematoma will be entered. Using continuous suction and irrigation, the hematoma will be aspirated and/or washed out.
223477561|NCT05681988|PROCEDURE|Best medical treatment (BMT)|The control group will receive the current gold standard treatment for SSICH according to the guidelines (BMT). This involves strict blood pressure control (SBP\<140mmHg), if needed with intravenous or intraarterial blood pressure lowering agents, reversal of anticoagulation if applicable, intensive care surveillance and nursing on a ICU or stroke unit, control of seizures as well as glucose levels as needed and neurointensive monitoring if deemed necessary
223477562|NCT01588275|DEVICE|mandibular repositioning appliance (MRA) (SomnoDent)|bibloc MRA type SomnoDent starting at 70% protrusion of the mandibula
223477563|NCT01588275|PROCEDURE|Continuous positive airway pressure (CPAP)|Proper CPAP-pressure will be set for each patient separately.
223477564|NCT06217471|PROCEDURE|Carotid Endoarterectomy|Surgical removal of atherosclerotic plaque from the carotid artery, collection of blood samples
223477565|NCT04512989|DIAGNOSTIC_TEST|Cognitive assesment using MOCA test|Cognitive assesment using MOCA test
223477566|NCT01269294|DRUG|TMC435|2 capsules of 75 mg once daily for 7 days in Treatment A
223477567|NCT01269294|DRUG|Placebo for TMC435|4 placebo capsules once daily for 7 days in Treatment C
223477568|NCT01269294|DRUG|TMC435|2 capsules of 75 mg and 2 capsules of 100 mg once daily for 7 days in Treatment B
223477569|NCT01269294|DRUG|Placebo for TMC435|2 placebo capsules once daily for 7 days in Treatment A
223477570|NCT01269294|DRUG|Moxifloxacin|1 tablet of 400 mg on Day 7 of Treatment C
223477571|NCT01269294|DRUG|Placebo for moxifloxacin|1 placebo tablet on Day 7 of Treatments A, B and D
223477572|NCT01269294|DRUG|Placebo for TMC435|4 placebo capsules once daily for 7 days in Treatment D
223477573|NCT04217759|BEHAVIORAL|Healthy lifestyle intervention|"The main goal was to provide knowledge and skills for targeted population in order for them to adapt healthy lifestyle throughout their life. At the end of intervention, participants were expected to be fully equipped with necessary knowledge and fundamental skills in adapting and maintaining healthy lifestyle throughout their life. Gradual improvements were emphasised and at least 5% loss of initial body weight was expected, aiming for at least 0.5% loss in the first month.~It was divided into three phases (preparation, implementation, maintenance) focusing on PA and diet, in which self-efficacy enhancement and self-regulatory skills were emphasised during the first month of intervention."
223477574|NCT05401175|OTHER|Autologous blood transfusion with haematopoietic stem cells|Transfusion of autologous blood containing haematopoietic stem cells for haematopoietic reconstruction after chemoradiotherapy.Blood tests were performed weekly, if the patient's neutrophils were less than 1.0 × 109 / L during chemoradiotherapy, G-CSF was given as a remedial treatment. If fever occurs, antibiotics were given promptly.Monitor peripheral blood after transfusion. If peripheral blood leukocyte count does not reach 1.0 x 109/L, administer G-CSF 150 μg subcutaneously daily until peripheral blood leukocyte count reaches 1.0 x 109/L.Patients were tested monthly for peripheral blood cells for 6 months after the end of treatment.
223477575|NCT00176735|DRUG|Capecitabine|
223477576|NCT03667521|PROCEDURE|nerve-sparing laparaoscopic sacrocolpopexy|nerve-sparing laparaoscopic sacrocolpopexy implemented after 2010
223477577|NCT01147796|DEVICE|computed tomography|64 slices CT with iodine injection
223583544|NCT05577546|OTHER|Moor S brace treatment|The rigid MOOR-S Brace controls the thoracic, lumbar and pelvis blocks very tightly, is modelled and produced according to deformity type and patients body size considering the standardization of the MOOR-S Model. It is a CAD-CAM design-based rigid torocolumbosacral orthosis, using polypropylene material, which is opened from the front, and tightness can be adjusted by the patients with the help of straps. Additional corrective forces can be applied with pads that can be added to the brace. The amount of corrective forces in the MOOR-S brace is decided by the experienced orthotist, taking into account risk of progression, the flexibility of the spine deformity, Cobb angle, bone maturation and age. An external stimulus is provided that directs the protracted shoulder to slightly to the posterior by the shoulder part, located on the anterosuperior side of the brace.
223744615|NCT02255981|OTHER|Acupuncture and massage|"Treatment consists in to put needles on specific points of skin one day each week initially, then with longer spaces of time according to improvement.A total of 11 Chinese needles stainless steel, 25 x 40 were used by manual insertion and left for 12-15 minutes.~Periocular massage is taught and is practiced daily by the patient him or herself."
223744616|NCT02884596|DRUG|selective serotonin reuptake inhibitor|Taking any type of SSRI medicaments
223744617|NCT04765579|BEHAVIORAL|visual analogy scala|We will investigate the effect of 4in1 block by questioning the vas score of the patients, its effect on quadriceps strength, and additional analgesia needs for 24 hours.
223477578|NCT01147796|DEVICE|computed tomography|64 slices CT with iodine injection
224163199|NCT03870906|BIOLOGICAL|Text message|Participants will receive regular text messages with similar frequency to those in the intervention group.
223477579|NCT06516224|OTHER|Liftactiv® B3 Serum|In Group 1: Application once daily for 6 months, 3-4 drops twice a day (morning before the sunscreen and evening) In Group 2 and Group 3: Application once daily, 3-4 drops twice a day (morning before the sunscreen and evening) for 3 months following HQ4% or Kligman Trio treatment.
223744618|NCT03888196|DIETARY_SUPPLEMENT|Panax Ginseng Supplementation|500 mg/day of Panax Ginseng
223744619|NCT03888196|DIETARY_SUPPLEMENT|Placebo Supplementation|500 mg/day of Cellulose
224163845|NCT00865202|DRUG|placebo|Similar appearing placebo administered post-operatively (1 enterally TID) for a total of nine doses or discharge from ICU (whichever occurs first)
224163846|NCT02865928|DRUG|Bupivicaine HCl|Ultrasound guided serratus plane block with bupivicaine
223477580|NCT06516224|OTHER|Liftactiv® B3 retinol night cream|In Group 1: Application once daily (morning) for 6 months In Group 2 and Group 3: During week 1, apply 2 evenings/week. During week 2, apply every other evening. During week 3, apply every evening. During nights when retinol night cream is not applied, replace with Mineral 89 cream for 3 months following HQ4% or Kligman Trio treatment.
223477581|NCT06516224|OTHER|Sunscreen UVAage® Inter SPF 50+|twice daily (morning and beginning of the afternoon)
223477582|NCT06516224|OTHER|Mineral 89 cream|2 drops in the morning before sunscreen application for 6 months
223477583|NCT04111302|OTHER|IV-PCA|IV-PCA contains dezocine 10mg, sufentanil 100ug, metoclopramide 20mg and normal saline are prepared into 100ml solution and pumped evenly at the speed of 2ml/h.
223477584|NCT04111302|OTHER|IV-dezocine|IV-dezocine contains dezocine 5mg and 250ml normal saline are made into solution and injected intravenously twice a day for 3 consecutive days after surgery.
223477585|NCT04111302|OTHER|IV-PCA+AA|IV-PCA contains dezocine 10mg, sufentanil 100ug, metoclopramide 20mg and normal saline are prepared into 100ml solution and pumped evenly at the speed of 2ml/h. And selecting the auricular points TF4, AH6a, HX2, HX5, CO4, AT4 and cowherb seeds will be attached to each auricular point after the auricle skin is disinfected. The participants will be asked to press the cowherb seeds against the auricular points every 2 hours during waking hours; each point is stimulated for one minute. Auricular points are pressed unilaterally, and the cowherb seeds will be replaced with new ones every 2 days, alternating from left to right.
223477586|NCT04111302|OTHER|IV-dezocine+AA|IV-dezocine contains dezocine 5mg and 250ml normal saline are made into solution and injected intravenously twice a day for 3 consecutive days after surgery.And selecting the auricular points TF4, AH6a, HX2, HX5, CO4, AT4 and cowherb seeds will be attached to each auricular point after the auricle skin is disinfected. The participants will be asked to press the cowherb seeds against the auricular points every 2 hours during waking hours; each point is stimulated for one minute. Auricular points are pressed unilaterally, and the cowherb seeds will be replaced with new ones every 2 days, alternating from left to right.
223744620|NCT03066674|OTHER|McKenzie group|Mobilization for lumbar spine,TENS,Exercises,Postural education ,Home exercises program.
223744621|NCT03066674|OTHER|Control group|TENS,Exercises,Postural education ,Home exercises program.
223744622|NCT02204787|DEVICE|transcranial direct current stimulation|
224163200|NCT02360449|BEHAVIORAL|Social Initiation Motivation Intervention|The SIMI approach under investigation uses behavioral strategies based in Applied Behavior Analysis and Pivotal Response Treatment to motivate children with ASD to initiate to peers. The adult arranges the play environment in order to promote cooperation and facilitates frequent prompting and reinforcement from peers, thereby enhancing the reward value of peer interactions.
224163201|NCT01639300|BIOLOGICAL|GNbAC1|Single dose intravenous (IV) GNbAC1 2mg/kg or 6mg/kg
224163202|NCT01639300|BIOLOGICAL|GNbAC1 placebo|Single dose intravenous (IV) GNbAC1 placebo
224163203|NCT04130100|BIOLOGICAL|Low Dose of Mesenchymal stem cell|Mesenchymal stem cell injection
224163204|NCT04130100|BIOLOGICAL|High Dose of Mesenchymal stem cell|Mesenchymal stem cell injection
224163205|NCT04130100|DRUG|Sodium Hyaluronate|Sodium Hyaluronate injection
224163206|NCT04884906|BIOLOGICAL|Camrelizumab|200mg/m2, iv, d1, Q3W, a total of 6 cycles
224163207|NCT04884906|RADIATION|radiotherapy|1.8-2.15Gy/time (radiotherapy started on the 8th day of camrelizumab treatment), a total of 28 times (5 times a week), a total of 50.4-60.2Gy.
224163208|NCT04884906|DRUG|Albumin Paclitaxel|260mg/m2, iv, d1, Q3W, a total of 6 cycles
223477587|NCT00900562|DRUG|Zalypsis ( PM00104)|Zalypsis (PM00104) (2.5 mg/vial) is provided as a powder for concentrate for solution for infusion
223477588|NCT03502824|DEVICE|PuraPly® Antimicrobial Wound Matrix|PuraPly® AM is a class II medical device, that has been 510(k) cleared by US Food and Drug Administration (FDA) (K051647) and is intended for the management of acute and chronic wound management across a variety of wound types, including partial- and full-thickness wounds, pressure ulcers, surgical wounds, trauma wounds, venous and diabetic ulcers.
223477589|NCT03502824|OTHER|SOC for Pressure Ulcers|SOC group will receive institutional standard of care which includes, but is not limited to, debridement, negative pressure wound therapy (i.e. VAC), ensuring perfusion and oxygenation, evaluating nutritional status and addressing deficits, offloading, keeping the ulcer bed moist with appropriate cleansing at the time of each dressing change. Standard dressings may include hydrocolloids, alginates, transparent film, foam, moist gauze dressings. In addition, a non-toxic topical antiseptic, may be used per NPUAP Clinical Practice Guidelines (2014) for SOC group only, if colonization is suspected.
223744623|NCT01056809|PROCEDURE|Chemotherapy and surgery|Treatment not specified but in accordance with national guidelines
223744624|NCT04335279|OTHER|SPIN-CHAT Program|Each session will include 3 segments: (1) engagement via therapeutic recreation activities (20-30 minutes); (2) education on information management and anxiety management through psychological and other strategies (20-30 minutes); and (3) open discussion and social support (20-30 minutes). Educational segment topics will include (1) healthy information management and social connection (session 1); (2) managing worry (sessions 2, 6, 10); (3) relaxation strategies (sessions 3; 7, 11); (4) adapted home exercise (sessions 4, 8, 12); and (5) activity engagement at home (sessions 5 and 9). All educational segments will be supported by resource materials available to participants via an online SPIN-CHAT resource link. Supervision and support of group moderators will be provided by a trained social worker. Educational segments in each session will be delivered by a research team member with experience and training related to the topic.
224163209|NCT04884906|DRUG|Cisplatin|80-120mg/m2, iv, d1-3, Q3W, a total of 6 cycles
224163210|NCT02799628|BEHAVIORAL|intervention|intervention with recommendation and therapist introduction
224163211|NCT02799628|OTHER|placebo|low back pain education, and physical therapy 3 times per week
224163212|NCT03964493|DRUG|TNP-2092|TNP-2092 100mg/vial
224163213|NCT03964493|DRUG|Vancomycin|Vancomycin 1g/vial
224163214|NCT03632551|OTHER|Specific binaural hearing evaluations|Specific binaural hearing evaluations (recognition of sentences in noise, sound source localization) and quality of life (SSQ questionnaire) will be carried out. Thereafter, the electroencephalographic examination will be performed
224163215|NCT02748278|PROCEDURE|Transvaginal ultrasound-guided oocyte retrieval|Transvaginal ultrasound-guided oocyte retrieval will be performed 34-36 hours after hCG injection.
224163216|NCT02748278|PROCEDURE|Embryo transfer|One or two embryos will be replaced on day 2-5 after oocyte retrieval.
224304867|NCT03548064|BIOLOGICAL|Recombinant Double Mutant Heat-Labile Toxin LT(R192G/L211A) (dmLT) Oral enterotoxigenic Escherichia coli (ETEC) Vaccine|LT(R192G/L211A), or dmLT is a derivative of wild-type enterotoxigenic Escherichia coli heat-labile enterotoxin that has been genetically modified by replacing the arginine at amino acid position 192 with glycine and the leucine at amino acid position 211 with alanine. These two amino acid substitutions take place in proteolytic cleavage sites which are critical for activation of the secreted toxin molecules.
224304868|NCT05011123|BIOLOGICAL|Yellow fever vaccine (produced on serum-free Vero cells)|Powder and diluent for suspension for injection - Subcutaneous
223477590|NCT03496740|PROCEDURE|Penile Block|Ultrasound guided dorsal penile nerve block will be done to this group of patients preoperatively, under general anesthesia. 0,25% Bupivacaine 0,5ml/kg (max. 20ml)
223744625|NCT01046682|DRUG|Salsalate|Salsalate 2 grams orally twice a day for 13 weeks. This is the maximum dosage. During the initial 9 days of the study salsalate dose will be titrated to reach this goal dosage.
223744626|NCT00298181|DRUG|YSPSL|YSPSL administered intravenously (IV) as a single bolus infusion open-label at 0.07, 0.22, 0.7 or 2.2 mg/kg
223477591|NCT03496740|PROCEDURE|Pudendal Block|Nerve stimulation guided bilateral pudendal block will be done to this group of patients preoperatively, under general anesthesia. 0,25% Bupivacaine 0,5ml/kg (max. 20ml)
223477592|NCT03496740|DRUG|Bupivacaine (Block Drug)|Block drug
223477593|NCT04660383|DEVICE|Inspiratory Muscle Training|Patients will be submitted to three weekly IMT sessions in three different intensities for a period of twelve weeks, totaling 36 sessions.
223583545|NCT05577546|OTHER|Schroth Three-Dimensional Scoliosis Exercise Treatment|Schroth Three-Dimensional Scoliosis Exercise Treatment has the main features of physiotherapeutic scoliosis-specific exercises: 1) Three-dimensional self-correction, 2) Training activities of daily living (ADL), and 3) Stabilization of the corrected posture. The basic principles of the Schroth method are autoelongation, deflection, derotation, rotational angular breathing and stabilization. Exercise therapy will be carried out at the brace center once a week with the researcher, and 45 min a day, 4 days a week in the form of home exercises. The number of exercise sets and repetitions will be determined by the physiotherapist according to the patient, considering deformity severity and flexibility, generalized joint hypermobility, bone maturation, menarche status and the risk of progression. Compliance with the home exercise program (frequency and duration) will be recorded by the patients in a home exercise diary for 12 weeks.
223583546|NCT02335060|DRUG|Delta-9-THC|Active Delta-9-THC (0.036mg/Kg) given intravenously.
223583547|NCT02335060|DRUG|N-acetylcysteine|A pill given orally.
223583548|NCT02335060|DRUG|Placebo|Placebo (about a quarter spoon of alcohol with no THC) given intravenously.
223583549|NCT02335060|DRUG|Placebo|"Placebo sugar pill given orally with no N-acetylcysteine."
224163217|NCT03557736|BEHAVIORAL|Training mode|type of exercise training completed for 12 weeks
223477594|NCT02499107|DIETARY_SUPPLEMENT|Rice treatment|All arms are given to all participants, in a randomized (cross over) order
223477595|NCT02499107|DIETARY_SUPPLEMENT|Pasta treatment|
223477596|NCT02499107|DIETARY_SUPPLEMENT|Boiled and mashed potato treatment|
223477597|NCT02499107|DIETARY_SUPPLEMENT|Baked french fries treatment|
223744627|NCT05595889|DRUG|Surufatinib|250 mg/day p.o. QD
223477598|NCT02499107|DIETARY_SUPPLEMENT|Fried french fries treatment|
223744628|NCT05595889|DRUG|Irinotecan|Participants will receive irinotecan，100 mg/m2，Intravenous drip, day 1 and day 8 of every 3 weeks
224163218|NCT03961893|DEVICE|G-EYE first and standard colonoscope|Patients undergo two successive colonoscopies, first balloon-assisted colonoscopy (G-EYE device) and then standard colonoscopy
224163219|NCT03961893|DEVICE|standard colonoscope first and G-EYE|Patients undergo two successive colonoscopies, first standard colonoscopy and then balloon-assisted colonoscopy (G-EYE device)
224163220|NCT00182013|DRUG|Risperidone|Open treatment with Risperidone
223477599|NCT05429996|OTHER|Skin Biopsy|Skin biopsy specimens will be collected for both groups and subjected to quantitative nano histology using atomic force microscopy to assess for structural profile of a single collagen fibril
223477600|NCT02139319|DRUG|Botulinum toxin|
223477601|NCT02139319|DRUG|Placebo|
223477602|NCT03965585|PROCEDURE|in-office hysteroscopy|in-office hysteroscopy with miniaturized instruments
223477603|NCT01228045|DRUG|Trastuzumab in Combination with TS-ONE and cisplatin|Subjects will receive treatment that combined TS-ONE, cisplatin and trastuzumab every 3 weeks in this study. This 3 weeks period of time is called a cycle. The cycle will be repeated until subject experience disease progression or unbearable toxicities or they choose to withdraw from the study. Each cycle is numbered in order.
223583550|NCT01020162|DRUG|Amitryptiline, gabapentin|For amitryptiline starting dose 20-30 mg at night, increasing until clinical effect. For gabapentin was the initial dose 300 mg tid with rapid increases up to 800 mg tid.
223583551|NCT01020162|PROCEDURE|Resection of the ilioinguinal nerve|In general anaesthesia the nerve was identified and resected as central as possible
223744629|NCT04935112|DRUG|Sitravatinib|100 mg sitravatinib on Day 1
223744630|NCT04935112|DRUG|Pantoprazole|40 mg QD on Day 1 to Day 7 of Period 2 in Group 1
223744631|NCT04935112|DRUG|Famotidine|40 mg PO 2 hrs after sitravatinib in Period 2 of Group 2
223744632|NCT04324580|OTHER|Splint|Participants will have their open reduction internal fixation of distal radius fractures treated with volar locked plating. for 2 weeks. Which will be replaced by a custom thermoplastic splint for 5 weeks.
223744633|NCT04324580|BEHAVIORAL|Formal Physical Therapy|Participants will also receive a prescription for formal physical therapy. Supervised physical therapy will be prescribed 1- 2 times per week for a total of 8 weeks along with a home exercise program. Active range of motion and strengthening exercises will be performed at home twice daily for 20 minutes for a total of 8 weeks.
224163221|NCT00182013|DRUG|Olanzapine|Open treatment with Olanzapine
224163222|NCT00182013|DRUG|Quetiapine|Open treatment with Quetiapine
224304869|NCT05011123|BIOLOGICAL|Yellow fever vaccine|Powder and diluent for suspension for injection - Subcutaneous
224304870|NCT05740982|BIOLOGICAL|JYNNEOS|JYNNEOS is FDA-approved and licensed as a smallpox and monkeypox vaccine in the United States. JYNNEOS is a live vaccine produced from the strain Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN), an attenuated, non-replicating orthopoxvirus.
224304871|NCT03117036|DRUG|Chemotherapy|Systemic chemotherapy with curative intent
223477604|NCT04459338|BIOLOGICAL|Exendin-9,39|Exendin-9,39 is a competitive antagonist of GLP-1 actions at the GLP-1 receptor
223477605|NCT04459338|OTHER|Saline|Placebo comparator
223477606|NCT04740853|BEHAVIORAL|Sensory Integration Therapy+Special Education|Sensory integration is a theory first put forward by Ayres in 1972. It is a neurological process that organizes sensory stimuli from our body and our environment for use in the daily life. When the sensory integrity organization of individuals is provided, it is possible to use their body effectively against the environment. Sensory integration therapy, which is defined as a physiologically based process by Ayres and Dunn, also provides changes in individuals' occupations.
223477607|NCT05731596|DRUG|Rosuvastatin 20 Mg Oral Tablet|Rosuvastatin 20 mg will be administered orally once daily for 3 Months
223477608|NCT05731596|DRUG|Coenzyme Q10 100 MG Oral Capsule|Coenzyme Q10 100 mg will be administered orally once daily for 3 Months
223477609|NCT01454284|DRUG|Glargine|
223477610|NCT01454284|DRUG|LY2605541|
223477611|NCT01454284|DRUG|Insulin Lispro|
223477612|NCT02665117|DRUG|Potassium Magnesium Citrate (KMgCit)|KMgCit will be administer for 4 months with chlorthalidone.
223477613|NCT02665117|DRUG|Potassium Chloride (KCl)|KCl will be administer for 4 months with chlorthalidone.
223477614|NCT02665117|DRUG|Chlorthalidone|Chlorthalidone will be administered for 2-3 weeks. Then either KCL or KMgCit will be added to Chlorthalidone and the combination will be taken for 4 months.
223477615|NCT03686592|OTHER|Measurement of body awareness|Questionnaires+ interviews
223477616|NCT06255483|OTHER|Osteoperiosteal pedicled clavicular flap for mandibular and facial bone reconstruction|"A clavicular flap with a vascular supply based on the transverse cervical artery which receives a reverse blood supply from the ascending cervical artery. This vascular pattern is reliable because of the existence of the sub-occipital microvascular network named the  Bosniak node ."
223477617|NCT04854746|BIOLOGICAL|VXA-GI.1.NN|GI.1 oral vaccine tablet
223583552|NCT00316420|DRUG|Capecitabine (Xeloda)|650 mg/m2 po bid Days 1-14 750 mg/m2 po bid Days 1-14 850 mg/m2 po bid Days 1-14 950 mg/m2 po bid Days 1-14
223583553|NCT00316420|DRUG|Gemcitabine|750 mg/m2 IV Days 1 \& 8 q 21 days
223583554|NCT04142190|DRUG|ELONVA|Elonva is a solution for injection that contains the active substance corifollitropin alfa. It is available as a pre-filled syringe (100 and 150 micrograms).Elonva is used in women who are undergoing fertility treatment to stimulate the development of more than one mature egg at a time in the ovaries.
223583555|NCT04142190|DRUG|PUREGON|Puregon contains the active substance follitropin beta. fertilisation). Puregon is administered to stimulate the ovaries to produce more than one egg at a time
223583556|NCT05790980|DEVICE|Abdominal ultrasound|Abdominal US to exclude splenomegaly and hepatomegaly or liver cirrhosis Echocardiology to show cardiac dysfunction
223477618|NCT04854746|BIOLOGICAL|Placebo Tablet|Tablets matching in number and appearance to active vaccine tablets
223477619|NCT01245348|GENETIC|SULT4A1-1 genetic test|SULT4A1-1 haplotype result (+/-)
223477620|NCT02178514|OTHER|Formula fed with BabyNes Nutrition System|
223583557|NCT04878744|BEHAVIORAL|Shmapped|Novel app-based intervention to improve wellbeing in patients with common mental health problems.
223583558|NCT01018095|DRUG|Metronidazole|2 gm single dose versus 7 day 500 mg BID dose
223583559|NCT00143533|DRUG|Irinotecan, Cefpodoxime|See Detailed description section for treatment details.
223583560|NCT04064645|DEVICE|Measurement of respiratory rate with DUT and comparison with reference|"The subject will follow the paced breathing app, once a stable Respiration Rate at the natural rate (without the breathing app) is captured. The breathing pattern on the app will be set to begin near the normal Respiration Rate of the subject and continue to go down by five intervals until reaching the Respiration Rate of 5 bpm. After that, we will pick back up at the rate above the subject's normal Respiration Rate and continue upwards until reaching 50 bpm or as high as the subject can tolerate up to 50 bpm.~The respiratory rate will be monitored simultaneously with an EtCo2 (Reference) and the BORA BAND™ wristband monitoring system, Device Under Test. These data will be continuously recorded electronically. Additional study notes that describe conditions of the test as well as deviations, device issues and any adverse events will be recorded in written documentation."
223744634|NCT04324580|BEHAVIORAL|Self directed physical therapy|Participants will be given a pamphlet with detailed instructions and demonstrations in home exercises. Active range of motion and strengthening exercises will be performed twice daily for 20 minutes for a total of 8 weeks.
223744635|NCT04324580|OTHER|Soft dressing (No Splint)|Participants will have their open reduction internal fixation of distal radius fractures placed in a soft dressing which will be kept in place for 2 weeks.
223477621|NCT00634556|DRUG|levodopa solution 2mg/ml for i.v. use|2mg/mL in normal saline
223477622|NCT00634556|DRUG|placebo|normal saline
223477623|NCT00470548|DRUG|Abraxane|ABI-007 IV administration following pemetrexed on Day 1 of each cycle (infused over 30 minutes)
223477624|NCT00470548|DRUG|Alimta|Pemetrexed IV administration on Day 1 of each cycle (infused over 10 minutes)
223477625|NCT04572035|BEHAVIORAL|Behavioural Coaching|behaviour change strategies (i.e., action planning, implementation intentions, relapse prevention, and goal setting)
223477626|NCT04572035|BEHAVIORAL|Self-compassion psychoeducation|self-compassion strategies (i.e., mindfulness, self-directed kindness meditations, and writing tasks)
223477627|NCT04572035|OTHER|Exercise|aerobic exercise program either delivered in a laboratory setting or via Zoom
223477628|NCT02271113|DRUG|GMI-1271|
223477629|NCT02271113|DRUG|Placebo|
223477630|NCT02271113|DRUG|Enoxaparin Sodium (Lovenox®)|
223477631|NCT03720119|DRUG|Lidocaine Hydrochloride|As per clinical practice, a local treatment with ORTODERMINA® over a 14-day period (once a day) was prescribed. ORTODERMINA® contains 5% of lidocaine hydrochloride.
223477632|NCT03456323|BEHAVIORAL|Palliative Care Consultation|The palliative care consultation team will be led by one of the board-certified palliative care physicians at Columbia University Medical Center. Over one or more visits, the palliative care consultation team will first review intervention participants' medical records and baseline Edmonton Symptom Assessment System (ESAS) scores. They will also directly assess participants' physical and psychological symptoms. They will provide supportive counseling, make treatment recommendations for burdensome symptoms to the primary team of physicians, and will address goals of care. They will document these activities in structured electronic medical record consultation notes.
223477633|NCT03456323|OTHER|Usual Care|Patient-surrogate pairs randomized to usual care will not have a palliative care consultation intervention offered, and will receive care by their primary physicians. However, if a palliative care consultation is requested after randomization to usual care by the primary team of physicians and/or the patient/surrogate, it will be provided.
223583561|NCT02356887|DIAGNOSTIC_TEST|Jugular venous ultrasound|All volunteers will be fully awake throughout the study and be kept comfortable. A cross will be marked where the left and right IJV cross the level of C6. This is where all the measurements will be taken in 3 different conditions at rest, jugular occlusion and valsalva maneuver. At each conditions, the left and right IJV will be scanned with an ultrasound measuring the cross sectional area and Doppler velocity of the IJV. The least amount of pressure will be used to press on the ultrasound probe and the measurements will be obtained at end inspiration. The IJV flow is then calculated.
223583562|NCT04890587|DRUG|AL8326 tablets|Tablet:10mg/tablet; administered orally once daily in part 1 and part 2, administered orally twice daily for continuous 28-Day cycles in part 3.
223583563|NCT01490294|DRUG|Gadobutrol (Gadavist,Gadovist, BAY86-4875)|0.01 mmol/kg BW (0.01 mL/kg) for stress MRI and 0.01 mmol/kg BW (0.01 mL/kg) for rest MRI (total dose 0.02 mmol/kg)
224163223|NCT03195686|DEVICE|PLE100(Inbody®)|PLE100(Inbody®) monitoring in children to be operated under the total intravenous anesthesia (Propofol)
224163224|NCT04998292|DEVICE|Piezo-surgery with low level laser therapy|Low level laser therapy
224163225|NCT04998292|DEVICE|Piezo-surgery only|Piezo-surgery only
224163226|NCT02470429|DEVICE|SYSTANE HYDRATION lubricant eye drops|Preserved with POLYQUAD (polidronium chloride) 0.001%
224163227|NCT02470429|DEVICE|Hyabak 0.15% eye drops|Preservative-free
224163228|NCT02470429|DRUG|0.9% saline eye drops|Preservative-free, one drop 4 times a day in each eye (run-in period)
224163229|NCT00850265|DEVICE|Volumatic spacer|A spacer is a plastic device to inhaler medication
224163230|NCT00675662|BEHAVIORAL|Lifestyle intervention|Lifestyle intervention with Trim Tots pre-school programme.
224163231|NCT00675662|BEHAVIORAL|waiting list control|waiting list control
224163232|NCT03401476|DRUG|Morphine Sulfate|Morphine Sulfate Tablets
224163233|NCT00074620|DRUG|PEG-hirudin|
224304872|NCT05137314|DRUG|PLG0206|PLG0206 is an engineered antibacterial peptide (EAP)
223583564|NCT01490294|DRUG|Gadobutrol (Gadavist,Gadovist, BAY86-4875)|0.025 mmol/kg BW (0.025 mL/kg) for stress MRI and 0.025 mmol/kg BW (0.025 mL/kg) for rest MRI (total dose 0.05 mmol/kg)
223477634|NCT02924155|DRUG|SJP002|"1. Period 1 (single dose)~   * Day1: Placebo, Topical administered one drop to each eye (Once a day)~  * Day2: SJP002, Topical administered one drops to each eye (Once a day)~  * Day3: SJP002, Topical administered one drops to each eye (Administered 4 times a day \[0h, 4h, 8h, 12h\])~2. Period 2 (multiple dose) - Day10\~Day23: SJP002, Topical administered one drops to each eye (Administered 4 times a day \[0h, 4h, 8h, 12h\])"
223583565|NCT01490294|DRUG|Gadobutrol (Gadavist,Gadovist, BAY86-4875)|0.05 mmol/kg BW (0.05 mL/kg) for stress MRI and 0.05 mmol/kg BW (0.05 mL/kg) for rest MRI (total dose 0.1 mmol/kg)
224163234|NCT00966680|OTHER|Anesthesia|How long anesthesiologists take to administer general and spinal anesthesia.
224163235|NCT06506292|DRUG|Adebrelimab|Adebrelimab:1200 mg, iv, d1
224163236|NCT06506292|DRUG|XELOX|oxaliplatin: 130 mg/m2,iv,d1; capecitabine: 1000 mg/m2,po,pid,d1-d14
224163237|NCT02915692|DEVICE|ERASE Silver Coated Foley Catheter|Foley catheter from ERASE CAUTI Kit will be administered as required.
224163238|NCT02915692|DEVICE|Comparator Silver Coated Catheter|Foley catheter coated with silver
224163239|NCT05740891|DRUG|BCMA CAR-T cells injection|Autologous hematopoietic stem cell transplantation combined with BCMA CAR-T cells
224163240|NCT04601844|DRUG|Pozelimab|Single dose administered subcutaneously
224163241|NCT04601844|DRUG|Cemdisiran|Single dose administered SC
224163242|NCT03094494|OTHER|none intervention|none intervention
224163243|NCT04247789|OTHER|Self-reported questionairres|the fatigue will be determined through self reported questionnairres
224163244|NCT02498327|OTHER|Gelatine Capsule|Gelatine capsules containing only the inactive ingredients of starch amyral white, di-calcium phosphate DC and magnesium stearate fine.
224163245|NCT02498327|OTHER|Venavine Intensive®|Gelatine capsules containing 360 mg Red Vine Leaf extract, 60 mg of Horse Chestnut extract, 35 mg of Butchers Broom extract and 3,2 mg of Vitamin B6 as well as the inactive ingredients of starch amyral white, di-calcium phosphate DC and magnesium stearate fine.
224163246|NCT06086457|RADIATION|Radiation|IMRT/VMAT technique. Patients receive radiotherapy once daily, 5 days a week for an average of 5 weeks. Radiotherapy is delivered to achieve a dosage of 50Gy in 25 fractions to planning gross tumor volume (PGTV) with involved site included.
224163247|NCT06086457|DRUG|TP or PF regimen depended on investigator's choice.|A maximum of six cycles was recommended for chemotherapy. Chemotherapy Regimen 1(TP regimen A): Nab-paclitaxel(Albumin-bound paclitaxel) 110-130mg/ m2，d1，d8; Cisplatin 60-75mg/ m2，d1；Q3W； Chemotherapy Regimen 2 (TP regimen B): Paclitaxel 150-175 mg/m2, d1; Cisplatin 60-75mg/ m2，d1；Q3W； PD-1 inhibitor 200mg, d1, Q3W Chemotherapy Regimen 3 (PF regimen): Capecitabine 800mg/m2, bid, d1-14; Cisplatin 25-30mg/m2, d1,d2, Q3W.
224163248|NCT06086457|BIOLOGICAL|PD-1 inhibitor|Camrelizumab (200mg, d1, Q3W) was continued until disease progression, unacceptable toxicity, death, physician or patient decision to withdraw, non-compliance, or discontinuation for administrative reasons (up to 35 cycles).
224163249|NCT01300767|DEVICE|Lotrafilcon B contact lens (AIR OPTIX® AQUA)|Silicone hydrogel, single vision contact lens worn in one eye in a daily wear modality for approximately 5 days or more per week, at least 10 hours per day, for up to 4 weeks.
224304873|NCT04193475|OTHER|Analysis|No intervention planned. Novel analysis of echocardiographic data.
224304874|NCT00006721|BIOLOGICAL|rituximab|Given IV
224304875|NCT00006721|DRUG|cyclophosphamide|Given IV
224304876|NCT00006721|DRUG|doxorubicin|Given IV
224304877|NCT00006721|DRUG|prednisone|Given orally
224304878|NCT00006721|DRUG|vincristine|Given IV
224304879|NCT00006721|RADIATION|tositumomab|Given IV
224304880|NCT04732221|DRUG|Frespaciguat|Frespaciguat (soluble guanylate cyclase stimulator) 380 µg, 100 µg or 32 µg administered as dry powder inhalation
224304881|NCT04732221|DRUG|Placebo to Frespaciguat|Placebo administered as dry powder inhalation
224304882|NCT00365313|DRUG|celecoxib, esomeprazole|
223477635|NCT02924155|DRUG|Placebo|"1. Period 1 (single dose)~   * Day1: Placebo, Topical administered one drop to each eye (Once a day)~  * Day2: Placebo, Topical administered one drops to each eye (Once a day)~  * Day3 Placebo, Topical administered one drops to each eye (Administered 4 times a day \[0h, 4h, 8h, 12h\])~2. Period 2 (multiple dose) - Day10\~Day23: Placebo, Topical administered one drops to each eye (Administered 4 times a day \[0h, 4h, 8h, 12h\])"
223477636|NCT01027156|BEHAVIORAL|High Intensity Exercise|In this study, participants will be instructed to sprint maximally for a period of 30 seconds. Following 30s rest, the participants will be instructed to repeat this procedure a further 3 times. This equates to 2 minutes of maximal effort sprinting interspersed with 2 minutes recovery. Participants will be requested to perform this protocol 3 times weekly. Training progression will be implemented by increasing the number of repeats from four repetitions during weeks 1 and 2, to five repetitions during weeks 3 and 4, to six repetitions during weeks 5 and 6. Finally, during week 7 participants will still perform six repetitions but interspersed by only 20 s recovery.
223583566|NCT01490294|DRUG|Gadobutrol (Gadavist,Gadovist, BAY86-4875)|0.1 mmol/kg BW (0.1 mL/kg) for stress MRI and 0.1 mmol/kg BW (0.1 mL/kg) for rest MRI (total dose 0.2 mmol/kg)
223583567|NCT00076518|DRUG|Fenofibrate|
223583568|NCT00076518|DRUG|Fish Oil|
223583569|NCT04279145|DEVICE|swan ganze catheter /echocardiography|"Right heart catheterization and mixed venous blood samples will be obtained for ABG, biomarkers (troponin , uric acid and micro RNA).~Each subject will have echocardiography, 6 MWD, clinical functional class and blood sample at the day of right heart catheterization or at least less than week of right heart catheterization"
223583570|NCT01697943|PROCEDURE|Roux-En-Y Pouch Reconstruction or Conventional Roux-En-Y Reconstruction|
223583571|NCT01020903|PROCEDURE|Aprepitant|40 mg po pre-op
223583572|NCT01020903|DRUG|Placebo|Orally, pre-op
223583573|NCT02030288|BEHAVIORAL|Relational Agent Intervention|"Relational Agents are on-screen characters that speak to the patient and establish a relationship with them. They have been used to improve several health behaviors including diet and exercise, and can overcome communication barriers related to low levels of computer literacy. The Relational Agent can be placed on a desktop or tablet computer with a touch screen, on which patients indicate their responses. Using Motivational Interviewing and behavior change principles, the Relational Agent guides patients to consider change."
223583574|NCT05186441|OTHER|DMPFC iTBS|The intermittent theta-burst stimulation (iTBS) (i.e. two excitatory intervention paradigm) to target DMFPC can improve out-of-control behavior and decision-making model.
223583575|NCT05186441|OTHER|DLPFC iTBS|The intermittent theta-burst stimulation (iTBS) to target DLFPC (i.e. region within the executive control network) can effectively reduce craving, which is probably associated with enhancement of executive function.
223583576|NCT02048215|DRUG|Caffeine|Patients are randomised to 30-day treatment with either EC (200/20mg t.i.d.) or placebo. The EC administration starts with an initial dose of 100/10 mg t.i.d. for the first week and then proceeds with the full dose of 200/20 mg t.i.d. Patients are hospitalised during the whole treatment period, at the metabolic unit of San Giuseppe Hospital-Istituto Auxologico Italiano at Piancavallo (VB, Italy). During the treatment period all patients are fed a hypocaloric diet (total energy content of \~70% of energy expenditure, as measured by indirect calorimetry), and containing 20% proteins, 55% carbohydrates, 25% fat half of which was monounsaturated, and 35 g/day fibres.
224163250|NCT01300767|DEVICE|Balafilcon A contact lens (PureVision® 2)|Silicone hydrogel, single vision contact lens worn in one eye in a daily wear modality for approximately 5 days or more per week, at least 10 hours per day, for up to 4 weeks.
224163251|NCT01300767|DEVICE|Contact lens solution (Clear Care®)|Hydrogen peroxide-based system used for cleaning, disinfection and overnight storage of the study contact lenses.
224163252|NCT05177289|DEVICE|Theradome® LH80 pro|The Theradome LH80 pro is a wearable laser helmet device, which uses red laser light to stop hair loss, thicken existing hair and stimulate the growth of new hair.
224163253|NCT05177289|DEVICE|Scalp cooling|Scalp cooling is a standard treatment that is applied to prevent hair loss during chemotherapy.
224070252|NCT01849172|OTHER|sham electroacupuncture|"Non-points proximate to RN4 (P1), EX-CA1(P2)，ST25 (P3) and SP6 (P4) (double sides) are used.P1 and P3 are at the sites 1 cm (outward in horizontal direction) proximate to RN4 and ST25 respectively. P2 is 2 cm (outward in horizontal direction) proximate to EX-CA1. P4 is at the middle site of the spleen meridian and the kidney meridian (backward in horizontal direction proximate to SP6).~Stick adhesive tapes to all points. Blunt needles will be used to be inserted to but not piercing the skin. Even lifting, thrusting and twisting manipulation methods will be given for each non-point for 3 times. Put the sham electric stimulator on the pair of P2 and P3 with the same parameters as the acupuncture group. But there is no current intensity actually."
224070253|NCT02972255|DRUG|RO7079901|RO7079901 will be administered as per schedule described in individual arm.
224070254|NCT02972255|DRUG|Meropenem|Meropenem will be administered as per schedule described in individual arm.
224163254|NCT00963313|DRUG|Adalimumab (HUMIRA®)|Prefilled syringes containing 40 mg Adalimumab in 0.8 ml injection solution. Study drug will be subcutaneously self-administered every 2 weeks during 24 weeks.
224163255|NCT02244008|OTHER|joint mobilization|The experimental group received joint mobilization (anteroposterior mobilization of the talus - Maitland grade III). During the mobilization cyclic movements were applied in an anteroposterior direction from the first tissue resistance barrier until the end of the accessory range of motion without any pain or discomfort. This mobilization maneuver was performed in 30-second duration sets with a 30-second interval between each set. The interventions lasted two weeks with three sessions each, completing six sessions.
224070255|NCT02972255|OTHER|RO7049389 Placebo|Placebo matching to RO7049389 will be administered as per schedule described in individual arm.
224070256|NCT02972255|OTHER|Meropenem Placebo|Placebo matching to meropenem will be administered as per schedule described in individual arm.
224163256|NCT02244008|OTHER|manual contact|The placebo group received only manual contact. This maneuver was performed in 30-second duration sets with a 30-second interval between each set. The interventions lasted two weeks with three sessions each, completing six sessions.
224163257|NCT05905679|DIETARY_SUPPLEMENT|Dietary Supplement: Probiotics|6 Billion CFU
224163258|NCT05905679|DIETARY_SUPPLEMENT|Dietary Supplement: Placebo|0 CFU per day
224163259|NCT00398138|BIOLOGICAL|WT-1 analog peptide vaccine|
224163260|NCT00398138|BIOLOGICAL|incomplete Freund's adjuvant|
224163261|NCT00398138|BIOLOGICAL|sargramostim|
224304883|NCT04731155|DRUG|PCSK9 inhibitor （Alirocumab）plus standard medications|PCSK9 inhibitor（Alirocumab） was giving to subjects before PPCI and continued twice a month until 3 month after AMI
223477637|NCT05051163|DRUG|Ceftriaxone Sodium|7 days of once daily dosing
223477638|NCT05051163|DRUG|Ampicillin|7 days of 6 hourly dosing
223477639|NCT05051163|DRUG|Gentamicin|7 days of once daily dosing
223477640|NCT03817528|DRUG|ITI-007|ITI-007 (Lumateperone tosylate)dosed 40-60 mg based on efficacy/adverse events
223477641|NCT06064201|OTHER|Short-chain fatty acids (SCFAs)|The SCFAs mixture contains acetate, butyrate, and propionate in a ratio of 60:20:20, and the total daily amount of SCFAs is equivalent to the fermentation of 10g of arabinoxylan oligosaccharides. Participants will be asked to consume these capsules spread at four intervals throughout the day. The nursing staff will distribute the capsules to the participants individually, supervise their intake, and monitor adherence by capsule count.
223477642|NCT06064201|OTHER|Placebo|To serve as a placebo, microcrystalline cellulose will be included in the same type of CDCs.
223477643|NCT04794257|DEVICE|Neuromonitoring of the recurrent laryngeal nerves|The NIM Vital system (Medtronic, Jacksonville, US) operates with surface electrodes integrated with an endotracheal NIM TriVantage tube 7.0-8.0 in diameter, which is inserted by an anesthetist between the vocal folds under direct vision during intubation. The standardized technique of IONM RLNs wll be used, including initial vagal response evaluation at the beginning and final vagal response evaluation at the end of surgery (IONM = L1+V1+R1+R2+V2+L2) according to the recommendations formulated by the International Intraoperative Neural Monitoring Study Group. The nerves will be stimulated using a monopolar electrode and the interrupted stimulation technique at 1mA, 100ms impulse duration and 4Hz frequency. In case of the bifurcated RLN nerves, the assessment includes post-stimulation response of each nerve branch. Adduction of the vocal folds is detected by the endotracheal tube electromyography and abduction by finger palpation of muscle contraction in the posterior cricoarytenoid.
223477644|NCT00033280|DRUG|temozolomide|
223477645|NCT00033280|PROCEDURE|neoadjuvant therapy|
223477646|NCT00033280|RADIATION|radiation therapy|
223477647|NCT03791320|DIAGNOSTIC_TEST|Vessel Fractional Flow Reserve|FFR measurement based on coronary angiography
223477648|NCT03177395|DRUG|PP100-01 (calmangafodipir)|PP100-01
223477649|NCT03177395|DRUG|Acetylcysteine|NAC
223583577|NCT02048215|DRUG|Placebo|Patients are randomised to 30-day treatment with either EC (200/20mg t.i.d.) or placebo. The EC administration starts with an initial dose of 100/10 mg t.i.d. for the first week and then proceeds with the full dose of 200/20 mg t.i.d. Patients are hospitalised during the whole treatment period, at the metabolic unit of San Giuseppe Hospital-Istituto Auxologico Italiano at Piancavallo (VB, Italy). During the treatment period all patients are fed a hypocaloric diet (total energy content of \~70% of energy expenditure, as measured by indirect calorimetry), and containing 20% proteins, 55% carbohydrates, 25% fat half of which was monounsaturated, and 35 g/day fibres.
223477650|NCT00906243|BIOLOGICAL|CV9103|CV9103 encodes for 4 prostate specific antigens.
223477651|NCT04078386|BIOLOGICAL|Placebo|Patients received the test group Placebo weekly administered subcutaneously for 24 times.
223477652|NCT04078386|BIOLOGICAL|RC18 240 mg|Arm Description:Patients received the test group RC18 240mg weekly administered subcutaneously for 24 times.
223477653|NCT04078386|BIOLOGICAL|RC18 160 mg|Patients received the test group RC18 160mg weekly administered subcutaneously for 24 times.
223477654|NCT00600522|PROCEDURE|Ultrasound-guided hepatectomy|"After laparotomy and staging by intraoperative ultrasound (IOUS), anterior surface of the hepatocaval confluence is exposed. Than, compression by means of the surgeon's finger-tip is applied at the MHV caval confluence verifying at color-Doppler IOUS the disappearance of the blood flow in the MHV or its inversion. Then, MHV clamping itself is carried out, and parenchymal sparing resection would be selected if at least one of these 3 findings is confirmed:~1. Reversal color-Doppler IOUS flow direction in the peripheral portion of the MHV, which suggests the drainage through collateral circulation in the RHV/LHV depending on the side of the MHV branch with reversal flow.~2. Detectable shunting collaterals at color-Doppler IOUS with RHV or LHV.~3. Hepatopetal flow in P5-8 and/or P4inf portal branches. If none of these finding is confirmed and in particular hepatofugal flow direction in the P5-8 and/or P4 inf is detected the hepatectomy has to be extended."
223477655|NCT03353077|DEVICE|Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)|An intratumoral insertion of a seed(s), loaded with Radium-224, securely fixed in the seeds. The seeds release by recoil into the tumor short-lived alpha-emitting atoms.
223477656|NCT00587665|DRUG|ketamine|Single IV dose of 0.1 mg/kg of ketamine
223477657|NCT00587665|DRUG|Placebo|Saline given of equal volume to drug
223477658|NCT00129636|PROCEDURE|Additional specific letter written to patient|
223477659|NCT01777646|BIOLOGICAL|MSC_NTF cells transplantation by multiple intramuscular injections at 24 separate sites, in addition to a single intrathechal injection into the CSF|
223583578|NCT02048215|DRUG|Ephedrine|Patients are randomised to 30-day treatment with either EC (200/20mg t.i.d.) or placebo. The EC administration starts with an initial dose of 100/10 mg t.i.d. for the first week and then proceeds with the full dose of 200/20 mg t.i.d. Patients are hospitalised during the whole treatment period, at the metabolic unit of San Giuseppe Hospital-Istituto Auxologico Italiano at Piancavallo (VB, Italy). During the treatment period all patients are fed a hypocaloric diet (total energy content of \~70% of energy expenditure, as measured by indirect calorimetry), and containing 20% proteins, 55% carbohydrates, 25% fat half of which was monounsaturated, and 35 g/day fibres.
224070257|NCT01098071|DRUG|mometasone furoate nasal spray|One spray (50 mcg per spray) in each nostril once daily (100 mcg daily) for 3 months
224070258|NCT06281639|DEVICE|RAPID|test the clinical screening potential for congenital heart disorders using a single ECHO image taken by the RAPID device
224304884|NCT04731155|DRUG|standard medications|standard medications was giving to subjects according guidelines
224304885|NCT06531395|DRUG|Abiprubart|humanized monoclonal antibody
224304886|NCT06531395|DRUG|Placebo|sterile preservative-free solution
223477660|NCT03277131|DEVICE|DURAFIBER Ag|DURAFIBER Ag is a commercially available absorbent, non-woven, silver-containing antimicrobial dressing
223477661|NCT01146483|DRUG|Rosuvastatin, Pantoprazole|"Rosuvastatin, 10 mg tablets, single dose on the morning~Concomitant drug: Pantoprazole; 40 mg tablets, 2 single doses administered 1 hour before rosuvastatin and 23 hours after rosuvastatin administration. A placebo is given on the other period as a crossover design study."
223477662|NCT03442062|OTHER|Assessment Feedback Incentives and eXchange|The adolescent AFIX (Assessment, Feedback, Incentives, and eXchange) Program is a quality improvement strategy developed by the CDC to improve the immunization practices and vaccination coverage levels of public and private health care providers. It has four main components: 1) Assessment of a provider's current immunization practices and vaccination levels, 2) Feedback of the assessment results and strategies to improve coverage levels, 3) Incentives to improve coverage levels, and 4) eXchange of information and resources necessary to facilitate improvement. Relevant AFIX information will be communicated to vaccine providers using several intervention and quality improvement components.
224163262|NCT00398138|GENETIC|polymerase chain reaction|
223477663|NCT03442062|OTHER|Physician-to-physician engagement|Physician-to-physician engagement is a quality improvement strategy in which trained physician educators deliver a 60 minute consultation via interactive webinar. The consultations will be delivered to providers in primary care clinics and will include didactic instruction on HPV-related cancers, HPV vaccination, communication training, and assessment and feedback about each clinics' vaccination coverage.
223477664|NCT03442062|OTHER|Active Intervention Control|Active Intervention Control will be a remotely delivered quality improvement strategy on a clinical topic other than HPV vaccination.
224163263|NCT00398138|OTHER|flow cytometry|
224163264|NCT00398138|OTHER|immunoenzyme technique|
224163265|NCT00528008|OTHER|povidone-iodine solution|Abdominal surgical field cleaned with 5% povidone-iodine detergent scrub, detergent cleaned from surgical area with sterile water, and then painted with 1% povidone-iodine solution.
223477665|NCT06479902|PROCEDURE|Core stability exercise|Core stability exercises featured moves such as planks and side planks.
223477666|NCT06479902|PROCEDURE|Diaphragmatic Strengthening Exercise|. Diaphragmatic exercises included diaphragmatic breathing in various positions.
223477667|NCT03451071|DRUG|Gardasil9|Gardasil 9
223477668|NCT00129831|DRUG|QAB149|
223477669|NCT04005872|DRUG|Nano Silver Fluoride|Nano silver fluoride (NSF) is a new material consisting of nano silver particles, chitosan and sodium fluoride. It is a bacteriostatic and bactericidal compound.
223477670|NCT04005872|DRUG|Calcium hydroxide|Calcium hydroxide is a gold standard for indirect pulp capping which induces hard tissue.
223477671|NCT04133389|OTHER|Growth mindset of personality educational intervention|This is a brief online educational intervention that teaches growth mindset of personality. The intervention includes pictures, text, videos, and questions administered through Qualtrics survey software.
224163266|NCT00528008|OTHER|chlorhexidine gluconate|Abdominal surgical field painted once using 2% chlorhexidine in 70% alcohol.
224163267|NCT01154322|DEVICE|Pixi pediatric mask|The study mask is designed for use with PAP therapy to treat OSA in pediatric patients aged 2-7 years. The study mask is designed to be used in the hospital and the home environment. The study subject will use the device for up to 30 days while participating in the study.
223477672|NCT04133389|OTHER|Growth mindset of athletic ability educational intervention|This is a brief online educational intervention that teaches growth mindset of athletic ability. The intervention includes pictures, text, videos, and questions administered through Qualtrics survey software.
223477673|NCT01934179|OTHER|cytology specimen collection procedure|Undergo blood sample collection
224070259|NCT00940355|BEHAVIORAL|Intervention pulmonary nurse|The intervention is conducted by a pulmonary nurse, directed at increasing awareness of problems in health status, and increasing motivation to engage in additional treatment, and improving health status.
224070260|NCT06093139|DIETARY_SUPPLEMENT|Probiotic capsule|probiotic capsule (composition same as described above - L. acidophilus FB0012, L. plantarum FB0015, and L. rhamnosus FB0047 encapsulated in acid-resistant capsules
224070261|NCT06093139|DIETARY_SUPPLEMENT|Placebo|placebo consisted of the same capsules filled with potato starch
224070262|NCT06063421|DEVICE|Electronic Cigarette (EC)|The intervention consists of the use of an Electronic cigarette device namely the Vaporesso Gen Air 40 Vape Kit. This is a complete kit including the EC device, integrated battery, refillable tank, charging cable, coil replacements and user manual. Three e-liquid flavours will be provided; tobacco, menthol and fruit flavour.
224070263|NCT06063421|DRUG|Nicotine Replacement Therapy|NRT will be in the form of combination therapy with a transdermal nicotine patch (7, 14, or 21mg) and an oral product: either gum or lozenge in 1, 2, or 4mg strength.
224070264|NCT01507272|DRUG|liraglutide|Administered as 5 single s.c. (under the skin) doses - 1.25, 2.5, 5, 10 and 20 mcg/kg once daily - in ascending order
224070265|NCT01507272|DRUG|liraglutide|Subjects receiving the dose level 5 mcg/kg s.c. will in addition receive, after a wash-out of at least 7 days, a single i.v. (into the vein) dose of 5 mcg/kg
224070266|NCT01507272|DRUG|placebo|Administered s.c. After a wash-out of at least 7 days, a single i.v. (into the vein) dose is administered
224070267|NCT01507272|DRUG|placebo|Administered as 5 single s.c. (under the skin) doses - 1.25, 2.5, 5, 10 and 20 mcg/kg once daily - in ascending order
224070268|NCT03648697|BIOLOGICAL|EBV-TCR-T (YT-E001) cells|"EBV-TCR-T (YT-E001) cells are prepared via lentiviral infection. 6-10 days prior to infusion of TCR-T cells (YT-E001), subjects receive fludarabine at dose 30mg/m2/day for 4 days and cyclophosphamide treatment at dose 30mg/kg/day for 2 days and take a rest for one day before infusion.~Patients, who receive an infusion of YT-E001, will remain in the hospital to be monitored for adverse events until they have recovered from the treatment. Patients will have frequent follow-up visit to monitor the persistence of modified T cells and efficacy of the treatment."
224070269|NCT03326843|DRUG|Avatrombopag 60 mg|Oral avatrombopag administered once daily for 5 days prior to procedure.
224070270|NCT03703973|DIAGNOSTIC_TEST|Neuropsychology test|We do the neuropsychological tests, Mini-Mental score examination (MMSE) and olfaction test 1 day before (baseline) and 1 week,3 months,1 year and 3 years after surgery without safety issue.
224070271|NCT00942474|DEVICE|Facilitate nerve stimulation lead placement with the nerve access tool|
224070272|NCT01662895|DRUG|Deferoxamine|Deferoxamine mesylate(62 mg/kg/day up to a maximum daily dose of 6000 mg/day) given by a continuous IV infusion for 5 consecutive days beginning within 24 hours of ICH symptom onset.
224163268|NCT03366974|DRUG|Midazolam|Midazolam 5 mg PO, Midazolam 1 mg IV
224163269|NCT03366974|DRUG|Clarithromycin|Clarithromycin 500 mg bid
223477674|NCT01934179|OTHER|laboratory biomarker analysis|Correlative studies
223477675|NCT01934179|OTHER|questionnaire administration|Ancillary studies
223477676|NCT02065557|BIOLOGICAL|Adalimumab|Subcutaneous (SC) injection
223477677|NCT02065557|BIOLOGICAL|Placebo|Subcutaneous (SC) injection
223477678|NCT00250588|BEHAVIORAL|Problem solving skills training|See description in Results
223477679|NCT00250588|BEHAVIORAL|Asthma care coordination|See description in Results
223477680|NCT00250588|OTHER|Usual Care|Usual clinical care
223583579|NCT02048215|OTHER|Hypocaloric diet|Patients are randomised to 30-day treatment with either EC (200/20mg t.i.d.) or placebo. The EC administration starts with an initial dose of 100/10 mg t.i.d. for the first week and then proceeds with the full dose of 200/20 mg t.i.d. Patients are hospitalised during the whole treatment period, at the metabolic unit of San Giuseppe Hospital-Istituto Auxologico Italiano at Piancavallo (VB, Italy). During the treatment period all patients are fed a hypocaloric diet (total energy content of \~70% of energy expenditure, as measured by indirect calorimetry), and containing 20% proteins, 55% carbohydrates, 25% fat half of which was monounsaturated, and 35 g/day fibres.
223583580|NCT01401712|PROCEDURE|ON-Q® Pain Relief System|Identify insertion site lateral to paraspinous muscles and posteromedial to the rib fractures. Then, incise skin and soft tissue down to the level of the rib. Advance tunneler perpendicular to chest wall until it contacts the rib, then, advance superiorly at 45° angle in the extrathoracic space. Remove tunneler and advance catheter in space created. Attach catheter to pump filled with 0.2% ropivacaine at infusion rate of 2-12ml/hr.
223583581|NCT01401712|PROCEDURE|Thoracic epidural catheter|Introduce needle into the interspinous space of the vertebral column and advance into the epidural space. Advance the epidural catheter about 3-5 cm into the epidural space and remove the needle.
223583582|NCT04512638|DRUG|Antibiotics|"Antibiotic treatment is the same in all groups.~Monotherapy for 4 weeks with:~No penicillin contra-indication~* Amoxicillin-clavulanate 875mg tid PO Penicillin contra-indication or intolerance~* Clindamycin 300mg tid PO~After 4 weeks patients will be switched to consolidation antibiotics:~No penicillin contra-indication~* Amoxicillin 1g bid PO Penicillin contra-indication or intolerance~* Clindamycin 300mg tid PO~Antibiotic treatment can be discontinued after 4 weeks when the MRONJ lesions has healed."
224070273|NCT01662895|DRUG|Normal saline|This is a placebo. Normal saline will be given by a continuous IV infusion for 5 consecutive days beginning within 24 hours of ICH symptom onset.
224070274|NCT01937650|DRUG|Radiotherapy plus metronidazole|Metronidazole was added to the standard radiotherapy that is routinely used.
224070275|NCT03313674|DEVICE|Bright Light Therapy|Light box that emits light at 10,000 lux or higher and has been demonstrated to regulate circadian rhythm that is aberrant in the SAD population
224163270|NCT03366974|DIETARY_SUPPLEMENT|Grapefruit juice|Grapefruit juice 500 mL
224070276|NCT06096558|DIETARY_SUPPLEMENT|Melatonin|5 mg Melatonin in one tablet, 30 minutes before night sleep
224163271|NCT00117572|DRUG|docetaxel|75 mg/m2 on day 1 (induction phase); 25 mg/m2 on day 1 (chemoradiotherapy phase)
224070277|NCT06096558|OTHER|placebo|1 tablet of placebo (starch)
224163272|NCT00117572|DRUG|cisplatin|75 mg/m2 on day 1
223477681|NCT01993199|PROCEDURE|deep biopsy via ESD technique|
223477682|NCT03025204|BIOLOGICAL|Enamel Matrix Proteins|EMD is composed of different proteins, 90% of which are amelogenins, which has the capacity to induce processes involved in the regeneration of periodontal tissues in a manner similar to normal tissue development (48). Several clinical and animal model studies have demonstrated the use of enamel matrix-derived proteins in regenerative periodontal procedures for the formation of a new periodontium.
223477683|NCT03025204|PROCEDURE|Open Flap Debridement|After administration of local anesthetics, full-thickness flaps will be raised in order to access all defect faces. Sulcular incisions will be performed extending to mesial and distal adjacent teeth, including the entire papilla in the flap. No relaxing incisions will be performed. All granulation tissue will then be carefully removed, and subsequently scaling and root planing will be performed. The surgical area will be irrigated with 0.9% saline and carefully inspected to ensure that all steps have been satisfactorily performed until then.
223477684|NCT03689517|OTHER|placebo|participants took placebos (pills made by starch) that were told to be an effective analgesic.
223477685|NCT03689517|DEVICE|orthodontic elastic separators|Orthodontic pain was introduced by placement of orthodontic elastic separators to the mesial and distal sides of the right mandibular first molar.
223477686|NCT00568971|DRUG|Docetaxel, Cisplatin, 5-Fu|Docetaxel 33.3 mg/m2, Cisplatin 30 mg/m2 and 5-FU 1500 mg/m2 of 24-hour continuous intravenous infusion;d1,8,15 q4w.The treatment will not stopped until disease progression or unaccepted toxicities.
224070278|NCT02393729|BEHAVIORAL|Neuropsychological assessment|"The neuropsychological assessment will include an assessment of:~* Intellectual ability~* Laterality~* Reading Skills~* Motor skills~* Oral Language~* Attention~* Child's behaviour"
224070279|NCT02393729|OTHER|MRI Study|"It will include a first session of about an hour outside MRI for familiarization with the environment of the MRI. The MRI will then be made after a break of 15 minutes~* Morphological time: this time include the initial acquisition of a sequence of anatomical 3D T1-weighted high-resolution contiguous axial slices and the imaging of diffusion tensor.~* Functional time: The experimental paradigm is a paradigm as a block with alternating phase of motor and rest conditions. The two motor tasks are: a Learning motor sequence or motor sequence task and Automated motor sequence or AT (automated task)."
224070280|NCT03353727|OTHER|Orthoptic rehabilitation|Orthoptic rehabilitation using innovative mechanisms (eye tracker and tactile device) for low vision people
224163273|NCT00117572|DRUG|hydroxyurea|Each cycle: 500 mg PO q 12 hours x 6 days (11 doses)
224163274|NCT00117572|DRUG|fluorouracil|750 mg/m2/day on days 1-5 (induction phase); 600 mg/m2/day, day 0-4 (chemoradiotherapy phase)
224163275|NCT00117572|PROCEDURE|chemotherapy|See protocol for details
224163276|NCT00117572|PROCEDURE|radiotherapy|See protocol for details
223477687|NCT02902575|PROCEDURE|Laparoscopic-assisted gastrectomy with D2 lymphadenectomy|After exclusion of T4b, bulky lymph nodes, or distant metastasis case by diagnostic laparoscopy, Laparoscopic-assisted gastrectomy with D2 lymphadenectomy will be performed with curative treated intent.The type of reconstruction will be selected according to the surgeon's experience and anastomotic procedure is performed extracorporeally using a mini-laparotomy
223477688|NCT03502798|DEVICE|scanning a/LCI|Imaging of the cervical epithelium using the scanning a/LCI device.
224163277|NCT00887068|DRUG|Azacitidine|32 mg/m\^2 given through a needle under the skin for five consecutive days of each 28 day cycle and the maximum treatment will be 12 cycles.
223477689|NCT02737137|PROCEDURE|Manual measurement|Monitoring by ultrasound, Neurostimulation and Measurement Manual of the injection pressure of the local anesthetic
223477690|NCT02737137|PROCEDURE|Measurement with a gauge|Monitoring by ultrasound, Neurostimulation and measurement with a gauge of the pressure of injection of the local anesthetic
223477691|NCT00485303|DRUG|Abiraterone acetate|Abiraterone acetate oral tablets 250 milligram (mg) each will be administered at a total dose of 1000 mg until documented disease progression or unacceptable toxicity.
223477692|NCT00485303|DRUG|Prednisone|Prednisone/Prednisolone 5 mg tablet will be taken orally twice daily.
223477693|NCT02738502|DRUG|darunavir monotherapy|darunavir 600 mg + ritonavir 100 mg 2 times 24 (DRV/r) monotherapy started after checking the tolerance of DRV/r600 mg/100 mg twice daily to replace whatever prior ARVs were used, while maintaining the NRTI backbone for 2 weeks.
223583583|NCT04512638|DRUG|Chlorhexidine mouthwash|Patients in all treatment groups will be prescribed aqueous chlorhexidine 0.12% tid rinse for 2 weeks, with subsequent switch to 0.05% for the duration of the study or until healing of the MRONJ lesion has occurred.
223583584|NCT04512638|PROCEDURE|Minimally invasive surgery with LPRF|Minimally-invasive surgical treatment, including sequestrectomy, debridement of soft tissue, and application of LPRF membranes before tension-free wound closure is obtained. Marginal resection of all necrotic bone is not part of this treatment strategy.
224070281|NCT03214484|OTHER|By comparing the evolution of the visual acuity curves.|By comparing the evolution of the curves, the investigator can confirm that the AV measured on ET / Computer can be an interesting and useful element to help us follow up our patients and improve the quality of life's patients by decreasing the number of visits control.
224070282|NCT03214484|OTHER|By comparing the evolution of the curves.|By comparing the evolution of the curves, the investigator can confirm that the AV measured on ET / Computer can be an interesting and useful element to help us follow up our patients and improve the quality of life's patients by decreasing the number of visits control.
224070283|NCT02164422|DRUG|Guanfacine 3mg/day|3 mg/day Guanfacine with 3-week lead-in period. Maintained at steady state throughout lab sessions. After lab sessions, given taper supply of medication. Follow up 2 weeks after completion of taper.
224070284|NCT02164422|DRUG|Guanfacine 1.5mg/day|1.5 mg/day Guanfacine with 3-week lead-in period. Maintained at steady state throughout lab sessions. After lab sessions, given taper supply of medication. Follow up 2 weeks after completion of taper.
224070285|NCT02164422|DRUG|Placebo|
223477694|NCT01391611|DRUG|Pazopanib|800 mg; PO
224070286|NCT02112370|DRUG|Ropivacaine with epinephrine injection|1 mg/mL 1cc epinephrine is diluted in 100cc normal saline and then 7.5 mg/mL 30cc ropivacaine is diluted in the same normal saline. The mixture is injected into the subcutaneous layer for the initial flap dissection for the experiment group.
223583585|NCT04512638|PROCEDURE|Surgical resection|Primary surgical management consisting of the removal of the necrotic bone without excessive resection of healthy bone. Buccal mucoperiosteal flaps will be used to achieve a tension-free mucosal coverage.
223583586|NCT02265315|OTHER|Transcranial Magnetic Stimulation|Treament adjuvant applied to accelerate vocal motor learning and overall voice improvement
223583587|NCT02265315|BEHAVIORAL|Lee Silverman Voice Treatment|Time intensive behavioral treatment for Parkinson's hypophonia
224070287|NCT02112370|OTHER|Placebo|100cc normal saline is injected into the subcutaneous layer for the initial flap dissection for the placebo group.
224070288|NCT02962050|PROCEDURE|Videofluoroscopic Swallowing Study (VFSS)|Videofluoroscopic swallowing study will be performed to measure oropharyngeal swallowing
224070289|NCT02962050|DEVICE|Voluntary Peak Cough Flow Testing|Voluntary peak cough flow testing will be performed to determine the peak expiratory flow (PEF) and volume of air expelled (FEV1) during voluntary coughing.
224070290|NCT02962050|DEVICE|Iowa Oral Performance Instrument|The Iowa Oral Performance Instrument (IOPI) is a device that measures the peak pressure performance of lingual strength and endurance via the action of a bulb placed on the hard palate.
224070291|NCT02962050|DRUG|Capsaicin Challenge|"A capsaicin challenge with three randomized blocks of 0, 50, 100, 200, and 500 μM capsaicin. The capsaicin will be dissolved in a vehicle solution consisting of 80% physiological saline, and 20% ethanol. Participants will be given the instruction cough if you need to prior to capsaicin delivery.The solution will be administered automatically upon detection of an inspired breath and there will be a minimum of one minute between each trial. This is to test the reflexive cough testing for upper airway sensitivity and motor thresholds."
224070292|NCT02962050|DEVICE|Pulmonary Function Testing|Pulmonary Function testing will be performed using conventional methods and will include the following outcomes: forced vital capacity (FVC), maximum inspiratory pressure (MIP), and maximum expiratory pressure (MEP) expressed as a percentage of predicted values.
224070293|NCT02962050|OTHER|Eating Assessment Tool 10|The Eating Assessment Tool-10 will be used for participant reporting of swallowing system severity.
224070294|NCT02962050|OTHER|The Center for Neurologic Study Bulbar Function Scale|The Center for Neurologic Studies Bulbar Function Scale (CNS-BFS) will be used to report bulbar function in study participants.
224070295|NCT04951687|DIETARY_SUPPLEMENT|Ecologic Barrier©|5x10\^9 CFU/ 2g per day of Ecologic Barrier©
224070296|NCT04951687|DIETARY_SUPPLEMENT|Placebo powder|matched placebo
224070297|NCT04004884|DRUG|Ulipristal Acetate|Assess the variations of liver blood test parameters during UPA treatment for symptomatic uterine fibroids
224070298|NCT03995615|PROCEDURE|scaling and root planing|"* After initial clinical evaluation, supra gingival calculus removal will be done. GCF samples will be collected from the control and test groups (Baseline samples) using paper strips (ORAFLOW). ® Group III patients will undergo a through oral hygiene instructions, full mouth supra-gingival and sub- gingival scaling and root planing clinical parameters will be re-recorded 6 weeks later and a 2nd GCF samples will be collected from selected test site from each patients following periodontal intervention.~* All the samples will be placed in eppendorf vials containing the buffer solution and samples will be stored at -800 c until the time of analysis by Enzyme -linked immune sorbent assay kit (ELISA) (GENX BIO) TM"
224070299|NCT02481973|OTHER|Individualised Homoeopathic Remedy|Each participant is to receive an individualised homoeopathic remedy prescribed according to their characteristic symptoms.
224070300|NCT03249571|DIETARY_SUPPLEMENT|Flavonoid supplement|2-weeks ingestion of flavonoid supplement
224070301|NCT03249571|DIETARY_SUPPLEMENT|Placebo|2-week ingestion of placebo supplement
223744636|NCT03360370|OTHER|Ages & Stages Questionnaires, Third Edition in French (ASQ-3™)|"This questionnaire screens 5 neurodevelopmental areas (communication, gross motor, fine motor, problem solving and personal-social); 30 items per questionnaire about the child's abilities are evaluated.~It takes about 15-20 minutes. Data are collecting and a scoring by a professional is provided. Follow-up action is taken for children at risk. Medical and surgical history is also collected to detect risk factors for neurodevelopmental disorders among neonatal data, characteristics of congenital heart disease and first surgery, and other comorbidities."
223477695|NCT06232343|OTHER|Parachute Resistance Training|The training programmed duration is of four weeks.The groups will follow the training programmed three times a week. The daily schedule (training group) included four repetitions of maximum intensity 30 m \& 50 m dashes (4 × 30 m, 4 × 50 m). The duration of recovery time between the 30 m \& 50 m runs will be 4 and 6 minutes respectively. Between the last 30 m dash and the first 50 m dash, a 10-minute recovery will be applied. Moreover, sprint speed training should not exceed 400-500 meters in total . To this end, the training programmed of the present study consisted of 4x30m and 4x50m runs, at a frequency of 3 times a week.
223477696|NCT06232343|OTHER|Sprinters|control group perform sprinters without any external resistance training for four weeks.
223477697|NCT03253822|OTHER|Decision aid|The DA is an online tool. The web-based design opens up possibilities to feature more advanced functions, e.g. questions for the participant during the process, and a summary of answers at the end. The DA is tailored to lower educational attainment citizens, and is designed to embrace different information needs in the target population, ranging from a desire to receive a clear recommendation and a minimum of information to the desire to receive full information and make a personalized choice.
223477698|NCT00445718|PROCEDURE|computed tomography|
223477699|NCT00445718|PROCEDURE|3-Tesla magnetic resonance imaging|
223477700|NCT00445718|PROCEDURE|Abdominal Sonogram|Sonogram of the abdomen area
223583588|NCT05714943|BEHAVIORAL|DigiKnowIt News: Teen|Participants will interact with a multimedia educational website that will teach them about pediatric clinical trials, including topics such as participant rights and safety and different types of procedures used in trials, and will provide strategies for parent-teen shared decision-making about clinical trials.
223583589|NCT03258060|PROCEDURE|Temporary pacing study|
223744637|NCT06470425|OTHER|Standard therapy group|Participants receive supplement prescriptions from a physician based on current standard practices, which include biochemical markers, genetic data, and metabolic profiles.
223744638|NCT06470425|OTHER|AI-Guided group|Participants receive supplement prescriptions determined by GenAIS, is an AI system that considers genetic data, metabolic profiles, biochemical markers, and patient history.
223744639|NCT00523250|DRUG|AR-102 0.003% Ophthalmic Solution|
223744640|NCT00523250|DRUG|AR-102 0.005% Ophthalmic Solution|
223744641|NCT00523250|DRUG|AR-102 0.01% Ophthalmic Solution|
223744642|NCT00523250|DRUG|AR-102 0.03% Ophthalmic Solution|
223744643|NCT00523250|DRUG|AR-102 Vehicle Ophthalmic Solution|
223477701|NCT05439564|DRUG|Dexmedetomidine|Group morphine-Dex (35 patients): patients will be received given 0.5% heavy bupivacaine (3.5 ml) plus 0.1 mg of morphine plus 5 mcg of dexmedetomidine.
223477702|NCT05439564|DRUG|Morphine|Group morphine (35 patients): patients will be received given 0.5% heavy bupivacaine (3.5 ml) plus 0.1 mg of morphine.
223477703|NCT05439564|DRUG|Dexmedetomidine|Group Dex (35 patients): patients will be received given 0.5% heavy bupivacaine (3.5 ml) plus 5 mcg of dexmedetomidine.
223477704|NCT03820401|DEVICE|choice of dialyzer|Fiber blocking is calculated in different commercially available dialyzers
223583590|NCT03258060|RADIATION|Body Surface Mapping|
223583591|NCT00160654|DRUG|Levetiracetam|"* Pharmaceutical form: oral tablets~* Concentration: 500 mg~* Route of administration: Oral use"
223744644|NCT05864508|DRUG|Oxytocin nasal spray|intranasal oxytocin treatment once a day during 6 weeks
223744645|NCT05953454|OTHER|Pain neuroscience Education|A pain neuroscience education session geared towards fear-avoidance beliefs
224070302|NCT01555203|BEHAVIORAL|liveWell: A healthy foundation for life|"liveWell is a unique online, mobile-compatible, multi-media, evidence-based program designed to help college students exercise, eat healthy, and manage stress. At the core of the Transtheoretical Model-based intervention is a computer-tailored behavior change intervention (CTI) that analyzes students' responses to reliable and valid assessments of key behavior change constructs using empirically derived pre-programmed decision rules. The rules determine which feedback users receive on how they are doing compared to their peers in their same stage. At follow-up, feedback is further tailored to how students are doing compared to their last session.~In addition to the CTI, completed three times during the semester, liveWell includes a dynamic portal that is populated with a variety of engaging and interactive stage-matched activities and resources. The portal provides more content and specifics on how to apply each of the processes and principles of change introduced in the CTI."
224163278|NCT05310760|DRUG|Vit C|Oral vitamin C (100 mg three times daily for one week then 100 mg once daily for 1-3 months)
223744646|NCT03695510|DRUG|Afatinib Oral Tablet|40mg oral, daily, continuously
223744647|NCT03695510|DRUG|Pembrolizumab Injection|200mg, intra-venous injection, every 3 weeks, for 35 cycles
223744648|NCT00371254|DRUG|Dasatinib|Tablets, Oral, 100 mg, twice daily as long as the patient benefits (avg \<6 months)
223744649|NCT00371254|DRUG|Dasatinib|Tablets, Oral, 70 mg, twice daily as long as the patient benefits (avg \<6 months)
223744650|NCT04572074|OTHER|Guided imagery|10 minutes of guided imagery experience
223744651|NCT04572074|OTHER|Virtual reality|10 minutes of virtual reality experience
223744652|NCT01154621|DRUG|AZD9742|Sterile solution, 620 mg (20 mg/mL) in 50 mL vial with a fill volume of 31 mL
223744653|NCT01154621|DRUG|Placebo|Sterile 5% dextrose solution
223744654|NCT00625859|DRUG|GSK189075|GSK189075 will be available as film-coated tablets with a dose of 250 milligrams.
223744655|NCT00625859|DRUG|Bupropion|Bupropion will be available as sustained release film-coated tablets with a dose of 150 milligrams administered orally.
223744656|NCT00625859|DRUG|Placebo|Placebo tablets will be given to subjects.
223744657|NCT00862810|BIOLOGICAL|Received HPV vaccine first|
223744658|NCT00862810|BIOLOGICAL|Received concomitant vaccines first|
223744659|NCT01768351|DRUG|Paricalcitol|Zemplar cp 1 mcg/day per os
223744660|NCT01768351|DRUG|Calcitriol|Rocaltrol cp 0,5 mcg every other day per os
223583592|NCT02220114|DRUG|Vigabatrin: Vigabatrin new ST formulation then Sabril®|"* first treatment phase (V1/D1-V3/D84), in which patients already under Sabril® granules for oral solution and naive patients start the new ST formulation; patients already under Sabril® will start at the same dose and regimen as their usual Sabril®. Dose and regimen for naive patients will be chosen according to SPC.~* second treatment phase (V3/D84-V4/D98) in which the patient is switched to Sabril® granules for oral solution (supplied by sponsor) for 15 days at the same dose as under the new ST formulation.~Dose and treatment regimen should be maintained as in first treatment phase.~\- At V4/D98, patients who received Sabril® granules for oral solution (supplied by sponsor) continue with marketed Sabril® treatment (or switches to another AED, according to the natural evolution of the patient's condition and upon investigator decision)."
223477705|NCT03820401|OTHER|choice of dialysis mode|Fiber blocking is calculated in different commercially available dialyzers used in different dialysis stategies
223477706|NCT03820401|OTHER|choice of anticoagulation strategy|Fiber blocking is calculated in different commercially available dialyzers using different anticoagulation strategies
223477707|NCT03820401|OTHER|preparation of dialyzer|Fiber blocking is calculated in different commercially available dialyzers either preprimed with Albumin or not
223744661|NCT02246673|DRUG|RDEA3170 15 mg|
223744662|NCT02246673|DRUG|RDEA3170 10 mg|
223744663|NCT02246673|DRUG|RDEA3170 2.5|
223477708|NCT05595226|PROCEDURE|RT3D-TEE-guided mitral valve repair|RT3D-TEE forms a surgical plan before surgery and 3 to 4 senior doctors with more than 50 cases of mitral valve repair perform the procedure.
223477709|NCT03644732|PROCEDURE|SEEG Group|Visual and quantitative SEEG signal analysis. As available, collection of behavioral and neuropsychological postsurgical data
223583593|NCT05052060|OTHER|Group A|19 patients will be treated with pelvic tilt exercises
223477710|NCT00296335|DRUG|Mitomycin, doxifluridine and cisplatin|Mitomycin-C 20mg/m2 intravenously (day 1), Doxifluridine 460-600mg/m2/day per oral (day 28- day 336), Cisplatin 60mg/m2 intravenously (day 28, day 56, day 84, day 112, day 140, and day 168)
223477711|NCT00296335|DRUG|Mitomycin and doxifluridine|Mitomycin-C 20mg/m2 intravenously (day 1), Doxifluridine 460-600mg/m2/day per oral (day 28-day 84)
223477712|NCT03331081|OTHER|Bladder Training|The patient will participate in a class in which the physiotherapist will provide the following information: on the anatomy and function of the MAP, using figures; on bladder function; guidelines on the positioning and voiding habits and the definition and main risk factors responsible for urinary incontinence. The bladder training will consist of a program of time micturition to increase bladder capacity and the interval between urinations. Urge suppression strategies will be targeted, and include distraction, relaxation, breathing, and MAP contraction (quick flicks).
223744664|NCT02246673|DRUG|RDEA3170 5 mg|
223583594|NCT05052060|OTHER|Group B|19 patients will be treated with pelvic tilt exercises and facet joint manipulation.
223583595|NCT06116695|DRUG|human treated dentin matrix|human treated dentin matrix is compared with mineral trioxide aggregate in apexogenesis
223583596|NCT06116695|DRUG|Mineral Tri-Oxide Aggregate|mineral trioxide aggregate was used as control
223744665|NCT02246673|DRUG|Febuxostat 40 mg|
223744666|NCT02246673|DRUG|Febuxostat 80 mg|
223477713|NCT03331081|OTHER|TMAP|There will be 36 monthly series of home training (totaling at the end of the 3 months of treatment 108 series) performed 3x / week, 3x / day. The training protocol consists of three daily TMAP series. One series consists of 8 maximum voluntary contractions, with maintenance of the contraction of 6 to 10 seconds (type I muscle fibers), with twice the rest time between contractions, followed by three to five rapid contractions (muscle fibers type II ). The protocol will total 24 contractions of MAP per day performed, which will be divided in the morning (8 contractions), late (8 contractions) and night (8 contractions).
223477714|NCT03331081|OTHER|Bladder Training + TMAP|Will perform the exercises of the bladder training group and the TMAP in an associated way.
223744667|NCT04567875|OTHER|No Intervention on patients|No Intervention on patients
223744668|NCT01199744|DRUG|zanamivir|zanamivir
224070303|NCT06282120|DRUG|Irinotecan Hydrochloride Liposome Injection ；Fluorouracil ；Leucovorin；immunotherapy|The recommended dose and regimen of Irinotecan Hydrochloride Liposome Injection is 70 mg/m2 intravenously over 90 minutes, followed by dl-LV 400mg/m2 or l-LV 200mg/m2 intravenously over 30 minutes, followed by 5-FU 2400 mg/m2 intravenously over 46 hours, administered every 3 weeks.It can be combined or partially combined immunotherapy.
224070304|NCT06118060|OTHER|Acupressure|In this study, the frequency of acupressure was twice a day (the interval between each acupressure was more than 6 hours, 6:00 to 9:00 in the morning and 1:00 to 4:00 in the afternoon); the acupressure was applied from the first day after surgery for a total of 5 days, that is, each patient received a total of 10 acupressure; the duration was 5 minutes, and the bilateral acupressure required 10 minutes.
224070305|NCT00002279|DRUG|Zalcitabine|
224163847|NCT02865928|DRUG|Normal Saline|Same injection technique as intervention arm with normal saline
224163848|NCT01547676|PROCEDURE|robot-assisted laparoscopic surgery|Unclamped partial nephrectomy
223744669|NCT05322174|BEHAVIORAL|Baby Sleep|See arm description
223744670|NCT05322174|BEHAVIORAL|Baby Care|See arm description
223744671|NCT03329495|PROCEDURE|SMA-orientated right hemicoloectomy|Laparoscopic right hemicoloectomy for right colon cancer with a medial-to-lateral approach orientated by SMA. The left boundary of resection is the left side of SMA, and artery sheath is not necessarily being opened.
223744672|NCT03329495|PROCEDURE|SMV-orientated right hemicoloectomy|Laparoscopic right hemicoloectomy for right colon cancer with a medial-to-lateral approach orientated by SMV. The left boundary of resection is the left side of SMV, and SMA is not exposed.
223744673|NCT06387992|OTHER|Three-dimensional dental acquisition|Consultation with a trained nurse who will perform a three-dimensional dental acquisition using a 3D intraoral camera
223744674|NCT03344042|DRUG|Fentanyl|100mcg Fentanyl
223744675|NCT03344042|DRUG|Sufentanil|10mcg sufentanil
223744676|NCT03501758|DIAGNOSTIC_TEST|Ultrasound|Transabdominal ultrasound of the bowel for categorisation of disease activity
223744677|NCT03501758|DIAGNOSTIC_TEST|Analysis of prouroguanyline and uroguanyline in full blood|Withdrawal of full blood at each study visit, Storage in biobank. Analysis of prouroguanyline and proguanyline.
223744678|NCT02290106|DRUG|pitavastatin|
223477715|NCT00012116|DRUG|temozolomide|Administered in a fasting state, once a day for 6 weeks followed by 4 weeks of rest. Cycles may be repeated every 10 weeks until patients have evidence of progressive disease, intolerable toxicity or unwillingness to continue therapy. Daily dose: 75mg/m2.
224163279|NCT04681365|OTHER|Staff will wear and evaluate Bubble-PAPR (non-CE marked PAPR)|Staff will wear and evaluate the Bubble PAPR instead of usual PPE consisting of FFP3/N95 facemasks. This novel, non-CE marked prototype PPE is a Powered air Purifying Respirator and is used 'in house' (not approved for use outside of the Sponsor organisation)
224163280|NCT04104841|BEHAVIORAL|Behaviorally Enhancing Adolescents' Mood in Schools|8-session modified behavioral activation intervention
224163281|NCT04104841|BEHAVIORAL|Usual Care|Referral to school mental health provider, social worker, or community care.
224163282|NCT04739241|DRUG|premixed insulin therapy|Premixed insulin treatment: 30% of the calculated dose was administered before breakfast and before lunch (biphasic insulin lispro 50% or biphasic insulin aspart 50%) and the remaining 40% of the dose before dinner (biphasic insulin lispro 25% or biphasic insulin aspart insulin 30%).
224163283|NCT04739241|DRUG|basal bolus insulin therapy|Basal-bolus insulin treatment: 50% dose in insulin glargine and 50% dose in insulin lispro or aspartic, distributed in equal parts in the 3 main meals
224163284|NCT03893851|BEHAVIORAL|Interactions Competencies with Children - for Teachers (ICC-T)|Core training components include teacher-student interaction, maltreatment prevention, effective discipline strategies, identifying and supporting burdened students and implementation of the training materials into the school setting.
224163285|NCT02891772|PROCEDURE|ultrasonographic measurement of corrected flow time(FTc) in carotid artery|Corrected carotid artery flow time is measured using 10-5 MHz linear probe on a portable ultrasound machine. On the two-dimensional image, the optimal image of the long-axis view is obtained at the left common carotid artery. The sample volume is placed on the center of the lumen, 2 cm proximal to the bulb, and a pulsed wave Doppler examination was performed. Then, cardiac cycle time and carotid flow time is measured. Carotid flow time is measured between the upstroke of the flow tracing and the dicrotic notch, and it is corrected for pulse rate by dividing flow time by the square root of the cardiac cycle time to calculate corrected carotid artery flow time (flow time/√cycle time). The blood pressure was taken before anesthetic induction and every two minutes after anesthetic induction till ten minutes after endotracheal intubation.
224163286|NCT03299452|DRUG|Non Chemotherapy|Drugs screened by the Alphacait screening system will be administered in accordance with the protocol of the drug specification or the CPSC guidelines.
223477716|NCT05508958|PROCEDURE|Anterior approach|Anterior approach
223477717|NCT05508958|PROCEDURE|Posterolateral approach|Posterolateral approach
223477718|NCT01401322|DRUG|Lenalidomide|50 mg; po
223477719|NCT05230836|OTHER|High-frequency alternating current stimulation|"For electrical stimulation in the active groups, unmodulated alternating currents with a symmetrical rectangular waveform of 30 kHz, 40 kHz and 50 kHz will be applied. The current intensity shall be adjusted individually for each participant by increasing the current intensity until the participant reports a strong but comfortable tingling sensation just below the excitomotor threshold on the palmar aspect of the hand in the dermatomes innervated by the median nerve. The intensity of the current shall be adjusted every two minutes if the tingling sensation decreases. This protocol has been used in previous studies conducted by our research group"
223477720|NCT05230836|OTHER|Sham current stimulation|"Sham electrical stimulation will be performed with the same equipment and electrodes as in the active groups without the participants and the evaluator having a view of the device screen. The intensity of the current will be increased for 30 seconds until the sensory threshold (strong but comfortable tingling sensation) is exceeded and once the threshold is reached, the intensity will be reduced to 0 mA with 30 seconds ramp down. Participants will not receive electrical current during the rest of the placebo intervention. This protocol was used in other studies with similar interventions to blind participants."
223477721|NCT03980912|DIAGNOSTIC_TEST|LiverFASt|LiverFASt™ is a blood based diagnostic test utilizing a patented algorithm to determine presence and the progression of liver disease. The test is non-invasive, simple, and less expensive than liver biopsy or liver imaging.
223477722|NCT02737722|DRUG|Bisphosphocin Nu-3|
223477723|NCT02737722|DRUG|Placebo|
223477724|NCT06032663|DIAGNOSTIC_TEST|PET-MRI|Patients that participate in the current study will have an extra PET-MRI scan, which will expose them to a small amount (4 - 6 mSv) of extra radiation.
223477725|NCT01231217|OTHER|Green tea (Camellia sinensis)|Patients are recommended to drink at least 5 cups of green tea per day
223477726|NCT01231217|OTHER|Coffee|Patients are recommended to drink as much coffee as they tolerate.
223477727|NCT00518570|DRUG|Levetiracetam|Levetiracetam was started at 250 mg qhs at the end of the first week of the follicular phase. Dose was gradually increased up to 1500 mg bid as tolerated or clinically effective. The treatment phase lasted 4 months.
223477728|NCT06471439|OTHER|single leg exercise intervantion in COPD|"single leg exercise intervantions~1. high intensity interval training~2. continous exercise training~3. resistance exercise training"
223477729|NCT03880513|DIAGNOSTIC_TEST|Cardiovascular status and quality of life|Psychosocial and cardiovascular evaluation includes medical history, physical examination, laboratory tests, analysis of endothelial function, 24h blood pressure profile, Holter ECG, transthoracic echocardiography, cardiac MRI, and quality of life assessment
223477730|NCT00454298|DRUG|AGG-523 (Aggrecanase Inhibitor)|
223477731|NCT02771964|OTHER|Quality of life survey|"All enrolled patients complete a survey of baseline health during their visit to the preoperative assessment clinic and then complete a follow-up survey approximately 30 days after surgery.~The intervention for this study is to compare self-reported quality of life (How would you rate your quality of life now? (better/same/worse)) to the quantitative change in their VR-12 quality of life scores between the baseline survey and 30-day follow-up survey."
223744679|NCT02290106|OTHER|PLACEBO|
224163287|NCT03299452|DRUG|Chemotherapy and target therapy|Drugs screened by the Alphacait screening system will be administered in accordance with the protocol of the drug specification or the CPSC guidelines.
224163288|NCT03299452|DRUG|Chinese herb medicine|Drugs screened by the Alphacait screening system will be administered in accordance with the protocol of the drug specification or the CPSC guidelines.
224163289|NCT04129190|BIOLOGICAL|Glucose|Oral Intake of Glucose
223744680|NCT04829773|DRUG|Palovarotene|oral capsules
223477732|NCT06039163|DRUG|HH-120|Participants randomized to active treatment in escalation phase will receive HH-120 administered via inhalation for 5 consecutive days (Day 1 to Day 5). Planned dose levels to be used for the escalation phase of the study are 50 (BID), 50 (TID), and 100 (BID) mg. The expansion phase will begin once the recommended dose for expansion phase determined, based on safety and preliminary efficacy data from the escalation phase.
223477733|NCT06039163|DRUG|placebo|Participants randomized to placebo group in escalation and expansion phase will receive placebo administered via inhalation for 5 consecutive days (Day 1 to Day 5).
223477734|NCT04422067|OTHER|Fetal cephalometry|Fetal cephalometry
223477735|NCT05423951|DRUG|REMIMAZOLAM BESYLATE 2.5 Mg in 1 mL INTRAVENOUS INJECTION, POWDER, LYOPHILIZED, for SOLUTION [BYFAVO]|For the induction of anesthesia, patients allocated to the remimazolam group will receive intravenous infusion of remimazolam at a rate of 6 mg/kg/h, followed by 1 mg/kg/h after the loss of consciousness. The infusion rate of remimazolam will be adjusted to a maximum rate of 2 mg/kg/h to achieve a bispectral index of 40 to 60.
223477736|NCT05423951|DRUG|Propofol|For the induction of anesthesia, patients allocated to the propofol group will receive a bolus dose of propofol 1.5 mg/kg. After the loss of consciousness, general anesthesia will be maintained with sevoflurane to achieve a bispectral index of 40 to 60.
223477737|NCT05423951|DRUG|Rocuronium|After the loss of consciousness, a bolus of rocuronium 1 mg/kg was intravenously administered. After 90 seconds of manual ventilation, endotracheal intubation was performed
223477738|NCT05423951|DRUG|Sufentanil|During the study period, a total dose of sufentanil 0.5-2.0 mcg/kg was intravenously administered at the attending anesthesiologists' discretion.
223583597|NCT02505568|DRUG|Infliximab|Participants will receive infliximab 5 milligram per kilogram (mg/kg) infusion at Week 0, Week 2, and Week 6 for the induction phase. Participants who complete the induction phase will continuously receive 5 mg/kg infliximab infusion every 8 weeks up to week 32 in the maintenance phase.
223477739|NCT04503460|DRUG|Salmeterol Xinafoate|All participants will receive inhaled salmeterol xinafoate 50 μg twice in the morning and twice in the evening for 2 weeks; this will be followed by a 2-week washout period during which time no beta-agonists will be administered. Participants will be asked to use 'as required' ipratropium bromide during this period when needed in place of short-acting beta agonists.
223583598|NCT06137872|OTHER|Music Group|Pregnant women who came to the hospital for non-stress testing were met and informed about the study. The procedure was applied for non-stress testing. In the music group, the pregnant woman, who was assigned to the next group according to randomization during the non-stress test, was allowed to listen to music with disposable headphones for at least 20 minutes until the procedure was completed. At the same time, the mother will be asked to close her eyes and be relaxed. Headphones used to prevent infection were given to the pregnant woman as a gift at the end of the procedure.
223583599|NCT06137872|OTHER|Control Group|Pregnant women who came to the hospital for non-stress testing were met and informed about the study. The procedure was applied for non-stress testing. During the non-stress test, routine non-stress test was performed on the pregnant control group, which was assigned to the next group according to randomization.
223744681|NCT04829773|DRUG|midazolam|oral syrup
223477740|NCT04503460|DRUG|Salmeterol Fluticasone|Following the 2-week washout period, all participants will receive inhaled salmeterol xinafoate 50 μg combined with fluticasone propionate 250 μg twice in the morning and twice in the evening for 2 weeks. Participants will be asked to use 'as required' ipratropium bromide during this period when needed in place of short-acting beta agonists.
224163290|NCT05319223|BEHAVIORAL|patient blood management|three pillars of patient blood management will be applied
224163291|NCT00003000|DRUG|fentanyl citrate|
224163292|NCT00003000|DRUG|morphine sulfate|
224163293|NCT01387594|PROCEDURE|lumbar puncture|2 lumbar punctures prior to treatment; study drug 225mg SC once a month X 3 doses.
224163294|NCT01387594|DRUG|lumbar puncture|1 lumbar puncture before and after 3 doses; study drug 225mg SC once a month X 3 doses.
223583600|NCT05002842|BEHAVIORAL|LovingKindess Meditation|Participants will have access to a recording of a script to guide them through meditation
223583601|NCT04430647|PROCEDURE|combined phacoemulsification and ultrasound ciliary plasty (Phaco-UCP)|performing ultrasound ciliary plasty then performing standard phacoemulsification
223583602|NCT04430647|PROCEDURE|Phacoemulsification alone|standard phacoemulsification for catarct extraction
223583603|NCT04664582|PROCEDURE|Sentinel Lymph Node Biopsy|see intervention group description
223583604|NCT04216407|PROCEDURE|Remote ischemic preconditioning|An orthopedic tourniquet was tied to the right lower extremities of the patients in RIPC arm, and tourniquet application was performed before the anhepatic phase in 3 periods of 3 minutes with an interval of 3 minutes.
223583605|NCT05734274|OTHER|Probiotics|Probiotics lozenge containing at least 200 million active Limosilactobacillus reuteri.
223583606|NCT05734274|OTHER|Negative control|Sugar-free negative control lozenges.
223583607|NCT03016923|DEVICE|FES Therapy|FES therapy will be administered over the course of 1 hour sessions that will be take place 3 times per week over 16 weeks, for a total of 48 sessions.
223583608|NCT03381027|PROCEDURE|Baby Massage|Structured massage of the baby
223744682|NCT00954642|DRUG|bevacizumab|Intravenous repeating dose
223744683|NCT00954642|DRUG|MNRP1685A|Escalating intravenous dose
223744684|NCT00954642|DRUG|paclitaxel|Intravenous repeating dose
223744685|NCT02716558|OTHER|ART Sealant Application|application of the ART sealant using high viscosity glass inomer cements.
223744686|NCT02716558|OTHER|Resin sealant application|application of the moisture tolerant sealant according to the manufacturers instructions.
224163295|NCT02845999|BIOLOGICAL|allogenic immunotherapy based on Natural Killer cells adoptive transfer|day -1 : donor NK cell purification ; day 0 : adoptive transfer (according to a dose escalation) ; Dose escalation protocol : 3.10\^6 ; 8.10\^6 and 12.10\^6 cells/kg of recipient body weight
224163296|NCT02845999|BIOLOGICAL|cetuximab|day -8 : cetuximab 400 mg/m2 ; day -1 and every week (for 7 weeks) : cetuximab 250 mg/m2
224163297|NCT02845999|DRUG|Cyclophosphamide|day -6 : cyclophosphamide 60 mg/Kg
223744687|NCT00017264|DRUG|atrasentan hydrochloride|
223744688|NCT00417092|PROCEDURE|Postoperative Pacing|
223744689|NCT04644614|DEVICE|Magnetic Stimulation - Armchair type|MS and Sham MS will be applied two days a week, 20 minutes a day, for 8 weeks, a total of 16 sessions.
223477741|NCT05273983|BEHAVIORAL|Behavioural Activation|The intervention will span 6 weeks, including two intervention sessions with the primary care psychologist, and 6-weeks use of a mobile activity scheduling app (Strides). In the first intervention session, the psychologist would provide psychoeducation about depression, therapeutic rationale of behavioural activation, aid the patient in identifying their values and corresponding activities that may correspond with their values, introduce the mobile app, and help the patient schedule initial activities/goals. The second intervention session, which would be flexibly scheduled according to patient need, would focus on troubleshooting/clarification of previously discussed topics.
223477742|NCT02668068|PROCEDURE|large volume whole-lung lavage (WLL)|Generally 1000 \~ 2000ml each time, 14 \~ 10 times totally, each side of the lung to 20 \~ 15 liters, until the lavage fluid from the black into a colorless clear clarification
223477743|NCT02668068|BIOLOGICAL|clinical grade umbilical cord mesenchymal stem cells|10\^6 (1 million) /Kg/person cells of clinical grade umbilical cord MSCs will be injected after whole-lung lavage
223583609|NCT01761500|OTHER|Modified BFM-90 protocol|Using Modified BFM-90 protocol to treat Chinese children and Adolescents with NHL
223583610|NCT05587166|OTHER|ultrasound guided adductor canal block|ultrasound-guided adductor canal block using oblique short-axis for catheter insertion
223583611|NCT03158181|OTHER|Non interventional study|None intervention will be conduct on patient. Only the operating room will be randomized to have an intervention or not (Bundle of measure for optimizing the discipline of personnel in the operating room)
223583612|NCT00963768|DRUG|JNJ 28431754|A liquid suspension of 30 mg, 100 mg, 300 mg of JNJ-28431754 taken once (or twice) daily or 600 mg taken once daily will be administered by study personnel directly into the patient's mouth using an oral liquid dispenser for 14 days (Day 1 and Days 3 through 16).
223744690|NCT02285907|OTHER|Macronutrient and Fiber Matched BEEF|The participants will consume the macronutrient and fiber matched BEEF lunch on a single testing day. BEEF contained 33% protein, 43% CHO, and 24% fat; the BEEF meal contained 24 g of beef protein from 96% lean ground beef (Cargill, KS). Soy fiber (Nutritional Designs, NY) was added to the BEEF meal to match total final content between meals.The participants will consume the serving size matched BEEF lunch on a single testing day. BEEF contained 33% protein, 43% CHO, and 24% fat; the BEEF meal contained 24 g of beef protein from 96% lean ground beef patty (Cargill, KS).
223744691|NCT02285907|OTHER|Macronutrient and Fiber Matched SOY|The participants will consume the macronutrient and fiber matched SOY lunch on a single testing day. SOY contained 33% protein, 43% CHO, and 24% fat; the SOY meal contained 24 g of textured soy protein concentrate (Boca Foods, WI).
224163298|NCT02845999|DRUG|fludarabine|day -6 to day -2 : fludarabine 25 mg/m2
224163299|NCT02845999|DRUG|interleukin-2|day -1 : addition of 1000 UI/ml of interleukin 2 to NK cells and overnight culture at 37°C, 5%CO2 ; day 0, hour +12 : 10 MUI of interleukin 2 injection, 2 times a week during 3 weeks.
224163300|NCT01886352|DRUG|Standard Injection of Levobupivacaine in portal sites.|All port sites will be injected with 0.1ml/kg levobupivacaine at the end of surgery, after trocar removal.
224163301|NCT01886352|DRUG|Additional injection of 0,5% levobupivacaine.|Immediately following insufflation 0.15ml/kg levobupivacaine will be injected in the peritoneal cavity via a trocar. At the end of the surgery, this process will be repeated with the same dose at 0.15ml/kg.
224163302|NCT01886352|DRUG|Intraperitoneal atomization of levobupivacaine.|"Immediately following insufflation the Optispray® surgical spray device will be inserted into the abdomen and directed towards the diaphragms, dome of inflated abdomen, bowel peritoneum and surgical dissection site and the study drug will be delivered as an atomized spray in the following volumes:~1. Each subdiaphragmatic area 0.05 ml/kg~2. Dome of abdomen then settling onto bowel 0.05 ml/kg~3. Surgical dissection site 0.05 ml/kg~4. At the end of the surgery - this process will be repeated with the same doses at 0.15 ml/kg."
224163303|NCT01990703|DRUG|Levonorgestrel IUD|Timing of IUD insertion
224163304|NCT06903988|PROCEDURE|laparoscopic lateral suspension|Laparoscopic lateral suspension: Place a 1/2 T4 mesh in the vesicovaginal space. The two lateral slings are passed out from the outer upper side of the bilateral anterior superior iliac spine, and the prolapsed organs are suspended to the abdominal wall.
223744692|NCT02285907|OTHER|Serving Size Matched BEEF|The participants will consume the serving size matched BEEF lunch on a single testing day. BEEF contained 33% protein, 43% CHO, and 24% fat; the BEEF meal contained 24 g of beef protein from 96% lean ground beef patty (Cargill, KS).
224163305|NCT06903988|PROCEDURE|Transvaginal sacrospinous ligament fixation|Transvaginal sacrospinous ligament fixation: Dissect the rectovaginal space to expose the right sacrospinous ligament, and fix the cervix or vaginal cuff to the right sacrospinous ligament.
224163306|NCT05849441|BEHAVIORAL|Aware Program|The program includes interactive, multimedia lessons for adolescent participants to learn, practice, and apply different mindfulness skills. Parent-adolescent pairs will have the option to subscribe to a mobile messaging service that includes progress reminders, encouragement, and practice content. Parent participants also have access to online resources to support and monitor their teen's use of the program.
224163307|NCT03971292|GENETIC|RNA sequencing|Testing interest of messenger RNA sequencing for the etiological diagnosis of unresolved patients after sequencing coding regions.
224163308|NCT03140657|DRUG|Nanocurcumin|Nanocurcumin capsules (the formulation of curcumin nanoparticles, Exirnanosina). Subjects randomized to Nanocurcumin Arm will receive 80 mg/day for 4 months
224163309|NCT03140657|DRUG|Placebo|Subjects randomized to Placebo Arm will receive placebo in the form of capsules for 4 months
224163849|NCT01547676|PROCEDURE|robot-assisted laparoscopic surgery|Undergo clamped partial nephrectomy
223583613|NCT00963768|DRUG|Placebo|A liquid suspension of placebo will be administered by study personnel directly into the patient's mouth using an oral liquid dispenser once or twice daily for 14 days (Day 1 and Days 3 through 16).
223583614|NCT01595594|DRUG|Systemic Doxycycline and Sham aPDT|It will be prescribed a protocol of 100mg/day of Systemic Doxycycline for 14 days
223583615|NCT01595594|DRUG|aPDT + Doxycycline Placebo|The aPDT protocol will consist in 5 applications on the experimental time 0, 1, 5, 7 and 14 days.
223583616|NCT00865839|DRUG|Metformin HCl 500 mg tablets, single dose|A: Experimental Subjects received Purepac formulated products under fasting conditions
223583617|NCT00865839|DRUG|CLUCOPHAGE® XR 500 mg tablets, single dose|B: Active comparator Subjects received Bristol-Myers Squibb Company formulated products under fasting conditions
223477744|NCT02465450|DRUG|JBT-101 (lenabasum)|Subjects will receive JBT-101 1 mg qd or JBT-101 5 mg qd on Days 1-28. Subjects will receive either JBT-101 20 mg q am (with placebo q pm) or JBT-101 20 mg twice a day on Days 29-84.
223477745|NCT02465450|OTHER|Placebo|Subjects will receive placebo once a day on Days 1-28, placebo q pm on Days 29-84 (with JBT-101 20 mg q am), or placebo bid on Days 29-84.
223477746|NCT04976374|DRUG|Dexmedetomidine and Gabapentin|Administration of intravenous dexmedetomedine for post operative analgesic purposes in combination with gabapentin
223477747|NCT04976374|OTHER|Saline|Intravenous Saline 0.9% for placebo purposes
223477748|NCT00610415|PROCEDURE|tumor biopsy|
223477749|NCT01836120|DRUG|Raltitrexed plus Docetaxel|"Raltitrexed plus Docetaxel (Raltitrexed 3mg/m2 d~1; Docetaxel 75mg/m2 d1, every 3 weeks, 4-6 cycles)"
223583618|NCT02404649|DEVICE|Two implant designs in a Sinus Bone Augmentation Procedure|Comparing TMDI (Zimmer Dental- Carlsbad, CA, USA) and Tapered Screw-Vent TSV-MTX (Zimmer Dental- Carlsbad, CA,USA) biological behavior after a sinus bone augmentation procedure.
223477750|NCT01836120|DRUG|Docetaxel|Docetaxel (Docetaxel 75mg/m2 d1, every 3weeks,4-6 cycles)
224163310|NCT03277794|BEHAVIORAL|HOP-C|Service provision will be provided by Loft and Covenant House for the transitional case management component, the peer component will be supported through Sketch Arts, and the mental health component will be provided by a post-doctoral fellow clinical psychologist and a mindfulness therapist from the Centre for Mindfulness Studies, supervised by Dr. Sean Kidd.
224163311|NCT03277794|BEHAVIORAL|Transitional Case Management Only|Participants in this arm will be provided with a transition-focused community support worker who will assist in areas ranging from general support and encouragement to assistance in navigating relevant systems. They will have weekly contacts with participants by phone, informal contact via text and email, and at least twice per month will visit the participant where they are residing. It is expected that all participants will engage a community support worker. The transitional case manager hired into this role will be highly experienced in case management for youth.
223477751|NCT01687660|OTHER|acupuncture|apply acupuncture to prevent the migraine attack
223477752|NCT00112957|BIOLOGICAL|rV-NY-ESO-1 vaccine|Patients received a single intradermal injection of rV-NY-ESO-1 (3.1 × 10\^7 PFU) on Day 1.
223477753|NCT00112957|BIOLOGICAL|rF-NY-ESO-1 vaccine|Patients received subcutaneous injections of rF-NY-ESO-1 (7.41 × 10\^7 PFU) on Days 29, 57, 85, 113, 141, and 169.
224163312|NCT02168660|DRUG|Vitamin D3|Vitamin D3, liquid formulation, 5000 IU/mL.
224163313|NCT06719102|BEHAVIORAL|MAGIC-FEED|Parents will be provided with responsive feeding coaching to help them recognize hunger and satiety cues and nutrition coaching that includes bottle-/breast-feeding and complementary feeding in alignment with the Dietary Guidelines. The intervention is delivered via virtual visits, binder, website and newsletters.
224163314|NCT06719102|BEHAVIORAL|MAGIC-SAFE|Parents will be provided with information about age-appropriate safety topics, including safe sleeping, car seats, baby-proofing, etc. The intervention is delivered via virtual visits, binder, website and newsletters.
224163315|NCT05258513|DIETARY_SUPPLEMENT|Placebo Supplementation|8 weeks of placebo supplementation
224163316|NCT05258513|DIETARY_SUPPLEMENT|GG sourced from Annatto|8-weeks of Geranylgeraniol supplementation
224163317|NCT00004360|DRUG|chlorothiazide|
224163318|NCT05274594|RADIATION|Radiotherapy|Patients who are candidate for radiotherapy and received neoadjuvant chemotherapy for breast cancer were evaluated after neoadjuvant chemotherapy. Cases that do not have clinical response received radiotherapy before surgery in order to increase complete response.
224163319|NCT00925691|DEVICE|RV lead|The RV lead is implanted at the apex or at the interventricular septum
224163320|NCT06916624|RADIATION|18F-NY104 PET/CT|The radionuclide ¹⁸F will serve as the tracer in this study. NY104 will be labeled with \[¹⁸F\]AlF to form the ¹⁸F-NY104 injection for use in this research.All participants will undergo ¹⁸F-NY104 PET scan.
223477754|NCT04026425|OTHER|Two-day cardiopulmonary exercise test|A series of two cardiopulmonary exercise tests (CPETs) performed over two days. Participants will perform a CPET and then will return approximately 24 hours later to perform the second CPET. The CPET begins with 3 minutes of seated rest followed by cycling during incremental workloads which increases 15 watts throughout each minute of exercise. The participant will cycle until volitional exhaustion and/or the participant and/or test administrator determines to stop the test. Actual exercise time usually varies between 8-10 minutes.
223583619|NCT02404649|DEVICE|Two implant designs in a Sinus Floor Elevation Procedure|Comparing TMDI (Zimmer Dental- Carlsbad, CA, USA) and Tapered Screw-Vent TSV-MTX (Zimmer Dental- Carlsbad, CA,USA) biological behavior after a sinus elevation only procedure.
223583620|NCT04075409|DRUG|Padsevonil|Padsevonil will be administered in predefined dosages.
223583621|NCT01754792|DIETARY_SUPPLEMENT|Pinitol|Fruit Up® (diluted with mineral water to a final volume of 250 ml) will be evaluated, and will be equivalent to an intake of 2 g of pinitol. The placebo beverage will contain equal amounts of non-polyol carbohydrates with similar macronutrient composition and energy intake as that those obtained through the pinitol beverage, but excluding pinitol.
223583622|NCT02221154|DIETARY_SUPPLEMENT|Inofolic®|
223477755|NCT00870142|DRUG|AMLODIPINE (as BESILATE) TABLETS 10 mg , single dose|A: Experimental Subjects received EMCURE PHARMACEUTICALS LTD. formulated products under fasting conditions
223477756|NCT00870142|DRUG|Norvasc® 10 mg Tablets|B: Active comparator Subjects received Pfizer Labs Division of Pfizer Inc. formulated products under fasting conditions
223477757|NCT02182804|DEVICE|Olympus|narrow band imaging with magnification
223477758|NCT02182804|DEVICE|Cellvizio|probe-based confocal laser endomicroscopy
223477759|NCT06467721|DEVICE|Self-adhesive silicone gel waterproof dressing|Self-adhesive silicone gel waterproof dressing is used after artificial joint replacement surgery.
223477760|NCT06467721|DEVICE|Sterile gauze dressing|Sterile gauze dressing is used after artificial joint replacement surgery.
223477761|NCT02366871|DRUG|Oral apixaban|To evaluate the incidence of major bleeding (including CRNM bleeding) events in women undergoing surgery for gynecologic cancer with apixaban 2.5 mg BID compared to current standard of care, subcutaneous enoxaparin 40 mg QD for 28 days post surgery.
223477762|NCT02366871|DRUG|Subcutaneous enoxaparin|To evaluate the incidence of major bleeding (including CRNM bleeding) events in women undergoing surgery for gynecologic cancer with apixaban 2.5 mg BID compared to current standard of care, subcutaneous enoxaparin 40 mg QD for 28 days post surgery.
223477763|NCT00167700|BEHAVIORAL|Dietary counselling and placebo|Counseling to conform with the dietary recommendations. Food products commercially available including spreads and salad dressing. Placebo capsules.
223477764|NCT00167700|BEHAVIORAL|Dietary counselling and probiotics|Counseling to conform with the dietary recommendations. Food products commercially available including spreads and salad dressing. Probiotics
223477765|NCT00167700|DIETARY_SUPPLEMENT|Placebo capsules|Placebo capsules
223477766|NCT00167700|DIETARY_SUPPLEMENT|Probiotics|
223477767|NCT00167700|DIETARY_SUPPLEMENT|Prebiotics|
223477768|NCT02803463|PROCEDURE|open appendectomy with peritoneal closure|open appendectomy with peritoneal closure under general anesthesia for acute appendicitis
223477769|NCT02803463|PROCEDURE|open appendectomy without peritoneal closure|open appendectomy without peritoneal closure under general anesthesia for acute appendicitis
223477770|NCT02634255|DRUG|Rocuronium elective surgery|Rocuronium onset time in patients undergoing inguinal herniorrhaphy
223477771|NCT02634255|DRUG|Rocuronium emergency surgery|Rocuronium onset time in patients undergoing appendectomy
223477772|NCT02634255|DRUG|Propofol|
223477773|NCT02634255|DRUG|Fentanyl|
223477774|NCT02634255|OTHER|Ringer Lactate|
224163321|NCT04661267|DIETARY_SUPPLEMENT|Stem Cell Support Formula|This liquid supplement contains the following ingredients: chondroitin sulfate, glucosamine sulfate, vitamin C (ascorbic acid), curcumin and Bioperine®, resveratrol, L-carnosine, bitter melon, and vitamin D.
224163322|NCT04661267|DIETARY_SUPPLEMENT|Placebo|The placebo comparator will look and taste similar without the active ingredients of the Stem Cell Support Formula.
224163323|NCT05676801|DRUG|Photodynamic Therapy|PDT with methyl aminolevulinate (MAL) as the prodrug for the photosensitizer Pp IX
224163324|NCT05671237|OTHER|bilateral infraorbital+infratrochlear block|we will perform bilateral infraorbital+infratrochlear nerve block
224163325|NCT00545467|DRUG|Aripiprazole|Aripiprazole will be given as a fixed does, 15 mg/day, orally throughout 8 weeks in the 2 arms.
224163326|NCT00458367|DRUG|Open label risperidone long acting injectable|intramuscular injections every 2 weeks for 26 weeks, flexible dose 25 to 50 mg
224163327|NCT04459104|OTHER|Low glycemic load|Participants will be given test beverages containing 50gr of isomaltulose (low glycemic index = 32). Isomaltulose powder will be dissolved in 250mL water, and participants will be instructed to consume this beverage within 5 minutes. Blood glucose levels will be collected at 15, 30, 45, 60, 90, and 120 minutes after consumption of the beverages. The first two drops of blood will be discarded, the third drop will be used for testing.
224163328|NCT04459104|OTHER|High glycemic load|Participants will be given test beverages containing 50gr sucrose (high glycemic index = 65). Sucrose powder will be dissolved in 250mL water, and participants will be instructed to consume this beverage within 5 minutes. Blood glucose levels will be collected at 15, 30, 45, 60, 90, and 120 minutes after consumption of the beverages. The first two drops of blood will be discarded, the third drop will be used for testing.
223477775|NCT02634255|DEVICE|Acceleromyography device|
223477776|NCT02060409|GENETIC|spliceosome|spliceosome mutations
223477777|NCT02715908|DRUG|LBEC0101|Etanercept 50mg
223583623|NCT02221154|OTHER|Gonadotropins; Folic Acid|standard ovarian stimulation
223477778|NCT00092001|DRUG|Sunitinib|Sunitinib 50 mg by oral capsule daily for 4 weeks in every 6 week cycle until progression or unacceptable toxicity.
223477779|NCT01578291|BEHAVIORAL|Parental information|An informational brochure indicating the study details
223477780|NCT01578291|BEHAVIORAL|Play therapy|Play therapy with a child life specialist
223477781|NCT05534542|OTHER|exercıse|ıntradıalıtıc core stabılızatıon
223583624|NCT01669213|DRUG|ramosetron|before 5 minutes spinal anesthesia, injection of ramosetron 0.3 mg
223744693|NCT02285907|OTHER|Serving Size Matched SOY|The participants will consume the serving size matched SOY lunch on a single testing day. SOY contained 24% protein, 49% CHO, and 24% fat; the SOY meal contained 14 g of textured soy protein concentrate (Boca Foods, WI).
223477782|NCT01242787|DRUG|LB80380|Optimal dose of LB80380, by oral for 48 weeks (optimal dose will be chosen early 2011 based on the results of LG-BVCL007 study)
223477783|NCT01242787|DRUG|Entecavir 0.5 mg|Entecavir 0.5 mg, by oral for 48 weeks
223477784|NCT02136693|DRUG|Psyllium fiber|3.5 g /day of pure Psyllium fiber for 180 days after STARR
223583625|NCT01669213|DRUG|ondansetron|before 5 minutes spinal anesthesia, injection of ondansetron 8 mg
223583626|NCT01669213|DRUG|ondansetron|before 5 minutes spinal anesthesia, injection of ondansetron 4 mg
223583627|NCT01669213|DRUG|placebo|before 5 minutes spinal anesthesia, injection of normal saline 5 ml
223583628|NCT01908088|BIOLOGICAL|Cell transplantation|autologous transplantation of cultured fibroblast on amniotic membrane in patients with Epidermolysis Bullosa with mitten hands.
223744694|NCT00002384|DRUG|Cidofovir|
224163329|NCT03441555|DRUG|Venetoclax|tablet, oral
224163330|NCT03441555|DRUG|Alvocidib|Intravenous
223477785|NCT02136693|DRUG|Placebo|3.5 g /day of inert compound for 180 days after STARR
223477786|NCT00386061|DRUG|rimonabant (SR141716)|
223477787|NCT01981083|DIETARY_SUPPLEMENT|Egg albumin-based protein supplement|
223477788|NCT01981083|DIETARY_SUPPLEMENT|Renal-specific oral supplement|
223477789|NCT00770406|DRUG|botulinum toxin type A|100 or 200 units intravesically
223477790|NCT03749200|OTHER|Obemat2.0 therapy|
223477791|NCT03749200|OTHER|Regular practise in primary care|
223477792|NCT06099535|DRUG|LNK01001 Dose A|Capsules taken orally
223477793|NCT06099535|DRUG|LNK01001 Dose B|Capsules taken orally
223477794|NCT06099535|DRUG|placebo|Capsules taken orally
223477795|NCT05297682|DEVICE|anesthesia with propofol|General anesthesia with propofol
223477796|NCT04451096|DIETARY_SUPPLEMENT|Probiotics with prebiotic|Patients were instructed to consume one sachet twice daily mixed with a glass of water, before or after meals, for a duration of 8 weeks
224163850|NCT04282460|BEHAVIORAL|Baduanjin practice|Use the Baduanjin training system to practice the whole set of Baduanjin at least once a day and at least 5 days each week for 3 months.
224163851|NCT04282460|BEHAVIORAL|Regular physical exercise|Take physical exercise for at least half an hour every day in addition to regular physical activities at school.
223477797|NCT04451096|DIETARY_SUPPLEMENT|Placebo|Patients were instructed to consume one sachet twice daily mixed with a glass of water, before or after meals, for a duration of 8 weeks
223477798|NCT05916209|PROCEDURE|Peripheral nerve blocks|Peripheral nerve blocks provide intense, site-specific analgesia administring local anesthetics near the nerves.
223477799|NCT00454870|DRUG|MEM 3454|
223477800|NCT02933814|DRUG|Liposomal Bupivicaine|Patients in Group 2 (Liposomal Bupivacaine + Plain Bupivacaine) will be treated intra-operatively with the initial injection of 0.25% bupivacaine 5 - 10 mL (12.5 - 25 mg) delivered to perform a field block of the soft tissue and subfascial plane at the initiation of the procedure.
223477801|NCT04725669|DIAGNOSTIC_TEST|ELISA IgG Testkit|All samples will be tested for IgG antibody level to pertussis toxin using a commercial Bordetella pertussis ELISA IgG Testkit in accordance to the manufacturers' protocol in the laboratory at the University Hospital for Infectious Diseases in Zagreb.
223477802|NCT06264713|DEVICE|Immersive Virtual Reality|Patients wear a head-mounted-display and will be immersed in a virtual environment. The stimuli will be provided in the left, center and right visual fields. Eye-tracking biofeedback will be provided about the real-time performance during each exercise.
223477803|NCT06264713|DEVICE|Sham Immersive Virtual Reality|The patients performed the same protocol of the experimental group, differently to the immersive virtual reality group, from session 2 to session 8 (7 sessions), the stimuli will be provided in the center and right visual fields.
223477804|NCT00290225|BEHAVIORAL|Breath Water Sound Course and Traumatic Incident Reduction|
223477805|NCT06000644|DEVICE|Combined group|The combined group will undertake progressive treadmill walking speed while performing a cognitive task with rhythmic auditory cueing for 30 minutes per session, 3 times a week for 4 weeks.
223477806|NCT06000644|DEVICE|Cognitive group|The cognitive group will receive cognitive training while treadmill walking with a progressive speed for 30 minutes per session, 3 times a week for 4 weeks .
223477807|NCT06000644|DEVICE|Rhythmic group|The rhythmic group will hear rhythmic auditory stimulation while treadmill walking for 30 minutes per session, 3 times a week for 4 weeks.
223477808|NCT06000644|DEVICE|Treadmill group|The treadmill group will train only in progressive treadmill walking for 30 minutes per session, 3 times a week for 4 weeks.
224163331|NCT03039569|BEHAVIORAL|Text messaging|"The messages will consist of information on how to increase fruits and vegetables and reduce high-fat and sugary foods intake, increase the availability of fruits and vegetables and reduce high-fat and sugary foods in the home, strategies to increase diabetes self-management skills, and awareness of cardiovascular disease risk perception and knowledge. The text messages will be derived from the American Association of Diabetes Educator (AADE) handouts (Reducing Risks, Monitoring, Healthy Coping, Problem Solving, Taking Medication, Healthy Eating, and Exercise). The control group will not receive text messages"
223477809|NCT02889419|DEVICE|Evaluation of underwear Selfia®|Patients are evaluated for a week using their usual underwear for the realization of SC. At the end of the week, they receive Selfia ® adaptated underwear and they use it for one week for a new evaluation. Finally, underwear will be given to patients and during follow-up consultations in routine at 6 months and 1 year, he will be asked if they reused or bought underwear.
223477810|NCT06140186|DRUG|Topical Timolol|Topical timolol 0.5% eye drops (liquid form) twice daily with occlusion (i.e. covered with adhesive badge) and betamethasone valerate 0.1% cream twice daily with occlsuion for 1 month.
224163332|NCT05412836|DEVICE|AqueousJoint|AqueousJoint is a liposomal boundary lubricant, which coats the cartilage surface and protects it from further damage and degradation.
223477811|NCT06140186|DRUG|Betamethasone Valerate|Betamethasone valerate 0.1% cream application twice daily
223477812|NCT05776992|DEVICE|Xbox virtual reality games|X-box balance evaluation was implemented in a completely dark and isolated room specially prepared for this treatment and evaluation
223477813|NCT05776992|DEVICE|Biodex balance training|the Biodex Balance System SD has been designed to meet the needs of everyone looking to improve balance, increase agility, develop muscle tone and treat a wide variety of pathologies.
223583629|NCT00330668|DRUG|rh IGF-1 (mecasermin)|Patients from untreated arm for prior study MS301 (NCT00125164) were randomized to a dose of either 80 or 120 mcg/kg twice daily. For patients receiving active treatment in previous study MS 301 (NCT00125164), they started on a dose of 80 or 120 mcg/kg twice daily based on the dose reached at end of the previous study. Following a protocol amendment in May 2009, all patients were switched to once daily doses of 160 µg/kg, escalated to a targeted maximum dose of 240 µg/kg.
224163333|NCT01820767|DRUG|Paricalcitol|Oral Paricalcitol. parathyroid hormone i mcg/100. 3 days per week, the same day as haemodialysis is done, during 12 weeks.
224163334|NCT01820767|DRUG|Paricalcitol, atorvastatin|"Oral Paricalcitol. parathyroid hormone i mgc/100. 3 days a week, the same day as haemodialysis, during 12 weeks.~Atorvastatin: 20 mg/day oral (1 take) during 12 weeks."
224163335|NCT01820767|DRUG|Atorvastatin|Atorvastatin: 20 mg/day oral (1 take) during 12 weeks
224163336|NCT00002413|DRUG|Emivirine|
224163337|NCT05455255|OTHER|Experimental|FL was applied by Jonathan Bergmann and Aaron Sams in 2007 for high school students who had to be absent from chemistry class. Bergmann and Sams published all the learning activities they used during the lesson as videos. Bergmann and Sams (2012) stated that in this model, which they developed over time, it is not compulsory for the trainer to explain the entire course content in the videos, and the important thing is to allocate time to active learning methods during the course. In the FL model, the summary of the course content is presented to the individuals outside the classroom with tools such as video and power point presentations. In the lesson, activities are carried out for the active participation of the student. The student performs the course content outside of the classroom, and the homework and learning the course in the classroom.
224163338|NCT00611988|BEHAVIORAL|Self-managed walking|The intervention includes individual therapy, group reinforcement, and follow-up phone contact
224163339|NCT00611988|OTHER|Control group|Attention control group will receive routine follow-up phone calls
224163340|NCT03991468|DIAGNOSTIC_TEST|Whole Slide Imaging|Scanning of a glass slide to create a digital image that can be viewed on a monitor
223583630|NCT01013779|DRUG|Carboplatin|"During radiotherapy: Carboplatin (AUC2) commences on day 1 of radiation and is repeated at weekly intervals on days 8, 15, 22 and 29 (of radiation).~After radiotherapy: 3 weeks after completing radiotherapy, 3 cycles of 3 weekly carboplatin (AUC4.5) intravenously on day 1."
223477814|NCT03955549|BEHAVIORAL|Insight Enhancement Program (IEP)|"IEP is comprised of 8 sessions, administered twice weekly, across a one month period. The session duration is 60-90 minutes. IEP will be administered in a group format with 8-12 patients in each group.~During sessions, different topics representing 8 different stages of illness are discussed according to a chronological schedule. These stages are presented on an Illness March Graph (IMG) and include: Stage I: Personality formation, Stage II: Pre onset confusion, Stage III: Prodroma, Stage IV: The illness, Stage V: Resistance, Stage VI: Remission, Stage VII: Maintenance, Stage VIII: Relapse. Patients actively participate through the exchange of their own experiences and interpretations, which are then reinterpreted by the therapist and by the patients themselves."
223477815|NCT03955549|BEHAVIORAL|Metacognitive Training for Psychosis (MCT)|The training consists of eight modules that are administered within the framework of a group intervention program that involves eight 1-hour group sessions with 4 to 10 patients in each group. MCT is manualized and currently available in thirty languages and can been downloaded via the following web address: http://www.uke.de/mct. Among the problematic thinking styles recognized as potential contributors to the development of delusions are attributional distortions (module 1), a jumping to conclusions bias (module 2 and 7), a bias against disconfirmatory evidence (module 3), deficits in theory of mind (module 4 and 6), over-confidence in memory errors (module 5) and depressive cognitive patterns (module 8).
223477816|NCT03955549|DRUG|Treatment As Usual (TAU)|"Treatment As Usual (TAU) consists of psychiatric management by a clinical team including at least one psychiatrist and one psychologist. Treatment involves antipsychotic medication, regular office-based contacts with the clinical team for treatment monitoring, recreational group activities, and unstructured psycho-educational groups. Participants in the interventional groups also will receive TAU.~Medications: In order to standardize treatment, Risperidone (Risperdal ) will be used as the antipsychotic medication in all three groups with a dose up to 6-8 milligrams according to clinical severity. The same dose will be used for 1 month prior to starting interventions). In case of occurrence of mild extrapyramidal symptoms associated with high doses of risperidone, an anticholinergic drug (Benztropine) might be used."
223477817|NCT00930618|DRUG|IMN|Administration of 2 x 20 mg of isosorbide mononitrate at each administration with a maximum of three administrations
223477818|NCT00930618|DRUG|Placebo|Administration of 2 X 20 mg of placebo of IMN at each administration with a maximum of three administration
223477819|NCT01131936|DRUG|Amlodipine|Amlodipine Tablets, 10 mg
223477820|NCT02049216|OTHER|Flexible tape|Flexible, elasticised, adhesive athletic tape
223477821|NCT02049216|OTHER|Fixomull|
223583631|NCT01013779|DRUG|Etoposide|After Radiotherapy: 3 weeks after completing the radiation therapy, 3 cycles of 3 weekly etoposide (80mg/M2/day) intravenously days 1-3
223583632|NCT01013779|RADIATION|Radiotherapy|"Microscopic Disease: 50Gy delivered in 2Gy doses over 25 fractions~Macroscopic Disease: 54Gy delivered in 2Gy doses over 27 fractions"
223583633|NCT02514668|DRUG|Isatuximab|"Pharmaceutical form: solution for infusion~Route of administration: intravenous"
223583634|NCT03055390|DRUG|hyoscine butylbromide|Intravenous administration of hyoscine butylbromide during first stage of labor
223583635|NCT03055390|DRUG|placebo|2ml of saline intravenous
223583636|NCT01052961|DRUG|Oseltamivir|oseltamivir 150 mg bd for 5 days
223583637|NCT00636012|PROCEDURE|verum acupuncture|acupuncture at St36 and Pe6
223583638|NCT00636012|PROCEDURE|sham acupuncture|superficial needling at sham points
223583639|NCT01839656|DRUG|nusinersen|Administered by intrathecal (IT) injection
223583640|NCT00865085|DRUG|Citalopram HBr 40 mg tablets, single dose|A: Experimental Subjects received Purepac formulated products under fasting conditions
223583641|NCT00865085|DRUG|CelexaTM 40 mg tablets, single dose|B: Active comparator Subjects received Forest Labs formulated products under fasting conditions
223583642|NCT03861156|DRUG|D-0316|Firstly, D-0316 was orally given 75mg for a cycle(21 days), if tolerated, the dose will be increased to 100mg. Otherwise, the dose will be maintained at 75mg.
223744695|NCT05755009|RADIATION|High- and Low-dose radiotherapy|High- and Low-dose radiotherapy combined with immunotherapy and maintain immunotherapy. Immunotherapy (Envafolimab) once every week (maintain a total of two years). Continuous high-(8Gy×5F) and low-dose (1.33Gy×5F) Radiotherapy starts at the second week after immunotherapy.
223744696|NCT00405873|DRUG|AMT2003|
223477822|NCT02049216|OTHER|Exercise|Participants in both groups will be prescribed a home exercise program to complete.
223477823|NCT04164238|DRUG|Toripalimab|Toripalimab Injection
223477824|NCT04164238|DRUG|Paclitaxel|Paclitaxel Injection
223477825|NCT04164238|DRUG|Carboplatin|Carboplatin Injection
223477826|NCT04164238|DRUG|Cisplatin|Cisplatin injection
223583643|NCT01295684|OTHER|Cranberry juice|base diet supplemented with two 8 ounce servings of low calorie cranberry juice per day
223583644|NCT01295684|OTHER|Placebo|base diet supplemented with two 8 ounce servings of a color and flavor matched placebo beverage
223477827|NCT04164238|DRUG|5-fu|5-fu injection
223477828|NCT03207399|DRUG|Epclusa|Patients will be treated with this drug for 12 weeks post lung transplant.
223583645|NCT04970160|PROCEDURE|TSARP|We make four different surgical operations for female patients with rectovestibular fistula
223583646|NCT04970160|PROCEDURE|PSARP|Posterior sagittal anorectoplasty
223583647|NCT04970160|PROCEDURE|Classic ASARP|Anterior Sagittal anorectoplasty
223583648|NCT04970160|PROCEDURE|Modified ASARP|External anal sphincter preservation
223583649|NCT02899923|OTHER|Data collection|
223583650|NCT00284713|PROCEDURE|intracoronary infusion of BMC|catheter delivery of stem cells
223744697|NCT02140658|BEHAVIORAL|multiple health education interventions|
223744698|NCT02140658|BEHAVIORAL|conventional health education|
223744699|NCT04211701|PROCEDURE|Connective Tissue Massage|Connective tissue massage (CTM) will be applied to the lumbo-sacral region, lower thoracic, scapular and interscapular regions. Three to five pulling will be applied during massage. The treatment will be administered for four weeks, five days a week.
223744700|NCT04211701|PROCEDURE|Classical Massage|Classic massage (CM) will be applied to the lower back and upper back while the patient is lying in the prone position. Three stroking will be applied during massage.The treatment will be administered for four weeks, five days a week.
224163341|NCT03991468|DIAGNOSTIC_TEST|Light Microscopy|Use of traditional light microscopy per institutional standard practice
223477829|NCT05836480|PROCEDURE|mitral valve repair|conservative surgery to treat mitral regurgitation. A mitral valve plasty is performed according to the most appropriate technique
223477830|NCT02595658|DIETARY_SUPPLEMENT|Meal composition|
223477831|NCT02595658|DRUG|Rapid-Acting Insulin Dose|
223477832|NCT00764634|BIOLOGICAL|Placebo (USP sterile saline for injection)|0.5 mL dose of placebo given by intramuscular injection at Days 0, 28, and 182
223477833|NCT00764634|BIOLOGICAL|rBV A/B-40 vaccine|0.5 mL dose of rBV A/B-40 vaccine given by intramuscular injection at Days 0, 28 and 182
223477834|NCT00764634|BIOLOGICAL|Placebo (USP sterile saline for injection)|0.5 mL dose of placebo given by intramuscular injection at Days 0, 56 and 182
223477835|NCT00764634|BIOLOGICAL|rBV A/B-40 vaccine|0.5 mL dose of rBV A/B-40 vaccine given by intramuscular injection at Days 0, 56 and 182
223477836|NCT01641042|BIOLOGICAL|Meningococcal vaccine GSK134612|2 doses of the vaccine administered intramuscularly in the anterolateral thigh muscle of the non-dominant leg for subjects aged 12 months to 2 years and in the deltoid of the non-dominant arm for older subjects.
223477837|NCT06305845|PROCEDURE|Digital crowns|crowns fabricated digitally by CAD-CAM technology
223477838|NCT06305845|PROCEDURE|zirconia crowns|crowns that are ready made for primary teeth
223583651|NCT05275322|BEHAVIORAL|Unified Protocol|The Unified Protocol for transdiagnostic treatment of EDs (hereinafter UP) is a transdiagnostic treatment based on emotional regulation published in 2011 by David H. Barlow et al. (Barlow et al., 2011). It consists of eight treatment modules, with five of them being central (mindfulness, cognitive flexibility, countering emotional behaviors, tolerating physical sensations, and emotional exposure).
223583652|NCT00161525|PROCEDURE|Pneumatic displacement|Pneumatic displacement of the subretinal hemorrhages is attempted with an intravitreous injection of 0.4 ml of pure C2F6 or 2 injections of 0.2 ml on subsequent days. The gas is withdrawn from a laboratory cylinder through a millipore filter and injected into the eye through a 30 gauge needle inserted 4.0 mm posterior to the limbus in the superior temporal quadrant. The tip of the needle is monitored in the vitreous by indirect ophthalmology prior to injecting the gas.Post injections the central retinal artery is examined whether is patent.The intraocular gas expands 3.3 times over the next 3 days to create a 40% bubble.The patient is asked to assume a gaze position 40° below the horizontal for 20 minutes every hour while awake and to sleep on 2 pillows with his head turned to the right.
223583653|NCT00704561|DEVICE|ENDEAVOR® drug-eluting stent (Medtronic, Santa Rosa, CA)|ENDEAVOR® drug-eluting stent implanted in acute myocardial infarction
223583654|NCT00704561|DEVICE|DRIVER bare metal stent (Medtronic, Santa Rosa, Ca)|DRIVER bare metal stent implanted in acute myocardial infarction
223583655|NCT00704561|DEVICE|Coronary stent implantation|Comparison of Drug Eluting versus Bare Metal Stent
223583656|NCT00704561|DEVICE|Bare Metal Coronary Stent|Comaprison between Drug Eluting and Bare Metal Coronary Stents
223583657|NCT05809804|DRUG|Esketamine|The initial dose of esketamine was set as 0.06 mg / kg, and the injection time of esketamine was 5 s. One minute after injection of esketamine, sufentanil 0.4 μg / kg was injected within 5 s, and the number of coughs within 1 min after injection was recorded. According to the evaluation of sufentanil-induced cough, the dose of esketamine was adjusted. If the patient had no cough ( negative reaction ), the dose of esketamine in the next patient was reduced until the cough reaction occurred. If the patient had a cough reaction ( positive reaction ), the dose of esketamine in the next patient was increased until the cough disappeared. The dose ratio of adjacent esketamine was 1.1. Each group was selected from the previous patient with positive reaction until the 7 groups of positive and negative reactions appeared alternately, and the test was completed.
223583658|NCT03322813|DEVICE|ExAblate 4000 - Type 2|Using ExAblate Model 4000 Type-2 to temporarily disrupt the blood brain barrier in non-enhancing suspected infiltrating glioma undergoing resection
223583659|NCT03762967|BIOLOGICAL|Lipoaspiration and SVF introduction.|Lipoaspiration, isolation of SVF and introduction into testis Interstitium.
223583660|NCT03762967|DRUG|Standard therapy.|Standard therapy include to give up bad habits, to establish a healthy diet, to eliminate excessive physical exertion. eliminate. In the case of endocrine disorders, hormone therapy is prescribed.
224070306|NCT03988595|OTHER|Exercise Treatment|Exercise sessions will consist of individualized, walking delivered following a non-linear (i.e.,exercise intensity is continually altered and progressed in conjunction with appropriate rest/recovery sessions across the entire intervention period) dosing schedule up to 7 individual treatment sessions/wk for 6 months. Remote supervised exercise sessions will be implemented and monitored using TeleEx. General physical activity as well as exercise performed outside of the structured treatment sessions will be evaluated via continuous monitoring using MSK approved telemedicine / wireless technology.
224070307|NCT01665807|BIOLOGICAL|Intanza|Intanza influenza vaccine, trivalent split-virion, inactivated, approved for the 2012-2013 influenza season in northern hemisphere
224070308|NCT01665807|BIOLOGICAL|Vaxigrip|Influenza vaccine, trivalent, split-virion, inactivated, approved for the 2012-2013 influenza season in the northern hemisphere
224070309|NCT04460976|BEHAVIORAL|Psychoeducation for Adults With Autism and Their Significant Others/Family members (Prisma)|Psychoeducation in groups
224070310|NCT04460976|BEHAVIORAL|Treatment as usual/standard care|Standard care at disability/habilitation services.
224070311|NCT03202966|OTHER|Rehabilitation therapy|Rehabilitation therapy will be provided by a trained community rehabilitation worker (CRW) and specialist (i.e., physical therapist, occupational therapist, special educator and/or speech therapist) with a focus on the one or more domains where delays are identified (i.e. speech, motor, cognition). Therapy will be tailored based on the needs of the individual child and will follow current evidence-based practice.
224070312|NCT05318456|DIETARY_SUPPLEMENT|MoodElite T-4003-1|Participants will be instructed to take two capsules of MoodElite T-4003-1 once daily with water, after dinner without food for 42 days.
224070313|NCT05318456|DIETARY_SUPPLEMENT|Comparator|Participants will be instructed to take two capsules of comparator once daily with water, after dinner without food for 42 days.
224070314|NCT05318456|OTHER|Placebo|Participants will be instructed to take two capsules of placebo once daily with water, after dinner without food for 42 days.
224070315|NCT02260843|OTHER|Generic Fitness|Subjects in this group will receive three fitness lessons in a week while each session last for 1 hour for 12 weeks
224070316|NCT02260843|OTHER|Tai Chi Intervention|Subjects in this group will receive three tai chi lessons in a week while each session last for 1 hour for 12 weeks
224070317|NCT03757910|DRUG|18F-MK-6240|This radiotracer will be used to detect Tau.The injected activity will equal 5 millicuries (mCi).
223477839|NCT04809116|DRUG|Pimavanserin|open-label, fixed-dose pimavanserin 34mg at bedtime for 6 weeks
223477840|NCT06060470|BEHAVIORAL|Virtual reality based dance group|"Participants will receive therapy using the Just Dance using the commercially available Kinect gaming system (Microsoft Inc, Redmond, WA, USA. Each song involves repetitive action for each dance step (at least 20 repetitions over the entire song) and visual cues on the screen (a stick figure at the bottom right) indicating the upcoming dance step. Participant's playing the game to reduce risk of exercise related adverse effects. Participants will dance on 10 songs starting from a slow-pace progressing to a medium pace (each max 5 minutes long). Participants will receive 5 minutes rest after playing on each song. This will be conducted by two physical therapists."
223477841|NCT06060470|BEHAVIORAL|Active Comparator: Control|Participants in the control group will receive current standard of care: education on conventional exercise and fall prevention programs. The control and intervention groups will have the same duration of 10 weeks (1session/week), while the format of the contact (Tele) and session time of the contact will be proportional to the content delivered (30-45 minutes/session) in the control group; 80-90 minutes in the intervention group). Participants, regardless of randomization, will complete assessments and follow-ups with blinded outcome assessors.
223477842|NCT02925468|DEVICE|Bite turbo|In this study the nature and speed of adaptation of the occlusal changes following insertion of an anterior bite plane (bite turbos) for the reduction of a deep overbite in growing patients will be investigated.
223477843|NCT04668677|OTHER|On-line questionnaire|On-line questionnaire about working life, medical care, functional recovery, quality of life and psychological state.
223477844|NCT00477685|DEVICE|OculusGen Biodegradable Collagen Matrix Implant|OculusGen Biodegradable Collagen Matrix Implant in Trabeculectomy.
223477845|NCT05414604|DIAGNOSTIC_TEST|3D spine CT|CT scan of the spine
223477846|NCT02500251|DRUG|belimumab|Belimumab will be administered per study protocol.
223477847|NCT02500251|DRUG|Bortezomib|Bortezomib will be administered per study protocol.
223477848|NCT02500251|DRUG|Rituximab|Rituximab will be administered per study protocol.
223583661|NCT02544256|PROCEDURE|Mild hypothermia|Mild hypothermia during surgical clipping of brain aneurysm will be reached by cooling to body temperature 33,8° C - 34,8° and this temperature maintained up to the end of microcirculation measurement after aneurysm clipping.
223477849|NCT02500251|DRUG|Plasmapheresis|Plasmapheresis will be administered per study protocol.
223583662|NCT03128190|OTHER|Pulse pressure variation monitoring|fluids boluses of colloids were given to maintain continuously measured PPV at 10% or less
223583663|NCT01595581|DRUG|Testosterone|8 weeks of testosterone administration beginning 2 weeks before ACL surgery
223583664|NCT01595581|DRUG|Placebo|8 weeks of saline administration beginning 2 weeks before ACL surgery
223477850|NCT03444584|DRUG|MEDI0382|Subcutaneous dose of MEDI0382 (titrated up from 100 μg for 7 days to 200 μg for 7 days and to 300 μg for 14 days).
223477851|NCT03444584|DRUG|Placebo|Subcutaneous dose of placebo matched to MEDI0382.
223477852|NCT03444584|DRUG|Dapaglifozin|Oral dose of dapaglifozin 10 mg tablet.
223477853|NCT03444584|DRUG|Metformin|Oral dose of metformin tablet (maximum tolerated dose \[MTD\] \> 1 g).
223477854|NCT02230215|DEVICE|Total Knee Arthroplasty with use of Visionaire Patient-Specific Instrumentation|The manufacturing of a patient-specific instrument to be used by the orthopaedic surgeon during the knee replacement surgery.
223477855|NCT03779646|DRUG|Bisoprolol Fumarate|Bisoprolol was initiated at a dose of 1.25 mg every 24hr. At subsequent biweekly visits, the bisoprolol dose was increased 1.25mg progressively until a daily dose of 0.2mg/kg or the maximum tolerated dose (The rest heart rate \<75bpm and systolic blood pressure \<90mmHg) is achieved. If the participant feel dizziness or the rest heart rate below 60 bpm or systolic blood pressure below 85mmHg or there is any new onset contraindication to bisoprolol, the doctor will decide to return back to the previous dose or stop bisoprolol. Each time the dose is increased, the medication is administered in an outpatient clinic setting, with assessment of the participant's heart rate, blood pressure, symptoms and ECG. Once reach the target dose, the patients will be followed up every 8 weeks in an face-to-face or video visit. After 12 months , the participants will repeat cardiac MR besides heart rate, blood pressure, symptoms, ECG and brain natriuretic peptide(BNP), echocardiography records.
223477856|NCT03451045|DRUG|Lenabasum 20 mg|Subjects will receive lenabasum 20 mg twice daily.
223583665|NCT00408590|BIOLOGICAL|carcinoembryonic antigen-expressing measles virus|
223583666|NCT00408590|BIOLOGICAL|oncolytic measles virus encoding thyroidal sodium iodide symporter|
223583667|NCT00408590|GENETIC|reverse transcriptase-polymerase chain reaction|
223583668|NCT00408590|OTHER|laboratory biomarker analysis|
223583669|NCT04391452|DIETARY_SUPPLEMENT|Stress Resist® (oral dietary supplement)|Stress Resist® (dietary supplement) is composed of Mg (150 mg), Vitamin B6 (0.7 mg), Vitamin B9 (100µg), Vitamin B12 (1.25 µg), rhodiola (222mg), and green tea/L-théanine (125 mg). Oral supplementation. All subjects in the MAGRITTE study will receive either a dietary supplement or a placebo for 28 days (morning intake). The effects on stress will be studied both with questionnaires, biological samples (blood, urine and stool), with a Heart Rate Variability test. 40 subjects (20 subjects per group) will have an fMRI exam.
224070318|NCT03757910|DRUG|11C-PIB|This radiotracer will be used to detect amyloid. Participants will be injected with an intravenous bolus of up to 5-15 mCi.
224070319|NCT00944164|BEHAVIORAL|Healthy eating and physical activity|Parent counseling and coaching regarding healthy eating and physical activity habits for their child
224070320|NCT00944164|BEHAVIORAL|Safety and injury prevention|Parent counseling and coaching regarding general personal and household safety
224070321|NCT03179332|DRUG|BioChaperone® insulin lispro|Single subcutaneous administration of a bolus of 0.15 U/kg body with a pump
224070322|NCT03179332|DRUG|Fiasp®|Single subcutaneous administration of a bolus of 0.15 U/kg body with a pump
224070323|NCT03179332|DRUG|Novorapid®|Single subcutaneous administration of a bolus of 0.15 U/kg body with a pump
224070324|NCT04791774|DIETARY_SUPPLEMENT|Milk protein (food grade protein)|Subjects will receive an enteral nutritional formula containing 20 grams intrinsically labeled (1-\[13C\]-phenylalanine) milk protein
223477857|NCT03451045|DRUG|Lenabasum 5 mg|Subjects will receive lenabasum 5 mg twice daily.
223477858|NCT03451045|OTHER|Placebo|Subjects will receive placebo twice daily.
223477859|NCT01553929|OTHER|Physical Training and cognitive activity (EPC group)|The patients of the EPC group will realize 2 weekly sessions of 20 minutes of pédalage. During the exercise, the patients will realize a series of tests of decision-making and perceptive cognitive capacity.
223477860|NCT01553929|OTHER|Physical training (EP group)|The patients of the group (EP) will realize 2 weekly sessions of 20 minutes of pédalage.
223477861|NCT01553929|OTHER|control group|no physical training and no cognitive activity
223477862|NCT04581915|DRUG|Triazavirin (Riamilovir)|Capsule - 250mg 8 hourly po
223477863|NCT04581915|OTHER|Placebo|Placebo capsule
223477864|NCT00863707|DRUG|Regadenoson|IV
223477865|NCT00863707|DRUG|Placebo|IV
223477866|NCT06374303|OTHER|NE + Meal Delivery (NE+MD) intervention|NE + Meal Delivery (NE+MD) participants received the same educational platform plus weekly meal deliveries using a commercial service that delivers premade, refrigerated meals directly to the participant's home.
223477867|NCT02291978|DEVICE|ExAblate 2100|The InSightec ExAblate 2100 MRgHIFU system is a non-invasive thermal ablation device fully integrated with an MR imaging system and used for the ablation of soft tissue and bone.
223477868|NCT00512590|BEHAVIORAL|Relaxation and Guided Imagery|"The intervention consisted of 3 relaxation and guided imagery audiotapes used in a proscribed order for 6 weeks and used in any order for weeks 7 through 10.~Protocol: Tape 1: Basic Relaxation used for weeks 1 and 2. Tape 2: Pleasant Scene Imagery to elicit sensory involvement for enhanced sense of overall well-being; used for weeks 3 and 4. Tape 3: End-State Imagery designed to facilitate improved symptom management; used for weeks 5 and 6. Any of the tapes used as often as desired but at least once daily for weeks 7 to 10."
223477869|NCT05415293|DIETARY_SUPPLEMENT|Expecta 200mg DHA|
223583670|NCT02352636|OTHER|magnetotherapy|The magnetic pellets will contain an average of \~200 gauss/pellet magnetic flux densities, with a diameter of 1.76 mm
223583671|NCT02352636|DEVICE|laser auriculotherapy|A laser device (pointer pulse) will be used in this study. This device has a wavelength of 650 nm, an average output power of 2.5 mW, energy density of 1 minute with 0.54 J/cm2, and a pulse of 10 Hz, which is a common acceptable dosage for clinical use. This application belongs to a low-energy laser therapy (LLLT), in which the energy level emitted from the device is approximately comparable to a teaching pointer.
223583672|NCT02352636|OTHER|Placebo|"Subjects will serve as a placebo control, and will receive LAT at power off mode (i.e. deactivated laser) for acupoint stimulation before the application of plaster without magnetic pellets that mimic MAT treatment."
223583673|NCT02580383|PROCEDURE|Radiofrequency neurotomy of lumbar medial branch|In above L5, The RF needle was placed to contact with bone as close as possible to the course of the target nerve in parallel. For L5 dorsal rami ablation, the needle was positioned in the groove between the S1 articular process and sacral ala. At each level, the electrodes were adjusted to optimize sensory stimulation at a frequency of 50 Hz and maximize multifidus contraction at 2 Hz. A 75 second 80°C lesion was made using an RF generator.
223477870|NCT05415293|DIETARY_SUPPLEMENT|Promise 275mg DHA|
223477871|NCT05232617|OTHER|Rheumatological rehabilitation training|Online rheumatological rehabilitation training is planned. Online rheumatological rehabilitation training will be video-based via the Edpuzzle application and interactively via the zoom application. Online trainings are planned for 15-person intern physiotherapy student groups 4 days a week, 2 hours a day, for 4 weeks on a case-based basis. With the Edpuzzle application, videos will be prepared for 10 different rheumatological diseases. In each video, a case with rheumatic disease will be introduced, evaluations made from a physiotherapy perspective and their results will be included. Before the lesson, students will watch the video defined for them every day from the application called Edpuzzle, answer the questions and plan a disease-specific assessment and treatment program according to the directions in the video. Then, the assessment and treatment programs prepared by a group of 15 people through the zoom platform will be discussed during the lesson.
223583674|NCT02671565|DRUG|Hyaluronic Acid injections|
224163342|NCT06124092|OTHER|neurocognitive tests|Cohort study: all parents and participants will have questionnaires to complete, based on participant's age.
223477872|NCT04909944|DEVICE|i-gel Supraglottic insertion|i-gel Supraglottic insertion for oxygenation
223477873|NCT04909944|DEVICE|Laryngeal Tube Suction Disposable Supraglottic insertion|Laryngeal Tube Suction Disposable Supraglottic insertion for oxygenation
223477874|NCT05590338|DRUG|GSK1070806|Participants will receive GSK1070806
223477875|NCT05590338|DRUG|Placebo|Participants will receive placebo
223583675|NCT06019806|OTHER|POSTURAL CORRECTION four exercises|"The program will involve four exercises, including two strengthening exercises and two stretching exercises.~1. Chin tuck (deep cervical flexor)~2. Strengthening shoulder retractors~3. Sternocleidomastoid muscle stretch~4. Pectoralis stretch Participants will be instructed to perform three sets of 12 repetitions for the strengthening exercises, with a 30-second rest period allotted between each set. For the stretching exercises, participants will be instructed to hold each stretch for 30 seconds, with a 30-second rest period allotted between each exercise The experimental group will also receive postural Correction education"
223583676|NCT06019806|OTHER|postural Correction education with a manuscript|The control group would receive postural Correction education and they would be provided with a manuscript. They would be then guided to follow these guidelines as a home plan for four weeks. At the end of the Fourth week, they would be assessed.
223583677|NCT04024423|OTHER|Epidemiologic investigation|Identification of overlaps in source(s) of care between participants with NTM isolates in a Cystic Fibrosis Care Center.
223583678|NCT03203733|DEVICE|Cooral™|An intraoral cooling device which is as effective as ice but with better patient comfort. The cooling device has the advantage that the water temperature can be modified. It enables that the unacceptable low temperatures that occur with ice cooling can be avoided.
223583679|NCT03203733|OTHER|cryotherapy|Oral cooling by ice chips or crushed ice or ice pop
223583680|NCT04252495|DRUG|Aprocitentan|A single oral dose of 25 mg.
224163343|NCT00000405|PROCEDURE|Exercise intervention|
224163852|NCT01925014|DIAGNOSTIC_TEST|Diagnostic CT with low-dose radiation|Effective dose is aimed at approximately 2 millisievert (mSv) in an average patient.
224163853|NCT01925014|DIAGNOSTIC_TEST|Diagnostic CT with standard-dose radiation|Effective dose is aimed at approximately 8 millisievert (or less) in an average patient.
224163651|NCT03262064|COMBINATION_PRODUCT|Pulmonary function tests,Bronchiectasis severity index score|"Pulmonary function tests: including spirometry, DLCO, and lung volumes. Sputum investigations: The following investigations will be performed on fresh sputum samples; gram stains and culture, smear and culture for mycobacteria and fungi and antibiotic sensitivity tests Bronchoscopy: Bronchoscopy with bronchoalveolar lavage will be used to obtain specimens for staining and culture to identify type of colonization.~Radiology: All patients will have a chest radiograph (PA and lateral) and high-resolution computed tomography (HRCT) scan.~Bronchiectasis severity index score parameters FACED Score"
224304887|NCT04696029|DRUG|Difluoromethylornithine|"DFMO (difluoromethylornithine is an inhibitor of ornithine decarboxylase (ODC) designated chemically as 2-(difluoromethyl)-DL-ornithine monohydrochloride monohydrate.~The dosage form to be used in this study is provided as a convex tablet containing 192 mg eflornithine (equivalent to 250 mg of eflornithine HCl, monohydrate). The tablets are packaged and sealed in opaque white HDPE bottles, and each bottle contains 100 tablets. The DMFO tablets are supplied by USWorldMeds (USWM).~The tablets are to be stored at room temperature (20-250C)."
223583681|NCT03633669|DIAGNOSTIC_TEST|Fecal calprotectin|Testing every 3 months
224304888|NCT04441619|BEHAVIORAL|Delayed onset muscle soreness.|Participants will perform a fatiguing exercise protocol for the upper extremity (biceps muscles)
224304889|NCT06110156|BEHAVIORAL|Patient-tailored deprescribing assessment and intervention|Patients are identified for enrollment via a risk prediction model and enrolled in a pharmacist-led polypharmacy clinic. The pharmacist will conduct a comprehensive medication review, which will include: medication reconciliation, assessment of patient risk factors (clinical, socioeconomic), identification of potentially inappropriate medications, identification of potential prescribing omissions, shared decision-making with the patient and/or caregiver, and confirmation of the results of the comprehensive medication review with the primary care clinician. Once the primary care clinician has approved the recommendations, the pharmacist will make the appropriate changes to the medication regimen, will provide tailored medication education and counseling (including Motivational Interviewing) and will follow-up with the patient at least once per month via video visit or phone to assess side effects, adverse effects, and provide support.
224304890|NCT05844761|RADIATION|Triggered imaging on TrueBeam with margin reduction|At interim analysis the Planning target volume (PTV) will be reduced based on the accuracy of the TrueBeam triggered imaging motion management technique.
224304891|NCT05844761|RADIATION|Synchrony MLC tracking on fiducials with margin reduction|At interim analysis the Planning target volume (PTV) will be reduced based on the accuracy of the Radixact Synchrony motion management technique.
224304892|NCT05844761|RADIATION|Synchrony MLC tracking and lung adaptive model with margin reduction|At interim analysis the Planning target volume (PTV) will be reduced based on the accuracy of the Radixact Synchrony motion management technique for lung cancer.
223583682|NCT03633669|OTHER|Routine care|As per treating gastroenterologist
223583683|NCT00473603|DRUG|lipid/heparin infusion|to perform an i.v. lipid heparin infusion infusion for 4 h
223583684|NCT03648216|BEHAVIORAL|HAPA behavioural counseling|Behavioural counseling grounded in the Health Action Process Approach (HAPA; i.e., action planning and coping planning) to maximize sedentary behaviour and minimize steps taken.
223583685|NCT04326816|PROCEDURE|Rehabilitation of severely worn dentitions using minimally invasive composite restorations (Estenia C&B or Clearfil AP-X, Kuraray, Osaka, Japan)|
223583686|NCT03918707|DIAGNOSTIC_TEST|Rapid Whole Genome Sequencing (rWGS)|rWGS will be performed on blood samples from subjects in the prospective group in addition to standard of care laboratory testing and imaging studies. Blood samples will also be obtained from biological parents (if available), to determine if variants are inherited or de novo and for variant segregation.
223583687|NCT02535416|DRUG|ARC-520|
223583688|NCT02535416|DRUG|cetirizine|
223583689|NCT02535416|DRUG|diphenhydramine|
223583690|NCT01176955|BEHAVIORAL|Internet survey|A weekly email link will be generated to an internet survey which questions subjects about their acne severity, compliance with the study medication, and attitudes toward acne and the study medication.
224163652|NCT03500536|BEHAVIORAL|IntelliCare|A suite of mobile apps that use principles of computerized therapy to decrease symptoms of depression.
224304893|NCT03782415|DRUG|MN-166|MN-166 is an anti-inflammatory/neuroprotective agent. MN-166 distributes well to the CNS (Sanftner et al. 2009) and it is a selective inhibitor of certain cyclic nucleotide phosphodiesterases (PDE) and the pro-inflammatory cytokine, macrophage migration inhibitory factor (MIF). At clinically-relevant plasma or CNS concentrations, MN-166 selectively inhibits macrophage migration inhibitory factor (MIF) (Cho et al 2010) and, secondarily, PDE3, 4 and 10 (Gibson et al 2006).
224304894|NCT03782415|DRUG|Temozolomide|Temozolomide is an oral chemotherapy drug. It is an alkylating agent used as a treatment of some brain cancers; and a first-line treatment for glioblastoma multiforme.
224304895|NCT05217459|DEVICE|Self-expanding intracranial drug stent system|All patients receive Percutaneous transluminal angioplasty and stenting with self-expanding intracranial drug stent system (Temporary abbreviations: SINOMED IS-DES)
224304896|NCT04347122|DRUG|Tranexamic Acid (TXA)|Intervention groups will receive TXA 1g TXA IVPB 10 minutes prior to incision and a second dose of 1g IVPB at the time of closure.
223583691|NCT01176955|DRUG|Benzoyl peroxide 5% gel|Topical benzoyl peroxide 5% gel, to be used once daily to the face.
223583692|NCT00862472|DRUG|DuoTrav APS|DuoTrav APS QD AM
223583693|NCT00862472|DRUG|DuoTrav|DuoTrav QD AM
223583694|NCT03713541|OTHER|No intervention|Survey during normal supply.
223583695|NCT02739321|DEVICE|Sound to Sleep System|Sound to Sleep System is a minimal risk device that is embedded in a mattress boxspring. The device syncs with an audio input and emits tactile vibrations in sync with the audio input.
223583696|NCT02994693|DEVICE|OFDI capsule imaging|Imaging of Barrett's esophagus (BE) using OFDI capsule imaging
223583697|NCT01711866|DRUG|Rotigotine|Rotigotine up to 16 mg / 24 hours, 4 weeks.
223583698|NCT04973462|DRUG|standard treatment COVID-19 + Triazavirin|to evaluate the efficacy and safety (side effects and / or adverse effects) of Triazavirin and Oseltamivir as treatment of Coronavirus Disease 2019
223583699|NCT01256762|DRUG|Imetelstat sodium|Imetelstat is administered at a dose of 300 mg/m2 on day one of a 21 day cycle.
223583700|NCT01256762|DRUG|Bevacizumab|Bevacizumab is administered at 15 mg/kg on day one of a 21 day cycle
224163344|NCT05401903|OTHER|Chiropractic Maintenance Care|"Subjects will receive high-velocity, low amplitude (HVLA) chiropractic manipulations to areas of defined restriction in the upper cervical spine, thoracic spine, lumbar spine, and pelvis. The clinician will use motion palpation to determine spinal segments with joint restrictions. Subjects will schedule weekly chiropractic visits.~The clinician will not use passive care modalities. The exclusions of passive modalities include heat and cold therapies, electric stimulation, massage, acupuncture, and cupping therapies. Subjects will be encouraged to maintain normal exercise activity levels throughout the study. The clinician will provide instructions on homecare exercises as needed to promote range of motion of spinal segments between chiropractic visits. A single clinician will deliver the HVLA chiropractic manipulations to ensure consistency of chiropractic care throughout the study."
224163345|NCT03408886|DRUG|Vancomycin|Oral vancomycin is administered to reduce pathogenic bacteria.
224163346|NCT03408886|DRUG|MoviPrep|MoviPrep is given at the end of vancomycin therapy to remove the vancomycin and remaining bacteria prior to administering Full-Spectrum Microbiota
224163347|NCT03408886|BIOLOGICAL|Full Spectrum Microbiota|Gut bacteria from healthy human donors are administered orally in a pill form
223477876|NCT06190028|DEVICE|Iridium A Gel|IRIDIUM® A gel is a sterile, preservative free ophthalmic gel, containing Carbopol, amino acids, Echinacea and Aloe extract. IRIDIUM® A gel is indicated for the protection of the eye surface particularly at night, even in the presence of changes in histological continuity and blepharitic conditions, including those of an iatrogenic nature, following the use of hypotonic eye drops and of the preservatives contained therein.
224163348|NCT01433692|BEHAVIORAL|Brief Intervention|CANABIC is a quantitative study to validate use of BI with cannabis users: a randomized controlled trial, clustered study, comparing an intervention group (IG) and a control group (CG). The intervention is the achievement of the IB during a specific consultation. The outcome is the consumption of cannabic (Number of joints / month).
224163349|NCT02813434|BIOLOGICAL|florbetapir|18F-AV-45 or 18F-Florbetapir
224163350|NCT05394012|BIOLOGICAL|RQ3013|Two doses of 30 μg/0.15 mL at an interval of 28 days, or two doses of 60 μg/0.3 mL at an interval of 28 days
224163351|NCT05394012|BIOLOGICAL|Comirnaty|Two doses of 30 μg/0.3 mL at an interval of 28 days
224163352|NCT02254304|DRUG|Rebif|Rebif will be administered at a dose of 44 microgram (mcg) subcutaneously using RebiSmart auto-injector three times a week for a total duration up to 12 months.
223477877|NCT01670370|DRUG|R-GemOx|Rituximab Gemcitabine Oxaliplatin
223477878|NCT04503044|OTHER|Retrospective observational study|No intervention to occur
223477879|NCT03761316|OTHER|interview regarding goals|interview regarding goals
223477880|NCT00174824|DRUG|Insulin glargine|
223477881|NCT04294537|PROCEDURE|TAP Block|At the end of surgery patients will receive bilateral ultrasound-guided single-shot TAP block: 0,15% levobupivacaine 0,75 mg/kg per side will be injected between internal oblique and transveralis fascia
223477882|NCT04294537|PROCEDURE|LIA local infiltration|At the end of surgery 0,5% levobupivacaine 1.5 mg/kg, equally distributed between ports, injected in the skin and subcutaneous tissue during wound closure.
223477883|NCT04294537|PROCEDURE|General anesthesia|"General anesthesia will be induced with fentanyl 1,5 mcg/kg, propofol 2 mg/kg, rocuronium 0,6 mg/kg; after intubation anesthesia will be mantained with sevoflurane (MAC 1).~30 minutes after induction will be administered paracetamol 15 mg/kg iv."
223477884|NCT04294537|DRUG|Postperative analgesia|"During first 48 hours after surgery all patients wil receive paracetamol 15 mg/kg iv every 8 hours and ibuprofen 10 mg/kg orally (or through gastric tube) every 12 hours after surgery.~In case of severe pain tramadol 0,5 mg/kg will be administered iv every 8 hours."
223477885|NCT01061996|DRUG|Basiliximab|Study Drug: basiliximab 40 mg, given as a short intravenous infusion Dosing Schedule: once every 4 weeks Concomitant Therapy: Oral corticosteroids (prednisone or equivalent) will be tapered during the first few months of the study participation Duration of Study Participation: The duration of individual study participation will vary.
223477886|NCT04054830|DRUG|Voltaren Ophtha 1 mg/ml, GSK|Voltaren Ophtha 1 mg/ml, eye drops used 6 times daily for the 2 first weeks, tapering to 4 drops per day for the next 4 weeks. Depending on the clinical condition of the eye, the topical anti-inflammatory treatment will be reduced with 1 daily drop per week.
223477887|NCT04054830|DRUG|Monopex 1 mg/ml, Théa|Monopex 1 mg/ml, eye drops used 6 times daily for the 2 first weeks, tapering to 4 drops per day for the next 4 weeks. Depending on the clinical condition of the eye, the topical anti-inflammatory treatment will be reduced with 1 daily drop per week.
223477888|NCT03704064|BEHAVIORAL|Stigma-Reduction Intervention|Session topics will be based on those tested in a previous pilot study, including: psychoeducation about weight and weight stigma; challenging myths and cognitive distortions related to weight; strategies for coping with instances of stigma; and increasing empowerment and body esteem. The effects of weight stigma on health behaviors will be discussed, and sessions will focus specifically on helping participants overcome stigma-related barriers to physical activity. For example, they will be given strategies to cope with anticipated stigma while exercising in public spaces (e.g., while walking), as well as to challenge self-critical beliefs (e.g., that they are lazy) which may otherwise lead them to avoid exercising. These concrete strategies, along with reducing WBI and improving self-confidence, are intended to increase participants' self-efficacy for and engagement in physical activity.
223583701|NCT01256762|DRUG|Paclitaxel|Paclitaxel is administered at 90 mg/m2 on days one and eight of a 21 day cycle
223583702|NCT01359462|DRUG|tolvaptan|"Drug: tolvaptan~tablet, 15mg, Qd, for 7 days."
223583703|NCT04353882|OTHER|Assess the difference in MOR-1 expression between healthy and tumor tissue|Assess the difference in the quantitative expression of MOR-1 (by means of RT-qPCR) between healthy tissue and tumor tissue, in patients with stage II and III colorectal cancer undergoing scheduled surgery.
223583704|NCT00604617|PROCEDURE|Interferon-Gamma Release Assay|IGRAs
223583705|NCT00604617|DRUG|RT-23|TST - tuberculin skin test
223583706|NCT02747212|DEVICE|network analyzer|The dielectric properties of the tissues were measured using the open-ended coaxial line method. The measurement system consisted of a network analyzer (Model 4395A, Agilent Corp., Santa Clara, CA) associated with an S-parameter test set (Model 87511A, Agilent Corp., Santa Clara, CA). A semi-rigid coaxial line with a diameter of 3.58 mm was connected to the network analyzer system by using a Bayonet Neill-Concelman connector. The other tip of the coaxial line (probe) was placed on the flat bare surface of the tissue that placed on a measurements experiment platform.
223477889|NCT03704064|BEHAVIORAL|Behavioral Weight Loss (BWL)|This intervention will be based on the Diabetes Prevention Program. A diet of 1200-1499 calories per day will be prescribed for participants \< 250 lb, and 1500-1800 for those ≥ 250 lb. Participants will be instructed to eat a balanced deficit diet. Session topics during the first 20 weeks will include self-monitoring, stimulus control, social support, portion sizes, and goal-setting. Those during weeks 21-72 will focus on skills required for weight loss maintenance and relapse prevention. Physical activity will be begin with a prescription of 60 min/wk, and will gradually progress by 10 minutes over 2-4 week intervals until achieving 150 min/wk by week 20, 200 min/wk by week 46, and 250 min/wk by week 72. Participants will be instructed to spread the activity equally across at least 5 days in bouts that are \>10 minutes in duration. Moderate intensity will be prescribed with an emphasis on walking; the vast majority of our research participants self-select this form of activity.
223477890|NCT00514696|DRUG|GCS-100|GCS-100: 160 mg/m2 IV (in the vein) Study Days 1-5 of each 21-day cycle
223477891|NCT00217230|BIOLOGICAL|CAIV-T|
223477892|NCT01745510|DIETARY_SUPPLEMENT|Docosahexaenoic acid (DHA)|Docosahexaenoic acid from algae source
223583707|NCT04451473|PROCEDURE|Enhanced Recovery After Surgery (ERAS )|the treatment of procedure according to Guidelines for enhanced recovery after lung surgery: recommendations of the ERAS Society and the ESTS
223583708|NCT04451473|PROCEDURE|Traditional perioperative management without Enhanced Recovery After Surgery (ERAS )|the treatment of procedure not abiding Guidelines for enhanced recovery after lung surgery
223583709|NCT01294163|DRUG|Xenon|Inhaled xenon, maximal inspired concentration of 65%.
223583710|NCT01294163|DRUG|Sevoflurane|Inhaled sevoflurane, maximal inspired concentration of 1.8%.
223583711|NCT01294163|DRUG|Propofol|Hourly dose of 2-4 mg/kg
223583712|NCT00958217|BEHAVIORAL|Cognitive Processing Therapy-Modified (CPT-M)|Psychotherapy that focuses on thoughts associated with traumatic experiences with the goal of developing skills to reduce trauma-related symptoms. We have modified this therapy to include substance relapse prevention skills, reduce depression and substance relapse. CPT-M was delivered in individual 1-hour sessions once weekly.
223583713|NCT00958217|BEHAVIORAL|Integrated Cognitive Behavioral Therapy (ICBT)|Psychotherapy that focuses on thoughts and behaviors associated with depression with the goal of developing skills to reduce depression symptoms. We have integrated substance relapse prevention skills. ICBT was delivered in individual 1-hour sessions once weekly.
223583714|NCT03239938|BEHAVIORAL|Modern pain neuroscience approach|The modern pain neuroscience approach includes 3 sessions (1 group and 2 individual sessions) of therapeutic pain neuroscience education followed by 15 individual sessions of dynamic and functional cognition-targeted exercise therapy and stress management techniques. In addition, participants will be instructed to perform a daily set of home exercises. The exercises will be performed in a time-contingent way. The 18 sessions will be spread over a period of 16 weeks.
223583715|NCT03239938|BEHAVIORAL|Usual care evidence-based physiotherapy|The usual care evidence-based physiotherapy includes 3 sessions (1 group and 2 individual sessions) of neck school followed by 15 individual sessions of graded and active exercise therapy focusing on strength, flexibility, endurance, and ergonomic principles. In addition, participants will be instructed to perform a daily set of home exercises. The exercises will be performed in a symptom-contingent way. The 18 sessions will be spread over a period of 16 weeks.
223583716|NCT06081192|PROCEDURE|Implant placement surgery|Placement of six mini implants in the edentulous maxilla using a partially-guided protocol
223583717|NCT03566121|OTHER|Pelvic ultrasound / Urodynamic ultrasound|Gynecological consultation: calculating the score ICI-Q Ultrasound consultation: pelvic ultrasound Urodynamic ultrasound during a Valsalva manoeuvers
223744701|NCT02192255|BEHAVIORAL|Intervention Phone Call|The intervention arm consisted of one protocol-structured telephone call from an interventionist who was a nurse health manager (1 site), diabetes educator or diabetes educator trainee (1 site), or pharmacist (2 sites). Interventionists followed the same structured telephone interview protocol to ascertain whether the subject had started taking the new prescription. Those taking the new medication as prescribed received positive reinforcement. Those who either had not filled the prescription or were not taking the medication as directed, were asked about reasons for nonadherence and assisted in identifying and resolving barriers. The median call lasted \< than 5 minutes, and up to 3 call attempts were made. Most intervention calls occurred within 2 to 6 weeks after the prescription date.
224070325|NCT04791774|DIETARY_SUPPLEMENT|Fee amino acids (food grade amino acids)|Nutritional formula containing 20 grams of a free amino acid mixture equivalent in composition to the milk protein with 1-\[13C\]-labeled phenylalanine
224070326|NCT02640417|DRUG|Nucleotides + B12|Oral treatment with either Nucleotides + Vitamin B12
223477893|NCT01745510|DIETARY_SUPPLEMENT|Placebo|Placebo was designed to mimic the color and consistence of the oil that contains DHA
223477894|NCT04142242|BIOLOGICAL|Meningococcal Polysaccharide (serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine|Pharmaceutical form: Solution for injection; Route of administration: Intramuscular
223477895|NCT04142242|OTHER|Blood sample|Blood sample for assessment of antibody persistence.
223477896|NCT05778344|BEHAVIORAL|Teletechnology-assisted home-based pulmonary rehabilitation|The accuracy and safety of home-based pulmonary rehabilitation will be checked regularly through technology devices such as smart watch and via videotelephony (or telephone calls if indicated).
223477897|NCT01369264|DEVICE|true left high frequency|10 Hz stimulation will be given at 110% motor threshold for 8 seconds to Brodmann areas 46, 9 and 10 in the left hemisphere. The coil will be held flat over the skull surface with the coil handle held at approximately 45 degrees to the floor
224070327|NCT02640417|DRUG|B Vitamins|Oral treatment with vitamins B1, B6, and B12
224070328|NCT02686593|DRUG|Clofarabine, AraC, mitoxantrone (CLAM)|The combination of clofarabine, cytarabine (Ara-C) and mitoxantrone will be used in patients with AML in first relapse or after failure of first salvage
224070329|NCT06252064|OTHER|Rehabilitation + Drug therapy|Patients in the Combo group underwent rehabilitation treatment combined with drug therapy: the rehabilitation protocol included daily sessions, 5 days a week, lasting 60 minutes, for a total of 4 consecutive weeks. Patients included in this group also took drug therapy, particularly Pridinol Mesylate orally, on an empty stomach, 2 mg x 3 times a day for 20 days.
224163353|NCT04421612|BEHAVIORAL|Co-mestring (co-coping)|8 modules with the aim to reduce stress, increase coping of social isolation and coping with the consequences of reduced positive experiences
224163354|NCT00074867|DRUG|CP-547,632|
223477898|NCT01369264|DEVICE|Passive sham left high frequency|10 Hz stimulation will be given at 110% motor threshold for 8 seconds to Brodmann areas 46, 9 and 10 in the left hemisphere. The passive (inactive) coil will be held flat over the skull surface with the coil handle held at approximately 45 degrees to the floor. An active coil will be held vertically in a mechanical holder 50 cm behind the subject head and run at 10 Hz with an intensity set to 150% of motor threshold.
223477899|NCT05913362|BEHAVIORAL|IVUS based ultralow contrast PCI|IVUS based ultralow contrast PCI
223583718|NCT05106010|OTHER|Balance Flow Yoga|The yoga class is based on hatha yoga which includes physical poses and mindful movement integrated with breath. Conducted in a local yoga studio for 75 minutes duration, twice per week and also open to the public. The specific yoga techniques reflect the objectives of our study and focus on addressing some of the physical, mental and emotional factors that potentially contribute to falls such as balance, balance confidence, strength, coordination, proprioception, core training strategies, and breathing techniques integrated with mindfulness practices and yoga philosophy. The practices will incorporate a combination of seated, kneeling, standing and lying postures and transitions between positions with individual modifications provided on an as-needed basis. The yoga classes will be co-designed by registered yoga teachers and taught by two trained and experienced and yoga teachers blinded to study testing measures.
223583719|NCT01286571|DRUG|BI 135585|one oral single dose per subject
223583720|NCT01286571|DRUG|BI 135585|one oral single dose per subject
223583721|NCT05007977|DRUG|ZT-01 low dose|Single subcutaneous (SC) injection of ZT-01 3 mg during hypoglycemic clamp
223583722|NCT05007977|DRUG|ZT-01 high dose|Single SC injection of ZT-01 20 mg during hypoglycemic clamp
223583723|NCT05007977|DRUG|Placebo|Single SC injection of placebo during hypoglycemic clamp
223583724|NCT02174744|OTHER|numeric pain rating scale|
223583725|NCT03052530|DEVICE|Sapphire II PRO|To pre-dilate coronary arteries or bypass grafts during the subject's index procedure with Sapphire II PRO 1.0 and 1.25 PTCA dilatation catheters.
223583726|NCT02434965|DRUG|HPDSC|Autologous HPDSC collected after birth will be infused in aliquots. one-half of the HPDSC infused on Day 2; one-half of the collected HPDSC will be infused on Day 8.
223583727|NCT02434965|DRUG|Cord blood|Autologous Cord Blood collected after birth will be infused in aliquots. One-third of the collected cord blood will be infused within the first 24 hours after birth (Day 0); one-third of the collected cord blood will be infused on day 3; and one-third of the collected cord blood unit will be infused on Day 7.
223583728|NCT06365138|BEHAVIORAL|Bahaviour at the time of an aortic aneurysm rupture|Questionnaire and patient interview, diary for day of rupture and the three previous days
223583729|NCT01384032|DIETARY_SUPPLEMENT|Low fat diet|Subjects were asked to consume a low fat diet for 8 weeks. Composition: 28% energy from fat, 8% energy from saturated fat, 55% energy from carbohydrate. Subjects were provided with low fat spread, cooking oil and snacks and asked to consume these in place of normally eaten equivalent foods. Subjects were asked to consume two extra portions of carbohydrate per day (e.g. two slices of bread, equivalent to 35g carbohydrate) and to consume low fat dairy products. Subjects also consumed 2g control oil per day during this period. Control oil comprised palm olein and soybean oil.
223583730|NCT01384032|DIETARY_SUPPLEMENT|Hgih saturated fat diet|Subjects were asked to consume a high saturated fat diet for 8 weeks. Composition: 38% energy from fat, 18% energy from saturated fat, 45% energy from carbohydrate. Subjects were provided with spread, cooking oil and snacks and asked to consume these in place of normally eaten equivalent foods. Subjects were asked to consume one less portion of carbohydrate per day (e.g. one slice of bread and to consume full fat dairy products. Subjects also consumed 2g control oil per day during this period. Control oil comprised palm olein and soybean oil.
223583731|NCT01384032|DIETARY_SUPPLEMENT|High saturated fat diet|Subjects were asked to consume a high saturated fat diet for 8 weeks. Composition: 38% energy from fat, 18% energy from saturated fat, 45% energy from carbohydrate. Subjects were provided with spread, cooking oil and snacks and asked to consume these in place of normally eaten equivalent foods. Subjects were asked to consume one less portion of carbohydrate per day (e.g. one slice of bread and to consume full fat dairy products. Subjects also consumed 6g DHA-rich oil per day during this period providing 3g DHA.
223583732|NCT03895255|PROCEDURE|Paraaortic lymph node dissection, IMA high ligation, TME, routine splenic flexure mobilization|Nerve-sparing paraaortic lymph node dissection is performed. The inferior mesenteric artery is divided at 1-2 cm from its origin from the aorta. Nerve-sparing total mesorectal excision is performed. Splenic flexure is mobilized. Side-to-end sigmoido-rectal anastomosis is created.
223583733|NCT03895255|PROCEDURE|Paraaortic lymph node dissection, IMA low ligation, TME, selective splenic flexure mobilization|Nerve-sparing paraaortic lymph node dissection is performed. Then inferior mesenteric artery is skeletonized down to the origin of left colic artery and divided below it. Nerve-sparing total mesorectal excision is performed. Splenic flexure is mobilized only if sigmoid colon is unsuitable for anastomosis or doesn't reach the rectal stump. Then descending-rectal side-to-end anastomosis is created.
223583734|NCT01579630|DRUG|Pemetrexed 500mg/m2 iv|EGFR mutation negative patients who continuously respond (CR, PR or SD) to the 4th cycle of pemetrexed/ cisplatin or pemetrexed/carboplatin will be randomized in a 1:1 ratio to receive either gefitinib/ pemetrexed, or pemetrexed alone as maintenance therapy until progression of disease (PD) or discontinuation of treatment for other reasons.
223583735|NCT01579630|DRUG|Pemetrexed 500mg/m2 iv and Gefitinib 250 mg|EGFR mutation negative patients who continuously respond (CR, PR or SD) to the 4th cycle of pemetrexed/ cisplatin or pemetrexed/carboplatin will be randomized in a 1:1 ratio to receive either gefitinib/ pemetrexed, or pemetrexed alone as maintenance therapy until progression of disease (PD) or discontinuation of treatment for other reasons.
223744702|NCT05074030|BEHAVIORAL|Personalized Normative Feedback|Normative Feedback on drinking behaviors.
224070330|NCT06252064|OTHER|Rehabilitation|Patients in the Reha group underwent rehabilitation treatment: the rehabilitation protocol included daily sessions, 5 days a week, lasting 60 minutes, for a total of 4 consecutive weeks. The treatment included an initial step, lasting 40 minutes, of Postural Reeducation ending with Stretching exercises of the posterior kinetic chain muscles lasting 20 minutes.
224163653|NCT01536418|DRUG|GSK1605786A|500 milligrams once daily, orally administered for 12 weeks
223477900|NCT01090180|DRUG|Dexamethasone|anti-inflammatory adrenocortical steroid The following dose schedule will be given: 0.15mg/kg (based on body weight) every 7 days for 4 consecutive weeks
223477901|NCT01090180|DRUG|Placebo (sugar pill)|inactive
223477902|NCT06351904|DRUG|RAG-01|RAG-01 is a therapeutic small activating RNA (saRNA) duplex molecule comprised of two partially chemically modified complementary oligonucleotide strands.
223477903|NCT02378389|DRUG|Pyrotinib/Pyrotinib with Docetaxel|Pyrotinib oral daily, 240 mg, 320 mg, 400 mg.... Docetaxel i.v. once every 21 days.
223477904|NCT04534998|PROCEDURE|Partial nephrectomy|Partial nephrectomy for localized kidney cancer as curative treatment.
223477905|NCT00289276|DEVICE|Fluid Status Monitoring (OptiVol™)|Thoracic Fluid Status Software downloaded on all subjects enrolled in the trial
223477906|NCT03939104|DRUG|Artemether-lumefantrine+amodiaquine|"AL: Currently available as dispersible tablets containing 20 mg of artemether and 120 mg of lumefantrine, in a fixed-dose combination formulation. The flavoured dispersible tablet paediatric formulation facilitates use in young children.~The dose of artemether-lumefantrine is administered approaching the WHO-recommended target ranges of artemether 5-24 mg/kg and lumefantrine 29-144 mg/kg over 3 days.~AQ: Amodiaquine is available as dispersible tablets of 40 mg. The weight-based treatment schedule aims for a dosage of approximately 10mg (4.5-15mg)/kg/day amodiaquine for three days."
223477907|NCT03939104|DRUG|Artemether-lumefantrine+placebo|"AL: Currently available as dispersible tablets containing 20 mg of artemether and 120 mg of lumefantrine, in a fixed-dose combination formulation. The flavoured dispersible tablet paediatric formulation facilitates use in young children.~The dose of artemether-lumefantrine is administered approaching the WHO-recommended target ranges of artemether 5-24 mg/kg and lumefantrine 29-144 mg/kg over 3 days.~PBO: Placebo tablets for amodiaquine are identical in size, shape and color to the amodiaquine tablets."
223477908|NCT03939104|DRUG|Artesunate-mefloquine+piperaquine|"AS: Artesunate will be administered according to an optimised dosing schedule using tablets of 32 or 100 mg artesunate with a dosing target of 4 mg/kg/day.~MQ: Mefloquine will be administered according to an optimised dosing schedule using tablets of 70 or 220 mg mefloquine hydrochloride with a dosing target of 8.3 mg/kg/day.~PPQ: Piperaquine will be administered according to an optimised dosing schedule using tablets of 160 or 500 mg of piperaquine tetraphosphate. The weight-based treatment aims for a dosage of approximately~* 24 mg/kg/day in patients \<25 kg (range 16.0 - 32.0 mg/kg) piperaquine for three days, thereby approaching the WHO-recommended target range of 20 - 32 mg/kg per day.~* 18 mg/kg/day in patients ≥25 kg (range 15.0 - 29.4 mg/kg) piperaquine for three days, thereby approaching the WHO-recommended target range of 16 - 27 mg/kg per day."
223583736|NCT04798716|DRUG|MSC-exosomes delivered intravenously every other day on an escalating dose: (2:4:8)|Escalating dose 2 X 10\^9, 4 X 10\^9, 8 X 10\^9/mL
223583737|NCT04798716|DRUG|MSC-exosomes delivered intravenously every other day on an escalating dose (8:4:8)|Escalating dose 8 X 10\^9, 4 X 10\^9, 8 X 10\^9 mL
223583738|NCT04798716|DRUG|MSC-exosomes delivered intravenously every other day (8:8:8)|Dosed 8 X 10\^9, 8 X 10\^9, 8 X 10\^9 mL
223583739|NCT03076723|OTHER|Change in shunt opening pressure|An individually determined change in shunt opening pressure is compared to no change in opening pressure.
223583740|NCT03076723|OTHER|Simulated change in shunt opening pressure|The shunt opening pressure is reset to the same setting.
223583741|NCT02406729|BIOLOGICAL|Dengue 1,2,3,4 (attenuated) vaccine|Dose 1000 PFU per virus (1,2,3,4) Route:subcutaneous
223583742|NCT02406729|OTHER|Placebo|Route:subcutaneous
223583743|NCT05607706|BEHAVIORAL|Exposure to maternal odor|Exposure to maternal odor; the shirt worn by the mother is put in the baby's incubator, kangaroo care; mother lays her baby naked between her breasts
223583744|NCT03317119|OTHER|Laboratory Biomarker Analysis|Correlative studies
223583745|NCT03317119|DRUG|Trametinib|Given PO
223583746|NCT03317119|DRUG|Trifluridine and Tipiracil Hydrochloride|Given PO
223583747|NCT00528996|DRUG|BEA 2180 BR|Solution
224070331|NCT06252064|OTHER|Drug therapy|The Drug Group had taken Pridinol Mesylate orally, on an empty stomach, 2 mg x 3 times a day for 20 days. The tablet was taken without chewing and with a glass of water (200 ml). The drug was taken in environments with temperature below 25° C.
224070332|NCT01227330|BEHAVIORAL|Medication adherence intervention|12-week behavioral feedback intervention to improve adherence to statin medication
224070333|NCT01227330|BEHAVIORAL|Attention-control|Health education visits that are unrelated to medications or cholesterol, provided on the same visit schedule as the intervention group
224070334|NCT02318472|DEVICE|VACOped orthosis|Weight-bearing orthosis with adjustable range of motion of the ankle
223583748|NCT00528996|DRUG|Tiotropium Bromide|Solution
224070335|NCT02318472|DEVICE|Plaster cast|Lower limb plaster cast
224163355|NCT06031181|PROCEDURE|Sublobar Resection|Sublobar Resection includes segmentectomy and wedge resection
224163356|NCT05182541|OTHER|Guided self help|Introduce the knowledge about twins pregnancy, and reduce the pregnant stress, and relief the anxiety and depressor.
224163357|NCT05182541|OTHER|Problem solving therapy|Based on the steps of problem-solving therapy, nurses guide mothers with mild psychological problems to solve the existing problems through wechat and telephone, 10-15 min each time for 4 weeks
224163654|NCT01536418|DRUG|GSK1605786A|500 milligrams twice daily, orally adminstered for 12 weeks
224163854|NCT03987867|BIOLOGICAL|CIK cell|CIK cell injection
223583749|NCT00528996|DRUG|Placebo|Solution
223583750|NCT00048113|DRUG|Alicaforsen|
223583751|NCT05196555|PROCEDURE|Repair of cleft palate with intravelar veloplasty (IVVP)|A triangular flap is designed comprising new epithelial tissue which will be turned over to help close the nasal mucosa. Using a single hook, the oral mucosa and gland layer is separated from the muscle layer. Dissection of the greater palatine nerve-vessel bundle. The anterior palatal flap is raised by a curved elevator. The closure of the nasal mucosa and muscle is completed. Dissection of Velo Palatine Levator begins from the posterior rim of muscle and 5 mm from the midline.
223583752|NCT02402413|PROCEDURE|Ultrasound|The patients will be subjected to ultrasound bi-dimensional or three-dimensional. Will Be calculated the ratio stroma/volume with both methods
223583753|NCT02402413|PROCEDURE|Determination of concentrations of androgens|Determination of concentrations of serum levels of circulating androgens
223583754|NCT02402413|DEVICE|Three dimensional ultrasound probe|Capture of ovarian three dimensional volumes
223744703|NCT05074030|BEHAVIORAL|Coping-Motive Specific Personalized Feedback Intervention plus an Ecological Momentary Intervention (PFIcope+EMI)|An EMA plus EMI intervention to decrease drinking to cope behaviors among emerging adults receiving psychiatric treatment.
223744704|NCT00003733|DRUG|carboplatin|
223477909|NCT03939104|DRUG|Artesunate-mefloquine+placebo|"AS: Artesunate will be administered according to an optimised dosing schedule using tablets of 32 or 100 mg artesunate with a dosing target of 4 mg/kg/day.~MQ: Mefloquine will be administered according to an optimised dosing schedule using tablets of 70 or 220 mg mefloquine hydrochloride with a dosing target of 8.3 mg/kg/day.~PBO: Placebo tablets for piperaquine are identical in size, shape and colour to the piperaquine tablets."
223477910|NCT05093582|DRUG|Levcromakalim|12 active episodic patients, 15 episodic patients in remission and 20 chronic patients of both genders are randomized to receive a 20-minute infusion of levcromakalim and/or sterile saline on two days, with at least 3 days in between.
223477911|NCT05093582|DRUG|Saline|12 active episodic patients, 15 episodic patients in remission and 20 chronic patients of both genders are randomized to receive a 20-minute infusion of levcromakalim and/or sterile saline on two days, with at least 3 days in between.
223477912|NCT01663389|DRUG|GSK1322322 1000 mg containing radioactive 14C-GSK1322322|GSK1322322 1000 mg is a mesylate salt powder for injection containing 45.5 μCi radioactive 14C-GSK1322322 1000 mg as free base.
223477913|NCT01663389|DRUG|GSK1322322 1200 mg containing radioactive 14C-GSK1322322|GSK1322322 1200 mg is a mesylate salt powder for oral solution containing 54.5 μCi radioactive 14C-GSK1322322 1200 mg as free base.
223477914|NCT02728323|DRUG|Levobupivacaine|100 mg of Levobupivacaine by intramuscular injection, at the end of surgery
223477915|NCT02728323|DRUG|Saline|20 ml of saline saline by intramuscular injection, at the end of surgery
223477916|NCT01884948|DRUG|Omegaven™|
223477917|NCT00513929|DIETARY_SUPPLEMENT|Zinc sulphate|Arm X : Zinc sulphate 10 mg will be given orally twice a day since admission to resolution of pneumonia episode in addition to standard antibiotic treatment.
223477918|NCT05302011|DRUG|Pembrolizumab|Pembrolizumab 200mg i.v. day 1-22-43-64
223477919|NCT05302011|DRUG|Carboplatin or Cisplatin|Carboplatin Area Under the Curve(AUC) = 4-5 i.v. day 1-22-43-64 or Cisplatin 75mg/m2 i.v. day 1-22-43-64
223477920|NCT05302011|DRUG|Docetaxel|75mg/m2 i.v. day 1-22-43-64
223477921|NCT02051868|DRUG|Cisplatin|Cisplatin 60 mg/m2 as a 1 hour i.v. infusion once every 3 weeks.
223477922|NCT02051868|DRUG|5-Fluorouracil (5-FU)|5-FU 1000 mg/m2/24h as a 96-hour continuous infusion over days 1 to 4 every 3 weeks.
223477923|NCT02051868|DRUG|Carboplatin|Carboplatin 1-hour i.v. infusion to an area under the curve (AUC) of 5 once every 4 weeks.
223477924|NCT02051868|DRUG|Paclitaxel|Paclitaxel 80 mg/m2 as a 1-hour i.v. infusion on day 1,8 and 15 of each (4-weekly) cycle.
223477925|NCT00001091|DRUG|Ritonavir|
223477926|NCT00001091|DRUG|Nelfinavir mesylate|
223477927|NCT00001091|DRUG|Nevirapine|
223477928|NCT00001091|DRUG|Lamivudine|
223477929|NCT00001091|DRUG|Stavudine|
223477930|NCT04850651|DRUG|Pyrotinib；Fluconazole|"Drug: Pyrotinib Participants received a single oral dose of Pyrotinib tablet on the morning of day1 in treatment period 1.~Drug: Pyrotinib/Fluconazole In treatment period 2, Participants received a single oral dose of pyrotinib tablet on the morning of day9, and received a loading dose of fluconazole capsule on day6 followed by single dose of fluconazole for oral administration from D7 to D18."
223477931|NCT01382550|DRUG|long-lasting OAT or 12-month OAT|"The antithrombotic treatment will be decided according to usual practice of enrolling Centers. The duration of the initial treatment with parenteral anticoagulation (Low Molecular Weight Heparin or Fondaparinux), the beginning of oral anticoagulation (OAT) with Vit K inhibitors and the International Normalized Ratio (PT-INR) target will be recorded.~According to Center indications the OAT duration (6 months, 12 months or long-lasting) will be recorded and population will be stratified accordingly. The length of therapy will be counted from the date when a stable PT-INR is achieved.~The occurrence of surgery, trauma, prolonged immobilization (\>7 days), pregnancy (VTE risk periods) during the follow-up and the use of adequate anti-thrombotic prophylaxis will be recorded."
223477932|NCT00496418|DEVICE|Mesh in permanent colostomy|
223477933|NCT01181973|DRUG|pegvisomant|One 1-mL subcutaneous injection at 30 mg/mL. A 30-mg vial is supplied as lyophilized powder. Each vial should be reconstituted with 1 mL of Sterile Water for Injection (WFI).
223477934|NCT01181973|DRUG|pegvisomant|Two 1-mL subcutaneous injections at 15 mg/mL each. Two 15-mg vials are supplied as lyophilized powder. Each vial should be reconstituted with 1 mL of Sterile Water for Injection (WFI).
223477935|NCT01181973|DRUG|pegvisomant|Two 1-mL subcutaneous injections at 15 mg/mL each. Two 15-mg vials are supplied as lyophilized powder. Each vial should be reconstituted with 1 mL of Sterile Water for Injection (WFI).
223477936|NCT01181973|DRUG|pegvisomant|One 1-mL subcutaneous injection at 30 mg/mL. A 30-mg vial is supplied as lyophilized powder. Each vial should be reconstituted with 1 mL of Sterile Water for Injection (WFI).
223477937|NCT03652896|PROCEDURE|anatomical liver resection|Liver resection is performed to achieve R0 resection for patients with appropriate BCLC staging, indocyanine green retention rate, Child-pugh grading and adequate liver remnant.
223477938|NCT03961399|DEVICE|Abbott Medical® CRT device with SyncAVTM stimulation function|patients with Abbott Medical® CRT device will be randomized and SyncAVTM stimulation will be activated.
223477939|NCT03961399|DEVICE|Abbott Medical® CRT device with biventricular stimulation (BiV)|patients with Abbott Medical® CRT device will be randomized and biventricular (BiV) stimulation will be activated.
223477940|NCT03720886|BIOLOGICAL|rhPTH（1-34） 28.2μg|Administered by subcutaneous injection
223583755|NCT03341455|BEHAVIORAL|Capacity building to support families affected by IPV & substance misuse|Training targeted groups (mothers, fathers, preschool teachers, community officers managing preschools) separately with the aim to identify and support high-risk families early enough to arrest the cycle of violence that results in children themselves becoming victims and perpetrators of such violence.
223583756|NCT01307462|DRUG|fluticasone propionate|Given inhaled PO
223477941|NCT03720886|BIOLOGICAL|rhPTH（1-34） 56.5μg|Administered by subcutaneous injection
223477942|NCT03720886|BIOLOGICAL|teriparatide acetate(Teribone™)|Administered by subcutaneous injection
223477943|NCT04582656|DEVICE|Targeted microwave ablation|Targeted ablation of the index tumor with microwaves, by using either a transperineal or a transrectal approach
223583757|NCT01307462|DRUG|montelukast sodium|Given PO
223583758|NCT01307462|DRUG|azithromycin|Given PO
223583759|NCT00952887|BIOLOGICAL|ACE-031|Either 2 or 3 subcutaneous doses of ACE-031 over a period of one month, or 7 subcutaneous doses of ACE-031 over a period of 3 months.
223477944|NCT04087512|OTHER|Training on perturbation treadmill|Perturbations into different directions are induced during static and dynamic tasks on a treadmill. Perturbations include announced and unannounced perturbations. Intensity and number of perturbations increases over the course of the intervention based on judgement of participant. Intervention duration: 6 weeks, 3 sessions a week, each session approx. 30 minutes.
223477945|NCT04087512|OTHER|Exercises of dynamic stability under unstable conditions|The mechanisms of dynamic stability recovery are trained under unstable conditions. Different unstable undergrounds are used to stand on, perform lunges or jumps. Additionally, balance is challenged by different restrictions (e.g. decreased base of support, closed eyes) or therapist-applied perturbations. Intervention duration: 6 weeks, 3 sessions a week, each session approx. 45 minutes.
223477946|NCT01997658|DRUG|Methylprednisolone|Patients in Methylprednisolone arm will receive injection methylprednisolone 500 mg I/V over 15 to 20 minutes, single dose, 30 minutes before starting surgery.
223477947|NCT01997658|DRUG|Placebo|Patients in the placebo group will receive standard perioperative care and surgery, without preoperative administration of methylprednisolone.
223477948|NCT03040726|DRUG|Netupitant|Given PO
223477949|NCT03040726|DRUG|Palonosetron|Given PO
223583760|NCT00952887|BIOLOGICAL|Placebo|Either 2 or 3 subcutaneous doses of placebo over a period of one month, or 7 subcutaneous doses of placebo over a period of 3 months.
223583761|NCT03419065|BEHAVIORAL|Relaxation Intervention|Relaxing Music combined with Progressive Muscle relaxation and guided imagery
223583762|NCT02913768|DRUG|Ondansetron|
223583763|NCT02913768|DRUG|Normal saline|
223583764|NCT02174653|DRUG|EPs® 7630|20 mg EPs® 7630 film-coated tablets during 4 months Orally intake three times a day (in the morning, midday and evening)
223583765|NCT02174653|DRUG|Placebo|Control: Placebo film coated tablets during 4 months Orally intake three times a day (in the morning, midday and evening)
223583766|NCT02687100|DRUG|Beclomethasone|beclometasone, 0.8 mg of saline to a volume of 8 mL, three times through the line for suctioning above the cuff: a) after positioning the tube; b) at the arrival in the cardiac intensive care unit; c) just prior to start respiratory weaning
223583767|NCT02687100|DRUG|Placebo|patients will receive 8 mL of saline without any drug
223583768|NCT05943210|RADIATION|Short Course Radiation Therapy (scRT)|Eligible patients will receive short course radiation therapy (scRT) of 25Gy over 5 days (fractions) for their localized rectal cancer. Research bloods stool and tissue will be collected at three time points: Baseline, end of radiation therapy and at surgery.
223583769|NCT05943210|PROCEDURE|Total Mesenteric Excision (TME)|Subjects are expected to undergo total mesenteric Excision(TME) even if subjects have achieved complete response by imaging.TME is a specific surgical technique used in the treatment of rectal cancer in which the bowel with the tumor is entirely removed along with surrounding fat and lymph nodes.
223583770|NCT04913662|PROCEDURE|Pressurized Intraperitoneal Aerosol Chemotherapy|Aerosolization of chemotherapic agent for intraperitoneal chemotherapy
223583771|NCT04073485|PROCEDURE|Microwave ablation|Ultrasonogram is performed to identify the fibroid or adenomyoma. A trocar needle is placed into the lesion under local anesthesia. The MWA procedure is performed using appropriate microwave power and application time are selected to provide sufficient ablation coverage to the target lesion.
224163358|NCT05182541|OTHER|Face to face PST course|Face to face interviews with nurses with psychological counselors, combined with auxiliary tools, identify patients' problems, set goals for patients, provide different solutions, and let patients choose appropriate ways according to their preferences. Once a week, 1 hour for the first time and 45 min for the rest for 5 weeks.
224163655|NCT05419284|OTHER|GAPP+Care|"standard physiotherapy 45 minutes per day, 5 day a week (GAPP)~\+ 3 extra exercise sessions led by a caregiver (+Care)"
223477950|NCT03040726|DRUG|Palonosetron Hydrochloride|Given PO
223477951|NCT03040726|OTHER|Placebo|Given PO
223477952|NCT03040726|OTHER|Questionnaire Administration|Ancillary studies
223477953|NCT02406820|DEVICE|Non-invasive hemodynamic monitoring (CVInsight™ [CVI])|
223477954|NCT03998072|OTHER|Five session cognitive analytic therapy (CAT) consultancy|Five session consultancy with patients and care coordinators using cognitive analytic therapy
223477955|NCT05244096|OTHER|No intervention|Observational study
223477956|NCT03578042|DRUG|Losartan and amlodipine and hydrochlorothiazide|this is a fixed combination containing the 3 drugs
223477957|NCT03578042|DRUG|Standard of care|any free triple combination therapy for hypertension given as 2 or 3 pills
223477958|NCT04749199|BEHAVIORAL|Enhanced mirror therapy|Participants of the enhanced mirror therapy group will perform complex, randomized, finger opposition and reposition movements, using the thumb, index, middle, ring, and little fingers, and will be shown a 35% blurred visual feedback through the computerized mirror therapy device. Each participant will receive a mirror training session for 60 minutes each day, three times per week for four consecutive weeks.
223477959|NCT04749199|BEHAVIORAL|Standard mirror therapy|Participants allocated to this group will perform simple, sequential finger opposition and reposition movements, using the thumb, index, middle, ring, and little fingers, and will be shown a clear image of the exercising hand. Each participant will receive a mirror training session for 60 minutes each day, three times per week for four consecutive weeks.
223583772|NCT03394352|OTHER|Activity on Board|During the collection phase, the study team will collect information on glucose values, activity measures and insulin settings. This information will be used to determine the meal and correction boluses during the study admission. Subjects will wear a continuous glucose monitor during the data collection phase and study admission.
223583773|NCT03394352|OTHER|Usual Diabetes Care|Subjects will perform their usual diabetes care including basal rate, meal and correction boluses during the study admission. Subjects will wear a continuous glucose monitor during the study admission.
223583774|NCT05645393|DRUG|topical estrogen product|estrogen topical gel or cream
223583775|NCT06304506|OTHER|Cross sectional study|Physiological testing, Sampling of blood and abdominal adipose tissue and respiratory measurements at rest and during exercise
223583776|NCT06203587|RADIATION|[68Ga]Ga-NOTA-WWH347 or [18F]F-H3RESCA-WWH347|The dose of \[68Ga\]Ga-NOTA-WWH347 or \[18F\]F-H3RESCA-WWH347, calculated from the patient's body weight, was 1.8-3.7 MBq \[0.05-0.1 mCi\]/kg, and was administered as an intravenous push, with a single dose given once.
223744705|NCT00003733|DRUG|paclitaxel|
223744706|NCT00003733|DRUG|topotecan hydrochloride|
223477960|NCT03401957|DRUG|Cetuximab|Cetuximab-based infusional 5-FU regimen as the 1st line treatment.
223477961|NCT03401957|DIAGNOSTIC_TEST|liquid biopsy|The blood samples taken from subjects will be evaluated for RAS genotype using MassARRAY technique.
223477962|NCT06178692|DIAGNOSTIC_TEST|Validation of miRNA-serum signatures associated with IDH1 status|Validation of miRNA-serum signatures associated with IDH1 status and prognosis, as reliable, specific and sensitive circulating diagnostic biomarkers also useful to improve prognostic stratification of patients.
223477963|NCT05709613|DEVICE|Use of a chest compressions' feedback device|The participants will have access to a chest compressions' feedback device
223477964|NCT06478914|DEVICE|Neuromuscular electrical stimulation (NMES)|NMES unit manufactured by Enraf-Holland was be used to administer the neuromuscular electrical stimulation (NMES) The study involved adjusting the patient's hips, knees, and ankles to achieve a comfortable position. Two electrodes of NMES were used in the first study group and a placebo in the control group. The electrodes were placed on the popliteal fossa and fibular head, and each session was conducted for 15 minutes daily for 2 months.
223477965|NCT06478914|DEVICE|low-intensity laser therapy (LILT)|"The laser unit is a small, hand-held, class III laser product manufactured by Laserex Technology Pty Ltd Australia. It offers continuous and pulsed laser therapy, with continuous therapy being the most effective. The device has a maximum average power of 5 milliwatts, a wavelength of 820 nm, and a power density of 0.39 W/cm2.~Patients were treated as outpatients, receiving full explanations about the purpose, therapeutic, and physiological benefits of low-intensity laser therapy (LILT). They were relaxed in supine position, with hips and knees adjusted. The patient was irradiated in a continuous mode and direct contact method, 3 times per week for 2 months, at 1-cm intervals and across the surface in grids. The laser applicator was applied to the surface, maintaining contact for maximum penetration."
223477966|NCT01767337|DEVICE|FLUGEN 101.2 device|
223477967|NCT05907447|OTHER|No interventions need to be specified for this study|No interventions need to be specified for this study
223477968|NCT05856487|DRUG|NVP-2203|Take it once daily for 8 weeks orally.
223477969|NCT05856487|DRUG|NVP-2203-R1|Take it once daily for 8 weeks orally.
223477970|NCT05856487|DRUG|NVP-2203-R2|Take it once daily for 8 weeks orally.
223477971|NCT05856487|DRUG|NVP-2203-R3|Take it once daily for 8 weeks orally.
223477972|NCT05856487|DRUG|NVP-2203 Placebo|Take it once daily for 8 weeks orally.
223477973|NCT05856487|DRUG|NVP-2203-R1 Placebo|Take it once daily for 8 weeks orally.
223477974|NCT05856487|DRUG|NVP-2203-R2 Placebo|Take it once daily for 8 weeks orally.
223477975|NCT05856487|DRUG|NVP-2203-R3 Placebo|Take it once daily for 8 weeks orally.
223477976|NCT02783911|DEVICE|MTA|Mineral Trioxide Aggregate grey paste
223583777|NCT04784624|BEHAVIORAL|Lifestyle program|The cardiometabolic and weight loss program is based on The Wellness Institute clinically validated lifestyle medicine program and will be delivered virtually using a digital platform and artificial intelligence that is supported by a health coach. The program focuses on building individual's self-efficacy, motivation and importance to make and sustain healthy choices. The 16-week program begins with a health risk assessment and a personalized wellness plan. The plan includes a personalized exercise plan and nutrition strategy. Each user will regularly check-in with their personal health coach whose role is to provide expert advice and also empower, support and help make the user accountable as they build a healthy lifestyle. Coaching includes identifying obstacles to changing behaviors and how to develop new behaviors that will become the norm.
223583778|NCT02108314|BEHAVIORAL|Video Screening and Counselling|The intervention comprises 1) GP counseling, 2) 3-minute promotional video on mammography and 3) an informational brochure with relevant contact details and information for arranging a mammography screening. Pre- and post-consultation questionnaire were administered to participants to evaluate their health beliefs, with emphasis on breast cancer and mammography.
223477977|NCT02783911|DRUG|Ferric Sulfate|Ferric Sulfate paste
223477978|NCT05583630|DEVICE|A gap plate with the function of knee joint pressure detection|A gap plate can measure knee joint pressure by tension sensor. This is a part of routine medical care.
223477979|NCT06466239|OTHER|PNF Stretching|PNF was applied to the hamstring muscle, with a 1-day washout period in between.
223477980|NCT06466239|OTHER|Static Stretching|Static stretching was applied to the hamstring muscle, with a 1-day washout period in between.
223477981|NCT01555593|DEVICE|Cardioline Exp'air by Medi-soft - Sorinnes (B)|FeNO measurement in four different moments, the first in the evening, the last three in the morning of the day after. These evaluations will be repeated when the patient enters the unit and after 15 days of rehabilitation activity
223744707|NCT00783601|DRUG|Comparator: MK0524 + placebo|Two 150 mg MK0524 tablets + one placebo tablet in the matching image of montelukast 10 mg once daily for 3 weeks
223477982|NCT03617302|DRUG|Experimental: Nitrate-containing|Experimental
223477983|NCT03617302|DRUG|Placebo: Nitrate-depleted|Placebo
223477984|NCT00216372|DRUG|Lanreotide (microparticle formulation)|A single 30 mg intra-muscular injection on day 0. The duration of the blinded phase is 10 days. Patients may enter the open phase where they receive 30 mg intra-muscular injections, every 10 days until investigator/or patient decide to stop treatment.
223477985|NCT00216372|OTHER|Placebo|A single intra-muscular injection on day 0.
223477986|NCT04673500|DRUG|Propofol lidocaine through large vein|A mixture of 2% lidocaine 1 ml and 1% propofol 2mg/kg was given through a large antecubital vein to assess pain severity on propofol injection during general anesthesia induction
223477987|NCT04673500|DRUG|Propofol lidocaine through small vein|A mixture of 2% lidocaine 1 ml and 1% propofol 2mg/kg was given through a small vein on the dorsum of hand to assess pain severity on propofol injection during general anesthesia induction
223477988|NCT01703468|DRUG|Oxcarbazepine|
223477989|NCT00071981|BIOLOGICAL|incomplete Freund's adjuvant|Given by injection
223477990|NCT00071981|BIOLOGICAL|melanoma helper peptide vaccine|Given by injection
223477991|NCT00071981|BIOLOGICAL|multi-epitope melanoma peptide vaccine|Given by injection
223477992|NCT00071981|BIOLOGICAL|sargramostim|Given by injection
223477993|NCT00071981|BIOLOGICAL|tetanus peptide melanoma vaccine|Given by injection
223477994|NCT05605990|DEVICE|Innovative tourniquet (Acusense Nonpneumatic tourniquet)|To use this innovative tourniquet before collecting blood samples, and setting IV catheter. We also use this innovative tourniquet to occlude the flow of blood.
223744708|NCT00783601|DRUG|Comparator: MK0524 + montelukast|Two 150 mg MK0524 tablets and one 10 mg montelukast tablet once daily for 2 weeks
223477995|NCT04244539|DEVICE|high-intensity laser Device.|Twenty four treatment sessions with pulsed Nd: YAG laser were applied to the subjects of the study group, three sessions per week, over 8 weeks in succession via HIRO® 3.0 device (ASAlaser, Arcugnano, Vicenza, Italy). The device gives pulsed emission (λ = 1064 nm), maximum power (3000 W), fluency range (360-1780 mJ/cm2), pulse duration (≤ 100 μs), frequency range (10-40 Hz), maximum energy per pulse (350 mJ), mean power (10.5 W), and power cycle of \~0.1%.
223477996|NCT04382482|DEVICE|Tachidino|Web-platform delivering remote treatment of reading and spelling disorders through the (visual or auditory) presentation of words and sentences to be either decoded or corrected (reordering wrong letter sequences).
223477997|NCT00802971|DIETARY_SUPPLEMENT|FOS|Oligofructose (FOS, BioCare Ltd, Birmingham, England) powder will be distributed in sachets of 10 g. Two sachets are to be included in daily nutrition, preferentially 10 g diluted in water at breakfast and before supper.
223477998|NCT01867255|DRUG|venlafaxine ER (extended-release) 75 mg|A single dose of venlafaxine ER 75 mg is to be administered once at each of two study visits, pre- and post-gastric bypass surgery.
223477999|NCT00036426|BIOLOGICAL|FavId (Id-KLH) active immunotherapy|
223478000|NCT05295589|PROCEDURE|Computed Tomography|Undergo CT scan
223478001|NCT05295589|DRUG|Copanlisib Hydrochloride|Given IV
223478002|NCT05295589|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223478003|NCT05295589|DRUG|Olaparib|Given PO
223478004|NCT05295589|DRUG|Paclitaxel|Given IV
223583779|NCT05971446|DEVICE|Visual Evoked Potential (VEP)|Small gold-cup electrodes will be placed on the participant's head using a small dot of adhesive paste. The handheld device is then connected to the electrodes, and the participant's eyes are exposed to a light flicker. Each eye will be tested separately, and while testing one eye, the other eye may be patched.
223583780|NCT05971446|DEVICE|Electroretinogram (ERG)|Skin electrodes will be placed under each eye. Eyes will then be exposed to a flashing light. Each eye will be tested separately and while testing one eye, the other eye may be patched.
223583781|NCT05039892|DRUG|3D185|All eligible subjects will receive the RP2D regimen to be established based on the results of the ongoing phase I study from Cycle 1 Day 1 (C1D1) until disease progression, intolerable toxicity, withdrawal of consent, whichever occurs first.
223583782|NCT05736419|DRUG|Fludarabine|PK-guided fludarabine dosing will be used for each of the 2 cycles, using the InsightRx DoseMeRx platform.
223744709|NCT00783601|DRUG|Comparator: placebo + montelukast|Two placebo tablets in the matching image of MK0524 150 mg and one 10 mg tablet montelukast once daily for 2 weeks
223744710|NCT00783601|DRUG|Comparator: Placebo|During the double-blind treatment periods, patients receive either two placebo tablets in the matching image of MK0524 150 mg or one placebo tablet in the matching image of montelukast 10 mg in a crossover manner. During the washout period before the crossover to the opposite treatment sequence, patients receive two placebo tablets in the matching image of MK0524 150 mg and one placebo tablet in the matching image of montelukast 10 mg once daily for two weeks.
223744711|NCT02971267|OTHER|Observational|None, observational only
224163359|NCT05182541|OTHER|Professional psychological intervention|The mental health physicians and (or) psychological counselors strengthened the intervention and carried out specialized nursing
223478005|NCT05295589|DRUG|Pegylated Liposomal Doxorubicin Hydrochloride|Given IV
223478006|NCT05295589|DRUG|Topotecan Hydrochloride|Given IV
223478007|NCT03210766|DRUG|Nabilone|
223478008|NCT03210766|DRUG|THC/CBD|
223478009|NCT03448198|PROCEDURE|Total knee replacement|Primary knee gonarthrosis treated with navigated total knee replacement and computer-assisted patellar replacement.
223478010|NCT02328612|OTHER|Intravenous infusion of cells|"The treatment administration will be infused intravenously to the subjects after randomization:~An hour after the end of the eASCs administration, all subjects will be given an intravenous dose of LPS. Subjects will be allowed to leave in the evening once deemed clinically stable by the investigator."
223478011|NCT02937597|BEHAVIORAL|ePBP: eProficiency Based Progression|National e-learning programme plus Proficiency-based progression through 4 scenarios in an online learning course and facilitator when requested
223478012|NCT02937597|BEHAVIORAL|eS: eScenarios|National e-learning programme plus access to 4 scenarios in an online learning course and facilitator when requested
223478013|NCT02937597|BEHAVIORAL|HSE|National HSE e-learning programme only
223478014|NCT01123655|DRUG|APLA12|Intervention: Drug treatment will be stopped or interrupted if indicated. Medical care will be provided at no cost to the patient.
223478015|NCT01123655|DRUG|Placebo|Drug treatment will be stopped or interrupted if indicated. Medical care will be provided at no cost to the patient.
223478016|NCT03456466|DRUG|TQB2303|375mg/m2 ，iv
223478017|NCT03456466|DRUG|Rituximab|375mg/m2 ，iv
223583783|NCT05736419|DRUG|Cyclophosphamide|Cyclophosphamide will be administered Post-Transplant
223583784|NCT05736419|DRUG|Tacrolimus|Tacrolimus will be administered beginning on day +5
223583785|NCT05736419|DRUG|Mycophenolate Mofetil|Mycophenolate mofetil (MMF) will be administered three times daily starting on day +5.
223583786|NCT05736419|BIOLOGICAL|Rabbit ATG|The dose and schedule of ATG will be determined according to the nomogram in Appendix A
223583787|NCT05736419|DRUG|Dexamethasone|Standard Regimen: Dexamethasone on days -68 to -64 and days -40 to -36.
223744712|NCT00180895|DRUG|Rituximab|
223744713|NCT01739582|DRUG|Androxal|
223744714|NCT03366155|DEVICE|Codman 3000 constant flow pump catheter|implanted Medtronic SynchroMed II Pump with codman 3000 Constant Flow Pump Catheter
224163360|NCT06439485|DRUG|Pemigatinib|Given by PO
224163361|NCT06439485|DRUG|Atezolizumab|Given by PO and IV
224163362|NCT06439485|DRUG|Bevacizumab|Given by PO and IV
224163363|NCT03619083|OTHER|SAE battery|The SAE battery yields 12 variables.
224163364|NCT03619083|BEHAVIORAL|Assessments|Assessments of their neurocognitive performance will be assessed longitudinally, at 4 time points: prior to adjuvant treatment (post-surgery); 1 month (with a +4 week window) post-chemotherapy; and again at the 12 and 24 months (with a +4 week window) post-treatment time points. These assessment time points are denoted as T1 though T4, respectively. The assessment schedule for the HC and CT- groups will be yoked against that of the CT+ cohort.
223478018|NCT05449665|OTHER|Phase 1 - Control|"Control diet (30% Fat, 15% Protein, 55% Carbohydrate, Fibre rising from 10 to 16g/d).~Fed to energy balance (1.5 x Resting Metabolic Rate, RMR)."
223478019|NCT05449665|OTHER|Phase 2 - High Fibre|High Fibre diet (30% Fat, 15% Protein, 55% Carbohydrate, 30g/day Fibre). Fed ad libitum, contains 20g/day pectin (split over breakfast, lunch and dinner) in drinks/yoghurts which will be compulsory to consume and 10g/day fibre coming from the diet provided.
223478020|NCT05449665|OTHER|Phase 3 - Low Fibre|Low Fibre diet (30% Fat, 15% Protein, 55% Carbohydrate, 10g/day Fibre). Fed ad libitum.
223583788|NCT05736419|DRUG|Bortezomib|Bortezomib on days -71, -68, -65, -61, -43, -40, -37, and -33
223583789|NCT05736419|DRUG|Rituximab|Rituximab on days -71, -58, -43, and -30.
223744715|NCT03366155|DRUG|Panitumumab|6 mg/kg, IV
223744716|NCT03366155|DRUG|FUDR-Dex|HAIP will be filled with mixture of Floxuridine and Dexamethasone. Pump will perfuse drugs to liver for 14 days. Floxuridine (0.12 mg/kg X pump volume X pump flow rate),Dexamethasone (1 mg/day X pump volume (30) X pump flow rate)
223744717|NCT03366155|DRUG|Oxaliplatin|85 mg/m2, IV
223744718|NCT03366155|DRUG|5FU|2000 mg/m2, IV 46-hour infusion of 5-Fluorouracil + 400 mg/m2, IV of Leucovorin
223744719|NCT03366155|DRUG|Irinotecan|150 mg/m2, IV
223744720|NCT03366155|PROCEDURE|HAIP installation|HAI pump installation
223744721|NCT03366155|DRUG|cetuximab|500 mg/m2, IV
223744722|NCT03366155|DEVICE|Medtronic SynchroMed II Pump|implanted Medtronic SynchroMed II Pump with Codman 3000 Constant Flow Pump Catheter
223744723|NCT04674748|DRUG|INCB086550|Each Participant will be treated at the specified dose level with a minimum of 3 subjects at each dose level. After the RP2D of INCB086550 is identified, the dose level will be expanded to better characterize the safety and tolerability and PK.
223744724|NCT01557296|DIETARY_SUPPLEMENT|dietary treatment: food of small particle size|Subjects with diabetes mellitus and gastroparesis. Insulin treatment. Dietary treatment with food of small particle size.
224163365|NCT04507360|BEHAVIORAL|Study 1, Demographics Survey|Participants will be shown a demographics survey (e.g., age range, gender, income).
223478021|NCT00843466|OTHER|Mild, moisturizing hand cleanser|"Hand cleanser ingredient list:~Ammonium Lauryl Sulfate, Ammonium Laureth Sulfate, Cocamide MEA, PEG-5 Cocamide Cocamidopropyl Betaine Sodium Lauroyl Sarcosinate Glycerin Petrolatum Soybean Oil Sodium Hydroxypropyl Starch Phosphate Lauric Acid Lauryl Alcohol PEG-14M Guar hydroxypropyl trimonium chloride DMDM Hydantoin; Iodopropynyl Butylcarbamate Etidronic Acid Tetrasodium EDTA Titanium Dioxide Fragrance Sodium Hydroxide Water"
223583790|NCT06434233|DRUG|Acetaminophen|"All patients will receive Acetaminophen 500 mg orally every 6 hours scheduled x 30 tablets at post-operative discharge.~All patients will be instructed to take Acetaminophen around the clock for the first 72 hours and as needed thereafter."
223583791|NCT06434233|DRUG|Ibuprofen|"All patients will receive Ibuprofen 600 mg orally every 6 hours scheduled x 30 tablets at post-operative discharge.~All patients will be instructed to take Ibuprofen around the clock for the first 72 hours and as needed thereafter."
223583792|NCT06434233|DRUG|Oxycodone|"Patients randomized to Arm 1 will receive Oxycodone 5 mg orally every 4 hours as needed x 12 tablets at post-operative discharge~Patients randomized to Arm 2 will not receive an Oxycodone prescription at post-operative discharge.~However, participants will be informed that if they need additional pain medications, these will not be withheld. Participants in the second arm who require additional pain medications will receive the same amount of Oxycodone as in arm 1"
223744725|NCT01557296|RADIATION|Validate X-ray diagnostic method.|Follow 20 radiopaque markers throw the ventricle by X-ray.
223744726|NCT01557296|OTHER|Can the motility be improved|Registered the gastric emptying after intervention. Comparing the registrations at the beginning and at the end of the study.
223744727|NCT01557296|BIOLOGICAL|postprandial plasma glucose|Measure the blood glucose response and gastrointestinal symptoms after a test meal
223744728|NCT01533454|OTHER|Financial Incentives|Incentive arm participants will be able to earn incentives for meeting specified weight loss targets or step goals. They will be offered a choice between traditional (payments with certainty) and behavioral(payments paid via lottery) incentives.
223744729|NCT01540708|DRUG|SERETIDE Rotacaps|The study will be conducted in 3 parts with an adaptive design where pharmacokinetic data analysis follows each part to enable a decision on whether progression to the subsequent parts is required. Thirty six subjects will be enrolled in each part. Part A will test an alternative version of the Rotahaler with a lower airflow resistance. The study will then test one or more of the following options depending on the outcome of part A. If progressed, part B will test modified Rotacap formulations including: (1) modified blend formulation, (2) reduced capsule fill weights, (3) different capsule types. Part B will also test other versions of the Rotahaler with intermediate airflow resistance. Part C will test the lower strength FP/salmeterol (100/50 mcg or lower) and/or a new unit dose DPI device (BUDI). In each arm, subjects will be administered 7 doses (3.5 days bid) with PK sampling following administration of the 7th dose on the morning of Day 4.
224070336|NCT03501030|BEHAVIORAL|Activity restriction|Women in the intervention group will be recommended activity restriction. Activity restriction is defined as the following forms of activity restriction: pelvic rest and prohibition of sexual activity, reduction of work and/or non work activity. Bed rest will not recommended.
224070337|NCT00540189|PROCEDURE|Initial appendectomy|
224070338|NCT00540189|PROCEDURE|Interval appendectomy|
224070339|NCT02592239|DEVICE|Functional brain MRI|Functional brain MRI before and after test meal ingestion
224070340|NCT02592239|DIETARY_SUPPLEMENT|A warm ham and cheese sandwich and a 200 ml fruit juice|
224070341|NCT01401634|OTHER|Oral water|2 Liters of water given orally
224070342|NCT01401634|OTHER|Intravenous normal saline|2 Liters Intravenous normal saline
224163366|NCT04507360|BEHAVIORAL|Study 1, Next Steps Survey|Participants will be shown the Next Steps Survey, which includes 2 items assessing intended next steps on the Mental Health America (MHA) website (e.g., take another mental health test, find a treatment provider near you) and perceived need (yes, no, or I don't know) in addition to the Demographics Survey items.
224163367|NCT04507360|BEHAVIORAL|Study 1, Generic Response|Participants will be provided with the generic/current response to screening.
224163368|NCT04507360|BEHAVIORAL|Study 1, Generic Resources|Participants will be provided with links to a list of 4 generic Mental Health America (MHA) resources.
224163855|NCT03987867|BIOLOGICAL|Sintilimab Injection|IBI308 injection
224163856|NCT03987867|DRUG|Pemetrexed|Pemetrexed injection
223478022|NCT03226795|OTHER|" Information-Motivation-Behavioral skills  intervention."|"* information -\> Reminders of medication: mobile application~* Motivation -\> Coaching by patients: intervention or coaching by an expert patient, animation of a social network of patients~* Behavioral skills -\> Accompaniment by professionals: therapeutic education, assessment of membership during medical visits, prioritization of treatments"
223478023|NCT02387086|DRUG|Thalidomide|
223478024|NCT02387086|DRUG|placebo|
223478025|NCT02387086|DRUG|Gefitinib|
223478026|NCT02387086|DRUG|Aspirin|
223478027|NCT02466503|DRUG|Fluticasone propionate|Inhaled corticosteroid, pMDI
223478028|NCT02466503|DRUG|Salmeterol (as xinafoate)|Beta-agonist, LABA, pMDI
223478029|NCT02905162|OTHER|Transitional HIV care for prison releasees|Transitional HIV care program for releasees
223583793|NCT05691010|RADIATION|Intensity-modulated radiation therapy|After cycles 1, 2, 3 or 4 of chemotherapy, patients will receive IMRT to the vaginal cuff and pelvic lymph nodes with a total dose of 25 Gy delivered in 5 daily fractions of 5 Gy
223583794|NCT05691010|DRUG|Carboplatin|Patients enrolled in this trial will receive chemotherapy with carboplatin IV AUC 5 at the discretion of the treating investigator plus paclitaxel 175 mg/m2 every 21 days for 6 cycles
223583795|NCT05691010|DRUG|Paclitaxel|Patients enrolled in this trial will receive chemotherapy with carboplatin IV AUC 5 at the discretion of the treating investigator plus paclitaxel 175 mg/m2 every 21 days for 6 cycles
223583796|NCT00988949|DRUG|PF-04455242|Single oral 18 mg dose of PF-04455242.
223583797|NCT00988949|DRUG|spiradoline|Spiradoline 3.2 mcg/kg to be administered intramuscularly once on the morning of the spiradoline challenge day.
223583798|NCT00988949|OTHER|Placebo|Oral placebo.
223583799|NCT00988949|DRUG|spiradoline|Spiradoline 3.2 mcg/kg to be administered intramuscularly once on the morning of the spiradoline challenge day.
223583800|NCT00988949|DRUG|PF-04455242|Single 30 mg oral dose of PF-04455242.
223478030|NCT00235261|DRUG|Pregabalin|
223478031|NCT00235261|DRUG|Dexamethasone|
223583801|NCT00988949|DRUG|spiradoline|Spiradoline 3.2 mcg/kg to be administered intramuscularly once on the morning of the spiradoline challenge day.
223583802|NCT01331967|DRUG|Pioglitazone|Pioglitazone 15-30mg, once daily for 9 months
223583803|NCT01088854|DEVICE|CPAP|unique session of 30-minute of continuous airway positive pressure
223583804|NCT03003507|DIETARY_SUPPLEMENT|Enteral Formula With Fructose|Low-carbohydrate Enteral Formula With Fructose
223583805|NCT03003507|DIETARY_SUPPLEMENT|Enteral Formula Without Fructose|Low-carbohydrate Enteral Formula Without Fructose
223478032|NCT03428334|DRUG|Oral roflumilast|Roflumilast, a phosphodiesterase 4 (PDE4) inhibitor is approved worldwide (including Hong Kong) for treatment of severe chronic obstructive pulmonary disease (COPD) with frequent exacerbations. Roflumilast has been shown to have anti-inflammatory effect in patients with COPD, with significant reduction of sputum absolute neutrophil count, IL-8 and neutrophil elastase compared with placebo treatment. Roflumilast can also improve the lung function parameters in patients with COPD and reduce the rate of moderate-to-severe exacerbations.
223478033|NCT01015027|BIOLOGICAL|REGN668|4 IV Cohorts (Dose 1, 2, 3, \& 4)
223478034|NCT04145063|OTHER|no stent|following uretroscopy, no stent will be placed
223478035|NCT05409365|OTHER|Immunohistochemical staining monoclonal antibodies to SCCA2 (SERPINB4/ SCCA2 antibody)|Immunohistochemical staining
223478036|NCT04411615|DRUG|Omega 3|rTG form Omega-3
223478037|NCT00885118|DRUG|Placebo (middle dose)|Placebo tablets once a day
223478038|NCT00885118|DRUG|Placebo|Placebo tablets once a day
223478039|NCT00885118|DRUG|BI 10773|BI 10773 middle dose tablets once a day
223478040|NCT00885118|DRUG|BI 10773|BI 10773 high dose tablets once a day
223478041|NCT00885118|DRUG|BI 10773|BI 10773 middle dose tablets once a day
223478042|NCT00885118|DRUG|Placebo (high dose)|Placebo tablets once a day
223478043|NCT00885118|DRUG|BI 10773|BI 10773 low dose tablets once a day
223478044|NCT00885118|DRUG|Placebo (low dose)|Placebo tablets once a day
223478045|NCT02816723|BEHAVIORAL|Mindfulness-based Stress Reduction|mindfulness/meditation/movement training
223478046|NCT02816723|BEHAVIORAL|Brain Health|Brain Health Education
223478047|NCT01313754|PROCEDURE|Vicryl Suture|Vicryl suture material will be placed on the patients left sided incision.
223478048|NCT01313754|PROCEDURE|Dermabond|Dermabond skin glue will be placed on the patients left sided incision.
223478049|NCT00057135|BEHAVIORAL|Unit of use medication packaging|
223478050|NCT00057135|BEHAVIORAL|Mailed reminders to patient when medication refills are due|
223478051|NCT00057135|BEHAVIORAL|Note to Mental Health Provider when refill is overdue|
223478052|NCT00057135|PROCEDURE|Aligning all prescriptions to fall due on same date|
223583806|NCT03372005|BEHAVIORAL|Floorball|This intervention will have one week of testing before the first 12 weeks of floorball, followed by one week of testing before the last 27 week training period.
223583807|NCT04601896|OTHER|SF36 questionnaire via telephone interview|SF36 questionnaire via telephone interview
223583808|NCT05565937|DEVICE|BL-3100-NBR03 multi-purpose solution|BL-3100-NBR03 multi-purpose solution used to clean and disinfect contact lenses
223583809|NCT05565937|DEVICE|renu® Advanced Formula multi-purpose solution|renu® Advanced Formula multi-purpose solution used to clean and disinfect contact lenses
223583810|NCT06276998|DRUG|LNK01001|Capsule; Oral
223583811|NCT06276998|DRUG|Placebo|Capsule; Oral
223583812|NCT05334277|DRUG|Furmonertinib|Furmonertinib 80mg QD
223583813|NCT05334277|DRUG|Furmonertinib|Furmonertinib 80mg QD
223583814|NCT05334277|DRUG|Furmonertinib/Pemetrexed/Carboplatin|Furmonertinib 80mg daily + Pemetrexed (500 mg/m2) plus carboplatin (AUC 5) on Day 1 of 21day cycles (every 3 weeks) for 4 cycles, followed by pemetrexed maintenance (500 mg/m2) every 3 weeks.
224163857|NCT03987867|DRUG|Liposome paclitaxel|Liposome paclitaxel injection
224163858|NCT03987867|DRUG|Carboplatin|Carboplatin injection
224163859|NCT04387695|RADIATION|SBRT+TACE+Sorafenib|SBRT first for the PVTT +TACE for HCC within a week next +Sorafenib with 2 weeks later
224163860|NCT04387695|DRUG|Sorafenib|Sorafenib 800 mg/day orally
224163861|NCT04778865|DIETARY_SUPPLEMENT|Vitamin D-correction|Capsule with 50.000 UI cholecalciferol
224163862|NCT04778865|DIETARY_SUPPLEMENT|Vitamin D-RDA|Capsule with 4.2000 UI cholecalciferol
223478053|NCT03699748|BEHAVIORAL|Lay Health Worker Intervention|Patients randomized into the intervention will be assigned a lay health worker who will contact the patient to begin the intervention. The intervention includes: education on early advance care planning, documenting goals of care, assessing symptoms, and coordinating community services (such as home health, home visits, and home hospice). The intervention is provided along with usual care as provided by Unite Here Health and local oncologists.
223744730|NCT01540708|DRUG|SERETIDE Diskus|The study will be conducted in 3 parts with an adaptive design where pharmacokinetic data analysis follows each part to enable a decision on whether progression to the subsequent parts is required. Thirty six subjects will be enrolled in each part. Part A will test an alternative version of the Rotahaler with a lower airflow resistance. The study will then test one or more of the following options depending on the outcome of part A. If progressed, part B will test modified Rotacap formulations including: (1) modified blend formulation, (2) reduced capsule fill weights, (3) different capsule types. Part B will also test other versions of the Rotahaler with intermediate airflow resistance. Part C will test the lower strength FP/salmeterol (100/50 mcg or lower) and/or a new unit dose DPI device (BUDI). In each arm, subjects will be administered 7 doses (3.5 days bid) with PK sampling following administration of the 7th dose on the morning of Day 4.
223744731|NCT01923454|PROCEDURE|Paracentesis|At presentation, patients received immediate anterior chamber paracentesis with a 30-gauge needle. The intraocular pressure (IOP) was recorded at immediately, 15 and 30 minutes, and then 1, 24 and 48 hours after paracentesis. The IOP was compared between before paracentesis and each time-point after paracentesis. All affected eyes received antiglaucomatous medications 60 minutes after ACP and underwent peripheral iridotomy within 24 hours.
223478054|NCT03699748|OTHER|Usual Care|Usual care as provided by Unite Here Health and local oncologists
223478055|NCT02582476|DRUG|Bumetanide|Participants will be randomly assigned to either bumetanide or placebo for the first visit. The assigned treatment will be taken by mouth at the onset of a focal attack defined as 40% decrement in ADM CMAP amplitude compared to the maximum CMAP amplitude recorded during or after the exercise. The second assessment will follow an identical protocol to the first, but with the other treatment administered.
223478056|NCT02582476|DRUG|Placebo|Participants will be randomly assigned to either bumetanide or placebo for the first visit. The assigned treatment will be taken by mouth at the onset of a focal attack defined as 40% decrement in ADM CMAP amplitude compared to the maximum CMAP amplitude recorded during or after the exercise. The second assessment will follow an identical protocol to the first, but with the other treatment administered.
223478057|NCT01646437|DRUG|Polycap|Polycap (thiazide 25mg, atenolol 100mg, ramipril 10mg, simvastatin 40mg) taken once daily
223478058|NCT01646437|DRUG|Aspirin|75 mg daily
223478059|NCT01646437|DRUG|Vitamin D|60,000 IU monthly
223478060|NCT01646437|DRUG|Matching Placebo|Matching Placebo
223583815|NCT05334277|DRUG|Furmonertinib/Pemetrexed/Carboplatin/Bevacizumab|Furmonertinib 80mg daily + Pemetrexed (500 mg/m2) plus carboplatin (AUC 5) plus bevacizumab (7.5mg/kg) on Day 1 of 21day cycles (every 3 weeks) for 4 cycles, followed by pemetrexed (500 mg/m2) with bevacizumab (7.5mg/kg) maintenance every 3 weeks.
223583816|NCT04135014|DRUG|Midazolam|oral midazolam 0.5mg.kg-1 approximately 30-40 minutes before surgery using a computer-generated random number table.
223583817|NCT04135014|DRUG|Dexmedetomidine|intranasal dexmedetomidine 2µg.kg-1 approximately 30-40 mins before surgery using a computer-generated random number table.
223583818|NCT04135014|DRUG|Midazolam and Dexmedetomidine|oral midazolam 0.5mg.kg-1 and intranasal dexmedetomidine 1ug.kg-1 approximately 30-40 mins before surgery using a computer-generated random number table.
223583819|NCT04544683|DRUG|Cervical Transforaminal Epidural Injection with dexamethasone sodium phosphate|Transforaminal epidural steroid injection: Injection of 1 to 2 mL of 1% lidocaine to the skin and subcutaneous tissues, a 25-gauge spinal needle will be placed at the level and side of radicular pathology, based on clinical correlation of symptoms/signs and magnetic resonance imaging findings. Advancement to the appropriate target position in the neuroforamen will be performed under fluoroscopic guidance. Satisfactory target position achieved and confirmed in both anterior-posterior and oblique views, 0.5 to 1 mL of contrast will be injected under live fluoroscopic observation with or without digital subtraction angiography depending on suggestion of vascular uptake. Upon confirmation of a satisfactory epidural contrast pattern without vascular uptake, the injectate will be delivered: dexamethasone sodium phosphate 1mL (10mg/mL) and 0.5 ml of 1% preservative-free lidocaine (total volume 1.5 mL).
223583820|NCT01992211|DRUG|Rosuvastatin|Participants will be co-administered a single oral dose of Rosuvastatin 10mg and Metformin SR 1000mg under Fed condition.
223583821|NCT01992211|DRUG|Metformin|Participants will be co-administered a single oral dose of Rosuvastatin 10mg and Metformin SR 1000mg under Fed condition.
223583822|NCT01992211|DRUG|BCWP_C003|Participant will be administered a single oral dose of BCWP\_C003 under Fasting condition or Fed condition according to sequence.
223583823|NCT04934644|PROCEDURE|Hyperbaric oxygen treatment|Hyperbaric oxygen treatment 90 min from start to start of decompression. The chamber is pressurized to 2,4 ATA and the patients will be breathing 100% oxygen. Treatments will be given once daily, five days a week (no treatments on weekends and holidays).
223583824|NCT06964620|DRUG|Sanggua tablets|Patients will continue their background medications and receive Sang Gua tablets, twice daily (bid).
223583825|NCT06964620|DRUG|Placebo|Patients will continue their background medications and receive placebo, twice daily (bid).
224163369|NCT04507360|BEHAVIORAL|Study 1, Tailored Response|Participants will be provided with a response to screening that is tailored to the match between screening score (above or below depression criteria) and expressed need for mental health support (yes, no, or I don't know).
223478061|NCT02473497|DRUG|Crizotinib|For adult patients, crizotinib 250 mg BID will be administered orally at approximately the same time each day on a continuous daily dosing schedule, ie, without break in dosing. For pediatric patients, crizotinib 280 mg/m2 BID will be administered orally at approximately the same time each day on a continuous daily dosing schedule, ie, without break in dosing.
223478062|NCT03180710|DRUG|BioChaperone® Combo 75/25 at 0.6 U/kg|Injection of BioChaperone® Combo 75/25 at 0.6 U/kg
223478063|NCT03180710|DRUG|BioChaperone® Combo 75/25 at 0.8 U/kg|Injection of BioChaperone® Combo 75/25 at 0.8 U/kg
223478064|NCT03180710|DRUG|BioChaperone® Combo 75/25 at 1.0 U/kg|Injection of BioChaperone® Combo 75/25 at 1.0 U/kg
223478065|NCT03180710|DRUG|Humalog® Mix25 at 0.8 U/kg|Injection of Humalog® Mix25 at 0.8 U/kg
223478066|NCT03156075|BEHAVIORAL|Nutrition and exercise program|"Nutrition education will be about increasing the intake calcium and vitamin D rich foods and exposure to sun will provided for the intervention group.~Education of the patients about exercises that increases the strength of lower limb and hip muscles to increase the mobility of the patients earlier and decrease the mortality in turn."
223478067|NCT01700491|DRUG|Epidural Catheter 0.2% ropivacaine|0.2% ropivacaine into epidural space and saline into paravertebral space
223478068|NCT01700491|DRUG|Paravertebral Catheter 0.4% ropivacaine|0.4% ropivacaine into paravertebral space and saline into the epidural space
223478069|NCT00287430|DRUG|Growth Hormone|
223478070|NCT00287430|PROCEDURE|Whole body Protein Turnover Study|
223478071|NCT00287430|PROCEDURE|Dual Energy X-ray Absorptiometry (DEXA)|
223478072|NCT00218751|BEHAVIORAL|Home Visiting|
223478073|NCT00800046|DEVICE|AccuCinch® Ventriculoplasty System|Mitral valve repair due to functional disease
223478074|NCT06377423|PROCEDURE|Direct technique|The composite was placed directly using free-hand technique
223478075|NCT06377423|PROCEDURE|Indirect technique|The ceramic was placed using indirect method via laboratory casts
223583826|NCT06479694|BEHAVIORAL|Real-life Dual-Task Training|The intervention is Real-life Dual-Task Training (Real-DTT) which uses instrumental activities of daily living training with explicit focus on the cognitive and motor elements and when to focus attention to one vs. the other to reduce fall risk. The Real-DTT sessions will be delivered once a week for 10 weeks during their occupational therapy sessions, delivered by a licensed occupational therapist. Real-DTT is a modified version of occupational therapy, with a protocol tailored to the participants.
223583827|NCT05415137|DRUG|Efzofitimod 3 mg/kg|EfzofitimodIV infusion every 4 weeks for a total of 12 doses
223583828|NCT05415137|DRUG|Efzofitimod 5 mg/kg|EfzofitimodIV infusion every 4 weeks for a total of 12 doses
223583829|NCT05415137|DRUG|Placebo|Placebo IV infusion every 4 weeks for a total of 12 doses
223583830|NCT06794372|DRUG|[68Ga]Ga-FAPI-46 PET/CT|\[68Ga\]Ga-FAPI-46 PET/CT
223583831|NCT06797037|OTHER|Decentralised Pathway Coordinated by the Advanced Practice Nurse|"For each patient enrolled in the study: a decentralised treatment delivery route will be organised. To achieve this, two visits will be planned by the investigating centre's Advanced Practice Nurse (APN) and carried out at the patient's home by a service-providing nurse. During these visits, the APN will take the patient's vital signs before handing over the treatment.~In addition, for the purposes of the study, during the 2nd visit the patient will be asked to complete a satisfaction questionnaire."
223583832|NCT04253587|DEVICE|LabyrinthVR|Head-mounted display virtual reality game designed to induce environmental enrichment in an adaptive, immersive regimen of wayfinding in novel urban and village neighborhoods.
223478076|NCT00889304|DEVICE|Position HTO system|open wedge high tibial osteotomy
223478077|NCT02814526|BEHAVIORAL|Aerobic exercise|Moderate/high intensity aerobic exercise will involve training at 70-80% heart rate reserve for 30 min, with an additional 10 minutes for warm-up and 5 minutes for cool-down, 4 times per week, for 12 months while supervised twice per week by a study-certified trainer at a participating YMCA .
223478078|NCT02814526|BEHAVIORAL|Stretching/balance/range of motion exercise|The stretching/balance/range of motion program will involve exercise at or below 35% heart rate reserve for 30 min, with an additional 10 minutes for warm up and 5 minutes for cool-down, 4 times per week, for 12 months while supervised twice per week by a study-certified trainer at a participating YMCA.
223583833|NCT04253587|DEVICE|Placebo Games|Commercially-available, narrative computer games marketed as cognitively enriching.
223583834|NCT04253587|DEVICE|Coherence|Head-mounted display virtual reality game designed to present an adaptive rhythm training routine.
223583835|NCT04253587|DEVICE|Tablet|Tablet computer playing Labyrinth VR game but in 2.5D
223583836|NCT04938037|PROCEDURE|US guided, SSNB with 1ml methylprednisolone acetate (1ml / 40mg) and 5 ml 0.5% bupivacaine|nerve block
223583837|NCT00556179|DRUG|Lactoserum (Dermacyd Femina®)|Once a day during three months
223583838|NCT04835168|DRUG|BT-11 low|Oral
223478079|NCT06389617|DRUG|supraclavicular block with 20mls of Ropivacaine 0.5% and Intravenous administered dexamethasone|Comparing the onset of sensory, motor block, duration of motor block and analgesic duration
223478080|NCT00914368|DRUG|Clopidogrel|Patients not already on clopidogrel treatment a loading dose of clopidogrel 600 mg followed by a maintenance dose of 75 mg once daily will be administered.
223478081|NCT03883386|DRUG|Loratadine|10 mg in a capsule
223478082|NCT03883386|DRUG|Placebo|Administered via capsule
223478083|NCT04198935|DEVICE|Span Health Mobile Application|A 12 week structured diabetes education program for type 2 diabetes delivered through a mobile application. The application also allows for interaction with a registered nutritionist via text messaging.
223478084|NCT03002402|BEHAVIORAL|Internet-based CBT-I|Internet-based cognitive-behavioral treatment for insomnia
223478085|NCT06088693|OTHER|Electroacupuncture and Standard Therapy|Acupuncture Needle Insertion with Electroacupuncture machine.
223478086|NCT02723240|DRUG|NUC-3373|
223583839|NCT04835168|DRUG|BT-11 high|Oral
223478087|NCT01409668|DIETARY_SUPPLEMENT|L. Amylovorus|L. Amylovorus
223478088|NCT01409668|DIETARY_SUPPLEMENT|L. Fermentum|L. Fermentum
223478089|NCT01061372|DRUG|Placebo|Placebo, orally administered once a day, 1-3 hours before bedtime for 12 weeks
223478090|NCT01061372|DRUG|pregabalin|pregabalin 150 mg, orally administered once a day, 1- 3 hours before the bedtime for 12 weeks
223478091|NCT01061372|DRUG|pregabalin|pregabalin 300 mg, orally administered once a day, 1- 3 hours before the bedtime for 12 weeks
223478092|NCT00908934|DRUG|AZD9056 formulation Phase III 50 mg (T)|Given as 50 mg tablet (T)
223478093|NCT00908934|DRUG|AZD9056 formulation Phase IIb 50 mg (R)|Given as 50 mg tablet (R)
223583840|NCT04835168|DRUG|Placebo|Oral
223583841|NCT01806064|DRUG|TRC105 and Axitinib|
223583842|NCT01806064|DRUG|Axitinib|
223583843|NCT01330966|DRUG|pazopanib|Pazopanib 800 mg orally once daily will be started on Cycle 1 Day 1 and will be administered continuously for a 28-day cycle.
224070343|NCT06252272|DIAGNOSTIC_TEST|Biopsy from patients undergoing surgery abdominal.|A small portion (about 10 mm in diameter) of liver tissue was collected macroscopically free from alterations of the parenchyma obtained in the open at the site surgery for primary or secondary liver tumors, for the preparation of cultures of organotypic liver slices.
223744732|NCT01923454|DRUG|Acetazolamide|All participants will receive oral acetazolamide (250 mg) 1 tablet at 1 hour after paracentesis to lower the intraocular pressure. After that, the dose of acetazolamide will be adjusted according to the level of intraocular pressure. If the eye pressure goes to normal (lower than 21 mmHg), acetazolamide will be discontinued.
223744733|NCT01923454|PROCEDURE|Peripheral iridotomy|All affected eyes underwent laser peripheral iridotomy within 24 hours after presentation. This procedure is a standard treatment for acute angle-closure. The fellow eyes will receive laser peripheral iridotomy in the same occasion or later to prevent acute angle-closure in the future.
223478094|NCT00908934|DRUG|AZD9056 formulation Phase III 200 mg (T)|Given as 400 mg (2 x 200 mg tablet (T))
223478095|NCT00908934|DRUG|AZD9056 formulation Phase IIb 200mg (R)|Given as 400 mg (2 x 200 mg tablet (R))
223478096|NCT04596904|OTHER|Lavender oil application group|Individuals, for 10 days, 3 drops of cotton drops of lavender oil, put on the shoulder parts, between 21:00 and 21:05 will smell every evening.
223478097|NCT04596904|OTHER|Distilled water application group|Individuals, for 10 days, 3 drops of cotton drops of distilled water, put on the shoulder parts, between 21:00 and 21:05 will smell every evening.
223478098|NCT00251758|DRUG|Dexlansoprazole MR|Dexlansoprazole MR 60 mg, capsules, orally, once daily for 4 weeks.
223478099|NCT00251758|DRUG|Dexlansoprazole MR|Dexlansoprazole MR 90 mg, capsules, orally, once daily for 4 weeks.
223478100|NCT00251758|DRUG|Placebo|Dexlansoprazole placebo-matching capsules, orally, once daily for 4 weeks.
223478101|NCT02426099|DRUG|Low dose spironolactone|4-week add-on low dose spironolactone in resistant hypertension
223478102|NCT02426099|OTHER|Routine intensification of antihypertensive treatment|4-week guidelines oriented intensification of antihypertensive treatment
223478103|NCT05650502|DRUG|saisonal malaria chimoprevention|Investigate the impact of saisonal malaria chimoprevention on children anti PfEMP1 construction and maintenance and their succeptibility to malaria infection
223583844|NCT05004948|OTHER|Exercise training|The first group conducted a resistance exercise program (REP, 50-60% of 1RM, for 40-50 min) combined with metformin, the second group conducted an aerobic exercise program (AEP, 50-70% maxHR, for 40-50 min) combined with metformin, and the third group received only metformin without exercise intervention (Met group). The study program was conducted thrice weekly for consecutive twelve weeks.
223583845|NCT01417364|DRUG|Testosterone enanthate|100 mg. IM weekly throughout study
223583846|NCT01417364|DRUG|Testosterone enanthate|100 mg IM weekly for one month alternating with placebo injections for one month throughout the study
223583847|NCT01417364|DRUG|Placebo|Injected IM weekly throughout study
223583848|NCT04631653|DEVICE|VeriSee®|Screening of diabetic retinopathy using a validated deep learning-based software,VeriSee®
223583849|NCT02163213|OTHER|Serum-derived bovine immunoglobulin protein isolate (SBI)|Serum-Derived Bovine Immunoglobulin /Protein Isolate (SBI) 5.0 g bid on Nutritional Status and intestinal functions in Subjects with IBS-D
223583850|NCT03046225|DEVICE|Transcutaneous electrical nerve stimulation|TENS was applied in the conventional mode, through two self-adhesive electrodes of size 5x9cm positioned parallel to the lumbar spine, on the nerve roots of L3, L4 and L5, with frequency of 100 Hz and pulse duration of 100 μs, for 30 minutes. The intensity was adjusted according to the maximum tolerance of the patient and was gradually increased, with his permission, during the application time.
223583851|NCT03046225|DEVICE|Continuous passive movement device|CPM device was used for 30 minutes and realized continuous passive flexion and extension of the operated knee.
223583852|NCT03046225|OTHER|Exercises|Active exercises of plantar flexion and dorsal flexion of the ankles, adduction and abduction of the hips and flexion and extension of the operated knees. All exercises were performed in 10 repetitions, with the patient positioned in the supine position in the bed.
223583853|NCT05287217|OTHER|Comparison of medication administration for pain control|Measuring pain control following FESS surgery
223583854|NCT04720846|OTHER|Matrix-based physical therapy|Matrix-based physical therapy will be physical therapy that is based on the matrix categorization of the patient (stiff vs. mobile hips, weak vs. strong hips) and involves instructions on the amount of time that should be spent doing stretching and strengthening therapy.
223583855|NCT04720846|OTHER|Standard-of-care physical therapy|Physical therapy that is being conducted as standard-of-care
223744734|NCT04518254|BIOLOGICAL|Blood collection|A blood sample will be collected before and after treatment administration
223478104|NCT01576614|BEHAVIORAL|Remote physician rounding|Use of Remote physician rounding using Remote Telepresence Robotics
223478105|NCT05293795|BEHAVIORAL|3D printed model|Mother is given 3D printed model of fetus' face
223478106|NCT05293795|BEHAVIORAL|Placebo|Mother is given a picture of 3D ultrasound of fetus
223478107|NCT00338780|DRUG|Lamivudine/ Placebo 100mg daily|
223478108|NCT05076734|DIAGNOSTIC_TEST|Redraw for analysis of blood samples from healthy pregnant women|If less than two fetal cells are recovered from maternal blood, a redraw is indicated
223478109|NCT01518062|DRUG|somatropin|4 IU/m\^2 body surface for 4 years (main period). In extension period subjects continue the reached dose until final height. Administered as once daily subcutaneous injection
223478110|NCT01518062|DRUG|somatropin|Initial dose 4 IU/m\^2 body surface the first year, then 6 IU/m\^2 body surface for 3 years (main period). In extension period subjects continue the reached dose until final height. Administered as once daily subcutaneous injection
223744735|NCT04518254|DRUG|L-Tyrosine 500 Mg|The participants will be administered 4 capsules of L-Tyrosine 500 mg per oral route
223744736|NCT04518254|DRUG|Placebo|The participants will be administered 4 capsules of Lactose 500 mg (placebo) per oral route
223744737|NCT04518254|BEHAVIORAL|Cognitive tasks|The participants will perform cognitive decision-making tasks: Simon task and masking task after treatment administration
224070344|NCT00459992|DRUG|Betahistine Hydrochloride|
224163863|NCT05762965|DIETARY_SUPPLEMENT|GOS 1|1 sachet each morning
224163864|NCT05762965|DIETARY_SUPPLEMENT|GOS 2|1 sachet each morning
224163865|NCT02044315|DEVICE|ICD programming|
224304897|NCT06541002|BEHAVIORAL|SHIFT Intervention Group|Participants assigned to SHIFT will meet with their HCT clinician for a brief medical examination to assess the need for medications for erectile dysfunction, vaginal atrophy, or genital graft-versus-host disease; and start using SHIFT at their desired pace over 8 weeks to complete five modules.
223478111|NCT01518062|DRUG|somatropin|Initial dose 4 IU/m\^2 body surface the first year, then 6 IU/m\^2 body surface, the second year and finally 8 IU/m\^2 body surface for 2 years (main period). In extension period subjects continue the reached dose until final height. Administered as once daily subcutaneous injection
223478112|NCT01518062|DRUG|oestrogen|Treatment with oestrogen was administered if spontaneous puberty had not occurred by age 12 years and was initiated in the extension period after at least four years of somatropin treatment
223478113|NCT04421417|PROCEDURE|Microfracture + Standard Arthroscopic Rotator Cuff Repair|drilling of rotator cuff footprint area on humerus and standard arthroscopic rotator cuff repair
223478114|NCT04421417|PROCEDURE|Standard Arthroscopic Rotator Cuff Repair|Standard Arthroscopic Rotator Cuff Repair
223478115|NCT06807346|DIETARY_SUPPLEMENT|Kids Plus Multi & Omega|Participants will be instructed to take two gummies of Kids Plus Multi and Omegas with or without food once daily for the duration of the study starting on Day 1 with a recommendation to consume in the morning for consistency.
223478116|NCT06807346|DIETARY_SUPPLEMENT|Placebo|Participants will be instructed to take two gummies of placebo with or without food once daily for the duration of the study starting on Day 1 with a recommendation to consume in the morning for consistency.
223478117|NCT01387269|DRUG|Anamorelin HCl|Anamorelin HCl will be orally administered daily at least one hour before meal
223478118|NCT01387269|DRUG|Placebo|Placebo tablets identical in appearance to active tablets; oral administration QD for 12 weeks, at least 1 hour before meal
223478119|NCT00006362|DRUG|bortezomib|
223478120|NCT01712711|DRUG|H.pylori eradication|The regimen consists of Omeprazole (20 mg/BD)+ Amoxicillin (1 g/day)+ Bismuth subcitrate (240 mg/BD)+ Azithromycin (500 mg/BD)for two weeks
223583858|NCT04617522|DRUG|Sacituzumab Govitecan-hziy|Administered intravenously
223583859|NCT04438291|OTHER|MDL-SHPVP|A 2-hour education session with multicomponent interventions including education sessions with small group dialogues with a registered nurse and trained healthcare and lay volunteers and educational computer games
223583860|NCT04438291|OTHER|30-minute educational video|A 30-minute education video (DVD) on HPV, cervical cancer and the HPV vaccine that is designed to enhance HPV vaccine acceptance
223583861|NCT01051401|DRUG|rosuvastatin|Given PO
223583862|NCT01051401|OTHER|placebo|Given PO
223583863|NCT01051401|OTHER|survey administration|Correlative study
223583864|NCT01051401|PROCEDURE|management of therapy complications|
223583865|NCT01282294|DEVICE|ETN PROtect|Expert Tibial Nail PROtect with Gentamicin coating
223583866|NCT04753021|OTHER|Exercise|Progressively increasing training load
223583867|NCT04167865|OTHER|Exercise|Orthosis, mobilization, strengthening, posture and segmental breathing exercises
223583868|NCT01278589|DIETARY_SUPPLEMENT|Plantago asiatica L. extract 5g|Liquid (80g) containing Plantago asiatica L. extract 5g
223583869|NCT01278589|DIETARY_SUPPLEMENT|Plantago asiatica L. extract 10g|Liquid (80g) containing Plantago asiatica L. extract 10g
223583870|NCT01278589|DIETARY_SUPPLEMENT|Plantago asiatica L. extract 20g|Liquid (80g) containing Plantago asiatica L. extract 20g
223478121|NCT00851149|DEVICE|Sangvia blood sampling system|Blood collected from abdominal aortic repair patients are compared against blood collected from total hip replacement patients
223478122|NCT04132765|OTHER|Drooling Impact Scale|A scale with 10 items which are scored with visual analog scale from1 to 10. Drooling impact increases with increased scores.
223478123|NCT04132765|OTHER|Drooling Frequency and Severity Scale|In this scale, parents or care givers were asked to rate the severity and frequency of drooling, classifying severity of drooling using a 5-level domain ranging from 1 (dry) to 5 (profuse drooling). The frequency of drooling was classified using a 4-level domain ranging from 1(no drooling) to 4 (constant drooling)
223478124|NCT04132765|OTHER|The Caregiver Priorities and Child Health Index of Life with Disabilities (CPCHILD™)|A quality of life scale that measure caregivers' perspectives on the health status, comfort, well being, and ease of caregiving of children with severe developmental disabilities. CPCHILD consists of 36 items distributed over six sections representing the following domains: (1) Personal Care (eight items); (2) Positioning, Transfer, and Mobility (eight items); (3) Communication and Social Interaction (seven items); (4) Comfort, Emotions, and Behaviour (nine items); (5) Health (three items); and (6) Overall Quality Of Life (one item). For the sections which involve the performance of skills, the degree of difficulty of accomplishing each task or activity was rated on a 7-point ordinal scale anchored by 0 ('No problem at all') to 6 ('Impossible').
223583871|NCT01278589|DIETARY_SUPPLEMENT|Placebo|Liquid (80g) without Plantago asiatica L. extract
223583872|NCT02943915|DEVICE|Ekso GT Rehabilitation Therapy|Walking Improvement for Spinal Cord Injuries with Exoskeleton
223583873|NCT02943915|DEVICE|Body Weight Supported (BWS) Treadmill Training|Standard gait training using BWS PT and overground training
223583874|NCT05455801|DEVICE|negative preassure wound therapy|wound treated with negative pressure therapy dressing
223583875|NCT01308229|DEVICE|Nile PAX® paclitaxel-eluting coronary stent|Implantation of a Nile PAX bifurcation dedicated drug-eluting stent in coronary arteries to treat stenosis lesions
223583876|NCT04677127|BEHAVIORAL|Health Belief Model and Health Literacy Level based Education and Counseling|Patients given education and counseling constructed with health belief model (perceived susceptibility, perceived severity, perceived benefits, perceived barriers, cue to action, self-efficacy). The constructed education given through groups dichotomised by health literacy levels (low/high). Groups of 11-13, had weekly educations for 6 weeks, 6 weeks of counselling and 12 week of follow-up.
224070345|NCT01142726|DRUG|Abatacept|Injection, subcutaneous, 125 mg by syringe, once weekly, 12 months
223478125|NCT04132765|OTHER|Drooling Quotient (DQ)|DQ is a semi-quantitative method that assesses the presence of newly formed saliva on the lips every 15 seconds with 40 observations in 10 minutes, expressed as a percentage based on the ratio between the number of observed drooling episodes and the total number of observations.
223478126|NCT04132765|OTHER|Patient and caregiver visual analog scale (VAS) for drooling|Patients will be asked to score their children's drooling severity on a visual analog scale (0-100 mm, 0 none to 100 severe)
223478127|NCT04132765|OTHER|Functional Oral Intake Scale (FOIS)|Functional Oral Intake Scale (FOIS) which is a 7-point ordinal scale document the functional level of oral intake of food and liquid.
223478128|NCT04132765|OTHER|number of bibs daily used|Parents will be asked their children's number of bibs daily used.
223478129|NCT04132765|OTHER|number of hospital admissions per year related to respiratory infections|Parents will be asked their children's number of hospital admissions per year related to respiratory infections.
223478130|NCT04132765|OTHER|Gross Motor Function Classification System (GMFCS)|The GMFCS describes self-initiated movement and use of assistive devices (walkers, crutches, canes, wheelchairs) for mobility during an individual's usual activity.
223583877|NCT03013049|PROCEDURE|Non cultured epidermal cell suspension|Non cultured epidermal cell suspension Split thickness skin specimen will be transferred under aseptic conditions to a container with normal salineand transferred to laboratory. There, the skin graft will be transferred to Trypsin-EDTA solution (0.25% trypsin and 0.02% EDTA) in a Petri dish and incubated overnight at 4°C in 5% CO2 to separate the epidermis from the dermis.Afterwards, the Trypsin-EDTA solution will be removed and PBS will be added and pipetted well so as to separate the cells from the tissue.The suspension will be centrifuged at 1000 rpm for 5 minutes.The supernatant will then be discarded and Phosphate buffer saline is added to make suspension of non-cultured epidermal cells.
223583878|NCT03013049|PROCEDURE|Non cultured dermal cell suspension|Non-cultured Dermal Cell Suspension Skin punch will be collected in phosphate buffer saline (PBS) with antibiotics (penicillin and streptomycin). The epidermis will be cut off from dermis carefully using a surgical blade (Epidermal part will be used for the epidermal cell suspension). Dermis will be then cut into small pieces and incubated in collagenase (1mg/ml) overnight at room temperature. Next day content will be diluted with PBS and centrifuged at 1000rpm for 5 minutes. Pellet will be washed three times with PBS to remove collagenase activity. Phosphate buffer saline is added to make suspension of non-cultured dermal cells and will be used for the autologous transplantation.
223744738|NCT04518254|OTHER|Stress exposure|Unpleasant but not painful skin stimulations will be administered to the participants at variable intervals on the left leg during the cognitive tasks
223744739|NCT04518254|BEHAVIORAL|Anxiety scale|Spielberger's State Trait Anxiety Inventory (STAI) will be filled by the participants before and after cognitive tasks
223744740|NCT04518254|DEVICE|Electromyography (EMG)|Electromyography measurements will be performed during cognitive tasks.
223744741|NCT04518254|DEVICE|Electroencephalography (EEG)|Electroencephalography measurements will be performed during cognitive tasks.
223478131|NCT04132765|OTHER|Manual Ability Classification System (MACS)|The MACS is also a simple, five-point ordinal classification system and was designed for use in children ages 4-18 years. The MACS is a validated measure in cerebral palsy that can be used to classify a child's typical use of both hands and upper limbs.
223478132|NCT04132765|OTHER|Communication Function Classification System (CFCS)|The CFCS is a simple, five-point ordinal classification system that assesses everyday communication (not optimal communication) of children with cerebral palsy.
223478133|NCT04132765|OTHER|Eating and Drinking Ability Classification System (EDACS)|EDACS is a measure to assess eating and drinking ability for children with CP, ages 3 and older. This classification is a simple five-point ordinal system.
223478134|NCT03999255|PROCEDURE|combined respiratory support (CRS)|combined respiratory support (CRS) which consisted of reduction of tidal volume to 250-300 ml and respiratory rate to 4-5 per minute with transcatheter high-frequency jet ventilation (HFJV) through an endotracheal tube with a respiratory cycle frequency (RCF) of 300 per minute and maintained during RIRS.
223478135|NCT05844540|PROCEDURE|harvesting bone block|Under local anesthesia, a sulcular incision was performed between lower right and left second premolars with an oblique incision distal to each one. After that, a full thickness mucoperiosteal flap was elevated to expose the anterior mandible including the entire symphysis and both mental nerves. By using piezo-surgery unit (Surgic Touch, Woodpecker, China), a rectangular bone block was harvested from the symphysis about 8mm in depth and 2mm wider than the recipient site to allow for contouring. The bone cuts were performed 5mm far from the apices of the anterior teeth, mental foramina, and inferior border of the mandible. Finally, thin curved osteotomes was used to detach the bone blocks. The harvested bone block was trimmed to form L-shape block and kept in normal saline. After hemostasis, the flap was closed with 4/0 vicryl interrupted sutures.
223583879|NCT05776212|RADIATION|18F-fluoride PET|Positron emission tomography using 18F-fluoride as a tracer
223583880|NCT01762813|PROCEDURE|open and laparoscopic surgery|Curative surgery for either primary (colorectal cancer, crc) or metastatic CRC (liver surgery)
223583881|NCT06010173|DRUG|Gadopiclenol|Dose/volume of gadopiclenol to be administered will be calculated based on patient's weight at the dose of 0.05 mmol/kg BW
223744742|NCT01381133|BEHAVIORAL|Chestnut Bloomington Outpatient (CBOP)|CBOP is an evidence-informed intervention that has developed over 20 years and been shaped by treatment research. The underlying theory of change is that the combination of multiple evidence-based and best-practice treatment components will increase the adolescent's desire to change, provide the necessary skills, and create an environment supportive for this change. The intervention is based on a manual and is primarily delivered through skill and therapy groups, combined with a limited number of family and individual sessions for treatment planning and progress reviews.
224070346|NCT01142726|DRUG|Methotrexate|Tablets, oral, 2.5 mg, once weekly, 12 months
224070347|NCT01142726|DRUG|Abatacept placebo|Injection, subcutaneous, to match 125 mg by syringe, once weekly, 12 months
224070348|NCT01142726|DRUG|Methotrexate placebo|Tablets, oral, to match 2.5-mg tablet, once weekly, 12 months
224163370|NCT04507360|BEHAVIORAL|Study 1, Tailored Resources by Demographics|Participants will be provided with links to Mental Health America (MHA) resources tailored to sexuality (Lesbian, Gay, Bisexual, Transgender, or Queer) status and age range.
223478136|NCT05844540|PROCEDURE|Recipient site preparation|At the maxillary recipient site, after induction of local anesthesia, a mid-crestal incision that continued in the sulcus for two teeth on either side of the defect with bilateral oblique incisions were performed. After that, the full thickness mucoperiosteal flap was elevated. While for mandibular recipient site, it was the same flap used for harvesting symphyseal bone block. For both upper or lower recipient sites, perforations (bone marrow penetration) were done to the recipient site by using a fissure surgical bur. The L-shape block graft was trimmed to obtain optimal adaptation to the recipient site, then it was fixed to the residual ridge with two 1.5mm self-tapping titanium screws. After attaining graft stability, any sharp edges were smoothed and any gap between the graft and underlying alveolar bone was filled with particulate bone curetted from the donner site.
223478137|NCT05844540|PROCEDURE|implant insertion|"Implant insertion:~After 6months, the surgical site was opened to remove fixation screws and insert dental implants, and the final restoration was done 4months after implant insertion."
223478138|NCT04425317|DIAGNOSTIC_TEST|Blood sample|Blood sample and endometrial biopsy on the moment of oocyte retrieval
223583882|NCT06010173|DRUG|Comparator|Dose/volume of comparator to be administered will be calculated based on patient's weight at the dose of 0.1 mmol/kg BW
223583883|NCT02587546|PROCEDURE|laryngeal carcinoma|treatment of laryngeal carcinoma using thulium contact laser
223583884|NCT02587546|PROCEDURE|bilateral vocal cord paralysis|treatment of bilateral vocal cord paralysis using thulium contact laser
223583885|NCT02587546|PROCEDURE|subglottic stenosis|treatment of subglottic stenosis using thulium contact laser
223583886|NCT05501795|DEVICE|WaveLight® FS200 femtosecond laser|Flap creation with the WaveLight® FS200 femtosecond laser
223583887|NCT06316973|DRUG|CS-1103|CS-1103 for infusion
223583888|NCT06316973|DRUG|Sterile Saline|Sterile Saline for Injection
223583889|NCT01665534|BEHAVIORAL|High salt intake|During the high salt intake period, patients received a 10-20 mmol sodium diet plus sodium tablets (180 mEq/die) to achieve a 200 mmol intake /day for two weeks
223583890|NCT05970120|DEVICE|NUVISION NAV Ultrasound Catheter|Participants will be scheduled to have a clinically-indicated ablation procedure using NUVISION NAV ultrasound catheter for management of atrial procedure.
223583891|NCT00004445|PROCEDURE|Surgery|
223583892|NCT00004445|DEVICE|IRS-8|
223583893|NCT06343532|DRUG|SXC-2023|200 mg capsules
223583894|NCT06343532|DRUG|SXC-2023 Placebo|200 mg capsules
223583895|NCT04667416|BIOLOGICAL|PalinGen Flow Amniotic Tissue Allograft|Participants will receive wound size-dependent dose of PalinGen Flow liquid human amniotic tissue allograft by subcutaneous injection in addition to SOC.
223583896|NCT03157765|PROCEDURE|endometrial biopsy|endometrial biopsy
223583897|NCT02297555|DEVICE|ENDOBARRIER®|This medical device consists of a tube (impermeable fluoropolymer) inserted endoscopically and secured by hooks in the wall of the duodenal bulb. From the anchor site, this duodeno-jejunal sheath covers 60 cm in the small intestine. It thus limits the contact of nutrients with digestive juices (bile and pancreatic juice) and initial absorption, at least in part mimicking duodenal exclusion of the gastric bypass, one of the techniques of bariatric surgery.
223583898|NCT04541511|DIAGNOSTIC_TEST|6-minutes walking test on a corridor|6-minutes walking test on a corridor : patient will be asked to achieve the longest possible distance without running. He/she will be allowed to take breaks if he/she feels the need to do so.
223583899|NCT04541511|DIAGNOSTIC_TEST|6-minutes walking test on a treadmill|6-minutes walking test on a treadmill : patient will be asked to achieve the longest possible distance without running on the treadmill. He/she will be allowed to take breaks if he/she feels the need to do so.
223583900|NCT04243330|BEHAVIORAL|Audit and Feedback|The following components will be incorporated into the audit and feedback intervention: i) individualized facility performance data (site level), ii) frequent delivery intervals (monthly), iii) comparisons with other sites, iv) graphical and text form displays of information, v) constructive, non-punitive tone, vi) target performance or benchmark provided, and vii) specific actions or recommendations for meeting the target.
224070349|NCT03608176|OTHER|PASO diet group|This group include a low-fat, low calorie diet (1200-1800 kcal), in addition of a behavioral change protocol. They will also be instructed to consume green tea (2 cups/day for 3 days/week), black tea (2 cups/day for 2 days/week), coffee (2 cups/day for 2 days/week), cinnamon (1 tsp/day for at least 3 days/week), psyllium fiber (3 tsp/day/week) and water (1.5 L/day/week).
223583901|NCT04243330|BEHAVIORAL|External Facilitation|Facilitation will be conducted by a team of facilitators who will employ the facilitation process to improve uptake of VA Risk ID. Trained external facilitators will flexibly deliver the facilitation process utilizing an integrated set of implementation strategies (e.g., stakeholder engagement, identification of barriers and facilitators, education, problem solving, the use of formative data, communication, and ongoing support).
223583902|NCT04927663|PROCEDURE|Computed Tomography|Undergo CT imaging
223583903|NCT04927663|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223583904|NCT04927663|PROCEDURE|Positron Emission Tomography|Undergo PET imaging
223583905|NCT04927663|DRUG|11C-YJH08|Given IV
223583906|NCT04927663|PROCEDURE|Optional Tumor Biopsy|Optional procedure to obtain tumor tissue
223583907|NCT06664502|DRUG|EYE201|EYE201 solution for intravitreal administration
223583908|NCT05414240|DRUG|Ibudilast|IBUD at a dosage of 20 mg twice daily for 2 days, with an increase to 50 mg twice daily on day 3. The dosage will remain at 50 mg twice daily through most of the rest of the 6-week treatment period. However, for the last three days of week 6, participants will reduce the dosage gradually to 20 mg twice daily prior to discontinuing it at the end of the treatment period.
223583909|NCT05414240|BEHAVIORAL|Medical management|All subjects receive 6 weeks of medical management (Pettinati et al. 2004) will support subjects efforts to reduce or stop their drinking.
223583910|NCT05414240|DRUG|Placebo|Placebo twice daily for 6-week treatment period. Placebo will match active medication in appearance and size.
224070350|NCT03608176|OTHER|Low-fat diet group|This group include a low-fat, low calorie diet (1200-1800 kcal), in addition of a behavioral change protocol.
224163866|NCT02264652|DEVICE|HD Transcranial Direct Stimulation|Genuine cathodal HD-tDCS will be delivered through High Definition electrodes that will be arranged on the skull according to a 4x1 ring configuration.
223478139|NCT01620645|RADIATION|CT scan and PA chest X-ray|"All participants will receive a single high resolution CT scan of the chest. This will be performed using a low tube current, helical technique. Participants may also receive a plain chest X-ray if clinically indicated.~The total research protocol dose is 2 mSv. The dose from the chest X-ray is insignificant compared with the dose from the CT scan of the chest, therefore all this dose can be considered to be additional to standard of care. A dose of 2 mSv represents a risk of radiation induced detriment of approximately 1 in 10,000 and is equivalent to about 11 months of average natural background radiation in the UK."
223478140|NCT00013507|PROCEDURE|Falls|
223478141|NCT04421755|OTHER|Produce delivery|weekly home delivery of fresh fruits and vegetables
223478142|NCT04421755|OTHER|Cooking classes|weekly home delivery of fresh fruits and vegetables participants will be invited to participate in a Culinary Medicine cooking series. The OU Culinary Medicine cooking curriculum will involve a 3-part class series designed to build nutrition knowledge and cooking self-efficacy for preparing fresh F/Vs. Each session is \~2 hr. Core nutrition guidelines for blood pressure and blood sugar management will also be emphasized informed by an evidence-based Conceptual Model of Healthy Cooking. Classes will be conducted in small groups (\~16 participants) in an established teaching kitchen used by the culinary medicine program. Classes will be facilitated by a professional chef, a healthcare professional (dietitian, medical doctor, or trained medical student), and other support staff, including trained medical, dietetic, and public health students.
223478143|NCT02499016|PROCEDURE|suprapubic single-incision laparoscopic appendectomy|the approach of appendectomy
223583911|NCT05915442|DRUG|Quemliclustat|100mg IV once every two weeks
223583912|NCT05915442|DRUG|Etrumadenant|150 mg orally (PO) once a day (QD)
223583913|NCT05915442|DRUG|Zimberelimab|240 mg IV once every two weeks starting within 1 week of completing metastasis-directed SBRT
224070351|NCT03608176|OTHER|Waiting list group|This group will only receive written information with recommendations on healthy eating. When the study finished, this group will receive a behavioral change protocol with a low-fat, low calorie diet.
224070352|NCT05143073|BEHAVIORAL|Alcohol use disorder and strategies to reduce risk educational material|Participants will be directed to educational information (\~5 minutes) regarding alcohol use disorder and strategies to reduce risk which they will read.
223478144|NCT00109993|BIOLOGICAL|alemtuzumab|alemtuzumab IV over 2 hours on days 4-6, 18, and 32
223478145|NCT00109993|DRUG|methylprednisolone|methylprednisolone IV on days 1-3 and then orally or IV on days 4-14
223478146|NCT00109993|DRUG|tacrolimus|tacrolimus IV continuously on days 1-7 and then orally once or twice daily on days 8-180, followed by a taper in the absence of chronic graft-vs-host disease
223478147|NCT01521000|DEVICE|Garment Sleeve|compression sleeve (20 to 30 mm of Hg)
223478148|NCT01311219|OTHER|Non-operative Treatment|A figure-of-8 brace will be applied to afflicted extremity in clinic. The patient will be instructed on proper application of the brace and asked to continue wearing the brace for 2 to 6 weeks, depending on the patient's level of comfort.
223478149|NCT01311219|PROCEDURE|Operative Treatment-Plate Fixation|Plate fixation of the clavicle fracture will be performed utilizing a 3.5-mm dynamic compression plate.
223478150|NCT01311219|PROCEDURE|Operative Treatment-Intramedullary Pinning|Clavicle fracture will be repaired through intramedullary pinning using The Rockwood Clavicle Pin (DePuy Orthopaedics, Warsaw, IN).
224070353|NCT05143073|BEHAVIORAL|Complex polygenic risk scores, alcohol use disorder, and strategies to reduce risk educational material|Participants will be directed to educational information (\~10 minutes) regarding complex polygenic risk scores, alcohol use disorder and strategies to reduce risk which they will read.
224070354|NCT01070264|DIETARY_SUPPLEMENT|Noni Juice|This was an open label three-month intervention pilot study. Data were collected by pre and post intervention survey as well as laboratory testing. Inclusion criteria were: adults of both sexes aged 40 to 75, with a diagnosis of OA on the hip or knee by their primary care physician, not on prescription medicine for OA, and who were willing to drink 3 oz of TNJ a day
224070355|NCT03134352|DRUG|ZL-3101|A brown ointment, 10g/tube, 0.4g herb/g ointment, Topical
224070356|NCT03134352|DRUG|Placebo|A brown ointment, 10g/tube, 0.02 g herb/g ointment (5% of Fugan active ointment), Topical
224304898|NCT06541002|BEHAVIORAL|Enhanced Usual Care Group|Participants assigned to the enhanced usual care group will meet with their HCT clinician for a brief medical examination to assess the need for medications for erectile dysfunction, vaginal atrophy, or genital graft-versus-host disease; and maybe referred to a psychologist, urologist, or gynecologist at the participants' request or at the discretion of the HCT clinician.
224304899|NCT02664935|DRUG|AZD4547|FGFR Inhibitor
223583914|NCT05915442|RADIATION|Stereotactic Body Radiation Therapy|Standard of care metastasis-directed hypofractionated radiotherapy treatment starting 4 weeks (+/- 1 week) of starting Etrumadenant and Quemliclustat
223583915|NCT02753127|DRUG|Napabucasin|Napabucasin 240 mg will be administered orally, twice daily, with doses separated by approximately 12 hours (480 mg total daily dose).
223583916|NCT02753127|DRUG|Fluorouracil|
223583917|NCT02753127|DRUG|Leucovorin|
223583918|NCT02753127|DRUG|Irinotecan|
223583919|NCT02753127|DRUG|Bevacizumab|
223583920|NCT05040906|DRUG|H02+CHOP|"Drug:H02 375 mg/m2,administered intravenously(IV) on Day1 of each 21-day cycle for 6 cycles.~Drug : Cyclophosphamide 750 mg/m2,administered intravenously(IV) on Day 2 of each 21-day cycle.~Drug:Doxorubicin 50 mg/m2,administered intravenously(IV) on Day 2 of each 21-day cycle.~Drug :Vincristine 1.4mg mg/m2,administered intravenously(IV) on Day 2 of each 21-day cycle.~Drug: Prednisone 100 mg administered orally on Days 2-6 of each 21-day cycle."
223583921|NCT05040906|DRUG|Rituxan +CHOP|"Drug: Rituxan 375 mg/m2,administered intravenously(IV) on Day1 of each 21-day cycle for 6 cycles.~Drug : Cyclophosphamide 750 mg/m2,administered intravenously(IV) on Day 2 of each 21-day cycle.~Drug: Doxorubicin 50 mg/m2,administered intravenously(IV) on Day 2 of each 21-day cycle.~Drug : Vincristine 1.4mg mg/m2,administered intravenously(IV) on Day 2 of each 21-day cycle.~Drug: Prednisone 100 mg administered orally on Days 2-6 of each 21-day cycle."
224070357|NCT00419380|DRUG|dornase alfa (Pulmozyme®)|This study will compare two treatment arms. Patients will be randomized to either traditional treatment (Ofloxin)or to experimental treatment \[dornase alfa (Pulmozyme®)\]. Each arm will have subjects instilling 5 drops twice daily for 7 days to the affected ear.
224070358|NCT03945708|DEVICE|CytoSorb|Addition of a hemofilter to the cardiopulmonary bypass circuit
223583922|NCT02785419|BEHAVIORAL|Arm Training with Action Selection|Treatment occurs in 1.5 hour sessions, 5 times a week for 3 weeks. In each treatment session, you will practice functional tasks with your weaker arm and hand. Additionally, you will be given cues on a computer screen that dictate your movement response (action selection). Practice will be scaled to match your current level of function and progressed over time as able.
223583923|NCT03694873|DRUG|Tramadol Hydrochloride|one tablet of Tramadol 100 mg (Tramaw, Global Napi, Giza,Egypt) administered orally immediately, 12 h and 24 h after randomization.
224304900|NCT02664935|DRUG|Vistusertib|MTORC1/2 Inhibitor
224304901|NCT02664935|DRUG|Palbociclib|CDK4/6 Inhibitor
224304902|NCT02664935|DRUG|Crizotinib|ALK/MET/ROS1 Inhibitor
224304903|NCT02664935|DRUG|Selumetinib|MEK Inhibitor
224304904|NCT02664935|DRUG|Docetaxel|Taxane, anti-mitotic cytotoxic chemotherapy
224304905|NCT02664935|DRUG|AZD5363|AKT Inhibitor
224304906|NCT02664935|DRUG|Osimertinib|EGFRm+ T790M+ Inhibitor
224304907|NCT02664935|DRUG|Durvalumab|Anti-PDL1
224304908|NCT02664935|DRUG|Sitravatinib|VEGFR Inhibitor
224304909|NCT02664935|DRUG|AZD6738|ATR inhibitor
224304910|NCT05619146|DEVICE|Motor-assisted arms and legs cycling|The participants will complete 60min of active cycling training paradigm, 5 times a week, for 12 weeks. The cycling ergometer will be used to provide motorized assistance during simultaneous arms and legs cycling to the participant while they are seated.
224304911|NCT04424511|DRUG|Placebo|Placebo mixture will be administered as a single dose in oral suspension form for children 1-11 months of age. Weight-based dosing will be used: single-dose of 0.5 ml / kg child weight.
224304912|NCT04424511|DRUG|Azithromycin|Azithromycin will be administered as a single dose in oral suspension form for children 1-11 months of age. Weight-based dosing will be used: single-dose of 0.5 ml (20 mg) / kg child weight.
224304913|NCT05949164|BEHAVIORAL|Insomnia|The primary exposure is insomnia
224304914|NCT05874193|DRUG|Belantamab mafodotin|Belantamab mafodotin 2.5mg/kg in 42-day cycles. Every 6 weeks until PD, unacceptable toxicity or withdrawal of consent, whichever comes first
224304915|NCT06381973|BEHAVIORAL|ELTGOL_Physio|The subject will be asked to slowly exhale with the glottis opened in the right lateral posture. The physiotherapist will accompany the subject by gently applying manual pressure on the chest wall and the abdomen during expiratory phases.
224304916|NCT06381973|BEHAVIORAL|ELTGOL_Auto|The subject will be asked to slowly exhale with the glottis opened in the right lateral posture. The physiotherapist will not intervene in this arm.
223478151|NCT05923996|DRUG|microbotox|Will be treated by single session of microbotox injection
224304917|NCT06381973|DEVICE|PEP|The subject will be asked to exhale through a positive expiratory pressure (PEP) device (Threshold PEP) while being in the right lateral posture.
224304918|NCT06381973|BEHAVIORAL|1L-Tidal-Breathing|The subject will be asked to breath with a fixed tidal-breathing of 1 liter per breath (monitored via a spirometer) while being in the right lateral posture.
224304919|NCT06381973|BEHAVIORAL|Spontaneous Breathing|The subject will be asked to breath spontaneously while being in the right lateral posture.
224304920|NCT05634057|DRUG|Anisodamine hydrobromide combined with heparin|The anisodamine hydrobromide combined with heparin treatment group is on the basis of conventional treatment.
223478152|NCT05923996|RADIATION|fractional carbon dioxide laser|Two sessions of the fractional CO2 laser on this side of the face at 4-weeks intervals
223478153|NCT05645926|PROCEDURE|Percutaneous coronary intervention (PCI)|Patients who underwent percutaneous coronary intervention (PCI), including percutaneous transluminal coronary angioplasty (PTCA), and coronary stent insertion
223478154|NCT05645926|PROCEDURE|Coronary artery bypass grafting (CABG)|Patients who underwent coronary artery bypass grafting (CABG)
223478155|NCT00688441|DRUG|Nasal CO2|Twice daily during the 14 day Treatment Period
223478156|NCT00688441|DRUG|Placebo|Use of the study drug dispenser at the same frequency as the active arm
223583924|NCT03694873|DRUG|Celecoxib 200mg|Celecoxib 200 mg (Celebrex® 200, Pﬁzer,USA) administered orally immediately, 12 h and 24 h after randomization.
224070359|NCT05725356|OTHER|Basic body awareness therapy|Participants were instructed to focus on maintaining good posture, balance, uninterrupted breathing, increased awareness, and decreasing unnecessary muscle tension.
224070360|NCT00962832|DRUG|Placebo|Placebo was supplied as a sterile liquid solution.
224070361|NCT00962832|DRUG|Rontalizumab|Rontalizumab was supplied as a sterile liquid solution.
224070362|NCT00758745|DEVICE|Model SN60WF|Implantation with the AcrySof Model SN60WF Single-piece intraocular lens (IOL) following cataract removal.
224304921|NCT06450028|DRUG|10 cc of 0.25% bupivacaine hydrochloride with 1:200,000 epinephrine|Injection of 10 cc of 0.25% bupivacaine hydrochloride with 1:200,000 epinephrine.
224304922|NCT06450028|DRUG|6.8 cc of 2% lidocaine hydrochloride with 1:100,000 epinephrine|Injection of 6.8 cc of 2% lidocaine hydrochloride with 1:100,000 epinephrine.
223478157|NCT01208285|DRUG|VX-770|150 mg oral tablet
223478158|NCT03684746|OTHER|No Intervention|It is an observational Study with staff
224304923|NCT05466461|PROCEDURE|Beautifil Flow Plus X.|Class V cavities will be prepared, Selective etching technique will be used with phosphoric acid etching gel for 15 seconds on enamel.Single Bond TM Universal will be applied to cavity walls and margins with agitation for 20 seconds.The adhesive will be light-cured for 20 seconds. Then Beautifil Flow Plus X composite will be placed
224304924|NCT05466461|PROCEDURE|Activa bioactive restorative|Class V cavities will be prepared, Selective etching technique will be used with phosphoric acid etching gel for 15 seconds on enamel. Bonding agent will be applied on the entire cavity and light-cured for 20 seconds then Activa bioactive restorative composite will be applied and cured for 20 seconds.
224304925|NCT05906810|PROCEDURE|Non-surgical periodontal treatment|Subgingival biofilm ultrasonic debridement
224304926|NCT03919877|OTHER|Dietary|Dietary counseling based on results of CGM analyses.
223478159|NCT03524378|BEHAVIORAL|Ergonomic and movement modifications|Introduction of basic ergonomic and self-management principles, participants will review video clips of the prioritized and revised solutions. Adjustments in work tasks, movement strategies or self-management techniques will be self selected by workers after an educational session using videotapes of work processes.
223478160|NCT05212298|DIETARY_SUPPLEMENT|The gel contains a mixture of glucose and maltodextrin|The gel contains a mixture of glucose and maltodextrin - a complex carbohydrate - along with fat and a trace of protein.
223478161|NCT05212298|DIETARY_SUPPLEMENT|Herbal compound low-dose|The total amount of herbal compound capsules is 557 mg.
223478162|NCT05212298|DIETARY_SUPPLEMENT|Herbal compound high-dose|The total amount of herbal compound capsules is 1114 mg.
223478163|NCT06395727|DRUG|Fentanyl|traditional fentanyl dose
223478164|NCT06395727|DRUG|Lidocain|lidocaine nebuliser and lidocaine spray targeting difficult swallowing
223478165|NCT03846375|BEHAVIORAL|Psychotherapy|DBT is a well-established treatment for recurrent self-harm and suicidal thoughts. The program is principle-based, but the skills training follow a manualized curriculum.
223478166|NCT03846375|OTHER|Pre-intervention testing|Pre-intervention testing for baseline measures.
223478167|NCT03279575|BEHAVIORAL|Night Shift|Physicians in this arm of the trial will be asked to play Night Shift, an adventure video game, for two hours.
223478168|NCT03279575|BEHAVIORAL|Graveyard Shift|Physicians in this arm of the trial will be asked to play Graveyard Shift, a puzzle video game, for two hours.
223478169|NCT03279575|BEHAVIORAL|Educational program|Physicians in this arm of the trial will be asked to use myATLS, an app designed by the American College of Surgeons to serve as an adjunct to the ATLS course, and Trauma Life Support MCQ Review, an app designed to help students prepare for the ATLS exam. They will be asked to spend at least two hours on the combined tasks.
223478170|NCT03279575|BEHAVIORAL|Control|Physicians in this arm will serve as a no-contact control group.
223478171|NCT04730609|DRUG|Dexmedetomidine|Doses of dexmedetomidine will be selected according to a sequential up-and-down method, using a biased coin design to find the estimated dose at which 90% of patients would have desired effect
223583925|NCT01744717|OTHER|Pain measurement|"Pain intensity will be measured using 2 scales based on behaviour items, the Behavioural Pain Scale (BPS) and the ESCID scale (Escala de Conductas Indicadoras de Dolor), by two independent observers , when applying two procedures registered as painful (PD) and common in clinical practice, and a non-painful procedure (PND). The measurement will be performed once per each patient and procedure.~The procedures to be studied are the following:~* TURNING / POSITIONING (moving side to side or up or down in bed)~* ENDOTRACHEAL SUCTIONING (insertion of suction catheter into the endotracheal tube or tracheostomy in order to aspirate secretions)~* NON PAINFUL PROCEDURE (Soft friction with gauze cloth on a healthy skin tissue portion, in the outer arm, forearm or anterior tibial area)"
223583926|NCT01124877|DRUG|ziprasidone oral capsules|Oral ziprasidone capsules of 20 mg, 40 mg, 60 mg, and 80 mg strength will be provided. Subjects will be dosed daily for 26 weeks using a flexible dose design with a minimal dose range of 40mg twice a day (BID) to a maximum dose range of 80 mg BID. For subjects weighing \<45 kg, the doses will range from 20 mg BID to 40 mg BID.
224070363|NCT00758745|DEVICE|Model MA60AC|Implantation with the AcrySof Model MA60AC multi-piece intraocular lens (IOL) following cataract surgery.
224070364|NCT01130571|PROCEDURE|Xenografts and cell cultures|
223478172|NCT06095999|BEHAVIORAL|Perfect Fit intervention: virtual coaching intervention to quit smoking and increase physical activity|The intervention, delivered through a virtual coach, has a personalized duration and intensity, but will last on average 16 weeks. The intervention has three phases: preparation, execution (including \[re\]lapse) and closing. By having chat conversations with the Perfect Fit virtual coach (using the mobile application 'NiceDay'), the user will be guided through the different phases of the intervention. In each phase, the user has chat conversations with the virtual coach (e.g. about goal setting, weekly reflection) and, in addition, receives exercises and educational video material to support smoking cessation and PA promotion. Additionally, a smartwatch is used to objectively assess PA. It allows participants to monitor their PA and the data (on the number of steps) is used to give automatic, personalized PA advice to the user.
223478173|NCT02539251|BEHAVIORAL|Arabic ASQ -3|Administration of a developmental questionnaire in Arabic (A-ASQ-3) and validation using BSID-III as a gold standard
223478174|NCT03054428|DRUG|Dupilumab|Subcutaneous injection among the different quadrants of the abdomen (avoiding navel and waist areas), upper thighs, and upper arms.
223478175|NCT03054428|DRUG|Placebo|Subcutaneous injection among the different quadrants of the abdomen (avoiding navel and waist areas), upper thighs, and upper arms.
223478176|NCT03092752|DRUG|oral antidiabetic drugs|OADs usage conditions and dose selection in T2DM patients
223478177|NCT00217945|BEHAVIORAL|Shared-Decision Making|
223478178|NCT03684408|DEVICE|RFID Localization|The RFID and wire localization devices used in this study are FDA approved for the image guided localization of breast tumors prior to surgical excision. The two techniques for localization will be compared in this trial.
223478179|NCT03684408|DEVICE|Wire Localization|The RFID and wire localization devices used in this study are FDA approved for the image guided localization of breast tumors prior to surgical excision. The two techniques for localization will be compared in this trial.
223478180|NCT03684408|DEVICE|RFID and Wire Localization|Both RFID and the standard of care wire localization will be performed for physician training.
223478181|NCT04987047|BIOLOGICAL|Blood collection|A blood sample will be collected at enrollment to perform pharmacogenetics analyses.
223583927|NCT04247126|DRUG|SY-5609|An oral CDK7 Inhibitor
223583928|NCT04247126|DRUG|Fulvestrant|Estrogen receptor antagonist
223583929|NCT04247126|DRUG|Gemcitabine|Nucleoside metabolic inhibitor
224070365|NCT04400812|OTHER|questionnaire|Arabic questionnaire focused on knowledge, perception and attitude
224070366|NCT05218512|OTHER|WB-EMS|"The group has been submitted to 2 experimental conditions:~1. At rest with superimposed WB-EMS.~2. During uphill walking exercise with superimposed WB-EMS."
224070367|NCT00715585|BEHAVIORAL|Active Control|patients receive 3 individualized visits with a health educator focused on general diabetes education and health promotion
224070368|NCT00715585|BEHAVIORAL|int arm 1|VVpatients receive 3 individualized visits with an rd-cde for education focused on modified plate method
224070369|NCT00715585|BEHAVIORAL|int arm 3|patients receive 3 individualized visits with an rd-cde for education focused on carb counting
223478182|NCT04987047|OTHER|Questionnaires|Several questionnaires will be filled by the participants or by the clinicians at every study visits: Hospital anxiety depression scale (HAD), Post Traumatic Stress Disorder Checklist for DSM-5 (PCL-5), Quick inventory of depressive symptomatology - self rated (QiDS), Beck's Anxiety Inventory (BAI), World Health Organization Quality Of Life (WHOQOL-BREF), EuroQol Group questionnaire (EQ5D), Frequency, intensity, burden of side effects rating (FIBSER), Udvalg for Kliniske Undersøgelser - Side Effects Rating Scale - for Patients (UKU-SERS-PAT), Clinical Global impression (CGI), Montgomery and Asberg Depression Rating Scale (MADRS).
223478183|NCT04987047|OTHER|Cognitive test battery (optional)|"For patients participating in the ELAN ancillary study : the participants will undergo a battery of neurocognitive tests assessing motivation (élan vital in French)."
223478184|NCT04499703|DEVICE|RHMS-RTM|Assessment of retinal thickness
223478185|NCT04499703|DIAGNOSTIC_TEST|SD-OCT|Assessment of retinal structure
223744743|NCT01381133|BEHAVIORAL|Motivational Enhancement Therapy/Cognitive Behavior Treatment (MET/CBT 7)|A manual-based 5-session MET/CBT model was supplemented with 2 family sessions. First was a family session to provide parents with an overview. Next was an individual adolescent MET session that focused on building rapport, explaining treatment, building motivation, and reviewing personalized feedback. In the third session, the therapist helped the adolescent complete a functional analysis of substance use and a personal goal worksheet. During sessions 4-6, the adolescent joined a closed group of 6 for 90-min CBT skills groups focusing on substance refusal skills, enhancing social support, planning for high-risk situations, and coping with relapse. The last session was a family session to review progress, relapse signs, and continuing care plans. Treatment lasted about 12 weeks.
223478186|NCT01399307|PROCEDURE|Liposuction|Elective Liposuction
223478187|NCT03397017|OTHER|Transfusion|
223478188|NCT05298241|OTHER|Hand-grip Strength Game|Interactive Handgrip Strength Game for ICU patients receiving the game and to assess the impact on psychological.
223478189|NCT01813747|DEVICE|1440 nm wavelength laser with handpiece (Cynosure)|To assess the effectiveness of device in skin tightening and laser lipolysis in the mandibular and sub-mandibular areas.
223744744|NCT01381133|BEHAVIORAL|Assertive Continuing Care (ACC)|ACC is a home-based continuing care approach that takes place over a 12-14 week period and has shown promise in a randomized clinical trial of adolescents discharged from residential treatment. Following an operant reinforcement and skills training model, ACC combines the Adolescent Community Reinforcement Approach and case management services to help adolescents and their caregivers engage in prosocial activities, skills, and needed community services during weekly home visits.
223744745|NCT03370003|OTHER|Standard medical care|All children will receive nutritional treatment and standard medical care in accordance with the nutritional guidelines of the national protocol, with the exception of the routine distribution of antibiotics.
223744746|NCT05945277|BEHAVIORAL|Critical Time Intervention - Peer Support|CTI-PS is a time-limited, 9-month long intervention, provided at the critical time when a person is discharged from an inpatient psychiatric treatment facility.
223744747|NCT06007638|DRUG|LY3876602|Administered IV.
223744748|NCT06007638|DRUG|Placebo|Administered IV.
224304927|NCT04533958|DEVICE|HYPNO VR® device|"The HYPNO VR® device is a software application of medical hypnosis in the treatment of pain and anxiety. It is associated with equipment: a virtual reality headset and a headphone.~Before each Docetaxel infusion, the nursing staff offers patients the choices: visual universe, musical theme, male or female voice. The nursing staff selects the chemotherapy program, selects a duration of 20 minutes and presses start to start the medical hypnosis session in virtual reality.~After completing the hypnotic trance sequence, as in a classic session, the patient is brought back to the return and exit hypnosis phase under the supervision of the nursing staff."
224304928|NCT03811613|OTHER|Transcranial photobiomodulation|Photobiomodulation was administered using red light-emitting diodes (LEDs) with a 670-nm wavelength (which has proven to penetrate the skull)
224304929|NCT05199311|DRUG|Carfilzomib|20 mg/m2 C1D1; 56 mg/m2 thereafter
223744749|NCT00868933|OTHER|Low glycemic index dietary intervention program|The intervention group involves dietary advice and monitoring. No drug or invasive procedure is involved.
223744750|NCT00868933|OTHER|simple lifestyle advice|The control group receives lifestyle advice from a clinician, and the clinical care is not inferior to current practice.
224070370|NCT00163774|DEVICE|Brain oxygenation and microdialysis catheters|
224304930|NCT05199311|DRUG|Iberdomide|Oral CC-220 at dose specified by cohort dose level from Day 1-21 of each 28-day cycle
224304931|NCT05199311|DRUG|Oral Dexamethasone|40 mg (\<=75 years old); 20 mg (\>75 years old)
224304932|NCT06242704|BEHAVIORAL|Working Memory Training|A multi-session computer-based working memory training program to improve delay discounting and prevent substance use among at-risk adolescents in a traditionally underserved area.
224304933|NCT06242704|BEHAVIORAL|Working Memory|A multi-session control computer training condition that is designed to not engage working memory among at-risk adolescents in a traditionally underserved area.
223478190|NCT02629783|OTHER|Psychomotor therapy|1 treatment of approximately 45 minutes the first 5 weeks after randomization. The treatment will focus on teaching the patients about body awareness and handling of there shoulder problems in daily living.
223478191|NCT02629783|OTHER|Physiotherapy|Patients are, in secondary care setting, given 3-5 basic physiotherapy exercises for there shoulder pain, targeting rotator cuff muscles and scapula thoracic muscles. Furthermore they are given advice on seeking further physiotherapy guidance in private setting.
223478192|NCT02629783|DRUG|corticosteroid injection|At baseline, patients with signs of inflammation in the subacromial bursa, can receive a ultrasound guided corticosteroid injection in the bursa
223478193|NCT03393182|PROCEDURE|TLDG arm|After lymphadenectomy, gastrectomy and reconstruction procedure are performed intracorporeally without mini-laparotomy(TLDG)
223744751|NCT04566315|PROCEDURE|Arteriography knee arteriography|arteriography and an injection of inert microparticles of 75 μm in neovessels
224070371|NCT01664728|DRUG|Abiraterone acetate|Phase 2 maximum tolerated dose from Study COU-AA-001 taken orally once daily
224304934|NCT05327816|BIOLOGICAL|RSV preF-based Vaccine|RSV preF-based vaccine will be administered as intramuscular injection.
224304935|NCT05327816|DRUG|Placebo|Placebo will be administered as intramuscular injection.
223478194|NCT03393182|PROCEDURE|LADG arm|After lymphadenectomy, gastrectomy and reconstruction procedure are performed extracorporeally through mini-laparotomy(LADG)
223478195|NCT00792285|BEHAVIORAL|Automated Telephone Outreach with Speech Recognition|Automated Telephone Outreach with Speech Recognition calls to health plan members to promote screening
224070372|NCT01664728|DRUG|Glucocorticoid|prednisolone/prednisone 5 mg taken orally twice daily or dexamethasone 0.5 mg taken orally once daily
224163371|NCT04507360|BEHAVIORAL|Study 1, Tailored Resources by Desired Resources|Participants will be provided with links to Mental Health America (MHA) resources aligned with their expressed interest (e.g., additional screening, self help tools).
224163372|NCT04507360|BEHAVIORAL|Study 2, Control|Participants in the Do-It-Yourself (DIY) control group will receive psychoeducation materials in W0. They will view content as usual (no DIY).
224163373|NCT04507360|BEHAVIORAL|Study 2, DIY tool without AI|Participants in the Do-It-Yourself (DIY) tool without Artificial Intelligence (AI) group will be instructed to use the DIY tool 3 times a week.
224163374|NCT04507360|BEHAVIORAL|Study 2, DIY tool with AI|Participants in the Do-It-Yourself (DIY) tool with Artificial Intelligence (AI) group will be instructed to use the DIY tool with AI 3 times a week.
224163375|NCT05844254|PROCEDURE|novel overlapping rotated double (NORD) flap|"After undergoing phase one of periodontal therapy, patients will be recalled after four weeks for root coverage surgery. Patients will be randomly allotted to either group by stratified block randomization after taking baseline measurement with respect to periodontal phenotype(PP) \[using transparency of periodontal probe through the gingival margin, when probe is visible, thin PP and when not visible, thick PP\] so that patients with thick and thin PP get an equal chance of being allocated to NORD and Sub epithelial connective tissue group.~1. Group 1(NORD group)- Patients treated with NORD flap~2. Group 2 (Sub epithelial connective tissue group)- Patients treated with sub epithelial connective tissue graft Patients will be followed up after 1 month,6, 12 and 15 months. 30 patients belonging to thin phenotype will be followed up as separate cohort for period of one year to evaluate phenotype modification."
224163376|NCT06381076|DRUG|Liposomal curcumin|participants will consume the product ad libitum for the 24 treatments.
224163377|NCT06381076|DRUG|Food colorant|participants will consume the product ad libitum for the 24 treatments as a placebo.
224163378|NCT00888316|PROCEDURE|magnetic resonance imaging|"MRI of the liver will be performed within 30 days prior to HSCT (day 0) and can be done during receipt of conditioning regimen chemotherapy and/or radiation therapy. MRI will also be performed in selected patients at 1 year post-HSCT. This MRI will be done within ± 30 days of their 1-year post-transplant followup date.~The R2 MRI is a specific MRI technique and cannot be used for the purpose of general diagnostic imaging. In our study, this modality is being used specifically for the estimation of LIC."
224163379|NCT00888316|PROCEDURE|Serum ferritin|Blood samples will be taken pre-transplant, 3, 6, 9 and 12 months post-transplant
224163380|NCT00027404|DRUG|Fluoxetine|
224163381|NCT05232903|BIOLOGICAL|SVF therapy group|The active treatment is an intravenous injection with the stromal vascular fraction (SVF) harvested from the patient's own fatty tissue.
224163656|NCT05419284|OTHER|+Care|"3 extra exercise moments led by a caregiver: one physiotherapist-caregiver-patient exercise session: the physiotherapist will educate and train the caregiver on the exercises and hands-on skills.~Two caregiver-patient exercise sessions"
223478196|NCT05724758|PROCEDURE|Breast-conserving surgery|"Following oncoplastic surgeries are performed at the Brust-Zentrum in Zurich:~* Oncoplastic reconstruction with round-block technique~* Oncoplastic reconstruction using J-Plastic~* Oncoplastic reconstruction using V-Plastic~* Oncoplastic reconstruction using Grisotti~* Oncoplastic reconstruction using Batwing~* Oncoplastic reconstruction using Mammareductionplasty (Wise Pattern, Vertical)~* Oncoplastic perforator flap surgery"
223478197|NCT05745623|DRUG|ICP-723|ICP-723 tablet administered orally，once a day，for every 28 days as one cycle
223478198|NCT06818825|BEHAVIORAL|Automated interactive messages|High ED utilizers will be sent SMS text messages guiding them through ED-alternative resources, with different guidance (including a follow-up phone call from a healthcare worker) depending on patient responses.
223478199|NCT06818825|BEHAVIORAL|Live outreach|High ED utilizers will be called (and possibly visited) by a CHW/CMA guiding them through ED-alternative resources.
223478200|NCT06814275|BEHAVIORAL|ARTEMIS|The ARTEMIS intervention includes 5 sessions delivered individually over Zoom across 3 months. The intervention teaches 9 positive affect skills: noting and capitalizing on positive events, gratitude journaling, formal and informal mindfulness, positive reappraisal and problem solving coping skills training, focusing on personal strengths, setting achievable goals, and small acts of kindness. Each session consists of a didactic portion with in vivo skills practice, and participants are asked to complete daily home practice of the skills between sessions.
224070373|NCT05925296|DEVICE|magnetic stimulation|Patients in the Experimental group underwent ten sessions of double-site high frequency rTMS over the bilateral primary motor cortex of the lower leg and supplementary motor area, whereas patients in the Active Comparator group underwent ten sessions of single-site active magnetic stimulation with high frequency rTMS over the bilateral primary motor cortex of the lower leg. In addition, patients in the Sham Comparator group underwent 10 sessions of double sham rTMS on motor cortex.
224070374|NCT03233555|OTHER|Informational Intervention|Receive brochure
224070375|NCT03233555|OTHER|Internet-Based Intervention|Have access to EXCELS
224070376|NCT03233555|OTHER|Quality-of-Life Assessment|Ancillary studies
224070377|NCT03233555|OTHER|Questionnaire Administration|Ancillary studies
224070378|NCT03233555|BEHAVIORAL|Telephone-Based Intervention|Receive quarterly calls
224070379|NCT02691442|DRUG|Ropivacaine 0.75%|The investigators adminster 5ml of Ropivacaine 0.75% in an ultrasound-guided inter scalene nerve block
224070380|NCT02691442|DRUG|Levobupivacaine 0.5%|The investigators adminster 5ml of Levobupivacaine 0.5% in an ultrasound-guided inter scalene nerve block
224070381|NCT02691442|DRUG|Levobupivacaine 0.5% + epinephrin 1/200000|The investigators adminster 5ml of Levobupivacaine 0.5% + epinephrin 1/200000 in an ultrasound-guided inter scalene nerve block
224070382|NCT04199637|OTHER|TVG|Therapeutic video game
224070383|NCT04458298|DRUG|OP-101|OP-101 infusion will be administered intravenously.
224070384|NCT04458298|DRUG|Placebo|Matching placebo infusion will be administered intravenously.
224163382|NCT00523172|PROCEDURE|manual or manipulative therapy|Active comparator will receive 9 treatments of manual or manipulative therapy to the hip (HVLA hip manipulations per protocol 1) with pre-manipulative static and post manipulative active-assisted stretch of hip muscles after each manipulation.
224163383|NCT00523172|PROCEDURE|Manual / Manipulative Therapy|Active comparator will receive 9 treatments of manual or manipulative therapy to the lumbosacral, sacroiliac, hip and knee, ankle and foot joints (HVLA and Grades I-IV mobilization per protocol 2) stretching and exercise.)
224163384|NCT00523172|PROCEDURE|Supportive Care|"Supportive Care 3) Groups A and B will receive supportive care after the 9th visit consisting of (up to a maximum of) 6 visits, PRN or as needed, until the 9 month follow up. This is to see if peak gains may be maintained (as noted in the previous trial) throughout the follow up period.~Enrolled subjects will commonly receive 2 treatments per week (occasionally, less or more than 1 to 2 treatments per week due to (College or University) semester breaks, exams, clinic closures and so forth) until 9 treatments are completed."
224163385|NCT04360291|OTHER|Eye tracker|In visual search tasks, participants will sit in front of a screen and observe during each visual scene for a maximum of 45 seconds. Their eye movements will be recorded
224163386|NCT04062513|OTHER|Olfactive stimulation intervention with familiarization|The intervention consists of placing a pad immersed with breast milk near the preterm infant's nose during heel prick. For the familiarization stage, infants were familiarized with the odor of their mothers' milk for 9 hours before heel prick.
224163387|NCT04062513|OTHER|Olfactive stimulation intervention|The intervention consists of placing a pad immersed with breast milk near the preterm infant's nose during heel prick.
224163388|NCT04062513|OTHER|Standard care|Preterm infants will receive sucrose during heel prick.
224163389|NCT04164264|DRUG|Propofol|At T0, a propofol infusion at a rate of 1.5 mg/kg/min will be started until apnea is achieved. Loss of consciousness will be defined clinically using loss of eyelash reflex (TLOER) and tolerance of nasal cannulae (TNC), tested every 10 sec., and by a BIS \<60 for 30 sec. (TBIS). Apnea will be defined as absence of end-tidal CO2 for at least 20 seconds (TAPNEA). A saliva sample with be taken under anesthesia for genome-wide association study and principal component analysis.
223478201|NCT06814275|BEHAVIORAL|Contingency management for Antiretroviral (ARV) adherence|All participants will received the contingency management (CM) intervention to support ARV adherence. They will use the Spotlight by Scene Health platform, a HIPAA-compliant mHealth application for directly observed therapy, to upload videos of ART adherence. The app records and uploads time-stamped videos of medication doses, which staff verify asynchronously. Participants will be paid for each verified dose and receive a weekly bonus if they complete 6 doses.
223478202|NCT04953195|DRUG|Levothyroxine Sodium Tablets|Levothyroxine Sodium(50ug/Tablets,dosage form 25ug,once a day) was administered to patients with autoimmune thyroiditis with mild subclinical hypothyroidism,
223478203|NCT02631447|DRUG|LGX818|LGX818 450 mg p.o. od
223478204|NCT02631447|DRUG|MEK162|MEK162 45 mg p.o. bid
223478205|NCT02631447|DRUG|Nivolumab|Nivolumab 1 mg/kg solution IV combined with ipilimumab 3 mg/kg solution IV every 3 weeks for 4 doses then nivolumab 3 mg/kg solution IV every 2 weeks
223478206|NCT02631447|DRUG|Ipilimumab|Nivolumab 1 mg/kg solution IV combined with ipilimumab 3 mg/kg solution IV every 3 weeks for 4 doses then nivolumab 3 mg/kg solution IV every 2 weeks
223478207|NCT06984627|DRUG|Rilzabrutinib dose 1|Pharmaceutical form:Tablet-Route of administration:Oral
223478208|NCT06984627|DRUG|Rilzabrutinib dose 2|Pharmaceutical form:Tablet-Route of administration:Oral
223478209|NCT01526408|DRUG|Famciclovir|Patients will be instructed to take 6 250mg pills orally for the first 7 days (Week 1: 2 pills every 8 hours or three times per day) at home. Patients will take a maintenance dose of one 250 mg pill twice a day for 77 days (11 weeks, total 3 months on drug).
223478210|NCT01526408|DRUG|Placebo|Patients will be instructed to take 6 250mg pills orally for the first 7 days (Week 1: 2 pills every 8 hours or three times per day) at home. Patients will take a maintenance dose of one 250 mg pill twice a day for 77 days (11 weeks, total 3 months).
223583930|NCT04247126|DRUG|Nab-paclitaxel|Taxane-type chemotherapy
224163390|NCT01369394|OTHER|Behavioral: Computer-based tailoring system|"Both the intervention and control groups will use a computer-based tailoring system to respond to survey questions. The computer-based tailoring system will generate educational messages based on participants' responses to survey questions. The intervention group will receive tailored educational messages, whereas the control group will receive generic educational messages. The tailored and generic educational messages will be presented as to look like web pages. However, the messages will only exist on the study computer, and will not be linked to any live server or website."
224163391|NCT02306525|PROCEDURE|Arthroscopic surgery of the hip joint|Arthroscopic treatment of Femoroacetabular Impingement
223478211|NCT06413966|PROCEDURE|Partially absorbable mesh|\- In this group, after bullectomy or blebectomy, partially absorbable mesh (ULTRAPRO size 15 x 15 cm, Ethicon) will be prepared and inserted into the pleural cavity through one of the working ports and placed at the apical part of the thoracic cage (over the staple line) using fixation device (ProTack™ 5 mm fixation device, Medtronic).
223478212|NCT06413966|PROCEDURE|Apical pleurectomy|\- In apical pleurectomy group, after bullectomy or blebectomy, the parietal surface from the apex to the fifth rib was dissected and abraded using a curved dissector with a diathermy scratch pad. Abrasion was done until a uniform aspect of bloody pleura was obtained.
223478213|NCT04155645|DRUG|AZD8233 subcutaneous injection|Randomized subjects will receive SC dose of AZD8233 (dose 1, dose 2, and dose 3) injection.
223478214|NCT04155645|DRUG|Placebo|Randomized subjects will receive SC dose of placebo injection.
223478215|NCT02062697|PROCEDURE|Lavage of the Cavum uteri and proximal fallopian tubes|
223478216|NCT02062697|PROCEDURE|Liquid-PAP smear|
223583931|NCT01509469|DIETARY_SUPPLEMENT|Casein|Ileal infusion of low dose casein (5 gram)
223583932|NCT01509469|DIETARY_SUPPLEMENT|Casein|Ileal infusion of high dose casein (15 gram)
223583933|NCT01509469|DIETARY_SUPPLEMENT|Sucrose|Ileal infusion of low dose sucrose (4.3 gram)
223583934|NCT01509469|DIETARY_SUPPLEMENT|Sucrose|Ileal infusion of high dose sucrose (12.9 gram)
223583935|NCT01509469|OTHER|Saline|Ileal infusion with saline (180mL in total)
223583936|NCT01509469|DIETARY_SUPPLEMENT|Safflower oil|Ileal infusion with safflower oil (6gr safflower oil in water)
223744752|NCT06325956|DRUG|Metformin|Take metformin for six months.
223478217|NCT04259138|BIOLOGICAL|Treatment Algorithm A|Participants who are not on UC treatment at screening (or who have only used topical therapy) will require standard first-line therapy. Either oral 5-ASA and/or immunosuppressive (azathioprine, 6-mercaptopurine, or methotrexate), with optional oral corticosteroid up to a maximum of 30 mg or prednisone or equivalent, will be initiated.
224163392|NCT01004159|DRUG|cetuximab with irinotecan|Cetuximab administered 500mg/m2 over 120 minutes Irinotecan administered Q 3 weeks, Q 2 weeks or Q week x 4 every 6 weeks depending on patients previous treatment
224163393|NCT03704233|PROCEDURE|Transbronchial cryobiopsy|Transbronchial cryobiopsy procedure
224163394|NCT06262646|BEHAVIORAL|Focused Acceptance and Commitment Therapy|Trained FACT interventionists will be guided by manualized FACT intervention to identify how many psychopathological processes need support and which ACT process(es) need to work on first, then offer parents process-matched ACT intervention strategies following the principles of FACT. The intervention strategies include ACT metaphors, experiential exercises, audio-guided mindfulness exercises, guided imagery exercises and value clarification exercises. The FACT steps in each session depend on the client's situation/stage.
224163395|NCT06262646|OTHER|Control Group|Both study groups will receive standard family support from collaborating NGOs.
224163396|NCT04058990|DEVICE|Device: Paclitaxel-Coated PTCA Balloon Catheter|Percutaneous Transluminal Coronary Angioplasty
223478218|NCT04259138|BIOLOGICAL|Treatment Algorithm B|"Participants who are taking oral 5-ASA, immunosuppressive (azathioprine, 6-mercaptopurine, methotrexate), and/or oral corticosteroid at screening will follow the treatment algorithm.~Participants will change to intravenous vedolizumab therapy.~Participants will be assessed to determine it remission target is achieved at weeks 16, 32 and 48. If the participant has achieved their treatment target, they will continue that line of therapy. If the participant has not achieved their treatment target, treatment and/or dose escalation will be administered according to the algorithm."
223478219|NCT04259138|BIOLOGICAL|Treatment Algorithm C|"Participants who are taking a TNFα antagonist (infliximab, golimumab, or adalimumab), tofacitinib, or ustekinumab therapy at screening will follow the treatment algorithm.~Participants will change to intravenous vedolizumab therapy.~Participants will be assessed to determine it remission target is achieved at weeks 16, 32 and 48. If the participant has achieved their treatment target, they will continue that line of therapy. If the participant has not achieved their treatment target, treatment and/or dose escalation will be administered according to the algorithm."
223478220|NCT06193889|DRUG|Standard of Care Treatment|Standard of Care Medications Optional Crossover to receive KYV-101 treatment
223478221|NCT06193889|DRUG|Standard lymphodepletion regimen|Standard lymphodepletion regimen
223478222|NCT06193889|BIOLOGICAL|KYV-101|Anti-CD19 CAR-T cell therapy
223478223|NCT06664567|BEHAVIORAL|Colorectal cancer screening test|delivery of colorectal cancer screening test by GP
223583937|NCT05705752|OTHER|Balance training|12 sessions of balance training en 4 weeks, with a duration of 40-45 min each.
223583938|NCT05705752|OTHER|Pilates training|12 sessions of Pilates training en 4 weeks, with a duration of 40-45 min each.
223583939|NCT01727011|RADIATION|IPAS|
223583940|NCT06546176|OTHER|End to end with Omega suture|After the rectum was divided with a linear stapler, the circular stapler was placed allowing the anvil rod to penetrate the rectal stump near the linear stapler line. An omega suture including both ends of the linear stapler line was placed. The linear stapler line was approximated around the anvil rod of the circular stapler in an omega shape fashion as the omega suture was tied. This technique resulted in a complete resection of linear stapler line by the circular stapler.
223583941|NCT06546176|OTHER|End to anterior rectal wall|"A burse string suture was applied over the anvil of the circular stapler at the transection point of the descending colon using prolene 2/0.~The circular stapler introduced though the anus and its rod directed toward the anterior rectal wall and colorectal anastomosis was performed."
223583942|NCT04648514|PROCEDURE|Using of hydraulic lifter device for closed sinus lifting|Using of recent closed minimally invasive technique (hydraulic left technique) by hydraulic lifter device for closed sinus lifting then evaluation of the amount of bone height gain will be done radiographically (by panorama and CBCT) after implant placement for patients with posterior edentulous maxilla .
223583943|NCT04648514|BEHAVIORAL|patient satisfaction evaluation after using hydraulic lifter device|Evaluation of patient satisfaction numerically will be done after using hydraulic lift technique by hydraulic lifter device for closed sinus lifting in posterior edentulous maxilla
223583944|NCT06504069|BEHAVIORAL|Prosocial VR intervention|A five-week gamified prosocial VR intervention program based on literature review and relevance to the local contexts will be developed for the proposed project. The intervention will be expanded to include five weekly sessions, each lasting between 10 to 15 minutes. Each session will depict a different daily life scenario-home, school, street, park, and shopping mall, respectively. During each session, participants will engage in a series of tasks that incorporate elements of prosocial behavior or helping actions within the scene. These tasks are designed to be more comprehensive and interactive, ensuring that participants are fully immersed in the experience for the entire duration of the session.
223583945|NCT03527524|OTHER|exercise with ball|exercise with ball
223583946|NCT03527524|OTHER|exercise without ball|exercise without ball
223583947|NCT01075503|PROCEDURE|brachial plexus block|0.5% Ropivacaine 40ml
223583948|NCT05251753|DEVICE|K-Lock|Patients will be randomized to either A) left side K-Lock with right side suture-based technique or B) right side K-Lock with left side suture-based technique.
223583949|NCT01761695|OTHER|Diagnosed as CML|All patients who will be enrolled in this prospective registry are confined to those who are diagnosed as chronic myeloid leukemia at Asan Medical Center, Seoul, Korea, from Jan 2013 till Dec 2047
223583950|NCT05730348|BEHAVIORAL|Post mealtime activity|Therapist lead movement post meals
223583951|NCT06433999|DRUG|Brepocitinib|Oral Brepocitinib PO QD
223583952|NCT03691350|PROCEDURE|Bronchoscopy with Bronchoalveolar Lavage|Undergo bronchoscopy with bronchoalveolar lavage
223583953|NCT03691350|DRUG|Cigarette|Smoke usual brand
223583954|NCT03691350|OTHER|Electronic Cigarette|Smoke SREC with nicotine
223583955|NCT03691350|OTHER|Electronic Cigarette|Smoke SREC without nictoine
224163397|NCT04058990|DEVICE|SeQuent Please Drug Eluting Balloon Catheter with Paclitaxel|Percutaneous Transluminal Coronary Angioplasty
224163398|NCT03024151|DRUG|Comthyroid|T4/T3 combination replacement
224163399|NCT03024151|DRUG|Synthroid|T4 mono replacement
223744753|NCT05194618|DIETARY_SUPPLEMENT|Valerian - lavender|1 tablet per day, half hour before bedtime, day 1 to day 28
223744754|NCT05194618|DIETARY_SUPPLEMENT|Placebo|1 tablet per day, half hour before bedtime, day 1 to day 28
223744755|NCT02007564|BEHAVIORAL|LIFE Intervention|RSVs received intensive training in the manualized intervention, including practice opportunities. The manual and accompanying workbook consist of instructions about using the steps of problem solving to decide on a period of life and creative activity project; constructing a project; evaluation of the activity; and additional questions. With the help of the RSV, dyads narrow the focus to one time period in the patients' life that could be adequately represented in one tangible project (scrapbook, audiotapes). The RSV and dyad brainstormed ways to portray the life story and then narrowed the focus to one meaningful project. The dyad gathered all necessary materials (such as pictures) and actively worked on completing a portion of the project between sessions.
223478224|NCT05525260|DRUG|Limonene capsule|Citrus foods rich in D-limonene were forbiden 2 days before taking the drug (washout period), which was maintained after taking the drug.Limonene capsules group and placebo group were used for treatment. The random number is generated by the central randomization system. All the recruiters were divided into placebo control group and limonene capsule administration group. The numbers will be assigned according to random numbers. In this study, qualified subjects were randomly assigned to the treatment group and the placebo control group at a ratio of 1:1. The drug was administered for 12 weeks, 3 times a day, 5 capsules each time.
223478225|NCT05525260|DRUG|Limonene capsules(Placebo)|Limonene capsules(Placebo)
223478226|NCT06986590|BEHAVIORAL|ADHINCRA Program|The ADHINCRA Program is a nurse-led intervention that includes the use of home blood pressure monitoring, a mobile health app, lifestyle counselling, and a simplified hypertension treatment protocol to achieve blood pressure control among people diagnosed with hypertension.
223478227|NCT05158569|OTHER|Slow breathing exercise group|The patient will be first asked to close one nostril with a thumb and slowly breathe in completely through the other for 6 seconds. This nostril will be then closed and the patient will exhale through the other nostril over a period of 6 seconds. These steps complete one breathing cycle. An attempt will be made to keep the breathing rate is about 5-6 breaths per minute. Such alternate nostril breathing cycles will be repeated continuously for a period of about 15 minutes (3 sets of 5 minutes) in one sitting.
223583956|NCT03691350|OTHER|Laboratory Biomarker Analysis|Correlative studies
223583957|NCT03691350|DRUG|Nicotine Replacement|Receive NRT comprising patch, gum, or lozenge
223583958|NCT03691350|OTHER|Questionnaire Administration|Ancillary studies
223583959|NCT00149019|DRUG|Cell therapy with bispecific antibodies|
223583960|NCT00913393|DRUG|FG-3019|3 mg/kg FG-3019 IV every 2 weeks for 22 weeks
223583961|NCT00913393|DRUG|FG-3019|10 mg/kg FG-3019 IV every 2 weeks for 22 weeks
223478228|NCT05158569|OTHER|Diaphragmatic breathing exercise group|"Patients would be instructed to Sit or lie down in a comfortable place and put their hands on their belly.~Relax the muscles in their neck and shoulders. Breathe in slowly through the nose, keeping their mouth closed. Feel the lungs fill with air and inflate like a balloon while their belly moves outward. Such breathing cycles will be repeated continuously for a period of about 15 (3 sets of 5 minutes) minutes in one sitting."
223478229|NCT01499810|PROCEDURE|Bilateral radiofrequency sympathetic renal denervation|Bilateral radiofrequency sympathetic renal denervation is performed as percutaneous transluminal radiofrequency (RF) ablation of neural pathways in the renal artery walls and surrounding tissue using standard equipment for RF ablation of cardiac electrical pathways
223478230|NCT05056207|OTHER|Cohort I (patients receiving annual lymphedema screening|patientns who previously underwent preoperative perometer lymphedema screening
223583962|NCT00913393|DRUG|Placebo|Placebo IV every 2 weeks for 22 weeks
223744756|NCT06167993|BEHAVIORAL|Complex Decongestive Physiotherapy|Complex Decongestive Physiotherapy; It consists of manual therapy, skin care, compression therapy and therapeutic exercise.
223583963|NCT06316752|OTHER|Observational study|It is an observational study involving non-invasive routine examinations without treatment, thus posing no additional risk to patients. This project does not involve the use of medications, medical techniques, or the market status of medical equipment.
223583964|NCT06012110|DEVICE|Transcutaneous electrical stimulation|While participants are supine with a pillow placed below the knees for comfort, one 30-minute transcutaneous electrical stimulation session will be performed at a frequency of 50 Hz, pulse width of 400 microseconds and individualized amplitude will be completed.
224163400|NCT01415973|DIETARY_SUPPLEMENT|3 ounces of cooked, 85% lean ground beef|Consumed once per subject.
223583965|NCT01818284|DRUG|Filgrastim|5 µg/kg in the morning daily for 4 days.
223583966|NCT01818284|DRUG|Plerixafor|240 µg/kg subcutaneously in the evening on the fourth day of Filgrastim mobilization.
223583967|NCT01818284|PROCEDURE|Apheresis Procedure|"The apheresis procedure will start in the morning of day 5, approximately 10 to 11 hours after the administration of Plerixafor.~The apheresis procedure may continue beyond day 1 until the target dose of 4x106 CD34+ cells/kg (recipient's weight) is obtained."
223583968|NCT06822439|DEVICE|Fetal ECG monitoring|Patients will wear a fetal ECG monitor which they will place on their abdomen
223583969|NCT03440190|DRUG|Methylphenidate|Patients are tested for their normal prescription methylphenidate medication
223744757|NCT03841734|DRUG|treatment|8 patients will be treat with bosentan at 145 mg per day during 14 days
223744758|NCT05413369|DRUG|Insulin glargine/Lixisenatide|solution, by subcutaneous injection
223744759|NCT05413369|DRUG|IDegAsp|solution, by subcutaneous injection
223744760|NCT05413369|DRUG|Metformin|Tablet, orally
223744761|NCT05413369|DRUG|SGLT2 inhibitor|Tablet, orally
224163401|NCT01415973|DIETARY_SUPPLEMENT|20 grams beef protein isolate|Subjects would drink 200 ml water mixed with 20 grams of beef protein isolate one time.
224163402|NCT05441124|BEHAVIORAL|Mindfullness Based Stress Reduction (MBSR) intervention|Mindfullness Based Stress Reduction (MBSR) intervention: Monitoring stress and anxiety levels with mindfulness program
224163403|NCT04772651|OTHER|Mediterranean Diet|Diet meeting the requirements for mediterranean style (rich in vegetables, fruit, olive oil, fish) (Davis et al., 2015)
224163404|NCT04772651|OTHER|Normal hospital diet|Normal hospital diet
224163405|NCT04772651|OTHER|dietary coaching|dietary coaching
224163406|NCT04772651|OTHER|Psychoeducation on depression|Psychoeducation on depression (50minutes once a week for 4 weeks)
224164073|NCT05134597|GENETIC|Genetic assessment|Blood samples will be collected in 3-mL K3 EDTA vacutainer tubes. Peripheral blood mononuclear cells will be isolated via density gradient centrifugation within 2 hours of sample collection. Primary CD4+ T cells will be purified from the peripheral blood lymphocytes using a magnetic cell sorting CD4+ T cell isolation kit, according to the manufacturer's instructions. RNA extraction will be performed. Total RNA will be quantified, and the quality of RNA will be assayed using formaldehyde agarose gel electrophoresis and by determining the 260/280 absorbance ratio. One microgram of total RNA from each sample will be subjected to reverse transcription. One microliter of cDNA will be amplified via real-time PCR and 10 pmol of primers specific to IL23R, IL17, SGK1, RANBP1, TFGB. Real-time PCR assays will be performed in triplicate The specificity of the PCR products will be determined via melting curve analysis.
224164074|NCT00796224|DRUG|60 mg/kg azithromycin ER|subjects taken 60 mg/kg azithromycin ER
224164075|NCT00796224|DRUG|30 mg/kg azithromycin IR|subjects taken 30 mg/kg azithromycin IR (Immediate Release)
224164076|NCT03953885|OTHER|Fire needle|"1. Participants wear eye masks and fully expose the lesions. After selecting the acupuncture points, the surgeon routinely disinfects the hands of the operator and the acupuncture points of the participants before the operation. After selecting an acupuncture needle with a specification of 0.4\*40mm and ignites the alcohol lamp, the operator continuously moves the needle from the needle root to the needle tip to burn the red needle to disinfect the needle in the outer flame of the alcohol lamp.~2. The operator ignites the alcohol lamp, and burns the needle tip and the needle body to the outer flame of the alcohol lamp until it is completely red (the length of the needle burning red is determined by the acupuncture depth), and then rapidly penetrates the skin lesion vertically, the depth of the acupuncture is based on the thickness of the skin lesion, when the operation is performed, the outer edge of the lesion is punctured to the center point, and the spacing is 0.3 to 0.5 cm."
224164077|NCT03953885|OTHER|Fire needle Placebo|"1. Participants wear eye masks and fully expose the lesions (no lesions on the head and face, external genitalia and skin folds). After selecting the acupuncture points, the surgeon routinely disinfects the hands of the operator and the acupuncture points of the participants before the operation, then selects an acupuncture needle with a specification of 0.4\*40mm to prepare for operation.~2. The operator rapidly penetrates the skin lesion vertically, the depth of the acupuncture is based on the thickness of the skin lesion, when the operation is performed, the outer edge of the lesion is punctured to the center point, and the spacing is 0.3 to 0.5 cm."
224164078|NCT00661167|DRUG|ABI-007|ABI-007 260 mg/m2, IV on day 1 of each 21 day cycle. Number of cycles: until progression or unacceptable toxicity develops.
224164079|NCT01285336|GENETIC||
224164080|NCT02232724|DEVICE|Choline PET/CT and Dual time point FDG PET/CT|Choline PET/CT and dual time point FDG PET/CT
224164081|NCT05103241|DRUG|[14C] GP681|40 mg suspension containing 100μCi of \[14C\]GP681
224164082|NCT04195750|DRUG|Belzutifan|Oral tablets
224164083|NCT04195750|DRUG|Everolimus|Oral tablets
224164084|NCT06927154|OTHER|Mobilization with movement|Group A will receive Mobilization with movement in which therapist manually applies a gentle mobilizing force to the joint while the patient actively performs a movement (2 to 3 sets) 6 to 10 repetitions per set in sitting position. Conventional treatment (TENS (2 to 10 Hz),10 mints, Heating pad, stretching of tight muscles Trapezius and SCM)should be included.
224164085|NCT06927154|OTHER|Facet joint oscillatory mobilization|Group B will receive Facet joint oscillatory mobilization on the cervical spine C2-C7 (6 to 10 repetitions in each session) in the sitting position.Conventional treatment (TENS (2 to 10 Hz) 10 mints, Heating pad, stretching of tight muscles Trapezius and SCM) should be included.
224164086|NCT06369038|BEHAVIORAL|observation of level of dental anxiety in children|analysis of children's drawings using CD:H index
224164087|NCT05620069|OTHER|Music listening|Participants are asked to select one of four music playlists and listen to it for appr. 30 minutes at bedtime during the intervention period.
223478639|NCT05945407|COMBINATION_PRODUCT|Indication-extended Fertility-sparing Therapy|"Patients will receive medroxyprogesterone acetate (FARLUTAL) 250-500mg/d or megestrol acetate (YiLiZhi) 160-320mg/d orally. If there is no response after 6 months of treatment, change the regimen to levonorgestrel intrauterine system (Mirena) and gonadotropin-releasing hormone agonist (Leuprorelin, Goserelin or Triptorelin) 3.75mg/28d injection subcutaneously. After complete remission, the same regimen will be used for consolidation treatment for another 1-3 months. Subsequently, if the patient has no intention of pregnancy, render maintenance treatment (Mirena, Progesterone, Dydrogesterone, or combined oral contraceptive). Otherwise, the patient will be encouraged to conceive either by an expectation for 3-6 months, or by assisted reproductive technology. Indications for stopping fertility-sparing therapy: 1) disease progression; 2) no response after 9 months of treatment; 3) repeated recurrence; 4) no longer require sparing fertility; 5) serious adverse reactions."
223478640|NCT03897335|DRUG|Aminophylline|Aminophylline pre cardiopulmonary bypass and immediately post cardiopulmonary bypass. The dose will be Aminophylline 5 mg/kg/dose, max 350 mg slow infusion. The infusion rate duration will be standardized to 20 minutes. There will be no other aminophylline treatments for the first post-op five days.
223478641|NCT03897335|DRUG|Placebo|The placebo group will not receive any aminophylline treatments for the first post-op five days
223478642|NCT05563558|DRUG|Pembrolizumab|Included in arm/group description
223478643|NCT05563558|DRUG|Carboplatin|Included in arm/group description
223478644|NCT05563558|DRUG|Cabazitaxel|Included in arm/group description
224164088|NCT04220567|OTHER|Experimental: Exercise and Patient-centred education|"An eight-week programme based on 24 sessions of exercise supervised by a physiotherapist. Exercise will be carried out three times a week. Once a week the exercise session is performed autonomously by patient at home (according to the physiotherapist's recommendations).~Patient-centred Education will follow the principles of transformative learning \& incorporate patients' narratives. It will precede 9 of the 24 exercise sessions and be delivered by the same physiotherapist"
224164089|NCT04220567|OTHER|Active Comparator: Exercise|An eight-week programme based on 24 sessions of exercise supervised by a physiotherapist. Exercise will be carried out three times a week. Once a week the exercise session is performed autonomously by patient at home (according to the physiotherapist's recommendations).
224164090|NCT03559192|DRUG|JNJ-67953964|JNJ-67953964 10 mg will be administered as two 5-mg capsules orally once daily.
224164091|NCT03559192|DRUG|Placebo|Matching placebo will be administered as 2 capsules orally once daily.
223584160|NCT05969132|PROCEDURE|Fully digital guided gingivectomy procedure|"1. Full history with clinical and radiographic examination (CBCT) to aid in patient's selection.~2. Supra- and sub-gingival debridement.~3. Oral hygiene instructions (OHI)~4. Presurgical intraoral scanning using an intraoral scanner (IOS)~5. Fabrication of the Gingivectomy guide:~   * Convert (DICOM) file to STL file then merged to STL file corresponding oral soft tissues 3D data obtained by IOS using software of surgical planning.~  * Digital waxing up with new desired positions of gingival margins and zenith points performed.~  * Designing Gingivectomy guide then exported to a 3D printer and mill a transparent resin gingivectomy guide.~6. Surgical Procedure: anesthetized the patient using local anesthesia, Surgical incision using 15c blade following CEJ anatomy will be made at each tooth using the Gingivectomy guide as reference to new gingival level and being careful to preserve the gingival papillae without involving the palatal surfaces.~7. Postoperative care"
224164092|NCT03517722|DRUG|Placebo|Participants will receive placebo matching to ustekinumab IV or SC.
224164093|NCT03517722|DRUG|Ustekinumab (approximately 6 mg/kg)|Participants will receive ustekinumab approximately 6 mg/kg via IV route based on body weight-range.
223584161|NCT05969132|PROCEDURE|Convectional guided gingivectomy procedure|"1. Full history with clinical and radiographic examination (CBCT) to aid in patient's selection.~2. Supra- and sub-gingival debridement with OHI~3. Gingivectomy guide fabrication:~   * Impressions and casts obtained.~  * Waxing-up included new positions of gingival margins and zenith points.~  * Silicone index with condensation silicone impression materials made with pressure on the cast to reproduce the details of the wax, then filled after setting with resin material and placed in the patient's mouth.~  * Resin mock-up trimmed with blade to define the correct new gingival level.~  * After the patient accept the mock-up design will used as Gingivectomy guide.~4. Surgical Procedure: anesthetized the patient using local anesthesia, Surgical incision using 15c blade following CEJ anatomy will be made at each tooth using the Gingivectomy guide as reference to new gingival level and being careful to preserve the gingival papillae without involving the palatal surfaces.~5. Postoperative care"
223584162|NCT04476875|OTHER|Open Outpatient Clinic Programme|
224164094|NCT03517722|DRUG|Ustekinumab 90 mg|Participants will receive 90 mg ustekinumab via SC route.
223584163|NCT01267175|DEVICE|X54 insulin pump with low suspend feature|Change from current insulin pump to new X54 pump
224164095|NCT02863705|DRUG|brimonidine tartrate/timolol malate Ophthalmic Solution|One drop of brimonidine tartrate/timolol malate (COMBIGAN®) Ophthalmic Solution in the affected eye, administered twice daily for 12 months
224164096|NCT02863705|DRUG|bimatoprost ophthalmic solution 0.01%|Bimatoprost ophthalmic solution 0.01% (LUMIGAN®) administered once daily in the evening 5 minutes after COMBIGAN® instillation if additional lowering IOP is needed
224164097|NCT01961128|BEHAVIORAL|Exercise Intervention|
224164098|NCT06930170|DEVICE|Cochlear implantation|During surgery at 8 weeks after inclusion, cochlear implant is implanted
224164099|NCT06930170|DEVICE|CROS or BiCROS device fitting|At 8 weeks after inclusion, CROS or BICROS (depending on the type of hearing loss) is fitting
224164100|NCT06930170|DIAGNOSTIC_TEST|French simplified matrix test (FraSimat)|The FraSimat is an adaptive test that measures speech intelligibility in noise. It consists of 14 sentences of 3 words each, recorded in the presence of background noise. The FraSimat will be performed in two different configurations in relation to the source of the signal and noise before implantation or fitting, and 1, 2, 3 and 4 months after.
224164101|NCT06930170|DIAGNOSTIC_TEST|Sound localization test (ERKI)|"ERKI for German Erfassung des Richtungshörens für Kinder is an automated test that assesses spatial localization skills. The test is performed with the child seated facing a semi-circular table, surrounded by a set of 5 loudspeakers arranged 1 meter apart.~The test consists of 5 stimuli, followed by 42 trials. Following the presentation of each stimulus, the child must turn a control knob and direct the LED light to the point where he or she has perceived it. The child validates his or her response by pressing the button.~ERKI is evaluated before implantation or fitting, and 1, 2 and 3 months after."
224164102|NCT06930170|DIAGNOSTIC_TEST|Cortical Auditory Evoked Potentials (PEAc)|"The recording of Auditory Cortical Evoked Potentials provides an objective means of assessing the maturation of the auditory system and its ability to process auditory signals. AEPs consist of a series of cortical responses to an auditory stimulus.~PEAc are assessed using a non-invasive EEG recording, made under quiet wakefulness. Four surface electrodes are glued to the patient's skull: one on the vertex, one on the forehead, and one on each mastoid. The latency (msec) and amplitude (mV) values of each of the four component waves will be analyzed.~PEAc is evaluated before implantation or fitting, and 3 and 4 months after."
224164103|NCT06930170|OTHER|Speech, Spatial and Qualities of Hearing Scale (SSQ)|"The Speech, Spatial and Qualities of Hearing Scale is a questionnaire for subjective evaluation of listening performance in everyday listening situations. The parent version is adapted for parents of hearing-impaired children.~SSQ is evaluated before implantation or fitting, and 4 months after."
223584164|NCT01013363|OTHER|iPod Nano digital music player|Digital music player pre-loaded with 10 playlists to be used intra-operatively by the participant randomized to the intervention group.
223584165|NCT01702168|OTHER|Provider training: Cognitive Processing Therapy (CPT)|
223584166|NCT02395211|BEHAVIORAL|Usual Physiotherapy|"Usual physiotherapy consist of active or passive mobilization, extensor digiti and carpi functional electric stimulation, occupational therapy and taping.~The intervention will last 30 minute a day x 4 weeks"
224164104|NCT06930170|OTHER|Peabody Picture Vocabulary Scale (PPVT or EVIP in french)|"Peabody Picture Vocabulary Scale assesses the extent of French listening vocabulary acquired by the child.~The PPVT is designed for patients aged from 2 years and 6 months to 18 years. The raw score is the number of images correctly identified.~Peabody Picture Vocabulary Scale is evaluated before implantation or fitting, and 4 months after."
224164105|NCT06930170|OTHER|NEPSY-II (A Developmental Neuropsychological Assessment)|"The NEPSY-II (A Developmental Neuropsychological Assessment) is a battery of neuropsychological tests designed to assess children's skills in 6 major neuropsychological domains. The various tests are validated for the age range indicated in brackets, and will be used for patients aged 5 and over.~NEPSY-II is evaluated before implantation or fitting, and 4 months after."
224164106|NCT06930170|OTHER|Pediatric Quality of Life Inventory™ Multidimensional Fatigue Scale (PedsQL MFS)|PedsQL MFS is a questionnaire used to assess subjective experiences of fatigue. The questionnaire consists of 18 items The parent version is adapted for parents of hearing-impaired children. PedsQL MFS is evaluated before implantation or fitting, and 4 months after.
224164107|NCT02422186|DRUG|Esketamine|All participants will start with first dose (Day 1 as 28 milligram \[mg\]); second dose (Day 4) is either 28 or 56 mg. All subsequent doses may be 28, 56 or 84 mg. After the first dose, all dosing decisions are determined by the investigator based on efficacy and tolerability.
223584167|NCT02395211|DEVICE|Gloreha device|Proprioceptive stimulation under visual feedback are provided by the Gloreha device. The intervention will last 30 minute a day x 4 weeks
223584168|NCT03546218|DEVICE|Smartphone Application (SPSRS)|"Participants use application on iPhone and watch videos showing positive-word stimuli. This application repeats positive-word stimuli every 5 seconds.~The participants watch 3-minute motion picture displaying positive-word stimuli."
223584169|NCT03546218|DEVICE|Smartphone Application (YouTube)|Participants will watch the same motion picture as the experimental group. However, a positive-word stimulus does not appear in the motion picture.
223584170|NCT00875173|DRUG|Selenium|selenium as a drug according to Brazilian regulation laws
223584171|NCT00875173|DRUG|Placebo (for Selenium)|Placebo with similar flavor, smell and colour.
223584172|NCT06427694|DRUG|Aldesleukin|IL2 antagonist
223584173|NCT06427694|DRUG|Dextrose 5% in water|matched placebo to active
223584174|NCT00261508|DRUG|risperidone|
223584175|NCT01836081|OTHER|Volume expansion|
223584176|NCT00242333|DRUG|AD 237|
224164108|NCT02422186|DRUG|Placebo|Participants will self-administer matching placebo, intranasally, twice per week for 4-weeks as a flexible dose regimen in the Double-Blind Induction Phase.
224305146|NCT04162132|DEVICE|Smartphone app|Study procedures related to the DynamiCare Rewards intervention were conducted via smartphone. Research visits included collection of urine samples and medical exams. Participants assigned to the DynamiCare Rewards group received: 1) the app on their smartphone, 2) drug testing devices when indicated (pocket-sized breathalyzer), and a reloadable debit card for receiving the financial incentives (the PEX debit card). Global Positioning System (GPS) tracking was used to track whether patients had attended their scheduled appointments but was not used at any other times. All information was uploaded from the app onto the DynamiCare Analytics website, which treatment providers could view. The information reported was: attendance status of appointments, the status of all alcohol and drug testing, and incentives earned. Each patient's intervention period (period of time when they used the app) lasted four months from the date of their enrollment.
223584177|NCT04773873|DEVICE|PFM Crowns on gold coping cast-on|Classic impressions are taken by the operators and sent to one and same laboratory who will deliver all the screw-retained PFM restorations. The crowns will be made using a gold coping cast-on synOcta gold abutment (Ceramicor) for wide (WN) or regular (RN) neck
223584178|NCT04773873|DEVICE|hybrid abutment lithium disilicate crown|Intraoral digital impression with respective scanbodies (Sirona) for Cerec OmniCam or Cerec Bluecam over the chosen TiBase. Cerec CAD designing (operator) and CAM milling (Cerec MCXL) of single crowns with perforated blocs (e.max CAD). crystallization/ characterization/ glaze firing for the e.max CAD crown using an oven with specific firing programmes for e.max CAD. Adhesive cementation steps of the ceramic crown onto the TiBase
223584179|NCT04773873|DEVICE|hybrid abutment ceramic polymer infiltrated crown|Intraoral digital impression with respective scanbodies (Sirona) for Cerec OmniCam or Cerec Bluecam over the chosen TiBase. Cerec CAD designing (operator) and CAM milling (Cerec MCXL) of single crowns with perforated blocs (Enamic). Surface polishing with rubber polishers. Adhesive cementation steps of the ceramic crown onto the TiBase
223584180|NCT05208775|PROCEDURE|PDT|"Drug: (Hematoporphyrin sodium injection) Hematoporphyrin sodium injection (xibofen):2mg/kg I.V.~Laser irradiation:~48 hours after the patient input the photosensitizer, the laser irradiation time is 900 seconds, and the output power is 200 watts."
223584181|NCT05208775|PROCEDURE|ESD|The patients received standard endoscopic submucosal dissection after enrollment.
223584182|NCT00689754|PROCEDURE|nasogastric tube placement|standard nasogastric tube placement, aspiration and lavage up to 1L of normal saline
223584183|NCT04888143|OTHER|questionnaires|evaluation of hearing performance and quality of life questionnaires
223584184|NCT04888143|OTHER|Evolutionary algorithm|application of the evolutionary algorithm and customized frequency allocation on a separate program.
223584185|NCT03412149|PROCEDURE|Mini Gastric Bypass|"Standardization of the techniques will be guaranteed:~1. Mini Gastric Bypass Arm~2. Roux en Y Gastric Bypass arm All patients will have intraoperative measurement of the whole length of bowel from Treitz ligament to the ileocecal junction (expected range 6-8 m).The common limb will be therefore about 2/3 of total small bowel length."
223761374|NCT02953899|BEHAVIORAL|Contingency Management|In addition to Cognitive Behavioural Therapy, this intervention uses small incentives to reinforce study attendance and gambling abstinence.
223761375|NCT02953899|BEHAVIORAL|Cognitive Behavioural Therapy|This intervention uses psychoeducation, behavioural strategies, and cognitive restructuring to assist the participant in their efforts to become abstinent from gambling.
224164109|NCT02422186|DRUG|Duloxetine (Oral Antidepressant)|Duloxetine could be selected as the oral antidepressant medication by the investigator based on review of Massachusetts General Hospital -Antidepressant Treatment Response Questionnaire (MGH-ATRQ) and relevant prior antidepressant medication information. The minimum therapeutic dose is 60 milligram per day (mg/day).
223584186|NCT03412149|PROCEDURE|Roux en Y Gastric Bypass|"Standardization of the techniques will be guaranteed:~1. Mini Gastric Bypass Arm~2. Roux en Y Gastric Bypass arm All patients will have intraoperative measurement of the whole length of bowel from Treitz ligament to the ileocecal junction (expected range 6-8 m).The common limb will be therefore about 2/3 of total small bowel length."
223584187|NCT00311116|DRUG|Vitamin E|
224164110|NCT02422186|DRUG|Escitalopram (Oral Antidepressant)|Escitalopram could be selected as the oral antidepressant medication by the investigator based on review of MGH-ATRQ and relevant prior antidepressant medication information. Escitalopram will be given at a dose of 10 mg/day throughout the Double-Blind Induction Phase. This dose (10 mg/day) is the also the minimum therapeutic dose.
224164111|NCT02422186|DRUG|Sertraline (Oral Antidepressant)|Sertraline could be selected as the oral antidepressant medication by the investigator based on review of MGH-ATRQ and relevant prior antidepressant medication information. Sertraline may be titrated up to a dose of 150 mg/day, but if not tolerated the dose can be reduced to the minimum therapeutic dose of 50 mg/day.
224305147|NCT00183937|DRUG|PS 341|PS 341 1.6 mg/m2 IV (in the vein) on days 1 and 8 of each 21 day cycle up to 12 cycles.
224164112|NCT02422186|DRUG|Venlafaxine Extended Release (XR) (New Antidepressant)|Venlafaxine Extended Release could be selected as the oral antidepressant medication by the investigator based on review of MGH-ATRQ and relevant prior antidepressant medication information. Venlafaxine Extended Release may be titrated up to a dose of 150 mg/day, but if not tolerated the dose can be reduced to the minimum therapeutic dose of 75 mg/day.
224164113|NCT06904196|COMBINATION_PRODUCT|Lenvatinib plus SIRT|Lenvatinib 12mg (body weight ≥60kg) or 8mg (body weight \<60kg) P.O. QD will be started at 3-7 days after the first SIRT.
224164114|NCT06904196|DRUG|Lenvatinib|Lenvatinib 12mg (body weight ≥60kg) or 8mg (body weight \<60kg) P.O. QD.
224164115|NCT00321009|DRUG|Enoxaparin|
224164116|NCT02150291|DIETARY_SUPPLEMENT|Folic acid|
224164117|NCT02150291|DRUG|Neurobion|
224164118|NCT02150291|DRUG|placebo|
224164119|NCT05016440|DRUG|Lisinopril|10mg Lisinopril daily for 6-8 weeks postpartum
224164120|NCT02762760|BIOLOGICAL|AMPION™|AMPION™, up to 3 mL, single intra-articular injection. Ampion is the ultrafiltrate of 5% HSA.
224164121|NCT02762760|BIOLOGICAL|Saline|Saline placebo, up to 3 mL, single intra-articular injection. Saline used as the comparator is 0.9% Sodium Chloride
224164122|NCT06939582|DRUG|Hydroxychloroquine Sulfate Tablets|the trial group use the hydroxychloroquine sulfate tablets (200mg/time, bid)
224164123|NCT06939582|OTHER|Placebo|the control group use the Placebo
224164124|NCT06942702|DRUG|Genicular blocks (bupivakain)|Genicular block is a regional analgesic technique performed with USG
224164125|NCT06942702|DRUG|Patient Control Analgesia (PCA) Morphine group|this group consists of the patients no any intervention preoperatively and they will be given morfin with PCA (Patient controlled analgesia) and paracetamol 3x1000 mg intravenous and diclofenac 75 mg intramuscular (if needed)
224164126|NCT06942702|DRUG|Paracetamol (acetaminophen) + Diclofenac Sodium|All patients are given paracetamol (3x1000 mg) and diclofenac (if needed)
224164127|NCT06937047|PROCEDURE|cold snare polypectomy|Cold snare polypectomy was conducted for the removal of 4-10 mm pedunculated colorectal polyps.
224164128|NCT06937047|PROCEDURE|hot snare polypectomy|Hot snare polypectomy was conducted for the removal of 4-10 mm pedunculated colorectal polyps.
224164129|NCT06942793|DRUG|CsA-PG Ophthalmic Gel|Administer to eyes
224164130|NCT06942793|DRUG|CsA Ophthalmic Gel|Administer to eyes
224164131|NCT06939608|DIETARY_SUPPLEMENT|Yohimbine|A single oral dose of 50 µg yohimbine, administered as 2 x 1 tablets of Yohimbinum hydrochloricum D4® will be co-administered with 25 mg of ¹³C₃-caffeine as drinking solution with 240mL of still water under overnight fasting conditions. A total of 19 blood samples will be collected at defined time points (baseline; 10; 20; 30; 40; 50; 60; 70; 80; 90; 100; 110 min; 2; 3; 4; 6; 8; 10; 24 h). At each time point, 4.9 mL of blood will be drawn for plasma separation to determine yohimbine, the primary metabolite 11-OH-yohimbine and ¹³C₃-caffeine with associated CYP1A2 dependent metabolites.
224164132|NCT06939608|OTHER|¹³C₃-caffeine|A single oral dose of 25 mg of ¹³C₃-caffeine as a drinking solution will be co-administered with yohimbine with 240 mL of still water under overnight fasting conditions. ¹³C₃-caffeine is a stable isotope-labeled standard probe for phenotyping CYP1A2 activity and assessing potential interactions between CYP2D6 and CYP1A2. Plasma concentrations of ¹³C₃-caffeine with associated CYP1A2 dependent metabolites will be measured at predefined time points, following the sampling schedule outlined for yohimbine.
224164133|NCT06942871|DEVICE|Remote Dielectric Sensing|The lung fluid monitor Remote Dielectric Sensing (ReDS™) is the world's first non-invasive device for heart failure monitoring and management. It directly reflects lung fluid content by measuring changes in thoracic dielectric constants, with a detection range of 15% \~ 60%. The device can sensitively identify pathological states ranging from mild compensation to severe pulmonary edema. ReDS™ technology cannot directly measure pulmonary artery pressure, but changes in lung fluid content may indirectly reflect disease progression in certain types of pulmonary hypertension.
224164134|NCT04765449|DRUG|Cytotoxic T Lymphocytes|Given IV. Cytotoxic T Lymphocytes collected from healthy volunteer donors who have recovered from COVID-19. The T cells are collected, manufactured to be COVID-specific, and stored frozen at Thomas Jefferson University.
224164135|NCT03084432|DIAGNOSTIC_TEST|Dual Energy X-ray Absorptiometry|Dual Energy X-ray Absorptiometry done for both studied groups
224164136|NCT06940258|PROCEDURE|ultrasound measurement of caval aorta index|ultrasound measurement of caval aorta index
224164137|NCT06940258|OTHER|control group|fixed fluid prescription
224305148|NCT00183937|DRUG|Docetaxel|Docetaxel 75mg/m2 IV (in the vein) on day 1 of each 21 day cycle up to 12 cycles.
224305149|NCT04549935|DRUG|Dextenza|Dextenza 0.4mg
223478645|NCT01771926|OTHER|potatoes|Daily intake of assigned treatment for 8 weeks
223478646|NCT01771926|OTHER|other carbohydrate|Daily intake of assigned treatment for 8 weeks
223478647|NCT03703895|DRUG|Topical AFX5931|Active Comparator, Topical AFX5931, a medication combining a small, potent anti-inflammatory molecule.
224305150|NCT04549935|DRUG|Topical Prednisolone|Standard of care topical drop treatment
224305151|NCT01294826|DRUG|AUY922|Weekly intravenous infusion on Day 1, 8, 15 and 22 of each 28 day cycle until unacceptable toxicity develops or disease progression. A minimum of 3 patients will be enrolled into each cohort. The anticipated dose escalation sequence of AUY922 is 40, 55, and 70 mg/m2 will be used.
223478648|NCT03703895|DRUG|Topical Placebo|Placebo Comparator, Topical Placebo.
223478649|NCT00338117|DRUG|Galantamine hydrobromide|
223478650|NCT04694469|PROCEDURE|Closed reduction and percutaneous pinning (CRPP)|Operated for supracondylar humeral fractures
223478651|NCT00413517|PROCEDURE|Epi-Lasik|A vision correcting surgery
223478652|NCT03731013|BEHAVIORAL|Mediterranean diet (MedDiet)|Participants randomized in the Mediterranean diet group without physical activity will be instructed and supported towards adhering to principles of the Mediterranean diet, without changes in physical activity habits.
223478653|NCT03731013|BEHAVIORAL|Physical activity (PA)|Participants randomized in the group physical activity without Mediterranean diet will participate in a structured, supervised PA program to achieve 150 min of moderate PA per week, without changes in dietary habits.
223478654|NCT03731013|BEHAVIORAL|Mediterranean diet and physical activity|The combination group (MedDiet + PA) will receive the combination of both interventions.
224164138|NCT06943456|PROCEDURE|Transversus Abdominis Plane (TAP) Block for Postoperative Pain Management|The intervention involves the administration of a Transversus Abdominis Plane (TAP) block performed at the end of an open appendectomy surgery. A mixture of 10 ml of 1% lignocaine and 10 ml of 0.5% bupivacaine is injected into the transversus abdominis plane, located between the transversus abdominis and internal oblique muscles, under direct vision. This procedure aims to provide localized pain relief by blocking the sensory nerves of the anterior abdominal wall, reducing the need for systemic opioid analgesics during post-operative recovery
224164139|NCT06943456|PROCEDURE|Standard Open Appendectomy with Postoperative Pain Management|The intervention involves the standard open appendectomy surgical procedure without the addition of a Transversus Abdominis Plane (TAP) block. Postoperative pain management in this group is managed using standard opioid analgesics. No local anesthetic block is performed, and pain management is entirely reliant on systemic medications, including opioids, for post-operative recovery
224164140|NCT06943547|BEHAVIORAL|Arm 2: Patient Navigator|The patient navigation model used in the study is aligned with the conceptual model for cervical cancer screening proposed by the Population-based Research Optimizing Screening Through Personalized Regimens (PROSPR) consortium. The initial contact, as well as most navigation activities, will occur mostly over the phone. In our study, the roles of the patient navigator (Arms 2 and 4) will include: exploring individual barriers to screening, use of motivational interviewing to educate and encourage patients to perform screening, performing reminder calls, and coordinating of referral and clinical services if needed. Also, providing other services to identify and overcome access barriers encountered during the cancer care process, including linkage to community resources. In arm 4, the patient navigator will also facilitate the explanation of the use of the self-collection kits by study participants.
224164141|NCT06943547|BEHAVIORAL|HPV self-collection kit|Each HPV testing kit will include an invitation letter, information sheet, one FLOQSwabs552C® and one sealable plastic bag to put the swab. Because home high risk (HR) HPV self-screening is not standard of care in the US, the kit will also include a letter advising women to receive routine Pap tests, regardless of their HR-HPV self-sampling results. Detailed instructions on how to collect the cervical sample and how to mail the kit back to the study site or bring it to the clinical visit (depending on their preference) will be included.
224164142|NCT06944717|BIOLOGICAL|VXA-G1.1-NN|Legacy vaccine, administered orally.
224164143|NCT06944717|BIOLOGICAL|VXA-G2.4-NS|Legacy vaccine, administered orally.
224164144|NCT06944717|BIOLOGICAL|VXA G1.1 NN-T|Next generation vaccine, administered orally.
224164145|NCT06944717|BIOLOGICAL|VXA G2.4 NS-T|Next generation vaccine, administered orally.
224164146|NCT05514925|DRUG|Bevacizumab Injection [Avastin]|Intravitreal injection of bevacizumab (1.25 mg, 0.05 ml) in the inferior temporal quadrant of the eye, 4 mm behind the limbus in phakic eyes, and 3.5 mm in pseudophakic eyes.
224164147|NCT05514925|PROCEDURE|Peripheral Retinal Cryoapplication|In the operating room under peribulbar anesthesia, four focal conjunctival incisions are made on each quadrant between the muscles insertions. The Tenon capsule is opened with scissors to expose the sclera. Four to six cryo-applications are made per quadrant, at the edge of muscle insertion and a line behind. The exposure time is 4 to 5 seconds. 7-0 resorbable sutures are then put on each quadrant to close the conjunctiva.
224164148|NCT04347616|BIOLOGICAL|UCB-NK cells|Natural killer cells generated from CD34+ hematopoietic progenitor cells derived from an allogeneic umbilical cord blood
224164149|NCT04347616|DRUG|IL-2|In vivo cytokine support
224164150|NCT01455233|DRUG|besivance|topical ocular antibiotic, 1 drop in study eye QID starting 3 days prior and for 7 days following cataract surgery
224164151|NCT01455233|DRUG|vigamox|topical ocular antibiotic, 1 drop in study eye QID for 3 days prior and for 7 days following cataract surgery
224164152|NCT01831011|DRUG|mildronate injection|
224164153|NCT01831011|DRUG|cinepazide maleate injection|
224164154|NCT01831011|DRUG|aspirin|
224164155|NCT02793804|DEVICE|Oraquick (made in Thailand)|
223478655|NCT01102634|DEVICE|Transcutaneous electrical nerve stimulation (TENS)|Application of TENS over acupuncture points
223478656|NCT01102634|DEVICE|Transcutaneous electrical nerve stimulation (TENS)|Placebo
223478657|NCT02437292|OTHER|Ischemic compression with stretching|
223478658|NCT05998967|BEHAVIORAL|Mobile Mantram Repetition Program|Internet-based instruction in a meditation practice that involves silent repetition of a spiritual word, one-pointed attention and slowing down
223478659|NCT01980758|PROCEDURE|Laparoscopic Gastric Plication|The study will examine the effects of a type of weight loss surgery on obese adolescents age 14-19. ) The study protocol includes pre-treatment assessments followed by a 2-month education and lifestyle modification treatment program. Following surgery, comprehensive follow-up care will be provided over a 3 year period.
223584188|NCT00286221|DRUG|PCA fentanyl|"PCA fentanyl 0.5 ug/kg with a dosing interval (lockout) of 15 minutes and a maximal permitted dosage of 4 demand doses per hour, according to their randomized preoperative assignment. The PCA pump (CADD-Solis Ambulatory Infusion Pump; Smiths Medical, Dublin, OH) had a preprogrammed dose limit of 50 ug fentanyl, and this was the maximal PCA dose permitted"
223584189|NCT00286221|DRUG|PRN fentanyl|IV fentanyl 25 to 50 ug every 30 minutes PRN (the maximal routine dose permitted in our Neurosciences Critical Care Unit (NCCU))
224164156|NCT01425307|DRUG|Hydroxyurea|Capsules (300 mg, 400 mg, or 500 mg) taken once daily liquid formulation (100 mg/mL)
224164157|NCT04553978|DRUG|WD-1603|WD-1603 CARBIDOPA/LEVODOPA EXTENDED-RELEASE TABLETS
223478660|NCT04418947|OTHER|Communication type|Control letter vs. intervention letter
223478661|NCT02152007|DRUG|1% sirolimus cream (TD201 1%)|1% sirolimus cream (TD201 1%)
223478662|NCT01792232|OTHER|Allergen|Subject specific allergen is placed in the lungs on day 1 of each triad
223478663|NCT01792232|OTHER|Saline|Saline will be placed in the lung on day 1 of each triad
223478664|NCT03316105|DEVICE|Elira Investigational TENS device|TENS unit placed on skin will deliver electric stimulation to abdominal area.
223478665|NCT03318172|DEVICE|Spinal Cord Stimulator|Implantation of spinal cord stimulator in patients included in the study and divided in conventional and high density stimulation groups
223478666|NCT05569096|DIAGNOSTIC_TEST|ELIZA , Flowcytometry|CD25 , CXCL9 by ELISA. T cell population , T regulatory cells by Flow cytometry.
223478667|NCT05755126|BEHAVIORAL|Iatrosedation|Alleviating the anxiety of patients by iatrosedative interview and clinical encounter
223478668|NCT05755126|BEHAVIORAL|Musical Therapy|Patients were provided with headphones and a playlist to listen to the music of their choice for 10 minutes
223478669|NCT02023489|DEVICE|1H/ 13C and 31P Magnetic Resonance Spectroscopy|Study participants will be studied in the fasting state after an overnight fast of at least 10 h. Participants will arrive at the MR-Centre in the morning of the study. Between 6:30 and 10:00 a.m., 1H MRI (3T) will be performed for the assessment abdominal adipose tissue distribution and composition as well as myocardial functional parameters. 1H/13C MRS examinations (7T) will be performed for measurements of myocardial, skeletal muscle and liver lipid content and composition as well as glycogen content. Additionally, ATP synthesis and energy metabolism will be assessed.
223478670|NCT02023489|OTHER|Meal Tolerance Test|"A meal tolerance test meal tolerance test according to Petersen et al. (PNAS, Vol 104, 2007) will be performed. After MRI and MRS examinations subjects will be returned at our outpatients clinic, where small polyethylene catheter will be inserted in an antecubital vein for hourly blood sampling. At 10:30 a.m. and 1:30 p.m. two liquid high carbohydrate meals of equal size containing all the required daily energy (30 kcal/kg of body weight; 55% carbohydrate, 10% protein, and 35% fat) with an additional 25% of the daily energy requirements added in the form of sucrose will be served.~At 5 p.m. subjects will be returned at the MR - Centre for postprandial 1H / 13C MRS (7T) of muscle, liver and myocardial lipid and glycogen contents. Myocardial function parameters and abdominal fat distribution will be assessed again by 1H MRI (3T)."
224164158|NCT03573804|OTHER|Prone to Supine MRI|The patient will be placed in the prone position and undergo a standard Gd contrast-enhanced bilateral breast MRI. Immediately after the prone MRI is completed, the patient will be repositioned for the supine MRI. Prior to starting the prone MRI, the study MRI technician/investigator will explain to the patient and practice with the patient the steps needed to transition from the prone to the supine MRI, so as to facilitate a timely transition. Additional MRI images will only take about 10-15 minutes to obtain and will not require a second injection of contrast material.
224164159|NCT02741089|PROCEDURE|Indication for a flexible bronchoscopy|"The data of patients are collected within the hospital routine documentation during the flexible bronchoscopy. The bronchoscopy is performed regardless of this study. Following the bronchoscopy the patients are asked a few questions about their health and their perception.~The follow-up of all patients is done via phone calls in order to collect data about the outcome of each patient."
223584190|NCT02447094|DRUG|Alteplase|Intravenous (i.v.) tPA per the standard of care
223584191|NCT00889200|DRUG|eszopiclone|6 weeks standard oral therapy
223584192|NCT00154362|DRUG|Oxcarbazepine|
223584193|NCT01839136|PROCEDURE|Intrauterine transfer of gametes|
223584194|NCT01839136|PROCEDURE|Intrauterine transfer of embryos|
223584195|NCT02553538|BEHAVIORAL|Patient Navigation|Navigators utilized TopCare to track participants, reach out to them in their own language, and provide intense outreach to help them complete cancer screening.
224164160|NCT02578095|DRUG|VK5211|Capsule
224164161|NCT02578095|DRUG|Placebo|Capsule
224164162|NCT06942676|BEHAVIORAL|Core Exercise Program|This intervention consists of a 4-week core training program including exercises like planks, side planks, bird-dogs, bridges, and dead bugs, performed 3 days per week alongside regular soccer training. Each session lasted approximately 25-30 minutes.
224164163|NCT06949852|DRUG|Nalbuphine Hydrochloride Injection|PCIA，The lockout interval is set at 10 minutes, with no background infusion.
224164164|NCT06949852|DRUG|Morphine Hydrochloride Injection|PCIA，The lockout interval is set at 10 minutes, with no background infusion.
224164165|NCT06948240|OTHER|AF related coronary embolism|AF related coronary embolism
224164166|NCT06948357|DRUG|BRIMOCHOL PF eye drops; CARBACHOL PF eye drops; Brimonidine eye drops; Placebo|BRIMOCHOL PF eye drops, CARBACHOL PF eye drops, Brimonidine eye drops and Placebo were administered in 7 treatment sequences in various combinations and doses
224205401|NCT03039517|DEVICE|ACTitouch|The device is applied to the lower leg (calf, ankle, and foot) and consists of an under-sock worn against the skin, a compression sleeve containing 4 inflatable chambers and a controller unit. The controller provides the airflow to inflate the chambers and monitors and adjusts the chamber pressure to maintain the intended treatment pressures.
223584196|NCT06373887|DIETARY_SUPPLEMENT|plant-based Low carbohydrate diet|In the research, the high, medium, low carbohydrate degradation subjects were randomized to either plant-based Low carbohydrate diet or low fat diet to loss weight.
223584197|NCT06373887|DIETARY_SUPPLEMENT|plant-based Low low fat diet|In the research, the high, medium, low carbohydrate degradation subjects were randomized to either plant-based Low carbohydrate diet or low fat diet to loss weight.
223584198|NCT02115360|DRUG|Calcitonin|Under full aseptic conditions, the epidural space was identified at the L 2-3 or L 3-4 lumbar interspace using the loss-of-resistance to saline technique using 16-gauge Tuohy needle. A test-dose of 3 mL of a 2% solution of lidocaine with adrenaline (1:200,000) will be given to exclude subarachnoid or intravenous catheter placement. An injection of a2 ml hyperbaric bupivacaine will be injected into the subarachnoid space through 25 gauge spinal needle, then 15ml 0.5% bupivacaine, 100 micrograms of fentanyl and 1ml normal saline will be injected epidurally in Bupivacain- fentanyl (BF) Group, then a 16G Portex catheter was inserted for post- operative analgesia.
223584199|NCT02115360|DRUG|Fentanyl|Under full aseptic conditions, the epidural space was identified at the L 2-3 or L 3-4 lumbar interspace using the loss-of-resistance to saline technique using 16-gauge Tuohy needle. A test-dose of 3 mL of a 2% solution of lidocaine with adrenaline (1:200,000) will be given to exclude subarachnoid or intravenous catheter placement. An injection of a2 ml hyperbaric bupivacaine will be injected into the subarachnoid space through 25 gauge spinal needle, then 15ml 0.5% bupivacaine, 100 micrograms of fentanyl and 1ml normal saline will be injected epidurally in Bupivacain- fentanyl (BF) Group, then a 16G Portex catheter was inserted for post- operative analgesia.
223584200|NCT02789891|PROCEDURE|D2 lymphadenectomy including No. 14v|After exclusion of T4b, or distant metastasis case by diagnostic laparoscopy, Laparoscopic distal with D2 lymphadenectomy including No. 14v Lymph Node Dissection will be performed with curative treated intent. The type of reconstruction will be selected according to the surgeon's experience
224305152|NCT01294826|DRUG|Cetuximab|Cetuximab will be administered after each AUY922 infusion, intravenously on Day 1, 8, 15 and 22 of each 28 day cycle until unacceptable toxicity develops or disease progression.
224164167|NCT06949839|DEVICE|Therapeutic exercise program combined with RMT|"For the RMT protocol, the Orygen-dual valve® device will be used. Each participant will start with a load of 30% of the maximal inspiratory pressure (MIP) and maximal expiratory pressure (MEP). Once every 10 days, the performance will be reviewed and the resistance will be increased by 10cmH2O of the initial MIP/MEP of each patient. Each session will consist of breathing through the device for 20 minutes (10 minutes dedicated to each muscle group). This process will be repeated once a day, five days a week, for eight weeks.~The therapeutic exercise program will be common to both groups and will be carried out at CHUAC hospital, in group sessions. The sessions will be held three days a week, for eight weeks. Each session will consist of a 10-minute warm-up part, 45 minutes of the main part (aerobic and strength-resistance exercise), and five minutes of cooling down."
224164168|NCT06949839|DEVICE|Therapeutic exercise program combined with sham RMT|The sham RMT protocol will have the same frequency as in the intervention group. The therapeutic exercise program will be common to both groups and will be carried out at CHUAC hospital, in group sessions. The sessions will be held three days a week, for eight weeks. Each session will consist of a 10-minute warm-up part, 45 minutes of the main part (aerobic and strength-resistance exercise), and five minutes of cooling down.
224164169|NCT06948539|DRUG|TQB2101 for injection|TQB2101 for injection is a receptor tyrosine kinase-like orphan receptor-1 antibody drug conjugate.
224164170|NCT06949501|OTHER|virtual patient simulation|Students in this group are expected to provide sexual counseling to a virtual patient model following theoretical training. In this context, a virtual patient model has been developed with whom the students will engage for the counseling process.
223584201|NCT02789891|PROCEDURE|lymphadenectomy excluding No. 14v|After exclusion of T4b, or distant metastasis case by diagnostic laparoscopy, Laparoscopic distal gastrectomy with D2 lymphadenectomy excluding No. 14v Lymph Node Dissection will be performed with curative treated intent. The type of reconstruction will be selected according to the surgeon's experience
224164171|NCT06949501|OTHER|peer simulation conducted in a virtual environment|Students in this group are expected to provide sexual counseling to their peers in a virtual environment following theoretical training. In the virtual peer simulation, students will see the same background displayed in the virtual patient simulation; however, instead of interacting with a virtual patient, they will connect with a peer via an online platform to conduct the counseling session.
224164172|NCT06949501|OTHER|face-to-face peer simulation|Students in this group are expected to provide sexual counseling to their peers following theoretical training. In the peer simulation, students will conduct their sessions in a communication skills laboratory designed to resemble a clinical consultation room.
224164173|NCT06949423|DEVICE|Deep Transcranial Magnetic Stimulation (dTMS) H7 coil - Active|The study will utilize the H7 coil to administer active Deep Transcranial Magnetic Stimulation (dTMS) to the dorsal anterior cingulate cortex (dACC), a core salience network node.
224164174|NCT06949423|DEVICE|Deep Transcranial Magnetic Stimulation (dTMS) H7 coil - Sham|The study will utilize an identical protocol using the H7 coil to administer a sham condition.
224164175|NCT06949917|DIETARY_SUPPLEMENT|body mass index for age|different body mass index according to age (normal weight,overweight,obeiece)
224164176|NCT06949878|DRUG|Antivet|"Complete stain removal from the Enamel-Use a compact cotton swab (3 mm) to apply Antivet solution (Dental Continental, México)to the stained dental piece according to manufacturer's instructions.-Replace the swab as it becomes stained and continue until the stain is removed.  This may take 1-5 minutes per tooth, but do not exceed 15 minutes in total.  - We will keep the tooth moist during the process for effective results and avoid reusing stained cotton swab.-Then we will apply the neutralizing solution to the tooth with a brush or micro brush, ensuring it reaches the gingival margin. Leave it on for 2 minutes.-Once the antivet solution is neutralized, rinse the area and remove the rubber dam."
224164177|NCT06949878|DRUG|opalustre|Complete stain removal from the Enamel. Product will be applied to the surface with a 1 mm thick layer; ten applications of 60s to help penetration of the gel into the enamel.- Using an abrasive rubber cup (OpalCup™ Ultradent) in contra-angle low-speed handpiece at low revolution.- Then will be rinsed with injectable water for 30 seconds between each application.
224305153|NCT03751956|DRUG|HSK3486|The subjects will receive an intravenous injection of 0.8 μCi/0.4 mg/kg of \[14C\]HSK3486 emulsion injection (i.e., a subject with the body weight of 60 kg is administered with a radiation dose of 48 μCi).
223478671|NCT02023489|OTHER|Hyperglycemic-hyperinsulinemic clamp|"All volunteers will be admitted in the morning and basal 13C tracer enrichment will be assessed.~At 8:00a.m. (0 min) a hyperglycemic-hyperinsulinemic-pancreatic clamp test will be initiated by somatostatin (-5-300 min: 0.1 µg·kg-1·min-1, UCB Pharma, Vienna, Austria) and insulin (0 - 8 min: 80 mU·min-1·m-2 body surface area; 8 -300 min: 40 mU·min-1·m-2 body surface area) infusion. Plasma glucose will be raised and maintained at \~180 mg·dL-1 by primed (0.2 g·kg-1)-variable dextrose infusion (20%w/v) enriched with \[1-13C\]glucose (40%w/w). A second catheter will be placed into an antecubital vein of the other arm and blood samples for the measurement of glucose, insulin and c-peptide. Glucose concentrations will be analysed immediately every 5 minutes, employing a glucose analyser. Myocardial glycogen concentrations will be measured before the clamp (-60 - 0 min) and from 90 min to 180 min during the clamp employing 13C MRS."
223478672|NCT06004960|DRUG|[14C]CCX168|Administered orally.
223478673|NCT05531955|DRUG|Pirfenidone Oral Capsule|pirfenidone capsules were added to patients receiving basic treatment
223478674|NCT05531955|OTHER|Placebo Oral Capsule|placebo oral capsules were added to patients receiving basic treatment
223478675|NCT01530919|PROCEDURE|Minimally invasive radioguided parathyroidectomy|After the patient is prepared for surgery and under local anesthesia, the initial incision by the surgeon will be 2-3 cm. The surgeon will dissect in the designated quadrant until the parathyroid gland is identified.
223478676|NCT00706797|DRUG|etanercept (EnbrelTM)|
223478677|NCT00706797|DRUG|methotrexate|
223584202|NCT04284566|BEHAVIORAL|TAU + multicomponent treatment FIBROWALK|"Group treatment protocol of 12 weekly 120 minute sessions. All sessions include the following ingredients (approx. in the same order):~* Pain neuroscience education (30 min.)~* Cognitive restructuring (30min.)~* Mindfulness techniques (30 min.)~* Physical exercise(30 min.)~* Treatment as Usual (TAU) Standard pharmacological treatment usually provided to patients with fibromyalgia."
223478678|NCT02039349|DRUG|PF-05190457|
223478679|NCT02197156|DRUG|10 mg HC-ER|Single dose
223478680|NCT02197156|DRUG|20 mg HC-ER|Single dose
224164178|NCT06948370|BEHAVIORAL|Intervention Name: PARADIGM-Q Diabetes Self-Management Education Program|PARADIGM-Q Diabetes Self-Management Education Program This is a culturally sensitive, structured education intervention tailored for adults with Type 2 Diabetes in Qatar. Developed using the PARADIGM model and delivered through a Case-Based Learning (CBL) approach, the program comprises three weekly group sessions of 3.5 hours each. Each session targets key self-management attributes: problem-solving, decision-making, taking action, resource utilization, and patient-provider relationships. The program emphasizes real-life applicability, cultural relevance, and skill-building to support sustainable diabetes self-care.
224305154|NCT01751035|BEHAVIORAL|Risk Reduction through Family Therapy|RRFT is an integrative, ecologically-based approach to risk reduction and treatment. A Stage 1a feasibility trial and a Stage 1b pilot randomized controlled trial (RCT) evaluating RRFT have been completed. This Stage 1 work has resulted in a treatment manual, a clinician training protocol, and a quality assurance system. Preliminary findings from these studies are promising, indicating that RRFT can be readily learned and implemented with fidelity, and that it can lead to improvements in drug use and drug use-related risk and protective factors, PTSD symptoms, and risky sexual behaviors.
223478681|NCT02197156|DRUG|30 mg HC-ER|Single dose
224164179|NCT06948370|BEHAVIORAL|Control Arm (DESMOND): DESMOND Diabetes Self-Management Education Program|The DESMOND Diabetes Self-Management Education Program is the standard diabetes education intervention currently offered to newly diagnosed patients with Type 2 Diabetes in Qatar. It is a UK-developed, theory-driven program delivered over two group sessions, each lasting approximately four hours. The program provides structured education on diabetes, lifestyle management, and risk reduction strategies. It does not incorporate case-based learning or cultural tailoring, distinguishing it from the experimental PARADIGM-Q intervention. DESMOND is used here as an active comparator to evaluate the added value of culturally sensitive, problem-based education.
224164180|NCT06948201|DIETARY_SUPPLEMENT|70mL Nitrate Rich Beetroot Juice followed by placebo (Nitrate depleted beetroot juice)|70mL Nitrate Rich Beetroot Juice for 14 days followed by placebo (Nitrate depleted beetroot juice) for 14 days
224164181|NCT06948201|DIETARY_SUPPLEMENT|Placebo (70 mL Nitrate depleted beetroot juice) followed by 70mL Nitrate Rich Beetroot Juice|Placebo (70 mL Nitrate depleted beetroot juice) for 14 days followed by 70mL Nitrate Rich Beetroot Juice for 14 days
224164182|NCT06949189|PROCEDURE|Nail Bed Repair with Nail Bed Coverage|Following debridement and suturing of the nail bed, the fingernail will be replaced and secured with a figure-of-eight suture using Prolene. A low-adherent dressing will be applied. If the fingernail is unavailable (e.g., due to damage or loss), a substitute material (such as foil) will be chosen by the operating surgeon
224164183|NCT06949189|PROCEDURE|Nail Bed Repair without Nail Bed Coverage|Following debridement and suturing of the nail bed, the fingernail will be discarded. A low-adherent dressing will be applied without any covering of the nail bed
224164184|NCT06949267|BIOLOGICAL|iMSC|1× 10\^6/kg each time, twice a week
224164185|NCT06949267|COMBINATION_PRODUCT|conventional aGVHD prophylaxis|Cyclosporine or tacrolimus(CNI)+Mycophenolate mofetil(MMF)± Short Course Methotrexate(MTX)+Anti-human T-lymphocyte Globulin（ATG）
224164186|NCT06950086|DRUG|TYK-00540|Increased dose cohorts from low to MTD (5mg Cohort 1;10 mg Cohort 2; 20 mg Cohort 3; 30 mg Cohort 4;40 mg Cohort 5) decreased dose cohorts for the combination (TYK-00540 30 mg+Fulvestrant Cohort 1;TYK-00540 20mg +Fulvestrant)
224164187|NCT06949904|DRUG|Melatonin|1 mg/dose in infants and 2.5 to 3mg/dose in children three times a day for 14 days
224164188|NCT06948383|PROCEDURE|Serratus Posterior Superior Intercostal Plane Block|administer 30 mL %0.25 bupivacain between third costa and serratus posterior superior muscle
224164189|NCT06948383|PROCEDURE|Serratus Anterior Plane Block|administer 30 mL %0.25 bupivacain between 5th costa and serratus anterior muscle in midaxiller line
224164190|NCT01766765|PROCEDURE|Jejunostomy|Routine placement of jejunostomy tube following laparoscopic gastrectomy for gastric cancer. Immediately drip 37°C saline 20 ml/h and exchange to drip 37°C enteral nutrition fluid 20 ml/h at postoperative 6 h via jejunostomy tube
224164191|NCT01766765|OTHER|Early oral nutrition|Free oral nutrition as tolerance allows on POD 1.
224305155|NCT01751035|BEHAVIORAL|Treatment as Usual|Participants assigned to the TAU condition will receive the standard treatment that a CSA victim would typically receive at community advocacy centers. In addition to treatment that is typically offered at the CACs, this will include a referral for substance abuse evaluation and may include referrals to other agencies in the community. TAU has been utilized as a comparison condition for several behavioral treatment evaluations involving adolescent substance abuse.
223478682|NCT02197156|DRUG|40 mg HC-ER|Single dose
223584203|NCT04284566|BEHAVIORAL|Treatment as Usual (TAU)|Treatment-as-Usual (TAU) consisted of prescribing drugs adapted to the symptomatic profile of each patient. The patients were instructed to continue their baseline medical treatment with no change throughout the 3-month period. In Spain, some counselling about aerobic exercise adjusted to patients' physical limitations is usually provided by first-line clinicians and specialists, but pharmacotherapy it's still the dominant treatment option.
223584204|NCT01420822|DRUG|Fluticasone|Collection of safety data
223584205|NCT03600454|DRUG|General anesthesia|The induction of general anesthesia will be delivered in a standardized manner with the intravenous administration of fentanyl 2µg/kg and propofol
224164192|NCT00373906|DRUG|Bortezomib (Velcade)|
224164193|NCT06949670|DIAGNOSTIC_TEST|18F-FIAT-2, 18F-C05-05, 18F-SPAL-T-06|Each subject receive a single intravenous injection of 18F-FIAT-2, 18F-C05-05, 18F-SPAL-T-06 and undergo PET/CT or MRI imaging within the specificed time.
224314190|NCT03262038|DRUG|Ondansetron|This arm will receive (in a blinded fashion) 0.1 mg/kg of Ondansetron IV made up to 5 mLs intra-operatively and Ondansetron IV 0.1 mg/kg made up to 5 mLs every 6 hours for 24 hours postoperatively.
223478683|NCT02197156|DRUG|10 mg HC / 325 mg APAP|Single dose
223478684|NCT02197156|DRUG|Matching Placebo|Single dose
223478685|NCT05850715|DIAGNOSTIC_TEST|Disability Assessment for Dementia (DAD)|The scale consists of 40 items and assesses patients' independence in basic and instrumental activities. The scale is completed by the patient's caregiver with the assistance of the assessor-therapist.
223584206|NCT03600454|DRUG|Spinal anesthesia|The level of puncture will be L4 - L5. 10 mg bupivacaine will be injected in the subarachnoid space, after spontaneous surge of cerebrospinal fluid
223478686|NCT00591877|PROCEDURE|Acupuncture|"Each patient will undergo a 30 minute session, twice a week, for a total of 12 sessions. The technique will involve electro-stimulation at predefined points followed by needle manipulation.~The acupoints that will be used are:~* ST-36: 3 finger breadths inferior to lower edge of patella between tibialis anterior muscle and the tibia, 1 finger breadth lateral to the anterior crest of the tibia.~* PC-6: 2 finger breadths proximal to and in the middle of the most distal transverse crease of the wrist, between the tendons of palmaris longus and flexor carpi radialis.~* CV-12: 4 finger breadths superior to the umbilicus."
223478687|NCT00591877|PROCEDURE|Sham Acupuncture|"The acupoints for SAC are:~* LI-4 : adjacent to and at the middle of the radial side of the 2nd metacarpal bone, at the same level as the end of the crease when the thumb and index fingers approximate.~* GB-32: on the lateral aspect of the thigh 5 finger breadths proximal to the popliteal crease, 2 finger breadths inferior to GB31.~* UB -15: 1.5 finger breadths lateral to the midline of the spine on a level between the 5 th and the 6 th thoracic vertebrae."
223478688|NCT00591877|OTHER|Yoga|The participants in this arm will undergo a 60 min session of yoga exercises. These exercises are specifically designed for reflux symptoms by a yoga instructor. This includes a set of specific physical postures (asana) and breathing techniques within the four-element setup. The set of asana are divided into (a) standing, (b) sitting, and (c) lying down positions. The session will begin with asana in standing position, followed by a position called Shavasan (relaxation), then asana in sitting down position followed by Shavasan, finally asana in lying down position followed by Shavasan. At the end of all asana, Pranayam (special breathing exercises) will be practiced.
223478689|NCT03835039|DEVICE|NIRS|Monitoring cerebral and perirenal perfusion using NIRS
223478690|NCT00156260|PROCEDURE|Ductal lavage|
223478691|NCT03341520|DRUG|Obinutuzumab Injection [Gazyva]|7x 1000mg flat dose
223478692|NCT03341520|RADIATION|Low dose radiation Therapy (LDRT)|2 x 2 Gy
223478693|NCT00412620|DRUG|ABT-925|
223478694|NCT00412620|DRUG|Placebo|
223478695|NCT01524315|DRUG|Vitamin B1-ratiopharm|300 mg Thiaminchloridhydrochlorid, once, intravenous, preoperative
223478696|NCT01524315|DRUG|Placebo|100 ml normal saline, intravenous, preoperative
223478697|NCT03646539|BEHAVIORAL|Use of smartphone application (app)|Use of a CBT-based automated conversational agent available as a mobile device smartphone application for the management of mood.
223478698|NCT03646539|OTHER|Treatment as usual|Treatment as usual will include (but may not be limited to) the participant's 6-week postpartum follow-up visit with their obstetrics care team. Participants will be sent surveys to evaluate their depressive and anxiety symptoms.
223478699|NCT03073928|PROCEDURE|Interscalene Block|Regional Anesthesia procedure in the neck
223478700|NCT03073928|PROCEDURE|Paracoracoid SPB|Regional anesthesia procedure under the collar bone
223478701|NCT03073928|DRUG|Ropivacaine|Amide local anesthetic Ropivacaine will be used in same concentration (milligrams) in both active comparator and experimental group
223478702|NCT04555148|BIOLOGICAL|GC5131|COVID19 Hyper-Immunoglobulin
223478703|NCT04555148|OTHER|Placebo|Placebo
223478704|NCT05986110|PROCEDURE|A training intervention on clinical ultrasound|To train 20 primary care family doctors in clinical ultrasound so that they have greater power of resolution and allow them to limit the diagnostic and surgical times on the waiting lists of their patients.
223478705|NCT02827526|DRUG|Ketamine|
223478706|NCT02827526|DRUG|Control|
223478707|NCT00382356|DRUG|Dutasteride|once daily dosing of 0.5mg Dutasteride for 12 months
223584207|NCT03600454|DRUG|General anesthesia and epidural analgesia|The induction of general anesthesia will be delivered in a standardized manner with the intravenous administration of fentanyl 2 µg/kg and propofol. A thoracic epidural catheter will be placed with 3 ml of xylocaine 2% (with epinephrine 1/200.000).
223584208|NCT00016965|DRUG|ixabepilone|
223478708|NCT00742937|DIETARY_SUPPLEMENT|vitamin A|second capsule 200,000 UI of retinol palmitate (vitamin A)plus vitamin E, eight days after delivery.
223478709|NCT00742937|DIETARY_SUPPLEMENT|Placebo|second capsule with vitamin E, eight days after delivery.
223478710|NCT03659630|BEHAVIORAL|MyCompass|Self-help tools to change behaviours in various different domains including sleep deprivation, anxiety and depression.
223478711|NCT03659630|BEHAVIORAL|Comparison group|An email containing a brief text on general tips regarding mental health was sent out once a week.
223478712|NCT03716960|OTHER|Pumpkin Seed Oil|This intervention consisted of 6 weeks of PSO consumption. Subject were supplemented with 3 g/day of PSO which was ingested in the form of 1g capsules with each main meal of the day (breakfast, lunch and dinner).
223478713|NCT03716960|OTHER|Placebo|This intervention consisted of 6 weeks of placebo consumption. Subject consumed 1 capsule of maltodextrin with each main meal of the day to match the dose and number of capsules ingested daily by the PSO group.
223478714|NCT03171090|OTHER|sphenopalatine block with local anesthetic|bilateral ultrasonic guided sphenopalatine ganglion block using local anesthetic after induction of general anesthesia in maxilofacial cancer surgeries
223478715|NCT03171090|OTHER|sphenopalatine block with saline|bilateral ultrasonic guided sphenopalatine ganglion block using saline after induction of general anesthesia in maxilofacial cancer surgeries
223478716|NCT05094427|PROCEDURE|Preoperative fluoroscopically-guided dorsal ramus block placed by the operative neurosurgeon|Patients received bupivicaine injections delivered via 22-gauge spinal needle to the junction of the facet and transverse process or ala at multiple spinal levels (2.5-5 cc per injection of 0.25% or 0.5% bupivacaine).
223478717|NCT06113978|PROCEDURE|Thoracoscopic sympathectomy|Medical file records of patients of both sexes, below 18 years of age, suffering from significant bilateral palmar hyperhidrosis, managed by thoracoscopic bilateral simultaneous sympathectomy.
223478718|NCT06113978|PROCEDURE|Thoracoscopic sympathotomy|Medical file records of patients of both sexes, below 18 years of age, suffering from significant bilateral palmar hyperhidrosis, who underwent thoracoscopic bilateral simultaneous sympathotomy.
223478719|NCT06113978|PROCEDURE|Thoracoscopic sympathetic chain clipping|Medical file records of patients of both sexes, below 18 years of age, suffering from significant bilateral palmar hyperhidrosis, treated by thoracoscopic bilateral simultaneous sympathetic chain clipping.
223478720|NCT03776279|DRUG|Mitoxantrone Hydrochloride Liposome Injection|Mitoxantrone Hydrochloride Liposome Injection 20 mg/m2 will be infused intravenously once over 60min in 250 ml 5％ glucose injection on the first day during a treatment phase of 4 weeks.
223478721|NCT05267717|OTHER|Non-interventional study, all patients being tested with AG Pregnolia System to assess the values of the Cervical Stiffness|Non-interventional study,
224164194|NCT06949488|PROCEDURE|Group A (DT): Dexmedetomidine group|The ultrasound probe is placed in the supraclavicular fossa in the transverse orientation parallel to the clavicle and aimed inferior toward the ipsilateral thorax. The brachial plexus and the subclavian artery are visualized. The first rib appears as a hyperechoic line with the lung pleura deeper to this bony border. Utilizing the in-plane approach, the needle is advanced from lateral to medial, aimed near the main neural cluster of the brachial plexus. After negative aspiration, local anesthetic, including 100 µg Dexmeditomidine and normal saline, with a total volume of 20 mL, is injected. Subsequently, smaller aliquots of local anesthetic are deposited near the surrounding satellite neural clusters.
224164195|NCT06949488|PROCEDURE|Group B (MG): Magnesium group|The ultrasound probe is placed in the supraclavicular fossa in the transverse orientation parallel to the clavicle and aimed inferior toward the ipsilateral thorax. The brachial plexus and the subclavian artery are visualized. The first rib appears as a hyperechoic line with the lung pleura deeper to this bony border. Utilizing the in-plane approach, the needle is advanced from lateral to medial, aimed near the main neural cluster of the brachial plexus. After negative aspiration, local anesthetic, including 150 mg of magnesium sulfate and normal saline, with a total volume of 20 mL, is injected. Subsequently, smaller aliquots of local anesthetic are deposited near the surrounding satellite neural clusters.
224164196|NCT06949488|PROCEDURE|Group C (DM): Dexamethasone group|The ultrasound probe is placed in the supraclavicular fossa in the transverse orientation parallel to the clavicle and aimed inferior toward the ipsilateral thorax. The brachial plexus and the subclavian artery are visualized. The first rib appears as a hyperechoic line with the lung pleura deeper to this bony border. Utilizing the in-plane approach, the needle is advanced from lateral to medial, aimed near the main neural cluster of the brachial plexus. After negative aspiration, local anesthetic, including 8 mg dexamethasone and normal saline, with a total volume of 20 mL, is injected. Subsequently, smaller aliquots of local anesthetic are deposited near the surrounding satellite neural clusters.
224164197|NCT06948253|OTHER|Erector Spinae Plane Block|The correct location of the needle tip in the fascial plane deep to the erector spinae muscle will be conﬁrmed by injecting 0.5-1 ml of saline and observing the ﬂuid lifting the erector spinae muscle off the transverse process while avoiding muscle distension (hydro dissection)
224164198|NCT06948253|OTHER|Caudal Block Anesthesia|"The needle will be advanced at a 20-degree angle with needle tip and length visualization. A pop can be appreciated as the needle passes through the sacrococcygeal ligament.~Once the needle will be confirmed to be in the caudal space on the screen, carefully aspirate to confirm absence of CSF or blood."
224164199|NCT06948253|OTHER|External Oblique Intercostal Plane Block|the needle will be advanced until the tip lay in the plane between the external oblique muscle and intercostal muscles between the sixth and seventh ribs
224164200|NCT06948461|BIOLOGICAL|ORAL-LYO-FMT|An oral capsule formulation of lyophilized fecal microbiota. Participants receive 7 capsules, three times per week (Monday, Wednesday, Friday), for either 4 or 7 weeks depending on treatment allocation. The product aims to restore healthy gut microbiota for treatment of IBS-D or prevention of rCDI.
224164201|NCT06948461|OTHER|Placebo|Double-coated oral capsules visually identical to ORAL-LYO-FMT but containing no active material. Participants receive 7 capsules, three times per week, for either 3 or 7 weeks depending on treatment allocation.
224164202|NCT06949527|DEVICE|Open Bite Activator with Skeletal Anchorage-Supported Vertical Elastics|A custom-made acrylic open bite activator was fabricated for each participant, with the bite registered 3-4 mm above freeway space. Miniscrews were placed between the lateral and canine teeth in both jaws. Vertical elastics (150g force) were applied bilaterally between miniscrews and the appliance. The intervention aimed to reduce vertical growth in posterior regions and stimulate anterior dentoalveolar development while improving masseter muscle morphology.
224164203|NCT03399786|DRUG|evinacumab|IV administration of evinacumab
224164204|NCT03399786|DRUG|Placebo|IV administration of placebo
224164205|NCT04498949|BEHAVIORAL|UP|"The unified protocol modules are as follows:~Module 1: Setting the treatment goals and motivation augmentation Module 2: Using psychoeducation to learn the function of emotions and their development Module 3: Mindful (present-focused and non-judgmental) emotional awareness- Core module Module 4: Cognitive flexibility- Core module Module 5: Identifying and countering emotional avoidance behaviors- core module Module 6: Increasing awareness and confronting physical sensations/ interoceptive sensitivity- core module Module 7: Both situational and interoceptive emotion-focused exposures- Core module Module 8: Recognizing accomplishments and looking to the future (relapse prevention)"
223478722|NCT06243302|PROCEDURE|OTSC Closure After VAAFT|Under general anesthesia,the fistulas will be drained at least for 8 weeks. Then a video camera will be inserted through the external opening to fulgurate the fistula tract under direct vision. Finally the internal fistula opening will be closed water tight by a circular clip. The patients will be followed up for complications as well as short and long term recurrences
223478723|NCT00956202|BIOLOGICAL|Swine A/H1N1 influenza vaccine (split virion, inactivated)|0.5 mL, Intramuscular on Day 0 and Day 21 (all participants); and 0.5 mL of a trivalent influenza vaccine (TIV) at Month 13 (antibody persistence subset)
223478724|NCT00956202|BIOLOGICAL|Swine A/H1N1 influenza vaccine (split virion, inactivated + Adjuvant)|0.5 mL, Intramuscular on Day 0 and Day 21 (all participants); and 0.5 mL of a trivalent influenza vaccine (TIV) at Month 13 (antibody persistence subset).
223478725|NCT00956202|BIOLOGICAL|Swine A/H1N1 influenza vaccine (split virion, inactivated + Adjuvant)|0.5 mL, Intramuscular on Day 0 and day 21
223478726|NCT03185078|DEVICE|Extracorporeal Shock Wave Therapy|Extracorporeal shock wave therapy (ESWT) is a treatment method for the application of single-pulse acoustic pressure waves generated by sudden changes in pressure by creating shock waves with piezoelectric, electrohydraulic and electromagnetic systems. It has been reported that ESWT treatment is effective in the treatment of pain with hyperstimulation analgesia by inhibiting afferent pain receptors, and also improve angiogenesis and restore and reorganize the musculoskeletal system
223478727|NCT03185078|OTHER|Placebo ESWT|In the placebo application, rESWT device was switched on but without pressing the pedal during the same session period. The applicator was positioned to be the same as the other groups.
223478728|NCT04042792|OTHER|pharmacokinetics (PK) measurement|two ADA-PK samples will be collected during routine rheumatology visits in case of medical indicated blood draw (1 trough PK sample and 1 random PK sample per subject)
224164206|NCT04498949|OTHER|Treatment as usual|Diagnostic test. Psychoeducation Supoortive care
224164207|NCT06102330|OTHER|HomeVENT decision support tool|Web-based decision support tool that describes diverse family experiences with making decisions about pediatric chronic home ventilation
224164208|NCT04884633|PROCEDURE|Pancreatic islet transplantation|New method of pancreatic islet transplantation into the omentum using a biodegradable scaffold
224164209|NCT00312390|PROCEDURE|Flicker|
224164210|NCT00312390|PROCEDURE|Retinal Vessel Diameter|
224164211|NCT00312390|PROCEDURE|Retinal Blood Flow|
224164212|NCT03978793|DEVICE|MyTPill, a digital pill|MyTPill is a digital pill containing an approved medication
224164213|NCT04640012|DRUG|DC371739|Participants received one of 6 dose levels of DC371739 administered as single oral doses.
224164214|NCT04640012|DRUG|Placebo|Placebo orally administered
224164215|NCT05620160|DRUG|RAY1216|RAY1216（tablet）
224164216|NCT05620160|DRUG|Placebo|placebo （tablet）
224164217|NCT05454709|DRUG|Dasiglucagon|Use of dasiglucagon in the AP system.
224164218|NCT05454709|DRUG|GlucaGen|Use of GlucaGen in the AP system.
224164219|NCT03883659|OTHER|Smartphone|patients with frozen shoulder in the smartphone group will use the smartphone to conduct the home exercise program. The patients will be asked to follow the description to have mobility assessment at least 1 week and do the individualized exercise themselves.
224164220|NCT03883659|OTHER|traditional paper hangouts|patients with frozen shoulder in the smartphone group will use the paper hangouts to conduct the home exercise program. The content of the paper hangouts were description of the home exercise.
224164221|NCT01673373|DEVICE|iCAST™ Rx Stent System|All enrolled subjects will undergo primary stenting of the target lesion(s) by placement of the iCAST™ RX Stent System.
224164222|NCT03511248|DIETARY_SUPPLEMENT|Nitrate-rich Beetroot Juice|The beetroot juice contains approximately 100kcal per 100mL of juice, equivalent to a glass of orange juice; the volume of juice per day for the study is 70mL. Volunteers will be informed that an average woman weighing 65kg should not consume more than 2000kcal per day, and an average man of 75kg not more than 2500kcal per day.
223478729|NCT02424695|DRUG|Gabapentin Enacarbil (GEn)|"HORIZANT Extended-Release Tablets containing 600 mg of gabapentin enacarbil are white to off-white, with occasional black/grey spots, oval-shaped tablets debossed with GS LFG, supplied as:~600 mg: NDC 53451-0101-1.The drug will be stored at 25°C (77°F) (excursions permitted 15° to 30°C (59° to 86°F)) Matching placebo will be provided by Xenoport Inc."
224164223|NCT03511248|DIETARY_SUPPLEMENT|Nitrate-deplete Beetroot Juice|The beetroot juice contains approximately 100kcal per 100mL of juice, equivalent to a glass of orange juice; the volume of juice per day for the study is 70mL. Volunteers will be informed that an average woman weighing 65kg should not consume more than 2000kcal per day, and an average man of 75kg not more than 2500kcal per day.
224164224|NCT02718664|OTHER|Test meal (breakfast)|Standardized test meal, in accordance with high-fat and high-calorie meal as described in the FDA guidance, but ingredients are changed to Dutch standards and ingredients are added that are expected to have the largest effects on dihydrouracil and uracil levels
224164225|NCT00486148|OTHER|Infant formula (with GOS)|Infant formula supplemented with 0.4 g/100 ml of galacto-oligosaccharides
224164226|NCT04759040|DIETARY_SUPPLEMENT|Migraineguard|2 Capsules per day for 7 Months
224164227|NCT01572844|DEVICE|Fractionated Carbon Dioxide (FCO2) Laser|At each treatment visit, a 2 X 2 cm (+/- 1 cm) area of the target calcinosis lesions will be treated with one pass of the Candela QuadraLase (TM) FCO2 laser. Patients will receive a total of 8-10 treatments over a 6 month period.
223478730|NCT02424695|DRUG|Placebo|
224164228|NCT01572844|DRUG|Sodium thiosulfate|Following treatment with FCO2 laser, 4 ml of 5% Sodium Thiosulfate solution will be applied to the treatment site only. Subjects will receive a total of 8-10 treatments over a 6 month period.
224164229|NCT00366444|DRUG|diclofenac potassium (XP21L)|25 mg every 6 hours
224164230|NCT00366444|DRUG|Placebo|Placebo every 6 hours
224164231|NCT06210165|DRUG|Sugammadex|IV Sugammadex 4mg/kg stat once TOF ratio 0.7-0.9 after completing surgery
224164232|NCT06210165|DRUG|Neostigmine and atropine|IV neostigmine 40mcg/kg in combination with IV atropine 10mcg/kg stat once TOF ratio 0.7-0.9 after completing surgery
223478731|NCT00808925|OTHER|exposure to heat|Dressed in shorts and tennis shoes the subjects will be exposed to exercise-heat stress for 12 consecutive days (excluding Saturday). Daily exposure will last 120 min, under the controlled environmental conditions of 40oC and 40% relative humidity. The exercise will consist of walking on a treadmill at a pace of 5km/h and 2% incline.
224164233|NCT05452876|OTHER|ABCp|Intervention is a care pathway that helps primary care physicians categorize back pain patients with each category having preferred interventions.
224164234|NCT05452876|OTHER|Usual Care|Standard of care treatment
224164235|NCT05406583|DRUG|Dolutegravir 0.5 mg/kg oral suspension|DTG 0.5 mg/kg liquid suspension administered orally
224164236|NCT05406583|DRUG|Dolutegravir 5 mg Dispersible Tablets|DTG 5 mg DT administered orally
224164237|NCT04829734|DEVICE|Active PBMT-sMF|The Active PBMT-sMF will be applied using MRM® MR5 Prototype manufactured by Multi Radiance Medical (Solon, OH, USA). PBMT-sMF will be applied using the direct contact method with light pressure on the skin. The PBMT-sMF will be applied in four regions of the epicondyle and the application time will be 60 seconds per region. The total dose of PBMT-sMF will be 108,30 J per treatment session.
224164238|NCT04829734|DEVICE|Placebo PBMT-sMF|The Placebo PBMT-sMF will be applied using MRM® MR5 Prototype manufactured by Multi Radiance Medical (Solon, OH, USA). Placebo PBMT-sMF will be applied using the direct contact method with light pressure on the skin. The Placebo PBMT-sMF will be applied in four regions of the epicondyle and the application time will be 60 seconds per region. The total dose of Placebo PBMT-sMF will be 0 J per treatment session and the sMF will be turned off. The sounds and signals emitted from the device as well as the information displayed on the screen will be identical, regardless of the type of treatment (active or placebo).
224164239|NCT02791477|DEVICE|Attune FB PS knee arthroplasty|
224164240|NCT04825704|DRUG|Bupivacaine|Topical administration of bupivacaine via gauze swab in the tonsillar fossae after removal of throat tonsils.
224164241|NCT04825704|DRUG|Sodium chloride|Topical administration of 0,9% sodium chloride via gauze swab in the tonsillar fossae after removal of throat tonsils.
224164242|NCT04098029|BIOLOGICAL|Low HLA group CBU infusion|CB-MNC (Cord Blood Mononuclear Cells) infusion from different donors. One dose consists of 2-15х10\^7 cells per 1 kg of patient weight for each infusion. The protocol includes 2 infusions with an interval of 6-x months. HLA compatibility of CB is 3 or fewer by A, B, DRB1 loci.
224164243|NCT04098029|BIOLOGICAL|High HLA group CBU infusion|CB-MNC (Cord Blood Mononuclear Cells) infusion from different donors. One dose consists of 2-15х10\^7 cells per 1 kg of patient weight for each infusion. The protocol includes 2 infusions with an interval of 6-x months. HLA compatibility of CB is 4 or more by A, B, DRB1 loci.
224164244|NCT04098029|OTHER|Standard therapy|The standard therapy can include drugs, special psychology training, etc.
224164245|NCT06415656|DEVICE|TempTraq|TempTraq (Blue Spark Technologies, Westlake, OH) is an FDA 510K cleared wearable, wireless temperature monitoring patch designed to continuously monitor and track body temperature.
224164246|NCT06415656|DEVICE|VitalTraq|VitalTraq (Blue Spark Technologies, Westlake, OH) is an experimental and novel multi-vital sign monitoring platform that allows for interval measurements of heart rate, heart rate variability, and blood pressure.
224164247|NCT04168905|DEVICE|AOTI Inc. TWO2 topical oxygen therapy equipment|Patients will apply themselves oxygen therapy at home for 5 days a week, 90 minutes a day, rest for 2 days, and follow-up once a week. A total of 12 weeks of treatment, or recieving treatment till wound healed.
224164248|NCT01335438|DEVICE|Cementless (Nexgen)|Cementless fixation of Nexgen CR TKR
224164249|NCT01335438|DEVICE|Cemented (Nexgen)|Cemented fixation of Nexgen CR TKR
224164250|NCT06073054|BEHAVIORAL|Research Pharmacist|The goal of this intervention is to determine if contact with the research pharmacist will improve the health of the mother and/or child.
224164251|NCT06499857|DRUG|Semaglutide|3ml pen-injector containing semaglutide 3.0mg/ml solution for subcutaneous use.
224164252|NCT06499857|DRUG|Placebo|3ml pen-injector containing placebo solution for subcutaneous use.
224164253|NCT04307277|DRUG|Standard of care + chemotherapy|Doxorubicine with Ifosfamide during 4 cycles Q3W Or Doxorubicine with Dacarbazine during 4 cycles Q3W (for patients with Leiomyosarcoma)
224164254|NCT04307277|OTHER|Standard of care|Surgical excision with external radiotherapy (if applicable)
224164255|NCT03601078|BIOLOGICAL|bb2121|bb2121 consists of autologous T lymphocytes transduced with an anti-BCMA CAR lentiviral vector to express a chimeric antigen receptor targeting the human B cell maturation antigen (anti-BCMA CAR)
224164256|NCT03601078|DRUG|Lenalomide|Specified dose on specified days
224164257|NCT03601078|DRUG|Talquetamab|Specified dose on specified days
224164258|NCT05738603|DEVICE|Hypotension Prediction Index|Hemodynamic perioperative monitoring with the Hypotension Prediction Index
224164259|NCT02186340|PROCEDURE|Inspiratory muscle training|
224164260|NCT02869451|DRUG|bupropion|Prescribed one week prior to quit and continued until the 6 month follow-up visit.
224164261|NCT02869451|DRUG|transdermal nicotine patch|Initiated at smoking quit date; 7 mg to 21 mg patch depending on amount smoked by participant
224164262|NCT02869451|DRUG|Nicotine polacrilex|Initiated at smoking quit date.
224164263|NCT02869451|DRUG|nicotine lozenge|Initiated at smoking quit date.
224164264|NCT02869451|BEHAVIORAL|counseling for marijuana and smoking cessation|5 sessions of cognitive-behavioral counseling designed to facilitate marijuana and smoking cessation and promote relapse prevention
224164265|NCT02869451|BEHAVIORAL|mobile contingency management|treatment that provides money rewards for abstinence from smoking and marijuana
224164266|NCT06186622|DRUG|Orforglipron|Administered orally.
224164267|NCT06186622|DRUG|Simvastatin|Administered orally.
224164268|NCT06186622|DRUG|Digoxin|Administered orally.
224164269|NCT06186622|DRUG|Rosuvastatin|Administered orally.
224164270|NCT06186622|DRUG|Acetaminophen|Administered orally.
224164271|NCT06186622|DRUG|Midazolam|Administered orally.
224164272|NCT06186622|DRUG|Sodium Bicarbonate|Administered orally.
224164273|NCT00413777|DRUG|Tolvaptan|Participants were titrated to either the tolvaptan 45/15 or 60/30 mg split-dose over a 2-month Titration Period. They received the titrated dose for 34 months during the Fixed-dose Period. Following a planned off-treatment period, participants had the option to enter an Extension Period for an additional 12 months. Tolvaptan was supplied as tablets.
224164274|NCT01712191|DEVICE|NUsurface Meniscus Implant|
224164275|NCT01490333|DIETARY_SUPPLEMENT|Vitamin D3|The vitamin D3 will be taken daily.
224164276|NCT05505734|DRUG|BDA MDI|Participants will receive Budesonide and Albuterol Sulfate MDI 80/90 μg per Actuation 1 to 6 doses (2 inhalations/dose) per day as needed via Oral inhalation route.
224164277|NCT05505734|DRUG|AS MDI|Participants will receive Albuterol Sulfate MDI 90 μg per Actuation 1 to 6 doses (2 inhalations/dose) per day as needed via Oral inhalation route.
224164278|NCT00764322|DRUG|tamoxifen citrate|Women found to be IM or PM will undergo increased tamoxifen to 40 mg/day (20 mg bid). Drug is given orally on a daily basis.
224164279|NCT00764322|GENETIC|gene expression analysis|Genetic analysis of blood sample.
224164280|NCT00764322|OTHER|pharmacogenomic studies|Genetic analysis of blood sample.
224164281|NCT00764322|OTHER|questionnaire administration|Questionnaire called the survey of participants. Questionnaires is self administered on paper documents and given pre-study, and at 4 months
224164282|NCT00764322|PROCEDURE|quality-of-life assessment|Self administration of a multiquestion questionnaire called the Functional Assessment of Cancer Therapy -Breast (FACT-B). Given pre-study, at 4 months and at 8-10 months.
224164283|NCT02951455|BEHAVIORAL|Critical Dialogue|Prompted by thematic images, aims to help participants develop a deeper understanding of how marginalizing processes (e.g., systematic stigma; feelings of rage as victims of discrimination) impact participants' lives and behavior.
224164284|NCT02951455|BEHAVIORAL|Capacity Building Project|Designed to create collaborative efforts to overcome and dismantle marginalizing processes by building positive social and organizational relationships and community capacity through the development and implementation of community projects aiming to address social determinants of health.
224164285|NCT02951455|BEHAVIORAL|Quality of Life Wheel|Aims to increase self-efficacy and help participants develop a vision for their future, breaking this vision down into small, feasible, measureable goals they can implement on a weekly basis (e.g. quitting smoking, improving relationships with family members, paying down debt).
223478732|NCT02912052|DRUG|Peri-operative chemotherapy|Patients receive 2 cycles of chemotherapy before surgery,and contniue to receive another 4 cycles of chemotherapy 21-28 days later after surgery.The chemotherapy regime is XELOX(oxaliplatin130mg/m2 ivd d1 + Capecitabine1000mg/m2 po bid d1-14, 21d/cycle)
223478733|NCT02912052|DRUG|postoperative chemotherapy|Patients receive 6 cycles of chemotherapy 21-28 days later after surgery.The chemotherapy regime is XELOX(oxaliplatin130mg/m2 ivd d1 + Capecitabine1000mg/m2 po bid d1-14, 21d/cycle)
223478734|NCT04410393|PROCEDURE|vaginal cuff prolapse surgery|Different surgical methods for the treatment of vaginal cuff prolapse in patients who have previously undergone hysterectomy for benign causes
223478735|NCT04258956|DRUG|Axitinib|"Avelumab 10 mg/kg will be administered every two weeks. Avelumab is administered as a 1-hour iv infusion, diluted with 0.9% saline solution; Axitinib 5 mg should be taken orally twice daily approximately 12 hours apart with or without food. They should be swallowed whole with a glass of water. If the patient vomits or misses a dose, an additional dose should not be taken. The next prescribed dose should be taken at the usual time.~The duration of treatment cycle is 28 days."
223584209|NCT02690649|OTHER|Health Messaging (Non-Procedural)|Tailored health messaging delivered via the PHR MyChart pertinent to non-valvular atrial fibrillation and anticoagulant use. Messages will be triggered by medication non-adherence information obtained from Surescripts e-prescribing data and use of AdhereTech smart pill bottle.
223584210|NCT06172400|DRUG|Mepivacaine, Combinations|Using local anesthesia with adrenaline for intraoperative vasoconstriction instead of a tourniquet.
223584211|NCT02686476|DRUG|Empagliflozin|group I (n = 50): T2DM patients receiving standard care for T2DM (metformin, sulfonylurea, DPP-4 inhibitor or insulin, in any combination) plus 10 mg of Empagliflozin per day
224164286|NCT02951455|BEHAVIORAL|PF|Whether the intervention is delivered by a peer facilitator.
224164287|NCT02951455|BEHAVIORAL|LC|Whether the intervention is delivered by a licensed clinician.
224164288|NCT04024241|DEVICE|Flow Cytometer|high dose
224164289|NCT04024241|DRUG|Mitoxantrone|high dose
223478736|NCT02841046|DEVICE|cardiac index|group cardiac index（CI） and group Stroke Volume Variation（SVV） are different treatment schemes of goal-directed fluid therapy guided by SVV and CI,group cardiac index with CI as the primary judgment.
223478737|NCT02841046|DEVICE|Stroke Volume Variation|group cardiac index（CI） and group Stroke Volume Variation（SVV） are different treatment schemes of goal-directed fluid therapy guided by SVV and CI,group Stroke Volume Variation with the combination of SVV and CI as the primary judgment.
223478738|NCT02309359|BIOLOGICAL|ALX-0061|
223584212|NCT00399399|DRUG|azathioprine|
223584213|NCT00399399|DRUG|cyclophosphamide|
223584214|NCT02276547|DEVICE|Mitral valve replacement|Transcatheter mitral valve replacement
224164290|NCT04024241|DRUG|Cytarabine|high dose
224164291|NCT05089188|OTHER|Immunomarkers|immunohistochemical expression profile of ambiguous melanocytic proliferation.
224164292|NCT00554853|DRUG|pioglitazone|daily dose, 30 mg daily for 2 weeks followed by 45 mg daily until completing 3 months unless higher dose not tolerated in which case patient remained at 30 mg daily
224164293|NCT00554853|DRUG|Sublingual nitroglycerine|Used during nitroglycerin-mediated dilatation vascular function measures in both arms of the study if patient's blood pressure permitted. One single tablet was used per vascular test performed.
224164294|NCT00948285|PROCEDURE|MRI|magnetic resonance imaging (MRI)
224164295|NCT04724772|DRUG|Tranexamic acid injection|Injection of tranexamic acid preoperatively
224164296|NCT02128919|DEVICE|tDCS|Transcranial Direct Current Stimulation
223478739|NCT02309359|OTHER|Placebo|
223478740|NCT02309359|DRUG|Methotrexate|Stable background dose of commercially available methotrexate (not provided by the Sponsor).
223478741|NCT02678533|DRUG|G-CSF|D1 to D4 : Injection of 12 µg/kg of G-CSF twice a day . D5 : injection of 12 µg/kg of G-CSF (once/ twice a day according to cytapheresis's realization)
223478742|NCT02678533|DRUG|Plerixafor|D5 : injection of 24mg/kg of plerixafor once a day until cytapheresis has be done (maximum of 4 days)
223584215|NCT03785951|DIETARY_SUPPLEMENT|Whey Protein Isolate|"Whey protein product isolated from whole milk. 79% Protein with minimal carbohydrate and fat.~50 grams of total supplemental protein/amino acids from whey protein powder consumed in two 25g (total protein/amino acids) nutrition shakes twice per day for 8 weeks in the form of a nutritional shake."
223584216|NCT03785951|DIETARY_SUPPLEMENT|Wheat Protein|"Enzymatically hydrolysed wheat protein containing wheat peptides. 75% Protein with minimal carbohydrate and fat.~50 grams of total supplemental protein/amino acids from whet protein peptide powder consumed in two 25g (total protein/amino acids) nutrition shakes twice per day for 8 weeks in the form of a nutritional shake."
224164297|NCT04543630|PROCEDURE|Sinus floor augmentation|Sinus floor augmentaion using the lateral window technique
224164298|NCT00349024|DRUG|polyvinylpyrrolidone-sodium hyaluronate gel|
224164299|NCT03660280|DIETARY_SUPPLEMENT|Probiotics|Specific probiotic lactobacilli (added to stabilized ongoing treatment)
224164300|NCT03660280|OTHER|Placebo|Placebo
224164301|NCT02325440|DRUG|Fingolimod|Fingolimod: 0.5 mg p.o. (o.i.d)
224164302|NCT02325440|DRUG|Natalizumab|Natalizumab: 300 mg i.v. (once at baseline);
224164303|NCT02348840|DEVICE|mHealth|A cell phone that can capture data measurements from devices on blood pressure, oxygen level, the heart rate of pregnant women, and the heart rate of the baby.
224164304|NCT05148689|DRUG|Oxymetazoline hydrochloride Cream, 1%|Cream
224164305|NCT05148689|DRUG|Rhofade™ (oxymetazoline) cream, 1%|cream
224164306|NCT05148689|DRUG|Placebo|cream
224164307|NCT04247529|OTHER|Exposure to conflicting health information|At 2 time points across a \~28-day period, participants will be exposed to news stories and social media posts about 6 health topics: mammography screening, prostate-specific antigen (PSA) testing, Vitamin D supplementation, carbohydrate consumption, alcohol consumption, and breastfeeding. Participants in the conflict (experimental) group will have conflicting information added to these news and social media posts.
224164308|NCT04247529|OTHER|No exposure to conflicting health information|At 2 time points across a \~28-day period, participants will be exposed to news stories and social media posts about 6 health topics: mammography screening, prostate-specific antigen (PSA) testing, Vitamin D supplementation, carbohydrate consumption, alcohol consumption, and breastfeeding. Participants in the no conflict (comparator) group will have no conflicting information included in these news and social media posts.
223478743|NCT03443648|PROCEDURE|External fixator assisted plaing|The plate length is marked on the skin. Limb reconstruction system (LRS) with one swivel clamp or Taylor Spatial frame (TSF) is used in all cases. The fixator is put in a plane parallel to that of the deformity. Two tapered pins are placed on either side of the planned osteotomy site and passed at a distance from the osteotomy so that they will not impede the subsequent internal fixation. Swivel clamps or the struts of the TSF are aligned in such a way that full correction is achieved. After osteotomy, swivel clamp is loosened and angular correction is achieved. Translation is carried out according to preoperative planning. If readjustment is required the swivel clamps or TSF struts are loosened and further correction is carried out. Once desired correction is achieved, the clamps or struts are tightened. Definitive internal fixation is carried out while external fixation holds the fragments. For internal fixation, locked T plate will be used.
223478744|NCT04502316|DEVICE|Barostim™ System|Implantation of the Barostim™ System
223478745|NCT01151436|DEVICE|hyaluronic acid dermal fillers|1 injection per indication and 1 touch-up injection if necessary
223584217|NCT03785951|DIETARY_SUPPLEMENT|Wheat Protein with Leucine|"Enzymatically hydrolysed wheat protein containing wheat peptides with and additional 1.4g of L-leucine. 75% Protein with minimal carbohydrate and fat and a L-leucine concentration equal to whey protein isolate.~50 grams of total supplemental protein/amino acids from wheat protein peptide powder, with added leucine to equal the total content of the whey protein condition, consumed in two 25g (total protein/amino acids) nutrition shakes twice per day for 8 weeks."
223584218|NCT01038726|OTHER|Exercise Training|Aerobic exercise training program designed by the Cardiac Rehabilitation department
224164309|NCT01728649|OTHER|Mild Hypothermia|Hypothermia will be achieved using the Zoll Thermoguard XP technology with the Quattro catheter. This catheter has a 9.3 Fr diameter and is 4 3cm long. It will be placed in the patients femoral vein via Seldinger technique, before reperfusion is achieved. Hypothermia will be initiated prior to reperfusion. Once temperature has reached 33.5 degrees centigrade the patient will remain at that temperature for 12 hours after which the patient will undergo active gradual rewarming at 0.2 degrees centigrade per hour.
224164310|NCT04933253|PROCEDURE|Saline irrigation|Mediastinal irrigation with 2 L of 37 degree Celsius saline prior to chest closure
224164311|NCT05355324|OTHER|no intervention|no intervention
224164312|NCT04028024|DRUG|Ulinastatin|Ulinastatin 5000U/Kg in 20 ml NS i.v. before occlusion of aorta
224164313|NCT02158962|BEHAVIORAL|Behavioral - Education|"Behavioral - Education~3 educational sessions aimed at reducing risks partner violence, and sexual transmitted infections"
224164314|NCT04626570|OTHER|Cognitive and Behavioral Therapy|12 sessions of CBT using a standardized approach
224164315|NCT02921906|OTHER|High protein meal|Breakfast with high protein / low carbohydrate content
224164316|NCT02921906|OTHER|High carbohydrate meal|Breakfast with high carbohydrate / low protein content
224164317|NCT02921906|DRUG|Paracetamol|Standard dose of paracetamol administered with each meal to allow measurement of rate of gastric emptying.
224164318|NCT02921906|OTHER|Fasting state - sulphonylurea only|People with diabetes take sulphonylurea medication in the absence of any food stimulus
224164319|NCT02203916|DRUG|Azilsartan medoxomil|Azilsartan medoxomil tablets
224164320|NCT02203916|DRUG|Azilsartan medoxomil placebo|Azilsartan medoxomil placebo-matching tablets
224164321|NCT02233894|DRUG|Atrovent® - inhalets|
224164322|NCT04098016|BEHAVIORAL|Digital Intervention|Participants will receive: 1) tailored behavior change goals, 2) self-monitoring with tailored feedback, 3) skills training.
224164323|NCT03441516|DRUG|Alfoatirin® Tab. + Aripezil® Tab.|Choline Alphoscerate 400 mg Oral Tablet bid + Donepezil 10 mg Oral Tablet qd for 24 weeks
224164324|NCT03441516|DRUG|Aripezil® Tab.|Donepezil 10 mg Oral Tablet qd for 24 weeks
224164325|NCT02330601|PROCEDURE|endoscopic papillary large balloon dilation|For the patients in EPLBD group, a CRE balloon (diameter 10, 11, 12, 13.5, 15 mm; Boston Scientific) was chosen according to the diameter of bile duct. It was placed across the papilla orifice and then gradually filled with diluted contrast. When the waist disappeared, the balloon was kept inflated for 120s. The stones were then retrieved by a basket or a retrieval balloon.Mechanical lithotripsy was used if necessary
224164326|NCT01245127|DRUG|Ilaris|"* Canakinumab 150 mg (or 2 mg/kg for patients weighing \<40kg) every 8 weeks over a 6 months treatment period (i.e., weeks 0, 8, 16 and 24).~* At Day 7, patients who show an improvement, but not a clinical remission, will be given another 150 mg (or 2 mg/kg for patients weighing \<40 kg) injection and continue at 300 mg (or 4 mg/kg for patients weighing \<40 kg) every 8 weeks beginning at Week 8.~* Patients who show no improvement of symptoms and signs of Schnitzler's syndrome will not receive any additional canakinumab dose and will be offered corticosteroid therapy. These patients will return for a follow-up visit 2 weeks later (Day 21) for safety reasons and will be discontinued from the trial.~* If a patient flares twice during the study, physician may optionally change the dosing frequency to every 4 weeks."
224164327|NCT00414973|DRUG|Teriparatide|Subcutaneous, 20 micrograms/day, 24 weeks
224164328|NCT00414973|DRUG|Salmon Calcitonin|Intranasal, 200 International Units (IU)/day, 24 weeks
224164329|NCT05575583|DEVICE|repetitive transcranial magnetic stimulation|The neural navigation system was used to accurately locate the stimulus target.Continuous theta short rapid pulse mode was used. CTBS mode consisted of a slave stimulus delivered every 0.2 seconds (5Hz), and each slave stimulus consisted of three bursts of 50Hz. A single stimulus lasts about 40 seconds and totals 600 pulses.
223584219|NCT01038726|OTHER|Cognitive Training|Based on cognitive training program Brain Fitness®
223584220|NCT01038726|OTHER|Flexibility Training|Non-aerobic flexibility training program designed by the Cardiac Rehabilitation department
224164330|NCT05575583|DEVICE|pseudo repetitive transcranial magnetic stimulation|Participant in control group receive pseudo repetitive transcranial magnetic stimulation
224164331|NCT01869452|BEHAVIORAL|therapeutic education|knowledge of disease, risk factors, diet, medication, alert symptoms
224164332|NCT03930927|DRUG|Self Assembling peptide|enamel regeneration
224314191|NCT03262038|DRUG|Placebo Comparator|This arm will receive (in a blinded fashion) a volume-matched placebo intraoperatively as well as IV every 6 hrs for 24 hours postoperatively.
224314192|NCT04933968|BIOLOGICAL|ALVR106|Infusion, visually identical to placebo
224314193|NCT04933968|BIOLOGICAL|Placebo|Infusion, visually identical to ALVR106
223478746|NCT06462287|DRUG|Aprepitant 125 and 80Mg Oral Capsule|Aprepitant 1 oral capsule time a day for 4 days (First day: 125 mg and the 3 last days: 80 mg)
223478747|NCT06462287|DRUG|Placebo|Placebo:1 oral capsule time a day for 4 days
223478748|NCT06291363|DRUG|Esmolol Hydrochloride|Patients in the experimental group will receive esmolol during general anesthesia
223478749|NCT06291363|DRUG|Saline|Patients in the standard of care group will receive saline as placebo during general anesthesia
223478750|NCT05055765|PROCEDURE|Microneedling|MN will be carried out 1mm below of the gingival margin on the gingiva of the tooth to be treated with thirty-gauge (0.255 mm) lancet needles.
223584221|NCT01038726|OTHER|Educational Sessions|DVD-based educational programs on history, art, and literature
223584222|NCT03721809|BIOLOGICAL|Blood samples|"There are 3 specific blood sampling times for each patient, on D1, D2 and D5 (D1 being the day of inclusion): cytokine samples (IL-1β, IL-6, IL-10, TNF-α, IFN-gamma) on 5ml dry tube.~On D1, a 2.5ml PAXgene tube will also be taken for each patient."
223584223|NCT01754194|PROCEDURE|Gastric Sleeve Resection|Laparoscopic Gastric Sleeve Resection
223584224|NCT01754194|PROCEDURE|Roux-en-Y Gastric Bypass|Laparoscopic Roux-en-Y Gastric Bypass
224164333|NCT03930927|DRUG|remineralizing agent|enamel regeneration
224164334|NCT06408987|PROCEDURE|arthroscopically assisted|Arthroscopically-Assisted reduction through anterolateral portal for visualization and other accessory portals for instrumentation to achieve reduction and postoperative immobilization in a hip spica.
224164335|NCT06408987|PROCEDURE|open surgical reduction|Open reduction through a bikini incision anterior approach and postoperative immobilization in a hip spica.
224164336|NCT02629887|DEVICE|Non-inflatable supraglottic airway|at delivery if resuscitation is required infant randomized to NI-SGA or face mask as the interface for positive pressure ventilation.
224164337|NCT02629887|DEVICE|Face Mask|at delivery - standard airway management per Neonatal Resuscitation Program utilizing face mask.
224164338|NCT02629887|DEVICE|T-Piece Resuscitator|T-Piece Resuscitator for providing postivie pressure ventilation via face mask or non-inflatable supraglottic airway
224164339|NCT04837690|PROCEDURE|UEMR|(1) the colorectal lumen was completed deflated with 500-1000 mL sterile water using a flushing pump; (2) the lesion and 2-3 mm of normal mucosa surrounding the base of the polyp were snared and subsequently resected with an electrosurgical generator
223478751|NCT05055765|PROCEDURE|injectable- platelet rich fibrin|I-PRF will be prepared according to Choukroun PRF method.
223478752|NCT03454035|DRUG|Ulixertinib|Ulixertinib 300mg, orally, twice a day concomitantly with palbociclib
223478753|NCT03454035|DRUG|Palbociclib|Drug: Palbociclib 125mg, orally, once a day concomitantly with ulixertinib
223761376|NCT06577493|DRUG|Phenazopyridine Hydrochloride 99.5 MG|Experimental arm to take two 99.5 mg phenazopyridine hydrochloride by mouth for a total of 199mg immediately prior to start of urodynamic testing
224164340|NCT04831892|OTHER|Moisturizer Containing Isosorbide Diesters and Colloidal Oatmeal|Study lotion containing 0.1% colloidal oatmeal along with 4% HydraSynol® DOI (Isosorbide Dicaprylate) and 4% HydraSynol® IDL/(Isosorbide Disunflowerseedate)
223478756|NCT05144945|BIOLOGICAL|Quadrivalent Recombinant Influenza Vaccine (RIV4)|Solution for intramuscular injection
223478757|NCT05144945|BIOLOGICAL|Quadrivalent inactivated influenza vaccine (IIV4)|Suspension for intramuscular injection
223478758|NCT00060411|DRUG|erlotinib hydrochloride|Given IV
223478759|NCT00060411|DRUG|fluorouracil|Given IV
223478760|NCT00060411|DRUG|leucovorin calcium|Given IV
223478761|NCT00060411|DRUG|oxaliplatin|Given IV
223478762|NCT00060411|BIOLOGICAL|bevacizumab|Given IV
223478763|NCT00284856|DRUG|montelukast sodium|montelukast 10 mg tablet once daily, 6 month treatment period
223478764|NCT00284856|DRUG|Comparator: Placebo|fluticasone propionate 250 mcg Placebo (Pbo) twice daily, 6 month treatment period
223584225|NCT01099657|BEHAVIORAL|Virtual Reality Hypnosis for chronic pain|At the time of their clinic visit,the subject will answer pain and anxiety questionnaires before experiencing Virtual Reality Hypnosis. After VRH, the will again answer Pain and anxiety questionnaires.
223584226|NCT01099657|BEHAVIORAL|Virtual Reality Distraction for Chronic Pain|At the time of their clinic visit,the subject will answer pain and anxiety questionnaires before experiencing Virtual Reality Distraction. After VRD, the will again answer Pain and anxiety questionnaires.
223584227|NCT06486272|OTHER|Financial Navigator|"Intervention: Access to a Financial Navigator We anticipate the Financial Navigator will meet at least 2 times and up to 2 additional visits, at a time convenient for the family. Examples of financial services that will likely be offered by the Financial Navigator are tax filing, applying for benefits and financial counseling. The program will be flexible and family centered. Families can choose if they would like to meet the Financial Navigator in person at the NNFU appointment, during another medical appointment, or at another time during a virtual visit. The Financial Navigator will be integrated into the existing SickKids Resource Navigation Service. At the 18-month NNFU visit the study will be completed."
223584228|NCT00450736|DRUG|celecoxib|
223584229|NCT00450736|PROCEDURE|adjuvant therapy|
223584230|NCT00450736|RADIATION|radiation therapy|
224164341|NCT04831892|OTHER|Moisturizer containing Colloidal Oatmeal only|Vehicle lotion containing 0.1% colloidal oatmeal.
224164342|NCT01466062|DRUG|Palivizumab|
224164343|NCT03531710|BIOLOGICAL|UB-311|Intramuscular injection
224164344|NCT03531710|DRUG|Placebo|Intramuscular injection
224164345|NCT03152110|OTHER|HIIT|"A handcycle or tabletop ergometer will be used for HIIT. Exercise sessions will be scheduled 3x/week for 6 weeks (2 sessions supervised, 1 session unsupervised). The HIIT goal is to achieve 10 sets of 60 second bouts of arm cycling at 90% of their PPO with 60 seconds of active recovery.~Supervised exercise sessions: Measures include HR, BP, RPEs, Feeling Scale, and PPO. After warming up, individualized work/rest phases will be prescribed based on their PPO from their maximal aerobic test. Participants will be held at 90% PPO as a constant target intensity to start, shortening the work phase, and if necessary, lengthening the recovery phase. These parameters will be progressed each session. The trainer will determine when to change their work/rest parameters based off of HR and RPEs.~Unsupervised exercise sessions: Participants will repeat the same HIIT protocol they performed during the previous supervised session. The bike computer automatically stores HR and PPO."
224164346|NCT03609710|DEVICE|Transanal tube placement|Transanual tube placement after anastomosis in low anterior resection for rectal cancer.
224164347|NCT03609710|PROCEDURE|Left colic artery preservation|Left colic artery preservation during operation for lower rectal cancer
223478765|NCT00284856|DRUG|Comparator: fluticasone|fluticasone propionate 250 mcg twice daily, 6 month treatment period
223478766|NCT00284856|DRUG|Comparator: Placebo|montelukast 10 mg Pbo tablet once daily, 6 month treatment period
224164348|NCT03609710|PROCEDURE|Anastomotic reinforcing sutures|Anastomotic reinforcing sutures during operation for lower rectal cancer
224164349|NCT03609710|DEVICE|Robotic surgery|Robotic low anterior resection for rectal cancer
224164350|NCT03199014|DEVICE|deploying the Drug-eluting Stents with a prolonged time|the inflation time was more than 30 seconds when the Drug-eluting Stents deploying.The PROMUS Element Plus Stent or Co-Cr sirolimus-eluting coronary stent system（GuReater）was used in this study
224164351|NCT03199014|DEVICE|deploying the Drug-eluting Stents with a conventional time|the actual inflation time was within 10s determined by interventional cardiologist.The PROMUS Element Plus Stent or Co-Cr sirolimus-eluting coronary stent system（GuReater）was used in this study
224164352|NCT04682795|DEVICE|Needle-free injector|Using needle-free injector as insulin carrier to treat T2DM
224164353|NCT04682795|DEVICE|Insulin pen|Using insulin pen as insulin carrier to treat T2DM
224164354|NCT02082665|DRUG|Rosuvastatin10 mg tablet|Commercially available Rosuvastatin 10 mg tablets will be supplied. Single oral dose of Rosuvastatin 10 mg will be administered on Day 1, 8 and 22
224164355|NCT02082665|DRUG|Midazolam 3 mg syrup|Commercially available Midazolam syrup will be supplied.Single oral dose of Midazolam 3 mg syrup will be administered on Days 1, 8 and 22
224164356|NCT02082665|DRUG|Dabrafenib 75 mg capsule|Dabrafenib 75mg will be supplied in the form of capsules. Oral dose Dabrafenib 150 mg (2 x 75 mg) BID will be administered at 12 h apart on Days 8 through 22 and 150 mg (2 x 75 mg) OD on Day 23.
224164357|NCT04584944|RADIATION|Dual energy X-ray absorptiometry|"Evaluation of the appendicular muscle mass of the limbs will be performed by Dual-Energy X-ray Absorptiometry, using a QDR 4500. Body composition analysis will also be evaluated with TANITA Body Composition Analyzer device,model BC-418MA. Bioelectrical Impedance Analysis measures the body composition using a constant power source (high frequency current 50kHz, 90 μA).~Muscle mass is also going to be measured by using ultrasound -U/S. It measures basic parameters such as muscle volume and spectrum length through the B-Mode imaging with Linear 7-12MHz frequency heads that can reliably determine the thickness and transverse incisions of the superficial muscular Groups."
224164358|NCT04743869|DEVICE|Kyphos FS™ Bone Substitute|Dorsal instrumentation via Longitude II (Medtronic Austria GmbH/Vienna) and balloon kyphoplasty are performed. KyphOs FS™ bone cement will be introduced in the fractured vertebral body.
224164359|NCT04743869|DEVICE|KYPHON ActivOs® Bone Cement with Hydroxyapatite|Dorsal instrumentation via Longitude II (Medtronic Austria GmbH/Vienna) and balloon kyphoplasty are performed. KYPHON ActivOs® Bone Cement with Hydroxyapatite will be introduced in the fractured vertebral body.
224164360|NCT05987514|DIAGNOSTIC_TEST|multimodal ultrasound|contrast-enhanced ultrasound and shear wave elastography on liver target lesion
224164361|NCT03813199|DRUG|ABX464 50mg|ABX464 is a new anti-inflammatory drug
224164362|NCT03813199|DRUG|Matching Placebo|placebo matching with ABX464
223478767|NCT01192815|DRUG|erlotinib hydrochloride|Given orally or via gastronomy tube
223478768|NCT01192815|RADIATION|intensity-modulated radiation therapy|IMRT will be given in 35 fractions over 7 weeks. The primary tumor and involved nodes (PTV70) will receive 2 Gy per fractions, intermediate-risk areas (PTV63) will receive 1.8 Gy per fractions, and subclinical disease sites (PTV56) will receive 1.6 Gy perfraction. The total doses will thus be 70 Gy, 63 Gy and 56 Gy, respectively.
224164363|NCT03813199|DRUG|ABX464 100mg|ABX464 is a new anti-inflammatory drug
224164364|NCT03813199|DRUG|Methotrexate|MTX ≥ 10 mg/week will be given at previous dose regimen kept stable throughout the study
223478769|NCT01192815|OTHER|pharmacogenomic studies|Optional correlative studies
223478770|NCT01192815|OTHER|gene expression analysis|Correlative studies
224164365|NCT05580237|PROCEDURE|Simultaneous right and left heart catheterization|Pressure recordings across the aortic valve with simultaneous flow measurements by right heart catheterization, during rest and during supine exercise.
224164366|NCT03961139|OTHER|Method of feeding; continuous feeding OR bolus feeding|"CF: Infants fed through a naso or orogastric tube in a continuous fashion using syringe pump. Each feed cycle is of 4 hours (3 hrs continuous feeding and 1 hour rest). 6 feed cycles in a day.~BF: Infants fed through a naso or orogastric tube in a gravity dependent bolus feeding every 2-3 hours. Each feed would take approximately 10 minutes."
224164367|NCT03278444|OTHER|Basic drugs therapy of HCC|Basic drugs include: 1. Molecular targeted drugs for HCC：apatinib; 2. Antiviral drugs (ETV or TDF) should be given to patients who were infected with HBV or HCV; 3. Patients with liver dysfunction should be treated with conventional hepatoprotective agents drugs (including glycyrrhizin, reduced glutathione, vitamin C，etc); 4. Patients with ascites symptoms should be treated with furosemide and spironolactone according to the urine volume, and they also should be treated with proton pump inhibitors in the prevention of gastrointestinal bleeding; 5. Other basic diseases were treated routinely.
223478771|NCT01192815|RADIATION|3-dimensional conformal radiation therapy|"The initial target volume encompassing the gross and subclinical disease sites will receive 2.0 Gy per fraction, five fractions a week to 54 Gy in 27 fractions in 5.4 weeks. The boost volume covering gross tumor and clinically/radiologically involved nodes will receive boost irradiation for additional 16 Gy at 2.0 Gy. The primary tumor and clinically/radiologically-involved nodes will thus receive 70 Gy in 35 fractions over 7 weeks, and uninvolved upper neck nodes will receive an elective dose of 54 Gy in 5.4 weeks.~The uninvolved lower neck nodes will receive 2.0 Gy per fraction at 3-cm depth to a total dose of 50 Gy in 25 fractions in 5.0 weeks through a matching AP or AP/PA lower neck field."
223478772|NCT01192815|OTHER|biopsy|Optional correlative studies
223478773|NCT01192815|OTHER|pharmacological study|Optional correlative studies
223478774|NCT01192815|OTHER|laboratory biomarker analysis|Optional correlative studies
223478775|NCT01192815|OTHER|questionnaire administration|Optional ancillary studies
223478776|NCT01192815|OTHER|enzyme-linked immunosorbent assay|Optional correlative studies
224164368|NCT03278444|DRUG|Arginine hydrochloride|Arginine hydrochloride injection 5g/dose; 40g/d; ivgtt; sustained medication for 24 days; drug withdrawal for 4 days.
224164369|NCT03278444|DRUG|Trimetazidine hydrochloride|Trimetazidine hydrochloride tablets 20mg/tablet, 40mg, twice a day.
224164370|NCT05909462|DRUG|2 ml of 40 mg triamcinolone acetonide and 4 ml of 1% lidocaine|ultrasonography-guided suprascapular nerve block and intra-articular shoulder injection
224164371|NCT02458742|DRUG|Morphine|0.5%Hyperbaric bupivacaine 2 ml add morphine 50 mcg for spinal anesthesia
224164372|NCT02458742|DRUG|Placebo|0.5%Hyperbaric bupivacaine 2 ml for spinal anesthesia
224164373|NCT04857606|DRUG|AMG 609|Single dose of AMG 609 administered as a subcutaneous injection.
224164374|NCT04857606|DRUG|Placebo|Single dose of placebo administered as a subcutaneous injection.
224164375|NCT05382806|DRUG|Flumazenil|During the procedure, continuous infusion of remimazolam dose of 2mg/kg/hr. when procedure ends, infusion remimazolam stops and 0.9% normal saline or 0.2mg of flumazenil according to allocated groups.
224164376|NCT00671476|DRUG|pegylated liposomal doxorubicin hydrochloride|
224164377|NCT00671476|GENETIC|DNA methylation analysis|
224164378|NCT00671476|GENETIC|TdT-mediated dUTP nick end labeling assay|
224164379|NCT00671476|GENETIC|fluorescence in situ hybridization|
224164380|NCT00671476|GENETIC|loss of heterozygosity analysis|
224164381|NCT00671476|GENETIC|polymerase chain reaction|
224164382|NCT00671476|OTHER|immunoenzyme technique|
224164383|NCT00671476|OTHER|immunohistochemistry staining method|
224164384|NCT00671476|OTHER|laboratory biomarker analysis|
223478777|NCT01192815|OTHER|polymorphism analysis|Optional correlative studies
223478778|NCT05473845|PROCEDURE|Acupressure intervention|Acupressure
224164385|NCT00671476|PROCEDURE|breast duct lavage|
224164386|NCT00671476|PROCEDURE|neoadjuvant therapy|
224164387|NCT00671476|PROCEDURE|therapeutic conventional surgery|
224164388|NCT00850135|DEVICE|The Seven Continuous Glucose Monitoring System|Between 24-28 weeks of gestation, the recommended period of glucola testing, a soft sensor for continuous glucose monitoring system (CGMS) will be inserted superficially under the skin. The patient will be instructed on how to wear and care for the device. She will wear the CGMS for 7 days, then return to the clinic for removal of the device, and downloading of the data. Finger stick blood glucoses will be checked by the patient 2 times daily during the 7 days of wearing the CGMS.
224164389|NCT00723086|DRUG|docetaxel (XRP6976)|combined treatment with prednisolone
224164390|NCT00125697|PROCEDURE|3T MRI Scanning|pre-radiation therapy, week 4 radiation therapy, 2 months post radiation therapy and every 4 months for the first year
224164391|NCT00113906|DRUG|melatonin|
224164392|NCT01401985|DRUG|TD-1211|Capsules
224164393|NCT01401985|DRUG|Placebo|Capsules
224164394|NCT04630444|DRUG|Riluzole|30 PTSD patients with riluzole 100 mg daily (50 mg bid).
224164395|NCT02237144|OTHER|Cash transfer|1500 taka ($18.75) per household distributed monthly
223478779|NCT05473845|PROCEDURE|Reiki intervention|Reiki
223478780|NCT00477009|DEVICE|Mandibular repositioning appliance, adjustable|Comparison between mandibular repositioning appliance for nightly use and a placebo device regarding effects on sleep apneas and daytime symptoms as well as blood pressure and markers of oxidative stress and sleepiness.
224164396|NCT02237144|OTHER|Food transfer|30 kg rice, 2 kg lentils, and 2 kg micro-nutrient fortified cooking oil per household distributed monthly
224164397|NCT02237144|OTHER|Food and cash transfer|15 kg of rice; 1 kg of lentils and 1 kg of micronutrient fortified cooking oil and 750 taka cash per household, distributed monthly
224164398|NCT02237144|BEHAVIORAL|Behavior Communication Change (BCC)|Weekly, one hour meetings on maternal and child nutrition, sanitation and health knowledge, attitudes and practice Occasional home visits
224164399|NCT00658866|PROCEDURE|Microdialysis|PK measurements with microdialysis
224164400|NCT05098249|DRUG|Verum|The participant takes two capsules Phoscap® (3mmol/capsule) orally three times a day over 30 days beginning the day of Ferinject administration.
224164401|NCT05098249|DRUG|Placebo|The participant takes wo capsules Placebo orally three times a day over 30 days beginning the day of Ferinject administration.
224164402|NCT00836316|DRUG|levobupivacaine|intraperitoneal administration of levobupivacaine on pain after laparoscopic cholecystectomy
224164403|NCT00338806|BEHAVIORAL|Interpersonal psychotherapy for prevention with adolescents|Individual interpersonal psychotherapy with the adolescents will be conducted over 12 weeks and will include a family psychoeducation component.
224164404|NCT00338806|BEHAVIORAL|Educational clinical monitoring|Educational clinical monitoring will include two individual sessions of psychoeducation on mood disorders with the adolescent followed by monthly (and if needed bimonthly) meetings with therapist. If more sessions are required, a referral will be made.
224164405|NCT02640430|DEVICE|standard treatment|20 minutes, twice a day for 10 sessions
224164406|NCT02640430|DEVICE|Free Aspire|20 minutes, twice a day for 10 sessions
224164407|NCT03284151|RADIATION|Cyberknife|
224164408|NCT00571051|BEHAVIORAL|Mindfulness Based Stress Reduction|8 week course in mindfulness training
224164409|NCT00311090|DRUG|Idrabiotaparinux sodium|"0.5 mL pre-filled syringe for 3.0 mg~Subcutaneous injection"
224164410|NCT00311090|DRUG|Idraparinux sodium|"0.5 mL pre-filled syringe for 2.5 mg~Subcutaneous injection"
224164411|NCT00311090|DRUG|Avidin|"100 mg in 10 mg/mL solution~Intravenous infusion for 30 minutes"
224164412|NCT00311090|DRUG|Placebo (for Avidin)|"Avidin matching powder in 10 mg/mL solution~Intravenous infusion for 30 minutes"
224164413|NCT00744991|DRUG|Enzastaurin|1125 milligrams (mg) loading dose then 500 mg, oral, daily, until disease progression
224164414|NCT05953103|DRUG|Synbixin/Placebo|Synbixin/Placebo
224164415|NCT02186886|DRUG|Golimumab|Physiological Intermolecular Modification Spectroscopy
224164416|NCT02302586|DRUG|Thoracic paravertebral block (TPVB)|Thoracic paravertebral block (TPVB) is being performed by injecting 5 mL of Bupivacaine 0.5% to 4 consecutive level of paravertebral spaces between T4 and T8 by using landmark technique
224164417|NCT02302586|DRUG|Patient Controlled Analgesia (IV PCA)|IV morphine patient controlled analgesia (PCA) is being used in the postoperative period for 48 hours. Basal infusion: 0.3 mg/kg/h, Bolus: 1 mg, Lock-out time: 20 min, 4-h limit: 10-12,5 mg
224164418|NCT01307228|OTHER|Health Systems Evidence|Health Systems Evidence (HSE) contains over 1400 research syntheses about governance, financial and delivery arrangements within health systems and about implementation strategies relevant to health systems. The syntheses have been: 1) categorized by topic, type of synthesis, and type of question addressed; 2) coded by the last year in which searches for studies were conducted and by the countries in which included studies were conducted; 3) rated for quality; and 4) linked to publicly available user-friendly summaries, scientific abstracts, and full-text reviews. We identified systematic reviews in HSE that are not accessible to study participants and developed a mechanism to reimburse publishers for full-text downloads of these reviews.
224164419|NCT01919086|DRUG|Bortezomib|Bortezomib SC (or IV if SC not tolerated) 1.5 mg/m\^2, days 1, 8, 15 and 22
224164420|NCT01919086|DRUG|Dexamethasone|Dexamethasone 40 mg PO or IV days 1, 4, 8,15 and 22 or on a split-dose regimen. (20mg BIW).
224164421|NCT01919086|DRUG|Lenalidomide|Lenalidomide may be added to the patient's regimen at any time if there is evidence of hematologic disease progression
224164422|NCT05299151|OTHER|Vestibular exercises|The vestibular exercise program basically consists of 3 groups of exercises: adaptation, substitution, and habituation exercises. It is aimed to provide vestibular adaptation with adaptation exercises. Exercises that include visual and somatosensory cues to improve gaze and postural stability constitute substitution exercises. Balance exercises can be performed with eyes open and closed, or somatosensory cues can be changed by performing them on soft ground. Removing or reducing clues allows the patient to use other systems as well. The basis of habituation exercises is the reduction of the pathological response as a result of repeated exposure to the provocative stimulus. Habituation is specific to the type, intensity, and direction of stimuli. In most cases, the movement that stimulates the pathological response is less frequently performed during daily activities and promotes compensation for the initially abnormal signal of treatment.
224164423|NCT05299151|OTHER|Standard neurorehabilitation exercises|A neurorehabilitation program based on stretching, strengthening, posture, mobilization, static and dynamic balance exercises (standing on one leg, tandem, balance board, etc.) will be applied.
224164424|NCT02644694|DRUG|Dexamethasone Phosphate Ophthalmic Solution|Experimental: Dexamethasone Phosphate Ophthalmic Solution (40 mg/mL) delivered via the EyeGate II Drug Delivery System
224164425|NCT00665691|OTHER|Nutritional Screening Tools|To compare the nutrition risk identification abilities of two nutrition screening tools: PEDSGA tool and the standard assessment tool.
224164426|NCT01858506|PROCEDURE|I-ACE intervention|lifestyle counselling using the interactive assessment, counselling and education (I-ACE)-based method.
224164427|NCT01858506|PROCEDURE|Standard Lifestyle Advice|lifestyle counselling using the standard lifestyle advice (SLA) program currently provided to Clalit Health Services patients.
224164428|NCT01215786|DRUG|AGN-207281 ophthalmic solutions (0.1% and 0.3%); AGN-207281 vehicle ophthalmic solution (placebo)|One drop of AGN-207281 ophthalmic solutions (0.1% on Days 1-7 and 0.3% on Days 8-14) instilled to both eyes in the morning followed by one drop of AGN-207281 vehicle ophthalmic solution (placebo) instilled to both eyes in the evening for 13 days.
224164429|NCT01215786|DRUG|timolol ophthalmic solution 0.5%|One drop of timolol ophthalmic solution 0.5% instilled to both eyes, in the morning for 14 days, and in the evening for 13 days
224164430|NCT01215786|DRUG|AGN-207281 vehicle ophthalmic solution (Placebo)|One drop of AGN-207281 vehicle ophthalmic solution instilled to both eyes, in the morning for 14 days and in the evening for 13 days.
224164431|NCT02515851|DRUG|Exparel|
224164432|NCT02515851|DRUG|Placebo|
224164433|NCT04259346|DRUG|Ixekizumab|Administered SC.
224164434|NCT03021928|OTHER|Time-To-Treatment Randomization|The time after symptom onset to initiate treatment will be randomized to one of four possible treatment arms: 72 (+/- 24) hours, 132 (+/- 12) hours, 228 (+/- 12) hours, and 324 (+/- 12) hours.
224164435|NCT00085644|BIOLOGICAL|adalimumab (D2E7)|Adalimumab 40 mg every other week, subcutaneous
224164436|NCT00085644|BIOLOGICAL|placebo|Placebo every other week, subcutaneous
224164437|NCT06026423|OTHER|Clinical examination and pictures|A clinical examination is needed to assess the healing process for the three groups. After assessing the healing process, we will take pictures of the tear for documentation.
224164438|NCT06026423|OTHER|Questionnaire|The participant will answer questions, serving as a baseline questionnaire, when arriving at the clinical examination one month post-partum. At three and 9-12 months post-postpartum, they will receive another questionnaire. The questionnaire will consist of validated questions regarding body image, pain, Urogynecological problems as symptoms of prolapse, urinary and anal incontinence, and questions about sexual problems.
224164439|NCT00572065|DRUG|arsenic trioxide|"Cytarabine will be administered at a dose of 10 mg/m2 subcutaneously (sc) twice daily (bid) from days 1-14. Triseonx will be administered at a dose of 0.25 mg/kg on days 1-5 and days 8-12. Trisenox will be restarted only when the QT interval returns to less than 500 msec. One treatment cycle consists of 2 weeks, with 14 days of cytarabine and 10 days of ATO.~Subsequent cycles will be administered at the investigator's discretion, depending on response and tolerability. Patients may continue to receive treatment with Trisenox /LDAC for a period of up to 2 years as long as stable disease or clinical benefit and absence of unacceptable toxicity can be demonstrated."
224205402|NCT03039517|DEVICE|Compression garments (stockings)|"Compression garments (stockings) now serve as the generally recommended standard of care for patients post DVT and will be utilized as the control compression method in this study. Compression garments utilized in this study will be below the knee style with a pressure range of 30-40 mmHg. If a patient does not have compression garments as indicated, these stockings will be provided."
224205403|NCT04008082|DRUG|Lenvatinib|Lenvatinib capsule.
223584231|NCT00905086|OTHER|questionnaire administration|Two weeks before completing planned radiotherapy, patients undergo assessment of stress appraisal and other factors predictive of post-radiotherapy psychosocial adjustment. At 1 month after completion of radiotherapy, patients undergo repeat assessment of stress appraisal and psychosocial adjustment.
223761377|NCT01574352|BEHAVIORAL|Small intervention|The control group are offered a weekly 1 hour training or activity session during six weeks. Furthermore two sessions where the parents are invited to participate in information about diet and exercise.
224164440|NCT00572065|DRUG|cytarabine|"Cytarabine will be administered at a dose of 10 mg/m2 subcutaneously (sc) twice daily (bid) from days 1-14. Trisenox will be administered at a dose of 0.25 mg/kg on days 1-5 and days 8-12. Trisenox will be restarted only when the QT interval returns to less than 500 msec. One treatment cycle consists of 2 weeks, with 14 days of cytarabine and 10 days of ATO.~Subsequent cycles will be administered at the investigator's discretion, depending on response and tolerability. Patients may continue to receive treatment with Trisenox /LDAC for a period of up to 2 years as long as stable disease or clinical benefit and absence of unacceptable toxicity can be demonstrated."
224164441|NCT03685929|PROCEDURE|Punch skin biopsy|Two punch biopsies will be performed in each patient, one at the border of the skin lesion, and one at the adjacent healthy skin. A disposable biopsy punch of 4 mm will be used. A biopsy punch is a small circular blade (like an apple corer) which is rotated into the skin to obtain a cylindrical specimen. Local anaesthesia will be applied and the circular wound will be closed by a single suture. Sutures will be removed after one week.
224164442|NCT02805894|DRUG|NBTXR3 activated by IMRT only|Single local administration of NBTXR3 by injection into the prostate gland prior to the IMRT treatment
224164443|NCT02805894|DRUG|NBTXR3 activated by Brachytherapy & IMRT|Single local administration of NBTXR3 by injection into the prostate gland prior to the Brachytherapy \& IMRT treatment
224164444|NCT06019091|DEVICE|Compass Health TENS 3000, 3 mode Analog Unit|The TENS unit Compass Health TENS 3000, 3 mode Analog Unit will be configured based on randomization to 20 Hz, 50 Hz, or 100 Hz. Pulse width 200 microseconds, Normal (N) Mode. It will be used on the posterior tibial nerve via a patch that is supplied each day for 30 minutes of the day. These 30 minutes of intervention will occur at the participants most painful time of the day for their pain.
224164445|NCT03330106|DRUG|Pevonedistat|Pevonedistat intravenous infusion.
224164446|NCT03330106|DRUG|Docetaxel|Docetaxel intravenous infusion.
224164447|NCT03330106|DRUG|Carboplatin|Carboplatin intravenous infusion.
224164448|NCT03330106|DRUG|Paclitaxel|Paclitaxel intravenous infusion.
224164449|NCT01404806|DRUG|GSK1349572 (dolutegravir)|Subjects will take an oral daily 50mg dose of GSK1349572 for 5-7 days. GSK1349572 in the CVF and BP will be measured over 24 hours after both the initial dose, and once steady state is reached 5-7 days later at the following time points: 0 (pre-dose) 1, 2, 3, 4, 5, 6, 8, 12, 18, and 24h. Cervical and vaginal biopsies will be collected once at initial dose at either 3, 6, 12 or 24 hours post dose, and again at steady state at the same single time point. Samples will be collected from 2 subjects per time point. BP and CVF samples will be obtained at 48 and 72 hours following the final GSK1349572 dose.
224164450|NCT00623766|DRUG|Ipilimumab|10 mg/kg, administered as an intravenous infusion every 3 weeks during induction and every 12 weeks during maintenance
224164451|NCT00623766|DRUG|Corticosteroid: Betamethasone|Participants in the corticosteroid-dependent arm for whom adequate control of metastatic brain lesion-related neurologic signs and symptoms required concurrent corticosteroid therapy with betamethasone
224164452|NCT00623766|DRUG|Corticosteroid: Dexamethasone|Participants in the corticosteroid-dependent arm for whom adequate control of metastatic brain lesion-related neurologic signs and symptoms required concurrent corticosteroid therapy with dexamethasone
224164453|NCT00623766|DRUG|Corticosteroid: Fludrocortisone|Participants in the corticosteroid-dependent arm for whom adequate control of metastatic brain lesion-related neurologic signs and symptoms required concurrent corticosteroid therapy with fludrocortisone
224164454|NCT00623766|DRUG|Corticosteroid: Hydrocortisone|Participants in the corticosteroid-dependent arm for whom adequate control of metastatic brain lesion-related neurologic signs and symptoms required concurrent corticosteroid therapy with hydrocortisone
224164455|NCT00623766|DRUG|Corticosteroid: Meprednisone|Participants in the corticosteroid-dependent arm for whom adequate control of metastatic brain lesion-related neurologic signs and symptoms required concurrent corticosteroid therapy with meprednisone
224164456|NCT00623766|DRUG|Corticosteroid: Methylprednisolone|Participants in the corticosteroid-dependent arm for whom adequate control of metastatic brain lesion-related neurologic signs and symptoms required concurrent corticosteroid therapy with methylprednisolone
224164457|NCT00623766|DRUG|Corticosteroid: Prednisolone|Participants in the corticosteroid-dependent arm for whom adequate control of metastatic brain lesion-related neurologic signs and symptoms required concurrent corticosteroid therapy with prednisolone
224164458|NCT00623766|DRUG|Corticosteroid: Prednisone|Participants in the corticosteroid-dependent arm for whom adequate control of metastatic brain lesion-related neurologic signs and symptoms required concurrent corticosteroid therapy with prednisone
224164459|NCT00623766|DRUG|Corticosteroid: Triamcinolone|Participants in the corticosteroid-dependent arm for whom adequate control of metastatic brain lesion-related neurologic signs and symptoms required concurrent corticosteroid therapy with triamcinolone
224164460|NCT05071911|PROCEDURE|TAD (Targeted Axillary Dissection)|Dual agent SLNB + resection of proven lymph nodes metastasis marked with clip at diagnosis
224164461|NCT04555811|DRUG|FT596|FT596 is given 2-3 days after rituximab; however, it may be delayed for up to 7 days until all rituximab infusion related toxicities resolve to ≤Grade 1.
224164462|NCT04555811|DRUG|Rituximab|Rituximab 375 mg/m\^2 is administered as an IV infusion per institutional standard of care and package insert on 2-3 days (48 to 72 hours) prior to the FT596 infusion
224164463|NCT00421590|DRUG|SMC021|
224164464|NCT00000895|DRUG|Nelfinavir mesylate|
224164465|NCT00000895|DRUG|Nevirapine|
223478781|NCT04113135|OTHER|Yoga|Participants will be lead through a series of yoga poses by a licensed physical therapist with advanced training in yoga. Participants in this group will also receive education related to MS as well as SMART goal setting, journaling and guided meditation. Modifications will be offered as needed.
223478782|NCT04113135|OTHER|Control|Participants in this group will receive education related to MS as well as SMART goal setting, journaling, and guided meditation.
223478783|NCT05692440|DEVICE|Intracept Procedure|Intraosseous radiofrequency ablation of the basivertebral nerve
223478784|NCT06298734|BEHAVIORAL|Exercise Program|A high-intensity interval training, aerobic exercise program virtually supervised, home-based, and appointment-based program under direct one-on-one supervision by a trained oncology exercise specialist. Sessions will be conducted via the Zoom platform. Participants will be provided with home stationary bike, heart rate monitor, blood pressure monitor. For participants who do not have a smart device, a Wi-Fi enabled tablet will be provided.
224164466|NCT00000895|DRUG|Azithromycin|
224164467|NCT05265390|OTHER|Adolescents watching an informational video|In the information video; The materials used during the PCR test, how long the process will take, how the sample will be taken, why healthcare professionals wear personal protective equipment, and what adolescents should do are included.
224164468|NCT01358006|DRUG|JNJ-40411813|Cohort 1: Type=2 to 3, unit=mg, number=200 to 300, form=capsule, route=oral use.Capsule(s) taken in the fed state Capsule(s) taken in the fed state.
224164469|NCT01358006|DRUG|JNJ-40411813|Cohort 2: Type=up to 7, unit=mg, number=up to 700 mg, form=capsule, route=oral use. Capsule(s) taken in the fed state.
224164470|NCT04085991|DRUG|131I-PSMA-1095 Radioligand Therapy (RLT)|Intravenous injection of 100 mCi of 131I-PSMA-1095, Q8 weeks up to a maximum of 4 doses.
224164471|NCT03198728|DRUG|SOV2012-F1|oral preparation of testosterone undecanoate (TU)
224164472|NCT03198728|DRUG|AndroGel|topical testosterone gel 1.62%
224164473|NCT04132128|OTHER|carbohydrate counting|taught how to count carbohydrates in their diet with their personal tool
224164474|NCT03593564|BEHAVIORAL|KINDER|KINDER is an online course for people assisting an older adult with dementia. It is intended to improve the quality of caregiver's relationship with the care recipient and reduce the chance of risky relationship behavior (e.g., yelling). Courses will cover topics including understanding cognitive impairments, navigating evolving roles, and dealing with frustration. During this course, participants will learn skills to deal with difficult situations caregivers frequently encounter in ways that support a healthy caregiving relationship. Videos will be story-based and represent different types of caregiving relationships and challenges encountered.
224164475|NCT04873895|DRUG|Axitinib 5 MG|axitinib 5 mg po BID until progression or intolerance
224164476|NCT04873895|DRUG|Hydroxychloroquine Pill|hydroxychloroquine 600 mg po BID until progression or intolerance
224164477|NCT04873895|PROCEDURE|trans arterial chemoembolization|segmental or lobar TACE at 4-8 week intervals until entire tummy burden is treated.
224164478|NCT01836029|DRUG|VTX-2337|TLR8 Agonist
224164479|NCT01836029|DRUG|Carboplatin|
224164480|NCT01836029|DRUG|Cisplatin|
224164481|NCT01836029|DRUG|5-fluorouracil|
224164482|NCT01836029|DRUG|Placebo|
224164483|NCT04476706|DRUG|canakinumab|canakinumab
224164484|NCT02625363|OTHER|Glucose Ref - Std|First, fasting blood glucose was measured. Then, subjects consumed the glucose sample in 5-10 minutes and blood sugar level were measured at 0', 15', 30', 45', 60', 90', and 120'
224164485|NCT02625363|OTHER|Glucose Ref and 450 ml water|First, fasting blood glucose was measured. Then, subjects consumed the glucose sample in 5-10 minutes. Subjects given additional 150 ml water at 45, 75, and 105 minutes and blood sugar level were measured at 0', 15', 30', 45', 60', 90', and 120
224164486|NCT02625363|OTHER|White Bread with 250 ml water|First, fasting blood glucose was measured. Then, subjects consumed the samples in 10-15 minutes and blood sugar level were measured at 0', 15', 30', 45', 60', 90', and 120'
224164487|NCT02625363|OTHER|White Bread and 700 ml water|"Sample consumed with 250 ml water immediately after meal consumption, and additional 150 ml water at 45, 75, and 105 minutes.~First, fasting blood glucose was measured. Then, subjects consumed the samples in 10-15 minutes and blood sugar level were measured at 0', 15', 30', 45', 60', 90', and 120'"
224164488|NCT02625363|OTHER|White Bread with 125 ml water (twice)|"Sample consumed with 125 ml water immediately after meal consumption, and additional 125 ml water after 60 minutes~First, fasting blood glucose was measured. Then, subjects consumed the samples in 10-15 minutes and blood sugar level were measured at 0', 15', 30', 45', 60', 90', and 120'"
224164489|NCT00004205|DRUG|letrozole|Letrozole 2.5 mg daily oral administration.
224164490|NCT00004205|DRUG|tamoxifen citrate|Tamoxifen 20 mg daily oral administration.
224164491|NCT01396031|BEHAVIORAL|Physical Therapy|Standard of care
224164492|NCT04051944|DRUG|Rozanolixizumab|Subjects will receive rozanolixizumab in a specified sequence during the treatment period.
224164493|NCT03518775|DEVICE|Biometry|Measurement of Cornea
224164494|NCT04224909|DIAGNOSTIC_TEST|Video Head Impulse Test|Diagnosis of dysfunction of the semicircular canals using the vHIT
224164495|NCT02139280|DRUG|Cyclophosphamide|Mechanism of action: Cyclophosphamide is a pro drug that requires activation. Following hepatic and cellular activation, phosphoramide mustard and acrolein are formed. Phosphoramide mustard is the alkylating agent that demonstrates cytotoxic effects. Acrolein binds to proteins but does not contribute to the anti-tumor effects.
224164496|NCT02615561|DEVICE|Bepanthen Itch Relief Cream: Phoenix 2 (Bepanthen Sensiderm, BAY207543)|2-3 times daily using multiples of Finger Tip Units (FTUs) depending on size of the area of the flares
224164497|NCT02615561|OTHER|New cosmetic Bepanthen product: Pumpkin (BAY207543)|Twice daily on the whole body; about 10 FTUs (i.e. 5g) per application depending on age of subject
224164498|NCT02615561|OTHER|Stelatopia (cosmetic comparator)|Twice daily on the whole body; about 10 FTUs (i.e. 5g) per application depending on age of subject
224164499|NCT00899366|GENETIC|microarray analysis|
224164500|NCT00899366|GENETIC|mutation analysis|
224164501|NCT00899366|OTHER|immunologic technique|
224164502|NCT05907083|RADIATION|cone beam computer tomography|Cone Beam CT Radiation
224164503|NCT02394366|OTHER|Original Healing Salve (OHS)|Topical salve (Puremedy, Inc.)
224164504|NCT02394366|OTHER|OHS base only|Olive and beeswax salve base
224164505|NCT03477864|BIOLOGICAL|Ipilimumab|Given via intraprostatic injection
224164506|NCT03477864|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|Undergo SBRT
224164507|NCT03477864|PROCEDURE|Radical Prostatectomy|Undergo radical prostatectomy
224164508|NCT03477864|BIOLOGICAL|Anti-PD-1 Monoclonal Antibody REGN2810|Given IV
224164509|NCT00736450|BIOLOGICAL|oblimersen sodium|Given IV
224164510|NCT00736450|BIOLOGICAL|rituximab|Given IV
224164511|NCT00736450|DRUG|cyclophosphamide|Given IV
224164512|NCT00736450|DRUG|doxorubicin hydrochloride|Given IV
224164513|NCT00736450|DRUG|vincristine sulfate|Given IV
224164514|NCT00736450|DRUG|prednisone|Given orally
224164515|NCT00736450|PROCEDURE|biopsy|Correlative studies
224164516|NCT00736450|GENETIC|microarray analysis|Correlative studies
224164517|NCT00736450|OTHER|immunohistochemistry staining method|Correlative studies
223584232|NCT00905086|PROCEDURE|cognitive assessment|Patients complete psychosocial assessments, including measures of patient perceptions of their illness (i.e., cognitive appraisal) and of the factors influencing their perceptions (i.e., uncertainty by the Mishel Uncertainty in Illness Scale-Community Form; symptom distress by the Memorial Symptom Assessment Scale Short Form; and comorbidity by the Charlson Comorbidity Index).
224164518|NCT00736450|GENETIC|gene expression analysis|Correlative studies
224164519|NCT00736450|GENETIC|cytogenetic analysis|Correlative studies
224164520|NCT04157751|DRUG|Empagliflozin|Film-coated tablet
224164521|NCT04157751|DRUG|Placebo to Empagliflozin|Film-coated tablet
224164522|NCT00524667|DRUG|Valproic acid & fludarabine|valproic acid (VPA) starting dose of 15 mg/day p.o. in divided doses, increased weekly by 5 mg/kg/day until \>1mM Fludarabine 40 mg/m2/day orally will be added after completing 28 days of VPA if participant has been identified as having stable or progressive disease.
224164523|NCT00427791|DRUG|Etoposide|60 mg/kg IV Daily Over 4 Hours for 1 Day
224164524|NCT00427791|RADIATION|Total Body Irradiation|3 Gy Daily for 4 Days
224164525|NCT00427791|DRUG|Rituximab|375 mg/m\^2 IV Weekly Over 4-8 Hours for 4 Weeks
224164526|NCT03420157|OTHER|Focus Group|Focus Group of 2 hours. Women will be asked to give their opinion about the communication media of the vaginal self-sampling kit.
224164527|NCT03705156|DRUG|ZL-2306(nirapairb)|The starting dose is 300 mg or 200 mg based on patient's body weight.
224164528|NCT03705156|DRUG|Placebos|The starting dose is the matched dose of placebo (3 capsules or 2 capsules).
224164529|NCT02352181|PROCEDURE|Conventional coagulation profile Analysis|"Transfusional protocol for Standard group Red Blood cells concentrate if Hemoglobin \<9 gram per liter Fibrinogen 3 gram, if fibrinogen \<1gram per liter~Platelet concentrate :~* if platelets \<50gram per liter before transfusion, at anhepatic phase, or in case of bleeding.~* if platelets \<30gram per liter at vascular unclamping time at the end of intervention or without bleeding 2 Fresh frozen plasma if :~* if prothrombin\<40% before transfusion at anhepatic phase or in case of bleeding.~* if prothrombin\<30% at vascular unclamping time at the end of intervention or without bleeding Bolus Tranexamic acid 1g and 3g every 24 hours in case of fibrin degradation products.~Analyses common to both groups: NFS, chemistry panel with ionized serum calcium, blood gas with lactates, HemoCue ®, capillary blood glucose.~Analyses in S Group only: coagulation profile (PT, APTT, INR, fibrinogen, platelet count, soluble complexes, PDF)."
224164530|NCT02352181|PROCEDURE|Rotem analysis|"Transfusional protocol for Rotem group. Red Blood cells concentrate if Hemoglobin \<9 gram per liter Fibrinogen 3 gram, if A10 FIBTEM \<8 mm~Platelet concentrate :~* If MCF EXTEM \<40mm or A10\<35 mm and MCF or A10 FIBTEM \>8mm.~* If platelets \<30gram per liter at vascular unclamping time at the end of intervention or without bleeding.~  2 Fresh frozen plasma if CT EXTEM \>100s.~Bolus Tranexamic acid 1g and 3g every 24 hours :~* if fibrinolysis in EXTEM~* Reduction of 15 % of clotting time or clot formation time and increase of maximum clot firmness in APTEM compared to EXTEM, or maximal lysis at 60 minutes \>15%.~Analyses in R group only: blood sampling on citrated tube for ROTEM analysis (EXTEM, INTEM, FIBTEM, APTEM +/- HEPTEM), coagulation profile (same as that of the S Group, for emergency procedure).~Analyses common to both groups: NFS, chemistry panel with ionized serum calcium, blood gas with lactates, HemoCue ®, capillary blood glucose."
224164531|NCT04282369|DEVICE|HHHFNC|noninvasive ventilation modality
224164532|NCT04282369|DEVICE|NCPAP|noninvasive ventilation modality
224164533|NCT04282369|DEVICE|NIPPV|noninvasive ventilation modality
223478785|NCT06298734|BEHAVIORAL|Diet Program|A virtual dietary consultation program supervised by trained research staff. Appointments will be conducted via the Zoom platform. Participants will receive an education handout at the baseline visit.
224164534|NCT04282369|DEVICE|NHFO|noninvasive ventilation modality
224164535|NCT06106308|DRUG|Onvansertib|Oral capsule
224164536|NCT06106308|DRUG|FOLFIRI|FOLFIRI (irinotecan + fluorouracil \[5-FU\] + leucovorin) as intravenous (IV) infusion
224164537|NCT06106308|DRUG|Bevacizumab|IV Infusion
224164538|NCT06106308|DRUG|FOLFOX|FOLFOX (leucovorin + fluorouracil \[5-FU\] + oxaliplatin) as intravenous (IV) infusion
224164539|NCT01395966|DRUG|DF289|Ear drops
224164540|NCT01395966|DRUG|DF277|Ear drops
223478786|NCT02837926|OTHER|questionnaire|
224164541|NCT01395966|DRUG|DF289 plus DF277|Ear drops
224164542|NCT03960372|BEHAVIORAL|ICT activities|Public education activities using ICT to promote family communication, sharing happiness with family members, and well-being in the community.
224164543|NCT02664389|GENETIC|Genetic analysis|Sequencing of 200 selected genes in the different study populations
224164544|NCT05957328|DRUG|Ferric Pyrophosphate Liposomal|Liposomal iron, a form of ferric pyrophosphate is transported within a phospholipid membrane, absorbed by the intestinal M cells, reaches to the liver directly through lymphatics and finally released. Due to this mechanism, liposomal iron has been reported to have better bioavailability than traditional iron preparations thus requiring lesser dose and producing fewer adverse effects The group would be given liposomal iron syrup at a dose of 1mg per kg per day once a day for 3 months
224164545|NCT05957328|DRUG|ferrous ascorbate|one of the most commonly used forms of iron syrup in children. The group would be given ferrous ascorbate syrup at a dose of 3mg per kg per day once a day for 3 months
224164546|NCT05514106|DRUG|meta-iodobenzylguanidine (MIBG) (123I)|1 administration of 123I-MIBG for a single SPECT scan
224164547|NCT05514106|DIAGNOSTIC_TEST|123I-MIBG scintigraphy|SPECT scan involving 123I-MIBG as the ligand
223478787|NCT02837926|BIOLOGICAL|Gardasil vaccine|
223478788|NCT02837926|BIOLOGICAL|Cervarix®|
223478789|NCT03630848|OTHER|Effect of Protein on Blastocyst Development|Embryo Development Related to The Protein Concentration
223478790|NCT01948245|DEVICE|TaurolockTMHep100|2-4 ml of the catheter lock solution will be instilled after each infusion of parenteral nutrition/intravenous fluids varying between twice weekly to once daily, depending on the individual patients HPN programme. The instilled solution is kept in the catheter until the next infusion, with a prior flushing with 10 ml of Saline both before the instillation of the catheter lock and before infusion of HPN/fluids.
224164548|NCT01425853|DRUG|Chondroitin/Glucosamine (Droglican)|Experimental
224164549|NCT01425853|DRUG|Celecoxib|Active comparator
224164550|NCT05376995|DIAGNOSTIC_TEST|Graston technique|Graston technique among patient of knee osteoarthritis
223478791|NCT01948245|DEVICE|Heparin 100 IE/ml|2-4 ml of the catheter lock solution will be instilled after each infusion of parenteral nutrition/intravenous fluids varying between twice weekly to once daily, depending on the individual patients HPN programme. The instilled solution is kept in the catheter until the next infusion, with a prior flushing with 10 ml of Saline both before the instillation of the catheter lock and before infusion of HPN/fluids.
224164551|NCT05376995|DIAGNOSTIC_TEST|muscle energy technique|muscle energy technique among patient of knee osteoarthritis
224164552|NCT03012282|DIAGNOSTIC_TEST|Computed Tomography Perfusion Imaging|Undergo CT perfusion sequence
224164553|NCT06095544|PROCEDURE|Enhanced recovery for SPK recipients|Pre-operative, perioperative and post-operative were consisted of evidenced-based systematic optimization approaches.
224164554|NCT01937624|DEVICE|Diagnostic Ultrasound|
224164555|NCT01937624|RADIATION|X-ray imaging|
224164556|NCT03374813|DEVICE|MimetikOss (bone grafting surgery)|Ridge preservation bone grafting after dental extraction.
224164557|NCT03374813|DEVICE|Bio-Oss (bone grafting surgery)|Ridge preservation bone grafting after dental extraction.
224164558|NCT03585465|DRUG|Vinblastine|"* Experimentals Arm A or C (First stage): 2 mg/m2/day IV, weekly per cycle, 28 days cycle~* Experimental Arms Metronomic or Metronomic+Nivolumab (second stage): see C"
223478792|NCT06046950|OTHER|Treatment target DAS28CRP-LDA|Aiming for DAS28CRP-low disease activity
223478793|NCT06046950|OTHER|Treatment target SDAI-remission|Aiming for SDAI-remission
223478794|NCT01862042|OTHER|Follow-up diary and questionnaire|A follow-up diary will be completed by the families and the different practitioners working with the patient. One year after the death of the patient, a questionnaire will be proposed to the parents of the child by a psychologist.
223478795|NCT05283434|DRUG|Arnica|Patients will be assigned to the placebo (e.g., unmedicated sugar pill) or experimental group (e.g., Arnica 1M pellets) via a randomization chart from that only the research pharmacist will have access to. Subjects assigned to the experimental group will take the recommended doses of Arnica 1M coated sugar pellets (i.e., 2 pills to be taken every 4 waking hours over a 24 hours period), and will track their pain scores, swelling measurements, sleep rate, ibuprofen doses, adverse reactions, further ED visits, and the number of days/activities the patient has missed for 3 days following their enrollment in the study.
224164559|NCT03585465|DRUG|Cyclophosphamide|"* Arm A (First stage): 30 mg/m2/day PO, D1-4// D8-11// D15-18// D22-25 per cycle, 28 days cycle~* Arm C (First stage): 30 mg/m2/day PO, D1-D4// D15-D18 per cycle, 28 days cycle~* Metronomic or Metronomic+Nivolumab Arm (second stage): see C"
224164560|NCT03585465|DRUG|Capecitabine|"* Arm B (First stage): 400 to 600 mg/m2/day PO, all days per cycle, 28 days cycle~* Arm C (First stage): 400 to 600 mg/m2/day PO, D8-D11// D22-D25 per cycle, 28 days cycle~* Metronomic or Metronomic+Nivolumab Arm (second stage): see C"
224164561|NCT03585465|DRUG|Nivolumab|"* Arm A, B or C (First stage): 3 mg/kg IV, D1 \& D15 per cycle, 28 days cycle~* Metronomic+Nivolumab Arm (second stage): 3 mg/kg IV, D1 \& D15 per cycle, 28 days cycle"
224164562|NCT06316687|OTHER|questionnaire for food consumption frequency|questionnaire about Food consumption frequency, Screen time , Dental neglect scale
224164563|NCT00422903|DRUG|lapatinib|1500 mg administered orally daily
224164564|NCT00422903|DRUG|letrozole|2.5 mg administered orally daily
224164565|NCT00422903|OTHER|placebo|1500 mg administered orally daily
224164566|NCT03885674|OTHER|Video Call Reminder Condition|Receive daily video call reminders from Kessler Foundation research staff directly at the time of each medication dose and instructed to take the medication while on the video call.
224164567|NCT03885674|OTHER|Automated Text Message Reminder Condition|Receive daily automated text messages at the time of each medication dose and will be instructed to take the medication at that time. Each text message reminder will also contain a photo of the medication to be taken. On a weekly basis, study personnel will contact participants in this group to make sure they are receiving the text messages appropriately.
224164568|NCT02688725|DEVICE|post mastectomy ultrasound|post mastectomy ultrasound
224164569|NCT03051269|DRUG|Calcium chloride|Tumour site is injected with a solution of 9 mg/ml calcium chloride and afterwards the tumour site is given electroporation to facilitate calcium to enter the cell cytosol.
224164570|NCT03051269|DEVICE|Electroporation|"Performed by single use electrodes attaches to a device called Cliniporator provided from IGEA, ITALY."
224164571|NCT00801138|DRUG|saline|2 ml 0.9% saline (placebo)
224164572|NCT00801138|DRUG|Dexamethasone|dexamethasone 8 mg (2 ml)
224164573|NCT00801138|DRUG|ropivacaine|30 ml 0.5% ropivacaine
224164574|NCT00801138|DRUG|Bupivacaine|30 ml 0.5% bupivacaine
224164575|NCT00788918|DRUG|Interferon and ribavirin|Interferon 180 microgram weekly s.c. and ribavirin (800/100/1200 mg daily) p.o.
224164576|NCT06081699|DRUG|TNP-2198|Oral
224164577|NCT06081699|DRUG|TNP-2198 Placebo|The placebo for TNP-2198 active drug
224164578|NCT06394076|DEVICE|Cross-linked sodium hyaluronate gel for injection containing lidocaine|Cross-linked sodium hyaluronate gel for injection containing lidocaine
223478796|NCT05283434|DRUG|Placebo|Sugar pill placebo
223478797|NCT02458066|OTHER|IRS: bendiocarb|carbamate insecticide
223478798|NCT02458066|OTHER|IRS: deltamethrin|Pyrethroid insecticide
224164579|NCT01947894|OTHER|Non Interventional Study|Non Interventional Study
224164580|NCT05965531|DRUG|Trifluridine/Tipiracil|TAS-102 is given in a dose of 35 mg/m2, twice daily on the 1st to 5th and 8th to 12th days of the period of neoadjuvant radiotherapy.
224164581|NCT05965531|RADIATION|intensity-modulated radiotherapy|intensity-modulated radiotherapy
224164582|NCT00254878|DRUG|Methylphenidate hydrochloride|
224164583|NCT01302691|DRUG|losartan potassium + hydrochlorothiazide + amlodipine besylate (MK-0954E)|One tablet, containing 50 mg losartan potassium, 12.5 mg hydrochlorothiazide, and 5 mg amlodipine besylate, orally, once daily, for 8 weeks.
224164584|NCT01302691|DRUG|Losartan potassium|One tablet, containing 50 mg losartan potassium, orally, once daily, for 8 weeks.
224164585|NCT01302691|DRUG|Amlodipine besylate|One capsule, containing 5 mg amlodipine besylate, orally, once daily, for 8 weeks.
224164586|NCT01302691|DRUG|Placebo to MK-0954E|One tablet, containing placebo, orally, once daily, for 8 weeks.
224164587|NCT01302691|DRUG|Placebo to losartan potassium|One tablet, containing placebo, orally, once daily, for 8 weeks.
224164588|NCT01302691|DRUG|Placebo to amlodipine besylate|One capsule, containing placebo, orally, once daily, for 8 weeks.
223478799|NCT05615077|OTHER|Combined exercise-education intervention|"Combined exercise and education intervention by fall risk state for 12 months during intervention period.~Exercise intervention includes balance exercise and strength exercise according to protocol.~Education intervention includes medication review, nutrition intervention, and home hazard modification.~The key to medication review is paying special attention to medications known to increase the risk of falls. Reduction of these medications is recommended, and redundant psychotropic medications are withdrawn. Nutrition intervention includes investigating dietary habits and calculate insufficient protein intake to provide customized diet and high protein drink. If vitamin D necessary, supplements are prescribed. Home hazard modification includes providing instructions to reduce and modify the home hazards that increase the risk of falls."
224164589|NCT01817660|PROCEDURE|Open repair of popliteal artery|
224164590|NCT01817660|PROCEDURE|Endovascular repair of popliteal artery|
224164591|NCT06158282|OTHER|Voluntary apnoea|Walking apneas at high lung volume with cycles of 15-10s (apnea - breathing) during 6 minutes
224164592|NCT01231126|DRUG|Misoprostol|Procedures were taken for induced labor delivery with misoprostol 25mcg, by vaginal rout. The pills were administered each 6 hours in a maximum number of six.
224164593|NCT04666025|PROCEDURE|Biospecimen Collection|Undergo collection of nasopharyngeal swabs, blood, and saliva samples
224164594|NCT04666025|OTHER|Diagnostic Laboratory Biomarker Analysis|Correlative studies
224164595|NCT04666025|OTHER|Electronic Health Record Review|Medical charts are reviewed
224164596|NCT04666025|OTHER|Questionnaire Administration|Complete questionnaire
224164597|NCT04309357|DRUG|Alteplase|Alteplase in dose 0.9 mg/kg in acute ischemic patient with indications of thrombolytic therapy
224164598|NCT06033690|BEHAVIORAL|multidisciplinary guide|use of the food guide for education, clarification of doubts
224164599|NCT01335490|OTHER|Cook stoves, either Biolite wood stove, or liquified petroleum gas stove plus fuel|The cooking stoves will reduce air emissions significantly in the home, resulting in improved infant health. It will be given to the mother in the second or third trimester.
224164600|NCT02426112|DRUG|Azithromycin|
224164601|NCT02426112|DRUG|Placebo|
224164602|NCT04858503|OTHER|internet-based cardiac rehabilitation enhancement intervention|Participants in the intervention group will receive a 12-week i-CARE intervention, which will be designed to cover the core elements of CAD self-care: self-care maintenance, self-care monitoring and self-care management. The intervention will comprise: 1) a single individualized face-to-face session and 2) an internet-based intervention through a mobile application. Various behaviour change techniques will be used to increase the self-efficacy of CAD patients in enacting self-care behaviours.
224164603|NCT02989311|DIETARY_SUPPLEMENT|Fortified maize porridge (MNP and Iron)|Maize porridge fortified with MNP and labelled iron compound
224164604|NCT02989311|DIETARY_SUPPLEMENT|Fortified Maize porridge (MNP + Iron + GOS)|Maize porridge fortified with MNP + GOS and labelled iron compound
224164605|NCT02251067|DRUG|VPI-2690B low dose|Comparison of different doses of study drug
224164606|NCT02251067|DRUG|VPI-2690B medium dose|Comparison of different doses of study drug
224164607|NCT02251067|DRUG|Placebo to match VPI-2690B|
224164608|NCT02251067|DRUG|VPI-2690B high dose|Comparison of different doses of study drug
224164609|NCT04321278|DRUG|Hydroxychloroquine + azithromycin|Intervention Group: Hydroxychloroquine + azithromycin. After randomization, Hydroxychloroquine \[400mg 2x/day, 12/12h\] + azithromycin \[500mg 1x/day\]) for 10 days. Standard treatment is according to the treatment protocol for 2019-nCoV infection.
224164610|NCT04321278|DRUG|Hydroxychloroquine|Active Control Group: Hydroxychloroquine. After randomization, Hydroxychloroquine \[400mg 2x/day, 12/12h\] for 10 days. Standard treatment is according to the treatment protocol for 2019-nCoV infection.
224164611|NCT01462968|DEVICE|Activated clotting time versus blood-heparin concentration|Activated clotting time used for heparinization strategy during cardiag surgery versus blood-heparin concentration
224164612|NCT03582969|OTHER|Fecal transplantation|Fecal transplantation administered orally via frozen capsules.
224164613|NCT03582969|OTHER|Placebo|Placebo capsules
224164614|NCT00005806|DRUG|carboplatin|
224164615|NCT00005806|DRUG|gefitinib|
224164616|NCT00005806|DRUG|paclitaxel|
224164617|NCT02280486|DRUG|Saxagliptin|5 mg/d
224164618|NCT02280486|DRUG|Glimepiride|1mg/d, up titrated 1mg if FPG \>6.1 mmol/L (110mg/dL) till 6 mg
224164619|NCT04348786|DRUG|Doxycycline|Doxycylcine 100 mg bid ,esomprazole 20 bid,Bismuth subsalicylate 262 tab.2 tab q.i.d,Tinadizole 500 bid
224164620|NCT04348786|DRUG|Levofloxacin 500mg|Levofloxacin 500 mg qd, amoxicillin 500 2cab bid,Tinadizole 500 bid, esomprazole 20 bid
224164621|NCT04720339|GENETIC|Molecular monitoring by quantification of cell-free DNA|"Molecular monitoring by quantification of cell-free DNA (absolute value and variation from baseline) of two house-keeping genes (RPP30, TMEM11) by droplet digital PCR, during based-immunotherapy treatments of NSCLC patients.~Cell-free DNA will be extracted from 4 ml of plasma before treatments by immunotherapy, obtained from blood Streck® tubes.~Quantification of house-keeping genes (or mutated genes if some are previously routinely identified in tumor tissue) by ddPCR."
224164622|NCT03446612|DRUG|Daprodustat|Daprodustat will be available as 1 mg, 2 mg and 4 mg oral tablets. Daprodustat will be administered once daily by oral route without regard for food.
224164623|NCT03446612|DRUG|Darbepoetin alfa|Darbepoetin alfa will be given as solution for injection for subcutaneous administration every 2 weeks.
224164624|NCT03446612|DRUG|Acetylcholine|Acetylcholine will be used as a challenge agent and will be infused at 7.5, 15 and 30 micrograms/minute each for 6 minutes per infusion into the brachial artery of the test arm.
224164625|NCT03446612|DRUG|Sodium nitroprusside|Sodium nitroprusside will be used as a challenge agent and will be infused at 3 and 10 micrograms/minute each for 6 minutes per infusion into the brachial artery of the test arm.
224164626|NCT03446612|DRUG|L-N-monomethyl arginine acetate (L-NMMA)|L-N-monomethyl arginine acetate will be used as a challenge agent and will be infused at a doses of 2 and 8 micromoles/minute for 6 minutes into the brachial artery of the test arm.
224164627|NCT00987610|DEVICE|Percutaneous coronary intervention (PCI)|PCI for chronic total occlusion is performed using either arm of guidewire
224164628|NCT02959112|DRUG|Epinephrine|
224164629|NCT02959112|OTHER|Sterile water|
224164630|NCT02959112|DRUG|Indomethacin Rectal Suppository|
223478800|NCT00465179|DRUG|Sunitinib Malate|50 mg by mouth daily for 4 weeks, then 2 weeks off.
223478801|NCT01366716|BEHAVIORAL|Cash CM|Participants in the cash CM condition will be assigned to the identical 12-week escalating schedule of reinforcement, except that the contingencies will be provided in cash rather than vouchers, and no negotiation process will be involved (although counselors may recommend how clients might best spend their money).
223478802|NCT01366716|BEHAVIORAL|Voucher CM|Participants in the voucher condition will earn voucher incentives according to the schedule developed by Higgins (1993, 1994). It involves a 12-week escalating schedule of reinforcement to initiate cocaine abstinence.
223478803|NCT05263193|DRUG|Caplacizumab|as in real world practice
223478804|NCT00112749|BIOLOGICAL|infliximab|A single infusion of 1mg/kg will be administered.
223584233|NCT00905086|PROCEDURE|psychosocial assessment and care|Patients complete psychosocial assessments, including measures of patient perceptions of their illness (i.e., cognitive appraisal) and of the factors influencing their perceptions (i.e., uncertainty by the Mishel Uncertainty in Illness Scale-Community Form; symptom distress by the Memorial Symptom Assessment Scale Short Form; and comorbidity by the Charlson Comorbidity Index).
223584234|NCT00905086|PROCEDURE|quality-of-life assessment|At 1 month after completion of radiotherapy, patients undergo repeat assessment of stress appraisal and psychosocial adjustment.
224164631|NCT07018635|DRUG|INCB161734|Oral; Tablet
224164632|NCT07018635|DRUG|Itraconazole|Oral; Tablet
224164633|NCT07018635|DRUG|Rifampin|Oral; Tablet
224164634|NCT07018635|DRUG|Esomeprazole|Oral; Tablet
224164635|NCT07018635|DRUG|Famotidine|Oral; Tablet
224164636|NCT00035477|DRUG|Azimilide Dihydrochloride|125 mg azimilide tablets once a day for 3 days in hospital and 125 mg azimilide tablets once a day for 6 months as outpatient
224164637|NCT00035477|DRUG|Placebo|placebo tablets once a day for 3 days in hospital and placebo tablets once a day for 6 months as outpatient
224164638|NCT04039789|BEHAVIORAL|Project active legs|Home program of exercises of lower extremities includes the performance of 4 exercises of lower extremities of progressive difficulty that must be carried out at home 5 days a week, twice a day and walking progressively until reaching the marked goal (150 min / week (30 minutes for 5 days a week)).
224164639|NCT04039789|PROCEDURE|Usual care|Evaluation, cleaning, debridement, topical treatment (moist healing) and compressive therapy according to the recommendations for the treatment of chronic cutaneous ulcers of the Community of Madrid.
224164640|NCT05022043|DIAGNOSTIC_TEST|Serum Presepsin|Estimation of Serum Presepsin at time of admission
224164641|NCT03261570|DRUG|Pyridostigmine|60mg by mouth
224164642|NCT03261570|DRUG|Digoxin|0.5 (500mcg) by mouth
223584235|NCT05928611|PROCEDURE|Inferior alveolar nerve block with dexamethasone|Using articaine for inferior alveolar block with intraligmentary dexamethasone
223584236|NCT05928611|PROCEDURE|Buccal infiltratation with dexamethasone|Using articaine for buccal infiltratation with intraligmentary dexamethasone
224164643|NCT03261570|DRUG|Placebo|Lactulose 50mg by mouth
224164644|NCT04134299|DIETARY_SUPPLEMENT|AXA4010|The study will initiate with approximately eight (8) adult subjects (≥18 y/o) with SCD (Cohort 1). Each subject will receive AXA4010 twice a day (BID) for 12 weeks. Safety and tolerability will be monitored, and study procedures will be performed. Analysis of safety, tolerability and laboratory assessments at week 12 would be performed. Based on the 12-week observations from at least three subjects in Cohort 1, subsequent Cohorts 2 and 3 in Part II may be initiated.
223478805|NCT00112749|OTHER|Clinical Assessment|Medical, psychiatric, and immune evaluation.
223478806|NCT00112749|OTHER|Self-report questionnaires|Fatigue Symptom Inventory, Multidimensional Fatigue Symptom Inventory, Hamilton Depression Rating Scale, Beck Depression Inventory II, Hamilton anxiety Rating Scale, Pittsburgh Sleep Quality Index, Brief Pain Inventory, MOS SF-36.
223478807|NCT00112749|OTHER|Immune Assessment|Proinflammatory cytokines and markers of cytokine activity and lymphocyte subsets and CBC.
223478808|NCT00976339|DRUG|Cholecalciferol|"Cholecalciferol is a vitamin D3. Vitamin D is important for the absorption of calcium from the stomach and for the functioning of calcium in the body. Cholecalciferol is used to treat or prevent many conditions caused by a lack of vitamin D.~Cholecalciferol will be available in gel capsule form at 10,000 IU (0.25 mg cholecalciferol) each."
223584237|NCT05928611|PROCEDURE|Inferior alveolar nerve block|Using articaine for injection
223584238|NCT00907296|BIOLOGICAL|Romosozumab|Administered by subcutaneous injection
223584239|NCT00907296|DRUG|Placebo|Administered by subcutaneous injection
223584240|NCT06476158|DEVICE|Kaiku Health|Digital follow-up with Kaiku Health as medical device
223584241|NCT02042313|OTHER|continuous epidural infusion|
224164645|NCT05698108|DEVICE|Instrument Assisted Soft Tissue Mobilization (IASTM)|Tools designed for soft tissue mobilization
224164646|NCT05698108|OTHER|Conventional Physical Therapy|Moist Hot pack, Ultrasound, Deep Friction Massage, Stretching and Strengthening Exercises.
224164647|NCT05765552|OTHER|Dual-Task Training|Motor-cognitive dual-task exercises will be applied for 2 days a week for 8 weeks.Sessions will last for 30 minutes.
224164648|NCT05765552|OTHER|Control Group|Upper and lower extremity range of motion exercises will be applied for 8-10 repetitions for 1 set 2 times a week for 8 weeks.
223584242|NCT02042313|OTHER|combined paravertebral infusion and single shot of TAP block|
223584243|NCT01657708|OTHER|Shared Decision Making|
223584244|NCT03208530|BEHAVIORAL|Brief motivational interview intervention|A brief (\<7minutes) interview by an emergency department clinician to empower patients to formulate and communicate their goals for medical care with patients' outpatient clinicians.
223584245|NCT02502513|BEHAVIORAL|Brief computerized intervention|"Computer game Tetris"
224164649|NCT02901080|DEVICE|Alpha Stim AID cranial electrotherapy stimulation|\- 60 minutes of cranial electrotherapy stimulation via Alpha Stim AID once per day, for a minimum of 6 and maximum of 12 weeks.
224164650|NCT02901080|BEHAVIORAL|Pregnancy test|\- Pregnancy test x 1 (day 1)
224164651|NCT02901080|OTHER|Anxiety questionnaire|\- GAD-7 questionnaire x 6 (day 1, week 4, week 6, week 8, week 12 and week 24)
224164652|NCT02901080|OTHER|Quality of life questionnaire|\- EQ-5D-5L questionnaire x 6 (day 1, week 4, week 6, week 8, week 12 and week 24)
223478809|NCT04622566|DRUG|Lenvatinib, Pembrolizumab|After enrollment, patients receive pembrolizumab 200 mg via IV infusion on Day 1 of each 3-week cycle for 6 weeks; Lenvatinib 20mg orally once daily for 6 weeks. Patients conduct surgery within 1-4 weeks after the last dose of Pembrolizumab and Lenvatinib. After complete surgery, Pembrolizumab will be as adjuvant treatment for up to 15 cycles, 200mg IV on day 1 of every 21 day-cycles.
223478810|NCT05150691|BIOLOGICAL|DB-1303/BNT323|Administered IV
223478811|NCT05150691|DRUG|Pertuzumab Injection|Administered IV
223478812|NCT05150691|DRUG|Ritonavir|Administered oral
223478813|NCT05150691|DRUG|Itraconazole|Administered oral
224164653|NCT02901080|OTHER|Work and social questionnaire|\- WASA questionnaire x 6 (day 1, week 4, week 6, week 8, week 12 and week 24)
224164654|NCT02901080|OTHER|Sleep questionnaire|\- Athens questionnaire x 6 (day 1, week 4, week 6, week 8, week 12 and week 24)
224164655|NCT02901080|OTHER|Depression questionnaire|\- PHQ-9 questionnaire x 6 (day 1, week 4, week 6, week 8, week 12 and week 24)
224164656|NCT02901080|OTHER|Quality of life and financial questionnaire|\- CSRI questionnaire x 3 (day 1, week 12 and week 24)
224164657|NCT01690819|PROCEDURE|Conventional Ventilatory Strategy|The conventional strategy will be the standard of care with a lower limit of tidal volume equal to 8 ml/Kg of predicted body weight and with a PEEP of 4 cmH2O
224164658|NCT01690819|PROCEDURE|Protective Ventilatory Strategy|The protective strategy will consist of a tidal volume of 6 ml/Kg of predicted body weight, with a PEEP of 8 cmH2O
224164659|NCT05185284|DRUG|Favipiravir|400 mg, lyophilizate for preparation of concentrate for solution for infusion
224164660|NCT05185284|DRUG|Favipiravir|200 mg coated tablets
224164661|NCT05185284|DRUG|Remdesivir|100 mg, lyophilizate for preparation of concentrate for solution for infusion
224164662|NCT00044993|BIOLOGICAL|Ad5CMV-p53 gene|
224164663|NCT00044993|DRUG|docetaxel|
224164664|NCT00044993|DRUG|doxorubicin hydrochloride|
224164665|NCT00044993|PROCEDURE|conventional surgery|
224164666|NCT00044993|PROCEDURE|neoadjuvant therapy|
223478814|NCT00262925|BIOLOGICAL|alemtuzumab|Given subcutaneously
223478815|NCT00262925|DRUG|asparaginase|Given IM
223478816|NCT00262925|DRUG|methotrexate|Given IV or orally
223478817|NCT00262925|DRUG|dexamethasone|Given orally
224164667|NCT02251171|DRUG|Tipranavir|
224164668|NCT02251171|DRUG|Ritonavir|
224164669|NCT02251171|DRUG|Rifabutin|
223478818|NCT00262925|DRUG|leucovorin calcium|Given IV
223478819|NCT00262925|DRUG|mercaptopurine|Given orally
223478820|NCT00262925|DRUG|vincristine|Given IV
223478821|NCT04682301|BEHAVIORAL|Behavioral Intervention|Receive SDM intervention
223478822|NCT04682301|OTHER|Discussion (focus group)|Attend focus group
223478823|NCT04682301|OTHER|Discussion (feedback on SDM)|Provide feedback on SDM
223478824|NCT04682301|OTHER|Interview|Attend a telephone interview
224164670|NCT01882192|BEHAVIORAL|Family physical activity planning|"This material will include skill training content (workbook how to plan for family physical activity) and practical material to create a plan (i.e., a colourful dry erase wall calendar for family activities with fridge magnets). The skill training material for planning is based on several streams of prior work in the adult physical activity literature. Families were instructed to plan for when, where, how, and what physical activity will be performed commensurate with the creation of implementation intentions/action planning. The workbook, however, also focuses on problem solving barriers to physical activity which is more akin to coping planning and traditional goal setting."
224164671|NCT01437267|BIOLOGICAL|Vi-CRM197 vaccine|
224164672|NCT01437267|BIOLOGICAL|Pneumococcal conjugate vaccine|
224164673|NCT01437267|BIOLOGICAL|Vi Polysaccharide (PS) vaccine|
223478825|NCT04682301|OTHER|Survey Administration|Ancillary studies
223478826|NCT02907827|OTHER|follow up DW MRI|Whole-body diffusion-weighted magnetic resonance imaging and cfDNA analysis
223478827|NCT00560404|DRUG|methoxy polyethylene glycol-epoetin beta [Mircera]|120, 200 or 360 micrograms sc monthly (starting dose)
223478828|NCT00560404|DRUG|Epoetin alfa|As prescribed
223511641|NCT02909114|RADIATION|Stereotactic body radiotherapy|"All patients will undergo planning CT simulation. 4-dimensional CT will be used for tumors in the lungs or liver. For all lesions, the gross tumor volume (GTV) will be defined as the visible tumor on CT and/or MRI imaging +/- PET. A Planning Target Volume (PTV) margin of 3-5 mm will be added depending on site of disease, immobilization, and institutional set-up accuracy.~The prescirbe dosage was as following: Lung lesion DT50-60 Gy/5 fractions; liver 50-60Gy/5-8 fractions; brain DT 40Gy/4-5fractions. All will be treated with SBRT"
223511642|NCT00002046|DRUG|Zidovudine|
223511643|NCT04989166|DIETARY_SUPPLEMENT|Nano-curcumin|Nano-curcumin soft gels
223511644|NCT04989166|DRUG|Placebo|Placebo
223511645|NCT00423462|BEHAVIORAL|Brief dynamic psychotherapy|
223511646|NCT00918398|DRUG|AZD1981|100 mg iv infusion, single dose, 4 hours infusion
223511647|NCT00918398|DRUG|AZD1981|514 mg oral solution, single dose
223511648|NCT00918398|DRUG|AZD1981|500 mg oral tablet A (optimal dissolution) give as 2x250 mg tablets, single dose
223511649|NCT00918398|DRUG|AZD1981|500 mg oral tablet B (slower dissolution) give as 2x250 mg tablets, single dose
223511650|NCT01065805|BIOLOGICAL|18F-FLT|"Phase I: Radioactive dose of 2.59 MBq/kg (111-222 MGq)per injection. A single injection of 18F-FLT and PET scan will be permitted per patient.~Phase II: Radioactive dose of 2.59 MBq/kg (100-350) MBq per injection. Up to five separate injections of 18F-FLT and PET scans will be permitted per patient"
223511651|NCT00059280|BIOLOGICAL|Myozyme|20 mg/kg qow or 40mg/kg qow
223511652|NCT03615430|PROCEDURE|serratus plane block with local anesthetic|The high-frequency linear array ultrasound transducer (UST) was placed parallel to the cephalocaudal axis of the body in T4 levels on the side of the mid-axillary line, identifying latissimus dorsi and serratus anterior, through the thoracic artery to help to find the serratus anterior and 15 ml 0.25% ropivacaine was administered.
224164674|NCT03348566|OTHER|fish|fish intkae
224164675|NCT06142968|DIAGNOSTIC_TEST|laboratory tests|Laboratory tests inform of Complete blood count , liver function tests , kidney function tests abdominal ultrasound
224164676|NCT03934203|DRUG|BI 409306|Film-coated tablet
224164677|NCT03934203|DRUG|Moxifloxacin|Film-coated tablet
224164678|NCT03934203|DRUG|Placebo matching to BI 409306|Film-coated tablet
224164679|NCT04746781|BEHAVIORAL|Mobile 360° Video intervention|Using 360° Videos to educate participants about the effect of diabetes.
224164680|NCT04746781|BEHAVIORAL|Motivation and Problem Solving (MAPS)|Using Motivation and Problem Solving to help people enroll in the Diabetes Prevention Program.
224164681|NCT04746781|BEHAVIORAL|Risk notification/education|Sending participants (all of whom meet the diagnostic criteria for prediabetes) educational information about the condition.
224164682|NCT00838695|DRUG|Phenylephrine|Intravenous phenylephrine at low doses (approximately 10 doses ranging from 0-5000 ng/min) Intravenous nitroglycerin at low doses (approximately 10 doses ranging from 0.05-100 ng/min)
224164683|NCT05226143|OTHER|Gel Cream|Gel Cream
224164684|NCT00333970|BEHAVIORAL|cognitive remediation|individual cognitive training
224164685|NCT03766542|DEVICE|Bi-level positive airway pressure with ventilatory support|Positive airway pressure will be applied in the experimental group through a oronasal interface, in ventilatory support mode (Bi-level) with a fixed backup rate.
224164686|NCT03766542|DEVICE|continuous positive airway pressure without ventilatory support|Continuous positive airway pressure (CPAP) will be applied in the active comparator group through a oronasal interface.
224164687|NCT01944488|DRUG|GnRH agonist|100 µg/m2 body surface max 100 µg i.v.
224164688|NCT03260283|DRUG|Pethidine hydrochloride|In Group I patients will be administered with low dose of pethidine hydrochloride (0.4 mgkg-1) diluted into normal saline up to 2 ml of total volume in order to perform subarachnoid anesthesia for urologic operations
224164689|NCT03260283|DRUG|Ropivacaine HCl Inj 7.5 MG/ML|In Group II patients will be administered with 2 ml of ropivacaine (0.75%)
224164690|NCT03260283|DRUG|Fentanyl|15 mcg of fentanyl will be added to the solution in order to perform subarachnoid anesthesia for urologic operations
224164691|NCT04319445|BEHAVIORAL|Mindfulness session(s)|The sessions will be hosted online using an online platform (such as through webex, private YouTube page, Facebook live, etc).
224164692|NCT05337345|DRUG|Cendakimab|Specified Dose on Specified Days
224164693|NCT05076994|OTHER|Exercise therapy|A series of home exercise videos to improve patient adherence to exercise prescription
224164694|NCT05076994|OTHER|Standard Care|An exercise prescription and verbal instructions in clinic
224164695|NCT02836080|BEHAVIORAL|Integrated Collaborative Care Team (ICCT)|An integrated, collaborative pathway of needs-based services. ICCTs will offer a wide variety of services, including Solution-Focused Brief Therapy (SFBT) on a scheduled and walk-in basis, care navigators, various clinician-guided interventions, psychiatry, nurse practitioner services, access to primary care, and peer support, all co-located in youth-friendly, community-based clinics. For each intervention, standardized intervention protocols will be used.
224164696|NCT02836080|OTHER|Treatment as Usual (TAU)|Standard out-patient treatment provided at each participating hospital site. This typically entails referral to a psychiatrist at the participating hospital, who will provide assessment and treatment, with referral to appropriate services, guided by local treatment protocols.
224164697|NCT03290794|DRUG|Aflibercept (Eylea, BAY86-5321)|Intravitreal Aflibercept as prescribed by the treating Physician
224164698|NCT00901862|DEVICE|Pulsed magnetic fields (Quantum MH-2MR bracelet)|Pulsed magnetic fields
224164699|NCT00901862|DEVICE|Sham pulsed magnetic fields (Quantum MH-2MR bracelet)|Hybrid circuits crucial for the generation of the electromagnetic field had been removed.
223478829|NCT06271642|BEHAVIORAL|Bluetooth Haptic Device (Experimental Frequency) + Needle Sham only|Participants will have the Bluetooth Haptic Device with experimental Frequency placed on their arm and randomized to a series of 4 different vibration patterns/frequencies. Mechanical pain threshold (MPT) will be measure using custom-made weighted pinprick stimuli as a set of five pinprick mechanical stimulators with fixed stimulus intensities (flat contact area of 0.2mm diameter) with forces of 32, 64, 128, 256, and 512mN. The stimulators will be applied at a rate of 2s on, 2s off in a randomized order on participants' forearms until the first sensation of pain is reached and will then be done in descending order until the sensation of pain disappears. This procedure will be repeated five times of ascending and descending stimuli served as pinprick pain threshold on 1 arm at 4 different frequencies/patterns in the BHD.
224164700|NCT00829062|DEVICE|Continuous glucose glucose sensor- physician ordered|Charts will be reviewed to identify recipients of Missouri Medicaid who receive daily injections to manage their diabetes. Children who have submitted an application for the Medtronic MiniMed insulin pump will be identified by the PI and Medtronic Diabetes. They will be asked to wear a 72 hour continuous glucose monitor. The children who wear the sensor will be asked to keep a daily logbook of their blood sugars, activities, food intake, and insulin doses during this 72 hour period. The families of the children will be provided with a pre-addressed FedEx envelope for them to return the digital recorder and daily logbooks to the PI. The results of the glucose sensor will be downloaded by the PI. The families will be contacted by the PI with the results and treatment recommendations.
223511653|NCT03615430|PROCEDURE|serratus plane block with saline|The high-frequency linear array ultrasound transducer (UST) was placed parallel to the cephalocaudal axis of the body in T4 levels on the side of the mid-axillary line, identifying latissimus dorsi and serratus anterior, through the thoracic artery to help to find the serratus anterior and 15 ml saline was administered.
223511654|NCT01045239|DEVICE|Micropulse 577 nm yellow diode laser|Laser administered at beginning of study and may be repeated at 16 weeks if needed
224164701|NCT05838794|OTHER|Mckenzie exercise for neck|The McKenzie protocol will be used to manage extension, rotation, and lateral flexion dysfunctions in patients with non-specific neck pain. An experienced physical therapist will perform the protocol 3 times a week for 6 weeks, tailoring exercises to each patient's individual needs based on limited and painful directions of movement. Exercises include retraction, extension, rotation, lateral flexion, and overpressure techniques. Patients will receive education on posture and body mechanics, and exercises will be progressed over time as the patient improves.
224205404|NCT06026449|DIETARY_SUPPLEMENT|Gluten-free diet|After initial fase of habitual diet (6 months), patients will start Gluten-free diet for a period of 12 months
224205405|NCT05678101|DEVICE|transcutaneous electrical nerve stimulation (TENS)|Chattanooga Physio TENS (DJO Global, Vista, CA)
224205406|NCT05678101|DEVICE|Sham transcutaneous electrical nerve stimulation (TENS)|Sham treatment with Chattanooga Physio TENS (DJO Global, Vista, CA)
224164702|NCT05838794|OTHER|Stabilization exercise|Cervical and scapulothoracic stabilization exercises will be performed by an experienced physical therapist 3 times a week for 6 weeks, with each session including a warm-up, stabilization exercises, and cool-down and stretching exercises. Postural education will be provided using mirrors to find a neutral balanced position, and the cervical bracing technique with deep neck flexor activation will be used to stabilize the cervical spine. Upper extremity range of motion exercises and cervical dynamic isometric exercises with elastic resistive bands will also be performed. Scapulothoracic stabilization exercises will include specific exercises for muscles affecting scapular orientation related to neck pain, using latex bands with mild or medium tension.
224164703|NCT04884529|BEHAVIORAL|Chair-yoga program|8-week chair yoga program with gentle postures, breathing techniques, and mindfulness.
224164704|NCT02324712|DEVICE|Acupuncture|Acupuncture using standard stainless steel acupuncture needles inserted into intramuscular tissue for 20 minutes
224164705|NCT02324712|DEVICE|Sham Acupuncture|Acupuncture using non-penetrating Park Sham Needles for 20 minutes
224164706|NCT05241665|DEVICE|SpectraWAVE Imaging System|Coronary imaging
224164707|NCT05021172|OTHER|Best Practice|Receive usual care
224164708|NCT05021172|OTHER|Informational Intervention|Receive Passport to Health booklet
224164709|NCT05021172|OTHER|Questionnaire Administration|Complete ePrognosis
224164710|NCT05021172|OTHER|Survey Administration|Ancillary studies
224164711|NCT00608842|DRUG|Deoxycholic Acid Injection|Administered via intralipomal injection.
224164712|NCT00608842|DRUG|Placebo|Matching vehicle placebo administered via intralipomal injection.
224164713|NCT06301594|BEHAVIORAL|Systematic simple swallowing training|"Systematic simple swallowing training includes the following:~Warm-up: including joint activities, chest expansion exercise, etc., totally 5 minutes.~Cognitive swallowing training: play video of food programs for five minutes. Lip training: Bounce the upper and lower lips to make a bo sound. 30-60 seconds.~Tongue training: Do the upper, lower, left, and right four-directional movements of the tongue muscle. 30-60 seconds.~Mandibular training: slowly open r mouth to the maximum, then slowly close it. 30-60 seconds.~Soft palate training: Make the sounds of g, k, and h for 1-2 minutes. Cheek puffing training: Close lips tightly and puff cheeks. 30-60 seconds. Swallowing training: We require the elderly to swallow small amounts of water intermittently and forcefully for 2-5 times.~Completing the above content in succession is called a round, and each training session includes 2-3 rounds. 2 sessions a day. Five days a week"
224164714|NCT02406339|DEVICE|NMES|Neuromuscular Electrical Stimulation
224164715|NCT02406339|DEVICE|Vascular Occlusion|Restriction of sanguine flow to the lower limbs
224164716|NCT02734095|DEVICE|Ultrasound|Intravascular ultrasound measurements after percutaneous transluminal angioplasty and stenting in the treatment of femoropopliteal lesions.
224164717|NCT01067651|DEVICE|Plaster of Paris (POP) casting using the Ponseti Method|
224164718|NCT01067651|DEVICE|Semi-Rigid Fiberglass softcast using the Ponseti Method|
224164719|NCT02939651|DRUG|Pembrolizumab|Pembrolizumab given intravenously at a fixed dose of 200mg every 3 weeks
223478830|NCT06271642|BEHAVIORAL|Bluetooth Haptic Device (Control Frequency) + Needle Sham only|Participants will have the Bluetooth Haptic Device with control frequency placed on their arm. They will be randomized to a series of 4 different vibration patterns/frequencies. Mechanical pain threshold (MPT) will be measure using custom-made weighted pinprick stimuli as a set of five pinprick mechanical stimulators with fixed stimulus intensities (flat contact area of 0.2mm diameter) with forces of 32, 64, 128, 256, and 512mN. The stimulators will be applied at a rate of 2s on, 2s off in a randomized order on participants' forearms until the first sensation of pain is reached and will then be done in descending order until the sensation of pain disappears. This procedure will be repeated five times of ascending and descending stimuli served as pinprick pain threshold on 1 arm at 4 different frequencies/patterns in the BHD.
223584246|NCT00003963|BIOLOGICAL|rituximab|Week 1-4: Rituxan is given at 375 mg/m2 weekly x4. Week 5-8: Rituxan given every 2 weeks. Week 9-12: Schedule same as week 5-8.
224164720|NCT04445051|DEVICE|SpeediCath® Standard male or female|Intermittent catheterization through the urethra draining the bladder, using SpeediCath® Standard male or female.
224164721|NCT04445051|DEVICE|New intermittent Variant 1 catheter for male or female|Intermittent catheterization through the urethra draining the bladder, using the new Variant 1 for male or female.
224164722|NCT04445051|DEVICE|New intermittent Variant 2 catheter for male or female|Intermittent catheterization through the urethra draining the bladder, using the new Variant 2 for male or female.
224164723|NCT03699904|DRUG|Valaciclovir|Participants will self-administer Valaciclovir 1 gram three times daily for 8 weeks.
224164724|NCT03699904|DRUG|Placebo capsules (containing Avicel blend)|Participants will self-administer two matching placebo capsules (containing Avicel blend) three times daily for 8 weeks.
224164725|NCT02154334|DRUG|Esketamine|Participants will self-administer one Intranasal spray of 14 mg esketamine solution in each nostril on Day 1 at time 0 and 5 minutes (total esketamine dose will be 56 mg) in Period 1 and Period 2.
224164726|NCT02154334|DRUG|Mometasone|Healthy participants will self-administer 2 intranasal sprays of 50 mcg mometasone suspension in each nostril for a total dose of 200 mcg on days 1 to 15 and 2 intranasal sprays of 50 mcg mometasone suspension in each nostril prior to 1 intranasal spray of esketamine solution 14 mg in each nostril at Time 0 and 5 minutes for a total dose of 56 mg on Day 16 in Period 2.
224164727|NCT02154334|DRUG|Oxymetazoline|Nasal rhinitis participants will self-administer 2 intranasal sprays of Oxymetazoline 0.05% w/v solution in each nostril at time -1 hour before administration of 1 Intranasal spray of 14 mg esketamine solution in each nostril at time 0 and 5 minutes, for a total dose of 56 mg in Period 1or Period 2.
224164728|NCT06244719|DEVICE|Vibrotactile Stimulation|Shirts contain embedded vibration motors that stimulate the impaired upper-extremity at 18 different locations. The gloves stimulates the fingertips.
224164729|NCT03024710|BEHAVIORAL|Intervention cluster|The mother- infant pairs (the infant who has completed his/her 6 month of age from the date of birth along with their mother) of intervention clusters will receive the CF practice counselling in groups as soon as enrolment is completed by CHRW at fixed site clinic and refreshers will be arranged 3 months apart from first training in groups at same place and by same person. However CHRWs will also counsel each participant during her bimonthly household visit.
224164730|NCT06101316|DRUG|CB06-036|CB06-036 Capsule
224164731|NCT01468038|DRUG|Trazodone|active trazodone and sentra pm-like placebo
223584247|NCT00003963|DRUG|vinorelbine ditartrate|"Week 1-4: Vinorelbine (25mg/m2) given 1 week after the first rituxan dose and immediately after the second rituxan dose.~Week 5-8: Vinorelbine given weekly x3, with one week off. Week 9-12: Schedule same as week 5-8. Week 13 and following: If subject doesn't have disease progression, they may continue on Vinorelbine until progression or until clinically indicated."
223584248|NCT02137187|PROCEDURE|AV junction ablation|AV junction ablation
223584249|NCT02137187|DEVICE|CRT|Implantation of device for pacing and cardiac resynchronization therapy (CRT-P or CRT-D according to guidelines)
224164732|NCT01468038|OTHER|Sentra PM|Active Sentra PM and trazodone-like placebo
224164733|NCT01468038|DRUG|Sentra PM and Trazodone (CoPack Kit Trazamine)|A CoPack Kit - Trazamine, consisting of the co-administration of Sentra PM and trazodone.
224164734|NCT01468038|DRUG|Placebo trazodone and placebo Sentra PM|Trazodone-like placebo and Sentra PM-like placebo co-administered as placebo of Trazamine CoPack Kit.
224164735|NCT02680106|DEVICE|SPINNER|The SPINNER device is aimed at the DSW from a distance of 20 cm and activated for 1 minute. A nano-fibrous matrix is thus created.
224164736|NCT02680106|DEVICE|JELONET / IBU Biatain|The patient's DSW will be dressed by JELONET/IBU Biatain
224164737|NCT04594018|DRUG|Finlândia Association + finasteride placebo|Finlândia association hair lotion + finasteride placebo
224164738|NCT04594018|DRUG|Minoxidil + finasteride|Minoxidil hair lotion + Finasteride 1 mg
224164739|NCT01553721|DRUG|udenafil|"Phase IIa - Udenafil Dose 1, Dose 2(Single dose)~Phase IIb - Udenafil(BID)"
224164740|NCT01553721|DRUG|placebo|Phase IIa - placebo Phase IIb - placebo
224164741|NCT03013959|DRUG|Pranoprofen|it is an NSAIDs.As is reported, NSAIDs(pranoprofen) eye drops can suppress herpes simplex virus（HSV-1） reactivation and reduce inflammatory reaction in vitro and in vivo. In Clinical, there is no risk of corneal tissue melting, glaucoma, cataract by topical application of NSAIDs.
224164742|NCT00647907|DRUG|Voriconazole|Oral or intravenous voriconazole. Oral tablets 400 mg twice daily loading dose on first day, followed by 200 mg twice daily taken at least 1 hour before or after a meal. Oral doses could be increased to a maximum of 300 mg twice daily if there was no clinical improvement after at least 3 days of treatment, no serious adverse events were reported, and clinical chemistry parameters were within the acceptable range for study entry. Intravenous treatment was initiated with a loading dose of 6 mg/kg twice daily for the first day followed by 4 mg/kg twice daily for at least 3 days (maximum infusion rate of 3 mg/kg/hr if administered by peripheral intravenous line). An intravenous loading dose was not required in patients who were restarted after oral treatment. Total duration of therapy (intravenous and oral) was 12 weeks.
224164743|NCT06508398|DIAGNOSTIC_TEST|Microbiological Diagnostic Testing|"This study involves microbiological diagnostic testing of clinical samples collected from ICU patients diagnosed with healthcare-associated infections (HAIs). The intervention includes:~Sample Collection: Blood, urine, sputum, bronchoalveolar lavage, wound swabs, and oropharyngeal/nasopharyngeal swabs.~Pathogen Identification: Using biochemical tests, MALDI-TOF mass spectrometry, and 16S rRNA sequencing to identify bacterial and fungal pathogens.~Antimicrobial Susceptibility Testing: Determining the resistance profiles of the identified pathogens to various antimicrobial agents.~Evaluation of New Compounds: Testing the antimicrobial efficacy of new 4-thiazolidinone derivatives against isolated pathogens.~This comprehensive approach aims to enhance the understanding of pathogen distribution and resistance patterns in HAIs."
224164744|NCT01526317|DRUG|Crestor 10mg(Rosuvastatin 10mg), Glucodown OR SR 750mg(Metformin SR 750mg)|For co-administration,Crestor 1 tablet and Glucodown 1 tablet a day for 5 day.(1 period) For separate administration, Crestor 1 tablet a day for 5 day and Glucodown 1 tablet a day for 5 day.
224164745|NCT00910013|DRUG|Ropivacaine|0.5% intra-articular ropivacaïne (20cc)
224164746|NCT01352013|DIETARY_SUPPLEMENT|Omega-3 (oil)|5ml daily with breakfast for 56 days.
224164747|NCT01352013|DIETARY_SUPPLEMENT|Fatty Acids (placebo)|5ml daily with breakfast for 56 days.
223584250|NCT02137187|DRUG|Optimized drug therapy|Optimized drug therapy for heart failure and atrial fibrillation rate control
223584251|NCT02137187|DEVICE|ICD|Implantable defibrillator (in control Group or in association with CRT in study Group) according to guidelines
224164748|NCT04157075|DRUG|Bupivacaine|Bupivicaine injection into uterosacral ligaments prior to colpotomy
224164749|NCT00303576|DRUG|dapivirine (TMC120) vaginal gel|
224164750|NCT04892680|BEHAVIORAL|Online Diabetes Self-Management Education and Support (DSMES) Program|Digital delivery of a DSMES program designed to build self-management skills and support diabetes management. Recipients have access to online curriculum, a live CDCES, group-based communication forums, and connected technology to track weight, food intake, physical activity and glucose levels.
224164751|NCT05461157|DEVICE|Preoperative silicone ointment|The silicone ointment in this study is the Biodermis Scar Aid Silicone Stick, an FDA-approved silicone ointment that is available for purchase over the counter.
224164752|NCT05461157|OTHER|Preoperative placebo ointment|The placebo ointment in this study is a generic, non-flavored lip balm that is identical in packaging and texture to the Biodermis Scar Aid Silicone Stick used in the treatment arm.
223584252|NCT01278784|DEVICE|0.05% Chitosan-N-Acetylcysteine eye drops|Subjects will be randomized to receive one drop of the medical device in either the right or left eye
223584253|NCT01278784|DEVICE|0.1% Chitosan-N-Acetylcysteine eye drops|Subjects will be randomized to receive one drop of the medical device in either the right or left eye
223584254|NCT02594800|DRUG|Rosuvastatin|standard or intensive dose rosuvastatin therapy based on other routine medication for stroke for 52 weeks.
224164753|NCT05783492|DRUG|Intranasal ketamine|10 mg/kg single dose in 0.5 mL sprays in each nare separated by 60 seconds
224164754|NCT02341404|DRUG|2-hydroxyflutamide (2-HOF)|Two components are mixed, transferred to a syringe and administered with injection into the prostate
224164755|NCT00287846|DRUG|imatinib mesylate|
223584255|NCT02283307|OTHER|Reduced contrast DECT scan|Subjects will undergo a dual energy CT scan with reduced contrast
223584256|NCT02283307|OTHER|Standard contrast SECT scan|Subjects will undergo standard of care single energy CT scan with a standard dose of contrast. (control)
224164756|NCT02957110|BEHAVIORAL|Laughter Frequency|Relationships between laughter frequency, momentary mood state, and pain will be observed.
223584257|NCT02238340|DRUG|Extended-release oxycodone|10 o 20 mgrs of extended-release oxycodone ,started 12 hours before orthopaedic surgery
223584258|NCT02238340|DRUG|Extended- release Oxycodone|
223584259|NCT02238340|DRUG|ketoprofen|
223584260|NCT02238340|DRUG|dipirone|
224164757|NCT04822441|OTHER|data collection|Ultrasound follow-up maternal dengue serology PCR (Polymerase Chain Reaction) and dengue serology of the umbilical cord
224164758|NCT05768893|DEVICE|Long-Pulsed Nd:YAG Laser 1064nm & Er:YAG Laser 2940nm|Warts with this intervention treated firstly with the Er:YAG laser, followed by the Nd:YAG laser in the same session.
224164759|NCT05768893|DEVICE|Er:YAG Laser 2940nm|Warts with this intervention treated only with the Er:YAG laser.
224164760|NCT04831593|OTHER|Group El|Gastric ultrasound is a point-of-care diagnostic tool to examine stomach contents and determine pulmonary aspiration risk at the bedside. Qualitative gastric sonography can determine the nature of gastric content ( empty, clear fluid or thick fluid/solid ) and quantitative gastric ultrasound can estimate the volume of gastric fluid.
224164761|NCT04831593|OTHER|Group Em|Gastric ultrasound is a point-of-care diagnostic tool to examine stomach contents and determine pulmonary aspiration risk at the bedside. Qualitative gastric sonography can determine the nature of gastric content ( empty, clear fluid or thick fluid/solid ) and quantitative gastric ultrasound can estimate the volume of gastric fluid.
224164762|NCT01041391|PROCEDURE|Discectomy-lumbar spine|Lumbar intervertebral discectomy performed on patients with herniated disc that chose to have surgical intervention
224164763|NCT04705350|DRUG|Zampilimab|Participants will receive a single intravenous dose of zampilimab at a pre-specified time point.
224164764|NCT04705350|DRUG|Placebo|Participants will receive matching placebo at a pre-specified time point to maintain the blinding.
224164765|NCT05009238|OTHER|lumbar stabilization exercises|selected exercises will taught to participant and practiced 3 times per week for 6 weeks
224164766|NCT03338036|DEVICE|Heart Rate Variability Biofeedback|HRV biofeedback constitutes initial training with the android device and application, and HRV training performed at home. This training will occur twice daily, and each session will take five minutes.
224164767|NCT03338036|DEVICE|Neurofeedback|LORETA Z-Score neurofeedback training will occur three times per week with a trained study investigator.
224164768|NCT04389268|DIAGNOSTIC_TEST|Visual Event-Related Potentials|Auditory P300-evoked brain potential: an eventrelated potential of cognitive neurophysiological significance. It represents the brain response to certain sensory/cognitive stimuli by paying attention to the different stimulus among the stereotypical ones (the auditory oddball paradigm). It measures mainly the decision-making process (Polich and Kok, 1995).
224164769|NCT01456520|DRUG|Vycavert|single dose Vycavert containing 10 mg hydrocodone bitartrate/325 mg acetaminophen
224164770|NCT01456520|DRUG|Norco|single dose Norco containing 10 mg hydrocodone bitartrate/325 mg acetaminophen
223584261|NCT02238340|DRUG|dexametasone|
223584262|NCT02238340|DRUG|Morphine IV (rescue)|
223584263|NCT00842101|DEVICE|Quick Pressure Monitor|The monitor measures actively the actual pressure inside the compartment affected.
223584264|NCT05041348|DIAGNOSTIC_TEST|CT at the level of the third lumbar vertebra (L3)|Muscle mass loss was defined as an skeletal muscle mass index (SMI) less than 46.96 cm²/m² for males and less than 32.46 cm²/m² for females
224164771|NCT03190967|DRUG|T-DM1|T-DM1 3.6 mg/kg intravenous (IV) every 21 days
224164772|NCT03190967|DRUG|TMZ|Phase I: TMZ 30, 40 or 50 mg/m\^2 daily Phase II: TMZ at recommended phase 2 dose (RP2D) estimated in Phase I dose escalation part of the study.
224164773|NCT00997555|PROCEDURE|bronchoscopy|Scheduled bronchoscopy.
224164774|NCT03021590|DRUG|Clarithromycin 500Mg Oral Tablet|"Amoxicillin 1000 mg Tablets every 12 hours , Esomeprazole 20 mg Capsule days all~,Clarithromycin 500 mg Tablets and Tinidazole 500 mg Tablets every 12 hours for 14 days all by mouth"
224164775|NCT03021590|DRUG|Levofloxacin 500Mg Oral Tablet|Amoxicillin 1000 mg Tablets , Esomeprazole 20 mg Capsule,Levofloxacin 500 mg Tablets and Tinidazole 500 mg Tablets all every 12 hours for 14 days all by mouth
224164776|NCT01188811|DRUG|lipoic acid|1200 mg taken by mouth daily starting on day one of the study and ending on the last day of study participation.
224164777|NCT01188811|DRUG|Placebo|The placebo comparator will be taken by mouth daily starting on day one of the study and ending on the last day of study participation
224164778|NCT03418220|OTHER|blood and aqueous humor sampling|The blood sample will be centrifuged. The plasma will be recovered. Plasma and aqueous humor will be frozen and stored at -80° Celsius. The search of 27 markers of inflammation will be performed by the kit LUMINEX Bio-rad (Bio-Rad, M500KCAF0Y).
224164779|NCT02782247|DEVICE|Transient elastography|"Transient elastography will be measured using a Fibroscan® machine which is manufactured by echosens®. It has a CE mark of 0459.~It is a non-invasive method to accurately measure stiffness of a patient's liver without the need for a liver biopsy. This is measured by an externally placed ultrasound probe which creates an elastic shear wave at 50Hz, and measures the velocity of the echo through the liver tissue. The liver stiffness is measured in kilopascals (kPa). It has been shown to be 99% effective in detecting cirrhosis in hepatitis C and has been shown to correlate with hepatoma production in both hepatitis C and hepatitis B. Values range from - normal \< 9.6 kPa, significant fibrosis 9.6-11.4kPa, cirrhosis \>11.5kPa. It cannot be used in patients with ascites."
223584265|NCT03313336|DRUG|EMLA test patch|EMLA® Test Patch containing the active ingredients lidocaine base 25 mg/g and prilocaine base 25 mg/g in an oil-in-water emulsion saturating the absorbent cellulose disc. The source of cellulose for the cellulose disc will be provided from a new supplier in this test patch.
223584266|NCT03313336|DRUG|EMLA current reference patch|EMLA current Reference Patch, containing the active ingredients lidocaine base 25 mg/g and prilocaine base 25 mg/g in an oil-in-water emulsion saturating the absorbent cellulose disc.
223584267|NCT03313336|DRUG|Placebo Patch|Placebo Patch, based on the EMLA Test Patch (incorporating the absorbent cellulose disc with cellulose from the current supplier), where the absorbent disc will be saturated with a placebo oil-in-water emulsion, where the eutectic mixture of lidocaine and prilocaine is replaced with fractionated coconut oil and chlorhexidine digluconate 20%, with identical appearance to the active EMLA patches.
223584268|NCT02163785|PROCEDURE|Abdominoperineal extra-elevators rectal resection for low lying rectal cancer|Abdominoperineal extra-elevators rectal resection for low lying rectal cancer involving anal sphincter complex
223584269|NCT00660985|DRUG|Adapalene|Gel, 0.3%, 2g, once daily for 30 days
223478831|NCT06255457|PROCEDURE|Mitral valve surgery|Mitral valve repair or replacement of mitral regurgitation
223478832|NCT04485949|COMBINATION_PRODUCT|IGV-001 Cell Immunotherapy|IGV-001, an immunotherapeutic product that combines personalized whole tumor-derived cells with an antisense oligonucleotide (IMV-001) in implantable biodiffusion chambers.
223478833|NCT04485949|COMBINATION_PRODUCT|Placebo|Placebo in implantable biodiffusion chambers containing a predetermined inactive solution.
224164780|NCT02782247|DEVICE|Indocyanine Green excretion|The machine to monitor the elimination of Indocyanine green is manufactured by PULSION medical systems (Munich, Germany) and consists of the PulsioFlex monitor and LiMON module. The LiMON module is a finger probe which measure near-infrared wavelengths between 805nm and 905nm. The absorption maximum for Indocyanine green is 800nm and emission at 830nm. This is then used to produce two calculations. The first is plasma disappearance rate of indocyanine green (PDRICG). This is based on working out the constant and backward extrapolation and expressed as a percentage per minute. The other is the retention ratio after 15 minutes (ICG15).
224164781|NCT04426292|DIAGNOSTIC_TEST|Serological testing|Antibody testing for Sars-COV-2 antibodies in blood.
224164782|NCT03199131|PROCEDURE|Right ventricular biopsies|a right ventricular biopsy will be taken intraoperatively during either pulmonary endarterectomy (experimental group) or open cardiac surgery (control group).
224164783|NCT02766972|PROCEDURE|Rapid Ventricular Pacing|Use of Rapid Ventricular Pacing to improve surgical clipping of intracranial aneurysms
224164784|NCT00085358|DRUG|carboplatin|Given intraperitoneally
224164785|NCT00085358|DRUG|paclitaxel|Given IV or intraperitoneally
224164786|NCT00085358|DRUG|docetaxel|Given IV
224164787|NCT00085358|BIOLOGICAL|bevacizumab|Given IV
224164788|NCT01431469|DIETARY_SUPPLEMENT|Cow's milk|Powdered Whole Cow's Milk
224164789|NCT01431469|DIETARY_SUPPLEMENT|Follow-On Formula|Powdered Follow-On Formula with added long-chain Polyunsaturated fatty acid, prebiotics, and polysaccharide
224164790|NCT03348813|BEHAVIORAL|HIV/STI Prevention Intervention|The targeted HIV/STI risk reduction intervention was delivered with groups of up to 8 participants through 8, 45-minute modules equally divided over 2 days (4 modules per session). It was designed to enhance participants' knowledge and ability to reduce their risk of HIV/STIs. Grounded in both social/behavioral and cognitive theories, the intervention includes psychoeducation, and was intended to enhance participants' HIV/STI prevention knowledge, attitudes, beliefs and skills in a manner relevant to Black adolescents.
224164791|NCT03348813|BEHAVIORAL|General Health Control Intervention|"The original Promoting Health among Teens (PHAT) Project was designed to increase knowledge and motivation regarding healthful dietary practices, aerobic exercise, and breast and testicular self-examination, and to discourage cigarette smoking. The 8-hour, 2-session PHAT intervention was shortened to mirror the Project GOLD HIV/STI risk reduction curriculum. This was done to control for the Hawthorne effect and reduce the likelihood that effects of the HIV/STI risk reduction intervention can be attributed to its nonspecific features, including special attention. From an ethical standpoint, adolescents in both conditions received a valuable and engaging health-risk-reduction intervention as opposed to usual care."
223478834|NCT04485949|PROCEDURE|Standard of Care (SOC): Radiation Therapy|Radiation therapy administered per institutional standards.
223478835|NCT04485949|DRUG|SOC: Temozolomide|Temozolomide administered orally.
223584270|NCT00660985|DRUG|Adapalene|Gel, 0.1%, 2g, once daily for 30 days
224164792|NCT01159821|DRUG|31001074/paroxetine|1 tablet of 31001074 will be administered on Day 1 and Day 13. One 20-mg paroxetine tablet will be administered once daily from Days 4 through 15
224164793|NCT04019236|OTHER|visual analogue scale (VAS),Respiratory distress observational scale (RDOS) and other Nursing care|Distressed patient will be assessed by visual analogue scale(VAS) or respiratory distress observational scale.Nursing interventions will be done according to its causes as giving supplemental O2 therapy, pharmacologic therapy ,initiating positive pressure ventilation or change Ventilator settings (TV, PEEP, Inspiratory pressure ), Improve inspiratory muscle function by Nutrition, positioning or by minimizing use of steroids , clearing airway by Suctioning, Check O2 saturation level frequently and maintain O2 saturation between 95-100%, ,Raising the HOB (Head of the Bed), high Fowler's ,Give pain medications as prescribed or diuretics as ordered and If thick secretions increase oral fluids intake
224164794|NCT03966352|OTHER|Questionnaire|Enrolled subjects will complete a questionnaire to ascertain information on treatment considerations, obstacles, motivations, and outcomes encountered on their pathway to fatherhood.
224164795|NCT04459442|PROCEDURE|Umbilical cord clamping at birth.|Umbilical cord clamping after delivery.
224164796|NCT04724213|OTHER|Testing of reliability / validity of new questionnaire|Participants will answer new questionnaire and other, established, generic and chronic generic HrQol instruments
224164797|NCT03924427|DRUG|BMS-986165|Oral tablet administration
224164798|NCT05068076|DRUG|Perfluorobutane|Perfluorobutane enhanced ultrasound will be done prior to ablation of HCC and after 2hours post ablation and comparison will be done with 1 month post procedure CT/MRI
224164799|NCT03625960|DRUG|Cantharidin|A thin film of cantharidin is applied to the surface of the wart and to 1 millimeter area surrounding the wart. After the film dries, it is covered with an occlusive dressing for 24 hours. The patient removes the area the next day and thoroughly washes the area with soap and water. Patients return to clinic a week later.
223478836|NCT02310542|DEVICE|MARS albumin dialysis system|
223478837|NCT02310542|DEVICE|SPAD albumin dialysis system|
223478838|NCT06680375|COMBINATION_PRODUCT|Flu Seasonal /SARS-CoV-2 mRNA Dose 1|A Flu mRNA vaccine composition in combination with Dose 1 of a COVID-19 component will be administered.
223478839|NCT06680375|COMBINATION_PRODUCT|Flu Seasonal /SARS-CoV-2 mRNA Dose 2|A Flu mRNA vaccine composition in combination with Dose 2 of a COVID-19 component will be administered.
223478840|NCT06680375|COMBINATION_PRODUCT|Flu Seasonal mRNA|An investigational mRNA Flu Seasonal vaccine will be administered.
223478841|NCT06680375|COMBINATION_PRODUCT|SARS-CoV-2 mRNA Dose 1|Dose 1 of an investigational mRNA COVID-19 vaccine will be administered.
223584271|NCT03695822|DRUG|Mirabegron 25mg|The aim of this study is to elucidate the impact of mirabegron on psychological distress, bladder blood flow and c reactive protein.
223584272|NCT03445221|DIETARY_SUPPLEMENT|IV Immunonutrition|patients will receive preoperative immunonutrition in the form of glutamine) Dipeptiven-Fresenius Kabi) given by intravenous infusion 0.4g/kg/day for 3 days before surgery.
223478842|NCT06680375|COMBINATION_PRODUCT|SARS-CoV-2 mRNA Dose 2|Dose 2 of an investigational mRNA COVID-19 vaccine will be administered.
223478843|NCT06680375|COMBINATION_PRODUCT|Licensed Flu Seasonal|A licensed Flu Seasonal vaccine will be administered.
224164800|NCT03625960|DRUG|Trichloroacetic Acid|Trichloroacetic acid is applied to the surface of the wart with a wooden applicator and after drying the area is washed with soap and water in an hour.
223478844|NCT06680375|COMBINATION_PRODUCT|Licensed COVID-19 mRNA|A licensed mRNA COVID-19 vaccine will be administered.
224164801|NCT01379560|DRUG|unoprostone isopropyl|"1. unoprostone isopropyl (2 drops)~2. placebo (2 drops)"
224164802|NCT01379560|DRUG|unoprostone isopropyl|"1. unoprostone isopropyl (3 drops)~2. placebo (3 drops)"
224164803|NCT00019214|BIOLOGICAL|MART-1 antigen|
223478845|NCT06680375|DRUG|Placebo|A placebo will be administered.
224164804|NCT00019214|BIOLOGICAL|aldesleukin|
224164805|NCT00019214|BIOLOGICAL|gp100 antigen|
224164806|NCT00663689|DRUG|erlotinib|erlotinib 150mg qd until disease progression or unacceptable toxicity.
224164807|NCT03975517|BEHAVIORAL|PrEP|Define the behavioral characteristics of the active file of patients using PrEP in Strasbourg in 2019.
224164808|NCT03028467|DRUG|GSK3196165 Dose 1|GSK3196165 is supplied as liquid and will be administered as SC injection.
224164809|NCT03028467|DRUG|GSK3196165 Dose 2|GSK3196165 is supplied as liquid and will be administered as SC injection.
224164810|NCT03028467|DRUG|GSK3196165 Dose 3|GSK3196165 is supplied as liquid and will be administered as SC injection.
223478846|NCT04340076|DRUG|Secukinumab|Maintenance/normal dose is 300 mg/4 weeks. First dose reduction step: 300 mg/6 weeks. Second dose reduction step: 300 mg/8 weeks.
224164811|NCT03028467|DRUG|Methotrexate|Methotrexate capsule/tablet 8-16 mg per week is given orally.
224164812|NCT03028467|DRUG|Placebo|Placebo is supplied as liquid as sterile 0.9% sodium chloride solution and will be administered as SC injection.
224164813|NCT03028467|DRUG|Folic acid|Folic acid tablet 5 mg per week is given orally.
224164814|NCT01574261|DRUG|Placebo|Placebo for four months
224164815|NCT01574261|DRUG|Inositol|Inositol 4g/die for four months
224164816|NCT06244524|OTHER|High indoor CO2 exposure|The participants will stay and sleep for eight hours in a closed bedroom.
224164817|NCT03411434|DRUG|Methylphenidate Oral Tablet|cf arm group description
224164818|NCT06360497|OTHER|mindfulness meditation intervention and loving-kindness and compassion meditation intervention|Interventions were conducted by two teachers separately. Mindfulness meditation group provided the knowledge and practice related with mindfulness, and loving-kindness and compassion meditation group provided knowledge and practice related with loving-kindness and compassion meditation.
224164819|NCT00069017|BIOLOGICAL|MEDI-522|MEDI-522 is formulated in a sterile isotonic solution of 10 mM histidine-HCl at pH 6 containing 100 mg of MEDI-522 protein at a concentration of 100 mg/mL.
224164820|NCT00069017|OTHER|Placebo|Placebo for MEDI-522 contains 10 mM histidine-HCl at pH 6, 0.1% Tween-80, 1.5% Mannitol, 4.3 µg/mL Vitamin B12, and 2 µg/mL D\&C Yellow #10.
224164821|NCT00003991|BIOLOGICAL|aldesleukin|
224164822|NCT00003991|DRUG|histamine dihydrochloride|
224164823|NCT00031135|DRUG|Choline Chloride|
224164824|NCT05889169|OTHER|Neurorehabilitation|Four to eight weeks motor rehabilitation (500 minutes per week across 6 day per week)
223478847|NCT04340076|DRUG|Ixekizumab|Maintenance/normal dose is 80 mg/4 weeks. First dose reduction step: 80 mg/6 weeks. Second dose reduction step: 80 mg/8 weeks
223478848|NCT04340076|DRUG|Brodalumab|Maintenance/normal dose is 210 mg/2 weeks. First dose reduction step: 210 mg/3 weeks. Second dose reduction step: 210 mg/4 weeks.
223478849|NCT04340076|DRUG|Guselkumab|Maintenance/normal dose is 100 mg/8 weeks. First dose reduction step: 100 mg/12 weeks. Second dose reduction step: 100 mg/16 weeks.
223478850|NCT04340076|DRUG|Risankizumab|Maintenance/normal dose is 150 mg every 12 weeks. First dose reduction step: 150mg/18 weeks. Second dose reduction step: 150mg/24 weeks.
223478851|NCT04340076|DRUG|Tildrakizumab|Maintenance/normal dose is 100 mg or 200 mg every 12 weeks. First dose reduction step: 100 mg or 200 mg/18 weeks. Second dose reduction step: 100 mg or 200 mg/24 weeks.
223478852|NCT04340076|DRUG|Bimekizumab|Maintenance/normal dose is 320 mg/8 weeks. First dose reduction step: 320 mg/12 weeks. Second dose reduction step: 320 mg/16 weeks.
224164825|NCT03422055|DRUG|99mTc-Fucoidan SPECT|Intravenous administration of 99mTc-Fucoidan on healthy volunteers.
224164826|NCT04443036|DRUG|Albumin-Bound Paclitaxel|"* 125mg/m2 IV d1、8，Q3W~* until disease progression, lost follow-up visit, death , unacceptable toxicity"
224164827|NCT04443036|DRUG|Toripalimab|"* 240 mg，IV d1，Q3W~* until disease progression, lost follow-up visit, death , unacceptable toxicity, Maximum treatment duration is 24 months"
224205407|NCT06076538|DIAGNOSTIC_TEST|2-Deoxy-2-[18F]fluoroglucose Positron Emission Tomography/Magnetic Resonance Imaging|PET/MR scan utilizing FDG Radiopharmaceutical
223511655|NCT01045239|DEVICE|532 nm green diode laser|Laser administered at beginning of study and may be repeated at 16 weeks if needed
223511656|NCT01345903|PROCEDURE|therapeutic conventional surgery|Undergo robotic-assisted surgery
223511657|NCT05609058|DEVICE|dedicated treatment board with no degree|the patients were placed in the prone position on a dedicated treatment board with no degree incline using an arm support (with both arms above the head). Te board contained an open aperture on one side to allow for the ipsilateral breast to hang freely away from the chest wall
223511658|NCT00770094|DEVICE|Excimer Lasers|WaveLight ALLEGRETTO WAVE™ wavefront guided excimer laser treatment AMO/VISX CustomVue™ wavefront guided Excimer Laser System
223511659|NCT00770094|DEVICE|Excimer Laser for the LASIK procedure|WaveLight ALLEGRETTO WAVE™ wavefront guided excimer laser treatment Bausch and Lomb Zyoptix™ wavefront guided Excimer Laser System
223511660|NCT00770094|DEVICE|Excimer Laser for LASIK|WaveLight ALLEGRETTO WAVE™ wavefront optimized excimer laser treatment Bausch and Lomb Planoscan™ Excimer Laser System
223511661|NCT00626665|DRUG|Tadalafil|Tablets Tadalafil, 20 mg, alternate days, 6 weeks
223511662|NCT05382325|BIOLOGICAL|MK-1484|Subcutaneous (SC) injection
223511663|NCT05382325|BIOLOGICAL|Pembrolizumab|Intravenous (IV) infusion
223511664|NCT03709030|DIAGNOSTIC_TEST|magnetic resonance cholangiopancreatography (MRCP)|magnetic resonance imaging of liver, gall bladder, pancreas
223511665|NCT05416632|DIAGNOSTIC_TEST|Athrometer|Arthrometer
223478853|NCT05519254|DIETARY_SUPPLEMENT|Lactoferrin|Caregivers of children will be instructed to provide 1.5g of lactoferrin with 40g of unmodified rice powder daily mixed with 125 mL of porridge or other complimentary food.
223478854|NCT05519254|DIETARY_SUPPLEMENT|Lysozyme|Caregivers of children will be instructed to provide 41.5g of Lysosure daily mixed with 125 mL of porridge or other complimentary food.
223478855|NCT05519254|COMBINATION_PRODUCT|Lactoferrin + Lysozyme|Caregivers of children will be instructed to provide 40g of Lysosure with 1.5 grams of lactoferrin daily mixed with 125 mL of porridge or other complimentary food.
223478856|NCT05519254|OTHER|Placebo|Caregivers of children will be instructed to provide 41.5 grams of unmodified rice powder daily mixed with 125 mL of porridge or other complimentary food.
223478857|NCT02187783|DRUG|LEE011|Study drug was provided in 200 mg and 50 mg hard gelatin capsules to be taken orally
223478858|NCT04352673|DIAGNOSTIC_TEST|Elbow flexion and extension strength measurements using a hand-held dynamometer|Elbow flexion and extension strength of the participants will be measured in both arms in the supine, prone, and sitting positions using a hand-held dynamometer.
223478859|NCT02283879|BIOLOGICAL|Human umbilical cord mesenchymal stem cells|A single dose of 2×107 hUC-MSC will treated to patients, IV, Repeat every weeks for four times.
224164828|NCT04487418|PROCEDURE|Electro cautery surgery|"Pre-anesthetics with therapeutic topic (benzocaine) will be administered and, as an anesthetic, or use of anesthetic drops (benzocaine or tetracaine) or local infiltrative anesthesia (2% lidocaine 1: 100,000 with adrenaline).~The surgery will be carried out with cauterization for incision of the lingual brake, division of the brake fibers and release, removing the brake fibers that are stored in the anterior ventral free parts of the tongue until reaching the base of the tongue, which are removed or cleaned, lingual movement, and the anterior axis of the tongue is repositioned or lingual brake in that region. No sutures will be performed and should be oriented on the formation of a pseudo-membranous repair plate in the second intention that will be formed between the first and the third day after surgery.~Postoperative care:~Guidance will be given to the person responsible for not bringing objects to the mouth that may hurt."
223478860|NCT03010072|DRUG|low-dose sucroferric oxyhydroxide|250 mg suroferric oxyhydroxide
223584273|NCT03445221|DIETARY_SUPPLEMENT|Conventional Diet|patients will continue preoperative oral conventional diet.
223584274|NCT02068417|DEVICE|shock waves|extracorporeal shock waves: Verum: 0.1 mJ/mm2 Placebo: placebo stand-off
223584275|NCT01990456|DEVICE|PHASE 1: impact of tidal ventilation on VILI|PHASE 1A - Baseline - Standard Ventilation Protocol (PCV 10 cmH2O, PEEP 10 cmH2O, RR 10, FiO2 0.30) PHASE 1B - CPAP Strategy - CPAP 10 cmH2O for 1 hour PHASE 1C - Higher Tidal Ventilation Strategy (PCV 20 cmH2O, PEEP 10 cmH2O, RR 10, FiO2 0.30) PHASE 1D - Return to Baseline - Standard Ventilation Protocol
224164829|NCT04487418|PROCEDURE|High power diode laser surgery|"Pre-anesthetics with therapeutic topic (benzocaine) and as anesthetic or use of anesthetic eye drops (benzocaine or tetracaine) or local infiltrative anesthesia (2% lidocaine 1: 100,000 with adrenaline) will be administered. The surgery will be performed with a high power diode laser (TW Surgical, MMOptics - São Carlos - Brazil). 808 nm wavelength, which can be operated in continuous or interrupted mode. Wattages from 1 to 1.5 W, up to a maximum of 2 W, can be used and must carefully respect the histological characteristics of the target tissue and the signs of overheating and carbonization, so that the choice of parameters is dynamic and very dependent on experience, mastery and care for the operator.~Preoperative care: Guidance will be given to the person responsible for not bringing objects to the mouth that may hurt."
224164830|NCT03506113|DRUG|Gram stain-guided antibiotic choice|The results of Gram staining of endotracheal aspirate are used to guide the selection of antibiotics.
224164831|NCT03506113|DRUG|Guidelines-based antibiotics choice|Patients are administered the combination of an anti-pseudomonal agent and anti-MRSA agent according to IDSA/ATS guidelines
224164832|NCT00700349|OTHER|Small loan|Applicants in the treatment group were offered an interest rate, loan size, and maturity per the lender's standard underwriting criteria, involving a 4-month maturity at 11.75% per month, charged on the original balance (200% annual percentage rate).
224164833|NCT04488549|OTHER|Survey|International E-survey
223478861|NCT03010072|DRUG|high-dose sucroferric oxyhydroxide|2000 mg suroferric oxyhydroxide
223478862|NCT05334394|OTHER|Mulligan Technique|Mulligan suggested that injuries or sprains can cause a minor positional error in a joint, thereby causing limitations in physiological movement. Unique to this concept is mobilization of the spine while weight bearing and directing the mobilization parallel to the spinal facet planes. Although it includes various mobilization techniques, one of the most important techniques, motion co-mobilization, is the SNAG's technique, which includes the application of accessory passive gliding to the lumbar vertebra while the patient performs active movement simultaneously.
223584276|NCT01990456|DEVICE|PHASE 2: impact of PEEP on VILI|PHASE 2A - Baseline - Standard Ventilation Protocol - (PCV 10 cmH2O, PEEP 10 cmH2O, RR 10, FiO2 0.30) PHASE 2B - Decremental PEEP Trial PHASE 2C - CPAP set at best compliance of respiratory system (as per decremental PEEP Trial) PHASE 2D - ZEEP PHASE 2E - Return to Baseline - Standard Ventilation Protocol
223584277|NCT00357656|DRUG|Recombinant Protein-Free Factor VIII (rAHF-PFM)|"An initial loading dose will be administered intravenously over a period \<= 5 minutes (maximum of infusion rate of 10 mL/minute) within 60 minutes prior to surgery dose in order to maintain a minimum target FVIII level of at least 80% of normal.~CI will start prior to surgery as soon as the loading dose has been administered, at a rate calculated according to a formula provided by the sponsor.~All study product must be administered with a syringe pump running at an infusion rate according to the dosing regimen, but always \>= 0.4 mL/h."
223761378|NCT01574352|BEHAVIORAL|Intervention camp|The children are participating in a 6 week day camp. The camp contains social activities, physical activity training, usual school classes and health education. All meals (healthy food) are consumed during the camp day.
223761379|NCT00436943|DRUG|nicotine replacement therapy and bupropion|3-6 months
223478863|NCT05334394|OTHER|Exercise Therapy|Exercise is recommended by physical therapists for most chronic low back pain patients.
223478864|NCT05605353|DIAGNOSTIC_TEST|Faecal microbiota sampling and blood sampling|There is no intervention in this study. We will obtain faeces and blood from the recruited patients and assess the microbiota and their metabolites therein. This is an observational work
223478865|NCT00471497|DRUG|nilotinib|Nilotinib was supplied as 50 mg, 150 mg and 200 mg hard gelatin capsules and administered orally at 300 mg BID (twice a day) or 400 mg BID (twice a day)depending on the randomized dose.
224164834|NCT03966664|DIAGNOSTIC_TEST|In vitro determination the dissociation constant (Ka) and total amount of non-volatile buffers (Atot) in isolated plasma.|Collection of a venous blood sample, centrifugation in order to harvest isolated plasma and performance of in-vitro tonometry in order to assess Ka and Atot.
224164835|NCT03966664|DIAGNOSTIC_TEST|In vitro determination the dissociation constant (Ka) and total amount of non-volatile buffers (Atot) in whole blood|Collection of a venous blood sample and performance of in-vitro tonometry in order to assess Ka and Atot.
224164836|NCT03966664|DIAGNOSTIC_TEST|Biomolecular analysis of plasma proteins.|Bidimensional electrophoresis, determination of oxidized albumin fraction, characterization of altered ligand binding properties of plasma albumin.
224164837|NCT06003452|PROCEDURE|surface treatment with Bioactive Glass Air Abrasion|giomer based fissure sealnt will be applied after surface treatment With Bioactive Glass Air Abrasion
224164838|NCT00510770|DEVICE|CPAP application|
224164839|NCT00998036|DRUG|Temsirolimus|"Temsirolimus will be administered intravenously weekly on days one and eight of a three week cycle. Temsirolimus will not be given on week three (usually dosed weekly) for increased tolerability given its possible plasma accumulation during week three. Temsirolimus will be given second over a 30 minute infusion during posthydration.~Dose escalation will follow the standard 3 by 3 design with three set dosing levels.~Dose Level 1: Temsirolimus 15mg~Dose Level 2: Temsirolimus 15mg~Dose Level 3: Temsirolimus 25mg"
224164840|NCT00998036|DRUG|Cisplatin|Cisplatin at 30mg/m2 will be administered intravenously weekly on days one and eight of a three week cycle. Cisplatin will be given first over a 30 minute infusion with prehydration.
224164841|NCT00998036|DRUG|Erlotinib|"Erlotinib will be taken by mouth daily starting at 100mg. On days of cisplatin and temsirolimus infusions, erlotinib should be taken at least two hours after the beginning of the temsirolimus infusion.~Dose escalation will follow the standard 3 by 3 design with three set dosing levels.~Dose Level 1: Erlotinib 100mg~Dose Level 2: Erlotinib 150mg~Dose Level 3: Erlotinib 150mg"
224164842|NCT03156725|DRUG|Ferrous Sulfate|
224164843|NCT03156725|DIETARY_SUPPLEMENT|Aspiron|
224164844|NCT01891604|DIETARY_SUPPLEMENT|breast milk with Bifidobacterium Longum subp. Infantis R0033|
224164845|NCT01891604|DIETARY_SUPPLEMENT|breast milk|
224164846|NCT01392768|DRUG|Levetiracetam|Oral solution (Each mL contains 100mg of levetiracetam) or immediate-release tablets (Tablets containing 500mg or 1000mg of levetiracetam)
224164847|NCT01392768|DRUG|Placebo|Placebo, properly standardized to suit the characteristics of each dosage form (oral solution and tablets) of levetiracetam
224164848|NCT06004089|PROCEDURE|V NOTES Sacrocolpopexy|The procedure involved a single-port laparoscopic surgery through the vaginal route, aiming to restore pelvic floor function by suspending the vagina to the anterior longitudinal ligament. The surgical approach differs from conventional methods, as these procedures are conducted through abdominal or vaginal routes without the aid of laparoscopic cameras, However, in our approach, we uniquely combine the widely acknowledged gold standard sacrocolpopexy procedure using vaginal route with laparoscopic camera assistance. No experimental drugs or devices were employed; only the surgical approach was modified.
224164849|NCT01833390|DRUG|HXe MRI lung ventilation|MagniXene (HXe) is an Investigational New Drug made of xenon noble gas. Through a physical process using alkali vapors and powerful lasers, xenon atoms have their nuclear spin preferentially aligned (hyperpolarized), thus offering a highly enhanced signal inside an MRI scanner. High-resolution images of the lung spaces are acquired within a short breath-hold after inhalation of HXe.
224164850|NCT02702284|BEHAVIORAL|Advance Directives|These subject's will have a research assistant (RA) review and walk through the advance directives brochure. The RA will read all of the brochure to the patient and prompt for questions. In addition, a link to an educational video on advance directives. The advance directive link will be either texted or emailed or given in paper per the subject's preference.
224164851|NCT02702284|BEHAVIORAL|Advance Directives without assistance|This group of subjects will be provided with the advance directive and then referred to clinic staff for assistance.
224164852|NCT05905861|PROCEDURE|Skin incision with scalpel.|"A Pfannenstiel skin incision will be performed using a scalpel, extending through the subcutaneous tissue and rectus sheath. After separation of rectus muscles, peritoneum will be visualized and opened. Optimal hemostasis will be achieved by applying pressure to skin blood vessels and ligating any subcutaneous bleeding.~Group A: skin incision with a scalpel."
223478866|NCT00471497|DRUG|imatinib|Imatinib was supplied as 100 mg and 400 mg tablets and administered orally at 400 mg QD (once a day).
223478867|NCT05074901|BEHAVIORAL|digital behavioral intervention|interaction with a conversational agent to implement physical and cognitive programs
224164853|NCT05905861|PROCEDURE|Skin incision with a diathermy.|"A Pfannenstiel skin incision will be made using a scalpel. Subsequently, a diathermy pen electrode will be employed for the dissection of deeper tissues.~Optimal hemostasis will be achieved by using the same blade pen electrode, set to coagulation mode.~Group B: skin incision with diathermy."
224164854|NCT01589692|PROCEDURE|Open Reduction and Internal Fixation|Internal fixation with a volar locking plating system
224164855|NCT01589692|PROCEDURE|External Fixation|External Fixation with a bridging external fixator. Can be done with or without percutaneous pinning.
224164856|NCT01589692|PROCEDURE|Percutaneous Pinning|Pinning with any number of Kirschner wires
224164857|NCT01589692|PROCEDURE|Closed Reduction and casting|Closed reduction and immobilization with a cast and/or splint
224164858|NCT00002394|DRUG|Terbinafine hydrochloride|
224164859|NCT01905904|DRUG|sevorane|Sevorane 4% Sevorane 7%
224164860|NCT03959345|DRUG|Combination therapy group|Adult patients with MSSA bacteraemia will be randomized to Combination therapy group: patients will receive intravenous cloxacillin 2g/4h and fosfomycin 3 g/6h for the duration of 7 days treatment. After the first week, antibiotic treatment and duration will be decided by responsible clinician following clinical practice.
224164861|NCT03959345|DRUG|Standard therapy group|Adult patients with MSSA bacteraemia will be randomized to Standard therapy group: patients will receive intravenous cloxacillin 2g/4h for the duration of 7 days IV treatment. After the first week, antibiotic treatment and duration will be decided by responsible clinician following clinical practice.
223478868|NCT01631942|DRUG|NNC172-2021|"Administered as subcutaneous (s.c., under the skin) injections every other day for two weeks.~Escalation to next dose level is based on a safety evaluation."
223478869|NCT00605020|DRUG|insulin detemir|
223478870|NCT00605020|DRUG|insulin aspart|
223478871|NCT00605020|DEVICE|biphasic insulin aspart|
223478872|NCT05054634|BEHAVIORAL|Psycho-oncological Intervention Based on Counselling (PIBC)|Patients in EG received a psycho-oncological intervention based on Counselling (PIBC) following the scheme proposed by Arranz and Cancio in addition to the standard treatment. The evolution of anxiety and depression was evaluated using Hospital Anxiety and Depression Scale (HADS). The aim of the study was to evaluate the effectiveness of a PIBC in reducing anxiety and depression of patients with DTC. Other QoL relevant items were also evaluated using the Short Form-36 Health Survey (SF-36) and Psychological General Well-Being Index (PGWBI) scales.
223478873|NCT02339688|OTHER|conventional MS rehabilitation|assessment pre and post conventional MS rehabilitation
223584278|NCT00357656|DRUG|Recombinant Protein-Free Factor VIII (rAHF-PFM)|The treatment schedule for intermittent BI of rAHF-PFM will begin with the administration of the loading dose according to the dose recommendations provided by the sponsor. If required by the hemostatic challenge, additional boluses may be administered after a blood sample for FVIII determination has been drawn. All infusions of rAHF PFM will be given over a period \<= 5 minutes (maximum infusion rate, 10 mL/min).
223584279|NCT01821456|DRUG|Antiinfectives|To analyze to efficacy of (novel) drug therapies
223584280|NCT02573246|BEHAVIORAL|Cognitive Restructuring|Cognitive restructuring is a cognitive behavioral intervention through which participants learn how to think differently about stressful events in order to feel less emotional arousal. Specifically, participants learn how to distance themselves from the situation, think of the memory as just a memory, or focus on alternative explanations or facets of the situation that are less emotionally upsetting.
223584281|NCT02573246|DEVICE|rTMS|rTMS is a neurostimulation intervention where the participant receives 15 minutes of high frequency (10 HZ) transcranial magnetic stimulation pulses
223584282|NCT02573246|DEVICE|Sham rTMS|Sham rTMS is a placebo intervention aimed to mimic the effects of repetitive transcranial magnetic stimulation with no known direct benefit for the participant.
224164862|NCT04996524|DRUG|epidural analgesia|Patients recieving epidural analgesia instead of systemic analgesia for acute pain in the intensive care unit
224164863|NCT04350372|DEVICE|MitraClip Procedure|MitraClip procedure with MitraClip NT System
224164864|NCT06401252|BEHAVIORAL|Mindfulness-based intervention|"• The mindful mediators are asked to act as neutral observers who view the world as it is, without reactions, judgments, and evaluations. They quietly attend to, note, and let go of every internal external stimulus such as thought, feeing, sensation, sound, idea that enters awareness. They do not try to think about, push away, and do anything with these stimuli experienced and do not have to figure out the connections between each 19 stimuli. They simply let each stimulus come and go and wait for the next stimulus. They do not have to be concerned about distractions. Each time they are distracted, they note it as yet another passing stimulus (Ah, a distraction… how interesting)"
224164865|NCT05488925|DRUG|Vitamin E|Evion, 400 mg
224164866|NCT05488925|DRUG|Diclofenac Sodium|Voltral SR100, 100 mg
224164867|NCT05488925|DRUG|Piroxicam|Feldene, 20 mg
224164868|NCT05488925|DRUG|Tramadol|Tramal, 50 mg
224164869|NCT02194452|RADIATION|gallium Ga 68-edotreotide|Undergo gallium Ga 68-edotreotide PET/CT
224164870|NCT02194452|PROCEDURE|positron emission tomography|Undergo gallium Ga 68-edotreotide PET/CT
224164871|NCT02194452|PROCEDURE|computed tomography|Undergo gallium Ga 68-edotreotide PET/CT
224164872|NCT02194452|OTHER|laboratory biomarker analysis|Correlative studies
224164873|NCT00641459|OTHER|Observational BPSD treatment study|Observational BPSD treatment study
224164874|NCT03104959|DIETARY_SUPPLEMENT|N-acetyl cysteine|
223584283|NCT00003358|DRUG|chemotherapy|
223584284|NCT00003358|DRUG|cisplatin|
224164875|NCT03104959|OTHER|placebo|
224164876|NCT00427375|PROCEDURE|local rectal excision|New surgical option in good responders after neoadjuvant treatment for low rectal cancer
224164877|NCT00427375|PROCEDURE|total mesorectal excision|standard surgery
223478874|NCT00392223|DRUG|Azithromycin microspheres|Azithromycin microspheres, powder for oral suspension, 2 g a week, in unique administration PO, repeated weekly for 8 weeks and minocycline-placebo capsules daily for 8 weeks plus minocycline placebo
223478875|NCT00392223|DRUG|minocycline-placebo capsules|minocycline-placebo capsules daily for 8 weeks plus minocycline placebo
223478876|NCT00392223|DRUG|Azithromycin microspheres-placebo|Minocycline capsules, PO, 100 mg daily for 8 weeks and Azithromycin microspheres-placebo once a week for 8 weeks plus azithromycin placebo.
223478877|NCT00392223|DRUG|Minocycline capsules,|Capsules, PO, 100 mg daily for 8 weeks.
223478878|NCT00003858|DRUG|mitoxantrone hydrochloride|
223584285|NCT00003358|DRUG|gemcitabine hydrochloride|
223584286|NCT01219933|DRUG|methylprednisolone|starting dose \>/= 1 mg and \</= 20 mg orally daily, according to dose-reduction schedule
223584287|NCT01219933|DRUG|tocilizumab [RoActemra/Actemra]|background therapy: 8 mg/kg iv every 4 weeks
223584288|NCT03661736|OTHER|Food for Specific Medical Purpose|Infants aged 1 to 8 months with moderate-to-severe cow's milk allergy fed an amino acid-based formula with two added human milk oligosaccharides
224164878|NCT02333136|DEVICE|raman spectroscopy (LighTouch)|near infrared light will be shone upon a fingerbed capillary and light scatter measured using in vivo raman spectroscpy
224164879|NCT06014021|BEHAVIORAL|Pelvic floor muscle training with biofeedback device|Use of the Smartphone application to perform a strengthening program for pelvic floor musculature, while using an intracavitary biofeedback device that will inform about vaginal pressure.
224164880|NCT06014021|BEHAVIORAL|Pelvic floor muscle training|Use of the Smartphone application to perform a strengthening program for pelvic floor musculature.
224164881|NCT06014021|BEHAVIORAL|Information about pelvic floor and communication with health professionals|Use of the Smartphone application with access to information about pelvic floor and direct communication with healthcare team.
224164882|NCT01144741|OTHER|PTSD Checklist-Civilian (PCL-C)|Completed by patients before the interview; it is a 17-item survey listing of symptoms of posttraumatic stress disorder.
224164883|NCT01144741|OTHER|Modified Flanagan Quality of Life Scale|Completed by patients before the interview; it is a 16-item survey designed for use in persons with chronic illness.
224164884|NCT01144741|OTHER|Center for Epidemiologic Studies Depression Scale (CES-D)|Completed by patients before the interview; it is a 20-item survey that asks about depressive feelings and behaviours in the past week.
223478879|NCT04926168|OTHER|Delay of TMZ|Delay of TMZ to analyze the current standard of care practice of prescribing TMZ post combination (RT and TMZ).
223478880|NCT04926168|OTHER|Standard of Care (SOC) Adjuvant TMZ (no intervention|SOC in Adjuvant Setting no intervention
223478881|NCT02990052|PROCEDURE|Volar plating|Open reduction and volar fixed-angle plate fixation of distal radius fracture
224164885|NCT01144741|OTHER|Functional Enquiry (or Review of Systems) Form|Completed during the interview; it is a checklist of medical problems.
224164886|NCT01144741|OTHER|Study of Therapeutic Outcomes and Practices in Freeman-Sheldon Syndrome (STOP-FSS) Questionnaire|The STOP Questionnaire is a guided interview form that will be used to assess diagnosis, problems, treatments, and outcomes.
224164887|NCT01144741|OTHER|FSRG Semi-Structured Quality of Life Interview (FSRG SSQLI)|Completed after data analysis from the existing surveys, it will be a specific quality of life interview, taking into consideration individual's total health outcome.
224164888|NCT01144741|OTHER|Medical Records Review|Review of medical records will be used, along with STOP-FSS Survey to assess patient histories and outcomes.
224164889|NCT00720720|DIETARY_SUPPLEMENT|plant sterol enriched margarine|Each group will have to consume 20 grams of margarines (either placebo or enriched in plant sterols) in one or two catches per day, for 8 weeks.
224164890|NCT00720720|DIETARY_SUPPLEMENT|placebo margarine|
224164891|NCT04757376|BIOLOGICAL|CT-P41|60 mg/mL single dose, Solution for injection in PFS
224164892|NCT04757376|BIOLOGICAL|US-licensed Prolia|60 mg/mL single dose, Solution for injection in PFS
224164893|NCT02702167|DEVICE|High-frequency rTMS|10 Hz active stimulation, once daily
224164894|NCT02702167|DEVICE|Low-frequency rTMS|1 Hz active stimulation, once daily
224164895|NCT02702167|DEVICE|Sham rTMS|Sham stimulation, once daily
224164896|NCT00374101|DRUG|omeprazole|
224164897|NCT00374101|DRUG|pantoprazole|
223478882|NCT02990052|PROCEDURE|Conservative treatment|Closed reduction \& casting of distal radius fracture
223478883|NCT06024460|PROCEDURE|non-pharmacological treatment strategy|Acupuncture, elctroacupuncture, spinal manual therapy, motion style acupucnture treatment
223478884|NCT06024460|PROCEDURE|pharmacological treatment strategy|"Prescription medication, injection therapy, nerve blocks, or other pharmacological interventions commonly used for managing lumbar disc herniation.~This group is treated using the above treatment strategies, and no drug is specified."
223478885|NCT04618913|DRUG|Apixaban|Anticoagulant
223478886|NCT04618913|DRUG|Rivaroxaban|Anticoagulant
223478887|NCT04618913|DRUG|Edoxaban|Edoxaban
223478888|NCT04618913|DRUG|Dabigatran|Dabigatran
223478889|NCT04618913|DRUG|VKA|Vitamin K antagonist
224164898|NCT00096304|DRUG|docetaxel|
223478890|NCT04618913|DRUG|LMWH|Low Molecular Weight Heparin
223478891|NCT06433284|PROCEDURE|25-gauge pars plana vitrectomy with inverted flap technique and SF6 tamponade|"Standard 3 port 25-gauge pars plana vitrectomy with inverted flap technique after brilliant blue dye staining and SF6 tamponade. Flower petal type of inverted flap will be performed - multiple small ILM flaps will be created around the macular hole and placed over the macular hole"
224164899|NCT00096304|DRUG|epirubicin hydrochloride|
224164900|NCT02544204|BIOLOGICAL|JVS-100|Biological/Vaccine: JVS-100 Intramuscular Injection
224164901|NCT02544204|BIOLOGICAL|Placebo|Biological/Vaccine: Placebo Intramuscular Injection
224164902|NCT01307046|DRUG|MK-0954A|Tablet containing losartan potassium (100 mg) and hydrochlorothiazide (12.5 mg), once daily
224164903|NCT01307046|DRUG|Losartan|Tablet containing losartan potassium (100 mg), once daily
224164904|NCT01307046|DRUG|Placebo to MK-0954A|Placebo tablet to match MK-0954A, once daily
224164905|NCT01307046|DRUG|Placebo to losartan 100 mg|Placebo tablet to match losartan 100 mg, once daily
224164906|NCT01307046|DRUG|Placebo to losartan 50 mg|Placebo tablet to match losartan 50 mg, once daily
224164907|NCT00428103|PROCEDURE|3 dimensional echocardiography|Lab tests: BNP, 6 minute walk test Transthoracic 3D echocardiogram
224164908|NCT00411970|DEVICE|20- and 23 gauge vitreoretinal surgery systems|
223478892|NCT06433284|PROCEDURE|25-gauge pars plana vitrectomy with complete internal limiting membrane peeling with amniotic membrane hydrogel filling and SF6 tamponade|Standard 3 port 25-gauge pars plana vitrectomy with complete internal limiting membrane peeling around the macular hole after brilliant blue dye staining then filling the hole with amniotic membrane hydrogel and sulfur hexafluoride (SF6) tamponade
223478893|NCT02323243|DEVICE|"Allium  Bulbar Urethral Stent  (BUS) system"|
223478894|NCT05949840|OTHER|Expressive Interviewing|Automated computer system designed to engage participants in discussion about challenges faced during the COVID-19 pandemic.
223478895|NCT02954081|DRUG|Phase I: Fumaric acid esters. Phase II: Apremilast|Apremilast
223511666|NCT03048019|DRUG|Tirofiban|Patients will receive Tirofiban during the PCI procedure
223511667|NCT03048019|DRUG|Cangrelor|Patients will receive Cangrelor during the PCI procedure
223511668|NCT05226000|DRUG|Benaglutide Injection|All subjects received multiple doses (tid) of 0.06 mg, 0.1 mg, 0.14 mg, and 0.2 mg in sequence, followed by the next dose after completing the previous multiple dosing. The administration time of each dose was 0.06 mg for 3 days, 0.1 mg for 3 days, 0.14 mg for 5 days, and 0.2 mg for 5 days.
223511669|NCT04121871|OTHER|No intervention|Not required
223511670|NCT00978185|OTHER|medical chart review|
224164909|NCT02628899|DEVICE|Transfemoral TAVR|
224164910|NCT02628899|DEVICE|SAVR|
224164911|NCT04288297|PROCEDURE|distal minimally invasive chevron osteotomy|With an electric motor-driven machine the resection of the medial eminence as well as a V-shaped osteotomy was performed in hallux valgus patients. Intraoperative fluoroscopy was used to identify the ideal osteotomy site and to control the Intervention. Fixation of the metatarsal head was achieved with a screw or with a K wire. Residual bone ridges were reamed and bone debris washed out.
224164912|NCT05942677|PROCEDURE|proportion of colorectal lesions|Evaluation of the proportion of colorectal lesions detected by a computer-aided detection system (CADe) compared with experienced endoscopists.
224164913|NCT00367705|DIETARY_SUPPLEMENT|VSL#3®|1-2 sachets/day per os, 6 months
224164914|NCT00367705|DIETARY_SUPPLEMENT|Placebo|1-2 sachets/day per os, 6 months
224164915|NCT03801798|DRUG|GC1102|NAs antivirals+GC1102 180,000 IU
224164916|NCT03801798|OTHER|GC1102 Placebo|NAs antivirals+GC1102 Placebo
224164917|NCT04399304|PROCEDURE|simultaneous bilateral high tibial osteotomy|One-stage simultaneous bilateral high tibial osteotomy
224164918|NCT04399304|PROCEDURE|Staged bilateral high tibial osteotomy|Two-stage bilateral high tibial osteotomy
224164919|NCT04746313|BIOLOGICAL|blood test|"* to analysis prolactin in healthy subjects and scleroderma patients~* then to analysis in only scleroderma patients: thyroid-stimulating hormone (TSH), thyroxine (T4), luteinizing hormone (LH), oestradiol, follicle-stimulating hormone (FSH), BAFF (B-cell activating factor), IL-6 (interleukin 6) and endoglin"
224164920|NCT01755104|DIETARY_SUPPLEMENT|Stablor|
224164921|NCT01755104|DIETARY_SUPPLEMENT|Placebo|
224164922|NCT06409507|GENETIC|FKBP12 expression|The expressions of FKBP12 were determined by immunohistochemistry (IHC) , and the immunoreactive score (IRS), calculated by multiplying the staining intensity grades by the proportion of positive cells, was used to assess the expression levels of FKBP12. IRS (0-7) represented low expression levels, and IRS (8-12) represented high expression levels.
224164923|NCT02550093|PROCEDURE|Intervention 1|Each subject will receive nasal spray(s) into each nostril of 4 Units up to 32 units of study drug prior to Thermal Evaluation System Testing on intervention 1 (Day 1).
224164924|NCT02550093|BEHAVIORAL|Washout Period|The wash-out period will be between intervention 1 and intervention 2. 13 days in length.
224164925|NCT02550093|PROCEDURE|Intervention 2|Each subject will receive nasal spray(s) into each nostril of 4 Units up to 32 units of study drug prior to Thermal Evaluation System Testing on intervention 2 (Day 14).
224164926|NCT05627791|DRUG|Oxytocin|Oxytocin vaginal gel that have oxytocin 400IU/1ml of gel, base gel contained HPMC 4,000 cps, 5% propylene glycol USP, 0.08% methylparaben, sterile water for irrigation and 0.02% propylparaben then adjusted pH by Lactic acid and sodium hydroxide keep pH 3.5-4.0
224164927|NCT05627791|DRUG|Placebo|Placebo gel that have base gel contained HPMC 4,000 cps, 5% propylene glycol USP, 0.08% methylparaben, sterile water for irrigation and 0.02% propylparaben then adjusted pH by Lactic acid and sodium hydroxide keep pH 3.5-4.0 without oxytocin
224164928|NCT04684160|DEVICE|Fixed-bearing TKA|
224164929|NCT04684160|DEVICE|Mobile-bearing TKA|
224164930|NCT03119922|OTHER|No intervention|
224164931|NCT00224497|DRUG|SB-742457|
224164932|NCT02903745|OTHER|observational|
224164933|NCT00740194|DRUG|Aromatase inhibition|Letrozole
224164934|NCT00740194|DRUG|Estradiol|Dermestril
224164935|NCT03421262|DIAGNOSTIC_TEST|IADPSG Criteria|One-step: 2 hr 75 gr OGTT
223478896|NCT06472622|DEVICE|Thermal Pain Stimulation|Thermal pain will be administered during fMRI neuroimaging via a thermal stimulation device (Medoc Ltd., Advanced Medical System, Israel; 510K: K052357; K041908; K922052) to examine brain activity corresponding to the experience of this stimulus. This device and associated system carries an FDA 510 (K) clearance.
223478897|NCT06472622|DEVICE|Physical Effort Stimulation|Physical effort will be administered during fMRI neuroimaging via a hand dynamometer attachment for a physiological monitoring system (BIOPAC Systems, Inc., Goleta, CA, USA) to examine brain activity corresponding to the experience of this stimulus. This device has not received pre-marked approval or 510 (K) clearance by the FDA.
223478898|NCT06301438|DRUG|dalpiciclib|dalpiciclib oral day 1-21, every 28 days
223478899|NCT01618877|DRUG|Levetiracetam|Levetiracetam 1.500 mg (500 mg/ 5 mL vials) administered as a 45 minutes intravenous infusion diluted in 100 mL 0.9 % saline solution every 12 hours from the morning of Day 3 (it is the first day in Part B) to the morning of Day 7 (it is the 5th day in Part B).
223511671|NCT00978185|OTHER|questionnaire administration|
223511672|NCT00978185|PROCEDURE|acupressure therapy|
223511673|NCT00978185|PROCEDURE|quality-of-life assessment|
224164936|NCT03421262|DIAGNOSTIC_TEST|NDDG Criteria|Osullivan test + 3 h 100 g OGTT
224164937|NCT02003768|DRUG|Propofol|80 patients are randomly allocated into two groups: In TIVA group, propofol based total intravenous anesthesia is used to induce and maintain anesthesia for laparoscopic cholescystectomy.
224164938|NCT02003768|DRUG|Desflurane|80 patients are randomly allocated into two groups : In Des group, inhalation anesthesia using desflurane is used to induce and maintain anesthesia for laparoscopic cholescystectomy.
224164939|NCT00993980|PROCEDURE|qigong|one therapy session once a week during three months, that is 12 therapy sessions altogether
224164940|NCT00993980|PROCEDURE|exercise therapy|one therapy session once a week during three months, that is 12 therapy sessions altogether
224164941|NCT04941976|DRUG|0.3% benzydamine hydrochloride spray oromucosal solution|"Single application of 0.3% benzydamine hydrochloride spray oromucosal solution. Drug applications will be performed at the investigational site, on the morning of Visit 0.~In case of persistent sore throat patients will continue the assigned treatment at home, according to the local SmPC and up to one week, until the symptoms' resolution."
224164942|NCT04941976|DRUG|Single 3 mg lozenge of benzydamine hydrochloride (mint flavour)|"Single 3 mg lozenge of benzydamine hydrochloride (mint flavour). Drug applications will be performed at the investigational site, on the morning of Visit 0.~In case of persistent sore throat patients will continue the assigned treatment at home, according to the local SmPC and up to one week, until the symptoms' resolution."
224164943|NCT03426644|BEHAVIORAL|Mobile Sleep and Growth Study|The intervention is designed to test if sleep tips delivered by text messages can aid with reaching time in bed targets. And if additional motivational text messages can further aide with reaching time in bed targets.
224164944|NCT02467660|BEHAVIORAL|Mindfulness Meditation|Using study-provided iPod device to listen to guided meditations daily
224164945|NCT02467660|BEHAVIORAL|Health & Wellness Education|Using study-provided iPod device to listen to educational podcasts daily
224164946|NCT00832689|DRUG|Irinotecan and Gemcitabine|
224164947|NCT04929691|DEVICE|CPAP helmet|helmet-based CPAP ventilation for eligible patients; assess the feasibility and acceptability of the helmet-based CPAP ventilation
224164948|NCT04929691|OTHER|Standard of care non-helmet based CPAP ventilation|Standard of care ventilation without helmet-based CPAP
224164949|NCT01365091|DRUG|Saxagliptin/metformin fixed-dose combination (FDC)|Tablet, oral, 5 mg/500 mg FDC, once on Day 1 only, 1 day
224164950|NCT01365091|DRUG|Saxagliptin|Tablet, oral, 5 mg, once on Day 1 only, 1 day
224164951|NCT01365091|DRUG|Metformin extended-release (XR)|Tablet, oral, 500 mg, once on Day 1 only, 1 day
224164952|NCT01365091|DRUG|Saxagliptin/Metformin FDC|Tablet, Oral, 5 mg/1000 mg FDC, once on Day 1 only, 1 day
224164953|NCT01365091|DRUG|Metformin|Tablet, oral, 1000 mg, once on Day 1 only, 1 day
224164954|NCT02250391|DRUG|NPB-06|5 days continuous-infusion
224164955|NCT02250391|DRUG|Placebo|5 days continuous-infusion
224164956|NCT05724381|DIAGNOSTIC_TEST|auramine phenol staining|The samples will be divided into 2 parts. The 1st part will be subjected to a direct wet saline smear, iodine smear, and concentration techniques. The 2nd part will be used to perform thin smears of the fecal concentrates and air-dried on 2 different slides. The first slide will be stained with Kinyoun's acid-fast stain and examined with the conventional light microscope and the second will be stained with auramine-phenol stain and examined with the fluorescent microscope.
224164957|NCT00583830|BIOLOGICAL|Mapatumumab|30 mg/kg IV (in the vein), on day 1 of each 21 day cycle
224164958|NCT00583830|BIOLOGICAL|Mapatumumab|10 mg/kg IV (in the vein), on day 1 of each 21 day cycle
224164959|NCT00583830|DRUG|Paclitaxel|200 mg/m\^2 IV (in the vein), on day 1 of each 21 day cycle
224164960|NCT00583830|DRUG|Carboplatin|AUC 6.0 mg min/ml IV (in the vein), on day 1 of each 21 day cycle
224164961|NCT06437548|DEVICE|Percutaneous spinal cord stimulation|The parameters of percutaneous cervical spinal cord stimulation leads will be adjusted for optimal upper extremity motor function.
224164962|NCT01375439|OTHER|Active search of lower genital tract infections|Two groups (G1 and G2) will be part of study, each one composed of 140 pregnant women with a history of premature birth, G1 will have the active search and etiologic diagnosis of lower genital tract infections and G2 do not search of these infections, keeping for this group, the protocol of routine care of basic health units in the city of Botucatu. Workup care of pregnant women (G1) will include the completion of direct examination of vaginal contents stained by Gram's method, culture in the medium of Diamonds and polymerase chain reaction (PCR) of endocervical secretions, collected by health services in primary care the municipality in two moments: before 20th pregnancy week (M1) and in 36th pregnancy week (M2). The moment M3 will be after the birth, to evaluate the perinatal outcome.
224164963|NCT04865224|DIAGNOSTIC_TEST|hemoglobin estimation|In this method, in which different deep learning models are used together, the age range is intended to be as wide as possible to provide a quick solution with a high accuracy and low error values.
224164964|NCT04363463|OTHER|prone position|Two sessions minimum of prone position over the day. With a total objective of at least 2h30 of cumulated duration over the day. The objective is to spend as much time as possible in prone position if the patient tolerates it well.
224164965|NCT02835235|DRUG|NNC9204-0530|Administered daily subcutaneously (s.c., under the skin)
224164966|NCT02835235|DRUG|placebo|Administered daily subcutaneously (s.c., under the skin)
224164967|NCT00801710|DEVICE|BridgePoint Medical System (CrossBoss Catheter, Stingray Catheter, Entera Guidewire)|"Revascularization of coronary artery chronic total occlusion.~Use of the BridgePoint Medical System to cross coronary CTOs prior to definitive revascularization treatment via angioplasty and/or stent implant"
224164968|NCT04052412|DRUG|18F-AraG|All arms of the study will receive an injection of 18F-AraG while on the PET imaging system. Following a 6 minute scan over the heart to acquire input function data, the patient will undergo a 1 hour multi-pass whole-body dynamic PET/CT acquisition to gather whole-body biodistribution data.
224164969|NCT00024206|DRUG|orantinib|Given orally
223478900|NCT01618877|OTHER|Placebo|15 mL 0.9 % saline solution added to 100 mL 0.9 % saline solution, administered as a 45 minutes intravenous infusion every 12 hours from the morning of Day 3 ( it is the 1st day in Part B) to the morning of Day 7 (it is the 5th day in Part B).
224164970|NCT00024206|OTHER|laboratory biomarker analysis|Correlative studies
224164971|NCT00024206|OTHER|pharmacological study|Correlative studies
224164972|NCT04808492|DEVICE|CureWave High Intensity Laser|"* The participant will lie prone and the HILT will be administered in 9 symmetrical positions which cover the lumbosacral region. Dose will be 1minute per position. The dose will include:~  * Power (44 Watts)~ * Mode (continues wave)~ * Time on (60000 ms)~ * Time off (1 ms)~ * Repeats (9)~* Distance of electrode from skin will begin 10 from skin surface. The participant may or may not feel mild warmth. Should the subject report excessive warmth or discomfort the probe distance will be increased in 2 intervals until it is comfortable. The entire process will take approximately 10 minutes.~* The participant will lie prone and the Placebo treatment will consist of positioning the HILT probe over the 9 symmetrical positions for 1 minutes each however the no laser will be admitted."
224164973|NCT04808492|OTHER|Placebo|"The participant will lie prone and the NON ACTIVE HILT will be administered in 9 symmetrical positions which cover the lumbosacral region. Dose will be 1minute per position. THE LASER WILL NOT BE ACTIVE.~o Distance of electrode from skin will begin 10 from skin surface. The entire process will take approximately 10 minutes."
224164974|NCT01006213|BEHAVIORAL|Motivational intervention|Two groups will be established in geographically separate areas, one of which will receive the group motivational intervention (intervention group) and the other will receive standard follow-up (control group)
223478901|NCT04887688|DEVICE|exciflex|untethered electronic bandage with all the components of a surface stimulation system mounted on a flexible substrate.
223478902|NCT06473532|BEHAVIORAL|TEXT4HF|In addition to usual care, participants in the intervention group will receive 5 TMs/week for 12 weeks at a time of their preference. Tailoring of the TMs is performed based on participants' responses to validated questionnaires (health beliefs scales, HF-knowledge scale, and self-efficacy about HF self-care scale), administered at baseline and 4 weeks. They will also receive an AHA HF discharge informational packet.
223478903|NCT05135091|BIOLOGICAL|NRTX-1001|Biological: NRTX-1001 is an experimental neural cell therapy product candidate derived from an allogeneic human embryonic stem cell line. The stem cells were converted into inhibitory nerve cells that produce GABA.
223478904|NCT05135091|BIOLOGICAL|NRTX-1001|Biological: NRTX-1001 is an experimental neural cell therapy product candidate derived from an allogeneic human embryonic stem cell line. The stem cells were converted into inhibitory nerve cells that produce GABA.
223478905|NCT05135091|PROCEDURE|Sham Comparator|Sham Comparator
224205408|NCT04311723|PROCEDURE|Anesthesia Procedure|Receive anesthesia using laryngeal mask
224205409|NCT04311723|PROCEDURE|Anesthesia Procedure|Receive anesthesia using endotracheal tube
224205410|NCT04311723|PROCEDURE|Bronchoscopy|Undergo standard of care bronchoscopy
223478906|NCT06851533|PROCEDURE|Standard Analgesia (No Block)|Participants receive standard perioperative analgesia (including intravenous paracetamol/tramadol), but no additional regional block is applied.
223478907|NCT06851533|PROCEDURE|Thoracolumbar Interfascial Plane (TLIP) Block|In addition to standard perioperative analgesia, a TLIP block is performed under sterile conditions and ultrasound guidance, after the surgical procedure is completed but before the patient is awakened. A total of 30 mL of 0.25% bupivacaine is injected into the thoracolumbar fascial plane, and spread is confirmed via ultrasound.
223478908|NCT06851533|PROCEDURE|Quadro Iliac Plane Block|In addition to standard perioperative analgesia, a Quadro Iliac Plane Block is performed under sterile conditions and ultrasound guidance, after the surgical procedure is completed but before the patient is awakened. A total of 30 mL of 0.25% bupivacaine is injected into the quadro iliac plane at the level of the iliac crest, and spread is confirmed via ultrasound.
223478909|NCT05942885|OTHER|anxiety questionnaire|Patient undergoing hypnosis session will have their anxiety measured just before the third session of hypnosis and after during a telephonic consultation. The result will be compared to the anxiety level before the first hypnosis session
223478910|NCT06395012|DRUG|LY3985297|Administered either IV or SC.
223478911|NCT06395012|DRUG|Placebo|Administered either IV or SC.
223478912|NCT06061952|BEHAVIORAL|Customized Adherence Enhancement for Schizophrenia (CAE-S)|6-session series spaced out over approximately 6-10 weeks
223584289|NCT06461728|DEVICE|a new prototye device that heat and activate sodium hyochlorite (Aseptico)|endoactivator : it is a sonic activator device
223584290|NCT05838014|OTHER|Sleep deprivation|Participants will undertake a period of 24 hours of total sleep deprivation prior to completing exercise
223584291|NCT05838014|OTHER|Normal sleep|Participants will undertake \~8 hours of normal sleep prior to completing exercise
223584292|NCT03329716|OTHER|Brace weaning|For AIS patients who have been wearing Boston brace and attend clinic consultation where the decision for brace weaning is made, then weaning protocol of either arm will be prescribed
224164975|NCT03944551|DEVICE|Bubble CPAP|Those assigned to the bCPAP group will receive a Total flow oxygen at a rate of 2 liters per kilogram to a maximum of 10 liters per minute using the appropriate nasal prongs for the age and size of the patient. The positive end-expiratory pressure (PEEP) provide by bCPAP will start at 8cm HO2. The FIO2 will be adjusted to obtain a saturation of oxygen of 90% or greater.
224164976|NCT03944551|OTHER|Standard Therapy|For patients in the standard therapy group, oxygen will be delivery by nasal cannula at a flow rate of 4 Liters per minute. If a patient in the standard group after 1 hour of treatment still has a SpO2 \< 90% or meeting criteria of treatment failure the patient will be move from the standard therapy group to the bCPAP group.
223584293|NCT00914550|OTHER|Procalcitonin level, caregiver informed|Procalcitonin levels will be measured and known by investigator, only 1/2 of the patients' caregivers will know the results of serial Procalcitonin levels. We will analyze the rate of antibiotic discontinuation for the two arms
223584294|NCT03084042|DEVICE|fMRI|
223584295|NCT05919641|OTHER|Comprehensive Geriatric Assessment|Comprehensive geriatric assessment (CGA) is defined as a multidisciplinary diagnostic and treatment process that identifies medical, psychosocial, and functional capabilities of an older adult in order to develop a coordinated plan to maximize overall health with aging.
223584296|NCT06218706|DEVICE|Low Intensity Focussed Ultrasound|The major objective of this study is to further test safety, tolerability, and feasibility of LIFU in this population as well as investigate the impact of LIFU on opioid and other substance use. The primary endpoint is 90 days (Post-LIFU Week 12) following Active/Sham LIFU. After the primary endpoint is reached, the blind will be broken and the group who received Sham LIFU will cross-over and receive Active LIFU
223584297|NCT03149003|DRUG|DSP-7888 Dosing Emulsion|DSP-7888 Dosing Emulsion will be administered i.d. every 7 ± 1 day for Doses 1 to 5, every 14 ± 3 days for Doses 6 to 15, and every 28 ± 7 days for Doses 16 and above.
223584298|NCT03149003|DRUG|Bevacizumab|Bevacizumab will be administered intravenously every 14 ± 3 days at 10 mg/kg.
224164977|NCT05021666|DRUG|Placebo|matching placebo
224164978|NCT05021666|DRUG|PB 718|dose in the next group will be determined following a review of data from the previous group
224164979|NCT00965549|DRUG|INSULIN GLARGINE (HOE901)|LANTUS®: Solution for injection. 100U/mL in a prefilled pen (SoloStar®)
224164980|NCT00965549|DRUG|Insulin aspart|NovoMix® 30: Suspension for injection. 100U/mL in a prefilled pen (FlexPen®)
224314194|NCT01952210|BEHAVIORAL|nutritional consultation and exercise program|The protocol involved 20-30 minutes of individual-based nutrition consultation every week during the 8-week chemoradiation therapy. The exercise program consisted of upper extremity muscle training and walking exercise at 45%-65% of maximal heart rate reserve, 3 times per week, 20-30 minutes per session.
223478913|NCT06061952|OTHER|Enhanced Treatment as Usual (eTAU)|eTAU participants will view a pre-taped series of 6 videos
223478914|NCT06554665|BEHAVIORAL|High-intensity Interval Training|There will be three sessions per week for 12 consecutive weeks, totaling 36 training sessions.
223478915|NCT06554665|BEHAVIORAL|Moderate-Intensity Continuous Training|There will be three sessions per week for 12 consecutive weeks, totaling 36 training sessions.
223478916|NCT06554665|BEHAVIORAL|Stretching|There will be three sessions per week for 12 consecutive weeks, totaling 36 training sessions.
223478917|NCT05837195|DEVICE|DDA Doppler|A new Doppler parameter to quantify the amount of vasodilatation in the middle cerebral artery (MCA) and other blood vessels.
223478918|NCT06666283|DRUG|AP303 150μg|AP303 Tablet 150μg QD
223478919|NCT06666283|DRUG|Placebo 150μg|Placebo Tablet 150μg QD
224164981|NCT00965549|DRUG|Insulin Glulisine|APIDRA®: Solution for injection. 100U/mL in a prefilled pen (SoloStar®)
223478920|NCT03418519|OTHER|Constraint Induced Movement Therapy|Constraint-induced movement therapy (CIMT) is a high-dosage, efficacious, rehabilitation approach used for children with hemiplegic cerebral palsy
223478921|NCT01356420|DIETARY_SUPPLEMENT|Cholesterol supplementation|Cholesterol supplementation may be achieved with SLOesterol instead of or in combination with egg yolk. SLOesterol is a powder formulation that contains cholesterol and natural emulsifier. It is considered a medical food developed by Solace Nutrition and available by prescription only.
224164982|NCT01025297|DRUG|Interleukin-7|3 dose levels: 3, 10 \& 20 µg/kg. 4 administrations, 1 per week
224314195|NCT01952210|BEHAVIORAL|usual care|pre-CCRT education included self-care during CCRT and body weight maintenance
223478922|NCT05852093|DRUG|Celecoxib+Buprenorphine Transdermal Patch|NSAIDs+narcotic analgesics
223478923|NCT05852093|DRUG|Celecoxib+Buprenorphine Transdermal Patch+Tizanidine|NSAIDs+narcotic analgesics+Skeletal Muscle Relaxant
224164983|NCT06074718|OTHER|pricking therapy and wheat grain moxibustion|pricking therapy and wheat grain moxibustion on the back shu points or positive reaction points
224164984|NCT02737176|OTHER|Tobacco cessation intervention|"The nicotine dependence status is evaluated by the Fagerstrom Test for Nicotine Dependence test; those who 3 or more score are eligible for the intervention.~During the study, attending doctors implement a tobacco cessation intervention with standard treatments for above oral diseases.~Even if the subjects failed to abstain from smoking, the treatment is continued.~In case of the use of the nicotine replacement therapy, The investigators supply NRTs (nicotine patch or gum) for 2 weeks as a free of charge, and later the subjects themselves purchase it as over the counter (OTC) drugs at a pharmacy."
224164985|NCT05730127|OTHER|Conditioning stimulus|Pain stimulus on non-dominant side
224164986|NCT04633031|DEVICE|Boston|
224164987|NCT04633031|DEVICE|Cheneau|
223478924|NCT00943436|OTHER|Exercise Session|"This study consists of two laboratory sessions. Participants will be randomly assigned to the order in which they go through these two sessions. The Exercise Session will consist of the participant coming into the lab and completing 45 min bout of exercise on an exercise bike, followed by a 60 min resting period, followed by the lunch buffet portion of the session where they will have 25 min to eat ad libitum."
224164988|NCT03940014|OTHER|Data collection from standard follow up|"Annual clinical consultation with an Hereditary Haemorrhagic Telangiectasia (HHT) specialist and/or pneumologist and organ specialists when necessary (such as hepatologists, cardiologists and neurologists).~Explorations (contrast echography, chest Computed Tomography and treatments performed according to international guidelines.~TransCatheter Embolotherapy for each treatable Pulmonary Arteriovenous Malformations (PAVMs) and follow-up every 3 years.~Chest Computed Tomography (CT) every 6-12 months."
224164989|NCT06039280|DRUG|N Acetylcysteine|NAC started at 12 hr prior to procedure - (150 mg/kg/hr for 1 hr followed by 12.5 mg/Kg/hr for 4 hr, then continuous infusion of 6.25 mg/h for 48 after the procedure.
224164990|NCT06039280|DRUG|Dexamethasone|Dexamethasone 20 mg in 5 ml NS 1 hour prior to procedure and 8 mg in 5 ml NS at day 2, day 3. Placebo 5 ml NS 1 hr prior to procedure.
224164991|NCT06039280|OTHER|Placebo|The placebo will be administered in the same way as the drug in the experimental group.
224164992|NCT06743620|OTHER|iltamiocel|This is an observational study with no intervention.
224164993|NCT06743165|BEHAVIORAL|Pelvic floor muscle training with ultrasound biofeedback|Pelvic floor muscle training (PFMT) will be given to both groups with transabdominal US. PFMT will be applied by physiotherapists who have received training and supervision from physiotherapists who are experts in the field of pelvic floor US imaging and pelvic floor muscle training with US. Pelvic floor muscle training will be applied with a GE Brand LOGIQ P8 model transabdominal ultrasound (GE HealthCare) US device under the supervision of an expert physiotherapist. Parents and children will be informed about PFMT.
224164994|NCT06743165|BEHAVIORAL|Dynamic neuromuscular stabilization exercise|Dynamic neuromuscular exercises (DNS) involve the joint activation of the intrinsic muscle group of the spine, which includes the cervical flexors and extensors, diaphragm, transversus abdominis, multifidus and pelvic floor, which form the integrated spinal stabilization system. The application principles are joint centering, core stabilization - Integrated spinal stabilization system and stabilization function of the diaphragm. DNS training will be applied in three stages. Preparation for exercises, IAB regulation and application of exercises according to developmental kinesiology positions. Exercises will start with preparatory training. In preparatory training, stroking, brushing and tapping techniques will be taught and self-facilitation will be demonstrated in order to increase proprioceptive input to the lower extremity, upper extremity, trunk and pelvic region. Fascial mobilizations will be performed to the foot and hand regions.
224164995|NCT00033111|DRUG|Cabergoline|
224164996|NCT00033111|DRUG|Placebo|sugar pill manufactured to mimic cabergoline 05mg tablet
224164997|NCT00418899|BEHAVIORAL|Questionnaire|Questionnaire, 30-40 minutes, about gliomas and its risk factors (such as environmental and genetic information).
223478925|NCT00943436|OTHER|Rest Session|"This study consists of two laboratory sessions. Participants will be randomly assigned to the order in which they go through these two sessions. The Rest Session will consist of the participant coming into the lab and completing a 45 min period of reading followed by a 60 min resting period, followed by the lunch buffet portion of the session where they will have 25 min to eat ad libitum."
223511674|NCT00978185|PROCEDURE|sham intervention|
223511675|NCT00978185|PROCEDURE|standard follow-up care|
223511676|NCT01627912|OTHER|Robola, Cabernet Sauvignon wines|4 treatments on separate days: the subjects randomly consumed 4ml of drink \[white wine or red wine or 12.5% ethanol or water\]/kg of individual, parallel with a standardized meal.
223511677|NCT04308993|PROCEDURE|percutaneous transhepatic choledochoscopy|percutaneous transhepatic choledochoscopy
223511678|NCT03684785|DRUG|Cavrotolimod|Intratumorally dosed cavrotolimod.
223511679|NCT03684785|BIOLOGICAL|Pembrolizumab|Pembrolizumab dosing as per the US prescribing information.
223511680|NCT03684785|BIOLOGICAL|Cemiplimab|Cemiplimab dosing as per the US prescribing information.
223511681|NCT03684785|DRUG|Cavrotolimod|Subcutaneously dosed cavrotolimod
223511682|NCT06296030|BEHAVIORAL|POOF ACT program|The goal of this study is to test this culturally tailored intervention (POOF) against classic ACT, to discover if POOF does better at decreasing race-based trauma in African Americans.Guided by the cultural humility framework and social determinants of health model, we examine POOF, a culturally-tailored ACT model for use with anxious African Americans. The POOF approach builds on research on ACT for the general population, an evidence-based intervention, by tailoring the language of ACT while retaining the fidelity of the ACT model. Our hypotheses examine acceptability and attitudes toward treatment, treatment outcomes for psychological symptoms (i.e., anxiety) and an ACT-related outcome (i.e., psychological flexibility), and a possible underlying mechanism of change (i.e., race-based stress).
223511683|NCT06296030|BEHAVIORAL|Classic ACT program|This protocol is for a classic, non-adapted ACT intervention.
223511684|NCT00092742|DRUG|MK0663, etoricoxib|
223511685|NCT00092742|DRUG|Comparator: Diclofenac sodium|
224164998|NCT05309395|COMBINATION_PRODUCT|FoodRx|Participants will receive weekly meal plans and recipes and the groceries required to prepare the recommended meals
224164999|NCT06759233|PROCEDURE|endoscopic cryoballoon ablation treatment(ECAT)+PD-1|"ECAT: A cryoballoon with catheter is inserted along the endoscopic forceps channel, the balloon is placed on the surface of the tumor, and the balloon is dilated so that it fits snugly over the lesion. The freezing cycle is initiated and continued for 2-3 minutes, and then the balloon is rewarmed and frozen again for 2-3 minutes; the freeze-rewarm cycle is repeated twice.~PD-1:The first PD-1 monoclonal antibody treatment in this study was given within 3 days before and after ECAT treatment, and subsequent treatment was given every three weeks according to the instructions."
224165000|NCT06861829|DRUG|BI 3731579|BI 3731579
224165001|NCT06747390|DRUG|Lidocaine 1% Injectable Solution|1% lidocaine will be injected under direct visualization (not exceeding the maximum tolerated dose of 4.5 mg/kg body weight) into the primary tumor with the aim to distribute the lidocaine evenly into the tumor.
224165002|NCT02569398|DRUG|Atabecestat, 5 mg|One atabecestat, 5 mg tablet orally once daily up to 54 months.
224165003|NCT02569398|DRUG|Atabecestat, 25 mg|One atabecestat, 25 mg tablet orally once daily up to 54 months.
224165004|NCT02569398|DRUG|Placebo|One matching placebo tablet orally once daily up to 54 months.
224165005|NCT04511338|DEVICE|Dialyzer with Endexo|"Sequence AB:~Period 1 Circuit A (Five Visits: 1,2,3,4,5) Period 2 Circuit B (Five Visits: 9,10,11,12,13)~Sequence BA:~Period 1 Circuit B (Five Visits: 1,2,3,4,5) Period 2 Circuit A (Five Visits: 9,10,11,12,13)"
224165006|NCT01698177|BIOLOGICAL|Influenza vaccine|Seasonal inactivated trivalent vaccine
224165007|NCT01698177|BIOLOGICAL|Influenza vaccine|Seasonal inactivated trivalent vaccine
224165008|NCT02428933|DRUG|Bromocriptine|The investigators will look at the physiological effect of dopamine on BAT activity rather than on the effect of the drug itself
224165009|NCT02116361|BIOLOGICAL|onabotulinumtoxinA|OnabotulinumtoxinA injected into protocol-specified areas on Day 1.
224165010|NCT02116361|DRUG|Normal Saline|Placebo (normal saline) injected into protocol-specified areas on Day 1.
224165011|NCT03485963|BIOLOGICAL|HST-NEETs|The primary objective of this study is to evaluate the safety and tolerability of expanded HIV-specific T cell therapy (HST-NEETs) in HIV-infected individuals suppressed on cART. Patients with a partial response or stable disease 8 weeks after T-cell infusion were eligible to receive additional T-cells, consisting of the same number of cells as their second injection.
224165012|NCT06805162|OTHER|Normal training|Athletes should continue their normal training
224165013|NCT06805162|OTHER|Specific training|Athletes should consider i) watching the educational videos on injury prevention, ii) perform the neuro-muscular exercises, iii) practice the techniques against stress and anxiety, and iv) consider the injury prognostic feedback.
224165014|NCT06833047|BEHAVIORAL|Emotional intervention|Participants will receive different emotional interventions such as boredom, positive valence, mind-wandering.
224165015|NCT03227224|DRUG|Placebo|Participants will receive 2 placebo capsules matching JNJ-42847922 once daily orally from Day 1 to Day 41 (Week 6).
224165016|NCT03227224|DRUG|JNJ-42847922|Participants will receive 2 capsules of JNJ-42847922 once daily orally from Day 1 to Day 41 (Week 6).
224165017|NCT06781593|DEVICE|Light therapy|The intervention consists of 30 minutes of daily exposure to light therapy glasses (active or sham according to randomization) on waking for 2 weeks. The light therapy will be delivered in the patient's home at the same time as CPAP is introduced.
224165018|NCT06926491|DRUG|KK8398|KK8398 will be administered.
224165019|NCT02406027|DRUG|JNJ-54861911, 10 mg|Participants will self-administer JNJ-54861911 tablet, 10 mg (2\*5 mg), orally, once daily.
224165020|NCT02406027|DRUG|JNJ-54861911, 25 mg|Participants will self-administer 1 tablet of JNJ-54861911, containing 25 mg orally, once daily.
224165021|NCT02406027|DRUG|Placebo|Participants will self administer placebo matching to JNJ-54861911 orally once daily.
224165022|NCT02406027|DRUG|JNJ-54861911, 5 mg|Participants will self-administer JNJ-54861911 tablet, 5 mg, orally, once daily.
223478926|NCT03181152|DIAGNOSTIC_TEST|Impulse Oscillometry|"1，Before the experiment, the patient is arranged to rest 10min. 2, IOS: The patient take seats, body relax, make sure the mouthpiece is fully covered by mouth, then clip nose with both hands to cover both sides of the cheek, and then calm breathing 1 minutes, the computer is automatically collected data calculation and print out the measurement results.~3, Bronchial Dilation Test: The patient is asked to take IOS again after gaven aerosol inhalation of 200g salbutamol for 15min, the computer is automatically collects the data computation and prints the measurement result."
223478927|NCT00001104|DRUG|Zidovudine|
223478928|NCT05911217|DRUG|CT041 autologous CAR T-cell injection|Treatment with anti-claudin18.2 chimeric antigen receptor T-cell infusion. Up to 3 times CT041 autologous CAR T-cell injection infusion
223478929|NCT05637502|OTHER|Graded Motor Imagery|Graded Motor Imagery programme consisting on three stages that will be gradually implemented. (i) Implicit Motor Imagery, that will be implemented through a developed app that resembles the Recognize app but adapted for Pelvic Floor disorders, (ii) Explicit Motor Imagery, applied through several sessions of motor imagery assisted through audio recordings and (iii) Graded Exposure, also guided through audio recordings and several practical tasks to perform.
223478930|NCT00402831|BIOLOGICAL|ProQuad®|Each dose (0.5 mL) contains live attenuated versions of measles virus Enders' Edmonston strain, mumps virus Jeryl Lynn™ (Level B) strain, rubella virus Wistar RA 27/3 strain, and varicella virus Oka/Merck strain.
224165023|NCT02497287|DRUG|Esketamine (Intranasal Spray)|Open-Label Induction Phase: Participants will self-administer esketamine intranasally twice per week for 4 weeks as a flexible dose regimen (56 mg or 84 mg for those \< 65 years; 28 mg, 56 mg or 84 mg for those \>= 65 years). Participants \>= 65 years old will start at a dose of 28 mg on Day 1. Optimization/Maintenance Phase: Participants will self-administer esketamine intranasally (56 mg or 84 mg for those \< 65 years; 28 mg, 56 mg or 84 mg for those \>= 65 years) once weekly then individualized to either once weekly or once every other week based on the severity of depressive symptoms. Transferred-entry responder participants from ESKETINTRD3005 \>= 65 years old will start at a dose of 28 mg in Week 5.
223511686|NCT03400787|DEVICE|Latera Implant|Treatment with implant
223584299|NCT06299722|OTHER|STEEL|Relatively heavy strength training
224165024|NCT02497287|DRUG|Duloxetine (Oral Antidepressant)|Duloxetine could be selected as the oral antidepressant medication by the investigator based on review of Massachusetts General Hospital - Antidepressant Treatment Response Questionnaire (MGH-ATRQ) and relevant prior antidepressant medication information. The minimum therapeutic dose is 60 milligram per day (mg/day).
224165025|NCT02497287|DRUG|Escitalopram (Oral Antidepressant)|Escitalopram could be selected as the oral antidepressant medication by the investigator based on review of MGH-ATRQ and relevant prior antidepressant medication information. The minimum therapeutic dose is 10 mg/day. Participants \>= 65 years of age will be titrated up to 20 mg/day, but can lower the dose to 10 mg/day for tolerability.
224165026|NCT02497287|DRUG|Sertraline (Oral Antidepressant)|Sertraline could be selected as the oral antidepressant medication by the investigator based on review of MGH-ATRQ and relevant prior antidepressant medication information. Sertraline will be titrated up to a dose of 150 mg/day, but if not tolerated the dose can be reduced to the minimum therapeutic dose of 50 mg/day.
224165027|NCT02497287|DRUG|Venlafaxine Extended Release (XR) (Oral Antidepressant)|Venlafaxine Extended Release could be selected as the oral antidepressant medication by the investigator based on review of MGH-ATRQ and relevant prior antidepressant medication information. Venlafaxine Extended Release will be titrated for participants \< 65 years of age up to a dose of 225 mg/day, but if not tolerated the dose can be reduced to the minimum therapeutic dose of 150 mg/day. For participants \>= 65, it can be titrated up to a dose of 150 mg/day, but if not tolerated the dose can be reduced to the minimum therapeutic dose of 75 mg/day.
224165028|NCT03238079|BIOLOGICAL|10% IGIV|300-900 mg/kg
224165029|NCT00509938|DRUG|human lactoferrin peptide 1-11|Each subject will receive a single intravenous dose of hLF1-11 given in a volume of 20mL given over 20 minutes i.e. 1mL/per minute.
224165030|NCT03782376|DRUG|Ustekinumab approximately 6 mg/kg (IV)|Participants will receive ustekinumab approximately 6mg/kg intravenously at Week 0.
224165031|NCT03782376|DRUG|Placebo (SC)|Participants will receive SC injection of placebo at Week 0.
224165032|NCT03782376|DRUG|Placebo (IV)|Participants will receive IV infusion of placebo at Week 0.
224165033|NCT03782376|DRUG|Ustekinumab 90 mg (SC) Group 1|Participants will receive SC injection of ustekinumab 90 mg at Weeks 8 and 16.
224165034|NCT03782376|DRUG|Ustekinumab 90 mg (SC) Group 2|Participants will receive SC injection of ustekinumab 90 mg at Weeks 0, 8 and 16.
224165035|NCT04614467|BIOLOGICAL|CLBS16|GCSF-mobilized autologous CD34+ cells
224165036|NCT04614467|BIOLOGICAL|Placebo|isotonic solution (no CD34+ cells)
224165037|NCT02912741|DRUG|Vanish xt Extended Contact Varnish|resin modified glass- ionomer cement varnish applied as a thin layer coating and cured
224165038|NCT02912741|DRUG|resin infiltration|low viscous light cure resin applied in layers and cured
224165039|NCT06935630|DIETARY_SUPPLEMENT|Folic Acid|Participants in this group will receive a daily oral dose of 600 mcg (1.35 μmol) of folic acid in film-coated tablet form for a duration of three months. This synthetic form of folate will be administered to assess its impact on red blood cell folate levels compared to 5-MTHF.
224165040|NCT06935630|DIETARY_SUPPLEMENT|5-MTHF (5-methyltetrahydrofolate)|Participants in this group will receive a daily oral dose of 1100 mcg (1.35 μmol) of 5-methyltetrahydrofolate (5-MTHF) glucosamine salt, specifically HY-FOLIC®, in film-coated tablet form for a duration of three months. This active form of folate will be administered to assess its impact on red blood cell folate levels compared to folic acid
224165041|NCT02814799|OTHER|bone removal|
224165042|NCT01780207|DEVICE|PFO Closure|
224165043|NCT01226472|BIOLOGICAL|KW-0761|In the first treatment course KW-0761 will be administered i.v. once a week for four weeks, followed by a 2-week observation period. Subsequent treatment courses are permissible for subjects demonstrating a response or maintaining stable disease and will consist of an infusion of KW-0761 every other week.
224165044|NCT00952419|BIOLOGICAL|Monovalent Subvirion A/H1N1 Influenza vaccine|0.5 mL, Intramuscular Day 0 and Day 21 (3 to 9 years); 0.25 mL, Intramuscular on Day 0 and Day 21 (6 months to 35 Months)
223584300|NCT06299722|OTHER|Circuit training|Circuit training
224165045|NCT00952419|BIOLOGICAL|Monovalent Subvirion A/H1N1 Influenza vaccine|0.5 mL, Intramuscular Day 0 and Day 21 (3 to 9 years); 0.25 mL, Intramuscular on day 0 and Day 21 (6 months to 35 Months)
224165046|NCT00952419|BIOLOGICAL|Normal saline solution (placebo)|0.5 mL, Intramuscular Day 0 and Day 21 (3 to 9 years); 0.25 mL, Intramuscular on day 0 and Day 21 (6 months to 35 Months)
224165047|NCT01251822|DRUG|PEG 3350 plus electrolytes|Each sachet of PEG 3350 is dissolved in 125 mL of water. Patients receive two sachets of PEG 3350 plus electrolytes followed by two placebo tablets for the first 14 days, after which dosage adjustment is permitted, according to effect. Each patient is treated for 28 days in total.
223584301|NCT03458858|OTHER|Mixed Berry Diet|Mixed Berry Treatment
223584302|NCT03458858|OTHER|Carbohydrate Control Jello|Carbohydrate Control
223584303|NCT03458858|OTHER|Fiber Enriched Jello|Fiber Control
223584304|NCT03458858|OTHER|Low Fiber Mixed Berry Juice|Anthocyanin Control
223584305|NCT04363047|OTHER|40ml blood sample|We'll be collecting cells, DNA and serum.
223584306|NCT04668235|DRUG|AZVUDINE|5 tablets QD + standard treatment for up to 14 days
223584307|NCT04668235|DRUG|AZVUDINE placebo|5 tablets QD + standard treatment for up to 14 days
224165048|NCT01251822|DRUG|Prucalopride|"Patients less than 65 years of age receive a solution containing two sachets of reconstituted placebo followed by two prucalopride 1 mg tablets for 28 days.~Patients more than 65 years of age receive a solution containing two sachets of reconstituted placebo followed by one prucalopride 1 mg tablet and one placebo tablet for 28 days."
224165049|NCT06949137|BIOLOGICAL|Human Umbilical Cord-derived Mesenchymal stem cell|Intravenous infusion of hMSC100 at 20-25 drops per minute
224165050|NCT06949943|BEHAVIORAL|Behavioral Intervention|Listen to guided meditation
224165051|NCT06949943|BEHAVIORAL|Behavioral Intervention|Wear noise cancelling headphones
224165052|NCT06949943|OTHER|Electronic Health Record Review|Ancillary studies
224165053|NCT06949943|OTHER|Survey Administration|Ancillary studies
224165054|NCT06948526|DRUG|Moringa Oleifera Leaf Extract|A plant-based extract derived from Moringa Oleifera leaves, used as an intracanal irrigant during pulpectomy procedures in primary molars. It is administered using a 3 ml syringe with a side-vented needle following canal preparation and working length determination. This intervention aims to evaluate the clinical and radiographic efficacy of a natural, biocompatible alternative to conventional chemical irrigants.
224165055|NCT06948526|DRUG|Sodium Hypochlorite 1%|A 1% concentration of Sodium Hypochlorite solution used as a standard intracanal irrigant in pediatric endodontics. It is administered using a 3 ml syringe with a side-vented needle after canal instrumentation. Known for its strong antimicrobial and tissue-dissolving properties, Sodium Hypochlorite serves as the active comparator in this study.
224165056|NCT06948474|DRUG|Dachengqi decoction|experimental Participants received Dachengqi decoction (50 ml BID) via pump infusion at 10 ml/h starting 12 hours postoperatively, continuing through postoperative days 1-3.
224165057|NCT06948474|PROCEDURE|modified gastrointestinal dual-lumen feeding tube|experimental and control group participants underwent intraoperative placement of modified gastrointestinal dual-lumen feeding tubes with distal ends positioned 15-20 cm distal to the gastrojejunostomy anastomosis (all devices were uniformly procured by China-Japan Friendship Hospital).
224165058|NCT06948474|DRUG|Normal Saline (0.9% NaCl)|control group participants were administered glucose and sodium chloride injection (50 ml BID) via pump infusion at 10 ml/h starting 12 hours postoperatively, continuing through postoperative days 1-3.
224165059|NCT06948123|OTHER|Educational intervention|The experimental group was trained with educational material prepared by the researcher using a computer at home for 15 days after hospital discharge.
224165060|NCT06948123|OTHER|control group|The control group was visited at home 15 days after discharge and the scales were applied. The final scales were applied to the patient who came to the hospital for 3 months. The patient was told that the study was over and given educational materials.
224165061|NCT06062810|DRUG|Raloxifene - Usual|"* Generic-1 - raloxifene hydrochloride tablet~* Raloxifene 60 mg taken orally daily"
224165062|NCT06062810|DRUG|Raloxifene - Study|"* Generic-2 - Raloxifene tablet~* Raloxifene 60 mg taken orally daily"
224165063|NCT00277823|DRUG|DVS-SR 50 mg|
224165064|NCT00277823|DRUG|DVS-SR 100 mg|
224165065|NCT00277823|DRUG|Placebo|
224165066|NCT06449612|DEVICE|TeleRehaStroke: Training programme using the 'Blended Clinic' mobile application|Primary end users (patients after stroke) will be familiarised with the application and the 'TeleRehaStroke' programme in two to three sessions during their last two to three weeks prior to discharge from the inpatient rehabilitation centre. This includes performing daily exercises, wearing an activity tracker and measuring blood pressure daily. Following discharge from rehabilitation, they will continue to use the application for 12 weeks.
224165067|NCT06097468|DRUG|NisinZ® P|NisinZ® P is an ultrapure Nisin Z concentrate produced by fermentation using the bacterium Lactococcus lactis obtained from sauerkraut
224165068|NCT06097468|PROCEDURE|Surgery (non-interventional, standard of care)|Surgical removal of tumor as part of standard of care treatment
224165069|NCT00400946|DRUG|asparaginase|
224165070|NCT00400946|DRUG|cyclophosphamide|
224165071|NCT00400946|DRUG|cytarabine|
224165072|NCT00400946|DRUG|dexamethasone|
224165073|NCT00400946|DRUG|dexrazoxane hydrochloride|
224165074|NCT00400946|DRUG|doxorubicin hydrochloride|
224165075|NCT00400946|DRUG|etoposide|Given IV
224165076|NCT00400946|DRUG|leucovorin calcium|
224165077|NCT00400946|DRUG|mercaptopurine|Given orally
224165078|NCT00400946|DRUG|methotrexate|
223478931|NCT05906849|BEHAVIORAL|ACT for anxiety disorders|A twelve session Acceptance and Commitment Therapy (ACT) for anxiety disorders, applied individually and remotely (through videoconference) to participants fulfilling inclusion criteria (i.e., participants included in the SAD and GAD Experimental Groups).
223478932|NCT03927170|COMBINATION_PRODUCT|Janumet XR tablet 100/1000 mg|To administrate the Janumet XR tablet
223478933|NCT03927170|COMBINATION_PRODUCT|GLH1SM tablet 100/1000 mg|To administrate the GLH1SM tablet
223511687|NCT03400787|DEVICE|Sham Procedure|Sham procedure where the Latera delivery device is inserted but no implant delivered.
223511688|NCT02157727|DEVICE|Infants hospitalized in health facilities performing Tele-expertise|
223511689|NCT02455726|DIETARY_SUPPLEMENT|Magnesium oxide|Oral magnesium oxide 300 mg twice a day
223584308|NCT01330654|DRUG|metoprolol|50mg PO BID starting two weeks prior to surgery. Patients will be reevaluated one week prior to surgery. If their pulse is above 70, the dose will be increased to 100mg BID. If the HR is 50-70, the dose will not be changed. If the pulse is below 50, the dose will be decreased to 25mg. This dose will be continued for thirty days after operation.
223511690|NCT02455726|DIETARY_SUPPLEMENT|Fructose|Oral fructose 10 g twice a day
223511691|NCT02455726|DRUG|Oxycodone|Oxycodone hydrochloride 5 mg at 8 am
223511692|NCT02455726|DRUG|Pregabalin|Pregabalin 25 mg at 8 pm
224165079|NCT00400946|DRUG|methylprednisolone|
224165080|NCT00400946|DRUG|pegaspargase|Given IV
224165081|NCT00400946|DRUG|prednisolone|
224165082|NCT00400946|DRUG|therapeutic hydrocortisone|
224165083|NCT00400946|DRUG|vincristine sulfate|
224165084|NCT00400946|RADIATION|radiation therapy|
224165085|NCT06955910|OTHER|questionnaires|"Anamnestic and socio-demographic information will be collected through a generic self-designed questionnaire including the following data: age, sex, residence (within or outside the Veneto region), marital status (married, divorced, cohabiting, single, widowed), employment status (employed, unemployed, retired), presence of dependents (yes/no), level of education (defined as primary, middle or high school, university degree), concomitant pathologies.~Additional data on the oncological history are also reported: histology and staging of the disease, presence or absence of metastatic disease, additional treatments before or after surgery (e.g. neoadjuvant treatments, adjuvant treatments, radiotherapy)."
224165086|NCT06431334|DIETARY_SUPPLEMENT|Amino Acid Intake|Amino acid intakes will vary between 0.2 to 2.8 g/kg/d
224165087|NCT03443921|PROCEDURE|Artery Divestment Technique|Tunica adventitia was pick up by forceps and opened by electrocoagulation at 1 cm distal from tumor-artery contact. Space between tunica adventitia and external elastic lamina (EEL) were blunt lifting tumor-invaded adventitia by angled clamp. Adventitia was then sectioned to show EEL. Loose dissect space could be achieve along long the plane between EEL and adventitia as long as tumor invasion outside EEL. Tumor and invaded adventitia were further cut open by electrocoagulation proximally. Circumferentially, separation could be done by blunt dissection around EEL. Nourishing blood vessels of the artery would be secured by electrocoagulation or ultrasonic scalpel while major branch would be ligated or transfixed.
224165088|NCT03443921|DRUG|Nab-paclitaxel|After eligibility testing as blood tests, contrast-enhanced CT and MRI scan, 3 cycles were administered (1,000 mg/m2 of gemcitabine and 125 mg/m2 of nab-paclitaxel on days 1, 8, and 15 every 28 days).Patients will be reevaluated and curative operation would be attempted if without disease progression.
224165089|NCT00805649|PROCEDURE|Low fluorescence Photodynamic therapy|42 J/cm2 for 72 sec
224165090|NCT00805649|PROCEDURE|core pars plana vitrectomy|24 hours after photodynamic therapy, 1.5 mL core pars plana vitrectomy
224165091|NCT00805649|DRUG|dexamethasone|intravitreal injection of 0.8 mg dexamethasone
224165092|NCT00805649|DRUG|bevacizumab|intravitreal injection of 1.25 mg bevacizumab
224165093|NCT00805649|PROCEDURE|core pars plana vitrectomy|0.4 mL core pars plana vitrectomy
224165094|NCT00805649|DRUG|triamcincolone|intravitreal injection of 8 mg triamcincolone
224165095|NCT02624661|DRUG|Glycerol|
224165096|NCT05643170|DRUG|Xanomeline and Trospium Chloride Capsules|KarXT 50 mg/20 mg BID KarXT 100mg/20 mg BID KarXT 125mg/30 mg BID
224165097|NCT01432756|BEHAVIORAL|Let's Talk Worksite Parenting Program|The Let's Talk Worksite Parenting Program is designed for Xhosa-speaking and Afrikaans speaking parents (separate sessions) with 11- to 15-year-old children. The 5-session program meets weekly for 2 hours. The program will include instruction on parenting skills and will cover topics relevant to promoting adolescent sexual health, such as; parental involvement; adolescent sexual behavior; HIV; violence; and alcohol/substance use. Parent participants will receive weekly exercises to help them practice their new skills at home with their child.
224165098|NCT02241356|DEVICE|bifocals|bifocal glasses with an addition of 2.5 Dioptres
224165099|NCT02241356|DEVICE|single vision glasses|single vision glasses
224165100|NCT01048827|DRUG|Busulfan|"1. 1250 uMol\*min (AUC to time 6 hrs)\^~2. 1400 uMol\*min (AUC to time 6 hrs~3. 1550 uMol\*min (AUC to time 6 hrs)\^"
224165101|NCT02845284|BEHAVIORAL|enhanced group support|Routine Care plus enhanced group support, and peer education beginning every 4 weeks post enrollment to delivery and at 6 and 10 weeks, 3, 6 and 9 months post delivery.
224165102|NCT02845284|BEHAVIORAL|enhanced individual support|Routine Care plus individual peer education and support beginning every 4 weeks post enrollment to delivery and at 6 and 10 weeks, 3, 6 and 9 months post delivery.
224165103|NCT02896998|PROCEDURE|Removal on demand of the syndesmotic screw|The syndesmotic screw will only be removed in case of a symptomatic implant (e.g. implant causing pain or restricted range of motion)
224165104|NCT02896998|PROCEDURE|Routine removal of fhe syndesmotic screw|The syndesmotic screw will routinely be removed 8 - 12 weeks following placement of the screw
224165105|NCT00365872|BIOLOGICAL|Dendritic Cell (DC) Injections|"* DCs (10\^7 cells) were injected intratumorally three times on the second, third, and fourth Friday during the course of radiation.~* One additional DC injection was given before surgery to assess DC migration~* Patients were assigned to one of three cohorts:~Group 1 - DC injection # 4 given 24 hours prior to surgery Group 2 - DC injection # 4 given 48 hours prior to surgery Group 3 - DC injection # 4 given 72 hours prior to surgery"
224165106|NCT00365872|PROCEDURE|Radiation therapy|Radiation was delivered 5 days per week (Monday-Friday).
224165107|NCT00365872|PROCEDURE|Complete Resection - Surgery for tumor removal|Tumors were surgically resected 3-6 weeks after the completion of EBRT.
224165108|NCT00534664|DEVICE|TheraBionic device|Daily outpatient treatment with theraBionic device
223478934|NCT03553147|OTHER|SARC-F score, handgrip test and impedancemetry|Participation in the study will be offered to any patient admitted to the geriatric ward, those who meet the inclusion criteria and do not have exclusion criteria will have to complete the SARC-F questionnaire during their stay, and to do the handgrip test and impedancemetry performed by a third party. Biological data (albumin, pre-albumin and C-Reactive Protein) and anthropometric data will be collected and analyzed to determine if the patient is malnourished or not, and the results of SARC-F will be compared between these 2 groups.
224165109|NCT03513575|OTHER|Group 1: no intervention|Unstimulated saliva samples are collected from the subject to measure the pH of saliva after 5, 15, 30, 45 and 60 minutes of consumption of the test flavored milk drink without any intervention.
223478935|NCT05354297|DEVICE|Cecelia Health plus OneTouch Verio Reflect® BGM and OneTouch Reveal® mobile app|Expert guidance via coaching
223478936|NCT05354297|DEVICE|Fitbit plus OneTouch Verio Reflect® BGM and OneTouch Reveal® mobile app|Fitness and wellness guidance
223478937|NCT05354297|DEVICE|Noom plus OneTouch Verio Reflect® BGM and OneTouch Reveal® mobile app|Behavioral weight loss program
223478938|NCT05354297|DEVICE|Welldoc plus OneTouch Verio Reflect® BGM and Welldoc app|Multi condition support
223478939|NCT03043053|DRUG|oxytocin nasal spray|oxytocin intranasal spray
223478940|NCT03043053|DRUG|Placebo|Placebo nasal spray
223478941|NCT00808223|BIOLOGICAL|alefacept|IM injection
223478942|NCT02524938|DIETARY_SUPPLEMENT|Chlorogenic Acid (CGA) enriched coffee|"Chlorogenic Acid (CGA) enriched coffee Phase I: CGA-enriched coffee provided with a CGA content of 70-90 mg/100g. Daily CGA intake of 400mg.~Phase II: recommendation for achieving a CGA-rich diet of at least 400mg/day (total polyphenol intake of at least 1g/day)"
223478943|NCT02524938|DIETARY_SUPPLEMENT|Conventional coffee|Phase I: conventional coffee provided (low in CGA) Phase II: standard dietary advice
223478944|NCT01436734|OTHER|Fasting glycemia|no intervention
224165110|NCT03513575|OTHER|Group 2: tap water gargle|The subject will use 10 ml of tap water as mouth rinse to swish for 60 seconds and spit, 15minutes after the subject has consumed the test flavored milk drink. Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes the gargle as an intervention.
224165111|NCT03513575|OTHER|Group 3: 0.2% Chlorhexidine|The subject will use 10 ml of 0.2% Chlorhexidine mouth rinse (Rexidine®, Indoco Remidies Ltd, Mumbai, India) to swish for 60 seconds and spit, 15minutes after the subject has consumed the test flavored milk drink. Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes the gargle as an intervention.
224165112|NCT03513575|OTHER|Group 4: Fluoridated tooth paste|The subject will Brush with fluoridated toothpaste-(Colgate Total®, Colgate-Palmolive Company, Mumbai, India) for 2 minutes using soft brush, 15minutes after the subject has consumed the test flavored milk drink. Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes using tooth paste as an intervention.
224165113|NCT03513575|OTHER|Group 5: Polyol containing gum|The subject will chew polyol containing gum (Orbit®, WrigleyCompany) for 5 minutes and spit, 15minutes after the subject has consumed the test flavored milk drink. Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes chewing as an intervention.
224165114|NCT03513575|OTHER|Group 6: 1% sodium bicarbonate solution|The subject will use 10 ml freshly prepared 1% sodium bicarbonate w/v solution to swish for 60 seconds and spit, 15minutes after the subject has consumed the test flavored milk drink. Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes the gargle as an intervention.
223478945|NCT01436734|OTHER|Hypoglycemia|Insulin induced hypoglycemia
224165115|NCT03580902|BEHAVIORAL|CBT4CBT-Buprenorphine|Computerized, user-driven cognitive-behavioral therapy (CBT) web-based program adapted for use in office based buprenorphine treatment
224165116|NCT03580902|DRUG|Buprenorphine/naloxone|Standard outpatient buprenorphine maintenance
224165117|NCT01786499|BEHAVIORAL|Relaxation Response Training|
224165118|NCT02993133|DRUG|Cellcept® in autoimmune bullous dermatoses|The administration will follow the recommendations for the use of Cellcept® in autoimmune bullous dermatoses
223478946|NCT01114724|DEVICE|Valiant Thoracic Stent Graft with the Captivia Delivery System|All subjects will be implanted with this device
223478947|NCT02873975|DRUG|LY2606368|
223478948|NCT03891225|PROCEDURE|Amniotic Membrane implantation|Surgical procedure will be performed with Longemire Traverso technique. At the end of all pancreatic, biliary and duodenal anastomosis, the AM will be implanted.
223478949|NCT04655417|DRUG|Sodium Tetradecyl Sulfate|DRUG WILL BE INJECTED TO ALLAPTIENTS ACCORDING TO STANDARD PROTOCOL
223478950|NCT01860196|DRUG|Meditoxin|
223478951|NCT01860196|DRUG|Normal saline|
223478952|NCT00687700|DRUG|GSK961081|GSK961081 multidose dry powder inhaler (Diskus inhaler) will be available with dosing strengths of 400 micrograms and 1200 micrograms administered once daily in the morning.
224165119|NCT04156984|DRUG|Golimumab Prefilled Syringe|See arm description
224165120|NCT04959474|OTHER|Best Practice|Given standard dietary recommendations
223478953|NCT00687700|DRUG|GSK961081 matching placebo|GSK961081 matching placebo multidose dry powder inhaler (Diskus inhaler) will be available to be administered once daily in the morning.
223478954|NCT00687700|DRUG|Propranolol|Propranolol over encapsulated tablet will be available with dosing strengths of 40 milligrams administered orally with 240 milliliters of water.
223478955|NCT00687700|DRUG|Propranolol matching placebo|Propranolol matching placebo over encapsulated tablet will be available to be administered orally with 240 milliliters of water.
223478956|NCT00720135|BIOLOGICAL|DI-Leu16-IL2 immunocytokine|Given IV
223478957|NCT00720135|BIOLOGICAL|rituximab|Given IV
223478958|NCT00720135|OTHER|flow cytometry|Correlative studies
223478959|NCT00720135|OTHER|immunohistochemistry staining method|Correlative studies
223478960|NCT00720135|OTHER|pharmacological study|Correlative studies
223478961|NCT00720135|OTHER|laboratory biomarker analysis|Correlative studies
223478962|NCT00720135|OTHER|enzyme-linked immunosorbent assay|Correlative studies
223478963|NCT00720135|GENETIC|reverse transcriptase-polymerase chain reaction|Correlative studies
223478964|NCT00864110|RADIATION|Radiolabeled (99Tc) EC-DG (ethylenedicysteine-deoxyglucose)|one injection of Technetium ethylenedicysteine-deoxyglucose to yield a target activity of 20 mCi (range 20-30 mCi) to be given by slow IV push (over 3-5 minutes) 1mg of EC-DG will be injected
224165121|NCT04959474|RADIATION|Stereotactic Body Radiation Therapy|Undergo SABR
224165122|NCT04959474|PROCEDURE|Resection|Undergo surgical resection
224165123|NCT04959474|PROCEDURE|Sentinel Lymph Node Biopsy|Undergo sentinel lymph node biopsy
224165124|NCT04959474|OTHER|Dietary Intervention|Undergo a caloric restriction diet
224165125|NCT04959474|OTHER|Questionnaire Administration|Ancillary studies
224165126|NCT04959474|OTHER|Quality-of-Life Assessment|Ancillary studies
224165127|NCT03163121|BIOLOGICAL|PfSPZ-GA1 Vaccine|Aseptic, purified, cryopreserved, genetically attenuated P. falciparum sporozoites (Pf∆b9∆slarp), strain NF54
224165128|NCT03163121|BIOLOGICAL|PfSPZ Vaccine|Aseptic, purified, cryopreserved, radiation attenuated P. falciparum sporozoites (PfSPZ Vaccine), strain NF54
224165129|NCT03163121|OTHER|Normal Saline|0.9% sodium chloride
224165130|NCT03163121|BIOLOGICAL|Mosquito-bite CHMI|Bites of 5 infected mosquitoes of NF54 strain
224165131|NCT00483431|DIETARY_SUPPLEMENT|Placebo|
223478965|NCT00864110|RADIATION|Technetium 99m ethylenedicysteine-deoxyglucose|99mTc EC-DG injection, single dose, slow IV push over 3-5 minutes, yielding a target activity of 20 mCi (range 20-30 mCi)
223478966|NCT00864110|RADIATION|18 F fluorodeoxyglucose|single injection of 18F FDG (range 10-20 mCi)
223478967|NCT03945630|PROCEDURE|anterior Quadratus Lumborum Block|Interfascial plane block
223478968|NCT03945630|PROCEDURE|Standard of Care|No QLB
223478969|NCT05782517|DEVICE|Supraglottic Airway Device|Placement of an I-gel Supraglottic Airway Device.
224165132|NCT00483431|DIETARY_SUPPLEMENT|MK7|
224165133|NCT01976403|BEHAVIORAL|Pain Booklet|The Pain Relief After Cardiac Surgery is originally a Canadian booklet. The booklet is further developed and modified for Norwegian patients
223478970|NCT05782517|DEVICE|Endotracheal Tube|Placement of an Endotracheal Tube.
224165134|NCT06787248|PROCEDURE|real-time fMRI sham-controlled neurofeedback training procedure|real-time fMRI neurofeedback training procedure running on the Turbo Brain voyager (TBV) 4.2 software (Brain Innovation, Maastricht, The Netherlands)
224165135|NCT00352404|DEVICE|Endomicroscope|
224165136|NCT03765736|OTHER|Genetic Testing|Undergo genetic testing
224165137|NCT06379087|DRUG|Anlotinib Hydrochloride Capsule|Anlotinib hydrochloride is a muti-target tyrosine kinase inhibitor that inhibits both tumor angiogenesis and tumor cell proliferation by blocking VEGFR, FGFR, PDGFR, and c-Kit simultaneously.
224165138|NCT06379087|DRUG|Tislelizumab Injection|Tislelizumab is a humanized IgG4 anti-PD-1 monoclonal antibody.
223478971|NCT05442008|DRUG|Erenumab 70/140 mg s.c.|Monoclonal antibody directed against the receptor of the Calcitonin Gene Related Peptide (CGRP)
223478972|NCT00966368|DRUG|insulin degludec|Single dose of NN1250, formulation 1, 0.4U/kg body weight injected subcutaneously (under the skin)
223478973|NCT00966368|DRUG|insulin degludec|Single dose of NN1250, formulation 2, 0.4U/kg body weight injected subcutaneously (under the skin)
223478974|NCT03252158|BEHAVIORAL|Availability of healthier vs. less healthy foods|"Altering the number of slots containing (a) healthier and (b) less healthy foods or beverages in hospital vending machines.~Changes follow a 2-step process whereby decreases are implemented in a separate study period prior to increases in the contrasting group. Following a 4-week baseline period, all vending machines will be standardised to have 75% healthier drinks and/or 25% healthier snacks (study period 1). Vending machines will be randomly allocated to the order in which they: (1) decrease less healthy foods and increase healthier foods or (2) decrease healthier foods and increase less healthy foods (study periods 2\&3 and 5\&6). After each decrease-increase pair, machines will return to the standardised 75% healthier drinks / 25% healthier snacks (study periods 4 and 7)."
223478975|NCT03514953|BEHAVIORAL|Reduced Physical Activity|"Preliminary Phase (Baseline to Day 7): Subjects will begin wearing an accelerometer for 7 days to track physical activity and sleep patterns.~Experimental Phase 1 (Day 7 to Day 21): Participants will be required to reduce their step count by 5,000 steps per day and engage in no moderate-vigorous physical activity during this timeframe. Every 7 days subjects undergo the blood draw, vascular health measures and questionnaire assessments.~Experimental Phase 2 (Day 21 to 28): During the week of assessment, subjects will be asked to return to their normal physical activity patterns."
223478976|NCT00102323|DRUG|Placebo|Weekly subcutaneous dosing based on screening weight and platelet count. Starting dose is at 1mcg/kg up to a maximum dose of 15mcg/kg. Placebo is supplied as a lyophilized power in a 5 mL single use glass vial.
223478977|NCT00102323|BIOLOGICAL|AMG 531|Weekly subcutaneous dosing based on screening weight and platelet count. Starting dose is at 1mcg/kg up to a maximum dose of 15mcg/kg. AMG 531 is supplied in a 5 mL single use glass vial as a sterile, white, preservative-free, lyophilized powder.
223478978|NCT01471626|DEVICE|polysomnograph Dream and Sleep Box|Portable polysomnograph will be placed at home around 7:00PM. The Sleep Box (wireless monitoring device) will be left near the patient, to allow real-time GPRS transmission of recorded sleep parameters to the sleep lab.
223478979|NCT01066572|DRUG|Lisinopril|5-10 mg Lisinopril per day for seven days, depending on blood pressure.
223478980|NCT01066572|DRUG|Placebo|Matched placebo; identical tablets to Lisinopril.
223478981|NCT04058509|COMBINATION_PRODUCT|Focused shockwave therapy|3 session of shockwave therapy. The wave is focused through a standoff and transmitted into the tissue. Enhanced Energy: 0.01 - 0.55mJ/mm2. Broad Frequency Range: 1 - 8Hz. 12.5 cm penetration with pinpoint focus. The patient will be treated in the lateral decubitus position. The shock wave will focus on the area of maximal tenderness, which will be treated in a circumferential pattern.
224165139|NCT06379087|RADIATION|Hypofractionated Radiotherapy|Hypofractionated Radiotherapy Extent of radiotherapy: Primary lesion in the lung. Radiotherapy technique: IGRT. Radiotherapy delivery equipment: linear accelerator or TOMO accelerator or CyberKnife.
224165140|NCT00917917|BEHAVIORAL|Type of physical activity (resistance, endurance)|"To determine which type of physical activity is the best to reduce metabolic syndrome parameters especially abdominal circumference.~Group 1 will perform mostly resistance activities, group 2 mostly endurance activities, and Group 3 performing both activities at low level, serves as a control group for physical activities."
224165141|NCT00917917|BEHAVIORAL|Restrictive diet|All subjects will have the same restrictive diet (500- 700 kcal/d).
224165142|NCT02238509|DRUG|Lapatinib|ARM A: oral lapatinib 1,000 mg daily in combination with intravenous trastuzumab 6mg/kg q3wks (after the initial 8 mg/kg loading dose).
224165143|NCT02238509|DRUG|Trastuzumab|ARM A: oral lapatinib 1,000 mg daily in combination with intravenous trastuzumab 6mg/kg q3wks (after the initial 8 mg/kg loading dose).
224165144|NCT04796649|DEVICE|B-Cure laser pro|The B-Cure laser Pro is a portal, non-invasive, low level laser therapy device, that emits light in the near infrared (808nm) over an area of 1X4.5 cm2 with power output of 250mW, and energy dose of 5J/min.
224165145|NCT04796649|DEVICE|Sham|The sham device is externally identical to the B-Cure Pro and emit the same guiding light, but does not emit the therapeutic near infrared rays.
223478982|NCT01222299|DRUG|bepotastine besilate nasal product - low dose|sterile nasal product
223478983|NCT01222299|DRUG|bepotastine besilate nasal product - medium dose|sterile nasal product
223478984|NCT01222299|DRUG|bepotastine besilate nasal product - high dose|sterile nasal product
223478985|NCT01222299|DRUG|placebo comparator nasal product|sterile nasal product
223478986|NCT06018090|OTHER|The presence and rate of MES measured by TCD monitoring|TCD monitoring within 24 hours from the last known well time. Bilateral M1 segments of middle cerebral artery were insonated at a single depth with 2-MHz transducers secured by a probe-holder.
223478987|NCT01981616|DRUG|Vedolizumab|Vedolizumab for intravenous infusion
223478988|NCT01981616|DRUG|Placebo|Placebo intravenous infusion
223478989|NCT01981616|BIOLOGICAL|Hepatitis B vaccine|
223478990|NCT01981616|BIOLOGICAL|Oral cholera vaccine|
224165146|NCT06793566|DEVICE|Repeated Muscle Vibration (rMV)|rMV treatment, carried out for three consecutive days by 2 trained physiatrists; each daily session consists of three 10-minute treatment (impaired upper limb), interspersed with a 1-minute break. During the rMV, subjects are required to make a voluntary isometric contraction of the treated muscle
224165147|NCT06840756|BIOLOGICAL|Sex-mismatched red blood cell transfusions|Sex-mismatched red blood cell transfusions
224165148|NCT06840756|BIOLOGICAL|Sex-matched red blood cell transfusions|Sex-matched red blood cell transfusions
224165149|NCT05079100|OTHER|postpartum contraception method counselling|It will be face-to-face counseling with females about the use of postpartum contraception methods within 6 weeks postpartum.
224165150|NCT00888992|BEHAVIORAL|Quitline Service + 10 automated monitoring calls|This group will receive the usual care provided in Alere Wellbeing's Quit For Life® program. The program includes 5 telephone counseling calls. In addition, participants receive 10 automated telephone monitoring calls to help them stay off cigarettes. The automated call schedule will be two calls per a week for 2 weeks, then once a week for 6 weeks. Participants whose answers indicate that they may be having trouble quitting smoking will be automatically connected to a Quit Coach for individualized relapse prevention counseling.
224165151|NCT00888992|BEHAVIORAL|Quitline service + 20 automated monitoring calls|This group will receive the usual care provided in Alere Wellbeing's Quit For Life® program. The program includes 5 telephone counseling calls. In addition, participants receive 20 automated telephone monitoring calls to help them stay off cigarettes. The automated call schedule will be one automated call a day for 2 weeks, then once a week for 6 weeks. Participants whose answers indicate that they may be having trouble quitting smoking will be automatically connected to a Quit Coach for individualized relapse prevention counseling.
224165152|NCT01092572|DRUG|Simvastatin|simvastatin 40 mg per day orally for 12 weeks.
224165153|NCT01092572|DRUG|placebo|placebo 1 tablet once daily for 12 weeks
224165154|NCT02899026|DRUG|Sirukumab|Sirukumab will be provided as 1 millilitre (mL) Pre-filled Syringe (PFS), containing 100 mg/mL or 50 mg/mL of sirukumab, fitted with a spring-powered, disposable autoinjector device for single use SC administration of liquid biologic drug
224165155|NCT02899026|DRUG|Placebo to match sirukumab|Placebo to match sirukumab will be provided as 1.0 mL PFS fitted with a spring-powered, disposable autoinjector device for single use SC administration of liquid biologic drug
224165156|NCT02899026|DRUG|Prednisone /Prednisone placebo|Prednisone will be provided as tablets with dosage level up to 20 mg/day. All subjects will receive 20 mg prednisone at Baseline (Randomization) and follow predefined taper regimen (6 weeks or 52 weeks) based on treatment assignment. Placebo to match prednisone will be provided as tablets
224165157|NCT05426460|BEHAVIORAL|Approach/Avoidance Task|The Approach/avoidance task (AAT) training is done using a joystick. The AAT tasks involves having participants push away pictures of smoking stimuli that appear on the screen by pushing the joystick forward, and pulling in pictures of nonsmoking stimuli that appear on the screen by pulling the joystick towards themselves. Pushing smoking-related pictures away causes the picture to shrink in size, whereas pulling a picture closer causes the picture to increase in size. This task consists of 4 blocks of 24 pictures, taking 30 minutes.
224165158|NCT05426460|DEVICE|Transcranial Direct Current Stimulation|Transcranial Direct Current Stimulation active (2.0 mA) (tDCS) will be used to temporarily increase cortical excitability of the dorsolateral prefrontal cortex (dlPFC) in healthy daily smokers. Participants assigned to active tDCS conditions will receive active (2.0 mA) tDCS, with anode electrode placement over the right dlPFC and cathode electrode placement over the left bicep. tDCS will be administered the first 20 minutes of each of the five 30 minute AAT training sessions.
224165159|NCT05426460|BEHAVIORAL|AC|During Active Control (AC) participants press a button on the left of right of the joystick to indicate the position the picture on a screen. Position of pictures will be balanced across the 4 blocks of 24 pictures, taking 30 minutes.
224165160|NCT05426460|DEVICE|Sham tDCS|Sham transcranial Direct Current Stimulation (0.1 mA) (sham tDCS) will be used as a control for active tDCS with anode electrode placement over the right dlPFC and cathode electrode placement over the left bicep. Sham tDCS will be administered during the first 20 minutes of each of the four blocks of 24 pictures, taking 30 minutes, across the 5 training sessions.
224165161|NCT06334354|OTHER|Assessments|Sociodemographics, Deficit Accumulation Questionnaires, Remote Cognitive Assessment, Deficit Accumulation Questionnaires,Remote Cognitive Assessment
224165162|NCT06334354|OTHER|Assessment (Survivors Only)|\*Tumor/Treatment Variables (Survivors Only)
224165163|NCT06334354|OTHER|APOE and DNA Isolation|Biospecimens procurement and processing
224165164|NCT02014545|DRUG|Lucanthone|The dose of lucanthone to be administered will be calculated based on the patient's body weight. The dose to be given will be 250 bid, 250 tid or 375 tid dependent upon study progression.
224165165|NCT02014545|OTHER|Placebo|Only standard treatment of whole brain radiation therapy is done.
223478991|NCT03619278|OTHER|HIVACAR|Participants will receive 5 vaccines of personalized RNA vaccine (HIVACAR01), 2 doses of 10-1074 antibodies and 3 doses of romidepsin
223478992|NCT03619278|OTHER|placebo|Participants will receive 5 vaccines of placebo of HIVACAR01, 2 doses of 10-1074 antibodies and 3 doses of romidepsin
223478993|NCT04092413|DEVICE|Dermoscope|It is a non invasive tool that permits the visualization of morphological features that are not visible to the naked eye thus representing a link between macroscopic dermatopathology .
223511693|NCT04469946|DEVICE|Oticon OpenSound Navigator speech enhancement algorithm|OpenSound Navigator (OSN) is a speech enhancement algorithm developed by Oticon. The feature is built in Oticon's current OPN™ hearing aid platform and can be adjusted and disabled in the programming. It is designed to automatically enhance speech while reducing unwanted background noise to improve communication for the user.
223584309|NCT03554135|OTHER|Personalization of palliative radiotherapy|Observe the rates of pain control and the need to retreat patient, when applied to personalization of indications and maximum technological support for palliative radiotherapy to patients with \< 6 months prognostic score attendance
223761380|NCT00436943|BEHAVIORAL|smoking cessation counseling and referrals|Organizational counseling and referrals
224165166|NCT00654394|DRUG|Rosuvastatin|
224165167|NCT04334044|DRUG|Ruxolitinib Oral Tablet|Ruxolitinib 5 mg twice a day
224165168|NCT05001269|DRUG|nedosiran|Monthly subcutaneous dosing throughout study period
224165169|NCT06016829|DIAGNOSTIC_TEST|Nutrition Risk Screening 2002 (NRS-2002)|Nutritional status assessment tool
223478994|NCT06269835|BEHAVIORAL|systemic therapy|"All participants were given routine rehabilitation treatment by professional rehabilitation therapists, including exercise therapy, guided education, psychological therapy, acupuncture and massage therapy, to promote the development of motor and cognitive function, as well as to improve intellectual development\[. Besides, swallowing function training was also provided, including direct training, indirect training, and compensatory training, as follows The mendelson maneuver: performed 5 days per week, twice per day, 5-10 minutes each time.~Cold stimulation of the pharynx: performed every day, twice per day, 3-5 minutes each time.~Passive head extension: to stretch the submental muscle for 2-3 seconds, with upward resistance applied to the lower cheek for no less than 5 times a day and no less than 5 minutes each time.~Direct feeding training: with powdered milk, once a day, 5 days a week."
223478995|NCT06269835|DEVICE|Intermittent Oro-Esophageal Tube Feeding|Within 4 hours of admission, the observation group were required to undergo nasogastric tube removal and initiated Intermittent Oro-Esophageal Tube Feeding for nutrition support. Before each feeding, the infant should rest for approximately 1 hour and undergo oral clean. During feeding, the infant should be held by the caregiver in a semi-reclined or upright position. Firstly, the tail of the tube was inserted via mouth into the upper part of the esophagus with a depth of 18-20cm, and the external part of the tube should be placed in water with the absence of bubbles indicating the successful tube placement. Subsequently, 1ml of water was slowly injected, followed by liquid food or water at a rate of approximately 50ml/min through a syringe connected to the feeding tube. After feeding, the tube should be slowly removed, and the feeding position should be maintained for 30-60 minutes to prevent reflux.
223478996|NCT06269835|DEVICE|Persistent Nasogastric Tube Feeding|The control group was given nutrition support with Persistent Nasogastric Tube Feeding, of which the tube passed through the nasal cavity into the stomach. After successful intubation, the tube was secured on the cheek. Liquid food was then syringe-fed into the stomach and the feeding was conducted every 2-3 hours, with each meal not exceeding 200 ml. The daily intake was generally consistent with that of the observation group. Besides, after successful intubation, the tube was secured on the infant's face and changed every one to two weeks.
223478997|NCT01924598|DEVICE|DBS to nucleus accumbens/anterior limb of internal capsule|deep brain stimulation followed by 12 month post switch on followup
223478998|NCT00513214|DRUG|XOMA 052|"* Part 1, Single IV infusion at one of six dose levels (mg/kg).~* Part 2, Single SC injection at one of three dose levels (mg/kg).~* Part 3, Three biweekly SC injections at one of two dose levels (mg/kg)."
223478999|NCT00513214|DRUG|Placebo|"* Part 1, Single IV infusion at one of six dose levels (mg/kg).~* Part 2, Single SC injection at one of three dose levels (mg/kg).~* Part 3, Three biweekly SC injections at one of two dose levels (mg/kg)."
223479000|NCT02160938|OTHER|3-year follow-up|"When the infants reach 24 months of age, the Study Follow-up Specialist will send all participants an age- appropriate Ages and Stages Questionnaire (ASQ) for completion.~At the age of 3, the following exams will be performed and are described below:~* The Vineland-II Adaptive Behavior Scale (VABS)~* Wechsler Preschool and Primary Scale of Intelligence IV (WPPSI-IV), or Wechsler Intelligence Scale for Children - Fifth Edition (WISC-V, for siblings older than 7 years 7 months, when necessary)~* Children will also be photographed (for review by the study dysmorphologist)"
223479001|NCT01213238|DRUG|Oxaliplatin|140 mg/m2 by Hepatic Arterial Catheter (HAI) on day 1 of a 21 day cycle.
223479002|NCT01213238|DRUG|Capecitabine|Starting dose of 500 mg/m2 by mouth twice daily, on days 1 - 14 of a 21 day cycle.
224165170|NCT06016829|DIAGNOSTIC_TEST|Global Leadership Initiative on Malnutrition (GLIM)|Nutritional status assessment tool
224165171|NCT06016829|OTHER|Measurement of body composition with computed tomography (CT)|The cross section of the third lumbar vertebrae in the CT scan images of the patients will be analyzed for assessment of body composition parameters including skeletal muscle area (SMA), visceral adipose tissue (VAT), subcutaneous adipose tissue (SAT)
224165172|NCT06016829|DIAGNOSTIC_TEST|Dietary inflammatory index (DII)|The Dietary Inflammatory Index (DII) is a scoring algorithm that indicates the inflammatory potential of the diet.
224165173|NCT06016829|DIAGNOSTIC_TEST|European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC-QLQ-C30)|Quality of life assessment tool
223479003|NCT01213238|DRUG|Bevacizumab|10 mg/kg by vein on day 1 of a 21 day cycle.
223479004|NCT02344823|DRUG|Vardenafil|per oral intake of 10mg Vardenafil once daily
223479005|NCT02344823|PROCEDURE|HVPG (Hepatic venous pressure measurement) baseline|HVPG measurement day 1
223479006|NCT02344823|PROCEDURE|HVPG (Hepatic venous pressure measurement) day 7|HVPG measurement day 7
223479007|NCT02344823|BEHAVIORAL|IIEF 5 (International Index of Erectile Function) questionaire baseline|IIEF 5 questionaire to define level of erectile dysfunction at baseline
224165174|NCT06016829|DIAGNOSTIC_TEST|European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Colorectal Cancer 29 (EORTC-QLQ-CR29)|Quality of life assessment tool
224165175|NCT06016829|DIAGNOSTIC_TEST|Prognostic Nutritional Index (PNI)|Prognostic Nutritional Index is diagnostic test based on serum albumin level and total lymphocyte count
224165176|NCT06016829|DIAGNOSTIC_TEST|Neutrophil-Lymphocyte Ratio (NLR)|The neutrophil-to-lymphocyte ratio (NLR) is calculated as the simple ratio between neutrophil and lymphocyte counts.
224165177|NCT02422160|OTHER|No interventions are planned|No interventions are planned
224165178|NCT02514213|BIOLOGICAL|2mg INO-5150 and electroporation device CELLECTRA®-5P|2mg INO-5150 delivered IM followed by electroporation using CELLECTRA®-5P
224165179|NCT02514213|BIOLOGICAL|8.5mg INO-5150 and electroporation device CELLECTRA®-5P|8.5 mg INO-5150 delivered IM followed by electroporation using CELLECTRA®-5P
224165180|NCT02514213|BIOLOGICAL|2mg INO-5150 plus 1mg INO-9012 and electroporation device CELLECTRA®-5P|2mg INO-5150 plus 1 mg INO9012 delivered IM followed by electroporation using CELLECTRA®-5P
224165181|NCT02514213|BIOLOGICAL|8.5mg INO-5150 plus 1mg INO-9012 and electroporation device CELLECTRA®-5P|8.5mg INO-5150 plus 1 mg INO9012 delivered IM followed by electroporation using CELLECTRA®-5P
224165182|NCT02514213|DEVICE|Electroporation using CELLECTRA®-5P|Electroporation device CELLECTRA®-5P
224165183|NCT04770090|OTHER|Blood samples|Peripheral blood samples at the beginning of surgery, after pneumoperitoneum creation and uterine pedicles coagulation.
224165184|NCT05897424|DRUG|SAR447537|A1PI, Recombinant, Bivalent Fc Fusion Protein
223479008|NCT02344823|BEHAVIORAL|IIEF 5 (International Index of Erectile Function) questionnaire at study phase end|IIEF 5 questionaire to define level of erectile dysfunction at end of study phase
224165185|NCT04464668|BEHAVIORAL|Provider Tools|Providers will be trained to use Electronic Medical Record (EMR) tools and prompts, and an organization wide cancer control champion will be trained to motivate providers and navigate patients.
224165186|NCT04464668|BEHAVIORAL|Provider surveys|Remote/electronic data collection surveys will be conducted with clinic institution leaders, cancer control champions, and providers from various clinic locations to solicit feedback about implementation processes at three time points (baseline, mid-point and end of study implementation)
224165187|NCT04997850|DRUG|lenvatinib + sindilimab/carrelizumab|4-6 weeks after the first TACE treatment, the resectability criteria were evaluated. If not, the next treatment cycle was carried out. The trial was terminated if the drug was stopped for more than 28 days due to adverse drug reactions or other reasons. Patients with PD after 6 cycles of sindilimab/carrelizumab treatment were terminated. The follow-up treatment was based on the principle of individualization, multidisciplinary discussion and patients' willingness.
224165188|NCT04997850|PROCEDURE|TACE|"TACE treatment is strictly in accordance with the Chinese guidelines for clinical practice of transcatheter arterial chemoembolization (TACE) for hepatocellular carcinoma (2018 Edition).~The patients with HCC were selected according to the inclusion criteria (referring to the conditions of the subjects). The subjects who met the inclusion criteria could enter the study after they signed the informed consent. 4-6 weeks after the first TACE treatment, the resectability criteria were evaluated. If not, the next cycle of TACE treatment was carried out. The general principle is to reduce the number of interventional treatment and extend the interval of interventional operation as far as possible under the condition of controlling the tumor and the survival of patients with tumor."
224165189|NCT02996305|DRUG|OV101 Regimen 1|
224165190|NCT02996305|DRUG|OV101 regimen 2|
224165191|NCT02996305|OTHER|Placebo|
224165192|NCT04891757|DRUG|FHD-286|FHD-286 administered orally
224165193|NCT04891757|DRUG|Low Dose Cytarabine|LDAC administered subcutaneously (SC)
224165194|NCT04891757|DRUG|Decitabine|Decitabine administered intravenously
224165195|NCT04807530|DEVICE|TMS|The investigators will use the NEXSTIM NAVIGATED BRAIN STIMULATION (NBS) SYSTEM to apply 10 Hz nrTMS to healthy controls (HC) and schizophrenia patients (SZ)
224165196|NCT01431521|DRUG|MK-4074 200 mg|2 x 100-mg capsules, orally, twice-daily (BID) for 4 weeks
224165197|NCT01431521|DRUG|Placebo for MK-4074|2 x 100-mg capsules, orally, BID for 4 weeks.
224165198|NCT01431521|DRUG|Pioglitazone hydrochloride 30 mg|1 x 30-mg tablet, orally, once daily for 4 weeks
223479009|NCT02344823|DRUG|Placebo intake once daily|
223479010|NCT06380283|DEVICE|Virtual reality headset|Use of a virtual reality headset during pediatric dental care
223479011|NCT01716273|OTHER|Granulated Sugar|30 grams of granulated sugar is used to cover the wound area and this is held in place using a dry dressing pad , bandage and tape.
223479012|NCT01716273|OTHER|Debridement Dressing|1 Aquacel or Sorbsan dressing will be put over the wound, and held in place with a dry dressing pad, bandage and tape.
223479013|NCT01367041|PROCEDURE|vibration|Vibration frequency: 40 Hz, duration: 30+30 s, 2mm amplitude
223479014|NCT01020123|DRUG|AZD1656|Different doses of AZD1656 administered to 5 groups of patients
223479015|NCT01020123|DRUG|Placebo|AZD1656 placebo and glipizide placebo administered to 1 group of patients
223479016|NCT01020123|DRUG|Glipizide|Glipizide administered to 1 group of patients
223479017|NCT01178788|DRUG|17 alpha-hydroxy progesterone caproate|weekly injection of 17 P
223479018|NCT01178788|DRUG|micronized Progesterone|daily administration of vaginal progesterone
223479019|NCT01178788|PROCEDURE|Control|
223479020|NCT01911741|DRUG|MDV3100|Oral
223479021|NCT02600260|DRUG|Enoxaparin|Patients who score higher or equal to 3, receive a prophylactic dose of enoxaparin. The first dose of enoxaparin is administered 8 hours after vaginal or abdominal delivery. Subsequent doses are administered daily for up to 15 days. The dose depends on patient weight.
223479022|NCT02600260|OTHER|No intervention|Hospitalized patients that score less than three are not prescribed enoxaparin.
223479023|NCT00336908|DRUG|a combination of MCT, LCT , and Fish Oil|
223479024|NCT00094445|DRUG|Curcumin|Starting dose 8 gm orally per day for 8 weeks. If patient experiences grade III toxicity, dose held and restarted with a 50% dose reduction after resolution of toxicity to \</= Grade I. Patients with grade IV toxicity will discontinue treatments. Patients with \</= grade I toxicity may have a 25% dose increase at each four-week period. Patients will continue on treatment until disease progresses, unless Grade III toxicity supervenes.
223479025|NCT01576848|DIETARY_SUPPLEMENT|Protein|"Subjects will receive a drink containing 20 gram intrinsically labelled casein.~Half of the subject are young males (YOUNG)(age between 18 and 35 y) and half of the subjects are elderly males (OLD)(age between 70 and 85 y)."
223479026|NCT01576848|DIETARY_SUPPLEMENT|Protein + carbohydrate|"subjects will receive a drink containing 20 gram intrinsically labelled casein plus 60 gram carbohydrates.~Half of the subject are young males (YOUNG)(age between 18 and 35 y) and half of the subjects are elderly males (OLD)(age between 70 and 85 y)."
224165199|NCT01431521|DRUG|Placebo for pioglitazone hydrochloride|1 x 30-mg tablet, orally, once daily for 4 weeks
224165200|NCT05907772|OTHER|No intervention|No intervention
224165201|NCT06631989|DRUG|WSD0922-FU|"Procedure: Biospecimen Collection - blood samples Undergo collection of blood samples~Procedure: Computed Tomography and/or Magnetic Resonance Imaging Undergo CT and/or MRI~Drug: WSD0922-FU Given PO"
224165202|NCT01996228|DEVICE|Stem Cell Educator|
224165203|NCT04482621|DRUG|Decitabine|"Study duration is 6 weeks after the last dose of study drug. Number of study visits is dependent on Length of hospitalization of study participant. Study visits are scheduled on days 0-7, 11, 15, 29, and may occur via telemedicine or inpatient assessment or outpatient assessment in COVID recovered participants.~Decitabine will be administered via Intravenous Administration 10/mg/m\^2/day Dosage: 10mg/m\^2/day IV day x 5 days (1 cycle only)"
224165204|NCT04482621|OTHER|Placebo Saline|Saline based placebo will be administered via Intravenous injection. Dosage Regimen: 10mg/m\^2/day IV day x 5 days (1 cycle only)
224165205|NCT05802290|DRUG|Nivolumab 240 MG in 24 ML Injection|nivolumab monotherapy at 240mg flat dose as a 30-minute IV infusion on Day 1 of a treatment cycle every 2 weeks (14 days) until confirmed progression of disease, unacceptable toxicity, death or withdrawal of consent
224165206|NCT00223613|DRUG|daily intranasal administration of insulin|
224165207|NCT00942656|OTHER|PHVO|base diet plus 3.0% energy mixed isomers of trans fatty acids from partially hydrogenated vegetable oil
224165208|NCT00942656|OTHER|CLA|base diet plus 1.0% energy added from cis-9, trans-11 conjugated linoleic acid
224165209|NCT00942656|OTHER|VA|base diet plus 3.0% energy added from vaccenic acid
224305156|NCT01612299|DRUG|Zortress® /Everolimus|"Standard immunosuppression: THY 1-1.5 mg/kg/d qd for a total of 6 mg/kg •TAC trough targets 0-3 mo 8-12 ng/ml 4-6 mo 6-10 ng/ml \>6 mo 5-8 ng/ml•Myfortic® or CEL 360mg or 500mg po BID, and receiving THY then Myfortic® or CEL 720 mg or 1000mg PO BID once THY induction completed• COR 500mg MET IV pre-op,125mg MET IV q24h x 2 doses (Post-Op Days 1 \&2) 20mg Pred PO daily x 2 wks 15mg Pred PO daily x 2 wks 10mg Pred PO daily x 4 wks 5mg Pred PO daily x 4 wks 5 mg Pred PO every other day through mon 12.~Experimental: TAC + Zortress® + COR In this arm patients will stop Myfortic®/CEL and start Zortress® at a dose of 1 mg PO BID with a target level of 3-8 ng/ml.At Zortress® level of at least 3 ng/ml TAC will be dosed to a target range as follows Randomization through mo 3 post-transplant 7-10 ng/ml 4-6 mo post transplant 5-8 ng/ml \>6 mo post transplant 4-7 ng/ml."
223479027|NCT05287815|BEHAVIORAL|training/observation|In the study, elderly individuals who met the sampling criteria and accepted to participate in the study were 30 in the experimental group and 30 in the control group, using the stratified randomization method to control and balance the effects of age (65-75 years, 76 and over) and gender (female and male) variables. It will be planned to be an elderly individual. Computer-assisted randomization, which is one of the simple randomization methods, was assigned to the groups according to the determined.
223479028|NCT06257888|OTHER|patient navigation|two trained patient navigators will admit breast cancer patients to HCM, navigate them from admission to commencement of first treatment and will collect all pertinent epidemiological data and variables
223479029|NCT04646382|DIETARY_SUPPLEMENT|Garlic and onion concentrate|Garlic extract concentrate (equivalent to 2 garlic cloves) and onion extract concentrate (equivalent to 1 onion).
223479030|NCT04646382|DIETARY_SUPPLEMENT|Control|Microcrystalline cellulose
223479031|NCT01376219|OTHER|asthma control test|results of asthma control testing collected
223479032|NCT01141608|OTHER|Vigorous Intensity High Dose Exercise|Participants randomized to the exercise condition will begin with supervised exercise sessions 3 times per week during the 12-week acute phase of the study. Supervised sessions will be conducted as one-on-one (i.e., individual) sessions. Vigorous intensity high dose exercise will be prescribed at a dose of 12 kcal/kg/week (KKW), with intensity ranging from 70-85% maximal heart rate.
223479033|NCT01141608|OTHER|Health Education Intervention|Participants randomized to the health education condition will also begin with visits 3 times per week during the 12-week acute phase. The health education sessions will be conducted as one-on-one (i.e., individual) sessions. Health education sessions will consist of information on health-related topics distributed via methods such as didactics, audio and video materials, and written materials.
223584310|NCT04202198|BIOLOGICAL|A-PRF|local anesthesia was administered followed by placement of a hole in the alveolar mucosa adjacent to mesial most recession tooth. tunneling instruments are used to elevate a full thickness tunnel upto the CEJ sparing the tip of the papilla.previously prepared PRF membranes are placed through the access hole and the flap is advanced. 5-0 polyglycolic acid sutures is used to secure the advanced flap.
223584311|NCT04202198|PROCEDURE|pinhole surgical technique only|local anesthesia was administered followed by placement of a hole in the alveolar mucosa adjacent to mesial most recession tooth. tunneling instruments are used to elevate a full thickness tunnel upto the CEJ sparing the tip of the papilla followed by advancement of the flap. 5-0 polyglycolic acid sutures is used to secure the advanced flap.
224305157|NCT00150891|PROCEDURE|Kidney transplantation|
224305158|NCT00150891|DRUG|cyclosporine A|
223479034|NCT02087098|DRUG|Solifenacin|Patients with residual OAB symptoms (urge urinary incontinence, urgency, and frequency) after treatment with other antimuscarinics
223479035|NCT00175227|DRUG|intravenous saline hydration + mannitol + furosemide|500 mls half-normal saline + 25g mannitol + 100 mg furosemide
223479036|NCT00175227|DRUG|intravenous saline hydration|500 mls half-normal saline
223479037|NCT02638532|PROCEDURE|Foot Fat Pad Grafting|Fat tissue to be used for grafting is harvested (usually from abdomen or thighs) with a small liposuction cannula. The fat tissue is then sterilely centrifuged and allowed to decant before separating the fluid and oil layers from the fat tissue fraction. The aspirated fat is then loaded into 1cc syringes and injected into the plantar fat pad using specialized injection cannulas.
223479038|NCT04434508|PROCEDURE|laparoscopic right hemicolectomy with CME and central v|laparoscopic right hemicolectomy with CME and central v
223584312|NCT02804308|BEHAVIORAL|Combined Training|
224165210|NCT00942656|OTHER|base|base diet containing approximately 0.1% energy of mixed trans fatty acid isomers
224165211|NCT01731275|DRUG|E6011|A single ascending dose (SAD) administration of E6011 is administered to 8 groups as a 30-minute intravenous infusion at a dose of either 0.0006, 0.006, 0.04, 0.2, 1, 3, 6, or 10 mg/kg. Each participant in each group will receive a single-dose only once. The study drug will not be administered to more than two participants on the same day, and the second participant must start the study treatment after at least a 2-hour interval from the start of the study treatment in the first participant. The subsequent ascending dose groups will start approximately at least every 3 weeks following the study treatment in the first participant of each group.
224165212|NCT01731275|DRUG|E6011 Matching Placebo|A SAD administration of E6011 Matching Placebo is administered to 2 participants in each of 8 groups as a 30-minute intravenous infusion at a placebo dose of either 0.0006, 0.006, 0.04, 0.2, 1, 3, 6, or 10 mg/kg. Each participant in each group will receive a single-dose only once. The study drug will not be administered to more than two participants on the same day, and the second participant must start the study treatment after at least a 2-hour interval from the start of the study treatment in the first participant. The subsequent ascending E6011 Matching Placebo dose groups will start approximately at least every 3 weeks following the study treatment in the first participant of each group.
224305159|NCT00150891|DRUG|tacrolimus|
223479039|NCT04434508|PROCEDURE|Open right hemicolectomy with CME and central v|Open right hemicolectomy with CME and central v
223584313|NCT02982499|DEVICE|magnetic resonance image (MRI)|Radiographic imaging that takes about 30-45 minutes
224305160|NCT00150891|DRUG|azathioprine|
224305161|NCT00150891|DRUG|mycophenolate mofetil|
223479040|NCT06039202|DRUG|CA102N|CA102N is a covalently bound conjugate of the biological polymer sodium hyaluronate (NaHA) and nimesulide (Nim)
224165213|NCT04764838|OTHER|Yoga|"Breath Awareness Training (5 minutes) Asanas (20 minutes)~* Bending sideways in Mountain Stance~* Standing Pelvic Shaking Warrior Stance II Squatting and malasana (wreath pose) Breath awareness in lotus pose (sitting) Cane pose Fixed Butterfly / Angel Pose~* Sitting wide in Angel Pose Cat Pose Tiger Breath Mudra and meditation (10 minutes)"
224165214|NCT02444689|BEHAVIORAL|Electronic Media Application|Children in the intervention group will receive motivation, education and coaching regarding therapeutic lifestyle changes via a smart phone electronic media application.
224165215|NCT02444689|BEHAVIORAL|Standard of care education|
224165216|NCT00497939|DRUG|Saw palmetto and sanmiaoshan capsule|
224165217|NCT02876315|DIETARY_SUPPLEMENT|Redoxon VI|"Each tablet contains:~Vitamin C (500mg) Vitamin A (1167IU) Vitamin B6 (3.3mg) Vitamin B12 4.8µg) Vitamin D (200IU) Vitamin E (22.5mg) Folic Acid (200µg) Zinc (5mg) Selenium (55µg) Copper (450µg) Iron (2.5mg)~Other ingredients: Microcrystalline cellulose, magnesium stearate, hydroxypropylmethylcellulose, hydroxypropylcellulose hypromellose, titanium dioxide, microcrystalline cellulose, iron oxide yellow, sodium croscarmellose, and talc"
224165218|NCT02876315|DIETARY_SUPPLEMENT|placebo|Ingredients: Microcrystalline cellulose, magnesium stearate, hydroxypropylmethylcellulose, hydroxypropylcellulose hypromellose, titanium dioxide, microcrystalline cellulose, iron oxide yellow, sodium croscarmellose, and talc
224165219|NCT03637959|DEVICE|Mechanical Vibrations with Ultrasound Shear Wave Imaging|Multiple miniature mechanical vibrators will be placed on the body surface of rib cage of the subject or introduced through an audio loudspeaker in contact with the subject's upper torso or through miniature vibrator attached to the ultrasound probe. Repeated ultrasound stiffness measurements will be made at different locations within the liver parenchyma while the mini vibrators introduce shear wave in the liver, similar to an MRE examination.
224305162|NCT05521139|DIAGNOSTIC_TEST|drug sensitivity results|drug sensitivity results including the carbapenem-resistant Klebsiella pneumoniae and carbapenem-sensitive Klebsiella pneumoniae
224305163|NCT00001365|DRUG|dextromethorphan|
224305164|NCT05379816|PROCEDURE|5% DW perineural injection|5% DW perineural injection to intercostal nerve
224305165|NCT05990153|OTHER|Myofascial Release (MR)|Myofascial release therapy is a type of gentle, constant massage that releases tightness and pain throughout myofascial tissues.
223479041|NCT06039202|DRUG|TAS-102|TAS-102 is a cytotoxic combination treatment of 2 drugs: trifluridine, a thymidine-based nucleoside analogue, and tipiracil an inhibitor of thymidine phosphorylase.
223479042|NCT06039202|BIOLOGICAL|Bevacizumab|Bevacizumab recombinant humanized monoclonal antibody that binds and neutralizes circulating vascular endothelial growth factor (VEGF)-A.
223479043|NCT03962829|DRUG|mCPP|Healthy participants administrate one capsule of mCPP (30mg)
223479044|NCT03962829|DRUG|Placebo oral tablet|Healthy participants administrate one capsule of placebo (containing lactose)
223479045|NCT06422533|DRUG|Ceftolozane/tazobactam|Ceftolozane/tazobactam 1.5 g tid IV infusion for 1 hour during 5 to 7 days
223479046|NCT06422533|DRUG|Piperacillin/tazobactam|Piperacillin/tazobactam 4.5 g qid IV infusion for 30 minutes during 5 to 7 days
223479047|NCT04368169|DIETARY_SUPPLEMENT|Teramune Botanical Extract|Combination blend of aromatic plant extracts in an emulsifier carrier.
223479048|NCT04368169|OTHER|Placebo|Emulsifier carrier without active supplement ingredients.
223479049|NCT05981846|BIOLOGICAL|BIMERVAX|One dose of booster vaccine
223479050|NCT05981846|BIOLOGICAL|SIIV|One dose
223479051|NCT02866643|DRUG|Etonogestrel-Immediate|The investigational intervention will be to insert the contraceptive implant immediately postpartum in the delivery room insertion (0-2 hours following delivery).
223479052|NCT02866643|DRUG|Etonogestrel-Delayed|The investigational intervention will be to insert the contraceptive implant 24-48 hours following delivery.
223479053|NCT05769972|DEVICE|Immersive Virtual Reality (Parkinson's disease)|This tool involves placing sensors in the space where it will be used, wearing virtual reality glasses, and using controllers to create realistic fictional spaces and interact with them. The program used for the study consists of an interface and a set of tasks designed specifically for the type of cognitive process deficits related to frontal function (executive functions) that are predominantly presented by patients with cognitive impairment associated with Parkinson's disease. This is due to the effect of the disease's pathophysiology on a series of brain circuits and structures that range from the basal ganglia to the frontal lobe. The affected functions correspond to the individual's ability to plan, sequence, organize, make decisions, be flexible, abstract, conceptualize, inhibit, among others.
223584314|NCT02982499|DEVICE|Optical Coherence Tomography (OCT)|Images taken from the back of the eye (retina)
223584315|NCT00970983|PROCEDURE|quadrantectomy and axillary dissection|standard quadrantectomy and axillary dissection
223584316|NCT00970983|PROCEDURE|quadrantectomy + sentinel node biopsy|standard quadrantectomy and selective axillary dissection only if sentinel node biopsy is positive
223584317|NCT05818761|DEVICE|virtual reality|wearing virtual reality glasses
223584318|NCT05818761|BEHAVIORAL|stress ball|squeezing the stress ball during the attempt
224305166|NCT05990153|DRUG|clinical practice drug treatment|drug treatment according to the medical indications of clinical practice
224305167|NCT05990153|OTHER|Manual therapy (MT)|The manual therapy consists of the concurrent application of sustained accessory mobilization applied by a therapist and an active physiological movement to end range applied by the patient. Passive end-of-range overpressure, or stretching, is then delivered without pain as a barrier.
223584319|NCT05799989|PROCEDURE|Surgical fixation|Pediatric patients with intravenous and/or intraarterial catheter in situ secured with surgical fixation
224305168|NCT05990153|OTHER|Therapeutic exercise (TE)|The ET consists of an initial phase of aerobic exercise (cyclette), subsequently the intervention foresees exercises for the cervical ROM, stretching exercises of the cervical and scapulothoracic muscles and muscle strengthening exercises (isometric, concentric and eccentrics of the cervical musculature).
223584320|NCT05799989|PROCEDURE|Atraumatic fixation|Pediatric patients with intravenous and/or intraarterial catheter in situ secured with atraumatic fixation
224165220|NCT05570747|DEVICE|Eclipse novel CPAP mask|"Participants will follow instructions to set up and put on the Eclipse nasal mask. The Eclipse removes the headgear associated with traditional CPAP masks, offering a small compact design weighing less than an ounce. The Eclipse uses small and lightweight adhesive seals around the nostrils to create an ergonomic design which accommodates the shape of each individual user. It completes a perfect circuit for CPAP therapy to deliver pressure to the airway and stabilize the user's disordered breathing during sleep (apnea and snoring).~Participants will follow instructions to set up and put on the mask. They will fill out a survey about the ease and comfort of putting on and wearing the mask, briefly."
224165221|NCT05570747|DEVICE|Phillips Respironics Nuance|Participants will follow instructions to set up and put on the Respironics Nuance, traditional nasal mask. Participants will follow instructions to set up and put on the mask. They will fill out a survey about the ease and comfort of putting on and wearing the mask, briefly.
224165222|NCT06382012|DRUG|Fosaprepitant 150 mg|Fosaprepitant 150mg IV administered over 15 minutes
224165223|NCT06382012|DRUG|Ondansetron 4 mg|Ondansetron 4mg IV administered over 15 minutes
224165224|NCT01828463|DRUG|Nitisinone|doses 1, 2, 4 \& 8 mg plus no treatment arm
224305169|NCT02879357|BEHAVIORAL|Training|"1. Clinician training~2. System for patient selection~3. System of triggering and tracking conversations~4. Training on how to use the Serious Illness Care Guide, a guide for patients about initiating conversations with family members about end-of-life goals and values~5. Longitudinal Medical Record (LMR) documentation module to serve as a Single source of truth about advance care preferences in the LMR."
223479054|NCT05769972|DEVICE|Computer-based cognitive rehabilitation (Parkinson's disease)|This consists of a 24-week computerized cognitive stimulation program using the NeuronUp software. The intervention includes a limited number of tasks developed ad hoc by NeuronUp and the researchers specifically aimed at stimulating the cognitive domains typically affected in movement disorders. These are cognitive processes mostly ascribed to frontal function, as well as other less prevalent but equally disabling processes mainly associated with basal ganglia and fronto-striatal circuitry, such as executive functions, attention and working memory, language, processing speed, and social cognition. Thus, the programs are the same for PD and HD, although the parameters of the number of errors, level of difficulty, and number of correct answers required to advance to the next level have been adjusted to be more demanding in PD and less in HD, with the aim of customizing this type of intervention to the clinical characteristics of each disease.
223479055|NCT05769972|DEVICE|Computer-based cognitive rehabilitation (Huntington's disease)|This consists of a 24-week computerized cognitive stimulation program using the NeuronUp software. The intervention includes a limited number of tasks developed ad hoc by NeuronUp and the researchers specifically aimed at stimulating the cognitive domains typically affected in movement disorders. These are cognitive processes mostly ascribed to frontal function, as well as other less prevalent but equally disabling processes mainly associated with basal ganglia and fronto-striatal circuitry, such as executive functions, attention and working memory, language, processing speed, and social cognition. Thus, the programs are the same for PD and HD, although the parameters of the number of errors, level of difficulty, and number of correct answers required to advance to the next level have been adjusted to be more demanding in PD and less in HD, with the aim of customizing this type of intervention to the clinical characteristics of each disease.
223479056|NCT05769972|BEHAVIORAL|Music-therapy (Huntington's disease)|The process used in each session will be standardized, while the content will be flexible, administering the guidelines according to the mood of the patients and their needs at that time. The therapist's clinical experience will guide them, providing sufficient space for flexible adaptation within the treatment guideline. While the sessions will be standardized, without limiting the music therapist in their interactions, the intervention itself will be applied during the experimental period, using all of the cognitive music therapy exercises detailed below in all groups: auditive perception training, musical sensorial orientation, control of musical attention, training of musical executive function, training in musical mnemotecnia and associative training of mood and musical memory
223479057|NCT04919707|BEHAVIORAL|Header Session|Participant fit with commercially available Storelli ExoShield Head Guard that has been fit with head impact sensors; participant completes a set of basic standing header tasks which mimic the types of purposeful heading anticipated to occur in actual play in soccer practice and games.
223479058|NCT04919707|PROCEDURE|MRI Session|Scanning will include high resolution T1w imaging for 3-dimensional structural analyses, DTI and resting-state MRI for assessment of structural and functional brain network connectivity, as well as susceptibility-weighted imaging and multicomponent relaxometry to assess for microhemorrhages and myelin damage.
223479059|NCT02339337|OTHER|Abbreviation of treatment duration|
223584321|NCT04027270|OTHER|Physical Therapy|Physical therapy 1-2 times per week for 3 months postoperatively to include lifestyle education, manual therapy, and exercise.
224165225|NCT03155776|DIAGNOSTIC_TEST|GUS|gastric volume estimation using gastric ultrasound was performed immediately after anesthetic induction, and after aspirating the residual gastric contents using nasogastric tube
224165226|NCT03569449|BEHAVIORAL|Usual care|Family partners will keep records and communicate with families using standard information technology, including telephones, electronic medical records, and standard desktop software.
224165227|NCT03569449|BEHAVIORAL|Clinic-based visits|Family partners will be restricted to working at the primary care clinic - communication will be restricted to telephone, text, and clinic visits
224165228|NCT03569449|BEHAVIORAL|Standard pediatric surveillance|Monitoring is determined by standard pediatric practice. Behavioral screening is usually done annually.
224305170|NCT01157559|DRUG|Ziprasidone|8 week prospective study
224165229|NCT03569449|BEHAVIORAL|Structured, schedule-based visits|Family Partners will utilize a predetermined schedule of contacts with families
224165230|NCT03569449|BEHAVIORAL|Enhanced pediatric surveillance|"In Massachusetts, behavioral screening is mandated at every pediatric visit, which for children in the target population (ages 3-12 years) is annually. With enhanced monitoring, Family Partners will screen children using validated instruments quarterly and communicate results to the child's care team"
224305171|NCT03876418|DIAGNOSTIC_TEST|Intra-abdominal Pressure|Aggressive screening, prevention and treatment of intra-abdominal hypertension
224305172|NCT02519335|DRUG|Dexrazoxane|Dose escalation every 4 subjects from 200mg/m2/dose; 300mg/m2/dose to 400mg/m2/dose
224305173|NCT02109419|OTHER|HHT-G|Helping Hands Technology global cognitive function assessment
223479060|NCT03721354|OTHER|NAVA vs PSV - TCCD|"Patients will be submitted to 3 different 30 minutes ventilation trials: the first one in PSV mode, the second one in NAVA mode and the third one in PSV mode again. PSV will have PEEP setted by clinician and pressure support set in order to obtain Vt 6-8 ml/kg. NAVA will have the same PEEP as PSV and NAVA level will be set to obtain the same Peak of Inspiratory Pressure) of PSV.~Trans cranial doppler technique will be performed to evaluate the blood cerebral flow speed (average/systolic speed) at the end of every ventilation trial. At the end of each trial, ABGs will be performed. Traces of flow, airways pressure (Paw) and electric diaphragmatic activity (EAdi) will be recorded and acquired through a dedicated ventilator software called NAVA tracker."
223479061|NCT03665870|BEHAVIORAL|Hypoglycemia Education|Two in-person visits to the home of the participant and 4 phone calls will be conducted to provided education on prevention of hypoglycemia.
224165231|NCT03569449|BEHAVIORAL|Technology enhanced care coordination|Behavioral: technology enhanced care coordination FPs will also have access to Act.MD, a cloud-based care coordination and communication tool that offers the potential to improve communication with families, schools, and the primary care site through administration of online questions, videoconferencing, and common portals that can be used by parents and multiple providers (e.g., FP, pediatrician, teacher).
224165232|NCT03569449|BEHAVIORAL|:Individually-tailored visits|Family Partners will be able to meet with families on an as-needed basis, with no predetermined schedule of contacts
224165233|NCT03569449|BEHAVIORAL|Clinic-based visits and community visits|In clinic-based visits the Family Partner is restricted to working at the primary care clinic and communication is restricted to telephone, text, and clinic visits. However in conditions with clinic based and community visits, the Family Partners will be available to meet families in their home and community (as well as the clinic), and accompany families to community-based meetings at school or childcare.
224165234|NCT06300437|PROCEDURE|jaw thrust|children who will receive jaw thrusting during fiberoptic intubation
224165235|NCT06300437|PROCEDURE|control (sub laxed jaw)|children who will not receive jaw thrusting (just sub laxed open mouth)
224165236|NCT01619436|DRUG|Clonidine|bolus, clonidine 2 mg/kg IV
223479062|NCT01531426|DEVICE|near infrared spectroscopy (INVOS®, Covidien)|Measurement of regional cerebral oxygen saturation with non-invasive near-infrared INVOS® (In-Vivo Optical Spectroscopy) monitor by Covidien.
223479063|NCT00117416|PROCEDURE|controlling the MAP|
223479064|NCT00769561|BEHAVIORAL|Biofeedback-Based Cognitive Behavioral Treatment|The biofeedback-based cognitive behavioral intervention comprises 8 individual sessions, each containing both cognitive behavioral and biofeedback elements. Treatment elements are education about the disorder, biofeedback training aimed at improving proprioceptive awareness and reversing parafunctional habits, relaxation techniques, and stress management. Furthermore patients receive portable biofeedback devices for EMG-biofeedback training during day and nighttime in order to reverse diurnal and nocturnal bruxing habits.
223479065|NCT00769561|DEVICE|Dental treatment with occlusal splint (OS)|Maxillary or mandibular occlusal splints are made of hard acrylic after taking impressions of the upper and lower dental arches, face bow registration and recording of centric relation. Splints are adjusted to provide even occlusal contact during jaw closing and chewing, and canine and incisor contact during protrusive movements of the jaw. Patients are instructed to use the splint each night and during day time for a period of 7 weeks. One week after initial insertion of the splint patients are requested to return for adjustment.
223479066|NCT03523637|BEHAVIORAL|Interoceptive Exposure|The intervention Interoceptive Exposure (IE) is an exposure to bodily sensations used in treatment of variety of problems where body sensations are experienced as threatening. This psychological technique is about focusing attention on pain, 'staying with the pain' without trying to escape it.
223479067|NCT03007875|BIOLOGICAL|high-activity natural killer|Each treatment: 8\~10 billion cells in all, transfuion in 3 times, i.v.
223479068|NCT04711005|DRUG|(2R,6R)-Hydroxynorketamine hydrochloride|(2R,6R)-Hydroxynorketamine is a metabolite of the drug ketamine. (2R,6R)-Hydroxynorketamine hydrochloride will be administered intravenously over a 40-minute period as a solution in a 25 mM sodium phosphate 0.9% w/v saline solution. The investigational drug product will be diluted into a 53 mL total volume of formulant.
223479069|NCT04711005|DRUG|Placebo|Placebo will be made up of a 0.9% w/v saline solution (53 mL total volume) administered via slow IV infusion over a 40-minute period.
223479070|NCT05576896|DRUG|Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab|"Prior to starting therapy, patients will have a pretreatment cross-sectional scan. Patients will then begin with encorafenib 300 mg daily starting with Cycle 1 day 1; then patients will receive IV cetuximab weekly, with 400 mg/m2 on C1D1 as a loading dose and 250 mg/m2 on all other days.~Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity."
223479071|NCT03024567|DIETARY_SUPPLEMENT|Salt|10 capsules daily for 14 days
223479072|NCT03024567|DIETARY_SUPPLEMENT|Placebo|10 capsules daily for 14 days
223479073|NCT02753881|DRUG|whole liver lobe cTACE doxorubicin|Doxorubicin CTACE administered in a whole liver lobe manner.
223479074|NCT02753881|DRUG|superselective cTACE doxorubicin|Doxorubicin CTACE administered in a super-selective (close to the tumor) manner.
223479075|NCT00506675|DEVICE|Patching|42 hours per week of patching
223479076|NCT00506675|DRUG|Atropine|daily atropine (1%)
223479077|NCT00506675|DEVICE|Patching|two hours of daily patching for 4 weeks, then no treatment
223479078|NCT00506675|DRUG|Atropine|once weekly atropine for 4 weeks, then no treatment
223479079|NCT05672875|DIAGNOSTIC_TEST|Anthrax LF Dx System|Lateral flow immunoassay for the detection of the LF biomarker in whole blood samples.
223479080|NCT02858908|DRUG|Tideglusib|Tideglusib for oral suspension,
223479081|NCT04236778|DRUG|VE303|The VE303 Drug Product is a live biotherapeutic product (LBP) consisting of 8 clonal human commensal bacterial strains manufactured under GMP conditions.
223584322|NCT00779961|PROCEDURE|Palatoplasty|Routine palatoplasty will be performed under the supervision of one of five surgeons within the Division of Plastic Surgery at Sick Kids
224165237|NCT01619436|DRUG|Ringer lactato|1 ML ringer lactato IV, as placebo
224165238|NCT05171816|DRUG|olaparib|300 mg (2 x 150 milligrams (mg) tablets) twice daily
224165239|NCT05171816|DRUG|abiraterone acetate|1000 milligrams (mg) once daily
224305174|NCT02109419|OTHER|HHT-D|Helping Hands Technology depression assessment
224305175|NCT02109419|OTHER|Geriatric Depression Scale (DGS)|Geriatric Depression Scale (DGS)
224165240|NCT06514105|OTHER|Physiotherapy program|All patients participating in the study will be included in the physiotherapy program. Physiotherapy program consist of hot-pack (for 15 minutes), ultrasound (Continuous ultrasound, for 5 minutes, 1-MHZ 1.5W/cm2, a 5-cm ultrasound head on the subacromial region),TENS (for 20 minutes with the BTL 4000 combined device) and exercise program (Stretching exercises for the rotator cuff, rhomboid muscles, levator scapula, serratus anterior and pectoaral muscles and strengthening the muscles around the shoulder with a resistance exercise band selected in a color appropriate to the patient's strength).
224165241|NCT06514105|OTHER|High intensity laser|High intensity laser will be applied using the BTL-6000 (BTL Company, UK) device. The first 5 sessions will be applied to the painful area by making circular movements from the center to the outside for 100 seconds at a power of 10W and a dose of 10 J/cm2 (analgesic effect). The last 5 sessions will be applied to the painful area with linear movements at 4W power and 100 J/cm2 dose (biostimulation effect) for 10 minutes and 25 seconds.
224165242|NCT06514105|OTHER|Sham high intensity laser|In sham application, the patient will be positioned on the treatment stretcher and the device will be turned on. The guide light of the high-intensity laser device, which gives the same color as the laser light, will be applied to the subacromial region in circular movements from outside to inside and from inside to outside.
224165243|NCT06793709|OTHER|No Intervention|This is a non-interventional study.
224165244|NCT03851120|DIETARY_SUPPLEMENT|Probiotics and LC-PUFA (480 mg DHA)|Probiotics and LC-PUFA (480 mg DHA)
224165245|NCT03851120|DIETARY_SUPPLEMENT|Placebo probiotics and control LC-PUFA (120 mg DHA)|Placebo probiotics and control LC-PUFA (120 mg DHA)
223479082|NCT04236778|DRUG|Oral Vancomycin|Vancomycin, when taken by mouth, is used to treat Clostridium difficile-associated diarrhea.
223479083|NCT06355349|DRUG|Reference Drug or Test Drug|Tablet, Oral, QD for 1 Day, Washout period is more than 21 days after administration
223479084|NCT01800370|DRUG|Hyperglycemia|Hyperglycemia (rest controlled) will be induced by i.v. injection of 25 mL of dextrose 50% over 3 minutes with the subject supine.
223479085|NCT01800370|DRUG|Saline|Saline (rest controlled) will be induced by i.v. injection of 25 mL of saline over 3 minutes with the subject supine.
223479086|NCT01800370|OTHER|Exercise|"Monitored exercise of 7-minute biking, 2-minute arm weights and a blood draw at the 10-minute time point will be repeated 3 times,which takes 30 minutes.~Bilateral arm curls begin at 20 pounds and decrease by 5 pounds as needed to sustain 2 minutes of exercise at a rate of 1 complete curl every 2 seconds."
223479087|NCT01800370|PROCEDURE|Blood Draws|Blood will be sampled every 10 min from 0700 to 1300 h. Each intervention will begin at 0800 h after 1 h of baseline sampling, and be completed by 0900 h. Intervention is followed by 4 additional h of sampling to capture recovery (total sampling 6 h). Ten-min samples are for Te, LH, ACTH, cortisol, and GH. Glucose will be checked every 30 min. At 07000 h an archival serum sample will be obtained for safety-monitoring purposes.
223479088|NCT01800370|OTHER|Fasting procedure|Beginning at 1900 h on the evening prior to each study visit, subjects will remain fasting except for water, diet soda, and other non-caloric and non-caffeinated fluids, until 1300 h the next day.
223479089|NCT03824561|DRUG|Vedolizumab|Vedolizumab IV infusion
223479090|NCT07133828|DRUG|BIIB142|Administered Orally
223479091|NCT07133828|DRUG|BIIB142-Matching Placebo|Administered Orally
223479092|NCT01773928|BIOLOGICAL|Vero cell-derived trivalent influenza vaccine manufactured with the modified manufacturing process (VCIV modified)|
223479093|NCT01773928|BIOLOGICAL|VCIV manufactured with the current manufacturing process (VCIV current)|
224165246|NCT03851120|BEHAVIORAL|Psychosocial stimulation and healthy eating education|Psychosocial stimulation and healthy eating education
223479094|NCT01773928|BIOLOGICAL|Fluzone®, licensed trivalent influenza vaccine (TIV)|
223479095|NCT03974464|DIAGNOSTIC_TEST|copeptin, PS100|"Age, sex and time between dizziness onset and ED visit were collected using Resurgences® software. PS100 concentrations were measured on serum samples by electro-chemiluminescence assay. Copeptin concentrations were measured on serum samples by the Kryptor method. The positivity threshold for copeptin was set at strictly above 10 pmol/L and that of PS100 was set at strictly above 0.105 μmol/L.~And after, we compared results with results of brain imaging: Magnetic Resonance Imaging alone, CT scan alone or both. Depending on clinical presentation, the imaging tests were performed during ED stay, during hospitalization or externally. Presence or absence of stroke was established on diffusion-weighted brain MRI . In case of normal contrast CT alone, a specialized opinion should exclude the need for diffusion-weighted MRI according to clinical presentation."
223479096|NCT06331351|OTHER|control group|2 times a day, 1 sachet each time.
224165247|NCT06636669|DRUG|Probiotic|Culturelle probiotic, one capsule daily to start following SOC surgical treatment for PJI during the initial 6 weeks of SOC antibiotic treatment.
224165248|NCT06636669|OTHER|Standard of care|Standard of care (SOC) treatment includes surgery and antimicrobials.
224165249|NCT04667949|DRUG|Fingolimod 0.5mg|Subjects received fingolimod 0.5mg capsule QD up to month 24
224165250|NCT05053139|DRUG|NNC0365-3769 (Mim8)|Mim8 will be injected into a skinfold on the stomach with a thin needle either once a week or once a month.
224165251|NCT06343558|OTHER|Questionnaires, clinical scales and instrumental tests|Questionnaires, clinical scales and instrumental tests to collect a wide range of balance and gait measures.
224305176|NCT02109419|OTHER|MMSE|Mini Mental State Exam
223479097|NCT06331351|OTHER|Jing Si herbal tea liquid packets|2 times a day, 1 sachet each time.
223479098|NCT04399642|PROCEDURE|Arthroplasty|All patients include in the study will undergo a lowerlimb arthroplasty, primary or revision
223479099|NCT01899911|DEVICE|Vital Signs Patch (VSP)|Infrared and red absorbance measurement
223479100|NCT03501251|DRUG|Moxidectin 8mg|Participants will receive the tablet with clean water and a package of biscuits.
223479101|NCT03501251|DRUG|Moxidectin 8 mg + albendazole 400 mg|Participants will receive the tablets with clean water and a package of biscuits.
223479102|NCT03501251|DRUG|Moxidectin 16 mg|Participants will receive the tablets with clean water and a package of biscuits.
223479103|NCT03501251|DRUG|Moxidectin 16 mg + albendazole 400 mg|Participants will receive the tablets with clean water and a package of biscuits.
223479104|NCT03501251|DRUG|Moxidectin 24 mg|Participants will receive the tablets with clean water and a package of biscuits.
223479105|NCT03501251|DRUG|Moxidectin 24 mg + albendazole 400 mg|Participants will receive the tablets with clean water and a package of biscuits.
223479106|NCT03501251|OTHER|Placebo|Participants will receive the tablet with clean water and a package of biscuits.
223479107|NCT04223947|PROCEDURE|DIGESTIVE ENDOSCOPY|DIGESTIVE ENDOSCOPY
224165252|NCT06432569|DIETARY_SUPPLEMENT|ButirBioma + PeaBioma|randomized in a 1:1 ratio to treatment Butir+Pea or treatment with Placebo for six weeks. After the first treatment period, there is a 14-day washout period.
224165253|NCT06432569|DIETARY_SUPPLEMENT|Placebo|Placebo( 3+3 cps/die)
224165254|NCT06639997|DRUG|AZD5148|Participants will receive AZD5148 as IM injection or IV bolus
224165255|NCT06639997|DRUG|Placebo|Participants will receive matching doses of placebo as an IM injection or IV bolus
223479108|NCT03573297|DRUG|Cariprazine|Cariprazine capsules, oral administration, once daily
223479109|NCT03573297|DRUG|Placebo|Matching placebo capsules, oral administration, once daily
223479110|NCT01508988|DRUG|ONO-9054|Eye drops 0.3 µg/mL both eyes on Day one
223479111|NCT01508988|DRUG|ONO-9054|Eye drops 1 µg/mL both eyes on Day one
224165268|NCT04357704|OTHER|S0N0|(no ITD)
224165269|NCT04357704|OTHER|S0N500|(ITD +500µs on noise)
224165270|NCT04357704|OTHER|S-500N500|(ITD -500µs on signal and +500 µs on noise)
223479112|NCT01508988|DRUG|ONO-9054|Eye drops 3 µg/mL both eyes on Day one
223479113|NCT01508988|DRUG|ONO-9054|Eye drops 10 µg/mL both eyes on Day one
223479114|NCT01508988|DRUG|ONO-9054|Eye drops 20 µg/mL both eyes on Day one
223479115|NCT01508988|DRUG|ONO-9054|Eye drops 30 µg/mL both eyes on Day one
223479116|NCT01508988|DRUG|ONO-9054|Matched-placebo eye drops dosed in the same manner as ONO-9054 in both eyes on Day one
224165271|NCT04357704|OTHER|S0N1000|(ITD + 1000 µs on noise)
224165272|NCT04357704|OTHER|S0Nuncorr|(no ITD cue, with uncorrelated stimulation frame)
224165273|NCT05275868|DRUG|MGY825|investigational drug
224165274|NCT06386302|DRUG|Chidamide|30 mg/d orally twice-weekly
223479117|NCT06983249|PROCEDURE|Rhomboid intercostal and Sub-serratus nerve block in nephrectomy|That block was performed when the patient was in the lateral position. A high frequency linear ultrasound transducer was placed longitudinally on the patient's back, just 2 cm medial to the medial scapular border. Then, the probe was slightly rotated to obtain an oblique parasagittal plane. The following landmarks were identified: the trapezius muscle, rhomboid major muscle, intercostal muscles, pleura, and lungs (from superficial to deep in order of appearance). Under ultrasound guidance, a 22 mm gauge spinal needle was directed to the plane by using high frequency ultrasound guidence (Sono SiteTM, Inc., Bothell, WA 98021, USA) between the rhomboid major and the underlying intercostal muscles and 15 ml bupivacaine (0.25%) was delivered into that plane (after repeated negative aspiration of blood), and its spread was manifested by the hydrodissection and widening of the plane visualized by ultrasound
223479118|NCT06983249|PROCEDURE|Quadratus lumborum nerve block in nephrectomy|"Ultrasound guided posterior quadrates lumborum block was done in lateral decubitus position and linear probe according to the depth was placed in the midaxillary line in the transverse plane immediately above the iliac crest and then it was slided dorsally until the Shamrock sign was clearly identified. In Shamrock sign The quadratus lumborum (QL) muscle is seen as a superior leaf of the Shamrock at the apex of the transverse process (TP) of L4"
223479119|NCT02714933|OTHER|MRI sequence Advanced ZTE|Evaluation of the image quality in terms of visualization of anatomical structures of the lung parenchyma in safe zone by a new imaging method of the pulmonary parenchyma by MRI (Advanced ZTE sequence).
224165275|NCT06386302|DRUG|Venetoclax|100 mg d1 200 mg d 2 400 mg d3-d28 Orally
224165276|NCT06386302|DRUG|azacitidine|75 mg/m 2 /d subcutaneous injection or IV d1-d7
224165277|NCT06699849|BIOLOGICAL|CSL889|CSL889 is a solution for infusion to be administered by the IV route.
224165278|NCT06699849|DRUG|Placebo|Volume and regimen matched to CSL899 will be administered.
224165279|NCT02000622|DRUG|Olaparib|Patients will be administered olaparib orally twice daily (bid) at 300 mg. Two (2) x 150 mg olaparib tablets should be taken at the same times each morning and evening of each day, approximately 12 hours apart with approximately 240 mL of water.
224165280|NCT02000622|DRUG|Physician's choice chemotherapy|"Investigators will declare one of the following regimens:~* Capecitabine 2500 mg/m2 po daily (divided in 2 doses) x 14 days, repeat every 21 days~* Vinorelbine 30 mg/m2 IV Day 1 and Day 8, repeat every 21 days~* Eribulin 1.4 mg/m2 IV Day 1 and Day 8, repeat every 21 days"
224165281|NCT00273806|BEHAVIORAL|Intervention for 4 behavioral risks by medical assistants.|
224165282|NCT00424840|DRUG|Bortezomib 1.3 mg/m2|"Level I (every 21 day cycle, D8), 1.3 mg/m2:~Day 1: bevacizumab 15 mg/kg ,carboplatin Area Under the Curve (AUC 6) 900mg, bortezomib 1.3 mg/m2 Day 8 : bortezomib 1.3 mg/m2~Level II (every 21 day cycle):~Day 1: bevacizumab 15 mg/kg, carboplatin Area Under the Curve (AUC 6) 900mg, bortezomib 1.6 mg/m2 Day 8 : bortezomib 1.6 mg/m2~Level III(every 21 day cycle):~Day 1: bevacizumab 15 mg/kg, carboplatin Area Under the Curve (AUC 6) 900mg, bortezomib 1.8 mg/m2 Day 8 : bortezomib 1.8 mg/m2"
224165283|NCT00424840|DRUG|Bortezomib 1.6 mg/m2|Level II (every 21 day cycle, D8), 1.6 mg/m2
224165284|NCT00424840|DRUG|Bortezomib 1.8 mg/m2|Level III (every 21 day cycle, D8) 1.8 mg/m2
224165285|NCT00424840|DRUG|Carboplatin AUC 6|Carboplatin AUC6
224165286|NCT00424840|DRUG|Bevacizumab|Bevacizumab 15 mg/kg
224165287|NCT00424840|DRUG|Taxotere|Taxotere 70 + G-CSF
224165288|NCT01405027|PROCEDURE|Educational Intervention|Receive patient education and management skills training from Hepatology Centers of Educational Expertise (HCEE) during four (4) educational interventions.The CLDF (Sponsor) intends to evaluate the effectiveness of the HCEE led educational interventions in improving a community site's HCV therapeutic management skills and patient outcomes.
223584323|NCT00779961|PROCEDURE|Palatoplasty|Palatoplasty will be performed under the supervision of one of five surgeons within the Division of Plastic Surgery at Sick Kids
224165289|NCT01405027|OTHER|Patient education and management skills training|Community sites received patient education and management skills training by HCEE investigators during four (4) educational interventions.The CLDF (Sponsor) intends to evaluate the effectiveness of the HCEE led educational interventions in improving a community site's HCV therapeutic management skills and patient outcomes.
224165290|NCT04541654|GENETIC|Data and Specimen Collection|"* Provide research team and access to relevant medical records~* Answer short questionnaires periodically~* Consider consenting to other optional parts of the research such as:~* Providing up to 3 tubes (15ml) of blood at or near the time of consent, as approved by treating physician (optional).~* Provide a saliva sample (optional).~* Provide eyebrow hairs for analysis of DNA from the bulb (15-20 eyebrow plucks) (optional).~* Provide permission for obtainment of stored tissue specimens from cancer or pre-cancer surgeries or biopsies from the pathology departments where they have been stored (optional).~* Consider inviting relatives to join the study (optional)."
224165291|NCT05085327|DRUG|ChapStick Lip Moisturizer Original|Sunscreen lip balm.
224165292|NCT05085327|DRUG|ChapStick Lip Moisturizer Mint|Sunscreen lip balm.
224165293|NCT05085327|DRUG|ChapStick Lip Moisturizer Black Cherry|Sunscreen lip balm.
224165294|NCT05085327|DRUG|SPF Standard Sunscreen|SPF Standard (7 percent \[%\] Padimate-O and 3% Oxybenzone)
224165295|NCT00171067|DRUG|valsartan|
224165296|NCT00171067|DRUG|lisinopril|
224165297|NCT01786278|RADIATION|Brachytherapy|Single dose of 12 Gy generated using a flexible applicator containing Iridium 192 with the range of irradiation of 1cm from the applicator axis. The extent of irradiation will cover the whole length of cancer stricture and 2cm beyond proximal and distal end of the tumor.
224165298|NCT01786278|PROCEDURE|Endoscopic stenting|Endoscopic stenting with partially covered selfexpandable metalic stents positioned across the cancer stricture and extending 2cm proximally and 2cm distally to the proximal and distal end of the tumor, respectively
224165299|NCT05727631|OTHER|gentle human touch|Mother will apply gentle human touch touch technique during venous blood collection from preterm babies between 32-37 weeks of gestation
224165300|NCT04377399|DRUG|Vitamin D|Patients will be randomised to receive either high dose vitamin D (40,000 IU weekly) or low dose vitamin D (5,000 IU weekly) for 24 weeks
224165301|NCT02716532|DIETARY_SUPPLEMENT|Peptamen AF|Each patient will receive Peptamen AF throughout the trial.
224165302|NCT01989936|DRUG|Placebo|Subjects were randomized to one of the 3 treatment groups (eletriptan 40 mg, eletriptan 80 mg, or placebo) in a 2:2:1 ratio and were given sufficient medication to treat 3 migraine attacks (including a second dose for each attack for recurrence) within 18 weeks of the initial visit. Subjects were instructed to treat a moderate to severe migraine within 6 hours of the onset of pain provided the headache was not decreasing in severity, the aura phase had ended and they had taken no analgesic or antiemetic within 6 hours. Efficacy data was collected in a diary. Subjects were allowed to take rescue medication if they had no response to the study medication within 4 hours of onset.
224165303|NCT01989936|DRUG|Eletriptan 40 mg|Subjects were randomized to one of the 3 treatment groups (eletriptan 40 mg, eletriptan 80 mg, or placebo) in a 2:2:1 ratio and were given sufficient medication to treat 3 migraine attacks (including a second dose for each attack for recurrence) within 18 weeks of the initial visit. Subjects were instructed to treat a moderate to severe migraine within 6 hours of the onset of pain provided the headache was not decreasing in severity, the aura phase had ended and they had taken no analgesic or antiemetic within 6 hours. Efficacy data was collected in a diary. Subjects were allowed to take rescue medication if they had no response to the study medication within 4 hours of onset.
224305177|NCT02628743|DRUG|Olesoxime|Participants will receive homogeneous suspension of olesoxime.
223584324|NCT01023386|DRUG|YM155|I.V.
223584325|NCT02657564|DRUG|Polyethylene glycol (PEG)|Participants receive blood tests for serum creatinine and electrolytes (Ca, P, Cl, Mg, Na, K) before and after taking polythylene glycol.
223584326|NCT05656833|DEVICE|Fractional 1927nm Low-Powered Diode Laser|Clear \& Brilliant Permea® Laser used on the side of the face randomized to receive laser
223584327|NCT05656833|OTHER|Topical Cysteamine|Topical Cysteamine cream will be used on the entire face.
224165304|NCT01989936|DRUG|Eletriptan 80 mg|Subjects were randomized to one of the 3 treatment groups (eletriptan 40 mg, eletriptan 80 mg, or placebo) in a 2:2:1 ratio and were given sufficient medication to treat 3 migraine attacks (including a second dose for each attack for recurrence) within 18 weeks of the initial visit. Subjects were instructed to treat a moderate to severe migraine within 6 hours of the onset of pain provided the headache was not decreasing in severity, the aura phase had ended and they had taken no analgesic or antiemetic within 6 hours. Efficacy data was collected in a diary. Subjects were allowed to take rescue medication if they had no response to the study medication within 4 hours of onset.
224165305|NCT01310985|DRUG|Capecitabine (Xelodaâ), XRT & Cetuximab (Erbitux®)|Capecitabine (Xelodaâ), External Beam Radiation and Cetuximab (Erbitux®)
224165306|NCT01320033|DRUG|CD2475/101 40 mg|Participants receive 40 mg of CD2475/101 tablets once a day for 16 weeks.
224165307|NCT01320033|DRUG|Doxycycline 100 mg|Participants receive 100 mg of Doxycycline capsule once a day for 16 weeks
223511694|NCT01889563|OTHER|Physical Exercise Training Program Exercise|Physical Exercise Training Program Exercise training was conducted in three times a week, during 12 weeks at high-intensity targets. Each session consisted of a five minute warm up (walking) at 2 km/h and 30 minutes with an intensity targets set at 70% of the peak speed rate. The increase of intensity was 0.5Km/h when the patient scored less than 4 point of Borg scale (moderate to intense effort) during each session. All evaluations were done at 6th week, in order to analyze the progression of outcomes and exactly adjust the intensity of training.
224165308|NCT01320033|DRUG|Placebo|Participants receive matching placebo tablet, matching placebo capsule once a day for 16 weeks.
224165309|NCT05238844|DRUG|ATI-2173 25mg|ATI-2173 is a liver-targeted phosphoramidate prodrug of clevudine designed to enhance anti-HBV activity while decreasing systemic exposure to clevudine. It will be dosed as a capsule by mouth.
224165310|NCT05238844|DRUG|Vebicorvir 300mg|Vebicorvir (formerly ABI-H0731) is an orally administered, potent and selective small molecule inhibitor of the HBV core protein
224165311|NCT05238844|DRUG|Viread 300Mg Tablet|Viread is a nucleotide analogue reverse transcriptase inhibitor used for chronic hepatitis B virus.
224165312|NCT00519571|DEVICE|ImplantLock device|dental implant
224165313|NCT00397449|BIOLOGICAL|GMZ2 (GLURP + MSP3 Hybrid) (malaria vaccine)|
224165314|NCT00242944|DRUG|Pitavastatin|Pitavastatin 4mg per day
224165315|NCT00242944|DRUG|Atorvastatin|Atorvastatin 20mg per day
224165316|NCT01216644|DRUG|5-Fluorouracil|2600 mg/m²d1 i.v. every 2 weeks
224165317|NCT01216644|DRUG|Leucovorin|200 mg/m², d1, i.v., every 2 weeks
224165318|NCT01216644|DRUG|Oxaliplatin|85 mg/m², d1, i.v., every 2 weeks
224165319|NCT01216644|DRUG|Docetaxel|50mg/m2, d1, i.v., every 2 weeks
224165320|NCT01216644|DRUG|Epirubicin|50 mg/m2, d1, i.v., every 3 weeks
224165321|NCT01216644|DRUG|Cisplatin|60 mg/m², d1, i.v., every 3 weeks
224165322|NCT01216644|DRUG|5-fluorouracil|200 mg/m², d1-d21, i.v., every 3 weeks
224165323|NCT00963469|DRUG|montelukast sodium|montelukast 10 mg tablet orally once daily in the morning for 4 weeks
224165324|NCT00963469|DRUG|Comparator: loratadine|loratadine 10 mg tablet orally once daily in the morning for 4 weeks
224165325|NCT00963469|DRUG|Comparator: placebo|placebo tablet orally once daily in the morning for 4 weeks
224165326|NCT03357328|OTHER|Therapy light room|See group description
224165327|NCT03357328|OTHER|Standard light|See group description
224165328|NCT04949139|DRUG|Dextrose 5% in water|Reducing the sodium concentration
224165329|NCT03979495|OTHER|mFOCUS|To evaluate the effectiveness of the system, team and individual components of mFOCUS vs. standard care by conducting a 4-arm cluster randomized controlled trial (RCT) of individuals who are due for follow-up of an abnormal screen.
224165330|NCT03725566|DRUG|Experimental|Recombinant humanized anti-VEGF monoclonal antibody injection 0.625mg/1.25mg/2.0mg/2.5mg by intravitreous injection,day 1 in the first month;
224165331|NCT01435564|BEHAVIORAL|Mobile phone|Participants in this group will receive both the pedometer and the mobile-phone based physical activity intervention fot three months.
224165332|NCT01435564|BEHAVIORAL|pedometer only|Participants in this group will receive only a pedometer.
224165333|NCT05524259|DIETARY_SUPPLEMENT|Myo-inositol and routinely recommended folic acid|Participants randomly allocated to the intervention group will receive 4 grams myo-inositol added to their routinely recommended 0.4 mg folic acid supplement, divided over two daily sachets of sugary powder throughout pregnancy.
224165334|NCT05524259|DIETARY_SUPPLEMENT|Routinely recommended folic acid|The control group will receive similar looking sachets of supplements containing only the standard dose of 0.4 mg folic acid without the added myo-inositol supplement as part of the current standard-of-care recommendation.
224165335|NCT01145833|OTHER|Immediate Treatment Group|The immediate treatment group starts the 5-month treatment right after baseline assessment.
224165336|NCT01145833|OTHER|Delayed Treatment Group|The delayed treatment group does not start treatment immediately after the baseline assessment. This group serves as the control group, by not receiving any treatment for 5 months. After the 5 months, the delayed group participants are asked to come in for a second assessment that involves completion of surveys and measurement of height, weight, and physical activity level. After this assessment is completed, the delayed group participants can begin the 5-month treatment.
224165337|NCT05883150|DRUG|Nebulized Midazolam|"All the drug solutions will be freshly prepared on the day of sedation session. Depending on the dosage calculated from the weight of each child The sedative drug, the dosage will be diluted with an equal volume by adding distilled water.~The child will be seated in an upright position on the dental chair. Before placing the mask of the nebulizer, the child will be coached into proper breathing pattern"
224165338|NCT05883150|DRUG|Intranasal Midazolam|All the drug solutions will be freshly prepared on the day of sedation session. Depending on the dosage calculated from the weight of each child, For children who will receive midazolam using the atomization device attached to a three-ml syringe, the child sitting reclined in knee-to-knee position. Half of the dose will be sprayed in the right nostril and the other half will be sprayed in the left nostril to double the absorptive surface area by short and quick puffs
224165339|NCT05547594|BEHAVIORAL|Multimodal surgical prehabilitation|Participants will be encouraged to engage in regular physical activity (endurance and resistance exercise), eat healthily and undergo cognitive behavioural therapy (the latter only if required) during the weeks prior to surgery.
224165340|NCT05241470|DRUG|ST-100 Ophthalmic Solution|One drop in each eye twice a day
224165341|NCT05241470|DRUG|Placebo Ophthalmic Solution|One drop in each eye twice a day
223479120|NCT04715087|OTHER|Blood sample (Day -42 to Day -28, Day 3),Skin swab sampling (Day -42 to Day -28, Day 0, Day 13) , patch test application (Day 0) , skin biopsies (Day 13)|A 50 mL blood sample will be collected in Lithium Heparin tubes (45 mL) and dry tube (5 mL), by venipuncture, at screening and Day 3. Bacteriological samples from AD patients will be performed by swabbing the skin at screening visit (Day -42 to Day -28). Each sample will be cultured in a RPMI/human serum AB medium and methi.R (methicillin Resistant) strains will be eliminated. Thus, only S. aureus methi.S (methicillin Sensitive) will be isolated to be re-applied (via patchtest) to AD patient. A well-characterized S. epidermidis lab strain will be also applied to AD patients. Patch tests containing S. aureus, S. epidermidis or a mix S. aureus/S. epidermidis will be applied on healed or improved area as defined by a lesional score ≤ 1 or a 2-point change from the baseline lesional score. Patch tests will be applied 48h and reading of the patch tests results and biopsies will be performed 72h after patch test application.
223479121|NCT04715087|OTHER|Blood sample (Day 0 ,Day 3),Skin swab sampling (Day 0,Day 13), patch test application (Day 1), skin biopsies (Day 13)|"A 50 mL blood sample will be collected in Lithium Heparin tubes (45 mL) and dry tube (5 mL), by venipuncture, at Day 0 and Day 3.~Each bacteriological sample from AD patients performed by swabbing the skin at screening visit will be cultured in a RPMI/human serum AB medium and methi.R (methicillin Resistant) strains will be eliminated. Thus, only S. aureus methi.S (methicillin Sensitive) will be isolated to be applied (via patchtest) to a paired (age/sex) healthy volunteer. A well-characterized S. epidermidis lab strain will be also applied to healthy volunteers. Patch tests containing S. aureus, S. epidermidis or a mix S. aureus/S. epidermidis will be applied on healthy skin. Patch tests will be applied 48h and reading of the patch tests results and biopsies will be performed 72h after patch test application"
223479122|NCT03847402|BEHAVIORAL|The early integrated intervention for GDD|The early integrated intervention for GDD integrates developmental approaches with strategies of applied behavior analysis.
223479123|NCT03847402|BEHAVIORAL|The early integrated intervention for ASD|The theoretical underpinnings of the early integrated intervention for ASD originate from Early Start Denver Model.
223479124|NCT03847402|BEHAVIORAL|The early integrated intervention for ADHD|The methods of the early integrated intervention for ADHD includes behavior training, sensory integration training and psychological counseling
223479125|NCT03847402|BEHAVIORAL|community intervention for ASD|TEACCH (Treatment and Education of Autistic and related Communication- handicapped Children) intervention or ABA(applied behavior analysis) intervention
223479126|NCT03847402|BEHAVIORAL|Community intervention for GDD|community intervention based on developmental approaches
223479127|NCT03847402|BEHAVIORAL|community intervention for ADHD|School and family education
223479128|NCT06861244|RADIATION|Radiotherapy (RT)|Undergo RT
223479129|NCT06861244|DRUG|Chemotherapy Drug, Cancer - Physician's Choice|One or more of the following may be assigned by the physician (physician's choice) per standard of care guidelines upon study enrollment following surgery: Cytarabine, Carboplatin, Cisplatin, Vincristine Sulfate injection (Vincristine PFS), Topotecan Hydrochloride, Dactinomycin, Thiotepa, Filgrastim, Cyclophosphamide, or Doxorubicin Hydrochloride. Not all participants will receive all possible drug regimens.
223479130|NCT06861244|PROCEDURE|Non-Investigational Surgical Resection|Undergo surgery directly before study enrollment as part of planned care.
223479131|NCT06861244|DRUG|Temozolomide|Participants assigned to or whom receive optional RT will receive concurrent temozolomide
223479132|NCT06861244|PROCEDURE|Tumor Tissue Sample|Tumor tissue will be collected for correlative studies
223479133|NCT06861244|PROCEDURE|Blood Sample|Blood samples will be collected for correlative studies
223479134|NCT06861244|PROCEDURE|Cerebrospinal Fluid (CSF) Sample|CSF samples will be collected for correlative studies
223479135|NCT02256865|DRUG|Ketoconazole|Ketoconazole is taken 4 times a day
223584328|NCT05990023|OTHER|Traditional vestibule rehabilitation training|"* Standing, using a gaze tracking system on a force plate to track a continuously moving target, with alerts when body sway exceeds a certain threshold.~* Standing, wearing an inertial sensor on the head and performing left-right or up-down head movements while maintaining gaze on a target, with a screen providing feedback on head movement speed.~* Standing, controlling body weight distribution on the force plate to reach a target position, with a screen displaying the current center of gravity position.~* Walking, synchronizing head movements with a rhythm or performing up-down head nods, with auditory cues indicating the desired head movement frequency.~* During continuous head rotations, stepping in a regular sequence of forward, backward, left, and right movements."
224165342|NCT02726204|OTHER|Gravity Elimination Alone|CAREX will compensate for the gravity of the subject's arm, i.e. subject can move their arm to a specific position and relax all the arm muscles, CAREX will hold the arm in that configuration
224165343|NCT02726204|OTHER|Path Assistance Alone|CAREX will push subject's arm to a pre-specified path. If the arm is not in the path, CAREX will generate some force that is proportional to the distance between the hand and the path. The subject will feel like having a spring connected between his hand and the path
223479136|NCT02256865|DRUG|Hydrocortisone|Hydrocortisone is taken 3 times a day
223479137|NCT02256865|DRUG|Testosterone|Testosterone gel is applied once a day
223479138|NCT02256865|DRUG|Placebo for ketoconazole|Placebo for ketoconazole
223479139|NCT02256865|DRUG|Placebo for hydrocortisone|Placebo for hydrocortisone
223479140|NCT02256865|DRUG|Placebo for testosterone|Placebo for testosterone
224165344|NCT02726204|OTHER|Path Assistance and Gravity Elimination|
224165345|NCT01485185|DRUG|Gabapentin lower dose|Repeat, oral dose
224165346|NCT01485185|DRUG|Donepezil|Repeat, oral dose
224165347|NCT01485185|OTHER|Placebo (Dop)|Placebo to donepezil, Repeat, oral dose
224165348|NCT01485185|OTHER|Placebo (Gaba)|Placebo to gabapentin, Repeat, oral dose
224165349|NCT01485185|DRUG|Gabapentin higher dose|Repeat, oral dose
224165350|NCT04312815|DRUG|SM03|SM03: 600 mg intravenous (IV)
224165351|NCT04312815|DRUG|Placebo|Placebo: 600 mg intravenous (IV)
224165352|NCT04312815|DRUG|MTX|Methotrexate: 7.5-20 mg/wk oral
224165353|NCT01824524|DRUG|Hydromorphone|Participants will be administered a single dose of Osmotic Release Oral System (OROS) hydromorphone tablet of 8 milligram (mg) orally on Day 1 under fasting conditions.
224165354|NCT06366503|PROCEDURE|Fractional Ablative CO2 Laser|A fractional ablative DEKA SmartXide Tetra CO2 laser treatment was performed after a 14-day washout period. Subjects were numbed for 1 hour prior to procedure with topical numbing cream (lidocaine 23%, tetracaine 7%). The global face was treated with a single pass. Treatment parameters include power 20 W, spacing 500 um (13% density), Dwell time 1200 us DEKA pulse mode, spray mode on.
224165355|NCT06366503|OTHER|Facial Cleanser|Facial cleanser was to be used by subjects twice daily during the 14-day washout period and three times daily during the 14-day post-procedure timeline.
224165356|NCT06366503|OTHER|Facial Moisturizer|A bland facial moisturizer was to be used by subjects twice daily during the 14-day washout period and three times daily between day 3 and 14 post-procedure. Two pumps were to be applied to the face (avoiding the upper eyelid) after applying the active and comparator.
224165357|NCT06366503|OTHER|Sunscreen|During the 14-day washout period, a bland sunscreen was to be used by subjects in the morning after cleansing and facial moisturizer application with reapplications as needed throughout the day per FDA recommendations. For days 3-14 post-procedure, the bland sunscreen was to be used daily by subjects in the morning and afternoon after cleansing, split-face application of the active post-procedure cream and comparator anhydrous formulation, and facial moisturizer application.
224165358|NCT06366503|OTHER|Basic Ointment|The basic ointment was used only on the comparator side for three days (72 hours) post-procedure. This was a requirement of the comparator anhydrous formulation.
224165359|NCT03624478|RADIATION|Hypofractionated Radiation Therapy|Undergo hypofractionated radiation therapy
224165360|NCT05789862|BEHAVIORAL|Counseling Sessions|Virtual sessions
224165361|NCT05789862|BEHAVIORAL|Quality of Life Questionnaires|Self administered questionnaires
224165362|NCT05874635|DEVICE|Continuous Glucose Monitor Device|Continuous glucose monitoring automatically tracks blood glucose levels, also called blood sugar, throughout the day and night. You can see your glucose level anytime at a glance. You can also review how your glucose changes over a few hours or days to see trends. Seeing glucose levels in real time can help you make more informed decisions throughout the day about how to balance your food and physical activity.
224165363|NCT06246552|BIOLOGICAL|JTM201|"JTM201 20U in 0.5mL~: JTM201 will be injected via IM in 5 glabellar location 0.1mL (4U / 0.1mL) at each location"
224165364|NCT06246552|BIOLOGICAL|Placebo|"Placebo 20U in 0.5mL~: Placebo will be injected via IM in 5 glabellar location 0.1mL (4U / 0.1mL) at each location"
224165365|NCT05220358|DRUG|Fostemsavir 600 MG [Rukobia]|FTR 600 mg PO BID added to daily suppressive HIV regimen
224165366|NCT05113251|DRUG|Trastuzumab Deruxtecan|administered by intravenous infusion
224165367|NCT05113251|DRUG|Paclitaxel|administered by intravenous infusion
224165368|NCT05113251|DRUG|Trastuzumab|administered by intravenous infusion
224165369|NCT05113251|DRUG|Pertuzumab|administered by intravenous infusion
224165370|NCT05113251|DRUG|Doxorubicin|administered by intravenous infusion
224165371|NCT05113251|DRUG|cyclophosphamide|administered by intravenous infusion
224165372|NCT02552823|OTHER|Group1|
224165373|NCT02552823|OTHER|Group2|
224165374|NCT03160872|DIAGNOSTIC_TEST|Anti Mullerian Hormone Measurement|Anti Mullerian Hormone was measured in all patients within two months before the first insemination cycle
224165375|NCT05861050|PROCEDURE|Biopsy|Undergo tumor biopsy
224165376|NCT05861050|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
224165377|NCT05861050|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
223479141|NCT06673628|DRUG|Pembrolizumab plus Lenvatinib|"One course is fixed at 21 days, and the length of course is not extended or shortened.~Participants receive 200 mg of pembrolizumab injection intravenously over approximately 30 minutes on day 1 of each course, and take 20 mg of lenvatinib capsules orally once daily, preferably at the same time each day.~Treatment with pembrolizumab and lenvatinib will be continued for up to 35 courses unless the criteria for termination of protocol treatment are met."
223479142|NCT02144558|OTHER|penile vibratory stimulation (PVS) or masturbation|penile vibratory stimulation (PVS) or masturbation
223479143|NCT06868186|DEVICE|RUS NE|The RUS NE is an endoscopic imaging treatment planning software program. It creates a patient-specific simulation of the intra-abdominal surgical environments, allowing for the visualization of tumor, vascular structures and intra-abdominal organs during the surgical planning process and the operation. RUS NE utilizes preoperative CT images of the patients to segment tumor, organs, and blood vessels and reconstructs them into a 3D model. Although there is no direct intervention on the patient, the surgeon uses RUS NE as a surgical navigation tool to simulate the surgery before performing the actual procedure.
223479144|NCT06870838|DIAGNOSTIC_TEST|7T MRI scan|MRI-scanning of the brain using a 7T MRI scanner
223479145|NCT06870838|DIAGNOSTIC_TEST|CSF|CSF collection via lumbar puncture
223479146|NCT06870838|DIAGNOSTIC_TEST|Blood withdrawal|Blood is collected by doing a blood withdrawal
223479147|NCT06870838|DIAGNOSTIC_TEST|Neuropsychological assessment|Tests for memory, language, attention, executive functions, praxis, social cognition, visuoconstructive skills
223479148|NCT06870838|DIAGNOSTIC_TEST|Clinical measures|Medical history, neurological assessment, neuropsychiatric inventory
223479149|NCT00275652|DRUG|LdT (Telbivudine) and lamivudine|
223479150|NCT04467021|OTHER|Best Practice|Receive usual blood pressure management
223479151|NCT04467021|OTHER|Blood Pressure Measurement|Undergo blood pressure measurement
223479152|NCT04467021|OTHER|Clinical Management|Undergo intensive systolic BP management
224165378|NCT05861050|PROCEDURE|Computed Tomography|Undergo CT scan
224165379|NCT05861050|BIOLOGICAL|Glofitamab|Given IV
223479153|NCT04467021|OTHER|Quality-of-Life Assessment|Ancillary studies
223479154|NCT04467021|OTHER|Questionnaire Administration|Ancillary studies
223479155|NCT01647178|PROCEDURE|TORQ assisted sternal closure|
224165380|NCT05861050|DRUG|Lenalidomide|Given PO
224165381|NCT05861050|BIOLOGICAL|Obinutuzumab|Given IV
224165382|NCT05861050|PROCEDURE|Positron Emission Tomography|Undergo PET scan
224165383|NCT05861050|DRUG|Venetoclax|Given PO
224305178|NCT06320808|OTHER|FDA template PMI|Intervention is an information format viewed by participants. The patient medication information format was designed according to a proposed FDA template, which provides information about safe and effective use of a medication. No drug or device is included as part of this intervention.
223479156|NCT01647178|PROCEDURE|Conventional closure|
224165384|NCT06331052|DEVICE|MR-guided Focused Ultrasound Ablation|3-D tractography Vim-FUSA -D tractography Vim-FUSA will be carried out as follows: (a) head shaving and placement of the stereotactic frame (Integra radionics frame, Integra Lifesciences, NJ, USA) secured to the skull with transcutaneous screws; (b) positioning on the procedure table and placement of the ultrasound transducer; (c) acquisition of conventional magnetic resonance (MR) imaging and co-registration with the CT head and 3-D tractography imaging acquired pre-surgically; (d) exploration of the target area with subtherapeutic sonications; (e) intraoperative monitoring with clinical testing of tremor and side effects with a standardized protocol. (f) Therapeutic sonications in the target area to deliver definitive ablation followed by clinical testing of tremor and side effects with a standardized protocol as described in section (e).
224165385|NCT00354484|DRUG|Ferric Carboxymaltose (FCM)|Up to a maximum cumulative dose of 2,500 mg administered IV based on iron-deficit calculations; the calculated dose was given in divided doses of up to 1,000 mg weekly.
223479157|NCT03308669|DRUG|Lasmiditan|Administered orally
224165386|NCT00354484|DRUG|Ferrous Sulfate tablets|325 mg of ferrous sulfate 3 times daily (TID) x 6 weeks.
224165387|NCT00378534|DEVICE|Miltenyi reagent system|Miltenyi Clinimax CD34 Reagent System for CD34 selection and delayed T cell depletion add back
224165388|NCT00378534|DRUG|Fludarabine|Therapeutic
224165389|NCT00378534|DRUG|Cyclosporine|Therapeutic
224165390|NCT00378534|DRUG|Cyclophosphamide|Therapeutic
224165391|NCT00378534|OTHER|FILGRASTIM (G-CSF)|An HLA 6/6 identical family member will be co-enrolled into this study as a stem cell donor. Stem cell Donors will receive G-CSF for stem cell mobilization. The stem cell collection aspect of this protocol is not investigational.
224165392|NCT04969900|OTHER|Placebo oil|The placebo group will receive placebo oil.
224165393|NCT04969900|OTHER|Lavender oil.|Investigational Product. This group will receive Lavender oil.
224165394|NCT03691649|DRUG|DE-117 Ophthalmic Solution|Topical DE-117 Ophthalmic Solution once daily and Vehicle once daily for 3 months for all subjects, followed by DE-117 Ophthalmic Solution once daily for additional 9 month for adult subjects only
224165395|NCT03691649|DRUG|Timolol Maleate Ophthalmic Solution 0.5%|Topical Timolol Maleate Ophthalmic Solution 0.5% twice daily for 3 months for all subjects, followed by DE-117 Ophthalmic Solution once daily for additional 9 month for adult subjects only
224165396|NCT03537937|OTHER|Lower SpO2 Target|SpO2 target 90% (range 88-92%)
224165397|NCT03537937|OTHER|Intermediate SpO2 Target|SpO2 target 94% (range 92-96%)
224165398|NCT03537937|OTHER|Higher SpO2 Target|SpO2 target 98% (range 96-100%)
224165399|NCT03671148|BIOLOGICAL|Placebo|Placebo for risankizumab administered by subcutaneous (SC) injection
224165400|NCT03671148|BIOLOGICAL|Risankizumab|Risankizumab administered by subcutaneous (SC) injection
224165401|NCT00246285|DRUG|risperidone|
224165402|NCT00673816|DRUG|Sunitinib Malate|Participants were expected to receive 9 months of sunitinib malate therapy administered in 6 cycles. Each cycle consisted of a daily oral dose of 50 mg sunitinib malate for 4 weeks followed by a 2-week rest period).
224165403|NCT04586322|OTHER|No intervention, (observational study).|"From every participant the following information was recorded for further analysis:~* BEWE score- Basic erosive tooth wear examination (from 2 calibrated examiners) to diagnose the presence of erosive tooth wear.~* Their answer to a validated questionnaire assessing the dietary habits based in the frequency of acidic diet.~* 2 Intra oral scans (IOS): Baseline and follow up (1 year after baseline) to perform a quantification of tissue loss (in Volume loss per mm3) using Wearcompare software."
224165404|NCT00591500|BEHAVIORAL|Questionnaire|Exposures of interest will be measured by a self-administered personal residence, occupation and vacation calendar, a telephone interview, and by testing DNA from buccal cells and blood, when available. Standardization of diagnosis will be undertaken by review of tissue slides. Questionnaire data will be completed by interviewers. DNA will be obtained from each individual in the form of 4-6 buccal swabs
223479158|NCT03308669|DRUG|Placebo|Administered orally
223479159|NCT03308669|DRUG|Topiramate|Administered orally
223479160|NCT07030088|DEVICE|Dual-Headed Manual Toothbrush|A novel toothbrush with a dual-headed design intended to clean both upper and lower buccal/ or upper and lower lingual/ palatal surfaces simultaneously. Participants were instructed to use this toothbrush on one side of the mouth only, twice daily using the Bass brushing technique. This intervention is evaluated for plaque removal efficacy, gingival health, brushing time, and patient comfort
223479161|NCT07030088|DEVICE|Conventional Single-Headed Manual Toothbrush|A standard single-headed manual toothbrush used as the active control. Participants used this toothbrush on the other side of the mouth, with the same brushing technique (Bass method), frequency (twice daily). It serves as the comparator for assessing the performance of the dual-headed design.
223479162|NCT06324617|PROCEDURE|Treatment of failed carpal tunnel syndrome by dorsal ulnar artery perforator adipofascial flap|"Treatment of failed carpal tunnel syndrome by dorsal ulnar artery perforator adipofascial flap The previous incision is reopened and extended, Neurolysis begins proximally preserving the palmar cutaneous branch. The subcutaneous tissue is exposed, leaving part of the superficial venous plexus with the adipofascial flap. Flap elevation is begun by incising the subcutaneous tissue through the deep fascia along the radial border of FCU and ECU .~When the flap reaches a suitable length (10-12 cm from the wrist), it is cut proximally and along the ulnar side. The flap is dissected proximally to distally in continuity with the underlying fascia . When the dissected flap is (2-5) cm proximal to the wrist. Ulnar retraction of the flexor carpi ulnaris permits identification of the perforator. the pivot point of the flap is localized (2-5) cm proximal to the pisiform.~The adipofascial flap is turned 180 degrees and anchored with a few absorbable stitches around the median nerve."
223479163|NCT02649010|DEVICE|Enlite 3 Sensor|Use of Enlite 3 Sensor over 168 hours (7 days) when inserted in the arm and used with the 640G Pump in subjects aged 14-75 years who have had a diagnosis of type 1 or type 2 diabetes for at least 12 months.
223479164|NCT02367300|DEVICE|BrainScope Ahead 200|A single-use, proprietary headset containing pre-gelled electrodes will be placed on the subject's forehead according to the standard locations of the modified International 10/20 system. Subjects will undergo approximately 5 minutes of eyes closed brain electrical activity recording.
224165405|NCT00591500|BEHAVIORAL|Questionnaire|Exposures of interest will be measured by a self-administered personal residence, occupation and vacation calendar, a telephone interview, and by testing DNA from buccal cells and blood, when available. Standardization of diagnosis will be undertaken by review of tissue slides. Questionnaire data will be completed by interviewers. DNA will be obtained from each individual in the form of 4-6 buccal swabs.
224165406|NCT03437993|OTHER|Recollect, the game|"Recollect is a working memory training game"
224165407|NCT03437993|OTHER|Tetris|App-based video game where shapes are rotated and placed to fit a grid
224165408|NCT06212466|DEVICE|CardioFlux|The device is a magnetocardiography (MCG) scanner named CardioFlux, which is paired with a cloud processing software for the acquisition, display, and analysis of magnetic fields generated by cardiac electrical activity.
224165409|NCT02401685|OTHER|Adjuvant therapy|Adjuvant therapy will include chemotherapy and/or endocrine therapy for all women, and radiotherapy to breast or chest wall if indicated. Human epidermal growth factor receptor 2 (HER2) targeted treatment may also be administered when indicated.
224165410|NCT02401685|PROCEDURE|Axillary treatment|Axillary treatment can be axillary node clearance or axillary radiotherapy as per local guidelines.
224165411|NCT05896423|BEHAVIORAL|PrEP awareness materials|Community-designed PrEP awareness materials - developed in the formative portion of this study
224165412|NCT06520345|DRUG|177Lu-TLX591|Participants randomized to Group A will receive two 76 mCi (±10%) doses of 177Lu-TLX591 14 days apart
224165413|NCT06520345|DRUG|Enzalutamide|Enzalutamide (starting dose 160 mg daily) + prednisone / prednisolone (5 mg twice a day) or equivalent.
224165414|NCT06520345|DRUG|Abiraterone|Abiraterone (starting dose 1,000 mg daily) + prednisone / prednisolone (5 mg once daily for the standard formulation), methylprednisolone (4 mg twice daily for the fine particle formulation) or dexamethasone (1 mg once daily)
224165415|NCT06520345|DRUG|Docetaxel|Docetaxel: Single agent chemotherapy will consist of docetaxel given at a recommended dose of 75mg/m2 IV every 3 weeks given in combination with oral prednisone / prednisolone (5mg twice a day) or equivalent for up to 10 cycles
224165416|NCT05480306|DRUG|DKN-01|30 minute IV infusion (400mg) every two weeks with an additional loading dose in the first cycle of treatment
224165417|NCT05480306|DRUG|FOLFIRI|90-min IV infusion of irinotecan, leucovorin, and fluorouracil followed by a continuous 46-hour infusion of fluorouracil every two weeks
224165418|NCT05480306|DRUG|Bevacizumab|90-min IV infusion (5mg)
224165419|NCT05480306|DRUG|FOLFOX|2 hour IV infusion of oxaliplatin, folinic acid, and fluorouracil followed by a continuous 46-hour infusion of fluorouracil every two weeks
224165420|NCT02234050|DRUG|Trabectedin|Trabectedin will be given as a 24-hour infusion every 3 weeks at a starting dose of 1.5 mg/m2 body surface area (BSA), until one of the treatment withdrawal criteria has been met.
224165421|NCT02234050|OTHER|Local standard of care|Left to the discretion of the investigator
224165422|NCT02365805|DRUG|Epirubicin + Ciclofosfamide + Fluorouracil + Paclitaxel|Epirubicin 90 mg/m2 + Ciclofosfamide 600 mg/m2 + 5-Fluorouracil 600 mg/m2 intravenous infusion on day 1 every three weeks, for four cycles; followed by Paclitaxel 100 mg/m2 weekly for eight weeks.
224165423|NCT02365805|DRUG|Epirubicin + Cisplatin + Fluorouracil|Epirubicin 60 mg/m2 + Cisplatin 60 mg/m2 intravenous infusion on day 1 every three weeks and 5-Fluorouracil 200 mg/m2/day for eight cycles.
224165424|NCT02365805|DRUG|Docetaxel + Ciclofosfamide|Docetaxel 75 mg/m2 + Ciclofosfamide 600 mg/m2, intravenous infusion on day 1 every three weeks, for eight cycles.
224165425|NCT04572685|DRUG|Paliperidone Palmitate|A long acting extended release injectable suspension intended for monthly intramuscular administration
224165426|NCT05064085|DRUG|Cemiplimab|Participants will be given Cemiplimab 350 mg IV day 1 every 21 days
224165427|NCT05064085|DRUG|Capecitabine|Participants will take Capecitabine at 2 dose levels: 800 mg/m\^2 and 1000 mg/m\^2 by mouth twice daily 14 days on, 7 days off starting on day 3 every 21 days.
224165428|NCT00592176|DRUG|local injection of bevacizumab|Upon enrollment into the study: - initial injection of bevacizumab, a 1 week post-injection visit,and monthly visits thereafter for a total of 6 months. At the 1-month and 3-month visit post-injection visit, an additional bevacizumab injection will be offered if pterygium regression has not occurred. All injections of bevacizumab will consist of injecting 0.1mL of a 2.5mg/0.1mL concentration of bevacizumab into the head of the pterygium.
223479165|NCT03798314|BIOLOGICAL|Nivolumab|Given IV
223479166|NCT03798314|DRUG|Pomalidomide|Given PO
223479167|NCT02273167|DRUG|NER1006, 2-Day Split-Dosing|The subject will self-administer the first dose of the assigned investigational product in the evening prior to the scheduled colonoscopy and take mandatory additional clear fluid. Subject will take the second dose together with mandatory additional clear fluids on the morning of the colonoscopy.
223479168|NCT02273167|DRUG|NER1006,1-Day Morning Split-Dosing|"The subject will self-administer the first dose of the investigational product on the morning of the colonoscopy and take mandatory additional clear fluid.~After a 1-2 hour break the subject will self-administer the second dose plus additional clear mandatory fluid."
224165429|NCT02365506|DRUG|Eleclazine|Tablets administered orally in a single dose
224165430|NCT02365506|DRUG|Placebo|Placebo to match tablets administered orally in a single dose
224165431|NCT06179355|PROCEDURE|manual astigmatic keratotomy|manual astigmatic keratotomy using a diamond knife
224165432|NCT06179355|PROCEDURE|femtosecond laser astigmatic keratotomy|astigmatic keratotomy using femtosecond lase
224305179|NCT06320808|OTHER|Decision Critical PMI|Intervention is an information format viewed by participants. The patient medication information format was designed according to a proposed FDA template and modified, according to decision science principles, to include benefit information, which provides information about safe and effective use of a medication. No drug or device is included as part of this intervention.
224305180|NCT06320808|OTHER|Standard Information|The intervention is an information format viewed by participants. This patient medication information format is the current standard of care patient medication information that is included with the drug. No drug or device is included as part of this intervention.
223479169|NCT02273167|DRUG|MOVIPREP, 2-Day Split-Dosing|The subject will self-administer the first dose of the assigned investigational product in the evening prior to the scheduled colonoscopy and take recommended additional clear fluid. Subject will take the second dose together with recommended additional clear fluids on the morning of the colonoscopy.
223584329|NCT05990023|OTHER|Dual-task vestibule rehabilitation training|"* Adding a dual task of digit countdown and recitation to clinical balance training exercises.~* Incorporating a numerical calculation task into interactive screens during clinical balance training, with the participant's responses input by the researchers.~* Introducing upper limb exercises, such as button pressing or arm swinging, during clinical balance training.~* During continuous head rotations, following visual prompts on the display to perform forward, backward, left, and right displacements."
223584330|NCT06183879|DEVICE|cryoballoon pulmonary vein isolation (Medtronic 4th gen balloon)|Standard of care cryoballoon pulmonary vein isolation with Medtronic 4th gen balloon
223584331|NCT06183879|DEVICE|cryoballoon pulmonary vein isolation (Boston 2nd gen balloon)|Standard of care cryoballoon pulmonary vein isolation with Boston 2nd gen balloon
223584332|NCT00983736|DRUG|Tramadol Hydrochloride|"89 mg or a lesser dose of 62 mg if side effects are experienced one tablet at least two hours before sexual intercourse (maximum of one tablet every 20 hours).~Subject will take the study drug for about 27 weeks."
223584333|NCT00983736|DRUG|Placebo|"89 mg or a lesser dose of 62 mg if side effects are experienced one tablet at least two hours before sexual intercourse (maximum of one tablet every 20 hours).~Subject will take the study drug for about 27 weeks."
223584334|NCT04433559|DRUG|Tadalafil 1,5 mg oral tablets|Use of tadalafil in the treatment of FSIAD
223584335|NCT04433559|DRUG|Placebo oral tablets|Use of placebo in control group
223584336|NCT06228690|OTHER|Gold Fish exercises|Specific exercise for the flexibility of TMJ that will target the Jaw muscles. Frequency: 3 times/week for 4 weeks Intensity: moderate intensity (pain free) Time: 30-45 minutes Type: Gold Fish exercises for jaw flexibility, pain and maximum mouth opening.
223584337|NCT06228690|OTHER|Cervico-thoracic postural correction training|"Cervico-thoracic postural correction training for upper thoracic and neck muscles.~Frequency: 3 times/week for 4 weeks Intensity: moderate intensity (pain free) Time: 30-45 minutes Type: Muscle energy technique to improve range of motion, pain and maximum mouth opening."
223584338|NCT06228690|OTHER|Conventional PT treatment|"Conventional PT including Hot Pack for 10mins, Active-Passive neck Stretching Exercise + jaw Isometric Exercises.~* Frequency: hold followed by 5secs rest. 2-3times for 3 times/week for 4 weeks, Intensity: moderate-high intensity (depending on pain tolerance) Time: 30-45 mins for Active-Passive neck Stretching.~* Frequency: 3secs hold, 6 times repetitions for Isometric Exercises. Type: conventional treatment for pain, ROM, MMO."
223584339|NCT02850900|BEHAVIORAL|Internet Survey|Weekly survey will be emailed, subjects should complete them
223584340|NCT00516035|BIOLOGICAL|Live Influenza A Vaccine H7N3 (6-2) AA ca Recombinant (A/chicken/British Columbia/CN-6/2004 x A/Ann Arbor/6/60 ca)|Vaccine given by nasal spray
223479170|NCT02781324|PROCEDURE|Posterior Spinal Fusion|
223479171|NCT02781324|DEVICE|Ultrasonic Bone Scalpel|
223479172|NCT03415152|DRUG|Omacor (Omega-3-acid ethyl esters)|Observational study without intervention, Omacor is prescribed in routine manner in accordance with clinical practice and the valid Instruction for Medical Use regarding the dose, duration of therapy, patient population, and therapeutic indication.
223479173|NCT06907667|OTHER|Vaccine injection|Injection of the vaccine in chronic renal insufficiency patients.
223479174|NCT06908083|OTHER|Analytical Treatment Interruption|Participants will stop their ART (Antiretroviral therapy) on Week 0 and will remain off of their ART for up to 48 weeks or until they meet restart criteria.
223479175|NCT02670707|DRUG|Cytarabine|Cytarabine 100 mg/m\^2/day IV for five consecutive days. This five-day cycle will be repeated every 21 days for a total of four cycles for all patients regardless of response. Each new cycle may not begin until absolute neutrophil count (ANC) is ≥ 750/mcL and platelet count is ≥ 75,000/mcL.
223479176|NCT02670707|DRUG|Vinblastine/prednisone|"Vinblastine/Prednisone +/- 6-mercaptopurine based on risk category. Patients with high-risk organ involvement (liver, spleen, hematopoeitic system) will receive 6-mercaptopurine during Continuation Therapy as this is the current standard of care treatment.~Vinblastine 6 mg/m\^2/dose IV push weekly for patients ≥ 12 months of age. Vinblastine will be dosed at 3 mg/m\^2/dose for patients under 6 months of age, and dosed at 4.5 mg/m\^2/dose for patients 6 months of age to 11.99 months of age.~Prednisone (or prednisolone) 20 mg/m2/dose by mouth twice a day"
223479177|NCT07091032|OTHER|Treatment as Usual|This is the comparison condition, in which participants will receive treatment as usual for their conditions at the clinic.
223479178|NCT07091032|BEHAVIORAL|Building Connections Intervention|The combined Building Connections intervention incorporates three areas. Participants take part in those for which they are eligible. The obesity/weight management intervention offers coaching and support for education on evidence-based anti-obesity medications (AOM) and a lifestyle behavioral intervention offered by Community Health Workers focused on diet and physical activity. The cancer screening intervention focuses on developing workflows and systems to offer a CHW-delivered population-based intervention to improve colorectal and cervical cancer, focusing on newer screening modalities and monitoring adherence for individuals with a positive screening test result. The mental health intervention uses the evidence-based Strong Minds intervention, a 10-session psychoeducational program provided by trained community health workers with clinical supervision. The skills-based intervention uses an integrative approach aimed at improving depression, anxiety, and trauma-related symptoms.
223479179|NCT07098169|BEHAVIORAL|iTEST|iTEST is a computerized training intervention delivered on a mobile device that is coupled with individual contacts with a therapist/coach. The mobile components train in improving participant's ability to form accurate judgments about their performance and their rate of functional activities. The intervention involves coaching coupled with automated training that is delivered on a mobile device. The automated training involves daily cognitive tests in which the goal for treatment is to improve judgments of accuracy of self-assessment, and coaching is aimed at applying improving metacognitive awareness to every day activities. i
223584341|NCT01389999|OTHER|Questionnaires|Each patient is asked to fill out several questionnaires: a french version of the BBQ, as well as the FABQ, the TAMPA score, and the Québec questionnaire, the Dallas score, the HAD score and a visual analog scale for pain.
223584342|NCT01404455|OTHER|HES 130/0.4 (VoluvenⓇ, Fresenius Kabi, Graz, Austria) 500mL loading|HES 130/0.4 (VoluvenⓇ, Fresenius Kabi, Graz, Austria) 500mL loading during 15 minutes after induction of anesthesia
223584343|NCT05141955|OTHER|Group Erector Spinae Plane Block (ESPB)|"Patients will receive general anesthesia initially then bilateral ESPB with a total volume of (0.3-0.4 ml/kg LBW) of bupivacaine 0.25% will be performed (not exceeding toxic dose) 150 mg "
224165433|NCT04252391|PROCEDURE|Perineural electrical dry needling|Standard care plus use of perineural electrical dry needling involving use of a monofilament needle of 15 or 30 mm length, 0.25 mm diameter will be placed utilizing the therapist's dominant hand following palpation of correct needle location. An electrical stimulation unit will be used to conduct an electrical impulse. The unit used will be an ES-130 by ITO (Japan) using a DC 9V battery producing an asymmetrical biphasic waveform. The unit has 6 available leads with alligator clamps, connecting to needle shafts. Parameters of PNED will include intensity set at a strong yet comfortable setting according to patient feedback. Treatment duration will be 15 minutes. Treatment frequency will be set to Medium at level 8 (80 Hz). Parameters will be set to elicit a sensory response.
224165434|NCT04252391|PROCEDURE|Standard Care|cervical or thoracic manipulation or mobilization, muscle stretching, muscle strengthening, electrical trigger point dry needling , soft tissue release and prescribed therapeutic exercises .
224165435|NCT01680991|DRUG|Obinutuzumab|Multiple doses of obinutuzumab.
224165436|NCT02597686|BEHAVIORAL|SD-PB training|
224165437|NCT03438591|DEVICE|Medtronic 4196 lead|Cerclage-CRT pacing with Medtronic 4196 lead (Attain Ability Lead)
224165438|NCT02638740|PROCEDURE|SCALING AND ROOT PLANING (SRP)|Scaling and root planning done with ultrasonic scalar with reinforcement of oral hygiene measures and follow up for 90 days.
224165439|NCT02638740|PROCEDURE|MUSTARD OIL AND SALT MASSAGE WITH SRP|Scaling and root planing was done with ultrasonic scalar. It was followed by gum massaging with 0.32gm salt in 5ml mustard oil for 5min, twice daily for 90 days.
224165440|NCT02375880|DRUG|DKN-01|Administration by intravenous (IV) infusion.
224165441|NCT02375880|DRUG|gemcitabine|Administered by IV infusion.
224305181|NCT04275206|OTHER|Harkány medicinal water|The aim is to prove the effectiveness of Harkány medicinal water on patients suffering from psoriasis and rheumatoid arthritis. The control group is treated with tap water.
224305182|NCT04275206|OTHER|Tap water (placebo control)|The control group is treated with tap water.
224305183|NCT02534844|DRUG|Parts A/B: Adrabetadex|900 - 1800 milligram (mg) of adrabetadex administered every 2 weeks via lumbar intrathecal infusion
224305184|NCT02534844|OTHER|Parts A/B: Sham Control|No experimental drug is administered to participants - intrathecal administrations are simulated by skin prick
224305185|NCT04142957|OTHER|COPD Pal|'COPD Pal' aims to allow people with COPD to track and manage their condition. It enables patients to log symptoms (e.g. COPD assessment Test), wellness (e.g. quality of life such as EQ-5D), and medications, to help them become more engaged in their own care.
223479180|NCT07098169|BEHAVIORAL|Active Control|Behavioral: Mobile cognitive tests will be administered to control subjects. Participants will receive feedback regarding their performance but not on the accuracy of their self-ratings. Coaching will also be coupled with mobile cognitive tests and will include goal-setting without specific mention of Introspective Accuracy (IA). in place of content related to IA, participants will receive psychoeducation about the benefits of sleep, physical activity, and social connection to overall cognitive health
223479181|NCT06891820|OTHER|Physical effort|The examined athletes will be subjected to an effort on a rowing ergometer, covering a designated distance in the shortest possible time.
224165442|NCT02375880|DRUG|cisplatin|Administered by IV infusion
224165443|NCT06446752|BIOLOGICAL|Bexsero|Administered as an IM injection by 0.5-mL single-dose syringe at enrollment (Visit 1) and 2 months post-enrollment (Visit 3).
224165444|NCT06446752|BIOLOGICAL|Placebo|Administered as an IM injection by 0.5-mL single-dose syringe at enrollment (Visit 1) and 2 months post-enrollment (Visit 3).
224165445|NCT04300946|DEVICE|TMS targeted on the cerebellum|Impact on EEG performance (preparation wave in temporal tasks) of cerebellar stimulation by MSD in healthy subjects. The contrast between the post-stimulation effects of verrum stimulation and placebo stimulation will indicate the magnitude of the effect and will allow us to optimize the type of protocol that may be useful in schizophrenia.
224165446|NCT05628194|OTHER|Observational/Survery|MSM participants will complete a one-time survey, delivered in an e-format. Survey will be accessible via Meta-based social media platforms (Facebook, Instagram).
224165447|NCT03728881|BIOLOGICAL|Quadrivalent Human Papillomavirus (types 6, 11, 16, 18) Recombinant Vaccine|Given IM
224165448|NCT03728881|BIOLOGICAL|Recombinant Human Papillomavirus Bivalent Vaccine|Given IM
224165449|NCT05718557|DRUG|PYX-106|Intravenous (IV) infusion
224165450|NCT05547620|DEVICE|LIFUS Online Real|Stimulation using NeuroFUS device while standing
224165451|NCT05547620|DEVICE|LIFUS Online Sham|Stimulation using NeuroFUS device while standing
224165452|NCT05547620|DEVICE|LIFUS Offline|Stimulation using NeuroFUS device prior to standing
224165453|NCT05507541|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
224165454|NCT05507541|PROCEDURE|Computed Tomography|Undergo PET/CT or CT scan
224165455|NCT05507541|DRUG|Ontorpacept|Given IV
224165456|NCT05507541|BIOLOGICAL|Pembrolizumab|Given IV
224165457|NCT05507541|PROCEDURE|Positron Emission Tomography|Undergo PET/CT scans
224165458|NCT05507541|DRUG|Maplirpacept|Given IV
224305186|NCT00003174|DRUG|bryostatin 1|
224305187|NCT00003174|DRUG|cladribine|
224305188|NCT01270165|DRUG|telbivudine|600mg, oral daily over 12 months
224305189|NCT03560986|DRUG|Neridronic acid 100 mg|100 mg neridronic acid supplied in glass vials in 8 mL of excipients.
224305190|NCT03560986|DRUG|Placebo|Glass vials with matching placebo.
224305191|NCT02807168|OTHER|NT-proBNP (Cardiac Biomarkers)|
224305192|NCT00708786|DEVICE|ICD|Ventricular arrhythmia treatment
224305193|NCT00708786|DEVICE|CRT-D|Ventricular arrhythmia treatment
224305194|NCT04060043|DRUG|Goserelin Acetate|The Pepti 10.8mg (goserelin acetate) implant is supplied as a cylindrical rod of biodegradable and biocompatible D, L Lactic and glycolic acids copolymer. Each implant contains goserelin acetate equivalent to 10.8mg of goserelin as well as a blend of high and low molecular weight range of D, L lactic and glycolic acids copolymer to total a weight of approximately 36.0mg per depot. The implant will be injected subcutaneously through the patient's anterior abdominal wall.
224165459|NCT05507541|PROCEDURE|Biopsy|Undergo tumor biopsy
224165460|NCT03149029|DRUG|Pembrolizumab|Pembrolizumab is a type of antibody that inhibits the cancer cell growth
224305195|NCT02183207|PROCEDURE|Percutaneous Endoscopic Gastrostomy|Percutaneous Endoscopic Gastrostomy by introducer method via visualization through E.G. ScanTM
224165461|NCT03149029|DRUG|Dabrafenib|Dabrafenib is also a cell inhibitor and works by stopping the cancer cell from duplicating
224165462|NCT03149029|DRUG|Trametinib|Trametinib is a cell inhibitor that binds to the cancer cells to inhibit the cancer cells' signals to decrease cell growth
224165463|NCT04657432|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|MagVenture MagPro TMS System would be utilized to deliver 3-minute sessions of intermittent theta burst to left dorsolateral prefrontal cortex.
224165464|NCT06245044|BEHAVIORAL|No MI Help|Participants will complete the medication verification task without any MI help
224165465|NCT06245044|BEHAVIORAL|Scenario #1|Participants will receive MI in the form of a pop-up message if their decision differs from the MI's determination.
224165466|NCT06245044|BEHAVIORAL|Scenario #2|MI help will be displayed concurrently with the filled and reference images.
224165467|NCT04574570|DEVICE|High Tibial Osteotomy|Personalised High Tibial Osteotomy (HTO) using a patient-specific fixation plate (TOKA®)
224165468|NCT04270565|BEHAVIORAL|In-Field Gait-Training|The intervention will deliver a series of vibrations on the participants' wrists through the Garmin when the sensors indicate that their contact time in milliseconds exceeds a threshold. The runners will be asked to reduce the amount of time their foot is in contact with the ground by picking their feet up more quickly. Participants will also receive a series of exercises based on noted impairments at baseline. The feedback during running will be completed twice per week for four weeks.
224165469|NCT04270565|BEHAVIORAL|Home Exercise|Participants will receive a series of exercises based on noted impairments at baseline. Exercises will be completed twice per week for four weeks.
224165470|NCT06792461|BEHAVIORAL|Physical activity and nutritional behavioural intervention|"The ePro-Schools intervention includes two digital platforms designed to promote physical activity and healthy nutrition among adolescents:~1. The Intervention Platform, which provides interactive content for both students and PE teachers.~2. The Information Platform, which offers educational resources for students, teachers, and families.~The intervention content-currently being refined through a co-creation process-will feature engaging modules focused on physical activity and healthy eating. Adolescents will have access to more than 15 interactive modules, while PE teachers will benefit from 8 targeted pedagogical modules aimed at enhancing their lessons and encouraging greater student participation in physical activity.~Control group will have access to the information platform"
224165471|NCT03145506|DEVICE|Multimodal Spectroscopy|optical measurement of excised tissue
224165472|NCT03630185|DEVICE|Custom-manufactured compression hosiery (Isobar)|The custom-fitted garment is manufactured specifically for each patient based on measurements taken with a 3-dimensional volumetric laser scan of the extremity, and can be sized individually to each limb.
224165473|NCT03630185|DEVICE|Off-the-rack stockings (Sigvaris)|Currently available off-the-rack compression hosiery are manufactured in eight fixed sizes (S-XLFC) that cannot be varied in size over their length to accommodate unusual anatomic patterns (eg., small ankle with large calf or vice versa) and may not achieve a comfortable fit that meets the compression goal over a uniform distribution of the limb.
224165474|NCT02079415|OTHER|Prevention of complications in infants of diabetic mothers|strict glycemic control in diabetic pregnancies
224165475|NCT03140267|DIAGNOSTIC_TEST|Difficult to wean patients|Subjects will be following during 18 hours in an invasive mechanical ventilation in a controlled mode. After failure of first single breath trial during 2 hours and presence of sevrability criterias defined by the European consensus conference in 2007, Maximal Inspiratory Pressure and Peak Pressure will be measure.
224165476|NCT00141167|DRUG|varenicline|
224165477|NCT05211492|OTHER|Questionnaire|Patients are asked to fill in an online questionnaire concerning their postoperative pain.
224165478|NCT02986165|DIETARY_SUPPLEMENT|Placebo control|The placebo control is water containing a commercially available orange flavoured powder (Kool aid) which will be diluted according to the manufacturer's instructions
224165479|NCT02986165|DIETARY_SUPPLEMENT|Low dose pomace extract|Immediately prior to ingestion, 'drinks' containing 1 g of tomato pomace extract will be prepared at the research facility. The water used to dilute the extract will be flavoured using a commercially available orange flavoured powder (Kool aid) which will be diluted according to the manufacturer's instructions before adding to the tomato pomace extract.
224305196|NCT02355483|DEVICE|Unenhanced abdominal Computed Tomography|Systematic Unenhanced abdominal Computed tomography
224305197|NCT02958982|DRUG|RP3128|Participants will receive single oral dose of RP3128 in SAD, multiple dose in MAD AND POC
224165480|NCT02986165|DIETARY_SUPPLEMENT|High dose pomace extract|Immediately prior to ingestion, 'drinks' containing 2.5 g of tomato pomace extract will be prepared at the research facility. The water used to dilute the extract will be flavoured using a commercially available orange flavoured powder (Kool aid) which will be diluted according to the manufacturer's instructions before adding to the tomato pomace extract.
224165481|NCT03908463|DEVICE|Percutaneous coronary intervention|All coronary intervention procedures will be performed according to current standard techniques.
224165482|NCT04833140|DRUG|Estradiol patch|The patch will provide 100mcg of estradiol daily.
224165483|NCT04833140|DRUG|Placebo|Placebo patch will contain no estradiol.
224165484|NCT00382044|DRUG|Eprex; Neorecormon; Aranesp|
224165485|NCT02375529|PROCEDURE|Single Incision Laparoscopic Cholecystectomy (SILC)|A 2.5-cm incision is made through the everted umbilicus down to the midline fascia, and through the fascia and the peritoneum. The multichannel port (Olympus) is introduced. Carbon dioxide is insufflated (12 mmHg) and a 30 degree 10-mm laparoscope is introduced. The operating table is put in the reverse Trendelenburg position (20 degrees), left side down. A pre-curved grasper and the monopolar electrocautery are introduced through the other 2 ports of the trocar and the dissection of the gallbladder starts in a retrograde manner. The triangle of Calot is exposed, the cystic duct and artery are separately dissected and ligated with 5 mm clips. The monopolar electrocautery is used to remove the gallbladder from the liver bed. The gallbladder is removed along with the port system from the abdominal cavity. The fascia at the port site is closed and the umbilicus is inverted.
224305198|NCT02958982|DRUG|Placebo|Participants will receive single oral dose of RP3128 in SAD, multiple dose in MAD AND POC
224305199|NCT03870282|BEHAVIORAL|Sleep Extension|The intervention is designed to test if sleep tips delivered by text messages can aid with reaching sleep targets. And if additional motivational text messages can further aide with reaching sleep targets.
224165486|NCT02375529|PROCEDURE|Four Ports Laparoscopic Cholecystectomy (4PLC)|"An 11-mm periumbilical port, a 10-mm left upper quadrant port , 5mm subxyphoid port, and 5-mm right lower quadrant port were used in 4-port LC. We adopted the single surgeon technique in the 4-port LC using 30-degree operating telescopes that was inserted into the umbilical port. Retraction of the gallbladder was done by the long grasping forceps through the 5-mm right lower quadrant port, whereas dissection was accomplished through the 10-mm left upper quadrant port. The cystic duct and cystic artery were clipped by a 5-mm multiple clip applicator. The gallbladder was retrieved through the umbilical port after the position of the operating telescope was changed.~Nontransparent surgical adhesive tape was applied to the standard 4-port sites at the end of the operation ."
224165487|NCT04461457|COMBINATION_PRODUCT|211-astatine MX35 F(ab')2|Alpha emitting radionuclide 211At conjugated to monoclonal antibody MX35 F(ab')2. Targeting the sodium phosphate transporter (NaPi2b).
224165488|NCT04088331|DEVICE|AMS 800 Artificial Urinary Sphincter|The AMS 800 Artificial Urinary Sphincter (AUS) is an implantable, fluid filled, solid silicone elastomer device used to treat stress urinary incontinence due to reduced urethral/bladder outlet resistance (intrinsic sphincter deficiency). It is designed to restore the natural process of urinary control. The device simulates normal sphincter function by opening and closing the urethra under the control of the patient.
223479182|NCT07103889|BEHAVIORAL|Spartacus Test|The Spartacus test was conducted on a 750 m (75 × 10 m) rectangular course marked with cones at regular intervals to indicate different speeds (from 7 to 18 km/h). Each participant began running at 7 km/h, with speed increasing by 1 km/h every three minutes.During the 3-minute intervals (for each speed stage), participants had 15 seconds to reach the corresponding marker, followed by 15 seconds of rest. Participants had to adjust their running pace to reach the target cone in synchrony with an audio signal. The test ended when a participant failed to reach the next cone within the given time. This test is validated for assessing maximal aerobic capacity (MAS) in obese adolescents. During the Spartacus test, maximal heart rate (HRmax) was recorded using a heart rate monitor (S810; Polar, Kempele, Finland).
223479183|NCT05441306|DEVICE|Personal Health Library (PerHL) + MyChart|Participants randomized to the PerHL arm will have access to PerHL + the standard of care patient portal (Epic®MyChart).
223479184|NCT05441306|DEVICE|Epic®MyChart|Participants randomized to the control arm will receive the standard of care patient portal (Epic®MyChart).
223479185|NCT06675955|DRUG|Ocrelizumab|Ocrelizumab will be administered according to the regimen in the parent study.
223479186|NCT07112443|BIOLOGICAL|NVD003|Bone correction and grafting surgery
223479187|NCT07112443|PROCEDURE|Iliac Crest Bone Graft|"Either a single-stage Grafting Surgery with internal fixation and cross-union or the 2-stage induced membrane Grafting Surgery approach, depending on the surgeon's own standard of care."
223479188|NCT00315341|DRUG|Buprenorphine/naloxone|Participants receive up to 16 mg BUP/4 mg NX on day 1 and up to 32 mg BUP/8 mg NX on day 2. It is recommended that dose changes be made in 2 to 8 mg increments, with the range of allowable daily doses between 2 mg and 32 mg starting on day 3 and thereafter according to clinical impression and depending upon the participant's clinical need.
223479189|NCT00315341|DRUG|Methadone|Participants will receive a maximum of 30 mg for the first dose and a maximum of 40 mg on Day 1. It is recommended that participants receive a dose on day 2 that is 10 mg higher than their total day 1 dose, and a dose on day 3 that is 10 mg higher than their total day 2 dose, unless, in the clinical judgment of the physician, a slower induction is needed. Doses will be adjusted on Day 4 and thereafter according to clinical impression and depending upon the participant's clinical need with no specific upper limit.
223479190|NCT06934785|PROCEDURE|IUI or intercourse|5 milligrams LE per day (Femara® 2.5 milligrams, Novartis, Switzerland) and 50 milligrams CC (Duinum 50 milligrams, Medochemie, Cyprus) or 5 milligrams LE per day (Femara® 2.5 milligrams, Novartis, Switzerland) will be started on the second to the fourth day of the cycle, for five consecutive days. An ultrasound will be carried out three days after the last dose of medicine (day 8 of OI) to evaluate ovarian follicles' growth and the endometrium's thickness. If the follicular diameter reach ≥14 millimetres, check-up will be planned every two days until it reaches 18 millimetres. If there is the appearance of at least one follicle reaching 18 millimetres or more, a human chorionic gonadotropin (hCG) injection (IVF-C 5000 IU, LG Life Science, Korea) will be administered on the same day of the ultrasound in order to induce ovulation. IUI will be scheduled 36 - 38 hours after hCG injection or intercourse will be scheduled in the next day.
223479191|NCT06928246|DRUG|Onabotulinum Toxin Type A - Phase 1b|The lesions receiving Botulinum toxin will get five 0.1 mL intradermal injections of 5 units of Botulinum toxin which equates to 25 units per lesion and 50 units per patient.
223479192|NCT06928246|DRUG|Onabotulinum Toxin Type A - Phase 2|The lesions receiving Botulinum toxin will get five 0.1 mL intradermal injections of 5 units of Botulinum toxin which equates to 25 units per lesion and 75 units per patient.
223479193|NCT00661388|DRUG|methoxy polyethylene glycol-epoetin beta [Mircera]|sc every month (starting dose 1.2 micrograms/kg)
223479194|NCT07140770|DEVICE|Fitbit|"You will wear the tracker on your wrist like a watch and it will continuously (non-stop) monitor your activity, sleep, and heart rate.~Functional testing will be completed with a research team member and will consist of 2 tests: testing your grip strength by having you squeeze a measuring device 3 times with your dominant hand and measuring how many minutes it takes for you to walk 15 feet."
223479195|NCT07140770|OTHER|Questionnaire|Complete questionnaires at 3 timepoints, at the time of enrollment on the day of allogeneic hematopoietic cell transplantation, 8 days after allogeneic hematopoietic cell transplantation, and 7 days after hospital discharge.
223479196|NCT05162742|DRUG|Colchicine|ATC: M04AC01
223479197|NCT05162742|DRUG|Placebo|Placebo tablets
223584344|NCT05141955|OTHER|Group Quadratus Lumborum Block (QLB)|"Patients will receive general anesthesia initially then bilateral QLB with a total volume of (0.3-0.4 ml/kg LBW) of bupivacaine 0.25% will be performed not exceeding toxic dose150 mg "
223584345|NCT05141955|OTHER|Group (C) (Control group)|Where patients will be operated under general anesthesia.
223584346|NCT01565941|DRUG|Insulin|IV insulin titration to target a blood glucose of 80-110 mg/dL
223584347|NCT01565941|DRUG|Insulin|IV insulin titration to target a blood glucose of 150-180 mg/dL
224165489|NCT01451567|BEHAVIORAL|Ergonomic plan|participants in the intervention group were evaluated by the REBA and received an overall coaching that stretched over four meetings Each session paid special attention to, and included explanations about, the anatomy and physiology of body regions
224165490|NCT03278925|PROCEDURE|Biopsy|Undergo biopsy
224165491|NCT03278925|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
224165492|NCT03278925|PROCEDURE|Computed Tomography|Undergo CT
224165493|NCT03278925|DRUG|Defined Green Tea Catechin Extract|Given PO
224165494|NCT03278925|OTHER|Laboratory Biomarker Analysis|Correlative studies
224165495|NCT03278925|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
224165496|NCT03278925|OTHER|Pharmacological Study|Correlative studies
224165497|NCT03278925|OTHER|Questionnaire Administration|Ancillary studies
224165498|NCT03278925|PROCEDURE|Ultrasound|Undergo ultrasound
224165499|NCT05942872|OTHER|This is a non-interventional study. We will collect clinical data exclusively, and will do so by reviewing all available patients clinical records.|This is a non-interventional study. We will collect clinical data exclusively, and will do so by reviewing all available patients clinical records.
224165500|NCT04582539|DRUG|INCB000928|INCB000928 will be administered once daily.
224165501|NCT05685849|DEVICE|Echocardiography|Maternal and fetal echocardiography：Time points for heart image acquisition in pregnant women: As per the Guidelines for Pre-pregnancy and Pregnancy Health Care (2018) formulated by the Obstetrics Group of the Gynecology Branch of the Chinese Medical Association, a total of five echocardiographic examinations will be performed in the first trimester(11-14 weeks of gestation), the second trimester(20-24 weeks of gestation), the third trimester(29-32 weeks of gestation), prenatal term (37-40 weeks of gestation), and 3-6 months after delivery. Time points for fetal heart image acquisition: Fetal heart images will be collected in the second trimester(20 to 24 weeks of gestation).
224165502|NCT01994109|DRUG|MYOBLOC|"MYOBLOC (rimabotulinumtoxinB) Injection, or botulinum toxin type B, is the B serotype of botulinum toxin. It is the only commercially available B serotype, and also the only available botulinum toxin that does not require reconstitution for use."
224165503|NCT01994109|OTHER|PLACEBO|
224165504|NCT06488014|PROCEDURE|Erector spina plan block (ESP)|"In both groups, the relevant methods will be applied at the level of the surgical incision before the surgical incision (pre-emptive) after the patient is asleep and before the patient wakes up at the end of surgery.~The dose of local anaesthetic to be administered is the same for both groups.~Drug content to be administered\*: total 25 cc volume (13.5 ml 0.5% bupivacaine + 5 ml 2% lidocaine + 1.5 ml morphine (morphine diluted with 0.9% NaCl to 1mg/ml) + 5 ml 0.9% NaCl) (These doses are the routine doses applied in such surgeries in our clinic)~\* Local anaesthetic drug doses in regional anaesthesia: source: Kirk, P. H. I. I. L. I. I. P. P., \& Berde, C. B. (2020). Local anaesthetics. Miller's Anaesthesia. 9th ed. Philadelphia: Elsevier Inc, 878-9."
224165505|NCT06488014|PROCEDURE|Paravertebral block|"In both groups, the relevant methods will be applied at the level of the surgical incision before the surgical incision (pre-emptive) after the patient is asleep and before the patient wakes up at the end of surgery.~The dose of local anaesthetic to be administered is the same for both groups.~Drug content to be administered\*: total 25 cc volume (13.5 ml 0.5% bupivacaine + 5 ml 2% lidocaine + 1.5 ml morphine (morphine diluted with 0.9% NaCl to 1mg/ml) + 5 ml 0.9% NaCl) (These doses are the routine doses applied in such surgeries in our clinic)~\* Local anaesthetic drug doses in regional anaesthesia: source: Kirk, P. H. I. I. L. I. I. P. P., \& Berde, C. B. (2020). Local anaesthetics. Miller's Anaesthesia. 9th ed. Philadelphia: Elsevier Inc, 878-9."
224165506|NCT06442514|BEHAVIORAL|PASS-IVR|An intervention that includes a proactive telehealth intervention combining evidence-based smoking cessation counseling augmented with behavioral approaches for coping with pain, and nightly Interactive Voice Response (IVR) calls to report smoking status, pain, and pedometer-measured step counts, which the clinician will use to provide individualized feedback.
223479198|NCT01268995|DRUG|Cyclosporine A|"Patients randomized into arm A will be switched from Tacrolimus to Cyclosporine A. Conversion will be done by a stop and go protocol. Patients will take their last dose Tacrolimus in the morning of the day of conversion and will start taking Cyclosporine A in the evening of the same day at a dose of 3mg/kg/d. The first measurement of Cyclosporine A trough levels will be performed 3 days after conversion and the dose will then be adjusted if necessary. Furthermore, treatment with NPH insulin once daily in the morning will be initiated."
224165507|NCT06442514|OTHER|Treatment as Usual|Referral to the local smoking cessation VA clinic.
224165508|NCT03233308|DRUG|Netarsudil Ophthalmic Solution 0.02%|1 drop daily (QD), in the morning (AM) Netarsudil Ophthalmic Solution 0.02% administered to one eye and Placebo comparator to the contralateral eye
224165509|NCT03233308|OTHER|Placebo Comparator|1 drop daily (QD), in the morning (AM) of Placebo comparator administered to one eye and Netarsudil Ophthalmic Solution 0.02% to the contralateral eye
223479199|NCT01268995|DRUG|Tacrolimus|Patients in arm B will remain on their immunosuppressive therapy with Tacrolimus. Furthermore, treatment with NPH insulin once daily in the morning will be initiated.
224165510|NCT06028178|DIAGNOSTIC_TEST|Droplet digital PCR|Droplet digital PCR has potential in resolving polymicrobial infection because it simultaneously achieves unprecedented high sensitivity , high specificity, and absolute quantification without the need for a standard curve.
224165511|NCT03659708|PROCEDURE|Lyon-VTE score|follow-up at 3 months, 5 months, 7 months during pregnancy and 3 months and 12 months after delivery.
224165512|NCT03659708|PROCEDURE|recommendations currently available|follow-up at 7 months during pregnancy and 3 months and 12 months after delivery.
224165513|NCT03491852|BEHAVIORAL|BOOST Intervention|A cognitive and behavioural group therapy designed to reduce self-stigma and promote effective communication skills for adults (16-65 years old) experiencing a first episode of psychosis.
224165514|NCT03491852|BEHAVIORAL|Waitlist Control|Participants on the waitlist will still receive treatment as usual, which includes medical, psychosocial, and occupational interventions to help maximize patients' integration within the community and support recovery from a first episode of psychosis.
224165515|NCT03082066|OTHER|CT or MRI scan|CT or MRI performed for underlying disease. CT and MRI scans used to asses bone and soft tissue diameter
224165516|NCT01172054|BIOLOGICAL|VAX128|one IM injection
224165517|NCT01172054|BIOLOGICAL|Placebo|One IM injection
224305200|NCT02642848|PROCEDURE|HTO with microfracture|High tibial osteotomy(HTO) with micro fracture on femoral condyle is an common treatment for the correction of malalignment of the knee treating osteoarthritis. Device: Tomofix
224305201|NCT02642848|PROCEDURE|Transplantation of bone marrow stem cell|Transplantation of autologous bone marrow cell concentrate using BMAC collecting from iliac bone. Bone marrow cell cell 6cc
224165518|NCT02548091|OTHER|Blood samples for assays of plasma inflammatory markers (cytokines InterLeukin-6, InterLeukin-8, InterLeukin-10)|"The same amount of blood sample is collected from both arms of study at the same time of the procedure.~In each patient, in the per procedure period, a total of 50 milliliters of blood sample is drawn from the pulmonary circulation downstream and upstream of obstructive lesion, the trunk of pulmonary artery, the superior vena cava and the femoral arterial line prior to angioplasty and at the end of procedure; in the post interventional care unit 10 milliliters of blood sample will be draw daily from the superior vena cava catheter line and femoral arterial line."
224165519|NCT02548091|PROCEDURE|Non invasive ventilation|
224165520|NCT02548091|PROCEDURE|monitoring system Pulse-Induced Contour Cardiac Output (Picco)|
224165521|NCT02548091|PROCEDURE|Computed tomography (CT)|
224165522|NCT01165294|DRUG|Placebo|An intravenous bolus will be given in 5 minutes time followed by a 1 minute break after which a continuous infusion will start. Dosage lowered every 10 minutes
223584348|NCT04395287|BEHAVIORAL|Leisure screen time|Questionnaire-based assessment of typical amount of time per week spent using screen-based media devices during leisure, assessed at two time points. Continuously scaled in main analyses; a difference is computed (18-month follow-up value minus baseline value). Additionally, screen time amount at the two time points will be scaled categorically, according to being classified as low or high according to WHO criteria for preschool children (Low (recommended): \<=1 hour/day, high: \>1 hour/day): High-high, high-low, low-high, and low-low.
224165523|NCT01165294|DRUG|ketamine|An intravenous bolus of 0.1 mg/kg will be given in 5 minutes followed by a 1 minute break after which a continuous infusion will start at 0.015625 mg/kg/min.
224165524|NCT00564265|OTHER|Observation|Not applied
223584349|NCT05367141|OTHER|"CDSS (MedicBK)"|"Clinical decision support system (MedicBK) is a computer-based program that analyzes published evidence and provides prompts and reminders to assist health care providers in implementing clinical guidelines and science-based medicine at the point of care."
223584350|NCT03470363|DRUG|Sevoflurane Volatile Liquid|
223584351|NCT03470363|DRUG|Bupivacaine / SUFentanil|
223584352|NCT01884415|BIOLOGICAL|HBV vaccine|Patients receive a second cycle of vaccination
224165525|NCT04715659|DIAGNOSTIC_TEST|Performance of step test (number of steps) for the assessment of exercise capacity|"The development of the step test will be designed according to the characteristics of other validated field tests - the walking tests (6-minute walk test and the incremental shuttle walking test) The step test will be performed on a 20 cm tall, single-step device with no handles. The criteria for stopping the test will be the same as described in standard operating procedures for the walking field tests, with the addition of the inability to follow the work rate for a period of 10 seconds.~The main outcome of the test will be the highest number of steps and work rate achieved."
224165526|NCT06127108|DIAGNOSTIC_TEST|Panbio™|The Panbio™ COVID-19/Flu A\&B Panel is a visual lateral flow in vitro immunoassay for the qualitative detection of the nucleocapsid protein antigen to SARS-CoV-2, Influenza A, and Influenza B in anterior nasal swab samples from individuals with symptoms and suspected of COVID-19 or Flu infection by their healthcare provider.
224165527|NCT00506740|DEVICE|Ultrasonic scalpel|A surgical instrument that uses ultrasonic energy that allows both cutting and coagulating at the precise point of application.
224165528|NCT00506740|DEVICE|monopolar electrosurgery generator and tip|
224165529|NCT06645834|DEVICE|Smart MDI System|"The Smart MDI system consists of the InPen™ system and Simplera™ system.~The InPen™ system includes a reusable smart bolus insulin pen injector with Bluetooth combined with the InPen™ app to help users take insulin doses.~And InPen™ app which communicates with the InPen™ injector and compatible continuous glucose monitoring (CGM) devices to collect and display information on insulin delivered by the injector as well as current and past glucose values.~The Simplera™ system consists of a disposable integrated sensor-transmitter platform (Simplera™ Sensor) and the Simplera™ app which receives data from the Simplera™ sensor via Bluetooth Low Energy (BLE) radio signal"
224165530|NCT04642274|OTHER|Preoperative Strategies|Patient Education Preoperative Oral Carbohydrate Loading Nutritional Optimization Glycemic Control Anemia Correction Preoperative Hair Removal
224165531|NCT04642274|OTHER|Intraoperative Strategies|Anesthetic Technique (Multimodal Analgesia) Antibiotics Glycemic Control Blood Transfusion Blood Conservation Optimization of Hemodynamics Protective Lung Ventilation Strategy Optimization of Anesthetic Depth Optimization of CPB Management
224165532|NCT04642274|OTHER|Postoperative Strategies|Postoperative Analgesia Temperature Management Renal Protection Glycemic Control Early Extubation Early Oral Intake Maintain Drain Patency and Early Removal Early Ambulation Thromboprophylaxis
224165533|NCT00976963|DRUG|TMP/SMX|Take one twice daily for 3 days for urinary tract infection
224165534|NCT00976963|DRUG|Fosfomycin|Mix sachet with 1/2 glass cold water and stir. Drink immediately
224165535|NCT04587973|PROCEDURE|Group Dexmedetomidine|Ropivacaine plus dexmedetomidine group
223584353|NCT01884415|BIOLOGICAL|HBV vaccine|Patients receive vaccination according to the guidelines.
223584354|NCT03262116|DRUG|Humalog|Subjects will participate in one week of wearing the insulin only bionic pancreas using humalog as the rapid acting insulin.
223584355|NCT03262116|DRUG|Novolog|Subjects will participate in one week of wearing the insulin only bionic pancreas using novolog as the rapid acting insulin.
223584356|NCT03262116|DRUG|BC222 insulin lispro|Subjects will participate in one week of wearing the insulin only bionic pancreas using BC222 insulin lispro as the rapid acting insulin.
223584357|NCT03262116|DEVICE|Bionic Pancreas|The insulin-only bionic pancreas will be used in all three arms of the study
223584358|NCT02365285|DRUG|Galantamine|16 mg po prior to the infusion of intralipid
223584359|NCT02365285|DRUG|Placebo Oral Capsule|Placebo oral capsule prior to the infusion of intralipid/heparin
223584360|NCT02365285|DRUG|Intralipid|Intralipid 20% will be infused at 0.8 mL/m2/min for 4h after oral placebo or Galantamine
223584361|NCT02365285|DRUG|Heparin|heparin bolus of 1000 U will be followed by 200 U/h infusion for 4h after oral placebo or Galantamine
224165536|NCT04587973|PROCEDURE|Group Ropivacaine|Plain ropivacaine group
224165537|NCT04587973|PROCEDURE|Group Control|Control group
224165538|NCT00060567|DRUG|E7070 + irinotecan combination|Escalating doses starting from 125 mg/m2 irinotecan plus 250 mg/m2 E7070 combination.
224165539|NCT00060567|DRUG|Irinotecan + E7070 combination|Escalating doses starting from 100 mg/m2 irinotecan plus 400 mg/m2 E7070 combination.
224165540|NCT00060567|DRUG|Irinotecan + E7070 combination|Escalating doses starting from 100 mg/m2 irinotecan plus 400 mg/m2 E7070 combination.
224165541|NCT05459519|DRUG|Dengzhanxixin Capsule plus Placebo Capsule|Dengzhanxixin Capsule, 0.54g (3 capsules) each time, twice daily; placebo, 1 capsule, twice daily
224165542|NCT05459519|DRUG|Placebo|Placebo, 4 capsules each time, twice daily
224165543|NCT05459519|DRUG|Dengzhanxixin Capsule plus Placebo Capsule|Dengzhanxixin Capsule, 0.72g (4 capsules) each time, once daily; placebo, 4 capsules, once daily
224165544|NCT04124224|OTHER|Unidos|The investigators will collaborate with our community partners to implement and evaluate a Community-Clinical Linkage (CCL) model in which Community Health Workers (CHWs) connect individuals to social determinant and community health services and build sociocultural resilience through CHW-facilitated individual and group support. As a public health practice-based study that incorporates evidence-based strategies, the investigators seek to establish Unidos effectiveness in Arizona counties with the highest percentage of Latinos of Mexican origin (Yuma, Pima, Santa Cruz, and Maricopa). Unidos CHWs, based in local health departments, will use evidence-based strategies to address three elements that are important in addressing chronic disease risk: 1) health promotion resources and programs; 2) individual and group-based social support; and 3) leveraging community resources to address social determinants of health.
224165545|NCT01775800|OTHER|Treatment modification|
224165546|NCT01755260|OTHER|Jejunostomy tube feeding|The patients at this arm receive the nutritional support through the feeding jejunostomy tube; they can only eat or sip water through mouth
224165547|NCT00622570|DRUG|Pentobarbital|10 mg/kg in 30 minutes; then 5 mg/kg/h during 3 hours; then 1 mg/kg/h
223479200|NCT06894810|OTHER|Decision-aid|Decision Aids (DA) are evidence-based clinical tools developed for patients to supplement clinicians' discussions and facilitate difficult preference-sensitive decisions. They are the gold standard approach (recommended by the Australian Commission of Safety and Quality in Healthcare) to facilitate complex healthcare decisions where there is more than one reasonable choice and where patients may value benefits and risks differently.
223584362|NCT02968914|BIOLOGICAL|Benralizumab|A humanized, afucosylated, monoclonal antibody (mAb) that binds specifically to the human IL-5 receptor alpha subunit (IL-5Rα) on the target cell.
223584363|NCT02968914|BIOLOGICAL|Benralizumab|A humanized, afucosylated, monoclonal antibody (mAb) that binds specifically to the human IL-5 receptor alpha subunit (IL-5Rα) on the target cell.
224165548|NCT00622570|DRUG|thiopental|"2 mg/kg in bolus; if ICP is not below 20 mmHg then 3 mg/kg in bolus; if ICP is not below 20 mmHg it can be administrated a third bolus of 5 mg/kg.~Maintenance: 3 mg/kg/h in perfusion"
224165549|NCT05668325|OTHER|Mini trampoline exercise group|In this study, patients performed a 30-45 minute mini-trampoline exercise program 3 times a week for eight weeks (two months) under the supervision of the investigator.
224165550|NCT05668325|OTHER|Control group|In this study, patients were visited at home once a week for eight weeks and their feet were checked.
224165551|NCT02331654|OTHER|Experimental treatment|Anodal DC stimulation (2 mA, 20 min) will be delivered by a constant direct current electrical stimulator connected to a pair of electrodes
224165552|NCT02331654|OTHER|Placebo treatment|Electrodes will be placed as for active stimulation, but the stimulator will automatically turn off after 10 s
224165553|NCT03030014|BEHAVIORAL|educational programm|Oral health education will be done for children and their care givers about various diseases affecting the oral cavity, the effects of bad oral hygiene and tooth decay, importance of tooth brushing, and correct methods of tooth brushing.Three follow up examination is assessed after one week, three weeks and six weeks using questionnaire for evaluation of participant satisfaction about oral health and using OHIS index for evaluating the effect of the dental educational program on the oral health status of deaf children.
224165554|NCT03030014|OTHER|no educational program|without oral health education will be done for children and their care givers about various diseases affecting the oral cavity, the effects of bad oral hygiene and tooth decay, importance of tooth brushing, and correct methods of tooth brushing.Three follow up examination is assessed after one week, three weeks and six weeks using questionnaire for evaluation of participant satisfaction about oral health and using OHIS index for evaluating the effect of the dental educational program on the oral health status of deaf children.
224165555|NCT03234270|DEVICE|Core temperature measurements|Core temperature measurements with coretemp pill
224165556|NCT01328769|DRUG|Febuxostat|
224165557|NCT01328769|DRUG|Placebo|
224165558|NCT04967911|OTHER|Rhythmic stabilization exercises|"PNF techniques and Conventional Treatment:~Experimental group received rhythmical Stabilization Technique on shoulder joint on all shoulder movements up to 1 minute in supine position For stability of joint ,re-establish dynamic rotator cuff stability and to enhance MS strength and decrease pain.~Conventional Treatment: heating pad for 15 minutes, TENS (Transcutaneous Electrical Nerve Stimulation) and after that shoulder stretching of upper trapezius muscle, pectorals and levator scapule and isometric exercises of rotator cuff muscles performed in supine .( 10 sec hold and 10 to 15 reps).."
224165559|NCT04967911|OTHER|conventional treatment|Conventional Treatment: heating pad for 15 minutes, TENS (Transcutaneous Electrical Nerve Stimulation) and after that shoulder stretching of upper trapezius muscle, pectorals and levator scapule and isometric exercises of rotator cuff muscles performed in supine .( 10 sec hold and 10 to 15 reps)..
224165560|NCT01688999|DRUG|Cabozantinib|60 mg by mouth (PO) daily each 28 day cycle. Treatment continues until toxicity or disease progression.
223479201|NCT06941194|DEVICE|PICO 14|PICO 14 application after neoadjuvant radiotherapy followed by surgery
223584364|NCT00276627|BEHAVIORAL|communication lecture|lecture on communication skills with oncology patients
223584365|NCT00276627|BEHAVIORAL|lecture plus CD-ROM|Interactive CD-ROM about responding to patients' negative emotions. The CD-ROM included tailored feedback on the oncologists' own recorded conversations.
223479202|NCT06945250|OTHER|Experimental Audio Visual|Participants in this group will receive the audiovisual presentation
223479203|NCT04240314|BIOLOGICAL|scAAV9.U7.ACCA|A single dose of scAAV9.U7.ACCA will be systemically delivered via a peripheral vein injection.
223479204|NCT07145229|DRUG|ABP-745 Dose A|ABP-745 Dose A + Colchicine placebo - tablets (PO)
223479205|NCT07145229|DRUG|ABP-745 Dose B|ABP-745 Dose B + Colchicine placebo - tablets (PO)
224165561|NCT02768103|BEHAVIORAL|task-based training|The 10-week training program is designed to incorporate requirements of motor learning and includes activities that require learning to coordinate the transferred Br with other synergists by producing pinch force in different upper limb postures and in a range of pinch openings. Biofeedback using a pinch dynamometer in self-selected postures provides feedback and knowledge of progress to the participant. A task board is used for practicing task-specific activities such as opening and closing zippers, using a remote, an ATM card, a key, and an electrical plug and focuses on pinch in dynamic conditions that require modulating force and maintaining specific positions. The pinch-pin device requires closing pinch-pins (clothes pin) of variable resistance ranging from approximately 1 to 8 lbs and placing them on rods arranged at different positions in the work space.
224165562|NCT00394693|GENETIC|Adenovirus Interferon gamma|intra-tumoral injections, 1 dose per lesion, up to 6 simultaneous lesions.
224165563|NCT05849545|DEVICE|Garston tool|GT group protocol included the use application of IASTM along with the application of ice therapy at the end of the session. Using the Graston instrument, 20 strokes per minute proximal to distal and 20 strokes per minute distal to proximal for a period of 3 minutes were given over the painful area. Baseline values were recorded for demographics evaluation and episodes of pain onsets. The assessment of patients was done at the initial and last visit before the completion of the treatment program. Three treatment sessions per week were given to each patient for a total of four weeks.
224165564|NCT05849545|PROCEDURE|Neuromuscular Re-education|General stretching and strengthening exercises for the neck muscles. The protocol of treatment for the NMR group included the use of the Neuromuscular re-education soft tissue mobilization technique (NMR) followed by active movements of the patient.
223479206|NCT07145229|DRUG|Colchicine|ABP-745 placebo + Colchicine - tablets (PO)
223479207|NCT07145229|DRUG|Placebo|ABP-745 placebo + Colchicine placebo - tablets (PO)
223479208|NCT06949774|BEHAVIORAL|Daily Text Messages|Participants will receive daily text message reminders to use their routine behavior to trigger medication adherence.
223479209|NCT06949774|BEHAVIORAL|Incentivization based on timely ART adherence|Participants will be eligible to (draw a prize in monthly prize group) or get a monthly prize (monthly escalated group) if they take their medication within +/-one hour of the stated existing routine to which pill-taking is anchored on at least 80% of days for 3-months.
223479210|NCT06952699|DRUG|TAK-360|TAK-360 tablet.
223479211|NCT06952699|OTHER|Placebo|TAK-360 matching placebo tablet.
223479212|NCT07146698|BEHAVIORAL|daily Interruption of Sedation|The patients will be managed by DIS. Richmond agitation and sedation score (RASS) will be used for monitoring the depth of sedation
223479213|NCT07151079|BEHAVIORAL|Trans Adolescent Group ThErapy for Alleviating Minority stress|The intervention, Trans Adolescent Group ThErapy for Alleviating Minority stress (TAG TEAM), is a group Cognitive Behavioural Therapy (CBT) program, originally developed using co-design methodology with trans and gender diverse young people. The 6 weekly, 2-hour session TAG TEAM program aims to improve mental health and wellbeing using evidence-based cognitive and behavioural strategies to target minority stressors discrimination and internalised stigma and facilitating community connection and pride. The intervention will be delivered by a psychologist facilitator and peer facilitator, who will both be trained and supervised by clinical psychologists, to groups of 8 participants from the same stratum.
223479214|NCT07153224|BEHAVIORAL|Peri-operative support measures [mentorship, intraoperative consult, surgical coaching, standard practice (no structured support)]|"Mentorship: Formal (assigned by an institution or via an official program) or informal (personal relationship built during the career pathway) professional guidance relationships that support early-career surgeons in clinical decision-making, technical development, and emotional processing.~Surgical Coaching: Structured, feedback-oriented discussions or sessions aimed at performance enhancement and reflective practice Intraoperative Consultation (IOC): Real-time assistance or second opinions provided by a more experienced surgeon or peers during a surgical procedure Standard practice: the surgeon performs the procedure supported by one or multiple assistants, as per internal hospital protocols and national/local regulations, receiving and providing natural feedback without a structured support system."
223479215|NCT07154628|DRUG|Lidocaine %2 ampoule|During general anesthesia, the anesthesiologist administers 1.5cc of lidocaine spraying on the vocal cords using Terumo SurfloTM I.V. Catheter 20G before intubation.
223479216|NCT07154628|DRUG|Normal Saline (0.9% NaCl)|During general anesthesia, the anesthesiologist administers 1.5cc of normal saline spraying on the vocal cords using Terumo SurfloTM I.V. Catheter 20G before intubation.
223479217|NCT07157163|BEHAVIORAL|Phase 1: standardized nudge messages|Participants receive uniform messages designed to encourage influenza vaccination. These messages, grounded in nudge theory, are delivered through a Chinese online platform to promote vaccination uptake.
223479218|NCT07157163|BEHAVIORAL|Phase 1: personalized nudge messages + chatbot|Participants receive tailored messages designed to encourage influenza vaccination. These messages, grounded in nudge theory, are delivered through a Chinese online platform to promote vaccination uptake. Additionally, they have access to an interactive chatbot to address questions and provide decision-making support for influenza vaccination.
223584366|NCT04660227|PROCEDURE|Exercise Trainning|Participants in the online exercise program group will be given a treatment protocol consisting of aerobic exercise and strengthening exercises in the presence of a physiotherapist for a total of 8 weeks, 2 days a week for 1 hour. Before starting the exercise, the risk of possible injury will be minimized by doing warm-up exercises and preparations will be made to start the exercise. Then, the exercise program will be started with aerobic exercise. Strengthening exercises will be planned for large muscle groups, targeting body parts such as hips, knees, shoulders, abdomen and trunk. In exercises, it is planned to do 2 sets of 10-15 repetitions using elastic band, free weights or body weight. The exercise program will be created according to the condition of the people and progression will be provided every 2 weeks. After the exercises are completed, cool down will be done with relaxation and stretching exercises.
224165565|NCT04574141|DIETARY_SUPPLEMENT|a prolonged release tablet and a spray containing melatonin|prolonged release tablet is dosed at 1.9mg and spray is dosed at 1mg for 2 oral sprays.
224165566|NCT06358976|OTHER|Vibration plus anti-spastic hand splint|vibration stimulation will be applied to the spastic hand antagonistic muscles using a volar anti-spastic hand splint and the Myovolt Arm vibrator.
224165567|NCT06358976|OTHER|Anti-spastic hand splint|the use of anti-spastic hand splint alone.
224165568|NCT06358976|OTHER|Vibration|The use of hand vibrator alone
224165569|NCT01666990|DRUG|TwHF|Taken oral, three times per day, at a dose of 20 mg/time for 48 weeks.
224165570|NCT01666990|DRUG|placebo treatment|Taken oral, three times per day, at a dose of 20 mg/time for 48 weeks.
224165571|NCT05336019|BEHAVIORAL|Diabetes self-management Coaching|A 12-week Diabetes self-management coaching program
224165572|NCT05336019|OTHER|Usual care|Assigned to 12 weeks of usual care which includes a physical examination, history taking,, medication refill, lab investigation, and health education
224165573|NCT04348188|BEHAVIORAL|Education program on healthy habits|6-week supervised educational program with 12-month follow-up compared to the same unsupervised intervention
224165574|NCT06590207|DRUG|plasma rich with WNV neutralizing antibodies|200 ml plasma of the convalescents: produced in the blood bank, from the blood of Sheba workers who participated in the SPRI study (Helsinki 0196-23) and whose blood was found to have neutralizing antibodies to WNV above 1:524. The blood units from the volunteers who will donate will meet all the requirements of a normal blood donation and will only include men or women who were not pregnant, and the units will pass all the tests accepted at the blood bank before donation.
224165575|NCT06590207|DRUG|Saline|Placebo
224165576|NCT05267938|DRUG|Topical Anesthetic|The topical anesthetic used in this experimental is EMLA® after the pre-treatment of the palatal mucosa
224165577|NCT05267938|DRUG|Local anesthetic|After the pre-treatment with microneedles and the use of topical anesthetic, the needle and injection of local anesthetic was inserted and pain was evaluated
224165578|NCT02762045|BIOLOGICAL|Ad5-gag|Ad5-gag is used as vaccine in all arms.
224165579|NCT02762045|BIOLOGICAL|Placebo|Preservation Solution is used as control in all arms.
224165580|NCT01048047|DRUG|aliskiren/amlodipine|aliskiren 300 mg /amlodipine 10 mg
224165581|NCT01962467|DRUG|FF/LEV FDC|Intranasal aqueous microsuspension containing 25.0 microgram (µg) of FF and 50 µg of LEV as a fixed dose combination. It will be administered as two 50 µL sprays per nostril in the morning in a fasted state
224165582|NCT01962467|DRUG|FF|Intranasal aqueous microsuspension containing 27.5µg of FF. It will be administered as two 50 µL sprays per nostril in the morning in a fasted state
224165583|NCT01962467|DRUG|LEV|Intranasal aqueous microsuspension containing 50 µg of LEV. It will be administered as two 50 µL sprays per nostril in the morning in a fasted state
223479219|NCT07157163|BEHAVIORAL|Phase 2: motivational Interviewing|Unvaccinated participants engage in one-on-one motivational interviewing sessions with a trained interviewer.
223479220|NCT07158216|DEVICE|TMS|Active TMS + sham tDCS. All patients will receive language therapy immediately after brain stimulation. The period of treatment will be 6 months, comprising 10 consecutive sessions in two weeks (intensive period) followed by once per week (maintenance period of 22 weeks)
223479221|NCT07158216|DEVICE|tDCS|sham TMS + active tDCS. All patients will receive language therapy immediately after brain stimulation. The period of treatment will be 6 months, comprising 10 consecutive sessions in two weeks (intensive period) followed by once per week (maintenance period of 22 weeks)
223479222|NCT07158216|DEVICE|Sham TMS|Sham TMS. All patients will receive language therapy immediately after brain stimulation. The period of treatment will be 6 months, comprising 10 consecutive sessions in two weeks (intensive period) followed by once per week (maintenance period of 22 weeks)
223479223|NCT07158216|DEVICE|Sham tDCS|Sham tDCS. All patients will receive language therapy immediately after brain stimulation. The period of treatment will be 6 months, comprising 10 consecutive sessions in two weeks (intensive period) followed by once per week (maintenance period of 22 weeks)
223479224|NCT07158060|BEHAVIORAL|Breathing Exercises|Breathing Exercises This intervention
223479225|NCT07149727|OTHER|Standard Care|Environmental temperature control, preoperative psychological counseling, and parent-guided distraction.
224165584|NCT05247060|OTHER|no experimental intervention|There will not be any experimental intervention. The study will be conducted according with normal clinical practice
224165585|NCT03906201|DIETARY_SUPPLEMENT|Ecdysterone|Food supplement of plant origin with pronounced biological activity and potentially hypoglycaemic
224165586|NCT03906201|OTHER|Placebo|no pharmacologic effect
224165587|NCT04104204|DRUG|Intrathecal morphine|0.5% Iso/Hyperbaric bupivacaine 2-3 ml add morphine 0.1 mg for spinal anesthesia
224165588|NCT04104204|DRUG|Ultrasound guided supra-inguinal fascia iliaca block|Ultrasound guided supra-inguinal fascia iliaca block with 0.25% bupivacaine 40 ml and 0.5% Iso/Hyperbaric bupivacaine 2-3 ml without spinal morphine for spinal anesthesia
224165589|NCT02108522|BIOLOGICAL|Multivirus Specific T cells|
224165590|NCT01045876|DRUG|Dexamethasone|One dose of 8 mg of Dexamethasone intravenously at induction of anesthesia
224165591|NCT01045876|OTHER|Placebo|2 ml of 0.9% Saline Solution administered intravenously at induction of anesthesia
224165592|NCT06595576|DRUG|Cannabis - Placebo Dose (0 mg)|Participants will consume placebo cannabis edibles.
224165593|NCT06595576|DRUG|Cannabis - Low Dose (2 mg)|Participants will consume a low dose (2 mg) of cannabis edibles.
224165594|NCT06595576|DRUG|Cannabis - Medium Dose (10 mg)|Participants will consume a medium dose (10 mg) of cannabis edibles.
223479226|NCT07149727|BEHAVIORAL|Immersive Game Experience (IGE)|Standard care plus immersive game experience, including role-playing scenarios (e.g., using dolls to simulate IV puncture), parent-child interactive games, environmental adjustments (children's music, colorful objects), and post-intervention rewards (cartoon stickers).
223479227|NCT07155096|DEVICE|Repetitive Transcranial Magnetic Stimulation|Repetitive Transcranial Magnetic Stimulation (rTMS): Participants will each receive Default Mode Network-targeted continuous theta burst stimulation (cTBS) administered at 100% Active Motor Threshold
223479228|NCT07155863|DEVICE|Earplugs and eye mask|Participants in the experimental group will use earplugs and eye mask during MRI. The use of these devices aims to decrease anxiety levels caused by noise and the MRI procedure. Physiological parameters and axiety scores will be monitored throughout the study.
224165595|NCT06595576|DRUG|Cannabis - High Dose (20 mg)|Participants will consume a high dose (20 mg) of cannabis edibles.
224165596|NCT01603706|PROCEDURE|Echo guided implantation group|Lead placement according echo strain imaging result
224165597|NCT05471024|PROCEDURE|Digitized Mounted Articulator Scan|Conventional articulator facebow mounting will be digitized using extraoral digital 3d scanner and used to position the maxillary cast on the virtual articulator. This positioning will be utilized during design of the occlusal surface of the restoration.
223479229|NCT07151963|DEVICE|prolonged continuous TBS|prolonged continuous theta burst stimulation
224165598|NCT05471024|PROCEDURE|Average Positioning on Virtual Bonwill Triangle|"Virtual Bonwill triangle will be used to position the maxillary cast on the virtual articulator.~This positioning will be utilized during design of the occlusal surface of the restoration."
224165599|NCT05471024|PROCEDURE|Digital Face Scan|"Digital face scan will be used to position the maxillary cast on the virtual articulator.~This positioning will be utilized during design of the occlusal surface of the restoration."
224165600|NCT02681640|OTHER|68Ga-NOTA-AE105|One injection of 68Ga-NOTA-AE105
224165601|NCT02681640|DEVICE|Positron Emission Tomography PET/CT|Following injection of 68Ga-NOTA-AE105 the patients will be subjected to Positron Emission Tomography PET/CT
224165602|NCT03812783|PROCEDURE|Hepatic arterial infusion chemotherapy|administration of Oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries
224165603|NCT03812783|DRUG|Folfox Protocol|Oxaliplatin , fluorouracil, and leucovorin
224165604|NCT03812783|DRUG|Sorafenib|administration of Sorafenib
224165605|NCT03812783|PROCEDURE|Hepatic arterial infusion chemotherapy|administration of Irinotecan, Oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries
224165606|NCT03812783|DRUG|FOLFIRINOX|Irinotecan, Oxaliplatin , fluorouracil, and leucovorin
224165607|NCT02505802|DRUG|BoNT-A injection|In BoNT-A treatment group patients received 200 units BoNT-A injection in the triceps surae (150iu) and tibial muscle posterior (50iu).
224165608|NCT02148952|BEHAVIORAL|WHO Safe Childbirth Checklist Program|The IHF group will receive the WHO Safe Childbirth Checklist Program designed to maximize likelihood of effective and sustained uptake of the program by birth attendants in the designated facilities. The program includes three key implementation steps that involve: engagement of leadership and clinicians at the state, district, and local levels, a formal launch to introduce the Checklist, and support through peer coaching and data feedback. The intervention facilities will also receive a standardized maternity register to ensure appropriate data collection.
224165609|NCT01160224|DRUG|GW766944|Drug: GW766944 (Active Drug Treatment)
224165610|NCT01160224|OTHER|Placebo|This is placebo to match.
224165611|NCT01600105|DRUG|Perfusion MRI|1\) Assess the role of a new FDA approved blood pool gadolinium contrast agent (gadofosveset trisodium, Ablavar, Lantheus) for the measurement of liver MR Perfusion, compared to extra-cellular contrast agents.
224165612|NCT01025232|DRUG|Ranibizumab|Intravitreal Injection of 2.0mg formulation
223479230|NCT07151963|DEVICE|20 Hz rTMS|20 Hz repetitive transcranial magnetic stimulation
223479231|NCT07158801|BEHAVIORAL|Project EMPOWER-OCD|"Project EMPOWER-OCD is a web-based intervention for caregivers that takes about 20-25 minutes to complete that reduces accommodation. The program is drawing from an empirically supported intervention, Project EMPOWER, and will be adapted for the OCD population pending stakeholder input during phase 1 and include 5 elements: (1) an introduction to the program's rationale; (2) psychoeducation around OCD-driven avoidance, along with how caregiver accommodation can inadvertently maintain these avoidance patterns; (3) information on how caregivers can better identify patterns of avoidance, validate, and encourage approach behaviors instead; (4) creation of an action plan to promote approach behavior and reducing avoidance; (5) a vignette exercise in which caregivers read about another case and provide possible solutions based on what they learned. Resources for finding mental health treatment for OCD are presented at the end."
224165613|NCT02021149|DEVICE|High intensity whole-body infrared heating|The Whole Body Hyperthermia system uses water-filtered infrared-A (wIRA) heat radiation. The rise in the body's core temperature is correspondingly rapid and well-tolerated. There are two phases of the thermal challenge, 1) Irradiation phase during which the patient lies recumbent with his/her head positioned outside the tent. The wIRA irradiators are arranged above the exposed upper part of the body; and 2) Heat retention phase during which the patient lies in the chamber with the walls of the tent positioned to retain heat. Core body temperatures will be raised to those comparable to a mild fever 37.8-38.5°C.
224165614|NCT02021149|BEHAVIORAL|Psychotherapy|Weekly psychotherapy using cognitive behavioral therapy sessions with a therapist.
224165615|NCT02021149|OTHER|Questionnaires|Weekly questionnaires to assess changes in mood, perceptions of self and perceptions of effectiveness of the therapist/patient bond will be administered.
224165616|NCT02021149|DEVICE|Low intensity whole-body infrared heating|Attenuated heating using only heating coils at the bottom of the Heckel device. This results in only a minor increase in skin temperature and no increase in core body temperature. The participant will still feel heat and will see similar lighting and hear similar sounds as those occurring during actual WBH, and will be in the chamber for the same period of time.
224165617|NCT01699776|DRUG|Ivabradine|7.5 my b.id. by mouth for 12-14 weeks
224165618|NCT01699776|DRUG|Digoxin|1.25 mg once a day by mouth, for 12-14 weeks.
224165619|NCT04629365|OTHER|Ketogenic Diet|KD group consumed less than 50g/day of carbohydrates
224165620|NCT04629365|OTHER|Normal Diet|ND group consumed 55% of the caloric intake from carbohydrates
224165621|NCT04708340|DRUG|Rejuveinix (RJX) Active Comparator|Active drug comprised of: ascorbic acid, magnesium sulfate heptahydrate, cyanocobalamin, thiamine, riboflavin 5' phosphate, niacinamide, pyridoxine, calcium d-pantothenate, and sodium bicarbonate.
223584367|NCT04660227|OTHER|Control Group|Participants in the control group will be put on the waiting list after all assessment methods have been applied and will be re-evaluated at the end of 8 weeks. After the final evaluations, they will be directed to the exercise group.
224165622|NCT04708340|DRUG|Placebo Comparator|0.9% Sodium Chloride in Water for Injection a.k.a. Normal Saline for injection
224165623|NCT04343391|BEHAVIORAL|Brief transdiagnostic cognitive-behavioral therapy|Time-limited transdiagnostic evidence-based psychological treatment
224165624|NCT04343391|DRUG|Pharmacological treatment|Treatment as usual in PC
224305202|NCT02642848|PROCEDURE|Transplantation of adipose derived stem cell|Transplantation of autologous adipose-derived stromal vascular fraction using LipoSculptor collecting from abdominal fat tissue. Adipose derived stem cell from abdominal fat tissue 3cc
224305203|NCT03633734|DRUG|Sequential Treatment|One cycle of the treatment lasts for 56 days. Patients will receive chemotherapy based on Nab-paclitaxel Plus Gemcitabine and modified Folfirinox in sequence order. The cycle will repeat until progression or intolerance of toxicity.
224305204|NCT00152724|DEVICE|pressure strain system, iontophoresis|
224305205|NCT00152724|DRUG|scopolamin|
224305206|NCT00152724|DRUG|emla|
224165625|NCT03928444|PROCEDURE|intradermal injection of adipose derived stem cells to one side of the face|"Lipoaspiration for preparation of ADSC will be done according to the following technique:~Under local anesthesia using strict aseptic technique, a small incision will be done in the lateral aspect of the thigh or lower abdomen, through which the infiltration cannula will be introduced to inject the local anesthetic solution using the wet technique. This will be followed 15 minutes later by lipo-aspiration of (50 ml fat ) using a blunt tipped cannula under the negative suction pressure of a 60 ml syringe.~* Autologous adipose tissue derived stem cells (At-ADSCs) will be separated from the lipo-aspirate using enzymatic digestion and differential centrifugation in the Center of Excellence for Research in Regenerative Medicine and its Application (CERRMA), Alexandria Faculty of Medicine.~* Viability of collected cells will be checked using trypan blue stain. Characterization of the isolated ADSCs population will be performed by flow cytometry."
224165626|NCT03928444|PROCEDURE|intradermal injection of saline to one side of the face|intradermal injection of saline to one side of the face
224165627|NCT00197340|DRUG|Epidural ropivacaine|
223584368|NCT04500340|BEHAVIORAL|Group CBT for test anxiety|The cognitive-behavioral therapy protocol developed by Flaxman, Bond \& Keogh (2004) will be used as the intervention protocol. This protocol consists of 10 Sessions which are provided twice a week (each group will have 10 students).
224165628|NCT01263444|DRUG|Brinzolamide 1% / timolol 0.5% Fixed Combination|
224165629|NCT01263444|DRUG|Habitual prostaglandin monotherapy|Topical ocular therapy used daily as prescribed
224165630|NCT01066650|DEVICE|Endeavor Resolute (Biolinx-based Zotarolimus-eluting stent)|Drug eluting Stent
224165631|NCT01066650|DEVICE|Xience V (Everolimus-eluting stent)|Drug eluting stent
224165632|NCT05689749|DEVICE|Superb Microvascular Imaging (SMI) (Toshiba)|To determine whether SMI has diagnostic value for detecting the inflammatory state in the lacrimal glands in Sjögren's syndrome and whether it has any superiority compared to Power Doppler and Color Doppler modalities.
224165633|NCT04007367|DRUG|SAGE-217|SAGE-217 capsule
224165634|NCT04007367|DRUG|Placebo|SAGE-217 matching placebo capsule
224165635|NCT02056756|DRUG|Carfilzomib|
224165636|NCT01611662|DRUG|gemcitabine hydrochloride|Given IV
224165637|NCT01611662|DRUG|cisplatin|Given IV
224165638|NCT01611662|PROCEDURE|therapeutic conventional surgery|Undergo radical cystectomy
224165639|NCT01611662|OTHER|laboratory biomarker analysis|Correlative studies
224165640|NCT03647462|DEVICE|Continuous Positive Airway Pressure|CPAP is an FDA approved therapy machine for patients diagnosed with OSA. CPAP provides positive air pressure to the patients throat to ensure the patients airway stays open during sleep. CPAP is the gold standard treatment for OSA, but there is limited research that demonstrates whether CPAP can improve clinical outcomes in patients with COPD. Therefore, our investigators want to initiate CPAP therapy in patients hospitalized for COPD to investigate whether there is an improvement in cardiac function and clinical outcomes (i.e. mortality).
224165641|NCT03774836|DRUG|Tramadol|IV Tramadol 50 mg, given at Hours 0, 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, and 44
224165642|NCT03774836|DRUG|Morphine|Morphine 4 mg, given at Hours 0, 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, and 44
224165643|NCT03774836|OTHER|Placebo|Placebo, given at Hours 0, 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, and 44
223584369|NCT02986100|DRUG|C-14 labeled Rucaparib|Each dosage unit consists of a hard gelatin capsule filled with cold rucaparib camsylate and \[14C\]-rucaparib camsylate salt. Each capsule contains approximately 150 mg rucaparib (free base weight) and approximately 35 µCi of \[14C\]-rucaparib. Each patient will ingest four capsules in the fasted state for a total dose of 600 mg rucaparib (free base weight) with approximately 140 µCi of \[14C\]-rucaparib
223584370|NCT02986100|DRUG|Rucaparib|200 \& 300 mg tablet
224165644|NCT01764022|DRUG|Trastuzumab|Patients will receive 6 courses of trastuzumab in combination with paclitaxel. Trastuzumab will be administered at a loading dose of 8 mg/kg (once), followed by maintenance dose of 6 mg/kg every 3 weeks (5 administrations) as 90 min intravenous infusion every 3 weeks (on Day 1 of each cycle).
224165645|NCT01764022|DRUG|Paclitaxel|Paclitaxel will be administered at a dose of 175 mg/m2 every 3 weeks (on Day 1 of each course) as 3 hour intravenous infusion (6 courses totally).
224165646|NCT00862524|DRUG|ARRY-334543, EGFR/ErbB2 inhibitor; oral|multiple dose, escalating
223584371|NCT02750384|DRUG|DSM265 50% SDD granules|Single oral dose 400 mg
223584372|NCT02750384|DRUG|DSM265 25% SDD powder for suspension|Single oral dose 400 mg
224165647|NCT00862524|DRUG|Gemcitabine, nucleoside analogue; intravenous|multiple dose, single schedule
224165648|NCT03216980|DIETARY_SUPPLEMENT|PTSD/GAD Antioxidant|Subjects will ingest an antioxidant cocktail containing 800 milligrams of alpha lipoic acid, 1 gram of vitamin C (ascorbic acid), and 400 milligrams of vitamin E (alpha tocopherol).
224165649|NCT03216980|DIETARY_SUPPLEMENT|PTSD/GAD Placebo|Subjects will ingest placebo (microcrystalline cellulose) pills.
224165650|NCT03216980|DIETARY_SUPPLEMENT|Healthy Control Antioxidant|Subjects will ingest an antioxidant cocktail containing 800 milligrams of alpha lipoic acid, 1 gram of vitamin C (ascorbic acid), and 400 milligrams of vitamin E (alpha tocopherol).
224165651|NCT03216980|DIETARY_SUPPLEMENT|Healthy Control Placebo|Subjects will ingest placebo (microcrystalline cellulose) pills.
223584373|NCT03414112|BIOLOGICAL|Intranasal oxytocin|oxytocin is a peptide hormone that influences social affiliation
223584374|NCT03864393|OTHER|Multimodal overground locomotor training|Locomotor training sessions use various movement drills emphasizing power, stability, and stepping in a specific direction: forward, backward, lateral, rotational. Sessions also have an additional focus on gait initiation or steady-state walking. After circuit-style warm up exercises, participants perform overground movement drills that are specific to the emphasis of the individual training session, culminating in practicing everyday overground walking. Participants wear a heart rate monitor to ensure that the majority of the training session is performed at an aerobic intensity greater than 60% age predicted heart rate maximum (220-age +/- 5 bpm).
224165652|NCT00467948|DRUG|cefazolin|
224165653|NCT00822640|DEVICE|Total Knee Arthroplasty|All patients receive the same posterior cruciate retaining implant but the tibial tray and bearing (B. Braun Aesculap Columbus CR and RP) by two experienced surgeons and will follow an identical rehabilitation regime.
224305207|NCT00152724|DRUG|capsaicin|
224305208|NCT00152724|DRUG|aspirin|
224305209|NCT00152724|DRUG|clopidogrel|
224305210|NCT00152724|DRUG|celecoxib|
224165654|NCT01541540|BEHAVIORAL|e-Counseling plus Usual Care|28 emails will be sent proactively over a 12-month period. Emails will be sent weekly for the first 4 months, biweekly from months 5 to 8, and monthly from months 9 to 12. Each email will contain an e-link to lifestyle counseling activities designed to enhance motivation and skill to initiate and maintain lifestyle change. e-Counseling includes video-based education and counseling as well as e-tools to self-monitor and reinforce adherence to self-management behavior for exercise, diet, prescribed medications and smoke-free living.
224165655|NCT01541540|BEHAVIORAL|Control|The control group will receive general educational material on heart healthy living. 28 emails will be sent proactively over a 12-month period. Emails will be sent weekly for the first 4 months, biweekly from months 5 to 8, and monthly from months 9 to 12.
224165656|NCT05726643|OTHER|resistive training|"5 minutes warming up exercise for various parts of the body as moderately energetic walking.~5 to 10 minutes stretching exercise for (pectorals major, hamstring, hip flexors, and calf muscles) with each static stretch held for at least 20 seconds in first week and then 30 seconds for the remaining 5 weeks and this will be repeated about four times.~10 to 15 minutes strengthening exercise by using weights for lower limbs (knee extensors, hip abductors, and hip extensors) at first session for each patient. Ten repetitions maximum (10 RM) will be determined, which is the maximal weight can be lifted through the entire range of motion 10 times."
224165657|NCT05726643|OTHER|kinesiotaping|Tape will be applied to each participant in the treatment group for the sartorius, rectus femoris, hamstrings, tibialis anterior, fibularis brevis, and the patella bilaterally using strips of the standard 2-inch Kinesio Tex Tape. The first and last inch of each strip will be applied without tension. The length of the strip will be applied with a 20%- 25% stretch and downward pressure to the insertion. Each of the sartorius, rectus femoris, hamstrings, tibialis anterior and fibularis brevis tapings used an I-strip. AY strip will be utilized for the patellar taping.
224165658|NCT01782976|DRUG|Cilengitide|2000 mg by vein twice weekly of each 28 day cycle.
224165659|NCT01782976|DRUG|Bevacizumab|10 mg/kg by vein on Days 1 and 15 of each 28 day cycle.
224165660|NCT01782976|BEHAVIORAL|Questionnaire|Completion of MD Anderson Symptom Inventory for Brain Tumors (MDASI-BT) at baseline, Day 1 of cycle 2, and at end of treatment visit. Questionnaire should take about 5 minutes to complete.
224165661|NCT02269982|DEVICE|AR-v7 assays|
224165662|NCT00515944|DRUG|Botulinum neurotoxin type A, free of complexing proteins|
224165663|NCT00481689|DRUG|Cipro XR (Ciprofloxacin, BAYQ3939)|Active Ciprofloxacin XR ( 1000mg) given for 7 to 14 days
224165664|NCT05770739|BEHAVIORAL|Perioperative accelerated rehabilitation surgical measures|To apply accelerated rehabilitation surgery to children with biliary dilatation during perioperative period
224165665|NCT05770739|BEHAVIORAL|Traditional treatment|To provide traditional perioperative treatment for children with cholangiectasia
224165666|NCT04493944|BEHAVIORAL|Culinary workshop|A 3-hour culinary workshop will be led by a chef. The aim of this workshop will be to develop participants' culinary skills related to the preparation and consumption of recipes based on seaweeds, through various practical activities in the kitchen (starter, main course, dessert). An evaluation questionnaire will be completed at the end of the workshop.
224165667|NCT02711410|DRUG|Clopidogrel|
224165668|NCT05153564|DRUG|Semaglutide 1.34 mg/mL|Semaglutide will be administered at a dose of 0.25, 0.50 or 1.0 mg as indicated on scale drum once weekly by subcutaneous (s.c.) (under the skin) injections in the abdomen for 14 weeks.
224165669|NCT05153564|DRUG|Semaglutide 3.0 mg/mL|Semaglutide will be administered at a dose of 2.0 mg corresponding to the increment of 67 (pen injector units) as indicated on scale drum. once weekly by subcutaneous (s.c.) (under the skin) injections in the abdomen for 14 weeks.
224165670|NCT05153564|DRUG|NNC0480-0389 10 mg/mL|NNC0480-0389 will be administered at a dose of 0.23, 0.45 or 0.90 mL once weekly by s.c. (under the skin) injections for 14 weeks.
224165671|NCT05153564|DRUG|NNC0480-0389 30 mg/mL|NNC0480-0389 will be administered at a dose of 0.60 mL once weekly by s.c. (under the skin) injections for 14 weeks.
224165672|NCT05153564|DRUG|Microgynon®|Microgyn® will be given as once daily oral dosing in two periods, each of 8 days' duration. One tablet contains levonorgestrel 0.15 mg and ethinylestradiol 0.03 mg.
224165673|NCT00662285|DIETARY_SUPPLEMENT|Iron supplement: Niferex 100 mg|A: 100 mg pr day in 8 days
224165674|NCT05283785|PROCEDURE|End To End or End to side sutures|End to end or End to side sutures of ulnar nerve by nerve to quadratus muscle ( branch of anterior interosseous nerve )
224165675|NCT03045640|OTHER|FSI ECD|The FSI ECD intervention was delivered in a structured curriculum format, covering a range of topics from health, water and sanitation, good hygiene, early stimulation, conflict resolution, to good communication. It was designed to improve vulnerable households home environment and engagement with their children in order to improve child development outcomes. The curriculum was delivered by bachelor-level trained staff with beneficiaries on an individual, one on one basis, using active coaching to promote child well being and behaviors with caregivers.
224165676|NCT02213081|DRUG|Ulipristal|Patient will take 15mg every other day, or every 4 days per week.
224165677|NCT01674972|OTHER|Oral glucose tolerance test|Oral intake of 75 g glucose after overnight fast
224165678|NCT02958033|RADIATION|Whole Breast irradiation Plus simultaneous tumor bed Boost|hypo-fractionated irradiation for experimental group and normal fractionated irradiation for comprator group
224165679|NCT00036946|BIOLOGICAL|ziv-aflibercept|
224165680|NCT04202432|DIAGNOSTIC_TEST|Mean systemic filling pressure|"Peri- and postoperative measurement of continuous cardiac output with thermodilution derived pulse contour calculated device (PiCCO).~Estimation of mean systemic filling pressure using a computerized algorithm and by creating venous return curves with inspiratory hold maneuvers, thereby extrapolating the VR-curve until mean systemic filling pressure is calculated."
224165681|NCT01283178|RADIATION|intensity-modulated radiation therapy|Undergo intensity-modulated image-guided adaptive radiotherapy
224165682|NCT01283178|DRUG|cisplatin|Given IV
224305211|NCT00152724|DRUG|indomethacin|
224305212|NCT00152724|DRUG|acetylcholine|
223584375|NCT03778320|DRUG|CTP-692|Single oral dose
223584376|NCT03778320|DRUG|D-Serine|Single oral dose
223584377|NCT02221518|BEHAVIORAL|Exposure & Response Prevention (EX/RP)|Exposure and Response Prevention (EX/RP) is a type of Cognitive Behavioral Treatment for treating OCD.
223584378|NCT03590132|BEHAVIORAL|Strong African American Families Program|SAAF is a 7 session family skills training program
224165683|NCT01283178|RADIATION|image-guided adaptive radiation therapy|Undergo intensity-modulated image-guided adaptive radiotherapy
224165684|NCT01283178|OTHER|3'-deoxy-3'-[18F]fluorothymidine|Undergo FLT-PET scans for IMRT/IGART
224165685|NCT01283178|PROCEDURE|positron emission tomography/computed tomography|Undergo FDG/FLT-PET scans for IMRT/IGARTT
224165686|NCT01283178|RADIATION|fludeoxyglucose F 18|Undergo FDG-PET scans for IMRT/IGART
224165687|NCT02772991|OTHER|troponin measurement|Cardiac catheterization (for patients with \>50% lesions) or discharge or in patients with intermediate risk.
224165688|NCT05513092|DIAGNOSTIC_TEST|placenta accreta index score|role of placenta accreta index score in prediction of conservative surgery for placenta placenta accreta spectrum
224165689|NCT02387073|OTHER|Electrical version patient reported outcome questionnaire|"Assess satisfaction of patients with electrical version patient reported outcome questionnaire."
224165690|NCT00033449|DRUG|gefitinib|Given orally
224165691|NCT00033449|RADIATION|radiation therapy|Undergo radiation therapy
224165692|NCT00033449|DRUG|cisplatin|Given IV
224165693|NCT00033449|OTHER|laboratory biomarker analysis|Correlative studies
224165694|NCT00039091|BIOLOGICAL|ipilimumab|Given IV
224165695|NCT06229808|DEVICE|Multifunctional Birthing ball|"In order to reduce low back pain in labor, massages will be applied to the experimental group in the first stage of labor for 30 minutes each at the end of the latent, active and transition phases (cervical dilatation 3-4 cm, 5-7 cm, 8-10 cm), respectively.~Perineal heating application is planned to be performed at least twice until the delivery occurs as 20 minutes of application and 20 minutes of tissue rest periods when the second stage of labor begins (the duration of this stage may reach 2 hours in primiparous women)."
224165696|NCT06283303|BIOLOGICAL|T3011 hepatic artery infusion|The study was divided into two dose groups, T3011 3×10\^8 PFU/time (HAI) and T3011 1×10\^9 PFU/time (HAI), with a 3+3 dose escalation design. After the completion of the lead-in period, the patient entered the combination therapy period（combination therapy with T3011 hepatic artery infusion , Regorafenib and Toripalimab）,and the dosage of T3011 was determined according to the safety observation results of the lead-in period, the dose of toripalimab was 80mg intravenously, and regorafenib was 80mg orally once a day.
224165697|NCT06283303|DRUG|toripalimab|The combination therapy period: toripalimab, 80mg intravenous ,D2 and D16, 4 weeks per cycle
224165698|NCT06283303|DRUG|regorafenib|The combination therapy period: regorafenib ,80mg orally once a day, D1-D21,4 weeks per cycle
224075810|NCT04867317|DRUG|Somatropin|Participants (n=172) will be randomized in a 1:1 ratio to rhGH (n=86) versus placebo (n=86) for six months, stratified by participating site. Both study participants and the study team will be blinded to treatment assignment. All participants will complete in-clinic follow-ups at Days 14, 40, 65, and 90 (3 months) and at day 180 (6 months). The primary outcome will be the mean difference in QoL-AGHDA scores between treatment arms at 6 months follow-up. Patients will discontinue the study intervention at 6 months, and will be followed-up two weeks subsequent, in order to assure patient safety and wellness, and to ensure maximal facilitation of patient transition back into routine care.
224165699|NCT04804111|DRUG|arm 0|placebo group
224165700|NCT04804111|DRUG|arm 1|3 mg of the URC102 group
224165701|NCT04804111|DRUG|arm 2|6 mg of the URC102 group
224165702|NCT04804111|DRUG|arm 3|9 mg of the URC102 group
224165703|NCT04804111|DRUG|arm 4|Febuxostat 80 mg
224165704|NCT04729595|DRUG|Tempol|Tempol 800 mg capsule will be administered at 400mg (2 capsules) two times daily for fourteen (14) consecutive days.
224165705|NCT04729595|OTHER|Placebo|Placebo capsules will be administered orally (2 capsules) two times daily for fourteen (14) consecutive days.
224165706|NCT03640728|DRUG|Tenofovir Alafenamide|Tenofovir alafenamide 25 mg/day orally
224165707|NCT03640728|DRUG|Entecavir|Entecavir 0.5 mg/day orally
224165708|NCT03640728|DRUG|Tenofovir disoproxil fumarate|Tenofovir Disoproxil Fumarate 300 mg/day orally
224165709|NCT01537289|DEVICE|Pigtail catheter insertion (Cook)|insertion of pigtail catheter to decompress pneumothorax
224165710|NCT01537289|DEVICE|chest tube (28-French)|inserting chest tube to decompress pneumothorax
224165711|NCT06377436|BEHAVIORAL|Experimental training|Through The Dividat Senso intelligent platform, subjects will be subjected to locomotion, cognitive and sensory domain-specific exercise programs. The exercises will be of increasing difficulty. Cognitive exercises will in fact be carried out by interacting with the DIVIDAT device consisting of a monitor and a pressure-sensitive platform through weight shifts, multidirectional steps and jumps.
224165712|NCT02324049|DRUG|SBC-103|
224165713|NCT00777686|PROCEDURE|MRI/MRS Scan|MRI/MRS brain scan with intravenous contrast prior to chemotherapy, then repeated every 8 weeks.
224165714|NCT03862586|DRUG|N-acetyl cysteine|
224165715|NCT03862586|DRUG|Placebos|
224165716|NCT02039128|DIETARY_SUPPLEMENT|Krill oil or Fish oil|
224165717|NCT02039128|DIETARY_SUPPLEMENT|Placebo|
224165718|NCT02618512|DRUG|SBC-103|SBC-103 is a recombinant human alpha-N-acetylglucosaminidase (rhNAGLU). Patients were started with low dose of SBC-103 for 12 weeks and then will escalate to a higher dose.
224165719|NCT00995189|DEVICE|Opti-Free RepleniSH|Contact lens care solution containing polyquaternium-1 (PQT)
224165720|NCT00995189|DEVICE|ReNu MultiPlus|Contact lens care solution containing polyhexamethylene biguanide (PHMB)
224165721|NCT00995189|DEVICE|Contact lenses|Daily wear, frequent replacement contact lenses per participant's habitual brand and power.
224165722|NCT01946568|DRUG|Dalbavancin|Intravenous dalbavancin given at 15 mg/kg (not to exceed 1000 mg) for patients ≥5 years of age, and 25 mg/kg for patients \<5 years of age.
224165723|NCT03164746|OTHER|Dry sheet Therapeutic body wraps|At the beginning of the session, the patient's consent to proceed was orally obtained, as no session was compulsory. The therapists checked behavioral manifestations of refusal. Then, the patient was first wrapped in Dry damp sheets (cold phase) and covered up with a rescue and a dry blanket. Afterward the body spontaneously warmed up (warm phase). The patient was then invited to freely express his feelings.
224165724|NCT03164746|OTHER|WET sheet Therapeutic body wraps|At the beginning of the session, the patient's consent to proceed was orally obtained, as no session was compulsory. The therapists checked behavioral manifestations of refusal. Then, the patient was first wrapped in wet damp sheets (cold phase) and covered up with a rescue and a dry blanket. Afterward the body spontaneously warmed up (warm phase). The patient was then invited to freely express his feelings.
224165725|NCT02809391|DEVICE|Orthotics alone|The sole thin sport orthotic will be heat moulded to participants footwear. A top cover will be used of similar cushioning thickness and durometer properties as the orthotics+texture intervention.
224165726|NCT02809391|DEVICE|Orthotics+textured top cover|The sole thin sport orthotic will be heat moulded to participants footwear. A textured material will be used as the orthotic top cover in this intervention.
224165727|NCT01785290|DRUG|Haloperidol 1 mg/q8h|"Patients receive prophylactic haloperidol until discharge from the ICU or when delirium occurs. In the latter case study drug will be stopped and patients will be subsequently treated according to the delirium protocol with open-label haloperidol. To avoid unnecessary risk for side-effects the dose will be halved in patients:~* aged ≥ 80 years~* weight ≤ 50 kg~* liver failure~Patients with an adjusted dosage of study drug remain allocated to their original group.~In case of occurrence of QTc-time prolongation the study drug will be stopped. After normalisation of QTc-time (\<500msec.) the study drug will be restarted. If QTc-time becomes prolonged again, the study drug will be stopped definitively. The patient will remain allocated to the original study group."
224165728|NCT01785290|DRUG|Haloperidol 2 mg/q8h|"Patients receive prophylactic haloperidol until discharge from the ICU or when delirium occurs. In the latter case study drug will be stopped and patients will be subsequently treated according to the delirium protocol with open-label haloperidol. To avoid unnecessary risk for side-effects the dose will be halved in patients:~* aged ≥ 80 years~* weight ≤ 50 kg~* liver failure~Patients with an adjusted dosage of study drug remain allocated to their original group.~In case of occurrence of QTc-time prolongation the study drug will be stopped. After normalisation of QTc-time (\<500msec.) the study drug will be restarted. If QTc-time becomes prolonged again, the study drug will be stopped definitively. The patient will remain allocated to the original study group."
224165729|NCT01785290|DRUG|Placebo|Sodium Chloride 0.9%
224165730|NCT02776306|OTHER|Mirror Box therapy|In mirror box therapy the patient uses the reflection of their good arm to trick to brain into thinking that the effected arm is working.
224165731|NCT03250819|OTHER|SNP analysis|The collected blood samples will be used to investigate the occurrence of SNPs (single nucleotide polymorphisms) in both study groups
224165732|NCT03388554|DEVICE|tDCS|
224165733|NCT01119924|DRUG|Smilon®|Smilon® tablet 15mg mg/day or placebo, once a day on the first week, and then for 7 consecutive weeks
224165734|NCT01119924|DRUG|Placebo|Smilon® tablet 15mg mg/day or placebo, once a day on the first week, and then for 7 consecutive weeks
224165735|NCT05998603|DIETARY_SUPPLEMENT|High protein intake|The participants received a 60g whey protein bolus each evening prior to sleep pre and post a military load carriage test.
224165736|NCT05998603|DIETARY_SUPPLEMENT|Moderate protein intake|The participants received a 20g whey protein bolus each evening prior to sleep pre and post a military load carriage test.
224165737|NCT05998603|DIETARY_SUPPLEMENT|Carbohydrate maltodextrin placebo|The participants received an isocaloric carbohydrate bolus each evening prior to sleep pre and post a military load carriage test.
224165738|NCT05998603|OTHER|Control no supplementation|Control group, no supplementation, only basic training
224165739|NCT05071794|DRUG|Propofol|Antiemetic effect of propofol
224165740|NCT05071794|DRUG|saline 0.9%|Placebo
224165741|NCT06172205|DRUG|intravenous FOLFOX7 plus Camrelizumab and apatinib|"Leucovorin 200mg/m2 administered IV on Days 1 of a 21 day cycle Oxaliplatin 85 mg/m2 IV on Days 1 of a 21 day cycle Fluorouracil 5-FU continuous infusion: 400mg/m2 on D1 and then 2400mg/m2 for 46h of each 21 day cycle.~Camrelizumab 200mg infusion on D1 for every 21 days Apatinib 250mg，po，qd for every 21 days"
224305213|NCT00152724|DRUG|sodium nitroprusside|
224165742|NCT06172205|DRUG|HAIC-FOLFOX plus Camrelizumab and apatinib|"2-h infusion of oxaliplatin at 85 mg/m2 ,a 2-3-h administration of leucovorin at 400 mg/m2 , and a 46-h delivery of fluorouracil at 2500 mg/m2.~camrelizumab (200 mg intravenously, commencing in 7 days after the first HAIC cycle and repeated every 21 days) and apatinib (250 mg daily, taken orally, beginning in 7 days after the initial HAIC cycle) Camrelizumab 200mg infusion on D1 for every 21 days Apatinib 250mg，po，qd for every 21 days"
224165743|NCT06543121|OTHER|Translating the Stroke Knowledge Test into Turkish and Related Processes|The first step is the translation from the original language to the other language. The ideal target in the translation phase is to use people who are familiar with the structure of the original language and who are familiar with the language. Two forward translation and one reverse translation methods will be applied after obtaining the written permission of the authors. After the completion of this phase, the terminological differences arising from the translators in the translation process from the original language to Turkish will be collected and discussed on the questions. The cultural adaptation study will be terminated by determining the equivalence between the Turkish version of the test and the English original. The final version of the questionnaire and the necessary changes will be arranged specific to the investigator's society and the authors of the original questionnaire will be consulted and the questionnaire will be finalized.
224305214|NCT00152724|DRUG|brethyllium|
224305215|NCT00152724|DEVICE|general and local heating|
224305216|NCT06490237|PROCEDURE|near field recording of human auditory nerve activity during retro sigmoid approach with contact electrode|"During surgery using a retro-sigmoid approach in the cerebellopontine angle (microvascular decompression, vestibular neurotomy, meningioma or schwannoma removal), near-field recording of human auditory nerve activity using a contact electrode is performed on patients with normal or impaired hearing threshold.~Each patient is explored preoperatively by hearing tests in noise and in silence. During the operation, stimuli are delivered in silence and in noise, under the same conditions as during the preoperative auditory exploration."
224305217|NCT05379049|BIOLOGICAL|Infliximab: Adalimumab; Etanercept;|Therapeutic drug monitoring, evaluation of clinical outcomes and laboratory analysis of biomarkers
223584379|NCT03590132|BEHAVIORAL|Strong African American Families--Teen Program|SAAF-T is a 5 session family skills training program
224305218|NCT00593736|DRUG|Ramelteon|Ramelteon 1 mg, tablets, orally, once daily for up to two weeks.
223584380|NCT02744807|OTHER|Chronic endometritis|with or without Chronic endometritis
223584381|NCT02608450|DRUG|CB-03-01 cream, 1%|CB-03-01 (cortexolone 17α-propionate) is a steroidal antiandrogen that is being developed as a 1% cream for the topical treatment of acne vulgaris.
223584382|NCT02608450|DRUG|Vehicle cream|Vehicle cream manufactured to mimic look and feel of CB-03-01 but without the active ingredient cortexolone 17α-propionate.
223584383|NCT02106247|DRUG|BI 1181181 high dose|two tablet
224165744|NCT06543121|OTHER|Validity|Content validity will be calculated with the Content Validity Index, which is a result of 10 expert opinions in terms of clarity, difficulty, and suitability of the Turkish version of the Stroke Knowledge Test. For face validity, the final version of the form will be provided with opinions from 3 stroke patients.
224165745|NCT06543121|OTHER|Internal consistency and Reliability|The internal consistency of the items will be tested with Cronbach alpha. Test-retest reliability will be tested with intraclass correlation coefficient.
224165746|NCT05124067|DRUG|Dexamethasone|patients will receive dexamethasone (0.15 mg/kg IV; maximum 5 mg)
224165747|NCT05124067|DRUG|Ondansetron|patients will receive ondansetron (0.05 mg/kg IV; maximum 4 mg)
224165748|NCT05124067|DRUG|Dexmedetomidine|Patients will receive dexmedetomidine (0.3 μg/kg)
223584384|NCT02106247|DRUG|BI 1181181 low dose|one tablet
224165749|NCT05124067|DRUG|normal Saline|patients will receive normal saline.
224165750|NCT04629976|DRUG|NCO-48 Fumarate 4 mg|2 x 2mg NCO-48 Fumarate over 28 days of therapy
224165751|NCT04629976|DRUG|NCO-48 Fumarate 20 mg|2 x 10 mg NCO-48 Fumarate over 28 days of therapy
224165752|NCT04629976|DRUG|Tenofovir Alafenamide 25 mg|25 mg over 28 days of therapy
224165753|NCT06859632|OTHER|3-hour educational intervention|"A 3-hour educational intervention on communication and the use of play in paediatric clinical practice.~Participants in both arms will have access to written learning material and an app that has been developed."
224165754|NCT06859632|OTHER|45-minute educational intervention|"A 45-minute educational intervention on communication and the use of play in paediatric clinical practice.~Participants in both arms will have access to written learning material and an app that has been developed."
224165755|NCT05186012|DRUG|APG-1252|APG-1252 administered via intravenous infusion for 30 minutes weekly (Day 1, 8, 15, 22).Every 28 days as a cycle.
224165756|NCT05186012|DRUG|Chidamide|Chidamide 30mg orally BIW. Every 28 days as a cycle.
224165757|NCT05008549|DIETARY_SUPPLEMENT|Cranberry Juice Product|"The cranberry juice product contains 100 % cranberry juice (ingredients: water, cranberry juice concentrate)~The cranberry juice + lemon balm extract product contains 100 % cranberry juice (ingredients: water, cranberry juice concentrate) + lemon balm extract (300 mg, Robertet Groupe)~The cranberry juice + tart cherry juice product contains 100 % cranberry juice (ingredients: water, cranberry juice concentrate) + 3 g tart cherry powder (Cherry PURE)~The cranberry juice + L-theanine product contains 100% cranberry juice (ingredients: water, cranberry juice concentrate) + 200 mg L-theanine (Suntheanine, Taiyo International)~L-theanine + placebo product contains L-theanine (200 mg, Suntheanine, Taiyo International) + placebo (see 5.2.1)~The placebo product contains water, dextrose, citric acid, malic acid, fumaric acid, natural flavor, Red #40, xanthan gum, Blue #1, gum Arabic, Reb M, Steviol glycosides, and ester gum."
224165758|NCT00124332|DRUG|Rimonabant (SR141716)|
224165759|NCT00124332|DRUG|Placebo|
224165760|NCT05730101|OTHER|Cognitive-behavioral treatment (CBT)|In the first individual session (CBT1), together with the therapist, participants develop a behavioral and conditional model of their procrastination behavior. In the next 2 group sessions (CBT2 and CBT3), participants receive psychoeducation on procrastination. The focus is on learning the method of starting on time. In the third group session (CBT4), participants identify key procrastination-promoting thoughts and are supported to develop alternative thoughts; deepened in the second individual session (CBT5). In the next 2 group sessions (CBT 6 and CBT7), participants are informed about action planning with focus on learning to plan realistically. The last group session is a concluding session: Experiences with the methods learned and an outlook on further steps and goals are discussed. At the end of both individual sessions (CBT1 and CBT5), participants receive a link to an online survey to rate their treatment expectations (treatment expectation 1 and 2).
224165761|NCT05730101|OTHER|Imaginary pill treatment (IP)|In the first session (IP1), participants will be asked about the nature of their procrastination behavior and receive a procedure to take an imaginary pill following a rationale of 5 steps. In the second IP session (IP2), experiences with taking the IP are discussed and the procedure of taking the IP is adapted according to previous experiences and current needs. The rationale of the second session encompasses the same five steps with small modifications: 1) discussing IP sensitive problem and adapting it if necessary, 2) building trust/belief/reality of the IP, 3) discussing the personally meaningful IP and adapting it if necessary, 4) taking the IP, 5) adapting the procedure for self-administering the IP in real life on daily basis if necessary and building adherence. At the end of both sessions, participants receive a link to an online survey to rate their treatment expectations (treatment expectation 1 and 2).
224165762|NCT01458795|PROCEDURE|Endovenous laser ablation|
224165763|NCT03672357|PROCEDURE|Laparoscopic liver resection|Laparoscopic hepatectomy
224165764|NCT03672357|PROCEDURE|Open liver resection|Traditional open hepatectomy
224165765|NCT01292525|DRUG|Tacrolimus|"A control group continued conventional therapy, Tacrolimus (Prograf®) (control group) and will be followed in parallel group withdrawal that will stop treatment with Tacrolimus (Prograf®)."
223584385|NCT02106247|DRUG|Placebo|tablet
223584386|NCT05501314|OTHER|Early discharge with remote home monitoring.|After at least 48 hours of hospital admission, patients are discharged early with the use of remote home monitoring. During home monitoring, heartrate, respiratory rate, posture and movement are monitored every 5 minutes for at least 4 days, using a wearable sensor. Core temperature is monitored using an ear thermometer. Patients are contacted once per day by a nurse from the Virtual Monitoring Centre (VMC) to assess pancreatitis related complaints, intake of fluids and food, pain and the use of analgesics. Patients are asked to provide information to the hospital using a smartphone app.
224165766|NCT01292525|DRUG|Placebo|"Patients randomized to the withdrawalgroup will begin the protocol with their usual dose of Tacrolimus (Prograf®) (initial dose). The initial dose of tacrolimus (Prograf®) will be reduced by one third at visit 3 (day 0) and again a third visit 5 (J60). The complete withdrawal Tacrolimus (Prograf®) begins to visit 7 (J120). The withdrawal of Tacrolimus (Prograf®) will be obtained in four months. Monitoring of all patients lasted 17 months in total from the screening visit, which corresponds to 12 months after complete withdrawal of Tacrolimus (Prograf®) for patients in the withdrawal group."
224165767|NCT02882022|DEVICE|Continuous positive airway pressure|A CPAP machine will be used to deliver positive pressure at various levels after which middle ear pressure and ear drums will be evaluated for changes.
224165768|NCT04134169|OTHER|Not applicable(observational study)|Not applicable(observational study)
224165769|NCT00423592|DRUG|ambrisentan|All eligible subjects received 2.5 mg ambrisentan once daily for a period of 4 weeks before increasing the dose to 5 mg once daily. After Week 24, investigators were allowed to adjust the dose of ambrisentan as clinically indicated (available doses were 2.5, 5, and 10 mg).
224165770|NCT01686100|PROCEDURE|No touch technique|The vein graft is harvested with its surronding tissues.
224165771|NCT01686100|PROCEDURE|Conventional technique|The vein graft is stripped from its surrounding tissues.
224165772|NCT04315597|DRUG|Laif® 900, BAY98-7108|1 x daily, 1 tablet, 900 mg
224165773|NCT04315597|DRUG|Placebo|1 x daily, 1 tablet, 900 mg
224165774|NCT04084405|OTHER|Pulmonary rehabilitation|The experimental group receives inspiratory muscle training and aerobic exercise. The Active Comparator group received only aerobic exercise.
224165775|NCT03314012|DEVICE|Catheter-Based Carotid Body Ablation|The Cibiem Transvenous Ultrasound System (CTUS) is a catheter based device delivering ultrasound energy to ablate the carotid body. The procedure is done via a percutaneous insertion of the CTUS and advancement through the femoral vein to the jugular vein in subjects with difficult to control hypertension. The procedure duration is expected to range between 60 to 90 minutes and is performed under fluoroscopic and ultrasound image guidance.
224165776|NCT04199546|OTHER|Chewing and swallowing rehabilitation|A home based chewing and swallowing training program (CST) will be applied by an experienced physical therapist. The Functional Chewing Training will be used to improve chewing function which has five steps including positioning the child and food, sensory stimulation, chewing training and adjustment of food consistency to improve chewing function. To support hyolaryngeal elevation, laryngeal mobilization will be performed. Hyolaryngeal mobilization will be performed by moving hyolaryngeal complex in right, left and up directions manually.
224165777|NCT02019498|BEHAVIORAL|Relaxation exercise|Participants allocated to the relaxation group will apply daily but at least five days a week a 15-minutes relaxation exercise, guided by a smartphone application (App). On a daily basis, participants can select one out of the three exercises (guided imagery, mindfulness based training, autogenic training) which they want to apply
224165778|NCT02019498|OTHER|ususal care|Participants allocated to the usual care waiting list group will continue with their usual care without receiving any additional therapy
224165779|NCT04553367|DRUG|Meropenem|all patients in both groups receive meropenam and put on the ventilators for 2 weeks
224165780|NCT04553367|PROCEDURE|bronchoscopy|Only patients of group B had three times bronchoscopy according to our protocol one at the end of first 5 days, second bronchoscopy at the end of the second 5 days and last one at the end of the studied period
224165781|NCT04553367|DEVICE|ventilator|ventilator
223479232|NCT07158801|BEHAVIORAL|Project CARE|To evaluate the effects of Project EMPOWER-OCD, we will compare it to an active psychoeducation-based SSI that provides general information on caregiving and caregiver mental health. The intervention includes 5 elements that mirror Project EMPOWER: (1) introduction to the rationale for the program; (2) introduce the concept of caregiving across relationships and situations; (3) present broad information on typical development processes; (4) helping caregivers identify their own role and reflect on how caregiving looks like in their life (5) vignette exercise where caregivers identify caregiving roles, prompting reflection on roles. This active comparator intentionally does not include any psychoeducational components explicitly designed to reduce accommodation of anxiety, OCD, and its related disorders.
224165782|NCT01779804|PROCEDURE|OFAR|OFAR
224165783|NCT03834480|OTHER|Ultrasound guided Sacroiliac intra-articular injection|At the level of the sacral hiatus, the sacral cornuae were identified. posterior aspect of the sacroiliac joint, at 4.5 cm depth the SIJ was found. localal anesthetic was injected at the medial edge of the transducer, the spinal needle was advanced in a medial to lateral direction, under direct vision, until the needle was positioned in the SIJ. Local steroid solution or PRP 4ml volume was injected according to the study group and patient enrollment. If the injection is extra-articular, injectate (hyperechoic solution as it contains particulate steroid) can be seen spreading medially over the sacrum. The visual analog score, Oswestry Disability Index (ODI) score and the overall success rate basal, after one week,after one month,after three and six month's follow-up period after the initial block.
224165784|NCT02253160|DEVICE|Spectra Optia CMNC|The Spectra Optia® Apheresis System is an automated centrifugal system that separates whole blood into its cellular and plasma components. The device is comprised of three major sub-systems, 1) the apheresis machine itself (centrifuge, centrifuge filler, pumps, valves, computerized safety and control systems, etc.), 2) a sterile, single-use, disposable blood tubing set, and 3) embedded software. The Spectra Optia system's investigational CMNC procedure will be used to collect MNC from the peripheral blood.
224165785|NCT02253160|DEVICE|COBE Spectra MNC|It is also a centrifugal system that separates whole blood into its cellular and plasma components. The COBE Spectra MNC collection procedure is chosen as the comparator device because it is the reference after which design of the Spectra Optia CMNC collection procedure was modeled.
224165786|NCT02253160|DRUG|Granulocyte-colony stimulating factor (G-CSF)|Each subject received an injection of the G-CSF approximately equivalent to 10 ug/kg body weight subcutaneous per day for 5 days prior to the MNC collection procedure.
224165787|NCT02756546|DRUG|Cyclophosphamide|
224165788|NCT02756546|DRUG|Hydroxychloroquine|
224165789|NCT02756546|DRUG|Hydrocortisone|
224165790|NCT05180604|BEHAVIORAL|experience learning programs of eHealth care|The experience learning programs of eHealth care was included six sections of activities. Six activities were conducted based on eHealth literacy framework and experience learning theory to improve patients' abilities to engage in eHealth care service. The outcome indicators were eHealth literacy, patient health engagement, the acceptance of eHealth care, eHealth usage status, and their learning experience
224165791|NCT03258944|OTHER|Breath-Stacking|Participants will be seated, with their elbows resting on the table, holding the face mask attached to a T-tube and a one-way valve. They will be instructed to inspire and force the expiration inside the mask. The training will be conducted three times a week for a period of four weeks, totaling twelve sessions. The breath-stacking application protocol will consist of three three-minute series, with a three-minute recovery interval between each series, obtaining a total time of fifteen minutes in each session.
224165792|NCT00149890|DRUG|Basiliximab|Basiliximab (10 mg) was supplied as a lyophilisate in vials with ampoules of sterile water for injection (5 mL) and had to be given of 10 mg (body weight \<35 kg) or 20 mg (body weight ≥35 kg) strength.
224305219|NCT00593736|DRUG|Ramelteon|Ramelteon 4 mg, tablets, orally, once daily for up to two weeks.
224165793|NCT00149890|DRUG|Cyclosporine/cyclosporine microemulsion|Cyclosporine/cyclosporine microemulsion had to be started with 100 mg/m²/day intravenous (i.v) (2x4h) for 7 days and was to be continued i.v. or orally from day 8 onwards as per center practice. During the 6 months treatment period Cyclosporine doses had to be adjusted according to Cyclosporine A (CsA)-trough levels.
224165794|NCT00149890|DRUG|Steroid|Intravenous prednisolone (loading dose: 300 mg/m2, maximum 500 mg) had to be administered intraoperatively only in treatment arm 1 (day 0). The first dose of steroids in treatment arm 2 (day 0) had to be administered within 8 hours after reperfusion of the graft. Beginning from day 1 to day 6 doses of 15 mg/m2/day had to be given intravenously (i.v.) in both treatment arms. Then, the steroid doses (oral prednisone or its equivalent) were to be decreased from 10 mg/m²/day orally (day 7-13), to 7.5 mg/m²/day orally (day 14-30), to 4 mg/m²/day orally (until end of month 2), to 2.5 mg/m²/day orally (until end of month 3) and to 1 mg/m²/day orally (until end of month 6).
224165795|NCT01894776|DRUG|Rifabutin|Substance: Rifabutin Daily dose: oral, 300 mg once daily (8:00 am) for 10 days
224165796|NCT01894776|DRUG|Maraviroc|Substance maraviroc daily dose 300 mg twice daily (8:00 am and 8:00 pm) for 15 days
224165797|NCT00988377|OTHER|dietary intervention|whey protein 10-40 g
224165798|NCT00988377|OTHER|water control|Iso-volumetric (300 ml) water control (Crystal Springs, Canada)
224165799|NCT03395860|DRUG|ATG|group A:low dose antithymocyte globulin rATG(2.5mg/kg/d) used at d-3-d-2 low dose post-transplant cyclophosphamide PTCy (50mg/kg/d) use at d+3 group B:low dose antithymocyte globulin rATG(2.5mg/kg/d) used at d-2-d-1 low dose post-transplant cyclophosphamide PTCy (50mg/kg/d) use at d+3
224165800|NCT02485860|DEVICE|Melectis G|
224165801|NCT01695460|DRUG|D3 Vitamin ®|"Vitamin D and placebo supplied as tablets in containers of 124. The containers must be kept in dry and not too hot environment.~All subjects randomized to vitamin D, will receive 100 micrograms of vitamin D3/day, equivalent to 4000 IU. Vitamin D is administered orally 1 time a day with breakfast."
224165802|NCT01695460|DRUG|Placebo|
224165803|NCT01895634|DEVICE|Rev-01|Treatment arm patients have used Rev-01 at least once
224165804|NCT04871386|BEHAVIORAL|Acceptance and commitment therapy (ACT) exercises|The ACT group received 14 (partially succeeding) daily exercises, with each of the following categories being focused twice: Acceptance, contact with the present moment, cognitive defusion, self as context, personal values and committed action. The exercises consisted of metaphors and questions for self-reflection, explanations about emotions and thoughts with techniques to handle them differently, as well as a body scan.
224165805|NCT04871386|BEHAVIORAL|Positive psychology (PP) exercises|The PP group received 14 daily exercises that were derived from positive psychology interventions that have been proven effective in alleviating clinical symptoms and increasing subjective well-being. In detail, these were: Identifying positive emotions and ways to increase them; Enhancing pleasure from daily activities; Writing a gratitude letter; Identifying and appreciating three personal traits; Receiving a letter of support from one's future self; Taking different perspectives on one's current situation; Envisioning a perfect day; Identifying energy boosters and drainers; Identifying 3 character strengths and using one in a new way; Life review: Writing a legacy; Identifying the positive relationships in one's life; Doing an act of kindness; Three good things; and Coping with failure.
223479233|NCT07167355|PROCEDURE|POEM|Children randomised to POEM arm will undergo a single session of POEM following an overnight fast. The procedure will be done in supine position under general anaesthesia. A gastroscope (Olympus GIF-HQ190) with a transparent tapered cap fit at its distal end will be used. A mucosal bleb will be created using a 21G sclerotherapy needle and a solution of saline with indigo-carmine dye. A posterior approach will be followed in all patients. A small mucosal incision (2-3mm) will be made using a needle knife and enlarged using an insulated tip knife (2-3cm). The submucosal tunned will then be entered and the submucosal fibres will be cleared using a triangular tip knife (TriangularTipKnife J, Olympus). Full thickness will be performed in all patients. Length of the myotomy will be \~3cm in the oesophagus and \~2cm in the cardia of the stomach. Minor bleeding will be controlled using coagulation forceps. Mucosal injury and resistance at the gastroesophageal junction will be examined. Mucosal i
224165806|NCT04171063|DEVICE|Thoracic compressor|The intervention is the use of the thoracic compressor for the conservative treatment of pectus carinatum
224165807|NCT03325010|DRUG|Valbenazine|vesicular monoamine transporter 2 (VMAT2) inhibitor
224165808|NCT03325010|DRUG|Placebo oral capsule|non-active dosage form
224165809|NCT02382614|DEVICE|Spiration Valve System|
224165810|NCT02402881|BEHAVIORAL|Patient-centered education bundle|A patient-centered education bundle that will be delivered as an in-person, 1-on-1 discussion session with a nurse educator. Supporting education materials include a 2-page patient education sheet and a patient education video.
224165811|NCT05855213|DEVICE|High Velocity Nasal Insufflation|A relatively new respiratory support modality which delivers very high velocity flows. This improves ventilatory efficiency via washing out carbon dioxide occupying the anatomical dead space of the upper airways.
224165812|NCT05855213|DEVICE|Non-invasive positive pressure ventilation|An established non-invasive ventilation method via delivery of an expiratory positive airway pressure and inspiratory positive airway pressure.
224165813|NCT05642793|DRUG|proactive Anti-VEGF (conbercept) use|preventive intravitreal injection of conbercept 2 weeks after vitrectomy, and repeat at 5 weeks and 8 weeks if either of the following is present: intravitreal VEGF concentration at 2 weeks postop is higher than 100 pg/ml, or clinical presentation of DME, VH or NVG.
224165814|NCT05642793|DRUG|passive Anti-VEGF (conbercept) use|No intravitreal injection of conbercept is used until the patient present with postoperative DME, VH, NVG
224165815|NCT04915105|DIAGNOSTIC_TEST|Markers data from PBMCs|Prescreen markers from patient individual PBMCs treating with streptococcus and different biologics.
224165816|NCT00938093|BEHAVIORAL|Cognitive behavioral therapy|Participants receive 10 telephone therapy sessions and an accompanying workbook focused on cognitive-behavioral techniques for managing anxiety.
224165817|NCT00938093|BEHAVIORAL|Enhanced usual care|Participants receive written information about anxiety, referrals for treatment, and an optional letter to their primary care physician.
224165818|NCT01848795|DEVICE|EndoBarrier Gastrointestinal Liner|Endoscopy placement of EndoBarrier, and clinical and biochemical follow up
224165819|NCT01848795|DEVICE|Easy life balloon|Endoscopy placement of EndoBarrier, and clinical and biochemical follow up
224165820|NCT01462591|DIETARY_SUPPLEMENT|L-citrulline|2 weeks of L-citrulline supplementation (100mg/kg of body weight).
224165821|NCT00125892|DRUG|duloxetine|
224165822|NCT00926263|BIOLOGICAL|CP-751,871|single dose, 1-hr IV infusion
224165823|NCT00926263|BIOLOGICAL|CP-751,871|single dose, 1-hr IV infusion
224165824|NCT00926263|BIOLOGICAL|CP-751,871, moxifloxacin, saline|Two doses at 20 mg/kg each on two consecutive days, each administered via 1-hr IV infusion
224165825|NCT01339845|BIOLOGICAL|ShanChol|Each dose of the vaccine contains whole cell Killed inactivated V.cholerae O1 and O139 strains.Vaccine is packaged as liquid formulations in 1.5-ml doses. The vaccine is given two doses separated by a two week interval and administered orally.
224165826|NCT01339845|BEHAVIORAL|Vaccine and behaviour|Together with vaccination the community health worker will offer a hand washing station and water treatment facilities that include both hardware and a software component. The idea of the handwashing station is to bring together with soap and water that people need for handwashing, especially for handwashing after defecation. The hardware for water treatment is a chlorine dispenser that is a reservoir which holds sodium hypochlorite and dispenses a measured dose of the dilute sodium hypochlorite into a 15 liter water tank. Community residents can collect water directly from the 15 L water tanks into their own personal water storage vessels. The community health worker will negotiate with compound residents for the development of a water treatment system.
224165827|NCT05793372|OTHER|Retrospective study of clinical features|Retrospective study of clinical features
224165828|NCT05791773|PROCEDURE|the robot assisted total knee arthroplasty|the robot assisted total knee arthroplasty
224165829|NCT05791773|PROCEDURE|the conventional jig-based total knee arthroplasty|the conventional jig-based total knee arthroplasty
224165830|NCT04556929|DIAGNOSTIC_TEST|Intra-operative imaging of 5-ALA fluorescence using ultra-high sensitivity camera|An ultra-high sensitivity camera attached to the side arm of the operative microscope will be used to take images of the anterior, posterior, lateral and inferior walls of the resection cavity on completion of tumour resection.
224165831|NCT04556929|DIAGNOSTIC_TEST|Intra-operative imaging of 5-ALA fluorescence using in-built operative microscope camera|In-built camera of the operative microscope will be used to take images of the anterior, posterior, lateral and inferior walls of the resection cavity on completion of tumour resection.
224165832|NCT04556929|DIAGNOSTIC_TEST|Biopsies|Following image capture, biopsies (approx 5x5x5mm size) will be taken from regions of the anterior, posterior, lateral and inferior walls of the resection cavity corresponding to the imaged areas.
224165833|NCT00460525|BIOLOGICAL|FMP2.1/AS02A|3 doses administered a month apart: 50 µg recombinant subunit protein FMP2.1 (Plasmodium falciparum Apical Membrane Antigen-1 from strain 3D7 expressed in and purified from Escherichia coli), adjuvanted with 0.5 mL of AS02A (proprietary oil-in-water emulsion and phosphate buffered saline with the immunostimulants monophosphoral lipid A and QS21).
224165834|NCT00460525|BIOLOGICAL|Rabies Vaccine|White, freeze-dried vaccine for reconstitution with the diluent prior to use; dosage 1.0 mL of rabies vaccine.
224165835|NCT00241657|BIOLOGICAL|BCG|
224165836|NCT05094882|PROCEDURE|pulmonary lobectomy|resection of lung lobe
224165837|NCT04984070|DRUG|Oral Contraceptives, Combined|One of the three medications like ethinylestradiol (35 μg) and cyproterone acetate, drospirenone and ethinylestradiol tablets (I) and (Ⅱ) will be used as an antiandrogen.
224165838|NCT04984070|DRUG|Metformin Pill|Metformin is used to lower insulin resistance or to modulate hyperinsulinism.
224165839|NCT04984070|OTHER|lifestyle intervention|Weight control including calorie restriction and moderate exercise will be recommended to obese PCOS patients
224165840|NCT00510575|DEVICE|Spinal rod|Posterior spinal fusion using a 5.5 or 6.35 size rod
224165841|NCT03073200|DRUG|Ixekizumab|Administered SC
224165842|NCT03073200|DRUG|Placebo|Administered SC
224165843|NCT03073200|DRUG|Etanercept|Administered SC
224165844|NCT02421640|DRUG|Cisplatin+TIL|cisplatin 100mg/m2(every three weeks),D1,D22,D43 of radiotherapy,then TIL infusing following concurrent chemoradiotherapy
224165845|NCT02421640|DRUG|Cisplatin|cisplatin 100mg/m2(every three weeks),D1,D22,D43 of radiotherapy only
224165846|NCT05810376|BEHAVIORAL|Digital-based physical activity intervention|The digital behavioral program comprises goal planning, motivational messages and video calls, social support, and routine follow-up of weekly goals.
224165847|NCT05810376|OTHER|Patient education and exercise|Patient education will include information on osteoarthritis, prognosis, pain management, importance of physical activity and exercise. The exercise program will include warm up, stretching and strengthening.
224165848|NCT00713557|DEVICE|drug-eluting stent|drug-eluting stent, including sirolimus-eluting, paclitaxel-eluting and other types of China-made drug-eluting stent
224165849|NCT00713557|DRUG|Tirofiban|upstream (in emergency room) versus downstream (in catheterization lab) intra-coronary loading versus conventional intravenous loading
224165850|NCT04443868|DRUG|Nitric Oxide-Releasing Drug|Nasal Spray + Nasal Irrigation
224165851|NCT05885906|DRUG|Aloevera|Mouthwash
224165852|NCT05885906|DRUG|Thyme honey|Mouthwash
224165853|NCT05885906|DRUG|Saline|Mouthwash
224165854|NCT00886691|BIOLOGICAL|Bevacizumab|Given IV
224165855|NCT00886691|DRUG|Everolimus|Given PO
224165856|NCT00886691|OTHER|Laboratory Biomarker Analysis|Correlative studies
224165857|NCT00886691|OTHER|Placebo|Given PO
224165858|NCT01739374|OTHER|reduced mesh implants|mesh for pelvic floor reinforcement
224165859|NCT05478967|PROCEDURE|IVA injection before vitrectomy|Patients in IVA group received an IVA (0.5 mg/0.05 ml) injection before surgery (1 to 5 days before surgery)
224165860|NCT02583464|DRUG|Tenofovir disoproxil fumarate and emtricitabine|Two period administration of a formulation containing a combination of emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg.
224165861|NCT03875833|DEVICE|Collagen Nerve Wrap Conduit|The collagen nerve wrap conduit will be placed on all exposed radial and ulnar nerves at the time of free flap harvest.
224165862|NCT05255497|DEVICE|Biodex Balance Exercise System|Patients in the intervention group (n=14) performed exercises using the computerized BBS. The control group (n=13) was just informed about diabetes self-management.
224305220|NCT00593736|DRUG|Ramelteon|Ramelteon 8 mg, tablets, orally, once daily for up to two weeks.
224305221|NCT00593736|DRUG|Placebo|Ramelteon placebo-matching tablets, orally, once daily for up to two weeks.
224305222|NCT05442710|BIOLOGICAL|ARTICE|Extracorporal treatment with purified granulocyte concentrate
224165863|NCT01238276|DRUG|Cefazolin|Cefazolin is approved for clinical use for some bacterial infections. The standard routes of administration are Intramuscular (IM) and intravenous (IV). For this study, the route of administration will be delivered using the Silberg TPS, which delivers the cefazolin by subcutaneous injection followed by external ultrasonic dispersion. The concentration delivered is one gram/100 ml saline. Cefazolin can safely be given IM at the much higher concentration of 1 gram/2.5 ml of saline. The maximum dose that may be administered is 3 grams in 300 ml, which is within the approved guidelines of a daily dose. The concentration of antibiotic will be the same; only the dose may vary depending on the size of the wound or area of induration. Each subject will receive only one treatment in this study.
224165864|NCT01238276|DEVICE|Silberg Tissue Preparation System|The TPS is FDA cleared for the subcutaneous infusion and ultrasonic dispersion of tumescent fluid excluding the parenteral delivery of drugs. Under this study, the TPS is a device to deliver cefazolin by subcutaneous injection followed by external ultrasonic dispersion. The TPS consists of a medical grade peristaltic pump that is used to infuse antibiotic solution using a sterile blunt-tipped infusion cannula into a superficial subcutaneous plane. After the cannula has been removed, high frequency external ultrasound is delivered transcutaneously over the area of infusion in order to disperse the antibiotic solution. The power density is within the range allowed for physical therapy.
224165865|NCT00392951|DRUG|sirolimus|Tablet or liquid; taken once or twice daily; dosage is based on establishing a serum trough of 5-15 ng/ml by high-performance liquid chromatography (initial loading dose of 3 mg/m2 then 2.5 mg/m2 with adjustment based on serum trough)
224165866|NCT04927351|BEHAVIORAL|Electronic Medical Record Based Discharge Medication Order Set|New medication discharge order set including recommended opioid quantities, adjunct pain medication
224165867|NCT03026205|DRUG|ARMS-I|
224165868|NCT05116683|DRUG|ATX-101|Patients will be given ATX-101 at 60 mg/m2 IV weekly in continuous 21 day cycles.
224165869|NCT06249880|OTHER|Observation|This project seeks to recruit 20 male and 20 female typically developing individuals, between the ages of 3 and 25 years of age. Non-invasive measurements of movement patterns (motion analysis and force plate data) will be collected during bipedal gait.
224165870|NCT06694233|OTHER|Aspirin prescription on outpatient basis|Improving aspirin prescription rates for candidate patients (moderate- and high-risk obstetric population)
224165871|NCT01474889|DEVICE|RT-CGM|Each device is approximately the size of a pager and transmits with a subcutaneously placed sensor consisting of a 21 - 26 gauge needle 5 - 12 mm in length. Sensors are placed using sterile precautions and changed every 3 - 7 days depending on the manufacturers' instructions. All devices are approved as adjunctive tools to blood glucose monitoring that will be continued at least 4 times daily, before each meal and at bedtime.
224165872|NCT05746689|DRUG|Sirolimus|Sirolimus The efficacy is evaluated at 12 weeks, and treatment will be adjusted according to the control of disease and adverse effects.For experimental group, if a patient is assessed as treatment failure (TS), the patient should be withdrawn from the study and receive rescue treatment. Whereas, a patient would be transferred to the control group if he/ she cann't stand the side effects of sirolimus but not serious adverse event (SAE).
224165873|NCT04245657|OTHER|Tissue Dielectric Constant Measurement|Sub-tissue fluid proportion will be evaluated via Moisture Meter D (Delfin Technologies, Kuopio, Finland) on both upper extremity (right and left) in predefined reference points on volar side (6 cm distal and 8 cm proximal points from cubital crease, 10 cm inferior side point from axilla and dorsal point of web space in the hand) by using four different probes which can assess 0.5 mm, 1.5 mm, 2.5 mm and 5.0 mm depth. Values taken by 2.5 mm depth probe will be used to calculate the ratio (affected side TDC value/Unaffected side TDC value) to stage lymphedema severity along with the International Society of Lymphology staging system. This device mainly aims to assess the dielectric constant of tissues which is related to the amount of tissue water. In the case of pre-lymphedema or lymphedema, one can assess objectively regarding sub-tissue fluid changes via this device. Triplicate measurements will be taken for each reference point.
224165874|NCT04245657|OTHER|Muscle strength measurement|Participants' muscle strength of shoulder flexion, abduction, and elbow flexion will be assessed via Handheld digital dynamometer (Lafayette Manual Muscle Tester, Model 01165, LaFayette Instruments, NY, USA). Both upper extremities will be assessed three times and the average value will be recorded.
224165875|NCT04245657|OTHER|Hand-Grip Strength Measurement|Handgrip strength will be assessed with LaFayette Professional Hand Dynamometer, Model 5030L1, LaFayette Instruments, NY, USA). The standard position which can be achieved by 90-degree elbow flexion, shoulder abducted, and hand mid-prone positioned; 90-degree shoulder abduction and 90-degree shoulder abduction positions will be used to assess hang-grip strength. Three measurements will be requested and the maximum value of them will be recorded. 1 minute resting period will be provided between the positions at which handgrip is assessed.
224165876|NCT04245657|OTHER|Pain Threshold Measurement|The sensitive pain threshold and normal pain threshold will be evaluated by a digital algometer (Wagner FDIX, Greenwich, USA) on reference points as follows: C5-C6 zygapophyseal joints' lateral points, upper trapezius (proximal, middle and distal lateral points, length measured by a tape from C7 Processus spinosus to acromion and this length will be divided equally into three parts for proximal, middle and distal lateral point), deltoid muscle (crista deltoidea), dorsum of the webspace.
224165877|NCT04245657|OTHER|International Physical Activity Questionnaire-Short Form (IPAQ-SF)|This scale was intended to be filled to assess participants' physical activity levels within the last seven days. Then, MET calculations will be done via a basic Excel Spreadsheet which is pre-defined MET values formulated inside. Scale data then obtained according to the participants' answers and recorded.
224305223|NCT01268332|DRUG|Non-medicated Intravaginal Ring|Cured silicone elastomer composed of an elastomer base, normal propylorthosilicate, and titanium dioxide. The ring will not contain an active pharmaceutical ingredient.
224075811|NCT04867317|OTHER|Placebo|Participants (n=172) will be randomized in a 1:1 ratio to rhGH (n=86) versus placebo (n=86) for six months, stratified by participating site. Both study participants and the study team will be blinded to treatment assignment. All participants will complete in-clinic follow-ups at Days 14, 40, 65, and 90 (3 months) and at day 180 (6 months). The primary outcome will be the mean difference in QoL-AGHDA scores between treatment arms at 6 months follow-up. Patients will discontinue the study intervention at 6 months, and will be followed-up two weeks subsequent, in order to assure patient safety and wellness, and to ensure maximal facilitation of patient transition back into routine care.
224165878|NCT04245657|OTHER|Fatigue Impact Scale|"This scale has 9 items that can be answered as Strongly Disagree through Strongly Agree by numbered as 1 and 7, respectively. Then total points will be calculated and divided into 9 to achieve the Fatigue Impact Scale score. The higher points will be indicated more perceived fatigue, while lower points indicate less."
224165879|NCT04245657|OTHER|Disabilities of Arm, Shoulder and Hand Scale (DASH)|"DASH has 30 items related to upper extremity function. Participants will be requested to grade some expressions related to the function within a 5-point Likert scale as follows: No difficulty: 1, Mild Difficulty:2, Moderate Difficulty: 3, Severe Difficulty: 4 and Unable to perform: 5). The symptom score of the DASH will be calculated as dividing filled items total score to filled items' number and minus one from this data then multiplying with 25. The higher points indicate a deteriorated shoulder and hand function while lower points indicate a better upper extremity function."
223479234|NCT07167355|PROCEDURE|BALLOON DILATATION|"Children randomised to BD arm will undergo BD of 30mm (Rigiflex II, Achalasia balloon dilators, Boston Scientific) following an overnight fast. The balloon will be positioned at the gastroesophageal junction and inflated to a diameter of 30mm with a pressure of 5psi initially and gradually the pressure will be increased to a maximum of 15 psi till the disappearance of waist fluoroscopically. A note will be made at the pressure at which the waist disappears and will be maintained for 1 minute. One month after the initial session, if the Eckardt score \>3 or if the TBE shows a barium column of \>5cm at 5 minutes, a second session of BD will be done using a 35mm balloon.~These children will be kept nil per oral for 4 hours post procedure. They will be observed for signs of perforation (crepitus, hemodynamic instability, chest pain). If they are stable, a clear liquid (water) will be provided. If there is no pain, they will be discharged with an advise to follow soft diet for a day"
223479235|NCT07167056|BEHAVIORAL|Standard of Care Psychotherapy|Participants will receive six psychotherapy sessions over the course of approximately 3 months.
223584387|NCT04214912|COMBINATION_PRODUCT|Personalized Survivor Care Plan (PSCP)|Based the above literature review and our previous 10 years' efforts in OC patients' distress and care needs survey, we categorize OC patients' distress and needs into 6 major dimensions (1) symptoms management and dysfunction prevention (different kind of symptom, such as swallowing difficulty, eating difficulty, speaking difficulty, difficulty in opening mouth/trismus, shoulder dysfunction, mucositis, pain, fatigue, etc), (2) enhancing physical function (exercise skills, types for major parts of muscle training), (3) Confronting and dealing with psychological distress (fear, anxiety, depression, uncertainty), (4) nutrition assessment and counseling, (5) Social connection and RTW counseling (attitudes and skills for returning to work), and (6) overall needs assessment and supports.
224075812|NCT06102434|DRUG|Psilocybin|Five oral capsules containing 5 mg of psilocybin each
224075813|NCT06085352|DRUG|TetraLens bandage contact lens|Methafilcon-A contact lens eluding tetracaine ophthalmic solution
224075814|NCT06085352|DEVICE|Control Acuvue Oasys Bandage contact Lens|Standard of care bandage contact lens
224075815|NCT03403686|BIOLOGICAL|blood draw|Blood sample will be obtained and CD34+ cells will be isolated for functional testing.
224075816|NCT05196035|DRUG|Finerenone (Kerendia, BAY94-8862)|Finerenone in different doses, treatment duration will be 180±7 days
224075817|NCT05196035|DRUG|Placebo|Placebo to finerenone, treatment duration will be 180±7 days
224075818|NCT06033079|BEHAVIORAL|Clinical Decision Support|For enrolled subjects assigned to the decision support arm, providers will receive prognostic information derived using our previously validated and best performing model. The decision support application will automatically calculate predicted risk for moderate (intensive care) and severe (respiratory failure or shock) outcomes using the parameters derived from the prognostic tool's regression equation. Outcome probabilities will be integrated into the decision support application and displayed within the EHR.
224075819|NCT05783596|DRUG|Obinutuzumab|Humanized glycoengineered type II anti-CD20 monoclonal antibody, via IV infusion.
224075820|NCT05783596|DRUG|Glofitamab|T-cell bispecific humanized monoclonal antibody, via IV infusion.
224075821|NCT03512418|BEHAVIORAL|PrEPsteps|Smartphone-based adherence intervention based in 1) LifeSteps, 2) Contingent Reinforcement/Corrective Feedback, and 3) Screening Brief Intervention and Referral to Treatment (SBIRT).
224075822|NCT03512418|DEVICE|Digital pill|The digital pill comprises a standard gelatin capsule with an integrated radiofrequency emitter that overencapsulates the desired medication (Truvada). When participants ingest the digital pill, the chloride ion gradient in the stomach activates the radiofrequency emitter which transmits direct evidence of medication ingestion to a wearable reader which relays this data to the participant's smartphone and cloud server.
224075823|NCT03512418|DRUG|Truvada|Participants receive once daily Truvada as PrEP to prevent HIV.
224075824|NCT06529120|BEHAVIORAL|Mindfulness-Based Therapy for Insomnia with Cognitive-Behavioral Symptom Coping Skills|Mindfulness-based sleep strategies and cognitive-behavioral symptom coping skills.
224075825|NCT05689983|DRUG|Maintenance ICS and Symptom Driven SABA|In this intervention, patients will be assigned to a standard therapy with a maintenance inhaled corticosteroid (Flovent) and an as needed short-acting beta-agonist and their adherence to this regimen will be assessed and compared to patients taking a regimen with an as needed inhaled corticosteroid and long-acting beta-agonist.
224075826|NCT05689983|DRUG|Symptom-driven budesonide/formoterol combination|In this intervention, patients will be assigned to a symptom-driven budesonide/formoterol combination therapy (Symbicort) and their adherence to this regimen will be assessed and compared to patients taking a standard therapy with a maintenance inhaled corticosteroid and as needed short-acting beta-agonist.
224075827|NCT04202679|DRUG|Dupilumab SAR231893|Pharmaceutical form:Injection solution Route of administration: Subcutaneous
224075828|NCT04202679|DRUG|Placebo|Pharmaceutical form:Injection solution Route of administration: Subcutaneous
224075829|NCT04202679|DRUG|Moisturizers|"Pharmaceutical form:~Route of administration: Topical"
224075830|NCT04202679|DRUG|Low to medium potent topical corticosteroids|"Pharmaceutical form:~Route of administration: Topical"
224075831|NCT04202679|DRUG|Topical calcineurin inhibitors|"Pharmaceutical form:~Route of administration: Topical"
224075832|NCT04201119|DEVICE|Oxiris|Oxiris membrane used on the Prismaflex device (Baxter) dedicated to that type of membrane at blood pump flow of 450 ml min-1
224075833|NCT05505552|DIETARY_SUPPLEMENT|Vitamin K|1 mg/day phylloquinone (vitamin K1)
224075834|NCT05505552|DIETARY_SUPPLEMENT|Placebo|Placebo capsule once daily
224165880|NCT04245657|OTHER|Exercise Benefits/ Barriers Scale|Exercise Benefits/Barriers Scale has 43 items each can be graded within a four-point Likert type scale. Barrier items are reverse coded. 43 items are all related to exercise and exercise beliefs in both in the aspect of health and general. Strongly disagree, disagree, agree, strongly agree will be scored as 1,2,3,4 or vice versa whether the item should de reversely coded, respectively. Total scores ranged between 29 and 172. The barrier scale score is ranged between 14 and 56. The benefits scale is also ranged between 29 and 116. The higher the score of Barriers scale, the greater the perception of barriers to exercise.
224165881|NCT04245657|OTHER|Beck Depression Scale|Beck Depression Scale has 21 items each can be scored within 0 to 3. All items are related to the depressive mood of a participant. The higher the score of the Beck Depression Scale, the higher the depression level.
224165882|NCT03298048|BIOLOGICAL|Low fecal microbiota dose|receiving healthy microbiota (PRIM-DJ2727) collected from 50g stool for 2 consecutive days
223479236|NCT07167056|BEHAVIORAL|WYSA App|Participants will have access to the WYSA mental health support artificial intelligence app over the course of the 3 months that they are participating in psychotherapy sessions per standard of care. The app will contain features intended to manage symptoms of depression and anxiety in individuals with cancer. The app will include an AI-powered chatbot with Cognitive Behavioral Therapy (CBT) and mindfulness techniques, visual progress elements (a progress roadmap, a weekly progress report, etc.), and a customizable tool library. Participants are instructed to use the app whenever they feel like it, if they are in distress, or if the app prompts them to use it. App prompts (notifications) will occur once daily.
224165883|NCT03298048|BIOLOGICAL|Mid fecal microbiota dose|receiving healthy microbiota (PRIM-DJ2727) collected from 100g stool on the 1st day of treatment and from 50g stool on the 2nd day of the treatment
224165884|NCT03298048|BIOLOGICAL|High fecal microbiota dose|receiving healthy microbiota (PRIM-DJ2727) collected from 100g stool for 2 consecutive days
224165885|NCT01492816|BEHAVIORAL|Community Mobilization|The proposed study seeks to continue C2P community mobilization efforts that have developed coalitions that plan for and bring about structural changes for purposes of reducing Human Immunodeficiency Virus (HIV) incidence and prevalence among youth in targeted communities at nine sites. Earlier phases of C2P have been outlined in ATN Protocols 016a, 016b, 040/040b. The C2P community mobilization model entails: determining a geographic area and population of focus for the coalitions to prioritize their planning and action (accomplished in an earlier phase of C2P); coalitions establishing a shared vision and mission; development of a strategic plan focused on structural changes to reduce risks associated with HIV; process documentation; and feedback as technical assistance to the coalitions.
224165886|NCT05056636|DIAGNOSTIC_TEST|Plasma α-Gal A activity; Plasma Lyso-GB3; GLA genetic sequencing.|"Screening Visit 1:~1. Male patient will first screened by enzymatic assay (Cutoff: 1.3 μM /hr)~2. Female patient will first screened by lyso-GB3 (Cutoff: \> 5ng/ml)~Screening Visit 2:~If both male and female who has deficient enzymatic level (Cutoff: 1.3 μM /hr) or lyso-GB3 level (Cutoff: \> 5ng/ml) respectively, those patients will be confirmed whether they have carried Fabry Disease causing mutation by whom GLA genetic sequencing."
224165887|NCT02282488|OTHER|Low protein formula|
224165888|NCT02282488|OTHER|High protein formula|
224165889|NCT04856215|DRUG|90-Yttrium-labelled anti-CD66 monoclonal antibody|"The Investigational Medicinal Product (IMP) consist of 1) 111Indium- and 2) 90Yttrium-labelled anti-CD66 (BW250/183) monoclonal antibody.~The anti-CD66 is a murine IgG1 monoclonal antibody originally developed as an in vivo leucocyte and bone marrow imaging agent (Boßlet 1985, Thomsen 1991). BW 250/183 anti-CD66 is a murine IgG1 kappa monoclonal antibody, originally produced as an anti-CEA antibody.~The batch of antibodies required for treatment will be radiolabelled by Royal Free Hospital radiology team with Indium 111 and Y90 for patient."
224165890|NCT03935594|BIOLOGICAL|PRP Injection|1mL platelet rich plasma will be injected into each 1cm x 1cm area of scar tissue of the experimental half of the scar.
224165891|NCT03935594|DRUG|Saline Injection|1mL NS will be injected into each 1cm x 1cm area of scar tissue of the control half of the scar.
224165892|NCT04229082|OTHER|observational|
224165893|NCT01963962|DRUG|Copper IUD|
224165894|NCT01963962|DRUG|Levonorgestrel IUD|
224165895|NCT01343576|DIETARY_SUPPLEMENT|milk fat|45 g milk fat per day in 4 weeks
224165896|NCT01803529|OTHER|heat-pack with massage|
224165897|NCT01803529|OTHER|heat-pack only|
224165898|NCT00909194|BEHAVIORAL|Psychoeducational Seminar and Relaxation Technique|Psychoeducational seminar on Juvenile Primary Fibromyalgia (pain management, diet, exercise and sleep hygiene) followed by a total body relaxation technique
224165899|NCT00438776|DRUG|olanzapine|2.5mg to 15mg daily
223479237|NCT07167004|BEHAVIORAL|Marketing Nudges Only|Marketing nudges encouraging whole grain purchasing, including displaying whole grains (e.g., whole wheat bread, brown rice) at the top of the study's online grocery store, featuring whole grain banner displays, and offering product swaps to highlight whole grain alternatives
224165900|NCT00438776|DRUG|sugar pill|matching placebo to olanzapine
224165901|NCT00372294|DRUG|pyrimethamine-sulfadiazine + prednisolone|Administration of pyrimethamine-sulfadiazine + prednisolone
224165902|NCT00372294|DRUG|Clindamycin+Dexamethasone|Intravitreal injection of Clindamycin+Dexamethasone
224165903|NCT01435122|DRUG|Axitinib|Axitinib Administration as outlined in Arm description
224165904|NCT00003992|BIOLOGICAL|trastuzumab|
224165905|NCT00003992|DRUG|cyclophosphamide|
224165906|NCT00003992|DRUG|doxorubicin hydrochloride|
224165907|NCT00003992|DRUG|paclitaxel|
224165908|NCT00003992|DRUG|tamoxifen citrate|
224165909|NCT03233672|RADIATION|Hypo-fractionated postoperative IMRT-SIB|intensity-modulated radiation treatment with simultaneous integrated boost
224165910|NCT03954704|DRUG|Dalutrafusp alfa|Administered intravenously
224165911|NCT03954704|DRUG|mFOLFOX6 Regimen|Chemotherapy regimen of oxaliplatin, 5-fluorouracil \[5-FU\], and leucovorin
224165912|NCT03954704|DRUG|Dalutrafusp alfa|Administered intravenously
224165913|NCT03628040|DRUG|Ropivacaine Injection [Naropin]|Ropivacaine will be injected in the erector spinae plane
224165914|NCT03628040|DRUG|Normal saline|Normal saline will be injected in the erector spinae plane
224305224|NCT05227911|PROCEDURE|Abdominal Surgery|Abdominal surgery (laparotomy or laparoscopy) ,which includes proper inspection of the abdominal cavity.
224305225|NCT01857271|DRUG|Erlotinib Hydrochloride|Given PO
223479238|NCT07167004|BEHAVIORAL|Marketing Nudges + Dynamically Adapted Financial Incentives|Marketing nudges encouraging whole grain purchasing, including displaying whole grains (e.g., whole wheat bread, brown rice) at the top of the study's online grocery store, featuring whole grain banner displays, and offering product swaps to highlight whole grain alternatives, plus personalized financial incentives with individual incentive amounts optimized weekly based on prior whole grain purchasing behavior and engagement
224165915|NCT04412668|DRUG|Efzofitimod 1 mg/kg|Concentrate for solution for infusion
224165916|NCT04412668|DRUG|Efzofitimod 3 mg/kg|Concentrate for solution for infusion
224165917|NCT04412668|DRUG|Placebo|Concentrate for solution for infusion
223479239|NCT07168239|BEHAVIORAL|ENHANCING VASCULAR ACCESS SELF-CARE IN HEMODIALYSIS PATIENTS|A set of health education sessions were developed for patients who did not exhibit fully adequate behaviour in the first assessment of the Scale of Assessment of Self-Care with AVF in HD. The sessions were conducted individually through an expository method and providing an informative leaflet. The sessions focused on the areas presented by the scale, i.e. prevention of thrombosis and infection, signs and symptoms of intra/interdialytic complications, haemostasis care, protection of the AV limb and correct assessment of signs and symptoms suggestive of complications with the AVF, evaluation of AVF functionality and detection of thrombosis, changes in colour and sensitivity of the hand corresponding to the AV, pain in the AV limb
223479240|NCT07168200|DRUG|SHR-1316 Injection|SHR-1316 injection.
223479241|NCT07168200|DRUG|Cisplatin Injection|Cisplatin injection.
223479242|NCT07168200|DRUG|Carboplatin Injection|Carboplatin injection.
223479243|NCT07168200|DRUG|Paclitaxel Injection|Paclitaxel injection.
223479244|NCT07168200|DRUG|SHR-1316 Placebo Injection|SHR-1316 placebo injection.
223479245|NCT07168148|DRUG|Oxymetazoline + Triamcinolone|"Participants will be stratified according to this usage and placed into a titration schedule.~* Titration 1: 0.05% 5x/day,~* Titration 2: 0.05% 4x/day,~* Titration 3: 0.05 3x/day,~* Titration 4: 0.05% 2x/day.~Participants with twice daily use, will then be placed in a titration schedule for oxymetazoline concentration which will stop when the oxymetazoline concentration is set to zero.~* Titration 5: 0.0375% Afrin/Nasacort 2x/day,~* Titration 6: 0.025% Afrin/Nasacort 2x/day,~* Titration 7: 0.0125% Afrin/Nasacort 2x/day,~* Titration 8: 0.0% Afrin/Nasacort 2x/day."
223479246|NCT07167342|DRUG|Clostridium butyricum capsules, Live|Oral Clostridium butyricum capsules, Live: take 3 capsules twice daily (bid) for the first 3 months after adenoma resection, then continue with 3 capsules once daily (qd) until 3 years post-resection (each capsule contains ≥6.3 × 10⁶ CFU of Clostridium butyricum).
224075835|NCT06388655|DEVICE|mobile neurofeedback|The participants were randomly assigned to the MNF active (N=31) or sham control (N=30) groups. The MNF program was administered using a mobile app (equipped with a headset with a 2-channel EEG sensor) for 30 min/day, 3 days/week, for 3 months.
224165918|NCT03017040|DEVICE|CT scan|A CT scan of the wrist
223479247|NCT07167342|OTHER|Control (placebo)|Placebo capsules containing corn starch, with identical appearance, weight, and administration method as the treatment group.
224165919|NCT03017040|DEVICE|Fluoroscopy Scan|A fluoroscopy scan of the wrist.
223479248|NCT07169175|DRUG|SNUG01|AAV (adeno-associated virus) Gene therapy
223479249|NCT07167420|PROCEDURE|RISE (Revolute Insert Side-End ileocecal valve reconstruction)|After performing a conventional right hemicolectomy, an additional step is carried out in which sutures are used to artificially reconstruct an ileocecal valve structure at the ileal stump before proceeding with the ileocolic anastomosis.
223584388|NCT06358586|DRUG|Tachipirina® 120 mg/5 mL oral suspension, new flavour|A single oral dose of the Tachipirina® 120 mg/5 mL oral suspension(10 mL) will be administered to healthy paediatric volunteers under fasting conditions for at least 1 h before IMP administration until completion of palatability assessment.
224165920|NCT05202002|BEHAVIORAL|Video clip|"After obtaining written informed consent, participants received a sealed envelope containing a preprinted paper referral to an online website, with a unique identifier.~After entering the online website, participants will be asked to enter the unique identifier they have received into a text box. Only those whose identifiers were predetermined to be associated with the intervention group will receive the intervention.~The intervention is twenty minutes long educational video clip, in which a brief discussion was presented, by an obstetrician, pediatrician, dietitian, and a breastfeeding consultant, each presenting the benefits of breastfeeding for mother and newborn."
224305226|NCT01857271|PROCEDURE|Therapeutic Conventional Surgery|Undergo thoracotomy
224305227|NCT01857271|OTHER|Laboratory Biomarker Analysis|Correlative studies
223584389|NCT00213096|DRUG|Nestorone/ethinyl estradiol contraceptive vaginal ring; levonorgestrel/ethinyl estradiol oral contraceptive|
223584390|NCT04468074|DEVICE|Virtual Reality Therapy for Chronic Pain|"1. A 1 1/2 PowerPoint-based education session on the science behind chronic pain and a basic overview of the VR therapy~2. Virtual Reality Therapy: a virtual reality therapy consisting of different psychological training exercises"
224305228|NCT02390609|DRUG|Ibrutinib (Treatment A) [Reference]|Participants will receive Ibrutinib 560 milligram (mg) (4\*140 mg) capsule as Treatment A under fasted conditions in one of the treatment periods.
224305229|NCT02390609|DRUG|Ibrutinib (Treatment B)|Participants will receive Ibrutinib 560 mg suspension as Treatment B under fasted conditions in one of the treatment periods.
224305230|NCT02390609|DRUG|Ibrutinib (Treatment C)|Participants will receive Ibrutinib 560 mg suspension as Treatment C under fed (high-fat) conditions in one of the treatment periods.
224305231|NCT02390609|DRUG|Ibrutinib (Treatment D)|Participants will receive Ibrutinib 560 mg sprinkle capsule granules as Treatment D under fasted conditions in one of the treatment periods.
224075836|NCT06388655|DEVICE|sham mobile neurofeedback|The sham neurofeedback was implemented through presenting randomized game outcomes, independent of real measurements. The scoring distribution was meticulously adjusted to achieve a realistic spectrum of results, prioritizing median scores to uphold uniformity in user experience.
224165921|NCT05202002|BEHAVIORAL|No video clip|Participants in this group will receive a unique identifier that belongs to the control group, thus no video clip will be displayed.
224165922|NCT01886495|OTHER|nutrition intervention|
224165923|NCT01001143|DRUG|Decitabine|
224165924|NCT01001143|DRUG|Bexarotene|
224165925|NCT01428414|DRUG|Trastuzumab|2 mg/kg, iv, d1,8,15(loading dose 4mg/kg wk1), qw
224165926|NCT01428414|DRUG|Paclitaxel|75mg/m2, iv d1, 8,15. qw; 4-6 cycles
224165927|NCT01428414|DRUG|Epirubicin|75mg/m2, iv d1, q3w, 4-6 cycles
224165928|NCT01428414|DRUG|Carboplatin|AUC 2, qw, iv d1, 8,15. 4-6 cycles
224165929|NCT01804647|OTHER|No study treatments administered - blood draws only|
223584391|NCT06164288|DRUG|Human Amniotic Epithelial Stem Cell Injection|"The dose escalation is carried out according to the 3+3 ascending principle, and a total of 3 dose levels are set:~1. Dose Level 1: 1×106 cells/kg;~2. Dose Level 2: 2×106 cells/kg;~3. Dose Level 3: 3×106 cells/kg; Note: In this study, if the maximum tolerated dose (MTD) is not explored at dose level 3 (3×106 cells/kg), it will be discussed by the Safety Review Committee (SRC) to decide whether to proceed with further dose escalation or expansion to 6 patients."
224165930|NCT00058773|DRUG|Infusion of EBV Specific Cytotoxic T-Lymphocytes|"EBV specific cytotoxic T-lymphocytes will be given by intravenous injection over 1-10 minutes.~Each patient will receive two injections, 14 days apart."
224165931|NCT02094664|DEVICE|Heated and humidified oxygen|
224165932|NCT04137055|DRUG|ZSP0678-10mg|ZSP0678 tablet administered orally under fasted condition
224165933|NCT04137055|DRUG|ZSP0678-30mg|ZSP0678 tablets administered orally under fasted condition
224165934|NCT04137055|DRUG|ZSP0678-60mg|ZSP0678 tablets administered orally under fasted condition
224165935|NCT04137055|DRUG|ZSP0678-120mg|ZSP0678 tablets administered orally under fasted condition
224165936|NCT04137055|DRUG|ZSP0678-180mg|ZSP0678 tablets administered orally under fasted condition
224165937|NCT04137055|DRUG|ZSP0678-240mg|ZSP0678 tablets administered orally under fasted condition
224165938|NCT04137055|DRUG|ZSP0678-320mg|ZSP0678 tablets administered orally under fasted condition
224165939|NCT04137055|DRUG|ZSP0678|ZSP0678 tablets administered orally under fasted or fed condition
224305232|NCT02390609|DRUG|Ibrutinib (Treatment E)|Participants will receive Ibrutinib 560 mg sprinkle capsule granules as Treatment E under fed (high-fat) conditions in one of the treatment periods.
224305233|NCT02390609|DRUG|Ibrutinib (Treatment F)|Participants will receive Ibrutinib 560 mg sprinkle capsule granules suspended in water as Treatment F under fasted conditions in one of the treatment periods.
224305234|NCT03881020|DRUG|Silver diamine Fluoride 38%|In the intervention group 38% Silver Diamine Fluoride will be applied to the surface of the isolated lesion for a period of 1 minute followed by glass ionomer restoration at the same visit.
224305235|NCT03881020|PROCEDURE|Conventional atraumatic restorative treatment|In the active comparator group caries will be removed from primary molars using sharp excavators then teeth will be restored using glass ionomer filling material at the same visit.
223479250|NCT07167251|DRUG|Low-dose corticosteroids for immune-related hepatitis grade 3|Prednisolone 0.5-1 mg/kg orally for grade 3 IR-hepatitis; adjusted based on liver function; treatment per local standard of care.
223479251|NCT07167251|DRUG|Low-dose corticosteroids for immune-related hepatitis grade 2|Hold immunotherapy and reassess liver function at the treating physician's discretion. If liver function tests persistently worsen or continue to rise, consider administering prednisolone at 0.5 mg/kg body weight
223479252|NCT07168304|DRUG|S. boulardii|Participants received zinc plus S. boulardii supplementation according to the World Health Organization recommendations.
224165940|NCT04137055|DRUG|ZSP0678-Dose 1|ZSP0678 tablets administered orally once daily for 14 Days
224165941|NCT04137055|DRUG|ZSP0678-Dose 2|ZSP0678 tablets administered orally once daily for 14 Days
224305236|NCT02192320|DRUG|Atorvastatin|20 mg (every evening orally) for 5 weeks
223479253|NCT07168785|DRUG|[18F]-AraG radiotracer|\[18F\]-AraG radiotracer, which occurs on the first and sixteenth day of treatment.
223479254|NCT07168785|DRUG|Chemotherapy|Concurrent chemoradiotherapy (CRT) with weekly doses of cisplatin.
223479255|NCT07168785|DEVICE|Radiotherapy|Concurrent chemoradiotherapy (CRT) of 70Gy of radiation dose in 33 fractions.
223479256|NCT00788385|DEVICE|ShuntCheck test|
224165942|NCT04137055|DRUG|ZSP0678-Dose 3|ZSP0678 tablets administered orally once daily for 14 Days
224165943|NCT04137055|DRUG|ZSP0678 Placebo|Participants will receive placebo matching to ZSP0678 orally.
224165944|NCT06335160|DRUG|Mebendazole|mebendazole group, n = 23) which will receive the standard treatment for UC plus mebendazole 500 mg twice daily for 6 months
224165945|NCT03327246|DEVICE|Connecare self managment system|The CONNECARE SMS will rely on a hybrid solution that, besides being autonomous (the patient may use the SMS to monitor and access to her/his data and information), has also a collaborative component (through the interaction with the SACM) to allow participation by clinicians and to provide feedback to them. In so doing, the patient may control her/his activity, receiving recommendations to improve the treatment and to be encouraged in following it.
224165946|NCT03377829|PROCEDURE|PLA|During the PLA, the patient is in supine position with head extended: the physician, ultrasound assistant and trained nurse work within the sterile field. Under constant ultrasound image guidance and after local anesthesia by means of 2% xylocaine infiltration, thin needles (21G) are positioned in the thyroid lesion, within safety distance from the surrounding anatomical structures. A plane-cut tip fiber optics is inserted into the PTMC through the needle. The laser at 1064 nm wavelength is turned on for 10 minutes until the pre-established energy dose is attained. There is usually no pain or very limited pain.
224165947|NCT03377829|PROCEDURE|Thyroid Surgery|Patients are routinely disinfected and spread the drapes after general anesthesia. Neck skin, fat, placenta muscle are incised successively. The flap is separated to the upper edge of thyroid cartilage, neck white line is incised and anterior muscle group is separated. Then both sides thyroid lobes are exposed. Cut off the isthmus, ligature the thyroid artery, cut off the upper pole. Ligature and cut off the ipsilateral thyroid vein. Reveal and protect the ipsilateral recurrent laryngeal nerve and the parathyroid gland during the entire process. Finally patient is performed total thyroidectomy or subtotal thyroidectomy.
224165948|NCT02482389|RADIATION|Single fraction of 7 Gy|All subjects will receive a single 7 Gy fraction of radiotherapy to the intact tumor prior to surgery.
224165949|NCT02159989|DRUG|Sapanisertib|Given PO
224165950|NCT02159989|BIOLOGICAL|Ziv-Aflibercept|Given IV
224165951|NCT00005629|BIOLOGICAL|AFP gene hepatocellular carcinoma vaccine|"Patients will receive three biweekly intradermal vaccinations with four HLA-A\*0201-binding AFP-derived peptides emulsified in 2 ml of Montanide ISA-51.~Group A AFP peptide dose 100 ug Group B AFP peptide dose 500 ug Group C AFP peptide dose 1000 ug"
224165952|NCT03557229|DRUG|Melatonin 5 mg|Oral: 50 mg once daily for 5 days
224165953|NCT03557229|DRUG|Vitamin C 1 GM Oral Tablet|Oral: 1 GM every 6 hours for 5 days
224165954|NCT03557229|DRUG|Vitamin E 400 UNT|Oral: 400 UNT every 8 hours for 5 days
223479257|NCT07167368|DRUG|Standardized Basic Drug Therapy for HFrEF with Chronic Kidney Dysfunction|Participants receive standardized basic drug therapy for HFrEF and chronic kidney dysfunction in accordance with clinical practice guidelines. Medications include but are not limited to angiotensin-converting enzyme inhibitors (ACEIs), angiotensin receptor blockers (ARBs), beta-blockers, mineralocorticoid receptor antagonists (MRAs), and diuretics, with dosage adjustments based on individual patient conditions.
223479258|NCT07167368|BEHAVIORAL|Home-based Personalized Exercise Rehabilitation|On the basis of basic drug treatment, participants in the exercise rehabilitation group receive personalized home-based exercise prescriptions. Prescriptions are developed according to cardiopulmonary exercise test results (using heart rate at anaerobic threshold) or 6MWT (for those unable to complete cardiopulmonary exercise tests). The 6-month exercise program includes aerobic exercises (e.g., brisk walking, cycling), with intensity, duration, and frequency adjusted based on individual tolerance and progress.
223479259|NCT07167277|DIETARY_SUPPLEMENT|Whey Protein|24g of whey protein will be given to the participant to be consumed daily. Participants will be asked to consume 1 serving per day for 3 months.
223479260|NCT07167277|DIETARY_SUPPLEMENT|Placebo|A calorie matched serving of carbohydrate powder will be given to participants to consume daily. Participants will be asked to consume 1 serving per day for 3 months.
223479261|NCT07166991|DRUG|Volatile anesthetic|"In the volatile anesthetic group, sevoflurane will be administrated during the organ procurement procedure. Administration will be initiated progressively after moving in the operating room and will be pursued until aortic clamping (targeted end-expiratory concentration suggested between 1 and 2%).~No opioid agent (or intravenous hypnotic agent) will be allowed in this group."
223479262|NCT07166991|DRUG|Opioid Anesthesia|In the opioid anesthetic group, intravenous sufentanil will be administrated during the organ procurement procedure. Continuous administration will be initiated after moving in the operating room (suggested dosage : 0,3 µg/kg/h) with supplemental dose if needed (at the discretion of the anesthesia team) and will be pursued until aortic clamping. No hypnotic drug administration will be allowed in this group.
223479263|NCT07166991|OTHER|Intraoperative brain-dead donor management|"In all groups (experimental and control groups), neuromuscular blocking agents will be administered during the entire procedure, according to national guidelines. In all groups, hemodynamic management (use of vasoactive agents as vasopressors or anti-hypertensive drugs) will be done according to the discretion of the anesthesia team.~In all groups, all the others aspects of the donor management will be not modified by the study protocol."
223479264|NCT07167459|DEVICE|ndividualized Stereotactic Body Radiotherapy (SBRT) System|The individualized SBRT system employs advanced image-guided radiation delivery to deliver highly conformal, ablative doses to early-stage peripheral non-small-cell lung cancer while minimizing exposure to surrounding normal tissues. Treatment is delivered via a state-of-the-art robotic radiosurgery platform (e.g., CyberKnife M6) according to patient-specific fractionation schedules based on tumor size and proximity to critical structures, following standard indications and institutional protocols for medically inoperable or surgically refused cases.
223479265|NCT07168070|OTHER|physical therapy and exercise|"Participants will receive one-on-one physiotherapy sessions, 45 minutes each, three times per week for 6 weeks. Sessions will include range of motion, strengthening, balance, and gait training.~Home-based Exercise Participants will be instructed to perform a structured home exercise program to complement in-clinic sessions."
223479266|NCT07168070|BEHAVIORAL|group physical therapy vs individualized physical therapy|group physical therapy vs individualized physical therapy
223479267|NCT07168070|OTHER|Group Physical therapy|Participants will attend group physiotherapy sessions, where several patients receive treatment at the same time. Each session lasts 45 minutes, three times per week for 6 weeks, and includes range of motion, strengthening, balance, and gait training.
223584392|NCT00249613|BEHAVIORAL|Women-Only|Gender-responsive treatment for women only
223584393|NCT02660892|DIETARY_SUPPLEMENT|Protein intake|"Oral consumption of eight hourly experimental meals~* 4 tracer free experimental meals containing a mixture of free amino acids and calories from protein free flavoured liquid, protein free cookies and corn oil~* 4 isotopically labeled experimental meals."
223584394|NCT06036953|DEVICE|electrical muscle stimulation|The electric muscle stimulator (EMS) used in this study was from Funcare (Funcare Co., Ltd, Taichung, Taiwan). EMS electrodes were attached to the biceps of both hands, the abdomen, and the quadriceps of both legs sequentially. Each part was stimulated once a day for 30 minutes.
223584395|NCT02051023|DRUG|FML 0.1% eyedrops|Ocular topical application of fluorometholone 0.1% 4 times a day during 22 days
223584396|NCT02051023|DRUG|Liquifilm artificial tears eyedrops|Liquifilm instillation 4 times a day for 22 days
224165955|NCT03557229|DRUG|N-acetylcysteine|Oral: 1200 mg every 12 hours for 5 days
224165956|NCT03371589|DRUG|Dexamethasone|Solution for otic injection
224165957|NCT02132689|DRUG|Actilyse (Thrombolytic therapy)|
224165958|NCT02132689|DRUG|Heparine (Standard anticoagulation therapy)|
224165959|NCT01614522|DRUG|ASLAN001|ASLAN001 500mg BID
224165960|NCT01808365|PROCEDURE|Posterior pharyngeal swab|Posterior pharyngeal swabs will be tested for the presence of N. meningitidis.
224165961|NCT01808365|OTHER|Data collection|Collection of socio-demographic data and recording of serious adverse events by interview of subjects or subjects' parents/legally acceptable representatives.
224165962|NCT04978922|DEVICE|Machine Learning: ML (Artificial Intelligence System)|To applicate an artificial intelligence system (Machine Learning: ML) on an active telemonitoring programme of readmitted COPD patients (TelEPOC)
224165963|NCT00755391|BEHAVIORAL|cognitive behavior therapy|The cognitive behavioral therapy used in this study will focus on developing patterns of regular eating, addressing body image issues, and ways to cope with situations that trigger eating disordered behaviors.
224165964|NCT00755391|BEHAVIORAL|Supportive Psychotherapy|The supportive psychotherapy treatment used in this study will involve identifying issues underlying your child's eating disorder and giving your child information about the psychological processes that tend to maintain or continue eating disorder symptoms.
224165965|NCT03099512|OTHER|SFE|The 'short foot exercise' has been described as a means to isolate contraction of the plantar intrinsic muscles.
224165966|NCT03099512|OTHER|Exercise|Exercises which improves muscle strength, ROM...
224165967|NCT00658450|BEHAVIORAL|Cognitive rehabilitation training|"A computerised cognitive training package where children will be required to complete several cognitive tasks. The aim is to strengthen the different cognitive processes during these tasks which in turn may lead to improve cognitive processes.~Children will complete these tasks in 16 session for 8 weeks."
224165968|NCT03677544|OTHER|laparoscopic approach with an extended pelvic lymph|Surgery was performed through either open or laparoscopic approach with an extended pelvic lymph node dissection up to the common iliac bifurcation
224165969|NCT00139633|DRUG|carboplatin, 5FU, Taxol and radiation|
224165970|NCT05135182|DRUG|Furazolidone|Furazolidone-tetracycline-containing quadruple regimens
224165971|NCT05135182|DRUG|Metronidazole|metronidazole-tetracycline-containing quadruple regimens
224165972|NCT02758561|BEHAVIORAL|Workshop|"The first 15 minutes will be an information session on either Urinary Incontinence (UI) or Pelvic Organ Prolapse (PO) led by a Nurse Continence Advisor.~The following 60 minutes will comprise a psychologist-led group discussion. The structured discussion will encourage participants to share experiences, thoughts, and feelings on pelvic floor disorders. Resistances and barriers to seeking treatment will be discussed. Decision-making processes will be explored.~During the final 15 minutes, participants will be asked to complete a survey to evaluate the workshop. The survey will assess satisfaction with the information provided, quality of group discussion, comfort level with the group experience, and their satisfaction with the roles of the nurse continence advisor and psychologist."
224165973|NCT04188210|OTHER|Presence of elbow pain in patients with end stage renal disease|The Beck Depression Inventory (BDI), the Nottingham Health Profile (NHP) scores were measured for all patients to evaluate depression symptoms and health-related quality of life. The elbow pain presence was asked to all the patients, the patients with elbow pain were also evaluated with The Disabilities of the Arm, Shoulder and Hand Score (Q-DASH) and Visual Analogue Scale (VAS). VAS detected as pain during rest, activity, night and pain at last week.
224165974|NCT06662747|DIAGNOSTIC_TEST|None - observational study only|No interventions, diagnostics tests for HIV, pregnancy, STIs and BV only
224165975|NCT06067295|OTHER|Non-Interventional Study|Non-interventional study
224165976|NCT06486805|DRUG|N acetyl cysteine|N-acetylcysteine (NAC) is a small molecule containing a thiol (sulfhydryl-containing) group, which has antioxidant properties and is freely filterable, thus making it readily accessible to the intracellular compartment
224165977|NCT06486805|OTHER|normal saline|the same volume of normal saline
224165978|NCT03695471|BIOLOGICAL|Pembrolizumab|Given IV
224165979|NCT06132529|DIAGNOSTIC_TEST|Brain Magnetic Resonance Imaging (MRI) Scan|Imaging of the brain
224165980|NCT06132529|OTHER|Speech Sample|Recorded reading aloud of pre-written words and sentences
224165981|NCT06132529|OTHER|Electronic Daily Headache Diary|Headache diary to provide information about headaches experience that day.
224165982|NCT04776252|DRUG|MK-8591A|FDC tablet of 100 mg doravirine, 0.75 mg islatravir taken orally, once daily for up to 192 weeks
224165983|NCT03935282|OTHER|AH-HA Tool in the EPIC EHR|The Automated Heart-Health Assessment tool implemented in clinics' EPIC EHR will be used by providers during routine follow-up care appointments.
224165984|NCT02628574|DRUG|TRX518 monotherapy|comparison of different (ascending) doses of TRX518 monotherapy
224305237|NCT02192320|DRUG|Atorvastatin and Dexamethasone|"Atorvastatin: 20 mg (every evening orally) for 5 weeks;~Dexamethasone:0.75mg Tid (1st-2nd week), 0.75mg Bid (3th week), 0.75mg Qd (4th week), 0.375mg Qd (5th week)"
224305238|NCT04581174|DIAGNOSTIC_TEST|24-hour monitoring of oropharyngeal pH by Restech, RYAN scores upright and supine, and pH values <5.5 will be evaluated|Patients with the 1st degree of hypertrophy according to Camacho, 2nd degree of hypertrophy according to Camacho, 3rd degree of hypertrophy according to Camacho, 4th degree of hypertrophy according to Camacho will undergo 24-hour monitoring of oropharyngeal pH by Restech, RYAN scores upright and supine, and pH values \<5.5 will be evaluated.
223479268|NCT07169461|DEVICE|The blue MY MASK-E|"Device-Specific Protocol Blue MyMask® LLLT (Espansione): Emits monochromatic photobiomodulation therapy at 633 nm, distinct from conventional red or near-infrared LLLT used in other studies.~Espansione IPL: Uses a patented Optimal Power Energy (OPE®) system with a polychromatic spectrum of 590-1200 nm, allowing sub-threshold energy pulses for selective thermal effects on abnormal telangiectasia and Demodex-related inflammation."
223479269|NCT07169461|DEVICE|IPL|"IPL : The Eye-light device (Espansione Marketing S.p.A., Bologna, Italy,waveleggths 1,200-1,500 nm, Delivery system 12cm2) (Thai FDA No 66-2-2-2-0012685) :~* Protective eye shields~* 5 flashes of light were applied for each eye (3 along the inferior orbital rim, 1 at the lateral canthus, and 1 applied horizontally along the inferior orbital rim)~* Therapeutic energy level (10-16 joules/ cm2) based on the degree of skin pigmentation."
224165985|NCT02628574|DRUG|TRX518 with gemcitabine|comparison of different (ascending) doses of TRX518 in combination with gemcitabine
224165986|NCT02628574|DRUG|TRX518 with pembrolizumab|comparison of different (ascending) doses of TRX518 in combination with pembrolizumab
224165987|NCT02628574|DRUG|TRX518 with nivolumab|comparison of different (ascending) doses of TRX518 in combination with nivolumab
224165988|NCT02859558|DRUG|elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide or bictegravir/emtricitabine/tenofovir alafenamide or other medically-appropriate FDA-approved antiretroviral therapy|Participants received one tablet of elvitegravir 150mg/cobicistat 150mg/emtricitabine 200mg/tenofovir alafenamide 10mg by mouth daily with food or one tablet of bictegravir 50mg/emtricitabine 200mg/tenofovir alafenamide 25mg by mouth daily with or without food. Other non-study-provided ARV regimens were allowed for participants who were pregnant, breastfeeding, or unable/unwilling to take EVG/COBI/FTC/TAF or BIC/FTC/TAF, or for participants whose local health care/primary care provider preferred starting a different initial ARV regimen.
224165989|NCT05176223|PROCEDURE|Computed Tomography|Undergo 68Ga PSMA PET/CT
224165990|NCT05176223|DRUG|Gallium Ga 68 Gozetotide|Undergo 68Ga PSMA PET/CT
224165991|NCT05176223|PROCEDURE|Positron Emission Tomography|Undergo 68Ga PSMA PET/CT
224165994|NCT04888507|DRUG|Pozelimab|Intravenous (IV) loading dose (once) followed after 30 minutes by sub-cutaneous (SC) administration
224165995|NCT04888507|DRUG|Cemdisiran|SC administration
224165996|NCT05921552|BEHAVIORAL|Resistance Training|Participants will be encouraged to perform approximately 30 minutes of resistance training exercises twice per week, until they undergo surgery. Exercises will be performed using resistance tubes (Bodylastics Inc) and the included accessories (handles and anchor straps) to perform resistance exercises. During Zoom sessions, certified exercise trainers will guide participants to utilize equipment to perform resistance exercises with proper form. Each groups resistance training session will span approximately 1 hour, including a brief warm-up, stretching, and 2 sets of ≥12 repetitions for each of 5 exercises: single arm chest press, single arm row, lateral raise, squat (or chair stand), and resistance tube deadlift.
224165997|NCT05921552|BEHAVIORAL|Aerobic Training|Participants will be encouraged to perform ≥30 minutes of moderate-intensity aerobic exercise on ≥3 days per week. Aerobic exercise intensity will be guided by heart rate zones, with participants exercising at 50-70% of their age-predicted maximum heart rate in bouts of at least 10 minutes at a time. Participants will be encouraged to gradually increase exercise intensity and duration until they are meeting the recommendation
224165998|NCT02621021|BIOLOGICAL|young TIL|Day 0: Cells will be administered intravenously (IV) on the Patient Care Unit over 20-30 minutes.
224165999|NCT02621021|DRUG|Pembrolizumab|(Cohort 1, Arm 2 ,Cohort 2 and Cohort 3, Arm 2) On day -2, and days 21 (+/- 2 days), 42 (+/- 2 days), and 63 (+/- 2 days) following cell infusion: Pembrolizumab 2mg/kg IV over approximately 30 minutes.
224166000|NCT02621021|DRUG|Aldesleukin|Aldesleukin 720,000 IU/kg IV (based on total body weight) over 15 minutes approximately every 8 hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 4 days (maximum 12 doses).
224166001|NCT02621021|DRUG|Fludarabine|Days -7 to -3, Fludarabine 25 mg/m2/day IVPB daily over 15-30 minutes for 5 days.
224166002|NCT02621021|DRUG|Cyclophosphamide|Days -7 and -6: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with mesna 15 mg/kg/day over 1 hour X 2 days.
224166003|NCT02342964|OTHER|Measure of hepatic elasticity|"Measure of hepatic elasticity by four non-invasive methods:~Fibroscan, Fibrotest, SWE, MRE."
224166004|NCT04645602|DRUG|Lenvatinib|Pill taken by mouth, once daily.
224305239|NCT04636060|DIETARY_SUPPLEMENT|Eisen|Treatment with low-dose iron in the form of tablets containing 6mg of iron. Treatment consists of twice-daily oral administration of iron-tablets for 8 weeks in total.
224305240|NCT05918731|BEHAVIORAL|Self Management|"A training book was given to this group, which was created for the study. The implementation process followed a five-step approach including sessions once a month for five consecutive months with a coach and follow-up phone calls after the end of the sessions.To inspire and engage patients, the sessions included a variety of educational techniques, including knowledge transfer, discussion, hands-on training, and homework. Additionally, coaches received training in motivational interviewing methods. The self-management program and all the process of data collection is described in detail on the supplementary file."
224305241|NCT06264401|OTHER|Alendronate|control group received (Alendronate) 70 mg 1 tab every week.
224305242|NCT06264401|OTHER|treatment exercises|the experimental group performed core stability and dynamic resistance exercises, a 45-min lumbar-pelvic/core strength and stability exercise program, each exercise was executed for three sets of 15 seconds, which gradually upgraded to three sets of 45-second at the fourth month and 10 sec rest between each set and dynamic resistance exercise performed by each woman for 2 sets for 8-12 repetitions gradually along the study of 90 sec rest between each set for a duration of 60 minutes.
224305243|NCT03031886|OTHER|low glycaemic index intervention|Low GI sweetener would be added to the treatment meals. 30 grams of isomaltulose to dinner and breakfast and 20 grams of isomaltulose to lunch and snack.
224305244|NCT03031886|OTHER|high glycaemic index intervention|High GI sweetener would be added to the treatment meals. 30 grams of sucrose to dinner and breakfast and 20 grams of sucrose to lunch and snack.
224305245|NCT02532725|PROCEDURE|Cardiopulmonary Exercise Stress Test|Test preceded by warm-up treadmill walking 5 min at 4.8 km/h, 5% grade with a 1 min sitting rest period. Test, then, begins at 4.8 km/h, 2.5% grade with incremental grade increases every 2 min until exhaustion. Ambient environment is maintained at neutral, with effective temperature of 19-21° C. Heart, lungs, temperature, and sweating is monitored during testing.
223479270|NCT07169461|PROCEDURE|Mechanical with pharmacological treatment|"Mechanical with pharmacological treatment : Warm compression 15 minutes + Lid hygiene + 1% TTO 2 times per day for 90 days~1%TTO : OCuSOFT Oust Demodex Eyelid Cleanser Foam Bottle 50ml (OCuSOFT, Richmond, TX) is the only commercially available medication in Thailand that contains 1% tea tree oil."
223479271|NCT07169461|DEVICE|ShamIPL|the Eye-light device (Espansione Marketing S.p.A., Bologna, Italy) - Protective eye shields, 5 time for each eye with flashes of light off , but flashes sound on.
223584397|NCT02012088|DRUG|RCOMP|Day 1: Rituximab 375 mg/m2; Myocet® 50 mg/m2; cyclophosphamide 750 mg/m2; vincristine 1.4 mg/m2 (maximum 2 mg); prednisone 60 mg/m2 Days 2-5: Prednisone, 60 mg/m2 Administered every 21 days × 6 cycles
223584398|NCT02012088|DRUG|RCHOP|Day 1: Rituximab 375 mg/m2; Doxorubicin 50 mg/m2; cyclophosphamide 750 mg/m2; vincristine 1.4 mg/m2 (maximum 2 mg); prednisone 60 mg/m2 Days 2-5: Prednisone, 60 mg/m2 Administered every 21 days × 6 cycles
224166005|NCT04645602|DRUG|Pembrolizumab|Intravenous injection through a vein (IV).
224166006|NCT06423352|DRUG|Zilebesiran|Zilebesiran administered by subcutaneous (SC) injection
224166007|NCT06423352|DRUG|Placebo|Placebo administered by SC injection
223479272|NCT07169461|DEVICE|ShamLLLT|the MY MASK-E (Espansione Marketing S.p.A., Bologna, Italy) - No eye shields, applying a power off special mask for 15 minutes but light on , once a week for 4 weeks
223584399|NCT00424190|DRUG|IV Vancomycin plus IV Aztreonam|vancomycin at 1 g parenteral infused over 60 minutes followed by aztreonam 1 g infused over 60 minutes, every 12 hours, for 5 to 14 days.
223584400|NCT00424190|DRUG|Ceftaroline|600 mg parenteral infused over 60 minutes, every 12 hours for 5 to 14 days
224166008|NCT05651282|DRUG|Provera|Progesterone Challenge Test
224166009|NCT05485961|DRUG|CSL300|IV administration
224166010|NCT05485961|DRUG|Placebo|0.9% w/v NaCl
224166011|NCT05485961|DRUG|Placebo|Matching the excipient content and concentration of the CSL300 product, minus the active ingredient.
223479273|NCT07169409|DRUG|Telemedicine Buprenorphine Treatment|With this NIDA-funded grant, the study team will identify app-based treatment workflows that are demonstrably effective in low-resource settings: namely, telehealth services that are accessible without high-speed internet and deliberately helping patients transition into OUD care from relevant health and community system settings. An intentional focus on rural areas and Black and Hispanic demographics will help enhance health equity, and support solutions for payors.
223479274|NCT07169227|DRUG|Lidocaine %2 ampoule|Patients who were administered 40 mg lidocaine.
223479275|NCT07169227|DRUG|Dexmedetomidine|Patients who were administered 0.25 mg/kg dexmedetomidine.
223479276|NCT07169227|DRUG|paracetamol|Patients who were administered 50 mg paracetamol.
223584401|NCT01926769|DRUG|Metformin|
223584402|NCT01672866|BIOLOGICAL|Placebo|Placebo to match SIM via subcutaneous injection every week
223584403|NCT01672866|BIOLOGICAL|SIM|Subcutaneous injection every week
224075837|NCT00980538|DRUG|Etravirine|Participants will be dosed with etravirine by weight up to a maximum dose of 200 mg bid until switched to an etravirine-based treatment regimens (i.e. commercially available and reimbursed, or accessible through another source) or local standard of care, as appropriate.
223479277|NCT07167537|BIOLOGICAL|OL-CD19-GDT|OL-CD19-GDT will be given through IV bolus with ascending dose levels to determine the RDE and RP2D as specified in the protocol
223479278|NCT07168486|BIOLOGICAL|CD19.20.22 CAR T cells|CAR19.20.22 is a type of immunotherapy known as a chimeric antigen receptor T-cells (CAR T-cells).
223479279|NCT07168486|DRUG|Fludarabine and Cyclophosphamide|Lymphodepletion with Flu-Cy prior to CAR T cell therapy
224075838|NCT01745770|DRUG|Mesalazine - TID 1000 mg|
224075839|NCT01745770|DRUG|Mesalazine - TID 2x 500 mg|
224075840|NCT01034007|COMBINATION_PRODUCT|Tissue Engineered Vascular Grafts|Patients will undergo EC TCPC interposition grafting with a tissue engineered vascular graft and serial magnetic resonance angiography (MRA)
224075841|NCT03864653|BEHAVIORAL|MoodGym|"MoodGym is a preexisting Internet-based CBT program that uses interactive content and character-driven narratives to help alleviate symptoms of depression and comorbid anxiety. The program also aims to improve the individual's functioning by promoting the development of skills and strategies to manage depression.~MoodGym consists of an introduction module, five structured intervention modules, and a workbook of assessments. Each MoodGym session takes place entirely on an Internet-connected tablet while in the physical co-presence of a Study Counselor, who can answer questions should they arise. Each session takes approximately one hour to complete."
224075842|NCT04069845|DRUG|liposomal doxorubicin|intravenous liposomal doxorubicin
224075843|NCT06026332|DRUG|ADSTILADRIN|Non-interventional
224075844|NCT01680900|DRUG|vilazodone|capsules once/day for 8 weeks. Dose starts at 10 mg for 7 days, increases to 20 mg/day for 7 days, increases to 40 mg/day at week 3 of unimproved.
224075845|NCT01680900|DRUG|placebo capsules|placebo capsules matched to drug capsules.
224075846|NCT00546052|DRUG|losartan potassium (+) hydrochlorothiazide|All patients received Losartan 50mg at Visit 2 titrated to Losartan 100mg (if target BP not achieved) titrated to Losartan 100mg + HCTZ 12.5mg (if necessary) up to Losartan 100mg + HCTZ 25mg. Duration of treatment was one year.
224075847|NCT05839912|PROCEDURE|Excision of clinically detected lymph node metastasis before any systemic therapy|Surgical intervention to remove the clinically detected lymph node metastasis after which physician choice adjuvant systemic therapy is permitted
224075848|NCT05839912|PROCEDURE|Excision of clinically detected lymph node metastasis after neoadjuvant systemic therapy|Surgical intervention to remove the clinically detected lymph node metastasis after physician choice neo adjuvant systemic therapy. Physician choice adjuvant therapy is allowed after surgery
224075849|NCT05125237|DRUG|Amiloride|Amiloride claim is used as the exposure group.
224075850|NCT05125237|DRUG|Triamterene|Triamterene claim is used as the reference group.
224075851|NCT03583190|OTHER|Cervical-cranial dry needling|Segmental needling of the neck and needling in the patient's headache distribution. Peripherally sensitized areas of the neck may also be dry needled based on the findings of the clinical evaluation.
224075852|NCT03583190|OTHER|Orthopedic manual therapy|Orthopedic Manual Therapy (OMT) that includes either mobilization or manipulation to the cervical spine applied pragmatically to the most symptomatic level.
224075853|NCT03583190|OTHER|Thoracic Manipulation|Thoracic Manipulation (applied pragmatically) to the levels determined to be provocative or hypomobile.
224075854|NCT03583190|OTHER|Exercise|Clinicians select 1 active range of motion exercise for the cervical spine, deep cervical flexion endurance exercise, and 5 upper extremity exercises (from a set of 10). Additionally, patients will be assigned a headache management technique.
224075855|NCT03583190|OTHER|Patient Education|Patients will receive education regarding their headache condition, proper performance of their symptom management technique, posture.
224075856|NCT06975046|DEVICE|Complete airflow interruption|Participants will produce a sustained vowel into a mouthpiece (with nose-clip) connected to a PVC tube, with a balloon valve
224075857|NCT06975046|DEVICE|Incomplete airflow interruption|Incomplete airflow interruption uses a Y-shaped device. The participant produces a sustained /a/ into a mouthpiece and air filter connected to the tube. The tube splits into two tubes distally.
224075858|NCT06975046|DEVICE|Airflow redirection|Participant phonates through a mouthpiece into a PVC tube that splits into two paths. One path is connected to an open balloon valve. When the balloon is inflated and blocks the path, air is redirected into the other path which is gated by a one-way valve.
224075859|NCT06163612|BEHAVIORAL|Clinical Interview|A study team member will meet the participant to ask questions regarding the degree of depression at the beginning of the study. This interview will take approximately 1 hour.
224075860|NCT06163612|BEHAVIORAL|Clinical Questionnaires|A study team member will ask the participant to complete questionnaires assessing the severity of the participant's depression, daily activities, personality/traits, and quality of life. If the participant opts to complete these questionnaires at home, they will be emailed them within 24 hours of this visit. These questionnaires will take approximately 1-2 hours.
224166012|NCT04962087|BEHAVIORAL|Experimental: Health enSuite Insomnia|Health enSuite: Insomnia has been designed based on established cognitive behavioral treatments for insomnia (2,5,6) and adapted to fit an automated interactive platform available via an internet enabled device. Previous research has found that CBT for insomnia can be delivered via a web-based platform (15,16). The program is divided into a series of treatment modules or levels that will be delivered over the course of 8 weeks. The content of these 8 levels includes the following components, a sleep diary, Introduction to Health EnSuite Insomnia, Sleep restriction clock, Medications, Herbal Remedies \& Sleep, Chronobiology \& Sleep Timing, Sleep hygiene, Relaxation techniques, Changing Negative Thoughts Related to Sleep, Light and Sleep.
224166013|NCT05339022|OTHER|Best Practice|Receive standard of care
224166014|NCT05339022|OTHER|Exercise Intervention|Undergo exercise intervention
224166015|NCT05339022|PROCEDURE|Physical Therapy|Undergo physical therapy
224166016|NCT05339022|OTHER|Quality-of-Life Assessment|Ancillary studies
224166017|NCT05339022|OTHER|Questionnaire Administration|Ancillary studies
224166018|NCT05339022|PROCEDURE|Relaxation Therapy|Undergo progressive muscles relaxation exercises
224166019|NCT01430598|PROCEDURE|Rotator Cuff Repair and Subacromial Decompression|Arthroscopic decompression and rotator cuff repair will be completed during the same surgical date.
224166020|NCT01430598|OTHER|Questionnaire|Patients will be asked to complete two separate questionnaires prior to the surgical intervention. Patients will be asked to complete the same two questionnaires at 12 weeks post surgery.
224166021|NCT01922518|PROCEDURE|Septal pacing|Put RV pacing lead around the right ventricular septum and is adjusted with normal pacing axis
224166022|NCT01922518|PROCEDURE|Apex pacing|Put RV lead around the apex
224166023|NCT00636155|DRUG|cenersen sodium|2.4 mg/kg/day as a continuous infusion over 24 hours starting on day one and ending on day 4
224166024|NCT00636155|DRUG|Rituximab|375 mg/m2 on day 2
224166025|NCT00636155|DRUG|Cyclophosphamide|250 mg/m2 on days 2, 3, and 4
224166026|NCT00636155|DRUG|Fludarabine|25 mg/m2 on days 2, 3, and 4
224166027|NCT05581810|BEHAVIORAL|Cognitive Behavioural Therapy (CBT)|Cognitive behavioural therapy for functional memory symptoms after concussion is delivered by a psychologist over 11 individual (1:1) secure videoconference sessions. The core active ingredients are 1) Behavioural experiments, which acts by phasing out compensatory strategies in order to increase normal memory use and 2) Cognitive reappraisal, which aids in re-interpreting memory lapses in order to reduce reactivity to them.
224166028|NCT05581810|BEHAVIORAL|Cognitive Rehabilitation|Training and practice with external memory aids/compensatory strategies, adapted from Shum et al. (2011). J Rehabil Med, 43(3):216-223.
224166029|NCT05193825|DEVICE|Remote Programming|Patients in the experimental group (Group B) will have their internal pulse generators (IPGs) adjusted through a novel software that allows for remote DBS programming (NeurosphereTM Virtual Clinic)
224166030|NCT05193825|DEVICE|Standard Programming|Patients in the active comparator group (Group A) will have their internal pulse generators (IPGs) adjusted through a standard procedure at their caregivers institution.
224166031|NCT00766142|BIOLOGICAL|cetuximab|
224166032|NCT00766142|DRUG|fluorouracil|
223479280|NCT07167680|PROCEDURE|Individualized reduction of falls (iROLL)|The iROLL program is a 6-week fall prevention and management program for people living with spinal cord injury (SCI) and multiple sclerosis (MS) who use wheelchairs and scooters. The program's overall goals are to reduce fall frequency, improve functional mobility skills, decrease fear of falling, increase quality of life, and increase community participation. It uses many active learning strategies such as: goal setting, journaling, small group discussions, practicing skills, and homework to apply content to one's daily life.
223479281|NCT07167680|PROCEDURE|Stopping Elderly Accidents, Deaths & Injuries (STEADI)|The CDC's Stopping Elderly Accidents, Deaths \& Injuries (STEADI) initiative is a coordinated approach to fall prevention for older adults. It focuses on helping healthcare providers implement clinical fall prevention strategies, including screening for fall risk, assessing modifiable risk factors, and intervening to reduce risk.
223479282|NCT02964871|DEVICE|Sofia Fluorescent Immunoassay Analyzer Influenza A+B|The Sofia Influenza A+B Fluorescent Immunoassay (FIA) uses advanced immunofluorescence-based lateral-flow technology to detect influenza A and influenza B viral nucleoprotein antigens.
223479283|NCT02964871|OTHER|Usual care|Our team will discuss our interest in monitoring influenza antiviral treatment and prophylaxis courses, antibiotic courses, clinician and emergency room visits, respiratory infection-related hospitalizations, all-cause hospitalizations, and deaths during the anticipated 4-month influenza season over 3 years.
224166033|NCT00766142|DRUG|leucovorin calcium|
223479284|NCT00195741|DRUG|divalproex sodium|
223479285|NCT02617095|DEVICE|T2762|One drop in each eye 3 to 6 times daily
223479286|NCT02617095|DEVICE|Optive|One drop in each eye 3 to 6 times daily
223479287|NCT06472362|DIAGNOSTIC_TEST|HRCT biomarkers|HRCT imaging biomarkers of airways, vessels, and overall extent of fibrosis
224166034|NCT00766142|DRUG|oxaliplatin|
224166035|NCT00766142|PROCEDURE|adjuvant therapy|
224166036|NCT00766142|PROCEDURE|therapeutic conventional surgery|
224166037|NCT06033365|BEHAVIORAL|care navigation|Dedicated care navigation throughout study enrollment and follow-up period. Care navigation consists of addressing social support needs (e.g. transportation, communication, housing).
224166038|NCT05909488|BIOLOGICAL|1.5 x 10^6 UC-MSC + CM|1.5 million cells of UC-MSC in 2 ml of Conditioned Medium (CM)
224166039|NCT05909488|BIOLOGICAL|5 x 10^6 UC-MSC + CM|5 million cells of UC-MSC in 2 ml of Conditioned Medium (CM)
224166040|NCT05756829|OTHER|High frequency, low touch virtual health care|Virtual visits between certified diabetes educators and patients occurring every 2 +/- 1 weeks for a total of 6 months
224166041|NCT06447220|PROCEDURE|washed microbiota transplantation|The prepared microbiota suspension was infused into the patients' gut.
224305246|NCT02532725|PROCEDURE|Climatic-Controlled Cardiopulmonary Exercise Stress Test|Test includes 30 min walking bouts on the treadmill, with two 5 min sitting rest periods between bouts (Rest I and Rest II) and 15 min sitting recovery period (Rest III), in effective temperatures of 21.1 (baseline), 26.7, 29.4, 32.2, and 35.0° C. Heart, lungs, temperature, and sweating is monitored during testing.
224166042|NCT05365685|BEHAVIORAL|Low energy turnover|"Low Energy Turnover. The adolescents with ingest low energy intake at lunch and breakfast and will not perform physical exercise during the day. The will will receive an ad libitum meal at dinner time. Their food reward will be assessed before dinner. Their appetite feelings will be assessed at regular intervals.~Moderate Energy Turnover. The adolescents with ingest moderate energy intake at lunch and breakfast and will perform one 45 minutes physical exercise during the day. The will will receive an ad libitum meal at dinner time. Their food reward will be assessed before dinner. Their appetite feelings will be assessed at regular intervals.~High Energy Turnover. The adolescents with ingest high energy intake at lunch and breakfast and will perform two 45-minute physical exercises during the day. The will will receive an ad libitum meal at dinner time. Their food reward will be assessed before dinner. Their appetite feelings will be assessed at regular intervals."
224166043|NCT04567732|COMBINATION_PRODUCT|injection of Filtered Autologous Adipose Tissue|Single injection of Filtered Autologous Adipose Tissue
224166044|NCT04567732|DRUG|Placebo|Single injection of Placebo
224166045|NCT06207162|DIAGNOSTIC_TEST|fMRI|Participants will be performing tasks while undergoing fMRI. Tasks include Stroop task, Emotion-regulation task and an Ambiguity reward task. There will also be a Resting state: Participants are not presented with any specific stimulus.
224166046|NCT06617390|OTHER|No drug|This is a non-interventional study and no study drug will be provided.
224166047|NCT06458998|BEHAVIORAL|Patient Navigation|Clinical Resource Hub (CRH) providers include a small group of nurses, advance practice providers, and physicians who work to improve care across a range of measures using virtual PN. CRH providers will 1) use existing dashboards to identify at-risk Veterans, 2) conduct Veteran outreach (two calls, one letter) to provide education, problem solve, and offer screening, 3) order and schedule HCC or CRC screening tests, and 4) provide reminders and follow up on results.
224166048|NCT06458998|BEHAVIORAL|Implementation Facilitation|Facilitators will provide 20 hours of virtual facilitation to site teams, through 1-hour meetings every other week and ad hoc meetings, over 12 months. They will guide site teams through a seven-step playbook called Getting To Implementation (GTI), which uses a series of tools to select context-specific strategies.
224166049|NCT06309563|DIETARY_SUPPLEMENT|Aminoacid supplementation|Low-calorie and low-protein diet + with 4 sachets of EEA-AC supplement per day for 2 weeks
224166050|NCT06309563|DIETARY_SUPPLEMENT|Placebo|Low-calorie and low-protein diet + placebo for 2 weeks
224166051|NCT05744713|OTHER|Observational|Observational
224166052|NCT03932903|BEHAVIORAL|ADAPTS (ADherence Assessments and Personalized Timely Support).|ADAPTS is a mobile app intervention that integrates contextually-tailored mobile messages and decision rules about when to deliver the messages, with the ultimate goal of improving oral chemotherapy adherence in AYAs with acute lymphoblastic leukemia and lymphoma. AYA participants will be micro-randomized to receive messages on some days that are adapted to their current characteristics (e.g., mood, pain, location) and designed to promote adherence, and no messages (no intervention) on other days. Other features in the app include a medication calendar that syncs with the electronic medication monitor (eCAP) to track daily adherence. A caregiver version of ADAPTS is also available, providing daily surveys (but no randomized mobile messages) and the medication calendar so that dyads can mutually track adherence.
224166053|NCT01711671|DRUG|DKN-01 300 mg|300 mg IV infusion of DKN-01 administered twice per 28 day cycle on Days 1 and 15, plus lenalidomide/dexamethasone
224166054|NCT01711671|DRUG|DKN-01 600 mg|600 mg IV infusion of DKN-01 administered twice per 28 day cycle on Days 1 and 15, plus lenalidomide/dexamethasone
224166055|NCT01711671|DRUG|Standard of Care|Current approved standard of care
224305247|NCT02532725|PROCEDURE|Body Composition Evaluation|Multiple methods are used to accurately estimate percentage of body mass (weight) composed of fat, muscle, bone, and other connective tissues. Four different methods, including caliper and hydrostatic (underwater weighing) are used in this study to ensure an accurate estimation.
223479288|NCT06348147|BIOLOGICAL|Daratumumab|Daratumumab is a CD38-directed cytolytic antibody indicated for the treatment of adults with multiple myeloma. 1800 mg will be given subcutaneously according to its standard package insert schedule.
223479289|NCT06348147|DRUG|Lenalidomide|Lenalidomide will be administered, once daily orally on Days 1-21 of a 28-day
223479290|NCT06348147|DRUG|Bortezomib|Bortezomib is a proteasome inhibitor indicated for the treatment of adult patients with multiple myeloma, will be given subcutaneously once weekly on days 1, 8, and 15 of every 28 day cycle.
223479291|NCT06348147|DRUG|Dexamethasone|Dexamethasone is a glucocorticoid.
223479292|NCT01022606|OTHER|Arterial sampling|Arterial pO2 (ABL5) Body Temperature (Vitalsens Cortemp) tcpO2 TCM400
224166056|NCT05974202|DEVICE|Active H7-coil repetitive transcranial magnetic stimulation (rTMS)|A magnetic current created by the device creates an electrical current in the brain to stimulate the medial prefrontal cortex and dorsal anterior cingulate cortex.
224166057|NCT05974202|DEVICE|Sham H7-coil repetitive transcranial magnetic stimulation (rTMS)|A sham coil is in the same helmet as the active coil. The sham coil mimics the sound, scalp sensations, and facial muscle activation caused by the active coil, but does not create an electrical current in the brain.
224166058|NCT05755269|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
224166059|NCT05755269|PROCEDURE|Genotyping|Undergo genotyping
224166060|NCT05755269|OTHER|Survey Administration|Complete surveys
224166061|NCT04685408|BEHAVIORAL|TEAM|TEAM is informed by principles of social cognitive theory TEAM uses nurses and peer educator dyads (PEDs) composed of patients and their care partners to co-deliver an intervention intended to help reduce future stroke risk. Team begins with one 60-minute 1:1 orientation session, in which the nurse and PED meet with the patient and his/her care partner. This is followed by 6 hour-long group sessions with 6-8 patients and their care partners held approximately weekly. The first orientation session will be done approximately 1 week post baseline, followed by group sessions were done at 2, 4, 6, 8, 10 and 12 weeks post-baseline.
224305248|NCT02532725|PROCEDURE|Pre-Exercise Risk Assessment|Includes non-invasive measurements of body functioning, a physical examination by a physician, and blood and urine testing to select subjects who can exercise with relative safety.
224305249|NCT03493386|DRUG|Daprodustat 2 mg tablet|Daprodustat is available as 2 mg tablet. Subjects will receive daprodustat orally as tablet. A single dose of 2 tablets of 2 mg daprodustat will be administered in a fasted state during Part 1 of the study.
224166062|NCT04685408|BEHAVIORAL|ETAU|ETAU will consist of an orientation visit with a nurse who will provide patient-education materials on stroke risk adapted from the American Heart Association materials and cover common risk factors such as hypertension, obesity, high salt/high fat diet and diabetes. Patients will also receive basic written information in their language of preference and tailored to the reading level of most patients at the clinic. Patients will be offered the opportunity to bring a family member with them to this visit who may also ask questions and who can assist them with understanding written materials for those with limited literacy. The nurse in ETAU will then follow-up with participants with a series of 9 brief phone calls spaced out over the course of 6 months (approximately every 2 weeks during months 1 and 2, then approximately monthly thereafter). Content will reinforce materials provided in the orientation visit and the nurse will be available to answer questions that may arise.
224166063|NCT06834217|DEVICE|Active transcranial direct current stimulation|Multifocal transcranial direct current stimulation will be delivered. The anode will be placed over the frontal pole (Fpz, 10-20 electroencephalogram \[EEG\]) and will be surrounded by 5 return electrodes (cathodes). Current will be set at 1.5mA and will be ramped in and out for 30 seconds at the beginning and end of a 20-minute stimulation period.
224166064|NCT06834217|DEVICE|Sham transcranial direct current stimulation|Multifocal transcranial direct current stimulation will be delivered. The anode will be placed over the frontal pole (Fpz, 10-20 electroencephalogram \[EEG\]) and will be surrounded by 5 return electrodes (cathodes). Current will be set at 1.5mA and will be ramped in and out for 30 seconds at the beginning of a 20-minute period.
224166065|NCT05761899|COMBINATION_PRODUCT|Gene-Corrected Macrophages administered by bronchoscopic instillation|This study will evaluate administration of autologous bone marrow CD34+ cell-derived, CSF2RA lentiviral vector-transduced macrophages (CSF2RA gene-corrected macrophages) by bronchoscopic instillation into individual lung segments on three occasions at 2-month intervals in patients with hPAP. The target (maximum) number of cells to be administered is 778 million gene-corrected macrophages per 70 kg patient, which is equal to 11.1 million cells/kg of ideal body weight.
224166066|NCT02306291|DRUG|GMI-1271|E-selectin antagonist
224166067|NCT02306291|DRUG|Mitoxantrone|induction chemotherapy
224166068|NCT02306291|DRUG|Etoposide|induction chemotherapy
224166069|NCT02306291|DRUG|Cytarabine|induction chemotherapy
224166070|NCT02306291|DRUG|Idarubicin|induction chemotherapy
224166071|NCT03356301|DEVICE|Cardiac MRI|Non injected cardiac MRI exam
224166072|NCT03356301|DEVICE|Applanation tonometry|Applanation tonometry and ECG
224166073|NCT01597934|DRUG|Group A (Zeffix, Sebivo, Hepsera)|Maintaining LAM/LdT+ADV combination Lamivudine 100mg / Telbivudine 600mg +Adefovir 10mg
224166074|NCT01597934|DRUG|Group B (Baraclude, Viread)|Switching to ETV plus TDF combination Entecavir 1.0mg + Tenofovir 300mg
223479293|NCT05539131|DEVICE|transcranial direct current stimulation (tDCS)|Transcranial direct current stimulation (tDCS) suppresses excitability and regulates excitability of neurons by injecting a small amount of current through electrodes attached to the scalp.
223479294|NCT03386981|OTHER|blood and saliva tests|Blood and saliva will be tested for: bone turnover markers, cytokines, chemokines, adipokines, myokines and hormones regulating bone and energy metabolism
223479295|NCT04211714|BIOLOGICAL|EXG34217|Single infusion
223479296|NCT03370172|DRUG|BAX 888|Participants will receive a single peripheral IV infusion of BAX 888 in Cohort 1 and 2 Day 0.
223479297|NCT04941274|DRUG|Abemaciclib|An initial dose of 200 mg twice daily and at an MTD dose will be administered orally every day of each 28-day cycle.
223479298|NCT06952998|DRUG|Topical application of Plasma Rich in Growth Factors (PRGF)|Topical application of PRGF will be maintained each time the patient undergoes the conventional treatment. The frequency of conventional treatment will be determined by the health specialist according to the evolution of the ulcer. The treatment will be maintained until complete wound closure or until the end of the follow-up period (6 months).
224166075|NCT05606549|BEHAVIORAL|Marital self disclosure|Intervention time during hospitalization is the first day after chemotherapy, and intervene once per chemotherapy, a total of 4 times, 40-60 min each time. Interventions included verbal and written disclosure. The researcher will preside over the MSD process and introduce of MSD for gastric patients and their spouse，both patient and their spouse will receive a training or review on MSD skills, 5-10 minutes each time. Couples practice MSD skills through 4 revealing themes. Couples are encouraged to express their FCR, and when one partner disclosure, supporters should allow the speaker to fully express their feelings and respond positively to the speaker's message, showing empathy for them, and acknowledging their point of view.
224166076|NCT02358863|DRUG|Modified FOLFOX6|Oxaliplatin 85 mg/m2 IV Day 1 every 14 days Leucovorin 400 mg/m2 IV over 2 hours Day 1 5-FU 400 mg/m2 IV over 2 hours Day 1 5-FU 2400 mg/m2 IV over 46 hours Day 1
224166077|NCT02358863|DRUG|Docetaxel/Capecitabine|Docetaxel 30 mg/m2 IV Days 1 and 8 Capecitabine 825 mg/m2 PO BID Days 1-14
224166078|NCT02358863|DRUG|Cisplatin/Irinotecan|Cisplatin 30 mg/m2 IV Days 1 and 8 every 21 days Irinotecan 65 mg/m2 IV days 1 and 8 every 21 days
224166079|NCT02358863|DRUG|Cisplatin/Docetaxel|Cisplatin 75 mg/m2 IV Day 1 every 21 days Docetaxel 75 mg/m2 IV Day 1
224166080|NCT02358863|DRUG|IRI/EPI|Irinotecan IV over 90 minutes Days 1 and 8 every 28 days Epirubicin IV over 10-15 minutes Days 1 and 8 every 28 days
224166081|NCT02358863|DRUG|EPI/Docetaxel|Docetaxel 75 mg/m2 Day 1 every 21 days Epirubicin 50 mg/m2 IV Day 2
224166082|NCT02358863|DRUG|Irinotecan/Docetaxel|Irinotecan 120 mg/m2 Day 1 every 21 days Docetaxel 50 mg/m2 IV Day 1
224166083|NCT02358863|DRUG|Docetaxel|Docetaxel 60-100 mg/m2 IV day 1 every 21 days
224166084|NCT00142818|DRUG|Naltrexone|150 mg daily for males; 100 mg daily for females
224166085|NCT00142818|DRUG|Modafinil|400 mg daily
224166086|NCT00142818|DRUG|Placebo|400 mg and/or 100-150 mg placebo pills
224166087|NCT03782467|BIOLOGICAL|ATOR-1015|Bispecific human monoclonal antibody targeting cytotoxic T-lymphocyte associated protein 4 (CTLA-4) and OX40 (also known as CD134)
224166088|NCT00311012|DRUG|Aliskiren|
224305250|NCT03493386|DRUG|Daprodustat 4 mg tablet|Daprodustat is available as 4 mg tablet. Subjects will receive daprodustat orally as tablet. A single dose of 4 mg daprodustat will be administered in a fasted state during Part 1 and in fed and fasted state in Part 2 of the study.
224305251|NCT02357563|DRUG|ulipristal acetate|5 mg/day will be administered starting from day 1 of the cycle and up to three months later for two courses, with an interval between the courses of 1 month
224166089|NCT02366715|DEVICE|HeatedHumidifiedHighFlowNasalCannula|"We will enroll children 0-2 years old, diagnosed with Bronchiolitis in our ward (Pediatrics C) during the months of November-March 2014-2016. Children will be evaluated according to a Bronchiolitis Severity Score devised by Wang and Co. \[3\] which was successfully used in previous research. Children answering criteria for moderate or severe Bronchiolitis according to Wang and Co. will be enrolled pending written consent by both parents.~Our prediction is to enroll a total of 200 children during the 2 winter seasons during 2014-2016."
224166090|NCT02940353|DEVICE|TREFOIL concept|
224166091|NCT01357720|BIOLOGICAL|Quinvaxem|"A single dose (0.5 mL) of Quinvaxem contains:~diphtheria antitoxin (\>= 30 IU), tetanus antitoxin (\>= 60 IU), whole-cell inactive pertussis bacteria (\>= 4 IU), 10 mcg Hib oligosaccharide conjugate (approx. 25 mcg CRM197), 10 mcg Hepatitis B surface antigen~One dose of Quinvaxem given at Weeks 6, 10 and 14"
224166092|NCT01357720|BIOLOGICAL|Quinvaxem/Tritanrix|"A single dose (0.5 mL) of Quinvaxem contains:~diphtheria antitoxin (\>= 30 IU), tetanus antitoxin (\>= 60 IU), inactive pertussis bacteria (\>= 4 IU), 10 mcg Hib polysaccharide conjugate (approx. 25 mcg tetanus toxoid), 10 mcg Hepatitis B surface antigen~One dose of Quinvaxem given at Weeks 6, 10 and 14"
224166093|NCT04978727|BIOLOGICAL|SurVaxM for patients with relapsed or progressive MB, HGG or ependymoma ages ≥10 and ≤21 years|500 mcg (1 mL) SurVaxM emulsion with Montanide ISA 51. Sargramostim dose is 3.33 mcg/kg/dose for patients \< 30 kg, and 100 mcg for patients ≥ 30 kg.
224166094|NCT04978727|BIOLOGICAL|SurVaxM for patients with relapsed or progressive MB, HGG or ependymoma ages ≥1 and <10 years|500 mcg (1 mL) SurVaxM emulsion with Montanide ISA 51. Sargramostim dose is 3.33 mcg/kg/dose for patients \< 30 kg, and 100 mcg for patients ≥ 30 kg.
224166095|NCT04978727|BIOLOGICAL|SurVaxM for patients with non-relapsed DIPG post radiation-therapy ages ≥1 and ≤21 years|500 mcg (1 mL) SurVaxM emulsion with Montanide ISA 51. Sargramostim dose is 3.33 mcg/kg/dose for patients \< 30 kg, and 100 mcg for patients ≥ 30 kg.
224166096|NCT06963840|DIETARY_SUPPLEMENT|Theronomic Ova-All Care|Two capsules of Theronomic Ova-All Care, one a day, for 12 weeks. Ova-All Care is a tribiotic, a health product that includes prebiotics, probiotics, and postbiotics. Ova-All Care affects ovarian health by regulating the gut microbiome, which affects oestrogen production and other factors.
224166097|NCT05551234|OTHER|Regular exchanges|The seniors and childrens will meet once a week, for 7 months, over a period of one and a half hours, outside school hours (4:30 p.m. to 6:00 p.m.) and school holidays.
224166098|NCT03561844|OTHER|aromatherapy|Each of participants in the aromatherapy (inhalation) group will receive inhalation aromatherapy and those in the aromatherapy (massage) group will receive aromatherapeutic massage. As to the waiting control group, participants will be given either one of these two interventions after the implementation phase is completed.
224166099|NCT01670487|DEVICE|Vapocoolant|Topical stream of 4 to 10 seconds duration to skin
224166100|NCT01670487|DEVICE|Sterile water|Topical intervention of sterile water stream 4 to 10 seconds to skin.
224166101|NCT00779181|DRUG|ADX415|ADX415 taken three times a day to achieve a high total daily dose
224166102|NCT00779181|DRUG|ADX415|ADX415 taken three times a day to achieve a mid level total daily dose
224166103|NCT00779181|DRUG|ADX415|ADX415 taken three times a day to achieve a low total daily dose
224166104|NCT00779181|DRUG|Placebo|Placebo taken three times a day
224166105|NCT04902833|PROCEDURE|Blood Draw|Blood specimen 2-4 teaspoons
224166106|NCT04675333|DRUG|evorpacept|IV Q3W
224166107|NCT04675333|DRUG|pembrolizumab|IV Q3W
224166108|NCT04675333|DRUG|Cisplatin/Carboplatin; 5FU|IV Q3W
224166109|NCT04275557|OTHER|Blood Sample collection|Participants will be asked to donate blood at baseline (+/- 30 days of diagnosis date), 4-6 weeks post-surgery, if applicable, and at the time of follow-up (approximately 1 year and approximately 2 years after baseline).
224166110|NCT04275557|OTHER|Tissue sample collection|At the time of tissue biopsy and surgical resection (if applicable), pancreatic tumor tissue, muscle, fat, tissue from site of metastasis, and cyst fluid (if applicable) will be collected.
223479299|NCT06952998|PROCEDURE|Conventional treatment (conventional treatment with adequate offloading and metabolic control, +/- antibiotic).|"Conventional treatment (conventional treatment with adequate offloading and metabolic control, +/- antibiotic). The TIME dynamic wound closure strategy will be followed, which summarizes the four key points to stimulate the natural healing process: control of non-viable tissue, control of inflammation and infection, control of exudate and stimulation of the edges. After healing, chlorhexidine spray will be applied topically to these patients. The frequency of conventional treatment will be determined by the health specialist according to the evolution of the ulcer. Treatment will be maintained until complete wound closure or until the end of the follow-up period (6 months)."
224166111|NCT04275557|OTHER|Data collection|Participants will be asked to complete questionnaires at baseline and at 1 year and 2 year follow-ups.
224166112|NCT00868738|DIETARY_SUPPLEMENT|Vitamin D|Subjects will be provided supplemental vitamin D3 (1000 IU) or placebo, given once daily (based on the stratification noted above). Vitamin D/placebo will be provided using a softgel or liquid. Subjects will be instructed to take the supplement daily for 8 weeks.
223479300|NCT06952153|PROCEDURE|Phacoemulsification with Goniosynechialysis|This procedure involves standard phacoemulsification cataract surgery combined with goniosynechialysis, which mechanically separates peripheral anterior synechiae to open the anterior chamber angle. It aims to both remove the cataractous lens and restore aqueous outflow in patients with primary angle-closure glaucoma.
224166113|NCT04689399|DIAGNOSTIC_TEST|Standard Q COVID-19 Ag - test, produced by SD Biosensor INC.|Alle Danish citizens tested for infection with SARS-CoV-2 by swabs in the oropharynx, and subsequently analysis of the specimens by RT-PCR test at Testcenter Danmark's test centers will be included in the study. Participants will, in addition to the oropharyngeal swab they are already schedule for, be examined by a rapid antigen test.
224166114|NCT06745479|BEHAVIORAL|Positive Emotion Upregulation|Participants will identify personal goals or activities that they would like to engage in more and describe these goals/activities in a written format with research staff. Participants will then complete a gambling task during functional MRI scanning. Prior to making some gambling decisions, participants are instructed to mentally imagine achieving a goal or engaging in an enjoyable activity. Prior to the other decisions participants are instructed to respond naturally (i.e., not use the cognitive strategy).
224166115|NCT00003899|BIOLOGICAL|filgrastim|
224166116|NCT00003899|DRUG|cyclophosphamide|
224166117|NCT00003899|DRUG|melphalan|
223479301|NCT06952153|PROCEDURE|Trabeculectomy with 5FU|Trabeculectomy is a glaucoma filtration procedure designed to lower intraocular pressure by creating a new drainage pathway from the anterior chamber to the sub-conjunctival space. It is considered the standard surgical intervention for medically uncontrolled glaucoma.
223744865|NCT06014242|DIAGNOSTIC_TEST|Peripheral vascular flow reserve measurement|Peripheral arterial (below knee popliteal and above the level of ankle distal tibial) thermodilution curves will be obtained. One of the distal tibial arteries (anterior tibial, posterior tibial or peroneal artery, whichever reaches the most distal part of the foot in the run off) will be picked for measurements. At room temperature, 3 ml of saline will be injected brisk manually to determine the peak arterial flow, presented as mean transit time (Tmn). Resting Tmn will be performed and averaged by triplicate measurements at baseline. Then maximal hyperemia will be induced by intra-arterial injection of 30 mg papaverine through the guiding catheter, then 3 ml of saline will be injected to get hyperemic Tmn averaged by triplicate measurements. The guidewire will be kept in a fixed position during the series of measurements. Peripheral vascular flow reserve was calculated as resting Tmn divided by hyperemic Tmn (Fukunaga 2015).
224075861|NCT06163612|OTHER|Brain Scan|The participant will be asked to undergo a magnetic resonance imaging (MRI) scan to look at the structure and function of their brain. The functional MRI measures the level of blood flow to areas of the brain associated with mood and behaviour, and the participant will be asked to complete two behavioural games while they are in the scanner. During the scan, the participant will be required to lie on a table within the cylindrical tube of the MRI scanner in order to complete the scan. This will result in limited movement for the duration of the scan. The scan will take approximately 60 minutes.
223479302|NCT04765904|PROCEDURE|SDF|1)Dry with cotton to affected tooth surfaces 2) Apply the SDF material 3)Dry with a gentle flow of compressed air for at least one minute. and Remove excess SDF with gauze
223479303|NCT04765904|PROCEDURE|Hall technique|Orthodontic separator being stretched between two pieces of floss, then placed between the contact points of primary molars (for five days.) 2)The correct size of crown will not impinge on the teeth on either side, and a slight 'spring back' will be felt when the PMC is gently pushed up
223479304|NCT03139162|OTHER|Swiss RAI-HC assessment|RAI-HC assessments done by trained nurses in clinical routine
224075862|NCT06163612|BEHAVIORAL|Behavioural Games|The participant will be asked to complete two behavioural games inside the scanner. One of these games includes a monetary payout. They will be given instructions about these tasks outside of the scanner.
224075863|NCT01261156|DRUG|E5555 100 mg and diltiazem|E5555 single 100 mg oral dose in Treatment Period 1 Day 1 and in Treatment Period 2 Day 8. Diltiazem 360 mg orally each day for 14 days (Days 1-14) in Treatment Period 2.
224075864|NCT01261156|DRUG|E5555 300 mg and diltiazem|E5555 single 300 mg oral dose in Treatment Period 1 and in Treatment Period 2 Day 8. Diltiazem 360 mg orally each day for 14 days (Days 1-14) in Treatment Period 2.
224075865|NCT02482129|DRUG|LME636 60 mg/mL ophthalmic solution|
224075866|NCT02482129|DRUG|Dexamethasone 0.1% ophthalmic solution|
224075867|NCT02482129|DRUG|LME636 Vehicle|Inactive ingredients used for masking purposes
224075868|NCT04955392|OTHER|Osteopathic treatment protocol|"The intervention protocol consists of 4 techniques that will be performed according to the following order:~1. Inhibition of the suboccipital muscles.~2. Parietal Lift.~3. Sutherland Technique of Sphenobasilar Synchondrosis.~4. Compression technique of the fourth ventricle (CV4)."
224075869|NCT04955392|OTHER|Sham technique|Sham technique that consists of placing the hands on top of the skull without any therapeutic intention for five minutes.
224075870|NCT00602108|PROCEDURE|adjuvant therapy|
224075871|NCT00602108|PROCEDURE|conventional surgery|
224075872|NCT00602108|RADIATION|hypofractionated radiation therapy|
224075873|NCT00602108|RADIATION|intraoperative radiation therapy|
224075874|NCT05481372|OTHER|Imaging|Trans-perineal ultrasound and Magnetic resonance image acquisition
224075875|NCT05713097|DIAGNOSTIC_TEST|TSI|TSI was measured several times during the course of treatment when planning to stop medication (at the discretion of the attending physician).
224075876|NCT01060358|PROCEDURE|method (non-surgical) to measure neuromuscular neutral zones|
224075877|NCT03413150|DRUG|Amiodarone|Data were extracted from the files of 80 consecutive critically ill patients who had received at least one dose of amiodarone to treat or prevent AT during their hospitalization in the ICU.
224075878|NCT05855447|OTHER|NIRS device usage during 6MWT|It will be performed by placing a traffic cone as the sign of the turning point in a straight 30 meter long corridor, after patients have rested for a sufficient time (\> 30 minutes) by sitting in a chair. Participants will be asked to walk as fast as possible but without running along the corridor within 6 minutes. Before and after the test, the patient's fatigue and dyspnea conditions will be questioned using the Modified Borg Scale and blood pressure using a digital sphygmomanometer, and saturation and pulse measurement will be evaluated using finger pulse oximetry before, during and after the test. During the 6-minute walk test, the muscle oxygenation of the patients and the amount of muscle oxygen will be measured using Moxy (Fortiori Design LLC, Minnesota, USA) brand NIRS technology. During the walking test, the change in intramuscular oxygenation will be monitored and recorded with the company's software program.
224075879|NCT05855447|OTHER|Peripheral Muscle Strength Measurement|The muscle strength of shoulder flexors, abductors, elbow flexors, hip flexors, abductors, and knee extensors will be evaluated using a Lafayette® 01165 model electronic hand dynamometer. The force measurement will be repeated 3 times and it will be requested to maintain muscle strength against the dynamometer for at least 5 seconds in each trial. The best value out of 3 test results will be recorded
224075880|NCT05855447|OTHER|Pulmonary Function Test|Pulmonary Function Test (PFT) with desktop type spirometry for FVC (Forced Vital Capacity), Forced expiratory flow rate (FEV1), FEV1/FVC.
224075881|NCT01928381|DRUG|AZD5213 + pregabalin|Double blind Investigational drug AZD5213 (capsules) given in combination with pregabalin (capsules)
224075882|NCT01928381|DRUG|Placebo|Double blind placebo capsules to match AZD5213 and pregabalin
224075883|NCT01928381|DRUG|pregabalin capsules|Double blind pregabalin capsules to match AZD5213 and placebo
224075884|NCT05816980|RADIATION|Hyperfractionated external beam radiation|40.8Gy/34 fractions (1.2Gy BID 5/7 days with minimum 6 hours interval) Concurrent capecitabine (825 mg/m2 BID 5/7 days)
224075885|NCT01209026|DRUG|Fluticasone furoate (200 mcg)/GW642444 (25mcg) combination|Novel dry powder inhaler
224166118|NCT00003899|DRUG|paclitaxel|
224166119|NCT00003899|DRUG|thiotepa|
224166120|NCT00003899|PROCEDURE|autologous bone marrow transplantation|
224166121|NCT00003899|PROCEDURE|peripheral blood stem cell transplantation|
223479305|NCT02987868|DRUG|Amino acid supplement first day|An orally administered supplement of the proprietary amino acid derivative
224166122|NCT02425813|DRUG|Budesonide|Given PO
224166123|NCT02425813|DRUG|Methylprednisolone Sodium Succinate|Given IA and IV
224166124|NCT04018391|BEHAVIORAL|Stepped care for nonadherence and depression|"* Problem Solving for Depression and Adherence: A 6-session adherence and depression intervention based on a culturally adapted LifeSteps and Problem Solving Therapy for Depression.~* Stepped Care Assessment for Antidepressant Treatment: If a participant's depression score remains above threshold in Session 6, the study interventionist will refer the participant to a Research Mental Health Nurse for a psychopharmacological assessment to prescribe an antidepressant to augment Problem Solving for Depression and Adherence."
224166125|NCT04018391|OTHER|Enhanced Usual Care|Enhanced Usual Care: A combination of 1) clinic-provided adherence counseling, 2) access to providers trained in the World Health Organization Mental Health Gap Intervention Guide (mhGAP), 3) a letter to the participant's medical provider detailing the depression diagnosis, 4) access to the treatment components of the TENDAI intervention at no cost, after the participant has completed their 12-month follow-up assessment.
224166126|NCT05179564|DIAGNOSTIC_TEST|iohexol administration|IV injection of weight-dependent low dose of iohexol at time 0
224166127|NCT05179564|DIAGNOSTIC_TEST|iohexol blood sampling|Blood sampling will be performed through an arterial (preferred) or venous line, other than the iohexol infusion line. In the first 30 minutes after iohexol injection, a blood sample of 2 ml will be obtained for iohexol concentration measurement and determination of renal biomarkers serum creatinine, cystatin C, betatrace protein. Subsequently, 2 up to 5 additional blood samples of 0,5 ml will be obtained for iohexol determination at 60,120 ,180, 240 and 360 minutes after iohexol injection to calculate iohexol plasma clearance from the plasma disappearance curve
224166128|NCT00031109|BIOLOGICAL|gp160 MN/LAI-2|
224166129|NCT00031109|BIOLOGICAL|Aluminum hydroxide|
224166130|NCT04899752|BEHAVIORAL|Motivational Interviewing|Participants will participate in three different communication styles to determine the effect of MI on cardiac rehab outcome measures.
224166131|NCT06436300|BEHAVIORAL|Motivational text messaging|Intervention sends up to 4 motivational messages by text or email to Alaska Native men who are active patients and due for colorectal cancer screening. Incentive arms include promise of a $50 gift card or entry into a raffle for prize worth about $200 if they complete screening.
224166132|NCT06379984|DRUG|Buprenorphine|Sublingual buprenorphine
224166133|NCT04362696|DEVICE|High definition transcranial electrical current stimulation|Low-intensity and safe, noninvasive application of electrical current to the human scalp with the goal of gradually modulating levels of neuronal excitability.
223479306|NCT02987868|DRUG|Placebo first day|A non-active orally administered supplement of the proprietary amino acid derivative
223479307|NCT02987868|DRUG|Amino acid supplement second day|An orally administered supplement of the proprietary amino acid derivative
223479308|NCT02987868|DRUG|Placebo second day|A non-active orally administered supplement of the proprietary amino acid derivative
223479309|NCT03286790|OTHER|Data collection on pneumonia events|
223479310|NCT00479752|DRUG|FOLFOX4 (Oxaliplatin), Cetuximab|"Arm A FOLFOX4:~* Oxaliplatin 85 mg/m² d1~* Leucovorin 200 mg/m² d1+d2, followed by~* Bolus 5FU 400 mg/m², followed by~* Infusional 5FU 600 mg/m²,over 22 hours, every 2 weeks~Cetuximab is administered to arm A of the study as an infusion with initial dose 400 mg/m² in week 1 followed by weekly doses of 250 mg/m².~Arm B FOLFOX4:~* Oxaliplatin 85 mg/m² d1~* Leucovorin 200 mg/m² d1+d2, followed by~* Bolus 5FU 400 mg/m² , followed by~* Infusional 5FU 600 mg/m², over 22 hours, every 2 weeks~Cetuximab is administered to arm B of the study as infusions of 500 mg/m² every two weeks."
223479311|NCT04363814|BIOLOGICAL|Bactek-R|BACTEK-R is a bacterial preparation that contains a mixture of Gram + and Gram - inactivated bacteria at the concentration of 300 FTU / mL (approx. 10\^9 bacteria / mL)
223479312|NCT01587313|DRUG|Isosorbide dinitrate / hydralazine capsules|Group 1: Day 1:Two SR capsules; Day 8: One IR capsule Group 2: Day 1:Two SR capsules; Day 8: One IR capsule Group 3: Day 1:Two SR capsules; Day 8: One IR capsule Group 4: Day 1:One IR capsule and two SR capsules; Day 8: Commercial BiDil Tablet tid
223479313|NCT00498550|DRUG|Clozapine|Clozapine up to 550mg per day
224166134|NCT06740708|BEHAVIORAL|SCALE-NCD|"1. FCHV home visits every three months, including~   * For hypertension i. Blood pressure measurement with digital BP devices ii. Lifestyle counseling iii. Referral if uncontrolled BP (≥140/90 mmHg) for 3 months~  * For type 2 diabetes i. Fasting blood glucose measurement with glucometer ii. Lifestyle counseling focusing on diabetes management iii. Referral if uncontrolled diabetes (≥126mg/dl) for 3 months~  * For current smokers i. Smoking cessation counseling ii. Referral for nicotine replacement therapy if request by participants~2. Mobile phone messages, including~   * Lifestyle modification~  * Conveyed as voice or text messages, depending on participant preference"
224166135|NCT05769153|DRUG|AR-14034 SR implant lower dose|AR-14034 SR administered as an intravitreal implant
224166136|NCT05769153|DRUG|AR-14034 SR implant higher dose|AR-14034 SR administered as an intravitreal implant
224166137|NCT05769153|DRUG|AR-14034 SR implant|AR-14034 SR administered as an intravitreal implant
224166138|NCT05769153|DRUG|Aflibercept Injection|Aflibercept administered as a 2 milligram (mg) intravitreal injection
224166139|NCT05769153|DRUG|Sham procedure|Needleless syringe used to simulate an intravitreal injection
224166140|NCT02670213|DRUG|recombinant factor XIII|No treatment given.Patients will be treated according to routine clinical practice at the discretion of the treating physician.
224166141|NCT02051088|PROCEDURE|Revascularization with drug-eluting technology|Endovascular intervention with the use of drug-eluting devices (drug-coated balloons and/or drug-eluting stents).
224166142|NCT02051088|PROCEDURE|Revascularization without drug-eluting technology|Endovascular intervention without using drug-eluting balloons or stents
224166143|NCT02051088|DEVICE|drug-coated balloons and/or drug-eluting stents|
224305252|NCT02357563|DRUG|Leuprolide acetate|One dose of 11.25 GnRH analogue depot will be administered in the luteal phase of the menstrual cycle (days 21-24) and repeated 3 months later
224305253|NCT04645966|BIOLOGICAL|MenABCWY|Neisseria meningitis groups A, B, C W, and Y vaccine
224166144|NCT06366425|DIAGNOSTIC_TEST|Blood sample then fibroscan|"The patient takes a blood test if none less than 6 months old is available, including a complete blood count (CBC) and a hepatic check. The FIB-4 score will be calculated from this blood test.~If the result of the FIB-4 test is greater than 1.3 the person will be contacted by the SELHV (Service Expert de Lutte contre les Hépatites Virales) of the University Hospital of Montpellier in order to schedule, if she wishes, a second non-invasive screening examination of liver fibrosis by Fibroscan."
224166145|NCT00615420|DIETARY_SUPPLEMENT|manuka honey|Irradiated organic manuka honey 5ml 4 times a day held in mouth for 30 secs then swallowed. May be diluted with equal or twice the volume of water to reduce nausea in patients already nauseated from chemotherapy.
224166146|NCT00615420|DIETARY_SUPPLEMENT|placebo gel|Sugar-free honey-flavoured gel 5ml 4 times a day swished and held in mouth for 30 secs then swallowed. May be diluted with equal or twice the volume of water to reduce nausea in patients already nauseated from chemotherapy.
224166147|NCT06538038|DRUG|Osimertinib|Single agent Osimertinib by mouth once daily. Dosing and administration of osimertinib will be administered as per routine standard of care per the package insert or per institutional guidelines.
224166148|NCT06538038|DRUG|Osimertinib + Chemotherapy|Osimertinib by mouth once daily + Chemotherapy. Chemotherapy choice will be per treating physician. Dosing and administration of osimertinib +/- chemotherapy agents will be administered as per routine standard of care per the package insert or per institutional guidelines.
224166149|NCT01333020|OTHER|cross-linking of an emulsion drink|This study will assess whether a subtle change in food structure (cross-linking of interfacial protein) can alter gastric emptying rate.
224166150|NCT05207371|BIOLOGICAL|Biological|Intravenous injection of GAIA-102 alone or with Pembrolizumab (KEYTRUDA®︎)
224166151|NCT00278044|PROCEDURE|blood sampling and medical records|
224166152|NCT04687475|OTHER|Clinical Tool (Mobile Spirometry and Survey)|The clinical tool is a combination of home spirometry measurements and a patient survey measuring patient reported outcomes including the Cystic Fibrosis Respiratory Symptom Diary (CFRSD) and Chronic Respiratory Infection Symptom Score (CRISS©), with permission from the Seattle Quality of Life Group.
224166153|NCT04413344|DRUG|Bromocriptine Mesilate|Each tablet contains 2.87 mg of bromocriptine mesilate (JP) (2.5 mg of bromocriptine)
224166154|NCT04413344|DRUG|Placebos|Identical tablets which contain no active ingredient
224166155|NCT00863434|DRUG|clofarabine|Given IV
224166156|NCT00863434|DRUG|cytarabine|Given IV
224166157|NCT00863434|BIOLOGICAL|filgrastim|Given SC
224166158|NCT05262946|BEHAVIORAL|sensorimotor training based on Feldenkrais method|8 weeks of balance and sensorimotor training twice a week
224166159|NCT05262946|BEHAVIORAL|foot care education|Recommendations for preventing foot ulcers
224166160|NCT05262946|COMBINATION_PRODUCT|usual care|drugs and diet usual care
224166161|NCT03963817|DIAGNOSTIC_TEST|adaptive optics AO-OCT/AF instrument|Using the new adaptive optics AO-OCT/AF instrument, the study team will image 10 normal subjects in order to optimize image acquisition and interpretation.
224075886|NCT01209026|DRUG|Fluticasone furoate (400 mcg)/GW642444 (50mcg) combination|Novel dry powder inhaler
224075887|NCT01209026|DRUG|Placebo Inhaler|Matching placebo Novel dry powder inhaler. Lactose monohydrate and magnesium stearate.
224075888|NCT01209026|DRUG|Moxifloxacin 400mg|Film coated oral tablet
224075889|NCT01209026|DRUG|Moxifloxacin placebo|Film coated oral tablet
224075890|NCT07120425|DRUG|IBI3032|"IBI3032:~Method of administration: oral, fasted administration."
224075891|NCT07120425|DRUG|placebo|Placebo (without active ingredients) Method of administration: oral, fasted administration.
224075892|NCT07120386|DEVICE|Negative Pressure Wound Therapy|NPWT creates a vacuum seal over your wound to promote healing
224075893|NCT07120386|DEVICE|Negative Pressure Wound Therapy with Instillation|NPWTi creates a vacuum seal over your wound and infuses the wound with hypochlorous acid (medical grade dilute bleach) to clean it.
224075894|NCT06216327|BEHAVIORAL|household safety intervention|This intervention includes a household safety intervention that is delivered by an interventionist with specific training in facilitating lethal means safety discussions, and the provision of no-cost safety devices for medications and firearms.
224075895|NCT06269783|BEHAVIORAL|sipIT|Automated and manual fluid tracking system with just-in-time reminder messages to support fluid intake habit formation.
224075896|NCT03939481|DRUG|Chemotherapy|Given chemotherapy regimen
224075897|NCT03939481|OTHER|Functional Assessment|Functional and sensory clinician assessments
224075898|NCT03939481|OTHER|Questionnaire Administration|Patient and physician reported responses
224075899|NCT06812260|DRUG|HLX10+chemo|Treatment arm
224075900|NCT05235425|BEHAVIORAL|Standard NDPP|"Participants in this arm will be taught to manage their prediabetes with the Centers for Disease Control's standard National Diabetes Prevention Program. It teaches a lower calorie, lower fat diet.~There will be a core phase and a maintenance phase of this study; the core phase will last for about 4 months and will involve weekly or every other week classes, home assignments, and brief check-in surveys. The maintenance phase will last for the remaining time, with classes and check-in surveys approximately once a month."
224075901|NCT05235425|BEHAVIORAL|Very low-carbohydrate diet|"Participants in this arm will be taught to manage their prediabetes with the Centers for Disease Control's National Diabetes Prevention Program, adapted to teach a very low-carbohydrate diet, also called a ketogenic or keto diet. This diet involves eating non-starchy vegetables, leafy greens, cheese, meats, berries, nuts, and seeds and avoiding starchy foods like pasta, bread, rice, beans, many fruits, etc.~There will be a core phase and a maintenance phase of this study; the core phase will last for about 4 months and will involve weekly or every other week classes, home assignments, and brief check-in surveys. The maintenance phase will last for the remaining time, with classes and check-in surveys approximately once a month."
224075902|NCT03676647|OTHER|Diagnostic DNA Methylation Signature|Undergo collection of tissue samples
224075903|NCT05852691|DRUG|Tobemstomig|Participants will receive intravenous (IV) tobemstomig every 3 weeks (Q3W) until disease progression or until up to 24 months after the first treatment, whichever is sooner.
224075904|NCT05852691|DRUG|Pembrolizumab|Participants will receive IV pembrolizumab Q3W until disease progression or until up to 24 months after the first treatment, whichever is sooner.
224166162|NCT03963817|DIAGNOSTIC_TEST|adaptive optics AO-OCT/AF instrument|Using the new adaptive optics AO-OCT/AF instrument, the study team will image 40 adult subjects with age-related macular degeneration (AMD) who have non-neovascular AMD and soft drusen or subretinal drusenoid deposits in the macula.
224166163|NCT06834789|DRUG|AGN-151586|Intramuscular injection
224166164|NCT06834789|DRUG|OnabotulinumtoxinA|Intramuscular injection
224166165|NCT06834789|DRUG|Placebo|Intramuscular injection
224166166|NCT01748149|DRUG|Vemurafenib|"Vemurafenib is supplied in 120-mg and 240-mg film-coated tablets packed in bottles for oral administration. Dosing is based on the body surface area (BSA) calculated at the beginning of each course of therapy. The dose prescribed should be rounded to the nearest deliverable dose based on the BSA adjustment and the available pill sizes. Dosing will not exceed the adult MTD of 960 mg twice a day (BID). Patients will be provided with a Medication Diary for vemurafenib, instructed in its use, and asked to bring the diary with them to each appointment.~Treatment will be administered on an outpatient basis. Dosing is based on the BSA calculated at the beginning of each course of therapy. The dose prescribed should be rounded to the nearest deliverable dose based on the BSA adjustment and the available pill sizes. Regardless of cohort, patients will self-administer vemurafenib BID at the assigned dose level. Patients will be instructed to hold their dose of vemurafenib for PK or surgery."
224166167|NCT06846398|DRUG|BW-20805|SC administrations of BW-20805 600 mg on Day1 to Day673
224166168|NCT06846398|DRUG|BW-20805|SC administrations of BW-20805 300 mg every 24 weeks on Day1 to Day169;Day337 to Day673
224166169|NCT06846398|DRUG|BW-20805|SC administrations of BW-20805 300 mg every 12 weeks on Day 1 to Day 589
224166170|NCT04678973|BEHAVIORAL|Self-compassion mindfulness practice|"Guided Mindfulness Practice: Participants in the intervention group will receive compassion-based guided meditation audio recordings. Recordings will target self-compassion and body concerns simultaneously.~Psychoeducation: Participants in the intervention group will receive psychoeducation delivered via daily PDF over days 1-6. Psychoeducation will orient users to their upcoming experience, provide education about internalized weight bias, the chronic stress system, the utility of self-compassion practice to regulate physiological and psychological targets, and guidance on establishing, maintaining, and generalizing a mindfulness practice.~Daily prompts: Participants will receive a text message every morning indicating their task for that day.~Weekly prompts: Participants will receive a text message at the end of every week (Days 7, 14, 21, and 28) with a link to a brief adherence survey."
224166171|NCT04607590|OTHER|Best Practice|Receive usual care
224166172|NCT04607590|PROCEDURE|Quality-of-Life Assessment|Ancillary studies
224166173|NCT04607590|OTHER|Questionnaire Administration|Ancillary studies
224166174|NCT04607590|PROCEDURE|Yoga|Participate in yoga sessions
224166175|NCT06030193|DRUG|QLS-111 ophthalmic solution (0.015%)|QLS-111 ophthalmic solution 0.015% applied QPM OU for 7 days followed by BID dosing OU for 7 days, to constitute a 14-day study treatment period. All IP for this study will be supplied masked in PF single use vials.
224166176|NCT06030193|DRUG|Timolol Maleate PF 0.5% Ophthalmic Solution (Timolol)|Timolol BID: Timolol Maleate PF 0.5% Ophthalmic Solution (Timolol) with BID dosing OU will be administered up to 14 days. All IP for this study will be supplied masked in PF single use vials.
224166177|NCT04718402|DRUG|Mitoxantrone Hydrochloride Liposome, intravenous injection|All subjects will receive Mitoxantrone Hydrochloride Liposome 20 mg/m2, IV, on day 1 of each 21-day cycle (q3w).
224166178|NCT02064829|DRUG|Nab-paclitaxel|260 mg/m2 administered intravenously over 30 minutes on Day 1 every 3 weeks
224166179|NCT02064829|DRUG|IG-001|260 mg/m2 administered intravenously over 30 minutes on Day 1 every 3 weeks
224166180|NCT00564915|DIETARY_SUPPLEMENT|Ketogenic diet|Ketogenic diet
224166181|NCT04749368|DRUG|BRII-835 (VIR-2218)|BRII-835 (VIR-2218) will be given by subcutaneous injection
224166182|NCT04749368|BIOLOGICAL|BRII-179 (VBI-2601) with IFN-α|BRII-179 (VBI-2601) with IFN-α will be co-administered by intramuscular injection
223584404|NCT00918554|DRUG|Methotrexate|All patients will receive three pulses of methylprednisolone (5 mg/kg) followed by four weeks of prednisone (1 mg/kg daily). After randomization, patients will receive either prednisone (1 mg/kg daily) plus methotrexate (0.3 mg/kg weekly) or prednisone (1 mg/kg daily) plus placebo. Therapies will be administered orally. Corticosteroids will be progressively tapered when macular oedema completely resolve. Unilateral macular oedema relapses will be treated with a single local injection triamcinolone acetonide. Increasing dose of prednisone will be administered in case of bilateral macular oedema relapses.
224166183|NCT04749368|BIOLOGICAL|BRII-179 (VBI-2601)|BRII-179 (VBI-2601) will be administered by intramuscular injection
224166184|NCT02916628|BEHAVIORAL|group counseling|Group counseling with positive psychology and motivational interviewing was undertaken once per week for 6 weeks.
224166185|NCT02916628|DEVICE|Auricular acupressure|Auricular acupressure using acupellets was performed for 6 weeks continuously
224166186|NCT02916628|DEVICE|placebo acupressure|Placebo acupellets were prepared without metal projections, and placed on both sides in the same areas of the ear as the active condition.
224166187|NCT03539614|DRUG|Prazosin|This is an antagonist of the alpha1 receptor for noradrenaline. It is FDA approved for the treatment of hypertension, and has also been used for benign prostatic hypertrophy (BPH). Most recently, it has been found to be helpful for symptoms of PTSD in some but not all participants.
224166188|NCT03539614|DRUG|Placebo|This is a capsule containing an inert substance, in order to provide blinding to participants and study staff of when participants are on active medication and when they are not during the later portions of the trial.
224166189|NCT01712776|DEVICE|Vapocoolant (Pain Ease)|Topical stream 4-10 seconds duration to skin.
224166190|NCT01712776|DEVICE|Nature's Tears Sterile Water|Topical stream 4-10 seconds duration to skin
224166191|NCT05230511|DRUG|Lactobacillus RhamnosusGG|LGG® (Culturelle Probiotic LGG®) will be used. This is the product we have used in the past and for which we have demonstrated safety, tolerability, and preliminary efficacy. For the LGG® instillation, participants will be instructed to mix the contents of 1 LGG® capsule into 45 cc sterile 0.9% saline. After mixing, participants will draw up the 45cc liquid LGG® mixture into a 60cc syringe and instill via the intermittent catheter after the last catheterization prior to going to bed. Participants will be asked to return any remaining capsules at the end of the study. Participants will be instructed to complete the USQNB-IC at the time of symptoms (in real time), and then continue completing the USQNB-IC at the determined frequency for the phase.
224166192|NCT05230511|DRUG|Saline bladder wash|Participants will draw up the 45cc of normal saline into a 60cc syringe and instill via the intermittent catheter after the last catheterization prior to going to bed after trigger symptoms occur. Participants will be instructed to complete the USQNB-IC at the time of symptoms (in real time), and then continue completing the USQNB-IC at the determined frequency for the phase.
224166193|NCT05924178|BEHAVIORAL|exercise rehablitation|Preoperative exercise rehabilitation in experimental group was performed.
224166194|NCT05924178|BEHAVIORAL|routine treatment|The control group receives conventional treatment preoperative.
224166195|NCT06023199|DRUG|Voxelotor|Voxelotor is administered orally at a dose of 1500mg daily.
224166196|NCT03956745|BEHAVIORAL|sleep-wake timing|Study participants will have one inverted day when they are scheduled to sleep \~12h opposite their usual sleep time.
224166197|NCT03956745|BEHAVIORAL|constant routine|Study participants will spend \~28-50 hours awake, inactive, sitting in bed, in constant lighting and temperature.
224166198|NCT01285752|DRUG|AK106-001616|
224166199|NCT01285752|DRUG|AK106-001616|
224166200|NCT01285752|DRUG|Active comparator|
223479314|NCT00498550|DRUG|Treatment as usual|Remain on pre-study antipsychotic treatment
224166201|NCT02737605|DRUG|Intranasal Esketamine|Participants will receive 84 mg intranasal esketamine as 3 devices, each with 28 mg esketamine.
224166202|NCT02737605|DRUG|Intravenous Esketamine|Participants will receive 0.8 milligram per kilogram body weight esketamine, 40 minutes, intravenous infusion.
224166203|NCT02737605|DRUG|Moxifloxacin|Participants will receive 400 mg Moxifloxacin orally.
224166204|NCT02737605|DRUG|Oral Placebo|Participants will receive matching placebo orally.
224166205|NCT02737605|DRUG|Intravenous Placebo|Participants will receive placebo 40 minutes, intravenous infusion.
224166206|NCT02737605|DRUG|Intranasal Placebo|Participants will receive intranasal placebo (1 spray in each nostril at 0, 5, and 10 minutes).
223479315|NCT02918344|OTHER|Hydroset|Calcium phosphate paste is used in mandibular lengthening surgery to avoid an unaesthetic notching at the lower border and to help stabilize the segments when osteosynthesis slippage is feared for.
223584405|NCT00918554|DRUG|Placebo|All patients will receive three pulses of methylprednisolone (5 mg/kg) followed by four weeks of prednisone (1 mg/kg daily). After randomization, patients will receive either prednisone (1 mg/kg daily) plus methotrexate (0.3 mg/kg weekly) or prednisone (1 mg/kg daily) plus placebo. Therapies will be administered orally. Corticosteroids will be progressively tapered when macular oedema completely resolve. Unilateral macular oedema relapses will be treated with a single local injection of triamcinolone acetonide. Increasing dose of prednisone will be administered in case of bilateral macular oedema relapses.
223584406|NCT04878536|DIETARY_SUPPLEMENT|Collagen drink|Testing product
223584407|NCT04878536|DIETARY_SUPPLEMENT|Blank|Placebo drink
224166207|NCT04011137|OTHER|Exercise|Arm-cranking exercise
224166208|NCT02531633|DRUG|Sirukumab|Sirukumab will be provided as 1 millilitre (mL) Pre-filled Syringe (PFS), containing 100 mg/mL or 50 mg/mL of sirukuma, fitted with a spring-powered, disposable autoinjector device for single use SC administration of liquid biologic drug.
224166209|NCT02531633|DRUG|Placebo to match sirukumab|Placebo to match sirukumab will be provided as 1.0 mL PFS fitted with a spring-powered, disposable autoinjector device for single use SC administration of liquid biologic drug.
224166210|NCT02531633|DRUG|Prednisone|Prednisone will be provided as tablets with dosage level up to-60 mg/day. The prednisone dose for all subjects will be determined by the Investigator and starting doses will be within 20-60 mg prednisone at Baseline (Randomization).
224166211|NCT02531633|DRUG|Placebo to match prednisone|Placebo to match prednisone will be provided as tablets.
224166212|NCT00957060|DRUG|GLIMEPIRIDE (HOE490)|Pharmaceutical form: 2 mg and 4 mg tablets Route of administration: oral
224166213|NCT00957060|DRUG|SITAGLIPTIN|Pharmaceutical form: 100 mg tablets Route of administration: oral
224166214|NCT06305000|PROCEDURE|Non-surgical treatment|Non-surgical treatment consists of oral hygiene instructions, full mouth supragingival scaling using titanium hand instruments, ultrasonic devices, and subgingival debridement under local anesthesia with titanium curettes and ultrasonic instruments in a single appointment.
224166215|NCT06305000|PROCEDURE|Free gingival graft|After adequate local anesthesia is achieved. A horizontal incision is placed mucogingival junction level to prepare the recipient bed. A split-thickness flap is raised without disturbing the periosteum. FGG is obtained from the palate, extending from the mesial surface of the second premolar to the middle of the first molar. The graft is shaped and stitched on the recipient surface.
223584408|NCT00810940|DRUG|AbelaDrug200|IV 200 ml 28%drug in D5W every six hours, 10 min. duration, until ICP \< 20 mmHg, then IV 100 ml same schedule for 24 hours
223584409|NCT00810940|DRUG|mannitol|mannitol plus standard treatment
224166216|NCT02169726|DEVICE|Diffuse Optical Spectroscopy|Diffuse Optical Spectroscopy Imaging measure blood flow,oxygen, temperature in back muscle when they are treated with therapeutic ultrasound and can improve the treatment
224166217|NCT01462422|DRUG|Misoprostol|Selective administration of 800 mcg sublingual misoprostol to women with at least 350 mL blood loss within 1 hour following delivery
224166218|NCT01462422|DRUG|Misoprostol|Universal administration of 600 mcg oral misoprostol given to all women within 5 minutes of delivery of the baby
224166219|NCT01486992|DRUG|mFOLFIRI+Nimotuzumab|irinotecan 180mg/m2，iv ，d1，LV 200 mg/m2 ，2h，d1，5-FU 400 mg/m2， iv，d1 5-FU 2400mg/m2，CIV，46h，q2w Nimotuzumab 200mg，iv，qw
224166220|NCT05910489|OTHER|Biomonitoring of MNPLs in biological samples of greenhouse workers and controls|Detection of biomarkers of exposure and genotoxic effect in biological blood, urine, exhalated air condensate, and feces
223479316|NCT02918344|PROCEDURE|Standard sagittal split osteotomy|The sagittal split osteotomy (SSO) is commonly used to correct dentofacial discrepancies.
223479317|NCT00863122|DRUG|lapatinib|1500 mg lapatinib by mouth per day for 10 days
223479318|NCT01171534|DEVICE|DermaClose fasciotomy closure|The DermaClose device provides continuous expanding of the skin around the wound until it has stretched enough to allow the skin edges to be sutured closed.
223479319|NCT01171534|DEVICE|Vessel loop|Vessel loops and staples for fasciotomy closure
223479320|NCT00849056|BIOLOGICAL|albiglutide|albiglutide weekly subcutaneous injection
223479321|NCT00849056|DRUG|placebo|placebo weekly subcutaneous injection
224166221|NCT00177606|BEHAVIORAL|withdrawal of life sustaining treatments|
224166222|NCT02894788|OTHER|ICU admission|
224166223|NCT00264628|DRUG|GW679769|
224166224|NCT00585104|DRUG|levosimendan|10-minute infusion
224166225|NCT00782756|OTHER|radiotherapy (RT) in combination with temozolomide and bevacizumab|"Bevacizumab10 mg/kg IV once every two weeks on days 1 and 15 of every cycle (Cycle defined as 28 days). Temozolomide 75mg/m2 daily beginning on day 1 through completion of radiotherapy. Hypofractionated dose painting IMRT will start on day 1 and will be delivered on a Monday, Wednesday, Friday schedule for a total of 6 fractions.~Post RT therapy: Bevacizumab 10mg/kg IV every two weeks. Temozolomide 150-200mg/m2 daily for 5 consecutive days will be given on 28 day cycles.~Follow up: CBC weekly, comprehensive panel and urinalysis monthly, blood pressure every other week. Neurological/physical examination monthly. Gd-enhanced MRI with perfusion every 2 cycles. Neurocognitive testing (approximately 4months post RT, 1 year after diagnosis and then annually in long term survivors). Blood sample for correlative studies monthly."
224166226|NCT00212667|DRUG|ONO-5920|
224166227|NCT04403802|DEVICE|Voxx Human Performance Technology Socks|"Voxx Human Performance Technology Socks are commercially-available socks that are drug and electrical free. The Voxx Human Performance Technology proprietary pattern is woven into a sock that is made of 70% cotton, 25% polyester, 3% spandex, and 2% nylon.~Prior to the 2-week treatment window, patients will be provided with 6 pairs of Voxx Human Performance Technology socks. Patients will be asked to wear the socks continuously during both waking and sleeping hours, except when showering, bathing, or swimming."
223479322|NCT01212510|OTHER|Blood sampling|blood rate of ACE, CA19-9, circulating tumor cell, circulating tumor DNA
223479323|NCT04800796|OTHER|Audiovisual|Receive blended learning before and reading the Standard operating procedure
223479324|NCT01026935|DEVICE|Open inguinal hernia repair|Altogether 400 patients are randomized to receive an open mesh repair with either sutured light weight mesh (38g/m2) or with a non-sutured light weight polypropylene mesh that adheres to tissues with polylactic micro hooks
223479325|NCT01104649|DRUG|riluzole|Study drug will be orally dispensed in doses of 50 mg twice daily for 12 months.
223479326|NCT01104649|DRUG|Placebo comparator|Study drug will be orally dispensed in doses of 50 mg twice daily for 12 months.
223479327|NCT03042546|DRUG|Calcium Sulfate|Calcium Sulfate with abx will be used in the defect
223479328|NCT03042546|DRUG|PMMA|PMMA with abx will be used in the defect
223479329|NCT03042546|OTHER|No treatment|The defect will not be treated
223479330|NCT03524001|DEVICE|Compare VVi mode versus DDD bifocal stimulation through crossover randomization|All patients undergo bifocal right ventricular resynchronization therapy: right atrial lead is implanted, whereas first ventricular lead is placed in His bundle area, and the second ventricular lead in the right ventricle apex.Then the leads are connected to CRT-D generator.After the implant, all devices are programmed in VVI mode. After the first 40±10 days (first f-up) patients are 1:1 randomized to VVI mode 40 beats/minute (placebo arm) or bifocal DDD-mode 60 beats/minute.After six months (second follow-up) a clinical and instrumental assessment equal to baseline is performed. Then arms cross-over is performed (from VVI-mode to bifocal DDD-mode and vice versa). At 12 months (end of follow-up) an evaluation equal to that performed at 6 months is assessed. Echocardiographic data are unravelled to the investigator that plans stimulation mode able to determine the best clinical improved.
223479331|NCT03227588|DIAGNOSTIC_TEST|Fractional Flow Reserve|This is a prospective data collection study for patients that have undergone FFR.
224166228|NCT04403802|DEVICE|Placebo Socks|"Placebo socks are identical to the Voxx Human Performance Technology socks but do not include the Voxx Human Performance Technology pattern woven into the sock. Placebo socks are made of the same fabric as Voxx Human Performance Technology socks and are drug and electrical free.~Prior to the 2-week treatment window, patients will be provided with 6 pairs of placebo socks. Patients will be asked to wear the socks continuously during both waking and sleeping hours, except when showering, bathing, or swimming."
224166229|NCT04009252|BEHAVIORAL|3D Model Education|A 3D model of the patients ankle fracture will be printed and used as a teaching tool to discuss long-term outcomes and potential complications.
224166230|NCT00965744|DEVICE|Vessel sealing system LigaSure|Patients in VS group undergoing esophagogastric decongestion (Azygoportal Disconnection) and splenectomy with or without esophageal transaction with the vessel sealing system LigaSure.
224166231|NCT03990324|PROCEDURE|Manual stretching|Manual stretching for the upper trapezius and levator scapulae muscle
224166232|NCT02337075|BEHAVIORAL|PATH program|A brief education session, use of a wearable physical activity tracker, and physical activity mentoring by an Activity Mentor every 2 weeks.
224166233|NCT02337075|DEVICE|Activity Mentor|
224166234|NCT00468273|DRUG|Immune Globulin Intravenous (Human) Omr-IgG-am IGIV|IGIV infusions of 300-900 mg/kg every 3 or 4 weeks
224166235|NCT02334813|DRUG|Prednisone|Continuous daily therapy
224166236|NCT02334813|DRUG|Dexamethasone|4-day pulses every 3 weeks
224166237|NCT00544193|DRUG|gemcitabine hydrochloride|
224166238|NCT00544193|GENETIC|polymerase chain reaction|
223479332|NCT03380156|DEVICE|TVS|Active TVS will be performed by use of a Tragus stimulator device with electrodes attached to the tragus of the ear. Stimulator will be applied continuously for 1 hour
223479333|NCT03380156|DEVICE|Sham TVS|Device will be applied but not to the Tragus of the ear but will be attached to the ear lobule.
223479334|NCT06426745|PROCEDURE|Bowel preparation|to compare bowel cleanliness, compliance, tolerability, and patient satisfaction of a single regimen versus a split regimen for colonoscopy.
223479335|NCT00895713|DRUG|intramuscular hepatitis B virus immune globulin|Biweekly intramuscular doses of 2000 IU administered during 6 consecutive months
223479336|NCT04156659|BIOLOGICAL|Tisagenlecleucel|A single intravenous (i.v.) infusion of CAR-positive viable T cells.
223479337|NCT02862509|DRUG|Budesonide nasal instillation|
223479338|NCT02862509|DRUG|Normal saline nasal instillation|
223479339|NCT02934178|BIOLOGICAL|Shigella sonnei Strain WRSS1 Vaccine|Live attenuated, oral Shigella WRSS1 vaccine
223479340|NCT02934178|BIOLOGICAL|Placebo|Sterile saline solution
223479341|NCT04663113|OTHER|Control Group/1st group ( standard physiotherapy|It comprised of parameters such as early mobilization and ambulatory training, pulmonary physiotherapy, active and passive normal joint movement exercises.
224166239|NCT00544193|OTHER|immunohistochemistry staining method|
224166240|NCT00544193|PROCEDURE|conventional surgery|
223584410|NCT05361642|DRUG|Bupivacaine HCl 0.5% Injectable Solution|using nasal block including sphenopalatine ganglion block with general anesthesia to optimize surgical field
223584411|NCT05361642|DRUG|Dexmedetomidine|using dexmedetomidine with induction of general anesthesia to optimize surgical field
223584412|NCT04333342|DEVICE|heart rate monitoring using wearable devices|Using Fitbit (TM) wearable devices, heart rate, activity data are collected. Based on these data, resting heart rate is monitored daily basis. If resting heart rate increase beyond set range, users are notified to visit the hospital.
223584413|NCT00424268|DRUG|Roflumilast|500 µg, once daily, oral administration in the morning
223584414|NCT00424268|DRUG|Placebo|once daily
223479342|NCT04663113|OTHER|2nd group- Standard physiotherapy + bicycle ergometer|"Standard physiotherapy + bicycle ergometer: In addition to the standard therapy, a bicycle ergometer for 20 minutes 5 days a week will be given.~Patients will turn the pedals of the bicycle while sitting on the edge of the bed.~In this protocol, a portable bicycle with adjustable pedal system, which can be placed on the edge of the bed, will be used.~Ratings of perceived exertion (RPE) will be used to determine the intensity of aerobic activity. According to the RPE, 10-12 strength exercises will be given."
223479343|NCT04663113|OTHER|3rd group- Standard physiotherapy + exercise protocol to be developed|"Standard physiotherapy + exercise protocol to be developed: In addition to standard therapy, exercise will be given according to the measured basal metabolic rate of the patients.~Portable indirect calorimetry will be used to measure the basal metabolic rates of the patients.~The basal metabolic rates of the patients will be measured before the exercise and aerobic exercise or resistant exercise will be given according to the metabolic state of the patient.~Ratings of perceived exertion (RPE) will be used as the aerobic exercise protocol and a 10-11 strength exercise will be given according to the RPE.~If resistance exercise will be given, the intensity of the exercise (12-14) will be determined according to the RPE. Sandbags attached to the ankle will be used as a resistance exercise and 9 exercises were determined. (Knee extension, knee flexion, trunk flexion, trunk extension, hip extension, hip flexion, hip abduction, shoulder flexion, shoulder abduction"
223584415|NCT06013436|DRUG|Autologous serum tears combined with 0.05% cyclosporin eye drop|All patients administrated autologous serum tears twelve times daily（per hour） and 0.05% cyclosporin eye drop twice times daily in each eye for 12 weeks.
223584416|NCT01908166|PROCEDURE|ultrasound elasticity imaging|Undergo ultrasound elastography
223584417|NCT01378429|DRUG|ciclesonide nasal aerosol|ciclesonide nasal aerosol (74 mcg)
223584418|NCT01378429|DRUG|Placebo|Placebo
223584419|NCT02241187|DRUG|PEGPH20|
223584420|NCT02241187|DRUG|Cetuximab|
223584421|NCT02241187|DEVICE|DW & DCE-MRI|
223584422|NCT02241187|OTHER|blood draws|Blood samples will be drawn at various time points.
223584423|NCT00261703|DRUG|Docetaxel, Cisplatin, 5-fluorouracil (5-FU), radiotherapy|Docetaxel 75 mg/m2, Day 1 of the cycle + Cisplatin 75 mg/m2 Day 1 + 5-FU 750 mg/m2/day in 24-h continuous infusion for 5 days. 3 cycles will be administered, every 21 days, before the local-regional treatment (same as control group)
223584424|NCT00261703|DRUG|Cisplatin, 5-fluorouracil (5-FU), radiotherapy|Cisplatin 100 mg/m2 Day 1, 5-FU 1000 mg/m2/day in 24-h continuous infusion for 5 consecutive days. 3 cycles will be administered every 21 days, before the local-regional treatment (same as control group)
223584425|NCT00261703|OTHER|Cisplatin + radiotherapy|Cisplatin 100 mg/m2 on days 1, 22 and 43 simultaneously with radiotherapy (2 Gy x 1/day, 5 days per week for 7 weeks-tumor- and 2 Gy x 1/day, 5 days per week for 6 weeks- lymph nodes)
223584426|NCT01676623|BEHAVIORAL|Standard government health services|This intervention will be basic preventive and curative health services provided by the commune health centers. This includes antenatal care, postnatal care and basic nutrition related counseling.
223584427|NCT01676623|BEHAVIORAL|Alive & Thrive IYCF franchise services|This intervention includes intensive behavioral counseling to improve infant and young child feeding. A package of 15 counseling contacts that are quality assured and branded will be offered to families of infants and young children. Services might also include user fees.
224075905|NCT05852691|DRUG|Nab-Paclitaxel|Participants will receive IV nab-paclitaxel weekly for 3 weeks, followed by 1 week off, until disease progression or until up to 24 months after the first treatment, whichever is sooner.
224075906|NCT06814262|DEVICE|Corresponding treatment order in the prescription with Align Technology|Treating orthodontist placing the corresponding order in the prescription with Align Technology.
224075907|NCT06814262|DEVICE|Superimposition of final and initial positions of lateral incisors: Predicted model|Superimposition of final and initial positions of lateral incisors, two superimpositions will be completed. The pretreatment model will be superimposed with the predicted final model to establish the predicted movement of the maxillary lateral incisors
224075908|NCT06814262|DEVICE|Superimposition of final and initial positions of lateral incisors: Gingivally beveled 1x1x3mm aligners|Superimposition of final and initial positions of lateral incisors, two superimpositions will be completed. The pretreatment model (Gingivally beveled 1x1x3mm aligners) will be superimposed with the posttreatment model to establish the actual movement of the maxillary lateral incisor.
224075909|NCT06814262|DEVICE|Superimposition of final and initial positions of lateral incisors: Gingivally beveled 1x1x4mm aligners|Superimposition of final and initial positions of lateral incisors, two superimpositions will be completed. The pretreatment model (Gingivally beveled 1x1x4mm aligners) will be superimposed with the posttreatment model to establish the actual movement of the maxillary lateral incisor.
224075910|NCT06814262|DEVICE|Superimposition of final and initial positions of lateral incisors: Gingivally beveled 1x1x5mm aligners|Superimposition of final and initial positions of lateral incisors, two superimpositions will be completed. The pretreatment model (Gingivally beveled 1x1x5mm aligners) will be superimposed with the posttreatment model to establish the actual movement of the maxillary lateral incisor.
224075911|NCT06443060|BEHAVIORAL|Virtual Reality Group|Before starting the Prick procedure, the child in the virtual reality group, which is determined by randomisation, will be given a brief information about how the allergy test will be performed and about virtual reality. Before the Prick test (approximately 2 minutes before the Prick test), the child will start to watch a film deemed appropriate by the experts by wearing virtual reality and headphones. After the child starts watching the film, the child will be asked to extend his/her left arm and solutions will be dripped on the forearm and the puncture will be performed with a lancet. The child will continue to watch the film during the whole procedure.
224166241|NCT00544193|RADIATION|intraoperative radiation therapy|
224166242|NCT00544193|RADIATION|radiation therapy|
224166243|NCT06418789|DRUG|High-dose chemotherapy (TI- 2 cycles, CE- 3 cycles )|"TI: Paclitaxel 200mg/m² on day 1, Ifosfamide 2000mg/m² daily from days 1 to 3 of 14-day cycle. G-CSF 10 micrograms/Kg SC daily day on days 6-14 day or until CD34 harvest. Leukapheresis will be performed starting on day 11 in case blood level of CD45+CD34+ above 20x10\^6/L is achieved.~CE: Carboplatin AUC=8 IV daily days -4 to -2, Etoposide 400mg/m\^2 IV daily days -4 to -2, autlologous stemm cell transplantation \>=2\*10\^6/Kg at day 0, GCSF support from day 4 until the recovery of neutrophils above 1\*10\^9/L.~Patients will receive two cycles of TI followed by 3 cycles of CE in case at least 6\*10\^6 CD34+ stem cells will be harvested."
224166244|NCT04901702|DRUG|Onivyde|Given intravenous on Days 1 and 8
224166245|NCT04901702|DRUG|Talazoparib|Given orally twice on Day 1 (daily maximum is 1000mcg/day), then daily on Days 2-6
224166246|NCT04901702|DRUG|Temozolomide|Given once a day on Days 1-5.
224166247|NCT05955274|BEHAVIORAL|Mobile Behavioral Parent Training (mBPT)|The mobile phone application includes behavioral parent training content (for example, praise, effective commands, reward systems) delivered in videos, examples, and quizzes that parents/caregivers access.
224166248|NCT05955274|BEHAVIORAL|Just-in-time intervention: Parenting Strategies|Parents will receive prompts via phone that provide parenting suggestions and parenting feedback when they are interacting with their child.
224166249|NCT02784496|OTHER|Long-term Follow-up|Undergo follow-up assessment
224166250|NCT02784496|OTHER|Quality-of-Life Assessment|Ancillary studies
224166251|NCT02784496|DRUG|Ruxolitinib|Given PO
224166252|NCT04327609|DEVICE|SELUTION SLR™ DEB|Subjects will receive standard high-pressure balloon angioplasty followed by local application of sirolimus with the SELUTION SLR™ 018 DEB (MedAlliance) of appropriate diameter and length to achieve full lesion coverage.
224166253|NCT04327609|DEVICE|Control Arm|The control arm will receive standard high-pressure balloon angioplasty of appropriate diameter and length and no further lesion treatment.
224166254|NCT05836324|DRUG|INCA33890|INCA33890 will be administered at protocol defined dose.
224166255|NCT05836324|DRUG|bevacizumab|Bevacizumab will be administered at protocol defined dose.
224166256|NCT05836324|DRUG|FOLFIRI|FOLFIRI will be administered at protocol defined dose.
224166257|NCT05836324|DRUG|FOLFOX|FOLFOX will be administered at protocol defined dose.
224166258|NCT05836324|DRUG|Cetuximab|Cetuximab will be administered at protocol defined dose.
224166259|NCT05611671|DRUG|MORF-057|MORF-057 is a small molecule that is designed to selectively inhibit integrin α4β7 and is administered orally.
223479344|NCT04323592|DRUG|Methylprednisolone|Usual standard of care plus Methylprednisolone (MP) 80 mg/kg IV bolus, followed by MP infusion of 80 mg/day in 240 mL normal saline at 10 mL/h. The infusion is continued for at least eight days and until achieving either a PaO2:FiO2 \> 350 mmHg or a CRP \< 20 mg/L. Treatment is then switched to oral administration of Methylprednisolone 16 mg or 20 mg IV twice daily until CRP returns to \< 20% of normal range and/or PaO2:FiO2 \> 400 or SatHbO2 ≥ 95%. The decision to apply the protocol to Covid-19 is left to the discretion of the treating team for each individual patient.
223479345|NCT04323592|OTHER|standard care|"usual standard of care:~* oxygen therapy (regular or high-flow) and monitoring~* empiric antibiotic therapy~* mechanical ventilation (invasive or noninvasive)~* ECMO when needed and available~* pronation when possible~* other treatment which can be used are: antivirals, chloroquine, vitamins"
223479346|NCT00542308|DRUG|Zalutumumab|Individual dose titration weekly i.v. doses
223479347|NCT01898078|DRUG|Alisertib|Alisertib ECT
223479348|NCT02588508|PROCEDURE|Warm packs|: The warm packs are held in the mother's perineum during birth. The warm packs are changed as needed to maintain warmth.
223584428|NCT01676623|BEHAVIORAL|Mass media campaign|Alive \& Thrive is implementing a nationwide mass media campaign in 2011, 2012 and 2013, with a focus on improving breastfeeding practices. The mass media intervention includes TV and radio spots as well as an internet site and a telephone hotline.
224166260|NCT05611671|DRUG|Placebo|Matching placebo (identical appearance to MORF-057) administered orally.
224166261|NCT06568497|OTHER|Food|Food
224166262|NCT05330611|DEVICE|Cryoneurolysis of Intercostal Nerves|"Patients will be offered a minimally invasive intervention procedure for pain control called cryoneurolysis using an ultrasound-guided device called the Iovera Smart Tip 190.~The direct application of cold to the intercostal nerves via Iovera device produces lesions in peripheral nervous tissue to block the pain caused by rib fractures.~This procedure is particularly beneficial for patients who are not candidates for surgical stabilization of their rib fractures.~Application of cryoneurolysis as an analgesic will reduce the amount of narcotics patients might need and instead provide them short- or long-term pain control with minimal risk.~Follow up includes pain surveys administered in Chest Wall clinic or via telephone at 30, 90, 365 days post discharge."
224166263|NCT05330611|OTHER|Standard of Care|"Patients will be provided regular standard of care at the Stanford Hospital with short- or long-term follow-up provided at the Stanford Center for Reconstruction after Chest Wall Injury.~Standard of care for patients with rib fractures that are not eligible for surgical stabilization includes multi-modal pain therapy and pulmonary toilet.~Follow up includes pain surveys administered in Chest Wall clinic or via telephone at 30, 90, 365 days post discharge."
224166264|NCT03728972|DRUG|Pembrolizumab|200mg IVPB every 3 weeks
224166265|NCT05914311|DEVICE|Suture|secures SCS trial leads with a suture
224166266|NCT05914311|DEVICE|Dermabond|secures SCS trial leads with dermabond
224166267|NCT04960202|DRUG|PF-07321332|PF-07321332 (tablet)
224166268|NCT04960202|DRUG|Ritonavir|Ritonavir (capsule)
224166269|NCT04960202|DRUG|Placebo|Placebo (tablet or capsule)
224166270|NCT05396001|BEHAVIORAL|LowSalt4Life Application|LowSalt4Life is a dietary sodium intervention mobile application that promotes lower sodium intake.
224166271|NCT05396001|BEHAVIORAL|Just-In-time Adaptive Intervention (JITAI)|LowSalt4Life is a dietary sodium application with a just-in-time adaptive intervention (JITAI) component enabled.
224166272|NCT05626907|OTHER|Diet modification #1|Participants will be provided all meals for a 14-day period. For 7 of the days, meals will be 130% of estimated daily caloric needs and for the other 7 days, meals will be low in calories, consistent with recommendations for weight loss.
224305254|NCT04645966|BIOLOGICAL|Bivalent rLP2086 (60-µg Dose)|Trumenba (half dose) - Meningococcal Group B vaccine
224166273|NCT05626907|OTHER|Diet modification #2|Participants will be provided all meals for a 14-day period. For 7 of the days, meals will be 150% of estimated daily caloric needs and for the other 7 days, meals will be meals will be low in calories, consistent with recommendations for weight loss.
224166274|NCT05626907|OTHER|Diet modification #3|Participants will be provided all meals for a 14-day period to be approximately 100% of estimated daily caloric needs.
224166275|NCT04934748|PROCEDURE|Routine Blood Pressure Management|Routine blood pressure control.
224166276|NCT04934748|PROCEDURE|Tight Blood Pressure Management|Tight blood pressure control.
224166277|NCT04934748|DRUG|Phenylephrine|Phenylephrine will be infused at a rate sufficient to maintain the intraoperative MAP designated in the underlying GUARDIAN trial.
224166278|NCT04934748|DRUG|Norepinephrine|Norepinephrine will be infused at a rate sufficient to maintain the intraoperative MAP designated in the underlying GUARDIAN trial.
224166279|NCT06465953|DRUG|Ivosidenib|Two 250 mg tablets, totaling 500 mg, administered orally once daily until disease relapse or progression, unacceptable toxicity, confirmed pregnancy, undergoing HSCT, death, withdrawal of consent, lost to follow-up, or Sponsor ending the study, whichever occurs first.
224166280|NCT06465953|DRUG|Azacitidine|Azacitidine 75mg/m\^2/day administered by subcutaneous (SC) or intravenous (IV) injection for 1 week (7 days) of each 4-week (28 day) treatment cycle until disease relapse or progression, unacceptable toxicity, confirmed pregnancy, undergoing HSCT, death, withdrawal of consent, lost to follow-up, or Sponsor ending the study, whichever occurs first.
224166281|NCT05242627|BEHAVIORAL|Clinical Firearm Safety Counseling Module|"The DGSOM class of 2024 will participate in a mandatory 1-hour module covering four main domains: (1) firearm epidemiology; (2) suicide epidemiology and introduction to means matter; (3) firearm counseling; and (4) an example of standardized patient encounter that includes a discussion of firearm safety with the patient. The module will be taught in combination by the study team, subject matter experts, and the DGSOM Standardized Patient Program."
224166282|NCT02346409|DEVICE|tACS of the cerebellum|tACS of the cerebellum
223479349|NCT02588508|PROCEDURE|Perineal massage|"The perineal massage will be gently held in the longitudinal direction of the muscle fibers, with movements of the thumb and forefinger, like count coins."
223479350|NCT04176523|DRUG|Carglumic Acid|Maintenance therapy with carglumic acid
223479351|NCT05528952|DRUG|Atezolizumab|1200 mg IV every 3 weeks until disease progression or unacceptable toxicity
223479352|NCT05528952|DRUG|Bevacizumab|15 mg/kg IV every 3 weeks until disease progression or unacceptable toxicity
223479353|NCT05528952|DRUG|UCPVax|UCPVax vaccine (combined with Montanide ISA51 as adjuvant) at 0.5 mg subcutaneously
223479354|NCT05226377|DIAGNOSTIC_TEST|Atherogenic Index of Plasma|\- The atherogenic index of plasma (AIP) is defined as the base 10 logarithms of the ratio of plasma triglyceride (TG) to high-density lipoprotein cholesterol (HDL-c) (17). AIP was employed as a predictor of cardiac risk (CR) with values of -0.3 to 0.1 are associated with low, values of 0.1-0.24 are associated with the medium, and values above 0.24 with high CR
223479355|NCT00234741|DRUG|STA-5326 mesylate|
224166283|NCT06483698|OTHER|Sublobar resection|Sublobar resection is a series of surgical approaches for lung cancer.
224166284|NCT06483698|OTHER|Lobectomy|Lobectomy is the surgical approach for lung cancer.
224166285|NCT04835051|BEHAVIORAL|Breastfeeding promotion|The intervention included training of health workers in private health facilities to provide in-person breastfeeding counseling to pregnant women and women with a child \<6 months during clinic visits. The health workers also offered a mobile phone support component for appointment reminders, breastfeeding SMS and WhatsApp messages, WhatsApp breastfeeding support groups, informational materials (posters and foldable pocket-sized cards), and family engagement activities. Breastfeeding-related mass media through television and radio spots was available state-wide, including to women in intervention and comparison facilities.
223479356|NCT06229938|OTHER|Passive leg raise manoeuvre|"Stroke volume measurements are performed with the Nexfin hemodynamic monitor and the volemic state measurement is based on the principle of the classic passive leg raise test. The Nexfin monitor (Nexfin CC, Edwards Life Sciences, the Netherlands) uses a small inflatable cuff around the index finger of the right hand, to measure the blood pressure, and uses a specific algorithm to calculate the stroke volume.~First a baseline measurement is performed during supine position while the patient is lying in bed. Next, the head end will be lowered until lying flat, and the legs will be passively raised until the lower end of the bed is 30 degrees elevated. The change in stroke volume following the passive leg raise test is used to assess fluid responsiveness. An increase of 10% indicates a fluid responsive status or hypovolemia."
223479357|NCT05700864|DRUG|Cenegermin-Bkbj|Cenegermin-bkbj ophthalmic solution administered as one drop in both eyes every 3 hours 4 times daily for 4 weeks
223479358|NCT00171535|DRUG|valsartan/amlodipine|
223479359|NCT00002844|DRUG|Cyclophosphamide|Daily intravenous infusions of cyclophosphamide for two days,
223479360|NCT00002844|PROCEDURE|Allogeneic Bone Marrow Transplantation|After completion of the TBI, allogeneic or autologous bone marrow infused intravenously.
223479361|NCT00002844|PROCEDURE|Autologous Bone Marrow Transplantation|After completion of the TBI, allogeneic or autologous bone marrow infused intravenously.
223479362|NCT00002844|RADIATION|Total Body Irradiation (TBI)|Following 2 days of cyclophosphamide, TBI in four daily exposures then bone marrow transplant.
223479363|NCT01075048|DRUG|Tivantinib|ARQ 197 is supplied as a 120-mg capsule, administered twice daily at the dose determined in the Phase 1 portion of the study. Administered until disease progression, unacceptable toxicity or other discontinuation criteria is met.
223584429|NCT00539929|DRUG|E6201 0.005%|
223584430|NCT00539929|DRUG|E6201 0.01%|
223479364|NCT01075048|DRUG|Placebo|Placebo to match ARQ 197, administered twice daily. Administered until disease progression, unacceptable toxicity or other discontinuation criteria is met.
223479365|NCT01075048|DRUG|Cetuximab|Cetuximab 500 mg/ m\^2 intravenous infusion over 120 minutes at the first cycle, then over 60-minutes at subsequent cycles. Administered on Day 1 and Day 15 of each 28 day cycle. Administered until disease progression, unacceptable toxicity or other discontinuation criteria is met.
223479366|NCT01075048|DRUG|Irinotecan|60 minutes after cetuximab, Irinotecan 180 mg/m\^2 intravenous infusion over 30 - 90 minutes. Administered on Day 1 and Day 15 of each 28 day cycle. Administered until disease progression, unacceptable toxicity or other discontinuation criteria is met.
224166286|NCT04021628|OTHER|No intervention- not applicable|No intervention - not applicable
224166287|NCT01518673|PROCEDURE|Blood test|Analysing X-ray induced genetic effects in pediatric patients directly after a computer tomography scan.
224166288|NCT01341925|DRUG|Omega-3 Supplementation|The Ω3 group will receive 1000 mg Ω3 (two 500 mg capsules, each containing 350 mg EPA: 50 mg DHA; 100 other Ω3) two times daily for a total daily dose of 2000 mg Ω3 (1400 mg EPA: 200 mg DHA; 400 other Ω3). The placebo group will receive two capsules two times daily matched for odor and appearance with the active intervention.
224166289|NCT01341925|BEHAVIORAL|Psychoeducational Psychotherapy (PEP)|Therapy sessions occur twice a week for up to 24 sessions of manualized treatment. The importance of separating symptoms from the individual is emphasized. The family is offered support, validation, and recognition for their own difficult experiences in living with the child's mood disorder. Family members are taught that patients are particularly vulnerable to stress and tension; thus, therapists work with families to reduce the level of stress and tension in their homes. Improvement of communication, problem solving and coping strategies can lead to restoration of hope for recovery and decrease family dysfunction. Goals include strengthening the parent-child bond and helping children and parents feel competent to manage depression now and in future recurrences.
224166290|NCT01341925|OTHER|Placebo|The placebo group will receive active monitoring (no IF-PEP) and two capsules two times daily matched for odor and appearance with the active intervention.
224166291|NCT05131035|BEHAVIORAL|SCORES (Specific COgnitive Remediation with Support)|"This study evaluates the effectiveness of a 10-week cognitive remediation program plus group coaching and therapy to improve processing speed and, in turn, social functioning and attenuated positive symptoms in CHR subjects. The SCORES (Specific COgnitive Remediation with Support) intervention is a novel CR program combined with group coaching, performance-based rewards, game-like tasks, and therapy elements to increase engagement and retention.~In the 2 year, R61 phase, all participants will complete 40 hours of CR (4 hrs per week) with a mid-point assessment (20 hours of CR at 5 weeks) to determine the impact of CR on processing speed as measured by the MCCB.~The second phase of the study (R33) will compare the 40 hours of speeded brain training to 40 hours of non-speeded brain training. This three year study will allow for a replication and assessment of specificity of the targeted intervention."
224166292|NCT03935828|DRUG|Oral versus topical antibioitics|Previously described in two arms
223584431|NCT00539929|DRUG|E6201 0.03%|
224166293|NCT01794546|BEHAVIORAL|Telehealth|Telehealth visits will alternate between a dietitian and behavioral medicine provider for either 30 minutes or 1 hour. Over a 6-month period, 12 telehealth sessions will be scheduled for each participant. The dietitian will provide dietary and physical activity recommendations, and the behavioral medicine provider will counsel on strategies for achieving specific goals. Applying a Chronic Care Model, self-management support will be augmented by linkages to community resources.
224166294|NCT01652222|OTHER|CONEM-BETA + socio-educational training|4 socio-educative training sessions during 8 weeks, and caregivers will systematically play with their patients with CONEM-BETA therapeutic game during the last 4 weeks. The dyads will be assessed (primary timepoint). Caregivers will then continue using the game with their patients for an extra 6 weeks period as needed, to assess adherence and games preferences.
224166295|NCT01652222|OTHER|Socio-educational training only|4 socio-educative training sessions during 8 weeks
224166296|NCT04161313|OTHER|Measurement of functional capacity|Functional capacity of participants will be measured with six-minute walk test.
224166297|NCT04161313|OTHER|pulmonary function test|It will be measured using basic spirometry and presented lung volume parameters such as FEV1,FVC,FEV1/FVC,PEF, FEF25-75
224166298|NCT04161313|OTHER|Functional capacity|Functional capacity of participants will be measured with six-minute walk test and sit-to-stand test
224166299|NCT04161313|OTHER|Peripheral muscle strength|Isometric M. Quadriceps strength will be measured using electronic hand held dynamometer in sitting position.
224166300|NCT04161313|OTHER|Respiratory muscle strength|Inspiratory and expiratory muscle strength has been assessed by maximal inspiratory and expiratory mouth pressures.
224166301|NCT05683483|OTHER|WEsleep Interventions|1\) Postponing morning nursing rounds to avoid waking patients early and daily assessment of sleep quality by the nurse during morning rounds; 2) Implementing sleep promoting interventions, including optimization of medication and iv fluid timing; 3) Education for health care professionals on sleep; 4) Implementing sleep rounds and change department infrastructure; including 'sleep menu' where patients can choose from earplugs, eye masks, and warm socks. Implement blackout curtains depending on baseline light intensity.
223584432|NCT00539929|DRUG|Placebo|
223584433|NCT00002342|DRUG|Tecogalan sodium|
223584434|NCT02186717|DIETARY_SUPPLEMENT|Chewing gum|Patients will be asked to chew gum three times a day for 30 minutes each time
223584435|NCT04419441|DRUG|Immune checkpoint inhibitor|concomitant administration of radiotherapy and immune checkpoint inhibitor
223584436|NCT00199888|DRUG|124-Iodine-cG250 (124I-cG250)|
223584437|NCT06197087|OTHER|cross-sectional observational survey study|Patients' pain intensity (with VAS), quality of life (with SF-12), sleep quality (with Pittsburgh sleep quality scale), anxiety and depression symptoms (with Beck Depression Inventory), cognitive aspect of pain (with Pain Catastrophizing Scale), presence of central sensitization (with the central sensitization scale), functional status (with the Fibromyalgia impact questionnaire), and chronotype preferences will be evaluated with the Morningness and Eveningness Questionnaire.
224166302|NCT02508363|BEHAVIORAL|questionnaires|
224166303|NCT06043271|BEHAVIORAL|The EMPOWER Program|The EMPOWER Program is a web-based, self-administered SSI for parents that takes about 30 minutes to complete.
224305255|NCT04645966|BIOLOGICAL|Bivalent rLP2086 (120-µg Dose)|Trumenba - Meningococcal Group B vaccine
223584438|NCT03100214|OTHER|Exercise|Patients randomized to the intervention group, in addition to routine physical therapy follow-up, will receive an early rehabilitation program, which will begin within the first 48 hours after admission. The patient will perform physical training (aerobic and anaerobic) 5 times a week during the hospitalization period, with sessions about an hour. The professional who supervises the training will be blinded to the results of the measurements.
223584439|NCT03100214|OTHER|Control|Patients randomized to the control group will continue to receive the physiotherapeutic follow-up performed by the physiotherapist of the Program for Adults with CF during the hospitalization period. Supervision includes respiratory physiotherapy involving inhalation therapy and techniques for removal of secretions
224166304|NCT03558828|BEHAVIORAL|Step 1: PA Monitor|The participant will receive an enhanced physical activity monitor treatment for weeks 1-8, which includes goal setting with a physical activity prescription, and self-monitoring with a physical activity monitor.
224166305|NCT03558828|BEHAVIORAL|Step 1: PA Monitor + Text|"The participant will receive an enhanced physical activity monitor treatment for weeks 1-8, which includes goal setting with a physical activity prescription, and self-monitoring with a physical activity monitor.~In addition, these participants will receive motivational text messages. For participants who remain less than halfway to their daily step goal by a designated daily time, a motivational text message with a strategy to overcome barriers will be sent."
224166306|NCT03558828|BEHAVIORAL|Step 2: PA Monitor with Calls|"Nonresponders to the enhanced physical activity monitor, will receive an augmented treatment.~The participant will continue to receive an enhanced physical activity monitor treatment for weeks 9-34.~In addition they will receive ten brief motivational telephone calls, made by an interventionist, every two to three weeks during weeks 9-34."
224166307|NCT03558828|BEHAVIORAL|Step 2: PA Monitor with Meetings|"Nonresponders to the enhanced physical activity monitor, will receive an augmented treatment.~The participant will continue to receive an enhanced physical activity monitor treatment for weeks 9-34.~In addition, the participant will take part in five 45-minute group meetings held every four to six weeks during Weeks 9-34."
224166308|NCT03558828|BEHAVIORAL|Step 2: PA Monitor + Texts with Calls|"Nonresponders to the enhanced physical activity monitor plus text messaging, will receive an augmented treatment.~The participant will continue to receive an enhanced physical activity monitor treatment for weeks 9-34.~In addition, these participants will continue to receive motivational text messages. For participants who remain less than halfway to their daily step goal by a designated daily time, a motivational text message with a strategy to overcome barriers will be sent.~In addition they will receive ten brief motivational telephone calls, made by an interventionist, every two to three weeks during weeks 9-34."
224166309|NCT03558828|BEHAVIORAL|Step 2: PA Monitor + Texts with Meetings|"Nonresponders to the enhanced physical activity monitor plus text messaging, will receive an augmented treatment.~The participant will continue to receive an enhanced physical activity monitor treatment for weeks 9-34.~In addition, these participants will continue to receive motivational text messages. For participants who remain less than halfway to their daily step goal by a designated daily time, a motivational text message with a strategy to overcome barriers will be sent.~In addition, the participant will take part in five 45-minute group meetings held every four to six weeks during Weeks 9-34."
224166310|NCT03558828|BEHAVIORAL|Step 3: PA Monitor|During Weeks 35-50, all women will receive enhanced physical activity monitors only.
224166311|NCT06632769|DEVICE|No intervention|No intervention
224166312|NCT06371989|PROCEDURE|Image guided vacuum assisted biopsy|Image guided VAB of tumor site. A needle is inserted into the affected tumor bed area using an US or stereotactic method to collect cells or tissue from a tumor mass.
224166313|NCT05788978|OTHER|Scale development|Scale development
223479367|NCT05816941|PROCEDURE|Conventional Periodontal Treatment (Complete Oral Disinfection)|"Oral hygiene instructions followed by complete oral disinfection (removal of hard and soft deposits, scaling and root planing, mouth rinse with 0.2% chlorhexidine twice in one minute, pocket rinse with 0.2% chlorhexidine three times in ten minutes). Ultrasonic (Piezoled, KaVo) and hand instruments (Gracey curettes, Hu-Friedy, USA) were used for this purpose.~For the next 14 days, all patients were asked to rinse their oral cavities twice daily with 0.12% chlorhexidine."
223479368|NCT05816941|PROCEDURE|Adjunctive Photodynamic Therapy|"Photodynamic Therapy as adjunctive treatment in pockets with PPD ≥ 5 mm. For this purpose, a Fotona XD -2 diode laser (Fotona, Ljubljana, Slovenia) with a wavelength of 810 nm, a power of 250 mW and the photosensitizing agent indocyanine green at a concentration of 1 mg/ml was used. First, the area to be irradiated was isolated, and the photosensitizing agent was applied to the periodontal pocket. After 60 seconds, the supragingival excess of the photosensitizing agent was removed by gentle rinsing with a saline solution. This was followed by irradiation for ten seconds on each side.~For the next 14 days, all patients were asked to rinse their oral cavities twice daily with 0.12% chlorhexidine."
223479369|NCT00193648|DRUG|Rosiglitazone (Avandia)|oral drug administration
223479370|NCT00193648|DRUG|Adalimumab (Humira)|Injection of drug biweekly
224166314|NCT05065866|DRUG|BMS-986345|"Patients will be treated at the following dose levels:~Duvelisib BMS-986345 Dose Level 15 mg twice daily 100mg daily -1 25 mg twice daily 100mg daily 1 50 mg twice daily 100mg daily 2 75 mg twice daily 100mg daily 3 75 mg twice daily 200mg daily 4 75 mg twice daily 300mg daily 5~After the first two cycles of treatment, the dose of Duvelisib will be dropped to 25 mg twice daily irrespective of the starting dose level unless the patient is at dose level -1 then they will stay on that dose level after the initial 2 cycles"
224166315|NCT05065866|DRUG|Duvelisib|"Patients will be treated at the following dose levels:~Duvelisib BMS-986345 Dose Level 15 mg twice daily 100mg daily -1 25 mg twice daily 100mg daily 1 50 mg twice daily 100mg daily 2 75 mg twice daily 100mg daily 3 75 mg twice daily 200mg daily 4 75 mg twice daily 300mg daily 5~After the first two cycles of treatment, the dose of Duvelisib will be dropped to 25 mg twice daily irrespective of the starting dose level unless the patient is at dose level -1 then they will stay on that dose level after the initial 2 cycles"
224166316|NCT01250899|DIETARY_SUPPLEMENT|Vitamin D|50,000 IU vitamin D3 twice weekly for 5 weeks, followed by 2000 IU daily maintenance supplementation to complete 12 weeks. At the end of the 12-week period, 25(OH)D levels will be checked. If the subject is still deficient, he/she may undergo a second period of supplementation (at the discretion of their provider) to complete a total of 24 weeks. After 24 weeks, we anticipate all subjects will be kept on daily maintenance supplementation by their primary physicians.
223479371|NCT00547144|DRUG|Gemcitabine|1000 mg/m2 intravenoulsy once a week according to protocol schedule
223479372|NCT00547144|PROCEDURE|Dendritic Cell Immunotherapy|The cells will be administered by intratumoral injection on 2 different days(at least 21 days apart)
223584440|NCT05219669|DRUG|Nalmefene Hydrochloride|30 mg/mL solution
223584441|NCT00636259|DRUG|Bicalutamide (Casodex)|150mg
223584442|NCT04229355|DRUG|DEB-TACE plus Sorafenib|Drug-eluting bead transarterial chemoembolization plus sorafenib (400 mg/d, po, bid)
223584443|NCT04229355|DRUG|DEB-TACE plus Lenvatinib|Drug-eluting bead transarterial chemoembolization plus lenvatinib (8 mg/d, po, qd)
223584444|NCT04229355|DRUG|DEB-TACE plus PD-1 inhibitor|Drug-eluting bead transarterial chemoembolization plus PD-1 inhibitor
224166317|NCT05479136|DRUG|PET imaging with 18F fluciclovine|PET with 18F fluciclovine injection, 185 MBq (5 mCi) ± 20%, delivered as an intravenous bolus
224166318|NCT04829006|DEVICE|Understand Me For Life|The aim of the current investigation is to test the efficacy of an app to measure sentence intelligibility in noise in speakers with Parkinson's disease and in healthy controls.
224166319|NCT05042570|OTHER|Instrument Assisted Soft Tissue Mobilization|"* This technique will be performed using instruments of different sizes, shapes and treatment styles.~* During the application, instruments will be applied to loosen the muscle tissue and fascia by gliding on the tissue at certain angles.~* The muscle groups to be treated with IASTM are gastrocnemius, soleus and tibialis posterior. It will also be applied to the superficial and deep fascia.~* The instrument will be sterilized before treatment.~* IASTM treatment will be applied without damaging the tissue after massaging cream is applied to the muscle fibers with the instrument."
224166320|NCT05042570|OTHER|Stretching Exercises|"* The muscle groups to be applied stretching exercises are gastrocinemius, soleus and tibialis posterior. It will also be applied to the superficial and deep fascia.~* 3 different functional stretching exercises will be applied;~* With the hands supported on the wall and with the help of the physiotherapist, the affected extremity is behind the knee in full extension m. gastrocnemius stretching exercise,~* With the hands supported on the wall and with the help of the physiotherapist, the knee is partially flexed, with the affected extremity behind. soleus stretching exercise,~* It is a stretching exercise that will be applied by asking the patient to squat without lifting his heels, with the patient's hands supported by the physiotherapist."
224166321|NCT05042570|OTHER|Control Group / NDT program|"* Efforts to eliminate tone disorders,~* Sensory-perception-motor integrity development studies,~* Activities aimed at facilitating movements in daily life,~* Stretching and strengthening exercises due to muscle shortness and weakness,~* Studies to increase lower and upper extremity functionality,~* It will include the training of activities such as standing up, walking and balance."
224166322|NCT00533780|PROCEDURE|Healing Touch|A gentle, non-invasive form of energy-balancing work that promotes relaxation and can help manage the side effects of chemotherapy.
224166323|NCT05017987|DRUG|ATB-101, ATB-1011, ATB-1012|"1. Test drug~   \- Code name: ATB-101~2. Control drug1~   * Code name: ATB-1011~  * Active ingredient: Olmesartan~3. Control drug2~   * Code name: ATB-1012~  * Active ingredient: Dapagliflozin"
224166324|NCT04300842|DEVICE|smart bracelet|to measure the stress, fatigue, and activity.
224166325|NCT00343395|DRUG|AVANDAMET|2/500 mg
224166326|NCT05879380|DIAGNOSTIC_TEST|MRPA|patients will receive an extra MRPA, on top of the standard CTPA
223479373|NCT04483765|PROCEDURE|spinal anesthesia|patients undergoing transurethral resection of the prostate (TURP) and transurethral resection of the bladder (TURB) surgery under spinal anesthesia.
223479374|NCT01287936|BIOLOGICAL|SB623|SB623, a modified stem-cell product
223584445|NCT01188057|DRUG|ALPRAZOLAM ORALLY DISINTEGRATING TABLETS, 2.0 MG|A: Experimental Subjects received Purepac Pharmaceutical Co. formulated products under non-fasting conditions
223584446|NCT01188057|DRUG|NIRAVAM TM 2 mg orally disintegrating tablets, single dose|B: Active comparator Subjects received Schwarz Pharma Inc. formulated products non-under fasting conditions
223584447|NCT05216627|DIAGNOSTIC_TEST|Self-administered saliva-based viral testing|Participants will be instructed on how to inactivate the virus and bring their sample to their laboratory's central PCR machine, where they will take an assay test. They will be instructed to collect saliva into a 1.5 milliliter (mL) collection tube containing inactivation buffer (TCEP and EDTA) using a small funnel and inactivate at 95°C for 10 minutes. Participants will then transfer 6ul of saliva into 2 PCR tubes containing amplification master mix and primers, put tubes in a heat block or PCR machine at 65°C for 45 minutes and assess fluorescence using a simple battery-powered fluorescence viewer. Once they assess their sample, they will be instructed to dispose of the saliva sample safely and in accordance with best laboratory practices. No saliva samples will be collected by the research team at any time as part of this study.
223584448|NCT02544373|DEVICE|PAP therapy|Positive airway pressure treatment for obstructive sleep apnea
223584449|NCT01927042|BEHAVIORAL|ECHOs plus TAU|A self-help DVD that provides information for carers on eating disorders and teaches coping strategies to carers.
223584450|NCT01927042|BEHAVIORAL|Treatment as Usual|Treatment as Usual at the Eating Disorder Services includes group psychotherapy and skills training, nutritional counselling, and meal support.
224166327|NCT05879380|DIAGNOSTIC_TEST|CPTA|patients will receive an extra MRPA, on top of the standard CTPA
224166328|NCT00766181|BEHAVIORAL|Zingo TM (lidocaine hydrochloride monohydrate) powder intradermal injection system|0.5 mg lidocaine hydrochloride
224166329|NCT00599222|BIOLOGICAL|ranibizumab|0.5 mg intravitreal injection
224166330|NCT00599222|PROCEDURE|TTT|Transpupillary thermotherapy (TTT)
224166331|NCT00599222|PROCEDURE|Sham TTT|Sham Transpupillary thermotherapy (TTT)
224166332|NCT01812395|DEVICE|Thyroidectomy using harmonic focus (r)|Harmonic focus(r) device is used to seal and cut the vessels during thyroidectomy.
224166333|NCT01812395|PROCEDURE|Conventional thyroidectomy|Vessels are ligated with sutures then cut using classic scalpel or scissors.
224166334|NCT01852591|BIOLOGICAL|PCV 13|
224166335|NCT03968107|OTHER|Reference ultrasound examination|Use of antenatal ultrasound examination to visualize and position the intestinal structures involved in digestive malrotation at high risk of volvulus and comparison to fetal MRI results.
223479375|NCT00325169|DRUG|Tiotropium + SERETIDE 50/500|
223479376|NCT02776293|BEHAVIORAL|Relaxation|
223479377|NCT02776293|BEHAVIORAL|Music|
223479378|NCT02022358|DRUG|Glucarpidase|Glucarpidase rescue (50 units/kg x 1, intravenously)
223479379|NCT02022358|DRUG|Methotrexate|Methotrexate (12 g/m2 x 1, intravenously)
223479380|NCT02022358|DRUG|Folinic Acid|Folinic acid rescue 15mg/m2 four times daily adjusted according to methotrexate levels
223479381|NCT03746496|DIAGNOSTIC_TEST|point-of-care laboratory analysis|POC analysis with i-STAT POC analyser from the intraosseous and arterial blood
223479382|NCT03957993|OTHER|Occupational Therapy via Telehealth|The caregiver will be with the participant in their home environment receiving occupational therapy via Telehealth (video-calling) with the occupational therapist.
223479383|NCT03957993|OTHER|Standard of Care Occupational Therapy|The caregiver and participant will be in the clinic receiving occupational therapy in-person with the occupational therapist.
223479384|NCT05297357|DIETARY_SUPPLEMENT|Mediterranean Diet weaning scheme|Kids in experimental group were weaned by using fresh foods traditionally used in MD and appropriately adapted to infants including seasonal fruit and vegetables, various kinds of fresh blue fish, spices and herbs. No salt was used while a small amount of Parmesan cheese was added. No sugar was added to any meal.
223479385|NCT01140906|DRUG|Placebo|capsules, daily, orally
223479386|NCT01140906|DRUG|Vortioxetine (Lu AA21004)|encapsulated tablets, daily, orally
224166336|NCT03774875|DRUG|Apremilast|Apremilast 30 mg tablets taken orally twice a day.
224166337|NCT03774875|DRUG|Placebo|Placebo tablets taken orally twice a day
224166338|NCT05706623|DRUG|Apraglutide|Single dose of apraglutide
224166339|NCT05405842|DEVICE|Transauricular Vagal Nerve Stimulation|TENS 7000 is a handheld device used to deliver electrical impulses for nerve stimulation to help modulate and treat chronic pain. The manufacturer, Roscoe, has regulatory approval for the use of nerve stimulator therapy in the acute and/or prophylactic treatment of headaches, migraines, sciatica, muscle spasms, acute and chronic pain, and improve circulation. It is FDA approved in the USA for the above indications, but has not been approved for use in gastrointestinal diseases such as gastroparesis or functional dyspepsia. It has been registered as an investigational new device in various clinical trials. The purpose of this protocol is to provide vagal nerve stimulation to patients with gastroparesis, functional dyspepsia, and healthy controls as a comparison.
224166340|NCT02013154|DRUG|DKN-01 150 mg|Administered by IV infusion
224166341|NCT02013154|DRUG|Paclitaxel|Administered by IV infusion
224166342|NCT02013154|DRUG|Pembrolizumab|Administered by IV infusion
224166343|NCT02013154|DRUG|DKN-01 300 mg|Administered by IV infusion
224166344|NCT05971992|DIETARY_SUPPLEMENT|Chicory-derived inulin-type β-fructans|This supplement will be portioned into moisture-impermeable sachets containing 7.5 grams of prebiotic. During the first two weeks, to avoid eventual side effects, PS participants will be advised to consume the contents of one sachet at breakfast only. Starting in week 3 until the end of the 8-weeks intervention the participants will consume the content of two sachets daily (at breakfast and at dinner) resulting in a total dose of 15 grams of prebiotic per day. Participants will be provided with a package of sachets in the amount required for the whole 8-weeks nutritional intervention. They will be instructed to dissolve the sachet content with water or juice and to drink it 15-20 minutes prior to their regular meal. The medium for suspending the supplement (water or juice) could be chosen by the participants and could be changed during the study.
224166345|NCT05971992|DIETARY_SUPPLEMENT|Maltodextrin|This supplement will be portioned into moisture-impermeable sachets containing 7.5 grams of maltodextrin. During the first two weeks, to avoid eventual side effects, PS participants will be advised to consume the contents of one sachet at breakfast only. Starting in week 3 until the end of the 8-week intervention the participants will consume the content of two sachets daily (at breakfast and at dinner) resulting in a total dose of 15 grams of placebo per day. Participants will be provided with a package of sachets in the amount required for the whole 8-weeks nutritional intervention. They will be instructed to dissolve the sachet content with water or juice and to drink it 15-20 minutes prior to their regular meal. The medium for suspending the supplement (water or juice) could be chosen by the participants and could be changed during the study.
224305256|NCT04645966|BIOLOGICAL|Bexsero|Bexsero - Meningococcal Group B vaccine
224305257|NCT04645966|DRUG|Prophylactic Liquid Paracetamol (PLP)|PLP administration during primary vaccinations 1 and 2
224305258|NCT04645966|BIOLOGICAL|Nimenrix|Nimenrix - Meningococcal Group A, C, W and Y vaccine
224305259|NCT04645966|OTHER|Placebo|Normal Saline
223479387|NCT01140906|DRUG|Duloxetine|encapsulated capsules, daily, orally
223479388|NCT00703534|DRUG|AZD3355|Immediate Release capsule administered as a single dose, 65mg, twice daily for 4 weeks
223479389|NCT00703534|DRUG|Placebo|capsule. administered as a single dose twice daily for 4 weeks
224305260|NCT04645966|DRUG|Scheduled Liquid Paracetamol (SLP)|SLP administration after primary vaccinations 1 and 2.
223479390|NCT00703534|DRUG|Gelusil®|Chewable tablets taken as needed
223479391|NCT05375916|DRUG|Hydromorphone|Sustained-release hydromorphone is a long-acting preparation opioid
223479392|NCT00038285|PROCEDURE|Amputation Prevention|
223479393|NCT05224830|OTHER|Nijmegen questionnaire score|We collected the Nijmegen Questionnaire in order to diagnosis of Hyperventilation Syndrome
223479394|NCT01327768|PROCEDURE|Olfactory ensheathing cells|Recruited patients should be received the endoscopic surgery for picking the olfactory mucosa 1 to 2 months before transplantation. The OECs will be cultured and expanded under the rule of GTP. Finally, we will transplant the OECs (about 2 to 8 X 10´6 cells in saline) into the peri-infarcted area of the brain for old stroke ischemic patients.
223479395|NCT06150820|OTHER|No Intervention|No investigational drug will be administered to participants in this study.
223479396|NCT03592628|OTHER|Visual Aid|The visual aid was a one-sheet diagram with illustrations of important features of post-cesarean wound care.
223479397|NCT03592628|OTHER|Standard Instructions|Standard discharge instructions WITHOUT supplement of visual aid.
224166346|NCT03348293|PROCEDURE|3D printing|Scope of tumor resection was simulated according to the MR imaging data. After meticulous design, we created the personalized porous biodegradable scaffold and printed by 3D printer, using porous PCL biomaterials. During operation, the biodegradable scaffold was implanted into the defective cavity after tumor resection.
224305261|NCT04645966|DRUG|Therapeutic Liquid Paracetamol (TLP)|TLP administration after primary vaccinations 1 and 2
224305262|NCT01020955|DRUG|NutropinAq (GH) and Increlex (IGF-I)|NutropinAq (GH)(0.15 mg/d for 1 month, 0.3 mg/d for 5 months) and Increlex (IGF-I) (15 µg/kg/d for 1 month, 30 µg/kg/d for 5 months)
224305263|NCT01020955|DRUG|NutropinAq and placebo|NutropinAq (0.15 mg/d for 1 month, 0.3 mg/d for 5 months) and placebo for 6 months.
224305264|NCT04938323|DRUG|BCG Vaccine|.1 mL of reconstituted BCG vaccine given intradermally at baseline.
224305265|NCT04938323|DRUG|Placebo|.1 mL of diluent (saline) given intradermally at baseline
224305266|NCT00201955|DRUG|Rebamipide|
224305267|NCT01604135|DEVICE|Corneal Collagen Crosslinking|Keratoconic corneas that show significant progression as specified in the inclusion criteria section will receive one single treatment with CXL if randomized to the treatment arm. A treatment protocol based on 30 minutes dropping with riboflavin/dextran solution and 10 minutes UV-illumination treatment will be used.
224166347|NCT04090710|DRUG|Ipilimumab/ Nivolumab|induction ipilimumab 1 mg/kg combined with nivolumab 3 mg/kg (I/N) every 3 weeks for cycles 1-4 followed by maintenance treatment with nivolumab 240mg every 2 weeks or 480mg every 4 weeks until disease progression
224166348|NCT04090710|RADIATION|SBRT + Ipilimumab/Nivolumab|SBRT to the primary disease in-situ, prior to cycle 2-4 of I/N. Patients randomized to SBRT will undergo radiation planning during the first cycle of I/N to their primary kidney mass, and then the radiation will be delivered between cycles 1 and 2 to a dose of 30-40 Gy in 5 fractions every other day over 1.5 weeks.
224166349|NCT04331704|DRUG|PrEP acronym (pre-exposure prophylaxis)|A daily tablet containing 245 mg of tenofovir disoproxil fumarate and 200 mg emtricitabine (Truvada; Gilead Sciences) for up to 30 days.
224166350|NCT04331704|BEHAVIORAL|Initial Web Survey|Web-based assessment questions regarding alcohol and other substance use and sexual health behaviors
224166351|NCT04331704|BEHAVIORAL|Interactive Voice Response (IVR) monitoring|Daily telephone-based assessment on alcohol and other substance use, sexual health behavior and PrEP taking
224166352|NCT04331704|BEHAVIORAL|Educational material on alcohol and sexual health behavior|Educational material to provide information, resources and techniques to enhance awareness regarding alcohol and other substance use, along with sexual health behavior.
224166353|NCT04331704|BEHAVIORAL|Interactive Voice Response (IVR) assessment with personalized information|Daily telephone-based assessment on alcohol and other substance use, sexual health behavior and PrEP taking with personalized and information based on daily IVR responses
224166354|NCT04331704|BEHAVIORAL|Personalized information based on web-based survey responses & standardized information|Personalized and information on alcohol use and sexual health behavior based on responses to the web-based survey along with standardized information.
224166355|NCT06448585|DRUG|Specific immunotherapy (SIT) treatment|Treatment with subcutaneous polymerized 100 specific immunotherapy (SIT) in its initiation phase with rapid (clustered) dosing, where the highest allergen concentration (0.2 + 0.3 mL) is administered directly, with an interval of 30 to 45 minutes between injections, in allergology consultations of the SES.
224166356|NCT06448585|DIETARY_SUPPLEMENT|Dietary Supplement: ABB C1|"Ingredients: betaglucanos, levadura Saccharomyces cerevisiae, selenio y zinc.~1 sachet/day; contains 3 grams"
224166357|NCT06448585|DIETARY_SUPPLEMENT|Mini-tablets with pork extract|Mini-tablets with pork extract containing the diamine oxidase enzyme (3 mini-tablets/day)
224166358|NCT06629233|PROCEDURE|Tumor resection|As the standard of care, estrogen receptor-positive breast tumors are surgically resected. From these resected tumors, small samples of both cancer tissue and healthy surrounding tissue will be analyzed using our patented Tn-Miner workflow to discover novel tumor-specific epitopes.
224166359|NCT06553898|BIOLOGICAL|anti-BCMA/CD70 CAR-T cells|Three dose groups (0.3×105/kg, 1×105/kg, 3×105/kg) were set up, starting from the low dose group climbing to explore the safe and effective dose.
224166360|NCT06420193|BEHAVIORAL|AYA Survivors Coping and Emotional Needs Toolkit (ASCENT)|Participants will receive access to a digital depression self-management tool (ASCENT), which aims to help AYAs manage symptoms of depression post-treatment. All users will have access to the core tool which includes daily mood tracking and a psychoeducational module about cancer and depression. Depending on assigned condition, participants will also receive access to up to 4 intervention modules which have been adapted from existing evidence-based treatments for digital delivery to AYAs through a rigorous user-centered design process. Within each module there are 6 micro-lessons that include an educational video, a real story from an AYA that demonstrates the topic, multiple choice questions that ask the participant to apply the educational information to the AYA story, open-ended questions that ask the participant to apply the educational information to their own experience, and a practice activity in which they are asked to try out a relevant skill.
224166361|NCT05563272|DIAGNOSTIC_TEST|89Zr-girentuximab for PET/CT imaging of CAIX positive tumors|On Day 0, participants will receive a single administration of 89Zr-girentuximab (37 Megabecquerel (MBq) \[1mCi\] ± 10%, containing a mass dose of 10 mg of girentuximab).
224166362|NCT05412693|DEVICE|Functional orthosis|See arm descriptions
224166363|NCT05412693|DEVICE|Cast immobilization|See arm descriptions
224166364|NCT06336876|OTHER|Survey|Online survey launched via the Survey Monkey® portal
224166365|NCT06500234|DRUG|Megestrol Acetate and olanzapine|megestrol acetate, 160 mg, oral everyday; olanzapine 2.5 mg, oral everyday
224166366|NCT06500234|DRUG|Starch powder 50 mg|Starch powder 50 mg, oral, everyday
224166367|NCT05400811|BIOLOGICAL|MM09 allergoid-mannan conjugates subcutaneous (3.000 UTm/mL)|Mixture of allergen extracts of Dermatophagoides pteronyssinus and Dermatophagoides farinae conjugated to mannan at 3.000 UTm/mL for subcutaneous administration.
224166368|NCT05400811|BIOLOGICAL|MM09 allergoid-mannan conjugates Sublingual (3.000 UTm/mL)|Mixture of allergen extracts of Dermatophagoides pteronyssinus and Dermatophagoides farinae conjugated to mannan at 3.000 UTm/mL for sublingual administration.
224166369|NCT05400811|BIOLOGICAL|MM09 allergoid-mannan conjugates Sublingual (9.000 UTm/mL)|Mixture of allergen extracts of Dermatophagoides pteronyssinus and Dermatophagoides farinae conjugated to mannan at 9.000 UTm/mL for sublingual administration.
223479398|NCT01131273|DRUG|methadone|12 weeks of methadone maintenance with counseling
223479399|NCT01131273|DRUG|buprenorphine-naloxone (Suboxone) for 12 weeks|12 weeks of maintenance with counseling
223584451|NCT04098978|OTHER|Pharmacist Drug Therapy Management|Patients will be seen by pharmacist for collaborative drug therapy management.
223584452|NCT02059954|PROCEDURE|Hysterectomy|
223584453|NCT05685056|BEHAVIORAL|Text messages|Texts with detailed information focusing on nutrition and iodine rich foods specifically, every 3-5 days.
223584454|NCT03999086|PROCEDURE|Intervention|We will utilize thromboelastography to discern when to transfuse blood products in the setting of multi-level spinal fusion
223584455|NCT03999086|OTHER|Control Group|Laboratory analysis to guide transfusion
223584456|NCT04243395|OTHER|Pork|1 oz lean pork
224166370|NCT05400811|BIOLOGICAL|Placebo subcutaneous|The same solution, presentation, method of administration, frequency, and duration as the active treatment, but without active ingredients.
224166371|NCT05400811|BIOLOGICAL|Placebo sublingual|The same solution, presentation, method of administration, frequency, and duration as the active treatment, but without active ingredients.
224166372|NCT01511549|DRUG|placebo|"Pharmaceutical form:injection~Route of administration: intra-articular"
223479400|NCT01316614|DEVICE|FNA with and without a stylet|If the patient agrees to enrollment in the study, the initial stage of the EUS exam will be performed in the usual manner. If a solid lesion that requires FNA is identified, an envelope will be opened which contains a computer generated randomization sequence for all passes. These sequences will be generated by a web-based program at http://www.randomizer.org/form.htm. Passes will be made based on the randomization, either with or without a stylet. Six passes (three with a stylet and three without a stylet) will be performed on solid lesions and four passes (two with and two without a stylet) will be performed on lymph nodes. Additional passes will be made at the discretion of the endosonographer as clinically indicated but will not be included in the data.
224166373|NCT01511549|DRUG|SAR113945|"Pharmaceutical form:injection~Route of administration: intra-articular"
224166374|NCT00536640|DRUG|Erlotinib|150 mg per os, given daily until tumor progression
224166375|NCT00536640|DRUG|Bevacizumab|15mg/kg i.v. on day 1 (three-week cycle) until tumor progression
224166376|NCT00536640|DRUG|Gemcitabine|1250 mg/2 i.v. on day 1 and day 8 (three-week cycle) until tumor progression for a maximum of 6 cycles
224166377|NCT00536640|DRUG|Cisplatin|80 mg/m2 i.v. on day 1 (three-week cycle) until tumor progression for a maximum of 6 cycles. (The administration of 40 mg/2 Cisplatin on day 1 and day 8 is also possible)
224166378|NCT01265173|DRUG|Cefotaxime|3 g
224166379|NCT01265173|DRUG|Ceftriaxone|2 g
224166380|NCT01265173|DRUG|Ciprofloxacin|400 mg
224166381|NCT06357429|OTHER|Cold Application|Cold application was applied to the LI4 acupressure point on the patients' hands using an ice battery.
224166382|NCT03683238|DIETARY_SUPPLEMENT|Mediterranean Diet|We aim to determine the effects of the traditional Mediterranean Diet on Hidradenitis suppurativa
224166383|NCT02971449|DEVICE|Amazon Fire Tablet|A generic amazon fire tablet with pre-loaded instructional videos
224166384|NCT02971449|OTHER|ICCM Traditional Trainins|Standard, Didactic VHT Training intervention as an active comparator
224166385|NCT00435929|DRUG|Ritonavir|100mg po bid
224166386|NCT00435929|DRUG|saquinavir [Invirase]|1000mg po bid
224166387|NCT03008889|DRUG|N-acetylcysteine|"Participants will start with taking 900mg of NAC once per day for one week (study days 1-7). At Day 7, parents (or primary caregiver) and subjects will return to the study site to review adverse events.~In the absence of dose limiting adverse events attributable to the study drug, the dose will be gradually increased to 900 mg twice per day for study days 8-28.~If this dose is well-tolerated, the dose will be increased to 900 three times per day for study days 29-63."
224166388|NCT03008889|DRUG|Placebo|"Participants will start with taking 900mg of the placebo once per day for one week (study days 1-7). At Day 7, parents (or primary caregiver) and subjects will return to the study site to review adverse events. The dosing for the placebo will increase in the same fashion as the active treatment.~In the absence of dose limiting adverse events attributable to the study drug, the dose will be gradually increased to 900 mg twice per day for study days 8-28.~If this dose is well-tolerated, the dose will be increased to 900 three times per day for study days 29-63."
224166389|NCT02931955|OTHER|Blood draw, stool collection.|Blood will be drawn by certified personnel according to local regulations. Stool will be collected by the patients after instructions on how to use a stool collection kit.
224166390|NCT02253680|PROCEDURE|Actico, short-stretch, inelastic dressing|Worn 24hr post-operatively
224166391|NCT00576147|DEVICE|Infrascanner|The main Near-Infrared spectroscopy (NIRS) head measurement
224166392|NCT03736590|BEHAVIORAL|Financial coaching and services|The intervention will consist of clinic-based financial coaching that focuses on improving financial stability through longitudinal visits with financial services professionals to address financial goals.
223479401|NCT01860209|PROCEDURE|Hemodialysis|Intermittent ambulatory hemodialysis session, according to the patient usual protocol (defined by the treating nephrologist independently of the study)
223479402|NCT03427411|DRUG|M7824|Flat dose of 1,200 mg of M7824 intravenous (IV) once every 2 weeks
223584457|NCT04243395|OTHER|Egg|1 large whole egg
223584458|NCT04243395|OTHER|Black beans|0.5 cups cooked black beans
223584459|NCT04243395|OTHER|Almonds|0.5 oz almonds
224166393|NCT06012097|DRUG|Diclofenac gel|using diclofenac as a comparator
224166394|NCT06012097|DRUG|Aromatherapy gel|using Aromatherapy gel as an experimetnal treatment
224166395|NCT03137888|RADIATION|Dose-Escalated Radiation Therapy|Undergo sMRI-guided radiation therapy, dose painted to maximum of 75 Gy over six weeks
224166396|NCT03137888|PROCEDURE|Spectroscopic Magnetic Resonance Imaging|Patients will undergo sMRI scans within a 14 day window prior to starting treatment
224166397|NCT03137888|DRUG|Temozolomide|Given PO
224166398|NCT04693806|OTHER|Continuous CO2 Level|Embryos will be cultured in a single, continuous CO2 setting
224166399|NCT05776355|BIOLOGICAL|NKG2D CAR-NK|Lymphodepleting chemotherapy followed by NKG2D CAR-NK infusion
224166400|NCT02155712|DEVICE|Triathlon Tritanium Knee|Cementless
224166401|NCT02155712|DEVICE|Triathlon Knee|Cemented
224166402|NCT05016037|BEHAVIORAL|Lexically based speech recast|"A child's spontaneous or elicited word production containing phonological errors is immediately followed with a clinician verbal model that corrects the error(s) at the word level rather than the isolated phoneme level. As an example, a speech recast of child's production of the word bake as \[be\] would be the whole lexeme bake \[bek\] rather than production drill on \[k\] in isolation."
224166403|NCT02394860|OTHER|echo Doppler lower limbs|
224166404|NCT04527991|DRUG|Sacituzumab Govitecan-hziy|Administered intravenously
224166405|NCT04527991|DRUG|Paclitaxel|Administered intravenously
224166406|NCT04527991|DRUG|Docetaxel|Administered intravenously
224166407|NCT04527991|DRUG|Vinflunine|Administered intravenously
224166408|NCT06576661|DEVICE|INTRARENAL PRESSURE MONITORING VISIBLE|In Arm 1, participants will undergo URS with real-time IRP monitoring visible to surgeons using the LithoVue Elite™.
224166409|NCT01095939|DRUG|Placebo|Tablets; oral administration; once a day for 6 months. After this period of 6 months blinded treatment, the treatment will be stopped for 2 weeks. At the end of this washout period, a new renal evaluation is done. At that time, opened label treatment will be proposed to the women who still show renal alterations after a 2 weeks washout period
224305268|NCT04013321|DEVICE|SleepScore Max coaching feature|The SleepScore max is a non-contact sleep tracking device. The app has an integrated feedback coaching feature to improve sleep.
224166410|NCT01095939|DRUG|Benazepril hydrochloride|Tablets (10 or 20 mg); oral administration; once a day for 6 months. After this period of 6 months blinded treatment, the treatment will be stopped for 2 weeks. At the end of this washout period, a new renal evaluation is done. At that time, opened label treatment will be proposed to the women who still show renal alterations after a 2 weeks washout period
224166411|NCT06027541|PROCEDURE|operation|operation methods: breast-conserving surgery, mastectomy, axillary lymph node dissection, sentinal lymphnodes biopsy; chemotherapy regimens: AC, TC, AC-T/P, TCrb, TAC, capecitabine; ovarian protection:GnRHa; endocrine therapy: Aromatase inhibitor, GnRHa, TAM, Fulvestrant, CDK4/6 inhibitors; target therapy: trastuzumab，patuzumab, Pyrotinib.
224166412|NCT05476380|DRUG|camrelizumab|Camrelizumab:200 mg, IV., d1, q3w; Paclitaxel:175 mg/m2,continuous IV., d1, 24h q3w; Cisplatin:75 mg/m2, iv., d1,q3w
224166413|NCT02219516|DRUG|RDEA3170|
224166414|NCT04685356|OTHER|IBAIP : Infant Behaviour Assessment and Intervention Program|The IBAIP intervention program consists of providing an intervention with the child and their family, at home, upon discharge from hospital and up to a corrected age of 6 months. Interventions therefore take place at the early stage of the child's brain development. The intervention is performed by a IBAIP-trained and certified physiotherapist or psychomotor therapist trained , at the rate of one session per month over a period of approximately 6 to 8 months (6 months of corrected age). The session takes place in the child's usual living environment, at home, in the presence of at least one of the parents. It focuses on the child's behaviors and consists of assisting the family in its interactions with the child so that these are adapted and responsive to the child's development needs over time through repeated interventions.
224166415|NCT04685356|OTHER|Standard Support|One medical consultation per month and, if indicated by the physician providing follow-up, medical specialist and / or paramedical (physiotherapy, speech therapy, psychomotricity, etc.) consultations including interventions in the case of developmental delays
224166416|NCT04685356|OTHER|Ages and Stages Questionnaire (ASQ)|Global development screening tool
224166417|NCT04685356|OTHER|Parenting Stress Index (PSI)|Index used to detect difficulties sufficiently significant that they might require psychosocial intervention
224166418|NCT04685356|OTHER|Bayley Scales of Infant and Toddler Development (BSID-IV)|This test was designed to measure the development of infants / young children. This assessment examines all spheres of child development, identifies children with developmental delay and assesses children's developmental performance compared to their peers.
224166419|NCT06039384|DRUG|INCB099280|Administered as specified in the treatment arm description
224166420|NCT06039384|DRUG|adagrasib|Administered as specified in the treatment arm description
224166421|NCT06331325|PROCEDURE|Frenotomy|Partial thickness procedure aiming to relocate high frenum attachment to a more apical level.
224166422|NCT06331325|PROCEDURE|Frenectomy|Full-thickness excision of the frenum down to the bone level and suturing by achieving primary closure.
223479403|NCT05307393|BEHAVIORAL|Positioning|Upon admission to labor and delivery, following an initial ultrasound to confirm fetal OP position, women in this study will be randomly assigned to one of three groups; one control (Group A), and two experimental (Groups B and C) groups. Those assigned to Group A will be allowed to remain in any position they chose during their labor and delivery course. Group B will be placed in a dorsal recumbent, modified sims position on the side of fetal movement. Group C, will be placed in the same position but opposite that of which fetal kicks are felt.
223479404|NCT00076570|DRUG|Sirolimus|
223479405|NCT00076570|DRUG|Tacrolimus|
223479406|NCT00481663|DRUG|Sitagliptin|
223479407|NCT00481663|DRUG|Placebo to sitagliptin|
223479408|NCT00481663|DRUG|Metformin|
223479409|NCT00481663|DRUG|Rescue|Patients whose FPG \>240 mg/dL from Week 16 or HbA1C \>8.5% from Week 25 up to (not including) Week 52 could receive rescue antihyperglycemic therapy with pioglitazone, and remain in the extension study (Extension 1). Participants were eligible for rescue with pioglitazone 30 mg (or rosiglitazone in countries where pioglitazone was not licensed) if they met the following criteria: from Week 16 and during the second extension: FPG consistently \>240 mg/dL (repeated and confirmed within 3 to 7 days); from Week 52 up to (not including) Week 70: HbA1C \>8%; from Week 70 up to (not including) Visit 21/Week 106: HbA1C \>7.5% (Extension 2). Participants placed on rescue therapy with pioglitazone (rosiglitazone where pioglitazone is not available) in the first or second extensions were not eligible for enrollment in the third extension. Rescue therapy was not available in the third extension.
223479410|NCT04548245|DEVICE|EEG|EEG
223479411|NCT00533338|BEHAVIORAL|Weight Gain Prevention Program|Intervention program including in-person instruction and counseling about exercise and diet, exercise practice sessions, and telephone counseling.
223479412|NCT00533338|BEHAVIORAL|Questionnaire|Packet of questionnaires will be completed.
223479413|NCT05859230|DIETARY_SUPPLEMENT|Experimental: The probiotic drink study group|The 100 ml volume of milk drink containing 10 billion Lacticaseibacillus paracasei strain Shirota is consumed once a day for 12-week intervention period, followed by a 6-week follow-up period. The intervention is double-blinded by study team members and subjects. The milk drink bottles are coded by the manufacturing company.
223584460|NCT03734068|DEVICE|Chemoembolization Using LifePearl|Chemoembolization Using LifePearl
223584461|NCT03734068|DRUG|Doxorubicin|Doxorubicin is loaded to LIfePearl
224166423|NCT03786354|RADIATION|3-Dimensional Conformal Radiation Therapy|Undergo 3DCRT
224166424|NCT03786354|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
224166425|NCT05630118|BEHAVIORAL|SHUTi Intervention|"Sleep Healthy Using the Internet (SHUTi) is a well-validated version of e-CBT-I comprised of 6 weekly educational modules and daily sleep diaries. Participants will have 9 weeks to complete 6 once-weekly educational cores. Cores consist of: insomnia overview, sleep restriction, stimulus control, cognitive restructuring, sleep hygiene, and relapse prevention, and last approximately 45 minutes each. Participants will receive weekly objectives, as well as review and feedback on the previous core's assignments and sleep diary data, new material, assignments, and a summary. These features are supplemented with interactive features (i.e., personalized goal-setting, video vignettes). Participants receive daily emails prompting them to complete the 11-item sleep and alcohol use diary daily during the intervention."
224305269|NCT04013321|BEHAVIORAL|Online CBTi|Online Cognitive Behavioral Therapy for insomnia is a user guided program to track sleep, receive sleep coaching, and initiate behavioral techniques such as tailored sleep scheduling and sleep hygiene to help improve sleep.
224166426|NCT05630118|BEHAVIORAL|Web-Based Insomnia Education Program|"Participants will be given access to a web-based program on sleep education to read at their own pace during the 9-week intervention period. The program content overlaps with SHUTi on the following topics: insomnia symptoms, impacts, and causes, basic sleep improvement strategies, and when to see a doctor. The information is akin to that found on WebMD or National Sleep Foundation website. Unlike the SHUTi program, the information is fixed, accessible immediately (no week-to-week information unlocking) and there are no customized bedtime or wake-time suggestions based on sleep diary data."
224166427|NCT00852098|PROCEDURE|Lap Nissen fundoplication with division of short gastric vessels|Dividing short gastric vessels
224166428|NCT00852098|PROCEDURE|Laparoscopic Nissen fundoplication without division of short gastric vessels|non-dividing short gastric vessels
224166429|NCT01172990|PROCEDURE|Immediate Invasive Management|Patients allocated to the immediate invasive strategy will be taken to the catheter lab immediately (\< 90 minutes from randomisation) in accordance with local primary angioplasty policy. Angiogram +/- same sitting PCI will be performed according to local policy and guidelines
224166430|NCT01172990|PROCEDURE|Conventional Management|Patients allocated to the conventional management group will have medical stabilisation and will undergo angiogram +/- PCI between 24 to 48 hours from randomisation according to local policy and guidelines
224166431|NCT05553587|DRUG|Amara drops|"The investigational drug is approved with a reduced dossier without indication according to Art. 25 para. 1 KPAV (SR 812.212.24). This study follows the indication text licensed by Swissmedic: … Weleda Amara-Drops can be used for digestive complaints such as heartburn, flatulence and bloating after meals, to stimulate the bile flow and for loss of appetite and nausea. The effect of Weleda Amara drops is based on a balanced mixture of medicinal plants with tonic (invigorating) and aromatic bitter substances, which are suitable for stimulating digestion. Further, no side effects have been reported in past studies so far. All these reasons lead us to the conclusion that this study is only associated with minimal risks and should be classified in risk category A."
224166432|NCT06618911|OTHER|5 Hz electroacupuncture|"Intervention Description:~The intervention in this study involves the use of electroacupuncture (EA), a combination of traditional acupuncture and electrical stimulation.~Acupoints Selection: Electroacupuncture will be performed at specific acupoints associated with the stomach and digestive system. The local acupoints chosen are Liangmen (ST21) and Tianshu (ST25), while the distal acupoints are Zusanli (ST36) and Xiajuxu (ST39). This selection is based on Traditional Chinese Medicine (TCM) principles for treating functional dyspepsia.~Frequency: 5 Hz"
224166433|NCT06618911|OTHER|Sham electroacupuncture|Participants will receive sham electroacupuncture at the same acupoints: Liangmen (ST21), Tianshu (ST25), Zusanli (ST36), and Xiajuxu (ST39). Non-penetrating needles will touch the skin but will not induce \&#34;deqi.\&#34; A sham electroacupuncture device (no actual current) will be used, and treatment will last 30 minutes per session. Participants will receive 3 sessions per week for 4 weeks (total: 12 sessions). This arm serves as a placebo control to evaluate the true effect of electroacupuncture.
224166434|NCT06618911|OTHER|100 Hz electroacupuncture|"Intervention Description:~The intervention in this study involves the use of electroacupuncture (EA), a combination of traditional acupuncture and electrical stimulation.~Acupoints Selection: Electroacupuncture will be performed at specific acupoints associated with the stomach and digestive system. The local acupoints chosen are Liangmen (ST21) and Tianshu (ST25), while the distal acupoints are Zusanli (ST36) and Xiajuxu (ST39). This selection is based on Traditional Chinese Medicine (TCM) principles for treating functional dyspepsia.~Frequency: 100 Hz"
224166435|NCT03669744|OTHER|telephone survey|a telephone survey will be conducted at 21 patients with trigeminal neuralgia resistant to usual treatments, according to the ICHD-3β criteria treating by one or more trigeminal nerve blocks at the peri operative pain management center of Limoges University Hospital between 2014 and 2018.
224166436|NCT00757081|DRUG|phosphatidylcholine and deoxycholate|50 mg phosphatidylcholine, 42 mg deoxycholate subcutaneous injection Every 8 weeks x 2 with additional 2 treatments optional
224166437|NCT04684849|OTHER|APP Diary|Subjects keep a multi- item electronic digital App survey of symptoms for 2 weeks
224166438|NCT04684849|OTHER|Paper Diary|Subjects keep a multi-item paper survey of symptoms for 2 weeks
224166439|NCT01933399|OTHER|Inextensible LSO (stiff back support)|Cotton/nylon canvas back support with velcro fasteners.
224166440|NCT01933399|OTHER|Extensible LSO, a back support that is flexible|Back support is constructed from lycra and neoprene with velcro fasteners.
223479414|NCT05859230|DIETARY_SUPPLEMENT|Placebo Comparator: The placebo drink study group|The 100 ml volume of milk drink without containing Lacticaseibacillus paracasei strain Shirota is consumed once a day for 12-week intervention period, followed by a 6-week follow-up period. The intervention is double-blinded to study team members and subjects. The milk drink bottles are coded by the manufacturing company.
223479415|NCT02186028|DRUG|Vitamin D|Vit D 400 IU vs. Vit D 200 IU
224166441|NCT01933399|OTHER|Standard of Care|Physician visit, physician advice, medications as determined by physician, over the counter medications, and physical therapy.
223479416|NCT00026130|DRUG|fluorouracil|200mg/sq m/d CIVI 5/7 days during radiation therapy (wks 1-6)
223479417|NCT00026130|DRUG|gemcitabine hydrochloride|200mg/sq m IV infusion over 30 min wkly (on d 1, 2, OR 3) during radiation tx (wks 1-6) 1000mg/sq m IV infusion over 30 min wkly for 3 weeks during ea chemotherapy cycle
223479418|NCT00026130|RADIATION|radiation therapy|4500cGy total in 25 fractions M-F followed by 540cGy in 3 fractions (Total dose 5040cGy)during radiation tx (wks 1-6)
224166442|NCT01805674|DIETARY_SUPPLEMENT|isoflavones combined with magnolia|1 tablet/day duration: 12 weeks
224166443|NCT04427904|DRUG|Bupivacaine 0.5% with 1:200 000 epinephrine|Bupivacaine 0.5% with 1:200 000 epinephrine. Total volume 10mL for local infiltration before neck incision.
224166444|NCT04427904|DRUG|Lidocaine 2% with 1:100 000 epinephrine|Lidocaine 2% with 1:100 000 epinephrine. Total volume 10mL for local infiltration before neck incision.
224166445|NCT01814891|OTHER|Orange maize feeding|This group was fed orange maize.
224166446|NCT01814891|OTHER|Vitamin A supplement|This group received a dose of vitamin A at the estimated average requirement each feeding day of the intervention.
224166447|NCT01814891|OTHER|Oil only|This group received a small amount of plain oil without vitamin A.
224166448|NCT02583828|DRUG|Cyclophosphamide 50mg|
223479419|NCT00001891|PROCEDURE|Myocardial contrast echocardiography|
224166449|NCT02583828|DRUG|Letrozole 2.5 mg|
224166450|NCT00085345|DRUG|arsenic trioxide|
224166451|NCT00085345|DRUG|ascorbic acid|
224166452|NCT00085345|DRUG|melphalan|
224166453|NCT00085345|PROCEDURE|chemosensitization/potentiation|
224166454|NCT00085345|PROCEDURE|chemotherapy|
224166455|NCT06408519|OTHER|Placebo (open-label)|P-Tabletten weiss 10mm (Lichtenstein, Zentiva) pills 3x/day
224166456|NCT06408519|DRUG|Ibuprofen 400 mg|Ibuprofen pills 3x/day
224166457|NCT05422222|DRUG|VX-121/TEZ/D-IVA|Fixed-dose combination for oral administration.
224166458|NCT06384300|OTHER|Financial Incentives|In the financial incentive group, participants will receive reimbursement for transportation, accommodation, and food costs, along with RMB 200 (about 30 US dollar) to compensate for potential income loss due to endoscopy, provided they undergo the endoscopy.
224166459|NCT06384300|OTHER|Motivational Intervention|For the motivational intervention group, researchers will provide detailed information about the social norms surrounding endoscopy screening, including the prevalence of screening participation, the potential risks of gastric cancer, and the health benefits of screening.
224166460|NCT06384300|OTHER|Mixed Intervention|Participants in the mixed intervention group will receive both financial incentives and motivational intervention.
224166461|NCT04097080|DRUG|NBTX-001|Active drug group will receive 6 doses of NBTX-001 given three times a week.
224166462|NCT04097080|DRUG|Standard of Care|Placebo group will receive reconstituted air given three times a week.
223584462|NCT03979599|PROCEDURE|ultra-sound guided transversus abdominis plan block|comparing ultrasound guided transversus abdominis plan block using combination of magnisum sulphate and levobupivacaine versus levobupivacaine
223744866|NCT05074693|OTHER|EASE app|EASE is a mobile intervention designed to reduce ongoing mental health concerns among BLAI individuals with elevated anxiety and/or depressive symptoms by targeting anxiety sensitivity. The EASE app employs a variety of features to educate its users on how to deal with increased levels of stress, anxiety, and depression, and train users on how to better cope with the negative feelings of stress. The app contains a series of on-demand features, including a coping toolkit, stress management trainings, and a series of educational videos designed to teach participants how to better deal with stress. EASE also utilizes Ecological Momentary Assessments (EMAs) to gather information, and provide personalized messages to users in real time. Finally, EASE is outfitted with COVID-19 related elements, including a symptoms tracker (which participants can use to report symptoms of COVID-19 they may be experiencing), and a collection of COVID-19 related food, housing, and job placement resources.
224166463|NCT02756845|DRUG|Talimogene Laherparepvec|Talimogene laherparepvec will be administered by intralesional injection only into injectable cutaneous, subcutaneous, nodal tumors, and other non-visceral tumors with or without image ultrasound guidance. The first dose of talimogene laherparepvec will be up to 4.0 mL of 10\^6 PFU/mL administered on day 1. The second injection, up to 4.0 mL of 10\^8 PFU/mL (or up to 4.0 mL of 10\^6 PFU/mL for a dose de-escalated cohort), will be administered 21 (+3) days after the initial injection. All subsequent injections, up to 4.0 mL of 10\^8 PFU/mL (or up to 4.0 mL of 10\^6 PFU/mL for a dose de-escalated cohort), will be administered every 14 (± 3) days. The treatment cycle interval may be increased due to toxicity.
224166464|NCT01878227|DRUG|Coenzyme A|Coenzyme A 400mg per day
224166465|NCT01878227|DRUG|Fenofibrate 200mg|Fenofibrate 200mg per day
224166466|NCT00255996|DRUG|linezolid|
224166467|NCT00134953|DRUG|Rivastigmine|
224166468|NCT05401604|DIETARY_SUPPLEMENT|Moderate probiotic beer consumption|Consumption of one can of probiotic beer per day for 14 days. Blood and fecal samples will be collected at the start and end of the intervention to analyse for immunological biomarkers and gut microbiome.
224166469|NCT05401604|DIETARY_SUPPLEMENT|Moderate normal beer consumption|Consumption of one can of normal beer per day for 14 days. Blood and fecal samples will be collected at the start and end of the intervention to analyse for immunological biomarkers and gut microbiome.
224166470|NCT02415504|BEHAVIORAL|Enhanced care transition|Enhanced care transition discharge package: (1) an integrated behavioural care plan, (2) an in-person discharge meeting including family, post-care transition staff (LTC or another hospital unit) and unit staff, (3) videos of responsive behaviours and non-pharmacological interventions, (4) a briefcase of favoured activities, (5) an in-person care demonstration, and (6) involvement of a transitional care team.
224166471|NCT02415504|BEHAVIORAL|Standard care transition|Standard care transition discharge package: The standard care transition varies by unit, and either consists of: (1) a discipline specific care plan, (2) a phone discharge meeting between unit staff and post-care transition staff (LTC or another hospital unit) and (3) a follow-up phone call with social work OR (1) a discipline specific care plan, (2) an in-person meeting between unit staff and (family) caregivers, (3) involvement of a transitional care team, and (4) a follow-up phone call with social work.
224166472|NCT05224752|OTHER|Online Survey|Online survey void of individual traceable identifiers, and launched via the Survey Monkey® portal
224166473|NCT00381108|DRUG|Placebo Tablet|Two tablets, twice daily.
224166474|NCT00381108|DRUG|Pomegranate Tablet|Two tablets, twice daily.
224166475|NCT03778580|DIETARY_SUPPLEMENT|Pyridoxamine Dihydrochloride|pyridoxamine dihydrochloride (over- the- counter type of vitamin B6) 200 mg po bid
223479420|NCT00001891|PROCEDURE|Dobutamine echocardiography|
223479421|NCT04044118|BEHAVIORAL|Low Calorie Diet|Low Calorie Diet consisted of \~50% calories of a normal-calorie diet (female, 1000kcal/day; male, 1200kcal/day)
223479422|NCT04889040|DRUG|RO7496998|275 mg tablets
223479423|NCT04889040|DRUG|Placebo|Matching tablets
223479424|NCT04897620|OTHER|Scanning the blood test results|"Participants' age, gender, duration of low back pain (days), if evaluated, conditions associated with low back pain in cases with subacute/chronic pain, ESR, CRP, RDW, MPV, neutrophil count, lymphocyte count, eosinophil count and platelet count in blood tests at admission examinations were recorded. NLR was calculated by dividing the number of neutrophils by the number of lymphocytes, PLR by dividing the number of platelets by the number of lymphocytes, ELR by dividing the number of eosinophils by the number of lymphocytes, and SII by the formula platelet numberxneutrophil number/lymphocyte number"
223479425|NCT04941872|DIAGNOSTIC_TEST|68Ga-DOTA-FAPI-46 and 68Ga-DOTA-2P(FAPI)2 PET/CT|Each subject receive a single intravenous injection of 68Ga-DOTA-FAPI-46 and 68Ga-DOTA-2P(FAPI)2, and undergo PET/CT imaging within the specified time.
224166476|NCT03778580|DRUG|placebo|placebo
223584463|NCT03979599|DRUG|magnesium sulphate& levobupivacaine|magnesium sulphate\& levobupivacaine
223584464|NCT03979599|DRUG|Levobupivacaine|levobupivacaine
224166477|NCT02433691|OTHER|simultaneous aerobic exercise|stationary bicycling at 65% of heart rate reserve for 30 minutes while receiving memory training.
224166478|NCT02433691|OTHER|sequential aerobic exercise|stationary bicycling at 65% of heart rate reserve for 30 minutes followed by memory training.
224166479|NCT02433691|OTHER|stretching and toning|anaerobic stretching and toning followed by memory training.
224166480|NCT03966092|PROCEDURE|Quadratus lumborum block|"* Bilateral Quatratus lumborum block is performed with ultra sound guidance. The high frequency probe is placed right to the umbilicus, and slips laterally to the side to block. It allows showing the three belts of larges muscles of abdomen (External Oblicum, internal oblicum, and transversal of the abdomen). Laterally, these three are merging to from fascia transversalis. Under fascia transversalis, we can see quadratus lumborum muscle. Punction point in lateral, 1cm in the plan separating quadratus lumborum block and fascia transversalis~* 20 ml of ropivacaïne 3.75mg/ml are injected after aspiration test. If in doubt, hydro localisation car be realised."
224166481|NCT03369704|DRUG|Omalizumab|Omalizumab were administered by subcutaneous injection. Dose (75 to 600 mg) and dosing frequency (every 2 or 4 weeks) were determined by serum total IgE level (IU/mL) and body weight (kg) measured at the screening epoch according the dosing table.
224166482|NCT03369704|DRUG|Placebo|Placebo were administered by subcutaneous injection. Dose (75 to 600 mg) and dosing frequency (every 2 or 4 weeks) were determined by serum total IgE level (IU/mL) and body weight (kg) measured at the screening epoch according the dosing table.
224166483|NCT02283840|DRUG|BIA 2-093|
224166484|NCT01855490|DRUG|Exenatide|
224166485|NCT01505140|OTHER|Whole walnuts|75 gm whole walnuts per day will be consumed with usual Western style diet
224166486|NCT01116804|PROCEDURE|MRI of the liver before start of treatment|MRI of the liver as classic work out of patients (CT-scan if MRI is contra-indicated)
224166487|NCT01116804|PROCEDURE|MRI after treatment|MRI of the liver after 3 - 6 months of treatment (CT-scan if MRI is contra-indicated)
224166488|NCT01116804|PROCEDURE|PET-scan before treatment start|PET-scan with 2 tracers is performed before treatment start
224166489|NCT01116804|PROCEDURE|PET scan after treatment|PET-scan with 2 tracers is repeated 4 weeks following start of treatment
224166490|NCT05324956|OTHER|No intervention|Individuals will not receive any interventions
224166491|NCT02876484|DRUG|Colesevelam|
224166492|NCT02876484|DRUG|Chenodeoxycholic Acid|
224166493|NCT02876484|OTHER|Water|
224166494|NCT05535270|DIAGNOSTIC_TEST|Oxford Depression Questionnaire (ODQ)|"The Oxford Depression Questionnaire (ODQ)is a patient-centered questionnaire. The scale contains three sections: i) the patient's experience in the past week; ii) the patient's experience before the illness worsened, and iii) the patient's emotional feelings about receiving antidepressant treatment. The 26-item questionnaire contains four dimensions of emotional blunting: not caring (NC), emotional detachment from others (ED), reduction in positive emotions (RP), and general reduction in emotions (GR). Patients not taking antidepressants were only required to rate the first two sections ."
224166495|NCT01537523|PROCEDURE|community-care program|community nurse care, physiotherapy
224166496|NCT02911051|DEVICE|Actreen Hydrolite Cath|Depending of the use of the self catheterized patient could be 4 to 6 Actreen Hydrolite Cath per day
224166497|NCT03283891|OTHER|Educational intervention - humanistic nursing practice|"Four educational sessions:~* Acquisition of core concepts of caring practice (I)~* Acquisition of core concepts of caring practice (II)~* Search for meaning: Influencing hope in persons through humanistic practice~* Enacting different caring attitudes and behaviours in an intermediary simulation exercise with actor"
224166498|NCT03873428|OTHER|FES PET|FES injection
223479426|NCT00128375|BEHAVIORAL|Financial incentives|
223479427|NCT05165784|PROCEDURE|femoral vein identification|Femoral vein identification using V technique
223479428|NCT05165784|PROCEDURE|femoral vein identification|Femoral vein identification using palpation technique
223479429|NCT02705430|DIETARY_SUPPLEMENT|EPA and DHA capsules of 2 g/day|EPA and DHA capsules of 2 g/day
223479430|NCT02705430|BEHAVIORAL|Stress management phone application (Eco Fusion Mentally)|Stress management phone application (Eco Fusion Mentally)
223479431|NCT02705430|BEHAVIORAL|life style program using a mobile phone (Eco Mentally and NewMe)|life style program using a mobile phone (Eco Mentally and NewMe)
223479432|NCT02705430|DEVICE|mobile phone|mobile phone
223479433|NCT02058095|DRUG|Tadalafil|"Tadalafil 5 mg tablet. Daily. Tadalafil dose varies from 5 mg to 20 mg for 12 weeks. If blood pressure is \>95 then subject dismissed from the Clinical Research Unit (CRU) on 2 (5 mg) tabs of tadalafil or placebo. If blood pressure is between 90 - 95 mmHg systolic, then dismiss on 1 (5 mg) tab of Tadalafil.~At 2 weeks (± 5 days) if blood pressure is\> 100 than add 1 (5 mg) tab of Tadalafil to make a total of 3 (5mg) tabs of Tadalafil.~At 4 weeks(± 5 days) if blood pressure is \> 100 add 1 (5 mg) tab to make a total of 4 (5 mg) tablets of Tadalafil."
223479434|NCT02058095|DRUG|Placebo|"Placebo tablet. Daily. Placebo tablets made to match appearance of 5mg Tadalafil tablets. Placebo dose varies from 5 mg to 20 mg (1 to 4 tablets) for 12 weeks. If blood pressure is \>95 then subject dismissed from CRU on 2 tabs of placebo. If blood pressure is between 90 - 95 mmHg systolic, then dismiss on 1 (5 mg) tablet of placebo.~At 2 weeks (± 5 days) if blood pressure is\> 100 than add 1 tab of placebo to make a total of 3 tablets of placebo.~At 4 weeks(± 5 days) if blood pressure is \> 100 add 1 (5 mg) tab to make a total of 4 tablets of placebo."
223479435|NCT05082480|DEVICE|Hyaluronic acid (HA)|Hyaluronic acid (HA)
223479436|NCT05082480|DEVICE|Saline|Saline
223479437|NCT00998946|DRUG|Pralatrexate|Pralatrexate injection administered as intravenous (IV) push
223479438|NCT00998946|DIETARY_SUPPLEMENT|Vitamin B12|1 mg intramuscular (IM) injection
223479439|NCT00998946|DIETARY_SUPPLEMENT|Folic Acid|Oral 1 mg tablet
223479440|NCT04252729|PROCEDURE|Psychotherapy|Psychotherapy sessions based on Psychoanalytic Psychosomatics
223479441|NCT00148798|DRUG|cetuximab + cisplatin + vinorelbine|cetuximab given as an intravenous (i.v.) infusion every week (400mg/m\^2 initial dose and 250mg/m\^2 subsequent doses) until progressive disease (PD) + cisplatin 80mg/m\^2 i.v. infusion on day 1 of each 3-week cycle + vinorelbine 25mg/m\^2 i.v. infusion on days 1 and 8 of each 3-week cycle.
223479442|NCT00148798|DRUG|cisplatin + vinorelbine|cisplatin 80mg/m\^2 i.v. infusion on day 1 of each 3-week cycle + vinorelbine 25mg/m\^2 i.v. infusion on days 1 and 8 of each 3-week cycle.
223584465|NCT06344260|PROCEDURE|human Neural Stem Cells (hNSC)|The patient is placed on a regular operating room table with or without rigid head fixation. Procedure will be performed whether under general anesthesia or sedation and local anesthesia. Image guidance will be registered using the frameless stereotactic AxiEM system. Image guidance will be used to perform ventricular cannulation with the catheter passed over an electromagnetic-tipped stylet, which is recognized and tracked by the navigation system. The correct placement of the catheter is verified by the egress of CSF. Finally the electromagnetic stylet will be removed and a Rickam reservoir connect to ventricular catheter. Operative time will be about 30 minute. A post-operative CT scan will be obtained in all patients to confirm the catheter position.
223584466|NCT06344260|PROCEDURE|Saline (Placebo)|The patient is placed on a regular operating room table with or without rigid head fixation. Procedure will be performed whether under general anesthesia or sedation and local anesthesia. Image guidance will be registered using the frameless stereotactic AxiEM system. Image guidance will be used to perform ventricular cannulation with the catheter passed over an electromagnetic-tipped stylet, which is recognized and tracked by the navigation system. The correct placement of the catheter is verified by the egress of CSF. Finally the electromagnetic stylet will be removed and a Rickam reservoir connect to ventricular catheter. Operative time will be about 30 minute. A post-operative CT scan will be obtained in all patients to confirm the catheter position.
223584467|NCT05077358|PROCEDURE|Intracorporeal anastomosis|In this group, the anastomosis is performed inside the abdominal cavity with a laparoscopic technique. Specimen extraction will be done through Pfannenstiel incision or similar incision in lower abdomen.
223584468|NCT05077358|PROCEDURE|Extracorporeal anastomosis|In this group, the anastomosis is performed by pulling out the bowel through a laparotomy.
223584469|NCT06194461|BIOLOGICAL|AZD5851|Safety follow-up for up to 15 years of subjects who received AZD5851 in study NCT06084884.
224166499|NCT01866306|BIOLOGICAL|RV16UB|RV16UB is administered by spraying an atomized viral suspension into a single nostril. Planned doses of RV16UB in Part 1 are 10 Tissue Culture Infective Dose 50 (TCID50), 100 TCID50, 1000 TCID50 and 10,000 TCID50.
224166500|NCT01866306|DRUG|LABA|Asthmatic participants were treated with LABA as part of their standard of care
224166501|NCT02980263|DRUG|Canakinumab|
224166502|NCT05560074|DEVICE|Buzzy|In the Buzzy® group, 30 seconds before the blood collection procedure and during the procedure, the Buzzy® device ist placed 3-5 cm above the area from where the blood would be taken by the PhD qualified nurse researcher
224166503|NCT05560074|OTHER|DistrACTION® Cards|In the DistrACTION® Cards group, picture cards containing various hidden pictures and patterns are used during blood collection by the PhD qualified nurse researcher
224166504|NCT01004874|DRUG|Bevacizumab|Bevacizumab (Avastin) at 10 mg/kg every other week during standard radiation therapy (XRT). Following XRT, bevacizumab will remain at 10 mg/kg every other week.
224166505|NCT01004874|DRUG|Temozolomide|Daily temozolomide at 75 mg/ m2 daily for 6.5 weeks of radiation therapy (XRT). Following XRT, temozolomide will be dosed at 150 mg/m2 daily the first 5 days of each 28-day cycle.
224166506|NCT01004874|RADIATION|Radiation Therapy (XRT)|Standard radiation therapy for approximately 6.5 weeks
224166507|NCT01004874|DRUG|Topotecan|Following standard radiation therapy, patients will receive topotecan on days 2 through 6 of each 28-day cycle at a dose of 1.5 mg/m2 for patients not taking enzyme-inducing anti-epileptic drugs (EIAEDs) and 2.0 mg/m2 for patients taking EIAEDs.
224166508|NCT04247828|DEVICE|Experimental AAC|Participant receives an AAC system comprising a single hybrid wearable sensor for head-mediated cursor control that is integrated with an adaptive and individualized keyboard to test communication performance.
224166509|NCT04247828|DEVICE|Generic AAC|Participant receives an AAC system comprising a single hybrid wearable sensor for head-mediated cursor control that is integrated with a generic QWERTY keyboard to test communication performance.
223584470|NCT06194461|BIOLOGICAL|AZD0754|Safety follow-up for up to 15 years of subjects who received AZD0754 in study NCT06267729.
223584471|NCT01815632|OTHER|Early infusion of autologous marrow|Intravenous infusion of autologous bone marrow without prior myeloablation on the day of bone marrow harvest and infusion of autologous blood at one year post-bone marrow harvest
223584472|NCT01815632|OTHER|Late infusion of autologous marrow|Infusion of blood on day of bone marrow harvest with intravenous infusion of autologous bone marrow without prior myeloablation one year post-bone marrow harvest.
223584473|NCT02546960|BIOLOGICAL|ExPEC4V (4 : 4 : 4 : 4)|Participants will receive single vaccination of ExPEC4V dose (4 : 4 : 4 : 4) as an intramuscular (i.m) injection into deltoid muscle in part 1 (age groups \>=18 to \<50 years and \>=50 years) and part 2 (based on review of safety data by the IDMC). The ExPEC4V doses contain polysaccharide antigen (in microgram \[mcg\]) from the ExPEC serotypes O1A, O2, O6A, and O25B.
223584474|NCT02546960|BIOLOGICAL|ExPEC4V (4 : 4 : 4 : 8)|Participants will receive single vaccination of ExPEC4V dose (4 : 4 : 4 : 8) as an i.m injection into deltoid muscle in part 1 (age groups \>=18 to \<50 years and \>=50 years) and part 2 (based on review of safety data by the IDMC). The ExPEC4V doses contain polysaccharide antigen (in mcg) from the ExPEC serotypes O1A, O2, O6A, and O25B.
224166510|NCT05634837|BEHAVIORAL|Decision Support System counseling|Decision Support System counseling to improve diet and lifestyle in pregnancy
224166511|NCT05634837|BEHAVIORAL|Standard nutritional counseling|Counseling to improve diet and lifestyle in pregnancy
224166512|NCT06396130|DEVICE|Photobiomodulation by low level diode laser|Diode laser exposure (Lite Medics 1.00-Watt serial number 148 Ver. SwvM. 150VS108VT.100) will be carried out using a continuous mode with 10 Hz frequency, 980 nm wavelength, and max power 15 WCW. The tip will be applied both at the buccal and the lingual side for 30 s each.
224166513|NCT06396130|OTHER|Mock Laser Application|Placebo for control group
224166514|NCT00593775|PROCEDURE|assisted hatching|assisted hatching with laser
224166515|NCT03797144|DEVICE|CD HORIZON® Fenestrated Screw System with Fenestrated Screw Cement|The CD HORIZON® Legacy™ and Solera™ Fenestrated Screw Spinal System consists of a variety of cannulated screws with a series of fenestrations to allow polymethylmethacrylate (PMMA) bone cement (Fenestrated Screw Cement) to be injected into the treated site. The Fenestrated Screw Cement is used to augment screw fixation in subjects with compromised bone quality.
224166516|NCT03620292|DRUG|Bevacizumab-IRDye800CW|Intravenous administration of Bevacizumab-IRDye800CW prior to surgery for hilar cholangiocarcinoma
224166517|NCT03620292|DEVICE|near infrared (NIR) fluorescence imaging|Intraoperative NIR fluorescence imaging of hilar cholangiocarcinoma, lymph nodes, resection margins, resection specimens
224166518|NCT05823428|PROCEDURE|Augmentation with subacromial bursa + acromioplasty|Two intervention was planned. Rotator cuff debridement + acromioplasty group is mentioned as Group A (18 patients) and augmentation with subacromial bursa + acromioplasty is Group B
224166519|NCT05823428|PROCEDURE|Rotator cuff debridement + acromioplasty|Two intervention was planned. Rotator cuff debridement + acromioplasty group is mentioned as Group A (18 patients) and augmentation with subacromial bursa + acromioplasty is Group B
224166520|NCT02573506|RADIATION|split-course radiotherapy|Patients are irradiation at a palliative dose in the initial course: 51Gy/17f to PTV-GTV. The disease is re-evaluated three weeks after the end of the initial course using CT. The patient without disease progression according to the RECIST criteria and had a recovery of lung function should get the additional boost. In the second course, the tumor is repositioned and scanned. The residual tumor is then treated with the second course of radiotherapy. A dose of 15-18 Gy/5-6f is delivered to the residue tumor.
224166521|NCT02573506|DRUG|Concurrent chemotherapy|Concurrent chemotherapy consists of weekly docetaxel(25mg/㎡) and nedaplatin(25mg/㎡), each of 1 day's duration.
224166522|NCT04728880|DRUG|Remdesivir|This study is a retrospective trial to assess the efficacy of Remdesivir in adult patients diagnosed with COVID-19 in Mansoura University Isolation Hospital. In this study we will analyze the data collected during treatment.
224166523|NCT00827125|DEVICE|LaborPro device|monitoring labor progression by using a new device The LaborPro system (Trig Medical Inc) allows determination of fetal head station and position using ultrasound and position tracking system.
224166524|NCT02610894|OTHER|mHealth application (PoCAH)|Participants will have unlimited access to the mHealth app via iPad Mini for 5 days post-operatively to aid in pain management
224166525|NCT02610894|OTHER|As usual standard discharge and care instructions|As usual standard discharge and care instructions are provided via iPad mini to orthopaedic ambulatory surgery patients.
224166526|NCT05049642|DEVICE|Lacrimera|A new preservative-free formulation of eye drops consists of a novel biopolymer, chitosan-N-acetylcysteine (C-NAC; Lacrimera®, Croma-Pharma GmbH, Leobendorf, Austria), which electrostatically binds to the mucine layer of the tear film forming a glycocalyx-like structure.
224166527|NCT03083470|DRUG|SOR007 (Uncoated Nanoparticulate Paclitaxel) Ointment|SOR007 will be applied topically to a target AK lesion test field twice daily for up to 28 days, or until all lesions resolve. The maximum total amount of SOR007 that will be applied daily will be 1 finger-tip unit (FTU), approximately 0.5g. No more than 25cm2, approximately 0.15% of the total body surface area, will be treated.
224166528|NCT03083470|OTHER|SOR007 Ointment Vehicle|SOR007 ointment vehicle will be applied topically to a target AK lesion test field twice daily for up to 28 days, or until all lesions resolve. The maximum total amount of Ointment vehicle that will be applied daily will be 1 finger-tip unit (FTU), approximately 0.5g. No more than 25cm2, approximately 0.15% of the total body surface area, will be treated.
224166529|NCT05399589|COMBINATION_PRODUCT|use on1 abutment instead of healing cap in test group|We will use on1 abutment instead of healing cap in a implant operation, since the former can protect the soft tissue barrier to a certain extent.
224166530|NCT05399589|COMBINATION_PRODUCT|use healing cap in control group|use healing cap in control group
223479443|NCT03050567|DIAGNOSTIC_TEST|Transcranial Doppler Ultrasound|Transcranial Doppler will be performed on the symptomatic (ipsilateral to an index event) middle cerebral artery in a quiet temperature controlled room. The middle cerebral artery will be identified through the temporal window in a supine position with a flow direction towards the probe. The subject will have a head frame (Marc 600 Spencer Technologies, USA) fitted to reduce motion and to secure a constant angle of the middle cerebral artery insonation depth at 50-60 mm from the skull surface. All recordings will be made using the ST3 Transcranial Doppler Ultrasound System (Spencer Technologies, USA) with a 2-MHz transducer for 1 hour. Emboli will be detected by listening for their characteristic short audible sound (range 10-100 ms, intensity threshold above 7 dB) and spectral appearance using the International Consensus Group microembolus identification criteria and an automated Embolus Detection Software (Spencer Technologies, USA).
223479444|NCT04040699|BIOLOGICAL|KN026 combined with KN046|KN026 and KN046 are given at 20mg/Kg and 3mg/Kg intravenously on day 1of each 2 weeks cycle at the beginning respectively.The dosage will be escalated if adverse events are tolerated according to the scheme.
223479445|NCT02254655|DRUG|Puerarin injection 400 mg|Patients receive treatment with oral anti-rheumatic agents and/or non-steroidal anti-inflammatory drugs, prednisone, aspirin, statins, bone metabolism regulators and gastric mucosal protective agents on as-needed basis.Furthermore, patients were administrated with 400 mg intravenously infused puerarin injection once a day.Each treatment course lasted for 2 weeks followed by a regular time interval of 15 days.
223479446|NCT02254655|DRUG|Control|Patients receive treatment with oral anti-rheumatic agents and/or non-steroidal anti-inflammatory drugs, prednisone, aspirin, statins, bone metabolism regulators and gastric mucosal protective agents on as-needed basis
223479447|NCT05106569|DIAGNOSTIC_TEST|Spirometry|All study participants will undergo pulmonary function testing using conventional spirometry in clinic and portable spirometry in clinic and at home. In-clinic conventional laboratory spirometry is compared with portable spirometry and Slow vital capacity is obtained in upright and supine positions.
223479448|NCT03483428|BEHAVIORAL|Interventionist training and supervision|"Online and in-person training and weekly supervision with licensed clinical social worker while delivering the Family Check-Up to 5 families."
223479449|NCT03483428|BEHAVIORAL|Behavioral parent training|"Up to 6 sessions of the Family Check-Up program, involving discussions, assessments, feedback, and skills training with a parent coach."
224166531|NCT00955344|BEHAVIORAL|eToolbox|Participants randomized to the Web-based intervention will be automatically routed to a URL that will contain the Web-based intervention.
224166532|NCT00955344|BEHAVIORAL|no link to eToolbox|Participants randomized to the Practice Improvement Module will not be automatically routed to a URL that will contain the Web-based intervention.
224166533|NCT04502199|OTHER|non interventional study|observational study
224305270|NCT03272464|DRUG|Trametinib|Trametinib may work by binding to your cancer cells to inhibit the cancer cells' signals to decrease cell growth.
224305271|NCT03272464|DRUG|Dabrafenib|Dabrafenib may work by stopping your cancer cells from duplicating.
224166534|NCT06984263|PROCEDURE|Circumcision|Circumcision performed as part of standard clinical care in patients with phimosis, which may be caused by lichen sclerosus. The procedure is not assigned by the study but observed as part of routine treatment
224166535|NCT02705313|DRUG|177Lu-DOTA0-Tyr3-Octreotate|The treatment regimen consists of 4 administrations of 7.4 GBq (200 mCi) at the date and time of infusion. The recommended interval between two infusions is 8 weeks, which could be extended up to 16 weeks in case of dose modifying toxicity.
224166536|NCT00041535|DRUG|OGT 918|
224166537|NCT04549675|BEHAVIORAL|Sun Safe Partners Online|Sun Safe Partners Online has 4 individual-focused modules and 4 couple-focused modules focusing on skin cancer prevention education and sun protection.
224166538|NCT04549675|BEHAVIORAL|Generic Online Sun Safety Information intervention|4 links to sent to participants from (1) The Skin Cancer Foundation's Skin Cancer Prevention guidelines, (2) the Centers for Disease Control and Prevention's information on risk factors for skin cancer, (3) the American Academy of Dermatology's information on how to select an appropriate sunscreen, and (4) The Skin Cancer Foundation's information on sun protective clothing. Participants were emailed a link to one of the resources each week for 4 weeks.
224166539|NCT02670187|BIOLOGICAL|GLS-5300|
224166540|NCT04688827|OTHER|Exercise therapy|15 weeks of resistance training (additional to endurance training)
224166541|NCT03077711|DRUG|Trimethoprim|suppressive antibiotic. Estrogen cream may be prescribed if the patient is post-menopausal (but not as a part of this study).
224166542|NCT03077711|DRUG|Methenamine hippurate|antiseptic used in the prevention of recurrent UTIs. Estrogen cream may be prescribed if the patient is post-menopausal (but not as a part of this study).
224166543|NCT04519476|DRUG|Selinexor|Selinexor (KPT-330) is a first-in-class, oral selective exportin 1 (XPO1) inhibitor (1,2). Selinexor functions by binding with and inhibiting the nuclear export protein XPO1 (also called CRM1), leading to the accumulation of tumor suppressor proteins in the cell nucleus along with inhibition of translation of oncoprotein mRNAs.
224166544|NCT04519476|DRUG|Lenalidomide|Immunomodulatory drug
224166545|NCT04519476|DRUG|Methylprednisolone|Glucocorticoid, steroid
224166546|NCT01110928|DRUG|somatropin|Norditropin® (somatropin) prescribed at the discretion of the physician according to normal clinical practice. Safety and effectiveness data is recorded by the physician, at study initiation and every 6 months until last visit.
224166547|NCT05257668|OTHER|High Intensity Interval Exercise Training|High Intensity Interval Training Group
224166548|NCT05257668|OTHER|Moderate Intensity Exercise Training|Moderate Intensity Training Group
224166549|NCT00274352|DRUG|adalimumab|Adalimumab 40 mg administered subcutaneously once weekly or placebo injection administered once weekly for 12 weeks, followed by open-label adalimumab 40 mg administered subcutaneously weekly for an additional 12 weeks.
224166550|NCT03052634|DRUG|RC48-ADC 1.5 mg/kg (HER2 Positive)|15 advanced breast cancer participants with HER2 Positive will be treated with RC48-ADC at a dose of 1.5 mg/kg, every 2 weeks. They will continue the medication until one of the following conditions occurred: disease progression, intolerance of toxicity, withdrawal of informed consent, or treatment for 1 year.
224166551|NCT03052634|DRUG|RC48-ADC 2.0 mg/kg (HER2 Positive)|15 advanced breast cancer participants with HER2 Positive will be treated with RC48-ADC at a dose of 2.0mg/kg, every 2 weeks. They will continue the medication until one of the following conditions occurred: disease progression, intolerance of toxicity, withdrawal of informed consent, or treatment for 1 year.
224166552|NCT03052634|DRUG|RC48-ADC 2.5 mg/kg (HER2 Positive)|15 advanced breast cancer participants with HER2 Positive will be treated with RC48-ADC at a dose of 2.5 mg/kg, every 2 weeks. They will continue the medication until one of the following conditions occurred: disease progression, intolerance of toxicity, withdrawal of informed consent, or treatment for 1 year.
224166553|NCT03052634|DRUG|RC48-ADC 2.0 mg/kg (HER2 Low Expression)|45 advanced breast cancer participants with HER2 Low Expression will be treated with RC48-ADC at a dose of 2.0 mg/kg, every 2 weeks. They will continue the medication until one of the following conditions occurred: disease progression, intolerance of toxicity, withdrawal of informed consent, or treatment for 1 year.
224166554|NCT01833026|DEVICE|Spirometry test|For the initial visit for the intervention group, an initial demographics form and a health questionnaire will given to the subject to complete. To evaluate the breathing and quality of living, a spirometry test will be performed that will evaluate how well and how fast the subject can breath and blow out air.
224166555|NCT01833026|DRUG|Levalbuterol|The spirometry test will be performed with a breathing medication called Levalbuterol (Xopenex®). Levalbuterol is used in standard practice for COPD and is commonly used during spirometry.
223479450|NCT03155698|COMBINATION_PRODUCT|microneedling and Platelet rich plasma|"Patient's skin is first cleaned with ethyl alcohol. Topical anaesthetic cream is then applied to skin for 30 min. Once anaesthesias is fully developed, Dermapen will be applied on the lesional skin in four direction, vertical, horizontal and the two diagonal until pin point bleeding occur which will be gently massaged.~* After ten minutes the prepared platelet rich plasma will be applied topically and after about 2 minutes. Occlusive dressing will be done and kept for 1 day then the patient will use topical antibiotic. The procedure will be repeated every 15 days."
223479451|NCT03155698|RADIATION|NB-UVB phototherapy|All patients will receive NB-UVB twice weekly for maximum 6 months, starting with a dose of 0.21 J/cm² independent of skin type and increased by 20% every session until we reach the minimal erythema dose
223479452|NCT00977197|DRUG|Pregabalin|Dose: 75 mg twice a day for three days, increasing to 150 mg (2 tablets) twice a day for three days, escalating to 225 mg (three tablets) twice a day, through week 12, day 1. Days 2-4 of week 12, participants will begin tapering and will receive 150 mg (two tablets) two times a day and then days 5-7, participants will receive 75 mg two times a day for the duration of the study.
223584475|NCT02546960|BIOLOGICAL|ExPEC4V (8 : 8 : 8 : 8)|Participants will receive single vaccination of ExPEC4V dose (8 : 8 : 8 : 8) as an i.m injection into deltoid muscle in part 1 (age groups \>=18 to \<50 years and \>=50 years) and part 2 (based on review of safety data by the IDMC). The ExPEC4V doses contain polysaccharide antigen (in mcg) from the ExPEC serotypes O1A, O2, O6A, and O25B.
223584476|NCT02546960|BIOLOGICAL|ExPEC4V (8 : 8 : 8 : 16)|Participants will receive single vaccination of ExPEC4V dose (8 : 8 : 8 : 16) as an i.m injection into deltoid muscle in part 1 (age groups \>=18 to \<50 years and \>=50 years) and part 2 (based on review of safety data by the IDMC). The ExPEC4V doses contain polysaccharide antigen (in mcg) from the ExPEC serotypes O1A, O2, O6A, and O25B.
224166556|NCT03570190|OTHER|Coordinator|"A THV coordinator will be responsible for communication with the patients and the caregivers as well as for monitoring medical documentation and treatment pathways. The registry will consist of 3 phases:~* Determination of the status quo~* Dedicated reflection and training followed by implementation of tailored changes~* Determination of the effect"
224166557|NCT00995215|PROCEDURE|Spinal Cord Stimulation|The participant will have wire electrodes temporarily placed - by a routine surgical procedure - over the surface of the spinal cord on the lower back. These electrodes will be activated in the operating room and the degree of muscle activation assessed. The wire electrodes will then be removed. Small, disc electrodes will then be permanently implanted to stimulate expiratory muscles and restore cough. These electrodes are activated using an external control unit.
224166558|NCT00995215|DEVICE|Expiratory Muscle Stimulator|The expiratory muscle stimulator consists of three small electrodes (metal discs) implanted over the surface of their spinal cords on the lower back to stimulate the expiratory muscles and restore cough. These electrodes are connected to an implanted receiver in the abdomen or chest wall. The device is activated through an external antenna connected to an external control box.
224166559|NCT05480631|PROCEDURE|autograft|autologous bone placed in the defect and then be secured with mini-screws to fill the fracture defect gap
224166560|NCT05480631|PROCEDURE|autograft with addition of concenterated growth factor|the bone particulate harvested from the donor site will then be mixed with concentrated growth factor to bridge the fracture defect.
224166561|NCT05480631|PROCEDURE|xenograft with concentrated growth factor|xenogenic bovine bone particulate mixed with platelet-derived concentrated growth factor to be held in place of fracture defect site.
224166562|NCT02943668|DRUG|Deferasirox|Given PO
224166563|NCT02943668|OTHER|Laboratory Biomarker Analysis|Correlative studies
224166564|NCT01487694|DRUG|cimicifuga racemosa|Cimicifuga racemosa (black cohosh) rhizome and root extract 40 mg once daily for 12 weeks (equivalent to triterpene glycosides 12.3 mg)
223479453|NCT00977197|DRUG|Placebo|A matching placebo will be administered twice a day
223479454|NCT01395719|OTHER|Remote ischemic conditioning|Patients receiving kidney transplantation from a deceased donor. Remote ischemic conditioning (rIC) is done by inflating a tourniquet (250mmHg) on the patients leg before reperfusion of the kidney. The tourniquet stays on the leg on the opposite site of were the kidney is placed. rIC is done 4 x 5 min with 5 min intervals between with free blood flow.
223479455|NCT01961492|OTHER|Fecal microbiota transplantation|A single fecal microbiota transplantation through colonoscope
223479456|NCT01374386|BEHAVIORAL|Exergaming|Participants will have access to Exergaming equipment (video games that require physical activity)
223479457|NCT02684929|DIETARY_SUPPLEMENT|branched chain amino acids|15 (women) or 20 (men) grams of BCAA daily for 3 months
223479458|NCT01432951|DRUG|Enzastaurin|Administered orally
223479459|NCT01963806|BEHAVIORAL|Smartphone-supplemented iCBT|"The Internet-administered cognitive behavioural self-help program (iCBT) will be divided into 10 weekly, progressively available modules covering CBT and Acceptance and Commitment Therapy (ACT) conceptualisations of anxiety disorders, as well as more specific therapeutic techniques such as cognitive restructuring, exposure training, attention and breathing exercises and relapse prevention . Each module also includes writing exercises.~Also included is a tailored smartphone application. Briefly, the application allows the user to access, create and modify a personal database of behaviours and check-off these behaviours immediately when completed. Frequency of carried-out behaviours are recorded and displayed as statistics. The application also allows users to browse and search a database of behaviours uploaded by other study participants, providing both inspiration and a sense of social support."
223584477|NCT02546960|BIOLOGICAL|ExPEC4V (16 : 16 : 16 : 16)|Participants will receive single vaccination of ExPEC4V dose (16 : 16 : 16 : 16) as an i.m injection into deltoid muscle in part 1 (age groups \>=18 to \<50 years and \>=50 years) and part 2 (based on review of safety data by the IDMC). The ExPEC4V doses contain polysaccharide antigen (in mcg) from the ExPEC serotypes O1A, O2, O6A, and O25B.
223479460|NCT01963806|BEHAVIORAL|Therapist support|The role of the therapists will be to provide feedback on the written exercises of each treatment module, as well as to provide support and encouragement. As a rule of thumb, the therapists will devote 15 minutes per participant and week.
223479461|NCT01963806|OTHER|Active waiting list|Completes measurements at day 24 and 48 and at the end of the initial treatment period, otherwise no activity until crossover.
223584478|NCT02546960|DRUG|Placebo|Participants will receive matching placebo (Tris-buffered saline) to ExPEC4V.
223479462|NCT03524209|DEVICE|Percutaneous instrumentation of the thoracolumbar spine|The spine is stabilized cranially and caudally of the level of spondylodiscitis. The percutaneous instrumentation consists of a rod and pedicle screw construct. The vertebrae are instrumented through minimal skin incisions using a fluoroscopic guidance or a spinal navigation system based on 3D imaging.
223479463|NCT03524209|OTHER|Brace|Brace treatment is associated in patients presenting back pain and a risk for vertebral body collapse due to infection with subsequent kyphotic deformity of the thoracolumbar spine
223479464|NCT04464460|DRUG|TAK-671|TAK-671 intravenous infusion.
223479465|NCT04464460|DRUG|TAK-671 Placebo|TAK-671 placebo-matching intravenous infusion.
223479466|NCT01244659|DRUG|Tacrolimus from EMS|Tacrolimus initial dose of 0.2 mg/kg/day Myfortic®: 720 to 1440 mg/day Steroids: methylprednisolone: first dose 500mg, 250 mg at first day and 125mg at second day, reducing to 30mg after third day post transplantation.
223584479|NCT01919736|BEHAVIORAL|Gait Retraining|
223584480|NCT02621073|DRUG|VeraFlo with Prontosan|VeraFlo device with Prontosan instillation (n=10).
223584481|NCT02621073|DEVICE|V.A.C Ulta System|V.A.C. Ulta Negative Pressure Wound Therapy System without instillation (n=10).
223584482|NCT00037674|DRUG|Topiramate|
224166565|NCT01487694|DRUG|placebo|matching placebo without active ingredient 1 tab daily for 12 weeks
224166566|NCT03397199|DRUG|Apatinib + S-1|Apatinib 250mg/d,q.d.,p.o. A course of treatment need 21days. S-1 40-60mg（40mg bid BSA \<1.4, 60mg bid BSA\>1.4），bid,from day1-day 14.
224166567|NCT04955574|OTHER|SH-DS01 + Antibiotic Placebo|Participants will be instructed to take 2 capsules of SH-DS01 probiotic once daily (at lunch) from cycle day 1 to the day of ovulation/day of luteal progesterone initiation, followed by 2 capsules of SH-DS01 probiotic once daily (at lunch) and 1 capsule of placebo for antibiotic twice daily (at breakfast and dinner) from the day of ovulation/day of luteal progesterone initiation to the day of frozen embryo transfer.
224166568|NCT04955574|DRUG|SH-DS01 + Metronidazole|Participants will be instructed to take 2 capsules of SH-DS01 probiotic once daily (at lunch) from cycle day 1 to the day of ovulation/day of luteal progesterone initiation, followed by 2 capsules of SH-DS01 probiotic once daily (at lunch) and 1 capsule of 500mg metronidazole twice daily (at breakfast and dinner) from the day of ovulation/day of luteal progesterone initiation to the day of frozen embryo transfer.
224166569|NCT04955574|OTHER|Probiotic Placebo + Antibiotic Placebo|Participants will be instructed to take 2 capsules of placebo for probiotic once daily (at lunch) from cycle day 1 to the day of ovulation/day of luteal progesterone initiation, followed by 2 capsules of placebo for probiotic once daily (at lunch) and 1 capsule of placebo for antibiotic twice daily (at breakfast and dinner) from the day of ovulation/day of luteal progesterone initiation to the day of frozen embryo transfer.
224166570|NCT06065787|DEVICE|NeuroGlove|The NeuroGlove is intended to provide peripheral sensory stimulation to the hand through pneumatic puffs of air to encourage collateral blood supply and sensorimotor development.
224166571|NCT05822960|DEVICE|far-infrared radiation|far-infrared radiation on foot acupoints (Yinlingquan and Sanyinjiao acupoints) during dialysis
224166572|NCT03595189|DRUG|Cilastatin|Dose escalation 3-hour single intravenous administration
224166573|NCT03595189|DRUG|Placebo|3-hour single intravenous administration
224166574|NCT04205474|DIAGNOSTIC_TEST|graded bicycle test|the subjects perform an exercise test on a reclining bicycle, and perform against increasing afterload
224166575|NCT03865849|DEVICE|Cooled radiofrequent treatment|In the cooled radiofrequency group a treatment of 60°C measured at the tip and on average 80°C in the targeted tissue is applied during 150 seconds using the Coolief system.
224166576|NCT03865849|DEVICE|Conventional radiofrequent treatment|In the conventional radiofrequency group a treatment of 80°C at the tip is applied during 90 seconds at each nerve.
224166577|NCT03814681|OTHER|Colorectal Surgery|elective Colorectal Surgery
224166578|NCT04231032|OTHER|Asynchronous dual chamber pacing (DOO) with paced ventricular activation|Alteration of the participant's existing pacemaker mode to either paced or intrinsic ventricular activation (in an order based upon randomisation).
224166579|NCT04231032|OTHER|Asynchronous atrial pacing (AOO) with intrinsic ventricular activation|Alteration of the participant's existing pacemaker mode to either paced or intrinsic ventricular activation (in an order based upon randomisation).
224166580|NCT02380482|OTHER|Transthoracic echocardiography on TBI patients|Two Dimensional and speckle trackingTransthoracic echocardiography on TBI patients within 24 hours of trauma
224166581|NCT02380482|OTHER|Transthoracic echocardiography on control patients|Two Dimensional and speckle trackingTransthoracic echocardiography on control patients while intubated-ventilated
224166582|NCT06261476|DIETARY_SUPPLEMENT|Ashwagandha (Withnia somnifera)|Ashwagandha is the active ingredient in Withania somnifera (a medicinal plant in Indian medicine). Ashwagandha is known as an adaptogen, an herb in capsule form that protects the body from stress.
224166583|NCT00087048|DRUG|topotecan hydrochloride|
224166584|NCT03949127|OTHER|Exercise Group|The group who will meet a physiotherapist who will show them strengthening and stretching muscles associated with pelvic tilt.
224166585|NCT00904176|DRUG|Dapagliflozin|Tablets, Oral, 20 mg, followed by 10 mg, Single Dose
223479467|NCT01244659|DRUG|Prograf|Prograf initial dose of 0.2 mg/kg/day Myfortic®: 720 to 1440 mg/day Steroids: methylprednisolone: first dose 500mg, 250 mg at first day and 125mg at second day, reducing to 30mg after third day post transplantation.
223479468|NCT00853385|DRUG|CP 690,550|tablets 5 mg BID PO plus q2 week placebo SC injections for 12 months
223479469|NCT00853385|DRUG|CP-690,550|tablets 10 mg BID PO plus q2 week placebo SC injections for 12 months
223479470|NCT00853385|OTHER|Placebo|placebo tablets BID PO advance to 5mg CP 690,550 BID at Month 3 or 6 visit plus q2 week placebo SC injections for 12 months
223479471|NCT00853385|OTHER|Placebo|tablets BID PO advance tablets to10mg CP 690,550 BID at Month 3 or 6 visit plus q2 week placebo SC injections for 12 months
223479472|NCT00853385|BIOLOGICAL|Biologic TNFi|placebo tablets BID PO plus adalimumab 40 mg q2 week SC injections for 12 months
223479473|NCT04111315|DRUG|Metamizole Sodium|Novalgin® Oblong tablets 0,5 g 2-2-2
223479474|NCT04111315|DRUG|Ibuprofen 600 mg|Ibufen-L® tablets 500 mg 2-2-2
223479475|NCT04111315|BEHAVIORAL|Patient education|Leaflet and phone call
223479476|NCT06265025|DRUG|GM103 (Part A)|dose escalation of GM103 as monotherapy, conducted in 12-24 patients. Part A will include a screening period of up to 28 days, a dose limiting toxicity (DLT) evaluation period of the first 2 cycles, and a treatment period from cycles 3-12 (each cycle will consist of 14 days \[2 weeks\]).
223479477|NCT06265025|DRUG|GM103 (Part B)|dose expansion study of GM103 as monotherapy, conducted in up to 40 patients (a minimum of 20 patients per target disease \[HNC, CRC\]). Part B of the study will include a screening period of up to 28 days, and 1 to a maximum of 12 treatment cycles (each cycle will consist of 14 days \[2 weeks\]).
223479478|NCT06265025|DRUG|GM103 and Pembrolizumab (Part C)|dose-escalation and dose-expansion of GM103 in combination with pembrolizumab, conducted in approximately 61 patients. Part C of the study will include a screening period of up to 28 days, a safety run-in period of 2 cycles (it consists of 2 cohorts and the first 1 cycle for the DLT assessment period of each cohort is included, each cycle will consist of 21 days \[3 weeks\]), and a dose expansion period from cycle 3 to a maximum of 12 treatment cycles (of 21 days \[3 weeks\]).
223479479|NCT01951950|DRUG|Nicardipine|
224166586|NCT00904176|DRUG|Warfarin|Tablets, Oral, 25 mg, Single Dose
224166587|NCT00904176|DRUG|Digoxin|Tablets, Oral, 0.25, Single Dose
224166588|NCT01711580|OTHER|EORTC QLQ-C30|The EORTC QLQ-C30 is a questionnaire developed to assess the quality of life of cancer patients. It is supplemented by disease specific modules for e.g. Breast, Lung, Head \& Neck, Oesophageal, Ovarian, Gastric, Cervical cancer, Multiple Myeloma, Oesophago-Gastric, Prostate, Colorectal Liver Metastases, Colorectal and Brain cancer which are distributed from the EORTC Quality of Life Department. Other disease specific modules are under development but not yet validated.
224166589|NCT01711580|OTHER|EORTC QLQ-BN20|The EORTC QLQ-C30 is a questionnaire developed to assess the quality of life of cancer patients. It is supplemented by disease specific modules for e.g. Breast, Lung, Head \& Neck, Oesophageal, Ovarian, Gastric, Cervical cancer, Multiple Myeloma, Oesophago-Gastric, Prostate, Colorectal Liver Metastases, Colorectal and Brain cancer which are distributed from the EORTC Quality of Life Department. Other disease specific modules are under development but not yet validated.
224166590|NCT01711580|OTHER|Hopkins Verbal Learning Test-Revised (HVLT-R)|The HVLT-R is a cognitive test to assess verbal learning and memory.
223479480|NCT01951950|DRUG|Esmolol|
224166591|NCT01711580|OTHER|Stroop color-word test|The Stroop Color and Word Test is a brief five minute test which is used to assess brain dysfunction, cognition, and psychopathology.
224166592|NCT01711580|OTHER|Controlled oral word association test (COWA)|The COWA is a measure of verbal fluency that requires expressive language and executive functions.
224166593|NCT01711580|OTHER|Jamar hand dynamometer|The Jamar hand dynamometer is a screening instrument that is used to assess grip strength.
224166594|NCT01711580|OTHER|EORTC QLQ- FA13|The Fatigue Questionnaire (QLQ-FA13) is a 13-item questionnaire to assess fatigue in patients with cancer. It is meant to be used in conjunction with the EORTC QLQ-C30
224166595|NCT01711580|OTHER|Trail Making Test (TMT)|The TMT The Trail Making Test is a neuropsychological test of visual attention and task switching. It consists of two parts in which the subject is instructed to connect a set of 25 dots as fast as possible while still maintaining accuracy.
224166596|NCT05321693|DEVICE|Transcranial Pulsed Current Stimulation|Current has a peak pulse amplitude of 2mA, with a frequency range from 6 to 10 Hz. A battery-powered current stimulator will be used. This device provides stimulation through biphasic and alternating square wave pulse, with random pulse width range from 1 to 20 ms
224166597|NCT05376189|DIETARY_SUPPLEMENT|400 IU|An Oral Vitamin D3 400 IU will be given once daily for a total of 8 weeks
224166598|NCT05376189|DIETARY_SUPPLEMENT|5000 IU|An Oral Vitamin D3 5000 IU will be given once daily for a total of 8 weeks
224166599|NCT05376189|DIETARY_SUPPLEMENT|10000 IU|An Oral Vitamin D3 10000 IU will be given once daily for a total of 8 weeks
224166600|NCT05376189|DRUG|Fixed Drug Combination|Standard Tuberculosis Regimen in a form of Fixed Drug Combination (FDC) given for Spondylitis Tuberculosis.
223479481|NCT02842866|BIOLOGICAL|Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine|0.5 milliliter (mL), Intramuscular (IM), single dose on Day 0.
223479482|NCT02842866|BIOLOGICAL|Meningococcal Polysaccharide Vaccine, Groups A, C, Y, and W-135 Combined|0.5 mL, Subcutaneous (SC), single dose on Day 0.
223479483|NCT02397616|OTHER|high resolution esophageal manometry|high resolution esophageal manometry using liquid and solid swallows and a test meal.
224166601|NCT02106104|DRUG|Linagliptin 5 mg QD (N=24)|Linagliptin 5 mg will be taken orally, once daily for 8 weeks
224166602|NCT02106104|DRUG|Glimepiride 1 mg QD (N=24)|Glimepiride 1 mg will be taken orally, once daily for 8 weeks
224166603|NCT04516824|PROCEDURE|Orthopaedic Surgical Procedures|Intramedullary nails, Dynamic Compression Plate, Dynamic Hip Screw, Manipulation Under Anaesthesia POP, Ilizarov, Cannulated Screw Fixators, Bipolar Hemiarthroplasty, Locking Compression Plate, AO External fixators, Tension Band Wiring Patella, Pelvis and Acetabulum Fixations, Elbow Reconstructions, K wiring, Disc Excision, Spine Fracture i-e TPSF, Posterior Cervical Decompression and LMS, Dura repair, AD cage,Bilateral Total Hip Replacement, Unilateral Total Hip Replacement, Bilateral Total Knee Replacement, Unilateral Total Knee Replacement, Knee Arthroscopy for Mensicectomy, Arthroscopic Anterior Cruciate Ligament reconstruction,Removal of Implant, Amputations, VAC dressings,Wound wash, Arthrotomy for Septic Arthritis, Biopsy
224166604|NCT02070341|DRUG|Polyethylene Glycol|
224166605|NCT02070341|DRUG|Picosalax|
224166606|NCT03081572|DIAGNOSTIC_TEST|Platelet aggregation|Platelet aggregation
224166607|NCT04509401|DRUG|Vitamin B 6 with Magnesium|Patients of intervention group will receive high dose of vitamin B6 with magnesium. This group will receive high dose of vitamin B6 with magnesium orally for 12 weeks.
224166608|NCT04509401|DRUG|placebo of vitamin B6 and magnesium|Patients of control group will receive oral placebo tablet in the same manner, schedule for 12 weeks.
224166609|NCT02005510|BEHAVIORAL|Mailed in-home high-risk HPV testing kit|
224166610|NCT02005510|OTHER|Usual care|
224166611|NCT01300949|DIAGNOSTIC_TEST|Spaeth/Richman Contrast Sensitivity Test|internet based computerized contrast sensitivity test measuring central and peripheral vision using black and white stripes that decrease in contrast by fading to a white background.
224166612|NCT01300949|DIAGNOSTIC_TEST|Pelli-Robson Contrast Sensitivity Chart|wall chart contrast sensitivity test measuring central vision using black letters that decrease in contrast by fading to a white background.
224166613|NCT04710992|PROCEDURE|Isolated needling procedure|The needle will be inserted into the common extensor tendon of the epicondyle (dominant elbow) for 90 seconds without galvanic current.
224166614|NCT04710992|PROCEDURE|Low intensity percutaneous electrolysis|Once the needle is located in the common extensor tendon of the epicondyle (dominant elbow), a single impact of galvanic current will be applied with an intensity of 0.3 mA for 90 seconds.
224166615|NCT04710992|PROCEDURE|High intensity percutaneous electrolysis|The needle will be inserted in the target position during the same time as in the other groups (90 seconds). During the first stage of intervention the needle will be imbedded without galvanic current and when the end of the application time approaches (approximately 75 seconds) three impacts of galvanic current will be applied with an intensity of 3 mA and a duration of 3 seconds each.
224166616|NCT00261794|BEHAVIORAL|computer-assisted cognitive remediation (CACR)|36 individual computer sessions with a staff clinician. computer activities consist of commercially available educational software designed for use in the classroom.
224166617|NCT00261794|BEHAVIORAL|manualized computer control condition (RC).|36 sessions of a manualized computer control condition.
224166618|NCT02136550|BEHAVIORAL|Smoking cessation|Smoking cessation is a program that gives all the support to the subject: orientation, medications, exams, etc
223584483|NCT03710304|DRUG|Oxytocin|20 IU oxytocin or placebo ampoules in 500 mL of intravenous solution infusion over 15 min after delivery of the baby.plus 2tab placebo buccal plus 110 ml saline by slow infusion
223584484|NCT03710304|DRUG|Tranexamic acid plus misoprostol|1 gm TA or separate placebo will be diluted in 100 mL normal saline and administered slowly (over 30-60 s) intravenously by the anesthetist before skin incision,
223584485|NCT03710304|DRUG|misoprostol|400 μg misoprostol (2 tablets of 200 μg) will be give buccally after spinal anesthesia and few minutes before skin incision;
223584486|NCT01516567|DRUG|Etoposide, Doxorubicin, Vincristine, Cyclophosphamide, Rituximab|6 courses of Dose Adjusted-EPOCH-Rituximab Rituximab 375 mg/m² i.v.: one injection at each of the 6 courses of EPOCH.
224305272|NCT03272464|DRUG|INCB039110|Itacitinib may work by stopping your tumor cells from living and growing.
223479484|NCT00577408|DRUG|depot naltrexone|On the afternoon of Day 7, patients assigned to Depot-BNT receive an intramuscular injection of Vivitrol (380 mg) in one buttock. The patient spends the night of Day 7 in the hospital and is discharged on the morning of Day 8. Each injection contains 192 mg of naltrexone. The double dose (384 mg) is what was found to produce optimal blockade and outcome in preliminary work. During the subsequent 6-month course of outpatient treatment, patients are dosed with two injections (384 mg total) of depot naltrexone at monthly intervals (weeks 4, 8, 12, 16, 20).
223479485|NCT00577408|DRUG|Oral Naltrexone|For patients assigned to BNT-Oral, administration is clinic-based for at least the first two weeks, and doses are 50mg, 100mg, or 150mg, depending on whether one, two or three days will elapse before the next visit (typically 100 mg on Monday and Wednesday and 150 mg on Friday). The ultimate goal with BNT-Oral is for patients to take naltrexone (50 mg per day) on their own at home under supervision of their significant other/monitor.
223479486|NCT03400189|DRUG|Sulthiame|Single dose (50, 100, 200 mg)
223479487|NCT00656617|DRUG|Idarubicin|12 mg/m\^2 IV over 1 hour daily for 3 days (days 4 to 6)
223479488|NCT00656617|DRUG|Cytarabine|1.5 g/m\^2 IV as a continuous infusion over 24 hours daily (days 4 to 7)
223479489|NCT00656617|DRUG|Vorinostat|Initial dose level 500 mg orally three times a day for 3 days (days 1 to 3).
224166619|NCT01160263|DRUG|SPECT : 123 I-FP-CIT (DATSCAN) and 123I-ADAM|"123 I-FP-CIT (DATSCAN) : 185 MBq (5 mCi), 2,5 ml will be injected via an arm intravenous catheter.~123I-ADAM:185 MBq,5 ml will be injected via an arm intravenous catheter."
224166620|NCT00087386|DRUG|tanespimycin|Given IV
224166621|NCT00087386|OTHER|laboratory biomarker analysis|Correlative studies
224166622|NCT01678560|DEVICE|Monitoring every 3 months by face-to-face visits|These patients will be monitored on a 3-month, 6-month, 9-month and 12-month intervals with scheduling face-to-face visits. Adherence and efficacy data will only be assessed by the clinician at these intervals.
224166623|NCT01678560|DEVICE|Frequent remote monitoring|These patients will be monitored using wireless modems as the method to obtain adherence and efficacy and follow-up phone calls
224166624|NCT05639829|BEHAVIORAL|Time-restricted eating|Restriction of calorie intake to an 8-hour window, with water only fasting in the remaining 16 hours of the 24-hour period
224166625|NCT00925067|PROCEDURE|laparoscopic (TEP) inguinal hernia repair|laparoscopic inguinal hernia repair with a standard heavyweight Marlex (control group) prosthesis or new generation lightweight VyproII and TiMesh prostheses (study group)
224166626|NCT00925067|DEVICE|lightweight TiMesh|
224166627|NCT00925067|DEVICE|lightweight VyproII|
224166628|NCT00925067|DEVICE|Heavyweight Marlex|
224166629|NCT02685618|DRUG|Iloprost|
224166630|NCT02685618|DRUG|Saline|
224166631|NCT02685618|DEVICE|Phillips M1006B, offset by -10mmHg|Administration of blood pressure module M1006B: offset by -10 mmHg
223479490|NCT01544036|DRUG|perflutren|Contrast Enhanced Ultrasound is performed during continuous intravenous infusion of Definity (drug) to assess changes in renal blood flow during the study
223479491|NCT02301455|BEHAVIORAL|Text messaging|persistently hypertensive participants will be randomized to receive these tailored, motivational text messages
223479492|NCT02349386|DRUG|BHR-200 (0.36% transdermal 17β-estradiol gel)|An absorptive hydroalcoholic gel preparation containing 17β-estradiol.
223479493|NCT02349386|DRUG|Placebo|An absorptive hydroalcoholic gel preparation gel of the same ingredients as BHR-200, but without 17β-estradiol.
223479494|NCT05270356|OTHER|MRI|Magnet Resonance Imaging of the Brain without Contrast
223479495|NCT05844423|BIOLOGICAL|0.5 ml dose of 1.1 mcg VAX-24|24 valent pneumococcal conjugate vaccine
223479496|NCT05844423|BIOLOGICAL|0.5 ml dose of PCV20|20 valent pneumococcal conjugate vaccine
224166632|NCT02685618|DEVICE|Philips M1006B, No offset|Administration of blood pressure module M1006B: No offset
224166633|NCT00068484|DRUG|topotecan hydrochloride|Given IV
224166634|NCT00068484|DRUG|bortezomib|Given IV
224166635|NCT00068484|OTHER|pharmacological study|Correlative studies
224166636|NCT00068484|OTHER|laboratory biomarker analysis|Correlative studies
224166637|NCT04173390|DRUG|Pregabalin 150mg|Preemptive use of pregabalin 150 mg starting three days before surgery up to the third postoperative day
224166638|NCT04173390|DRUG|Placebo oral tablet|Preemptive use of Placebo oral tablet starting three days before surgery up to the third postoperative day
224166639|NCT01429155|GENETIC|Interleukin 28B genotype|Interleukin 28B genotype will be obtained from a tissue block of the liver explant (liver transplanted patients) Interleukin 28B genotype will be obtained from a blood sample drawn (liver donors)
224166640|NCT01835314|DRUG|Stiripentol|Stiripentol 5-50mg/kg/d divided twice or three times a day by mouth
224166641|NCT02545452|DRUG|Anastrozole / Levonorgestrel (BAY98-7196)|Release rate of the IVR: 1050 μg/d ATZ + 40 μg/d LNG
224166642|NCT02545452|DRUG|Gyno-Daktarin|400 mg miconazole nitrate per day for 3 consecutive days
224166643|NCT02545452|DRUG|Sobelin vaginal creme|100 mg clindamycin 2-dihydrogen phosphat per day for 3 consecutive days
223479497|NCT05844423|BIOLOGICAL|0.5 ml dose of 2.2 mcg VAX-24|24 valent pneumococcal conjugate vaccine
223479498|NCT05844423|BIOLOGICAL|0.5 ml dose of 2.2/4.4 mcg VAX-24|24 valent pneumococcal conjugate vaccine
224166644|NCT02545452|DRUG|Patentex oval|75 mg Nonoxynol-9 per day for 3 consecutive days
224166645|NCT02545452|OTHER|Tampon|
224166646|NCT01853852|DRUG|GR181413A/AT1001 solution|Powder for reconstitution
224166647|NCT01853852|DRUG|GR181413A/AT1001 capsule|Size 2, hard gelatin capsule, white opaque / blue opaque
224166648|NCT01853852|OTHER|Potable water|Matched, Size 2, hard gelatin capsule, white opaque/blue opaque
224166649|NCT01853852|DRUG|Placebo capsule|Solution matched
224166650|NCT04509557|DRUG|[177Lu]Ludotadipep|Dose is sequentially elevated starting from a low dose to a high dose (50±5 mCi, 75±8 mCi, 100±10 mCi, 125±13 mCi, 150±15 mCi). If DLT is observed in 2 or less of 6 subjects at each level, advance to the next step. If DLT is observed in 3 or more participants, no further subject will participate in the study at the relevant dose. Appropriateness of the dose elevation is evaluated 8-9 weeks after drug administration.
224305273|NCT00057421|DRUG|prednisolone|
224305274|NCT05131243|PROCEDURE|Chemotherapy time|6 months of chemotherapy
224305275|NCT05131243|PROCEDURE|Chemotherapy time|3 months of chemotherapy
224305276|NCT02116608|DRUG|Betadine|Apply locally as needed.
224166651|NCT06427148|OTHER|"The biofeedback-assisted VR game Golden Breath"|"The biofeedback-assisted VR game Golden Breath that we presented in this study was designed to meet children's healthcare needs quickly and efficiently while reducing pain and fear during medical procedures in the pediatric population. Golden Breath u"
224166652|NCT02823236|DRUG|Topical Pirfenidone|Pirfenidone 8% gel will be applied three times per day during 6 months in the surface of the keloid scar.
223479499|NCT03879330|DEVICE|NIRS monitoring|aSAH patients will be given continuous NIRS and blood pressure monitoring at same time. The correlation curve between the brain oxygenation index or the brain hemoglobin index (ORI/THx) and the blood pressure will be obtained through continuous monitoring of 4 hours. According to the correlation curve, the optimal blood pressure will be determined which provides the optimal CPP.
224166653|NCT02823236|DRUG|Triamcinolone + Pirfenidone|Triamcinolone will be injected in the keloid scar 4 mg/cm2 every 4 weeks for 6 months. And pirfenidone 8% gel will be applied three times per day during 6 months in the surface of the keloid scar.
224166654|NCT02823236|DRUG|Intralesional Triamcinolone|Triamcinolone will be injected in the keloid scar 4 mg/cm2 every 4 weeks for 6 months.
224166655|NCT01963936|DEVICE|Supreme LMA|
224166656|NCT01963936|DEVICE|Facial mask|
223479500|NCT01451073|BIOLOGICAL|Autologous cultured dermal and epidermal cells|Two pieces of occipital scalp are taken from the subject, three weeks apart. The dermal and epidermal cells from these tissues are expanded in culture. The cells are then harvested and, for certain types of product, combined. On the day the cells are harvested after manufacture, they are then injected into the balding area of the scalp of the original subject within a certain time period.
223479501|NCT04992247|BIOLOGICAL|COVI-MSC|"2, 4 or 6 MSC vials (approximately 15 million cells/vial) will be intravenously infused on Day 0, Day 2, or Day 4 depending on assignment to treatment group.~Group A: 2 MSC vials infused on D0 and 2 vials of placebo on D2 and D4~Group B: 2 MSC vials infused on D0 and D2 and 2 vials of placebo on D4~Group C: 2 MSC vials infused on D0 and D4 and 2 vials of placebo on D2~Group D: 2 MSC vials infused on D0, D2 and D4"
223479502|NCT04992247|BIOLOGICAL|Placebo|6 vials of placebo will be intravenously infused on Day 0, Day 2, or Day 4.
223479503|NCT06366308|PROCEDURE|Transperineal Prostate Biopsy|The investigators plan to retrospectively review data from over 10000 men receiving transperineal prostate biopsy in our center.
223479504|NCT02118623|BEHAVIORAL|Moderated discussion board|"All groups will have access to asynchronous, moderated discussion boards. Assignment to discussion board will be stratified by randomization group (Level 1, 2 or 3). Level 1 access to the discussion board will serve as our peer support control condition, although we do expect some modest benefit from this intervention alone.~The discussion boards will be moderated by research staff, who will be supervised by a trained clinician (masters levels or higher). Discussion boards will be asynchronous, with all posts screened by the moderator(s) before appearing to the group."
223479505|NCT02118623|BEHAVIORAL|Psychoeducation|"Online psychoeducation is only available to those randomized to Levels 2 and 3. The core modules of MoodSwings 2.0 will use videos and improved organization of content based on feedback from previous pilot work. Module topic areas include:~1. What is bipolar disorder? - Content about symptoms and diagnosis~2. Stress and triggers of illness~3. Medication and the biological basis of bipolar disorder~4. Depression - Symptoms, early detection and helpful strategies~5. Mania and hypomania - Symptoms, early detection and helpful strategies."
223584487|NCT01345552|RADIATION|Stereotactic Radiosurgery (SRS)|Dose and fractionation will be dependent on the lesion location and lesion size and is up to the exact fractionation and dose is at the discretion of the treating physician. A minimum of 48 hours must be used in between SRS treatments at each site. Note that patients can have SRS everyday or multiple SRS sessions in one day as long as the minimum time for each treatment site is met. For example, if two lung lesions, brain, adrenal, and liver sites were being treated both lung sites could be treated Monday, Wednesday, and Friday and the adrenal, liver and brain lesions treated Tuesday, Thursday
224166657|NCT06455384|BEHAVIORAL|Genetics Navigator|The Genetics Navigator will be used to support patients during the delivery of genetic services, including intake, education, pre- and post-test counselling, and physician-generated management recommendations
224166658|NCT06455384|BEHAVIORAL|Standard Care with Genetics Professionals|Standard care for the delivery of genetic services, including receiving genetic counselling and test results
224166659|NCT03638713|BEHAVIORAL|colonoscopy first|Received water exchange colonoscopy followed by EGD
224166660|NCT03638713|BEHAVIORAL|EGD first|Received EGD followed by water exchange colonoscopy
224166661|NCT02863861|DRUG|Dexmedetomidine-ketamine|
224166662|NCT02863861|DRUG|propofol-ketamine|
224166663|NCT00691977|RADIATION|Radiation Therapy followed by prostatectomy|Radiation Therapy
224166664|NCT05688540|OTHER|e book|e book
224166665|NCT05688540|OTHER|traditional education booklet|traditional education booklet
224166666|NCT01376895|BEHAVIORAL|PROJECT POWER|POWER is a three session intervention to help Black men who have sex with men and women lead healthier lives, make informed sexual choices and reduce their chances of getting or giving HIV to their sex partners. Interventions are designed to be delivered via the internet in real time by a trained health educator. Each session will last between 1 and 2 hours. The sessions are grounded on the social learning theory and use cognitive behavioral approaches. Participants learn the multiple influences on their behavior, how to identify their triggers and then use problem solving skills to develop a safer strategy for life. The sessions use videos and games to teach the lessons; participants are also given work that they must complete between the sessions.
224166667|NCT01376895|BEHAVIORAL|Power Health|Power Health is a one session intervention designed to help Black men who have sex with men and women improve their general health. It focuses on health issues (including HIV) that affect Black men. The program consists of 1 session delivered via the internet in real time by a trained health educator and last approximately 2 hours
224166668|NCT02636738|DEVICE|Vela XL thulium laser, laser fiber and accessories.|The VelaTM XL Laser is a continuous wave thulium laser that uses an optimized 1.94μm wavelength. This powerful, highly precise laser is designed for hemostatic cutting or ablation of soft and hard tissue
224305277|NCT02116608|DRUG|Silver Nitrate|Arzol Silver Nitrate Applicators may be applied directly to mucous membranes and other moist surfaces. In the case of dry skin, the applicator tip should be dipped in water immediately before use. Apply carefully to the area to be treated.
224166669|NCT02725736|DRUG|Atosiban|"After random allocation to a treatment group, women will receive Atosiban as follows:~Atosiban was given as a single loading intravenous dose, 6.75 mg in 0.9% sodium chloride solution, followed by an intravenous infusion of 300 micrograms/min in 0.9% sodium chloride solution for the first 3 hours and then 100 micrograms/min for another 45 hours. The choice of the dose regimen for Atosiban was consistent with the recommendations of the product labeling."
224166670|NCT02725736|DRUG|Nifedipine|"After random allocation to a treatment group, women will receive Nifedipine as follows:~Nifedipine was given as a loading dose of 20 mg orally followed by another two doses of 20 mg, 20-30 minutes apart as needed. Maintenance was started after 6 hours with 20-40 mg four times a day for a total of 48 hours."
224166671|NCT01715090|DEVICE|Web-based insulin titration|
224166672|NCT01555736|DRUG|grass (80%) and rye (20%) pollens allergoids|comparison of two schemes of immunotherapy - preseasonal and perennial immunotherapy.
224166673|NCT04781049|PROCEDURE|Trans-Perineal Laser Ablation of Prostate|"TPLA treatment will be performed using the EchoLaser EVO system (Elesta SpA - Calenzano, FI, Italy). EchoLaser EVO consists of four echolasers, a multi-source laser system with a wavelength of 1064nm and Echolaser Smart Interface (ESI), a treatment planning device for safely inserting introductor needles and optical fibers into prostate tissue. EchoLaser therapy is a micro-invasive percutaneous procedure that uses laser light transmitted through applicators (optical fibers) for a few minutes, causing a heating of the affected tissue to its irreversible damage in situ, without the need to remove it. EchoLaser therapy, through flat-tip fibers, produces an ellipsoidal clotting area (area where the tissue has irreversible damage). EchoLaser therapy will be performed under ultrasound guidance."
224166674|NCT04781049|PROCEDURE|Trans-Urethral Resection of Prostate|TURP is the gold standard for the treatment of benign prostatic obstruction. It will be performed by using a bipolar energy resectoscope. The procedure will be carried out with patient in a lithotomic position.
223479506|NCT02118623|BEHAVIORAL|Interactive Psychosocial Tools|"Online psychosocial tools are only available to those randomized to Level 3. They include structured mood monitoring, medication monitoring, and life charting visual tools. There are also interactive worksheets that encourage awareness of negative thoughts and strategies to challenge them, help participants weight the costs and benefits of different behaviours, problem solving and goal setting, and reinforcing self-affirmation. Participants have the opportunity to build a record of personal triggers of illness and illness profile - including early warning signs, and symptoms typically experienced during an episode of illness, as well as a personal relapse prevention plan."
224166675|NCT02157584|DRUG|Telotristat etiprate|2 × 250 mg (as free base) telotristat etiprate tablets (fed conditions /high-fat / high caloric meal)
224166676|NCT02157584|DRUG|Telotristat etiprate|2 × 250 mg (as free base) telotristat etiprate tablets (fasted conditions)
224166677|NCT03650036|DRUG|Pulp Therapy CTZ Paste|CTZ paste is composed of 62.5 mg of chloramphenicol, 62.5 mg of tetracycline and 125 mg of zinc oxide and manipulated with 0.1ml of eugenol in a sterile glass plate with flexible metal spatula at the time of use.
224166678|NCT03650036|DRUG|Pulp Therapy ZOE Paste|The zinc oxide of the ZOE paste will be supplied in 250mg capsules and handled with 0.1ml eugenol in a sterile glass plate with metal spatula at the time of use.
224166679|NCT00322387|DRUG|G-CSF and plerixafor|G-CSF and plerixafor were administered as described in the treatment arms.
224166680|NCT00674687|DRUG|2-weeks placebo then gabapentin|Placebo for 2 weeks followed by gabapentin 300 mg oral capsule once daily titrated over 1 week to gabapentin 600 mg three times daily for 1 week
224166681|NCT00674687|DRUG|1-week placebo then gabapentin|Placebo for 1 week followed by gabapentin 300 mg oral capsule once daily titrated over 1 week to gabapentin 600 mg three times daily for 2 weeks
224166682|NCT01086449|BIOLOGICAL|Herpes Zoster Vaccine GSK 1437173A|Investigational vaccine (GSK 1437173A) administered intramuscularly.
224166683|NCT05928104|OTHER|Medication review|Pharmacist-led medication review in primary care using a co-designed document
224166684|NCT01924195|DRUG|Anlotinib|Anlotinib QD po.
224166685|NCT01924195|DRUG|Placebo capsule|Placebo QD po.
224166686|NCT05255627|OTHER|Control|"Prevention, Care and Treatment of Pressure Injury was explained by 1 researcher who is responsible for the Nursing Fundamentals course, using written educational material prepared in line with the literature."
224166687|NCT05255627|OTHER|Mobile application group (Experimental Group)|"A mobile application program was installed on the phones of the experimental group students for their benefit. Prevention, Care and Treatment of Pressure Injury was explained by 1 researcher who is responsible for the Nursing Fundamentals course, using a mobile application program prepared in line with the literature."
224166688|NCT00348491|DRUG|Lumiracoxib|
224166689|NCT05021380|OTHER|GROUP|Non-invasive diagnosis of dental pain, dental root canal treatment, salivary specimen collection from the first visit to next and the last during 4 weeks of dental care
223479507|NCT00526617|DRUG|ABT-888|Oral capsules
223479508|NCT00526617|DRUG|Temozolomide|Oral capsules
223479509|NCT05531877|DIAGNOSTIC_TEST|Penile Prosthesis Implantation|Penile measurement are taken preoperatively to serve as a guide to the surgeon to optimize post-operative penile size.
223479510|NCT00676143|DRUG|bapineuzumab|Bapineuzumab 0.5 mg/kg administered by IV infusion approximately every 13 weeks through week 65.
223479511|NCT00676143|DRUG|placebo|Placebo will be administered by IV infusion approximately every 13 weeks through week 65.
224166690|NCT00774969|DRUG|Metronidazole|Metronidazole 10% ointment three times a day 7 days
223584488|NCT01762995|DRUG|Dolutegravir 50 mg|One tablet ( 50 mg) will be administered orally as a single dose in each period per the random code
223584489|NCT01762995|DRUG|Calcium Carbonate 1200 mg|Two tablets (2 X 600 mg) will be administered orally as a single dose in three out of four periods to Cohort 1 only per the random code. Calcium carbonate will be given in fasted state, fed state and 2 hours before dolutegravir administration.
223584490|NCT01762995|DRUG|Ferrous Fumarate 324 mg|One tablet (324 mg) will be administered orally as a single dose in three out of four periods to Cohort 2 only per the random code. Ferrous fumarate will be given in fasted state, fed state and 2 hours before dolutegravir administration.
223584491|NCT05365737|OTHER|Oral rinse|Participants use mouthwasher for a given time.
223584492|NCT05365737|OTHER|Saliva harvest|Non-stimulated saliva harvesting
223584493|NCT00220207|BEHAVIORAL|Internet co-management module|
224166691|NCT05620173|DEVICE|Vedea Amblyopia Therapy (VAT)|Children will use the VAT for 5 days per week, 30 minutes per day. They play VR-games using a VR-headset, which content is optimized for dichoptic training.
224166692|NCT05620173|DEVICE|Occlusion therapy|Children are given an eye patch to occlude their dominant eye with for a prescribed number of hours per day. This may typically range anywhere between 2-8 hours per day, depending on the severity of the amblyopia.
224075912|NCT06443060|BEHAVIORAL|Buzzy Application Group|Before starting the prick procedure, the child in the buzzy group, which was determined by randomisation, will be given a brief information about how the allergy test will be performed and the buzzy device. The children in the buzzy experimental group will be connected to the buzzy cold and vibration device at least 8-10 cm above the area to be treated (upper part of the left arm antecubital fossa) 5-10 seconds before starting the procedure and the prick test application will be started.
224075913|NCT06443060|OTHER|Control Group|Before starting the prick procedure, the children in the control group determined by randomisation will be given routine explanations according to the outpatient clinic procedure before starting the procedure and the prick test will be applied.
224305278|NCT02116608|DRUG|Hydrocortisone Butyrate Cream, 1.0%|Hydrocortisone butyrate cream, 1.0% should be applied to the affected area as a thin film two or three times daily depending on the severity of the condition.
224305279|NCT03468075|DRUG|Ascorbate|Following 15g test dose, 75g administered on Days 1, 2, 8, 9, 15 and 16 of a 28-day cycle
223479512|NCT06403657|OTHER|An enhanced model of hepatitis B testing and linkage to care|Implementing CME sessions (\<50 attendees) at Le Van Thinh Hospital will focus on preventive strategies for hepatitis B (HBV). We'll collaborate with IT to integrate a Best Practice Advisory (BPA) system into the hospital's electronic records for hepatitis B testing reminders. The system prompts healthcare workers when a patient lacks HBV screening notes, ensuring timely education and testing. Also, we'll introduce Point-of-Care (POC) HBsAg testing using SD Bioline HBsAg WB® for efficient screening and counseling, with follow-up to ensure care linkage within two weeks.
223479513|NCT00001011|DRUG|Zidovudine|
223479514|NCT03862638|OTHER|Yoga Therapy|Yoga therapy is therapeutic application of yoga, specifically designed to treat the condition using physical posture, breathing exercises, guided relaxation and meditation.
223479515|NCT00787878|DRUG|somatropin|SGA previously treated with Norditropin®
223479516|NCT00787878|DRUG|No treatment given|Untreated SGA
223479517|NCT00787878|DRUG|No treatment given|AGA (Average gestational age)
223479518|NCT00091429|DRUG|Ranolazine|
224075914|NCT05763329|DRUG|Lemborexant 5 MG Oral Tablet [Dayvigo] Day 1|Patients will receive Lemborexant 5 mg per day on the first day of sleep test
223479519|NCT01144832|DRUG|ebastine|20 milligram capsule once daily
223479520|NCT01144832|DRUG|placebo capsule|one capsule once daily
224075915|NCT05763329|DRUG|Lemborexant 5 MG Oral Tablet [Dayvigo] Day 2|Patients will receive Lemborexant 5 mg per day on the second day of sleep test
224075916|NCT05763329|DRUG|Placebo Day 1|Patients will receive placebo on the first day of sleep test
224075917|NCT05763329|DRUG|Placebo Day 2|Patients will receive placebo on the second day of sleep test
224075918|NCT04979338|OTHER|Ultrasound guided Continuous Infraclavicular Brachial Plexus Block|20cc of 0.25% bupivacaine + 1:200K epinephrine will be administered at start of case, 20cc of 0.25% bupivacaine + 1:200K epinephrine at end of case, and 6cc/hr of 0.25% bupivacaine at post-op \[administered by anesthesiologist\]
224075919|NCT04979338|OTHER|Ultrasound guided Continuous Femoral Nerve Block|20cc of 0.25% bupivacaine + 1:200K epinephrine will be administered at start of case, 20cc of 0.25% bupivacaine + 1:200K epinephrine at end of case, and 6cc/hr of 0.25% bupivacaine at post-op \[administered by anesthesiologist\]
224075920|NCT04979338|OTHER|Ultrasound guided Pudendal Nerve Block|20-40cc of 0.25% bupivacaine + 1:200K epinephrine \[administered by anesthesiologist, pre-incision\]
224075921|NCT04979338|DRUG|Bupivacaine|0.25% or 0.5% with or without 1:200K epinephrine
224075922|NCT04979338|OTHER|Bilateral ultrasound guided Transversus Abdominis Plane Block|40-60cc of 0.25% bupivacaine + 1:200K epinephrine \[administered by anesthesiologist post-op or at end of surgery\]
224075923|NCT04979338|OTHER|Bilateral spermatic cord block|10cc per spermatic cord of 0.5% bupivacaine \[administered by surgeon @ intraop\]
224075924|NCT04979338|OTHER|Pecs I & II Block|0.25% bupivacaine: 15-30mL per side for Pecs I-III
224075925|NCT04979338|OTHER|Local anesthetic|0.25% or 0.5% bupivacaine into the appropriate surgical site
224075926|NCT06612827|OTHER|organoid etablishment|"Prior to initiation of 1st-line therapy:~* Collection of an additional study-specific tumor sample for tumoroid analysis (1 fresh tumor sample)~* A blood test blood a for tumoroid realization and :~* Analysis of ex vivo tumoroid response to treatment and correlation with patient response in vivo~* Analysis of correlation between in vivo and ex vivo tumor characteristics~* Analysis of first- and second-line survival rates and overall survival"
224075927|NCT06990841|DEVICE|sperm separation device|comparison of DNA damage between the 2 interventions and subsequent embryo development and pregnancy rates
224075928|NCT06599762|DRUG|Tranexamic acid|Tranexamic acid 1000mg orally two or three times daily
224075929|NCT06599762|DRUG|Placebo|Placebo orally two or three times daily
224075930|NCT06995820|DRUG|AZD1613|AZD1613 will be administered as either SC injection or IV infusion on Day 1 in Part A and on Days 1, 29 and 57 in Part B of the study.
224075931|NCT06995820|DRUG|Placebo|Placebo will be administered as either SC injection or IV infusion on Day 1 in Part A and Days 1, 29 and 57 in Part B fo the study.
224075932|NCT06670859|OTHER|Intervention-Control:|Patients will complete the STAI before the first mobilization after surgery and then the patients' pain status and the level of anxiety they feel about their physical privacy with the mobilization coverall they will wear during mobilization will be assessed with the VAS.Than,will be asked to perform 4 activities (putting on the coverall-mobilization-sitting in the wheelchair and moving-taking off the coverall) with the overall.Than,will be asked to evaluate the indicator level that they think the coverall they wear protects physical privacy and the levels of comfort and satisfaction they feel about the coverall with the VAS.During the next mobilization,patients will be asked to perform the same application protocol with a traditional hospital gown.Participants who have tried both clothing designs will be interviewed about their experiences using 'interview form' their satisfaction.Than interview,participants will have completed the study by filling out the QUEST 2.0.
224166693|NCT06039657|OTHER|SEAS training|Patients who opted to participate in the SEAS group underwent SEAS therapy. The SEAS therapy program initially comrised patient education and active self-correction. Subsequently, stabilization of active self correction was tried to be performed through various functional activities. These activities were selected from everyday life examples, with increasing levels of difficulty over time. With SEAS exercises, the activation of self-correction was aimed to be increased through various activities in sitting, standing and walking conditions, with the goal of correcting scoliosis in this way
224166694|NCT06039657|OTHER|Standard Care|Patients who declined or were unable to participate in outpatient exercise programs received standard care. Standard care included exercises for postural re-education, traditional strengthening and stretching exercises for one session, followed by observation for one year.
224166695|NCT05125991|PROCEDURE|Prepectoral reconstruction|Prepectoral breast reconstruction
224166696|NCT05125991|PROCEDURE|Submuscolar reconstruction|Submuscolar breast reconstruction
224166697|NCT02803814|PROCEDURE|Superior mesenteric artery approach for pancreatoduodenectomy|Pancreaticoduodenectomy in tumors of the head of the pancreas and peripancreatic area using the superior mesenteric artery approach
224166698|NCT02803814|PROCEDURE|Classic approach for pancreatoduodenectomy|Pancreaticoduodenectomy in tumors of the head of the pancreas and peripancreatic area using the classical approach
224166699|NCT00723853|BEHAVIORAL|Reach-Out Program, nutritional and exercise program|"This group will participate in the Reach-Out nutritional and exercise program. This includes 14 weekly, group sessions involving both parents and children.~During these sessions, participants will receive hands-on education regarding food and exercise habits. Sample nutrition activities include learning to read nutrition labels on foods, a tour of a grocery store and practicing a recipe substituting low fat for high fat ingredients. Exercise activities involve physical activities appropriate for children and adults, respectively. Session leaders will help subjects set personal goals in the areas of nutrition and physical activity, and follow up on subjects' progress each week at sessions and with telephone calls between sessions. At the end of the 14-week program, subjects will be asked to attend four bi-monthly and 18 monthly follow-up sessions in which subjects will continue to meet as a group to work on goals in the areas of nutrition and exercise."
224166700|NCT00723853|BEHAVIORAL|Reach-In Program, standard of care|This group will received standard medical care for their health condition. This includes meeting individually with a dietician to learn about diet, exercise and diabetes. This also includes developing an individualized meal plan.
224166701|NCT04954391|PROCEDURE|Pulsed radiofrequency neuromodulation of the suprascapular nerve only|"PRF stimulation of the suprascapular nerve under ultrasound navigation in the notch of the scapula using the Cosman G4 apparatus with the introduction of stimulation: sensory: 50 Hz; 1 ms; up to 0.5 V; motor: 2 Hz; 1 ms; voltage - twice the sensory threshold, but not less than 1V; after introduction of 1 ml of 0.75% ropivacaine, PRF is performed: 42 С, 45V, 2Hz, 20 ms, 1 cycle - 480 sec. Before removing the cannula, local administration of 0.75% ropivacaine 2 ml, dexamethasone 4 mg.~Under the US navigation, an RF cannula will be placed sequentially at the axillary nerve in the quadrilateral foramen and at the lateral pectoral nerve. After confirmatory sensory and motor stimulation and local administration of 0.75% ropivacaine 1 ml PRF session imitation lasting 480 sec will be carried out. After that local administration of 0.75% ropivacaine 2 ml, dexamethasone 4 mg will follow. The total dose for the entire procedure is ropivacaine 0.75% - 9 ml, dexamethasone 12 mg"
224166702|NCT04954391|PROCEDURE|Pulsed radiofrequency neuromodulation of the suprascapular, axillary, and articular branch of the lateral pectoral nerves|Under ultrasound navigation an RF cannula will be placed sequentially at the suprascapular nerve, at the axillary nerve and at the lateral pectoral nerve. After confirmatory sensory and motor stimulation from RF generator and local administration of 0.75% ropivacaine 1 ml to each nerve, PRF neuromodulation session will be carried out: 42 С, 45V, 2Hz, 20 ms, 1 cycle - 480 sec to each nerve. After that local administration of 0.75% ropivacaine 2 ml, dexamethasone 4 mg will follow to each nerve. The total dose for the entire procedure is ropivacaine 0.75% - 9 ml, dexamethasone 12 mg
224166703|NCT00920946|DRUG|Dimebon|20 mg Dimebon orally TID
224166704|NCT00920946|OTHER|Placebo|Orally TID
224166705|NCT02278380|OTHER|Low GI Standard Breakfast|Low GI Standard Breakfast
224166706|NCT02278380|OTHER|Medium GI Standard Breakfast|Medium GI Standard Breakfast
224166707|NCT02278380|OTHER|Enfamama A+|Nutritional pregnant milk supplement
224166708|NCT02278380|OTHER|Glucerna Triple Care|Nutritional product for diabetics
223584494|NCT05607329|PROCEDURE|Secondary cytoreduction|Open surgery is conducted by senior clinicians in gynecological oncology. Operation time，location and number of relapsed lesions, location and number of excised lesions, Whether achieved R0 or not, and other information are recorded.
223584495|NCT05607329|DRUG|Chemotherapy|chemotherapy
223584496|NCT02918708|BIOLOGICAL|Synflorix|10-valent pneumococcal conjugate vaccine
223584497|NCT02918708|BIOLOGICAL|Prevenar13|13-valent pneumococcal conjugate vaccine
223584498|NCT01440881|DRUG|Nesiritide|infuses at 0.01MCG/KG/min for 48 hours
224166709|NCT02278380|OTHER|Dumex Precima|Pregnant and lactation women milk powder
224166710|NCT02278380|OTHER|Diasip|Nutritional drinks for diabetics
224166711|NCT02278380|OTHER|Test product|Test product not patented yet
224166712|NCT00034892|DRUG|Olanzapine, risperidone|
224166713|NCT06152692|DEVICE|SHAM Continuous positive airway pressure|Placebo treatment
224166714|NCT06152692|DEVICE|Continuous positive airway pressure|Continuous positive airway pressure treatment for patients randomized to CPAP treatment group
224166715|NCT00090766|DRUG|valganciclovir [Valcyte]|po daily (dose based on body surface area and CrCL)
224305280|NCT03468075|DRUG|Gemcitabine|Administered on Days 1, 8 and 15, after the infusion of ascorbate
224305281|NCT00348452|DRUG|tramadol HCl ER; celecoxib|
224305282|NCT02312518|DEVICE|PRP Concepts Fibrin Bio-Matrix|PRP Concepts Fibrin Bio-Matrix in addition to usual and customary practice
223584499|NCT01440881|DRUG|Placebo|infuses at 0.01MCG/KG/min for 48 hours
223584500|NCT00307554|BIOLOGICAL|Pneumococcal (vaccine)|
223584501|NCT02033213|OTHER|Restrictive group|"A group of patients who received ≤ 8ml/kg/h of intraoperative fluid during esophageal carcinoma surgery.~The fluid administered: Plasma-Lyte 148 (pH 7.4; Viaflo, Baxter, US), 10% Aminoven (Fresenius Kabi AG, Bad Homburg, Germany) at 0.5 ml/kg/h, 5 ml/kg of colloid (6% Voluven 130/0.4, Fresenius Kabi AG, Bad Homburg, Germany), packed red blood cells."
224166716|NCT04304404|BEHAVIORAL|Breast Cancer Risk Reduction Program (BrCaRRP)|Women in the intervention group will complete the pre-tests electronically, and a 12-week intervention program will be implemented. The first meeting will be face-to-face individual training. In this training session, the risk of developing breast cancer will be calculated with each participant using breast cancer risk assessment tools. Modifiable and non-modifiable factors that increase breast cancer risk will be explained. With the participant, it will be decided which of the modifiable risk factors will be improved. Guidance will be given on topics such as genetic counseling, breast cancer screenings, increasing physical activity, healthy nutrition, weight control, smoking and alcohol use. The interventions will continue with phone calls and the 12-week program will be completed.
224166717|NCT03296072|DRUG|0.254% w/w sodium fluoride and 5% KNO3|Dentifrice containing 0.254% w/w sodium fluoride (1150 ppm fluoride) and 5% KNO3; plus 0.25% PVM/MA copolymer and 2.5% sodium lactate. Participants will brush it on the buccal surfaces of their natural teeth for 25 timed seconds and then swish the resulting toothpaste slurry around the mouth, without further brushing, for a timed period of 95 seconds. After expectorating the slurry, the participants will gently rinse their mouths with 15 millilitres \[mL\] of tap water for 10 seconds before expectorating again.
224166718|NCT03296072|DRUG|0.454% w/w stannous fluoride|Dentifrice containing 0.454% w/w stannous fluoride (1100 ppm fluoride). Participants will brush it on the buccal surfaces of their natural teeth for 25 timed seconds and then swish the resulting toothpaste slurry around the mouth, without further brushing, for a timed period of 95 seconds. After expectorating the slurry, the participants will gently rinse their mouths with 15 mL of tap water for 10 seconds before expectorating again.
223479521|NCT01901185|DRUG|Etanercept / Autoinjector A|Autoinjector A, a hand-held, reusable electromechanical device, and a single-use, disposable cassette preassembled with an etanercept 50-mg liquid prefilled syringe (PFS).
224166719|NCT03296072|DRUG|5% KNO3|Fluoride free placebo dentifrice containing 5% KNO3 (0 ppm fluoride), 0.25% PVM/MA copolymer and 2.5% lactate. Participants will brush it on the buccal surfaces of their natural teeth for 25 timed seconds and then swish the resulting toothpaste slurry around the mouth, without further brushing, for a timed period of 95 seconds. After expectorating the slurry, the participants will gently rinse their mouths with 15 mL of tap water for 10 seconds before expectorating again.
224166720|NCT00396422|DRUG|RWJ-445380|
224166721|NCT00654368|BIOLOGICAL|Etanercept|Commercially available etanercept administered subcutaneously at 50 mg/week.
224166722|NCT00654368|DRUG|Methotrexate|Commercially available methotrexate administed orally, subcutaneously or intramuscularly 15 mg/week (or 10 mg/week in case of documented intolerance to higher doses)
224166723|NCT04403620|RADIATION|Intensity-modulated Radiation Therapy (IMRT)|Patients will receive adjuvant radiation therapy using intensity-modulated radiation therapy (IMRT) within 8 weeks of surgical resection
223479522|NCT06228989|PROCEDURE|Restorative therapy|Restorative treatment of first permanent molars affected with severe MIH
223479523|NCT06228989|PROCEDURE|Extraction therapy|Extraction treatment of first permanent molars affected with severe MIH
223479524|NCT02318264|DEVICE|Kinesio Tape|Elastic tape placed over the skin
223479525|NCT04525196|OTHER|Physical activity.|"The procedure under study (physical activity program) will include, each week for 12 months, two sessions dedicated to the development of aerobic capacity and a muscle building session.~The experimental group will therefore be offered 3 sessions of Physical Activity (PA) per week. The PA will be positioned in the first two hours after the start of the dialysis session. Each session will include 5 minutes of general warm-up, then 15 minutes of PA itself and finally 5 minutes of cool down period. The PA time itself will be increased as the sessions progress, according to the progress and improvement of physical capabilities of patients."
223479526|NCT04772443|DRUG|DWJ1506|DWJ1506
223479527|NCT04772443|DRUG|DWJ1507|DWJ1507
223479528|NCT04772443|DRUG|DWC202011|DWC202011
223584502|NCT02033213|OTHER|Liberal group|"A group of patients who received \> 8 ml/kg/h of intraoperative fluid during esophageal carcinoma surgery.~The fluid admnistered: Plasma-Lyte 148 (pH 7.4; Viaflo, Baxter, US), 10% Aminoven (Fresenius Kabi AG, Bad Homburg, Germany) at 0.5 ml/kg/h, 5 ml/kg of colloid (6% Voluven 130/0.4, Fresenius Kabi AG, Bad Homburg, Germany), packed red blood cells."
224166724|NCT00804986|DRUG|LY2428757|Once weekly for 12 weeks as a subcutaneous injection.
224166725|NCT00804986|DRUG|Placebo|1 of 5 volumes of placebo given once weekly for 12 weeks as a subcutaneous injection.
223479529|NCT04772443|DRUG|DWJ1177|DWC202011
223479530|NCT02914327|DRUG|SNX-5422 plus ibrutinib|SNX-5422 capsule(s) dosed every other day for 21 days out of a 28-day treatment cycle to a total dose of 56 mg/m2 SNX-5422. Subjects will self-administer daily oral ibrutinib in the afternoon at least 8 hours apart from SNX-5422 for 28 days of each cycle.
223479531|NCT02442128|DRUG|propofol /Fentanyl|fentanyl 2 μg/kg and propofol 2 mg/kg Both test drugs will be made up to 10 ml with saline. fentanyl will be first administered intravenously over 30 s followed by propofol over 20 s.
223479532|NCT02442128|DRUG|Fentanyl / propofol|fentanyl 2 μg/kg and propofol 3 mg/kg. Both test drugs will be made up to 10 ml with saline. fentanyl will be first administered intravenously over 30 s followed by propofol over 20 s.
223479533|NCT00694772|PROCEDURE|Electrocautery-tonsillectomy|standard of care electrocautery tonsillectomy
223479534|NCT00694772|PROCEDURE|Coblation-tonsillotomy|use of Arthrocare Coblation Technology to perform tonsillotomy
223479535|NCT00774917|DEVICE|Numen|Numen Co-Cr coronary stent implant
223584503|NCT02383433|DRUG|Regorafenib|Given PO
223584504|NCT02383433|DRUG|Gemcitabine Hydrochloride|Given IV
223584505|NCT02035722|BEHAVIORAL|Printed materials|AMD-related information is presented to patients in the form of a brochure (i.e. printed materials)
223584506|NCT02035722|BEHAVIORAL|Video|AMD-related information is presented as in the form of a video
223584507|NCT05164146|DRUG|propofol|during the induction, remimazolam dose was controlled according to sedline (Psi target 40)
224166726|NCT02708004|DRUG|Aprocitentan|Formulated in capsules in 2 different strengths; 2 capsules per day
224166727|NCT02708004|OTHER|Placebo|Matching active drug
224166728|NCT00014586|DRUG|bicalutamide|
224166729|NCT00014586|DRUG|goserelin acetate|
223479536|NCT02502370|DRUG|observation alone|
223479537|NCT02502370|DRUG|LV5FU2|
223479538|NCT02502370|DRUG|FOLFOX|
223479539|NCT00047762|DRUG|Erlotinib (aka Tarceva or OSI-774)|
224166730|NCT00014586|PROCEDURE|orchiectomy|
224166731|NCT03327363|DEVICE|Feedback using ICT based monitoring system|In experimental group, the subjects the check their lung function using self FEV1 monitoring device (microlife PF-200). They send the information to central monitoring system(EDC systems). In case of decreased FEV1 compared with own average FEV1, the ICT based monitoring system send the feedback message to the subject and medical staffs.
224166732|NCT00815776|DEVICE|Clayton Intra-aural Device (CID)|"The CID is a patented small, hollow, ear insert made of medical grade polymers that is custom-fit to each subject's ear. Each subject that is randomized to the CID study group will wear a pair of inserts, one in each ear. (For the purpose of this protocol, the pair of inserts will be referred to as the CID)."
224166733|NCT00815776|DEVICE|Mouth Splint|Group 2 subjects will be assigned to the active control device, which is current standard of care therapy. The device is an intraoral flat-planed splint full coverage plastic (hard) orthotic that fits over the occlusal one-third surfaces of the dentition. The appliance is made by taking a standard wax bite registration and is made using the standard technique of taking alginate impressions of the subject's teeth, pouring dental laboratory stone into the impression and processing the acrylic appliance on the stone model. This appliance raises the plane of occlusion and provides complete contact with the opposing dentition.
224166734|NCT00815776|OTHER|Exercise Group|Subjects assigned to Group 3 will be asked to track daily compliance with the protocol-specific exercise plan in their 4 week diaries. The exercise plan will consist of the following instructions: subjects will be instructed to open their jaw as far as possible, without pain and hold the jaw in that position for 5 seconds. Subjects will then close their jaw and rest 10 seconds. The exercise should be repeated exactly ten times in a row, with a 10 second rest in between each stretch. Subjects will be advised to apply a warm compress to the jaw area after completing their exercises for 10 minutes.
224166735|NCT01204424|DEVICE|minimal-invasive sinus floor augmentation with the DKK and SVP (JEDER Syst.)|minimal-invasive sinus floor augmentation with the DKK and SVP (JEDER Syst.)
224166736|NCT01204424|DEVICE|minimal invasive crestal sinus lift with the JEDER Systh.|"The mucous membrane is opened from the toothless part of the maxillary crest up to the bone and the bone is scraped by a cylindrical cutter in the shape of a tunnel up to slightly underneath the maxillary sinus membrane and hydraulic pressure is being built up within the DKK. A centrally placed drill within the DKK slowly moves in the direction of the membrane. At the moment of the first minimal perforation of the remaining bone the pressurized fluid pushes the membrane back and ensures that the membrane is not perforated by the drill.~The SVP is used to generate hydraulic vibrations, which help to further raise the membrane from the bone (principle of the percussion drill). After the maxillary sinus membrane has successfully been elevated, the working fluid is extracted and bone replacement material is introduced via the bore."
224166737|NCT02927184|DRUG|VK2809|
224166738|NCT02927184|DRUG|Placebo|
224166739|NCT01816386|OTHER|Acupuncture Regimen|Patients in the acupuncture and the acupressure group will receive a standardised treatment comprising 12 SEIRIN® press needles (with a sharp tip) at 7 acupuncture points (Du 26, He 9, Ren 17, bilateral LI 4, He 9, LV 3, Ma 36 and Pe 6). The point regimen is based on consensus process of national and international experts. All needling will be documented by the acupuncturist. Application time is supposed to be 84-96 hours. Modification, especially less points according to the patients reaction during treatment is allowed.
224166740|NCT01816386|OTHER|Acupressure Regimen|Patients in the acupuncture and the acupressure group will receive a standardised treatment comprising 12 SEIRIN® press plasters (with a blunt knob instead a sharp needle) at 7 acupuncture points (Du 26, He 9, Ren 17, bilateral LI 4, He 9, LV 3, Ma 36 and Pe 6). The point regimen is based on consensus process of national and international experts. All needling will be documented by the acupuncturist. Application time is supposed to be 84-96 hours. Modification, especially less points according to the patients reaction during treatment is allowed.
224166741|NCT02340572|DRUG|PRS-080#022-DP|hepcidin antagonist
224166742|NCT02340572|DRUG|PRS-080-Placebo#001|Placebo treatment
223479540|NCT00047762|DRUG|Bevacizumab (aka Avastin or Rhu MAb VEGF)|
223584508|NCT05164146|DRUG|remimazolam|During induction, remimazolam dose was controlled according to sedline (Psi target 40)
223584509|NCT01107938|DRUG|10 mg ilaprazole|Two 5-mg ilaprazole tablets (Livzon Pharm Group Inc., China) together with one placebo tablet of ilaprazole and one placebo tablet of esomeprazole in a package being taken orally each morning on an empty stomach for 8 weeks
223584510|NCT01107938|DRUG|15 mg ilaprazole|Three 5-mg ilaprazole tablets (Livzon Pharm Group Inc., China) together with one placebo tablet of esomeprazole in a package being taken orally each morning on an empty stomach for 8 weeks
223584511|NCT01107938|DRUG|40 mg esomeprazole|One 40-mg esomeprazole tablet (AstraZeneca, Nexium) together with three 5-mg placebo tablets of ilaprazole in a package being taken orally each morning on an empty stomach for 8 weeks
224166743|NCT02584023|DEVICE|Lung ultrasound|Lung ultrasound on both hemithorax in supine position
224166744|NCT05333536|OTHER|Experimental: Experimental group exercises|Experimental performs Strengthening exercises of core.10 reps , 3 sets of each.Prone plank(10 sec hold)(18) ,Side plank (8 sec hold),Bridging (8 sec hold)(19),Bird dog (10 reps ,3 sets),Leg drop (10 reps, 3 sets)(15),Dying bug with their regular swimming practice. First 2 weeks simple strengthening exercises.Next 4 weeks stability ball exercises. Dying bug without stability ball. And strengthening exercises of Upper Limb and Lower Limb with theraband ,10 reps each.Upper Limb: Latissimus dorsi,Serratus anterior, Upper trapezius.Lower limb : Flexors of hip, Extensors of hip,Plantar flexors.
224166745|NCT05333536|OTHER|No Intervention: Control group|control only participates in their yearly swimming trainings.
224305283|NCT02312518|OTHER|Usual and Customary Practice|Usual and Customary Practice for non-healing venous leg ulcers
223479541|NCT02474186|RADIATION|Radiation therapy|Patients with metastatic breast cancer and other metastatic solid tumors receiving single-agent chemotherapy will receive 3.5 Gy/fraction to a total dose of 35 Gy/10 fractions over 2 weeks with concurrent systemic therapy
223479542|NCT02474186|DRUG|Xeloda|chemotherapy agent daily for two weeks
223479543|NCT02474186|DRUG|paclitaxel|chemotherapy agent weekly for two weeks
223479544|NCT02597608|BEHAVIORAL|CLP: Livelihoods|Capital for purchase of income generating asset, physical infrastructure (plinths, latrines, tubewells), livelihood maintenance stipend, monthly asset maintenance cost stipend, agricultural livelihood training, non-agricultural livelihood training, financial training, health and nutrition training.
224166746|NCT06082349|PROCEDURE|Lymphaticovenous anastomosis|Lymphaticovenous anastomosis (LVA) involves connecting a lymphatic vessel to a adjacent vein of similar size, thereby facilitating the ouflow of lymphatic fluid in patients suffering from secondary lymphedema
224166747|NCT06082349|PROCEDURE|Sham surgery|Sham surgery involves the process of surgery, including local anesthesia and incisions, but no LVA is made.
224166748|NCT03606655|DRUG|Kava|Kava: 75 mg three times daily (3 capsules)
224166749|NCT01059890|DRUG|cefotaxime|
224166750|NCT01059890|DRUG|Metronidazole|
224166751|NCT01059890|DRUG|Ciprofloxacin|
224166752|NCT01059890|DRUG|Fosfocine|
224166753|NCT00559013|DEVICE|Staple line reinforcement|Placement of reinforcement material on circular anastomotic staple line for prevention of leak during and post surgery.
224166754|NCT05666206|PROCEDURE|fibrin sealant in hypospadias|fibrin sealant will be used over the suture line
224166755|NCT00959699|DRUG|PegIFN-2b|PegIFN-2b (1.5 μg/kg/week subcutaneously)
224166756|NCT00959699|DRUG|RBV|Ribavirin (600-1400 mg/day, orally, divided into two daily doses)
224166757|NCT00959699|DRUG|Placebo to Boceprevir|Placebo to boceprevir (orally, three times per day)
224166758|NCT00959699|DRUG|Boceprevir|Boceprevir (800 mg, orally, three times per day)
223479545|NCT02597608|DIETARY_SUPPLEMENT|CLP: Nutrition|Counseling on breastfeeding and complementary feeding; five components micronutrients (iron 12.5 mg, folic acid 0.16 mg, zinc 5 mg, vitamin A 0.3 mg, vitamin C 30 mg) for children 7-23 months dosage of 120 sachets per year; 180 iron and folic acid tablets (60 mg iron and 400 mg folic acid) tablets to each pregnant woman after first trimester and up to 180 for each breastfeeding woman per year, as well as 104 tablets to each adolescent girl; deworming treatment for children aged 1-5 years, adolescent girls, pregnant women after first trimester; identification and referral of acute malnutrition; facilitation of government campaigns on nutrition.
223479546|NCT02597608|BEHAVIORAL|Shiree: Livelihoods|Financial training; input support for livelihoods (cropping, livestock, poultry, fishing, bamboo working, small businesses, tailoring etc.); capacity building (mobilising Self Help Groups, facilitating community based organizations (CBOs), skills transfer); innovation support (market linkage and access to value chains); credit and savings groups; support in mobilizing communities to advocate for their needs.
223584512|NCT03038893|DIAGNOSTIC_TEST|Point Of Care Ultrasound (PODUS)|Patients were first submitted to Point Of Care Ultrasound (POCUS) and then to Echo Doppler Ultrasound (EDUS) for the diagnosis of DVT.
224166759|NCT05891470|DEVICE|MonaLisa Touch device|sessions with intra-vaginal CO2 laster system
224166760|NCT05891470|DEVICE|Vaginal dilatators|Home use of vaginal dilatators (at least twice a week for minimum 5 minutes)
224166761|NCT02583360|DIAGNOSTIC_TEST|Combined testing (diagnostic VFSS + research HRM) + Parent Preferred Therapy|Addition of research HRM along with diagnostic VFSS with parental choice of therapy
224166762|NCT04583345|BEHAVIORAL|Questionnaires|Questionnaires: Physical therapists ask questions these assess quality of life, anxiety and depression, physical activity level.
224166763|NCT04228445|DRUG|3,3'-Dioxo-2,2'-bisindolylidene-5,5'-disulfonate disodium 0.8%|Experimental contrast dye that is commonly used as a visualization aid in pelvic and abdominal surgeries and for various diagnostic procedures in medical practice.
224166764|NCT04228445|DRUG|Saline spray|Placebo
223584513|NCT03038893|DIAGNOSTIC_TEST|Echo Doppler Ultrasound (EDUS)|Patients were submitted only to Echo Doppler Ultrasound (EDUS) for the diagnosis of DVT.
223584514|NCT00320138|PROCEDURE|Acupuncture, using Chinese Medicine methodology|4 weeks of 2/week treatments (8 total); 4 standardized and 4 individualized treatments
223584515|NCT03705975|OTHER|Manual treatment|Scapula mobilization, glenohumeral joint mobilization
223584516|NCT05053412|DIAGNOSTIC_TEST|Helio Liver Test|A Helio Liver Test is used as the basis of performance evaluation for specificity and sensitivity for all patients enrolled in the study.
223584517|NCT00402493|DRUG|ibuprofen, latanoprost, brimonidine|to determine whether commonly used OTC non-steroidal anti-inflammatory agents taken orally has any effect on the ability of either latanoprost or brimonidine to lower high eye pressure
223584518|NCT00402493|DRUG|Ibuprofen, brimonidine, latanoprost|to determine whether commonly used OTC non-steroidal anti-inflammatory agentsn(200mg ibuprofen) taken orally has any effect on the ability of either latanoprost or brimonidine to lower high eye pressure
224166765|NCT01061645|DRUG|MOC31-PE|Immunotoxines
224166766|NCT05490498|OTHER|Collection of breast milk|Collection of breast milk through a sterilized breastfeeding device. Once the collection is completed, the milk will be transferred to a sterile jar provided in a dedicated survey package for transport to the laboratory.
224166767|NCT06153394|DRUG|Redesca (enoxaparin sodium for injection)|Redesca is low molecular weight heparin and a biosimilar biologic drug (biosimilar) to Lovenox. Indications have been granted on the basis of similarity between Redesca and the reference biologic drug Lovenox. As such, Redesca (enoxaparin sodium) is indicated for thromboprophylaxis in patients undergoing high risk abdominal and colorectal surgeries. Doses are provided as self-administered subcutaneous injections using a pre-filled syringe with a protective shield.
224166768|NCT06153394|DRUG|Fragmin (dalteparin)|Fragmin is a low molecular weight heparin indicated for thromboprophylaxis in patients undergoing high risk abdominal and colorectal surgeries. Doses are provided as self-administered subcutaneous injections using a pre-filled syringe with a protective shield. Our institution uses this drug for standard of care thromboprophylaxis (30 days) in this patient population.
224166769|NCT02887365|DRUG|tegafur-uracil|
224166770|NCT05108961|PROCEDURE|Acupuncture|one session with precise acupunture points
224166771|NCT05108961|BEHAVIORAL|A digital stress scale|The digital stress scale before and after the session: Oral digital scale. The doctor asks the participant to quantify their anxiety on a virtual scale ranging from 0 (absent anxiety) to 10 (maximum anxiety imaginable)
224166772|NCT05108961|BEHAVIORAL|a relaxation questionnaire|The Global Relaxation Questionnaire after the session: Dovero Global Relaxation Scale
224166773|NCT05108961|DIAGNOSTIC_TEST|Bispectral Index|BIS is based on an EEG analysis algorithm
224166774|NCT03879460|DRUG|Naltrexone Hydrochloride|50 mg per os naltrexone hydrochloride
224166775|NCT00606294|RADIATION|fluorine-18-labeled fluoro-misonidazole (18F-FMISO)|
224166776|NCT00606294|DEVICE|18F-FMISO PET scan|
224166777|NCT00606294|DEVICE|MRI|
224166778|NCT00606294|DEVICE|FDG PET/CT scan|
224166779|NCT02823613|DIETARY_SUPPLEMENT|High salt diet followed by low salt diet|High salt diet (250 mmol/day) in 5 days followed by low salt diet (60-70 mmol/day) in 5 days.
224166780|NCT02823613|DIETARY_SUPPLEMENT|Low salt diet followed by high salt diet|Low salt diet (60-70 mmol/day) in 5 days followed by high salt diet (250 mmol/day) in 5 days.
224166781|NCT00002097|DRUG|Nystatin|
224166782|NCT01405378|DEVICE|Robot therapy and transcranial direct current stimulation|"Administration of Robot Therapy:~Therapy will be administered by making use of the Armeo Robot. Sessions will involve high-intensity, repetitive, task-oriented movements directed by video screens. Administration of tDCS:~Anodal tDCS will be administered using a CE marked transcranial Direct Current Stimulator (Newronika Italy). Direct current will be transferred by a saline-soaked pair of surface sponge electrodes (35 cm2)."
224166783|NCT01063946|DRUG|Ombrabulin (AVE8062)|"Pharmaceutical form:concentrate solution~Route of administration: intravenous infusion"
224166784|NCT01651234|DRUG|GCC-4401|"* Swedish Orange opaque hard gelatin capsules of size 1 with no markings for oral use~* single dose~* dosage~  * Cohort 1: 2.5-mg GCC-4401C~ * Cohort 2: 5.0-mg GCC-4401C~ * Cohort 3: 10-mg GCC-4401C~ * Cohort 4: 20-mg GCC-4401C~ * Cohort 5: 40-mg GCC-4401C~ * Cohort 6: 80-mg GCC-4401C"
224166785|NCT01651234|DRUG|GCC-4401C|"* Capsule, identical in appearance to GCC-4401C, for oral use~* single dose~* dosage~  * Cohort 1: 2.5-mg matching placebo~ * Cohort 2: 5.0-mg matching placebo~ * Cohort 3: 10-mg matching placebo~ * Cohort 4: 20-mg matching placebo~ * Cohort 5: 40-mg matching placebo~ * Cohort 6: 80-mg matching placebo"
224166786|NCT03797157|DIETARY_SUPPLEMENT|H2MF|H2MF is a human milk-based breastmilk fortifier for preterm infants
224166787|NCT03797157|DIETARY_SUPPLEMENT|Bovine milk-based fortifier|Bovine milk-based fortifier is the standard breast milk fortifier in Sweden
224166788|NCT04308408|BEHAVIORAL|Guideline Daily Amounts|All food items displayed the corresponding GDA label in the lower left corner of the front of the package.
223479547|NCT02597608|DIETARY_SUPPLEMENT|Shiree: Nutrition|Counseling on breastfeeding, complementary feeding, and sanitation; community discussions including adolescent girls on early and forced marriage; five components micronutrients (iron 12.5 mg, folic acid 0.16 mg, zinc 5 mg, vitamin A 0.3 mg, vitamin C 30 mg) for children aged 7-23 months; 180 iron and folic acid tablets (60 mg iron and 400 mg folic acid) tablets to each pregnant woman after first trimester and up to 180 for each breastfeeding woman per year, as well as 104 tablets to each adolescent girl; deworming treatment for children aged 1-5 years, adolescent girls, pregnant women after first trimester.
223479548|NCT02597608|BEHAVIORAL|UPPR: Livelihoods|Monetary support for communities to improve infrastructure (drains, footpaths, latrines and water dwells, access to roads and markets); financing for apprenticeships; grants for small businesses; education grants for girls; grants for urban food production activities; financial training; establishment of savings and credit groups; support for communities in advocating for their needs; microcredit; improving access to health facilities; improving housing conditions; provision of plinths.
224166789|NCT04308408|BEHAVIORAL|Multiple Traffic Light|All food items displayed the corresponding MTL label in the lower left corner of the front of the package.
224166790|NCT04308408|BEHAVIORAL|Warning Labels|"Food products were labeled with High in labels In the lower left corner of the front of the package. In total, 37 of the 60 food products in the shopping site did not display a WL."
224166791|NCT04308408|BEHAVIORAL|Video|Participants viewed a short (less than 1 min) video explaining how to interpret the label.
223479549|NCT02597608|DIETARY_SUPPLEMENT|UPPR: Nutrition|Counseling on breastfeeding, complementary feeding, and sanitation; community discussions including adolescent girls on early and forced marriage; five components micronutrients (iron 12.5 mg, folic acid 0.16 mg, zinc 5 mg, vitamin A 0.3 mg, vitamin C 30 mg) for children aged 7-23 months; 180 iron and folic acid tablets (60 mg iron and 400 mg folic acid) tablets to each pregnant woman after first trimester and up to 180 for each breastfeeding woman per year, as well as 104 tablets to each adolescent girl; deworming treatment for children aged 1-5 years, adolescent girls, pregnant women after first trimester.
223479550|NCT02597608|OTHER|UPPR: Control|No interventions provided.
223479551|NCT03528941|DRUG|Lamivudine|Patients who received lamivudine to prevent hepatitis B
223479552|NCT03528941|OTHER|No prophylaxis|Patients who did not receive any prophylaxis to prevent hepatitis B
223479553|NCT01610518|DIETARY_SUPPLEMENT|oat beta-glucan|4g dose for each arm of trial. Form (volume and viscosity) varies between arms. 2h acute trial beginning between 8 and 10 am. Minimum 1 day wash out between arms.
223479554|NCT01610518|DIETARY_SUPPLEMENT|Placebo|Control without beta-glucan. Form (volume) varies between arms. 2h acute trial beginning between 8 and 10 am. Minimum 1 day wash out between arms.
223479555|NCT06579300|DRUG|ABBV-1088|Oral Capsule
223479556|NCT06579300|DRUG|Placebo for ABBV-1088|Oral Capsule
223479557|NCT06579300|DRUG|Itraconazole (ITZ)|Oral Capsule
224166792|NCT01902836|BIOLOGICAL|Conventional treatment plus DLE|"Paediatric patients with diagnosis of atopic dermatitis according to Hanifin and Rajka and evaluated with SCORAD as moderate atopic dermatitis were included. Patients were randomized and received in a double blind placebo-controlled treatment:~Group 1: Conventional treatment plus DLE Conventional Treatment: oral Cetirizine 0.25mg/kg, every day, for 4 weeks; chlorpheniramine 0.35 mg/Kg, daily divided in 3 doses, for 4 weeks; and topical Methylprednisolone 0.1% over affected skin area, every 12h for 10 days, then every 24h for 10 days and then every 48h for 10 days and suspend; plus oral DLE (Transferon) (2mg/5mL), every day for 5 days, then every 72hrs to complete one month"
224166793|NCT01902836|BIOLOGICAL|Conventional treatment plus placebo|Group 2: Conventional treatment plus placebo. Conventional treatment: Cetirizine 0.25mg/kg oral, every day, for 4 weeks; chlorpheniramine 0.35 mg/Kg, daily divided in 3 doses, for 4 weeks; topical Methylprednisolone 0.1% over affected skin area, every 12h for 10 days, then every 24h for 10 days and then every 48h for 10 days and suspend; and oral placebo, every day for 5 days, then every 72hrs to complete one month.
224166794|NCT02982642|DRUG|1612 capsule|Subjects will be assigned 1612 capsule,3 capsules per time(0.38g per capsule), 3 times per day.1612 capsule is a Chinse herbal medicine,which can tonification of spleen and kidney, mainly contains shudihuang(Rehmannia glutinosa),shanyao(Dioscorea opposita),shichangpu(Uncaria rhynchophylla)and so on,
224166795|NCT02982642|DRUG|Placebos|Subjects will be assigned placebo identified to 1612 capsule,3 capsules per time, 3 times per day
224166796|NCT00651768|DRUG|budesonide/formoterol|
224166797|NCT00651768|DRUG|Symbicort pMDI + budesonide HFA pMDI|Symbicort 2 X 160/4.5mcg \& budesonide HFA pMDI 4 X 160mcg
223584519|NCT00402493|DRUG|Ibuprofen|ibuprofen 200mg
223584520|NCT02920957|DEVICE|comfilcon A|contact lens
223584521|NCT02920957|DEVICE|senofilcon C|contact lens
224166798|NCT01316380|DRUG|placebo|To evaluate efficacy and safety of 2.5 and 5 mcg tiotropium versus placebo delivered via Respimat inhaler
223479558|NCT03428373|DRUG|Rivaroxaban|Rivaroxaban 10mg daily
223479559|NCT03428373|DRUG|ASA|ASA 81mg
223479560|NCT04677257|PROCEDURE|PCI, invasive coronary physiology and CMR|Patients with acute STEMI will undergo invasive assessment of coronary physiology (IMR and CFR) following successful primary PCI and CMR within a week of the acute event
223479561|NCT03163966|DRUG|CR6086|oral CR6086 capsules
223479562|NCT03163966|DRUG|Methotrexate|oral Methotrexate tablets
223479563|NCT03163966|DRUG|Placebo|oral CR6086 Placebo capsules
223479564|NCT04375046|DRUG|Recombinant Bacterial ACE2 receptors -like enzyme of B38-CAP (rbACE2)|In this study, the experimental group will receive 0.4 mg/kg rbACE2 IV
223479565|NCT05813561|DRUG|DWP14012|DWP14012 40mg
223479566|NCT03607318|BEHAVIORAL|iASIST|Integrated Alcohol and Suicide Intervention for Suicidal Teens
223479567|NCT02739126|PROCEDURE|Radial EBUS biopsy|Radial EBUS is an endobronchial USS which is used to obtain biopsies from a peripheral lung mass.
223479568|NCT02739126|DEVICE|Types of Radial Ultrasound probes|The Radial USS probe comes in two sizes. A thick USS probe that is 1.7mm and the thin USS is 1.4mm in diameter.
223479569|NCT00110708|DRUG|Oralgam (human immunoglobulin)|
224166799|NCT01316380|DRUG|tiotropium 2.5 mcg|To evaluate efficacy and safety of 2.5 and 5 mcg tiotropium versus placebo delivered via Respimat inhaler
223479570|NCT06080126|OTHER|Control: per usual practice|160 patients were included as per usual practice.
223479571|NCT06080126|OTHER|Intervention MAF|160 patients were included with MAF intervention.
223479572|NCT05100563|DRUG|50 mg naltrexone|Medication combined with twice a week psychotherapy
223479573|NCT00390715|DRUG|chemotherapy|
223479574|NCT05803707|BEHAVIORAL|Home-based Adapted Physical Activity|There will be 8 weekly sessions at a time defined in advance for the same group and for the 8 sessions
223584522|NCT02472236|DRUG|PEX168|200µg,injected subcutaneously,once a week.
224166800|NCT01316380|DRUG|tiotropium 5 mcg|To evaluate efficacy and safety of 2.5 and 5 mcg tiotropium versus placebo delivered via Respimat inhaler
223479575|NCT00067834|DEVICE|Pulsing electromagnetic field (PEMF)|
223479576|NCT01414296|DRUG|PSMA ADC|PSMA ADC administered IV
223479577|NCT00696033|DRUG|Diazepam|Diazépam drug (0,3 mg/kg) on a single oral intake
223479578|NCT00696033|DRUG|Lorazepam|Lorazépam drug (0,038 mg/kg) on a single oral intake
223479579|NCT00696033|DRUG|placebo|lorazépam placebo or Diazépam placebo
223479580|NCT05470504|DRUG|Pegvisomant|30 mg subcutaneously every day for 4 weeks.
223479581|NCT05469490|RADIATION|Stereotactic Body Radiotherapy (SBRT)|SBRT is specialize radiation that is effective for ablating tumors at primary and metastatic locations that increases antigen uptake/processing/presentation.
223479582|NCT05469490|DRUG|navoximod|A small molecule inhibitor with potent inhibition of IDO1 enzymatic activity as shown both in vitro and in vivo. As the main function of IDO1 is the regulation of acquired immune tolerance, and its expression in tumor- and dendritic cells in tumor draining lymph nodes negatively correlates with cancer prognosis and survival, navoximod-mediated IDO1 inhibition may restore immune reactivity towards tumors.
223479583|NCT05469490|DRUG|NLG802 (indoximod Prodrug)|An anti-tumor immunomodulator with the active ingredient of 1-methyl-D-tryptophan (NSC- 721782, 1-MT), which is an inhibitor of the indoleamine 2,3-dioxygenase (IDO) pathway that increases the bioavailability of indoximod by leveraging existing mechanisms of absorption, increasing the exposure of indoximod.
223584523|NCT02472236|DRUG|Digoxin|0.5mg,oral,two times.
223584524|NCT03449433|DRUG|LY900014|Administered SC
223584525|NCT03449433|DRUG|Insulin Lispro|Administered SC
223584526|NCT03449433|DRUG|Insulin Aspart|Administered SC
223584527|NCT03449433|DRUG|Insulin Aspart|Administered SC
223584528|NCT05433740|DEVICE|Proseal Laryngeal mask fixation|fixation with Proseal Laryngeal mask adjustable ligament
223584529|NCT01958892|PROCEDURE|TURP, TUERP|
223584530|NCT04254120|BEHAVIORAL|Cognitive-behavioral therapy|Psychological treatment focusing on changing cognitions and behaviors using information processing theory and learning theory approaches.
223584531|NCT04254120|BEHAVIORAL|Integrated motivational interviewing and cognitive-behavioral therapy|Motivational interviewing is a psychological treatment approach focusing on increasing motivation by eliciting patient talk favoring behavior change and resolving patient ambivalence about change.
223584532|NCT01345682|DRUG|Afatinib|Once daily
223584533|NCT01345682|DRUG|Methotrexate|Weekly
223584534|NCT05042609|DRUG|TRS01|TRS01 eye drops Dosed four times a day (QID)
223584535|NCT05042609|DRUG|FDA approved steroid eye drop (masked)|FDA approved steroid eye drop Dosed four times a day (QID)
223479584|NCT04249843|DRUG|BGB-3245|administered orally (PO)
223584536|NCT02643823|BIOLOGICAL|hUC-MSC + DMARDs|Patients will be treated by conventional drugs (DMARDs) for alleviating disease. Combinated with a single dose of 2×107 hUC-MSC will treated to patients, IV, Repeat every weeks for four times.
223584537|NCT02643823|DRUG|DMARDs|Patients will be treated by conventional drugs (DMARDs) for alleviating disease.
223584538|NCT00795288|DRUG|Simvastatin, 80 mg/day for 21 days|Active treatment group
223584539|NCT00795288|DRUG|placebo|Control group
224166801|NCT00565240|DRUG|Marvelon|oral contraceptive
224166802|NCT00565240|DRUG|Nuvaring|contraceptive vaginal ring
224166803|NCT00565240|DRUG|Letrozole|Aromatase Inhibitors
224166804|NCT02240992|BIOLOGICAL|PBSC|
224166805|NCT02240992|BIOLOGICAL|MSCs|
224166806|NCT00000767|BIOLOGICAL|TBC-3B Vaccine|
224166807|NCT00000767|BIOLOGICAL|Smallpox Vaccine|
224305284|NCT01172119|DEVICE|Biofreedom Drug Eluting Stent|Biofreedom DES with a standard dose of Biolimus A9TM
224305285|NCT01172119|DEVICE|Biofreedom Drug Eluting Stent|Biofreedom DES with a low dose of Biolimus A9TM
224305286|NCT01172119|DEVICE|Tuxus Liberte Drug Eluting Stent|Standard paclitaxel dose Taxus Liberte DES
224305287|NCT00190190|PROCEDURE|With Peeling of Limiting the Intern of the Retina|With Peeling of Limiting the Intern of the Retina
224166808|NCT04594304|BEHAVIORAL|Behavioral: Usual care plus eToolkit|A baseline e-survey will be sent to participants prior to their scheduled appointment to collect baseline alcohol/tobacco use levels as well as a series of questions evaluating precursors to behaviour change. If randomized into the intervention group, patients will be sent a link to a tailored toolkit based on their behaviours, motivation to change and other pertinent factors. Patients who identify as non-smokers and meet the low-risk drinking guideline, will complete a third screening survey for physical activity. The cumulative patient profile (CPP) status for the patient for alcohol/smoking will be automatically updated post-baseline survey, and the PCP will receive a notification via EMR about the status update. For patients identifying with risky behaviours, the PCP will receive a prompt to update the CPP for the patient and will receive a link, embedded in the EMR, to a PCP-facing toolkit that facilitates evidence-based intervention.
224166809|NCT05447260|DRUG|Ruxolitinib|Dosage based on platelet count
224166810|NCT05838820|DIAGNOSTIC_TEST|Nine-Hole Peg Test|The Nine-Hole Peg Test is a standardized test that measures manual dexterity and finger movement speed in individuals with hand impairments. The test involves the placement of nine pegs in a pegboard, one at a time, and then removal of each peg as quickly as possible using one hand. The test is timed, and the time required to complete the test provides an indication of manual dexterity and finger movement speed. The Nine-Hole Peg Test has been previously validated and is commonly used in clinical practice.
224166811|NCT05838820|DIAGNOSTIC_TEST|Jebsen-Taylor Hand Function Test|is a standardized test that assesses fine motor skills and functional abilities of the hand. The test involves the completion of seven subtests, including writing, simulated page turning, picking up small objects, stacking checkers, lifting large objects, simulated feeding, and stacking cans. Each subtest is timed, and the time required to complete each subtest provides an indication of hand function. The Jebsen-Taylor Hand Function Test has been previously validated and is commonly used in clinical practice.
224166812|NCT04929847|OTHER|Self-prepared emollient|The emollient is hypo-allergenic, free of perfume and has very high hydrating capacities together with antioxidants.
224166813|NCT04917731|DRUG|Botulinum toxin type A|Botox injected at digital artery
224166814|NCT03333512|BEHAVIORAL|Nap|Looking at the difference between continuous sleep opportunities and split-sleep opportunities.
224166815|NCT04669509|DIAGNOSTIC_TEST|Liver function tests|Patients' age, gender, comorbidity, Acute Physiology and Chronic Health Evaluation II (APACHE II), Sequential Organ Failure Assessment (SOFA) scores when first admitted to the ICU, hemogram parameters (white blood cell count, neutrophil, lymphocyte, hemoglobin, platelet count), coagulation parameters (prothrombin time, activated partial thromboplastin time and D-dimer, blood biochemistry results (C-reactive protein, lactate dehydrogenase, creatine kinase , alanine aminotransferase, aspartate aminotransferase, total bilirubin, direct bilirubin and indirect bilirubin), procalcitonin and ferritin levels will be recorded. In addition, the number of days spent in the ICU and whether mortality develops or not will be recorded. It will also be recorded whether mortality develops on day 7 and day 28.
224166816|NCT00397891|DRUG|bapineuzumab|The dose cohorts are as follows: 0.15 mg/kg AAB-001; 0.5 mg/kg AAB-001; 1.0 mg/kg AAB-001. Placebo is vehicle (all ingredients except active). In each dose cohort, designated as groups 1 to 3, study drug (AAB-001 or placebo) will be administered as an intravenous infusion over 1 hour.
224166817|NCT00397891|DRUG|bapineuzumab|The dose cohorts are as follows: 0.15 mg/kg AAB-001; 0.5 mg/kg AAB-001; 1.0 mg/kg AAB-001. Placebo is vehicle (all ingredients except active). In each dose cohort, designated as groups 1 to 3, study drug (AAB-001 or placebo) will be administered as an intravenous infusion over 1 hour.
224166818|NCT00397891|DRUG|bapineuzumab|The dose cohorts are as follows: 0.15 mg/kg AAB-001; 0.5 mg/kg AAB-001; 1.0 mg/kg AAB-001. Placebo is vehicle (all ingredients except active). In each dose cohort, designated as groups 1 to 3, study drug (AAB-001 or placebo) will be administered as an intravenous infusion over 1 hour.
224166819|NCT00845299|DRUG|Latanoprost punctal plug|Control of IOP compared to baseline for the experimental dose of Latanoprost punctal plug for 6 weeks or until loss of efficacy.
224166820|NCT00845299|DRUG|artificial tears preserved with Benzalkonium Chloride|
224166821|NCT02050672|DIETARY_SUPPLEMENT|Myo-inositol|
223479585|NCT04126525|DRUG|Pyrotinib|dual HER2 blockade in the neoadjuvant setting
223479586|NCT00626145|PROCEDURE|saline infusion|Patients receive intracoronary injections of saline 7 days after PCI.
223479587|NCT00626145|PROCEDURE|autologous bone marrow mononuclear cells infusion|Patients receive intracoronary injections of autologous bone marrow mononuclear cells 7 days after PCI.
223479588|NCT00701363|DRUG|Lanreotide Autogel 120 mg|120mg, injections every 6 weeks, then depending on IGF-1 results at Week 24
223479589|NCT04759131|DRUG|efanesoctocog alfa (BIVV001)|Pharmaceutical form: solution for injection Route of administration: IV
224166822|NCT02050672|OTHER|untreated|
224166823|NCT07102355|OTHER|Experimental: Group A = Dry Cupping|Dry cupping, originating in Middle Eastern and Asian countries, gained popularity in the United States after the 2016 Summer Olympics. It has two main forms: wet and dry cupping. Wet cupping involves laceration of the skin, while dry cupping uses negative pressure to pull the skin into the cup. Cupping is used to reduce musculoskeletal or myofascial pain, with the most accepted mechanism being localized hyperemia, which improves microcirculation and promotes healing
224305288|NCT00190190|PROCEDURE|Internal limiting membrane peeling|Traditional Procedure Without Peeling of Limiting
224305289|NCT05254600|BEHAVIORAL|RISE for Nurse Leaders Program|Psychoeducational sessions designed to impact resilience, insight, self-compassion, and empowerment
223479590|NCT00049569|DRUG|cytarabine|Given IT
223479591|NCT00049569|DRUG|methotrexate|Given IT
223479592|NCT00049569|DRUG|vincristine sulfate|Given IV
223479593|NCT00049569|DRUG|prednisone|Given PO
223479594|NCT00049569|DRUG|pegaspargase|Given IM
223479595|NCT00049569|DRUG|doxorubicin hydrochloride|Given IV
223479596|NCT00049569|DRUG|imatinib mesylate|Given PO
223479597|NCT00049569|DRUG|cyclophosphamide|Given IV
223479598|NCT00049569|DRUG|etoposide|Given IV
223479599|NCT00049569|BIOLOGICAL|filgrastim|Given SC
223479600|NCT00049569|DRUG|leucovorin calcium|Given IV
223479601|NCT00049569|DRUG|asparaginase|Given IM
223479602|NCT00049569|DRUG|therapeutic hydrocortisone|Given IT
223479603|NCT05347628|DRUG|PLB1004|PLB1004 is a capsule in the form of 10mg and 40mg.
224166824|NCT07102355|OTHER|Experimental: Group B = Graston Technique|Instrument-assisted soft tissue mobilization (IASTM), derived from Cyriax cross-friction massage, is a popular alternative to traditional manual therapy techniques, with its first controlled study published in 1997 (Seffrin \&amp; Gardiner-Shires, 2019) .The Graston Technique(GT), also known as instrument-assisted soft tissue mobilization (IASTM), is used by chiropractors, doctors, and therapists to alleviate pain and range-of-motion restrictions caused by musculoskeletal injuries and scar tissue. (McKivigan, J. M., \&amp; Tulimero, G. et al. , 2020) . The Graston technique, is also used to alleviate upper cervical pain.
224166825|NCT02451254|PROCEDURE|circumferential ablation|circumferential ablation of the pulmonary veins
224166826|NCT02451254|DEVICE|SVT ablation|SVT ablation
224166827|NCT02456571|DEVICE|CTC biomarker expression prevalence|
224166828|NCT04756349|OTHER|composite resin restoration|All patients will receive adhesive composite resin restorations. There will be 3 groups (different adhesives): Clearfil SE, Optibond All-in-One and Prime \& Bond Universal.
223479604|NCT05914376|BIOLOGICAL|Recombinant human IL-21-expressing oncolytic vaccinia virus injection|hV01 is a recombinant vaccinia virus with deletions of the viral thymidine kinase (TK) and viral growth factor (VGF) genes and insertion of the human IL-21 gene.
223744867|NCT05074693|OTHER|INSIGHT (Control) App|"A standard of care control intervention was developed using the INSIGHT platform. This app contains a library of educational videos that cover topics such as meditation and mindfulness, as well as general stress reduction techniques. Additionally, participants have access to a Report Distress feature that enables them to report moments when they are feeling high levels of stress. Finally, participants will be able to report any COVID-19 related symptoms they experience using a COVID-19 symptom tracker feature. Participants assigned to this condition will received 2 daily EMAs, during which they will be prompted to watch one of the aforementioned educational videos."
224166829|NCT03476928|DRUG|Vilaprisan (BAY1002670)|2mg, once daily, oral
223479605|NCT05196386|BEHAVIORAL|Admission conciliation interview|Previous treatment conciliation at hospital admission
223479606|NCT05196386|BEHAVIORAL|Discharge conciliation interview|Allocated treatment during hospital stay
223744868|NCT02014363|DRUG|ETS6103 (low dose)|
223744869|NCT02014363|DRUG|ETS6103 (high dose)|
223744870|NCT02014363|DRUG|Amitriptyline|
223744871|NCT03773887|OTHER|collection of liver biopsies collection of blood samples|blood and ascites samples; extraction of explants, hepatic resection parts; hepatic parenchyma on liver biopsies
223744872|NCT02433756|DEVICE|CRTD|
223744873|NCT03938584|DIETARY_SUPPLEMENT|Vitamin C|Just after induction of anesthesia in the OR, subjects will be administered a single intravenous (IV) dose of Vitamin C at 66mg/kg/hr for 2 hours during surgery. Post-operatively (beginning the morning after surgery) Vitamin C Treatment Group subjects will receive a 4 week prescription of oral, liquid Vitamin C, 500mg by mouth two times a day. These dosages are known to be safe and effective.89-91
224166830|NCT07057817|DEVICE|Cerament G|Partial Calcanectomy plus cerament G
224166831|NCT07057817|OTHER|Standard Surgical Managment|Partial Calcanectomy as standard of care
224166832|NCT04142944|DEVICE|Dexcom G6 with alert|Dexcom G6 CGM device with the predictive hypoglycaemia alert function
224166833|NCT04142944|DEVICE|Dexcom G6 without alert|Dexcom G6 CGM device without the predictive hypoglycaemia alert function
224166834|NCT05136040|DRUG|Bupivacaine|Two Different Low-Doses Of Isobaric Bupivacaine ( Group İzobarik bupivakain (5 mg) + fentanil and Group İzobarik bupivakain (7 mg)+ fentanyl ) were administered to the subarachnoid space
224166835|NCT06942572|GENETIC|SB-007|Subretinal Administration of SB-007
224166836|NCT04339725|OTHER|DNA extraction|Extraction fecal DNA and compare disease group to normal group
224166837|NCT05104086|DEVICE|ultrasound elastography|strain ratio and resistivity index
224166838|NCT06949306|OTHER|"Bracelet, assistant, APP: the golden triangle of smart life"|The lifestyle intervention was carried out through the bracelet, Little Assistant and Keyhealth APP for 24 weeks, and the daily data synchronization of the APP and weekly AI feedback were performed. After 24 weeks, blood glucose, blood lipid, blood pressure, CAI and other indicators were monitored.
224166839|NCT06949332|DEVICE|electromyography|In this study, surface Electromyography (EMG) was employed to assess the electrical activity of the masseter muscles. Surface EMG is a physiological measurement technique that allows for the recording of electrical potentials generated by muscle fiber depolarization through non-invasive electrodes placed on the skin. This method is widely accepted for objectively determining muscle activation levels and timing, enabling the quantitative analysis of changes in masseter muscle activity during the performance of various Rocabado exercises in this study. The validity and reliability of the EMG device utilized (Noraxon USA Inc., Scottsdale, AZ, USA) have been established in the literature.
224166840|NCT06948162|DEVICE|dental-dedicated MRI (ddMRI)|This descriptive observational research is comparative in design, that is comparing existing standard clinical dental images, not obtained in this study, to test (i.e., ddMRI) images.
224166841|NCT04901104|DRUG|Thymosin Alpha1|Drug interventions have been done in previous clinical studies
224166842|NCT00479934|DRUG|imatinib mesylate|6 month treatment with 400mg/day (per os)
224166843|NCT05375825|PROCEDURE|Cytoreductive surgery|Cytoreductive surgery: minimally invasive (VATS/robotic) or open (thoracotomy)
224166844|NCT05375825|DRUG|LMB-100|1000 mcg/mL (DL1) post-operative dose as a single 90-minute normothermic intrathoracic perfusion using a closed circuit and roller pump with a heat exchanger following maximal cytoreductive surgery
224305290|NCT00271154|DEVICE|Cardiac Resynchronization Therapy (CRT) Device or Implantable Cardioverter Defibrillator (ICD) with CRT|All randomized patients will be implanted with a market-released Medtronic CRT or CRT/ICD device.
223479607|NCT05196386|BEHAVIORAL|Targeted pharmaceutical interview|Specific information about treatment delivered by pharmacist
223479608|NCT00004921|BIOLOGICAL|filgrastim|
223479609|NCT00004921|DRUG|carboplatin|
223479610|NCT00004921|DRUG|cyclophosphamide|
223479611|NCT00004921|DRUG|melphalan|
223479612|NCT00004921|DRUG|paclitaxel|
223479613|NCT00004921|PROCEDURE|adjuvant therapy|
223479614|NCT00004921|PROCEDURE|bone marrow ablation with stem cell support|
223479615|NCT00004921|PROCEDURE|peripheral blood stem cell transplantation|
224166845|NCT05375825|DIAGNOSTIC_TEST|Immunohistochemical Assay for Mesothelin|Performed at screening to determine mesothelin expression; separate testing of tumor mesothelin expression will be assessed retrospectively in resected tumor tissues. The device is not diagnostic; protocol assessment of mesothelin expression status will only be used to help to increase the possibility that all persons enrolling on the study might derive benefit from therapy.
224166846|NCT06384352|DRUG|YL211|Patients will be treated with YL211 intravenous (IV) infusion.
224166847|NCT02527031|OTHER|ECMO Insertion on pre hospital setting|ECMO Insertion on pre hospital setting
224166848|NCT02527031|OTHER|In Hospital ECMO|ECMO Insertion on in hospital setting for a refractory cardiac arrest
224166849|NCT05501405|OTHER|Electroencephalogram and eye-tracking recordings|"Participants will perform two tasks: recognize the expression (explicit recognition of the expression) or detect the change in color of the cross (implicit processing of the expression). Each participant will perform two tasks x 6 models x 5 expressions, i.e. 60 stimulations, for a stimulation duration of approximately 30 minutes.~Recognition of the emotional facial expression with a choice among 5 possibilities. Two neutral faces of the same person will be presented side by side. When the participant has looked at the central fixation cross for one second, one of the two faces will produce an expression. The participant will have to indicate as quickly as possible which expression it is, while his or her eye movements are recorded. Each participant will have to recognize 5 expressions x 8 models, i.e. 40 trials for a duration of approximately 5 to 10 minutes"
224166850|NCT06031584|DRUG|BL-M07D1|BL-M07D1 was administered by intravenous infusion every 3 weeks in 3-week cycles.
224166851|NCT05317247|DIAGNOSTIC_TEST|Cough sounds|The investigators will discover a cough audio signature and then validate it.
224166852|NCT06464276|OTHER|No intervention|No intervention
224166853|NCT00003309|BIOLOGICAL|filgrastim|
224166854|NCT00003309|DRUG|cisplatin|
224166855|NCT00003309|DRUG|cyclophosphamide|
224166856|NCT00003309|DRUG|etoposide|
223479616|NCT06468358|DRUG|LB1410|anti-PD-1/TIM3 bispecific antibody
223479617|NCT06468358|DRUG|LB4330|anti-claudin18.2/IL-10 fusion protein
223479618|NCT01072591|DRUG|MEDI-578|intravenous infusion, once
223479619|NCT01072591|DRUG|Placebo for MEDI-578|Intravenous infusion, once
223479620|NCT03019380|DEVICE|removing cerumen from external ear (Wondertip)|The wondertip will be coiled into the external ear canal with the purpose of grasping and evacuating the cerumen. Following the evacuation, the depth of the external ear canal will be messured.
223479621|NCT00000965|DRUG|Zidovudine|
223479622|NCT04226170|DRUG|DAS-001|ondansetron + pyridostigmine
223479623|NCT05598697|BEHAVIORAL|Life Skills Building (LSB) curriculum for males|"The LSB curriculum offers ten weekly 90-minute sessions. Topics include effective communication, gender roles, power dynamics in the household; work-life balance and time management; conflict resolution; household decision making. The LSB teachers are trained in facilitation techniques to deliver the sessions.~All male study participants attending LSB curriculum classes are married to BISP-CT clients.~For men, the MEWE intervention provides access to the LSB curriculum only."
223479624|NCT05598697|BEHAVIORAL|Life Skills Building (LSB) curriculum for females|"The LSB curriculum offers ten weekly 90-minute sessions. Topics include effective communication, gender roles, power dynamics in the household; work-life balance and time management; conflict resolution; household decision making. The LSB teachers are trained in facilitation techniques to deliver the sessions.~All female study participants attending LSB curriculum classes are BISP-CT clients.~For females, the MEWE intervention comprises access to LSB curriculum + BISP CTs."
223479625|NCT05598697|OTHER|Cash transfer to adult females|The BISP intervention offers access to quarterly unconditional cash transfers to adult females.
224166857|NCT00003309|DRUG|vincristine sulfate|
224166858|NCT00003309|PROCEDURE|adjuvant therapy|
224166859|NCT00003309|RADIATION|radiation therapy|
224166860|NCT06771869|DIAGNOSTIC_TEST|Sodium balance|cumulative sodium balance and cumulative fluid balance will be estimated in the first three days after admission
224166861|NCT06797076|BEHAVIORAL|Health enSuite Headache|"The program consists of treatment modules delivered over 8 weeks. Modules include topics such as Headaches and Triggers, Relaxation, Breathing, Changing Thoughts, Imagery, Problem Solving, Nutrition, Sleep, Exercise, Medication, and more. Each module features sections like Goals, Getting Started, Let's Talk, and a Quiz, with Let's Practice in four modules. Intervention participants track headaches using a structured tracker to log impacts, daily events (e.g., exposure, strategies, medication), and notes. Control group participants track headaches only at baseline, two months, and five months post-randomization. Weekly reminders (nudges) encourage app usage, with the same frequency for all users. Reports summarizing daily headache data are available to participants."
223479626|NCT05047900|DIAGNOSTIC_TEST|Rapid antigen testing kit|COVID-19 Saliva Antigen Rapid Test Tigsun COVID-19 Speichel Antigen-Schnelltest
223479627|NCT03692949|DRUG|LY3451838|Administered IV Part A
223479628|NCT03692949|DRUG|LY3451838|Administered IV Part A
223479629|NCT03692949|DRUG|LY3451838|Administered IV Part A
223479630|NCT03692949|DRUG|LY3451838|Administered IV Part A
223479631|NCT03692949|DRUG|LY3451838|Administered IV Part A
223479632|NCT03692949|DRUG|LY3451838|Administered IV Part A
223479633|NCT03692949|DRUG|LY3451838|Administered SC Part B
223479634|NCT03692949|DRUG|Placebo|Administered IV in Part A and SC in Part B
223479635|NCT06425237|OTHER|music therapy|standard patient care in interventional radiology associated with a well-being atmosphere with the implementation of music therapy (soothing sound environment) in the preparation box and in the examination room.
223479636|NCT06425237|OTHER|aromatherapy|standard patient care in interventional radiology associated with a well being atmosphere with the implementation of aromatherapy (essential oil of Ylang Ylang) in the preparation box and in the examination room.
223479637|NCT05312996|OTHER|Heart Rate Variability|Caretaker Heart Rate Variability ECG wrist monitor and chest patch.
223479638|NCT05312996|OTHER|Galvanic Skin Response (Biopac)|Galvanic Skin Response- measuring autonomic response-via perspiration
224166862|NCT05442060|BIOLOGICAL|30 μg OBI-833/100 μg OBI-821|Each subject in the OBI-833/OBI-821 + erlotinib combination arm will be treated with OBI-833/OBI-821 weekly for 4 doses (Weeks 1, 2, 3, 4), then every 2 weeks for 2 doses (Weeks 6, 8), then every 4 weeks for 4 doses (Weeks 12, 16, 20, 24), and then every 8 weeks until documented disease progression, intolerable adverse events (AEs)/toxicity, consent withdrawal, death, loss to follow-up, or up to 80 weeks from randomization.
224166863|NCT05442060|DRUG|Erlotinib (150 mg daily)|All subjects in both arms will continue to receive erlotinib as the background therapy (150 mg daily).
224166864|NCT06793449|BIOLOGICAL|anti-BCMA CAR-T|Autologous BCMA-directed CAR-T cells, infusion intravenously at a target dose of 2.0-4.0 x 10\^6 anti-BCMA CAR+T cells/kg.
224166865|NCT06793449|BIOLOGICAL|ASCT|Autologous stem cell infusion
224166866|NCT06959160|OTHER|Atlanto-occipital manipulation|Participants in the first group received atlanto-occipital manipulation. The patient was positioned in a supine position, with the head rotated to one side. The therapist placed the middle and ring fingers of one hand on the patient's mastoid process, while the palm of the other hand made contact with the patient's jawline and cheek. A gentle traction force was applied to the cranial region using both hands. When the therapist sensed joint tension, a high-velocity, low-amplitude thrust was delivered in the direction of the traction with a slight rotational force. The procedure was performed bilaterally and lasted approximately 5 minutes.
224166867|NCT06959160|OTHER|Cervical mobilization|Participants in the second group underwent Grade II-III cervical mobilization techniques, administered over a period of 10 minutes. The patient was positioned in a supine position, and the physiotherapist performed 10 minutes of Grade II-III mobilizations with an upward and downward incline (postero-anterior and antero-posterior mobilizations following the movement plane of the cervical zygapophyseal joints).
224166868|NCT06959160|OTHER|Trigger point therapy|Participants in the third group received trigger point therapy, which included ischemic compression followed by myofascial stretching on the upper trapezius muscle. The patient was positioned in a supine position, and the physiotherapist performed 10 minutes of Grade II-III mobilizations with an upward and downward incline (postero-anterior and antero-posterior mobilizations following the movement plane of the cervical zygapophyseal joints).
224166869|NCT06114043|OTHER|Conservative treatment with orthopedic aid/wide shoe for participants with mild to moderate hallux valgus|60 participants will receive conservative treatment with orthopedic aid/wide shoe. Participants will be followed for 2 years.
224166870|NCT06114043|OTHER|Operation for mild to moderate hallux valgus|60 participants will receive the traditional operative treatment for the deformity. Participants will be followed for 2 years.
224166871|NCT06794073|DEVICE|Multimodal Thermal Therapy|The high-burden tumor is identified as the target lesion for treatment. A pre-treatment biopsy of the target lesion is performed to obtain tumor tissue. Multimodal ablation therapy of the target lesion is conducted under CT guidance. The treatment procedure follows the tumor ablation protocol using the multimodal therapy radiofrequency temperature-controlled mode.
224166872|NCT04547816|PROCEDURE|Biofeedback therapy|Biofeedback therapy is a procedure when the patient is taught to make proper squeezing by adequate increase of intra-abdominal and rectal pressures and relaxation of the muscles of the pelvic floor. This procedure is widely described and is to be performed with the use of devices registered for this purpose Urostim and WPM Solar, MMS, the Netherlands
224166873|NCT04547816|PROCEDURE|Tibial neuromodulation|TNM is a standard procedure that is previously described as an effective method to treat functional insufficiency of the anal sphincter. It acts on the lumbosacral nerve plexus with an electric current through the posterior tibial nerve of one of the patient's limbs. For the study purpose a registered device for electric therapy (BioBravo, MTR Plus Vertriebs GmbH, Germany) is to be used.
224166874|NCT04547816|BEHAVIORAL|Pelvic floor muscles training|"PFMT is a complex of 5 exercises aimed to make functional training of pelvic floor muscles. This complex does not require additional equipment. It may be performed at home. The patients will be trained to perform this complex of exercises by a healthcare provider.~The complex of physical therapy consists of a single basic exercise for training coordinated muscle tension of abdominal wall and relaxation of the pelvic floor muscles, and 4 exercises to increase the contractility of pelvic floor muscles without additional involvement of the muscles of the abdominal wall. This allows to coordinate and consciously control the contraction and relaxation of the pelvic diaphragm. Initial course of training is 10 working days. Than patients continue the intervention for 6 months at home with online monitoring of the correctness and regularity of training."
224166875|NCT04547816|BEHAVIORAL|Diet modification|Diet modification play an important role in the regulation of colonic transit and defecation. Dietary factors may act through faecal bulk by additional stimulation of mechanoreceptors of the rectum. At the same time, adequate intake of vitamins (for example, B12) may improve electric conductivity of nerves and thus impact the tone of pelvic floor muscles. Among other factors known to affect functional state of pelvic floor muscles and colonic transit are dietary fibers, adequate intake of water, regular meal intake. For the study purposes, it is planned to provide standard recommendation based on the national recommended daily allowances according to patients' sex, age and physical activity level.
224166876|NCT06479811|DRUG|68Ga-DOTATATE|68Ga-DOTATATE PET/CT whole-body scanning will be done at at different intervals to monitor disease.
224166877|NCT06479811|DRUG|[203Pb]VMT-alpha-NET|\[203Pb\]VMT-alpha-NET will be given IV 7 days prior to \[212Pb\]VMT-alpha-NET.
223479639|NCT00937196|DRUG|Placebo globuli|placebo globuli administered together with verbal suggestions of a hypotensive drug effect
223479640|NCT00937196|DRUG|Histaminum hydrochloricum globuli|
223479641|NCT05933083|BEHAVIORAL|In-person cardiac rehabilitation|In-person exercise training, health education, and counseling
223479642|NCT05933083|BEHAVIORAL|Telehealth cardiac rehabilitation|Telehealth exercise training, health education, and counseling
223584540|NCT06340490|BIOLOGICAL|RJMty19 (CD19-CAR-DNT cells)|Lentiviral vector-transducted double negative T cells (DNT) to express anti-CD19 CAR. Prior to cellular infusion, each patient received cyclophosphamide and fludarabine lymphodepleting chemotherapy.
223584541|NCT04166539|BEHAVIORAL|Questionnaires|You will be asked to complete a questionnaire about your family history of neurological diseases and current and past physical thinking activities.
223584542|NCT04166539|BEHAVIORAL|Interviews|Behavioral and Memory interviews will take place with the patient.
223584543|NCT04166539|OTHER|Blood draw|Have a sample of blood drawn (4.2-5 tablespoons) for clinical and research tests.
224166878|NCT06479811|DRUG|[212Pb]VMT-alpha-NET|\[212Pb\]VMT-alpha-NET will be given IV on Day 1 of every cycle for 4 cycles total at escalating doses in Phase I and at MTD during dose expansion. One cycle is 8 weeks.
224166879|NCT06150560|DRUG|Losartan|50mg administered orally once daily for 52 weeks.
224166880|NCT06150560|DRUG|Amlodipine|5mg Amlodipine administered orally once daily for 52 weeks.
224166881|NCT06150560|DRUG|Placebo|Oral capsules that contain no active drug ingredients administered orally once daily for 52 weeks.
224166882|NCT03662685|OTHER|Goeckerman Therapy|The Goeckerman regimen consists of exposure to narrowband ultraviolet B (NB-UVB) light phototherapy and application of crude coal tar to the skin 5 days per week. The treatment will occur the UCSF outpatient skin treatment center for approximately 4-5 hours, 5 days a week for 6 weeks (total of 30 sessions). The treatment is consistent with the standard of care Goeckerman treatment protocol at UCSF.
224166883|NCT03662685|DRUG|Crude Coal Tar Only|A topical medication consisting of crude coal tar will be applied to the psoriatic skin under plastic wrap occlusion for approximately up to 4-5 hours, 5 days a week for 6 weeks (total of 30 sessions), at the outpatient skin treatment center at UCSF.
224166884|NCT03662685|DEVICE|Phototherapy Only|Light treatment with narrowband ultraviolet B (NB-UVB) phototherapy three days per week for 12 weeks at the UCSF Phototherapy Center per the standard UCSF phototherapy protocol, in which starting dose is based on the subject's Fitzpatrick skin type and gradually increased as tolerated. Each phototherapy treatment will last approximately from under 1 minute to less than 15 minutes.
224166885|NCT03738878|DRUG|Valsartan|oral valsartan
224166886|NCT03738878|DRUG|LCZ696|oral LCZ696
224166887|NCT03738878|DRUG|Bradykinin|Intra-arterial bradykinin at three graded doses
224166888|NCT03738878|DRUG|Substance P|Intra-arterial substance P at three graded doses
224166889|NCT03738878|DRUG|BNP|Intra-arterial BNP at three graded doses
224166890|NCT03738878|DRUG|Sitagliptin|oral sitagliptin
224166891|NCT06518473|DIAGNOSTIC_TEST|Skin prick test|"Skin Prick Test (SPT): Common allergens including pollen, dust mites, Pet dander and mold.~Serum IgE Levels: Total IgE Peripheral blood eosinophil was defined as an eosinophil count ≥ 5%, Quality of Life Assessment: COPD Assessment Test (CAT)"
224166892|NCT04681248|DRUG|DKN-01|Administered by IV infusion
224166893|NCT05302765|OTHER|Normal Saline Intravenous Fluids|Administration of normal saline intravenous fluids (20 milliliters/kilogram).
224166894|NCT06496854|DRUG|Lorazepam 1 mg|1 mg oral lorazepam, a sedative used to relieve anxiety
224166895|NCT06496854|DRUG|Ibuprofen 800 mg|800 mg ibuprofen, Nonsteroidal anti-inflammatory drug to treat pain
224166896|NCT06198959|DEVICE|Adult blanket plus, MA2220 blanket connected to the Mistral Air, Blower MA1200-PM system.|Evaluate cutaneous heat loss/ gain using thermal flux transducers while volunteers are covered with the Adult Blanket plus, MA2220 blanket connected to the Mistral Air, Blower. MA1200-PM system for 30 minutes.
223584544|NCT04166539|RADIATION|Magnetic Resonance Imaging|Each MR examination takes about 45 minutes and does not require the use of needles, medication or contrast enhancement. You will lie on your back and enter the MR scanner for the study, during which time you will hear knocking noises. People with pacemakers, aneurysm clips, cochlear implants, or metal/foreign objects in their eyes are not permitted to undergo MR studies. We will review your implants and determine your eligibility.
224166897|NCT06198959|DEVICE|Premium adult blanket, 3320 blanket connected to the Mistral Air, Blower MA1200-PM system.|Evaluate cutaneous heat loss/ gain using thermal flux transducers while volunteers are covered with the premium adult blanket, 3320 blanket connected to the Mistral Air, Blower MA1200-PM system.
224166898|NCT06198959|DEVICE|Blanket full body, 30000 blanket connected to the 3M, Bair Hugger, Blower 775|Evaluate cutaneous heat loss/ gain using thermal flux transducers while volunteers are covered with the blanket full body, 30000 blanket connected to the 3M, Bair Hugger, Blower 775 system.
224166899|NCT06198959|DEVICE|FilteredFlo® Air Blanket connected to the WarmAir® Convective Warming system.|Evaluate cutaneous heat loss/ gain using thermal flux transducers while volunteers are covered with the FilteredFlo® Air Blanket connected to the WarmAir® Convective Warming system.
224166900|NCT06198959|DEVICE|Blanket Full Body blanket (CLM0101) connected to the Care Essential, Cocoon, Blower CWS5000 system|Evaluate cutaneous heat loss/ gain using thermal flux transducers while volunteers are covered with the Blanket Full Body blanket (CLM0101) connected to the Care Essential, Cocoon, Blower CWS5000 system.
224166901|NCT05704257|DEVICE|fetoscopy|The fetoscopic arm is described above. All patients will have a laparotomy, exteriorization of the uterus, and a fetoscopic repair of the gastroschisis.
224166902|NCT03872947|BIOLOGICAL|TRK-950|10 mg/kg administered intravenously over 60 minutes (weekly)
224166903|NCT03872947|BIOLOGICAL|TRK-950|5 mg/kg administered intravenously over 60 minutes (weekly)
224166904|NCT03872947|BIOLOGICAL|TRK-950|Treatment Phase: 20 mg/kg administered intravenously over 60 minutes (bi-weekly) Maintenance Phase: 30 mg/kg administered intravenously over 60 minutes (every 3 weeks)
224166905|NCT03872947|DRUG|Irinotecan|Intravenously over 30 - 90 minutes
224166906|NCT03872947|DRUG|Leucovorin|Intravenously over 30 - 90 minutes
224166907|NCT03872947|DRUG|5-FU|Intravenously bolus and intravenously for two days
224166908|NCT03872947|DRUG|Gemcitabine|Intravenously over 30 minutes
224166909|NCT03872947|DRUG|Cisplatin|Intravenously over 60 minutes
224166910|NCT03872947|DRUG|Carboplatin|Intravenously per package insert
224166911|NCT03872947|DRUG|Ramucirumab|Intravenously over 60 minutes
224166912|NCT03872947|DRUG|Paclitaxel|Intravenously
224166913|NCT03872947|DRUG|Nivolumab|Intravenously over 30 minutes
224166914|NCT03872947|DRUG|Pembrolizumab|Intravenously over 30 minutes
224166915|NCT03872947|DRUG|Imiquimod Cream|Topically
224166916|NCT03872947|DRUG|Bevacizumab|Intravenously over 90 minutes for the first dose, over 60 for the second dose and over 30 minutes for all subsequent doses
224166917|NCT03872947|DRUG|PLD|Intravenously over 60 minutes
224166918|NCT05810402|BIOLOGICAL|Liquid Biopsy|"30mL blood sample:~* 1 x 10mL CellSave tube specifically designed for the collection and preservation of CTCs for CellSearch® analysis~* 1 EDTA tube for PBMCs isolation and circulating immune cells study (5mL),~* 2 EDTA tubes and 1 dry tube (15mL) for the preparation of the biobank (serum, plasma and cell)."
224166919|NCT05611242|PROCEDURE|MT+CAS with IV-AP|Mechanical Thrombectomy is a treatment for stroke that removes clots that block large blood vessels. Carotid stenting is a procedure that is deployed within the lumen of the carotid artery which treats the narrowing of the carotid artery. With added intravenous antiplatelet therapy.
224166920|NCT05611242|PROCEDURE|MT+CAS with PO-AP|Mechanical Thrombectomy is a treatment for stroke that removes clots that block large blood vessels. Carotid stenting is a procedure that is deployed within the lumen of the carotid artery which treats the narrowing of the carotid artery. With added oral antiplatelet therapy.
224166921|NCT05611242|PROCEDURE|MT+CAT with PO-AP|Mechanical Thrombectomy is a treatment for stroke that removes clots that block large blood vessels. Carotid stenting is a procedure that is deployed within the lumen of the carotid artery which treats the narrowing of the carotid artery. With added oral antiplatelet therapy
224166922|NCT06845345|OTHER|early time restricted Mediterranean diet|Participants will start with a calorie restricted Mediterranean diet, with an eating window between 8AM till 6PM (early time-restricted eating) for a period of six months. Participants are asked to stop eating at 6PM. This results in a daily fasting window of approximately 14 hours. A daily caloric intake of 500 kcal compared to the calculated energy requirement is assumed to stimulate weight loss.
224166923|NCT06845345|DRUG|Mysimba|Participants will take Mysimba twice daily at a total dose of 32 mg/360 mg naltrexone/bupropion per day for a duration of six months. The dosage will be built up in the first month following the stepped care approach used in the SmPC. Participants receive usual care, including the advice of 60 minutes of exercise per day and standard dietary recommendations according to the guidelines for the Dutch population.
224166924|NCT02632344|DRUG|Pembrolizumab|200 mg will be administered as a 30 minute IV infusion every 3 weeks on day 1 of each cycle after all procedures/assessments have been completed.
224166925|NCT03144206|DRUG|Hyperbaric oxygen|Patients with soft tissue sarcomas will receive HBOT treatment in the immediate postoperative period
223479643|NCT05689645|DRUG|F573 for injection|"The first stage:the first 16 patients with liver injury were given doses of 0.5, 1.0 and 2.0 mg/kg, and the subsequent 9 patients with CHB were given doses of 2.0 mg/kg, with an administration volume of 2 mL and intramuscular injection (IM) according to the efficacy and safety test results of the first 16 patients. The dose was given once a day for 7 days and calculated according to the weight of the last visit.~The second stage:According to the results of Phase I efficacy and safety trials, the dosage was determined to be 0.5 mg/kg and 2.0 mg/kg, the dosage volume was 2 mL, intramuscular injection (IM), once a day for 14 days, and the dosage was calculated according to the weight of the latest visit.~The third stage:The dosage was determined according to the results of the first and second phase efficacy and safety trials. The dosage volume was 2 mL, intramuscular injection (IM), once a day for 28 consecutive days, and the dosage was calculated according to the weight of the latest ."
224166926|NCT02171104|BIOLOGICAL|Stem Cell Transplantation|Infusion given on Day 0
224166927|NCT02171104|DRUG|IMD Preparative Regimen|"* Anti-thymocyte Globulin (ATG)~* Fludarabine~* Busulfan"
224166928|NCT02171104|DRUG|Osteopetrosis Only Preparative Regimen|"* Anti-thymocyte Globulin (ATG)~* Fludarabine~* Busulfan~* Thiotepa"
224166929|NCT02171104|DRUG|Osteopetrosis Haploidentical Only Preparative Regimen|"* Rituximab~* Alemtuzumab~* Busulfan~* Fludarabine"
224166930|NCT02171104|DRUG|cALD SR-A (Standard-Risk, Regimen A)|N-acetylcysteine start day +1 through day +28
224166931|NCT02171104|DRUG|cALD SR-B (Standard-Risk, Regimen B)|N-acetylcysteine start day +1through day +56
223584545|NCT04166539|DIAGNOSTIC_TEST|Echocardiogram|Each echocardiogram takes about 30 minutes. This test uses sound waves to look at your heart. The person doing the test will press on your chest with a machine to obtain the pictures. The pressure may be uncomfortable. The echocardiogram will involve an image enhancement agent infusion to obtain better images.
224166932|NCT02171104|DRUG|cALD HR-D (High-Risk, Regimen C)|N-acetylcysteine and celecoxib start day of admission (prior to conditioning regimen) and continue through day +100
224166933|NCT02171104|DRUG|cALD HR-D (High-Risk, Regimen D)|N-acetylcysteine, celecoxib, vitamin E and alpha lipoic acid start day of admission (prior to conditioning regimen) and continue through day +100
224166934|NCT04065295|DRUG|BI 1356225|Oral Dose
224166935|NCT04065295|DRUG|Placebo|Oral dose
224166936|NCT05509699|DRUG|Surufatinib|The recommended dosage is 250 mg orally once daily (QD) within 1 hour after breakfast for continuous administration.
224166937|NCT05509699|DRUG|Anti-PD-1/L1|Anti-PD-1/L1 therapy, Q3W or Q4W, the same immune checkpoint inhibitor from patients' first-line therapy.
224166938|NCT00638651|DEVICE|1064 nm Nd:YAG laser|The laser used will be a 1064 nm Nd:YAG, with a 10ns pulse, 3mm spot size and 4 joules of energy
224166939|NCT00638651|DRUG|Imiquimod, 5% cream|2 weeks after the laser procedure the imiquimod will be applied 3 times a week for one month
224166940|NCT05110963|BEHAVIORAL|Uniform Standard of Care Counseling|Routine HIV counseling services available to patients with protocol delivered services. Three sessions of patient education monitored for protocol adherence
224166941|NCT05110963|BEHAVIORAL|Behavioral Self-Regulation Skills Counseling|Mobile phone-delivered counseling grounded in Behavioral Self- Regulation Theory to improve retention in HIV care and HIV viral suppression. Counseling is delivered by lay counselors in differentiated health care context. This is a culturally tailored adaptation of CDC disseminated Phone-Delivered Support Counseling for HIV treatment Adherence.
223584546|NCT05011799|BEHAVIORAL|Cancer Educational Materials|Receive prostate cancer educational materials
223584547|NCT05011799|OTHER|Questionnaire Administration|Ancillary studies
224166942|NCT05110963|BEHAVIORAL|Behavioral Self-Regulation Skills Counseling + Stigma Management|Mobile phone-delivered counseling grounded in Behavioral Self- Regulation Theory with stigma management to improve retention in HIV care and HIV viral suppression. Counseling is delivered by lay counselors in differentiated health care context with added components directly targeting stigma-related experiences and concerns.
224166943|NCT06319534|BEHAVIORAL|Comprehensive rehabilitation|All the participants are provided with the comprehensive rehabilitation (routine rehabilitation and swallowing function training). The routine rehabilitation included intervention for risk factors (blood pressure, blood lipids, blood glucose, smoking and alcohol restriction, exercise, etc.).
223584548|NCT05011799|OTHER|Educational Intervention|Attend peer-led education sessions
224305291|NCT02498106|DIETARY_SUPPLEMENT|Orthica Soft Multi Mini and Orthica Fish EPA Mini|daily intake of 2 Orthica Soft Multi Mini capsules (containing vitamins \[B1, B2, B3, B5, B6, B11, B12, C, D, E, Beta Carotene\] and minerals \[Iodine, Copper, Selenium, Iron, Zinc, Chrome, Manganese\]) and 1 Orthica Fish EPA Mini capsule (containing n-3FA: eicosapentaenic acid \[EPA\] and docosahexaenic acid \[DHA\])
223479644|NCT05689645|DRUG|Sterilizing water for injection|"The composition of this product is water for injection, and the dosage volume is 2mL for intramuscular injection.~Medication course: The first stages were administered once a day for 7 days and second stages were administered once a day for 14 days. The third stage was administered once a day for 28 days."
223479645|NCT04431206|DRUG|Oxytocin|Oxytocin, 8.2 IU, administered by 30minute IV infusion starting at time 0
223479646|NCT06274827|DIAGNOSTIC_TEST|Superficial Electromyography|For all MVICs, five seconds of each repetition were included in the analysis and the maximum value of three repetitions was taken. For all exercises, the middle 3 seconds of the 5 second data collection period were included in the analysis and the average muscle activation level of the three repetitions was recorded. The average signal amplitude of each exercise was divided by the MVIC of each muscle of interest to obtain the %MVIC value.
223479647|NCT03350919|DEVICE|Training in the blind field|A computer software and chin-rest necessary to perform visual training will be loaned to each patient to use at home. They will perform one to two daily training sessions in their home, consisting of 200-300 trials each. The visual task performed repetitively will involve discriminating the direction of motion of a small cloud of dots located at a pre-determined location in the blind field. The computer program will automatically create a record of patient performance during each home training session. They will train daily (about 40-60 minutes total), 5 to 7 days per week, for at least 24 weeks.
223479648|NCT03350919|DEVICE|Training in the intact field|A computer software and chin-rest necessary to perform visual training will be loaned to each patient to use at home. They will perform one to two daily training sessions in their home, consisting of 200-300 trials each. The visual task performed repetitively will involve discriminating the direction of motion of a small cloud of dots located at a pre-determined location in the intact field of vision. The computer program will automatically create a record of patient performance during each home training session. They will train daily (about 40-60 minutes total), 5 to 7 days per week, for at least 24 weeks.
223479649|NCT00572845|OTHER|Weaning of Antispasticity Medication|Weaning of antispasticity medication over a three day period and then titration back to previous dose over a three day period.
223479650|NCT03879031|DIAGNOSTIC_TEST|Cluster of Clinical tests to measure lumbar stability|"All subjects will be submitted to a cluster of clinical test before the starting of the first session, and at the ending of the last session of the physical therapy program. This cluster will include:~* Aberrant Movements (AM) Test,~* Active Straight Leg Raise Test (ASLR) Test,~* Supine Bridge Test (SuBT),~* Right Side Bridge Test (RBT),~* Left Side Bridge Test (LBT),~* Prone Bridge Test (PrBT),~* Passive Lumbar Extension (PLE) Test,~* Prone Instability Test (PIT)."
223479651|NCT01032928|BEHAVIORAL|Respiratory-Swallow Phase training|Patients were presented with visually guided respiratory feedback to train optimal respiratory-swallow coordination patterns.
223479652|NCT05213780|OTHER|No intervention is involved|No intervention is involved
223479653|NCT05966103|OTHER|Exercises|For control group; Cervical conventional exercises. For treatment group; scapulothoracic exercises including strengthening, proprioceptive and stabilization exercises in addition to cervical conventional exercises
223479654|NCT02749409|DRUG|Parecoxib|
223479655|NCT02749409|DRUG|Morphine|
223479656|NCT01449565|DRUG|Naltrexone|3 monthly intramuscular injections of naltrexone 380 mg (extended release)
223479657|NCT01449565|DRUG|Placebo|3 monthly intramuscular injections of placebo, matched to naltrexone 380 mg (extended release)
223479658|NCT04836377|OTHER|Safety and efficacy assessments|Safety evaluations, disease-specific assessments, and other assessments to monitor for long-term complications of gene therapy intervention
223479659|NCT02592824|DRUG|glutamate infusion|Intravenous infusion of 0.125M L-glutamic acid solution at a rate of 1.65 ml/kg BW and hour commencing at or up to 20 minutes before the release of aortic cross-clamp. The infusion is continued for two hours after declamping the aorta after which an additional 50 ml is given at a halved infusion rate.
223479660|NCT02592824|DRUG|saline infusion|Intravenous infusion of saline at a rate of 1.65 ml/kg BW and hour commencing at or up to 20 minutes before the release of aortic cross-clamp. The infusion is continued for two hours after declamping the aorta after which an additional 50 ml is given at a halved infusion rate.
223479661|NCT04074811|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|The investigators will use the Figure of 8 coil, which affects \~10cm2 of cortical surface. The active condition will deliver stimulation at 110% of resting motor threshold (RMT). To determine RMT, the protocol will be: 10 trials of single-pulse TMS on the scalp position of the abductor pollicis brevis muscle (which controls thumb flexion); RMT is the lowest TMS power setting yielding visible motor contraction on \>50% of trials.
223479662|NCT05266768|DRUG|IBI346|IBI346 Antibody and IBI346 CAR-T cell injection
223479663|NCT02559167|DRUG|Cannabidiol|The investigators will carry out a double-blind, randomized, controlled trial comparing the effects of 92 days of 400 (only for the first 2 Days starting on the Day 2 of the study) or 800 mg CBD (subjects who report side effects with the 800mg dose will be administered the CBD 400 mg dose for the remainder of the trial) vs. placebo administration on cocaine craving and relapse in 110 cocaine-dependent subjects.
223479664|NCT04971655|OTHER|Music therapy|Music therapy will be applied throughout diabetes education. Turkish Folk, Classical, Turkish Art and Sufi Music genres will be offered to individuals as an option and will be listened to throughout the process. Instrumental works will be uploaded to the computer by the researchers and will be played on the loudspeaker during the training.
223479665|NCT04388423|OTHER|simulated puncture training|The residents are trained of simulated puncture : 1.the location puncture; 2. finding fixed-point needle on the model for 5 times, each time for 30 minutes.
223479666|NCT04388423|OTHER|traditional bedside teaching|The residents are trained by traditional bedside teaching
223479667|NCT01781247|BEHAVIORAL|Minimal behavioral intervention|The minimal behavioral intervention consists of one single counseling session of 45 minutes that targets specific MI-triggered traumatic reactions. The focus of the intervention is an educational and resource-oriented approach targeting individual patient resources and cognitive (re)structuring.
224166944|NCT06319534|PROCEDURE|Stellate ganglion block|The percutaneous approach via the paratracheal route was used for Stellate ganglion block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck. The ultrasonic instrument is used to determine the position.
224166945|NCT06319534|DRUG|Lidocaine Hydrochloride|the patients are provided with Stellate ganglion block, using 2.8ml of 0.8% Lidocaine hydrochloride and 0.2 ml of 0.5% vitamin B12. The percutaneous approach via the paratracheal route was used for Stellate ganglion block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck. The ultrasonic instrument is used to determine the position.
224166946|NCT06319534|BEHAVIORAL|placebo injection|2.8 milliliter of normal saline will be used for injection. The percutaneous approach via the paratracheal route was used for Stellate ganglion block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck. The ultrasonic instrument is used to determine the position.
224166947|NCT04248127|OTHER|Honey sweetened yogurt|2 tbsp. of daily honey intake in 1.2 cups of yogurt per day, split into two equal portions
224166948|NCT04248127|OTHER|Sugar sweetened yogurt|sugar added, in an isocaloric fashion to the honey, to 1.2 cups of yogurt per day, split into two equal portions
224166949|NCT04923659|DRUG|Carbamazepine|600 mg reconstituted as one table. Administered once
224166950|NCT04923659|DRUG|Lorazepam|2.5 mg mg reconstituted as one table. Administered once
224166951|NCT04923659|DRUG|Dextromethorphan|150 mgmg reconstituted as one table. Administered once
224166952|NCT04923659|DRUG|Nimodipine|30 mg reconstituted as one table. Administered once
224166953|NCT04923659|DRUG|Placebo|Administered once
224166954|NCT01980381|OTHER|Tree Theme Method ® (TTM)|The TTM method is based on creative activities and occupational life story telling, implies that the paints trees representing different life periods, looking back and forward, as well as the present.
224166955|NCT05957549|OTHER|Speech discrimination|Two different speech sounds are played at the same sound intensity.
224166956|NCT05706909|DEVICE|Genex with ABMC|Core decompression, injection of autologous bone marrow concentrate and the use of genex® Bone graft Substitute as an adjunct associated with the decompression procedure
224166957|NCT06525389|DRUG|Liposomal Amphotericin B (LAmB)|Antifungal dosed at 10 mg/kg/day IV x one single dose.
223479668|NCT01781247|BEHAVIORAL|Control intervention|"The control intervention consists of one single counseling session of 45 minutes that targets more general information about the role of psychological stress in coronary heart disease. Any terminology related to trauma will be completely avoided."
223479669|NCT00820378|OTHER|No special interventioin|Comprehensive transthoracic M-mode, 2-dimensional, and Doppler echocardiographic studies will be performed using commercially available equipment. The aortic dimensions were assessed at end-diastole at the different levels:
223479670|NCT01840631|BEHAVIORAL|Nutritional Counseling|Participants enrolled will be randomized into group nutrition counseling or individual nutrition counseling classes, for a total of 6 classes. Classes will meet one time a month. Classes will cover topics including nutrition, exercise, and behavior to promote healthy eating.
223479671|NCT05868161|DEVICE|Pounce Thrombectomy System|Non-surgical removal of thrombi and emboli from the peripheral arterial vasculature with the Pounce Thrombectomy System.
223479672|NCT03163732|GENETIC|Blood and tumor samples|Evaluation of the added value of a large molecular profiling panel versus a limited molecular profiling panel
223479673|NCT04704050|DRUG|dronedarone 400 mg Oral Tablet|"Dronedarone is an anti-arrhythmic drug with properties belonging to Vaughan-Williams class I-IV.~Participants will receive dronedarone 400 mg tablet, to be taken orally and twice daily for 52 weeks."
223479674|NCT04704050|DRUG|Placebo|Participants will receive a placebo tablet matching the physical appearance of dronedarone, to be taken orally and twice daily for 52 weeks.
224166958|NCT06525389|DRUG|Flucytosine (5FC)|Antifungal dosed at 25mg/kg oral 3x daily.
224166959|NCT06525389|DRUG|Flucytosine (5FC) placebo pill|Similar in appearance to flucytosine. Also dosed at 25mg/kg oral 3x daily.
224166960|NCT06525389|DRUG|Deoxycholate Amphotericin B (DAmB)|Antifungal dosed at 0.7 mg/kg/day IV x 2 weeks.
224166961|NCT05499546|DEVICE|SCALE EYE|Polyp size measurement using the SCALE EYE functionality
224166962|NCT02474368|RADIATION|Intensity Modulated Radiation Therapy (IMRT)|
224166963|NCT02474368|DRUG|Cisplatin|
224166964|NCT02474368|RADIATION|Stereotactic Body Radiotherapy (SBRT)|
224166965|NCT03724994|DRUG|Gemcitabine|Adjuvant or palliative chemotherapy according to national guidelines
224166966|NCT06057207|DIAGNOSTIC_TEST|serum levels of adiponectin|adiponectin level will be measured on a day of surgery, 24 hours and 72 hours after surgery
223479675|NCT03426878|OTHER|Modified genetic counseling|After participants at high risk for a hereditary cancer syndrome receive exome sequencing, they will receive modified genetic counseling to help them understand the results.
224166967|NCT06057207|DIAGNOSTIC_TEST|IL-6|IL-6 level will be measured on a day of surgery, 24 hours and 72 hours after surgery
224166968|NCT06057207|OTHER|Postoperative systemic infflamation|systemic infflamatory response syndrome (SIRS) will be estimated in firs 72 hours after surgery by clinical criteria: apperance of at least 2 from 4 major clinical signs of SIRS: heart rate\>90/min, body temperature \>38 C or \<36 C, WBC \>12 000 or \<4000, hyperventilation, CRP \>50mg/L, PCT \> 0.5 ug/L.
224305292|NCT02734654|PROCEDURE|remote ischemic preconditioning (RIPC)|Remote ischemic preconditioning: The limb RIPC was applied after the induction of anaesthesia and consisted of 3 cycles: 5 min of ischemia by a cuff-inflator on a thigh and inflated to 200 mmHg, followed by 5 min deflated. The control group had during the same time a deflated cuff on a thigh.
224305293|NCT02925507|OTHER|Swallowing Screen|Patient will be ask to undergo a swallowing screen by study staff
224305294|NCT00548509|DRUG|Menatetrenone (Vitamin K2)|
223479676|NCT03426878|OTHER|Traditional genetic counseling|After participants at high risk for a hereditary cancer syndrome receive exome sequencing, they will receive traditional genetic counseling to help them understand the results.
224166969|NCT06057207|OTHER|Postoperative complications|Complications in early postoperative period during hospitalisation will be including: surgical operation site related: anastomotic or laparotomic dehiscence, wound/local infection, postoperative bleeding, reoperation and nonsurgical site complications: sepsis, pneumonia, noncardiac respiratory failure, (need for noninvasive oxygen therapy), prolonged mechanical ventilation \>24 hours postoperative, reintubation, repeated mechanical ventilation atrial fibrillation, congestive heart failure, myocardial infarction, acute kidney injury/failure, postoperative delirium. Length of ICU and overall hospital stay with after discharge from hospital will be documented.
224166970|NCT04076579|DRUG|Olaparib|Olaparib taken by mouth twice daily
224166971|NCT04076579|DRUG|Trabectedin|Trabectedin administered intravenously (IV) every 21 days
224166972|NCT05067764|PROCEDURE|Aponeurectomy with grafting|"The lipofilling is performed, once the incisions are closed and is performed with the Puregraft® system.~The fat graft is taken from the posterior, medial and anterior sides of the arm, by skin puncture. Approximately 10 cc are harvested, allowing a reinjection of about 2 cc per digital radius treated. After conditioning, the fat graft is redistributed to the curettage areas through the skin incisions."
224166973|NCT05067764|PROCEDURE|Aponeurectomy alone|The patient is installed in dorsal decubitus position and the arm to be treated is anesthetized by axillary block. The procedure is performed in the operating room, respecting all the rules of asepsis and safety in force. A tourniquet is placed on the arm to be treated and inflated to 250mmHg. Broken incisions are then made opposite the cords to be excised, which are located by palpation. Once the noble elements have been identified, the excision of the cords and fibrous nodules can be done as completely as possible. Sometimes an arthrolysis procedure is necessary in order to restore extension to a joint that has been fixed in a flexion position for several years. Skin closure is most often possible by direct suture or by means of local fatty skin flaps. In some cases, the surgeon may use total skin grafts, or directed healing in certain areas where direct skin suture is not possible.
224166974|NCT06309550|DIAGNOSTIC_TEST|exercise test|exercise test
224166975|NCT04481997|OTHER|Exposure to Anti-thrombotic treatment agents and glucose lowering therapy|Exposure to Anti-thrombotic treatment agents and glucose lowering therapy
224166976|NCT05761236|OTHER|Exercise|Sessions are consisted of scoliosis-specific pilates-based exercises.The exercises were kept constant in total content, but the bilateral or unilateral application directions, the number of repetitions for the right and left sides, and the extremities used were modified for each patient according to the localization of the major curve and the type of the curve. The taught postural corrections were requested to be maintained during all exercises. Exercises for flexibility were performed asymmetrically or symmetrically according to the chosen exercise, extremities were chosen according to the curve type, with 5 repetitions and 30 seconds for each repetition. Exercises aimed at strengthening were performed for a total of 12 repetitions, during a 5-second contraction, by arranging the number of repetitions for the right and left in line with the target muscles, again considering the curve type, and the patients were asked to rest between the exercises.
224166977|NCT05284383|BEHAVIORAL|Closed-label nocebo conditioning|"Conditioning consists of a learning and test phase. In the learning phase, a message indicating the sham activation of a Transcutaneous Electrical Nerve Stimulation (TENS) device (CS) will be repeatedly paired with a moderate intensity pressure pain stimulus, whereas a message indicating the deactivation of the sham device will be repeatedly paired with a slightly painful pressure pain stimulus. Participants will be given a verbal suggestion in line with the conditioning procedure (i.e. activation of the device will increase their pain). The testing phase is similar to the learning phase, but a slight pressure pain intensity is used for all trials, to test for a nocebo effect (i.e. to test whether participants score TENS on trials as more painful than TENS off trials)."
224166978|NCT05284383|BEHAVIORAL|Closed-label counterconditioning|"Counterconditioning consists of a learning and test phase. In the learning phase, a message indicating the sham activation of the TENS device (CS) is now repeatedly paired with a non-painful intensity pressure pain stimulus, whereas a message indicating the sham deactivation of the TENS device will be repeatedly paired with a slightly painful pressure pain stimulus. Participants will be given a verbal suggestion in line with the counterconditioning procedure (i.e. activation of the device will reduce their pain). The testing phase is similar to the learning phase, but a slight pressure pain intensity is used for all trials, to test whether the nocebo effect is successfully reduced (i.e. to test whether participants no longer score TENS on trials as more painful than TENS off trials or even score TENS on trials as less painful)."
224166979|NCT05284383|BEHAVIORAL|Open-label counterconditioning|"Counterconditioning consists of a learning and test phase. In the learning phase, a message indicating the sham activation of the TENS device (CS) is now repeatedly paired with a non-painful intensity pressure pain stimulus, whereas a message indicating the sham deactivation of the TENS device will be repeatedly paired with a slightly painful pressure pain stimulus. Participants will be given a open-label verbal suggestions in line with the counterconditioning procedure (i.e. they are told counterconditioning will be used to reduce nocebo effects and they are told the device is sham, but that their pain will still be influenced because of the placebo effect). The testing phase is similar to the learning phase, but a slight pressure pain intensity is used for all trials, to test whether the nocebo effect is successfully reduced (i.e. to test whether participants no longer score TENS on trials as more painful than TENS off trials or even score TENS on trials as less painful)."
224305295|NCT02013011|PROCEDURE|recruitment maneuver(RM) and positive end expiratory pressure(PEEP) or PEEP only|application of recruitment maneuver(RM) and positive end expiratory pressure(PEEP) in RM and PEEP group and application of only PEEP in PEEP group
223479677|NCT06038721|BEHAVIORAL|The Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders in Children|The UP-C is administered in-person to parents and children over the course of up to 15 weekly group sessions, which last approximately 90 minutes each.
223479678|NCT06038721|BEHAVIORAL|The Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders in Adolescents|The UP-A is administered to parents and teens over the course of approximately 15-24 weekly individual sessions, which last approximately 50 minutes each. Sessions can be administered in-person or online, with at least one session occurring in person.
224166980|NCT05284383|BEHAVIORAL|Closed-label extinction|"Extinction consists of a learning and test phase. In the learning phase, slightly painful stimuli are used for all trials. During the testing phase, again a slight pressure pain intensity is used for all trials, to test whether the nocebo effect is successfully reduced (i.e. to test whether participants no longer score TENS on trials as more painful than TENS off trials)."
224166981|NCT03793010|DRUG|FX006|Single Intra-articular injection
224166982|NCT03793010|DRUG|Normal saline|Single Intra-articular injection
224166983|NCT02804685|OTHER|exercise protocol|The multi-intervention exercise protocol consists in a performance of agility, strength and balance exercises. It has to be fulfilled during 6 weeks (twice a week) before the regular training performance. The exercises should be done for almost 15 minutes approx. There will be 6 exercises in total: squat with toe raise, one-leg squats, single-leg balance (throwing a ball with a partner), vertical jumps, hamstring exercise, quick forwards and backwards sprints.
224166984|NCT05247398|OTHER|Dynamic Stability Exercise Program|The thumb CMC DS intervention involves four 60-minute occupational therapy visits as well as a daily home program across a 8-week period. Clinic visits focus primarily on home program coaching, and progression of the exercise regimen. Home programs involve daily exercises which follow the intensity and duration recommended for older adults.
224166985|NCT06042933|OTHER|Post operative early oral feeding|To start oral feeding 6 hours after perforated peptic ulcer repairs
224166986|NCT06042933|OTHER|Traditional delayed oral Feeding Post-perforated Peptic Ulcer Repairs|To start oral feeding after 48 hours
224166987|NCT05661916|DRUG|ALN-TTRSC04|ALN-TTRSC04 will be administered by subcutaneous (SC) injection.
224166988|NCT05661916|DRUG|Placebo|Placebo will be administered by SC injection.
224166989|NCT02263742|BEHAVIORAL|Peer whole health intervention|Provide wraparound peer support, education, and navigation to individuals
224166990|NCT02263742|BEHAVIORAL|EBPs at Wellness Center|four EBPs: a) on-site primary care; b) screening of clients for modifiable risk factors and medical conditions; c) care coordination; and d) peer health navigation
224166991|NCT05087641|DEVICE|IAB System|Bronchoscopic implantation of one or multiple IABs
224166992|NCT02230072|DEVICE|fetoscopy|The fetoscopic arm is described above. All patients will have a laparotomy, exteriorization of the uterus, and a fetoscopic repair of the fetal open neural tube defect.
224166997|NCT05334316|DRUG|Dexamethasone|Administered intravenously or orally based on daily CRP values and CRP corticosteroid dosing algorithm
224166998|NCT06427616|BEHAVIORAL|Short Duration Moderate Intensity Soleus Push-ups|participants performed moderate intensity soleus push-ups with ankle weights, calculated as 30-40% of individuals 1RM of soleus muscle's strength. The single set of MSPU was performed 15 minutes after the meal for time till the point where the muscle started to fatigue. The participants were in sitting position with legs positioned at 90 degree angle relative to floor and feet flat on ground performed continuous planter flexion against the ankle weight. Three sets of MSPU was performed at every 15 and Session lasted in 60 minutes.
224166999|NCT06427616|BEHAVIORAL|Sustained Soleus Push-ups|"Participants will start soleus push-ups in sitting. To do so, the participants will be in a seated position, the legs will be at 90 degrees to the floor, and feet will be placed flat on the ground. Participants will then move their heels up and down continuously for.~Sustained soleus push-ups will be performed with light intensity for up to 270 mins.~No external resistance will be added. Participants will be provided with a maximum of 4 min break time after every 90 mins intervention. In the meantime, their blood sample will be collected"
224167000|NCT01351714|PROCEDURE|D3 resection|Radical D3 resection of the right colon through the use of preoperative MDCT angiography
224167001|NCT02903966|DRUG|GSK2982772|GSK2982772 is available as a 30 mg white to almost white, round film coated tablet which will be administered as two tablets three times a day as directed.
224167002|NCT02903966|DRUG|Placebo|Placebo is available as a white to almost white, round film coated tablet which will be administered as two tablets three times a day as directed.
224167003|NCT01476033|DIETARY_SUPPLEMENT|nutraceutical group|6 capsules of supplement or placebo for 8wk
224167004|NCT01227694|OTHER|Autologous MSC knee implantation|"Isolation and Ex-Vivo expansion of Mesenchymal stem cells (MSC) obtained from each patient's bone marrow under GMP conditions at Xcelia-División de Terapias avanzadas del Banc de Sang I Teixits. After 21 days, approximately 40 millions of autologous MSC will be implanted in the knee by articular injection."
224167005|NCT06231654|DEVICE|Remote photoplethysmography for physiological parameters|"Patients participating in the study will be recruited from our emergency department.~The child will be placed in a dedicated, quiet, well-lit office with their parents. The following data are then collected: sex, age, phototype according to Fitzpatrick's classification. The child sits in a chair facing a camera connected to a laptop running Caducy® Medical Device software. At the same time, and following the usual procedure, three ECG electrodes will be positioned on the patient. The whole device is connected to our standard device. Once the child is immobile and ready, the Caducy® application is launched. At the same time, our standard device is activated. After 30 seconds, we will collect the HR and FR values revealed by the Caducy® application via the non-contact plethysmography method. On the other hand, it will collect the HR and FR values revealed by our standard device (Mindray® scope)."
224305296|NCT05321511|DRUG|Triptorelin acetate (a-GnRH)|Adminsitration of triptoreline acetate 0.2 mg for final oocyte maturation in the second ovarian stimuation inthe Double stimulation protocol.
224305297|NCT05321511|DRUG|Ovitrelle® (hCG)|Adminsitration of coriogonadotropine alfa 250 mcg for final oocyte maturation in the second ovarian stimuation inthe Double stimulation protocol.
224305298|NCT05321511|DRUG|Decapeptyl 0.1 mg® (a-GnRH) and Ovitrelle® (hCG) used together|Adminsitration of triptoreline acetate 0.2 mg and coriogonadotropine alfa 250 mcg for final oocyte maturation in the second ovarian stimuation inthe Double stimulation protocol.
224305299|NCT00002883|DRUG|cisplatin|
224305300|NCT00002883|DRUG|fluorouracil|
224305301|NCT00002883|PROCEDURE|adjuvant therapy|
224305302|NCT00002883|PROCEDURE|conventional surgery|
224305303|NCT00002883|PROCEDURE|neoadjuvant therapy|
224167006|NCT05231694|DRUG|Nerver growth factor (NGF) injection|The 20ug nerve growth factor (NO.S20060051, Jinlujie) will be obtained from Hiteck Biopharmaceutical Co., Ltd, Wuhan, China. mNGF will be dissolved in 1 ml sterile water for injection and then injected intramuscularly at gluteal muscle, once a day for 4 weeks. Dose modification is not allowed for mNGF.
224167007|NCT05231694|DRUG|Placebo injection|The patients will receive 1ml volume of physiological saline (PS) injected into the gluteal muscle, once a day for 4 weeks.
224167008|NCT05231694|DEVICE|EA intervention|"Patients take supine position. After skin disinfection with 75% ethanol routine disinfection, the stainless needle (size 0.25mm×40mm, Hua Tuo brand, Suzhou Medical Supplies Company Ltd in Jiangsu, China) will be inserted in GV20（Baihui) and the stainless needle(size 0.25mm×25mm, described above) will be inserted in GV26 (Shuigou), acupoints will be stimulated manually until patients feel soreness, distension or heaviness (the reaction of De Qi). Then, the needles are stimulated by using an acupuncture point nerve stimulator (HANS-200, Nanjing Jinsheng, Ltd., China) with a frequency of 2/100 Hz and an intensity of 3 mA for 40 min (a homemade relay cycled power to the electrode for 6 sec on and 6 sec off), 28 days as a course of treatment, once a day."
224167009|NCT05231694|DEVICE|sham EA intervention|The only difference between sham EA intervention and EA intervention is that the stimulator is connected to the needle handle without power for 40 min intervention.
224167010|NCT04924114|DRUG|MK-6194|Subcutaneous injection
224167011|NCT04924114|DRUG|MK-6194-matching placebo|Subcutaneous injection
224167012|NCT03928938|DEVICE|Electronic patient reported outcomes|Electronic patient reported outcomes-tool
224167013|NCT04974411|OTHER|infection|this study had two observation cohorts, one that observed sepsis in the presence of infection; the other cohort was monitored during sepsis until septic shock appeared
224167014|NCT04974411|OTHER|sepsis|this study had two observation cohorts, one that observed sepsis in the presence of infection; the other cohort was monitored during sepsis until septic shock appeared
224167015|NCT00979264|BEHAVIORAL|Intensive quality improvement tools|Personalized performance improvement interventions, including premier site data reports, personalized feedback/teleconferences, comprehensive toolkits, and focused webinars; in addition to other general QI tools typically available through participation in Get With the Guidelines Heart Failure.
224167016|NCT04423718|DRUG|Aflibercept High Dose VEGF Trap-Eye (BAY86-5321)|Solution in Vial, intravitreal (IVT) injection
224167017|NCT04423718|DRUG|Aflibercept VEGF Trap-Eye (Eylea, BAY86-5321)|Solution in Vial, 2 mg, intravitreal (IVT) injection
224167018|NCT06581198|BIOLOGICAL|rapcabtagene autoleucel Regimen 1|single infusion of rapcabtagene autoleucel
224167019|NCT06581198|BIOLOGICAL|rapcabtagene autoleucel Regimen 2|single infusion of rapcabtagene autoleucel
223584549|NCT03442660|OTHER|Data collection|Subjects will be treated in accordance with usual medical practice during their participation in this study. No additional diagnostic or treatment procedures will be required. Subjects will be asked to complete electronic (or on paper when it's not possible to use electronic version) questionnaires.
224167020|NCT06581198|OTHER|Standard of Care|The treatment regimen must be in line with KDIGO guidelines for treatment of class III/IV LN.
224167021|NCT00425945|DRUG|Pine Bark Extract (Flavangenol®)|"Flavangenol 200 mg per day. Flavangenol is a brand of pine bark extract manufactured by Toyo Shinyaku of Saga, Japan.~Dosage delivered as four tablets, each containing 50 mg Flavangenol, all 4 tablets taken once per day orally for 12 weeks."
224167022|NCT02743975|DRUG|Bevacizumab-800CW|dose finding: 4.5mg; 10mg; 25mg; 50mg
224167023|NCT06098794|DIETARY_SUPPLEMENT|Sodium Bicarbonate|Capsules containing 0.3 g/kg of body weight of sodium bicarbonate were ingested in two doses. The first intake (0.2 g/kg) was performed together with a carbohydrate-enriched meal 2 h before a repeated sprint exercise protocol, and the second (0.1 g/kg) occurred 1 h later.
224167024|NCT06098794|DIETARY_SUPPLEMENT|Placebo|Capsules containing 0.3 g/kg of body weight of celulose were ingested in two doses. The first intake (0.2 g/kg) was performed together with a carbohydrate-enriched meal 2 h before a repeated sprint exercise protocol, and the second (0.1 g/kg) occurred 1 h later.
224167025|NCT05411224|OTHER|Custom made orthosis|In patients with Morton Neuroma, stride length, stance phase percentage, swing phase percentage, cadence and speed parameters, and fore, mid and hind foot pressure distribution will be recorded with the Zebris FDM-THM-S treadmill system in the analysis of barefoot walking after the physical examination evaluation of the cases.While the treadmil is in a static state, pressure distribution measurement will be taken by baropedography, and personalized insoles will be produced according to the baropedographic pressure map. Patients will be delivered to the patient for indoor and outdoor use for 4 weeks. After a 4-week usage period, measurements related to pressure and walking parameters will be repeated.
224167026|NCT03637166|OTHER|Assessment at Low Altitude (470m above sea level)|Assessment at Low Altitude (in Zurich; 470m above sea level) in order to compare this data with High altitude exposure
224167027|NCT03637166|OTHER|Exposure to High Altitude (2500m above sea level)|"Exposure to High Altitude (Säntis; 2500m above sea level) for approximately 5 hours"
224167028|NCT02881151|DEVICE|Deep brain stimulation|Delivery of continuous, low-voltage electrical pulses to deep portions of the brain via an implantable pacemaker-like device.
224305304|NCT01521065|DEVICE|IRay|Approved dose of Anti-VEGF injection given at Day 0 followed by treatment with 16 Gy dose of IRay up to 14 days later.
224305305|NCT01468818|DRUG|Cyclophosphamide|Cyclophosphamide 60 mg/kg/day X 2 days intravenous (IV) in 250 ml dextrose 5% in water (D5W) with Mesna 15 mg/kg/day X 2 days over 1 hr.
224305306|NCT01468818|DRUG|Fludarabine|Fludarabine 25 mg/m2/day intravenous piggyback (IVPB) daily over 30 minutes for 5 days.
223584550|NCT02737384|BIOLOGICAL|Depletion in CD45RA graft donor|"Experimental treatment: negative fraction after CD34+ selection from PBSC graft is depleted of naïve CD45RA+ cells. this fraction is reinjected to the recipient and is the experimental product.~Conditioning regimen:~Up-front ATG from D-14 toD-11 Busulphan IV from D-8 to -5 Fludarabine from D-7 to D-4 Thiothepa D-3 to D-2~Graft: CD34+ cells positively selected cells from PBSC of the donor~Post transplant immunosuppression: ciclosporin started at D-1 to D+100"
223584551|NCT02666794|DRUG|Epidural bupivacaine with vasoconstrictor 0.125%|10 ml
223584552|NCT02666794|DRUG|Epidural sufentanil|20 mcg
224167029|NCT01731808|BEHAVIORAL|Nursing counseling|The participants who were randomized in the intervention group received outpatient physician-prescribed wound care. Additionally, they received standardized education regarding diabetic foot care. The nurse-led outpatient intervention started a few days after randomization and went on for five weeks. The study nurses conducting the interventions were wound care nurses and trained in foot examination, foot care, education, and counseling. During a period of five weeks, the participants were provided with weekly, one-hour education, skill training, and counseling sessions on foot care. Each participant received a foot care kit with essential foot care material and a foot care diary.
224167030|NCT02974738|DRUG|Belzutifan|Belzutifan is a highly selective small molecule that inhibits the function of the HIF-2α transcription factor. As a result, hypoxic signaling in cancer cells is impaired, blocking the transcription of several genes involved in oncogenesis
223479679|NCT05642676|OTHER|Clinics remodeling|changes to the clinics will be planned based on baseline surveys
224167031|NCT04610671|DRUG|CG0070|CG0070 will be administered at a dose of 1x10\^12 vp intravesically following a sequence of bladder washes with 5% DDM and normal saline.
223479680|NCT05769816|DRUG|Anti-PD-1 antibody|Once/two or three weeks, dose lower than the dose used in cancer patients, subcutaneous/intravenous injection
223479681|NCT05769816|DRUG|NAs|Once/day, 1 capsule/time, oral
223479682|NCT02204943|DEVICE|Biomarker analysis|Pharmacodynamic study of Radium-223 in bone biopsy and circulating tumor cell samples
223479683|NCT02204943|DRUG|Administration of radium-223|Subjects will receive radium-223 treatment for their disease as standard of care in this protocol. They will be receiving this treatment regardless of their participation in this protocol.
223479684|NCT02574585|BIOLOGICAL|Autologous mesenchymal cells transplantation|Two percutaneous injections of mesenchymal stem cells, with a 3-month interval between the injections.
223479685|NCT00634478|RADIATION|Pre-lemniscal Radiation Deep Brain Stimulation|
223479686|NCT01286129|PROCEDURE|Nasal allergen challenge|Allergen sprayed into nostrils. Allergen used will be house dust mite or cat allergen. Allergens will be given in increasing ten-fold dilutions until a positive response occurs.
223479687|NCT04071379|BIOLOGICAL|Recombinant Hepatitis B + DTP-HB-Hib|1 dose of 0.5 ml Recombinant Hepatitis B + 3 dose of 0.5 ml of DTP-HB-Hib
223479688|NCT04071379|BIOLOGICAL|Hep B + Pentabio (registered)|1 dose of 0.5 ml Recombinant Hepatitis B (registered) + 3 dose of 0.5 ml of Pentabio (registered)
223584553|NCT02666794|PROCEDURE|Placement of the epidural catheter|Placement of the epidural catheter
224167032|NCT04610671|DRUG|Nivolumab|Two neoadjuvant doses of nivolumab 480 mg Q4W (every 4 weeks) for 2 doses (week 2 and 6)
224167033|NCT04284787|DRUG|Azacitidine|Given IV or SC
223479689|NCT02111200|DRUG|Sodium Benzoate|Subjects will be instructed to take the study medication with meals (08:00 breakfast; 13:00 lunch; 19:00 dinner) for 3 days.
223479690|NCT02111200|DRUG|Sodium Phenylbutyrate|Subjects will be instructed to take the study medication with meals (08:00 breakfast; 13:00 lunch; 19:00 dinner) for 3 days.
223479691|NCT00713076|OTHER|Polyquaternium-preserved Multi-purpose Lens Cleaning Solution 109182|Lens Cleaning Solution Formulation Identification Number 109182
223479692|NCT00346437|GENETIC|Ad5FGF-4 vs. Placebo|Intracoronary infusion
223479693|NCT02823886|OTHER|MRI at D7|The infarct size measured on MRI at 7 days.
223479694|NCT02823886|BIOLOGICAL|Blood samples|Blood samples at H0; H4; H12; H24, H48, D7 and 1 month post MI
223479695|NCT05146739|DRUG|Cytarabine|Given IV and IT
223479696|NCT05146739|DRUG|Fludarabine|Given IV
223584554|NCT02666794|DRUG|Intrathecal hyperbaric bupivacaine solution 0.5%|2.5 mg
223479697|NCT05146739|DRUG|Leucovorin|Give PO or IV
223479698|NCT05146739|DRUG|Triple Intrathecal Chemotherapy|Given IT
223479699|NCT05146739|DRUG|Uproleselan|Given IV
223479700|NCT06098508|OTHER|Osteopathic Manual Treatment|This study will be using osteopathic manual therapy as the primary intervention. Osteopathic manual therapy (OMT) is a hands-on treatment that is performed by a specially trained physician known as a Doctor of Osteopathic Medicine (DO). This treatment can be used to diagnose and treat somatic dysfunctions, which are palpable areas of tightness, misalignment, and/or restricted motion within the musculoskeletal system and its related vascular and neural structures. A combination of myofascial release, strain/counterstain, soft tissue, balanced ligamentous release, facilitated positional release and muscle energy techniques will be used for the OMT treatment.
223479701|NCT06098508|OTHER|Sham Treatment|The sham treatment will include a hands-on evaluation typically used to diagnose somatic dysfunctions, but no treatment will be performed. The sham treatment will assess the upper extremities/scapulae, ribs, cervical spine, thoracic spine, thoracic inlet, and occipital-atlantal regions.
223584555|NCT02666794|DRUG|Intrathecal morphine|60 mcg
223479702|NCT05259709|DRUG|89Zr˗DFO˗REGN5054|Administered by intravenous (IV) infusion during Part A and B.
223479703|NCT05259709|DRUG|cemiplimab|Administered by IV infusion every 3 weeks (Q3W).
223479704|NCT04497116|DRUG|RP-3500 (camonsertib)|Oral ATR inhibitor
223479705|NCT04497116|DRUG|Talazoparib|Oral PARP inhibitor
223479706|NCT04497116|DRUG|Gemcitabine Injection|Gemcitabine
223479707|NCT05785169|BEHAVIORAL|All-facility Training|The HP+ curriculum includes total-site training and co-facilitation via participatory modules. To change clinic culture, a multi-level approach that includes the whole facility and reaches all parties is required. The intervention aims to modify top-down mechanisms of influence. The training is modeled on these principles and supports the development of multiple stigma-reduction strategies to improve patient and staff wellbeing.
223479708|NCT05233761|DRUG|Defined CBD|300 mg CBD and 8 mg Terpenes administered as two small capsules.
223584556|NCT02666794|PROCEDURE|Placement of an epidural catheter to the catheter through technical needle|Placement of an epidural catheter to the catheter through technical needle
223584557|NCT02666794|DRUG|Intrathecal sufentanil|5 mcg
223584558|NCT04350307|DEVICE|22-gauge needle|22-gauge Quincke needle used for epidural injection
224167034|NCT04284787|PROCEDURE|Biopsy Procedure|Undergo biopsy
224167035|NCT04284787|PROCEDURE|Biospecimen Collection|Undergo blood specimen collection
224167036|NCT04284787|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
224167037|NCT04284787|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
224167038|NCT04284787|PROCEDURE|Echocardiography Test|Undergo ECHO
224167039|NCT04284787|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA scan
224167040|NCT04284787|BIOLOGICAL|Pembrolizumab|Given IV
224167041|NCT04284787|DRUG|Venetoclax|Given PO
224167042|NCT06628869|DIETARY_SUPPLEMENT|Fructanase|Participants will consume one capsule containing 400 INU inulinase (325 mg, includes maltodextrin) with a mixture of oatmeal (40 grams) and inulin (25 grams). Participants will be directed to consume the capsule after two spoonfuls of oatmeal. The fructanase was obtained from Aspergillus tubingensis.
224167043|NCT06628869|DIETARY_SUPPLEMENT|Maltodextrin placebo|Participants will consume one capsule containing 300 mg maltodextrin with a mixture of oatmeal (40 grams) and inulin (25 grams). Participants will be directed to consume the capsule after two spoonfuls of oatmeal. The maltodextrin was obtained from tapioca.
224167044|NCT06630286|DRUG|ISL/LEN|Tablet administered orally
224167045|NCT06630286|DRUG|B/F/TAF|Tablet administered orally
224167046|NCT06630286|DRUG|PTM B/F/TAF|Tablet administered orally
224167047|NCT06630286|DRUG|PTM ISL/LEN|Tablet administered orally
224167048|NCT04413994|DIETARY_SUPPLEMENT|Humavant|"Premature infants are randomized to either:~1. An exclusive human milk diet which contains mother's milk or pasteurized donor human milk and the human milk fortifier until 36 weeks of gestation; OR~2. Human milk (as long as available) and the human milk fortifier (as long as human milk is available) until a maximum of 32 weeks of gestation and thereafter human milk with a bovine-based fortifier or preterm formula.~After 36 weeks of gestation, human milk with a bovine-based fortifier or preterm formula is used in both groups. As a control group, term-born age-matched controls are included."
224167049|NCT04919369|BIOLOGICAL|Atezolizumab|Given IV
224167050|NCT04919369|DRUG|Tretinoin|Given PO
224167051|NCT03567733|DEVICE|XIENCE Sierra|Percutaneous coronary intervention
224167052|NCT04561453|DIAGNOSTIC_TEST|Multi-Platform Profiling with Organoid Drug Sensitivity Screening and ctDNA Monitoring|All patients in the study will have organoid creation and organoid drug sensitivity screening attempted on their fresh tumor tissue from surgical resection. All patients will also have blood taken pre-operatively and at multiple post-operative time points to monitor circulating tumor DNA.
224167053|NCT05187611|DEVICE|Conduction system pacing|Lead placed in the His-Purkinje system in order to achieve QRS shortening.
224167054|NCT05187611|DEVICE|Biventricular pacing|Lead is placed in a tributary of the coronary sinus.
223584559|NCT04350307|DEVICE|25-gauge needle|25-gauge Quincke needle used for epidural injection
224167055|NCT01797055|DRUG|Human apotransferrin|intravenous infusion
224167056|NCT06803602|DEVICE|EMSELLA®|Subjects will receive 100% intensity of the EMSELLA® (BTL Industries, Marlborough, MA) High-Intensity Focused Electromagnetic (HIFEM) treatment, in a single 30-minute session, twice per week for 3 weeks.
224167057|NCT06803602|DEVICE|Sham Comparator Device|Subjects will be asked to sit on the EMSELLA® (BTL Industries, Marlborough, MA) treatment head which will be powered off and instead have a small remote control vibration device that will simulate active treatment, in a single 30-minute session, twice per week for 3 weeks.
224167058|NCT05848895|PROCEDURE|Osteopathic Manipulative Treatment|Osteopathic Manipulative Treatment is a manual treatment therapy applied by licensed physicians that consists of using ones hands to improve the structure and function of the body. In this situation it will involve gentle and passive modalities that are well-tolerated by infants.
224167059|NCT05848895|BEHAVIORAL|Standard of Care Repositioning|Parents will receive standardized handouts/materials instructing on repositioning intended to help improve head shape in infants with plagiocephaly.
224167060|NCT06085443|OTHER|Ear Hygiene|2 sprays in each ear, every 3 days at home
224167061|NCT03502785|BIOLOGICAL|INO-5401|INO-5401 (9 milligram \[mg\] dose IM): mixture of 3 synthetic plasmids that target Wilms' tumor gene-1 (WT1) antigen, prostate-specific membrane antigen (PSMA) and human telomerase reverse transcriptase (hTERT) antigen.
224167062|NCT03502785|BIOLOGICAL|INO-9012|"INO-9012 (1 mg dose IM): A synthetic plasmid that expresses human interleukin-12 (IL-12).~INO-5401 + INO-9012 will be administered IM followed by EP with CELLECTRA™ 2000 device every 3 weeks for 4 doses then every 6 weeks for 6 additional doses, thereafter every 12 weeks until confirmed disease progression, unacceptable toxicity, or deemed intolerable by the investigator."
224167063|NCT03502785|DRUG|Atezolizumab|Atezolizumab will be administered by intravenous (IV) infusion every 3 weeks until confirmed disease progression, unacceptable toxicity, or deemed intolerable by the investigator.
224167064|NCT03502785|DEVICE|CELLECTRA™ 2000|IM injection of INO-5401 and INO-9012 is followed by EP with the CELLECTRA™ 2000 device.
224167065|NCT06646627|DRUG|B7-H3CART|"Dose Levels:~Dose Level -1 Dose Level 1 Dose Level 2 Dose Level 3~Arm A IP(± 20%) (flat dose) Dose Level -1: 1 x 107 B7-H3CART Dose Level 1: 5 x 107 B7-H3CART Dose Level 2: 15 x 107 B7-H3CART Dose Level 3: 5 x 108 B7-H3CART~Arm B: IV (± 20%) (weight based) Dose Level -1: 3 x 105 transduced cells/kg Dose Level 1: 1 x 106 transduced cells/kg Dose Level 2: 3 x 106 transduced cells/kg Dose Level 3: 10 x 106 transduced cells/kg"
224167066|NCT05243875|BEHAVIORAL|LEAP Education + Navigation|COVID education involving providing information about COVID for people with SLE and CDC recommendations for testing, testing options (e.g., pharmacies, doctors' offices, at-home), treatment in the event of a positive COVID result, and current recommendations around vaccination for those with SLE; and (2) navigation, which involves individual tailoring of information about where and how to get tested, and where to get vaccinated, and when appropriate, guiding participants in scheduling testing and vaccination appointments.
224167067|NCT05243875|BEHAVIORAL|LEAP Education|COVID education involving providing information about COVID for people with SLE and CDC recommendations for testing, testing options (e.g., pharmacies, doctors' offices, at-home), treatment in the event of a positive COVID result, and current recommendations around vaccination for those with SLE.
224167068|NCT05426083|OTHER|Physiological Assessment|Observational only
224167069|NCT04992507|PROCEDURE|Anesthesia Procedure|Given TIVA
224167070|NCT04992507|DRUG|General Anesthesia Procedure|Given inhaled volatile anesthetics
224167071|NCT04992507|PROCEDURE|Resection|Undergo surgical resection
223584560|NCT01075984|DRUG|Posaconazole|
223584561|NCT01075984|DRUG|Dextrose 5% in water|
223584562|NCT01524081|DRUG|Metronidazole, Cefuroxime|"administration of Cefuroxime 1.5 g and Metronidazole 1g in 2 following intravenous infusions 60 minutes prior the surgery.~1. \- Cefuroxime in 100ml saline~2. \- Metronidazole in 500ml saline"
224167072|NCT02945852|DRUG|apatinib|apatinib 500mg/d until progressive Disease
224167073|NCT06305819|BEHAVIORAL|self-management support program|The SEMPO program is inspired by established self-management principles and established rehabilitation strategies. The program is manualized and integrates components from rehabilitation strategies within relevant functional domains. The program includes elements, such as tailored psychoeducational content, action planning, guided skills mastery, learning and practicing helpful compensatory strategies, problem solving techniques and sharing of experiences. The intervention is delivered by a multidisciplinary team and the participants are provided with written materials and a work book containing information about each session and work tasks.
224167074|NCT06305819|OTHER|Control group|Treatment as usual
224167075|NCT04893395|OTHER|Pharmacogenomic Screening|"First telehealth appointment:~1. Pharmacogenomics education and informed consent~2. Medical history~3. Sample collection~Second telehealth appointment:~1. Results of pharmacogenomic testing~2. Utility and limitations of pharmacogenomic testing~3. Patient-specific potential impacts on current or future medication therapies~4. Answering of patient questions~5. Referral to mental health provider(s) for treatment-specific recommendations"
223479709|NCT05233761|DRUG|Placebo|Capsules that smell and look exactly like Defined CBD but contain no CBD or terpenes.
223479710|NCT00466830|OTHER|questionnaire administration|
223479711|NCT00466830|PROCEDURE|management of therapy complications|
223479712|NCT00466830|PROCEDURE|psychosocial assessment and care|
223479713|NCT00466830|PROCEDURE|quality-of-life assessment|
223479714|NCT06546345|DEVICE|KeriFlex®|The KeriFlex® finger joint prothesis MCP is designed to replace a damaged metacarpophalangeal (MCP) joint and the KeriFlex® finger joint prothesis PIP is designed to replace a damaged proximal interphalangeal (PIP) joint.
223479715|NCT05685342|DRUG|Acetaminophen/Ibuprofen fixed-dose combination|Intravenous administration of Acetaminophen (1000 mg)/Ibuprofen (300 mg) fixed-dose combination (total 100 ml)
223479716|NCT06468956|DRUG|SHR-1819|SHR-1819 injection
223479717|NCT06468956|DRUG|Placebo|placebo
223479718|NCT05073705|BEHAVIORAL|Empowerment and personal transformation intervention|The intervention to be delivered is the Empowerment and Personal Transformation (EPT) intervention. The EPT intervention is 6-session weekly intervention that will be given in groups. A closed group format of at least 8 participants will be used to maximize confidentiality and group cohesion. It involves elements of communication skills, empowerment and mindfulness, values and beliefs, trauma and healing, addresses issues of dependence and independence, and experiential therapy which addresses issues of emotional processing, resolution of conflicts from the past, and creative expression. The EPT intervention is 6-session weekly intervention that will be given in groups. Intervention content will be delivered by a degree level trained counselor at the MRRH HIV clinic following a manual.
223479719|NCT02816359|OTHER|head-bed position|Head-bed position at 0° for 30 minutes then head-bed position at 30° for 30 minutes
223479720|NCT04128917|DRUG|Tegoprazan|Tegoprazan 50 mg or 100 mg/Clarithromycin/Amoxicillin BID peroral
223479721|NCT04128917|DRUG|RAPAE01|RAPAE01/Clarithromycin/Amoxicillin BID peroral
223479722|NCT00998569|BEHAVIORAL|Neurocognitive Enhancement|Neurocognitive Enhancement Therapy (NET) uses behavioural treatment strategies that are designed to improve a range of cognitive skills. NET uses strategies such as coaching, repetition, practice, teaching, group discussion, and compensation for deficits by using cognitive strengths.
223479723|NCT00998569|BEHAVIORAL|Wait List|Participants will be wait listed for 10 weeks, following which time they will receive the intervention previously described.
223479724|NCT01604785|DRUG|Propofol|Sub-anesthetic dose propofol: 0.25 mg/kg IV push to maximum dose of 30mg q5 minutes to a maximum of 5 doses
223479725|NCT01604785|DRUG|Standard Treatment|Ketorolac, Diphenhydramine and Metoclopramide
223479726|NCT02793986|DRUG|propofol|For patients in Group P, the sedation was achieved with a target-controlled infusion (TCI) of propofol, and the effect site concentration was set to 0.8-1.0μg/ml.
223479727|NCT02793986|DRUG|dexmedetomidine|For patients in Group D, the sedation was achieved with a bolus of dexmedetomidine at 1.0 μg/kg (over a period of 15 to 20 min) and followed by an infusion of dexmedetomidine at 0.2-0.7 μg/kg/h. The depth of sedation was considered enough when patient was unresponsive to voice.
223479728|NCT05720598|PROCEDURE|Sentinel Node Assessment|The SN assessment will be conducted similarly to the method proposed by Märkl et al. All LNs will be stored in a -80 °C freezer, immediately after retrieval. Within 1 to 3 days, each LN will be individually measured and weighed. Small LNs (\<5 mm in short diameter) will be bisected, and half of the node will be processed for histological evaluation while the remaining half will be used for OSNA analysis. For intermediate-sized LNs (5-10 mm), a middle slice of about 2 mm thickness will be cut out for the histology, and the remaining parts of the node will be processed by OSNA. In large LNs (\>10 mm), at least two slices will be cut out for histology, and the remaining parts of the node will be analyzed by OSNA.
223744874|NCT03938584|OTHER|Placebo|Subjects will receive IV placebo (normal saline) identically packaged. Post-operatively Placebo Control Treatment Group participants will receive a 4-week prescription of the aqueous solution base used for the treatment group without the active component (Vitamin C).
223744875|NCT01748981|OTHER|Physical training|"Physical training three times a week for 20 week including endurance and strength training compare to the as usual group as controls"
223744876|NCT01748981|OTHER|As usual|Controls, not training
223744877|NCT00975481|DRUG|dimebon|Oral tablet; 20 mg dimebon, single dose
224167076|NCT02752178|OTHER|MA|Monoaminergic antidepressant use
224167077|NCT02752178|OTHER|DEP|Depression measured using the Hamilton Depression (HAM-D) questionnaire
224167078|NCT00421460|DRUG|Testosterone Undecanoate,1000mg|duration for 4 injections
224167079|NCT06183281|BEHAVIORAL|CBT, Mindfulness, and Movement|Blended CBT, mindfulness, and movement delivered through a mobile app and supported by a weekly telehealth pain management coach.
224305307|NCT01468818|BIOLOGICAL|Young Tumor Infiltrating Lymphocytes (TIL)|Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of young TIL. On day 0, cells (1x10e9 to 2x10e11) will be infused intravenously (i.v.) on the Patient Care Unit over 20 to 30 minutes (between one and four days after the last dose of fludarabine).
224305308|NCT06244849|BIOLOGICAL|Blood samples|A 28 mL (5 EDTA tubes of 4 mL and 2 dry tubes) venous blood will be collected added to the standard blood analysis performed in routine
223479729|NCT05720598|PROCEDURE|Staging laparoscopy|Pneumoperitoneum (10-12mmHg) will be obtained with Veress needle or 10mm trocar after minilaparotomy. Peritoneal cavity will be thoroughly assessed after insertion of two additional trocars. In cases of macroscopic dissemination, peritoneal cancer index (PCI) will be determined. After switching the optical camera into near-infrared / indocyanine green fluorescence mode, the primary tumor will be visualized, followed by assessment and possible dissection of sentinel lymph node with a high-energy device. The lymph node will be retrieved with a sterile bag, and the area of dissection will be marked with a clip. Trocars will be removed under visual assistance, and the pneumoperitoneum will be released through trocars in order to prevent port-site metastases.
223479730|NCT05720598|PROCEDURE|Gastroscopy with indocyanine green (ICG) injection|Patients will undergo gastroscopy one day prior to staging laparoscopy. The ICG powder contains 0.125 mg/ml. Two milliliters of ICG (0.125mg/ml) solution is injected in the submucosa with into four peritumoral sites, 0.5 ml for each site.
223479731|NCT00869960|DRUG|tenofovir|tenofovir 300 mg one dose on 2 separate visits: within 5 days after Day 1 of Follicular phase and then within a 4 day window of the leutal phase (day 14 of the menstrual cycle)
223479732|NCT00869960|DRUG|emtricitabine|emtricitabine 200 mg on 2 separate visits: within 5 days after Day 1 of Follicular phase and then within a 4 day window of the leutal phase (day 14 of the menstrual cycle).
224167080|NCT05222373|BEHAVIORAL|CBT-based lifestyle intervention|The standard care plus a theoretically-based, diet, activity, and mental health lifestyle intervention integrated within a culturally sensitive curriculum (materials in Spanish and English). Trained CHWs will promote CBT-based lifestyle-change aims and assist in goal setting with participants to reach the primary goal of appropriate glycemic control (fasting blood glucose and HbA1c) and weight reduction, in addition to decrease in depressive symptoms and stress and an increase in quality of life. Participants' body weight, body composition, metabolic measures, and mental health outcomes will be obtained at enrollment and at the end of the intervention.
224167081|NCT04170894|OTHER|Periods of Apnea|Periods of apnea throughout atrial fibrillation ablation.
224167082|NCT04170894|OTHER|Control Arm - No Periods of Apnea|Standard of care atrial fibrillation ablation.
224167083|NCT04972955|DEVICE|Freestyle Libre 2|Participants will wear a continuous glucose monitoring device, the Freestyle Libre 2, for two weeks following delivery.
224167084|NCT04972955|DEVICE|Freestyle Libre 2|Participants will wear a second continuous glucose monitoring device, the Freestyle Libre 2, for two weeks at 4-6 months postpartum and before their standard of care postpartum bloodwork after having gestational diabetes.
224167085|NCT05879653|DRUG|MK-3475|During the induction phase, MK-3475 200 mg will be administered as four cycles of 3-weeks regimen, with ASG-22CE 1.25 mg/kg administered on Day 1 and Day 8 of each cycle. The treatment and maintenance phases will consist of 9 cycles of one course per 6 weeks, with MK-3475 400 mg administered on Day 1 of each course at Q6W.
224167086|NCT05879653|DRUG|ASG-22CE|During the induction phase, four cycles of 3-weeks regimen are administered, with ASG-22CE 1.25 mg/kg administered on Day 1 and Day 8 of each cycle.
224167087|NCT05879653|PROCEDURE|maximal TURBT|All participants who were not determined to have PD on imaging during the induction phase should have had a maximal TURBT performed at 13 (± 1week) weeks after the first dose of trial drug.
224167088|NCT05879653|RADIATION|Radiation therapy|Radiotherapy will be initiated no later than 8 weeks after maximal TUR-BT. In this trial, a total dose of 56 Gy will be delivered using 2 Gy per dose. 40 Gy/20 fr (2 Gy/fr) to the small pelvis followed by 16 Gy /8 fr (2 Gy/fr) to the whole bladder 5 times a week for 5 consecutive days using Three-Dimensional Conformal Radiation Therapy (3D-CRT).
224167089|NCT05951439|DIETARY_SUPPLEMENT|CRE + HMB|3 g/day of CRE and 3 g/day of HMB
224167090|NCT05951439|DIETARY_SUPPLEMENT|Placebo|6 g/day of inulin
224167091|NCT04920539|DRUG|Active Delta-9-THC|Active Delta-9-THC (0.03 mg/kg) administered intravenously.
224167092|NCT03218137|DRUG|Adenosine|Adenosine: 0.84 mg/kg (140 mcg/kg/minute IV for 6 minutes) Verapamil 0.15 mg/kg
223479733|NCT00869960|DRUG|atazanavir|atazanavir 300mg one dose on 2 separate visits: within 5 days after Day 1 of Follicular phase and then within a 4 day window of the leutal phase (day 14 of the menstrual cycle).
224305309|NCT06244849|BIOLOGICAL|Stool simple|A fresh stool sample will be collected and conserved at room temperature until shipment
224305310|NCT06244849|BIOLOGICAL|Ileocolonic biopsies|An ileo-colonoscopy with 10 ileal biopsies scheduled in their regular medical follow-up will be performed
223744878|NCT00975481|DRUG|dimebon|Oral tablet; 40 mg dimebon, single dose
224305311|NCT01212588|DRUG|mifepristone|Mifepristone 600mg (3x200mg tablets) once daily for seven days
223479734|NCT00869960|DRUG|ritonavir|ritonavir 100 mg one dose on 2 separate visits: within 5 days after Day 1 of Follicular phase and then within a 4 day window of the leutal phase (day 14 of the menstrual cycle).
223479735|NCT02938780|OTHER|placebo text message|The subjects in the control group will receive placebo text messages which will be timed as the intervention group that are unrelated to the study or topics of exercise and nutrition.
223479736|NCT02938780|OTHER|nutrition physical activity text message|The subjects in the intervention group will receive text messages with nutrition and physical activity-related information throughout the study period on a daily basis, varying text message arrival over a 10 am to 7 pm time frame. The American Cancer Society recommends a set of exercise and nutrition behaviors for cancer survivors based upon developed expert evidence. These behaviors have been structured to achieve healthier lifestyles, improve quality of life and reduced mortality. The intervention will provide via text messaging exemplars and social norms designed to improve compliance with this advice.
224167093|NCT02974621|BIOLOGICAL|Bevacizumab|Given IV
223479737|NCT02373267|BIOLOGICAL|Technozyme|determination of ADAMTS13 activity
223479738|NCT01332825|OTHER|saline nasal irrigation|subjects irrigate with nasal saline daily for one week
223744879|NCT00975481|DRUG|dimebon|Oral tablet; 60 mg dimebon, single dose
223744880|NCT00975481|DRUG|placebo|Oral tablet or capsule; placebo, single dose
224167094|NCT02974621|DRUG|Cediranib|Given PO
224305312|NCT01212588|DRUG|Placebo|3 tablets once daily for seven days
223744881|NCT00975481|DRUG|alprazolam|Oral capsule; 1 mg alprazolam, single dose
223744882|NCT00975481|DRUG|alprazolam|Oral capsule; 3 mg alprazolam, single dose
224167095|NCT02974621|DRUG|Cediranib Maleate|Given PO
224167096|NCT02974621|DRUG|Olaparib|Given PO
224167097|NCT06103565|OTHER|Clinical Decision Support Tool|Clinical decision support tool to enable pharmacists to monitor adherence to guideline-directed medical therapy for patients with heart failure with reduced ejection fraction
224167098|NCT03936335|DRUG|dupilumab|No study drug will be administered. This study is based on an analysis of automated medical and prescription claims, supplemented by information abstracted from the medical record.
224167099|NCT04313673|DIAGNOSTIC_TEST|second trimester ultrasonography|Patients undergoing routine antenatal screening between 18-24 weeks and measuring cervical length with transabdominal ultrasonography in the same session
224167100|NCT01641224|DRUG|Pinaverium|To test the effectiveness and safety of the formula for pain and diarrhea, we will randomly assign patients into one 3 groups: Pinaverium, TCM (Formula for pain and diarrhea) group, and placebo group, and treat them accordingly.
224167101|NCT01641224|DEVICE|Atractylodes|Atractylodes (\~10-15g)
224167102|NCT01641224|DEVICE|Paeonia Lactiflora|Paeonia Lactiflora (\~15-30g)
224167103|NCT01641224|DEVICE|Tangerine Peel|Tangerine Peel (\~10g)
224167104|NCT01641224|DRUG|Ledebouriella Root|Ledebouriella Root (\~10g)
224167105|NCT01641224|DRUG|Radix codonopsitis|Radix codonopsitis (\~10-15g)
224167106|NCT01641224|DRUG|Radix curcumae|Radix curcumae (\~10g)
224167107|NCT01641224|DRUG|Fingered citron|Fingered citron (\~10g)
224167108|NCT01641224|DRUG|Tuckahoe|Tuckahoe (15g)
224167109|NCT01641224|DRUG|Placebo|Placebo is blindly given to patients.
224167110|NCT04347434|DRUG|Atorvastatin 80mg|Atorvastatin is prescribed at a dose of 80 mg / day from the first 24-96 hours of AMI in addition to the standard therapy
224167111|NCT00926562|DRUG|Iopromide (Ultravist)|Iopromide (contrast agent), 370 mgl/ml, an nonionic, monomeric, LOCM
224167112|NCT00926562|DRUG|Iodixanol (Visipaque)|Iodixanol (contrast agent) 320 mgl/ml, a nonionic, dimeric, IOCM
224167113|NCT06312046|OTHER|HiBalance-MS|See arm description for intervention group.
224167114|NCT02049294|BIOLOGICAL|Omalizumab (Xolair)|
224167115|NCT02049294|DRUG|Placebo|
224167116|NCT04955301|BEHAVIORAL|Priming intervention|The priming manipulation will be embedded in one discrete choice experiment to test the effect of three priming interventions: priming with health benefits, environment benefits, and co-benefits of having sustainable diets, respectively, on consumers' preference for sustainable foods, and the relative importance of proximal attributes (e.g. taste and price) and distant attributes (e.g., attributes related to environmental sustainability) in determining food choice preference, as well as testing whether the effects of these three priming interventions can be modified by consumers' social orientation values. The cueing manipulation will be achieved by asking participants to complete a word-search exercise.
223479739|NCT04134039|DEVICE|Polyurethane (PU) condom|A minimum of 5 condoms (maximum 7 condoms) of each condom type will be provided to couples to be used during vaginal intercourse over a 4 week period, the assessment period. Couples will repeat the assessment period each of the 2 condom types.
223479740|NCT04134039|DEVICE|Natural Rubber Latex (NRL) condom|A minimum of 5 condoms (maximum 7 condoms) of each condom type will be provided to couples to be used during vaginal intercourse over a 4 week period, the assessment period. Couples will repeat the assessment period each of the 2 condom types.
223744883|NCT01172457|PROCEDURE|Epiduroscopy with oxygen therapy|Patients in this group will receive 30 mL of oxygen by epiduroscopy.
224167117|NCT03037112|BEHAVIORAL|Education|The first intervention is an educational intervention regarding appropriate diagnosis and treatment of common respiratory infections. This education will be delivered in an interactive lecture format for providers with follow up short informational video clips available over the course of the project.
224167118|NCT03037112|BEHAVIORAL|Communication Skills|The second intervention is an education plus communication skills training intervention. This training session will include identical antibiotic education training, good and bad communication examples, training on negative behavioral framing, and education regarding key drivers of patient satisfaction. Additionally providers will be informed of parent's desire for antibiotics rating prior to their consultation with the patient.
224167119|NCT05126550|BIOLOGICAL|SARS-CoV-2 vaccine (Vero cell) inactivated|"Two doses of 0.5 mL intramuscular injection containing 4 mcg (6.5 Unit) antigens with an interval of 21-28 days in accordance with Vaksinasi Gotong Royong (mutual cooperation vaccination program)"
224305313|NCT01568060|OTHER|Infanrix-IPV data collection|Safety monitoring: recording of adverse events using diary cards and recording of serious adverse events using the latest version of Korea's Post-Marketing Surveillance Serious Adverse Event Reporting Form.
224167120|NCT00534560|DRUG|Tonabersat|Tablets, 4 week dose titration and 16 weeks treatment at target dose of 40 mg per day
224167121|NCT00534560|DRUG|Tonabersat|Tablets: 4 week titration and 16 weeks at target dose of 80 mg per day
224167122|NCT00534560|DRUG|Placebo|Tablets; 4 week dose titration with 16 weeks at target dose
224167123|NCT00557323|DRUG|Lanthanum carbonate|
223479741|NCT05646914|OTHER|Complex training exercises|Squats and drop jumps, Barbell step-ups and hops, Bench press and plyometric press-up, Barbell lunge and box jumps were performed.
223479742|NCT05646914|OTHER|Plyometric training exercises|Drop Jumps, Hops, Plyometric press-up, Box Jumps were performed.
223479743|NCT05398627|DEVICE|Amygdala Neurofeedback|real-time feedback on the hemodynamic response of the amygdala during positive autobiographical memory recall
223744884|NCT01172457|PROCEDURE|Epiduroscopy with ozone therapy|Patients in this group will receive 30 mL of ozone at a concentration of 30 mcg / ml by epiduroscopy.
223744885|NCT01248442|DRUG|Cholecalciferol|monthly dose of 140.000 IU of cholecalciferol orally, 3 times.
223744886|NCT01248442|DRUG|Placebo|Matching Placebo
224167124|NCT03003130|DEVICE|Restylane Defyne|Intradermal injection
224167125|NCT03003130|DEVICE|Restylane|Intradermal injection
224167126|NCT04164849|DRUG|5-aminolevulinic acid|5-aminolevulinic acid (30 mg/ml) will be added to mononuclear cells in a dose of 3 millimolar and incubated for 1 hour
224167127|NCT04164849|PROCEDURE|Blue light photopheresis|The mononuclear cells incubated with 5-aminolevulinic acid for 1 hour will be exposed to blue light.
224167128|NCT04164849|PROCEDURE|Transfusion|The treated cells are transferred back to the patient as a standard blood transfusion
224167129|NCT04164849|PROCEDURE|Continuous Mononuclear Cell Collection (CMNC)|The mononuclear cells are collected using the Spectra Optia with the Continuous Mononuclear Cell Collection protocol. 90 ml of mononuclear cells will be collected and 100 ml of 0,9% saline will be added to dilute the cells before incubation with drug and photopheresis.
224167130|NCT01814449|OTHER|18FMISO PET/CT scan|The baseline 18F-FMISO PET/CT scans were scheduled before initiation of endocrine therapy. All patients were injected intravenously with 370 MBq of 18F-FMISO and PET/CT static emission scans were conducted at 4 hours after injection.
224167131|NCT01814449|DRUG|Letrozole|Patients were assigned to primary endocrine therapy with letrozole 2.5mg daily for at least 4 months.
224167132|NCT01905514|DEVICE|internet mobile application|
224167133|NCT05639361|BEHAVIORAL|Repeated Exposure|Caregivers will be asked to offer a novel vegetable to their infant/toddler 10 times at home according to the schedule of repeated exposure to which they are randomized.
224167134|NCT04960332|DEVICE|Prevena|RCT (no blinding) where the patients will be randomized to wound closure with staples and either Negative Pressure Wound Therapy (PREVENA PLUS™ Incision Management System) for 7 days or a conventional wound dressing.
224167135|NCT01196091|DRUG|LY2127399|120 mg administered via subcutaneous (SC) injection for 52 weeks. 240 mg loading dose will be administered as the first dose of study drug.
224167136|NCT01196091|DRUG|Placebo every 2 weeks|Administered via subcutaneous injection for 52 weeks. A matching loading dose of corticosteroids, NSAIDs, antimalarials, or immunosuppressants will also be administered at the first dose
224167137|NCT01196091|DRUG|Placebo every 4 weeks|Administered via subcutaneous injection for 52 weeks.
224167138|NCT01196091|DRUG|Standard of Care|
224167139|NCT03733249|DRUG|Rimiducid|Rimiducid is administered to treat chronic graft versus host disease
224167140|NCT03733249|BIOLOGICAL|rivogenlecleucel|donor T-cells modified with iCasp safety switch
224167141|NCT05260450|DEVICE|1064 nm Nd:YAG-laser therapy|"All interventions and mycological tests for each subject were performed over the course of one day.~After subjects were included, toenails with a clinical suspicion of OM were tested for fungal infection by culture and microscopy. At the same time, nail clippings from said toenails were obtained and randomised into one of two treatment groups, i.e., group A and group B.~The nail clippings were then treated with a 1064 nm Nd:YAG-laser with laser settings as specified by the treatment groups. All nail clippings were treated only once.~Immediately after treatment, nail clippings were again tested for fungal infection by culture and microscopy."
223479744|NCT04140110|OTHER|Intensive BP lowering|The aim is to achieve a systolic BP level of \<120mmHg within 1 hour after randomisation and to maintain this BP level for the next 72 hours (or until hospital discharge or death if this should occur earlier).
223479745|NCT04478617|DRUG|Metronidazole Vaginal|Vaginal metronidazole 0.75% (MetroGel or Vandazole) will be inserted per vagina days 1 through 5 prior to date of surgery.
224167142|NCT00806650|GENETIC|gene expression analysis|Testing performed on blood draw taken prior to surgery or other treatment and on fresh or frozen primary or metastatic tissue samples
224167143|NCT00806650|GENETIC|protein expression analysis|Testing performed on blood draw taken prior to surgery or other treatment and on fresh or frozen primary or metastatic tissue samples
223479746|NCT03911531|DIAGNOSTIC_TEST|Whole Exome Sequencing|Whole exome sequencing (WES) provides more detailed information through greater resolution, identifying single base-pair changes and small insertions and deletions. WES performs sequencing on the protein-coding exons, which are contained in 1-2% of the genome but make up over 85% of all known pathogenic mutations.
223479747|NCT03911531|DIAGNOSTIC_TEST|Whole Genome Sequencing|Whole Genome Sequencing (WGS) has emerged in recent years as a diagnostic tool that sequences the entire genome and can pick up insertions or deletion of bases, structural variants and intronic single nucleotide variations.
223479748|NCT01563783|PROCEDURE|Global Fibroid Ablation (GFA)|GFA is being used for the treatment of symptomatic uterine fibroids
223479749|NCT01563783|PROCEDURE|Abdominal or Laparoscopic Myomectomy|Myomectomy is a procedure in which uterine fibroids are surgically removed from the uterus.
223479750|NCT01563783|PROCEDURE|Uterine Artery Embolization (UAE)|UAE is a minimally invasive surgical procedure used to treat uterine fibroids.
223479751|NCT02960451|OTHER|PRIME care|Specialist medication, cognitive behavior therapy, family-focused therapy
223479752|NCT02960451|OTHER|Usual care|Medication and psychotherapy as available form community providers
223479753|NCT03860688|DRUG|TED + glucose|Teduglutide, up to 0.05mg/kg, subcutaneous, single dose Glucose, 25g, oral, single dose
223479754|NCT05578053|DRUG|Dalpiciclib|a new, orally administered, selective CDK4/6 inhibitor
224167144|NCT00806650|DIAGNOSTIC_TEST|diagnostic laboratory biomarker analysis|Testing performed on blood draw taken prior to surgery or other treatment and on fresh or frozen primary or metastatic tissue samples
224167145|NCT00806650|OTHER|immunoenzyme technique|Testing performed on blood draw taken prior to surgery or other treatment and on fresh or frozen primary or metastatic tissue samples
224167146|NCT00806650|OTHER|immunohistochemistry staining method|Testing performed on blood draw taken prior to surgery or other treatment and on fresh or frozen primary or metastatic tissue samples
224167147|NCT03988790|DEVICE|VOC analysis|VOC analysis in exhaled air with e-noses and mass spectrometry.
224167148|NCT00606229|DRUG|Aripiprazole|oral, 24mg/day
224167149|NCT00298311|BEHAVIORAL|mci guidance peer support|12 weeks of home visits by peer mentor recovered from PPD and Keys to Caregiving (NCAST, 1990) program
224167150|NCT01526928|DRUG|Rociletinib|Phase 1: Rociletinib \<900 mg BID FB will be administered in escalating dosages in a period of 21-day cycles
224167151|NCT01526928|DRUG|Rociletinib|Phase 1: Rociletinib 900 mg BID FB will be administered in escalating dosages in a period of 21-day cycles
224167152|NCT01526928|DRUG|Rociletinib|"Phase 1: Rociletinib 500 mg BID HBr will be administered in escalating dosages in a period of 21-day cycles~Phase 2: Rociletinib 500 mg BID HBr will be administered daily"
224167153|NCT01526928|DRUG|Rociletinib|"Phase 1: Rociletinib 625 mg BID HBr will be administered in escalating dosages in a period of 21-day cycles~Phase 2: Rociletinib 625 mg BID HBr will be administered daily"
224167154|NCT01526928|DRUG|Rociletinib|"Phase 1: Rociletinib 750 mg BID HBr will be administered in escalating dosages in a period of 21-day cycles~Phase 2: Rociletinib 750 mg BID HBr will be administered daily"
224167155|NCT01526928|DRUG|Rociletinib|"Phase 1: Rociletinib 1000 mg BID HBr will be administered in escalating dosages in a period of 21-day cycles~Phase 2: Rociletinib 1000 mg BID HBr will be administered daily"
224167156|NCT01108068|DRUG|Lithium|lithium will be given for 6 months to patients with OPPG, starting at a low dose of 2.5 mg/kg daily, gradually increasing until a lithium blood level of 0.3-0.6 ng/dl is achieved.
224167157|NCT00836953|BIOLOGICAL|Influenza virus vaccine (Pediatric formulation)|0.25 mL, Intramuscular
224167158|NCT05474924|DRUG|Budesonide intrapolyp injection|intrapolyp injection of budesonide in cases of nasal polyps and assessment of side effects compared to systemic steroids
224167159|NCT05474924|DRUG|Budesonide nasal wash|Budesonide Nasal wash in cases of nasal polyp 0.5 mg/2ml added to 250 ml normal saline using squeeze bottle.
224167160|NCT05474924|DRUG|Prednisolone tablets|oral prednisolone tablet dosage 1 mg/kg/d tapered daily for 2 weeks.
224167161|NCT04249791|PROCEDURE|Transplantation of the uterus from live donor.|Laparoscopic-robotic hysterectomy for uterine transplantation in live-donor patient.
224167162|NCT00376675|DRUG|methylphenidate hydrochloride|Given orally
224167163|NCT00376675|OTHER|placebo|Given orally
224167164|NCT00419237|DRUG|GW685698X|GW685698X will be available as dry white powder to be inhaled via DISKUS containing cellobiose octaacetate (COA) blended with lactose.
224167165|NCT03317912|DRUG|Lidocaïne 2%|Continuous infusion during per and postoperative periods
224167166|NCT03317912|DRUG|Placebo (for Lidocaïne)|Continuous infusion during per and postoperative periods
224167167|NCT04854226|DIETARY_SUPPLEMENT|Macronutrients_CARB|Breast milk 150 to 170 mL/d; Target fortification: 9.0 g/100mL COH, 3.0 g/100mL protein, 4.0 g/100mL fat, 86.4 kcal/100mL
224167168|NCT04854226|DIETARY_SUPPLEMENT|Macronutrient_FAT|Breast milk 150 to 170 mL/d; Target fortification: 5.5 g/100mL COH, 3.0 g/100mL protein, 5.5 g/100mL fat, 86 kcal/100mL
224167169|NCT00472823|DIETARY_SUPPLEMENT|Vitamin D3|Orally for one year
224167170|NCT00472823|DIETARY_SUPPLEMENT|Calcium Citrate (Citracal)|Orally for one year; dosage adjusted so that calcium intake is 1200-1400mg daily
224167171|NCT04771104|DIETARY_SUPPLEMENT|Amino Acid Challenge (AAC)|The AAC contains 54 g banana flavoured amino acid mixture added 200-300 mL of water. The AAC simulates the composition of haemoglobin in approximately 400 mL of blood.
224167172|NCT02381067|OTHER|NuCel with Allograft Bone|NuCel is a minimally manipulated allograft product derived from amniotic membrane along with cells from amniotic fluid. Allograft bone is bone that comes another patient. NuCel and Allograft bone will be combined for this treatment.
224167173|NCT06341569|OTHER|Respiratory breathing techniques group|"Target group: subjects in the respiratory breathing techniques group. Program duration: the program lasts for 14 weeks.~Breathing techniques: the program includes various breathing exercises, including:~Diaphragmatic breathing teaches participants to breathe deeply, engaging the diaphragm muscle, which can improve lung capacity and relaxation.~Pursed-lips breathing: this technique involves inhaling through the nose and exhaling slowly through pursed lips, which can help slow down breathing and manage shortness of breath.~Alternate nostril breathing: this technique involves closing one nostril while inhaling and exhaling through the other nostril alternately.~Relaxation techniques: the program incorporates progressive muscle relaxation techniques. This involves progressively tensing and relaxing different muscle groups.~Medical education: topics like the anatomy of the respiratory system, the importance of proper breathing, potential benefits of specific breathing exercises."
223479755|NCT06646302|OTHER|Personalized 40 Hz Broadband Stimulation|Broadband acoustic stimulus (125 Hz-12 kHz) amplitude-modulated at 40 Hz with a 50% duty cycle. A polynomial regression and FFT-based algorithm applies individualized frequency weighting, combining population data (70%) and patient-specific responses (30%). Delivered for 60 seconds at 10 dB above the individual minimum masking level (MML).
223744887|NCT00643682|OTHER|Educational card|"A 4x6 inch educational card containing a photo of an unprepared colon and a clean colon with the caption: Drinking all the bowel cleaning medicine as described in the enclosed instructions lets the doctor see your colon better during your colonoscopy."
223744888|NCT00206947|DRUG|donepezil (5-10 mg/day)|Donepezil will be administered in a dose optimized for treatment, to patients who are stabilized on a ziprasidone treatment
224167174|NCT05045339|PROCEDURE|Ball Exercises|Different ball exercises which include stability ball roll, stability ball hug, catching, throwing was performed. Along with these exercises, ball tapping exercise was also performed.
224167175|NCT06997393|BEHAVIORAL|Prevention programme|The prevention programme consists of a validated educational video and training in the basic recognition and prevention of hand eczema.
224167176|NCT06541990|BEHAVIORAL|HARMONY|A psychoeducational intervention for patients with HCC
224167177|NCT06541990|OTHER|Enhanced usual care|A supportive care resource guide
224167178|NCT07005986|DIAGNOSTIC_TEST|Plasmatic PPi level|Plasmatic PPi level dosage at visit 1
224167179|NCT03416972|RADIATION|Standard platinum-based chemoradiotherapy|Stage III patients: Standard platinum-based chemotherapy, total radiation dose 60 Gy in 30 fractions. Stage I/II patients: Standard radiotherapy, total radiation dose of 54 Gy in 3 fractions (peripheral), 55 Gy in 5 fractions (near chest wall), or 60 Gy in 8 fractions (central).
224167180|NCT05292573|DRUG|Metformin|During the intervention period, metformin is given 500 mg tablet b.i.d. Those who stopped taking metformin will remain in the study not counting as protocol violation.
224167181|NCT06623409|BIOLOGICAL|GARDASIL®9 (G9)|Suspension administered via intramuscular (IM) injection
224167182|NCT06623409|BIOLOGICAL|V540B|Experimental vaccine and adjuvant administered via IM injection
224305314|NCT01906450|DRUG|Scaling and root planing plus Azithromycin|Single session of scaling and root planning using ultrasonic device. Azithromycin tablets 500mg, 1 tablet every 24 hours for 5 days
224305315|NCT01906450|DRUG|Scaling and root planing plus placebo|Single session of scaling and root planning placebo tablets 500mg, 1 tablet every 24 hours for 3 days
224305316|NCT00362544|DRUG|Ambisome|
224305317|NCT02076373|DRUG|recombinant human Erythropoietin|i.v. administration
224305318|NCT02076373|DRUG|Placebo|i.v. administration
224305319|NCT01059344|DRUG|Mesalamin|4.8g/day, 800 mg tablets
224305320|NCT05386940|OTHER|PKN1 level|different PKN1 level after on-pump cardiac surgery
224305321|NCT01739348|DRUG|Verubecestat (Part I and Part II)|Single 12 mg verubecestat tablet once daily, taken orally
224167183|NCT06625905|DIAGNOSTIC_TEST|Ultrasound imaging|Both groups of participants-those with myofascial and/or musculoskeletal pain and those without musculoskeletal alterations-will undergo a standardized intervention focused on the application of vibratory stimuli, alongside real-time ultrasound imaging. Vibratory stimuli will be applied directly to the region of interest, specifically over the identified MTrP in participants with active myofascial pain. In participants without musculoskeletal alterations, the stimuli will be applied either over a latent MTrP or in a randomly selected area of the gastrocnemius medialis muscle, ensuring a consistent methodology across both groups. Simultaneously, real-time ultrasound imaging will be performed to capture detailed images of the muscle tissue during the application of vibratory stimuli. Imaging will be conducted in two planes (longitudinally and transversely).
223744889|NCT00206947|DRUG|Placebo|Placebo will be added to the medication of schizophrenia patients who are first stabilized on a ziprasidone treatment
224167184|NCT06685679|DRUG|Melatonin|oral melatonin 3 mg/kg/day divided in 3 doses , after enteral feeding, for 3 consecutive days, as combined therapy to milrinone
224167185|NCT06685679|OTHER|Placebo|Equivalent amount of distilled water will be given every hours as combined therapy to milrinone
224167186|NCT00546936|DRUG|ranibizumab|0.5mg ranibizumab
224167187|NCT00546936|DRUG|verteporfin|Photodynamic therapy with verteporfin every 3 months for 1 year
224167188|NCT02829775|DRUG|Pegylated Interferon Alfa-2a|Participants will maintain the same dose they were receiving in the parent protocol.
224167189|NCT02829775|DRUG|Recombinant Interferon Alfa 2a|Participants will maintain the same dose they were receiving in the parent protocol.
224167190|NCT02608125|DRUG|PRN1371|
224167191|NCT01249157|DEVICE|Positron Emission Mammography (PEM) and Magnetic Resonance Imaging (MRI)|An additional 5 women will be enrolled at the beginning of the study for training purposes only and will not be included in the assessment of this study. Once the patient has had both breast MRI and PEM, the location of each site of potential breast cancer will be listed for each modality. The location of each abnormality on each imaging examination will be documented. Once the histopathologic evaluation has been performed, the pathology results will be compared to the imaging results for each modality. Furthermore, comparison of the performance of MRI and PEM will then be made with the pathological results as the truth. Comparison of the histology and biomarkers in each lesion detected by each modality will be done in order to determine if these factors affect detection by each modality.
224167192|NCT04804904|DRUG|TQ-B3101|TQ-B3101 oral capsule
224167193|NCT00396825|BEHAVIORAL|Video-based coping skills training with telephone coaching|Subjects will view the 10 modules of Williams LifeSkills Caregiver Video, do Workbook exercises for each module, and receive telephone coaching to enhance their ability to apply the skills taught in each module to caregiver situations.
224167194|NCT00062647|DRUG|Telavancin|Telavancin 10mg/kg/day IV every 24 hrs for up to 14 days
224167195|NCT00062647|DRUG|Vancomycin, nafcillin, oxacillin, or cloxacillin|Vancomycin 1 Gram every 12 hr IV (intravenously) OR nafcillin, oxacillin, or cloxacillin 2 Grams every 6 hr IV (intravenously) for up to 14 days.
224167196|NCT01844427|DRUG|Memantine|Memantine HCl is an NMDA antagonist currently FDA approved for the treatment of moderate to severe Alzheimer's-type dementia.
224167197|NCT01844427|DRUG|Placebo|
224167198|NCT00390429|DRUG|docetaxel|Given IV
223479756|NCT06646302|OTHER|40 Hz Pure Tone Stimulation|Pure tone stimulus at the optimized frequency (matched to tinnitus characteristics or high-frequency carrier), amplitude-modulated at 40 Hz with a 50% duty cycle. Delivered for 60 seconds at 10 dB above MML.
223479757|NCT06646302|OTHER|Continuous Broadband Noise|Continuous broadband noise spanning 125 Hz-12 kHz without 40 Hz modulation. Delivered for 60 seconds at 10 dB above MML as an active control condition.
223479758|NCT04108390|OTHER|Dry needling|For this intervention, the physiotherapist will be placed a needle in the gluteus medius trigger point from 8 to 15 times.
223479759|NCT06524258|DIAGNOSTIC_TEST|testicular elastography|testicular elastography for predicting non obstructive azoospermia
223479760|NCT04451083|DRUG|FOY-305|Multiple-dose of FOY-305 will be administered orally at 4 times/day.
223479761|NCT02123381|RADIATION|preoperative radiotherapy|"Patients receive intensity modulated radiation therapy(IMRT) or image-guided radiation therapy(IGRT)from week 1 to week 4,once a day, 5 times per week.~Radiotherapy dose：95% gross tumor volume（GTV-T） 40Gy/20f，GTV-N 40Gy/20f，CTV-T 40Gy/20f，CTV-N 40Gy/20f."
223479762|NCT02123381|DRUG|cetuximab|400mg/m2/week, 2 hours,iv,at week 1;250mg/m2/week,1hour,iv,at week 2-4
223744890|NCT04846660|OTHER|Production pressure|Participant exposed to production pressure
224167199|NCT00390429|DRUG|erlotinib hydrochloride|Given orally
224167200|NCT02353689|DIETARY_SUPPLEMENT|low FODMAP|consumed EN formula containing low FODMAPs (0.320g/can) during 14-day intervention
224167201|NCT02353689|DIETARY_SUPPLEMENT|moderate FODMAP|consumed EN formula containing moderate FODMAPs (0.753g/can) during 14-day intervention
224167202|NCT02353689|DIETARY_SUPPLEMENT|high FODMAP|consumed EN formula containing high FODMAPs (1.222g/can) during 14-day intervention
224167203|NCT01012804|GENETIC|western blotting|
224167204|NCT01012804|OTHER|immunohistochemistry staining method|
223479763|NCT02857504|DEVICE|double lumen tube with a hook|The tube with the hook (after passing the bronchial cuff trough the vocal cords) was rotated for 180 degrees to the left and removed the stylet and when the hook passed the vocal cords, the tube was rotated for 90 degrees back to the right and push it into the bronchus. Following formula was used for the right depth (height (cm)/10 + 12 (cm)) of the tube without the hook. The tube with hook was inserted into the bronchus so that hook was placed on the carina and stopped.
223479764|NCT02857504|DEVICE|double lumen tube without a hook|Tube without the hook was inserted with the following technique: after the bronchial cuff was passed the vocal cords, the stylet was removed and the tube was rotated 90 st towards left.
223744891|NCT03907293|BEHAVIORAL|Exercise-based cardiac rehabilitation|Moderate intensity aerobic exercise, lifestyle advice, and psychological support.
223744892|NCT05014750|OTHER|None intervention|There is no intervention included in this study.
223744893|NCT04311424|DRUG|14C Tirzepatide|Administered SC.
223744894|NCT01079091|DEVICE|ADVOS (Hepa Wash)|"Intervention frequency: 1-10 treatments (decision of the investigator)~Duration of intervention per patient: Treatment until recovery or death (max. 6 weeks)"
224167205|NCT01012804|OTHER|laboratory biomarker analysis|
224167206|NCT06195904|OTHER|NA (No intervention)|NA (No intervention)
224167207|NCT06225804|DRUG|ABSK112|In the escalation part, patients will receive a single dose of oral ABSK112 on Cycle1 Day1 only, and then patients will continuously receive ABSK112 once daily (QD) or twice daily (BID) in subsequent cycles. In the expansion part, patients will each be treated at the selected RDE dose level.
224071694|NCT05938673|OTHER|Active stimulation- intermittent theta-burst (iTBS) stimulation|During active stimulation, patients will receive intermittent theta-burst (iTBS) stimulation in T2-T3 toracic region while seated using a circular magnetic coil positioned at 90º, handle facing to the right, connected to a magnetic stimulator.Each participant will receive a total of 1,200 rTsMS pulses at 120% of resting motor threshold, determined by abdominal muscle contractions. In 3 minutes and 58 seconds, 20 trains with 20 bursts and each burst with 3 pulses at 50 Hz repeated at 5Hz with an intertrain interval of 8 seconds will be applied.Immediately after, participants will proceed with 30 minutes of treadmill training, starting at 80% of the comfortable walking speed. Progressive speed increments of 0.2 km/h will be performed every 5 minutes as tolerated. The intensity of the exercise will be adjusted to the patient's tolerance and maintained between light to moderate intensity.
224167208|NCT02392468|DRUG|Placebo matching BI 409306 25 mg|Film-coated tablet
224167209|NCT02392468|DRUG|Placebo matching BI 409306 50 mg|Film-coated tablet
224167210|NCT02392468|DRUG|BI 409306 25 mg|Film-coated tablet
224167211|NCT02392468|DRUG|BI 409306 50 mg|Film-coated tablet
224167212|NCT02353676|DRUG|Bupivacaine|1.5 ml of 0.55 bupivacaine solution to be used as postoperative anesthetic agent for prolonged analgesia
224167213|NCT02353676|OTHER|SALINE|1.5 ml of placebo (saline solution) to be injected into the opposite site postoperatively.
224167214|NCT01313039|DRUG|AZ6244|AZD6244 75 mg (3 x 25mg capsules) orally twice per day on Days 1 - 15
224167215|NCT00502619|PROCEDURE|Acupuncture|A specific regimen of acupuncture sites will be needled twice weekly for eight weeks and once weekly for a subsequent eight weeks.
224167216|NCT00502619|OTHER|Treadmill Exercise|After the first four weeks of acupuncture treatments, subjects will initiate a three times per week treadmill program, which will continue for a total of 12 weeks in conjunction with the acupuncture treatments.
224167217|NCT03185312|DIAGNOSTIC_TEST|skin biopsy|"Clinical evaluation including full history taking and dermatological examination will be done for all patients. Assessment of disease severity will be performed using VASI score for vitiligo and Global acne severity grading for acne vulgaris Skin biopsies will be taken from lesional and non-lesional skin of patients as well as controls. immunohistochemical staining using specific antibodies for detection of expression of JAK1, JAK2 and JAK3.~Additionally, biopsies will be preserved in RNA later solution at -20°C. RNA isolation and real-time qPCR analysis will be performed for measurement of cutaneous JAK1, JAK2 and JAK3 gene expression."
224167218|NCT05083949|DRUG|FDC 12.5mg empagliflozin/850mg metformin|empagliflozin/metformin
224167219|NCT05083949|DRUG|Empagliflozin|empagliflozin 10mg (R1)
224167220|NCT05083949|DRUG|Glifage®|Glifage® 850mg (R2)
224167221|NCT02049788|BEHAVIORAL|low calorie/fat diet|Conventional behavioural lifestyle modification instructions x 1/month for 6 months about low-calorie (approximately 1200-1300 kcal/day), low-fat (25% of total calories from fat) and about physical activity (increase non-weight bearing exercise 30 minutes/day at least x 3 times/week, increase physical activity in their routine and decrease sedentary activity).
224305322|NCT01739348|DRUG|Verubecestat (Part I and Part II)|Single 40 mg verubecestat tablet once daily, taken orally
224305323|NCT01739348|DRUG|Verubecestat (Part I and Part II)|Single 60 or 40 mg verubecestat tablet once daily, taken orally
224305324|NCT01739348|DRUG|Placebo (Part I)|Single placebo tablet matching verubecestat treatment once daily, taken orally
224167222|NCT02049788|BEHAVIORAL|Low glycaemic index diet|Experimental behavioural lifestyle modification instructions x 1/month for 6 months about low glycaemic index diet (selection of low-GI carbohydrates with the caloric distribution of carbohydrate 50-55%: protein 15-20%: fat 30-35%, instruction by two-hour small classes with parental participation low GI cooking demonstration and food labeling guidance) and about physical activity (increase non-weight bearing exercise 30 minutes/day at least x 3/week, increase physical activity in their routine and decrease sedentary activity).
224167223|NCT05369793|DRUG|Alpha lipoic acid|Administration of alpha-lipoic acid 600mg plus vildagliptin/metformin combination (50/1000mg) orally once daily for 3 months.
224167224|NCT05369793|DRUG|Roflumilast|Administration of 500 mcg plus vildagliptin/metformin combination(50/1000mg) orally once daily for 3 months.
224167225|NCT00776334|DRUG|Fosinopril 40mg Tablets|
224167226|NCT02996500|DRUG|PF-06650833|Investigational
224167227|NCT02996500|DRUG|Placebo|Placebo
224167228|NCT02996500|DRUG|Tofacitinib|Investigational
224167229|NCT03437629|PROCEDURE|Temporary cement based on Calcium Hydroxide|Confection of a temporary crown with acrylic resin; Finishing and polishing; relative isolation with cotton and gauze; Manipulation of the temporary cement based on Calcium Hydroxide; Cement insertion on the internal surface of the temporary crown; Excess cement removal; Occlusal Adjustment.
224167230|NCT03437629|PROCEDURE|MTA temporary cement|Confection of a temporary crown with acrylic resin; Finishing and polishing; relative isolation with cotton and gauze; Manipulation of the temporary cement based on Mineral trioxide aggregate; Cement insertion on the internal surface of the temporary crown; Excess cement removal; Occlusal Adjustment.
224167231|NCT04180917|OTHER|Survey|survey
224167232|NCT04904341|DRUG|Cerebrolysin|neuroprotection treatment
224167233|NCT03675919|DEVICE|Scale|self-monitoring of body weight; with automatic data transfer into the personalized and secured online portal
224167234|NCT03675919|DEVICE|Step counter|self-monitoring of physical activity; with automatic data transfer into the personalized and secured online portal
224167235|NCT03675919|DEVICE|Blood glucose meter with test stripes|self-monitoring of blood glucose; with automatic data transfer into the personalized and secured online portal
224167236|NCT03675919|OTHER|Access to the online portal|self-monitoring of health parameters
224167237|NCT03675919|OTHER|Telemedical coaching|regular telephone calls providing information about T2DM, healthy lifestyle, low-carbohydrate diet and physical activity
224305325|NCT01739348|DRUG|Verubecestat (Part II)|Single 40 mg verubecestat tablet once daily, taken orally
224305326|NCT05180916|DEVICE|TVNS|Cerbomed NEMOS
224167238|NCT03189810|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|On Day 1, the resting motor threshold (RMT) will be determined according to previous published methods \[Cardenas-Morales et al. 2013\] and the rTMS will be delivered at an intensity of 90% of the participant's RMT. rTMS will be administered at 20 Hz (25 trains, 30 pulses per train, 30 second intertrain interval).
224167239|NCT03189810|DEVICE|Sham Repetitive Transcranial Magnetic Stimulation (rTMS)|On Day 1, the resting motor threshold (RMT) will be determined according to previous published methods \[Cardenas-Morales et al. 2013\] and the Sham rTMS will be delivered at an intensity of 90% of the participant's RMT. rTMS will be administered at 20 Hz with the B65 placebo coil (25 trains, 30 pulses per train, 30 second intertrain interval).
223584563|NCT01524081|DRUG|Amoxicillin (+ clavulanic acid) and Fluconazole|"Administration of amoxicillin (+ clavulanic acid) 2.4 g and Fluconazole 800mg in 2 following intravenous infusions 60 minutes prior the surgery.~1. \- 2x amoxicillin in 100ml saline~2. \- Fluconazole in 500ml saline"
223584564|NCT01524081|DRUG|Placebo|"Administration of saline infusion (Natrii chloridum: 9,0 g/l) 60 minutes prior the surgery~1. \- 100ml saline solution~2. \- 500ml saline solution"
223584565|NCT01524081|DRUG|Placebo|"Administration of saline infusion (Natrii chloridum: 9,0 g/l) 60 minutes prior the surgery~1. \- 2x 100ml saline solution~2. \- 500ml saline solution"
223584566|NCT06530134|OTHER|Driving situation and video feedback|At the end of the driving situation, 35 patients will be asked to express themselves and analyze 4 driving situations resulting from the course of the driving situation using video feedback.
223584567|NCT06530134|OTHER|Driving situation and usual recommendations (without video feedback)|"At the end of the driving situation, 35 patients will be asked to express themselves and analyze 4 driving situations resulting from the course of the driving situation without video feedback, according to the usual recommendations.~Comparison of responses to all questionnaires and interview grids sent before and after driving, to patients and professionals will determine whether video feedback promotes awareness of the difficulties of driving post-stroke patients."
223584568|NCT03083145|DIETARY_SUPPLEMENT|Whey Protein Beverage|Beverage administered and postprandial appetite assessed for 2 hours followed by 1 hour monitoring of food intake from ad libitum snack tray.
224167240|NCT03189810|BEHAVIORAL|Weekly Counselling Session|In order to support participants in their abstinence plan, individual weekly sessions of supportive counselling will be administered over the course of the study on 1 time per week over 4 weeks (28 days of abstinence).
224167241|NCT05540210|DEVICE|measurement of PSP|one or two blood samples
223479765|NCT01434511|BIOLOGICAL|OBI-1|intravenous infusion, up to every 2-3 hours for the first 24 hours of treatment
223479766|NCT03993912|DRUG|Daratumumab SC in combination with Lenalidomide|"Daratumumab SC 1800 mg~* once every week for 8 weeks~* then once every other week for 16 weeks~* thereafter once every 4 weeks, until progression"
223584569|NCT03083145|DIETARY_SUPPLEMENT|Pea Protein Beverage|Beverage administered and postprandial appetite assessed for 2 hours followed by 1 hour monitoring of food intake from ad libitum snack tray.
223584570|NCT03083145|BEHAVIORAL|Snack Tray Choices|Items were selected from a snack tray filled with healthy and unhealthy snacks in order to determine if educational messaging influenced snack choices. Shack choices wre recorded on a check list by a third party observer.
223584571|NCT01048450|RADIATION|Joint Resection- Keller Procedure|These subjects had received a surgical intervention of removing the proximal portion of the proximal phalanx of the hallux
223744895|NCT01079091|PROCEDURE|Standard Medical Therapy|Standard of care treatment
224167242|NCT05840523|OTHER|Proprioceptive Neuromuscular Facilitation exercises|The PNF group performed flexion-abduction-internal rotation and extension-abduction-internal rotation patterns as 15 repetitions, 2 sets. The metronome was used to fix the construction speed of the exercises (50bpm). PNF exercises were performed with EB at a metronome speed of 50bpm at a ratio of 1:2 sec. In other words, while transition from the antagonist to agonist pattern in 3 clicks, there was return from agonist to antagonist in 6 clicks.
224167243|NCT05840523|OTHER|The Range Of Motion exercises|The ROM group performed hip flexion abduction, neutral abduction and extension abduction exercises with an EB at 50bpm metronome speed in 3 sets of 10 repetitions. In both groups, 30 seconds of rest was given between exercises.
224167244|NCT05522855|DEVICE|EEG Sensorband and mobile application|EEG headband to record brain signals. The Sensorband uses Bluetooth to link to the mobile application on a user's device. This raw EEG data is processed on a HIPPA compliant cloud based server and displays mental workload and brain energy data on the application. This can help the user with cognitive pacing to avoid overexertion. The control version will not display mental workload and brain energy data on the application.
224167245|NCT03108300|DRUG|Propranolol Hydrochloride|propranolol hydrochloride is a beta-adrenergic receptor blocker
224167246|NCT03108300|DRUG|Doxorubicin|Doxorubicin is a chemotherapy which will be injected by a dose 60 mg per meter square of body surface area to be repeated every 21days
224305327|NCT01963143|BIOLOGICAL|Gammaplex (5%)|
224305328|NCT01963143|BIOLOGICAL|Gammaplex 10|
223479767|NCT03993912|DRUG|Lenalidomide PO (25mg)|Lenalidomide PO (25mg): days 1 through 21 of each 28-day cycle, until progression
223479768|NCT03993912|DRUG|Dexamethasone PO (20mg): days 1, 8, 15, 22 of each 28-day cycle, until progression|Dexamethasone PO (20mg): days 1, 8, 15, 22 of each 28-day cycle, until progression
223479769|NCT00769769|BEHAVIORAL|Psychotherapy|Participants will receive 12 sessions of cognitive behavioral therapy delivered weekly over a period of 3 months.
223479770|NCT00769769|BEHAVIORAL|Psychotherapy|Participants will receive 12 sessions of telephone-based cognitive behavioral therapy delivered weekly over 3 months.
223479771|NCT06422208|BIOLOGICAL|Autologous midbrain dopamine neurons|The autologous midbrain dopamine neurons are a experimental cryopreserved cell product derived from human autologous induced pluripotent stem cells. The autologous midbrain dopamine neurons will be surgically administered into the putamen, unilaterally, in a single surgical session.
224305329|NCT02326441|DRUG|KX2-361|
224305330|NCT01762930|DRUG|Shanchol|Each dose of the vaccine contains inactivated whole cell, heat killed and formalin killed bacteria measured as ELISA Units (EU) of lipopolysaccharide (LPS). It contains formalin-killed V. cholerae Inaba, El Tor biotype (strain Phil 6973; 600 EU); heat-killed V. cholerae Ogawa classical biotype (Cairo 50; 300 EU); formalin killed V. cholerae Ogawa classical biotype (Cairo 50; 300 EU); LPS of heat-killed V. cholerae Inaba, classical biotype (Cairo 48; 300 EU); and formalin killed V. cholerae O139 (4260B; 600 EU).
224167247|NCT02892175|PROCEDURE|Advance Directives on End of Life|after information transmitted orally by the doctor (Dr P.Priollet) and agreement of the patient to participate, patients will be interviewed (Questionary) and data collected during visits to consultations City office of Dr. Priollet by Dr. Priollet assisted by Mrs. Helena Sanson (internal medicine), anonymized and handled within the vascular medicine department of Dr. Priollet to GHPSJ.
224167248|NCT03122652|DRUG|Teriflunomide 14 MG Oral Tablet [Aubagio]|1 tablet once a day
224167249|NCT03122652|DRUG|Placebo Oral Tablet|1 tablet once a day
224167250|NCT01126294|DIETARY_SUPPLEMENT|5 mg melatonin|Patients will receive 5 mg melatonin once the evening before surgery and then again at 90 minutes before surgery.
224167251|NCT01126294|DIETARY_SUPPLEMENT|10 mg melatonin|Patients will receive 10 mg melatonin once the evening before surgery and then again at 90 minutes before surgery.
224167252|NCT01126294|DIETARY_SUPPLEMENT|Placebo|Patients will receive placebo once the evening before surgery and then again at 90 minutes before surgery.
224167253|NCT00533351|DRUG|AGN201781|AGN201781 50 mg capsules three-times daily for 2 weeks
224167254|NCT00533351|DRUG|placebo|placebo 50 mg capsules three-times daily for 2 weeks
224167255|NCT03322085|PROCEDURE|radiofrequency ablation or cryoballoon|Patients in radiofrequency ablation group receive circumferential pulmonary vein isolation,and no additional ablation is performed in the extrapulmonary sites unless the patient is diagnosed with atrial flutter before the operation. And Cryoablation is performed using a single cryoballoon. The diameter of the cryoballoon is determined as 28 mm or 23 mm according to pulmonary venography results.
223479772|NCT05716893|BEHAVIORAL|Adaptive Aerobic Training/AT Dosing|o In Phase A (\~32 weeks), AT will consist of supervised walking delivered up to 7 days per week using an adaptive dosing schedule that starts at 90 min/wk and is escalated 30 min/wk every 2 weeks to a maximal dose of 300 mins/wk. In Phase B (\~20 weeks), AT will consist of supervised adaptive AT dosing in patients with a CRF Δ\<3.50 ml O2 .kg-1.min-1 from baseline to \~32 weeks, or unsupervised AT in patients with a CRF Δ\>3.50 ml O2 .kg-1.min-1 from baseline to \~32 weeks. Supervised AT will be monitored using TeleEx.
223479773|NCT05716893|BEHAVIORAL|Standard (fixed) Aerobic Training/AT dosing|In Phase A (\~32 weeks), AT will consist of supervised walking delivered up to 7 days per week to achieve a cumulative total duration of: 90 min/wk (standard fixed dosing). In Phase B (\~20 weeks), AT will consist of supervised adaptive AT dosing in patients with a CRF Δ\<3.50 ml O2 .kg-1.min-1 from baseline to \~32 weeks, or unsupervised AT in patients with a CRF Δ\>3.50 ml O2 .kg-1.min-1 from baseline to \~32 weeks. Supervised AT will be monitored using TeleEx.
223479774|NCT03609047|DRUG|Palbociclib|CDK4/6 inhibitor
223479775|NCT03609047|DRUG|Docetaxel / cyclophosphamide|Adjuvant Chemotherapy
223584572|NCT01048450|PROCEDURE|Joint Fusion|Those who had a surgical intervention of fusion of the 1st metatarsal phalangeal joint.
224167256|NCT00628342|DRUG|Esomeprazole|20mg Oral tablet once daily
224167257|NCT00628342|DRUG|Esomeprazole|40mg Oral tablet once daily
224167258|NCT00628342|DRUG|Placebo|Oral once daily
224167259|NCT03362489|PROCEDURE|IVF / IVF-ICSI|"In the IVF arm, oocyte retrieval is performed 36 hours after the HCG injection, in the operating room, under transvaginal ultrasound guidance, under local or general anesthesia. The procedure lasts about 20 minutes and the patients are discharged on the same day. The oocytes retrieved from the follicles are transported immediately to the lab for fertilization with the partner's sperm. Fertilization is done either via conventional IVF, or via ICSI, depending on the indication. Embryos are later transferred into the uterus on day 3 or day 5, under ultrasound guidance, in the outpatient department."
224167260|NCT03362489|PROCEDURE|IUI|"In the conversion to IUI arm, IUI is performed 24 to 36 hours after ovulation trigger. The partner provides the sperm on site on the morning of the insemination, which is performed in the outpatient department."
223479776|NCT03609047|DRUG|doxorubicin/cyclophosphamide|Adjuvant Chemotherapy
223479777|NCT03609047|DRUG|epirubicin/cyclophosphamide|Adjuvant Chemotherapy
223479778|NCT03609047|DRUG|paclitaxel|Adjuvant Chemotherapy
223479779|NCT04155307|DEVICE|Anal EndoFLIP®|Anal EndoFLIP® measure to evaluate anal compliance
223479780|NCT04155307|DIAGNOSTIC_TEST|Anal Manometry|Anal Manometry done in standard care
223479781|NCT04155307|DIAGNOSTIC_TEST|Defecography|Defecographydone in standard care
224167261|NCT05578313|DRUG|Medical Cannabis|Patients will be observed throughout their treatment with medical cannabis, prescribed to them by for clinically treating their disease (treatment is not an intervention of the study).
224167262|NCT05798819|DRUG|GLS-010|IV infusion
224167263|NCT05798819|DRUG|Placebo|IV infusion
224167264|NCT05798819|DRUG|paclitaxel|IV infusion
223479782|NCT04155307|DIAGNOSTIC_TEST|Electromyogram|Electromyogram done in standard care
223479783|NCT05468307|BIOLOGICAL|Membrane Bound Cytokine Modified TIL|Adoptive transfer of 2x10\^8-1x10\^10 autologous TIL engineered with membrane-binding cytokine to patients i.v. in 30-120 minutes.
223584573|NCT01048450|PROCEDURE|Hemi-metallic Joint Implant|Those who had a surgical procedure of a hemi-metallic joint implant
223584574|NCT02440789|DRUG|Sirolimus|"Participants on a non-protease inhibitor (PI), non-non-nucleoside reverse transcriptase inhibitor (NNRTI) regimen, and for those on a non-PI, rilpivirine (RPV) based regimen received 0.025 mg/kg/day initial dose for 20 weeks.~Participants on an NNRTI regimen with the exception of RPV received 0.05 mg/kg/day initial dose for 20 weeks."
223584575|NCT00359723|DRUG|methylphenidate|
223584576|NCT04140981|DEVICE|ultrasounography|in preoperative period, airway ultrasounagraphy for all patients will be made
224167265|NCT05798819|DRUG|cisplatin|IV infusion
224167266|NCT05798819|DRUG|carboplatin|IV infusion
224167267|NCT05798819|DRUG|bevacizumab|IV infusion
224167268|NCT04298749|DRUG|GX-P1 or Placebo (dose level 1)|GX-P1 dose level 1 or placebo
224167269|NCT04298749|DRUG|GX-P1 or Placebo (dose level 2)|GX-P1 dose level 2 or placebo
224167270|NCT04298749|DRUG|GX-P1 or Placebo (dose level 3)|GX-P1 dose level 3 or placebo
224167271|NCT02410590|DRUG|Rocuronium|
224167272|NCT02410590|DRUG|Sugammadex|
224167273|NCT02410590|DRUG|Cisatracurium|
224167274|NCT02410590|DRUG|Neostigmine/Atropine|
224167275|NCT02410590|DRUG|Succinylcholine|
224167276|NCT04434261|DIAGNOSTIC_TEST|PT-PCR test for SARS-CoV-2|Screening test for the diagnosis of SARS-CoV-2 in asymptomatic patients
224305331|NCT04290975|OTHER|Task-shifting of follow-up care for pediatric epilepsy|For the intervention arm, follow-up care of children with epilepsy will be shifted to be performed primarily by Community Health Workers (CHWs) with specialized epilepsy training
224305332|NCT04290975|OTHER|Enhanced usual care for pediatric epilepsy|For the intervention arm, follow-up care of children with epilepsy will be performed primarily by physicians, with CHWs serving to collect standardized data regarding outcomes
224071695|NCT05938673|OTHER|Sham stimulation|During sham stimulation, a circular magnetic coil will be positioned in the T2-T3 toracic region disconnected to the stimulation device and the active coil will be positioned about 15 cm behind the patient, away from his field of vision, to provide sound stimulus. To create a sensation of muscle contraction and impression of active stimulation, the group will be submitted to the sensory effect of transcutaneous electrical neurostimulation (TENS) for 5 minutes, with surface electrodes placed in parallel at the T2-T3, with the parameters (80Hz,150ms, 60 mA).Immediately after, participants will proceed with 30 minutes of treadmill training, starting at 80% of the comfortable walking speed. Progressive speed increments of 0.2 km/h will be performed every 5 minutes as tolerated. The intensity of the exercise will be adjusted to the patient's tolerance and maintained between light to moderate intensity.
224071696|NCT06438432|OTHER|RAIT|The RAIT program focuses on improving postural control and balance of the entire body, including the trunk and other affected muscles, through autonomous actions in intermediate postures. This approach uses fundamental automatic control of postural support and balance to enhance the use of affected muscles during all postural and locomotor tasks. The child controls their balance during various voluntary actions from intermediate postures like alternating between four-legged and cobra postures, or swinging from the camel posture. These actions, less difficult than standing and walking, are expected to benefit the latter. The child also performs more challenging trunk movements, requiring dissociation of scapular and pelvic girdle movements or reducing lumbar lordosis.
224071697|NCT04341948|DEVICE|SPRINT Peripheral Nerve Stimulation (PNS) System|"The SPRINT System delivers mild electrical stimulation to nerves in the affected limb. The SPRINT System includes two small wires (called Leads) that are placed through the skin in the upper leg. It also includes a device worn on the body that delivers stimulation (called the SPRINT Stimulator)."
224071698|NCT05406635|DIAGNOSTIC_TEST|Biomarkers: Troponins and natriuretic peptides|Biomarker monitored treatment with measurement of NT-proBNP and cTNT / TNI in weeks 0, 9, 18, 30 and 48 of the treatment period.
224071699|NCT04319510|PROCEDURE|Craniosacral therapy|The first experimental group of patients will receive 24 units à 45 minutes over 12 weeks (2 consecutive units per week) offered by a trained craniosacral therapist within a 1:1 setting. Treatment as usual is allowed.
224071700|NCT04319510|PROCEDURE|Craniosacral self-help group training|The second experimental group of patients will receive 24 teaching units (TUs) à 45 minutes over 12 weeks offered by a trained craniosacral therapist within a group setting. The group training will start with an introductory day (8 TUs), followed by 6 practice evenings every two weeks (2 TUs each) and a final afternoon (4 TUs). The patients have to agree to participate in the introductory day and 90% of the following TUs. All patients will receive a script with theoretical CST information and descriptions of the learned techniques, which should facilitate the correct practice at home. Treatment as usual is allowed.
224071701|NCT04319510|PROCEDURE|Treatment as usal / wait list|The control group will receive no specific study treatment for a waiting period of six months. Treatment as usual is allowed. Afterwards they were offered self-selection to 1:1 CST or participation in the CST self-help group training.
224071702|NCT04062318|DEVICE|Online active TMS|"One single pulse or triple pulse train (3 pulses, 20ms inter-pulse interval) of TMS will be delivered per trial (at least 5 seconds apart) online, or during the tactile detection task, at less than or equal to 80% active motor threshold."
224071703|NCT05861531|BEHAVIORAL|Oromotor stimulation|This will begin around 33 weeks corrected, the day following the first NTrainer measurements. The oral stimulation program will be modeled after the protocol designed and studied for preterm infants and will be implemented for a goal of 10 consecutive days within a 14 day period. This includes 10 minutes of stroking the cheeks, lips, gums, and tongue, and the final 5 minutes consisting of mid tongue stroking, eliciting a suck with gloved finger, and sucking on a pacifier provided in the NICU. This will occur 15-30 minutes before a scheduled tube feeding when the infant is tolerating bolus enteral feeds of 120 ml/kg/day for at least 48 hours. This will occur behind a curtain to ensure blinding of staff and parents. Modifications will be made for infants that remain intubated and only 10 minutes of the stroking of the cheeks, lips, gums, and tongue will occur. Stimulation will cease if episodes of oxygen desaturation and/or apnea/bradycardia occur during the stimulation.
224071704|NCT05861531|BEHAVIORAL|Reading curriculum|Written packets with biweekly lessons. The first two lessons include how to begin to read and talk to their baby. The second two lessons include reading or talking about the day using infant directed speech. The final two lessons include continuing to engage with the baby through interactive reading.
224071705|NCT05861531|BEHAVIORAL|LENA recording|The LENA device provides 24 hours of language recordings placed inside an infant vest. The recordings are uploaded to a computer which analyzes total adult word counts, infant vocalizations, conversational turns, background noise, and silence.
224071706|NCT05861531|BEHAVIORAL|LENA linguistic feedback|LENA recordings of adult word counts, infant vocalizations, and conversational turns will be provided in printed form after each recording with review of each recording and progress over time.
224071707|NCT05861531|BEHAVIORAL|No oromotor stimulation|This will begin around 33 weeks corrected, the day following the first NTrainer measurements. The standard care group will not receive any stimulation but will have a study personnel present behind a curtain to ensure blinding of family, staff, and investigators. The study personnel will remain behind a curtain for 10-15 minutes prior to a feed for 10 days over a 14-day period beginning when the infant is tolerated 120 mL/kg/day for at least 48 hours.
224071708|NCT06800014|OTHER|Telerehabilitation|Participants in the telerehabilitation group will receive weekly home exercise instructions through a mobile application installed on their or their caregivers' smartphones, in addition to their standard rehabilitation program. These instructions will include videos, reminders, and directives for the exercises, with compliance monitored through mini-surveys delivered via the app.
224071709|NCT06800014|OTHER|Conventional exercise|Participants in the conventional exercise group will continue their standard rehabilitation program supplemented with printed home exercise instructions, including visuals and text, similar to the content provided to the TG.
223479784|NCT05010265|OTHER|Clinician Questionnaire|Surveys will serve to identify preferences, expectations and concerns among clinicians and researchers surrounding data-sharing of uncertain diagnostic data generated through investigative neurotechnologies which will then be systematically evaluated.
223479785|NCT05010265|OTHER|Semi Structured Interviews|Semi-structured interviews will further serve to identify preferences, expectations and concerns among patients, surrogates, clinicians and researchers surrounding data-sharing of uncertain diagnostic data generated through these investigative neurotechnologies which will then be systematically evaluated.
223479786|NCT06293248|OTHER|musical application|Rast, Acemasiran, and Huseyni from Classical Turkish Music modes were optionally offered to the patients in the music group, and the patient's preferred music was listened to through headphones for 15-20 minutes before the CAG procedure. Following the interviews, musical genres were arranged as instrumental, without words, at 70 decibels in terms of rhythm and duration, at approximately 60 metronomes per minute, and were played according to the person's preference. Instrumental music was loaded onto the portable MP3 player provided by the researchers.
223479787|NCT06106256|DEVICE|Galvanic Vestibular Stimulation (GVS)|Four electrodes, forehead, behind both ears, and back of your neck, provide bidirectional electrical stimulation and receive information about the amplitude delivered accounting for skin impedance
223479788|NCT06106256|OTHER|Flight simulations in virtual reality (VR)|Highly immersive, 3D virtual flight simulation environment
223479789|NCT06106256|OTHER|3-DOF Bertec Portable Essential's dual-balance force plate system|Firm surface/plate to stand on while being presented disorienting visual patters of moving vertical and/or horizontal bars of alternating black and white.
223479790|NCT06217302|DRUG|Sotagliflozin|Oral sotagliflozin (200 mg per day)
223479791|NCT06217302|DRUG|Placebo|Inactive tablets identical to sotagliflozin tablets
223479792|NCT06326905|BEHAVIORAL|CAPABLE Transplant- Open Label Pilot|"As in CAPABLE, the delivery characteristics of CAPABLE Transplant consist of an assessment-driven, individually tailored package of interventions delivered over the course of 4 months by an occupational therapist (OT) (\~6 home visits for ≤ 1hour), a registered nurse (RN) (\~4 home visits for ≤ 1hour) and a handy worker (HW).~Adaptations targeting those currently KT inactive will be made on a per-client basis as part of the open-label pilot. We will further refine and develop the intervention by receiving feedback from the open label pilot participants and CAPABLE clinicians who implemented the pilot to gain their perspective of the acceptability and feasibility of implementing the CAPABLE-Transplant intervention. Based on this feedback, the study team will have developed an adapted iteration of the prototype."
223479793|NCT06326905|BEHAVIORAL|CAPABLE Transplant- Randomized Control Trial|As in CAPABLE, the delivery characteristics of CAPABLE Transplant consist of an assessment-driven, individually tailored package of interventions delivered over the course of 4 months by an occupational therapist (OT) (\~6 home visits for ≤ 1hour), a registered nurse (RN) (\~4 home visits for ≤ 1hour) and a handy worker (HW). Refinements based on the open label pilot results will be included.
223479794|NCT04657185|OTHER|OR PathTrac Feedback Optimization|OR PathTrac (RDB Bioinformatics, Omaha, NE 68154) uses a systematic phenotypic approach leveraging temporal association to monitor 13 anesthesia work area reservoirs proven to be associated with high-risk intraoperative bacterial transmission events and subsequent infection development.
223479795|NCT06271590|DEVICE|Sirolimus Drug Coated Balloon|Magic TouchTM (Concept Medical) is a semi-compliant sirolimus drug coated balloon (SCB) for PCI, based on a polymer-free and nanocarrier based drug delivery technology.
223479796|NCT06271590|DEVICE|Drug eluting stents (DES)|For subjects randomized to the control group (DES), the treating physician will choose an FDA cleared DES (ZES or EES) and follow lesion preparation and stent deployment according to the Instructions per use (IFU) and institutional practices.
223479797|NCT06015490|OTHER|Sucrose drink|Participants will consume flavored beverage solutions containing 110 calories of sucrose in 6 exposure sessions within 1 week. One exposure session will include pre- and post-consumption blood draws and indirect calorimetry measurements inside a metabolic chamber over a 2-hour period. The other 5 exposure sessions will occur at specified times outside the laboratory sessions. Subjective ratings of internal state (i.e., hunger, fullness, and thirst) will be collected throughout each exposure. Subjective ratings of liking and wanting of each beverage will also be assessed.
223584577|NCT02576808|DRUG|Ginger extract|Ginger extract capsule at dose of 250 mg two times a day after meal daily for 42 days
223584578|NCT02576808|DRUG|Loratadine|Loratadine tablet at dose of 10 mg one times a day after morning meal daily for 42 days
224071710|NCT00836134|PROCEDURE|rectus sheath block|ultrasound-guided rectus sheath block using 0.2ml/kg 0.25% bupivacaine bilaterally prior to skin incision
224071711|NCT00836134|PROCEDURE|local anesthetic infiltration|Wound infiltration using 0.4ml/kg 0.25% bupivacaine by the surgeon at the end of surgery
224071712|NCT04705051|DRUG|Venglustat GZ402671|Pharmaceutical form: capsule Route of administration: oral
224071713|NCT00622986|DRUG|an extract of Cimicifuga Foetida L.|Each patient will be given the medication of extract of Cimicifuga Foetida L. 2 tablets each day for 3 months.
224071714|NCT00622986|DRUG|an extract of Cimicifuga Foetida L.|Each patient will be given the medication of extract of Cimicifuga Foetida L. 2 tablets each day for 3 months.
224071715|NCT00622986|DRUG|placebo|Each patient will be given placebo of 2 tablets each day for 3 months.
224071716|NCT00622986|DRUG|placebo|Each patient will be given placebo of 2 tablets each day for 3 months.
224071717|NCT02355288|PROCEDURE|Minimally Invasive Coronary Bypass|Bypass graft of the Left Anterior Descending (LAD) artery using minimally invasive cardiac surgery. MICS is a bypass surgery done with a small (4-6 cm) incision under the left breast, instead of the usual incision down the middle the chest.
224071718|NCT02355288|PROCEDURE|Percutenous Coronary Intervention|Stenting of the Left Anterior Descending (LAD) artery using a drug-eluting stent.
224071719|NCT01055158|BEHAVIORAL|Telephone-based CBT|A form of CBT delivered over the telephone by a trained, licensed, master's or doctoral level clinician. The intervention consists of approximately 10 sessions conducted over approximately 14 weeks. Each session is approximately 30 to 50 minutes. All sessions begin with a depression rating and agenda setting and end with task assignments and summaries.
224071720|NCT01055158|BEHAVIORAL|Enhanced Usual Care|Participants randomized to this condition will be referred to receive in-person psychotherapy. Research study staff will help participants to set up their first appointment with a psychotherapist.
224167277|NCT03382327|PROCEDURE|Surgical planning|Two surgical plans will be established preoperatively. The first plan will be based on standard preoperative images (CT-scan, MRI) review. The second plan will be based on the 3D model review. Both will be compared to the actual surgery performed in the operating room.
224167278|NCT02773472|DEVICE|electroacupuncture|The acupoints that will be stimulated are: daheng, tianshu, zhongwan, xiawan, qihai, guanuian, hegu, guchi, zusanli, sanyinjiao, gongsun. An alternating fast-slow frequency of 20Hz/6Hz will be used with an interval of 250msec. The intensity (mA) will be adjusted to a level tolerated by each individual patient.
224167279|NCT02773472|DRUG|morphine|Patient will not receive electroacupuncture. Patient will use morphine for analgesia.
223479798|NCT06015490|OTHER|Glucose drink|Participants will consume flavored beverage solutions containing 110 calories of glucose in 6 exposure sessions within 1 week. One exposure session will include pre- and post-consumption blood draws and indirect calorimetry measurements inside a metabolic chamber over a 2-hour period. The other 5 exposure sessions will occur at specified times outside the laboratory sessions. Subjective ratings of internal state (i.e., hunger, fullness, and thirst) will be collected throughout each exposure. Subjective ratings of liking and wanting of each beverage will also be assessed.
223584579|NCT00007644|PROCEDURE|Radical prostatectomy|Surgical removal of the prostate
223584580|NCT02648672|DRUG|BPN14770|BPN14770 is an investigational new drug being developed for the treatment of Alzheimer's disease and other cognitive disorders. BPN14770 is a small molecule, subtype selective, negative allosteric modulator of phosphodiesterase 4D.
223584581|NCT02648672|DRUG|Placebo|
224167280|NCT01611922|OTHER|Ophthalmic dye|Topically instilled for the purpose of assessing lid margin staining
224167281|NCT01611922|DEVICE|Contact lenses|Silicone hydrogel contact lenses per subject's habitual brand and power, worn for a minimum of 8 hours on the day of assessment, after which lenses will be removed and dye will be instilled.
224167282|NCT02826655|DEVICE|WF-AO-OCT|WF-AO-OCT allows noninvasive, high-resolution imaging of the microvasculature of the retina and choroid, without intravenous dye administration. This unit is being conducted under an abbreviated IDE.
224167283|NCT00056550|BIOLOGICAL|Recombinant Human Antithrombin (rhAT)|Biological/Vaccine: Recombinant human antithrombin(rhAT) Phase III clinical trial.
224167284|NCT03243955|DEVICE|Verum TEAS|TENS unit with electrodes applied to acupuncture point locations
224167285|NCT03243955|DEVICE|Sham TEAS|TENS unit with electrodes applied to non-acupuncture point locations
224167286|NCT00645203|DRUG|cefdinir|cefdinir oral suspension, 25 mg/kg once daily for 10 days
223584582|NCT05491434|DIETARY_SUPPLEMENT|Protein supplement|One líquid brick every day during 3 weeks
223584583|NCT05042180|BEHAVIORAL|Virtual Reality Cognitive Behavioral Therapy (CRAVR)|Participants in the intervention group will scheduled for 14 treatment sessions based on manualized cognitive behavioral therapy assisted with alcohol-related high risk situations in virtual reality. VR-assisted gradual exposure therapy is integrated as a part of CBT. I.e. VR scenes are used in CBT to induce craving for coping strategy skill training and cognitive analysis.
223584584|NCT05042180|BEHAVIORAL|CBT|The active comparator receives 14 conventional cognitive behavioral therapy sessions with
223584585|NCT03684694|DRUG|Loncastuximab Tesirine|Intravenous (IV) infusion.
223584586|NCT03684694|DRUG|Ibrutinib|Oral capsule.
223584587|NCT02881528|DRUG|Metformin Hydrochloride|Liquid formula metformin administered by oral syringe in a dose of 10mg/kg body weight once daily for 2 weeks, then to 10mg/Kg twice daily (maximum 500mg twice daily) for a further two weeks during the first month, increasing to 20mg/kg body weight twice daily (maximum 1000mg twice daily) thereafter.
223584588|NCT02881528|DRUG|Placebo|Liquid formula of placebo administered by oral syringe in an equivalent volume to a metformin dose of 10mg/kg body weight once daily for 2 weeks, then to 10mg/Kg twice daily (maximum 500mg twice daily) for a further two weeks during the first month, increasing to 20mg/kg body weight twice daily (maximum 1000mg twice daily) thereafter.
223744896|NCT05515757|BEHAVIORAL|Mobile-app based contingency management|We are adapting an evidence-based outpatient mobile-app based CM intervention to the hospital setting for hospitalized patients with stimulant use disorders requiring prolonged hospitalization. Participants will be enrolled into an 8-week mobile-app based contingency management intervention.
223744897|NCT01895855|BIOLOGICAL|PXVX0200|Single dose; liquid suspension after reconstitution with buffer; 5x10\^8
223744898|NCT01895855|BIOLOGICAL|placebo|
223744899|NCT06320145|DEVICE|Cryotherapy|This device used at the first, second and third day of period to decrease pain for 20 min at first, second and third day
223744900|NCT06320145|OTHER|core stability exercises|core stability exercises
224167287|NCT05977803|RADIATION|MRI with CEST sequence, IVIM and ASL sequence|"Three sequences will be added as part of the protocol (for an additional duration of about 10 minutes) :~* The CEST sequence~* The ASL infusion sequence~* The IVIM sequence"
224167288|NCT00767299|DRUG|arzoxifene|20 mg, QD, PO,24 weeks
224167289|NCT00767299|DRUG|Placebo|QD, PO, 24 weeks
224167290|NCT05628987|OTHER|no intervention|Observational studies, no intervention
224167291|NCT02518542|PROCEDURE|Endoscopic intervention A|POEM: Per oral endoscopic myotomy
224167292|NCT02518542|PROCEDURE|Endoscopic intervention B|PRD: Prolonged dilatation by temporary implantation of large diameter stent . Stents are additionally attached to the esophageal wall by different technical options.
224167293|NCT02518542|PROCEDURE|Endoscopic intervention C|Endoscopic balloon dilatation
224167294|NCT02518542|PROCEDURE|Laparoscopic Surgery|Laparoscopic Heller myotomy
224167295|NCT01171742|PROCEDURE|Intermittent hepatic inflow occlusion (IHIO)|Intermittent hepatic inflow occlusion (IHIO)'ll be usually performed 3 times during donor liver parenchymal resection, with each IHIO consisting of clamping of the hepatoduodenal ligament for 15 minutes, followed by reperfusion for 5 minutes.
224167296|NCT01609738|DEVICE|Left ventricular septum pacing lead|A left ventricular septum pacing lead is permanently placed by introducing a custom lead with extended helix transvenously and, after positioning it against the RV septum, driving it through the inter-ventricular septum into the LV endocardial layer.
224167297|NCT06248242|DRUG|Edaravone dexborneol|edaravone 10 mg and dexborneol 2.5 mg twice daily
224167298|NCT01659359|DEVICE|Virtual reality glasses and Lidocaine|The samples were randomly allocated to use Virtual reality glasses and 5 ml Lidocaine2% for decreasing pain and anxiety in episiotomy repair.
223584589|NCT05805644|DEVICE|Robot mediated upper limb therapy|"The OR is classified as a Class A device with the Health Sciences Authority. The OR is capable of delivering RMIT as well as RMTT. It can provide zero, partial or full assistance to the patient to complete the movement or task. Its teach-and-follow mode allows a movement to be performed by the therapist, with the device then replaying the movement at either zero, partial or full assistance for the patient.~Impairment oriented training will focus on the following movements:~1. Diagonal movement~2. Shoulder abduction~3. Shoulder adduction~4. Shoulder flexion~5. Shoulder extension~6. Elbow flexion~7. Elbow extension~Task-specific training will focus on the following activities:~1. Picking up a cup/glass by the side and drink~2. Brushing hair~3. Cleaning unaffected upper limb (hand to arm)~4. Wiping table~5. Wiping wall~6. Sliding card on table to a designated location~7. Clipping a clothe peg"
223584590|NCT05365126|BEHAVIORAL|Complete Vocal Technique Voice Therapy|A Complete Vocal Technique (CVT) Practitioner will assess the patient's voice and voice problems using the CVT framework and then apply CVT therapy, a form of voice therapy
224167299|NCT01659359|DRUG|Lidocaine|The samples were randomly allocated to use 5 ml Lidocaine2% for decreasing pain and anxiety in episiotomy repair.
224167300|NCT03229304|OTHER||
224167301|NCT05579223|DRUG|Intrathecal Hydromorphone Mono Injection|Experimental Drug: Hydromorphone Hydrochloride Injection. Administration: subarachnoid space mono bolus inject, + 5% glucose injection diluted to 75 μg:1.5ml, Speed ≤ 0.5 ml/s
224167302|NCT05579223|DRUG|Intrathecal Placebo Mono Injection|Placebo: 5% glucose injection. Administration: subarachnoid space mono bolus inject, 1.5ml, Speed ≤ 0.5 ml/s
224167303|NCT01151176|DRUG|Regular Insulin|1,8U Regular insulin/h from 180mg/dL of blood glucose increasing each hour according to capillary blood glucose. Between 100-150mg/dL keep infusion and bellow 100mg/dL stop infusion
224167304|NCT01151176|DRUG|Regular Insulin|"Regular Insulin SC according to Blood Glucose(mg/dL) and Insulin Sensitive with usual dose describe and less 2U for sensitive and plus 2U for insulin resistant:~Blood Glucose \>141-180=4U ;181-220=6U; 221-260=8U; 261-300=10U;301-350=12U; 351-400=14U; \> 400=16U"
224167305|NCT05832060|DEVICE|Active tDCS|Active tDCS will be delivered over TPC for a stimulation session. The anodal electrode will be placed on the left TPC, T7/TP7 position according to the 10-20 International EEG 10-20 System for electrode placement. The cathodal electrode will be placed on the right TPC, T8/TP8 position. Intensity will be set at 1 mA, the duration of stimulation will be 20 min.
224167306|NCT05832060|DEVICE|Active tRNS|Active tRNS will be delivered to bilateral TPC for a stimulation session. The electrodes will be placed on the left and right TPC, respectively T7/TP7 and T8/TP8 position, at 0.75 mA (100-500 Hz) for 20 min.
224167307|NCT05832060|DEVICE|Sham tRNS or tDCS|Sham tRNS or tDCS will be delivered over bilateral TPC for a stimulation session. The same electrodes placement as well as the stimulation set-up will be used as in the active stimulation conditions, but the current will be applied for 30 s and will be ramped down without the participants awareness.
224167308|NCT05433974|BIOLOGICAL|Blood sample collection|Blood sample collection : 2 X 6 mL
224167309|NCT04110444|DRUG|Sildenafil|oral sildenafil t.d.s for high-risk pregnancies
224167310|NCT02092168|DRUG|BIA 9-1067|
224167311|NCT06262672|OTHER|Evaluation form|This form is a form of demographic information, questions that question the habits of COVİD-19 era, and evaluation scales.
224167312|NCT03930667|PROCEDURE|clips|
224167313|NCT03930667|PROCEDURE|knotting|
223584591|NCT06347146|BEHAVIORAL|Financial Literacy Training (FLT) workshops|Adolescents and youths and their caregivers will receive six 1-2 hour workshop sessions that cover components on saving, and financial management. The sessions will: introduce participants to saving, saving strategies, career planning, and the utilization of financial institutions, including saving in banks.
223744901|NCT05736107|DRUG|CBL-514 Injection|Formulated as an injectable CBL-514 solution at a concentration of 5 mg/mL.
224167314|NCT00345514|BEHAVIORAL|Behavioral Intervention Arm|The arm emphasized individual provider behavior (interactive CME, feedback at the provider, clinic and program levels, expert modeling, academic detailing and opinion leaders)
224167315|NCT00345514|BEHAVIORAL|Organizational Interventions Arm|Leadership, team building, benchmarking at the clinic and program level
224167316|NCT00195624|BIOLOGICAL|Alemtuzumab (Campath )|Campath administered at a dose of 10/mg/day for 10 days
224167317|NCT00195624|DRUG|Cyclosporine|Subjects who relapse after initial response to alemtuzumab therapy will have cyclosporine added to the regimen after the 6 month visit. Dosing will be based on ideal body weight and will be adjusted to maintain a target level of 200 - 400 ng /ml.
224167318|NCT01353183|PROCEDURE|colonoscopy or rectosigmoidoscopy|Usual procedure
224167319|NCT04673461|DRUG|STA363 containing 90 mg (60 mg/mL) lactic acid|STA363 (90 mg) will be injected into maximally two pain-generating degenerated intervertebral discs
224305333|NCT05604248|OTHER|Intervention|Mother : 2.0 μmol 13C2 -retinyl acetate diluted in soybean oil Children : 1.0 μmol 13C2 -retinyl acetate diluted in soybean oil
223744902|NCT05736107|OTHER|0.9% Sodium Chloride|Sodium Chloride (0.9% NaCl) placebo for injection
223744903|NCT00445159|DRUG|UT-15C SR (treprostinil diethanolamine) 1mg oral tablets|
223744904|NCT03104595|DRUG|EC-18|oral administration
223744905|NCT03617081|DRUG|NNC0113-2023|Participants will receive dose levels of 1 mg, 2 mg, 4 mg, 8 mg, 16 mg or 32 mg of NNC0113-2023 orally. Each participant will receive only one dose.
224167320|NCT04673461|DRUG|STA363 containing 180 mg (120 mg/mL) lactic acid|STA363 (180 mg) will be injected into maximally two pain-generating degenerated intervertebral discs
224167321|NCT04673461|DRUG|Placebo|Placebo will be injected into maximally two pain-generating degenerated intervertebral discs
224167322|NCT02195947|DRUG|Growth Hormone|Growth hormone (Norditropin, Novo nordisk) was administrated on day 6 of HMG stimulation daily in a dose of 2.5 mg S.C. till the day of hCG administration.
224167323|NCT02566876|DRUG|Mixture of three Bifidobacteria|This investigation will be a randomized, double-blind, placebo-controlled, cross-over trial. The study will include 70 children with FD or IBS and will be articulated in 16 weeks as follows. Fifty-nine children (median age 11.2 years, range 5.2-17.9) with IBS and FD were randomized to receive either a mixture of three Bifidobacteria or a placebo for 6 weeks. At the end, after a 2-week-''washout'' period, each patient was switched to the other group and followed for 6 further weeks. At baseline and at follow-up, patients and/or their parents completed a dairy for bowel habit and gastrointestinal symptoms, and a quality of life (QoL) questionnaire.
224167324|NCT03105245|OTHER|Electroconvulsive Therapy (ECT) time interval + Anaesthetic (Thiopentone)|The intervention in this study is the time interval between anaesthetic administration and ECT stimulus
224167325|NCT04745247|PROCEDURE|RSS|"Repetitive somatosensory stimulation (RSS) applied on a small region of the face for 3 hours~Sham Repetitive somatosensory stimulation (RSS) applied on a small region of the face for 3 hours : the number of stimuli is reduced compared to the effective RSS"
223584592|NCT06347146|BEHAVIORAL|Mentorship|Each adolescent and youth will have a mentor who will visit with them monthly for the duration of the intervention. The one-to-one mentorship program is intended to help AYaAIDS overcome a variety of challenges they face in daily life by fostering meaningful and lasting relationships with near peer or adult role models. Resilience theory posits that having a supportive adult outside the family reduces the impact of stress on AY's mental health. Mentors will be high school students who will be trained by the schools or NGO staff depending on study condition. All mentors will be reimbursed for their transport expenses to the field, plus an equivalent of a $5 gift card for airtime per visit.
223584593|NCT06347146|BEHAVIORAL|Income Generation Activity (IGA)|Participants will be trained on investing in income-generating activities (IGA) during the FLT workshops and will be allowed to use up to 30% of their matched savings to invest in an IGA intended to benefit the adolescent and youth (AY) and their caregiving families. The IGA portion is intended to promote economic stability.
223584594|NCT06347146|BEHAVIORAL|Youth Development Accounts (YDA)|Each adolescent and youth (AY) will receive a youth development account, which is a matched savings account held in the AY's name in a financial institution under the Central Bank (Bank of Uganda). Any of the AY's family members, relatives, or friends is encouraged to contribute towards the YDA. The account is then matched with money from the program. The match cap (maximum family contribution to be matched by the program) will be an equivalent of US$10 a month per family or US$200 for the 20-months intervention period. AY who save the maximum amount will have $600 ($200 plus $400 in match-a 2:1 match rate).
223584595|NCT03175224|DRUG|APL-101 Oral Capsules|Subjects will receive APL-101 capsules BID for oral administration.
223584596|NCT03172130|DEVICE|Straight CPAP|
224167326|NCT04528394|RADIATION|Photon|Photon combined with Carbon ion in Arm 1
224167327|NCT04528394|RADIATION|Proton|Proton combined with Carbon ion in Arm 2
224167328|NCT04528394|RADIATION|Carbon ion|Same dose and fractionation will be used in both arms.
224167329|NCT00000345|DRUG|Lofexidine|
224167330|NCT00707486|DEVICE|Hemcon Dental Dressing|The Hemcon Dental Dressing is an oral wound dressing made of chitosan.
224167331|NCT00707486|DEVICE|Gauze with Pressure and/or Gelfoam|Common practice for oral surgery patients involves the use of sterile dressing over the extraction site. The subject will provide the pressure by biting down on the sterile gauze. As previously discussed, other practices involve the use of Gelfoam prior to application of sterile gauze.
224167332|NCT00831857|OTHER|89Zr-Bevacizumab PET-scan|At baseline, after two weeks of treatment and after 6 weeks of treatment.
224167333|NCT00944957|DRUG|Raltegravir for the first 2 weeks|Patient receives raltegravir and efavirenz placebo during the first 2 weeks
223584597|NCT03172130|DEVICE|Sham CPAP|
223584598|NCT03709394|PROCEDURE|Full utrasound guidance|The target vein is directly identified by portable ultrasound device and the complete procedure of peripheral venous cathether insertion is controlled by ultrasound guidance in real time
223584599|NCT03709394|PROCEDURE|Partial ultrasound guidance|The target vein is directly identified by ultrasound but the procedure of peripheral venous cathether insertion is performed conventionally, without ultrasound guidance
223584600|NCT03709394|PROCEDURE|No ultrasound guidance|The target vein is identified and peripheral venous catheter is inserted by conventional approach without use of any guiding devices
223584601|NCT03295396|DRUG|Dordaviprone (ONC201)|Dordaviprone (ONC201) is a central nervous system (CNS)-penetrant, small-molecule imipridone that acts as a mitochondrial caseinolytic protease P (ClpP) agonist and a dopamine receptor D2 (DRD2) antagonist.
223584602|NCT05445895|DRUG|Renexin CR 200/160mg|Renexin CR 200/160mg will be added to Aspirin 100mg
223584603|NCT05445895|DRUG|Plavix 75mg|Plavix 75mg will be added to Aspirin 100mg
223584604|NCT02218593|DEVICE|WREX orthosis|Upper extremity exoskleton used to assist movement
223584605|NCT03878901|COMBINATION_PRODUCT|high risk warm|Bair HuggerTM Forced-air Warming System to 30min pre- and entire operation warming, combined fluid warming
223744906|NCT03617081|DRUG|Placebo (NNC0113-2023)|Participants will receive NNC0174-0833 matched placebo orally.
224071721|NCT04365465|DEVICE|NSS-2 Bridge|The NSS-2 BRIDGE (Appendix 1) is a battery operated and disposable percutaneous auricular nerve field stimulator (Innovative Health Solutions, Versailles, IN, USA), that was recently cleared by the FDA and assigned a Class II Risk Designation; a class which includes surgical drapes, pumps and power wheelchairs.
224071722|NCT04365465|DEVICE|Inactive NSS-2 Bridge|This is a sham device which is identical to the active NSS-2 Bridge, but will not provide percutaneous auricular nerve field stimulation when applied.
224071723|NCT04365465|OTHER|Active control|Active control will include standard of care pain management during the postoperative period. Participants in this intervention arm will not receive or wear a device.
224071724|NCT05570123|DIETARY_SUPPLEMENT|Flexofytol Forte|standardized exclusive dry extracts of Curcuma longa and Boswellia serrata. 2 tablets a day, one in the morning, one in the evening
224071725|NCT05570123|DIETARY_SUPPLEMENT|Placebo|2 tablets a day, one in the morning, one in the evening
224071726|NCT01461174|DRUG|Modafinil|200 mg tablet, single dose
224167334|NCT00944957|DRUG|Efavirenz for the last 2 weeks|Patient receives efavirenz and raltegravir placebo during the last 2 weeks
224167335|NCT00944957|DRUG|Efavirenz for the first 2 weeks|Efavirenz and raltegravir placebo for the first 2 weeks
224167336|NCT00944957|DRUG|Raltegravir for the last 2 weeks|Raltegravir and efavirenz placebo for the last 2 weeks
224167337|NCT02031757|OTHER|perturbation training|training utilizing a system that provides small, controlled and unpredictable perturbations during treadmill walking.
224305334|NCT03107312|PROCEDURE|Single blood sample collection|Collection of single blood sample of 10 ml volume by venepuncture
224071727|NCT01461174|DRUG|Donepezil|Donepezil or placebo, 5 mg tablet one per day, 15 days
224071728|NCT01461174|DRUG|Memantine|Memantine or placebo, 10 mg tablet one per day, 15 days
224071729|NCT04381442|RADIATION|Low Level Laser Therapy|
223479799|NCT06015490|OTHER|Fructose drink|Participants will consume flavored beverage solutions containing 110 calories of fructose in 6 exposure sessions within 1 week. One exposure session will include pre- and post-consumption blood draws and indirect calorimetry measurements inside a metabolic chamber over a 2-hour period. The other 5 exposure sessions will occur at specified times outside the laboratory sessions. Subjective ratings of internal state (i.e., hunger, fullness, and thirst) will be collected throughout each exposure. Subjective ratings of liking and wanting of each beverage will also be assessed.
223479800|NCT05399875|OTHER|Augmented reality virtual ruler|Use of augmented reality virtual ruler to measure catheter length
224071730|NCT04156555|DRUG|Amoxicillin-Clavulanate 875 Mg-125 Mg Oral Tablet|Oral amoxicillin-clavulanate 1 g twice a day for total of 6 doses
224071731|NCT02381431|DEVICE|FLIR ONE|
224071732|NCT03508492|OTHER|Surgical tinted Chloraprep® applicators|We randomized knee, hip, cardiac and colon surgeons making them using two applicators of each brand in four of theirs surgeries. Randomization will be carried out in blocks of four for each surgeon.
224071733|NCT03508492|OTHER|Surgical tinted Nex Clorex 2% applicators|We randomized knee, hip, cardiac and colon surgeons making them using two applicators of each brand in four of theirs surgeries. Randomization will be carried out in blocks of four for each surgeon.
224071734|NCT05689931|BIOLOGICAL|Mepolizumab|"Mepolizumab is administered by subcutaneous injection with guideline recommended patient selection and dosing for treatment of eosinophilic asthma.~Accordingly, the Mepolizumab treatment is given as add-on therapy to standard inhaled corticosteroids (ICS) and long-acting beta 2 agonists (LABA)"
224071735|NCT05689931|DRUG|Standard inhaled corticosteroids (ICS) and long-acting beta 2 agonists (LABA)|Routine asthma treatment with inhaled corticosteroids (ICS) and long-acting beta 2 agonists (LABA)
224071736|NCT06407310|DRUG|Pembrolizumab|I.V Pembrolizumab (keytruda) 200 mg every 3 weeks for 6 cycles
224071737|NCT06407310|DRUG|Carboplatin|I.V Carboplatin at AUC 1.5 weekly for a total of 12 weeks.
224071738|NCT06407310|DRUG|Paclitaxel|I.V Paclitaxel at 80 mg/m2 weekly for a total of 12 weeks.
224071739|NCT05814289|OTHER|To assess telephone head tilt and cervical, thoracic, and lumbar spine mobility and disturbances.|To assess telephone head tilt and cervical, thoracic, and lumbar spine mobility and disturbances.
224071740|NCT01761266|DRUG|Lenvatinib|12 mg (or 8 mg) once daily (QD) oral dosing.
224071741|NCT01761266|DRUG|Sorafenib|400 mg twice daily (BID) oral dosing.
224071742|NCT03447158|PROCEDURE|15% Dextrose|inject 15% dextrose and xylocaine into subacrominal bursa under sonographically guidance
224071743|NCT03447158|PROCEDURE|Normal saline|inject normal saline and xylocaine into subacrominal bursa under sonographically guidance
224071744|NCT05313997|DRUG|Diclofenac Sodium|"at first diclofenac sodium was prescribed to patients with chronic upper back pain.~If the patient's pain persisted, she/he was included in the physical therapy (hotpack 20 minutes, ultrason 5 minutes, Transcutaneous electrical nerve stimulation 20 minutes) program."
224071745|NCT02802605|DRUG|Bemiparin|Bemiparin subcutaneus administration
224071746|NCT01540799|DEVICE|ATI Neurostimulation System|ATI Neurostimulator (NS-100) and Remote Controller (RC-200)
224071747|NCT03283631|BIOLOGICAL|EGFRvIII-CARs|Gamma-retroviral MSGV1 139 scFv EGFRvIII CAR gene-modified T cells
224071748|NCT06025266|DEVICE|Evaluation of Viscoelastic and mechanical properties with MyotonPRO|MyotonPro™, a handheld, non-invasive and painless device, is used for non-invasive measurement of the biomechanical and viscoelastic properties of soft biological tissues such as superficial skeletal muscles, fascia, tendons and ligaments. The properties of the structures can be measured from different regions during complete rest or contraction.
224071749|NCT01284114|DRUG|Aliskiren|150mg/day for all as initial dose, 300mg/day for the patients that still show hypertension(above 140/90mmHg)after one month 150mg treatment,oral,on 6 months
224071750|NCT02686229|OTHER|no interventions|
224071751|NCT01984255|DRUG|Arm A-Bavituximab 3mg/kg IV over 90 minutes weekly x 3 followed by Bavituximab 3mg/kg IV over 90 minutes weekly x 12 plus ipilimumab 3mg/kg IV|Bavituximab 3mg/kg IV over 90 minutes weekly x 3 followed by Bavituximab 3mg/kg IV over 90 minutes weekly x 12 plus ipilimumab 3mg/kg IV over 90 minutes every 3 weeks x 4. Total number of treated patients will be 16.
224071752|NCT01984255|DRUG|Arm B-Ipilimumab 3mg/kg IV over 90 minutes day 1 followed three weeks later by ipilimumab every 3 weeks x 3.|Ipilimumab 3mg/kg IV over 90 minutes day 1 followed three weeks later by ipilimumab every 3 weeks x 3. Total number of treated patients will be 8.
224071753|NCT03936387|DRUG|Ropivacaine|Erector spinae blocks: T4/5 transverse process is identified with the ultrasound transducer in a parasagittal orientation; the needle tip is advanced until it contacts the transverse process, just below the erector spinae muscle complex; the erector spinae muscle is visualized to be elevated up off of the transverse process with normal saline injection. Following a bolus injection of 2ml/kg of 0.2% ropivacaine, a catheter is threaded into the space occupied by the local anesthetic bolus. Repeated on contralateral side.
224071754|NCT01418547|DRUG|Torrent's Isosorbide Mononitrate 120 mg ER Tablets|
224071755|NCT03595540|OTHER|Prolon|Prolon by L-Nutra is a medically-designed dietary kit providing the food to eat for five days. Day 1 of Prolon provides \~4600 kJ (11% protein, 46% fat, and 43% carbohydrate), whereas days 2-to-5 provide \~3000 kJ (9% protein, 44% fat, and 47% carbohydrate) per day.
224071756|NCT05638854|DRUG|ZB002|ZB002 will be administered subcutaneously as per schedule specified in the respective arm.
224071757|NCT05638854|DRUG|Placebo|Placebo will be administered subcutaneously as per schedule specified in the respective arm.
223479801|NCT05579015|DEVICE|Theta-burst stimulation (TBS)|TBS comprises 3-pulse 50-Hz bursts, applied every 200 ms (at 5 Hz), as described previously. iTBS consists of 2-second trains with an inter-train interval of 8 seconds. The investigators will repeat the trains (30 pulses; 10 bursts) 20 times to reach a total number of 600 pulses (3x10x20). cTBS will comprise uninterrupted bursts to reach a total of 600 pulses. Concurrent TBS/fNIRS stimulation will be applied over the left (iTBS) and right (cTBS) DLPFC at an intensity of 90% resting motor threshold (RMT). This corresponds to \~110% of the active motor threshold. Stimulation at 90% RMT will also ensure compliance, reduce sensory discomfort and minimize dropout rates. Still, scalp discomfort will be recorded directly after the stimulation. The stimulation site over the DLPFC will be determined using the international 10-20 system and correspond to the F3 label.
223584606|NCT03878901|COMBINATION_PRODUCT|moderate risk warm|30 min prewarming The Bair HuggerTM Forced-air Warming System cotton blanket warming and fluid warming through operation
223479802|NCT05579015|OTHER|telephone interviews|Telephone interviews will be conducted at the follow-up stage. RMDD group will receive follow-up telephone interviews every 3 months for 2 years to monitor major depressive episode recurrence
224167338|NCT02031757|OTHER|balance exercises|specific exercises regularly used in rehabilitation aiming to improve balance
224167339|NCT04552626|BEHAVIORAL|Prolonged sitting (social breaks)|Participants are required to sit for 80 minutes doing schoolwork, with a toilet break in between. Every twenty minutes participants will have a short social break. Test day begins at 8:00 with pretest measures, followed by the intervention at about 9:00, which will end around 12:00, with subsequent posttest measures.
223584607|NCT03878901|COMBINATION_PRODUCT|low risk warm|30 min prewarming The Bair HuggerTM Forced-air Warming System and cotton blanket warming through operation
223584608|NCT03878901|OTHER|passive warming|cotton blanket warming through operation
223584609|NCT04291768|OTHER|Shortened antibiotic treatment|Shortened antibiotic treatment of 5 days. Participation in the study will only affect treatment duration and will have no influence on the choice of treatment in respect to type and dose of antibiotic treatment.
223584610|NCT04291768|OTHER|Standard antibiotic treatment|Standard antibiotic treatment of minimum 7 days at the discretion of treating physician. Participation in the study will only affect treatment duration and will have no influence on the choice of treatment in respect to type and dose of antibiotic treatment.
223584611|NCT04580095|OTHER|AI algorithm for apical foreshortening in echocardiography|The algorithm is based on artificial intelligence, giving the sonographer performing the echocardiographic exam real-time feedback on left ventricular apical foreshortening.The algorithm is developed using deep learning techniques by technologists at the Department of Circulation and Medical Imaging, NTNU.
223584612|NCT03087292|OTHER|Resistance training with vascular occlusion|Patients will perform unilateral leg extension resistance training with vascular occlusion 2 times per week for a period of 8 weeks. Each training session will consist of 3 sets of 15 repetitions at the intensity of 30% 1 RM with 30 s of rest period between sets.
223479803|NCT06823037|OTHER|HAPPI software|"We will enroll 15 community pharmacies. These 15 pharmacies will continue to provide birth control services as normal for several months (control).~Then, we will introduce the intervention: the HAPPI software. The pharmacies will continue to provide birth control services while using the HAPPI software in place of any paper or electronic processes that they were previously using. The results will then be compared between the control and the intervention period."
223479804|NCT06827236|DRUG|BNT323|Intravenous infusion
223479805|NCT06827236|DRUG|BNT327|Intravenous infusion
223479806|NCT06510504|DRUG|225 mg BNC210|225 mg BNC210
223479807|NCT06510504|DRUG|Placebo|Placebo
223584613|NCT03708666|OTHER|Telemonitoring of blood pressure|Blood pressure monitoring at least once a week.
223584614|NCT01232855|GENETIC|protein expression analysis|
223584615|NCT01232855|GENETIC|western blotting|
223744907|NCT03630120|DRUG|Lenvatinib|"Standard of Care: Lenvatinib 24 mg daily. All participants will start receiving standard of care treatment.~Participants in the Adaptive Therapy regimen will receive TKI therapy in cycles: continuous treatment at the indicated dose until the patients' tumor marker (thyroglobulin in DTC or calcitonin in MTC patients) drops by ≥50% from the level at the time of enrollment (baseline level). A new cycle of TKI treatment will begin when/if the tumor marker increases to or above the baseline level."
223584616|NCT01232855|OTHER|flow cytometry|
223744908|NCT03630120|DRUG|Sorafenib|"Standard of Care: Sorafenib 400 mg twice daily. All participants will start receiving standard of care treatment.~Participants in the Adaptive Therapy regimen will receive TKI therapy in cycles: continuous treatment at the indicated dose until the patients' tumor marker (thyroglobulin in DTC or calcitonin in MTC patients) drops by ≥50% from the level at the time of enrollment (baseline level). A new cycle of TKI treatment will begin when/if the tumor marker increases to or above the baseline level."
223584617|NCT01232855|OTHER|laboratory biomarker analysis|
223584618|NCT02831933|BIOLOGICAL|ADV/HSV-tk|Replication-defective recombinant adenovirus vector
223584619|NCT02831933|DRUG|Valacyclovir|Prodrug of the antiviral drug acyclovir
223584620|NCT02831933|RADIATION|SBRT|Low-dose SBRT
223584621|NCT02831933|DRUG|nivolumab|Fully human immunoglobulin (Ig) G4 anti-PD-1 monoclonal antibody
223584622|NCT06502808|OTHER|Hyperbaric oxygen therapy|Series of 30 HBOT sessions of 60 minutes at 2 ATA in the hyperbaric chamber for five consecutive days per week.
224071758|NCT05638854|DRUG|ZB002|ZB002 will be administered subcutaneously as per schedule specified in the respective arm.
224071759|NCT05638854|DRUG|Placebo|Placebo will be administered subcutaneously as per schedule specified in the respective arm.
224071760|NCT06840808|DEVICE|Active Transcranial direct current stimulation|Transcranial direct current stimulation will be delivered via a Neuroelectrics Starstim tES. Stimulation will consist of 1 milliamp stimulation, with anodal stimulation delivered at electrode Fz (International 10/10 System for electroencephalography electrode placement) and electrodes F7, FP1, FP2, and F8 as returns. All electrodes are 1 cm diameter Ag/AgCl electrodes and make contact with the scalp via connective gel. Stimulation will linearly ramp up from 0 milliamps to 1 milliamp over 60 seconds, then remain at 1 milliamp of stimulation over 20 minutes, and finally ramping down at to 0 milliamps over 60 seconds.
223744909|NCT03630120|DRUG|Cabozantinib|"Standard of Care: Cabozantinib 140 mg daily. All participants will start receiving standard of care treatment.~Participants in the Adaptive Therapy regimen will receive TKI therapy in cycles: continuous treatment at the indicated dose until the patients' tumor marker (thyroglobulin in DTC or calcitonin in MTC patients) drops by ≥50% from the level at the time of enrollment (baseline level). A new cycle of TKI treatment will begin when/if the tumor marker increases to or above the baseline level."
223479811|NCT01739140|BEHAVIORAL|Yoga|
223584623|NCT01089790|DRUG|Dutogliptin|400 mg tablet, once daily
223584624|NCT01089790|DRUG|Sitagliptin|100 mg capsule (each capsule contains two 50-mg tablets), once daily
223584625|NCT01456312|DRUG|Peginterferon alfa-2a|Duration and combination
223584626|NCT01456312|DRUG|Entecavir|combination
223584627|NCT02317978|PROCEDURE|ICSI|records of women who had ICSI will be reviewed and analysed for determining FSI
224167340|NCT04552626|BEHAVIORAL|Prolonged sitting with step-up exercise break|Participants are required to sit for 80 minutes doing schoolwork, with a toilet break in between. Every twenty minutes participants will have a physical activity break, where they will perform a simple moderate-intensity step-up exercise for three minutes at a predetermined pace. Test day begins at 8:00 with pretest measures, followed by the intervention at about 9:30, which will end around 12:00, with subsequent posttest measures.
223584628|NCT02349685|PROCEDURE|H. pylori culture and antimicrobial susceptibility test|Antral and body biopsy specimens were evaluated separately. Organisms were identified as H. pylori by Gram staining, colony morphology, and positive oxidase, catalase, and urease reactions. Minimum inhibitory concentrations (MICs) were determined by the agar dilution method. Amoxicillin (Sigma Chemical Co., St. Louis, Mo.), clarithromycin (Abbott Laboratories, Abbott Park, Ill.), metronidazole (Sigma), tetracycline (Sigma) and moxifloxacin (Sigma) for the H. pylori isolates were examined by use of the serial twofold agar dilution method and the reference of susceptibility testing was according to the recommendations of the Clinical and Laboratory Standards Institute \[amoxicillin (AMC), MIC ≥ 0.5 μg / ml; clarithromycin (CLA), MIC \> 1.0 μ g / ml; metronidazole (MET), MIC \> 8 μ g / ml; tetracycline (TC), MIC \> 4 μ g / ml; and moxifloxacin (MOX), MIC \> 1 μ g / ml).
223584629|NCT02349685|DRUG|14 day PBMT group|Rescue therapy using 14 day PBMT regimen \[Proton pump inhibitor (PPI) regular dose b.i.d., tripotassium dicitrate bismuthate 300 mg q.i.d. (three tablets at 30 min before meals and one tablet at 2 hours after dinner), metronidazole 500 mg t.i.d., and tetracycline 500 mg q.i.d\]
223584630|NCT02349685|DRUG|14 day MEA group|Rescue therapy using 14 day MEA regimen (PPI regular dose b.i.d., moxifloxacin 400 mg q.d., and amoxicillin 1g b.i.d.)
223584631|NCT05280600|OTHER|Not applicable - non-interventional study|Not applicable - non-interventional study
224167341|NCT04552626|BEHAVIORAL|Prolonged sitting with simple resistance activity breaks|Participants are required to sit for 80 minutes doing schoolwork, with a toilet break in between. Every twenty minutes participants will have a physical activity break, where they will perform simple resistance activities following a video for about three minutes. Test day begins at 8:00 with pretest measures, followed by the intervention at about 9:30, which will end around 12:00, with subsequent posttest measures.
223584632|NCT01816867|DEVICE|Intramesh T1 implantation|
223584633|NCT03875664|DRUG|Liposomal bupivacaine|Extended-release local anesthetic
223584634|NCT03875664|DRUG|Placebo - injection|Injectable normal saline solution
223584635|NCT01688115|PROCEDURE|Video|The afternoon before the surgery session, a researcher will show to the child a video of the length of 6 minutes, using an I-pad. The video shows two clown doctors working constantly at Meyer Children's Hospital, which, through skits and gags, will tell the child how is an operating room and some devices and procedures used during the induction of anesthesia.
223584636|NCT01688115|OTHER|Standard care|In this arm orally information will be given by the nurse of the ward only to the parents of the child. Any additional information or explanation will be given to the child
224167342|NCT02048657|DEVICE|Foley Airway Stylet Tool|
224167343|NCT02048657|DEVICE|introducer-tool|
224167344|NCT02482792|OTHER|Norwegian Psychomotor Physiotherapy|The recruited patients will after randomization receive either Norwegian Psychomotor Physiotherapy (NPMP) or COPE combined with active individual physiotherapy. In NPMP the treatment is individualized, targeting body-mind awareness through exercise, massage and therapeutic conversation
223479812|NCT03622567|BEHAVIORAL|Smartphone push notifications|The purpose of this study is to assess how smartphone push notifications can impact the overall score, accuracy and reaction time of participants using the Brain Power Score application (app). Push notification quantity will be varied and counter-balanced.
223479813|NCT00121056|DRUG|Enbrel®|
223584637|NCT02927821|BEHAVIORAL|ADS Plus|Contact occurs at a minimum for about 1 hour per month over 12 months (face-to-face/ telephone). Targeted education materials concerning clients' conditions and related matters are shared via email or traditional mail. The goal of each contact is to provide ongoing emotional support, situational counseling, education about importance of taking care of self, referrals/linkages and skills (e.g., stress reduction, behavioral management, how to talk with doctors). The care planning process is collaborative and flexible, reflecting CG fluctuating needs
223584638|NCT06258590|DEVICE|Transcutaneous auricular vagus nerve stimulation|Patients will receive non invasive vagus nerve stimulation via electrodes attached to the ear.
223584639|NCT05226078|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|Cognitive behavioral treatment of insomnia
223744910|NCT03630120|DRUG|Vandetanib|"Standard of Care: Vandetanib 300 mg daily. All participants will start receiving standard of care treatment.~Participants in the Adaptive Therapy regimen will receive TKI therapy in cycles: continuous treatment at the indicated dose until the patients' tumor marker (thyroglobulin in DTC or calcitonin in MTC patients) drops by ≥50% from the level at the time of enrollment (baseline level). A new cycle of TKI treatment will begin when/if the tumor marker increases to or above the baseline level."
224167345|NCT02482792|OTHER|Cognitive Patient Education and PT|The comparison group will receive a combination of education about how to manage pain (COPE) followed by active individual physiotherapy.
224167346|NCT05609136|OTHER|Bobath+Scapular Stabilization Exercises|Scapular stabilization exercises will be given to patients in addition to Bobath therapy. It will be applied with the patient in a sitting position, with the shoulder at 90 degrees and the elbow extended. The patient will be given exercises with isometric contraction while the shoulder is in protraction and retraction by the physiotherapist. Isometric contraction will last for 5 seconds and each exercise will be repeated 2x15 times. There will be a 1-minute rest period between sets. The exercises will be performed in 2 different positions, in the flexion position and in the diagonal position.
224167347|NCT04500223|OTHER|Cervical Cranioflexion exercise plus cardiopulmonary exercise|Intervention:Cervical Cranioflexion exercise plus cardiopulmonary exercise
223479814|NCT00121056|DRUG|Kineret®|
223479815|NCT00997945|DRUG|ZD4054 (Zibotentan)|10 mg ZD4054 (Zibotentan) once daily on Day1, Day4 to Day15
223479816|NCT00888875|DEVICE|i-gel|insertion after induction of anaesthesia. Afterwards, intubation over the device fiberoptically
223479817|NCT00888875|DEVICE|ILMA|Insertion after Induction. Insertion of tracheal tube over device
223479818|NCT00309517|DRUG|Fluourouracil|
223479819|NCT00309517|DRUG|Leucovorin|
223479820|NCT00309517|DRUG|MAb 17-1A|
224167348|NCT04500223|OTHER|Cervical stretch exercise plus cardiopulmonary rehabilitation|control:Cervical stretch exercise plus cardiopulmonary rehabilitation
224167349|NCT02421146|DEVICE|Transcranial direct current stimulation|Transcranial direct current stimulation (tDCS) is a form of neurostimulation which uses constant, low current (at 2 mA) delivered to the brain area of interest(anode over the left DLPFC while cathode over the right suborbital region) via electrodes on the scalp.
224167350|NCT02421146|DEVICE|Transcranial direct current stimulation - Sham|Transcranial direct current stimulation (tDCS) is a form of neurostimulation which uses constant, low current (at 2 mA) delivered to the brain area of interest(anode over the left DLPFC while cathode over the right suborbital region) via electrodes on the scalp.
224167351|NCT02296294|DRUG|Elo-mel® (Fresenius Kabi Austria)|an iv isotonic crystalloid fluid therapy at a rate of 0,50ml/kg/min for one hour.
224167352|NCT02296294|DEVICE|Body Composition Monitoring|BCM measurements every 10 minutes for 6 hours.
223479821|NCT01654276|DRUG|Febuxostat|One 40 mg tablet once a day for 6 months
223479822|NCT04163874|DRUG|Fiasp|Fiasp Insulin delivered in a basal-bolus manner.
224071761|NCT06840808|DEVICE|Sham Transcranial direct current stimulation|Sham transcranial direct current stimulation will be delivered via a Neuroelectrics Starstim tES. The sham setup will consist of anodal electrode Fz (International 10/10 System for electroencephalography electrode placement) and electrodes F7, FP1, FP2, and F8 as returns. All electrodes are 1 cm diameter Ag/AgCl electrodes and make contact with the scalp via connective gel. Stimulation will linearly ramp up from 0 milliamps to 1 milliamp over 60 seconds, ramp down to 0 milliamps over 60 seconds and then be left off for 20 minutes.
224071762|NCT03445000|DRUG|Alectinib|"Alectinib is administered orally 600mg (4x150mg capsules), twice per day (8 capsules, total 1200mg daily). The appropriate number of alectinib capsules will be provided to patients to be self-administered at home.~Alectinib capsules must be taken at the same time each day with food. If a planned dose of alectinib is missed, patients can take the missed dose up until 6 hours before the next dose."
224167353|NCT04969627|DRUG|Metformin|Use Metformin for 3 months to treat PCOS
224167354|NCT04969627|DRUG|Exenatide|Use Exenatide for 3 months to treat PCOS
223479823|NCT04163874|DRUG|Pramlintide Acetate|Pramlintide delivered in a basal-bolus manner with a fixed ratio with insulin.
223479824|NCT04163874|DRUG|Placebo|Placebo delivered in a basal-bolus manner with a fixed ratio with insulin.
223479825|NCT04163874|DEVICE|Artificial Pancreas|Tandem insulin pump, dexcom G5 sensor, Nexus 5 cellphone running the iMAP algorithm.
223479826|NCT06492629|DRUG|Toripalimab|Intravenous infusion, 240mg, administered once every 3 weeks, until the subject has been treated for 2 years, disease progression occurs, intolerable toxic reactions are experienced, or treatment is discontinued for other reasons.
223479827|NCT06492629|DRUG|chidamide|Take 30 mg (6 tablets) each time, and take the medication twice a week, with at least 3 days between doses (such as on Monday and Thursday, Tuesday and Friday, Wednesday and Saturday, etc.), to be taken 30 minutes after meals.
223479828|NCT03904654|BEHAVIORAL|Mindfulness-based cognitive therapy (MBCT)|MBCT is an evidence-based psychotherapy which combines mindfulness skills with cognitive therapy strategies.
223479829|NCT04334369|DEVICE|Proclear Single Vision Contact Lenses manufactured by CooperVision|FDA approved single vision contact lenses.
223479830|NCT04334369|DEVICE|Proclear Multifocal Contact Lenses manufactured by CooperVision|FDA Approved Multifocal Contact Lenses
223479831|NCT02243657|DRUG|ASP3652|oral
223479832|NCT02243657|DRUG|Placebo|oral
224071763|NCT03409744|DRUG|evinacumab|Intravenous (IV) administration
224071764|NCT02532231|OTHER|Laboratory Biomarker Analysis|Correlative studies
224071765|NCT02532231|BIOLOGICAL|Nivolumab|Given IV
224071766|NCT00264004|DRUG|AZD2171|30 mg \& 45 mg oral tablet
224071767|NCT00691483|DRUG|placebo|placebo tablet taken orally twice daily for 12 weeks
224071768|NCT00691483|DRUG|varenicline|varenicline tablets, 1 mg taken orally twice daily for 12 weeks
224071769|NCT06282003|PROCEDURE|The procedure of protective lung ventilation|The procedure of protective lung ventilation in the PV group of patients included preoxygenation with 60% oxygen in a mixture with air for 3 min, which maintained the target peripheral oxygen saturation at values above 94%, endotracheal intubation, volume-controlled mechanical ventilation, a tidal volume of 6 ml per kg of body weight. Normocarbia during the protective ventilation procedure was maintained by adjusting the minute ventilation, which is the product of the respiratory rate (12-14 breaths per minute) and the tidal volume set to 6 ml/kg of body weight. The most critical variable for the adjustment was the inhalation-exhalation ratio of 1:2, which ensured adequate oxygenation and removal of carbon dioxide during anesthesia. Identically as in the PV group, the target peripheral saturation was kept above 94% with an inspiratory oxygen concentration of 50% and peak airway pressure values of up to 40 kPa.
224071770|NCT00439946|DRUG|treprostinil|rapid switch from intravenous epoprostenol on the CADD ambulatory pump to intravenous Remodulin on the Crono Five ambulatory pump
224071771|NCT00439946|DEVICE|Crono Five ambulatory pump|Used for administration of IV Remodulin (treprostinil)
224071772|NCT06471868|DRUG|IY-HCR21|Betanechol 50mg
224071773|NCT06471868|DRUG|IY-MIC|Betanechol 25mg
224071774|NCT05244265|BEHAVIORAL|Mindfulness-based stress reduction (MBSR)|The 8 week (plus one-day retreat) manualized MBSR program according to the manual (Kabat-Zinn, 1982).
224071775|NCT05244265|BEHAVIORAL|Treatment as usual (TAU)|Different interventions and support in outpatient and other services.
224167355|NCT00871676|BEHAVIORAL|Lifestyle modification|16 weekly followed by 8 monthly group behavioral weight loss sessions.
224167356|NCT00871676|BEHAVIORAL|Lifestyle modification plus gum|16 weekly followed by 8 monthly group behavioral weight loss sessions. Subjects were also given gum along with instructions for times and occasions to chew with the aim of facilitating weight loss and appetite control.
224167357|NCT00835276|DRUG|Fexofenadine 180 mg tablets|1 x 180 mg
224167358|NCT00835276|DRUG|ALLEGRA® 180 mg tablets|1 x 180 mg
224167359|NCT02565862|DRUG|Daclatasvir|
224167360|NCT02565862|DRUG|Metformin|
224167361|NCT04189380|OTHER|HLQ (Health literacy questionnaire)|each patient complete survey and self-assessment questionnaire before or after his medical consultation
224167362|NCT04189380|OTHER|MoCA (Montreal Cognitive Assessment)|each patient complete survey and self-assessment questionnaire before or after his medical consultation
224167363|NCT04922710|BEHAVIORAL|Home-based aerobic exercise|Guidelines for exercise programming (ACSM, 2018) will be followed including a warmup and cool down, progressive and gradual increments in duration, and instruction regarding avoidance of physical activity related injury. The exercise group will receive moderate to vigorous intensity aerobic exercise for 60 minutes per day, three times a week, for 12 weeks. Participants who are unable to do a 60-minute session would instead complete it in two 30-minute sessions. The prescribed intensity will be based on estimated heart rate reserve, calculated using resting heart rate and age-adjusted heart rate maximum (220-age in years). Participants will maintain a minimum heart rate from their specific calculation that will be monitored by Polar Heart Rate straps.
224167364|NCT01574417|DIETARY_SUPPLEMENT|control margarine|"Subjects will undergo a postprandial test for 5.5 hours, in which 26.7gram of the control margarine is consumed together with a high-fat milkshake.~Daily consumption of 20 gram of a control margarine (providing daily 3.0 gram of plant stanols), for a period of 3 weeks."
224167365|NCT01574417|DIETARY_SUPPLEMENT|plant stanol-enriched margarine|"Subjects will undergo a postprandial test for 5.5 hours, in which 26.7gram of the plant stanol-enriched margarine is consumed together with a high-fat milkshake.~Daily consumption of 20 gram of a plant stanol-enriched margarine (providing daily 3.0 gram of plant stanols), for a period of 3 weeks."
224167366|NCT02774291|BIOLOGICAL|Aldesleukin|Given IV
224305335|NCT05080101|OTHER|Conventional Therapy Program|Patients in control group (n=14) will receive 40-mins conventional physiotherapy session for 3-days per week, over 6 weeks. Conventional physiotherapy will consist of stretching and strengthening exercises, postural alignment exercises, as well as electrotherapy such as transcutaneous electric magnetic stimulation (TENS) which will be applied to lumbar region with a frequency of 100 Hz, 50-100 μsec current duration for 20 minutes, hotpack which will be applied to lumbar region for 20 mins, and ultrasound application which will be applied to the lumbar region with a Chattanooga Intelect Mobile device at a frequency of 1 MHz, at a dose of 1.5 W/cm2, for 6 minutes using a 10 cm2 head.
223479833|NCT01492959|DRUG|insulin human|Insulin human delivered with the InnoLet® device was prescribed according to product labelling to subjects in need of insulin treatment
223479834|NCT03332537|BEHAVIORAL|Personalized IBS Pain SM|
223479835|NCT01763229|PROCEDURE|transthoracic echocardiography|
223479836|NCT03966066|DRUG|erythromycin|3-5mg/kg.d orally for 6 months
223479837|NCT02844595|BEHAVIORAL|Standard cognitive-behavioural smoking cessation treatment|"Standard cognitive-behavioural smoking cessation treatment is an effective treatment for tobacco dependence. The treatment elements are: treatment contract, self-report and graphic representation of cigarette consumption, information about tobacco, stimulus control, activities for the avoidance of withdrawal syndrome, physiological feedback (CO in expired air) on cigarette consumption, nicotine fading (change of cigarette brands each week progressively decreasing the intake of nicotine and tar), and relapse-prevention strategies (assertion training, problem solving training, change tobacco related misconceptions, management of anxiety and anger, exercise, weight control, self-reinforcing, and changing irrational beliefs).~Treatment will be delivered in eight 60-minute sessions over 8 consecutive weeks."
223479838|NCT02844595|BEHAVIORAL|Standard cognitive-behavioural smoking cessation treatment and behavioural activation|"Behavioural activation will be applied along with standard cognitive-behavioural smoking cessation treatment. The treatment elements are: those present in the standard cognitive-behavioural smoking cessation treatment, plus analysis of the relationship between behaviour and mood, identification of situations and behaviours that decrease mood, identifying avoidance behaviours, and identifying thoughts of rumination and worry, self-report of pleasant daily activities, pleasant activity scheduling to increase engagement in rewarding activities, and to reduce patterns of behavioural avoidance.~Treatment will be delivered in eight 60-minute sessions over 8 consecutive weeks."
223479839|NCT03832556|OTHER|CT scan|CT scan with biphasic injection of contrast product
223479840|NCT03832556|OTHER|MRI examination|MRI with injection of contrast
223479841|NCT00236626|DRUG|topiramate|
223479842|NCT04683575|DRUG|Selenium Yeast|oral medication
223479843|NCT04683575|DRUG|Placebo|oral medication
223479844|NCT00774085|OTHER|No intervention was given|Participants included patients treated with long-acting injectable risperidone (Risperdal Consta) in daily practice according to local label by the physicians
223479845|NCT01991795|DRUG|Ticagrelor 60 mg|Ticagrelor 60 mg bd taken orally as tablets
223479846|NCT01991795|DRUG|Ticagrelor placebo|Ticagrelor placebo bd taken orally as tablets
223479847|NCT05880719|OTHER|Computer-assisted Music remediation|"These sessions of computer-assisted music remediation last 1h and are each divide in 4 parts :~* 15 minutes of music improvisation~* 20 minutes of harmony and rythm exercices~* 20 minutes of Lesson about the software and musical interfaces~* 5 minutes of debrief."
223479848|NCT02484521|DEVICE|PPI monitoring device protocol|The investigators would use a monitoring device that would assess startle reflex reaction measured by blinking or the eye. Monitoring would be done with electrodes of EMG device that would be located on orbicularis oculi muscle and will monitor response.
223479849|NCT02484521|OTHER|Questionnaires|"Group of patients diagnosed with schizophrenia would be interviewed using well validated questionnaires.~Questionnaires what would be used are:~1. GAF- Global assessment of functioning~2. PANSS- Positive and negative syndrome scale~3. SANS- Scale for the Assessment of Negative Symptoms~4. The Calgary Depression Scale for schizophrenia~5. Demographic Questionnaire~6. Hamilton Anxiety scale"
223479850|NCT05041465|OTHER|Clay mask|Clay mask powders- French green, Rhassul and bentonite
223584640|NCT05065190|DRUG|Nintedanib|Soft gelatin capsule
223584641|NCT05065190|DRUG|Placebo|Soft gelatin capsule
223584642|NCT01797523|DRUG|Metformin|500 mg by mouth daily for 4 days on Days 1 - 4 of Cycle 0 and then 2 times a day (about 12 hours apart) every day after that. Metformin taken for 7 - 10 days in Cycle 0 before Cycle 1 begins.
223584643|NCT01797523|DRUG|Letrozole|2.5 mg tablet by mouth once daily in a 28 day cycle.
223584644|NCT01797523|DRUG|Everolimus|10 mg by mouth once daily in a 28 day cycle.
224167367|NCT02774291|BIOLOGICAL|Anti-thyroglobulin mTCR-transduced Autologous Peripheral Blood Lymphocytes|Given IV
224167368|NCT02774291|DRUG|Cyclophosphamide|Given IV
224167369|NCT02774291|BIOLOGICAL|Filgrastim|Given SC
224167370|NCT02774291|DRUG|Fludarabine Phosphate|Given IVPB
224167371|NCT02774291|OTHER|Laboratory Biomarker Analysis|Correlative studies
223584645|NCT00463554|DEVICE|GYNECARE TVT-SECUR* System|A sub-urethral sling for the treatment of SUI resulting from urethral hypermobility and/or intrinsic sphincter deficiency
224071776|NCT02816918|DEVICE|Extraluminal use of Univent bronchial Blocker|"Patients assigned to the Extraluminal use of Univent Blocker group were first inserted Univent bronchial Blocker into the glottis via direct laryngoscopy then advanced the Blocker to the target bronchus until slight resistance was encountered.A conventional tracheal tube with appropriate size was intubated via direct laryngoscopy into the appropriate depth, inflating the tracheal tube cuff, and fixing the tube firmly at the patient's mouth with cloth tape .~So the Univent Blocker Extraluminal of the endotracheal tube,then the fibreoptic bronchoscopy was inserted into the tracheal tube and guided bronchial blocker cuff to the target main bronchus under direct vision"
224071777|NCT02816918|DEVICE|Innerluminal use Univent bronchial Blocker|Patients in Innerluminal use of Univent Blocker group: When the endotracheal tube had been intubated via direct laryngoscopy, the bronchial blocker was advanced Innerluminal of the endotracheal tube and directed into the right or left mainstem bronchus, then the fibreoptic bronchoscopy was inserted into the tracheal tube. After further pushing and twisting, the bronchial blocker tube will move into the mainstem bronchus under direct vision by FOB.the tracheal tube cuff is inflated with the tube being fixed firmly at the patient's mouth with cloth tape
224071778|NCT03165097|DRUG|ACT-709478|Hard gelatine capsules for oral administration
223479851|NCT03318458|OTHER|Pilates|The duration of the intervention is 12 weeks, with 2 sessions per week of Pilates. Each session lasts approximately 1 hour and is structured in three parts: initial warm-up, which reviews the basic principles of the Pilates Method (centralization, concentration, movement control, breathing, movement precision and fluency) of 10 minutes duration, a 40-45 minute Pilates session and finally 10 minutes of guided relaxation. No complement was used (magic rings, fitball, elastic bands, etc.) during classes
223479852|NCT03890965|OTHER|Reflex locomoction therapy|"The intervention of the stimulation of the reflex locomotion is carried out in this study in a sitting position in a conventional chair, an unorthodox posture in the usual treatment of Vojta therapy.~The reflex stimulation is performed by the passive pressure exerted by the weight of the wrist (pisiform) on the rubber sphere. Simultaneously the patient has to exert a slight pressure with the heel towards the ground with his foot. This foot will be the opposite of the wrist that has the sphere under the pisiform.~Alternating each diagonal 4 times, 5 minutes each. Total session 20 minutes, 2 times x day, every day according to degree of affectation."
223479853|NCT04716543|DIAGNOSTIC_TEST|ILI and COVID-19 detection|"All participants presenting with ILI symptoms will have non-invasive exam for SARS-CoV-2 detection (nasal, throat, swab, saliva) and a questionnaire.~All family members more than 6 months living with SARS-CoV-2 positive individuals will have will have non-invasive exam for SARS-CoV-2 detection (nasal, throat, swab, saliva) and a questionnaire."
223479854|NCT03854110|DRUG|GP-2250|GP-2250 monotherapy for pharmacokinetics and safety; GP-2250 plus gemcitabine for safety, tolerability, pharmacokinetics, and biomarker assessments
223479855|NCT05126316|DRUG|Lu AG09222|Lu AG09222 will be administered per schedule specified in the arm description.
223479856|NCT05126316|DRUG|Placebo|Placebo matching to Lu AG09222 will be administered per schedule specified in the arm description.
223479857|NCT02587208|DEVICE|Plastibell|In the Plastibell group, the size of the device is chosen according to the lateral-lateral diameter of the glans. A dorsal slit incision is made and then the foreskin is pulled up and the Plastibell device placed between the prepuce and the glans. A non-absorbable string was tightly tied around the device and the distal prepuce is removed.
223479858|NCT02587208|PROCEDURE|conventional sleeve|In the sleeve dissection group, a double incision technique on both outer and inner layers of the foreskin is employed. Hemostasis is achieved by bipolar diathermy, and cut edges are sutured with 5/0 rapide vicryl.
223479859|NCT06472739|DRUG|GM-CSF|GM-CSF mouthwash four times per day at radiotherapy initiate, during the whole radiotherapy phase
223479860|NCT03989544|BIOLOGICAL|Tezepelumab|Tezepelumab subcutaneous injection
223584646|NCT00168454|BIOLOGICAL|botulinum toxin Type A|botulinum toxin Type A injected into detrusor on Day 1
223584647|NCT00168454|DRUG|Placebo|Placebo (normal saline) injected into detrusor on Day 1
223584648|NCT05669872|DRUG|Ferric Carboxymaltose 50Mg/Ml Inj 20Ml|ferric carboxymaltose 1000mg, fixed dose for intervention group
223584649|NCT05669872|DRUG|RBC|pack RBC transfusion
223584650|NCT03568669|OTHER|NIH Toolbox Cognition Battery|An app-based cognitive assessment of executive function, attention, memory, and language that takes approximately 45 minutes to complete on an iPad
224071779|NCT03165097|DRUG|Placebo|Placebo capsules matching ACT-709478 capsules
224071780|NCT03165097|DRUG|Midazolam|Midazolam oral solution (2 mg/mL) applied with a syringe
224071781|NCT03165097|DRUG|ACT-709478 combined with midazolam|Hard gelatine capsules for oral administration (ACT-709478) to be taken first followed by Midazolam oral solution (2 mg/mL) applied with a syringe
224071782|NCT00179387|BEHAVIORAL|Mind-Body Psychotherapy Group|Psycho-educational group
224071783|NCT00179387|BEHAVIORAL|Mind-Body Psychotherapy Group|Spiritual-Existential Group
224071784|NCT01185405|OTHER|Use of different strategy for voriconazole dosage adjustment|Patients will be randomly assigned into 2 groups: conventional adjustment group (CA group) and early adjustment group (EA group). Voriconazole plasma levels will be measured on day 1 (both peak and trough levels), day 3, day 5, day 10, and day 14 (all trough levels). For CA group patients, voriconazole dosage will be adjusted according to the trough levels of day 5 (steady-state level). Predefined dose adjustment protocol will be used (\< 1 µg/ml: 50% increase, 1\~5.5 µg/ml: no change, \> 5.5 µg/ml: 50% decrease). For EA group patients, voriconazole dosage will be adjusted according to the each measurements of voriconazole levels from day 1. Adjusted dosage will be calculated using the NONMEN software.
224071785|NCT06213727|DRUG|lowe-dose ZKY001 eye drops|eye drops
224071786|NCT06213727|DRUG|Medium-dose ZKY001 eye drops|eye drops
224071787|NCT06213727|DRUG|ZKY001 simulated eye drops|eye drops
224071788|NCT04209803|DRUG|Minoxidil 5% topically and oral NAC 600 mg|Topical 5% Minoxidil and N-Acetyl-Cysteine 600 mg orally
224167372|NCT02556580|DRUG|Albumin 20%|Intervention: intravenious infusion Drug: albumin
224167373|NCT02332876|BEHAVIORAL|Exercise|
224167374|NCT02332876|BEHAVIORAL|Control|
224167375|NCT04117594|DIAGNOSTIC_TEST|WB-MRI|Whole body MRI with diffusion-weighted imaging (DWI)
224167376|NCT05142176|OTHER|Erector spinae catheters insertion|Ultrasound-Guided ESPB The ESPB will be performed with the child in a right lateral decubitus position under aseptic precautions by a high frequency (6-13 MHz) linear ultrasound transducer
224167377|NCT05142176|DRUG|Postoperative pain management|IV acetaminophen 15 mg/kg every 8 hours as a component of multimodal analgesia.
224167378|NCT01381224|OTHER|Observation of biomechanical effects post injection|Observation of effects on gait, lumbar spine range of motion and pain symptoms immediately following injection and at two weeks post injection
224167379|NCT02853786|BEHAVIORAL|LENA and advice|Language recording with the LENA device, with the LENA results, we will advise the parents how to improve the language environment to help their children with CIs for their language development
224167380|NCT02853786|OTHER|LENA without advice|Language recording with the LENA device. Regular speech therapy follow blindly the results of LENA
223479861|NCT04896671|BEHAVIORAL|Physical exercise (running on a treadmill)|Participants in the intervention group join a total of 12 treadmill running sessions, two sessions per week and each session for 30 minutes. In each session, every participant will be trained to run for 30 minutes on a treadmill. According to Exercise and Sports Science Australia (ESSA) exercise intensity guidelines, the intensity of running is suggested to be moderate and vigorous (alternating between the two) in this study.
223479862|NCT01413802|PROCEDURE|Continuous nerve monitoring|Continuous nerve monitoring is performed during thyroid surgery.
223479863|NCT02644746|DEVICE|acupuncture|Shenshu (BL23), Dachangshu (BL25), Weizhong (BL40), Chengshan (BL57), Taixi (KI3) acupoints will be used. For bilateral Dachangshu (BL 25), the needle will be inserted vertically at approximately 40-70 mm until participants got a electric shock feeling downward to calves, then the needle should be elevated up 2 mm, without rotating or lifting. For other four acupoints (BL23, BL40, BL57, KI3), they will be inserted 10 to 15 mm in depth with three times light amplitude rotation and lift to induce a sensation of soreness. The manipulations will be performed 3 times in total during 1 session (every 10 min). There are 24 treatment sessions after baseline, 3 times a week, and the patients will undergo a 30-min treatment each session.
223479864|NCT02644746|DEVICE|placebo needle|Acupuncturists will use blunt tip needles (Huatuo, Suzhou, China) that cannot penetrate skin and stimulate deep tissues, and the thrusting and twisting motions will be used by acupuncturists to simulate the treatment and blind the patients. Each placebo needle consists of four parts: needle handle, needle body, blunt tip and adhesive pad. The chosen of acupoints, treatment duration, and frequency of sessions will be the same as the acupuncture group. To guarantee blinding, the investigators will make appointments with each participant on alternate days to prevent crosstalk among groups.
223479865|NCT05397496|BIOLOGICAL|PIT565|Intravenous (i.v.) infusion or Subcutaneous (s.c.) injection
223479866|NCT03344757|BEHAVIORAL|Cultural CBSM|The Culturally Adapted Cognitive Behavioral Stress Management (C-CBSM) Intervention is a 10 weekly in-person group program. Each session will last about 90 minutes. The meetings will give facts on stress, coping with difficult events, managing anger, social support and stress reactions. Participants will also receive information on how to practice relaxation on their own. The delivery of C-CBSM places a greater emphasis on salient sociocultural determinants of symptom burden and Health Related Quality of Life (HRQoL) in Hispanics (e.g., fatalistic attitudes, family interdependence, perceived discrimination, machismo).
223479867|NCT03344757|BEHAVIORAL|Standard CBSM|The standard Cognitive Behavioral Stress Management (CBSM) Intervention is a 10 weekly in-person group program. Each session will last about 90 minutes. The meetings will give facts on stress, coping with difficult events, managing anger, social support and stress reactions. Participants will also receive information on how to practice relaxation on their own.
223479868|NCT04511013|DRUG|Binimetinib|Given PO
223479869|NCT04511013|DRUG|Encorafenib|Given PO
223479870|NCT04511013|BIOLOGICAL|Ipilimumab|Given IV
223584651|NCT05455931|DRUG|Poteligeo|Poteligeo treatment will be used as prescribed by the Investigator in accordance with the terms of the reimbursed indication within the relevant country. The assignment of the patient to a particular therapeutic strategy falls within current practice and the prescription of Poteligeo is clearly separated from the decision to include the patient in the study.
223584652|NCT05698524|DRUG|PCI 24781|Participants will take PCI-24781/Abexinostat on days 1 - 4, 8 - 11, and 15 - 18 of each 28-day cycle.
223584653|NCT05698524|DRUG|Temozolomide|Participants will receive temozolomide at a dose of 50 mg/mg2, taken by mouth once daily.
223584654|NCT05767827|DRUG|ropivacaine, lidocaine with adrenaline|Group R includes 0.35% ropivacaine 20ml, 1.5 % lidocaine with adrenaline 10ml
223584655|NCT05767827|DRUG|Dexmedetomidine, ropivacaine, lidocaine with adrenaline|Dexmedetomidine 1mcg/kg and 0.35% ropivacaine with normal saline (20ml), 1.5% lidocaine with adrenaline (10ml) in group RD
223584656|NCT05042284|DRUG|Non-enteric coated pancreatic enzyme preparation|The patients will be given a non-enteric coated pancreatic enzyme capsule containing 30000 U of protease thrice daily along with meals for 3 months.
224167381|NCT00017524|DRUG|pelitrexol|
224167382|NCT06204510|OTHER|complex decongestive therapy|This application consists of manual lymph drainage, skin care, compression bandage and exercises. This phase will continue for 3 weeks, 5 days a week.
224167383|NCT02415595|DRUG|BMS-955176|HIV Maturation Inhibitor
224167384|NCT02415595|DRUG|EFV|EFV
224167385|NCT02415595|DRUG|TDF/FTC|TDF/FTC
224167386|NCT00962481|DRUG|Bimosiamose|
224167387|NCT00962481|DRUG|Placebo|
224167388|NCT00493714|BEHAVIORAL|Questionnaire|Surveys lasting 30 minutes or more.
224167389|NCT03942549|DEVICE|Retropubic midurethral sling|Midurethral sling
224167390|NCT00471315|DRUG|Duloxetine|A preliminary, open-label single center study of duloxetine in patients with SOD
224167391|NCT05764811|DRUG|Canagliflozin 100mg|100 mg daily for a month
224167392|NCT02614261|DRUG|Galcanezumab|Administered SC
224167393|NCT02614261|DRUG|Placebo|Administered SC
224167394|NCT00275041|BIOLOGICAL|cetuximab|
224167395|NCT00275041|DRUG|irinotecan hydrochloride|
224167396|NCT00108277|BEHAVIORAL|Breathing Training-Raise CO2|while breathing 9 breaths per minute, patients are instructed to raise CO2
224167397|NCT00108277|BEHAVIORAL|Breathing Training- Lower CO2|while breathing 9 breaths per minute, patients are instructed to lower CO2
224167398|NCT02089867|OTHER|Ezetimibe + plant sterols|The ezetimibe + plant sterols group will receive ezetimibe 10 mg/day + spread enriched with 2g daily of plant sterols for 6 weeks
224167399|NCT02089867|DRUG|Ezetimibe|The ezetimibe group will receive 10 mg/day ezetimibe for 6 weeks.
224167400|NCT02089867|DIETARY_SUPPLEMENT|Plant sterols|The plant sterol group will receive spread enriched with 2g daily of plant sterols for 6 weeks
224167401|NCT02315833|DRUG|Acetium|Capsule for oral administration contains L-cysteine 100mg
224167402|NCT02315833|DRUG|Placebo|A placebo capsule matching Acetium for oral administration.
224167403|NCT03050606|OTHER|Pilates|Exercises performed on the mat and apparatus, following the six principles of the Pilates method. The exercises will be performed in three levels of difficulty: basic, intermediate and advanced, according to the capacity of the patient.
224167404|NCT03050606|OTHER|Aerobic|Aerobic exercise will be carried out individually on treadmills or stationary bikes. The intensity of the training will be mild to moderate (57% to 76% of the maximal heart rate monitored by the frequencymeter).
224167405|NCT03479658|BEHAVIORAL|High intensity interval training|Two schools with four classes/groups of 4th degree of children will participate in the pilot study (i.e., age of children 9-10 years old). One of them has two physical education (PE) sessions per week and the other has only one PE session per week. In the school with two PE sessions, two classes will be randomly assigned to HIIT (2 sessions/week) +nutrition group, and two to the nutrition group. Similarly, in the school with one PE session per week, two classes will be randomly assigned to HIIT (1 session/week) + nutrition and two classes to the nutrition goup. Both HIIT and nutritional education sessions will be integrated integrated into the physical education and sciences sessions of the schools. The duration of the intervention will be of eight weeks.
224167406|NCT03479658|BEHAVIORAL|Nutritional education|School-based nutritional education on healthy dietary habits
224167407|NCT01426724|DRUG|Contrast Enhanced Ultrasonography|Definity microbubbles will be infused intravenously at a rate of 2mL/min. contrast enhanced images of the kidneys will be obtained during the infusion and following the destruction of microbubbles within the kidney tissue with ultrasound to measure renal blood flow two times within a 90 day (plus or minus 10 day) window
224167408|NCT03824457|DRUG|Rheosorbilact®|Rheosorbilact® is administered as a part of the infusion therapy intravenously (with speed 40-60 drip per minute) at a dose of not more than 400 ml (6 to 7 ml/kg body weight per 24 hours) for 3 days.
224167409|NCT03824457|DRUG|Ringer lactate|Rheosorbilact® is administered as a part of the infusion therapy intravenously (with speed 40-60 drip per minute) at a dose of not more than 400 ml (6 to 7 ml/kg body weight per 24 hours) for 3 days.
224167410|NCT00036231|DRUG|RG1068 (Synthetic Human Secretin)|
224167411|NCT00200889|DEVICE|active TEAS|non-painful active transcutaneous electro-acupoint stimulation will be delivered to the abdomen and leg
224167412|NCT03440892|DRUG|methotrexate|folate antagonist
224167413|NCT03440892|DRUG|sulfasalazine|Immunomodulatory
224167414|NCT03440892|DRUG|abatacept|Targeting CTLA-4 (fusion protein composed of the Fc region of the immunoglobulin IgG1 fused to the extracellular domain of CTLA-4)
224167415|NCT03440892|DRUG|tocilizumab|IL-6 receptor antagonist
224167416|NCT03440892|DRUG|tofacitinib/baricitinib|JAK inhibitor
224167417|NCT05437692|DRUG|zimberelimab combined With concurrent radiotherapy and chemotherapy|zimberelimab: 240 mg Q2W Intravenous drip，The maximum duration of medication shall not exceed one years; chemotherapy: Starting from the first week of radiotherapy and chemotherapy, cisplatin 40mg/m2 and paclitaxel 35mg/m2 were given intravenously for 30-60min; Radiotherapy: intensity modulated radiation therapy (IMRT) was used for external irradiation. The total dose of pelvic cavity and lymph drainage planning target area (PTV) was 45-50 gy/25-28f. The metastatic lymph nodes should be able to supplement or synchronously push 10-15 Gy; The internal irradiation was started within 2 weeks after the end of external irradiation treatment. The image-guided three-dimensional brachytherapy was used, and 30-40gy was added to make the total dose of point a reach 80-85 Gy, twice a week, 5-6gy each time. All radiotherapy was completed within 8 weeks.
224167418|NCT06417268|PROCEDURE|Caudal epidural analgesia|"patient will be placed in the left lateral position with flexed hips.After palpating the landmarks (the upper posterior iliac spine and sacral hiatus from the edges of an equilateral triangle), an epidural puncture is performed in the most proximal region of the sacral hiatus with the needle inclined 45-60° to the skin. While palpating with the index finger of the left hand, the needle is inserted immediately below the spinous process S4.~After perforating the membrane, the needle will be advanced no more than 1-3 mm to avoid a bloody puncture or an intrathecal injection, The confirmation of the correct position of the caudal needle before injection by performing the modified 'swoosh' test performed by auscultation at the thoracolumbar region with a stethoscope while injecting 2 mL of saline. Bupivacaine 0.25% at a dose of 1 ml/kg will be injected, with care taken not to exceed the maximum recommended dose (2 mg/kg)."
224167419|NCT06417268|PROCEDURE|Ultrasound-guided Combined Pericapsular Nerve Group Block|"With supine position, the probe will be put in a transverse plane along the anterior inferior iliac spine (AIIS) to identify the iliopsoas muscle, femoral nerve, and femoral artery (FA).~Then the probe will be rotated counter clockwise to align with the pubic ramus to visualize the AIIS, iliopsoas prominence (IPE), FA, iliopsoas, and iliopsoas notch.~Under direct vision, a 22-gauge, 50-mm echo needle will be advanced in the lateral-medial plane between the psoas tendon and the pubic ramus until the needle tip touches the IPE. The needle will be withdrawn, and after negative aspiration, 1 ml/kg (Bupivacaine 0.25%) is injected"
224167420|NCT06417268|PROCEDURE|Ultrasound-guided Lateral Femoral Cutaneous Nerve Block|patient remains supine, and the transducer is parallel to the inguinal ligament. With the femoral artery and vein as guidance, the lateral part of the sartorius muscle and fascia lata is visualized. Approximately 3 cm inferior from this point, the branches of the lateral femoral cutaneous nerve are visualized in the hypoechoic fat-filled subfascial space between the sartorius muscle medially and the tensor fascia lata muscle laterally. A 22-gauge, 50-mm needle is inserted with in plane approach at a shallow angle to reach the area of the nerve and after negative aspiration, 0.1 ml/kg (Bupivacaine 0.25%) is injected.
223479871|NCT04511013|BIOLOGICAL|Nivolumab|Given IV
224167421|NCT06417268|DRUG|Fentanyl|patients will receive an induction dose at 1 mcg/kg. If the analgesia was inadequate in the form of increase in heart rate and or arterial blood pressure by more than 20% of baseline values during surgery, this warrants the administration of intravenous fentanyl (0.5µg/kg).
224167422|NCT06417268|DRUG|Morphine|If a FLACC pain Score is ≥ 4/10, the patient in the PACU will receive morphine (intravenous, 0.03 mg/kg), and the maximum allowed dose is 0.1mg/kg every 4 hours.
224167423|NCT06417268|DRUG|Acetaminophen|P atients will receive postoperative IV acetaminophen IV 10 mg/ kg q 6 hours
224167424|NCT02460172|DEVICE|Zip Surgical Skin Closure|Non invasive, reversible, skin closure device for closure of the skin layer following surgical incisions or laceration repair.
224167425|NCT02460172|DEVICE|Steel Staples|Skin closure device for the closure of the skin layer following surgical incision
224167426|NCT04197206|OTHER|costotransverse block|patient controlled analgesia devices with tramadol
224167427|NCT03512275|DRUG|Bermekimab Monoclonal Antibody 400 mg|subcutaneous injection
224167428|NCT00067444|DRUG|Paroxetine CR|
224167429|NCT00609167|DRUG|bortezomib|"First 33 patients: 1.3 mg/m\^2 IV Days 1, 4, 8 \& 11~Remaining 30 patients: 1.5 mg/m\^2 IV Days 1, 8, 15 \& 22"
224167430|NCT00609167|DRUG|cyclophosphamide|300mg/m\^2 PO days 1, 8, 15 \& 22
224167431|NCT00609167|DRUG|dexamethasone|"First 33 patients: 40 mg PO Days 1-4, 9-12, 17-20~Remaining 30 patients: 40 mg PO Days 1-4, 9-12, 17-20 for cycles 1-2; Days 1, 8, 15, 22 for cycle 3+2 for cycle 3 and beyond"
224167432|NCT03288623|DIETARY_SUPPLEMENT|Dark Chocolate (85% cocoa)|Dark chocolate (85% cocoa) in tablet
224167433|NCT03288623|DIETARY_SUPPLEMENT|White/Milk chocolate (<35% cocoa)|white or milk chocolate (\<35% cocoa) in tablet
223479872|NCT06119854|BEHAVIORAL|Attitudinal inoculation|A brief video focused on bolstering resistance to mis/disinformation about the COVID vaccine. Participants will receive two messages via text or email (1 and 3 days after the inoculation intervention). These messages will include reminders to get vaccinated.
223479873|NCT06119854|BEHAVIORAL|Cognitive-behavioral therapy-informed intervention|A brief video using a CBT-informed approach and focused on addressing barriers to COVID-19 vaccination. Participants will receive two messages via text or email (1 and 3 days after the inoculation intervention). These messages will include reminders to get vaccinated.
223479874|NCT06119854|BEHAVIORAL|Conventional public health messaging|A brief video conveying conventional public health messaging adapted from a review of public health public service announcements with no inoculation messaging. Participants will receive two messages via text or email (1 and 3 days after the inoculation intervention). These messages will include reminders to get vaccinated.
224167434|NCT03898323|DEVICE|Alcohol Approach Bias Modification|Computerized training
224167435|NCT06455423|PROCEDURE|Thoracic Manipulation|Thoracic manipulation will be administered at hypomobile or stiff segments.
223479875|NCT05190770|DRUG|Triamcinolone Acetonide|Triamcinolone acetonide is a derivative of prednisolone with high glucocorticoid activity and low mineralocorticoid activity. It is applied topically.
223479876|NCT05190770|DRUG|Oleogel-S10|Oleogel-S10 consists of birch bark extract (TE): 10 mg/100 mg; Sunflower oil, refined: 90 mg/100 mg. It is applied topically.
224167436|NCT06455423|PROCEDURE|Chin tuck in exercises|Chin tuck in exercises
224167437|NCT06455423|PROCEDURE|Thoracic Extension Exercise|Thoracic Extension Exercise
223479877|NCT05710575|BIOLOGICAL|probiotic|Probiotic or placebo administration will be started from the first feed of the infants. Infants in the probiotic group will receive five drops of oil-based suspension containing 1×108 colony-forming units of L reuteri (DSM 17938 Biogaia AB, Stockholm, Sweden) once a day, until death or discharge from the hospital. For infants on oral feeds, after suctioning oral secretions, five drops will be placed in the posterior oropharynx of the infants. For infants without per oral feeds, five drops will be administered through a gastric tube followed by a flash of 0.5 mL of sterile water. For the infants in the placebo group, five drops from an identical vial containing only oil base will be administered following the same protocol as the probiotic group.
223479878|NCT05710575|OTHER|placebo|Probiotic or placebo administration will be started from the first feed of the infants. Infants in the probiotic group will receive five drops of oil-based suspension containing 1×108 colony-forming units of L reuteri (DSM 17938 Biogaia AB, Stockholm, Sweden) once a day, until death or discharge from the hospital. For infants on oral feeds, after suctioning oral secretions, five drops will be placed in the posterior oropharynx of the infants. For infants without per oral feeds, five drops will be administered through a gastric tube followed by a flash of 0.5 mL of sterile water. For the infants in the placebo group, five drops from an identical vial containing only oil base will be administered following the same protocol as the probiotic group.
224167438|NCT06455423|PROCEDURE|Scapular Retraction Exercises|Scapular Retraction Exercises
224167439|NCT06455423|DEVICE|Hot Pack|Hot Pack
224167440|NCT06455423|DEVICE|TENS|Trans Cutaneous Electric Nerve Stimulation (TENS)
224167441|NCT06455423|PROCEDURE|ELDOA|ELDOA exercises
224167442|NCT01948323|BEHAVIORAL|HEDUAfrica IT package+ standard care|"The HEDUAfrica website aims to target disadvantaged pregnant women representing the core aspect of the intervention. The website is available on a touch screen panel at the two intervention clinics, (Cape Town and Soweto, South Africa). A trained healthcare worker will assist women by means of a touchscreen tablet at the follow up sessions. The website content includes a number of short videos and health messages related to a pregnancy-specific-disease outcomes.~Participants are also asked to complete 2 questionnaires (24 hour dietary recall assessment and short messaging service technology driven) in conjunction to engaging with the HEDUAfrica website. The intervention is standardized across all participants in the intervention group."
224167443|NCT03175250|BEHAVIORAL|Health Education|Videos (AIDSvideos.org) were presented on individually-assigned laptops and covered HIV risk, condom use, safe sex, and infection testing
224167444|NCT03175250|BEHAVIORAL|Action Plan|Participants selected situations for condom use and screening for HIV and hepatitis on individually-assigned laptops. They linked these situations to preventive behaviors regarding screening and condom use.
224167445|NCT03175250|BEHAVIORAL|Memory Practice|Participants engaged in several different types of memory practice procedures on assigned laptops. The procedures focused on memory for action plans for screening and condom use.
224167446|NCT01547806|DRUG|Filgrastim|Filgrastim will be administered as a single daily dose in a dose range of 10-16ug/kg/day subcutaneously for 5-7days
223479879|NCT06968637|OTHER|care recommendations|Provision of specific care recommendations for diabetes management. Based on existing guidelines, when any DR is present, the PIS will prompt diabetologists to check, and if necessary, change medicines to optimize, blood sugar, blood pressure and lipids.
224167447|NCT01547806|DRUG|Plerixafor|Plerixafor will be given on day 4, 8-10 hours before the day 5 apheresis, dose calculated according to patient weight
223479880|NCT06194825|DRUG|Eplontersen|Eplontersen by subcutaneous injection
224167448|NCT01547806|PROCEDURE|Apheresis|The minimum cluster of differentiation 34 (CD34)+ cell dose that must be collected in order to proceed with a single autologous transplantation is 2 x 106 CD34+ cells/kg.
224167449|NCT01997138|DRUG|Anakinra 100 mg in 2 ml saline IA|
224167450|NCT02448797|DRUG|Icotinib|125 mg three times daily (375 mg per day) orally for two years.
224167451|NCT02448797|DRUG|Chemotherapy|Vinorelbine 25 mg/m\^2, intravenously guttae, day 1 and day 8, 21 days/cycle, 4 cycles, cisplatin 75 mg/m\^2, intravenously guttae, day 1, 21 days/cycle, 4 cycles. For adenocarcinoma: pemetrexed (500 mg/m\^2, day 1)/cisplatin (75 mg/m\^2, day 1) for 4 cycles.
224167452|NCT06247449|DIAGNOSTIC_TEST|Brain imaging|Brain Magnetic resonance (or computed tomography if magnetic resonance is contraindicated)
223479881|NCT06194825|DRUG|Placebo|Eplontersen-matching placebo by subcutaneous injection
224167453|NCT06247449|DIAGNOSTIC_TEST|Analysis of circulating tumor DNA|One single blood draw for analysis of circulating tumor DNA
223479882|NCT06851858|DRUG|AZD6234|Weekly SC injections of AZD6234
223479883|NCT06851858|DRUG|Placebo to match|Weekly SC injections of matching placebo
223479884|NCT03958877|DRUG|BIIB017 (peginterferon beta-1a)|Administered as specified in the treatment arm
223479885|NCT03958877|DRUG|Interferon beta type 1a|Administered as specified in the treatment arm
223479886|NCT04798027|BIOLOGICAL|SARS-CoV-2 mRNA vaccine formulation 1|Pharmaceutical form: Sterile suspension Route of administration: Intramuscular injection
223479887|NCT04798027|BIOLOGICAL|SARS-CoV-2 mRNA vaccine formulation 2|Pharmaceutical form: Sterile suspension Route of administration: Intramuscular injection
223479888|NCT04798027|BIOLOGICAL|SARS-CoV-2 mRNA vaccine formulation 3|Pharmaceutical form: Sterile suspension Route of administration: Intramuscular injection
223479889|NCT04798027|BIOLOGICAL|Placebo (0.9% normal saline)|Pharmaceutical form: Liquid Route of administration: Intramuscular injection
224167454|NCT06247449|BEHAVIORAL|Testing Morbidities Index|Questionnaire regarding the participant's perception of brain imaging.
223479890|NCT06970080|DRUG|Inhaled corticosteroid (ICS)|In Phase I, participants will receive additional same dose of extra-fine particle ICS (i.e., their ICS would be doubled) for 12-weeks.
223479891|NCT06970080|DRUG|Oral Corticosteroid (OCS)|In phase II, participants will receive add-on oral prednisone (30mg/day) for one-week.
223479892|NCT05787574|DRUG|Emapalumab|Emapalumab on Days -22 (22 days before the day of the stem cell transplant), -15, -8, and -1.
223584657|NCT02769962|DRUG|EP0057|"EP0057 (formerly CRLX101) intravenous (IV) every (Q) 2weeks Day 1 and Day 15, administered in 28-day cycles, until disease progression or development of intolerable side effects.~Plus olaparib (by mouth (PO) days 3-13\* and days 17-26\*) administered in 28-day cycles, until disease progression or development of intolerable side effects. Phase (P)1: Dose Escalation P2: recommended phase 2 dose (RP2D).~(\* On days 13 and 26, only one dose of olaparib will be administered in the morning)"
224071789|NCT05058183|DIAGNOSTIC_TEST|ctDNA|Patients with stage 1 HER2 positive and triple negative breast cancer will receive ctDNA test after surgery. Treating clinicians will receive results and may change treatment plans in event of negative test.
224071790|NCT05980715|DRUG|PD-1inhibitor|The PD-1 monoclonal antibody was the same as the neoadjuvant therapy before surgery, and the postoperative level was maintained at Q3\*6.
224167455|NCT02852291|BEHAVIORAL|Parents Make the Difference|10 parent training sessions delivered to groups of caregivers
224167456|NCT02852291|BEHAVIORAL|Parents Make the Difference Plus|10 parent training sessions delivered to groups of caregivers, with 3 home visits
224305336|NCT05080101|OTHER|Basic Body Awareness Therapy Group Program|Patients in study group (n=14) will receive Basic Body Awareness Therapy (BBAT) 3 days in a week, over 6 weeks in addition to conventional physiotherapy. BBAT will consist of flexibility exercises and various cognitive exercises in supine, position, sitting position and standing position. These exercises will be consist of exercises such as body scanning, breathing, sound resonance.
224071791|NCT05980715|RADIATION|concurrent chemoradiotherapy|According to the guidelines, concurrent chemoradiotherapy is required, and carboplatin (50mg/m2) plus concurrent radiotherapy or cisplatin (30mg/m2) plus concurrent radiotherapy is optional.
223479893|NCT05787574|DRUG|Fludarabine and Dexamethasone|Fludarabine and dexamethasone for 5 days in a row on Days -22 through -18.
223479894|NCT05787574|PROCEDURE|Stem Cell Transplant|Participants in both groups will receive their standard-of-care stem cell transplant on Day 0.
223479895|NCT06971445|DIETARY_SUPPLEMENT|omega-3 polyunsaturated fatty acids (PUFA n-3)|1280 mg of omega-3 polyunsaturated fatty acids (650mg EPA, 450mg DHA, and 179mg ALA) per day for 8 weeks
223479896|NCT06971445|DIETARY_SUPPLEMENT|Olive oil (placebo)|Softgels containing extra virgin olive oil, with a similar appearance to the experimental group, were given to participants for 8 weeks.
223479897|NCT06431841|DRUG|Atropine 0,025%|Atropine 0,025% (1 drop per day)
223479898|NCT06431841|DEVICE|DIMS Lenses|Use of peripheral defocus lenses with DIMS technology, the design of which simultaneously introduces myopic defocus and provides clear vision to the wearer at all viewing distances.
223479899|NCT06431841|DEVICE|Monofocal lenses|Use of monofocal lenses.
223479900|NCT06022354|DRUG|SIM0278 Injection/Placebo|SIM0278 Injection/Placebo
223479901|NCT06684990|OTHER|POC testing|POC testing for HbA1c and cystatin C
223479902|NCT05046808|DRUG|Famitinib Malate Capsules|Famitinib Malate Capsules 10mg single dose
223479903|NCT05046808|DRUG|Famitinib Malate Capsules|Famitinib Malate Capsules 15mg single dose
223479904|NCT05046808|DRUG|Famitinib Malate Capsules|Famitinib Malate Capsules 20mg single dose
223479905|NCT05046808|DRUG|Famitinib Malate Capsules|Famitinib Malate Capsules 10mg\*2 single dose
224167457|NCT02828995|OTHER|Comprehensive Diabetes Stigma Survey|"The surveys to be administered in the ENDSTIGMA study are as follows:~1. The Adherence to Refills and Medications for Diabetes survey is a validated, diabetes-specific survey measure utilizing patient self-report to assess diabetes medication adherence.~2. The Demographics survey will be used to assess participant baseline characteristics, including body mass index (BMI). The questions contained in this survey have been validated by Dr. Kerri Cavanaugh's research group.~3. Comprehensive Diabetes Stigma Survey is a novel survey being developed and validated in the ENDSTIGMA study. The ENDSTIGMA study will also compare the results from this survey with the medication adherence results, to determine if there is an association between diabetes stigma and medication adherence."
224167458|NCT00712270|DRUG|Aripiprazole|Target dose = 15mg by mouth per day for 16 weeks. The dosage will be titrated in accordance with the treating physician's clinical judgment, generally reaching full dosage within one week of initiation. The dosage may be increased as clinically indicated, by the treating physician. Any deviation from these target dosing schedules must be reviewed and approved by the principal investigator, generally prior to the adjustment unless clinical circumstances require more immediate adjustment (in which case the treating physician should consult with the principal investigator as soon as is practically possible).
224167459|NCT00712270|DRUG|Risperidone|Target Dose = 2mg by mouth per day for 16 weeks. The dosage will be titrated in accordance with the treating physician's clinical judgment, generally reaching full dosage within one week of initiation. The dosage may be increased as clinically indicated, by the treating physician. Any deviation from these target dosing schedules must be reviewed and approved by the principal investigator, generally prior to the adjustment unless clinical circumstances require more immediate adjustment (in which case the treating physician should consult with the principal investigator as soon as is practically possible).
224167460|NCT04915872|PROCEDURE|Blood sampling (T0, inclusion)|Blood sample (5 ml) at 30 minutes after the loading dose of 4g/0.5g over 30 minutes for therapeutic drug monitoring at peak concentration (Cmax)
223479906|NCT05046808|DRUG|Famitinib Malate Capsules|Famitinib Malate Capsules 25mg single dose
223479907|NCT06020508|DEVICE|Group 1 - Lumoptik BrightPoint Epidural Device|Participants will undergo a neuraxial procedure to measure loss of resistance with saline in conjunction with the Lumoptik BrightPoint Epidural Device.
223479908|NCT01581450|DRUG|Nitrous Oxide|35%
223479909|NCT01581450|DRUG|Nitrous Oxide|50%
223584658|NCT02769962|DRUG|olaparib|"Olaparib (by mouth (PO) days 3-13\* and days 17-26\* administered in 28-day cycles, until disease progression or development of intolerable side effects Plus EP0057 (formerly CRLX101) (intravenous (IV) every (Q) 2 weeks, Day 1 and Day 15) administered in 28-day cycles, until disease progression or development of intolerable side effects. Phase (P)1: Dose Escalation P2: recommended phase 2 dose (RP2D).~(\* On days 13 and 26, only one dose of olaparib will be administered in the morning)."
223479910|NCT03104374|DRUG|Placebo|Oral tablet
223479911|NCT03104374|DRUG|Upadacitinib|Oral tablet
223479912|NCT06079424|OTHER|high-precision carotid echo-tracking|evaluation of vascular aging parameters and baroreflex sensitivity
223479913|NCT04210284|DIETARY_SUPPLEMENT|Ensure|"Ensure Max Protein Shake is an over the counter available drinkable nutritional supplement. Per serving, it contains:~* 160 Calories, 20 from fat~* 2g Total fat~* 0.5g Saturated fat~* 20mg Cholesterol~* 135mg Sodium~* 170mg Potassium~* 19g Total carbohydrate~* \<1g Fiber~* 4g Sugar~* 16g Protein~Participants will receive Ensure High Protein for 2 weeks pre- and 4 weeks post-operatively. These patients will be instructed to consume 1 serving (16fl oz) of Ensure High Protein daily. They will be provided with this product at a pre-operative clinical visit or have it mailed to their home. Hematologic nutritional values will be measured as specified previously.~Descriptive statistics will be used to report baseline characteristics and primary study objectives. Hematologic outcomes will be compared between the control (NO ENSURE) and oral supplementation (ENSURE) arms for the aforementioned baseline and perioperative variables"
223584659|NCT02769962|DIAGNOSTIC_TEST|CT scan|Screening and baseline.
223584660|NCT02769962|DIAGNOSTIC_TEST|CT chest, abdomen, and pelvis|Metastatic castration-resistant prostate cancer (mCRPC) participants only at screening, baseline, cycle 2 Day 1, and end of treatment/disease progression.
223584661|NCT02769962|DIAGNOSTIC_TEST|Bone scan|Metastatic castration-resistant prostate cancer (mCRPC) participants only at screening, baseline, cycle 2 Day 1, and end of treatment/disease progression.
223584662|NCT02769962|DIAGNOSTIC_TEST|ECG|Screening, baseline, Day 1, Day 15 and cycle 2, Day 1.
223584663|NCT02769962|DIAGNOSTIC_TEST|Echocardiogram|At screening.
224071792|NCT01243905|OTHER|Family psychoeducational therapy plus TAU|Group psychoeducation every two weeks for eight weeks in addition to treatment as usual administered by physicians
224071793|NCT01243905|OTHER|Treatment as usual|Treatment as usual administered by physicians
224071794|NCT01592981|DRUG|Bortezomib|1.6 mg/m2 subcutaneous bortezomib on days1, 8 and 15 of 28 days cycle
224071795|NCT01592981|DRUG|Cyclophosphamide|"Cyclophosphamide:250 mg/sq m, oral, days 1, 8 and 15 of each cycle in the experimental arm.~Cyclophosphamide:250 mg/sq m, oral, days 1, 2 and 3 of each cycle in the control arm."
224071796|NCT01592981|BIOLOGICAL|Rituximab|Rituximab: 375 mg/m2 i.v. infusion; days 1, 8, 15 and 22 of cycles 2 and 5 only
224071797|NCT01592981|DRUG|Fludarabine|Fludarabine: 40 mg/sq m, oral, days 1, 2 and 3
224071798|NCT05402644|PROCEDURE|hepatectomy|Liver resection
224071799|NCT00505258|DRUG|ceftobiprole medocaril|
224071800|NCT03936504|BEHAVIORAL|Control Group ：conventional exercise rehabilitation programs (CERP)|The participants in the control group will receive a conventional exercise rehabilitation programs (CERP) thrice a week for 12 weeks. Each training session lasts for 60 minutes, including ordinary warm-up exercises (10 minutes), aerobic activity (30 minutes), resistive exercise (10 minutes), and cool-down exercises(10 minutes). Each training session includes:(1) an active warm-up including arm-swinging, gentle stretches of the neck, shoulders, spine, arms, legs and so on;(2) aerobic activity mainly including aerobic radio exercise;(3) resistive exercise mainly including elastic belt exercise;(4) cool-down session involving active and static stretching exercises with primary body movements.
224167461|NCT04915872|PROCEDURE|other samplings (T1)|"\- T1 : Day of the first surgical revision, under PTZ administered by continuous infusion : Blood sample (5 ml) for therapeutic drug monitoring at steady state concentration (Css).~Urinary sample and collection of urinary volume between T0 and T1 (Urinary Clearance) NPT fluid sample and collection of NPT volume between T0 and T1 (Peritoneal Clearance) Peritoneal sampling for therapeutic drug monitoring at the site of infection (CPt)"
224167462|NCT01041040|DRUG|gemtuzumab|gemtuzumab ozogamicin (GO) during consolidation for patients with acute myeloid leukemia (AML)
224167463|NCT02574520|DRUG|SABER-Bupivacaine (Part 1)|5 ml once at end of surgery
223479914|NCT05899023|OTHER|Telehealth Bridge Visits|Patients will be scheduled for a telemedicine visit staffed by a family or internal medicine trained physician who will assess their understanding and answer any questions about the new diagnosis of diabetes, start initial conversations about how to improve their habits around diet and exercise, and discuss medication options for diabetes and, if appropriate, initiate treatment. At the end of the telemedicine visit, providers will attempt to address any difficulties that patients are experiencing in accessing primary care by providing an alternative contact for care or reaching out to a primary care doctor as necessary. If the patient experiences difficulties accessing a primary care provider based on their first telemedicine visit, then an additional telemedicine visit can be scheduled for the patient.
223479915|NCT05899023|OTHER|Standard of Care|Standard of care currently includes calls from the site's follow-up center to see if patients received their HbA1c result, understood what their result meant, had any problems accessing medications prescribed or any difficulty scheduling an outpatient follow-up visit.
223479916|NCT03686124|BIOLOGICAL|IMA203 Product|The cell dose will be based on viable CD3+CD8+ HLA- Dextramer+ cells per body surface area (BSA) as defined by the Mosteller formula
223479917|NCT03686124|BIOLOGICAL|IMA203 product- flat dose|The cell dose will be based on viable CD3+CD8+ HLA- Dextramer+ cells
223584664|NCT02769962|PROCEDURE|Biopsy|Baseline Day 4 and end of treatment/disease progression.
223584665|NCT00694850|DRUG|Riociguat (Adempas, BAY63-2521).|BAY63-2521 will be up-titrated from 1,0 mg TID to 2,5 mg TID
223584666|NCT05869500|DEVICE|Left Bundle Branch Area Pacemaker|Implantation of Medtronic 3830 lead for left bundle branch area pacing
223584667|NCT05869500|DEVICE|Right Ventricular Pacemaker|Implantation of a conventional right ventricular pacemaker lead
223584668|NCT05266560|DRUG|ciprofol|A new type of anesthetic drug, Ciprofol, which is newly listed and has national independent intellectual property rights, is an analogue of propofol. Its chemical name is 2-\[(1R)-1-cyclopropylethyl\]-6-isopropyl-phenol, and it acts on GABAA receptors like propofol. Compared with propofol, ciprofol is 4-5 times more potent, which can significantly reduce the amount of anesthetics.
223584669|NCT05266560|DRUG|Propofol|Propofol is a commonly used anesthetic in clinical practice and is often used before ECT.
224071801|NCT03936504|BEHAVIORAL|Experimental Group ：Tai Chi cardiac rehabilitation program (TCCRP)|Participants perform Tai Chi cardiac rehabilitation program(TCCRP) thrice a week for 12 weeks. Each training session lasts for 60 minutes, including Tai Chi warm-up exercises(10 minutes), Bafa Wubu of Tai Chi(30 minutes), Tai-Chi in conjunction with X-light-band resistance exercise(10 minutes), and Tai Chi cool-down exercises(10 minutes). All participants are encouraged to practice Tai Chi followed the instructional video until finishing 12-week exercise.
224071802|NCT02073773|DRUG|Levodopa|"Levodopa 100mg with benserazide 25mg will be administered 3 hours prior to the start of the daily PT/OT session to maximize its pharmacokinetic window ie. blood plasma levels in the narrow window during which functional rewiring of neural circuits is thought to occur.~Levodopa at the lowest available dose (100mg P.O qd) has been shown to improve motor function of stroke patients and their corresponding quality of life. The treatment proposed can be incorporated into their daily rehabilitation routine. Early intervention (within 7-21 days of the infarct) raises the chance for neuroplasticity and improved recovery of their motor function in the short and long run. Levodopa has been proven to be safe to be used in stroke patients (Lancet. 2001 Sep 8;358(9284):787-90., Arch Phys Med Rehabil. 2008 Sep;89(9):1633-41.), however, the side effects of this medication may include nausea, unusual tiredness, dizziness, excessive watering of mouth."
224071803|NCT02073773|OTHER|Virtual Reality based therapy|The VR therapy session consists of the subject interacting with a computer-based program in which they guide an avatar to gather items by using flexion and extension gestures of the affected upper limb. VR therapy sessions will last for 15-30 minutes depending on the subject's tolerance and participation. For patients who are unable to overcome gravity fully, they can still participate in this therapy by resting their arm on a table.
224071804|NCT01280136|BEHAVIORAL|It's Your Game Tech|An interactive web-based intervention for 8th grade students. This web-based intervention will be adapted from the computer-based component of an existing successful prevention program, It's Your Game…Keep it Real, (IYG) as well as include critical elements from the IYG classroom component. The web-based intervention will consist of 13 lessons and will tailor information to the individual's gender and to his/her intentions or behaviors related to sexual risk-taking. The program will address peer norms, attitudes, self-efficacy, refusal skills, and communication skills related to healthy relationships, dating, and sexual risk-taking behavior.
224071805|NCT01535365|OTHER|Heat|Application of heat pack to the back or neck sprain.
224071806|NCT01535365|OTHER|Cold|Application of ice pack to the back or neck sprain.
224071807|NCT02615990|DEVICE|Erigo Pro|Verticalization table with two integrated robotic devices for leg movement and cyclic loading
224071808|NCT02615990|OTHER|Standard Physical Therapy|Patients receive standard physical therapy.
224071809|NCT01175746|DRUG|Nicardipine|
224071810|NCT01175746|DRUG|remifentanil|0.1-0.5 ugkg/min during hypotensive anesthesia
224071811|NCT00036179|DRUG|FK463|
224071812|NCT01897246|PROCEDURE|Corrective osteotomy with computer-assisted pre-operative planning|The corrective osteotomy will be planned with computer-assisted pre-operative planning and virtual osteotomy.
224071813|NCT01897246|PROCEDURE|Corrective osteotomy with conventional preoperative planning|The corrective osteotomy will be planned with conventional preoperative planning.
224071814|NCT04135898|DRUG|SIBP-04|3mg/kg, infusion in 90 minutes
224071815|NCT04135898|DRUG|Bevacizumab|3mg/kg, infusion in 90 minutes
224071816|NCT00023530|DRUG|fluconazole|
224071817|NCT00023530|DRUG|voriconazole|
224071818|NCT00023530|PROCEDURE|bone marrow transplant|
224071819|NCT00023530|DRUG|thalidomide|
224071820|NCT00023530|DRUG|dexamethasone|
224167464|NCT02574520|DRUG|SABER-Bupivacaine (Part 2)|5 ml once at end of surgery
224167465|NCT02574520|DRUG|Saline Placebo|5 ml once at end of surgery
224167466|NCT02574520|DRUG|Bupivacaine HCl|0.5%, 15 ml, once at end of surgery
224167467|NCT04573491|GENETIC|Pharmacogenetic test|genotyping for genes that affect drug metabolism
224167468|NCT04573491|OTHER|Medication review|systematic and interdisciplinary method aiming to increase quality of medication treatment
224167469|NCT00005640|PROCEDURE|Preoperative Endoscopy|
224167470|NCT00005640|RADIATION|Technetium Tc 99m Sulfur Colloid|
224167471|NCT00005640|PROCEDURE|Gamma Probe|
224167472|NCT00005640|PROCEDURE|Biopsy of Sentinel Lymph Nodes|
224167473|NCT01703715|DEVICE|The Hydrant|"The Hydrant is a new form of drinking system that may be used to provide continuous access to hydration will be given to 20 patients. 10 of the patients will have mild cognitive impairment with Mini Mental State Examination less than 24 and 10 with normal cognitive function. Patients and staff will be interviewed to assess the feasibility of the hydrant."
224167474|NCT00128362|PROCEDURE|Radio-guided sentinel node biopsy|
224167475|NCT00128362|PROCEDURE|Axillary sampling|
224167476|NCT02391298|BEHAVIORAL|Mindfulness Meditation|
224167477|NCT05908929|PROCEDURE|SRP and concomitant insertion of PRF membrane|The pockets were treated with scaling and root planing (SRP) along with the simultaneous insertion of a Platelet Rich Fibrin (PRF) membrane. Blood samples were drawn without anticoagulants in 10 mL tubes, which were immediately centrifuged at 4000 rpm for 8 minutes. Upon centrifugation, the blood showed three distinct layers: the uppermost layer contained platelet poor plasma, the middle layer consisted of a fibrin clot, and the lowermost band appeared bright red due to the presence of red blood cells. The fibrin clot polymerized in a diffuse manner within the tube, which was then cut with sharp scissors and squeezed between two glass slides to obtain a thick membrane. The PRF membrane was carefully handled using a carrier and isolated with a periodontal pack dressing (Coe-Pak). All patients were followed up at one week and six weeks after the treatment.
224167478|NCT05908929|PROCEDURE|SRP|The pockets were treated using the conventional procedure of scaling and root planing (SRP) utilizing curettes and an ultrasonic device. All patients were followed up at one week and six weeks after the treatment.
224167479|NCT03822780|DRUG|Hydroxychloroquin|Hydroxychloroquine Sulfate (HCQ, Quensyl) in a loading dose of 10 mg/kg\*d, p.o., bid. After the illness gradually alleviate to maintain dose between 5mg/kg\*d to 10mg/kg\*d, p.o., bid ; the maximum daily dose is 400mg.
224167480|NCT04341025|BEHAVIORAL|Mindfulness based psychosexual therapy ( MBPST)|The group treatment sessions will integrate empirically supported elements of psychoeduation, cognitive behavioural therapy, and mindfulness skills. Each of the six sessions will follow the well-defined manualized treatment protocol. The treatment is adapted from the study team's previous mindfulness-based treatment group (H15-03172), for situational ED which has been shown to be effective. Participants will be provided with handouts and asked to complete approximately 10-60 minutes/day of at-home practice/skills, which may include reading material, mindfulness exercises, and/or behavioural exercises between sessions. During the 2 follow-up sessions, participants will be invited to share their experience since the conclusion of group, ask questions, and participate in troubleshooting.
224167481|NCT01428986|DRUG|Maraviroc|Maraviroc, 300mg BID for 72 weeks, except for cases with Efavirenz or Etravirine, 600mg BID for 72 weeks
223479918|NCT03686124|BIOLOGICAL|IMA203CD8 Product|The cell dose will be based on viable CD3+CD8+ HLA- Dextramer+ cells per body surface area (BSA) as defined by the Mosteller formula
223584670|NCT04584242|DRUG|gluconon tab 15mg|frosting and formulation : a round, convex tablet of white to gray. path of administration : once a day, two tabs, oral Amount of raw material medication (1 pill) : Pioglitazone hydrochloride 16.53mg storage method : Store 15 to 30°C to avoid light-tight containers and moisture manufacturing source : DONG-A ST
224167482|NCT05570136|BEHAVIORAL|Functional Exercise|Treatment group will receive the 12-week STEP by a trained interventionist. During the intervention period, an occupational therapist will help the participant to learn the STEP exercise and principles and help the older adults to be more independent on functional exercising.
224167483|NCT05570136|BEHAVIORAL|Education|In the education group, participant will receive weekly health newsletters containing general health aging materials. A staff member will call the control group participants weekly to document any new exercise programs from usual community services.
224167484|NCT01228838|DRUG|NGX-1998|Capsaicin topical liquid to be applied for 5 minutes one time only.
224167485|NCT01228838|DRUG|Placebo Liquid|Placebo topical liquid to be applied for 5 minutes one time only.
224167486|NCT01992328|DRUG|Immune Globulin|6 months once a month intravenous immunoglobulin (400mg/kg/4weeks)
224167487|NCT01660997|DRUG|MLN9708|
223479919|NCT03686124|DRUG|Nivolumab|Nivolumab will be given post IMA203/IMA203CD8 infusion, after hematologic recovery is achieved. Clinical supply provided by Bristol Myers Squibb.
223479920|NCT03686124|DEVICE|IMADetect®|IMADetect® is developed as a companion diagnostic to aid in selecting patients with relapsed and/or refractory solid cancers who might be eligible for enrollment in Immatics clinical trials.
223479921|NCT04233866|DRUG|Fluorouracil|Given IV
223479922|NCT04233866|DRUG|Gemcitabine|Given IV
223479923|NCT04233866|DRUG|Gemcitabine Hydrochloride|Given IV
223584671|NCT04584242|DRUG|suganon tab 5mg|frosting and formulation : pink circular film coating tablets path of administration : once a day, one tabs, oral Amount of raw material medication (1 pill) : Evogliptin tartrate 6.869mg(5mg as evogliptin) storage method : Confidential containers, stored at room temperature (1-30°C) manufacturing source : DONG-A ST
224167488|NCT01660997|DRUG|Dexamethasone|
224167489|NCT01269827|DRUG|Pentoxifylline|Over a period of 4 months, patients of the study group received one PTX tablet (400 mg) orally once a day (at dinner time)
224167490|NCT01269827|DRUG|starch tablets|Over a period of 4 months, patients of the control group received one starch tablet orally once a day (at dinner time)
224167491|NCT00216229|BIOLOGICAL|Combined vaccine against hepatitis A and B (Twinrix)|
224167492|NCT06690255|BEHAVIORAL|Pivotal Response Treatment|PRT will target functional communication abilities
223479924|NCT04233866|DRUG|Leucovorin|Given IV
223479925|NCT04233866|DRUG|Leucovorin Calcium|Given IV
223479926|NCT04233866|DRUG|Liposomal Irinotecan|Given IV
223479927|NCT04233866|DRUG|Nab-paclitaxel|Given IV
223479928|NCT04233866|OTHER|Quality-of-Life Assessment|Ancillary studies
223479929|NCT04233866|OTHER|Questionnaire Administration|Ancillary studies
223479930|NCT06105749|DEVICE|contrast-enhanced mammography|Contrast-enhanced mammography (CEM) is a new FDA-approved exam that is similar to magnetic resonance imaging (MRI) in depicting breast cancers due to increased and leaky blood vessels. Contrast-enhanced mammography is used as an adjunct following mammography and/or ultrasound examinations to localize a known or suspected lesion.
223479931|NCT04802057|DRUG|SAR445088|"Pharmaceutical form: solution for injection~Route of administration: IV and SC (Part 1) IV (Part 2)"
223479932|NCT04622345|DRUG|VSJ-110|ophthalmic solution
223479933|NCT04622345|DRUG|Placebo|ophthalmic solution
223479934|NCT04047264|PROCEDURE|Microdialysis|Undergo microdialysis
223479935|NCT04047264|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223479936|NCT06622187|DRUG|Desmopressin (DDAVP)|Patients in the intervention group will receive desmopressin 0.3ug/kg administered as an intravenous infusion 1h before the proposed procedure
223479937|NCT06622187|DRUG|Sodium Chloride|Patients in the control group will receive sodium chloride 0.9% 100mL administered as an intravenous infusion 1h before the proposed procedure
223479938|NCT04931342|DRUG|Ipatasertib|Ipatasertib will be administered by mouth once a day on Days 1-21 of each cycle. (Cycle length = 28 days)
223479939|NCT04931342|DRUG|Cobimetinib|Cobimetinib will be administered by mouth once a day on Days 1-21 of each cycle. (Cycle length=28 days)
223479940|NCT04931342|DRUG|Trastuzumab Emtansine|Trastuzumab Emtansine will be administered intravenously on Day 1 of each cycle. (Cycle length=21 days)
223479941|NCT04931342|DRUG|Atezolizumab|Atezolizumab will be administered intravenously on Day 1 of each cycle. (Cycle length=21 days)
223479942|NCT04931342|DRUG|Bevacizumab|Bevacizumab will be administered intravenously on Day 1 of each cycle. (Cycle length=21 days)
224071821|NCT01363986|DRUG|trastuzumab [Herceptin]|Initial loading dose of 4 mg/kg i.v. infusion, followed by weekly doses of 2 mg/kg for up to 18 weeks.
224071822|NCT05572034|PROCEDURE|Electrophysiological study|Electrophysiological study: patients in a fasting state and under total intravenous anesthesia Intracardiacelectrogramsare displayed simultaneously on a multichannel recorder. Programmed atrial and ventricular stimulation are performed to rule out sustained arrhythmias, primary conduction system dysfunction, and sick sinus syndrome.
224071823|NCT05572034|PROCEDURE|Electrophysiological study and Right side Ganglionated Plexi ablation|"Electrophysiological study: patients in a fasting state and under total intravenous anesthesia Intracardiacelectrogramsare displayed simultaneously on a multichannel recorder. Programmed atrial and ventricular stimulation are performed to rule out sustained arrhythmias, primary conduction system dysfunction, and sick sinus syndrome.~GP Mapping and Cardiac denervation: Specific atrium sites are empirically identified as GP by presumed anatomic location based on previous works (anatomic mapping):~In the RA: the posterior aspect of the interatrial septum, between the posterior wall and coronary sinus ostium; and, the septal aspect of the superior vena cava junction (opposite to the LA GP tags).~A 3.5-mm irrigated tip catheter will be used to deliver radiofrequency energy (50°C, 20-30 W, for 30-60 seconds) with a 17 mL/min irrigation flow."
224071824|NCT05572034|PROCEDURE|Electrophysiological study and bi-atrial Ganglionated Plexi ablation|"Electrophysiological study: patients in a fasting state and under total intravenous anesthesia Intracardiacelectrogramsare displayed simultaneously on a multichannel recorder. Programmed atrial and ventricular stimulation are performed to rule out sustained arrhythmias, primary conduction system dysfunction, and sick sinus syndrome.~GP Mapping and Cardiac denervation: Specific atrium sites are empirically identified as GP by presumed anatomic location based on previous works(anatomic mapping):~In the LA: the inferior right GP (septal aspect of the right pulmonary veins \[PV\]) antra, and LA posterior wall. In the RA: the posterior aspect of the interatrial septum, between the posterior wall and coronary sinus ostium; and the septal aspect of the superior vena cava junction (opposite to the LA GP tags).~A 3.5-mm irrigated tip catheter will be used to deliver radiofrequency energy (50°C, 20-30 W, for 30-60 seconds) with a 17 mL/min irrigation flow."
224071825|NCT05350826|OTHER|Ambulatory medical assistance|Ambulatory medical assistance is a patient-empowerment program and consists to programmed phone calls (bi-monthly for the first 6 months then monthly for the following 6 months) delivered by an oncology nurse, in link with the hematologist.
224071826|NCT02439125|DRUG|Eltoprazine HCl|2.5 mg b.i.d. orally for 3 weeks
224071827|NCT02439125|DRUG|Eltoprazine HCl|5.0 mg b.i.d. orally for 3 weeks
224071828|NCT02439125|DRUG|Eltoprazine HCl|7.5 mg b.i.d. orally for 3 weeks
224071829|NCT02439125|DRUG|Placebo|b.i.d. orally for 3 weeks
224071830|NCT00130832|BIOLOGICAL|Rotavirus Vaccine, Live, Oral, Pentavalent|Three doses of rotavirus vaccine, live, oral, pentavalent. Dose 1 was given on Day 1, Dose 2 was given 56 to 84 days post Dose 1, and Dose 3 was given 56 to 84 days post Dose 2.
224071831|NCT00130832|BIOLOGICAL|Comparator: Oral Poliovirus Vaccine (OPV)|Three doses OPV. Dose 1 was given on Day 1, Dose 2 was given 56 to 84 days post Dose 1, and Dose 3 was given 56 to 84 days post Dose 2.
224071832|NCT00130832|BIOLOGICAL|Comparator: Oral Poliovirus Vaccine (OPV) (staggered)|Three doses OPV. Dose 1 was given 14 to 28 days post Dose 1 of RotaTeq, Dose 2 was given 14 to 28 days post Dose 2 of RotaTeq, and Dose 3 was given 14 to 28 days post Dose 3 of RotaTeq.
224071833|NCT04634175|BEHAVIORAL|Yoga intervention|The yoga intervention is composed of kundalini yoga techniques.
224071834|NCT04634175|BEHAVIORAL|Sham intervention|The sham intervention is composed of stretching and muscle flexion techniques.
224071835|NCT03905863|DEVICE|Natrox® Oxygen Wound Therapy|A battery-operated device which delivers pure humidified oxygen to the wound bed through water electrolysis via a sterile oxygen delivery system.
224071836|NCT01207973|DRUG|BI 113823|5 dose-groups of multiple oral doses of BI 113823
224071837|NCT00532480|DRUG|Duloxetine|60 mg capsules
224071838|NCT02881268|OTHER|blood sample|
224071839|NCT05135715|DRUG|RC48-ADC|2.0 mg/kg IV every 2 weeks
224071840|NCT01977235|DRUG|Irinotecan|
224071841|NCT01977235|DRUG|Cisplatin|
224071842|NCT02213601|BEHAVIORAL|Yoga|
224071843|NCT00545701|BIOLOGICAL|A/H5N1 inactivated, split-virion influenza virus|0.5 mL, Intramuscular
224071844|NCT01471080|PROCEDURE|RFA|using RFA to treat cavernous hemangiomas
224071845|NCT01471080|PROCEDURE|hepatectomy|using hepatectomy to treat cavernous hemangiomas
224167493|NCT06902246|DRUG|Regorafenib|"Participants will orally self-administer Regorafenib tablets for the first 21 days of each 28-day cycle as follows. Dose-escalation will occur only if there are no significant drug-related adverse events:~* Safety Run-in Phase: For the first six (6) participants enrolled. The starting dose is 80 mg/day during Cycles 1 and 2. In Cycle 3, the starting dose is 80 mg/day on Days 1 to 7, escalating to 120 mg/day on Days 8 to 14, and then escalating to a maximum dose of 160 mg/day on Days 15 to 21. Participants will continue to receive the maximum tolerated dose determined at the end of Cycle 3.~* Phase 2: For participants enrolled after the Safety Run-in phase. In Cycle 1, the starting dose is 80 mg/day on Days 1 to 7, escalating to 120 mg/day on Days 8 to 14, and then escalating to a maximum dose 160 mg/day on Days 15 to 21. From Cycle 2 onward, participants will take 160 mg/day (or maximum tolerated dose from Cycle 1), on Days 1 to 21."
223479943|NCT04931342|DRUG|Paclitaxel|Paclitaxel will be administered intravenously on Days 1, 8, and 15 of each cycle. (Cycle length=28 days)
223479944|NCT04931342|DRUG|Giredestrant|Giredestrant will be administered by mouth once a day on Days 1-28 of each cycle (Cycle length=28 days)
224167494|NCT06902246|RADIATION|TheraSphere™ Yttrium-90 Trans-Arterial Radioembolization|Y-90 absorbed glass microspheres will be administered standard of care once via the percutaneous trans-arterial approach after the first 3 weeks of Regorafenib treatment but before Day 28. Additional Y-90 absorbed glass microsphere administration is allowed for treatment of baseline disease in the absence of disease progression within 6 months of the initial Y-90 TARE treatment.
224167495|NCT00726310|DEVICE|SpineLink® , SpineLink® II|Spine plate system for lumbar spinal fusions
224167496|NCT03551106|OTHER|Web based learning module|Web based learning module available on a especially designed website
224167497|NCT02725749|RADIATION|Laser|Laser used were GaAs (904 nm, 60 mW), in continuous emission. The participants received application of laser three times or week for eight weeks, on 9 shoulder points (3 Joules/point) per session.
224167498|NCT02725749|OTHER|EXE|"Isotonic strengthening exercises were performed for the scapular pivot, scapula stabilizer, and humeral propellant muscle groups. Three sets of 15 repetitions of each isotonic strengthening exercise were performed. The isometric exercises were performed in ten sets of ten seconds each. Analytical stretching of each muscle group was performed at the beginning of the session for 30 seconds.~The participants performed the exercises three times a week for eight weeks."
223479945|NCT04931342|DRUG|Abemaciclib|Abemaciclib will be administered by mouth twice a day during each 28-day cycle
224167499|NCT02725749|RADIATION|Laser + EXE|"Laser used were GaAs (904 nm, 60 mW), in continuous emission. The participants received application of laser three times or week for eight weeks, on 9 shoulder points (3 Joules/point) per session.~Isotonic strengthening exercises were performed for the scapular pivot, scapula stabilizer, and humeral propellant muscle groups. Three sets of 15 repetitions of each isotonic strengthening exercise were performed. The isometric exercises were performed in ten sets of ten seconds each. Analytical stretching of each muscle group was performed at the beginning of the session for 30 seconds.~The participants performed the exercises three times a week for eight weeks."
224167500|NCT06507215|DIAGNOSTIC_TEST|Protein analysis|The investigator enrolled 149 healthy volunteers and collected peripheral blood samples for protein analysis. While 18 of these individuals with protein levels in the range of 40%-64% were predicted to be carriers by the monocyte assay, subsequent DYSF sequencing analysis in 14 of 18 detected missense variants in only four. Analysis of DNA methylation patterns at the DYSF locus showed no changes in methylation levels at CpG islands and shores between samples.
224167501|NCT06216769|DRUG|Rivaroxaban|"Those in the non-interrupted anticoagulation group, anticoagulation is continued regardless of atrial fibrillation recurrence.~Those in the pill-in-the POCKET anticoagulation group will receive direct oral anticoagulation only if they have atrial fibrillation recur over 6 hours."
223479946|NCT04931342|DRUG|Inavolisib|Inavolisib will be administered by mouth once a day on Days 1-28 of each 28-day cycle
223479947|NCT04931342|DRUG|Palbociclib|Palbociclib will be administered by mouth once a day on Days 1-21 of each 28-day cycle
223479948|NCT04931342|DRUG|Letrozole|Letrozole will be administered by mouth once a day on Days 1-28 of each 28-day cycle
223479949|NCT04931342|DRUG|Olaparib|Olaparib will be administered by mouth twice a day on Days 1-28 of each 28-day cycle
223479950|NCT04931342|DRUG|Luteinizing Hormone-Releasing Hormone (LHRH) Agonists|LHRH agonists are required beginning at least 2 weeks prior to initiation of study treatment for premenopausal or perimenopausal women. Acceptable agents include goserelin or leuprolide; triptorelin is also acceptable. Monthly injections of LHRH agonist are preferred.
223479951|NCT04931342|DRUG|Cyclophosphamide|Cyclophosphamide will be administered by mouth once a day on Days 1-21 of each cycle. (Cycle length = 21 days)
223479952|NCT04931342|DRUG|Inavolisib|Inavolisib will be administered by mouth once a day on Days 1-21 of each 21-day cycle
223479953|NCT04270838|BIOLOGICAL|ChAdOx2 RabG|Single dose of ChAdOx2 RabG at different concentrations: 1x10\^10 and 5x10\^10
223479954|NCT04270838|BIOLOGICAL|Inactivated Rabies Vaccine|A complete pre-exposure prophylactic course of an existing rabies vaccine, ≥2.5 international units
223584672|NCT05597332|OTHER|Care bundle for AKI|To maintain mean arterial pressure (MAP) ≥ 65 mmHg; to keep the patient euvolemic; to avoid nephrotoxic drugs; to adjust dose of medication for kidney function; to exclude urinary obstruction; to monitor urine output and serum creatinine levels.
223479955|NCT06973863|DRUG|PEP08|PEP08 is an oral, potent, MTA-cooperative PRMT5 inhibitor.
223479956|NCT05948579|DRUG|Intervention B Vilazodone Hydrochloride (HCl)|Vilazodone HCl will be administered at 10 mg once daily for 7 days, followed by 20 mg for 7 days, followed by 40 mg for the remainder of the trial. There must be a minimum of 7 days between dosage increases. One reduction in dose due to tolerability will be allowed. After Week 8, dose reduction for tolerability is allowed, but dose increase is not allowed.
223479957|NCT05948579|DRUG|Intervention B Placebo|A matching placebo will be administered at 10 to 40 mg daily in the same regimen as the intervention.
224167502|NCT03828565|PROCEDURE|ScvO2 Perioperative continue monitoring|"ScvO2 Perioperative continue monitoring with PreSep® system. If SvcO2 is less than 65% or decreases by more than 10% of its base value, the other parameters affecting ScvO2 (BIS (40-60% objective), Hb (objective\> 8g / dL), SaO2 (objective\> 94%)) are evaluated. If, after correcting for these parameters, the ScvO2 is not corrected, the preload-dependence parameters are evaluated (variation of the pulsed pressure) to guide the vascular filling: VF of 250 mL of crystalloids if PPV\> 13%, norepinephrine if PPV\<9%, reassess if PPV between 9 and 13%.~If VF or norepinephrine does not correct ScvO2 (\> 65%), a measurement of arterial lactate is performed. If lactatemia is\> 2 mmol / L, a positive inotrop is introduced after ETO if possible. If lactatemia is \<2 mmol / L, a return to the evaluation phase of the parameters influencing ScvO2 is necessary."
224167503|NCT06146140|DIETARY_SUPPLEMENT|Oral herbal supplement|Take one capsule daily
224167504|NCT06146140|DIETARY_SUPPLEMENT|Oral placebo supplement|Take one capsule daily
224167505|NCT00721357|BEHAVIORAL|Treadmill walking|Subjects will perform treadmill walking at a self-selected velocity
224167506|NCT00721357|OTHER|Magnetic resonance spectroscopy|Muscle oxidative capacity will be assessed via Magnetic resonance spectroscopy (31P-MRS)
224167507|NCT01722214|BIOLOGICAL|Adalimumab|Injection of adalimumab (80 mg followed by 40 mg at week 1 and 40 mg EOW thereafter for 52 weeks). For Adalimibab group and Placebo group.
224167508|NCT01722214|OTHER|Placebo|Injection of placebo that is physicaly identical to adalimumab without the active ingredient at identical intervals.
224167509|NCT04120480|DIAGNOSTIC_TEST|Pharmacogenomic test|The RightMed test is an end-to-end solution which includes sample collection, PGx testing services, data analysis, and clinical interpretation that helps prescribers select treatments based on evidence-driven predictions of patient drug response and tolerance. Genetic components of an individual's drug response are well established and often included on FDA medication labels. The RightMed test has incorporated existing evidence to classify the risk and likelihood of an antidepressant working for different patients. Patient results for each medication can fall into one of three categories: 1) Green - use as directed; 2) Yellow - use with caution; and 3) Red - adjust dose or choose alternative mediation.
224167510|NCT00985140|RADIATION|Total Skin Electron Beam Therapy (TSEBT)|The purpose of the study is to examine the efficacy and safety of total skin electron beam therapy to a dose of 12 Gray (TSEBT 12 Gray) in patients who have mycosis fungoides (MF) staged as IB to IIIB.
224167511|NCT05203744|DRUG|Tafenoquine prophylaxis|"The study will be conducted in three parts with 200 participants invited to participate in the study.~* Part 1 consist of 200 participants to be administered a loading dose of 600 mg tafenoquine (200 mg daily for 3 days) followed by 200 mg weekly for two weeks.~* Part 2: The same participants from Part 1 will be administered a monthly dose of tafenoquine (600 mg total, given as 300 mg split over 2 days) for two consecutive months. This monthly dose of 600 mg tafenoquine is designated the low monthly tafenoquine dose.~* Part 3: The same participants from Parts 1 and 2 will be administered a monthly dose of tafenoquine (800 mg total, given as 400 mg split over 2 days) for two consecutive months. This monthly dose of 800 mg tafenoquine is designated the high monthly tafenoquine dose."
224167512|NCT03253029|DIETARY_SUPPLEMENT|Pure Encapsulations Branched Chain Amino Acid powder|
224167513|NCT03253029|DIETARY_SUPPLEMENT|control group (no BCAAs provided)|
224167514|NCT03562689|OTHER|Delirium and with septic encephalopathy.|Delirium or septic encephalopathy survivors will be analized in the same way: Cognitive tests, EEG and MRI.
224167515|NCT02021474|DRUG|AGX-201|Subcutaneous injection
224167516|NCT02021474|DRUG|Subcutaneous placebo (Evan's solution = phenol 0.4%, isotonic sodium chloride).|Subcutaneous injection
224167517|NCT03729908|BEHAVIORAL|Animal assisted mindfulness based intervention|A mindfulness based intervention in the presence of an animal
224167518|NCT03729908|BEHAVIORAL|Anti-stress program|A mindfulness based intervention with no reference to animals
224167519|NCT00833612|DEVICE|Counterpulsation with IAB|IABC pre-reperfusion PCI
224071846|NCT01300182|OTHER|Whole body vibration therapy|The WBVT will be carried out in a vibration plates operated in vertical direction. The frequency of that vibration can be adjusted step of 5Hz with vibration frequency ranges from 20Hz to 60Hz. The amplitude can be set as 4mm.
224071847|NCT01300182|OTHER|Control|Conventional post-operative physical therapy exercises and rehabilitation.
224071848|NCT01989000|DRUG|Gadobutrol|0.1 ml/kg Gadovist is administered at 5 ml/s followed by a 15 ml saline flush
223479961|NCT06578416|DIAGNOSTIC_TEST|Standardized assessments of speech and language abilities|Standardized and observational assessment of speech and language abilities
223479962|NCT03883126|BEHAVIORAL|Contingency management|Monetary incentives are delivered to participants contingent upon on-time breathalyzer submissions and verified abstinence from alcohol.
223479963|NCT03883126|BEHAVIORAL|Contingency management|Monetary incentives are delivered to participants contingent upon on-time breathalyzer submissions only with no contingency on alcohol use.
223479964|NCT02330952|DRUG|Prednisone|40mg/day per os for 5 days
223479965|NCT02330952|DRUG|Placebo|40mg/day per os for 5 days
223479966|NCT05012124|OTHER|Collaborative care|Receive u-CoCM
223479967|NCT05012124|OTHER|Interview or Focus Group|Participate in an interview or focus group
223479968|NCT05012124|OTHER|Media/technology Intervention with collaborative care|Use t-CoCM digital platform with collaborative care
223479969|NCT05012124|OTHER|Survey Administration|Complete surveys
223479970|NCT05678738|DIETARY_SUPPLEMENT|Antioxidant Berry Supplementation|Participants who opt-in will be instructed to consume 300mL of the bioactive (antioxidant berry) supplement every morning and afternoon during days of participation.
223479971|NCT05678738|OTHER|Acute and Chronic Exercise-Heat Stress|All participants (male and female) will be exposed to repeated bouts of exercise-heat stress.
224071849|NCT01989000|DRUG|[F-18]HX4|400 MBq \[F-18\]HX4, is administered in a single intravenous bolus injection, followed by a saline flush.
224071850|NCT01989000|DRUG|Gemcitabine|1000 mg/m2/dose on day 1 and 8 in 2 cycles of 21 days (three weeks) each, one cycle before and one cycle after radiochemotherapy. During radiotherapy gemcitabine is administered at 1000 mg/m2/dose on day 1, 8 and 15.
224071851|NCT01989000|RADIATION|Radiotherapy|A hypofractionated scheme of 15 fractions of 2.4 Gy in three weeks will be applied, combined with the second course of gemcitabine.
224167520|NCT05405569|OTHER|CPR Arms Angle 90º|Within each independent group, a randomized crossover design will be used: half of the group will start with arms position at 90º.
224167521|NCT05405569|OTHER|CPR Arms Angle 60º|Within each independent group, a randomized crossover design will be used: half of the group will start with arms position at 60º.
223479972|NCT05678738|DIETARY_SUPPLEMENT|Placebo (non-juice) Supplementation|Participants who opt-in will be instructed to consume 300mL of the placebo (non-juice) supplement every morning and afternoon during days of participation.
223479973|NCT04393701|PROCEDURE|Additional blood sampling|Additional blood sampling on blotting paper will be done in neonates in Normandy, France, compared to National neonatal screening program
223479974|NCT04421573|PROCEDURE|BCPHD with D5W|D5W is injected under the investing fascia of the sternocleidomastoid muscle (SCM) using ultrasound guidance in order to infiltrate the space containing the cervical plexus. This is performed on both sides.
223479975|NCT04421573|PROCEDURE|Waiting period with usual care|Same as previous group description
223479976|NCT05370391|BEHAVIORAL|Comprehensive Behavioral Intervention for Tics (CBIT)|The CBIT (or CBIT-JR) intervention consists of a minimum of 6 sessions of 50-minutes each week in an individual or group setting.
223479977|NCT03207997|OTHER|unenhanced MR sequences|2 additional unenhanced MR sequences
223479978|NCT06279013|OTHER|Counseling|Receive TIPC
223479979|NCT06279013|BEHAVIORAL|Health Education|Receive handbook
223584673|NCT05827315|DIAGNOSTIC_TEST|Echocardiography|Echocardiography will be performed by BSE accredited echocardiographers in all 175 patients preoperatively and on day 2-4 postoperatively.
223584674|NCT05827315|DIAGNOSTIC_TEST|T1 Cardiovascular Magnetic Resonance|T1 CMR will be performed in 10 patients from each of the 5 surgical groups (50 patients in total) preoperatively and on day 2-4 postoperatively.
223584675|NCT05827315|DIAGNOSTIC_TEST|Right heart catheterisation and coronary sinus blood sampling|10 patients from the thoracic surgical group will undergo right heart catheterisation and coronary sinus blood sampling.
223584676|NCT06957444|PROCEDURE|Sylke Adhesive Dressing|Topical wound closure device, made from silk fibroin woven mesh coated with a pressure-sensitive acrylic adhesive.
223584677|NCT06957444|PROCEDURE|Exofin Skin Glue|2-octil cyanoacrylate formulation, applied using a soft and flexible applicator.
223584678|NCT06957444|PROCEDURE|Suture Strip Plus|Flexible wound closure strip designed for primary wound closure made up of macroporous non-woven polyamide with a pressure sensitive adhesive.
223584679|NCT06450886|DRUG|Ulviprubart (ABC008)|All eligible subjects, regardless of treatment assignment or dose level in their initial study, will be administered ulviprubart at a dose of 2.0 mg/kg via subcutaneous (SC) injection Q8W.
224167522|NCT00000703|DRUG|Bleomycin sulfate|
224167523|NCT00000703|DRUG|Vincristine sulfate|
224167524|NCT00000703|DRUG|Doxorubicin hydrochloride|
224167525|NCT00000703|DRUG|Cyclophosphamide|
224167526|NCT00000703|DRUG|Allopurinol|
224167527|NCT00000703|DRUG|Methotrexate|
224167528|NCT00000703|DRUG|Cytarabine|
224167529|NCT00000703|DRUG|Leucovorin calcium|
223479980|NCT06279013|OTHER|Interview|Ancillary studies
223479981|NCT06279013|OTHER|Medical Chart Review|Ancillary studies
223479982|NCT06279013|OTHER|Monitoring|Receive IVR symptom monitoring
223479983|NCT06279013|OTHER|Questionnaire Administration|Ancillary studies
223479984|NCT01316718|DRUG|Mesalazine|2g oral granules, once a day for 1 week, then 2g oral granules, twice a day for 11 weeks
223479985|NCT01316718|DRUG|Placebo|2g oral granules, once a day for 1 week, then 2g oral granules, twice a day for 11 weeks
223479986|NCT02970383|BEHAVIORAL|Initial prescription for 10 narcotic tabs|Reduced number of pills in initial prescription post-operatively
223479987|NCT02970383|BEHAVIORAL|Inital prescription for 30 narcotic tabs|
223479988|NCT02933853|DRUG|Faster-acting insulin aspart|A single dose administered subcutaneously (s.c., under the skin). The dose level will be 0.3 U/kg body weight.
223479989|NCT02933853|DRUG|Insulin Aspart|A single dose administered subcutaneously (s.c., under the skin). The dose level will be 0.3 U/kg body weight.
223479990|NCT02121210|DRUG|sarilumab SAR153191 (REGN88)|Pharmaceutical form: Solution for injection; Route of administration: Subcutaneous
223479991|NCT02664675|PROCEDURE|Crown lengthening|After a local anesthesia, gingival tissue is removed around the teeth to extend the length of the crown for aesthetic or prosthetic matter.
223479992|NCT02664675|PROCEDURE|Open Flap Debridement|"After local anesthesia, intra-sulcular incisions are done and a flap is released to access to the intra-bony defect.~Granulation tissue is removed and carefully laid aside for further analysis. Interrupted sutures are done to close the flap."
223479993|NCT02642705|OTHER|High intensity interval training N|Exercise training and ambient air breathing
223479994|NCT02642705|OTHER|High intensity interval training H|Exercise training and hypoxic breathing
223479995|NCT02642705|OTHER|Constant load exercise training N|Exercise training and ambient air breathing
223479996|NCT02642705|OTHER|Constant load exercise training H|Exercise training and hypoxic breathing
223479997|NCT02642705|OTHER|Hypoxic conditioning at rest|Hypoxic breathing at rest
223479998|NCT02642705|OTHER|Normoxic conditioning at rest|Normoxic breathing at rest (placebo)
223479999|NCT04108078|BEHAVIORAL|Health Policy Plus (HP+)|HP+ is a stigma-reduction intervention that is designed to reduce stigmatizing attitudes and beliefs among all workers (clinical and non- clinical) in a healthcare facility.
224167530|NCT00000703|DRUG|Zidovudine|
224167531|NCT00000703|DRUG|Dexamethasone|
224167532|NCT02626299|DRUG|Docosahexaenoic acid - 800mg/day|All participants will take 1000 mg/DHA per day (1 capsule will be labeled with 200 mg; 2 capsules will be masked with 400 mg each)
224167533|NCT02626299|DRUG|Docosahexaenoic acid - 200mg/day|The control group will receive 1-capsule containing 200 mg DHA/d.
224167534|NCT02626299|OTHER|Placebo|Participants will receive 2 capsules (masked) containing half soybean oil and half corn oil equaling 800 mg.The soybean and corn oil combination does not contain DHA.
224167535|NCT03256006|OTHER|Blood sample|Blood sample to study per and post effort evolution markers of systemic inflammation
224167536|NCT06870019|BEHAVIORAL|GPS tracker device|GPS tracker device
224167537|NCT05307081|DRUG|Artificial Tears|Artificial Tears are an FDA approved intervention
224167538|NCT02307604|GENETIC|Tumour markers testing|
224167539|NCT02159001|DEVICE|electroconvulsive therapy|10-course, three times a week bilateral frontotemporal ECT
224167540|NCT03882866|PROCEDURE|3D-printed non-coplanar template|3D-printed non-coplanar template is used in the intervention group. Iodine-125 seed implantation therapy is assisted using 3D-printed non-coplanar template as a guide in patients with locally advanced pancreatic cancer. 3D-printed non-coplanar template is designed and printed according to a preoperative CT scan and treatment planning system.
224167541|NCT03882866|PROCEDURE|3D-printed coplanar template|3D-printed coplanar template is used in the intervention group. Iodine-125 seed implantation therapy is assisted using 3D-printed coplanar template as a guide in patients with locally advanced pancreatic cancer. 3D-printed coplanar template is designed and printed according to a preoperative CT scan and treatment planning system.
224167542|NCT04501965|COMBINATION_PRODUCT|Hydroxychloroquine/Azithromycine|Dual treatment with Hydroxychloroquine and Azythromycin
224167543|NCT04501965|COMBINATION_PRODUCT|Quinquina-Stevia/Azythromycin|Dual treatment with Quinquina/Stevia (3/0,5) and Azythromycin
224167544|NCT04501965|COMBINATION_PRODUCT|4Plants/Azythromycin|Dual treatment with 4 plant species drug and Azythromycin
224167545|NCT04844567|DEVICE|COVVR_Synch|"Participants wear a respiration belt (Vernier, Go Direct) that continuously transmits thoracic circumference readings to a mobile phone (Samsung Galaxy S8) in real-time. The mobile device is placed in a headset (Zeiss VR ONEPLUS) and used to create a stereoscopic, immersive scene in Virtual Reality. The data from the respiration belt is used to map the on-going respiration pattern onto a virtual body in the scene in one of two feedback conditions.~COVVR\_Synch provided synchronous feedback: participants receive real-time feedback of their respiration."
224167546|NCT04844567|DEVICE|COVVR_Asynch|"Participants wear a respiration belt (Vernier, Go Direct) that continuously transmits thoracic circumference readings to a mobile phone (Samsung Galaxy S8) in real-time. The mobile device is placed in a headset (Zeiss VR ONEPLUS) and used to create a stereoscopic, immersive scene in Virtual Reality. The data from the respiration belt is used to map the on-going respiration pattern onto a virtual body in the scene in one of two feedback conditions.~COVVR\_Asynch provided asynchronous feedback: participants receive asynchronous, frequency modulated feedback of their respiration."
224167547|NCT02065635|PROCEDURE|maintenance with sevoflurane|in patients allocated to the sevoflurane group, general anesthesia will be maintained with sevoflurane
224167548|NCT02065635|PROCEDURE|maintenance with propofol|in patients allocated to the propofol group, general anesthesia will be maintained with propofol
223480000|NCT04108078|BEHAVIORAL|Many Men Many Voices (3MV)|3MV is a group-level HIV prevention intervention designed specifically for use with Black men who have sex with men (MSM). It is a 7- session intervention that is facilitated by trained peers. The intervention has previously been adapted and used with MSM in Ghana.
223480001|NCT04108078|BEHAVIORAL|HIV Education, Empathy and Empowerment (HIVE3)|The HIVE3 is a telephone-based peer support intervention. It utilizes trained peers, who are also MSM, to provide emotional, informational and affirming support via text message or phone. The intervention was developed specifically for use with MSM in Ghana and demonstrated acceptability and feasibility in a preliminary study in Ghana.
223480002|NCT04609514|DEVICE|Learn to Quit-HIV|A smartphone app developed by the research team designed for people with HIV that provides Acceptance and Commitment Therapy skills to address smoking cessation.
223480003|NCT04609514|BEHAVIORAL|QuitGuide|A smartphone app developed by the National Cancer Institute which uses smoking cessation recommendations contained in the US DHHS Clinical Practice Guidelines.
224071852|NCT01989000|PROCEDURE|Pancreaticoduodenectomy|
224071853|NCT03767322|DRUG|Allopurinol|Eligible patients will receive allopurinol 300 mg before and after coronary intervention
224071854|NCT03767322|DRUG|Febuxostat|Eligible patients will receive febuxostat 80 mg before and after coronary intervention
224071855|NCT03767322|DRUG|Placebo|Eligible patients will receive before and after coronary intervention
224071856|NCT03049904|BEHAVIORAL|Vr2L 2Spirit|"Three weeks exploring the Vr2L 2Spirit island.~Week 1: Learning Level. Contains the Vr2L 2Spirit island orientation, the learning paths covering HIV testing, harm reduction, safer sex, and condom use \& condom use negotiation, the lodge, the in-world Motivational Interviewing (MI) counseling, and leisure activities.~Week 2: Skills Building Level. The purpose of the city level is for participants to practice the knowledge gained in the Learning level through quests, challenges, and role play scenarios.~Week 3: Experiential Level. Experiential interactions with other participants where they can practice the knowledge and skills they gained in the previous levels."
224071857|NCT00477126|DRUG|GPO ritonavir versus Norvir|RTV generic compared to reference drugs (Norvir, Abbott)
224071858|NCT04176185|BIOLOGICAL|Sublingual allergy immunological tablet|For daily administration (1 tablet per day)
224071859|NCT04176185|OTHER|Placebo|For daily administration (1 tablet per day)
224071860|NCT01675986|DRUG|hydroxyzine|75 mg
224071861|NCT01675986|DRUG|Pregabalin|150 mg
224071862|NCT01675986|DRUG|Lactose|4 g
224071863|NCT06268379|PROCEDURE|Surgery|Not an interventional study, it is an observational, longitudinal study.
224071864|NCT02584491|BEHAVIORAL|Functional gait-related training|The motor learning (ML)-based functional gait-related training program is designed to improve advanced gross motor skills and athleticism. It will involve 45-min sessions twice to three times weekly over 6 weeks for a total of 16 active sessions. A maximum of 7 weeks will be permitted. Each session will consist of 35-min of active training along with a 10-min active warm-up/cool-down that incorporates ML. Scheduling flexibility will promote adherence, with a minimum one day between sessions to provide opportunity for rest. Children will be given a 3- to 5-min mental motor imagery script to practice on days when they do not have active training sessions. The total number of sessions (combined active/imagery) will be five per week.
224071865|NCT04789733|OTHER|Tight pressure management|Norepinephrine or phenylephrine infusion to maintain intraoperative MAP ≥85 mmHg, delayed resumption of chronic antihypertensive medications, and a target ward MAP ≥80 mmHg (tight pressure management)
224167549|NCT06388356|OTHER|Educational intervention - Yksityisyyttä ensihoitoon / Informational privacy for preospital emergency care|"Educational intervention is a self-study, online course on Koulumaali platform about patient's informational privacy (IP) in prehospital emergency care (PEC).~It comprises three separate educational modules approximately 30 min. long: module I) the meaning and significance of IP and its protection, module II) legislation regarding IP and its protection in healthcare and module III) breaches of IPand its protection in PEC.~Each module contains theoretical sections as well as case-exercises and tests.~Participants will have four weeks time to execute the entire course independently. Participants can execute the modules according to their own schedule. The modules need to be completed in certain order by following the numerical order from first to third. Only one of the modules is open at a time and the second module activates after the previous modules has been completed. Already completed modules become inactive."
224167550|NCT06220188|DRUG|[177Lu]Lu-PSMA I&T|2 cycles (3 GBq in first cycle and 6 GBq in the second cycle) of \[177Lu\]Lu-PSMAI\&T radioligand therapy at 6-week intervals
224167551|NCT04060433|BEHAVIORAL|Family Therapy|Swedish version of the evidence based manualized Family Therapy
224167552|NCT05509556|OTHER|talocalcaneal angle measurement|talocalcaneal angle measurement on lateral foot radiographs
224167553|NCT01312285|DEVICE|Resonator device|low level magnetic fields
224167554|NCT02371694|OTHER|Test drink|"The intervention is a drink taken 4 hours after the evening meal insulin injection, or 10PM, whichever is later. All drinks are 116-120g in weight and similar volume.~All drinks are served in a double blind fashion, apart from the 20g carbohydrate which is visibly different from other drinks in colour, texture and flavour."
224167555|NCT02834494|PROCEDURE|3D Shear Wave Elastography (SWE)|Ultrasound imaging with Elastography will be performed at the inclusion (T0), after course 1 and course 2 respectively with anthracyclines, at the end of anthracycline treatment and at the end of taxane treatment.
224167556|NCT02834494|BIOLOGICAL|Biopsy|Optional biopsy of breast tumor under neoadjuvant chemotherapy after the course 2 of anthracycline.
223584680|NCT03623009|BEHAVIORAL|An article meant to trigger certain psychosocial behaviors|An article meant to trigger certain psychosocial behaviors is administered to the intervention arm prior to laparoscopic skills assessment.
223584681|NCT03623009|BEHAVIORAL|a neutral article|The control arm will receive a neutral article prior to completing the assessment.
224071866|NCT04789733|OTHER|Routine pressure management|Routine intraoperative blood pressure management and immediate restart of antihypertensive medications.
224071867|NCT02996747|PROCEDURE|curettage (intralesional surgery)|comparison of two different tumors treated by curettage
224071868|NCT04622176|DIAGNOSTIC_TEST|MMUS|MMUS will be used to perform diagnostics, we will compare with MRI and histology
224071869|NCT03573453|OTHER|enteral nutrition|administration of enteral nutrition
224071870|NCT01014845|BIOLOGICAL|hepatitis E vaccine|Intramuscularly given at 0, 1, 6m for three doses.
224071871|NCT01014845|BIOLOGICAL|Hepatitis B vaccine|Intramuscularly given at 0, 1, 6m for three doses.
224071872|NCT02354703|DRUG|Ondansetron|Ondansetron (0.33 mg) bid+ BBCET counseling
224071873|NCT02354703|DRUG|Placebo|Placebo + BBCET counseling
224071874|NCT01492998|OTHER|guggulsterone, a natural FXR antagonist.|Gugulipid®, natural extract from Commiphora mukul tree, containing 2.5% guggulsterone
224071875|NCT05618743|PROCEDURE|Non Surgical Periodontal Therapy|Scaling and root planing using scalers and periodontal curettes will be done
224071876|NCT05948280|OTHER|Virtual reality-supported mindfulness|A single mindful stretching exercise provides a conscious stretch of VR scenario. The implementation of VR exercises will be performed by the interventionist who have received training in the application of VR scenarios and have extensive experience in VR research.
224071877|NCT05948280|OTHER|Mindfulness|The interventionist will guide the participant to do a mindful stretching exercise in the first week. During the second week, the interventionist will send participants an audio recording on how to do mindful stretching exercise via WeChat/WhatsApp.
224071878|NCT05439187|PROCEDURE|hernia repair|Open or laparoscopic hernia repair with mesh placement.
224071879|NCT02135731|OTHER|Medication review software with pictures|The intervention is a self-service software program that displays each prescription on screen along with an image of the pharmaceutical product. Patients must use response buttons to describe adherence patterns and to advance through the questionnaire items.
224071880|NCT04390087|OTHER|Exercise|Upper-body rowing performed while participants are sitting in their own wheelchair.
224071881|NCT00397722|DRUG|GW876008|
224071882|NCT00397722|DRUG|paroxetine|
224071883|NCT01872728|DRUG|Bilateral facial block after general anesthesia before surgery|Bilateral facial block (infraorbital and infratrochlear) after general anesthesia before surgery with intravenous placebo or bilateral block with placebo and intravenous morphine
224071884|NCT01817738|BIOLOGICAL|CV9104|Intradermal injection of CV9104
224071885|NCT01817738|BIOLOGICAL|Placebo|Intradermal injection of placebo
224071886|NCT02944448|DRUG|CR845 tablet 1 mg|CR845 tablets will be provided as 1 mg enteric-coated tablets. All tablets are white in color with no markings and are identical in appearance, regardless of dose and treatment.
224071887|NCT02944448|DRUG|CR845 tablet 2.5 mg|CR845 tablets will be provided as 2.5 mg enteric-coated tablets. All tablets are white in color with no markings and are identical in appearance, regardless of dose and treatment.
224071888|NCT02944448|DRUG|CR845 tablet 5 mg|CR845 tablets will be provided as 5 mg enteric-coated tablets. All tablets are white in color with no markings and are identical in appearance, regardless of dose and treatment.
224071889|NCT02944448|DRUG|Placebo tablet|Placebo tablets will be provided as enteric-coated tablets. All tablets are white in color with no markings and are identical in appearance, regardless of dose and treatment.
224071890|NCT03871855|DRUG|SHR-1702|Administered IV
224071891|NCT03871855|DRUG|Camrelizumab|Administered IV
224071892|NCT01098890|DRUG|Tissue Plasminogen Activator|2mg tPA will be given every twelve hours for a maximum of 5 doses
223480004|NCT04609514|DRUG|Nicotine patch|All participants will receive an 8-week course of nicotine patches. They will start off with 4 weeks of 21mg/24 hours patches, then move to 2 weeks of 14mg/24 hours patches, and finally end with 2 weeks of 7mg/24 hours patches.
224167557|NCT04330989|BEHAVIORAL|iNSC and Adherence supporter training|"Integrated next step counseling: iNSC is a structured, patient-centered approach informed by motivational interviewing techniques, which aims to foster an environment for joint-problem solving in order that the participant may identify their individual needs to increase or sustain sexual health through biomedical and non-biomedical approaches. iNSC frames the counselling sessions as a non-judgmental discussion to explore the facilitators and challenges to sexual health and medication adherence.~Adherence supporter training: Participants will be asked to identify a partner, family member, or friend to whom they are willing to disclose their HIV status (for HIV-positive women) or their intent to initiate PrEP (for HIV-negative women). Participants may also select a clinic-based peer to serve this adherence supporter role. Trainings will emphasize basic HIV knowledge, importance of antiretroviral adherence, potential drug side effects, and practical strategies for supporting adherence."
224167558|NCT04105595|DEVICE|Septal defect closure|Device closure of atrial septal defect
224167559|NCT00112840|DRUG|CCI-779|CCI-779 is taken IV on days 1, 8, 15, 22 of a 28-day cycle. Dose level is dependent on phase.
223480005|NCT04609514|BEHAVIORAL|Smartphone coaching|All participants will partake in over-the-phone smartphone coaching lead by the PI or a research assistant. This will be a time for participants to bring up any technical issues they are experiencing with the study smartphone or app.
223480006|NCT04405336|DRUG|tab block|injection of tab block to women who are doing cs
223480007|NCT04405336|DRUG|PCA|giving women PCA
223480008|NCT04405336|DRUG|women who will not receive tab block or PCA|no tab block or PCA will be given
224167560|NCT00112840|DRUG|Bevacizumab|Bevacizumab is taken IV on Days 1 and 15 of a 28-day cycle. Dose Level determined by phase.
224167561|NCT05616572|BEHAVIORAL|OncoWhiz|OncoWhiz is an online educational tool designed to supplement current institutional caregiver education. OncoWhiz requires low graphical demands, has no-end user downloads, and is compatible with both desktop and mobile phones. Questions are derived from the institutional binder and are written at a fifth-grade reading level for user accessibility.
223480009|NCT00909870|DEVICE|Dermagraft(R)|Weekly application of Dermagraft(R) with Profore compression as a secondary layer, in combination with systematic surgical wound debridement.
223480010|NCT00909870|DEVICE|Profore|Weekly application of Profore compression dressings, in combination with systematic surgical wound debridement.
223480011|NCT04054401|DEVICE|DRG Neurostimulation with Spinal Fusion|Surgeons will implant a neurostimulator during the same open back procedure as fusion devices (spinal fusion hardware and interbody cage) and begin neurostimulation in a short time following surgery (24 hours).
223480012|NCT03070873|DEVICE|Perigee and Apogee Mesh|The investigators divided the patients randomly into three groups :the group A received Perigee and Apogee polypropylene mesh(PA)；the group B received Gynecare prolift polypropylene mesh；the group C was without any mesh.
223480013|NCT03070873|DEVICE|Gynecare Prolift Mesh|The investigators divided the patients randomly into three groups :the group A received Perigee and Apogee polypropylene mesh(PA)；the group B received Gynecare prolift polypropylene mesh；the group C was without any mesh.
223480014|NCT03070873|PROCEDURE|Traditional Surgery|The investigators divided the patients randomly into three groups :the group A received Perigee and Apogee polypropylene mesh(PA)；the group B received Gynecare prolift polypropylene mesh；the group C was without any mesh.
223480015|NCT02923765|OTHER|Aerobic training by a stepper|Aerobic training by a stepper: 35 minutes/session, 5 sessions/week and 4-5 weeks in total
223480016|NCT00989222|PROCEDURE|closed reduction and external fixation|Fixation of an unstable dorsally displaced fracture of the distal radius with bridging external fixation
223480017|NCT00989222|PROCEDURE|Internal fixation with a volar locked plate|Open reduction and fixation of a unstable dorsally displaced fracture of the distal radius with a volar locked plate
223480018|NCT02590458|PROCEDURE|Short Breast MRI (SBMRI)|One day after routine MRI, short breast MRI (SBMRI) with contrast performed. Scan will take about 10 minutes to complete.
223480019|NCT02590458|BEHAVIORAL|Questionnaire|After SBMRI, participant completes a questionnaire about their comfort level and experience of the research scan. It should take about 10 minutes to complete the questionnaire.
223480020|NCT03043196|DRUG|SRP plus Rosuvastatin gel|SRP followed by Rosuvastatin placement into intrabony defect
223480021|NCT03043196|DRUG|SRP plus placebo gel|SRP followed by placebo gel placement into intrabony defect
223480022|NCT00000320|DRUG|Buprenorphine formulation: liquid vs. tablet|random assignment to liquid buprenorphine or tablet buprenorphine
223480023|NCT00053625|PROCEDURE|deep brain stimulation|Deep brain stimulation (DBS) is a surgical intervention used to treat movement disorders such as Parkinson's disease (PD). Target sites of stimulation may differ among patients. The Gpi and STN are two commonly targeted sites within the brain for treatment of PD, yet differences in outcomes between stimulation at the Gpi vs the STN (unilateral and bilateral) are not currently well understood.
223480024|NCT05830760|BIOLOGICAL|Myocardium biopsy|The expression of SGLT2 on small myocardium specimens harvested during aortic valve replacement operation in patients with aortic stenosis
223480025|NCT02102555|DRUG|IV acetaminophen|Single dose of one gram of IV acetaminophen given in pre-operative area
223480026|NCT02102555|DRUG|placebo|placebo (IV normal saline)
223480027|NCT01316575|DEVICE|nCPAP|The experimental group will receive nasal CPAP at 10cmH20 for one hour in the Post Anesthetic Care Unit.
223480028|NCT01316575|DEVICE|Low Flow Oxygen|The control group will receive standard therapy of low flow oxygen via simple mask at 8 litres per minute.
223584682|NCT02636686|DRUG|Drisapersen|Subjects will receive 6 mg/kg of drisapersen by subcutaneous injection once weekly. If subjects have experienced an intolerable injection site reaction(s), in consultation with the investigator, the subject may be allowed intermittent injections (8 weeks on/4 weeks off) or weekly intravenous infusions of 3 or 6 mg/kg
223584683|NCT02204488|PROCEDURE|Total Joint Arthroplasty|Total Joint Arthroplasty with device: Maïa® trapezio-metacarpal joint prosthesis, Groupe Lépine, Genay, France
223584684|NCT02204488|PROCEDURE|Trapeziectomy|Trapeziectomy
223584685|NCT03665584|DEVICE|FxCO2 Laser|The FxCO2 laser allows a microablative effect in soft tissue.
224167562|NCT04394013|BEHAVIORAL|Mindfulness intervention|Gentle body stretching with the incorporation of breathing technique
223480029|NCT03137810|PROCEDURE|placental cord drainage|"In the study group a of total number of 90 women placental end of the cut umbilical cord 1st will be clamped for few seconds and then unclamped and left open to drain blood in a vessel until flow stoped. This will prevent the drained blood from getting mixed with blood lost in the 3rd stage.~Blood loss in the third stage will be measured using a Kelly's pad which will be used during delivery and the blood lost will be collected in a clean metal bowl which will be kept at the tail end of Kelley's pad."
223480030|NCT03137810|PROCEDURE|non placemtal cord drainage|In 90 women after vaginal delivery of the baby placental end of the cut umbilical cord will be kept clamped.
223480031|NCT01565213|BEHAVIORAL|CBT|group cognitive behavioural based therapy (CBT) administered by psychologists once a week for 12 weeks,
223480032|NCT01565213|BEHAVIORAL|MMI|group multimodal intervention (MMI) based on a protocol comprising a mix of existing group interventions and exercises borrowed from multiple techniques and therapeutic schools and administered by assistant nurses with brief training, including two sessions per week for 6 weeks.
223480033|NCT01565213|BEHAVIORAL|CAU|Care as usual by the GPs
223480034|NCT02164292|PROCEDURE|ALPPS|Associating Liver Partition and Portal vein ligation for Staged hepatectomy
223480035|NCT01232283|DRUG|Apremilast|Apremilast 30mg by mouth (PO) twice a day (BID) for 32 weeks
223480036|NCT01232283|DRUG|Placebo|Identically matching placebo by mouth BID for first 16 weeks. Placebo participants will be switched to receive apremilast 30 mg BID at Week 16-32.
223480037|NCT01232283|OTHER|Topical or Phototherapy Therapy|Topical therapies such as low-potency or weak corticosteroids or phototherapies such as light therapy are added for non-responders at Week 32, (\< PASI-50) and added to their treatment regimen. The decision to add these treatments during this phase can only be made at the Week 32 visit.
223480038|NCT03728569|OTHER|Vanicream Moisturizing Skin Cream|Vanicream Moisturizing Skin Cream daily application
223480039|NCT03728569|OTHER|Vanicream Cleansing Soap|Vanicream Cleansing Soap daily use
223480040|NCT04534751|BIOLOGICAL|Fibrinogen + PCC|"Patients randomized to the intervention group will receive 4g of Fibryga and 2000 IU Octaplex will be released as part of the first and second MHP packs, if requested.~If a third MHP pack is required, and thereafter, FC will be administered if the fibrinogen level drops below 1.5-2.0 g/L at the discretion of the clinical team or based on conventional laboratory test results or viscoelastic methods.~Patients in both groups will otherwise receive identical MHP treatment packs (4 units of red blood cells \[RBC\] in pack 1 and 4 units of RBC and 1 pool of platelets in pack 2 (equivalent to 4 units)."
223480041|NCT04534751|BIOLOGICAL|Frozen Plasma|"4U FP will be released as part of the first and second MHP packs.~Patients in both groups will otherwise receive identical MHP treatment packs (4 units of red blood cells \[RBC\] in pack 1 and 4 units of RBC and 1 pool of platelets in pack 2 (equivalent to 4 units).~Patients randomized to the control group may receive FC if the fibrinogen level drops below 1.5-2.0 g/L at the discretion of the clinical team or based on conventional laboratory test results or viscoelastic methods. FC dosing in MHP packs 3 and above will be site-specific and at the discretion of the treating clinician."
223584686|NCT03665584|DEVICE|Sham Laser|The Sham laser will be used on the participants who receive the sham treatment.
224071893|NCT01098890|DRUG|Placebo|Placebo will be administered every 12 hours for a maximum of 5 doses.
223584687|NCT01099436|DRUG|cyclophosphamide|
223584688|NCT01099436|DRUG|docetaxel|
223584689|NCT01099436|DRUG|doxorubicin hydrochloride|
223584690|NCT01099436|DRUG|zoledronic acid|
223584691|NCT01099436|PROCEDURE|neoadjuvant therapy|
223584692|NCT01882868|DRUG|Aflibercept|Pharmaceutical form: Concentrated solution (100 mg/4 mL \[25 mg/mL\], 200 mg/8 mL \[25 mg/mL\]) for infusion; Route of administration: Intravenous
224071894|NCT00652353|OTHER|44-55-66-PM|"The mnemonic 44-55-66-PM helps to remember the components of the Ottawa Ankle and foot Rule.~44: Is to remember that an X-ray is required if the patients is unable to walk 4 steps at the moment of the Accident AND during the physical examination 55: Is to remember that an X-ray of the foot is required if the patient has pain at the basis of the 5Th metatarsal of at the 5caphoid 66-PM: Is to remember that an X-ray of the ankle is required if the patient has pain in the Posterior of the lateral or medial malleolar"
224071895|NCT00652353|OTHER|control|Participants will be instructed of the components of the Ottawa Ankle Rule on a standardized sheet
224071896|NCT04086251|OTHER|Gaido|Patients will participate for up to 21 days. Over the course of the study, 25-100 patients will be enrolled.
224071897|NCT00091910|DRUG|Epoetin alfa|
224071898|NCT02117726|DRUG|Dexmedetomidine,midazolam|
224071899|NCT02117726|DRUG|Propofol,midazolam|
224071900|NCT01135589|DRUG|Micafungin|i.v.
224071901|NCT06147557|PROCEDURE|Heat therapy|14 heat sessions, during each session subjects were fully immersed in a 45°C water bath for 5 minutes.
224071902|NCT06068972|DEVICE|MolecuLight|Point-of-care fluorescence imaging of high bacterial loads
224071903|NCT02070107|OTHER|On Plan|"On Plan is a highly customizable software package developed by our co-investigator at the University of Louisville for a variety of applications related to compliance."
224071904|NCT04527198|DIAGNOSTIC_TEST|Brainstem Responses Assessment Sedation Score (BRASS)|"It consists of a standardized evaluation of brainstem reflexes with a score of 1 attributed for absence of pupillary light reflex, cough reflex and the combined absence of grimace and oculocephalic reflex, a score of 2 for absent corneal reflex and a score of 3 for absent grimace in the presence of oculocephalic The resulting sum ranges from 0 to 7.~It will be performed at two times points: a first time under sedation and a second time 3 to 5 days after sedation weaning."
224071905|NCT04527198|DIAGNOSTIC_TEST|Electroencephalogram with EKG lead|"A 20 minutes clinical (12 electrodes) EEG with an EKG lead will be performed a first time under sedation and a second time 3 to 5 days after sedation weaning.~These EEG recordings will allow to measure the sympathic-parasympathetic ratio using spectral analysis of the EKG and also to measure quantitative markers of brain EEG activity (spectral power and connectivity in delta, theta, alpha, beta and gamma band; complexity)."
224071906|NCT05627076|DEVICE|Blood Sampling|Blood samples will be collected for the PSP measurement using the abioSCOPE.
224071907|NCT03644433|PROCEDURE|Single layer closure|Uterine incision will be approximated with continuous unlocked suture avoiding the inclusion endometrium and without trimming incision edges.
223584693|NCT01882868|DRUG|Levofolinate|Pharmaceutical form: Solution for infusion (marketed formulation); Route of administration: Intravenous
223584694|NCT01882868|DRUG|Irinotecan|Pharmaceutical form: Solution for infusion (marketed formulation); Route of administration: Intravenous
223584695|NCT01882868|DRUG|5-FU|Pharmaceutical form: Solution for infusion (marketed formulation); Route of administration: Intravenous
223584696|NCT06206655|DIAGNOSTIC_TEST|rapid ACTH stimulation test|Take 2ml blood/saliva sample at baseline. Then, we will inject synacthen 250mcg IV to patients and collect 2ml blood/saliva after 30minutes and 60 minutes.
223584697|NCT00102284|DRUG|levodopa|
223584698|NCT00102284|DRUG|rivastigmine|
223584699|NCT00102284|DRUG|pergolid|
223584700|NCT00102284|DRUG|modafinil|
223584701|NCT06208566|BEHAVIORAL|Conversational Agent Zenny|The intervention group involves a newly developed conversational agent self-care program. This program consists of 40 separate modules based on empirically supported techniques. Modules include the following core sections: cognitive behavioral skills, interpersonal relationships, positive psychological growth, relaxation, goal setting, and emotional regulation skills. The modules focus on cognitive-behavioral skills for reducing emotional distress, improving behavioral activation and healthy behaviors, and problem-solving skills. The intervention was delivered via a decision-tree based conversational agent in WhatsApp messenger.
223584702|NCT06208566|BEHAVIORAL|Web-based Wellness Resources|"The control group involved referral to a menu of freely-available evidence-based wellness resources linked from the study website, Your Healthiest Self: Wellness Toolkits, Doing What Matters in Times of Stress, and How Right Now. These website choices involved self-selection of relevant modules for improving mood, reducing stress and anxiety, addressing relationship problems, and other wellness topics. These programs required only access to the websites and could be completed in a self-help format by participants at their own pace."
223584703|NCT01073930|DRUG|PicoPrep|PICOPREP (sodium picosulfate, magnesium oxide and citric acid) powder for oral solution consisted of 2 pouches of powder administered in a divided dose. Each PICOPREP pouch was reconstituted by mixing the contents in a cup with 5 ounces of cold water. The first pouch was taken between 5:00 PM and 9:00 PM the evening prior to the colonoscopy procedure. Subjects were to consume five (5) 8-ounce glasses of clear liquids over the next few hours. The second pouch was taken approximately 5 hours before but no more than 9 hours prior to the colonoscopy procedure. Subjects were to consume three (3) 8-ounce glasses of clear liquids.
223584704|NCT01073930|DRUG|HalfLytely|HalfLytely contains polyethylene glycol electrolyte solution (PEG-EL), sodium chloride, sodium bicarbonate and potassium chloride. The day prior to the colonoscopy procedure and after the first bowel movement or after 6 hours following administration of the bisacodyl tablets, whichever occurred first, subjects were to drink the 2 liter HalfLytely at a rate of one 8-ounce glass every 10 minutes. The entire solution was to be consumed.
224167563|NCT04394013|BEHAVIORAL|Non-Mindfulness intervention|Gentle body stretching without the incorporation of breathing technique
224167564|NCT03960385|BIOLOGICAL|CYD-TDV|Dengue vaccine
224167565|NCT02986425|OTHER|STRIP intervention|"The STRIP intervention consists of 9 steps:~1. structured history taking of medication~2. recording medication and diagnoses in STRIPA~3. structured drug review based on the STRIPA with the integrated Screening Tool of Older Person's Prescriptions (STOPP)/ Screening Tool to Alert Doctors to the Right Treatment (START) criteria~4. communication and discussion of the structured drug review with prescribing physician with possible adaptation of the recommendation~5. shared decision-making with the patient with possible adaptation of the recommendation~6. optional revision based on new accumulating data during hospitalisation (e.g. new diagnoses, adverse drug reactions)~7. generation of general practioner (GP) report~8. delivery of the report to the patient and to the GP (optional additional direct communication)~9. follow-up"
224167566|NCT02986425|OTHER|Control|Standard care in the department where the trial is conducted. To keep the patients and the blinded team members blinded one questionnaire will be conducted by the intervention team in both arms. This is considered a SHAM intervention.
224167567|NCT03699527|BEHAVIORAL|Multiple questionnaires administered|This is an observational trial
224167568|NCT04101227|DRUG|AD04 (ondansetron)|AD04 (ondansetron) 0.33 mg, orally (p.o.) twice a day (BID)
224167569|NCT04101227|DRUG|Matching placebo|Matching placebo to AD04 (ondansetron), orally (p.o.) twice a day (BID)
224167570|NCT04101227|DEVICE|Companion Diagnostic for Genetic Testing|Companion Diagnostic for Genetic Testing
224167571|NCT04101227|BEHAVIORAL|Brief Psychological Counseling|Brief Psychological Counseling
224167572|NCT03419351|DIAGNOSTIC_TEST|Smartphone|Smartphone based measurement of refractive error and visual acuity testing using these measurements.
223584705|NCT01073930|DRUG|bisacodyl|Two 5 mg bisacodyl tablets were taken in the afternoon on the day prior to the colonoscopy procedure.
223584706|NCT04660396|DEVICE|BVA-100|"The BVA-100 is a software package designed to calculate human blood volume using the method of tracer dilution. It uses tagged serum albumin (a commonly used tag is 131I, resulting in 131I -HSA). Data inputs to the software come from the measured characteristics of subject blood samples (hematocrit and tracer concentration) and tracer calibration standards. The package also calculates the subject expected (or ideal) blood volume from physical parameters. Hyper- or hypovolemia, associated red blood cell volumes, and transudation rate are reported, with statistics showing the quality of the results. The subject blood samples and calibration standards are measured in a gamma counter, whose output is automatically, or manually, input to this calculation program."
223584707|NCT01022424|DRUG|OPC-41061|Repeated oral administration at doses of 15 mg twice daily (morning and evening)
223584708|NCT00555737|DEVICE|Capsule Endoscopy|Given® Diagnostic system with Pillcam SB
223584709|NCT00959127|DRUG|ARRY-438162 (MEK162), MEK inhibitor; oral|Part 1: multiple dose, escalating; Part 2: multiple dose, single schedule; Part 3: multiple dose, single schedule.
223584710|NCT04708860|BEHAVIORAL|Prolonged Nightly Fasting|Restriction of consumption of calorie-containing food/drinks after 8pm
224167573|NCT03419351|DIAGNOSTIC_TEST|Autorefractor|Autorefractor based measurement of refractive error and visual acuity testing using these measurements.
224167574|NCT03419351|DIAGNOSTIC_TEST|Individual|Individual, human measurement of refractive error and visual acuity testing using these measurements.
224167575|NCT03631394|OTHER|beetroot and anthocyanin|Beetroot and anthocyanin will be taken for 7 days during the study two hours prior to eating.
224167576|NCT03631394|OTHER|beetroot and placebo|Beetroot and placebo will be taken for 7 days during the study two hours prior to eating.
224167577|NCT01153568|DIETARY_SUPPLEMENT|Vitamin D 3|Patients will bew given a single capsule to take once daily
224167578|NCT01153568|OTHER|placebo|placebo tablets
224167579|NCT03249441|BEHAVIORAL|Compassion-focused therapy|"Session-by-session summary of CFT:~Week 1: Understanding your relationship with food Week 2: Making sense of overeating Week 3: The Compassionate Mind/ Preparing your mind for compassion Week 4: Developing the skill of self-compassion Week 5: Why we overeat - a Compassionate approach Week 6: Understanding your current eating pattern Week 7: Motivating yourself to change Week 8: Determining what your body needs Week 9: Towards a new way of eating Week 10: Compassionate letter writing and developing a compassionate focus on eating.~\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_"
224167580|NCT01453686|DRUG|Hydrocortisone 1%|Topical cream, used twice daily for 6 weeks on affected area, followed by 6 weeks of no treatment, followed by an additional 6 weeks of the same intervention.
224167581|NCT01453686|DRUG|Clobetasol Propionate 0.05%|Topical cream, used twice daily for 6 weeks on affected area, followed by 6 weeks of no treatment, followed by an additional 6 weeks of the same intervention.
224167582|NCT00691054|DRUG|Abraxane|One treatment-cycle is 28 days with chemotherapy (Abraxane® 100 mg/m2) given on day 1, 8, and 15, followed by rest on week 4. Treatment cycles will be repeated every 28 days for as long as disease is not progressing and patient tolerates treatment
224167583|NCT00198367|DRUG|Cisplatin-Gemzar|
224167584|NCT00198367|DRUG|Cisplatin-Navelbine-Radiotherapy|
224167585|NCT00198367|DRUG|Carboplatin-Taxol-Radiotherapy|
224167586|NCT02551328|DRUG|sevofluorane|Continuous infusion of sevofluorane
224167587|NCT03595176|DEVICE|Lithotripsy|Deliver Lithotripsy to the target vessel prior to placing a coronary stent.
224167588|NCT01250392|BEHAVIORAL|The Effect of Active Choice on Nurse Visit Participation|"The goal of this project is to see if active choice will increase an individual's likelihood of participating in a nurse visit.~The employees in our sample will schedule their nurse visit time slot via e-mail and a health service provider website. The control group will be informed via e-mail of the window of dates during which they can take part in the on-site screening and given instructions for scheduling an appointment. The treatment group, the active choice only arm, will be given the same information as the control group, but they will also be asked to make an appointment immediately, defer the scheduling decision, or decline to receive a screening. The treatment group will also receive email reminders one week before their appointment."
224167589|NCT01731197|DIETARY_SUPPLEMENT|Dry-Blended Beverage|
224167590|NCT07025382|OTHER|Home-based pulmonary rehabilitation|"An eight-week (three sessions per week) telerehabilitation home-based program, including:~Twenty-four PR sessions (approximately 1 hour 45 minutes each), including a 15-minute warm-up period, endurance training on a cycle ergometer, muscle strengthening exercises, balance exercises, as well as therapeutic patient education sessions tailored to the patient's needs based on the initial assessment. Training is adjusted according to patient tolerance and healthcare professional recommendations. Participants will receive a cycle ergometer, pulse oximeter, activity tracker, and a tablet application (TELEREHAPP) for guidance throughout the program, remote monitoring, and communication. Home-based sessions include:~* Endurance training on the cycle ergometer (15 to 45 minutes per session).~* Strength training and balance exercises (30 minutes per session).~* Physical activity coaching, including a daily step goal."
224167591|NCT07025382|OTHER|Center-based pulmonary rehabilitation|"An eight-week (three sessions per week) center-based pulmonary rehabilitation program, including:~Twenty-four center-based PR sessions (approximately 1 hour 45 minutes each), including a 15-minute warm-up period, endurance training on a cycle ergometer, muscle strengthening exercises, balance exercises, as well as therapeutic patient education sessions tailored to the patient's needs based on the initial assessment. Training is adjusted according to patient tolerance and healthcare professional recommendations."
224167592|NCT05455645|OTHER|targeted intrinsic foot muscle exercises|4 targeted intrinsic foot muscle exercises
224167593|NCT00141544|DRUG|esterified estrogens 1.25 mg and methyltestosterone 2.5 mg|ESTRATEST® administered orally QD
224167594|NCT00141544|DRUG|Esterified estrogens 1.25 mg|Esterified estrogens 1.25 mg administered orally QD
224167595|NCT00441194|DEVICE|Visual Field (Octopus 311 and the HFA 700 series)|
224167596|NCT03125681|PROCEDURE|Remote ischemic conditioning|In the RIC group, RIC is performed before and after coronary anastomoses by 5 minutes limb ischemia and reperfusion with pneumatic cuff up to 200 mmHg repeated by four times.
223480042|NCT01226329|BEHAVIORAL|Right Question Project - Mental Health (RQP-MH)|"The RQP-MH trainings each take approximately 45 minutes to complete and are delivered approximately three weeks apart. The manualized intervention uses a Question Formulation Technique (QFT) and a Framework for Active Decision-Making (FADM). The QFT consists of asking patients to generate and revise questions to obtain more informative answers from their providers. The FADM teaches participants to identify questions that will help them consider their role in a decision, the process of decision-making, and the reasons behind a decision. All intervention sessions will be taught by a bachelors-level Care Manager."
224167597|NCT03125681|PROCEDURE|Control|In the control group, all the procedures will be same with RIC group, except for the fact that the three-way stopcock between the pneumatic cuff and the cuff inflator was opened and therefore the cuff pressure did not increase.
224167598|NCT05309499|DRUG|ferric carboxymaltose|ferric carboxymaltose is i.v. iron, 121 patiants will be randomised to this group
224167599|NCT05309499|DRUG|ferrous sulphate|ferrous sulphate is oral iron, 121patiants will be randomised to this group
224167600|NCT00685828|DRUG|imatinib mesylate|By mouth
224167601|NCT02886442|OTHER|Standard adhesive strip|This is a standard adhesive strip (hydrocolloid)
224167602|NCT02886442|OTHER|New adhesive strip|This is a newly developed adhesive strip
223480043|NCT01226329|BEHAVIORAL|Pamphlet|"Participants in this group receive a handout called Managing Your Mental Health (available in Spanish and English) that provides tips on how to manage mental health through the proper maintenance of physical health and stress."
224167603|NCT02462200|PROCEDURE|Breast-conserving surgery (BCS)|
224167604|NCT02462200|PROCEDURE|Cavity shave margins (CSM)|
224167605|NCT02462200|BEHAVIORAL|BREAST-Q Questionnaire|
224167606|NCT02462200|DEVICE|3-D breast imaging|Using a 3-D breast imaging camera Vectra 3-D XT
224167607|NCT02462200|OTHER|Indocyanine green|
224167608|NCT02462200|DEVICE|Intraoperative imaging device|The goggle device is wearable, compact, and battery-operated, and it allows for hands-free operation by the wearer. The goggles provide functional information via a NIR light-emitting diode (LED) integrated within one of the eyepieces, which causes NIR fluorescence excitation of the molecular probes within the surgical field
224167609|NCT02462200|PROCEDURE|Peripheral blood draw|-Time of surgery if coordinator is available
224167610|NCT01868594|DRUG|Subetta|"Each Subetta tablet contains a mixture of affinity purified polyclonal antibodies to β-subunit of the rINS (6 mg) and antibodies to eNOS (6 mg) in released-active form produced by the patented technology in accordance with the applicable European Pharmacopeia requirements.~Standard therapy of type I diabetes mellitus + Subetta (1 tablet 4 times a day) for 36 weeks.~Subetta: oral administration, per 1 intake - 1 tablet (keep in the mouth until complete dissolution, not at mealtime)."
223480044|NCT02776566|OTHER|Patient Self-Monitoring vs Anticoagulation Clinic|"Patient Self-Monitoring (intervention): entails 3 education sessions of 90-120 minutes each (week 0, week 2, week 4): 2 provided on site in clinic and 1 in the patient's home, during which, self-testing competency and barriers and facilitators to self-monitoring will be evaluated. Subjects will follow with weekly (or sooner, if clinically indicated) in-home self-monitoring and follow-up weekly phone calls over 6 months by clinical pharmacists to guide warfarin dosing and reinforce key educational messages.~Anticoagulation Clinic (control): subjects will have their INR tested in clinic monthly (or more frequently if clinically indicated) via the Coaguchek® point-of-care device (which is the standard of care in the Anticoagulation Clinic) and receive dosing instructions and standardized education related to warfarin by a clinical pharmacist who provides care in the Anticoagulation Clinic."
223480045|NCT06195644|DEVICE|Galvanic vestibular stimulation|galvanic current generated by Gymna DUO 200 and delivered through conductive medium (electrode gel) by two small carbon rubber electrodes 3 cm 2 each bilaterally over two mastoid processes for 30 minutes, two times per week for 12 weeks .
223480046|NCT06195644|DEVICE|MovAlyzeR® software from Neuroscript|MovAlyzeR® movement analysis software from Neuroscript turns a pen tablet or mouse into a high-quality system for examining movements by a pen, mouse or finger. Hence, it can train and analyze hand dexterity and handwriting using pen tablets such as sentence parameters.
223480047|NCT06195644|DEVICE|BODYFIT Mini Portable Pedal Home Exerciser (cyclic ergometer)|stationary upper body pedaling as a moderate intensity aerobic training
223480048|NCT01219023|DRUG|sildenafil citrate|Subjects will be given 2 types of topical creams, one containing 1% sildenafil and one containing placebo control. Subjects will be randomized to apply sildenafil cream to either the right or left hand/foot; placebo cream will be applied to the opposite hand/foot. The cream will be supplied to subjects with proper labeling to indicate right and left application assignment. Cream will be applied to each affected hand/foot two times per day.
223480049|NCT02986464|DEVICE|Virtual Reality Prototype|VR prototype installed around the tank in the hydrotherapy room to give the child a sense of immersion in the virtual world with a possibility of interaction depending on the child's age and condition.
223480050|NCT02986464|OTHER|Standard Pharmacological Treatment|According to the unit's protocol and adjusted to each participant's age, weight and condition by the anesthetist and the pain clinic nurse.
223480051|NCT04393649|OTHER|ESOGER|Questionnaire
223480052|NCT06477978|DIAGNOSTIC_TEST|Hand grip function testing|The use of Bio-impedance to measure the skeletal muscle mass
223480053|NCT03662412|DRUG|Sirolimus|Oral solution of sirolimus, 2mg, once a day.
223480054|NCT02483884|DRUG|[68Ga]RM2|\[68Ga\]RM2 is a novel 68Ga labeled, radiopharmaceutical agent for PET imaging. It is administered intravenously as a single dose of 140 MBq (corresponding to ≤ 40 μg mass dose)
223480055|NCT02483884|PROCEDURE|PET/CT|Patients received \[68Ga\]RM2 undergo PET/CT 60 min p.i. for at least 20 min
223480056|NCT04773028|OTHER|matrix metalloproteinase enzymes 2 and 9|concentration of matrix metalloproteinase 2 and 9 enzymes
223480057|NCT02203266|DEVICE|Feedback|Feedback on the patient's own inhaler use, with personalized information on the patients technique and timing of use of the diskus inhaler as recorded on the INCA device will be provided to patients in the feedback group after 1,2 and 6 months.
224167611|NCT01868594|DRUG|Placebo|"Placebo (identical to Subetta in shape and taste tablet containing exсipients). Standard therapy of type I diabetes mellitus + Placebo (1 tablet 4 times a day) for 36 weeks.~Placebo: oral administration, per 1 intake - 1 tablet (keep in the mouth until complete dissolution, not at mealtime)."
223480058|NCT02203266|BEHAVIORAL|Education|Feedback on the patient's own inhaler technique as observed by pharmacist and education to support best use will be provided to patients in the demonstration group after 1,2 and 6 months.
223480059|NCT03068104|OTHER|No intervention|
223480060|NCT03122795|PROCEDURE|Microbiome transplant|A raw microbiome, collected from a donor without any sinonasal health problems, as a nasal lavage.
223480061|NCT01725672|DRUG|Metformin, 500 mg extended release tablet|In Part A and Part B of the study, Metformin 500 mg XR tablet will be administered with 240 millilitre (mL) water ; 125 mL of LUCOZADE was administered every 30 mins for 4 hours after dosing.
223480062|NCT01725672|DRUG|Metformin, 1000 mg extended release tablet|In Part A and Part B of the study, Metformin 1000 mg XR tablet will be administered with 240mL water; 125 mL of LUCOZADE was administered every 30 mins for 4 hours after dosing.
223480063|NCT01725672|DRUG|Glimepiride, 1 mg immediate release tablet|In Part A and Part B of the study, Glimepiride 1 mg IR tablet will be administered with 240mL water; 125 mL of LUCOZADE was administered every 30 mins for 4 hours after dosing.
224167612|NCT00356434|DEVICE|Kendall A-V foot impulse pump, model 6060|Will wear device for DVT prevention and receive questionnaire about compliance and comfort. Will also undergo random checks to confirm compliance with instructions and use
224167613|NCT00356434|DEVICE|Kendall sequential compression device, model 9525|Will wear device for DVT prevention and receive questionnaire about compliance and comfort. Will also undergo random checks to confirm compliance with instructions and use
224167614|NCT07032272|DRUG|remibrutinib|Tablet with oral route of administration
224167615|NCT06186895|DRUG|Dexmedetomidine|received an intravenous loading dose of DEX (1 μg/kg) over 15 minutes prior to the anesthetic induction. Following the intubation procedure, a maintenance infusion of DEX was delivered at a rate of 0.6 μg/kg/h. The infusion was discontinued upon trocars removal.
224167616|NCT06186895|DRUG|Fentanyl|fentanyl (1 μg/kg) that was given intravenously slowly over 60 seconds before induction of anesthesia as a loading dose. Following intubation, a continuous infusion of fentanyl was administered at a rate of 1μg/kg/hr. The infusion was discontinued upon the removal of the trocars.
224167617|NCT02505009|DRUG|Engerix-B|The case group will receive 5 Engerix-B injections during the last 6 months of a 3-year NA therapy.
224167618|NCT02505009|DRUG|Tenofovir|Both case and control will receive 300 mg Tenofovir for at least 3 years
224167619|NCT02505009|DRUG|Entecavir|Both case and control will receive 0.5 mg entecavir therapy for at least 3 years
224167620|NCT05412667|DIETARY_SUPPLEMENT|TWK10|"1. 4 days without training: drink 2 hours before bedtime.~2. 3 days of training: drink within 30 minutes after training (uniformly brewed in the laboratory).~3. To analyze the amino acid concentration in blood, drink it immediately before blood collection."
224167621|NCT05412667|OTHER|Placebo|"1. 4 days without training: drink 2 hours before bedtime.~2. 3 days of training: drink within 30 minutes after training (uniformly brewed in the laboratory).~3. To analyze the amino acid concentration in blood, drink it immediately before blood collection."
224167622|NCT04964557|DRUG|AZD8233|PCSK9-targeted ASO for the reduction of circulating levels of LDL-C.
224167623|NCT04964557|DRUG|Placebo|Placebo solution
224167624|NCT06706869|DRUG|PF-07258669|Tablet
224167625|NCT06706869|DRUG|Itraconazole|Solution
223480064|NCT01725672|DRUG|Glimepiride, 2 mg immediate release tablet|In Part A and Part B of the study, Glimepiride 2 mg IR tablet will be administered with 240mL water; 125 mL of LUCOZADE was administered every 30 mins for 4 hours after dosing.
223480065|NCT01725672|DRUG|Metformin, 500 mg and Glimepiride, 1 mg extended release film coated tablet containing release controlling polymers|In Part A of the study, 1 XR film coated tablet combination of Metformin 500 mg and Glimepiride 1 mg will be administered with 240 mL water; 125 mL of LUCOZADE was administered every 30 mins for 4 hours after dosing.
223480066|NCT01725672|DRUG|Metformin, 1000 mg and Glimepiride, 2 mg extended release film coated tablet containing release controlling polymers|In Part A of the study, 1 XR film coated tablet combination of Metformin 1000 mg and Glimepiride 2 mg will be administered with 240 mL water; 125 mL of LUCOZADE was administered every 30 mins for 4 hours after dosing.
223480067|NCT01725672|DRUG|Metformin, 500 mg and Glimepiride, 1 mg extended release tablet coated with release controlling polymers|In Part B of the study, 1 XR tablet combination of Metformin 500 mg and Glimepiride 1 mg will be administered with 240 mL water; 125 mL of LUCOZADE was administered every 30 mins for 4 hours after dosing.
223480068|NCT01725672|DRUG|Metformin, 1000 mg and Glimepiride, 2 mg extended release tablet coated with release controlling polymers|In Part B of the study, 1 XR tablet combination of Metformin 1000 mg and Glimepiride 2 mg will be administered with 240 mL water; 125 mL of LUCOZADE was administered every 30 mins for 4 hours after dosing.
223480069|NCT01577797|BEHAVIORAL|Text messages|Messages sent at random intervals 4 times per day during weeks 1 and 3. Subjects can also request messages if they are craving methamphetamine
223480070|NCT04405752|DEVICE|12-mm metallic biliary stent|Metallic biliary stent, covered or uncovered,KEBOMED HILZO 12mm in diameter (length 4 or 6 cm).
224167626|NCT06706778|BEHAVIORAL|Music intervention|Based on the NIH toolkit and MBIs reporting guidelines, the engagement in this pilot study will be receptive by providing participants with prerecorded, preselected playlists. Participants will also receive a guided video on maximizing music's therapeutic benefits. The playlists will be purely instrumental, with a 60-80 bpm tempo, and feature melodies and harmonies designed for stress relief, including soothing, grounding, meditation, emotional release, etc. This approach is resource-efficient and easily accessible, allowing participants to integrate it into daily pain self-management strategies. Participants will be asked to engage in the MBI in the morning and at night for 30 minutes each, wearing the abdominal belt and smartwatch.
224167627|NCT07135388|DIETARY_SUPPLEMENT|Food for special medical purposes|Oral supplementation with a protein supplement high in branched-chain amino acids and β-hydroxy-β-methyl-butyrate (HMB)
223480071|NCT04405752|DEVICE|10-mm metallic biliary stent|Biliary, metallic, covered or uncovered stent, COOK EVOLUTION 10mm in diameter (length 4 or 6 cm)
223480072|NCT01535924|DRUG|gemcitabine hydrochloride|Given IV
223480073|NCT01535924|DRUG|bendamustine hydrochloride|Given IV
223480074|NCT03225638|COMBINATION_PRODUCT|Intramuscular ZENEO® injection of nominal strength|Sodium Chloride (0.9%)
223480075|NCT03225638|COMBINATION_PRODUCT|Intramuscular ZENEO® injection of low strength (upper limit)|Sodium Chloride (0.9%)
223480076|NCT03225638|COMBINATION_PRODUCT|Intramuscular ZENEO® injection of low strength (lower limit)|Sodium Chloride (0.9%)
223480077|NCT01737736|DEVICE|Neurokeeper stroke detector|Electrophisoloigcal monitoring
223480078|NCT04721418|RADIATION|11C-UCB-J|11C-UCB-J PET scan
223480079|NCT00848497|DRUG|Testim®|Testim® 5 g of gel (one tube) containing 50 mg of testosterone once daily. This was the dose given to the patient which he started.
223480080|NCT00848497|OTHER|Placebo Testim®|Placebo Testim® 5 g of gel (one tube)
223584711|NCT04708860|BEHAVIORAL|Exercise|Personalized moderate-intensity, aerobic exercise and strength training
223584712|NCT04043468|OTHER|Audit and feedback|Audit and feedback (A\&F) is an intervention that aims to improve professionals practices by providing professionals with a summary of their performance over a period of time.
223584713|NCT01266590|DRUG|LY2216684|Administered orally
224167628|NCT03709940|DRUG|MPH|Participants undergo behavioural tests and brain scanning twice, once under placebo and once under an acute dose of MPH, before starting long-term treatment with a long-acting formulation of MPH used routinely at the Adult ADHD Clinic.
224167629|NCT06880393|BIOLOGICAL|anti-BCMA-CAR-T|Autologous BCMA-directed CAR-T cells, infusion intravenously at a target dose of 2.0-4.0 x 10\^6 anti-BCMA CAR+T cells/kg
224167630|NCT06722664|DRUG|Recombinant Human Chymotrypsin(OsrhCT) 4000U|Recombinant Human Chymotrypsin (OsrhCT), provided by Wuhan Healthgen Biotechnology Corporation, 4,000U/vial, freeze-dried powder
223480081|NCT00848497|DRUG|Viagra®|Viagra 25mg was the dose given to the patient which he started.
223480082|NCT05916547|PROCEDURE|pancreatic extracorporeal shock wave lithotripsy|Pancreatic extracorporeal shock wave lithotripsy is based on the principle of shock wave energy. Whenever energy is abruptly released in an enclosed space, shock waves are generated and then cross to the surface of pancreatic duct stones to cause further fragmentation.
224167631|NCT06722664|DRUG|Placebo for Recombinant Human Chymotrypsin(OsrhCT)|Recombinant Human Chymotrypsin (OsrhCT), provided by Wuhan Healthgen Biotechnology Corporation, 0 U/vial, freeze-dried powder
224167632|NCT06722664|DRUG|Dimethicone emulsion 4ml|Dimethicone emulsion，produced by Sichuan Jian Neng Pharmaceutical Co., Ltd, 6ml/bottle.
224167633|NCT06724406|BEHAVIORAL|Family Skills Training Session Quantity: 5|The number of family skills training sessions administered: 5 sessions
224167634|NCT06724406|BEHAVIORAL|Family Skills Training Session Mode: In-person|The mode of administration of family skills training sessions: in person or online
224167635|NCT06724406|BEHAVIORAL|Family Skills Training Content: Communication|The content of family skills training sessions administered focused on communication and conflict resolution : communication and conflict resolution
224167636|NCT06724406|BEHAVIORAL|Family Skills Training Content: Cohesion|The content of family skills training sessions administered focused on cohesion: cohesion or no cohesion
224167637|NCT06724406|BEHAVIORAL|Family Skills Training Session Quantity: 10|The number of family skills training sessions administered: 10 sessions
224167638|NCT06724406|BEHAVIORAL|Family Skills Training Session Mode: Online|The mode of administration of family skills training sessions: online
224167639|NCT06724406|BEHAVIORAL|Family Skills Training Content: No Communication|The content of family skills training sessions administered focused on communication and conflict resolution : no communication and conflict resolution
223480083|NCT03647592|DRUG|Erlotinib/Gefitinib combined with Bevacizumab|Erlotlnib,150mg po qd/gefitinib 250mg po qd +Bevacizumab(15mg/kg),lvgtt,every 21 day ,evaluate every 2 months
223480084|NCT00469131|DRUG|tacrolimus + steroid|
223480085|NCT00469131|DRUG|tacrolimus + mycophenolate mofetil|
223480086|NCT05149339|DRUG|Cholecalciferol 2800 I.U. ml oral drops|"(Cholecalciferol 2800 I.U. ml) Oral Drops 15 ml. supplied with a dropper.~* Composition:~Each 1 ml (= 28 drops) of oral solution contains: Vitamin D3 (Cholecalciferol) 2800 I.U., (each drop contains 100 IU of vitamin D3)."
223480087|NCT02342626|BEHAVIORAL|Dashboard|With the health care provider, subjects will use the decision dashboard to augment the discussion of treatment options.
223480088|NCT01990326|DRUG|XAF5 Gel|
224167640|NCT06724406|BEHAVIORAL|Family Skills Training Content: No Cohesion|The content of family skills training sessions administered focused on cohesion: no cohesion
224167641|NCT03796871|DEVICE|Dermapol|Use of the experimental medical device before lesion excision : skin lesion lighting (4 wavelengths) for less than 1 minute and image recording
224167642|NCT06727032|DEVICE|Brain Metastasis AI|There will be no intervention
224167643|NCT06885827|DIETARY_SUPPLEMENT|Vitamin B-mix|"Daily oral supplementation with:~Vitamin B6 (pyridoxine, 25 mg), 1 capsule Vitamin B9 (folic acid, 400 µg) + Vitamin B12 (cyanocobalamin, 1 mg), 2 capsules.~Choline (choline bitartrate, 500 mg), 2 capsules Administered alongside standard glaucoma care."
224167644|NCT06885827|OTHER|Standard Care|Usual glaucoma management (e.g., monitoring and/or IOP-lowering treatments) without additional supplementation.
223480089|NCT01990326|DRUG|Placebo Gel|
223480090|NCT04538508|DEVICE|Diathermy|10 sessions of 12 minutes of radiofrequency diathermy at the anterior surface of the knee, in constant movement
223480091|NCT04538508|OTHER|Supervised knee exercises|Daily hamstrings exercises, quadriceps exercises and hip exercises, 20 minutes of duration.
223480092|NCT00176449|DRUG|Bupropion SR|150mg twice a day (starting with 150mg once a day for three days)
223480093|NCT00176449|DRUG|Placebo Oral Tablet|Comparable placebo
223480094|NCT02966834|DRUG|Placebo|GSK2330672 matching placebo will be supplied as white film-coated tablets.
223480095|NCT02966834|DRUG|GSK2330672|GSK2330672 will be supplied in 2 dose strengths of 10 mg and 45 mg white film-coated tablets.
223480096|NCT03406520|DEVICE|Chlorhexidine-impregnated disk|The chlorhexidine-impregnated sponge, named biopatch, is a protective disk (2.5 cm x 0.7 cm), which is hydrophilic polyurethane absorptive foam with chlorhexidine gluconate, in average of 86.8mg per disk
223480097|NCT04929015|PROCEDURE|Biospecimen Collection - blood and tissue sample collection|The original tissue sample from each patient will be obtained at time of surgery or prior to surgery. Plasma for ctDNA will be obtained at baseline, pre-surgery, post-surgery and every 3 months up 2 years
223480098|NCT04929015|OTHER|Electronic Health Record Review|Medical record reviewed
224167645|NCT06731075|DRUG|ORMD-0801 8 mg|1 x 8 mg capsule between 8 PM to 12 Midnight and no sooner than 1 hour after dinner and 2 placebo capsules (1 in the morning and 1 at night).
224167646|NCT06731075|OTHER|Placebo capsule|Placebo capsule
224167647|NCT06731075|DRUG|ORMD-0801 16 mg|2 x 8 mg capsules between 8 PM to 12 Midnight and no sooner than 1 hour after dinner and 1 placebo capsule in the morning.
224167648|NCT06926530|OTHER|No intervention|Participants will complete a one-time 33-question survey. The survey is comprised of three sections: (1) Section A includes 12 questions related to demographic information, (2) Section B consists of 2 questions addressing treatment characteristics, \& (3) Section C contains 19 questions focusing on supplement usage.
224167649|NCT06925321|DRUG|Fosmanogepix IV infusion|Fosmanogepix will be administered IV
224167650|NCT06925321|DRUG|Standard of care antifungal therapy|Standard of care antifungal therapy will be administered in accordance with their respective product labels and/or standard practice guidelines
224167651|NCT06925321|DRUG|Fosmanogepix oral tablet|Fosmanogepix will be administered orally.
224167652|NCT06725004|DRUG|Oxytocin|Injection Oxytocin 10 mg intramuscular as trigger for ovulation induction
223480099|NCT02450643|OTHER|Test extensively hydrolyzed formula|extensively hydrolyzed formula made with a new enzyme
223480100|NCT02450643|OTHER|Control extensively hydrolyzed formula|commercially available extensively hydrolyzed formula
223480101|NCT01430377|PROCEDURE|SB predilatation|Initial SB \[predilatation.
223480102|NCT01430377|PROCEDURE|No SB predilatation|Without SB predilatation
223480103|NCT04139252|OTHER|No intervention|No intervention
223480104|NCT05858983|GENETIC|FT-001 Low Dose|Comparison of different dosages of FT-001
223480105|NCT05858983|GENETIC|FT-001 Mid Dose|Comparison of different dosages of FT-001
223480106|NCT05858983|GENETIC|FT-001 High Dose|Comparison of different dosages of FT-001
223480107|NCT00333528|DRUG|Human butyrylcholinesterase (HuBChE) derived from human plasma|Intramuscular administration
223480108|NCT00333528|DRUG|Placebo: Normal saline|Intramuscular administration
223480109|NCT01542762|DRUG|LMWH|"Each hospital will use a LMWH according to their own preferences.~Prophylactic dosage of LMWH (for example nadroparin 2850 IE s.c.) once daily for the duration of the immobilization (average 6 weeks). If the patient's weight is more than 100kg a double dose of LMWH will be given (in case of Nadroparin 5700 IE s.c. once daily)."
223480110|NCT01132508|DEVICE|Norian Drillable Bone Void Filler|Norian Drillable Bone Void Filler is a moldable, biocompatible bone void filler with added reinforcing fibers. Norian Drillable is intended to be placed into bony voids either before or after final fixation. The material can be drilled and tapped, and screws can be placed through it at any time during the setting process. Norian Drillable is a composite, two-component, self-setting calcium phosphate bone void filler
223480111|NCT01714115|DRUG|Aflibercept|2.0 mg Intravitreal Injection, every 2 to 4 weeks
223480112|NCT04660045|DRUG|Acalabrutinib|Acalabrutinib, oral, 100 mg BID, continuous
223480113|NCT05105347|DRUG|Adalimumab plus different doses of oral glucocorticosteroid|A loading dose of 80mg adalimumab will be given subcutaneously and then change to 40mg adalimumab every two weeks. Medium dose oral glucocorticosteroid (30mg/d prednisone or equivalent) will be given to the experimental dose group and high dose oral glucocorticosteroid (60mg/d prednisone or equivalent) will be given to the high dose group.
223480114|NCT06001879|OTHER|Simulation in basic life support training (SBLST)|The interventional tools, simulation in basic life support training (SBLST), were prepared in English. The researcher will use an already established BLS training from the American Guidelines 2020, a simplified two-part; PowerPoint presentation, and clinical simulation training.
223480115|NCT06001879|OTHER|standard treatment by using an AHA-BLS 2020 brochure|The participants will read and understand this brochure over 30 minutes, including a brief guideline about basic life support guidelines, and after these 30 minutes, the participants will move to the post-test
223480116|NCT05998135|DRUG|Atovaquone|Given PO
223480117|NCT05998135|PROCEDURE|Biopsy|Undergo biopsy
223480118|NCT05998135|PROCEDURE|Computed Tomography|Undergo CT
223480119|NCT05998135|PROCEDURE|Paracentesis|Undergo paracentesis
223480120|NCT02414126|OTHER|Effect of CPAP on respiratory work and cardiac function indices during wakefulness|"Comparison of three periods of 3 hours~1. st period: Spontaneous breathing for 10 minutes~2. nd period: CPAP for 10 minutes~3. rd period: Spontaneous breathing for 10 minutes to check the return to baseline.~After each period, the following parameters will be recorded during 5 minutes:~* oesogastric pressures~* air flow~* gas exchange~* right and left cardiac function~Patients \> 6 years old will assess their dyspnea on a visual analogue scale"
223480121|NCT02414126|OTHER|Effect of CPAP on respiratory work and cardiac function indices during wakefulness|"Comparison of three periods of 3 hours~1. st period: Spontaneous breathing for 10 minutes~2. nd period: CPAP for 10 minutes~3. rd period: Spontaneous breathing for 10 minutes to check the return to baseline.~After each period, the following parameters will be recorded during 5 minutes:~* oesogastric pressures~* air flow~* gas exchange~* right and left cardiac function~Patients \> 6 years old will assess their dyspnea on a visual analogue scale"
223480122|NCT02414126|OTHER|Effect of CPAP on respiratory work and cardiac function indices during wakefulness|"Comparison of three periods of 3 hours~1. st period: Spontaneous breathing for 10 minutes~2. nd period: CPAP for 10 minutes~3. rd period: Spontaneous breathing for 10 minutes to check the return to baseline.~After each period, the following parameters will be recorded during 5 minutes:~* oesogastric pressures~* air flow~* gas exchange~* right and left cardiac function~Patients \> 6 years old will assess their dyspnea on a visual analogue scale"
223480123|NCT02414126|DEVICE|CPAP|
223480124|NCT06514989|DIETARY_SUPPLEMENT|Low-residue full nutrition formula podwer|The day before the colonoscopy, subjects were given a low-residue full nutrition formula podwer instead of a traditional self-prepared low-residue diet. Subjects were given 6 packs (60g/pack) pre-packaged FNFP and asked to use the FNFP according to individual needs. The 2 liters of polyethylene glycol solution is taken in split dosing, with 1 liter taken at 8pm the day before the colonoscopy and 1 liter taken 3-5 hours before the colonoscopy.
224167653|NCT06725004|DRUG|Human Chorionic Gonadotropin|Injection Human Chorionic Gonadotropin 5000 IU intramuscular as trigger for ovulation induction
223480125|NCT06514989|DIETARY_SUPPLEMENT|Self-prepared low-residue diet|Subjects in the self-prepared Low-residue diet group were instructed to follow and prepare an Low-residue diet in the day prior to colonoscopy. The 3 liters of polyethylene glycol solution is taken in split dosing, with 1 liter taken at 8pm the day before the colonoscopy and 2 liter taken 4-6 hours before the colonoscopy.
223480126|NCT05896332|DEVICE|Active, Open Label iTBS-rTMS|Participants in this group will receive 10 sessions of iTBS-rTMS per day, 5 days per week for one week (50 sessions total)
223480127|NCT03729362|BIOLOGICAL|Cipaglucosidase Alfa|Participants received an intravenous (IV) infusion dose over a 4-hour duration every 2 weeks (Q2W).
223480128|NCT03729362|DRUG|Miglustat|Participants received weight-based doses 1 hour prior to cipaglucosidase alfa infusion Q2W.
223480129|NCT03729362|BIOLOGICAL|Alglucosidase Alfa|Participants received an IV infusion dose over a 4-hour duration Q2W.
223480130|NCT03729362|DRUG|Placebo|Miglustat matching placebo was administered orally 1 hour prior to alglucosidase alfa infusion Q2W.
223480131|NCT06814730|DRUG|THN391|THN391, IV infusion, 3\*Q4W (every 4 weeks)
223480132|NCT06814730|DRUG|Placebo|Placebo for comparison with THN391, IV infusion, 3\*Q4W
223584714|NCT01266590|DRUG|Digoxin|Administered orally
223584715|NCT04274335|DRUG|Tranexamic Acid 100Mg/Ml Inj Vil 10Ml|1 gram of tranexamic acid to be administered intravenously
223584716|NCT04274335|DRUG|Tranexamic Acid Oral Solution|4 grams of tranexamic acid given as an oral solution
223584717|NCT04274335|DRUG|Tranexamic Acid Injectable Product|1 gram of tranexamic acid given as 2 separate intramuscular injection
224314196|NCT03621501|DEVICE|Percutaneous coronary intervention|At the index procedure, the culprit lesion (cause of complaints/acute coronary syndrome) will be treated according to standard of care with a Biotronik Orsiro DES (Sirolimus-Eluting stent). If there are additional significant lesions besides the culprit lesion, patients will be randomized to direct complete revascularization or staged complete revascularization. In the direct complete revascularization group all lesions will be treated during the index procedure. In the staged complete revascularization group, only the culprit lesion will be treated during the index procedure. The remaining significant lesions will be treated later but within six weeks after the index procedure. In both arms the additional lesions will also be treated with Biotronik Orsiro DES (Sirolimus-Eluting stent).
223480133|NCT06784934|DEVICE|NeuroSky Mindfulness-Based Neurofeedback|NeuroSky will monitor participants' brain response to the intervention and provide feedback based on the participants' performance. Neurofeedback Intervention: When practicing the mindfulness-based intervention, NeuroSky will provide instructions before beginning the sessions. Dr. Saul will assist with set up and answer any questions. The apps audio and visual feedback will assist the participants as they practice mindfulness meditation. Participants in the experimental group will practice for 10 minutes in the lab during Sessions 1 and 5 and then at home for 10-20 minutes daily for 4 weeks with weekly 10-minute virtual check-ins with Dr. Saul to ensure acceptability and feasibility. Dr. Saul will also monitor participants' progress using the secure participant portal and de-identified usernames available through NeuroSky.
223480134|NCT05954312|DRUG|VVD-130037|Oral tablets
223480135|NCT05954312|DRUG|Docetaxel|IV infusion
223480136|NCT05954312|DRUG|Paclitaxel|IV infusion
223480137|NCT01701310|DRUG|Ferric carboxymaltose|A minimum of 1 dose of 1000mg of intravenous ferric carboxymaltose will be administered at least 14 days prior to the date of operation.
223480138|NCT01701310|DRUG|Ferrous Sulphate|(Control) 200mg twice a day of oral ferrous sulphate will be administered for a minimum of a two week period
223480139|NCT05502887|DIAGNOSTIC_TEST|Sublingual in vivo microscopy with the Glycocheck microscope|For the collection of longitudinal microscopy data, sublingual in vivo microscopy with the Glycocheck microscope will be performed at the following timepoints: 2-3 x between day (D) -28 of allogeneic HSCT or CAR T cell therapy and before start of the conditioning regimen, once between D2-D14, once between D15-28, once between D30- D100 and at the onset of endothelial complications such as acute GvHD, TMA, sepsis, VOD and IPS following allogeneic HSCT or CAR T cell therapy. Sublingual microscopy requires 15-30 minutes and is similar to sublingual temperature measurement. To this extent, a tube with a diameter of approximately 1cm carrying a microscope at the tip is inserted into the mouth and under the tongue to measure endothelial structures (blood flow through small capillaries). Biological samples are collected and processed within the established Biobank of the Internal Medicine V of the Heidelberg University Hospital.
223480140|NCT00322322|DRUG|L-Carnitine|L-Carnitine
223480141|NCT05367999|DIAGNOSTIC_TEST|initial Paroxysmal Event Profile|The initial Paroxysmal Event Profile (iPEP) was derived from the paroxysmal event profile (PEP) and paroxysmal event observer (PEO) to provide a diagnostic tool aiming to differentiate between the most common underlying reasons for TLOC presentations: syncope, epilepsy, and dissociative seizures. The iPEP is a 35-item questionnaire developed from the PEP and PEO.5,25 The 5-point frequency scales used in response to each symptom in the PEP and PEO have been replaced with a binary 'present'/'not present' classification in recognition of the fact that the target patient group may have experienced only one or a few episodes of TLOC.
223480142|NCT02382302|DEVICE|Telemedicine system|The data such as photographs can be collected simply using built-in cameras installed in smart-phones that used the standard touch-screen user interface (UI) and camera installed in the iPhone3GS and iPhone4 using iOS 3.0 and iOS 5.0, respectively. Subjects were instructed to transmit the photographs of the wounds then investigator performed the photography in such a manner that the size of pressure ulcer should be automatically measured based on a 1 cm x 1 cm-sized indicator on the screen.
223480143|NCT02530840|BEHAVIORAL|medical team|Lowering HbA1c by behavioral changes in meetings with the medical team.
223480144|NCT02530840|BEHAVIORAL|peers group|Lowering HbA1c by behavioral changes in meetings with the peers group.
223480145|NCT02530840|BEHAVIORAL|SMS notification|Lowering HbA1c by behavioral changes in meetings with the SMS notification
223480146|NCT04861298|DRUG|standard of care for COVID-19 as per the hospital guidelines|Hospital standard of care treatment for COVID-19
223480147|NCT04861298|DIETARY_SUPPLEMENT|Quercetin Phytosome (QP)|Daily dose of 600 mg of Quercetin for 1st week and then 400 mg for the 2nd week
223480148|NCT05608434|BEHAVIORAL|Floreo Virtual Reality application|Floreo VR is a novel VR-based cognitive training therapy for ADHD. It incorporates multiple learning modules, each of which targets a neuropsychological domain relevant to ADHD (inhibitory control, working memory, temporal processing, processing speed). The demands of the training intervention adapt to the subject s practice-driven improvements in performance. Specifically, when the subject is deemed to perform adequately well at a given level of difficulty, the training adapts by presenting a more challenging difficulty. This adaptation to the subject s performance is designed to allow for continued incremental improvements in the trained domains. The VR games take place in a spaceship themed environment. The VR training is designed to be used at home, under the supervision of a parent.
223584718|NCT02706197|DEVICE|OxyChip|The OxyChip is an investigational device to assess oxygen level in tissues, when measured with Electron Paramagnetic Resonance (EPR).
224167654|NCT07041723|BEHAVIORAL|Visual-acoustic biofeedback for Sibilants|Participants will view a real-time FFT spectrum and will be cued to match a visual target for /s/ where the spectral energy is concentrated to the right side of the display, primarily in the 5000-10,000 Hz region of the spectrum. Practice will occur in blocks of 10 consecutive trials on the same item (e.g., 10 /sa/), after which a new item will be addressed (e.g., 10 /se/). Within each block, the clinician will provide qualitative (knowledge of performance) feedback as prompted by the research team's custom open-source software, Challenge Point Program (CPP). The CPP software prompts clinician actions such as delivery of knowledge of performance (KP) feedback. Following each block of ten trials, the software automatically tallies the scores entered by the clinician and uses the summed scores to make adaptive changes in practice difficulty.
224167655|NCT06732362|OTHER|Different DPN ratings|According to the TCSS grading scale, DPN patients were graded into different grades, and the mild and severe groups and the control group were selected to observe the clinical effects between the three groups
224167656|NCT06733506|DRUG|Chlorhexidine gluconate|"Chlorhexidine gluconate (CHG) is a cationic bisguanide that works through disruption of cell membranes. CHG has broad spectrum activity against gram-positive bacteria and to a lesser extent gram negative bacteria. CHG has significant residual activity and addition of alcohol based preparations results in even greater residual activity compared to alcohol alone. CHG acts in the presence of organic material (e.g., blood and biofilm) and its antimicrobial activity is slower than that of alcohols.~Prevantics® 1 ml Swab contains a cutaneous solution of 3.15% w/v chlorhexidine gluconate (CHG) and 70% v/v isopropyl alcohol (IPA), which is commonly used for the preparation of a patient's skin prior to surgery or venipuncture. Prevantics® Swab is available as a single use pre-moistened 2-sided applicator (1.0 ml)."
223584719|NCT02783170|BIOLOGICAL|Tetanus, Diphtheria, and Pertussis Vaccine|
224167657|NCT06733506|DRUG|Isopropyl Alcohol 70% Topical Application Solution|Isopropyl alcohol (IPA), a topical skin disinfectant, is effective against many pathogens and is commonly supplied as 2x2 inch pre-soaked, single-use gauze wipes.
224167658|NCT06733506|BEHAVIORAL|Skin Prep Before Injecting Recreational/Street Drugs|During a single 10 minute session, a healthcare provider gives the participant verbal and written information, counseling, and training to reinforce participant knowledge, motivation, and skills to practice skin swabbing correctly and routinely before injecting.
223480149|NCT02711137|DRUG|INCB057643|Initial cohort dose of INCB057643 at the protocol-specified starting dose (Part 1), with subsequent dose escalations based on protocol-specific criteria. The recommended treatment group-specific dose(s) will be taken forward into expansion cohorts (Part 2).
223480150|NCT02711137|DRUG|Gemcitabine|Standard of Care (SOC) agents
223480151|NCT02711137|DRUG|Paclitaxel|Standard of Care (SOC) agents
223480152|NCT02711137|DRUG|Rucaparib|Standard of Care (SOC) agents
223480153|NCT02711137|DRUG|Abiraterone|Standard of Care (SOC) agents
223480154|NCT02711137|DRUG|Ruxolitinib|Standard of Care (SOC) agents
223480155|NCT02711137|DRUG|Azacitidine|Standard of Care (SOC) agents
223480156|NCT01113749|OTHER|Feeding Options in Dementia Decision Aid|Structured decision aid on feeding options in dementia care with prompting to share information in discussion with primary treating health care provider.
223480157|NCT03770819|PROCEDURE|Photodynamic therapy|"Zinc oxide gel/placebo gel will be placed into the periodontal pockets using a blunt cannula ensuring that starting from the bottom, it completely fills the periodontal pockets. The gel will be retained in the pocket for 5 minutes. The perio tip will be attached to the hand piece of the light cure unit (Wavelength: 420-480nm. Light power: 1200mw/cm2 in continuous mode) and light will be activated for 60 seconds. Following this, the pockets will be irrigated with normal saline solution (0.9%Sodium chloride).~For groups 1 and 2, sham PDT will be performed by directing the Light cure device without turning on the light beam."
223480158|NCT04723862|DRUG|Spironolactone|Spironolactone is an androgen-receptor blocker commonly used (off-label) for hyperandrogenism. The spironolactone dose will be 50 mg taken orally twice daily (for two weeks before admission to the Clinical Research Unit).
223480159|NCT04723862|DRUG|Placebo|Placebo contains only inert ingredients and is not expected to exert any direct physiological effects.
224167659|NCT03607604|GENETIC|Next generation sequencing (NGS)|Patients will be tested for known MODY genes with specific focus on HNF1A, GCK and HNF4A genes. Furthermore, gene panel testing may be performed for any known diabetes genes.If the results are negative, WES/WGS will be performed in patients suspected of having MODY for identification of novel MODY mutations.
223480160|NCT05413317|OTHER|Color Doppler Ultrasound|Comparison with conventional diagnosis strategy including a clinical probability score, D-dimers and chest imaging.
223480161|NCT03427892|DRUG|Brexpiprazole|Brexpiprazole is an atypical antipsychotic drug that is used to treat mental/mood disorders.
223480162|NCT00548327|DRUG|Atomoxetine|Comparison between Atomoxetine and Placebo
223480163|NCT00548327|PROCEDURE|Functional magnetic resonance imaging|Comparison between Atomoxetine and Placebo arms
223480164|NCT00548327|PROCEDURE|Neuropsychological Testing|Comparison between Atomoxetine and Placebo arms
223480165|NCT00548327|DRUG|Placebo|25 mg, 40 mg, 60 mg and 80 mg Atomoxetine Placebo
223480166|NCT02287428|RADIATION|Radiation Therapy|Standard radiotherapy (approximately 60 Gy over 6 weeks)
223480167|NCT02287428|BIOLOGICAL|Personalized NeoAntigen Peptides|NeoVax Vaccine (Personalized NeoAntigen Peptides + Poly-ICLC) will be administered on an individual basis using a dosing schedule that incorporates both priming and boost phases.
223480168|NCT02287428|DRUG|Pembrolizumab|Pembrolizumab will be administered every 3 weeks at a flat dose of 200 mg intravenously. Pembrolizumab should be administered as a 30 minute IV infusion (Pembrolizumab treatment cycle intervals may be increased due to toxicity per protocol).
223480169|NCT02287428|DRUG|Temozolomide|Concurrent Temozolomide (TMZ) = 75 mg/m2/day for 6 weeks, administered with XRT
223480170|NCT02287428|DRUG|Temozolomide|Adjuvant Temozolomide (TMZ) = 150 mg/m2/day on days 1-5 of each 28-day cycle for up to 6 adjuvant cycles
224167660|NCT00962468|OTHER|COPD evidence based care pathway|A care pathways, as complex intervention, will be implemented.
223480171|NCT02287428|BIOLOGICAL|Poly-ICLC|NeoVax Vaccine (Personalized NeoAntigen Peptides + Poly-ICLC) will be administered on an individual basis using a dosing schedule that incorporates both priming and boost phases.
223480172|NCT04475276|DRUG|Placebo|Lifestyle modification with placebo for 12 weeks
223480173|NCT04475276|DRUG|Alphalipoic acid|Lifestyle modification with Alphalipoic acid for 12 weeks
223480174|NCT05096377|OTHER|ESP block|ESP block performed using ultrasound guidance. Diaphragmatic excursion was measured using M-mode ultrasound during normal breathing, deep breathing and with the sniff manoeuvre.
223480175|NCT02314546|DRUG|Midazolam|"Study participants will be randomly assigned to one of three treatment groups:~* Group 1 - Placebo - Control patients will receive intranasal saline.~* Group 2 - Nasal Midazolam Only - Patients will receive 0.2 mg/kg of intranasal midazolam.~* Group 3 - Midazolam Plus Xylocaine - Patients will receive 0.2 mg/kg intranasal midazolam plus xylocaine 4% in a dose based on 25% of the volume of the midazolam."
223480176|NCT02314546|DRUG|xylocaine|Midazolam Plus Xylocaine - Patients will receive 0.2 mg/kg intranasal midazolam plus xylocaine 4% in a dose based on 25% of the volume of the midazolam.
223480177|NCT02314546|DRUG|saline placebo|Placebo - Control patients will receive intranasal saline.
223480178|NCT00274456|DRUG|ABI-007|ABI-007 administered by intravenous infusion over 30 minutes at one of three different dosing levels (100, 150 or 300 mg/m\^2) with a treatment cycle length of either 3 or 4 weeks depending upon treatment arm assignment.
223480179|NCT00274456|DRUG|Docetaxel|Docetaxel dosed q3w at 100 mg/m\^2
223480180|NCT00629577|GENETIC|microarray analysis|
223584720|NCT02783170|BIOLOGICAL|2016-2017 Quadrivalent Inactivated Influenza Vaccine|
223480181|NCT00629577|OTHER|flow cytometry|
223480182|NCT00629577|PROCEDURE|biopsy|
223480183|NCT00629577|PROCEDURE|colposcopy|
224167661|NCT06738485|BIOLOGICAL|Recombinant single-chain factor VIII (rVIII-SingleChain)|Lyophilized powder for solution for intravenous injection
224167662|NCT07048808|COMBINATION_PRODUCT|XC001|XC001 administered by percutaneous catheter delivery using the Extroducer® Infusion Catheter System.
224314197|NCT01724489|DRUG|Growth hormone|
223480184|NCT03255187|DIETARY_SUPPLEMENT|Fish oil supplementation|Participants of this randomized double-blind placebo-controlled trial include 70 healthy Chinese adults. The investigators randomly assign participants to two parallel groups at baseline using a random-number table. Compliance is determined by directly observed supplement intake. Participants in fish oil group are assigned to receive 2.5 g/day in divided doses. Each capsule contains 60% n-3 PUFA \[24% docosahexanoic acid (C22:6 n-3 DHA) and 36% eicosapentaenoic acid (C20:5 n-3 EPA)\].
223480185|NCT03255187|DIETARY_SUPPLEMENT|Sunflower seed oil supplementation|Participants of this randomized double-blind placebo-controlled trial include 70 healthy Chinese adults. The investigators randomly assign participants to two parallel groups at baseline using a random-number table. Compliance is determined by directly observed supplement intake. Participants in sunflower seed oil group receive 2.5 g/day in divided doses, and the capsules are identical as the fish oil capsules.
223480186|NCT03231176|DRUG|Varlitinib|oral tablets, twice daily
223480187|NCT03231176|DRUG|Capecitabine|oral tablets, twice daily for 2 weeks followed by a 1-week rest period in 3-week cycles
223480188|NCT02664688|OTHER|Lumbar stabilization exercises|"The home-exercise program included an initial phase, with use of therapeutic heat via a hot pack for 15 minutes at the lumbosacral region, stretching exercises of the thoracolumbar fascia, hip flexors, hamstrings plus the stabilization exercises to encourage stabilizing motor patterns and determine the neutral position of the spine, with the target in control of transversus and internal oblique abdominis, multifidus, pelvic floor muscles, and diaphragmatic breathing control. Progression stages included hot packs, stretching exercises, and lateral, anterior bridges, leg raises in supine position, and arm and leg lifts in quadruped position (bird-dog)"
223480189|NCT02664688|OTHER|Flexor exercises|The home-exercise program included a hot pack for 15 minutes and flexor exercises routine
223480190|NCT04571489|DRUG|Gimatecan|Patients will receive gimatecan orally at 0.8mg/m2 on day 1-5 every 4 weeks.
223480191|NCT04571489|DRUG|tegafur, gimeracil and oteracil potassium|Patients will receive tegafur, gimeracil and oteracil potassium orally at 40 or 60mg twice daily on days 1 to 14 every 3 weeks.
223480192|NCT04571489|DRUG|gemcitabine|Patients will receive gemcitabine IV at 1000mg/m2 on days 1、8 every 3 weeks.
223480193|NCT00375752|DRUG|Letrozole|2.5 mg.tablet.
223480194|NCT00375752|DRUG|Zolendronic Acid|4 mg or an adjusted dose based on renal function in 100 ml physiologic (o.9%) normal saline, (as an intravenous infusion over no less than 15 minutes)
223480195|NCT01933724|DRUG|5 mg prednisone|Subjects will be randomized to take 5 mg per day of prednisone for a 6 month period.
223480196|NCT01933724|DRUG|0 mg prednisone|Subjects will be randomized to taper their prednisone dose to no prednisone for a 6 month period.
223480197|NCT04167813|DRUG|Ondansetron 8mg or matched placebo tablets|"Participants will take one tablet daily in weeks 1 and 2, two tablets daily in weeks 3 and 4 and 3 tablets daily in weeks 5 and 6.~Dose escalation will be guided by tolerability, through telephone safety monitoring prior to each dose increase"
223480198|NCT06094036|BEHAVIORAL|Structured and personalized program of physical exercise|"In line with the most recent guidelines, exercise prescription will require the clear definition of modality, intensity, frequency, duration and progression of exercise, tailored on patient's clinical conditions and goals.~This intervention will be accompanied by a nutrition program aiming for proper dietary habits in terms of both quantity and quality."
223480199|NCT03369782|DRUG|Rocuronium|rocuronium is administered in bolus and continuous infusion
223480200|NCT03369782|DRUG|Sugammadex|Sugammadex is administered just before reduction of the joint
223480201|NCT03369782|DRUG|Placebo|"Placebo is administered as alternative to rocuronium in a bolus and in a syringe pump.~Placebo is administered as alternative to sugammadex"
223480202|NCT05726253|DRUG|Supportive Care + Amoxicillin|Participants will be randomized to receive oral amoxicillin for a standard course (7 days)
223480203|NCT05726253|DRUG|Supportive Care + Placebo (no antibiotics)|Participants will be randomized to receive oral placebo for a standard course (7 days)
223480204|NCT02034006|DRUG|Ranibizumab|All patients received a single initial intravitreal injection of ranibizumab 0.5 mg/0.05 ml as per Committee for Human Medicinal Products (CHMP)approval. Further injections might have been required when monitoring reveals disease activity. Disease activity, defined as reduced visual acuity and/or signs of lesion activity, was evaluated based on clinical examination (BCVA, fundus), and/or optical coherence tomography (OCT), and/or fluorescein angiography (FAG). Bilateral treatment was allowed provided at least 14 days of intercurrence.
223584721|NCT02783170|BIOLOGICAL|2017-2018 Quadrivalent Inactivated Influenza Vaccine|
223584722|NCT06081894|DRUG|Aficamten|Oral Tablet
223480205|NCT00109343|BIOLOGICAL|Comparator: ProQuad™ (V221)|0.5-mL subcutaneous injection of measles, mumps, rubella, varicella virus vaccine live (MMRV)
223480206|NCT00109343|BIOLOGICAL|Comparator: PREVNAR™ (pneumococcal 7-valent conjugate vaccine)|0.5-mL intramuscular injection of pneumococcal 7-valent conjugate vaccine
223584723|NCT06081894|DRUG|Placebo|Oral Tablet
223584724|NCT02870738|PROCEDURE|Pelvic Floor Physical Therapy|Internal and/or external myofascial release of the pelvic floor muscles
223584725|NCT02870738|DRUG|Bladder Instillations|A solution of heparin sulphate 40,000 IU (4 cc of 10,000 units/cc), lidocaine 2% 16 ml, Sodium bicarbonate 8.4% 4 ml and Kenalog 40 mg (1cc) to reach a total fluid volume of 25 ml will be instilled into the bladder with a urinary catheter
224314198|NCT01724489|DRUG|Placebo|
224314199|NCT04576923|DIAGNOSTIC_TEST|Velacur by Sonic Incytes|liver stiffness measurement
223584726|NCT05006833|BEHAVIORAL|Brief Provider Training - Bundled Approach|At each clinic randomized to bundled training, providers will be invited to participate in one, in-clinic, group-based training. Each training will last one-hour and providers will receive continuing medical education (CME) credit for participating. Trainings will focus on introducing the HPV vaccine in a bundle of the other two adolescent vaccines (Tdap and MenACWY).
223584727|NCT05006833|BEHAVIORAL|Brief Provider Training - Benefits Approach|At each clinic randomized to benefits training, providers will be invited to participate in one, in-clinic, group-based training . Each training will last one-hour and providers will receive continuing medical education (CME) credit for participating. Trainings will focus on providers presenting the HPV vaccine as safe, best if received at 11- to 12-years of age, and prevents cancer.
223584728|NCT05006833|BEHAVIORAL|Parent Interactive Text Message - Bundled Approach|Text messages sent to parents will focus on receiving all three adolescent vaccines.
224167663|NCT07048808|COMBINATION_PRODUCT|Sham (No Treatment)|Subjects randomized to the sham catheterization procedure group will receive the same procedure as the treatment group (with introduction of an iliofemoral or radial sheath, positioning of the pigtail catheter in the left ventricle, generation of ventriculograms, and mimicking of the injection procedure by the interventional team following a Cath Lab script), except they will not have the delivery catheter inserted and will not receive any endocardial injections
224167664|NCT07050589|BEHAVIORAL|Exercise and art|Weekly SMARTfit dual-task exergaming and group art-making
223480207|NCT03740893|DRUG|AZD6738|"PART 1: Pre-operative exposure of 160mg AZD6738 to be administered orally twice daily on Days 5 -14 of the WOP.~PART 2: 12 months post-operative exposure to 160mg AZD6738 to be administered orally twice daily on Days 1 - 14 of a 28 day cycle.~AZD6738 was removed as intervention under investigation as of 06 August 2024 (due to formal closure of cohort B)"
223480208|NCT03740893|DRUG|Olaparib|"PART 1 (cohort C, and cohorts E-G): Pre-operative exposure to 300mg of olaparib to be administered orally twice daily on Days 1-14 of the WOP.~PART 2 (cohort C, and cohorts F and G): 12 months post-operative exposure to 300mg olaparib (2 x 150mg tablets) to be administered orally twice daily on a continuous schedule Day 1-28 of a 28 day cycle.~Cohort C was formally closed to recruitment since 06 August 2024."
223480209|NCT03740893|DRUG|Durvalumab|"PART 1 (cohort D): Pre-operative exposure to 1500mg durvalumab to be administered via intravenous (IV) infusion on Day 1 only of the WOP.~PART 2 (cohorts A and D, and cohorts F and G): 12 months post-operative exposure to 1500mg durvalumab to be administered via intravenous (IV) infusion on Day 1 only of a 28 day cycle.~Cohorts A and D were formally closed to recruitment since 06 August 2024."
223480210|NCT02983123|PROCEDURE|1-hour hs-cTnT|
223480211|NCT03729284|DRUG|Cymbalta Capsules|Active Comparator: Cymbalta®- hard gelatinous capsule with delayed release microgranules ( Eli Lilly do Brasil Ltda) equivalent to 60 mg of duloxetine.
223480212|NCT03729284|DRUG|Duloxetine Hydrochloride Capsules|Experimental Drug: Duloxetine hydrochloride - hard gelatinous capsule with delayed release microgranules (Pfizer S.R.L - Argentina.) equivalent to 60 mg of duloxetine.
223480213|NCT00750269|RADIATION|SBRT 40.0 Gy|SBRT delivered in 5 fractions of 8.0 Gy/fraction over 1.5 to 2 weeks for a total of 40.0 Gy
223480214|NCT00750269|RADIATION|SBRT 42.5 Gy|SBRT delivered in 5 fractions of 8.5 Gy/fraction over 1.5 to 2 weeks for a total of 42.5 Gy
223480215|NCT00750269|RADIATION|SBRT 45.0 Gy|SBRT delivered in 5 fractions of 9.0 Gy/fraction over 1.5 to 2 weeks for a total of 45.0 Gy
224167665|NCT07047300|DIAGNOSTIC_TEST|Record EMG maximum amplitude from bilateral erector spinae, rectus femoris, and medial and lateral gastrocnemius muscles.|"Conduct measurements under two conditions:~Condition 1: Standing with standardized flat shoes. Perform three trials for each participant. Calculate and record the mean as baseline data. Condition 2: Standing with a standardized heel lift insole inside the flat shoes.~Conduct three trials. Record the mean for comparative analysis."
224167666|NCT07047300|DIAGNOSTIC_TEST|Photograph participants from anterior and lateral views to assess knee valgus angle and lumbosacral angle.|"Capture two sets of photographs for each participant:~Set 1: Wearing flat shoes. Set 2: Wearing the heel lift insole inside the flat shoes. Compare knee valgus angle and lumbosacral angle under both conditions. Ensure consistency and reliability by following standardized protocols and performing repeated measurements.~Analyze the effects of heel lift insoles on muscle activity and postural alignment."
224167667|NCT07044388|BEHAVIORAL|Coping with asthma through life management program|Participants will complete surveys, learn stress coping strategies, receive asthma education information, and obtain access local community financial resources.
224167668|NCT07044388|BEHAVIORAL|Waitlist Control (CALM)|Participants in this group will complete surveys but will not receive the CALM intervention. Upon completing the study after 12 weeks they will be able to complete the program if they would like the resources/materials to learn healthy stress coping strategies, asthma health education, and access to financial resources.
224167669|NCT07048262|BIOLOGICAL|CSL787|CSL787 high or low doses once daily (QD) will be administered via inhalation over a period of \>= 6 months but not exceeding 12 months.
224167670|NCT07048262|DRUG|Placebo|Participants will receive a matching volume of placebo QD over a period of \>= 6 months but not exceeding 12 months.
223480216|NCT00750269|RADIATION|SBRT 47.5 Gy|SBRT delivered in 5 fractions of 9.5 Gy/fraction over 1.5 to 2 weeks for a total of 47.5 Gy
223480217|NCT00750269|RADIATION|SBRT 50.0 Gy|SBRT delivered in 5 fractions of 10.0 Gy/fraction over 1.5 to 2 weeks for a total of 50.0 Gy
223480218|NCT00750269|RADIATION|SBRT 52.5 Gy|SBRT delivered in 5 fractions of 10.5 Gy/fraction over 1.5 to 2 weeks for a total of 52.5 Gy
223480219|NCT00750269|RADIATION|SBRT 55.0 Gy|SBRT delivered in 5 fractions of 11.0 Gy/fraction over 1.5 to 2 weeks for a total of 55.0 Gy
223480220|NCT00750269|RADIATION|SBRT 57.5 Gy|SBRT delivered in 5 fractions of 11.5 Gy/fraction over 1.5 to 2 weeks for a total of 57.5 Gy
223480221|NCT00750269|RADIATION|SBRT 60.0 Gy|SBRT delivered in 5 fractions of 12.0 Gy/fraction over 1.5 to 2 weeks for a total of 60.0 Gy
223480222|NCT01447966|BEHAVIORAL|Cognitive Behavioral Therapy|Family based cognitive behavioral therapy with exposure and response prevention. Twice weekly for 45-60 minute visits.
223480223|NCT03889132|PROCEDURE|Bariatric Surgery|Subjects with obesity (N=60) will be undertaken a hypocaloric diet and a periodic follow up, also 30 of them will undergo bariatric surgery
223480224|NCT00185159|DRUG|Olmesartan medoxomil|tablets
223480225|NCT00185159|DRUG|Placebo Tablets|Tablets
223480226|NCT05759871|OTHER|GnRH antagonist|The GnRH antagonist in the control group (standard therapy) is administered from day 6 of FSH treatment at the dose of 0.25 mg per day until the triggering day and is injected each time immediately after the injection of FSH.
223480227|NCT04555447|DIETARY_SUPPLEMENT|Agavins (prebiotic fiber)|Agavins contained in ready-to-use sachets were dissolved in water, and participants consumed the corresponding dose daily (2.5, 5.0, 7.0, 10 or 12 g) for 1 week, preferentially in the evening. Participants followed a 5-week dose-escalation intervention.
223480228|NCT04555447|DIETARY_SUPPLEMENT|Placebo|Maltodextrin contained in ready-to-use sachets was dissolved in water, and participants consumed the corresponding dose daily (2.5, 5.0, 7.0, 10 or 12 g) for 1 week, preferentially in the evening. Participants followed a 5-week dose-escalation intervention.
223480229|NCT03069664|PROCEDURE|ERCP|endoscopic retrograde cholangiopancreatography
223480230|NCT03069664|DEVICE|Covered Self-expandable Metal Stent|Pancreatic duct stent
223480231|NCT06469086|OTHER|Clinical data collection|The clinical significance of appendicoliths in the conservative management of acute complicated appendicitis with abscesses.
223480232|NCT00662337|DRUG|Diphenhydramine hydrochloride|After a ten-hour fast and a one-hour fluid restriction prior to each dosing period, subjects received supervised dosing of their first 25 mg treatment with approximately eight ounces of water. Following a seven-day washout, the comparison treatment was administered according to thye same procedure.
223480233|NCT04294823|DIAGNOSTIC_TEST|Helicobacter Pylori Diagnostic|"Helicobacter Test INFAI with standard test Meal (1g citric acid as test meal and 75 mg C\^13 urea)~\+ The C\^13 UBT with the new test (REFEX). All patients will take Nexium mups (40 mg) orally once daily 30 min before breakfast from day 1 to 28."
223480234|NCT04294823|DEVICE|Vital signs measurments|No description;
223480235|NCT04294823|DIAGNOSTIC_TEST|endoscopy|Upper endoscopy where 6 biopsy samples will be obtained . Two biopsies will be taken from antrum and corpus for histology. The biopsies will be stained with Haematoxylin \& Eosin and Giemsa stains, and gastritis wilt be scored using the Updated Sydney System 12,13 Two biopsies will be taken from antrum and corpus for rapid urease test (RUT) and two biopsies will be taken from antrum and corpus for culture. All biopsy samples will be analysed in the local laboratory of the centre.
223480236|NCT04294823|DRUG|Nexium Pill|patients will take Nexium mups 40 mg orally once daily, 30 min before breakfast Nexium mups 40 mg will be discontinued after Day 28.
223480237|NCT04084704|DEVICE|Cingal|Cingal will be administered by fellowship-trained physicians through ultrasound-guided injection using a 21-gauge needle into the joint space of the hip under sterile conditions. The needle track will be anesthetized with local anesthetic.
223480238|NCT05054387|DRUG|Agalsidase beta|Powder for concentration into a solution Intravenous (IV) infusion
223480239|NCT05596175|BEHAVIORAL|Super Rehab|A 12-month healthcare-delivered lifestyle intervention involving exercise, nutritional support and optimisation of AF-related clinical risk factors.
223480240|NCT00297011|DRUG|valacyclovir+clobetasol gel|
223480241|NCT00938938|OTHER|Press Guide|The press guide is a 1-page summary of the study findings, written by the investigators.
223480242|NCT03625674|BEHAVIORAL|explanation when prescribing psychoactive medicine|explanation of the pathogenesis of FD and the mechanism of psychoactive medicine
224167671|NCT07048262|DEVICE|Nebulizer|The nebulizer is a CE-marked device.
224167672|NCT06745882|DRUG|Cisplatin|Given on day 1 of every 21-day cycle.
224167673|NCT06745882|DRUG|Carboplatin|Given on day 1 of every 21-day cycle.
224167674|NCT06745882|DRUG|Pemetrexed|Given on day 1 of every 21-day cycle.
223480243|NCT02746861|BEHAVIORAL|Peer-Supported DSMS|Phone, SMS/text, and smartphone-based intervention.
223480244|NCT05848284|DEVICE|VDyne Transcatheter Tricuspid Valve Replacement System|The study investigational device is the VDyne Transcatheter Tricuspid Valve Replacement System which consists of a bioprosthetic implantable tricuspid valve, the VDyne Delivery System, Drop Tether, accessories that facilitate the placement of the valve and the VDyne Retrieval System. The VDyne Valve is deployed by transfemoral implantation within the native tricuspid valve and is implanted under fluoroscopic and transesophageal echocardiography (TEE) guidance, while the heart remains beating, without the use of CPB. The valve is repositionable and fully retrievable intraoperatively. Repositioning allows optimization of the valve position following deployment, and retrieval, with the VDyne Retrieval System, allows use of an alternative valve size or removal of the index VDyne Valve in the event of suboptimal valve delivery or other intraoperative complication.
223480245|NCT04638244|BEHAVIORAL|Music|Brief Online Music
223480246|NCT04638244|BEHAVIORAL|Reading messages|Reading psychoeducational messages
223584729|NCT05006833|BEHAVIORAL|Parent Interactive Text Message - Benefits Approach|Text message will state that the HPV vaccine prevents cancer, is safe and effective, and is recommended for 11- to 12-year-olds.
223584730|NCT03320330|OTHER|Laboratory Biomarker Analysis|Correlative studies
223584731|NCT03320330|BIOLOGICAL|Pepinemab|Given IV
223584732|NCT03320330|OTHER|Pharmacological Study|Correlative studies
223480247|NCT06492837|DRUG|Mosunetuzumab in combination with Zanubrutinib|Combinations of Mosunetuzumab and Zanubrutinib as salvage strategy in patients with relapsed/refractory follicular lymphoma who have received at least one line of prior systemic therapy.
223480248|NCT05425979|DRUG|Mepivacaine|Up to two 30 ml vials of mepivacaine 1.5% via ultrasound-guided nerve blockade of the tibial and deep peroneal nerves
223480249|NCT05425979|DRUG|Bupivacaine|Up to two 30 ml vials of bupivacaine 0.5% via ultrasound-guided nerve blockade of the tibial and deep peroneal nerves
223480250|NCT02967029|DRUG|Esmolol Hydrochloride|the influence of brevibloc as a hypotensive agent on rSO2
223480251|NCT02967029|DRUG|Remifentanil Hydrochloride|the influence of remifentanyl as a hypotensive agent on rSO2
223584733|NCT01885910|DRUG|Doxycycline 100mg|Doxycycline 100mg by mouth once daily
223584734|NCT01885910|DRUG|Aczone 5% gel|Aczone 5% gel twice daily
223584735|NCT04437992|GENETIC|NIPT|The test, which requires two 10 ml tubes of blood, will be performed simultaneously with the chemical biomarkers of the combined test at 10-12 weeks of gestation
224167675|NCT06745882|DRUG|Pembrolizumab|Given on day 1 of every 21-day cycle. After cycle 4 is given every 6 weeks.
223584736|NCT00258466|RADIATION|radiation therapy|
224167676|NCT06745882|DRUG|Abraxane|Given on days 1, 8, and 15 of each 21-day cycle.
224167677|NCT06745882|DRUG|Paclitaxel|Given on day 1 of every 21-day cycle.
224167678|NCT00826709|DEVICE|fluID Rapid Influenza Test|The fluID™ Rapid Influenza Test is an in vitro diagnostic assay designed to be used with a reader for the qualitative detection of influenza type A and type B nucleoprotein antigens, and the differentiation of influenza type A subtypes A/H1 and A/H3 antigens associated with the seasonal influenza H1N1 and H3N2, in nasal swabs, nasopharyngeal swabs and nasal wash/aspirate specimens. The test is intended as an aid in the rapid, qualitative diagnosis of influenza type A and type B viral infections in patients symptomatic with influenza-like illness. The fluID™ Rapid Influenza Test is intended for use by a healthcare professional in a laboratory or Point-of-Care (POC).
224167679|NCT04737707|OTHER|Dialectical Behavior Therapy (DBT)|Dialectical Behavior Therapy (DBT)
224167680|NCT07052552|OTHER|osteopathic manipulative tratment only|focuses on restoring proper muscle balance and joint mechanics through techniques that address the shortened, tight muscles and the lengthened, weak muscles characteristic of the syndrome
224167681|NCT07052552|OTHER|ujjayi pranayama and osteopathic manipulative treatment|"Ujjayi pranayama, often called ocean breath, can be a helpful practice for individuals with Upper Cross Syndrome (UCS) by promoting relaxation and improving breath control. While not a direct cure, it can alleviate some symptoms and improve overall posture and body awareness.~Osteopathic manipulative treatment focuses on restoring proper muscle balance and joint mechanics through techniques that address the shortened, tight muscles and the lengthened, weak muscles characteristic of the syndrome"
224167682|NCT02466204|DRUG|corifollitropin alfa|Drug is injected subcutaneously. Seven days after, 300 IU FSH daily injected subcutaneously, until at least two leading ovarian follicles reach 17mm in diameter.
223480252|NCT04155554|DRUG|Bictegravir/emtricitabine/tenofovir alafenamide|Switch patients from dolutegravir/lamivudine/abacavir to bictegravir/emtricitabine/tenefovir alafenamide to study neuropsychiatric side effects and neurocognitive function
223480253|NCT04155554|DRUG|Dolutegravir/lamivudine/abacavir|Continuing dolutegravir/lamivudine/abacavir to study neuropsychiatric side effects and neurocognitive function
223480254|NCT02361931|DRUG|A hydrogel containing erythropoietin|Standard of wound care, which includes initial debridement, wound cleansing, pressure relief, and infection control. RMD-G1 applied daily onto a clean wound at 0.25g per sq.cm. of wound surface. After its application, the wound is covered with a dressing in order to prevent leakage of the gel and contamination of the wound area.
223480255|NCT02361931|DRUG|Hydrogel (as a part of SOC)|Standard of wound care, which includes initial debridement, wound cleansing, pressure relief, and infection control. Hydrogel applied daily onto a clean wound at 0.25g per sq.cm. of wound surface. After its application, the wound is covered with a dressing in order to prevent leakage of the gel and contamination of the wound area.
223480256|NCT03417297|DEVICE|High Intensity Focused Ultrasound|Participants will undergo high intensity focused ultrasound surgery utilizing magnetic resonance (MR) imaging guidance using a 3 Tesla scanner.
223480257|NCT05138575|DRUG|Empagliflozin + Potassium Chloride|"Empagliflozin is the active intervention that may improve mitochondrial function and energy fuel metabolism in skeletal muscle.~KCl is an active control."
223480258|NCT05138575|DRUG|Empagliflozin + Potassium Nitrate|Empagliflozin + KNO3 is the active intervention that may improve mitochondrial function and energy fuel metabolism in skeletal muscle, as well as increase skeletal muscle perfusion during exercise.
223480259|NCT05138575|DRUG|Potassium Chloride + Placebo for Empagliflozin|Active control.
223480260|NCT03588624|DEVICE|TearCare|The TearCare procedure includes the delivery of thermal energy to the external surface of the eyelids for 15 minutes, immediately followed by manual expression of each eyelid.
223480261|NCT05051839|PROCEDURE|Implant surgery and restoration|Implants with two different transmucosal neck configuration are placed.
223480262|NCT04060836|DRUG|Xyntha|Recombinant Coagulation Factor VIII Injection produced by Pfizer Inc.
223584737|NCT06264856|PROCEDURE|bronchoscopic sputum suction|"Bronchoscopy is a medical procedure in which a flexible tube called a bronchoscope is passed through the mouth or nose and into the lungs. Bronchoscopic suction is a technique used during bronchoscopy to remove secretions, mucus, or foreign objects from the airways.~The bronchoscope is equipped with a suction port and a suction channel that allows the doctor to remove fluids or other material from the airways. The suction port is connected to a vacuum source, and the suction channel runs through the bronchoscope and terminates at the tip of the instrument."
223584738|NCT06264856|PROCEDURE|negative pressure aspiration suction|The procedure involves inserting a catheter into the airway and applying negative pressure to the catheter to suction out the secretions or fluids. The patient could receive sputum suction as medical routine (every 2-4 hrs) if needed.
223584739|NCT04349956|DRUG|UBX0101 or placebo|This is an observational study. No intervention is administered.
223584740|NCT02796508|BEHAVIORAL|Experimental: Non-action video game training|PSI2013-41409R. Effects of video game training on behavioral and neuroimaging measures of attention and memory
223584741|NCT02796508|BEHAVIORAL|Active Comparator: Non-cognitive video game training|16 training sessions with The Sims over 8-10 weeks in small groups
223584742|NCT06777303|DRUG|curcurmin loaded on chitosan nano-particles|the formulation of curcumin and incorprating it with chitosan nano-particles will increase the absorption rate in the gingival sulcus
224167683|NCT02466204|DRUG|Follitropin Beta|Drug is injected subcutaneously, daily, until at least two leading ovarian follicles reach 17mm in diameter.
224167685|NCT06860815|PROCEDURE|Biopsy|Undergo tumor biopsy
224314200|NCT06369597|PROCEDURE|Robotic telesurgery|Telesurgery by domestic surgical robot
224314201|NCT06369597|PROCEDURE|Laparoscopic surgery|Local laparoscopic surgery
224314202|NCT00128271|DRUG|Bavituximab|
223480263|NCT04060836|DRUG|Recombinant Coagulation Factor VIII Injection|A kind of Recombinant Coagulation Factor VIII Injection produced by sponsor.
223480264|NCT04823104|OTHER|Home visitation|Home visitation for pregnancy follow-up
223480265|NCT03117127|BEHAVIORAL|Resistance Exercise|Participants will perform leg extension and leg press immediately prior to ingestion of whole eggs or egg whites
223480266|NCT03117127|OTHER|Whole Eggs|Participants will ingestion whole eggs immediately after resistance exercise
223480267|NCT03117127|OTHER|Egg Whites|Participants will ingestion whole eggs immediately after resistance exercise
223480268|NCT05188508|DRUG|Pembrolizumab|Patients will receive pembrolizumab 200mg IV on day 1 (± 3days) of each cycle. Pembrolizumab will continue every 21 days (± 3 days) throughout the trial.
223480269|NCT05188508|COMBINATION_PRODUCT|Olaparib and Temozolomide|Olaparib and temozolomide will begin on cycle 3 day 1 and continue through cycle 11. Olaparib will be dosed 200mg orally twice a day (bid) days 1-7 each cycle. Temozolomide 50 mg/m2 will be administered orally days 1-7 each cycle.
223480270|NCT02871596|OTHER|Placebo|A combination of maltodextrins and red and blue food colors.
223480271|NCT02871596|DIETARY_SUPPLEMENT|Flavonoids|A combination of blueberry extract, black current extract, and black rice extract.
223480272|NCT02871596|DIETARY_SUPPLEMENT|Flavonoids+Prebiotics|A combination of blueberry extract, black current extract, black rice extract, inulin, and fructooligosaccharide.
224167686|NCT06860815|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
224167687|NCT06860815|BIOLOGICAL|Cemiplimab|Given IV
224167688|NCT06860815|PROCEDURE|Computed Tomography|Undergo CT
224305337|NCT04140435|DEVICE|EUS-guided through-the-needle microbiopsy forceps (Moray)|"EUS-TTNB procedure technique. An endosonographer of each institution will perform the EUS procedures. Cysts morphology will be recorded and then punctured by using a 19-gauge EUS-FNA needle. Then the through-the-needle microbiopsy forceps (Moray) will be inserted through the needle into the cystic lumen. Microbiopsies will be obtained from the cyst wall randomly and from mural nodules or septae when observed. The open jaws of the forceps will be pushed onto the cyst wall, closed and pulled back to cause visible tenting. Two bites per pass will be obtained. Then the forceps will be removed and the specimen placed in formalin vials. The procedure will be repeated 2 times, or until 2 visible specimens are obtained. After completion of biopsies, the cyst fluid will be completely aspirated and sent for CEA, amylase, glucose and cytology analyses. If a mural nodule is visualized on EUS, it will be accessed separately by using the 19-gauge needle for EUS-FNA cytology."
223480273|NCT00912119|DRUG|Epsilon-Aminocaproic Acid|Group C (high dose) will receive a loading dose of EACA of 100 mg/kg over ten minutes followed by a continuous EACA infusion at 40 mg/kg/hr, which will be continued until the end of surgery.
223480274|NCT00912119|DRUG|Epsilon-Aminocaproic Acid|Group A (low dose) will receive a loading dose of EACA of 25 mg/kg over ten minutes followed by a continuous EACA infusion at 10 mg/kg/hr, which will be continued until the end of surgery
223480275|NCT00912119|DRUG|Epsilon-Aminocaproic Acid|Group B (intermediate dose) will receive a loading dose of EACA of 50 mg/kg over ten minutes followed by a continuous EACA infusion at 20 mg/kg/hr, which will be continued until the end of surgery
223480276|NCT00912119|DRUG|Epsilon-Aminocaproic Acid|Group D (extra low dose) will receive a loading dose of EACA of 12.5 mg/kg over ten minutes followed by a continuous EACA infusion at 5 mg/kg/hr, which will be continued until the end of surgery
223480277|NCT02857920|DRUG|Bevacizumab|7.5 mg/kg, i.v, once every 3 weeks (continuous)
223480278|NCT02857920|BIOLOGICAL|NK immunotherapy|Each treatment: 8\~10 billion cells in all, transfusion in 3 times, i.v.
223480279|NCT02686255|OTHER|complete blood count|complete blood count during follow up in the heart institute
223480280|NCT05767970|BEHAVIORAL|Integrated Stress Toolbox for Healthcare Providers (ISTH)|The ISTH is a 12-week meditation-based well-being training. In weeks 1-8, participants engage in weekly 2-hour class sessions that are recorded and posted on a private Youtube channel for one week. There is a final two-hour session at week 12. In-class learning is augmented and extended through content in a special version of the Healthy Minds Program smartphone app that participants are asked to use on a daily basis throughout the intervention.
223480281|NCT01527669|DRUG|LipoCol Forte capsules|The pharmacokinetic study of red yeast rice capsule compared to lovastatin tablet in healthy subjects.
223480282|NCT01527669|DRUG|Lovastatin Tablet|The pharmacokinetic study of red yeast rice capsule compared to lovastatin tablet in healthy subjects.
223480283|NCT02100631|BIOLOGICAL|PXVX0200|
223480284|NCT02100631|BIOLOGICAL|Placebo|
223480285|NCT06422780|OTHER|Maternal Role Preparation Training|Maternal Role Preparation Training: Maternal Role Preparation Training (MRHE) is an occupational training programme aimed at increasing the competence of first-time mothers regarding motherhood. In this four-session programme, pregnant women will be provided with written materials, face-to-face talks and practical training covering topics related to their babies (maternal attachment, training on the sensory and developmental abilities of babies) and themselves (training on adopting a new role as a mother).The sessions will be applied 2 days a week, each session 1 hour, a total of 8 weeks-16 sessions.
223584743|NCT06777303|DRUG|hyaluronic acid loaded on chitosan nano-particles|the formulation of hyaluronic acid and incorprating it with chitosan nano-particles will increase the absorption rate in the gingival sulcus
223480286|NCT06422780|OTHER|Awareness Centred Occupational Therapy Group|Awareness Centred Occupational Therapy (FME); In FME, areas that affect the occupational performance of pregnant women in their daily lives will be identified and appropriate occupational therapy interventions will be applied. Awareness training on the applications will be given before starting the sessions. The sessions will be applied 2 days a week, each session 1 hour, a total of 8 weeks-16 sessions. Awareness training will be given before starting the sessions.
223480287|NCT06721247|DRUG|Magnesium|oral intake of magnesium for asthmatic patients with dose 200 mg per day for one year in addition to usual asthmatic treatment according to GINA guidelines 2024
223584744|NCT06777303|PROCEDURE|scaling and root planning|the -ve control group in the study
223584745|NCT06777303|DRUG|chitosan nano-particles|the +ve control group in the study
223584746|NCT05816395|DRUG|RHH646|RHH646 capsule for oral use
223584747|NCT05816395|DRUG|Placebo|RHH646 placebo capsule for oral use
223584748|NCT06078956|DEVICE|Measuring of analytes|Method Comparison Study for pH, pCO2, pO2, cCa2+, cCl-, cK+, cNa+, cGlu, cLac, ctHb, sO2, FO2Hb, FMetHb, FCOHb and FHHb in whole blood in adult population.
223584749|NCT06578234|DRUG|Adenosine|Standard dose 140 μg/kg/min and high dose 210 μg/kg/min adenosine
223584750|NCT04538313|DRUG|Tumor infiltrating lymphocyte|Tumor infiltrating lymphocytes were isolated from tumor tissues from tumor biopsy or operation. These TILs were cultured in human IL-2 medium for 4 to 5 weeks. 10e9 to 10e10 TILs were yielded. The phenotype, function and sterile were detected before these TILs infused patients.
223584751|NCT03893877|DEVICE|nasal cannula|experimental group will be applied nasal cannula
223584752|NCT03893877|DEVICE|nasal mask|active comparator group will be applied nasal mask
223584753|NCT01943006|DRUG|Hirudoid cream 0.3 % Mucopolysaccharide polysulfate|Hirudoid cream
223584754|NCT01943006|DRUG|Placebo cream without active substance|
223584755|NCT06341010|PROCEDURE|Angiojet Rheolytic Thrombectomy in The Management of Iliofemoral Deep Venous Thrombosis|Angiojet Rheolytic Thrombectomy in The Management of Iliofemoral Deep Venous Thrombosis
224167689|NCT06860815|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
224167690|NCT06860815|RADIATION|Transarterial Radioembolization|Undergo TARE
224167691|NCT06860815|RADIATION|Yttrium Y 90 Resin Microspheres|Given intratumorally
224167692|NCT07061691|DEVICE|WIM Robotic Exoskeleton|Wearable hip-powered exoskeleton
224167693|NCT06898450|DRUG|NDI-219216|NDI-219216 is a highly selective small molecule inhibitor of WRN helicase activity.
224305338|NCT00110526|GENETIC|Ad.hIL-12|Ad.hIL-12 intraprostatic injection IND
223480288|NCT06721247|DRUG|ICS+LABA|inhaled corticosteroids with long acting Beta 2 agonist are given to control group patients twice daily
223480289|NCT02340676|PROCEDURE|Extracorporeal Photopheresis (ECP)|Participants receive ECP treatment twice a week for 16 weeks
224167694|NCT06763627|OTHER|Gamification ( Board game )|"A three- or four-player board game will be designed to teach acute cholecystitis and pancreatitis. The game has two stages: educational (houses 1-9) and reinforcement (houses 10-30). Players roll dice and move their pieces to answer various questions such as multiple-choice, true/false, matching, puzzles, and scenario-based problem-solving. Each player starts with three hearts, and if they land on one of the three red trap spaces and answer incorrectly, they lose one heart. Yellow spaces introduce random events like gaining or losing hearts. One space features a general knowledge question for variety. Players must achieve a point threshold in the educational section to move to the reinforcement section, and the highest scorer at the end of the hour wins. Groups of 3 or 4 students will play for one hour under the supervision of the investigator."
224167695|NCT06763627|OTHER|Traditional lecture-based teaching|Students will attend a standard one-hour lecture delivered by a general surgery faculty member, covering the same topics. PowerPoint presentations prepared by the research team will ensure consistency with the game content.
224167696|NCT06784791|DRUG|Amivantamab Intravenous|Stage 1: Pre-operative amivantamab monotherapy Stage 2: Pre-operative amivantamab treatment plus chemotherapy (carboplatin/pemetrexed)
224167697|NCT06784791|DRUG|Carboplatin/Pemetrexed|Stage 2: Pre-operative amivantamab plus chemotherapy (carboplatin/pemetrexed)
224167698|NCT02978638|DEVICE|Finetech Vocare Bladder System|Participants will be implanted with the existing FDA-approved Finetech Vocare Bladder System stimulator and electrodes.
224167699|NCT05977322|DRUG|68Ga-FF58|Kit for radiopharmaceutical preparation of 68Ga- FF58 solution for injection
224167700|NCT05977322|DRUG|177Lu-FF58|Solution for injection/infusion
224167701|NCT02659098|DRUG|CNTO 2476 3.0 x 10^5 cells|Participants will receive a single subretinal administration of CNTO 2476 3.0 x 10\^5 cells in 50 microliter (mcL) given by subretinal Delivery System.
224167702|NCT02659098|DEVICE|Subretinal Delivery System|Participants will receive CNTO 2476 by using the Delivery System.
224167703|NCT04363944|DEVICE|mRehab|mRehab (mobile Rehab) was created to better support in-home upper limb rehabilitation programs. It incorporates a task-oriented approach and immediate performance-based feedback. mRehab consists of 3D-printed household items (a mug, bowl, key, and doorknob) integrated with a smartphone and an app. The app guides participants through practice of activities of daily living (ADL), for example, sipping from a mug. It can also consistently measure time to complete an activity and quality of movement (smoothness/accuracy) during the performance of ADLs. In each session of exercise participants receive feedback on the number of repetitions they complete for each activity, the average time to complete the activity and the average smoothness to perform the activity. Participants were trained in use of mRehab in lab visits and then took mRehab home to use the system. mRehab recorded longitudinal data.
224167704|NCT07077213|COMBINATION_PRODUCT|18F-FAPI-74|10 millicurie (mCi) of 18F-FAPI-74 in adult tuberculosis patient followed by a PET/CT scan, performed during the first 6 weeks of treatment and a second dose of 10 millicurie (mCi) of 18F-FAPI-74 in adult tuberculosis patient followed by a PET/CT scan within 6 weeks after tuberculosis treatment completion.
224167705|NCT06823193|BEHAVIORAL|Mental Time Travel task|"A psychophysical task (D'Angelo et al., 2023) will be adopted. In this task, a projection in time will be induced by faces of different ages. Face stimuli will be presented with a short sentence describing a particular life event, commonly occurring around 60. Participants will perform a two-alternative forced-choice task under two experimental conditions. In the past projection condition, they will indicate whether it is likely or unlikely that the person of the face shown could have experienced the indicated event 10 years earlier. In the future projection, they will indicate whether it is likely or unlikely that the person depicted will experience the indicated event in 10 years."
223480290|NCT02340676|DRUG|Interleukin-2|Participants receive daily IL-2 injections starting Week 8 of study and ending at Week 16
224167706|NCT06823193|BEHAVIORAL|Age Estimation control task|In this task participants will estimate the age of the faces adopted as stimuli.
224167707|NCT06823193|BEHAVIORAL|Lifeline task|In this task participants will be instructed to associated each event with the age at which they believe it typically occurred.
224167708|NCT06748144|DRUG|Intraosseous Vancomycin|The intervention is specific to the method of administration that will be used when giving the dose of antibiotic vancomycin which is done to prevent infection following surgery.
224167709|NCT06748144|DRUG|Intravenous Vancomycin|This is the standard method of giving the antibiotic vancomycin to patients undergoing surgery across many specialties in order to prevent infection.
224167710|NCT05681442|DRUG|continuous pivotal βL-AB|continuous pivotal βL-AB
224167711|NCT05681442|DRUG|intermittent pivotal βL-AB|intermittent pivotal βL-AB (IID = control group)
224305339|NCT01447420|DRUG|peginterferon alfa-2a|180 mcg sc weekly, 48 weeks
224305340|NCT01447420|DRUG|ribavirin [Copegus]|1'000 or 1'200 mg orally daily, 48 weeks
224305341|NCT00430820|PROCEDURE|per intervention|per intervention
223480291|NCT04533581|DRUG|ME-401|In the first 2 cycles (1 cycle is 28 days), subjects will be administered 60 mg of ME-401 orally once a day on a continuous schedule (CS). After that, subjects will be administered 60 mg of ME-401 orally once a day for the first 7 days, followed by rest for 21 days on an intermittent schedule (IS).
223480292|NCT06074835|DEVICE|Gamete preparation, ICSI, embryo culture and vitrification robot assistant|Patients undergoing an assisted conception treatment with medical indication to perform ICSI may be recruited in this study. The study will follow a sibling-oocyte and/or sibling embryo study design where oocytes and/or embryos obtained from a specific patient or couple will be randomly distributed across two groups (test and control) and undergo one or more elements of an automated assisted conception laboratory workflow (for the test group) or a standard assisted conception laboratory workflow (for the control group). Before distributing the samples, an embryologist will slightly blur the vision of the samples so that their morphology can no longer be clearly assessed. Robotic automation may include any of the following steps: robotic sperm preparation, robotic oocyte selection and denudation, robotic sperm injection, automated embryo culture, and automated cryopreservation. The resulting embryos may be employed for embryo transfer.
224305342|NCT04312386|OTHER|OPTIMAT|Baseline menue, not optimized
224305343|NCT02592135|OTHER|hsTnT level|hsTnT and NTproBNP levels at baseline and baseline plus 3 hours.
223480293|NCT06074835|OTHER|Routine Manual ICSI Workflow|Routine Manual Icsi Workflow
223480294|NCT06471010|OTHER|Blended Dynamic Interpersonal Therapy (B-DIT)|The B-DIT intervention, developed collaboratively by Dutch mental health care institute De Viersprong and OnlinePsyHulp (http://www.onlinepsyhulp.be), integrates FTF therapy and online modules into a cohesive treatment program for clients with personality pathology. Both FTF and online treatment components are anchored in the Dynamic Interpersonal Therapy (DIT) framework (Lemma et al., 2011).The program spans three phases: an individual phase lasting approximately two months, followed by a five-month group phase, concluding with a four-month booster phase to reinforce positive changes. Face-to-face therapy sessions and online treatment modules are utilized alternately and complementarily throughout all treatment phases. Both verbal psychotherapy and art therapy are offered as treatment modalities in the face-to-face treatment sessions. The program is implemented by a multidisciplinary team.
223480295|NCT03944616|BEHAVIORAL|Diet Beverage|Participants will receive and consume three daily servings (24 ounces) of a non-caloric commercial diet beverage of their choice sweetened with FDA approved artificial sweeteners.
223480296|NCT03944616|BEHAVIORAL|Water|Participants will receive and consume three daily servings (24 ounces) of plain bottled/canned water in place of their usual commercial diet beverage. The water will be unflavored, unsweetened, non-caloric, and may be plain or sparkling. Participants randomized to consume water will be instructed to avoid intake of diet beverages.
223480297|NCT01614652|DEVICE|CardioKinetix Parachute Implant and All Appropriate Medical Therapy (AAMT)|CardioKinetix Parachute implant and all appropriate medical therapy
223480298|NCT05707221|OTHER|cleaning removable acrylic appliance with denture brush and chlorhexidine toothpaste|mechanical cleaning of removable appliance by the patient for 7 days before bedtime for one minute
223480299|NCT05707221|OTHER|cleaning removable acrylic appliance with cleansing tablet|chemical cleaning by patient for 7 days with cleansing tablet
224071908|NCT03644433|PROCEDURE|Double layer closure after resection uterine scar|Uterine incision will be trimmed and old scar tissue will be removed. Then first, endometrium will be approximated by continuous unlocked suture mimicking subcuticular suture avoiding the inclusion of endometrium and second, upper part of myometrium will be approximated by a continuous unlocked suture.
223480300|NCT05707221|OTHER|combination of mechanical and chemical cleaning|cleaning the appliance with denture brush and CHX toothpaste followed by the cleansing tablet
223480301|NCT03000972|PROCEDURE|Cement augmentation|
223480302|NCT03000972|PROCEDURE|PFN-A Nail|
224071909|NCT06064344|DRUG|Rituximab|Intralesional Rituximab Injection
224071910|NCT06064344|RADIATION|Involved Site Radiation Therapy|Involved Site Radiation Therapy
224071911|NCT04357106|BIOLOGICAL|Convalescent plasma|Convalescent plasma obtained by aphaeresis from recovered patients.
224071912|NCT01980472|BIOLOGICAL|bevacizumab, carboplatin and paclitaxel|4-6 initial cycles of bevacizumab, carboplatin and paclitaxel bevacizumab until progression or toxicity
224071913|NCT06565156|OTHER|BR-AM|BR-AM is a single-layer amniotic membrane allograft. BR-AM is manufactured by BioStem Technologies, Inc. and is processed by the bioREtain method which, briefly, includes initial disinfection, processing with isotonic solutions, dehydration at 37-40°C and electron beam sterilization.
224071914|NCT06565156|OTHER|Standard Care|"Standard of care is defined as:~* Debridement,~* Wound cleansing with a neutral, non-irritating and non-toxic solution,~* Non-adherent wound contact layer, a foam pad, alginate or hydrofiber dressing for moderately draining wounds, a secondary retention bandage, and~* An off-loading device."
224071915|NCT00521521|DRUG|docetaxel and cisplatin|
224071916|NCT00521521|DRUG|docetaxel|
224071917|NCT00870337|DRUG|everolimus|
224071918|NCT04858893|DIAGNOSTIC_TEST|CoMDA associated with Neural Net 91 classificator|
224071919|NCT01144585|PROCEDURE|remote ischemic preconditioning and postconditioning|"RIPC is done before the use of CPB. It consists of 4 cycles of 5 minutes inflation of pneumatic cuff to 200 mmHg and deflation for 5 minutes. RIPoC is exactly same procedure done after CPB."
224071920|NCT01144585|PROCEDURE|Control|This group has same pneumatic cuff during the surgery, but it is not inflated during the surgery
224071921|NCT02070861|OTHER|Ventricular pacing and passive leg raise|Ventricular pacing and passive leg raise
224071922|NCT03546855|DRUG|Apatinib|Apatinib 500mg/d po,28 days as one cycle
224071923|NCT03253263|DRUG|OHB-607|Participants will receive intravenous infusion of OHB-607 from birth up to PMA 29 weeks + 6 days.
224071924|NCT04022382|DEVICE|Restylane Defyne|Restylane is a gel of hyaluronic acid generated by Streptococcus species of bacteria, chemically crosslinked with BDDE, stabilized and suspended in phosphate buffered saline at pH=7 and concentration of 20 mg/mL.
224071925|NCT06327373|DRUG|Oxygen|Supplemental oxygen by oxygen concentrator
224071926|NCT06327373|DRUG|Room air|Room air without oxygen concentrator
224071927|NCT02392013|OTHER|Home Modification|Removal of home barriers or hazards.
224071928|NCT00639249|DRUG|placebo|Oral administration
224071929|NCT00639249|DRUG|SA4503 Low|Oral administration
224071930|NCT00639249|DRUG|SA4503 High|Oral administration
224071931|NCT00925015|BIOLOGICAL|Dalotuzumab 10 mg/kg|Dalotuzumab at 10 mg/kg was intravenously administered once weekly
224071932|NCT00925015|BIOLOGICAL|Cetuximab|Following pre-treatment with a histamine-receptor antagonist, Cetuximab was administered with an initial intravenous infusion of 400 mg/m\^2, followed by subsequent once weekly intravenous infusions of 250 mg/m\^2
224071933|NCT00925015|DRUG|Irinotecan|Irinotecan was administered with an intravenous infusion of 150 mg/m\^2, once every other week for 42 days
224071934|NCT00925015|BIOLOGICAL|Dalotuzumab 15/7.5 mg/kg|Dalotuzumab was intravenously administered, with the first infusion of 15 mg/kg, followed by subsequent infusions of 7.5 mg/kg
224071935|NCT04252430|DRUG|MD1003|Single oral dose administration of MD1003 at Day 1
224071936|NCT05499559|BEHAVIORAL|Joint Academy digital treatment|The Joint Academy® (www.jointacademy.com) program for people with hand OA consists of video instructed and progressively adaptable daily exercises, patient education through text lessons, possibility for a social chat group with other patients and a continuous asynchronous chat function with a personal reg. physiotherapist who supervises the patient during the full participation period. The program also contains three telephone consultations with a physiotherapist that were compulsory, one at the start, one after six weeks and one after three months.
223480303|NCT00668616|DRUG|Cyclophosphamide, Epirubicin, Paclitaxel|4 cycles of 600 mg/m² cyclophosphamide i.v. and 90 mg/m2 Farmorubicin i.v. on day 1, q21d followed by 4 cycles of 175 mg/m² Taxol, day 1, q21d
223480304|NCT00668616|DRUG|Epirubicin, Paclitaxel, Filgrastim|cycle 1-4: 120 mg/m² Epirubicin i.v. on day 1, q14d, 5 µg/kg s.c. filgrastim day 5-10 (if leucocytes are lower than 10000/µl) cycle 5-8: 175 mg/m² Paclitaxel i.v. on day 1, q14d, 5 µg/kg s.c. filgrastim day 5-10 (if leucocytes are lower than 10000/µl)
223480305|NCT04037605|DRUG|Ketoconazole Pill (also known as nizoral)|Ketoconazole pill is taken 4 times per inpatient visit
223480306|NCT04037605|DRUG|Ganirelix|Ganirelix subcutaneous injection is administered twice per inpatient visit
223480307|NCT04037605|DRUG|Dexamethasone Pill|Dexamethasone pills is taken twice per inpatient visit
224071937|NCT06582745|DRUG|Trametinib|Participants will be given trametinib as a single agent once a day dosing, with a maximum dose of 2kg. Participants who are able to swallow pills will be given oral tablets. Participants unable to swallow pills will be dispensed the liquid formula concentrate at 0.05mg/mL with dosing of 0.015mg/kg.
224071938|NCT03389971|PROCEDURE|catheter-directed thrombolysis|catheter-directed thrombolysis with commercially available multi-sidehole catheter or USAT catheter
224071939|NCT02200380|DRUG|CDX-301|Related donors will receive CDX-301 for 5 days or 7 days.
224071940|NCT02200380|DRUG|CDX-301 and plerixafor|Related donors will receive CDX-301 for 5 or 7 days plus plerixafor.
224071941|NCT05942092|PROCEDURE|Breast conserving surgery|Breast conserving surgery after lesion's localization with ROLL or magnetic seed
224071942|NCT06126627|BEHAVIORAL|Stress induction|Induction of anticipatory stress to compare voice and speech control and production with and without exposure to stress.
224071943|NCT02493348|DEVICE|Rhythmic Sensory Stimulation|Rhythmic Sensory Stimulation (RSS) can be delivered through sound devices. In this study, the stimuli will be delivered with a portable consumer device called Sound Oasis Vibroacoustic Therapy System (VTS) 1000 unit, which is a low-voltage consumer product device that has two built-in mid to high-frequency speakers and one built in low frequency (subwoofer-type) speaker. The low frequency sounds played by the subwoofer speaker is experienced as vibrotactile vibration. Although the Intervention of Interest in this study is the gamma-frequency acoustic-driven rhythmic sensory stimulation, the efficacy of the Sound Oasis VTS-1000 device to deliver this sound will also be observed.
224071944|NCT01049841|DRUG|perifosine + temsirolimus|The patient will take oral tablets of perifosine at a dose and frequency to be determined their height, weight and time when they enter the study as those entering early will be treated with lower dose levels (dosing frequency will vary from once a week to daily). The patient will receive an intravenous injection of temsirolimus once a week at a dose to be determined by their height, weight and time when they enter the study as those entering early will be treated with lower doses. In addition they will be asked to keep a medicine diary.
224071946|NCT03118297|DRUG|Ulipristal Acetate|Women who have bothersome bleeding with the etonogestrel implant will be randomized to receive ulipristal acetate versus placebo daily for 7 days.
224071947|NCT03118297|DRUG|Placebo oral capsule|Women who have bothersome bleeding with the etonogestrel implant will be randomized to receive ulipristal acetate versus placebo daily for 7 days.
224071948|NCT03733223|DRUG|Ateptidase|Treatment of ischemic stroke with Ateptidase
224071949|NCT05474300|OTHER|mechanical ventilation|Pressure controlled ventilation mode on mechanical ventilation
224071950|NCT02969798|DRUG|Dapagliflozin|10mg/day
224071951|NCT02969798|DRUG|Saxagliptin|5mg/day
224071952|NCT02969798|DRUG|Pioglitazone|the dose will increase from 15 mg/day to 30 mg/day at month two
224071953|NCT02969798|DRUG|Metformin|starting at 1000 mg/day and increased to 2000 mg/day at month 2.
224071954|NCT02792803|DRUG|Xalatan|A prostaglandin analogue used to reduce intraocular pressure in patients diagnosed with glaucoma.
224071955|NCT02792803|DRUG|Apo-Latanoprost|A prostaglandin analogue used to reduce intraocular pressure in patients diagnosed with glaucoma.
224071956|NCT02792803|DRUG|Co-Latanoprost|A prostaglandin analogue used to reduce intraocular pressure in patients diagnosed with glaucoma.
224071957|NCT03822975|DRUG|Bivalirudin|Bivaliruding 0.75 mg/kg intravenous bolus loading dose, and immediately followed by intravenous infusion of 1.75 mg/kg/h until 2-4 hours after PCI. It is recommended that ACT be monitored 5 minutes after the first administration, and if ACT is \<225 s (Hemotec method), intravenous injection of 0.35 mg/kg of bivalirudin should be administered, and the ACT re-checked to ensure it is \>225 seconds.
224071958|NCT03822975|DRUG|unfractionated Heparin|Heparin 70 U/kg is started before coronary angiography. ACT is monitored 5 min after the first administration, and if the ACT \<225 s (Hemotec method), an intravenous injection of 1000 U of heparin is administered, and the ACT re-checked to ensure it is \>225 seconds.
224071959|NCT01833130|BIOLOGICAL|OnabotulinumtoxinA|OnabotulinumtoxinA (botulinum toxin Type A) 155 U total dose per treatment injected into specified head and neck muscles on Day 1 followed by a second treatment at Week 12.
224071960|NCT01833130|DRUG|Normal saline (placebo)|Placebo (Normal saline) injected into specified head and neck muscles on Day 1 followed by a second treatment at Week 12.
224071961|NCT05346835|DRUG|Cilta-cel OOS Therapy|Ciltacabtagene Autoleucel (Cilta-cel) Out-of-Specification (OOS) will be provided as a one-time administration as an intravenous infusion.
224071962|NCT04514029|DRUG|Simvastatin|Simvastatin 40 mg started 2 weeks (+/-5 days) prior to apheresis through day +30
224071963|NCT04514029|DRUG|Dexamethasone|Intrathecal dexamethasone 8 mg on days -1, +6, +13 (+/-2 days)
224071964|NCT02959463|OTHER|Laboratory Biomarker Analysis|Correlative studies
224071965|NCT02959463|RADIATION|Palliative Radiation Therapy|Undergo palliative radiation therapy
224071966|NCT02959463|BIOLOGICAL|Pembrolizumab|Given IV
224071967|NCT02959463|RADIATION|Radiation Therapy|Undergo hemithoracic radiation therapy
224071968|NCT02118688|DRUG|Risperidone|
224071969|NCT02118688|DRUG|Trazodone|
224167712|NCT05681442|DRUG|AG infusion most 1 dose|AG infusion most 1 dose (AMT group )
224167713|NCT05681442|DRUG|AG infusion for 5 days|AG infusion for 5 days (ACT Group)
224167714|NCT07085975|DRUG|Adenosine 5'-triphosphate|Participants will inhale increasing doubling concentrations of adenosine 5'-triphosphate dissolved in 0.9% saline through the Aerogen Solo vibrating mesh nebulizer.
224167715|NCT00353327|PROCEDURE|Plasma infusion|
224167716|NCT07086560|DRUG|IV adenosine|Patients will not be randomized to intervention but will be categorized based on the exposure of IV adenosine for treatment of SVT received prior to study enrollment
224167717|NCT07086560|DRUG|IV diltiazem|Patients will not be randomized to intervention but will be categorized based on the exposure of IV diltiazem for treatment of SVT received prior to study enrollment
224167718|NCT06466876|BEHAVIORAL|retrieval-based word learning|Word learning intervention that compares two strategies for teaching novel words
224167719|NCT06853860|OTHER|reflexology massage|classic hand massage
223480308|NCT04037605|DRUG|Dexamethasone injection|Dexamethasone IV injection is given twice per inpatient visit
223480309|NCT04037605|DRUG|Cosyntropin Injectable Product|Cosyntropin injection is given twice per inpatient visit
223480310|NCT04037605|DRUG|Recombinant Human Luteinizing Hormone (also known as luveris)|Recombinant Human Luteinizing Hormone is given as 6 IV infusion pulses per inpatient visit
223480311|NCT04037605|DRUG|Hydrocortisone Injection (also known as solu-cortef)|Hydrocortisone IV push is given twice per inpatient visit
223480312|NCT04037605|DRUG|Gonadorelin (also known as Lutrepulse)|Gonadorelin IV injection is given twice per inpatient visit
223480313|NCT04037605|DRUG|Corticorelin (also known as Acthrel)|Corticorelin IV injection is given twice per inpatient visit
223480314|NCT04037605|DRUG|Placebo oral tablet|Placebo for Ketoconazole are given 4 times per inpatient visit
223480315|NCT04037605|DRUG|Saline Solution|Saline Solution (Placebo) for Dexamethasone IV injection or hydrocortisone IV injection given up to four times per inpatient visit
223480316|NCT04037605|DRUG|Saline solution for injection|Saline Solution (placebo) for ganirelix subcutaneous injection
223480317|NCT01721798|DEVICE|Mirena levonorgestrel IUD|Intrauterine contraception system
223480318|NCT01721798|DEVICE|Copper T-380a IUD|intrauterine contraception system
223480319|NCT01308515|DEVICE|Vanguard Knee System with AS Bearing|FDA cleared Tibial bearing that stabilizes the knee with an anterior lip, and is used with FDA cleared Vanguard CR (Cruciate Retaining) Femoral Component.
223480320|NCT01308515|DEVICE|Vanguard Knee System with PS Bearing|FDA cleared Tibial bearing that stabilizes the knee with a post that articulates with the FDA cleared Vanguard PS(Posterior Stabilizing) Femoral Component.
223480321|NCT02564341|BEHAVIORAL|Collaboration with an IT enabled nurse care manager|The nurse care manager at each site will collaborate with intervention physicians to implement key essential elements of guideline driven care, namely opioid treatment agreements, urine drug testing, random pill counts and periodic checking of on-line Prescription Monitoring Programs. The nurse care manager will use an electronic registry to retrieve pain medication information from the electronic medical record (EMR). Registry data will be collected on the patients of the intervention group providers. The nurse care manager will be able to use the registry to generate reports that will allow him/her to monitor those patients who are receiving opioids for chronic pain.
223480322|NCT02564341|BEHAVIORAL|Education and academic detailing|All intervention participants will receive a 60 minute group didactic session by a national expert on opioid prescribing for pain. Physicians will receive two academic detailing sessions, and will be given the option of having a third, booster academic detailing session if desired.
223480323|NCT02564341|BEHAVIORAL|Facilitated access to a specialist in addictions|The nurse care manager will encourage and arrange referral of challenging patients with potential abuse or dependence to prescription opioids to an addiction specialist.
223480324|NCT06833697|PROCEDURE|erector spinae plane block|"the ESP block will be administered after surgery but before the patient is awakened, under sterile conditions and ultrasound guidance.~Patient Positioning: The patient will be placed in the lateral position with the surgical side up, and a sterile ultrasound probe cover will be used.~Ultrasound Imaging: A high-frequency (11-12 MHz) linear probe will be placed transversely at the T5 thoracic vertebra.~Anatomy Identification: The erector spinae muscle and transverse processes will be visualized.~Needle Insertion: Using an in-plane technique, the needle will be advanced to the transverse process.~Injection: After confirming the needle position with 1-2 mL saline, 30 mL of 0.25% bupivacaine will be injected between the erector spinae muscle and transverse process, with spread monitored via ultrasound."
224071970|NCT02118688|DRUG|Placebo|
224071971|NCT06963216|BIOLOGICAL|Coagadex(R)|Coagulation Factor X (Human)
224071972|NCT04283669|DRUG|Crizotinib|Oral
224071973|NCT03987763|DRUG|IDP-122 Lotion|Topical
224071974|NCT04283123|BEHAVIORAL|Automated Bidet|During the first intervention visit, a licensed contractor will install the bidets in participants' homes. The OT will then educate and train the caregiver and care recipient to successfully use the bidet, and make any modifications to the remote as needed. Throughout the intervention, the OT will use motivational enhancement strategies. The OT will make minor modifications to the remote as needed. A second intervention visit will occur 1-2 weeks post-installation to address any new difficulties. Check-in phone calls will be offered to the caregiver and care recipient if needed.
224071975|NCT04283123|OTHER|No Intervention|Waitlist control
224071976|NCT03532516|DRUG|Brivaracetam|"Patients will start on the individual Brivaracetam (BRV) dose that they had reached at the completion of the previous study. The BRV dose can be adjusted based on the individual patient's seizure control and tolerability; however, the BRV dose may not exceed 200 mg/day in divided (preferably symmetrical) morning and evening doses, taken with or without food.~Up- and down-titration steps should be performed in steps of maximum 50 mg/day on a weekly basis. The full down-titration should include a 1-week step at 20 mg/day."
224071977|NCT02174055|BEHAVIORAL|Patient Interviews|participate in a brief interview
224071978|NCT02174055|BEHAVIORAL|newly developed questionnaire|10-16 patients will review draft items and participate in a cognitive interview. 15 older patients will complete the draft measure in order to generate preliminary psychometric data. All interviews will be audio recorded and transcribed by Ubiqus Transcription Company. The audio recordings are uploaded through Ubiqus's secure server and the transcribed audio is returned to the research staff within 48 hours.
223584756|NCT06120101|BEHAVIORAL|Reflexology Massage|The researcher washed his hands with an antibacterial soap before cleaning the patient's feet. The feet were cleaned according to the patient's preference; To wash feet with water or use disposable wet cloth. The patients were placed in a supine position on the bed in the room and their joint points were supported. The researcher stood at the end of the patient's bed during treatment. Unscented sesame oil at room temperature was used to provide lubrication during reflexology. The application started with the patient's right foot. The foot was first relaxed by applying effleurage, shaking, rotation and stretching methods. During the application, the researcher used the fingers of the other hand while supporting the patient's foot with one hand, and the thumb and caterpillar technique was mostly used. In other applications, the index finger and other fingers were used. The training ended by applying solar plexus pressure to both feet.
223584757|NCT05207163|BEHAVIORAL|Continuing medical education|Education section about knowledge of transmissions, severity of viral hepatitis B-C and update treatment strategy of the HBV-HCV
223584758|NCT04692077|DRUG|Cabotegravir (CAB) tablet|30 mg tablets
224167720|NCT06853860|OTHER|classic hand massage|classic hand massage
224305344|NCT05640219|DEVICE|laparoscopic trocar 12mm|long laparoscopic trocar 12mm (36 french) with central hole from its tip till its handle with transparent sheath
223584759|NCT04692077|DRUG|CAB LA|Administered as one 3 mL (600 mg) IM injection in the gluteal muscle at two time points 4 weeks apart and every 8 weeks thereafter.
223584760|NCT04692077|DRUG|Tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) tablet|300 mg/200 mg fixed-dose combination tablets
224305345|NCT01989962|OTHER|E4E intervention|The E4E intervention consists of a one-day face-to-face workshop and a series of follow-up online learning modules. Workshop and online content will be tailored to meet individual participants' needs determined by a pre-program needs assessment. E4E intervention will emphasize clinically based case scenarios and are designed to reinforce the workshop concepts and stimulate reflection. Participating family physicians will attend the workshop and engage in reflections and small-group interactions.
224305346|NCT02256527|OTHER|Observational|compare data
224305347|NCT03839030|OTHER|MBHP-Educa|This intervention is a meditative practice which the individuals will practice in their daily life following the MBHP-educa protocol
224305348|NCT02150135|OTHER|Oncothermia|Oncothermia is a kind of hyperthermia treatment. It serves heat energy more selectively than conventional hyperthermia.
224305349|NCT03437226|DRUG|Levosimendan 2.5 MG/ML|Levosimendan Arm: 1 x 5 ml (1 vial) of levosimendan infusion concentrate is added to one 250 ml infusion bag of 5% glucose or 0.9% NaCl in diabetic patients.
224305350|NCT03437226|DRUG|Placebos|Placebo Arm: 1 x 5 ml (1 vial) of placebo levosimendan infusion concentrate is added to one 250 ml infusion bag of 5% glucose or 0.9% NaCl in diabetic patients.
224305351|NCT00446901|DIETARY_SUPPLEMENT|Selenium|Selenized yeast, 300 ug/day
223480325|NCT06833697|PROCEDURE|serratus posterior superior intercostal plane block|"In Group 3, SPSIP block will be administered after surgery but before the patient is awakened, under sterile conditions and ultrasound guidance.~Patient Positioning: The patient will be placed laterally with the surgical side up, using a sterile ultrasound probe cover.~Ultrasound Imaging: A high-frequency (11-12 MHz) linear probe will be positioned sagittally at the scapula's upper corner to visualize the rhomboid major, trapezius, serratus posterior superior muscles, and the third rib.~Anatomy Identification: The third rib and serratus posterior superior muscle will be identified.~Needle Insertion: Using an in-plane technique, the needle will be advanced between the serratus posterior superior muscle and the third rib.~Injection: After confirming the needle position with 1-2 mL saline, 30 mL of 0.25% bupivacaine will be injected into the space, with spread monitored via ultrasound."
223584761|NCT05755568|OTHER|No Intervention|As this is an observational study, no intervention will be administered.
224167721|NCT07087743|BEHAVIORAL|VR-Based Gait Training with End-Effector Robot|A single-session gait training protocol using the Morning Walk® end-effector robot with real-time virtual reality visual feedback to encourage paretic limb propulsion and symmetrical gait. This intervention is intended to study participants' behavioral and biomechanical responses to the VR feedback, not to evaluate the robot as a device.
224167722|NCT06343376|PROCEDURE|Biopsy|Undergo tissue biopsy
224305352|NCT04026386|BEHAVIORAL|Center Based or In Home Early Intervention Program|This is a 12-week early intervention program that will include 12 weekly hours of treatment in an intensive center-based preschool environment or in home to treat social communication deficits in children with developmental disorders.
224305353|NCT00025012|DRUG|isotretinoin|
223584762|NCT06583681|OTHER|The measuring of the sagittal curvatures of the spine|Research tool was Baseline Bubble inclinometer.
223584763|NCT03024190|OTHER|Kinesiotaping|The technique of Kinesiotaping for spastic wrists and fingers in stroke patients is performed from the proximal interphalangeal joints of all fingers acted on the extensor carpal and digital muscle groups, with an anchor at the proximal one-third forearm.
223584764|NCT03024190|OTHER|stretching exercise|15- min stretching exercise for upper extremity twice daily
224167723|NCT06343376|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
224167724|NCT06343376|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow biopsy and aspiration
224167725|NCT06343376|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy and aspiration
224167726|NCT06343376|PROCEDURE|Computed Tomography|Undergo CT
224167727|NCT06343376|DRUG|Cyclophosphamide|Given IV
224167728|NCT06343376|PROCEDURE|Echocardiography|Undergo ECHO
224305354|NCT05736653|DEVICE|Task-specific PCMS|120 pairs of TMS and PNS volleys will be administered during electromyography-triggered functional electrical stimulation (FES)-assisted task-specific training (task-specific PCMS). In the task-specific PCMS, participants will first grasp a spherical ball when prompted by an auditory 'Ready' cue, and upon seeing a visual 'Go' cue will voluntarily extend the wrist and fingers to release the ball. After the 'Go cue', our customized stimulation delivery algorithm triggers the TMS and PNS only when the extensor digitorum communis (EDC) muscle activity exceeds a pre-determined threshold. The algorithm will then trigger FES to EDC after detecting EDC activity (\~2 ms after PNS) for the next 2 seconds, allowing the pairing of PCMS (TMS and PNS) with the voluntary movement of EDC without the confounding effects of FES.
224167729|NCT06343376|BIOLOGICAL|EGFRt/19-28z/IL-12 CAR T-lymphocytes|Given IV
224167730|NCT06343376|DRUG|Fludarabine Phosphate|Given IV
224167731|NCT06343376|PROCEDURE|Leukapheresis|Undergo leukapheresis
223480326|NCT06833697|DRUG|0.25% bupivacaine|0.25% bupivacaine
223480327|NCT00961064|DRUG|Eltrombopag|Eltrombopag will be initiated at 50 mg/day (Asians 25 mg/day) and dose adjusted up to 150mg/day based response and safety
224167732|NCT06343376|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
224167733|NCT06343376|PROCEDURE|Positron Emission Tomography|Undergo PET
224167734|NCT03219476|DRUG|Anastrozole|1 mg once daily.
224167735|NCT03219476|DRUG|Letrozole|2.5mg once daily.
224167736|NCT03219476|DRUG|Exemestane|25 mg once daily.
224167737|NCT03219476|DRUG|Tamoxifen|20 mg once daily.
224167738|NCT05884268|DRUG|Venlafaxine|Patients scheduled for elective LC will receive 150 mg venlafaxine before surgery
223480328|NCT01262586|DRUG|Vildagliptin|
223480329|NCT01262586|DRUG|Glimepiride|
223480330|NCT04023968|BEHAVIORAL|YESplus workshop|"See description in Arms section."
223480331|NCT04023968|BEHAVIORAL|WOW! workshop|"See description in Arms section."
223480332|NCT04265001|DRUG|Hyaluronic acid in the form of hyaluronan sodium 25 mg/100 ml as a mouthwash|Topical mouthwash used three times daily for one week and patients were not allowed to eat or drink for one hour after rinsing.
223480333|NCT02866981|OTHER|Observation|
224167739|NCT05884268|DRUG|Placebo|Patients scheduled for elective LC will receive placebo venlafaxine before surgery
223480334|NCT02166112|PROCEDURE|Permacol mesh placement|All patients were treated for a complex abdominal wall hernia by implantation of Permacol mesh. This intervention took place before patients were included in the cohort.
223480335|NCT01294046|DEVICE|Deep Brain Stimulation of SPG for Migraine|Deep Brain Stimulation of SPG for Migraine
224167740|NCT06932822|OTHER|Mental Imagery|Placement of a peripheral venous catheter on a simulation mannequin after a mental visualization session
223480336|NCT05721313|PROCEDURE|root resection|It will be carried out under local anestesia. Intra-crevicular or para-marginal gingival incision will be carried out and full-tickness mucoperiostal flaps will be raised to expose the affected roots. Whit the use (if possible) of a surgical stent an incision will be performed on the root to be removed. Biodentine will be used for retrogade obturation. The flaps will be sutured.
223480337|NCT00761319|DRUG|Travoprost ophthalmic solution 0.004% with SofZia® preservative system (TRAVATAN Z®)|Ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension, one drop a day, dosed topically for 90 days. Referred to as travoprost.
223480338|NCT00761319|DRUG|Latanoprost ophthalmic solution 0.005% (XALATAN®)|Ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension, one drop a day, dosed topically for 90 days. Referred to as latanoprost.
223480339|NCT00123136|DEVICE|foot energizer|
223480340|NCT01902667|PROCEDURE|Magnetic Resonance Imaging|
223480341|NCT05105685|DRUG|recombinant human growth hormone|RhGH treatment was started at 0.1 IU/kg once daily
223480342|NCT05105685|DRUG|Saline|Saline was started at 0.1 IU/kg once daily as the placebo
223480343|NCT05226429|BIOLOGICAL|UNAIR Inactivated COVID-19 Vaccine|UNAIR Inactivated Covid-19 Vaccine contains S protein of SARS-CoV-2 virus, Aluminium hydroxide gel, 10 mM L-Histidine buffer, 0.005% Tween Polysorbate 80, and 0.9% Sodium chloride. Vaccine will be prepared in vial (1 ml per vial). One vial will be used for one injection only. The vial should be shaken well before injection.
223480344|NCT05226429|BIOLOGICAL|CoronaVac Biofarma COVID-19 Vaccine|Control vaccine in this study is existing CoronaVac-BioFarma inactivated COVID-19 vaccine which has been used widely in Indonesia.
223480345|NCT00152048|DRUG|Eflornithine hydrochloride|
223480346|NCT03261401|DRUG|M5717|Participants received single ascending oral dose of M5717 after at least 8 hours of fasting together with water on Day 1, followed by a 4-hour post-dose fast
223480347|NCT03261401|DRUG|Placebo|Participants received placebo matched to M5717
223480348|NCT03261401|DRUG|M5717|Participants received single ascending oral dose of M5717 from Part A after at least 8 hours of fasting together with water on Day 1, followed by a 4-hour post-dose fast
223480349|NCT02934646|DEVICE|Robotic treatment|Passive/active elbow mobilizzation provided by NEUROExos Elbow Module Robotic device
223480350|NCT01724268|DRUG|Pred + Meth|PREDNISOLONE 10mg orally ONCE DAILY and Methotrexate 25 mg / day
223480351|NCT01724268|DRUG|Anti TNF + Meth|
223480352|NCT04044508|DIETARY_SUPPLEMENT|Ketocal 4:1 liquid Nutricia (intervention)|Modified ketogenic diet
223480353|NCT04044508|DIETARY_SUPPLEMENT|Fortini multifibre Nutrica (placebo)|Placebo diet
223480354|NCT06305481|DEVICE|P200TE|SLO and OCT imaging
223584765|NCT03024190|OTHER|OT rehabilitation program|regular rehabilitation program for 3 weeks
224167741|NCT06932380|PROCEDURE|Talus prosthesis|The Episealer Talus is an individualised resurfacing implant intended for use on either the medial or lateral talus. It aims to treat patients suffering from pain and reduced mobility due to focal osteochondral lesions in the talus.
224167742|NCT05434936|PROCEDURE|Oophorectomy|Patients undergoing surgery for any indicated procedure for fertility-threatening treatment will have attempt at collecting ovarian tissue at time of surgery.
224167743|NCT02369211|DRUG|Acetaminophen (Ofirmev)|The patient was administered IV Ofirmev during anesthesia and then 3 more IV doses (1g each) every 6 hours up to 24 hrs.
224167744|NCT02369211|OTHER|Placebo|The patient was administered IV Placebo during anesthesia and then 3 more doses of IV Placebo every 6 hours up to 24 hrs.
224167745|NCT05956262|DEVICE|AR-toothbrush machine|Student in AR group received a two-time repeated AR-based training for 30 minutes at two-week intervals. The AR-based training system (PVIX Oral, EPED) digitized the steps of the toothbrushing technique applying optical tracking technology to enable the participants to obtain immediate scoring after the completion of practice. The scoring depends on the level of removing simulated dental plaque. The AR system was equipped with an optical tracking unit, a 3D training head model, and a wireless toothbrush. The toothbrushing practice time for the upper and lower jaw is 3 minutes, respectively. A tooth-brushing song played while the students implemented.
224167746|NCT05956262|BEHAVIORAL|Teach proper brushing skills|Students in the traditional group received a two-time repeated 10-minute lesson regarding proper toothbrushing skills in the classroom at two-week intervals. The students were taught by a well-trained dental hygienist using teaching aids (such as dental models, and toothbrushes).
224167747|NCT00874224|PROCEDURE|laparoscopic left lateral hepatic sectionectomy|laparoscopic left lateral hepatic sectionectomy
224167748|NCT00874224|PROCEDURE|open left lateral hepatic sectionectomy|open left lateral hepatic sectionectomy
224167749|NCT03649815|COMBINATION_PRODUCT|App4Independence|"The mobile, app-based platform was designed to:~* Help prevent social isolation through personalized prompts, scheduling of activities, and connections to a range of resources relevant to social engagement~* Enhance hopeful and informed engagement in the recovery process through functions that foster resilience and draw on evidence based strategies to enhance wellness (e.g., personalized affirmations; tip sheets; relaxation exercises)~* Encourage and check-in on daily essential activities for patients - addressing memory, attention, and initiation challenges that often occur as a part of this illness~* Provide basic health/safety functionality and track level of wellness~* Provide an anonymous peer-peer online network for strategy sharing~* Provide an ambient sound detector to assist with identifying hallucinations"
224167750|NCT06948058|OTHER|Electronic Cigarettes (EC)|Participants will receive information about the comparative risk of alternative nicotine products relative to smoking and will be asked to switch to EC for 8 weeks, with EC provided.
224167751|NCT06948058|OTHER|Nicotine replacement therapy (NRT)|Participants will receive information about the comparative risk of alternative nicotine products relative to smoking and will be asked to switch to combination NRT (transdermal + oral) for 8 weeks, with NRT provided.
224167752|NCT06948071|OTHER|Discharge on oral antibiotics|Patients will be discharged to home on an oral antibiotic regimen for 3 days instead of being admitted for intravenous antibiotics.
224167753|NCT06949397|OTHER|Change in VAS voice performance score following the characteristics of the menstrual cycle of two women|application of menstrual belt and stress ball to women in the research group
223480355|NCT01620424|DRUG|biphasic insulin aspart 30|Single dose administered subcutaneously (s.c., under the skin) on two dosing vists. A wash-out period of 2-28 days will take place between dosing visits
223480356|NCT01620424|DRUG|biphasic insulin aspart 50|Single dose administered subcutaneously (s.c., under the skin) on two dosing vists. A wash-out period of 2-28 days will take place between dosing visits
223480357|NCT03808246|OTHER|using the demo version of a self-injector pen|Participants, whatever the arm they are included in, will have to use the demo version of the auto-injector pen during a simulation of an anaphylactic shock.
223480358|NCT06522425|OTHER|mindfulness-based serious games|The intervention consists of a single session using a digital serious game designed to teach mindfulness techniques for pain management. In addition to explaining mindfulness concepts, the game provides a variety of mindfulness exercises to help users manage and reduce pain perception. For example, it involves relaxation through breathing or becoming aware of the state of one's body and mind. Additionally, it includes various interaction elements such as touch, voice, and motion controls to increase user immersion.
223480359|NCT01859039|BIOLOGICAL|Administration of Live attenuated influenza vaccine|
223480360|NCT01115270|OTHER|Non-invasive measures|assessment of cerebrovascular fluid movement
223480361|NCT02503046|OTHER|Estimation of Pentraxin3|5ml of blood to be collected from each subject, centrifuged, to separate the plasma for estimation of Pentraxin3 (Quantikine ELISA)
223480362|NCT02503046|GENETIC|Estimation of P.Gingivalis levels|Pooled plaque sample will be collected and sent for DNA Extraction by PCR for assessment of levels of PGingivalis
223480363|NCT05262179|DRUG|CTO0101|1 drop/ once or three times a day/ for 17 days divided into stage2
223480364|NCT05262179|OTHER|Placebo (vehicle)|1 drop/ once or three times a day/ for 17 days divided into stage2
223480365|NCT02995148|DRUG|BAY987521|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation Code: Z43-104)
223480366|NCT02995148|DRUG|SPF Control|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.
223480367|NCT00674726|OTHER|Observation and measurement of axilo-rectal temperature|Measurement of axilo-rectal temperature
223480368|NCT05024448|DRUG|Prednisone|oral administration, 60mg/d for 10d
223480369|NCT00815529|DEVICE|Acupuncture, Pak-sham needle|25\*40mm, from 10 to 15 per each person, with the death from 5 to 20 mm, for from 15 to 20 minutes.
223480370|NCT05764499|OTHER|Physiotherapy Scoliosis Specific Exercise (PSSE)|Patients completed 120 hours of group based PSSE over a four week time frame. Monday - Friday, 10.00-17.00.
223480371|NCT00953433|DEVICE|Endoflex tube|Size decided upon gender.
224167754|NCT06949384|OTHER|observational study|This observational study focuses on the measurement of self-esteem in medical students using the Rosenberg Self-Esteem Scale. There is no intervention or treatment applied, and participants are only assessed for their self-esteem levels based on their demographic information.
223480372|NCT00953433|DEVICE|Polyvinyl chloride endotracheal tube with a stylet|Size decided upon gender.
223584766|NCT04043598|DRUG|0.9% Sodium-chloride|We will compare two already established treatment protocols: the use of normal saline versus lactated Ringer's for fluid therapy in patients with subarachnoid hemorrhage.
224167755|NCT05673928|DRUG|Trastuzumab emtansine|Given by IV (vein)
223480373|NCT04652089|DRUG|Simvastatin 20mg|Simvastatin 20mg once a day for 7 days
223480374|NCT04652089|DRUG|Placebo|Placebo once a day for 7 days
223480375|NCT06076590|DRUG|maintenance fluid|Patients are randomized to receive ether Multiple electrolytes injection II or Normal Saline for maintenance fluid during the 72 hours after enrollment. Resuscitation fluids and fluids used for drug delivery are not limited.
223480376|NCT05733338|OTHER|Intermittent Hypoxia|The intermittent hypoxia protocol refers to four cycles of 10 minutes hypoxia inhaling interval by 5 minutes normoxia, which is performed twice a day (at least 6 hours apart) in 5 days.
223480377|NCT05733338|OTHER|Sham Intermittent Hypoxia|The sham intermittent hypoxia protocol refers to 55 minutes normoxia inhaling, which is performed twice a day (at least 6 hours apart) in 5 days.
223480378|NCT00635713|DRUG|Fulvestrant|125mg
223480379|NCT00635713|DRUG|Anastrozole|ARIMIDEX
223480380|NCT00635713|DRUG|Fulvestrant|250mg
223480381|NCT02865291|DEVICE|ForConti device|
224167756|NCT05673928|DRUG|Tucatinib|Given by PO
224167757|NCT02918734|DEVICE|Endobutton CL BTB|ACL reconstruction with Endobutton CL BTB
224167758|NCT02918734|DEVICE|Metal interference screw|ACL reconstruction with metal interference screw
224167759|NCT05487092|DRUG|Letrozole|Letrozole 2.5mg daily for 6 months
224167760|NCT05487092|OTHER|Placebo|Placebo
224167761|NCT03807765|DRUG|Nivolumab|480 mg intravenous Nivolumab administered every 4 weeks.
224167762|NCT03807765|RADIATION|Stereotactic Radiosurgery|"Patients will receive single session SRS to intact brain metastases and post-operative cavities.~A linear accelerator (LINAC)-based frameless delivery system will be used to deliver the stereotactic radiation. The lesion will be defined using gadolinium enhanced MRI with 1 mm slices for treatment planning purposes prior to the delivery of radiation. The MRI image will be co-registered and fused with CT imaging. Doses will be prescribed to ensure coverage of at least 95% of the planning target volume (PTV) with the prescription dose. Treatments will be delivered using dynamic conformal arcs or intensity modulated radiotherapy."
224167763|NCT06572345|DIETARY_SUPPLEMENT|Low-energy diet|For the first 12 weeks during the LED, participants will have 4 meal replacement products each day. The following 12 weeks consists of a gradual reintroduction of food one meal at a time, in a structured stepwise progression, under the supervision of a dietitian. They will then undergo 28 weeks of weight maintenance to see if they are able to keep their weight stable.
224167764|NCT06572345|OTHER|Qualitive interview - LED participants|Semi-structured interviews with 10 of the LED participants and their relative/carer.
224167765|NCT06572345|OTHER|Qualitive interview - Participants declining LED|Semi-structured interviews with 10 participants who declined the LED, and their relative/carer.
224167766|NCT06572345|OTHER|Qualitive interview - Health Care Professionals (HCPs)|Semi-structured interviews with 10 HCPs involved in delivery of the trial.
224167767|NCT05213689|BEHAVIORAL|Educational comic book|An educational comic book was developed with qualitative data collected from an earlier study phase involving focus groups with youth from Bidi Bidi. The comic book is focused on HIV testing information and decision making as it follows the story of youth in Bidi Bidi who are seeking out HIV testing. Each youth in the appropriate arm with receive a copy of the comic book and together with 5-10 other youth will meet with a PN to read through and discuss the comic book. The comic will also include blank pages so that the youth can participate in the dialogue of the comic book. The comic will be available in English, Bari and Juba Arabic.
223480382|NCT03310840|OTHER|others|others
223480383|NCT05707676|DRUG|LB4330|LB4330
224167768|NCT05213689|DIAGNOSTIC_TEST|HIV Self-testing|Participants will receive HIVST kits so that they can perform their HIV testing.
224167769|NCT03692195|DEVICE|WHOOP Strap 2.0|The WHOOP Strap 2.0 is worn on the wrist, continuously throughout the 7-day period of which participants will be assigned. It measures heart rate, sleep, strain, and recovery.
224167770|NCT03692195|OTHER|No Device|The WHOOP Strap 2.0 is not worn on the wrist for a seven day period.
224167771|NCT05980611|DIAGNOSTIC_TEST|IL B,IL 3 in nasal swap and serum|Interleukin (IL)-1-beta and IL-3 will be measured in patients' serum and supernatant from the nasal swap using enzyme linked immunosorbent assay (ELISA).
224167772|NCT00692393|PROCEDURE|Hartmann intervention|sigmoid resection, peritoneal and rectal lavage, terminal stoma
224167773|NCT00692393|PROCEDURE|Protected anastomosis resection|sigmoid resection , peritoneal and rectal lavage, anastomosis, diverting stoma
224167774|NCT01620801|BIOLOGICAL|AAV8-hFIX19|One-time IV vector administration.
224167775|NCT06114511|DRUG|BL-M07D1|Administration by intravenous infusion
224167776|NCT06961786|BIOLOGICAL|TILT-123|TNFalpha and IL-2 coding oncolytic adenovirus TILT-123
224167777|NCT06961786|BIOLOGICAL|TIL|Adoptive T cell therapy with TILs
224167778|NCT06961786|DRUG|Cyclophosphamide|Lymphocyte-depleting chemotherapy
223480384|NCT01345799|DRUG|TRK-170|
223480385|NCT01345799|DRUG|Placebo|
224167779|NCT06961786|DRUG|Fludarabine|Lymphocyte-depleting chemotherapy
224167780|NCT04436406|DIAGNOSTIC_TEST|[99mTc]-NM-01 SPECT/CT|Technetium labelled anti-PD-L1 single-domain antibody (NM-01) single-photon emission computed tomography (SPECT)/CT
224167781|NCT03258593|DRUG|Durvalumab|Durvalumab 1500 mg is administered intravenously (IV) once every 4 weeks for 12 months with an option to continue therapy for an additional 12 months (total of 24 months) provided that, participant is tolerating therapy and remains free of recurrent high grade NMIBC (see Treatment Period below). The dose of durvalumab is 1500 mg. If optional maintenance therapy continued in the second year, durvalumab 1500 mg will be administered intravenously once every 3 months to provide an immune boost.
224167782|NCT03258593|DRUG|Vicineum|Vicineum is administered in a 12-week Induction Phase followed by a Maintenance Phase for at least one year with an option for a total of up to 2 years of treatment. During the Induction Phase, Vicineum is administered once weekly for 12 weeks. During the Maintenance Phase, Vicineum is administered every other week. The dose of Vicineum is 30 mg in 50 mL of saline.
224167783|NCT03258593|DRUG|Acetaminophen|Acetaminophen or equivalent medications per institutional standard may be administered at the discretion of the investigator.
224167784|NCT03258593|DRUG|Antihistamine|Antihistamine (e.g., diphenhydramine) or equivalent medications per institutional standard may be administered at the discretion of the investigator.
224167785|NCT03258593|PROCEDURE|Bladder Biopsy|Bladder biopsy at screening and every 3 months before each cystoscopy per schema.
224167786|NCT03258593|PROCEDURE|TURBT|Transurethral resection of a bladder tumor (TURBT) at screening and every 3 months before each cystoscopy per schema.
223480386|NCT03969537|OTHER|Telemedicine follow-up visit|Study participants will experience two telemedicine (live audio/video) visits.
223480387|NCT00915525|BIOLOGICAL|botulinum toxin Type A|Botulinum toxin Type A 100U or 150U injected into the detrusor, after protocol specified criteria are met, and no more frequently than every 12 weeks.
223480388|NCT06436859|BEHAVIORAL|stress ball group|"According to randomization, pregnant women in the intervention group will receive stress ball therapy during labor."
223584767|NCT04043598|DRUG|Ringer's Lactate|We will compare two already established treatment protocols: the use of normal saline versus lactated Ringer's for fluid therapy in patients with subarachnoid hemorrhage.
223480389|NCT05781802|OTHER|Level of pressure support|"Patients will be evaluated in two different conditions sequentially. The first condition will be at a clinically selected level of pressure support under stable clinical conditions.~This condition will be labeled according to P0.1:~* In case of P0.1\<2, the clinically selected level of pressure support will be considered High Pressure support.~* In case of P0.1\>2, the clinically selected level of pressure support will be considered Low Pressure support.~After data collection at clinically selected level of pressure support, pressure support level will be transiently increased or decreased (i.e. from high to low/ from low to high) to the lowest/highest clinically tolerated level, aiming at the predefined P01 thresholds, and then kept for 20 minutes under stable clinical conditions. Data collection will be repeated and then the clinically selected level of pressure support restored."
223480390|NCT00176046|DRUG|viscum album pini|s.c. injection of 0,001-20 mg 3 times per week
223480391|NCT00176046|DRUG|viscum album pini|s.c. injection 0,001-20 mg 3 times per week
223480392|NCT05550181|BEHAVIORAL|intraoperative mechanical ventilation with hypocapnia (etCO2 < 35 mm Hg)|A patient is considered 'hypocapnic' if the etCO2 was \< 35 mm Hg at any point during surgery, from start of the study till end of the study and classified as 'without hypocapnia' otherwise. In case of a missing value immediately before extubation, we will use the values as reported in the last hour of surgery.
223480393|NCT02955927|DRUG|0.01% atropine eye drops|
223480394|NCT02955927|DEVICE|ortho-k|
223480395|NCT06216340|DRUG|Henagliflozin|10mg of Henagliflozin and diet-exercise therapy
223480396|NCT06216340|DRUG|Placebo|Placebo and diet-exercise therapy
223480397|NCT00126945|BIOLOGICAL|Meningococcal Vaccine|
223480398|NCT01625767|BEHAVIORAL|AAT experiment|Smokers and nonsmokers complete AAT experiment
223480399|NCT05009550|PROCEDURE|Group ESP|Single-shot ultrasound guided ESP block is performed at the T8 vertebral level before the procedure to all patients in ESP block Group
224167787|NCT03258593|PROCEDURE|Cystoscopy|Urine cytology at screening and every 3 months before each cystoscopy per schema.
223480400|NCT05009550|OTHER|Non-blocked Group|This Group is received no intervention.Patients will be sedated as standard and radiofrequency procedure will be applied.
223480401|NCT04571593|BEHAVIORAL|Yoga Nidra|The practice of Yoga Nidra, is a scripted and reproducible, guided meditation technique that promotes mental, emotional and physical relaxation while also facilitating the transition between waking and sleeping.
223480402|NCT01575990|BEHAVIORAL|Making A Decision About CRC Screening|"Targeted by age and gender with 3 components.~1. Educational component~2. Values clarification exercise~3. Individualized decision making worksheet~The intervention or control condition is administered before the index visit with the patient's provider."
223480403|NCT01575990|BEHAVIORAL|Drivers 65 Plus|This text booklet is provided as an attention control for those in the control arm and like the intervention is administered prior to the index visit with the patient's provider.
223480404|NCT03104413|DRUG|placebo for risankizumab IV|placebo for risankizumab administered as intravenous (IV) infusion.
223480405|NCT03104413|DRUG|risankizumab SC|risankizumab administered by subcutaneous (SC) injection
223480406|NCT03104413|DRUG|risankizumab IV|risankizumab administered as intravenous (IV) infusion.
224167788|NCT03258593|DIAGNOSTIC_TEST|Urine cytology|Urine cytology at baseline and every 3 months before each cystoscopy per schema.
224167789|NCT03258593|DIAGNOSTIC_TEST|Electrocardiogram|Electrocardiogram (ECG) at screening, pre-durvalumb infusion and as clinically indicated during the trial.
224167790|NCT03258593|DIAGNOSTIC_TEST|CT|Computed tomography (CT) at screening and every 12 months while on study.
224167791|NCT03258593|DIAGNOSTIC_TEST|MRI|Magnetic resonance imaging (MRI) at screening and every 12 months while on study.
224167792|NCT05454696|OTHER|Exercise|Patients in the exercise group will participate in online clinical pilates exercise sessions under the supervision of a physiotherapist twice a week. The exercises will be done via the Zoom application and will continue for 6 weeks. The exercise program will last one hour with a warm-up and cool-down period. The exercises will be done by adhering to the basic principles of clinical pilates. The exercise program includes mat exercises that provide general body strengthening and stretching. Progression will be provided according to the health status of the patients and their compliance with exercise. The intensity of exercise will be planned as medium according to the Rating of perceived exertion (RPE) Scale.
224167793|NCT05454696|OTHER|online physical activity counselling|CG will receive online physical activity counselling by a physiotherapist only once. The importance of physical activity after surgery and the points to be considered during physical activity will be explained to the patients.
223480407|NCT02765035|DEVICE|C-Leg 4|Microprocessor Controlled Knee
223480408|NCT02765035|DEVICE|C-Leg 3|Microprocessor Controlled Knee
223584768|NCT03462953|PROCEDURE|Gingival tissue samples will be harvested|"Gingival tissue samples will be harvested during the premolar extraction (Orthodontic ttt) or third molar extraction for the healthy controls and during periodontal surgery or extraction of hopeless teeth with periodontal disease ..~The dissected gingival samples will be washed in saline solution and fixed in 4% buffered formalin for 48 hours, dehydrated in ascending grades of ethyl alcohol, cleared in xylene and embedded in paraffin and will be subjected to the following:.~1. Sections of 4-5 µm in thickness will be obtained, deparaffinized, rehydrated and subjected to histological staining and histomorphometric analysis.~2. Real time- PCR for TGF-B1 ,Vimenten , E-Cadherin ."
224167794|NCT06624475|DRUG|Nivolumab|Nivolumab is a fully humanized monoclonal antibody that binds to the PD-1 receptor, blocking its interactions with PD-L1 and PD-L2, and thus additionally inhibiting PD1-driven immune suppression. Nivolumab 490 mg via IV administration 28 day cycle
223480409|NCT05684107|PROCEDURE|IPACK block|the probe is applied to the popliteal fossa for identification of the popliteal artery and femur. Then, the probe is slid distally for revealing the two femoral condyles followed by proximal sliding of the probe until the humps of the femoral condyles disappeared and the flat metaphysis appeared. a spinal needle 22G x 3.5 inches is advanced from the lateral aspect and directed across the space between the popliteal artery and femur and once the needle reached the medial edge of the femur, nearly at the level of the popliteal artery, negative aspiration is confirmed and 20 ml of bupivacaine 0.25% is injected incrementally as the needle was withdrawn
223480410|NCT05684107|PROCEDURE|adductor canal block|"the transducer is placed anteromedially, approximately at the junction between the middle and distal third of the thigh or somewhat lower.~The saphenous nerve block should be performed at the most distal level where the artery still lies immediately deep to the sartorius muscle, thus minimizing the amount of motor nerve block of the vastus medialis; an adductor canal nerve block is typically performed more proximally, around the mid-thigh level. The needle is inserted in-plane in a lateral-to-medial orientation and advanced toward the femoral artery. Once the needle tip is visualized anterior to the artery and after careful aspiration, 20 ml of bupivacaine 0.25% is injected incrementally as the needle was withdrawn"
224167795|NCT06624475|DRUG|Opdualag|Opdualag (Opdualag) is supplied as a single dose vial containing 240 mg of Nivolumab and 80 mg. Relatlimab per 20 mL for intravenous administration ; 28 day cycle.
224167796|NCT05763693|DRUG|Azithromycin at Baseline|this group will be randomized to receive a single oral dose of azithromycin (20mg/kg) at baseline
224167797|NCT05763693|DRUG|Azithromycin at Day 21|this group will be randomized to receive a single oral dose of azithromycin (20mg/kg) at the day 21 visit
224167798|NCT05763693|OTHER|Placebo at Baseline|this group will be randomized to receive Placebo at baseline
224167799|NCT05763693|OTHER|Placebo at Day 21|This group will be randomized to receive Placebo at the day 21 visit
224167800|NCT06136195|DRUG|Mavoglurant|The 200mg mavoglurant will be administered in the form of two 100mg oral tablets. Placebo will be administered with matching tablets.
224167801|NCT04574076|DRUG|Turoctocog alfa pegol (N8-GP)|Patients will be treated with commercially available N8-GP for prophylaxis and treatment of bleeding episodes according to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available N8-GP has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician before and independently from the decision to include the patient in this study.
224167802|NCT04224350|DRUG|TacroBell SR cap.|"* Orally, once-daily in the morning~* After first dose 0.2mg/kg, check the blood concentration of tacrolimus at each visit and adjust the dose to achieve the blood concentration maintaining at 3\~12ng/ml for 0 to 3months and then at 3\~8ng/ml for 3 to 6months of study treatment."
224167803|NCT04224350|DRUG|Tacrolimus cap.|"* Orally, twice a day in the morning and night~* After first dose 0.1mg/kg, check the blood concentration of tacrolimus at each visit and adjust the dose to achieve the blood concentration maintaining at 7\~12ng/ml for 0 to 3months and then at 5\~8ng/ml for 3 to 6months of study treatment."
224167804|NCT00732654|DRUG|Milk Protein Extract Immunotherapy goal of 4mg/day|Sublingual extract given daily in escalating doses with goal of 4 mg/day for approximately 20 weeks.
224167805|NCT00732654|DRUG|Milk Protein Extract Immunotherapy goal of 7mg/day|Sublingual extract daily in escalating doses to goal of 7mg/day for approximately 1 1/2 years.
224167806|NCT00732654|DRUG|Milk Powder Immunotherapy goal dose 2000 mg/day|Milk powder given orally in escalating doses with a goal dose of 2000mg/day given for approximately 1 1/2 years.
224167807|NCT00732654|DRUG|Milk Powder Immunotherapy goal dose 1000mg/day|Milk powder given orally in escalating doses with a goal of 1000mg/day for approximately 1 1/2 years.
224167808|NCT01430910|DRUG|CAZ104|IV infusion
224167809|NCT01430910|DRUG|Avibactam|IV infusion
224167810|NCT01430910|DRUG|Ceftazidime|IV infusion
224167811|NCT02429206|OTHER|SQIN|Each patient will be asked to self-apply both creams (experimental vs positive control) on the right and left sides of their body (sides will be randomly assigned).
224305355|NCT05736653|DEVICE|Task-specific sham-PCMS|120 pairs of sham-PCMS stimuli will be administered during task-specific practice. The TMS coil will be placed \~10 cm behind the participant's head, and PNS electrodes will be placed in the same position as for task-specific PCMS, but no stimulation will be delivered. Like the task-specific PCMS condition, participants will perform the same grasp and release a ball task in an identical manner. FES will be delivered after detecting voluntary EDC activity, similar to the task-specific PCMS condition.
224167812|NCT02429206|OTHER|standard moisturizing cream (Glaxal Base)|
224167813|NCT04076904|DIAGNOSTIC_TEST|transvaginal us with 2D and 3D SHG|transvaginal us is made to all women with SHG
224167814|NCT03857464|DIAGNOSTIC_TEST|Near Patient Testing|Near-patient testing will be conducted at Foothills Hospital rapid response lab. Negative results using C. DIFF QUIK CHEK COMPLETE® will be reported immediately to the patient wards. Positive results will be confirmed using nucleic acid testing at the centralized testing facility.
224167815|NCT03857464|DIAGNOSTIC_TEST|SOP for C. difficile diagnostics|Two-step testing algorithm for Clostridium difficile at centralized testing facilities. No change from the current protocol.
224167816|NCT05614700|RADIATION|Brachytherapy|High Dose-Rate Brachytherapy
224167817|NCT05614700|RADIATION|Sterotactic Body Radiotherapy|Hypofractionated External Beam Radiotherapy
223584769|NCT04924153|OTHER|No Intervention|Administered as specified in the treatment arm.
223584770|NCT03826342|BEHAVIORAL|Health Check-up for Expectant Moms|A brief intervention (one session plus two booster sessions)
223584771|NCT03826342|BEHAVIORAL|Time, attention, and information-matched control|We will include facts about alcohol/drug use and risky sex during pregnancy, along with informational brochures that provide face validity.
224167818|NCT05318183|OTHER|Whole Wheat Bread|Standardized whole wheat bread (128 g daily)
224167819|NCT05318183|OTHER|White Bread (control)|Standardized white bread (128 g daily)
224167820|NCT02098655|OTHER|Stabilometric platform|Stabilometric platform is a device used for assessment and training of balance basing on ground reaction force evaluation in static conditions.
224167821|NCT01608139|DRUG|Curcumin|Starting dose: 4 grams by mouth per day. During the first cycle only, Curcumin given on Day 1. Beginning with Cycle 1 Day 5, all agents will be administered continuously.
224167822|NCT01608139|DRUG|Sorafenib|Starting dose: 200 mg by mouth daily. During the first cycle only, Sorafenib given on Day 5. Beginning with Cycle 1 Day 5, all agents will be administered continuously.
224167823|NCT01608139|DRUG|Vorinostat|Starting dose: 100 mg by mouth daily. During the first cycle only, Vorinostat given on Day 3. Beginning with Cycle 1 Day 5, all agents will be administered continuously.
224167824|NCT03474939|DRUG|Midazolam Oral Tablet|Midazolam Oral tablet
223480411|NCT05684107|PROCEDURE|sciatic nerve block|patient in a supine position with the hip and knee on the operated side flexed and the leg externally rotated at approximately 45 degrees. The ultrasound transducer is first positioned perpendicular to the skin approximately 8 cm distal to the inguinal crease. The location is then scanned by sliding and tilting the transducer until a clear transverse image of the hyperechoic sciatic nerve located posterior and medial to the lesser trochanter is obtained. a spinal needle 22G x 3.5 inches is advanced parallel and in line with the ultrasound transducer while the sciatic nerve is kept in the middle of the screen. The needle is advanced slowly under real-time ultrasound guidance until it is near the nerve then negative aspiration is confirmed and 20 ml of bupivacaine 0.25% is injected incrementally as the needle was withdrawn
224167825|NCT03474939|OTHER|Placebo Oral Tablet|Glucose 1000mg tablet night before surgery and 60 minutes before surgery
224167826|NCT01594463|OTHER|ultrasound examination|ultrasound examination between week 30+1 weeks to 31+6 weeks
224167827|NCT01594463|OTHER|ultrasound examination|ultrasound examination between 34+1 weeks to 35+6 weeks
224167828|NCT05846542|OTHER|Video-game based therapy|Video-game based therapy will be designed for the individual basis for the upper extremity.
224167829|NCT05846542|OTHER|Conventional physiotherapy|Conventional physiotherapy within a specific program
224167830|NCT05072834|PROCEDURE|Upper Gastrointestinal Endoscopy|"Procedure Upper gastro-intestinal endoscopic procedure involves collection of intestinal samples and it can be helpful in identifying the causes of malnutrition. Upon parental approval, the child along with two relatives will be provided transportation to Karachi, accommodation and the compensation for their time and expenses.~For this procedure the child will be admitted to the hospital a day before the procedure till one day after the procedure. This procedure takes 30 minutes, requires general anesthesia and involves insertion of a flexible tube with a small TV camera and a light on one end and an eyepiece on the other. The endoscope will allow the doctor to examine the inside of certain tube-like structures in the body. Some tissue samples for laboratory testing will be taken."
224167831|NCT02875353|DEVICE|Doppler Endoscopic Probe|A colon length catheter (probe).
224167832|NCT05713513|OTHER|Leukapheresis|Leukapheresis to isolate 1x10e9 cells, examined for purity and specificity under Good Manufacturing Practice (GMP)
224167833|NCT03880123|DRUG|Selinexor|"Selinexor will be taken orally on Days 1, 8, 15, and 22 of each cycle at the following dose levels (DLs):~DL 1: 40 mg; DL 2: 60 mg; DL 3: 80 mg; DL 4: 100 mg~The selinexor product is provided as 20 mg tablets in wallet-sized blister packs. Selinexor should be taken together with ixazomib."
224167834|NCT03880123|DRUG|Ixazomib|"Ixazomib will be taken orally on Days 1, 8, and 15 of each cycle at the same dose level: 4 mg.~The ixazomib product is provided in strengths of 4.0, 3.0, and 2.3 mg capsules as the active boronic acid. Ixazomib should be taken on an empty stomach (no food or drink) at least 1 hour before or at least 2 hours after food."
224167835|NCT03963076|OTHER|nasal hypertonic spray: combination of hypertonic sea water and organic rosemary floral water with essential oils (ravintsara, geranium, eucalyptus radiata, niaouli)|One spray of nasal hypertonic spray morning and evening every day during 30 days
223480412|NCT03997877|OTHER|Physical activity|Increase physical activity Balanced diet
223480413|NCT01604772|DRUG|Akt Inhibitor MK2206|Given PO
223480414|NCT01604772|OTHER|Laboratory Biomarker Analysis|Correlative studies
223480415|NCT04147156|PROCEDURE|Epley's Maneuver|Treatment with Epley's Maneuver in the ROTUNDUM-chair
223480416|NCT04147156|PROCEDURE|Semont Maneuver|Treatment with the Semont Maneuver in the ROTUNDUM-chair
223480417|NCT04147156|PROCEDURE|360 degree vertical rotation|Treatment with 360 degree vertical rotation in the ROTUNDUM-chair
223480418|NCT03931564|PROCEDURE|PRESERFLO Microshunt implantation|The intervention consists of the microshunt implantation augmented with mitomycin C application.
223480419|NCT03931564|PROCEDURE|Trabeculectomy|The usual care / control group will undergo a standard fornix based trabeculectomy augmented with mitomycin C application.
223480420|NCT02236377|BEHAVIORAL|Exposure, Relaxation, and Rescripting Therapy|Brief cognitive behavioral treatment targeting trauma-related nightmares and sleep problems
223480421|NCT04772976|OTHER|Observational study, not applicable|Observational study, not applicable
223480422|NCT04782141|PROCEDURE|hand motor coordination in a sitting positin|The subject sat on the therapeutic table (without back support), feet resting on the floor. The upper limb was examined in adduction, with the elbow bent in the intermediate position between pronation and supination of the forearm. Wrist and a hand free from stabilization.
223480423|NCT04782141|PROCEDURE|hand motor coordination in a supine position with the upper extremity positioned perpendicularly to the trunk|motor tasks carried out in starting positions: supine with the upper extremity positioned perpendicularly to the trunk; the upper limb in adduction and flexion in the humeral joint, elbow extension, forearm in the intermediate position; elbow, wrist, hand free from stabilization.
223480424|NCT04782141|PROCEDURE|hand motor coordination in a supine position with adduction in the humeral joint, elbow flexion in the intermediate position|In the supine position, the upper limb was held beside the subject's body (adduction in the humeral joint, elbow flexion in the intermediate position between pronation and supination of the forearm. Wrist and a hand free from stabilization.
223480425|NCT00255580|DRUG|Smoked cannabis|
223480426|NCT03423771|DRUG|NPF-08|Drug: NPF-08 Arms: NPF-08 oral sulfate solution
223584772|NCT05207046|OTHER|Mechanical Ventilation|Patients will be assessed and measurements will be taken during controlled ventilation (most likely \<72 hours of ICU admission), during partially assisted ventilation, and until spontaneous unassisted breathing is reached.
223584773|NCT00238914|DRUG|Naltrexone|50mg of oral naltrexone daily
224167836|NCT06102993|OTHER|Non-interventional study|The only intervention is to analyze serum molecules of patients with COPD and controls without COPD.
224167837|NCT03863964|DIAGNOSTIC_TEST|blood test|13 blood samples will be drawn: at 3 min, 7 min, 15 min, 30min, 1h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 4.5h, and 5h post-treatment with TXA. Blood samples will be processed for ROTEM® analysis and for plasma concentration of TXA. TXA plasma concentrations will be modeled with a non-linear mixed-effects strategy using Monolix 4.1 and NONMEM(®) 7.2.
224167838|NCT04502095|DRUG|Clindamycin|Given PO
223480427|NCT01712178|BIOLOGICAL|Adalimumab, current formulation|Current formulation adalimumab 40 mg every other week
223584774|NCT00238914|BEHAVIORAL|Behavioral Naltrexone Therapy (BNT)|a hybrid of Relapse Prevention, the Community Reinforcement Approach, and Network Therapy
224167839|NCT04502095|OTHER|Diary|Complete drug diary
224167840|NCT04502095|DRUG|Ertapenem|Given PO
223480428|NCT01712178|BIOLOGICAL|Adalimumab, new formulation|New formulation adalimumab 40 mg every other week
223480429|NCT04104971|DIAGNOSTIC_TEST|blood tests , abdominal US and doppler|
223480430|NCT02278653|OTHER|Questionnaires for the evaluation of Quality of Life|"1. European Organisation for Research and Treatment of Cancer (EORTC) QLQ-30 questionnaire, version 3.0, Global Quality of Life Score~2. Short Form (36) health survey~3. EORTC CR38~4. Vaizey score~5. Low Anterior Resection Syndrome (LARS) score~6. International Index of Erectile Function for men~7. International Prostate Symptom Score for men~8. Female Sexual Function Index for women"
223480431|NCT02278653|OTHER|Manometry|Manometry is a tool to measure the anal sphincter function. Patients do not need any bowel preparation before this procedure. During the examination a catheter tip will be positioned in the rectum above the sphincter and a small balloon will be inflated. This balloon is connected to a device that registers the measurements. Patients will receive instructions; e.g. squeeze, push, and cough. The procedure takes approximately 10 minutes and is not experienced as painful. Several parameters will be measured: the mean basal pressure, the maximum squeeze pressure, first sensation, first urge to defecate and the maximum tolerable volume. The manometric measurement will take place on the same day as the endoscopy and MRI (standard follow-up).
223480432|NCT00091819|DRUG|Telavancin|Telavancin 10 mg/kg/day, IV for up to 14 days.
223480433|NCT00091819|DRUG|Vancomycin|Vancomycin 1 Gm IV q 12 hrs for up to 14 days.
223480434|NCT00984867|DRUG|Dapagliflozin|10 mg tablet, oral, once daily, 48 weeks
223480435|NCT00984867|DRUG|Placebo|Matching placebo tablet
223480436|NCT02900716|DRUG|DTRMWXHS-12|DTRMWXHS-12
223480437|NCT02900716|DRUG|DTRM-505|DTRMWXHS-12 and everolimus
223480438|NCT02900716|DRUG|DTRM-555|DTRMWXHS-12 and everolimus and pomalidomide
223480439|NCT05115396|OTHER|Mirror therapy|The patient shall be seated in a chair with a table in front of him/her. On the table there is a mirror in the sagittal plane between the two upper extremities. The affected hand will be behind the mirror, without visibility, while the hand without symptoms will be reflected laterally in the mirror. Thus, the mirror will reflect the movements of the unaffected side as if these movements were executed with the affected side. During the procedure, patients will be instructed to concentrate on the hand reflected in the mirror.
223480440|NCT05115396|OTHER|Cross-education treatment|Participants will perform the same exercise protocol with the unaffected hand and without the use of a mirror.
223480441|NCT05664906|DRUG|Chinese Medicine Oral Rinse Formula-I (CMORF-I)|"* Prescription of Chinese Medicine Oral Rinse Formula-I (CMORF-I)~* Instruction to rinse:~  1. The above amount of concentrated CM granules will be divided and packed in 4 bags per day.~ 2. Dissolve 1 bag of concentrated CM granules with 150ml 80'C boiled hot water, and wait for 20 mins to cool down.~ 3. Clean the mouth thoughtfully by rinsing with 150ml of distilled water for 2 minutes.~ 4. Rinse the mouth thoughtfully with one-third of the dissolved and cooled CM oral rinse, gargle, expel after 3 minutes, do not swallow and repeat twice.~ 5. To ensure better contact of the CM oral rinse in all parts and folds of the oral cavity, our research assistant and CMP will guide the patients to fully agitate the mouth, use the tongue to stir repeatedly among the teeth, cheeks and palate surface, and to raise the tip of the tongue for a moment and tilt the head back.~ 6. 4 times a day (half an hour after every meal, half an hour before sleep), from baseline to 2 weeks after RT."
223480442|NCT05664906|OTHER|Standard Care|• Standard care including normal saline or medical mouthwash, optional analgesics and antibiotics will be offered by hospital.
223480443|NCT05664906|OTHER|Placebo|Placebo granules, instruction is the same as CMORF-I.
223480444|NCT03582683|BEHAVIORAL|Chronic Pain Self-Management Program (CPSMP)|Stanford University's Chronic Pain Self-Management Program (CPSMP) was developed by Sandra LeFort in 1996 and based on Stanford's Arthritis Self-Management Program and the Chronic Disease Self-Management Program. The 6-week community-delivered workshop consists of 2.5-hour weekly sessions for people with a primary or secondary diagnosis of Chronic Pain.
223480445|NCT05510492|OTHER|EDUCATION|THE EXPERIMENT GROUP WAS GIVEN THEORETICAL AND APPLIED EDUCATION,
223480446|NCT05510492|OTHER|APPLIED EDUCATION|"the injection was applied on the model by the researcher with the demonstration method according to the Procedure Steps of Intramuscular Injection with the Z Technique from the Ventrogluteal Region. This process was first ensured by the nurses, and then"
223480447|NCT00275613|DRUG|Rituximab|The Rituximab dose is 1000 mg (1 gm) given as an IV infusion every two weeks for 2 doses (days 1 and 15)
223480448|NCT01503424|DRUG|Olanzapine|Olanzapine Tablets, 5 mg
224167841|NCT04502095|DRUG|Levofloxacin|Given PO
224167842|NCT04502095|DRUG|Nitrofurantoin|Given PO
223480449|NCT01516099|OTHER|General Practitioners|The general practitioner can refer his patients to a physical activity counselor for an individual coaching (intake session with development of program and pretesting, follow up by e-mail or phone (max 4x), personal contact moments (max 3x) and exit session with evaluation and posttesting).
223480450|NCT01516099|OTHER|Social-cultural organizations|In the social-cultural organization, members can sign in for group sessions led by the physical activity counselor (intake session with development of program and pretesting, follow up by email or letters (max 4x), personal contact moments (max 4x) and exit session with evaluation and posttesting).
223584775|NCT00238914|BEHAVIORAL|Compliance Enhancement (CE)|a controlled therapy intended to simulate outpatient psychiatric care.
223584776|NCT02060032|DRUG|1.2% Atorvastatin local drug delivery|
223584777|NCT02060032|DRUG|1.2% simvastatin local drug delivery|
223584778|NCT02060032|DRUG|Placebo local drug delivery|
223584779|NCT04142151|DRUG|Sanchitongshu|SanchiTongshu capsule produced by Chengdu Huashen Group Co., Ltd.
224167843|NCT04502095|DRUG|Trimethoprim-Sulfamethoxazole|Given PO
224167844|NCT03657576|BIOLOGICAL|C134|C134 is a virus that was created from an oncolytic Herpes Simplex Virus (oHSV) known to infect and kill tumor cells. The Investigators have made changes to the original virus to make C134. It efficiently infects tumor cells (not normal healthy cells) and induces an immune response to fight the cancer as well.
224167845|NCT06083857|DRUG|Amivantamab|Given by IV (vein)
224167846|NCT06083857|DRUG|Tepotinib|Given by PO
223480451|NCT05668559|PROCEDURE|repetitive transcranial magnetic stimulation|"The rTMS mode consists of a cluster stimulus delivered every 0.2 seconds (5 Hz), with each cluster stimulus consisting of three burst stimuli with a 50 Hz body frequency. The duration of a single stimulus was approximately 40 seconds, for a total of 600 pulses. Stimulation takes place bilaterally in the dorsolateral prefrontal cortex (DLPFC).~All enrolled patient in the rTMS group will receive 1 set simulation per day with an intersession interval (ISI) of over 30 minutes on postoperative day 1 to 5 after the surgery."
223480452|NCT05668559|PROCEDURE|Sham Stimulation|Shaman stimulation uses the same protocol (600 pulses per session, 3 sessions per set, ISI≥30 min, 3 sets) with the coil set at 90 against the skull on postoperative day 1 to 5 after the surgery.
223480453|NCT02682758|DRUG|Xenon|Wash-in of xenon for maintenance of anaesthesia
223480454|NCT00879216|DRUG|VA106483|4 mg orally on either Day 7 or 10 with the placebo crossover treatment on the alternate day.
223480455|NCT00879216|DRUG|Placebo|4 mg orally on either Day 7 or 10 with the placebo crossover treatment on the alternate day.
223480456|NCT02112201|BEHAVIORAL|Integrated intervention for parents and adolescent girls|The intervention will consist of individually administered preventive curriculum for adolescent girls involved in the juvenile justice system that integrally addresses delinquency, drug abuse, and trauma exposure, along with group-based training and support for parents.
223480457|NCT00919672|DEVICE|Sacral nerve stimulation|The stimulation is set individually to provide the best possible stimulation for each individual person. This setting is found before the study starts and will not be altered during the study.
223480458|NCT00513799|DRUG|Mupirocin ointment|Add a small amount of Mupirocin to the cotton end of a swab. Swab in inner nostril, then repeat in other nostril using new cotton swab with ointment. Twice daily treatment for 5 days.
223480459|NCT00513799|GENETIC|Chlorhexidine showers|Apply Clorhexidine wash to entire body once daily for 5 days.
223480460|NCT00513799|PROCEDURE|Bleach baths (dilute)|Pour 2 ounces of bleach into water-filled bath tub. Soak in bath for 15 minutes. Apply once daily for 5 days.
223584780|NCT04142151|DRUG|Aspirin|Aspirin produced by Bayer Co., Ltd.
223584781|NCT04142151|DRUG|Clopidogrel|Clopidogrel produced by Shenzhen Salubris Co., Ltd.
223584782|NCT04142151|DRUG|placebo of Sanchitongshu|SanchiTongshu palcebo capsule contained dark brown muscovada sugar and the same inactive excipient (starch). Produced by Chengdu Huashen Group Co., Ltd.
223584783|NCT06507475|DRUG|Semaglutide|Participants treated with commercially available oral semaglutide according to local label and to routine clinical practice at the discretion of the treating physician.
223480461|NCT00513799|BEHAVIORAL|Intensive education on personal hygiene|Repeat hygiene methods for 5 days.
223480462|NCT00634504|DRUG|glucarpidase, high-dose methotrexate, leucovorin|single intravenous dose
223480463|NCT00634504|DRUG|high-dose methotrexate, leucovorin|standard of care, leucovorin every 6 hours
223480464|NCT05224375|DEVICE|Left Atrial Appendage Closure|Closure of the left atrial appendage with the Laminar Left Atrial Appendage Closure System
223480465|NCT00204737|DRUG|prednisone|20mg x 2 weeks
223480466|NCT00204737|DRUG|placebo|placebo
223584784|NCT04771325|BEHAVIORAL|Support from a trained companion|Birth companions trained on how to effectively support women during labor
223584785|NCT02733653|DEVICE|Jetstream Atherectomy System|A rotating, aspirating, expandable catheter system for active removal of atherosclerotic debris and thrombus in the SFA and/or PPA
224167847|NCT06643988|BEHAVIORAL|MemFlex|MemFlex employs cognitive training exercises in self-led sessions to improve 1) switching between specific and general AMs, 2) access to positive AMs, and 3) vividness of positive AMs.
224167848|NCT00945269|BIOLOGICAL|therapeutic autologous lymphocytes|Given IV
223480467|NCT03727165|OTHER|Continuous enteral nutrition infusion|Enteral nutrition administration in continuous infusion during 24 hours per day
223480468|NCT03727165|OTHER|Cyclic enteral nutrition infusion|Enteral nutrition administration in continuous infusion during 16 hours per day
223480469|NCT01456923|OTHER|Treatment with chemotherapy|
223480470|NCT01456923|OTHER|Only chemotherapy treatment for study cohort|Control patients were treated both with surgery and chemotherapy. Study patients were treated only with chemotherapy
223480471|NCT01456923|PROCEDURE|surgery|
223480472|NCT01873144|DRUG|Epinephrine 1/1000|Nebulization of 0.5 mL/kg (maximum 3 mL) of epinephrine 1/1000 every 4h for three times and afterwards at physician in charge criteria
223480473|NCT01873144|DRUG|HSS 3%|Nebulization 2 mL of HSS (3%)+ epinephrine every 4h for three times and afterwards at physician in charge criteria
223584786|NCT02504307|DEVICE|Sirolimus Eluting Stent Inspiron|Angioplasty with Sirolimus Eluting Stent Inspiron implantation
223584787|NCT02504307|DEVICE|Bare Metal Stent|Angioplasty with Bare Metal Stent Cronus implantation
223584788|NCT03418558|DRUG|Trastuzumab emtansine|
223584789|NCT04387266|RADIATION|modified reduce-volume target IMRT|The gross tumor volume of the nasopharynx and neck nodes (GTVnx and GTVnd) were delineated according to the tumor extension. The CTVnx was defined as GTVnx + nasopharynx mucosa + 8mm +corresponding anatomical structure without the delineation of CTV1. The CTVnd was defined as GTVnd plus the elective neck area. The prescribe doses of GTVnx/GTVnd, CTVnx, CTVnd were 66-70Gy,54-56Gy and 50-54Gy in 31-35 fractions, respectively.
223584790|NCT06200883|DRUG|Placebo oral vial|In the Placebo group the participants take vehicle (1 vial per os every 24 hours) for 4 weeks
223584791|NCT06200883|DRUG|Choline Bitartrate|In the CEREBRAIN group the participants take CEREBRAIN (1 vial per os of 1.2 g every 24 hours) for 4 weeks
223584792|NCT02390180|OTHER|Tasting solutions|Participants will taste a variety of food grade compounds including: hexenoic acid, decenoic acid, oleic acid, linoleic acid, glucose, fructose, salt, citric acid, acetic acid, quinine, urea, caffeine, sucrose octaacetate, propylthiouracil, phenylthiocarbamide, monosodium glutamate, and inosine monophosphate.
223584793|NCT00828152|BEHAVIORAL|Internet-delivered CBT.|12 weeks. Therapist contact through e-mail.
224167849|NCT00945269|BIOLOGICAL|aldesleukin|Given SC
224167850|NCT00945269|BIOLOGICAL|denileukin diftitox|Given IV
224167851|NCT00945269|PROCEDURE|biopsy|Optional correlative studies
224167852|NCT00945269|OTHER|immunohistochemistry staining method|Correlative studies
224167853|NCT00945269|OTHER|laboratory biomarker analysis|Correlative studies
224167854|NCT00945269|GENETIC|polymerase chain reaction|Correlative studies
224167855|NCT06229236|BEHAVIORAL|Diabetes Navigator|Participants in the Diabetes Navigator (DN) arm will receive support from a trained navigator to help them improve progression (improving use/optimization) in use of advanced diabetes technology. The Diabetes Navigator will engage with participants immediately after randomization, throughout the duration of study, using a predefined toolkit, educational resources and interventions to assist them in optimizing use of advanced diabetes technology.
224167856|NCT06144229|DIAGNOSTIC_TEST|Self-Collection HPV testing kit from Abbott|Self-swab collection kits, participates will self-collected vaginal swab for hrHPV test (at home or in the clinic)
224167857|NCT06471608|OTHER|Ambulatory management|"* Chest tube drainage in emergency department (Furhmann drain connected to Heimlich valve), connected to suction system at -5 to -10 cm H2O until bubbling stops~* Follow-up imaging at 4 hours (chest X-ray or low-dose CT scan, depending on management practices in the centers)~  * if the pneumothorax is still very large, or if clinical tolerance is unsatisfactory (dyspnea, unrelieved pain, abnormal vital parameters), the patient should be admitted to hospital~ * if the lung is in the process of reattachment and a minimal detachment persists, and clinical tolerance is good (assessed on vital parameters, with oxygen saturation above 98%, good hemodynamic stability and pain relieved by analgesics), the patient may be discharged home."
224167858|NCT06471608|OTHER|Standard Care|"Hospitalisation in a hospital department (pulmonology, thoracic surgery, short-stay emergency unit, critical care, according to the usual pathway of the center in which the patient is included).~In-hospital monitoring until complete resolution of pneumothorax and drain removal (average 4-6 days)."
224167859|NCT04334057|DRUG|Turoctocog alfa pegol|Patients will be treated with commercially available Esperoct® according to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available Esperoct® has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician before and independently from the decision to include the patient in this study.
224167860|NCT03922334|BEHAVIORAL|Patient Navigation Program|A postpartum patient navigation program is designed to reduce barriers to care, enhance access, and improve multiple postpartum health outcomes, including retention in care, contraception uptake, vaccination, and depression screening.
224167861|NCT04217447|DRUG|OAC + Aspirin 100mg od|Patients will receive full-dose of OAC + Aspirin 100mg od during 24 to 48 months (until death or the end of the study : i.e. achievement of 2-year follow-up of the last included patient, maximum of 48-month followup for the first included patient)
224167862|NCT04217447|DRUG|OAC + placebo of Aspirin 100mg od|Patients will receive full-dose of OAC + placebo of Aspirin 100mg od during 24 to 48 months (until death or the end of the study : i.e. achievement of 2-year follow-up of the last included patient, maximum of 48-month followup for the first included patient)
224314203|NCT04327739|OTHER|Intervention 1 Exercise|• Exercise programme Endurance and Resistant training exercise program (Duration: 45 minutes) • Muscle retraining of longus colli and endurance training of the deep cervical flexors. • Resistant exercises for the muscles involved in neck flexion, extension, side bending and rotation of the neck region. Isometric contractions exercises (20-70% of MVC) and resistant exercises (12-15RM). • Active ROM exercises for the neck muscles • Upper limbs exercises with resistant bands • Stretching exercises for the neck and upper limbs muscles
223480474|NCT01873144|DEVICE|HHHFNC|Precision Flow (Vapotherm Inc. Stevensville, Maryland, US ) and RT329 (Fisher and Paykel Healthcare, Auckland, New Zealand) were the dispositive used depending on the availability. Fisher and Paykel nasal cannula was used in both devices, depending on age
223480475|NCT01873144|DRUG|NS (0.9%)|Nebulization of 2 mL of NS (0.9%)+ epinephrine every 4h for three times and afterwards at physician in charge criteria
223480476|NCT05001620|OTHER|Palliative Care Consultation|The PC provider conducts the structured PCC-PAC via videoconference or telephone with the PLWD and/or their care partner and the social work (SW) champion in the NH. The SW and PC provider will set up a mutually agreed upon consultation day/time with the PLWD and/or care partner, within 5 business days of NH admission and follow up visits will occur no more than 30 days later (if needed).
223480477|NCT02036918|DRUG|Sipuleucel-T|
223480478|NCT02036918|PROCEDURE|Lymph Node Biopsy|
223480479|NCT06249230|DIAGNOSTIC_TEST|Hematologic features|Hematologic features include coagulation indicators, autoimmune indicators, and endocrine indicators.
223480480|NCT06249230|DIAGNOSTIC_TEST|Ultrasound indices of uterine artery blood flow|Ultrasound indices of uterine artery blood flow include endometrial thickness, endometrial artery blood flow parameters , and bilateral uterine artery blood flow parameters.
223480481|NCT06249230|OTHER|Demographic characteristics|Demographic characteristics include age, the number of previous spontaneous abortions (including biochemical pregnancies), BMI, fertility history, past disease history, chromosomal status, family and genetic history, etc.
223480482|NCT02104102|OTHER|Mirror Therapy|Mirror Therapy, which is based on the activation of mirror neurons from the illusion generated by viewing the reflection of a member in a mirror, that is, intended to facilitate the movement through the practice of bilateral symmetric activities, since it is able to stimulate cortical plasticity, promoting reversal of the decrease and the reestablishment of motor function.
223480483|NCT02104102|OTHER|Kinesiotherapy|Hands movements.
223480484|NCT03806816|DIETARY_SUPPLEMENT|Melatonin|5 daily enteral doses of melatonin 10 mg/kg. (=2 ml/kg)
223480485|NCT03806816|OTHER|PLACEBO group|5 daily enteral doses of placebo 2 ml/kg
223480486|NCT00481676|DRUG|Omalizumab 75-375 mg|Omalizumab was supplied as lyophilized, sterile powder in a single-use, 5 ml vial designed to deliver 150 mg of omalizumab upon reconstitution with 1.4 ml sterile water for injection.
223480487|NCT00481676|DRUG|Placebo to omalizumab|Placebo to omalizumab was supplied as lyophilized, sterile powder in a single-use, 5 ml vial designed to deliver 150 mg placebo to omalizumab upon reconstitution with 1.4 ml sterile water for injection.
223480488|NCT00481676|DRUG|Loratadine|All participants received antihistamines on demand (loratadine and clemastine), as the trial was designed to investigate the effect of omalizumab as an add-on to antihistamines in people with chronic urticaria (CU). Administration of antihistamines is the current gold standard treatment of CU. A significant proportion of people with CU is not well controlled by this standard or by using high doses of antihistamines.
224167863|NCT05032755|OTHER|SPECTRUM NRC 102/103 investigational cigarettes|Very low nicotine content (nonmenthol/menthol) SPECTRUM investigational cigarettes
224167864|NCT05032755|OTHER|SPECTRUM NRC 600/601 investigational cigarettes|Normal nicotine content (nonmenthol/menthol) SPECTRUM investigational cigarettes
224167865|NCT04944420|BEHAVIORAL|Health enSuite Caregivers|"Advice within Health enSuite Caregivers is organized into 5 priority areas: Taking Care of Yourself (Self-care), Support for You (Support), Supporting the Person Living with Dementia (Characteristics of Persons Living with Dementia), Communication, and Time Management.~Under My Priority Areas, participants will see these in order from highest to lowest need, based on their answers to the needs assessment. Each priority area contains small subtopics and specific tips for things to Try or Avoid. Navigation through the priority areas is user directed and at the participant's discretion. The goal is to make the information they need easy to access."
224167866|NCT02330926|OTHER|standard care|Routine oncology and palliative care
224167867|NCT02330926|DIETARY_SUPPLEMENT|nutritional supplements and advice|n-3 PUFA enriched supplements, dietary advice
224167868|NCT02330926|BEHAVIORAL|home-based self-assisted exercise program|Strength and aerobic
224167869|NCT02330926|DRUG|Ibuprofen|400mgx3
224167870|NCT05031390|PROCEDURE|Physiotherapist-led training|Patients will undergo a 12-week physiotherapist-led training program consisting of 8 supervised sessions and home-based training in between
224167871|NCT06358898|BEHAVIORAL|Standard dCBT-I|This standard digital CBT-I intervention will cover (1) psycho-education about sleep, circadian and sleep hygiene education, (2) stimulus control, (3) sleep restriction, (4) relaxation techniques, (5) structured worry time, (6) cognitive restructuring (targeting sleep-related dysfunctional cognitions), and (7) relapse prevention. In order to have comparable dosage as modified CBT-I, the treatment will be dispersed to 8 modules (8-week) which is still in the range of standard CBT-I duration (usually last for 6-8weeks).
224305356|NCT05736653|DEVICE|PCMS-rest|120 pairs of TMS and PNS volleys will be administered with the EDC muscle at rest every 10 s (\~20 min, 0.1 Hz). TMS will be used to elicit motor-evoked potentials (MEPs). Antidromic activation of spinal motor neurons will be elicited by supramaximal peripheral nerve stimulation (PNS) applied to the radial nerve near the elbow. Volleys will be timed to arrive in the spinal cord based on central and peripheral conduction times calculated for each subject so that the pre-synaptic terminal is depolarized via TMS \~1-2 ms before spinal motor neurons are depolarized via PNS at a pulse duration of 200us. We will also perform stimulation of the cervical roots (C-root) by placing the coil behind the neck and stimulating the C-root (C6 and C7 vertebrae), which innervate the finger extensor muscles. Conduction times will be calculated from latencies of the primary motor area (M1) MEP, C-root, and M-wave.
224305357|NCT02681211|OTHER|Auricular Acupuncture|ASP (acupuncture semi-permanent) gold needles will be placed in the efficacious ear points with a maximum of 3 needles in each ear.
223480489|NCT00481676|DRUG|Clemastine|All participants received antihistamines on demand (loratadine and clemastine), as the trial was designed to investigate the effect of omalizumab as an add-on to antihistamines in people with chronic urticaria (CU). Administration of antihistamines is the current gold standard treatment of CU. A significant proportion of people with CU is not well controlled by this standard or by using high doses of antihistamines.
223480490|NCT04226443|DRUG|Midazolam intravenous injection|The midazolam was prepared as 5 mg midazolam in 20 mL syringe of 5% dextrose water solution (0.25 mg/mL) in both arms. Both groups of patients received an intravenous bolus dose of midazolam was administered before the start of the surgery. In Group 1, continuous infusion of intravenous midazolam was started and in Group 2, intravenous bolus doses of midazolam were administered. The doses were adjusted depending on pain level and sedation level using appropriate scales for monitoring during the surgical time period. The drip rate was adjusted according to pain intensity. The infusion of drugs was discontinued at the end of the procedure.
223480491|NCT04226443|DRUG|Remifentanil intravenous bolus dose|A remifentanil infusion was prepared as follows; 0.5 mg remifentanil was added into 100 mL of 0.9% saline at a concentration of 5 μg/mL. The preparation of remifentanil solution and installation of the device was done by an anesthesiologist who was blinded for the study groups. The dose and number of patients that required remifentanil were recorded. The infusion of drugs was discontinued at the end of the procedure. A rescue medication of intravenous remifentanil bolus dose was used as 1 to 3 mL (5 μg or 15 μg) every 5 minutes if necessary for pain scores greater than 3. This infusion was prepared prior to the use during the study and was discontinued at the end of the procedure.
223480492|NCT05207501|BEHAVIORAL|Exercise|Participants will perform 3 times a week for 4 weeks a moderate intensity interval training.
223744911|NCT01069146|PROCEDURE|Mild therapeutic hypothermia induction|Mild Therapeutic hypothermia was induced immediately after patient inclusion. Patients were cooled between 32 and 34°c (33 ± 1°C; 90 and 93°F) for 36 hours, using the automatic mode of an external water cooling blanket (Meditherm II®, Gaymar, Orchard Park, NY, USA). The machine constantly compares actual patient temperature (measured by a rectal probe) with the set point, and automatically adjusts the blanket water temperature so that the desired patient temperature is achieved. The target temperature was to be reached within eight hour following inclusion. Rewarming was only passive (blanket switched off), and paralytic agents were to be stopped when the body temperature reached back 36°C (97°F).
223744912|NCT00425230|DRUG|Duloxetine|
224167872|NCT06358898|BEHAVIORAL|Modified Mood enhanced CBT-I (M-dCBT-I)|Additional depression specific components will be added to the standard CBT-I, including behavioral activation and problem solving.
224167873|NCT03596268|DIAGNOSTIC_TEST|Imaging|3T Prisma MRI
224167874|NCT03596268|DIAGNOSTIC_TEST|Serum Laboratory Tests|Blood (plasma and cellular) will be collected.
224167875|NCT03596268|DIAGNOSTIC_TEST|Lumbar Puncture|CSF will be collected
224167876|NCT00814905|DRUG|saline|A saline infusion after delivery (one dose)
224167877|NCT00814905|DRUG|ampicillin gentamicin|one additional dose of antibiotics (ampicillin 2 grams IV, gentamicin 1.5 mg/kg IV) following their vaginal delivery
224167878|NCT00814905|DRUG|Ampicillin gentamicin clindamycin|one dose of ampicillin 2 grams IV, gentamicin 1.5 mg/kg IV, clindamycin 900 mg IV and then saline infusions instead of antibiotics until they are afebrile for 24 hours ( they will receive saline infusions instead of antibiotics)
224167879|NCT00814905|DRUG|ampicillin gentamicin clindamycin|ampicillin 2 g IV every 6 hours, gentamicin 1.5mg/kg every 8 hours, and clindamycin 900 mg IV every 8 hours until the patient has been afebrile for 24 hours
224167880|NCT06509568|RADIATION|Neoadjuvant chemoradiotherapy followed by immunotherapy|Patients in the nCRIT group will receive neoadjuvant concurrent chemoradiotherapy: radiation therapy will be administered using IMRT or VMAT with involved-field irradiation at a dose of PTV 41.4 Gy/23 fractions/31 days. Chemotherapy will consist of weekly administration of paclitaxel (albumin-bound) 50 mg/m² and carboplatin (AUC 2) for five weeks, given on the days of radiotherapy. Patients who do not progress on CT and meet immunotherapy criteria will receive fixed-dose tislelizumab (200 mg IV) on days 8 and 29 after chemoradiotherapy, followed by minimally invasive esophagectomy four weeks after completing immunotherapy.
224167881|NCT06509568|DRUG|Neoadjuvant chemoimmunotherapy|Patients in the nCIT group will receive two cycles of TC chemotherapy combined with immunotherapy, specifically paclitaxel (albumin-bound) 100 mg/m² on days 1, 8, 15 or 260mg/m² d1, carboplatin (AUC=5) on days 1, and tislelizumab (200 mg) on days 1. Minimally invasive esophagectomy will be performed 4-6 weeks after completing chemotherapy, and adjuvant immunotherapy is recommended for one year after surgery.
224167882|NCT03381274|BIOLOGICAL|Oleclumab|Participants will receive oleclumab in combination with osimertinib or AZD4635 as stated in the arms' description.
224167883|NCT03381274|DRUG|Osimertinib|Participants will receive osimertinib in combination with oleclumab as stated in the arms' description.
224167884|NCT03381274|DRUG|AZD4635|Participants will receive AZD4635 in combination with oleclumab as stated in the arms' description.
224167885|NCT02566122|OTHER|measurements|
224167886|NCT03613532|DRUG|Venetoclax|Part 1: 6-7 total doses depending on dose level assigned
224167887|NCT03613532|DRUG|Fludarabine|Given once daily for 4 days
224167888|NCT03613532|DRUG|Busulfan|Given twice daily for 4 days
224167889|NCT03613532|DRUG|Venetoclax|Part 2, Part 3, and Part 4: 14 doses for 8-12 cycles depending on dose level assigned
224167890|NCT03613532|DRUG|Azacitidine|Part 2 and Part 4: 5 doses for 8-12 cycles depending on dose level assigned
224167891|NCT03613532|DRUG|Decitabine/cedazuridine|Part 3: 3 doses for 8 cycles
224167892|NCT05805839|DRUG|C-11 ER176 Radiotracer|Administered at a single time IV prior to the PET imaging. The injected dose of C-11 ER176 will be 518 MBq (14 mCi) (range 370-666 MBq; 10-18 mCi).
224167893|NCT05805839|DRUG|C11 Pittsburgh Compound B|Administered at a single time IV prior to the PET imaging. The injected dose of C-11 PiB will be 555 MBq (range 370 - 629 MBq).
224167894|NCT05805839|DIAGNOSTIC_TEST|PET/CT scan|Imaging of entire brain
224167895|NCT05805839|DIAGNOSTIC_TEST|MRI|Magnetic Resonance Imaging of the Brain
223480493|NCT03937778|BEHAVIORAL|Deep pressure block|Apply deep pressure block by using blood pressure cuff.
224167896|NCT06097832|BIOLOGICAL|NXC-201 CAR-T|NXC-201 (formerly HBI0101) CAR-T is defined as autologous T cells transduced ex-vivo with anti-BCMA CAR retroviral vector encoding the chimeric antigen receptor (CAR) targeted to human BCMA. The NXC-201 CAR-T is provided fresh without cryopreservation.
224167897|NCT06798337|OTHER|Conventional Physiotherapy group|Participants in the regular physical therapy group performed balance and coordination exercises three times a week without the use of rewards. These subjects completed only physical exercises, without engaging in game-like interactive tasks using virtual reality (VR) glasses. Each session was conducted at the same time for each subject, with a potential variation of ±1 hour.
224305358|NCT02681211|DRUG|Ketorolac 0.5mg/kg, max 30mg|"If assigned to receive intravenous medications and fluid the subject will be treated with the ED standard of care medications which include:~1. Ketorolac 0.5mg/kg, max 30mg~2. Metoclopramide 0.1 mg/kg, max 10mg~3. Diphenhydramine 1mg/kg, max 50mg~4. Normal saline fluid bolus 20mL/kg, max 1000mL"
223480494|NCT04816344|PROCEDURE|Outpatient Anesthesia|The inclusion criteria were children aged between 2 and 10 years, undergoing outpatient anaesthesia for elective MRI under sedation, and classified as American Society of Anesthesiologists (ASA) grade I-II. The study exclusion criteria were defined as difficult airway, allergies to the study drugs, asthma, severe central nervous system disease (eg, brain tumour, uncontrolled seizures), mental motor retardation, the application of another procedure after MRI sedation, and those whose parents declined to participate in the study.
223480495|NCT01703156|PROCEDURE|Stress Test|
223480496|NCT01703156|PROCEDURE|No Stress Test|
224167898|NCT06798337|OTHER|Reward based physiotherapy group|Subjects in the reward group performed balance and coordination exercises three times a week, with the inclusion of rewards. At the end of each exercise session, participants engaged in game-like interactive tasks using virtual reality (VR) glasses. Exercise sessions were conducted at the same time for each subject, with a permissible variation of ±1 hour.
224167899|NCT06016738|DRUG|Palazestrant|Participants will be treated with palazestrant once daily on a 4 week (28 day) cycle. Doses evaluated in the dose-selection part will be 120 mg once daily and 90 mg once daily.
223480497|NCT03748667|DIAGNOSTIC_TEST|White light endoscopy (WLE)|Subjective endoscopic assessment of deep submucosal invasion based on the presence of gross morphological malignant features, morphology and size.
224167900|NCT06016738|DRUG|Fulvestrant|Participants will be treated with fulvestrant on C1D1, C1D15, and then on Day 1 of every subsequent 4 week (28 day) cycle
224167901|NCT06016738|DRUG|Anastrozole|Participants will be treated with anastrozole once daily on a 4 week (28 day) cycle
224167902|NCT06016738|DRUG|Letrozole|Participants will be treated with letrozole once daily on a 4 week (28 day) cycle
224167903|NCT06016738|DRUG|Exemestane|Participants will be treated with exemestane once daily on a 4 week (28 day) cycle
224167904|NCT01874353|DRUG|Olaparib 300mg tablets|300mg Olaparib or placebo tablets taken orally twice daily until objective radiological disease progression as per RECIST as assessed by the investigator (or as long as in the investigator's opinion they are benefiting from treatment and they do not meet any other discontinuation criteria). Dose reduction to 250mg and subsequently 200mg is permitted following confirmation of toxicity.
224305359|NCT02681211|DRUG|Metoclopramide 0.1 mg/kg, max 10mg|"If assigned to receive intravenous medications and fluid the subject will be treated with the ED standard of care medications which include:~1. Ketorolac 0.5mg/kg, max 30mg~2. Metoclopramide 0.1 mg/kg, max 10mg~3. Diphenhydramine 1mg/kg, max 50mg~4. Normal saline fluid bolus 20mL/kg, max 1000mL"
224305360|NCT02681211|DRUG|Diphenhydramine 1mg/kg, max 50mg|"If assigned to receive intravenous medications and fluid the subject will be treated with the ED standard of care medications which include:~1. Ketorolac 0.5mg/kg, max 30mg~2. Metoclopramide 0.1 mg/kg, max 10mg~3. Diphenhydramine 1mg/kg, max 50mg~4. Normal saline fluid bolus 20mL/kg, max 1000mL"
223744913|NCT01169610|DRUG|Varenicline|Varenicline is an oral medication with a recommended dosage of 0.5 mg once daily for 3 days, increasing to 0.5 mg twice daily for days 4 to 7, and then to the maintenance dose of 1 mg twice daily for the remaining 23 weeks of treatment. All subjects will receive open-label varenicline in blister packs.
224167905|NCT01874353|DRUG|Placebo to match olaparib 300mg|300mg Olaparib or placebo tablets taken orally twice daily until objective radiological disease progression as per RECIST as assessed by the investigator (or as long as in the investigator's opinion they are benefiting from treatment and they do not meet any other discontinuation criteria). Dose reduction to 250mg and subsequently 200mg is permitted following confirmation of toxicity.
224167906|NCT04392154|BIOLOGICAL|Lebrikizumab|Subcutaneous injection
224167907|NCT03059823|DRUG|retifanlimab|Anti-PD-1 monoclonal antibody
224167908|NCT05240300|BIOLOGICAL|BX005-A|phage gel
224167909|NCT05240300|OTHER|Placebo|vehicle gel
224305361|NCT02681211|DRUG|Normal saline fluid bolus 20mL/kg, max 1000mL|"If assigned to receive intravenous medications and fluid the subject will be treated with the ED standard of care medications which include:~1. Ketorolac 0.5mg/kg, max 30mg~2. Metoclopramide 0.1 mg/kg, max 10mg~3. Diphenhydramine 1mg/kg, max 50mg~4. Normal saline fluid bolus 20mL/kg, max 1000mL"
224305362|NCT05875103|DIAGNOSTIC_TEST|linguistic processes|"Linguistic processes are assessed by performance score on the following tests:~* naming tests : BNT 34 (Colombo \& Assal, 1992) and semantic naming adapted from the BECS-GRECO (Merck et al., 2011)~* vocabulary test (Mill Hill - Deltour, 1993),~* repetition tests (Gremots - Bézy et al., 2016),~* articulatory speed (Majerus, 2014 ; Roussel et al., 2012)~* semantic matching task adapted from the PPT (Howard \& Patterson, 1992) and from the BECS-GRECO (Merck et al., 2011),~* semantic categorization and attributes adapted from the BECS-GRECO (Merck et al., 2011),~* phonologic and semantic research tasks adapted from the color TMT (D'helia et al., 1996)"
223480498|NCT03748667|DIAGNOSTIC_TEST|NBI/BLI +/- chromoendoscopy (NBIBLI +/- CE)|Endoscopic assessment of deep submucosal invasion with NBI and dual focus/magnification or BLI and magnification. In the case of demarcated areas or JNET 2B, Kudo pit pattern assessment with crystal violet will be performed.
223480499|NCT04909723|COMBINATION_PRODUCT|NOV-001|NOV-001 is an investigational combination product composed of NB1000S, a recombinant live biotherapeutic product, and NB2000P, a botanically derived polysaccharide.
223480500|NCT04909723|BIOLOGICAL|NB1000S|A recombinant live biotherapeutic product.
224071979|NCT02174055|BEHAVIORAL|Pilot Testing the Draft Measure|The draft measure (approximately 35 items, described above) will be administered to a large sample of older cancer patients (n=150) to generate data to evaluate preliminary psychometric properties (item properties including measures of central tendency, skewness/kurtosis, internal consistency, test/re-test reliability, and construct validity (i.e, convergent and discriminant).and known group differences) to further winnow the measure to include approximately 20 items.
223480501|NCT04909723|DRUG|NB2000P|A botanically derived polysaccharide.
223480502|NCT04909723|DRUG|Placebo|Placebo
223480503|NCT00819039|DRUG|Aprepitant|Aprepitant administered orally or intraveously.
223480504|NCT00819039|DRUG|Ondansetron|Ondansetron administered intravenously.
224071980|NCT04521231|DRUG|Blinatumomab|Blinatumomab will be administered as a subcutaneous (SC) injection.
224071981|NCT05768659|BEHAVIORAL|Fear Conditioning|"It is a 2-day paradigm. Participants will undergo an auditory fear conditioning task in 3 phases: (1) pre-conditioning habituation, (2) unconditioned stimulus (US) calibration, where USs will be delivered to set the individual stimulation intensity threshold, and (3) fear conditioning, in which participants will be exposed to the conditioned stimulus (CS) associated with the US with an 80% pairing rate. 24 hours later, the (1) implicit recognition of the CS and novel stimuli (NSs), and the (2) explicit recognition, through an alternative forced-choice task will be assessed. Also, (3) the perceptual discrimination (among the CS and NSs) will be tested.~Event-related skin conductance responses (SCRs) will be collected as an implicit index of defensive fear responses, while the accuracy in detecting and discriminating the CS from NSs as the explicit index. Psychological questionnaires about anxiety symptoms will be also administered."
224071982|NCT06802380|DEVICE|Low-level tragus stimulation|Low-level tragus stimulation will recruit the fibers from the inner part of the tragus of the external ear and sent afferent signals through the greater auricular branch of the vagus nerve. Ultimately the stimulation is transmitted to the dorsal vagal complex and the brainstem thereby modulating the neuronal activity in the vehicle output. Sham stimulation will be performed by clipping the electrode to the ear lobule which will not relay any afferent signals through the greater auricular branch of the vagus nerve.
224071983|NCT06802380|DEVICE|Sham stimulation|In the sham stimulation the electrodes will be attached to the ear lobule which are devoid of any afferent nerves traveling to the greater auricular branch of the vagus nerve.
224071984|NCT03494881|DRUG|Nucala|All study participants will receive Nucala (2) 100mg SQ injections administered at two different anatomical sites at week zero, 2,4,6, and 8 for a total of 5 doses.
224167910|NCT06085495|PROCEDURE|mechanical thrombectomy (PMT)|After the establishment of the pathway, Angiojet (Boco, USA) was used to infuse urokinase into the blood vessels of the thrombotic segment. After waiting for 15 minutes, mechanical thrombectomy was performed. After thrombectomy, the effectiveness of thrombectomy was evaluated through angiography. For residual thrombi, repeated thrombectomy was performed, with a maximum thrombectomy volume of 480ml. After thrombectomy, antegrade angiography of the dorsal vein of the foot was performed again. If iliac vein stenosis was found to be greater than 50%, Then, Mustang balloons (Boko, USA) that match the normal blood vessel diameter are used for dilation. If the residual stenosis after dilation is greater than 30%, Wallsten stents that match the normal blood vessel diameter are inserted (Boko, USA). After all operations are completed, a dorsalis pedis venography is performed again to evaluate the thrombus burden and calculate the immediate thrombus clearance rate and thrombus clearance level.
224167911|NCT04195945|DRUG|Liposome-encapsulated Daunorubicin-Cytarabine|Given IV
224167912|NCT04195945|DRUG|Cladribine|Given IV
223480505|NCT03310047|DRUG|Infusion, Lidocaine, 0.5%, 5 mL|A catheter-based perineural infusion of 5 mL Lidocaine 0.5%
223480506|NCT03310047|DRUG|Infusion, Lidocaine, 0.5%, 10 mL|A catheter-based perineural infusion of 10 mL Lidocaine 0.5%
223480507|NCT02494024|DRUG|Single dose C2N-8E12|C2N-8E12 is a humanized recombinant anti-human tau antibody.
223584794|NCT00828152|BEHAVIORAL|On line discussion group|Placebo. On line discussion group.
224071985|NCT05768633|BEHAVIORAL|Counterfactual Inference Test|All participants will be asked to complete the Counterfactual Inference Test - CIT (McNamara et al., 2003), a neuropsychological test that measures the ability to produce counterfactual-derived inferences. Moreover, the decision-making ability will be specifically tested through ad-hoc questionnaire (i.e., the Decision-Making Questionnaire). Finally, all participants will be screened with an extensive neuropsychological assessment, particularly on executive functioning.
224071986|NCT05466422|BIOLOGICAL|MK-2214|MK-2214 in escalating doses as an IV infusion on Days 1, 29, and 57
224071987|NCT05466422|DRUG|Placebo|Placebo as an IV infusion on Days 1, 29, and 57
224071988|NCT05313464|OTHER|parent-pushed enteral feeding|skin-to-skin enteral nutrition pushed by the parent
224071989|NCT05313464|OTHER|syringe-push enteral feeding|skin to skin nutrition with syringe pump
224071990|NCT05838287|DRUG|Pioglitazone|Participants will be taking Pioglitazone tablets 1/day for 24 weeks.
224071991|NCT05838287|DRUG|Placebo|Placebo for Pioglitazone
224071992|NCT05635968|RADIATION|Low-dose whole brain irradiation|In the experimental group (1), 20 patients receive 4cGy x 6 times, a total of 24 cGy of irradiation. In the experimental group (2), 20 patients receive 50 cGy x 6 times, a total of 300 cGy of irradiation. All experimental groups and control group visit the hospital about 1, 6, and 12 months after irradiation to evaluate efficacy and safety.
224071993|NCT01415752|BIOLOGICAL|rituximab|Given IV
224071994|NCT01415752|DRUG|Bendamustine|Given IV
224071995|NCT01415752|DRUG|bortezomib|Given IV or SC
224071996|NCT01415752|DRUG|lenalidomide|Given PO
224071997|NCT03530371|DRUG|Dexmedetomidine Hydrochloride|intranasal administration of 2.5µg/kg of dexmedetomidine to fall asleep the patients
224071998|NCT02507011|DRUG|Carvedilol|Beta-adrenergic receptor blocker
224071999|NCT02507011|DRUG|Placebo|Placebo
224072000|NCT04208477|PROCEDURE|one site blockade of the stellate ganglion|Ultrasound guided one site blockade of the stellate ganglion.
224072001|NCT03066102|OTHER|muscle fatigue|"Modified push-up plus exercise:~the participants first supported by both knees and the single elbow, and then performed sustained scapular protraction for three minutes with ten repetitions in males and two minutes with five repetitions in females with forty-five seconds rest between."
224072002|NCT01240460|DRUG|XL765 (SAR245409)|Supplied as 10-mg and/or 50-mg capsules
224072003|NCT01240460|DRUG|XL147 (SAR245408)|Supplied as 100-mg, 150-mg and/or 200-mg tablets
224072004|NCT03324997|DRUG|Restylane Silk|Restylane Silk is a temporary hyaluronic acid filler currently approved for the lips and fine lines around the mouth.
224072005|NCT03324997|DRUG|Saline|Saline as placebo
224072006|NCT03324997|DEVICE|Optical Coherence Tomography|An FDA-cleared non-invasive imaging device
224072007|NCT01441063|DRUG|Zidovudine|Zidovudine (AZT) 600 mg orally q6 hours (every 6 hours)
224072008|NCT01441063|DRUG|Tocilizumab|Tocilizumab 8mg/kg every 2 weeks
224072009|NCT01441063|DRUG|Valganciclovir (VGC)|Valganciclovir (VGC) 900 mg orally q12 hours (every 12 hours) on days 1-5 of a 14-day cycle.
224072010|NCT02510287|DRUG|Bupivacaine and Fentanyl Initial Dose|10 ml of 0.1% bupivacaine (2 ml of 0.5% bupivacaine and 50 mcg / ml fentanyl in 7 ml of normal saline solution)
224072011|NCT02510287|DRUG|Bupivacaine and Fentanyl: Continuous Epidural Infusion|0.1% bupivacaine and fentanyl 2 mcg / ml (8-12 ml / hour)
224072012|NCT02510287|DRUG|Bupivacaine and Fentanyl: Programmed Intermittent Epidural Bolus|A 0.1% bupivacaine and fentanyl 2 mcg / ml (8-12ml) bolus will be administered each hour at a rate of 500ml/hour
224072013|NCT02510287|DRUG|Rescue Bolus|Upon patient request, rescue bolus of 8-10 ml of 0.1% bupivacaine will be administered.
224072014|NCT02510287|DRUG|Lidocaine|If needed, during the second phase (9-10 centimeters of cervical dilation) a 2% lidocaine without epinephrine (8-10 cc) bolus will be administered.
224072015|NCT01119170|OTHER|Starter formula|standard starter formula given from birth to 6 months of age
224072016|NCT01119170|OTHER|starter formula with D-lactate producing probiotics|starter formula containing probiotics given from birth to 6 months of age
224072017|NCT01851850|DRUG|Opicapone|25mg or 50mg once per day
223584795|NCT03922165|PROCEDURE|Adenotonsillectomy|Routine AT per clinical care.
223584796|NCT02764684|DRUG|Probiotic|The probiotic strain Lactobacillus rhamnosus will be self-administrated twice a day, one capsule in the morning and one in the evening for eight weeks.
223584797|NCT02738424|OTHER|Calculate the ADC scores|The MRI will be performed on the two groups of patients in the usual care. The intervention will be based on the ADC scores calculation. The scores will be obtained with three types of post-processing softwares : Siemens, PACS Carestream, Osirix.
223584798|NCT06960629|DRUG|Netarsudil 0.02%/latanoprost 0.005% fixed dose combination ophthalmic solution|Patients with pseudophakic bullous keratopthy and glaucoma will receive topical netarsudil/latanoprost 1x daily for 3 months.
224072018|NCT01926782|DRUG|Placebo (for alirocumab)|Solution for injection, subcutaneous injections in the abdomen, thigh, or outer area of upper arm with an auto-injector.
224072019|NCT01926782|DRUG|Alirocumab|Solution for injection, subcutaneous injection in the abdomen, thigh, or outer area of upper arm with an auto-injector.
224072020|NCT01926782|DRUG|Statin|Atorvastatin, rosuvastatin and simvastatin at stable dose in participants with stable statin therapy
224072021|NCT02615743|BEHAVIORAL|Daily Text message reminder|Subjects in the intervention arm will receive once daily text messages at the time of their choice or at a default time of 7am. The text message will remind them to give their child their controller medication and provide a helpful information on asthma controller use.
224072022|NCT02615743|DEVICE|Inhaled steroid canister monitor|An electronic monitor will be affixed to subjects' inhaled steroid canister and families will be instructed to use the inhaler as directed by their physician. Subjects will not receive daily text messages.The canister monitor, the Propeller sensor (Propeller, Madison, Wisconsin) is an FDA-approved, portable device which affixes to the top of most metered dose inhaler canisters. The devices records the number and time of each inhaler actuation and transmits this information to either a smart phone or cellular modem. Data is then sent via the cellular network to the secure Propeller server. The data will then be downloaded monthly.
224072023|NCT01207622|DRUG|Atomoxetine|
224072024|NCT01207622|DRUG|Placebo|
224167913|NCT04195945|DRUG|Cytarabine|Given IV
223584799|NCT06960629|DRUG|Placebo|Patients with pseudophakic bullous keratopathy and glaucoma will receive topical placebo 8artificial tear substitute) 1x daily for 3 months.
223584800|NCT00890682|DRUG|SKY0402|Local infiltration of 8cc SKY0402
223584801|NCT00890682|DRUG|Placebo|Local infiltration of 8cc Placebo
224167914|NCT04195945|BIOLOGICAL|Recombinant Granulocyte Colony-Stimulating Factor|Given SC
224167915|NCT04195945|DRUG|Mitoxantrone|Given IV
224167916|NCT04195945|OTHER|Questionnaire Administration|Ancillary studies
224167917|NCT04195945|OTHER|Quality-of-Life Assessment|Ancillary studies
224167918|NCT05624710|DRUG|INCB054707|INCB054707 75 mg will be administered orally on Day 1.
224167919|NCT05705401|RADIATION|Standard of Care Adjuvant Breast Radiation|adjuvant breast radiotherapy per the current standard of care
223480508|NCT02494024|DRUG|Single dose placebo|Subjects will be block randomized to receive a single dose of C2N-8E12 or placebo in two blocks of 4 subjects (3:1, C2N-8E12:placebo) per cohort.
223480509|NCT01240694|DRUG|CEP-33457|CEP-33457 will be administered subcutaneously per dose specified in the arm description.
223480510|NCT01513590|DRUG|insulin degludec/insulin aspart|Administered s.c. (under the skin) twice daily. Dose individually adjusted. Pre-trial metformin treatment to be continued.
223480511|NCT00005996|DRUG|cisplatin|
223480512|NCT00005996|DRUG|gemcitabine hydrochloride|
223584802|NCT02915185|PROCEDURE|strength training intervention|The strength training program will last 4 weeks (3 times/week, 60 minutes). Using dead weights, the 1RM (i.e. the maximal load that an individual can lift once) will be estimated by the 10RM in order to avoid tendino-muscular injuries and fatigue. The 10RM will be determined for the muscles playing a key role in the functional performance of the upper limb, which are the wrist extensors and the elbow and shoulder flexors. In addition, the grip muscles of the affected hand will be trained with a JAMAR® dynamometer. Participants' maximal grip force will be determined and used to dose the training of the hand muscles and its progression. The training will begin and end by a 5-minute warm-up and relaxation period comprising of active movements of the trained muscles.
223584803|NCT02915185|DEVICE|tDCS|An anodal montage over the ipsilesional hemisphere will be used where the anode will be placed over the ipsilesional M1 area whereas the cathode will be placed on the contralateral supra-orbital region.For the tDCS real group, a direct current will be generated by a tDCS stimulator and gradually increased in a ramp-like fashion over the first 8 seconds until a maximum intensity of 2 mA is achieved. The tDCS will be applied for 20 minutes during each training session for a total of 12 sessions. For the group receiving sham tDCS, the protocol will be similar to the tDCS real group although the stimulation will be applied for the first 30 seconds only; a duration long enough to induce similar perceived sensation as real tDCS (tingling), to keep participants' blind to the tDCS type.
223744914|NCT03755414|PROCEDURE|Stem cell transplantation|Standard of care
224167920|NCT05705401|DRUG|Standard of Care HER2-targeted Therapy Without Adjuvant Breast Radiation|participants are randomized to continue their standard of care systemic HER2-targeted therapy without adjuvant breast radiotherapy
224167921|NCT05645692|DRUG|Atezolizumab|Participants will receive 1200 mg IV atezolizumab Q3W.
224167922|NCT05645692|DRUG|Tobemstomig|Participants will receive 600 mg IV tobemstomig Q3W.
224167923|NCT05645692|DRUG|Tiragolumab|Participants will receive 600 mg IV tiragolumab Q3W.
224167924|NCT03250247|DEVICE|Stents|"US-guided puncture of vein, fluoroscopic monitoring of catheter/guidewire manipulations, baseline venogram of CFV through infrarenal IVC.~Iliac vein should be pre-dilated to at least 12 mm. Bare, self-expanding stents made of elgiloy or nitinol legally marketed in the US for any indication and that are at least 12 mm in diameter should be used to recanalize the entire diseased segment of vein.~The use of devices \> 14 mm is highly recommended for the iliac vein and dilated to at least 14 mm, unless compelling patient factors dictates dilatation to a smaller diameter.~Balloon angioplasty of inflow veins.~After successful iliac vein recanalization, patients who continue to be symptomatic beyond 2 weeks follow-up and who have valvular reflux in GSV, accessory GSV, anterolateral thigh circumflex, and/or SSV should be offered endovenous ablation.~Any FDA-approved method may be used including radiofrequency or laser ablation, sclerotherapy or pharmacomechanical ablation."
224167925|NCT01239134|BIOLOGICAL|TRX518|Humanized, Fc disabled, anti-human GITR (glucocorticoid-induced tumor necrosis factor receptor) monoclonal antibody
224167926|NCT06103955|BEHAVIORAL|Digital Breathing Biofeedback system|The biofeedback system provides information to the patient and physio about the muscle coordination of breathing.
224167927|NCT04250155|DRUG|XmAb24306|Participants will receive intravenous (IV) XmAb24306.
224167928|NCT04250155|DRUG|Atezolizumab|Participants will receive IV XmAb24306 followed by IV atezolizumab
224167929|NCT04250155|DRUG|XmAb24306|Participants will receive IV XmAb24306 followed by IV atezolizumab.
224167930|NCT06225141|OTHER|Clinical Data reuse|Clinical Data reuse
224167931|NCT00740090|DRUG|AMA1-C1/Alhydrogel plus CPG 7909|
224167932|NCT04849676|OTHER|visual neurofeedback|"Neurofeedback is a neuromodulatory intervention that does not require applying external stimuli. It relies on displaying participants' brain activity in real time, with the aim of modifying it. Electrical activity (EEG) will be recorded from participants and displayed in real time on a computer screen, in the form of three bars. They will be asked to increase the middle bar, while keeping the side bars low.~The intervention requires training to achieve voluntary control of the targeted brain activity."
224305363|NCT04257149|DIAGNOSTIC_TEST|Hemorrhagic stroke group (group A)|Group A: A microwave measurement (Stroke finder MD100) will be performed with the patient lying on the ambulance stretcher, in the hospital bed or another suitable surface.
223480513|NCT00005996|DRUG|semaxanib|
223480514|NCT00251472|DRUG|Paclitaxel Albumin Nanoparticle for Injectable Suspension|125mg/m2 by 30-minute IV infusion, once a week.
223480515|NCT01056276|DRUG|Bendamustine|Treatment: 80 mg/m2 via intravenous (IV) Days 1 and 2; repeat cycles every 28-days for 8 cycles or 2 cycles beyond confirmed complete response.
223480516|NCT01056276|DRUG|Bortezomib|"1.3 mg/m2 IV Days 1, 8, 15; repeat cycles every 28-days for 8 cycles or 2 cycles beyond confirmed complete response.~Maintenance: 1.3 mg/m2 IV or SQ Days 1, 15"
223480517|NCT01056276|DRUG|Dexamethasone|20 mg orally (PO) Days 1, 2, 8, 9, 15, 16 every 28-days for 8 cycles or 2 cycles beyond confirmed complete response, Maintenance: 20 mg PO Days 1, 15
223744915|NCT03755414|DRUG|Itacitinib|Itacitinib may be taken without regard to food.
223744916|NCT03755414|OTHER|Functional Assessment of Cancer Therapy-Bone Marrow Transplant (FACT-BMT)|"* Screening, day 14, day 28, day 42, day 74, day 100, taper period, and follow-up (pilot study)~* Screening, day 14, day 28, day 42, day 74, day 100, day 180, taper period, and follow-up period (expansion study)"
223744917|NCT03755414|OTHER|Human Activity Profile|"* Screening, day 14, day 28, day 42, day 74, day 100, taper period, and follow-up (pilot study)~* Screening, day 14, day 28, day 42, day 60, day 74, day 100, day 180, taper period, and follow-up period (expansion study)"
224167933|NCT05371795|DEVICE|Comfort Marker 2.0|The set-up markings are created during the simulation session, after the CT simulation is acquired. For the experimental group, patients' markings are tattooed using an electric marking device developed for set-up marking, the Comfort Marker 2.0® (CM), designed by CIVCO medical solutions, using the 0.2mm deep application depth and the brand-included black pigment. After cleaning the excess ink, if the tattooing was considered unsuccessful, the process was repeated. Markings arrangement followed our departmental protocol. No limit on the maximum number of cutaneous reference points is specified.
224167934|NCT05371795|DEVICE|Lancets|The set-up markings are created during the simulation session, after the CT simulation is acquired. For the control group, patients' markings are tattooed using a 28-gauge disposable lancet and india ink. After cleaning the excess ink, if the tattooing was considered unsuccessful, the process was repeated. Markings arrangement followed our departmental protocol. No limit on the maximum number of cutaneous reference points is specified.
224167935|NCT04004026|OTHER|Assesment|3-m backwards walk test, timed up and go test, 12-item MS Walking Scale, 2-min walk test, timed 25-foot walk test, 4-square step test.
224167936|NCT01327573|DRUG|eculizumab|"* Eculizumab Induction 600mg IV every 7 days for 4 doses~* Eculizumab 900mg IV 7 days later~* Eculizumab Maintenance 900mg IV every 14 days for total of 26 weeks"
224167937|NCT00095394|DRUG|Irbesartan/HCTZ|Tablets, Oral, Irbesartan 150mg/HCTZ 12.5 mg, Once daily, 7 weeks.
224167938|NCT00095394|DRUG|Irbesartan monotherapy|Tablets, Oral, 150 mg, Once daily, 7 weeks.
223480518|NCT01881425|PROCEDURE|Glaucoma Surgery|"An initial pocket is created under the conjunctiva and Tenon's capsule and the wound bed is treated for two minutes with mitomycin C (MMC, 0.2 mg/ml)soaked sponges. This is done using a fornix-based conjunctival incision at the corneoscleral junction. A partial thickness scleral flap with its base at the corneoscleral junction after cauterization of the flap area, and a window opening is created under the flap with a Kelly-punch to remove a portion of the sclera, Schlemm's canal and the trabecular meshwork to enter the anterior chamber. An iridectomy is done in many cases to prevent future blockage of the sclerostomy. The scleral flap is then sutured loosely back in place with several sutures. The conjunctiva is closed in a watertight fashion at the end of the procedure."
223480519|NCT01881425|DEVICE|InnFocus MicroShunt|"An initial pocket is created under the conjunctiva and Tenon's capsule and the wound bed is treated for two minutes with mitomycin C (MMC, 0.2 mg/ml)soaked sponges. This is done using a fornix-based conjunctival incision at the corneoscleral junction. After cauterization of the flap area, a knife is used to create a shallow pocket at the scleral surface and an opening into the AC. The device is then threaded through the track until the proximal end is in the anterior chamber and the fin of the device is pushed into the shallow scleral pocket. The device is checked to observe aqueous flow and the distal end placed under the Tenons/conjunctiva. The conjunctiva is closed in a watertight fashion at the end of the procedure."
223480520|NCT00521495|DEVICE|neodymium permanent magnet|"3/4 diameter by 1/8 thick permanent magnet"
223480521|NCT00521495|DEVICE|neodymium magnet|A. 450 Gauss static magnetic field at target B. 150 Gauss static magnetic field at target C. 0 Gauss static magnetic field at target
223480522|NCT00521495|DEVICE|magnet|0 Gauss magnets are worn every night during hours of sleep for 6 weeks.
223480523|NCT06351176|DIAGNOSTIC_TEST|Clinical tests|The investigators perform the following clinical tests: vibration threshold test, monofilament test, and height, weight and waist circumference measurement in every participant.
223480524|NCT06351176|DIAGNOSTIC_TEST|Biochemical tests|The investigators perform blood and urine tests in every participant.
223480525|NCT06351176|DIAGNOSTIC_TEST|DXA scan with TBS and VFA|The investigators perform a dual energy x-ray absorptiometry (DXA scan or osteodensitometry) including trabecular bone score (TBS) and Vertebral Fracture Assessment (VFA) in every participant.
223480526|NCT06351176|DIAGNOSTIC_TEST|AGEReader|The investigators perform a skin advanced glycation end products (AGEs) measurement with the AGE Reader machine in every participant.
223480527|NCT03493971|PROCEDURE|Carotid revascularization performed using CAS|Carotid artery stenting (CAS) is an endovascular stent procedure used to treat narrowing of the carotid artery and decrease the risk of stroke
223480528|NCT03493971|PROCEDURE|Carotid revascularization performed using CEA|Carotid endarterectomy (CEA) is a surgical procedure used to correct stenosis in the common carotid artery or internal carotid artery and reduce the risk of stroke
223480529|NCT04057092|DIETARY_SUPPLEMENT|Dietary Supplement INergy-FLD|INergy-FLD® is an immune modulating formula containing various ingredients including L-Arginine, whey protein isolate, and omega-6 fatty acid, aimed to attenuate excessive inflammatory responses without being immunosuppressive and to replenish nutrients that are depleted in a state of surgical stress, thereby enhancing the recovery process and decreasing the risk of infection. The volume of the beverage is 250mL per serving and patients will be asked to consume 3 servings periodically per day for 5 days prior to surgery and 5 days following surgery.
223480530|NCT06456307|BEHAVIORAL|Integrated Perinatal Mental health program (systematic screening for PMAD, PM+ and tele-psychiatry)|The intervention includes systematic screening for PMAD symptoms using PHQ-2 and GAD-2, non-specialist delivery of PM+ for participants with likely depression (PHQ-9≥10) or anxiety (GAD-7≥10) and in-facility tele-linkage to mental health specialist for participants with severe depressive symptoms (PHQ-9≥15), those who endorse suicidality, or non-responders to PM+
223480531|NCT00351247|PROCEDURE|Postconditioning|
223480532|NCT00034632|DRUG|Posaconazole oral suspension|
223584804|NCT05588245|BEHAVIORAL|Standard of Care|Participants will undergo the same SDoH screener (AHC-Health Related Social Needs Tool) as full intervention participants, which will serve as the basis for a one-time brief session with the clinical research coordinator that will involve review of a 'Resource Guide' that provides a listing of available community resources to meet common social needs. Participants in this arm will also complete other prenatal and postpartum data collection items over the course of the study (with the exception of qualitative interviews).
224167939|NCT04084873|BEHAVIORAL|PBrE|PbRE is a word reading task implementing through an App developed for smartphones. The patient will choose emotional positive and negative words related to personal and clinical characteristics.
224167940|NCT04084873|BEHAVIORAL|PBrE-Control|Participants are exposed to several neutral words. These words do not have any emotional content and there are no reasons to think that they have any effect over the emotional regulation.
223480533|NCT04892160|OTHER|Guided Imagery|Upon completion of study paperwork and 3-5 minutes prior to the nurse entering the room, study personnel will play an audio recording of an underwater guided imagery during one of these procedures: port access, dressing changes, and IV sticks. Guided imagery is an intervention that relies on a patient's imagination to create a sensory experience that utilizes mental images, sounds, smells, tastes, and touch. The guided imagery script used in this study describes an underwater scene and is meant to closely mimic the VR condition with the exception that it will be non-immersive. It will last approximately 15 minutes but can be played again if the procedure lasts longer than 15 minutes. Study personnel will remain in the room to record the time of the procedure, staff number, time in the room, and complete an observational measure of distress.
223480534|NCT04892160|OTHER|Virtual Reality|Upon completion of study paperwork and 3-5 minutes prior to the nurse entering the room, study personnel will assist the patient in beginning the VR intervention during one of these procedures: port access, dressing changes, and IV sticks. The VR intervention consists of interactive audio and visual underwater experience. The VR software offers both passive and active gameplay over the course of 15 minutes, which can be repeated. In the passive experience, the software moves patients through an ocean filled with sea creatures and allows them to look around and observe the underwater scene. In the active experience, patients launch balls at the fish. Patients will be encouraged but not required to actively participate; staff will record whether the patient participates in the active portion of the VR program. Study personnel will remain in the room to record the time of the procedure, staff number, time in the room, and complete an observational measure of distress.
223480535|NCT00620906|PROCEDURE|Manipulation|HVLA manipulation to Sacroiliac Joint
223480536|NCT02821845|BEHAVIORAL|Untrained and Trained SCI Hip or Knee|Individuals with SCI will perform downhill walking training 3 times a week for 12 wks with a 4 wk follow-up period. This intervention will be delivered by trained therapists. In order to focus on rehabilitation of hip control or knee control, members of this group will be trained at slow to moderate gait speeds,
223584805|NCT05588245|BEHAVIORAL|Community-based prenatal/perinatal/postpartum patient navigator|Uses Freeman's principles of navigation to enhance patient access to care (e.g., help patients manage appointments), promote patient self-efficacy (e.g., connect patients to community housing, food, transportation resources), and sustain engagement with the healthcare system (e.g., bridge perinatal and primary care).
224072025|NCT01441752|DRUG|TCM|three types with functions such as benefiting Qi recipe, benefiting Yin recipe and detoxication and resolving masses recipe.
224072026|NCT01441752|DRUG|placebo|three types with functions such as benefiting Qi recipe, benefiting Yin recipe and detoxication and resolving masses recipe，with the same color, smell ，taste weight and package
224072027|NCT03064477|BEHAVIORAL|Unified Protocol|Intervention group that carries out the Unified Protocol in a group format
224072028|NCT03064477|BEHAVIORAL|Cognitive Behavioral Therapy (TAU)|TAU group that carries out Cognitive Behavioral Therapy in an individual format
224072029|NCT00902785|OTHER|no drug|observational no drug
224072030|NCT04624165|OTHER|Survey|o We plan to hand out copies of a survey to examine patient's perspective on telemedicine.
224072031|NCT00958139|OTHER|Permethrin|Permethrin 0.5% treatment of clothing one time
224072032|NCT00958139|OTHER|Placebo|water sprayed on clothing one time
224072033|NCT04372927|DRUG|Cisplatin|Given IV
224072034|NCT04372927|BIOLOGICAL|Durvalumab|Given IV
224072035|NCT04372927|DRUG|Etoposide|Given IV
224072036|NCT04372927|RADIATION|Hypofractionated Radiation Therapy|Undergo hypofractionated radiation therapy
224072037|NCT04372927|DRUG|Pemetrexed|Given IV
224072038|NCT06501417|OTHER|mainstreaming|mainstreaming in EC patients
224072039|NCT04743947|OTHER|No intervention; observational study|no intervention
224072040|NCT00374309|DRUG|VRC-EBOADV018-00-VP|
224072041|NCT06437808|COMBINATION_PRODUCT|Training with Portable Force Plates Integration|This group will undergo football training sessions that incorporate the use of portable force plates. These devices will measure ground reaction forces and provide real-time data on players' movements, balance, and pressure points. The data collected will be used to create personalized training programs aimed at optimizing performance and reducing the risk of injuries.
224072042|NCT06437808|OTHER|Standard Training|This group will continue with the existing football training regimen without the use of portable force plates. Training will follow the traditional methods used at the Multan Sports Complex, focusing on physical conditioning, technical skills, and tactical awareness without the advanced biomechanical analysis provided by the force plates.
224072043|NCT00299832|DRUG|Aliskiren|
224072044|NCT05823597|BEHAVIORAL|Sugar Intensive Treatment|see arm description
224072045|NCT05823597|BEHAVIORAL|General Health Control|see arm description
224072046|NCT04509921|OTHER|asthma treatment adjustment taking account on degree of bronchial hyperresponsiveness|Modification of inhaled corticosteroid dose based on the symptoms and the result of bronchial provocation (BHR group)
224072047|NCT06164379|DRUG|Finerenone|At every visit, the clinic and ambulatory blood pressure will be measured. The levels of serum potassium, creatinine, renin, aldosterone will be examined. The urinary microalbumin creatinine ratio will be also examined.
224072048|NCT06164379|DRUG|Spironolactone|At every visit, the clinic and ambulatory blood pressure will be measured. The levels of serum potassium, creatinine, renin, aldosterone will be examined. The urinary microalbumin creatinine ratio will be also examined.
224072049|NCT00661271|BEHAVIORAL|Mindfulness-based stress reduction (MBSR)|8 weekly sessions with instruction designed to enhance mindfulness--mindful meditation, mindful yoga, and discussion of mindfulness practice, with one retreat session.
224072050|NCT00661271|BEHAVIORAL|Healthy topics|8 week health education program with one retreat session
224072051|NCT01243320|DRUG|10ppm Oral Silver Particle|Silver nanoparticles at 10ppm
224072052|NCT01243320|DRUG|32ppm Oral Silver Particle|Silver nanoparticles at 32ppm
224072053|NCT05244850|OTHER|Test|Measurements
224167941|NCT04084873|BEHAVIORAL|Control|Participants do not receive the intervention.
224167942|NCT01748006|OTHER|Standard of care therapy for severe decompensated heart failure|
224167943|NCT03923829|DRUG|Zinc Sulfate|systemic administration of Zinc sulfate with scaling and root planing
223480537|NCT02237664|PROCEDURE|Continuous paravertebral analgesia (C-PVB)|Patients will receive continuous paravertebral infusion of bupivacaine 0.2% and fentanyl 2 μg mL-1 at rate of 8 mL h-1
223480538|NCT02237664|PROCEDURE|Patient-controlled paravertebral analgesia (PC-PVB)|Patients will receive background continuous paravertebral infusion of bupivacaine 0.2% and fentanyl 2 μg mL-1 at rate of 8 mL h-1 with patient demand bolus dose of 3 mL and lockout time of 15 min with a 20 mL h-1 maximum dose, irrespective of their age
223480539|NCT01649219|BEHAVIORAL|Exercise|
223480540|NCT04383678|DEVICE|Extracorporeal membrane oxygenation|Veno-venous or veno-arterial extracorporeal oxygenation
223480541|NCT01200355|DRUG|micafungin|Micafungin 100 mg intravenously once daily. Randomized treatment will be initiated 24-48 h after completion of the last dose of chemotherapy.
223480542|NCT01200355|DRUG|posaconazole|Posaconazole 400 mg orally twice daily. Randomized treatment will be initiated 24-48 h after completion of the last dose of chemotherapy.
223480543|NCT00724776|BIOLOGICAL|Albinterferon alfa 2b|recombinant human albumin-interferon alfa fusion protein, 600-1800mcg single dose by S.C. on Day 0
223480544|NCT01404481|DEVICE|clean intermittent self catheterisation single use vs re use|Over the 16 week period all patient will participate in 8 weeks of single use cathetersation and 8 weeks of re use catheterisation. The study is a randomised control crossover trial
223480545|NCT00005988|DRUG|cyclophosphamide|
223480546|NCT00005988|DRUG|cyclosporine|
223480547|NCT00005988|DRUG|leucovorin calcium|
223480548|NCT00005988|DRUG|methotrexate|
223480549|NCT00005988|DRUG|methylprednisolone|
223480550|NCT00005988|PROCEDURE|in vitro-treated bone marrow transplantation|
223584806|NCT05727722|BIOLOGICAL|a single course of micro-encapsulated hepatocytes intraperitoneal transplantation therapy|"A single course will be divided into an accelerated titration design phase and a 3+3 design phase to reduce the number of subjects exposed to potentially ineffective doses that may not benefit from treatment. The accelerated titration design phase starts at a starting dose of 0.15x10\^9, moving to the 3+3 design phase at the dose of 0.5x10\^9. According to the semi-logarithmic incremental (10\^0.5-fold) approach, the treatment dosage was set into four groups at a maximum dose of 4.5×10\^9 (allowing for a ±20% difference between the actual dose and the planned dose, considering production specifics). The number or the incremental ratio of subsequent dose groups can be adjusted based on the evaluation of available data in the study, and intermediate doses can be explored."
223584807|NCT05327127|DRUG|K-877-ER|K-877-ER tablet
223584808|NCT05327127|DRUG|CSG452|CSG452 tablet
223480551|NCT00005988|RADIATION|radiation therapy|
223584809|NCT05327127|DRUG|Placebo|Placebo tablet
224167944|NCT03923829|PROCEDURE|scaling and root planing|scaling and root planing
224167945|NCT05609500|BEHAVIORAL|Warfarin dosage adjustment model|Warfarin dosage adjustment model use to predict the initiation and the maintenance dose of warfarin. Variation of warfarin dose during stable maintenance phase for the same patient might be influenced more by temporal factors such as modification of drug regimens that utilize the CYP450 pathway, or dietary vitamin K intake
223480552|NCT04991584|DRUG|Amoxicillin,Tetracycline,Furazolidone,Levofloxacin,Vonoprazan fumarate, Esomeprazole ,|Patients will go through a gastroscopy and antimicrobial susceptibility test. Liver and kidney function will be monitored by blood test before and after the treatment.
223480553|NCT06192732|BEHAVIORAL|A more plant-based diet during weight loss|Participants receive dietary counseling on a more plant-based diet during weight loss. They will be counseled by a dietician to increase their plant-based protein intake up to 60%, focusing on 1.2 grams of protein per kg body weight.
223744918|NCT02589574|OTHER|electronic text message|"Besides the reminder of the free vaccination, the messages included information that vaccination reduces the personal risk of influenza illness. It also reduces the risk to infect patients and family members. It is also the social expectation on and professional as well as personal responsibility of nurses in protecting own selves and their patients from contacting influenza.~it is a safe vaccine. The reminders are developed with reference to promotion messages from Hospital Authority."
223480554|NCT02191501|PROCEDURE|Pyloric restriction|"The Apollo Overstitch Suturing Device is FDA approved for suturing in the gastrointestinal tract.~However, the suturing device has never been used for suturing the pylorus in humans before. This procedure is not standard medical care. The safety and effectiveness of this procedure are being tested."
223480555|NCT05526768|DEVICE|VITLS Device|VITLS remote vital sign monitoring device will be applied to consented patients so data obtained by the device can be compared to data obtained by traditional inpatient hospital monitoring devices.
223480556|NCT02993276|DEVICE|Neurocap®|NEUROCAP®, a bioresorbable nerve capping device based upon the NEUROLAC® nerve guide, is indicated to protect a peripheral nerve end and to separate the nerve from surrounding environment to reduce the development of a symptomatic neuroma.
223480557|NCT04424901|DRUG|Placebo|Daily dose while hospitalized up to 9 days
223480558|NCT04424901|DRUG|Dipyridamole Tablets|Daily dose while hospitalized up to 9 days
223480559|NCT03697590|DRUG|No curettage|Standard PDT without curettage
223480560|NCT03697590|DRUG|Curettage|Standard PDT
223480561|NCT04735302|OTHER|Radiographic Feature|Radiographic rewiev
223744919|NCT00605670|BEHAVIORAL|questionnaires|patients will fill out two questionnaires post surgery
224167946|NCT00377468|DRUG|Delta9-Tetrahydrocannabinol|
224167947|NCT05848557|BEHAVIORAL|mSaada|mSaada is an integrated digital platform to support patients, community health volunteers (CHVs), providers and health systems in an HPV-based cervical cancer screening strategy. mSaada is hosted on an open-source platform (Dimagi, CommCare) as a mobile health application to support patient data collection, protocol support and counseling aids. mSaada will include an education module, patient and specimen tracking, screening reminders, and messaging functionality.
224167948|NCT03995121|DRUG|[11C]APP311|It has been shown that radiotracer \[11C\]APP311 (aka \[11C\]UCB-J) displays high specificity and selectivity for the synaptic vesicle protein SV2A. Since this protein is expressed ubiquitously in active synapses, this tracer has the potential to be a general purpose tool for quantitative imaging of synaptic density.
224167949|NCT05124912|PROCEDURE|Radiation Therapy|Post-op hypofractionated therapy or no radiation therapy
224167950|NCT05124912|DRUG|Steroid Therapy|Best medical management with steroid therapy
224167951|NCT05124912|PROCEDURE|Laser Interstitial Thermal Therapy|Minimally invasive technique to necrotize intracranial lesions using the NeuroBlate® System (NBS)
224167952|NCT05863754|DEVICE|Networked Neuroprosthesis Device|The Networked Neuroprosthesis Device is an implantable, configurable neuromodulation platform that provides functional movement by the coordinated activation of peripheral neural pathways activating innervated paralyzed muscles, and sensing of physiological signals.
224167953|NCT06527456|OTHER|participation of the general practitioner|participation of the general practitioner in encouraging cervical cancer screening
223480562|NCT03874962|OTHER|Routine oral cleaning and professional oral care group|Besides routine oral cleaning was conducted by caregivers, professional oral care intervention was conducted by dental hygienists, and it included muscle massage, oral cleaning, and oral health education once a week.
223480563|NCT02857153|DRUG|Urapidil|If necessary, intravenous urapidil 0.2-0.5 mg/kg when mean arterial pressure exceeded 10 mmHg of the target value, rather than more anesthesia, may be used in situations wherein sympathetic stimulation was high; yet a sufficient amount of anesthesia was being administered and bispectral index showed an adequate depth of hypnosis. Sedation was provided by a propofol infusion targeted to a BIS number of approximately 50 during general anesthesia.
224167954|NCT04440085|DRUG|Midodrine Hydrochloride|All patients become standard care resuscitation treatment using liquids and vasoactive drugs in order to get a median arterial pressure ≥ 65 mmHg. Midodrine will be administered according to the evolution of the patient's mean pressure.
224167955|NCT04440085|DRUG|Placebo|All patients become standard care resuscitation treatment using liquids and vasoactive drugs in order to get a median arterial pressure ≥ 65 mmHg. Placebo will be administered according to the evolution of the patient's mean pressure.
224167956|NCT04488991|OTHER|Cervical Cancer Rate|In the end of the Research, we will compare cervical cancer rates between groups
224167957|NCT00166244|DRUG|Mycophenolate Mofetil|"1 g for adult patients and 300 mg/m2 for paediatric patients. Fixed dose arm: 1 g twice a day (bid) for adults and 600mg/m2 bid for paediatric patients.~Concentration controlled arm: initial dose will be 1 g bid for adults and 600mg/m2 bid for paediatric patients. Abbreviated AUCs (taken at timepoints: 0, 30min and 120min in fasted patients) on Days 3 and 10, Week 4, Months 3, 6 and 12 will be performed to determine mycophenolic acid levels in plasma."
224167958|NCT03894657|DIAGNOSTIC_TEST|Nasal brushing|Nasal scrapping at visit V0
224305364|NCT04257149|DIAGNOSTIC_TEST|Ischemic stroke group (group B)|Group B: A microwave measurement (Stroke finder MD100) will be performed with the patient lying on the ambulance stretcher, in the hospital bed or another suitable surface.
223480564|NCT02857153|DRUG|Phenylephrine|If necessary, intravenous phenylephrine 4-6 μg/kg when mean arterial pressure exceeded 10 mmHg of the target value, rather than more anesthesia, may be used in situations wherein sympathetic stimulation was high; yet a sufficient amount of anesthesia was being administered and bispectral index showed an adequate depth of hypnosis. Sedation was provided by a propofol infusion targeted to a BIS number of approximately 50 during general anesthesia.
223480565|NCT02857153|PROCEDURE|Low-level MAP|MAP is regulated to the goal level (60-70 mmHg) during general anesthesia.
223480566|NCT02857153|PROCEDURE|High-level MAP|MAP is regulated to the goal level (90-100 mmHg) during general anesthesia.
223480567|NCT04034472|OTHER|Interdisciplinary intervention in obesity|Interdisciplinary weight loss intervention associate to the use of digital technology to treat obesity and related disorders
223480568|NCT03581006|DIETARY_SUPPLEMENT|Low-Calorie Mediterranean Diet|Participants in the intervention group will receive 6 months of education and behavioral counseling with self-monitoring to help them adopt a Mediterranean-style, calorie-restricted diet, and engage in physical activity
223480569|NCT03581006|COMBINATION_PRODUCT|Technology based monitoring and behavioral participation|Intervention participants will use smart phones to connect to intervention applications, WebEx, MyNetDiary
223480570|NCT03581006|OTHER|Usual care group|Control group, who will receive no dietary or behavioral intervention during the trial
223480571|NCT02141932|PROCEDURE|Bed-side pocket size ultrasound imaging|
224167959|NCT03894657|OTHER|Sputum sample|"Visit V0 : 1 Aliquot for Sputum biobank~Visit V1 : 2 Aliquots~* for Sputum biobank~* for pharmacokinetic (PK) study~Visit V2 : 2 Aliquots~* for Sputum biobank~* for pharmacokinetic (PK) study"
224305365|NCT04257149|DIAGNOSTIC_TEST|Stroke mimic group (group C)|Group C: A microwave measurement (Stroke finder MD100) will be performed with the patient lying on the ambulance stretcher, in the hospital bed or another suitable surface.
223480572|NCT02141932|DEVICE|GE Ultrasound Vscan|
223480573|NCT04698434|DRUG|Esketamine|each group was given a single intravenous dose of the corresponding esketamine.
223480574|NCT03365180|DEVICE|Starter Kit Algorithm|Long acting insulin titration to target
224305366|NCT06014905|DRUG|Hyperpolarized carbon C 13 pyruvate|Given Intravenously (IV)
224305367|NCT06014905|PROCEDURE|Magnetic Resonance Image (MRI)|Imaging procedure
224305368|NCT06014905|OTHER|Saline|Given IV
224305369|NCT00997204|DRUG|Icatibant|Single subcutaneous injection of icatibant, 30 mg
224305370|NCT04420273|BEHAVIORAL|SSE educational intervention|Women participants receive a SSE brochure and three monthly reminders to perform SSE. In the second month, women select goals for SSE.
223584810|NCT05501743|DRUG|Intra-articular injection of microfat and PRP|The treatment by intra-articular injection of autologous microfat and PRP will be performed during a half-day outpatient stay in the hand and limb repair surgery department at the Hôpital de la Timone. The total duration of the procedure is approximately 4 hours and includes 2 surgical times performed in the operating room and an intermediate waiting time for the patient in an outpatient room during the preparation of the experimental products.
223584811|NCT05501743|PROCEDURE|Total denervation of the wrist|The surgical treatment by total denervation of the wrist will be performed during a one-day outpatient stay in the hand and limb surgery department at the Hôpital de la Timone. It will be performed under loco-regional anesthesia by axillary plexus block.
223584812|NCT02846649|BEHAVIORAL|PIER|Daily text message queries with tailored support
223584813|NCT06065657|DIETARY_SUPPLEMENT|Ketone Supplement|Ketone supplement 3x day with control diet for 3 days.
223584814|NCT06065657|OTHER|Control Diet|Control Diet breakfast, lunch, and dinner for 3 days.
224167960|NCT03894657|OTHER|blood sample|"Visit V0 : Additional 14 mL~* 5 mL in ethylenediaminetetraacetic acid (EDTA) tube for DNA Analysis~* 3 mL in Dry tube for Serum biobank~* 6 mL in acid citrate dextrose (ACD) tube for peripheral blood mononuclear cell (PBMC) biobank~Visit V1 : Additional 9 mL~* 2x3 mL in dry tube for pharmacokinetic (PK) study~* 3 mL in Dry tube for Serum biobank~Visit V2 : Additional 6 mL~* 3 mL in dry tube for pharmacokinetic (PK) study~* 3 mL in Dry tube for Serum biobank"
224167961|NCT03894657|DRUG|Orkambi|"Study the predictive value for improvement of the respiratory function after 24 weeks of Orkambi treatment.~Orkambi treatment is part of usual care."
224167962|NCT02844322|DRUG|Bortezomib|compare the efficiency of bortezomib and rituximab in Waldenström macroglobulinemia
224167963|NCT02844322|DRUG|Rituximab|compare the efficiency of bortezomib and rituximab in Waldenström macroglobulinemia
224167964|NCT03698214|OTHER|reversed shock index < 1|Among patients with isolated TBI, those with an RSI \< 1 had higher mortality
223480575|NCT03609463|BEHAVIORAL|Small change intervention|The small change intervention is a behavioral intervention to help people gradually lose weight by making small changes in their lifestyle. At the beginning of the intervention participants will be met in person to be guided in setting an eating and a physical activity goal. Participants will be then contacted through the phone or met in person weekly for 3 months to check on their adherence to the selected goals and to discuss about facilitators and barriers to goal completion, in order to increase their motivation and problem solving skills. Every weekly contact will last about an hour and will be administered in an individual setting. At each contact selected goals can be revised, changed or another goal can be added based on levels of adherence.
223480576|NCT03609463|BEHAVIORAL|Well-being intervention|The well-being intervention is a coaching intervention aimed at motivating people in making lifestyle changes by reducing levels of stress through the promotion of psychological well-being. It will consists in 4 weekly sessions to be held before starting the small change intervention. Each session will last about an hour and will be administered in an individual setting.
223480577|NCT03609463|OTHER|Treatment as usual|The treatment as usual includes any recommendation given to the participants by their physicians, including diet, physical activity, medication and glycemic control instructions.
223480578|NCT02059837|PROCEDURE|recurrent pterygium excision and following grafting|The excision of recurrent pterygial tissue and autograft of conjunctiva was done.
223480579|NCT01206764|DRUG|RAD001|
223480580|NCT04824001|OTHER|exercise stress echocardiography|Stress echocardiography test. The standardized exercise test was conducted by 50-W semi-recumbent cycling for 3 min. Stress echocardiograph images were acquired at the third minute of cycling to ensure that subjects had reached a steady-state HR.
223480581|NCT06414863|DEVICE|IPE|"Invisalign palatal expander system:~The Invisalign® Palatal Expander System (AlignTechnology, inc.) is 3D-printed orthodontic device for maxillary expansion."
223480582|NCT06414863|DEVICE|HE|"Hyrax expander:~The Hyrax-type maxillary expander will include a midline self-locking screw. The expansion screw is connected to the conventional molar bands or printed clasps, which are cemented on the maxillary first molars (or on the maxillary primary second molars), via 0.9 mm stainless-steel wire. The framework is soldered to the bands and extends on the palatal side to the primary canines or canines. The expander will be fabricated by a qualified laboratory technician"
223480583|NCT05893238|PROCEDURE|Natural cycle In Vitro Fertilisation (IVF)|In Vitro Fertilisation (IVF) without hormonal stimulation
223480584|NCT05893238|DIAGNOSTIC_TEST|Blood samples for analysis|Test hormone levels in serum
223480585|NCT05893238|DIAGNOSTIC_TEST|Follicular fluid for analysis|Test hormone levels in follicular fluid Test Oxidation-reduction potential
223480586|NCT05893238|DIAGNOSTIC_TEST|Sperm samples for analysis|Oxidation-reduction potential
223480587|NCT05893238|PROCEDURE|Conventional In Vitro Fertilisation (IVF)|In Vitro Fertilisation (IVF) with conventional hormonal stimulation
223480588|NCT03052686|OTHER|Childbirth with uterine rupture|No intervention. Follow-up of women with rupture uterine at the childbirth.
223744920|NCT00605670|BEHAVIORAL|questionnaires|Patient will fill out questionnaire before and 3 to 6 months after treatment.
224167965|NCT03698214|OTHER|reversed shock index ≥ 1|Among patients with isolated TBI, those with an RSI ≥ 1 had lower mortality
224167966|NCT05815862|DRUG|AL2846 capsule|AL2846 is a multi-target tyrosine kinase inhibitor.
224167967|NCT06019351|DEVICE|OrthoAnalyzer™ software|OrthoAnalyzer™ software module from 3Shape Software
224167968|NCT03287830|BEHAVIORAL|Text message influenza vaccine reminders|Text message reminders for second dose of influenza vaccination
223480589|NCT02427009|OTHER|Prone position for 1 hour after blood patch|After performing a blood patch, the patient will be placed in a prone position for 1 hour. This applies to all blood patches required during her hospitalization.
223480590|NCT02427009|PROCEDURE|Blood patch|And indicated in inclusion criteria, patients in this protocol will have at least 1 blood patch. The amount of blood to be injected into the peridural space is fixed at 20 ml, but can be less in case of pain.
223480591|NCT03384199|RADIATION|Dose escalation to prostate focal lesion|For each patient the radio-opaque marker (used for treatment verification) will be inserted by ultrasound guidance \& local anaesthetic with an 17ga x 30cm brachytherapy needle that has 1.2mm x 3mm one gold marker. The ultrasound probe (as used for transrectal biopsy) will be introduced rectally with the patient in the left lateral position. After measuring the volume of the prostate and determining the desired position (preferably in the corpus of prostate), three gold markers will be inserted as follows: one into right side, one into left side of the base and the third in the apex of the prostate
223480592|NCT01408069|DRUG|MIGRANE|1 to 2 tablets(ergotamine 1mg + caffeine 100mg + acetylsalicylic 350 mg + homatropine 1,2 mg)
223480593|NCT01408069|DRUG|PARCEL|1 to 2 tablets(ergotamine 1mg + paracetamol 450 mg + caffeine 40 mg)
224167969|NCT01364948|OTHER|Coconut oil application|Four ml coconut oil application twice daily for first week
224167970|NCT01364948|OTHER|No oil application|Oil application was not done
224167971|NCT05722288|PROCEDURE|Biospecimen Collection|Undergo collection of blood
224167972|NCT05722288|OTHER|Informational Intervention|Receive nutritional counseling
224167973|NCT05722288|OTHER|Quality-of-Life Assessment|Ancillary studies
224167974|NCT05722288|OTHER|Questionnaire Administration|Ancillary studies
224167975|NCT05722288|BEHAVIORAL|Short-Term Fasting|Undergo time-restricted eating
224167976|NCT04423224|OTHER|GDFM|Stroke volume variation fluid management
223584815|NCT06065657|OTHER|Ketogenic diet|Ketogenic Diet breakfast, lunch, and dinner for 3 days.
223584816|NCT06065657|DRUG|Ethanol|After 3 days of diet intervention, participants will receive alcohol drinks that dose-adjusts for body weight and sex differences in pharmacokinetics and calculated to obtain a final breath alcohol concentration of 0.08%
223584817|NCT04531514|OTHER|Sensitivity to phonological rules & referents OR: Toddlers|Assess whether the inclusion of a semantic reference decreases OR phonological rule learning
223480594|NCT06002191|BEHAVIORAL|Flourish|Flourish is a text messaging program that aims to improve coping following cyberbullying and reduce suicide risk among youth.
223584818|NCT04531514|OTHER|Sensitivity to phonological rules & referents FR: Toddlers|Assess whether the inclusion of a semantic reference increases FR phonological rule learning
223584819|NCT05661903|OTHER|Spinal Cord Stimulator Set to Minimal/No Stimulation Setting|Patients in this intervention group will have their spinal cord stimulator turned off or to the minimal settings possible.
223584820|NCT05661903|OTHER|Usual Care|Patients in this intervention group will have their spinal cord stimulator turned on to their usual stimulation settings.
223584821|NCT05661903|DRUG|Positron Emission Tomography / Magnetic Resonance Imaging|Patients with imaging compatible devices will undergo positron emission tomography/magnetic resonance imaging at three time points during the study. This imaging involves administration of the \[11C\]PBR28 radioligand, which is an investigational drug. Only a subset of patients who have 3 Tesla magnetic resonance imaging compatible stimulators will undergo this imaging.
223584822|NCT06328452|DEVICE|FibroScan|All the study population will be submitted to Fibroscan examination with CAP (Echosens FibroScan® Compact 530). To evaluate steatosis and fibrosis, participants will be asked to fast for at least 3 hours before the test. To capture a controlled attenuation parameter (CAP) score and liver stiffness measurement (LSM), 10 valid scans per subject will be needed.
223480595|NCT06002191|BEHAVIORAL|Questionnaires of Online Experiences|Adolescents will receive brief questionnaires related to their online experiences and the impact those experiences have had on their stress level.
223480596|NCT02373527|OTHER|No Fasting prior to catheterization|No restriction for oral intake
223480597|NCT00366496|DEVICE|Acrysof single piece (SA60AT)|
223480598|NCT00366496|DEVICE|Acrysof IQ (SN60WF)|
223584823|NCT01556321|DIETARY_SUPPLEMENT|placebo|Subjects will receive placebo (soy oil; 757 mg/capsule, 3 capsules with each breakfast, lunch and dinner) in capsule form after their baseline measurement, which they have to consume daily for a period of twelve weeks.
223584824|NCT01556321|DIETARY_SUPPLEMENT|green tea (757 mg/capsule [84.5 mg EGCG + 2.1 mg caffeine ]|Subjects will receive green tea (757 mg/capsule \[84.5 mg EGCG + 2.1 mg caffeine \], 3 capsules with each breakfast, lunch and dinner)in capsule form after their baseline measurement, which they have to consume daily for a period of twelve weeks.
223584825|NCT00214474|BEHAVIORAL|ATSM Intervention|Participants randomized to ATSM Intervention received weekly, automated (pre-recorded) telephone calls over 39 weeks (9 months). Patient responses triggered either immediate, automated health education messages and/or subsequent nurse phone follow-up.
223584826|NCT00214474|BEHAVIORAL|GMV Intervention|GMV Intervention involved 90-minute monthly sessions over 9 months, involving 6-10 participants, co-facilitated by a primary care physician and health educator.
223584827|NCT02046070|DRUG|Cyclophosphamide|Cyclophosphamide tablets
223584828|NCT02046070|DRUG|Ixazomib|Ixazomib capsules
224072054|NCT04779203|DEVICE|Osseodensification Densah Bur|Implants placed with osseodensification surgical drilling compared to those placed with subtractive conventional drilling technique in a split-mouth design will result: 1) in the same insertion torque values and; 2) in the same implant stability quotient values when measured immediately after implant placement and after 1, 2, 3, 4, 5, 6, 7, 8, and 12 weeks.
223480599|NCT02411643|DRUG|topical calcipotriene 0.005% ointment|Affected area will be treated twice daily for 3 months
224072055|NCT00430508|DRUG|olmesartan medoxomil (OM)/hydrochlorothiazide (HCTZ) tablets and placebo|olmesartan medoxomil (OM)/hydrochlorothiazide (HCTZ) Tablet 40mg/0mg + 20mg/12.5mg matching placebo tablet once daily for 8 week
224167977|NCT04423224|OTHER|USUAL CARE - CONTROL|Usual care fluid management
223480600|NCT04793945|COMBINATION_PRODUCT|topical steroid and 308nm-Excimer light therapy|applying topical steroid in combination with 308nm-Excimer light therapy to treat Alopecia Areata
223480601|NCT04832035|OTHER|"coordinated and peer supported mental health care"|Health services, coordination of services, method to support utilization
223480602|NCT04832035|BEHAVIORAL|"standard psychotherapeutic care in the public healthcare system"|Psychotherapeutic services that are financed by the public health insurance system.
223584829|NCT02046070|DRUG|Dexamethasone|Dexamethasone tablets
223480603|NCT03889288|DEVICE|Medical device - electronic-pain killer|Treatment sessions with the medical device (no-marked EC): 2 sessions before surgery and 4 or 5 sessions until 48 hours after surgery. Each treatment sessions takes 45 minutes. Each session is spaced by 12 +/-3 hours.
223584830|NCT00835133|OTHER|biologic sample preservation procedure|one blood sample
223584831|NCT00835133|OTHER|medical chart review|confirmation of cancer diagnosis
223584832|NCT00835133|OTHER|survey administration|at baseline enrollment and 12 months post-enrollment
223584833|NCT02593656|BEHAVIORAL|High Protein|Protein-pacing throughout the day and exercise training for 12 weeks
223584834|NCT02593656|BEHAVIORAL|Normal Protein|Normal protein intake throughout the day and exercise training for 12 weeks
223584835|NCT06256926|DRUG|Test Product: Curcuvail® 250mg capsule (Curcuma longa Extractcontaining 35% Curcuminoids)|Curcuma longa Extract containing 35% Curcuminoids Dose: One capsule Frequency: Twice Daily Route of administration: Oral Duration of therapy: 60Days
223584836|NCT06256926|DRUG|Placebo product|Placebo product Dose:One capsule Frequency: Twice Daily Route of administration: Oral Duration of therapy: 60Days
223584837|NCT04213378|DEVICE|Paclitaxel eluting PTCA balloon|Treatment of coronary in-stent re-stenosis with paclitaxel eluting PTCA balloon
223584838|NCT04213378|DEVICE|SeQuent® Please paclitaxel eluting balloon|Treatment of coronary in-stent re-stenosis with SeQuent® Please paclitaxel eluting balloon
223584839|NCT05663957|DRUG|Evusheld|EVUSHELD users
223584840|NCT06970184|PROCEDURE|tooth extraction with alveolar ridge preservation|alveolar ridge preservation performed after tooth extraction
223584841|NCT06970184|PROCEDURE|Implant placement|Implant placement
223480604|NCT00267540|BEHAVIORAL|cholecalciferol (D3) (vitamin)|
223480605|NCT01963871|OTHER|Yoga|Twice weekly one hour sessions of Hatha Yoga for 12 weeks
224167978|NCT05010564|GENETIC|Autologous TRICAR-ALL T-cells and lymphodepletion chemotherapy|"Three dose levels will be evaluated with the opportunity to dose de-escalate (dose level -1) for toxicity.~DL-1: 3x10\^6 cells/m2~DL1: 1×10\^7 cells/m2~DL2: 3×10\^7 cells/m2~DL3: 1×10\^8 cells/m2~Lymphodepletion chemotherapy consisting of Fludarabine 30 mg/m2 IV once daily x 4 doses; and Cyclophosphamide 500mg/m2 IV once daily x 2 doses (starting with the first dose of fludarabine)must be completed greater than or equal to 48 hours prior to infusion of CAR-T cells."
224167979|NCT04053114|OTHER|DNA and RNA extraction from FFPE or frozen tissue sample|Next generation sequencing (NGS)
224305371|NCT04420273|BEHAVIORAL|Active control:Healthy Living|Women participants receive a Healthy Living brochure and three monthly reminders to perform the following activities of healthy living: get quality sleep, walk briskly for 30 min, eat 5 servings of fruits and vegetables a day. In the second month, women select goals for healthy living.
224305372|NCT01687972|COMBINATION_PRODUCT|Insorb absorbable staples|Placement of Insorb absorbable staples at cesarean section
224305373|NCT01687972|COMBINATION_PRODUCT|Absorbable sutures|placement of absorbable sutures at cesarean section
224305374|NCT04534907|COMBINATION_PRODUCT|The combination of exposure and response prevention (ERP) and VR|The combination of exposure and response prevention (ERP) and VR aimed to investigate the combination of an immersive virtual reality environment (VRE) alongside therapist delivered CBT to reduce anxiety when the OCD patients were induced by virtual scene.Specially, patients will get the first CBT session in the first week for 90 minutes in order to gather detailed information of individual's symptom. Then the next 2 weeks, patients will get VR+ERP session twice a week. From the fourth week to the seventh week, patients weill get VR+ERP session once a week. In the end of the eighth week, patients will get the last session of the exposure-based CBT for relapse prevention.
224305375|NCT04534907|BEHAVIORAL|Traditional ERP|Patients will achieve the exposure based CBT for total 10 times excluding 8 sessions of ERP. Structured protocol described by Foa et al., 2012. Specially, patients will get the first CBT session in the first week for 90 minutes in order to gather detailed information of individual's symptom. Then the next 2 weeks, patients will get ERP session twice a week. From the fourth week to the seventh week, patients weill get ERP session once a week. In the end of the eighth week, patients will get the last session of the exposure-based CBT for relapse prevention.
224305376|NCT05674903|DEVICE|Verum stimulation with Diadem prototype|Diadem prototype device delivers focused low-intensity ultrasound stimulation
224305377|NCT05674903|DEVICE|Sham stimulation with Diadem prototype|Diadem prototype device delivers active sham, unfocused low-intensity ultrasound stimulation
223480606|NCT00481039|PROCEDURE|Medical history and basic laboratory analysis|Medical history and basic laboratory analysis
223480607|NCT00410163|DRUG|Ofatumumab 500mg|Ofatumumab 500mg or should be diluted into 1000mL pyrogenefree saline and administered as an IV infusion.Duration of infusion will be approximately 6½ hours.Infusions should be given every 4 weeks until a total of 6 infusions has been given.
223480608|NCT00410163|DRUG|Ofatumumab 1000mg|Ofatumumab 1000mg or should be diluted into 1000mL pyrogenefree saline and administered as an IV infusion.Duration of infusion will be approximately 6½ hours.Infusions should be given every 4 weeks until a total of 6 infusions has been given.
223480609|NCT00410163|DRUG|Fludarabine|Fludarabine (25 mg/m2) should be administered as an IV infusion daily, Days 2 through 4 of Course 1, and Days 1 through 3 of Courses 2 through 6, every 4 weeks for 6 courses
223480610|NCT00410163|DRUG|Cyclophosphamide|Cyclophosphamide (250 mg/m2) should be administered as an IV infusion daily, Days 2 through 4 of Course 1, and Days 1 through 3 of Courses 2 through 6, every 4 weeks for 6 courses.
223480611|NCT03601676|OTHER|Integration of electronic clinical decision support|Integration of an electronic clinical decision support system into the emergency department patient care workflow to assist with site-of-care decision-making for emergency department patients with acute pulmonary embolism.
223480612|NCT03147963|DRUG|Docetaxel|Docetaxel will be given until progression or patient intolerance
223480613|NCT00021242|DRUG|docetaxel|Continuous IV infusion
223480614|NCT03612219|DRUG|Apatinib mesylate tablet|Adjuvant treatment by apatinib mesylate tablet to local advanced nasopharyngeal carcinoma after IMRT with concurrent chemotherapy.the dose of apatinib mesylate tablet was 250 mg,orally,qd,28 days for an observation period,six cycles.
224072056|NCT00430508|DRUG|olmesartan medoxomil (OM)/hydrochlorothiazide (HCTZ) tablets|olmesartan medoxomil (OM)/hydrochlorothiazide (HCTZ) tablets 40mg/12.5mg + 20mg/12.5mg matching placebo tablet once daily for 8 weeks
224072057|NCT00430508|DRUG|olmesartan medoxomil/hydrochlorothiazide tablets|olmesartan medoxomil (OM)/hydrochlorothiazide (HCTZ) tablets 40mg/25mg + 20mg/12.5mg matching placebo tablet once daily for 8 weeks
224167980|NCT02136134|DRUG|Daratumumab|Daratumumab will be administered as an IV infusion or 16 mg/kg weekly for the first 3 cycles, on Day 1 of Cycles 4-9, and then every 4 weeks thereafter. As per protocol amendment-6 participants receiving treatment with daratumumab IV will have the option to switch to daratumumab SC 1800 mg on Day 1 of any cycle, at the discretion of the investigator.
223480615|NCT03612219|RADIATION|Intensity-modulated radiation therapy (IMRT)|Intensity-modulated radiation therapy (IMRT):GTVnx 69.69Gy, GTVnd 60-68Gy, PTV1 59.4Gy and PTV2 54Gy in 33 fractions, 5 days/week.
223480616|NCT03612219|DRUG|Cisplatin|Concurrent chemotherapy: patients received intravenous cisplatin 80mg/m2(D1-3), 3-week chemotherapy for 3 cycles.
223480617|NCT05824026|DEVICE|Gelling fiber wound dressing with silver|intervention involving a wound dressing with silver
223480618|NCT05109715|PROCEDURE|Continued ventilation|Ventilation is continued from going on CPB until clamping of the ascending aorta with tidal volume 3ml/kg ideal body weight, Fraction of inspired oxygen (FiO2) 50%, respiratory rate 5/min and Inspiratory:Expiratory (I/E) ratio 1/2.
224072058|NCT00430508|DRUG|olmesartan medoxomil/hydrochlorothiazide tablets|olmesartan medoxomil (OM)/hydrochlorothiazide (HCTZ) tablets 20mg/12.5mg + 40mg/0mg matching placebo tablet once daily for 8 weeks
224072059|NCT00703664|DRUG|Bortezomib|Bortezomib: 1.3 mg/m\^2/d IV days 1, 4, 8, and 11.
224072060|NCT00703664|OTHER|Laboratory Biomarker Analysis|Correlative studies
224072061|NCT00703664|DRUG|Vorinostat|Vorinostat: 400 mg (total daily dose as a single dose) days 1-5 and 8-12.
224072062|NCT04211207|OTHER|non invasive monitoring value|heart's respiratory quotient as non invasive monitoring value
223480619|NCT05109715|PROCEDURE|Discontinued ventilation|Ventilation is discontinued after going on CPB and lungs are exposed to atmospheric pressure
224167981|NCT02136134|DRUG|VELCADE (Bortezomib)|VELCADE will be administered at a dose of 1.3 mg/m2 subcutaneously (SC) on Days 1, 4, 8 and 11 of each 21-day cycle. Eight VELCADE treatment cycles are to be administered.
224167982|NCT02136134|DRUG|Dexamethasone|Dexamethasone will be administered orally at 20 mg on Days 1, 2, 4, 5, 8, 9, 11 and 12 of the first 8 VELCADE treatment cycles.
224167983|NCT05674838|OTHER|Leg Elevation|Immediately after epidural placement, patient will be placed in a left tilt position with her hip on a wedge and both of her legs elevated on an orange peanut ball. She will remain in this position for approximately 40 minutes.
224167984|NCT06639958|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223480620|NCT05215288|BIOLOGICAL|ExoFlo|Intravenous administration of bone marrow mesenchymal stem cell derived extracellular vesicles
223480621|NCT06369688|OTHER|IDEAL SKIIN CARES bundles|The investigators developed a specialized PIP care bundle, named IDEAL SKIIN CARES, through extensive review of literature and expert insights, which will be utilized for training WSNs and patients in the intervention group. This comprehensive bundle comprises 15 key components aimed at effectively preventing PIs: (1) Incontinence care status; (2) Dehydration status; (3) Elevate at-risk surfaces; (4) Attention to attached devices to skin; (5) Lotion use; (6) Skin assessment; (7) Keeping repositioning; (8) Individualized up-to-date knowledge; (9) Individualized medical devices selection; (10) Nutrition status; (11) Caregiver (formal and informal) participation; (12) Activity assessment; (13) Reducing friction/shear forces; (14) Evaluate hemodynamic instability; (15) and Scrutinizing comorbidities.
223480622|NCT06369688|OTHER|IDEAL SKIIN CARES bundles workshop|IDEAL SKIIN CARES bundles will be explained in detail by a trained research assistant in a workshop. This workshop is different from clinical training and following up about the IDEAL SKIIN CARES bundles.
223480623|NCT06369688|OTHER|Respiratory care workshop|An unrelated topic, specifically respiratory care will be held in a workshop. This training will involve the distribution of educational pamphlets, brochures, and visual posters outlining key aspects of respiratory care
223480624|NCT02421042|DRUG|Lenvatinib|5- or 10-mg single oral dose of E7080, depending on their hepatic status \[Mild (10 mg), Moderate (10 mg), and Severe Hepatic Impairment (5 mg) and Normal Hepatic Function (10 mg)\].
223480625|NCT00797563|DEVICE|Apollo Blood Glucose Monitoring System|Subjects with diabetes use a new blood glucose monitoring system with capillary blood; healthcare professionals use the new blood glucose monitoring system with subject capillary and venous blood. All results are compared to a laboratory glucose method - Yellow Springs Instrument (YSI).
223480626|NCT06412822|OTHER|Blood sampling|Blood sampling
223480627|NCT06412822|OTHER|Urine sampling|Urine sampling
223480628|NCT05378503|DRUG|Qsymia 3.75Mg-23Mg Extended Release Capsule|From W0 to W2, once a daily.
223480629|NCT05378503|DRUG|Qsymia 7.5Mg-46Mg Extended Release Capsule|"1. From W2 to W14, once a daily.~2. At W14, if the weight loss rate is 3% or more, from W14 to W56(the end of visit), once a daily."
223480630|NCT05378503|DRUG|Qsymia 11.25Mg-69Mg Extended Release Capsule|At W14, if the weight loss rate is NOT 3% or more, from W14 to W16, once a daily.
223480631|NCT05378503|DRUG|Qsymia 15Mg-92Mg Extended Release Capsule|At W14, if the weight loss rate is NOT 3% or more, from W16 to W56(the end of visit), once a daily.
223480632|NCT05378503|DRUG|Placebo|From W0(Randomisation) to W56(the End of visit) once a daily.
223480633|NCT00453687|DRUG|GSK233705|investigational drug
223744921|NCT01682902|DRUG|Faster-acting insulin aspart|Administration: Subcutaneous infusion. The subjects will remain on their own pump during the trial. Subjects will have blinded continuous glucose monitoring (CGM) throughout the trial (3 treatment periods of 14 days) and meal tests consisting of a standardised breakfast (liquid meal) will be performed on the 14th day of each treatment period.
224072063|NCT00683033|BEHAVIORAL|Contingency Management|For 4 weeks starting on the quit date, daily brief (about 5 minutes) counseling based on public health service guidelines for quitting smoking is delivered. Expired carbon monoxide (CO) tests are conducted twice daily and urinary cotinine tests are conducted once each week. Participants earn the opportunity to win prizes for submitting samples that meet smoking abstinence criteria (e.g., CO ≤ 6ppm; cotinine ≤ 30ng/mL).
223480634|NCT05493631|BIOLOGICAL|MG1113|MG1113 subcutaneous (SC) injection
223480635|NCT04908501|OTHER|Intervention|The program intervention has three focuses : the prioritization of appropriateness indicators, the automation and visualization of the prioritized indicators, and support for practice analysis groups (PAG) based on e-feedback from automated indicators
223480636|NCT00688597|DRUG|Duvoglustat|Powder in a bottle for dissolution in water for oral administration
223480637|NCT03980678|DIETARY_SUPPLEMENT|Mineral Rich Algae|Lithothamnion species is rich in calcium, magnesium (Mg) and 72 other trace elements absorbed from sea-water during the organisms life. Mineral-rich 'fronds' break off from the living organism, fall to the ocean floor and are harvested (AquaminF). The mineral extract in soluble form contains \~13.1% Calcium, \~1.04% Magnesium and measurable levels of 72 other trace minerals. Following or prior to a washout period (crossover intervention), participants will consume the Aquamin Soluble equivalent of 1000mg Calcium in 250 ml of orange flavored water for a 7 day loading period.
223744922|NCT01682902|DRUG|Faster-acting insulin aspart|Administration: Subcutaneous infusion. The subjects will remain on their own pump during the trial. Subjects will have blinded continuous glucose monitoring (CGM) throughout the trial (3 treatment periods of 14 days) and meal tests consisting of a standardised breakfast (liquid meal) will be performed on the 14th day of each treatment period.
224072064|NCT00683033|BEHAVIORAL|Brief smoking cessation counseling|For 4 weeks starting on the quit date, daily brief (about 5 minutes) counseling based on public health service guidelines for quitting smoking. Expired carbon monoxide tests are conducted twice daily and urinary cotinine tests are conducted once each week.
224167985|NCT06639958|BEHAVIORAL|Compliance Monitoring|Receive DST
224167986|NCT06639958|BEHAVIORAL|Compliance Monitoring|Healthcare provider reviews DST response rates with the patient and any challenges they are having with 6MP adherence every 4 weeks at clinic visits
224167987|NCT06639958|OTHER|Health Promotion and Education|Receive customized printed medication schedules
224167988|NCT06639958|OTHER|Informational Intervention|Receive Patient Supply Kit
224167989|NCT06639958|OTHER|Media Intervention|View MIPE program videos
224167990|NCT06639958|OTHER|Media Intervention|Review booster MIPE videos
224167991|NCT06639958|OTHER|Medical Device Usage and Evaluation|Use MEMS® with TrackCap™
224167992|NCT06639958|DRUG|Mercaptopurine|Given PO
224167993|NCT06639958|OTHER|Questionnaire Administration|Ancillary studies
224167994|NCT06639958|BEHAVIORAL|Telephone-Based Intervention|Receive automated customized electronic reminders via smartphone
224167995|NCT06639958|BEHAVIORAL|Telephone-Based Intervention|Receive additional automated reminders
224167996|NCT06639958|BEHAVIORAL|Telephone-Based Intervention|"Manually activate daily smartphone reminders with successive alerts (using the snooze function)"
224167997|NCT06639958|BEHAVIORAL|Telephone-Based Intervention|"Receive electronic reminders with successive alerts (using the snooze function)"
224167998|NCT06639958|BEHAVIORAL|Training and Education|Undergo training for prompting and supervising 6MP
224167999|NCT06821425|DRUG|Melatonin gel mixed with xenograft|This study will be conducted to evaluate the effect of melatonin (5% gel) when used as an adjunct to xenograft for the surgical management of intrabony periodontal defects.
224168000|NCT06821425|OTHER|Xenograft|Application of Xenograft alone for the surgical management of intrabony periodontal defects.
224168001|NCT06821802|DIETARY_SUPPLEMENT|Moltein PURE Protein Powder|80 g protein supplementation per day (two bottles, each containing 40 g protein)
224168002|NCT06821802|BEHAVIORAL|Fluid restriction|total daily fluid intake to a maximum of 1000 ml
224168003|NCT06177535|DIETARY_SUPPLEMENT|Kavalactones|Three 75 mg capsules orally once daily within one hour of bedtime (225 mg total/day)
224168004|NCT06177535|DRUG|Placebo|Three capsules orally once daily within one hour of bedtime. Looks exactly like the study drug, but it contains no active ingredient.
224168005|NCT05196867|BEHAVIORAL|Intervention Group|Participants in the intervention group will receive (1) weekly telephone or videoconference coaching; (2) health education print materials and tip sheets;(3) navigation to programs and resources to help participants meet behavioral goals (e.g., fitness events, classes and webinars, etc); (4) text messages related to behavioral skills; (5) a Fitbit activity tracker and Aria scale; (6) resistance tubes and instructional video for strengthening exercise (if resistance exercise module is chosen); and (7) tools to manage portion sizes.
224168006|NCT05196867|BEHAVIORAL|Control Group|Patients in the control arm will initially receive written education material about the risk factors for liver cancer and management options. They will be offered the intervention after they complete the 6-month assessment.
223480638|NCT03980678|DIETARY_SUPPLEMENT|Orange flavoured water with maltodextrin as the placebo|Following or prior to a washout period (crossover intervention), participants will consume 250 ml of orange flavoured water (containing 20mg of Calcium with maltodextrin) for a 7 day period.
223480639|NCT00167791|DRUG|rituximab|Rituximab 375mg/m2 IV weekly times 4 weeks
223480640|NCT02749825|DRUG|Trelstar|As labeled
223480641|NCT02749825|DRUG|Lupron|As labeled
223480642|NCT02749825|DRUG|Zoladex|As labeled
223480643|NCT04524156|OTHER|Physiology|"Percutaneous O2 and CO2 partial pressures. A PeriFlux system 5000 (Perimed©, Järfälla, Sweden) will be used to monitor TcpO2 and TcpCO2 tensions by means of a PF 5040 unit and a dual TcpO2/CO2 E5280 electrode. The E5280 electrode, covered by a membrane permeable to oxygen (O2) and carbon dioxide (CO2) heats (44°C) the underlying tissue to maximize gas diffusion through the skin. .~Pulse Oximeter and hemodynamic parameters Pulse oximeter is a portable device largely used to measure real time finger oxygen saturation (SatO2) and heart rate Blood collection After the above said measurements, a venous blood simple will be realized. Plasma concentration of ACE2, Angiotensin II, Angiotensin 1-7, angiotensin 1-9, CC16, will be measured at the Erasme hospital (ELISA method)."
223480644|NCT03756675|OTHER|haplotype PBSCT|"haplotype peripheral blood stem cell transplantation (PBSCT) of GIAC system"
223480645|NCT01355965|BIOLOGICAL|Autologous T cells|
223480646|NCT03186664|DEVICE|Lokomat training|The neurorobotic treatment will be performed by using the Lokomat (Lokomat, Hocoma, Volketswil, Switzerland) device. The work load will be progressively adjusted based on the improvement of motor performances. Training parameters (weight support, etc) will be individually adapted. During the first Lokomat session, support will be set at 50% of the body weight and will be adapted on observation of the gait. The Lokomat motor guidance system will be first set at 100%, corresponding to a passive walk.
224168007|NCT06030505|OTHER|No intervention required by the protocol|No visits or samples will be taken specifically for this study. This research involves only prospective or retrospective data collection in relation to the usual hospital management of the child included. Similarly, patient follow-up will be strictly within the framework of their usual hospital care in relation to their pathology.
224168008|NCT04042701|DRUG|Trastuzumab deruxtecan (DS-8201a)|"Part 1: Two dose levels of DS-8201a (3.2 mg/kg Q3W and 5.4 mg/kg Q3W via intravenous (IV) infusion will be administered for the dose escalation part of the study in combination with pembrolizumab.~Part 2: Once Part 1 of the study is complete and a RDE for DS-8201a has been established, Part 2 will begin. All participants will receive DS-8201a at the RDE in combination with pembrolizumab."
224168009|NCT04042701|DRUG|Trastuzumab deruxtecan (DS-8201a)|"Part 1: Two dose levels of DS-8201a (3.2 mg/kg Q3W and 5.4 mg/kg Q3W via intravenous (IV) infusion will be administered for the dose escalation part of the study in combination with pembrolizumab.~Part 2: Once Part 1 of the study is complete and a RDE for DS-8201a has been established, Part 2 will begin."
224168010|NCT04042701|DRUG|Pembrolizumab|All participants will receive pembrolizumab (200 mg Q3W) via intravenous (IV) infusion prior to DS-8201a in Parts 1 and 2 of the study.
223480647|NCT03186664|DRUG|Sativex|"Patients in treatment with Sativex will receive cannabis-based medicine extract presented in a pump action sublingual spray. Sativex is composed of whole cannabis plant extract, containing THC (27 mg/mL) and CBD (25 mg/mL), in ethanol/propylene glycol (50:50) excipient.~Each actuation delivers 100 KL of spray, containing THC 2.7 mg and CBD 2.5 mg. The number and frequency of dosing (sprays) with Sativex will vary from individual to individual and it may take a number of weeks to find the correct dose of Sativex for the individual patient."
223480648|NCT01560117|DRUG|Rituximab|Rituximab 375 mg/m2 i.v. every 2 months for 24 months
223480649|NCT00544271|BIOLOGICAL|INFANRIX|
223480650|NCT00544271|BIOLOGICAL|BOOSTRIX|
223480651|NCT00544271|BIOLOGICAL|HAVRIX|
224168011|NCT04255693|BEHAVIORAL|diet adherence|"This type of intervention is to be established in a-posteriori analysis by the assessment of a fact whether a subject kept to use his usual diet or it contained substantial changes."
224168012|NCT04255693|BEHAVIORAL|No diet adherence|"A-posteriori established intervention based on the examinations at the end-point"
224168013|NCT04255693|BEHAVIORAL|Change in physical activity|The changes in physical activity will be assessed a-posteriori based on the examination at the end-point versus baseline data
224168014|NCT04255693|BEHAVIORAL|No change in physical activity|The changes in physical activity will be assessed a-posteriori based on the examination at the end-point and comparison to the baseline data
224168015|NCT04255693|BEHAVIORAL|Use of antisecretory agents|"This intervention will be established a-posteriori, based on the examination at the end-point and compared to the baseline data. The need for the use of anti-secretory agents depends on the form of GERD and will be on the treating physician discretion. It is principal to account the use of anti-secretory agents (H2-histamine receptors blockers, proton pump inhibitors) as a major factors that may influence the outcomes."
224168016|NCT04255693|BEHAVIORAL|No use of antisecretory agents|"This intervention will be established a-posteriori, based on the examination at the end-point and compared to the baseline data."
224168017|NCT06585631|BEHAVIORAL|CC PrTNER|Participants randomized to CC PrTNER will be assigned a peer coach. They will conduct interviewer-administered behavioral surveys. The surveys provide an in-depth assessment of SU, HIV prevention and care, engagement, and adherence. Behavioral surveys are administered monthly. The coach will discuss with the participant the areas that are flagged by the psychiatrist; provide psychoeducation around areas identified, and work with the participant to identify their health goals and how changes in SU may help feed into self-defined goals. The coach will meet weekly with the consultant addiction psychiatrist who will make a provisional diagnosis and define a treatment plan with clear goals for treatment outcome. Recommendations will be communicated electronically to the HIV or PrEP provider to facilitate implementation. The coach utilizes MI skills to implement the individually tailored to facilitate the adoption and maintenance of health behaviors.
224168018|NCT02381886|DRUG|IDH305|
224168019|NCT05965713|DEVICE|Neurolutions IpsiHand System|The IpsiHand system utilizes a Brain-Computer Interface (BCI) to enable operation of a robotic hand exoskeleton worn on the hand and wrist as participants are guided through a rehabilitation program on a tablet. Participants will complete 12 weeks of home therapy with the IpsiHand system. Motor function of their impaired upper extremity will be evaluated at baseline and at 12 weeks completion of IpsiHand use.
224168020|NCT05965713|OTHER|Standard of Care - Home Exercise Program for Upper Extremity|Subjects will receive a customized standard of care home exercise program. Subjects will be recommended to complete their exercises daily, 5 out of 7 days per week for 12 weeks.
224168021|NCT06038578|BIOLOGICAL|TRK-950|5 mg/kg or 10 mg/kg IV infusion over 60 minutes on Day 1, 8, 15 and 21 of each 28 day cycle
224168022|NCT06038578|DRUG|Ramucirumab|8 mg/kg IV infusion on Days 1 and 15 of a 28-day cycle
224168023|NCT06038578|DRUG|Paclitaxel|80 mg/m\^2 IV infusion on Days 1, 8, and 15 of a 28-day cycle
224168024|NCT05977686|DEVICE|Masimo Root Radical 7 Pulse CO-Oximeter|The Masimo device is non-invasive and placed externally on a patient's finger to generate an estimation of a patient's hemoglobin value.
224168025|NCT05977686|DEVICE|HemoCue Hb 801|The HemoCue® device is a minimally-invasive device that relies on the finger prick method to get a capillary hemoglobin measurement.
224168026|NCT03070119|DRUG|Tofersen|Participants will receive a loading dose regimen followed by maintenance dosing.
224168027|NCT05232929|DRUG|Risdiplam|Risdiplam taken by participants as prescribed by their physician.
224072065|NCT02254889|DRUG|proton pump inhibitor|). In the pre-ESD therapeutic group, a standard intravenous dose of PPI was given 2 hours before ESD. In the post-ESD therapeutic group, patients also received intravenous PPI in standard doses, once in the evening after ESD.
223480652|NCT01045278|DRUG|Pegylated interferon-alfa-2b and ribavirin|Pegylated interferon-alfa-2b 1.5 microg/kg subcutaneously once weekly plus weight based ribavirin 800-1200 mg PO for a variable period depending on their HCV genotype and response to treatment.
224072066|NCT01899235|DEVICE|drug eluting balloon|
224072067|NCT01899235|DEVICE|drug eluting stent|
224072068|NCT04989101|DRUG|Nigella|The candidate must take one capsule / day of nigella 5 for 21 days (1 bottle). Follow-up should be done weekly for 1 month.
224072069|NCT03138876|DEVICE|EEG Cap|Patient will be fitted with an EEG cap by the on-call neurology resident to assess for NCSE.
224072070|NCT03138876|DRUG|Anti-seizure medication|Patients may be treated for NCSE or seizures based on EEG cap findings, if the findings are clear to an attending EEG reviewer. If the subject is treated with anti-seizure medication, the primary care provider will choose which medication will be given.
224072071|NCT03138876|PROCEDURE|Standard EEG|An electroencephalogram (EEG) is a test used to find problems related to electrical activity of the brain. An EEG tracks and records brain wave patterns. Small metal discs with thin wires (electrodes) are placed on the scalp, and then send signals to a computer to record the results.
224072072|NCT04854681|DRUG|TQB2928 Injection|4 weekly IV infusions (Days 1, 8, 15, and 22) of TQB2928 in each 28-day treatment cycle until unacceptable toxicity, documentation of confirmed progressive disease (PD), or subject withdrawal.
224072073|NCT01707693|BEHAVIORAL|Lifestyle Physical Activity Intervention|Physical Activity Information given plus Behavioral counseling using motivational interviewing \& follow-up
224072074|NCT01707693|BEHAVIORAL|Information / Attention Comparison|Physical Activity information given \& follow-up, no behavioral counseling
224072075|NCT04223310|DRUG|Virtual AAD TEST group|"1. Perform virtual AAD test using a voltage map acquired during de novo AF ablation procedure~2. Preselect drug with optimal antiarrhythmic effects in the patient.~3. Take an AAD selected by virtual AAD simulation in patients who recur AF after catheter resection~4. Drug selection should be decided according to the guidelines.~5. A follow-up of rhythm follow-up has to be conducted according to the above study design."
224072076|NCT04223310|DRUG|Empirical AAD group|"1. Perform virtual AAD test using a voltage map acquired during de novo AF ablation procedure~2. Selection of AAD based on the experience of the attending physician, independent of the results of the virtual AAD test in patients who recur AF after catheter resection~3. Drug selection should be decided according to the guidelines.~4. A follow-up of rhythm follow-up has to be conducted according to the above study design."
224168028|NCT05232929|DEVICE|SMA-DAT Application and ADAM Sensor|Participants will perform a programmed selection of SMA-DAT tasks while wearing the ADAM Sensor.
224168029|NCT05978557|OTHER|Biospecimen collection|Biospecimen will be collected during surgery.
224168030|NCT03217318|DEVICE|ureteral stenting with standard or modified ureteral stent|Ureteral stenting because of kidney and or ureteral stones at the iliacal vessel crossing of the ureter or proximally
224168031|NCT02549521|DIETARY_SUPPLEMENT|Oral magnesium substitution|The elderly was given tablets two times daily with calsium and vitamin D. They were further given magnesium tablets 120 mg two times daily for 28 days.
224168032|NCT02549521|DIETARY_SUPPLEMENT|Placebo tablets without magnesium|The elderly was given tablets two times daily with calsium and vitamin D. They were further given placebo without magnesium two times daily for 28 days.
224168033|NCT00732472|DRUG|GSK573719|7 day repeat dose
224168034|NCT02159768|DEVICE|Airtraq visualization|Larynx visualization with Airtraq and attached handphone
224168035|NCT06053281|DRUG|Cholecalciferol|Daily Cholecalciferol 1000 IU in 24 weeks
224168036|NCT06053281|OTHER|Placebo|Placebo
224168037|NCT02502955|PROCEDURE|Comparison autopsy methods|Comparison of post-mortem angiography/virtual autopsy and medical autopsy
224168038|NCT00255983|DRUG|Faropenem medoxomil|600 mg BID for 5 days
224168039|NCT00255983|DRUG|placebo|placebo tablets BID for 5 days
224168040|NCT00554346|DRUG|Arcoxia(etoricoxib 90 mg/tablet)|Arcoxia(etoricoxib 90 mg/tablet) or placebo, #1, 3 days
224168041|NCT03353441|DIETARY_SUPPLEMENT|Microencapsulated Sublingual Glycine (MSG)|Glycine (MSG) tablet
224168042|NCT03353441|DIETARY_SUPPLEMENT|Placebo|Lactose tablet manufactured to mimic Glycine (MSG) tablet
224168043|NCT05544214|DRUG|CKD-371|PO
224168044|NCT00443365|PROCEDURE|Mitral valve repair|mitral valve annuloplasty
224168045|NCT04691531|DEVICE|The use of classical Gauge 22 needle|After induction of general anesthesia, patients will undergo caudal block by using classical Gauge 22 needle under ultrasound guidance using a linear probe 5.5-12 MHz.
224168046|NCT04691531|DEVICE|The use of classical Gauge 27 needle|After induction of general anesthesia, patients will undergo caudal block by using Gauge 27 needle under ultrasound guidance using a linear probe 5.5-12 MHz.
224168047|NCT02954861|OTHER|No intervention|No intervention
224168048|NCT02446028|DRUG|BIOD-531|
224168049|NCT02446028|DRUG|Humalog® Mix 75/25|
224168050|NCT02106845|DRUG|Digoxin|Single dose of digoxin 0.5 mg (2 tablets 0.25 mg) orally without and with regorafenib
224168051|NCT02106845|DRUG|Rosuvastatin|Single dose of rosuvastatin 5mg (1 tablet 5 mg) without and with regorafenib 160 mg q.d. (4 tablets 40 mg)
224168052|NCT02106845|DRUG|Regorafenib (Stivarga, BAY73-4506)|Once daily orally 160 mg (4 tablets 40 mg)
224168053|NCT03082768|DRUG|[18F]MNI-968|Healthy volunteers recruited for the study will undergo two \[18F\]MNI-968 injections and PET scans.
224168054|NCT03211104|DIETARY_SUPPLEMENT|curcumin|
224168055|NCT03211104|DIETARY_SUPPLEMENT|Placebo|
224168056|NCT01064986|BIOLOGICAL|Endotoxin, Lipopolysaccharide, LPS|Clinical Center Reference Endotoxin, lot 2, sterile saline, 1 ng/kg, bolus IV administration (\~5 minutes)
224168057|NCT01064986|BIOLOGICAL|Endotoxin, Lipopolysaccharide, LPS /Epinephrine|Clinical Center Reference Endotoxin, lot 2, sterile saline, 1 ng/kg, continuous IV administration (Hydrocortisone 3mcg/kg/min)
224168058|NCT01064986|BIOLOGICAL|Placebo|Saline vehicle (placebo)
224168059|NCT01064986|BIOLOGICAL|Hydrocortisone|Hydrocortisone
224168060|NCT00099840|PROCEDURE|Procalcitonin guided antibiotic therapy|
224168061|NCT04102657|OTHER|Intermittent Fasting|Participants will be instructed to limit their daily food consumption to an 8-hour period in the day of their choosing. For the 16-hour fasting period, subjects are to eliminate caloric intake.
224168062|NCT04102657|OTHER|Free-Living Diet|Participants will maintain their current daily food consumption with no caloric restriction. Patient must not have participated in a specialized diet or weight loss program within 2 weeks of enrollment.
224168063|NCT04102657|OTHER|Left Arm Exercise|Participants will complete a 20-minute period of rest followed by a 20-minute unilateral arm exercise on the left arm. In the middle of the study, participants will switch to the right arm to complete their unilateral arm exercises.
223480653|NCT00300729|DRUG|Celecoxib|Celecoxib 400 mg twice daily, orally, starting on the same day as palliative chemotherapy. Maximum duration of treatment is one year. Treatment should be terminated earlier in case of disease progression, unacceptable toxicity, or if the patient wants to stop treatment.
223480654|NCT00300729|DRUG|Placebo|One capsule twice daily, starting on the same day as palliative chemotherapy. Maximum duration of treatment is one year. Treatment should be terminated earlier in case of disease progression, unacceptable toxicity, or if the patient wants to stop treatment.
223480655|NCT05354934|OTHER|quetionnaire|"The questionnaire includes the following modules~* Demography and socio-economic conditions~* Screening and modalities of discovery and announcement of HIV infection~* Time and modalities of introduction of antiretroviral drugs after diagnosis~* Knowledge of HIV infection~* The perception of follow-up in the health care service~* Experiences of stigma~* Barriers to accessing care~* Periods of loss of sight and reasons for this~* Perceived health status, mental health (PHQ4), chronic illness, functional limitations~* Addictions~* Social network and support~* Clinical data Date of HIV diagnosis Date of introduction of antiretrovirals CD4 count at diagnosis Viral load at diagnosis Period without follow-up for more than 12 months CD4 nadir Last CD4 count Last viral load Antiretroviral treatment at last consultation Comorbidities Initial hospitalisation Recent hospitalization"
223480656|NCT01543191|DRUG|PUR118|low dose and high dose for 3 doses, BID
223480657|NCT02852759|PROCEDURE|Selective Cold|The volunteers of intervention group will undergo Selective Cold treatment below 10 degree celsius to neck, supraclavicular interscapular regions for 2 hours daily for 8 weeks. The electroacupuncture is conducted by commercially available device. Hyperinsulinemic euglycemic clamp, glucose tolerance test, blood parameter measurements, and PTC-CT scans will be conducted before and after the intervention. The participants will be instructed to maintain their normal behavior and calorie intake.
223480658|NCT02852759|DEVICE|Electroacupuncture|Electroacupuncture (EA) is an add-on treatment and it is applied when starting the cold treatment at the cold treated region to patients.The device is Huatuo SDZ-II model made by Suzhou Medical Appliance Factory, China.
223480659|NCT01379612|OTHER|Ultrasonic Elastography|Non-invasive
223480660|NCT03638791|BEHAVIORAL|Exposure and response inhibition|Cognitive behavioural therapy designed for treatment of Obsessive-compulsive disorder
223480661|NCT02548546|DEVICE|ECHO|Imaging
223480662|NCT02548546|DEVICE|ECG-gated MRA|Imaging
223480663|NCT05545501|DIETARY_SUPPLEMENT|No Salt, No β-OHB|Participants will consume the following for ten days. Enteric capsules will be filled with a dextrose placebo. The placebo supplement will be a β-OHB-free, taste and viscosity-matched, beverage produced by KetoneAid.
223480664|NCT05545501|DIETARY_SUPPLEMENT|High Salt, No β-OHB|Participants will consume the following for ten days. Enteric capsules will be filled with Morton's table salt. Sodium consumption will be normalized to caloric intake (2 mg Sodium/Calorie). The placebo supplement will be a β-OHB-free, taste and viscosity-matched, beverage produced by KetoneAid.
223480665|NCT05545501|DIETARY_SUPPLEMENT|High Salt, High β-OHB|Participants will consume the following for ten days. Enteric capsules will be filled with Morton's table salt. Sodium consumption will be normalized to caloric intake (2 mg Sodium/Calorie). Ketone beverage will be the β-OHB supplement produced by KetoneAid. Participants will consume 24 mL (12 grams β-OHB) of the ketone beverage three times a day (total 36 grams β-OHB).
223480666|NCT02038192|BEHAVIORAL|Living with Hope Program|"The Living with Hope Program is based on the research team's grounded theory study Hope and Connection. The film  Connecting with Hope reflects the findings of the grounded theory study. Stories of the Present has been utilized in the team's previous research with family caregivers of persons with advanced cancer."
223480667|NCT02038192|BEHAVIORAL|Stories of the Present|Stories of the Present is a directed journaling activity in which participants write in a journal at the end of the day their challenges, hope and hope for tomorrow
223480668|NCT05247320|DRUG|Sotalol Injection|Standard of care IV sotalol infusion for atrial arrhythmias
223480669|NCT04764292|DEVICE|Contrast-enhanced mammography|supplemental breast cancer screening with contrast-enhanced mammography
223480670|NCT04764292|DRUG|Iodinated Contrast Media (ICM)|supplemental breast cancer screening with contrast-enhanced mammography
223480671|NCT05728411|OTHER|Remote foot temperature monitoring system|"Remote temperature monitoring involves a thermometric mat that can detect hot spots on the plantar surface of the foot. The mat has embedded cellular connectivity so that data can be transmitted from the patient's home to the company, where the temperature data can be analyzed. The company has a team of health coaches that work with patients and providers to detect signs of damage early in order to prevent ulceration."
223480672|NCT05728411|OTHER|Enhanced usual care|"Usual care is based on the VA's amputation prevention program (PAVE - Preventing Amputation in Veterans Everywhere - VHA Directive 1410), which provides a model of care for patients at risk for amputation as well as patients who have already undergone an amputation.~Usual care will be enhanced by providing resources (e.g., information through written newsletters) relevant to a population of Veterans with diabetes, including information on nutrition and cooking, physical activities, and whole health opportunities"
223480673|NCT04497961|DRUG|Lenalidomide|dose of 10mg oral lenalidomide on days 1-21 of each 28-day cycle.
223480674|NCT04497961|DRUG|Daratumumab|1800 milligrams (mg) subcutaneous (SC) injection of daratumumab as follows: days 1, 8, 15, and 22 of cycles 1 and 2; days 1 and 15 of cycles 3-6; day 1 of cycles 7-36
223480675|NCT04497961|BEHAVIORAL|Questionnaires|EORTC QLQ-C30, EORTC QLQ-MY20, PRO-CTCAE)
223480676|NCT04497961|OTHER|Dietary Intervention|The intervention, consisting of fully prepared whole foods plant based (WFPBD) meals and behavioral coaching provided by Daily Harvest. Patients receive self-selected WFPBD meals (lunch/dinner) for 12 weeks, along with guidance for snacks and breakfast. Behavioral counseling will be provided by health coaches and a research dietitian. The first 15 participants on each arm interested in this intervention will be enrolled on C13D1 or C25D1.
223480677|NCT02365779|PROCEDURE|bilateral laparoscopic salpingectomy|Use of the confocal laser endomicroscopy Cellvizio® system during laparoscopy salpingectomy
223480678|NCT02365779|DEVICE|endomicroscopy Cellvizio® system|
224072077|NCT05946369|DIAGNOSTIC_TEST|Neutrophil to lymphocyte ratio|Complete blood count with differential to evaluate the Neutrophil to lymphocyte ratio for each patient
224072078|NCT00781716|DEVICE|Drug eluting coronary stent system|Cypher Sirolimus-Eluting Coronary Stent System vs Endeavor Zotarolimus-Eluting Coronary Stent System
224072079|NCT00973076|DRUG|AZD8055|Tablets, orally administered, twice daily
224072080|NCT02480127|PROCEDURE|PIPELLE Endometrial injury|The endometrial injury which is induced with pipelle.
224072081|NCT00302965|DRUG|Frozen Plasma|
224072082|NCT06076655|OTHER|EXERCISE AND MOBILIZATION PROGRAM|"EXERCISE AND MOBILIZATION PROGRAM The Hallux Valgus exercise program determined by the physiotherapist will be applied twice a week in the rehabilitation unit under the supervision of a physiotherapist. Each exercise and mobilization will be planned as 2 sets of 10 repetitions and 15 seconds between sets, and will be carried out throughout the interval for 12 weeks. In addition, home exercises will be given twice a day, and each exercise will be followed in 2 sets of 10 repetitions with a 15-second interval between sets.~The exercise and mobilization program planned to be implemented in this study for children with diplegic cerebral palsy is an exercise and mobilization program that has yielded positive results in various studies in adults. We created a sample protocol with exercise and mobilization practices that were found effective in these studies."
224072083|NCT00375726|BIOLOGICAL|rDEN3/4delta30(ME)|Live attenuated rDEN3/4delta30(ME) vaccine (one of three doses)
224072084|NCT00375726|BIOLOGICAL|Placebo|Placebo for rDEN3/4delta30(ME)
224072085|NCT03638232|OTHER|Administrative data|Gender Birthdate Department and town of residence Date of death Affiliation to french Universal Health Coverage
224072086|NCT03638232|OTHER|Medical data|Long term affection code, number and medical codification Date of onset and end of care Codification of medical acts and consultation (With common classification of medical acts)
224072087|NCT03638232|OTHER|Drug exposition data|Speciality of prescribing physician CIP code of drug Name of speciality prescribed Date of deliverance Date of prescription Number of treatment box delivered
224072088|NCT03987854|BEHAVIORAL|diet and lifestyle program|Participants will be taught how to follow a very low carbohydrate, ketogenic diet, become more physically active, and get adequate sleep. They will also be taught taught about positive affect skills (such as gratitude, positive reappraisal, and personal strengths) and mindfulness (general mindfulness and mindful eating).
224168064|NCT04102657|OTHER|Right Arm Exercise|Participants will complete a 20-minute period of rest followed by a 20-minute unilateral arm exercise on the right arm. In the middle of the study, participants will switch to the left arm to complete their unilateral arm exercises.
224168065|NCT05669144|BIOLOGICAL|mitochondria and MSC-derived exosomes|autologous mitochondria and MSC-derived exosomes
224168066|NCT05237713|DRUG|Canakinumab Injection|Administration for a duration of 6 months for all patients and in case of response further treatment for up to three years
224168067|NCT03215849|DEVICE|CRT-pacemaker device set to Routine Medical Therapy|Medtronic Serena™ QUAD CRT-P MRI™ SureScan™ W4TR05 set to Routine Medical Therapy
224168068|NCT03215849|DEVICE|CRT-pacemaker device set to Routine Medical Therapy + LVP|Medtronic Serena™ QUAD CRT-P MRI™ SureScan™ W4TR05 set to Routine Medical Therapy + LVP
224168069|NCT03215849|DEVICE|CRT-pacemaker device set to Routine Medical Therapy + BiVP|Medtronic Serena™ QUAD CRT-P MRI™ SureScan™ W4TR05 set to Routine Medical Therapy + BiVP
223480679|NCT05960695|OTHER|Stretching|"Among the stretching exercises, iliopsoas, adductor, and hamstring stretches will be taught. Participants will repeat the stretches 3 times a week with 3 repetitions of each stretch for 20 seconds. The exercises will be done online by the physiotherapist.~The experimental group will be given both stretching and relaxation exercises. The Control group will be given only stretching exercises."
223480680|NCT05960695|OTHER|Relaxation|Diaphragmatic breathing will be taught as a relaxation exercise. The experimental group will be given both stretching and relaxation exercises. The Control group will be given only stretching exercises.
223480681|NCT06511076|DRUG|Zilucoplan|Participants will receive a single sc injection of zilucoplan in the pre-specified sequence.
223480682|NCT05138562|DRUG|Placebo Comparator: Placebo|4 x placebo capsules, QD
223480683|NCT05138562|DRUG|Active Comparator: TU2670 320mg|320mg (80mg x 4), QD
223480684|NCT05138562|DRUG|Active Comparator: TU2670 240mg|240mg (80mg x 3 + placebo x 1), QD
223480685|NCT05138562|DRUG|Active Comparator: TU2670 120mg|120mg (80mg x 1 + 20mg x 2 + placebo x 1), QD
223480686|NCT05567341|PROCEDURE|Remote ischemic preconditioning|A blood pressure cuff is inflated to 200 mmHg for 4x5 min (5 min rest between cycles) at the right upper extremity when the vestibular schwannoma surgery is started
223480687|NCT05567341|PROCEDURE|Sham-control|A blood pressure cuff is inflated to 0 mmHg for 4x5 min (5 min rest between cycles) at the right upper extremity when the vestibular schwannoma surgery is started
223480688|NCT06638125|DEVICE|3-Dimensional VR Modelling (Elucis) with Intravascular Indocyanine Green Fluorescence Mapping|All patients in Phase I and those randomized to Intervention in Phase II will have preoperative 3D VR reconstructions of their pulmonary anatomy with the target lesion created using the Elucis platform. Segment identification and confidence rating will be collected before and after visualizing the 3D VR reconstruction. Intraoperatively, the surgeon will use this 3D VR model as a guide to determine which inflow and outflow vessels to the involved segment need to be removed. After vascular ligation, a 8mL bolus of ICG solution will be injected into a peripheral vein catheter by anesthesia. The surgeon will mark out the segmental plane based on the fluorescence pattern seen on the infrared mode of the robotic camera. The surgeon will then perform the pulmonary resection and the resected non-fluorescent lung segment will be extracted from the body cavity. Study patients will receive routine postoperative care as non-study patients and will be followed until the 3-4-week mark.
223480689|NCT06638125|DEVICE|3-Dimensional Modelling (Synapse 3D) with Intravascular Indocyanine Green Fluorescence Mapping|The patients that are randomized to Control in Phase II will undergo the same intervention as above, but instead of using Elucis for 3D VR reconstructions, Synapse 3D will be used for 3D reconstructions.
223480690|NCT05595577|OTHER|Exercise with Trainerize application|1-2 sessions per week consisting of slow 15 minute aerobic warm, 20 minutes of strength training, 15 minutes progressive intensity aerobic exercise and 10 minute cool down (stretching/toning) with elastic bands.
223480691|NCT05595577|DIAGNOSTIC_TEST|Cardiopulmonary exercise testing|Maximal peak VO2 (to monitor the body's oxygen consumption) and 6-minute exercise walking test.
223480692|NCT05595577|DIAGNOSTIC_TEST|MRI scan|Images of the heart will be taken.
223480693|NCT05595577|BEHAVIORAL|Quality of Life Questionnaires|Participants will be asked to complete several questionnaires that will measure fatigue, general health, social determinants of health, cognitive function (tasks that assess memory, ability to count, etc.) and physical activity. The questionnaires will take 15-40 minutes to complete.
223480694|NCT05595577|BEHAVIORAL|Cognitive and Brain Function Questionnaires|Participants will be asked to complete several questionnaires that will measure fatigue, general health, social determinants of health, cognitive function (tasks that assess memory, ability to count, etc.) and physical activity. The questionnaires will take 15-40 minutes to complete.
223480695|NCT05595577|OTHER|Blood draws|Approximately 2 teaspoons of blood withdrawn from either a vein in your arm or a currently placed central line port-a-cath. A portion of blood from each visit will be used to collect information about blood cell count.
223480696|NCT05806658|OTHER|Visual arts-based intervention|This visual arts-based intervention is grounded on Bandura's Self-Efficacy Theory. It consists of four weekly group and face-to-face sessions delivered by a qualified facilitator. The contents of the intervention involve structured visual art-making activity, group discussion, and workbook assistance.
223480697|NCT06252480|DEVICE|tDCS|4 variance of different intensities of tDCS (0.5mA, 1 mA, 1.5mA and 2mA). At F3 and F4, tDCS was applied to the desired region. Electrodes were put in using the 10-20 EEG technique throughout the parietal cortex, with the current electrode being set on F3 area and control electrode being positioned on the F4 area. For 20 minutes over three days per week for up to three weeks, current intensities of 0.5mA for group A, 1.0mA for group B, 1.5mA for group C, and 2.0mA for group D were administered. when engaging in dual-task cognitive processes. The groups are going to receive 9 sessions of tDCS treatment.
224168070|NCT01058395|DRUG|Minocycline|Minocycline 800 mg loading followed by 200 mg Q12 or Minocycline 800 mg loading followed by 400 mg Q12 will be delivered in an open-label study for seven days intravenously in one of two different dosing tiers to assess safety and toxicity per FDA recommendations. There will be tow different arms or groups differing by the amount of minocycline given over 7 days.
224168071|NCT01266876|DRUG|Alirocumab|Alirocumab two SC injections in the abdomen only.
224168072|NCT01266876|DRUG|Placebo|Placebo two SC injections in the abdomen only.
223584842|NCT05803252|BEHAVIORAL|Focused Acceptance and Commitment Therapy|"FACT aims to increase one's psychological flexibility so that one will not generate feelings of distress and suffering when confronted with painful life situations. The intervention of this study will follow the FACT principles laid out by Strosahl, Robinson and Gustavsson to increase parents' psychological flexibility. Three core processes influence one's psychological flexibility: awareness, openness, and engagement.~The key objectives of each core process are:~1. Awareness: Able to experience the present moment, able to take perspective on self~2. Openness: Able to detach distressing private experiences and associated rules, able to take a non-judgemental, accepting stance towards painful material~3. Engagement: Exhibits strong connection with values, able to sustain values-consistent action"
224168073|NCT00640575|DRUG|triamcinolone and lidocaine hydrochloride|Ultrasound-guided lidocaine hydrochloride 5 ml (10 mg/ml) injection in the subacromial bursa and a triamcinolone 2 ml (10 mg/ml) and 2 ml lidocaine hydrochloride (10 mg/ml) intramuscular injection in the gluteal region
224168074|NCT00640575|DRUG|triamcinolone and lidocaine hydrochloride|Ultrasound-guided injection of 2 ml triamcinolone (10 mg/ml) and 5 ml lidocaine hydrochloride (10 mg/ml) in the subacromial bursa and 4 ml intramuscular injection of lidocaine hydrochloride in the gluteal region
223584843|NCT05803252|OTHER|Waitlist Control|The waitlist control group participants will commence their FACT intervention immediately after they complete their follow-up assessment.
224168075|NCT06313242|DRUG|Polyethylene Glycol Electrolytes Powder (II)|Polyethylene Glycol Electrolytes Powder (II) was used for bowel preparation.
223584844|NCT05332275|BEHAVIORAL|Intervention Arm - T.E.C.H. Parenting|"Intervention Arm participants will enroll in a web-based psychoeducational group (15 parents per group across 4 groups). Participants will receive psychoeducational information on media parenting, and they will be invited to participate in an online group discussion board to share their experiences with other parents in the intervention. In weeks 2-5, participants will learn about 4 domains of media parenting: 1) Talk to your child about media; 2) Educate your child about media-related risks; 3) Co-View/Co-Use media and technology actively with your child; and 4) establish House rules for media usage. Week 6 will review information and provide an expert clinician to support parent problem solving. Participants will receive 2-3 weekly push messages via text messaging prompting practice of skills learned in the group setting. Participants will be assessed at baseline, immediately following the 6 week intervention, and 3 months after the intervention is completed."
223584845|NCT05332275|BEHAVIORAL|Control Arm - General Positive Parenting|The Control Arm of the RCT is the attention control group. These participants will enroll in a web-based psychoeducational group (four groups of 15 parents each). They will receive 6 weeks of online psychoeducational material, including 2-3 push messages prompting skill practice. Parents will have access to an online discussion board to share experiences with other parents. This group will match the intervention arm of the study in number of study staff contacts, time of start/duration of the group, peer support, and availability of a professional in week six for consultation on parenting issues. Control participants will not receive information on media parenting. Participants in this group will be assessed at baseline, immediately following the six-week intervention period, and 3 months after intervention completion. Participants will be asked about exposure to TECH Parenting content at baseline and followup to address potential contamination effects across study arms.
224168076|NCT06313242|OTHER|Low residue diet|Low residue diet 1 day before the test, fasting from 20:00 pm.
224168077|NCT06313242|OTHER|Normal diet|Normal diet 1 day before the test, fasting from 20:00 pm.
224168078|NCT02765191|OTHER|Plasma expansion with Ringer's Acetate|7,5 ml/kg mL Ringer's acetate during 5-10 minutes will be administered intravenously
224168079|NCT06186154|DIETARY_SUPPLEMENT|Folinic acid (oral); Cyanocobalamin sublingual|"* Vitamin B12 (also known as Cyanocobalamin) daily sublingual supplementation of 1000 mcg/day and folinic acid orally 1mg/day~* Laboratory: Complete blood count, electrolytes, reticulocytes, creatinine, urea, alkaline phosphatase (ALP), alanine transaminase, ferritin, total homocysteine, lactate and hemoglobin A1c. Routine blood will be collected as regular standard of care with each visit. MMA will also be assessed. Peripheral serum values (CBC, B12) will serve as a representation of central micronutrient availability~* Clinical Evaluation: the Newcastle mitochondrial disease adult scale (NMDAS)"
223480698|NCT05091190|OTHER|Blood draws|"Blood draws will be realized at the following time points:~C1T1: at the baseline, before treatment administration. C1T2: cycle 1, after treatment administration. C2T1: the day of the 2nd cycle, before treatment administration. C2T2: the day of 2nd cycle, after treatment administration. C3T1: the day of the 3rd cycle, before treatment administration. C3T2: the day of 3rd cycle, after treatment administration."
223480699|NCT05439655|DEVICE|Brain Interchange System|The CorTec Brain Interchange (BIC) is an implantable system with sensing and stimulation capability dedicated to promoting brain computer interface and closed-loop neuromodulation research. It is an externally powered implant which can provide neural data to a nearby computing station (communication unit connected to a personal computer) continuously. In return, computing station controls the implant e.g. for generating therapeutic electrical stimulation to the brain. It is expected that BIC will catalyze translational applications of electroceuticals in human subject by making the neural data immediately available as well as permit the investigation of novel closed-loop neuromodulation applications.
224168080|NCT06967675|PROCEDURE|Low-Flow Anesthesia (LFA)|General anesthesia with a fresh gas flow rate of 1 L/min (50% oxygen + 50% air).
224168081|NCT05180721|BEHAVIORAL|Use of patient portal for diabetes management|A multi-level intervention aimed at increasing access and use of patient portals for diabetes management (MAP) in community health centers (CHCs).
224168082|NCT05846282|BEHAVIORAL|STRIVE|The STRIVE intervention will include all activities and BREATHE skill training components of L2B with content framed within the needs of high achieving college-bound BIPOC students who can benefit from health promoting practices to offset the costs of resilience. The intervention will include twelve 60-minute group sessions, with two sessions on each of the six core themes. Each session will include an opening mindful movement, short didactic presentation of the topic or theme of that week, group activities that illustrate the theme, guided discussion about the activity, and in-session group mindfulness meditation practice.
224168083|NCT05846282|BEHAVIORAL|Study Skills|The sessions will focus on goal setting (4 sessions), organization and time management (3 sessions), and study skills for reading comprehension, writing papers, note-taking, and test-taking (4 sessions). Parallel to the final L2B session, the last meeting will include activities to share and reflect on how students plan to incorporate and sustain new skills.
224168084|NCT04870099|BEHAVIORAL|Doing What Matters in Times of Stress: An Illustrated Guide|"From the WHO's website: Doing What Matters in Times of Stress: An Illustrated Guide is a stress management guide for coping with adversity. The guide aims to equip people with practical skills to help cope with stress. A few minutes each day are enough to practice the self-help techniques. The guide can be used alone or with the accompanying audio exercises.~Informed by evidence and extensive field testing, the guide is for anyone who experiences stress, wherever they live and whatever their circumstances."
224168085|NCT04081558|DEVICE|Electronic patient reported outcomes tool|Electronic patient reported outcomes
224168086|NCT01996865|DRUG|Lenalidomide|
224168087|NCT01996865|DRUG|Rituximab|
224168088|NCT06399952|DIAGNOSTIC_TEST|Brain Magnetic Resonance Imaging (MRI)|Participants will undergo a 5-10 minute non-anesthesia brain MRI in order to evaluate for changes in brain structure. A 20 to 30 minutes 20 channel surface electroencephalography will be performed in the wake and sleep states.
224168089|NCT06399952|GENETIC|Whole Genome Sequencing|15 milliliters of blood will be collected at the initial visit. Blood samples will be centrifuged, and plasma stored in the University of Missouri Next Gen Precision Health building. Next generation whole genome sequencing and proteomics will be performed on plasma samples. Additional blood will be collected for the DNA biobank.
224168090|NCT06399952|OTHER|Induced Pluripotential Stem Cells|A 3 mm skin punch biopsy will be collected for developing induced pluripotential stem cells.
224168091|NCT05058859|DRUG|Dapagliflozin|Dapagliflozin is to lower blood sugar levels in adults with type 2 diabetes
224168092|NCT06342843|PROCEDURE|Total Hip Arthroplasty|a surgical procedure in which an orthopaedic surgeon removes the damaged bone and cartilage and replaces this with prosthetic components.
224168093|NCT06217575|BEHAVIORAL|Alpha neurofeedback training|Alpha neurofeedback training affords the participant the ability to monitor cortical EEG waves and entrain to a specific rhythm using visual feedback. Alpha is measured between 8-12Hz and is associated with cortical inhibition. Aging related changes in alpha have been associated with loss of modulation ability. However, alpha training may afford increased perception of visual details.
224168094|NCT06217575|BEHAVIORAL|Visual Attention Training|"Visual attention training involves repeated testing on the location and identity of objects in the visual field. Also called the Dual Decision task training, objects are briefly presented in a radial field of view surrounding a gaze fixation point. The participant is asked to remember the location and object presented within the field. The test progressively increases in difficulty by limiting the amount of time the object is presented on screen. Accuracy is measured by either a correct or incorrect response (binary response)."
224168095|NCT05667623|DRUG|1% OPA-15406 Ointment|Twice-daily administration for 4 weeks/24 weeks.
224168096|NCT05667623|OTHER|0% OPA-15406 Vehicle|Twice-daily administration for 4 weeks/24 weeks.
224168097|NCT04084795|BEHAVIORAL|Eye Movement Desensitization and Reprocessing therapy|"EMDR is a psychotherapeutic approach using a standardized 8-phase protocol to alleviate the distress associated with traumatic memories, facilitating the access to and processing of traumatic memories. Patients will receive 20 individual EMDR sessions of 60 minutes each using the standard protocol, as well as a specific pain protocol and the fibromyalgia protocol. EMDR is an integrative psychotherapy that uses standardized protocols and elements of cognitive-behavioral, interpersonal, and body-centered therapies, as well as dual stimulation (e.g., side-to-side eye movements).~The current standard protocol includes eight phases:~Patient history. Patient preparation. Patient assessment. Memory desensitization. Installing the positive cognition. Body scan. Closure. Reevaluation."
224168098|NCT04084795|OTHER|transcranial Direct Current Stimulation|tDCS represents a promising intervention option, given its capacity to modulate cerebral excitability in a simple, safe manner. F3 anodal; Fp1, F7, Fc5, AF3, Fc1, Fz, return montage will be used with the anode over the left DLPFC. Half of the patients will receive active stimulation and the other half sham stimulation. Active stimulation will consist of 2mA tDCS for 20 minutes applied immediately before EMDR sessions. The same protocol and montage will be used for sham stimulation.
224168099|NCT05438004|OTHER|Ambulatory nice birth|discharge from the maternity ward from the 2nd hour and before the 24th hour following an uncomplicated delivery
224168100|NCT05455294|DRUG|Navitoclax|See Arm Description
224168101|NCT05455294|DRUG|Venetoclax|See Arm Description
223480700|NCT02745106|PROCEDURE|Radiofrequency pulmonary artery denervation|Radiofrequency ablation of pulmonary artery will be performed with standard electrophysiological catheter and non-fluoroscopic 3D-navigation system. Right heart catheterization (thermodilution method with Swan-Ganz catheter) will be performed before and after procedure. The radiofrequent impact will be performed 2mm after pulmonary artery bifurcation in both right and left main pulmonary artery branches. The radiofrequent impact will be performed at temperature 40-42 C, up to 12 watts and 60 second duration in every ablation point under impedance control.
223480701|NCT02745106|DEVICE|Ablation catheter|4MM RF CONDUCTR (MULTI-CURVE) SERIES ABLATION CATHETER Standart procedure for radiofrequency ablation: Radiofrequency ablation of pulmonary artery will be performed with standard electrophysiological catheter and non-fluoroscopic 3D-navigation system. Right heart catheterization (thermodilution method with Swan-Ganz catheter) will be performed before and after procedure. The radiofrequent impact will be performed 2mm after pulmonary artery bifurcation in both right and left main pulmonary artery branches. The radiofrequent impact will be performed at temperature 40-42 C, up to 12 watts and 60 second duration in every ablation point under impedance control.
223584846|NCT06108830|DRUG|Esketamine|Patients undergoing gastroenteroscopies were given propofol 2 to 3mg/kg and esketamine 0.2mg/kg before the procedure began
224168102|NCT05455294|DRUG|Decitabine|See Arm Description
224168103|NCT04934956|OTHER|Split-belt walking|These will be used in all experiments and consists of a time period during which the legs move at different speeds (0.5 m/s vs. 1 m/s). The investigators select those speeds since the investigators have observed in our preliminary data and published study (Sombric et al. 2017) that older individuals adapted at these speeds exhibit large deficits at motor switching when transitioning to overground walking. This large reference signal will facilitate the detection of a change in motor switching (Aim 2) following the Intervention.
223584847|NCT06108830|DRUG|Remimazolam|Patients undergoing gastroenteroscopies were given propofol 2 to 3mg/kg and remimazolam 0.15mg/kg before the procedure began
223584848|NCT06108830|DRUG|Esketamine and remimazolam|Patients undergoing gastroenteroscopies were given propofol 2 to 3mg/kg and remimazolam 0.15mg/kg before the procedure began
224168104|NCT04934956|OTHER|Multiple transitions between split-belt and tied-belt walking|This intervention consists of multiple short adaptation blocks (i.e., 6 blocks of 200 strides each) interleaved with short de-adaptation blocks (i.e., 5 blocks of 200 strides of tied-belt walking each). It was designed based on several studies showing improvements in adaptation rate in young adults with a similar protocol (Malone et al. 2011; Day et al. 2018; Leech et al. 2018).
224168105|NCT03044210|OTHER|Metabolic evaluation|"* diet assessment~* biological evaluation~* clinical evaluation~* metabolic evaluation (calorimetry)"
224168106|NCT04685486|OTHER|Virtual Reality|Immersive and interactive game played through a portable head-mounted display as a distraction mechanism
224168107|NCT06206746|DEVICE|May Health System|The intervention includes the short-term use of the May Health System, which is comprised of three elements: (1) the May Health Needle-Catheter Ablation Device (NCAD) (the Device) a 16 gauge echogenic needle including a bipolar temperature-controlled RF ablation catheter which is clipped and secured onto a vaginal ultrasound probe; (2) the May Health Adapter which is clipped onto the ultrasound probe; and (3) the May Health Generator: a bipolar radiofrequency (RF) ablation platform utilizing the single use May Health NCAD for ovarian tissue ablation. Once the patient is under conscious sedation, the physician guides the May Health system transvaginally with the use of a transvaginal ultrasound. Once the May Health device is safely and securely positioned, the physician will deliver radio frequency energy inside the ovary in order to ablate the tissue.
224168108|NCT03580785|GENETIC|genetic analysis|saliva is collected for DNA extraction
224168109|NCT03580785|RADIATION|panoramic radiography|panoramic radiography
224168110|NCT03580785|RADIATION|teleradiography|teleradiography
224168111|NCT03580785|RADIATION|intraoral X-rays|intraoral X-rays
224168112|NCT03580785|RADIATION|CT scan of maxillary and mandible|CT scan of maxillary and mandible
224168113|NCT06253065|DIAGNOSTIC_TEST|Artificial intelligence (AI)-based diagnostic model (developed)|Collect pathological slides of resected lymph nodes of the enrolled patients. Digitise these slides into whole-slide images (WSIs). Analyze the WSIs using the AI model to generate diagnostic results (with or without lymphatic metastasis). No intervention to patients would be performed in this diagnostic test study.
224168114|NCT06105970|OTHER|No intervention|cross sectional study#no intervention
224168115|NCT04783506|OTHER|Observational Study|There is no intervention provided by this study. Observed for 12-month period using questionnaires and study visits.
224305378|NCT05909865|OTHER|Therapeutic resistance exercise|Therapeutic exercise program based on individualized progressive resistance exercises performed during 3 months at home, with a frequency of 1-3 sessions per week at the hospital.
224305379|NCT05909865|OTHER|Education|Education applied during all the therapeutic process, focusing on diverting the patient's attention away from the structural lesion, explaining the relationship between pain/disability and tissue injury, explaining the meaning of pain during exercises, and explaining the objectives of the implemented treatments.
223480702|NCT02745106|DEVICE|Swan-Ganz catheter for right heart catheterization|"Standart procedure of right catheterization:~* punction of right jugular vein with Seldinger technique, introducer placement~* insertion of Swan-Ganz catheter via introducer in jugular vein under fluoroscopic control and wave form of monitor's curve.~* positioning of swan-ganz catheter in pulmonary artery~* direct central hemodynamics measurements: systolic/diastolic/mean pulmonary artery pressure, pulmonary capillary wedge pressure, cardiac output (thermodilution technique)~* calculating of indirect parameters (pulmonary vascular resistance)"
223480703|NCT04850105|OTHER|Data Collection|"Data on each patient will be collected at study enrollment and at each follow-up visit.~No mandatory visits, tests, or assessments are required for this study. All visits will be scheduled and conducted according to the clinical site's normal clinical practice."
223480704|NCT05186480|DIETARY_SUPPLEMENT|Neo Mune|"Neo-mune is a nutritional formula used in enteral feeding for critically ill patients. It's mainly indicated in cases of malnutrition, post surgeries and traumas and immunocompromisation.~Its composition:~Composition in approximate %w/w Maltodextrin 42.44% Sodium caseinate 18.25% MCT oil 6.28% Arginine 5.21% Polydextrose 4.00% Corn oil 3.48% Glutamine 2.61% Fish oil 2.32% Minerals 1.96% Vitamins 0.86% Artificial flavor (vanilla)"
223480705|NCT04908787|DRUG|BD0801|Subjects receive BD0801 , intravenously, d1, d15, q4w, Dosage form: injectable, Strength: 1.5 mg/kg
223480706|NCT04908787|DRUG|Paclitaxel|Subjects receive Weekly Paclitaxel, intravenously, d1, d8, d15, d22, q4w, Dosage form: injectable, Strength: 80 mg/m2
223480707|NCT04908787|DRUG|Placebo|Subjects receive Placebo, intravenously, d1, d15, q4w, Dosage form: injectable, Strength: 1.5 mg/kg
223480708|NCT04908787|DRUG|Topotecan|Subjects receive Topotecan, intravenously, d1, d8, d15, q4w, Dosage form: injectable, Strength: 4mg/m2
223480709|NCT04908787|DRUG|doxorubicin liposome|Subjects receive doxorubicin liposome, intravenously, d1, , q4w, Dosage form: injectable, Strength: 40mg/m2
223584849|NCT06108830|DRUG|normal saline|Patients undergoing gastroenteroscopies were given propofol 2-3mg/kg and 10ml 0.9% saline before the procedure began
223584850|NCT06026163|DRUG|Caffeine citrate|Caffeine citrate in loading dose 20 mg/kg (equivalent for 10 mg/kg caffeine base) and maintenance dose 10 mg/kg/day (equivalent for 5 mg/kg caffeine base)
223584851|NCT06026163|OTHER|Placebo|Equivalent volume of saline
223584852|NCT04030962|DRUG|AGN-242428|Ophthalmic solution administered as a topical eye drop
223480710|NCT04762186|DRUG|human SARS-CoV 2 specific T lymphocytes|"In dose level one, SARS-CoV-2 infected patients will receive 1,000 viable human SARS CoV-2 specific T lymphocytes per kg BW.~In dose level two SARS-CoV-2 infected patients will receive 5,000 viable human SARS CoV-2 specific T lymphocytes per kg BW.~In parallel, all patients will receive the current SoC treatment for COVID-19."
223480711|NCT05719961|DRUG|INS062 injection|Part I: A single dose of 1.2noml/kg is administered.
223480712|NCT05719961|DRUG|Insulin Aspart|Part I: A single dose of 0.2U/kg is administered.
223480713|NCT05719961|DRUG|HR20014 injection|Part II: Ascending single doses at three dose levels
223480714|NCT05719961|DRUG|Insulin Aspart 30 Injection|Part II: A single dosewas administered
223584853|NCT04030962|DRUG|AGN-231868|Ophthalmic solution administered as a topical eye drop
223584854|NCT04030962|OTHER|AGN-242428 Vehicle|Matching placebo (vehicle) ophthalmic solution administered as a topical eye drop
224168116|NCT04083781|DRUG|Concizumab|Concizumab will be administered daily subcutaneously (s.c., under the skin). When patients are randomised to concizumab prophylaxis they will receive a loading dose of 1.0 mg/kg concizumab at visit 2a (week 0: arm 2, 3 \& 4) or visit 9a (week 24: arm 1) followed by an initial daily dose of 0.20 mg/kg concizumab from treatment day 2. Within an initial 5-8-week dose adjustment period on 0.20 mg/kg concizumab, the patients can be increased or decreased in dose to 0.25 mg/kg or 0.15 mg/kg concizumab. A potential dose adjustment will take place at visit 4a.1 (week 6: arm 2, 3 \& 4) or 9a.3 (week 30: arm 1) and will be based on the concizumab exposure level measured at the previous visit 4a (week 4) or 9a.2 (week 28). Patients who have concizumab exposure levels of 200-4000 ng/mL will stay at 0.20 mg/kg concizumab. Patients in arm 1 will continue on-demand treatment with their usual bypassing product until visit 9a (week 24: end of main part for arm 1).
224168117|NCT04571684|OTHER|HITSystem 2.1|HITSystem 2.1 is an intervention that tracks HIV+ pregnant women and their infants to improve the completeness and efficiency of PMTCT services. Key intervention features include: (1) SMS messages sent to enrolled women and mothers to support essential PMTCT services, (2) automated, algorithm-driven alerts for providers when per-guidelines PMTCT services are missed, and (3) automatic enrollment of infants into early infant diagnosis (EID) and linkage with maternal PMTCT file at documentation of infant birth to improve the continuum of care for HIV+ mothers and HIV-exposed infants. The HITSystem 2.1 intervention aims to facilitate complete PMTCT retention and viral load (VL) monitoring with prompt clinical action (adherence support, antiretroviral therapy (ART) regimen change) in the antenatal, delivery, and 6-month postpartum periods to increase viral suppression during windows critical for HIV prevention.
224168118|NCT03575351|DRUG|Standard of Care|Standard of Care
224168119|NCT03575351|GENETIC|JCAR017|JCAR017
224168120|NCT06295991|DEVICE|Lycra garment|Investigation of the effect on balance and respiratory functions by using specially produced lycra garments for 6 hours a day for 16 weeks
224168121|NCT06976437|DRUG|RN1101 injection|RN1101 injection is an allogenic CAR-T targeted CD19 and BCMA. A single infusion of CAR-T cells will be administered intravenously.
224168122|NCT06976554|PROCEDURE|weaning|gradual weaning from the mechanical ventilator
224168123|NCT03733132|DRUG|Metformin Hydrochloride|Metformin treatment of 2500mg for 10 months in the Metformin group
224168124|NCT03733132|DRUG|Placebo Oral Tablet|Placebo treatment of identical tablets to metformin group
224168125|NCT02968277|DEVICE|LifeWalker Upright|LifeWalker (LW) upright walker
224168126|NCT02968277|DEVICE|Predicate Device|Individual's personal walker
224168127|NCT02968277|DEVICE|Standard Rollator|A control rollator device
224168128|NCT05103501|DRUG|PF regimen (cis-platinum ; 5-fluorouracil ) combined with PD-1 inhibitors（pembrolizumab）|immunotherapy:PD-1 inhibitor chemotherapy:5-Fu and DDP
223480715|NCT00844311|DRUG|rFSH|150 iu/day of rFSH
223480716|NCT00844311|DRUG|human chorionic gonadotropin|50 iu/day of hCG from stimulation day 1
223480717|NCT00844311|DRUG|human chorionic gonadotropin|100 iu/day of hCG from stimulation day 1
223480718|NCT00844311|DRUG|human chorionic gonadotropin|150 iu/day of hCG from stimulation day 1
223480719|NCT06546306|DEVICE|TOUCH® CMC 1|TOUCH® prosthesis is a total CMC 1 (1st Carpo-metacarpal) joint replacement prosthesis.
223480720|NCT06829485|BEHAVIORAL|Community health workers (CHW)|Participants will meet with a Community Health Worker (CHW) who will help facilitate and provide personalized navigation to existing resources for addressing health challenges such as food insecurity and access to care. CHW will meet with participants in person or virtually at least three times for approximately 15-60 minutes for over the six month period
223480721|NCT06829485|BEHAVIORAL|Educational Materials|Participants will receive one time educational materials including information of existing health resources. Participants will be able to review materials at participant discretion.
223480722|NCT05077800|DRUG|FOLFIRNINOX|Combination of 4 different drugs (5-Fluorouracil (5-FU), Oxaliplatin, Irinotecan and Leucovorin) administered by intravenous infusion
223480723|NCT05077800|DRUG|Losartan|Taken Orally
223480724|NCT05077800|DRUG|9-ING-41|Administered by intravenous infusion
223480725|NCT05146336|DEVICE|CytoSorb|Sorbent hemoperfusion system
223480726|NCT06390345|OTHER|FOCuSEd Integrated Intervention|"Participants randomized to the intervention will receive an integrated telehealth-delivered, remote lifestyle intervention that promotes healthy eating and 150 minutes per week of moderate-intensity physical exercise. This intervention will include a core curriculum during the first 3 months that includes: 1) a 12-session video based program; 2) goal setting and self-monitoring using a Fitbit tracker and MyFitnessPal; 3) lifestyle coaching; and 4) three tele-pulmonary rehab sessions and an additional 60-75 minutes of gradually increasing self-directed exercise per week. At the end of 3 months, we will offer to enter a recommendation for weight loss medications to intervention participants with a BMI of ≥ 27 kg/m2. In the post-core period (months 4-12), participants will continue to have as-needed access to the lifestyle coach."
223480727|NCT06390345|OTHER|Enhanced Usual Care|"Participants in the enhanced usual care group will be referred to MOVE! (VA's weight loss management program) and pulmonary rehabilitation in coordination with their primary care provider."
223584855|NCT04030962|OTHER|AGN-231868 Vehicle|Matching placebo (vehicle) ophthalmic solution administered as a topical eye drop
224168129|NCT04288089|DRUG|Palbociclib (75, 100, 125 milligram [mg])|Palbociclib orally, once daily (QD).
224168130|NCT04288089|DRUG|H3B-6545 (150, 300, 450 mg)|H3B-6545 orally, QD.
224168131|NCT06519682|DRUG|Nivolumab|All patients will be administered Nivolumab with or without radiation
224168132|NCT06519682|RADIATION|Radiation|Radiation
224168133|NCT03715205|DRUG|Pembrolizumab|Administered as an intravenous (IV) infusion every 3 weeks (Q3W)
224168134|NCT05674955|DIAGNOSTIC_TEST|Circuit weight versus aerobic training|"Circuit weight :Duration: 30 min-60 min (total session) Frequency: 3 times / week. Intensity: increased load was established when subject was able to complete 12 repetitions ( Wayne, 2014)~B- Aerobic training:~This mode of exercise will be conducted for study group B as follows:~Intensity: started by 60-85% of target heart rate according to each patient response Target heart rate (THR) = 60% -85% (maximum heart rate-resting heart rate) + resting heart rate Maximum heart rate (MHR) = (220-Age). Mode: Walking on treadmill. Duration: Each session consisted of 10 minutes warming up firstly then 30 minutes time of session ended by 10 minutes cool down exercises.~Frequency: Three times / week (Nishi et al., 2011).~C-Traditional medical treatment:~This treatment will be conducted for all group A, B and C."
223584856|NCT04030962|DRUG|Lifitegrast 5% Ophthalmic Solution|Ophthalmic solution administered as a topical eye drop
224168135|NCT04684589|DRUG|Tadalafil 20 MG|Tadalafil is an FDA approved, clinically-available drug that inhibits the enzyme phosphodiesterase type 5A (PDE5). Subjects who are randomized to this arm will be provided with 20mg of Tadalafil to take every day for 12 weeks, beginning at their baseline visit.
224168136|NCT04684589|DRUG|Placebo|Subjects in this arm will be provided with 20mg Placebo to take every day for 12 weeks, beginning at their baseline visit.
224168137|NCT05245071|DRUG|Tusamitamab ravtansine|Pharmaceutical Form: Concentrate for solution Route of Administration: Intravenous infusion
224168138|NCT05860036|BIOLOGICAL|anti-BCMA CAR-T|Autologous BCMA-directed CAR-T cells, infusion intravenously at a target dose of 2.0-4.0 x 10\^6 anti-BCMA CAR+T cells/kg.
224168139|NCT05860036|DRUG|VRd|Bortezomib, Lenalidomide and Dexamethasone
224168140|NCT00807443|DRUG|Raltegravir|Raltegravir (INN), 400 mg tablets, developed and supplied by Merck Sharp \& Dohme. A dose of 400 mg will be administered every 12 hours
224168141|NCT04617639|BEHAVIORAL|Physical exercise|Supervised home-based and community-based physical exercise with a dose required to increase cardiorespiratory fitness, i.e. intensity, duration and frequency that accumulates to at least 115 minutes a week of exercise, divided into at least 20 minutes a week of high/vigorous intensity physical activity (active minutes at about 85% of peak heart rate or Rated Perceived Exertion \[RPE\] of about 16 on Borg scale) and 95 minutes a week at moderate-intensity physical activity (active minutes at about 70% of peak heart rate or RPE of about 13 on Borg Scale), or continuous heart rate measurements amounting to at least 100 Personal Activity Intelligence (PAI) equivalents per week.
224168142|NCT04617639|BEHAVIORAL|Standard care|Standard care, i.e. advice at study start to follow international guidelines of moderate to vigorous physical activity intensity without further guidance and follow-up by study personnel.
224168143|NCT04617639|BEHAVIORAL|Observation group|Follow-up through mandatory national heath registries for primary endpoint, without any contact by study personnel
224168144|NCT05304611|BIOLOGICAL|L9LS (VRC-MALMAB0114-00-AB) Subcutaneous injection|Administered one time via subcutaneous route.
224168145|NCT05304611|BIOLOGICAL|L9LS (VRC-MALMAB0114-00-AB) intravenous injection|Administered one time via intravenous route.
224168146|NCT05304611|OTHER|Placebo|Normal saline administered one time via subcutaneous route.
224168147|NCT06435806|OTHER|Medical Illustration design|We will test 10 binary design variants for medical illustrations (for example, with and without cut-away, with and without text labels, etc). Specific variants to be identified during first task of project.
224168148|NCT01165463|BEHAVIORAL|SOPT basic training|10 hours of basic training
224168149|NCT01165463|BEHAVIORAL|Crossword Puzzles|Subjects train with puzzles 10 hrs in lab.
224168150|NCT01165463|BEHAVIORAL|SOPT booster training|4 hours of subsequent booster-training
224168151|NCT06144333|DIAGNOSTIC_TEST|RIPH2|"* Blood sampling by capillary~* Swab sampling~* Blood sampling by venous punction~* Salivary sample, sputum, expectoration:"
224168152|NCT02814747|OTHER|quantitive study: 500 patients likely to be candidates for HTS|
224168153|NCT02814747|OTHER|qualitative study: 30 patients who have benefited from HTS|
223584857|NCT06976255|BEHAVIORAL|Cinnamon sugar|In the 2nd and 3rd month of the study, the participants were asked to eat 1 g of cinnamon candies 3 times a day for a total of 4 days, three days before the menstrual cycle and the first day of menstruation.
223584858|NCT06976255|BEHAVIORAL|Dark chocolate|In the 2nd and 3rd month of the study, they were asked to eat 40 mg of 60% cocoa dark chocolate daily for a total of 4 days, three days before the menstrual cycle and the first day of menstruation.
223584859|NCT06574139|BEHAVIORAL|Unstained|Unstained is an individual-level, virtual intervention that involves three \~60-minute sessions delivered over a 3-6 week period. Each session includes watching two videos (six videos total), followed by a discussion facilitated by study coordinators.
223584860|NCT06574139|BEHAVIORAL|Like|Like is an hour-long film that discusses the impact of social media on the brain. Participants will receive a link to the film and will be asked to watch it independently. The film does not include information related to the outcomes of interest for the study.
224168154|NCT03239769|PROCEDURE|thyroidectomy|Thyroidectomies have different approaches. The aim of this study was to evaluate and compare the aesthetic effects of different access procedures in patients with differentiated thyroid carcinoma (DTC).
224168155|NCT02354690|DRUG|Vemurafenib|Vemurafenib is used to treat patients with BRAF mutated metastatic melanoma. Patients will start treatment in a dose of 960 BID 7 days before tumor harvest and ends at the day of admission (day -8).
224168156|NCT02354690|DRUG|Lymphodepleting chemotherapy|First patients undergo lymphodepleting chemotherapy regimen consisting of cyclophosphamide 60 mg/kg for 2 days and fludarabine 25 mg/m2 for 5 days (constitutes day -7 to -1 of admission).
224168157|NCT02354690|DRUG|TIL infusion|"7 days after start of vemurafenib treatment, patients undergo surgery to removal of a tumor in order to isolate, activate and expand tumor infiltrating lymphocytes (TIL) to high numbers. In vitro preparation usually takes 4-6 weeks using the young TIL method.~On day 0 patients receive an infusion of TIL (1x10e9-2x10e11 cells)."
224168158|NCT02354690|DRUG|Interleukin-2|After infusion of TILs, patients will receive interleukin-2 infusions according to the decrescendo regimen (18 MIU/m2 for 6 hours, 18 MIU/m2 for 12 hours, 18 MIU/m2 for 24 hours followed by 4,5 MIU/m2 for another 3 x 24 hours)
224168159|NCT00963820|DRUG|Ixazomib citrate|Ixazomib citrate capsules
224168160|NCT00557362|DRUG|Natamycin 5%|One drop of medication will be given every one hour while awake for one week. For another 2 weeks, one drop of medication should be given every 2 hours while awake
224168161|NCT00557362|DRUG|Voriconazole|"Voriconazole (VFEND® I.V., Pfizer, New York, NY) will be prepared as a 1% solution.~One drop of medication should be given every one hour while awake for one week. For another 2 weeks, one drop of medication should be given every 2 hours while awake"
224168162|NCT00557362|PROCEDURE|Corneal de-epithelialization|Corneal de-epithelialization at 1 week and 2 weeks from enrollment to increase epithelial penetration of antifungal medications.
224168163|NCT02836548|DRUG|Vorinostat|vorinostat 360 milligram once daily
223584861|NCT00306475|DRUG|Divalproex Sodium Extended-Release Tablets|divalproex sodium extended-release (ER) 1000 mg
223584862|NCT00306475|DRUG|placebo|placebo identical in appearance to active comparator
223584863|NCT06638710|DRUG|oral administration of midazolam or placebo|If the patient is opposed to a treatment (resistance to care ≥3 on the Pittsburgh scale), the nurse administers an oral dose of midazolam or placebo to the patient according to the random allocation.
223584864|NCT06426914|OTHER|Clinical Pilates|"Warmup: 5-10 minutes Pilates Clinical (Introductory program) The Hundred modified The Roll-up modified The roll-over modified Spine twist modified Single-leg circle modified Rolling like a ball Shoulder Bridge modified~For every Step emphasizing:~FOCUS: On muscle involved REPETITIONS: 3-5 VISUALIZATION: Imagination process (Different for each step) Cool down: 5 minutes Total Time: 30 minutes"
223584865|NCT06426914|OTHER|Cardiac Rehabilitation|"Chest Physical therapy (Chest percussions and active huffs as per need) Breathing strategies (Diaphragmatic and purse lip 1-3 sets \* 5 Reps/Day)~Functional mobility (walk /cycling as per patient tolerance)~Patient education and Wound care Sternal Precaution guidance"
224168164|NCT05273996|DRUG|Sertraline, bupropion, desvenlafaxine|Study geriatric psychiatrists prescribe FDA-approved antidepressants using a treatment algorithm consistent with the STAGED (Duke Somatic Treatment Algorithm for Geriatric Depression) approach, with standardization of treatment in the first six months beginning with sertraline, with the option of augmentation with bupropion or switch to desvenlafaxine. Beyond six months of acute treatment, subjects are treated based on the study psychiatrist's clinical assessment and recommendations, consistent with STAGED guidelines.
224168165|NCT03593005|OTHER|Assessment at Low Altitude (470m above sea level)|Assessment at Low Altitude (in Zurich; 470m above sea level) in order to compare this data with High altitude exposure
224168166|NCT03593005|OTHER|Exposure to High Altitude (2500m above sea level)|Exposure to High Altitude (Säntis; 2500m above sea level) for approximately 5 hours
223480728|NCT05853120|DRUG|Doxycycline|Doxycycline is used to treat or prevent infections that are strongly suspected to be caused by bacteria; it is an antimicrobial drug indicated for bacterial infections such as sexually transmitted infections. Doxycycline (DOX) will be given orally at 100 and 200 mg doses.
223480729|NCT05834179|OTHER|cold endotracheal tube|patients who were intubated with an ETT which kept in the fridge.
224168167|NCT06198829|OTHER|Physical examination tests and surveys|Patients'hip joint range of motion range of motion, pain levels, pressure-pain threshold levels, kinesiophobia levels, and hip dysfunction levels will be measured, and the alpha angle will be evaluated on hip radiographs.
223480730|NCT04159142|DRUG|Nab-paclitaxel + Carboplatin|nab-paclitaxel given IV at 125 mg/m\^2 on days 1, 8 and carboplatin given IV at AUC 5 on days 1 every 21 days x 6 cycles；
223480731|NCT04159142|DRUG|Nab-paclitaxel + Capecitabine|Nab-paclitaxel given IV at 125 mg/m\^2 on days 1, 8 and capecitabine given IV at 1000 mg/m\^2 bid, d1-14 every 21 days x 6 cycles；
223480732|NCT06401603|DRUG|Decitabine|Given by IV
223480733|NCT06401603|DRUG|Listaftoclax|Given by PO
223480734|NCT06401603|DRUG|Olverembatinib|Given by PO
223480735|NCT05555732|DRUG|Datopotamab Deruxtecan|Dato-DXd will be administered as an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle.
223480736|NCT05555732|DRUG|Pembrolizumab|Pembrolizumab will be administered as an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle.
223480737|NCT05555732|DRUG|Pemetrexed|Pemetrexed will be administered as an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle.
223480738|NCT05555732|DRUG|Carboplatin|Carboplatin will be administered an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle for up to 4 cycles.
223480739|NCT05555732|DRUG|Cisplatin|Cisplatin will be administered an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle for up to 4 cycles.
223480740|NCT02484248|DRUG|Ketotifen|Ketotifen is an anti-histamine approved by the U.S. FDA to prevent and treat itching of the eyes caused by allergies.
223480741|NCT02484248|DRUG|Placebo|The placebo tablet looks identical to the ketotifen tablet, but does not contain ketotifen.
223584866|NCT02159755|DRUG|Ibrutinib|Given PO
223584867|NCT02159755|OTHER|Laboratory Biomarker Analysis|Correlative studies
223584868|NCT02159755|DRUG|Palbociclib|Given PO
224305380|NCT05788289|DRUG|Tafasitamab|Participants will receive treatment with intravenous tafasitamab and oral lenalidomide for up to 12 cycles. Each cycle is 28 days in length.
224305381|NCT05788289|DRUG|Lenalidomide|Lenalidomide will be self-administered by patients orally on days 1-21 of each 28-day cycle of induction (cycles 1 through 12).
223480742|NCT04228289|DRUG|Oxytocin|40 IU intranasal spray
223480743|NCT04228289|OTHER|Placebo|matching intranasal spray
223480744|NCT05612594|DRUG|Bexagliflozin 20 mg|15mg once daily
223480745|NCT05612594|DRUG|Placebo|matching placebo once daily
223480746|NCT06525935|DRUG|Placebo|Placebo will be volume- matched and administered subcutaneously (SC) once weekly.
223480747|NCT06525935|DRUG|CT-388|CT-388 will be administered subcutaneously (SC) once weekly at the randomized dosing regimen.
223480748|NCT02580812|OTHER|Clinical and neuropsychological evaluation procedure|WPPSI, NEPSY, Brief, SDQ, Vineland and SCQ evaluation Clinical examination
223480749|NCT06209242|PROCEDURE|Percutaneous pinning|Using k- wire percutaneous pinning with local anesthesia with one-day surgery protocol
223480750|NCT06209242|PROCEDURE|Cast immobilization|Using sugar tong slab and then replace to short arm casting within 1 week
223584869|NCT02159755|OTHER|Pharmacological Study|Correlative studies
223584870|NCT05879276|DRUG|Empagliflozin 10 MG|Patients in cardiogenic shock receiving empagliflozin in addition to standard management at a dose of 10 mg per day per os (or through nasogastric tube in intubated patients) for a duration of 12 weeks.
223584871|NCT06644222|BEHAVIORAL|AIRROSTI exercises|Group A will receive AIRROSTI exercises for 45 minutes / one session daily for five days per week
223584872|NCT06644222|BEHAVIORAL|Thera band exercises|Group B will receive Thera band exercises for 45 minutes/one session per day for five days per week.
223584873|NCT06433180|DRUG|Administration of fecal microbiota transplantation ( FMT capsules)|Oral, capsulized, frozen fecal microbiota transplantation FMT delivering approximatively 24 g of stools taken in one day in two separate meals. Administration of the FMT after colon cleaning.
223584874|NCT06433180|DRUG|Administration of the sham (PLACEBO)|Oral, capsulized, frozen capsules without fecal matter but containing cryopreservation solution will be administered at the same volume and same time point as in the experimental group. Taken in one day in two separate meals. Administration of the sham after colon cleaning.
223584875|NCT06971757|OTHER|Routine Follow-Up (RFU)|Standard follow-up care with scheduled X-ray and clinical visit at 3 months and 1 year after surgery.
224305382|NCT05301413|BEHAVIORAL|Culturally Tailored Diabetes Prevention Program|This intervention includes a culturally tailored DPP curriculum, class procedures, and handouts
223480751|NCT06961877|BEHAVIORAL|Cannabis Conversation Skills for Families (CCSF)|The purpose of the intervention is to train family members in communication skills that may increase contemplation of change in their loved one with first episode psychosis to reduce cannabis use, decrease conflict surrounding these discussions, and provide skills to understand when and how to approach their loved one about cannabis use and encourage treatment. Because families report confusion from the mixed messages they receive about cannabis and also desire research-based information, CCSF will involve psychoeducation on the risks and relationship of cannabis to psychosis to increase participants motivation to engage in the intervention. frequency of cannabis use as it relates to psychosis treatment outcomes.
223480752|NCT03454620|DRUG|irinotecan|GC1118 combination with irinotecan
223480753|NCT03454620|DRUG|FOLFIRI|GC1118 combination with FOLFIRI
223744923|NCT01682902|DRUG|insulin aspart|Administration: Subcutaneous infusion. The subjects will remain on their own pump during the trial. Subjects will have blinded continuous glucose monitoring (CGM) throughout the trial (3 treatment periods of 14 days) and meal tests consisting of a standardised breakfast (liquid meal) will be performed on the 14th day of each treatment period.
224072089|NCT05559827|DRUG|Isatuximab|Isatuximab treatment at a dose of 10 mg/kg by intravenous route. The first injection of isatuximab will be performed at randomization (month 6 +/- 2 days). A second injection may be performed at day 15 if the reticulocytes \<10 G / L, and a third at day 29 if reticulocytes \<10 G / L. Patients will be assessed on day 1, day 15, day 29, day 45, 2 months, 3 months, 6 months and 9 months after randomization.
224072090|NCT02895061|DRUG|Alfacalcidol|Alfacalcidol 1 microgram/capsule
224072091|NCT02575287|DEVICE|Optical Enhancement|A endoscopic visualization of the mucosa using the pre-processor filter called Optical enhancement (Pentax Video Processor EPK-i7010; HOYA Co. Tokyo, Japan)
223480759|NCT04855136|BIOLOGICAL|BB2121|CAR T Cell Therapy
223480760|NCT04855136|DRUG|CC-220|Cereblon (CRBN) E3 ligase modulatory compound (CELMoD)
223480761|NCT04855136|DRUG|BMS-986405|gamma secretase inhibitor (GSI)
223480762|NCT00621101|DRUG|1 tablet Ezetrol(R) (ezetimibe), MSD Sharp & Dohme GmbH, Germany|administration of 1 tablet Ezetrol(R) (10 mg ezetimibe), 0-144 h blood sampling, 0-5 d urine sampling (24 h intervals) and 0-10 d feces sampling
223480763|NCT00621101|DRUG|1 tablet Rapamune(R) (sirolimus), Wyeth Pharma, Germany|administration of 5 ml Rapamune(R) oral solution (1 mg/ml sirolimus), 0-144 h blood sampling
223480764|NCT00621101|DRUG|1 tablet Ezetrol(R) + 1 tablet Rapamune(R)|administration of 1 tablet Ezetrol(R) (10 mg ezetimibe) and 5 ml Rapamune(R) oral solution (1 mg/ml sirolimus), 0-144 h blood sampling, 0-5 d urine sampling (24 h intervals) and 0-10 d feces sampling
223480765|NCT01850316|RADIATION|Stereotactic Ablative Radiotherapy|Preferred target coverage of 40 Gy: coverage and total dose determined by irradiated liver volume NTCP (normal tissue complication probability) nomogram and OAR dose limits
223480766|NCT04290104|DRUG|1gr oral ampicillin/sulbactam group|Group prescribed 1 g oral ampicillin/sulbactam 2 times a day.
223480767|NCT00490308|DRUG|Treatment with estradiol valerate|
223480768|NCT05871801|DRUG|Bowel preparation for colonoscopy|one day liquid diet will be administered to every patient included in the study and: split-dose bowel preparation with 4 Liters of Polyethylenglycol (PEG) solution, 2 Liters of PEG-Asccorbic acid or 2L sodium picosulphate.
223480769|NCT05871801|DEVICE|Colonoscopic examination|Colonoscopy will be performed to every patient included in the study
223480770|NCT05910398|DRUG|pyrotinib|an irreversible anti-HER2 tyrosine kinase inhibitor
223480771|NCT05791643|BEHAVIORAL|Personalized internal and external coping strategies|A series of interactive, automated messages will recommend use of the internal coping strategies and external coping strategies (i.e., sources of social support/distraction) from the participant's personalized safety plan.
223480772|NCT05791643|BEHAVIORAL|Personalized internal coping strategies|A series of interactive, automated messages will recommend use of the internal coping strategies from the participant's personalized safety plan.
223480773|NCT05791643|BEHAVIORAL|Personalized external coping strategies|A series of interactive, automated messages will recommend use of the external coping strategies (i.e., sources of social support/distraction) from the participant's personalized safety plan.
223480774|NCT05791643|BEHAVIORAL|General internal and external coping strategies|A series of interactive, automated messages will recommend use of general (non-personalized) common internal and external coping strategies for suicidal thoughts.
223480775|NCT05791643|BEHAVIORAL|General internal coping strategies|A series of interactive, automated messages will recommend use of general (non-personalized) common internal coping strategies for suicidal thoughts.
223480776|NCT05791643|BEHAVIORAL|General external coping strategies|A series of interactive, automated messages will recommend use of general (non-personalized) external coping strategies (i.e., sources of social support/distraction) for suicidal thoughts.
223584876|NCT06971757|OTHER|Check-Up on Demand (COD)|Follow-up care with scheduled X-ray and clinical visit at 3 months and only at 1 year if requested.
223480777|NCT05791643|BEHAVIORAL|General internal coping strategies, relaxation|A series of interactive, automated messages will recommend use of general (non-personalized) common internal (and specifically, relaxation-based) coping strategies for suicidal thoughts.
223480778|NCT05791643|BEHAVIORAL|General internal coping strategies, distraction|A series of interactive, automated messages will recommend use of general (non-personalized) common internal (and specifically, distraction-based) coping strategies for suicidal thoughts.
223480779|NCT05791643|BEHAVIORAL|General internal coping strategies, physical activity|A series of interactive, automated messages will recommend use of general (non-personalized) common internal (and specifically, physical activity-based) coping strategies for suicidal thoughts.
223480780|NCT03331380|DEVICE|MRI scan - obj 1|For objective 1 (protocol optimization), healthy volunteers undergo imaging using an investigational low SAR CMR scanner for up to two hours, some without and some with administration of intravenous gadolinium based contrast agents (GBCAs).
223584877|NCT05601102|BEHAVIORAL|danceSing Care|\- Physical activity interventions, including multi-component (chair-based) exercises or dancing, and music therapies have been shown to improve multidimensional health markers in older adults.
223584878|NCT04648202|DRUG|FS120|Dosing of participants with FS120 or the combination pembrolizumab will occur intravenously (IV), at a fixed dose in treatment cycles once every 4 weeks (Q4W) or once every 3 weeks (Q3W) until confirmed progressive disease (CPD)/immune-confirmed progressive disease (iCPD) or unacceptable toxicity.
224168168|NCT06190717|DEVICE|EchoMark/EchoSure|Subjects assigned to the Diagnostic Arm will have the EchoMark implanted at the time of AVF creation. The subject will return every 2 weeks for a follow-up assessment to include an EchoSure scan until fistula maturation and/or permanent access use is achieved. The EchoSure scans are to be reviewed by the investigator(s) or delegated study staff and aid in the determination when a further assessment, including a physical exam, is required to determine cannulation clearance or if an intervention(s) may be required to prevent failure of fistula maturation. All physical exams will include assessing the fistula for bruit and thrill. The subject's medical history will be reviewed at each visit and will include all interventions, cannulation attempts, and adverse event reporting.
224168169|NCT06190717|PROCEDURE|Standard of Care|Subjects are assessed using standard of care per KDOQI guidelines, which includes a physical exam at the 2-week follow-up visit and at the 4-6-week follow-up visit. All follow-up visits will include an assessment of adverse events and medical history review to include all interventions, cannulation attempts, and laboratory results. If evaluation yields an abnormal finding, subjects will undergo a Duplex ultrasound assessment and treatment under the institution's standard of care. All SOC Arm subjects will be followed per the institution's standard of care until fistula maturation occurs and/or permanent access use is achieved but no more frequently than once per month.
224168170|NCT04774419|RADIATION|Intensity modulated radiation therapy (IMRT)|To the pelvic nodes and vaginal cuff (total dose of 45-50.4Gy at 1.8 Gy per fraction) for 5-6 weeks.
223480781|NCT03331380|DEVICE|MRI scans - obj 2|For objective 2 (comparative scanning of normals), healthy volunteers undergo two CMR examinations on two different MRI scanners (investigational low SAR CMR and conventional 1.5T CMR), some without and some with administration of intravenous GBCA.
223480782|NCT03331380|DEVICE|MRI scans - obj 3|For objective 3 (comparative scanning of patients), subjects with known stable cardiovascular disease undergo two CMR examinations on two different MRI scanners (investigational low SAR CMR and conventional 1.5T CMR), some without and some with administration of intravenous GBCA.
223480783|NCT03331380|DEVICE|MRI scans - obj 4|For objective 4 (comparative scanning of patients), subjects with known or suspected disease, including neurological, musculoskeletal disease, abdominal or lung disease, will undergo two MR examinations on two different MRI scanners (investigational low SAR CMR and conventional MR).
223480784|NCT04512105|DRUG|Pitavastatin|Given PO
223480785|NCT04512105|DRUG|Venetoclax|Given PO
223480786|NCT05642208|DRUG|Dupilumab step-down|step down dupilumab injections
223480787|NCT02679846|OTHER|Standardized protocol|The standardized protocol of AEDs withdrawal will be implemented and applied to all inpatients
223480788|NCT02610010|DRUG|Cisplatin|Cisplatin 100 mg/m² every 3 weeks for 3 cycles during radiotherapy.
223480789|NCT02610010|RADIATION|Intensity-modulated radiotherapy|Intensity-modulated radiotherapy
223480790|NCT05563324|GENETIC|DNA extraction and genotyping of candidate genetic polymorphisms|
223480791|NCT05563324|OTHER|self-assessment questionnaires|
223480792|NCT06546332|DEVICE|KeriFuse®|The intramedullary arthrodesis Implant (KeriFuse®) is indicated for consolidation or bone fusion (arthrodesis) of degraded or arthritic distal interphalangeal (DIP) of hand digits or interphalangeal (IP) joint of the hand thumb.
223480793|NCT06486844|DRUG|Vericiguat (Verquvo, BAY1021189)|Vericiguat was given following routine clinical practice.
223480794|NCT05691543|PROCEDURE|sacrospinous fixation Using Posterior Vaginal wall flap|"* Identification of the sacro spinous ligament.~* Insertion of the sacrospinous stitch. Using a long - handled needle holder, a J - shaped Ethibond suture is placed 2 - 3 cm medial to the right ischial spine. Using posterior vaginal wall flap (rectangular flap )will be incised and retracted Superior to the right , the stitch of sacro spinous ligament will be attached to the flap not the vault after adjusting its size , then the sit . The stitch should be placed through and not around the ligament. The application of firm traction to the suture length will test the correctness of its placement. A second suture is inserted for additional support. We may do it directly or by using an alternative surgical instruments for placement of the suture include the knee scorpion. Per rectum examination should be undertaken to check for misplaced sutures.~* Attachment of the sutures to the vaginal flap . The two sutures are then secured to the upper posterior aspect of the vaginal flap ,"
223480795|NCT05667441|COMBINATION_PRODUCT|Standard lifestyle recommendations + dietary supplementation|refrain from smoking; perform physical exercise regularly; increase the intake of dietary food groups such as green leafy vegetables, fruits, and fatty fish and recommendations for supplementation with antioxidants according an established formula
223480796|NCT05667441|COMBINATION_PRODUCT|Risk profiling|Personalized risk profiling for lifestyle and genetics.
223480797|NCT05667441|BEHAVIORAL|Coaching|Coaching
223480798|NCT06552260|DRUG|Troriluzole|Tripeptide prodrug of Riluzole, 100 mg capsule, taken orally per protocol.
223480799|NCT02803489|DEVICE|medical device intervention|
223480800|NCT02855268|DRUG|lademirsen (SAR339375)|Pharmaceutical form: Solution for injection Route of administration: Subcutaneous injection
223584879|NCT05765175|DEVICE|Varian Cardiac Radioablation (CRA)|Subjects randomized to CRA will be treated with the Varian CRA system according to a uniform CRA protocol. A dose of 25 Gy in a single fraction is prescribed to the planning target volume (PTV), and delivered using a stereotactic body radiotherapy (SBRT) technique.
223584880|NCT05765175|PROCEDURE|Catheter Ablation (CA)|Subjects randomized to the CA arm will be treated according to a uniform CA protocol.
223584881|NCT05759793|DRUG|CAR-GPRC5D|CAR-GPRC5D (RD118) is an individualized, gene-modified autologous T-cell immunotherapy product targeting GPRC5D that identifies and eliminates malignant and normal cells expressing GPRC5D. The CAR structure comprises a fully human single-domain antibody fragment (VHH) targeting GPRC5D, fused with intracellular co-stimulatory (4-1BB) and activation (CD3ζ) signaling domains.
223584882|NCT06321055|DRUG|Regorafenib (Stivarga, BAY73-4506)|Retrospective analysis.
223584883|NCT03460210|DRUG|Atomoxetine|Patients are tested for their normal prescription atomoxetine medication
223584884|NCT06653010|BIOLOGICAL|Universal CAR-T cells injection for treating mCRC|A novel universal CAR-T platform to treat cancer patients
223584885|NCT02144545|PROCEDURE|Bougie Size 33 Fr|Comparison of the bougie size and distance from the pylorus for the sleeve gastrectomy
223480801|NCT02855268|DRUG|Placebo|Pharmaceutical form: Solution for injection Route of administration: Subcutaneous injection
223480802|NCT02607813|DRUG|LXH254|pan-RAF inhibitor
223584886|NCT02144545|PROCEDURE|Bougie Size 42 Fr|Comparison of the bougie size and distance from the pylorus for the sleeve gastrectomy
224168171|NCT04774419|DRUG|Dostarlimab|IV Dostarlimab every 3 weeks for 4 cycles followed by 1 dose of 1000mg (C5). Patients will receive a maximum of 5 cycles of Dostarlimab.
224168172|NCT04774419|RADIATION|Hypofractionated IMRT|Treatment will consist of short-course, hypofractionated IMRT to deliver 25 Gy to the vaginal cuff and pelvic lymph nodes in 5 daily fractions over one week.
223480803|NCT02607813|DRUG|PDR001|Biological: PDR001 anti-PD1 antibody
223480804|NCT00435617|DEVICE|Hand Mentor|Use of the Hand Mentor therapy device at home for 6 weeks. Therapy programs include spasticity reduction, motor control, and emg biofeedback for encouraging activity.
223480805|NCT04634188|DIAGNOSTIC_TEST|Procalcitonin|Samples were categorized based on demographic data (age and gender), then the samples were categorized based on the type of brain tumor suffered. Once categorized, the levels of inflammatory markers was examined. Specimens were taken from the patient's peripheral blood examination and analyzed in laboratorium. The results of these examinations are grouped on a nominal scale, and analyzed statistically
223480806|NCT03504618|DRUG|FOLFOXIRI|"Treatment of FOLFOXIRI regimen at first line with dosage:~Irinotecan: 165 mg / m2, intravenous infusion for 1 hour. Day 1, 15. Oxaliplatin: 85 mg / m2, intravenously for 2 hours Day 1, 15 Calcium folinate 200 mg / m2, intravenously for 2 hours Day 1, 15 5FU 3200 mg / m 2, intravenous infusion continuously for 48 hours Day 1, 2, 3, 15, 16, 17 Every 4 weeks. Each cycle has 2 infusion times, the first one is the first day, the second one is the 15th day"
223480807|NCT03028311|PROCEDURE|Angiography|Undergo angiography
223480808|NCT03028311|PROCEDURE|Computed Tomography|Undergo SPECT-CT
223584887|NCT02144545|PROCEDURE|Distance pylorus 2 cm|Comparison of the bougie size and distance from the pylorus for the sleeve gastrectomy
223584888|NCT02144545|PROCEDURE|Distance pylorus 5 cm|Comparison of the bougie size and distance from the pylorus for the sleeve gastrectomy
223584889|NCT02106611|OTHER|Clinical Assessment|HL treatment will be determined by review of available medical records as archived at MSKCC. Recorded variables will include: (1) RT - field, fractional and cumulative dose, and duration; (2) chemotherapy - regimen, planned interval, dose per cycle, and cumulative dosages. Patients will also be asked to complete the FACT-LYM questionnaire and the FACIT Fatigue questionnaire.
223584890|NCT02106611|PROCEDURE|Stress cardiac MRI|Both imaging tests will be performed within a 30 day interval, with the two modalities interpreted by dedicated study investigators blinded to the results of the other modality.
223584891|NCT02106611|PROCEDURE|Stress echocardiogram|Both imaging tests will be performed within a 30 day interval, with the two modalities interpreted by dedicated study investigators blinded to the results of the other modality.
223744924|NCT01973907|OTHER|Fluid Sparing Resuscitation Strategy|"Tier 1: Initiate IV/IO vasoactive medication infusion support immediately. Further IV/IO isotonic fluid bolus therapy \[crystalloid (0.9% Normal Saline or Ringers Lactate) or colloid (5% Albumin)\] should be avoided; small volume isotonic fluid boluses \[5-10 mL/kg (250-500 mL for participants ≥ 50 kg)\] may be provided if required due to A. Clinically unacceptable delay in ability to initiate vasoactive medication infusion(s) and/or 2. Documented intravascular hypovolemia.~Tier 2: Vasoactive medication(s) should be preferentially titrated/escalated to achieve recommended ACCM hemodynamic goals. Further IV/IO isotonic fluid bolus therapy \[crystalloid (0.9% Normal Saline or Ringers Lactate) or colloid (5% Albumin)\] should be avoided; small volume isotonic fluid boluses \[5-10 mL/kg (250-500 mL for participants ≥ 50 kg)\] may be provided if required due to A. Documented intravascular hypovolemia.~Intervention end: Patient is free from vasoactive medication support and shock is reversed."
224168173|NCT03554174|DRUG|Low Dose Psilocybin|0.1 mg/kg psilocybin capsule
224168174|NCT03554174|DRUG|Placebo|microcrystalline cellulose capsule
224168175|NCT03554174|DRUG|Medium Dose Psilocybin|0.3 mg/kg psilocybin capsule
224168176|NCT06570603|BEHAVIORAL|Self-Efficacy|Brief skills based psychotherapy session to increase perceived self-efficacy for withstanding distress, giving participants increased beliefs that they \*can\* do it.
224168177|NCT06570603|BEHAVIORAL|Willingness|Brief skills based psychotherapy session to increase perceived willingness to engage with distress for withstanding distress, giving participants increased motivation to try.
223480809|NCT03028311|PROCEDURE|Planar Imaging|Undergo planar imaging
223480810|NCT03028311|RADIATION|Radioembolization|Undergo radioembolization
223480811|NCT03028311|PROCEDURE|Single Photon Emission Computed Tomography|Undergo SPECT-CT
223480812|NCT03028311|RADIATION|Technetium Tc-99m Albumin Aggregated|Given via arterial catheter
223480813|NCT03028311|OTHER|Yttrium Y 90 Resin Microspheres|Given via arterial catheter
223584892|NCT06851130|DIETARY_SUPPLEMENT|ferrous sulfate 80 mg|1 tablet per day
223584893|NCT06851130|DIETARY_SUPPLEMENT|ferrous sulfate 160 mg|2 tablets per day
223584894|NCT05288166|DRUG|Abemaciclib|Administered orally.
223584895|NCT05288166|DRUG|Abiraterone|Administered orally.
223584896|NCT05288166|DRUG|Prednisone or Prednisolone|Administered orally.
223584897|NCT05288166|DRUG|Placebo for Abemaciclib|Administered orally.
223584898|NCT06980831|PROCEDURE|ECT group|VR-ECT group, nursing students will practice via virtual reality for taking care of patients with ECT.
223584899|NCT06979765|BIOLOGICAL|blood sampling|3 blood tubes will be taken during a standard check-up
223584900|NCT06979765|OTHER|self-administrated questionaires|4 self administrated questionaires and scales at the inclusion
223584901|NCT06980974|BEHAVIORAL|ACT-for-chemsex|16 weeks of acceptance and commitment therapy, delivered online weekly, 45-55 minute sessions
223584902|NCT06980974|OTHER|Treatment as Usual (TAU)|Participants in TAU will receive health/mental health interventions as needed
223744925|NCT03597958|GENETIC|Next generation sequencing (NGS)|NGS panel, whole exome / genome sequencing (WES/WGS), transcriptome analysis
224168178|NCT06570603|BEHAVIORAL|Psychoeducation|Psychoeducation about the components and functions of emotion.
224168179|NCT04432324|BIOLOGICAL|Intravenous Immune Globulin|IVIG Intravenous infusion
224168180|NCT04432324|DRUG|Standard Medical Treatment|SMT
224168181|NCT00236574|DRUG|Galantamine hydrobromide|
224168182|NCT05297552|DRUG|RC48-ADC|Drug: RC48-ADC 2.0 mg/kg by intravenous (IV) infusion, given on Day 1 of each 14-day cycle
224168183|NCT05297552|DRUG|JS001|Drug: JS001 3.0 mg/kg by intravenous (IV) infusion, given on Day 1 of each 14-day cycle
224168184|NCT04209634|DRUG|Pozelimab|Single loading intravenous (IV) dose on day 1, then fixed doses sub-cutaneous (SC) (based on body weight) QW (±2 days) over the treatment period.
224168185|NCT06975293|COMBINATION_PRODUCT|STC-15 in combination with toripalimab|STC-15 in combination with toripalimab in 21-day cycles
224168186|NCT00586833|PROCEDURE|O2 consumption max bike test|Single visit exercise study
224168187|NCT01478178|DRUG|VAL-083 (Dianhydrogalactitol)|VAL-083 given by intravenous infusion with a starting dose of 1.5 mg/m2 IV. Escalating doses to be administered in sequential dose cohorts.
224168188|NCT04462978|OTHER|Non IgE-mediated food allergy|
224168189|NCT02192619|OTHER|observational|
224168190|NCT02972281|BIOLOGICAL|Immunological diagnosis tests|(Non exhaustive list): hemogram, IgG, A, M, IgG subclasses, complement, vaccinal response to protein and polysaccharide antigens, ...
224168191|NCT03438760|BEHAVIORAL|Science + Phonological Awareness|The goal is to facilitate phonological awareness during science lessons. Because phonological awareness does not relate to science learning, this is a placebo.
224168192|NCT03438760|BEHAVIORAL|Science + Grammar Intervention|The goal is to facilitate science learning by providing models, prompts, and experiences with grammatical structures related to science processes.
224168193|NCT03438760|BEHAVIORAL|Science + Vocabulary Intervention|The goal is to facilitate science learning by providing models, prompts, and experiences with vocabulary related to science processes.
224168194|NCT05103995|OTHER|no intervention|no intervention, just observation
224168195|NCT01938560|OTHER|Survey Responses|Subject understanding of the risk of urinary retention and the symptoms of acute urinary retention associated with retigabine will be assessed using the survey instrument.
224168196|NCT01863901|DEVICE|Treatment with Cryo-Touch III device|
224168197|NCT01821885|BEHAVIORAL|Spirometry and a brief advice to quit smoking|During a year, recruitment for active smoker patients was done by doctors in primary care medical offices. In the intervention group, after been randomized, one trained nurse completed the questionnaires and did the spirometry with bronchodilator test and set a date with its family doctor who did a minimal smoking cessation counselling intervention and informed the patients about the spirometry results according to established protocol.
223480814|NCT06115174|DRUG|Pentoxifylline|"Pentoxifylline (PTX) is a methylxanthine derivative that is commercially available in the name of Trental. It is currently used for management of peripheral vascular diseases. Its postulated mechanism of action is thought to be mediated through reducing blood viscosity and enhancing RBCs flexibility. However, it has been shown that PTX also may potentially be used in the anticancer therapy \[15\].~The studies demonstrated the potential effects of pentoxifylline on angiogenesis inhibition. It can affect the release and function of some predominantly proangiogenic vascular endothelial growth factors. Specifically, the release of the VEGF family of pro-angiogenesis factors (notably VEGF-A and VEGF-C) \[16\]. Furthermore, the mechanism by which pentoxifylline inhibits angiogenesis may be through the inhibition of activation of STAT3 which contributes to tumor cell survival by regulating the expression of metastatic genes, MMPs, serine protease uPA and potent angiogenic genes \[17\]."
223480815|NCT06115174|RADIATION|FOLFOX|(leucovorin, fluorouracil, oxaliplatin)
223480816|NCT06115174|RADIATION|XELOX|(oxaliplatin + capecitabine)
223480817|NCT06115174|DRUG|Monoclonal antibodies (target therapy)|target therapy (Bevacizumab).
223480818|NCT00465517|DRUG|Ganaxolone|Oral suspension 200-500 mg 3x/day
223480819|NCT00465517|OTHER|Placebo|non-active placebo
223480820|NCT04737733|OTHER|The dementia friendly program|Implementation of a systematic screening and risk modification and management plan, to identify and enhance the management of patients with cognitive impairment and risk of delirium.
224168198|NCT01821885|BEHAVIORAL|Brief advice to quit smoking|During a year, recruitment for active smokers patients occurred through doctors in primary care medical offices. After be randomized, in de control group, a nurse complete the questionnaires. Below, patients go to the family doctor who will do a minimal smoking cessation counselling intervention.
224168199|NCT04783376|DRUG|: Insulin, lispro and regular insulin|"* A: the participant will have a mealtime bolus dose of fast-acting insulin 10 minutes before the meal representing 100% of the dose calculated according to the carbohydrate content of the meal and the individual insulin to carbohydrate ratio~* B: the bolus insulin dose for the meal will be calculated according to the carbohydrate content of the meal and the individual insulin to carbohydrate ratio and additional 30% of the calculated dose will added to cover the fat and protein content of the meal. This total dose will be divided into 2 portions. A premeal portion (60%) will be given 10 minutes before the meal and (40%) will be given 30 minutes after the premeal dose. Both doses will be given as fast-acting insulin.~* C: the same as intervention B but the 40% of the total dose will be given as regular insulin."
224168200|NCT04099836|DRUG|Atezolizumab|1200 mg IV every 3 weeks
224168201|NCT04099836|DRUG|Bevacizumab|15 mg/kg IV every 3 weeks
224168202|NCT02455440|DRUG|Esmolol|effect of esmolol on intraoperative fluctuations of propofol and sevoflurane. Propofol and sevoflurane intraoperative concentration will be expressed as mean ± SD. Differences in categorical data will be evaluated using the student t test.
224168203|NCT02455440|DRUG|Placebo|
224168204|NCT02455440|DRUG|Propofol and sevoflurane|
224168205|NCT00930501|BIOLOGICAL|blood tests|time 0 is pretreatment time 3, 6 , 9, 12 months from the end of chemotherapy
224168206|NCT03281356|BEHAVIORAL|Intervention Group|Participants will receive a total of 8 text messages during a 4 week period.
224168207|NCT02330640|DRUG|ticagrelor|After the operation, the subjects will be randomized into two groups according to the proportion of 1:1; and receive the treatment of aspirin 100mg qd+ticagrelor 90mg bid or the treatment of aspirin 100mg qd+ clopidogrel 75mg qd. The study will plan to enroll 140 subjects in 12 months and the treatment will last for 30 days.
224168208|NCT02330640|DRUG|clopidogrel|After the operation, the subjects will be randomized into two groups according to the proportion of 1:1; and receive the treatment of aspirin 100mg qd+ticagrelor 90mg bid or the treatment of aspirin 100mg qd+ clopidogrel 75mg qd. The study will plan to enroll 140 subjects in 12 months and the treatment will last for 30 days.
224168209|NCT02330640|DRUG|asprin|All patients will be given asprin 100mg Qd within 24hours after operation,and will continue taking aspirin at the end of the study
224168210|NCT01829672|RADIATION|Dual-energy computed tomography investigation|"1x 20ml Ultravist (370mg J/ml)3-5ml/s, i.v.~1x 40ml Ultravist (370mg J/ml)3-5ml/s i.v. Contrast agent administration"
224168211|NCT05789914|PROCEDURE|Flap surgery+bone graft+guided tissue regeneration|after flap elevation and debridement, intrabony defect was filled with Bio-Oss and covered with membrane.
224168212|NCT00883792|PROCEDURE|Colonoscopy|Once-only colonoscopy screening
224168213|NCT01637844|DRUG|Telbivudine|HBsAg- and HBeAg-positive pregnant women at 28-32 weeks of gestation are given with telbivudine (oral 600 mg/day) until 4 weeks after delivery. Newborn infants are administered 100-200 IU HBIG within 12 hours after birth and vaccinated against hepatitis B with yeast recombinant hepatitis B vaccine (10 µg) at 0, 1, and 6-month schedule. HBV DNA and ALT levels are measured before the use of telbivudine, at delivery, and 1-2 months after stopping the drug. HBV serological markers, including HBsAg, anti-HBs, and anti-HBc, HBeAg and anti-HBe are tested in infants at age of 7-12 months.
224168214|NCT03219554|DRUG|Palbociclib|oral palbociclib 125mg daily for 21days followed by a 7-day break. Cycle will be repeated every 28 days.
223480821|NCT03735823|OTHER|No intervention, just collect blood samples and CSF samples|No intervention
223480822|NCT01657396|PROCEDURE|Standard Oral Hygiene|Current local standard of care - minimum q2h mouthcare with a green Toothette swab dipped in sterile water, with excess liquid aspirated using a Yankauer suction. Brushing of teeth (if applicable) with a toothbrush and standard toothpaste q12h. Replacement of Yankauer suction device daily.
223480823|NCT01657396|PROCEDURE|SAGE Q-care q2|Oral hygiene provided with a commercial pre-packaged product (SAGE Q-care q2 Oral Cleansing and Suctioning System) - minimum q2h mouthcare using the supplied applicator swabs and covered Yankauer suction device using supplied Perox-A-Mint (a hydrogen peroxide based oral hygiene solution) alternating with alcohol-free mouthwash. Brushing of teeth (if applicable) with supplied applicator using Antiplaque solution (a cetylpyridinium based solution) q12h. Use of a new kit (which includes new covered Yankauer suction device) daily.
223480824|NCT01657396|PROCEDURE|SAGE Q-care q2 with Chlorhexidine|Oral hygiene provided with a commercial pre-packaged product with chlorhexidine (SAGE Q-care Rx q2 Oral Cleansing and Suctioning System with CHG) - minimum q2h mouthcare using the supplied applicator swabs and covered Yankauer suction device using supplied Perox-A-Mint (a hydrogen peroxide based oral hygiene solution) alternating with alcohol-free mouthwash. Brushing of teeth (if applicable) with supplied applicator using chlorhexidine oral rinse (solution containing 0.12% chlorhexidine) q12h. Use of a new kit (which includes new covered Yankauer suction device) daily.
223480825|NCT02309021|OTHER|Sport|
223480826|NCT02309021|OTHER|Non-sport activities|
223480827|NCT06277674|DRUG|Cadonilimab plus Pemetrexed and Anlotinib|Cadonilimab was administered intravenously at a dose of 10 mg/kg every 3 weeks. Pemetrexed was administered intravenously at a dose of 500 mg/m² every 3 weeks Anlotinib was taken at doses of 10mg orally once daily for two weeks on a one-week-off schedule.
223480828|NCT04486261|OTHER|High-intensity strength training|The high-intensity strength training protocol will consist of 2 training sessions per week. The first two weeks will be familiarisation training, where each exercise will be performed in three sets of 10 repetitions at an intensity of 15 repetitions maximum (RM). At week three each session will consist of 3 sets of each exercise corresponding to 10 RM, which will be kept for the remaining part of training intervention. The weights for each exercise will be adjusted throughout the intervention period, so the training load will correspond to 10 RM for each exercise in the entire intervention period.
223480829|NCT04390165|OTHER|Patient-Reported Online Questionnaire on Olfactory & Taste Disturbances|This is an online patient-reported questionnaire that examines the presence or absence of olfactory and taste disturbances, the onset of olfactory and taste disturbances in relation to other COVID-19 symptoms, and the temporal evolution of the severity of olfactory and taste disturbances. The occurrence of ear symptoms in COVID-19 infection will also be evaluated in this questionnaire as a secondary outcome. The questionnaire will also have questions relating to the patient's underlying health conditions, risk factors for COVID-19 infection, and demographics.
223480830|NCT05033041|DRUG|Study drug metoclopramide|Intravenous administration of 10 mg metoclopramide
223480831|NCT05033041|DRUG|Study drug placebo administration|Intravenous administration of placebo (sterile normal saline)
223480832|NCT03142893|DRUG|Ketoconazole Pill|Ketoconazole pill is taken 4 times per Inpatient Stay
223480833|NCT03142893|DRUG|Ganirelix|Ganirelix subcutaneous injection is administered twice per Inpatient Stay
223480834|NCT03142893|DRUG|Dexamethasone|Dexamethasone Pills is taken twice per Inpatient Stay
223480835|NCT03142893|DRUG|Dexamethasone Injection|Dexamethasone IV injection is given twice per Inpatient Stay
223480836|NCT03142893|DRUG|Cosyntropin Injectable Product|cosyntropin injection is given twice per Inpatient Stay
223480837|NCT03142893|DRUG|Recombinant Human Luteinizing Hormone|Leutinizing-Releasing Hormone is given 6 IV infusion pulses per Inpatient Visit
223480838|NCT03142893|DRUG|Hydrocortisone Injection|Hydrocortisone IV push is given twice per Inpatient Visit
223480839|NCT03142893|DRUG|Gonadorelin|Gonadorelin IV injection is given twice per Inpatient Stay
223480840|NCT03142893|DRUG|Corticorelin|Corticorelin IV injection is given twice per Inpatient Stay
223480841|NCT03142893|DRUG|Placebo oral capsule|Placebo for ketoconazole are given 4 times per Inpatient Stay
224168215|NCT02253992|BIOLOGICAL|Urelumab|
224168216|NCT02253992|BIOLOGICAL|Nivolumab|
224168217|NCT06141889|DRUG|Azelaprag|oral, apelin receptor (APJ) agonist
224305383|NCT05301413|BEHAVIORAL|Culturally Tailored DPP Enhanced with Socioeconomic Supports|This intervention includes the culturally tailored DPP curriculum, class procedures, and handouts along with promotional items for class participation, opportunities to attend class in-person or virtually through a digital platform, and assistance from a community health worker to provide linkage to health care services and community resources
224305384|NCT05301413|BEHAVIORAL|Diabetes Prevention Program|This is the CDC TD2 evidence-based Diabetes Prevention Program
224168218|NCT03683095|PROCEDURE|Lymphovenous bypass|"Lymphovenous bypass will be performed under general anesthetic. Indocyanine green lymphangiography will be performed by injecting indocyanine green into each finger / toe web of the lymphedematous limb and mapping the lymphatic system with the NOVADAQ SPY Fluorescence Imaging (Mississauga, Canada).~Subdermal dissection of lymphatics and venules will be carried out under a surgical microscope. Lymphatic vessels will be anastomosed to adjacent recipient venules to create the bypass between the lymphatic and the venous systems. In total, 1-5 anastomoses will be performed. This will require 1-5 incisions, each with a length of 2-3 cm.~Postoperatively, the limb will be wrapped loosely with compression bandages. No special postoperative monitoring is required.~The surgery will be performed on an outpatient basis with no planned hospital stay."
223480842|NCT03142893|DRUG|Saline Solution|Saline Solution (Placebo) for Dexamethasone IV injection or hydrocortisone IV injection given up to four times per Inpatient Stay
223480843|NCT03142893|DRUG|Saline Solution for Injection|Saline Solution (placebo) for ganirelix subcutaneous injection
223480844|NCT02398773|PROCEDURE|Computed Tomography|Undergo PET/CT
223480845|NCT02398773|DRUG|F-18 16 Alpha-Fluoroestradiol|Given IV
223480846|NCT02398773|OTHER|Laboratory Biomarker Analysis|Correlative studies
223480847|NCT02398773|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
223480848|NCT06802445|OTHER|Self-Management Therapy|Participants in this group will receive self management therapy. The self-administered therapy programme will consist of prevention of parafunctional activities, information about sleep hygiene and home exercise programmes, the effectiveness of which has been reported in the literature and is in line with the International Delphi Guidelines. Home exercises will start with 2 times a day, 8 repetitions and progress will be made weekly according to the patient's condition.
223480849|NCT06802445|DEVICE|Placebo Non-Invasive Vagal Nerve Stimulation|Participants in this group will receive self managemenet therapy and placebo vagal nerve stimulation. For Placebo Non-Invasive Auricular Transcutaneous Vagal Nerve Stimulation, the technique will be similar to active stimulation. The VaguStim device will be set to 0 Hz by the practitioner, indicating that no actual stimulation is being delivered. Patients will be told that they will not be able to feel the current due to its lower intensity during the intervention, without explaining the true nature of the placebo stimulation.
223480850|NCT06802445|DEVICE|Non-Invasive Vagal Nerve Stimulation|Participants will receive Non-Invasive Vagal Nerve Stimulation and self management therapy. : Non-Invasive Auricular Transcutaneous Vagal Nerve Stimulation, CE certified (CE No: 2460) non-invasive stimulation device will be applied with. The application will be performed with 3 different sized electrodes (small, medium, large) specially designed according to the size of the inner ear. The stimulation will be delivered bilaterally from the symba concha and tragus regions innervated by the auricular branch of the n.vagus, which guarantees effective and targeted vagal modulation. With reference to the studies in the literature; VaguStim application frequency will be 25 Hz, pulse width 250 µs, current level 0.5 mA with biphasic waveform. The treatment will continue 3 days a week for a total of 6 weeks, with each session lasting 20 minutes.
223480851|NCT02118285|DRUG|Fludarabine|Fludarabine 25 mg/m\^2 IV on days -6 through -2 from NK cell infusion
223480852|NCT02118285|DRUG|Cyclophosphamide|Cyclophosphamide 30 mg/kg IV on days -5 and -4 from NK cell infusion
223480853|NCT02118285|BIOLOGICAL|NK cells|CD3-/CD19- selected NK cells administered by intraperitoneal (IP) infusion on day 0
223480854|NCT02118285|BIOLOGICAL|IL-2|IL-2 at 6 million units/dose IP 3 times a week x 6 doses with the 1st dose given immediately after the NK cell infusion
223480855|NCT02118285|DRUG|INCB024360|INCB024360 at assigned dose by mouth twice a day begin day -2 and continue for 90 days (+/- 3 days)
223480856|NCT06486883|DRUG|Trastuzumab deruxtecan (T-DXd, DS-8201a)|Patients will receive T-DXd 5.4 mg/kg body weight administered as an intravenous (IV) infusion on Day 1 (D1) of each 21-day cycle. The initial dose will be administered as a 90-minute IV infusion.
223480857|NCT06486883|DRUG|CDK4/6i plus ET|Patients will receive physician's choice of CDK4/6 inhibitor (CDK4/6i) including palbociclib, ribociclib, and abemaciclib; physician's choice of endocrine therapy (ET) including fulvestrant, letrozole, anastrozole, and exemestane.
223480858|NCT03567681|DRUG|Extended release oxcarbazepine vs Immediate release oxcarbazepine|Extended release oxcarbazepine vs Immediate release oxcarbazepine
223480859|NCT02284100|BEHAVIORAL|animal assisted therapy|"For the AAT session, a 7 year old Golden Retriever was employed as the therapy animal. Prior to the study, the dog underwent rigorous screening although she had previous experience in Animal Assisted Interventions and was already trained and prepared prior for this type of work. The dog was fully vaccinated, bathed regularly, screened for enteric pathogens, and treated for internal and external parasites on a monthly basis. The dog and handler met hospital policy for participating in animal-assisted therapy, including documentation of the dog's current vaccinations, controllability and temperament.~The welfare of the dog was monitored and certificated by a dedicated veterinary during and at the end of the all sessions."
223480860|NCT00486681|DEVICE|Accu Chek Inform and Cobas IT 1000|period II (warning activated)
223480861|NCT01706562|DRUG|Itraconazole|Itraconazole intravenous (IV) 200 mg twice daily for 2 days, a total of 4 doses and then 200 mg once daily until clinically significant resolution of neutropenia.
223480862|NCT04887649|DRUG|Morphine|morphine 3 mg
223480863|NCT04887649|DRUG|saline solution|4 cc of saline solution in epidural cateter in postpartum
223480864|NCT04887649|DRUG|Morphine|morphine 2 mg for epidural cateter in postpartum
223480865|NCT06983743|DRUG|ERAS-0015|ERAS-0015 Administered orally
223480866|NCT06983743|DRUG|ERAS-0015 in combination|ERAS-0015 Administered orally and in combination with either Keytruda (pembrolizumab) via IV administration or Vectibix (panitumumab) via IV administration.
223480867|NCT06606002|BEHAVIORAL|Group schema therapy|Group schema therapy based on the model by Farrell and Shaw, which is complemented with separate group sessions for the participants\&#39; parents
223480868|NCT06606002|BEHAVIORAL|Treatment as Usual (TAU)|TAU typically comprises visits at the outpatient clinic with variable frequency and content
223480869|NCT06604442|DRUG|Flotufolastat (18F)|Positron emission tomography (PET)
223480870|NCT06604442|DRUG|piflufolastat (18F)|Positron emission tomography (PET)
223480871|NCT06822738|DEVICE|XEN63 Glaucoma Treatment System|Gel Stent
224305385|NCT01974440|DRUG|Bendamustine|90 milligram per meter square (mg/m\^2) administered intravenously on Days 1 to 2 of Cycles 1 to 6.
223480872|NCT06994299|RADIATION|Radiation Therapy|Hypofractionated radiotherapy - 8Gy x3 fractions (week 0)
223480873|NCT06994299|DRUG|Tremelimumab|Tremelimumab - single dose of 300 mg IV (week 0).
223480874|NCT06994299|DRUG|Durvalumab|Durvalumab-500 mg IV every 4-weeks (weeks 0-3) prior to hepatic resection
223480875|NCT06994299|PROCEDURE|Surgery|Hepatic resection
223480876|NCT07001800|DRUG|Ataciguat|Ataciguat will be administrated daily for up to 156 weeks
223480877|NCT07001800|DRUG|Placebo|Placebo will be administrated daily for up to 156 weeks
223480878|NCT04719897|BEHAVIORAL|FIRST: Repairing Thoughts|"This intervention uses the Repairing Thoughts cognitive restructuring module of the FIRST (Feeling Calm, Increasing Motivation, Repairing Thoughts, Solving Problems, Trying the Opposite) cognitive behavioral therapy protocol. This psychotherapy module teaches adolescents that thoughts are linked to feelings and behaviors, and that thoughts are often guesses to interpreting the world around us. Adolescents are taught to notice their thoughts in real-time and evaluate the evidence that supports or contradicts the thoughts and interpretation. Adolescents are then taught strategies to re-interpret thoughts in a more realistic manner and notice changes in emotional and behavioral responses. Clinicians are provided with examples to enhance learning, and between-session practice is assigned as homework."
223480879|NCT05382897|OTHER|Plant-based fasting-mimicking diet|Participants will be on a low caloric plant-based diet or a caloric-sufficient plant-based diet for 3 x 5 day cycle each month followed by 3 weeks of eating normally for a total period of 3 months.
223480880|NCT07004764|DRUG|Nitroglycerin Ointment 2%|Patients will have pre- and post-nitropaste tissue perfusion measurement with the LA-ICG system.
223480881|NCT06428825|DRUG|BAY3283142|oral administration
223480882|NCT06428825|DRUG|Placebo to BAY3283142|oral administration
223480883|NCT07011459|BEHAVIORAL|Cooking class|3-month community teaching kitchen-based culinary education of MedDiet
223480884|NCT07011459|OTHER|Standard of care|Participants will continue to receive clinical care recommendations from their physicians
223480885|NCT03244488|DRUG|Scopolamine Injectable Product|2.5 or 5 mcg/kg of scopolamine via IV
223480886|NCT03244488|DRUG|Mecamylamine Pill|10 or 20mg of mecamylamine orally
223480887|NCT00676949|BIOLOGICAL|5 peptide vaccines of KOC1, TTK, CO16, DEPDC1, MPHOSPH1|1mg each of 5 peptides with IFA. 4 weekly s.c. administration.
223480888|NCT04291040|BEHAVIORAL|Decision Aid|Following randomization, participants will independently view the multimedia based decision aid on a provided tablet. They will also receive provider counseling. For the remainder of the pregnancy, they will receive a text message with a link to the multimedia based presentation. This will occur every 4 weeks until 12 weeks postpartum.
223480889|NCT04291040|BEHAVIORAL|Routine Care|The control arm will receive routine prenatal care including provider counselling on postpartum contraceptive options.
223480890|NCT05947253|OTHER|Buyteko breathing technique|group A 20 participants received Buyteko breathing technique 2 session for 3 weeks
223480891|NCT05947253|OTHER|active cycle of breathing technique|Group B 20 participants received active cycle of breathing technique 2 session for 3 weeks
223480892|NCT01220284|DRUG|Satraplatin in combo with vinorelbine|"* Satraplatin (gelatin capsules) p.o. on days 1 to 5 (from 60 mg/m2 up to 80 mg/m2)~* Vinorelbine (soft capsules) p.o. on days 1, 8 and 15 (from 60 mg/m2 up to 80 mg/m2) The treatment is repeated every 4 weeks."
223480893|NCT04539990|BEHAVIORAL|Behavioral treatment for sleep difficulties|"This intervention is mediated by the parents. Parents are educated regarding sleep hygiene and instructed to follow simple rules which create a reliable evening routine and reduce exposure to stimulating factors that delay sleep onset (e.g., caffeine or exercise). In addition, parents are asked to initiate a fading behavioral protocol whereby they teach their child to fall asleep independently, with less parental attention. This requires parents to limit their interaction with their child after the children are put to bed so as not to interfere with sleep onset. This includes limiting conversations and lying in bed with the child. This behavioral approach is applied gradually and is expected to reduce the time it takes children to fall asleep."
223480894|NCT01721538|OTHER|Weight reduction program|
223480895|NCT01721538|OTHER|Lecture on healthy nutrition|
223480896|NCT00763360|DEVICE|DisCoVisc®|Injection of DisCoVisc® Ophthalmic Viscosurgical Device (OVD) into the anterior chamber prior to and throughout the cataract surgery procedure
223480897|NCT00763360|DRUG|Healon|Injection of Healon into the anterior chamber prior to and throughout the cataract surgery procedure
223480898|NCT00763360|DRUG|Amvisc Plus|Injection of Amvisc Plus into the anterior chamber prior to and throughout the cataract surgery procedure
223480899|NCT03404245|BEHAVIORAL|Education, Fitbit/self-management app, physiotherapist counselling.|Participants will receive a brief education session, use a physical activity tracker Fitbit Flex paired with a self-management app, and remote counseling by a PT. Intervention will be received immediately.
223480900|NCT03404245|BEHAVIORAL|Same intervention with a 6 month delay|The Delayed Intervention Group will receive the same intervention as the Immediate Intervention Group, but with a 6 month delay.
223480901|NCT04066374|DEVICE|Peripheral Nerve Stimulation|Medtronic Intellis Spinal Cord Stimulation Device to be implanted in thoracic cavity to treat postoperative acute pain.
223480902|NCT03011996|DRUG|CLR 500mg|Cohort 1: bid for 5 days Cohort 2: bid for 7 days
223480903|NCT03011996|DRUG|CJ-12420 100mg|Cohort 1: bid for 5 days Cohort 2: bid for 7 days
223480904|NCT03011996|DRUG|CJ-12420 50mg|Cohort 2: bid for 7 days
223480905|NCT03011996|DRUG|AMX 1g|Cohort 1: bid for 5 days Cohort 2: bid for 7 days
223480906|NCT03011996|DRUG|Pantoprazole 40mg|Cohort 2: bid for 7 days
223480907|NCT00505635|DRUG|Temozolomide|250 mg/m\^2 By Mouth Every 4 Hours x 3 Doses On Day 1
223480908|NCT00505635|DRUG|Velban|1.5 mg/m\^2 By Vein Over 15-30 Minutes On Days 1-4
223480909|NCT00505635|DRUG|Cisplatin|20 mg/m\^2 By Vein Over 45-120 Minutes On Days 1-4
223480910|NCT00505635|DRUG|Interleukin-2|9 MIU/m\^2 By Vein Over 24 Hours x 4 Doses On Days 1-4
223480911|NCT00505635|DRUG|Intron-A|5 mu/m\^2 Subcutaneously (Under the skin) Daily On Days 1-5
223480912|NCT00505635|DRUG|Thalidomide|400 mg By Mouth Daily
223744926|NCT01736150|DRUG|Placebo|"* Starting dose of 1 tablet (800mg), three times per day (2.4g/day)with meals.~* If serum phosphorus is higher than 5.5 mg/dL on Visit 3, 4, or 5, then dose increased by one additional tablet (800 mg). Three times daily with meals."
223744927|NCT01736150|DRUG|Sevelamer carbonate|"* Starting dose 1 tablet (800 mg), three times per day (2.4 g/day) with meals.~* If serum phosphorus is higher than 5.5 mg/dL on Visit 3, 4, or 5, then dose increased by one additional tablet(800mg).Three times daily with meals."
224168219|NCT06369584|PROCEDURE|prone position|The process of prone positioning requires 5-6 people, with one person acting as the commander responsible for directing and monitoring. The process of monitoring includes ECMO flow and the vital signs. The second person is in charge of the patient's head, including endotracheal intubation, ventilator lines, and jugular ECMO cannula. The third person is responsible for femoral ECMO cannula and central venous line. The fourth to sixth individuals are responsible for rotating the patient's torso towards the side without an ECMO tube. Before initiating prone ventilation, pressure ulcer protection patches should be placed on the patient's forehead, ears, anterior chest, and iliac crest to protect areas under pressure. During ECMO support period, each patient needs to undergo at least four sessions of prone ventilation until their condition improves enough to discontinue ECMO support. Each session should last between 16 to 24 hours.
224168220|NCT00772889|BIOLOGICAL|Influenza vaccine GSK2186877A|One intramuscularly injection at Day 0
224168221|NCT00772889|BIOLOGICAL|GSK Biologicals' Fluarix™|One intramuscularly injection at Day 0
224168222|NCT03206983|DEVICE|Cana's Ring|The device is used during cataract surgery to help dilate small pupils (under 5mm)
224168223|NCT00149006|PROCEDURE|Cell therapy|
224168224|NCT03323086|BEHAVIORAL|Brief Intervention (BI) with Technology Extender|One, 45-60 minute BI, followed by three months of access to technology extenders
224168225|NCT03323086|OTHER|Brochure|Brochures provided one time
224168226|NCT02812329|BEHAVIORAL|HIV prevention videogame|Assess acceptability and efficacy of a HIV prevention videogame
223480913|NCT01989858|OTHER|peri-operative cht|"CHT treatment have to be chosen between the following associations:~Chemotherapy regimen containing epirubicin, cisplatin and capecitabine (EOX) E: epirubicin 50 mg/m² intravenous (iv) bolus, day 1 every 3 weeks O: oxaliplatin 130 mg/m² iv infusion, day 1 in 2-3 hours every 3 weeks X: capecitabine 625 mg/m² bis in die (bid), day 1 per os (po) continuously~or~Chemotherapy regimen containing epirubicin, cisplatin and 5-fluorouracil (ECF) E: epirubicin 50 mg/m² iv bolus, day 1 every 3 weeks C: cisplatin 60 mg/m² iv with standard hydration day 1 every 3 weeks F: 5FU 200 mg/m² daily by continuous infusion via central line."
223480914|NCT01989858|OTHER|post-operative CHT|"CHT treatment have to be chosen between the following associations:~EOX E: epirubicin 50 mg/m² intravenous (iv) bolus, day 1 every 3 weeks O: oxaliplatin 130 mg/m² iv infusion, day 1 in 2-3 hours every 3 weeks X: capecitabine 625 mg/m² bis in die (bid), day 1 per os (po) continuously~or ECF E: epirubicin 50 mg/m² iv bolus, day 1 every 3 weeks C: cisplatin 60 mg/m² iv with standard hydration day 1 every 3 weeks F: 5fluorouracil (5FU) 200 mg/m² daily by continuous infusion via central line."
223480915|NCT01989858|OTHER|peri-operative cht + post-operative cht-rtx|"CHT treatment have to be chosen between the following associations:~* EOX E: epirubicin 50 mg/m² intravenous (iv) bolus, day 1 every 3 weeks O: oxaliplatin 130 mg/m² iv infusion, day 1 in 2-3 hours every 3 weeks X: capecitabine 625 mg/m² bis in die (bid), day 1 per os (po) continuously or~* ECF E: epirubicin 50 mg/m² iv bolus, day 1 every 3 weeks C: cisplatin 60 mg/m² iv with standard hydration day 1 every 3 weeks F: 5FU 200 mg/m² daily by continuous infusion via central line.~The prescribed RTX dose to clinical target volume should be 45 gray (Gy) delivered in daily fraction of 1.8 Gy, five times per week for six weeks. RTX will be administered concurrently with CHT. The choice of the associated CHT should be between the following schedules:~* 5FU 225 mg/m² given as a continuous iv infusion or~* capecitabine 825 mg/m² bid given as a continuous oral administration during the entire course of RTX."
223480916|NCT01989858|OTHER|post-operative cht + post-operative cht-rtx|"CHT treatment have to be chosen between the following associations:~* EOX E: epirubicin 50 mg/m² intravenous (iv) bolus, day 1 every 3 weeks O: oxaliplatin 130 mg/m² iv infusion, day 1 in 2-3 hours every 3 weeks X: capecitabine 625 mg/m² bis in die (bid), day 1 per os (po) continuously or~* ECF E: epirubicin 50 mg/m² iv bolus, day 1 every 3 weeks C: cisplatin 60 mg/m² iv with standard hydration day 1 every 3 weeks F: 5FU 200 mg/m² daily by continuous infusion via central line.~The prescribed RTX dose to clinical target volume should be 45 gray (Gy) delivered in daily fraction of 1.8 Gy, five times per week for six weeks. RTX will be administered concurrently with CHT. The choice of the associated CHT should be between the following schedules:~* 5FU 225 mg/m² given as a continuous iv infusion or~* capecitabine 825 mg/m² bid given as a continuous oral administration during the entire course of RTX."
223480917|NCT03000946|DRUG|Somatostatin|Lyophilisate and solution for IV use (glass ampoule of lyophilisate + 1 ml glass ampoule of solvent) 6 mg per day Continuous intravenous infusion for 6,5 days
223480918|NCT03000946|DRUG|Octreotide|Solution for Subcutaneous use 100μg, every 8 hours Subcutaneous injection for 6,5 days
223480919|NCT00834041|DRUG|Aliskiren 3.125 mini-tablets|Oral mini-tablets (3.125 mg) of aliskiren once each morning
223480920|NCT06753396|PROCEDURE|Platelet rich fibrin|The injectable platelet rich fibrin will be integrated into the tissue by subgingival and submucosal application to the keratinized gingiva of the implant sites with insufficient peri-implant soft tissue phenotype. Then, the prepared injectable platelet rich fibrin will be injected into the mucogingival junction apical to the keratinized gingival site. This procedure will be repeated 3 times in total, 1 time in 30 days for 3 months.
223480921|NCT02634177|GENETIC|Assay-guided treatment (AGT)|The assay provides information to guide pharmacotherapeutic decisions personalized to a patient's genetic profile, to maximize improvement in symptomatology and minimize treatment failure and treatment intolerability.
223480922|NCT02634177|OTHER|Treatment-as-usual (TAU)|Subjects are treated-as-usual without the aid of the assay.
223480923|NCT05831878|DRUG|Disitamab vedotin|2.0mg/kg, iv, day1, every 2 weeks
223744928|NCT05810792|DRUG|Histamine Dihydrochloride (HDC)|HDC is administrated in combination with IL-2 as peri- and post-operative treatment in patients undergoing surgery. 0.5 mg HDC is administered twice daily by subcutaneous injections 1 to 3 minutes after each IL-2 injection during three 3 week cycles, with 3-week resting periods inbetween. The first treatment cycle is initated 2 weeks prior to surgery, with an additional 2-3 days rest period during the surgical procedure, before the third treatment week is initiated.
224168227|NCT00355615|DRUG|Rosuvastatin|oral
224168228|NCT00355615|DRUG|Placebo|oral
224168229|NCT05155410|DIETARY_SUPPLEMENT|Exogenous Ketone Monoester|Participants will consume 15g of the oral ketone monoester supplement 15 minutes prior to each meal of the day for 14 days. All meals will be provided throughout the 14-day supplementation period.
223480924|NCT06040619|BEHAVIORAL|Therapy Together|8-week caregiver-led pediatric constraint-induced movement therapy program
223480925|NCT06040619|BEHAVIORAL|Usual Care|8 weeks of usual care received in an early intervention therapy program
223480926|NCT07069426|DIETARY_SUPPLEMENT|20 grams protein|20 grams of whey protein provided as beverage
223480927|NCT07069426|DIETARY_SUPPLEMENT|40 grams protein|40 grams of whey protein provided as beverage
223480928|NCT07062679|OTHER|Maitland Oscillatory Glides/Mobilization|"Hot pack for 15 minutes Ultrasound for 5 minutes Maitland Mobilization Oscillatory Glides inferiorly during normal abduction. Glenohumeral caudal glide mobilization was given at the rate of 2-3 glides per second for 30 seconds for each glide, 5 sets were given.~(3 sessions per week for 4 weeks)"
223480929|NCT07062679|OTHER|Mulligan Mobilization with Movement (MWM)|"Hot pack for 15 minutes Ultrasound for 5 minutes Mobilization with Movement (MWM) Patient sitting with therapist posterolateral to him/her. Therapist places the Mulligan belt across the humeral head and to his waist. Patient movement (Flexion, extension, \& abduction respectively) combined with therapist-applied joint gliding (postero-lateral Glide) MWM will be performed.~3 sets of 10 reps per session (30 seconds rest between sets)~(3 sessions per week for 4 weeks)"
223480930|NCT06901297|DRUG|Raphamin|Oral administration
223480931|NCT06901297|DRUG|Placebo|Oral administration
223480932|NCT06805175|DEVICE|vestibular implant|vestibular implant
223480933|NCT06717308|DEVICE|Comfort Release® NPWT drape|Comfort Release® NPWT drape- painless and trauma-free removal, as compared to the control NPWT drape.
223480934|NCT07080775|DRUG|human allogeneic induced pluripotent stem cell (iPSC)-derived dopaminergic neural progenitor cell injection|5.0×10\^7 cells/mL, injection, once, 12 months
223480935|NCT06765980|GENETIC|VV-14295|VV-14295 will be administered as a single suprachoroidal injection.
223480936|NCT06682013|DEVICE|Virtual agent|"The virtual agent is an interactive audio agent that is similar to voice agents that interact with callers in many industries today. They create a very human-like interaction in contrast to more traditional virtual call agents that can only respond to menu options (e.g. choose 1 for appointments, choose 2 for questions about your bill, etc.). The virtual agent is engineered to accomplish the very specific task of onboarding the patient on use of the RPM devices. It is trained to understand normal human English speech, detects emotional tone and frustration of callers, and is trained to deescalate when appropriate."
223480937|NCT06682013|OTHER|Human agent|The human agent will onboard the patient on use of the RPM devices.
223480938|NCT07080619|DRUG|SC-101|Receive 7.5 mg/m² of SC-101 intravenously once weekly (QW).
223480939|NCT06903104|OTHER|Mindfulness closed program|MAEva program will be proposed with meditative practices and three different themes will be addressed (one theme per session): Meditation, Acceptance and Commitment to values.
223480940|NCT06903104|DIAGNOSTIC_TEST|Quality of life evaluation|The assessment will be carried out at inclusion and after completion of the program.
223480941|NCT06903104|DIAGNOSTIC_TEST|Perceived Stress Scale|The assessment will be carried out at inclusion and after completion of the program.
223480942|NCT06903104|DIAGNOSTIC_TEST|Multidimensional Psychological Flexibility Inventory|The assessment will be carried out at inclusion and after completion of the program.
223480943|NCT06903104|OTHER|satisfaction questionnaire and semi-structured interview|The assessments will be carried out after completion of the program.
223617561|NCT05429216|PROCEDURE|mEMR-C procedure|A transparent cap with an inner groove (MH-593; Olympus, Tokyo, Japan) was attached to the forward-viewing colonoscope. After the endoscope was inserted into the rectum, a crescent-shaped electrosurgical snare was passed through the sheath and looped along the inner groove of the cap. Submucosal injections were not required in this method. The tumor was suctioned into the cap and grasped by tightening the snare. After confirming the appropriate snare placement, both the tumor and overlying mucosa were resected using electric cautery (Endocut Q, effect 2, VIO 200D; ERBE, Tübingen, Germany), and the resected tumor was sent for pathological examination. Endoscopic examination was repeated without a transparent cap to evaluate the wound carefully in cases of perforation or bleeding and to ensure the absence of residual tumor tissues. If there was spurting or active bleeding, hot forceps were used to stop the bleeding.
224305386|NCT01974440|DRUG|Rituximab|375 mg/m\^2 administered intravenously on Day 1 of Cycles 1 to 6.
223480944|NCT06924541|DIETARY_SUPPLEMENT|Choline|Each subject gets one of two oral choline doses or placebo on each of three study days, 550 mg, 1100 mg, and placebo
223480945|NCT06924541|DIETARY_SUPPLEMENT|Placebo|Each subject gets one of two oral choline doses or placebo on each of three study days, 550 mg, 1100 mg, and placebo
223480946|NCT06846606|DRUG|AUTX-703|AUTX-703 administered orally
223480947|NCT02912130|DIETARY_SUPPLEMENT|Protein Supplementation|1.2-1.5g/kg/body weight per day
223480948|NCT02912130|OTHER|Aerobic Exercise|30-60 minutes per week of moderate intensity exercise
223480949|NCT02912130|OTHER|Resistance Exercise|60 minutes per week of progressive resistance training
223480950|NCT06776159|OTHER|Active Control|Patients in the control group will receive the usual practice of subcutaneous LMWH injection administered by nurses.
223480951|NCT06776159|OTHER|Standardized injection protocol|Nurses administer LMWH according to the standardized evidence-based protocol.
223480952|NCT07084948|DRUG|Flavonoid|"The daily maintenance, Tenofovir 150mg + SB Flavon 1345mg dose is to be taken 2 times a day, 1 tablet each time.~The composition treats acute hepatitis, chronic hepatitis, cirrhosis, and hepatocellular carcinoma at an early stage. The product is Acid ascorbic, L-Arginine hydrochloride, Kaempferol, Urinariaflavone, 5,6-dihydroxy-7,8,4'-trimethoxy-flavone, Quercetin, Rutin.~Use these ingredients to protect liver cell membranes, preventing the growth of HBV in the body."
223480953|NCT07084948|DRUG|Tenofovir|"The daily maintenance, Tenofovir 300mg dose is to be taken 1 time a day, 1 tablet each time.~The composition treats acute hepatitis, chronic hepatitis, cirrhosis, and hepatocellular carcinoma."
223480954|NCT06902077|BEHAVIORAL|low carb diet|diet based on low carb with max 50-80 grams of carbohydrates daily
223480955|NCT06902077|BEHAVIORAL|diabetic diet|Balanced diet based on standard of care recommendations for type 2 diabetes
223480956|NCT06742801|DEVICE|Onyx™ Liquid Embolic System|The proposed indication for Onyx™ LES is: Onyx™ LES is indicated for the embolization of arterial hemorrhage in the peripheral vasculature.
223480957|NCT06826768|DRUG|REGN5678|Given by IV infusion
223480958|NCT06826768|DRUG|Cemiplimab|Given by IV infusion
224168230|NCT05155410|DIETARY_SUPPLEMENT|Placebo|Participants will consume an equivalent volume (30ml) of the active intervention supplement 15 minutes prior to each meal for 14 days. All meals will be provided throughout the 14-day placebo supplementation period.
224168231|NCT02516891|DEVICE|Drug-Eluting Stents implantation in bifurcation lesions|
224168232|NCT00820963|DRUG|temozolomide|Given orally
224168233|NCT00820963|RADIATION|hypofractionated radiation therapy|Patients undergo hypofractionated radiotherapy
224168234|NCT00820963|RADIATION|radiation therapy|Patients undergo standard radiotherapy
224168235|NCT04797494|DEVICE|acrylic removable appliance|"Hand-made, dental laboratory-manufactured, acrylic removable appliances were made on the mandible after intraoral impressions (Alginate, Cavex).~Patients were asked to wear the RA for a period of 3 weeks prior to restorative treatment, for 24 h per day, except for when eating."
224168236|NCT03140046|PROCEDURE|photorefractive keratectomy (PRK)|"The cornea will be ablated while the patient fixating on target light under constant eye-tracking control. The ablations will be made using the ALLEGRETTO X 500WAVE excimer laser (WaveLight Laser Technologie AG)."
224168237|NCT02789189|DRUG|nedaplatin and gemcitabine|
224168238|NCT06432491|BEHAVIORAL|Drinking cold water|Volunteers in the intervention group will be asked to drink up 500 ml 4℃ water within 10 minutes four times per day throughout the study.
224168239|NCT02159365|DRUG|Elotuzumab|
224168240|NCT02159365|DRUG|Lenalidomide|
224168241|NCT02159365|DRUG|Dexamethasone|
223617562|NCT05429216|PROCEDURE|ESD procedure|ESD was performed as the standard procedure and has been widely described and used. First, dots were marked approximately 5 mm from the periphery of the lesion using coagulation. Subsequently, a diluted sodium hyaluronate solution with indigo carmine dye was injected submucosally. Mucosal incision and submucosal dissection were performed using a T-Type ESD Knife (Micro-Tech, Nanjing, China) or Dual-knife (Olympus Medical, Tokyo, Japan). After resection was completed, all visible vessels on the artificial wound were thoroughly coagulated to prevent postoperative bleeding.
224168242|NCT05141565|OTHER|No intervention|No intervention
224168243|NCT02460094|DRUG|BIIB092|See Arm Descriptions for dosing information.
224168244|NCT02460094|DRUG|Placebo|See Arm Descriptions for dosing information. (0.9% Sodium Chloride for Injection or 5% Dextrose Injection if Sodium Chloride is not available)
224168245|NCT04311437|PROCEDURE|Self-acupressure therapy|The self-acupressure therapy is as follows: Patients are in sitting position, applied firm pressure (3-5 kg of pressure) with the fingertips in a circular motion at a speed of two circles per second for a duration of one min per acupoint. A 1-2-s rest is applied after each ten circles. The complete process lasts for about 5 min.
224168246|NCT04311437|PROCEDURE|Combined Valsalva and Toynbee maneuvers|Valsalva maneuver: blowing against a closed mouth and nostrils, increasing the middle ear pressure. Toynbee maneuver: swallowing while the mouth and nostrils are closed, decreasing the middle ear pressure.
224168247|NCT03170765|BIOLOGICAL|Measles vaccine|Live attenuated measles vaccine of brands currently being used in National Immunization Schedule of India.
224168248|NCT05246228|OTHER|Peripheral blood sampling in order to evaluate changes in the circulating immune population|Eveluation: circulating T cells CD3+CD8+ and CD3+CD4+, absolute lymphocyte count (ALC) and neutrophil counts (ANC) and neutrophil/lymphocyte ratio (NLR), Treg lymphocytes, Naïve/Memory T lymphocytes CD4+ and CD8+,myeloid-derived suppressor cells, Plasmacytoid Dendritic Cells NK cells dimension and bright, NKT cells, Myeloid Dendritic cells, Monocytes subsets, B lymphocytes ,Analysis of plasma cytokines (TNFalpha, TGFbeta, IL-6, IL-10) by ELISA,FN signature: real-time PCR on mRNA from peripheral blood mononuclear cells (PBMCs)
224168249|NCT00796549|DRUG|BiBW 2992|BIBW 2992 in EGFR FISH positive NSCLC patients
224168250|NCT01095328|OTHER|screening|screening for Q-fever with a single blood sampling
224168251|NCT00245349|PROCEDURE|F-18 Fluorothymidine|
224168252|NCT01102946|DRUG|Ranibizumab|Ranibizumab (Lucentis), intravitreal injections of 0.05ml
224168253|NCT01102946|PROCEDURE|Panretinal Photocoagulation|Panretinal photocoagulation with green laser according to ETDRS
224168254|NCT02719210|BIOLOGICAL|High Volume Plasma Exchange|
224168255|NCT02719210|DRUG|Hypertonic 3% saline|
224168256|NCT02719210|DRUG|Mannitol|
224168257|NCT02719210|DEVICE|Elective positive pressure ventilation|
224168258|NCT02608294|DEVICE|Kinesio Taping|The patient is placed on a stretcher, his ankle positioned in plantar flexion and inversion, a measure was held between Point A and B with a tape measure, right after the KT was removed from the paper and cut to the same extent. The KT was pulled to its maximum limit and measured with a tape for a second evaluator. This measure found after the maximum tensile strain represented 100% and a rule of three was applied in order to find the 35% voltage for muscle activation. After finding the measure of 35% strain in centimeters, the evaluator cut KT this measurement and the same was discarded. Finally the tape was positioned at Point A; pulled up to Point B; and fixed. This procedure was carried out with the ankle positioned in plantar flexion and inversion.
224168259|NCT02608294|DEVICE|Kinesio Taping Sham|The sham group received the tape applied without tension. The patient was positioned supine; the ankle was placed in a neutral position (90 degrees); and measured between Point A and Point B with a tape measure placed on the skin was performed. Once registered this measure in centimeters the evaluator cut the KT with the same measure, but without the presence of paper attached to it to ensure that there was no tension, because the KT needs a minimum voltage to be applied on paper. After measured and cut the KT, it was applied to the patient in the supine position with the ankle positioned at 90 degrees with no traction.
224168260|NCT02966899|DIETARY_SUPPLEMENT|Omega-3 fatty acids|
224168261|NCT00474773|DRUG|Celecoxib|
224168262|NCT00004194|DRUG|fludarabine phosphate|
224168263|NCT02661256|DEVICE|NCPAP|Does NCPAP induce dysphagia in neonates? Each baby will be evaluated for dysphagia (using fluoroscopy) while on NCPAP and off NCPAP.
224168264|NCT02661256|DIETARY_SUPPLEMENT|Varibar® Thin Liquid Barium Sulfate for Suspension|Liquid barium is used as a contrast material to allow visualization of swallowed boluses under fluoroscopy.
224305387|NCT01974440|DRUG|Cyclophosphamide|750 mg/m\^2 administered intravenously on Day 1 of Cycles 1 to 6.
224305388|NCT01974440|DRUG|Doxorubicin|50 mg/m\^2 administered intravenously on Day 1 of Cycles 1 to 6.
224305389|NCT01974440|DRUG|Vincristine|1.4 mg/m\^2 (maximum total 2 mg) administered intravenously on Day 1 of Cycles 1 to 6.
224305390|NCT01974440|DRUG|Prednisone|100 mg administered orally on Days 1 to 5 of Cycles 1 to 6.
223584903|NCT06979830|BEHAVIORAL|yoga exercises|"The yoga program, based on Hatha yoga content, will be conducted in groups of 10 participants, for 12 weeks, 3 days a week, at the same time each day (12:00-13:00), and will be administered by an experienced physiotherapist (Appendix 4).~Before starting the training program, the exercise group will be given a one-week adaptation period, during which the exercises to be performed in three sessions per week will be taught.~Participants in the exercise group who miss sessions for various reasons will be given an additional one-week period to make up for missed sessions. Participants who miss more than four sessions will be excluded from the study.~Participants were informed in advance about any personal items they might need before each yoga session (such as towels, tissues, etc.) and were advised to bring their own. The yoga sessions were held in the sports hall of the Artvin Çoruh Dormitory, where the required equipment for yoga (e.g., mats, blocks) was provided. The yoga program was"
223584904|NCT06981039|DEVICE|Patella Anatomical Locking Plate|Patients in the patella anatomical locking plate group will undergo internal fixation with an anterior locking plate and screw construct using the 2.7mm variable angle (VA) locking patella plating system (DePuy Synthes, Zuchwil, Switzerland)
223584905|NCT06981039|DEVICE|Tension Band Wiring|Patients in the tension band wiring group will undergo open anatomical reduction and internal fixation with a tension band wire construct.
223584906|NCT06980935|DEVICE|NervioX-2400|To design the individualized tTIS, each participant completed a T1-weighted anatomical magnetic resonance imaging (MRI) scan. The individual's structural brain MRI data were used to determine the tTIS montage and stimulation settings via computational modeling.
223584907|NCT06980155|BIOLOGICAL|Personalized neoantigen tumor vaccine|Neoantigen tumor vaccine
223584908|NCT06980155|BIOLOGICAL|PD-1 inhibitor|Toripalimab
223584909|NCT06980779|OTHER|ultrasonographic examination|ultrasonographic examination
223584910|NCT06980558|OTHER|Progressive relaxation exercises|"Sit or lie down comfortably and close your eyes.~* Feel the rhythm of your breathing.~* Breathe in through your nose and out through your mouth throughout the process.~* Relax as much as you can.~* Get rid of negative thoughts in your mind.~* Stretch your hands by hanging your arms down to your sides, tighten your fists as much as you can and then open them and let them relax."
224072092|NCT02575287|DEVICE|Optical Enhancement with optical magnification|A endoscopic visualization of the mucosa using the pre-processor filter called Optical enhancement associated with an optical magnification using the scope called magniview (PENTAX Medical EG-2990Zi)
223584911|NCT06980610|PROCEDURE|digestive stoma closures|"Both surgical techniques (Collatamp interposition and directed healing) are routinely used in the CVMC and Digestive Cancer Surgery departments for stoma closure or restoration of digestive continuity. The choice of technique is at the surgeon\&#39;s discretion.~Specific procedures related to the research:~Procedures that differ from standard management are randomization and patient completion of a questionnaire."
223584912|NCT03553186|DRUG|Tranexamic Acid 100 MG/ML|TXA lavage solution (200 cc sterile normal saline + 5 g tranexamic acid 100mg/ml (50cc)) will be poured into the surgical field and left in contact for five minutes. This will occur after instrumentation. Excess solution will be suctioned away using a non-cell saver suction.
223584913|NCT03553186|DRUG|Placebo|Placebo solution (200 cc sterile normal saline + placebo TXA ampule (50cc)) will be poured into the surgical field and left in contact for five minutes. This will occur after pedicle screw instrumentation. Excess solution will be suctioned away using a non-cell saver suction.
223584914|NCT06981494|DRUG|Dexmedetomidine|"Loading Dose:~Dexmedetomidine is usually administered as a loading dose of 0.25 mcg/kg slowly.~Maintenance Dose:~After the loading dose, the maintenance infusion rate is typically 0.2 to 0.7 mcg/kg/hour in syringe pump . The exact rate can be adjusted based on the hemodynamics of the patient (blood pressure and heart rate) and the patient's response."
223584915|NCT06981494|DRUG|Dexmedetomidine and ketamine ( Ketodex )|"Ketodex Group (Combination of Ketamine and Dexmedetomidine) (K):~Ketamine Component:~Loading Dose:~Ketamine is typically given at a dose of 0.5 mg/kg as a bolus injection.~Maintenance Dose:~A maintenance infusion of 0.2 to 0.5 mg/kg/hour is common to maintain anesthesia in syringe pump.~Dexmedetomidine Component:~Loading Dose:~As with the dexmedetomidine group, a loading dose of 0.25 mcg/kg slowly is administered.~Maintenance Dose:~The maintenance infusion rate for dexmedetomidine remains 0.2 to 0.7 µg/kg/hour in syringe pump."
224072093|NCT02575287|DEVICE|Optical magnification without Optical enhancement|A endoscopic visualization of the mucosa using optical magnification without the use of the pre-processor filter called Optical enhancement
224072094|NCT02833103|DRUG|Danshu Capsules|Danshu Capsules (0.9g potid/day) for three months by oral
223480961|NCT07117968|OTHER|Standard-of-care|Management of the first year post-CI follow-up according to current center practices
223480962|NCT07117968|OTHER|Experimental hybrid care pathway|First year post-CI follow-up including early activation of the implant and hybrid follow-up, including remote or in-center monitoring visits, adjustable according to the evolution of their hearing performance and comfort. In this new care pathway, compared with the Standard-of-care, the 2-week visit and the 9-month visit are omitted, due to early activation and remote follow-up. Visits at 1 and 6 months are the same as those in the conventional, on-site routine. Visits at 3 and 12 months will be carried out remotely by default via the remote monitoring application.
224072095|NCT02833103|DRUG|Pinaverium Bromide|Pinaverium Bromide (100mg potid/day) for three months by oral
224072096|NCT02956993|DRUG|vonapanitase|
224072097|NCT02956993|DRUG|Placebo|
224072098|NCT03217838|DRUG|AZD2811|AZD2811 will be administered by IV infusion with the specified dose level as reported in arms in 28-day cycles.
224072099|NCT03217838|DRUG|Azacitidine|Azacitidine is supplied in vials of 25 mg/mL powder for suspension for injection. After reconstitution, each vial contains a maximum of 100 mg. Participants should be pre-medicated for nausea and vomiting according to institutional standards before receiving azacitidine. Participants will receive 75 mg/m² on Days 1 through 7 or for 5 consecutive weekdays with rest on the 2 weekend days, and azacitidine dosing the first 2 weekdays of the next week of each 28-day cycle.
224305391|NCT01974440|DRUG|PCI-32765 (Ibrutinib)|560 mg (4\*140 mg) capsules administered orally once daily, continuously starting on Cycle 1, Day 1.
224305392|NCT01974440|DRUG|Placebo|Placebo (4 capsules) matched to ibrutinib administered orally once daily, continuously starting on Cycle 1, Day 1.
224305393|NCT00762437|DEVICE|Zeltiq Dermal Cooling Device|Non-invasive cooling is applied to the treatment area with a defined cooling rate and duration.
224168265|NCT00126763|DRUG|Fentanyl Transdermal Matrix Patch ZR-02-01|ZR-02-01 patch contains fentanyl dispersed in a solid matrix, and was available in 25, 50,75 and 100 mcg/hr patches. For patients who were using transdermal fentanyl (ie,Duragesic®), the initial dose of ZR-02-01 was the same as their current Duragesic dose. For patients who were taking oral opioids, the initial dose of ZR-02-01 was determined by the investigator using sponsor-provided conversion guidelines. The patches were worn on the chest or upper arm and an overlay was placed over the patch. Patches (and overlays) were replaced every 3 days
224168266|NCT03868475|PROCEDURE|Vacuum-assisted percutaneous excision|The intervention group will undergo the vacuum assisted percutaneous excision (VAPE). All VAPE procedures will be performed on a digital supine table using the ATEC© Breast Biopsy System hand piece (Hologic) with a 9-gauge needle and a 10 or 20 mm aperture providing 6-mmHg of suction strength to completely excise the breast lesion.
224168267|NCT03868475|PROCEDURE|Open surgical excision|The control group will undergo standard open surgical excision of the breast lesion. This will be done in the operating room using preoperative image-guided localization with radioactive seed (I-125) or in the procedure room of the Breast Care Centre if appropriate (i.e. lesion is palpable and localization is not required).
224168268|NCT04143490|OTHER|Exercise|60 minutes of continuous exercise at 65% VO2peak and drink ingestion
224168269|NCT03426761|DRUG|Dalbavancin|Dalbavancin 1,500mg intravenously every fourteen days for two to four infusions
224168270|NCT03426761|DRUG|Vancomycin|Examples of standard of care arm; infusions one to three times per day depending on the antibiotic for a total of three to eight weeks
223480963|NCT07126535|DIAGNOSTIC_TEST|Radiofrequency ablation alone|If there is no evidence of nodularity, these patients will undergo RFA. Clinical biopsies utilizing a large-capacity biopsy forceps (Radial Jaw 4, Boston Scientific, Marlborough, MA) are obtained. RFA may be delivered through several devices under the BarrX RFA System (Medtronic USA, Minnetonka, MN), including a circumferential balloon catheter (Halo 360; figure 1), or over the scope focal catheter (Halo 90 or 60). The Halo 360 treats a circumferential 4 cm segment at a time, whereas the focal catheters treat a 1.3x2 cm (Halo 90) or 1.0x1.5 cm (Halo 60) area.
223480964|NCT02177500|DRUG|Telmisartan + hydrochlorothiazide|
223480965|NCT02177500|DRUG|Telmisartan|
223480966|NCT02177500|DRUG|Placebo|
223480967|NCT07133607|OTHER|education about pain and physical excersice|"The sessions will be conducted in groups of 10 to 15 patients.~* 4 pain science education sessions, each lasting 1.5 hours (6 hours), with one session per week, for 4 weeks.~* 12 therapeutic physical exercise program sessions, each lasting 1 hour, to be conducted over 6 weeks (12 hours), with two sessions per week. Although the intervention is group-based, individual instructions will be given to patients. Reference will be made to the content learned in the neuroeducation sessions. The exercise dose must be adjusted to the patient's condition, keeping in mind that, due to the inhibition of the descending pain modulation system, they may experience an initial increase in pain during the first sessions, so as not to alarm the patient and prevent the activity from being discontinued. The main objective is to increase the patient's functionality, an aspect that will be constantly reinforced.~The session structure will be as recommended by the American College of Sports Medicine, with se"
223480968|NCT07133607|OTHER|education about pain and physical excersice with somatosensorial treatment|"Patients assigned to this group will receive, in addition to the same intervention as the AADC study group intervention type 2 (education about pain), somatosensory and body schema treatment for the changes observed in an initial assessment during the 4 weeks prior.~The prescribed treatment will be repeated daily at home. To facilitate~the progress of the treatment, it is recommended that a companion participate in the first session, when possible, where the daily intervention to be performed at home will be explained.~If the participation of a companion is not possible, the patient will attend the Health Center's physiotherapy room once a day to be accompanied by the physiotherapist and offered the same treatment opportunities.~As a control and monitoring measure, the patient will attend the physiotherapy room once a week and will be called again weekly to verify that the treatment is being performed correctly. They will also be provided with a form to record their home treatment."
223480969|NCT07133607|OTHER|Classic physiotherapy treatment with physical exercise, analgesic electrotherapy and thermotherapy|The patients will receive the usual physiotherapy treatment provided in Primary Care Physiotherapy units, supported by the current Primary Care Physiotherapy protocols of Castilla y León, since Andalusia does not currently have any published. The patient will receive 12 sessions of thermotherapy (Infrared/Microwave) and analgesic electrotherapy (analgesic Tens currents) in the painful area(s), and will be prescribed exercises recommended by the Spanish Society of Physical Medicine and Rehabilitation (SERMEF). The learning and execution of the exercises will be supervised by a Primary Care physiotherapist. The sessions will be with a frequency of 2 per week on alternate days for 6 weeks.
223480970|NCT06507553|BIOLOGICAL|Trivalent-Darwin influenza vaccine|Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular
223480971|NCT06507553|BIOLOGICAL|Augment-Tasmania influenza vaccine|Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular
223480972|NCT06507553|BIOLOGICAL|TIV-2X Darwin influenza vaccine|Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular
223480973|NCT06507553|BIOLOGICAL|Trivalent-Tasmania influenza vaccine|Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular
223480974|NCT06939036|DRUG|225Ac-SSO110 + SoC|Dose Level -2-7
223480975|NCT06939036|DRUG|Atezolizumab|Extensive Stage Small Cell Lung Cancer Checkpoint Inhibitor (SoC)
224168271|NCT00747708|DRUG|Granulocyte-colony stimulating factor|5 days subcutaneous injection
224168272|NCT00747708|PROCEDURE|Percutaneous intracoronary injection|Bone marrow derived stem/progenitor cells or placebo infusion is delivered through an over-the-wire balloon catheter into the target coronary vessels using a stop-flow technique.
224168273|NCT00747708|PROCEDURE|Percutaneous intramyocardial injection|Direct intramyocardial injections of bone marrow derived stem/progenitor cells or placebo will be delivered using the electromechanical NOGA mapping and injection system
223480976|NCT06939036|DRUG|Durvalumab|Extensive Stage Small Cell Lung Cancer Checkpoint Inhibitor (SoC)
223480977|NCT06939036|DRUG|Avelumab|Merkel Cell Carcinoma Checkpoint Inhibitor (SoC)
223480978|NCT06939036|DRUG|Pembrolizumab|Merkel Cell Carcinoma Checkpoint Inhibitor (SoC)
223480979|NCT06939036|DRUG|Retifanlimab|Merkel Cell Carcinoma Checkpoint Inhibitor (SoC)
223480980|NCT06943963|BEHAVIORAL|Self Stigma Tailored Cognitive Behavioral Therapy on Gambling Disorder|"The Self Stigma Tailored Cognitive Behavioral Therapy for Gambling Disorder (SSCBT) is a novel intervention designed specifically for this study and has not been previously used or named in existing literature. This 4-session protocol can be integrated into any part of GD treatment. Each session was accompanied by materials specifically designed for that session's content, and assignments related to the session's topics were given at the end of each session.~Session 1: Gambling Disorder from a bio-psycho-social perspective, stigma and self-stigma, CBT introduction, cognitive-behavioral model of self-stigmatization, impact of emotions and cognitive distortions.~S. 2: Self-stigmatizing thoughts and behaviors, identifying automatic thoughts with cognitive techniques, cognitive awareness, and restructuring with evidence examination.~S. 3: Aligning behaviors with values, cognitive restructuring, behavior change, and self-awareness.~S. 4: Prevention strategies, relapse prevention planning."
223480981|NCT06943963|DRUG|standart pharmacotherapy|All participants continued to receive standard pharmacotherapy from their respective psychiatrists.
223480982|NCT06943963|BEHAVIORAL|motivational intervention|All participants continued to receive the standard motivational interviewing intervention for addiction from their psychiatrist.
223480983|NCT07150884|DIETARY_SUPPLEMENT|Lactase|The lactase drops that will be used in the study will be Delictase®, which is a dietary supplement that helps the proper digestion of lactose through its breakdown. Delictase® lactase drops offer an exogenous source of the lactase enzyme, which is essential for the proper absorption and digestion of lactose, can be administered from birth, mixed into the administered milk and contain high levels of lactase (\>3,000 ALU\*). The supply of Delictase® lactase preparations will be carried out by Galenic Pharmacy, every 2 months at the study site.
223480984|NCT07153913|OTHER|Intensive growth support|For women in the intervention group, we will develop a nutritional plan for the child in collaboration with the mother. Mothers will then receive a visit every other week - during this visit, children's health and nutrition will be discussed, and height and weight will be measured by field officers. Detailed food recommendations will be made based on national and international infant and young child feeding guidelines. To ensure appropriate foods are available, field workers will drop off local foods on a weekly basis.
223480985|NCT07157176|BEHAVIORAL|Daily 3-Minute Laughter Practice (Laughie Prescription)|"The intervention will consist of 3-minutes of laughter (joyful and natural laughter is recommended) per day. Each day participants will laugh for one minute in a group (virtual and/or actual) guided by a professional laughter practitioner who is not going to be involved in the analysis of the data. That laughter will be recorded. The recording (the Laughie) will then be prescribed for participants to laugh with (with others - family, friends, colleagues, or alone) twice a day. This will result in 3 minutes of laughter per day (the first in a group, the second two prompted by the Laughie)"
224168274|NCT01878175|BEHAVIORAL|Functional Movement Retraining|15-week rehabilitation / exercise intervention, including visits at the Durham VA medical center, in-home with clinical personnel, and via telephone. The intervention is tailored to participants' post-operative functional status, particularly unilateral balance asymmetries. The exercise program will focus on three areas: lower extremity mobility (ankle, knee and hip), muscle stability (quadriceps and gluteal muscle strength) and functional movement patterns (lower extremity focus). Participants will be instructed to perform their prescribed stretching exercises daily and strengthening exercises three times per week (on non-consecutive days).
223480986|NCT07156760|DIAGNOSTIC_TEST|Ultrasound diagnostics|Non-invasive ultrasound evaluation of the upper limb on the hemiplegic side (Ekipomed Portable Ultrasound) to determine its pathological morphology (thickness, fiber orientation, and echogenicity) using the modified Heckmatt scale. This procedure will be performed by a physician who is an expert in muscle ultrasound.
224168275|NCT04591873|OTHER|telemedicine|Using telemedicine system to communicate
224168276|NCT04591873|OTHER|traditional communication tools|Use telephone or direct verbal communication
224168277|NCT03102463|DIETARY_SUPPLEMENT|Water Control|120mL water given as a control, followed by a hyperinsulinemic-euglycaemic clamp
224168278|NCT03102463|DIETARY_SUPPLEMENT|Milk derived hydrolysate|Milk derived hydrolysate made up as a milkshake in 120mL water, followed by a hyperinsulinemic-euglycaemic clamp
224168279|NCT03102463|DIETARY_SUPPLEMENT|Parent Protein|Parent protein made up as a milkshake in 120mL water, followed by a hyperinsulinemic-euglycaemic clamp
224168280|NCT03102463|OTHER|Lipid Load|100mL oral lipid load
224168281|NCT04611204|OTHER|Descriptive cohort|NT-proBNP assay, electrocardiogram and transthoracic echocardiography before CTS surgery release. Pathological analysis for amyloid deposits of transverse carpal ligament of patients included.
224168282|NCT01498497|DRUG|EUR-1100|
224168283|NCT01498497|DRUG|Placebo|
224168284|NCT02617199|DRUG|Epidural anesthesia|Epidural anesthesia placed at L1-L2 Epidural infusion of ropivacaine 0.2% + 3-4 mcg/ml fentanyl + saline 0.9% (100 ML) 3-5ml/ hr during 120 hours
224168285|NCT02617199|DRUG|intravenous analgesia|ketorolac 1mg/kg every 8 hours or metamizol 15 mg/kg every 8 hrs and intravenous opioids (buprenorphine 3 mcg / kg or tramadol 1mg/ kg in continuos infusion
224168286|NCT00345956|BIOLOGICAL|Human rotavirus liquid vaccine|
224168287|NCT03523715|DIETARY_SUPPLEMENT|Prunes|12 oz of prunes daily
224168288|NCT03523715|DRUG|Docusate Sodium|Oral docusate sodium twice daily
224168289|NCT01369667|DIETARY_SUPPLEMENT|Vitamin D3|
224168290|NCT01369667|OTHER|Placebo|
224168291|NCT00151528|DRUG|Pregabalin|
224168292|NCT01654328|DRUG|Sodium chloride tablets|sodium chloride 1g/10kg of body weight /day per os on day -2 and -1 before contrast exposure. With a maximum dose of 10 gram sodium chloride a day.
224168293|NCT01654328|DRUG|Isotonic saline intravenously|isotonic saline (Nacl 0.9%) total 1000ml in 4 hrs or (in case of heart failure or severe renal failure) 12 hrs before and in 4 or in 12 hrs after contrast administration.
224168294|NCT02301728|OTHER|sampling of breast milk, obtaining information about the maternal diet|take samples of 3 ml breast milk and 3-days diet diaries
224168295|NCT04430036|DRUG|AGEN1884|A fully human monoclonal Anti-PD-1 Antibody
224168296|NCT04430036|DRUG|AGEN2034|A fully human monoclonal Anti-PD-1 Antibody
224168297|NCT04430036|DRUG|Cisplatin|Alkylating antineoplastic agent
224168298|NCT04430036|DRUG|Gemcitabine|Antimetabolite antineoplastic agent
224168299|NCT03698929|OTHER|Dietary Effect of Cholesterol - Egg Phase|After the study entry, you will be assigned by chance, like the flip of a coin, to one of two groups. You will have an equal chance of being assigned to either group. Each group will be asked to consume baked goods daily. The two groups will consume the same baked goods, but in a different order. Each week, you will be given a week's worth of baked goods.
224168300|NCT03698929|OTHER|Dietary Effect of Cholesterol - Non-Egg Phase|After the study entry, you will be assigned by chance, like the flip of a coin, to one of two groups. You will have an equal chance of being assigned to either group. Each group will be asked to consume baked goods daily. The two groups will consume the same baked goods, but in a different order. Each week, you will be given a week's worth of baked goods.
224168301|NCT05299216|OTHER|Manual Diaphragm Technique|Treatment group will receive Manual Diaphragm Technique in addition to Conventional Physical Therapy. Therapist will make physical contact to the underside of the 7th to 10th rib costal cartilages. During the inspiratory phase, the therapist will use both hands to gently pull the points of contact in the direction of the head. During exhalation, the therapist will maintain resistance. The procedure will be done in two sets of ten deep breaths, separated by a one-minute pause.
224168302|NCT05299216|OTHER|Conventional Physical Therapy|"Conventional Physical Therapy group comprises electrotherapeutic treatment and exercise plan. Subjects will undergo a thermal continuous ultrasound, conventional transcutaneous electrical nerve stimulation and a hot pack.~Stretching activities for the back, iliopsoas, and hamstring muscles, as well as abdominal muscle strengthening exercises, will be included in the workout."
224168303|NCT05299216|OTHER|Sham Diaphragm Manual Technique|The Control group will also receive a sham diaphragm release technique. The therapist and participant will have the same manual contacts, duration, and placement as the treatment group, but the therapist will simply use a light touch with the same anatomical landmarks and will not apply pressure.
224168304|NCT01842334|BEHAVIORAL|Cognitive Behavioral Therapy|CBT administered to to both DCS and placebo group.
224168305|NCT01842334|DRUG|Nicotine Replacement Therapy|NRT administered to both DCS and placebo group.
224168306|NCT00276224|DRUG|ferrous sulphate (drug)|
224168307|NCT02268942|DEVICE|HeartWare HVAD|Implant of HeartWare HVAD via thoracotomy implant technique
224168308|NCT02268942|PROCEDURE|Thoracotomy|Thoracotomy implant technique
223480987|NCT07168252|DRUG|Rocuronium dosing|Rocuronium doses of 0.6ng/kg, 1.2mg/kg, 1.6mg/kg and 2.0 mg/kg will be compared for onset speed of muscle relaxation and information on speed, cardiac output and patient body size entered into a computer model
223480988|NCT07169201|DIAGNOSTIC_TEST|Angiography based RWS and OCT based plaque characteristcis|Angiography based RWS and OCT based plaque characteristcis
223480989|NCT07168265|DRUG|androgen replacement therapy|intramuscular testosterone
223480990|NCT07169019|DRUG|Probiotics and methotrexate|weekly oral methotrexate 15-25 mg/week, along with an oral daily dose of probiotics.
223480991|NCT07169019|DRUG|Methotrexate|weekly oral methotrexate 15-25 mg/week
223480992|NCT07169383|DRUG|Melatonin tablet|Group A will receive oral melatonin 5mg every night for 3 months
223480993|NCT07169383|DRUG|Tranexamic Acid (TXA)|Group B will receive oral tranexamic acid 250mg twice daily for 3 months.
223480994|NCT07169253|OTHER|GAP Index|For each patient in the IPF, fibrotic HP, and non-fibrotic HP groups, the GAP index was calculated based on age, gender, FVC, and DLCO values. According to the GAP index, patients were classified as Stage 1 (0-3 points), Stage 2 (4-5 points), and Stage 3 (6-8 points).
224168309|NCT01688479|DRUG|Calendula Weleda cream (Weleda AG, Sweden) contains extracts of marigold plant (Calendula Officinalis 10%), wool fat and sesame oil|
224168310|NCT01688479|DRUG|Essex® cream (Schering-Plough), aqueous cream without parabens|
224168311|NCT02347202|OTHER|Online counseling via Zoom teleconferencing|
224168312|NCT02347202|OTHER|Telephone support as needed|
224168313|NCT04787263|BIOLOGICAL|CD19-CAR_Lenti T cell|Fresh peripheral blood mononuclear cells are manufactured to obtain CD19-CAR\_Lenti T cell, second generation CAR T cells incorporating the 4-1BB costimulatory domain. The fresh product is infused following lymphodepletion chemotherapy at a dose of 1.0-3.0x10\^6 CAR+ cells/kg.
224168314|NCT06116474|BEHAVIORAL|Web-Based Physical Fitness Intervention|The exercise program has been designed according to the progressive overload method. Therefore, the volume of the exercise program increased as the weeks progressed. Exercise videos were uploaded to YouTube on Mondays, Wednesdays and Fridays send to participants via a message group to follow the program. The videos featured the experts' explanations of the movements for each exercise.. The equipment that the participants should use in the training sessions was selected from the materials available at home (eg., use of water bottles instead of weight dumbbells). The exercise sessions is divided into 3 parts: warm-up (2-4 min. average), main part (14-19 min. average), cool-down (3-5 min. average). The warm-up includes movements to increase the heart rate and warm up the muscles to be worked on for that session. The main part of the exercise program also included rest breaks when the participants were asked to move and stretch.
224168315|NCT04272814|OTHER|Compression therapy|Compression application
224168316|NCT04272814|DIAGNOSTIC_TEST|initial clinical assessment|Initial clinical assessment (includes history, vascular assessment, limb examination and wound assessment where necessary)
223480995|NCT07169253|OTHER|ILD-GAP Index|In addition to the GAP parameters, the index was calculated to include the ILD subtype as well.
223480996|NCT07169253|OTHER|Composite Physiologic Index (CPI)|"The CPI (Composite Physiologic Index) was calculated using the following formula:~CPI = 91 - (0.65 × %DLCO) - (0.53 × %FVC) + (0.34 × %FEV1).~DLCO: Diffusing Capacity of the Lung for Carbon Monoxide FVC: Forced Vital Capacity FEV₁: Forced Expiratory Volume in One Second"
223480997|NCT07167849|BEHAVIORAL|UKADO Content - problem-focused|UKADO is a digital ultra-brief intervention intended to reduce symptoms of depressive disorders and anxiety disorders. Content is either problem-focused or resource-focused. This version is problem-focused
223480998|NCT07167849|BEHAVIORAL|UKADO Content - resource-focused|UKADO is a digital ultra-brief intervention intended to reduce symptoms of depressive disorders and anxiety disorders. Content is either problem-focused or resource-focused. This version is resource-focused.
223480999|NCT07167849|BEHAVIORAL|Human support|Human support is provided as two weeks of guidance for study participants
224168317|NCT06066190|OTHER|Web-Based Training on ERAS Protocols Applied in Gynecological and Obstetric Surgery|Web-Based Training will be given to Midwives and Nurses on ERAS Protocols Applied in Gynecological and Obstetric Surgery. The training will last 6 weeks and they will be asked to watch a training video every week.
224168318|NCT03814460|DIAGNOSTIC_TEST|Assessment of Tone, Pain and Thickness|Evaluation of Muscle state of tension, self-reported response to mechanical pressure pain and muscle thickness. The evaluation process of muscle tone and pressure pain sensitivity will be carried out following a topographical mapping covering myotendinous and muscle belly sites in the biceps brachii and the gastrocnemius muscles
224168319|NCT05467072|DEVICE|Annular closure|Lumbar discectomy patients treated with Annular Closure Device BARRICAID
224168320|NCT03583112|DRUG|Dapoxetine Hydrochloride Tablet|oral one dapoxetine hydrochloride tablet before MRI scan
223481000|NCT07167849|BEHAVIORAL|Expectation fostering elements|Patient in the expectation-fostering condition receive elements in UKADO that are meant to foster expectations.
224168321|NCT03583112|DRUG|Placebo Tablet|oral one placebo tablet before MRI scan.
224168322|NCT05801172|PROCEDURE|ketoprofen for pain relief in office hysteroscopy|ketoprofen ketoprofen 100 mg intravenously 30 minutes pre-procedure for pain relief in office hysteroscopy
224168323|NCT05801172|PROCEDURE|ketoprofen plus infiltration anesthesia with lidocaine for pain relief in office hysteroscopy|ketoprofen ketoprofen 100 mg intravenously 30 minutes pre-procedure for pain relief in office hysteroscopy plus 20 ml 1% lidocaine in intracervical administration at the start of the procedure
224168324|NCT05801172|PROCEDURE|ketoprofen plus paracervical block anesthesia with lidocaine for pain relief in office hysteroscopy|ketoprofen ketoprofen 100 mg intravenously 30 minutes pre-procedure for pain relief in office hysteroscopy plus 20 ml 1% lidocaine in paracervical block at the start of the procedure
224168325|NCT03712995|PROCEDURE|'Cutler-Beard modified with graft'|A tarsoconjunctival graft was harvested from the contralateral upper eyelid, with an extra 3 mm of conjunctiva from the superior edge of tarsus and was attached to the upper eyelid defect, differently than previously described.
224168326|NCT05790902|DRUG|Silodosin|The patients used Silodosin for Medical expulsive therapy of ureteric calculi
223481001|NCT07169487|DRUG|Methylene Blue|Intravenous infusion of methylene blue once daily for 3-5 consecutive days at doses of 1 mg/kg, 2 mg/kg, or 3 mg/kg, administered over 20 minutes, following CAR-T or bispecific antibody infusion in patients who develop Grade ≥1 CRS or ICANS.
223481002|NCT07166926|DEVICE|Mobile CT|SOMATOM On.site
223481003|NCT07167511|OTHER|This study is a retrospective study, and all data have been collected in advance with no active intervention required.|This study is a retrospective study, and all data have been collected in advance with no active intervention required.
223481004|NCT07167771|OTHER|No intervention|There is not intervention in these patients, appart from their normal dental check-up visits.
223481005|NCT07169474|PROCEDURE|Isolated trapeziometacarpal arthroplasty with double mobility|Isolated trapeziometacarpal arthroplasty with double mobility in all cases, using a MAIA or TOUCH prosthesis depending on the operator's habits.
224168327|NCT05790902|DRUG|Tamsulosin|The patients used Tamsulosin for Medical expulsive therapy of ureteric calculi
223481006|NCT07167160|DRUG|Camrelizumab combined with chemotherapy|Camrelizumab combined with chemotherapy for adjuvant treatment of patients with pathologically confirmed lymph node-positive cervical cancer after staging surgery
223584916|NCT06979791|DRUG|Dexmedetomidine + Midazolam 0.4 mg/kg|Participants in this arm will receive intranasal dexmedetomidine at a dose of 2 mcg/kg combined with intranasal midazolam at a dose of 0.4 mg/kg, administered 30 minutes before the induction of general anesthesia.
223584917|NCT06979791|DRUG|Dexmedetomidine + Midazolam 0.2 mg/kg|Participants in this arm will receive intranasal dexmedetomidine at a dose of 2 mcg/kg combined with intranasal midazolam at a dose of 0.2 mg/kg, administered 30 minutes before the induction of general anesthesia.
223584918|NCT06981260|PROCEDURE|Group A Deactivated TENS with beeping sound (15-second interval)|Deactivated TENS with beeping sound (15-second interval)
223584919|NCT06981260|PROCEDURE|Group B|Deactivated TENS without sound
224072100|NCT03217838|DRUG|Venetoclax|Venetoclax (VENCLEXTA®) is approved by the FDA for use in combination with azacitidine, or decitabine, or low-dose cytarabine for the treatment of newly-diagnosed AML in adults who are age 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy. Venetoclax is planned to be given at a dose of 100 mg orally (PO) on Day 1 and 200 mg (PO) on Days 2- 28 of each 28-day cycle or 100 mg orally (PO) on Day 1, 200 mg PO on Day 2, and 400 mg PO from Days 3 to 28 of each 28-day cycle. The third participant in Group 3 Arm A will only be enrolled after the first 2 participants will receive ≥2 weeks of treatment and have shown no evidence of toxicity observed to be compatible with a DLT.
224072101|NCT04577443|DRUG|Adenosine|To investigate the role of adenosine on cerebral hemodynamic and headache in healthy volunteers and migraine patients
224072102|NCT04577443|DRUG|Saline|To investigate the role of saline on cerebral hemodynamic and headache in healthy volunteers and migraine patients
224072103|NCT06128460|DRUG|Zimberelimab|240mg, q3w，8 cycles
224168328|NCT01236131|OTHER|no intervention|Not Applicable- no intervention
224168329|NCT03873259|DEVICE|Burst Wave Lithotripsy|Fragment upper urinary tract stones
224168330|NCT05581927|DEVICE|modified Whole-Body Hypothermia|patients were allocated to modified Whole-Body Hypothermia with normal base excess and blood pressure
224168331|NCT05581927|DEVICE|standard Whole-Body Hypothermia|patients were allocated to standard Whole-Body Hypothermia
224168332|NCT06612008|DEVICE|Mandibular Advancement Device|MADs are custom-fitted oral appliances designed to reposition the mandible (lower jaw) forward during sleep, which helps to keep the airway open by preventing upper airway collapse.
224168333|NCT04937608|DIAGNOSTIC_TEST|Sperm analysis|Routine sperm analysis including analysis of sperm concentration, motility, vitality and morphology. Sperm DNA integrity will also be assessed.
224168334|NCT02201251|DRUG|Topiramate|Topiramate weight based dosing for participants 2 to \<10 years of age not to exceed 350 mg/day, as tolerated; not to exceed 400 mg/day in participants 10-15 years of age, as tolerated.
224168335|NCT02201251|DRUG|Levetiracetam|Levetiracetam weight based dosing for all participants 2-15 years of age, not to exceed 60 mg/kg/day, as tolerated. The maximum recommended daily dosage is 3,000 mg.
223481007|NCT07168759|OTHER|VR game -based education program|The schoolchildren in the intervention group participate in an innovative VR game-based educational programme featuring: (1) Web-based health education on (i) SARS-CoV-2 and Influenza virus transmission, (ii) proper hand and respiratory hygiene practices and (iii) the importance of rapid screening and vaccination in the prevention of upper respiratory tract infections.
223481008|NCT03549026|DRUG|Duloxetine|The investigator will give the patients duloxetine capsule 60 mg orally before operation (skin incision) and anesthetize them with general anesthesia, then the investigator will test the postoperative analgesic efficacy in the form of 24 h analgesic consumption
223481009|NCT03549026|DRUG|placebo|Patients will receive single oral dose of placebo capsule, 2 hours before operation and will be anesthetized with general anesthesia that includes, Induction of anesthesia will be done by intravenous fentanyl, 2 µg / kg and propofol 1 - 2 mg / kg. Endotracheal intubation will be achieved by cis-atracurium, 0.15 mg / kg. Maintenance of anesthesia will be done by isoflurane and cis-atracurium, 0.03 mg / kg on demand. Additional intraoperative analgesia will be consisted of administration of intravenous boluses of fentanyl, 50 µg according to the attending anesthesiologist's decision. At the end of surgery, muscle relaxation was reversed using neostigmine 0.05 mg / kg and atropine 0.01 mg / kg
223481010|NCT04262349|BEHAVIORAL|sleep education|As a training program to increase sleep, pregnant women will be given 2 training sessions per week for two weeks and four sessions in total for 60 minutes.
223481011|NCT01799889|DRUG|Entospletinib MM|Entospletinib MM tablet administered orally
223481012|NCT01799889|DRUG|Entospletinib SDD|Entospletinib SDD tablet administered orally
223481013|NCT01636843|DRUG|NNC0109-0012|Administered subcutaneously (s.c., under the skin), once weekly.
223481014|NCT01636843|DRUG|placebo|Administered subcutaneously (s.c., under the skin), once weekly.
223584920|NCT06980194|DIAGNOSTIC_TEST|99mTc-4BOH SPECT myocardial perfusion imaging|Participants undergo myocardial perfusion imaging using the investigational radiotracer 99mTc-4BOH with SPECT. Imaging is performed according to a standardized protocol. Each participant receives both this SPECT imaging and a PET imaging procedure using 13N-ammonia, in a randomized sequence, within a 7-day interval.
223584921|NCT06980194|DIAGNOSTIC_TEST|13N-ammonia PET myocardial perfusion imaging|Participants undergo myocardial perfusion imaging using 13N-ammonia with PET as the active comparator. This procedure is performed according to standard clinical protocols. Each participant also receives 99mTc-4BOH SPECT imaging in a randomized sequence, with both tests completed within a 7-day window.
223584922|NCT06979648|DIETARY_SUPPLEMENT|Qualia Magnesium+®|Qualia Magnesium+® manufactured by Qualia Life Sciences
223584923|NCT06979648|DIETARY_SUPPLEMENT|Placebo|Rice Flour
223584924|NCT06981091|OTHER|XH-S004 20 mg|Administered once per day for 24 weeks.
223584925|NCT06981091|OTHER|XH-S004 40 mg|Administered once per day for 24 weeks.
223584926|NCT06981091|OTHER|Placebo|Administered once per day for 24 weeks.
224168336|NCT06989463|OTHER|12 Week Exercise Intervention|Participants will be provided with the results of their physical functioning and fitness assessments and will receive an individually tailored exercise prescription, written by an exercise specialist and approved by the study physician. The prescription will include aerobic and strengthening components designed to progress persons gradually to 150-300 minutes of the equivalent of moderate aerobic activity and twice weekly strengthening106 over 12 weeks.
223584927|NCT06979960|BEHAVIORAL|cancer screening education|It will be carried out to examine the effect of the educational intervention given using the cancer screening training booklet on women's knowledge, attitude and shyness levels.
223584928|NCT06575400|DRUG|BI 3804379|BI 3804379
223584929|NCT06575400|DRUG|Placebo matching BI 3804379|Placebo matching BI 3804379
223584930|NCT06981468|DIETARY_SUPPLEMENT|Low Sodium Beverage 1|The first interventional product for this study is a low-sodium beverage containing Dose 1 of glycerol, whey protein, and water. It will come in a ready to drink format for the participants.
223481015|NCT05105256|DRUG|Prednisolone|Patient will have 1 infiltration of 3mL to 5 mL corticosteroids on average distributed equally over all the posterior joints affected by arthritis phenomena.Lumbar facet joint injection with corticosteroids will be performed at inclusion
223481016|NCT05105256|DRUG|Platelet-rich plasma|Patient will have 1 infiltration of 3mL to 5 mL of PRP on average distributed equally over all the posterior joints affected by arthritis phenomena.Lumbar facet joint injection with PRP will be performed at inclusion.
223481017|NCT01889381|DRUG|Bone marrow cell-based therapy & 1-drug immunosuppression.|This protocol uses a novel bone marrow cell-based therapy for composite tissue allotransplantation (CTA) rather than conventional triple-drug immunosuppression to facilitate long-term graft survival of deceased donor human faces under low-dose maintenance immunosuppression. Initial T-cell depletion with alemtuzumab is followed by upper extremity transplantation and tacrolimus maintenance therapy. Donor bone marrow cells are infused on Day 10 (±4 days) post-transplantation to elicit a host alloimmune response triggering exhaustion and deletion of the respective host (anti-donor) lymphocyte clones. Subsequently, tacrolimus therapy is given for at least 6 months before spaced weaning is considered in stable recipients.
223481018|NCT00890162|DRUG|Epinephrine|
223584931|NCT06981468|DIETARY_SUPPLEMENT|Low Sodium Beverage 2|The second interventional product for this study is a low-sodium beverage containing dose 2 of glycerol, whey protein, and water. It will come in a ready to drink format for the participants.
223584932|NCT06981468|OTHER|Control (placebo) group|Water
224072104|NCT06128460|DRUG|Platinum|cisplatin 40mg/m2 for 5-6 cycles
224072105|NCT06128460|RADIATION|radiotherapy|45-50Gy/1.8Gy/25-28f
224072106|NCT04673786|BIOLOGICAL|CT-P43|45mg or 90mg dose subcutaneous administration
224072107|NCT04673786|BIOLOGICAL|Stelara|45mg or 90mg dose subcutaneous administration
224072108|NCT04099303|BIOLOGICAL|Diphtheria,Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed|0.5 mL, Intramuscular Other Name: DTcP
224072109|NCT04099303|BIOLOGICAL|Diphtheria and Tetanus Combined Vaccine, Adsorbed|2mL, Intramuscular Other Name: DT
224072110|NCT04099303|BIOLOGICAL|Diphtheria-tetanus-acellular pertussis vaccine|0.5 mL, Intramuscular Other Name: DTaP
224072111|NCT04099303|BIOLOGICAL|Diphtheria,tetanus,pertussis(acellular,component),poliomyelitis(inactivated) vaccine(absorbed) and Haemophilus influenzae type b conjugate vaccine|0.5 mL, Intramuscular Other Name: PENTAXIM
223481019|NCT00890162|DRUG|Omalizumab (Xolair)|
223481020|NCT00890162|DRUG|Placebos|
223481021|NCT01176175|DRUG|Progesterone|Progesterone microspheres injectable suspension 50 mg, intramuscular weekly injection for a total of 7 doses.
223481022|NCT01176175|DRUG|Progesterone|Progesterone microspheres injectable suspension 100 mg, intramuscular weekly injection for a total of 7 doses.
223481023|NCT01176175|DRUG|Progesterone|Progesterone microspheres injectable suspension 200 mg, intramuscular weekly injection for a total of 7 doses.
223481024|NCT01176175|DRUG|Progesterone|Progesterone microspheres injectable suspension 300 mg, intramuscular weekly injection for a total of 7 doses.
223481025|NCT04896775|BEHAVIORAL|NiteCAPP CARES|Web-based intervention that will include 4 weekly sessions and 4 bimonthly boosters. Each session is to be completed individually by CG (with PWD to extent able) in a single sitting (less than 45 mins). Each session should be completed in 7 days with next session released only after prior one completed. Session 1 focuses on sleep education, sleep hygiene, and stimulus control. Session 2 focuses on sleep compression, relaxation, and problem solving. Session 3 focuses on coping and stress management and cognitive therapy. Session 4 focuses on a review of skills and plan for maintenance of behavior change.
223481026|NCT04896775|BEHAVIORAL|NiteCAPP SHARES|Web-based intervention that will include 4 weekly sessions and 4 bimonthly boosters. Each session is to be completed individually by CG (with PWD to extent able) in a single sitting (less than 45 mins). Each session should be completed in 7 days with next session released only after prior one completed. Session 1 focuses on expanded sleep education and sleep hygiene. Session 2 focuses insomnia education and sleep hygiene support. Session 3 focuses on targeted sleep education and sleep in dementia. Session 4 focuses on a review of skills and plan for maintenance of behavior change. Boosters review skills, encourage practice, and troubleshoot issues.
223481027|NCT01237730|DRUG|cefuroxime|Use the cefuroxime as prophylaxis.
223481028|NCT01237730|DRUG|Tailored antibiotic|Select the prophylactic antibiotics according to the patients oropharyngeal microorganism.
223481029|NCT02939391|DRUG|KW-6356|Oral administration
223481030|NCT02939391|DRUG|KW-6356|Oral administration
223481031|NCT02939391|DRUG|Placebo|Oral administration
223481032|NCT03628326|OTHER|Pulmonary arterial tree|The investigators performed 3D reconstruction of the pulmonary arterial tree on the CT angiography data set acquired during preoperative work-up.
223481033|NCT01544881|DRUG|Technosphere Insulin Inhalation Powder|Inhalation Powder using the Gen2C inhaler
223481034|NCT01544881|DRUG|Rapid Acting Analog|Subcutaneous Injection
223481035|NCT02196103|DEVICE|Double balloon cervical catheter|
223481036|NCT00070434|DRUG|capecitabine|825mg/m2 BID, PO, daily
223481037|NCT00070434|DRUG|fluorouracil|Bolus + IV for 46 hrs on Day 1
223481038|NCT00070434|DRUG|irinotecan hydrochloride|IV infusion over 90 min on Day 1
223481039|NCT00070434|DRUG|leucovorin calcium|200mg/m2 IV 2 hour infusion on Day 1
223481040|NCT00070434|DRUG|oxaliplatin|85mg/m2 IV infusion for 90minutes on Day 1
223481041|NCT00070434|RADIATION|radiation therapy|Original Planning Target Volume (PTV1): The total dose to the prescription point shall be 4500 cGy in 25 fractions (Monday - Friday inclusive). Boost Planning Target Volume (PTV2): The cumulative dose within the boost volume to the prescription point shall be 5,040 - 5,400 cGy (per Section 7.5b). Daily Dose: The daily dose to the prescription point of the original and boost volumes shall be 180 cGy. Fractionation: Treatment shall be given 5 days/week. All radiation fields shall be treated once daily.
223481042|NCT00070434|DRUG|Pyridoxine|50mg TID, PO daily
223481043|NCT06478212|DRUG|Vorasidenib|To be taken by mouth once daily in 28-day cycles with no break between cycles
223481044|NCT06478212|DRUG|Temozolomide (TMZ)|To be taken by mouth once daily for the first 5 days of each 28-day cycle, for a maximum of 12 cycles
223481045|NCT04804644|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223481046|NCT04804644|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223481047|NCT04804644|DRUG|Memantine Hydrochloride|Given PO
223481048|NCT04804644|OTHER|Neurocognitive Assessment|Ancillary studies
223481049|NCT04804644|RADIATION|Stereotactic Radiosurgery|Undergo SRS
223617563|NCT03526744|DIETARY_SUPPLEMENT|marine protein hydrolysate 1234|"Dietary Supplement for e.g. in this order: MPH 1600 mg for 7 days, than 7 days wash-out. Dietary Supplement: MPH 800 mg for 7 days, than 7 days wash-out. Dietary Supplement: MPH 2400 mg for 7 days, than 7 days wash-out. Dietary Supplement: MPH 3200 mg for 7 days, than 7 days wash-out."
223481050|NCT04804644|OTHER|Survey Administration|Ancillary studies
223481051|NCT04804644|RADIATION|Whole-Brain Radiotherapy|Undergo HA-WBRT
223481052|NCT01446185|DEVICE|Oncotype DX breast cancer test|The Oncotype DX breast cancer test measures the expression of 21 genes of an individual tumor to generate an Recurrence Score result that quantifies the magnitude of chemotherapy benefit and the likelihood of recurrence for early-stage breast cancer patients.
223481053|NCT05666024|OTHER||Prospective observational study
223481054|NCT05049005|BEHAVIORAL|Simplified dietary tracking|Mobile-delivered nutrition program using simplified dietary monitoring with a focus on weight loss.
223481055|NCT03705325|DEVICE|Spirobank Smart spirometer|The spirometer is a compact, portable, home-based spirometer that pairs with a smartphone app. Exhaled air flow causes the turbine to rotate, generating a voltage analogous to the rate of air flow across the turbine. The spirometer measures Forced expiratory volume in 1 second (FEV1), or the volume of air that is exhaled in the first second. The device prompts the user to perform a minimum of three expiratory maneuvers in and records the best of the three maneuvers. The information generated is then transmitted to the VitalFlo App (password protected) on the user's iPhone. The user is alerted, by the App, if their expiratory effort is inadequate (such as early termination of exhalation) and is provided coaching for proper technique.
223481056|NCT01528085|DRUG|Nilotinib|Nilotinib, p.o Chemotherapy (Dexamethasone, Methotroxate, Cyclophosphamide (optional), Vincristine, Vindesine, Cytarabine, 6-Mercapto-Purine)
223481057|NCT00478621|BIOLOGICAL|GSK Biologicals' HPV vaccine (GSK1674330A)|Intramuscular administration, 5 different formulations
223481058|NCT00478621|BIOLOGICAL|Cervarix TM|Intramuscular administration
223481059|NCT00090532|DRUG|AG-013,958|
223481060|NCT00113165|DRUG|LAMICTAL extended-release|
224168337|NCT06989463|OTHER|Cognitive Training Intervention|"Participants will complete cognitive training with Lumosity (Lumos Labs, Inc.; San Francisco, California; cognitive training program). This computer-based training consists of games focused on specific executive function skills (shifting attention, working memory, verbal fluency, problem solving). Each 20-minute session includes five games focused specifically on these executive functioning skills.~Participants will be prescribed three 20-minute sessions each week for 12-weeks."
224168338|NCT06989463|OTHER|Mindfulness practice intervention|"The mindfulness practice intervention is a modified version of the University of California at Los Angeles Mindfulness Awareness Research Center's Mindful Awareness Practices designated to be remotely delivered.~during odd weeks, participants will watch the educational lecture video once and practice meditation daily. During even weeks, they will review the educational video as needed and continue daily meditation practice."
224168339|NCT01497002|DRUG|Cytarabine|Induction chemotherapy (1 or 2 courses): AraC 100 mg/m²/day i.v. 24h-infusion day 1-7 and Daunorubicin 60 mg/m² day 3+4+5. Consolidation chemotherapy (2 courses): AraC 1 g/m² i.v. 3h-infusion a 12h day 1+3+5.
224168340|NCT01497002|BIOLOGICAL|human stem cells|Induction chemotherapy (1 or 2 courses): AraC 1 g/m² i.v. 3h-infusion a 12h day 1+3+5+7, Mitoxantrone 10 mg/m² day 1-3 and Pegfilgrastim 6 mg s.c. day 10. Consolidation chemotherapy (1 course): AraC 500 mg/m² i.v. 1h-infusion a 12h day 1+3+5, Mitoxantrone 10 mg/m² day 1+2 and Pegfilgrastim 6 mg s.c. day 8. Allogeneic stem cell transplantation using reduced intensity conditioning: Fludarabine 30 mg/m² day -4 - -2, TBI 200 cGy day 0; GvHD prophylaxis: cyclosporine A and mofetil mycofenolate
224168341|NCT03592589|DEVICE|high flow nasal canula|high flow nasal canula to obtain a positive expiratory pressure
224305394|NCT05203718|BEHAVIORAL|Food Response Training (FRT)|All patients will complete the 12-week FRT intervention consisting of one in-person session (during the baseline visit) and three weekly sessions at home, one delivered via video conference (WebEx) and two self-guided. Food Response Training (FRT) is a computer-based attention bias modification intervention. The intervention will be delivered on a computer or smart device (e.g. iPhone). Patients will use the FoodTrainer application available for Android and iPhone (https://www.exeter.ac.uk/foodt/about/).
223481061|NCT06958042|OTHER|Questionnaire and Physical Exam|\- St George Respiratory Questionnaire (SGRQ): The SGRQ developed by Jones (2000), which is used specifically for respiratory diseases, consists of 50 questions. In the questionnaire, there are three categories in which symptom, activity and the effect of the disease on quality of life are questioned and each category is evaluated within itself and there is an evaluation scale between 0-100 points. In the evaluation, high scores indicate an inadequate and low quality of life.
223481062|NCT05220423|OTHER|sms and emails reminders|6 reminders encouraging influenza vaccination on top of the National annual communication campaign organized by the French Health System authorities
223481063|NCT05220423|OTHER|No reminders|no reminders on top of the National annual communication campaign organized by the French Health System authorities
223481064|NCT01467752|PROCEDURE|MCP joint|reconstruction of metacarpophalangeal (MCP) joint using a bone graft
223481065|NCT02071537|DRUG|Chloroquine|Dose is 50, 100, 150, and 200 mg per day cohorts. It is given one week prior to the initiation of chemotherapy and then given for four 21 day cycles in combination with chemotherapy.
223481066|NCT02071537|DRUG|Carboplatin|Administered day 1 of each 21 day cycle for 4-6 cycles.
223481067|NCT02071537|DRUG|Gemcitabine|Administered days 1 and 8 of each 21 day cycle for 4-6 cycles.
223481068|NCT01923558|DRUG|Donepezil|Donepezil Hydrochloride tablets,23 mg
223481069|NCT04763967|DEVICE|PedSCath Pediatric Urinary Catheter|PedSCath Pediatric Sampling Catheter is a pediatric sampling catheter. The product is supplied as a catheter and syringe. PedSCath Pediatric Sampling Catheter is manufactured by Medical Murray Inc. for Big Blue Biotech. The device consists of a blend of LDPE/Elvax/Crodamide.
223481070|NCT04763967|DEVICE|Standard of Care|Current Standard of Care for pediatric patients
223481071|NCT00219609|DRUG|UK-390,957|
223481072|NCT05151185|OTHER|Case Management Service Program|The dementia case manager in experiment group will undergo training (Competency-based Dementia Case Management Train-the-trainer Program; CDCMTP); The family caregiver in experiment group will receive competency-based Dementia Case Management Service Program: Needs Assessment, Intervention, evaluation and follow up, etc. The case management program is provided by a trained case manager in a dementia clinic, as well as telephone consultations and follow-up are provided.
223481073|NCT01469871|DEVICE|Dressing of wound|The wound will be dressed using the Hypafix Transparent dressing after hip surgery.
223481074|NCT01469871|DEVICE|Dressing of wound|The wound will be dressed using the Mepore Pro dressing after hip surgery.
223481075|NCT01469871|DEVICE|Dressing of wound|The wound will be dressed using the Mepilex Border dressing after hip surgery.
223481076|NCT02144909|BEHAVIORAL|Partners in Care with Semi-Structured Support Group|
223481077|NCT03821129|DEVICE|PFO closure with GORE® CARDIOFORM Septal Occluder|PFO closure with GORE® CARDIOFORM Septal Occluder in patients with ischemic stroke
223481078|NCT01082471|DRUG|Morphine 6-glucuronide|
223481079|NCT01082471|DRUG|Morphine|
223481080|NCT01242319|BEHAVIORAL|HeartAge intervention|Computerized kiosk in waiting room with HeartAge risk calculator, PDA based decision support tool regarding hyperlipidemia management, website and tool box with coronary risk reduction tools for smoking cessation, diet and exercise, medication adherence
223481081|NCT04065308|DRUG|Drug Combinations|"Daratumumab plus DCEP,combination therapy is administered total of three cycles,every 4weeks(28 days).~Daratumuamb 16mg/kg body weight in 500mL (the first dose,16mg/kg body weight in 1000mL) Weeks 1 to 8: weekly Weeks 9-24 : every 2 weeks if ASCT ineligible or PR but Plasmacytoma response \<CR: every 2 weeks for 12weeks and then every 4 weeks for 8weeks (Total of 8 times, additional administration of daratumumab) if ASCT eligible: From 6 to 12 weeks after ASCT, administration of daratumumab is initiated within 12 weeks of ASCT and twice a month for 12 weeks and then every a months for 8 weeks. (Total of 8 additional administration of daratumumab after ASCT)~1. dexamethasone :40mg/day D1-4, intravenous~2. cyclophosphamide: 400mg/m2 D1-4, intravenous~3. etoposide: 40mg/m2 D1-4, intravenous~4. cisplatin : 7mg/m2 D1-4, intravenous Pegteograstim: 6mg once, SC on day 5 or 6 of each 28-day cycle"
223481082|NCT03328065|OTHER|Interviews|Semi-directed interviews, recorded and transcribed for analysis
223481083|NCT03328065|OTHER|Questionnaires|economic and psycho-social questionnaires
223584933|NCT06980662|OTHER|laughter yoga|Laughter yoga is a type of complementary therapy that also includes some other components, including light physical exercises. This type of therapy combines unconditional laughter with yoga breathing exercises and yoga stretching positions, enabling patients to laugh in a different way from jokes or humour programmes. Laughter yoga steps; Warm-up exercises (5-10 minutes), Deep breathing exercises (10 minutes), Childish games (10 minutes), Laughter exercises (15 minutes). During laughter yoga, laughter is achieved without any jokes, comedy or humour and supports the realisation of a sincere laughter that does not involve cognitive thinking in individuals. Laughter yoga sessions should be done at home in a quiet and calm environment by making eye contact. Laughter yoga is applied in sessions that include warm-up, breathing and laughing exercises accompanied by applause and songs. The sessions take place in groups and last 45 minutes.
223584934|NCT06187987|DEVICE|Mechanical thrombectomy|Aspirational mechanical thrombectomy
223584935|NCT06187987|DRUG|Intravenous thrombolysis|Intravenous thrombolysis with tissue-type plasminogen activator (tPA)
223584936|NCT06979895|OTHER|Multi-gene methylation testing|Undergo multi-gene methylation testing in blood during follow-up
223584937|NCT06979895|OTHER|Multi-gene methylation testing|Undergo multi-gene methylation testing in blood during follow-up
223584938|NCT06980870|DRUG|Anti-inflammatory drug (ibuprofen)|Effect of pre-medication with anti-inflammatory drugs(ibuprofen and dexamethasone)on Post-Endodontic pain
223584939|NCT06980870|DRUG|Anti-inflammatory drug (dexamethsaone)|Effect of pre-medication with anti-inflammatory drugs(ibuprofen and dexamethasone)on Post-Endodontic pain
223584940|NCT06980753|DEVICE|Participants will use the biossensor for 48 h|Participants will use the biossensor for 48 h
223584941|NCT04908280|DRUG|Ruxolitinib|1.5% cream; Ruxolitinib cream will be applied topically twice daily to areas with active lesions.
223584942|NCT06980532|DRUG|Glumetinib Combined with Fruquintinib|"Fruquintinib: 3mg, po.qd, d1-14，q3w;~Guemitinib:~Grade 1:200mg, po, qd, q3w; Grade 2:250mg, po, qd, q3w; Phase I: The dose of Glumetinib (200 mg → 250 mg) is dynamically adjusted using the 3+3 dose-escalation rule to determine the optimal dose of Fruquintinib.~Phase II: The RP2D (Recommended Phase II Dose) of Glumetinib identified in Phase I is continued in combination with Fruquintinib."
223584943|NCT06675630|BEHAVIORAL|Education|Consumers will receive monthly targeted educational materials on fibre
223584944|NCT06675630|BEHAVIORAL|Control|Consumers will receive educational materials on healthy eating at two timepoints
223584945|NCT02759536|RADIATION|Boronophenylalanine and IHNI-based BNCT|Patients will be infused Boronophenylalanine (BPA)-fructose solution intravenously at a dose of 350mg/kg over 90 minutes. After BPA infusion, patients will receive neutron irradiation in IHNI for a certain period of time based on his boron bio-distribution curve and BPA concentration in the blood.
223584946|NCT06675513|BIOLOGICAL|An armored GCC targeting WD-01 CAR-T to treat cancer patients Other Name:|"Autologous WD-01 CAR-T therapy with Wondercel's Warrior armor strategy will be explored for its advantage over other armor platforms."
223584947|NCT06621407|PROCEDURE|24 hours active subperiostal drainage|24 hours active subperiostal drainage after single burr hole evacuation of a chronic subdural hematoma
223584948|NCT06621407|PROCEDURE|24 hours passive subdural drainage|24 hours passive subdural drainage after single burr hole evacuation of a chronic subdural hematoma
223584949|NCT06600867|DIAGNOSTIC_TEST|Tooth mobility assessment|The examiner, holding the instruments (two clinical mirror handles), will apply labial/lingual or labial/palatal displacement movements using the subjective technique, just as routinely done. Using the endodontic spacer and the stop, the deflection will be measured in millimeters. Subsequently, the examiner, with the instruments in hand (tensiometer and dynamometer), will apply labial/lingual and labial/palatal displacement movements, determining the force required to achieve the same displacement previously established by the subjective method (reference/limit of displacement).
224168342|NCT05393570|BEHAVIORAL|Healthy Lifestyle Behavioral Intervention (MBS -supported intervention)|After patient/parent consent is completed, participants will begin the pre-MBS intervention phase. A minimum of 6 1- hour sessions will occur pre-MBS, and 26 will occur post-MBS.Dr. Klement, MBS coordinator and a diabetes educator will manage session delivery to adolescents/parents. All content will follow the Diabetes Prevention Program (DPP)-adapted curriculum flow. After that the research assistant will perform outreach, reminder calls, and follow-up for missed appointments. Pre-and post-MBS intervention delivery (based on adapted curriculum/model) may consist of a combination of 1-on-1 and group sessions (in-person or virtually), and online support tools, dependent upon adolescent/parent qualitative feedback on delivery method preference.
224168343|NCT06614361|BEHAVIORAL|Health education on COVID and flu vaccination|1 session (30 min) with a health educator on vaccination
224168344|NCT06614361|BEHAVIORAL|Nurse-led shared decision-making|1 session and FU calls with a trained nurse
223584950|NCT03957941|BEHAVIORAL|FamilyLink Pumping|Viewing baby via FamilyLink while pumping
223584951|NCT03957941|BEHAVIORAL|Standard Pumping|Not viewing baby via FamilyLink while pumping
223584952|NCT07033247|DEVICE|EDDY Sonic Activation System|EDDY is a sonic irrigation activation system operating at 6,000 Hz frequency with a flexible polyamide tip (25/04). In endodontic procedures, the EDDY tip is inserted 2 mm short of the working length into the root canal and activated for 20 seconds in three consecutive cycles. The sonic activation enhances irrigant agitation through cavitation and acoustic streaming, improving cleaning efficacy within the root canal system, especially in curved canals. The device does not contact dentin walls, reducing the risk of iatrogenic damage. In this study, EDDY was used to activate sodium hypochlorite solutions of either 2.5% or 5.25% concentration depending on the assigned group.
224168345|NCT06614361|BEHAVIORAL|Text messages|Health \&amp; wellness interactive text message (TM) intervention (12 weeks, 2 texts/week)
224168346|NCT06614361|BEHAVIORAL|Lottery prize for vaccination|Modest lottery prize for COVID vaccination
224168347|NCT06614361|BEHAVIORAL|Peer navigation|Peer navigation (4 months duration, contact as needed).
224168348|NCT06996444|OTHER|Program Including Various Workshops aiming to preserve elderly's autonomy through foot health|Combination of minimalist footwear, foot massages, and workshops to re-learn walking and posture
224168349|NCT01914939|DRUG|Oxytocin|
224168350|NCT01914939|BEHAVIORAL|Social Skills focused CBT|
224168351|NCT01914939|BEHAVIORAL|Stress management/relaxation training|
224168352|NCT01914939|DRUG|placebo drug|
224168353|NCT06993675|DRUG|Talquetamab|Talquetamab is a GPRC5DxCD3 bispecific antibody. It is supplied as a sterile, preservative-free solution for subcutaneous administration.
224168354|NCT06993675|DRUG|Teclistamab|Teclistamab is a BCMAxCD3 bispecific antibody. It is supplied as a sterile, preservative-free solution for subcutaneous administration.
224168355|NCT06427967|BEHAVIORAL|Project Dream Team|Five total sessions, 60-minutes each, with one session every 7 days (+/- 21 days between sessions), Session activities include discussion prompts, interactive learning methods, skill rehearsals, mindfulness / somatic exercises and lecture slides facilitated by a trained facilitator.
224168356|NCT06538064|OTHER|No Intervention|This is a non-interventional study.
224168357|NCT06541678|DRUG|Danuglipron|MR Tablet
224168358|NCT06541678|DRUG|Cyclosporine|Capsule
224168359|NCT06541678|DRUG|Itraconazole|Oral solution
224168360|NCT05248529|OTHER|Education booklet|Hip/Knee Replacement Adaptation Booklet explains preoperative preparation, post-operative care practices, how to walk with walker, what needs to be done at home after discharge
224168361|NCT03531918|DRUG|Cladribine|Given IV
224168362|NCT03531918|DRUG|Cytarabine|Given IV
224168363|NCT03531918|DRUG|Gemtuzumab Ozogamicin|Given IV
224168364|NCT03531918|BIOLOGICAL|Recombinant Granulocyte Colony-Stimulating Factor|Given SC
224168365|NCT03531918|OTHER|Laboratory Biomarker Analysis|Correlative studies
224168366|NCT03531918|DRUG|Mitoxantrone Hydrochloride|Given IV
223481084|NCT06450288|BEHAVIORAL|GO|"Green Oasis wellness program: include physical exercises, gardening, interaction with the developed website. Participants' general health status and website evaluation will be measured at T0 (baseline), T1 (3 months), T2 (9 months), using standardized questionnaires.~Study Design: pre-post study, 50 participants will be recruited from the Concordia Tsat Sing Kong transitional housing estate."
223481085|NCT02194465|DRUG|LY2623091|Administered orally
223481086|NCT02194465|DRUG|Tadalafil|Administered orally
224168367|NCT03313752|DRUG|Dapagliflozin 10Mg Tab|Dapagliflozin, will be administered according to the approved posology and to the approved dose as stated by Local Health Indication and by the Drug Brochure
224168368|NCT03313752|OTHER|Placebo|placebo
223481087|NCT02194465|DRUG|Spironolactone|Administered orally
223481088|NCT02194465|DRUG|Placebo|Administered orally
223481089|NCT04260165|PROCEDURE|Proximal Row Carpectomy|Excision of the proximal carpal row - the scaphoid, lunate and triquetrum
223481090|NCT04260165|PROCEDURE|Four-corner fusion|Scaphoid excision and four-corner fusion with cannulated headless compression screws/dorsal plate
223584953|NCT07033247|DEVICE|Passive Ultrasonic Irrigation (PUI)|Passive Ultrasonic Irrigation (PUI) involves the use of an ultrasonically activated file or tip inserted into the root canal 2 mm short of the working length, without contacting the dentinal walls. The ultrasonic tip is operated in a non-cutting, passive manner to generate acoustic streaming and cavitation within the irrigant. In this study, after initial irrigation with 2 mL of sodium hypochlorite (either 2.5% or 5.25%, depending on the group), ultrasonic activation was performed for 20 seconds in three consecutive cycles. Each activation was followed by 1 mL NaOCl irrigation. This method is designed to enhance the penetration and effectiveness of irrigants, especially in anatomically complex areas of the root canal system.
224168369|NCT06666764|OTHER|NBO|NBO will be conducted with inhalation of 100% oxygen.
224168370|NCT06666764|OTHER|Control|Best medical care
224168371|NCT02877134|DRUG|JNJ-64304500|Participants will receive JNJ-64304500 Subcutaneously.
224168372|NCT02877134|DRUG|Placebo|Participants will receive placebo Subcutaneously.
224168373|NCT02877134|DRUG|Ustekinumab|Participants will receive ustekinumab as per the dosing regimen.
224168374|NCT06675188|DRUG|PF-07275315|PF-07275315 solution for injection (single use only)
224168375|NCT06675188|OTHER|Placebo|Placebo solution for injection (single use only)
224168376|NCT03820479|OTHER|Protocol|Best practice of protocol
224168377|NCT07001852|OTHER|Endovascular Therapy (Mechanical Thrombectomy)|Endovascular therapy performed with CE-approved thrombectomy devices, initiated within 6 to 72 hours after stroke onset in patients with anterior circulation large vessel occlusion. The procedure is guided by an automated non-contrast CT detection tool and follows standard device-specific instructions for use.
224168378|NCT07001852|OTHER|Standard Medical Management|Standard medical management including therapies such as antiplatelet agents, anticoagulants, blood pressure control, and general supportive care. Delivered in accordance with institutional guidelines for acute ischemic stroke.
224168379|NCT01332851|BEHAVIORAL|Promoting First Relationships (PFR)|PFR is a parenting intervention based on attachment theory and is strengths based. It is a 10 week intervention that is delivered in the home of the family.
224168380|NCT01332851|BEHAVIORAL|Resource and Referral|Needs assessment, followed with a resource packet sent by mail
224168381|NCT01563406|OTHER|15 second scrub|Scrub catheter hubs for 15 seconds before every access.
224168382|NCT01563406|OTHER|5 second scrub|Scrub catheter hubs for 15 seconds before every access.
224168383|NCT01563406|DRUG|3.15% chlorhexidine/70% isopropyl alcohol|3.15% chlorhexidine gluconate in 70% isopropyl alcohol pads will be used to disinfect catheter hubs prior to accessing central venous catheters during half of the study period.
224168384|NCT01563406|DRUG|70% isopropyl alcohol|70% isopropyl alcohol pads will be used to disinfect catheter hubs prior to accessing central venous catheters for the other half of the study period.
224168385|NCT06390150|DEVICE|Spinal Cord Stimulator|The spinal cord stimulator is an implantable pulse generator connected to electrodes with leads that stimulate the spinal cord. The device is programmed to deliver therapeutic stimulation to treat pain.
224168386|NCT07007806|DRUG|Treatment A-Bemnifosbuvir/Ruzasvir FDC administered fasting|On day 1 single 550 mg/180 mg dose BEM/RZR FDC (2 × 275 mg/90 mg FDC tablets) will be administered under fasting conditions.
223481091|NCT01408641|DRUG|Topiramate|Topiramate titrated over 6 weeks to 400mg or highest tolerated dose.
223481092|NCT01408641|DRUG|Placebo|Placebo capsules without topiramate
223481093|NCT00574314|OTHER|No Intervention|Participants will be consented.
223481094|NCT02480296|DRUG|MYK-461|
223481095|NCT02480296|DRUG|Placebo|Placebo comparator
223481096|NCT02397525|DRUG|LIPO-202|
224168387|NCT07007806|DRUG|Treatment B-Omeprazole 20 mg dose administered fasting|On Day 4 to Day 13, a 20 mg dose omeprazole (1 × 20 mg) will be administered QD under fasting conditions.
224168388|NCT07007806|DRUG|Treatment C-Bemnifosbuvir/Ruzasvir FDC administered simultaneously with 20 mg dose of Omeprazole fasting|On Day 8, a single 550 mg/180 mg dose BEM/RZR FDC (2 × 275 mg/90 mg FDC tablets) will be administered under fasting conditions simultaneously with a 20 mg dose omeprazole (1 × 20 mg).
224168389|NCT07007806|DRUG|Treatment D-Bemnifosbuvir/Ruzasvir FDC administered 0.5 hour prior to 20 mg dose of Omeprazole|On Day 13, a single 550 mg/180 mg dose BEM/RZR FDC (2 × 275 mg/90 mg FDC tablets) will be administered 0.5 hour before the administration of a 20 mg dose omeprazole (1 × 20 mg).
224168390|NCT07007806|DRUG|Treatment E-Omeprazole 40 mg administered fasting|On Day 14 to Day 22, a 40 mg dose omeprazole (2 × 20 mg) will be administered QD under fasting conditions.
224168391|NCT07007806|DRUG|Treatment F-Bemnifosbuvir/Ruzasvir FDC administered 2 hours after 40 mg dose Omeprazole|On Day 18, a single 550 mg/180 mg dose BEM/RZR FDC (2 × 275 mg/90 mg FDC tablets) will be administered 2 hours after the administration of a 40 mg dose omeprazole (2 × 20 mg).
224168392|NCT00255606|DRUG|docetaxel|Given in 3- or 4- week courses
224168393|NCT00255606|DRUG|prednisone|Given in 3- or 4- week courses
224168394|NCT00682409|OTHER|MR Imaging|MR imaging in the post operative follow-up of cholesteatoma in children
224168395|NCT06373978|DRUG|Diclofenac|50mg every 8hours as needed for pain
224168396|NCT06373978|DRUG|Tramadol|50mg every 8hours as needed for pain
224168397|NCT06373978|OTHER|Acetaminophen|1000mg every 8hours as needed for pain
223584954|NCT07036822|DEVICE|Skeletal Anchored Maxillary Expander (MARPE)|Mini implant assisted rapid maxillary expander (MARPE) used for skeletal maxillary expansion in adolescent and adult patients
223584955|NCT06847867|DRUG|Momelotinib|Momelotinib will be administered.
223584956|NCT06545656|DRUG|Doxycycline|Doxycycline (DOX) will be given orally at 100mg doses. Participants will take the study medication for 7 consecutive days.
223584957|NCT02981524|DRUG|CY|CY is administered intravenously at 200 mg/m2
223584958|NCT02981524|BIOLOGICAL|GVAX|GVAX is administered intradermally at 5E8 colon cancer cells + 5E7 GM-CSF secreting
223584959|NCT02981524|DRUG|Pembrolizumab|Pembrolizumab is administered intravenously at 200 mg
223617564|NCT03526744|DIETARY_SUPPLEMENT|marine protein hydrolysate 2134|"Dietary Supplement for e.g. in this order: MPH 3200 mg for 7 days, than 7 days wash-out. Dietary Supplement: MPH 800 mg for 7 days, than 7 days wash-out. Dietary Supplement: MPH 2400 mg for 7 days, than 7 days wash-out. Dietary Supplement: MPH 1600 mg for 7 days, than 7 days wash-out."
223617565|NCT03526744|DIETARY_SUPPLEMENT|marine protein hydrolysate 3124|"Dietary Supplement for e.g. in this order: MPH 2400 mg for 7 days, than 7 days wash-out. Dietary Supplement: MPH 3200 mg for 7 days, than 7 days wash-out. Dietary Supplement: MPH 1600 mg for 7 days, than 7 days wash-out. Dietary Supplement: MPH 800 mg for 7 days, than 7 days wash-out."
224168398|NCT05259800|OTHER|Peppermint oil vapors|Subjects will be exposed to vapor of peppermint oil
224168399|NCT05259800|OTHER|Mineral Oil|Subjects will be exposed to vapor of placebo (mineral oil)
224168400|NCT07011667|DRUG|CagriSema (Cagrilintide B and Semaglutide I)|CagriSema (Cagrilintide B and Semaglutide I) will be administered subcutaneously using DV3384 pen-injector.
224168401|NCT07011667|DRUG|Placebo matched to CagriSema (Cagrilintide B and Semaglutide I)|Placebo matched to Cagrilintide B and placebo matched to Semaglutide I will be administered subcutaneously using DV3384 pen-injector.
224168402|NCT06867575|OTHER|Progressive Relaxation Exercise|Progressive Relaxation Exercise Steps
224168403|NCT03299166|DRUG|Troriluzole|Troriluzole, 140 mg capsules once daily (QD) orally for the first 4 weeks and 200 mg (140 mg+ 60 mg capsules QD) for an additional 8 weeks
224168404|NCT03299166|DRUG|Placebo|Matching capsule once daily (QD)
224168405|NCT05277116|OTHER|Genome Informed Risk Assessment (GIRA) report|A Genome Informed Risk Assessment (GIRA) report that combines genetic (monogenic risks and polygenic risk scores), family history, and clinical risk information from participants.
224168406|NCT06687278|BEHAVIORAL|Interpersonal Relationship Psychotherapy-Based Intervention Program|The Interpersonal Relationship Psychotherapy-Based Intervention Program is based on IPR and developed with reference to relevant literature and a previously published study (Cort et all., 2014). Subsequent to the development of the program, a series of expert opinions were obtained from seven specialists in the field. The Interpersonal Relationship Psychotherapy-Based Intervention Program is a 2.5-3 month program comprising eight individual sessions. The program is designed to be administered on a weekly basis, with each session lasting approximately 45-60 minutes. The participants in this group will receive an Interpersonal Relationship Psychotherapy Based Intervention Programme, which consists of eight individual sessions.
224168407|NCT04111653|OTHER|Mud therapy|Application of sludge poultice
224168408|NCT02455362|DRUG|Morphine sulfate|Treatment with sustained-release morphine sulfate is given as one double-blind capsule in the morning.
224168409|NCT02455362|DRUG|Placebo|
224168410|NCT00698776|DRUG|Lenalidomide|10 mg/day in cohort 1, and 25 mg/day in cohort 2. LEN is administered orally in standard 21 day cycles starting one week before each DC injection and ending 14 days after each DC injection. All patients will receive a total of three cycles of LEN.
224168411|NCT00698776|BIOLOGICAL|Monocyte derived DCs loaded with KRN7000|10 million DCs injected intravenously
224168412|NCT03777397|OTHER|Questionnaire|Questionnaire on the level of awareness of this risk among health sector employees, and more specifically the Lyon Civilian Hospices, and on participation in breast cancer screening for HCL employees, particularly among night shift staff.
224168413|NCT00255008|BIOLOGICAL|peginterferon alfa-2b|Powder for injection in Redipen (50, 80, 100, 120, and 150 microgram strengths), subcutaneous, dose of 1.5 micrograms/kg, weekly for up to 48 weeks
224168414|NCT00255008|DRUG|ribavirin|200 mg capsules, oral, weight-based dose of 800, 1000, or 1200 mg daily for up to 48 weeks
224168415|NCT00255008|BIOLOGICAL|peginterferon alfa-2b|Powder for injection in Redipen (50, 80, 100, 120, and 150 microgram strengths), subcutaneous, dose of 1.5 micrograms/kg, weekly for up to 24 weeks
224168416|NCT00255008|DRUG|ribavirin|200 mg capsules, oral, weight-based dose of 800, 1000, or 1200 mg daily for up to 24 weeks
224168417|NCT01833806|DEVICE|ExAblate MRgFUS|Focused Ultrasound Ablation
224168418|NCT03457636|DRUG|Doxycycline Anhydrous 40 MG|One Oracea Capsule (40 mg) should be taken once daily in the morning on an empty stomach, preferably at least one hour prior to or two hours after meals
223584960|NCT06213142|OTHER|CBToolkit|CB Toolkit Mindful Awareness module to increase awareness and tolerance of physical sensations and emotional experiences using mindfulness practices. The module involves videos with motion graphics, video demos, voiceover, music, and sound effects intermixed throughout with a variety of interactive exercises tailored to specific core components. The module aims to establish understanding of the intervention concept (psychoeducation), increase self-efficacy in mindfulness skills via active practice and personalized feedback, and facilitate self-reflection and understanding of strengths and improvement areas related to mindfulness. CBToolkit Flexible Problem Solving module to promote cognitive flexibility, applying problem-solving strategies in difficult scenarios, and learning to modify behavioral action tendencies. Videos and activities will be tailored to provide examples of effective problem-solving techniques and provide personalized reinforcing and/or scaffolded feedback.
224168419|NCT03457636|DRUG|Adapalene/Benzoyl Peroxide Gel 0.3-2.5%|Epiduo Forte should be applied in a thin layer to affected areas of the face and/or trunk once daily after washing, with care taken to avoid the eyes, lips, and mucous membranes
224168420|NCT00881699|BEHAVIORAL|HIV Prevention Intervention - Project PRISSMA - HIV I have my eye on you|Eight weekly 2-hour HIV risk reduction intervention sessions, with three weekly 2-hour booster sessions completed 6 months after the initial intervention. Specific goals of the intervention are to (1) increase information about HIV risk behaviors and safer sex options; (2) increase identification of personal risk of HIV and enhance the motivation to engage in safer sex behaviors; and (3) enhance skills to achieve safer sex, particularly negotiating safer sex, using condoms, and communicating within a relationship.
224168421|NCT00881699|BEHAVIORAL|Health Promotion Intervention|Eight weekly 2-hour health promotion intervention sessions with three weekly 2-hour booster sessions completed 6 months after the initial intervention. Specific goals of the intervention are to (1) increase information about health issues specific to psychiatric patients, (2) increase identification of personal health risks and enhance motivation to engage in healthier behaviors, and (3) enhance skills to achieve healthier behaviors.
224168422|NCT00319683|DRUG|ADH300004|
224168423|NCT00971360|OTHER|conversion disorder|Proinflammatory cytokine levels in conversion disorder
224168424|NCT04450641|OTHER|GuessWhat Mobile Application|The GuessWhat app is a charades style game and app that engages parent and child in fluid social interaction where the parent must guess what the child is acting out based on the prompt shown on the phone screen. Participants will use their own personal phone to download the study app. Parent and child will be encouraged to play using the emojis and emotion game mode at least 3 individual game sessions per week. Parents are asked to play GuessWhat with their child 3-4 times per week for 4 weeks.
224168425|NCT01722357|BEHAVIORAL|Pedometer|Participants are provided with Omron Model HJ-151 pedometers and given instruction on how to use the pedometer to set goals for increasing physical activity. They are given diaries to track their daily step counts.
224168426|NCT01722357|BEHAVIORAL|Exercise Counseling|Manualized cognitive behavioral treatment program including goal setting, adding exercise throughout the day, physical limitations/injuries, maintaining motivation, benefits of exercise, FITT principles, exercise as recreation, and restructuring thoughts related to activity.
224168427|NCT05475444|DEVICE|Chitosan Coated PLGA nanoparticles entrapping Ciprofloxacin incorporated in smart gels|antibacterial nanoparticles were used because of their small size, sustained release and positive charge which interact with the negatively charged surface of bacterial cell causing its destruction.
224168428|NCT05475444|DEVICE|Ciprofloxacin paste and solution|Conventional antibacterial paste and solution were compared to nanoparticles smart gels to treat endodontics bacterial infection
224168429|NCT04010812|OTHER|Questionnaire|RHDS- Readiness For Hospital Discharge Scale, Patient Self-Assessment Form
224168430|NCT03978572|BEHAVIORAL|Resistance Training|Exercise intervention designed to improve muscular strength and power
224168431|NCT03978572|BEHAVIORAL|Moderate-Intensity Continuous Cycling|Exercise intervention designed to improve cardiorespiratory fitness and muscular endurance
223481097|NCT04753801|BEHAVIORAL|Thinking, writing and imagination|All participants are asked to take some time to think and write about the respective intervention group's content. In some groups (after the writing exercise (approx. 15min)), participants are also asked to imagine that content or engage in a mindfulness activity or recall task for about 5 minutes.
224168432|NCT03978572|BEHAVIORAL|High-Intensity Interval Cycling|Exercise intervention designed to improve cardiorespiratory fitness, muscular endurance, and muscular strength and power
224168433|NCT00004772|DRUG|Immune globulin|
224168434|NCT03821480|DRUG|Test drug|Fluconazole capsule 50 mg Manufacturer: West Ryde
224168435|NCT03821480|DRUG|Reference drug|Fluconazole capsule 50 mg Manufacturer: Amboise
224168436|NCT01977807|DEVICE|Proscan, Zyoptix and Supracor|One device (500 Hz Excimer Laser) with three interventions (Proscan, Zyoptix and Supracor as algorithms)
224168437|NCT02746445|OTHER|No intervention|No intervention. This is a longitudinal study looking at subjects who received MeRT treatment.
224168438|NCT01210976|DRUG|levosimendan|12 mcg/kg/10min bolus and 24 hour infusion at a rate of 0.2 mcg/kg/min
224168439|NCT01210976|DRUG|placebo|nacl 0.9% coloured with thiamin in same volume and time than levosimendan
223481098|NCT00576758|DRUG|obinutuzumab (RO5072759)|1000 mg obinutuzumab intravenous (IV) infusion once a week for 4 weeks.
223481099|NCT00576758|DRUG|rituximab|375 mg/m\^2 rituximab IV infusion once a week for 4 weeks.
223481100|NCT02456311|DEVICE|HARMONIC ACE+7|Pulmonary artery sealing with Harmonic Ace+7 in open lobectomy in humans
223481101|NCT00726245|BIOLOGICAL|PRGF|3-6mg IM (to area of muscle tear)
223481102|NCT00726245|BIOLOGICAL|Placebo|3cc IM of physiological saline
223481103|NCT00279929|PROCEDURE|DHEA Replacement|
223481104|NCT02764736|DRUG|Atorvastatin|Patients will be given 20mg atorvastatin daily for 12 weeks and then increased to 40mg atorvastatin daily for an additional 12 weeks.
223481105|NCT05530005|OTHER|Manual Therapy|Manual Therapy according to Kaltenborn Evjenth method. Exercises with PT resistance, massage.
223481106|NCT02556749|DIETARY_SUPPLEMENT|Cranberry Juice Beverage|16 ounces of 54% cranberry juice cocktail
223481107|NCT02556749|DIETARY_SUPPLEMENT|Placebo Beverage|Color, calorie, and taste matched beverage without cranberry bioactives
224168440|NCT02797769|DRUG|Other Biologics|Exposure data will be gathered from claims databases, and no medicine will be administered in this non-interventional study. There are no protocol-specified biologic agents, although the analyses will be stratified by TNFi and non-TNFi targeted therapies. The drug selection and regimen are at the discretion of the prescribing physician.
224168441|NCT02797769|DRUG|Tocilizumab|Tocilizumab exposure data will be gathered from claims databases, and no medicine will be administered in this non-interventional study. The regimen is at the discretion of the prescribing physician.
224168442|NCT05177224|OTHER|Ultrasound acquisitions to define liner position during movements|"Ultrasound acquisition of the dual mobility cup will be performed before and after movement. Acquisitions will be performed on the groin area.~Movement will be performed 3 times and are:~* Walking~* Knee-bending~* Standing up~* Stair climbing Movement acquisition of the lower limb will be performed using reflective markers placed on the skin. The movements will be recorded using motion capture system (infrared cameras). The load applied by the patients on the ground when doing these movements will be recorded with a force plate."
224168443|NCT04259034|OTHER|diagnosis of periodontitis in oral lichen planus patients|diagnosis of periodontitis in oral lichen planus patients
224168444|NCT04259034|OTHER|diagnosis of periodontitis in systemically healthy individuals without oral lichen planus|diagnosis of periodontitis in systemically healthy individuals without oral lichen planus
224168445|NCT02233582|DRUG|Ibuprofen|We are simply testing if taking ibuprofen upon ascent to altitude is associated with a delayed acclimatization response to the high altitude hypoxia.
224168446|NCT02233582|DRUG|Sugar pill|
224168447|NCT04878276|DEVICE|Dimet 5|The application is carried out according to the enclosed instructions for use.
224168448|NCT04962490|PROCEDURE|Repair: suture, reinsertion, tendon graft, surgery in two stages (Hunter, Paneva Holevich)|Repair tendon flexor sections in the hand: Suture, reinsertion, tendon graft, surgery in two stages (Hunter, Paneva Holevich). The surgery depends on the anatomical area of the tendon section and the time between the injury and the operation.
224168449|NCT06309498|PROCEDURE|blood test|11 DOC levels will be measured in enrolled patients
224168450|NCT05925400|DEVICE|Virtual Reality during Embryo Transfer|Patients randomized to the study group, will be provided with the VR headset. The VR exposure will take place 10-15 minutes before the Embryo Transfer (ET) and a 10 min immersion after the ET
224168451|NCT05213676|DRUG|Inhaled Nitric Oxide (iNO) use|The center will use iNO per their usual protocol in the initial resuscitation period (defined as birth through stabilization and CDH repair). No center will alter any component of their standard clinical practice guideline or protocol governing CDH care.
224168452|NCT05213676|OTHER|De-implementation of Inhaled Nitric Oxide (iNO) use|The center will stop using iNO in the initial resuscitation period (defined as birth through stabilization and CDH repair).
224168453|NCT04451486|DRUG|SB cells|1x10\*5 CD61-Lin- cells /0.25mL DPBS
224168454|NCT04451486|DRUG|SB cells|1x10\*6 CD61-Lin- cells /0.25mL DPBS
224168455|NCT04451486|DRUG|SB cells|1x10\*7 CD61-Lin- cells /0.25mL DPBS
224168456|NCT02832817|DEVICE|Pulse oximeter|For each monitoring of Arterial Oxygen Saturation, measures of Arterial Pulsed Oxygen Saturation will be made for each pulse oximeter.
224168457|NCT02858713|DRUG|Calcipotriene + Betamethasone Dipropionate|Participants received Calcipotriene + Betamethasone Dipropionate once daily when needed for the entire study period.
224168458|NCT02858713|DEVICE|App|App named MyPso SmarTopTM Version 1.0 (LEO Pharma) was used for 28 days by participants in the intervention arm.
224168459|NCT04985513|PROCEDURE|Ventilation during cardiopulmonary bypass|Ventilation was performed using an inhaled oxygen fraction of 20% and a tidal volume of 5ml/kg at the time of cardiopulmonary bypass.
224168460|NCT06016335|DIAGNOSTIC_TEST|CT scan|Participants receive a CT scan of the head as part of their regular care. A larger part of the head will be scanned than for standard care.
224168461|NCT06016335|DIAGNOSTIC_TEST|MRI scan|Participants receive an MRI scan, specifically for the purpose of the study.
224168462|NCT06016335|OTHER|Synthetic CT scan|Synthetic CT scans will be generated from MRI scans, using the trained machine learning algorithm.
224168463|NCT05859906|OTHER|mechanical power measurement|"Mechanical power values of the patients;~* Before insufflation (baseline value),~* 0 min after insufflation,~* 15th min after insufflation,~* 30 minutes after insufflation,~* 45th minute after insufflation (if insufflation continues),~* 60th minute after insufflation (if insufflation continues),~* Intraoperative after insufflation It will be measured with the following formula in the specified periods. MP = 0.098 x minute ventilation x \[Peak inspiratory pressure - 0.5 x (Plateau pressure - Positive end-expiratory pressure)\]"
224168464|NCT03581799|OTHER|Oral dispersible tablet|Administration of a 5 mm calcium carbonate based ODT placed in the buccal pouch (children aged 2-5 years) or on the tongue (children aged 6-10 years).
224168465|NCT00126425|DRUG|123I-mIBG (meta-iodobenzylguanidine)|Single dose
224168466|NCT00654576|DRUG|Chlorpromazine, Sulpiride, Clozapine, Olanzapine, Risperidone, Quetiapine, Aripitrazole|patient will receive one of the seven study drugs (Chlorpromazine, Sulpiride, Clozapine, Olanzapine, Risperidone, Quetiapine, Aripitrazole) as the maintain treatment. the dose is flexible, is based on the study doctor's judgment.
224168467|NCT00654576|BEHAVIORAL|psychosocial intervention|the psychosocial interventions include psychoeducaiton, family intervention, skill training, and cognitive-behavioral therapy.
224168468|NCT03965546|COMBINATION_PRODUCT|Sorafenib combined with ET140202-T cell|"1. Sorafenib starting dose of 400mg b.i.d. a.c.~2. Autologous T cells transduced with lentivirus encoding an anti-AFP (ET140202) expression construct by intravenous (IV) infusion"
224168469|NCT03965546|COMBINATION_PRODUCT|TAE combined with ET140202-T cell|"1. Transarterial embolization(TAE) treatment~2. Autologous T cells transduced with lentivirus encoding an anti-AFP (ET140202) expression construct -intravenous (i.v.)"
224168470|NCT03965546|BIOLOGICAL|ET140202-T cell|Autologous T cells transduced with lentivirus encoding an anti-AFP (ET140202) - expression construct -intravenous (i.v.)
224305395|NCT03569228|DEVICE|Study 1 - ITE hearing aids|Experienced users of in-the-ear (ITE) hearing aids will receive replacement ITE hearing aids that are fitted and verified in a test box coupler, then mailed to the patient for a 4-week field trial.
223481108|NCT01687439|DRUG|Endostar|7.5mg/m2, D1-14
223481109|NCT01687439|DRUG|Vinorelbine|25-30mg/m2, D1,8
223481110|NCT01687439|DRUG|Cisplatin|25 mg/m2, D1-3
223481111|NCT01687439|RADIATION|Radiotherapy|
223584961|NCT03116542|DEVICE|Diagnostic (18F-FLT PET/CT)|The tracer compound \[F-18\] FLT will be injected into the patient's veins in a small volume of normal saline solution. The PET scan data collection is started immediately and is continued for 2 hours.
224168471|NCT00991367|OTHER|Cicatrix|Dosage commensurate with surface to be treated. After washing and drying the affected area, a thin layer of CICATRIX (Topical use) will be applied on the lesion rubbing in different directions for 2 minutes, three times a day, for 4 weeks.
224168472|NCT00991367|OTHER|Placebo|Dosage commensurate with surface to be treated. After washing and drying the affected area, a thin layer of PLACEBO (Topical use) will be applied on the lesion rubbing in different directions for 2 minutes, three times a day, for 4 weeks.
224168473|NCT05295940|DRUG|LY3841136|Administered SC.
224168474|NCT05295940|DRUG|Placebo|Administered SC.
224168475|NCT03336476|DEVICE|Videolaryngoscopy|Patients will be intubated with the video laryngoscope
224168476|NCT03336476|DEVICE|Direct laryngoscopy|Patients will be intubated with the direct laryngoscope
224168477|NCT00236405|DRUG|epoetin alfa|
223481112|NCT01454752|DRUG|Intermittent parasite clearance|Sulphadoxine-pyrimethamine (500/25mg) according to age, given on day 1; Amodiaquine (200mg) according to age, given daily for 3 days
223481113|NCT01454752|OTHER|Placebo|Placebo tablets, similar in appearance and taste to active treatment, given daily over 3 days
223481114|NCT01443884|DIETARY_SUPPLEMENT|Grape powder, followed by placebo powder|For three weeks, twice per day, volunteers will consume one packet of freeze-dried grape powder containing the equivalent of approximately 2 servings of fresh grapes (46 grams of powder) stirred into water. Following a two week washout, volunteers will consume one packet of placebo powder twice per day for three weeks.
223481115|NCT01443884|DIETARY_SUPPLEMENT|Placebo powder followed by grape powder|For three weeks, twice per day, volunteers will consume one packet of placebo powder stirred into water. Following a two week washout, volunteers will consume one packet of freeze-dried grape powder containing the equivalent of approximately 2 servings of fresh grapes (46 grams of powder) twice per day for three weeks.
223584962|NCT00612859|DRUG|levetiracetam|
223584963|NCT00266344|DRUG|MK0928, gaboxadol / Duration of Treatment 3 Weeks|
223584964|NCT00266344|DRUG|Placebo / Duration of Treatment 3 Weeks|
224168478|NCT00944580|BIOLOGICAL|MAGE-A1, MAGE-A3, and NY-ESO-1 Vaccine|A regimen of three vaccines every two weeks. Each vaccine will contain 3,000,000-5,000,000 peptide pulsed dendritic cells. Imiquimod, a topical cream, will be applied to the vaccination site before and after each vaccination.
224168479|NCT05265104|DRUG|SDF with stainless steel crown|Silver Diamine Fluoride (38%) applied to the carious lesion in the primary molars with a brush and the tooth is sealed with a stainless steel crown
224168480|NCT05265104|DEVICE|Diode laser application with stainless steel crown|Diode laser will be applied to the carious lesions primary molars to eradicate the bacteria and then the tooth will be sealed with stainless steel crown
224168481|NCT05265104|OTHER|stainless steel crown only|the primary molars with carious lesions will be sealed with stainless steel crowns following the concept of hall technique
224305396|NCT03569228|DEVICE|Study 1 - BTE hearing aids|Experienced users of behind-the-ear (BTE) hearing aids will receive replacement BTE hearing aids that are fitted and verified in a test box coupler, then mailed to the patient for a 4-week field trial.
224305397|NCT03569228|DEVICE|Study 3 (open-fit comparison)|This group will serve as the active comparator group for experienced hearing aid user receiving replacement receiver in the canal (RIC) or receiver in the aid (RITA) hearing aids with OPEN coupling using the standard of care approach, then undergoing a 4-week field trial.
223481116|NCT00089648|DRUG|Sunitinib|50 mg orally daily for 4 weeks followed by 2 weeks off treatment for approximately 1 year or until disease progression/unacceptable toxicity; after completion of 1 year, pts with clinical benefit can continue the study treatment in a separate continuation protocol
223481117|NCT00872118|BEHAVIORAL|Brief Intervention for Socially Anxious Drinkers (BISAD)|integrated alcohol and social anxiety individual intervention
223481118|NCT00872118|BEHAVIORAL|Enhanced Alcohol Skills Building and Education Program|alcohol-focused group intervention
223481119|NCT04454606|DEVICE|Fit test|"Bitrex Fit Test The Bitrex test uses a person's ability to test a bitter solution to determine whether a respirator fits properly\[11\]. Each subject was given a taste-threshold screening test prior to each fit test to ensure that he or she could taste. This process was done without subject wearing a respirator. After passing the sensitivity test, the subject will process to 7 steps of fit test as following~* Breathe normally~* Breathe deeply~* Head side to side~* Head up and down~* Bent over wrist, jogging~* Talking~* Breath normally Each step took 60 seconds and the Bitrex solution was refilled into the hood every 30 seconds with half dosage of the amount of the previously test. We asked the participant if he / she could taste the solution during each steps of the test . The test was considered a failure, otherwise, a pass."
223584965|NCT00247442|BEHAVIORAL|Decision aid|
223584966|NCT05046691|BEHAVIORAL|8-week mindfulness program|The .b Foundations course is an 8-week mindfulness program developed by Mindfulness in Schools Project (MiSP) for school teachers and personnel. It includes a taster session and 8 weekly sessions. Each session lasts for 1.5 hours with a specific theme (e.g. Lesson 1 waking up from autopilot). Formal and informal mindfulness practices (e.g. mindful eating, body scan, mindful walking, habit releaser etc.), psychoeducation, cognitive exercises, inquiry, and home practice are involved.
223584967|NCT01194622|DRUG|Azelastine, Fluticasone|TEST = MP29-02 = Combination product Azelastine Hydrochloride and Fluticasone Propionate nasal spray (= US formulation as used in pivotal studies)
223584968|NCT01194622|DRUG|Fluticasone mono|REF = FLU mono Fluticasone Propionate nasal spray (= essentially combination product formulation without any AZE; US FLU mono formulation as used in pivotal studies)
223584969|NCT01194622|DRUG|Fluticasone|COMP = Fluticasone Propionate Nasal Spray, Roxane Laboratories = FLU mono Fluticasone propionate nasal spray (= US marketed product)
223584970|NCT01521299|DRUG|Hydroxyurea|oral hydroxyurea on days 1,8 and 15
223584971|NCT00003842|BIOLOGICAL|interleukin-4 PE38KDEL cytotoxin|
223584972|NCT00003842|DRUG|isolated perfusion|
223584973|NCT00003842|PROCEDURE|surgical procedure|
223584974|NCT05087719|COMBINATION_PRODUCT|experimental group|patients will receive the hot pack initially for 15 minutes .Then for proprioception training of graphesthesia for 15 mints,stereognosis will be of 15 minutes. For motor training patients will practice 15 mints motor tasks
224168482|NCT04631367|BEHAVIORAL|Kukaa Salama: mHealth intervention|Kukaa Salama is a 8-week social group program of COVID-19 prevention messaging, which includes sending informational SMS once per week and holding secure group discussions on COVID-19 prevention. Weekly SMS messages will focus on COVID-19 knowledge, including information about transmission, hand washing, respiratory hygiene (coughing and sneezing in ways that won't spread germs), face masks, and physical distancing. Participants can also respond to the SMS with any questions about COVID-19, and the study team will respond with further information and/or additional resources. Weekly group chats will be administered using the customized WelTel platform, and will focus on discussions of how participants can apply and practice the information on COVID-19 prevention in their daily lives. Each group chat will be composed of 15-20 participants, and will be facilitated by a research assistant in Kampala as well as a peer navigator.
224168483|NCT04631367|DEVICE|Face Mask + Soap|Participants will be offered the opportunity to pick up a parcel that contains a face mask, bar of soap, and a small parcel of food from the partner agency YARID.
224168484|NCT06078306|DRUG|Azacitidine Injection|Azacitidine Injection 75mg/square meter/day, day1-7, subcutaneous injection
224168485|NCT06078306|DRUG|Venetoclax|Venetoclax 100mg day 1, 200mg day 2, 400mg d3-d21, oral
224168486|NCT06078306|DRUG|CD19CD22 CAR-T|After induction chemotherapy with Azacitidine+Venetoclax, each subject receives CD19CD22 CAR-T cells by intravenous infusion
224168487|NCT02469584|PROCEDURE|small stitch anterior colporrhaphy|A midline plication will be performed with continuous delayed absorbable sutures (3-0 polydioxanone) and the distance between the sutures will be 0.5 cm.
224168488|NCT03202368|DRUG|Tocilizumab|162 milligrams (mg) of tocilizumab every week for a maximum of 156 weeks or until the commercial availability of tocilizumab, whichever comes first
224168489|NCT02602704|DRUG|Bazedoxifene|Bazedoxifene 20mg/day (Viviant) for 48 weeks
224168490|NCT02602704|DRUG|Calcium/Vit D|Elemental calcium 1200mg daily and vitamin D 800 IU daily (Caltrate D 400 \* 2/day) for 48 weeks
224305398|NCT03569228|DEVICE|Study 3 (closed-fit comparison)|This group will serve as the active comparator group for experienced hearing aid user receiving replacement receiver in the canal (RIC) or receiver in the aid (RITA) hearing aids with CLOSED coupling using the standard of care approach, then undergoing a 4-week field trial.
223481120|NCT04454606|DEVICE|Filtration Test|"Respirator Performance~The real time respirator performance test method was developed using MT-05U machine (SIBATA model, Saitama, Japan), which measure particle concentrations of diameter 0.03 - 0.06 µm using and particle generator laser beam scattering particle counter that measure particles outside and inside the mask. The ratio between these two values reflected % leak as following:~* leak=((Paticle inside the filter))/((Paticle inside the filter)) x 100 And calculate % filter performance = 100 - % leak We tested at the airflow rate of 40L/min which is 3-4 times higher than normal physiology, assuming that there should be no leakage through the filter. We tested 2 types of filter is CareStar and SafeStar that was incorporated with the silicone mask. CareStar is limited for 24 hour usage and SafeStar is for 72 hour duration.~Study protocol"
223481121|NCT02224417|BEHAVIORAL|Diabetes Educational Program (DEP)|"Participants in this Arm will receive the Diabetes Educational Program (DEP), as required, which is part of usual care at the Polyclinic. It is delivered by a Health Counsellor at the point of diagnosis and focused education is provided during doctor visits for medication. The program at the Polyclinic comprises information on a series of diabetes-related issues.~The participant will receive the 2 or 3 study devices (patients will receive a glucometer if they do not already have one). The Site Study Coordinator will provide education on the use of the Fitbit Zip™ and the eCAP™. As part of usual care, patients who have difficulties with their glucometer will be referred to a Health Counsellor at the Polyclinic."
223584975|NCT05087719|COMBINATION_PRODUCT|conventional treatment|patients will receive the baseline treatment of hot pack for 15 minutes. The patients in this group will get muscle strengthening exercise of the hand, Range of motion, and stretching of the hand muscles, 3 sets of 8 repetitions were given to the patient, gap of 2 minutes will be given between regimes. For 20 minutes this session will be given to patient by the therapist.
223584976|NCT04832945|DRUG|Ivermectin 6 Mg Oral Tablet|Ivermectin weekly oral dose 0.2 mg/kg equivalent for 4 weeks
223584977|NCT03688243|DEVICE|SS-OCT imaging|All subjects will undergo retinal imaging using the Zeiss PlexElite SS-OCT, a non-contact, non-invasive ocular imaging instrument
223584978|NCT03119389|BEHAVIORAL|Donning Non-Sterile Gloves without HH|Current practice is to perform hand hygiene before donning of non-sterile gloves. In units assigned to the intervention, healthcare workers within the units will be educated that performing hand hygiene before donning non-sterile gloves is not necessary.
223744929|NCT05810792|DRUG|Interleukin-2 (IL-2)|IL-2 is administrated in combination with HDC during three 3 week cycles as peri- and post-operative treatment in patients undergoing surgery. IL-2 is administered twice daily as a subcutaneous injection 1 to 3 minutes prior to the administration of histamine dihydrochloride; each dose of IL-2 is 16,400 IU/kg (1µg/kg).
223744930|NCT00281684|DRUG|SB705498 400 mg|SB705498 400 mg
223744931|NCT00281684|DRUG|SB705498 1000 mg|SB705498 1000 mg
223744932|NCT00281684|DRUG|Placebo|Placebo
223744933|NCT00281684|DRUG|Co-Codamol|Co-Codamol
224168491|NCT04474366|DRUG|Ropivacaine 0.2% Injectable Solution|Ropivacaine 0.2% Injectable Solution injected as part of the Pectoralis Nerve Block
224168492|NCT04474366|OTHER|Saline (0.9%)|Saline injection as sham block in identical fashion as Pectoralis Nerve Block
224168493|NCT03253185|DRUG|SC-007|intravenous
224168494|NCT03053973|DEVICE|nocturnal noninvasive ventilation|Patients will be initiated on bilevel positive pressure non-invasive ventilation via a mask according to regular clinical practice.
224168495|NCT03053973|OTHER|Standard Care|Standard COPD care is given to all patients (pharmacological management, oxygen, rehabilitation if neccesary, etc.)
224168496|NCT04063865|DRUG|Tacrolimus|Tacrolimus (FK / Prograf) titrated to a goal trough of 6 - 8 ng/ml
224168497|NCT04063865|DRUG|Everolimus|Everolimus monotherapy - target trough levels 4 - 8 ng/ml as maintenance immunosuppression
224305399|NCT03569228|DEVICE|Study 3 (experimental open-fit)|Experienced hearing aid user receiving replacement receiver in the canal (RIC) or receiver in the aid (RITA) hearing aids with OPEN coupling that are fitted and verified in a test box coupler, then mailed to the patient for a 4-week field trial.
224168498|NCT02374073|OTHER|Functional Massage|The functional massage is a manual therapy technique, indicated in cases of painful muscle tightness that combines a rhythmical and non painful passive joint mobilization in the direction of muscle stretching together with compression/decompression of the muscle to be treated.
224168499|NCT02374073|OTHER|Protocolized physiotherapy|therapeutic exercises, analgesic electrotherapy and cryotherapy
224168500|NCT03364062|PROCEDURE|cemented shoulder replacement|proximal humeral fracture receiving hemi-shoulder replacement with cement when inserting the stem
224168501|NCT03659240|OTHER|Cranberry beverage|During the intervention period, research participants will consume a cranberry beverage daily.
224168502|NCT03659240|OTHER|Placebo beverage|During the intervention period, research participants will consume a placebo beverage daily.
224168503|NCT04064372|BEHAVIORAL|Mindful response to adversity brief training|Participants will attend a group training session, led by a professional instructor, about responding to adversity with an approach of mindfulness, equanimity, and non-judgment, which will include a description of the skills, a writing and sharing activity focused on the proposed approach, and a practice session. Following the training, participants will be instructed to practice the skills that they just learned during a group version of a standard stress-induction task called the Trier Social Stress Task (the TSST-G).
224168504|NCT04064372|BEHAVIORAL|Strengths-based response to adversity brief training|Participants will attend a group training session, led by a professional instructor, about responding to adversity with an approach of strengths-based, narrative self-analysis, which will include a description of the skills, a writing and sharing activity focused on the proposed approach, and a practice session. Following the training, participants will be instructed to practice the skills that they just learned during a group version of a standard stress-induction task called the Trier Social Stress Task (the TSST-G).
224168505|NCT05409092|DIETARY_SUPPLEMENT|Astaxanthin|8 mg/day in one capsule for 4 weeks
223481122|NCT02224417|BEHAVIORAL|DEP + Process Incentive|"Participants will receive the DEP as required. In addition, participants will have the opportunity to earn financial incentives (in vouchers) for meeting specified goals:~* SGD3.50 weekly for meeting Glucose testing goals: measuring blood glucose on three non-consecutive days each week.~* SGD0.50 daily for Medication adherence: taking medications daily as prescribed, monitored by eCAP device. Assessed based on medication-taking times within specified time windows. Participants should be adherent at all specified mealtimes to be fully adherent for the day.~* SGD1.00 daily for Regular Physical activity: taking 8,000 steps during the day as recorded by Fitbit."
223481123|NCT02224417|BEHAVIORAL|DEP + Outcome Incentive|"Participants will receive the DEP as required. In addition, participants will have the opportunity to earn financial incentives (in vouchers) for recording glucose readings within the normal range (i.e. between 4 to 7mmols/L two before a meal) on 3 non-consecutive days within the week using the glucometer.~* SGD 2 weekly if one glucose readings falls within the normal range,~* SGD 7 weekly if two glucose readings fall within the normal range,~* SGD 14 weekly if all three glucose readings fall within the normal range."
223481124|NCT03758508|DEVICE|High Flow Oxygen nasal cannula|High Flow Oxygen nasal cannula
223481125|NCT03758508|DEVICE|Noninvasive ventilation|In this arm, participants receive noninvasive ventilation through an interface (such as full face mask or oro-nasal mask) alternated with continuous high flow oxygen though humidified nasal cannula
223481126|NCT06074510|DRUG|Piflufolastat F 18 Intravenous Solution [PYLARIFY]|Participants will receive a single dose of 333 MBq (9 mCi) \[296 MBq-370 MBq (8 mCi - 10 mCi)\] PYLARIFY injection followed by a single whole-body PET/CT or PET/MRI scan acquired at 1 to 2 hours post-dosing
223584979|NCT04489121|DRUG|Omalizumab|For patients in the Omalizumab group, subcutaneous injections of Omalizumab based on the specific participant's weight and serum total IgE was performed 2 weeks prior the anticipated pollen season.
223584980|NCT01123473|DRUG|capecitabine|
223584981|NCT01123473|DRUG|cisplatin|
223584982|NCT01123473|DRUG|epirubicin hydrochloride|
223584983|NCT01123473|DRUG|fluorouracil|
223584984|NCT01123473|DRUG|lapatinib ditosylate|
223584985|NCT04825431|DRUG|TAS-205, [14C]TAS-205|single oral administration under fasted conditions on day 1
223584986|NCT05183269|DEVICE|Oncomfort virtual reality monitor (Oncomfort SA, Wavre, Belgium)|Use of the Oncomfort virtual reality monitor
223584987|NCT04981028|OTHER|Questionnaires (including PHQ-9, TYM and SF-36)|For the acute group, a questionnaire is completed on neurological symptoms at presentation plus specific questions to include brain imaging performed, treatments received and whether they survived the hospital admission (AQ1). There will be a healthcare practitioner led questionnaire (AQ2) and 3 patient led questionnaires (PHQ-9, TYM and SF-36) plus a supplementary questionnaire (AQ3) completed at 1 week, 1 month, 3 months, 6 months and 12 months following diagnosis. For the chronic TTP group, participants will have a questionnaire completed (CQ1) and 3 patient-led questionnaires (PHQ-9, TYM and SF-36) plus a supplementary questionnaire (CQ2). Where neurological symptoms are present, questionnaires will be completed 6 monthly; where there are no neurological symptoms questionnaires are completed every 12 months. The healthy volunteers will complete participant led questionnaires (namely PHQ-9, TYM, SF-36) plus a supplementary baseline questionnaire at two time points 12 months apart.
223481127|NCT03347591|GENETIC|WES|136 bleeding related OMIM (Online Mendelian Inheritance in Man)-proved genes involved in haemostasis will be selected from Whole Exome Sequencing (WES)
223584988|NCT00605891|DRUG|carmoterol (CHF 4226)|"carmoterol pMDI 2.0 μg once a day, in the morning~(1 puff of carmoterol 1.0 mcg + 1 puff of carmoterol 1.0 mcg)"
223584989|NCT00605891|DRUG|carmoterol (CHF 4226)|"carmoterol pMDI 1.0 μg once a day, in the morning~(1 puff of carmoterol 1.0 mcg + 1 puff of placebo pMDI))"
224168506|NCT05409092|DIETARY_SUPPLEMENT|Placebo|8 mg/day in one capsule for 4 weeks
224168507|NCT03258450|BEHAVIORAL|Psycho-behavioural intervention arm (PBI)|The first session introduces the rationale of the intervention and is designed to encourage participants to recognize the autonomous role they can play in their health and well-being. Patients will be trained on breathing as a relaxation technique. The second session focuses on building behavioural skills to manage common symptoms for colorectal cancer patients. The third session focuses on cognitive strategies to address worries and existential distress. The last session focuses on maximizing social support and applying skills learned so far in dealing with loved ones. Participants will be provided an MP3 player that contains the relaxation exercise recording and a folder with summaries of the session content.
224168508|NCT00782106|BIOLOGICAL|Recombinant human hyaluronidase + immune globulin intravenous|Dose (calculated) of rHuPH20 followed by subcutaneous infusion of IGIV, 10% to determine tolerability: doses of rHuPH20 and IGIV, 10% to be increased, as tolerated and as per protocol, until a full 4-week IgG dose can be administered
224168509|NCT00782106|BIOLOGICAL|Recombinant human hyaluronidase + immune globulin intravenous|"1. IV infusion of IGIV, 10% to determine pharmacokinetics~2. Intervention as in Arm 1: Dose (calculated) of rHuPH20 followed by subcutaneous infusion of IGIV, 10% to determine tolerability: doses of rHuPH20 and IGIV, 10% to be increased, as tolerated and as per protocol, until a full 4-week IgG dose can be administered"
224168510|NCT00320190|DRUG|Imatinib|Imatinib tablets administered orally at a dose of 400 mg twice daily. Each 400- mg dose to be taken with a meal and a large glass of water.
224168511|NCT00320190|DRUG|Dasatinib|Dasatinib tablets administered orally at a dose of 100 mg once daily.
224168512|NCT06503133|OTHER|Birth preparation training|Birth preparation training is based on Albert Bandura's self-efficacy theory. It is a 60-minute training once a week. The first 10 minutes of the training are devoted to the initial activity, 40 minutes to sharing the training content, and 10 minutes to answering the participants' questions and receiving feedback. The training will be conducted in closed groups via the online meeting program (Zoom®).
224168513|NCT06503133|OTHER|Prenatal yoga practice|Prenatal yoga practice is a 60-minute practice once a week. The first 5 minutes of the prenatal yoga practice are devoted to guided meditation, 40 minutes to active asanas (yoga pose), 5 minutes to pranayama practice (breathing exercise) and 10 minutes to savasana (relaxing yoga pose). Prenatal yoga practice will be conducted in closed groups via the online meeting program (Zoom®)
224168514|NCT00620737|BIOLOGICAL|Autologous Human Fibroblasts (Isolagen TherapyTM)|"1. Collection of skin biopsy.~2. Administration of 2 study injections~3. Performance of various study assessments during clinic visits"
224168515|NCT00620737|BIOLOGICAL|Placebo|"1. Collection of skin biopsy.~2. Administration of 2 study injections~3. Performance of various study assessments during clinic visits"
224168516|NCT00515554|DRUG|Rituximab|addition of Rituximab to BEACOPP escalated
223481128|NCT03347591|DIAGNOSTIC_TEST|Several assays|Patients will be approached by their own treating physician. Data will be collected through questionnaires, a clinical interview, a blood and saliva sample obtained from each participant, and thorough review of electronic patient records. All procedures are study related. In case a physician visit with the treating physician is already planned, or in case a venepuncture for regular diagnostics or treatment is already planned, this can be combined with the study procedures to prevent an extra visit.
223481129|NCT01445340|DRUG|Romidepsin (FR901228)|
224168517|NCT00515554|DRUG|BEACOPP escalated|chemotherapy with BEACOPP escalated
224168518|NCT05129683|OTHER|Anodal tDCS cerebellar stimulation group|Single-session atDCS (2 mA, 20 min). The active (anode) and the returning (cathode) electrodes will be placed bilaterally over the cerebellum (1 -2 cm below inion of occipital bone) and the right buccinator muscle, respectively Xbox kinect based balance and mobility training using games from Xbox Adventure Pack for 50 mins will also be given
223481130|NCT00423605|DRUG|Xyrem®|flexible dosing
223481131|NCT00744341|DRUG|SLV320|1.25mg i.v. bid
223481132|NCT00744341|DRUG|SLV320|3.75mg i.v. bid
223481133|NCT00744341|DRUG|SLV320|7.5mg i.v. bid
224168519|NCT05129683|OTHER|Anodal tDCS cerebral (M1) stimulation group|single session a-tDCS (2 mA, 20 min), the anode will be positioned over the lesioned M1 (C3, International 10-20 system) and the cathode would be located over the supraorbital area. xbox kinect based balance and mobility training using games from Xbox Adventure Pack for 50 mins.
224168520|NCT05129683|OTHER|sham group|single session a-tDCS (2 mA, 20 min), Sham tDCS followed a similar protocol as Anodal tDCS cerebral (M1) stimulation and arrangement but stimulation for 30 s, after which the current was ramped-down and turned off for the rest of the treatment. xbox kinect based balance and mobility training using games from Xbox Adventure Pack for 50 mins.
224168521|NCT04429074|PROCEDURE|Minimally invasive distal pancreatectomy|Minimally invasive distal pancreatectomy
224168522|NCT03780088|BEHAVIORAL|mTranS-C|mobile health
223481134|NCT00744341|DRUG|SLV320|15.0mg i.v. bid
223481135|NCT00744341|DRUG|Placebo|
223481136|NCT02101567|DRUG|Pabal 100 mcg iv infusion over 1 minute given after delivery of fetal head|In the first group of patients, carbitocin 100 mcg will be given iv infusion over one minute after delivery of the head in cesarean section.
223481137|NCT02101567|DRUG|Oxytocin 5 IU iv infusion and Methtergine 0.2 mg iv|In the second group of patients oxytocin 5 IU will be given iv infusion and Methergine 0.2 mg iv
223481138|NCT00396292|DRUG|Oral iron tablets|325 mg tablets (65 mg elemental iron) with instructions to take 1 tablet by mouth (PO) TID with 8 ounces of tap water, 1 hour before meals from Day 0 until Day 42
223481139|NCT00396292|DRUG|VIT-45|A maximum of 1,000 mg iron as IV VIT-45 given at weekly intervals until the the cumulative dose has been reached or a maximum of 2,500 mg has been administered
223481140|NCT05243706|DRUG|Loratadine|Intervention is given to study its' effect on vinca alkaloids induced neuropathy
223481141|NCT05243706|DRUG|Diosmin/ Hesperidin|Intervention is given to study its effect on vinca alkaloids induced neuropathy
223481142|NCT05203315|DRUG|Duobrii 0.01 % / 0.045 % Topical Lotion|Duobrii® lotion (halobetasol propionate \[HP\] and tazarotene \[Taz\] 0.01%/0.045%) is currently on the market for the treatment of moderate to severe stable plaque psoriasis, and is classified as a high potency (Class II) corticosteroid.
223584990|NCT00605891|DRUG|carmoterol (CHF 4226)|"carmoterol pMDI 4.0 μg once a day, in the morning~(1 puff of carmoterol 2.0 mcg + 1 puff of carmoterol 2.0 mcg)"
223584991|NCT00605891|DRUG|salmeterol|Salmeterol 50 μg DPI, in the morning and in the evening (1 blister BID)
223584992|NCT00605891|DRUG|placebo|Placebo pMDI once a day, in the morning (1 puff of placebo pMDI + 1 puff of placebo pMDI)
223584993|NCT03917550|BEHAVIORAL|Recovery (Transdiagnostic & self)|This transdiagnostic program is based on the general Cognitive Behavioral Therapy (CBT) principles and targets core higher order factors such as negative affectivity and emotion dysregulation, using common intervention techniques applicable across disorders. The program was designed to directly address the aversive emotional experiences often reported by clients, hoping to reverse participants' maladaptive thinking style and dysfunctional behaviors. In addition, specific intervention designed to improve self-compassion, unconditional self-acceptance, self-esteem and self concept clarity were added.
224168523|NCT01611311|DRUG|BI 409306|Film-coated tablet
224168524|NCT01611311|DRUG|Placebo|Elderly healthy subjects received 50 mg of BI 409306 film-coated tablets orally after an overnight fast once daily for 14 days
224168525|NCT01376505|BIOLOGICAL|HER-2 vaccine|Three intramuscular (IM) injections (separated by 21 days) of a mixture of two peptides {MVF-HER-2(597-626) and MVF-HER-2 (266-296)} vaccine emulsified with nor-MDP in ISA 720 vehicle. Increasing doses of the combined vaccine preparation emulsified with nor-MDP (0.025) mg and Montanide ISA 720 will be administered in a final volume of 1.0 ml. Starting at dose level 1, 1.0mg of each peptide will be used for vaccination. In increasing dosing cohorts 1.5mg, 2.0mg and 2.5mg will be used. Patients may also receive 6 months booster shots.
224168526|NCT01376505|BIOLOGICAL|Extension HER-2 vaccine trial at OBD|Three intramuscular (IM) injections (separated by 21 days) of a mixture of two peptides {MVF-HER-2(597-626) and MVF-HER-2 (266-296)} vaccine emulsified with nor-MDP in ISA 720 vehicle. The dose level has been determined to be cohort 2. The combined vaccine preparation consists of 1.5mg of each of the HER-2 vaccine emulsified with nor-MDP (0.025) mg and Montanide ISA 720 will be administered in a final volume of 1.0 ml. Patients may also receive 6 months booster shots.
224168527|NCT00433927|DRUG|5-FU|5-FU 400 mg/m² Bolus day 1 5-FU 2400 mg/m² iv over 46 h day 1-2
224168528|NCT00433927|DRUG|folinic acid|Folinsäure (racemisch) 400 mg/m² iv, 120 min d 1
224168529|NCT00433927|DRUG|irinotecan|Irinotecan 180 mg/m² iv, 30 - 90 min day 1
224168530|NCT00433927|DRUG|cetuximab|Cetuximab initial 400mg/m² as 120 min infusion, than 250 mg/m² iv as 60 min infusion d 1 + 8
224168531|NCT00433927|DRUG|bevacizumab|Bevacizumab 5 mg/kg iv over 30 to 90 minutes d 1
224168532|NCT01636167|DEVICE|computerized intraoperative keratomer|computerized intraoperative keratomer can analyze the axis of corneal astigmatism accurately as well as rapidly by self-designed software during surgery
224168533|NCT00655239|BEHAVIORAL|Neuroadaptive cognitive training|Neuroadaptive cognitive training includes cognitive remediation exercises that participants will practice 1 hour per day, 5 days per week, for 8 weeks. The exercises are specifically designed to improve speed and accuracy in the perception of and response to verbal targets. The treatment will focus on TCT.
224168534|NCT00655239|BEHAVIORAL|Computer games|The control treatment involves commercially available computer games that participants will practice 1 hour per day, 5 days per week, for 8 weeks.
224168535|NCT06168981|OTHER|Chewing Gum|The patient will be asked to chew gum before the surgery during the 2 minutes. Anxiety level will evaluated before and after chewing gum.
224168536|NCT06302608|GENETIC|NGGT001|Safety and Effectiveness of subretinal injection of NGGT001 for treating crystalline retinal degeneration
224168537|NCT05637567|DRUG|Acetylsalicylic acid|100 mg per os once daily
224168538|NCT05637567|DRUG|Placebo|Placebo pill per os once daily
224168539|NCT03028532|DRUG|Clomid|Participants will self-administer Clomid (50mg oral tablet) once daily for 30 consecutive days
224168540|NCT01251315|DRUG|Placebo low dose|This is a prospective randomized controlled pilot study, which will include twenty-four (24) healthy individuals.The first 12 subjects (low dose) will be randomized into three sub groups. The first group will be given a single dose of placebo.
224168541|NCT01251315|DRUG|N Acetyl cysteine, 600mg (low dose)|The sub-group of four subjects (low dose) will be given a single dose of 600 mg of N-Acetyl Cysteine (NAC).
224168542|NCT01251315|DRUG|Proimmune 200 (FT061452) 3000mg low dose|The sub-group of four subjects (low dose) will be given a single dose of Proimmune 200 (FT061452) 3000mg low dose'
224168543|NCT01251315|DRUG|Placebo (high dose)|The second sub set of 12 subjects (high dose) will be randomized into three sub groups. The first group will be given a single dose of placebo.
223584994|NCT03917550|BEHAVIORAL|Transdiagnostic|This transdiagnostic program is based on the general Cognitive Behavioral Therapy (CBT) principles and targets core higher order factors such as negative affectivity and emotion dysregulation, using common intervention techniques applicable across disorders. The program was designed to directly address the aversive emotional experiences often reported by clients, hoping to reverse participants' maladaptive thinking style and dysfunctional behaviors.
223584995|NCT02784600|DEVICE|Bioinductive implant|
224168544|NCT01251315|DRUG|N Acetyl cysteine, 1200mg (high dose)|N Acetyl cysteine (high dose) N-Acetyl Cysteine(NAC)1200mg (high dose) given as a single dose.
224168545|NCT01251315|DRUG|FT061452, 6000mg high dose|Proimmune 200(FT061452) high dose group given 6000 mg as a single dose.
224168546|NCT03455504|DRUG|Venetoclax|Venetoclax add in combination with fludarabine, cyratabine and idarubicine
224168547|NCT02672644|DEVICE|Emervel Classic|Subjects requiring bilateral correction of NLFs and meeting eligibility criteria will be enrolled and treated with Emervel Classic (moderate NLFs; WSRS = 3/3)
224168548|NCT02672644|DEVICE|Emervel Deep|Subjects requiring bilateral correction of NLFs and meeting eligibility criteria will be enrolled and treated with Emervel Deep (severe NLFs; WSRS = 4/4).
223584996|NCT01458834|BEHAVIORAL|Attention bias modification task|Participants will complete a computerized probe-discrimination task from their home computer or handheld electronic device 3 times per day for one week. Each training session will consist of 160 trials. In each trial, two pictures (smoking-related or neutral) will appear on the screen simultaneously and then disappear. An arrow will appear in the location of one of the pictures (\< or \>). Participants are asked to quickly identify the direction of the arrow by pressing a button. In the active training task, the arrow will replace the neutral pictures 80% of the time.
223617566|NCT03526744|DIETARY_SUPPLEMENT|marine protein hydrolysate 4123|"Dietary Supplement for e.g. in this order: MPH 1600 mg for 7 days, than 7 days wash-out. Dietary Supplement: MPH 800 mg for 7 days, than 7 days wash-out. Dietary Supplement: MPH 3200 mg for 7 days, than 7 days wash-out. Dietary Supplement: MPH 2400 mg for 7 days, than 7 days wash-out."
223617567|NCT02619760|DRUG|1-month DAPT|1-month dual antiplatelet therapy (DAPT) composed of aspirin and P2Y12 receptor antagonists
224168549|NCT02669446|DEVICE|Medical devices|
224168550|NCT02669446|DEVICE|traditional household remedy|
224168551|NCT00916396|DRUG|Dehydroepiandrosterone|100 mg of DHEA a day (50 mg twice a day) for six weeks
224168552|NCT00916396|DRUG|placebo|100 mg of Placebo a day (50 mg twice a day) for six weeks
224168553|NCT00102804|DRUG|Pemetrexed|500 milligrams per square meter (mg/m\^2), intravenous (IV) administration, every (q) 21 days, until disease progression
224168554|NCT00102804|DRUG|Placebo|IV administration, q 21 days
223481143|NCT05203315|DRUG|CeraVe, Topical Cream|CeraVe cream will be used twice daily (in the morning and again in the evening) by the study participant in conjunction with Duobrii and Hydrocortisone cream.
223584997|NCT01458834|BEHAVIORAL|Control Condition|Participants will complete a computerized probe-discrimination task from their home computer or handheld electronic device 3 times per day for one week. Each training session will consist of 160 trials. In each trial, two pictures (smoking-related or neutral) will appear on the screen simultaneously and then disappear. An arrow will appear in the location of one of the pictures (\< or \>). Participants are asked to quickly identify the direction of the arrow by pressing a button. In the control training task, the arrow will replace the neutral and smoking-related pictures with equal frequency.
224168555|NCT00102804|OTHER|Best Supportive Care|Treatment without a specific antineoplastic regimen, given with the intent to maximize quality of life, as judged by the treating physician.
224168556|NCT03993301|OTHER|Probiotic A formula|Feeding baby two meals a day with Infant formula with probiotics (10\^8 colony-forming unit per day) at least.
224168557|NCT03993301|OTHER|Probiotic B formula|Feeding baby two meals a day with Infant formula with probiotics (10\^8 colony-forming unit per day) at least.
224168558|NCT03993301|OTHER|Regular formula|Feeding baby two meals a day with regular formula at least.
224168559|NCT04273568|OTHER|Scapular PNF|Rhythmic initiation and repetitive stretching techniques in scapula anterior elevation-posterior depression and anterior depression-posterior elevation patterns were applied twice a week for 6 weeks.
224168560|NCT04273568|OTHER|Exercise program|An exercise program consisting of exercises used in the conservative treatment of shoulder impingement syndrome for both groups was applied twice a week for 6 weeks.
224168561|NCT02507050|DRUG|Ivabradine|To start Ivabradine 6 weeks prior to PCI.
224168562|NCT01896414|DIETARY_SUPPLEMENT|EPA (marine fatty acids)|Subjects will be randomized to receive either EPA or placebo, four 1 gram capsules daily.
224168563|NCT01896414|DIETARY_SUPPLEMENT|Placebo|Subjects will be randomized to receive either EPA/ or placebo, four 1 gram capsules daily.
224168564|NCT00877227|DRUG|5-formyltetrahydrofolate (10 mg/ml) (Pharmachemie bv)|Folinic acid was given for two weeks as 5-formyltetrahydrofolate (10 mg/ml) (Pharmachemie bv). This solution was administered either intravenously (first week) or orally. To lower homocysteine in adults 5 mg/day folic acid is frequently used. Using an average bodyweight of 70 kg for adults we calculated a daily dose of 70 microgram/kg/day for our newborns.
224168565|NCT03769389|DIETARY_SUPPLEMENT|Birhi|"Birhi which contain the following:~43.6g of Freeze-dried date powder+ 150g of 0% fat yoghurt"
224168566|NCT03769389|DIETARY_SUPPLEMENT|Khassab|34.6g of freeze-dried date powder+ 150g of 0% fat yoghurt
224168567|NCT03769389|DIETARY_SUPPLEMENT|placebo|50g of pure glucose dissolved in 100ml of water
223584998|NCT04730427|DRUG|GX-I7|Recombinant human interleukin-7 hybrid Fc
223584999|NCT04730427|DRUG|GX-I7 vehicle|Formulation buffer of recombinant human interleukin-7 hybrid Fc
223585000|NCT03623061|DIAGNOSTIC_TEST|F-Point|F-Point (point of care in vitro diagnostic device for measuring plasma fibrinogen concentration)
223585001|NCT01496105|DRUG|Lidocaine|
223585002|NCT01496105|DRUG|saline|
223585003|NCT06269237|DEVICE|M22|"Participants in the group with 3 sessions of IPL, 2 weeks apart. Device: Intense pulsed light IPL treatment intensity was chosen based on the Fitzpatrick scale as follows: Fitzpatrick scale I, II, III, 10-15 J/cm2 with a 570-nm filter.~Other Names:~• IPL"
223585004|NCT06269237|DEVICE|sham M22|Participants in the group with 2 sessions of IPL, 1 session of sham IPL, 2 weeks apart. Device: Intense pulsed light IPL treatment intensity was chosen based on the Fitzpatrick scale as follows: Fitzpatrick scale I, II, III, 10-15 J/cm2 with a 570-nm filter.
224168568|NCT05736042|DEVICE|Lens fragmentation|Lens fragmentation with the microinterventional microfilament loop device (miLOOP)
224168569|NCT00407251|DRUG|Patupilone|
224168570|NCT00683774|DRUG|diazoxide|100mg orally three times per day for 10 days
224168571|NCT03623204|OTHER|Dyspnea evaluation|
224168572|NCT02484040|RADIATION|Two-week course of radiation|33 Gy in 10 fractions for 2 weeks
224168573|NCT02484040|DRUG|Two-week course of radiation|oral capecitabine, 825mg/m2, bid
223481144|NCT03183908|BIOLOGICAL|FLUAD®|Advisory Committee on Immunization Practices (ACIP) Recommended Vaccine
224168574|NCT00001302|DRUG|PSC 833|
224168575|NCT03148249|OTHER|interview|control group: interview, study group: explanation and exploration
224168576|NCT03330548|BEHAVIORAL|TeleMOVE!|Active comparator- telehealth treatment program for weight management and health promotion
224168577|NCT03330548|BEHAVIORAL|Culinary Rx|Experimental Arm- An online instructional cooking and nutrition course to promote a whole-foods, plant-based lifestyle.
224168578|NCT04673630|BIOLOGICAL|Tezepelumab|Single dose subcutaneous injection
224305400|NCT03569228|DEVICE|Study 3 (experimental closed-fit)|Experienced hearing aid user receiving replacement receiver in the canal (RIC) or receiver in the aid (RITA) hearing aids with CLOSED coupling that are fitted and verified in a test box coupler, then mailed to the patient for a 4-week field trial.
224305401|NCT01758055|BIOLOGICAL|Autologous MSCs transplantation|Autologous mesenchymal stem cells derived bone marrow, bronchoscopy
224305402|NCT02039466|PROCEDURE|volume controlled ventilation|
224305403|NCT02039466|PROCEDURE|pressure controlled ventilation|
223481145|NCT03183908|BIOLOGICAL|Fluzone® High-Dose|Advisory Committee on Immunization Practices (ACIP) Recommended Vaccine
224305404|NCT02880657|DIETARY_SUPPLEMENT|SODB®|Subjects are supplemented with SODB®, daily over 10 weeks. Each volunteer was seen for the 4 visits: - visit of pre-inclusion V1, - visit V2, so-called inclusion visit, - visit V3 after 4 weeks of physical training and - visit V3 after 8 weeks of physical training
223481146|NCT06078982|DRUG|Disitamab Vedotin|2.0mg/kg, intravenously D1, once every 14 days (Q2W)
223481147|NCT06078982|DRUG|Toripalimab|3.0 mg/kg, once every 14 days (Q2W)
223481148|NCT05031767|OTHER|Usual care|"Conventional follow-up strategy with blood tests, patient-reported outcomes, and pre-scheduled visits at the hospital every 6th month.~Continue using medical treatment with tumour necrosis factor inhibitors (TNFi). Patients will be instructed to use NSAIDs should they experience minor worsening of symptoms, but if the patients experience significant symptom worsening and suspect a severe disease worsening (flare) or adverse events, they will be instructed contact the hospital."
224168579|NCT02308709|RADIATION|Ventilation image-guided radiotherapy|Patient's treatment plan will be created and optimized to minimize the dose to highly-functional lung regions
223481149|NCT05031767|OTHER|Remote monitoring|"Hospital health professionals perform remote monitoring of frequent patient-reported outcomes, blood test results, and physical activity data available on a digital platform.~Continue using medical treatment with tumour necrosis factor inhibitors (TNFi). Patients will be instructed to use NSAIDs should they experience minor worsening of symptoms, but if the patients experience significant symptom worsening and suspect a severe disease worsening (flare) or adverse events, they will be instructed contact the hospital ."
223481150|NCT05031767|OTHER|Patient-initiated care|"No pre-scheduled visits or remote monitoring.~Continue using medical treatment with tumour necrosis factor inhibitors (TNFi). Patients will be instructed to use NSAIDs should they experience minor worsening of symptoms, but if the patients experience significant symptom worsening and suspect a severe disease worsening (flare) or adverse events, they will be instructed contact the hospital."
223585005|NCT02688868|DEVICE|FirehawkTM 2.25mm|Implantation of the released specification (2.25mm) of FirehawkTM rapamycin target-eluting coronary stent systems
224168580|NCT02875782|BEHAVIORAL|Smoking cessation and DM specific component intervention|A brief stage-matched smoking cessation intervention plus a DM-specific leaflet on smoking cessation
224168581|NCT02875782|BEHAVIORAL|Control group|A simple, brief advice and a self-help general leaflet on smoking cessation
224168582|NCT05612191|DRUG|AL3818|It inhibits VEGFR2-mediated downstream signal transduction, thereby inhibiting tumor angiogenesis. It also has high potency against FGFr as well as VEGFr, and as such acts as a mainly dual inhibitor.
223481151|NCT04413045|OTHER|Prevalence of COVID-19|All COVID-19 cases to be admitted in the assigned hospital with positive results of nasopharyngeal swab for SARS-CoV-2 during one-month duration.
223481152|NCT03977480|DRUG|Hemay007|Hemay007 will be orally administered.
223481153|NCT03977480|DRUG|Placebo|Placebo
223481154|NCT01060501|DRUG|Folinic Acid, interferon-alpha|5-FU, 450 mg/m² i.v. for 60 min, weekly for 52 weeks postoperatively Folinic acid, 200 mg/m² i.v. 10 min, weekly for 52 weeks postoperatively 6x10 (high6) I.U. as subcutaneous self injection 3x weekly. Training of self injection was initiated on day 28 (duration until week 52)
223481155|NCT00132626|DRUG|[123I]ß-CIT and SPECT imaging|
223481156|NCT03920800|OTHER|Data extraction from medical files|Data extraction from medical files
223481157|NCT03920800|BIOLOGICAL|Immunohistochemistry|Immunohistochemistry with Ki67 and p16 antibodies on residual samples, if this had not been foreseen in the standard of care management of the patient.
223481158|NCT01562990|DRUG|Rituximab, CMC544, Gemcitabine and Oxaliplatine|"2 cycles of induction of 56 days each, starting with the administration of R-CMC544 on day 1, followed by the administration of R-GEMOX on day 29 and 43.~2 cycles of consolidation of 56 days each, starting with the administration of R-CMC544 on day 1, followed by the administration of R-GEMOX on day 29 and 43."
223481159|NCT04159376|DIAGNOSTIC_TEST|PET/MR|"All patients will have a PET/CT and PET/MR study performed at the same clinical setting using a single dose of tracer administration.~The study cohort includes 150 patients 18 years or older, having metastatic skeletal involvement on baseline PET/CT prior to treatment. Baseline studies and follow up studies of the patients referred post treatment, will be reviewed.~The tracers will be FDG, labelled PSMA labelled Somatostatin and F-DOPA in order to assess skeletal lesions detection of all tumor types.~Skeletal lesions will be divided into marrow-based lesions, lytic, blastic and scleroric lesions. Tracer uptake will be measured at baseline and after treatment. Metabolic PET parameters, CT appearance and MR parameters will be assessed.~The best MR-based attenuation algorithm for detection of lesions and monitoring response will be derived."
223481160|NCT00623610|PROCEDURE|islet cell grafts|Intraportal injection of an islet cell graft into the liver.
223481161|NCT01278368|PROCEDURE|Pancreatic resection after preoperative chemotherapy|Pancreatic resection after preoperative chemotherapy
223481162|NCT01278368|PROCEDURE|Pancreatic resection|Pancreatic resection
223481163|NCT05393219|OTHER|Cardiac biofeedback|6 minutes of relaxing breathing exercise coupled with heart rate variability biofeedback guided on emWave Pro software on a computer just before entering the examination circuit
223585006|NCT05687006|PROCEDURE|Colour Doppler Ultrasound|The main perforators were examined using a LOGIQ S8/V1 CDU device (GE Healthcare, Chalfont St Giles, Great Britain) with a linear transducer of frequency 4-11 MHz. Measured parameters were: 1) calibre of artery and vein; 2) Peak systolic velocity (PSV) of blood in the artery \[cm/s\]; 3) blood velocity in the perforator vein \[cm/s\]; 2) the thickness of the subcutaneous tissue of the lower abdomen measured 4 cm caudal and lateral to the umbilicus. Any additional perforators were marked nor have CTA deducted XY coordinates of marked perforators changed based on the CDU examination. The same sonography surgeon performed all CDU examinations. The time duration of the CDU examination was measured.
223481164|NCT05393219|OTHER|Mindfulness|6 minutes of a guided video tape made for the study that inspires mindfulness like meditation associated just before entering the examination circuit.
223481165|NCT05393219|OTHER|Resources mobilization|6 minutes of a guided video tape that purpose to mobilize inner resources and strength of the student just before entering the examination circuit.
223481166|NCT05393219|OTHER|Control|6 minutes of standardized neutral video on general topics that generates no modification of affects just before entering the examination circuit.
223617568|NCT02619760|DRUG|12-month DAPT|12-month dual antiplatelet therapy (DAPT) composed of aspirin and P2Y12 receptor antagonists
224168583|NCT02141854|DRUG|FS MDPI|"FS MDPI is an inhalation-driven multidose dry powder inhaler (MDPI) containing fluticasone propionate and salmeterol xinafoate dispersed in a lactose monohydrate excipient and contained within a reservoir. A metered dose of drug is delivered to a dose cup via an air pulse activated when the cap is opened.~During the treatment period, participants were randomized to either fluticasone propionate/salmeterol MDPI 200/12.5 mcg or fluticasone propionate/salmeterol MDPI 100/12.5 mcg twice a day for a total daily dose of 200/25 mcg or 400/25 mcg.~Participants were instructed to rinse their mouth and expectorate (not swallow) after study drug administration."
224305405|NCT02880657|DIETARY_SUPPLEMENT|Placebo|Subjects are supplemented with Placebo, daily over 10 weeks. Each volunteer was seen for the 4 visits: - visit of pre-inclusion V1, - visit V2, so-called inclusion visit, - visit V3 after 4 weeks of physical training and - visit V3 after 8 weeks of physical training
224305406|NCT03690882|OTHER|systematic review of medical imaging|
224168584|NCT02141854|DRUG|Fp MDPI|"Fp MDPI is an inhalation-driven multidose dry powder inhaler (MDPI) containing fluticasone propionate (Fp) dispersed in a lactose monohydrate excipient and contained within a reservoir. A metered dose of drug is delivered to a dose cup via an air pulse activated when the cap is opened.~During the treatment period, participants were randomized to either 200 mcg or 100 mcg of Fp one inhalation twice a day for a total daily dose of 400 mcg or 200 mcg.~Participants were instructed to rinse their mouth and expectorate (not swallow) after study drug administration."
224168585|NCT02141854|DRUG|Placebo MDPI|The placebo multidose dry powder inhaler (MDPI) was identical to the devices used to deliver active drug, and indistinguishable from the active treatments. Patients took one inhalation twice a day (approximately 12 hours apart). Patients were instructed to rinse their mouth and expectorate (not swallow) after study drug administration.
224168586|NCT02141854|DRUG|Albuterol/salmeterol HFA MDI|Albuterol/salmeterol hydrofluoroalkane (HFA) metered dose inhaler (MDI) was supplied to participants throughout the study to be used as needed as a rescue medication.
224168589|NCT07101991|OTHER|Standard monitoring|Administration of fluids and vasoactive drugs guided by standard vital signs monitoring
224168590|NCT07101991|OTHER|Goal-Directed Therapy|Administration of fluids and vasoactive drugs guided by non-invasive haemodynamic monitoring
224168591|NCT07100262|OTHER|Effortful swallow exercise|"The participants will be practiced effortful swallow exercises as follows:~When you are ready to swallow your saliva, squeeze your tongue against the roof of your mouth.~B) As you swallow squeeze all the muscles in your throat. Imagine you are trying to swallow a large tablet or a golf ball.~C) If it has been recommended by your speech and language therapist, this exercise may be repeated when eating and drinking.~Frequency of exercise:~Exercises will be two 30-minutes sessions of effortful swallow practice daily, 5 days/week.~For every patient: 4 sets (1 set = 8-12 repetitions) 5 days/week, for 18 weeks."
224168592|NCT07100262|DEVICE|Pulsed electromagnetic therapy|"The participants will receive pulsed electromagnetic therapy as the following:~Position of patient: supine lying position with head supported by pillow. Sleeve of device: above anterior neck area.~Parameters of application of device: according to programs for sarcopenia and muscular pain as the following:~Power: 30 GAUSS. Frequency: in first 6weeks: 5Hz - second 6weeks: 10Hz - last 6weeks: 15Hz. Time of session: 30 min. Sessions frequency: 3 sessions per week. Time of treatment course: 18 weeks."
223481167|NCT01688713|DRUG|Icotinib|The patients will receive Icotinib in doses of 250mg thrice per day until disease progression or undue toxicity.
224168593|NCT07101497|DRUG|BN104 monotherapy|BN104 will be started at 200 mg or 300mg, to a target dose of 400mg, twice daily, orally, 28 days a cycle, for a total of 24 to 36 cycles . When used in combination with posaconazoles and voriconazole, the dose of BN104 should be reduced by 50%.
223761381|NCT04642729|PROCEDURE|Fresh Corneal Lenticule Implantation using Relex-Smile Surgery|Knowing that the most important element is damage of stroma we used all preoperative procedures atlas, optic tomography and especially electron microscope. Approximately we planned how much microns we remove and insert, for example we remove 80 µm and we insert fresh corneal lenticule 90 µm with the purpose to remove more dead keratocytes which increase biomechanical instability of corneal metabolism (abnormal increase collagenase activity, decrease proteinase inhibitors, excessive premature keratocyte apoptosis, increase cytokine binding). Fresh Corneal Lenticule and autologous serum contains live stem cells that produce keratocytes, collagen fibers, extracellular matrix which contribute to the regeneration of the cornea, and all this results at increasing of corneal transparency and visual acuity in patients with corneal macular dystrophy.
224168594|NCT07101354|DRUG|0.01mg/kg DGPR1008 Injection Dose Group 1 (n=6)|Within the specified time period, conduct dose escalation, and administer the corresponding dose via intravenous drip according to the randomization information.
224168595|NCT07101354|DRUG|0.02mg/kg DGPR1008 Injection Dose Group 2 (n=6)|Within the specified time period, conduct dose escalation, and administer the corresponding dose via intravenous drip according to the randomization information.
224168596|NCT07101354|DRUG|0.04mg/kg DGPR1008 Injection Dose Group 3 (n=6)|Within the specified time period, conduct dose escalation, and administer the corresponding dose via intravenous drip according to the randomization information.
224305407|NCT04795908|DEVICE|Transcranial Magnetic Stimulation|rTMS will be delivered using a MagStim Super Rapid2 TMS therapy system.
223481168|NCT06098183|OTHER|Whey Protein Isolate|Whey protein isolate essential amino acids (25 g), 5.5 grams of branched-chain amino acids (BCAAs), and 2.7 grams of Leucine per serving
223481169|NCT06098183|OTHER|Non-caloric Placebo water|Non-caloric placebo
224168597|NCT07101354|DRUG|0.08mg/kg DGPR1008 Injection Dose Group 4 (n=6)|Within the specified time period, conduct dose escalation, and administer the corresponding dose via intravenous drip according to the randomization information.
223481171|NCT03738696|DRUG|Exparel|A long-acting injectable sodium channel blocker bound to lipid that is indicated in controlling postoperative pain
223481172|NCT03738696|DRUG|Ropivacaine|A short-acting injectable sodium channel blocker bound to lipid that is indicated in controlling postoperative pain
224168598|NCT07101354|DRUG|Dose Group 0 (n=8)|Within the specified time frame, dose escalation will be conducted. Intravenous infusions will be administered according to randomization, with subjects receiving either the corresponding dose or placebo.
224168599|NCT07100509|OTHER|Major Vascular Injury During Elective Thoracic Surgery|This exposure refers to patients who experienced major vascular injuries during elective thoracic surgery. Injuries involved central vessels such as the subclavian artery, brachiocephalic vein, superior vena cava, and innominate vein. No experimental intervention was applied. The study retrospectively evaluated the surgical management, transfusion requirements, preoperative planning, and clinical outcomes associated with these intraoperative events.
224168600|NCT07101120|DRUG|KH607 tablets|oral 30mg , once daily for 14 days
224168601|NCT07101120|DRUG|placebo|oral, once daily for 21 days
224168602|NCT07101120|DRUG|KH607 tablets|oral 20mg, once daily for 21 days
224168603|NCT07101120|DRUG|KH607 tablets|oral 30mg, once daily for 21 days
224305408|NCT04795908|BEHAVIORAL|Comprehensive behavioral intervention|Patients will receive CBIT with a therapist trained in CBIT. Each session will last about an hour and will be delivered remotely via telemedicine. Sessions will be tailed to the patient's individual needs.
223481173|NCT00197743|DIETARY_SUPPLEMENT|Vitamin A + Beta Carotene|one daily oral dose of 30 mg beta-carotene + 5000 IU preformed vitamin A
223481174|NCT00197743|DIETARY_SUPPLEMENT|Multivitamins|one daily oral dose of 20 mg thiamine (vitamin B-1), 20 mg riboflavin (vitamin B-2), 25 mg vitamin B-6, 100 mg niacin, 50 ug cobalamin (vitamin B-12), 500 mg vitamin C, 30 mg vitamin E, and 0.8 mg folic acid
224168604|NCT07102511|BIOLOGICAL|lerodalcibep 300 mg Monthly SC|lerodalcibep or placebo
224168605|NCT06535932|DEVICE|Amara View Minimal Contact Full Face Mask|The Amara View Full-Face Mask is a minimal contact full face mask manufactured by Philips Respironics (Murrysville, PA) that covers the mouth and seals under the nose compared to traditional full-face masks which seal over the nose. The Amara View mask is intended to reduce discomfort on the bridge of the nose. There is no forehead arm, offering patients an enhanced design to keep the field of vision clear.
224168606|NCT06535932|DEVICE|F40 Minimal Contact Full Face Mask|The AirFit F40 is a minimal contact FFM manufactured by ResMed (San Diego, CA) that rests softly and securely under the patients nose and is designed to let patients sleep in any position and move freely throughout the night. The mask consists of three cushion sizes and three headgear sizes. Headgear adjustments can be made with magnetic clips that easily snap on and off.
224168607|NCT06917651|DRUG|sufentanil sublingual 30 mcg tablet|"patient randomized in the SST 30mcg arm will receive a 30-microgram sublingual sufentanil tablet"
223481175|NCT00197743|OTHER|Placebo|Placebo pill
223481176|NCT02335281|PROCEDURE|FMT|Standardized FMT once
223585007|NCT06516744|DIETARY_SUPPLEMENT|Bye Bye Bloat Capsules|Bye Bye Bloat Capsules contain the following ingredients: Organic Fenugreek Seed Powder, Organic Dandelion Root Powder, Organic Fennel Seed Powder, Organic Ginger Root Powder, Organic Parsley Leaf Powder, Amylase Complex, Protease Complex, Pepsin Complex, Lipase Complex, Bromelain Complex, Papain Complex. Other ingredients include Hypromellose Capsule, Maltodextrin, Microcrystalline Cellulose, and Magnesium Stearate. Participants will take 2 capsules immediately after eating at least 3 times a week and during times of hormonal bloating for 4 weeks.
223585008|NCT00895661|DRUG|rituximab|Increased dose (750 mg/m2) intravenously for 4 weekly doses followed by maintenance dosing once every three months for up to 2 years. Maintenance dose is standard (375 mg/m2).
224168608|NCT06917651|OTHER|Standard of Care (SOC)|"patients randomized in the SOC arm will receive analgesic treatment according to the department's internal pain management protocol."
224168609|NCT06948448|DRUG|ONO-4578|ONO-4578 tablets once a day
224168610|NCT06948448|DRUG|Opdivo®|Specified dose on specified days
224168611|NCT06948448|DRUG|Oxaliplatin|Specified dose on specified days
224168612|NCT06948448|DRUG|5-Fluorouracil|Specified dose on specified days
224168613|NCT06948448|DRUG|Bevacizumab|Specified dose on specified days
224168614|NCT06948448|DRUG|Leucovorin|Specified dose on specified days
224168615|NCT06949579|BIOLOGICAL|blood sampling for DNA|Blood sampling for DNA and serum and plasma colection and PBMC
224168616|NCT06948994|COMBINATION_PRODUCT|autologous NK cell plus GD2 antibody|Combination of autologous NK cells and GD2 monoclonal antibody
223481177|NCT02335281|DRUG|Mesalazine|2g Po perday
223481178|NCT03890575|PROCEDURE|Airway stent implantation|The airway stents modified with 3D printing were implanted to treat malignant stricture involving carina and bronchi distal to carina.
223481179|NCT00407875|PROCEDURE|Intensity Modulated External Beam Radiation Therapy|
223481180|NCT01060462|DRUG|Pts. w/ neutropenic fever associated w/ hematologic malignancy|Itraconazole 200 mg twice daily for 2 days for a total of 4 doses, then 200 mg once daily for 12 days. After 14 days of IV administration, itraconazole oral solution 200 mg twice daily should be continued for a total of 14 days until clinically significant resolution of neutropenia resolves
223617569|NCT01316016|DIETARY_SUPPLEMENT|Rose hip|40 g of rose hip powder daily for 6 weeks.
224168617|NCT07147712|BEHAVIORAL|Psychological Group Intervention|6-session psychological group intervention, delivered once per week over six weeks. The intervention is designed to promote well-being and improve the quality of social relationships. It includes psychoeducational content, experiential exercises, and guided group discussions focused on emotional expression, social connection, and mutual support. A follow-up session will be offered after 4 weeks. Sessions will be led by trained psychologists and conducted in a university setting.
224168618|NCT07147998|OTHER|Oral hygiene instruction|Oral hygiene and gingival health of all patients were assessed using the Turesky Modification of the Quigley-Hein Plaque Index and the Gingival Index. Tooth brushing frequency was recorded. The 2D:4D ratio was calculated by dividing the second digit length by the fourth, with three measurements taken per finger to ensure reliability. A cut-off value of 1 was used to evaluate prenatal androgen influence, and participants were grouped by 2D:4D ratio (≥1 or \<1). All participants received standardized oral hygiene instructions from the same instructor, including Modified Bass brushing and interdental cleaning. A second clinical exam was performed one week later by the same examiner, and both indices were re-scored.
224168619|NCT07148882|DRUG|fentanyl|"Intra nasal fentanyl group: will receive intranasal fentanyl using nasal dose of INF is 1.5µg/kg/dose, and typically one dose is given After 5minutes, a second dose could be administrated based on the clinical assessment (maximum two doses per procedure).~Intravenous fentanyl group: will receive intravenous fentanyl 1 µg/kg/dose and typically, one dose is given After 5minutes, a second dose could be administrated based on the clinical assessment maximum two doses per procedure.~Measure MDA Malondialdehyde level as oxidative stress marker in pain response , venous blood sample 0.5 ml will be collected twice, just before and 30 minutes after the procedure.~Monitor adverse events after fentanyl use as apnea cessation of breathing for \>20 s, bradycardia heart rate \< 100 beats/minute, desaturation oxygen saturation \< 80%"
223481181|NCT04319224|DRUG|Vopratelimab|Specified dose on specified days
223481182|NCT04319224|DRUG|Ipilimumab|Specified dose on specified days
223481183|NCT04319224|DRUG|Nivolumab|Specified dose on specified days
223481184|NCT00559260|DEVICE|Passive monitoring with pulse-oximetry, NIBP and ECG|
223481185|NCT01595828|DRUG|Pitavastatin|
223481186|NCT00861081|BEHAVIORAL|Care Management|Over a period of one year, subjects will participate in two regular stroke clinics, three group clinics, obtain self-management tools, and will receive a series of four scheduled telephone calls by nurse practitioners to review information delivered during the group clinics and help with care coordination. Usual care will also be available.
223585009|NCT03576313|DRUG|dihydroartemisinin-piperaquine (DP)|DP will be available as tablets of 320/40mg and 160/20mg piperaquine/ dihydroartemisinin per tablet. Administration of a full course of DP will be done as per manufacturer's guidelines once daily for 3 days and according to body weight. DP will be taken orally with water and without food
223585010|NCT03576313|DRUG|ivermectin (IVM)|IVM will be available as tablets of 3mg or 6mg strength. It will be given at 300-400μg/kg/day over 3 days (to the nearest whole tablet). IVM will also be taken on an empty stomach with water
224168620|NCT07149311|BEHAVIORAL|Intervention|The intervention group will receive the usual consultation from their doctor and referral to a diabetes educator for individualised structured DSME training. A clinical sheet will be used while delivering the education to ensure that all core topics are covered. For this study, 2 diabetes educators will offer the individualised DSME sessions using the American Association of Diabetes Education (AADE) 7 self-care behaviour model. The participants are scheduled to attend a 1-hour individualised session at the hospital every 3 months as well as telephone consultations lasting up to 15 minutes every 2 weeks at the convenience of the participant to reinforce DSME for 6 months. The first session is arranged on the first day after consultation with the doctor. At the end of the sessions, the participants will receive a patient guide to diabetes booklet and graphic material illustrating several self-care activities such as foot care
224168621|NCT07147257|BIOLOGICAL|CHS-1420|Dose of 40 mg will be subcutaneously administered to participants in
224168622|NCT07147257|BIOLOGICAL|HUMIRA®|Dose of 40 mg will be subcutaneously administered to participants in
224168623|NCT07149077|DRUG|Echo-guided scalp blocks|Classic anesthetic strategy in association with echo-guided scalp blocks
224168624|NCT07149077|DRUG|Classic anesthetic strategy|classic anesthetic strategy with postoperative analgesia associating Paracetamol and Morphine with standardized dose.
224168625|NCT01820494|OTHER|Experimental Infant Formula|Infant formula to be fed ad libitum
224168626|NCT06481241|COMBINATION_PRODUCT|CAR-T cells|CAR-T cells as consolidation therapy
224168627|NCT06481241|DRUG|Venetoclax|VEN
224168628|NCT00638768|OTHER|Physiotherapy|10 weekly individual sessions with the therapist each lasting approximately 45 minutes. Techniques included postural taping, massage, mobilisation, exercises. The patients also performed home exercises
224168629|NCT01327924|DRUG|Norditropin NordiFlex®|Daily administration by subcutaneous injection (under the skin). Starting dose and frequency will be determined by the physician as part of normal clinical practice.
224168630|NCT04970433|PROCEDURE|Electroacupuncture (EA)|Acupuncture at Hegu (LI4), Neiguan (PC6), Zusanli (ST36), Sanyinjiao (SP6) and Sishencong (EX-HN1). Electrical stimulation with a pair of electrodes connecting on LI4/PC6 and ST36/SP6.
224168631|NCT04970433|PROCEDURE|Laser acupuncture (LA)|The laser applies to each point for 40 seconds, which delivers 3 J of energy at each of the acupoints as those in electroacupuncture group.
224168632|NCT04970433|PROCEDURE|Sham laser acupuncture (SLA)|The laser device without any laser output applies on the acupoints the same as those in the LA group.
223481187|NCT00861081|BEHAVIORAL|Written Materials|Educational materials about stroke that will be distributed during the group clinic session will be mailed to these subjects. These materials have been developed by the American Heart Association. Usual care will also be available.
223481188|NCT04319705|DRUG|Azithromycin|Azithromycin, 500mg, 3 times per week, 12-week treatment period, administered orally
223585011|NCT03576313|OTHER|standard malaria control interventions only|this is the standard malaria control interventions in the Gambia
223585012|NCT00046150|DRUG|Insulin glulisine (HMR1964)|
223585013|NCT03062241|PROCEDURE|Cryoablation|After left atrial appendage (LAA) thrombus exclusion, the transseptal puncture will be performed and intravenous heparin will be administered to achieve Activated Clotting Time (ACT) ≥300 seconds.The pulmonary vein (PV) isolation will be performed. Optimal cryoballoon positioning will be confirmed by PVs angiography. Pulmonary veins isolation will be confirmed by entrance/exit block using appropriate catheter. During cryoablation of the right PVs, high-output right phrenic nerve stimulation will be performed using a diagnostic catheter placed in the superior vena cava. Whenever decrease/loss of pacing capture will be observed, cryoablation will be immediately terminated.
223481189|NCT04319705|DRUG|Placebo oral tablet|capsule containing placebo, 3 times per week, 12-week treatment period, administered orally
223481190|NCT02566005|DEVICE|misoprostol|25mcg of misoprostol per vagina every 4hours per the standard hospital protocol. Once the cervix becomes favorable or if the patient is in active labor, or if there is no progress for 24 hours, misoprostol administration will be discontinued. Further management of labor will depend on the labor team. (25mcg tablets are not available commercially; a 100mcg table is cut into fourths by the hospital pharmacist).
223585014|NCT04325230|DEVICE|Arterial Spin Labeling sequence|ASL sequence added to the usual care brain MRI
223585015|NCT02072525|BIOLOGICAL|Menveo®|One dose administered intramuscularly (IM) in the upper left deltoid of the arm.
223585016|NCT02072525|BIOLOGICAL|Boostrix®|One dose administered intramuscularly (IM) in the upper right deltoid of the arm.
223585017|NCT02072525|BIOLOGICAL|Pneumovax 23®|One dose administered intramuscularly (IM) in the non-dominant deltoid of the arm.
223585018|NCT02072525|BIOLOGICAL|Prevnar 13®|One dose administered intramuscularly (IM) in the non-dominant deltoid of the arm.
223585019|NCT05701436|DRUG|Oxaliplatin|130 mg per square body surface area for a total of four transcatheter hepatic artery infusions per month.
224168633|NCT00665249|BEHAVIORAL|Motivational Interviewing|See MotivationalInterviewing.org
224168634|NCT00665249|BEHAVIORAL|Spirit-Only Motivational Interviewing|Non-directive elements encompass the use of MI-consistent, and avoidance of MI-inconsistent, behaviors, as well as attention to MI-spirit.
224168635|NCT00665249|OTHER|Self-Change|Participants are followed for 8 weeks, without therapeutic intervention. At end of assessment period, they receive 4 sessions of full MI.
224168636|NCT06388200|GENETIC|Sub-Retinal Administration of OCU400-301|Sub-Retinal Administration of OCU400-301
223761382|NCT04060407|DRUG|CD24Fc|CD24Fc will be administrated as IV infusion in a dose of 480 mg, q3w x 4, then q4w for up to 6 times.
223761383|NCT04060407|DRUG|Ipilimumab|Ipilimumab will be administrated as IV infusion, q3w x 4. For metastatic melanoma, the dose will be 3mg/kg, q3w x4.
224168637|NCT03057106|DRUG|Durvalumab|MEDI4736
224168638|NCT03057106|DRUG|Tremelimumab|Tremelimumab
224168639|NCT03057106|DRUG|Platinum-Based Drug|Pemetrexed, cisplatin, carboplatin or gemcitibine
223481191|NCT02566005|DEVICE|Foley bulb|a foley bulb will be inserted digitally or by direct visualization with the use of a sterile speculum. The foley will be inserted through the internal os and filled with 60cc of normal saline. The catheter will be taped to the patient's inner thigh under gentle traction. When the foley bulb has fallen out (spontaneous expulsion), further management of labor depends on the labor team. If this does not occur, the catheter will be deflated and removed after 24 hours.
223481192|NCT00080054|DRUG|Motexafin Gadolinium Injection|
223481193|NCT02834273|BEHAVIORAL|stroke education workshops|
223481194|NCT02905708|DEVICE|Air-Activated heating packs|The subject disrobe and will dress in a jacket, pants, gloves and socks (ensemble) which will be removed from a vacuum pack. He will be assisted by the nurse in pre-operative area. The ensemble will remain in place until the subject is fully recovered from anesthesia.
223481195|NCT02905708|DEVICE|Forced Air Warming Device|forced air-warming inflatable device applied according to standard hospital protocol.
223481196|NCT03332342|OTHER|Eye wash|Research subjects will perform a wash of their ocular surface with phosphate buffered saline
223481197|NCT02381691|OTHER|maternal breast milk odor|
223481198|NCT02381691|OTHER|no odor|
223481199|NCT06452550|DIAGNOSTIC_TEST|Logistic regression (LR) prediction models|Logistic regression model was used to establish a model to distinguish different levels of intestinal inflammation.
223481200|NCT02882971|BEHAVIORAL|Pain Assessment|To create an objective observational pain scoring system and validate.
223481201|NCT03617588|DRUG|Gallium-68 THP-PSMA|Subjects will undergo a Gallium-68 THP-PSMA scan in addition to standard of care monitoring. The results of this scan may influence the patient management plan.
223481202|NCT00732914|DRUG|Sunitinib (Sutent)|Sunitinib 50 mg once daily 4 weeks on, 2 weeks off, and after discontinuation (due to PD or toxicity), followed by sorafenib 400 mg BID
223481203|NCT00732914|DRUG|Sorafenib (Nexavar)|Sorafenib 400 mg BID, followed by Sunitinib 50 mg once daily 4 weeks on, 2 weeks off, and after discontinuation (due to PD or toxicity)
223481204|NCT06293820|DRUG|TL-925|TL-925 is an eye drop.
223481205|NCT06293820|DRUG|Placebo|The composition of the placebo is identical to the active formulation except for the exclusion of the active ingredient.
223481206|NCT03831022|OTHER|Capillary refill time and skin mottling score measurement at the admission to the emergency department|Patients who meet the inclusion criteria and none of the non-inclusion criteria will benefit from capillary refill time and skin mottling score measurement at the admission to the emergency department (ED) and followed during their hospital stay to precise the destination after ED (home, ICU, ward) and 30- and 90-days mortality after hospital admission.
223481207|NCT01184911|DRUG|Sulfadoxine-pyrimethamine|Sulfadoxine-pyrimethamine tablets, once
223481208|NCT03734341|DEVICE|EZ START Titration|"The auto CPAP device gradually increases air pressure night-by-night until the preset therapeutic pressure is reached.~Pressure range: from 5 to 14 cmH2O. Ramp: 4cmH2O, 20 minutes. Mask: nasal (if no contraindication).~Titration pressure: fixed pressure that reduces rAHI below 10, mask leak below 10% of the session, time session above 4 hours."
223481209|NCT03734341|DEVICE|APAP Titration|"The auto CPAP device continuously adjusts the pressure in real time to the minimum pressure needed to maintain upper airway patency at any moment. Pressure range: 5 to 14 cm H2O. Ramp: 4cmH2O, 20 minutes. Mask: nasal (if no contraindication).~Titration pressure: visual analysis pressure that reduces rAHI below 10 during 90% of the session, mask leak below 10% of the session, therapeutic session above 4 hours."
224168640|NCT03289494|OTHER|Balanced diet high in Slowly Digestible Starch|The carbohydrate present in the diet high in Slowly Digestible Starch were selected according to the general recommendations made for diabetics and according to their SDS content. The diet will be consumed during one week.
224305409|NCT00762931|DEVICE|Resolve Stimulator and Proximity Lead|An electrical neurostimulation signal will be applied to the neck via subcutaneous lead placement for vagal nerve stimulation
223481210|NCT06078670|DRUG|CVL218|Arm1: Triple negative breast cancer CVL218 is administered orally Triplelizumab injection was administered intravenously (IV) 240mg on D1 Paclitaxel injection (Kealil) 125mg /m2, D1, D8 administration Every 21 days for a drug cycle; Arm2: Gastric cancer CVL218 is administered orally Sindilizumab injection was given intravenously (IV) 200mg on D1 Paclitaxel injection (Taxol) 175mg /m2, D1 administration Every 21 days for a drug cycle; Arm3: Intestinal cancer CVL218 is administered orally Sindilizumab injection was given intravenously (IV) 200mg on D1 Fuquinitinib capsule 5mg QD orally, D1-14 administration Every 21 days is a medication cycle.
223481211|NCT00439439|RADIATION|Beamer Ablation (Argon Plasma Coagulation)|APC-Beamerablation of heterotopic gastric mucosa
223585020|NCT05701436|DRUG|Doxorubicin|20 mg per square body surface area for a total of four transcatheter hepatic artery infusions per month.
223481212|NCT06158945|DIAGNOSTIC_TEST|urinary endothelin 1|assesment of endothelin 1 in urinary sample
223481213|NCT04719559|DEVICE|Laser-assisted drug delivery|All patients received treatment using the same protocol with the same fractional ablative carbon dioxide laser (eCO2 PlusTM, manufactured by Lutronic, South Korea). Each patient was applied with Lidopin 5% cream (Panion \& BF Biotech Inc.), which remained on the scar for 30 min for pain relief before each laser course. Later, the Lidopin 5% cream was gently removed using a normal saline-rinsed gauze, and the scar was treated with a fractional ablative carbon dioxide laser with two passes under a 10,600 nm wavelength, 120 mm spot size, pulse energy of 50 mJ, 30 W of power, and a density of 200. A topical steroid cream (clobetasol propionate, 0.05%) was evenly applied on the scar gently back and forth using a cotton swab immediately after the laser treatment. The patients underwent five full courses by the same doctor according to the same protocol, with each course given 4 weeks apart.
223481214|NCT05240690|BIOLOGICAL|Umbilical Cord Blood Derived MAK Immune Cells|Intravenous drip
223481215|NCT05110612|BEHAVIORAL|Episodic Future Thinking|Episodic Future Thinking involves generating positive, autobiographical events that could realistically occur following each of five delays in the subsequent DD task: 1 day, 1 week, 1 month, 3 months, and 1 year. Participants will be told to not include events related specifically to smoking. Using a five-point Likert scale, participants will rate each event according to four dimensions: vividness, enjoyment, importance, and excitement. The event rated the most vivid at each time frame will be chosen for use in subsequent behavioral testing (ties will be settled randomly). Participants will then be recorded reciting a self-created two or three-sentence summary of each event. These recordings will serve as audio cues. Participants will also create abbreviated versions of each description to serve as text cues.
224168641|NCT03289494|OTHER|Balanced diet low in Slowly Digestible Starch|The carbohydrate present in the diet low in Slowly Digestible Starch were selected according to the general recommendations made for diabetics and according to their SDS content. The diet will be consumed during one week.
224168642|NCT05127356|DEVICE|DIAGNOdent|Laser fluorescence device
224168643|NCT05127356|DIAGNOSTIC_TEST|ICDAS II|International Caries Detection and Assessment System (ICDAS II)
224168644|NCT05977569|OTHER|Prolonged Fasting|Participants are asked to refrain from caloric intake for 3 days following a period of habitual lifestyle assessment and metabolic assessment.
224168645|NCT02119611|DEVICE|Deep Brain Stimulation management|The DBS surgery will be performed according to standard of care in the centers of referral. If performed at the NIH, this will be done under protocol 11-N-0211 or other protocols permitting DBS surgery depending on future availability.
224168646|NCT05220098|DRUG|TAK-280|Participants will receive TAK-280 as IV infusion.
224168647|NCT06003387|GENETIC|CSL222 (AAV5-hFIXco-Padua)|Administered as a single IV infusion.
224168648|NCT06849310|BEHAVIORAL|Group that will receive emotional regulation training|The content of the program is based on the current literature (Dennison, 2024; Holmqvist Larsson et al., 2020; Kara \& Yüksel, 2022; Kılıçarslan \& Varol, 2023; Siegel \& Brayson, 2021; Vafaei et al., 2021) for four weeks, once a week (average 50 minutes/week). The module on noticing emotions, which will be applied in the first week, is aimed at adolescents to think about and notice emotions. The content of the training will include determining the beliefs and effects of the group members about emotions, teaching the nature of all emotions and the function of adaptation, distinguishing between emotions and thoughts, teaching similar and opposite emotions, and situations that contribute to the positivity of the emotional state.
224168649|NCT06430840|BEHAVIORAL|CostCOM (Cost Communication, Financial navigation and counseling)|"Patients will receive two 1-hour, phone or video sessions with a remote financial counselor, each session will cover each of these 3 components of CostCOM.~Out-of-pocket cost communication (OOPC): A review of insurance benefits and education of the patient-specific OOPC for anticipated treatment regimen if any (i.e., medication). The OOPC is provided as a total estimate and will be updated at 3-month session in case of changes in treatment or insurance.~Financial navigation: Real-time professional guidance to identify financial assistance programs (e.g., co-pay, living expenses) that alleviate costs of care and discuss information to improve insurance coverage.~Financial counseling: To address the range of patients' financial concerns and enroll patients in financial assistance programs."
223481216|NCT05110612|BEHAVIORAL|Control Episodic Thinking|Control Episodic Thinking will report three real, positive events that occurred earlier in the session while playing mobile video games. Participants will be told to not include events related specifically to smoking. Using a five-point Likert scale, participants will rate each event according to four dimensions: vividness, enjoyment, importance, and excitement. The event rated the most vivid at each time frame will be chosen for use in subsequent behavioral testing (ties will be settled randomly). Participants will then be recorded reciting a self-created two or three-sentence summary of each event. These recordings will serve as audio cues. Participants will also create abbreviated versions of each description to serve as text cues.
223481217|NCT00102635|DRUG|Fenretinide (4-HPR)|Oral 100 mg capsules in two divided doses at least 8 hours apart for 7 days each cycle.
223481218|NCT00102635|DRUG|SCH66336|Oral capsules with 50 mg, 75 mg, or 100 mg formulation in two divided doses at least 8 hours apart for 21 days each cycle.
223585021|NCT05701436|DRUG|Lobaplatin|50 mg per square body surface area for a total of four transcatheter hepatic artery infusions per month.
223585022|NCT05701436|DRUG|Cisplatin|50 mg per square body surface area was used for monthly transhepatic arterial infusions.
224168650|NCT06430840|BEHAVIORAL|Provision of local and national resources to address financial and social needs|Patients will be provided with a comprehensive list of local resources (in patients' preferred language) in Orange County that can help with food insecurity, ir transportation, as well as contact information for national non-profit organization where patients can self-refer for financial navigation (e.g., Patient Advocate Foundation (PAF)
223481219|NCT01715298|DRUG|NVA237|NVA237 (Glycopyrronioum bromide) as a powder for inhalation in single-dose capsules
223481220|NCT01715298|DRUG|Placebo|Placebo powder for inhalation in single-dose capsules (matching those for NVA237).
223585023|NCT05701436|DRUG|Oxaliplatin, Leucovorin, fluorouracil|Oxaliplatin(130 mg per square body surface area), Leucovorin(400 mg per square body surface area), and fluorouracil(2800 mg per square body surface area) were used for monthly transhepatic arterial infusions.
223585024|NCT05701436|DRUG|Lobaplatin, Raltitrexed|Lobaplatin(50 mg per square body surface area) and Raltitrexed(3 mg per square body surface area) were used for monthly transhepatic arterial infusions.
223585025|NCT04139681|DRUG|A. Vogels Sore Throat lozenges|5 times 1 A. Vogels sore throat lozenges daily for 4 days
223585026|NCT04094584|DRUG|Vivitrol (Extended Release Naltrexone)|Monthly Injections of 380mg Extended-Release Naltrexone, case management services as needed tailored to the individual participant
223585027|NCT05269030|DRUG|Ivermectin Topical|Ivermectin 1% in a dose of two drops per nostril twice daily.
223585028|NCT05269030|DRUG|Budesonide Nasal|64 µg per puff in a dose of 1 puff for each nostril twice daily.
223585029|NCT03677297|DRUG|Rosuvastatin|Test sites were treated with access flap surgery and 1.2% Rosuvastatin gel
223585030|NCT04264143|DRUG|Infusate with MTX110 and gadolinium|Pulses 1 and 2 will be prepared with 30, 60 or 90 uM concentration of MTX110. The infusate consists of gadolinium and MTX110 (30, 60, or 90 uM) at approximately 1:100 ratio.
223585031|NCT04264143|DEVICE|Convection-Enhanced Delivery (CED)|CED is the method by which the drug are delivered to the brain under controlled pressure to the brain by targeted micro-catheters.
223585032|NCT05640609|COMBINATION_PRODUCT|Capeox regimen combined with Sintilimab and Bevacizumab|Stage Ib：Oxaliplatin +Capecitabine Tablets +Sintilimab +Bevacizumab Stage II：Bevacizumab (the dose determined in phase Ib clinical study)，the dosage of other drugs was the same as before
223761384|NCT04060407|DRUG|Nivolumab|Nivolumab will be administrated as IV infusion. For metastatic melanoma, the dose will be 1mg/kg, q3w x 4, then 480 mg, q4w for up to 1 year.
223481221|NCT03871413|DEVICE|TRV-chair|Repositioning maneuvers in TRV-chair
223481222|NCT03871413|PROCEDURE|Manual repositioning maneuver|Treatment with manual repositioning maneuver
224168651|NCT06430840|BEHAVIORAL|Financial Education|Patient will receive online and paper educational materials on topics such as health insurance and health insurance literacy, navigating hospitals' price estimator tool.
223481223|NCT00193635|DRUG|mycophenolate mofetil|oral drug administration
223481224|NCT00838851|BIOLOGICAL|Clinical Center Reference Endotoxin (CCRE)|Inhalation of 20,000 EU Clinical Center Reference Endotoxin (CCRE)
223481225|NCT00910975|DRUG|Peg-interferon-alfa2a (Pegasys)|Peg-interferon-alfa2a 180 µg per week
223481226|NCT00910975|DRUG|Ribavirin (Copegus)|Ribavirin 1000 or 1200 mg per day depending on if body weight is below or above 75 kg
223481227|NCT00454077|PROCEDURE|radioiodine therapy after rhTSH|
223481228|NCT06249971|PROCEDURE|Dermal subsitute Glyaderm + skin graft|A human donor-derived dermal substitute will be implanted together with a skin graft
223481229|NCT06249971|PROCEDURE|Skin graft alone|Skin graft alone with no dermal substitute
223481230|NCT03208153|PROCEDURE|Invasive|Coronary angiogram and revascularization if anatomically feasible
223481231|NCT03208153|PROCEDURE|Conservative|Conservative
223481232|NCT03837847|BEHAVIORAL|Health Coaching Calls|Participants in this group will receive 12 weekly health coaching calls
223481233|NCT03837847|BEHAVIORAL|Control|Participants in this group will receive 6 educational guides
223481234|NCT04087447|PROCEDURE|Thyroidectomy|Thyroidectomy
223481235|NCT01160302|DRUG|Microgranular Curcumin C3 Complex®|4 grams twice daily for 21-28 days
224168652|NCT06430840|OTHER|Usual care|Patients in all arms will receive usual care, which includes routine oncology visits, use of available ancillary staff, and internal or external resources for co-pay assistance or free medication per normal clinic procedures.
224168653|NCT06430840|OTHER|Screening for financial and social needs|Patients will be screened for financial hardship and health-related social risks.
223481236|NCT00187434|DEVICE|Infant Flow System|
223585033|NCT04292457|DRUG|Propofol|Anesthesia is maintained with a continuous infusion of Propofol. Induction of anesthesia and anesthetic management are otherwise the same in both study arms.
224168654|NCT06491368|PROCEDURE|Cesarean Delivery|A Pfannenstiel abdominal incision is made. The skin and rectus sheath are transversely opened using sharp dissection, and the rectus sheath is separated from the underlying rectus abdominis muscles. The peritoneum is then longitudinally opened using sharp dissection. A transverse incision is made in the lower segment of the uterus, which is subsequently closed with two layers of continuous sutures. Both peritoneal layers are closed with continuous sutures. The fascia is closed using either continuous or interrupted sutures. Finally, the skin is closed with either interrupted sutures or a continuous intracutaneous suture.
224168655|NCT03883295|PROCEDURE|Control|The specimens will be root canal treated conventionally
224305410|NCT00657228|DRUG|Intravenous heparin|"Intravenous heparin as an adjunct for the treatment of anaphylactic/anaphylactoid reactions in the Emergency Department.~To determine if a single bolus of intravenous unfractionated heparin (in conjunction with standard therapy) given to patients with anaphylactic/anaphylactoid reactions results in a faster time to recovery when compared to standard therapy alone."
223481237|NCT00187434|DEVICE|Bubble CPAP|
223481238|NCT03259893|OTHER|AliveCor mobile ECG cardiac monitor|AliveCor mobile ECG cardiac monitor is capable of providing real-time heart telemetry using a smart phone. Participants will be instructed to transmit rhythm data twice weekly and during symptomatic AF.
223481239|NCT03259893|BEHAVIORAL|AF Program|The AF program includes a bundle of sub-interventions that target specific AF risk factors including hypertension, obesity, physical inactivity, sleep hygiene, and smoking. Participants randomized to the intervention group 2 will undergo counseling by the nurse and guided through the structured, goal-directed AF program. Each participant will receive an AliveCor cardiac monitor which is capable of providing real-time heart telemetry using a smart phone.
223481240|NCT03259893|OTHER|Standard of care|Guideline-directed medical therapy according to clinical standard practice at Boston Medical Center.
223481241|NCT06109298|OTHER|Cold spray|Cold spray was applied for 5 seconds at a distance of 15 cm to an area of approximately 5 cm2 at the site of the procedu
223585034|NCT04292457|DRUG|Sevoflurane|Anesthesia is maintained with a continuous inhalation of Sevoflurane. Induction of anesthesia and anesthetic management are otherwise the same in both study arms.
223481242|NCT06109298|OTHER|Refrigerated gel ice|Refrigerated gel ice was applied for 5 minutes at 2 cm above the area to be treated.
223481243|NCT03629301|BEHAVIORAL|ID-DPP group|This group will receive a 6 month long online behavioral change protocol adapted from the Diabetes Prevention Program. It includes 18 sessions, 12 delivered weekly (during the first 3 months) and 6 delivered biweekly (during the last 3 month period). A web page will be used to deliver the sessions, while the nutritional counseling will be delivered using video calls via Facebook chat. Participants will receive an hypocaloric (1200-1800 kcal, carbohydrates: 45-65%, fats: 20-35% and protein: 10-35%), personalized diet.
223481244|NCT03629301|OTHER|Wait-list Group|This group will only receive written information with recommendations on healthy eating. When the study has finished this group will receive a behavioral change protocol with nutritional counseling using a face-to-face format.
223481245|NCT02508792|DEVICE|LASER|Low level LASER therapy will be applied in six different regions of the thight from the dominant limb, before a fatigue protocol using a isokinetic equipment.
223481246|NCT02508792|DEVICE|LASER PLACEBO|The low level LASER therapy turned off (placebo) will be applied in six different regions of the thight from the dominant limb, before a fatigue protocol using a isokinetic equipment.
223585035|NCT05271825|DEVICE|Broadband amplification from hearing aids|Amplification from 125 Hz to 10 kHz
223585036|NCT05271825|DEVICE|Band-limited amplification from hearing aids|Amplification from 25 Hz to 3-4 kHz
223481247|NCT00846599|OTHER|Omega-3 study meal|Participant will eat a study meal high in omega-3 fatty acids.
223585037|NCT00791557|DRUG|Infliximab|IV drug given at weeks 1,2,14,22
223585038|NCT02554214|DEVICE|Glafkos drainage device|
223585039|NCT01824706|PROCEDURE|craniectomy|craniectomy
223585040|NCT06007625|OTHER|Machine learning-based prediction model|This model will utilize patient characteristics and disease features to determine the disease's prognosis. The scoring system will also include management information to facilitate prediction of clinical outcomes of different management strategies and potential management that would yield the best prognosis.
223585041|NCT02126007|BEHAVIORAL|Sleep and Rhythm Intervention|
224168656|NCT03883295|PROCEDURE|NeoMTA Plus|The specimens will be subjected to vital pulp amputation using NeoMTA Plus.
224168657|NCT04319835|DEVICE|OnZurf Probe|
224168658|NCT03733106|DIAGNOSTIC_TEST|digital breast tomosynthesis|pseudo three dimension mammography
224168659|NCT03733106|DIAGNOSTIC_TEST|standard two dimension digital mammogram|standard two dimension mammogram
224168660|NCT00741767|DRUG|salmeterol-fluticasone|250ug salmeterol/50ug fluticasone inhaled via an oral inhaler twice daily
224168661|NCT03991936|DRUG|Placebos|Normal saline intralesional injection
224168662|NCT03991936|DRUG|Triamcinolone Acetonide 2.5 mg/mL|2.5 mg/mL intralesional injection
223481248|NCT00846599|OTHER|Saturated fat study meal|Participant will eat a study meal high in saturated fat.
223481249|NCT01283347|DRUG|18F-DTBZ|"During this study, subjects will receive a single i.v. administration of approximately 10 mCi 18F-FP-(+)-DTBZ immediately prior to imaging.~The proposed dose for this study is based on our phase I study. At the proposed human dose of 10 mCi, the whole body effective dose (ED) will be approximately 680 mrem. The estimated human ED is expected to be comparable to or below the range of other approved brain imaging agents, such as 18F-FDG"
223481250|NCT03860753|DRUG|Pioglitazone|For the current trial we will follow recommended adult initial dosing at 30 mg/d to reach maintenance dose of 45 mg/d by week 2, which is within standard titration parameters as per the investigator's brochure.
223481251|NCT03860753|DRUG|Placebo|Pill capsules will look same as that of active drug.
223481252|NCT04554251|OTHER|Survey|invited questionnaire
223481253|NCT03415880|BEHAVIORAL|Interactive workshops LiPAT intervention group|Workshops include practical behavior change strategies and address barriers to movement, awareness of the immediate benefits of movement and implementation-intentions. Participants will be encouraged to cultivate a learning mind-set in order to better tolerate potential set-backs and to apply strategies such as pre-planning their week to incorporate physical activity, engaging their social network, and setting up systems and habits. Participants' progress in changing their physical activity patterns which will be compared and discussed.
223481254|NCT03415880|DEVICE|Wrist-worn feedback physical activity monitor|Participants receive the feedback monitor (Fitbit inspire®; commercially available consumer product (https://www.fitbit.com/inspire)
223585042|NCT02126007|BEHAVIORAL|Dietary Modifications|
223585043|NCT00518297|DRUG|Raltegravir|Tablet, Oral, 400 mg, twice daily for 5 Days
223585044|NCT00518297|DRUG|Atazanavir|Capsule, Oral, 300 mg, twice daily for 7 Days
224168663|NCT03991936|DRUG|Triamcinolone Acetonide 5.0 mg/mL|5.0 mg/mL intralesional injection
224168664|NCT03991936|DRUG|Triamcinolone Acetonide 7.5 mg/mL|7.5 mg/mL intralesional injection
224168665|NCT03991936|DRUG|Triamcinolone Acetonide 10 mg/mL|10 mg/mL intralesional injection
224168666|NCT04905810|DRUG|Azacitidine|Given IV
224168667|NCT04905810|DRUG|Decitabine|Given IV
224168668|NCT04905810|DRUG|Venetoclax|Given PO
224168669|NCT02095249|DRUG|Pimonidazole|Pimonidazole is to be administered to patients scheduled for radical prostatectomy one day prior to surgery.
224168670|NCT00551967|PROCEDURE|Hip replacement|Surgical implantation of hip replacement components for the treatment of osteoarthritis
224168671|NCT05516940|OTHER||
223585045|NCT00518297|DRUG|Atazanavir + Raltegravir|Capsule/Tablet, Oral, 300/400, twice daily for 14 Days
223585046|NCT01804309|PROCEDURE|Sentinel lymph node biopsy (SLNB)|The intervention (SLNB) is no different in the care of patients' in the study then in those who were not included in the past or will not be included after the trial terminates. SLNB is performed according to strict professional guidelines adopted by the National Institute of Oncology, Budapest, Hungary.
224168672|NCT02462811|DRUG|CL-108 (hydrocodone 7.5 mg, acetaminophen 325 mg, promethazine 12.5 mg)|
224168673|NCT02462811|DRUG|Placebo|
223585047|NCT00803972|DRUG|rHuPH20|recombinant human hyaluronidase PH20
223585048|NCT00803972|DRUG|Insulin Human Injection|injection
223585049|NCT00803972|DRUG|Insulin Lispro Injection|injection
223761385|NCT02311491|DEVICE|Ceramic coated orthodontic archwire|Hard ceramic coatings will reduce the sliding resistance of archwires in their brackets during orthodontic treatment procedures. The new coated archwire is expected to reduce treatment time.
223761386|NCT03717038|DRUG|Sym004|Sym004 is a 1:1 mixture of two recombinant mAbs (futuximab and modotuximab) which bind specifically to non-overlapping epitopes located in the extracellular domain (ECD) of the EGFR.
223585050|NCT03344640|DRUG|secukinumab|AIN457 300 mg subcutaneously for 12 weeks
223585051|NCT03344640|OTHER|Placebo|Placebo to match AIN457 subcutaneously for 12 weeks
223585052|NCT01243489|OTHER|compliance supporting measures|"Patients will be treated for a total of 12 months, 6 months without and 6 months with compliance supporting measures. Patient can choose between an information service Leben mit CML or the use of a daily diary"
223761387|NCT03717038|DRUG|TAS-102|TAS-102 is a combination of trifluridine, a thymidine-based nucleic acid analogue, and tipiracil, a thymidine phosphorylase inhibitor.
224168674|NCT02462811|DRUG|Norco (hyrdocodone 7,5 mg, acetaminophen 325 mg)|
224168675|NCT00939055|DEVICE|StomaphyX|Transoral incisionless fastening device that allows for GI tissue approximation and creation of full-thickness (serosa-to-serosa) plications.
224168676|NCT00939055|PROCEDURE|Sham procedure|False procedure
224168677|NCT03139435|PROCEDURE|Biopsy|Undergo skin biopsy
224168678|NCT03139435|OTHER|Questionnaire Administration|Ancillary studies
224168679|NCT03139435|DIAGNOSTIC_TEST|Ultrasound Tomography|Undergo peripheral nerve ultrasound
224168680|NCT00584987|DRUG|Fluticasone furoate|2 puffs of each nasal spray in each nostril in the pm
224168681|NCT00584987|DRUG|Placebo Fluticasone furoate|2 puffs of each nasal spray in each nostril in the pm
224168682|NCT00584987|DRUG|Oxymetazoline|2 puffs of each nasal spray in each nostril in the pm
224168683|NCT00584987|DRUG|Placebo Oxymetazoline|2 puffs of each nasal spray in each nostril in the pm
224168684|NCT05997173|OTHER|Control|Investigation of scale of control
224168685|NCT05997173|OTHER|Non erosive OLP|Investigation of cale of non erosive OLP patients
224168686|NCT05997173|OTHER|Erosive OLP|Investigation of cale of erosive OLP patients
223585053|NCT01827813|PROCEDURE|Transrectal prostate biopsy with ultrasonography.|Transrectal prostate biopsy was performed in left lateral decubitus position with sedo-analgesia in saturation biopsy group and without sedoanalgesia in 10-12 core biopsy group on outpatient basis. After preparation of the rectal ultrasound probe and assuming an appropriate position, ultrasonographic examination of the prostate was performed on axial and sagittal plane. Periprostatic block was performed with the injection of 3 cc of prilocaine to each of the right and left lobes in the right and left periprostatic region in both groups before biopsy. Biopsy procedure was performed with an 18 G, 20 cm tru-cut biopsy needle and an automatic biopsy gun. After passing beyond the rectal mucosa, the needle was advanced until 0.5 cm proximal to the area of interest by tracking the image of the needle on the screen.
223585054|NCT01827813|PROCEDURE|Periprostatic block|Periprostatic block was used for local anesthesia. 3 cc 2% prilocaine was injected to both periprostatic region in both saturation biopsy and 10-12 core biopsy group with transrectal ultrasonography.
223761388|NCT01242657|BEHAVIORAL|Physical Activity Module|"Participants were provided pedometers in order to track specific Step Goals, which were defined for male or female participants. In addition, each participant recorded other forms of physical activity in a Challenge Log."
224168687|NCT02346799|BEHAVIORAL|Workout Window Reminders|Participants will receive emails at prespecified times reminding them to exercise, either during a specific two hour window or at any time during the day.
224168688|NCT02346799|BEHAVIORAL|Individual Workout Incentive Payment|Participants will be paid $3 or $7 for each workout completed during the appropriate times.
224168689|NCT02346799|BEHAVIORAL|Lump Incentive Payments|Participants will receive $20 payments for completing post treatment survey.
224168690|NCT02346799|BEHAVIORAL|Partner Assignment|"Participants will be required to have same workout window as partners."
224168691|NCT03225833|DRUG|WVE-120101|WVE-120101 is a stereopure antisense oligonucleotide (ASO)
224168692|NCT03225833|DRUG|Placebo|0.9% Sodium Chloride
224168693|NCT02599727|OTHER|Isometric exercises|subjects will perform specific isometric exercises for 10-20 minutes, three times a week throughout the enrollment period
224168694|NCT02599727|OTHER|No exercise|Subjects will go on with their life without any specific isometric exercise regimen during the enrollment period
224168695|NCT03315702|OTHER|mechanical ventilation|mechanical ventilation protocol: tidal volume 6-8 ml/kg, positive end-expiratory pressure 5 cm H2O, oxygen concentration 40%; respiratory rate 10-15/min, inspiratory/expiratory ratio 1:1.5.
224168696|NCT02542566|PROCEDURE|Physiotherapy rehabilitation|Physiotherapy rehabilitation
224168697|NCT01319045|DRUG|Iloprost|Aerosolized iloprost, 5 mcg/dose x 6 doses daily for 3 months
224168698|NCT03713151|OTHER|Dividat FIT|The study intervention is a blended therapy approach of face-to-face physiotherapy sessions with an interactive tablet-based home exercise program.
224168699|NCT00058006|DRUG|celecoxib|
224168700|NCT00058006|PROCEDURE|adjuvant therapy|
224168701|NCT00180206|DEVICE|Birmingham Hip Resurfacing|
224168702|NCT02749552|BEHAVIORAL|Acceptance and Commitment Therapy|weight-related interventions using values, acceptance, and mindfulness based on Acceptance and Commitment Therapy
223481255|NCT03415880|DEVICE|Smartphone application LiPAT|With a cloud-based platform the iHealth data is synchronized with a mobile phone app developed by the research team. The app is designed to help the participant to self-monitor their physical activity levels and includes information on total activity and number of steps taken.
223481256|NCT03415880|BEHAVIORAL|Telephone Coaching|participants in the intervention group will receive telephone coaching during the first 3 months of the intervention. Telephone coaching will be conducted twice in the first month and once each in months two and three. The researcher will enquire about the progress with increasing LiPA, about the experiences of applying the strategies discussed during workshops, and about the experience with Fitbit Inspire® and the corresponding app. If needed, the coach will offer suggestions to improve goal adherence.
223761389|NCT01242657|BEHAVIORAL|Not On Tobacco (N-O-T) Program|Not On Tobacco (N-O-T) Program, a proven teen smoking cessation program
224168703|NCT00081263|DRUG|Celecoxib|Given orally
224168704|NCT00081263|OTHER|Laboratory Biomarker Analysis|Correlative studies
224168705|NCT00081263|OTHER|Placebo|Given orally
224168706|NCT02440828|DRUG|tobramycin inhalation|tobramycin inhalation 300 mg twice daily
224168707|NCT02440828|DRUG|placebo|NaCl 0.9% inhalation 4 ml twice daily
224168708|NCT06239675|DEVICE|tDCS|tDCS will be delivered anodal for 20 minutes at an intensity between 1mA and 2mA for 15 sessions.
224168709|NCT06239675|BEHAVIORAL|CIMT|CIMT will be administered for two hours a day, five days a week, and three weeks in a row.
224168710|NCT06239675|DEVICE|sham tDCS|sham tDCS
224168711|NCT03537378|PROCEDURE|Hybrid APC|• HybridAPC is integrated with traditional APC and water-jet technique, which has been successfully applied for endoscopic treatment of mucosal lesions in GI, such as Barrett esophageal and lesions in colon. Submucosal injection of water jet can elevate superficial lesion, and then APC can be more effective in ablation of superficial tumor with a protection for muscular layer. The application of HybridAPC in respiratory intervention could theoretically protect cartilage, adventitia, reduce damage and formation of scare, and increase ablation energy to reach radical treatment. • High-frequency EBUS, could display the boundary between cartilage endomembrane and cartilage, in order to determine the depth of tumor.
224168712|NCT01081262|BIOLOGICAL|Bevacizumab|Given IV
224168713|NCT01081262|DRUG|Capecitabine|Given PO
224168714|NCT01081262|DRUG|Carboplatin|Given IV
224168715|NCT01081262|OTHER|Laboratory Biomarker Analysis|Correlative studies
224168716|NCT01081262|DRUG|Oxaliplatin|Given IV
224168717|NCT01081262|DRUG|Paclitaxel|Given IV
224168718|NCT01081262|OTHER|Quality-of-Life Assessment|Ancillary studies
224168719|NCT04331522|DIAGNOSTIC_TEST|Oral provocation test|Titrated provocation with allergen
224168720|NCT06254950|DRUG|TAK-279|TAK-279 capsules.
224168721|NCT06254950|DRUG|Placebo|TAK-279 placebo-matching capsules.
224168722|NCT06246513|BIOLOGICAL|SRP-9003|Solution for single IV infusion
224168723|NCT06246513|DRUG|Glucocorticoid|Oral tablet (prophylactic)
224168724|NCT05485948|DRUG|Ropeginterferon alfa-2b|Initial dose of 250 µg at Week 0, a medium dose of 350 µg at Week 2, a target dose of 500 µg at Week 4, and a maintenance dose of 500 µg until Week 52.
224168725|NCT05370911|DRUG|Psilocybin|"The first oral dose will be 25 mg, and the second dose will be either 25 mg or 30 mg, depending on response to first dose.~Psilocybin is a naturally occurring hallucinogenic ingredient found in some varieties of mushrooms that can be produced synthetically. It is considered to be a serotonergic psychedelic. We will use synthetically produced oral psilocybin in this study.~Other Names:~Magic Mushrooms"
224168726|NCT05451524|BEHAVIORAL|Insomnia prevention program|Youths in the intervention group will receive 4 weekly insomnia prevention program. Each session will last for about 60-90 mins.
224168727|NCT05451524|BEHAVIORAL|General health education|Youths in the control group will be provided with group-based general health education with same dosage (4 weeks) as intervention group.
224168728|NCT06144294|OTHER|Whole-Body Hyperthermia|The Clearlight dome sauna is portable infrared sauna consisting of two lightweight domes and an infrared heating pad. The sauna will be used to deliver the intervention to the participant and the sauna session will end as soon as (1) an internal body temperature of 38.5 C (101.3 F) is reached for two consecutive minutes or, (2) 140 minutes have passed.
224168729|NCT06144294|DIAGNOSTIC_TEST|fMRI|A standard magnetic resonance imaging (fMRI) machine will be used to take images of the brain.
224168730|NCT03467516|BIOLOGICAL|Tumor Infiltrating Lymphocytes (TIL)|TIL infusion intravenously through a central vein catheter over 20-30 minutes. Folowed by Aldesleukin, administered at a dose of 600,000 IU/kg (based on total body weight) as an intravenous bolus over a 15-minute period approximately every 8 hours beginning within 24 hours of TIL infusion and continuing for up to a maximum of 6 doses.
224168731|NCT05306964|PROCEDURE|Restrictive UFnet Rate Strategy|In the restrictive group, the UFnet rate will be titrated between 0.5-1.5 mL/kg/h and maintained throughout fluid removal.
224168732|NCT05306964|PROCEDURE|Liberal UFnet Rate Strategy|In the liberal group, the UFnet rate will be titrated between 2.0-5.0 mL/kg/h and maintained throughout fluid removal.
224168733|NCT05219955|BEHAVIORAL|Morning Action Plan Execution|Each day, participants are asked to track if they do the morning activity plan.
223481257|NCT03415880|BEHAVIORAL|Workshops control group LiPAT|During the first 6 months of the study (the intervention period) participants in the control group will attend 4 workshops in which the benefits of physical activity and the health-risks of sedentary behavior will be discussed. Additionally, information will be provided on healthy lifestyle for patients with type 2 diabetes.
223481258|NCT03424304|DEVICE|Excel V™ Laser With Green Genesis|Subject(s) will receive treatments with a Cutera Excel V™ Laser
223481259|NCT05080985|PROCEDURE|TPVB|20 ml 0.375 % bupivacaine was injected between superior costotransverse ligament and pleura.
223481260|NCT05080985|PROCEDURE|ESPB|20 ml 0.375 % bupivacaine was injected between deep fascia of the erector spinae muscle and transverse process.
223481261|NCT05080985|DRUG|Bupivacain|20 ml 0.375 % bupivacaine was injected
223481262|NCT00667264|PROCEDURE|perineural ropivacaine|Subjects will be randomized to one of two groups: ropivacaine 0.4% or normal saline (placebo). The basal rate will be set at 7 mL/h.
223481263|NCT01104844|DRUG|Full Dose Strength|Acetaminophen + ibuprofen, 2 tablets every 6 hours, with food for 24 hours (i.e a total of 4 x 1000/300 mg doses of study drug comprising of 8 tablets)
223481264|NCT01104844|DRUG|Quarter dose strength|Investigational drug quarter dose strength (acetaminophen 125mg + ibuprofen 37.5mg) i.e. 2 tablets equating to 1/4 the dose in the standard investigational drug.
223481265|NCT01104844|DRUG|Half dose strength|Investigational drug half dose strength (acetaminophen 250mg + ibuprofen 75mg) i.e. 2 tablets equating to 1/2 the dose in the standard investigational drug
223481266|NCT01104844|DRUG|Acetaminophen standard dose|Acetaminophen standard dose 500mg i.e. 2 tablets equating to the same acetaminophen dose as in the standard investigational drug
224168734|NCT05219955|BEHAVIORAL|Activity Strategy-based Session with Therapist|Participants will meet weekly with a trained therapist to discuss their prescribed activity plan. If unsuccessful, at weekly follow-ups, participants are asked to refine their plan or make a new one. Each session lasts about 30-45 minutes.
224168735|NCT05219955|BEHAVIORAL|Attention-based Session with Therapist|Participants will meet weekly with trained a therapist to talk about stressors they experience, providing an opportunity to voice and self-address their problems. In this control condition, therapists will not deliver any particular strategy except for active listening and referring to the educational materials
223481267|NCT01104844|DRUG|Ibuprofen low dose|Ibuprofen low dose 150mg tablet i.e. 2 tablets equating to the same ibuprofen dose as in the standard investigational product
224168736|NCT05219955|BEHAVIORAL|Advance sleep-wake time|Some participants will be asked to adjust their sleep schedule to accommodate morning activity engagement by introducing or altering mechanisms known promote early rising (i.e., light exposure, reward and processes, etc.)
224168737|NCT04757220|OTHER|Cognitive tasks with EEG recording|questionnaires and cognitives tasks
223481268|NCT01104844|DRUG|Ibuprofen high dose|Ibuprofen high dose 300mg i.e. 2 tablet equating to twice the ibuprofen dose as in the standard investigational drug
223481269|NCT01104844|DRUG|Placebo|2 placebo tablets
223481270|NCT04454502|OTHER|Oral colostrum administration|In accordance with the oral colostrum protocol, a total of 0.2ml colostrum will be administered into the cheek and on the tongue for the infants weighing between 1001-1500 g.
224168738|NCT06060561|OTHER|Non-Interventional Study|Non-interventional study
224305411|NCT00657228|DRUG|Saline|Standard treatment (epinephrine, corticosteroids, diphenhydramine, and H2 blockers) and saline.
224305412|NCT05372783|DRUG|STI-9199|STI-9199 is a fully human monoclonal antibody which is a neutralizing antibody to SARS-CoV-2
223481271|NCT00726453|DEVICE|Resolute Zotarolimus-Eluting Coronary Stent|Implantation of a Resolute Zotarolimus-Eluting Coronary Stent
223481272|NCT02348333|DRUG|FYU-981, (Oral daily dosing for 7 days)|Subjects randomized to the FYU-981 arm receive active drug, FYU-981.
223481273|NCT02348333|DRUG|Placebo, (Oral daily dosing for 7 days)|Subjects randomized to the placebo arm receive placebo.
223481274|NCT01653418|DRUG|Bortezomib|
223481275|NCT01653418|DRUG|Carmustine|
223481276|NCT01653418|DRUG|Etoposide|
223481277|NCT01653418|DRUG|Cytarabine|
223481278|NCT01653418|DRUG|Melphalan|
223481279|NCT01653418|PROCEDURE|Stem cell infusion|
223481280|NCT01668043|DRUG|Antibody UB-421|UB-421 is administered by intravenous infusion
223481281|NCT02331732|BEHAVIORAL|Virtually Observed Treatment|
223481282|NCT02331732|OTHER|Directly Observed Treatment|
224168739|NCT05690256|BEHAVIORAL|Resilience Clinic|A psychoeducational caregiver-child intervention based in primary care, designed to mitigate toxic stress and promote child resilience. Participants engage in 6 weekly visits in primary care using an interactive curriculum based in the evidence-based Circle of Security Parenting along with mindfulness principles.
224168740|NCT05690256|BEHAVIORAL|Enhanced primary care|In addition to usual pediatric primary care, enhanced primary care (the control condition for this study) provides navigational services to link to community resources based on screening for unmet social needs (e.g., food insecurity, housing, financial strain).
224168741|NCT04564027|DRUG|Ceralasertib|Tablets will be administered orally
224168742|NCT05292521|OTHER|Best Practice|Receive usual care
224168743|NCT05292521|OTHER|Informational Intervention|Receive QOL fact sheet
224168744|NCT05292521|OTHER|Questionnaire Administration|Ancillary studies
224168745|NCT04632589|DRUG|Losartan Potassium|subjects ingest 50mg losartan potassium tablet daily for 6 weeks
224168746|NCT04632589|DRUG|Placebo|subjects ingest placebo tablet daily for 6 weeks
224168747|NCT06388759|DRUG|TQ05105 Tablets|TQ05105 Tablets is a Janus kinase 1 (JAK1) and Janus kinase 2 （JAK2） Inhibitor
224168748|NCT06436534|DRUG|Ganciclovir Oral Capsule|2-week treatment phase：Ganciclovir capsules(250mg), take 2 capsules twice a day
224168749|NCT06436534|DRUG|Ganciclovir Simulant Oral Capsule|2-week treatment phase：Ganciclovir simulant capsules(0mg), take 2 capsules twice a day
224168750|NCT06436534|DRUG|Mometasone Nasal|From screening phase to follow-up phase：Mometasone furoate aqueous nasal spray(50μg/spray), take 1 spray once a day
224168751|NCT06648486|DEVICE|With the assistance of wearable isokinetic training robot （ 7 children with SMA type II）|A child with SMA will use a wearable isokinetic training robot to train the knee joint for three stages. ( Stage 1: 1.5 months=30 sessions; Stage 2 (follow up): 1.5 months=18 sessions, Stage 3(follow up) = 0 session)
224168752|NCT05346536|OTHER|Detection of circulating tumor cells expressing Axl: CTC-AXL(+)|"Detection of CTC-AXL(+) using 2 techniques:~* CellSearch®, FDA-USA approved technology~* EPIDROP System~CellSearch® (Menarini Company) The current gold-standard CellSearch® technique requires the use of CellSave tubes. This technique allows the isolation of fixed CTCs. This technique uses a positive (CellSearch® Epithelial Cell Kit) enrichment method from total blood using magnetic beads coupled to an EpCAM capture antibody. CTCs are then detected (anti-panCK antibodies, DAPI, anti-CD45 and characterized (anti-AXL antibody) by immunofluorescence (IF).~EPIDROP It requires the use of EDTA tubes. This technique is based on a method of negative enrichment of CTCs from total blood using a cocktail of tetrameric antibodies to eliminate unwanted blood cells and to preserve only purified tumor cells (RosetteSep - StemCell Technology).Then, cells are loaded in a microfluidic chip. The detection and characterization is done by IF to the single cell in micro-droplets."
224168753|NCT01267955|OTHER|Laboratory Biomarker Analysis|Correlative studies
224168754|NCT01267955|OTHER|Pharmacogenomic Study|Correlative studies
224168755|NCT01267955|DRUG|Vismodegib|Given PO
223481283|NCT04128553|BEHAVIORAL|Intervention motivational interview group|"Motivational interviewing (MI) a client-centered, goal-oriented method for enhancing intrinsic motivation to change by exploring and resolving ambivalence. Motivational interviewing is underpinned by a series of principles that emphasise a collaborative therapeutic relationship in which the autonomy of the patient is respected and the patient's intrinsic resources for change are elicited by the therapist.~In the present study, an effort was made to help the IG to realize the dilemmas of individuals in the precontemplation stage about exercising, and individuals in the contemplation stage to produce their own solutions. In this direction, techniques such as decision balance, importance, and trust technique were applied, thus enabling them to reveal their feelings, thoughts, and reactions regarding the benefits/harms of doing/not doing exercise. They were supported to raise awareness about the consequences and solutions of the causes."
224168756|NCT04334109|BEHAVIORAL|Family Diabetes Self-Management Education and Support|Family Diabetes Self-Management Education and Support demonstrates the effectiveness of family-centered models of DSME that explicitly address diabetes self-management within a family context by educating both patients and family members and focusing on family motivational interviewing, family goal setting, understanding supportive and nonsupportive behaviors, and family behavioral changes.
224168757|NCT04334109|BEHAVIORAL|Standard Diabetes Self-Management Education and Support|Diabetes Self-Management Education and Support demonstrates the effectiveness of individual model DSMES that explicitly address diabetes self-management within an individual context by educating individual patients on individual motivational interviewing, individual goal setting, and individual behavioral changes.
224168758|NCT06575387|PROCEDURE|Partogram|to evaluate the utility of partogram in management and progress of active labor in Primigravidae.
223481284|NCT03507101|OTHER|No intervention|No particular intervention or exposure is of particular interest
223481285|NCT02856217|PROCEDURE|tunneling|In this arm of the study which is Peritoneal tunneling group in SCP, standard minimal invasive sacrocolpopexy procedure will be performed. Placement of mesh between vaginal apex and sacrum is retroperitoneally (creating a tunnel between vaginal apex and sacrum under peritoneum without disturbing the integrity of the peritoneum)
224168759|NCT03801083|BIOLOGICAL|Tumor Infiltrating Lymphocytes (TIL)|TIL are to be infused intravenously through a central vein catheter over 20-30 minutes followed by Aldesleukin, administered at a dose of 600,000 IU/kg (based on total body weight) as an intravenous bolus over a 15-minute period approximately every 8 hours beginning within 24 hours of cell infusion and continuing for up to a maximum of 6 doses.
224168760|NCT04168866|PROCEDURE|Operative management|Surgery for computer tomography (CT)-proven complicated appendicitis with phlegmon or abscess.
224168761|NCT04168866|OTHER|Drainage or antibiotics|If an abscess is present and amenable to percutaneous drainage this will be performed. If there is no abscess or it is not amenable to drainage antibiotics alone will be provided.
223481286|NCT02856217|PROCEDURE|non-tunneling|In this arm of the study which is Peritoneal non-tunneling group in SCP, standard minimal invasive sacrocolpopexy procedure will be performed. Placement of mesh between vaginal apex and sacrum is retroperitoneally (incised and sutured peritoneum between vaginal apex and sacrum).
224305413|NCT05372783|DRUG|Placebo|Diluent solution
224305414|NCT02508753|DRUG|CXA-101/tazobactam|1000/500 mg single IV dose administered over 60 minutes
224305415|NCT02508753|DRUG|CXA-101/tazobactam|3000/1500 mg single IV dose administered over 60 minutes
224305416|NCT02508753|DRUG|Moxifloxacin|400 mg tablet
224168762|NCT05852600|BEHAVIORAL|Parents and Adolescents Talking about Healthy Sexuality (PATHS)|"PATHS is an intervention delivered to parents of AMSM that aims to increase parent communication about sexuality and HIV, as well as other parent behaviors supportive of sexual risk reduction. PATHS can all be accessed online, is self-paced, and typically takes parents 40-60 minutes to complete. The toolkit is comprised of 7 modules, covering a range of topics relevant to increasing parents' motivation, self-efficacy, and intention for communicating about sex. Material is presented in a variety of modalities (e.g., text, videos of experts, videos of other parents describing their experiences). Parents set personalized goals for themselves regarding activities and conversations they want to have with their sons, selecting from a menu of options provided by the intervention. One month later parents complete a refresher module that queries them about whether they have achieved their goals, and provides customized content to support the behaviors parents have yet to enact."
224168763|NCT05852600|BEHAVIORAL|Lead with Love (LWL)|"Lead with Love is a 35-minute education entertainment film created to provide support, information, and behavioral guidance to parents of lesbian, gay, or bisexual (LGB) children. Drawing from stage-based models of behavior change, and social cognitive theory, it aims to help parents progress through the process of coming to accept their child's sexual orientation, recognizing the importance of their behaviors and reactions to their child's health, and accepting their child's sexual orientation, and engaging in behaviors that are more supportive and less rejecting. This is achieved by telling the true stories of four families and how they responded to the news that their child was LGB, and by having experts (psychologists, teachers, clergy) provide information and guidance. One month after watching LWL, parents return to the website to review refresher materials that summarize the most important lessons from the film."
224168764|NCT06194929|DRUG|Defactinib|Defactinib will be administered at 200 mg twice daily orally per arm description.
224168765|NCT06194929|DRUG|Avutometinib|Avutometinib will be administered at 3.2 mg twice a week orally per arm description.
224168766|NCT06194929|DRUG|Encorafenib|Encorafinib administered orally per arm description.
223761390|NCT03771833|DEVICE|MARIA scan|The MARIA breast imaging system comprises of a scanning unit, housed under a patient bed. The scanning unit houses a hemispherical array, into which varying sizes of insert are fitted to ensure a close fit to the breast. The patient lies prone on the bed with their breast pendulous through an aperture in the bed and the scanning unit is risen to meet the breast. The fit is non-compressing and the scanner does not use ionising radiation.
224168767|NCT06247384|DEVICE|Hypotension Prediction Index Hemodynamic Monitoring|The application of the perioperative hemodynamic management according to the hypotension prediction index algorithm.
224168768|NCT05920343|DRUG|Rivaroxaban 10 MG|The intervention in the experimental arm will be rivaroxaban, 10 mg PO once daily (prophylactic dosing) for 180 days after the start of systemic therapy or until one of the primary study outcomes occurs (VTE or major bleeding).
224168769|NCT05920343|OTHER|Placebo control|Identical to Rivaroxaban intervention except participants will receive a matched placebo instead of the study drug
224168770|NCT05379686|DRUG|GlucaGen|150 ug glucagon will be administered to the participants before exercise.
224168771|NCT04517253|DRUG|Baricitinib|Administered orally
224168772|NCT04979429|BEHAVIORAL|Perioperative Pain Self-management (PePS)|4 sessions of telephone CBT-based pain self-management.
224168773|NCT03811535|DRUG|Somapacitan|Somapacitan will be administered subcutaneously (s.c.; under the skin) once weekly by PDS290 pen-injector. Somapacitan can be injected any time during the once weekly dosing day. The dose will be calculated based on the subject's current body weight.
224168774|NCT03811535|DRUG|Norditropin®|Norditropin® will be administered s.c. once daily by FlexPro® pen-injector. Norditropin® should be injected daily in the evening. The dose will be calculated based on the subject's current body weight.
224168775|NCT04003649|BIOLOGICAL|IL13Ralpha2-specific Hinge-optimized 4-1BB-co-stimulatory CAR/Truncated CD19-expressing Autologous TN/MEM Cells|Given ITV/ITC
224168776|NCT04003649|BIOLOGICAL|Ipilimumab|Given IV
224168777|NCT04003649|BIOLOGICAL|Nivolumab|Given IV
224168778|NCT04003649|OTHER|Quality-of-Life Assessment|Ancillary studies
224168779|NCT04003649|OTHER|Questionnaire Administration|Ancillary studies
224168780|NCT04428580|OTHER|Online FBT Training|Therapists will receive online training in Family-Based Treatment (FBT)
224168781|NCT04428580|OTHER|Webinar FBT Training|Therapists will receive webinar training in Family-Based Treatment (FBT)
224168782|NCT06083077|OTHER|Chest wall strapping|An elastic band (6 cm wide) is placed around the lower part of the chest wall (at the junction of the chest and abdomen) to tighten the chest wall for 10 min at PEEP 7 cmH2O and 10 min without PEEP
224168783|NCT05302986|DRUG|Tranexamic acid injection|The dose will be 0.1 mg / kg (= 10 mg/kg) and diluted in a 100 mL infusion bag of sodium chloride. The product will have to be administered as a slow infusion over 10 minutes during the shoulder surgery.
224168784|NCT05302986|DRUG|Placebo|Surgery with intravenous injection of Placebo (0.9% sodium chloride). A 100 mL infusion bag of sodium chloride will be administered as a slow infusion over 10 minutes during shoulder surgery.
224168785|NCT06048367|DRUG|CNSI-Fe(II) 30 mg|The trial comprises a treatment period, including the DLT evaluation period with a duration of 21 days, and a maintenance treatment period. If the subject completes DLT evaluation without intolerable toxicity, an additional dose may be administered based on the investigator's determination of the benefits outweighing the risks. The original protocol planned for three dose groups: 30 mg, 60 mg, and 90 mg. The protocol was amended on March 28, 2024, to add 120 mg and 150 mg dose groups. A single tumor lesion amenable to intratumoral injection will be selected, regardless of tumor size, number, or location. The drug should be administered at the dose specified for the current dose cohort. The injection volume should be adjusted based on the size of the injected lesion.
224305417|NCT02508753|DRUG|placebo|single IV dose of a saline solution administered over 60 minutes plus oral over-encapsulated moxifloxacin placebo tablet administered at the start of infusion.
224305418|NCT01802749|DRUG|Bevacizumab|
224305419|NCT01802749|DRUG|Paclitaxel|
224305420|NCT01802749|DRUG|Carboplatin|
223761391|NCT00132015|DRUG|tanespimycin|
223761392|NCT01282424|DRUG|Idelalisib|Idelalisib 150 mg tablet administered orally twice daily
224305421|NCT01802749|DRUG|pegylated liposomal doxorubicin|
224305422|NCT01802749|DRUG|Gemcitabine|
223481287|NCT05570422|DRUG|KRC-01|KRC-01 is a solution that contains hydrogen peroxide 3% with sodium hyaluronate 1%. Hydrogen peroxide is the active ingredient for this radiosensitizer.
223481288|NCT05570422|RADIATION|External Beam Radiation Therapy|"* Target definition for EBRT will be based on 3D imaging by computed tomography, positron emission tomography with computed tomography, or MRI.~* Intensity-modulated radiotherapy (IMRT) must be used.~* IMRT should be given once daily Monday-Friday, 5 fractions per week."
223481289|NCT05570422|DRUG|cisplatin|"* Weekly concomitant cisplatin (40 mg/m2) during EBRT~* Neo-adjuvant chemotherapy or other forms of antineoplastic treatment apart from weekly concomitant cisplatin (40 mg/m2) are not allowed.~* Adjuvant chemotherapy (after completion of EBRT+BT) is not allowed."
223481290|NCT05570422|RADIATION|brachytherapy|"* BT treatment planning will be based on 3D-image-guided BT by MRI.~* Low-dose-rate, pulsed-dose-rate, or high-dose-rate BT"
223481291|NCT03284554|DIETARY_SUPPLEMENT|Encapsulated nutrients|Amino acid + Lipid; Probiotic bacteria
223481292|NCT03284554|DIETARY_SUPPLEMENT|Non-encapsulated nutrients|Amino acid + Lipid; Probiotic bacteria
223481293|NCT03284554|DIETARY_SUPPLEMENT|Placebo|Nutrient not expected to stimulate release of GLP-1 and PYY
223481294|NCT03564262|OTHER|Low Sodium Meal (138 mg sodium)|One Low Sodium Meal
223481295|NCT03564262|OTHER|High Sodium Meal (1,495 mg sodium)|One High Sodium Meal
223481296|NCT04130087|DRUG|Selegiline Hydrochloride 10 MG|Single 10mg tablet of Selegiline Hydrochloride
223481297|NCT04130087|DRUG|Placebo|Single Placebo Tablet, identical appearance to experimental tablet.
223481298|NCT03951389|OTHER|Non-interventional|Non-interventional
223481299|NCT01067391|DRUG|tadalafil|20 mg tablet, administered once per study protocol
223481300|NCT01067391|DRUG|placebo|placebo tablet administered once per study protocol
223481301|NCT03049566|OTHER|preoperative questionnaires|no intervention, cross-sectional survey in a single group
223481302|NCT04826562|DRUG|Dolutegravir/Lamivudine|single tablet antiretroviral
223481303|NCT06535659|DEVICE|VitaFlow Liberty™ Transcatheter Aortic Valve System|"Transcatheter Aortic Valve Replacement with VitaFlow Liberty™ Transcatheter Aortic Valve System.~Patients will receive transcatheter aortic valve replacement and examinations at the screening, procedure, discharge, and follow-up per local standard of care."
223481304|NCT02820415|OTHER|chromosomal status of blastocysts from fresh and vitrified/warmed oocytes|
223481305|NCT01526980|DRUG|biphasic insulin aspart 30|Administrated subcutaneously (s.c., under the skin) once daily before dinner for 30 days in each treatment period
223481306|NCT01526980|DRUG|biphasic insulin aspart 70|Administrated subcutaneously (s.c., under the skin) twice daily before breakfast and lunch for 30 days in each treatment period
223481307|NCT01526980|DRUG|biphasic human insulin 30|Administrated subcutaneously (s.c., under the skin) twice daily before breakfast and dinner for 30 days in each treatment period
223481308|NCT04649723|DRUG|Rifampin|single oral dose, 600 mg, fasted.
223481309|NCT04649723|DRUG|SHR1459|single oral dose, 200 mg, fasted.
223481310|NCT01603147|BIOLOGICAL|normal saline|saline 225 ml
223481311|NCT01603147|BIOLOGICAL|ch-mAb7f9|The single doses to be administered in each cohort are 0.2, 0.6, 2, 6, and 20 mg/kg, respectively. Volume to be administered 225 ml
223481312|NCT05572918|DIAGNOSTIC_TEST|Urodynamics aka filling cystometry|Participants will be undergoing a routine diagnostic test to characterise bladder function and volume
223481313|NCT01021384|BEHAVIORAL|Problem Solving Education|Problem Solving Education (PSE) is an evidenced-based empowerment strategy, targeted to mothers of young children to promote family well-being by decreasing the burden of maternal depressive symptoms and maternal parenting stress and improving social functioning.
223481314|NCT03345797|DRUG|Testosterone Nasal Gel [Natesto]|nasal gel containing 4.5% w/w testosterone
223481315|NCT06535568|DEVICE|Drug-coated balloon|Essential pro (iVascular, Barceona, Spain) paclitaxel eluting coronary balloon dilatation catheter is a rapid exchange catheter, also known as RX because it has a proximal simple lumen configuration and a distal coaxial dual lumen, intended for coronary arteries percutaneous transluminal angioplasties. Patients assigned to this Arm will be treated with a Drug-Coated Balloon (DCB) after pre-dilatation, the angiography will be conducted as standard of care.
223761393|NCT04976530|DEVICE|DrugSorb-ATR system|Sorbent hemoperfusion system integrated into the cardiopulmonary bypass (CPB) circuit
224072112|NCT04760561|PROCEDURE|prone position group|Patients randomized to this arm will receive self-prone positioning. Each patient in the intervention group will be helped into the prone position and encouraged to stay in the prone position as long as tolerated (at least 1 hour). The prone positioning consists of placing the patient on his or her stomach with the head on the side. Self-prone position will be performed 45 minutes up to 1 hour after meals to avoid gastrointestinal side effects. The patient will be maintained in prone position until the patient becomes too tired and uncomfortable to keep that position. If patients will asked to regain the supine position before the 1 hour period was complete, patient's prone position will be considered unfeasible and the reason will be reported. Patients who required invasive mechanical ventilation at any time point will be intubated and excluded from the study.
224072113|NCT02758340|DRUG|Misoprostol|Women would be given misoprostol tablet by mouth
224072114|NCT02758340|DEVICE|foley's balloon catheter|foley's balloon catheter would be inserted through vagina into cervix.
224072115|NCT00866138|DRUG|masitinib (AB1010)|masitinib 9 mg/kg/day per os
223761394|NCT04976530|DEVICE|Sham comparator|Sham comparator in similar position to the investigative device, but NOT integrated into the cardiopulmonary (CPB) circuit
224072116|NCT04029012|DRUG|Methoxyflurane|Methoxyflurane inhaler before Rezum procedure
224072117|NCT03852394|OTHER|Respiratory mechanics assessment|The study protocol consisted of two consecutive phases; in the first step measurements of static respiratory mechanics and end expiratory lung volume (EELV) were performed after 30 minutes of MV in volume control mode. In the second step transdiaphragmatic pressure (Pdi) was calculated by means of a sniff maneuver (Maximal Pdi) after 30 minutes of spontaneous breathing trial. Linear regression analysis and Pearson's correlation coefficient was used to asses the association between Maximal Pdi values and static and dynamic mechanical features and the association between Maximal Pdi and Pdi/Maximal Pdi.
224072118|NCT01325428|DRUG|Afatinib once daily (OD)|Patient to receive afatinib monotherapy until progression of their disease
223585055|NCT01827813|PROCEDURE|Sedoanalgesia|Sedoanalgesia was used in saturation biopsy group. It was given by an anesthesiologist. Patients were given adequate counselling regarding sedoanesthesia as well as the biopsy procedure. They were advised to fast the night before the procedure.Before induction of sedoanalgesia all patients were monitorized for peripheric oxygen saturation and electrocardiography (ECG).Additionally nasal oxygen with 3ml/min was given to all patients by nasal canula.Sedoanalgesia was induced with 0.05mg/kg of midazolam, 1mg/kg of propofol and 1mg/kg of fentanyl. additional propofol was given with dose of 0.3mg/kg as patients needed.
223585056|NCT01902888|DEVICE|GORE® VIABAHN® Endoprosthesis|
223585057|NCT03930550|PROCEDURE|Tracheal intubation by endoscopy with flexible bronchoscope|A blinking infrared light source is placed on the anterior neck at the level of the cricothyroid membrane to serve as a guide to facilitate finding the way to the trachea
223585058|NCT06244836|OTHER|Implementation of a bundle of care|
223585059|NCT01944579|OTHER|Blackberries|Participants will receive blackberries as part of a controlled diet.
223585060|NCT01944579|OTHER|Control|Participants will receive a control food (jello) as part of a controlled diet.
224168786|NCT06048367|DRUG|CNSI-Fe(II) 60 mg|The trial comprises a treatment period, including the DLT evaluation period with a duration of 21 days, and a maintenance treatment period. If the subject completes DLT evaluation without intolerable toxicity, an additional dose may be administered based on the investigator's determination of the benefits outweighing the risks. The original protocol planned for three dose groups: 30 mg, 60 mg, and 90 mg. The protocol was amended on March 28, 2024, to add 120 mg and 150 mg dose groups. A single tumor lesion amenable to intratumoral injection will be selected, regardless of tumor size, number, or location. The drug should be administered at the dose specified for the current dose cohort. The injection volume should be adjusted based on the size of the injected lesion.
224168787|NCT06048367|DRUG|CNSI-Fe(II) 90 mg|The trial comprises a treatment period, including the DLT evaluation period with a duration of 21 days, and a maintenance treatment period. If the subject completes DLT evaluation without intolerable toxicity, an additional dose may be administered based on the investigator's determination of the benefits outweighing the risks. The original protocol planned for three dose groups: 30 mg, 60 mg, and 90 mg. The protocol was amended on March 28, 2024, to add 120 mg and 150 mg dose groups. A single tumor lesion amenable to intratumoral injection will be selected, regardless of tumor size, number, or location. The drug should be administered at the dose specified for the current dose cohort. The injection volume should be adjusted based on the size of the injected lesion.
224168788|NCT06048367|DRUG|CNSI-Fe(II) 120 mg|The dosing regimen is the same as that for the 30 mg, 60 mg, and 90 mg dose groups. Additionally, if a single lesion cannot accommodate the full corresponding dose of the investigational drug, additional lesions may be selected for simultaneous injection. When multiple lesions are injected, the drug distribution should be allocated proportionally according to the size of each lesion or determined based on the investigator's assessment of an appropriate distribution.
223481316|NCT06535568|DRUG|Single antiplatelet therapy (SAPT)|The antithrombotic regimen is single antiplatelet therapy (SAPT). The Investigator will decide if to use aspirin or clopidogrel, whereas ticagrelor or prasugrel are not recommended in our study population since no benefit (or even harm) has been shown by these drugs in head-to-head trials versus clopidogrel in elderly PCI populations. The type of agent and treatment duration will be selected according to the clinical characteristics of the patient.
223481317|NCT06535568|DRUG|Dual antiplatelet therapy (DAPT)|The antithrombotic regimen will follow the standard of care with a dual antiplatelet regimen (DAPT) per local preferences and international guidelines/ARC consensus paper. The type of agent and treatment duration will be selected according to the patient's clinical characteristics.
223481318|NCT01611675|DRUG|Vemurafenib|take orally, twice daily
223481319|NCT01611675|DRUG|Leflunomide|take orally, once daily
223481320|NCT03171259|OTHER|care as usual|The investigators will be following patients with critical limb ischemia and documenting the usual care that the participants receive.
223585061|NCT04656106|DRUG|Ryzodeg®|All patients have been treated at the discretion of the treating physician in accordance with the Ryzodeg® label in South Korea. Hence independently of this study, the treating physician has determined the starting dose of Ryzodeg® as well as any dose adjustments thereafter.
223585062|NCT00680758|DRUG|cisplatin|"* Dose Level: -3 20mg/m2/week 3-6 patients~* Dose Level: -2 20mg/m2/week 3-6 patients~* Dose Level: -1 25mg/m2/week 3-6 patients~* Dose Level: 1 25mg/m2/week 3-6 patients~* Dose Level: 2 25mg/m2/week 3-6 patients~* Dose Level: 3 25mg/m2/week 3-6 patients"
223585063|NCT00680758|DRUG|everolimus|"* Dose Level: -3 20mg/m2/week 3-6 patients~* Dose Level: -2 20mg/m2/week 3-6 patients~* Dose Level: -1 20mg/m2/week 3-6 patients~* Dose Level: 1 20mg/m2/week 3-6 patients~* Dose Level: 2 25mg/m2/week 3-6 patients~* Dose Level: 3 30mg/m2/week 3-6 patients"
223585064|NCT00680758|DRUG|paclitaxel|"* Dose Level: -3 65mg/m2/week 3-6 patients~* Dose Level: -2 70mg/m2/week 3-6 patients~* Dose Level: -1 70mg/m2/week 3-6 patients~* Dose Level: 1 80mg/m2/week 3-6 patients~* Dose Level: 2 80mg/m2/week 3-6 patients~* Dose Level: 3 80mg/m2/week 3-6 patients"
223481321|NCT03750565|DRUG|TD-1473 - Dose A|oral capsule/tablet, QD
223481322|NCT03750565|DRUG|TD-1473 - Dose B|oral capsule/tablet, QD
223481323|NCT03750565|DRUG|TD-1473 - Dose C|oral capsule/tablet, QD
223481324|NCT03750565|DRUG|Placebo|oral capsule/tablet, QD
223481325|NCT05301634|PROCEDURE|infraorbital block|the patients will receive bilateral infraorbital block
223481326|NCT05301634|PROCEDURE|topical intranasal bupivacaine|the patients will receive topical intranasal application of bupivacaine
223481327|NCT00355641|DRUG|Ropinirole Extended Release (XR)|Dose range of Ropinirole XR of 0.5mg to 6.0mg daily
223481328|NCT00941928|DRUG|Epratuzumab|360 mg/m\^2 once a day by vein on Day -4, Day -1 and Days 3, 6, 10, 13 and 17.
223585065|NCT03444454|BEHAVIORAL|VRRS Khymeia|"Participants will receive an individualized exercise program set up by the therapist. The intervention applied to the experimental group will consist of 30 sessions of Khymeia VRRS training distributed in five sessions for week, each lasting 45 minutes.~Each session is constructed by alternating physical with cognitive activities. The sessions will initially be tailored to the patient's baseline characteristics. Remotely, the therapist will then adjust the participant's exercise program as appropriate, by changing exercises, level of difficulty or number of repetitions."
223585066|NCT03444454|BEHAVIORAL|Usual care program|The usual care group will have written, home-based exercise program, provided to them at an initial face-to-face assessment.
223585067|NCT03444454|BEHAVIORAL|VRRS Khymeia plus active tDCS|"Participants will receive 5 sessions each lasting 45 minutes of an individualized home-based VRRS training combined with active (anodal) tDCS applied to the left dorsolateral prefrontal cortex over 1 week, followed by 5 weeks of home-based VRRS training.~The sessions of VRRS will initially be tailored to the patient's baseline characteristics. Remotely, the therapist will then adjust the participant's exercise program as appropriate, by changing exercises, level of difficulty or number of repetitions."
223585068|NCT03444454|BEHAVIORAL|VRRS Khymeia plus placebo tDCS|"Participants will receive 5 sessions each lasting 45 minutes of an individualized home-based VRRS training combined with active (anodal) tDCS applied to the left dorsolateral prefrontal cortex over 1 week, followed by 5 weeks of home-based VRRS training.~The sessions of VRRS will initially be tailored to the patient's baseline characteristics. Remotely, the therapist will then adjust the participant's exercise program as appropriate, by changing exercises, level of difficulty or number of repetitions."
223481329|NCT00941928|DRUG|Fludarabine|25 mg/m\^2 once a day by vein on Day -6 through Day -2 over 30 minutes.
223481330|NCT00941928|DRUG|Cyclophosphamide|60 mg/kg once a day by vein on Days -5 and -4 over 2 hours.
223481331|NCT00941928|DRUG|Mesna|12 mg/kg by vein 5 times per day on Days -5 and -4 over 15 minutes.
223481332|NCT00941928|PROCEDURE|Infusion of NK cells|Transplant of Haploidentical NK cells by vein on Day 0.
223481333|NCT00941928|DRUG|Interleukin-2|Subcutaneous injections three times a week for 9 doses on Days 0 to 21.
223481334|NCT02690129|DRUG|Vaginal Progesteron|
223481335|NCT03562130|DRUG|Teduglutide|Daily sub cutaneous injection 0,05 mg/kg/day
223481336|NCT04686331|DIAGNOSTIC_TEST|Biomarkers for pneumonia|"Blood samples will be collected by a medical laboratory technologist and transferred to the local laboratory for analysis of surfactant protein D, Krebs von den Lungen (KL-6), and YKL-40. Laboratory staff will be blinded to participant diagnosis and outcome. None of the biomarkers will be available to the treating physician.~* Diagnostic test of surfactant protein D - will be quantified using enzyme-linked immunosorbent assay (ELISA)-based analysis~* Diagnostic test of KL-6: will be quantified using enzyme-linked immunosorbent assay (ELISA)-based analysis~* Diagnostic test of YKL-40 - will be quantified using enzyme-linked immunosorbent assay (ELISA)-based analysis"
223481337|NCT05250869|DIAGNOSTIC_TEST|HPLC/MS|Quantification of MTX and its metabolites by HPLC/MS under various preanalytical conditions
223481338|NCT05164211|OTHER|Didgeridoo|the children will have 6 didgeridoo lessons given by a teacher spread over 3 months.
223481339|NCT02650817|DRUG|RAD1901|RAD1901, a novel selective ER degrader (SERD)
223481340|NCT05716464|BEHAVIORAL|Lifestyle medicine intervention|The lifestyle medicine intervention includes six weekly sessions (i.e., participants will receive the intervention once per week) that are related to the following topics: (a) lifestyle psychoeducation, (b) physical activity, (c) dietary recommendation, (d) stress management, (e) sleep management and (f) motivation and goal-setting techniques. Each topic will be delivered during each face-to-face session and the duration of each session will be around 120 minutes.
223481341|NCT05716464|BEHAVIORAL|Cognitive-behavioral therapy for depression (CBT-D)|The group-based CBT-D therapy includes six weekly sessions (i.e., participants will attend one 120-minute, face-to-face group therapy per week, and will be asked to practice taught-skills every day, for 42 days) that are related to the following topics: (a) psychoeducation, (b) cognitive restructuring, (c) behavioral activation, (d) self-care and relapse prevention.
223481342|NCT03613298|DEVICE|HIFU (Focal One®)|Endometriosic lesion localization and HIFU treatment will be conducted with the Focal One® device. The treatment area will be defined using sonography, pelvic MRI and a transrectal sonography data. Once the pre-defined lesion will be located with Focal One device, succession of HIFU exposure will then be used to treat maximum lesion volume, excluding a security margin of 3 mm with the digestive mucosae.
223481343|NCT03006120|PROCEDURE|Retroperitoneal hematoma due to cardiac catheterization|
223481344|NCT06277167|DRUG|Human interferon alfa 1b inhalation solution|Participants will receive Human interferon alfa 1b inhalation solution orally for a single dose.
223481345|NCT06277167|DRUG|Human interferon alfa 1b inhalation solution placebo|Participants will receive Human interferon alfa 1b inhalation solution placebo orally for a single dose.
223481346|NCT06277167|DRUG|Human interferon alfa 1b inhalation solution|Participants in the 1,200,000 IU and 1,800,000 IU dose groups will be given multiple consecutive doses after a single dose safety assessment, i.e. Human interferon alfa 1b inhalation solution administered by aerosol inhalation twice a day at the dose of the corresponding group, for 5 consecutive days respectively (only one morning dose on the last day, for a total of 10 doses during the study).
223481347|NCT06277167|DRUG|Human interferon alfa 1b inhalation solution placebo|Participants in the 1,200,000 IU and 1,800,000 IU dose groups will be given multiple consecutive doses after a single dose safety assessment, i.e. Human interferon alfa 1b inhalation solution placebo administered by aerosol inhalation twice a day at the dose of the corresponding group, for 5 consecutive days respectively (only one morning dose on the last day, for a total of 10 doses during the study).
223481348|NCT03587597|PROCEDURE|socket shield technique|socket shield technique with immediate temporization
223481349|NCT03587597|PROCEDURE|conventional immediate implant placement with immediate temporization|conventional immediate implant placement with immediate temporization
223481350|NCT04247971|PROCEDURE|Blood draw|23 ml of blood collected
223481351|NCT04247971|PROCEDURE|Sputum collection|Induced sputum sample collected
223481352|NCT04247971|PROCEDURE|Pulmonary function test|Pulmonary function testing
223481353|NCT01055912|DRUG|Lixivaptan|Capsule. Patients will be screened for entry into the study and will be randomized (2:1) to lixivaptan or placebo. One hundred (100) patients will be randomized to receive lixivaptan 100 mg once daily (QD) for 8 weeks. Fifty (50) placebo patients will receive matching oral placebo for 8 weeks.
223481354|NCT01055912|DRUG|Placebo|Patients will be screened for entry into the study and will be randomized (2:1) to lixivaptan or placebo.
223481355|NCT02337582|OTHER|Opportunistic Breast cancer screening|Opportunistic breast screening offered to women attending clinics for non-breast health issues
224072119|NCT01325428|DRUG|Vinorelbine Weekly|Patients additionally receive vinorelbine weekly on disease progression on afatinib monotherapy
224072120|NCT04593654|DRUG|Dose of tinzaparin or dalteparin|The patients will be categorised into three groups depending on initial dose of thromboprophylaxis in the ICU
224072121|NCT00022529|DRUG|BMS-214662|Given IV
224072122|NCT00022529|BIOLOGICAL|trastuzumab|Given IV
223481356|NCT02337582|OTHER|Usual Care|No breast screening was explicitly offered to women attending clinics for non-breast health issues, unless the health care provider felt that it was appropriate
223481357|NCT00869180|DRUG|Diclofenac Sodium|Topical diclofenac patch applied once daily to area of pain
223481358|NCT00869180|DRUG|Matching Placebo Patch|Matching placebo patch, containing identical constituents to the active comparator except for diclofenac sodium; applied once daily
223481359|NCT03797053|PROCEDURE|Biological sample|"Biological sample performed :~* before treatment~* 1 months after the beginning of treatment~* every tumoral assessment"
223481360|NCT06317974|BEHAVIORAL|Breastfeeding education based on the Health Belief model|Training was given face to face with the participant, lasting approximately 40 minutes. One week after the training presentation, three short messages about the training were sent to the couples (both the pregnant woman and her partner) every other day. Two weeks after the training was given, a phone call was made for feedback. Post-test data were taken four weeks later.
223481361|NCT06551844|DRUG|Molnupiravir 400 mg|"This is an antiviral drug (an RNA dependent RNA polymerase inhibitor, with broad spectrum antiviral activity) currently approved for use in treatment for COVID-19 patients.~In this trial, its antiviral effectiveness on the early phase of dengue virus infection will be assessed."
223481362|NCT06551844|DRUG|VIS513 (a monoclonal antibody)|VIS513 is an engineered humanised monoclonal antibody produced by recombinant DNA technology in a mammalian cell (i.e. Chinese hamster ovary) line. It was discovered in the USA by Visterra Inc and subsequently technology for manufacturing and further development was transferred to Serum Institute of India Pvt. Ltd., Pune, India. It has shown potent, specific neutralization of all four serotypes of DENV.
223481363|NCT05737511|DRUG|Hydroxyzine|Oral tablet of hydroxyzine 25mg at night which could be increased to TID or QID
223481364|NCT05737511|DRUG|Escitalopram Oxalate|The treatment as usual can include first-line, second-line and third-line recommendations
223481365|NCT05799950|DEVICE|AcrySof single-piece IOL|Acrylic single-piece intraocular lens placed in the capsular bag in the posterior chamber of the eye during cataract surgery as a replacement for the natural crystalline lens.
223481366|NCT05799950|DEVICE|AcrySof multi-piece IOL|Acrylic multi-piece intraocular lens placed in the capsular bag in the posterior chamber of the eye during cataract surgery as a replacement for the natural crystalline lens.
223481367|NCT02805998|BEHAVIORAL|Web-based CBT-I|
223481368|NCT02805998|OTHER|Treatment as Usual|
223481369|NCT05207358|DRUG|Rituximab|2 doses of Rituximab 1 g and Methylprednisolone 500 mg on days 1 and 15.
223481370|NCT05207358|DRUG|Mycophenolate Mofetil|Patients will receive Mycophenolate Mofetil, initially 500 mg twice daily, titrated to a maximum of 1.5 g twice daily, depending on leukocyte count and digestive tolerance, which will be maintained 24 months.
223481371|NCT05207358|DRUG|Cyclophosphamide|All patients will receive Cyclophosphamide intravenously starting day 1, 6 pulses at a fixed dose of 500 mg given at 2 weeks. After 3 months, Azathioprine (2 mg / kg / day) is initiated 2 weeks after the last administration of Cyclophosphamide and maintained for the next 21 months.
223481372|NCT05207358|DRUG|Corticosteroids|3 daily pulses of 750 mg of intravenous Methylprednisolone, followed by oral corticosteroid therapy starting with a dose of 0.5 mg / kg / day for 4 weeks, then decreased by 2.5 mg of Prednisolone / day each 2 weeks. A low dose of glucocorticoid (5-7.5 mg / day) is maintained until 24 months after enrollment.
223585069|NCT05525949|DEVICE|VIVID Brain|Participants receive visual perceptual training using the VIVID Brain software.
224072123|NCT00022529|OTHER|pharmacological study|Correlative studies
224072124|NCT02141711|DRUG|TAK-438|TAK-438 tablets
224072125|NCT02141711|DRUG|TAK-438 Placebo|TAK-438 placebo-matching tablets
224072126|NCT02025387|BEHAVIORAL|Physical activity feedback|
224072127|NCT02025387|BEHAVIORAL|Usual care except physical activity measurement|
224072128|NCT02335996|BIOLOGICAL|Blood samples for measuring adiponectin, leptin and omentin plasma|
224072129|NCT02335996|DEVICE|MRI at 3 Tesla|Evaluation by MRI at 3 Tesla of the amount of ectopic fat heart, liver and pancréas and bone marrow.
224072130|NCT01242449|DRUG|Trastuzumab|Initial dose 8 mg/kg i.v. Subsequently, 6 mg/kg i.v. at intervals of 3 weeks
224072131|NCT01242449|DRUG|Vinorelbine|Initial dose 70 mg/m2 on days 1 and 8 (capsules) If well tolerated, subsequently 90 mg/m2 on days 1 and 8. Capsule on day 1 to be taken at the hospital, and on day 8 at home.
224072132|NCT04639180|DRUG|Camrelizumab|Subjects receive Camrelizumab intravenously, Dosage form: lyophilized powder
224072133|NCT04639180|DRUG|Rivoceranib (Apatinib)|Subjects receive Rivoceranib (Apatinib) orally, Dosage form: tablet
224072134|NCT04375774|DEVICE|FFP2|Face Fit test of the FFP2 with the PortaCount® PRO+ 8038 from TSI
224072135|NCT04375774|DEVICE|Facial mask|Face Fit test of a conventional respirator facial mask with the PortaCount® PRO+ 8038 from TSI
224072136|NCT04375774|DEVICE|MFS|Face fit test of a MFS with the PortaCount® PRO+ 8038 from TSI
224072137|NCT01827033|BEHAVIORAL|meditation training|
224072138|NCT04437355|DIAGNOSTIC_TEST|Specific provocation test|To compare the results the investigators invite a healthy control group matching in age and gender with the intervention cohort. The control group is informed about the study and asked to participate in the outpatient clinic. In case of informed consent, the participants are invited to the study site. The participants undergo the same provocation test of the ankle, and are asked to complete the specific provocation test. In case of substantial underachievement in the provocation test (\<60% of maximum) an X-Ray of both ankles in a.p. and lateral projection is performed. The aim is to radiologically analyse the ankles, and to rule out any morphological reasons for the above mentioned underperformance.
224072139|NCT03730337|DRUG|ONO-7475|ONO-7475 specified dose on specified days
224072140|NCT03730337|DRUG|ONO-7475 + ONO-4538|ONO-7475+ONO-4538 specified dose on specified days
224072141|NCT04430244|PROCEDURE|Deep anterior lamellar keratoplasty|Deep anterior lamellar keratoplasty using dehydrated corneas
224072142|NCT04430244|PROCEDURE|Deep anterior lamellar keratoplasty|Deep anterior lamellar keratoplasty using standard organ culture stored corneas
224072143|NCT04593069|BEHAVIORAL|Neurocognitive assessment|6 months after admission to the intensive care unit of Ziekenhuis Oost-Limburg, the patients will be tested on cognitive impairment
224072144|NCT05181527|DRUG|Selective Serotonin Reuptake Inhibitors|Patients in both the study arms will receive SSRI for 8 weeks.
223481373|NCT01608594|DRUG|administration of ipilimumab10mg/kg|"Ipilimumab IV infusion:~* Day 0 (within 1-2 weeks of baseline biopsy) every 3 weeks for 2 doses followed by definitive surgery~* After surgery recover-y resume at the same dose for 2 additional doses given 3 weeks apart~* Dose continued 12 weeks later for 4 additional doses given 12 weeks apart~Interferon Alfa-2b will be given concurrently with ipilimumab. Each patient will receive Interferon Alfa-2b at 20 MU/m²/day intravenously for 5 consecutive days out of 7 every week for 4 weeks, followed by 10 MU/m²/d subcutaneously every other day, 3 times each week for 2 weeks, followed by definitive surgery. After surgery recovery, Interferon Alfa-2b will be resumed at 10 MU/m²/d subcutaneously, every other day three times a week for 46 additional weeks."
223481374|NCT01608594|DRUG|administration of ipilimumab 3mg/kg + HDI|"Ipilimumab IV infusion:~* Day 0 (within 1-2 weeks of baseline biopsy) every 3 weeks for 2 doses followed by definitive surgery~* After surgery recover-y resume at the same dose for 2 additional doses given 3 weeks apart~* Dose continued 12 weeks later for 4 additional doses given 12 weeks apart~Interferon Alfa-2b will be given concurrently with ipilimumab. Each patient will receive Interferon Alfa-2b at 20 MU/m²/day intravenously for 5 consecutive days out of 7 every week for 4 weeks, followed by 10 MU/m²/d subcutaneously every other day, 3 times each week for 2 weeks, followed by definitive surgery. After surgery recovery, Interferon Alfa-2b will be resumed at 10 MU/m²/d subcutaneously, every other day three times a week for 46 additional weeks."
223481375|NCT01107015|DEVICE|Tailored Patient Intervention|Patients select one of two mobile phone models, receive a one-year unlimited mobile phone data and phone service plan, receive the study treatment phone software and have access to the web-based individual patient portal. Given system-driven guidance on when to test blood glucose (bg) based on disease status, medication regimen, and time of poorest control. Patients enter bg data, carbohydrates consumed, diabetes medications taken and miscellaneous comments regarding diabetes self-care. Messages are sent to the patient's mobile phone giving feedback on entered data. Entered data are captured in real-time in the web-based logbook. Patients may provide their PCPs with printed copies of their logbooks and other information but physicians do not have access to the patient portal system. Patient action plans summarizing the patient-entered data and identifying possible self-management actions for improving their diabetes control are electronically sent to the patients every 2.5 months.
223481376|NCT01107015|DEVICE|Patient-physician intervention|"Patients select one of two mobile phone models, receive a one-year unlimited mobile phone data and phone service plan, receive the study treatment phone software and have access to the web-based individual patient portal. Given system-driven guidance on when to test blood glucose (bg) based on disease status, medication regimen, and time of poorest control. Patients enter bg data, carbohydrates consumed, diabetes medications taken and miscellaneous comments regarding diabetes self-care. Messages are sent to the patient's mobile phone giving feedback on entered data. Entered data are captured in real-time in the web-based logbook. PCPs are provided access to a web portal where they may choose to review their patients' electronic logbooks. This is raw patient data that have not been analyzed."
223481377|NCT01107015|DEVICE|Patient and PCP intervention with analyzed data|Patients select one of two mobile phone models, receive a one-year unlimited mobile phone data and phone service plan, receive the study treatment phone software and have access to the web-based individual patient portal. Given system-driven guidance on when to test blood glucose (bg) based on disease status, medication regimen, and time of poorest control. Patients enter bg data, carbohydrates consumed, diabetes medications taken and miscellaneous comments regarding diabetes self-care. Messages are sent to the patient's mobile phone giving feedback on entered data. Entered data are captured in real-time in the web-based logbook. PCPs are provided access to a secure web portal where they can see their patients' electronic logbooks. PCPs are provided with data analysis reports. The PCP is reminded that all data analysis is based on patient-entered, unvalidated data. The PCP has the option to use this information and remains responsible for all treatment decisions.
224072145|NCT05181527|DRUG|Dextromethorphan|Patients in the test group will get Dextromethorphan 30 mg once daily orally as an add-on to ongoing SSRI treatment for 8 weeks.
224072146|NCT05181527|DRUG|Placebo|Patients in the control group will get placebo tablet once daily orally as an add-on to ongoing SSRI treatment for 8 weeks.
224072147|NCT04094220|PROCEDURE|Lateral lumbar interbody fusion|LLIF is an indirect decompression technique, and does not directly remove the disc or osteophyte protruding into the spinal canal. Its decompression effect is not as thorough as traditional posterior decompression surgery. Usually, posterior decompression is required for patients who have unsuccessful indirect decompression.
224072148|NCT02723123|OTHER|Recording of cardio-respiratory signals|Biological signals: ECG, RIP, SpO2 and Pulse rate will be recorded during the interventions and analyzed offline.
224072149|NCT02889432|DRUG|Oral Melatonin 10mg|
224072150|NCT02889432|DRUG|Placebo|
224072151|NCT03198208|DRUG|Fentanyl dose administration|
224072152|NCT00248183|DRUG|PRX-00023|
224072153|NCT02499861|DRUG|Decitabine and Genistein|intravenous Decitabine with oral genistein
224072154|NCT05957991|DRUG|Metformin Hydrochloride tablet|Treatment with metformin
224072155|NCT05957991|DRUG|Placebo|Treatment with placebo
224072156|NCT05957991|BEHAVIORAL|Lifestyle intervention|Changing behaviour on diet and excersise
224072157|NCT05957991|BEHAVIORAL|No lifestyle intervention|No changes in behaviou on diet and excersise
224072158|NCT04891289|DRUG|Gemcitabine|See arm for details.
224072159|NCT04891289|DRUG|Oxaliplatin|See arm for details.
224072160|NCT04891289|DRUG|Dexamethasone|See arm for details.
224072161|NCT04891289|DRUG|Floxuridine (FUDR)|See arm for details.
224072162|NCT04891289|DEVICE|Implanted Medical Device|Implanted hepatic arterial infusion pump by surgical oncology, to deliver HAI therapy
224072163|NCT03862352|DEVICE|Covered coronary stent|Insertion of covered coronary stent as part of standard care
224072164|NCT00610831|DEVICE|DIRECTVIEW CR Mammography|4 views screening mammogram
224072165|NCT02171611|DRUG|Dabigatran etexilate pellets|
224072166|NCT02171611|DRUG|Dabigatran etexilate powder|
224072167|NCT02171611|DRUG|Dabigatran etexilate capsule|
224072168|NCT00129168|DRUG|Zosuquidar|
224072169|NCT00129168|DRUG|Daunorubicin|
224072170|NCT00129168|DRUG|Cytarabine|
224305423|NCT05682846|DRUG|Sodium glycerophosphate pentahydrate solution|Glycophos is a 20 ml vial of Sodium glycerophosphate pentahydrate containing 1 mmol glycerophosphate and 2 mmol sodium per ml
224168789|NCT06048367|DRUG|CNSI-Fe(II) 150 mg|The dosing regimen is the same as that for the 30 mg, 60 mg, and 90 mg dose groups. Additionally, if a single lesion cannot accommodate the full corresponding dose of the investigational drug, additional lesions may be selected for simultaneous injection. When multiple lesions are injected, the drug distribution should be allocated proportionally according to the size of each lesion or determined based on the investigator's assessment of an appropriate distribution.
224168790|NCT05374564|DRUG|(18F)Flutemetamol|18F-Flutemetamol binds to β-amyloid plaques and the F-18 isotope produces a positron signal that is detected by a PET scanner. Multiple recent studies have shown that thioflavin-analogue tracers such as 18F-flutemetamol may be able to fulfill the unmet need of elucidating the presence of amyloid deposition in the heart. Because it binds to the beta-pleated motif of the amyloid fibril due to their similarity to the thioflavin structure, 18F-Flutemetamol could potentially be used to image cardiac amyloidosis (CA)
224168791|NCT02906098|BEHAVIORAL|Patient centered oral health education|Procedure: The theory-based educational intervention follows a specific structure. The initial phase contain 3 treatment sessions (45-60 min each) during a period of 12 weeks (baseline, 2-3 weeks and 10-12 weeks). Follow up are performed at 6- and 18-months.
224168792|NCT02906098|BEHAVIORAL|Standard educational intervention|Procedure: The initial phase contain educational intervention in accordance with conventional routines (oral health information and oral hygiene instruction at one or several occasions). Follow up are performed at 6- and 18-months.
224168793|NCT05403385|DRUG|inupadenant|Adenosine 2a receptor antagonist
224168794|NCT05403385|DRUG|Placebo|matched placebo capsule to inupadenant
224168795|NCT05403385|DRUG|Carboplatin|standard of care chemotherapeutic, alkylating agent
224168796|NCT05403385|DRUG|Pemetrexed|standard of care chemotherapeutic, anti-metabolite
224168797|NCT04303169|BIOLOGICAL|Pembrolizumab|Administered via IV infusion at a specified dose on specified days
224168798|NCT04303169|BIOLOGICAL|Vibostolimab|Administered via IV infusion at a specified dose on specified days
224168799|NCT04303169|BIOLOGICAL|Gebasaxturev|Administered via IT injection at a specified dose on specified days
224168800|NCT04303169|BIOLOGICAL|MK-4830|Administered via IV infusion at a specified dose on specified days
224168801|NCT04303169|BIOLOGICAL|Favezelimab + Pembrolizumab|Administered via IV infusion at a specified dose on specified days
224168802|NCT04303169|DRUG|ATRA|Administered via oral capsules at a specified dose on specified days
224168803|NCT05490043|DRUG|ATG-101|ATG-101 will be administered intravenously once every 28 days. The dose levels will be determined by the starting dose and the escalation steps taken in the trial. The Dose Expansion Phase will begin at the defined MTD, RP2D, or biologically optimal dose.
224168804|NCT06378099|OTHER|Patient guided and followed by the pharmacist|"The Study Coordinating Group will train the pharmacy Staff regarding these protocols.~This training will cover both pharmacological and non-pharmacological aspects of MA management. The pharmacological component will emphasize the appropriate selection and safe use of nonprescription drugs, with a focus on identifying potential drug interactions, contraindications, and moderate and serious ADRs. Pharmacy staff will also be equipped with tools to apply proper criteria for referral to a GP when necessary.~The staff will be divided into three groups, and every group will have a minimum of two sessions, each one of 4 hours. Additionally, there will be a practical component where simulations of real situations will be conducted.~Throughout the 12-month follow-up and intervention period, one of the researchers will be available to receive phone calls to address doubts and concerns about the Consensus-based Protocols."
224168805|NCT03833349|BEHAVIORAL|Spinning Class|Spinning Class twice a week for six weeks.
223481378|NCT03409965|DEVICE|Lutronic Infini System|A microneedle radiofrequency device
223481379|NCT03409965|DEVICE|Lutronic LaseMD System|A fractional thulium laser device
224168806|NCT03833349|BEHAVIORAL|Yoga Class|Yoga Class twice a week for six weeks.
224168807|NCT03833349|BEHAVIORAL|Dance Class|Dance Class twice a week for six weeks.
224168808|NCT05044351|DEVICE|Fluobeam LX|See arm description
224168809|NCT05044351|OTHER|Conventional surgery without NIRAF assistance|Patients undergoing conventional hemithyroidectomy without NIRAF-assistance
224168810|NCT04257006|DEVICE|oXiris membrane|Open heart surgery patients in early postoperative period with clinical signs of fluid overload undergoing CRRT
224168811|NCT05004363|DRUG|Lokelma Oral Product|Potassium binder
224305424|NCT00115297|DRUG|Montelukast|Participants who are 2 to 3 years old received 5-mg montelukast tablets and participants who are 12 months to 2 years old received 4-mg montelukast granules.
223481380|NCT06518291|DRUG|Nitrofurantoin 100 MG|Comparing two drugs in UTI treatment
223481381|NCT06518291|DRUG|Fosfomycin|treatment of UTI
223481382|NCT05031351|DRUG|Withania somnifera|Nuclear Factor Kappa Beta Inhibitor
223481383|NCT05031351|DRUG|Placebo|Placebo Comparator
223481384|NCT00651846|DRUG|Yasmin (DRSP 3mg/EE 0.03 mg)|The study medication was packaged in 21-tablet blister packs. Each subject kit contained 7 blister packs plus 1 reserve blister pack.Subjects randomly assigned to the treatment group received 21 consecutive days of hormonally active tablets (3mg DRSP/0.03 mgEE). In each treatment cycle 21 tablets (1 tablet daily) have to be taken in sequence, followed by a pill-free interval of 7 days. The treatment period was 7 cycles (28 days per cycle).
223481385|NCT00651846|DRUG|Microgynon (LNG 0.15 mg/EE 0.03 mg)|The study medication was packaged in 21-tablet blister packs. Each subject kit contained 7 blister packs plus 1 reserve blister pack.Subjects randomly assigned to the treatment group received 21 consecutive days of hormonally active tablets (LNG 0.15 mg/EE 0.03 mg). In each treatment cycle 21 tablets (1 tablet daily) have to be taken in sequence, followed by a pill-free interval of 7 days. The treatment period was 7 cycles (28 days per cycle).
223585070|NCT05525949|OTHER|No-treatment Control|No-treatment is administered during control period.
223585071|NCT02097342|DRUG|Linagliptin|Tablet Linagliptin (5mg) per oral, once daily will be given to 10 patients for 6 months
223585072|NCT02097342|DRUG|Placebo|Tablet placebo per oral, once daily will be given to 10 patients for 6 months
224305425|NCT00115297|DRUG|Placebo|Participants who were 2 to 3 years old received placebo montelukast tablets and participants who were 12 months to 2 years old received placebo montelukast granules.
224305426|NCT05380076|OTHER|Mindfulness meditation|6 minutes of watching a video tape made for the study that inspire mindfulness like meditation just before entering the examination circuit.
224168812|NCT06630585|DRUG|Tirzepatide|"Tirzepatide is a clear, colorless to slightly yellow solution available in cartons containing four pre-filled single-dose pens or one single-dose vial: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, or 15 mg per 0.5 mL in a single-dose pen or vial.~In this study, the investigators will start with the recommended starting dosage of tirzepatide: 2.5 mg injected subcutaneously once weekly (for four weeks). After four weeks, the dosage will be increased to 5 mg once weekly injected subcutaneously for 12 weeks."
224168813|NCT05120284|DRUG|Dichloroacetate (DCA)|"Study medication DCA is a liquid formulation mixed with an artificial sweetener containing aspartame and strawberry extract (50mg/mL)~Participants will be genotyped to determine GSTZ1 (glutathione S-transferase Zeta-1) haplotype status, which will stratify this group into 1 of 2 dose regimens:~EGT carriers will receive 12-14 mg/kg/12hr DCA. EGT non-carriers will receive 6-7 mg/kg/12 hr."
224168814|NCT05120284|GENETIC|Genotype|Participants will be genotyped to determine GSTZ1 haplotype status.
224168815|NCT01003340|BEHAVIORAL|Wee Wheezers|The intervention, Wee Wheezers, modified to the needs of the targeted population will include 6 bi-weekly 1 hour educational home visits conducted by Community Health Workers at homes of children with persistent asthma
224168816|NCT06281314|DEVICE|Vespa software|The Vespa2.0 project refers to the production of tasks useful for neuropsychological rehabilitation, aimed at subjects suffering from Alzheimer's Dementia, Parkinson's and Multiple Sclerosis. It is a neuropsychological rehabilitation project using Virtual Reality (VR).
224168817|NCT06154460|PROCEDURE|Laterjet Surgery|The laterjet procedure is an operation in which the coracoid process is transferred to the glenoid rim with a screw.
224168818|NCT06154460|PROCEDURE|Reimplissage Surgery|"Reimplissagge operation, which means to fill, is an open procedure designed to limit the engagement of Hill-Sachs deformity by passing the infraspinatus into the Hill-Sachs defect."
223585073|NCT02097342|DRUG|Voglibose|Tablet Voglibose (0.2mg) per oral thrice daily(with meals) to 10 patients for 6 months
224168819|NCT06154460|PROCEDURE|Capsular Reconstruction|Allografts or autografts are used for capsular reconstruction. In the procedure performed with capsular repair and grafts, the capsule is strengthened and stabilization is attempted
224168820|NCT00284258|DRUG|CPT-11 and TS-1|TS-1 was administered orally at 40-60 mg twice daily for 14 days with a rest period of 14 days as one course. CPT-11 was administered intravenously 125 mg per square meter at day1 and day14 in 4 weeks as one course.
224168821|NCT00284258|DRUG|CPT-11, 5-FU and l-LV|Patients were administered FOLFIRI every 2 weeks in one course. FOLFIRI:CPT-11 150 mg per square meter on day1 with l-LV 200 mg per square meter administered as a 2-hour infusion before 5-FU 400 mg per square meter administered as an intravenous bolus injection, and 5-FU 2400 mg per square meter as a 46-hour infusion immediately after 5-FU bolus injection on day1 in 2 weeks.
224168822|NCT04796012|DRUG|Atezolizumab|Feasibility and RMS Cohorts: Administered at 15 mg/kg (max 1,200 mg) IV on Day 1 of each 21-day cycle
224168823|NCT04796012|DRUG|Vincristine|Feasibility and RMS Cohorts: Administered at 1.5 mg/m\^2 (max 2 mg) IV on Day 1 of each 21-day cycle
224168824|NCT04796012|DRUG|Irinotecan|Feasibility and RMS Cohorts: Administered at 50 mg/m2 IV on Days 1-5 of each 21-day cycle
224168825|NCT04796012|DRUG|Temozolomide|Feasibility and RMS Cohorts: Administered at 100 mg/m\^2 (max 200 mg) IV or PO 1 hour before irinotecan injection on Days 1-5 if each 21-day cycle
224168826|NCT05064007|BEHAVIORAL|A: 40 Hz music|The participant will listen to the 40 Hz music playlist one hour each day, 5 days a week for 4 weeks
224168827|NCT05064007|BEHAVIORAL|B: 40 Hz sound|The participant will listen to the 40 Hz sound playlist one hour each day, 5 days a week for 4 weeks
224168828|NCT05064007|BEHAVIORAL|C: Preferred music|The participant will listen to the preferred music playlist one hour each day, 5 days a week for 4 weeks
224168829|NCT06563479|DIAGNOSTIC_TEST|FMISO-PET Scan|Patients will undergo 18F-FMISO scan (only 1 injection) that occurs at week two of radiation treatment, typically day 10 but a window of 8-10 radiation treatment days\* after start of radiation is allowed.
224168830|NCT06563479|COMBINATION_PRODUCT|Chemoradiation|30 Gy or 70 Gy of radiation in combination with standard chemotherapy (cisplatin, carboplatin, and 5-FU)
224168831|NCT06563479|COMBINATION_PRODUCT|Chemoradiation|70 Gy of radiation in combination with standard chemotherapy (cisplatin, carboplatin, and 5-FU)
224168832|NCT06563479|OTHER|Assessments|EQ-5D-5L (5 questions); 2. MDADI-HN (total of 20 questions); 3. COST-FACIT (total of 12 questions).
224168833|NCT05164341|DRUG|metreleptin|Metreleptin is a recombinant human leptin analog that is indicated as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency
223585074|NCT00281190|PROCEDURE|Blood drawing|blood will be drawn at the time of starting the intravenous (IV) line for the procedure.
224168834|NCT05164341|DRUG|Placebo|Placebo
224168835|NCT04577313|BEHAVIORAL|Behavioral Self-Regulation Adherence Counseling|Telephone-delivered counseling to focus on cognitive-behavioral skills to improve HIV treatment adherence.
224168836|NCT06287814|BIOLOGICAL|Blood sample/lliquid biopsy|ctDNA analysis
224168837|NCT05393362|PROCEDURE|Cardiac Rehabilitation Program (CR)|"Strength exercises: strengthe exercise will be performed twice a week for 12 weeks, 4-6 series at 60% RM at the beginning of the program, with a progression towards 85% RM in each functional movement at the end of the intervention. The patients will rest for 90 seconds between series and 3 minutes between exercises. Each session has an estimated duration of between 45-60 min.~Aerobic exercise: aerobic exercise it will be performed twice a week for twelve weeks, between 45-60 min each session of aerobic exercise. It will be developed on a treadmill or cycle ergometer at 50% of HR max at the beginning of the program with a progression towards 80% of HR max at the end, continuously or internally. The Borg scale will prevail over the objective data to adjust the intensity of each patient, Borg = 10/20 or mBorg = 5/10 at the beginning, with progression to Borg = 14/20 or mBorg = 8/10 at the end."
224168838|NCT05393362|BEHAVIORAL|Control Group (CG)|The control group will receive two education sessions per week for twelve weeks on the complications derived from Heart Failure (HF), functional deterioration, and healthy lifestyle habits.
224168839|NCT02682511|DRUG|Oral Ifetroban|Subjects will be treated with oral ifetroban or placebo daily for 365 days
223585075|NCT00281190|PROCEDURE|Bronchoalveolar lavage during indicated bronchoscopy|A small amount of liquid will be introduced and immediately sucked back out of portions of the lung, and the cells that are recovered will be analyzed in the laboratory. All test will be solely for research, and there will be no results reported to the subject from that fluid.
223585076|NCT00997399|DRUG|panobinostat (LBH589)|
224168840|NCT02682511|DRUG|Oral Placebo|Subjects will be treated with oral ifetroban or placebo daily for 365 days
224168841|NCT04316117|PROCEDURE|Computed Tomography|Undergo PET/CT
224168842|NCT04316117|OTHER|Fludeoxyglucose F-18|Given IV
224168843|NCT04316117|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
224168844|NCT05549505|DRUG|ARV-471|100 mg tablet
224168845|NCT05549505|DRUG|Anastrozole|1 mg tablet
224168846|NCT05549505|PROCEDURE|Surgical resection of breast tumor|Surgical resection approximately 5.5 months after starting treatment (C6D18 ± 14 days)
224168847|NCT06555991|OTHER|SIRSI and TSK-SI|The SIRSI and TSK-SI as well as the WOSI and RTS-, Clinical- and Demographic Information are gathered. The SIRSI and TSK-SI are re-administered one week later
223481386|NCT03416101|PROCEDURE|Total Gastrectomy|The esophagus was resected at the arch level of the azygos vein, a frozen section of the resection margin was routinely performed to achieve a proximal clean resection margin. The surgical specimen was comprehensive of distal esophagus, stomach and omentum. Digestive tract continuity was established with Roux-en-Y esophagojejunostomy. Lymphadenectomy was extended to the thoracic stations R 2-4, 7-8-9, and L 4, numbered according to the Mountain's classification \[39\] (Suppl. File 2 Figure A) and to the abdominal stations 1-12, numbered according to the Japanese Research Society for Gastric Cancer (JRSGC) 1998 classification.
224168848|NCT06408818|BEHAVIORAL|Media Aware Parent - Tween|Media Aware Parent - Tween, is an online program for parents of tweens ages 9-12 designed to help parents have effective conversations with their child about body image, sexual development, gender stereotypes, romantic relationships, and media.
224168849|NCT06408818|BEHAVIORAL|Active Control Resource|Parents will have access to medically-accurate information about topics such as body image, sexual development, gender stereotypes, and romantic relationships.
224168850|NCT01602822|DRUG|Tenofovir DF and Emtricitabine; Ritonavir-boosted Atazanavir|TDF 300mg and FTC 200mg fixed-dose combination tablet (TDF/FTC) once daily, and atazanavir, one 300mg tablet and one 100 mg ritonavir given once daily
224168851|NCT03739892|BEHAVIORAL|standard stroke rehabilitation|standard rehabilitation according to the french standard care and to the severity of the patient
224168852|NCT03288311|OTHER|Protocolized post-extubation respiratory support|Qualifying patients undergoing extubation in an ICU bed randomized to post-extubation respiratory support will receive either non-invasive ventilation or high flow nasal cannula (as determined by a prespecified protocol and applied by a respiratory therapist) from the time of extubation until 5AM the following morning
224168853|NCT03288311|OTHER|Usual Care|Qualifying patients undergoing extubation in an ICU bed randomized to usual care will receive standard-of-care treatment, which may include post-extubation respiratory support at the discretion of their clinical team.
224168854|NCT02110550|OTHER|IPS.emmax endocrown|
224168855|NCT02960308|RADIATION|Computed Tomography Perfusion Imaging|Undergo WNCTP scan
224168856|NCT05322083|DRUG|Doravirine|Doravirine will be given to patients after failure on the first NNRTI regimen.
224168857|NCT00854061|DRUG|T-Pred|sterile ophthalmic solution
224168858|NCT00854061|DRUG|Pred Forte|sterile ophthalmic solution
224168859|NCT03799523|OTHER|Temporary skin markings|To use temporary markings in lieu of localization tattoos.
224168860|NCT03799523|OTHER|Surface imaging|To use light-based surface imaging for patient positioning during radiation treatment.
224168861|NCT05022706|OTHER|Community-based accompaniment and home visits|"Trained health promoters will accompany adolescents to their first appointments; facilitate enrollment in public health insurance and completion of other administrative requisites (e.g. obtaining a foreign identification card for migrants; transferring to a different health facility); help troubleshoot new logistical and/or social challenges; and will foster communication between the adult care providers and the patient.~Health promoters will visit the participant's home or another mutually-agreed upon location at least monthly, to review ART adherence, identify barriers to care and adherence, remind patients of upcoming medical encounters, screen and follow-up for clinical and social problems, and offer social support."
224168862|NCT05022706|BEHAVIORAL|Directly Observed Therapy|Among adolescents who have already initiated combination antiretroviral therapy (cART), directly observed therapy (DOT) will be provided to the subset of adolescents identified as being at high risk of non-adherence, defined by meeting at least one of the following criteria: 1) identified by the pediatric health provider as having unstable adherence; or 2) having a detectable viral load at one of their two previous measurements. In adolescents newly initiating cART, there will not be an adherence precedent. This group will choose whether they wish to receive DOT. As part of this research, trained community health workers (CHWs) will deliver DOT in participant's homes or in a mutually agreed upon location. CHWs will observe ingestion of cART daily, ensure it is taken as prescribed and record each dose as DOT, self-administered, not taken or not prescribed.
224168863|NCT05022706|BEHAVIORAL|Monthly Peer Support Groups|The investigators will assign ALWH to a social support group with 9 to 11 other adolescents also participating in the research. The goal of the social support groups is to provide a venue for participants to share experiences and resources and provide encouragement and support to one another. Each group will last approximately 3 to 4 hours. Support groups will be led by adult peers or trained community health workers. The final group session will incorporate a discussion about the group experience, how it may change behavior, recommendations for improvement, and unmet needs that should be considered for a future intervention.
224168864|NCT04711915|DRUG|0.1 mg/kg Dimethyltryptamine (DMT)|0.1 mg/kg DMT
224168865|NCT04711915|DRUG|0.3 mg/kg Dimethyltryptamine (DMT)|0.3 mg/kg DMT
224168866|NCT05492877|DRUG|Mitiperstat (AZD4831)|Oral dosage, once daily.
224168867|NCT05492877|OTHER|Placebo|Oral dosage, once daily.
224168868|NCT02286089|BIOLOGICAL|OpRegen|Targeted dose of 50,000 - 200,000 cells will be delivered into the subretinal space.
224305427|NCT05380076|OTHER|Mobilization of inner resources|6 minutes of watching a video tape made for the study that provide psychological stimulation just before entering the examination circuit
224305428|NCT05380076|OTHER|Biofeedback|6 minutes of relaxing breathing exercise coupled with heart rate variability biofeedback guided on eMWave Pro software on a computer just before entering the examination circuit.
223481387|NCT01214122|DRUG|AZD9668|60 mg orally twice daily for 11 days
223481388|NCT01214122|DRUG|Warfarin|10 x 2.5 (25) mg orally once daily on day 1 and on day 14
224168869|NCT03844529|DEVICE|Sunmax FULLSGEN with Lidocaine|Subject who voluntarily sign the informed consent form (day -14\~1) will be randomly assigned to investigational or control group and have intradermal allergy test. After the injection treatment by randomly choosing the device, every subject would have 6 follow-up visits.
224168870|NCT03413228|OTHER|Questionnaire|An interview to collect some informations will be done: demographic informations, medical history, vaccination against influenza status, symptoms and virological informations. Then, a nasal swab was performed in order to identified the influenza virus.
224168871|NCT03407027|DRUG|Quadratus triamcinolone|40mg of triamcinolone and 10ml of levobupivacaine 0,25%.
224168872|NCT03407027|DRUG|Gluteus triamcinolone|40mg of triamcinolone and 10ml of levobupivacaine 0,25%.
224168873|NCT03407027|DRUG|quadratus without triamcinolone.|10ml of levobupivacaine 0,25%.
224168874|NCT05835167|PROCEDURE|Inferior part-sternotomy|A midline skin incision of 8 to 10cm in length is made over the sternum, starting from 2-3cm below the sternal angle inferiorly and extending slightly beyond the xiphoid process. A sternal saw is used to split the sternum from the xiphoid process to the second intercostal space where the sternum is partially transected by turning the saw rightward.
224168875|NCT05835167|PROCEDURE|Full median sternotomy|A midline skin incision is made over the sternum, starting from the sternal angle and extending slightly beyond the xiphoid process. The sternum is fully split by a sternal saw.
224168876|NCT06459856|OTHER|Balloon blowing|Ask the patient to take in a deep breath; steadily and slowly blow up the huge balloon. See the balloon getting bigger, and bigger. Now ask the patient to close the eyes and imagine the balloon floating into the air. Let the patient continue blowing of balloons until he or she gets relaxed and calm.
224168877|NCT06459856|OTHER|Percussion|Percussion is a technique involving rhythmic tapping or clapping on the chest or back, serves as a means to move and loosen retained secretions within the airways. This mechanical intervention helps in removing mucus from the bronchial walls, and facilitates its expectoration and clearance
224168878|NCT00136461|DRUG|All-trans retinoic acid|
224168879|NCT00136461|DRUG|Bryostatin 1|
224168880|NCT00129376|DRUG|Doxorubicin|
224168881|NCT00129376|DRUG|Cyclophosphamide|
224168882|NCT00129376|DRUG|Docetaxel|
223481389|NCT03273972|OTHER|Written Informed Consent|To be completed prior to conducting any study related procedures
223481390|NCT03273972|OTHER|Inclusion/Exclusion check|Eligibility check
223481391|NCT03273972|OTHER|Full Clinical Chemistry and Haematology Bloods|Participant required to fast for at least 6-8 hoursprior to visit. (Clear, non-caffeinated fluids are allowed)
224168883|NCT04131127|DEVICE|Sentinel Device|Sentinel Device used during TAVI in a Low Risk Patient
224168884|NCT04486404|OTHER|Online survey|Online survey including questions related to PPE availability, perceptions, emotions and EASE scale (Acute Stress Scale).
224168885|NCT00000515|BEHAVIORAL|diet, reducing|
224168886|NCT00536094|BEHAVIORAL|Cognitive behavioral therapy (CBT)|CBT includes 45-minute psychotherapy sessions once a week for a period of approximately 12 weeks.
224168887|NCT00536094|BEHAVIORAL|Treatment as usual (TAU)|TAU includes 45-minute psychosocial treatment sessions once a week for a period of approximately 12 weeks.
223481392|NCT03273972|OTHER|Serum sample for systemic markers and lipid sub-fractions|Serum samples may be stored for later analysis.
224168888|NCT01858337|OTHER|green beans group|Infants were weaned with vegetable purees for the first 18 days of weaning. One vegetable type per day. With green beans every other day.
224168889|NCT01858337|OTHER|Artichoke group|Infants were weaned with vegetable purees for the first 18 days of weaning. One vegetable type per day. With artichoke every other day.
224168890|NCT01858337|OTHER|Apple group|Infants were weaned with fruit purees for the first 18 days of weaning. One fruit type per day. With apple every other day.
224168891|NCT01858337|OTHER|Plums group|Infants were weaned with fruit purees for the first 18 days of weaning. One fruit type per day. With Plums every other day.
224168892|NCT06977321|OTHER|Kinesiotaping|Kinesiotaping, unlike wrist splints, which are frequently used in the treatment of carpal tunnel syndrome, does not restrict daily living activities. Space correction technique will be applied while performing kinesio taping.
224168893|NCT06977321|OTHER|Peloidotherapy|Peloidotherapy stands out among superficial heating physical therapy modalities with its mineral and natural origin.
224168894|NCT06977321|OTHER|Home exercise|Flexor tendon gliding exercises, median nerve gliding exercises, and isometric wrist strengthening exercises will be given as exercises.
224168895|NCT02404909|OTHER|IVC diameters evaluation by intraoperative ultrasound|Out of consecutive patients who underwent hepatectomy for primary and secondary liver tumors, patients in whom IVC diameters were intraoperatively measured for clinical reasons were retrospectively selected and analyzed
224168896|NCT02093741|BIOLOGICAL|Octocog alfa (recombinant human coagulation factor VIII) [ADVATE]|The investigators shall determine all treatment regimens according to product labeling information and standard practice.
224168897|NCT07126600|OTHER|No investigational intervention administered|No investigational intervention administered
224168898|NCT06648655|DRUG|TMP-301|Daily (QD) x 14 weeks.
224168899|NCT06648655|DRUG|Placebo|Daily (QD) x 14 weeks.
224168900|NCT06827275|PROCEDURE|Feeding process|Nutritional therapy is administered according to the feeding procedure
224305429|NCT00085423|BIOLOGICAL|aldesleukin|‡Interleukin-2 (aldesleukin) IV (600,000 U/kg; Chiron, Emeryville, CA): two 5-day courses on days 8 and 22. Interleukin-2 was given over 15 minutes every 8 hours. Goal is 14 doses/5-day course
224305430|NCT00085423|BIOLOGICAL|sargramostim|GM-CSF was given subcutaneously daily from day 8 until absolute granulocyte count exceeds 5,000 cells/mL for 2 consecutive days.
223481393|NCT03273972|OTHER|Pregnancy Test|If applicable for women of child bearing potential
223481394|NCT03273972|OTHER|12 Lead ECG|participant resting supine
223481395|NCT03273972|OTHER|Blood Pressure and Heart Rate|Measured in the seated position after 5 minutes rest
223481396|NCT03273972|OTHER|Arterial Stiffness|Measure of functional and structural changes which accompanies cardiovascular disease
223481397|NCT03273972|OTHER|Central Haemodynamics|Measure of functional and structural changes which accompanies cardiovascular disease
224168901|NCT06439654|OTHER|Supportive care|The study model will utilize the accepted standard of care while implementing key enhancements to proactively reach high-risk patients as early as possible. Wrap around comprehensive care is defined as database screening, outreach, encouraging genetic testing for participants and their family members, and provide ongoing education, medical management (e.g., adherence to FDA-approved medications), routine laboratory testing, specialist referrals, Epic referrals to integrated care support such as pharmacy, nutrition, social work, and community health), and routine follow-up either in-person or using virtual visits. Consultations with pharmacists, nutritionists and genetic counselors or specialists to manage co-morbidities may be requested.
224168902|NCT06479278|BEHAVIORAL|Talk with Me Baby|Primary care providers will embed Talk With Me Baby (TWMB) within standard-of-care Well-Child Care visits for children ≤36 months of age. Children will receive usual care plus a brief language-promotion intervention (TWMB) in up to 4 consecutive Well-Child Care visits during their 12-month period.
224168903|NCT05941052|DIAGNOSTIC_TEST|Tongue swab-based molecular assays|The investigators will evaluate semi-automated or automated molecular assays intended for use at near point of care or point of care.
224168904|NCT06338631|OTHER|Diet|Pesonalized diet plan, devoloped according to Guidelines for dietary treatment of obesity, to be followed for a duration of 12 months
224168905|NCT06842147|DEVICE|7-day single-lead long-term ECG monitoring device.|Participants in the long-term screening group will undergo baseline data collection and a 12-lead ECG at baseline, followed using a 7-day single-lead long-term ECG monitoring device. This device continuously collects dynamic ECG data for seven days and allows participants to view and store ECGs through the accompanying software (registration number: 20192070163).
224168906|NCT06842147|DEVICE|Standard Screening Group|Patients in the standard screening group will undergo baseline data collection and a standard 12-lead ECG at the start of the study, with follow-up including opportunistic ECG checks as needed. Those diagnosed with AF will receive anticoagulation and antiarrhythmic therapy according to clinical guidelines.
224168907|NCT04921865|DEVICE|DPS VA-LCP® Clavicle Plate 2.7 System; DPS VA-LCP® Clavicle Hook Plate 2.7 System|"The DPS VA-LCP® Clavicle Plate 2.7 System is indicated for the fixation of clavicle bone fragments. The system consists of three plate types: lateral, shaft, and medial, each available in different sizes and materials (titanium alloy and stainless steel). Each plate is available in left and right.~The DPS VA-LCP® Clavicle Clavicle Hook Plate 2.7 System is indicated or the fixation of lateral clavicle fractures and AC joint dislocations. The Clavicle Hook Plate system consists of three plate types: long, short and button plates."
224168908|NCT05993455|DRUG|Oral sotorasib + IV Panitumumab|Oral sotorasib at a dose of 960 mg once daily with Panitumumab is administered intravenously (IV) at a dose of 6 mg/kg every 14 days, infused over 60 minutes (≤ 1,000 mg) or 90 minutes (\> 1,000 mg).
224168909|NCT06806657|BIOLOGICAL|Garadacimab|Participants will receive a loading dose of garadacimab, followed by once monthly garadacimab administration for 2 months. Garadacimab will be given as a subcutaneous injection. The timing for the administration of the loading dose (first administration of garadacimab) is determined by the dosing schedule of the current HAE prophylactic treatment. No washout necessary.
224168910|NCT01081028|OTHER|First-line therapy|As prescribed by treating physician
224168911|NCT01081028|DRUG|Second-line Multiple Myeloma treatments|As prescribed by the treating physician
224168912|NCT03307473|BEHAVIORAL|E6BIKE|During 3 months in a the geographic area of Clermont-Ferrand (France), new e-bike buyers and renters are invited to take part in VELONAPS study before starting to use their e-bike
224168913|NCT03218826|DRUG|Docetaxel|Given IV
223481398|NCT03273972|OTHER|Carotid Intima Media Thickness|Measurements will be repeated three times, and the average of the median values will be recorded
224168914|NCT03218826|OTHER|Laboratory Biomarker Analysis|Correlative studies
224168915|NCT03218826|OTHER|Pharmacological Study|Correlative studies
224168916|NCT03218826|DRUG|PI3Kbeta Inhibitor AZD8186|Given PO
224168917|NCT01790763|DEVICE|Keramatrix|Dressing for second degree burn
224168918|NCT01790763|DEVICE|Mepilex|Dressing for second degree wound
224168919|NCT02497053|DRUG|pemetrexed/platinum chemotherapy|Four cycles of pemetrexed/platinum chemotherapy
224168920|NCT02497053|DRUG|Pemetrexed/platinum chemotherapy|Six cycles of pemetrexed/platinum chemotherapy
224168921|NCT01426009|DRUG|EP-101 via nebulizer (eFlow®) 25 ug|EP-101 (25 ug ) Dose 1 administered once daily for 7 days
224168922|NCT01426009|DRUG|EP-101 via nebulizer (eFlow®) 50 ug|EP-101 (50 ug ) administered once daily for 7 days
224168923|NCT01426009|DRUG|EP-101 via nebulizer (eFlow®) 100 ug|EP-101 (100ug) administered once daily for 7 days
224168924|NCT01426009|DRUG|Placebo EP-101|Placebo EP-101 administered once daily for 7 days
224168925|NCT01426009|DRUG|Tiotropium bromide via (Spiriva® Handihaler®)|Tiotropium 18 µg administered once daily for 7 days using Handihaler® DPI
224168926|NCT01426009|DRUG|Ipratropium bromide Inhalation Solution via Handihaler® DPI|Ipratropium 500 µg administered three times daily for 7 days using general purpose nebulizer
224168927|NCT01426009|DRUG|EP-101 via nebulizer (eFlow®) 200 ug|EP-101 (200) ug administered once daily for 7 days
224168928|NCT04996277|PROCEDURE|angiography|All STEMI patients will be treated according to the hospital's standard procedures and the plaque will be monitored for 7-30 days to stabilize. Treatment options for STEMI include: March thrombus aspiration without balloon or stent implantation; Stabilization with drug therapy in a relatively small hospital that does not provide PCI, and transfer to a tertiary hospital for further evaluation; Thrombolytic therapy.
224305431|NCT00085423|DRUG|cyclophosphamide|Cyclophosphamide (60 mg/kg/d; Baxter, Deerfield, IL) intravenously (IV) for 2 days with sodium 2- mercaptoethanesulfonate (Mesna; Sicor, Irvine, CA) at 20% of cyclophosphamide dose IV 15 minutes before and 40% of the cyclophosphamide dose orally at 2 and 6 hours after the initiation of chemotherapy.
224305432|NCT00085423|DRUG|fludarabine phosphate|Fludarabine IV (25 mg/M2/day)-five daily doses from Day 3
223481399|NCT03273972|OTHER|Forearm blood flow studies|Assess and determine vascular function, which can interrogate endothelium dependent and independent mechanisms of nitric oxide bioavailability
223481400|NCT03273972|OTHER|Concomitant medication check|Review of medication taken by the participant
223481401|NCT03273972|OTHER|Medication compliance check (Pill count)|Ensure prescribed statin has been taken
224305433|NCT01555008|DRUG|LX4211|Subjects will receive LX4211 once daily for 7 days
224168929|NCT04996277|PROCEDURE|Thrombus suction|All STEMI patients will be treated according to the hospital's standard procedures and the plaque will be monitored for 7-30 days to stabilize. Treatment options for STEMI include: March thrombus aspiration without balloon or stent implantation; Stabilization with drug therapy in a relatively small hospital that does not provide PCI, and transfer to a tertiary hospital for further evaluation; Thrombolytic therapy.
224168930|NCT04996277|PROCEDURE|Fibrinolytic therapy|All STEMI patients will be treated according to the hospital's standard procedures and the plaque will be monitored for 7-30 days to stabilize. Treatment options for STEMI include: March thrombus aspiration without balloon or stent implantation; Stabilization with drug therapy in a relatively small hospital that does not provide PCI, and transfer to a tertiary hospital for further evaluation; Thrombolytic therapy.
224168931|NCT04996277|BEHAVIORAL|Medication stabilized the condition|All STEMI patients will be treated according to the hospital's standard procedures and the plaque will be monitored for 7-30 days to stabilize. Treatment options for STEMI include: March thrombus aspiration without balloon or stent implantation; Stabilization with drug therapy in a relatively small hospital that does not provide PCI, and transfer to a tertiary hospital for further evaluation; Thrombolytic therapy.
224168932|NCT05320211|DEVICE|3D-printed hand orthosis|3D-printed hand orthoses (intervention) will be compared with custom-fabricated conventional orthoses (control condition at baseline)
223481402|NCT03273972|OTHER|Physical examination|Check overall health
224168933|NCT02283333|BEHAVIORAL|BATE-G|Behavioral Activation and Therapeutic Exposure - Grief therapy is delivered in 7 weekly sessions to the participant.
224168934|NCT02283333|BEHAVIORAL|Standard Treatment|Cognitive Restructuring and Supportive Grief Counseling is delivered in 7 weekly sessions to the participant.
224168935|NCT02974660|DRUG|Protamine sulfate|
224168936|NCT02974660|DRUG|0.9% NaCl|
224168937|NCT03426449|PROCEDURE|posterolateral sphincterotomy|Fissurectomy and limited division of internal anal sphincter at 5 o'clock position for 8-10 mm
224168938|NCT03426449|PROCEDURE|lateral sphincterotomy|Fissurectomy and limited division of internal anal sphincter at 3 o'clock position for 8-10 mm
224168939|NCT04955652|BEHAVIORAL|Health Maintenance Topic|Alert
224168940|NCT04955652|BEHAVIORAL|Actionable Sidebar Item|Alert
224168941|NCT04955652|BEHAVIORAL|Best Practice Alert|Alert
224168942|NCT01378676|DRUG|Placebo (Part A)|Placebo tablets once daily for 14 days (Part A)
224168943|NCT01378676|DRUG|CK-2017357 (Part A)|One 125 mg CK-2017357 tablet once daily for 14 days (Part A)
224168944|NCT01378676|DRUG|CK-2017357 (Part A)|Two 125 mg CK-2017357 tablets once daily for 14 days (Part A)
224168945|NCT01378676|DRUG|CK-2017357 (Part A)|Three 125 mg CK-2017357 tablets once daily for 14 days (Part A)
224168946|NCT01378676|DRUG|Riluzole 50 MG (Part B)|One 50 mg tablet once daily for 14 days (Part B)
224168947|NCT01378676|DRUG|Placebo (Part B)|Placebo tablets once daily for 14 days (Part B)
224168948|NCT01378676|DRUG|CK-2017357 (Part B)|One 125 mg tablet once daily for 14 days (Part B)
224168949|NCT01378676|DRUG|CK-2017357 (Part B)|Two 125 mg tablets once daily for 14 days (Part B)
224168950|NCT01378676|DRUG|CK-2017357 (Part B)|Three 125 mg tablets once daily for 14 days (Part B)
223481403|NCT03273972|OTHER|Medical history|Review of volunteers medial history
224168951|NCT04372979|DRUG|Transfusion of SARS-CoV-2 Convalescent Plasma.|2 Convalescent Plasma units of 200-230mL each, inactivated by amotosalen.
224168952|NCT04372979|DRUG|Transfusion of standard Plasma.|2 Standard Plasma units of 200-230mL each, inactivated by amotosalen.
224168953|NCT02482415|OTHER|Psycho-educational|
224168954|NCT00451074|DRUG|Gentamicin infusions twice a week for six months|Gentamicin infusions twice a week
224168955|NCT00909883|DRUG|Botulinum Toxin: Xeomin|45 patients with an Idiopathic Parkinson's disease and a foot dystonia. Double blind, randomized study
223481404|NCT03273972|OTHER|AE/SAE review & reporting|Monitor safety from the point of consent
223481405|NCT03273972|DRUG|Dosing|To be performed at the end of the visit following completion all other study visits
223481406|NCT05306704|OTHER|placebo Oil|participants will receive placebo(olive oil) orally in all visits from visit 1 to visit 4
223481407|NCT05306704|DRUG|25-Hydroxyvitamin D|Participants will receive vitamin D (100000IU) orally during all visits i.e. from visit-1 to visit-4
223481408|NCT01922453|OTHER|Music and Sound|
223481409|NCT03655431|OTHER|Telerehabilitation|Participants complete a standard physical therapy evaluation in-person. They are then provided telerehabilitation equipment for the telerehabilitation intervention. This intervention utilizes an Xbox Kinect sensor and tablet-based exercise software called Jintronix. The Jintronix exercise library includes an array of exercise activity options for varying functional levels. Exercise activities could be completed in sitting or standing postures and includes activities which focused on active range of motion, strength, balance, or calisthenic movements. Each activity requires the participant to complete a goal-directed game or replicate movements of an on-screen avatar. The therapist will adjust and progress the home exercise program using information provided by the Jintronix and the participant's verbal reports during clinical video teleconferencing. At the end of the intervention, the therapist will complete in-person discharge assessments.
223585077|NCT00582738|DRUG|CsA-TAC (standard Treatment)|Continuation of current immunosuppressive regimen (continuation of CNI with or without MPA, with or without steroids) / no everolimus introduction.
224168956|NCT00909883|DRUG|Placebo|Placebo injection
224168957|NCT06085937|DRUG|Ketamine|Patients will receive 0.2mg/kg of IV ketamine
224168958|NCT01501734|DEVICE|watch-pat|"The Watch-PAT is a home sleep testing (HST) device. The Watch-PAT is a patient-worn, self-contained, non-invasive device used in the patient's home.~The Watch-PAT diagnoses obstructive sleep apnea (OSA) by measuring the PAT signal, heart rate, oxygen saturation, and actigraphy. The PAT signal is a validated surrogate measure of sympathetic activation that is associated with apneic events and respiratory effort related arousals (RERA). The Watch-PAT provides measures of all the OSA indices, i.e., Apnea Hypopnea Index (AHI), Respiratory Disturbances Index (RDI), and Oxygen Desaturation Index (ODI), which enable accurate assessment of the presence and severity of OSA and its effect on sleep architecture, sleep quality.~Based on the PAT and actigraphy signals, Watch-PAT differentiates between sleep and wake and detects sleep stages (light, deep, and REM) providing, the effect on additional specific conditions such as REM related apnea."
224168959|NCT04885075|DRUG|IV diazepam|inj.diazepam 0.2mg/kg/dose stat
224168960|NCT04885075|DRUG|I/N Midazolam|intranasal midazolam 0.2mg/kg/dose stat
224168961|NCT04063540|DRUG|Amiloride|Treatment by Amiloride vs placebo in crossover
224168962|NCT04063540|DRUG|Placebos|Treatment by Amiloride vs placebo in crossover
224168963|NCT04461145|BEHAVIORAL|command|The participant was asked to walk along the walkway while backward counting numbers with increment of seven starting from a randomly given number.
224168964|NCT05633160|DRUG|64Cu-SAR-BBN|64Cu-SAR-BBN
224168965|NCT05633160|DRUG|67Cu-SAR-BBN|67Cu-SAR-BBN
224168966|NCT00513370|BIOLOGICAL|Humira (adalimumab)|Study drug will be provided as a sterile, preservative-free solution for subcutaneous injection, contained in a pre-filled syringe housed in a pen device (pre-filled pen). Loading dose of 80 mg of adalimumab subcutaneously (sc) at Baseline, and 40 mg of adalimumab sc at Week 1, followed by 40 mg of adalimumab sc every other week (eow) for 24 weeks.
224168967|NCT01492166|DRUG|biphasic human insulin 30|Dose and timing of dose for each subject was at the discretion of the attending physicians based on current clinical practice guidelines
224168968|NCT01856855|RADIATION|Stereotactic Body Radiation Therapy with Integrated Boost|SBRT with Integrated boost at 7.25 Gy and 8.00 Gy per fraction for five fractions
224168969|NCT04103203|DIAGNOSTIC_TEST|PathoRobot/ Patho-Doc Test result|Test results of the new diagnostics will be available to the treating physician.
224168970|NCT03598660|GENETIC|Sorcin gene expression|Sorcin gene expression Will be measured by real time PCR
224168971|NCT03598660|OTHER|Annexin A3 serum mesurement|serum mesurement of Annexin A3 by enzyme linked immuno sorbent assay (ELISA)
224168972|NCT01122823|BEHAVIORAL|chronic disease self-management program (online)|The online CDSMP is an internet-based program for people with 1 or more chronic conditions. It's built on self-efficacy theory, facilitated by lay leaders, and uses a curriculum emphasizing problem solving, decision making, and confidence building in weekly sessions over six weeks. It addresses generic topics and skills relevant to managing any chronic condition, including: action plans; problem solving; nutrition; exercise; fatigue; breathing; managing medications; managing stress and emotions; working with health care providers. The structure includes: 1) password-protected, interactive web-based instruction; 2) web-based bulletin board discussion groups to enable participatory learning and support; 3) and a reference book that contains the program content and supplemental information.
224168973|NCT02394990|BEHAVIORAL|Violence Brief Intervention|Strategies for self assessment of consequences of violent behavior and strategies for avoidance of violence
224168974|NCT02394990|BEHAVIORAL|ABI|
224168975|NCT00809055|DRUG|Caffeine citrate|Caffeine to be administered as outlined to compare efficacy of different dosages.
224168976|NCT02353338|PROCEDURE|Surgical intervention|Surgical management of radial fracture
224168977|NCT02353338|PROCEDURE|Conservative management|Immobilized/cast for 6 weeks
224168978|NCT02353338|DEVICE|cast|
223481410|NCT03655431|OTHER|Standard treatment|Participants complete standard in-person physical therapy evaluation, follow-up, and treatment. Therapeutic exercise and activities will be prescribed to participants to perform at home between standard follow-up treatment appointments. At the end of the intervention, the physical therapist will complete in-person discharge assessments.
223481411|NCT02214810|DRUG|Bupivacaine/Exparel|The opaque envelope, which was selected by the treating physician, will accompany each of the study participants will be opened and the patient identified as belonging to either Group 1 or Group 2. It is important to note that randomization of the envelopes were computer-generated and placed by a co-investigator; the treating physician is completely unaware of the order of the opaque envelopes. Patients in Group 1 will receive a standardized medication regimen including non-liposomal bupivacaine by soft-tissue injection at the conclusion of their surgical procedure. Those in Group 2 will receive non-liposomal bupivacaine and ExparelTM by soft-tissue injection at the conclusion of their surgical procedure. Study participants will undergo injection in this manner until the conclusion of the study.
223481412|NCT05432817|BEHAVIORAL|Cognitive Processing Therapy|CPT: a type of cognitive behavioral therapy recommended for the treatment of PTSD. Delivered over 12 sessions with an emphasis on addressing trauma-related cognitions and challenging trauma-related beliefs. Includes homework assignments. For this study, CPT will be conducted in groups.
223481413|NCT03482024|DRUG|Tirzepatide|Administered SC.
223481414|NCT00469794|PROCEDURE|stress test|
224168979|NCT02576093|DRUG|0.1% WOL071-007|Application of approximately 2 mg cream/cm² skin to a defined surface area. SAD part: Single application to ≤ 100 cm² of non-lesional or lesional skin; MAD part: Multiple application (6 Days) to 2000 cm² of lesional and non-lesional skin.
224168980|NCT02576093|DRUG|0.3% WOL071-007|Application of approximately 2 mg cream/cm² skin to a defined surface area. SAD part: Single application to ≤ 100 cm² of non-lesional or lesional skin; MAD part: Multiple application (6 Days) to 2000 cm² of lesional and non-lesional skin.
224168981|NCT02576093|DRUG|1.0% WOL071-007|Application of approximately 2 mg cream/cm² skin to a defined surface area. SAD part: Single application to ≤ 100 cm² of non-lesional or lesional skin; MAD part: Multiple application (6 Days) to 2000 cm² of lesional and non-lesional skin.
224168982|NCT02576093|DRUG|Placebo of WOL071-007|Application of approximately 2 mg cream/cm² skin to a defined surface area. SAD part: Single application to ≤ 100 cm² of non-lesional or lesional skin; MAD part: Multiple application (6 Days) to 2000 cm² of lesional and non-lesional skin.
224168983|NCT00515099|DRUG|Antithymocyte globulin|Daily 4-day escalating dose
224168984|NCT00515099|DRUG|Placebo|Daily 4-day saline solution
224168985|NCT03639688|PROCEDURE|Threading on the left lip commissure|Threading of the endotracheal tube over the fiberoptic bronchscope from the left lip commissure
224168986|NCT03639688|PROCEDURE|Threading on the right lip commmissure|Threading of the endotracheal tube over the fiberoptic bronchoscope from the right lip commissure
224168987|NCT01905306|PROCEDURE|computer guided implant planning|
224168988|NCT01905306|PROCEDURE|free hand implants placement|
224305434|NCT01555008|DRUG|LX4211 Placebo|Subjects will receive LX4211 placebo once daily for 7 days
224305435|NCT02684708|DRUG|cyclophosphamide, vincristine, prednisone, dacarbazine|28-day chemotherapy cycle
224305436|NCT02684708|DRUG|cyclo, vcr, pred, dacarb,etop and doxo|21-day chemotherapy cycle
224305437|NCT02390141|DRUG|ZP4207|
224305438|NCT02390141|DRUG|Placebo|
224305439|NCT02735850|DRUG|L19-IL2|L19-IL2 added to SBRT
224305440|NCT02735850|RADIATION|SBRT|
224305441|NCT02735850|OTHER|No intervention|
223481415|NCT03518684|DRUG|Natalis|"A specially-designed sterile obstetric gel (Natalis) will be used for this trial. The obstetric gel is a birth gel with no pharmacologic effects that has a purely physical activity. It contains propylene glycol, glycerol, sodium chloride, xanthan gum, hydroxyethylcellulose and water.~Starting with the first vaginal examination the obstetric gel will be used. After each vaginal examination, 3-5 mL of obstetric gel will be introduced into the vaginal birth canal in the area in front of the child using the sterile obstetric gel applicator without any manipulation or massaging. Additional obstetric gel will be added 15-30 minutes after rupture of the membranesOnce the head of the child is visible, the mouth and nose region will be wiped clean. A dry towel will be used to liberate the child in order to prevent the child from slipping"
223481416|NCT02593240|BEHAVIORAL|The iDiet® (also called Healthy Weight for Living when used as a not-for-profit intervention) with Food|The intensive iDiet® group behavioral weight loss program will be delivered in person at the worksite or by videoconference and with support of the program's web platform. This intervention will be delivered by trained group leaders and will initially include weekly 1-hour support and education meetings of 20 participants/group with a message board for group communication and individual communication with the group leader. Over time support will be provided online rather than in live meetings. The intervention involves a weight loss behavioral program with particular emphasis on hunger reduction and craving control for both weight loss and prevention of weight regain. Half of the participants per worksite receiving the iDiet® intervention will be randomized to receive commercial dried food products (partial supply) from Yevo Intl., which are designed to help with weight control and health.
223481417|NCT02593240|BEHAVIORAL|The iDiet® (also called Healthy Weight for Living when used as a not-for-profit intervention) with Voucher|The intensive iDiet® group behavioral weight loss program delivered in person at the worksite or by videoconference and with support of the program's web platform. This intervention will be delivered by trained group leaders and will initially include weekly 1-hour support and education meetings of 20 participants/group with a message board for group communication and individual communication with the group leader. Over time support will be provided online rather than in live meetings. The intervention involves a weight loss behavioral program with particular emphasis on hunger reduction and craving control for both weight loss and prevention of weight regain. Half of the participants per worksite receiving the Diet® intervention will be randomized to receive gift cards monthly for the first 6 months to purchase foods at their local grocery store (partial costs).
223481418|NCT02593240|BEHAVIORAL|Human Performance Institute©|The Human Performance Institute© (HPI) training workshop is a comprehensive individual development training program that focuses on the concept of energy management. The primary aim of this program is to help individuals develop attitudes, habits, and behaviors that increase their levels of daily energy, life satisfaction, and overall functioning. The course is delivered at an off-site location over 2.5 days, by 3 coaches, in a group format of 25 - 32 participants (with employees from more than one worksite per group).
224072171|NCT04643028|OTHER|Home exercise|Exercise program will include active normal joint movements in the cervical region, postural exercises, strengthening exercises for the scapular retractor muscles, and stretching exercises for the pectoral muscles, levator scapula and upper part of the trapezius and breathing/relaxation exercises.
224072172|NCT04643028|OTHER|Mulligan mobilization|Mulligan mobilization: Mulligan mobilization will be applied to this group in addition to the exercises in the home exercise group. In painless directions, each session will be applied in 3 sets, a set of 10 repetitions.Sixty seconds of rest will be given between sets.
224072173|NCT04643028|OTHER|Cervical stabilization|Cervical stabilization group: In addition to the exercises in the home exercise group, this group will be given cervical stabilization training that focuses on the deep neck muscles.
224072174|NCT02487420|BEHAVIORAL|shorter or longer period of specific dietary restrictions|step by step gradual introduction of egg containing food products
224072175|NCT02340338|BIOLOGICAL|rTSST-1 Variant Candidate Vaccine|"In the absence of adverse events classified as clinically relevant, interval between dose escalations 1 week. Immunization to be repeated at the same dose level 1 - 2 months later. If immunogenicity can be shown after the second administration of 1 µg, the sample size will be increased from 3 + 1 to 9 + 3. Otherwise, the sample size of 3 + 1 will continue until immunogenicity is seen at a higher dose level. If there is no immune response in any dose group after the second immunization, a third injection will be given 4 -8 weeks thereafter in dose groups of 1 µg and above.~Immunogenicity is defined by seroconversion from a TSST-1 Ab titer of \< 20 to \> 40 or a 4-fold increase in TSST-1 Ab titer .~Patients 3 µg or more will be randomized."
224072176|NCT06218095|OTHER|Simulation application|Teaching the risk of thromboembolism during pregnancy and postpartum through simulation
224072177|NCT00343889|BIOLOGICAL|DTaP-HB-PRP~T vaccine + OPV|0.5 mL, Intramuscular
224072178|NCT00343889|BIOLOGICAL|Tritanrix-HepB/Hib™ + OPV vaccine|0.5 mL, Intramuscular
224072179|NCT00343889|BIOLOGICAL|Oral Polio Vaccine|Oral co-administered with study vaccine
224072180|NCT06084520|DIAGNOSTIC_TEST|Current Opioid Misuse Measure (COMM)-SWE|Patients in test group should fulfill the the COMM and the battery of validation forms as well as leave the oral fluid for illicit drugs test and whole blod for phosphatidylethanol test.
224072181|NCT06084520|DIAGNOSTIC_TEST|Oral fluid drug test|Oral fluid sampling to detect drugs. Analysis with LC-HRMS
224072182|NCT06084520|DIAGNOSTIC_TEST|PETh|Alcohol use detection
224072183|NCT06084520|DIAGNOSTIC_TEST|ASI-SR|Cross-validation form
224072184|NCT06084520|DIAGNOSTIC_TEST|AUDIT|Cross-validation form
224072185|NCT06084520|DIAGNOSTIC_TEST|DUDIT|Cross-validation form
224072186|NCT06084520|DIAGNOSTIC_TEST|Brief Pain Inventory - BPI|Cross-validation form
224072187|NCT06084520|DIAGNOSTIC_TEST|Patient Global Impression of Change PGIC|Cross-validation form
224072188|NCT06084520|DIAGNOSTIC_TEST|GAD-7|Cross-validation form
224072189|NCT06084520|DIAGNOSTIC_TEST|Patient Health questionnaire (PHQ9)|Cross-validation form
224072190|NCT06084520|DIAGNOSTIC_TEST|DBS - cannabis test|cross-validation form
224305442|NCT00589030|RADIATION|brachytherapy|The target dose of TheraSphere® is 80-150Gy
224305443|NCT00589030|RADIATION|yttrium Y 90 glass microspheres|The target dose of TheraSphere® is 80-150Gy
224305444|NCT00944268|DRUG|Passiflora, Crataegus e Salix|Comparison of different pharmaceutics forms of drug
224305445|NCT01948986|DRUG|Ertugliflozin|Single oral administration of 3 X 5 mg tablets.
223481419|NCT00413803|PROCEDURE|4-hour thrice weekly in center hemodialysis|conventional hemodialysis
223481420|NCT00413803|PROCEDURE|8-hour thrice weekly in center hemodialysis|long dialysis
223481421|NCT01513499|DRUG|Oxytocin|Intranasal oxytocin 24 IU single-dose administration
223481422|NCT01513499|DRUG|Placebo|Intranasal Placebo single-dose administration
223481423|NCT06393231|OTHER|acupuncture|Acupuncture is applied to ST8, GB14, BL12, SJ23, ST2, SI18, ST4, ST7, RN24, Ex-HN16, SJ17 and LI4 on the affected side and needles are retained for half an hour.Add infrared irradiation therapy in the same time
223481424|NCT01687803|BEHAVIORAL|Physical Activity|Physical activity intervention that will consist of brisk walking or other aerobic-type activities (6 days per week), resistance exercise (using free weights, resistance bands or weight stacks for weight lifting, 3 days per week), and 'active lifestyle' activities such as gardening, dancing, participation in sporting activities. The total time spent in these activities will add up to \~60 min/day for 6 days/week (\~360 minutes per week).
223481425|NCT01687803|BEHAVIORAL|Control|The control group will maintain their usual level of physical activity and participate in testing protocols, record keeping, and interviews.
223481426|NCT02921165|DRUG|analgesic mouth rinses (dissolved Aspirin)|Group 1 and Group 2 patients will be prescribed analgesic mouth rinses (dissolved Aspirin) twice daily along with the standard prescription of analgesics and antibiotics.
223481427|NCT02921165|DRUG|Normal saline rinses.|Non Hypertensive patients will be prescribed normal saline rinses twice daily along with the standard prescription of analgesics and antibiotics.
223481428|NCT01555814|DRUG|Amisulpride|4-week open label amisulpride treatment
223585078|NCT00582738|DRUG|Everolimus|Hepatitis C recurrence after orthotopic liver transplantation (OLT)
223585079|NCT02634021|DRUG|dexmedetomidine group|intravenous loading of dexmedetomidine for 1 mcg/kg
223585080|NCT02634021|DRUG|midazolam group|intravenous loading of midazolam for 0.1 mg/kg
223585081|NCT00964301|OTHER|Telemedicine Education|"Student Asthma Education. Each student will engage in 6 age-appropriate sessions on various aspects of asthma health.~Caregiver Asthma Education. The primary caregiver will engage in 2 asthma education sessions.~School Nurse Asthma Education. School nurses will participate in 2 sessions.~Primary Care Provider (PCP) Communication. The PCP of the intervention group participant will be notified of his/her patient's baseline asthma assessment. They will receive updates summarizing each telemedicine intervention."
223585082|NCT00964301|OTHER|Usual care|Participants will receive asthma care by their PCP with no education sessions or PCP communications by the research staff.
223481429|NCT02699164|DEVICE|DRX 9000, Axiom Worldwide, Tampa, Florida|non-surgical spinal decompression therapy consist 18 traction cycles. Traction force applied herniation levels according to Magnetic Resonance Imaging (MRI).
223481430|NCT02699164|OTHER|physiotherapy|electrotherapy was used. electrotherapy consisted of 20 minutes of hot-pack, 20 minutes of TENS and 5 minutes of ultrasound.
223481431|NCT02699164|OTHER|spinal stabilization exercise|spinal stabilization exercises started elementary exercises. According to patient tolerance, exercise program reestablished.
223481432|NCT00089388|DRUG|cilengitide|Given IV
223481433|NCT05529433|PROCEDURE|Atraumatic Restorative Treatment (ART)|Atraumatic Restorative Treatment is highly accepted by the patients as there is no need for local anesthesia. It is a minimal invasive technique which preserves sound tooth structure as caries removal will be done by a sharp spoon excavator. It requires less time during caries removal. There is a chemical bond between the tooth and the glass ionomer adhesive material. So, there is no need for cutting sound tooth structure for retention of the restoration.
223481434|NCT05529433|PROCEDURE|Smart Burs|Smart Bur is a polymer bur which removes only soft infected dentin as the cutting edges become dull in contact with the hard affected dentin.Caries removal will be done by Smart Bur mounted on a low speed hand-piece leaving the affected dentin intact. It requires less time for caries removal.
223481435|NCT05529433|PROCEDURE|Chemo-Mechanical Caries Removal (CMCR)|Selecti-Solve gel is a dental gel which main active ingredient is Papain enzyme which selectively removes the caries without pain and has bacteriostatic, bactericidal and anti-inflammatory properties. The use of CMCR is recommended as an alternative treatment technique in anxious patients. The gel will be applied with a blunt spoon instrument and distributed well into the cavity according to manufacturer's instructions.
223481436|NCT01693952|BIOLOGICAL|blood draw|
223585083|NCT02538133|BIOLOGICAL|99mTc-Exametazime (HMPAO)-labeled leukocytes|Hybrid tomoscintigraphy with labeled leucocytes for patients with suspected vascular prosthesis infection
223585084|NCT05349383|DRUG|Antibody-Drug Conjugate|"Compared the case reporting of sepsis-related toxicities among ADC and other common cancer drug therapies.~ADC:including Gemtuzumab Ozogamicin, Trastuzumab Emtansine, Inotuzumab Ozogamicin, Enfortumab vedotin, Trastuzumab deruxtecan, Sacituzumab govitecan, Brentuximab Vedotin, Moxetumomab pasudotox, Polatuzumab Vedotin, Belantamab Mafodotin, loncastuximab tesirine and Tisotumab vedotin."
223585085|NCT05349383|DRUG|Antineoplastic and immunomodulating agents other than Antibody-Drug Conjugate|We would like to include other common cancer drug therapies such as chemotherapy, targeted therapy, immunotherapy and so on as a comparator group.
224072191|NCT06084520|OTHER|Sample of Blood for later DNA and immunological analysis in future studies|sample collection for future studies
224072192|NCT02829840|DRUG|Ponatinib|"Part 1: Ponatinib at starting dose of 30 mg by mouth every day for one 28 day cycle.~Part 2 Phase I Dose Escalation: Ponatinib at starting dose of 30 mg by mouth every day of a 28 day cycle.~Part 2 Phase II Dose Expansion: Ponatinib at maximum tolerated dose from Phase I by mouth every day of a 28 day cycle."
224072193|NCT02829840|DRUG|5-azacytidine|"Part 2 Phase I Dose Escalation: 5-azacytidine at dose of 75 mg/m2/d administered subcutaneously (SQ) or intravenously (IV) for on Days 1-7 of every 28 day cycle.~Part 2 Phase II Dose Expansion: 5-azacytidine 75 mg/m2/d administered subcutaneously (SQ) or intravenously (IV) on Days 1-7 of every 28 day cycle."
224072194|NCT02829840|BEHAVIORAL|Phone Calls|"About 30 days after end-of-study visit, study staff calls participant and asks if they have had any side effects and/or started any new treatment(s).~If disease appears to be responding to study drugs, study staff calls participant every 3-6 months for up to 5 years and asks how they are doing and about any side effects they may be having."
224072195|NCT01951820|DRUG|Pliaglis|Apply 0.2mg of compounded topical anesthetic (Pliaglis) to gums for 2.5 minutes before giving patient injection of local anesthetic.
224168989|NCT05724147|BEHAVIORAL|Mandala Activity|Three sessions of mandala activity, once a week, will be applied to the participants from the elderly people in the nursing home included in the study. The mandala activity planned to be done with the group will be done in addition to the standard monitoring applied in the institution, so it will be held at an appropriate time according to the flow in the institution. Before leaving the individuals, the most appropriate time for the next mandala session will be determined by taking into account the preferences of the individuals. Individuals to be included in the study will be grouped in groups of 10. Mandala activity application time is planned to last approximately 2 hours. If individuals have any physical symptoms, the time of the mandala activity is rescheduled, and each individual is expected to attend five sessions during the total study period.
224168990|NCT03872336|DRUG|Experimental labetalol dose|Subjects who have sustained severe hypertension (SBP≥160 mmHg and/or DBP≥110 mmHg), 15 min apart receive the experimental dosing of labetolol. Subjects in both groups are managed following the standard guidelines established by ACOG (Committee Opinion #623). For each successive episode of hypertension treatment, patients are asked a set of questions to monitor for adverse medication side-effects. The fetus is electronically monitored for four hours after the last IV dose.
224168991|NCT03872336|OTHER|Current standard of care|Subjects who have sustained severe hypertension (SBP≥160 mmHg and/or DBP≥110 mmHg), 15 min apart receive the standard dosing of labetolol. Subjects in both groups are managed following the standard guidelines established by ACOG (Committee Opinion #623). For each successive episode of hypertension treatment, patients are asked a set of questions to monitor for adverse medication side-effects. The fetus is electronically monitored for four hours after the last IV dose.
224168992|NCT02630394|DRUG|Azithromycin|
224168993|NCT05394181|OTHER|Notification|Notification of patient and primary care clinician of presence of at least moderate coronary artery calcium on a prior non-gated chest CT
224168994|NCT03239262|PROCEDURE|Concomitant Mapping and Radiofrequency Ablation|"Mapping of GP around the orifice of pulmonary veins was performed, together with their radiofrequency ablation. In the area of right-side pulmonary veins, the procedure was performed prior to initiation of extracorporeal circulation. In case of the left-side PVs; the procedure was performed after initiation of extracorporeal circulation. Part of this procedure was also a decision and ablation of the ligament of Marshall.~GP mapping was performed using high-frequency stimulation (1000 beats min-¹, potential 18V, pulse width 1.5ms). The indication for GP ablation was a doubling in the R-R interval in the sinus rhythm, or ventricular rate slowing of more that 50% associated with a decrease of blood pressure\>20mmHg in patients with AF. In case of a positive response, radiofrequency ablation of the ganglia was performed following switching of the pen at the console. This procedure was repeated until the activity of the ganglia has disappeared."
224168995|NCT03239262|PROCEDURE|No intervention|No intervention was performed in patients without ganglionated plexi.
224168996|NCT00748306|DRUG|GSK2190915 - 100mcg|GSK2190915 is a high affinity 5-lipoxygenase-activating protein (FLAP) inhibitor
224168997|NCT00748306|DRUG|Placebo|Matching Intervention Drug
224168998|NCT05274009|OTHER|No cooling (control)|Participants are exposed to 35°C, 60% relative humidity for 8 hours.
223481437|NCT04796415|BEHAVIORAL|the DEMA-Pro intervention|Trained DEMA-Pro coaches will deliver six weekly, 1-hour telephone sessions. The first session is an orientation to the DEMA-Pro intervention and development of the initial Weekly Activity Plan based on the patient's self-identified meaningful activity. Over the next five weekly sessions, the coach uses problem-solving strategies to facilitate dyad collaboration to mutually identify meaningful activities and make a realist plan to achieve the patient-identified meaning activity goals. In each session, the patient and caregiver also select, review, and discuss one of six topics in the Self-Management Toolkit (e.g., planning meaningful activities; learning strategies for living with subjective cognitive impairment; finding resources, planning for the future).
224168999|NCT05274009|OTHER|Recommended cooling|Participants are exposed to 35°C, 60% relative humidity for 3 hours, are then moved to an air-conditioned room for 2 hours (\~23°C, \~50% relative humidity), and then return to the heat for a final 3 hours.
224169000|NCT05274009|OTHER|Hybrid cooling|Participants are exposed to 35°C, 60% relative humidity for 2 hours, are moved to an air-conditioned room for 1 hour (\~23°C, \~50% relative humidity), return to the heat for 2 hours, move back to the air-conditioned room for 1 hour, and then return to the heat for a final 2 hours
224169001|NCT02381262|BEHAVIORAL|Fitbit|The Fitbit is a wrist based wearable technology device designed to monitor physical activity by tracking steps, distance and calories burned as well as sleep patterns and heart rate. It has wireless capabilities to sync with smart devices and summarize data for the user or export for synchronize with electronic health records.
224169002|NCT00221689|DRUG|baclofen (drug)|
223585086|NCT03181295|BEHAVIORAL|Personalized exercise Rx and resources|Patients will receive the IPAQ to collect baseline PA levels as well as questions evaluating precursors to behaviour change and identifying medical conditions that may affect PA capability. In the Electronic Medical Record chart, a 'stamp' will be automatically created, accompanied by a link which will open a printable 'toolkit' with individualized PA recommendations, a personalized exercise Rx, as well as educational and community resources, all based on the patient's survey responses. The exercise Rx and resources can be edited by the PCP based on the resulting discussion between patient and PCP, and printed during the PHR for the patient to take home. The exercise Rx and resources will also be emailed to the patient following their appointment.
223585087|NCT00493519|PROCEDURE|chocolate cake|
223585088|NCT06406803|BEHAVIORAL|Dietary energy restriction|Patients enrolled in the dietary energy restriction group will reach an energy deficit of 40% only through reduced dietary intake.
223585089|NCT06406803|BEHAVIORAL|Daily exercise|Patients in the daily exercise group will reach an energy deficit of 40% through reduced dietary intake and increased physical activity (exercise).
224169003|NCT00218569|DRUG|Naltrexone|Naltrexone
224169004|NCT00218569|DRUG|Placebo|Placebo
224169005|NCT00776581|PROCEDURE|CSEA with PCA|Records regarding combined spinal-epidural analgesia with patient-controlled pump
224169006|NCT00776581|PROCEDURE|CSEA with IBI|Records regarding combined spinal-epidural analgesia with intermittent bolus injection
223481438|NCT00375661|DRUG|interferon-alfa-2b and ribavirin|Interferon, pnce per week plus daily ribavirin
223481439|NCT04985162|OTHER|Intervention group|Differential learning based physiotherapy to improve torso control, balance and gait
223481440|NCT04985162|OTHER|Control group|Ordinary physiotherapy program
223585090|NCT02152514|DRUG|Intrathecal Morphine/Sufentanil|
223585091|NCT02152514|DEVICE|PCA|
223585092|NCT02611141|PROCEDURE|Retromolar laryngoscopy and scoring of the visualisation of the vocal cords according to Cormack & Lehane|"To facilitate the insertion of the straight blade laryngoscope (Miller #4) the head of the patient will be turned to the left side. The blade will be inserted and then pushed laterally rightwards until the retromolar space will be finally reached. Thereafter the epiglottis will be lifted up in order to achieve the best direct view to the vocal cords and scored according to Cormack \& Lehane .~This score will be assessed at least 2 minutes after muscle relaxation:~1. Once without a backward, upward, rightwards pressure maneuver (=BURB) and immediately thereafter (i.e. 5-10 seconds later):~2. If 100% visualization of the vocal cords is not possible a BURP maneuver will be performed and the scored again.~Intubation will then be performed by the conventional method using a Macintosh blade #3. In the case that intubation with the conventional method is not successful the retromolar technique will be used."
223481441|NCT05902065|DEVICE|AVR Treadmill training with C-Mill|The protocol will include three sessions per week for 8 weeks of gait training using C-Mill with AVR applications. An anchoring system will prevent possible falls, activities will be stopped on patient request, or when a heart rate considered safe will be exceeded. The patient will be supervised by a physical therapist and asked not to use lateral bars. Treatment is planned to be progressive and will be individualized to the participant's level of performance. Progression in gait speed: at the training start, gait speed will be set at 80% of the individual's overground walking speed and weekly increased by 10%, to a maximum of 120%; progression in trial duration: at the training start the duration will be set at 25' and every two weeks increased by 5'; the maximum duration of a session will reach 45'; progression in difficulty: the protocol has 5 levels for each AVR application, and the transition among levels will be set at 80% success achievement.
223585093|NCT02196428|OTHER|Telemonitoring and Teleconsultation|The interventions of this study are supported by a so-called Ambient Assisted Living Wizard (AAL Wizard). This is an IHE-compliant documentation and communication platform with an integrated electronic health record, which enables the study participants (elderly) to manage and store their relevant health data. It includes personal master data and the documentation of telemonitoring data. Additionally, the AAL-Wizard provides the communication modules such as telephone -, video- and time- and online consultation. The tele doctor assess the data (eg, vital signs and content of the medical teleconsultation) and collaborates in this way with the older person, family physicians and other health care providers based on an innovative and flexible telemedical home care service.
224169007|NCT00776581|PROCEDURE|EA with PCA|Records regarding epidural analgesia with patient-controlled pump
224169008|NCT00776581|PROCEDURE|EA with IBI|Records regarding epidural analgesia with intermittent bolus injection
224169009|NCT04340687|DEVICE|Pancreatic duct stenting|A stent placed in the pancreatic duct to reduce PEP possibly by relieving pancreatic ductal hypertension that develops because of transient procedure-induced edema and stenosis of the pancreatic orifice
224169010|NCT05431335|OTHER|Structured exercise program|"It consists of aerobic exercise combined with breathing, strengthening exercises, and stretching exercises. Aerobic exercise will be performed similarly to the other group, only consisting of a five-minute warm-up period and a 15-minute aerobic load period.~Strengthening exercises consist of deep cervical flexor muscles and shoulder region resistive exercises. Each exercise will be repeated as 15 repetitions, 2 sets.~Stretching exercises are neck region stretching exercises. Each exercise will be performed with 10 seconds of stretching and 5 repetitions."
224169011|NCT05431335|OTHER|Aerobic exercise program|Aerobic exercise intensity will be determined by the Perceived Fatigue Scale (Borg scale). It consists of a ten-minute warm-up period (Borg 11), a 15-minute aerobic load (Borg 13-14), and a five-minute cool-down period(Borg 11). The warm-up and cool-down periods include brisk walking combined with breathing, and calisthenic exercises involving the upper and lower extremities; the loading period consists of exercises using a step-dance board accompanied by music. The number of repetitions will be increased progressively to keep the exercise intensity constant.
224169012|NCT03714789|OTHER|Blood and spent dialysate collection|A certain amount of blood and spent dialysate are collected during and after dialysis for quantification of drug concentration.
224169013|NCT01680562|OTHER|in-vivo skin tumor imaging via optical coherence tomography|optical coherence tomography imaging of skin lesion; digital dermoscopy imaging of skin lesion
224169014|NCT03678506|DRUG|Apixaban|Apixaban 2.5 mg x 2 will be administered to patients with positive D-dimer results
224169015|NCT03659695|DIETARY_SUPPLEMENT|Grape Powder|69 g/d freeze dried grape powder
224169016|NCT03659695|DIETARY_SUPPLEMENT|Placebo Powder|69 g/d placebo powder matched for taste and appearance
224169017|NCT03607240|PROCEDURE|lung ultrasound-guided alveolar recruitment|Alveolar recruitment maneuver will be performed under lung ultrasound-guidance. Positive pressure will be not exceed 40cmH2O and duration of positive pressure inflation will not exceed 10 seconds.
224169018|NCT03607240|PROCEDURE|conventional alveolar recruitment|Alveolar recruitment will be provided with positive pressure of 30cmH2O for 10 seconds
224169019|NCT03839576|BEHAVIORAL|Exercise|Each session will last 60 min, consisting of 10 min of warm-up, 45 min of exercise, and a 5-min cool-down.
224169020|NCT03839576|BEHAVIORAL|Computerized training|Attention, memory, speed of processing, and executive functioning.
224169021|NCT04476108|DRUG|LY3016859|Administered IV
224169022|NCT04476108|DRUG|Placebo|Administered IV
224169023|NCT05009836|DRUG|Savolitinib|Subjects will receive Savolitinib orally once per day (QD) + Osimertinib orally QD,21day cycles (every 3 weeks) until disease progression, death, adverse event (AE) leading to discontinuation or withdrawal of consent.
224169024|NCT05009836|DRUG|Placebo|Subjects will receive placebo orally once per day (QD) + Osimertinib orally QD,21day cycles (every 3 weeks) until disease progression, death, adverse
224169025|NCT00011375|DRUG|Rolipram|
224169026|NCT02968966|OTHER|Therapy regime|Patient will receive Phenytoin, if no success is obtained, Vimpat is given. In case of success after one of the treatments, the endpoint is reached. Success is defined as reduction of seizures to 50% compared to baseline.
224169027|NCT03946592|DRUG|Normal saline|Inject the Drug into submental fat via subcutaneous
224169028|NCT03946592|DRUG|DWJ211|Inject the Drug into submental fat via subcutaneous
224169029|NCT05825365|DRUG|Selumetinib|Selumetinib
224169030|NCT05825365|DRUG|Placebo|Placebo (Transfer to selumetinib on REiNS-defined PD)
224169031|NCT03681873|DIAGNOSTIC_TEST|Extremely Low Dose CT|Patients undergoing a clinically indicated chest CT will also undergo the extremely low dose CT
224169032|NCT03676465|OTHER|CloudConnect Report|Subjects and their parents will be asked to download the data from the study devices as well as download their insulin pump/pen. The participants will receive a weekly CloudConnect Report that is based on analysis of the data gathered from the downloads provided by the subject during that week. Participants will both receive weekly contact from the study team to discuss the communication that the subject \& their parent had during the week about the participant's diabetes management.
224169033|NCT03676465|OTHER|Will not receive a CloudConnect Report|Subjects and their parents will be asked to download the data from the study devices as well as download their insulin pump/pen. Participants will receive weekly contact from the study team to discuss the communication that the subject \& their parent had during the week about the participant's diabetes management.
224169034|NCT03908866|OTHER|PICC(Peripherally inserted central catheter)|The peripherally inserted central catheter with different sizes (French scale). Trained vascular access nurses will perform the insertion of the PICC, guided by ultrasound at bedside using the Seldinger technique. A suitable sterile field will be established.
224169035|NCT03908866|OTHER|CVC(Central venous catheter )|The central venous catheter with different sizes (French scale). Trained doctors will perform the insertion of the CVC, using the Seldinger technique. A suitable sterile field will be established.
224169036|NCT02952430|PROCEDURE|Emergency laparotomy|Patients already undergoing emergency laparotomy - groups divided pre-operatively into frail and not frail based on modified Rockwood score. Then outcomes observed.
224169037|NCT01614366|DRUG|AM 5 + DM 0|Amlodipine 5 mg + DMTA07 0mg, once daily
224169038|NCT01614366|DRUG|AM 5 + DM 2.5|Amlodipine 5 mg + DMTA07 2.5mg, once daily
223481442|NCT05902065|DEVICE|Conventional Treadmill training with C-Mill|The protocol will include three sessions per week for 8 weeks of gait training using C-Mill without AVR applications, walking on the treadmill. An anchoring system will prevent possible falls, activities will be stopped on patient request, or when a heart rate considered safe will be exceeded. All sessions will be supervised by a physical therapist, who will give guidance and standardized cues on walking patterns (e.g., step length). The patient will be asked not to use the lateral bars. Treatment is planned to be progressive and will be individualized to the participant's level of performance: progression in gait speed: at the training start, gait speed will be set at 80% of the individual's overground walking speed and weekly increased by 10%, to a maximum of 120%; progression in trial duration: at the training start the duration will be set at 25' and every two weeks increased by 5'; the maximum duration of a session will reach 45'.
223481443|NCT00305526|DEVICE|Contak Renewal (CRT-D)|
224072196|NCT01951820|DRUG|Benzocaine|Apply 0.2mg of topical anesthetic (benzocaine) to gums for 2.5 minutes before giving patient injection of local anesthetic.
224072197|NCT01951820|DRUG|Articaine|Injection of 0.4mg of local anesthetic in gum tissue where topical anesthetic was placed
224072198|NCT03506243|BIOLOGICAL|Follitrope PFS|Follitrope PFS
224072199|NCT03506243|BIOLOGICAL|Gonal-f pen|Gonal-f pen
224072200|NCT01294579|BIOLOGICAL|Ofatumumab|"1000 mg intravenous (IV) on day 1 of each cycle (cycles 1-6) for induction phase~1000 mg IV every 2 months for 2 years"
224072201|NCT01294579|DRUG|Bendamustine|90 mg/m2 on day 1 (after the ofatumumab infusion) and day 2 of each cycle (cycles 1-6)
224072202|NCT05671432|BIOLOGICAL|CM326|CM326 injection
224072203|NCT05671432|OTHER|Placebo|Placebo
224072204|NCT01972555|PROCEDURE|Minimally invasive aortic valve replacement|
224072205|NCT01972555|PROCEDURE|Conventional aortic valve replacement|
224072206|NCT00176995|DRUG|15% Eflornithine Hdyrochloride|
224072207|NCT00102206|DRUG|Abacavir sulfate|
224072208|NCT00102206|DRUG|Emtricitabine|
224072209|NCT00102206|DRUG|Lamivudine|
224072210|NCT00102206|DRUG|Lopinavir/ritonavir|
224072211|NCT00102206|DRUG|Saquinavir|
224072212|NCT00102206|DRUG|Tenofovir disoproxil fumarate|
224072213|NCT00102206|DRUG|Zidovudine|
224072214|NCT01431664|DRUG|multikinase inhibitor AT9283|
224072215|NCT01431664|OTHER|laboratory biomarker analysis|
224072216|NCT01431664|OTHER|pharmacological study|
224072217|NCT04434521|BEHAVIORAL|Questionnaire|Questionnaire about habits in terms of near vision activities
224072218|NCT04434521|OTHER|Eye examination|"The eye examination involves the following measurements:~* Distant vision phoria with Thorington method~* Close vision with Thorington method~* Objective eye-to-eye refraction with self-refractometer~* Binocular objective refraction with autorefractometer~* Monocular/biocular/binocular refraction with Nidek TS610~* SiView automatic refraction~* Humphriss binocular refraction~* MOU Binocular refraction"
224072219|NCT06146725|PROCEDURE|Tumor resection|Maximal safe resection of the tumor
224072220|NCT06146725|PROCEDURE|Tumor biopsy|Biopsy of the tumor
224072221|NCT02085434|BEHAVIORAL|FITLINE practice-based referral program|The FITLINE practice-based referral program provides pediatric practices an easily accessible resource to help families make AAP-recommended Stage 1 lifestyle changes. The program includes a pediatric practice-based component (systems to identify overweight and obese children ages 8-12, a brief pediatric provider-delivered intervention, referral to the FITLINE counseling program, and feedback from the FITLINE nutritionist) and a parent support component(eight weekly FITLINE counseling telephone calls delivered by centrally located nutritionists). Providers receive a summary from the nutritionist of the progress made by families so they may support maintenance of an improved lifestyle, or refer for additional intervention.
224072222|NCT04113772|DRUG|Nitisinone|Measure bio equivalency/efficacy of nitinosine and orfadin
224072223|NCT04113772|DRUG|Orfadin|Orfadin
224072224|NCT00356941|DRUG|docetaxel|60 mg/m2 on day 1 of each week during radiation therapy
224072225|NCT00356941|DRUG|oxaliplatin|Escalating dose per assignment: 20-50 mg/m2 on day 2 of each week during radiation therapy
224072226|NCT00356941|PROCEDURE|radiation therapy|2 Gy Days 1-5 each week, total dose of 70Gy
224072227|NCT03759535|DIAGNOSTIC_TEST|Acute rejection|Donor derived cell free DNA
224072228|NCT01440621|DRUG|Modafinil|Tablet Modafinil 100mg (Generic) to be given in 100mg once a day dose, at 8AM daily in the morning, and to be given from Day 1 of Radiation Therapy till the first post treatment follow-up
223585094|NCT00652899|BIOLOGICAL|Allopurinol|All patients are to receive allopurinol 300 mg PO daily (unless known allergy) before beginning chemotherapy and continuing through day 14 post natural killer cell infusion.
223585095|NCT00652899|DRUG|Cyclophosphamide|60 mg/m\^2 on Days 4 and 5 preceding natural killer cell infusion.
224169039|NCT01614366|DRUG|AM 5 + DM 7.5|Amlodipine 5 mg + DMTA07 7.5mg, once daily
224169040|NCT01614366|DRUG|AM 5 + DM 30|Amlodipine 5 mg + DMTA07 30mg, once daily
224169041|NCT03160066|DIETARY_SUPPLEMENT|Lactobacillus Rhamnosus (JB-1)|Lactobacillus Rhamnosus (JB-1) capsule
224169042|NCT03160066|DIETARY_SUPPLEMENT|Placebo|Placebo
224169043|NCT06218628|DRUG|Talazoparib|pacritinib in combination with talazoparib
224169044|NCT06218628|DRUG|pacritinib|pacritinib in combination with talazoparib
224169045|NCT01936428|OTHER|interview|
224169046|NCT04585633|OTHER|Quality of Recovery-15|Quality of Recovery-15 is a scale consisting of 15 questions indicating the recovery quality of the patient after anesthesia and a score between 0-150.
224169047|NCT04585633|OTHER|Glasgow Result Scale|Glasgow Outcome Scale; It is a scale developed to categorize people suffering from head trauma or non-traumatic acute brain injury into broad outcome categories. It shows postoperative mortality and morbidity of patients who underwent intracranial surgery.
224169048|NCT04585633|OTHER|Risk Factors|Pre-operative: medical histories, drugs used, demographic features, additional diseases, ASA class, pre-operative routine parameters, operation history, GCS, tumor histology, location, dimensions and intracerebral radiological data, laboratory values Intraoperative; hemodynamic data of patients; highest and lowest values of heart rate, diastolic, systolic and mean arterial pressures, fluid and blood products given, anesthetic and other drugs administered, duration of anesthesia, duration of surgery, surgical position, blood loss, urine output and blood gas samples Post-operation; extubation time, MAS score, use of mechanical ventilation, post-operative complications, hemodynamic data, blood gas data
224169049|NCT03685643|BEHAVIORAL|Intervention - Dating application topic|The intervention will consist of multimedia content to promote the safe usage of dating applications and raise awareness of the risks associated with dating application usage. The intervention will be delivered one-time in a classroom setting.
224169050|NCT03685643|BEHAVIORAL|Control - Health and exercise topic|The placebo control will consist of multimedia content regarding exercise and healthy living. It will be delivered once-time in a classroom setting.
223481444|NCT03555552|DEVICE|Anticoagulation and Thrombosis Point of Care Test(AT-POCT)|Capillary action automatically draws blood into the channel containing printed assay reagents which solubilize upon contact with blood and react with analytes of interest.
223481445|NCT03555552|DEVICE|Duke Central Automated Laboratory (DCAL)|DCAL measurement of INR will occur by an ACL TOP 750 Analyzer (IL Inc.), and LDH by standard enzymatic activity assay will be run on the automated Beckman DxC800.
223585096|NCT00652899|DRUG|Fludarabine phosphate|25 mg/m\^2 on Days 6 through 2 preceding natural killer cell infusion.
223585097|NCT00652899|RADIATION|total-body irradiation|200 cGy Day 1 preceding natural killer cell infusion.
224169051|NCT04916301|BEHAVIORAL|Early Mother-Infant Attachment|Early Mother-Infant Attachment Indicators will be observed.
224169052|NCT00718991|DEVICE|Spectranetics Turbo elite™ excimer laser catheter|The Spectranetics Turbo elite™ excimer laser catheters are percutaneous intravascular devices constructed of multiple optical fibers around a guidewire lumen. The laser catheters transmit ultraviolet energy from the Spectranetics CVX-300® Excimer Laser System to the obstruction in the artery. The ultraviolet energy is delivered to the tip of the laser catheter to photo-ablate fibrous, calcific and atheromatous lesions, thus recanalizing diseased vessels.
224169053|NCT04196049|PROCEDURE|fragmatome|Patients with massive subretinal hemorrhage from age related macular degeneration and organized subretinal blood clot were managed by inferior retinectomy. The subretinal organized blood clot was dragged to the preretinal space and removed by fragmatome. The retinal was reattached with perfluorocarbon liquid and laser was applied at the margin of retinectomy. Silicon oil was infused at the end of surgery.
224169054|NCT03510728|BEHAVIORAL|college drinker's check up|The College Drinker's Check-up (CDCU) is a single session, computer-based brief motivational intervention for heavy drinking college students. It takes a student about 45 minutes to go through it.
223481446|NCT04452175|OTHER|JUUL E-CIGARETTE|JUUL E-CIGARETTE USAGE FOR 24 WEEKS
223481447|NCT04636047|OTHER|The method of gene mutation detection|All samples were detected by NGS CGP panel.
223481448|NCT02819128|OTHER|Swabs skin, pharyngeal, and blood sample|Collection of one blood sample with a volume of 10 mL (2 tubes of blood 5 mL ) and 2 swabs ( throat and skin ).
223481449|NCT02819128|OTHER|Collection of body lice|For the subjects infested with body lice , if they want, their underwear will be recovered and sent to the laboratory to measure the resistance to permethrin.
223585098|NCT00652899|BIOLOGICAL|Allogeneic natural killer cells|Given day 0 - dose of 1.5-8.0 \* 10\^7/kg
223585099|NCT00652899|BIOLOGICAL|Aldesleukin|10 MU 3 times/week for a total of 6 doses beginning Day 0
223585100|NCT02706028|DEVICE|underwater ultrasound|underwater US therapy with an intensity of 0.7 W/cm2 in a total of 10 sessions (10 working days) using a 830 kHz ULTRON home OE-302® device with treatment head size of 4.2 cm2.
223585101|NCT02706028|DEVICE|sham underwater ultrasound|ULTRON home OE-302® device is not turned on
223585102|NCT03412097|OTHER|active surveillance|Provides a structure to systematically gather adverse event information from healthcare providers and sometimes directly from patients.
223585103|NCT02385916|OTHER|EstroSense®/MD|A natural product already approved by Health Canada
223585104|NCT02385916|OTHER|Placebo|Placebo
223585105|NCT04100434|DRUG|Evolocumab|Patients were randomly assigned of the ratio of 1:1 using a computer-generated random number and divided into two treatment groups: the statin alone therapy and the evolocumab plus statin therapy.
223585106|NCT04067778|DIAGNOSTIC_TEST|Intervention Group|Standard colonoscopy with targeted biopsies only
223585107|NCT04067778|DIAGNOSTIC_TEST|Control Group|Standard colonoscopy with random AND targeted biopsies
223585108|NCT04135859|BEHAVIORAL|Physical Activity Lifestyle Intervention|Coaches work with participants on three elements of behaviors change: (1) changing attitudes towards physical activity; (2) increase perceptions of other people's approval of physical activity for the participants; (3) increase perceptions of control over being physically active. These elements will be delivered using a non-judgmental stance accompanied by promoting appropriate goal-setting.
224169055|NCT03510728|BEHAVIORAL|Protective Behavioral Strategies Intervention|This intervention component focuses on educating and promoting PBS activities in future college drinking situations
224169056|NCT03510728|BEHAVIORAL|Ecological Momentary Intervention|This EMI is delivered during drinking situations and focuses on promoting PBS use during that particular drinking situation.
224169057|NCT02081911|PROCEDURE|High Volume Adductor Canal Block|Adductor canal block performed in the distal thigh (1/3 of the total distance between the superior border of the patella and the femoral crease, cephalad to the patella) utilizing an injectate volume of 30 mL 0.25% bupivacaine/ epinephrine
224169058|NCT02081911|PROCEDURE|Low Volume Adductor Canal Block|Adductor canal block performed in the distal thigh (1/3 of the total distance between the superior border of the patella and the femoral crease, cephalad to the patella) utilizing an injectate volume of of 10 mL 0.75% bupivacaine/ epinephrine
224169059|NCT02081911|PROCEDURE|Femoral Nerve Block|Femoral nerve block with 10 mL 0.75 % bupivacaine/epinephrine
224169062|NCT03931889|DIETARY_SUPPLEMENT|Vitamin D3|Cap. Cholecalciferol 40,000 IU
224169063|NCT03094338|BEHAVIORAL|stress, psychological|students respond to questionnaires
224169064|NCT04022304|BIOLOGICAL|Biocon Insulin N|Biocon Insulin N is an intermediate-acting isophane suspension of human insulin produced by recombinant deoxyribonucleic acid(rDNA) technology utilizing Pichia pastoris (yeast).
224169065|NCT04022304|BIOLOGICAL|Humulin® N|Humulin® N (human insulin \[recombinant deoxyribonucleic acid origin\] isophane suspension) is an intermediate-acting human isophane insulin. Humulin® N is a suspension of crystals produced from combining human insulin and protamine sulphate.
224169066|NCT04760691|DRUG|Truvada alone|TDF/FTC 300 mg (milligrams) / 200 mg by mouth once daily
224169067|NCT04760691|DRUG|Truvada plus Leuprolide|TDF/FTC 300mg/ 200 mg by mouth once daily Leuprolide 11.25 mg im once
224169068|NCT04760691|DRUG|Truvada plus Estradiol 1 mg|TDF/FTC 300mg/ 200 mg by mouth once daily Estradiol 1 mg by mouth once daily
224169069|NCT04760691|DRUG|Truvada plus Estradiol 6 mg|TDF/FTC 300mg/ 200 mg by mouth once daily Estradiol 3 mg by mouth twie daily
224169070|NCT04760691|DRUG|Estradiol 6 mg alone|Estradiol 3 mg by mouth twice daily
224169071|NCT00428285|PROCEDURE|Argon Plasma Coagulation|Argon Plasma Coagulation (APC) is a non-contact electrosurgical technique delivering a high-frequency electrical current through ionized argon gas i.e. the argon plasma. This current produces a zone of coagulation, desiccation, and devitalisation 2-3 mm deep. Patients will be offered up to 3 treatments if recurrence occur after the first two.
224169072|NCT04686929|DRUG|Abatacept s.c.|subcutaneous abatacept: 250mg (d-1) , 125mg (d+5, +14, +21, +28, +35, +42, +49, +56) combined with CsA, MTX, MMF.
224169073|NCT05761405|COMBINATION_PRODUCT|mannitol-enhanced aminoglycoside|"Preselected patients with ureteral stents in situ who are scheduled to undergo endourological ureteral stent manipulation will have routine urine cultures prior to intervention.~Procedures: Consented patients will be randomized for the type of antibiotic prophylaxis according to a global randomization list (i.e. CRO, AMK, AMK1/2+MAN)).~Antibiotics (± mannitol) will be delivered in a single infusion that will be administered within 30 minutes."
224169074|NCT05761405|DRUG|Ceftriaxon|"Preselected patients with ureteral stents in situ who are scheduled to undergo endourological ureteral stent manipulation will have routine urine cultures prior to intervention.~Procedures: Consented patients will be randomized for the type of antibiotic prophylaxis according to a global randomization list (i.e. CRO, AMK, AMK1/2+MAN)).~Antibiotics will be delivered in a single infusion that will be administered within 30 minutes."
224169075|NCT05761405|DRUG|Amikacin|Preselected patients with ureteral stents in situ who are scheduled to undergo endourological ureteral stent manipulation will have routine urine cultures prior to intervention.
224169076|NCT00605228|DRUG|MOVIPREP|2L Drug
223481450|NCT01710423|BEHAVIORAL|Peer mentoring intervention ('Cooking with Friends')|"'Cooking with Friends' is a community-located, peer mentoring intervention aimed at improving home food preparation practices in families with young children.~The intervention was developed in an iterative, community-based research approach, and will be conducted in partnership with Early Head Start (EHS) at The Children's Hospital of Philadelphia. Cooking with Friends builds on existing monthly cooking classes at EHS that have proven popular with EHS families. Through 5 weekly classes, this intervention will explore topics of how to prepare healthy foods at home.~The peer mentoring component is a novel innovation to this intervention. The intervention pairs peer mentors to individual mentees in a community setting, to effect behavioral change among caregivers of young children."
223481451|NCT00537836|DRUG|BAY 86-5310 (ZK 283197)|3 mg (3 x 1 mg tablet) or 2 mg (2 x 1 mg tablet) ZK 283197 in respective treatment group, once daily p.o. over 8 weeks
223585109|NCT04135859|BEHAVIORAL|Physical Activity Monitoring|A physical activity monitor (Fitbit) will be provided to both groups.
223585110|NCT04346030|DRUG|Triamcinolone Acetonide|ultrasound guided steroid injection using 1ml of 10mg triamcinolone acetonide (Shincort) mixed with 1ml of 2% lidocaine hydrochloride (Xylocaine) and 8cc NS
224169077|NCT00605228|DRUG|COLOPEG|4L Drug
224169078|NCT02912832|DEVICE|TBDx|The TBDx is an automated platform is based on an Olympus BX41 microscope with a 40 x objective lens, fitted with an Olympus XC 10 colour camera and a movable slide stage, with an attached computer that receives high-quality digital images acquired from the camera. The computer then operates detection algorithms that segment, evaluate, and classify objects of interest in these images which can be stored for subsequent review. The platform is able to integrate an optional 200-slide automated slide loader for high volume settings. The application can capture 100, 300 or more digital fields-of-view and can provide results for positive or negative smears in 5 minutes or less.
223481452|NCT00537836|DRUG|Placebo|Placebo, once daily p.o. over 8 weeks
224305446|NCT04659252|OTHER|n/a - samples collected along routine care samples only|This is a non-interventional study.
224305447|NCT02833701|DIETARY_SUPPLEMENT|Ascorbic Acid|Given IV
224305448|NCT02833701|BIOLOGICAL|Bevacizumab|Given intravenously (IV)
223481453|NCT00537836|DRUG|17ß-estradiol|1 mg (2 x 0.5 mg tablet) 17ß-estradiol, once daily p.o. over 8 weeks
223481454|NCT02832713|DRUG|Botulinum toxin A ( BoNT-A)|Intra-articular injection of BoNT-A
223481455|NCT02832713|DEVICE|Hyaluronic acid (HA)|Intra-articular injection of Hyaluronic acid
224169079|NCT06009406|OTHER|Physiotherapy|This group will be applied to the soleus, gastrocnemius muscle and Achilles tendon with Graston, an instrumental myofascial mobilization technique, until they feel warmth in the skin and tonus relaxation in the target muscles. The control group will be subjected to 3 repetitions of passive stretching for 30 seconds for the same structures.
224169080|NCT03830463|DRUG|CTP-692|Single oral dose
224169081|NCT03830463|DRUG|Placebo|Single oral dose
224169082|NCT03928990|DEVICE|ActiGraph accelerometer|ActiGraph accelerometer + calibration with Cortex MetaMax3B ergospirometer
224169083|NCT05018091|DRUG|Dexamethasone 4mg|4mg intravenous dexamethasone, administered shortly after induction of anesthesia
224169084|NCT05018091|DRUG|Dexamethasone 8 Mg/mL Injectable Suspension|8mg intravenous dexamethasone, administered shortly after induction of anesthesia
224169085|NCT05018091|DRUG|Dexamethasone 16mg|16mg intravenous dexamethasone, administered shortly after induction of anesthesia
224169086|NCT00645736|OTHER|No intervention|No intervention
223481456|NCT05801692|PROCEDURE|Weaning of mechanical ventilation|Weaning of mechanical ventilation is the time when the patient is ready for separation from ventilatory support until breathing without invasive support
223481457|NCT02205138|DRUG|ALLOB® cells with ceramic scaffold|Each patient will undergo a single administration of ALLOB®/ceramic scaffold mix into the lumbar interbody fusion site under anaesthesia
223481458|NCT00745602|PROCEDURE|non-invasive testing|non-invasive tests including Transcranial Doppler ultrasound (TCD), manual cuff blood pressure (BP), beat to beat BP monitoring by a Portapress monitor, and respiratory tidal CO2
223481459|NCT00397579|DRUG|DT388IL3|Intravenously via a 3 cc plastic syringe as a 15 minute bolus infusion daily for five days.
224169087|NCT05130229|BEHAVIORAL|Sleep Well Bee Well|Sleep program to help toddlers sleep better
224169088|NCT05017727|DEVICE|Closed-loop automated oxygen control with Oxygenie Auto-O2 software (SLE6000)|The 'Oxygenie' is a closed loop automated oxygen control system that has been incorporated into a software module for the SLE6000 infant ventilators. This software control system allows targeting SpO2 values by controlling FiO2.
224169089|NCT01751373|BEHAVIORAL|Optimal muscle activation therapy|The proposed study uses a longitudinal, within-subject, pre/post intervention, cross-over design. All participants will complete each of 4 study phases (each 12 weeks long). These include: a) focal BTX injections in combination with either Standard Therapy or Optimal Muscle Activity Therapy; b) a three-month period where no treatment is given; c) focal BTX injections in combination either Standard Therapy or Optimal Muscle Activation Therapy; d) another three-month period where no treatment is given. The order of treatment phases will be counter-balanced across participants.
224169090|NCT01751373|BEHAVIORAL|Standard Therapy|
224169091|NCT05620485|PROCEDURE|laparoscopic-assisted CDC excision and hepaticojejunostomy|After birth, the liver and gallbladder ultrasound were regularly rechecked. If the maximum diameter of the cyst was greater than 5 cm, surgery was performed.
223481460|NCT03421587|BEHAVIORAL|Processing of social olfactory and tactile stimuli|Processing of social olfactory and tactile stimuli in trauma-exposed individuals and controls is examined using functional magnetic resonance imaging.
223481461|NCT03763981|PROCEDURE|prolene seton treatment|patients with perianal fistulas will treated with seton placement by prolene thread
223481462|NCT03763981|PROCEDURE|silk seton treatment|patients with perianal fistulas will treated with seton placement by silk thread
223481463|NCT02524119|DRUG|LEE011|600 mg PO once daily will be given orally on days 1-21 of a 28 day cycle (3 weeks on / 1 week off) :until disease progression, unacceptable toxicity, death, or discontinuation from the study treatment due to any other reason
223481464|NCT02524119|PROCEDURE|Chemoembolization|Patients will be treated with chemoembolization once every 4 weeks with up to 4 total chemoembolizations within the first 6 months from the initial chemoembolization.
223481465|NCT02054156|DRUG|azithromycin|3 times weekly, oral suspension, 10 mg/kg/dose up to 500 mg, for 18 months
223481466|NCT02054156|DRUG|placebo|3 times weekly, oral suspension, volume-matched to azithromycin, for 18 months
223481467|NCT02054156|DRUG|Tobramycin solution for inhalation|300 mg, twice daily for 28 days when respiratory cultures are found positive for Pa at study visits for 18 months
223481468|NCT05106478|DEVICE|AuraGain|Ambu® AuraGain, a relatively novel supraglottic airway device, has been introduced recently. AuraGain has an inflatable cuff and a curved body.
223481469|NCT04640896|DRUG|Trigger point injection with bupivacaine|Trigger point injections will be performed within an hour of arrival in post anesthesia care unit, given that the patient has adequately woken up from general anesthesia. Injections will be performed by an anesthesiology provider using a standardized technique under strict aseptic conditions. The trigger point will be located between two fingers, and a 1-2cm sterile needle with a thickness of 25 or 26 gauge inserted at 30 degrees with respect to the skin. Negative aspiration will be confirmed before injecting the study solution. The needle will be withdrawn to the subcutaneous tissue and redirected superiorly, inferiorly, laterally and medially, injecting study solution at each location. Pressure will be applied to the area to ensure hemostasis, and the area dressed with gauze and tape as needed.
223585111|NCT04346030|DRUG|lidocaine hydrochloride|ultrasound guided steroid injection using 1ml of 10mg triamcinolone acetonide (Shincort) mixed with 1ml of 2% lidocaine hydrochloride (Xylocaine) and 8cc NS
223585112|NCT04346030|DRUG|normal saline|ultrasound guided steroid injection using 1ml of 10mg triamcinolone acetonide (Shincort) mixed with 1ml of 2% lidocaine hydrochloride (Xylocaine) and 8cc NS
223585113|NCT02073357|PROCEDURE|Light general anaesthesia (BIS = 50)|
223585114|NCT02073357|PROCEDURE|deep general anaesthesia (BIS = 35)|
224169092|NCT04319861|PROCEDURE|Anal fistula plug procedure|A fistula probe was used to identify fistula tracts, and internal and external openings. Gentle mechanical debridement was performed with a blunt curette to remove the necrotic tissue with care not to enlarge the track, then hydrogen peroxide and sterile saline were used to repeatedly to irrigate the fistula. The anal fistutla plug was filled into the fistula, and sutured with a figure-of-eight 2-to-0 Vicryl suture to ensure the plug was fixed in the internal opening of the fistula, avoiding the anal fistula plug being extruded. Trimming the plug at the external fistula and the external opening was left open to ensure adequate drainage.
224169093|NCT06594185|DEVICE|enVista Aspire EA or Aspire Toric ETA IOLs|enVista Aspire EA or Aspire Toric ETA IOLs
224169094|NCT04566523|OTHER|telerehabilitation|Patients undergo an online exercise training program via a certified host of health data website.
224169095|NCT06001892|BEHAVIORAL|Tennessee Youth Prepared for Success|both 5 day classroom interventions.
223481470|NCT04640896|DRUG|Trigger point injection with normal saline|Trigger point injections will be performed within an hour of arrival in post anesthesia care unit, given that the patient has adequately woken up from general anesthesia. Injections will be performed by an anesthesiology provider using a standardized technique under strict aseptic conditions. The trigger point will be located between two fingers, and a 1-2cm sterile needle with a thickness of 25 or 26 gauge inserted at 30 degrees with respect to the skin. Negative aspiration will be confirmed before injecting the study solution. The needle will be withdrawn to the subcutaneous tissue and redirected superiorly, inferiorly, laterally and medially, injecting study solution at each location. Pressure will be applied to the area to ensure hemostasis, and the area dressed with gauze and tape as needed.
223481471|NCT04640896|DRUG|Lidocaine skin wheal|"Patients in the control group will receive a small skin wheal of lidocaine. This will keep the patient blinded to the study group they are in since all patients will receive an injection.~However, this skin wheal is not considered a trigger point injection."
223481472|NCT01928849|DRUG|Valproic Acid|"Intervention patients will receive standard regional anesthesia catheters (either peripheral nerve or epidural catheter), anesthetic management and oral valproic acid 250mg preoperatively, then three times per day for either 6 days post-operatively or until discharge from the hospital."
223481473|NCT01928849|OTHER|Cherry Syrup|Intervention arm patients will receive standard regional anesthesia catheters (either peripheral nerve or epidural catheter), anesthetic management, and valproic acid 250mg preoperatively, and then three times per day for 6 days post-operatively.
223481474|NCT03704077|BIOLOGICAL|Relatlimab + Nivolumab|Specified dose on specified days
223481475|NCT03704077|BIOLOGICAL|Nivolumab|Specified dose on specified days
223481476|NCT03704077|DRUG|Paclitaxel|Specified dose on specified days
223481477|NCT03704077|DRUG|Ramucirumab|Specified dose on specified days
223481478|NCT06022575|PROCEDURE|Telehealth integrated care|Followed up in online Internet hospital, estimated and adjusted treatment accroding to clinical efficacy, and send individualized health education messages regularly.
223481479|NCT06022575|PROCEDURE|Conventional health care|Followed up face-to-face in cardiacmetabolic clinics, estimated and adjusted treatment accroding to clinical efficacy, and conducted health education.
223481480|NCT02641821|DRUG|Nifedipine GITS|
223481481|NCT05098561|OTHER|Music Treatment|The nurse will set up the appropriate music genre for the each music treatment patient, based on patient's preference obtained from the pre-operative questionnaire, by using the bedside computer and using Pandora, the internet music streaming service.
223481482|NCT01502553|DEVICE|Comparison Test to Yuyue Medical BP Meter, YYBP-212|DUT: Transtek Blood Pressure Monitor, LS-802. Reference Device: Yuyue Medical Blood Pressure Meter, YYBP-212, accuracy: ±1mmHg and range: 0-300mmHg.
223481483|NCT01490710|OTHER|collection of clinical and biological parameters|Investigation focal lies in hemodynamic monitoring during the last 10 minutes (Cardiac Index Assessment and clinico-biological parameters as: ventilatory and respiratory parameters, NIRS, GDS, Omega Score, heart rate, blood pressure, lactate, BNP, perfusion coefficient…)
223481484|NCT01490710|OTHER|assign optimal ventilatory mode|End of study: At the end of the second session, clinician will assign optimal ventilatory mode regarding patient clinical response.
224072229|NCT01440621|DRUG|Pyridoxine|Tablet Pyridoxine 10mg once a day at 8AM daily, from Day one of RT till first post-treatment followup. Tab Pyridoxine 10mg has been chosen as placebo as it resembles Tab Modafinil 100mg in physical appearance, size and shape. Tab Pyridoxine is unlikely to affect Cancer Related Fatigue on its own as all patients on RT are already on multivitamin supplements as per our institutional guidelines.
224072230|NCT03826732|BEHAVIORAL|Guided self-help based on ACT|ACT-based self-help book and regular support by trained facilitators
224072231|NCT03057925|DEVICE|Microwave Ablation|Ultrasound-guided Percutaneous Microwave Ablation
223481488|NCT06436417|DEVICE|Analgesia Nociception Index (ANI) Monitor|Non-invasive monitoring of HRV to evaluate autonomic nervous system activity using the indices of Energy (SDNN) and ANI (HFnu).
223481489|NCT06436417|BEHAVIORAL|Trimodal Prehabilitation|Program of physical exercise, nutritional supplementation, and psychological support according to the RICA guidelines of the Spanish Group for Multimodal Rehabilitation.
223481490|NCT01655836|RADIATION|Brachytherapy|Undergo high dose rate brachytherapy
223481491|NCT01655836|RADIATION|Stereotactic Body Radiation Therapy|Undergo stereotactic body radiation therapy
223481492|NCT01655836|PROCEDURE|Quality-of-life assessment|Ancillary studies
224072232|NCT02573155|DRUG|Dose 1, AZD8871 50 μg (Part 1)|50 µg of AZD8871 on Day 1; each dose of AZD8871 inhalation powder will be administered via single-dose dry powder inhaler (Genuair®)
224072233|NCT02573155|DRUG|Dose 2, AZD8871 100 μg (Part 1)|100 µg of AZD8871 on Day 1; each dose of AZD8871 inhalation powder will be administered via single-dose dry powder inhaler (Genuair®)
224072234|NCT02573155|DRUG|Dose 3, AZD8871 300 μg (Part 1)|300 µg of AZD8871 on Day 1; each dose of AZD8871 inhalation powder will be administered via single-dose dry powder inhaler (Genuair®)
224072235|NCT02573155|DRUG|Dose 4, AZD8871 600 µg (Part 1)|600 µg of AZD8871 on Day 1; each dose of AZD8871 inhalation powder will be administered via single-dose dry powder inhaler (Genuair®)
224072236|NCT02573155|DRUG|Dose 5, AZD8871 1200 µg (Part 1)|1200 µg of AZD8871 on Day 1; each dose of AZD8871 inhalation powder will be administered via single-dose dry powder inhaler (Genuair®)
224072237|NCT02573155|DRUG|Dose 6, AZD8871 1800 μg (Part 1)|1800 µg of AZD8871 on Day 1; each dose of AZD8871 inhalation powder will be administered via single-dose dry powder inhaler (Genuair®)
224072238|NCT02573155|DRUG|Placebo, AZD8871 placebo (Part 1)|AZD8871 placebo on Day 1; each dose of AZD8871 placebo inhalation powder will be administered via single-dose dry powder inhaler (Genuair®)
224072239|NCT02573155|DRUG|Treatment A, AZD8871 dose A (Part 2)|AZD8871 dose A once on Day 1; each dose of AZD8871 placebo inhalation powder will be administered via single-dose dry powder inhaler (Genuair®)
224072240|NCT02573155|DRUG|Treatment B, AZD8871 dose B (Part 2)|AZD8871 dose B once on Day 1; each dose of AZD8871 placebo inhalation powder will be administered via single-dose dry powder inhaler(Genuair®)
224072241|NCT02573155|DRUG|Treatment C, Indacaterol 150 μg (Part 2)|150 μg of Indacaterol once on Day 1; each dose of Indacaterol dry inhalation powder will be administered via a dry powder inhaler (Onbrez Breezhaler®) as 1 hard capsule
224169096|NCT05605041|DEVICE|Headspace|Headspace is an app that allows users to practice mindfulness through guided meditation
224169097|NCT07009119|PROCEDURE|laparoscopic Pancreaticoduodenectomy|The patient is positioned in French position (right arm in, left arm abducted 90°), with a suprapubic area reserved for Pfannenstiel incision. A 6-port technique is used: sub-umbilical (12 mm), four semi-circular trocars (two 12 mm, two 5 mm), and a sub-xiphoid trocar for liver retraction. Laparoscopic pancreaticoduodenectomy (LPD) proceeds if no vascular invasion/metastasis is found. Key steps include Kocher's maneuver, vessel ligation (gastroepiploic, gastric, gastroduodenal), lymphadenectomy (stations 5-17), pancreatic neck transection, and jejunal division. Reconstruction involves duct-to-mucosa pancreaticojejunostomy (or invaginating if duct unfound), hepaticojejunostomy, and stapled gastrojejunostomy. Margins are examined post-resection. Harmonic scalpel/Ligasure and staplers are used.
224169098|NCT01742663|DRUG|Diclofenac Sodium Gel 3%|Diclofenac Sodium Gel 3% (Taro Pharmaceuticals Inc.) applied twice daily for 60 days.
224169099|NCT01742663|DRUG|Solaraze® (diclofenac sodium) Gel 3%|Solaraze® (diclofenac sodium) Gel 3% (Fougera Pharms)applied twice daily for 60 days.
223481493|NCT01655836|OTHER|Questionnaire administration|Ancillary studies
224169100|NCT01742663|DRUG|Vehicle Topical Gel|Vehicle Topical Gel (Taro Pharmaceuticals Inc.) applied twice daily for 60 days.
224169101|NCT05464498|DEVICE|MD-Tissue Collagen Medical Device|"MD-Tissue (GUNA, Milan-Italy) Composition per 2 ml: collagen 100 micrograms Excipients: Ascorbic acid, Magnesium gluconate, Pyridoxine hydrochloride, Riboflavin, Thiamine hydrochloride, NaCl, Water for injection.~Subjects will be treated with No. 6 peri-tendon injections (2 infiltrations per week for three weeks)."
224169102|NCT05464498|OTHER|eccentric strengthening protocol|Group B which, will implement only physiotherapy (eccentric strengthening protocol)
224169103|NCT02521740|OTHER|Research questionnaires, blood sample|assessment of health (frailty, nutrition, physical performance, depression, burden, sense of coherence, caregiver reaction)
224169104|NCT00552994|DEVICE|Cypher Select plus|Drug eluting stent
224169105|NCT00552994|DEVICE|Xience V stent|Drug eluting stent
224169106|NCT01913509|DEVICE|Combined Therapy of FES and BAT|FES treatment is applied to stimulate the supraspinatus muscle and the posterior deltoid muscle of the affected shoulder. Then patients receive bilateral arm training focused on reaching, shoulder abduction, and shoulder horizontal abduction.
223481494|NCT00147238|DRUG|Ferumoxtran-10 (USPIO)|Intravenous infusion of 2.6 mg/kg of ferumoxtran-10
223481495|NCT00147238|PROCEDURE|MR lymphangiography|First MRI examination before ferumoxtran-10 contrast injected and second MRI examination about 24 hours after injection of contrast agent, each MRI taking 20 minutes.
223481496|NCT00128427|DRUG|Colchicine (for 1 month)|
223481497|NCT02572154|OTHER|Blood and sperm samples|20 ml of blood and sperm samples for sperm DNA fragmentation exploration
223585115|NCT04283565|OTHER|Systematic screening of AOMI by BPI measurement.|The strategies will be associated according to a 2\*2 factorial design in order to obtain 4 arms
223585116|NCT04283565|OTHER|Management of CVRF by a motivationnal interviewing.|The strategies will be associated according to a 2\*2 factorial design in order to obtain 4 arms
224169107|NCT01913509|DEVICE|Conventional Rehabilitation|Stroke patients in CR group receive the protocol which includes (1) TENS; (2) BAT. The activities are adapted based on the level of motor impairment, and functional needs of individual patients.
224169108|NCT03049930|DRUG|Ketamine|Ketamine is a medication used for starting and maintaining anesthesia. Participants randomized to the ketamine arm will receive 1 mg/ml solution infused at 0.2 mg/kg/hour (0.2 ml/kg/h) for a maximum of 20 ml/hour.
223481498|NCT03287765|DRUG|18F-AV-1451|Participants will receive a single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807. For those who cannot tolerate the full exam, participants will receive single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807.
223481499|NCT00297167|DRUG|EUR-1008 (APT-1008)|EUR-1008 (APT-1008) microtablets (5000 lipase units) or minitablets (10000, 15000 or 20000 lipase units) contained in a capsule will be given orally daily in first double-blind intervention period; at a dose based on investigator's discretion as achieved during dose titration and stabilization period (6 to 9 days). The capsules could be opened and sprinkled on acidic food and half of the established dose was used with snacks. Treatment duration for first double-blind intervention period will be 2 days home treatment and 3 to 5 days hospital treatment.
223481500|NCT00297167|DRUG|Placebo|Placebo matched to EUR-1008 (APT-1008) microtablets or minitablets contained in a capsule will be given orally daily in second double-blind intervention period; at a dose based on investigator's discretion as achieved during dose titration and stabilization period (6 to 9 days). Treatment duration for second double-blind intervention period will be 2 days home treatment and 3 to 5 days hospital treatment.
223481501|NCT00297167|DRUG|Placebo|Placebo matched to EUR-1008 (APT-1008) microtablets or minitablets contained in a capsule will be given orally daily in first double-blind intervention period; at a dose based on investigator's discretion as achieved during dose titration and stabilization period (6 to 9 days). Treatment duration for first double-blind intervention period will be 2 days home treatment and 3 to 5 days hospital treatment.
223585117|NCT04246814|DEVICE|LG1|Application of LASER AsGa 904nm 10 J/cm².
223585118|NCT04246814|DEVICE|LG2|Application of LASER AsGa 904nm 8 J/cm².
223585119|NCT04246814|DEVICE|LG3|Application of LASER AsGa 904nm 4 J/cm².
224169109|NCT03049930|DRUG|Sodium chloride|Participants randomized to the placebo arm will receive 0.9 mg/ml sodium chloride, infused at a rate of 0.2 ml/kg/hour
224169110|NCT03511300|BEHAVIORAL|Goal-Setting Instructions|"In the goal-setting instruction condition, participants will be asked to increase their performance by 20% from the previous similar test (e.g., On this task, you generated 10 words when I asked you to name as many words as you could that start with the letter 'F.' Now, I want you to aim to generate at least 12 words for the letter 'F'.)"
223585120|NCT04246814|DEVICE|CC|Application of placebo LASER.
223585121|NCT04246814|PROCEDURE|Dressing|Application of Helianthus annuus oil dressing.
223585122|NCT02412709|DEVICE|QTScreen ECG Recorder|Subjects will be randomly assigned to the: Parents Performing ECG (PPE) group or Staff Performing ECG (SPE) group. This will assess whether parents are able to use QTScreen on babies at home.
223585123|NCT00551291|DRUG|Mycophenolate mofetil|1 gm twice daily orally until end of study.
223585124|NCT00551291|DRUG|Prednisone|10 mg/day orally until end of study.
224169111|NCT03511300|BEHAVIORAL|Standard Instructions|Participants in this group will receive the standardized instructions for completing the tests, as outlined in the test appendices.
224169112|NCT00778310|DRUG|methylphenidate-OROS|The collaborator (Ortho-McNiel Janssen Scientific Affairs, LLC) will provide capsules of Concerta that are made to appear similar to placebo capsules. The subject will be administered their usual dose of Concerta the morning of the scan.
224169113|NCT00778310|DRUG|Placebo|The collaborator (Ortho-McNiel Janssen Scientific Affairs, LLC) will provide capsules of placebo that are made to appear similar to Concerta capsules. The subject will be administered placebo the morning of the scan.
224169114|NCT00995605|DRUG|AMAP102|AMAP102 or Placebo
224169115|NCT03163173|DRUG|GC4419|30 mg (\~100 μCi) dose of \[14C\]GC4419
224169116|NCT05964712|PROCEDURE|Medical surgery therapy|De novo patients with acromegaly will undergo medical/surgical therapy of this disease, according to the guidelines of the Endocrine Society. In this population (group #1) morpho-functional examinations together with the evaluation of the stage of the disease, with serum dosage of GH and IGF-1, will be performed at baseline and at months 3, 6 and 12 after initiating the treatment.
224169117|NCT04815876|PROCEDURE|Transperineal MRI-guided prostate biopsy|Transperineal prostate biopsy will be performed under local anesthesia in the office. This approach avoids transrectal needle tracking.
224169118|NCT04815876|PROCEDURE|Transrectal MRI-guided prostate biopsy|Transrectal prostate biopsy is currently the most popular approach to evaluate a positive screening test for prostate cancer.
224169119|NCT04815876|DRUG|Antibiotic (prophylaxis)|"For men undergoing transrectal biopsy, antibiotic prophylaxis will be administered in accordance with guidelines from the American Urological Association (AUA).~No antibiotic prophylaxis will be administered for men undergoing transperineal biopsy."
224169120|NCT01197794|DRUG|AZD1981|AZD1981 twice daily
224169121|NCT01197794|DRUG|AZD1981|AZD1981 once daily
224169122|NCT01197794|DRUG|Placebo|Placebo to match AZD1981
224169123|NCT01055457|DEVICE|Vistakon Investigational Multi-Purpose Solution II|contact lens care solution
224169124|NCT01055457|DEVICE|ReNu MultiPlus Multi-Purpose Solution|contact lens care solution
224169125|NCT00043004|BIOLOGICAL|bevacizumab|
224169126|NCT00043004|DRUG|FOLFOX regimen|
224169127|NCT00043004|DRUG|fluorouracil|
223481502|NCT00297167|DRUG|EUR-1008 (APT-1008)|EUR-1008 (APT-1008) microtablets (5000 lipase units) or minitablets (10000, 15000 or 20000 lipase units) contained in a capsule will be given orally daily in second double-blind intervention period; at a dose based on investigator's discretion as achieved during dose titration and stabilization period (6 to 9 days). Treatment duration for second double-blind intervention period will be 2 days home treatment and 3 to 5 days hospital treatment.
223481503|NCT04232137|BEHAVIORAL|Postpartum coffee ceremony|The promise of a postpartum coffee ceremony
223481504|NCT00145561|DRUG|Saquinavir and Ritonavir|
224169128|NCT00043004|DRUG|leucovorin calcium|
223585125|NCT00551291|DRUG|Erythropoietin Beta|Recombinant human erythropoietin beta at doses of 30,000 IU/week by the subcutaneous route for 6 weeks.
224169129|NCT00043004|DRUG|oxaliplatin|
224169130|NCT00043004|PROCEDURE|conventional surgery|
224169131|NCT00043004|PROCEDURE|radiofrequency ablation|
223481505|NCT01927588|DRUG|Everolimus+Tacrolimus+Prednisone|Certican, introduced at Day7 post transplant + TACreduced + Steroids.
223585126|NCT05102968|BEHAVIORAL|Home-based rehabilitation supporting with the mobile application|For patients with mobile application supportive rehabilitation, patients managed rehabilitation exercise by themselves after the surgery without supervision. Rehabilitation protocol and exercise instruction video were available in the application. Patient could communicate with the physician and therapist via the application.
224169132|NCT04055844|DRUG|Decitabine|10 days of decitabine 20 mg/m2 IV daily; or, alternatively, per institution, physician, or patient preference on a 5-2-5 schedule with no weekend infusion. If a CR is achieved after 2 cycles using the 10-day schedule, subsequent cycles will change to a 5-day schedule.
224169133|NCT04055844|DRUG|Ruxolitinib|Starting with day 1 of cycle 1 and continuing for up to 6 months after the end of the last cycle, patients will receive ruxolitinib 5 mg twice daily orally. Dose may be increased to 10 mg twice daily in cycles 2 through 4 if platelets improve to \>100 x 10\^9/L.
224169134|NCT04055844|DRUG|Donor Lymphocyte Infusion (DLI)|DLI from the original donor will be infused within 10 days after the last dose of decitabine in each cycle.
224169135|NCT05263544|OTHER|measuring uterocervical angle and uterine dimensions|in both groups with and without displaced IUD, uterus size, uterine width, cervical canal length, endometrial canal length, endometrial canal width, and the angle at the intersection of the imaginary lines corresponding to the middle of the endometrium and cervical canal, which can be detected by transvaginal ultrasound will be measured
224169136|NCT02732184|DRUG|Co-ArgI-PEG modified human arginase I|
224169137|NCT03732521|OTHER|Educational therapy|educational intervention to the caregiver and individualization according to their family and social context
224169138|NCT04716010|OTHER|Control|Participants will complete a shopping task in the online grocery store, and the products that contain red meat will not have warning labels or a 30% increase in price.
224169139|NCT04716010|OTHER|Warning Labels|While completing the shopping task in the online grocery store, the health and environmental warning labels will appear next to the image of every product that contains red meat.
224169140|NCT04716010|OTHER|Tax|While completing the shopping task in the online grocery store, all products containing red meat will have a 30% increase in price.
224169141|NCT04716010|OTHER|Combined Warning Labels and Tax|While completing the shopping task in the online grocery store, all products containing red meat will have the health and environmental warning labels appear next to the product image and a 30% increase in price.
224169142|NCT03538990|OTHER|DASH Eating Pattern|The DASH diet is a heart-healthy eating pattern that is focused on adequate consumption of fruits, vegetables, whole grains, low-fat dairy, fish, poultry, beans, nuts, and vegetables oils while emphasizing limited intake of foods containing saturated fat, such as fatty red meats, full-fat dairy products, and tropical oils, such as coconut, palm kernel, and palm oils, as well as sugar-sweetened beverages and sweets.
224305449|NCT02833701|OTHER|Laboratory Biomarker Analysis|Correlative studies
224305450|NCT02833701|OTHER|Quality-of-Life Assessment|Ancillary studies
224305451|NCT00536263|DRUG|pegylated interferon alpha-2b|1.0 mcg/kg subcutaneously (S.C.) QW for 24 weeks
224169143|NCT06013319|DRUG|Esmolol|The load dose of esmolol was first injected intravenously: 0.5mg/kg.min, for about 1 minute; then the maintenance dose was pumped intravenously: from 0.05mg/kg/min, and continued after 4 minutes if the efficacy was ideal; if the efficacy was poor, the load dose could be repeated and the maintenance dose increased by 0.05mg/kg/min. The maintenance dose should not exceed 0.3mg/kg/min.
224169144|NCT04598841|DIETARY_SUPPLEMENT|supplement nutritional supporting|Special medical formula for the purpose of formula food
224169145|NCT00307814|DRUG|Epoetin Alfa|
224169146|NCT00572728|PROCEDURE|CT|Undergo 18F-FLT PET/CT
224169147|NCT00572728|DRUG|18F-FLT|Undergo 18F-FLT PET/CT
224169148|NCT00572728|PROCEDURE|PET|Undergo 18F-FLT PET/CT
224169149|NCT00679380|PROCEDURE|Blood sampling, endoscopy|Blood sampling for hematology and biochemistry and endoscopy with biopsy for histological and endoscopic assessment scores
224169150|NCT00679380|DRUG|Budesonide MMX® 6 mg|6 mg/day, 6 mg tablets
224169151|NCT00679380|DRUG|Budesonide MMX® 9 mg|9 mg/day, 9 mg tablets
224169152|NCT00679380|DRUG|Entocort EC® 3 mg|9 mg/day, 3 mg tablets
224169153|NCT00679380|DRUG|Placebo|Placebo
223481506|NCT01927588|DRUG|Mycophenolate+Tacrolimus+Prednisone|Myfortic + Tacrolimus full + Steroids, as control arm.
224169154|NCT02615262|DRUG|Dexamethasone|
224169155|NCT02615262|DRUG|Placebo|0.9% Sodium Chloride
224169156|NCT04356872|DRUG|Sintilimab|immune check point inhibitor, 200mg, iv, d1
224169157|NCT04356872|DRUG|Doxorubicin Hydrochloride|ADM, 60mg/m2, iv, d1
224169158|NCT04356872|DRUG|Ifosfamide|IFO, 1.8 g/m2/d, d1-5
224169159|NCT00656760|OTHER|PET/CT|PET/CT is being performed on all patients in the study.
224169160|NCT06435962|DEVICE|sonography|measurement of optic nerve in RRMS by sonography and visual evoked potential( VEP) as correlation of axonal affection in RRMS patient
224169161|NCT02719457|OTHER|6 minute walk test (6 MWT)|6 minute walk test is the standard testing for COPD patients to evaluate their exercise capacity
224169162|NCT02719457|OTHER|Spot marching test (SMT)|Spot marching test is a new test that developed to evaluate their exercise capacity of COPD patients. This test is alternative method and practical to evaluate exercise capacity. The main benefit of this testing is use a small area to test and movement pattern involve both arm and leg. We expect that SMT may make COPD patient to more dyspnea in a short period of exercise.
224169163|NCT03630016|DIAGNOSTIC_TEST|Pulse oximetry with Owlet BabySat v1.0 sensor|A comparative, single-center, non-randomized study to evaluate the SpO2 accuracy guidelines for pulse oximetry over the range of 70-100% SaO2 under non-motion conditions. Arterial blood sampling measured by functional SaO2 CO-Oximetry, was used as the basis for comparison with Owlet BabySat v1.0 and Owlet Smart Sock 2 sensors
224169164|NCT04407624|OTHER|Intermittent Exercise|Exercise programs including warm-up, loading, cooling, and relaxation exercises are shown. The warm-up period is consist of light-paced walking, active movements of several large muscle groups. During the loading period, taking into consideration the heart rate, fatigue and shortness of breath, exercises such as walking, squat, limb movements with weights, stepping on the steps, walking on different floors are shown. Stretching exercises are done during the cooling period. Intermittent loading workouts will consist of 3-minute loads and 1-minute rest intervals. Participants are contacted every two weeks via communication methods such as e-mail, message and telephone conversation. Exercise diary is given to all patients and is taken from them at the end of the study.
224169165|NCT04407624|OTHER|Control|Exercise programs including warm-up, loading, cooling, and relaxation exercises are shown. The warm-up period is consist of light-paced walking, active movements of several large muscle groups. In loading period, moderate aerobic exercise is consist of brisk walking to reach 60-85% of the person's maximum heart rate. Stretching exercises are done during the cooling period.
224169166|NCT04113512|OTHER|Jalaneti|Sterilised and lukewarm isotonic salt water using neti pot was poured into one nostril, so that it leaves through the other. The procedure is then repeated on the other side, and the nose is dried by bending forward and by rapid yoga breathing
224169167|NCT02715596|DIETARY_SUPPLEMENT|EPA supplementation|2.7 g EPA supplementation in a 15 cc emulsion stick-pack
224169168|NCT02715596|OTHER|Placebo|placebo in 15 cc emulsion stick-pack
224169169|NCT00002981|PROCEDURE|positron emission tomography|
224169170|NCT00002981|RADIATION|fludeoxyglucose F 18|
224169171|NCT00002981|RADIATION|methionine C 11|
224169172|NCT01529450|DRUG|LDE225|800-mg (4 200-mg capsules/day) capsule
224169173|NCT02142855|BEHAVIORAL|Concentric Exercise Training|8 weeks concentric exercise training, 3 x per week, 60% 1-RM; 4 x 12-15 repetitions, 2 min rest between sets
224169174|NCT02142855|BEHAVIORAL|Eccentric Exercise Training|8 weeks eccentric exercise training, 3 x per week, 60% 1-RM; 4 x 12-15 repetitions, 2 min rest between sets
224169175|NCT00358709|BEHAVIORAL|Cognitive-Behavioral therapy and Symptom Management|A group cognitive-behavioral therapy approach to lessening psychotic symptoms of individuals with a first episode of psychosis, and comparison its effects to a known skills training approach and a control group.
224169176|NCT01487707|BEHAVIORAL|Voluntary Health Worker (VHW) Program|Voluntary Health Workers will conduct door-to-door campaigns on maternal and child health, and will visit pregnant women regularly to to educate and to encourage use of antenatal care and facility-based deliveries.
224169177|NCT01487707|BEHAVIORAL|Safe Birth Kit|A safe birth kit, containing sterile materials to diminish infection risk will be given to pregnant women.
224169178|NCT01487707|BEHAVIORAL|Community Folk Media Campaigns|Community-wide media activities, including dramas, intended to address community norms regarding maternal and child health.
224169179|NCT02724111|DRUG|sufficient dose of rocuronium|
224169180|NCT02724111|DRUG|sugammadex 10 min after position change|
224305452|NCT00536263|DRUG|pegylated interferon alpha-2b|1.5 mcg/kg S.C. QW for 24 weeks
224305453|NCT00536263|DRUG|pegylated interferon alpha-2b|1.5 mcg/kg S.C. QW for 48 weeks
224305454|NCT04263402|DRUG|Methylprednisolone|Patients in the Group I will receive basic symptomatic supportive treatment,plus methylprednisolone(\<40mg/d intravenous drip for 7 days).
223481507|NCT02448082|OTHER|Shampoo (inactive)|Shampoo which is made to look and feel the same as the experimental shampoo but does not contain the active ingredient of sodium shale oil sulponate 1%.
223481508|NCT02448082|OTHER|Sodium shale oil sulponate 1% shampoo|Shampoo containing the active ingredient of sodium shale oil sulponate 1%.
224169181|NCT02230839|BEHAVIORAL|Exercise|Participants will complete a progressive 6-month exercise training program, 4-5 days per week, 45 min per session (180 min per week), consisting mostly of walking (both outside and on an indoor treadmill) but with the option to include stationary cycling, elliptical and rowing machines, similar to what we have utilized previously to elicit significant improvements in insulin sensitivity in both middle-age and older adults (52-55). Beginning at week 8, these subjects will also perform 2 non-consecutive resistance exercise sessions per week, 30 min per session, focused on major muscle groups using resistance machines (total days of exercise will still be 4 to 5).
224169182|NCT02230839|BEHAVIORAL|Energy Restriction-Induced Weight Loss|The goal of the weight loss intervention will be to produce a weight loss of 10% body weight. A reduction of 500-1000 kcal/day - based on baseline weight -and low fat (\<30% of calories from fat) diet will be used as part of the weight loss intervention.
224169183|NCT04431804|OTHER|silver nanoparticle|fungicidal effect of silver nanoparticles on aspergillus isolates
224169184|NCT04823741|GENETIC|PLEURAL BIOCOLLECTION OF MALIGNANT PLEURAL MESOTHELIOMA|All patient with suspected malignant pleural mesothelioma requiring surgical biopsy after validation in oncologic multidisciplinary board will be included. During a standardized routine procedure of pleural biopsy by mean of general anesthesia and video thoracoscopic approach, 3 - 5 biopsies are realized. During this procedure, blood samples are collected and a piece of biopsy will be used for the constitution of a specific bio collection in the CRB (centre de ressources biologiques).
224169185|NCT03465046|COMBINATION_PRODUCT|intensive therapies(CIMT/BIT): protocol 1 or protocol 2|"The therapies applied in both protocols are intensive therapies that allow the execution of unimanual activities or bimanual activities with the affected upper limb with different doses.~the protocols were carried out at home through the family"
224169186|NCT00731952|DRUG|Velcade and Vorinostat|Subjects will receive one of 3 doses of Velcade (at a dose of 1.0 - 1.6 mg/m2 once weekly for 3 weeks) and one of 4 doses of Vorinostat (at a dose of 100mg every day 3 times a week for 3 weeks to 300mg twice per day, 3 times per week for 3 weeks). Doses determined by a predetermined escalation schedule.
224169187|NCT00540527|DRUG|local interarterial recombinant tissue plasminogen activator|Endovascular treatment must be performed asap after random.and definitely within 6h from symp. onset.It includes intrarterial thrombolysis with rt-PA,if necessary,associated to or substituted by mechanical clot disruption and/or retrieval.Fibrinolytic therapy should be performed within 1h,the full dose of rt-PA infusion should not exceed 0.9 mg/kg (max 90 mg in the case of body weight ≥100 kg).If a complete recanalization is achieved,rt-PA infusion can be interrupted before reaching the maximum dosage.The option of performing a thrombolysis by mechanical means to obtain a mechanical disintegration/shift/detach/fissure of the thrombus and/or a retraction/aspiration can be considered on the basis of the type,location and characteristics of the occlusion.These choices may involve the use of the microguidewire as a mechanical instrument to favour the disintegration of the thrombus,using systems to capture the thrombus by extraction or more complex systems to crush and aspirate the thrombus
224169188|NCT00540527|DRUG|intravenous (IV) rt-PA|IV thrombolytic treatment is started immediately after randomization, within 4.5 h of symptoms onset. IV rt-PA is administered at a dose of 0.9 mg/kg (max 90 mg), 10% of which is given as a bolus, followed by the delivery of the remaining 90% as a constant infusion over 60 mins
224169189|NCT03815760|DEVICE|Blood Flow Restriction|Subjects will perform sidelying external rotation exercise
224169190|NCT04001660|PROCEDURE|Subbrow Blepharoplasty Combined with Double Eyelid Surgery|An upper incision is made along the inferior margin of the eyebrow. A lower incision is determined according to necessary amount of skin excision. Then the skin and subcutaneous tissue were excised. The orbicularis oculi muscle (OOM) was separated and an OOM flap dissection was extended to the width of 15mm. A dissected OOM flap was lifted up and three transverse 3-0 nylon sutures were placed to fix it to the periosteum and then covered by the upper myocutaneous flap of the supraorbital rim. Through eyelid-crease approach the supratarsal upper eyelid skin and orbital fat was excised, adjusted and reshaped double-fold eyelids at the same time.
224169191|NCT01770886|DRUG|UE2343|Oral capsule
224169192|NCT01770886|DRUG|Placebo|Oral capsule
224169193|NCT01828567|BEHAVIORAL|Shared decision making with a Prevention Coach|A series of two phone sessions with a prevention coach. The first to engage the veteran to choose a preferred prevention program and link them to Patient Aligned Care Team (PACT), and a follow-up call one month later to assess the progress of the prevention plan.
224169194|NCT01427660|BEHAVIORAL|Community Health Worker Diabetes Education: Print media|Providing information to patients about potential benefits, harms, costs, and burdens of medications and discussing patients' treatment preferences.
224169195|NCT01427660|BEHAVIORAL|CHW Diabetes Education: tailored web site|Providing tailored and interactive information to patients about potential benefits, harms, costs, and burdens of medications and discussing patients' treatment preferences.
224169196|NCT06338852|OTHER|Socio demographic and evaluation questionnaires|Socio demographic and evaluation questionnaires Used to measure the awareness of gynaecologists about role of physical therapy in genital prolapse
224169197|NCT02683460|PROCEDURE|Patella resurfacing|
223481509|NCT05254379|DEVICE|tDCS|"tDCS is a painless brain stimulation treatment that uses direct electrical currents (at a constant, low-intensity level) to stimulate specific parts of the brain and help modulate neuronal activity. Participants will receive a series of tDCS treatments during the Intensive Outpatient Program (IOP) coupled with blood and saliva collections.~Participants will administer a stimulation session via the Soterix 1x1 tDCS mini-CT Stimulator, after being provided a single-use code to unlock the device by the research staff once proper contact quality is achieved. After the participant enters the unlock code, the screen on the device will show a timer that counts down the minutes until the end of the session. After 20 min, the device will turn off automatically and the study staff will instruct the participant to remove the headset and discard the sponges and to store safely all materials for the next session."
223481510|NCT03083041|BIOLOGICAL|SHR-1210|SHR-1210 will be administered as a 30-minute IV infusion Q2W at a dose of 200mg
223481511|NCT03083041|DRUG|Apatinib|Apatinib tablet will be administered orally,once daily until progression
223481512|NCT03185208|DRUG|Lithium Carbonate|See lithium carbonate arm
223481513|NCT03185208|DRUG|Placebo oral capsule|See placebo arm
223481514|NCT05364424|DRUG|Glofitamab|Participants will receive intravenous (IV) glofitamab for up to 3 cycles.
223481515|NCT05364424|DRUG|Obinutuzumab|Participants will receive IV obinutuzumab on Cycle 1 Day 1.
224169198|NCT02683460|PROCEDURE|Patella retention|
223481516|NCT05364424|DRUG|Tocilizumab|Participants will receive IV tocilizumab as necessary to manage cytokine release syndrome (CRS) events.
223481517|NCT05364424|DRUG|Rituximab|Participants will receive up to 2 doses of IV rituximab.
223481518|NCT05364424|DRUG|Ifosfamide|Participants will receive IV ifosfamide for up to 3 cycles.
223481519|NCT05364424|DRUG|Carboplatin|Participants will receive IV carboplatin for up to 3 cycles.
223481520|NCT05364424|DRUG|Etoposide|Participants will receive IV etoposide for up to 3 cycles.
223481521|NCT04960267|DEVICE|Use of pre-peritoneal drainage after rTAPP|Use of pre-peritoneal drainage after rTAPP
223481522|NCT01855269|DIETARY_SUPPLEMENT|Lactobacillus reuteri|Lactobacillus reuteri (BioGaia, Stockholm, Sweden):at a dose of 100 million colony forming unit in 5 drops, 30 minutes after feeding, once per day for 3 weeks
223481523|NCT01855269|DIETARY_SUPPLEMENT|Herbal drop|Herbal drop containing sodium bicarbonate, Pimpinella anisum oil,foeniculum vulgare oil, Mentha piperita (Babs, Berko, Istanbul, Turkey):5 drops 30 minutes after feeding, once per day for 3 weeks
223481524|NCT01855269|DIETARY_SUPPLEMENT|placebo sterile water|
223481525|NCT00573924|DRUG|Proton pump inhibitor (lansoprazole)|"1. 120 mg PO and then 30 mg PO q 3 h from 3 to 21 hrs~2. 90 mg IV bolus followed 9 mg/hr infusion for 24 hrs"
223481526|NCT03834350|OTHER|BREATHES Program|Participants will complete inhaler education using the virtual education module at the baseline visit of the study. Additionally, they will be asked to complete the lesson at least once before their 30 day follow-up visit on their personal device once they have been discharged from the hospital. At the time of their initial study visit, study participants will be given a SpiroPD device for use at home following instruction in the hospital or clinic. Patient adherence to daily testing over one-month will be monitored using real-time capture Wi-Fi-data from the SpiroPD data portal. A small device will be attached to track real-time medication use.
224072242|NCT02573155|DRUG|Treatment D, Tiotropium 18 μg (Part 2)|18 μg of Tiotropium once on Day 1; each dose of Indacaterol dry inhalation powder will be administered via a dry powder inhaler (HandiHaler®) as 1 hard capsule
224072243|NCT00179582|DRUG|VSL#3|
224072244|NCT02173743|OTHER|PRP|platelet enriched autologous blood plasma
224072245|NCT02173743|OTHER|Control|Regular barbotage/care as usual
224072246|NCT04963257|DRUG|sertraline fluvoxamine|the initial dose of sertraline was given 50mg/d and the initial dose of fluvoxamine was 50mg/d, and the target dose of sertraline was gradually increased to 200mg/ d and the target dose of fluvoxamine was 200-300mg/d within 2 weeks, and the specific dose adjustment process was determined by the doctors on the basis of patients' conditions
224072247|NCT04963257|DRUG|sertraline|The initial dose of sertraline was 50mg/d and the initial dose of aripiprazole was 5mg/d. The target dose of sertraline was 200mg/ d and the target dose of aripiprazole was 5-20mg/d within 2 weeks, and the specific dose adjustment process was determined by the doctors on the basis of patients' conditions
224072248|NCT01148277|DRUG|Propofol and Remifentnyl|Intervention group (Propofol and remifentanyl): It will be administered under direct gastroenterologists' and hepatologist
224072249|NCT01148277|DRUG|midazolam and fentanyl|Intervention group (Propofol and fentanyl ): It will be administered under direct gastroenterologists'and hepatologist
224072250|NCT01148277|DRUG|midazolam anf fentanyl|group (Midazolam with Fentanyl): Both drugs will be administered by the gastroenterologists and/ or hepatologist and/ or anesthiologist
224072251|NCT00903929|DRUG|Eltrombopag|dose escalation
224072252|NCT04397094|DRUG|Theracal LC|pulpotomy
224072253|NCT04397094|DRUG|Formocresol|Pulpotomy
224072254|NCT02189850|DRUG|BLI800 - Dose 1|BLI800 oral solution
224072255|NCT02189850|DRUG|BLI800 - Dose 2|BLI800 oral solution
224072256|NCT01076582|DRUG|EE20/DRSP (YAZ, BAY86-5300)|4 cycles of treatment / per cycle: 1 tablet (EE 0.02 mg / DRSP 3 mg) daily for 24 days followed by 1 placebo tablet daily for 4 days
224072257|NCT01076582|DRUG|Ethinylestradiol (EE) and desogestrel (DSG) (Mercilon)|4 cycles of treatment / per cycle: 1 tablet (EE 0.02 mg / DSG 0.15 mg) daily for 21 days followed by 1 placebo tablet daily for 7 days
224072258|NCT03290495|DRUG|ketamine|ketamine hydrochloride 250microgram/ ml for iv injection after 30 minutes of stable isoflurane anesthesia
224072259|NCT03290495|DRUG|saline|a similar volume of normal saline 0.9% for intravenous injection instead of ketamine will be given to the control group. this because the attending anesthesiologist will be blinded to the study drugs and aim according to the study proposal.
224072260|NCT01141595|DRUG|sapropterin dihydrochloride|Patients will be instructed to take 20 mg/kg/day of Kuvan® orally dissolved in 4 - 8oz. of water or apple juice with breakfast.
224072261|NCT05427266|OTHER|Tap Block - Bupivacaine|The medicinal product for both groups is the same - Bupivacaine. The mode of administration is what this study is reviewing: Control group (Standard port site infiltration) and Study Group - Laparoscopic Transversus Abdominis Plane Block (LTap Block)
224072262|NCT01716572|DRUG|Erythromycin|Intravenous 250 mg of erythromycin, single-dose, 30 minutes before the endoscopy
224072263|NCT01716572|PROCEDURE|gastric lavage|gastric lavage by nasogastric tube with 1 liter of saline before the endoscopy
224072264|NCT04082000|DRUG|BOL-DP-o-04|BOL-DP-o-04
224072265|NCT04082000|DRUG|Placebo|Placebo
224072266|NCT03150225|OTHER|Concurrent training|"In this protocol the participants will perform aerobic and resistance training according to published evidence for middle-aged men; Characterized as concurrent training.~The protocol will last six months and will be divided into two quarters. In the first trimester, initial 30 minutes will be assigned to resistance training, followed by 30 minutes of aerobic training; Already in the second trimester will be 20 initial minutes for the aerobic training and later 40 minutes for the resistance training; Aiming to obtain benefits in the levels of muscular strength, aerobic capacity, body composition, besides positive results in relation to the hormonal adaptations of testosterone, as well as in the psychological well being of the participants. Classes will occur at a frequency of three times weekly, lasting 60 minutes a session."
224072267|NCT03150225|DIETARY_SUPPLEMENT|Eurycoma longifolia|Eurycoma longifolia will be administered by supplementation with the standard aqueous-soluble extract extract (Physta ™) in single 200mg capsules daily, and placebo by starch capsules. The supplementatio will last six months.
224169199|NCT04296929|OTHER|Complex Decongestive Physiotherapy|Complete decongestive therapy (CDT), also called complex decongestive therapy, is an intensive program that combines many of the different treatment approaches, including bandaging, compression garments, manual lymphatic drainage, exercise, and self care.
224169200|NCT01885104|DRUG|Polyethylene Glycol (PEG 3350)|Oral 17 g dose of PEG 3350 solution concentrate in a volume of approximately 30 mL, once a day, for 14 days.
224169201|NCT01885104|DRUG|Placebo|Oral 17 g dose of Placebo solution concentrate in a volume of approximately 30 mL, once a day, for 14 days.
224169202|NCT01885104|DRUG|Bisacodyl laxative tablets (rescue medication)|5.0 mg tablets, 1 to 3 tablets in a single daily dose, to be provided for use as rescue medication if participant has not had bowel movement for 72 hours after start of treatment.
224169203|NCT03887286|DEVICE|Philips EPIQ 7 ultrasound machine|Standard transthoracic echocardiography
224169204|NCT03887286|DEVICE|Philips Lumify Broadband sector array transducer|Portable hand-held ultrasound device
224169205|NCT05823649|DIETARY_SUPPLEMENT|Early feeding/intervention group|The patients will be given orally 5 to 10 ml of warm water as first feeding. If there will be no problem of swallowing and other clinical complication, they will be further provided 20 ml of water after 10 minutes. If further patients do not suffer from nausea, vomiting and other discomfort, 100 ml clear fluid or less than it will be provided as based on the protocol followed by the study. We will use oral rehydration solution (ORS) as clear fluid.
224169206|NCT04236531|OTHER|Cognitive tests and neuroimaging|comparison of cognitive performances and brain anatomy
224169207|NCT02419586|OTHER|bubble gum|Chewing gum group patients performing gum chewing on postoperative day 1 at three times daily for 30 minutes after operation and until discharged.
224169208|NCT04369586|DRUG|meplazumab for injection|single dose: 6 dose level, multiple dose: 0.3mg/kg/dose
224169209|NCT04369586|DRUG|Placebo|placebo
224169210|NCT00895908|BEHAVIORAL|Friendship Group|Social skills training for 30 sessions, held twice per week over 4 to 5 months
224169211|NCT00895908|BEHAVIORAL|Academic tutoring|Tutoring to support emergent literacy skills, held 1 to 2 times per week over 4 months
224169212|NCT05622656|DRUG|Dexmedetomidine|Dexmedetomidine 0.0005%
224169213|NCT05622656|DRUG|Placebo|0.9% Sodium Chloride Solution
224169214|NCT03304093|DRUG|Nivolumab Injection|Nivolumab 3mg/kg every 2 weeks
224169215|NCT04046601|DEVICE|impedance|After endoscopic resection of early esophageal cancer, the tissue will be measured by an impedance probe between 10Hz-1000000Hz, 20mV. 8 gold electrodes have been integrated to the probe. The impedance will be measured in different ways between the elctrodes. There will be 10 measurements in total for each specimen.
224169216|NCT00113555|DEVICE|ACT (Adjustable Continence Therapy)|surgically implanted device
223481527|NCT03834350|DEVICE|BREATHES SpiroPD or Propeller Health|At the time of their initial study visit, study participants may be given a SpiroPD device for use at home following instruction in the hospital or clinic. Patient adherence to daily testing over one-month will be monitored using real-time capture Wi-Fi-data from the SpiroPD data portal. A small device will be attached to track real-time medication use.
223481528|NCT02410629|DEVICE|Music Glove|Participants will exercise at home using the music glove for 3 times a week for 3 weeks with a minimal of 3 hours per week.
223481529|NCT02410629|OTHER|Conventional Hand Exercise Program|Participants will exercise at home using the hand exercise program designed by an occupational therapist for 3 times a week for 3 weeks with a minimal of 3 hours per week.
223481530|NCT04121143|BIOLOGICAL|IL-17A Antagonist|SHR-1314 subcutaneous injection
223481531|NCT04121143|BIOLOGICAL|Placebos|placebo subcutaneous injection to maintain consistency and to prevent blindness
223481532|NCT05675800|DRUG|Psilocybin|Psilocybin administered with psychological support
223481533|NCT04789122|OTHER|Attitude assessment|The study covered a representative group of 1000 people. Own questionnaire and standardized tools sent online via the Statistical Research and Analysis Office, in compliance with the privacy policy and personal data protection of the General Data Protection Regulation.
223481534|NCT04968236|OTHER|Deep Dry Needling|In-and-out into different directions technique to encounter sensitive spots in an MTrP region.
223481535|NCT04968236|OTHER|Superficial Dry Needling|This technique involves inserting a needle at a depth that is into the subcutaneous tissue and may be combined with manipulation of the needle while in situ.
223481536|NCT04968236|OTHER|passive stretching|Type of stretching in which you stay in one position for a set time. In this case, hip extension and knee flexion.
224169217|NCT03749850|DRUG|LTLD|"Patients will receive up to six cycles at three-weeks intervals of:~* Intravenous LTLD dosed at 50mg/m2 administered during the MR-HIFU treatment~* 60 minutes of MR-HIFU mild local hyperthermia at 40 °C - 42 °C to the primary breast tumour~* Intravenous Cyclophosphamide 600 mg/m2 after MR-HIFU treatment~In case of toxicity, LTLD, cyclophosphamide and/or hyperthermia dosages will be adjusted as specified in the study protocol."
224169218|NCT03749850|PROCEDURE|MR-HIFU induced hyperthermia|"Patients will receive up to six cycles at three-weeks intervals of:~\- 60 minutes of MR-HIFU mild local hyperthermia at 40 °C - 42 °C to the primary breast tumour.~In case of toxicity, hyperthermia dosages will be adjusted as specified in the study protocol."
224169219|NCT03749850|DRUG|Cyclophosphamide|"Patients will receive up to six cycles at three-weeks intervals of:~\- Intravenous Cyclophosphamide 600 mg/m2 after MR-HIFU treatment~In case of toxicity, cyclophosphamide dosages will be adjusted as specified in the study protocol."
224169220|NCT04426240|DRUG|Cyclosporine microemulsion|Intervention group receives topical cyclosporine dry eye treatment before cataract surgery
224169221|NCT01576224|DEVICE|"Removable splint omni med, Fischer Medical Aps, DK-2800 Lyngby, Denmark"|To be removed during training exercises three to five times a day
224169222|NCT01864486|DEVICE|Intelligent Retinal Implant System|
224169223|NCT05307523|DEVICE|Enriched Play Environment with Partial Body Weight Support Harness|A low-tech portable canopy with a partial-body weight harness system that allows a child and their caregiver to play freely in an 81 square foot space, which provides partial body weight offset to support movement and exploration.
224169224|NCT05307523|OTHER|Enriched Play Environment without Partial Body Weight Support Harness|Child and caregiver will play freely in the 81 square foot play space without being connected to the partial body weight support harness.
224169225|NCT01562197|DRUG|axitinib|The starting dose of axitinib (AG-013736) is 5 mg BID administered orally with food.
224169226|NCT01562197|DRUG|Axitinib plus Lomustine|Lomustine 90mg/m²
223585127|NCT05102968|BEHAVIORAL|Supervised rehabilitation by the therapist|For patients with therapist supervised rehabilitation, patients attended one-on-one instructions with a therapist (once a week at post-operative 2nd\~12th week and once two weeks at post-operative 13th\~24th week; totally 16 sessions in the 6-month rehabilitation program) and exercised under supervision at hospital. Subjects would receive additional sessions based on the rehabilitation progress. Subjects could cancel scheduled sessions by personal reasons. We provided telephone consultation without APP communication for subjects in the supervised group.
223744934|NCT05409144|PROCEDURE|Thoracic epidural infusion|Upon locating the desired site spot, lidocaine 1% must be injected into the skin and underlying tissues to decrease the discomfort with the advancement of the epidural needle. Once achieving local anesthesia, the epidural needle advanced with its stylet in place and with its bevel point cephalad; this will ultimately contribute to the proper location of the epidural catheter. The epidural needle must be advanced through the skin, subcutaneous tissue, supraspinous, and interspinous ligaments. Once there, the stylet must be removed, and the Loss of Resistance syringe (filled up with saline, air, or both) must be attached to the needle. The needle must be advanced while applying pressure to the plunger. Once the ligamentum flavum is pierced, a loss in resistance will be noted; this is the epidural space, and 5 to 10 cc of saline is injected to expand the epidural space; this may decrease the risk of vascular injury.
224072268|NCT03347071|BEHAVIORAL|Prevention Course Group|The undergraduate prevention course is structured around Eat Breathe Thrive Program curriculum. The course aims to teach somatic practices, provide healthy tools for emotional regulation, allow for the creation of community-based networks of support, foster a sense of meaning and purpose through service activities, and practice these learned skills through yoga.
223481537|NCT02765165|DRUG|USL311|Administered once weekly in a 21-day cycle
223481538|NCT02765165|DRUG|USL311|Administered once daily in a 21-day cycle
224072269|NCT05051007|DRUG|fentanyl|patients will receive 1 mcg/kg of fentanyl (the drug will be diluted to 10 mcg/mL)
224072270|NCT05051007|DRUG|Lidocaine IV|patients will receive 1 mg/kg lidocaine (the drug will be diluted to10mg/mL)
224072271|NCT02820428|OTHER|Healthy participants|Semi-structured interview
224072272|NCT03580421|PROCEDURE|ambulatory surgery|total hysterectomy and bilateral salpingo-oophorectomy with or without lymphadenectomy
223481539|NCT02765165|DRUG|USL311|Administered once daily in a 42-day cycle
223481540|NCT02765165|DRUG|Lomustine|Administered once every 6 weeks in a 42-day cycle
223481541|NCT00006032|DRUG|etoposide|
223481542|NCT00006032|DRUG|ifosfamide|
223481543|NCT00006032|DRUG|topotecan hydrochloride|
223481544|NCT00006032|PROCEDURE|peripheral blood stem cell transplantation|
223481545|NCT06551753|OTHER|virtual reality app|virtual reality app
223481546|NCT05337761|BEHAVIORAL|Peer-led training on lifejacket wear|Training on proper lifejacket wear will be given to peers who will be the change agents amongst their fellow boaters
223481547|NCT03732378|DIETARY_SUPPLEMENT|Omega-3 capsule|Daily one capsule of omega-3 (EPA 300mg, and 200mg DHA) were given anti depressent( citalopram, escitalopram, paroxetine 1 tablet at night time)
223585128|NCT05848765|DRUG|Epcoritamab|Bispecific antibody
223585129|NCT05848765|DRUG|Lenalidomide|Immunomodulatory agent
224072273|NCT03580421|PROCEDURE|standard surgery|total hysterectomy and bilateral salpingo-oophorectomy with or without lymphadenectomy
224072274|NCT02147483|BEHAVIORAL|Mindfulness Based Relapse Prevention|Mindfulness based relapse prevention therapy provided over eight sessions in person to prevent alcohol relapse.
224072275|NCT02147483|BEHAVIORAL|Treatment as usual|Treatment usually provided by clinician
224072276|NCT06062862|DEVICE|The Incentive Spirometer|Tri-flow device flow-oriented incentive spirometer .
224072277|NCT06062862|DEVICE|The breather respiratory muscle training device|The breather respiratory muscle training device which allows for adjustable levels of resistance using easy-to-read dials, which allows to adjust the device to the settings require
224072278|NCT04850209|OTHER|oral and written education|oral and written education
224072279|NCT04850209|OTHER|Wechat group|Wechat group: oral and written education plus Wechat group based interactive education provided by medical professional
224072280|NCT03183882|BEHAVIORAL|Personal Feedback|One-time summary report of their individual history of opioid prescribing over the past 14 months
224072281|NCT03183882|BEHAVIORAL|Peer Normative Comparison Feedback|One-time summary report of their individual history of opioid prescribing over the past 14 months WITH comparisons to (a) other providers at their site and (2) other providers at all 15 ED sites with similar prescribing
224072282|NCT00971386|BEHAVIORAL|Slow breathing|The subjects will be given instructions in slow breathing at a rate of 6 to 10 breaths per minute and asked to practice it for some time. Hemodynamic measurements would be repeated before, during and after the trial of slow breathing. A Noninvasive Cardiac Output Monitor will be used. It uses a technology called impedance to measure cardiac output and other hemodynamic parameters by the passage of electric currents through the thorax. This device uses four electrode stickers applied to the thorax and the neck.
224072283|NCT00516737|DRUG|Comparator: rizatriptan benzoate|Rizatriptan 10 mg Orally Disintegrating Tablet (ODT); one dose, treatment of a single migraine attack
224072284|NCT00516737|DRUG|Comparator: Placebo|Matching placebo; one dose, treatment of a single migraine attack
224072285|NCT03405948|DRUG|Intra muscular injection of Botulinum toxin|posture and gait analysis were performed before injection and 4 to 6 weeks after injection
224072286|NCT03911765|BEHAVIORAL|digital cognitive training|Digital cognitive exercises, used in the intervention group, have the primary objective of stimulating executive functions, and will be made available through the Internet using the BrainHQ platform.
224072287|NCT05578742|PROCEDURE|PEEP increase|Positive End Expiratory Pressure (PEEP) will be increased from 5 to 15 cmH2O.
224072288|NCT05578742|PROCEDURE|PEEP decrease|Positive End Expiratory Pressure (PEEP) will be decreased from 15 to 5 cmH2O.
224072289|NCT02423915|DRUG|Rituximab|375 mg/m2 by vein on Day -12 for for participants with CD20+ malignancies.
224072290|NCT02423915|DRUG|Fludarabine|40 mg/m2 by vein on Days -8 to -5.
224072291|NCT02423915|DRUG|Cyclophosphamide|50 mg/kg by vein on Day -8.
224072292|NCT02423915|RADIATION|Total Body Radiation|2 Gy delivered on Day -4.
224169227|NCT00417833|DRUG|Intravitreal Bevacizumab|
224169228|NCT02244125|DRUG|PCD|"STUDY TREATMENT PHASE: All patients~* 4x 28 days cycles of PCD~\[Pomalidomide: 4mg/day oral route on 21 days per cycle\]~\[Cyclophosphamide: 300mg/day oral route on days 1, 8, 15, 22 per cycle\]~\[Dexamethasone: 40mg/day oral route on days 1, 2, 3, 4 and 15, 16, 17, 18 per cycle\]~CONSOLIDATION PHASE: depends on previous IFM/DFCI 2009's arm:~Arm A:~* Melphalan 200mg/m2 followed by Autologous Transplantation~* 2x 28 days cycles of PCD, three months post transplantation~Arm B:~* 5x 28 days cycles of PCD~\[Pomalidomide: 4mg/day oral route on 21 days per cycle\]~\[Cyclophosphamide: 300mg/day oral route on days 1, 8, 15, 22 per cycle\]~\[Dexamethasone: 40mg/day oral route on days 1, 8, 15, 22 per cycle\]~MAINTENANCE PHASE: All patients~\- Until progression/relapse or discontinuation for any other reason~\[Pomalidomide: 4mg/day oral route on 21 days per cycle\]~\[Dexamethasone: 20mg/day oral route on days 1, 8, 15, 22 per cycle\]"
224169229|NCT02244125|PROCEDURE|Autologous transplantation (ASCT)|"Arm A:~•Melphalan 200mg/m2 followed by Autologous Transplantation"
224169230|NCT04552067|DRUG|Lovenox|patients given curative dose of Lovenox
224169231|NCT04552067|DRUG|Enoxaparin|patients given curative dose of Enoxa
224169232|NCT05758974|PROCEDURE|dental treatment|Extraction, pulp therapy or both
224169233|NCT00374127|DRUG|Marijuana blunt|Blunts were fabricated by cutting the bottom third off a Dutch Master® cigar, removing all of the cigar tobacco, and replacing it with all of the marijuana contained in a NIDA marijuana cigarette (ca. 800 mg).
224169234|NCT00374127|DRUG|marijuana cigarette|Marijuana cigarettes were provided by the National Institute on Drug Abuse.
224169235|NCT04035473|DRUG|HM30181 methanesulfonate monohydrate plus oral paclitaxel capsules|"HM30181 methanesulfonate monohydrate plus oral paclitaxel capsules~Oral paclitaxel capsules"
224169236|NCT01040494|DRUG|Aliskiren|all eligible patients will be randomized to receive aliskiren 150 mg on top of optimal HF therapy, including ACEI, ARB, beta blockers as considered appropriate by the investigator and in accordance with standard therapy guidelines for 6 months
224169237|NCT01040494|DRUG|Placebo|all eligible patients will be randomized to receive placebo on top of optimal HF therapy, including ACEI, ARB, beta blockers as considered appropriate by the investigator and in accordance with standard therapy guidelines for 6 months
224169238|NCT00166621|DRUG|Buspirone|
224169239|NCT04610320|DRUG|Daratumumab-SC|\>Daratumumab-SC 1800 mg subcutaneous weekly for 8 doses and then every other week for 2 doses.
224169240|NCT02875366|DRUG|LUM/IVA|
224169241|NCT02875366|DRUG|Placebo|
224169242|NCT01145404|DRUG|Lapatinib|Lapatinib (Tyverb) po 1500mg daily d1-21, new cycle will be started on day 22 until progression.
224169243|NCT01145404|DRUG|Lapatinib plus capecitabine|Lapatinib po 1250mg daily d1-21; new cycle will be started on day 22 until progression
224169244|NCT01531933|DRUG|DLBS3233|For the first 4 weeks, subjects should take DLBS3233 at the dose of 50 mg once daily. For the next (or last) 8 weeks, all subjects who do not respond well (poor responders) to the study regimen will receive a titrated dose of 100 mg once daily, while the (good) responders will remain at the previous dose regimen. Good responders are defined as those who achieve 2h-PG level of \< 140 mg/dL or a decrease of 2h-PG level of ≥ 10% from baseline; otherwise will be called poor responders. At every study visit, subjects will be provided with an education on lifestyle modification given by the assigned nutritionist.
224169245|NCT01531933|DRUG|Placebo of DLBS3233|For the first 4 weeks, subjects should take placebo of DLBS3233 at the dose of 50 mg once daily. For the next (or last) 8 weeks, all subjects who do not respond well (poor responders) to the study regimen will receive a titrated dose of 100 mg once daily, while the (good) responders will remain at the previous dose regimen. Good responders are defined as those who achieve 2h-PG level of \< 140 mg/dL or a decrease of 2h-PG level of ≥ 10% from baseline; otherwise will be called poor responders. At every study visit, subjects will be provided with an education on lifestyle modification given by the assigned nutritionist.
224169246|NCT01220596|DRUG|Entecavir and Pegylated interferon α-2a Sequential Treatment Group|Entecavir/Baraclude(TM), 0.5mg, oral administration, once daily, for the first 12 weeks Pegylated interferon α-2a/Pegasys(TM), 180mcg, subcutaneous injection. once a week, from week 4 to 52 for 48 weeks
224169247|NCT01220596|DRUG|Pegylated interferon α-2a Monotreatment Group|Pegylated interferon α-2a/Pegasys(TM), 180mcg, subcutaneous injection. once a week, for the first 48 weeks
223481548|NCT02528448|DRUG|Plasma-lyte|Continuous 1 hour infusion of plasma-lyte 15 micrograms/kg/hour for the first hour then 5 micrograms/kg/hour + amount needet for blood replacement
223481549|NCT02528448|DRUG|0,9% saline|Continuous 1 hour infusion of 0,9% saline 15 micrograms/kg/hour for the first hour then 5 micrograms/kg/hour + amount needet for blood replacement
223481550|NCT01186770|DRUG|Methylnaltrexone|Methylnaltrexone will be administered as per the dose and schedule specified in the respective arms.
223481551|NCT01186770|DRUG|Placebo|Placebo matching to methylnaltrexone will be administered as per the schedule specified in the respective arms.
223481552|NCT02567188|OTHER|MIRCERA|
223481553|NCT02964624|OTHER|Rehabilitation|Protocol will consist of three exercise/week for eight weeks. Each session will begin with the evaluation of pain by the volunteer. Starting with a warm up exercise in a cycle ergometer (CEE), for 5 minutes at free cadence, then the intensity will be set at 90% of the intensity obtained during the incremental test and maintained for 10 min. Afterward, four sets of three different resistance exercises (RE) will be performed at 70% of the load correspondent to 1RM test with one minute interval between sets and exercises. During CEE Borg scale will be taken every two minutes and during RE the OMNI scale taken at the end of every set to monitor the intensity. At the end of the session, cool down global stretching exercises for inferior members will be performed and the VAS evaluated.
223481554|NCT02686411|OTHER|Survey Administration|Complete survey
223481555|NCT00930462|DEVICE|Cap (Olympus Medical Systems: D-201-15004, D-201-14304 and D-201-12704)|Plastic cap fitted on the colonoscope
224305455|NCT04263402|DRUG|Methylprednisolone|Patients in the Group II will receive basic symptomatic supportive treatment,plus methylprednisolone(40\~80mg/d intravenous drip for 7 days).
224305456|NCT05656521|DRUG|101-PGC-005|'005 is a targeted prodrug of dexamethasone that binds to activated macrophages.
224305457|NCT05656521|DRUG|Dexamethasone|Dexamethasone is a glucocorticoid commonly prescribed to treat inflammation.
224305458|NCT02553902|DEVICE|Sleep position trainer|
223585130|NCT05848765|DRUG|Rituximab|Monoclonal antibody
223585131|NCT05848765|DRUG|Obinutuzumab|Monoclonal antibody
224169248|NCT02308904|OTHER|Blood Draw/Semen Exam|"Females:~1\. Obtain levels of LH/FSH, Estradiol, and AMH in all enrolled women. Males: We expect to enroll approximately 15 males ages 12 years and older.~1. Levels of FSH/LH and testosterone will be obtained. In addition, we will examine the association of the hormone inhibin B with mean fertility measures. Inhibin B levels were shown to correlate with azospermia and could demonstrate better prediction of reproductive potential.~2. Semen exam for determination of volume, sperm count, motility and sperm DNA integrity will be determined for interested adult thalassemia males (age ≥18 years and older)."
224169249|NCT02308904|OTHER|Retrospective data/Chart Review/Relevant Clinical Results|"1. 1\. Documentation of liver iron from SQUID or MRI. 2. Transfusion data on age at onset of regular transfusions, transfusion frequency over the previous five years, and years of chronic transfusion therapy (defined as 8 or more per year). 3. Data on cardiac iron as indicated by T2\* MRI. 4. Ferritin levels.~2. NTBI will be accessed using a mobilizer ligand to collect NTBI from all pools as Fe-NTA which is then measured by HPLC.~3. 1\. Age at onset of chelation 2. Estimated periods of known or recalled non-compliance with regular chelation. 3. Listing of all chelation drugs previously used including dose and time period.~4. 1\. Vitamins E and C, at time closest to obtaining reproductive hormone levels. 2. Measuring the ratio of reduced gluthatione (GSH) to oxidized gluthatione (GSSG).~5. Assessment of time for pubertal development, assessment of menstrual history and need for treatment with gonadal hormone replacement."
224169250|NCT02308904|OTHER|Pituitary MRI|"MRI has been shown to demonstrate well the changes related to iron toxicity in the pituitary gland. An MRI protocol was optimized at Children's Hospital and Research Center Oakland (CHRCO) and Texas Children's Hospital. Utilizing 1.5 T clinical scanner to evaluate the iron accumulation in the anterior pituitary. The total data acquisition time is approximately 32 minutes. No sedation will be given.~MRI data will be sent to Dr. Wang, department of Radiology, Children's Medical Center, University of Texas Southwestern Medical Center, Dallas, Texas. Quantification of R2, pituitary height and volume will be conducted."
224169251|NCT03592173|DIAGNOSTIC_TEST|Paired TMS & Peripheral Nerve Stimulation|Method of assessing neurophysiology and activity of the spinal cord
224169252|NCT06700291|PROCEDURE|Surgery|Patient undergoing Anesthesia and Surgery
224169253|NCT02735044|DRUG|Insulin glargine,300 U/mL|Subcutaneous injection in the morning or evening using a prefilled pen. Dose titration to achieve fasting self-monitored plasma glucose (SMPG) from 90 to 130 milligram/deciliter (mg/dL) (5.0 to 7.2 millimol per liter \[mmol/L\])
224169254|NCT02735044|DRUG|Insulin glargine (100 units /mL)|Subcutaneous injection in the morning or evening using a prefilled pen. Dose titration to achieve fasting SMPG from 90 to 130 mg/dL (5.0 to 7.2 mmol/L)
224169255|NCT02735044|DRUG|Background therapy|Fast-acting mealtime insulin analogs
224169256|NCT00004728|DRUG|Warfarin|
224169257|NCT00004728|DRUG|Aspirin|
224169258|NCT03088410|DRUG|Zidovudine|neonatal 4 weeks prophylactic
224169259|NCT03088410|DRUG|Nevirapine|neonatal 4 weeks prophylactic
224169260|NCT03435328|DEVICE|TENS|"* Duration of stimulation: 5 minutes.~* Frequency: will be fixed at 50 Hertz.~* Pulse duration: 250 µs.~* Intensity: optimal intensity of TENS (amplitude will be gradually increased to the maximum intensity that the subject will be comfortable and tolerate it).~* Sessions: only one session"
223481556|NCT04409613|OTHER|Education and counseling|All patients or their caregivers will receive twenty minutes educational sessions for the first three visits according to patient ability to understand. At subsequent visits along the study duration, we will briefly review our educational material to refresh the patient's information. This will include: The objectives of treatment, disease progression process, risk factors, common symptoms of bleeding/thrombotic events and how to deal with this. Lifestyle modifications, including smoking cessation, blood pressure and diabetes control. Drug information: drug action, dose, indication, possible side effects, how to deal with the side effects, actions to take when missing the dose, storage conditions and when and how to administer. Possible interactions including drug-drug and drug-food interactions. Target INR and INR monitoring
223481557|NCT02645890|DRUG|CKD-397|Arm A:Tamsulosin/ Tadalafil Fixed dose combination
223481558|NCT02645890|DRUG|TD+TM|Arm B: Tamsulosin/ Tadalafil Coadministration
223481559|NCT02844478|BEHAVIORAL|SBP English|The SBP caregiver intervention has been successfully delivered and disseminated in the US. It is currently offered in 9 states and 16 Texas counties . The SBP is designed to a) improve the QoL of family caregivers who provide care for people with ADRD and b) help caregivers manage their stress and cope better with their lives. The SBP is implemented using a Master Trainer/Group Facilitator (lay leader) model. The SBP is a multi-component intervention that meets for 90 minutes once a week for 9 consecutive weeks.
223481560|NCT02844478|BEHAVIORAL|SBP SPANISH|The SBP caregiver intervention has been successfully delivered and disseminated in the US. It is currently offered in 9 states and 16 Texas counties . The SBP is designed to a) improve the QoL of family caregivers who provide care for people with ADRD and b) help caregivers manage their stress and cope better with their lives. The SBP is implemented using a Master Trainer/Group Facilitator (lay leader) model. The SBP is a multi-component intervention that meets for 90 minutes once a week for 9 consecutive weeks. The Spanish translation and cultural adaptation of the SBP has been completed under the direction of the PI.
223481561|NCT00321763|BIOLOGICAL|Candidate Influenza Vaccine GSK1247446A - 3 different formulations|Single dose, Intramuscular injection
223481562|NCT00321763|BIOLOGICAL|Fluarix TM|Single dose, Intramuscular injection
223481563|NCT00405769|DRUG|red yeast rice|600 mg 3 caps bid
223481564|NCT00405769|DRUG|placebo|3 caps bid
224169261|NCT04677803|DRUG|BT200|BT200 is a PEGylated synthetic RNA oligonucleotide
224169262|NCT05136612|OTHER|conventional physiothrapy|Conventional physiotherapy program will be applied to the control group for 6 weeks, 3 days a week, 45 minutes a day. Strengthening, dynamic stretching, coordination and balance exercises and functional exercises for upper and lower extremities will be applied in this treatment program.
223585132|NCT05848765|DRUG|Bendamustine|Alkylating agent (chemotherapy drug)
223585133|NCT05848765|DRUG|Vincristine|Antineoplastic, Vinca Alkaloid
223585134|NCT05848765|DRUG|Doxorubicin|Anthracycline
223585135|NCT05848765|DRUG|Cyclophosphamide|Alkylating agent (chemotherapy drug)
223585136|NCT05848765|DRUG|Prednisone|Corticosteroid
223585137|NCT05848765|DRUG|Investigation agent 2|The drug used in round 2 is yet to be confirmed, round 2 is estimated to open in Q4 2025 and the record will be updated when the drug has been confirmed
224169263|NCT05136612|OTHER|robotic rehabilitation|The study group will be included in the rehabilitation program with the Hocoma brand Armeo Spring pediatric upper extremity robot for 30 minutes a day, 3 days a week, for 6 weeks at hospital. Armeo spring robot enables the individual to perform active movement by carrying the weight of the upper extremity of children who have active movement in their upper extremities but do not have enough strength to overcome gravity with their upper extremities. The individual is actively involved in the study during the study. With the adjustments made, it becomes suitable for use for right and left extremities. In the process of working; The games named High Flyer, Frisbee, Balloons, Goalkepper, Save the Monster, Fishing, Helicopter Rescue, which are included in the Armeo Spring robot and created to increase shoulder, elbow and wrist movements, will be used.
224169264|NCT05625659|DIAGNOSTIC_TEST|Dual-Energy Contrast-Enhanced Spectral Mammography (CESM)|In addition to their standard, digital breast tomosynthesis mammogram (DBT) performed at their regular screening visits, all participants will also receive a contrast-enhanced spectral mammography (CESM). These same diagnostic tests, both the DBT and CESM, with be repeated at 1 year post study entry for all participants. At year 2 post study entry, all participants will return to their usual breast screening exams and no longer received a CESM.
224169265|NCT03374891|OTHER|Educational video and/or handout|The intervention includes a video and/or handout (whichever is easier for the participant) that will give information about defibrillators and about other patients' experiences with their decisions about defibrillators.
224169266|NCT06878131|BEHAVIORAL|Colorectal Cancer|Participants that take part in this research, will be responsible for following study directions and allowing blood samples to be collected every 3 months for correlative studies.
224169267|NCT07100314|DIAGNOSTIC_TEST|Multi-Drug One Step Screen Test Panel (Urine)|Tested positive
224169268|NCT07100314|DIAGNOSTIC_TEST|Multi-Drug One Step Screen Test Panel (Urine)|tested negative
224169269|NCT05976685|PROCEDURE|Left atrial appendage Occlusion|Left atrial appendage Occlusion and therapy with direct oral anticoagulants. Choice of DOAC is at the discretion of the treating physician.
224169270|NCT05976685|DRUG|DOAC|Therapy with direct oral anticoagulants. Choice of DOAC is at the discretion of the treating physician.
224169271|NCT01201967|OTHER|Collaborative care|Study care manager provides psychoeducation, therapy, and care coordination between patient, psychiatrist, and primary medical physicians.
224169272|NCT01201967|OTHER|Usual care|Patient's primary medical physician informed of mental health symptoms/diagnosis
224169273|NCT05844657|OTHER|Case report form|Sociodemographic information (age, gender, height, body mass index, marital status, occupation, education level, contact information), frequency of smoking and alcohol use, frequency of caffeine consumption, frequency of salt consumption, dominant side, background, family history, medical and audiological information were recorded.
224169274|NCT05844657|OTHER|Tinnitus disability scale|Tinnitus disability scale was used to evaluate the tinnitus severity of Meniere's patients. It consists of 25 items in total. The questions are scored between 0-2-4. It is calculated as 'Yes (4 points)', 'Sometimes (2 points)', 'No (0 points)'. Tinnitus level or severity is determined by calculating the total score of the answers given.
224169275|NCT05844657|OTHER|A feeling of fullness and/or pressure in the ear|The feeling of fullness or pressure in the ear was evaluated verbally by receiving yes/no responses from the participants.
224169276|NCT05844657|OTHER|Dizziness intensity and frequency|In order to determine the frequency and severity of dizziness, the participants were asked to mark the appropriate score between 1-10 points.
224169277|NCT05844657|OTHER|Dizziness disability inventory|The dizziness disability inventory was used to determine the disability level of the individuals participating in our study. It consists of 25 questions in total. The questions are scored between 0-2-4. It is calculated as 'Yes (4 points)', 'Sometimes (2 points)', 'No (0 points)'.
224169278|NCT05844657|OTHER|Vertigo symptom scale-short form|The short form of the vertigo symptom scale was used to determine the frequency and duration of vertigo in the individuals participating in our study. The vertigo symptom scale consisting of 8 questions consists of vertigo (VSS-V), and the vertigo symptom scale consisting of 7 questions consists of two subsections consisting of a total of 15 questions: anxiety (VSS-A). Each item; Never (0), Very rarely (1 point), Often (2 points), Often - every week (3 points), Very often - On average, at least twice a week (4 points). The total score ranges from 0 to 60.
224169279|NCT05844657|OTHER|Hearing Impairment Scale|The Adult Hearing Impairment Scale was used to determine the effect of the current hearing impairment levels of the individuals participating in our study on their daily living activities. The scale consists of 25 questions in total. The questions are scored between 0-2-4. It is calculated as 'Yes (4 points)', 'Sometimes (2 points)', 'No (0 points)'. Participants mark the most appropriate expression for them.
224169280|NCT05844657|OTHER|Cervical Range of Motion (CROM 3) device|"Cervical Range of Motion (CROM) device was used to evaluate the sense of proprioception and range of motion (ROM) in the cervical region muscles. A total of six positions were performed: right cervical rotation, left cervical rotation, right cervical lateral flexion, left cervical lateral flexion, cervical extension and cervical flexion."
224169281|NCT05844657|OTHER|Temporomandibular joint range of motion assessment|In our study, the temporamandibular joint range of motion (ROM) was evaluated with a ruler specific to each participant in four positions, including mandibular depression, protraction, and right and left lateral deviation.
224169282|NCT05844657|OTHER|Posture evaluation with New York posture analysis|The New York Posture Evaluation method was used to obtain information about the general posture correctness of the participants. Posture changes that may occur in 13 different parts of the body, 7 from the side and 6 from the back, including the head, neck, shoulder, back, waist, hip and ankle, were examined in the anatomical position of the individuals. As a result of the observation, the posture of the individual was scored according to whether it was severely bad (1 point), moderately bad (3 points), and straight (5 points). The total score obtained varies between 13-65.
224305459|NCT02553902|DEVICE|Mandibular advancement device|
224305460|NCT02553902|DEVICE|Continuous positive airway pressure|
224305461|NCT00569621|DRUG|Moxaverine|intravenous administration
224305462|NCT00569621|DRUG|physiological saline|intravenous administration
223481565|NCT04443192|DRUG|ZF874|ZF874 is a novel chemical chaperone that is specifically designed to rescue the folding of the Z variant of alpha-1-antitrypsin (A1AT). It is being developed for the treatment of alpha-1-antitrypsin deficiency (AATD) caused by the Z-mutation.
223481566|NCT04443192|DRUG|Placebo|Placebo to ZF874
223585138|NCT05848765|DRUG|Investigation agent 3|The drug used in round 3 is yet to be confirmed, round 3 is estimated to open in Q3 2027 and the record will be updated when the drug has been confirmed
223744935|NCT05409144|DEVICE|Erector Spinae Plane Block|The block-level will be at T5. The ultrasound probe will be placed on the back in a transverse orientation to identify the tip of the T5 transverse process; these are recognizable as flat, squared-off acoustic shadows with only a very faint image of the pleura visible. The tip of the transverse process will be centered on the ultrasound screen and the probe will then be rotated into a longitudinal orientation to produce a parasagittal view, in which the following layers will be visible superficial to the acoustic shadows of the transverse processes: skin and subcutaneous tissue, trapezius, erector spinae muscle and T5 transverse process. 3ml lidocaine 1% will be used on skin and subcutaneous fat, Echogenic block needle will be inserted in-plane to the ultrasound beam in a cranial-to-caudal direction until contact is made with the T5 transverse process.
224072293|NCT02423915|PROCEDURE|Fucosylated Regulatory T Cells|"Phase I: Participants treated at cell dose level 1: 1 x 10\^6/kg Fucosylated T-reg cells on Day -1.~Phase II: Participants treated at cell dose level 2: 1 x 10\^7/kg Fucosylated T-reg cells on Day -1."
223481567|NCT05287789|OTHER|Squatting position by footstool|"Before the study, the height of the toilet bowls in the patient rooms was measured as 42 cm. The stools to be used for the study are manufactured by ordering laminated with white medium density fiberboard and synthetic resin resistant to harsh chemicals. Stools are made of high quality non-slip materials for patient safety.~After the first postoperative ambulation, stable patients whose bowel movements resumed met their initial defecation needs with the squatting position created using a stool at the appropriate height on the water closet type toilet.~The patients used footstools throughout a week after discharge at home and in the hospital for defecation."
224305463|NCT00195637|DRUG|Immune Globulin|
224305464|NCT02548611|DRUG|Prasugrel|see arm description
224305465|NCT02548611|DRUG|Clopidogrel|see arm description
223481568|NCT03534674|DIETARY_SUPPLEMENT|vitamin D3|a single oral loading dose of 100,000 IU vitamin D3 on the day of hospital admission for aHSCT, then 2000 IU vitamin D3 daily.
223481569|NCT04369417|BEHAVIORAL|Relaxation Response Resiliency Program for Siblings of Children with ASD|Virtually delivered psycho-educational resiliency training program for teenage siblings of children with ASD.
223481570|NCT05936307|PROCEDURE|High-definition transcranial direct current (HD-tDCS), active condition|Participants will receive a session of active HD-tDCS at a current intensity of 2 mA for a duration of 25min. The placement of electrodes will be determined to specifically target the brain area that has been identified as being involved in the process of externalization, as evidenced by fMRI. During the stimulation, participants will be engaged in a computer-based externalization task.
223585139|NCT01943552|DRUG|placebo|normal saline
224072294|NCT02423915|PROCEDURE|Cord Blood Infusions|Cord blood transplant, MRD, or MUD infused on Day 0.
223585140|NCT01943552|DRUG|ipratropium bromide|ipratropium bromide
223585141|NCT03756831|DIAGNOSTIC_TEST|Core Stability Assessment|Core Stability Assessment will be consisted of bilateral static balance with open and close eye, right foot balance test, and dynamic balance test.
223585142|NCT01600053|DRUG|Lenalidomide|Lenalidomide will be taken orally days 1-21 for up to six 28-day cycles (6 cycles = 1 course of Revlimid consolidation). Revlimid will be initiated at 5mg and can be dose escalated at the start of each cycle based on individual patient tolerability to a maximum of 25 mg. The total number of treatment cycles cannot exceed 12 cycles or two courses of six cycles each.
224072295|NCT02423915|DRUG|Mycophenolate mofetil|15 mg/kg (actual body weight with a maximum dose of 1 gram twice daily) by vein or mouth from Day -3 to Day +100 in the absence of GVHD.
224072296|NCT02423915|DRUG|Sirolimus|12 mg by mouth load followed by 4 mg by mouth daily from Day -3 to Day +180 in the absence of GVHD.
224072297|NCT02423915|PROCEDURE|Bone Marrow Aspiration|Bone marrow aspiration performed at 1, 3, 6, and 12 months after transplant to check status of disease.
224072298|NCT02423915|DRUG|G-CSF|5 mcg/kg/day subcutaneously beginning on D+0, and continuing until absolute neutrophil count (ANC) is \> 500 x 10/L for 3 consecutive days.
224072299|NCT02423915|PROCEDURE|Non-Fucosylated Regulatory T Cells|"Phase I: Participants treated at cell dose level 1: 1 x 10\^7/kg Non-Fucosylated T-reg cells on Day -1.~Phase II: Participants treated at cell dose level 2: 1 x 10\^7/kg Non-Fucosylated T-reg cells on Day -1."
224072300|NCT06667752|DEVICE|Advanced Antibacterial Wound Dressing|For the first 4 weeks, wound dressing will be changed twice weekly. Subsequently, dressing selection and change frequency will be managed by the investigator as part of the standard of care for another 8 weeks.
224072301|NCT06667752|DEVICE|Aquacel Ag+ Extra|For the first 4 weeks, wound dressing will be changed twice weekly. Subsequently, dressing selection and change frequency will be managed by the investigator as part of the standard of care for another 8 weeks.
224072302|NCT04595214|OTHER|TTTS cases are treated by intra-uterine laser for separation.|MC twin anaestemosis separatio by laser. Vasa previa and placenta accreta are treated with steroids or other protocols, Positive trisomies by NIPS undergoes CVS or amniocentesis
224072303|NCT05066490|OTHER|Endurance exercise|Treadmill training at moderate intensity.
224072304|NCT05066490|OTHER|Resistance exersises.|Resistance exercises using the 10 repetition maximum.
224072305|NCT02757170|DEVICE|Thromboelastography|Patients whole blood will be subjected to undergo coagulation process under monitoring with thromboelastography and various tracings will be recorded and will be interpreted as results.
224072306|NCT05072132|OTHER|Personal information on genetic susceptibility to arsenic toxicity|The intervention groups will receive information regarding their genetic results that informs them of their arsenic metabolism efficiency. They will receive this information through a factsheet appropriate for a lay audience. The factsheet will contain information regarding arsenic metabolism and its role in removing arsenic from the body. The factsheet will describe how there is variability among individuals with respect to the efficiency with which arsenic is removed from the body, due to inherited differences in genes that affect arsenic metabolism. The factsheet describe how slower metabolizers remove arsenic slower from the body, which leads to increased in toxicity risk. The factsheet will inform participants in the intervention groups that they have been identified as a slow/fast metabolizer of arsenic based on their genes. This information will be given to participants by the URB staff, with a study physician available to address questions and concerns from the participant.
224169283|NCT05844657|OTHER|Evaluation of the anterior tilt angle of the head|Anterior tilt angles of the head of the participants were evaluated with photographs taken from the lateral (lateral) side. The anterior tilt angle was calculated as the angle between the line drawn between the C7 cervical spinous process and the tragus and the straight line drawn vertically from C7.
224169284|NCT05844657|OTHER|Evaluation of postural balance with the Freemed pressure platform|Postural sway and lower extremity weight transfer were evaluated with the Freemed baropodometric pressure platform (Rome, Italy) system, which has been shown to be valid and reliable.
224169285|NCT05844657|OTHER|Static balance assessment with tandem stance test|In our study, the tandem stance test was used for static evaluation. A total of four assessments were made on the participants, first with their right foot in front, eyes open and eyes closed, then left foot in front with eyes open and eyes closed.
224169286|NCT05844657|OTHER|Dynamic balance assessment with tandem gait test|In our study, the tandem gait test was used for dynamic evaluation. A straight line was created with a white tape attached to the floor, almost 2 feet away from the 10-foot-long wall. The participant was asked to walk along the line created by taping the heel of the forward foot to touch the toe of the back foot, at a comfortable pace in daily life and with eyes open.
224169287|NCT05844657|OTHER|Headache, Temporomandibular pain and Craniocervical pain presence and severity assessment|Headache, temporomandibular pain and craniocervical pain were asked to mark the person from the photographs taken from the front, back and side in the form of a human figure. Pain severity was evaluated with the numerical rating scale (NRS).
224169288|NCT05844657|OTHER|Pain sensitivity assessment in the head, neck, shoulder girdle and upper back region|In our study, muscle tenderness was evaluated by manual pressure algometry and palpation. Muscle tenderness was assessed in the upper and lower regions of the masseter, temporalis, sternocleidomastoid, and upper trapezius muscles on both right and left sides.
224169289|NCT05844657|OTHER|International physical activity questionnaire-measurement of physical activity level with short|The short form of the international physical activity questionnaire was used to determine the physical activity level of the individuals participating in our study. The short form of the international physical activity questionnaire evaluates the last week and consists of a total of 4 sections and 7 questions. Duration of physical activity that requires intense physical effort, such as heavy lifting, soccer, or fast cycling; times of doing moderate physical activities that cause breathing slightly more often than usual; The total duration of walks at work, home, for sports, exercise and hobby, and the total sitting time spent in a day at work, at home or while resting are calculated.
224169290|NCT05844657|OTHER|Evaluation of sleep quality with the Pittsburgh sleep quality index|The Pittsburgh Sleep Quality Index (PUKI) was used to evaluate the sleep quality and disturbance of the individuals participating in our study in the last month. It consists of a total of 24 questions. The participant responds to each item according to the frequency between 0-3 points. The total score (0-21 points) from these components indicates whether the sleep quality is good or not.
224169291|NCT05844657|OTHER|Evaluation of fatigue with the fatigue severity scale|The Fatigue severity scale was used to evaluate the fatigue status of the individuals participating in our study. The scale uses a scoring system ranging from 1-7, which starts as I do not agree (1 point) and increases gradually towards I agree (7 point). It consists of 9 items in total and people mark the option that suits them.
224169292|NCT05844657|OTHER|Evaluation of anxiety-depression status with hospital anxiety and depression scale|The Hospital Anxiety and Depression Scale (HADS) was used to evaluate the anxiety and depression status of the individuals participating in our study. For each item, the participant answers with a four-point (0-3 points) response option. Therefore, the possible score probabilities in line with the answers given are minimum '0' and maximum '21'. The cut-off point for the anxiety subscale is 10 points, while the cut-off point for the depression subscale is 7 points.
224169293|NCT05844657|OTHER|Evaluation of quality of life with short form-12 (SF-12)|The Short form SF-12 Questionnaire was used to evaluate the quality of life of the individuals participating in our study. The summary score of the physical and mental components varies between 0-100, and the higher the score in the components, the better the quality of life.
223481571|NCT05936307|PROCEDURE|High-definition transcranial direct current (HD-tDCS), placebo condition|"Participants will receive a session of placebo HD-tDCS, which will be delivered following the same procedures as active HD-tDCS but the intensity of the current will be set at 2mA during the 30 first seconds at the beginning of the 25-min period of the stimulation, and equal to 0 mA for the reminding period of stimulation to simulate the tingling sensation often experienced by individuals during active stimulation.~The placement of electrodes will be determined to specifically target the brain area that has been identified as being involved in the process of externalization, as evidenced by fMRI. During the stimulation, participants will be engaged in a computer-based externalization task"
223585143|NCT05047575|OTHER|REASSURE|REASSURE utilizes remote patient-reported outcomes assessments to comprehensively assess symptoms, promotes practice change by providing feedback reports to oncologists and engaging primary care providers (PCPs) in survivorship care, and reduces the burden of follow-up by substituting an oncology visit for thriving survivors with reassurance messaging and encouragement to pursue preventive care.
223585144|NCT04047420|DRUG|TAF/EVG Insert|TAF/EVG Insert (20/16 mg) administered rectally by study staff
223585145|NCT04250597|DRUG|GNX102|Dose Escalation
223585146|NCT04250597|DRUG|GNX102|Expansion Phase
223585147|NCT05610046|DEVICE|Infrared sauna heating|Participants will sit in an infrared sauna at 60° Celsius (humidity not controlled in an infrared sauna) for a total of 40 minutes.
223585148|NCT05610046|DEVICE|Sham sauna|Participants will sit in an inactive infrared sauna at room temperature (21° Celsius) for a total of 40 minutes.
223585149|NCT00538993|BEHAVIORAL|Stage based counseling|
223585150|NCT01903889|OTHER|clinic based intervention|counseling C\&T clients on FP; offering condoms, pills and injectables; and referring clients for other FP methods
223585151|NCT01903889|OTHER|clinic and community based intervention|basic intervention is introduced along with an intervention for constructive male engagement in HIV and FP services
223585152|NCT02641522|DRUG|Siltuximab|Single infusion of siltuximab (11 mg/kg)
223585153|NCT05883618|OTHER|Exposure|Human Development Index of Country
223585154|NCT03444012|DRUG|ticagrelor 90 mg|persistence and adherence on ticagrelor in ACS patients
224169294|NCT05844657|OTHER|the International Fall Efficiency Scale|The International Fall Activity Scale (UDES) was used to evaluate both the attack and the general fear of falling of the individuals participating in our study. It consists of 16 questions in total. The answer to each question is marked on a scale between 1 and 4 points. Expressions such as I never worry (1 point), I worry a little (2 point), I am very worried (3 point), I am very worried (4 point) are used as the level of anxiety increases as the score increases. The total score obtained ranges from 16 (no worries) to 64 (extremely worried).
224169295|NCT05844657|OTHER|assessment of muscle performance|In our study, the strength of cervical flexors, anterior and oblique trunk flexors, cervical extensor muscles, back extensor muscles, trapezius muscle, and rhomboid major-minor muscles were evaluated. In addition, the endurance of the deep cervical flexor muscles, cervical flexors and cervical extensor muscles were also evaluated.
224169296|NCT07045519|DEVICE|Local Vibration Therapy|Local vibration (LV) will be applied using the Vibrasens© device (Techno Concept, Mane, France). Vibrasens© is a non-invasive therapeutic mechanical vibrator used for transcutaneous vibratory stimulation in sensorimotor rehabilitation. The system includes one pilot unit, one manual vibrator (VB200), four flat skin contactors for tendon applications, four round skin contactors for surface applications, a power supply, a user manual, and a protocol guide.
224169297|NCT07045519|DEVICE|Sham Vibration|Participants will receive sham stimulation by placing the Vibrasens© device on the same area as the treatment group for 10 minutes, without activating the vibration function. They will be informed that they will only feel the contact of the device.
224169298|NCT06922656|DRUG|Dapagliflozin (DAPA)|The hypothesis tested in the original study was whether the addition of pioglitazone in patients with type 1 diabetes mellitus (T1DM) receiving therapy with dapagliflozin would amplify the decrease in HbA1c and prevent the increase in plasma ketone concentration caused by dapagliflozin.
224169299|NCT06922656|DRUG|Pioglitazone 45 mg|The hypothesis tested in the original study was whether the addition of pioglitazone in patients with type 1 diabetes mellitus (T1DM) receiving therapy with dapagliflozin would amplify the decrease in HbA1c and prevent the increase in plasma ketone concentration caused by dapagliflozin.
224169300|NCT06922656|DRUG|Placebo|Placebo
223481572|NCT01572792|DRUG|Aclidinium bromide/formoterol Fixed-Dose Combination (FDC)|Inhaled Aclidinium bromide/formoterol Fixed-Dose Combination (FDC) high dose, twice per day
223481573|NCT01572792|DRUG|Aclidinium bromide/formoterol Fixed-Dose Combination (FDC)|Inhaled Aclidinium bromide/formoterol Fixed-Dose Combination (FDC) low dose, twice per day
223481574|NCT01572792|DRUG|Aclidinium bromide|Inhaled Aclidinium bromide 400 μg, twice per day
223481575|NCT01572792|DRUG|Formoterol Fumarate|Inhaled Formoterol Fumarate 12 μg, twice per day
223481576|NCT01572792|DRUG|Placebo|Inhaled dose-matched placebo, twice per day
223481577|NCT04777513|PROCEDURE|CCTA (Coronary Computed Tomography Angiography)|Per the protocol, patients had a coronary computed tomography angiography within standard of care before the enrollment to the study.
223481578|NCT04777513|PROCEDURE|ICA (Invasive Coronary Angiography)|Per the protocol, patients will have an Invasive Coronary Angiography within standard of care.
223481579|NCT04777513|PROCEDURE|FFR (Fractional Flow Reserve)|Per the protocol, patients will have a Fractional Flow Reserve procedure within standard of care.
223481580|NCT04777513|DEVICE|CNBP measurement|Per the protocol, patients will have the measurement of the resting Continuous Non-Invasive Blood Pressure (CNBP). The signal is required for iSIL-FFR technology.
223481581|NCT04777513|DEVICE|Cardiolens FFR-CT Pro|Per the protocol, non-invasive FFR measurements will be perfomed via Cardiolens FFR-CT Pro technology for the enrolled patients.
223481582|NCT00710658|BEHAVIORAL|WebChoice|"Patients in the experimental group had over the study period access to the Internet support system WebChoice that allowed them to monitor symptoms over time, and provided access to evidence-based self-management options tailored to their reported symptoms as well as a communication area where patients could ask questions to a clinical nurse specialist in cancer care and exchange experiences with other cancer patients.~Patients in the control group received usual care"
223481583|NCT00896831|DRUG|L-ornithine-L-aspartate|L-ornithine-L-aspartate: 5 g (1 sachet) three times per day for 60 days
223481584|NCT00896831|DRUG|placebo|Placebo: 5 g (1 sachet) three times per day for 60 days
223481585|NCT00259103|DRUG|Serelaxin|
223481586|NCT00259103|DRUG|Placebo|
223585155|NCT04139278|OTHER|Observational|Observational retrospective study
223585156|NCT01555515|PROCEDURE|implantation of autologous skin graft after ex-vivo treatment|Subcutan implantation of autologous skin graft after ex-vivo treatment
223585157|NCT01555515|BIOLOGICAL|Subcutan implantation of autologus skin graft after ex-vivo treatment|Subcutan implantation of autologus skin graft after ex-vivo treatment
223585158|NCT03889548|OTHER|Mental Imagery|Immediately after determination of the resting motor threshold and pre-test measurements, the TMS administrator will leave the room so as to be blinded to the treatment condition of the participant. At this time the participant will be given instructions regarding the mental imagery protocol from a separate investigator who will not be blinded to the condition. During the mental imagery protocol, participants will be instructed to close their eyes and imagine they are maximally contracting the muscles in their forearm and imagine that they are making their wrist flex and that they are pushing maximally against a hand grip in their hand. This will be a kinesthetic imagery task, in which they are urging their muscles to contract maximally.
224169301|NCT06724913|OTHER|specialized food product based on ice cream|Day 1: ice cream with 0.014% brazzein, 6% maltitol and 8% oligofructose Day 2: ice cream with 0.014% brazzein, 7.5% erythritol, 2.5% maltitol and 4% inulin Day 3: standard ice cream (12% fat)
224169302|NCT06724913|OTHER|specialized food product based on ice cream 2|Day 1: ice cream with 0.014% brazzein, 7.5% erythritol, 2.5% maltitol and 4% inulin Day 2: ice cream with 0.014% brazzein, 6% maltitol and 8% oligofructose Day 3: standard ice cream (12% fat)
224169303|NCT06724913|OTHER|specialized food product based on ice cream 3|Day 1: standard ice cream (12% fat) Day 2: ice cream with 0.014% brazzein, 6% maltitol and 8% oligofructose Day 3: ice cream with 0.014% brazzein, 7.5% erythritol, 2.5% maltitol and 4% inulin
224169304|NCT06853210|DEVICE|Type-I Collagen-based Skin Substitute and SOC|The SOC in this study is wound care covering with High Purity Type-I Collagen-based Skin Substitute applied weekly or as needed followed by a padded 3-layer dressing comprised of first layer - non-adherent and porous, second layer - absorbent 4x4 gauze pads \& third layer - soft roll and compressive wrap
224169305|NCT06853210|DEVICE|Human Amnion/Chorion Membrane and SOC|The SOC in this study is wound care covering with Dehydrated Human Amnion/Chorion Membrane followed by a padded 3-layer dressing comprised of first layer - non-adherent and porous, second layer - absorbent 4x4 gauze pads \& third layer - soft roll and compressive wrap
224169306|NCT07060456|DRUG|HRS953|HRS953-low dose
224169307|NCT07060456|DRUG|HRS953|HRS953-high dose
224169308|NCT07060456|DRUG|Placebo|Placebo
224169309|NCT07063069|OTHER|Abdominal ultrasound|All patients included will have an abdominal ultrasound scan to mesure anterior/posterior external diameter of gastric antrum upstream of pyloru and external diameter upper/lower of gastric antrum upstream of pylorus
224169310|NCT06853470|DEVICE|VA-ECMO circulatory support|Venoarterial extracorporeal membrane oxygenation (VA-ECMO) is a percutaneous mechanical circulatory support device that can provide short-term hemodynamic support during high-risk PCI.
224169311|NCT06853470|DEVICE|SynFlow 3.0 circulatory support|The SynFlow 3.0 is a novel percutaneous left ventricular-assist device that can provide temporary hemodynamic support during high-risk procedure.
224169312|NCT06853470|PROCEDURE|percutaneous coronary intervention|The percutaneous coronary intervention is a percutaneous endovascular intervention technique that can restore coronary blood flow by various intervention methods such as angioplasty and stent implantation.
224169313|NCT07085468|DRUG|LY3549492|Administered orally
224169314|NCT07085468|DRUG|Placebo|Administered orally
224169315|NCT07094087|BIOLOGICAL|BE1116|A single dose of BE1116 will be administered by intravenous (IV) infusion intraoperatively.
224169316|NCT07094087|BIOLOGICAL|FFP|A single dose of FFP will be administered as investigational product (IP) by IV infusion intraoperatively.
224169317|NCT07094971|DEVICE|Pure Impact|Pure Impact is an EMS module. Pure Impact generates electrical impulses, which are delivered through electrodes on the skin in direct proximity to the muscles to be stimulated.
224169318|NCT06174389|BEHAVIORAL|Behavioral Weight Loss Program|Behavioral Weight Loss Program is a modified version of the Diabetes Prevention Program.
223481587|NCT01902069|DIETARY_SUPPLEMENT|Phospholean|"Phospholean supplied by Cheminutra (White Bear Lake, MN). PhosphoLean® N-Oleoyl-PE + EGCG (NOPE + EGCG) is a proprietary phosphobioflavonic complex of N-oleoyl-phosphatidyl-ethanolamine (NOPE), which contains oleoyl ethanolamine (OEA) bound to phosphatidylethanolamine (PE), and epigallocatechin gallate (EGCG).~PhosphoLean® 40P is a dietary ingredient under the Dietary Supplement Health and Education Act (DSHEA) regulations of the US FDA (1994)."
223481588|NCT01902069|DIETARY_SUPPLEMENT|Placebo|Placebo consists of rice flour
223481589|NCT01129128|BIOLOGICAL|Echinacea purpurea product|5 ml by mouth 3 times per day for 10 days
223481590|NCT01129128|BIOLOGICAL|Echinacea purpurea product|1 ml by mouth 3 times per day for 10 days
224169319|NCT03083106|DEVICE|Elevoplasty|The Elevo™ Kit Snoring Intervention Device is designed to facilitate deployment of the Elevo™ suture implant into the submucosal tissue of the soft palate via a minimally invasive, outpatient procedure performed by an otolaryngologist in a medical office setting.
224169320|NCT07137611|BEHAVIORAL|Low Exercise|• Low-Intensity Continuous Training (LICT): Participants will run continuously for 24 minutes at 50-60% of their MAS without breaks.
224169321|NCT07137611|BEHAVIORAL|Moderate-Intensity Exercise|Moderate-Intensity Continuous Training (MICT): Participants will run at a speed corresponding to 70-80% of their MAS. The protocol consists of four 4-minute bouts, separated by 2-minute active recovery periods, during which participants performed light jogging. This pattern totaled 24 minutes of exercise.
224169322|NCT07137611|BEHAVIORAL|HIIT Exercise|High-Intensity Interval Training (HIIT): Participants will run at 110% of their MAS for 15-second intervals, covering a pre-calculated distance during each bout. After each 15-second sprint, they will rest passively for 15 seconds and returned to their starting point. This will be repeated continuously for 3 minutes, constituting one set. A total of four 3-minute sets will be completed, interspersed with 3-minute passive rest periods, yielding a total exercise time of 24 minutes.
224169323|NCT07137741|BEHAVIORAL|FICare nursing method guided by Swanson's caring theory|"encompasses the following five dimensions: Understanding: A neonatologist provided a comprehensive explanation regarding the developmental progress of premature infants, potential complications, and essential aspects of nursing care to ensure the family gained a thorough understanding of the care requirements for premature infants.~Accompaniment: Two nursing guides provided essential support to parents of newborns in the NICU, helping to alleviate the anxiety and sense of helplessness among family members and fostering a relationship of trust between the medical staff and the families.~Help: A neonatal nurse played a guiding role in facilitating parental involvement in the daily care of premature infants, which encompassed feeding guidance, introduction of complementary foods, skin care, and related aspects.~Empowerment: A psychological counselor was assigned to provide psychological counseling and guidance to new parents, offering appropriate emotional support and assisting them in ac"
224169324|NCT05819021|DEVICE|SAINT® Neuromodulation System (NMS)|The SAINT® NMS utilizes a type of accelerated iTBS delivered to a personalized treatment target derived from a functional MRI scan. SAINT® was designed to optimize the individual patient response to treatment. This novel approach to TMS is accomplished by focusing on three critical aspects of the treatment that drive effect. These aspects are personalized stimulation target, total course dose of stimulation, and neurophysiologically relevant stimulation pattern.
224169325|NCT06794554|DRUG|Rezafungin Acetate|IV with a 400 mg loading dose on Day 1 of Week 1, followed by 200 mg once weekly, for a total of 26 doses (6 months).
224169326|NCT07070323|DRUG|Autologous CD5 CAR T-cells|Peripheral blood mononuclear cells for the production of CD5 CAR T-cells from patients.
223481591|NCT01129128|BIOLOGICAL|Placebo|either 5 ml or 1 ml by mouth three times per day for 10 days
223481592|NCT04278313|PROCEDURE|PRP - Platelet Rich Plasma|Using a sterile vacutainer technique two 8 ml samples of whole blood is drawn into two Regen Lab A-PRP vacutainers with gel separator and citrate. Invert the tube to mix with citrate. The whole blood undergoes two centrifugations, once for 3 minutes and again for 5 minutes. Using a 20-gauge 6-inch spinal needle 2 ml of Platelet POOR Plasma will be drawn off the supernatant from each tube to leave 2.5 ml of Platelet Rich Plasma in the tube. The tube is inverted several times to suspend the platelet pellet. The prepared plasma labeled with the participants name and randomization code will be transported to the procedure room.
224169327|NCT07070323|DRUG|Previous stem-cell transplantation (SCT) donor-derived CD5 CAR T-cells|Peripheral blood mononuclear cells for the production of CD5 CAR T cells are collected from previous SCT donors.
224169328|NCT07070323|DRUG|Newly matched donor-derived CD5 CAR T-cells|Peripheral blood mononuclear cells for the production of CD5 CAR T cells are collected from newly matched donors.
224169329|NCT06481228|COMBINATION_PRODUCT|CAR-T cells|CAR-T cells as consolidation therapy
224169330|NCT06481228|DRUG|Venetoclax|BCL2 inhibitor
224169331|NCT06481228|DRUG|Olverembatinib|TKI
224169332|NCT06831734|DRUG|Concizumab|Participants will be treated with commercially available Alhemo according to routine clinical practice at the discretion of the treating physician. Administration will be according to the approved product labelling. The decision to treat a participant with Alhemo is made at the physician's discretion before and independently from this study.
224169333|NCT07096167|BEHAVIORAL|Voucher for Afterschool Care|Intervention includes a voucher for afterschool care and enrollment assistance
224169334|NCT07099274|DRUG|lparomlimab and Tuvonralimab Injection in Combination with TACE and Lenvatinib|lparomlimab and Tuvonralimab Injection (QL1706): 7.5 mg/kg, q3w; Lenvatinib: 8 mg once daily for patients weighing \<60 kg, or 12 mg once daily for those weighing ≥60 kg, administered orally, continuous daily dosing； TACE: Administered 4-6 times, using a combination of anthracyclines, lipiodol, and microspheres. The procedure should be performed within one week before or after QL1706 administration.
224169335|NCT01394211|DRUG|anastrozole|Given PO
224169336|NCT01394211|DRUG|pazopanib hydrochloride|Given PO
223481593|NCT04278313|PROCEDURE|PPP - Platelet Poor Plasma|Using a sterile vacutainer technique two 8 ml samples of whole blood is drawn into two Regen Lab A-PRP vacutainers with gel separator and citrate. Invert the tube to mix with citrate. The whole blood undergoes two centrifugations, once for 3 minutes and again for 5 minutes. Using a 20-gauge 6-inch spinal needle 2 ml of Platelet POOR Plasma will be drawn off the supernatant from each tube. The prepared plasma will be transported to the procedure room. The prepared plasma labeled with the participants name and randomization code will be transported to the procedure room.
223481594|NCT00961415|DRUG|bevacizumab [Avastin]|7.5mg/kg iv on day 1 of each 3-week cycle
223481595|NCT00961415|DRUG|cisplatin|75mg/m2 iv on day 1 of each 3-week cycle
223481596|NCT00961415|DRUG|pemetrexed|500mg/m2 iv on day 1 of each 3-week cycle
223481597|NCT02547831|OTHER|Observational approach|Patients will be placed under wait and see approach without any specific treatment
223481598|NCT04587908|DRUG|TAS-205 [Ambulatory Cohort] [Non-ambulatory Cohort]|・Treatment period：oral administration for 52 weeks, BID after meal
223481599|NCT04587908|DRUG|Placebo [Ambulatory Cohort] only|"* Observation period：oral administration for 2 weeks, BID after meal~* Treatment period：oral administration for 52 weeks, BID after meal"
223481600|NCT06368427|DRUG|budesonide / glycopyrronium / formoterol|"Trixeo Aerosphere 5 micrograms/7.2 micrograms/160 micrograms pressurised inhalation, suspension.~The COnCORD study is an observational study that will be conducted in a real-life setting in Romania and is not designed to evaluate medicinal products given according to a specific randomised schedule. Treatment with BGF MDI treatment prescribed as per current practice, according to the SmPC and local market reimbursement criteria"
223481601|NCT04497883|DRUG|Maribavir (400 mg)|Non-Hispanic, Caucasian group and Japanese descent group participants will receive 400 mg maribavir tablets orally once on Day 1 during treatment period 1.
224169337|NCT01394211|PROCEDURE|therapeutic conventional surgery|Undergo definitive surgery
223481602|NCT04497883|DRUG|Maribavir (200 mg)|Japanese descent group participants will receive 200 mg maribavir tablets orally once on Day 1 during treatment period 2 or 3.
223481603|NCT04497883|DRUG|Maribavir (800 mg)|Japanese descent group participants will receive 800 mg maribavir tablets orally once on Day 1 during treatment period 2 or 3.
223481604|NCT03570788|PROCEDURE|Amputation|Major amputation defined as at or above ankle
223585159|NCT03047018|BEHAVIORAL|The Changing Health in Autism through Nutrition, Getting fit and Expanding variety (CHANGE) Program|The CHANGE program is a a six-month long intervention consisting of 16 sessions. The first 10 sessions occur weekly while the remaining 6 sessions occur bi-weekly. Sessions last about 1 hour each. Nutrition intervention focuses on decreasing excess calories from liquids and solids and creating a balanced meal plan. Physical activity intervention uses fading strategies to increase participation in exercise. Behavior strategies promote success with meeting goals. Problem-solving techniques address challenges to adherence with implementing the program in the home setting. The standardized protocols include educational handouts, clinic-based activities and assessment procedures, and caregiver-directed homework and data collection.
224169342|NCT07102446|OTHER|Opioid Stewardship Program|The Opioid Stewardship Program (OSP) includes pain and functional assessments, opioid prescription review and coordination, patient education, and counseling provided by trained pharmacists.
224169343|NCT07101627|DRUG|Hetrombopag Tablets|"Stage 1: After screening and enrollment, patients will receive oral administration of hetrombopag, 7.5 mg/day, for 14 days from the first day after the end of chemotherapy in this cycle.~Stage 2: Patients who met the inclusion criteria were randomized 1:1 to the experimental group and the control group after enrollment. Patients in the experimental group began to orally take hetrombopag 7.5 mg/day for 14 days on the first day after the end of chemotherapy in this cycle; patients in the control group began to orally take hetrombopag simulated tablets 7.5 mg/day for 14 days on the first day after the end of chemotherapy in this cycle. Randomization was stratified by concomitant immunotherapy (yes versus no) and chemotherapy with gemcitabine plus platinum (yes versus no)."
223481605|NCT04156529|BEHAVIORAL|ESU position|Semi-elevated supine (ESU) position was given during tube feeding
223481606|NCT04156529|BEHAVIORAL|ESRL position|Semi-elevated right lateral (ESRL) position was given during tube feeding
223481607|NCT06555796|DRUG|Xaluritamig|IV infusion
224169344|NCT07101822|DRUG|Cemiplimab|Cemiplimab maintenance plus best supportive care: cemiplimab 350 mg IV every 3 weeks until week 24, disease progression, unacceptable toxicity or consent withdrawal. patients who continue to derive clinical benefit on the experimental arm may continue to receive treatment until week 48.
224169345|NCT07101796|DEVICE|continous positive airway pressure (CPAP)|using CPAP to treat OSA
224305466|NCT03966248|OTHER|Chinese Tuina therapy|"1. The doctor presses the affected lower limb from the anterior superior iliac spine to the ankle;~2. The doctor gives the pressure on the Biguan(ST31), Futu(ST32), Heding(EX-LE2), Neixiyan(EX-LE4), Waixiyan(Dubi, ST35), Zusanli(ST36) and Sanyinjiao(SP6) of the affected lower limb;~3. Massage the spleen and stomach meridians of the affected lower extremes;~4. Roll the soft tissues around the affected knee;~5. Relax the gastrocnalis muscle~6. The doctor gives the pressure on the Xuehai(SP10), Liangqiu(ST34), Neixifeng(medial patellofemoral ligament), Waixifeng(lateral patellofemoral ligament), Neixiyan(EX-LE4) and Waixiyan(Dubi, ST35) at the same time;~7. Push the patella and do the passive movement of the affected knee;~8. Strength training of the affected knee.~This group receives 8 treatments over a 3 week period with a one week follow-up on site and a 3 month follow-up by mail, phone or email."
224305467|NCT03966248|OTHER|Physical Manual therapy|"1. Manual therapy: Stretching the knee joint, stretching the knee joint with valgus or abduction, stretching the knee joint with varus or adduction is suitable for patients with knee flexion and extension difficulty.Patellar manipulation by bending the knee 5-10 degrees downward is suitable for patients with patellar sliding difficulty.The lower end of the muscle length manipulation is suitable for patients with muscle tension and soft tissue tension.Soft tissue loosening is performed in the suprapatellar and peripatellar regions, medial and lateral capsule joints, and popliteal fossa.~2. Activity training: Mainly about the knee joint flexion and extension movement training.~3. Strength training: Mainly about quadriceps muscle resistance exercises~This group receives 8 treatments over a 3 week period with a one week follow-up on site and a 3 month follow-up by mail, phone or email."
224305468|NCT01172483|PROCEDURE|general practice in primary care and education|education of chronic disorders in PC
224305469|NCT01172483|OTHER|Multimodal community program|The intervention was an 8-week programme of MMPP combined with DWR, delivered by physiotherapists in groups of 8 to 10 participants. One-hour sessions were conducted 3 times per week, consisting of DWR and an individualised MMPP of therapeutic exercises combined with education based on cognitive-behavioural principles. Each session was comprised of 30 minutes of land-based exercise followed by 20 minutes of DWR, with an additional 10 minutes of warm-up and cool-down time. Deep water running stimulates running using a flotation device in water levels over head height. During the first two weeks of the intervention, participants undertook a low-intensity adaptation interval to learn proper exercise technique. For the remaining six weeks, participants were instructed to maintain a constant speed to achieve the prescribed HRAT. If experiencing pain while exercising, participants were asked to temporarily reduce intensity and return to target HR as capable.
224305470|NCT04371328|OTHER|RECOP unit patient|"All patients admit in RECOP unit for dyspnea can be included in this study if patient is agree. Then, doctor collects demographic variables, the usual history and treatments, the characteristics of the episode (symptomatology, evolution, treatment taken) and the data from the initial clinical examination will be identified.~30 days after inclusion, virological status and mortality will be collect"
224305471|NCT02930486|DEVICE|ZipTight suture endobutton|Zimmer Biomet ZipTight suture endobutton
224305472|NCT02930486|DEVICE|Tricortical 3.5 mm syndesmotic screw|Depuy Synthes 3.5 mm screw
224305473|NCT03073785|DRUG|Capecitabine|Given by mouth (PO)
224305474|NCT03073785|DRUG|Fluorouracil|Given Intravenously (IV)
224305475|NCT03073785|OTHER|Laboratory Biomarker Analysis|Correlative studies
224305476|NCT03073785|OTHER|Pharmacological Study|Correlative studies
224305477|NCT03073785|RADIATION|Stereotactic Body Radiation Therapy|Undergo hypofractionated stereotactic radiotherapy
224305478|NCT03073785|DRUG|Zoledronic Acid|Given IV
224305479|NCT00475150|DRUG|cediranib maleate|Given orally
224305480|NCT00475150|OTHER|laboratory biomarker analysis|Correlative studies
224305481|NCT05240170|DEVICE|RIRS|The standard RIRS will be performed using a disposable flexible ureteroscope. Holmium: YAG laser will be used for stone dusting and fragmentation. If indicated, JJ ureteral stent will be placed at the end of the procedure.
224305482|NCT05240170|DEVICE|SWL|Patients who underwent SWL at our institution in the past five years. According to (a) the type of renal anomaly (rotation, position, or rotation/position anomaly), (b) the size of the stone (±5 mm), (c) location of the stone (lower polar or non-lower polar), and (d) density of the stone (\>800 HU or ≤800 HU), matched cases will be selected for comparison.
224305483|NCT03851926|RADIATION|Hypofractionated volumetric radiotherapy in 20 fractions|Hypofractionated radiotherapy at 3 Gy per fraction for localized prostate cancer.
224169346|NCT07100899|OTHER|Dual task training|Dual motor task training for 30 minutes. The dual motor training was divided into two phases. The first part involved a single task condition in which the stroke patient was instructed to stand up from a seated position at a self-selected speed without the use of upper limb assistance. Cognitive and physical tasks, is the second part of training. In addition to a 30-minute selected physiotherapy program.
224169347|NCT07100899|OTHER|Task-specific training|Began with a highchair before switching to a low one. In addition to a 30-minute selected physiotherapy program.
224169348|NCT07100899|OTHER|Selected physiotherapy program|Consisting of trunk control, trunk stabilization, balance training and lower extremity strengthening exercises (primarily for the hip adductors and abductors) for 60 minutes.
224169349|NCT07101913|BIOLOGICAL|Incidence of acute kidney injury|"* Creatinine measurement before lymphodepletion chemotherapy, before CAR-T cells injection (day 0) and at day 1, day 3, day 5, day 7, day 10, day 14, day 21 and day 28.~* AKI according to 2012 KDIGO."
224305484|NCT03856112|DRUG|Dexamethasone|Given PO
224305485|NCT03856112|DRUG|Ixazomib|Given PO
224305486|NCT03856112|DRUG|Ixazomib Citrate|Given PO
224305487|NCT03856112|DRUG|Venetoclax|Given PO
224305488|NCT04301908|DRUG|interferon|Antiviral therapy for patients with chronic hepatitis B and cirrhosis. Antiviral therapies included interferon and / or nucleoside (acid) analogs, and patients who were continuously treated for more than 6 months were included in the study.
223481608|NCT05692726|OTHER|Patients|Patients will get study-specific measurements within first 5 days of standard of care treatment of hyponatremia or until discharge
223585160|NCT00226863|BEHAVIORAL|meditation plus education|
223585161|NCT00226863|BEHAVIORAL|group psychotherapy with hypnosis plus education|
223585162|NCT00226863|BEHAVIORAL|education|
223585163|NCT01956045|OTHER|Patient's capacity|
223585164|NCT04147598|OTHER|LFD|Participants will receive daily prepared food trays to achieve a diet with approximately 10% of total fat, 1-5% of calories from saturated fat, and 5-9% of MUFA and PUFA. This diet will contain an approximate ratio of 1:1 of omega-6/omega-3 fatty acids.
223585165|NCT04147598|OTHER|SAD|Participants will receive daily prepared food trays to achieve a diet with approximately 35-40% of calories from fat, 10-11% of saturated fats, and 25-29% would be mono-unsaturated (MUFA) and PUFA. This diet will contain a 20-30:1 ratio of omega-6/omega-3 fatty acids, representing the current SAD.
224169350|NCT07101913|OTHER|Describe risk factors in AKI occurrence.|"Comparison of caracteristics between participants with AKI and participants without AKI :~* Baseline caracteristics of participants : age, gender, BMI (Body mass index), medical history…~* Caracteristics of hematology disease : severity of lymphoma, previous treatments (chemotherapy, autologous/allogenic stem cell transplant), type of CAR-T cells (axi-cel, tisa-cel)~* Other adverse affects : cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS)~* Use of nephrotoxic medications Informations found in medical field."
224169351|NCT07101913|OTHER|Focus on patient with chronic kidney disease at baseline|Looking at the subgroup with chronic kidney disease at baseline : are the outcomes different in this population ? Efficacity of CAR-T ? More adverse effects ?
224169352|NCT07101913|OTHER|Long term evolution after treatment by CAR-T cells|Creatinine measurement 1 year after CAR-T treatment. Informations found in medical field.
224169353|NCT07100626|DEVICE|BlueCheck|Caries Detection and Monitoring
224169354|NCT07101965|DRUG|RSS0343 tablets ；placebo|RSS0343 tablets and placebo were given orally as a single dose
223481609|NCT04555005|OTHER|Mindfulness based intervention|Mindfulness based intervention for frontline healthcare workers during COVID-19 outbreak
223481610|NCT05570253|DRUG|Eribulin|Eribulin 1.4 mg/m2 IV on days 1 and 8 of an every 21 day cycle.
223481611|NCT05570253|DRUG|SDX-7320|SDX-7320 at the dose of 49 mg/m2 SC on a Q14D basis
223481612|NCT05570253|OTHER|Placebo|Placebo
223481613|NCT05110664|DRUG|PYY (3-36) Peptide|oral PYY3-36 solution
223481614|NCT05110664|DRUG|Placibo|oral placebo solution
223481615|NCT03492203|BEHAVIORAL|Active Cognitive Remediation|Cognitive remediation engages participants in computerized exercises meant to improve cognitive functions and provides therapist feedback for how these improvements manifest in everyday life. The novel components of CR in this study will be the delivery of treatment remotely.
223481616|NCT03492203|BEHAVIORAL|Cognitive Remediation Control|The investigators have developed a 'comparison' cognitive remediation treatment in collaboration with the same company that produced the cognitive exercises. These procedures include the same stimuli but are adjusted without increasing cognitive load.
223585166|NCT05620784|DRUG|Furosemide|20mg of IV furosemide injection during the morcellation phase of HoLEP
224169355|NCT07101965|DRUG|RSS0343 tablets ；placebo|RSS0343 tablets and placebo were taken orally multiple times
223481617|NCT03492203|BEHAVIORAL|Online computer exercises|There are 30 unique cognitive exercises in the program (sbtpro.com). The investigators will prescribe 24 exercises in the domains most commonly impaired in MDD: six targeting executive functions, ten targeting memory, and eight targeting attention and working memory. The specific activities are prescribed in a fixed, systematic order, such that the participants have a schedule of exercises that address several different cognitive domains each week and return to exercises in subsequent weeks. Parameters are automatically adjusted based on participant performance across 30 difficulty levels. Participants are prescribed two 20-minute sessions per day, five days per week, for the duration of the study.
223481618|NCT03492203|BEHAVIORAL|Strategy monitoring|Therapists communicate with participants in asynchronous private and group forums, where specific responses to questions prime flexible strategy formation, monitoring of strategies, and bridging to real world functioning. Participants use logs to track their own strategies and upload this information to the forum for therapist feedback. The purpose of the therapist responses is to reinforce the development of multiple strategies and help supplement or reshape those that are concrete, based on a predetermined list of strategies developed for each of the computer exercises.
223585167|NCT02478450|BIOLOGICAL|Q-Cells|cellular therapeutic comprised of human cells of the glial lineage
223585168|NCT02090361|PROCEDURE|skin graft|Epidermization of the defect by applying a thin layer of autologous epidermis
224169356|NCT07101315|PROCEDURE|Laparoscopic Cholecystectomy|Standard four-port laparoscopic cholecystectomy was performed by a specialist or resident surgeon.
224169357|NCT07095972|DEVICE|Abbot Freestyle Libre CGM|Participants assigned to the CGM group will receive the Libre 2+ systems (Abbott Diabetes Care, Alameda, CA) upon randomization. This will include comprehensive training provided by a qualified healthcare professional. The training will cover detailed instructions on sensor placement, how to download and use the associated smartphone application, and guidance on interpreting the glucose data effectively. To ensure continuous and accurate monitoring, the CGM sensor will be routinely replaced every 14 days following randomization. Additionally, in the event of sensor detachment or loss, immediate replacement will be arranged to maintain uninterrupted glucose tracking. Regular sessions are conducted to analyze glucose trends, refine management strategies, and provide additional support or education on device usage.
223585169|NCT02636946|DRUG|Bimatoprost SR|Up to three Bimatoprost SR 15 micrograms (μg) administrations at Day 4, Weeks 16 and 32 (Stage 1) or two Bimatoprost SR 15 μg administrations at Day 4 and Week 16 (Stage 2).
223585170|NCT02636946|DRUG|Sham Bimatoprost SR|Up to three Sham Bimatoprost SR administrations at Day 4, Weeks 16 and 32 (Stage 1) or two Sham Bimatoprost SR administrations at Day 4 and Week 16 (Stage 2).
223585171|NCT02636946|PROCEDURE|Selective Laser Trabeculoplasty|Selective Laser Trabeculoplasty administered on Day 1.
223585172|NCT02636946|PROCEDURE|Sham Selective Laser Trabeculoplasty|Sham Selective Laser Trabeculoplasty administered on Day 1.
223585173|NCT00068510|BIOLOGICAL|therapeutic autologous dendritic cells|
223585174|NCT04625868|OTHER|Educational video|Patients will watch a preoperative educational video on proper opioid use and disposal.
223585175|NCT00477269|DRUG|Imatinib mesylate|
223585176|NCT00477269|DRUG|Placebo|
223585177|NCT03168100|DRUG|Elotuzumab|administered via IV infusion
224169358|NCT07099742|DRUG|Tirzepatide|Exposure
224169359|NCT07099742|BEHAVIORAL|Life Style Modification|Referent group - Lifestyle interventions, exercise, and diet control
224169360|NCT07102017|DEVICE|Passive Robotic Support for Enhanced Well-Being|Previous research primarily compared scenarios with robots versus without robots, while this study examines how differences in robot activity levels and interaction levels affect older adults' well-being. In this study, this intervention includes a passive robot that would not initiate any interactions with older adults. In this arm, we employed LOVOT as a passive comfort object that only reacts to older adults when being triggered. Besides, this robot has no voice (i.e. the device was muted).
224169361|NCT07102017|DEVICE|Proactive Robotic Support for Enhanced Well-Being|This intervention differs significantly from the Passove Robotic Support for Enhanced Well-Being primarily through its proactive social engagement capabilities and autonomous agency. This intervention actively seeks interaction by enabling free movement, approaching individuals, and following them. Furthermore, the robot in this intervention responds dynamically to auditory stimuli with sounds and head tilts, offering a richer, reciprocal interaction compared to Arm 1's limited reactive purring and eye blinks. This shift transforms the LOVOT's role from a passive comfort object into an active social catalyst designed to stimulate engagement and reciprocity.
224169362|NCT07101185|DEVICE|VIRTUAL REALITY|"The interventional part of the study is limited to 3 centers. It explores SOCIAL COGNITION throught a newly developed paradigm in Virtual Reality.~In detail: an adapted version of the Virtual Reality Social Prediction Improvement and Rehabilitation Intensive Training (VR-SPIRIT) using a VR Head Mounted Display (HMD) will be implemented on a portable HMD, the Oculus Quest, equipped with two controllers with motion sensors that are used to track hand position.~In a VR-SPIRIT session, participants are immersed in the playground scenario and engaged in a competition with four avatars. Each avatar has a pre-established probability to move toward one of the three described games.~Different indices about a partecipant's performance are recorded automatically by the system during the session, such as the duration of each trial and the prediction score (percentage of trials in which the participant correctly predicted an avatar's intention)."
224169363|NCT07101549|DRUG|R-Star001|"Drug: Nectin-4-targeted CAR T-cell injection with inducing IL-18 secretion (R-Star001).~The trial consists of a traditional '3 + 3' pattern dose-escalation phase and a dose-expansion phase."
224169364|NCT03463954|DEVICE|Novilase Laser ablation|Image-guided, percutaneous laser ablation of breast tumors
224169365|NCT00024544|DRUG|anti-IL-4 monoclonal antibody (pascolizumab)|
224169366|NCT06911723|BEHAVIORAL|Brief Activities|The activities will be completed online.
224169367|NCT06832982|DRUG|FS-8002 injection|Q3W or until the patient develops PD, intolerable toxicity, death, loss of follow-up, voluntary withdrawal, or the end of the study, whichever occurs first
224169368|NCT07101081|DIAGNOSTIC_TEST|HER-2 Test|Samples from patients with gynecological tumors eligible to the study will be retrospectively identified and the paraffin slides will be sent to central laboratory to perform HER2 IHC testing using the automated protocols (Dako and Ventana). Expert pathologists will select primary tumor samples from surgery or excisional biopsies with enough material to perform HER2 testing using both antibodies without exhausting the cancer tissue. The entire cohort will be tested with both Dako HercepTest and Roche Ventana 4B5 antibody using gastric cancer and breast cancer criteria for positivity (3+, 2+ and 1+, 0).
224305489|NCT03285308|DRUG|Placebo|Placebo injected subcutaneously twice daily.
224305490|NCT03285308|DRUG|Relamorelin|Relamorelin 10 micrograms (μg) injected subcutaneously twice daily.
223481619|NCT03492203|BEHAVIORAL|Bridging strategies|The online forum will have illustrations for bridging cognitive abilities and problem solving strategies related to each game to experiences in the real world. An at home workbook will also be used to facilitate active application of skills in various domains (e.g., work, socialization, recreation, household maintenance).
223481620|NCT03713918|OTHER|Reinforced lithium silicate endocrowns|The endodontically treated tooth will be impressed, and an endocrown restoration will be manufactured with reinforced lithium silicate and cemented with self adhesive cement
223481621|NCT03713918|OTHER|Post retained reinforced lith silicate crn|The endodontically treated tooth will receive a fiber post cemented with self adhesive cement and after this, the tooth will be impressed and reinforced lithium silicate crown will be cemented with self adhesive cement.
223481622|NCT02687802|OTHER|mechanical ventilation|we will measure static resistance, compliance and intrinsic positive end-expiratory pressure (PEEP) and other variables as risk factors for asynchrony occurrence
223481623|NCT01052948|OTHER|Retrospective study-|
223481624|NCT01052948|OTHER|Retrospective study-|
223481625|NCT01052948|OTHER|Retrospective study-|
223481626|NCT01052948|OTHER|Retrospective study-|
223481627|NCT02244632|DRUG|Modufolin (arfolitixorin)|IV injection every second week for 8 weeks.
223481628|NCT02244632|DRUG|Fluorouracil|IV injection every second week for 8 weeks.
223481629|NCT02244632|DRUG|Oxaliplatin|IV infusion every second week for 8 weeks.
223481630|NCT02244632|DRUG|Irinotecan|IV infusion every second week for 8 weeks.
223481631|NCT02244632|DRUG|Bevacizumab|IV infusion every second week for 8 weeks.
223481632|NCT01935115|DRUG|Propofol|Propofol anesthesia for ECT
223481633|NCT01935115|DRUG|Ketamine|Ketamine anesthesia for ECT
223481634|NCT02016326|DEVICE|HD Colon|High Definition White Light
223481635|NCT02016326|DEVICE|I-scan 1|I-Scan 1 has Contrast Enhancement(CE), Surface Enhancement(SE). SE mode highlights light-dark contrast thereby providing more mucosal surface detail. CE mode digitally adds blue to darker areas providing detailed imaging of subtle mucosal irregularities.
223481636|NCT02016326|DEVICE|I-Scan 2|I-Scan 1 has Contrast Enhancement(CE), Surface Enhancement(SE)and Tone Enhancement(TE). SE mode highlights light-dark contrast thereby providing more mucosal surface detail. CE mode digitally adds blue to darker areas providing detailed imaging of subtle mucosal irregularities. TE provides a uniform color image and is intended for detailed inspection of distinct lesions.
223481637|NCT00797758|OTHER|Cord blood transplantation|Umbilical cord blood transplantation after reduced intensity conditioning
223481638|NCT00914069|DEVICE|RIVS vascular access|Access to peripheral vasculature
223585178|NCT03168100|DRUG|Lenalidomide|taken by mouth
223585179|NCT03168100|DRUG|Dexamethasone|taken by mouth
224169369|NCT06756685|OTHER|Core Strengthening Exercises|The Core Strengthening Program participants will have supervised gym-based sessions for 8 weeks. In the first 4 weeks , participants will attend two 1 hour training sessions, followed by self-selected one or two sessions per week. The session will begin with 20min of aerobic conditioning of walking or running on a treadmill, starting at 65% and moving to 85% of HR max. The 5 key elements of focus are i. Centering ii. Breathing iii. Head and neck placement iv. Shoulder placement v. Chest wall placement
224169370|NCT06756685|OTHER|Motor Control Training|"Participants in Motor Control group will receive two physiotherapy sessions of 1hour / week in the first 4 weeks, during stage 1. i. Abdominal drawing-in maneuver (ADIM) : isometric contraction of the local stability muscles (e.g., lumbar multifidus, transversus abdominis) in minimally loading positions (supine lying, quadruped, sitting, and standing) by maintaining a neutral spine while maintaining normal breathing. During Phase 2, One 1 hour session / week in the second 4 weeks.~Activation and facilitation of transversus abdominis, lumbar multifidus and pelvic floor motor control(36).Exercises target the transversus abdominis, multifidus and pelvic floor muscles plus postural correction to restore optimal motor control during non-weight-bearing activities. Exercises and progressions will follow previous protocols of motor control exercise."
224169371|NCT04191096|BIOLOGICAL|Pembrolizumab|Pembrolizumab is administered as an IV infusion at 200 mg on Day 1 of each 21-day cycle for up to 35 cycles.
224169372|NCT04191096|DRUG|Enzalutamide|Enzalutamide is administered orally as capsules/tablets at a dosage of 160 mg daily. Enzalutamide is administered continuously until criteria for discontinuation are met.
223585180|NCT03168100|DRUG|Bortezomib|administered as a subcutaneous injection
223585181|NCT04464824|OTHER|no intervention|no intervention
224169373|NCT04191096|DRUG|Androgen Deprivation Therapy (ADT)|Stable regimen of ADT (LHRH agonist or antagonist) at a dose and frequency of administration that is consistent with the local product label.
224169374|NCT04191096|OTHER|Placebo|Placebo infusion solution is administered as an IV infusion on Day 1 of each 21-day cycle for up to 35 cycles.
224169375|NCT07102186|DRUG|use of adapalene gel 0.1% and hyaluronic acid at bedtime|in this intervention a combination of adapalene gel 0.1% and hyaluronic acid will be used
224169376|NCT07102186|DRUG|use of adapalene gel 0.1% once daily at bedtime|in this intervention involves the use of adapalene gel 0.1% once daily only topically at bedtime
224169377|NCT07100704|DRUG|Nivolumab|240 mg will be administered on Day 1 and Day 15 of each cycle, or 480 mg will be administered on Day 1 of each cycle, and this will be continued until disease progression. One cycle is 28 days. The decision on which treatment to administer will be made through consultation between the participant in this trial and the site principal investigator or site co-investigator.
224169378|NCT07100808|PROCEDURE|Using the tunnel technique in the treatment of gingival recession|Microsurgical periodontal instruments were used during surgical procedures. In this study, specially developed tunnel instruments (Helmunt Zepf, Seitingen-Oberflacht, Germany) were used to mobilize the gingivo-papillary unit and prepare the supraperiosteal tunnel bed. After passing the coronal edge of the alveolar bone with the tunnel instrument placed in the soft tissue, it was advanced towards the apical mucogingival junction with small, circular movements. This procedure was repeated by entering from the sulcus of each tooth. Care was taken to ensure that the prepared flaps were in the same layer and opened towards each other. In the interdental areas, the papillary complex was carefully separated from the periosteum and mobilized in the buccal direction. Thus, mobilization of the entire buccal soft tissue complex was achieved in the coronal direction. After these procedures, it was checked whether the flap covered the recession areas without tension.
224169379|NCT07102251|DRUG|HEC-007 injection|Single dose escalation of HEC-007 injection in healthy subjects
224169380|NCT07102251|DRUG|Placebo|Single dose of placebo in healthy adults
224169381|NCT07102251|DRUG|HEC-007 injection|Multiple dose escalation of HEC-007 injection in Overweight or Obese Subjects
224169382|NCT07102251|DRUG|Placebo|Multiple dose of placebo in Overweight or Obese Subjects
224169383|NCT07100925|DRUG|tolododekin alfa|IT administration of ANK-101 once every 3 weeks for 2 cycles, followed by surgical resection
224169384|NCT06287047|PROCEDURE|Epidural analgesia|Epidural analgesia alone or with dural puncture with different sizes of spinal needles
224169385|NCT04443842|BEHAVIORAL|Financial and social incentives|"Participants will be credited with HK$1000 in their virtual accounts at the beginning of the trial. After baseline step counts are gathered in the second week, participants will lose HK$40 for each subsequent week that they do not meet their personal weekly step target.~The social incentives are peer comparison and social support. Participants receive feedback of their physical activity performance by assessing whether they met or exceeded their step count target, followed by positive messages for encouragement. Nominated supporters will be informed of participants' performance for social support."
223481639|NCT00914069|DEVICE|Conventional vascular access|Vascular access using conventional venous access device
223481640|NCT00557232|DRUG|bevacizumab|1.25mg/month
223481641|NCT00639509|BIOLOGICAL|cixutumumab|Given IV
223481642|NCT00639509|PROCEDURE|computed tomography|Undergo contrast-enhanced computed tomography
223481643|NCT00639509|PROCEDURE|contrast-enhanced magnetic resonance imaging|Undergo contrast-enhanced magnetic resonance imaging
223481644|NCT00295802|DEVICE|Integrated Imaging High Intensity Focused Ultrasound|
223481645|NCT00295802|DEVICE|Endocare CRYOcare Cryosurgical and Galil Medical CRYO-HIT Systems (cryotherapy)|Cryotherapy
223481646|NCT04795349|PROCEDURE|Vacuum-assisted breast biopsy|In those patients with a radiological complete response by all the radiological imaging methods, a stereotactic biopsy will be performed before surgery. After that, a comparison will be done between the results of the pre surgical biopsy and the definitive pathology of the specimen.
223481647|NCT04773132|OTHER|Low Protein|Low protein/protein-free diet for 3 days (Day 1, 2 and Day 3) in order to deplete the label protein pool. The diet provided will meet the daily energy requirements of all the subjects.
223481648|NCT00683137|DRUG|valdecoxib|valdecoxib 40 mg tablet by mouth followed by a valdecoxib 20 mg tablet by mouth after 1 to 12 hours of the initial dose on Day 1 then a valdecoxib 20 mg tablet by mouth once daily on Days 2 through 5
223585182|NCT01583660|DRUG|celecoxib|200mg, PO.Bid, last from admission to hospital to one week after operation.
223585183|NCT01583660|DRUG|Acetaminophen oxycodone|1 tablet(Acetaminophen 325mg oxycodone 5mg), Q6h orally take,last from admission to hospital to one week after operation.
224169386|NCT06364709|BEHAVIORAL|Criterion-learning practice|The experiments will be presented on a computer. On each criterion-learning trial, a picture is presented and the participant is asked to try to produce the name for the object with or without a cue. Correct-answer feedback is provided. Criterion learning involves presenting a block of items in fixed order, and on each trial, the experimenter or a voice-recognition component will code the response during the trial as correct/incorrect. When the item reaches its assigned criterion level, it is dropped from further training in a session.
224169387|NCT07115732|DEVICE|Total Hip Replacement|Primary elective total hip replacement
224169388|NCT06921941|DRUG|Digoxin vs Digoxin + BEM/RZR vs Digoxin + 2h BEM/RZR|"Treatment-A (Digoxin): A single dose of digoxin will be administered under fasting conditions.~Treatment-B (Digoxin + BEM/RZR): A single dose of digoxin will be co-administered a single dose of BEM/RZR under fasting conditions.~Treatment-C (Digoxin + 2h BEM/RZR): A single dose of digoxin will be administered under fasting conditions. Then, a single dose of BEM/RZR will be administered approximately 2 hours later under fasting conditions."
224169389|NCT06921941|DRUG|Rosuvastatin vs Rosuvastatin + BEM/RZR vs Rosuvastatin + 2h BEM/RZR|"Treatment-D (rosuvastatin): A single dose of rosuvastatin will be administered under fasting conditions.~Treatment-E (rosuvastatin + BEM/RZR): A single dose of rosuvastatin will be co-administered with a single dose BEM/RZR under fasting conditions.~Treatment-F (rosuvastatin + 2h BEM/RZR): A single dose of rosuvastatin will be administered under fasting conditions. Then, a single dose BEM/RZR will be administered approximately 2 hours later under fasting conditions."
224305491|NCT02191631|BEHAVIORAL|Internet-delivered Cognitive Behavior Therapy|The treatment consists of standard cognitive behavior therapy for obsessive-compulsive disorder and is delivered via an internet plattform and regular therapist contact several times per week via email and telephone. The treatment is 12 weeks.
224305492|NCT02829294|DEVICE|E002 - cerumen removal aid|topical treatment
224305493|NCT03452332|BIOLOGICAL|Durvalumab|Given IV
224305494|NCT03452332|OTHER|Laboratory Biomarker Analysis|Correlative studies
223481649|NCT00683137|DRUG|valdecoxib|valdecoxib 40 mg tablet by mouth followed by a valdecoxib 20 mg tablet by mouth after 1 to 12 hours of the initial dose on Day 1 then a valdecoxib 20 mg tablet by mouth twice daily on Days 2 through 5
223481650|NCT00683137|DRUG|valdecoxib/placebo|valdecoxib 40 mg tablet by mouth followed by a valdecoxib 20 mg tablet by mouth after 1 to 12 hours of the initial dose on Day 1 then placebo on Days 2 through 5
223481651|NCT03510000|DRUG|Empagliflozin 25mg|Individuals will test insulin dosing during different meal strategies (carbohydrate counting, plain meal announcement, no meal announcement) in a setting of the single hormone artificial pancreas with or without SGLT2 inhibitor (empagliflozin) addition. After starting the empagliflozin therapy, there will be 1-2 weeks long therapy optimization period and afterwards meal strategies will be administered. Randomization will be used to determine whether participant will start meal strategies on empagliflozin or without empagliflozin, cross-over design enables all participants to undergo all combination of approaches.
223481652|NCT03510000|DEVICE|Single hormone artificial pancreas|Single hormone artificial pancreas will be used as a baseline background intervention standardizing the delivery and dosing of insulin. Artificial pancreas (insulin pump, continuous glucose monitoring device and dosing-suggestion algorithm) will be used by all participants on days when meal strategy intervention will be performed.
223481653|NCT03510000|BEHAVIORAL|Meal strategies|Participants will use different approaches (strategies) to insulin dose estimation for ingested carbohydrates on study days. Goal of these various strategies is to recognize magnitude of empagliflozin effect in situations when artificial pancreas algorithm is working with information of different accuracy. Individual meal approach strategies include carbohydrate counting, meal size announcement and no meal announcement. The exception will be combination of no empagliflozin and no meal announcement, which didn't result in sufficient glucose control in previous trials therefore will not be repeated in a current trial. Meal approach strategies will occur on separate days- 5 days in total each day using one meal strategy for all meals during the day.
223481654|NCT02517788|DRUG|Interferon beta-1a HSA-free biosimilar|6 MIU/0.53 mL in pre-filled glass syringe solubilized in aqueous isotonic buffered solution without albumin
223481655|NCT02517788|DRUG|Interferon beta-1a HSA+ biosimilar|6 MIU/0.53 mL in pre-filled glass syringe solubilized in aqueous isotonic buffered solution combined with albumin solution
223481656|NCT02517788|DRUG|Interferon beta-1a original|6 MIU/0.50 mL in pre-filled glass syringe solubilized in HSA and mannitol solution (marketed formulation)
223481657|NCT05818787|BEHAVIORAL|Roll Tilt Training|The participants will be tilted and asked to indicate their perceived direction of self-motion (e.g., left or right). Feedback will be provided to promote learning (i.e., improved perception of motion). Feedback will only be provided after the subject response, and thus vestibular (i.e., self-motion) perception is required to judge the direction of the tilt stimulus. After each trial, a three second period of rest will be given. Each day of training will include four blocks of one-hundred trials each. Testing will take place in the dark (except for aims where a visual cue is provided). Subjects will be seated on a motion platform with a 5-point harness and the head restrained. Insert earbuds (along with a white noise signal) will be used to reduce external noise. Subjects will always be asked to make a decision (e.g. left versus right) by pressing buttons with their left or right hands. If not certain, subjects are instructed to provide their best guess.
223481658|NCT05818787|BEHAVIORAL|Translation Training|The participants will be translated and asked to indicate their perceived direction of self-motion (e.g., left or right). Feedback will be provided to promote learning (i.e., improved perception of motion). Feedback will only be provided after the subject responds, and thus vestibular (i.e., self-motion) perception is required to judge the direction of the translation stimulus. After each trial, a three second period of rest will be given. Each day of training will include four blocks of one hundred trials each. Testing will take place in the dark (except for aims where a visual cue is provided). Subjects will be seated on a motion platform with a 5-point harness and the head restrained. Insert earbuds (along with a white noise signal) will be used to reduce external noise. Subjects will always be asked to make a decision (e.g. left versus right) by pressing buttons with their left or right hands. If not certain, subjects are instructed to provide their best guess.
224169390|NCT06921837|DRUG|BDC-4182|Immune stimulating antibody conjugate (ISAC), consisting of an anti-claudin 18.2 monoclonal antibody conjugated to a TLR 7/8 dual agonist
224169391|NCT05964413|DRUG|vilobelimab|vilobelimab infusion
224169392|NCT05964413|DRUG|Placebo|Placebo Infusion
224169393|NCT00404638|DRUG|Desmopresin|
224169394|NCT00404638|BEHAVIORAL|Paula Method of Circular Muscle Exercise|
223481659|NCT05818787|BEHAVIORAL|Both Tilt and Translation Training|The participants will be equally tilted and translated and asked to indicate their perceived direction of self-motion (e.g., left or right) . Feedback will be provided to promote learning (i.e., improved perception of motion). Feedback will only be provided after the subject responds. After each trial, a three second period of rest will be given. Each day of training will include four blocks; 2 blocks of roll tilt and 2 blocks of translation - one hundred trials each. Testing will take place in the dark (except for aims where a visual cue is provided). Subjects will be seated on a motion platform with a 5-point harness and the head restrained. Insert earbuds (along with a white noise signal) will be used to reduce external noise. Subjects will always be asked to make a decision (e.g. left versus right) by pressing buttons with their left or right hands. If not certain, subjects are instructed to provide their best guess.
223481660|NCT05818787|BEHAVIORAL|Placebo Control|Participants will complete home-based exercises that are not associated with improving vestibular perception or balance (e.g. saccades, smooth pursuit). Participants will sit in a comfortable chair facing out into a living space. They will then find a stationary object to the right and to the left of themselves as well as above and below their line of sight. Without moving their heads, they will look back and forth and up and down between the objects. Participants will complete a total of 400 eye motions per day for six days.
223481661|NCT00327327|DRUG|imexon|30-60 minutes IV, days 1,8,15 every 28 days
223481662|NCT00327327|DRUG|gemcitabine|30 minutes IV, days 1,8,15 every 28 days
223481663|NCT05579132|DRUG|MK-1045|MK-1045 is administered by IV infusion once a week (QW), 4 weeks per treatment cycle, starting with 2 cycles of induction treatment. After a 2-week treatment-free interval, responders to induction treatment receive 3 cycles of consolidation therapy, and up to 7 cycles of maintenance treatment or until intolerable toxicity, disease progression, withdrawal of informed consent, loss to follow-up, receipt of other antitumor therapy, or death, whichever occurs first. Each 4 week treatment cycle is followed by a 2-week treatment-free interval
224072307|NCT05072132|OTHER|standard information on arsenic exposure reduction|In this study, intervention and control groups will receive a standard informational intervention which will remind them of the effects of arsenic exposure and potential strategies that can be implemented to reduce their exposure.
224072308|NCT03252483|OTHER|Bundled HCV/HIV Screening|Participants were randomized to a bundled HIV/HCV test group (intervention) to evaluate whether integrating HIV and HCV rapid screening would adversely impact HIV test acceptance.
223481666|NCT06003400|DEVICE|Study treatment administration (TriO FITT)|Patients will be treated with the study device 2-3 times per week (determined by their wagner score) for an hour at each visit. treatment will include a combination of methods (the exact details is patented by the company and can not be elaborated).
223481667|NCT06003400|DIAGNOSTIC_TEST|Physical Examination|physical examination will include an overall examination of the patient's body for any iregular findings and or physical changes from baseline.
223481668|NCT06003400|DIAGNOSTIC_TEST|Vital Signs|vital signs measurement will include blood pressure, pulse and oral temperature as well as hight and weight.
223481669|NCT06003400|DIAGNOSTIC_TEST|Hematology Blood Tests|complete CBC, coagulogram (PT, aPTT); D-dimer; C-reactive protein;; Ferritin; fibrinogen,
224072309|NCT03252483|OTHER|HIV Screening|Participants were randomized to an HIV-only screening group as a control comparator.
224072310|NCT01902550|DRUG|Metoprolol tartrate immediate-release (metoprolol IR)|Metoprolol IR will be administered as single oral dose of 100 mg tablet or capsule.
224072311|NCT01902550|DRUG|JNJ-54452840|JNJ-54452840 (12 ml solution containing 240 mg JNJ-54452840) will be administered intravenously over 1 minute.
224169395|NCT01171313|DRUG|XP21279 and carbidopa (experimental)|Eligible subjects entering the study will be randomized into 1 of 4 sequences where they will be dosed XP21279 and Carbidopa
224169396|NCT01171313|DRUG|Sinemet (comparator)|Eligible subjects entering the study will be randomized into 1 of 4 sequences where they will be dosed Sinemet.
224169397|NCT01171313|DRUG|Placebo for XP21279 and carbidopa|Eligible subjects entering the study will be randomized into 1 of 4 sequences where they will be dosed placebo for XP21279 and carbidopa
224169398|NCT01171313|DRUG|Placebo for Sinemet|Eligible subjects entering the study will be randomized into 1 of 4 sequences where they will be dosed placebo for Sinemet
224169399|NCT01105468|DEVICE|Breath Collecting Unit|Collect two breath gas samples per patient on one day before surgery
224169400|NCT01105468|DEVICE|Breath Collecting Unit|Collect two or more breath gas samples on different days during adjuvant or neo-adjuvant therapy.
224169401|NCT00683501|DRUG|DNB-001|four dosages of DNB-001, one placebo dosage
224305495|NCT03452332|RADIATION|Stereotactic Radiosurgery|Undergo SABR
224072312|NCT01902550|DRUG|Placebo|Matching Placebo (normal saline) to JNJ-54452840 will be administered intravenously over 1 minute on Day 1.
224072313|NCT00512798|DRUG|PS-341 (VELCADE)|"Dose Levels PS-341 (day 1)~* Level -1 0.7 mg/m2~* Level 1 1.0 mg/m2~* Level 2 1.0 mg/m2~* Level 3 1.3 mg/m2~* Level 4 1.5 mg/m2"
224072314|NCT00512798|DRUG|temozolomide|"Temozolomide (day 8)~* Level - 1 50 mg/m2~* Level 1 50 mg/m2~* Level 2 75/mg/m2~* Level 3 75 mg/m2~* Level 4 75 mg/m2"
224072315|NCT00512798|OTHER|immunoenzyme technique|Not noted
224072316|NCT00512798|DRUG|PS-341 (VELCADE)|1.3 mg/m2 by IV on days 1, 4, 8, and 11 of every 21 days
224072317|NCT00512798|DRUG|Temozolomide|75 mg/m2 by mouth, daily, during weeks 2-8 (42 days) of every 9-week course.
224072318|NCT05701332|BIOLOGICAL|Bacillus Calmette Guerin|effect of local B.C.G and Gemcitabine on semen parametes and testicular volume
224305496|NCT03452332|BIOLOGICAL|Tremelimumab|Given IV
224305497|NCT02812979|DEVICE|Airvo2 with Aerogen Solo|Nebulization of salbutamol with Airvo 2 and Aerogen solo
224305498|NCT02812979|DEVICE|Mask|Usual nebulization of salbutamol with mask
224305499|NCT02812979|DEVICE|arm control Airvo2 without nebulization of salbutamol|Airvo2 with Aerogen Solo. No nebulization of salbutamol
223481670|NCT06003400|DIAGNOSTIC_TEST|Biochemistry Blood Test|urea, creatinine, uric acid, sodium, potassium, chloride, calcium, glucose, glycated hemoglobin, alkaline phosphatase (FA), alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin and fractions ( BTF), total proteins and fractions (PTF), lipid profile (total cholesterol, fractions and triglycerides).
223481671|NCT06003400|DIAGNOSTIC_TEST|Wound Digital Photography|3 photographs of the wound taken before wash, after wash and after treatment.
223481672|NCT06003400|DIAGNOSTIC_TEST|Urine pregnancy test|for women with childbearing potential
223481673|NCT06003400|OTHER|Visual Analogue Scale|Visual Analogue Scale - visual scale scoring 1-10 measuring pain, 10 being worst pain.
223585184|NCT03984487|BEHAVIORAL|Surviving and Thriving in the Real World|The STRW intervention consists of 14 weekly concurrent adolescent and parent group sessions. The DLS to be targeted in the intervention include: Morning Routine (i.e., completing a morning personal hygiene routine); Laundry (i.e., sorting clothing, using a washing machine and dryer, and folding and putting clothes away); Kitchen/Cooking (i.e., cooking items in the microwave, oven, and stove, safe kitchen practices, cleaning up the kitchen after cooking, and grocery shopping); Self-Management (i.e., managing worry and stress related to learning DLS and transitioning to adulthood); and Money Management (i.e., using money to purchase items, evaluating the quality and price of items, understanding and using a checking and savings account, and budgeting money to cover expenses).
223585185|NCT03984487|BEHAVIORAL|Program for the Education and Enrichment of Relational Skills|PEERS is an evidence-based social skills training program for youth with social challenges between the ages of 13-18.The program includes a teen group and a parent group that meet concurrently. Teens learn about conversations, electronic communication, joining groups, humor, handling teasing and disagreements, and planning get-togethers with other teens. Parents learn how to coach their teens to continue to use the skills when the program is complete.
223585186|NCT00993733|PROCEDURE|Continuous veno-venous haemodiafiltration|Dialysis procedure administrated to the patients with acute renal failure
223585187|NCT02332733|BIOLOGICAL|TV003|10\^3 plaque forming units (PFU) of rDEN1 delta 30, 10\^3 PFU of rDEN2/4 delta 30(ME), 10\^3 PFU of rDEN3 delta 30/31-7164, and 10\^3 PFU of rDEN4 delta 30 to be administered as 0.5 mL by subcutaneous injection in the deltoid region of the upper arm or the thigh in pediatric participants
223585188|NCT02332733|BIOLOGICAL|Placebo for TV003|To be administered as 0.5 mL by subcutaneous injection in the deltoid region of the upper arm or the thigh in pediatric participants
223585189|NCT00897624|GENETIC|gene expression analysis|
223585190|NCT00897624|GENETIC|reverse transcriptase-polymerase chain reaction|
223585191|NCT00897624|OTHER|laboratory biomarker analysis|
223585192|NCT03823950|DRUG|Granulocyte Colony-Stimulating Factor|Begin G-CSF 72 hours following chemotherapy
223585193|NCT04941404|DRUG|TQ05105 tablets|Participants began oral administration of TQ05105 tablets at 10 mg twice daily (BID),followed by 5 mg or 15 mg BID depending on the situation of the study. twice daily in 28-day cycle until disease progression/intolerance occurs or the sponsor terminates the study.
223585194|NCT01792518|DRUG|Placebo|
223585195|NCT01792518|DRUG|Linagliptin 5mg|
223585196|NCT05648682|OTHER|Salin|Patients were told that they should gargle using approximately 2 tablespoons of the solution given for each use. SF solution was obtained from the medical company as 500 ml separately for each patient.
223585197|NCT05648682|OTHER|Sodium bicarbonate|Patients were told that they should gargle using approximately two tablespoons of the solution given for each use. The 500 ml distilled water bottle to be used for the SB solution was obtained from the medical company, separately for each patient.
223585198|NCT05648682|OTHER|Thyme honey|Patients were told that they should gargle using approximately 2 tablespoons of the solution given for each use.
223585199|NCT05648682|OTHER|Control|The patients continued to use the antifungal solution containing the active ingredient nystatin, which was prescribed routinely in the clinical procedure, 3 times a day.
223585200|NCT02706665|OTHER|SEDline monitor|The SEDline monitor gives us the Patient State Index (PSI), a dimensionless number within a range of 0 to100.
223585201|NCT05386212|DEVICE|web app healthcare instructions for relieving back pain|This study designed web-based dynamic pain relief instructions for women with spinal compression fractures.
223481674|NCT06003400|OTHER|SF-36|SF-36 - quality of life questionnaire scaling from 0-100, 100 being best quality of life.
223481675|NCT06003400|DIAGNOSTIC_TEST|Wounds evaluation|including size measurements and visual description.
223481676|NCT06511778|DRUG|Hemoblast Bellows application|Hemoblast bellows is a hemostatic agent clinically proven effective on the validated SPOT GRADE scale for minimal, mild, and moderate bleeding. Patients will have the Hemoblast bellows applied during on pump sternotomy surgery.
223481677|NCT02656030|OTHER|semispinalis cervicis resisted exercise|semispinalis cervicis resisted exercise, 2 time per week, 6 weeks duration
223481678|NCT02656030|OTHER|cranio-cervical flexion exercise|cranio-cervical flexion exercise, 2 time per week, 6 weeks duration
223481679|NCT02656030|OTHER|usual care|usual care, 2 time per week, 6 weeks duration
223481680|NCT03202303|DRUG|Cannabidivarin|Weight-based dosing of 10 mg/kg/day of CBDV
223481681|NCT03202303|DRUG|Matched Placebo|Weight-based dosing of 10 mg/kg/day of placebo
223481682|NCT00519350|PROCEDURE|Blood collection|In arterial or venous lines already present, small amounts of blood will be collected at certain timepoints following operation
223481683|NCT03789877|OTHER|Physical Activity|Participate in home-based walking program
223481684|NCT03789877|OTHER|Questionnaire Administration|Ancillary studies
223481685|NCT03789877|PROCEDURE|Repetitive Transcranial Magnetic Stimulation|Undergo rTMS
223585202|NCT04469348|DIAGNOSTIC_TEST|nasal swab|nasal swab will be performed to analysis biological markers at every visit.
223481686|NCT03789877|PROCEDURE|Sham Intervention|Undergo sham rTMS
223481687|NCT04222049|DEVICE|Vibro Tactile Gadget|The concept is to apply vibro tactile gadget to different nerve points which when applied transmit waves to the focused parts of brain which will result in blood flow and activation of dead cells. As a result some disabled part of the body because of those dead cells can show improvement.
223481688|NCT01933594|DRUG|Romidepsin|RMD administered over 4 hours via an intravenous (IV) catheter.
223481689|NCT01933594|DRUG|Placebo for Romidepsin|Placebo for RMD administered over 4 hours via an IV catheter.
223481690|NCT04796701|OTHER|Follow-Home-intervention|x
224169402|NCT07120477|DRUG|Intravenous Esketamine|Single-session intravenous esketamine infusion (0.5 mg/kg) administered over 40 minutes in a medical setting with continuous monitoring of vital signs, blood pressure, ECG, and oxygen saturation for 4 hours post-infusion. Administration supervised by trained medical staff with emergency protocols available. Participants will be discharged 24 hours post-infusion if no clinical complications arise, with ambulatory evaluations at 48 hours, 72 hours, and 7 days post-infusion.
224169403|NCT07120477|OTHER|Crisis Response Planning intervention (structures safety planning)|Collaborative safety planning intervention delivered by trained clinical psychologists in 20-45 minute sessions. Participants create personalized, written crisis response plans identifying warning signs of emotional distress, internal coping strategies, social support contacts, professional resources, and means restriction methods. The intervention follows a structured format focusing on practical crisis management tools that participants can implement during suicidal crises.
224169404|NCT07122219|BEHAVIORAL|NIATx|The Network for the Improvement of Addiction Treatment (NIATx) model uses a bundle of implementation tools that include expert facilitation (coaching) and quality process improvement specifically for behavioural healthcare settings to improve access and retention in treatment.
224169405|NCT06932146|DRUG|LLX-424|Tablets for oral administration
224169406|NCT07124832|BEHAVIORAL|Socratic Questioning Method|"Socratic questioning is a method in which behaviour is examined through questions such as what, where, which, who, when, how, and why. It consists of four stages: defining the problem, evaluating and identifying alternatives, redefining, and discussing feasible outcomes. Through this process, individuals develop their critical thinking skills and make self-evaluations."
224169407|NCT07134101|DRUG|Serplulimab|Serplulimab 300 mg IV on Day 1
224169408|NCT07134101|DRUG|Bevacizumab|Bevacizumab 5 mg/kg IV on Day 1
224169409|NCT07134101|RADIATION|Short-Course Radioterapy|25 Gy in 5 fractions over 1 week
224169410|NCT07134101|DRUG|Chemotherapy (CAPOX or capecitabine)|Capecitabine: 800 mg/m² orally, twice daily (BID), on Days 1-14 of each cycle Oxaliplatin: 130 mg/m² intravenous infusion, on Day 1 of each cycle
224169411|NCT04341311|DRUG|Marizomib|\- Intravenously initially given every other week over a 28 day course but will go to weekly x 3 and weekly x 4 as the dose levels increase Up to 26 courses.
224169412|NCT04341311|DRUG|Panobinostat|\- Panobinostat: Oral dosage is given 3 times weekly, every other week over a 28 day course
224169413|NCT07140861|OTHER|Conventional|"patients will receive conventional therapy that include~1. Short foot exercises~2. Towel-curl exercise~3. Heel raise exercise~4. Calf stretch"
224169414|NCT07140861|OTHER|Experimental|"Core stability exercises:~The training programs will last 6 weeks and comprise 3 training sessions per week. Each training session lasted 30 min, starting with a brief, standardized warm-up program mainly consisting of low-intensity core strength exercises to prepare the neuromuscular system for the training loads and ending with a cool-down program (i.e., dynamic stretching). During the main part of training, research group will conduct the big 3 exercises as described by McGill (Mcgill, 2001). These include the curl-up, side bridge, and quadruped position. In other words, every single training session consisted of frontal, dorsal, and lateral core exercises. Training intensity will be progressed and individually increased over the 6-week training program by modulating lever lengths, movement velocity"
224169415|NCT02941861|OTHER|Recurrence Rate of HCC after surgery|Recurrence Rate of HCC after surgery
224169416|NCT02941861|OTHER|Recurrence Rate of CCA after surgery|Recurrence Rate of CCA after surgery
223585203|NCT04807387|DEVICE|Vaginal Stent A|Ring stent
223585204|NCT04807387|DEVICE|Vaginal Stent B|Flower stent
224169417|NCT01287767|BEHAVIORAL|A multidimensional support program|Counseling, education and problem-solving in support group, ad hoc counseling
224169418|NCT04350060|OTHER|Retro-fitted room with technological enhancements|Reconstructing and retrofitting a currently existing memory care room at Samaritan Bethany Arbor Terrace Senior Living with integrated technologies specifically to accommodate the needs of persons with dementia to enhance sensory stimulation in sight, sound and sleep.
224169419|NCT07138651|OTHER|Aspiration care bundle|Evidence-based aspiration care protocol
223481691|NCT03012646|DRUG|Inhaled Treprostinil|Inhaled treprostinil (6 mcg/breath) administered four times daily
223481692|NCT05049122|DRUG|Dupilumab SAR231893|Pharmaceutical form: solution for injection Route of administration: subcutaneous (SC)
223481693|NCT01745588|DRUG|Pomalidomide|
223481694|NCT01745588|PROCEDURE|stem cell|
223481695|NCT01745588|DRUG|Dexamethasone|
223481696|NCT01745588|DRUG|Clarithromycin|
223481697|NCT03275506|DRUG|Pembrolizumab Injectable Product - Chemotherapy - Bevacizumab|Pembrolizumab 200 mg then carboplatin (AUC5 or 6) and paclitaxel (175mg/m²), +/- bevacizumab (15 mg/kg Q3W)
223481698|NCT03275506|DRUG|Chemotherapy - Bevacizumab|Carboplatin (AUC5 or 6) and paclitaxel (175mg/m²), +/- bevacizumab (15 mg/kg Q3W)
223481699|NCT03678077|OTHER|Mild traumatic brain injury|This is a register based observational study and does not include interventions. Exposure is mild traumatic brain injury.
223585205|NCT04807387|DEVICE|Vaginal Stent|Vaginal stent chosen from A or B that is the most comfortable
224169420|NCT03128307|DEVICE|Zyppah Anti-snoring Appliance|Use of an OTC mouth guard at night to prevent snoring
224169421|NCT05829811|DEVICE|Lifestyle APP and Artificial Intelligence solutions validation|The lifestyle APP will take into account all the psychological aspect linked to the disease, including the social isolation. Lifestyle APP is not a measurement technology but it is a preventive measures against diabetes evolution that provide insights and advices daily, by the collection of structured data of parameters, essential to feed the AI for Risk analysis module. The involvement of Physicians expert in this discipline will evaluate the effectiveness of the psychosocial education.
223481700|NCT00004261|DRUG|EF5|
223481701|NCT00004261|OTHER|flow cytometry|
223481702|NCT00004261|OTHER|fluorescent antibody technique|
223481703|NCT00004261|OTHER|immunohistochemistry staining method|
223481704|NCT00004261|PROCEDURE|biopsy|
223481705|NCT05295719|DIETARY_SUPPLEMENT|Omega-3 polyunsaturated fatty acid|4 grams n-3 PUFA (AlaskOmega®) per day (3000 mg EPA and 1000 mg DHA)
223585206|NCT04808193|OTHER|Survey|Participants will fill in the survey
224169422|NCT02112461|BEHAVIORAL|SCP-Hospice Alert|The intervention in Project 1 SCP utilizes a multi-faceted system. The SCP-Hospice symptom management model will include several features: 1) a computer-based telecommunication system to monitor symptoms as perceived and reported by the family caregiver; 2) tailored care management messages that SCP provides directly to the caregivers to promote care management based on the individualized patient symptom profile and caregiver distress; and 3) an automated alerting function that notifies the hospice nurse of unrelieved symptoms that have exceeded a pre-set threshold.
224169423|NCT06949787|PROCEDURE|Membrane sweeping|Participants in the membranes sweeping group will receive membrane sweeping. If labor will not initiate within 48 hours, the procedure will be repeated up to a maximum of three times at 48-hour intervals.
224169424|NCT07149285|OTHER|Mandala coloring|"Intervention Group:~The content of the study and the mandala application will be explained to women diagnosed with menopause, and after obtaining consent, a personal information form and scales regarding menopause symptoms and quality of life will be applied. Participants will be given a sample and blank mandala, 12 colored crayons and a follow-up form. The mandala application will be done for 20-30 minutes every day for 15 days, and will be monitored by phone every other day. At the end of the process, the scales will be re-applied and the follow-up forms will be collected. Their routine treatments will continue."
224169425|NCT07148648|PROCEDURE|Chest Wall Reconstruction|there are many methods described in literature for reconstruction of chest wall after chest wall resection. The investigators are focusing on chest wall reconstruction using steel wires in this study.
224169426|NCT07147517|OTHER|Component A0|It will be implemented as a recruitment strategy. This strategy will enable members of the community to access no cost testing for respiratory infections. If a participant feels sick or thinks they have been exposed to a respiratory infection and wants to be tested, they can complete a symptoms and exposure survey in the PREVENT APP, retrieve a PCR test kit from a vending machine using a unique code received through the PREVENT APP, self-collect an anterior nares nasal swab following instructions provided, and return the test kit at one of the vending machines or drop off locations for the EXCITE lab to pick up and process. The anterior nares nasal swab will be tested for SARS-CoV-2, influenza, Respiratory Syncytial Virus, and other germs (viruses or bacteria) that cause respiratory infections. At the time of consent and registration for the Community Testing Component, participants will be used to screen for Cohorts A/B.
224169427|NCT07147517|OTHER|Component A1|Participants will be invited to 'test' out the PREVENT App and a provide a 'baseline' sample to ensure competency for requesting a nasal swab, retrieving the test kit from a vending machine, self-collecting a sample, and returning the test for PCR testing, with the assistance of study staff. Weekly Symptom Surveys, Annual Surveys, and immunization status.
224169428|NCT07147517|OTHER|Component A2|Investigators will collect immunologic specimens from a subset of participants in Component A (the subset herein referred to as Component A immunologic sub-study). Investigators will combine testing data from these immunologic specimens with multiple data elements already captured in Component A (such as data from pathogen testing and sequencing, survey data, medical records, or immunization services) and Component B (serum obtained at enrollment and 28 post-enrollment) to meet sub-study objectives. Overall, the Component A sub-study will provide critical insight into the immune response to respiratory pathogen infections and immunizations.
224169429|NCT07147517|OTHER|Component B|"Participants will be asked to complete the enrollment survey after enrolling in Component B if the survey has not already been completed as part of Component A. They will also be asked to complete:~1. Daily anterior nares nasal swab collection~2. All household participants, including the index case, will be asked to self-collect an enrollment swab and daily nasal swab specimens for 14 days and return them for testing.~3. Mucosal specimen collection~4. Survey data collection"
224169430|NCT07147894|BEHAVIORAL|Nongamified N-back training|This Single Task Training is an adaptive N-back task in which participants respond to colors and/or shapes.
224169431|NCT07147894|BEHAVIORAL|Gamified N-back training|Participants train on a gamified version of the N-back task, specifically, players control an astronaut that collects resources (target stimuli) needed to feed a colony and keep the technology working, while avoiding non-targets and other obstacles.
224169432|NCT07147894|BEHAVIORAL|Multiple Domain Training|Participants train on a gamified versions of the N-back task, Complex span, Set-shifting and Inhibitory control task.
224169433|NCT07147894|BEHAVIORAL|Nongamified N-back training|This Single Task Training trains a visual, adaptive N-back task in which participants respond to colors and/or shapes.
224169434|NCT07147894|BEHAVIORAL|Coaching Session|Participants in coaching conditions receive weekly, motivational coaching sessions via videoconference to (i) provide encouragement taking into account individual training performance and self-reported engagement (strength-based feedback), (ii) set realistic goals for training (time management, scheduling, and session completion plan, performance goals) while emphasizing autonomy and choice, and (iii) re-explain task and provide corrective feedback as needed.
224169435|NCT07148154|DEVICE|Cytology|Two cervical samples are collected using a cervical brush or swab, following the standard procedure for cervical cytology. Cells are taken from the cervix using a brush/spatula during a gynecological exam. (1) The first sample is kept in the clinical center's pathology department for examination. (2) The second sample is sent to MiMARK's facilities for the investigational project, where it will be processed and stored for future cohort selection and analysis.
224169436|NCT07149103|OTHER|Percutaneous Tibial Nerve Stimulation|By wearing the Confidanz Smart Patch, the Tibial Nerve will be stimulated
224169437|NCT07149103|OTHER|Placebo|No active stimulation will be provided
224169438|NCT07148622|DRUG|Antibiotic regimen 1: sulbactam + ampicillin + azithromycin|For the first 48 hours, 4×2 g IV sulbactam + ampicillin, 1 g oral azithromycin on day 1, and from days 3-7, 3×500 mg oral amoxicillin
224169439|NCT07148622|DRUG|Antibiotic regimen 2: ceftriaxone + clarithromycin + amoxicillin|For the first 48 hours, 1×1 g IV ceftriaxone + 2×500 mg oral clarithromycin, and from day 3 onwards, 3×500 mg oral amoxicillin + 2×500 mg oral clarithromycin.
224169440|NCT07148141|OTHER|Ovarian stimulation|Ovarian stimulation before oocytes retrieval
224305500|NCT01727882|BEHAVIORAL|Brief feedback|A brief feedback was given on the results of the daily assessments, including a recommendation to the paroled offender and a email report was sent to the probation officer.
223585207|NCT05612360|BEHAVIORAL|COVID Booster text messages|Participants will receive text messages per descriptions listed in the arms.
224169441|NCT07148479|OTHER|Telerehabilitation group|The telerehabilitation group participated in balance training sessions delivered through secure virtual platforms such as WhatsApp video calls. Participants completed 3 sessions per week, each lasting 45-60 minutes, over a total of 6 weeks (18 sessions). The program target static, dynamic, anticipatory, and reactive balance. participants will use households items.session began with warm-up exercises such as gentle marching, arm circles, and hamstring stretches, followed by balance training targeting static, dynamic, anticipatory, and reactive components. Exercises included heel-to-toe standing, single-leg stance, tandem stance, obstacle walking, heel-to-toe walking, side stepping, functional reach, weight shifting, caregiver-assisted perturbations, and foam surface standing. All exercises were performed in 3 sets with specified holds or repetitions. Sessions concluded with cool-down activities including tricep stretches, forward bends, and deep breathing.
224169442|NCT07148479|OTHER|Traditional balance training group|Same as telerehabilitation group but it will concluded in a clinical setting.
224169443|NCT06948409|DRUG|Choice of reversal agent (sugammadex or neostigmine [with muscaranic antagonist])|The use of sugammadex or neostigmine (in co-administration with muscarinic antagonist) will be compared. The muscarinic antagonists that will be considered are atropine and glycopyrrolate.
224169444|NCT06949696|OTHER|Dual Task Training|In dual task training, patients will be given cognitive exercises such as counting backwards from 100 by 3, counting the names of cities, girls and boys while walking.
224169445|NCT06949696|OTHER|Cognitive Rehabilitation|In cognitive rehabilitation, patients will be given paper-and-pencil activities and exercises to find the difference between two pictures.
224169446|NCT06949696|OTHER|Conventionel Physiotherapy|In conventionel physiotherapy, patients will be given posture exercises for balance and strengthening.
224169447|NCT06949215|DIAGNOSTIC_TEST|68Ga-NYM096 PET/CT|"Participants will be administered a single, intravenous bolus of 68Ga-NYM096 The recommended administered activity of 68Ga-NYM096 is 1.8-2.2 MBq per kilogram bodyweight, subject to variation that may be required owing to variable elution efficiencies obtained during the lifetime of the 68Ga / 68Ga generator.~The CT and PET imaging session will begin approximately 45 to 75 minutes after 68Ga-NYM096 administration."
224169448|NCT06949826|DRUG|Buprenorphine Transdermal System|The buprenorphine transdermal system is unique from other interventions in the study, as it is the experimental drug in the study. The buprenorphine transdermal system will be applied in the pre-operative holding area. Aside from the buprenorphine transdermal system, participants assigned to this intervention will otherwise receive the standard of care in their post-operative pain management following ankle fracture surgery.
224169449|NCT06949826|DRUG|Placebo Patch|The placebo patch is unique from other interventions in the study, as it is the placebo drug in the study. The placebo patch will be applied in the pre-operative holding area. Aside from the placebo patch, participants assigned to this intervention will otherwise receive the standard of care in their post-operative pain management following ankle fracture surgery.
223481706|NCT05295719|BEHAVIORAL|High-Intensity Interval Training|A 4 x 4 high-intensity interval training (HIIT) exercise program 3 days/week for 4 weeks. This will include a 3 min warm up at 15% watt max followed by 4 intervals for 4 min at 65% watt max with 3 min active recovery at 15% watt max.
223481707|NCT05295719|DIETARY_SUPPLEMENT|Safflower oil|4 grams safflower oil (AlaskOmega®) per day
223481708|NCT05295719|BEHAVIORAL|Low-intensity training|A low-intensity training exercise program 3 days/week for 4 weeks. This will include consistently cycling at 50% HRmax for 30 min.
223481709|NCT04289038|OTHER|Autogenic Relaxation|Autogenic relaxation
223481710|NCT04289038|OTHER|virtual reality game application|virtual reality game application,
223585208|NCT03759470|DIAGNOSTIC_TEST|CSF examination|"The CSF samples will be stored at -80°C until testing . CSF specimens will be prepared for GS and culture examinations by centrifugation at 3,000 rpm for 10 minutes at room temperature. Culture will be performed by inoculating 1-2 drops of CSF sediment directly onto each of the following agar plates: horse-blood agar, Thayer-Martin agar, choc- olate agar and Sabouraud agar. Moreover, a broth tube (brain-heart infusion, BHI) will be inoculated with one drop of the sediment. Agar plates and broth will be incubated for 1 to 5 days at 35-37°C (with \~5% CO2, or in a candle-jar, for Thayer-Martin and chocolate agar) .~In addition to GS and culture method , India ink test and culture and latex agglutination test (LAT). LAT assay will be performed on CSF samples using Latex-antigen detection system kit."
223585209|NCT03010020|BEHAVIORAL|PCC|Personalized Cognitive Counseling (PCC) sessions will be delivered as described above.
224169450|NCT06948513|DRUG|Naproxen|Naproxen given immediately post-operatively following Mohs surgery reconstruction
224169451|NCT06948513|DRUG|Acetaminophen (Standard of Care)|Acetaminophen alternated with ibuprofen on an as needed, patient directed basis
224169452|NCT06948513|DRUG|ibuprofen|Ibuprofen alternated with acetaminophen in a patient directed manner for as needed pain control
224169453|NCT07147244|OTHER|Treatment 1: Full GRIN course (Lessons 1-8)|multi module online training
224169454|NCT07147244|OTHER|Treatment 2: Part 1 of GRIN (Lessons 1-4)|multi module online training
224169455|NCT07147244|OTHER|Treatment 3: Part 2 of GRIN (Lesson 1, 5-8)|multi module online training
224305501|NCT01727882|BEHAVIORAL|Daily assessments|Daily assessment of stress, mental symptoms, alcohol and substance use during 30 consecutive days after parole.
224305502|NCT05683327|DIETARY_SUPPLEMENT|UltraHA® 75 mg/capsule|Take 2 capsules per day at any time.
224305503|NCT05683327|DIETARY_SUPPLEMENT|UltraHA® 40 mg/capsule|Take 2 capsules per day at any time.
224305504|NCT05683327|DIETARY_SUPPLEMENT|Placebo|Take 2 capsules per day at any time.
223481711|NCT04289038|OTHER|kidney function narration|kidney function narration
223481712|NCT02325778|PROCEDURE|CTI ablation Timing|The timing of when the CTI ablation is performed. There are no other relevant interventions used in the procedure.
223481713|NCT02105090|DRUG|Anesthetics, Local|
223481714|NCT02105090|DRUG|Sodium Chloride 0.9%|
223481715|NCT03039075|DRUG|Metformin SR Tablet|Metformin SR Tablet made in Conquer pharmaceutical co., LTD
223481716|NCT03419468|OTHER|Self Geriatric Assessment Measure (SGAM)|Self Geriatric Assessment Measure
223481717|NCT06520891|DRUG|Statin and SGLT2i|Statin as atrovastatin SGLT2i as dapagliflozin
223481718|NCT03547570|OTHER|Progressive heavy shoulder resistance training|The training programme includes five exercises identified in literature to target scapular and rotator cuff muscles.
224169456|NCT07147543|DEVICE|Electrically Powered Orthopedic Exercise Device|Participants who pass the screening undergo an evaluation of gait function and balance ability without wearing the Electrically Powered Orthopedic Exercise Device. Afterward, the patient wears the motorized orthopedic exercise device for a total of four adaptation sessions. In each session, the patient performs short-distance walking within 10 meters while wearing the device to explore the appropriate assistive mode and level of support that match their physical condition. No evaluations are conducted while wearing the device during sessions 1, 2, and 3. After the 4th session, an evaluation identical to the one conducted without the device is performed while wearing it, and a satisfaction survey is conducted.
224169457|NCT07148596|OTHER|It is an observational study without any intervention measures.|All patients will fast for 6 hours and will abstain from drinking for 2 hours preoperatively, with no premedication. Preoxygenation will be performed with an oxygen flow rate of 6 L/min. Ciprofol will be continuously infused via a micropump at a rate of 12 mg/kg/h. During preoxygenation with a facemask, if respiratory depression occurs during ciprofol infusion, assisted ventilation via facemask will be initiated. After LOC and completion of observation indices, the anesthesiologist may administer midazolam (1-3 mg), sufentanil (0.2-0.5 μg/kg), and rocuronium (0.3-0.6 mg/kg) sequentially based on the patient's age, physical condition, and BIS values to complete anesthesia induction. If hypotension (systolic blood pressure \<90 mmHg or \<80% of baseline) or bradycardia (heart rate \<50 beats/min) occurs during induction, vasoactive agents such as ephedrine or atropine will be administered for management.
224169458|NCT07148830|PROCEDURE|Total Mesopancreas Excision (TMpE) (as part of Pancreaticoduodenectomy)|"* All patients undergo pancreaticoduodenectomy with total mesopancreatic excision (TMpE) and Adjuvant chemotherapy.~* Meticulous dissection and en bloc removal of the fatty tissue and perineural lymphatic layer located between the head of the pancreas and the superior mesenteric vessels (superior mesenteric artery and portal vein) and the celiac axis, performed during pancreaticoduodenectomy."
224169459|NCT07148219|BEHAVIORAL|Embrace Your Power: A VR Journey to Overcome Negative Emotions|"EYP-VR represents a virtual reality (VR) educational tool to combat bullying. Using Meta Quest 3 passthrough technology, the app combines real-world classroom elements with immersive virtual scenarios, enabling safe and interactive experiences that simulate bullying situations but that do not place students in the roles of victims or aggressors but heroes or protectors.~The app guides participants through narrative episodes focused on building empathy, practicing assertiveness, and learning conflict resolution techniques. AI-driven characters dynamically respond to students' actions as they engage in puzzles, and sensory feedback (visual, auditory, and haptic) reinforces key socio-emotional learning outcomes.~The program will take place in classrooms during instructional hours. Each session will end with a feedback phase so that the school counselor can manage any issues that interest them."
224169460|NCT07149129|DEVICE|Electromyographic Biofeedback|"This intervention phase will last 30 minutes of training, during which the participant will be encouraged to actively and voluntarily relax their spastic muscles and will receive visual feedback through the software when this occurs. Two modes will be used in the software: the first, called Recovery, which consists of a game in which the participant is encouraged to contract and relax their muscles in order to guide a rocket in a specific direction to earn points. The second, called Maestro, in which the participant's objective is to keep the rocket below the specified line while maintaining their muscles relaxed. The participant will perform each mode for 15 minutes, totaling the proposed 30 minutes. There may be a break between each mode if the participant experiences fatigue. Afterward, they will receive standard occupational therapy."
224169461|NCT07149129|DEVICE|Sham (No Treatment)|The intervention with the placebo group will have an identical structure to that of the intervention group, but during the biofeedback phase, the software screen will be a simulation, not corresponding to the patient's muscle activity. The patient will receive occupational therapy as usual, in a manner identical to that of the intervention group after the placebo biofeedback therapy.
224169462|NCT07139223|BEHAVIORAL|laughter yoga|Intervention arm: Laughter yoga group sessions will be implemented twice a week for 4 weeks (8 sessions in total); the first session will be \~45 min, the subsequent sessions \~30 min. Sessions will be conducted face-to-face in a suitable room within the institution. Following the interim measurement in week 4, the intervention arm will continue structured individual laughter practices daily for 4 weeks.
223481719|NCT05905835|DEVICE|Synaptic Cryoablation System|The Synaptic Cryo Balloon must be used to isolate all targeted pulmonary veins. Entrance block will be confirmed in all targeted pulmonary veins (PVs) after a 20-minute waiting period or provocative testing with adenosine or isoproterenol. Any additional ablation in the LA beside PV isolation is not allowed in this protocol. Additional ablation of the cavo-tricuspid isthmus (CTI) with a conventional market-approved RF catheter is allowed only in case a typical atrial flutter is documented in prior patient history or occurs during the case (either spontaneously or inducible).
223481720|NCT05735340|BEHAVIORAL|Diabetes Education|Participants in this arm will receive traditional diabetes education over 5 sessions in the first 3 months of participation and be followed for 6 months.
223481721|NCT05735340|BEHAVIORAL|T1DES|Participants in this arm will receive the T1DES behavioral interventions over 5 sessions in the first 3 months of participation and be followed for 6 months.
223481722|NCT06458530|BEHAVIORAL|Vivo|Participants will meet virtually twice a week with their small group and certified trainer for 45 minutes exercise sessions for a 12-week period.
223481723|NCT06285825|DRUG|Emapalumab|Given by Infusion
223481724|NCT06154278|DRUG|Imdusiran (AB-729)|60mg subcutaneously, every 8 weeks, for a total of 4 doses
223481725|NCT04208230|DEVICE|XtremeCT|HRpQCT technology provides information on bone microarchitecture, bone density and bone strength by measuring the cortical and trabecular bone structures with improved spatial resolution and defining the surfaces in three-dimensional manner.
223481726|NCT06423716|DRUG|Duloxetine|60mg duloxetine given 2 weeks prior to total knee arthroplasty and continued for 6 weeks after surgery.
223481727|NCT06423716|DRUG|Placebo|Placebo given 2 weeks prior to total knee arthroplasty and continued for 6 weeks after surgery.
223481731|NCT05722015|BIOLOGICAL|Pembrolizumab Formulated with Berahyaluronidase Alfa|Pembrolizumab (+) Berahyaluronidase alfa SC will be administered for squamous and nonsquamous NSCLC as per the schedule specified in arm; participants may be eligible for second course.
223481732|NCT05722015|DRUG|Pemetrexed|Pemetrexed 500 mg/m² by IV Infusion will be administered for nonsquamous NSCLC as per the schedule specified in arm.
224169463|NCT07149259|DEVICE|At Home Use|Participants will take the device home for 4 weeks to use in daily living, such as the home and community settings. There will be regular follow-up phone calls once per week from a member of the research team (e.g., an occupational therapist, or low vision therapist) who is familiar with the device to assist with possible troubleshooting as well as device use strategies. The follow up calls will also collect information about device use time and activities. The device will be returned at visit 2.
224169464|NCT07148180|DRUG|Tagraxofusp|A CD123-directed cytotoxin, Single-use vial, via intravenous (into the vein) infusion per protocol.
224169465|NCT07148180|DRUG|Azacitidine (AZA)|A cytidine nucleoside analog, single-use vial, via intravenous infusion or subcutaneous (under the skin) injection per standard of care.
224169466|NCT07148180|DRUG|Venetoclax|A BCL-2 inhibitor, tablet, via orally per standard of care.
224169467|NCT06948149|DIETARY_SUPPLEMENT|Creatine monohydrate|Participants will consume one serving of creatine daily (0.10g of creatine/kg of body weight). This relative dosing approach ensures that smaller participants do not receive excessive doses, while larger participants receive an adequate amount. There is currently limited evidence to conclude the effectiveness of timing daily creatine intake, but it is recommended that creatine be consumed at mealtime for optimal absorption. Participants will choose what meal they will take the supplement and will be asked to keep timing consistent throughout the study. This daily low dose method was chosen because other methods (high-dose loading) may have negative side effects (e.g., water retention, cramping).
224169468|NCT06948149|BEHAVIORAL|Resistance training|Participants will use the programmable weight machines along with free weights to target primary muscle groups. In addition, they will complete mini-squats, mini-lunges, and lunge walks. Participants will complete two sets of 6-8 reps. Training stimulus will be increased using the 7RM method - when 2 sets of 6-8 reps are completed with proper form and without discomfort. The investigators will record the number of sets completed and the load lifted for each exercise for each participant at every class.
224169469|NCT07147972|DRUG|Propranolol 80 mg|Propranolol 40-80 mg/day
224169470|NCT07147972|DRUG|Magnesium 400Mg|Magnesium 400 mg daily
224169471|NCT07148609|BEHAVIORAL|Video game-facilitated group activity|The intervention is a 12-week group activity program for each participant in the intervention group, and the program consists of three 50-minute video game facilitated group activity sessions per week. Participants in the intervention group will engage in those group activity session which will be mediated by the game of Super Mario Party on Nintendo Switch.
224169472|NCT03757260|DEVICE|Antimicrobial photodynamic therapy|Antimicrobial photodynamic therapy is carried out in the residual pockets using the Periowave system. The photosensitizing agent is methylene blue. Approximately 0.2 mL of the solution is applied over 60 seconds to each pocket with a blunt-ended side-port irrigator. The site is illuminated for 60 seconds to activate the agent using a disposable, light-diffusing tip that is introduced into the pocket via a diode laser (wavelength = 675 nm, 160 mW of output power).
224169473|NCT03757260|DEVICE|Placebo of photodynamic therapy|The placebo of the antimicrobial photodynamic therapy is carried out in the residual pockets using the Periowave system. The photosensitizing agent is saline solution. Approximately 0.2 mL of the solution is applied over 60 seconds to each pocket with a blunt-ended side-port irrigator. The site is not illuminated (falsely activated) for 60 seconds using a disposable, light-diffusing tip that is introduced into the pocket via a diode laser (wavelength = 675 nm, 160 mW of output power).
224169474|NCT00168168|DRUG|G-CSF/Filgrastim|
224169475|NCT03853252|OTHER|Skin biopsy|Skin biopsy on a location preliminarily anesthetized Disinfection protocol Combined required blood tests (HIV, Hepatitis B)
224169476|NCT06156293|BEHAVIORAL|Cognitive behavioral prevention program for insomnia (CBP-I)|CBP-I will be provided to participants once their districts are exposed.
224169477|NCT04748159|OTHER|Prone position/ Abdominal position|Standardized positioning of the infant in the prone position respectively abdominal position. Depending on age and size, one or two rolled towels are placed lengthwise under the baby. Both arms are placed cranially in U-position towards the head. Since the position of the head has no significant influence on lung ventilation, the head is placed according to the infant's tolerance.
224169478|NCT04290000|OTHER|additional biological samples during CAR-T CELL treatment|"Blood samples (additional tubes) and marrow (quantity taken in addition from the same aspiration) will be collected in addition to those useful for the follow up of the patients (progress of their disease after treatment with CAR-T Cells) at specific points in his treatment journey.~The following samples will also be collected during Apheresis and at Car-T Cells reinjection :~* Apheresis sampling~* CAR-T Cells collected from bag rinsate~In case of invasion, a skin biopsy will be made, 2 days and 8 days after the beginning of the CAR T Cell Treatment, during the patient's hospitalization and during a consultation visit in case of therapeutic progression or failure."
224169479|NCT06231251|OTHER|upper gastrointestinal endoscopy|reduction of ghrelin rich gastric mucosa with band ligation or argon plasma
224169480|NCT04173910|PROCEDURE|Ultrasound LPEC/Sellick|We will perform an ultrasound of the carotid artery and then apply a Sellick manoeuvre and a left paratracheal compression of the cervical esophagus respectively.
224314204|NCT04327739|OTHER|Intervention 2 Exercise and INIT|"* Exercise programme same as Intervention Group 1 and~* Integrated Neuromuscular Inhibition Technique application. Integrated Neuromuscular Inhibition Technique application. (Duration: 15min) The protocol was applied to the following muscles: • Upper border of the trapezius muscle • sternocleidomastoid • levator scapulae muscle • splenius capitis muscle Integrated Neuromuscular Inhibition Technique includes the combination of the following technique: • Ischemic compression • Muscle energy technique • Straincounterstrain technique"
223481733|NCT05722015|DRUG|Cisplatin|Cisplatin 75 mg/m² by IV Infusion will be administered for nonsquamous and squamous NSCLC as per the schedule specified in arm.
223481734|NCT05722015|DRUG|Carboplatin|Carboplatin AUC 5 mg/mL/min in nonsquamous and AUC 6 mg/mL/min in squamous NSCLC will be administered as per the schedule specified in arm.
223481735|NCT05722015|DRUG|Paclitaxel|Paclitaxel 200 mg/m² by IV Infusion will be administered for squamous NSCLC as per the schedule specified in arm.
223481736|NCT05722015|DRUG|Nab-paclitaxel|Nab-paclitaxel 100 mg/m² by IV Infusion will be administered for squamous NSCLC as per the schedule specified in arm.
223481737|NCT05722015|BIOLOGICAL|Pembrolizumab|Pembrolizumab by IV Infusion will be administered for squamous and nonsquamous NSCLC as per the schedule specified in arm; participants may be eligible for second course.
224169481|NCT04370574|DIAGNOSTIC_TEST|Soluble Biomarkers dosage|"1. CytoLyt® fluid will be first processed for routine PDAC diagnosis. In essence, the samples are filtered, tissue fragments and cells are kept for analysis while flow-through is kept until the diagnosis is confirmed. Once this is completed, the samples will be transferred to the lab where the proteins found in the CytoLytR fluid will be precipitated and then solubilized. The protein extracts are stored at -80°C pending proteomic analysis. The remaining CytoLytR fluid supernatant is also stored at - 80°C to be used for metabolomics.~2. Blood sample will be collected from each patient that underwent diagnostic biopsy. Dry tube for serum analysis will be collected at the time of inclusion during the routine blood test. The serum samples are intended for the validation phase (WP4) and will be exclusively dedicated to this study."
224169482|NCT03787355|COMBINATION_PRODUCT|Morse connection Implants|2 neighboring morse connection Implants of Zinedent - Strauman
224305505|NCT03267420|DIAGNOSTIC_TEST|BpTRU First, Unattended Omron Second|"Visit 1: The participants will have the oscillometric device, BpTRU applied to their arm with the higher blood pressure. This will allow assessment with the commonest used Canadian device, which provides an average after 5 unattended readings. This assessment will be followed by the participant wearing a 24 hour ambulatory blood pressure monitor (ABPM) for 24 hours.~Visit 2: Upon returning the 24 hour ABPM device, the patient will have their blood pressure measured with an unattended Omron second. The Omron HEM 907XL will be applied to the same arm that the BpTRU was applied to in the first visit. There will be 5 minutes of quiet rest (participant alone) and three readings subsequently while the patient is still alone with the average blood pressure measurement being noted."
224305506|NCT03267420|DIAGNOSTIC_TEST|Unattended Omron First, BpTRU Second|"Visit 1: The participants will have the Omron HEM 907XL will be applied to their arm with the higher blood pressure. There will be 5 minutes of quiet rest (participant alone) and three readings subsequently while the patient is still alone with the average blood pressure measurement being noted.This assessment will be followed by the participant wearing a 24 hour ambulatory blood pressure monitor (ABPM) for 24 hours.~Visit 2: Upon returning the 24 hour ABPM device, the participants will have the oscillometric device, BpTRU applied to the same arm that the Omron HEM 907 XL was applied to in the first visit. This will allow assessment with the commonest used Canadian device, which provides an average after 5 unattended blood pressure readings."
224305507|NCT03267420|DIAGNOSTIC_TEST|Partially Attended Omron First, Unattended Omron Second|"Visit 1: The participant will have the Omron HEM 907 XL applied to the arm with the higher blood pressure. There will be five minutes of quiet rest (patient alone) and three reading subsequently, but with the nurse entering the room (i.e., partially attended), with the average being noted. This assessment will be followed by the participant wearing a 24 hour ambulatory blood pressure monitor (ABPM) for 24 hours.~Visit 2: Upon returning 24 hour ABPM device, the participant will have the Omron HEM 907 XL applied to same arm that was used during the first visit. There will be five minutes of quiet rest (patient alone) and three readings subsequently (patient still alone) with the average blood pressure measurement being noted."
224305508|NCT04346966|OTHER|Study Group|Video Based Exercises 64 young adults aged 18-40, who are socially isolated due to coronavirus, will be included in this group. A video-based exercise protocol was created for individuals to participate in the study. Each exercise session is planned as 30 minutes 7 days a week for 6 weeks. The protocol was planned to start with warm-up exercises and end with cooling exercises. The exercise protocol has also been determined as a combination of aerobic exercises, strengthening and posture exercises. Individuals will be classified at 4 levels according to their physical activity levels and will be shared with volunteers according to their level of exercise. Volunteers will be evaluated before and after 6 weeks of exercise.
224305509|NCT05927831|DRUG|Grape Seed Extract|Grape seed extract will be applied in the form of a gel on the tooth surface
224305510|NCT05927831|DEVICE|Low-level laser therapy|The device will be set at a wavelength of 810 nm, with a power output of 0.5 watts tip of diameter 300 μ in non-contact mode
224305511|NCT06332001|OTHER|Experimental Group|Listening of music of patient's choice during WB-MRI
224305512|NCT06332001|OTHER|Control Group|Standard care condition during WB-MRI
224305513|NCT04283916|DRUG|Botulinum Toxins|Botulinum toxin injection to abdominal wall
224305514|NCT02575612|PROCEDURE|vacuum-assisted biopsy|Ultrasound guided VAB was used directly prior to breast conserving surgery or mastectomy. It was performed by experienced physicians (\> 50 ultrasound guided minimal invasive biopsies per year, \> 500 breast ultrasound examination of the breast per year). The needle was placed below or beside the target lesion according to physician's choice. At least six biopsies should be taken; up to 12 according to the physicians choice. After the VAB a clip marker was placed to highlight the position of the biopsy for specimen radiography and pathology.
224305515|NCT02251119|DRUG|Tipranavir|
224305516|NCT02251119|DRUG|Ritonavir|
224305517|NCT02251119|DRUG|Loperamide|
224169483|NCT04495673|DEVICE|Transcranial Direct Current Stimulation (tDCS)|Participants receive 10 sessions (2 5-visit blocks of 46 minutes) of active tDCS to DLPFC (dorsolateral prefrontal cortex)
224169484|NCT04495673|DEVICE|Sham Transcranial Direct Current Stimulation (tDCS)|Participants receive 10 sessions (1 5-visit block of 46 minutes of active tDCS and 1 5-visit block of sham tDCS)
224169485|NCT04495673|BEHAVIORAL|Cognitive Training|Executive functioning tasks
224169486|NCT05560009|DRUG|Fluorodopa F 18|Given IV
224169487|NCT05560009|PROCEDURE|Magnetic Resonance Imaging|Undergo PET/MRI
224169488|NCT05560009|PROCEDURE|Positron Emission Tomography|Undergo PET/MRI
224169489|NCT05560009|RADIATION|Radiation Therapy|Receive standard of care radiation therapy
224169490|NCT05560009|PROCEDURE|Surgical Procedure|Undergo standard of care surgery
224169491|NCT05110157|DRUG|Placebo|Oral capsules
224169492|NCT05110157|DRUG|Valbenazine|Oral capsules
223481738|NCT05722015|DRUG|Filgrastim|Filgrastim will be administered as per the schedule specified for the arm.
223481739|NCT05722015|DRUG|Pegylated filgrastim|Pegylated filgrastim will be administered as per the schedule specified for the arm.
224169493|NCT05248789|BIOLOGICAL|OH2 injection|OH2: Oncolytic Type 2 Herpes Simplex Virus
224169494|NCT06799377|BEHAVIORAL|Restricted Activity Reccomendations|"Patients in this respective group will be given restricted activity recommendations over the casting period. They will be told Your child has a forearm/wrist fracture. It is unknown if remaining active while in a cast affects the risk of complications after this type of fracture. Your child has been randomized to the restricted activity group. We ask that you limit sprinting, jumping, and organized sports during the time of cast immobilization. As a rule of thumb, we recommend feet on the floor activities while playing and avoiding playgrounds and gym class if possible. While it is not realistic to restrict a young child entirely, do your best to avoid strenuous or intense exercise until cleared by your physician or nurse practitioner"
224169495|NCT06799377|BEHAVIORAL|Full Activity/Limited Activity Reccomendations|"Patients in this respective group will be allowed to engage in most activities. They will be read Your child has a forearm/wrist fracture. It is unknown if remaining active while in a cast affects the risk of complications after this type of fracture. Your child has been randomized to the activity as tolerated group. Your child may participate in all desired activities except contact sports. Your child does not need to increase his/her activity level but should participate in activities as they feel comfortable doing so. Sprinting, jumping, and organized sports are acceptable as long as your child is not experiencing pain. Your child may use playgrounds and participate in gym class as desired. Do your best to avoid restricting your child from activities unless they are experiencing pain or you have concerns about their safety."
224169496|NCT05471609|DRUG|levodopa/carbidopa oral formulation A|Outer sachet 100mg CD/100mg LD and inner sachet 0mg CD /300mg LD
224169497|NCT05471609|DRUG|levodopa/carbidopa oral formulation B|Outer sachet 100mg CD/0mg LD and inner sachet 0mg CD /400mg LD
224169498|NCT01711931|DEVICE|Implantation of everolimus-eluting bioresorbable vascular scaffold stent|
224169499|NCT01711931|DEVICE|Implantation of everolimus-eluting stents|
224169500|NCT01711931|DEVICE|Implantation of biolimus-eluting stents|
224169501|NCT05230355|DEVICE|standard technique|The probe was moved over each hemisphere for 120 seconds (a total of 240 seconds). Total energy = 2.5 x 0.313 x 240 = 187.8 J
224169502|NCT05230355|DEVICE|modified pattern|The probe was moved over 3 quadrants for 80 seconds for each quadrant (a total of 240 seconds). Total energy = 2.5 x 0.313 x 240 = 187.8 J
224169503|NCT05238324|BIOLOGICAL|Genetic HMI-203|HMI-203 delivered intravenously
224169504|NCT06296667|OTHER|core muscles training exercises|The sessions will be conducted three times per week for four weeks and each exercise will be performed two sets of 10 repetitions. For the static exercises, the final position will be held for 6 second. There will be a pause of 3 second between repetitions, and a 60 sec rest between each exercise. The exercise will be performed in three forms: abdominal bracing, dynamic stabilization, and advanced core strengthening.
223481740|NCT05740618|DRUG|Mannitol Inhalant Product|A sugar alcohol indicated as an add-on maintenance therapy to improve pulmonary function in adult patients 18 years of age and older with cystic fibrosis.
223481741|NCT04513366|DRUG|SEL-212 low-dose|IV infusion of SEL-212 low-dose every 28 days for a total of up to 12 infusions
223481742|NCT04513366|DRUG|SEL-212 high-dose|IV infusion of SEL-212 high-dose every 28 days for a total of up to 12 infusions
223481743|NCT04513366|OTHER|Normal Saline|IV infusion of Normal Saline every 28 days for a total of up to 12 infusions
223481744|NCT06237296|BIOLOGICAL|RSV/hMPV mRNA LNP 1|Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular Injection
223481745|NCT06237296|BIOLOGICAL|RSV/hMPV mRNA LNP 2|Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular Injection
223481746|NCT06237296|BIOLOGICAL|RSV mRNA LNP 1|Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular Injection
223481747|NCT06237296|BIOLOGICAL|hMPV mRNA LNP 1|Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular Injection
224072319|NCT03900871|DRUG|Acetylsalicylic acid|Aspirin (aspirin), also known as acetylsalicylic acid (acetylsalicylic acid), is a salicylic acid drug commonly used as a painkiller, antipyretic and anti-inflammatory drug. There is growing evidence that aspirin has a preventive effect on certain cancers, especially gastrointestinal cancers, and that taking aspirin every day can reduce the risk of colon cancer, and in vitro experiments have also shown that aspirin inhibits the growth of a variety of cancer cells and induces apoptosis.
223481748|NCT05768646|BEHAVIORAL|Neuropsychological instruments|Neuropsychological instruments assessing cognitive (including counterfactual abilities), behavioural and psychopathological features
223481749|NCT00892021|DRUG|NSA-789|
223481750|NCT00892021|DRUG|Placebo|
223481751|NCT02835716|DRUG|roflumilast|DALIRESP is used in adults with severe chronic obstructive pulmonary disease (COPD) to decrease the number of flare-ups or the worsening of COPD symptoms (exacerbations
223481752|NCT02835716|BIOLOGICAL|ustekinumab|STELARA is approved to treat adults 18 years and older with moderate or severe plaque psoriasis that involves large areas or many areas of their body
223481753|NCT04745728|DRUG|Prednisone|1mg/kg/d p.o.which will be tapered after 2 months and discontinued over a 6-12 month period.
224072320|NCT05820425|OTHER|LFP and EEG recording|STN LFP and EEG recording during the OFF and ON medication condition
224072321|NCT02235194|DIETARY_SUPPLEMENT|Amino Acid and chromium-picolinate containing drink|Amino Acid and chromium - picolinate containg water ist taken with a test meal to study efects on glucose and insulin response.
224072322|NCT02235194|DIETARY_SUPPLEMENT|Placebo Drink|Placebo drink ist taken with a test meal to study efects on glucose and insulin response.
224072323|NCT00393874|BEHAVIORAL|Behavioral Sleep Intervention|Participants will receive a workbook with information related to the intervention. The three core components are presented and discussed during these sessions are:1) education about sleep and nightmares; 2) imagery rehearsal; 3) stimulus control and sleep restriction. Session 1 focuses on education on PDSD-related insomnia, nightmares, and sleep avoidance behaviors. The rationale for imagery rehearsal will then be presented, and the technique will be practiced once. Strategies for managing intrusive thoughts and images during the practice of imagery rehearsal will be discussed. Participants will be instructed to practice this technique at least three times each day for the duration of the treatment phase. During the second 45-minute session (Week 3), sleep schedules extracted from the pre-intervention sleep diary will be used to identify goals to reduce insomnia, i.e., for sleep restricted schedules, and activities to be performed out of bed when awake.
224169505|NCT00784316|DRUG|metoprolol, amiodarone|to compare the effectiviness of intravenous administration of metoprolol and amiodarone in the prevention of atrial fibrillation after cardiac surgery
224169506|NCT05157685|DRUG|Azithromycin Oral Tablet|Treatment assigned by randomization will be prescribed immediately. The active or placebo will be dispensed by the centre's pharmacy. Treatment will be taken in the morning or evening for 3 months.
224169507|NCT05157685|DRUG|Placebo|Treatment assigned by randomization will be prescribed immediately. The active or placebo will be dispensed by the centre's pharmacy. Treatment will be taken in the morning or evening for 3 months.
224169508|NCT04765306|DEVICE|Traditional Direct Fascial Closure|Fascial closure using traditional surgical instruments and suture without laparoscopic guidance.
224169509|NCT04765306|DEVICE|Fascial Closure Device|Fascial closure using a fascial closure device under direct laparoscopic guidance.
223481754|NCT04745728|DRUG|Cyclophosphamide|1-2mg/kg/d p.o. with a target accumulated dose of 12g.
224169510|NCT03276494|DEVICE|Intraosseous|Intraosseous administration of hypertonic saline
224169511|NCT03276494|DRUG|Hypertonic saline|Intraosseous administration of hypertonic saline
223481755|NCT04745728|DRUG|Rituximab|1000mg I.V. on D1 and at 6 month. After 6 month, in patients with response but not complete remission, Rituximab could be stopped or repeated with a 6 month-interval (12 month, 18 month, 24 month) until complete remission. Rituximab 1000mg I.V. will be repeated on the 15th day of each Rituximab infusion if CD19+ B cell count\>5/ul.
223481756|NCT01426581|BEHAVIORAL|Teach-To-Goal|"Participants observe a demonstration on the use of each inhaler, with corresponding verbal step-by-step instructions (demonstration, verbal instruction), then participants 'teachback or re-demonstrate the steps; cycles are repeated are read step-by-step instructions (verbal instructions) for each respective inhaler (Metered Dose Inhaler +/- Diskus), and receive a copy of these instructions with images depicting the steps (written instructions)"
223585210|NCT03010020|BEHAVIORAL|Traditional Counseling|GC/CT-infected participants in the standard of care arm (and all GC/CT-negative participants screened for infection) will receive standard post-test counseling in accordance with Peruvian Ministry of Health guidelines.
223585211|NCT06933706|DRUG|losartan 25 mg|Losartan is an angiotensin-II inhibitor that modulates the renin-angiotensin system by blocking the activation of angiotensin type 1 receptors, thus preventing binding with angiotensin-II and decreasing blood pressure. Losartan has a broader therapeutic potential for muscle healing and treatment for diseases ranging from rheumatoid arthritis, osteoarthritis, chronic kidney disease, Marfan syndrome, and fatty liver. TGF-β plays an active role in fibrosis leading to the formation of adhesions and scar tissue. By limiting the formation of adhesions and scar tissue, losartan may reduce pain, myofibroblast activity, synovitis, fibrosis, and cartilage degeneration.
224169512|NCT05421585|OTHER|observational drug study|Postoperative opioid consumption will be evaluated by applying 2 different block methods to patients who have undergone lumbar disc surgery
224169513|NCT01888965|DRUG|Dovitinib|"All patients in the study will receive Dovitinib, 500 mg orally daily for 5 days followed by 2 days off (7 day cycles) for up to 2 years.~If 500 mg is intolerable, 400 mg will be dosed. If 400 mg is intolerable, 300 mg will be dosed"
224169514|NCT01710215|OTHER|FIT Screening Strategy|"* Mailed outreach invitation to complete FIT, including a test kit (1-sample FIT, simplified instructions on how to perform the test, and return mailer with prepaid postage).~* Two live phone reminders from project staff 2 to 3 weeks after the invitation to encourage screening completion.~* Centralized processes to promote guideline-based follow up."
224169515|NCT01710215|OTHER|Colon Screening Strategy|"* Mailed outreach invitation to complete a colonoscopy, including a number to call to schedule a colonoscopy.~* Two live phone call reminders from project staff 2 to 3 weeks after the mailed invitation to encourage screening completion.~* Centralized processes to promote guideline-based follow up."
224169516|NCT05359991|OTHER|Exercise|Cardiopulmonary Exercise Testing (CPET) will be used with Multiple Brief Exercise Bouts (MBEB) in order to obtain the necessary data to yield information on the study outcome variables
224169517|NCT04814355|DRUG|Celecoxib 400 mg|Patients will receive 400 mg/day of celecoxib for 8 weeks.
224169518|NCT03871075|DEVICE|intermittent pneumatic compression|Intermittent pneumatic compression is a non-invasive intervention, consisting of an air pump inside inflatable cuffs that are wrapped around the feet, ankles, and calves. The cuffs rapidly inflate to a pressure of 120 mm Hg, which is sustained for three seconds, followed by rapid deflation. Participants will be asked to wear the device for two hours daily. The device will inflate 180 times/hour.
224169519|NCT03871075|BEHAVIORAL|exercise|Participants will be asked to walk for exercise five days/week, working up to 50 minutes of exercise per day. The intervention includes a) group meetings at the medical center with the coach and other PAD participants; b) regularly scheduled individual telephone check-in by the coach c) weekly remote monitoring by the coach; d) use of the activity monitor to monitor exercise intensity and duration.
223481757|NCT01426581|BEHAVIORAL|Brief Intervention|Participants are read step-by-step instructions (verbal instructions) for each respective inhaler (Metered Dose Inhaler +/- Diskus), and receive a copy of these instructions with images depicting the steps (written instructions)
223481758|NCT02713672|OTHER|Dose adjustment according to genotype|Patients in the intervention group received a dose adjustment according to their CYP2D6 or CYP2C19 genotype based on guidelines of the KNMP
223585212|NCT06933706|OTHER|Placebo capsule|The placebo capsule will look identical to the active study drug, but will not have any active ingredient and will be filled with corn starch
223585213|NCT06160830|DIETARY_SUPPLEMENT|synbiotic|Two capsules of synbiotic per day, each containing 500 mg of synbiotic
224169520|NCT03871075|DEVICE|Sham device|The sham control device is a non-invasive intervention, consisting of an air pump inside inflatable cuffs that are wrapped around the feet, ankles, and calves. The cuffs rapidly inflate to a pressure of 25 mm Hg, which is sustained for three seconds, followed by rapid deflation. Participants will be asked to wear the device for two hours daily. The device will inflate 180 times/hour.
224169521|NCT03871075|BEHAVIORAL|Health Education|Participants attend health-education lectures and receive telephone calls at the same frequency as the exercise group. On-site lectures are delivered by faculty and staff at the medical center. Telephone calls review health-related handouts from the NIA website that are mailed in advance of the telephone call. Content does not include exercise information.
224169522|NCT06481150|DRUG|Tenapanor|Each tablet 30 mg
224169523|NCT06481150|OTHER|Placebo|Placebo
224169524|NCT02084472|OTHER|Baby oil|patient in study 1, arm B washed unscented liquid paraffin (baby oil) in place of aqueous cream
224169525|NCT02084472|OTHER|petroleum jelly|patients in this arm, use petroleum jelly (vaseline), replacing emulsifying ointment as a moisturiser
224169526|NCT02084472|OTHER|Glycerine:petroleum jelly 2:1|patients in this arm use glycerine and petroleum jelly mixed at a ratio of 2:1 in place of cetomacrogol as a moisturiser
224169527|NCT04809467|DRUG|tafasitamab|tafasitamab will be administered at a protocol defined dose once a week for cycles 1-3 and every other week from cycle 4 until progression.
224169528|NCT04809467|DRUG|parsaclisib|parsaclisib will be administered at protocol defined dose for cycles 1 through disease progression.
224169529|NCT04884802|PROCEDURE|Tight blood pressure management|Norepinephrine or phenylephrine infusion to maintain intraoperative MAP ≥85 mmHg.
224169530|NCT04884802|PROCEDURE|Routine blood pressure management|ACEIs, ARBs, and/or calcium channel blockers can be given the morning of surgery if deemed appropriate by the attending anesthesiologist. Intraoperative blood pressure will be managed per clinical routine.
224169531|NCT05057377|DIAGNOSTIC_TEST|Standard Overground Assessment|The standard overground methods to assess three main components of walking are the 10 Meter Walk Test (meters/second, used to measure speed), 5x Sit-to-Stand (seconds, used to measure strength), and the 6-Minute Walk Test (meters, used to measure endurance).
224169532|NCT05057377|DIAGNOSTIC_TEST|Robotic Safety-Environment Assessment|The methods for assessment of the three main components of walking in the robotic environment will be the maximum walking speed tolerated (meters/second, to measure speed), deadband resistance (kilograms, to measure strength), and the 6-minute walk test (meters, to measure endurance).
224169533|NCT01246921|DRUG|Fluticasone proprionate 0.05% cream|Fluticasone proprionate 0.05% cream . In each patient a representative target lesion will be selected which will be assessed by digital analysis. Patients will apply Fluticasone proprionate 0.05% cream once daily during the first 3 months. I nthe following 9 months FP will be applied in a scheme of 3 days per week
224169534|NCT01970436|OTHER|Remote Prenatal Care|Remote Prenatal Care using a combination of in-person and telemedicine prenatal care visits.
224169535|NCT02993640|DRUG|vasopressin + nitro|vasopressin infusion 4,8 U/h for 20 minutes, thereafter nitroglycerine infusion to a MAP of 60 for 5 minutes.
224305518|NCT01051713|BEHAVIORAL|Technology Supported|Those randomized to the Technology Supported condition will record dietary intake and weight on the smartphone, using the user-friendly, persuasive interface developed in Phase I. They will be expected to enter their dietary intake into the smartphone daily throughout the day. They will also be expected to enter their weight and to wear the accelerometer daily. Time-stamped data from the smartphone will upload automatically to the study server throughout the day, where it will be visible to the lifestyle coach. The participant's real-time diet, activity, and weight data relative to goals will also be visually depicted on the participant's smartphone. The anticipated web platform will be developed specifically for the ENGAGED participants. The coach will provide feedback on diet and activity self-monitoring and goal adherence at least weekly by phone, e-mail or text during weeks 1-8 and then at least monthly through the 6 month follow-up.
224305519|NCT01051713|BEHAVIORAL|Standard|"Those randomized to the Standard condition will record everything they eat and will total their daily fat grams and calories on the Keeping Track form used in the DPP. They will turn in their self-monitoring diaries and download their accelerometer (but not see those data) at weekly group sessions 1 through 8. Thereafter they will be expected to turn in paper data monthly, in person at the months 3 and 6 assessments and via mail, fax or e-mail for months 4 and 5. Accelerometer data will be downloaded at in-person visits."
224305520|NCT01782508|DRUG|imatinib|a selectively inhibits the KIT protein tyrosine
224305521|NCT01782508|DRUG|Interferon|Interferon belongs to the large class of glycoproteins known as cytokines.
224305522|NCT03916523|PROCEDURE|Sustained lung inflation|"Preterm infants will receive a total of 15 sustained lung inflations during the first 4 days of life as follows:~1. On day 1 of life (a total of 6 sustained lung inflations, 20 cmH2O for 21 seconds each) once at enrollment and then once every 4 hours~2. On day 2 of life (a total of 3 sustained lung inflations, 15 cmH2O for 21 seconds each) once every 8 hours.~3. On day 3 of life (a total of 3 sustained lung inflations 10cmH2O for 21 seconds each) once every 8 hours.~4. On day 4 of life (a total of 3 sustained lung inflations 10cmH2O for 21 seconds each) once every 8 hours."
224305523|NCT03916523|PROCEDURE|Continuous positive airway pressure (CPAP)|Preterm infants will receive CPAP for respiratory support.
224305524|NCT03916523|PROCEDURE|Mechanical ventilation|Preterm infants in this group will receive mechanical ventilation for respiratory support
223481759|NCT03424278|OTHER|Motor control exercises|Motor control exercises for the deep trunk muscles in patients with chronic low back pain is based on evidence of motor control dysfunction, including delayed onset of activity in the transversus abdomens and internal oblique abdominal muscles and segmental hypertrophy of the lumbar multifidus muscle.
223481760|NCT03424278|OTHER|Resistance training exercises|A type of strength-building exercise program that requires the body muscle to exert a force against some form of resistance, such as weight, stretch bands, water, or immovable objects. Resistance exercise is a combination of static and dynamic contractions involving shortening and lengthening of skeletal muscles.
224169536|NCT06536101|DRUG|GIM-407|GIM-407 oral dose
224169537|NCT06536101|DRUG|Placebo|Matching placebo oral dose
224169538|NCT05032131|BIOLOGICAL|ADSVF|Group 1 and 2 : Escalating dose of ADSVF injection (5 millions of cells, 10 millions of cells and 20 millions of cells).
224169539|NCT05031182|PROCEDURE|Laparoscopy|The hysterectomy is performed by laparoscopy as described in the EMC.
224169540|NCT05031182|PROCEDURE|vNOTES|The hysterectomy is performed by vNOTES as described Dr BAEKELANDT and this team.
224169541|NCT05890599|BEHAVIORAL|Yoga Therapy|"The range of interventions is based on previous studies on yoga interventions specifically for fatigue patients as well as on recommendations, for example, from the WHO. The yoga therapy includes 3 elements: yoga postures (asanas), breathing techniques (pranayama) and relaxation moments.~Emphasis on postures and breathing techniques that are considered to be effective for fatigue symptoms, as well as specific breathing exercises to strengthen the respiratory muscles and increase lung volume."
224169542|NCT05890599|BEHAVIORAL|Health Education|Health education courses are conducted on-site once a week for 90 minutes over a 12-week period by a psychologist with clinical experience. The courses are didactic in nature and consist of lectures on topics of interest to patients with post-COVID syndrome and fatigue, followed by questions and discussion sessions. Topics include information on post-COVID syndrome and fatigue, an introduction to self-help for post-viral symptoms, psychosocial problems and fatigue, relaxation and stress management, nutrition, sleep hygiene, exercise, respecting one's own limits, acceptance, finding meaning, and achieving goals.
224169543|NCT06464679|BIOLOGICAL|anti-CD19 CAR NK cells|Patients will receive Fludarabine (25 mg/m2 per day) and Cyclophosphamide (300mg/m2 per day) on day -5, -4, and -3. Multiple doses of CD19 CAR NK cells will infused using the dose-escalation strategy.
224169544|NCT06013449|DEVICE|Pulsed Electromagnetic Field (PEMF) Device|Pulsed Electromagnetic Field (PEMF) Device BEMER Device consist of a total body mat (B. BODY) plus a targeted pelvic mat (B.PAD), and a Control Unit which powers the device and logs usage. Both B.BODY and B.PAD must be plugged into the Control Unit simultaneously and activated individually. B. Body must be placed on a flat surface (i.e. bed, floor, reclining chair etc.) for best results.
224169545|NCT06013449|DEVICE|Sham Pulsed Electromagnetic Feild (PEMF) Device|The sham PEMF device appears identical to the BEMER PEMF device, with all of the same components and accessories, but does not emit a pulsed electromagnetic field.
223481761|NCT05898412|DRUG|Andexanet alfa|Patients treated with andexanet alfa
223481762|NCT05227716|DRUG|Perioperative magnesium sulfate|Administration of magnesium sulfate as an adjunct in anesthesia
223481763|NCT06200103|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223481764|NCT06200103|PROCEDURE|Bone Scan|Undergo bone scan
223481765|NCT06200103|OTHER|Clinical Observation|Undergo active monitoring
223481766|NCT06200103|PROCEDURE|Computed Tomography|Undergo SPECT/CT or PET/CT
223481767|NCT06200103|OTHER|Gallium Ga 68 Gozetotide|Given IV
223481768|NCT06200103|DRUG|Lutetium Lu 177 Vipivotide Tetraxetan|Given IV
223481769|NCT06200103|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
223585214|NCT06160830|OTHER|placebo|Two capsules of placebo containing maltodextrin per day
223585215|NCT04705948|DRUG|Magnesium sulfate versus ketamine|Magnesium sulfate versus ketamine for of post-operative sore throat after endotracheal intubation
224169546|NCT06397131|COMBINATION_PRODUCT|NT-501 CNTF Implant|Single implantation of CNTF-secreting NT-501 hCNTF device into one eye.
223481770|NCT06200103|OTHER|Questionnaire Administration|Ancillary studies
223481771|NCT06200103|PROCEDURE|Single Photon Emission Computed Tomography|Undergo SPECT/CT
223481772|NCT06360484|DIAGNOSTIC_TEST|investigations for Hepatitis D virus|Investigations included liver function tests, abdominal ultrasounds to identify features of chronic liver disease, and evidence of decompensation. ELISA for Ant-HDV-IgG was conducted.
223481773|NCT01498549|DRUG|Atomoxetine|Atomoxetine 40mg and 80mg compared to the sugar pill
223481774|NCT01498549|DRUG|Sugar Pill|Sugar pill compared to Atomoxetine 40mg and 80mg.
223481775|NCT04478266|DRUG|Amcenestrant-matching placebo|Pharmaceutical form: Tablets Route of Administration: Oral
223481776|NCT04478266|DRUG|SAR439859|Pharmaceutical form: Tablets Route of Administration: Oral
223481777|NCT04478266|DRUG|Palbociclib|Pharmaceutical form: Capsules/Tablets Route of Administration: Oral
223481778|NCT04478266|DRUG|Letrozole|Pharmaceutical form: Capsules Route of Administration: Orally
223481779|NCT04478266|DRUG|Goserelin|Pharmaceutical form: Depot Injection Route of Administration: Subcutaneous
223481780|NCT04478266|DRUG|Letrozole-matching placebo|Pharmaceutical form: Capsules Route of Administration: Orally
223481781|NCT05385770|DRUG|AZM X mg + AML Y mg|tablet, single dose, QD, oral administration
223481782|NCT05385770|DRUG|AZM X mg + AML Y' mg|tablet, single dose, QD, oral administration
223481783|NCT05385770|DRUG|AZM X' mg + AML Y mg|tablet, single dose, QD, oral administration
223481784|NCT05385770|DRUG|AZM X' mg + AML Y' mg|tablet, single dose, QD, oral administration
223585216|NCT04369508|RADIATION|permanent brachytherapy|"Briefly, the patient had a general anesthesia and PPB was performed by using the real-time intraoperative planning method guided by TRUS. The radioactive seeds were inserted transperineally according to a modified peripherally loaded Seattle technique 17. I-125 was used for all implants with a mean seed activity of 0.45 mCi per seed. All procedures were completed by a single surgeon."
224169547|NCT05534126|PROCEDURE|Stellate Ganglion Block Treatment|Stellate ganglion block procedure is a treatment that involves injection of local anesthetic around the stellate ganglion (located at the base of the neck) to block its transmission of pain signals.
224169548|NCT05534126|PROCEDURE|Placebo|Sham
223481785|NCT05385770|DRUG|AZM X mg|tablet, single dose, QD, oral administration
223481786|NCT05385770|DRUG|AZM X' mg|tablet, single dose, QD, oral administration
223481787|NCT05385770|DRUG|AML Y mg|tablet, single dose, QD, oral administration
223481788|NCT05385770|DRUG|AML Y' mg|tablet, single dose, QD, oral administration
223481789|NCT06123117|PROCEDURE|single transversus abdominis laparoscopy-guided plane block|please see arm/group descriptions
223481790|NCT06123117|PROCEDURE|local trocar site ropivacaine infiltration|please see arm/group descriptions
223481791|NCT04058717|OTHER|Normal Nicotine Content research cigarettes|Research cigarettes with 11.6 mg nicotine/cigarette.
223481792|NCT04058717|OTHER|High Nicotine e-cigarette|E-cigarette containing high nicotine e-liquid
223481793|NCT04058717|OTHER|Very Low Nicotine Content research cigarettes|Research cigarettes with 0.2 mg nicotine/cigarette.
223481794|NCT04058717|OTHER|Zero Nicotine e-cigarette|E-cigarette containing zero nicotine e-liquid
223481795|NCT01937468|OTHER|Treg-enriched infusion|Treg-enriched Cell Dose: Participants will be targeted to a defined dose of donor Treg-enriched total nucleated cells. Initial enrollment will be at target dose-level A. Subsequent cohorts will be dose escalated/de-escalated per the schema
223585217|NCT02107872|DRUG|REGN1500|
223585218|NCT02107872|DRUG|placebo|
224169549|NCT06631820|DIETARY_SUPPLEMENT|Epicatechin extract|In the experimental phase, patients will take 50 mg of (-)- Epicatechin twice a day for 8 weeks (total dose 100mg/day). The nutraceutical will be supplied as monodose sachets from Aayam Therapeutics.Study participants will mix the sachet powder with juice (10-20mL) in the morning 15 minutes before breakfast and in the evening 15 minutes before sleeping or 1h after dinner.
224169550|NCT02170558|DEVICE|TM- Ardis implant and Metal Reduction CT software|TM- Ardis implant and Metal Reduction CT software
224169551|NCT02911337|DIETARY_SUPPLEMENT|lifestyle modification|Subjects will be given meal replacements (shakes and bars) to be consumed twice per day for 8 weeks, and then once per day for an additional 3 weeks, and then transitioned to a structured diet.
224169552|NCT02340936|DRUG|LR-ESHAP (lenalidomide 5 mg)|3 cycles of lenalidomide 5mg, etoposide, methylprednisolone, cisplatin, cytarabine and rituximab every 3 weeks.
224169553|NCT02340936|DRUG|LR-ESHAP (lenalidomide 10 mg)|3 cycles of lenalidomide 10mg, etoposide, methylprednisolone, cisplatin, cytarabine and rituximab every 3 weeks.
224169554|NCT02340936|DRUG|LR-ESHAP (lenalidomide 15 mg)|3 cycles of lenalidomide 15mg, etoposide, methylprednisolone, cisplatin, cytarabine and rituximab every 3 weeks.
224169555|NCT02340936|DRUG|LR-ESHAP (lenalidomide 20 mg)|3 cycles of lenalidomide 20mg, etoposide, methylprednisolone, cisplatin, cytarabine and rituximab every 3 weeks.
224169556|NCT01693562|DRUG|MEDI4736|Participants will receive IV infusion of MEDI4736 for maximum of 12 months or until confirmed progressive disease, initiation of alternative cancer therapy, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurs first.
223481796|NCT01937468|DRUG|Interleukin-2|Interleukin-2: Starting the day of Treg-enriched cell infusion, each participant will receive daily subcutaneous IL-2 for self-administration for 8 weeks, followed by a 4-week hiatus. IL-2 will be administered on an outpatient basis. Expected toxicities and potential risks as well as dose modifications are described in Section 6 (Expected Toxicities and Dosing Delays/Dose Modification).
223481797|NCT06222697|DRUG|Damoctocog-alfa-pegol (Jivi, BAY94-9027)|Follow clinical practice/administration. No drug is provided to participants due to the observational nature of the study.
223481798|NCT06967454|OTHER|Water|Participants will receive 600ml water with a strawberry flavour, in four equal aliquots across 30 minutes (150ml every 7.5minutes)
224169557|NCT00050570|BEHAVIORAL|Web-based intervention to reduce eating disorder risk factors|
224305525|NCT05044884|OTHER|Otago Exercise training|"1. Warm-up exercises. Chair March, Arm swings ( 30 second), Head movement, neck movement, back extension, trunk movement, ankle movement (repeat 5 times).~   Back of thigh stretch, calf stretch, (hold for 8 seconds).~2. Strengthening exercises Front knee strengthening, back knee strengthening, side hip strengthening (2 or more sets of 10 reps) Calf raises, toe raises (repeat this exercises 10 to 20 times)~3. Balance improvement exercises Knee bends, heel-toe standing, heel toes walking, one leg stand ( start with 5 sec move up to 10 sec) Side walk, heel walking, sit to stand, backwards walking, heel toes walking backwards, walking and turning around, stair walking (10 steps).~4. Cool-down session Back of thigh stretch, calf stretches ( 10 to 20 sec hold, 1 to 3 reps)~5. Pulmonary rehabilitation program~   * Daily breathing exercises (e.g. diaphragmatic, pursed lip breathing).~  * Stretch exercise for major respiratory muscles."
223481799|NCT06967454|OTHER|Semi-skimmed milk|Participants will receive 600ml semi skimmed milk with a strawberry flavour, in four equal aliquots across 30 minutes (150ml every 7.5minutes)
223481800|NCT06967454|OTHER|Whey permeate|Participants will receive 600ml whey permeate with a strawberry flavour, in four equal aliquots across 30 minutes (150ml every 7.5minutes)
223481801|NCT06967454|OTHER|'Low dose' water|Participants will receive 150ml water with a strawberry flavour, across 30 minutes
223481802|NCT06222762|OTHER|Experimental arm|Personalized follow-up in adapted physical activities
223481803|NCT01842295|OTHER|Blood and sperm samples|Blood and sperm samples will be done in each visit
223481804|NCT03915431|BIOLOGICAL|NCS-01|single infusion
223481805|NCT05999747|DRUG|pudexacianinium chloride|Intravenous
223585219|NCT06421922|DIETARY_SUPPLEMENT|Group 1 received a regular constipation diet|Group 1 received only regular constipation diet, the constipation diet included 2 litres of water, 2 portions of vegetables, 3 portions of fruits and legumes 2 times a week. Followed 8 weeks.
224169558|NCT02125812|OTHER|scaling and systemic moxifloxacin|scaling and root planing (SRP) combined with systemic moxifloxacin
224169559|NCT02125812|OTHER|scaling and root planing|scaling and root planing
224169560|NCT03174392|OTHER|Resistance Based Training|Resistance based training study: Each training session will begin by determining the treadmill walking speed that an individual will train. The speed of the treadmill will be incrementally increased stepwise and individuals will affirm which speed feels the most comfortable to walk. Thus, the training speed of individuals will not necessarily be fixed over the 8-week study. Heart rate will be monitored and resistive force will be applied stepwise until the heart rate reaches at least 60% heart rate reserve. Individuals will be encouraged to walk at least five minutes and then allowed to rest. Achieved heart rate reserve and time the spent training at 60-80% heart rate reserve will be quantified for each session. Subjective measures of effort will also be sampled using the Borg Scale.
224169561|NCT03174392|OTHER|Speed Based Training|Speed based training study: Individuals will train at the fastest walking speed that an individual asserts that they can maintain for five minutes. The training time will then begin. Individuals will be encouraged to walk at least five minutes and then be allowed to rest. Speed will be progressed for each individual every 1-2 weeks at increments between 0.02 m/s and 0.08 m/s. Treadmill inclination will remain at 0°. Participants will be allowed to use the handrail or forearm support while being encouraged to walk without support if possible. Achieved heart rate reserve and the time the spent training at 60-80% heart rate reserve will be quantified for each session. Subjective measures of effort will also be sampled using the Borg Scale.
224169562|NCT01030757|RADIATION|Tomotherapy treatment|"* A total of 60 Gy using 12 Gy per fraction over 5 fractions to be given within 10 calendar days~* Each fraction of 12 Gy will be divided into 2 fractions of 6 Gy given in one day within 6 hours~* Dose will be prescribed to the isodose line which covers at least 90% of the PTV~* Dose homogeneity +/- 5%"
224169563|NCT02966106|DEVICE|Right prefrontal low frequency rTMS|A treatment session each day in four weeks apart from weekends. Each session is administered with 2 pulse trains of 180 sec with a 2 min interval
224169564|NCT02966106|OTHER|Sham-rTMS|Right prefrontal rTMS sham treatment. A treatment session each day in four weeks apart from weekends. Each session is administered with 2 pulse trains of 180 sec with a 2 min interval
223481806|NCT04513717|DRUG|Apalutamide|Given PO
224169565|NCT02362256|DRUG|Naltrexone|
224169566|NCT02362256|DRUG|Clonidine|
224169567|NCT02362256|DRUG|Lorazepam|
224169568|NCT03256123|DIETARY_SUPPLEMENT|red palm shortening group|Biscuits made of red palm shortening will be distributed to the subjects given four days a week on schooling days for a duration of 6 months. This biscuit would be given four days a week on schooling days for a duration of 6 months. On average in a week, subject is expected to receive 326.3 µg RE of vitamin A/day. This would fulfill \~59.3% of the RNI of vitamin A for children aged 7-12 years old.
223481807|NCT04513717|DRUG|Bicalutamide|Given bicalutamide
223481808|NCT04513717|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223481809|NCT04513717|PROCEDURE|Bone Scan|Undergo bone scan
223481810|NCT04513717|DRUG|Buserelin|Given buserelin
223481811|NCT04513717|PROCEDURE|Computed Tomography|Undergo CT scan
223481812|NCT04513717|DRUG|Degarelix|Given degarelix
223481813|NCT04513717|DRUG|Flutamide|Given flutamide
223481814|NCT04513717|DRUG|Goserelin|Given goserelin
223481815|NCT04513717|DRUG|Histrelin|Given histrelin
223744936|NCT05409144|DEVICE|Serratus Anterior Plane Block|The block is performed with full aseptic precautions. Arm abduction is preferred. The ultrasound probe will be placed on the patient's midaxillary line in the transverse plane, at the level of the fifth rib, with the indicator oriented toward the operator's left. With the rib, pleural line, and overlying serratus anterior and latissimus dorsi muscles visualized, then, 3ml lidocaine 1% will be used for skin and subcutaneous fat, using ultrasound guidance, a 38-mm 22-gauge regional block needle is going to be advanced in-plane at an angle of approximately 45 degrees towards the fifth rib. After aspiration to avoid intravascular injection 30ml of levobupivacaine 0.25% will be injected anteriorly to the rib and deep into the serratus anterior muscle.
224169569|NCT03256123|DIETARY_SUPPLEMENT|palm shortening group|Biscuits made of palm shortening (control group) will be distributed to the subjects given four days a week on schooling days for a duration of 6 months. The palm shortening biscuits contain corresponding fatty acids as red palm shortening group.
224169570|NCT01013636|PROCEDURE|Blood sampling|"* Anaplasma diagnosis test : serology and PCR~* If presence of Anaplasma infection, proposition of treatment with doxycylin 200 mg once-a-day during 10 days"
224169571|NCT03770689|DRUG|Peposertib 50 mg|Participants received peposertib 50 milligram (mg) once daily 5 days per week up to 5.5 weeks.
224169572|NCT03770689|DRUG|Peposertib 100 mg|Participants received peposertib 100 mg once daily 5 days per week up to 5.5 weeks.
224169573|NCT03770689|DRUG|Peposertib 150 mg|Participants received peposertib 150 mg once daily 5 days per week up to 5.5 weeks.
224169574|NCT03770689|DRUG|Peposertib 250 mg|Participants received peposertib 250 mg once daily 5 days per week up to 5.5 weeks.
224169575|NCT03770689|DRUG|Capecitabine|Participants received capecitabine at a dose of 825 milligram per square meter (mg/m\^2) twice daily 5 days per week up to 5.5 weeks.
224169576|NCT03770689|RADIATION|Radiotherapy (RT)|Participants received RT 50 to 50.4 Gray (Gy) to the tumor area and 45 Gy to the electively irradiated tissues in 25 to 28 fractions up to 5.5 weeks.
223481816|NCT04513717|DRUG|Leuprolide|Given leuprolide
223481817|NCT04513717|PROCEDURE|Magnetic Resonance Elastography|Undergo MRI
223481818|NCT04513717|PROCEDURE|Positron Emission Tomography|Undergo PET scan
223481819|NCT04513717|OTHER|Quality-of-Life Assessment|Ancillary studies
223481820|NCT04513717|OTHER|Questionnaire Administration|Ancillary studies
223481821|NCT04513717|RADIATION|Radiation Therapy|Undergo radiation therapy
223481822|NCT04513717|DRUG|Relugolix|Given relugolix
223481823|NCT04513717|DRUG|Triptorelin|Given triptorelin
223481824|NCT03068741|DRUG|Comparison 1: Prehospital Ceftriaxone|Paramedics will administer 1g of intramuscular ceftriaxone.
223481825|NCT03068741|DRUG|Comparison 1: Placebo|Paramedics will administer an identical volume of reconstituted intramuscular placebo.
223481826|NCT03068741|DRUG|Comparison 2: Liberal fluids|Paramedics will administer up to 2 litres of intravenous saline (0.9%) to all patients regardless of systolic blood pressure, and reassessing this infusion after each 250ml are infused.
223481827|NCT03068741|DRUG|Comparison 2: Conservative fluids|Paramedics will administer intravenous saline (0.9%) according to the Medical Directive, which allows for infusion of fluids if systolic blood pressure is \<90mmHg and continued until systolic blood pressure is \>=100mmHg.
223481828|NCT06334198|DRUG|Naldemedine|Naldemedine is administered orally once daily in the morning in a dosage of 0.2 mg.
223481829|NCT06334198|DRUG|Placebo|Placebo is administered orally once daily in the morning.
223481830|NCT06334198|DRUG|Tramadol|In both arms, tramadol is administered orally twice daily in a dosage of 100 mg (daily total of 200mg).
223481831|NCT05388656|DRUG|Estradiol Patch, 0.1 mg/24 Hours Weekly Transdermal Film, Extended Release|0.1 mg/day transdermal patch administered for 3 weeks
223481832|NCT05388656|DRUG|Placebo|Estradiol-matched placebo patch administered for 3 weeks
223481833|NCT05388656|DRUG|Progesterone 200 mg|200 mg tablet administered by mouth once per day for 10 days after completion of the experimental phase of the study
223481834|NCT06933069|DRUG|CMAB017|CMAB017 was administered at a preset dose, and body weight was measured before each study dose; if body weight changed ≥10% from baseline, the dose should be recalculated. Administration was by intravenous infusion: for doses ≤1000 mg, intravenous infusion lasted 60±5 min; for doses \>1000 mg, intravenous infusion lasted 90±5 min.
223481835|NCT00671788|DRUG|Dasatinib|Given orally
223481836|NCT00671788|OTHER|Laboratory Biomarker Analysis|Correlative studies
224169577|NCT02890940|BEHAVIORAL|Pet Therapy|"Patients will be asked to complete the standardized QLQ-C30/BN20 questionnaires. Following completion of the questionnaires, a trained pet therapy dog will be brought to the patients for approximately 10 minutes. After approximately 10 minutes, the dog will be removed and the patients will be asked to re-complete the standardized QLQ-C30/BN20 questionnaires. Patients will be photographed and videographed during this time.~Finally, patients will be asked to talk about how their perspectives on life have changed with their diagnosis. These responses will be captured for use in the art exhibit created from images collected during the study."
223481837|NCT03290625|DRUG|Dexmedetomidine Hydrochloride|Dexmedetomidine hydrochloride (PrecedexTM), presented in ampoule containing 2 mL of 100 mcg / mL solution for injection
223481838|NCT03290625|DRUG|Ketamine Hydrochloride|Dextrocetamine hydrochloride (KetaminTM), presented in a 10 mL vial containing 50 mg / mL solution for injection
223481839|NCT04331106|DIAGNOSTIC_TEST|Online Questionnaire|Online Questionnaire via SoSci Survey
224169578|NCT06097299|BIOLOGICAL|mRNA-1345|Sterile liquid for injection
224169579|NCT06097299|BIOLOGICAL|Placebo|0.9% sodium chloride (normal saline) injection
224169580|NCT03349957|DRUG|Transarterial chemoembolization using TANDEM and idarubicin|Transarterial chemoembolization using TANDEM and idarubicin
224169581|NCT05846919|PROCEDURE|face-mask preoxygenation|face-mask preoxygenation (flow 2 L/kg/minute, max 6 L/minute) with 100 % oxygen for three minutes.
224169582|NCT05846919|PROCEDURE|HFNOC preoxygenation|HFNOC preoxygenation (flow 2 L/kg/minute, max 6 L/minute) with 100 % oxygen for three minutes.
224169583|NCT05846919|PROCEDURE|HFNOC + face-mask preoxygenation|HFNOC (flow 2 L/kg/minute) + face-mask preoxygenation (flow 2 L/kg/minute, max 6 L/minute) - with 100 % oxygen for three minutes.
224169584|NCT03935893|BIOLOGICAL|Tumor Infiltrating Lymphocytes (TIL)|TIL are to be infused intravenously through a central vein catheter over 20-30 minutes followed by Aldesleukin, administered at a dose of 600,000 IU/kg (based on total body weight) as an intravenous bolus over a 15-minute period approximately every 8 hours beginning within 24 hours of cell infusion and continuing for up to a maximum of 6 doses.
223481840|NCT01832766|DRUG|Dronabinol|dronabinol 10 mg one capsule by mouth at 8:00 a.m.
223481841|NCT01832766|OTHER|Placebo Comparator|one capsule given by mouth at 8:00 a.m.
223481842|NCT02066571|DRUG|Droxidopa|Droxidopa will be supplied in 100 and 200 mg pill sizes. The proposed dosing is 100mg twice daily at baseline, then titrate to 200 mg twice daily at day 7 and then titrate to 300mg twice daily at day 14. Subjects will stay on the 600mg daily for 2 weeks. Total exposure 28 days of study drug.
224169585|NCT03935893|DRUG|Fludarabine + Cyclophosphamide combination|Preparative lymphocyte depleting (immunosuppressive) combination regimen consisting of fludarabine and cyclophosphamide administered prior to TIL infusion.
224169586|NCT06455800|DIAGNOSTIC_TEST|lung function measurements|Patients will once a year be monitored with different lung function methods
223481843|NCT02066571|DRUG|sugar pill|Sugar pill or placebo will be supplied in pill sizes matched to droxidopa formulation. The study titration will be the same. Sugar pills will be used for 5 weeks during the study.
223481844|NCT00646724|BIOLOGICAL|cotransplantation of islet and mesenchymal stem cell|islet of allograft and MSCs of autograft
223481845|NCT02493959|BIOLOGICAL|PYY1-36 infusion|Infusion of 1.6 pmol/kg/min PYY1-36 for 2 hrs.
223481846|NCT02493959|BIOLOGICAL|PYY1-36 + sitagliptin|Infusion of 1.6 pmol/kg/min PYY1-36 for 2 hrs. Two doses of 100 mg sitagliptin are administered 10 and 1 hour before start of infusion, respectively.
223481847|NCT02493959|BIOLOGICAL|PYY3-36 infusion|0.8 pmol/kg/min infusion of PYY3-36.
223481848|NCT02493959|BIOLOGICAL|placebo|Infusion of saline for 2 hrs.
223481849|NCT04562376|OTHER|High-intensity resistance training|The program consists of high-intensity resistance training for 60 minutes twice a week (group A) during 12 weeks
223481850|NCT04562376|OTHER|Low frequency of high-intensity resistance training|The program consists of high-intensity resistance training for 60 minutes once a week (group B) during 12 week
223481851|NCT03169439|PROCEDURE|Irreversible electroporation|minimal invasive ablative technique for tumors
223481852|NCT00960427|DRUG|systemic chemotherapy|
223481853|NCT00960427|GENETIC|RNA analysis|
223481854|NCT00960427|GENETIC|gene expression analysis|
223481855|NCT00960427|GENETIC|reverse transcriptase-polymerase chain reaction|
223744937|NCT04022096|DRUG|Tegoprazan 25mg QD|Tegoprazan 25mg tablets will be orally administered, once daily, for up to 6 months.
224169587|NCT03808194|OTHER|Conditional lottery incentive|Participants in the lottery incentive arm must fulfill the following criteria to be entered into the lottery. Participants must visit the clinic by month 1, initiate ART by month 3 and achieve viral suppression by month 6. Participants in this arm will be eligible to win the lottery.
224169588|NCT03808194|OTHER|Optimized ART linkage package|Optimized ART linkage package
224169589|NCT05093660|DIAGNOSTIC_TEST|Blood specimen collection|Blood specimen collection for analysis of CRP (C-reactive protein), WBC (White blood cells) and LRG1 (Circulating Human Leucine-rich α-2-glycoprotein) levels
224169590|NCT05093660|DIAGNOSTIC_TEST|Saliva specimen collection|Saliva specimen collection for analysis of LRG1 (Circulating Human Leucine-rich α-2-glycoprotein) levels
224169591|NCT00887822|DRUG|Bevacizumab|7.5 mg/kg IV infusion on Day 1 of every 3-week cycle
224169592|NCT00887822|DRUG|Placebo|Placebo matched to bevacizumab on Day 1 of every 3-week cycle
224169593|NCT00887822|DRUG|Capecitabine|1000 mg/m\^2 orally twice daily on Days 1-14 of every 3-week cycle
224169594|NCT00887822|DRUG|Cisplatin|80 mg/m\^2 IV infusion on Day 1 of every 3-week cycle for a maximum of 6 cycles
223481856|NCT00960427|OTHER|immunohistochemistry staining method|
223481857|NCT00960427|OTHER|laboratory biomarker analysis|
223481858|NCT00960427|PROCEDURE|endoscopic biopsy|
223481859|NCT00960427|PROCEDURE|neoadjuvant therapy|
223481860|NCT00960427|PROCEDURE|sigmoidoscopy|
223481861|NCT00960427|RADIATION|radiation therapy|
223481862|NCT05203185|OTHER|Pulmonary Embolism Risk Kalculator (PERK)|Nudges are applications of behavioral science, defined as positive reinforcement and indirect suggestions that have a non-forced effect on decision making. Nudges will be to the PE CALC CDS tool to develop the new CDS tool, PERK.
223481863|NCT05063240|BEHAVIORAL|Mobile phone text messaging plus prospective motivational interviewing|Interactive weekly mobile phone text messaging plus prospective motivational interviewing at study follow up visits
223481864|NCT05063240|BEHAVIORAL|Standard infant feeding counselling|Standard infant feeding counselling as part of routine practice at primary healthcare facility
223481865|NCT04646278|DRUG|Hyperemic stimuli|Hyperemic simuli of coronary flow by adenosine or nicorandil injection
223744938|NCT04022096|DRUG|Lansoprazole 15mg QD|Lansoprazole 15mg capsules will be orally administered, once daily, for up to 6 months.
223744939|NCT05162209|DIETARY_SUPPLEMENT|Synbiotic|Oral sachet, for 12 weeks
224169595|NCT06548074|BEHAVIORAL|H-PACE Behavioral Intervention|Participate in the H-PACE program
224169596|NCT06548074|OTHER|Accelerometer|Wear an accelerometer
224169597|NCT06548074|OTHER|Questionnaire Administration|Ancillary studies
224169598|NCT06548074|OTHER|Supportive Care|Parents may participate in an optional virtual peer support group
224169599|NCT00236210|BEHAVIORAL|Action Score|Improvement in a novel 100-point score summarizing cardiovascular risk.
223481866|NCT03349307|DEVICE|Thin Convex Probe Endobronchial Ultrasound (TCP-EBUS)|Patients scheduled for a lobectomy will be recruited to this study and approached for informed consent. At the time of surgery, once the lobe has been removed, the TCP-EBUS will be inserted through a bronchial stamp for brief operability evaluations and image acquisition. Once this data has been captured standard of care will continue.
223481867|NCT05771402|DRUG|Anti-PD-1 antibody|Once/two or three weeks, dose lower than the dose used in cancer patients, subcutaneous/intravenous injection
223481868|NCT05771402|DRUG|NAs|Once/day, 1 capsule/time, oral
223481869|NCT05771402|DRUG|Peg-IFNα|Once/week, 180μg/time, subcutaneous injection
223481870|NCT06978127|BEHAVIORAL|Technology Assisted Stepped Collaborative Care|The TĀCcare 2.0 intervention will provide pharmacotherapy recommendations and/or CBT for pain, fatigue and depression. A stepped-treatment approach will be used to intensify treatment. CBT will be provided through 12 weekly telehealth sessions (done during dialysis treatment or from home) with the behavioral specialist. Booster sessions will be used to enhance the maintenance of effect following the initial intervention to complete a total 12 month intervention. A collaborative care approach will be used so that patients' symptom management will be integrated with their dialysis treatment. Throughout the study, participants will be asked to complete phone surveys about their symptoms and health.
223481871|NCT06978127|OTHER|Usual Care Arm|Participants in the Usual Care Arm will continue with their usual care.
223481872|NCT06615908|DRUG|Psilocybin|See treatment arm description.
223481873|NCT06428175|BEHAVIORAL|Focused Dose Hospital-to-Home Transitional Care Interventions|Focused dose H2H-TCIs will consist of a one-time post-discharge phone call completed within 72 hours post-hospital discharge by a clinical interventionist (e.g., nurse care coordinator or care manager). Calls will follow a structured template that provides empirically supported core H2H-TCI functions (follow-up care access, contingency planning, medication review, family education). The interventionist will also conduct a pre-hospital discharge clinical needs assessment with the parent.
223481874|NCT06428175|BEHAVIORAL|Extended Dose Hospital-to-Home Transitional Care Interventions|Extended dose H2H-TCIs will include a pre-discharge clinical needs assessment and initial phone call within 72 hours post-discharge, similar to the focused arm. After the initial contact, the dose of the extended H2H-TCI will increase as subjects receive high-intensity support during weekly post-discharge phone contacts through 30 days post-discharge. All contacts in the extended dose arm will be completed by a transition coach interventionist (e.g., nurse care coordinator or care manager) who will be formally trained on pillars of the Care Transitions Intervention© (CTI), a multi-faceted H2H-TCI that is the basis for the extended dose arm.
223585220|NCT06421922|DIETARY_SUPPLEMENT|Group 2 received a constipation diet rich in soluble fiber|Soluble fiber (resistant starch) (5 g/day) was added to the constipation diet in group 2 as 1 sachet/day (5 g/day) during the initial 4 weeks and 2 sachets/day (10 g/day) in the following 4 weeks.
223585221|NCT06421922|DIETARY_SUPPLEMENT|Group 3 received a constipation diet supplemented with probiotic yogurt.|"Bifidobacterium İnfantis 35624 (B. İnfantis 35624)\&#34; strain, which is specific to IBS, was added to yogurt in group 3, consumed before the lunch. The follow-up period was 8 weeks."
223585222|NCT02235103|OTHER|Sperm Chromatin Dispersion Test|
223585223|NCT03057470|DRUG|50% bolus insulin correction|Patients will receive 50% of their usual bolus insulin correction for post-exercise hyperglycemia
223585224|NCT03057470|DRUG|100% bolus insulin correction|Patients will receive 100% of their usual bolus insulin correction for post-exercise hyperglycemia
223585225|NCT03057470|DRUG|150% bolus insulin correction|Patients will receive 150% of their usual bolus insulin correction for post-exercise hyperglycemia
224169600|NCT00236210|BEHAVIORAL|VIP program|Risk assessment, lifestyle counselling, exercise program
224169601|NCT04427228|RADIATION|Radiosurgery Single Treatment|Frameless single-fraction SRS. One large treatment done on each brain tumor. 20 Gy for GTVs (or resection cavity CTVs) \< 2 cm, and 18 Gy for GTVs (or resection cavity CTVs) between 2-3 cm in the single-fraction.
224169602|NCT04427228|RADIATION|Radiosurgery Three Treatments|Multi-fraction SRS. Three small doses done on each brain tumor. 27 Gy in 3 fractions in the multi-fraction group
224169603|NCT00232050|DRUG|Omalizumab|
223585226|NCT03057470|OTHER|0% bolus insulin correction|Patients will receive no bolus insulin correction for post-exercise hyperglycemia
223585227|NCT06089902|PROCEDURE|unroofing or other surgery if needed|unroofing of coronary artery
223585228|NCT02894450|OTHER|blood test|bioassay xaban
223585229|NCT02754960|DRUG|Thalidomide|Interventions administered (dosage, 100mg; dosage form, 25mg; frequency of administration, 1 time daily at 10 p.m)
223585230|NCT02754960|DRUG|Placebo|Placebo administered (dosage, 100mg; dosage form, 25mg; frequency of administration, 1 time daily at 10 p.m)
223585231|NCT04809155|BEHAVIORAL|Girl2Girl|The program has a 'core' 7 weeks of daily messages and then a week 'booster' that is delivered 3 months later.
223585232|NCT02904655|OTHER|healthy diet|Participants were provided meals and snacks for one month that represented a healthy diet that is high in unsaturated fats, approximating a Mediterranean diet
223585233|NCT04334564|DRUG|Ginkgo biloba capsule|Ginkgo biloba capsule may improve visual function of primary open-angle glaucoma by repairing of the optic nerve.
223585234|NCT04334564|DRUG|Placebos|Placebos were controls.
223585235|NCT01030614|DRUG|Dexamethasone|intravenous dexamethasone 8 mgr before laparoscopic cholecystectomy or intravenous placebo before laparoscopic cholecystectomy
223585236|NCT01030614|DRUG|placebo|One hundred five patients were randomized to receive intravenous placebo before laparoscopic cholecystectomy
223585237|NCT01171209|DRUG|Interferon-beta and human leukocyte Interferon-α|One single injection of interferon(IFN)- β and one single injection of human leukocyte IFN-α (Multiferon® ) 6 MIU s.c. with 1-7 days follow-up.
223585238|NCT03307031|OTHER|High Volume Group|Performed four weekly session, during 10 weeks with 45 to 55 minutes per session.
223481875|NCT03879070|DEVICE|Ankle active and passive mobilization using an Ankle mobilization device|The treatment consists in 20 rehabilitation sessions, 5 times/week for 4 weeks. The device is capable of generating ankle dorsi/plantarflexion movements using two activation modes: passive and assistive. In the passive mode the device generates a movement pattern which the patient follows passively without exerting any force on the device. During the assistive mode, the device follows the active movement of the patient. During the intervention, these two modes will be alternated.
223481876|NCT01420159|DRUG|Methoxyflurane|Patients will have access to two 3 mL methoxyflurane (Penthrox) Inhalers or two 5mL placebo Inhalers to be self-administered.
223481877|NCT05784051|DRUG|Experimental group|medical treatment including drug administration ± catheter ablation (Ablation can be performed if the PVC burden remain \>10% after 2 lines of AAD treatment).
223481878|NCT05784051|DRUG|Control group|patients of this group have no therapeutic or no treatment modification such as drug therapy
223481879|NCT05058989|DIAGNOSTIC_TEST|Advanced ultrasound measurements (Duplex ultrasound (DUS) and Vector flow imaging (VFI)|PPG is a non-invasive method used to evaluates the severity venous reflux by measuring the venous refiling time (VRT).The principal of PPG works by using a small light source and a photoelectric cell attached to the skin in the medial supramalleolar area of the leg (the distal lower medial area of the leg).
223481880|NCT05058989|OTHER|Clinical interventions and procedures|"First trimester (0-13 weeks):~* Consent~* Clinical data collection~* Blood samples (genomic+ hormonal)~* Duplex ultrasound~* Vector flow imaging (advanced ultrasound software)~* Truncated cone tool (measuring leg circumference using a tape measure)~* PPG~* AVVQ (Aberdeen varicose veins questionaire)~Second trimester (14-26 weeks):~* Clinical data collection~* Blood sample (hormonal only)~* DUS~* VFI~* Truncated cone tool~* PPG~* AVVQ~Third trimester (27-40 weeks):~Same as second trimester~Three months after giving birth:~Same as second trimester"
223481881|NCT04092478|OTHER|Spinal Anesthesia Position|The patient positions during the spinal anesthesia
223481882|NCT01586052|DRUG|Erythropoietin|250 IU/kg, Twice a week for 4 weeks
223481883|NCT06804824|DRUG|VVD-159642|Oral capsules
223481884|NCT06804824|DRUG|Sotorasib|Oral tablets
223481885|NCT06804824|DRUG|Trametinib|Oral tablets
223481886|NCT06593938|DRUG|HRS-5965 capsule|HRS-5965 capsule for 24 weeks
223481887|NCT06593938|DRUG|Eculizumab Injection|Eculizumab Injection for 24 weeks
223481888|NCT03485599|DIAGNOSTIC_TEST|ELIZA , Westron blot|Blood sample will be taken then rapid test by ELIZA will be done if positive then confirmatory test by Westron blot will be done
223481889|NCT04697797|OTHER|Device Programming|Intervention includes (1) pacemaker reprogramming (2) echocardiographic parameters acquisition (3) ECG recording
223481890|NCT01549665|BIOLOGICAL|Human umbilical cord blood-derived mesenchymal stem cells|1st infusion(1x1,000,000 hMSC/kg)IV, 2nd infusion(2x1,000,000 hMSC/kg)IV and 3rd infusion(3x1,000,000 hMSC/kg)IV if no complete response at 28 days.
223481891|NCT04400266|DRUG|Buspirone|Buspirone 15mg once daily
223481892|NCT04400266|DRUG|Mealatonin|Melatonin 3mg once nightly
223481893|NCT05408364|DIETARY_SUPPLEMENT|probiotic or natural yoghurt|Bifidobacterium animalis subsp. lactis DN-173010 containing probiotic yoghurt
223481894|NCT05408364|PROCEDURE|SRP|Scalling and root planing
223481895|NCT02396667|OTHER|5D ultrasound|Measure the femur length by 5DLB to calculate fetal weight
223481896|NCT07037082|OTHER|Self-saliva sampling|Self-saliva samples are taken every day from D1 inclusive over 1 consecutive cycle, to measure progesterone (P4) and estradiol (E2) concentrations.
223481897|NCT07037082|OTHER|Self-collection of dried blood spots|Self-blood sampling is done 5 times during the cycle to measure protéine C-Réactive (CRP) concentrations.
223481898|NCT07037082|OTHER|Wearing the connected ring|A connected ring is worn every day of the observed cycle, while maintaining lifestyle habits, to measure daily body temperature, assess heart rate variability and resting heart rate, evaluate physical activity and energy expenditure, assess stress level, and evaluate sleep quality.
223481899|NCT07037082|OTHER|Ovulation test|An ovulation test (Ovulatest®) is carried out from day 7 until a test is positive, or until day 39 if ovulation is not detected
223481900|NCT06711926|OTHER|Distilled water|Participants will receive 600ml distilled water with a strawberry flavour, in four equal aliquots across 30 minutes (150ml every 7.5minutes)
223481901|NCT06711926|OTHER|Semi-skimmed milk|Participants will receive \~600ml semi-skimmed milk with a strawberry flavour in four equal aliquots across 30minutes (150ml every 7.5minutes).
223585239|NCT03307031|OTHER|Low Volume Group|Performed only twice a week, during 10 weeks with 45 to 55 minutes per session.
223585240|NCT03307031|OTHER|Control Group|Did not exercise, during 10 weeks.
223585241|NCT01105585|DEVICE|Tecnis 1-piece Aspheric Acrylic (ZCB00) IOL|Tecnis 1-piece Aspheric Acrylic (ZCB00) intraocular lens implanted in the capsular bag during cataract surgery. The IOL is intended for the lifetime of the patient.
223585242|NCT01105585|DEVICE|AcrySof Natural IQ (SN60WF) IOL|AcrySof Natural IQ (SN60WF) intraocular lens implanted in the capsular bag during cataract surgery. The IOL is intended for the lifetime of the patient.
223481902|NCT06711926|OTHER|Whey permeate|Participants will receive \~600ml whey permeate (30g sachet, rehydrated with distilled water)with strawberry flavour in four equal aliquots across 30minutes (150ml every 7.5minutes).
223481903|NCT06887842|DEVICE|Posterior Nasal Nerve neurectomy|Posterior Nasal Nerve neurectomy which is done by surgical resection.
223481904|NCT06887842|DEVICE|Posterior Nasal Nerve neurectomy|Posterior Nasal Nerve neurectomy which is done by using radiofrequency ablaion.
223481905|NCT06887842|DEVICE|Posterior Nasal Nerve neurectomy|Posterior Nasal Nerve neurectomy by coblation of the surface of the course of the nerve
223481906|NCT07057388|DEVICE|continous wave compaction|post operative pain measurement using continous wave compaction
223481907|NCT06747507|DRUG|Dolutegravir Pill|Dose will be based on weight; brand names will be as supplied through the respective national programs
223481908|NCT06747507|DRUG|Darunavir+Ritonavir|Dose will be based on weight
223585243|NCT05234203|DIETARY_SUPPLEMENT|HTB Rejuvenate|90 days of BID dosing of 2 capsules of HTB Rejuvenate
223585244|NCT00915148|OTHER|Ultrasound examination|Trans-abdominal and trans-perineal 3D ultrasound examination
223585245|NCT04639817|DRUG|Levofloxacin|Levofloxacin administration
223585246|NCT04639817|DRUG|trimethoprim-sulfamethoxazole|Trimethoprim-sulfamethoxazole administration
223585247|NCT03132025|DRUG|"Apatinib and Capecitabine"|"Combine Apatinib and Capecitabine to Maintain Treating Metastatic Colorectal Cancer"
223585248|NCT03132025|DRUG|"Capecitabine"|"Single Drug Capecitabine to Maintain Treating Metastatic Colorectal Cancer"
223585249|NCT03283436|DRUG|Bupivacaine Hydrochloride 0.25% Injection Solution|10 mL of 0.25% bupivacaine hydrochloride (2.5 mg/mL = 25 mg)
223585250|NCT03854539|OTHER|Transdermal Vagus Nerve Stimulation|intermittent transdermal stimulation of the aurical vagus
223481909|NCT07059091|DRUG|Omalizumab (Xolair®)|The study drug (omalizumab or placebo) will be given as a subcutaneous injection, which means an injection into the fat layer just under the skin in your arm or leg. This is similar to an insulin injection and not as deep as a typical vaccine injection. After the injection, participants will be monitored for any side effects. The study team will determine the dose and how often the injection is given based on the participant's weight and blood test results. Injections will be either be given monthly, 12 doses, or twice per month, 24 doses. All injections will be given at the clinic.
223481910|NCT07059091|DRUG|Sodium Chloride (NaCl) 0.9 %|The study drug (omalizumab or placebo) will be given as a subcutaneous injection, which means an injection into the fat layer just under the skin in your arm or leg. This is similar to an insulin injection and not as deep as a typical vaccine injection. After the injection, participants will be monitored for any side effects. The study team will determine the dose and how often the injection is given based on the participant's weight and blood test results. Injections will be either be given monthly, 12 doses, or twice per month, 24 doses. All injections will be given at the clinic.
223481911|NCT06580470|BEHAVIORAL|Tailored Cognitive Behavioral Therapy for Menopause|Cognitive Behavioral Therapy for Menopause (CBT-Meno) is an evidenced-based intervention that includes psychoeducation, cognitive, and behavioral strategies for coping with common menopause symptoms and experiences. In Aims 1 and 2, CBT-Meno materials and procedures will be tailored for women Veterans through an iterative process involving: a) data from preliminary studies and a pre-pilot trial; b) input from content area experts; and c) stakeholder advisory panels. This tailored version of CBT-Meno will then be test in this clinical trial.
224169604|NCT04729010|OTHER|Acupuncture to treat anxiety in Parkinson disease|Subjects will be randomized in a 1:1 ratio to receive sham acupuncture.
224169605|NCT03898752|DIETARY_SUPPLEMENT|Omega 3|Omega 3: 1g daily for 3 months CoQ10: 100 mg daily for 3 months Multivitamin: 1 normal multivitamin tablet daily for 3 months
224169606|NCT00949806|DRUG|BNT (intradermal injection)|"Patients with severe RLS will receive a one-time intradermal administration of BNT into the most symptomatic areas of both legs.~Injections will be distributed in a grid distribution pattern covering a total of 20 equidistant sites per symptomatic area. Each symptomatic area will receive a maximum 250 units of BNT (12.5 units per injection). The total BNT injected units should not exceed 1000 units per patient."
224169607|NCT04536350|DRUG|Aviptadil 67μg|Participants will receive standard care plus a dose of 67μg nebulized Aviptadil three times a day for ten days.
224169608|NCT04536350|DRUG|Placebo 0.9% NaCl solution|Patiens will receive Standard care plus 0.9% NaCl solution three times a day for ten days
224169609|NCT04648995|DEVICE|High energy (UltraPulse)|Half of the face that receives low energy, their central base of boxcar scar will be treated with 30mJ, while shoulder of scar will be treated with 60 mJ
223481912|NCT03074500|DEVICE|Kinesiotaping|Kinesio tape will be applied by using space correction and fascia correction technique on forearm of the patients for the treatment of lateral epicondylitis
224169610|NCT04648995|DEVICE|Low energy (UltraPulse)|Half of the face that receives low energy, their central base of boxcar scar will be treated with 20mJ, while shoulder of scar will be treated with 50 mJ
224169611|NCT03601091|DRUG|Precedex 200 MCG in 2 ML Injection|Infusion therapy of the drug
223481913|NCT03074500|OTHER|Sham taping|Sham taping will be performed without using any technique
224169612|NCT03601091|DRUG|DORMICUM 5MG/5 ML|Infusion therapy of the drug
223481914|NCT03074500|OTHER|Exercise|Stretching exercises of wrist 30 seconds to one minute, twice a day and strengthening exercises will performed be 10 repetitions in 2 or 3 series. .
223481915|NCT05881629|BEHAVIORAL|Maternal position change to side-lying lateral with peanut ball|Participants will be assisted into a position lying on their side, specifically the same side as the fetal spine diagnosed by ultrasound. An inflated peanut ball will be positioned between the legs to open the pelvis. They will be asked to maintain the position for 60 minutes.
223481916|NCT05881629|BEHAVIORAL|Free maternal position|Participants will be asked to adopt any position of their choosing and to maintain it for 60 minutes. They will be asked to not use a peanut ball during the 60 minute study period.
223585251|NCT00882739|DRUG|Clopidogrel 300 mg|Patients will receive a 300 mg clopidogrel loading dose in the cath-lab setting
223585252|NCT00882739|DRUG|Clopidogrel 600 mg|Patients will receive a 600 mg clopidogrel loading dose at first medical contact
224169613|NCT03501615|DRUG|Moxetumomab Pasudotox|A recombinant conjugated immunotoxin composed of a disulfide-stabilized anti-CD22 Ig Fv genetically fused to a truncated form of Pseudomonas exotoxin, PE38
224169614|NCT03363789|BIOLOGICAL|Brisement injection|An injection of Lidocaine into the tendon sheath to break up adhesions that could be causing the condition.
223585253|NCT00882739|DRUG|Clopidogrel 900 mg|Patients will receive a 900 mg clopidogrel loading dose at first medical contact
223585254|NCT03875807|PROCEDURE|ACLR done at 0 degrees KFA|Patients randomized to this arm will undergo the following intervention: Anterior Cruciate Ligament Reconstruction (ACLR) done at 0 degrees knee angle flexion (KFA)
223585255|NCT03875807|PROCEDURE|ACLR done at 30 degrees KFA|Patients randomized to this arm will undergo the following intervention: Anterior Cruciate Ligament Reconstruction (ACLR) done at 30 degrees knee angle flexion (KFA)
223585256|NCT02605317|OTHER|WhatsApp|Consultations used WhatsApp Messenger
224169615|NCT03363789|PROCEDURE|Physical Therapy|Patients will receive a prescription for physical therapy.
224169616|NCT04576273|DIAGNOSTIC_TEST|Pathology examination|Gross and microscopic evaluation
223585257|NCT00002460|DRUG|goserelin acetate|
223585258|NCT00002460|DRUG|tamoxifen citrate|
223585259|NCT00002460|PROCEDURE|ablative endocrine surgery|
223585260|NCT00002460|PROCEDURE|oophorectomy|
223585261|NCT01985763|DRUG|Genistein|Genistein combined with FOLFOX or FOLFOX-Avastin
223744940|NCT01297907|OTHER|Methacholine Challenge Test|Methacholine challenge test to evaluate airway hyperreactivity
224169617|NCT03837301|PROCEDURE|NESS-EFTR with sentinel lymph node navigation|Non-exposure Simple Suturing Endoscopic Full-Thickness Resection with sentinel lymph node navigation (basin dissection) for early gastric cancer patients
223481917|NCT05668273|OTHER|education with simulated patient|Students in the education with the simulated patient group will practice auscultation skills on the simulated patient with heart, lung, and bowel sounds. There will be a lecturer at the head of the group who will provide the necessary coordination. A debriefing session will be held with the students by the educator right after the students have finished the application.
223617570|NCT05669859|PROCEDURE|Exercise|"The rehabilitation program designed in our study was based on the development of core muscle control and dynamic stabilization of the spine, which is generally required by patients. All exercises were combined with controlled breathing, focusing on the mobility of the extremities and the activity of multiple muscle groups.~Our program created in this direction will start with face-to-face patient education; For 8 weeks, will be carried out remotely online under the supervision of a physiotherapist.On non-telerehabilitation days, they will be asked to keep an exercise diary, instructed to practice the exercise approach presented in sessions at home daily in 20-minute periods. The exercise diary will be checked during online sessions."
224169618|NCT00865358|BEHAVIORAL|Yoga Group|Reproducible standardized 12 week series of hatha yoga classes specifically developed for patients with chronic low back pain and little or no experience with yoga
224169619|NCT00017225|BIOLOGICAL|filgrastim|
224169620|NCT00017225|DRUG|carboplatin|
224169621|NCT00017225|DRUG|cisplatin|
224169622|NCT00017225|DRUG|cyclophosphamide|
224169623|NCT00017225|DRUG|dacarbazine|
224169624|NCT00017225|DRUG|doxorubicin hydrochloride|
224169625|NCT00017225|DRUG|etoposide|
224169626|NCT00017225|DRUG|ifosfamide|
224305526|NCT05044884|OTHER|Circuit training|"1. Functional strength exercises Heel raise, toe raise, walking on toes, step ups in all directions ( forward, backward and sideways) (2 sets and 8 reps)~2. Stance exercises Tandem, narrow, one leg stance, and stand on uneven surfaces with open eyes (each exercise 30 seconds) Tandem, narrow, one leg stance, and stand on uneven surfaces with eyes closed (each exercise 15seconds).~3. Transition exercises Sit to stand from chair with arms (10 reps) and then without arms support (5 reps).~   Sit on floor and stand up with assistance and then without assistance.~4. Gait training Walking tandem, sideway and backward with arm support. Walking tandem, sideway and backward without arm support Walking tandem, sideway and backward over obstacles~5. Pulmonary rehabilitation program~   * Daily breathing exercises (e.g. diaphragmatic, pursed lip breathing).~  * Stretch exercise for major respiratory muscles"
223481918|NCT05668273|OTHER|education with simulator|Students in the simulator group will practice auscultation skills on high fidelity simulator with heart, lung, and bowel sounds. There will be a lecturer at the head of the group who will provide the necessary coordination. A debriefing session will be held with the students by the educator right after the students have finished the application.
223481919|NCT05668273|OTHER|control group|Students in the control group will practice auscultation skills on their peers with heart, lung, and bowel sounds. There will be a lecturer at the head of the group who will provide the necessary coordination.
223481920|NCT06843447|BIOLOGICAL|Raludotatug Deruxtecan|IV infusion on Day 1 of every 3-week cycle.
223481921|NCT06843447|DRUG|Carboplatin|IV infusion on Day 1 of every 3-week cycle for a maximum of 6 cycles.
223481922|NCT06843447|DRUG|Paclitaxel|IV infusion on Day 1 of every 3-week cycle for a maximum of 6 cycles.
223481923|NCT06843447|BIOLOGICAL|Bevacizumab|IV infusion on Day 1 of every 3-week cycle.
223481924|NCT06771219|DRUG|SLV-154|SLV-154
223481925|NCT07070895|BEHAVIORAL|Cough Management|"CoughPro is a smartphone wellness application that uses algorithms to detect and count coughs continuously and passively (similar to a step counter, but for cough). CoughPro also includes a Cough Management (CM) component, which delivers short, structured behavioral lessons (based on BCST) designed to help users recognize their urge to cough and apply cough suppression strategies in real-world settings. The Cough Management wellness feature is the key area of investigation in this study.~The novel CM program is delivered entirely through participants' devices. The application aims to help users better understand and manage their cough by coupling real-time cough detection with self-management BCST resources:~* Reduce cough frequency (coughs per hour).~* Reduce cough intensity (as measured by cough bouts).~* Improve cough-related quality of life (as reported by patients and its correlation with cough-free time as measured objectively)."
223481926|NCT07070895|DEVICE|CoughMonitor Suite|CoughMonitor Suite's smartwatch is used in this study to continuously, automatically, and passively monitor cough frequency in a fully privacy-preserving way - no audio is recorded, stored, or synced to the cloud, and no human is in the loop.
223481927|NCT07168668|PROCEDURE|Transarterial chemoembolization|"1. Targeting 1-3 prognostically relevant tumor nodules.~2. Administration of anti-cancer drugs (doxorubicin 20 mg in each section of TACE).~3. Embolization with Drug-Eluting Beads (doxorubicin 20 mg loaded Hepasphere 20 mg of TACE)~4. Embolization was done when there was a slight decrease in blood flow for each tumor feeder."
223481928|NCT07168668|DRUG|durvalumab and tremelimumab|Combine TACE with immunotherapy
223481929|NCT07166952|DEVICE|SPRINT PNS System|This study will evaluate patient-reported outcomes, including pain and function, following standard clinical use of the SPRINT PNS System for posterior sacroiliac joint complex (PSIJC) pain.
223481930|NCT07168421|DRUG|Landiolol|The main dose range is 1-40 mcg/kg/min, titrated to the effect on heart rate aiming for a heart rate of below 90 beats per minute throughout. This dose can be decreased to 0 if heart rate stays below target.
223481931|NCT07168278|DRUG|TNK|a dose of 0.25 mg/kg (max 25 mg) administered as a bolus
223481932|NCT07168278|DRUG|Standard medical treatment|antiplatelet drugs, anticoagulation or combinations of these treatment modality according to national and institutional guidelines.
224169627|NCT00017225|DRUG|melphalan|
224169628|NCT00017225|DRUG|tretinoin|
224169629|NCT00017225|DRUG|vincristine sulfate|
224169630|NCT00017225|DRUG|vindesine|
224169631|NCT00017225|PROCEDURE|autologous bone marrow transplantation|
224169632|NCT00017225|PROCEDURE|conventional surgery|
224169633|NCT00017225|PROCEDURE|peripheral blood stem cell transplantation|
224169634|NCT00017225|RADIATION|radiation therapy|
224169635|NCT04343612|DEVICE|Transcranial Direct Current Stimulation|Subjects received a micro-current through their scalp to induce cortical and subcortical changes
224169636|NCT01271608|DEVICE|needle exchange|Comparing the pain intensity on a numeric scale (0-10) with intramuscular and subcutaneous injection between a retractable fixed syringe needle and the technique involving needle exchange; Comparing bruise formation following administration of insulin subcutaneous injections between retractable fixed needle and the conventional technique.
224169637|NCT00765830|DRUG|vildagliptin|50mg qd
224169638|NCT00765830|DRUG|Placebo|qd
224169639|NCT02045979|DRUG|BI 695501|BI 695501 single s.c. injection
224169640|NCT02045979|DRUG|adalimumab-EU source|adalimumab-EU source single s.c. injection
224169641|NCT02045979|DRUG|adalimumab-US source|adalimumab-US source single s.c. injection.
224169642|NCT02036983|PROCEDURE|Transversus abdominis plane block (TAP BLOCK)|Ultrasound guided TAP block with local anesthetics and dexamethasone.
224169643|NCT02036983|PROCEDURE|Instillation of surgical site with local anesthetic.|Instillation of surgical site with local anesthetics and dexamethasone.
224169644|NCT02036983|PROCEDURE|Opioid IV medications (Control)|Standard anesthetic technique.
224169645|NCT01920516|DRUG|Melphalan|Melphalan 1mg/kgr is rapidly infused into the isolated limb via the arterial catheter after the inflation of venous baloon catheter.
223481933|NCT07167394|PROCEDURE|Interactive Virtual Reality Guidance with Restorative Dental Treatment|"Participants in this group will undergo a standardized restorative dental procedure on mandibular primary molars involving local anesthesia, caries excavation, and compomer restoration. Prior to the treatment, children will wear a virtual reality (VR) headset through which they will experience an interactive, animated educational game.~The VR content simulates the treatment steps-including sitting in the chair, receiving local anesthesia, caries removal, filling, and polishing-using engaging characters and storytelling. The aim is to reduce anxiety and perceived pain through immersive visual and cognitive distraction while standard dental procedures are being performed."
223481934|NCT07167394|PROCEDURE|Tell-Show-Do Guidance with Restorative Dental Treatment|Participants in this group will also receive a standardized restorative dental procedure identical to the VR group, including local anesthesia, caries removal, and compomer filling of mandibular primary molars. Behavioral preparation will be conducted using the conventional Tell-Show-Do technique. The clinician will verbally explain each step, demonstrate the procedure using visual and tactile tools in a child-friendly manner, and then proceed with the actual intervention. This method aims to reduce dental fear and increase compliance by familiarizing the child with the clinical environment before the surgical procedure.
223481935|NCT03114150|BEHAVIORAL|Cardiorespiratory fitness training|Physical exercise of moderate intensity designed to improve cardiorespiratory fitness
223481936|NCT03114150|BEHAVIORAL|Functional fitness training|Physical exercise of light intensity designed to improve functional fitness
223617571|NCT04532268|DRUG|Humanized CD19 CAR-T cells|Each subject receive humanized CD19 CAR T-cells by intravenous infusion
223617572|NCT01638455|DEVICE|Noninvasive device|Noninvasive device
223617573|NCT01475877|DRUG|Bromfenac|Bromfenac 0.09% 1 drop in study eyes q day
223617574|NCT06129526|DIETARY_SUPPLEMENT|EPAVasc|EPAVasc: 1,875mg EPA / 125mg DHA / 3.75μg Vitamin D / 12mg tocopherol
223617575|NCT06129526|DIETARY_SUPPLEMENT|Corn Oil|Corn Oil
224169646|NCT00192465|BIOLOGICAL|MEDI-524 (Numax-TM)|Grp.1: 3 mg/kg IV (single dose)
224169647|NCT00192465|BIOLOGICAL|MEDI-524 (Numax-TM)|Grp. 2: 15 mg/kg IV (single dose)
224169648|NCT00192465|BIOLOGICAL|MEDI-524 (Numax-TM)|Grp. 3: 30 mg/kg IV (single dose)
223617576|NCT04564846|DRUG|ORMD-0801|8 mg capsules of ORMD-0801 (Oral Insulin)
224169649|NCT00192465|BIOLOGICAL|MEDI-524 (Numax-TM)|Grp. 4: 3 mg/kg IM (single dose)
224169650|NCT00192465|BIOLOGICAL|MEDI-524 (Numax-TM)|Grp.5: 3 mg/kg IM (two doses)
224169651|NCT02086760|OTHER|Ultrasonography with oral hydration|Before, 30 min and 90 min following oral hydration
224169652|NCT02086760|RADIATION|Scintigraphy|
224169653|NCT02447393|DRUG|levocetirizine|levocetirizine
224169654|NCT02447393|DRUG|cetirizine|cetiridine
224169655|NCT02447393|DRUG|placebo|placebo
224169656|NCT00004084|RADIATION|indium In 111 LL2 IgG|single dose, intravenous infusion over 30 minutes
224169657|NCT00004084|RADIATION|yttrium Y 90 epratuzumab|single dose, intravenous infusion over 30 minutes
223481937|NCT04585750|DRUG|rezatapopt|First-in-class, oral, small molecule p53 reactivator selective for the TP53 Y220C mutation.
223481938|NCT04585750|DRUG|pembrolizumab|Participants receive pembrolizumab 200 mg by intravenous (IV) infusion over 30 minutes.
223481939|NCT02709902|DRUG|Adapalene/BP gel, 0.3%/2.5%|Gel
224169658|NCT01924260|DRUG|alisertib|Given PO
224169659|NCT01924260|DRUG|gemcitabine|Given IV
223481940|NCT02709902|DRUG|EPIDUO® FORTE|Gel
224169660|NCT01719627|DRUG|Maraviroc|Unique dose of Maraviroc 300mg
224169661|NCT01719627|DRUG|TVD 300/200 QD|TVD 300/200 QD during 7 days
224169662|NCT01719627|DRUG|Maraviroc|Unique dose of Maraviroc 600mg
224169663|NCT00833066|BIOLOGICAL|gpASIT+TM|entero-coated capsules containing 25µg of gpASIT+TM
223481941|NCT02709902|DRUG|Placebo|Gel
223481942|NCT03344393|DRUG|Ketamine Hydrochloride|intravenous ketamine infusion intraoperatively
223481943|NCT03344393|DRUG|Normal saline|intravenous normal saline infusion intraoperatively
223481944|NCT06385041|OTHER|Multicomponent training group|Additional exercise program with balance and strength trainings will include 3 times/week. Patients will get an individualized exercise program for frailty syndrome, which will include strength exercises (with elastic resistance bands and weights up to 2kg 30-50% 1RM) and balance training (with unstable surfaces). The program will be performed by 3 sets with 10 repetitions 3 times/week 30-45 minutes.
224169664|NCT00833066|BIOLOGICAL|Placebo|placebo entero-coated capsules
224169665|NCT00833066|BIOLOGICAL|gpASIT+TM|entero-coated capsules containing 100µg of gpASIT+TM
224169666|NCT00833066|BIOLOGICAL|gpASIT+TM|entero-coated capsules containing 400µg of gpASIT+TM
224169667|NCT00421616|BEHAVIORAL|High protein diet study|
224169668|NCT03654963|PROCEDURE|Medication reconciliation|Medication reconciliation is the systematic process described above.
224169669|NCT02306928|OTHER|Blood draw|
224305527|NCT01181271|DRUG|Busulfan (conditioning for AUTO transplant)|0.8 mg/kg intravenous (IV) bolus every six hours (Q6H) on days -8,-7,-6,-5 (total of 14 doses). The total daily dose of busulfan will be 3.2 mg/kg on days -8,-7, and -6 and 1.6 mg/kg on day -5
224169670|NCT03501394|OTHER|Magnetic Resonance Imaging|Patients will undergo 4 MRI sessions during NACT treatment. The first scan will take place at treatment baseline before their first cycle of NACT treatment. The second scan will take place following the first treatment cycle prior to the second treatment cycle. Likewise, the third and last scan will take place after the third treatment cycle and sixth (final) treatment cycle prior to surgery. MRI scan sessions will be composed of research scans including diffusion and lipid profiling MR imaging methods and MR spectroscopy (MRS) methods.
224169671|NCT03501394|OTHER|Histopathological Analysis|Study specific analysis will be performed on the core biopsy and tissue removed in surgery following the completion of NACT treatment. Standard routine histological analysis will be performed, as well as study specific analysis for immunostaining, grading and slide scan imaging for measurement of cellularity markers.
224169672|NCT03501394|OTHER|Health Questionnaire|Health and demographic information will be collected.
224169673|NCT02203006|BIOLOGICAL|OVIHD|7 ml of blood will be taken during a follow-up consultation and kept in a biological collection. Clinical data will be collected in a database.
224169674|NCT04205188|OTHER|therapeutic exercises|aerobic- balance -stretching and strengthening exercises
224169675|NCT03682042|OTHER|Umbilical Cord Milking|At delivery, the umbilical cord is grasped, and blood is pushed toward the infant 4 times before the cord is clamped. This procedure infuses a placental transfusion of blood into the infant and can be done in 10-15 seconds.
224169676|NCT02987205|DEVICE|Revanesse Ultra|NLF correction
224169677|NCT02987205|DEVICE|Restylane|NLF Correction
224169678|NCT02145429|BEHAVIORAL|Problem Solving therapy and Brief Behavioral Treatment of Insomnia|"Problem Solving therapy teaches problem solving skills that participants can use in their everyday life. A problem is identified, various solutions identified and explored with the underlying focus to learn behavioral and self management strategies.Social casework and management of chronic disease is also included as per the participant's need.~Brief Behavioral Treatment of Insomnia focuses on improving sleep by promoting sleep hygiene such as time spent in bed and decreasing night time stimuli. The therapy has been suitably modified to suit the needs of the participants to be recruited in the Low and Middle income countries keeping in mind the low level of literacy and the local social and health care services."
223481945|NCT06385041|OTHER|Computer-based interactive training group|Additional exercise program with balance and strength trainings will include 3 times/week 30-45 minutes. Patients will get an individualized program for frailty syndrome, with interactive technologies: gait training with Biodex GaitTrainerTM3 with visual, audio feedback and incline up to 10-15 min, Zebris FDM-T, with virtual barriers, thus simulating real environment for the patient, while performing a cognitive task up to 10-15 min, for balance training investigators used a computerized Biodex board. Exercises will be performed with the programs: Postural stability training, Limits of stability training, Weight shift training, Maze control training, Random control training, Percent weight-bearing training. For strength training investigators used equipment HUR based on pneumatic (air pressure) technology. For strength training intensity 30-50% 1-RM, 10 repetitions with 3 sets. Leg press, leg extension, leg abduction, leg adduction will be performed with pneumatic technology.
223481946|NCT03997305|DEVICE|AltaValve|Transcatheter Mitral Valve Replacement
223481947|NCT04799288|DRUG|Teriflunomide|Teriflunomide 14mg will be administered orally as 1 tablet once daily during the 9-month treatment phase of the study.
223585262|NCT04713332|DIETARY_SUPPLEMENT|Vitamin E|Members of the vitamin E family are hydrophobic fat-soluble compounds found in a variety of food sources such as vegetable oils, fruits, and vegetables consumed through diet. Vitamin E exists in 8 isoforms, a, b, g, d-tocopherol, and a, b, g, d-tocotrienol. The recommended daily allowance for adults is 15 mg per day for alpha-tocopherol, an amount which is easily met by dietary sources, and 30 mg per day for synthetic all-rac-alpha-tocopherol. The upper limit for intake is 1,000 mg per day. Very often, the dosage of vitamin E is given in international units (IU) as capsules, with a typical dose being 400 IU per day, which is above the recommended daily allowance. The health benefits of consuming vitamin E through diet or supplementation are believed to be for its antioxidant properties as a peroxyl radical scavenger. Vitamin E protects cells from cell damage caused by free radicals that damage cell membranes through lipid oxidation leading to DNA damage and cancer development.
223585263|NCT04713332|DIETARY_SUPPLEMENT|Hydrogen rich water|Molecular hydrogen is a new medical gas that can be dissolved in water and administered through drinking, inhalation, baths, intravenous drip. A growing body of evidence indicates that hydrogen, as a novel antioxidant, scavenges hydroxyl radical and peroxynitrite. In contrast to other antioxidants, gaseous molecular hydrogen efficiently penetrates cytoplasmic membranes and targets intracellular organelles, largely owing to its small size and neutral electricity. Thus, hydrogen has been suggested as a suitable candidate for the therapeutic strategies for various diseases, including certain types of cancer. Hydrogen has emerged as a promising cancer remedy as a preventative agent or in combined therapy with anticancer drugs. Hydrogen water consumption might mitigate the side effects of anticancer drugs by decreasing oxidative stress and ameliorating metamorphosis due to decreased apoptosis.
223617577|NCT04564846|OTHER|Placebo|Placebo capsule (Fish Oil)
223744941|NCT01297907|OTHER|Fractional Exhaled NO (FENO)|Fractional Exhaled NO to evaluate eosinophilic inflammation
223744942|NCT01297907|OTHER|Blood Test|Blood Tests (Eosinophil Count)
224169679|NCT00650689|DRUG|Ezetimibe + Atorvastatin|oral tablets: ezetimibe 10 mg + atorvastatin 10 mg once daily for 6 weeks
224169680|NCT00650689|DRUG|Atorvastatin|oral tablets: atorvastatin 10 mg + ezetimibe placebo once daily for 6 weeks
223481948|NCT03990428|BEHAVIORAL|online surveys|Survey data about supportive care needs, mood, and the experience of IC's finding meaning and purpose in the caregiving experience.
223481949|NCT03244995|PROCEDURE|Mind-Body Intervention Procedure|Undergo CBMB program
223481950|NCT03244995|OTHER|Quality-of-Life Assessment|Ancillary studies
223481951|NCT03244995|OTHER|Questionnaire Administration|Ancillary studies
223481952|NCT04235764|DEVICE|modified resectoscope|The modified resectoscope will be used post cystectomy (En-bloc TURBT) to resect areas of the tumor from the cystectomy specimen. These resected tumors will be sent for histopathology to assess the size of resection, depth of resection, and ability to ascertain tumor orientation and compared to the remainder of the cystectomy specimens to see if the modified resectoscope can provide improved pathologic standards for the TURBT procedure.
223481953|NCT04235764|PROCEDURE|TURBT|All patients will receive routine surgical transurethral resection of bladder tumors (TURBT).
223481954|NCT06108674|OTHER|Pharmaceutical care via telepharmacy and usual care|Pharmacotherapeutic monitoring via telephone consultation
223481955|NCT06108674|OTHER|Pharmaceutical care in-person and usual care|Face-to-face pharmacotherapeutic monitoring
223481956|NCT05751655|OTHER|Prehospital care following drowning accident|Prehospital care provided by the emergency medical service 83 (SAMU 83)
223481957|NCT02320435|DRUG|Pertuzumab|In general, patients will continue to receive 420 milligrams (mg) of pertuzumab administered as an intravenous infusion every 3 weeks following the guidance of the Parent protocol.
223481958|NCT02320435|DRUG|Trastuzumab|If trastuzumab intravenous infusions were given in combination with pertuzumab as part of the Parent study, patients will continue to receive treatment at the same dose, schedule and under the same administration guidelines which were in effect at the time of Parent study closure.
223481959|NCT02320435|DRUG|Other Combination Anti-Cancer Therapies|If other anti-cancer therapies were given in combination with pertuzumab as part of the Parent study, patients will receive all treatments at the same dose, schedule and under the same administration guidelines which were in effect at the time of Parent study closure.
223481960|NCT05852860|OTHER|Clinician Nudge|"The clinician nudge will use the BPA functionality within the electronic medical record to deliver a message with a defaulted option to refer to the health system's tobacco treatment program. Changing the default to no referral will require an explanation using the options provided or by entering free text."
223481961|NCT05852860|OTHER|Patient Nudge|The patient nudge will deliver a message within 72 hours of a patient's next scheduled clinic visit. The message will be delivered through the Penn patient portal (MyPennMedicine) or by text with security measures for privacy.
223481962|NCT05833035|DRUG|BI 1291583 mixed with [C-14] BI 1291583|BI 1291583 mixed with \[C-14\] BI 1291583
223481963|NCT02967445|DEVICE|Arabin Pessary|Arabin silicon pessary
223481964|NCT02967445|DEVICE|Cervical cerclage|
223481965|NCT06425640|BEHAVIORAL|24-hour movement behavior|Cross-sectional observational study investigating the 24-hour movement behaviors and glucose control
223481966|NCT05702632|DEVICE|1- Reciprocal electrical stimulation|A specialized programmable electrical stimulation device was used (Uniphy is the manufacturer of Phyaction787; Uniphy, Eindhoven, the Netherlands). The device has two channels that can alternatively stimulate two opposing groups of muscles (reciprocate).
223481967|NCT05702632|DEVICE|TheraTogs orthotic treatment|A sleeveless top vest and two pairs of shorts with two thigh cuffs and limb cuffs each make up the TheraTogs strapping system which is applied to the children in the TheraTogs group. The TheraTogs suit is providing breathable, comfortable- Latex over the torso and thigh, as well as free toileting. For infection control and size fitting problems, participants are not allowed to share their TheraTogs with other patients. TheraTog's orthotic undergarment and strapping system were worn under their regular clothes, so it was neither distracting nor irritating.
223481968|NCT05702632|PROCEDURE|traditional physical therapy program|Facilitation of balance and gait training
223481969|NCT04367246|OTHER|No Intervention|No intervention is assigned.
223481970|NCT04134390|DRUG|Cabozantinib|Subjects will receive cabozantinib 40mg p.o. as long as they continue to experience clinical benefit or until unacceptable toxicity, the need for alternative anticancer treatment, or other reasons for treatment discontinuation
223481971|NCT06964815|DIETARY_SUPPLEMENT|Silibinin as STAT3 inhibitor|Sillbrain will be available as granulate in sachets of 3.7g and it will be administered twice a day during chemo-radiotherapy and day 1-28 in maintenance phase every cycle. Each 3.7 g sachet of Sillbrain contains 500 mg silibinin. Every patient will assume 2 sachets/day for a total of 1 g/day of silibinin.
223481972|NCT06964815|OTHER|Placebo|Placebo will be available as granulate in sachets of 3.7g and it will be administered twice a day during chemo-radiotherapy and day 1-28 in maintenance phase every cycle. Every patient will assume 2 sachets/day for a total of 1 g/day of placebo.
223481973|NCT04716829|DEVICE|LUNA-EMG|The LUNA-EMG (Samcom) system is a robot that allows the evaluation of muscular strength through the recording of muscle activity (electromyography - EMG) in order to provide precise objective data on the patient's muscle function. In addition to the diagnostic aspect (evaluation of muscle strength, range of motion and proprioception), the LUNA-EMG robot allows the adaptation of movements during rehabilitation sessions according to the individually generated strength.
223481974|NCT04431544|DEVICE|AcQMap System|To evaluate procedural and long-term outcomes when using the diagnostic AcQMap System as an imaging and mapping system for ablation of arrhythmias in accordance with the Instructions for Use (IFU).
223481975|NCT04594187|OTHER|Immunotherapy|All patients must be planned for treatment with any immunotherapy agent after sentinel lymph node biopsy (e.g. pembrolizumab or nivolumab). For patients receiving radiation therapy initiation may be before, during or after radiation.
223481976|NCT04594187|OTHER|Quality-of-Life Assessment|Ancillary studies
223481977|NCT04594187|RADIATION|Radiation Therapy|Undergo nodal radiation therapy
223481978|NCT06953323|DRUG|Paclitaxel/Paclitaxel-albumin|"WJB001 Capsules:120mg(or 80mg,40mg,or 100mg,60mg),Oral QD Days 1-5, 8-12, 15-19 or other dosing frequencies (e.g., days 1-4, 8-11, 15-18),Every 21 days;~Paclitaxel:80 mg/m2(or 60 mg/m2 ,50 mg/m2), Day 1, day 8, day 15, intravenous infusion, 21 days 1 cycle, up to 6 cycles;~Paclitaxel-albumin:260mg/m2(220mg/m2,180mg/m2),On day 1, intravenous infusion, 21 days 1 cycle, up to 6 cycles；"
223481979|NCT06953323|DRUG|Carboplatin/Nedaplatin|"WJB001 Capsules: 80mg(or 60mg,40mg,or 100mg,60mg),Oral QD Days 1-5, 8-12, 15-19 or other dosing frequencies (e.g., days 1-4, 8-11, 15-18), Every 21 days;~Carboplatin: AUC 5 mg/ml\*min(or 4mg/ml\*min,3mg/ml\*min), Day 1, day 8, day 15, intravenous infusion, 21 days 1 cycle, up to 6 cycles;~Nedaplatin: 100mg(80mg/m2 ,60mg/m2), Day 1, intravenous infusion, 21 days 1 cycle, up to 6 cycles;"
223585264|NCT04713332|DIETARY_SUPPLEMENT|placebo|Placebo containing gelatin is made by cooking down the protein collagen found in the skin, hooves, connective tissues, and bones of animals. The cooking process breaks down the bonds between proteins to make smaller, more bioavailable building blocks that your body can easily absorb. Like collagen, gelatin is packed with beneficial amino acids, especially the anti-aging superstar's glycine and proline, which are lacking in the standard Western diet. These amino acids make gelatin especially powerful for healing skin, gut, and joint damage. Because collagen and gelatin come from the same source, they have identical amino acid profiles
223585265|NCT02131519|PROCEDURE|internal jugular vein catheter placement|
223585266|NCT03554980|DRUG|Silver Diamine Fluoride|SDF will be applied with a brush.
224169681|NCT04803006|BIOLOGICAL|TCD601|Investigational Product
224169682|NCT05439135|OTHER|washed microbiota transplantation|Each patient will receive washed microbiota transplantation each day for three consecutive days. After WMT, participants will receive free diet plus home enteral nutrition (solution at a 750ml daily dosage that provides 750 kcal energy) at home for 8 weeks.
224169683|NCT05587439|GENETIC|Data and Specimen Collection|"* Provide blood and/or saliva sample~* Answer short questionnaires~* Consider consenting to other optional parts of the research such as:~  * use stored tissue samples related to prior cancer treatment~ * Allow access to deceased relatives' medical records and stored specimens~ * Provide blood 1x per year for up to 5 years~ * Provide contact information of family members"
224169684|NCT04675632|PROCEDURE|Endovascular Therapy|the most commonly used surgical options include: ordinary balloon dilatation， drug-coated balloon (DCB) dilatation and bare stent implantation.
223481980|NCT06953323|DRUG|Paclitaxel+Carboplatin|"WJB001 Capsules: 40mg,Oral,QD,Days 1-5, 8-12, 15-19 or other dosing frequencies (e.g., days 1-4, 8-11, 15-18),Every 21 days;~Paclitaxel: 60 mg/m2, Day 1, day 8, day 15, intravenous infusion, 21 days 1 cycle, up to 6 cycles;~Carboplatin: AUC 2mg/ml\*min, Day 1, day 8, day 15, intravenous infusion, 21 days 1 cycle, up to 6 cycles;"
223481981|NCT06953323|DRUG|Niraparib|"WJB001 Capsules: 120mg(or 80mg,40mg,or 100mg,60mg),Oral QD Days 1-5, 8-12, 15-19 or other dosing frequencies (e.g., days 1-4, 8-11, 15-18),Every 21 days;~Niraparib:Niraparib:300mg(or 200mg,100mg),Oral QD Every 21 days;"
223481982|NCT06953323|DRUG|Bevacizumab|"WJB001 Capsules: 120mg(or 80mg,40mg,or 100mg,60mg),Oral QD Days 1-5, 8-12, 15-19 or other dosing frequencies (e.g., days 1-4, 8-11, 15-18),Every 21 days;~Bevacizumab: 15mg/kg(or 7.5mg/kg),intravenous infusion, 21 days 1 cycle, up to 22 cycles or unacceptable side effects；"
223481983|NCT04429542|DRUG|BCA101|EGFR/TGFβ fusion monoclonal antibody
223481984|NCT04429542|DRUG|Pembrolizumab|anti-PD-1
223481985|NCT01691651|PROCEDURE|Subcutaneous injection of botulinum toxin type A|Subcutaneous injection of botulinum toxin type A (2.5 units per application point) at two points in a nasal and temporal extent of the orbicularis muscle will be performed in the Botulinum toxin type A group.
223481986|NCT01691651|DRUG|Botulinum Toxin Type A|2.5 units per point of application at two points in a nasal and temporal extent of the orbicularis muscle.
223481987|NCT04935632|BEHAVIORAL|prevention training|Evaluate the impact of hypothermia prevention training on the proportion of patients hypothermic patients in the operating room
223481988|NCT00362232|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Rivaroxaban (Xarelto, BAY59-7939) 10 mg tablet administered once daily (od) in the evening.
223481989|NCT00362232|DRUG|Enoxaparin|Syringes of enoxaparin active substance 30 mg twice a day administered once in the morning and once in the evening.
223481990|NCT00362232|DRUG|Placebo: tablet of Rivaroxaban|Placebo tablet of rivaroxaban administered once daily in the evening.
224169685|NCT06113471|DRUG|Povorcitinib|Oral, Tablet
224305528|NCT01181271|DRUG|Etoposide (conditioning for AUTO transplant)|Etoposide 30 mg/kg IV bolus every day (QD) on day -4. The total daily dose of etoposide will be 30 mg/kg.
224305529|NCT01181271|DRUG|Cyclophosphamide (conditioning for AUTO transplant)|Cyclophosphamide 60 mg/kg IV bolus QD on days -3 and -2. The total daily dose of cyclophosphamide will be 60 mg/kg.
223481991|NCT00362232|DRUG|Placebo: syringes of Enoxaparin|Placebo syringes of enoxaparin twice a day (bid) administered once in the morning and once in the evening.
223481992|NCT01043419|DRUG|xenon|Inhalational gas; dose allowed max.70 Vol.% in 30 % oxygen; the duration of the treatment will be to 30 minutes
223481993|NCT06290102|DRUG|TEV-56248|"Pharmaceutical form: Dry powder~Route of administration: Oral inhalation"
223481994|NCT06290102|DRUG|Fp MDPI|"Pharmaceutical form: Dry powder~Route of administration: Oral inhalation"
223481995|NCT05423743|OTHER|Arm 1: Routine Care|Routine Antibiotic Stewardship Arm - Continuation of antibiotic stewardship activities in accordance with national standards.
223481996|NCT05423743|OTHER|Arm 2: INSPIRE Stewardship Bundle for Abdominal Infection|Quality improvement intervention that includes (1) computerized physician order entry (CPOE) decision support alert that provides physicians with patient-specific risk estimates for having an abdominal infection due to a multidrug-resistant organism (MDRO) and recommends standard spectrum antibiotics for low risk patients in the first 3 days of hospitalization; (2) clinician feedback reports, and (3) activities to support CPOE adoption (including education and alignment of CPOE workflows). Other antibiotic stewardship activities to continue in accordance with national standards.
223481997|NCT05024929|PROCEDURE|Whole body scan|"Patients will receive oncogene-specific molecularly targeted therapy independently of this protocol either via commercial supply of an FDA approved agent, or as part of a separate therapeutic clinical trial/compassionate use protocol/single patient investigational new drug (IND).~During screening, patients will undergo a baseline RAI-whole body scan (WBS) to assess RAI-avidity of their tumor per standard of care. Following approximately 28 days of targeted therapy, the WBS will be repeated to determine whether this therapy is associated with an increase in RAI-avidity of their tumor."
223481998|NCT06088979|DRUG|TOUR006 - 20 MG|TOUR006 20 MG
223481999|NCT06088979|OTHER|Placebo|Placebo
223482000|NCT06088979|DRUG|TOUR006 - 50 MG|TOUR006 - 50 MG
223482001|NCT01246167|DEVICE|Philos|"Conservative treatment versus Philos locking plate in 2 part fracture group.~Conservative treatment versus Philos locking plating versus Epoca prosthesis in MFF group."
223482002|NCT01246167|DEVICE|Epoca|Conservative treatment versus Philos locking plate versus Epoca fracture prosthesis in MFF group
223482003|NCT01246167|OTHER|Control group|Conservative control group
223482004|NCT01583361|DRUG|Oxaliplatin+S-1|S-1: 40\~60mg bid，po, d1\~14 （S-1：BSA \<1.25m2, 40mg bid, 1.25m2≤BSA≤1.5m2,50mg bid, BSA\>1.5m2, 60mg bid） oxaliplatin：130mg/m2，iv drip for 2h，d1
223482005|NCT01583361|DRUG|Adjuvant Oxaliplatin/S-1（SOX）|S-1：40\~60mg bid，d1\~14 q3W oxaliplatin：130mg/m2，iv drip for 2h，d1,q3W 8 cycles (6 months)
224169686|NCT06113471|DRUG|Placebo|Oral, Tablet
224169687|NCT06436599|OTHER|plane block with %0.25 30 ml bupivacaine|evaluation of the efficacy of two different plan blocks for postoperative analgesia
224169688|NCT03292835|DEVICE|LeiProtect®|Filmogenic dressing gel
224169689|NCT03750344|DEVICE|Diagnostic test|Comparison of respiratory rates in normal subjects as observational with end tidal CO2. No treatment or interventions will be performed
224169690|NCT03952676|DEVICE|Moving cupping|"1. We use a black opaque eye mask to shield the patient's eyes and choose different sizes of cup according to the location of the treatment (There are three sizes of cups)~2. (1) First apply Vaseline to the skin lesions area; (2) Then hold the 95% ethanol cotton ball with tweezers, and hold the cup with the facing down, after the cotton ball is ignited, immediately sway down in the cup and then exit, and quickly buckle the cup to the skin lesions area. (3) After using the cup to absorb the skin lesions area, hold the cup body in one hand and push and pull the cup along the certain route with a little strength, so that the skin purple color of the treatment area is suitable. (4) Apply even force when pushing the cup to prevent the cup from falling off due to air leakage. (5) Acting on the skin lesions area 30 times, change cup 5 times per push and pull, the interval is not more than 10 seconds."
223482006|NCT01800253|BEHAVIORAL|Inhibitory task|Participants perform a binary decision on each presented stimuli. Of the two possible outcomes, participants are instructed to make a motor response (go) for one type, and are to withhold a response (no-go) for the other type. Reaction time and accuracy are measured for each event
224169691|NCT03952676|DEVICE|Moving cupping placebo|Using of special perforated cups, the manipulation method is the same as the intervention group.
223482007|NCT01800253|PROCEDURE|Blood samples|Hormone levels, neuromolecular levels and gene expression profiles will be analyzed from repeated blood samples obtained before and after the nighttime intervention
224169692|NCT04525911|DIAGNOSTIC_TEST|Diagnostic Test: serology test for COVID-19|a serology test will be performed at M3
224169693|NCT02627196|DEVICE|BAROSTIM NEO® System|
224169694|NCT02627196|DRUG|Medical Management|
224169695|NCT05010434|DRUG|Sintilimab and Bevacizumab Combined with Radiotherapy|Before radiotherapy: Bevacizumab+Sintilizumab, Q3w, 2 cycles in total. Radiation therapy: 30-50Gy/10 fractions. After radiotherapy: Bevacizumab+Sintilizumab, Q3w until disease progression or toxicity is intolerable.
224169696|NCT02094612|DEVICE|Quotient®|Patients will be randomized once at the time of ADHD assessment to either usual clinic ADHD care or usual clinic ADHD care plus the Quotient using computer-generated random numbers.
224169697|NCT02094612|BEHAVIORAL|Usual Clinic ADHD Care|Usual ADHD care as provided by the clinic
224169698|NCT02088736|DEVICE|Intraosseous|
224169699|NCT02088736|DEVICE|Intravenous|
224169700|NCT00633425|DRUG|GLIMEPIRIDE|
223482008|NCT01800253|PROCEDURE|Tissue samples|Expression profiles will be analyzed from samples obtained from tissues involved in metabolism
223482009|NCT01800253|PROCEDURE|Oral glucose tolerance test|75 g of glucose will be dissolved in 300 ml of water and given to participants, followed by blood sampling at 0, 15, 30, 60, 90, 120 and 150 minutes following the ingestion of the glucose solution.
224169701|NCT04167514|BIOLOGICAL|Alpha-1 antitrypsin (AAT)|AAT is a lyophilized product for intravenous administration
223585267|NCT03554980|DRUG|Sodium Fluoride varnish|NaF will be applied with a brush
224169702|NCT04167514|DRUG|Placebo|Albumin solution administered intravenously
224169703|NCT05711693|DEVICE|Laser doppler vibrometry (LDV), heart(cordium) carotid pulse wave velocity (ccPWV)|Patients scheduled for thoracic aorta MRI will have LDV measurement of ccPWV. Both techniques will be compared
224169704|NCT05711693|PROCEDURE|Blood pressure and heart rate measurement|"To all patients:~\- blood pressure and heart rate will be measured"
224169705|NCT05711693|DEVICE|carotid to femoral PWW measurement|"To all patients:~\- carotid to femoral PWW will be measured by LDV and tonometry for comparison"
224169706|NCT05711693|PROCEDURE|Questionnaire completion|All patients will complete a questionnaire of acceptability
223482010|NCT01800253|BEHAVIORAL|Portion Size Task|Participants are given a computer program that gives them the opportunity to choose the portions of a variety of food items that they would ideally like to consume
223482011|NCT00121875|DRUG|somatropin (rDNA)|"Form/Strength: 10 mg aqueous suspension; 5 mg/ml~Dosage/Frequency: 0.35 mg/kg/week, daily divided doses~Duration: 6 months with 3-month washout period"
223482012|NCT02233413|DEVICE|Active LLLT helmet application|LED helmet applied with light activated
223482013|NCT02233413|DEVICE|Non-active LLLT helmet application|LED helmet applied without light activated
223482014|NCT00090103|DRUG|dutasteride 0.5mg once daily for 4 years|combination or single agent
223482015|NCT00090103|DRUG|tamsulosin 0.4mg once daily for 4 years|combination agent or single agent
223482016|NCT00675480|PROCEDURE|Thrombectomy|Aspiration Thrombectomy prior to stent implantation in patients with ST segment elevation myocardial infarction
223482017|NCT00675480|PROCEDURE|Primary angioplasty|Standard primary angioplasty with stent implantation
223482018|NCT01259999|DIETARY_SUPPLEMENT|Calogen extra strawberry|A daily dose of 3 x 30 ml Calogen extra strawberry flavour will be distributed at the same time as the medicines i.e. at 8.00, 12.00 and 20.00.
223585268|NCT04644913|BEHAVIORAL|Quality of life questionnaire|Sending of 2 questionnaires (SF 36 and TESS)
223585269|NCT06204861|OTHER|Capacitive and Resistive Electric Transfer Therapy|Participants received a 10-minute intervention in CAP mode followed by a 20-minute intervention in RES mode.
224169707|NCT05719064|BEHAVIORAL|Adaptive Cell Phone Support|Mobile health adherence promotion based on the supportive accountability model
224169708|NCT04305041|BIOLOGICAL|Pembrolizumab|Administered via IV infusion at a specified dose on specified days
224169709|NCT04305041|BIOLOGICAL|Quavonlimab|Administered via IV infusion at a specified dose on specified days
224169710|NCT04305041|BIOLOGICAL|Vibostolimab|Administered via IV infusion at a specified dose on specified days
224169711|NCT04305041|DRUG|Lenvatinib|Administered via oral capsules at a specified dose on specified days
224169712|NCT04305041|DRUG|ATRA|Administered via oral capsules at a specified dose on specified days
224169713|NCT00058318|DRUG|capecitabine|Capecitabine will be given 625 mg/m\^2 (1250 mg/m\^2/day) by mouth twice a day on day 1-21 for every cycle (1 cycle =28 days) until disease progression
223744943|NCT01297907|OTHER|PCDAI|Clinical Evaluation for Pediatric Crohn's Disease Activity Index (PCDAI)
223744944|NCT05422677|DRUG|Hanmi Tams® Capsule|Hanmi Tams®, Once daily administered per the locally approved product information
224169714|NCT00058318|DRUG|gemcitabine hydrochloride|Gemcitabine will be given 900 mg/m\^2 by intravenous infusion over 30 minutes on day 1, 8, and 15 for every cycle (1 cycle = 28 days) until disease progression.
224169715|NCT02255162|DRUG|Lenalidomide|Patients will receive lenalidomide starting on day 6 of each post-remission cycle, following conclusion of cytarabine post-remission therapy on days 1-5. Following count recovery in the third post-remission cycle, patients will then receive lenalidomide daily as a maintenance therapy.
224169716|NCT02255162|GENETIC|HLA-mismatched stem-cell Microtransplantation|Patient will receive HLA-mismatched stem cell microtransplant infusion on day 6 of each post-remission cycle, following conclusion of course of cytarabine in each cycle.
224169717|NCT02255162|DRUG|Cytarabine|Patients will receive cytarabine post-remission therapy for 3 cycles, on days 1-5 of each cycle.
224169718|NCT03345849|DRUG|Upadacitinib|Oral; Tablet
224169719|NCT03345849|DRUG|Placebo for Upadacitinib|Oral; Tablet
223482019|NCT03186352|PROCEDURE|photoactivated disinfection|"After manual preparation of the cavity with an excavator and taking a sample for a microbial analysis with a rose bur on micro motor (size 014) the cavity undergoes the procedure of photodynamic disinfection:~application of photosensitizer 'Fotosan' Agent (CMS Dental, Denmark) for 5 minutes, radiation with low power laser, wavelength 635 nm power 200mW 120 s. ('Lasotronix', DiodeLX model SMART) rinsing with water and drying"
223482020|NCT03471819|DIAGNOSTIC_TEST|Serum serotonin level|blood sample will be obtained to evaluate serum level of serotonin
223482021|NCT01499407|DEVICE|ClearWay RX catheter|
223482022|NCT01499407|DRUG|Abciximab|
223482023|NCT01679470|DEVICE|AuroLase Therapy|Infusion of AuroShell particles followed by laser illumination for photothermal ablation of target lesions.
223482024|NCT05514990|DRUG|Bortezomib|Given SC or IV
223482025|NCT05514990|DRUG|Dexamethasone|Given PO, IV, or IM
223482026|NCT05514990|BIOLOGICAL|Pelareorep|Given IV
223482027|NCT05514990|BIOLOGICAL|Pembrolizumab|Given IV
223482028|NCT05530018|BEHAVIORAL|Brief contact intervention|The brief contact intervention (BCI) will send out text messages to the participants. The text messages will include caring messages, reminders of appointments, and a link to a web page. The web page is anticipated to include safety planning, volitional helpsheet, and resources information. The text messages are anticipated to send out to the participants on a weekly base for 6 weeks in a row, and then change to monthly reminders. The monthly reminders are anticipated to include caring messages, reminders of appointments, and invitations to encourage the participants to click the previous web links again. The monthly reminders are anticipated to send out to the participants three times in a row. In the final reminder, the participants will be told that this intervention is going to end. In total, the participants will receive 9 texts within 5 months.
223482029|NCT05267704|DEVICE|Samsung Gear Virtual Reality Headset|VR headset displaying preselected game during renal biopsy
223482030|NCT03979313|DRUG|MEDI8897|Anti-RSV monoclonal antibody with an extended half-life
223482031|NCT03979313|DRUG|Placebo|Commercially available 0.9% (w/v) saline
223482032|NCT02232230|DRUG|Provenge|
223482033|NCT00300053|BIOLOGICAL|CLBS14 (low-dose)|Eligible subjects will receive subcutaneous injections of 5 µg/kg/day G-CSF for 5 days to mobilize CD34+ cells from the bone marrow to the peripheral blood. Mononuclear cells (MNCs) will be collected via apheresis on day 5. On the day of the cell/placebo injection (day 6), the apheresis product will be enriched for CD34+ cells using the Isolex 300i Magnetic Cell Selection System (Baxter Healthcare). Autologous CD34+ cells will be delivered in 10 intramyocardial injections of 0.2 mL at a dose of 1 x 10\^5 (=100000) cells/kg bodyweight each using the MyoStar injection catheter (Biosense Webster, Inc.) into the target areas of myocardial ischemia.
223482034|NCT00300053|BIOLOGICAL|CLBS14 (high-dose)|Eligible subjects will receive subcutaneous injections of 5 µg/kg/day G-CSF for 5 days to mobilize CD34+cells from the bone marrow to the peripheral blood. Mononuclear cells (MNCs) will be collected via apheresis on day 5. On the day of the cell/placebo injection (day 6), the apheresis product will be enriched for CD34+ cells using the Isolex 300i Magnetic Cell Selection System (Baxter Healthcare). Autologous CD34+ cells will be delivered in 10 intramyocardial injections of 0.2 mL at a dose of 5 x 10\^5 (=500000) cells/kg bodyweight each using the MyoStar injection catheter (Biosense Webster, Inc.) into the target areas of myocardial ischemia.
223744945|NCT05228145|GENETIC|NGN-101|Participants with confirmed mutations in the CLN5 gene who meet all the inclusion and none of the exclusion criteria will be treated with a single intracerebroventricular (ICV) dose and a single intravitreal (IVT) dose of the study treatment.
224169720|NCT00397644|BEHAVIORAL|Prompting (survey instrument/resources list) (behavior)|
224169721|NCT03261037|OTHER|Spirometry|Daily spirometry will be conducted by the participant at home using the study kit provided. Spirometry assessments (FVC) will be conducted at approximately the same time each day with the participant in a seated position. Additionally, site spirometry will also be performed during pre-diagnosis assessment period, on the day of diagnosis, post-diagnosis assessment period, and at end of study.
224169722|NCT03261037|OTHER|Accelerometry|Daily physical functional capacity assessments (e.g., steps per day, calorie expenditure) will be measured on an ongoing basis using the accelerometry device provided.
224169723|NCT03261037|OTHER|6MWT|The 6MWT will be performed only at sites where a formalized process is available and the test can be performed under safe conditions, during pre-diagnosis assessment period, on the day of diagnosis, post-diagnosis assessment period, and at end of study.
224169724|NCT01376765|DRUG|Aluminum hydroxide adjuvant (Alhydrogel®)|Aluminum hydroxide adjuvant (Alhydrogel®);given with SARS vaccine; 2 intramuscular doses, 28 days apart, Cohort 1: 12 subjects given vaccine with adjuvant at 5 micrograms per dose; Cohort 2: 12 subjects given vaccine with adjuvant at 15 micrograms per dose; Cohort 3: 12 subjects given vaccine with adjuvant at 45 micrograms per dose
224169725|NCT01376765|OTHER|Phosphate buffered saline Placebo|Phosphate buffered saline Placebo; 2 intramuscular doses, 28 days apart. Cohort 1: 4 subjects given placebo at 5 micrograms per dose; Cohort 2: 4 subjects given placebo at 15 micrograms per dose; Cohort 3: 4 subjects given placebo at 45 micrograms per dose
223585270|NCT06204861|OTHER|Balance Training|The training program consists of five exercises: single-limb stance, single-limb stance with ball toss, single-limb stance with kicking, step-down with a single-limb stance, and wobble board. The program is conducted three times a week, and the difficulty level is increased every two weeks. Before and following the training, a physiotherapist will lead a warm-up and stretching session.
223585271|NCT06204861|OTHER|Balance Training Combined with Capacitive and Resistive Electric Transfer Therapy|Participants received a 10-minute intervention in CAP mode followed by a 20-minute intervention in RES mode. However, the B+CRET group received balance training along with CRET treatment.
223585272|NCT03335254|DRUG|TSX-011|TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient.
223585273|NCT03645317|DIAGNOSTIC_TEST|Blood tests & cardiac imaging|Blood tests (full blood count, lipids, cholesterol, high sensitivity Troponin levels, C-reactive protein (CRP) and brain natriuretic peptide) Cardiac imaging - cardiac CT, cardiac ultrasound, 12-lead ECG
223585274|NCT00906958|DEVICE|Nexus Flow Generator|The modified device to be assessed in this study will act in a similar way to the existing device, VPAP Auto, but utilises an improved algorithm which should maintain or enhance the effectiveness of the treatment.
223585275|NCT00906958|DEVICE|VPAP Flow Generator 25|Exiting VPAP Auto 25 Flow Generator with A10 Algorithm
223585276|NCT05004974|DRUG|Sintilimab|Sintilimab is administered every 3 weeks (200mg, IV).
223585277|NCT05004974|DRUG|Pemigatinib|Pemigatinib 13.5 mg once daily (QD) orally, continuous administration.
223585278|NCT03371953|DRUG|Vecuronium|A top-up dose of vecuronium will be administered when the TOF count is 1 on the accelerometer. However, if there is a diaphragmatic contraction which interferes with surgical procedure then a dose will be given irrespective of the TOF count.
223482035|NCT00300053|BIOLOGICAL|placebo injection|Eligible subjects will receive subcutaneous injections of 5 µg/kg/day G-CSF for 5 days to mobilize CD34+ cells from the bone marrow to the peripheral blood. Mononuclear cells (MNCs) will be collected via apheresis on day 5. On the day of the cell/placebo injection (day 6), the apheresis product will be enriched for CD34+ cells using the Isolex 300i Magnetic Cell Selection System (Baxter Healthcare). Placebo will be delivered in 10 intramyocardial injections of 0.2 mL each of 0.9% NaCl (saline) in 5% autologous plasma into the target areas of myocardial ischemia.
223482036|NCT00771108|BEHAVIORAL|exercise|For 16 weeks subjects will exercise from 30-60 minutes five times a week.
223482037|NCT02156258|DEVICE|FFDM Mammography|Standard mammography image collection
224169726|NCT01376765|BIOLOGICAL|Recombinant S protein SARS vaccine|Recombinant S protein severe acute respiratory syndrome (SARS) vaccine given with adjuvant or without adjuvant; 2 intramuscular doses, 28 days apart, Cohort 1: 12 subjects given vaccine only or vaccine with adjuvant at 5 micrograms per dose; Cohort 2: 12 subjects given vaccine only or vaccine with adjuvant at 15 micrograms per dose; Cohort 3: 12 subjects given vaccine only or vaccine with adjuvant at 45 micrograms per dose
223482038|NCT02156258|DEVICE|DBT Mammography|Collection of breast images using DBT mammography
223482039|NCT02934594|OTHER|Palliative Decompression|palliative decompression to MSCC patients: before motor deficit (Group A), within 48 hours after motor deficit (Group B1), 48 hours after motor deficit (Group B2)
223482040|NCT03290651|DIETARY_SUPPLEMENT|Probiotic Natural Health Product - RepHresh Pro-B|Participants will take the probiotic or placebo daily for 90 days.
224169727|NCT06128629|BIOLOGICAL|NTLA-2001|NTLA-2001 (55mg) by IV infusion
224169728|NCT06128629|DRUG|Placebo|Normal saline (0.9% NaCl) by IV infusion
223482041|NCT03290651|DIETARY_SUPPLEMENT|Placebo|Participants will take the probiotic or placebo daily for 90 days.
223482042|NCT01749371|DRUG|Vitamin E|1200 IU dl-alpha tocopheryl acetate after the initial excision surgery after admission (days 1-15 or days 16-30)
223482043|NCT02049203|DRUG|Ataciguat|
223482044|NCT02049203|DRUG|Placebo|
223482045|NCT05739071|DIETARY_SUPPLEMENT|JING SI HERBAL TEA|JING SI HERBAL TEA is a food, contain with herbal extracts
223482046|NCT05739071|DIETARY_SUPPLEMENT|Placebo|Placebo will have the same appearance as JING SI HERBAL TEA
223482047|NCT02472405|DEVICE|595/1064nm Multiplex Laser|The multiplex cynergy laser will be used for this study. A third of the scar will solely be treated with the 595nm PDL.
223482048|NCT02472405|DEVICE|595nm PDL|One third of the scar will be treated with 595nm PDL solely for 3 weeks (1 treatment session per week).
223482049|NCT06307379|OTHER|no intervention|only observational
223585279|NCT03371953|DRUG|Atracurium|A top-up dose of vecuronium will be administered when the TOF count is 1 on the accelerometer. However, if there is a diaphragmatic contraction which interferes with surgical procedure then a dose will be given irrespective of the TOF count.
223585280|NCT03371953|DRUG|Vecuronium + Atracurium|A top-up dose of vecuronium + atracurium will be administered when the TOF count is 1 on the accelerometer. However, if there is a diaphragmatic contraction which interferes with surgical procedure then a dose will be given irrespective of the TOF count.
223585281|NCT01965899|DEVICE|Insertable Cardiac Monitor Implant|The Reveal LINQ is a leadless device that is recommended to be implanted in the region of the thorax. Two electrodes on the body of the device continuously monitor the patient's subcutaneous ECG. The device stores ECG recordings from the patient-activated episodes and ECG recordings from automatically detected arrhythmias. Documentation of episode occurrence will be retained.
223585282|NCT01443832|DIETARY_SUPPLEMENT|Fe57 and Fe58-FeSO4 stable isotopes|\[57Fe\] and \[58Fe\]- FeSO4 prepared from isotopically enriched 57Fe and 58Fe respectively, by dilution of each compound in 0.1 mol H2SO4/L.
223585283|NCT00535821|DEVICE|Esophageal Doppler monitoring - CardioQ, Deltex Inc|6-hour hemodynamic optimization of severe sepsis or septic shock guided by EDM
223585284|NCT00535821|DEVICE|Central line with CVP and continuous ScvO2 monitoring|6-hour hemodynamic optimization of severe sepsis or septic shock guided by CVP and ScvO2 monitoring
223585285|NCT01567995|DRUG|Clobetasone Butyrate 0.05% Cream|Clobetasone Butyrate 0.05% Cream
223585286|NCT01567995|DRUG|Vehicle (base cream)|Vehicle (base cream)
224169729|NCT05858645|DRUG|deucravacitinib|Treatment with deucravacitinib, skin biopsy and blood analysis pre- and mid-treatment
224169730|NCT06156306|BEHAVIORAL|CBT-I|The CBT-I intervention will cover sleep education, stimulus control, sleep restriction, cognitive therapy and relaxation training.
224169731|NCT06156306|BEHAVIORAL|CBT-I combined ACT|In addition to the standard CBT-I components, mindfulness, thought diary, and other ACT components will be taught in the group.
224169732|NCT01377324|OTHER|Diagnostic intervention: Positron Emission Tomography with 16-alpha-[18-fluoro]-17betaestradiol|A FES-PET/(CT) will be performed thrice during protocol execution. Patients will be injected with \~200MBq 18F-FES
224169733|NCT02090218|DEVICE|I-Gel|I-Gel supraglottic airway device
224169734|NCT02090218|DEVICE|LTS, ETI or current airway management practice|Laryngeal tube, endotracheal tube, bag-mask-ventilation
224169735|NCT03783013|OTHER|High Lycopene Tomato Juice With Soy Germ Extract|Tomato juice made from high lycopene tomatoes with soy germ extract added
224169736|NCT03783013|OTHER|Low Lycopene Tomato Juice|Tomato juice made from low lycopene tomatoes with no soy germ extract added
224169737|NCT04950933|DRUG|Huolingshengji Granules|1 bag of Huolingshengji Granules each time + 1 tablet of Riluzole tablet simulation agent each time, twice a day, orally;
224169738|NCT04950933|DRUG|Riluzole tablet|Huolingshengji granules simulation agent 1 bag each time + Riluzole tablet 1 tablet each time, 2 times a day, orally.
224169739|NCT02233140|DEVICE|Extra-corporeal pulsed-activated therapy or shockwave therapy|
224169740|NCT02483351|OTHER|Liberal Red Blood Cell Transfusion Strategy|RBC Transfusion strategy with hemoglobin trigger of 100g/L
224169741|NCT02483351|OTHER|Restrictive Red Blood Cell Transfusion Strategy|Optional RBC Transfusion with hemoglobin trigger of \<=80g/L
224169742|NCT01128452|DRUG|EVT 101|HPMC Capsule, 15 mg, once daily for 28 days
224169743|NCT01128452|DRUG|Placebo|HPMC Placebo capsules, once daily for 28 days
224169744|NCT01370772|DRUG|Rituximab|"* Cycle 1 Rituximab : 375 mg/m² i.v on day 1~* Cycle 2-6 Rituximab:500 mg/m² i.v on day 1, repeated every 28 days"
224169745|NCT01370772|DRUG|Rituximab|"* Prephase: Rituximab:500 mg on day 0, 2000 mg on days 1, 8, and D15~* Cycle 1-6 cycle 1 beginning at D22: Rituximab: 500 mg/m2 i.v on day 1, repeated every 28 days"
224169746|NCT01370772|DRUG|Cyclophosphamide|•FCR Cycle 1-6: Cyclophosphamide : 250 mg/m² per os, days 2-4, repeated every 28 days
224169747|NCT01370772|DRUG|Fludarabine|FCR Cycle 1-6: Fludarabine :40 mg/m² per os, days 2-4, repeated every 28 days
224169748|NCT06282302|OTHER|Group control|Group control The control session will consist of keeping the volunteer sitting in a calm, air-conditioned environment for 40 minutes.
224169749|NCT06282302|OTHER|Isometric Exercise|The intervention with isometric exercise for the lower limbs, the volunteers will start in a vertical position, with shoulders and hips in contact with the wall, feet parallel and shoulder-width apart and hands at the sides of the body. Then (second phase), the volunteers, maintaining contact with the wall, squatted and advanced their feet in the desired position until the knee joint angle reached the previously determined value. The third phase referred directly to the isometric effort of the isometric exercise session. For the isometric wall squat exercise session, volunteers will be asked to perform 4 repetitions of 2 minutes, with a 2-minute rest interval in a seated position for adequate rest between each repetition.
224169750|NCT06282302|OTHER|Aerobic Exercise|Volunteers will perform 50 minutes of horizontal exercise cycling (brand: pro-user), continuously and at moderate intensity (50% to 60% of HR reserve).
223482050|NCT03246178|OTHER|MSD-HSCT|"1. Conditioning regimens: (A) Patients had SAA and PNH, or heavy transfusion (RBC≥25U), or failed rabbit ATG therapy, and received 0.8 mg/kg/6h busulfan (days -7 to -6), 30mg/m2/day fludarabine (days -5 to -2), 25 mg/kg/day cyclophosphamide (days -5 to -2) and 2.5 mg/kg/day r-ATG (days -5 to -2). (B) The other patients with SAA or VSAA received same procedure but without busulfan;~2. Allogeneic HSC infusion: Doner BM cells were harvested to achieve a target mononuclear cell count (MNC) of 2-4 × 108 per kilogram of recipient weight. The target MNC from PB was 4-6× 108 per kilogram of recipient weight;~3. Prophylaxis and treatment of GVHD: GVHD prophylaxis consisted of intravenous CSP 2-3 mg/kg/day in divided doses beginning on the day before transplantation (day -5) and the target concentration was adjusted to 150-250 ng/ml. The oral MMF dose was 20 mg/kg/day from day -1 and was tapered off after 1 months if no aGVHD was observed."
223585287|NCT04588181|BEHAVIORAL|cognitive behavioral therapy (CBT)|Cognitive behavioral therapy (CBT) is a psycho-social intervention that aims to improve mental health. CBT focuses on challenging and changing unhelpful cognitive distortions (e.g. thoughts, beliefs, and attitudes) and behaviors, improving emotional regulation, and the development of personal coping strategies that target solving current problems.
223585288|NCT01325714|BEHAVIORAL|PAVeD Intervention|In the PAVeD Intervention, the caregiver will receive six to eight 45-minute visits to teach caregiver about pain and memory problems. The person with dementia will also be able to learn from these visits. These visits will take place over three months.
224169751|NCT02622802|DRUG|paracetamol|In an ex vivo placenta perfusion study, placental tissue is exposed to paracetamol
224169752|NCT02622802|DRUG|Erythromycin|In an ex vivo placenta perfusion study, placental tissue is exposed to erythromycin
224169753|NCT02622802|DRUG|Azithromycin|In an ex vivo placenta perfusion study, placental tissue is exposed to azithromycin
223585289|NCT01325714|BEHAVIORAL|Enhanced Usual Care|"In Enhanced Usual Care, the caregiver will receive information in the mail about memory problems and pain; and the caregiver will receive eight short telephone calls to check on how the person with dementia is doing.~Primary Care providers will be notified through electronic medical records about any significant behavioral problems or pain."
223585290|NCT00169221|DRUG|Iressa (Gefitinib)|postoperative chemoradiotherapy with cisplatin + gefitinib
224305530|NCT01181271|DRUG|Mesna (prior to AUTO transplant)|Mesna 15 mg/kg IV bolus on days -3 and -2 infused over 15 minutes and given 15 minutes prior to cyclophosphamide administration. This is followed by Mesna given 15 mg/kg IV bolus three times daily (TID) on days -3 and -2 infused over 15 minutes at 3, 6, and 9 hours after completion of cyclophosphamide infusion. Total daily dose of Mesna should be equivalent to daily dose of cyclophosphamide. Lastly, Mesna will be given at 15 mg/kg IV bolus QD on day -1. This makes a total of 9 doses of Mesna
223585291|NCT00169221|RADIATION|chemoradiotherapy with cisplatin|postoperative chemoradiotherapy with cisplatin
223585292|NCT03503981|OTHER|Psychotherapy|There are different psychotherapy models offered across the units. All patients receive individual treatment and group therapy or psychoeducative groups.
224169754|NCT02481986|BEHAVIORAL|Community Health Worker|A community health worker is para-professional who performs education, case management, and social support.
224169755|NCT02481986|BEHAVIORAL|Certified asthma educator|A certified asthma educator has is certified and performs asthma education.
224169756|NCT01873196|BEHAVIORAL|Receive extra oil|
224169757|NCT01873196|BEHAVIORAL|Receives behavior changed messages on CSB package|
224169758|NCT04475029|DRUG|Methadone|One intravenous administration of methadone (0.15 mg/kg treatment weight (height(cm)-100)) one hour prior to expected extubation.
224169759|NCT04475029|DRUG|Morphine|One intravenous administration of morphine (0.15 mg/kg treatment weight (height(cm)-100)) one hour prior to expected extubation.
223482051|NCT03246178|OTHER|HFD-HSCT|"1. Conditioning regimens: (A) Patients had SAA and PNH, or heavy transfusion (RBC≥25U), or failed rabbit ATG therapy, and received 0.8 mg/kg/6h busulfan (days -7 to -6), 35mg/m2/day fludarabine (days -5 to -2), 25 mg/kg/day cyclophosphamide (days -5 to -2) and 2.5 mg/kg/day r-ATG (days -5 to -2). (B) The other patients with SAA or VSAA received same procedure but without busulfan;~2. Allogeneic HSC infusion: Doner BM cells were harvested to achieve a target mononuclear cell count (MNC) of 2-4 × 108 per kilogram of recipient weight. The target MNC from PB was 4-6× 108 per kilogram of recipient weight;~3. Prophylaxis and treatment of GVHD: GVHD prophylaxis consisted of intravenous CSP 2-3 mg/kg/day in divided doses beginning on the day before transplantation (day -5) and the target concentration was adjusted to 200-300 ng/ml. The oral MMF dose was 20 mg/kg/day from day -3 and was tapered off after 2 months if no aGVHD was observed."
224169760|NCT02110472|DEVICE|Corneal inlay|Presbia Flexivue Microlens implantation in corneal pocket created in nondominant eyes of emmetropic presbyopes.
224169761|NCT01633372|DRUG|itacitinib|
224169762|NCT04868513|DRUG|Pregnant women to whom applied silane fluoride|Pregnant women who received 0.1% silane fluoride applied as varnish in the teeth.
224169763|NCT04868513|DRUG|Pregnant women to whom applied silane fluoride + 1% chlorhexidine|Pregnant women who received silane fluoride + 1% chlorhexidine applied as varnish in the teeth.
223482052|NCT05424120|PROCEDURE|Manual aspiration|One option from standard of care
223482053|NCT05424120|PROCEDURE|Wall suction|One option from standard of care
223482054|NCT05424120|PROCEDURE|Vacuum bottle drainage|One option from standard of care
223482055|NCT01451658|DRUG|propranolol|Starting from 20 mg daily, titrated weekly to decrease heart rate more than 25 % of baseline, administrated during the whole study period
223482056|NCT00806065|DRUG|ENMD-2076|
223482057|NCT01366391|DRUG|Metformin|Metformin 500 mg tablet (1000 or 1500 mg/day)
223585293|NCT01589913|BEHAVIORAL|ICD-Forum|"The CBT based internet program ICD-Forum is designed to increase QoL, and decrease anxiety and depression in ICD-patients. The program includes a therapist moderated asynchronous discussion group and content focused modules following a six weeks schedule:~1. Introduction to participants and online system~2. Knowledge regarding ICDs~3. Strategies for behavior change~4. Psychological models for anxiety and depression~5. Strategies to cope with avoidance, anxiety and depression~6. Resume, evaluation, resolution of open questions, goal setting, good bye"
224169764|NCT03760302|OTHER|analgesics|analgesics given to a patient treated from HEMS
223482058|NCT00599001|DRUG|SD-101|Single subcutaneous escalating dose
223482059|NCT00599001|DRUG|placebo|placebo
223482060|NCT03873584|OTHER|Fatigue|Iron deficiency anemia with fatigue symptoms
223482061|NCT00668239|DRUG|intravitreous triamcinolone|Intravenous injection of 0.1 ml (4 mg) of triamcinolone acetate was performed through the pars plana in a surgical environment. The medication used was manipulated by the Ophthalmos chemist. This type of formulation is different from the similar American one (Kenalog ®) since it does not use a conservation agent
223482062|NCT00668239|PROCEDURE|laser therapy|pan fotocoaglulation by laser therapy
223482063|NCT01173250|PROCEDURE|adding diverting ileostomy|
223482064|NCT01173250|PROCEDURE|omitting diverting ileostomy|
223482065|NCT00442793|DRUG|Epoetin beta|As prescribed, 3 times weekly
223585294|NCT03447093|DRUG|Methimazole Pill|Patients who developed GD received methimazole treatment
223585295|NCT03447093|DRUG|Propylthiouracil Pill|Patients who developed GD received propylthiouracil treatment
223585296|NCT01741337|PROCEDURE|Adaptive servo-ventilation post-operative treatment for 6 months|
223744946|NCT03056391|DRUG|Paracetamol|"\>50kg: Paracetamol 1gm PO/NG 6 hourly for 72 hours (maximum dose 4g/24h) plus IV artesunate or oral artemether/lumefantrine.~\<50kg: Paracetamol 12.5-15mg/kg/dose 6 hourly for 72 hours (maximum total dose 5doses/24hours;75mg/kg) plus IV artesunate or oral artemether/lumefantrine."
224169765|NCT03760302|OTHER|hypnotics|hypnotics given to a patient treated from HEMS
224169766|NCT06801639|DEVICE|Transcranial direct current stimulation (tDCS)|The active-tDCS treatment will consist of a constant 2mA current applied during daily 30-minute sessions with a 30 second ramp up and ramp down at the start and end of the stimulation. The anode electrode will be placed over the left dorsolateral prefrontal cortex (DLPFC) and the cathode electrode over the right DLPFC.
224169767|NCT06801639|DEVICE|Sham tDCS|Sham-tDCS treatment will consist of the same montage as the active-tDCS but the electric current will be applied only in the first and final 30s of stimulation.
224169768|NCT05618808|DRUG|REGN9933|Participants will receive a single dose of REGN9933 by IV infusion
224169769|NCT05618808|DRUG|Enoxaparin|Participants will receive enoxaparin by SC administration daily through the time of venography (or day 12, whichever is earlier)
224169770|NCT05618808|DRUG|Apixiban|Participants will receive apixaban orally twice a day through the time of venography (or day 12, whichever is earlier)
224169771|NCT03874052|DRUG|Azacitidine|Given IV or SC
223482066|NCT00442793|DRUG|methoxy polyethylene glycol-epoetin beta [Mircera]|0.4 micrograms/kg iv every 2 weeks
223482067|NCT06042075|OTHER|Questionnaire on congenital birthmarks|Questions will be put to health professionals on representation using a semi-quantitative questionnaire.
223482068|NCT02234271|OTHER|Mobile Health Application|Mobile Health application for contraception information
223482069|NCT02234271|OTHER|Health Educator Counseling|Counseling via health educator
223482070|NCT05124548|DIAGNOSTIC_TEST|Sleep diagnostics|On study day 4, all participants perform a single night sleep assessment in a sleep lab via Polysomnography (PSG) and WHOOP strap, a digital Fitness and health Coach.
223482071|NCT03815513|OTHER|brain MRI|both case and control groups received brain MRI to evaluate cerebrovascular reactivity
223482072|NCT02145819|DRUG|hCG|
223482073|NCT02145819|OTHER|LH peak|
223482074|NCT01782092|OTHER|Chiropractic Adjustment|Chiropractic adjustments will be administered using Activator Methods Basic protocol
223744947|NCT01215370|OTHER|High-fat shake with Pea protein|Shake containing 95 gram of fat, additive 30 gram pea protein
224169772|NCT03874052|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
224169773|NCT03874052|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration and biopsy
224169774|NCT03874052|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow aspiration and biopsy
224169775|NCT03874052|PROCEDURE|Echocardiography Test|Undergo ECHO
224305531|NCT01181271|OTHER|autologous (auto) peripheral blood stem cell transplantation|Infusion of autologous peripheral blood stem cells on Day 0.
223482075|NCT01814085|DRUG|Escitalopram|Escitalopram tablets will be administered orally in the dose range of 10 to 20 milligram per day (mg/day) for 8 weeks. Dose can be adjusted as per Investigator's discretion depending on participant's response.
223482076|NCT02219542|DRUG|transversus abdominis plane block|transversus abdominis plane block with 20 mL saline
223482077|NCT02219542|DRUG|transversus abdominis plane block|transversus abdominis plane block with 20 mL 0.25% ropivacaine
223744948|NCT01215370|OTHER|High-fat shake with Pea protein hydrolysate|Shake containing 95 gram of fat, additive 30 gram gluten protein hydrolysate
223482078|NCT01859819|DRUG|Rituximab|
223482079|NCT01859819|DRUG|IT Cytarabine|
223482080|NCT03399344|OTHER|MRI|In addition to the standard diagnostic work-up patients will receive an additional MRI scan 0-21 days prior to their scheduled surgery.
223482081|NCT01062191|DEVICE|Aquacel AG, typical carboxymethylcellulose dressing|"4 X 4, Aquacel silver sheet"
223482082|NCT01062191|DEVICE|Altrazeal Flexible Hydrogel Nanoparticle Wound Dressing|Wound dressing
223482083|NCT06055582|DIETARY_SUPPLEMENT|Bread|81g (3 slices) harvest gold white bread as standard food.
223482084|NCT06055582|DIETARY_SUPPLEMENT|Mango|250g of mango pulp of each mango variety was given to the subjects.
223482085|NCT03155477|DIETARY_SUPPLEMENT|"Cholecalciferol and C. Xanthorrhiza"|Cholecalciferol are given 400 IU 3 times daily for 3 months C. Xanthorrhiza are given 200 mg 3 times daily for 3 months
223482086|NCT03155477|DIETARY_SUPPLEMENT|"Cholecalciferol and placebo"|Cholecalciferol are given 400 IU 3 times daily for 3 months Placebo are given 3 times daily for 3 months
223482087|NCT04877002|DIAGNOSTIC_TEST|Sona Saliva C-19 Rapid Test|Rapid Antigen diagnostic device performance comparative to RT-PCR
223482088|NCT02736617|DRUG|Ibrutinib|Given PO
223482089|NCT02736617|BIOLOGICAL|Obinutuzumab|Given IV
223482090|NCT04657913|OTHER|cold water spray application|It will be sprayed into the mouth of patients every hour.
223482091|NCT04657913|OTHER|cold saline spray application|It will be sprayed into the mouth of patients every hour.
223482092|NCT01718691|DRUG|SyB L-0501|A dose of 90 mg/m\^2/day of SyB L-0501 is administered on Day 1 and Day 2 as an IV drip infusion, followed by 26-day observation. This is 1 cycle (28 days), which will be repeated for a maximum of 6 times.
223482093|NCT01718691|DRUG|rituximab|A dose of 375 mg/m\^2 of rituximab is administered on Day 1 (Day 0 in Cycle 1 only) as an IV drip infusion, followed by 26-day observation. This is 1 cycle (28 days), which will be repeated for a maximum of 6 times. From Cycle 2, rituximab will be coadministered with SyB L-0501 on Day 1. However, if the investigator or sub-investigator judges that the coadministration is difficult, rituximab may be administered on Day 0.
223482094|NCT02502500|DRUG|Celecoxib|
223482095|NCT02502500|DRUG|AKB-6548|
223482096|NCT04383132|DEVICE|Abdominal Binder|abdominal binder is a kind of elastic abdominal compression device
223482097|NCT03883373|PROCEDURE|alveolar bone graft with cancellous bone and a cortical block|alveolar bone graft with cancellous bone only
223482098|NCT03883373|PROCEDURE|alveolar bone graft with cancellous bone only|alveolar bone graft with cancellous bone only
223482099|NCT02911116|DRUG|Ustekinumab|Subcutaneous Injection
223482100|NCT02911116|DRUG|Ustekinumab|Intravenous Infusion
224169776|NCT03874052|PROCEDURE|Punch Biopsy|Undergo skin punch biopsy
224169777|NCT03874052|OTHER|Questionnaire Administration|Ancillary studies
224169778|NCT03874052|DRUG|Ruxolitinib|Given PO
224169779|NCT03874052|DRUG|Venetoclax|Given PO
224169780|NCT06799286|DRUG|BMS-986489|Specified dose on specified days
224169781|NCT04228276|DEVICE|Repetitive transcranial magnetic stimulation (rTMS)|rTMS is a non-invasive procedure in which administering a transient magnetic field induces electrical currents in specific, targeted brain regions. The intervention (active and sham) will be administered in 8 sessions across 2 weeks. The brain region targeted is the dorsolateral prefrontal cortex.
224169782|NCT06431126|OTHER|Nature and animal-assisted activities|Supervised activities on a farm, 2 half day/week for 12 weeks
224169783|NCT03803553|DRUG|FOLFIRI Protocol|FOLFIRI cycle will be two weeks (14 days) long, with FOLFIRI administered on Days 1-3. Participants will receive up to 12 two-week cycles (for a total of 24 weeks) of FOLFIRI chemotherapy.
224169784|NCT03803553|OTHER|ACTIVE SURVEILLANCE|Will be followed with observation and monitoring with imaging, tumor markers, and ctDNA collections
224169785|NCT03803553|DRUG|Nivolumab Protocol|Nivolumab cycle will be four weeks (28 days) long, with Nivolumab administered on day 1. Participants will receive up to 12 four-week cycles (for a total of 48 weeks) of Nivolumab treatment.
223482101|NCT03974958|GENETIC|Tissue-library|circulating biomarkers (miRNA panel) analysis of blood samples
223482102|NCT03045172|BIOLOGICAL|Platelet Rich Plasma|PRP
223482103|NCT03045172|DRUG|Placebo|Saline
223482104|NCT02469857|DRUG|AB103 0.5 mg/kg|
223482105|NCT02469857|OTHER|NaCl 0.9%|
223482106|NCT02368392|OTHER|Exposure for cardiac arrests|There is no particular intervention. This study merely observes the occurrence of cardiac arrests
223744949|NCT01215370|OTHER|High-fat shake - Control|Shake containing 95 gram of fat, no protein additive
224305532|NCT01181271|DRUG|Neupogen|Neupogen 5 mcg/kg subcutaneous (SQ) daily starting on day +1 until absolute neutrophil count (ANC) is greater than or equal to 1000 per micro liter on two separate occasions or greater than 5000 per micro liter once
224305533|NCT01181271|DRUG|Fludarabine (conditioning for ALLO Transplant)|Fludarabine 30 mg/m2/day will be administered as a bolus infusion over approximately 30 minutes for 4 days on days -5, -4, -3, -2.
224305534|NCT01181271|DRUG|Busulfan (conditioning for ALLO Transplant)|Busulfan will be administered by IV infusion over approximately 3 hours on days -5, -4, -3, -2. The dose of busulfan will be 0.8 mg/kg/day
224169786|NCT03803553|DRUG|Encorafenib/Binimetinib/Cetuximab Protocol|Encorafenib/Binimetinib will be taken orally every day and Cetuximab will be administered intravenously on day 1 of each cycle. Cycles are 14 days long. Participants will receive up to 12 two-week cycles (for a total of 24 weeks) of Encorafenib/Binimetinib/Cetuximab.
224169787|NCT03803553|DRUG|Trastuzumab + Pertuzumab|Trastuzumab (Herceptin) is received by intravenous administration and Pertuzumab is received intravenously by infusion on Day 1 of each cycle. Cycles are 21 days long. Participants will receive up to 8 cycles of Trastuzumab and Pertuzumab.
223482107|NCT06340659|BEHAVIORAL|HbAEx|Participants will have a 1-week (3 session) on-boarding period where study interventionists will deliver all necessary equipment (bike, pulse oximeters, etc.) to the participants' home, review the AEx program and prescription, and supervise the first 3 sessions to ensure participant understanding and fidelity of the AEx program. Thereafter, the remaining 33 sessions will be conducted by the participant without the direct supervision (asynchronous telerehabilitation) of the study interventionists. Subjects will cycle on recumbent stationary cycles at moderate-vigorous intensity individualized as 50-70% of heart rate reserve (HRR) and/or 11-14 on Borg Category Ratio-15 Rating of Perceived Exertion (RPE) Scale, for 30-50 minutes per session. Following the completion of each session, during the check-in meeting with the participant, the study interventionist will gather information from the participant (including HR and RPE) for dose quantification.
223482108|NCT06340659|BEHAVIORAL|HbExergame|Participants will cycle as described in the HbAEx protocol while engaging in cognitive training for the duration of cycling. Cognitive training will include 20 levels of difficulty with 8-10 task scenarios in the context of three virtual worlds (environments. In each of the environments, the participant must follow directions and navigate to a destination where the scenario (cognitive task) will be performed. The game will inform the participant of the assigned task and, automatically, determine and inform the participant of the fastest route from the starting point to the scenario destination where the task will be performed. The participant will be required to remember the assigned task, follow the directions and navigate to the destination, and then remember what action is required to complete the task. A scenario-specific cognitive task will be triggered once the destination has been reached. The cycling and cognitive tasks will be completed throughout the sessions.
223482109|NCT02110693|OTHER|Interviewer and tablet administration of the TAPS Tool|All participant will self-administer substance use screening instrument (TAPS Tool) on a tablet computer and will be administered the TAPS Tool by an interviewer.
223482110|NCT02590783|PROCEDURE|experimental intervention surgery|Patients are placed supine on the carbon table. Screw paths are planned on a spiral CT scan from the sacrum on transversal slices, two Kirschner-wires 2.5 mm in diameter are introduced into the iliac bone through a stab incision and advanced into the ilio-sacral joint, through the lateral part of sacrum into the first and second sacral body, through the contralateral lateral part of the sacrum and exiting the contralateral iliac bone through the sacra-iliac joint with aid of CT-guidance. Over the Kirschner-wires 7.0 mm cannulated screws are introduced and the Kirschner-wires withdrawn. Several low-dose computer tomography scans are performed to secure the correct position. Total radiation dose is 300 mille gray square centimetres (mGycm).
223482111|NCT02590783|PROCEDURE|control intervention|Mobilization guided by our physiotherapists. Full weight bearing is allowed. Analgetic treatment with metamizol, ibuprofen or paracetamol to the attending physicians discretion under regular surveillance laboratory values and/ or morphine or methadone. Patients will be treated with an individually based approach, if necessary involving our anesthesiologic pain service. Thrombo-embolic prophylaxis with a low molecular weight heparin or rivaroxaban for 6 weeks unless there is an indication for oral anticoagulation. All patients will be followed up by the Geriatric Fracture Center considering osteoporosis, fall prophylaxis, malnutrition and delirium. For the duration of the study the patients will not receive Parathyroid Hormone Substitution or Phosphonates.
223482112|NCT05190133|DRUG|UIC201602 and co-administration of UIC201601 and UIC201602|"* UIC201602 4 Cap/day for 14 days~* Wash out 21 days~* UIC201601 4 Tab + UIC201602 4 Cap / day for 14 days"
223482113|NCT05190133|DRUG|UIC201601 and co-administration of UIC201601 and UIC201602|"* UIC201601 4 Tab/day for 7 days~* Wash out 14 days~* UIC201601 4 Tab + UIC201602 4 Cap / day for 14 days"
223482114|NCT01489423|GENETIC|RNA analysis|
223482115|NCT01489423|GENETIC|in situ hybridization|
223482116|NCT01489423|GENETIC|polymerase chain reaction|
223482117|NCT01489423|OTHER|enzyme-linked immunosorbent assay|
223482118|NCT01489423|OTHER|flow cytometry|
223482119|NCT01489423|OTHER|immunohistochemistry staining method|
223482120|NCT01489423|OTHER|laboratory biomarker analysis|
223482121|NCT00004059|DRUG|7-hydroxystaurosporine|
223482122|NCT00004059|DRUG|fluorouracil|
223482123|NCT06326047|DRUG|NNC0519-0130|NNC0519-0130 will be administered subcutaneously.
223482124|NCT06326047|DRUG|Placebo|Placebo will be administered subcutaneously.
223482125|NCT06326047|DRUG|Trizepatide|Trizepatide will be administered subcutaneously.
223482126|NCT00956189|DRUG|amisulpride|Amisulpride dosage was increased from 200 up to a maximum of 1000 mg/day and the dosage of their previous antipsychotics can be tapered gradually under stable clinical condition.
223482127|NCT00956189|DRUG|aripiprazole|Aripiprazole dosage was increased from 5-7.5 up to a maximum of 30 mg/day and the dosage of their previous antipsychotics can be tapered gradually under stable clinical condition.
223482128|NCT03183206|PROCEDURE|Cryosurgery , IRE surgery ,surgery|surgery will be used in local tumor
223482129|NCT03183206|BIOLOGICAL|γδ T cells|γδ T cells will be used against
223482130|NCT03183206|OTHER|γδ T cells/ Surgery|Combination γδ T cell and Cryosurgery, IRE surgery or surgery will be used in Breast Cancer
223482131|NCT01285544|DRUG|Atorvastatin (Lipinon)|treatment of dyslipidemia administration : PO, qod
223482132|NCT01285544|DRUG|Atorvastatin (Lipitor)|treatment of dyslipidemia administration : PO, qod
223482133|NCT00002302|DRUG|Epoetin alfa|
223482134|NCT00777842|DEVICE|GTX™ Drug Eluting Coronary Stent System|Drug eluting stent
223482135|NCT03036943|RADIATION|Fluciclovine|Fluciclovine (18F) PET/CT scan completed \>= 48 hours prior to surgical resection for breast cancer
223482136|NCT04807413|DRUG|Nitric Oxide|The balloon will be opened to deliver nitric oxide at 40 ppm through the cardiopulmonary bypass machine
224169788|NCT04526938|DEVICE|Physician-Modified Cook Zenith Alpha Thoracic Endovascular Graft|Cook Zenith® Alpha Thoracic Endovascular Graft will be modified to allow for the maintenance of blood flow into the visceral and renal branch vessels.
224169789|NCT03527472|DRUG|Memantine|Memantine is an FDA-approved drug for the treatment of Alzheimer's disease.
224169790|NCT03527472|DRUG|Placebo|The placebo will match the study drug in appearance, dose, and frequency. It will not contain any active drug (memantine).
224169791|NCT04601233|DRUG|XYOSTED 75 milligram (mg) in 0.5 ML Auto-Injector|Self injection testosterone treatment
224169792|NCT06803771|DEVICE|Avantect Pancreatic Cancer Test|Avantect test
224169793|NCT03825536|DRUG|Oral Methamphetamine|An initial 10 mg of oral methamphetamine (over-encapsulated to look similar to placebo capsule) study drug will be administered to assess tolerability, followed by a subsequent 15 mg oral dose (over-encapsulated to look similar to placebo capsule) two hours later.
224169794|NCT03825536|OTHER|Placebo oral capsule|One placebo capsule will be administered orally on treatment day, followed by a second oral placebo capsule two hours later.
224169795|NCT02498600|BIOLOGICAL|Ipilimumab|Given IV
224169796|NCT02498600|BIOLOGICAL|Nivolumab|Given IV
224169797|NCT05602363|DRUG|Docirbrutinib|oral tablet, twice daily
224169798|NCT05298774|DEVICE|G-tech WPS|G-tech WPS patches applied and activated within 4 hours of surgery
224169799|NCT01492036|OTHER|Blood Tests|If participant received retroviral gene therapy, blood test performed to check for a type of infection called the replication-competent retrovirus (RCR). Blood (up to 4 tablespoons each time) drawn every 3 months for first year after gene transfer therapy and once a year after that.
224169800|NCT01492036|BEHAVIORAL|Questionnaires|"Once a year during Years 1-5, questionnaire completions that asks about medical history (general health, the status of any medical conditions, and any illnesses or hospitalizations that may have occurred). It should take about 15-30 minutes to complete.~Once a year during Years 6-15, completion of mailed questionnaire. Participant will be asked about medical history (including if participant has had any children since the infusion) and whether there have been any changes in contact information. The questionnaires should take about 15-30 minutes each time."
224169801|NCT04269239|BEHAVIORAL|Healthy Habits|Participants in this group will be coached during four hour-long sessions on topics such as physical activity, nutrition, pain coping skills, bladder health, diabetes, heart health, eyes/vision, hearing, and doctor-patient communication.
224169802|NCT04269239|BEHAVIORAL|Sleep Habits|Participants in this group will be coached during four hour-long sessions on topics such as sleep education, sleep restriction, stimulus control, cognitive restructuring, sleep hygiene education, and relapse prevention.
224169803|NCT05422573|BEHAVIORAL|post-test cardiovascular genetic counseling with pre-test education by video|post-test cardiovascular genetic counseling with pre-test education by video
224169804|NCT05422573|BEHAVIORAL|required phone call with genetic counselor pre-test|REQUIRED phone call with genetic counselor pre-test.
224169805|NCT05422573|BEHAVIORAL|optional phone call with genetic counselor pre-test|OPTIONAL phone call with genetic counselor pre-test
224169806|NCT04154332|OTHER|Sample collection|Blood, urine, placental samples, and the patient's vascular reactivity will be collected from each person enrolled in this study.
224169807|NCT06563596|DRUG|Zanubrutinib|Bruton tyrosine kinase inhibitor, 80 mg immediate-release capsule, taken orally per protocol.
224169808|NCT06563596|DRUG|Rituximab|Chimeric anti-CD20 monoclonal antibody, 10 or 50 mL single-use vials, via intravenous infusion per institutional standard.
224169809|NCT06563596|DRUG|Epcoritamab|Bispecific antibody, 5 or 60 mg/mL vials, via subcutaneous (under the skin) injection per protocol.
224169810|NCT06285071|DRUG|Concizumab|Participants will be treated with commercially available Alhemo (Concizumab) according to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available Concizumab has been made by the participant/ legally acceptable representative (LAR) and the treating physician before and independently from the decision to include the participant in this study.
224169811|NCT04934683|PROCEDURE|Routine Blood Pressure Management|Routine blood pressure control.
224169812|NCT04934683|PROCEDURE|Tight Blood Pressure Management|Tight blood pressure control.
224169813|NCT04934683|DRUG|Etomidate Induction|Anesthetic induction with etomidate.
224169814|NCT04934683|DRUG|Propofol Induction|Anesthetic induction with propofol.
223482137|NCT04807413|OTHER|standard of care treatment|standard of care treatment
224169815|NCT05165160|DIAGNOSTIC_TEST|Blood sample|Pre- and postoperative blood sample
224169816|NCT05999435|DRUG|LAU-7b for 3 cycles|Three cycles of 14 days of once-a-day intake of LAU-7b, each followed by a treatment intake pause of14 days.
224169817|NCT05999435|DRUG|LAU-7b for 1 cycle, then placebo|One cycle of 14 days of once-a-day intake of LAU-7b followed by two cycles of 14 days of placebo administered similarly, each followed by a treatment intake pause of14 days.
224169818|NCT05999435|OTHER|Placebo for 3 cycles|Three cycles of 14 days of once-a-day intake of placebo, each followed by a treatment intake pause of14 days
224169819|NCT05085275|DRUG|Ferric Citrate 1 GM Oral Tablet [AURYXIA]|All subjects will be instructed to take study drug (ferric citrate or placebo) at a fixed dose of 2 tablets per meal or snacks, up to three times per day. The maximum dose is 6 tablets per day. No additional tablets (beyond a total of 6 per day) should be taken. Tablets should not be crushed or chewed.
224169820|NCT05085275|DRUG|Placebo|All subjects will be instructed to take study drug (ferric citrate or placebo) at a fixed dose of 2 tablets per meal or snacks, up to three times per day. The maximum dose is 6 tablets per day. No additional tablets (beyond a total of 6 per day) should be taken. Tablets should not be crushed or chewed.
224169821|NCT04039243|BEHAVIORAL|Being Brave|Up to 12 weekly sessions
224169822|NCT04039243|OTHER|Parent Education|Parents receive educational materials about helping children overcome shyness and fear
224169823|NCT02912572|DRUG|Avelumab|Avelumab will be administered intravenously twice per cycle Each Cycle lasts 28 days Premedication Antihistamine and Paracetamol will be administered prior to treatment
223482138|NCT04820504|DEVICE|Augmented Infant Resuscitator (AIR)|Device provides visual feedback related to air leak, obstruction, hyperventilation, hypoventilation, and harsh breaths
223482139|NCT04820504|DEVICE|AIR device without feedback|Device provides no visual feedback to clinician but records data on ventilation effectiveness
223482140|NCT02768155|OTHER|Amniotic Fluid 4.0ml dose|Injection of Amniotic Fluid
223585297|NCT05027620|OTHER|Motor-cognitive exercise therapy in the home|"Participants engage in a progressive 10-week exercise program targeted at improving motor and cognitive function. Motor exercises target functional strength, gait and physical activity level. Training sessions occur 3 times weekly and supported by a digital application which has been adapted for people with Parkinson's disease. Weeks 1-2 focus solely on motor exercises. Dual-task (Motor-cognitive) exercises are introduced at week 3 and progressed until week 10. Participants are also encouraged to increase the physical activity levels during the 10 week period.~Weekly contact is made using the video function/ telephone with clinical specialists/ researchers. Two home visits will occur, the first one week prior to the intervention and at the 5-week period. Participants receive motivational messaging and reminders via the app during the intervention period."
223585298|NCT03156959|BEHAVIORAL|EMDR|The Eye Movement Desensitization and Reprocessing (EMDR) is a psychotherapy developed by Francine Shapiro (2001) that emphasizes disturbing memories as the cause of psychopathology. These memories and associated stimuli are inadequately processed and stored in an isolated memory network (Shapiro and Laliotis, 2010). The goal of EMDR is to reduce the long-lasting effects of distressing memories by developing more adaptive coping mechanisms.
223585299|NCT03156959|BEHAVIORAL|CBT-Eb|"The broad form of Enhanced Cognitive Behavioural Therapy (CBT-Eb; Fairburn and colleagues, 2009) addresses psychopathological processes external to the eating disorder, such as clinical perfectionism, low self-esteem or interpersonal difficulties, which interact with the disorder itself."
223585300|NCT03139799|BEHAVIORAL|Experimental - Puzzle Video Game Intervention|The psychological intervention consists of two custom-made versions of popular commercial casual puzzle video games (Flow Free, Big Duck Games LCC; Bejeweled, PopCap Games). The puzzle games are delivered on tablet-computers computer (12.9-inch tablet computer iPad Pro, Apple Inc., Cupertino, CA, USA).
223744950|NCT01215370|OTHER|High-fat shake with Gluten protein|Shake containing 95 gram of fat, additive 30 gram gluten protein.
223744951|NCT01215370|OTHER|High-fat shake with Gluten protein hydrolysate|Shake containing 95 gram of fat, additive 30 gram gluten gluten hydrolysate
223744952|NCT05750355|DRUG|TPN171H 10 mg Group|6 subjects will receive TPN171H 10 mg, orally; 2 subjects will receive placebo, orally.
223744953|NCT05750355|DRUG|TPN171H 30 mg Group|6 subjects will receive TPN171H 30 mg, orally; 2 subjects will receive placebo, orally.
223744954|NCT05750355|DRUG|TPN171H 40 mg Group|6 subjects will receive TPN171H 40 mg, orally; 2 subjects will receive placebo, orally.
223744955|NCT05750355|DRUG|TPN171H 50 mg Group|6 subjects will receive TPN171H 50 mg, orally; 2 subjects will receive placebo, orally.
223744956|NCT01207518|BEHAVIORAL|Intervention Group|This group of healthcare organizations will be given the Guide, web-based tools and access to a Guide facilitator throughout the study.
224169824|NCT02912572|DRUG|Talazoparib|Talazoparib will be taken one time per day by mouth Each Cycle lasts 28 days
224169825|NCT02912572|DRUG|Axitinib|Axitinib will be taken twice per day by mouth Each Cycle lasts 28 days
224169826|NCT05381818|BEHAVIORAL|Daily Inspiratory Muscle Training (dIMT)|Daily IMT training sessions for 2-4 weeks prior to surgery
224169827|NCT05381818|BEHAVIORAL|Acute Inspiratory Muscle Training (aIMT)|A single session of IMT provided within 30 minutes prior to anesthesia induction.
224169828|NCT05381818|OTHER|Standard of Care (SOC)|Standard of care only pre and post-operatively.
224169829|NCT06216964|DIAGNOSTIC_TEST|Chlamydia trachomatis (CT) and/or Neisseria gonorrhoeae (NG) NAAT(s)|Test every week after the start of treatment, until NAAT negativation and up to a maximum of 4 weeks
224169830|NCT01368055|RADIATION|70 Gy/CGE|Low Risk
224169831|NCT01368055|RADIATION|72.5 Gy/CGE|Intermediate Risk
224169832|NCT06549400|DRUG|Mexiletine granules for prolonged-release oral suspension|Mexiletine PR
224169833|NCT02560090|BEHAVIORAL|Surveys|The following information will be collected: demographics, literacy screener, depression screener, medication adherence, self-efficacy, tobacco use, patient activation, health questionnaire, eating patterns, diabetes self-management assessment, stages of change questionnaire, vitals, and self-care behaviors.
223744957|NCT01207518|BEHAVIORAL|Control Group|This group will provide their immunization rates for the base and study years and will provide information on their campaign activities. No other intervention will be provided.
223744958|NCT04177602|COMBINATION_PRODUCT|Trifluridine/tipiracil chemoradiation|Trifluridine/tipiracil based chemoradiation
223744959|NCT04177602|COMBINATION_PRODUCT|Capecitabine based chemoradiation|Capecitabine based chemoradiation
223744960|NCT03098173|PROCEDURE|Early colonoscopy|Performance of prepared colonoscopy within 24 h of arrival
224169834|NCT02560090|BEHAVIORAL|Telephonic Nurse Intervention|A nurse will contact patients by phone at least weekly for month 1 and at least every other week for months 2 and 3 and will collect the following information: medication adherence, discharge plan adherence, problem solving, diet and physical activity issues and to assess self-management, dietary, and physical activity improvements. In addition the nurse will link participants with resources.
223744961|NCT03098173|PROCEDURE|Elective colonoscopy|Performance of prepared colonoscopy between 24 and 96 h after arrival
223744962|NCT04300595|PROCEDURE|Combination of General anesthesia and local anesthesia in dacryocystorhinostomy surgery|"all patients were assigned randomly to receive either general anesthesia with intravenous opioids and local infiltration of saline (Group G) or general anesthesia with intravenous saline and local infiltration of a mixture of lidocaine/epinephrine (Group L).~In both groups, general anesthesia was induced with 2 mg/kg propofol and tracheal intubation was facilitated by 0.1 mg/kg cisatracurium. All patients underwent mechanical ventilation with 100% oxygen. Anesthesia was maintained with isoflurane, and muscle relaxation was provided by an injection of cisatracurium 0.02 mg/kg every 20 minutes."
224169835|NCT02560090|BEHAVIORAL|In-person Community Health Worker|An in-person Community Health Worker will contact patients in-person at least weekly for month 1 and at least every other week for months 2 and 3 and will collect the following information: medication adherence, discharge plan adherence, problem solving, diet and physical activity issues and to assess self-management, dietary, and physical activity improvements. In addition the nurse will link participants with resources.
224169836|NCT04931251|BEHAVIORAL|Financial Navigation|providing financial navigation for cancer patients in NC to identify available financial assistance resources to assist patients with the cost of cancer
224169837|NCT01381731|DRUG|diquafosol tetrasodium ophthalmic solution 2%|opthalmic solution 2 drops in each eye QID
224169838|NCT01381731|DRUG|placebo|opthalmic solution 2 drops in each eye QID
224169839|NCT06578819|BEHAVIORAL|doll therapy|Doll therapy applied to the experimental group 4 days a week.
224169840|NCT00777036|DRUG|Dasatinib|
223585301|NCT03139799|BEHAVIORAL|Control - Tablet Newspaper Reading Intervention|The control intervention uses a newspaper/ magazine reading task that will be delivered to participants using the same device (iPad Pro) as in the experimental intervention. The newspaper/ magazine reading task will be running on the built-in Apple Newsstand application. Participants will be offered subscriptions for two newspapers and/or magazines that they are instructed to read following the same regime as in the experimental condition.
223585302|NCT05625373|DRUG|Vancomycin|The powder will be placed within the surgical wound prior to skin closure.
224169841|NCT03745924|DRUG|Nonacog beta pegol|Participants are treated with commercially available nonacog beta pegol (N9-GP) according to local clinical practice at the discretion of the treating physician
223585303|NCT05661045|PROCEDURE|low-flow anesthesia|Changes in blood carboxyhemoglobin levels as a result of exposure to rebreathing during low-flow anaesthesia.
223585304|NCT04499911|DRUG|Isotonic dextrose 5% in water solution|The isotonic dextrose 5% in water solution (a total volume of about 5 ml). Subcutaneous perineural injection of dextrose (5%) in sterile water was given once. The injection was administered by using the Lyftgot technique of neural prolotherapy on the lateral aspect of the thigh along the tender areas.
223585305|NCT04464525|DRUG|Omecamtiv mecarbil|Film-coated tablet administered orally.
223585306|NCT06233994|BIOLOGICAL|ZG005 Powder for Injection|ZG005 will be administered at a dose of 10 mg/kg by intravenous (IV) infusion, once every 3 weeks (Q3W).
224169842|NCT05868668|DEVICE|Focused shockwave|Storz Duolith SD-1 (Storz Medical, Tagerwilen, Switzerland)
224169843|NCT05868668|DEVICE|Radial wave|Zimmer enPuls Pro (Zimmer MedizinSysteme GmbH, Neu-Ulm, Germany)
224169844|NCT05868668|DEVICE|Sham treatment|Handheld sham probe
224169845|NCT05935176|BIOLOGICAL|MCV4|2 dose of MCV4 on Day 0 and Month 1
224169846|NCT05935176|BIOLOGICAL|MCV4|2 dose of MCV4 on Day 0 and Month 3
223482141|NCT02768155|OTHER|Amniotic Fluid 2.0ml dose|Injection of Amniotic Fluid
223482142|NCT02768155|OTHER|Placebo Control|Normal Saline
223585307|NCT06233994|DRUG|Donafenib Tosilate Tablets|Donafenib will be administered at a dose of 0.2 g by orally, Bis in die(Bid).
223585308|NCT06233994|BIOLOGICAL|Bevacizumab|Bevacizumab will be administered at a dose of 15 mg/kg by IV infusion, once every 3 weeks (Q3W).
224169847|NCT04278235|DRUG|Elezanumab|Solution for intravenous (IV) infusion
224169848|NCT05814042|DRUG|Next Generation ORS (oral rehydration solution) (including placebo|Nutrition used to stop diarrhea
224169849|NCT05814042|DRUG|Current standard control ORS (oral rehydration solution)|current standard control ORS in diarrheic patients with cholera
224169850|NCT05827978|BIOLOGICAL|mRNA-1010|Sterile liquid for injection
224169851|NCT05827978|BIOLOGICAL|Licensed Quadrivalent Inactivated Seasonal Influenza Vaccine|Sterile suspension for injection
224169852|NCT06524908|BEHAVIORAL|Exercise and dietary calorie restriction|The intervention group received an exercise intervention three times a week (resistance exercise from 4:30-5:00 p.m. and aerobic exercise from 5:00-5:30 p.m.), and a caloric restriction intervention (guided semi-libre diet with caloric intake restricted to 75% of overall consumption, with parents keeping track of calories and food groups and receiving regular check-ups)
224169853|NCT06065449|DRUG|Radiation Therapy|"Arm 1: standard 8 Gy delivered in a single fraction or 20 Gy delivered in 5 fractions~Arm 2: 16 Gy delivered in a single fraction or 27 Gy delivered in 3 fractions prescribed to planning target volume (PTV)."
224169854|NCT04583878|DIAGNOSTIC_TEST|Blood draw (Visit 1)|Labs will be drawn at Visit 1, also referred to as screening (within 60 days of diagnosis) with the standard of care labs drawn.
224169855|NCT04583878|DIAGNOSTIC_TEST|Blood draw (Visits 2 and 3)|Labs will be drawn at Visit 2 (12 weeks post-diagnosis with a range of 10-16 weeks) and Visit 3 (12 months ± 30 days) for research purposes only and will be collected at Children's Medical Center and processed at UT Southwestern Medical Center.
224169856|NCT05633459|DRUG|Multiple ascending doses of QRL-201|Multiple ascending doses of QRL-201 will be intrathecally administered to individuals with sporadic ALS.
224169857|NCT05633459|DRUG|Multiple ascending doses of Placebo|Multiple ascending doses of placebo comparator will be intrathecally administered to individuals with sporadic ALS.
224169858|NCT05633459|DRUG|QRL-201|QRL-201 will be intrathecally administered to individuals with C9orf72 ALS.
224169859|NCT05633459|DRUG|Placebo|Placebo comparator will be intrathecally administered to individuals with C9orf72 ALS.
223482143|NCT03873532|DRUG|Surufatinib|Patients receive oral Surufatinib at a dose of 300mg/d within 1 hour after breakfast (once-daily dosing continuously, every 21-day treatment cycle).
223482144|NCT03873532|DRUG|Capecitabine|Capecitabine is given at 1250 mg/m2 by oral administration twice a day (BID, one dose each in the morning and evening, with a total dose of 2500 mg/m2 per day) for 2 weeks followed by 1 week of drug interruption. Each course of treatment will last 3 weeks. Capecitabine tablets should be swallowed with water within 30 minutes after a meal.
223585309|NCT00351273|DRUG|Doxycycline and Rifampin|doxycycline 100mg daily; rifampin 300mg daily (both for 6 months)
223585310|NCT00351273|DRUG|Azithromycin and Rifampin|Azithromycin 500mg daily for 5 days and then twice weekly; Rifampin 300mg daily (both for 6 months)
223585311|NCT00351273|DRUG|Placebo|Methylcellulose
223585312|NCT06172920|DRUG|Tramadol hydrochloride|Patients are receiving tramadol hydrochloride under thoracic surgery
223585313|NCT06172920|DRUG|Aldolan|Patients are receiving meperidine under thoracic surgery
223585314|NCT06172920|DRUG|Morphine hydrochloride|Patients are receiving Morphine hydrochloride under thoracic surgery
223744963|NCT04597307|COMBINATION_PRODUCT|IN.PACT™ Admiral™ Drug Coated Balloon (DCB)|For percutaneous transluminal angioplasty (PTA) in subjects with obstructive disease of the peripheral arteries.
223482145|NCT01799694|DRUG|Inject of Autologous Adipose-derived stem cells|Inject in muscle of autologous adipose derived stem cells
223482146|NCT00257530|DRUG|Imiquimod|
223482147|NCT00102973|DRUG|TLK286 in Combination with Carboplatin|Experimental Arm
223482148|NCT00102973|DRUG|Doxorubicin HCl Liposome Injection|Active Comparator
223482149|NCT01242007|OTHER|Supine spirometry|In addition to the current upright lung function evaluation we performed a supine spirometry
224169860|NCT04651777|DRUG|FF/UMEC/VI|The investigational drug is a single Ellipta inhaler containing 200 ug fluticasone furoate, 62.5 ug umedlidinium and 25 ug vilanterol. The drug is delivered in an Ellipta inhaler in a single dose once daily.
224169861|NCT04566445|DRUG|GT005|GT005 is a recombinant, non-replicating AAV2 expressing human complement factor I (CFI). GT005 was administered as a single time subretinal injection into the study eye of subjects allocated to one of the two GT005 doses.
224169862|NCT05841355|OTHER|Educate|Education sessions
224169863|NCT05841355|OTHER|Empower|Empowerment sessions
224169864|NCT05664113|DRUG|Fecal microbiota transplant (FMT)|FMT Lower Delivery Microbiota Preparation, Dose: 250 mL of Microbiota Preparation Material and Route of administration: colonoscopy FMT Upper Delivery Microbiota Preparation, Dose: 60 mL of Microbiota Preparation Material and Route of administration: Naso-enteral tube
224169865|NCT04785144|BIOLOGICAL|mRNA-1273|Lipid nanoparticle (LNP) dispersion containing an mRNA that encodes for the pre fusion stabilized spike protein of the Wuhan-Hu-1 strain of SARS-CoV-2. mRNA-1273 consists of an mRNA Drug Substance that is manufactured into LNPs composed of the proprietary ionizable lipid, SM-102, and 3 commercially available lipids, cholesterol, 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), and PEG2000 DMG.
224169866|NCT04785144|BIOLOGICAL|mRNA-1273.351|Lipid nanoparticle (LNP) dispersion containing an mRNA that encodes for the pre fusion stabilized spike protein of the B.1.351 variant SARS-CoV-2 strain. mRNA-1273.351 consists of an mRNA Drug Substance that is manufactured into LNPs composed of the proprietary ionizable lipid, SM-102, and 3 commercially available lipids, cholesterol, 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), and PEG2000 DMG.
223482150|NCT04810962|DRUG|APP13007, 0.05%|APP13007 eye drop, 0.05%
223585315|NCT03094559|DEVICE|FlowMet|The FlowMet device will be placed on the index finger of the right hand. Signal fidelity will be assured by confirming the presence of a pulse waveform if one is expected and by assuring that an appropriate amount of light is be detected by the FlowMet device. Following placement of the FlowMet device, a period of 10 seconds will be allowed to elapse to allow transient changes in perfusion due to device placement to diminish. FlowMet blood flow data will be recorded for 20 seconds using the FlowMet data acquisition software. These steps will be repeated for digits 1 and 2 on the limb with diagnosed or suspected CLI, or on both limbs if both are diagnosed or suspected of having CLI.
223585316|NCT03217799|DEVICE|Measurement of coagulability of blood|A small pneumatic cuff is attached to the root of the index finger. The sensor cuff is attached several centimeters distal to the pneumatic cuff. Measurement is taken for a 60-second control period, and then the pneumatic cuff is inflated to above-systolic blood pressure (200 mm Hg) for 180 seconds, and measurement is taken during this period of time. The cuff is then deflated, and another 60-second measurement is taken. Data is collected by the measuring device for later analysis.
223585317|NCT03204669|OTHER|Trace elements replacement|
223585318|NCT03740568|DRUG|Low Progesterone|"Additional daily dosage of subcutaneous progesterone (Psc) 25 mg/day at night since D4 (vaginal micronized P 200mg/200mg/200mg + Psc 25 mg/night) New Progesterone analysis on D5 before warming the embryo. Group 2a (Canceled Group, P on D5 \<10.64 ng/mL): cancel PGT-FET. Scheduling a new procedure under different P supplementation.~Group 2b (Restored Progesterone Group, P on D5 \>10.64 ng/mL): continue HRT as previously described (vaginal micronized P 200mg/200mg/200mg + Psc 25 mg/night). Warming and transfer the same day (D5)~Beta-hCG and P analysis is performed on the 14th day of P supplementation (D14). In case of positive Beta-hCG analysis:~If P is \>10.64 ng /mL: the same P supplementation is continued. If P is \<10.64 ng /mL: an additional dosage of vaginal micronized P (200 mg) is added at night"
223585319|NCT03740568|DRUG|Normal Progesterone|"Same Progesterone supplementation (vaginal micronized P 200mg/200mg/200mg) Warming and transfer on D5~Beta-hCG and P analysis is performed on the 14th day of P supplementation (D14). In case of positive Beta-hCG analysis:~If P is \>10.64 ng /mL: the same P supplementation is continued. If P is \<10.64 ng /mL: an additional dosage of vaginal micronized P (200 mg) is added at night"
223585320|NCT01387724|GENETIC|RNA analysis|
223585321|NCT01387724|GENETIC|polymerase chain reaction|
223585322|NCT01387724|GENETIC|protein expression analysis|
223585323|NCT01387724|GENETIC|proteomic profiling|
223585324|NCT01387724|GENETIC|western blotting|
223744964|NCT03645551|DIAGNOSTIC_TEST|checkup, no test|In this study we would like to examine if existing restorations already applied in teeth which we treated with laminate veneers had an effect. We will evaluate the laminate veneers by sight and take pictures and use a questionnaire
224169867|NCT00949104|DRUG|Sucrose|1 ml of 24% sucrose was administered 2 minutes prior to the procedure
224169868|NCT00949104|DRUG|Double distilled water|1 ml of double distilled water (Placebo) was administered 2 minutes prior to the procedure
224169869|NCT06128733|BIOLOGICAL|Pentavalent Meningococcal ABCYW vaccine|Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular (IM)
224169870|NCT06128733|BIOLOGICAL|MenACYW conjugate vaccine|Pharmaceutical form:Solution for injection in vial-Route of administration:Intramuscular (IM)
224169871|NCT06128733|BIOLOGICAL|Meningococcal group B vaccine|Pharmaceutical form:Suspension for injection in pre-filled syringe-Route of administration:Intramuscular (IM)
223482151|NCT04810962|DRUG|Matching Vehicle Placebo for APP13007, 0.05%|Matching vehicle placebo eye drop
223482152|NCT00070525|DRUG|tipifarnib|Given orally
223482153|NCT03111433|DIETARY_SUPPLEMENT|Coenzyme Q10|Coenzyme Q10 soft gelatin capsule 100mg
223482154|NCT03111433|DRUG|Insulin|multiple dose insulin injection therapy
223585325|NCT01387724|OTHER|enzyme-linked immunosorbent assay|
223585326|NCT01387724|OTHER|immunohistochemistry staining method|
223585327|NCT01387724|OTHER|laboratory biomarker analysis|
223585328|NCT01387724|OTHER|liquid chromatography|
223585329|NCT01387724|OTHER|mass spectrometry|
223585330|NCT01531972|DRUG|SEP-228432|40 mg, orally, once daily for 3 days followed by 200 mg orally, once daily for 5 days
223585331|NCT01531972|DRUG|SEP-228432|40 mg orally once daily for 3 days followed by ≤ 300mg, orally once daily for 5 days
223585332|NCT06129110|BEHAVIORAL|Diet Weight Loss|Low calorie diet of meal replacement shakes
223585333|NCT01713556|DRUG|Propranolol|
223585334|NCT01713556|OTHER|Trauma reactivation|Trauma reactivation: script-driven mental imagery of the traumatic event
223585335|NCT01713556|DRUG|placebo|
224169872|NCT06128733|BIOLOGICAL|Meningococcal group B vaccine|Pharmaceutical form:Suspension for injection in pre-filled syringe-Route of administration:Intramuscular (IM)
224169873|NCT06128733|BIOLOGICAL|Meningococcal group B vaccine|Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular (IM)
224169874|NCT06128733|BIOLOGICAL|MenACYW conjugate vaccine|Pharmaceutical form:Powder and solvent for solution for injection-Route of administration:Intramuscular (IM)
224169875|NCT06128733|BIOLOGICAL|Placebo|Pharmaceutical form:Solution for injection in vial-Route of administration:Intramuscular (IM)
224169876|NCT06128733|BIOLOGICAL|MenABCYW conjugate vaccine|Pharmaceutical form: Suspension for injection Route of administration: Intramuscular (IM)
224169877|NCT02691923|DRUG|Fluorescein|
224169878|NCT02691923|DRUG|Fluorescein + ALA|
224169879|NCT03947099|DRUG|Ketamine Hydrochloride|Participants are treated with six one-hour infusions of ketamine hydrochloride over a three week period in hopes of treating symptoms of PTSD.
223482155|NCT03491488|OTHER|Brain Games|The Brain Games intervention package is used as a tool to improve children's self-regulation and executive function skills. Brain Games were developed as part of larger behavioral intervention package in the US, and are designed to build the fundamental self-regulation skills that children need to be successful in school as well as later in life. The games are designed to be played in the classroom between regular activities.
223482156|NCT00937807|DRUG|xenon|Inhalational gas; dose allowed: 60 % Xenon; the duration of the treatment will be defined through anesthesia-time for a carotid surgery
223482157|NCT00937807|DRUG|sévoflurane|Inhalation gas; dose allowed: 1,4 %; the duration of the treatment will be defined through anesthesia-time for a carotid surgery
223482158|NCT02955693|DRUG|LAS41008 120 mg / Fumaderm® 120 mg|Single dose of LAS41008 120 mg or Fumaderm® 120 mg in each Period
223482159|NCT05136638|BEHAVIORAL|dCBTi|The dCBTi adopts a multi-module approach, consisted of 6 weekly modules including psychoeducational on sleep, insomnia, sleep hygiene, sleep restriction and prescription, stimulus control, relaxation and worry time, cognitive restructuring, and relapse prevention. In each module, participants will watch short videos to learn strategies to improve their sleep.
223482160|NCT05136638|BEHAVIORAL|Virtual coaching|A virtual coach will be added to the app functionality. It will be in the form of a text-based forced-choice conversation bot. It will initiate conversations with the users to check their understanding of treatment materials and guide them to come up with specific action plans to implement the treatment strategies.
223482161|NCT05136638|BEHAVIORAL|Non-therapist coaching|A research intern will answer questions and address concerns raised by the participant at the end of modules 1, 3, and 6 by phone. The contact time will be within 30 minutes on each occasion.
223482162|NCT05136638|BEHAVIORAL|Therapist coaching|A clinical psychology trainee will provide therapeutic support to enhance the use and adherence to CBTi treatment strategies at the end of modules 1, 3, and 6 by phone. The contact time will be within 30 minutes on each occasion.
223482163|NCT05136638|BEHAVIORAL|Sleep Hygiene and Self-Monitoring Control|An app with self-monitoring function and videos and written materials about sleep hygiene will be provided.
223482164|NCT00805532|BEHAVIORAL|Behavioral Activation treatment|Behavioral Activation (BA) is a present-focused psychotherapy based on behavioral theory and principles of change, that aims to re-engage individuals with meaningful and pleasurable life activities by targeting and problem-solving patterns of avoidance. It is well-established as a treatment for depression and has been modified for the current study to address PTSD-related problems.
223482165|NCT00805532|OTHER|Treatment as Usual|Usual Care for PTSD (UC)-that is provided in the VA PTSD Specialty clinics. Actual clinical practice varies between sites and between providers within sites, as is typical of the VA health care system. Subjects assigned to Usual Care will be permitted to receive medical intervention (i.e., pharmacotherapy) and any additional psychotherapy deemed appropriate by the provider. They will also be offered a minimum of 6 sessions of individual therapy.
223482166|NCT01761188|PROCEDURE|Ablation|electrophysiology substrate mapping is the critical difference between both groups
223482167|NCT02475668|DEVICE|Pulse oximeter|Hypoxia
223482168|NCT05202405|DRUG|AD-221|AD-221 Oral Tablet
224169880|NCT04752228|OTHER|Philadelphia ACE Survey|The Philadelphia ACE survey assesses the three major domains featured within the original ACE Study Questionnaire developed by Felitti et al. (abuse, neglect, and family dysfunction), in addition to five community-level stressors.
224169881|NCT04752228|OTHER|Lifestyle Assessment|The Lifestyle Assessment questionnaire features the Short Form (36) Health Survey, Patient Health Questionnaire-9, General Anxiety Disorder-7 questionnaire, Seattle Angina Questionnaire-7, and modified Perceived Need for Card Questionnaire, which are validated questionnaires for the assessment of quality of life, depression, anxiety, angina, and perceived need for care, respectively.
224169882|NCT00579462|OTHER|Blood and Tissue studies|Blood will be collected from participating patients at baseline, as close as possible to the date of their baseline radiologic assessment. Three follow-up blood collections will be drawn, each within 7-10 days of each follow-up radiologic evaluation.
224169883|NCT01263470|DRUG|Alogliptin|Alogliptin 6.25 mg, tablets, orally, once daily for up to 12 weeks
224169884|NCT01263470|DRUG|Alogliptin|Alogliptin 12.5 mg, tablets, orally, once daily for up to 12 weeks.
223482169|NCT05202405|DRUG|AD-221A and AD-221B|AD-221A Oral Tablet + AD-221B Oral Tablet
223482170|NCT02315183|OTHER|This is an observational Study|THis study has no intervention
223482171|NCT06485505|DRUG|ISOtretinoin 10 MG|Low dose isotretinoin as an adjuvant for itraconazole in treating onychomycosis
223482172|NCT06485505|DEVICE|excimer light|excimer light as an adjuvant for itraconazole in treating onychomycosis
223482173|NCT06485505|DRUG|Itraconazole 200 mg|Itraconazole alone
223482174|NCT00178373|DRUG|Modafinil|
223482175|NCT00178373|DRUG|sugar pill|
223744965|NCT02049333|PROCEDURE|Phacoemulsification|
223744966|NCT02049333|PROCEDURE|Endoscopic Cycloplasty (ECPL)|
224169885|NCT01263470|DRUG|Alogliptin|Alogliptin 25 mg, tablets, orally, once daily for up to 12 weeks.
224169886|NCT01263470|DRUG|Alogliptin|Alogliptin 50 mg, tablets, orally, once daily for up to 12 weeks
224169887|NCT01263470|DRUG|Voglibose|Voglibose 0.2 mg, tablets, orally, three times daily for up to 12 weeks.
224169888|NCT01263470|DRUG|Placebo|Placebo-matching tablets, orally, once or three times daily for up to 12 weeks.
223585336|NCT03825159|DEVICE|Spinal Orthosis with an Integrated System of Electric Surface Stimulation and Heat Sensing|The electrical stimulation technology integrated with the total contact spinal orthosis combines the external correction forces on the spinal skeleton from the passive orthosis with the muscle forces at the lateral trunk from the stimulation process.
223585337|NCT03825159|DEVICE|spinal orthosis|The ventrally opened total contact spinal orthosis will be designed and made of Copolymer and Aliplast. Correcting pressure points have to use the pressure pads at relevant points.
223585338|NCT05378295|DIETARY_SUPPLEMENT|Fermentable oligosaccharide|Supplementation period 12 weeks
223585339|NCT05378295|DIETARY_SUPPLEMENT|Personalized fiber mixture|Supplementation period 12 weeks
223585340|NCT05118490|DRUG|Daily rifapentine and isoniazid for 4 weeks|Arm A: isoniazid (300mg) and rifapentine (600mg) daily for 4 weeks (1HP)
223585341|NCT05118490|DRUG|Weekly rifapentine and isoniazid for 12 weeks|Arm B: isoniazid (900mg) and rifapentine (900mg) weekly for 12 weeks (3HP)
223585342|NCT04052776|DRUG|Buspirone|40mg
224169889|NCT04890730|OTHER|Esophagogastroduodenoscopies|Each enrolled patient needs to undergo Esophagogastroduodenoscopies and elastography
224169890|NCT00610714|DRUG|AZD0530|oral once daily dose
224169891|NCT00610714|DRUG|Carboplatin|intravenous injection
224169892|NCT00610714|DRUG|Paclitaxel|intravenous infusion
224169893|NCT05275127|OTHER|changes of gingival crevicular fluid miRNA|Evaluation of changes of gingival crevicular fluid miRNA after periodontal treatment
224169894|NCT00066443|BIOLOGICAL|pegfilgrastim|Dose escalation schedule A\&B = 6mg fixed dose once per cycle on day 2
224169895|NCT00066443|DRUG|docetaxel|Dose Escalation schedule A = 75-85 mg/m2 Dose Escalation schedule B = 50-75 mg/m2
224169896|NCT00066443|DRUG|epirubicin hydrochloride|Dose escalation schedule A = 75-120 mg/m2 IV Dose escalation schedule B = 50-90 mg/m2 IV
224169897|NCT05288179|DRUG|Pirfenidone Capsules|After randomization, the experimental group took pirfenidone capsules 3 times a day，Week 1, 2 capsules/time; Week 2, 4 capsules/time; Week 3-52, 6 capsules/time
223482176|NCT04899037|OTHER|No intervention|This is an observational study of participants that either choose or not choose to utilize an OID. This is not an intervention prescribed study, however, participants may choose uptake of standard of care intervention and obtain and utilize an OID. An OID is an FDA-approved device commonly recommended to patients with conductive, mixed, or singled-sided hearing loss. There is no experimental intervention evaluated in this study.
223482177|NCT04120818|PROCEDURE|secondary IOL implantation|reopened the fibrotic, closed capsular bag and achieve IOL placement
223585343|NCT04052776|DRUG|Levodopa-Carbidopa|400mg/100mg
223585344|NCT04052776|DRUG|Buspirone + Levodopa-Carbidopa|40mg + 400mg/100mg
223585345|NCT04052776|DRUG|Placebo oral tablet|Non-active metabolite
223585346|NCT00005079|PROCEDURE|conventional surgery|
223585347|NCT05538390|OTHER||
224169898|NCT05288179|DRUG|placebo capsules|After randomization, the experimental group took placebo capsules 3 times a day，Week 1, 2 capsules/time; Week 2, 4 capsules/time; Week 3-52, 6 capsules/time
223482178|NCT04120818|PROCEDURE|primary IOL implantation|lensectomy and anterior vitrectomy and primary IOL implantation
223482179|NCT02027493|DRUG|Reiferon R|subcutaneous injection of 100 μg/m2
223482180|NCT02027493|DRUG|Ribavirin|15 mg/kg daily on two divided doses
223482181|NCT03101345|OTHER|Peptamen® 1.5 vanilla|Administration orally
223482182|NCT05265754|BEHAVIORAL|sujok therapy|sujok therapy
223482183|NCT00550004|DRUG|RP101|190 mg oral tablet
223482184|NCT00550004|DRUG|Gemcitabine (1000 mg/m2)|30 minute intravenous infusion
223585348|NCT00327990|DRUG|Ibandronate|
223585349|NCT00327990|DRUG|Alendronate|
223585350|NCT02312778|OTHER|HVLA Manipulation|Intervention Group who receives a high velocity and low amplitude (HVLA) lumbar manipulation. A manual procedure also known as high velocity and low amplitude lumbar spinal manipulation are delivered for the subjects in the side lying position. The lumbar segment more restrict (mobility restriction) will be the target region for the manipulative procedure.
223585351|NCT01256021|DRUG|Botulinum Toxin Type A|1 time, gastrocnemius muscles injection, dose of 4U/kg body weight in patients with hemiplegia, dose of 6U/kg body weight in patients with diplegia, Maximum dosage 200U
223585352|NCT02752464|BEHAVIORAL|Counseling|Up to 12 sessions of behavioral counseling using motivational interviewing techniques focused on diet and physical activity behaviors over a 12 week period. Counselors will be guided in their sessions by a computer program called CuesWeight. Participants also receive text messages to enable participants to track their behaviors; this information is relayed to the counselors to inform the counseling sessions.
223585353|NCT02752464|BEHAVIORAL|feedback report|All participants receive a brief printed feedback report displaying their current levels of nutrition and physical activity behaviors and tips for meeting recommended guidelines.
223585354|NCT05285306|BEHAVIORAL|PEACE Program|This pilot will consist of 3 individual telemedicine sessions to teach cognitive behavioral coping skills and provide education related to gynecologic cancer surveillance and psychological distress.
223585355|NCT03631212|BEHAVIORAL|Flexiquit|Digital avatar-led Acceptance and Commitment Therapy for smoking cessation
223585356|NCT04912752|GENETIC|Migraine CNV|Copy number variation effect on migraine disease
223585357|NCT01977690|DEVICE|Clavicle Brace|
224169899|NCT00712712|DRUG|Acetaminophen|Intravenous administration of paracetamol (4 g / 24h) and patient-controlled analgesia (PCA).
224169900|NCT00712712|DRUG|Morphine Sulfate|Patient-controlled analgesia (PCA), allowing morphine consumption to be titrated to the patient's needs and thus allowing morphine doses to be adapted to an increase in pain in the patient's post-operative period or a rapid analgesic effect of radiofrequency.
224169901|NCT00712712|OTHER|Questionnaire administration|"Pain notebook will allow the patient to describe the pain specific to the metastasis concerned, containing information on :~* The intensity of the minimum, average and maximum pain of the last 24 months. hours as well as the intensity of the pain of the moment according to a scale 11-point digital,~* the background morphine analgesic treatment during the last 24 hours,~* the morphine analgesic treatment taken during painful attacks,~* the possible undesirable effects of morphine treatment.~* the morphinic, non-morphinic and co-antalgic treatment is noted, as well as that the total dose of oral morphine or oral morphine equivalent"
223585358|NCT04276974|OTHER|Organic diet|Organic plant-rich foods (2000kcal for women, 2500kcal for men)
223585359|NCT04276974|OTHER|Non-organic diet|Likewise Non-organic plant-rich foods (2000kcal for women, 2500kcal for men)
223585360|NCT05729139|DRUG|Cemiplimab-Rwlc|350 mg via IV infusion over 30 minutes every 3 weeks for up to two years
224169902|NCT00712712|PROCEDURE|Quality-of-life assessment|Patients' quality of life will be assessed using the quality of life questionnaire EORTC QLQ-C30 at inclusion in the study and at 8 weeks after radiofrequency. ablation.
224169903|NCT00712712|PROCEDURE|Radiofrequency ablation|"Recent technique of thermal destruction of tumors.~This technique consists of inserting an electrode needle into the tumour under X-ray or ultrasound guidance or intraoperatively under laparoscopy for example. This needle carries a current or a light wave depending on the characteristics of the generator to which it is connected (radiofrequency, laser).~Radio frequencies are radiation non-ionising electromagnets. In this context of tissue ablathermia wavelengths ranging from 400kHz to 500kHz."
224169904|NCT00292513|DEVICE|standard suture (5-0 prolene), topical skin adhesive (dermabond), absorbable suture (5-0 Chromic gut)|
224169905|NCT03606707|DRUG|Steroids|intra-articular steroid injection for atlantoaxial joint
224169906|NCT03072368|OTHER|Photograph|Babies will be photographed and eye color will be observed and documented at birth, 3 months and one year of age
224169907|NCT00249522|BEHAVIORAL|Contingency management|
224169908|NCT01732133|DEVICE|Nexfin|
224169909|NCT05132140|DEVICE|adaptive optics system|the system consists of a wavefront sensor and a deformable mirror that measure and correct (or modify) the eye's optical imperfections (aberrations).
223482185|NCT05584345|OTHER|Conventional Treatment and manual therapy|Cold pack, ultrasound, TENS, finger ladder, Codman, shoulder wheel, and Wand exercises, as well as stretching and capsule exercises, will be used in addition to conventional physiotherapy. There will be 30 repetitions in each direction of the Codman exercises. 5 days a week, for a total of 30 sessions, the afflicted shoulder will get 6 minutes of daily US treatment, with complete contact to the shoulder area and at a right angle. All patients will receive manual stretching in the shoulder flexion, abduction, extension, external rotation, and internal rotation directions. In addition, participants will receive manual therapy techniques, including Glenohumeral joint (GH) distraction, glenohumeral joint inferior gliding, anterior gliding, and posterior gliding, scapulothoracic joint distraction, scapulothoracic joint superior, inferior, medial, and lateral gliding. Each manual therapy technique was performed with 10 repetitions per participant
223482186|NCT05584345|OTHER|Manual therapy and Respiratory Exercises|In addition to the treatment program applied in conventional therapy and manual therapy,, participants in this group also will perform diaphragmatic breathing exercises, pursed-lip breathing exercises, and relaxation breathing exercises. Each breathing exercise will be performed with 10 repetitions under physiotherapist supervision. Participants were also asked to continue the breathing exercises at home, performing them three times a day with 10 repetitions per session for a duration of six weeks.
223482187|NCT03349047|BEHAVIORAL|Behavioral intervention group|Patients will hold the peanut or tree nut in a cup and will be asked to touch the nut with their finger.
223482188|NCT03349047|BEHAVIORAL|Education|The group will be educated about what can occur with contact with or being in proximity of peanuts or tree nuts.
223482189|NCT00088855|DRUG|Bortezomib|Given IV
223482190|NCT00088855|OTHER|Laboratory Biomarker Analysis|Correlative studies
223482191|NCT00088855|DRUG|Pegylated Liposomal Doxorubicin Hydrochloride|Given IV
223482192|NCT01537588|OTHER|Autograft STG harvest from ACL-deficient leg|Semitendinosus-gracilis graft harvest is undertaken on same limb that is undergoing ACL reconstruction
223482193|NCT01537588|OTHER|Autograft harvest contralateral to ACL-deficient leg|Semitendinosus-gracilis graft harvest is undertaken on limb contralateral to that undergoing ACL reconstruction
223482194|NCT04831554|PROCEDURE|single chest tube drainage|place single chest tube after surgery of PSP
223482195|NCT00754923|DRUG|sorafenib|administered orally at 400 mg taken twice daily , continuously on a 28 day cycle as an outpatient.
223482196|NCT04186273|DRUG|Fibrosis-Inhibiting-Compound-FS2|There are three (3) experimental interventions: vehicle moisture balancing base, FS2-0.25 moisturizer, and 0.5 moisturizing base.
223482197|NCT04186273|OTHER|Vehicle moisture balancing base|Vehicle base without FS2.
223482198|NCT00815074|OTHER|No intervention|no intervention
223482199|NCT05316493|BEHAVIORAL|Intensive Lifestyle Intervention (ILI)|dietary guidance, exercise guidance, lifestyle intervention
223482200|NCT05316493|DRUG|Megestrol Acetate 160 MG Oral Tablet|enrolled participants will take Megestrol Acetate 160mg daily
223585361|NCT05729139|DRUG|PEG-IFN alfa-2a|"Self-administered by the participant via subcutaneous injection in the abdomen or thigh weekly for up to one year. Participants will receive one of three doses:~Dose level 0: 45 mcg~Dose level 1: 90 mcg~Dose level 2: 135 mcg~Dose level 0 is considered the starting dose and sequential cohorts of three participants will be treated with escalated doses until the maximum tolerated dose is established."
223585362|NCT05514249|DRUG|CRD-TMH-001|Participant will receive a single dose of CRD-TMH-001 administered via intravenous injection.
223585363|NCT03149952|OTHER|Evaluation of the feasibility of the establishment of a logbook in patients hospitalized for allogeneic haematopoietic stem cells|Evaluation of the feasibility of the establishment of a logbook in patients hospitalized for allogeneic haematopoietic stem cells.
223744967|NCT00000560|DRUG|adrenergic beta antagonists|
223744968|NCT03642717|DRUG|JARDIANCE DUO®|empagliflozin and metformin
224169910|NCT01404689|DRUG|Dexmedetomidine|dexmedetomidine 1μg/Kg•hr IV continuous infusion, initiated 15 min before the procedure (ERCP) till complete procedure
224169911|NCT01404689|OTHER|normal saline|0.9% NaCl 1μg/Kg•hr IV continuous infusion, initiated 15 min before the procedure (ERCP) till complete procedure
224169912|NCT06022432|OTHER|Video of a patients testimonial|The intervention is a prerecorded video of a re-enacted patient-therapist interaction whereby the patient gives a testimonial about the treatment process while either reducing negative expectations or maximizing positive expectations about therapy, respectively.
224169913|NCT06022432|OTHER|Writing Task|Participants write freely about their current treatment expectations / apprehensions to seek treatment
223744969|NCT05375695|OTHER|Time-restricted eating|"The intervention consists of an 8-week strict time-restricted eating period, where participants follow the same 10-hour eating window (self-selected timing from 6 am to 8 pm) each day with minimal support to obtain lived experiences with challenges associated with time-restricted eating. Followed by an individually adjusted 4-week time-restricted eating period, including supporting components.~Staff will help participants select a time-interval that fits into their daily life. Diet is ad libitum and with no further dietary restrictions. The time-restricted eating intervention is an addition to standard care."
223744970|NCT04535895|RADIATION|Simultaneous integrated boost|Adjuvant breast cancer irradiation including simultaneous integrated boost
223744971|NCT00302458|DRUG|OROS-Methylphenidate|Each dose of OROS MPH will be 72 mg which will be supplied as two 36 mg overencapsulated capsules
224169914|NCT03184805|DRUG|Continuing aspirin|Subject assigned to control arm will maintain antiplatelet therapy using aspirin only at least 7 days before surgery. If subject is taking one or more antiplatelet drugs, it should be changed (for subjects taking antiplatelet drug except aspirin at enrollment) or continued (for subject taking aspirin at enrollment) with low-dose, aspirin monotherapy before surgery. Cessation of clopidogrel, ticagrelor, and prasugrel should be started at least 5 days, 3 days and 7 days before surgery, respectively. Administration of aspirin will be started at the day of cessation of previous antiplatelet regimen and maintained until third postoperative day with 100 mg once a day.
224169915|NCT03184805|DRUG|Stopping aspirin|Subject assigned to comparison arm will stop antiplatelet therapy before scheduled surgery or procedure. If subject is taking aspirin, clopidogrel, ticagrelor, or prasugrel, it should be discontinued for 7 days, 5 days, 3-5 days, and 7 days before surgery. Antiplatelet therapy may be restarted as previous regimen at fourth postoperative day or sooner unless significant bleeding risk or bleeding event occurs.
224169916|NCT03598140|DRUG|Sildenafil Citrate|Sildenafil 60mg once (Group 1) or daily for 2 weeks (Group 2)
224169917|NCT03598140|DRUG|Placebo oral capsule|Placebo once (Group 1) or daily for 2 weeks (Group 2)
224169918|NCT01029691|DEVICE|Positive Airway Pressure|Women will use positive airway pressure until delivery
223482201|NCT05316493|DRUG|Levonorgestrel-Releasing Intrauterine Contraceptive System (Mirena), 52 Mg|enrolled patients will be treated with LNG-IUS.
223482202|NCT04687397|BEHAVIORAL|Rehabilitation|Multidisciplinary rehabilitation
223482203|NCT04292886|DRUG|Tamoxifen and femoston|oral
223482204|NCT04292886|DRUG|Vitamin C and femoston|Vitamin C and femoston
223482205|NCT05404841|DIETARY_SUPPLEMENT|CoffeeBerry Supplement|A Coffeeberry supplement containing 200mg Caffeine and 14mg polyphenols, manufactured by FutureCeuticals Inc.,
223585364|NCT02401204|OTHER|Longitudinal surveillance study|"Regular specimens will be routinely collected as standard of practice.~A rectal swab and stool specimen will be collected twice a week since first admission on NICU until discharge from NICU.~If participant is intubated/ventilated, a throat swab will be collected."
223585365|NCT01803867|DRUG|rHIgM22|Administered via IV infusion
223585366|NCT01055483|DRUG|panobinostat/LBH589B|
223585367|NCT04044976|DRUG|Caffeine Citrate|Infants will receive 20 mg/kg of caffeine citrate intravenously, via the umbilical vein, or enterally, through an orogastric tube, within 10 min of birth.
223585368|NCT05823272|OTHER|ONS|oral nutritional supplement
223585369|NCT01744314|DRUG|Indomethacin and Pantoprazole|
223585370|NCT01744314|DRUG|microcrystalline cellulose powder tablets|
223585371|NCT01853956|DRUG|Alprazolam 0.25 mg|Reference product
224169919|NCT05103631|GENETIC|CATCH T cells|"Four different dosing schedules will be evaluated. Three to six patients will be evaluated on each dosing schedule. The following dose levels will be evaluated:~DL1: 3x10\^7/m2~DL2: 1x10\^8/m2~DL3: 3x10\^8/m2~DL4: 1x10\^9/m2~The doses are calculated according to the actual number of GPC3-CAR transduced T cells."
224169920|NCT06647433|OTHER|Observation|case study will be observed participants, methods will include observation, interview and video reflexive ethnography
224169921|NCT05081245|DRUG|ML-004 (IR)/(ER) tablet|Participants will receive ML-004 once daily.
224169922|NCT05081245|DRUG|ML-004 Placebo|Participants will receive matching placebo once daily.
224169923|NCT04331028|DEVICE|Shockwave therapy|A shockwave therapy device will be applied in the alveolar socket area of a maxillary tooth, 2 weeks after tooth extraction was performed.
223482206|NCT05404841|DIETARY_SUPPLEMENT|Placebo|Placebo
223482207|NCT04736433|DRUG|ACE inhibitor|ACE inhibitor dispensing claim is used as the reference
223482208|NCT04736433|DRUG|Sacubitril/Valsartan|Sacubitril/Valsartan dispensing claim is used as the reference
223482209|NCT04541121|BEHAVIORAL|3D printed model|Mother is given 3D printed model of fetus' face
223482210|NCT04541121|BEHAVIORAL|Placebo|Mother is given a picture of 3D ultrasound of fetus
223482211|NCT06134388|DRUG|Sulfasalazine|Sulfasalazine is an anti-inflammatory drug that is indicated for treatment of ulcerative colitis and rheumatoid arthritis.
223482212|NCT03183440|DIETARY_SUPPLEMENT|PREBIOTICS|women will daily take a mixture of Galacto-Oligo-Saccharide/inulin (ratio 9:1) from inclusion to delivery
223482213|NCT03183440|OTHER|PLACEBO|women will daily take placebo (maltodextrin) from inclusion to delivery
223482214|NCT04909788|BEHAVIORAL|a long-distance running (over 3 km)|Complete a long distance running（over 3 km） within the specified time (30 minutes)
223585372|NCT01853956|DRUG|Alprazolam 0.25 mg|Test product
223585373|NCT01649024|DRUG|Tremelimumab|Given IV
223585374|NCT05571774|OTHER|collection data|collection data
223585375|NCT03511456|PROCEDURE|PELD operation|"Under local anesthesia, the introduction of 20G needles could be performed with fluoroscopy. After the needle traveled through TFS space, extremely care was needed to avoid nerve root injury.~Discography was recommended. The following steps were performed as usual: the needle was replaced by a guide wire; a 9 mm incision was made in the skin; a tapered cannulated dilator was inserted along the guide wire; and finally a working cannula was inserted.~The remove of disc was performed carefully under endoscope. The first step was to locate the annulus fibrosis of L5/S1 disc, then by using nerve dissector and bipolar elliquence, soft tissue including fat tissue, muscle and fibers of ligaments were pushed cephalad until the blue stained herniated disc was visible and removed."
223585376|NCT01181674|DRUG|insulin glargine|sc injection
223585377|NCT01181674|DRUG|metformin|oral administration
223585378|NCT01181674|DRUG|acarbose|oral administration
224169924|NCT00486590|PROCEDURE|Prolact-Plus Human Milk Fortifier|
224169925|NCT03447067|PROCEDURE|computer guided surgical|has three cutting guided plane for identify the position of place of the third molar, it have beveled cut for stability after remove the teeth and placing the bony window
224169926|NCT03447067|PROCEDURE|Conventional surgery|Low speed motor with surgiacl round burs and surgical fissure for removal a covering bone with decapitation and guttering formation
224169927|NCT03447067|DEVICE|CBCT|For measuring the bone removeal
224169928|NCT03447067|DEVICE|CBCT|for identifed the nerve
224169929|NCT05655416|PROCEDURE|Endovenous chemical ablation with Trendelenburg's operation (eCAT)|Endovenous chemical ablation with trendelenburg's operation (e CAT) is a method for the treatment of varicose veins
224169930|NCT05415865|COMBINATION_PRODUCT|Alkalinized Lidocaine|20 ml of Lidocaine Hydrochloride and 10 ml of Sodium hydrogen carbonate will be pulled up and mixed in a syringe on site, and 30 ml mixed solution in total will afterwards be installed in the bladder with a catheter.
224169931|NCT05415865|DRUG|Placebo Sodium Chloride 0.9% Inj|20 ml of Sodium Chloride 9 g/L and 10 ml of Sodium Chloride 9 g/L will be pulled up and mixed in a syringe on site, and 30 ml solution in total will afterwards be installed in the bladder with a catheter.
224169932|NCT05060081|OTHER|Pilates exercise program group|Pilates exercise program group will do a warm-up for 10 minutes and then perform five exercises includes standing footwork, hundreds with knee straight, articulating bridge, rolling like a ball, plank for 25 minutes. For first three weeks, each player will do 8 repetitions × 3 sets of exercises and for next three weeks, each player will do 15 repetitions × 3 sets of exercises. There will be cool-down for 10 minutes after exercises. Total program will be of 45 minutes.
224169933|NCT05060081|OTHER|Traditional plank exercise program group|Traditional plank exercise program group will do a warm-up for 10 minutes and then perform five exercises includes prone bridge, side bridge, supine bridge on exercise ball, prone bridge on exercise ball, superman on exercise ball. For first three weeks, each player will do 8 repetitions × 3 sets of exercises and for next three weeks, each player will do 15 repetitions × 3 sets of exercises. There will be cool-down for 10 minutes after exercises. Total program will be of 45 minutes.
223482215|NCT02751229|BEHAVIORAL|Honest Open Proud (HOP)|"five lessons in three modules, two for each two-hour session~1. Considering pros and cons of disclosing:~   * hurtful and helpful attitudes about mental illness~  * identify beliefs participants hold about themselves~  * explore five-step process to challenge their personally hurtful beliefs~  * weigh pros and cons of coming out in order to facilitate a decision on whether to disclose~2. Different ways to disclose:~   * different levels of (non-) disclosure and how to weigh the cons and pros~  * disclosure via social media versus disclosing face to face~  * how to find people that are better to disclose to than others and how to 'test them out'~  * participants will discuss how others might respond to their disclosure and how that will affect them~3. Telling your story:~   * how to tell one's story in a personally meaningful way, how to identify peers who might help with the coming out process, to review how telling one's story felt"
223482216|NCT02701634|DRUG|ENTO|Tablets administered orally
223482217|NCT02701634|DRUG|Placebo|Tablets administered orally
223482218|NCT02458495|BEHAVIORAL|Diabetes MAP Intervention|
223482219|NCT03523286|OTHER|RAPID-VT Software guided ablation|Catheter ablation will target VT exit sites at scar margin as determined by the RAPID-VT software
223482220|NCT02689960|DRUG|100mg prednisone suppository|vaginal administration of 100mg prednisone suppository (Rectodelt)
223482221|NCT02511717|OTHER|Transcutaneous tibial nerve stimulation|Patch electrodes applied posterior to the medial malleolus, and 5-10 cm above the medial malleolus of the same leg, just behind the medial tibial edge. Bipolar stimulation setting will be used, with a frequency of 10 Hz, 200ms pulse, and the amplitude will be titrated up to patient's maximum nonpainful tolerance (between 0.5-10mA). This will be done by the patients at home 3x/week for 30 minutes, over 12 weeks.
223482222|NCT02511717|OTHER|Sham transcutaneous tibial nerve stimulation|Patch electrodes applied posterior to the lateral malleolus, and 5-10 cm above the lateral malleolus of the same leg. Bipolar stimulation setting will be used, with a frequency of 10 Hz, 200ms pulse, and the amplitude will be set a 1mA. This will be done by the patients at home 3x/week for 30 minutes, over 12 weeks.
223482223|NCT05342571|OTHER|Behavioral, Psychological or Informational Intervention|Participate in ABC session
223482224|NCT05342571|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
224169934|NCT05841277|DRUG|LY3819469|Administered SC.
223482225|NCT05342571|OTHER|Electronic Health Record Review|Medical records reviewed
223482226|NCT05342571|OTHER|Informational Intervention|Receive patient guidebook
223482227|NCT05342571|OTHER|Survey Administration|Complete surveys
223482228|NCT01337934|DRUG|Lactated Ringer|Lactated Ringer
223482229|NCT01337934|DRUG|Albumin|Albumin 4%
223482230|NCT02636621|DEVICE|Brazilian Dental Appliance|Brazilian Dental Appliance is an oral appliance worn only during sleep that supports the jaw in a forward position to help maintain an open upper airway.
224169935|NCT03481296|BEHAVIORAL|Advanced Control|Participants receive linguistically and culturally tailored information booklet on colorectal cancer and colorectal cancer screening, colonoscopy instructions, stool blood test kits and reminder by mail. Participants' height, weight, and waist/hip circumference, blood pressure, blood glucose, and cholesterol levels will be measured by trained research staff. Participants will also receive the result of body measurements right away as a free service.
224305535|NCT01181271|OTHER|non-myeloablative allogeneic (allo) transplant|Donor peripheral blood stem cells (PBSC) will be infused intravenously beginning on Day 0. The minimum total CD34+ cell dose will be 2 x 10\^6 CD34+cells/kg of recipient's actual body weight with a maximum dose of 8 x 10\^6/kg of recipient's actual body weight
224305536|NCT01181271|DRUG|Tacrolimus|Tacrolimus (FK506) will be given orally at a dose of 0.05 mg/kg orally (PO) twice a day (BID) starting day -3.
223482231|NCT02636621|OTHER|Placebo|The placebo consists in a protective dental plate worn only during sleep that do not interfere in the size of the upper airway.
223482232|NCT04519190|DIAGNOSTIC_TEST|Prolonged continuous single-lead ECG monitor|We use Smartpatch, a listed ambulatory electrocardiographic system that can continuously record and save patients' cardiac rhythm for up to 45 days.
223585379|NCT01181674|BEHAVIORAL|lifestyle therapy|diet and exercise
223585380|NCT01181674|DRUG|insulin glargine|sc injection
223585381|NCT01181674|DRUG|metformin|oral administration
224169936|NCT03481296|BEHAVIORAL|Culturally-Adapted Decision Support Navigation Intervention|Participants in this group receive everything that advanced control group receives. In addition to a set of standard materials, they receive culturally and linguistically adapted decision counseling from the patient navigator. The patient navigator develops an individualized colorectal cancer screening plan using a theory-based online Decision Counseling Program. After the Program is completed, the patient navigator develops individualized colorectal cancer screening plan and shares the information with participants and participants' primary care physicians. Then, primary care physicians encourage the colorectal cancer screening to participants.
224169937|NCT02350192|BEHAVIORAL|e-health educational intervention (eHEI)|The e-HEI link (e-health link http://ehealth.nur.cuhk.edu.hk) provides the content of culture-specific cognitive knowledge related to CVD and measures to modify risk factors. The member area and interactive platform of the e-HEI website allows the self-monitoring of individual health and exercise records. Members can view and retrieve their own exercise records daily, and health measures trend regularly.
224169938|NCT03727633|DRUG|Idarubicin and Lipiodol|Hepatic intra-arterial chemotherapy consisting of the hepatic intra-arterial injection Idarubicin, emulsified with Lipiodol
224169939|NCT04430894|DRUG|Carfilzomib|"* Induction: protocol determine dose,via IV on 3 days per cycle up to 8 cycles, dependent on Upfront Stem Transplant or Deferring Stem Cell Transplant determination~* Maintenance: protocol determine dose,via IV on 2 days per cycle- Maintenance Cycle until progressive disease (PD) or unacceptable toxicity"
224169940|NCT04430894|DRUG|Isatuximab|"* Induction: At predetermined dose, via IV up to 8 cycles, dependent on Upfront Stem Transplant or Deferring Stem Cell Transplant determination:~  \-- Cycles 1 and 2 once per week, Cycles 3-4 every other week, Cycles 5 and 6 every other week, Cycles 7 and 8 once every 4 weeks.~* Maintenance: At predetermined dose, via IV, once per cycle, Maintenance Cycle until progressive disease (PD) or unacceptable toxicity"
224169941|NCT04430894|DRUG|Lenalidomide|\- Induction Predetermined Dose, oral, days 1-21 of up to 8 cycles, dependent on Upfront Stem Transplant or Deferring Stem Cell Transplant determination Maintenance: At predetermined dose, oral days 1-21 per cycle until progressive disease (PD) or unacceptable toxicity
224169942|NCT04430894|DRUG|Dexamethasone|Induction: Predetermined dosage, oral, Predetermined times per cycle up to 8 cycles dependent on Upfront Stem Transplant or Deferring Stem Cell Transplant determination Maintenance: orally or IV will be administered as a preinfusion medication prior to isatuximab dosing
224169943|NCT01553695|OTHER|questionary|Subjects have to fill out a booklet of questionnaires
224169944|NCT01553695|OTHER|questionary|Subjects have to fill out a booklet of questionnaires
224169945|NCT03369340|OTHER|P3P 1|2 mg of nicotine; no flavor; nicotine powder particle size of 2.25 ± 0.2 μm
224305537|NCT01181271|DRUG|Sirolimus|Sirolimus (rapamycin) will be given orally at a dose of 12 mg times one on day -3 and then the dose shall be 4 mg by mouth daily starting on day -2. The dose may then be adjusted according to serum levels at the discretion of the treating physician
224305538|NCT01181271|DRUG|Methotrexate|Methotrexate will be administered once daily on days 1, 3, and 6 as an IV bolus over 15 minutes at a dose of 5 mg/m2
223482233|NCT04519190|DIAGNOSTIC_TEST|Intermittent ECG monitor|When using Smartpatch, we can set time markers by pressing the button on the device. We ask our subjects to press that button twice a day and also when they feel any discomfort. Analyzing the ECG 1 minute after those time markers can serve as a surrogate for intermittent ECG monitor.
223482234|NCT04519190|DIAGNOSTIC_TEST|Routine practice|Perform pulse palpation and also ECG if irregular rhythm is found.
223482235|NCT02478333|DRUG|ALS-008176 (250 mg)|Participants will receive ALS-008176, 250 mg oral suspension once on Day 1 under fasted conditions.
224169946|NCT03369340|OTHER|P3P 2|2 mg of nicotine; flavor; nicotine powder particle size of 2.25 ± 0.2 μm
224169947|NCT03369340|OTHER|P3P 3|1 mg of nicotine; flavor; nicotine powder particle size of 2.25 ± 0.2 μm
223482236|NCT02478333|DRUG|ALS-008176 (500 mg)|Participants will receive ALS-008176, 500 mg oral suspension once on Day 1 under fasted conditions.
224169948|NCT03369340|OTHER|P3P 4|2 mg of nicotine; flavor; nicotine powder particle size of 1.8 ± 0.2 μm
224169949|NCT05119998|DRUG|IBI325 + sintilimab|IBI325 + sintilimab combination does-escalation Patients will receive IBI325 and sintilimab until progressive disease, intolerability, or other reasons leading to treatment discontinuation
224169950|NCT05119998|DRUG|IBI325|IBI325 monotherapy does-escalation Patients will receive IBI325 until progressive disease, intolerability, or other reasons leading to treatment discontinuation
224169951|NCT03840681|OTHER|Augmentation|non invasive technique to increase bone width and eliminate need for second surgery
224169952|NCT04006821|DRUG|PD-1 antibody|Camrelizumab will be administered 200mg iv every 2 weeks until disease progression or lasts for two years.
224169953|NCT04006821|DRUG|Apatinib mesylate|Apatinib mesylate will be administered 250mg or 500mg (according to the patient's tolerance), qd, oral, until disease progression.
224169954|NCT06813365|DRUG|DZD6008|Daily dose of DZD6008
224169955|NCT06485778|RADIATION|Photon intensity modulated radiation therapy (IMRT)|Patients will receive bilateral cervical nodal irradiation with the primary post operative site excluded (30 fractions).
224169956|NCT06485778|OTHER|Life questionnaire's|EORTC QLQ C30/HN 35 and MDADI
224169957|NCT05117242|BIOLOGICAL|Acasunlimab|Acasunlimab will be administered intravenously (IV)
224169958|NCT05117242|BIOLOGICAL|Pembrolizumab|Pembrolizumab will be administered IV
224169959|NCT06647485|PROCEDURE|PF-only PVI|It consists in performing a point-by-point PVI using the Dual Energy THERMOCOOL SMARTTOUCH™ SF (DE STSF) ablation catheter with the TRUPULSE™ generator, employing only PF energy for ablation
223482237|NCT02478333|DRUG|ALS-008176 (750 mg)|Participants will receive ALS-008176, 750 mg oral suspension once on Day 1 under fasted conditions.
223585382|NCT01181674|DRUG|acarbose|oral administration
224305539|NCT01193036|BEHAVIORAL|Part 1: Interview + Questionnaires|Questionnaires to be completed immediately after interview, which will take approximately 15 minutes.
224305540|NCT01193036|BEHAVIORAL|Part 2: Multiple Questionnaires|Questionnaires to be repeated about every 2 weeks for 1 year.
224305541|NCT02885649|DRUG|Enzalutamide|Given PO
224305542|NCT02885649|OTHER|Laboratory Biomarker Analysis|Correlative studies
224305543|NCT02885649|PROCEDURE|Nephrectomy|Undergo partial or radical nephrectomy
224169960|NCT06647485|PROCEDURE|Hybrid PVI|It consists in performing a point-by-point PVI using the Dual Energy THERMOCOOL SMARTTOUCH™ SF (DE STSF) ablation catheter with the TRUPULSE™ generator, employing both PF and RF energy for ablation. Specifically, PF energy is used for the posterior segments and RF energy for the anterior segments of the pulmonary veins
224169961|NCT06647485|PROCEDURE|RF-only PVI|It consists in performing a point-by-point PVI using the Dual Energy THERMOCOOL SMARTTOUCH™ SF (DE STSF) ablation catheter with the TRUPULSE™ generator, employing only RF energy for ablation
224169962|NCT05182294|DEVICE|AIRVO 2, the new asymmetric nasal cannula|The AIRVO 2 is a humidifier with integrated flow generator that delivers warmed and humidified respiratory gases to spontaneously breathing patient through a variety of patient interfaces. This is an FDA-approved 510k device for use in hospitals and nursing homes. During HFNT, oxygen will be passed through a heated humidifier (AIRVO 2, Fisher and Paykel Healthcare) and applied continuously through conventional large-bore binasal symmetric prongs or the new asymmetric prongs cannula device, with a gas flow rate of 20-35 liters per minute or as high as the patient will tolerate and an FiO2 to keep SaO2 ≥ 90% (Airvo 2, Fisher and Paykel Healthcare). Gas flow temperature will be adjusted based on patient's comfort and range from 34-37 degrees centigrade. After completion of the study, patients will be switched back to oxygen therapy administered by nasal prongs or mask..
224169963|NCT05506813|OTHER|cognitive training and conventional training|cognitive training along with conventional therapy
224169964|NCT05506813|OTHER|motor dual task training along with conventional therapy|motor dual task training along with conventional therapy
224169965|NCT06981741|BIOLOGICAL|BP CC 001|10-20 x 10\^6 UC-MSC in 1 ml suspension, applied to a collagen carrier structure (Chondro-Gide®)
224169966|NCT01756365|PROCEDURE|Surgical transplantation of ACCE|The culture of corneal epithelium strives to produce a reconstructed tissue with the therapeutical aim of treatment of limbal stem cell deficiency.
224169967|NCT05999240|DRUG|Pimavanserin Tartrate 34 Mg ORAL CAPSULE [NUPLAZID]|Participants will be randomized to take a single dose of either pimavanserin 34 mg or placebo at Visit 2.
224169968|NCT05999240|DRUG|Placebo|Placebo for Pimavanserin Tartrate 34 Mg ORAL CAPSILE \[NUPLAZID\]
224305544|NCT04624347|BEHAVIORAL|Access to video and movement curves|intervention of caregivers with access to videos and motion curves of the premature infant
224305545|NCT05507762|BIOLOGICAL|UC-MSCs|"Usage: The stem cell preparation in this study is used intravenously in the elbow.~Dose: The dose of stem cell injection in this clinical study is set at 1×10\^6/Kg/time per injection Duration: 5 injections per trial group for the entire duration of the course, at 1st treatment, 2-week, 4-week, 16-week, and 24-week respectively"
224305546|NCT05507762|BIOLOGICAL|Saline solution|Usage: The saline solution in this study is used intravenously in the elbow. Dose: The dose of saline solution in this clinical study is set at 250ml/time per injection Duration: 5 injections per person for the entire duration of the course, at 1st treatment, 2-week, 4-week, 16-week, and 24-week respectively
224305547|NCT00181220|DRUG|valproic acid|
224305548|NCT00769626|OTHER|Usual Care|Patients in the usual care group will receive advice and education to remain active and anticipate a favorable prognosis. Patients will also receive medication from the primary care provider consistent with current evidence-based guidelines(acetaminophen or non-steroidal anti-inflammatories). Consistent with current practice guidelines, patients will be instructed to return to the primary care provider if they are not satisfied with their progress after 4 weeks.
223482238|NCT02478333|OTHER|Placebo|Participants will receive placebo oral suspension once on Day 1 under fasted conditions.
223482239|NCT00772837|DRUG|Omeprazole + Clarithromycin + Amoxycillin|Omeprazole 20mg BID for 1 week along with Clarithromycin 500mg BD and Amoxycillin 1g BD for 1 week
223482240|NCT00772837|DRUG|Omeprazole + placebo antibiotics|omeprazole 20 mg bid for 1 week along with placebo antibiotics for 1 week
223482241|NCT05335616|OTHER|Guideline|Hypothetical guideline regarding the indications and treatment steps involved in dental restoration repair.
223482242|NCT05335616|OTHER|Treatment fee item|Arrangement of a hypothetical treatment fee item which can be charged in addition to the actual repair restoration.
223482243|NCT01033136|BEHAVIORAL|Multiple Channel Exposure Therapy - Veterans|MCET-V offers individual therapy that provides psychoeducation about panic attacks and trauma and involves behavioral and cognitive exposure exercises.
223482244|NCT01033136|BEHAVIORAL|Cognitive Processing Therapy|CPT offers individual therapy that targets trauma and PTSD symptoms via cognitive restructuring.
223482245|NCT05655871|OTHER|Transtheoretic Model Based Video Exercise Training|Initial follow-up 1-3. Between weeks 4-6, the second follow-up. Between weeks 7-9, the third follow-up. was done within weeks. Participants 10-12. No application will be made between weeks and the last test will be done in the 12th week.
223482246|NCT05655871|OTHER|Standard Maintenance Practice|Initial follow-up 1-3. Between weeks 4-6, the second follow-up. Between weeks 7-9, the third follow-up. was done within weeks. The final test will be done at week 12.
223482247|NCT00630292|OTHER|Magnetic Resonance Angiography (MRA) of the Breast|Magnetic Resonance Angiography (MRA) of the breast will be performed before or after pre-treatment magnetic resonance imaging (MRI) and then once again before or after the post-treatment MRI.
223482248|NCT03602001|BEHAVIORAL|Attentive eating smartphone application.|A smartphone application that encourages a more attentive eating style.
223482249|NCT03602001|BEHAVIORAL|Standard dietary advice and text tips.|Standard dietary advice for weight loss booklet and weekly text tips containing dietary advice.
223585383|NCT01181674|BEHAVIORAL|lifestyle therapy|diet and exercise
223585384|NCT01181674|OTHER|Standard glycemic care|as informed by the current clinical practice guidelines
223585385|NCT02530996|DRUG|BH4|BH4 10 mg/kg/day given once to a total of 12 SSc patients
223585386|NCT02530996|DIAGNOSTIC_TEST|Vasculopathy assessment|Non-invasive technique, flow mediated dilatation (FMD) to define vasculopathy in SSc.
223585387|NCT02530996|DRUG|Placebo|On the experimental days, patients reported to the laboratory after having consumed a standardized breakfast and oral BH4 (10mg/kg) or placebo five hours prior to their arrival. All measurements were taken at the same time of day to eliminate any diurnal effects. All participants abstained from alcohol, caffeine, and exercise for ≥12 hours prior to the study. Additionally, vasodilatory medications were discontinued 12 hours prior to study visit. In premenopausal women, measurements were performed during the early follicular phase of the menstrual cycle. All measurements were made under quiet, comfortable, ambient (\~22°C) laboratory conditions.
224169969|NCT06605859|DEVICE|GlucoTab|"Insulin therapy will be started and adjusted according to the GlucoTab system with incorporated software algorithm. The goal of the basal-insulin algorithm is to maintain blood glucose within acceptable targets according to the predefined health status.~For a limited time period after therapy start, three measurements per day are suggested by the algorithm to determine blood glucose. Insulin dosage titration will be performed according to the algorithm in GlucoTab under supervision of the nurses of the nursing homes/domiciliary nursing care. Correctional bolus insulin will be administered at defined time-points according to BG targets in the predefined health status.~Nurses and nursing assistants will be trained in the use of the GlucoTab."
224169970|NCT06605859|OTHER|Diabetes Treatment|Diabetes Standard Care
224169971|NCT06421415|DRUG|Allergen Immunotherapy Extract|Patients will be treated as usual. The study is an observation of the long term effect of the treatment
224169972|NCT06229028|OTHER|hand rehabilitation with verbal explanation|Patients in all groups will undergo a 12-week hand rehabilitation process that includes the use of appropriate orthoses if necessary, approaches to edema and pain, restoration of joint range of motion, strengthening, and functional return to work or activities. The application of the rehabilitation process will change according to the assigned group.
224169973|NCT06229028|OTHER|hand rehabilitation with patient information and exercise forms|hand rehabilitation with patient information and exercise forms
224169974|NCT06229028|OTHER|hand rehabilitation with video recording|hand rehabilitation with video recording
224169975|NCT04883099|DEVICE|APIOC for Presbyopia and APIOC for Presbyopia for Astigmatism|Contact Lenses for Presbyopia
224169976|NCT00705380|BEHAVIORAL|Cognitive behavioral therapy (CBT) with panic control treatment (PCT) for adolescents|CBT with PCT treatment will consist of 11 weekly sessions that are designed to be developmentally appropriate for a younger population. The primary aim of this treatment will be to directly influence three aspects of panic attacks and general anxiety: the cognitive/misinterpretational aspect, the hyperventilatory response, and the conditioned reactions to physical sensations. Throughout treatment, participants will keep daily records of their anxiety and will complete self-monitoring forms to monitor panic attacks.
224169977|NCT00705380|BEHAVIORAL|Waitlist control|During the 12-week waitlist period, participants will keep daily records of their anxiety and will complete self-monitoring forms to monitor panic attacks. Participants will also meet with a therapist every other week to discuss the nature of any panic attacks or address any concerns.
224169978|NCT05529862|GENETIC|Pre-treatment biopsy|Pre-treatment fragments will be collected during the biopsy visit organised as part of routine medical practice, prior to the start of treatment with ribociclib + ET
223585388|NCT03442296|BEHAVIORAL|Baltimore HEARS|Tailored aural rehabilitation for participant and communication partner (if applicable)
224169979|NCT05529862|GENETIC|Post treatment biopsy|Post-treatment fragments will be collected during a biopsy visit specifically planned for Trans-RosaLEE study.
224169980|NCT05529862|GENETIC|Pre treatment blood sampling|Sampling of 4 EDTA Tubes (4ml) and 2 Streck tubes (10ml)
224169981|NCT05529862|GENETIC|Post treatment blood sampling|Sampling of 2 Streck tubes (10ml)
224169982|NCT02789072|OTHER|central aortic pressure (measured in mmHg).|"Blood pressure will only be measured during the 0g (microgravity) phase. Seven 5 ml blood sample will be drawn in the aircraft: before the first parabola (1) and after each block of 5 parabola (6).~On ground after flight, a 9th 5 ml blood sample will be drawn and then the mobil-o-graph, the SOMNOtouch NIBP and the intravenous cannula will be removed."
224169983|NCT00681902|DRUG|Lidocaine|Jet lidocaine compared to jet placebo before needle insertion
224169984|NCT00681902|DRUG|Placebo|Jet saline
224169985|NCT06594627|DEVICE|Smart pillow|Utilize a smart pillow that is designed to reduce snoring issues and OSA symptoms during sleep
224169986|NCT06662994|DRUG|Aflibercept 8 mg (VEGF Trap-Eye, BAY86-5321)|Identify patients that have had a previous vitrectomy and have DME that requires anti-VEGF therapy. Then using a treat-extend-stop protocol6,7 that I previously published, treat patients with DME using high dose aflibercept, until the fluid has resolved and then extend the time interval in between treatments for those patients, while maintaining a fluid-free macula.
224169987|NCT02723019|BEHAVIORAL|Volunteer Peer Mentor+Behavioral Health Nurse|Intervention group participants receive intervention services from a Volunteer Peer Mentor and a Behavioral Health Nurse
223482250|NCT00025402|BIOLOGICAL|filgrastim|
223482251|NCT00025402|BIOLOGICAL|recombinant interferon alfa|
223482252|NCT00025402|DRUG|busulfan|
223482253|NCT00025402|DRUG|cyclophosphamide|
223482254|NCT00025402|DRUG|cytarabine|
223482255|NCT00025402|DRUG|etoposide|
223482256|NCT00025402|DRUG|hydroxyurea|
223482257|NCT00025402|DRUG|idarubicin|
223482258|NCT00025402|PROCEDURE|allogeneic bone marrow transplantation|
223482259|NCT00025402|PROCEDURE|peripheral blood stem cell transplantation|
223482260|NCT00025402|RADIATION|radiation therapy|
223482261|NCT00142415|DRUG|111-In-DOTA-cG250|On Day 1, each subject received a single intravenous (IV) infusion of 10 mg of cG250 coupled to DOTA and labeled with 5 mCi of 111-In.
223482262|NCT00142415|DRUG|177-Lu-DOTA-cG250|On Day 8, 9, or 10, each subject received a single IV infusion of 10 mg of cG250 coupled to DOTA and labeled with a dose of 177-Lu at a starting dose of 30 mCi/m\^2 in the initial cohort.
223482263|NCT03781271|DEVICE|Electromagnetic Navigation|Electromagnetic navigation is a form of surgical navigation that can be incorporated into the cervical interstitial brachytherapy workflow to improve the current standards of guidance.
223482264|NCT04342169|DRUG|Hydroxychloroquine|HCQ 400mg po BID x 1 day, then 200mg po BID x 4 days
223482265|NCT04342169|DRUG|Placebo oral tablet|Placebo to be taken on the same schedule as HCQ.
223482266|NCT02456896|DRUG|Oxcarbazepine|After baseline assessments, patients in test group will be prescribed Tab. Oxcarbazepine (600mg/daily in two divided dose for 1 week followed by 900mg/daily in two divided dose for next 3 weeks).
223482267|NCT04096131|PROCEDURE|cataract surgery|phacoemulsification
224169988|NCT06490536|DRUG|Oxaliplatin|"Oxaliplatin is used as part of the chemotherapy regimens for patients with ctDNA+ results in the SAGITTARIUS trial. It is administered in the following ways:~CAPOX Regimen: Oxaliplatin 130 mg/m² is given intravenously on day 1, in combination with capecitabine 1000 mg/m² taken orally twice daily on days 1-14 of each 21-day cycle.~FOLFOX Regimen: Oxaliplatin 85 mg/m² is administered intravenously on day 1, alongside folinic acid 400 mg/m² and fluorouracil 400 mg/m² IV bolus, followed by 2400 mg/m² IV infusion over 46 hours, in each 14-day cycle.~Dosages are standardized, while the duration of treatment can be adjusted based on patient response and liquid biopsy results, typically up to 6 months."
224169989|NCT06490536|DRUG|Capecitabine|"Capecitabine is used as part of the chemotherapy regimens for patients with ctDNA+ and ctDNA- results in the SAGITTARIUS trial. It is administered in the following ways:~CAPOX Regimen: Capecitabine 1000 mg/m² is taken orally twice daily on days 1-14 of each 21-day cycle, in combination with oxaliplatin 130 mg/m² given intravenously on day 1.~Capecitabine Monotherapy for High-Risk ctDNA- Patients: Capecitabine 1250 mg/m² is taken orally twice daily on days 1-14 of each 21-day cycle for patients identified as high-risk but with negative ctDNA results.~The dosage of capecitabine is standardized, while the duration of treatment varies based on patient response and monitoring results, typically up to 6 months."
223482268|NCT03742596|DIETARY_SUPPLEMENT|Probiotic Formula Capsule|The Probiotic will be coded in a specific label by a researcher. The patient will receive 2 bottles of the drug every 2 weeks and will be followed weekly for 7 weeks.
223482269|NCT03742596|DRUG|Control|The Placebos will be coded in a specific label by a researcher.
223482270|NCT06516770|DEVICE|Transcranial direct current stimulation|The subject will receive the tDCS using 5X7 cm electrodes. The anodal electrode will be placed on M1 representing the back muscles (1 cm anterior and 4 cm lateral to the vertex), while cathodal electrode will be placed on contralateral supraorbital area. The intensity will be set at 2 mA with 10-second fade in/out. The subject will be stimulated by tDCS for 20 minutes
223482271|NCT06516770|DEVICE|Neuromuscular electrical stimulation|The participants will receive the NMES using interferential mode (6000 Hz, beat frequency 20-50 Hz, scanning effect) on bilateral LM. The intensity will be set at the subject's maximum tolerance. Stimulation will be set at 10 seconds on and 60 seconds off to minimize muscle fatigue. The total NMES time is 20 minutes.
223482272|NCT06516770|OTHER|Motor control exercise|The participant will be instructed to perform co-contraction of transverse abdominis and lumbar multifidus muscle, while performing self-selected pace forward bend. Emphasis will be given to move in control manner (smooth and symmetrical movement). The participant will perform 4 minutes of continuous movement for 4 sets with 1 minute rest between sets.
223482273|NCT06516770|OTHER|Isometric exercise|The participant will be instructed to perform isometric back extension exercise in modified Sorensen position. The participant will hold 60 seconds in neutral position for 5 repetitions with 3 minutes rest between repetitions.
223482274|NCT00139529|BEHAVIORAL|Motivational Interviewing Telephone Counseling|Participants will receive up to 5 phone calls.
223482275|NCT00139529|BEHAVIORAL|Educational Intervention|Educational intervention will be completed during pregnancy.
223482276|NCT01189266|RADIATION|3-Dimensional Conformal Radiation Therapy|Undergo 3D conformal radiation therapy
223482277|NCT01189266|RADIATION|Intensity-Modulated Radiation Therapy|Undergo intensity-modulated radiation therapy
223482278|NCT01189266|OTHER|Laboratory Biomarker Analysis|Correlative studies
223482279|NCT01189266|DRUG|Vorinostat|Given PO
223482280|NCT01849614|OTHER|Cardiac SPECT perfusion scan|A SPECT cardiac perfusion scan provides a three-dimensional map of blood flow to the heart tissue. The scan will be taken at rest only.
223482281|NCT01776957|DEVICE|Device: Intrauterine device (IUD)|Women choosing to have an intrauterine device (IUD) inserted immediately post-abortion
223482282|NCT00300599|DEVICE|Continuous Positive Airway pressure|Continuous positive pressure device with a time clock
223482283|NCT00300599|OTHER|Placebo|Placebo
223482284|NCT00627692|DRUG|Prucalopride|0.5 mg o.d.
223482285|NCT00627692|OTHER|Placebo|o.d.
223482286|NCT00627692|DRUG|Prucalopride|1 mg o.d.
223482287|NCT00627692|DRUG|Prucalopride|2 mg o.d.
223482288|NCT00627692|DRUG|Prucalopride|4 mg o.d.
223482289|NCT02294266|DRUG|Mephedrone and alcohol|"Single oral dose mephedrone~Single oral dose alcohol"
223482290|NCT02294266|DRUG|Mephedrone|Single oral dose mephedrone
223482291|NCT02294266|DRUG|Alcohol|Single oral dose alcohol
223482292|NCT02294266|DRUG|Placebo|Single oral dose placebo
223482293|NCT02146183|DIETARY_SUPPLEMENT|Carbohydrate steviol glycosides|To investigate if intake of stevioside in addition to a carbohydrate-containing composition after work related depletion of muscle glycogen will increase the rate of glycogen re-synthesis as compared with intake of the carbohydrate-containing composition alone.
223482294|NCT02146183|DIETARY_SUPPLEMENT|Placebo Corn Starch|500 mg/day
223482295|NCT04779177|DRUG|Lumateperone 42 mg|Lumateperone 42 mg, oral administration
223482296|NCT04779177|DRUG|Lumateperone 28 mg|Lumateperone 28 mg, oral administration
223482297|NCT04729517|DRUG|AI201901|Twice daily inhaled AI201901 for 4 weeks
223482298|NCT04729517|DRUG|Azelastine Hydrochloride|Twice daily inhaled Azelastine Hydrochloride for 4 weeks
223482299|NCT03807024|DIAGNOSTIC_TEST|Bladder diary|3-day bladder diary: The classification of OAB-wet or OAB-dry is based on the record of the three-day bladder diary of each patient. The diagnosis of OAB in each patient was based on the presence of at least one episode of urgency in her three-day bladder diary and with the absence of stress urinary incontinence. The presence of at least one episode of urgency associated incontinence was defined to be OAB-wet, otherwise, OAB-dry
223482300|NCT01640977|PROCEDURE|Open PLIF (posterior lumbar interbody fusion)|The PLIF procedure achieves access to the degenerated disc from the back of the spine.
223482301|NCT01640977|PROCEDURE|MAS PLIF|The MAS PLIF technique is a minimally invasive variant of the traditional PLIF procedure. It is similarly performed through a single midline posterior incision but is conducted through a more medialized posterior approach.
223585389|NCT03442296|DEVICE|Baltimore HEARS|Tailored fitting and programming of a personal sound amplifier. This will be accompanied by a component of aural rehabilitation.
223585390|NCT02517671|DEVICE|Enhanced External Counterpulsation (EECP)|EECP is a non-invasive therapy that has been approved by the United States Food and Drug Administration (FDA) for the management of refractory angina and heart failure. This study is using the device to potentially improve 1.5 mile run times and VO2max in healthy volunteers.
223585391|NCT01487993|DRUG|Metformin|Oral administration, 500 mg daily at week 1. Every week metformin dosage increases with 500 mg, to a maximum dose of 1000 mg bid. This maximum dose will be administered till the end of the study.
224169990|NCT06490536|DRUG|Folinic acid|"Folinic acid is used as part of the FOLFOX chemotherapy regimen for patients with ctDNA+ results in the SAGITTARIUS trial. It is administered in the following way:~FOLFOX Regimen: Folinic acid (leucovorin) 400 mg/m² is given intravenously on day 1, in combination with oxaliplatin 85 mg/m² IV on day 1 and fluorouracil 400 mg/m² IV bolus followed by 2400 mg/m² IV infusion over 46 hours, in each 14-day cycle.~The dosage of folinic acid is standardized, while the duration of treatment can be adjusted based on patient response and liquid biopsy results, typically up to 6 months."
224169991|NCT06490536|DRUG|Fluorouracil|"Fluorouracil is used as part of the FOLFOX chemotherapy regimen for patients with ctDNA+ results in the SAGITTARIUS trial. It is administered in the following way:~FOLFOX Regimen: Fluorouracil 400 mg/m² is given as an intravenous (IV) bolus on day 1, followed by 2400 mg/m² as a continuous IV infusion over 46 hours, in combination with folinic acid (leucovorin) 400 mg/m² IV on day 1 and oxaliplatin 85 mg/m² IV on day 1. This regimen is repeated every 14 days.~The dosage of fluorouracil is standardized, while the duration of treatment is typically up to 6 months, adjusted based on patient response and liquid biopsy results."
224169992|NCT06490536|DRUG|Temozolomide|"Temozolomide is used as part of the tailored chemotherapy regimen for patients with ctDNA+ results in the SAGITTARIUS trial, specifically for those with MGMT-negative tumors. It is administered in the following way:~TEMIRI Regimen: Temozolomide 150-200 mg/m² is taken orally once daily on days 1-5 of each 28-day cycle, in combination with irinotecan 250 mg/m² administered intravenously on day 1 of each cycle.~The dosage of temozolomide is standardized, while the duration of treatment can be adjusted based on patient response and liquid biopsy results."
223482302|NCT03094156|DRUG|Placebo|1 capsule of placebo \[to be taken orally, with 240 mL of potable water\]
223482303|NCT03094156|DRUG|BIA 6-512|1 capsule of BIA 6-512 25mg or 1 capsule of BIA 6-512 50 mg or 1 capsule of BIA 6-512 75 mg or 1 capsule of BIA 6-512 100 mg \[to be taken orally, with 240 mL of potable water\]
223482304|NCT03094156|DRUG|Madopar® 250|Levodopa/benserazide immediate release tablets 200mg/50mg \[to be taken orally, with 240 mL of potable water\]
223482305|NCT03094156|DRUG|Comtan®|Entacapone 200 mg tablets \[to be taken orally, with 240 mL of potable water\]
223482306|NCT05145764|DRUG|Suvorexant|Encapsulated suvorexant (matched for color, weight, and size)
223482307|NCT05145764|DRUG|Placebo|Encapsulated placebo (matched for color, weight, and size)
223482308|NCT00003297|DRUG|mitoxantrone hydrochloride|
224305549|NCT00769626|OTHER|Early Treatment|Patients in the early treatment group will receive the usual care intervention (advice and education, and medication consistent with current evidence-based guidelines). Patients will also be referred to physical therapy for 4 sessions over a 3-week period. A standardized protocol will be used in physical therapy including spinal manipulation and trunk strengthening exercises. Patients will be instructed to return to the primary care provider if they are not satisfied with their progress after completion of the 4 sessions.
223482309|NCT00003297|DRUG|thiotepa|
223482310|NCT00003297|DRUG|topotecan hydrochloride|
223482311|NCT00003297|PROCEDURE|peripheral blood stem cell transplantation|
223585392|NCT01487993|BEHAVIORAL|Lifestyle intervention|Lifestyle intervention: 18 months physical therapy and dietary advice
223585393|NCT01873248|DRUG|68Ga-DOTATATE|68Ga-DOTATATE will be given in tracer doses and injected intravenously to image Neuroendocrine tumors by Positron Emission Tomography.
223585394|NCT03299712|DEVICE|ArteFill|soft tissue filler
223585395|NCT01381536|DRUG|GSK1550188 1mg/kg or 10mg/kg|IV one shot
223585396|NCT02741037|BEHAVIORAL|Dyadic lifestyle intervention|Dyadic lifestyle intervention: The dyadic behavioral lifestyle intervention was modeled after the Diabetes Prevention Program (DPP), and was adapted to make it more easily accessible to low-income Latinas. In addition, this intervention arm has a dyadic component to examine the effectiveness of mothers and daughters engaging in the lifestyle intervention together as partners. Participants also will receive usual care.
223585397|NCT02741037|BEHAVIORAL|Individual lifestyle intervention|Individual lifestyle intervention: The individual behavioral lifestyle intervention was modeled after the Diabetes Prevention Program, and was adapted to make it more easily accessible to low-income Latinas. Mothers participate in the Unidas intervention alone, without their related daughters. Unrelated daughters participate in the Unidas intervention alone without their related mothers. Participants also will receive usual care.
223585398|NCT02741037|OTHER|Usual Care|Usual Care: Mother and daughter participants will receive Usual Care.
223585399|NCT01086852|BIOLOGICAL|FACTOR X|"Presurgery loading dose- The FX level of 70%-90% should be achieved.This will be calculated based on the patients weight on day of surgery and the required rise. Initial dose should not exceed 60IU/kg.~Post surgery- FX trough levels of 50% should be achieved.~Intravenous infusion of factor X is given at a suggested rate of 10mL/min but not exceeding more than 20mL/min."
223482312|NCT01493713|OTHER|Evaluate the correlation of overall different objective response.|Evaluate the correlation of overall different objectives response. Chemotherapeutic agents: XELOX scheme (Xeloda; Oxaliplatin) Device: MDCT (MultiDetector Computed Tomography)
223482313|NCT02372461|DRUG|Placebo|This is an non inferiority trial, the intervention is a placebo
223482314|NCT02372461|DRUG|Amoxicillin|Amoxicillin Liquid
223482315|NCT06462677|DIAGNOSTIC_TEST|Babesia NAT|Blood donors will be tested with Babesia NAT
223585400|NCT00221494|DRUG|citalopram + tiodothyronine, or + pindolol, or + placebo|
223585401|NCT00447122|DRUG|Gemcitabine 1000mg/m2 30 minutes|1000mg/m2 30 minutes
223585402|NCT00447122|DRUG|Lapatinib 1000mg/d|1000mg/d
223585403|NCT00447122|DRUG|Lapatinib 1500mg/d|1500mg/d
223585404|NCT00447122|DRUG|Gemcitabine 1000mg/m2 100minutes|1000mg/m2 100minutes
223585405|NCT00447122|DRUG|Oxaliplatin 100mg/m2|100mg/m2
224169993|NCT06490536|DRUG|Irinotecan|"Irinotecan is used as part of the tailored chemotherapy regimen for patients with ctDNA+ results in the SAGITTARIUS trial. It is administered in the following ways:~TEMIRI Regimen: Irinotecan 250 mg/m² is administered intravenously on day 1 of each 28-day cycle, in combination with temozolomide 150-200 mg/m² taken orally once daily on days 1-5.~FOLFIRI Regimen: Irinotecan 180 mg/m² is given intravenously on day 1, in combination with folinic acid (leucovorin) 400 mg/m² IV, fluorouracil 400 mg/m² IV bolus, followed by 2400 mg/m² IV infusion over 46 hours, in each 14-day cycle.~The dosage of irinotecan is standardized, while the duration of treatment can be adjusted based on patient response and liquid biopsy results."
224169994|NCT06490536|DRUG|Nivolumab|"Nivolumab is used as part of the tailored immunotherapy regimen for patients with ctDNA+ results, specifically for those with MSI-H/MMRd tumors in the SAGITTARIUS trial. It is administered in the following way:~Nivolumab: 3 mg/kg is given intravenously every 2 weeks. This dosage is standardized, while the duration of treatment can be adjusted based on patient response and liquid biopsy results."
224169995|NCT06490536|DRUG|Ipilimumab|"Ipilimumab is used as part of the tailored immunotherapy regimen for patients with ctDNA+ results, specifically for those with MSI-H/MMRd tumors in the SAGITTARIUS trial. It is administered in the following way:~Ipilimumab: 1 mg/kg is given intravenously every 6 weeks. This dosage is standardized, while the duration of treatment can be adjusted based on patient response and liquid biopsy results."
224169996|NCT06490536|DRUG|Trastuzumab|"Trastuzumab is used as part of the tailored targeted therapy regimen for patients with ctDNA+ results, specifically for those with HER2-amplified tumors in the SAGITTARIUS trial. It is administered in the following way:~Trastuzumab: 8 mg/kg as an initial intravenous (IV) loading dose, followed by 6 mg/kg IV every 3 weeks.~The dosage is standardized, while the duration of treatment can be adjusted based on patient response and liquid biopsy results."
224169997|NCT06490536|DRUG|Pertuzumab|"Pertuzumab is used as part of the tailored targeted therapy regimen for patients with ctDNA+ results, specifically for those with HER2-amplified tumors in the SAGITTARIUS trial. It is administered in the following way:~Pertuzumab: 840 mg as an initial intravenous (IV) loading dose, followed by 420 mg IV every 3 weeks.~The dosage is standardized, while the duration of treatment can be adjusted based on patient response and liquid biopsy results."
224169998|NCT06490536|DRUG|Panitumumab|"Panitumumab is used as part of the tailored targeted therapy regimen for patients with ctDNA+ results, specifically for those with multiple wild-type tumors (MSS/MMRp extended RAS/RAF wild-type) in the SAGITTARIUS trial. It is administered in the following way:~Panitumumab: 6 mg/kg is given intravenously every 2 weeks. The dosage is standardized, while the duration of treatment can be adjusted based on patient response and liquid biopsy results."
224169999|NCT01453933|DRUG|raltegravir|Switch of lopinavir/ritonavir to raltegravir 400 mg BID (duration 8 weeks)
224170000|NCT03012360|DRUG|ceftriaxone|2 g iv every 24h
224170001|NCT03012360|DRUG|ciprofloxacin|400 mg iv every 8h
224170002|NCT03012360|DRUG|imipenem|1 g iv every 8h
223482316|NCT01019993|PROCEDURE|conventional OLV followed with IL-HFPPV|The patients' lungs were mechanically ventilated with intermittent positive pressure ventilation using fraction of inspired oxygen (FiO2) of 0.5 in air, tidal volume (VT) of 8 mL/kg, inspiratory to expiratory \[I: E\] ratio of 1:2.5, zero positive end-expiratory pressure (PEEP), respiratory rate (R.R) was adjusted to achieve an arterial carbon dioxide tension (PaCO2) 35-45 mm Hg and peak inspiratory pressures were limited to 35 cm H2O. After pleurotomy, OLV was initiated with the same ventilatory settings for the dependent lung. After 30 min, the non-dependent collapsed lung was ventilated using HFPPV mode (IL-HFPPV) with another identical ventilator, with an internal circuit of low compliance, using FiO2 of 0.5 in air, VT 3 mL/kg, I: E ratio \<0.3 and R.R 60 breaths/min.
224170003|NCT03012360|DRUG|linezolid|600 mg iv every 12h
224170004|NCT03012360|DRUG|placebo|The SSI 0.9% or dextrose 5% used are based on routine procedure in different participating centers.Placebo will be prepared using IV bags, with the same of quantity as IMP
224170005|NCT04639505|DIAGNOSTIC_TEST|ELISA|ELISA kit detecting the serum AMH level
223482317|NCT04367896|OTHER|Survey Group|"The survey sought to elucidate equity principles that are influencing transplant decision making. The group of respondents included solid organ transplant doctors (surgeons, referring doctors, transplant physicians, transplant coordinators, ICU transplant doctors), COVID-doctors (ICU doctors, Infectious Disease Doctors, Pulmonologists, Internists), and Ethicists with experience of transplant related issues.~Respondent identification:~A. The e-mail addresses of corresponding authors from Scopus January 1, 2017 and march 20, 2020:~All (surgery) AND subj (medi) and key (transplantation), All (critical care) AND subj (medi) and key (transplantation), All (ethics) AND subj (medi) and key (transplantation). B. Emailing through the mailing list of scientific societies. C. The link to the survey published online. D. The link to the survey circulated through personal contacts and via social media sites."
223482318|NCT03336346|DRUG|dolutegravir|HIV integrase strand transfer inhibitor used in combination ART
224170006|NCT04639505|DIAGNOSTIC_TEST|Chemiluminescence|CLIA method detecting the serum AMH level
224170007|NCT02324036|DEVICE|EMPATHy Toolkit|Software-based toolkit to help patients identify and prioritize barriers to medication adherence; community health worker provides participation training to patient
223482319|NCT03336346|DEVICE|ENG implant|Reversible contraception implant
223482320|NCT03336346|DRUG|Efavirenz|non-nucleoside reverse transcriptase inhibitor used in combination ART
223482321|NCT06094465|OTHER|Different phase of the learning curve of RPD|Different phases of the learning curve of RPD (learning phase or proficiency phase)
223482322|NCT05273359|DRUG|Benralizumab|15 subjects (≥220 eosinophils/microliter) will receive benralizumab 100 mg subcutaneous injection every 4 weeks for 4 complete doses.
223482323|NCT05273359|OTHER|Benralizumab placebo|15 subjects (\>220 eosinophils/microliter) will receive a matching benralizumab placebo subcutaneous injection every 4 weeks for 4 complete doses.
223482324|NCT05273359|OTHER|Comparison (control) group; no intervention|15 subjects (\<150 eosinophils/microliter) will not receive any intervention.
223482325|NCT04865809|OTHER|Peribioma Toothpaste and Mousse|Use of Peribioma Toothpaste and Mousse for home oral care.
223482326|NCT04865809|OTHER|Standard toothpaste|Use of Biorepair Plus Parodontgel for home oral care
223585406|NCT01149902|BIOLOGICAL|Cyclophosphamide, Docetaxel, Dendritic cells, OK-432|Cyclophosphamide 50mg/day, day1-7 and 22-28 Docetaxel 30mg/m2, day6 and 27 OK-432 5KE/day, day7,14,28,35
223585407|NCT02476123|BIOLOGICAL|Mogamulizumab: KW-0761, Nivolumab: (ONO-4538/BMS-936558)|i.v. administration
224170008|NCT02324036|BEHAVIORAL|Coached Care|Community health worker provides participation training to patient
224170009|NCT05017168|DRUG|CT-P63|CT-P63 will be administered
224170010|NCT05017168|DRUG|Placebo|Placebo-matching CT-P63
224170011|NCT05448937|PROCEDURE|Lesion sterilization and tissue repair|Pulp therapy for necrotic primary molars
224170012|NCT05448937|PROCEDURE|zinc oxide and eugenol pulpectomy|Pulp therapy for necrotic primary molars
224170013|NCT05379192|OTHER|Group 1, Group 2, Group 3, Group 4|The total amount of antiemetic,the time of first antiemetic use and VAS scores at 1, 2, 3, 6, 9, 12, 15, 18, 21 and 24th hours postoperatively will also be recorded according to circadian rhythm
224170014|NCT00941707|DRUG|JNJ 38518168|JNJ-38518168 100 milligram (mg) capsules orally (by mouth) once daily for 12 weeks.
224170015|NCT00941707|DRUG|Placebo|Placebo capsules matching to JNJ-38518168 orally once daily for 12 weeks.
224170016|NCT00608491|DRUG|Stepped pharmacologic care|Stepped care will provide treating physicians with guidelines for the intensification of diuretic therapy and the possible use of vasodilators and inotropes.
224170017|NCT00608491|DEVICE|Ultrafiltration|All loop diuretics will be discontinued. Treatment will involve slow continuous ultrafiltration until an optimal volume status has been achieved. Ultrafiltration therapy will be initiated after the placement of appropriate intravenous access and will continue until the participant's signs and symptoms of congestion have been optimized. Fluid status will be managed exclusively by ultrafiltration using the Aquadex system 100 (CHF Solutions, Inc.) according to the manufacturer's specifications. The use of vasodilators or inotropic agents will be prohibited unless deemed necessary for rescue therapy.
224170018|NCT03648411|GENETIC|Drug resistance molecular markers|Proportion of the drug resistance molecular markers will be found-out and compared.
224170019|NCT00592072|DIETARY_SUPPLEMENT|Medium chain fatty acid (Octanoic and Decanoic acid)|Octanoic acid(67%) and Decanoic acid (27%); MCFA 50g total at 25 minute intervals with front loading of 20g then 10g for three administrations.
224170020|NCT00592072|OTHER|Splenda (Placebo Control)|Placebo drink will consist of dietary sweetener Splenda mixed in water at a concentration of 1g/100mL. An unsweetened cherry flavor Koolaid mix will be added at a concentration of 0.3g/100mL of the Splenda drink to enhance flavor.
224170021|NCT05002036|DEVICE|Trium eyedrops|given three times daily from day 1 after surgery to end of Week 4
223482327|NCT04264741|DEVICE|repetitive transcranial magnetic stimulation (rTMS)|The iTBS group received 900 pulses per day: 3-pulse 50-Hz bursts given every 200 ms (at 5 Hz), 2 s on and 8 s off for 5 min, at 100% resting motor threshold (rMT), over the left DLPFC (F3, EEG system) (4 weeks, 20 daily sessions). A figure-8-shaped Cool-B70 stimulation coil from MagPro X100 device (MagVenture, Farum, Denmark) was used for accurately targeted stimulation. Motor threshold was determined over the left motor cortex, by finding the lowest intensity that produced a motor response in the right abductor pollicis brevis muscles (APB), which produced five motor-evoked potentials responses of at least 50 mV in 10 trials.
223482328|NCT04264741|DEVICE|sham repetitive transcranial magnetic stimulation (rTMS)|The iTBS group received 900 pulses per day: 3-pulse 50-Hz bursts given every 200 ms (at 5 Hz), 2 s on and 8 s off for 5 min, at 100% resting motor threshold (rMT), over the left DLPFC (F3, EEG system) (4 weeks, 20 daily sessions). A figure-8-shaped sham Cool-B70 stimulation coil from MagPro X100 device (MagVenture, Farum, Denmark) was used for accurately targeted stimulation. Motor threshold was determined over the left motor cortex, by finding the lowest intensity that produced a motor response in the right abductor pollicis brevis muscles (APB), which produced five motor-evoked potentials responses of at least 50 mV in 10 trials.
223482329|NCT04009837|BEHAVIORAL|Hip-focused rehabilitation intervention|The hip-focused intervention includes a blend of hip-focused rehabilitative techniques and some basic lumbar spine-directed techniques. The hip-focused arm includes tailored manual therapy, progressive strengthening exercises, and flexibility exercises for the hip, as well as spinal flexibility and trunk muscle training exercises. The intervention will be delivered by licensed physical therapists in one-hour sessions, twice per week, for 8 weeks.
223482330|NCT04009837|BEHAVIORAL|Spine-focused rehabilitation intervention|The spine-focused rehabilitation intervention is a direct and comprehensive lumbar spine rehabilitative program, but it does not include hip treatment. The spine-focused arm includes spinal manual therapy, spinal flexibility exercises, and trunk muscle training exercises. The intervention will be delivered by licensed physical therapists in one-hour sessions, twice per week, for 8 weeks.
223482331|NCT04270188|OTHER|evolution of patient symptoms|evolution of symptoms on the PGI-I scale (score 1, 2, or 3) 2 months after surgery
223482332|NCT01005381|DIETARY_SUPPLEMENT|Small Particle Size Calcium Carbonate Supplement|Small Particle Size Calcium Carbonate - tablet, 325 mg/tablet. Given once or twice daily depending on study arm.
223482333|NCT01005381|DIETARY_SUPPLEMENT|Large Particle Size Calcium Carbonate Supplement|Large Particle Size Calcium Carbonate Supplement - tablet, 325 mg/tablet. Given twice daily.
223482334|NCT01005381|DIETARY_SUPPLEMENT|Vitamin D|Vitamin D - capsule, cholecalciferol, 1000 IU/tablet. Given once daily.
223482335|NCT01005381|DIETARY_SUPPLEMENT|Calcium Placebo|"Placebo tablets identical to the large and small particle size calcium carbonate tablets.~Given twice daily."
223482336|NCT03579667|BEHAVIORAL|Diet intervention|12-week program of dietary behavior modification treatment (LEVA-method by Bertz et al, Am J Clin Nutr 2012;96:698.), leading to 6 kg weight loss (0.5 kg per week) and a healthier diet (less sugar, snacks, full fat products, more vegetables and fruit, smaller portion sizes). Weight is monitored by phone contact every second week. After 12 weeks, the women are followed up by e-mail contact for 9 additional months.
223482337|NCT05107037|DRUG|TQ-B3234 capsule|TQ-B3234 is an anti-tumor molecular targeted drug, which is a selective Mitogen-activated protein kinase kinase（MEK）1/2 inhibitor
224170022|NCT01071291|DRUG|Niaspan|Niaspan™
224170023|NCT01071291|DRUG|Comparator: Placebo|Placebo
224170024|NCT01149525|DRUG|L-Carnitine|2g oral solution , twice per day (morning/evening), during 3 months
224170025|NCT01149525|DRUG|Placebo|oral solution, twice per day (morning/evening), during 3 months
224305550|NCT04135196|OTHER|voluntary forearm loading task|voluntary task, consisting of leaning onto the palm of the hand until a target force is reached. Each loading bout consists of 100 loading cycles, which takes approximately 2 minutes to complete. The task is performed 4 times per week during the intervention period.
224305551|NCT00001713|DRUG|Recombinant Tissue Plasminogen Activator|
224305552|NCT00001713|DRUG|Heparin|
224305553|NCT00001713|DRUG|Warfarin|
224170026|NCT04732780|OTHER|No intervention|No intervention
224170027|NCT05678504|DEVICE|The phlebotomy procedure|The process of blood collection with a vascular imaging device
224170028|NCT05333289|BIOLOGICAL|mRNA-1030|Sterile liquid for injection
224170029|NCT05333289|BIOLOGICAL|mRNA-1020|Sterile liquid for injection
224170030|NCT05333289|BIOLOGICAL|mRNA-1010|Sterile liquid for injection
223482338|NCT02674659|BEHAVIORAL|resistance training|resistance training consists of lower and upper extremities exercises. We focus on biceps and hamstring to be trained. One session was held for around 30 minutes.
223482339|NCT02674659|BEHAVIORAL|aerobic training|aerobic exercise consists of warming up session, treadmill exercise (around 20-30 minutes), and wrap-up session (for all session about 1 hour)
223482340|NCT04632121|DRUG|Nicorandil 20 MG|Nicorandil is a nicotinamide ester that dilates peripheral and coronary resistance vessels via action on ATP-sensitive potassium channels and possesses a nitrate moiety that promotes systemic venous and coronary vasodilation. As a result of these dual actions, nicorandil reduces preload and afterload and results in an increase in coronary blood flow. In addition to these effects, nicorandil may have cardioprotective actions mediated through the activation of potassium channel
223482341|NCT04561791|DEVICE|Tethered Capsule Endomicroscopy|Participants will be asked to swallow the TCE device. Participants may use mild numbing spray, and lubrication spray to help swallowing. Imaging will be conducted once the TCE device is past the pharynx. The TCE device will be advanced until the stomach and then slowly pull the TCE back up the esophagus. This may be repeated twice.
223482342|NCT03932357|RADIATION|CBCT|measuring soft tissue thickness using a CBCT
223482343|NCT03530696|DRUG|Palbociclib|Palbociclib is to be taken orally on days 5-18 (14 days) of each cycle (each cycle length is 21 days). The starting dose will be 125mg.
223482344|NCT03530696|DRUG|T-DM1|The recommended dose of T-DM1 is 3.6 mg/kg and is given as an intravenous infusion on Day 1 of every cycle (every 21 days).
223585408|NCT05538351|DEVICE|Body Composition Monitor (BCM)|The hydration status of each participant from the clinical assessment and the patient reported signs and symptoms will be compared with the readings from bioimpedance (BCM machine).
223585409|NCT03907033|DRUG|Liposomal bupivacaine|Liposomal bupivacaine is a novel formulation of local bupivacaine and allows prolonged release of the medication, thereby providing longer lasting effects. It is approved by the FDA and has been shown to provide excellent pain control after surgery.
223585410|NCT03907033|DRUG|Bupivacaine Hydrochloride|We currently administer local plain bupivacaine during vaginal hysterectomy to decrease pain in the postoperative period. Bupivacaine is an anesthetic that works by blocking nerve conduction and producing a numbing effect.
223585411|NCT00951405|DRUG|activated recombinant human factor VII, long acting|After an observation period of 3 months, every 2nd day intravenous (i.v.) injection with 25 microgrammes/kg activated recombinant human factor VII, long acting, for 3 months
224170031|NCT05333289|BIOLOGICAL|Active Comparator|Sterile liquid for injection
224170032|NCT04530318|OTHER|Autologous peripheral blood differentiated adult tolerogenic dendritic cells expanded|The infusion of the cells / placebo will take place at the Hospital Clínic de Barcelona (weeks 0, 2 and 4).
224170033|NCT04530318|OTHER|Placebo|The infusion of the cells / placebo will take place at the Hospital Clínic de Barcelona (weeks 0, 2 and 4).
224170034|NCT01047462|PROCEDURE|Surgery for acute perforated diverticulitis|Primary resection vs laparoscopic lavage
224170035|NCT04282967|BEHAVIORAL|Exercise|For the first 12 weeks on study (Part 1), participants will train with an exercise physiologist for 150 minutes/week. This training will be delivered by web-based video conferencing. For the next 12 weeks (Part 2), participants will be instructed to do patient-directed exercise.
224170036|NCT05046236|OTHER|Interactive POWER rehabilitation|Interactive POWER rehabilitation training for twice a week, total 12 weeks, that consisted of 6 types of equipment for strength training.
224170037|NCT05046236|OTHER|Conventical physical training|Conventional physical training models in current clinical use for twice a week, total 12 weeks, that consisted of strength training, balance training, stretching, gait training, and etc.
224170038|NCT03652506|DEVICE|regional oxymetry probe|The regional oxymetry probe will be placed in the abdominal region of the umbilicus in the middle clavicular line before the disease operation begins.
224170039|NCT03652506|PROCEDURE|Quadratus Lumborum block|Ultrasound guided unilateral anterior Quadratus Lumborum block with 20 ml %0.25 bupivacaine+The regional oxymetry probe will be placed in the abdominal region of the umbilicus in the middle clavicular line before the disease operation begins.
224170040|NCT03652506|PROCEDURE|Thoracic Epidural block|Thoracic Epidural block with 20 ml %0.25 bupivacaine+The regional oxymetry probe will be placed in the abdominal region of the umbilicus in the middle clavicular line before the disease operation begins.
224170041|NCT01818128|DEVICE|Neutral shape of bronchial tip|Intubation is performed without transforming the shape of the bonchial tipof a double lumen tube.
224305554|NCT00809159|BIOLOGICAL|AIN457|AIN457A is a fully human recombinant IgG1 antibody that targets and neutralizes IL-17A.
224305555|NCT00809159|DRUG|Placebo|Placebo to AIN457
224305556|NCT02944942|PROCEDURE|General anesthesia|Patients undergoing general anesthesia
224170042|NCT01818128|DEVICE|Bent shape of bronchial tip|Intubation is performed with the double lumen tube, which bronchial tip has been bent 45 degrees and maintained for 5 min.
224170043|NCT01368952|DEVICE|Pure prone positioning|Pure prone positioning device consisted of a pillow mounted on a table designed to keep the subjects sleeping prone.
224170044|NCT02758912|DRUG|оral intake of study drug capsules; study drug - Cardionat ® (trimethylhydrazinium propionate dihydrate), oral capsules 250 mg|
224170045|NCT00215189|BEHAVIORAL|In SHAPE (Pilot Health Promotion Intervention)|
224305557|NCT03201211|BIOLOGICAL|Blood sampling|A volume of approximately 20 mL of whole blood should be drawn from each subject, at each study visit, for antibody determination and assay validation/development.
224305558|NCT03201211|BIOLOGICAL|GSK biologicals investigational NTHi Mcat vaccine containing 10µg of PD, PE-PilA and UspA2.|2 doses, not administered as part of this study but administered at Day 0 and Day 60 during STEP 2 of NTHi Mcat-001 (201281 - NCT02547974) study, to subjects who were then enrolled in this study. Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
224170046|NCT04720560|DIAGNOSTIC_TEST|regulatory B cell by flow cytometry|"4-Evaluation of the Frequency of regulatory B cells (Bregs) by Flow Cytometry Using flow cytometry, circulating Bregs will be detected using FITC-conjugated-CD38, PE-conjugated-CD24 (Bioscience, USA), and PerCP-conjugated CD19 (BD Bioscience, USA). Briefly, 100 µl of blood sample will be incubated with 10 µL of CD24, CD38 and CD19 for 20 minutes at 4 °C in the dark. Following incubation, RBCs will be lysed and washed. Cells will be fixed and permeabilized then stained with APC-conjugated IL-10 (BD Bioscience, San Jose, CA, USA) and analysis will be done by FACS Calibur flow cytometry with CellQuest software (Becton Dickinson Biosciences, San Jose, CA, USA).~An isotype-matched negative control will be used for each sample. Forward and side scatter histograms will be used to define the lymphocytes population. CD19+ IL-10+ B cells will be gated, then the expression of CD38 and CD24 on the CD19+B cells will be detected. Bregs will be identified as CD19+ IL-10+CD24+hiCD38+hi cells."
224170047|NCT01028040|DRUG|AZD3043|Intravenous, single dose
224170048|NCT01028040|DRUG|AZD3043|Infusion, single dose
224170049|NCT01379430|BIOLOGICAL|AdCh63 ME-TRAP followed by MVA ME-TRAP|AdCh63 ME-TRAP 1x10\^10 vp intramuscularly, MVA ME-TRAP 2x10\^8 pfu intramuscularly
223482345|NCT02297126|OTHER|Pharmacogenetic Intervention Arm (pharmacogenetic testing)|In the design of this trial, pharmacogenetic testing will be triggered by the incident prescription of one or more of the targeted medications listed in the control arm. The pharmacogenetic array to be used incorporates 51 genetic variants for the following 16 genes/transporters: ATP-binding cassette sub-family C member 2, ATP-binding cassette, sub-family C, member 4, Cytochrome P450 2B6, Cytochrome P450 2C19, Cytochrome P450 2C9, Cytochrome P450 2D6, Cytochrome P450 3A4/3A5, Cytochrome P450 4F2, Dihydropyrimidine dehydrogenase, Glucose-6-Phosphate Dehydrogenase, Human Leukocyte antigen-B, I interleukin-28B, Inosine Triphosphatase, Solute Carrier Organic Anion Transporter Family, Member 1B, Thiopurine methyltransferase and V vitamin K epoxide reductase complex, subunit 1.
223482346|NCT02472353|DRUG|Metformin|Metformin will begin to be administered prior to treatment with doxorubicin. Metformin will continue to be given throughout doxorubicin cycles until the completion of doxorubicin therapy.
223482347|NCT02472353|DRUG|Doxorubicin|Standard of care treatment with doxorubicin
223482348|NCT05326516|DRUG|Revumenib|Participants will receive revumenib until meeting criteria for discontinuation.
223482349|NCT05326516|DRUG|Chemotherapy Regimen 1|Participants will receive 2 treatment cycles of chemotherapy. During Cycle 1, participants will receive prednisone, vincristine, pegaspargase/calaspargase pegol-mknL, and daunorubicin. During Cycle 2, participants will receive etoposide and cyclophosphamide.
223482350|NCT05326516|DRUG|Chemotherapy Regimen 2|Participants will receive 2 treatment cycles of chemotherapy. During Cycles 1 and 2, participants will receive fludarabine and cytarabine.
223482351|NCT04769297|DRUG|Sublingual Micro-Dose Ketamine|daily micro-dosing of frontline healthcare workers suffering from acute stress disorder due to the COVID-19 pandemic
223482352|NCT03416179|DRUG|glasdegib|"Daily Glasdegib (100 mg, PO), beginning on Day 1 and is to continue up to 2 years post randomization.~Following consolidation therapy, glasdegib or placebo will be administered daily for up to 2 years after randomization or until they have minimal residual disease (MRD) negative disease, whichever comes first.~Daily Glasdegib (100 mg, PO) or matching placebo will continue throughout Induction(s) and Consolidation therapies regardless of dose modifications/delays in the chemotherapy."
223482353|NCT03416179|DRUG|daunorubicin + cytarabine|"'7+3' (cytarabine 100 mg/m2, IV for 7 days by continuous infusion and daunorubicin 60 mg/m2 for 3 days).~If a second induction is needed, Investigators may choose either a 5 day cytarabine continuous infusion plus daunorubicin for 2 days ('5+2') or a 7 day cytarabine continuous infusion plus daunorubicin for 3 days ('7+3');"
223482354|NCT03416179|DRUG|azacitidine|Azacitidine (75 mg/m2, SC or IV) daily for 7 days, in 28 day cycles for as long as they do not meet the criteria for disease progression, unacceptable toxicity, consent withdrawal, or death.
223482355|NCT03416179|DRUG|Placebo|"Matching placebo (PO) given on Day 1 and is to continue up to 2 years post randomization. Following consolidation therapy, placebo will be administered daily for up to 2 years after randomization or until they have MRD negative disease, whichever comes first.~Daily placebo will continue throughout Induction(s) and Consolidation therapies regardless of dose modifications/delays in the chemotherapy."
223482356|NCT03416179|DRUG|Placebo|Matching placebo (PO) is to be administered by mouth daily beginning on Day 1 of chemotherapy and will continue if subjects demonstrate reasonable evidence of clinical benefit and do not meet the criteria for progression regardless of any delays/modifications in the chemotherapy treatment. Subjects will continue placebo until disease progression, unacceptable toxicity, consent withdrawal, or death, whichever comes first.
223482357|NCT03416179|DRUG|glasdegib|"Glasdegib 100 mg PO QD is to be administered by mouth daily beginning on Day 1 of chemotherapy and will continue if subjects demonstrate reasonable evidence of clinical benefit and do not meet the criteria for progression regardless of any delays/modifications in the chemotherapy treatment.~Subjects will continue glasdegib until disease progression, unacceptable toxicity, consent withdrawal, or death, whichever comes first."
223585412|NCT00951405|DRUG|activated recombinant human factor VII, long acting|After an observation period of 3 months, every 2nd day intravenous (i.v.) injection with 100 microgrammes/kg activated recombinant human factor VII, long acting, for 3 months
224170050|NCT01379430|BIOLOGICAL|AdCh63 ME-TRAP followed by MVA ME-TRAP|AdCh63 ME-TRAP 5x10\^10 vp intramuscularly, MVA ME-TRAP 2x10\^8 pfu intradermal
224170051|NCT03374436|BEHAVIORAL|High-Carbohydrate Sedentary|Three high-carbohydrate meals will be consumed (breakfast, lunch, and dinner) at \~3 hour intervals while participants remain in a seated position for the entire 9 hour intervention period.
224170052|NCT03374436|BEHAVIORAL|High-Carbohydrate Active|"Three high-carbohydrate meals will be consumed (breakfast, lunch, and dinner) at \~3 hour intervals while participants remain in a seated position for the entire 9 hour intervention period except that once every hour they will ascend three flights of stairs vigorously (stair climbing sprint snack) for a total of 8 active breaks."
224170053|NCT03374436|BEHAVIORAL|Low-carbohydrate Sedentary|Three low-carbohydrate meals will be consumed (breakfast, lunch, and dinner) at \~3 hour intervals while participants remain in a seated position for the entire 9 hour intervention period. This condition will provide a condition where the blood glucose and insulin responses are relatively low and stable throughout the day.
224170054|NCT01503619|OTHER|laboratory biomarker analysis|Correlative studies
224170055|NCT00810251|DEVICE|MatrixRIB (FDA Approval # K081623)|MatrixRIB implants are comprised of anatomic rib plates and intramedullary rib splints for internal surgical stabilization of rib fractures.
224170056|NCT01297023|DIETARY_SUPPLEMENT|calcium phosphate|20 subjects consume for 8 weeks a bread enriched with calcium phosphate \[1g calcium/d\]
224170057|NCT01297023|DIETARY_SUPPLEMENT|vitamin d|20 subjects consume for 8 weeks a bread with vitamin d3 \[10µg/d\]
224170058|NCT01297023|DIETARY_SUPPLEMENT|calcium phosphate and vitamin d|20 subjects consume for 8 weeks a bread enriched with calcium phosphate \[1g calcium/d\] and vitamin d3 (10µg/d\]
224170059|NCT01297023|OTHER|placebo|All participants consume two weeks before intervention a bread without calcium an vitamin d.
224170060|NCT04568876|DIETARY_SUPPLEMENT|Micronized and ultra-micronized Palmitoylethanolamide (mPEA and umPEA, 300mg + 600mg) oral suspension|Micronized and ultra-micronized Palmitoylethanolamide is on the market in Italy as a Food for Special Medical Purposes
224170061|NCT04568876|COMBINATION_PRODUCT|Standard Therapy|Standard therapy established for individual patients
224170062|NCT02315417|DRUG|gevokizumab|
224170063|NCT02315417|DRUG|Placebo|
224170064|NCT02315417|DRUG|gevokizumab open-label|
224170065|NCT00366938|DRUG|Lumiracoxib|
224170066|NCT03228849|PROCEDURE|Suture anchor technique|Suture anchors were used to attach bony fragment. On week 6, patients were then started on physical therapy for 2 weeks.
224170067|NCT03228849|PROCEDURE|Conservative Treatment|The injured finger was immobilized in an aluminium splint for 6 weeks. Patients were then started on physical therapy for 2 weeks.
224170068|NCT05748236|DRUG|Lamotrigine tablet|Lamotrigine: Starting dose 25mg once daily for 2 weeks, then 50 mg once daily for next 2 weeks . Then dose will be increased until seizure control or side effects develop (Maximum 500 mg/day).
224170069|NCT05748236|DRUG|Carbamazepine-Containing Product in Oral Dose Form|Starting dose 100mg twice daily for 2 weeks, then 200 mg twice daily for next 2 weeks. Then dose will be increased until seizure control or side effects develop (Maximum 1600 mg/day).
224170070|NCT02094625|DRUG|N-Acetylcysteine|"NAC will be administered intravenously over \~60 minutes starting 4 hours following completion of cisplatin chemotherapy.~Three dose levels have been pre-determined:~Dose Level 1: 225 mg/kg Dose Level 2: 300 mg/kg Dose Level 3: 450 mg/kg~Should Dose Level 3 exceed the MTD, the study will examine blood levels of NAC and if below the target blood level necessary for hearing protection, the study will de-escalate from Dose Level 3 to an intermediate Dose Level 2.5 and test a dose of 375 mg/kg.~As of August 2018: Dose escalation completed with MTD not reached. Dose level 3 (450mg/kg) selected for expansion with NAC."
224170071|NCT01099761|BIOLOGICAL|ACE-031 0.5 mg/kg q4wk|ACE-031 0.5 mg/kg subcutaneously once every 4 weeks for 12 weeks.
224170072|NCT01099761|BIOLOGICAL|ACE-031 1.0 mg/kg q2wk|ACE-031 1.0 mg/kg subcutaneously once every 2 weeks for 12 weeks.
224170073|NCT01099761|OTHER|Placebo|Matching volume placebo subcutaneously every 2 or 4 weeks for 12 weeks.
224305559|NCT03201211|BIOLOGICAL|GSK biologicals investigational NTHi Mcat vaccine containing 10µg of PD, 10µg of PE-PilA, and 3.3µg of UspA2.|2 doses, not administered as part of this study but administered at Day 0 and Day 60 during STEP 2 of NTHi Mcat-001 (201281 - NCT02547974) study, to subjects who were then enrolled in this study. Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
224305560|NCT03201211|DRUG|Placebo|2 doses, not administered as part of this study but administered at Day 0 and Day 60 during STEP 2 of NTHi Mcat-001 (201281 - NCT02547974) study, to subjects who were then enrolled in this study. Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
224305561|NCT02612220|PROCEDURE|BioFoam® Surgical Matrix|Complete hemostasis is achieved by direct application of BioFoam® (Cryolife Inc., Kennesaw, GA) to the transection surface area of the liver. In addition, the surgeon may use conventional methods such as argon beam coagulation and warm sponges. If more than one syringe of BioFoam® is required to cover the entire transection surface area, a second syringe maybe used. BioFoam® Surgical Matrix will be used according to the supplier's instructions.
223482358|NCT03416179|DRUG|cytarabine|Consolidation with single agent cytarabine 3 g/m2 IV for adults \<60 years and 1 g/m2 for adults 60 years over 3 BID on Days 1, 3, and 5, every 28 days for up to 4 cycles or alternative single agent cytarabine consolidation schedules may be used per local prescribing information.
224170074|NCT00044694|DRUG|Placebo 0.01 mL|2-week placebo lead-in period (0.01 mL) followed by 4 weeks of Placebo 0.01 mL subcutaneously injected twice daily
224170075|NCT00044694|DRUG|Placebo 0.02 mL|2-week placebo lead-in period (0.01 mL) followed by 4 weeks of Placebo 0.02 mL subcutaneously injected twice daily
224170076|NCT00044694|DRUG|Placebo 0.03 mL|2-week placebo lead-in period (0.01 mL) followed by 4 weeks of Placebo 0.03 mL subcutaneously injected twice daily
224170077|NCT00044694|DRUG|Placebo 0.04 mL|2-week placebo lead-in period (0.01 mL) followed by 4 weeks of Placebo 0.04 mL subcutaneously injected twice daily
224170078|NCT00044694|DRUG|AC2993 2.5 mcg|2-week placebo lead-in period (0.01 mL) followed by 4 weeks of AC2993 2.5 mcg (0.01 mL) subcutaneously injected twice daily
224170079|NCT00044694|DRUG|AC2993 5.0 mcg|2-week placebo lead-in period (0.01 mL) followed by 4 weeks of AC2993 5.0 mcg (0.02 mL) subcutaneously injected twice daily
224170080|NCT00044694|DRUG|AC2993 7.5 mcg|2-week placebo lead-in period (0.01 mL) followed by 4 weeks of AC2993 7.5 mcg (0.03 mL) subcutaneously injected twice daily
224170081|NCT00044694|DRUG|AC2993 10.0 mcg|2-week placebo lead-in period (0.01 mL) followed by 4 weeks of AC2993 10.0 mcg (0.04 mL) subcutaneously injected twice daily
224170082|NCT03193944|DRUG|D-vitin, soft gelatin capsule (vitamin D3,50000 IU)|Intervention group: The respondents in intervention group will receive 50000 vitamin D for 8 weeks. Plus, brochures and pamphlets related to nutrition and health.
224170083|NCT03193944|DRUG|Placebo vitamin D3|vitamin D as a placebo
224305562|NCT02612220|OTHER|Conservative hemostasis|Complete hemostasis will be achieved without the use of topical agents
224305563|NCT03063762|DRUG|Atezolizumab|"Arms A and B Atezolizumab will be administered at a dose of 840 milligrams (mg) prior to RO6874281 administration as an intravenous (IV) infusion on Days 1, 15, 29, and once in 2 weeks from Day 29 onwards. Doses in the extension part will be based on the maximum tolerated dose determined in the escalation part.~Arms C and D Atezolizumab will be administered at a dose of 1200mg as it is a Q3W schedule"
224170084|NCT05859867|OTHER|Promotion of Healthy Nutrition and Physical Activity|Through scheduled and specific activities, enrolled subjects receive information for the promotion of the Mediterranean diet and Mediterranean lifestyle habits, according to the pyramid of the Mediterranean diet. In addition, subjects receive general recommendations about the promotion of regular recreational motor activity, the pyramid of physical activity for pediatric age, and free games appropriate to age. These activities are conducted by professionals in the food (nutritionists) and sports sectors and are aimed in the preparation of simple recipes repeatable at home, and in motor play activities to encourage physical activity. Information regarding clinical, and socio-demographic parameters and family habits will be collected through validated questionnaires.
224170085|NCT06041191|DIAGNOSTIC_TEST|Assessment|The children included in the study were evaluated in terms of hypermobility and then divided into two groups. Children in both groups were evaluated in terms of sensory processing skills.
224170086|NCT03580525|DRUG|Nicotine saline infusion 0.00mcg/kg/s|saline 0.00mcg/kg/s
224170087|NCT03580525|DRUG|Nicotine infusion 0.24mcg/kg/s|nicotine 0.24mcg/kg/s
223482359|NCT03416179|PROCEDURE|HSCT|If required, and done per standard of care post Induction(s).
223482360|NCT05445089|DRUG|Carvacrol|Carvativir 6 mg/ml diluted for oral solution.
223482361|NCT05445089|OTHER|Control group|Placebo
223482362|NCT00042211|BEHAVIORAL|Problem Solving Treatment|Brief Cognitive Behavioral Therapy
223482363|NCT00042211|BEHAVIORAL|Control|No treatment control
223482364|NCT05956743|OTHER|progressive relaxation exercise sessions|"Intervention Group: A total of 6 weeks of planning will be made with the working group.~1. week: Patients included in the study group and meeting the research criteria will be informed about the research. Pre-test data forms for each patient who accepted to participate in the study, Patient Identification Form, Pittsburgh Sleep Quality Index (PUKI) within 30 minutes will be collected.~2. ,3.,4.,5. week: Patients will practice a total of 12 progressive relaxation exercise sessions for 30 minutes, 3 times a week (Monday, Wednesday, Friday) for 4 weeks, accompanied by the training booklet and music player.~6\. week: In the last week of the application, individuals will be called to the hospital and in the Diabetes Polyclinic training room. A final test will be made by the researcher. The Pittsburgh Sleep Quality Index (PUKI) will be reapplied."
224170088|NCT03580525|DRUG|Nicotine infusion 0.096mcg/kg/s|nicotine 0.096mcg/kg/s
224170089|NCT03580525|DRUG|Nicotine infusion 0.048 mcg/kg/s|nicotine 0.048mcg/kg/s
224170090|NCT03580525|DRUG|Nicotine infusion 0.024mcg/kg/s|nicotine 0.024mcg/kg/s
224170091|NCT04925830|BEHAVIORAL|Heart rate variability biofeedback; haemoncephalography biofeedback|Ten 25-minute weekly heart rate variability biofeedback and 30 minute haemoencephalogrphy biofeedback sessions
224170092|NCT01638676|DRUG|Vemurafenib|Vemurafenib (960 mg PO daily) in patients with unresectable BRAFV600E positive Stage IIIC and Stage IV melanoma
223482365|NCT05956743|OTHER|Sham|"1\. week: After informing Sham group patients about the research at the first interview, Patient Information Form, Pittsburgh Sleep Quality Index (PUKI) will be applied.~6\. week: In the 6th week of the study, individuals will be called to the hospital and the post-test Pittsburgh Sleep Quality Index (PUKI) will be re-administered by the researcher in the diabetes outpatient training room. Since the study was terminated after the 6th week, a booklet and music player will be given to the patients. In addition, progressive relaxation exercise training will be given to the patients and the importance of using it in their lives will be explained."
223482366|NCT06330415|OTHER|The SME tool|The intervention comprises of an open-access website targeting the employer of the sick-listed employee. The website provides practical resources, including templates, communication videos and information on legislation, workplace accommodations and most common reasons of sickness absence.
223482367|NCT06519630|DEVICE|Rehabotics Physiotherapy|The intervention will be consisted of sessions for participants in the intervention group which includes a repetition of each of the four Sollerman AR Games named, Wallet, Key, Jar, Screwdriver and one repetition of Balloon Pop. Participants will interact with the AR Box and Block Test (BBT) and the serious games under controlled conditions. A clinician will be present throughout the whole session providing help if participants encounter any difficulties. Following the games, the clinician will initiate a stretching program using the Active Exoskeletal Aid, performing 3 sets of 10 repetitions on the finger flexors of the patient's hand. Each rehabilitation session will last 30 minutes and will be conducted three times a week. Similarly, the traditional physiotherapy training program will be prescribed for the control group and will be consisted of sessions lasting 30 minutes per day, three days per week. Both programs duration will be five weeks.
223482368|NCT06519630|OTHER|Traditional Physiotherapy|Similarly, the hand functional training program prescribed for the control group consisted of sessions lasting 30 minutes per day, three days per week. Both programs lasted for five weeks and were designed by two clinical experts.
223482369|NCT00475332|DRUG|Iodine I -01 Tositumomab (Bexxar)|"Patients will be treated in two dosing phases, each phase includes two infusions. The first phase, termed dosimetric dose, involves an intravenous administration of 450 mg unlabeled tositumomab followed by an intravenous administration of 5 mCi (0.18 GBq) of I-131 tositumomab for the purpose of determining the rate of whole body clearance of radioactivity (residence time) so that the administered activity (mCi or GBq) to deliver a 75 cGy (or 65 cGy for patients with baseline platelet count from 100,000 to 149,999/mm\^3) total body radiation dose can be calculated."
223482370|NCT00475332|PROCEDURE|External Beam Radiation Therapy|All patients are to receive 20 Gy in 10 fractions of 200 cGy to the PTV
223482371|NCT01334359|BEHAVIORAL|Physical Activity|9-month afterschool program designed to increase physical activity and aerobic fitness.
223482372|NCT05209919|DIAGNOSTIC_TEST|Transthoracic Echocardiography|All patients undergo physical examination, ECG, Transthoracic Echocardiography, six minutes walking test and blood sample (natruretic peptides, renal and liver function)
223482373|NCT03134768|OTHER|This is not an interventional study|This is an observational study
223482374|NCT00325637|DRUG|cilnidipine|Cilnidipine 10\~20mg, qd, po for 4 weeks.
224170093|NCT01638676|DRUG|Metformin|Metformin (500 mg PO BID x 2 weeks, then 850 mg PO BID)
224170094|NCT04152668|PROCEDURE|Titanium curette.|Implant debridement.
224170095|NCT04152668|PROCEDURE|Ultrasonic|Implant debridement.
224170096|NCT04152668|PROCEDURE|Air-polishing|Implant debridement and polishing.
224170097|NCT03398824|DRUG|metformin HCl|Receive metformin HCl
224170098|NCT03336203|DRUG|Febuxostat 80 MG Oral Tablet or Allopurinol 300 MG Oral Tablet|treatment either with allopurinol or febuxostat
224170099|NCT01359111|DEVICE|PATH ID Adapter|Intradermal delivery device which fits on the end of a syringe to limit the depth and angle of needle penetration into the skin.
223482375|NCT01369550|OTHER|SDA soybean oil-containing foods|3 servings per day of foods containing 500 mg each SDA soybean oil plus 3 x 500 mg high-oleic sunflower oil in softgels per day.
223482376|NCT01369550|OTHER|High-oleic sunflower oil containing foods|3 servings per day of foods containing 500 mg high-oleic sunflower oil plus 3 x 500 mg high-oleic sunflower oil in softgels per day
223482377|NCT01369550|OTHER|Eicosapentaenoic acid|3 x 500 mg per day of Eicosapentaenoic acid as an ethyl ester in softgels plus 3 servings per day of high-oleic sunflower oil-containing foods
223482378|NCT01481467|BEHAVIORAL|Influenza vaccination implementation strategy|A multi-faceted influenza vaccination implementation strategy
223482379|NCT06429709|DEVICE|Advanced Ultrasound Otoscope|The Advanced Ultrasound Otoscope is a tool for visualization of the human tympanic membrane and detection of middle ear effusion type
223482380|NCT05523596|DRUG|ICM20|small molecules
223482381|NCT05523596|DRUG|Benznidazole|small molecule
223482382|NCT06275087|DRUG|Propofol|The experimental group will not receive volatile anesthetic, instead, they will receive propofol infusion
223482383|NCT06275087|DRUG|Sevoflurane|The control group will not receive TIVA, instead, they will receive sevoflurane via inhalation
223482384|NCT05043324|DRUG|AntiCov-220|The daily maintenance, AntiCov-220 dose is to take 3 times a day, 1 tablet each time.
223482385|NCT05043324|DRUG|AntiCov-220 (placebo)|The daily maintenance, AntiCov-220 (placebo) dose is to take 3 times a day, 1 tablet each time.
223482386|NCT05171686|DRUG|Diuretic augmentation (hydrochlorothiazide, chlorthalidone, furosemide, torsemide, or bumetanide)|The participant's blood pressure medication regimen will then be altered to initiate a thiazide-type (hydrochlorothiazide or chlorthalidone) or loop diuretic (furosemide, bumetanide, or torsemide) in those not already prescribed a diuretic, or to increase the dose if one is already prescribed
223744972|NCT00302458|DRUG|Immediate Release Methylphenidate|Each dose of IR MPH will be 40 mg which will be supplied as two 20 mg overencapsulated capsules
224170100|NCT04063397|DIAGNOSTIC_TEST|Echocardiogram|Serial echocardiograms will be done on all patients pre-delivery, and at 3-6 months
224170101|NCT04063397|DIAGNOSTIC_TEST|Blood draw|Serial blood draws at same time points as echocardiograms for biomarker levels
223482387|NCT06830109|DRUG|Oxymetazoline Nasal Spray|Intra-nasal alpha-adrenergic agonist and vasoconstrictor that is available over-the-counter (OTC)
223482388|NCT06830109|DRUG|Budesonide nasal spray|Intranasal corticosteroid that is available over-the-counter (OTC)
224170102|NCT02111070|BIOLOGICAL|IL-YANG FLU Vaccine|0.5mL
224170103|NCT00957190|DRUG|Dorzolamide 20 mg and Timolol 5 mg|Twice daily in the affected eye(s)
224170104|NCT05937490|DRUG|Enantone|administration of depot leuprorelin 3.75 mg on day 21 of the previous luteal phase of the stimulation cycle.
224170105|NCT05937490|DRUG|Dienogest 2 MG (milligram)|Before COH, patients will be treated with DNG at high dose (2 mg+2 mg/day) for 28 days, from the first day of previous menstrual cycle. COH will be performed using a long GnRH agonist protocol (administration of depot leuprorelin 3.75 mg on day 21 of the previous luteal phase of the stimulation cycle).
224170106|NCT05937490|DRUG|Enantone|COH will be performed using a ultra-long GnRH agonist protocol (administration of the first depot leuprorelin 3.75 mg on day 21 of menstrual cycle, repeated after 28 days for other two times).
224170107|NCT05937490|DRUG|long GnRH agonist or flexible GnRH antagonist protocol.|During TV-US monitoring, when at least one follicle reached 14 mm in diameter, to achieve LH suppression avoiding spontaneous ovulation, GnRH antagonist 0.25 mg/day will be added subcutaneously until the day of HCG administration.
224170108|NCT03137056|DEVICE|Hemodialysis with Theranova|"Theranova is a polyarylethersulfone-based hemodialysis membrane manufactured by Baxter International Corp All the dialysis sessions in this arm will be performed with the theranova membrane. This membrane will exclusively be used in hemodialysis.~Modalities of hemodialysis : Blood flow: 300-400 mL/min; Dialysate flow: 500-800 mL/min"
223482389|NCT03456934|OTHER|Modified infant formula|Test formula with lower protein content than standard formula
223482390|NCT03456934|OTHER|Standard infant formula|Standard infant formula
223482391|NCT01911949|DRUG|Single shot femoral nerve block|Nerve block in lingual crease using ultrasound guidance
223482392|NCT05156008|OTHER|Ultrasound-guided vascular access|Patients in this arm will have peripheral venous cannula inserted under realtime ultrasound guidance. Out of plane technique (in plane technique if too deep when tip of the needle is on vessel wall) used by experienced physicians in UGVA. Out of plane technique strictly used in step by step manner. That means moving probe with the tip of the needle to always locate its exact position, all the way into the vein. All performed insertions are carried out by skilled operators in UGVA with out of plane technique. Just before surgery in block room.
224170109|NCT03137056|DEVICE|Hemodialysis with FX1000|"FX1000 is a helixone-based membrane manufactured by Fresenius All the dialysis sessions in this arm will be performed with the FX1000 membrane. This membrane will be used in hemodialysis.~Modalities of hemodialysis: Blood flow: 300-400 mL/min ; Dialysate flow: 500-800 mL/min"
223482393|NCT06846281|DRUG|Remibrutinib oral treatment|Remibrutinib tablet taken daily
223482394|NCT06846281|DRUG|Ocrelizumab|Ocrelizumab 600mg infusion or 920mg injection
223482395|NCT06850402|DEVICE|DeepDOF Images|Women referred for consultation for cervical biopsy(ies) and/or LEEP will be recruited into the experimental group of the study.
223482396|NCT06041789|DRUG|Donepezil|10 mg tablet
223482397|NCT06041789|DRUG|Memantine|10 mg tablet
223482398|NCT04727619|BEHAVIORAL|SLEEP program|SLEEP is a 6-week educational program designed to improve sleep hygiene and habits.
223482399|NCT01840111|BEHAVIORAL|Quit Smoking 6 hours|participants will quit smoking 6 hours prior to the cue-exposure sessions
223482400|NCT01840111|BEHAVIORAL|Quit Smoking 24 hours|participants will quit smoking 24 hours prior to the fMRI scan
223482401|NCT01850992|DEVICE|Active CPAP|Effective CPAP will be administered
223482402|NCT01850992|DEVICE|Sham CPAP|This is placebo CPAP
223482403|NCT05989152|RADIATION|FDG-PET at the end of treatment for IE|FDG-PET at the end of treatment for IE in patients with a prosthetic valve
224170110|NCT03137056|DEVICE|Hemodiafiltration with FX1000|FX1000 is a helixone-based membrane manufactured by Fresenius All the dialysis sessions in this arm will be performed with the FX1000 membrane. This membrane will be used in hemodiafiltration Modalities of hemodialysis: Blood flow: 300-400 mL/min; Dialysate flow: 500-800 mL/min ; post reinjection convection volume of at least 25L.
224170111|NCT00275106|DRUG|asparaginase|
224170112|NCT00275106|DRUG|cyclophosphamide|
224170113|NCT00275106|DRUG|cytarabine|
224170114|NCT00275106|DRUG|daunorubicin hydrochloride|
224170115|NCT00275106|DRUG|dexamethasone|
224170116|NCT00275106|DRUG|doxorubicin hydrochloride|
224170117|NCT00275106|DRUG|leucovorin calcium|
223585413|NCT00951405|DRUG|activated recombinant human factor VII, long acting|After an observation period of 3 months, every 2nd day intravenous (i.v.) injection with 200 microgrammes/kg activated recombinant human factor VII, long acting, for 3 months
223585414|NCT02393053|PROCEDURE|Treatment with subepithelial connective tissue graft (SCTG)|Miller Class I or II gingival recessions were treated with subepithelial connective tissue graft (SCTG)
223585415|NCT02393053|PROCEDURE|Treatment with non-pedicled buccal fat pad graft (BFPG)|Miller Class I or II gingival recessions were treated with non-pedicled buccal fat pad graft (BFPG)
223585416|NCT01174173|DRUG|Ranolazine|ranolazine 1000 mg PO BID for 3 months
223585417|NCT00595816|OTHER|physical training and counselling|Neuromuscular training program 3 times per week 30 minutes per session and counselling on back problems and other musculosceletal injuries
224170118|NCT00275106|DRUG|mercaptopurine|
224170119|NCT00275106|DRUG|methotrexate|
224170120|NCT00275106|DRUG|prednisolone|
224170121|NCT00275106|DRUG|thioguanine|
224170122|NCT00275106|DRUG|vincristine sulfate|
224170123|NCT00275106|PROCEDURE|radiation therapy|
224170124|NCT01666015|OTHER|EXERCISE (EX)|"This study will examine the effect of two phases of an EX program on several health related outcomes in pediatric patient undergoing autologous SCT. The first phase of the EX program will be an inpatient intervention and will begin when the child is hospitalized undergoing conditioning therapy and will continue until discharge.~The second phase will be a 10-week outpatient intervention, beginning once the child is discharged. We will utilize a mixed EX program, including supervised (at the University of Calgary) and home-based training incorporating the use of the Nintendo ® Wii device™ (Wii Fit, Wii Dance and Sports™ games)."
224170125|NCT01666015|OTHER|Standard Care|This group will be under standard care without any EX intervention.
224170126|NCT04662645|OTHER|Palliative Therapy|Undergo embedded palliative care
224170127|NCT04662645|OTHER|Questionnaire Administration|Ancillary studies
224170128|NCT00906828|DRUG|levodopa/carbidopa|intestinal gel, continuous infusion (daytime or 24-hour)
224170129|NCT00906828|DRUG|entacapone|Tablet, 200 mg, given twice during the study at t=0h and t=5hrs
224170130|NCT00906828|DRUG|tolcapone|Tablet, 100 mg, given twice during study, at t=0h and t=5hrs.
224170131|NCT05242809|BEHAVIORAL|Group-based PFMT group|The intervention group receives PFMT supervision in groups of about 6-8 women
224170132|NCT05651074|DRUG|Vicagrel and omeprazole|18 mg vicagrel capsules and 40 mg omeprazole magnesium enteric-coated tablets
224305564|NCT03063762|DRUG|Bevacizumab|"Arms A and B Bevacizumab will be administered at a dose of 10 milligrams per kilogram (mg/kg) after the atezolizumab administration, and prior to RO6874281 administration as an IV infusion on Days 15, 29, and once in 2 weeks from Day 29 onwards.~In Arm D, Bevacizumab will be administered at a dose of 15mg/kg on Day 8 of Cycle 2 and on Day 8 of each consecutive cycle."
224305565|NCT03063762|DRUG|RO6874281|"Arms A and B RO6874281 will be administered as an IV infusion on Days 1, 8, 15, 22, and 29, and once in 2 weeks from Day 29 onwards. Starting dose of RO6874281 will be 5 mg, and will be increased subsequently. Doses in the extension part will be based on the maximum tolerated dose determined in the escalation part.~In Arms C and D, RO will be administered on Q3W schedule at the dose defined in the dose escalation part"
224305566|NCT04407091|DRUG|14C]AZD4831 Oral Solution|10 mg dose of \[14C\]AZD4831 Oral Solution
224305567|NCT01083810|DRUG|Lopinavir/Ritonavir (Kaletra)|3 capsules 2xdaily or 2 tablets 2xdaily Kaletra
224305568|NCT05215080|DIETARY_SUPPLEMENT|Organic Formula Milk|Organic formula milk is given to the infants three times a day for three months. Each serving contains 7 spoons (1 spoon contain 4,6 grams) of milk powder and 210 ml of water.
224305569|NCT03347760|DRUG|DOTATOC-68Ga PET initial|DOTATOC is a tracer of high affinity for the type 2 somatostatin receptors and is used for imaging of tumours which are expressing them, including endocrine tumours
224305570|NCT03347760|DRUG|DOTATOC-68Ga PET at 6 months|DOTATOC is a tracer of high affinity for the type 2 somatostatin receptors and is used for imaging of tumours which are expressing them, including endocrine tumours
224305571|NCT03347760|BIOLOGICAL|blood sample|blood tests will be carried out during the control visit to ensure that biological parameters are normalized
224170133|NCT05086094|DRUG|BHV3241, verdiperstat|BHV3241/Verdiperstat 600mg BID
224170134|NCT01651676|OTHER|VQ11 validation|"Two visits per patient are planned: V1 and V2.~For each visit, the pulmonologists ask the patients participating in the study to fill out the VQ11 questionnaire, which will be correlated to the other parameters (Likert scale, IPAQ, RFE, SGRQ,...)~LABD treatment consist in β 2 agonists or anticholinergic drug."
224170135|NCT04856969|DRUG|Olmesartan|First stage: ATB-1011 for 5days, repeated administration, Second stage: ATB-1012 + ATB-1011 for 5days, repeated administration
224170136|NCT04856969|DRUG|Dapagliflozin|First stage: ATB-1012 for 5days, repeated administration, Second stage: ATB-1012 + ATB-1011 for 5days, repeated administration
224170137|NCT01688427|BEHAVIORAL|Standard IPV Assessment|Test the effectiveness of the eMOCHA DOVE application using mHealth technology for routine assessment of IPV vs. Pencil and paper at enrollment, delivery, and 2 months post birth.
224170138|NCT01688427|BEHAVIORAL|Standard DOVE Intervention|Intervention will be administered via eMOCHA tablet vs. home visitor over 6 sessions in 6 months.
224170139|NCT04738240|DIAGNOSTIC_TEST|Intra-operative endoscopy|Intra-operative endoscopy to assess rectal anastomosis
224170140|NCT02002624|DEVICE|PSI|
224170141|NCT02002624|DEVICE|Conventional instrumentation|
224170142|NCT03858686|DRUG|FP-025 capsules|FP-025 capsules, BID will be administered to subjects in either Period 1 or Period 2, and given for 12 consecutive dosing days.
224170143|NCT03858686|DRUG|Placebo FP-025 capsules|Placebo FP-025 capsules, BID will be administered to subjects in either Period 1 or Period 2, and given for 12 consecutive dosing days.
224170144|NCT01045551|DRUG|Apremilast|20mg taken orally twice per day for 12 weeks
224170145|NCT03651128|BIOLOGICAL|bb2121|bb2121
224170146|NCT03651128|DRUG|Daratumumab|Daratumumab
224170147|NCT03651128|DRUG|Pomalidomide|Pomalidomide
224170148|NCT03651128|DRUG|Dexamethasone|Dexamethasone
224170149|NCT03651128|DRUG|Bortezomib|Bortezomib
224170150|NCT03651128|DRUG|Ixazomib|Ixazomib
224170151|NCT03651128|DRUG|Lenalidomide|Lenalidomide
224170152|NCT03651128|DRUG|Carfilzomib|Carfilzomib
224170153|NCT03651128|DRUG|Elotuzumab|Elotuzumab
224170154|NCT00290680|DRUG|bortezomib|
224170155|NCT00290680|DRUG|celecoxib|
224170156|NCT02415829|DRUG|capecitabine plus oxaliplatin|The neoadjuvant chemotherapy consisted of oxaliplatin, 130 mg/m² on day 1, with capecitabine, 1000 mg/m² twice daily for 14 days every 3 weeks (the XELOX regimen)
224170157|NCT04453891|DEVICE|Monitoring physiological data with the Hexoskin smart shirt|Participants will be monitored using a validated biometric garment (Hexoskin smart shirt). Cardiorespiratory and activity data will be collected over a 28-day monitoring period. Participants will be invited to wear the shirt during the day and at night.
224170158|NCT03832023|OTHER|Screening and initiating preventive therapy in communities|Symptom-based screening of tuberculosis household child contacts by community health workers; initiation of preventive therapy (3 months of a fixed-dose combination of rifampicin-isoniazid or 6 months isoniazid for HIV+ children on protease inhibitors) in the household by a nurse; follow-up of children under preventive therapy by a community health worker for eligible children at community level, and referral of presumptive tuberculosis cases (children and adults) to the facility.
224170159|NCT01626755|PROCEDURE|Sciatic name block|Ultrasound-guided sciatic nerve block.
224170160|NCT03231228|DRUG|Cefazolin 1 g Infusion|1 g cefazolin infusion for pediatric surgical subjects weighing ≥25 to \<60 kg
224170161|NCT03231228|DRUG|Cefazolin 2 g Infusion|2 g cefazolin infusion for pediatric surgical subjects weighing at least 60 kg
224170162|NCT03061227|DRUG|Intravenous glucagon|Randomized application of glucagon or saline during oral glucose tolerance test
224170163|NCT03061227|DRUG|Intravenous saline|Randomized application of glucagon or saline during oral glucose tolerance test
224170164|NCT05686876|DRUG|68Ga-FAPI|Intravenous injection of one dosage of 74-148 MBq (2-4 mCi) 68Ga-FAPI. Tracer doses of 68Ga-FAPI will be used to image lesions of PsA by PET/CT.
224170165|NCT02299206|DRUG|CeraVe Baby Diaper Rash Cream|Parents/caregivers of subjects will administer CeraVe Baby Diaper Rash Cream (ingredients: Zinc oxide 10mg in 1g (1%) and dimethicone 10mg in 1g) with each diaper change throughout the course of the study period. The product can be applied liberally as needed. Diapers and skin cleansing interventions will stay constant throughout the treatment period.
224170166|NCT02299206|DRUG|Desitin Maximum Strength Original Paste|Parents/caregivers of subjects will administer Desitin Maximum Strength Original Paste (ingredients: Zinc Oxide 40%) with each diaper change throughout the course of the study period. The product can be applied liberally as needed. Diapers and skin cleansing interventions will stay constant throughout the treatment period.
224170167|NCT05254925|DRUG|Sunscreen oil with 6% Bemotrizinol|Sunscreen oil with 6% BEMT (PARSOL® Shield) and 10% ethanol as penetration enhancer
224170168|NCT05254925|OTHER|Sunscreen oil vehicle|Sunscreen oil vehicle with 10% ethanol as penetration enhancer without BEMT (BEMT replaced by Isopropylmyristate)
224170169|NCT05254925|DRUG|Dispersion of 6% BEMT in petrolatum|Dispersion of 6% BEMT (PARSOL® Shield) in petrolatum
224170170|NCT05254925|OTHER|Petrolatum vehicle|Petrolatum vehicle
224170171|NCT03566498|DIETARY_SUPPLEMENT|Immediate hydration|They will be allowed to start oral fluids immediately (within the first 2 hours post operatively) beginning with water or clear fluids (but not milk or soda containing drinks), the amounts will be according to their needs, solid food will be given gradually after tolerating the drinks and intravenous fluids will be given beside all of that and till the return of intestinal movements
223585418|NCT01908439|OTHER|whole-body vibration|High amplitude whole-body vibration
223585419|NCT02291926|BIOLOGICAL|Human umbilical cord mesenchymal stem cells|A single dose of 2×107 hUC-MSC will be implanted to patients by intra-articular injection, and repeated every month for four times.
224170172|NCT03566498|DIETARY_SUPPLEMENT|Early hydration|They will receive the routine intravenous fluids and the oral fluids will be given after 8 hours post operatively and gradually, solid food will be allowed after that gradually too and the intravenous fluids will be stopped after return of intestinal movements.
224170173|NCT02033291|PROCEDURE|Dynamic contrast enhanced Brain MRI|DCE-MRI is used to quantify the BBB permeability
224170174|NCT03053713|BEHAVIORAL|Mediterranean diet pattern|Subjects assigned to the Mediterranean diet pattern arm will receive nutrition advice from a Registered Dietitian (RD). The RD will meet with the subjects (in-person) to provide diet education at randomization, week 3 and week 6 of the intervention. Phone and e-mail follow-up will occur at week 2 and week 9 to provide cooking tips, recipes, videos and answer questions.
224170175|NCT03053713|BEHAVIORAL|Habitual diet (control)|Subjects assigned to follow their habitual group will be instructed to make no changes to their diet over 12 weeks.
224170176|NCT04033380|DEVICE|Resin blocs (Grandio Blocs, VOCO)|composite-base bloc (Grandio Blocs, VOCO)
224170177|NCT04033380|DEVICE|Ceramic (Suprinity, VITA)|glass ceramic zirconia enhanced lithium silicate glass ceramics (Suprinity, VITA)
224170178|NCT01744340|DRUG|Head and neck|"Eribulin mesylate is administered by IV infusion over 2-5 minutes on day 1 and 8 of a 21 day cycle 1.4mg/m2 and Cetuximab 400 mg/m2 cycle 1 week 1, then 250 mg/m2/weekly thereafter~Dose Level 1: 0.7 mg/m2 IV infusion days 1 and 8 of 21 day cycle Dose Level 2: 1.0 mg/m2 IV infusion days 1 and 8 of 21 day cycle Dose Level 3: 1.4 mg/m2 IV infusion days 1 and 8 of 21 day cycle"
224170179|NCT01744340|DRUG|Colon- Closed as of May 2014|"Eribulin Mesylate:~1.4 mg/m2 IV infusion days 1 and 8 of 21 day cycle"
224170180|NCT00781183|OTHER|pulmonary rehabilitation|6-weeks of in-patient pulmonary rehabilitation or 12-weeks of out-patient pulmonary rehabilitation
224170181|NCT06166251|BEHAVIORAL|low ıntensity aerobic exercise|The exercise intervention was 30 min of treadmill jogging/running. After a two-minute warm-up walk at 1.0 m/s, the treadmill speed was increased to 57-63% maximum heart rate.
224170182|NCT06166251|BEHAVIORAL|moderate ıntensity aerobic exercise|The exercise intervention was 30 min of treadmill jogging/running. After a two-minute warm-up walk at 1.0 m/s, the treadmill speed was increased to 64-76% maximum heart rate.
224170183|NCT00779597|BEHAVIORAL|SCION (Self care improvement through oncology nursing)-PAIN program|The intervention will be conducted by specially trained oncology nurses and will include the components of knowledge, skills training, and coaching to improve self care regarding pain management beginning with admission followed by booster session every third day and one follow up telephone counseling within 3 to 4 days after discharge from hospital.
224170184|NCT02621281|DEVICE|Kidney Transporter machines|Kidney Transporter gently pumps the special cold solution through the kidney which outside the body.
224170185|NCT02621281|DEVICE|cold storage|The kidneys procurement from the donor will be cold stored using some cold preservation solution.
224170186|NCT04337203|BEHAVIORAL|SHARE-S Implementation Program|The program consists of three components: An electronic referral among clinical teams for potential participants, patient engagement with survivorship care planning guidelines through self-management/health coaching. One coaching call before a clinic visit (60 minutes) and two coaching calls after the clinic visit (30 minutes each). Participants will also receive automated, tailored text messages (daily for three weeks before and after a clinic visit for a total of six weeks).
223482404|NCT06309394|DRUG|INCB099280|INCB099280 will be administered orally, followed approximately 10 minutes later by an oral dose solution of radiolabeled INCB099280.
223482405|NCT06645158|DEVICE|Transcutaneous bilirubin level monitoring|self-monitoring by parents long-term: from birth to 30 days of age
223482406|NCT04556747|OTHER|VR - Distraction|Participants will be instructed to use any application.
223482407|NCT04556747|OTHER|VR - Biofeedback|Participants will be instructed to use the Mindful Aurora application.
223482408|NCT02266524|DRUG|Tamsulosin hydrochloride, very low dose|
223482409|NCT02266524|DRUG|Tamsulosin hydrochloride, low dose|
223482410|NCT02266524|DRUG|Tamsulosin hydrochloride, medium dose|
223482411|NCT02266524|DRUG|Tamsulosin hydrochloride, high dose|
223482412|NCT03609177|OTHER|Clinician Communication Skills Training|Communication skills training
223482413|NCT03609177|OTHER|Advance Care Planning (ACP) Decisions Videos Decisions Aids|ACP Decisions video decision aids
223482414|NCT03609177|OTHER|Video Declarations (ViDec)|Recording of patient advance care planning videos
223482415|NCT00888745|DRUG|placebo|Intravenous and subcutaneous ascending dose
223585420|NCT05981183|DEVICE|Transcutaneous electrical nerve stimulation unit (TENS)|The TENS unit will be applied to participants' right ear at the cymba conchae. The dose is dependent on which arm (Intervention A or Intervention B) the participant is assigned to. Participants will undergo 15 minutes of vagal nerve stimulation.
224170187|NCT01352624|BEHAVIORAL|$AFE|$teps for Achieving Financial Empowerment ($AFE) is an individualized, psycho-educational intervention that aims to teach veterans with psychiatric disabilities how to save money, create a viable budget, avoid money scams and financial exploitation, and access vocational and mental health resources.
224170188|NCT04670042|DEVICE|SPRINT® Peripheral Nerve Stimulation (PNS) System (510k Cleared)|Same as Arm Description.
223482416|NCT00888745|DRUG|PRO283698|Intravenous and subcutaneous ascending dose
223482417|NCT03097263|OTHER|Physical Rehabilitation program|
223482418|NCT06356493|PROCEDURE|caesarean hysterectomy with prior placement of prophylactic occlusion balloons of both internal iliac arteries|Preoperative placement of prophylactic occlusion balloons of both internal iliac arteries (OBIIA) was performed at radiology department. Access to the internal iliac arteries was achieved by retrograde transcutaneous introduction of hydrophilic sheath kits of 8.5 mm under fluoroscopic guidance from both femoral arteries. Once in the lumens of the two internal iliac arteries, the radiologist inflated the balloons until blood flow ceased. The pressure at which occlusion of both internal iliac arteries was achieved was recorded for subsequent replication in the operating room. The radiologist secured the two kits to the skin and applied a compressive dressing. The patient was then directly transferred to the operating room.
223482419|NCT06356493|PROCEDURE|caesarean hysterectomy without prior placement of prophylactic occlusion balloons of both internal iliac arteries|"Caesarean hysterectomy was performed through a midline infraumbilical incision. The bladder-uterine peritoneum was dissected, followed by a vertical fundal hysterotomy away from the placenta, and the baby was delivered This was followed by clamping the umbilical cord and closure of the hysterotomy while leaving the placenta in situ without any attempt at traction or delivery and without oxytocin administration.~We proceeded with the remaining steps of hysterectomy."
223585421|NCT05549557|DRUG|IMM40H|IMM40H is a monoclonal antibody with a molecular generated from ImmuneOnco's antibody platform. IMM40H targets CD70 (a tumor cell marker).
223585422|NCT04483336|OTHER|Virtual Reality Distraction|Virtual reality goggles are commercially available wearable devices that are used to view view videos and play video games three dimensionally.
223585423|NCT04483336|OTHER|TV Screen Distraction|A cartoon video was played on a regular TV screen.
223585424|NCT01372176|OTHER|Early Goal-Directed Nutrition|"1. Initiation of early supplementary parenteral nutrition (≤ 24 hours of admission).~2. Measurement of requirements (indirect calorimetry, 24-hour urinary urea) leading to patient-specific, individualised and goal-directed nutritional therapy.~3. Intervention goal: delivering 100% of patient-specific requirements, measured or calculated throughout entire admission (EN+PN)."
223585425|NCT01372176|OTHER|ASPEN-guidelines|EN will be the preferred route of nutrition, and will be initiated within the first 24 hours of ICU admission, in accordance with best evidence. The amount is gradually increased over the first days of admission as tolerated by the patient (assessed from gastric aspirates). If EN fails to reach calculated goals at day 7, supplementary PN will be initiated at admission day 8 to reach goals. Protein and energy goals will be calculated as 25 kcal/kg/day and 1.2 g protein/kg/day.
223585426|NCT04558359|OTHER|Standard of Care|These patients will receive standard of care treatment. Plasma renin levels and biomarkers of renal function will be measured.
223585427|NCT04558359|DRUG|Angiotensin II|These patients will receive angiotensin II in addition to standard of care treatment. Plasma renin levels and biomarkers of renal function will be measured.
223744973|NCT00302458|DRUG|Placebo|Placebo will be administered during the first part of the day, and again during the second part of the day.
224170189|NCT04002206|OTHER|Muscle Energy Technique|In experimental group, post-isometric relaxation technique has given to the athletes. The position of athlete was prone and the involved group of muscle was quadriceps. Firstly end range of the quadriceps muscle group assess and guide the athlete to put 20% of their maximum voluntary contraction and physiotherapist resist the athlete and isometric contraction of quadriceps remain for 6-10 seconds
224170190|NCT04002206|OTHER|Static Stretch|Control group has treated with static stretching after the pre-assessment that includes three repetitions with duration of fifteen seconds with twenty second rest intervals on lower extremities
224170191|NCT01682759|DRUG|Omarigliptin|
224170192|NCT01682759|DRUG|Placebo to Omarigliptin|
224170193|NCT01682759|DRUG|Glimepiride|Glimepiride (1 mg and/or 2 mg tablets). During the 54-week double-blind treatment period, glimepiride can be up-titrated, as appropriate, to a maximum total daily dose of 6 mg/day. Throughout the trial, down-titration of glimepiride may also occur based upon the participant's glucose measurements and clinical symptoms of hypoglycemia.
224170194|NCT01682759|DRUG|Glimepiride Placebo|
224170195|NCT01682759|DRUG|Metformin|Participants will continue on their stable dose (\>=1500 mg/day) of open-label metformin throughout the trial.
224170196|NCT01682759|DRUG|Insulin Glargine|Insulin glargine can be used for rescue therapy, if glycemic control is not maintained. Insulin therapy should be initiated as per local country insulin glargine label.
224305572|NCT01174082|BIOLOGICAL|KLH Vaccine|"Donor: 0.5 cc subcutaneously, 3 times on weeks -8, -6 and -2 prior to lymphocyte collection.~Patient: 0.5 cc subcutaneously, 3 times immediately after infusion of donor cells (DLI), and again 4 and 8 weeks post DLI."
224305573|NCT01174082|BIOLOGICAL|KLH-id Vaccine|"Donor: 0.5 cc subcutaneously, 3 times on weeks -8, -6 and -2 prior to donor lymphocyte collection.~Patient: 0.5 cc subcutaneously, 3 times immediately after infusion of donor cells (DLI), and again 4 and 8 weeks post DLI."
223482420|NCT05001048|DRUG|Phenylephrine Hydrochloride|Series of three incremental bolus injections to observe α1-adrenoreceptor mediated vasoconstriction.
223482421|NCT05001048|OTHER|Cold Pressor Test|Standardized sympathetic stressor involving submersion of the hand in ice-cold water for 3-minutes, aiming to elicit endogenous neurotransmitter release and blood pressure increases.
223482422|NCT05001048|OTHER|Isocapnic Acute Hypoxia|During low altitude assessment, participants will be exposed to isocapnic hypoxia equivalent to 3,800m to assess responses to acute exposure.
223482423|NCT05001048|OTHER|Hyperoxia|During high altitude assessments, participants will breathe an oxygen concentration comparable to their end-tidal values at low altitude for the assessment of the influences of acclimatization.
223744974|NCT00946712|BIOLOGICAL|Bevacizumab|Given IV
224305574|NCT01174082|DRUG|GM-CSF|250 mcg/m2 subcutaneously daily for 4 days after each vaccine
223482424|NCT03727867|DRUG|Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor|Oral EGFR TKI begins on day 1 and continues until disease progresses.
223482425|NCT03727867|DEVICE|Stereotactic Body Radiation Therapy|Participants were given Stereotactic Body Radiation Therapy in a dose of 60 Gy/8 fraction for the central tumor or 50 Gy/5 fraction for the peripheral lung cancer, respectively.
223482426|NCT03136198|OTHER|LUS-guided strategy-of-care|"For patients randomized to the strategy-of-care arm, the LUS guided protocol will be initiated and continued until there is a decrease in B-lines to ≤ 15 or 6 hours of care has been delivered, whichever comes first.~Treatment protocol:~1. IV furosemide (unless already given): 2x single oral dose if on chronic therapy or 20-40 mg if diuretic naive.~2. Optional therapies: non-invasive ventilation, vasodilators (SL, topical, or IV)~3. Reassessment every 2 hours"
223482427|NCT03136198|OTHER|Usual Care|Patients will receive usual AHF care
223482428|NCT03136198|DRUG|Intravenous Loop Diuretic|IV loop diuretic
223482429|NCT03136198|DRUG|Vasodilator|IV, topical, or SL Vasodilator
223744975|NCT00946712|DRUG|Carboplatin|Given IV
224305575|NCT01174082|PROCEDURE|Apheresis|Day 0 (day of lymphocyte collection) donors undergo a steady state pheresis to obtain lymphocytes.
224305576|NCT01174082|PROCEDURE|Donor Lymphocyte Infusion (DLI)|Day 0, infusion to patient of collected donor cells.
224305577|NCT02991430|DEVICE|active neuromodulation for episodic migraine headache|Non-invasive brainstem neuromodulator. Active and placebo devices appear identical
224305578|NCT02991430|DEVICE|placebo neuromodulation for episodic migraine headache|Sham non-invasive brainstem neuromodulator. Active and placebo devices appear identical
224305579|NCT04860596|BEHAVIORAL|collaborative health management model|nursing education program
224305580|NCT01938404|BIOLOGICAL|Octaplas|Octoplas infusion solution for IV administration
224305581|NCT01938404|DRUG|Standard Plasma|Plasma given as replacement fluid
224305582|NCT05596721|DRUG|Azithromycin|Treat patient with azithromycin for 12w.
224305583|NCT05596721|DRUG|ICS/LABA|Treat patient with ICS/LABA according to Global Initiative for Asthma (GINA) guideline.
224305584|NCT03118570|DRUG|setrusumab|Intravenous infusion
223744976|NCT00946712|BIOLOGICAL|Cetuximab|Given IV
223744977|NCT00946712|OTHER|Laboratory Biomarker Analysis|Correlative studies
223744978|NCT00946712|DRUG|Paclitaxel|Given IV
224170199|NCT06435455|DRUG|GH21|GH21 Capsules, Oral Drug Specification: 3mg/capsule; 10mg/capsule
224170200|NCT06435455|DRUG|D-1553|D-1553 Film-coated Tablets, Oral Drug Sepcification: 200mg/tablet
224170201|NCT00134589|BEHAVIORAL|Academic Detailing (Medical Practices)+Decision Aids (Patients)|
224305585|NCT03118570|DIETARY_SUPPLEMENT|Calcium|tablets
224305586|NCT03118570|DIETARY_SUPPLEMENT|Vitamin D|capsules
224305587|NCT03118570|DRUG|zoledronic acid (optional)|Following completion of the study treatment (Month 12) participants can receive an optional single dose of zoledronic acid. Participants can receive an optional further dose of zoledronic acid at Month 18 at the discretion of their treating physician.
224305588|NCT04335175|OTHER|None - observational study|None - observational study
224305589|NCT03970837|BIOLOGICAL|GSK3196165 (Otilimab)|GSK3196165 solution in vial/pre-filled syringe (PFS) was administered SC.
224170202|NCT04041258|PROCEDURE|pseudoarthrosis of clavicle|Pseudoarthrosis represents a complication following a fracture, resulting in persistent symptoms and functional limitation, which prolongs the recovery time for the patient and necessitates new surgery. The purpose of surgery for pseudoarthrosis is to re-establish the length and alignment of the clavicle in an environment favorable to the union of bone fragments.
224170203|NCT00582764|OTHER|perform dynamic contrast enhanced (DCE) MRI|With an IV catheter in place, the patient will lie prone on the MRI scanner table with the breasts positioned in the commercial breast coil and then be moved feet first to the center of the MRI scanner. The only difference introduced by the addition of DCE MRI is that before the patient is moved into the scanner for the first time, the IV catheter will be hooked up with a programmable power injector (Medrad, Indianola, PA) which is loaded with Gd contrast and saline. The contrast injection and saline flush will be delivered by the injector while the patient is inside the scanner and the DCE MRI data collection is in process. The Gd contrast dose used for DCE MRI is the same as for clinical MRI: 0.1 mmol/kg. The injection speed of 2 mL/sec is safe and similar to that of manual injection.
224170204|NCT01063361|DIETARY_SUPPLEMENT|Low glycemic index diet with pulses|Subjects will be advised to follow a diabetic diet, using low glycemic index foods, emphasizing pulses.
224170205|NCT01063361|DIETARY_SUPPLEMENT|High Cereal Fibre|Subjects will be advised to follow a healthy high fibre diabetic diet.
224170206|NCT02336880|BEHAVIORAL|Internet-delivered cognitive behavioural therapy|
224170207|NCT06709430|OTHER|Classical education group|Students will be divided into standardized patient and Classical education group. Theoretical courses, standardized patient-based pain management laboratory practice, and clinical practice processes will be applied to students in the experimental group.
224170208|NCT06709430|OTHER|Standardized Patient Group|Students will be divided into standardized patient group and control groups. Theoretical courses, standardized patient-based pain management laboratory practice, and clinical practice processes will be applied to students in the
224170209|NCT06720896|DRUG|APT-001 topical ophthalmic ointment (spinosad)|APT-001 topical ophthalmic ointment, administered once daily
224170210|NCT06720896|DRUG|Vehicle control for APT-001 topical ophthalmic ointment|Vehicle control for APT-001 topical ophthalmic ointment, administered once daily
224170211|NCT06727279|OTHER|Specialized food - Plant-Based Meat Analog|Experimental group receives specialized food made of plant-based (soy) meat analog. A portion of standard (animal) meat in a daily ration of the enrolled subjects is substituted by plant-based analog.
224170212|NCT06727279|OTHER|standard isocalorie diet|Isocalorie (based on resting energy expenditures measurements) diet is provided to subjects of the control group with no modification of the protein and fat content
224170213|NCT07047014|DRUG|Tenecteplase (0.25mg/kg)|Each vial of tenecteplase is reconstituted with 3 ml sterile water for injection and adjusted to a concentration of 5.33 mg/ml. Calculate the total amount of drug according to the subject's actual body weight and measure the required drug volume. The maximum dose should not exceed 25mg. Tenecteplase should be given as a single, intravenous bolus (within 5-10 seconds).
224170214|NCT07047014|DRUG|Standard medical treatment|Aspirin combined with clopidogrel, aspirin alone, or clopidogrel alone after randomization at the discretion of site researchers according to Chinese Guidelines for Diagnosis and Treatment of Acute Ischemic Stroke 2023.
224305590|NCT03970837|DRUG|Tofacitinib|Tofacitinib capsule (over encapsulated 5mg tablet) was administered orally.
223482430|NCT03136198|DEVICE|Non invasive Ventilation (NIV)|Face, mouth, or nasal mask applied to provide positive pressure ventilation
224305591|NCT03970837|DRUG|Placebo|Placebo matching GSK3196165 and Tofacitinib was administered.
224305592|NCT04063488|DRUG|Metreleptin|This is an observational study in which the subjects will serve as their own controls. Study testing will be conducted at baseline (pre-treatment) and for 2 years, post-treatment with metreleptin.
224305593|NCT02132754|BIOLOGICAL|MK-4166|
223482431|NCT03639415|DRUG|Increasing the Controlled-Release Oxycodone dose frequency|Keep the daily dose while increase the dose frequency of Controlled-Release Oxycodone so that reduce the single dose
223482432|NCT05774951|DRUG|Camizestrant|Camizestrant. Experimental. Administered orally
223482433|NCT05774951|DRUG|Tamoxifen|Tamoxifen. Comparator. Administered per local approved label
223482434|NCT05774951|DRUG|Anastrozole|Anastrozole. Comparator. Administered per local approved label
223482435|NCT05774951|DRUG|Letrozole|Letrozole. Comparator. Administered per local approved label
223482436|NCT05774951|DRUG|Exemestane|Exemestane. Comparator. Administered per local approved label
223482437|NCT01503788|DRUG|Midazolam|participants will be given Midazolam IV 10-5 minutes prior to diagnostic lumbar puncture
223482438|NCT06307548|DRUG|Aminolevulinic Acid|Given PO
223585428|NCT06034249|BEHAVIORAL|Mindfulness-Based VR|Participants will be ask to attend the six-week course encompassed various mindfulness practices, including breathing observation, body scanning, mindful yoga, mindful walking, holistic meditation, and non-selective awareness practices.
223585429|NCT06034249|BEHAVIORAL|Audio|The mindfulness-based audio files for six weeks.
224305594|NCT02132754|BIOLOGICAL|Pembrolizumab|
223482439|NCT06307548|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223482440|NCT06307548|PROCEDURE|Computed Tomography|Undergo CT
223482441|NCT06307548|PROCEDURE|Fluorescence-Guided Surgery|Undergo fluorescence-guided surgery
223482442|NCT06307548|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223482443|NCT06307548|DRUG|Photodynamic Therapy|Undergo PDT
223482444|NCT06307548|PROCEDURE|Surgical Procedure|Undergo surgery
224305595|NCT03036553|OTHER|Diagnosis/Prognosis|The present study will be a prospective multi-centric 12-month study that will be conducted between May 2017 and April 2019 in four primary care centers and a hospital in the province of Malaga. Several questionnaires assessing different psychological factors will be administered to these participants. The results will be evaluated at baseline (t1) and at 3-fold follow-up (after 3 (t2), 6 (t3) and 12 months (t4)).
224305596|NCT01045174|DEVICE|Nebulizer (breath-actuated versus conventional continuous-output)|Participants are randomly assigned to receive bronchodilator treatments for asthma according to the standard of care using either a breath-actuated nebulizer device or a conventional continuous-output nebulizer. Standard unit doses of albuterol/ipratropium bromide or albuterol are used in both devices.
224170215|NCT06728540|OTHER|Investigation of Physical Activity Levels, Respiratory and Pelvic Floor Muscle Function|The sociodemographic and clinical characteristics of the children participating in the study will be evaluated with an evaluation form, respiratory muscle strength with an RP Check brand electronic pressure measurement device, and body composition with a Tanita MC-580 brand bioelectrical impedance analyzer. Pelvic floor muscle functions of children with LUTD will be evaluated with a 632 Myomed biofeedback device. The survey questions and the evaluation form will be filled out by the parents.
224170216|NCT06372327|BEHAVIORAL|Daily Exercise Snacks|Participants will be encouraged to break up prolonged sitting at work with brief, high-intensity exercise snacks of varying length / total number depending on condition assignment.
224170217|NCT06720597|DRUG|Daily low-dose PDE5 inhibitor therapy|Neither arm of the study includes a control group, and the two interventions will not be compared directly. The primary objective is to evaluate endothelial function using the EndoPAT device at baseline, 3 months, and 6 months following the intervention in each arm.
224170218|NCT06720597|DRUG|Testosterone therapy as per clinical guidelines.|Neither arm of the study includes a control group, and the two interventions will not be compared directly. The primary objective is to evaluate endothelial function using the EndoPAT device at baseline, 3 months, and 6 months following the intervention.
224170219|NCT06075498|PROCEDURE|transversus abdominis plane block,|2 different plan blocks; 1. transversus plane block 2. quadratus lumborum plane block
224170220|NCT07047820|DRUG|Zuranolone|Administered as specified in the treatment arm
224170221|NCT07052279|OTHER|water based burpee exercises|water based burpee exercises ( Aquatic exercise ) is one method that has previously been shown to improve muscle strength, balance, and coordination in those of advancing age Although the evidence supports the effectiveness of both water-based burpee exercise in middle-aged and elderly individuals, has, to our knowledge, never been investigated. Thus, the objective of this study was to assess the long-term effect of water-based burpee exercises
224170222|NCT07052279|OTHER|aerobic exercises|Traditional aerobic exercises for post-menopause include activities like brisk walking, jogging and cycling. These exercises help improve cardiovascular health, boost metabolism, and enhance mood. They can also be beneficial for maintaining bone density, especially weight-bearing exercises like walking and jogging.
224170223|NCT07054983|OTHER|Qualitative Research Interview|Qualitative research interview of parents of pediatric patients seen in an interdisciplinary feeding clinic who underwent a tube weaning program
224170224|NCT07057531|PROCEDURE|Tubeless thoracic surgery|Tubeless thoracic surgery is a minimally invasive procedure performed without tracheal intubation or mechanical ventilation, allowing for spontaneous breathing. Anesthesia combines conscious sedation with local nerve blocks to ensure pain relief while preserving diaphragmatic movement. The surgical approach is similar to conventional video-assisted thoracic surgery (VATS), used for procedures like lung resections and mediastinal mass excisions. Post-operative care focuses on early mobilization and quick discharge.
224170225|NCT06369285|DRUG|Alisertib|Alisertib enteric-coated tablets will be taken by mouth twice daily on days 1-3, 8-10, and 15-17 of each 28-day cycle.
224170226|NCT06369285|DRUG|Endocrine therapy|"Investigator selected endocrine therapy will be taken in 28-day dosing cycles according to the approved prescribing information.~1 mg of anastrozole tablet by mouth once daily or~2.5 mg of letrozole tablet by mouth once daily or~25 mg of exemestane tablet by mouth once daily or~20 mg of tamoxifen tablet by mouth once daily or~500 mg of fulvestrant intramuscular injection on Study Day 1, 15, 29, and once every 28 days thereafter"
224170227|NCT05768347|BIOLOGICAL|Adoptive Cell Therapy with Tumor-infiltrating Lymphocytes (TIL)|Tissue samples are harvested, prepared and cryopreserved from post Bacillus Calmette-Guerin (BCG) bladder biopsies.
224170228|NCT07069179|BEHAVIORAL|Choose to Move Replacement Ready|As described under study arm description.
224170229|NCT07069309|BIOLOGICAL|BNT162b2 (Omi LP.8.1)|BNT162b2 monovalent (Omicron LP.8.1)
224170230|NCT07136883|DEVICE|POBA|The intervention consists of preparing the artery with a traditional/regular angioplasty balloon before using the DCB (Luminor™; Manufacturer: iVascular, S.L.U., Barcelona, Spain) as the definitive treatment.
224170231|NCT07136883|DEVICE|Scoring Balloon|The intervention consists of preparing the artery with a scoring balloon (Angiosculpt™; Manufacturer: Spectranetics Corporation, Fremont, California, USA) before using the DCB (Luminor™; Manufacturer: iVascular, S.L.U., Barcelona, Spain) as the definitive treatment.
224170232|NCT07137845|PROCEDURE|Virtual reality|The VR intervention will take place in a quiet room. The participant will be installed in a seated position, wearing a virtual reality headset that includes an audio device playing sounds. The eyes are covered by a mask featuring a screen showing calming 3D VR images (e.g. beach landscapes), designed by our team. The intervention lasts 20 minutes. The hypnotic suggestions with auditory and visual calming stimulations will help the person to focus on the present moment, to reduce anxiety and painful sensations.
224170233|NCT07137845|PROCEDURE|Cranial nerve non-invasive neuromodulation (CN-NINM)|During each intervention including CN-NINM, this latter will be applied for 20 minutes, with the help of a portable stimulator comprising a network of 18 electrodes, directly on the tongue of the participants. The participants will hold the CN-NINM in place by pressing their tongue upwards. The CN-NINM will generate high-frequency pulses (50 µsec to 150 Hz), and the intensity of the stimulus will be set by each participant to a comfortable level of sensation, similar to the sensation in the mouth of a soft drink.
223482445|NCT03417960|DEVICE|iTBS|"The investigators will treat post-partum depressed subjects with accelerated intermittent theta burst stimulation. iTBS will be delivered via a MagVenture MagPro100 and Cool-B65 coil. The investigators will use a standard resting motor threshold (rMT) determination to determine the TMS dose. Treatment will be delivered at 120% of the motor threshold.~In study 1, the accelerated paradigm will consist of 10 such sessions separated by 15 minutes, for three treatment days per week. There will be 2 weeks of 10 sessions on each of three days for a total of six treatment days, divided by one treatment-free week between treatment weeks. In study 2, the accelerated paradigm will consist of 12 sessions per day for 5 total treatment days. Treatments will be delivered at the 10-20 EEG coordinate for F3 (approximating the left DLPFC), and will be found using the Beam-F3 method."
223482446|NCT06386601|OTHER|Ergonomics Knowledge|Participants will participate in a lecture/module on surgical ergonomics
224170234|NCT07137845|PROCEDURE|Sham CN-NINM|In this study, we will have a control intervention which will be placebo CN-NINM. For placebo CN-NINM, participants will wear the device such as the real CN-NINM group, without having experienced the tingling sensation beforehand, so they will not know what the CN-NINM potential effect is.
224170235|NCT06889571|BEHAVIORAL|Nurse-Supported Mobile App for Self-Help CBT-I|The intervention consists of two components: 1) a mobile app delivered 6-week self-help CBT-I program; and 2) Weekly nurse support session.
224170236|NCT07084467|OTHER|EF1 guided CRT optimisation|In the EF1-guided optimisation group, the settings of the CRT device are adjusted to maximise early heart pumping efficiency, measured by a parameter called first-phase ejection fraction (EF1). Depending on the patient's heart rhythm, either the timing between heart chambers (AV or VV delay) is adjusted in small steps. The device setting that gives the best EF1 reading is chosen to help improve the heart's response to CRT.
224170237|NCT07084467|OTHER|Standard of Care (SOC)|This group will receive standard of care for their health condition and CRT management.
224170238|NCT07076342|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|Cognitive Behavioral Therapy for Insomnia (CBT-I) will be delivered through an online program, Sleep Healthy Using The Internet Sleep Healthy Using The Internet (SHUTi)
224170239|NCT07076342|DRUG|PET Scan with [11C]ABP688|Prior to and after completing the CBT-I protocol, participants will undergo a PET scan using tracer \[11C\]ABP688) to quantify hippocampal mGluR5 density.
224170240|NCT06102382|DRUG|Norepinephrine (0.1)|An intravenous bolus dose of norepinephrine (5 µg) followed by infusion of 0.1 µg/kg/min till 5 minutes after delivery of the fetus.
224170241|NCT06102382|DRUG|Norepinephrine (0.075)|An intravenous bolus dose of norepinephrine (5 µg) followed by infusion of 0.075 µg/kg/min till 5 minutes after delivery of the fetus.
224170242|NCT07125534|DRUG|Alcohol beverage|This intervention involves the administration of an alcohol beverage (vodka mixed with juice or soda) in a controlled laboratory setting, targeting a blood alcohol concentration (BAC) of 0.08%. The alcohol is consumed over a 36-minute period in three equal parts.
224170243|NCT07125534|OTHER|Control - non alcoholic beverage|This intervention involves the administration of a non-alcoholic control beverage in a controlled laboratory setting. The beverage is matched in volume and palatability to the alcohol condition but co
224170244|NCT06931080|DRUG|EB-1020 (Centanafadine) 164.4 mg|164.4 mg, capsule, oral, once daily, for 6 weeks
224170245|NCT06931080|DRUG|EB-1020 (Centanafadine) 328.8 mg|328.8 mg, capsule, oral, once daily, for 6 weeks
224170246|NCT06931080|DRUG|Placebo|Placebo, capsule, oral, once daily, for 6 weeks
224170247|NCT07089459|DEVICE|Low-Level Laser Therapy (LLLT)|Low-Level Laser Therapy (LLLT) will be administered using an 830 nm wavelength and 150 mW power output with 5 W/cm² power density. The laser probe will be applied 2-3 times per week for 6 weeks over the affected knee. Treatment is performed using a direct skin contact method with 3-4 minutes of exposure per point around the knee joint. The goal is to reduce inflammation, enhance collagen synthesis, and support ligament healing in patients with partial anterior cruciate ligament (ACL) tears. This intervention is provided in addition to standard physiotherapy and shortwave diathermy.
223482447|NCT06386601|OTHER|Ergonomics Feedback/Guided Practice|Participants will practice minimally invasive surgical skills while receiving feedback on ergonomic positioning/practice
223482448|NCT04674956|DRUG|Camrelizumab|PD-1 antibody（Camrelizumab）, 200mg, D1; every 21 days as a cycle.
223482449|NCT04674956|DRUG|Paclitaxel(Albumin Bound) and Gemcitabine|Paclitaxel(Albumin Bound), 125 mg/m2D18; Gemcitabine, 1000mg/m2D1, 8;every 21 days as a cycle.
223585430|NCT02404428|DIETARY_SUPPLEMENT|Standard broccoli soup|300g/week of standard broccoli soup consumed for a period of six months delivering standard level of glucoraphanin (sulforaphane precursor)
223585431|NCT02404428|DIETARY_SUPPLEMENT|Beneforte extra broccoli soup|300g/week of beneforte extra broccoli soup consumed for a period of six months delivering enriched levels of glucoraphanin (sulforaphane precursor)
223585432|NCT03970369|BEHAVIORAL|Usual care|Personalized goals and an activity prescription.
223744979|NCT04665050|BIOLOGICAL|V116|Pneumococcal 21-valent conjugate vaccine with 2 μg of each of the following pneumococcal polysaccharides (PnPs) antigen: 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15C, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F, and 35B in each 0.5 mL sterile solution
223744980|NCT04665050|BIOLOGICAL|PNEUMOVAX™23|Pneumococcal 23-valent polyvalent vaccine with 25 μg of each of the following PnPs antigen: 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F in each 0.5 mL sterile solution
224170248|NCT07089459|BEHAVIORAL|Shortwave therapy|Participants in this group will receive standard physiotherapy exercises combined with shortwave diathermy (SWD), without the application of Low-Level Laser Therapy (LLLT). The exercise protocol includes heel slides, supported partial knee bends, quadriceps sets, and step-ups, performed in 2 sets of 10 repetitions with 3-5 second rest intervals. SWD will be delivered 2-3 times, using a 27.12 MHz frequency for 20-30 minutes per session, targeting pain relief and enhanced soft tissue healing. This group functions as an active comparator to assess the additional therapeutic value of LLLT used in the intervention group.
223482450|NCT04674956|DRUG|Placebo|Placebo, 200mg, D1; every 21 days as a cycle.
223482451|NCT06693765|DRUG|AZD4144|AZD4144 will be administered orally.
223482452|NCT06338566|OTHER|Follow-up|Follow-up at D45, 3 months and 6 months, with scoring, radiological monitoring and assessment of wound healing
223482453|NCT03084237|BIOLOGICAL|HLX02|8 mg/kg administered intravenously over 90 minutes as a loading dose on Day 1, Cycle 1 then 6 mg/kg every 3 weeks for subsequent cycles.
223585433|NCT03970369|BEHAVIORAL|Monitor|Participants wear a step counter to track activity goals.
223585434|NCT02446080|DIETARY_SUPPLEMENT|Milk drink with probiotic culture|The Probiotc group was asked to drink 150 ml per day of dairy drinks with probiotic culture
223585435|NCT02446080|DIETARY_SUPPLEMENT|Milk drink|The control group was asked to drink 150 ml per day of dairy drinks.
223585436|NCT00720343|DRUG|Choline|Oral Choline 20 grams before surgery
223585437|NCT00720343|DRUG|Placebo|Gelatin Capsule
223585438|NCT03305978|DEVICE|Ultra low dose chest CT|An additional ultra low dose CT row is performed for every subject besides standard diagnostic low dose chest CT.
223585439|NCT03305978|DEVICE|Low dose chest CT|standard diagnostic low dose chest CT
223585440|NCT05862649|OTHER|NeuraLight|NeuraLight software-based platform
223482454|NCT03084237|BIOLOGICAL|Herceptin®|8 mg/kg administered intravenously over 90 minutes as a loading dose on Day 1, Cycle 1 then 6 mg/kg every 3 weeks for subsequent cycles
223482455|NCT03084237|DRUG|docetaxel|75 mg/m2 will be administered on Day 2, Cycle 1.then be given every 3 weeks on Day 1 of each subsequent cycle
223482456|NCT00213681|DEVICE|Boussignac CPAP - bilevel ventilation support|
223482457|NCT04087772|BEHAVIORAL|Mental Health Enhanced Positive Behavioral Interventions and Supports (PBIS-MH)|Mental health-enhanced Positive Behavioral Interventions and Supports (PBIS-MH) integrates mental health into the three core elements of PBIS. 1) School-based mental health clinicians are included on leadership teams. 2) Data from teacher and student perceived school climate, as well as universal screening for aggression and mental health difficulties, are used to inform intervention decision-making. 3) Evidence-based mental health prevention and intervention practices are layered into PBIS' three-tiered continuum.
223482458|NCT04087772|BEHAVIORAL|Racial/Ethnic Discrimination Interventions (RED)|Racial/Ethnic Discrimination Interventions are a set of components to address multiple forms of school-based racial and ethnic discrimination. 1) Unintentional bias training for school personnel, involving teaching participants to conceptualize prejudice as well as strategies to reduce bias. 2) Unintentional bias training for students that is delivered in a classroom in a developmentally appropriate lesson format. 3) Vulnerable Decision Point process: Leadership teams are trained to reduce disparities in school discipline by a) using disaggregated student discipline data to identify particular settings or practices that are drivers for racial/ethnic disproportionality in a school and b) using iterative problem-solving to address these drivers. 4) Teacher stress reduction training where they are provided with strategies to reduce stress.
224170249|NCT07089797|BEHAVIORAL|Nurse-Supported Mobile App for Self-Help CBT-I|The intervention consists of two components: 1) a mobile app (i.e., WeChat mini program) delivered 6-week self-help CBT-I program; and 2) Weekly nurse support session (up to 20 minutes each) across a 6 week intervention period.
224170250|NCT07089797|BEHAVIORAL|Sleep hygiene education|The participants in the control group will receive only sleep hygiene (one-page handout) via WeChat. Access to the CBT-I WeChat mini program will be offered to these participants after the completion of the 3-month follow-up assessment.
224170251|NCT01412762|BEHAVIORAL|patient interviews|The pre-operative interview will be within 4 weeks of planned surgery and the postoperative interview within 8 weeks of surgery completion. This initial study is designed to develop an instrument to measure patient preoperative expectations in this patient population.
224170252|NCT01412762|BEHAVIORAL|CITSAV survey|Individual semi-structured qualitative interviews will be conducted with a total of 10 patients and 5 clinicians during this phase to identify and discuss levels of satisfaction, level of burden, potential obstacles to implementation, as well as suggestions for improving the intervention
224170253|NCT06360718|BEHAVIORAL|"Who is Luke Eemia? Storybook"|"Parents in this group will receive the Who is Luke Eemia? storybook, and will receive guidance from the child life specialist on how to utilize the storybook with their school-aged child. Parents in this study will complete surveys at three timepoints, these surveys include: (1) Comfort Survey (prior to child life intervention), (2) Discharge Survey and (3) Storybook Assessment survey to review the parent's impression of the storybook intervention tool (at the time of discharge, or about 1 week following the child life intervention), and the (4) Parenting Stress Index -4-Short Form (at baseline, at the time of the discharge survey, and about 3.5 months later)."
224170254|NCT06893341|DEVICE|The Sensing Device|Children diagnosed with diabetes that wear a continuous glucose monitor will be given the Sensing Device. The subjects will provide breath samples into the device during euglycemia, hypoglycemia, and hyperglycemia, and the breath data will be analyzed to draw correlations with blood glucose levels.
224170255|NCT07102342|BIOLOGICAL|Human Dopaminergic Progenitor Cells|Single injection of Human Dopaminergic Progenitor Cells into the biliteral putamen/striatum regions of the brain
224170256|NCT07101848|DRUG|Cemiplimab|Cemiplimab maintenance plus best supportive care: cemiplimab 350 mg IV every 3 weeks until week 24, disease progression, unacceptable toxicity or consent withdrawal. Patients who continue to derive clinical benefit on the experimental arm may continue to receive treatment until week 48.
224170257|NCT07101432|DRUG|Fludarabine|Given by infusion
224170258|NCT07101432|DRUG|Cyclophosphamide|Given by infusion
224305597|NCT05981820|DIETARY_SUPPLEMENT|Creatine|To observe the effects of creatine in the study, 10 g of creatine supplementation was taken only on training days during the study period. Participants used 10 g of creatine monohydrate by dissolved in 200 ml of water. Creatine supplementation was taken in two doses of five grams, 30 minutes before and after training.
224305598|NCT05981820|OTHER|HIIT training|"In the first three weeks:~Warm-up: Warm-up at 70 rpm for 4 minutes, including 2-3 seconds of maximal sprint at 1.30 and 2.30 minutes Wingate-based HIIT: HIIT 4 sets of 12x15 seconds of maximal repetitions with 15 seconds of passive rest between reps in each set Cool-down: 4 minutes of passive rest between sets~In the last three weeks:~Warm-up: Warm-up at 70 rpm for 4 minutes, including 2-3 seconds of maximal sprint at 1.30 and 2.30 minutes Wingate-based HIIT: HIIT 5 sets of 20x15 seconds of maximal repetitions with 15 seconds of passive rest between reps in each set Cool-down: 4 minutes of passive rest between sets"
224305599|NCT01333280|BEHAVIORAL|Double Trouble in Recovery|DTR is a 12 Step-based fellowship for individuals with co-occurring problems of substance abuse and mental illness
224305600|NCT01333280|BEHAVIORAL|Treatment as usual|Receive usual treatment at the programs
224305601|NCT00836329|BEHAVIORAL|Intensive Glucose Management|Participants in the intensive glucose management group will undergo strict management of their blood glucose levels with a target whole blood glucose level of 100-140 mg/dL preoperatively, intraoperatively, and postoperatively in the intensive care unit (ICU). Once meals are started, targets for glycemia management will be (a) fasting: 80-140 mg/dL, (b) postprandial: 140-180 mg/dL. Prior to hospital discharge, participants will receive an in-depth diabetes education session. After hospital discharge, participants will attend monthly study visits for 6 months so that study researchers can monitor their glycemia management.
224305602|NCT00836329|BEHAVIORAL|Traditional Glucose Management:|Participants will receive traditional management of blood glucose levels while in the hospital. They may receive insulin several times a day, based on the results of glucose monitoring.
224305603|NCT02881060|DIETARY_SUPPLEMENT|Alcohol|
224305604|NCT02881060|DIETARY_SUPPLEMENT|Placebo|
224305605|NCT01997229|BIOLOGICAL|Eculizumab|Induction Phase: 900 mg IV weekly X 4 Maintenance Phase: 1200 mg IV every 2 weeks during Weeks 4-26
224305606|NCT01997229|DRUG|Placebo|Placebo
224170259|NCT07102537|DEVICE|Hyaluronic acid combined with calcium hydroxyapatite injection|The filler was injected in nasolabial folds in a before-after setting
224170260|NCT07100561|OTHER|Extensive post discharge counselling and phone-based follow up|Counselling by their attending physicians plus Extensive post-discharge counselling from a study doctor/pharmacist/a trained nurse and telephone follow-ups in addition to their normal outpatient reviews. The telephone follow-ups will be weekly for the first 30 days and then 4 weekly till day 90.
224170261|NCT07102498|BEHAVIORAL|BG mmol/L|BG presented in mmol/L (the standard presentation in Canada)
224170262|NCT07102498|BEHAVIORAL|BG mg/dl|BG presented in mg/dl
224170263|NCT07102498|BEHAVIORAL|A1c percent|HbA1c presented in percent (the standard presentation in Canada)
224170264|NCT07102498|BEHAVIORAL|A1c mmol/mol|HbA1c presented in mmol/mol
223482459|NCT04124133|DEVICE|dressing with hyaluronic acid|Application of ialuset cream or gauzepad (hyaluronic acid)
223482460|NCT05729347|BEHAVIORAL|Virtual Reality headset with calming scenery|Participants will be immersed in a virtual environment. Calming scenery will be shown via the headset for 20-30 minutes
223482461|NCT02504164|DRUG|midazolam 0.02mg/kg|
223482462|NCT02504164|DRUG|No premedication|No premedication before sedation for endoscopic submucosal dissection
223482463|NCT03869268|DRUG|Aspirin|Aspirin will be allocated in different doses and will be used in conjunction with ticagrelor depending on the arm of the trial the participant is randomised to. The different doses are as follows: 20 mg, 75 mg and 300 mg.
223585441|NCT06494085|OTHER|Measuring Respiratory Mechanics|"First, for each patient enrolled we will perform inspiratory and expiratory occlusions - routinely performed diagnostic maneuvers to measure patient's breathing effort - at the clinically set level of breathing assistance by the mechanical ventilator. Importantly, we will measure pressure-muscle-index (PMI).~Second, we will set the level of assistance (i.e. pressure support, PS) in order to make PMI=0. The PS level at which PMI=0 (PS PMI=0) will be used as reference for the study protocol. After 5 minutes at PS PMI=0 we will perform inspiratory and expiratory occlusions."
223585442|NCT06494085|OTHER|Randomized Pressure Support|3 steps of PS above (+2, +4, +6 cmH2O) and 3 below (-2, -4, -6 cmH2O) PSPMI=0 done in a randomized order (sequence in envelopes opened blindly by the investigators). Each step will last ≤5 minutes if poorly tolerated (see tolerance rule in description). At the end of each step we will perform 1 inspiratory occlusion and 3 expiratory occlusions. Each of the expiratory occlusion will be separated by 30 seconds in order to restore the patient's breathing pattern. We will resume a 3-minutes clinical PS in between each step to minimize changes in PaCO2. If not yet comprised by the study steps each patient will undergo an adjunctive 5 minutes step at PS 0 (zero) cmH2O.
223744981|NCT00994955|DEVICE|selective retina therapy (SRT)|laser treatment
224170265|NCT07100977|DIETARY_SUPPLEMENT|Bragg ACV Supplement|Participants will be instructed to consume 1 capsule of either Bragg ACV Supplement or placebo 10 minutes prior to consumption of a standardized meal.
224170266|NCT07100977|OTHER|Placebo|Participants will be instructed to consume 1 capsule of either Bragg ACV Supplement or placebo 10 minutes prior to consumption of a standardized meal.
224170267|NCT07100210|BIOLOGICAL|IL-22BP mRNA vaccine injection|During the injection of IL-22BP/LNP compound, there were three dose groups, namely 25 μg, 50 μg, and 100 μg of mRNA, with three participants in each dose group, aiming to evaluate the safety and tolerability of the IL-22BP/LNP compound formulation. The treatment will be administered by intratumoral injection. Enrolled subjects will receive inoculations of IL-22BP/LNP compound injection according to their respective dose groups, which include 5 doses for basic immunization and subsequent personalized treatment. During the basic immunization, the first 4 doses will be given at an interval of 1 week each, and the 5th dose will be administered 1 month after the 4th dose.The entire treatment period lasts for 2 months.
224170268|NCT07101068|DEVICE|Dental Anesthesia Injector|Topical anesthesia lidocain for 1 minute will be applied on previously dried mucosa. Local anesthesia administration( artican 4% +1/100,000 With extra short needles 30G-10mm ) using Dental Anesthesia Injector.
224170269|NCT07101068|OTHER|conventional syringe|Topical anesthesia lidocain for 1 minute will be applied on previously dried mucosa. Local anesthesia administration( artican 4% +1/100,000 With extra short needles 30G-10mm ) using conventional syringe
224170270|NCT06911970|OTHER|Exercise|"Moderate-Intensity Continuous Exercise (MOD):~The MOD condition will consist of a 37-minute continuous aerobic exercise session on ergocycle. This includes a warm-up and cool-down period at low intensity, and a 32-minute period at moderate intensity at a power corresponding to 50% of the last stop completed in the modified YMCA test completed in the preliminary visit.~High-Intensity Interval Exercise (HIIE):~The HIIE condition will consist of a 35-minute high-intensity aerobic exercise session on ergocycle. This includes a warm-up at low intensity, followed by 10 blocks of 1 minute at high intensity (110% of power highest poweroutput reached during the submaximal test) and 2 minutes of active rest (25% of highest power output)."
224170271|NCT06909422|BEHAVIORAL|Mobile Intervention for Biased Thinking|This intervention will be delivered via a mobile application.
223482464|NCT03869268|DRUG|Ticagrelor|Ticagrelor will be allocated as a single loading dose of 180 mg (2 x 90 mg orodispersible tablets) and will be used in conjunction with aspirin depending on the arm of the trial the participant is randomised to.
223482465|NCT06234228|BEHAVIORAL|Bluetooth Haptic Device (BHD)|The BHD will deliver constant low-frequency vibration (CF).
223482466|NCT06234228|BEHAVIORAL|BHD synced with mobile game|The BHD delivers a constant low-frequency vibration as well as tactile feedback from the game (GF).
223482467|NCT06109922|DIETARY_SUPPLEMENT|Active|40g bio-active whey protein concentrate powder containing phospholipids
223482468|NCT06109922|DIETARY_SUPPLEMENT|Placebo|Around 40g pea protein powder not containing phospholipids
223482469|NCT03678025|DRUG|Abiraterone|Given PO
223482470|NCT03678025|DRUG|Bicalutamide|Given PO
223482471|NCT03678025|DRUG|Degarelix|Given via injection
223482472|NCT03678025|DRUG|Docetaxel|intravenous
223585443|NCT05315726|OTHER|Dynamometer|Measurement of elbow/wrist spasticity
223744982|NCT04750031|PROCEDURE|Liver Biopsy|Liver biopsy is a procedure to obtain small amount of liver by a needle.
223744983|NCT06284226|DRUG|Allogeneic NK（CCT-ANK-11)|allogeneic natural killer cells
223744984|NCT01375387|DRUG|Lacosamide|100 mg oral tablet, single dose
223744985|NCT01375387|DRUG|Lacosamide|Lacosamide 2 X 100 mg tablet
224170272|NCT07101952|OTHER|Braded Suture material|The Cesarean section hysterotomy was closed using a double-layer technique involving unlocked continuous running sutures. The first layer incorporated the decidua, which was then overlapped by the second. The suture material used for this closure was barbed suture; which is absorbable synthetic monofilament polydioxanone with bars.
224170273|NCT07101952|OTHER|Multifilament vicryl suture material|The Cesarean section hysterotomy was closed using a double-layer technique involving unlocked continuous running sutures. The first layer incorporated the decidua, which was then overlapped by the second. The suture material used for this closure was barbed suture; which is absorbable synthetic monofilament polydioxanone with bars.
224170274|NCT07102056|DIAGNOSTIC_TEST|18F-AlF-NOTA-Octreotide PET-CT or PET-MR|18F-Octreotide PET/CT or PET/MR And enhanced CT or MR Imaging
224170275|NCT07102290|BEHAVIORAL|Free Help|Text message offering free quitline coaching. FREE HELP: Hello #first name#, Kick It California works with your provider to help you quit smoking at no cost. A Quit Coach can double your chances of quitting. For more info call 1-844-XXXXXXX.
224170276|NCT07102290|BEHAVIORAL|Free NRT|Text message for free nicotine patches with free quitline counseling. FREE NRT: Hello #first name#, Kick It California works with your provider to help you quit smoking at no cost. You may be able to get nicotine patches mailed to your home at no cost. For more info call 1-844-XXXXXXX.
224170277|NCT07100197|DEVICE|continuous Theta-burst stimulation|Treatment parameters: each cTBS session consists of 50 Hz triplets of pulses delivered at 5 Hz for 40 s, totaling 600 pulses, and every set simulation includes 3 sessions. Electrodes are attached to designated head regions (right dorsolateral prefrontal cortex).
224170278|NCT07100197|DEVICE|Sham|the treatment mode was with sham coil.
224170279|NCT04867616|OTHER|Placebo|"* Pharmaceutical form: Solution for infusion~* Route of administration: Intravenous infusion~Participants will receive Placebo during the Double-blind Treatment Period."
224170280|NCT04867616|BIOLOGICAL|Bepranemab|"* Pharmaceutical form: Solution for infusion~* Route of administration: Intravenous infusion~Participants will receive pre-specified doses of bepranemab during the Double-blind Treatment Period and the Open-label Extension Period."
224170281|NCT05954065|DEVICE|Erchonia CFL Laser|405nm violet and 520nm green laser light therapy.
224170282|NCT07139886|DRUG|Stillen® Tab|Oral administration 3 times per day (in-between meals and before sleep) for 2 weeks
224170283|NCT07139886|DRUG|Stillen® Tab Placebo|Oral administration 3 times per day (in-between meals and before sleep) for 2 weeks
224170284|NCT06932731|BEHAVIORAL|Mind-body Intervention|The Mind-Body Intervention group designed to included several elements with mind and body involvement such as mindful breathing, body scan, stretching, mindful movement as well as adapting mindful practice in their routine. Mind-Body Intervention group will join the activities in a group setting for 5 sessions. Each session 45 to 60 minutes. Intervention is led by a registered nurse. Each session (except for the first session) will start by sharing of practice from the past week. Followed by mind-body practices. Before the end of session, a group discussion on the practice of that day and reflection will be done.
224170285|NCT06932731|BEHAVIORAL|Befriending Intervention|In this group, volunteer will spend time with the participants, engaging in conversation and join their routine activities by the time of visit or other scheduled activities in the institution (such as arts and crafts, playing board games or reminiscing activities).
224170286|NCT07142486|DRUG|Omeprazole 20 mg|"Omeprazole 20mg capsule~1 dose = 1 capsule~Participants will consume one dose per day for 5 days prior to their study visit. They will also consume one dose the day of the study visit in the laboratory setting. They will also consume one dose with the standardized mixed meal containing chicken, peas, potatoes, and butter the day of the study treatment visit in the laboratory."
224170287|NCT07142486|OTHER|Placebo|"Placebo~1 dose of placebo = 1 capsule filled with maltodextrin~Participants will consume 1 dose per day for 5 days prior to their study visit. They will then consume 1 dose the day of their study visit in the laboratory setting. They will also consume one dose with the standardized mixed meal containing chicken, peas, potatoes, and butter the day of the study treatment visit in the laboratory."
224170288|NCT03285061|DEVICE|Deterra Drug Deactivation System|A portable bag that will neutralize and dissolve excess medication, rendering it completely unusable and safe for landfill disposal. The system meets FDA and DEA standards for at home disposal systems.
224170289|NCT02683668|COMBINATION_PRODUCT|Handihaler-Tiotropium 18 mcg untrained|We are looking at the untrained used of Handihaler
224170290|NCT02683668|COMBINATION_PRODUCT|Handihaler-Tiotropium 18 mcg trained|We are looking at the trained use of Handihaler after 14 days treatment
224170291|NCT02683668|COMBINATION_PRODUCT|Respimat-Tiotropium 5 mcg trained|we are looking at the trained use of Respimat after 14 days treatment
224305607|NCT03330912|DEVICE|Neutral seat height|Seat height set relative to participant's leg length with neutral set at the measured lower leg length
224305608|NCT03330912|DEVICE|Very low seat height|"Seat height set relative to participant's leg length, 2 below the measured lower leg length"
223482473|NCT03678025|DRUG|Flutamide|Given PO
223482474|NCT03678025|DRUG|Goserelin Acetate|Given SC
223482475|NCT03678025|DRUG|Histrelin Acetate|Receive SC
223482476|NCT03678025|DRUG|Leuprolide Acetate|Receive SC or IM
224170292|NCT06949150|DIAGNOSTIC_TEST|coronary angiography|Invasive coronary angiography (ICA), with or without percutaneous coronary intervention (PCI), intravascular ultrasound (IVUS), optical coherence tomography (OCT), or fractional flow reserve (FFR).
224305609|NCT03330912|DEVICE|Low seat height|"Seat height set relative to participant's leg length, 1 below the measured lower leg length"
224305610|NCT03330912|DEVICE|Very high seat height|"Seat height set relative to participant's leg length, 2 above the measured lower leg length"
224305611|NCT03330912|DEVICE|High seat height|"Seat height set relative to participant's leg length, 1 above the measured lower leg length"
224305612|NCT05136118|PROCEDURE|TAPB|TAPB will be given to parturients whether by the modified surgeon assisted approach or by the ultra-sound guided approach.
224305613|NCT00477295|DRUG|Zonisamide|Week 1 and 2 either 100mg zonisamide or 200 mg carbamazepine Week 3 and 4 either 200mg zonisamide or 4800 mg carbamazepine Week 5 and 6 either 300mg zonisamide or 600 mg carbamazepine; this dose then to be maintained unless a subject has a seizure more than two weeks post a dose increase.
224170293|NCT06949150|OTHER|Medical therapy|Patients do not undergo invasive coronary angiography (ICA), recieving medical treatment, lifestyle intervention or further test
224170294|NCT06948890|OTHER|Music intervention|"Subjects will listen to two songs of their choosing. They will be prompted: Please choose two songs that you really enjoy and that make you feel relaxed or take away stress."
224170295|NCT06948890|OTHER|Silence|Subjects will listen to 10 minutes of silence through high quality noise canceling headphones
224170296|NCT06950021|DEVICE|Magnetic seed|All patients enrolled will receive a single Sirius Canopus Marker with two anchors added to it for improved tissue fixation. Implantation will be done by a radiologist before breast conserving surgery, usually scheduled within a few days after Canopus Marker implantation. The Canopus Marker is removed with the specimen during the surgery.
224170297|NCT07148661|PROCEDURE|Removal of PPcT|Iatrogenic Pulmonary Parenchymal Chest Tube is removed as a staged procedure in which gradual retraction of 2cm of chest tube is done from lung parenchyma keeping an eye on the hemodynamic status of Patient.
224170298|NCT07147959|DRUG|[89Zr]Zr-CIT|radiolabelled CIT-013
223482477|NCT03678025|DRUG|Nilutamide|Given PO
224170299|NCT07147738|BEHAVIORAL|Kapot Sterk (translate as Incredibly Strong)|The program consists of five lessons of approximately 60 minutes long, delivered over a period of four to eight weeks. The lessons are facilitated by trained pedagogical staff (e.g., youth workers), while the school's own teachers are always present during the sessions. Lessons include active learning strategies such as role-playing, group discussions, and reflection exercises, often based on realistic and recognizable scenarios. The program focuses on strengthening key social-emotional skills, such as self-esteem, self-control, and resistance to peer pressure.
224170300|NCT07148193|OTHER|No intervention (observational study)|No intervention (observational study)
223482478|NCT03678025|PROCEDURE|Orchiectomy|Undergo bilateral orchiectomy
223482479|NCT03678025|DRUG|Prednisone|Given PO
223482480|NCT03678025|OTHER|Quality-of-Life Assessment|Ancillary studies
223482481|NCT03678025|RADIATION|Radiation Therapy|Standard radiation
223482482|NCT03678025|PROCEDURE|Radical Prostatectomy|Standard surgery
223482483|NCT03678025|DRUG|Triptorelin|injection
223482484|NCT05084495|DIAGNOSTIC_TEST|Global peak atrial longitudinal strain and ECG|During the follow-up period the patient will have four clinical visits, during which clinical data, advanced echocardiographic data (strain and speckle tracking) and ECGs (Glasgow criteria) will be collected
223482485|NCT00455871|DRUG|reduced fluence photodynamic therapy with Visudyne|reduced fluence photodynamic therapy with visudyne
224170301|NCT07148037|GENETIC|Atorvastatin|10mg once a day for 2 months
223482486|NCT00455871|DRUG|Lucentis|Lucentis intravitreal injection
224170302|NCT07147686|BEHAVIORAL|Slow tempo basic motor skills exercises with music (30 BPM)|Participants performed basic motor skills exercises synchronized with slow-tempo music at 30 beats per minute (BPM). The slow tempo was intended to enhance internal timing, cognitive inhibition, controlled movement coordination, and sustained attention. Each session lasted 10-15 minutes per exercise, using traditional Turkish music (e.g., Erik Dali, Horon, Sari Zeybek) to provide culturally relevant rhythmic patterns.
224170303|NCT07147686|BEHAVIORAL|Fast tempo basic motor skills exercises with music (60 BPM)|Participants performed basic motor skills exercises synchronized with fast-tempo music at 60 BPM. The faster tempo aimed to increase reaction speed, attention demand, processing speed, decision-making, and cognitive flexibility. Each session lasted 10-15 minutes per exercise, using traditional Turkish music with asymmetric rhythms to challenge timing and planning skills.
224170304|NCT07147335|DIAGNOSTIC_TEST|serum AKR1B10 levels|Investigators collected blood from the patients every three months to test their serum AKR1B10 levels.
224170305|NCT07148817|BEHAVIORAL|Noise canceling earplugs|Modifiable noise cancelling earplugs will be used to attempt to limit individual noise exposure in those with high levels of exposure or high levels of annoyance related to noise
223482487|NCT04157179|OTHER|Carbon Dioxide|Participants inhale carbon dioxide while in magnetic resonance imaging scan to measure cerebrovascular reactivity
223482488|NCT05388591|OTHER|Musicotherapy|Music listening with the application Music Care (style of music chosen by the patient) during wound suturing
223482489|NCT00370617|DRUG|metformin|
223482490|NCT02750722|DEVICE|Flutter®|Acute exercise with Flutter® breathing therapy.
223482491|NCT02750722|DEVICE|No Flutter®|Acute exercise without Flutter® breathing therapy.
223482492|NCT04698811|BEHAVIORAL|VIRTUAL ENEAGRAM|"Presentation of the Virtual Enneagram and its content and realization of the first battery of tests (World Health Organization Quality of Life - (WHOQOL-BREF). Stress Perception Scale 10 (EPS-10) The Trait-State Anxiety Inventory: IDATE E and T.) .~Guidance and training on personality and the Enneagram, its classification system, personality subtypes and dynamics of stress and growth allowing self-recognition.~Second test battery ((World Health Organization Quality of Life - (WHOQOL-BREF). Stress Perception Scale 10 (EPS-10) The Trait-State Anxiety Inventory: (IDATE E and T.) and Enneagram Questionnaire."
223482493|NCT02410330|PROCEDURE|Therapeutic ultrasound with 20 usec|A custom designed high mechanical index (MI) impulses at 4-20 usec and \>1.0 mechanical index designed for the 1.7 MHz S5-1 transducer
223482494|NCT02410330|PROCEDURE|Repeated diagnostic high mechanical index|Repeated diagnostic high mechanical index impulses (all \<2 usec pulse duration; MI=1.0) whenever very low mechanical index perfusion imaging detected microbubbles within the microvasculature
223482495|NCT03774446|DRUG|Seliciclib|Drug: Seliciclib
223482496|NCT02657551|DRUG|Regorafenib|Regorafenib is a small molecule inhibitor of multiple membrane-bound and intracellular kinases involved in normal cellular functions and in pathologic processes.
223482497|NCT01314729|DEVICE|Fiber-reinforced-composite retainer|this type of retainer is placed on the lingual surface of teeth from canine to canine just before the completion of orthodontic treatment
224170306|NCT07148817|BEHAVIORAL|Usual care|No behavioral changes to limit noise exposure
224170307|NCT07147647|DEVICE|Direct Selective Laser Trabeculoplasty|DSLT using the Belkin Vision Eagle Device
224170308|NCT07147283|BEHAVIORAL|Educational film and volitional help sheet|The intervention consists of a bespoke online gynaecological cancer awareness educational film and a volitional help sheet to plan future gynaecological help seeking and monitoring based on implementation intention principles \[24\]. The intervention will be delivered online using Qualtrics™.
224170309|NCT07148804|DRUG|Fermented Deglycyrrhizinated Licorice|Oral capsules containing 500 mg of fermented deglycyrrhizinated licorice root extract standardized to 2500 IU/gm of α-amylase enzyme and naturally occurring flavonoids and acid-lipase. Administered twice daily (1000 mg/day).
224170310|NCT07148804|DIETARY_SUPPLEMENT|Non-fermented Deglycyrrhizinated Licorice|500 mg non-fermented deglycyrrhizinated licorice root extract capsules, matching FDGL in appearance, color, weight, and excipients. Administered twice daily.
224170311|NCT07149272|DEVICE|Virtual Reality Exercise (VRE) using VRAGMENT software|Adjuvant Virtual Reality Exercise (VRE) delivered via Oculus Quest 2 headset with VRAGMENT software, a culturally adapted VR program simulating daily activities (e.g., grocery shopping, phone calls) to induce physical movement. Participants received VRE alongside conventional multimodal exercise (breathing, resistance, aerobic) during hospitalization. Sessions were tailored to individual clinical conditions and aimed to improve fatigue and mobility through gamified rehabilitation
224170312|NCT07149064|DIETARY_SUPPLEMENT|Nextida GC-B|One liquid shot contains 5 g of collagen hydrolysate.
224170313|NCT07149064|OTHER|Placebo|One liquid shot contains non-active ingredients in Nextida GC-B (water, Erythritol, Citric Acid, DL-Malic Acid, Natural Apples Flavor, Steviol Glycosides).
224170314|NCT07147699|DEVICE|cardiostory|measure the pressure of remplissage
224170315|NCT07147413|BEHAVIORAL|Behavioral/Digital Health Intervention|Participants in this group will utilize an AI-powered digital health management platform designed to optimize blood pressure control. The platform provides personalized medication and blood pressure measurement reminders, tailored health education, and interactive quizzes to improve hypertension awareness and engagement. Data from blood pressure monitors will be scanned and uploaded, and the system will alert participants and case managers to abnormal readings, enabling timely interventions.
224170316|NCT07149220|DRUG|Mucoadhesive fenretinide-releasing system (FMS)|All persons with premalignant oral epithelial lesions will receive active intervention. The intervention consists of b.i.d. application of the FMS to the premalignant lesion for a total of six weeks. Please note that the intervention title Drug and intervention titled Other are the same entity.
224170317|NCT07148687|BEHAVIORAL|Conventional Exercise Program|Exercise protocol targeting subacromial pain syndrome, including shoulder mobility, strengthening, and posture correction exercises based on established clinical guidelines.
224170318|NCT07148687|BEHAVIORAL|ChatGPT-Guided Rehabilitation|AI-generated exercise recommendations from ChatGPT-4 tailored to the patient's profile and applied under physiotherapist supervision.
224170319|NCT07148687|BEHAVIORAL|DeepSeek-Guided Rehabilitation|Personalized rehabilitation exercises generated by DeepSeek-R1 and implemented under physiotherapist guidance.
224170320|NCT07148050|BIOLOGICAL|SC-CAR.GPC3xIL15.21 CAR T cells|Autologous SC-CAR.GPC3xIL15.21 T cell products infusion
224170321|NCT07148557|BIOLOGICAL|LP-003 Dose 1 (Single)|A single dose of LP-003 (400 mg/dose) was SC
224170322|NCT07148557|BIOLOGICAL|LP-003 Dose 2 (Single)|A single dose of LP-003 (600 mg/dose) was SC
224170323|NCT07148778|BEHAVIORAL|Educational intervention|"In this study, a web-based postpartum care package program supported by a chatbot will be administered to the intervention group.~A pre-test will be administered to participants in the intervention group within 24-48 hours after birth.~Participants in this group will be informed that they must watch the videos in the educational modules until the sixth week postpartum. Reminder messages will also be sent to participants via the website, email, and phone calls (between days 7 and 14 postpartum and week 3 postpartum). Participants who have completed the module training will be eligible for post-tests at 6 weeks postpartum and 3 months postpartum."
224170324|NCT07147920|DEVICE|Chest-Worn ECG Monitoring Device|"The Perin Health Patch is a non-invasive, chest-worn wearable device designed to continuously monitor electrocardiogram (ECG) signals using dry conductive adhesive electrodes. In this validation study, the device will be evaluated for its ability to accurately measure ECG parameters including heart rate, QT interval, QRS duration, and R-R intervals compared to FDA-cleared Holter monitors.~The study intervention involves three components: (1) simultaneous ECG recording with the patch and reference Holter monitor for 15 minutes while participants remain seated, (2) placement tolerance testing where the patch is positioned at various locations (±20mm from optimal placement) to assess performance under suboptimal positioning, and (3) long-term wear evaluation where participants wear the patch continuously for 15 days with periodic assessments. The intervention is limited to device application and ECG data collection under controlled conditions, with no therapeutic treatment provided."
224170325|NCT07148323|DEVICE|HemoSphere Alta Monitor, Swan-Ganz IQ pulmonary arterial catheter, ForeSight IQ Large sensor, and Acumen IQ sensor|Subjects with planned monitoring with a pulmonary artery catheter in the operating room, will be monitored with the above listed devices.
224170326|NCT07148856|OTHER|Conventional Physiotherapy|A standard physiotherapy program provided after Achilles tendon surgery, including stretching, strengthening, mobility, and functional training exercises
224170327|NCT07148856|OTHER|Myofascial Release Technique|A manual therapy technique applied to the lower limb and ankle region, aiming to release fascial restrictions, improve soft tissue flexibility, and enhance ankle range of motion.
224170328|NCT06950112|DEVICE|lung ultrasound|The lung ultrasound score between 0 and 3 (0 = normal A lines, 1 = multiple separated B lines, 2 = coalescing B lines or light beam, 3 = consolidation). The aeration score will be built by the sum of the scores of the 12 segments, with a minimum of 0 and a maximum of 36 according to the aeration loss.
224170329|NCT06949865|OTHER|video recording|The patient's motor symptoms were recorded via video for assessment purposes.
223482498|NCT01314729|DEVICE|Composite-wire retainer|this type of retainer is placed on the lingual surface of teeth from canine to canine just before the completion of orthodontic treatment to prevent treatment relapse
223482499|NCT01010178|DRUG|Macrolid, Theophylline, Inhaler Corticosteroids|we have no permission to include them in detail because of privacy policy of mentioned journal for publication
223585444|NCT05315726|OTHER|Muscle vibrations|1 session of 10 minutes
223585445|NCT05315726|OTHER|Muscle vibrations|3 times/week for 6 weeks
223585446|NCT05315726|OTHER|Placebo muscle vibration|3 times/week for 6 weeks
223744986|NCT01375387|DRUG|Lacosamide|Lacosamide 4 X 100mg tablet
223744987|NCT01375387|OTHER|Placebo 3|Placebo - 3 tablets
224170330|NCT07148869|BEHAVIORAL|LAUGHTER YOGA|Patients will be divided into groups of at least 5 people according to the sample size. Laughter yoga sessions will be conducted under the leadership of the researcher in a suitable room / hall determined within the hospital. A total of 8 sessions will be applied, 2 sessions per week for 4 weeks, with each session lasting an average of 40 minutes.
224170331|NCT07148869|OTHER|control group|there will be no application to this group
224170332|NCT07148492|PROCEDURE|Antireflux suture|Antireflux suture will be taken in this intervention group
224170333|NCT07148492|PROCEDURE|No Antireflux suture|Antireflux suture will not be taken in this intervention group
224170334|NCT07149025|PROCEDURE|Osteopathic Manipulative Therapy|1 session of OMT
224170335|NCT07147595|PROCEDURE|Isometric handgrip exercise|Participants will train 3 times per week for 4 weeks. Each session will consist of four sets of 2-minute contractions sustained at 30% of maximum voluntary contraction (MVC), performed with a handgrip device for each arm, with 1-minute rest intervals between sets and between arms.
224170336|NCT07147595|PROCEDURE|Isometric knee extension exercise|Participants will train 3 times per week for 4 weeks. Each session will consist of four sets of 2-minute contractions sustained at 30% of maximum voluntary contraction (MVC), performed with adjustable ankle weights for each leg, with 1-minute rest intervals between sets and between legs.
224170337|NCT07147322|OTHER|Medical education, basic life support training|One basic life support training session / participant. Duration of educational session aprox. 30min.
224170338|NCT07149090|DRUG|Lenvatinib|"Description: Lenvatinib: 12 mg (for body weight ≥ 60 kg) or 8 mg (for body weight \< 60 kg) per oral once daily~* Dose level 1: 8mg per oral once daily (for \<60kg) 12mg per oral once daily (for ≥ 60kg)~* Dose level 2: 4mg per oral once daily (for \<60kg) 8mg per oral once daily (for ≥ 60kg) Nivolumab: 360 mg administered intravenously every 3 weeks Chemotherapy(Oxaliplatin+Capecitabine) every 3 weeks~* Capecitabine 1000 mg/m² per oral twice daily on Days 1-14~* Oxaliplatin 130 mg/m² administered intravenously on Day 1"
224170339|NCT07148284|OTHER|Isolation of EVs + RNA sequencing|Isolation of EVs + RNA sequencing
224170340|NCT07148635|PROCEDURE|Electrical Dry Needling (EDN)|Electrical dry needling will be performed at active myofascial trigger points in lumbar muscles (quadratus lumborum, multifidus, iliocostalis lumborum). Fine monofilament needles are inserted into trigger points and connected to a low-frequency stimulator (2-10 Hz) for 10-15 minutes per session. Treatment is delivered once weekly for six weeks by a trained physiotherapist. Participants will also receive standardized conventional physiotherapy including core strengthening, stretching, posture education, and a home-based exercise program.
224170341|NCT07148635|PROCEDURE|Sham Dry Needling (SDN)|Sham dry needling will be administered at the same anatomical sites as the experimental group, using superficial or blunt needle placement without penetration into muscle tissue and without electrical stimulation. Sessions are delivered once weekly for six weeks by a trained physiotherapist. Participants will also receive the same standardized conventional physiotherapy including core strengthening, stretching, posture education, and a home-based exercise program to maintain consistency with the experimental arm.
224305614|NCT00477295|DRUG|Carbamazepine|Week 1 and 2 either 100mg zonisamide or 200 mg carbamazepine Week 3 and 4 either 200mg zonisamide or 4800 mg carbamazepine Week 5 and 6 either 300mg zonisamide or 600 mg carbamazepine; this dose then to be maintained unless a subject has a seizure more than two weeks post a dose increase.
224305615|NCT03370731|PROCEDURE|adenotonsillectomy|Resection of adenoidal tissue or hypertrophy tonsils by radiofrequency ablation or other methods.
224305616|NCT03370731|OTHER|Nonsurgical management|Nasal Irrigation or inhaled corticosteroids, etc.
224305617|NCT02122120|DIETARY_SUPPLEMENT|HEN|Patients with tube feeding with FSMP for at least twelve months
224305618|NCT03939299|PROCEDURE|OCT|Patients with coronary chronic total occlusion received successful stenting. Optimal coherence tomography imaged immediately and at 9-12 months after the index procedure to explore long-term vascular response and healing profile.
224305619|NCT04940260|DIAGNOSTIC_TEST|Renal function|measure eGFR at one year post partum
224305620|NCT04940260|DIAGNOSTIC_TEST|proteinuria|measure urine protein creatinine ratio at one year postpartum
224305621|NCT00283491|BEHAVIORAL|Active Lactobacillus plantarum 299v|10\^11 cfu/meal in 2 meals on 2 consecutive days
224305622|NCT00283491|DIETARY_SUPPLEMENT|Inactive Lactobacillus plantarum 299v|Inactive form of the active treatment but with the fermentation products in the same concentration
224305623|NCT04691180|DRUG|BRII-196 and BRII-198|BRII-196 and BRII-198 given intravenously
224305624|NCT04691180|DRUG|Placebo|Placebo given intravenously
224305625|NCT05145582|BEHAVIORAL|The Self-Guided PSP Wellbeing Course|An unguided version of a transdiagnostic ICBT program that has shown promising initial outcomes in prior research (https://doi.org/10.2196/27610).
224305626|NCT05145582|BEHAVIORAL|Online Discussion Forum|An online discussion forum designed to provide an opportunity for participants to support one another in their use of the ICBT program.
224305627|NCT03566576|DRUG|Anlotinib|Anlotinib 8mg p.o. qd in first cohort (3 subjects). 10mg p.o. qd in second cohort (3 subjects). 12mg p.o. qd in third cohort (3 subjects).
224305628|NCT03566576|DRUG|Pemetrexed|Pemetrexed 500mg/m2 as a 10-minute intravenous infusion on day 1 of a 21-day cycle.
224305629|NCT03566576|DRUG|Docetaxel|Docetaxel 60mg/m2 as a 10-minute intravenous infusion on day 1 of a 21-day cycle.
224305630|NCT01362127|DRUG|Chemotherapy|Cisplantin 100 mg/m2 day 1. 5-fluoracil 750 mg/m2/24 hours infusion day 1-5. Three cycles. In the chemoradiation arm the radiotherapy start week 4 and continuing until week 7. Dose adjustet according to current LPK and TPK values.
224305631|NCT01362127|RADIATION|Radiochemotherapy|Cisplantin 100 mg/m2 day 1. 5-fluoracil 750 mg/m2/24 hours infusion day 1-5. Three cycles. In the chemoradiation arm the radiotherapy start week 4 and continuing until week 7. Dose adjustet according to current LPK and TPK values.
224305632|NCT00872482|DRUG|nimotuzumab|Nimotuzumab (200 mg fixed dose) will be administered by the intravenous route weekly during WBRT and following WBRT Radiotherapy will consist of 30 Gy, in 10 fractions of 3 Gy/day.
224305633|NCT03015727|DRUG|Docetaxel|3 cycles of DOC neoadjuvant chemotherapy at day1,22 and 43 with docetaxel 75mg/m2.
224305634|NCT03015727|DRUG|Cisplatin|3 cycles of DDP neoadjuvant chemotherapy at day1,22 and 43 with cisplatin 75mg/m2.
224305635|NCT03015727|RADIATION|IMRT/TOMO|intensity modulated radiation therapy or tomotherapy
223744988|NCT01375387|OTHER|Placebo 4|Placebo - 4 tablets
223744989|NCT01375387|OTHER|Placebo 2|Placebo - 2 tablets
223744990|NCT03041246|PROCEDURE|Pelvic floor fascial mobilization|The manual manipulation of the pelvic floor involves intra vaginal superficial as well as pelvic skin area pressure points.
223744991|NCT01176227|DIETARY_SUPPLEMENT|Kyodophilus multi-strain probiotic capsules|"The Kyo-Dophilus study product is a gelatin capsule containing three proprietary probiotic bacterial strains. The total quantity of bacteria per capsule is 1.5 billion colony forming units (1.5 x 109 cfu) and is composed of the following strains:~* Lactobacillus gasseri KS-13 1.2~* Bifidobacterium bifidum G9-1 0.15~* Bifidobacterium longum MM-2 0.15~Subjects will be provided with two bottles containing 30 capsules each of matching placebo upon randomization. Subjects will be instructed to take one capsule with breakfast daily for the full 12 weeks duration of the trial. While one bottle contains enough capsules for the time frame between each visit, two bottles have been provided to permit a surplus in the event scheduling conflicts arise. The third bottle, providing the remainder or study capsules, will be provided at visit 2."
224305636|NCT03015727|DRUG|Chemotherapy|2 cycles of cisplatin concurrent chemotherapy at day 64 and 85 with cisplatin 100mg/m2.
224305637|NCT01102062|DIETARY_SUPPLEMENT|orange juice|
224305638|NCT04427644|PROCEDURE|Laparascopic Sleeve Gastrectomy|Operations performed for complciation of laparascopic sleeve gastrectomy
224170342|NCT07148531|BEHAVIORAL|Seeds for Attachment (translated version)|"Developed by, and base at Universidad de los Andes, this is a community-based psychosocial model for caregivers of young children in conflict-affected settings.~The program is implemented through a 15-week group-based model with approximately 15 caregivers per group, and led by community facilitators (non-professionals).~The program follows four sequential goals: (1) promoting awareness of and tools for emotional regulation of the psychological consequences of conflict and forced displacement; (2) understanding children's emotional needs and the caregiver-child relationship; (3) developing responsive caregiving practices that foster secure attachment; and (4) strengthening social support networks. The approach integrates psychosocial support with attention to the social determinants of caregiving and mental health."
224170343|NCT07147881|DEVICE|IpsiHand|IpsiHand is a therapeutic device that uses a brain-computer interface system which detects neural signals associated with motor intent and translates them into assisted hand movements in individuals with upper extremity impairment following a stroke.
224170344|NCT07148167|OTHER|Magnetic resonance imaging|use Magnetic Resonance Imaging (MRI) to evaluate the cervical muscle planes in AS patients in more detailed and objective ways. In this study, in addition to cervical muscle volumes in AS patients, we also aimed to evaluate cervical fat infiltration and cervical alignment, which have not been previously evaluated in AS patients.
224305639|NCT04427644|PROCEDURE|İnterventional radiologic drainage|İnterventional radiologic drainage of gastric leakage
224305640|NCT04427644|DIAGNOSTIC_TEST|Complte Blood Count and Biochemical evaluation|blood samples obtained from patients to determine the hgb and htc levels of patients and biochemical changes of patients after surgery
224305641|NCT04427644|DIAGNOSTIC_TEST|Computed tomography|Admitted to observe leakage
224305642|NCT04557202|DRUG|Tamsulosin Oral Capsule|To assess the efficacy of peri-operative alpha1 blockers on improving the success rate and decreasing complications of non-stented ureteroscopic laser lithotripsy for ureteric stones.
223744992|NCT01176227|DIETARY_SUPPLEMENT|Kyodophilus Matching Placebo Capsules|Subjects will be provided with two bottles containing 30 capsules each of matching placebo upon randomization. Subjects will be instructed to take one capsule with breakfast daily for the full 12 weeks duration of the trial. While one bottle contains enough capsules for the time frame between each visit, two bottles have been provided to permit a surplus in the event scheduling conflicts arise. The third bottle, providing the remainder or study capsules, will be provided at visit 2.
223744993|NCT03379649|COMBINATION_PRODUCT|Platelet rich plasma|Patients will have 60ml of blood drawn. Platelet rich plasma will be obtained by placing the blood in the Arteriocyte Magellan device. 0.5ml of Platelet rich plasma will be placed into the uterus at least 48 hours prior to embryo transfer.
223744994|NCT03379649|COMBINATION_PRODUCT|Placebo|Patients will have 60ml of blood drawn. 0.5ml of embryo culture media (the placebo) will be placed into the uterus at least 48 hours prior to embryo transfer.
224170345|NCT07148921|DIAGNOSTIC_TEST|Quantitative Sensory Testing|"Quantitative sensory testing (QST) is a psychophysical test procedure. With the help of calibrated stimuli and subjective sensory information, the functional state of the somatosensory system of a subject or patient is examined with regard to the expression of clinical signs.~The test includes:~* Cold detection threshold~* Warm detection threshold~* Paradoxical heat sensation~* Cold pain threshold~* Heat pain threshold~* Mechanical detection threshold~* Mechanical pain threshold~* Mechanical pain sensitivity~* Dynamic mechanical allodynia~* Wind-up phenomena~* Vibration threshold~* Pressure pain threshold"
224170346|NCT07148921|DIAGNOSTIC_TEST|Patient Health Questionnaire 9|The Patient Health Questionnaire 9 (PHQ-9), a validated and internationally used health questionnaire, will also be completed twice at the first study day before the sex hormone therapy is initiated and during the last study day in month 6. The questionnaire consists of 9 items on the topic of mental well-being.
224170347|NCT07148921|DIAGNOSTIC_TEST|Hormone concentrations|"Blood concentrations of the following laboratory parameters will be determined:~* Follicle stimulating hormone (FSH)~* Luteotropic hormone (LH)~* Prolactin (PRL)~* Oestradiol (E2)~* Sex hormone-binding globulin (SHBG)~* Testosterone"
224305643|NCT04557202|DRUG|Placebo|Placebo - control group
224305644|NCT06526455|DRUG|Vonoprazan|oral drug 3-56 days after ESD.
224305645|NCT06526455|DRUG|Esomeprazole|oral drug 3-56 days after ESD.
224305646|NCT00777413|DRUG|Minocycline 100mg Tablets|
224305647|NCT00228423|DRUG|Clopidogrel 75 mg daily|Daily dose of 75 mg Clopidogrel
224305648|NCT00228423|DRUG|water pill daily|Daily dose of water pill (placebo)
224305649|NCT04614623|DEVICE|AHCL pump|Advanced Hybrid Closed Loop (AHCL) pump automatically adjusts insulin infusion rate of pump customized to patient's needs to reduce occurrence of hypo and hyperglycemia
224305650|NCT04614623|OTHER|Video conferencing Application|Video conferencing application will be used to enhance communication between participant and parent with the study certified diabetes educator (CDE) nurse coordinator. These individualized sessions will be designed to help the family with solving diabetes management problems to enhance glycemic control
224305651|NCT06438536|BEHAVIORAL|Virtual Reality-based Social Cognitive Training|Virtual reality assisted social cognitive training embedded in cognitive behavioral therapy, that aims at enhancing social cognition and daily life functioning.
223585447|NCT05293626|DRUG|NR082 Injection|"The starting dose is 1.5E9 vg, 0.05 mL eye/dose.~Dose Escalation:~If drug-related dose-limiting toxicity (DLT) events are observed in ≤ 2 of the 6 evaluable subjects using the starting dose within 6 weeks after the dosing of NR082, the dose can be escalated to 4.5E9 vg, 0.05 mL eye/dose (high dose) after approval by SRC.~Dose De-escalation： If drug-related dose-limiting toxicity (DLT) events are observed in \> 2 of the 6 evaluable subjects using the starting dose within 6 weeks after the dosing of NR082, the dose can be de-escalated to 0.5E9 vg, 0.05 mL eye/dose (low dose) after approval by SRC.~If drug-related dose-limiting toxicity (DLT) events are observed in \> 2 of the 6 evaluable subjects within 6 weeks after the dosing of NR082 at the high dose, the dose can be de-escalated to 3.0E9 vg, 0.05 mL eye/dose (intermediate dose) after the approval by SRC."
223585448|NCT05293626|DEVICE|Injection needle|"19G 1 1/2IN TW filter needle with filter element (BD 305200)，used to NR082 Intraocular injection solution dose preparation; 30G 1/2IN injection needle (BD 305106)，used to NR082 Intraocular injection solution administration;~1 ml screw top syringe (BD 309628),used to NR082 Intraocular injection solution dose preparation and administration."
223585449|NCT06060028|DEVICE|Interoceptive stimulation treatment with mechanical stimulation of C-LTMRs afferences|The intervention is a non-invasive interoceptive stimulation (affective touch) delivered to the left volar forearm. The stimulation is delivered using a device with a small tactile probe that touches the skin in a circular motion. The device is designed to induce maximum firing frequency in the peripheral C-Ts nervous afferents, which respond to low-force, low-velocity stimuli, specifically 3 cm/sec, 2.5mN. The stimulation will be delivered in 18 blocks, each consisting of 6 short periods of stimulation of varying durations presented in random order, with pauses of 6 seconds after every single stimulation, the entire stimulation protocol will have a total duration of 30 minutes.
223585450|NCT06060028|DEVICE|Sham treatment|In the sham condition, patients will receive a similar stimulation with the interoceptive tactile device, however, the device will be turned on for only 3 seconds every minute, and consequently turned off for 57 seconds. The entire duration of the stimulation will be approximately 30 minutes, similar to the experimental condition.
223585451|NCT06371417|DRUG|RAY121|Injection
223744995|NCT01531387|DRUG|Hydroxyurea|Hydroxyurea will be administered once daily, in either capsule form (300mg, 400mg, or 500mg) or as a liquid formulation (100mg/ml). Dosing will commence at 20 mg/kg/day. Dose escalation will occur in 5 mg/kg/day increments, adjusting every 8 weeks unless hematological toxicity occurs.
223744996|NCT02616042|OTHER|Centella asiatica and bamboo salt|Participants uses three types of dentifrices for four days after each wash-out period of 10 days. Dentifrice with Centella asiatica and bamboo salt is compared with control dentifrice.
223744997|NCT02616042|OTHER|Centella asiatica|Participants uses three types of dentifrices for four days after each wash-out period of 10 days. Dentifrice with Centella asiatica is compared with control dentifrice.
224170348|NCT07147660|OTHER|Compensatory scanning training|Individual home-based vision training exercises for 20 minutes every day for 8 weeks. A training program with online and manual oculomotor exercises, scanning and visual search-exercises. Weekly short follow up-conversation by telephone to check in and keep the motivation high with the participants.
224170349|NCT07147660|OTHER|Delayed Compensatory scanning training|Delayed track start. Individual home-based vision training exercises for 20 minutes every day for 8 weeks. A training program with online and manual oculomotor exercises, scanning and visual search-exercises. Weekly short follow up-conversation by telephone to check in and keep the motivation high with the participants.
224170350|NCT07147582|OTHER|Transcranial alternating current stimulation with two electrodes placed on scalp|Transcranial alternating current stimulation with anode and cathode electrodes and frequency ranged from 8 to 13 HZ
224170351|NCT03893630|DRUG|Acetylsalicylic Acid 81 mg|Patients will receive 81mg acetylsalicylic acid daily, initiated between 11 and 16 weeks of gestation and continued until 36 weeks of gestation.
224170352|NCT03893630|DRUG|Acetylsalicylic Acid 162 mg|Patients will receive 162mg acetylsalicylic acid daily, initiated between 11 and 16 weeks of gestation and continued until 36 weeks of gestation.
224170353|NCT03893630|OTHER|Control|Standard of Care
224170354|NCT04826640|OTHER|Observational|Observational
224170355|NCT00002624|PROCEDURE|adjuvant therapy|
224170356|NCT00002624|PROCEDURE|diagnostic thoracoscopy|
224170357|NCT00002624|PROCEDURE|therapeutic thoracoscopy|
224170358|NCT00002624|PROCEDURE|video-assisted surgery|
224170359|NCT00002624|RADIATION|radiation therapy|
224170360|NCT02201199|DRUG|insulin glargine U200 HOE901|Pharmaceutical form:solution for injection Route of administration: subcutaneous
224170361|NCT02201199|DRUG|insulin glargine U500 HOE901|Pharmaceutical form:solution for injection Route of administration: subcutaneous
224170362|NCT02201199|DRUG|insulin glargine U100 HOE901|Pharmaceutical form:solution for injection Route of administration: subcutaneous
224170363|NCT01562379|DIETARY_SUPPLEMENT|Wheat Soy Blend (WSB++)|A wheat formulation containing protein from milk solids and soybeans, essential fats and sugar to provide optimal caloric density, and added vitamins and minerals.
224170364|NCT01562379|DIETARY_SUPPLEMENT|Chickpea based complementary food supplement|A chickpea-based complementary food supplement with added milk powder, oil, sugar and added vitamins and minerals.
224170365|NCT01562379|DIETARY_SUPPLEMENT|Rice based complementary food supplement|Locally developed rice based complementary food with and added vitamins and minerals.
224170366|NCT01562379|DIETARY_SUPPLEMENT|Plumpy Doz|Plumpy Doz is a prepackaged ready-to-use complementary food supplement enriched with added vitamins and minerals.
224170367|NCT04630561|BEHAVIORAL|Postural Intervention Program|Dynamic warmup program designed to target several areas of physical and mental wellbeing.
224305652|NCT03500653|DIETARY_SUPPLEMENT|Curcumin|4 gr curcumin
224305653|NCT03500653|DIETARY_SUPPLEMENT|Placebo|4 gr placebo
224170368|NCT00852358|DRUG|laronidase|For the treatment group, intrathecal rhIDU injections will consist of 3 cc of Aldurazyme® (laronidase) (approximately 1.74 mg) diluted with 6 cc of Elliotts B® solution for a total injection of 9 cc. The diluted enzyme will be administered via a lumbar puncture (IT) on day 0 after baseline assessments. IT injections will be repeated on days 30, 60, and 90. The subsequent doses will be administered at 3-month intervals for a total of 10 doses during the two-year period. Control patients will not receive treatment, lumbar puncture, or placebo, but will undergo all other study procedures and assessments during year one. Control patients will then enter a treatment phase consisting of four IT doses at 3-month intervals.
224170369|NCT01997827|DEVICE|metal-ceramic RBFDP|Rehabilitation of tooth loss with a metal-ceramic RBFDP
224170370|NCT01997827|DEVICE|all-ceramic RBFDP|Rehabilitation of tooth loss with an all-ceramic RBFDP
224170371|NCT04865380|DRUG|Tranexamic Acid 100 MG/ML|1g IV x 1 dose of Tranexamic Acid administered preoperatively.
224170372|NCT04917536|PROCEDURE|Humeral neailling in humeral fractures|Humeral neailling in humeral fractures
224170373|NCT03650387|DEVICE|RADIESSE® (+) Lidocaine|RADIESSE® (+) Lidocaine will be injected as per its current approved labelling and investigator's usual practice
224170374|NCT01912482|OTHER|Cardiorespiratory training|The cardiorespiratory training group will undergo 18 sessions, these also periodized in a maximum six weeks, respecting the minimum weekly frequency of 3 sessions.
224170375|NCT01912482|OTHER|ventilatory training|The ventilatory training group will undergo 18 sessions, periodized in a maximum six weeks, respecting the minimum weekly frequency of three sessions.
224170376|NCT05815758|DRUG|Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Ophthalmic Solution (Combo)|Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Ophthalmic Solution (Combo)
224170377|NCT05815758|DRUG|Vehicle of brimonidine tartrate 0.025%/ketotifen fumarate 0.035% ophthalmic solution|Vehicle of brimonidine tartrate 0.025%/ketotifen fumarate 0.035% ophthalmic solution
224170378|NCT03661983|DRUG|Aripiprazole|Participants received aripiprazole tablets, orally as per the regimen specified in the arm description.
224170379|NCT03661983|DRUG|Placebo|Participants received aripiprazole matching-placebo tablets, orally as per the regimen specified in the arm description.
224170380|NCT02829606|OTHER|small scotoma using Head Mounted Display No re-mapping|re-mapping software turned off
224170381|NCT02829606|OTHER|Large scotoma using Head Mounted Display PLUS re-mapping|re-mapping software turned on
224170382|NCT06278584|DEVICE|iLUX Treatment System|Local heat using an electrical warming mask for 5 minutes.
224170383|NCT01913652|DRUG|Cabazitaxel|
224170384|NCT03932292|DRUG|Ectoin Mouth Wash|According to medical prescription of the instruction for use under consideration (at least 4x1 ampoule (5ml) daily, rinsed in the mouth for at least 30 seconds)
224170385|NCT03932292|DRUG|Supersaturated solution of calcium and phosphate ions|According to medical prescription of the instruction for use under consideration (4 times a day).
224170386|NCT03934515|OTHER|etCO2|"At the end of the procedure, therefore, for each patient two values of etCO2 are acquired which will allow to obtain two populations of values of the etCO2: the values at the endotracheal level and the esophageal level values. The authors will find the threshold value of etCO2 collected when the NGT is well positioned in trachea. The study manager is not directly involved in the measurement and recording of etCO2 values."
224170387|NCT03934515|OTHER|pH|"At the end of the procedure, for each patient two values of pH are acquired which will allow to obtain two pH value populations: a value at esophageal level and a value at the gastric level. The authors will find the threshold value of pH collected when the NGT is positioned in the esophagus and in the stomach. The study manager is not directly involved in the measurement and recording of pH values."
224170388|NCT02425891|DRUG|Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody|Atezolizumab at a fixed dose of 840 milligrams via intravenous (IV) infusion on Days 1 and 15 of each 28-day cycle until disease progression or unacceptable toxicity.
224170389|NCT02425891|DRUG|Nab-Paclitaxel|Nab-Paclitaxel at a starting dose of 100 milligrams per square meter via IV infusion on Days 1, 8, and 15 of each 28-day cycle. Nab-Paclitaxel was administered for a target of at least 6 cycles, with no maximum in the absence of disease progression or unacceptable toxicity.
223482500|NCT04679207|PROCEDURE|Vacuum-assisted excision|Vacuum-assisted biopsy (VAB) is a minimally invasive technique performed under local anaesthetic as an outpatient procedure by radiologists using x-ray or ultrasound guidance. It was developed in the USA in the mid 1990s and has become well established as a diagnostic test for suspected breast disease. It uses the combination of a large gauge biopsy needle and suction to allow larger pieces of tissue to be removed than can be obtained with a standard needle biopsy device. The technique is used widely for diagnostic purposes and, in some centres, for the therapeutic removal of benign breast lumps such as fibroadenomas and papillomas.
223482501|NCT00034866|DRUG|Protease inhibitor tipranavir|
223482502|NCT04105270|DRUG|Oral Restorative Microbiota Therapy (RMT) Capsules|Patients with PD-L1 TC expression will receive sixteen doses of oral RMT capsules weekly
223482503|NCT04105270|DRUG|Durvalumab 1500 mg IV|Patients with PD-L1 TC expression receive durvalumab 1500 mg IV every 4 weeks (Q4W) until disease progression or for a maximum of two years from the 1st dose of durvalumab
223482504|NCT04105270|DRUG|Cisplatin/pemetrexed or Carboplatin/pemetrexed|Patients with PD-L1 TC receive cisplatin/pemetrexed or carboplatin/pemetrexed given every 3 weeks (Q3W) for 4 cycles followed by pemetrexed maintenance given Q3W
223482505|NCT04105270|OTHER|Placebo|Sixteen doses of oral placebo capsules given weekly
223482506|NCT06968611|OTHER|Education/information of risk|Participant will receive a message underscoring risk of vision loss from poorly controlled DM, and how this risk can be largely eliminated with excellent compliance with mediations and clinical visits.
223482507|NCT06968611|OTHER|Free eye glasses|Participants will receive a free pair of reading glass at their first appointment
223482508|NCT05445141|BEHAVIORAL|Little ACF [in Swedish: Lilla ABC]|Little ACF is a modified version of the program called All Children in Focus \[in Swedish: Alla Barn i Centrum (ABC)\] that originally is developed for parents with children 3-12 years of age. The content is based on positive developmental psychology and involves role plays, discussions and exercises to try at home with the child. Printed material will be provided to the parents at each meeting/session. Little ACF is offered once a week during four weeks. Each session is 60 minutes, thereafter the parents can stay in the facility for 30 minutes to continue discussing with each other.
224170390|NCT02425891|DRUG|Placebo|Placebo administered via IV infusion on Days 1 and 15 of each 28-day cycle until disease progression or unacceptable toxicity.
224170391|NCT04124952|DEVICE|Panoptix|Alcon Acrysof(R) Panoptix(R) intraocular lens (IOL)
224170392|NCT02299128|OTHER|Physical Therapy Treatment|
224170393|NCT05117580|DEVICE|telemedicine lifestyle guidance|Telemedicine lifestyle advices are given during 3 months, based on telemonitoring system data.
224170394|NCT01087151|DRUG|ABT-263|Oral repeating dose
224170395|NCT01087151|DRUG|rituximab|Intravenous repeating dose
224170396|NCT00784680|DRUG|Anastrozole|1mg, orally, once daily
224170397|NCT00784680|DRUG|Tamoxifen|20mg, orally, once daily
223482509|NCT05445141|BEHAVIORAL|Lectures|The lectures are pre-recorded and available during four weeks. Each lecture is 10 minutes and the content is similar to, but more superficial than, the content in Little ACF.
224170398|NCT01334008|BIOLOGICAL|Blood sampling|30ml of patient peripherical blood will be collected
224170399|NCT03558503|DRUG|UGN-102|"UGN-102 consists of mitomycin and sterile hydrogel (a proprietary thermally responsive gel) that is used to reconstitute mitomycin before instillation. The reverse thermal properties of UGN-102 allow for local administration of mitomycin as a liquid, with subsequent conversion to a semi-solid gel depot following instillation into the bladder.~The UGN-102 admixture for intravesical instillations contains 75 mg mitomycin in 56 mL admixture (1.33 mg mitomycin per 1 mL)."
224170400|NCT01967082|BEHAVIORAL|APPSPIRE|Given APPSPIRE app
224170401|NCT01967082|BEHAVIORAL|Focus Group|Attend focus group
224170402|NCT01967082|OTHER|Survey Administration|Complete survey
224170403|NCT06504433|DIAGNOSTIC_TEST|Confirmed variant/deletion in either nuclear or mitochondrial genes involved in the mitochondrial respiratory chain|This is a 10-year, longitudinal, non-randomised, retrospective and prospective, observational study that will be used to characterise the natural history of primary mitochondrial disease (MITO) in 400 participants and their asymptomatic family members (with no genetic risk), non-MITO healthy controls (100 participants) and form a biobank that can be used in future research using separate ethics approved protocols to identify biomarkers of disease onset and progression.
224170406|NCT02473016|DRUG|Carbon Dioxide Drug Delivery System (CDDS)|Doses will be administered to the nostril on the side of the trigeminal episode \[ipsilateral nostril\].
224170407|NCT05623059|DRUG|Slow Release DHEA|DHEA is a hormone produced by the body's adrenal gland. In drug form, it is available as an over-the-counter supplement that is available on the market without prescription.
224170408|NCT05929937|DRUG|Opioids|Patients will receive a prescription of 5 tablets of opioids (preferred: Oxycodone, or surgeon preference for Oxycodone intolerance)
224170409|NCT05929937|OTHER|No opioids|Standard of care, patients will not receive a prescription for opioids.
224305654|NCT01918540|PROCEDURE|Hollow Centralizer|The stem used (MS30)was originally designed with a solid centralizer but has been redesigned to be used with a hollow centralizer. The patients are randomized to either solid or hollow centralizer
223482510|NCT04604522|PROCEDURE|Biospecimen Collection|Undergo collection of blood, airway brushings.
223482511|NCT04604522|OTHER|Medical Chart Review|Patients' medical records are reviewed
223482512|NCT03563573|DRUG|Potassium Gluconate Oral Capsule|Each subject will receive a dose of \~8 mg/kg of potassium. We will be giving a maximum of 14 mEq in a single dose.
223482513|NCT03563573|DRUG|Placebo oral capsule|Each subject will receive a dose of \~8 mg/kg of a placebo capsule
223482514|NCT04062695|DRUG|Tofacitinib 5 MG Oral Tablet [Xeljanz]|verum tablets
224170412|NCT06528496|BIOLOGICAL|DANYELZA|DANYELZA is a humanized monoclonal antibody of the IgG1 subclass
224170413|NCT06528496|BIOLOGICAL|Sargramostim|Yeast derived recombinant human Sargramostim (GM-CSF)
224170414|NCT06528496|DRUG|Cytoxan|Cyclophosphamide is an alkylating agent related to nitrogen mustard
224170415|NCT06528496|DRUG|Topotecan|Topotecan is a topoisomerase I-inhibitor that is a semisynthetic derivative of camptothecin.
224170416|NCT06528496|DRUG|Vincristine|Vincristine is an alkaloid isolated from Vinca rosea Linn (periwinkle).
224170417|NCT06528496|DRUG|Doxorubicin|Doxorubicin is an anthracycline antibiotic
224170418|NCT06528496|DRUG|Ifosfamide|Ifosfamide is a structural analogue of cyclophosphamide
224170419|NCT06528496|DRUG|Etoposide|Etoposide for Injection is available as a 20 mg/mL solution in sterile multiple dose vials (5 mL, 25 mL, or 50 mL each).
223482515|NCT04062695|DRUG|Placebo oral tablet|tablets containing placebo
223482516|NCT04140409|DRUG|Sandostatin|All patients will be treated with octreotide LAR intramuscular injections at maximum doses of 60 mg every 4 weeks or a frequency up to 30 mg octreotide LAR each 2 weeks. Change of dose or frequency is left at the discretion of the investigator until symptom control is obtained.
223482517|NCT05350020|DRUG|Solu-Cortef 100 MG Injection|Licensed medicine used in clinical practice. Preparations will be used unmodified in this trial withinmarketing authorisations.
223482518|NCT05350020|DRUG|Hydrocortisone 100mg/ml|Licensed medicine used in clinical practice. Preparations will be used unmodified in this trial within marketing authorisations.
224170420|NCT06528496|DRUG|Carboplatin|Carboplatin is available in 50 mg, 150 mg, 450 mg, and 600 mg vials.
224170421|NCT06528496|DRUG|Irinotecan|Irinotecan hydrochloride trihydrate (CPT-11) is a topoisomerase I inhibitor
224170422|NCT06528496|DRUG|Temozolomide|Temozolomide is administered intravenously
224305655|NCT01918540|PROCEDURE|Solid Centralizer|The stem used (MS30)was originally designed with a solid centralizer but has been redesigned to be used with a hollow centralizer. The patients are randomized to either solid or hollow centralizer
224305656|NCT01918540|DEVICE|MS-30 femoral stem|This is the stem used in the study.
224305657|NCT05197218|DIETARY_SUPPLEMENT|Prebiotic|Combination of a polyphenol rich extract of chokeberry (Aronia melanocarpa) and a polyphenol rich extract of cranberry (Vaccinium macrocarpon Aiton) will be administered for 18 days.
224170423|NCT00187148|BIOLOGICAL|EnvDNA|administered as 100 mcg of DNA in 1.5mL PBS every 28 days for 3 injections
224170424|NCT02943577|DRUG|Rapastinel|Rapastinel pre-filled syringes for weekly IV injections.
224170425|NCT02943577|DRUG|Placebo|Placebo-matching rapastinel pre-filled syringes for weekly IV injections.
224170426|NCT01355224|GENETIC|Genetic|Relative risk estimates will be presented based on individuals' risk for obesity based on FTO genotype results.
224170427|NCT01355224|BEHAVIORAL|Lifestyle|Relative risk estimates will be presented based on individuals' risk for obesity due to lifestyle factors.
224170428|NCT05422690|DRUG|Induction Chemotherapy Triplet Therapy|Gemcitabine 1000 mg/m2, Cisplatin 25 mg/m2 infused on both day 1 and day 8 of a 21-day cycle. Durvalumab 1500 mg will be given on day 1 of each cycle.
223482519|NCT03837717|BEHAVIORAL|Holding|Mothers will be assisted with holding their infants (and the cooling blanket) for a single 30-minute period, with the use of a thin foam barrier for thermal protection. Mothers and infants will not be skin-to-skin.
223482520|NCT03837717|OTHER|Saliva collection|Saliva will be collected from infants (via syringe suction) and mothers (via passive drool), and tested for levels of cortisol and oxytocin
223482521|NCT03837717|BEHAVIORAL|No Holding|Saliva will be collected from Mothers and infants, and vital sign information will be collected from infants in the same manner as the Holding intervention, with the exception of having mother's hold their infants.
223482522|NCT03736655|DEVICE|Interposition supraciliary implant|Surgical placement of an interposition supraciliary implant in the supraciliary space
223482523|NCT00713804|BEHAVIORAL|Genetic Counseling|One face-to-face genetic counseling session of 1-2hours duration, with a board certified or board eligible genetic counselor which will involve, documentation of a detailed family history, discussion of: the contributors to mental illness pathogenesis, illness risk reduction strategies, chances for family members to develop mental illness (if required), supportive counseling around living with illness/risk of illness/managing illness vulnerability, and referral to support organizations as required.
223482524|NCT00713804|BEHAVIORAL|Educational Booklet|One educational booklet that provides information about the causes of mental illnesses, and the chances for relatives of affected individuals to develop mental illness will be provided to participants.
223482525|NCT06230263|DIAGNOSTIC_TEST|Visual acuity test|"Assess near high-contrast visual acuity (40cm) using EyeChart PRO on an iPad.~Use the MNREAD app to measure:~Reading Acuity: Smallest font size read without errors. Critical Print Size: Smallest font size for peak reading speed. Maximum Reading Speed: Time to read comfortable font size, in words per minute. Reading Accessibility Index: Single metric summarizing visual access to print. Assess near visual function with the Near Activity Visual Questionnaire.~Evaluate distance visual acuity, both high and low contrast, using logMAR and the E-ETDRS (NIDEK SC-2000)."
223585454|NCT05266339|OTHER|Cross-education training|The strengthening exercises for rotator cuff muscles will be performed in the contralateral side of the affected side.
224170429|NCT05422690|RADIATION|Concurrent Y-90 treatment|Patients will undergo a Y-90 treatment planning consultation by the treating interventional radiologist during cycle 1. One or two cycles (depending on tumor size) of cisplatin, 25 mg/m2 and gemcitabine 300 mg/m2 given on day 1 and day 8 in combination with Yttrium-90 (Y-90) microspheres which will be given on day 3-7 or day 10-21 at the discretion of the interventional radiologist, separated in time by at least 2 days from a chemo infusion during that cycle
223482526|NCT02573714|DRUG|Ketamine|Intranasal ketamine (concentration: 50 mg/ml, dose: 1 mg/kg) will be given at time zero. Intranasal administration will be performed by placing the needleless syringe gently into the nares with the patient sitting upright. Volumes of ≤ 0.75ml will be nasally inhaled in a single nare, while volumes \> 0.75ml will be divided between both nares. Patients who are unable to inhale the medication nasally will receive drip administration of the same volume while recumbent on the bed.
223482527|NCT02573714|DRUG|Normal Saline|Intranasal normal saline (placebo: volume-matched with intranasal ketamine) will be given at time zero. Intranasal administration will be performed by placing the needleless syringe gently into the nares with the patient sitting upright. Volumes of ≤ 0.75ml will be nasally inhaled in a single nare, while volumes \> 0.75ml will be divided between both nares. Patients who are unable to inhale the medication nasally will receive drip administration of the same volume while recumbent on the bed.
223482528|NCT02573714|OTHER|Standard Pain Therapy|Typical management strategy for pediatric sickle cell disease vasoocclusive crises including acetaminophen/paracetamol, ibuprofen, oral opioids, and injectable opioids depending on pain severity.
223482529|NCT02573714|OTHER|Pediatric Quality of Life - Sickle Cell Disease Module|Standardized quality of life assessment performed 2-3 weeks post intranasal medication administration to evaluate pain management and severity of symptoms after discharge from the hospital.
223585455|NCT05266339|OTHER|Standard exercise program|The standard exercise program, which prepared according to The American Society of Shoulder and Elbow Therapists' consensus statement on rehabilitation following arthroscopic rotator cuff repair, will be applied.
223585456|NCT05646862|DRUG|Inavolisib|Participants will be administered a 9 milligram (mg) inavolisib tablet orally once a day (PO QD) on Days 1-28 of each 28-day cycle.
224170430|NCT05422690|DRUG|Consolidation Doublet Therapy:|Gemcitabine 1000 mg/m2 and Cisplatin 25 mg/m2 given on days 1 and 8 of a 21-day cycle with durvalumab 1500 mg given on day 1 of each cycle for 3-5 additional cycles. For the cycle directly after Y-90, gemcitabine will be kept at a dose of 300 mg/m2 to minimize risk of toxicity.
224170431|NCT04576663|DRUG|Normal saline|Normal saline infusion simultaneous with subarachnoid block
224170432|NCT04576663|DRUG|Phenylephrine|Different infusion dose of phenylephrine simultaneous with subarachnoid block
224170433|NCT03537001|OTHER|Penthrox|Self-administration of penthrox by the patient under the supervision of a physician trained in its administration, in strict compliance with its MA.
224170434|NCT05522543|OTHER|Conventional treatment with Passive translatoric intervertebral glides|"Patient education (Postural correction, lifting, sitting and sleeping positions) • Hot Pack 10 mins~• PA Glides (Central and Transverse mobilizations) (10 sec each) x5 sets • Core stabilization exercise (Knee to chest, bridges, prone press ups, cat and camel stretches) • Home plan (bridges, knee to chest, cat and camel stretch and prone press ups"
223482530|NCT02573714|OTHER|Faces Pain Scale - Revised|All patients will answer the FPS-R at 0 minutes (immediately prior to receiving intranasal medication), 30 minutes, 60 minutes, and 120 minutes to assess current pain status.
223482531|NCT04091165|OTHER|My Plate Calorie Tracker|"My Plate Calorie Tracker is a user-friendly weight management, calorie record application, available for smart phone devices. Users have the option to input items manually (i.e., calories, carbohydrates, fats, and proteins), select from a list of popular food items, or scan barcodes on the food packaging. In addition to food entries, users can also enter daily water intake and physical activities. Once an account is created, data entered into the mobile application can be sync'd to the My Plate Calorie Tracker website."
223482532|NCT06083129|DRUG|Grafalon|10 mg/Kg/day IV for 3 consecutive days (day-3 to -1 before transplantation)
223482533|NCT06083129|DRUG|Thymoglobulin|2.5 mg/Kg/day IV for 2 consecutive days (day-3 and -2 before transplantation)
224170435|NCT05522543|OTHER|Conventional treatment with manual segmental lumbar traction|"Patient education (Postural correction, lifting, sitting and sleeping positions) • Hot Pack 10 mins~• Manual lumbar Traction (L1-L5) for 15-20 sec x5 sets • Lumbar facet gapping (LFG) in side lying (10 sec 3 sets) and Lumbar rotational facet gapping (LRFG) in side lying (10 sec 3 sets) • .Core stability exercises (Knee to chest, bridges, prone press ups, cat and camel stretches) • Home plan"
224170436|NCT06491992|DRUG|Chitosan Phonophresis|Chitosan Phonophresis, three times per week for four weeks.
224170437|NCT06491992|OTHER|selected physical therapy exercise|selected neck exercise and electrotherapy on cervical region
224170438|NCT03410602|PROCEDURE|Full-mouth supragingival scaling|Control group comprised of 15 patients who were treated with routine full-mouth supragingival scaling.
224170439|NCT03410602|PROCEDURE|Subgingival scaling|Test group comprised of 15 patients who were treated with subgingival scaling only around all banded first molars.
224170440|NCT03410602|DRUG|Subgingival irrigation|Test group comprised of 15 patients who were treated with subgingival irrigation only around all banded first molars with 0.2% chlorhexidine gluconate solution (Trade name: HEXIDINE), an antiseptic - antiplaque agent.
224170441|NCT02363673|OTHER|Individualised homoeopathic remedy in aqua distilla|Each participant is to receive an individualised homoeopathic remedy according to their symptoms and characteristic manifestations of their disorder.
224170442|NCT02085486|DEVICE|Ultrasound-assisted puncture|Portable ultrasound device
223482534|NCT03113734|OTHER|Construction and validation of a functional score|"All patients will be treated at the same way:~Completion of questionnaire by the physician with him. Once the consultation has been completed, the physician will issue prescriptions for the usual medical treatment, laximetry prescription (GNRB) to be performed when the knee is indolent and the prescription of the MRI to be performed .The physician will inform the patient that they should consult with the investigator's orthopedic surgeon once the results of GNRB and MRI are available.The study will end there for the patient. The surgeon will then follow his usual diagnostic procedure to decide on the future care of the patient."
223482535|NCT03851575|OTHER|Accelerated treatment of endocarditis|For the three main bacteria species we shorten the duration of antibiotic treatment
223482536|NCT03851575|OTHER|Usual guideline therapy|Usual guideline therapy
223482537|NCT00636727|PROCEDURE|arthrocentesis|Irrigate the TMJ with lactated ringers
223482538|NCT00636727|PROCEDURE|arthroscopy|The TMJ will be inspected with an arthroscope and the joint irrigated with lactated ringers
223482539|NCT00636727|PROCEDURE|arthroplasty|The disc will be surgically repositioned with open surgery
223482540|NCT01035138|DRUG|semagacestat|140mg administered orally, once daily for 24 months; dose reduction to 100mg or 60 mg possible due to intolerability
223482541|NCT03468621|PROCEDURE|Wound closure|Method of wound closure
223482542|NCT01518101|DRUG|Vildagliptin/ Metformin|Single pill combination of Vildagliptin/ Metformin (50/1000 mg).
223482543|NCT01518101|DRUG|Liraglutide|1.2 mg once daily by commercially available injection pens
223482544|NCT01518101|DRUG|Metformin|1000 mg tablets twice daily
223482545|NCT06032806|OTHER|moderate intensity|"* Arm circles~* Leg swings~* Lunges"
224170443|NCT02085486|OTHER|Standard|Standard inspection, palpation.
223482546|NCT06032806|OTHER|High intensity|"* Arm circles~* Leg swings~* Lunges~* Butt kicks"
223482547|NCT02916927|DRUG|Ketamine IV Infusion|Ketamine 0.3 mg/kg in 100mL normal saline minibag administered over 15 min and placebo 10 mL normal saline syringe administered over 1 minute.
224170444|NCT05211973|DEVICE|Wrist Actigraphy Device|a watch like wearable sensor
224170445|NCT05211973|DEVICE|Smart Body Weight Scale|a full body composition scale that provides fat and muscle mass, water retention, bone mass, and weight trends (conducted based on participant's abilities)
224170446|NCT05211973|DEVICE|Chair Scale|a wheel-chair compatible scale to measure body weight
224170447|NCT05211973|DEVICE|Handheld Body Fat Percentage Device|a handheld device that measures body fat percentage
224170448|NCT05211973|DEVICE|Bioelectric Impedance Analysis Scale|a research-grade full body composition scale that provides fat and muscle mass, water retention, bone mass, and weight trends (conducted based on participant's abilities)
223482548|NCT02916927|DRUG|Ketamine IV push|Ketamine 0.3 mg/kg in 10 mL normal saline syringe administered over 1 minute and placebo 100mL normal saline minibag administered over 15 min.
223482549|NCT04938336|BEHAVIORAL|Delphi Procedure and interviews|Delphi procedure with expert healthcare professionals and interviews with patients, healthcare professionals and informal carers
223482550|NCT00492011|DRUG|Ramelteon|Ramelteon 1 mg, tablets, orally, once nightly for 4 nights.
223482551|NCT00492011|DRUG|Ramelteon|Ramelteon 4 mg, tablets, orally, once nightly for 4 nights.
223482552|NCT00492011|DRUG|Ramelteon|Ramelteon 8 mg, tablets, orally, once nightly for 4 nights.
223482553|NCT00492011|DRUG|Placebo|Ramelteon placebo-matching tablets, orally, once nightly for 4 nights.
223585457|NCT05646862|DRUG|Fulvestrant|Participants will be administered 500 mg of fulvestrant on Days 1 and 15 of Cycle 1 and then on Day 1 of each subsequent 28-day cycle.
223585458|NCT05646862|DRUG|Alpelisib|Alpelisib will be administered to participants at the approved dose in combination with fulvestrant: 300 mg taken PO QD and on days 1-28 of each 28-day cycle.
223585459|NCT05710432|OTHER|Quasi-Isometric Neck Flexion|Patients will be asked to minimally lift their head from the pillow generating a quasi-isometric neck contraction (2 sets of 6-10 flexions).
224170449|NCT04400669|OTHER|Mechanical Bowel Preparation|oral sodium phosphate (NaP) enema
224170450|NCT04400669|DIETARY_SUPPLEMENT|Low fibre diet|3 days
224170451|NCT04400669|OTHER|MBP plus low-fibre diet|3 days low fibre diet preoperative mechanical bowel preparation
224170452|NCT03942640|OTHER|subctaneous perineural injection|"Buffered glucose preparation :~2.4 ml of Na Bicarbonate 8.4% are mixed with 500ml dextrose 5%. Patients received 8 weekly injection"
224170453|NCT03942640|OTHER|deep prolotherapy|The injection fluid contain 1 ml of 255 glucose and 1ml of lidocaine
224305658|NCT04673513|OTHER|Psychotherapy|In light of COVID-19 considerations, interventions are currently being provided via telehealth technology.
224305659|NCT02876575|DEVICE|A bipolar instrument for tonsillectomies|A bipolar electrosurgical device that employs RF energy and pressure to ligate vessels interposed between its jaws which can then be transected using the built in knife deployed by the device trigger.
224305660|NCT06417138|OTHER|biological and targeted synthetic disease modifying anti rheumatic drugs (bDMARDs) and (tsDMARDs)|This is a registry-based study. It is an observational, retrospective trial. There is/are no interventional drug(s).
224305661|NCT03041649|OTHER|GT button change - Mic-Key|After 2 months with each button, parents will be asked which button they prefer at the 4-month post-operational follow-up visit.
224305662|NCT03041649|OTHER|GT button change - Mini One|After 2 months with each button, parents will be asked which button they prefer at the 4-month post-operational follow-up visit.
224305663|NCT04559971|DRUG|SLN124|SLN124 for subcutaneous (s.c.) injection
224305664|NCT04559971|DRUG|Placebo|Sodium chloride for s.c. injection
224305665|NCT00199771|DRUG|7.5% NaCl in 6% dextran 70 solution|
224305666|NCT00193427|DRUG|Docetaxel|30mg/m2 administered on days 1 and 8, 21-cycle days, 3 cycles
224305667|NCT00193427|DRUG|Gemcitabine|1000 mg/m2 administered by 30-minute IV infusion on day 1 and 8, 21-cycle days, 3 cycles
224305668|NCT00193427|DRUG|Carboplatin|AUC = 1.5 weekly x 7
224305669|NCT00193427|RADIATION|Radiation|To 63 Gy
224305670|NCT03787576|DEVICE|Cataract surgery|Evaluation of patient satisfaction after bilateral cataract surgery with multifocal intraocular lens implantation
224305671|NCT04213976|PROCEDURE|Ileostomy|Use of an ileostomy to decompress the proximal bowel, perfored either as a conventional loop ileostomy or as described by Santulli et al. or by Bishop and Koop.
224305672|NCT04099173|BEHAVIORAL|Brief Mindfulness Based Intervention|This intervention will consist of four, 45 minute individual mindfulness training sessions (one session per day, over a range of 12 subsequent days) provided by a trained mindfulness facilitator.
224305673|NCT01072474|PROCEDURE|Capnography|Capnographic monitoring
224305674|NCT01072474|PROCEDURE|Standard monitoring|Standard monitoring
224305675|NCT03170427|DEVICE|Impedance cardiography|hemodynamic variation measured by impedance cardiography in healthy pregnant undergoing to cesarean section treated with 8mg or 6mg of levobupivacaine
224305676|NCT03170427|DIAGNOSTIC_TEST|Sensory levels|Sensory levels are checked using ice test cold
224170454|NCT02506972|OTHER|Classic Quaker Quick Oats|Various doses of oats without or with sugar
224170455|NCT02506972|OTHER|Cream of Rice Cereal|Various doses of cereal without sugar
224170456|NCT06038968|DRUG|Methotrexate 25 MG/ML|Methotrexate is a folate derivative that inhibits several enzymes responsible for nucleotide synthesis. This inhibition leads to suppression of inflammation as well as prevention of cell division.
224170457|NCT06038968|PROCEDURE|parsplana vitrectomy|Pars plana vitrectomy (PPV) is a technique in vitreoretinal surgery that enables access to the posterior segment for treating tractional retinal detachment in advanced proliferative diabetic retinopathy, in a controlled, closed system.
224170458|NCT03530189|DRUG|10% dextrose|After birth the intravenous 10% dextrose at 60-90 ml/kg/day will be started as soon as possible
224170459|NCT03530189|DRUG|bolus of dextrose, reducing the glucose infusion, insulin|"Hypoglycemia will be treated with 2 mL/kg to 3 mL/kg (200-300 mg/kg) intravenous bolus of 10% dextrose.~Hyperglycemia will be managed by reducing the glucose infusion rate or initiation of an insulin infusion."
224170460|NCT04837768|DRUG|Twice-daily transvaginal progesterone supplementation|Patients with serum progesterone levels \>9.2 ng/ml on the day of embryo transfer in artificial frozen cycles will receive the traditional twice-daily vaginal progesterone supplementation till 12 weeks gestation.
224170461|NCT04837768|DRUG|Twice-weekly intramuscular + Twice-daily transvaginal progesterone supplementation|Patients with serum progesterone levels \<9.2 ng/ml on the day of embryo transfer in artificial frozen cycles will receive the twice-daily vaginal progesterone in addition to twice-weekly intramuscular progesterone supplementation till 12 weeks gestation.
224170462|NCT02894606|DRUG|Thymoglobulin Induction|The choice of the induction therapy is not a procedure of the study. This choice is made by the practioner, based on the graft recipient profile. This is a predefined group, the Thymoglobulin treatment is not an intervention in the study but must be considered as an exposure that is defined before the patient enters the study.
224305677|NCT03170427|DIAGNOSTIC_TEST|Motor block|motor block is measured by modified Bromage scale
224305678|NCT03170427|DIAGNOSTIC_TEST|Sensory level|Sensory levels are checked using touch with alcohol puffs
224305679|NCT04682730|BEHAVIORAL|Deliberative Loop|"The investigators will give background information to the stakeholders before they engage in the Deliberative session.~Stakeholders from a given clinic will come together for a Deliberative session (i.e., facilitated conversation), enabling them to hear the full range of perspectives held by their fellow colleagues and to share their own perspective regarding how best to implement the guideline in small-group discussions.~Following the Deliberative session, each stakeholder will have the opportunity to record their opinions regarding possible implementation interventions. The investigators will share these opinions with the clinic's decision-makers to help guide their decision-making about which implementation interventions to deploy. If a stakeholder happens to be absent the day of their clinic's Deliberative session, they will still have the opportunity to complete the survey."
224305680|NCT02683265|DRUG|Aptensio XR|Optimized dose of Aptensio XR (10, 15, 20, 30 or 40 mg) administered orally, once daily
224305681|NCT02683265|DRUG|Placebo|Placebo capsules
224305682|NCT06420791|OTHER||
224170463|NCT02894606|DRUG|Basiliximab Induction|The choice of the induction therapy is not a procedure of the study. This choice is made by the practioner, based on the graft recipient profile. This is a predefined group, the Basiliximab treatment is not an intervention in the study but must be considered as an exposure that is defined before the patient enters the study.
224170464|NCT01944462|BEHAVIORAL|Pharmacist Pneumococcal Vaccine Program (PPVP)|1.5 hour educational intervention delivered onsite at collaborating senior center consisting of 3 components: presentation about pneumococcal disease and the vaccine given by a infectious disease-certified pharmacist; 2) skits given by volunteer actors at the senior center to illustrate real world scenarios related to pneumococcal disease and the vaccine; 3) action planning to consist of small group breakouts led by licensed pharmacists and 4) vaccination day which is an optional component following the education program, for participants eligible to receive the vaccine. Vaccination to be provided free of charge to eligible participants who opt to receive it.
224170465|NCT03702023|DRUG|Acetaminophen|Intervention group will receive 1000 mg of acetaminophen
224170466|NCT03702023|DRUG|Placebo Oral Tablet|Control group will be given a placebo capsule.
224170467|NCT02672306|BIOLOGICAL|UCMSCs|Biological: Human UCMSCs 20 million cells per subject (0.5×10\^6 UCMSCs per kg) intravenous injection Infusion number: 8 (Once every two weeks)
224170468|NCT02672306|BIOLOGICAL|Placebo|Subjects with Alzheimer's Disease placebo comparator (normal saline) intravenous injection Infusion number: 8 (Once every two weeks)
224170469|NCT05193292|DRUG|Camrelizumab|200mg, iv, 21d for a treatment cycle
224170470|NCT05193292|DRUG|Trastuzumab|8 mg/kg loading dose, followed by 6 mg/kg maintenance, iv, 21d for a treatment cycle
224170471|NCT05193292|DRUG|XELOX regimen|Oxaliplatin, 130 mg/m2, iv, d1; Capecitabine, 1000 mg/m2, po, bid, d1-d14; q3w
224170472|NCT05193292|DRUG|mFOLFOX6 regimen|Oxaliplatin, 85 mg/m2, iv, d1; Leucovorin, 400 mg/m2, iv, d1; 5-FU, 400mg/m2, iv, d1 followed by 1200 mg/(m2·d)\*2d, civ, 46h; q2w
224170473|NCT05193292|DRUG|FOLFIRI regimen|Irinotecan, 180 mg/m2, iv, d1; Leucovorin, 400 mg/m2, iv, d1; 5-FU, 400mg/m2, iv, d1 followed by 1200 mg/(m2·d)\*2d, civ, 46h; q2w
224170474|NCT05193292|DRUG|mXELIRI regimen|Irinotecan, 200 mg/m2, iv, d1; capecitabine, 800 mg/m2, po, bid, d1-d14; q3w
224170475|NCT05193292|DRUG|mIRIS regimen|Irinotecan, 180 mg/m2, iv, d1; Tiggio Capsules (S-1), 40-60 mg/m2, po, bid, d1-d9; q2w
224170476|NCT00231972|BEHAVIORAL|Project Enhance|The behavioral intervention will be administered by a trained medical social worker on an individual basis. It will include an education component, as well as motivational and behavioral skills enhancement. Treatment will occur for only the first 3 months, after which follow-up sessions will be held every 3 months for the remainder of the year.
224170477|NCT00231972|BEHAVIORAL|Standard prevention case management (PCM)|Participants will receive standard PCM for HIV prevention.
224170478|NCT05924997|DRUG|adebrelimab, camrelizumab plus apatinib|adebrelimab (RP2D, Q3W)+ camrelizumab 200mg Q3W+ apatinib 250mg qd, with 3 weeks (21 days) as a treatment cycle
224170479|NCT03225027|BEHAVIORAL|Emotional judgment task|Participants had to indicate on a computer the emotional intensity of audio recordings.
224170480|NCT03225027|BEHAVIORAL|Post-experimental questionnaire|Participants will be invited to give us the cognitive strategy used to resolve the emotional judgment task.
223482554|NCT05446103|OTHER|Blood flow restriction training|"After warming up, the load is set at 80% of the predicted 1Repetition Maximum (RM) for elbow flexors. Following each successful repetition, the load is increased by 0.5 to 1kg until patients: fail to execute the exercise through the entire range of motion; used improper form to complete the repetition; needed assistance; reported pain. We will allow a 2-3 min of rest between each attempt to ensure recovery.~The session starts by calculating the arterial occlusion pressure in the standard anatomical position. Participants rest in the standing position for 3-5 minutes before measurement to ensure restoration of blood flow circulation and a cuff is placed in the most proximal part of their dominant upper-limb. BFR application is conducted by using an automatic personalized tourniquet system (Mad-Up Pro, France). An 40% occlusion pressure is set and subjects perform 4 sets of elbow flexion (30-15-15-15 reps) using 30% of 1 RM"
223585460|NCT05710432|OTHER|Inspiratory Muscle Training|"Patients will be asked to complete 2 sets of 6-10 breaths through a POWERbreathe device, which applies a variable resistance provided by an electronically controlled valve (variable flow resistive load).~During each IMT and neck flexion maneuver ultrasound measurements will be performed (measurements of the diaphragm, sternocleidomastoid, parasternal intercostal, internal oblique \[IO\], external oblique \[EO\], transversus abdominis \[TrA\] and rectus abdominis \[RA\] will be taken) and, during the entire period, sEMG monitoring of the target muscles (diaphragm, sternocleidomastoid, parasternal intercostal and EO) will be continued."
223585461|NCT06441617|DEVICE|Online Program for Fatigue|An MS-specific fatigue management program, delivered as a stand-alone, fully automated intervention via an internet-browser.
224170481|NCT03225027|BEHAVIORAL|Recognition task|Participants will be invited to indicate which recordings they had heard during the emotional judgment task to verify that they have paid attention to the emotional task.
224170482|NCT03225027|BEHAVIORAL|Detection task|Participants indicate every time they heard a given sound in order to verify their audition level.
224170483|NCT03225027|OTHER|CAPE-42|This questionnaire allows evaluating the nature of psychotic experiences.
224170484|NCT03225027|DIAGNOSTIC_TEST|Trait Emotional Intelligence Questionnaire|To evaluate their emotional intelligence.
224170485|NCT03225027|DIAGNOSTIC_TEST|Positive And Negative Syndrome Scale|Evaluating the clinical status of patients with schizophrenia.
224170486|NCT03225027|OTHER|Mini International Neuropsychiatric Interview|Evaluating the exclusion criteria in healthy participants.
224170487|NCT05950373|OTHER|Education video|six minute long education video focusing on protein and energy meals for older adults.
224170488|NCT01304927|DRUG|Cholecalciferol and calcium|Initial one dose oral mixture of 300.000 IU Cholecalciferol followed by 5 months treatment with one tablet daily containing 35 ug Cholecalciferol and 500 mg calcium
224170489|NCT01304927|OTHER|Placebo|microcrystalline cellulose maltodextrin Arachidis oil
224170490|NCT02023892|DRUG|atorvastatin|
224170491|NCT02023892|DRUG|placebo|
224170492|NCT04665492|DIAGNOSTIC_TEST|EEG recording 1|"Multichannel EEG recording in eyes opened and eyes closed relaxed state and during imagined movement (all one experimental session). EEG device usbamp (company Guger Technologies, Austria) will be used."
223482555|NCT05446103|OTHER|Sham Blood flow restriction training|"After warming up, the load is set at 80% of the predicted 1Repetition Maximum (RM) for elbow flexors. Following each successful repetition, the load is increased by 0.5 to 1kg until patients: fail to execute the exercise through the entire range of motion; used improper form to complete the repetition; needed assistance; reported pain. We will allow a 2-3 min of rest between each attempt to ensure recovery.~The session starts by calculating the arterial occlusion pressure in the standard anatomical position. Participants rest in the standing position for 3-5 minutes before measurement to ensure restoration of blood flow circulation and a cuff is placed in the most proximal part of their dominant upper-limb. BFR application is conducted by using an automatic personalized tourniquet system (Mad-Up Pro, France). An \<20% of occlusion pressure is set and subjects perform 4 sets of 10 reps of elbow flexion using 65% of 1 RM"
223482556|NCT06235554|PROCEDURE|Renal Stimulation|Renal Denervation procedure as per hospital routine practice
223482557|NCT06532305|BEHAVIORAL|HOPE empowerment classes|A three-month empowerment course.
223482558|NCT01154660|OTHER|Tidal Volume|observation of IJV circumference and cross sectional area using ultrasonography by changing of tidal volume
223482559|NCT00392106|DRUG|propafenone|Anti-arrhythmic drug prescribed for treatment of atrial fibrillation
223482560|NCT00392106|DRUG|flecainide|Anti-arrhythmic drug prescribed for the treatment of Atrial fibrillation
223482561|NCT00392106|DRUG|dofetilide|Anti-arrhythmic drug prescribed for treatment of atrial fibrillation
223482562|NCT00392106|DRUG|sotolol|Anti-arrhythmic Drug prescribed for treatment of Atrial Fibrillation
223482563|NCT00392106|DEVICE|Pulmonary vein ablation|Electrical isolation of pulmonary vein with high-intensity focused ultrasound
223482564|NCT00392106|DRUG|Amiodarone|Anti-arrhythmic Drug prescribed for the treatment of Atrial Fibrillation
223482565|NCT06160271|DRUG|PET scan of 68Ga-FAPI|Use of a positron emission tomograph equipped with an X-ray scanner (PET/CT), essential for recording images after injection of a positron-emitting radiopharmaceutical (in this study, 68Ga-FAPI-46).
223482566|NCT04909060|DEVICE|noninvasive blood pressure, 3 lead ECG, peripheral oxygen saturation|Children between 1 and 3 years old, scheduled for elective adeno-tonsillectomy, tonsillectomy or adenoidectomy and with no neurological or cardiac congenital deficits, no cardiac arrythmias (non-sinus rhythm), no implanted pacemakers, nor with a history of prolonged resuscitation at birth, and chronic therapy with drugs that have known effects on sympathetic and parasympathetic activity, ASA physical status III or higher and parent/guardian refusal will have a NIPE placed on their electrocardiogram, at least 20 minutes before the expected end of the surgery, the NIPE monitor will be connected to the anesthesia monitor at the end of the surgery, when the patient is considered ready to be transferred to the PACU, the NIPE will be disconnected and reconnected to the patient monitor once in PACU. Values will be recorded until the patient meets the discharge criteria from PACU not before 2hours
224170493|NCT04665492|DIAGNOSTIC_TEST|EEG recording 2|"Multichannel EEG recording in eyes opened and eyes closed relaxed state and during imagined movement (all one experimental session). This intervention will take place six month after EEG recording 1. EEG device usbamp (company Guger Technologies, Austria) will be used."
224170494|NCT04665492|DIAGNOSTIC_TEST|Sensory Test|Test for mechanical sensations of the feet and shins of both legs as well as on the trapezoidal muscle on both sides. Semmes-Weinstein Monofilaments will be used
223482567|NCT04440488|BIOLOGICAL|ARALAST NP|Partcipants will be randomized to receive ARALAST NP 60 or 120 mg/kg BW/week IV infusion for a total of 104 weeks.
223482568|NCT03153657|DRUG|Piroxicam-Beta-Cyclodextrin|The patients will receive a single-dose of Piroxicam-Beta-Cyclodextrin (20 mg) thirty minutes before the bleaching procedure.
223482569|NCT03153657|DRUG|Placebo|The patients will receive a single-dose of placebo with the same presentation of the experimental drug thirty minutes before the bleaching procedure.
223482570|NCT00655889|BIOLOGICAL|Autologous Human Fibroblasts (azficel-T)|"1. Collection of biopsy from palate~2. Papillary priming procedure~3. Seven injection treatments to target sites~4. Performance of study assessments (investigator and subject)"
223482571|NCT02255747|DRUG|Lactulose|
223482572|NCT02721784|DEVICE|mpMRI/VERDICT|Combined MRI sequences of T2, DCE, Diffusion and VERDICT
223482573|NCT02721784|RADIATION|External Beam Radiotherapy|78Gy (Gray) to Prostate +/- Pelvic
223482574|NCT01281696|DRUG|Bevacizumab, etoposide, cisplatin|Bevacizumab (15mg/kg) on D1, etoposide (70mg/m2) on D2-D4, cisplatin (70mg/m2) on D2; 21 days a cycle, for a maximum of 6 cycles
223482575|NCT01281696|DRUG|Intrathecal methotrexate|Additional intrathecal methotrexate only given in patients with leptomeningeal metastasis
223482576|NCT04945811|DIAGNOSTIC_TEST|Interlukein 6 and procalcitonin serum levels|Blood tests
223482577|NCT06381232|OTHER|No Intervention|This is an observational study, there are no interventions.
223482578|NCT02688790|DRUG|Dalbavancin|
223482579|NCT00439998|PROCEDURE|Ultrasound|ultrasound scan of the lumbar spine with 2-5 MHz curved array probe
223585462|NCT06231966|DRUG|Combination therapy of high-intensity dose rosuvastatin and ezetimibe|Combination therapy of rosuvastatin 20 mg and ezetimibe 10 mg
223585463|NCT06231966|DRUG|Rosuvastatin monotherapy for treat-to-target|Rosuvastatin monotherapy for treat-to-target (LDL cholesterol \<70 mg/dL)
223585464|NCT04214678|PROCEDURE|Underwater clip closure|Closure of post-resection defect with endoscopic clips by underwater technique
223585465|NCT04214678|PROCEDURE|Conventional clip closure|Closure of post-resection defect with endoscopic clip by conventional technique
224170495|NCT04665492|DIAGNOSTIC_TEST|Brief Pain Inventory 1|This questionnaire that ask about any acute or chronic pain
224170496|NCT04665492|DIAGNOSTIC_TEST|Multidimensional health locus of control|Questionnaire that test personal belief about control of one's own health
224170497|NCT04665492|DIAGNOSTIC_TEST|Sensory test thermal|"Test of thermal sensations (thermal roller) of the feet and shins of both legs as well as on the trapezoidal muscle on both sides. A Somedic SenseLab Rolltemp device will be used"
224170498|NCT04665492|DIAGNOSTIC_TEST|Neuropathic pain symptoms|Questionnaire that test for neuropathic pain symptoms
224170499|NCT04665492|DIAGNOSTIC_TEST|McGill pain questionnaire|Questionnaire assess three separate components of experiencing pain; the sensory intensity, the emotional impact and the cognitive evaluation of pain.
224170500|NCT04665492|DIAGNOSTIC_TEST|Pain Catastrophising Scale|Questionnaire use to identify individual pain experience.
224170501|NCT01854957|BIOLOGICAL|Autologous Mesenchymal Stem Cells|Single dose of 1-2 x 1000000 cells/Kg body weight
223585466|NCT06523985|BEHAVIORAL|Push messages (standard)|Push messages will be developed based on best practice recruitment principles in cooperation with an external marketing team and then reviewed and finalized by the study team. Messages will be different each month and sent across 12 months. The monthly time frame was selected based on our need to balance contact with responders and research or expert opinions on push messaging saturation.
224170502|NCT03307408|OTHER|blood collection|Standard routine practice clinico-biological data will be collected
224170503|NCT02532816|DIETARY_SUPPLEMENT|Nutrient dense complementary foods|"Mothers/caregivers will receive optimized CFRs to improve children diets and fortified biscuits (3 types of biscuit) for 6 days per week (in 12 months).~Nutrition eduction for mothers/caregivers. Monthly body weight and length/height measurements"
224170504|NCT03175822|BEHAVIORAL|Visual Arts Training|The art training program has been designed as a drawing program and focuses on basic visual art concepts (the elements \[e.g., colour and line\] and principles \[e.g., proportion and balance\] of design). Each week has a different activity and a different focus (one activity per week focusing on one element and principle of design). Each art training program will occur one hour per day, two days per week, for eight weeks. The art training program will take place at the participants' respective dementia care location in an area separate from waitlist control participants and uninvolved clients. All art programs are free for participants.
224170505|NCT01207921|DRUG|Lenalidomide|
224170506|NCT02696590|DIETARY_SUPPLEMENT|Vitamin D3|two forms of vitamin D3 (Oral versus injection) were compared in MS and healthy groups.
224305683|NCT04241991|RADIATION|Active laser|Participants will receive laser irradiation on the rectus femoris muscle of both legs immediately before the test (trial 1) and training (trial 2) sessions. A researcher blinded to the treatment conditions will apply the irradiation on eight points distributed over the muscle belly, using a gallium arsenide aluminum (Ga-As-Al) laser (λ: 808 nm) equipment. The points will placed at 25, 35, 50 and 75% of the total distance between the anterior superior iliac spine and superior border of the patella, bilaterally, with 2 cm of distance between each point.
223585467|NCT06523985|BEHAVIORAL|Push messages (customized)|These messages are similar to content in the standard push messages but are customized to address common misperceptions about opioid overdose and naloxone.
224170507|NCT01181336|BIOLOGICAL|Influenza vaccine (FLU-v)|Comparison of different dosages of FLU-v (sterile lyophilised mixture of polypeptide T-cell epitope sequences). Administration: A single subcutaneous injection of (Low Dose / High Dose with adjuvant / water for injection)
224170508|NCT01181336|BIOLOGICAL|FLU-v Control|Adjuvant only or water for injection only Administration: a single subcutaneous injection
224170509|NCT02827084|DEVICE|Kinesio Taping|Application of the Kinesio Taping with tension in the vatus mediallis muscle.
224305684|NCT04241991|RADIATION|Placebo laser|Participants will receive placebo irradiation on the rectus femoris muscle of both legs immediately before the test (trial 1) and training (trial 2) sessions. A researcher blinded to the treatment conditions will apply the placebo irradiation on eight points distributed over the muscle belly. The points will placed at 25, 35, 50 and 75% of the total distance between the anterior superior iliac spine and superior border of the patella, bilaterally, with 2 cm of distance between each point.
224305685|NCT05294939|DIETARY_SUPPLEMENT|Ketone monoester|Consumption of 800mg/kg body weight of ketone monoester, divided in two intakes. The mixture will be prepared with bicarbonate. In addition, every hour they should consume 90g of carbohydrates.
224305686|NCT05294939|DIETARY_SUPPLEMENT|Control product consumption|Consumption of placebo product (carbohydrates) masked with citric, divided in two intakes. The mixture will be prepared with bicarbonate. In addition, 90g of carbohydrates should be consumed every hour.
224305687|NCT05031689|BIOLOGICAL|SPF 30 sunscreen plus pharmaceutical formulation without green banana peel extract|Control Group will use SPF 30 sunscreen plus pharmaceutical formulation without green banana peel extract
224305688|NCT05031689|BIOLOGICAL|SPF 30 sunscreen and pharmaceutical formulation containing green banana peel extract|Study Group In addition to the SPF 30 sunscreen, a pharmaceutical formulation containing green banana peel extract will be used.
224305689|NCT02261844|DIETARY_SUPPLEMENT|Resveratrol|Resveratrol 1 gm po x 10 days prior to liver resection
224305690|NCT02261844|DRUG|Placebo|Placebo 1 pill daily X 10 days
224305691|NCT06514690|OTHER|Sedation|Different degrees of intravenous sedation according to the Ramsay scale
224305692|NCT04565613|DIETARY_SUPPLEMENT|Enteral protein supplementation|"The participants in the study interventional group will receive protein supplementation to reach a final goal of 1.5 g/kg/day of protein on full feeds. This will be via 100% whey protein isolate (Nestle Beneprotein). Doses will be calculated on the patient's admission weight and rounded up to the nearest 1g. Doses will not be adjusted to account for weight changes in the PICU.~Protein supplementation will continue for a total of 7 days from the start of enrolment into the study or until PICU discharge, whichever is earlier. If the patient is able to take solid feeds during the study intervention period, the intervention will be stopped. However, if the device required for feeding is removed but the patient takes milk/liquid feeds fully, protein supplementation will continue."
224305693|NCT05285670|BEHAVIORAL|Digital counseling plus interactive two-way SMS dialogue|We will utilize a digital counseling tool on a tablet to provide initial reproductive life planning counseling while waiting for an HIV care provider. We will then use Mobile WACh, a human-computer hybrid system that enables seamless two-way SMS communication and patient tracking, to provide consistent support to women following enrollment and for up to 2 years. Women will receive automated theoretically grounded SMS messages targeting the appropriate reproductive health needs and will have the capability to respond and spontaneously message a nurse based at the clinic. . Automated SMS will be delivered at times and in languages based on patient preferences, weekly the first 3 months, every other week in months 4-12, and monthly during the last year of the trial. If there is a change in the reproductive health needs, more frequent messaging will be re-initiated at the same frequency as enrollment.
224305694|NCT00771745|DRUG|Thymoglobulin|Preloading Induction with Thymoglobulin® X 4 doses given day -4, day -2, day 0, and day 2 at 1.5 mg/kg/dose + corticosteroid taper + tacrolimus + MMF
224170510|NCT02827084|DEVICE|Placebo|Application of the Kinesio Taping without tension in the vatus mediallis muscle.
224170511|NCT05836428|OTHER|no intervention|no intervention
224170512|NCT03484052|OTHER|Jugular ultrasound|Performing a jugular ultrasound by 2 operators before and after transfusion
224170513|NCT02094781|DIETARY_SUPPLEMENT|Whey protein and creatine supplement|Each sachet contained 30g whey protein powder and 5g creatine powder, administered twice a day. The first serving was consumed with breakfast and the second serving was consumed within 60 minutes of completing training or in the evening on non-training days. Participants also drank at least 2 litres of water per day
224170514|NCT02094781|DIETARY_SUPPLEMENT|Whey protein only supplement|Each sachet contained 30g of whey protein powder and 5g of bulking agent powder, administered twice a day. The first serving was consumed with breakfast and the second serving was consumed within 60 minutes of completing training or in the evening on non-training days. Participants also drank at least 2 litres of water per day
224170515|NCT02094781|DIETARY_SUPPLEMENT|Placebo|Each sachet contained 30g of isocaloric carbohydrate powder and 5g of bulking agent powder, administered twice a day. The first serving was consumed with breakfast and the second serving was consumed within 60 minutes of completing training or in the evening on non-training days. Participants also drank at least 2 litres of water per day
224305695|NCT00771745|DRUG|Thymoglobulin|Preloading Induction with Thymoglobulin® X 3 doses given day -4 (1.5mg/kg), day -2 (1.5mg/kg), and day 0 (3mg/kg) + corticosteroid taper + tacrolimus + MMF
224305696|NCT04995705|BEHAVIORAL|Acceptance and Commitment Therapy (ACT)|"ACT is a psychological intervention. ACT encourages individuals to remain open to internal experiences (positive, negative and neutral), rather than attempting to control or ameliorate them (which may only serve to increase pain and suffering). It also encourages individuals to focus on committing to a life that is congruent with their core values, regardless of the experiences that show up for them. The premise of this model is to learn to modify the relationship one has with their internal experiences (thoughts, feelings, physical sensations etc.), rather than change the experiences per se. This is achieved through different processes including mindfulness, acceptance, defusion and exploration of values. These core tenets of ACT help to cultivate psychological flexibility.~This ACT intervention is delivered as a 5-week group for stroke survivors and adults with brain injury. It comprises of experiential and didactic components."
224305697|NCT01725776|DRUG|Inhaled milrinone 5 mg|Inhaled milrinone 5 mg (as for the injectable solution)
224305698|NCT05341882|BEHAVIORAL|Mindfulness|Participants took part in a live, facilitated Zoom-delivered training that involved learning mindfulness and education about moral injury. The participants were interviewed regarding the program.
223482580|NCT03164824|OTHER|questionnaire|"Cross-cultural adaptation stage:~The FRI was cross-culturally adapted to Thai (called the Thai FRI) and the pre-final version of the Thai FRI was administered to patients.~Psychometric properties testing stage:~The questionnaires were administered 3 times: the first visit, the second visit and at 2 weeks.~At the first visit: the patients with back pain completed the Thai FRI , Thai Roland-Morris Disability (Thai RM), Thai modified Oswestry Low Back Pain Disability (Thai modified ODQ), Thai multi-level Roland-Morris Disability (Thai multi-level RM). The patients with neck pain completed the Thai FRI and Thai Neck Disability Index.~At the second visit: all patients completed the Thai FRI and Global Perceived Effect Scale (GPES).~At 2 weeks: the patients completed the same questionnaires as the first visit. All patients and their treating physical therapists completed the GPES."
223482581|NCT03922373|DRUG|Group A: Benzonatate 100mg|Subjects in group A will be given benzonatate 100mg once after a 10-hour fast in the first day of the trail
223482582|NCT03922373|DRUG|Group B: Benzonatate 200mg|Subjects in group B will be given benzonatate 200mg once after a 10-hour fast in the first day of the trail, and they will be given benzonatate 200mg thrice in the second and third day of the trail, in the fourth day, they will be given benzonatate 200mg once after a 10-hour fast.
223482583|NCT03922373|DRUG|Group C: Benzonatate 400mg|Subjects in group C will be given benzonatate 400mg once after a 10-hour fast in the first day of the trail
223482584|NCT01093508|DRUG|APD916|
223482585|NCT03475238|PROCEDURE|Nursing care|The nursing care will be defined as a lateral mobibization and a length of care superior or equal to 10 min
223482586|NCT01811719|BEHAVIORAL|Enhanced NFP (NFP+)|Women in the experimental group received three possible interventions. First they received regular and periodic structured intimate partner violence (IPV) assessments from their nurse. Those who indicted any IPV - whether physical violence or emotional abuse or controlling behavior - were then given the Parker-McFarlane Brochure Intervention. Finally, all women were provided the Markman and Stanley Within My Reach curriculum according to their needs and interests.
223482587|NCT01811719|BEHAVIORAL|NFP as usual|The Nurse Family Partnership is a well-known and widely used nurse home visit program developed by David Olds. It has been rigorously tested and replicated and is now considered a best practice.
223744998|NCT02517996|DRUG|Lidocaine|Total 20cc (10cc bilateral) of 1% Lidocaine: Lidocaine is a commonly used anesthetic agent suitable for infiltration, block and surface anesthesia. It is characterized by a rapid onset of action, intermediate duration of efficacy, and its elimination half-life is 90-120 minutes. Lidocaine alters signal conduction in neurons by blocking the fast voltage gated sodium (Na) channels in the neuronal cell membrane that are responsible for signal propagation. With sufficient blockage the membrane of the postsynaptic neuron will not depolarize and will thus fail to transmit an action potential. This creates the anesthetic effect by not merely preventing pain signals from propagating to the brain but by stopping them before they begin. Adverse drug reactions are rare when lidocaine is used as a local anesthetic and when administered correctly.
223482588|NCT04270877|DRUG|Naltrexone Pill|Treatment with LDN for 12 weeks, including af titration phase of 4 weeks. Initial dosage of 1.5 mg, dose is increased by 1.5 mg every 7th day to 6 mg at week 4. Dosing is increased based on safety and tolerability and delayed increments are allowed. The participants are maintained on the highest tolerable dose for the last 8 weeks of the treatment period.
223482589|NCT04270877|DRUG|Placebo oral tablet|Treatment with LDN-placebo for 12 weeks, including af titration phase of 4 weeks. Initial dosage of 1.5 mg, dose is increased by 1.5 mg every 7th day to 6 mg at week 4. Dosing is increased based on safety and tolerability and delayed increments are allowed. The participants are maintained on the highest tolerable dose for the last 8 weeks of the treatment period.
223482590|NCT04376567|PROCEDURE|One stage approach|Upper extremity brachial basilic arteriovenous fistula will be created either using one stage or two stage approach.
223744999|NCT02517996|DRUG|Placebo|Patients randomized in this arm will receive preemptive bilateral pudendal nerve block with 20 cubic centimeters normal saline after anesthesia induction.
224170516|NCT01222767|DRUG|Zalypsis|Zalypsis is provided as a lyophilized powder for concentrate for solution for infusion in a strength of 2.5 mg/vial.
224170517|NCT04768920|BEHAVIORAL|MI-CBT Teletx|"Participants will first receive a 20-45 min phone or video session focused on raising participants' motivation to engage in treatment activities and psychoeducation material about substance use (i.e. engagement session) including possible discussion about risks of substance use, value of alternative healthier activities, and the community and crisis resources pamphlet. The evidence-based manualized psychosocial programs that will be delivered via telehealth are adaptations of cognitive behavioral therapy, motivational interviewing, and other psychosocial interventions to enhance initial and ongoing treatment engagement. TeleTx consists of up to 8 \~30-50 minute psychosocial sessions delivered via phone or videoconference platform (e.g. Zoom etc)"
224170518|NCT05202249|PROCEDURE|muscle layer fixation of thoracic drainage tube|The thoracic drainage tube is fixed on the muscle layer of the uniport
224170519|NCT05427058|PROCEDURE|Superior Hypogastric Plexus Block|this procedure uses a transdiscal approach at the level of the L5-S1 vertebrae by injecting 5 ml of 1% lidocaine + 10 ml of 96% alcohol and confirmed by C-arm.
224170520|NCT05427058|PROCEDURE|Ganglion Impar Block|this procedure uses a trans-sacrococcygeal approach by injecting 4 ml of 1% lidocaine + 6 ml of 96% alcohol and confirmed by C-arm.
224305699|NCT05341882|BEHAVIORAL|Educational Support|As an active control condition, the investigators developed an education support (ES) group, which ran concurrently to the mindfulness intervention group. Within the military community, peer support and psychoeducation are considered critical components of alleviation of suffering from traumatic exposure.
224305700|NCT00105976|DRUG|MM-093|
224305701|NCT03810755|OTHER|Personalized Supervised physical activity|personalized exercise program for patients, supervised during 3 months by nursing in primary and autonomous care afterwards, with support from community resources
223482591|NCT04585893|DRUG|Rituximab|375 mg/m\^2 administered via IV infusion weekly for four weeks. Administered via slow IV infusion, starting at 50mg/hr and increasing by 50mg/hr every 30 minutes to a maximum infusion rate of 400mg/hr.
223482592|NCT04585893|DRUG|Etoposide|Subjects with high-risk disease will receive 100 mg/m\^2 etoposide weekly for four weeks administered over one hour via IV infusion after completion of rituximab
223482593|NCT03332615|BEHAVIORAL|Motivational Interviewing|Clinicians in the intervention arm will be taught Motivational Interviewing via a coaching model in which a didactic session is followed by feedback through review of clinicians' audio-recorded encounters.
223482594|NCT03332615|BEHAVIORAL|Wait-list control|After consent, clinicians in the wait-list control arm will complete a survey to self-assess their motivational interviewing skills and burnout.
223482595|NCT01665742|DIETARY_SUPPLEMENT|Supplement containing fish oil, vitamin C, alpha-tocopherol, green tea extract and lycopene|"1 x fruit juice fortified with salmon oil containing 1000mg EPA and 1000mg DHA daily for 8 weeks~AND~4 x film-coated tablets containing 561mg vitamin C, 389mg alpha-tocopherol, 416mg green tea extract and 15mg lycopene daily for 8 weeks~in conjunction with a weight management programme"
223482596|NCT01665742|DIETARY_SUPPLEMENT|Placebo supplement|"1 x fruit juice fortified fortified with high oleic sunflower oil daily for 8 weeks~AND~4 x film-coated placebo tablets daily for 8 weeks~in conjunction with a weight management programme"
223482597|NCT03112551|DRUG|Adminstration of magnesium Sulphate for treatment of eclampsia|A total of 100 eclamptic patients are suspected to be approached alternately and subcategorized into two groups - one group will be treated with 24 hours maintenance dose of magnesium sulphate (Group-1; n=50), and the other with 12 hours maintenance dose of magnesium sulphate (Group-2; n=50).
223482598|NCT03942770|BEHAVIORAL|Contingency Management|Monetary incentives are delivered to participants contingent upon on-time breathalyzer submissions and verified abstinence from alcohol.
223482599|NCT03942770|BEHAVIORAL|Contingency management|Monetary incentives are delivered to participants contingent upon on-time breathalyzer submissions only with no contingency on alcohol use.
223482600|NCT05614063|DRUG|XEN1101|XEN1101 Capsules
223482601|NCT05614063|DRUG|Placebo|Placebo Capsules
223482602|NCT05923632|BEHAVIORAL|Dijital Game and Health Education|After the children in the experimental group are informed about the digital game designed according to The The Information-Motivation-Behavioral Skills Model (IMB) in diabetes management, active participation of the children in the digital game will be ensured for 9 weeks; and participation status will be followed in the background of the game. At the end of 9 weeks, children will be asked to complete all stages of the game. Children who do not complete the game will be contacted once a week in line with their background follow-up and reminders will be made.
223482603|NCT06562153|OTHER|Neuroimaging with Magnetic Resonance Imaging (MRI)|MRI will be used to observe brain states over time.
223482604|NCT02750293|DRUG|Cholecalciferol|Vitamin D preparation
223482605|NCT02750293|DRUG|Placebo|placebo
223482606|NCT01499589|PROCEDURE|regional anesthesia|regional anesthesia procedure
223482607|NCT03803137|OTHER|VOC analysis|VOC analysis in exhaled air with e-noses and mass spectrometry
223482608|NCT00757653|DEVICE|Hip stem with plasma sprayed porous Ti 6Al4V alloy + plasma sprayed HA|Hip stem with plasma sprayed porous Titanium 6Al4V alloy + plasma sprayed HA
223482609|NCT00757653|DEVICE|Hip stem with plasma spayed porous Titanium 6Al4V alloy + Bonemaster HA|Hip stem with plasma spayed porous Titanium 6Al4V alloy + Bonemaster HA
223482610|NCT00757653|DEVICE|Hip stem with Interloc Titanium surface + Bonemaster H.A|Hip stem with Interloc Titanium surface + Bonemaster H.A
223482611|NCT00988780|DRUG|maraviroc|"Maraviroc 600mg po BID every day from the entry visit until week 48 or until IRIS event or unacceptable toxicity develops.~Efavirenz 600 mg qd every day from the entry visit until week 48 or until IRIS event or unacceptable toxicity develops.~Tenofovir/Emtricitabine 300/200 mg qd from the entry visit until week 48 or until IRIS event or unacceptable toxicity develops."
223482612|NCT00988780|DRUG|Placebo|"Placebo tablets po BID every day from the entry visit until week 48 or until IRIS event or unacceptable toxicity develops.~Efavirenz 600 mg qd every day from the entry visit until week 48 or until IRIS event or unacceptable toxicity develops.~Tenofovir/Emtricitabine 300/200 mg qd from the entry visit until week 48 or until IRIS event or unacceptable toxicity develops."
223482613|NCT05047744|DEVICE|Touch Dual Mobility CMC I Prosthesis|Surgery
223745000|NCT03873870|DIAGNOSTIC_TEST|68Ga -DOTATATE PET scans|PET scan using 68Ga-DOTATATE contrast
223745001|NCT00002173|BIOLOGICAL|HIV-1 Immunogen|
224170521|NCT05283122|PROCEDURE|Mostafa Maged Technique|pfannestiel incision . dissection of the bladder downwards , and Ligation of the uterine arteries on both sides then , we turn over the upper part of the lower uterine segment onto the lower part of the lower uterine segment from the inside of uterine cavity .We do this turnover (flipping ) by our hands and holding the imaginary line by two Allis forceps and by making three knots by three needles in the lower edge of the uterine incision and we enter the needles of simultaneously into the lower segment through the uterine cavity , at the same level of , the inside wall of lower uterine segment to drag the upper (half) part of the lower uterine segment on the lower part of lower uterine segment ( sandwich - like ) Third , we stitch the both sides of the flipped lower uterine segment , then we do plication of the anterior lower uterine segments to strengthen the wall of the flipped lower uterine segment and place a drain in the doglus pouch
224170522|NCT04838340|OTHER|Standart care|This group will leave in the hospital's usual care and no intervention will be applied.
224170523|NCT04838340|BEHAVIORAL|Hypnobirthig training|"Hypnobirthing training of the Hypnobirthing group will carry out with its partner. Hypnobirthig training will be given in small groups of 5 or 6 couples for 4 weeks and 3 hours a week. In addition, the usual care will be provided by healthcare professionals to this group.~Breathing, relaxation exercises, birth stories and birth videos will be used to reduce fears of chlildbirt women.~Deepening and endorphin massage techniques will be given for labor pain. After the endorphin massage technique will be applied individually by the researcher, it will be applied by the couples and they will ask for repeating all exercises at home.~In the last week of the training, there will be a birth rehearsal with Hynobirthing methods with the partners.~The second meeting will take place when labor begins and after labor."
224170524|NCT05736302|OTHER|Doubly-Labeled Water|All eligible participants will receive a dose of doubly-labeled water.
224170525|NCT04073472|DRUG|mesenchymal stem cells (MSCs)|Allogeneic bone marrow derived mesenchymal stem cells (MSCs) direct injection to an ileal pouch fistula in the setting of Crohn's disease of the pouch
224170526|NCT00671190|DRUG|Ramelteon|Ramelteon 1 mg, tablets, orally once daily for up to 5 days
224170527|NCT00671190|DRUG|Ramelteon|Ramelteon 2 mg, tablets, orally once daily for up to 5 days
224170528|NCT00671190|DRUG|Ramelteon|Ramelteon 4 mg, tablets, orally once daily for up to 5 days
224170529|NCT00671190|DRUG|Ramelteon|Ramelteon 8 mg, tablets, orally once daily for up to 5 days
224170530|NCT00671190|DRUG|Placebo|Ramelteon placebo-matching tablets, orally once daily for up to 5 days
224170531|NCT03033992|DEVICE|Optune System (NovoTTF-200A System, Tumor Treating Fields, TTFields)|The Optune, a.k.a. Tumor Treating Fields (TTFields), will be worn for a minimum of 18 hours a day, with a recommendation of 22 hours/day for at least 23 days in a 28-day cycle. Cycle 1 includes 7 days training period, followed by 28 days treatment (total 35 days). The patients will receive multiple 28-day cycles of continuous Optune treatment. In the absence of treatment related serious adverse events or disease progression, Optune will continue up to 26 cycles.
224170532|NCT03033992|COMBINATION_PRODUCT|Concurrent Optune and RT followed by Optune System alone|In Stratum II patients will be treated with standard of care focal RT concurrently with Optune followed by Optune treatment. This study specifies a 1 cm clinical target volume margin.The duration of the first cycle of therapy will be from Day 1 of RT to 14 days after completion of RT (approximately 8 weeks total). Subsequent cycles of therapy will be 28 days in duration. The Optune device will be worn for a minimum of 18 hours/day, with a recommendation of 22 hours/day. For the phase I part, the initial treatment will involve RT delivery with Optune arrays remaining in place but turned off. If this is not tolerated, two treatment de-escalation levels are planned, Specifically, Level -1: remove the Optune arrays during RT delivery and reapply daily after RT; Level -2: initiate Optune therapy after completion of RT. The established safe treatment approach from phase I will be investigated for feasibility and efficacy in phase II. Treatment with Optune may continue for up to 5 years.
224170533|NCT06538389|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
224170534|NCT06538389|DRUG|BRC-001|Given PO
224170535|NCT06538389|DRUG|Placebo Administration|Given PO
224170536|NCT06538389|OTHER|Questionnaire Administration|Ancillary studies
224170537|NCT04437511|DRUG|Donanemab|Given IV
224170538|NCT04437511|DRUG|Placebo|Given IV
224170539|NCT04061304|DEVICE|Repetitive Transcranial Magnetic Stimulation|A non-invasive method of brain stimulation.
224170540|NCT04061304|DEVICE|Sham Transcranial Magnetic Stimulation|A device designed to look, sound, and feel like a real magnetic stimulation coil without actually stimulating the brain.
224305702|NCT03378050|BEHAVIORAL|HEART|"The intervention group will receive a multi-component individualized support intervention HEART, which will consist of 12 sessions in four stages. By using a comprehensive assessment targeting five components, an individualized intervention plan will be developed to address identified problems and unmet needs. Those five components consist of: Health, Emotion, Activities, Resources and Training."
223482614|NCT05157373|DIAGNOSTIC_TEST|Endometrial sampling and Peripheral blood collection|The endometrial biopsy will be performed with a pipette. The pipelle will be inserted gently through the cervix and into the uterus. The pipelle procedure takes approximately one minute and involves gently moving the pipelle back and forth to obtain a sample. Then 10cc of peripheral blood will be collected.
223482615|NCT05157373|BEHAVIORAL|FSFI Scale|"The participants will fill up the Female Sexual Function Index (FSFI) questionnaire.~The FSFI is a 19-item self-report questionnaire designed to measure sexual functioning in women. It assesses six domains of sexual function: sexual desire, sexual arousal, lubrication, orgasm, satisfaction, and pain (i.e., pain associated with vaginal penetration)."
223745002|NCT00046696|DRUG|NM-3|
224205411|NCT03094949|PROCEDURE|Partial Nephrectomy|The renal capsule is cut in a monopolar fashion around the tumor. After the renal artery is clamped with a bulldog clamp, cold cutting by scissors into the renal parenchymal boundary of the tumor is performed with an optimal surgical margin (a few millimeters). After retrograde injection of diluted indigo carmine, continuous suturing of the opened collecting system and transection of the major vessels is performed with intracorporeal knot-tying. Parenchymal suturing is performed in a continuous fashion. The 20-30 cm length of thread is used, and a knot is made at the end of the thread. A large Hem-o-lok polymer clip (Weck Closure System, Research Triangle Park, NC) is attached on the proximal side of the knot. Before the thread is tightened or cinched, the parenchyma is sutured in a running fashion with three or four stitches without any bolster so that the renal bed is kept in its natural position during the suturing.
224170541|NCT06377605|PROCEDURE|ESPB|the target vertebral level ( T7 transverse process ) \[8\] in the lateral or sitting position and moved in approximately 3-cm lateral to the spinous process . The Erector Spinae muscle and transverse process will be then identified, and a blunted tip , 20-gauge, short bevel needle (Pajunk Sonoplex, Geisingen, Germany) will be advanced, using the in-plane approach, in cephalad-to-caudal direction, through the interfascial plane between the Erector Spinae and the underlying transverse process under strict aseptic precautions until the tip is deep to erector spinae muscle. The block will be performed bilaterally by injecting 60 mL of 0.25% bupivacaine (30 mL into each side) \[16\] into the fascial plane between the deep surface of the Erector Spinae muscle and the transverse processes of the lumbar vertebrae laterally (at the most lateral part of the transverse process) and since it is a fascial plane block , the greater the volume of the local anaesthetic injected ,
224170542|NCT06377605|PROCEDURE|local anaesthetic infiltration|the participant will receive 5 ml bupivacaine infiltration to each trocar site (total of 25 ml 0.5 %) at the beginning of the operation.
224170543|NCT06377605|DRUG|midazolam and lidocaine|midazolam administration intravenous , and 5 cm lidocaine 1% infiltration
224170544|NCT06377605|DRUG|Bupivacain|bupivacaine infiltration
224170545|NCT00911183|BIOLOGICAL|filgrastim|Given subcutaneously
223745003|NCT03837873|DRUG|Rituximab|rituximab 750mg/m2 i.v. on day 0
224170546|NCT00911183|BIOLOGICAL|pegfilgrastim|Given subcutaneously
224170547|NCT00911183|BIOLOGICAL|rituximab|Given IV
224170548|NCT00911183|DRUG|cyclophosphamide|Given IV
224170549|NCT00911183|DRUG|liposome-encapsulated doxorubicin citrate|Given IV
224170550|NCT00911183|DRUG|prednisone|Given orally
224170551|NCT00911183|DRUG|vincristine sulfate|Given IV
224170552|NCT04654468|DRUG|Crovalimab|Crovalimab will be administered at a dose of 1000 milligrams (mg) IV (for participants with body weight between 40 and 100 kg) or 1500 mg IV (for participants with body weight ≥ 100 kg) on Week 1 Day 1. On Week 1 Day 2 and on Weeks 2, 3 and 4, it will be administered at a dose of 340 mg SC. For Week 5 and Q4W thereafter, it will be administered at a dose of 680 mg SC (for participants with body weight between 40 and 100 kg) or 1020 mg SC (for participants with body weight ≥ 100 kg). Dosing schedule will be as described above.
224170553|NCT05852925|OTHER|Traditional Venipuncture|Traditional blood collection is performed and the necessary amount of blood is collected into the collection tubes (either SST or Lithium Heparin tubes based on the biomarker being tested).
224170554|NCT05852925|DEVICE|Tasso+|The Tasso+ is the blood self-collection device used in the study and this device enables the collection of microliter capillary whole blood samples into compatible reservoirs. In this study, the reservoirs utilized include either SST or Lithium Heparin microtainers based on the biomarker being tested.
224170555|NCT05088460|DRUG|REGN4461|Intravenous (IV) infusion loading dose followed by subcutaneous (SC) injection weekly (QW).
224170556|NCT05088460|DRUG|Matching Placebo|Intravenous (IV) infusion loading dose followed by subcutaneous (SC) injection weekly (QW).
224170557|NCT05879822|DRUG|INCB099280|Administered as specified in the treatment arm description
224170558|NCT04146285|DRUG|BAT4406F|"Open-label dose escalation starting from 20mg.~Route of administration: intravenous infusion."
224170559|NCT03900026|DRUG|Evolocumab|REPATHA (evolocumab) is a human immunoglobulin G2 (IgG2) monoclonal antibody that has high affinity binding to Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9); it will be administered via subcutaneous injection
224170560|NCT03900026|OTHER|Placebo|Placebo cartridges will contain vehicle only; placebo will be administered via subcutaneous injection.
224170561|NCT02073604|OTHER|Healthy volunteers|Morphological and functional brain MRI; transcranial magnetic stimulation
224170562|NCT02073604|OTHER|Congenital mirror movements|Morphological and functional brain MRI; transcranial magnetic stimulation
224170563|NCT05741346|DRUG|BCX9930|Taken orally at 400 mg twice daily (BID)
224305703|NCT03378050|OTHER|Usual Care|"Caregivers in the control group will receive 12 week follow-up as usual (FU) including two brief check-in calls and an outcome measures call during the study period."
224305704|NCT05498402|DEVICE|i-gel ® device|Ventilations will be delivered through an i-gel ® device
224305705|NCT05498402|DEVICE|bag-valve-mask ventilation|Ventilations will be delivered using a bag-valve-mask
223482616|NCT07015541|OTHER|NMES and BFR|NMES is applied when patients perform quadriceps strengthening exercises. BFR is applied during compound exercises.
223482617|NCT07015541|OTHER|Standard physical therapy|Standard physical therapy (week 1-16) includes interventions for typical impairments following ACLR. The initial phase will focus on pain and effusion control, restoration of knee range of motion, followed by gait normalization, lower extremity strength training, then running and plyometrics.
223482618|NCT06626828|DEVICE|Electroacupuncture|Disposable sterilized needles are inserted into selected acupoints at a depth of approximately 17-25 mm and an angle of 15-30° along the scalp. Acupoints are then stimulated by the SDZ-II electroacupuncture device, with a dilatational wave pattern at 4/20 Hz. The intensity of the stimulation was adjusted to the patient\&#39;s tolerance.
223745004|NCT03837873|DRUG|Etoposide|50mg/m2, continuous i.v. on day 1-4
223745005|NCT03837873|DRUG|Vincristine|0.4mg/m2, continuous i.v. on day 1-4
223745006|NCT03837873|DRUG|Doxorubicin|10mg/m2, continuous i.v. on day 1-4
223745007|NCT03837873|DRUG|Dexamethasone|30mg/day, i.v. on day 1-5 for R-DA-EDOCH regimen; 40mg/day, i.v. on day 1-4 for R(2)-DHAP regimen
223745008|NCT03837873|DRUG|Cyclophosphamide|750mg/m2, i.v. on day5
223745009|NCT03837873|DRUG|Lenalidomide|25mg/day, p.o. on day 0-9
223745010|NCT03837873|DRUG|Cisplatin|100mg/m2 continuous i.v. on day 1
224170564|NCT06530927|DIAGNOSTIC_TEST|3D rotational digital tomography|DHTM is label-free and records the phase shift of low-energy light passing through the specimen on a transparent surface with minimal perturbation. DHTM measures the refractive index (RI) and computes the refractive index gradient (RIG), unveiling optical heterogeneity in cells. We will analyze blood samples for the detection of altered neutrophil phenotypes and microclots.
224170565|NCT06530927|DIAGNOSTIC_TEST|Atomic Force Microscopy|The atomic force microscope (AFM) is widely used in materials science and has found many applications in biological sciences but has been limited in use in vision science. The AFM can be used to image the topography of soft biological materials in their native environments. We will analyze blood samples for the detection of altered neutrophil phenotypes and microclots
224170566|NCT06530927|DIAGNOSTIC_TEST|Micro-Computertomography|"Micro-CT is a 3D imaging technique utilizing X-rays to see inside an object, slice by slice. Micro-CT, also called microtomography or micro computed tomography, is similar to hospital CT or CAT scan imaging but on a small scale with greatly increased resolution. Samples can be imaged with pixel sizes as small as 100 nanometers and objects can be scanned as large as 200 millimeters in diameter. We will use micro-CT to analyze blood clots from patients with large vessel occlusion."
224170567|NCT06109935|DRUG|Somapacitan|Sogroya® treatment regimen will be in accordance with the approved product labelling in Japan.
224170568|NCT03093350|BIOLOGICAL|TAA-specific CTLs|"Each patient will receive 2 injections at a fixed dose, 28 days apart, according to the following dose schedule: The expected volume of infusion will be 1 to 10 cc.~Dose schedule:~Day 0: 2 x 10\^7 cells/m2~Day 28: 2 x 10\^7 cells/m2~If patients have stable disease or a partial response by the Response Evaluation Criteria in Solid Tumors (RECIST) criteria at their 6 week evaluation after the 2nd cell dose, they will be eligible to receive up to 6 additional doses of CTLs, At least one month should have passed before each additional dose.. Each additional infusion will consist of the same cell number or less (if there is not enough product available for the subject's original dose) than their second infusion. Patients will not be able to receive additional doses until the initial safety profile is completed at 6 weeks following the second infusion."
224170569|NCT05994482|OTHER|adenoma vs no adenoma|For Aim 1, the investigators will examine colorectal cancer risk among older adults with prior removal of a precancerous polyp (adenoma) vs a prior normal colonoscopy
224170570|NCT05994482|OTHER|colonoscopy vs no colonoscopy|For Aim 2, the investigators will examine colorectal cancer risk among older adults with prior history of polypectomy, exposed vs unexposed to subsequent surveillance colonoscopy
224170571|NCT05994482|OTHER|survey and expert panel|The investigators will conduct 44 semi-structured one-on-one qualitative interviews with VA patients (older adults) and providers (primary care, GI, geriatrics) to understand perspectives on CRC risk, and potential benefits and harms of surveillance (Aim 3a). The investigators will then convene an expert panel with key stakeholders including Veterans, primary providers, geriatricians, gastroenterologists, VA leaders, and policy makers to present Aim 1, 2, and 3a findings (Aim 3b). The primary outcome will be specific recommendations regarding use of surveillance colonoscopy in older adults, ranked by priority and feasibility, that can guide VA policy around future implementation (or de-implementation) of surveillance among older adults.
224170572|NCT05127174|DRUG|Fedratinib Pill|Fedratinib is taken orally once per day, in 100 mg capsules. Fedratinib is an oral kinase inhibitor with activity against wild type and mutationally activated Janus Associated Kinase 2 (JAK2) and FMS-like tyrosine kinase 3 (FLT3).
224170573|NCT05898802|DIETARY_SUPPLEMENT|Kimchi|Two different kimchi, one traditional kimchi and one fermented with a lactic acid bacteria having anti-obesity effect, hereafter starter kimchi, are flash freeze dried, powdered and encapsulated.
224170574|NCT05898802|DIETARY_SUPPLEMENT|Placebo|Lactose with kimchi flavor
223482619|NCT02416037|DEVICE|level of positive end expiratory pressure (Prone Proseva)|PEEP based on PEEP/FIO2 table vs PEEP based on the value of oesophageal pressure
224170575|NCT06127173|OTHER|Positive End Expiratory Pressure PEEP|children will receive different levels of PEEP during induction of anesthesia
224170576|NCT05798247|OTHER|Characteristics description|Caregivers who follow the patients of the study group will be contacted to collect these patients clinical and epidemiological characteristics
224170577|NCT06441643|DRUG|AR-17043 Ophthalmic Solution|Investigational monotherapy supplied in three concentration levels: low, medium, high
224170578|NCT06441643|DRUG|PG043 Ophthalmic Solution|Investigational fixed dose combination supplied in two concentration levels: low and high
224170579|NCT06441643|DRUG|Latanoprost 0.005% Ophthalmic Solution|Marketed monotherapy
224170580|NCT06441643|DRUG|Netarsudil 0.02% Ophthalmic Solution|Marketed monotherapy
224170581|NCT06441643|DRUG|Netarsudil 0.02%/Latanoprost 0.005% Ophthalmic Solution|Marketed fixed dose combination
224170582|NCT06441643|DRUG|AR-17043 Vehicle|Placebo comparator
224170583|NCT04134598|RADIATION|Breast irradiation (RT)|Irradiation of volume's portion Index quadrant) or whole volume of the residual breast.
224170584|NCT04134598|DRUG|Endocrine Therapy (ET): letrozole, anastrozole, exemestane, tamoxifen|Adjuvant endocrine therapy as per local policy (letrozole/anastrozole/exemestane/tamoxifene for 5-year or switch schedules aromatase inhibitors/tamoxifen for 5-year).
224170585|NCT06171945|BEHAVIORAL|AYA Connect intervention|Participants will receive a smart scale, activity tracker, an individual kickoff videochat session with a health coach, and access to a mobile smartphone app that includes weekly behavioral lessons, dietary tracking log, daily weight-related behavioral goals, tailored feedback summaries, and in-app health-related messages.
224170586|NCT06171945|BEHAVIORAL|Positive Psychology (PP) intervention|Participants will receive lessons about positive psychology (PP) strategies, weekly goals for PP exercises, and in-app health-related messages that include reminders to practice PP exercises.
223482620|NCT02416037|DEVICE|level of positive end expiratory pressure (Prone Talmor)|PEEP based on PEEP/FIO2 table vs PEEP based on the value of oesophageal pressure
223482621|NCT07022093|DEVICE|Custom made insoles|For the production of insoles using the CAD-CAM method; In the production of insoles, medial longitudinal arch support will be added so that the subtalar joints are in a neutral position, and additionally, transverse arch support between 3.5-5 mm, lateral longitudinal arch support between 4-6 mm, and finger-under supports to assist with palmar grip will be designed in three dimensions using the EasyCad modelling interface. Using a Vulcan Computer Numerical Control (CNC) milling machine, the insoles will be machined from Ethylene Vinyl Acetate (EVA) material placed in blocks. After this process, the insoles will be adjusted on the milling machine to fit the patient's shoes.For the production of insoles using the 3D printing method, the Elegoo Neptune 4 Max 3D printer will be used. Using TPU material, medial longitudinal arch support will be added, along with transverse arch support between 3.5-5 mm, lateral longitudinal arch support between 4-6 mm, and finger support to aid palmar grip.
223745011|NCT03837873|DRUG|Cytarabine|2g/m2 q12h, i.v. on day 2
224170587|NCT06171945|BEHAVIORAL|Positive Psychology Plus (PP+) intervention|Participants will receive weekly individual videochat sessions with a health coach.
224170588|NCT06272942|OTHER|An ICU admission and a temporally related ARDS diagnosis|"This is a disease study to learn more about the morbidity after an ICU admission and a temporally related ARDS diagnosis.~ARDS stands for acute respiratory distress syndrome."
224170589|NCT06037954|OTHER|Questionnaires|Patient demographic characteristics, Clinical variables, Cornell Service Index-Short Form (CSI), Patient Health Questionnaire-9 (PHQ-9), Generalized Anxiety Disorder scale-7 (GAD-7), Client Satisfaction Questionnaire (CSQ-8), Intention to Seek Help Scale, Health Beliefs about Mental Illness Instrument (HBMII) - Emotional/Nervous Severity Scale, Health Beliefs about Mental Illness Instrument (HBMII) - Emotional/Nervous Benefits Scale, Barriers to Mental Health Services Scale-Revised, Cues to action, Self-Efficacy to Seek Mental Health Care (SE-SMHC)
224170590|NCT06037954|OTHER|Interviews|Interviews will be conducted by the qualitative methods specialist and trained study staff and will last 30-45 minutes.
224170591|NCT06037954|OTHER|30-minute telephone or videoconference sessions|"Includes five components delivered in three 30-minute telephone or videoconference visits over six weeks and one booster telephone call. All sessions are audio-recorded. The five components are:~1. Provide education about depression and treatment options~2. Identify treatment preferences and a personal goal achievable with mental health care~3. Assess barriers to treatment initiation~4. Recommend a referral using standardized referral options~5. Address barriers to accessing care"
224170592|NCT05465538|DRUG|[11C]UCB-J PET|Single PET scan using the radioligand \[11C\]UCB-J
224170593|NCT03534453|DRUG|Olaparib 300mg tablets|300mg Olaparib tablets taken orally twice daily until objective radiological disease progression as per RECIST as assessed by the investigator (or as long as in the investigator's opinion they are benefiting from treatment and they do not meet any other discontinuation criteria). Dose reduction to 250mg and subsequently 200mg is permitted following confirmation of toxicity.
224170594|NCT05564039|DRUG|Tirzepatide|Administered SC
224170595|NCT05564039|DRUG|Dulaglutide|Administered SC
223482622|NCT06871553|OTHER|Self management education program|"After returning home, patients will be encouraged to practice their self-management behaviors and record the behavior and data to the self-monitoring notebook.~At their next hemodialysis session, patients will bring their self-monitoring notebook, and the nurse will review the behavior and data, and offering feedback. The nurses will provide additional videos and education, and request the patients to share their experiences with other patients in the hemodialysis room. This cycle of education, self-monitoring, and feedback will continue with each hemodialysis session."
223482623|NCT07025369|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
223482624|NCT07025369|PROCEDURE|Computed Tomography|Undergo PET/CT
223585468|NCT02933554|DEVICE|Embospheres Microspheres|Via a radial artery in the wrist or the femoral artery in the groin, arterial access will be obtained.Under live X-ray monitoring and using contrast, a catheter will be advanced into the artery of the stomach (left gastric artery). A CT scan will be performed on the X ray table to confirm the placement of catheter. Once this is confirmed small micro spherical particles (Embopheres Microspheres) will be injected though the catheter to occlude the artery and cut off blood supply to the stomach. Once the procedure is complete, in case of wrist access compression will be achieved with a band; in case of groin access a closure device will be used to plug the site of entry.
223585469|NCT04624763|PROCEDURE|Left bundle branch pacing|"LBBP is defined if fulfilling criterion 1 and at least one in criteria 2:~1. Paced morphology of RBBD in surface lead V1 (QR, Qr, rSr', rSR' or Qrs);~2. One of the following should be met:~   1. Selective LBBP with an iso-electrical window between the pacing spike and QRS onset;~  2. If using dual-lead method with one at His-bundle and the other at LBB region, a retrograde His-bundle potential is recorded from His-bundle lead during LBBP;~  3. LVATs at lead tip pacing of 1.5V/0.5ms and 10V/0.5ms are ≤ 80ms and the difference is \< 10ms;~  4. A discrete LBB potential is recorded from lead tip and LVAT at tip pacing of 3V/0.5ms is ≤ 80ms19.~If criterion 1 is fulfilled but none in criteria 2 is met, the procedure is considered to be left ventricular septal pacing (LVSP)."
223585470|NCT04624763|PROCEDURE|Right ventricular pacing|Implantation of a RV pacing lead is attempted using the standard-of-care technique first.
224170596|NCT02421939|DRUG|gilteritinib|tablet, oral
224170597|NCT02421939|DRUG|LoDAC (Low Dose Cytarabine)|subcutaneous (SC) or intravenous (IV) injection
224170598|NCT02421939|DRUG|Azacitidine|SC or IV injection
223482625|NCT07025369|OTHER|Flotufolastat F-18 Gallium|Given flotufolastat F 18
223482626|NCT07025369|PROCEDURE|Laparoscopic Radical Prostatectomy with Robotics|Undergo robotic assisted radical prostatectomy
223482627|NCT07025369|PROCEDURE|Pelvic Lymphadenectomy|Undergo pelvic lymph node dissection
223482628|NCT07025369|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
223482629|NCT07025369|DRUG|Relugolix|Given PO
223482630|NCT07024589|DRUG|AN2-502998|Oral Capsule
223482631|NCT07024589|DRUG|Placebo|Oral Capsule
223585471|NCT04667910|DRUG|601 1.25mg|Solution for injection (intravitreal use)
223585472|NCT04667910|DRUG|Ranibizuman 0.5 mg|Solution for injection (intravitreal use)
223745012|NCT03336775|PROCEDURE|acupuncture|Acupuncture for 30 minutes per day for up to 20 sessions (over 4 weeks).
224170599|NCT02421939|DRUG|MEC (Mitoxantrone, Etoposide, Cytarabine)|IV injection
224170600|NCT02421939|DRUG|FLAG-IDA (Granulocyte-Colony Stimulating Factor (G-CSF), Fludarabine, Cytarabine, Idarubicin)|SC (G-CSF) and IV (Fludarabine, Cytarabine, Idarubicin) injection
224170601|NCT03493048|DRUG|Irinotecan|Irinotecan 130 mg/m²
224170602|NCT03493048|DRUG|Cetuximab|Cetuximab, iv, 500mg/m2
224170603|NCT03493048|DRUG|5-fluorouracil|5-FU 2400 mg/m² cont. inf.
224170604|NCT03493048|DRUG|Oxaliplatin|oxaliplatin 85 mg/m²
224170605|NCT03493048|DRUG|Leucovorin|leucovorin 200 mg/m²
224170606|NCT04972825|BEHAVIORAL|Mind the Gap|This intervention will help parents with children newly diagnosed with autism or other neurodevelopmental disorders learn how to navigate the system of acquiring services for their child. These parents will be assisted by a coach, an employee at the child's agency, that will help them through this process.
224170607|NCT03336606|DRUG|MEDI0562|Surgical resection of tumor
224170608|NCT04453722|DEVICE|Oxalert Monitor Mode|The investigator will evaluate the feasibility of a fully randomized validation trial for the Oxalert EPO. Using the Oxalert in monitor only mode.
224170609|NCT04453722|DEVICE|Oxalert Normal mode|The investigator will evaluate the feasibility of a fully randomized validation trial for the Oxalert EPO using the Oxalert in monitor in normal mode
224170610|NCT04683952|DEVICE|Exercise training with Humified High Flow Nasal Cannula|The experimental group will be trained using HHFNC with the most adequate continuous flow, in a range between 25 and 30 L / min.
224170611|NCT04683952|OTHER|Exercise training - Control Group|The control group will perform exercise training in spontaneous breathing.
223482632|NCT07027345|DRUG|5% TolaSure Topical Gel|TolaSure Topical Gel is applied once-daily to designated treatment areas for up to 4 months (Part 2 End of Study).
223482633|NCT07027345|DRUG|Topical Placebo Gel|Topical Placebo Gel is applied once-daily to designated treatment areas for up to 2 months (Part 1 End of Study).
224170612|NCT04270890|DEVICE|Abdominal compression belt system|"The abdominal compression belt system is provided free of charge from CDR systems, Canada.~The belt has specifically been chosen from other similar devices commercially available as it is independent of other immobilisation devices and can be used with the patient located within a full body vacbag as per current immobilisation position."
224170613|NCT01211067|PROCEDURE|Lichtenstein hernioplasty|"* Mesh hernioplasty~* Ultrapro mesh (Ethicon, Johnson \& Johnson)"
224170614|NCT01197872|OTHER|Preimplantation Genetic Diagnosis|Genetic testing on embryos to identify embryos that are affected by a single gene disorder (e.g. cystic fibrosis, Tay-Sachs, sickle cell anemia).
224170615|NCT00962416|DEVICE|Biolimus eluted from an erodable stent coating (Biomatrix)|The Biolimus-eluting stent (Biomatrix) has a corrugated ring design available in six and nine cell models and is laser cut from 316L VM stainless steel hypotube. The nominal dosage of Biolimus A9 goes from 133 to 442 microgram. The producer of the drug is Nippoon Kayaku Co., Ltd Takasaki Plant, 239, Iwahanamachi, Takasaki-shi, Gumma 370-1028 Japan. The biodegradable polymer is polylactic acid, which has become one of the most commonly used biodegradable polymers. Polylactic acid, its co-polymers, and mixtures have been evaluated in the preclinical, and clinical studies, revealing a favorable biocompatability profile. The polymer has been demonstrated to be safe when used as implant of drug release-control polymer for both animals and humans.
224170616|NCT00962416|DEVICE|bare-metal stent (Gazelle)|A bare-metal stent of identical design without surface application of polymer and drug.
224170617|NCT05150171|OTHER|e-self-management intervention|The app is developed based on a combination of behavioural change techniques informed by Social cognitive theory and the EULAR recommendations on management of hand osteoarthritis. The 12-week intervention consists of 25 short informational videos addressing the themes prioritized by the patient research partners. Additionally, the intervention includes a hand exercise program consisting of 8 videos providing instructions on warm up, exercises to improve mobility, strength and coordination, and a stretching exercise. The informational videos and exercise program are delivered in a progressive order across the 12 weeks. Encouragement and motivational messages are provided each week to enhance continued adherence to the intervention.
224170618|NCT03140033|DRUG|Misoprostol Oral Tablet|at cord clamping the patient will recieve 400 micrograms of misoprostol sublingually
224170619|NCT03140033|DRUG|Ranitidine Oral Tablet|at cord clamping the patient will recieve ranitidine sublingually
224170620|NCT05681780|BIOLOGICAL|Tumor-infiltrating Lymphocytes (TIL)|Tumor harvest for TIL growth in the lab: A sample of the participant's tumor will be collected and sent to the lab for TIL growth. TIL will be prepared and cryopreserved.
224170621|NCT05681780|DRUG|Nivolumab|Nivolumab (Opdivo®), 360 mg, IV infusion every 3 weeks prior to TIL infusion, and then after TIL infusion 480 mg ever 4 weeks for up to 12 months.
224170622|NCT05681780|DRUG|Cyclophosphamide|Cyclophosphamide will be administered on days -7 and -6.
223482634|NCT06810193|OTHER|Aerobic exercise|After the end-of-season assessments, participants in the Intervention (Exercise or Stretching) arm will be randomized to 2 weeks of daily aerobic exercise for 30 minutes or to 30-minutes of prescribed stretching.
224170623|NCT05681780|DRUG|Fludarabine|Fludarabine will then be infused per institutional standard on Days -7 to -3.
224170624|NCT05681780|OTHER|Tumor-infiltrating Lymphocyte Therapy|On day 0, all patients will receive a dose infusion TIL cells.
224170625|NCT05681780|DRUG|Interleukin-2 (IL2)|Participants will receive IL-2 for up to 6 doses, based on participants tolerance and investigator judgement. This will be given after the infusion of the T-cells.
224170626|NCT02966236|DRUG|Tranexamic Acid|
223482635|NCT04902573|OTHER|Non-interventional|As this is a non-interventional trial, only data obtained within the current routine management of asthma at outpatient respiratory centres or GP centres will be documented.
223482636|NCT06705660|OTHER|WEB-based progressive relaxation training|"WEB-based progressive relaxation training will be given for 8 weeks, 2 days a week for 30-45 minutes (16 sessions), following the menstrual cycles of women. Measurements will be taken before and after (at the end of) the intervention. Measurements will be taken 4 weeks after the next menstrual cycle to ensure follow-up.~Progressive relaxation training is an easy-to-learn, non-invasive and side-effect free method. PGE beginners will be trained for at least 30 minutes and practitioners who have learned the basics of the method will be trained to introduce PGE for 15 minutes. Prior to the PGE, individuals will be informed that they should not come overly hungry or overly full (eating should be finished 2 hours before), wear loose and comfortable clothes, avoid clothes that tightly wrap the abdomen (pants, dresses, belts), remove contact lenses, glasses, jewelry and tight shoes. PGE will be administered in a quiet, comfortable and dimly lit place. Women will perform PCI in the supine posit"
223745013|NCT06584396|OTHER|Non-Interventional Study|Non-interventional study
223745014|NCT00000766|DRUG|Foscarnet sodium|
224170627|NCT02966236|DRUG|Placebos|
224170628|NCT06339281|DRUG|apatinib mesylate+Capecitabine Tablets|"Apatinib Mesylate Tablets: 500 mg, qd, orally until disease progression or intolerable adverse reactions.~Capecitabine Tablets: 1000 mg/m2, po, twice a day, d1-d14, discontinued for 1 week after 2 weeks of treatment;"
224170629|NCT06339281|DRUG|apatinib mesylate+Fulvestrant injection|"Apatinib Mesylate Tablets: 500 mg, qd, orally until disease progression or intolerable adverse reactions.~Fulvestrant injection 500 mg, intramuscular injection, q4w, once on d1 and d15 in the first cycle;"
224170630|NCT00729560|DRUG|Flutamide|250 mg twice daily for 4 weeks
224170631|NCT00729560|DRUG|Placebo|Placebo twice daily for 4 weeks
223585475|NCT02008773|DRUG|Valacyclovir HCI 500 mg tablets|Valacyclovir HCI 500 mg capsules 6/day oral for 16 weeks
223585476|NCT02008773|DRUG|placebo|placebo capsules 6/day oral for 16 weeks
223585477|NCT02759081|DEVICE|cap-assisted water exchange|a transparent cap was mounted to the tip of colonoscopy when water exchange was performed.
223585478|NCT02759081|PROCEDURE|water exchange|water was infused and suctioned at the same time during insertion of colonoscope
223585479|NCT01773304|OTHER|Dietary meal intervention|Test meals with different protein types (dairy versus meat)
223585480|NCT06232785|DRUG|Ibuprofen|0.8g intravenous injection 30min before the end of the operation
223585481|NCT06232785|DRUG|sufentanil|0.2ug/kg intravenous injection 30min before the end of the operation
223585482|NCT04179253|DIAGNOSTIC_TEST|office micro hysteroscopy|One hundred women with unexplained infertility recruited for office micro hysteroscopic sessions. A rigid fiberoptic 2-mm, 0 and 30 degrees angled hysteroscopy along with an operative channel for grasping forceps or scissors were used for both diagnostic and operative indications. The findings, complications, and patient tolerance were recorded.
223585483|NCT02198794|DRUG|SD-809|SD-809 will be administered per dose and schedule specified in the arm.
223585484|NCT02198794|DRUG|Placebo|Placebo matching to SD-809 will be administered per schedule specified in the arm.
223585485|NCT00081133|DRUG|arsenic trioxide|
223585486|NCT00081133|DRUG|imatinib mesylate|
223585487|NCT04159792|OTHER|no intervention|No intervention
223585488|NCT03137498|DRUG|Lidocaine|Lidocaine 1.5mg/kg IVPB in 50ml normal saline over 10 minutes x 1dose
224170632|NCT04709094|DRUG|Danicopan|Danicopan was dosed as 2 x 100 milligram (mg) tablets.
224170633|NCT04709094|DRUG|Warfarin|Warfarin was dosed as 2 x 10 mg and 1 x 5 mg warfarin sodium tablets (Coumadin or generic equivalent).
224170634|NCT04709094|DRUG|Bupropion|Bupropion was dosed as Wellbutrin (or generic equivalent) as 1 x 100 mg tablet.
224170635|NCT04709094|DRUG|Ethinyl Estradiol/Norethindrone|EE/NET (0.035 mg/1 mg) was dosed as Ortho-Novum-1/35 (or generic equivalent) fixed-dose combination tablets.
224170636|NCT02881892|OTHER|Measure plasma and dialysate level of IL-6, procalcitonin and VEGF|correlation between plasma levels, dialysate appearance rate of VEGF, inflammatory cytokines (IL- 6, procalcitonin) and PSTR, dialysis adequacy in CAPD patients.
224170637|NCT04729699|OTHER|Aerobic exercise and exercise for TMJ|Aerobic exercise
224170638|NCT04729699|OTHER|Aerobic exercise at home|Aerobic exercise
224305706|NCT05865821|PROCEDURE|Negative pressure drainage|Negative pressure drainage is a drainage catheter which is placed in subcutaneous surgical wound for draining fluid such as hematoma, seroma, and pus. In this study the drainage the catheter will be placed in the wound for 5 days and/or removed if fluid content is less than 20 ml per day. Jackson-Pratt catheter or Redivac is used in this study because it is cheap and widespread in all hospitals. The drainage catheter is placed after completion of surgery and before skin closure
224305707|NCT05865821|OTHER|No pressure drain|Negative pressure drainage is a drainage catheter which is placed in subcutaneous surgical wound for draining fluid such as hematoma, seroma, and pus. In this study the drainage the catheter will be placed in the wound for 5 days and/or removed if fluid content is less than 20 ml per day. Jackson-Pratt catheter or Redivac is used in this study because it is cheap and widespread in all hospitals. The drainage catheter is placed after completion of surgery and before skin closure
224305708|NCT01709838|DRUG|deferasirox|Deferasirox dispersible tablets at strengths of 125 mg, 250 mg, and 500 mg were administered by oral daily dosing.
224305709|NCT03524989|DEVICE|Hyperbaric Oxygen Therapy|40 daily sessions, 60 minutes of 100% oxygen at pressure of 2 ATA each, five days a week for 2 months.
224305710|NCT03524989|DEVICE|SHAM treatment|40 daily sessions, 60 minutes of 21% oxygen at pressure of 1.01 ATA each, five days a week for 2 months.
223585489|NCT03137498|DRUG|Ketorolac|Ketorolac 30mg (1ml) intravenous push injection x 1dose
223585490|NCT02995798|OTHER|Cortical Bone thickness and Hounsfield unit (HU) numbers|Cortical Bone thickness and Hounsfield unit (HU) numbers considering BMD
223585491|NCT03404622|DRUG|IUCD|IUCD will be inserted in 100 women post placental removal and will be inserted in anther 100 women after six weeks post cesarean delivery
224305711|NCT00295295|DEVICE|High frequency, low magnitude vibration|High frequency, low magnitude vibration at 30 Hz, 10 min/day using vibrating platform from Juvent Medical Inc.
223585492|NCT00710463|DEVICE|non invasive ventilation (Resmed VPAP III ST-A, Respironics Harmony)|non invasive ventilation was performed with commercially available ventilators from the manufacturers Resmed and Respironics.
223585493|NCT00299117|BEHAVIORAL|Brief preoperative smoking intervention|One counseling session of approximately 45 minutes duration 3-4 days preoperatively. The intervention is inspired by the principles of motivational interviewing and The Stages of Change Model.
223585494|NCT05164614|COMBINATION_PRODUCT|RT-102 (80 μg)|RaniPill capsule containing PTH with doses of 20 and 80 μg
223585495|NCT05164614|DRUG|Forteo|A commercial formulation of PTH for SC control (20 µg)
224305712|NCT00295295|OTHER|Standing|Standing 10 min/day
223585496|NCT05164614|COMBINATION_PRODUCT|RT-102 (20 μg)|RaniPill capsule containing PTH with dose of 20μg
223585497|NCT05265897|OTHER|CAQ|Informational document
223585498|NCT03631134|DRUG|SGLT2 inhibitor|Patients will be gave SGLT2 inhibitor 10mg per day
223745015|NCT00000766|DRUG|Ganciclovir|
223745016|NCT00149942|DRUG|Enteric-coated Mycophenolate sodium (EC-MPS)|
223745017|NCT02642432|DRUG|ABT-493/ABT-530|Tablet; ABT-493 coformulated with ABT-530
223745018|NCT02871388|BEHAVIORAL|CONECT|1 monthly in person + 1 monthly telephone + 4 monthly email contact for behavior modification. Focus on motivation, self efficacy and information provision.
224170639|NCT01256957|DEVICE|HEPA filter|
224170640|NCT03928106|OTHER|pharmacists' recommendation|For patients in the intervention group, upon identification of drug discrepancies, pharmacist responsible for enrollment will be intervened by contacting the responsible clinician using a structured written consult form. The number of accepted recommendations by the clinicians will be documented and recorded. When the researcher suggests resolving an identified discrepancy and the responsible clinicians accept the suggestion will be called an accepted recommendation (just an acceptance without any correction), if the accepted suggestion is implemented then this will be called implemented recommendation.
224170641|NCT00172003|DRUG|Zoledronic acid|
224170642|NCT02137902|BEHAVIORAL|Tobacco/Physical Activity Intervention|Telemedicine stage-tailored counseling intervention focused on increasing intrinsic motivation and goal setting for tobacco and physical activity, adherence with nicotine replacement therapy (NRT, patch plus gum or lozenge), and self-monitoring with a pedometer-based walking program.
223482637|NCT06705660|OTHER|The WEB-based lifestyle interventions|The WEB-based lifestyle interventions will be administered to women by monitoring their menstrual cycles for 8 weeks, with sessions held twice a week for 30-45 minutes each (totaling 16 sessions). Measurements will be taken both before the intervention and after its completion. An additional measurement will be conducted during the following menstrual cycle, 4 weeks later, to ensure follow-up.In this study, telehealth and counseling services will be provided. Through telehealth and counseling, women will have the opportunity to communicate online with healthcare professionals and receive guidance on health goals, nutrition, exercise, and stress management
223482638|NCT01366092|DRUG|Interleukin-2|Daily subcutaneous IL-2 (1 x 10\^6 IU/m\^2/day) for self-administration for 12 weeks followed by 4-week hiatus
223482639|NCT06715891|DRUG|Raphamin|Tablet for oral use.
223482640|NCT06715891|DRUG|Placebo|Tablet for oral use.
223482641|NCT07039617|DEVICE|AIDANET + FCL|All participants will use AIDANET in fully closed loop (FCL) mode with instructions to avoid announcing meal boluses whenever possible during the four weeks.
223482642|NCT07039617|DEVICE|AIDANET + HCL|All participants will use AIDANET in hybrid closed loop (HCL) mode with instructions to announce all meal boluses using carbohydrate counting or easy bolus during the four weeks. All components of AIDANET will remain active during this phase but BPS in particular is expected to be triggered less often due to meal announcements.
223482643|NCT07039617|DEVICE|AIDANET in FCL-HCL-mixed mode|All participants will use AIDANET with instructions to choose whether to use fully closed loop (FCL) or hybrid closed loop (HCL) mode with meal announcements (carb counting or easy bolus) per their discretion each day.
223482644|NCT07039617|OTHER|Automated Insulin Delivery (AID) (usual care)|Participants will manage their diabetes as they normally do at home.
223482645|NCT07037875|DRUG|Linaprazan glurate 50 mg Twice Daily (BID)|"Participants in this group will receive a total daily dose of 100 mg of linaprazan glurate, administered as 50 mg in the morning and 50 mg in the evening.~In the morning, they take one 50 mg linaprazan glurate tablet along with a placebo capsule that matches the appearance of the lansoprazole capsule. In the evening, they take another 50 mg linaprazan glurate tablet, without any additional placebo."
223482646|NCT07037875|DRUG|Linaprazan Glurate 50 mg Once Daily (QD)|"Participants in this group will receive a total daily dose of 50 mg of linaprazan glurate, taken once daily in the morning.~In the morning, they take one 50 mg linaprazan glurate tablet along with a placebo capsule that mimics the lansoprazole capsule. In the evening, they take a placebo tablet that mimics the appearance of the linaprazan glurate tablet."
223482647|NCT07037875|DRUG|Lansoprazole 30 mg Once Daily (QD)|"Participants in this group will receive a total daily dose of 30 mg of lansoprazole, taken once daily in the morning.~In the morning, they take one 30 mg lansoprazole capsule along with a placebo tablet that mimics the linaprazan glurate tablet. In the evening, they take another placebo tablet resembling linaprazan glurate."
223482648|NCT07042451|BEHAVIORAL|Pink Cloud|Participants randomized to the Pink Cloud condition will receive a subscription code to access the Pink Cloud mobile application for approximately 365 days. The app includes features such as a searchable database of over 245,000 12-Step meetings (in-person and virtual), a sobriety counter, customizable daily planners, personal inventory tools, and a resentment journal. Participants are encouraged to use the app as they see fit throughout the study period. No prompts or required usage schedules will be imposed; instead, engagement will be self-directed to reflect real-world usage patterns.
223482649|NCT07042451|BEHAVIORAL|Active Control|Participants randomized to the control condition will receive a code to access recovery-related resources hosted on a private study website. These materials include links to mutual-help groups, crisis support services, and educational content and treatment options. Participants may access the website at their discretion and engage with the resources as often and in whatever ways they choose. No prompts or required usage schedules will be imposed.
223482650|NCT07045974|OTHER|Group A-Mulligan Mobilization|"Group A will receive Mulligan mobilizations (SNAGs). Mulligan SNAGs mobilization technique was applied at level C4/5. Subjects were placed in sitting position and therapist stood behind the patient with therapist's thumbs on spinous process of particular vertebra. Mobilization was given by active movement followed by passive overpressure based on the movement restricted. The duration of treatment was three sets of ten repetitions each.~Conventional treatment include the following:~Subjects in both the groups were treated with hot pack (20 min), TENS (2 to 10 Hz), and manual traction along with deep neck flexor, and isometric neck strengthening."
223585499|NCT02156778|BEHAVIORAL|Active Comparator: Extended Standard Care (Stroke Card)|"Standard Care plus~extended training with access to weekly educational lectures (education of patients and relatives), implementation of My Stroke Card containing (a) an adopted version of the 'post-stroke checklist' (ascertainment of post-stroke complications), (b) self-administered internet-based tools for risk factor monitoring and reinforcement of target level achievement, and (c) information and educational materials.~3-Mo outpatient appointment with standardized assessment of risk factors and screening for complications, health problems and residual deficits, estimation of the patient's demand for nursing services and support, guideline-conform secondary prevention with full achievement of target levels, assessment of patient adherence to drug prescriptions.~6-Mo and 9-Mo visits on the discretion of the study team in case of medical needs.~12-Mo clinical visit and outcome assessment."
223745019|NCT04444414|OTHER|Manual therapy|bilateral manipulation lumbosacral, hip joint gapping, stretching the hip rotators with hip and knee flexion, femorotibial gapping, decompression of connective tissue of the patellofemoral region, internal and external joint line opening in laterality, mobilization of the base of the fibula, tibiofibular-talus gapping, and muscle strengthening.
223745020|NCT04444414|OTHER|Control group|The control group received no treatment, they only attended the evaluations.
224170643|NCT02137902|BEHAVIORAL|Diet plus BP/CHOL Intervention|Telemedicine stage-tailored counseling intervention focused on increasing intrinsic motivation, goal setting for managing HTN and HCL, and adherence with antihypertensives and statins with supportive dietary changes. Includes a native diet cookbook and medication bag.
224170644|NCT00103207|BIOLOGICAL|cetuximab|
224305713|NCT03823495|OTHER|12-week PAP|It is a non-drug intervention, using exercises to reduce elderlies chronic pain.
224170645|NCT04412226|DEVICE|aerosol box|The aerosol box is a barrier that protects the staff against the aerosols during the aerosol generating procedures like endotracheal intubation. It is a transparent cube that covers the patient's head during the endotracheal intubation. Operator can intubate the patient through the two holes for arms.
224170646|NCT04412226|DEVICE|transparent sheet|The transparent sheet is a barrier that protects the staff against the aerosols during the aerosol generating procedures like endotracheal intubation. It is a transparent cover that covers the patient's head and body during the endotracheal intubation. Operator can intubate the patient through the space under the cover
224170647|NCT04977778|DRUG|Fatty Acids Compounds (F.A.G.) Mouthwash|Fatty Acids Compounds (F.A.G.) Mouthwash
224170648|NCT04977778|DRUG|Stannous Fluoride (SF) Mouthwash|Stannous Fluoride (SF) Mouthwash
224170649|NCT05312359|DEVICE|Transcranial alternating current stimulation-true stimulus|The adhesive electrodes were placed at F3 and F4 positions of the 64-bit EEG caps of the 10-20 system, corresponding to bilateral prefrontal lobes respectively. Before the intervention, the individual alpha frequency (IAF) of the subjects was measured according to the average peak value of α waves at dorsolateral prefrontal cortex in the closed state. Then an alternating current at θ frequency (θ = IAF - 5Hz) was applied to each subject based on its IAF value. The amplitude of stimulation was increased with a step of 20μA starting from 0. When the subjects had a slight prickling sensation or optical illusion, the stimulation current was decreased with a step of 20μA until the sensation disappeared. The current value at this time was used as the stimulation current of the subjects.
224170650|NCT05312359|DEVICE|Transcranial alternating current stimulation-sham stimulus|The adhesive electrodes were placed at F3 and F4 positions of the 64-bit EEG caps of the 10-20 system, corresponding to bilateral prefrontal lobes respectively. The actual stimulation waveform was just implemented in the first 60 s (or more longer) and then faded out.
224170651|NCT03927820|OTHER|Benefits investigation|The study pharmacist will review the prescribed inhaler for 1) insurance coverage and 2) clinical appropriateness. The pharmacist will conduct a benefits investigation at time of hospital admission. The benefits investigation involves running test claims for inhalers to determine the most cost-effective inhaler for the patient's insurance plan. The study pharmacist will utilize clinical practice guidelines to assess appropriateness of the prescribed inhaler. Based on this review, the study pharmacist will submit a pharmacy consult to the inpatient pharmacist on the patient's healthcare team who will pend the inhaler orders (changing the patient's prescribed inhaler, if necessary) for the prescriber to send to the Meds to Beds discharge pharmacy. The Meds to Beds pharmacist will counsel the patient on inhaler use techniques prior to discharge.
224170652|NCT02117362|BIOLOGICAL|1 mg/kg GR-MD-02|1 mg/kg GR-MD-02 on Days 1, 22, 43, and 65.
224170653|NCT02117362|BIOLOGICAL|2 mg/kg GR-MD-02|2 mg/kg GR-MD-02 on Days 1, 22, 43, and 65.
224170654|NCT02117362|BIOLOGICAL|4 mg/kg GR-MD-02|4 mg/kg GR-MD-02 on Days 1, 22, 43, and 65
224170655|NCT02117362|BIOLOGICAL|8 mg/kg GR-MD-02|8 mg/mg GR-MD-02
224170656|NCT02117362|BIOLOGICAL|Ipilimumab|3 mg/kg ipilimumab on Days 1, 22, 43, and 65
224170657|NCT01286896|DRUG|Sunitinib|"Patients will start treatment with a continuous once-daily dose of 37.5 mg sunitinib. After 22 days the first dose modification will be performed based on the total trough levels (TTL) combined for sunitinib plus SU12662 as measured by dried blood spot (DBS) analyses taken at day 15 ± 1day. A second dose modification will be performed after 36 days (7 days after the first dose adjustment) based on the TTL taken at day 29 ± 1day. One treatment cycle is defined as 28 days.~After 8 weeks a third analyses for TTL will be performed without further consequences for sunitinib dosing. Patients will be evaluated by CT- or MRI-scans for the response to therapy at week 8, and thereafter every 12 weeks. One blood sample will be harvested for pharmacogenetic analyses."
224170658|NCT03662789|DRUG|Iron Isomaltoside 1000|Intravenous infusion
224170659|NCT03662789|OTHER|Placebo: NaCl 0,9%|Intravenous infusion
224170660|NCT05472051|OTHER|Community-based healthcare offer provided by an the ARCAD Santé PLUS NGO and integrated into the activities of the ADDAD NGO|"In the framework of the current activities of the ARCAD Santé PLUS a team formed by a doctor, a nurse and laboratory assistant will provide prevention and medical activities during the community-based activities organized by the housekeepers ADDAD NGO. The medical consultation will propose:~* HIV screening, including pre- and post- counseling~* Hepatitis B and hepatitis C screening, including pré- and post- counseling. The HBV vaccine will be proposed to housekeepers with negative results to both HBV and HCV testing~* Tuberculosis screening will be proposed to housekeepers with symptoms suggesting the possibility of TB~* For housekeepers sexually active, the medical team will propose a gynecological test in order to screen for genital infections. Furthermore, a pregnancy test will be proposed.~Medicines for current diseases (headache, diarrhea, etc. will be provided by the medical staff)."
224170661|NCT02603939|PROCEDURE|Joint replacement surgery|We are assessing pain responses in participants with osteoarthritis before an after joint replacement surgery
224170662|NCT00739440|BIOLOGICAL|serum antiscorpion|The dose may be required for the patient according to clinical manifestations and evolution
224305714|NCT05813366|OTHER|Acupuncture|Tony disposable, single-use 0.20×40 mm Chinese needles will be used. The needle penetrates the skin sufficiently to reach the required depth and elicit de qi. The needles remains for 30 min, with gentle rotational movements applied three times during the session.
223482651|NCT07045974|OTHER|Group B-Stretching Exercises|"Group B will receive stretching exercises. Subject was asked to lie supine on the plinth and the head was held at the edge of the plinth by the therapist. Then with one hand the therapist held the neck in cervical lateral flexion to the opposite side so as to achieve the stretching of the trapezius muscle. Myofascial release by applying sustained finger pressure for 5-10 s on the involved trapezius was given. A gentle myofascial stretching force was applied to take up slack and sustained until a release occurred. This protocol comprised four sets of 15 stretches with 3 min rest.~Conventional treatment include the following:~Subjects in both the groups were treated with hot pack (20 min), TENS (2 to 10 Hz), manual traction along with deep neck flexor, and isometric neck strengthening."
223482652|NCT07045948|DIAGNOSTIC_TEST|Blood eosinophil Count|Blood sample for blood eosinophil count
223482653|NCT07045727|PROCEDURE|Accelerometry|Ancillary studies
223482654|NCT07045727|OTHER|Aerobic Exercise|Participate in aerobic training program
223482655|NCT07045727|PROCEDURE|Biospecimen Collection|Undergo collection of blood and urine samples
224170663|NCT05727891|DRUG|Tonabersat|Two pills of Study Drug (80 mg tonabersat) is taken orally once daily. It is recommended the Study Drug be taken at bedtime. The first dose (two pills) will be taken at bedtime on the day the participant is randomized.
224170664|NCT05727891|OTHER|Placebo|Two pills of Study Drug (placebo) is taken orally once daily. It is recommended the Study Drug be taken at bedtime. The first dose (two pills) will be taken at bedtime on the day the participant is randomized.
224170665|NCT06364943|OTHER|with/without dry eye syndrome|compare tear ferning structure between dry eye and non-dry eye patients
224170666|NCT03602235|OTHER|Ascorbate|Ascorbate is in the vitamin drug class
224170667|NCT03602235|DRUG|Melphalan|Melphalan is an alkylating agent coupled to an amino acid
224170668|NCT04834258|OTHER|Walking and respiratory training|"Walking and respiratory muscle training group ( W+ RMT) received walking training in addition to respiratory muscle training for a period of 8 weeks.~Walking training was performed at least 5 days a week, twice a day, for 15 min. Walking distance was calculated according to patients' 6 minute walking distance.~Respiratory muscle training was performed using the threshold loading method as inspiratory and expiratory muscle training. This training was applied at least 5 days per week, twice a day, 15 minutes each session. (15 minutes inspiratory muscle training + 15 minutes expiratory muscle training). A Threshold Inspiratory Muscle Trainer (IMT) and threshold positive expiratory pressure (Threshold PEP) were used for the training.~Patients were called for the hospital once a week to asses mouth pressure and 6 minute walking test (6 MWT) and their training intensity was arranged"
224170669|NCT04834258|OTHER|Respiratory muscle training|In the Respiratory muscle training group, Respiratory muscle training was performed using the threshold loading method as inspiratory and expiratory muscle training. This training was applied at least 5 days per week, twice a day, 15 minutes each session. (15 minutes inspiratory muscle training + 15 minutes expiratory muscle training). A Threshold Inspiratory Muscle Trainer (IMT) and threshold positive expiratory pressure (Threshold PEP) were used for the training. Patients were called for the hospital once a week to asses mouth pressure and their training intensity was arranged.
224170670|NCT06380556|DEVICE|ShotBlocker|The protruding surface of the ShotBlocker was placed on the heel lance procedure site. While applying pressure on the skin through the ShotBlocker, the nurse performed heel lancing with the needle through the opening in the center of the ShotBlocker. During the 10-second waiting phase, the ShotBlocker was kept at the procedure site with the same pressure. Then ShotBlocker was removed from the skin and routine capillary blood collection procedure was performed.
224170671|NCT06380556|DEVICE|Mechanical vibration|The vibration device was placed on the infant's left extremity in the mid/lateral region just below the knee where the sural nerve passes. The device was secured to the extremity with a gauze bandage. The vibration device was operated for 30 seconds with reference to previous studies. While the vibration continued, the nurse punctured the heel with a needle. Then, the vibration device continued to work in the waiting phase for 10 seconds. The vibration device was removed from the baby's extremity and routine capillary blood collection procedure was performed.
224170672|NCT02432690|DRUG|BBI503|BBI503 will be administered orally, once daily. Dosing will begin at 200 mg once daily, preferably at bedtime and 2 hours after a meal. Dose modification in case of adverse events is allowed according to the schedule below; Full dose: 200 mg daily, Modification Level-1: 100 mg daily, Modification Level-2: 50 mg daily.
224170673|NCT01023516|DRUG|AZD9668|2 x 30 mg oral tablets bd for 12 weeks
224170674|NCT01023516|DRUG|Placebo|2 x matched placebo to oral tablet bd for 12 weeks
224170675|NCT02559115|RADIATION|68Ga-RM2 (RM2)|
224170676|NCT02559115|DEVICE|PET/CT Scan|
224170677|NCT02705547|DRUG|Rosuvastatin|Daily oral administration of Rosuvastatin (10 mg) for 3 months
224170678|NCT03200028|OTHER|Computerized Plasticity-Based Adaptive Cognitive Training|Thirty minutes of training on computerized exercises that targets executive function, memory and attention.
224170679|NCT03330093|BEHAVIORAL|Sleep Health in Preschoolers|In-person, family-based behavioral intervention
224170680|NCT03330093|BEHAVIORAL|Health and Safety Intervention|In-person, family-based behavioral intervention
224170681|NCT03432585|BEHAVIORAL|Applicant Survey|This survey will ask a few brief demographic questions and will assess feedback from participants about preferences and barriers to conference attendance.
224170682|NCT03617471|PROCEDURE|Venopuncture for PK profiling|Blood samples at T0, T0.5, T1, T2, T4, T6
224170683|NCT02591511|DEVICE|smart phone and pad|Smart phone and pad is the mobile include the smart phone and pad, that can download the APP from internet.
224170684|NCT02591511|OTHER|stroke-related health education manual|stroke-related health education manual is the manual mainly contained information regarding the prevention of stroke risk factors.
223482656|NCT07045727|OTHER|Electronic Health Record Review|Ancillary studies
223482657|NCT07045727|OTHER|Exercise Counseling|Receive health coaching check-in calls
223482658|NCT07045727|OTHER|Internet-Based Intervention|Use Connected mHealth app
223482659|NCT07045727|OTHER|Interview|Ancillary studies
223482660|NCT07045727|OTHER|Physical Performance Testing|Ancillary studies
223482661|NCT07045727|OTHER|Resistance Training|Participate in resistance training program
223482662|NCT07045727|OTHER|Survey Administration|Ancillary studies
223482663|NCT07045727|PROCEDURE|Tailored Intervention|Receive personalized exercise plan
224170685|NCT00369564|DRUG|glutamic acid|Given orally 3 times daily
224170686|NCT00369564|OTHER|placebo|Given orally 3 times daily
224170687|NCT05327244|OTHER|Real-world vibration feedback gait retraining|Participants will walk with a vibration feedback tool attached to their shoelaces. A small force sensing resistor is taped to the foot bed of the shoe under the lateral foot and a vibration motor is placed over the outside of the ankle with a strap. When a participant walks on the outside of their foot, they will exceed the pressure threshold and activate the feedback which signifies an incorrect foot placement. The feedback is intended to prompt a correct foot placement on the subsequent step. Participants will use the same feedback tool for 6 real world training sessions.
224170688|NCT06138704|PROCEDURE|Retrograde Intrarenal Surgery|All RIRS procedures were performed under general anesthesia with direct videoscopic and fluoroscopic guidance. The decision to use a flexible or semirigid ureteroscope depended on the location of the Stones. If this was not enough to pass the ureteroscope, we placed a JJ catheter for passive dilatation. Stones were fragmented using a holmium-YAG laser and grasped by a stone basket when applicable. Contrast injection was performed at the end of the procedures to confirm the absence of extravasation and stone-free status. Ultrasonography (USG) was performed three months, six months, and one year after the procedures to evaluate stone recurrence and hydronephrosis.
224170689|NCT00667940|BEHAVIORAL|Rater training workshop|Rater training workshop: rater error training, performance dimension training, behavioral observation training, and frame of reference training using lecture, video, and facilitated discussion
224170690|NCT00693563|BEHAVIORAL|Scheduled Telephone Intervention|Participants and their significant others will be contacted by telephone within 24 to 48 hours after discharge and 10 additional times at weeks 1, 2, 4, 6, and months 2, 3, 4, 6, 8, and 10. The frequent early telephone contacts are meant to address early concerns that frequently arise after discharge are expected to last between 30 and 45 minutes. Later phone calls may be brief if no concerns are raised and are expected to address resource needs as well as ongoing questions that arise through the first year after injury. Content of each phone call will be dependent on issues raised by each individual participant and their significant other and/or follow-up on concerns raised in prior phone contacts rather than a specific structured interview.
224170691|NCT04507516|OTHER|Water-only Fasting|Water-only fasting for at least 10 days followed by 5 days of refeed.
224170692|NCT05902611|BEHAVIORAL|BMI determination, Eruption Time Assessment, Caries Assessment|BMI determination, Eruption Time Assessment, Caries Assessment
224170693|NCT02060903|DRUG|Abametapir Lotion 0.74% w/w|Abametapir Lotion 0.74% was dispensed to subjects on Day 0 for self-administration at home on the same day.
224170694|NCT02060903|DRUG|Vehicle Lotion|Vehicle Lotion was dispensed to subjects on Day 0 for self-administration at home on the same day.
224170695|NCT03523403|OTHER|Apples|3 whole Ontario-grown Gala apples
224170696|NCT04727411|PROCEDURE|XEN45 Gel stent|XEN Gel stent implantation either combined or as a stand-alone procedure
223482664|NCT06883292|DIETARY_SUPPLEMENT|Tyrosol|phenolic compound found in olive oil
223482665|NCT06883292|DIETARY_SUPPLEMENT|Creatine|chemical produced naturally by the body used to rapidly regenerate ATP
224170697|NCT04727411|PROCEDURE|Trabeculectomy|XEN Gel stent implantation either combined or as a stand-alone procedure
224170698|NCT05576415|DRUG|Varenicline Tartrate Nasal Spray|Intranasal delivery of OC-01 (varenicline solution) 0.6 mg/mL twice a day (BID) for 28 days.
224170699|NCT00004842|DRUG|budesonide|Oral budesonide, 9 mg daily was administered for 1 year
224170700|NCT00002274|DRUG|Didanosine|
224170701|NCT01235767|OTHER|Food|Animal-source food (ASF) supplement rich in iron, zinc, vitamin A, and vitamin B12 taken week-days at mid-morning separate from other food. Length of intervention is either from pre-pregnancy (time of registration to marry) to term or from 16 weeks gestation to term.
224170702|NCT00137267|BEHAVIORAL|Time limited case management|This group will receive treatment as usual on Acute Psychiatry and at the Day Treatment Center along with an enhanced Time Limited Case Management community linkage intervention (TLC). Patients assigned to TLC will be offered enhanced services that begin on Acute Psychiatry and continue for a total of eight weeks through the community and Day Treatment Center transition.
224170703|NCT00137267|BEHAVIORAL|Health Education|This group will receive treatment as usual in Acute Psychiatry and at the Day Treatment Center in addition to participating in four group and one individual health education sessions (i.e., the attention control group). The length of the health education sessions (four group sessions and one individual session) will match the amount of attention provided to the treatment group. The health education sessions will cover topics such as nutrition, disease prevention, injury prevention, and healthy aging.
223482666|NCT06883292|DIETARY_SUPPLEMENT|Resistant Dextrin|A type of soluble dietary fiber that is resistant to digestion in the small intestine. It is a byproduct of the starch hydrolysis process, where starch is broken down into smaller chains of glucose molecules
224170704|NCT02265445|DRUG|Deescalation therapy|Intravenous therapy Switch for a narrow spectrum beta-lactam active on the causative ESBL-PE.
224170705|NCT02265445|DRUG|Maintaining carbapenem therapy|Intravenous therapy, Maintaining carbapenem therapy
224170706|NCT04354701|OTHER|Web-based REDCap survey|The survey takes approximately 5-10 minutes to complete and includes five parts: 1) basic demographics about the patient, including performance status and comorbidities; 2) initial COVID-19 diagnosis and clinical course; 3) cancer and cancer treatment details; 4) respondent details; 5) long-term COVID-19 outcomes.
224170707|NCT02400840|PROCEDURE|cardiac MRI|Cardiac MRI is done using gadobenic acid intravenous injection 0.2 ml/kg one time
224170708|NCT02400840|DRUG|gadobenic acid intravenous injection 0.2 ml/kg|gadobenic acid intravenous injection 0.2 ml/kg is used one time for cardiac MRI assessment
224170709|NCT00638989|BIOLOGICAL|CAT-354 150 mg (intravenous)|A single dose of CAT-354 150 milligram (mg) intravenous infusion over 30 minutes on Day 0.
224170710|NCT00638989|BIOLOGICAL|CAT-354 150 mg (subcutaneous)|A single dose of CAT-354 150 mg injection subcutaneously on Day 0.
224170711|NCT00638989|BIOLOGICAL|CAT-354 300 mg (subcutaneous)|A single dose of CAT-354 300 mg injection subcutaneously on Day 0.
224170712|NCT02638363|BEHAVIORAL|Cognitive behavioral therapy|The participants will receive 12-16 sessions of manualized group-based CBT with a maximum of 8 participants in each group. The therapists are trained psychiatrists, psychologists, or nurses under supervision. The treatment manuals are developed by mental health professionals in the Capital Region of Denmark. The treatment program includes traditional CBT components (e.g., psychoeducation, identification of thoughts and feelings, exposure, cognitive restructuring, and relapse prevention).
223482667|NCT06732193|PROCEDURE|On-site respiratory physiotherapy|The patient attends face-to-face physiotherapy sessions prescribed by the doctor.
223482668|NCT06732193|DEVICE|Fissios App|The patient uses the Fissios App to perform respiratory physiotherapy exercises.
223482669|NCT07047716|DRUG|Lenacapavir Injection|Administered intramuscularly
223482670|NCT07047716|DRUG|Lenacapavir Tablet|Administered orally
224170713|NCT04704206|OTHER|Children will perform activities on interactive tablet|"The main difference between the types of interventions is the mode of use and the level of interactivity of the interactive media, where the AIMG actively performs activities, that is, there is user interaction with the equipment through touch or verbal response and the performance of activities like rotating an object, dragging and zooming. PIMG is not the same, the user is just a spectator, having contact with the equipment only when switching on / off, choosing the content, performing activities such as increasing / decreasing the volume and touching certain specific objects such as giving play / pause . Both groups will have a total of 48 intervention sessions."
224170714|NCT06445400|DRUG|BL-M07D1|Administration by intravenous infusion for a cycle of 3 weeks.
224170715|NCT06445400|DRUG|Pertuzumab|Administration by intravenous infusion for a cycle of 3 weeks.
224170716|NCT06445400|DRUG|Docetaxel|Administration by intravenous infusion for a cycle of 3 weeks.
223482671|NCT05554341|PROCEDURE|Biopsy Procedure|Undergo biopsy
223482672|NCT05554341|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
223482673|NCT05554341|PROCEDURE|Computed Tomography|Undergo CT
223482674|NCT05554341|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223482675|NCT05554341|DRUG|Nilotinib Hydrochloride Monohydrate|Given PO
223482676|NCT05554341|DRUG|Paclitaxel|Given IV
223482677|NCT06341205|DRUG|RiTUXimab Injection|Dose administered will depend on randomisation and for experimental Arm on the risk of having undetectable rituximab level after 3 months
223482678|NCT06745024|OTHER|Best Practice|Given SOC systemic anti-cancer therapy
224170717|NCT03445962|DIAGNOSTIC_TEST|Assessment of OSAS predictive factors|"All subjects of the two groups realized the same assessment:~* Anthropometric evaluation~* biological examination (hormonal, inflammatory and complete blood count, and lipidic profile)~* rest electrocardiogram~* motor assessment (strenght, flexibility and balance)~* actigraphy~* Autonomic nervous system assessment during sleep~* Autonomic nervous system assessment during head up tilt test before and after physical exercise~* maximal treadmill test (VO2 max measure)~* polysomnography~* seismocardiography~* questionnaires :sleep and physical activity"
224170718|NCT03501979|DRUG|Tucatinib|Tucatinib study drug is given in tablet form and taken daily.
224170719|NCT03501979|DRUG|Trastuzumab|Trastuzumab is approved by the FDA and is available commercially. Trastuzumab must be prepared and is administered intravenously.
224170720|NCT03501979|DRUG|Capecitabine|Capecitabine is approved by the FDA and is available commercially as an oral drug.
224170721|NCT05879484|DRUG|pembrolizumab|"Phase Ib: Pembrolizumab 200mg will be administered by IV infusion every 3 weeks.~Phase II: Pembrolizumab 200mg will be administered by IV infusion every 3 weeks."
224170722|NCT05879484|DRUG|valemetostat|"Phase Ib: Valemetostat will be given orally every day of every cycle (DL-1: 100mg, DL1: 150mg, DL2: 200mg).~Phase II: Valemetostat will be given orally daily at the recommended phase 2 dose."
224170723|NCT06246149|DRUG|Tebentafusp|Tebentafusp will be administered weekly i.v.
224170724|NCT05448807|DRUG|OraVerse|Phentolamine mesylate is a vaso-dilator that was used for treating dermal necrosis and severe hypertension cases since 1952. It is alpha-adrenergic antagonist. Oraverse is supplied in a dose equal to the amount of LA taken in adults and children with weights more than 30 kg. While in children less than 30 kg, it is advised to use only half carpule according the manufacturer's instructions.
223482679|NCT06745024|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223482680|NCT06745024|OTHER|Bone Metastases Treatment|Given bone modifying agent
223482681|NCT06745024|PROCEDURE|Computed Tomography|Undergo CT
223482682|NCT06745024|PROCEDURE|Conventional Radiotherapy|Undergo conventional RT
223482683|NCT06745024|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223482684|NCT06745024|OTHER|Patient Observation|Undergo SOC observation
223482685|NCT06745024|OTHER|Questionnaire Administration|Ancillary studies
223482686|NCT06745024|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
223482687|NCT06868797|OTHER|Biological sample for the measurement of suPAR levels.|Biological sample for the measurement of plasminogen activator receptor (suPAR) level at baseline and at 6 months follow up to assess the evolution of cardio-renal interaction in HF patients listed for heart transplant treated by GDMT including dapagliflozin.
223482688|NCT06796114|OTHER|blood sample|"A total of 48 ml of blood will be collected at baseline (before STRIDE initiation):~* 6 EDTA 6 ml tubes for PBMC collection~* 2 EDTA 6 ml tube for plasma collection"
223482689|NCT04983888|DRUG|Obinutuzumab|1g IV on day one and 1 g IV on day 15, followed by identical course at month 6
223482690|NCT06343402|DRUG|BBO-8520|Participants will receive assigned dose of BBO-8520 orally (PO), QD
223482691|NCT06343402|DRUG|Pembrolizumab|Patients will receive IV pembrolizumab
223482692|NCT04386447|DRUG|Oxytocin|In addition to standard treatment, patients in the experimental arm will receive intravenous OT with dilution of 25 UI or 40 UI OT in 500cc physiological solution NaCl 9%. OT will be administered with continuous pump infusion with 62,5 ml/h. The clinician will have the option to decrease infusion speed based on significant variations in arterial pressure, otherwise, the total 25 UI or 40 UI amount will be infused in 8 hours. Treatment duration will be 10 days
223482693|NCT04386447|DRUG|Standard of Care|"Standard of Care (SoC). Standard of Care will comply with the indications of the Emilia-Romagna Region for the treatment of covid-19, and will include the following:~* Oxygen supply or non-invasive ventilation to target peripheral blood saturation \> 94%~* Hydroxychloroquine 200mg b.i.d w/o an initial 1-2 days loading dose of 400 mg bid for 1-2 days (the dose may be reduced in patients with advanced CKD according to local protocols) or remdesivir 200 mg in.v on day 1, followed by a 100 mg q.d.~* Antiretroviral therapy (usually for 5 days) with lopinavir / ritonavir or darunavir / cobicistat is permitted~* Azithromycin 500 mg q.d., usually for 5 days, is permitted in patients with suspected bacterial superinfection, paying particular attention to safety, considering reports of risk of adverse events in association with hydroxychloroquine~* Prophylaxis for deep vein thrombosis~* Steroids are not routinely recommended but may be considered in selected patients."
223745021|NCT00260858|DRUG|Test Meal: Reference food (glucose or white bread)|
223745022|NCT00260858|DRUG|Test Meal: Pirate's Booty|
223745023|NCT00260858|DRUG|Test Meal: Ceaprove wafer|
223745024|NCT00260858|DRUG|Test Meal: Stretch Island Strawberry Fruit Leather|
224170725|NCT06624150|DEVICE|Active tDCS sessions, StarStim device|10 active sessions of transcranial direct current stimulation paired with cognitive training tasks. Device used is StarStim.
224170726|NCT06624150|DEVICE|Sham (fake) tDCS sessions|10 fake sessions of transcranial direct current stimulation paired with cognitive training tasks. The device will be on the participants head, but the current will not be active.
223482694|NCT04724135|OTHER|Survey|The first part will assess the sociodemographic variables and reproductive characteristics, and the second part contain the Menopause-Specific Quality of Life (MENQOL) questionnaire The 29 questions of the MENQOL are divided into four domains: vasomotor (items 1-3), psychosocial (items 4-10), physical (items 11-26), and sexual (items 27-29).
223482695|NCT02804217|OTHER|Genetic: mutation profile|
223482696|NCT06783907|BEHAVIORAL|Non-invasive blood glucose monitoring|"Non-invasive wearable glucose monitoring device for capturing participants' blood glucose.~The intervention will include:~1. Training for self-management of diabetes and phone consultation.~2. Follow-up through phone calls or WhatsApp for hypoglycaemic or hyperglycaemic events.~3. Personalized care guided by sensor data.~The Investigator will monitor the health data from the device regularly. A mobile app will track and record compliance with blood glucose monitoring."
223482697|NCT06783907|BEHAVIORAL|Traditional blood glucose monitoring|"Traditional blood glucose monitoring~Participants will engage in traditional self-monitoring of blood glucose at home over the course of 8 weeks. They are recommended to check their blood glucose levels one to two times per week and record all results. This will allow for the collection of data using traditional monitoring methods."
223482698|NCT03608163|DRUG|Naloxone|Naloxone Nasal Spray
223482699|NCT03608163|DRUG|Diazoxide|Diazoxide (oral)
223482700|NCT03608163|DRUG|Placebo (for Naloxone)|Sterile water nasal spray
223482701|NCT03608163|DRUG|Placebo (for Diazoxide)|Taste matched oral placebo for diazoxide
223482702|NCT06735469|OTHER|Discrete choice experiment|Participants will state their preferences for 1) return of full versus limited results to participants (trust/personal benefit), 2) balancing a study's participant burden with the study's ability to address multiple research aims (burden/knowledge generation), 3) incentivizing clinical assessments vs. conducting home-based assessments (personal benefit/burden), and 4) results generalizable to specific social groups versus the broader population. Participants will evaluate these attributes within a hypothetical trial to prevent chronic diseases.
223482703|NCT06755736|DRUG|superficial cervical plexus block|In anterior cervical discectomy surgeries, superficial cervical block will be used for analgesia.
223482704|NCT07073963|BEHAVIORAL|Virtual Mindfulness Based Cognitive Therapy Group|Mindfulness-Based Cognitive Therapy (MBCT) is an 8-week, group-based psychological intervention that integrates principles of cognitive behavioral therapy (CBT) with training in mindfulness meditation. The intervention is designed to help participants develop greater awareness of thoughts, emotions, and bodily sensations, with the goal of preventing depressive relapse and reducing psychological distress. Each weekly session includes guided mindfulness practices (e.g., body scan, sitting meditation, mindful movement), group discussion, and cognitive-behavioral exercises focused on recognizing and disengaging from unhelpful thought patterns. Participants are assigned daily home practice using audio recordings and written materials. The MBCT intervention will be delivered over a video platform for this trial.
223482705|NCT07073963|BEHAVIORAL|Virtual sarcoidosis support group|Participants attend a once-monthly, virtual support group via secure video conferencing. Each session includes a brief didactic presentation on topics relevant to living with chronic illness (e.g., symptom management, coping strategies, navigating healthcare) followed by a facilitated group discussion. The discussion emphasizes peer support, shared experiences, and emotional processing in a safe, respectful environment. Groups are led by an experienced facilitator with experience in chronic illness care. No home practice is required.
223745025|NCT01073852|DRUG|Placebo|Placebo pill, 1 pill orally twice daily for 9 weeks.
223745026|NCT01073852|DRUG|Hydroxychloroquine|Patients will be taking hydroxychloroquine 200mg orally twice/daily.
223482708|NCT06603155|BEHAVIORAL|Time restricted eating (TRE)|TRE is defined as limiting daily food intake to 10 hour period with a nightly fasting period of 14 hours.
223482709|NCT07075159|DEVICE|Hydrocolloid Wound Dressing|one time hydrocolloid dressing application
224170727|NCT06574555|DRUG|Norepinephrine|"The outcome of patient n in each sequence will determine the dose to be allocated patient n+1.~Successive doses will be determined with the up-and-down k-in-row design method for ED90 determination:~* Failure: the dose should be increased in one level (+0.02 µg/kg) after failure to respond (arterial hypotension);~* Success: decrease in one level (-0.02 µg/kg) upon successful response (no arterial hypotension), but only after observing at least k-consecutive positive responses at the same dose (in this case, k=7); otherwise, remain at the same dose.~This will be done until each sequence completes n=30."
224170728|NCT04332848|DRUG|ET|Empirical therapy Based on drug history: Levofloxacin sequential therapy or bismuth quadruple therapy (10 or 14 days) or rifabutin triple/quadruple therapy or concomitant therapy
224170729|NCT04332848|DRUG|SGT|Susceptibility testing guided therapy Based on susceptibility test: Levofloxacin sequential therapy or bismuth quadruple therapy (10 or 14 days) or rifabutin triple/quadruple therapy or concomitant therapy
224170730|NCT04106180|DRUG|GM-CSF|Patients will receive GM-CSF 125μg/m2 daily for 14 consecutive days after completing SBRT treatment.
224170731|NCT04106180|DRUG|Sintilimab|Patients will receive Sintilimab 200 mg every 3 weeks up to 2 years after completing SBRT treatment.
224170732|NCT04106180|RADIATION|SBRT|Patients will receive SBRT for one previously unirradiated primary or metastatic lesion (size: 1-5cm). 24 Gy in 3 fractions (8Gy/Fx) administered once-daily for 3 consecutive days.
223482710|NCT06943859|DRUG|Treatment with Ketamine|Participants will receive four doses of ketamine spaced 1-6 days apart of 0.75 mg/kg intramuscular ketamine (n=25) for two weeks (first ketamine session must occur no later than 28 days post-intake). Individuals will be monitored for two hours post-dose by a clinician.
224170733|NCT05501457|DEVICE|Muscle strengthening with neuromuscular electrical stimulation|The effect of peripheral muscle strengthening training in addition to pulmonary rehabilitation in COPD patients on the patient's performance will be examined.
224170734|NCT06358430|DRUG|Fludarabine Phosphate|Given by IV
224170735|NCT06358430|DRUG|Cyclophosphamide|Given by IV
224170736|NCT06358430|DRUG|Cetuximab|Given by IV
223745027|NCT04366037|OTHER|Routine training|Training will be defined by each club coach
223585500|NCT02156778|BEHAVIORAL|Active Comparator: Standard Care|"In-hospital training (education of patients, next of kin and caregivers on risk factor management and assessment, life style improvement, and compliance).~Complimentary provision of a book / information material dealing with patient and caregiver relevant aspects of stroke care.~Advise by a dietitian (general advise and individualized recommendations in patients with diabetes and obesity).~Standardized information materials (e.g. for OAK or NOAK therapy). Support for smoking cessation and weight reduction if necessary or requested. Detailed medical reports (doctor's letter for the general practitioner and patient) at discharge containing target levels for risk factor management.~AF detection at the Stroke Unit (1-5 day monitoring) and/or at the ward (24-hour ECG).~12-Mo clinical visit and outcome assessment."
223585501|NCT00136552|DRUG|rituximab|
224170737|NCT06358430|DRUG|TROP2-CAR-NK Cells|Given by IV
223585502|NCT04083950|BIOLOGICAL|Vivotif Typhoid Oral Vaccine|One capsule is swallowed on alternate days, e.g. days 15, 17, 19, and 21, for a total of 4 capsules.
223585503|NCT04083950|DRUG|Aspirin (Positive Control)|Three tablets (325 mg aspirin in each tablet or 975 mg total) are swallowed on days 2 and 3.
223585504|NCT05360069|DEVICE|Linear stapler|Linear stapler is adopted in esophagojejunostomy
224170738|NCT06358430|DRUG|Rimiducid (AP1903)|Given by IV
224170739|NCT06358430|PROCEDURE|Lymphodepleting Chemotherapy|Given by Chemotherapy
224170740|NCT03993119|DRUG|Non-vitamin K antagonist oral anticoagulant|Non-vitamin K antagonist oral anticoagulant
224170741|NCT03085342|DIAGNOSTIC_TEST|Liver MRI|Multiparametric Liver MRI including following sequences: DCE, DWI, MRE, precontrast flow measurement, fat quantification.
224170742|NCT03800758|BEHAVIORAL|Expressive Helping|Expressive Helping (EH) is completed in 4 brief structured writing sessions during and immediately after transplant, with instructions focused on having participants write about their transplant experience using previously-tested EH instructions, adapted for this population.
224170743|NCT03800758|BEHAVIORAL|Factual Writing|Factual Writing has been used with cancer patients and in the investigators' prior EH trial. It is completed in 4 brief structured writing sessions during and immediately after transplant, with instructions focused on having participants write about their transplant experience using standard Factual Writing instructions.
223482711|NCT06943859|DRUG|Treatment with Active Placebo|Participants will receive four doses of an active placebo (diphenhydramine 50 mg) (n=25) spaced 1-6 days apart for two weeks (first placebo session must occur no later than 28 days post-intake). Individuals will be monitored for two hours post-dose by a clinician.
223482712|NCT07150078|DIAGNOSTIC_TEST|test|Descriptive tests will be applied
223482713|NCT07155070|DRUG|Kera Sol Eye Drops|Eye drops
223482714|NCT07167485|OTHER|Assessment of sleep quality|Sleep quality will be assessed each night in intensive care using a Richards-Campbell sleep questionnaire and an intensive care sleep questionnaire, completed by the patient.
223585505|NCT05360069|DEVICE|Circular stapler|Circular stapler is adopted in esophagojejunostomy
224170744|NCT04693091|DEVICE|Senti V1.0 Device|"This device class I, CE marked garment, with a similar form to a T-Shirt, embedded with ten sensor modules encased in silicone; the device comes with a charging stand in the form of a clothes hanger. Depending on the outcome of this feasibility study, the device may, in the future, form part of a class IIb medical device system, when accompanied by cloud-based software to listen to both current and historically recorded breath sounds for each Senti patient. The Senti Version One device will be labelled clearly to indicate the device version, on the inside of the garment, conforming to the MDR.~The garment itself will be made from textile composite, including cotton, elastase, micromodel, spandex, and polyester. All other components (including electronic and other plastic components) will be entirely encased in medical-grade silicone."
224170745|NCT05029193|BEHAVIORAL|Langerian mindfulness|A 3-week Langerian mindfulness intervention will be offered entirely online. The purpose of the intervention is: 1) to increase participants' mindfulness, and 2) to encourage participants to change their beliefs about the disability associated with stroke to improve their psychological state. Mindfulness refers to the act of being aware: aware of thoughts, aware of emotions, aware of physical sensations, aware of others. The intervention consists of educational texts, daily exercises, audio recordings and videos. Five different topics related to mindfulness will be introduced throughout the intervention.
223482715|NCT07169240|DRUG|BT-114143|6 subjects will receive a single dose of BT-114143 injection at 0.03 mg/kg.
223482716|NCT07169240|DRUG|BT-114143|6 subjects will receive a single dose of BT-114143 injection at 0.07 mg/kg.
223482717|NCT07169240|DRUG|BT-114143|3 subjects will receive a single dose of BT-114143 injection at 0.15 mg/kg.
223482718|NCT07169240|DRUG|BT-114143|6 subjects will receive a single dose of BT-114143 injection at 0.3 mg/kg.
223482719|NCT07169240|DRUG|BT-114143|6 subjects will receive a single dose of BT-114143 injection at 0.6 mg/kg.
223482720|NCT07169240|DRUG|BT-114143|6 subjects will receive a single dose of BT-114143 injection at 1.2 mg/kg.
223482721|NCT07169240|DRUG|BT-114143|6 subjects will receive a single dose of BT-114143 injection at 2.4 mg/kg.
223482722|NCT07169240|DRUG|BT-114143|6 subjects will receive a single dose of BT-114143 injection at 4.8 mg/kg.
223482723|NCT07169240|DRUG|BT-114143|6 subjects will receive a single dose of BT-114143 injection at 8.4 mg/kg.
223585506|NCT01918332|DRUG|Valsartan 160mg|
223482724|NCT07169240|DRUG|BT-114143|6 subjects will receive a single dose of BT-114143 injection at 12.6 mg/kg.
223482725|NCT07169240|DRUG|BT-114143|6 subjects will receive a single dose of BT-114143 injection at 15 mg/kg.
223585507|NCT01918332|DRUG|Rosuvastatin 20mg|
223585508|NCT01918332|DRUG|Valsartan 160mg placebo|
223585509|NCT01918332|DRUG|Rosuvastatin 20mg placebo|
223585510|NCT05330793|DIETARY_SUPPLEMENT|Oral probiotic|an oral probiotic intervention with or without a novel ADP1 toothpaste
223585511|NCT05330793|DIETARY_SUPPLEMENT|Placebo|placebo without Oral probiotic or toothpaste
223585512|NCT00771797|DIETARY_SUPPLEMENT|high dose flavanoids|flavanoid rich cocoa 2 times daily over 60 days
223585513|NCT00771797|DIETARY_SUPPLEMENT|low dose flavanoids|treatment with flavanoid-low cocoa two times daily over 60 days
224170746|NCT06069999|DEVICE|HandyMotion Treatment Program|A pair of sensor-based wireless remote controllers to allow the performance of functional exercises and games that target arm movement.
224170747|NCT06202027|DRUG|FGF23-related hypophosphataemic rickets and osteomalacia|FGF23-related hypophosphataemic rickets and osteomalacia
224170748|NCT05398068|OTHER|Exercises and Diet|"Non-Invasive Ventilation (NIV) will be included in the treatment program of all patients participating in the study. For the Mediterranean diet protocol planned in training groups; each patient will be evaluated by a dietitian at the beginning of the study and individual diet programs will be planned.~A 10-week exercise training will be planned for the training group.~Aerobic exercise sessions will be planned as a 5-minute warm-up - 20-minute bicycle ergometer - 5-minute cooling-down program. The intensity of exercise will be planned to be of medium intensity according to the heart rate reserve (40-50%). According to the Modified Borg Scale, walking will be given 3 days a week at a intensity of 4-6, also as a home exercise.~Strengthening exercises will be planned with reference to 10 RM (repetition maximum) with theraband for large muscle groups (10 repetitions-3 sets)."
224170749|NCT05398068|OTHER|Diet|Non-Invasive Ventilation (NIV) will be included in the treatment program of all patients participating in the study. A regular diet program will be planned for 10 weeks for the control group. . For the Mediterranean diet protocol planned in control groups; each patient will be evaluated by a dietitian at the beginning of the study and individual diet programs will be planned. After that, after 1 week, patients will be re-evaluated for compliance by a dietitian. And than, each patient included in the study will be evaluated for 2 weeks during the treatment period.
224170750|NCT06807957|DEVICE|Group with IMT|Group with IMT + CrossFit training
224305715|NCT05813366|OTHER|Tryptophan-Rich Diet|"All participants in both groups (A and C) will be treated by high protein foods rich with tryptophan including: chicken , turkey, red meat, salmon, fish, tuna, beans, milk, cheese, seeds, nuts, egg, banana, kiwi, leafy greens, mushroom, broccoli and peas, etc.~Total daily calorie intake will be calculated for each participant in both groups (A and C) before diet description. All females will serve the meals that met their required kilocalorie levels and physical activity levels so that the participants will not lose weight, feel hungry or be over-fed."
223482726|NCT07169240|DRUG|0.9% Sodium Chloride Injection as Placebo|Except that the S1 dose group was a pilot study group with 1 subject matched to receive a placebo, all other dose groups were each matched with 2 subjects who received placebo treatment as controls.
223482727|NCT07169331|DRUG|Zanubrutinib|Administered orally
223482728|NCT07166978|BEHAVIORAL|Social story|Social story is a training method constituting of short stories to convey information in a step-by-step manner, so that ASD children can understand what to expect and how to behave in different situations in daily lives. Social stories have been implemented to introduce dentistry and improve oral hygiene to individuals diagnosed with ASD with promising results. However, the certainty of evidence for its effectiveness in reducing dental fear during dental visit was low as the results were derived from small-scaled non-randomized controlled studies.
223482729|NCT07167264|OTHER|PGHD's AI intelligent model(APP)|To collect patient PRO (physical strength, pain, defecation, appetite, weight, etc.) data through the PGHD's AI intelligent model(APP), and use corpus collection cards, facial photography and other technologies to collect PGHD characteristic phenotypes.
223482730|NCT07169422|OTHER|Usual care for diabetic kidney disease management without primary care provider.|Participants in the control group will receive usual care for diabetic kidney disease which includes virtual care, walk-in clinics, or mobile health clinics for people without a primary care provider.
223482731|NCT07169422|OTHER|Pharmacist-led validated diabetic kidney disease decision support algorithm.|Pharmacist working in community pharmacy primary care clinic in Nova Scotia will utilize previously validated diabetic kidney disease decision support algorithms for renin-angiotensin system inhibitors (RASi), sodium-glucose co-transporter 2 inhibitors (SGLT2i), or nonsteroidal mineralocorticoid receptor antagonists (nsMRA).
223482732|NCT07168902|DRUG|BL1107 Low dose|Dosed twice daily for 28 days.
223482733|NCT07168902|DRUG|BL1107 High dose|Dosed twice daily for 28 days.
223482734|NCT07168902|DRUG|Timolol maleate 0.5%|Dosed twice daily for 28 days.
223482735|NCT07167654|OTHER|Smartphone Application|"The Intervention: Serene Motherhood Application The Serene Motherhood application was a newly developed Android-based application created specifically for this study by the research team in collaboration with professional software developers. The content was adapted from authoritative guidelines provided by the American College of Obstetricians and Gynecologists (ACOG), the National Institute for Health and Care Excellence (NICE), the World Health Organization, and the American Psychological Association (APA, 2023; Mota \& Bø, 2021; NICE, 2016; WHO, 2022). The application was developed using the research project budget and was provided free of charge to all participants.~The app aimed to integrate emotional and behavioral strategies, social support, and education for women with symptoms of PPD. The application combines evidence-based therapeutic techniques with user-friendly features supporting daily engagement with the app and self-management. Content and activities were grounded"
223482736|NCT07168941|BEHAVIORAL|KF-STRIDE|KF Stride works to improve identification (awareness) of personal character strengths and 2) express them in a socially appropriate way during a job interview
223482737|NCT07167979|BEHAVIORAL|Combining neck muscle strengthening with oculomotor saccade tasks.|"he exercise program begins at 30% of 1RM, progressing by first increasing repetitions (8-10 up to 8-12) and then intensity (+5% of 1RM). Training sessions include a 5-minute warm-up, 20 minutes of exercise, and a 5-minute cool-down, performed twice per week for 30 minutes per session.~Neck strengthening is performed using the Iron Neck, which provides constant resistance. Exercises include maintaining a neutral neck position, protraction-retraction, left-right rotation, dynamic figure-8 movements, and synchronized 360° head-body rotations. Each exercise consists of two sets of 8-12 repetitions, with 30 seconds rest between repetitions and 1 minute between sets.~After neck training, participants in the intervention group perform oculomotor saccade tasks while maintaining a neutral head position. Five visual targets appear randomly in front of the participant for 1 second each. The task lasts 40 seconds, followed by 1-2 minutes of rest, and is repeated three times."
223482738|NCT07167979|BEHAVIORAL|Neck Strengthening Only|he exercise program begins at 30% of 1RM, progressing by first increasing repetitions (8-10 up to 8-12) and then intensity (+5% of 1RM). Training sessions include a 5-minute warm-up, 20 minutes of exercise, and a 5-minute cool-down, performed twice per week for 30 minutes per session. Neck strengthening is performed using the Iron Neck, which provides constant resistance. Exercises include maintaining a neutral neck position, protraction-retraction, left-right rotation, dynamic figure-8 movements, and synchronized 360° head-body rotations. Each exercise consists of two sets of 8-12 repetitions, with 30 seconds rest between repetitions and 1 minute between sets.
224170751|NCT06807957|BEHAVIORAL|CrossFit® Training|The training routine will occur seven days a week, with participants encouraged and motivated to attend at least five training sessions. CrossFit® classes will include: warm-up exercises, strength training (with a focus on Olympic weightlifting and free weights), strength endurance (body weight and external loads), aerobic capacity (across multiple domains), maximal aerobic power (across multiple domains), anaerobic capacity (across multiple domains), cool-down activities, and mobility exercises. Each training session will be designed and supervised by a team of certified physical educators.
224170752|NCT04556175|BEHAVIORAL|Oral Health|Motivational interviewing for mothers pre-and postpartum; fluoride varnish for infants/children.
224170753|NCT04556175|BEHAVIORAL|Healthy Lifestyle|Didactic maternal and child health educational sessions for mothers pre-and postpartum; fluoride varnish for infants/children.
224170754|NCT05664126|DRUG|VST infusion|single intravenous (IV) infusion.
224170755|NCT05664126|DEVICE|CliniMACS|Cells infusions are prepared using the ClinMACS
224170756|NCT05889273|DRUG|ML-004 (IR)/(ER) tablet|Participants will receive ML-004 once daily.
223482739|NCT07168811|PROCEDURE|Hyaluronic Acid (HA)|"• After achieving complete hemostasis:~1. Mix HA (0,5% gengigel teething) with ZO powder until a mixture, then apply it on pulp stumps.~2. all teeth will be restored with glass ionomer (Prevest Denpro Micron Superior Limited, India),then a stainless steel crown (3M, ESPE, USA) to ensure proper coronal seal and long-term success, which was cemented by glass ionomer cement(Prevest Denpro Micron Luting Limited, India)"
223482740|NCT07168811|PROCEDURE|TheraCal|"• After achieving complete hemostasis:~1. TheraCal L.C will be applied directly to the radicular pulp by a disposable syringe tip and light cure will be done for 20 seconds.~2. all teeth will be restored with glass ionomer (Prevest Denpro Micron Superior Limited, India),then a stainless steel crown (3M, ESPE, USA) to ensure proper coronal seal and long-term success, which was cemented by glass ionomer cement(Prevest Denpro Micron Luting Limited, India)"
223482741|NCT07168811|PROCEDURE|Mineral Trioxide Aggregate|"• After achieving complete hemostasis:~1. mix MTA with sterile saline and put on pulp stumps. A moist cotton pellet was placed for initial setting.~2. all teeth will be restored with glass ionomer (Prevest Denpro Micron Superior Limited, India),then a stainless steel crown (3M, ESPE, USA) to ensure proper coronal seal and long-term success, which was cemented by glass ionomer cement(Prevest Denpro Micron Luting Limited, India)"
223482742|NCT07167615|BEHAVIORAL|Caring Connections|Participants receive the Caring Connections intervention.
223482743|NCT07167615|BEHAVIORAL|Treatment as Usual (TAU)|Participants receive treatment as usual.
223482744|NCT07168135|DRUG|propofol (drug)|Withholding the continuous propofol intravenous drip upon intubating the cecum during the colonoscopy.
223482745|NCT07169552|DRUG|HC010|HC010 Q3W intravenous infusion
223482746|NCT07167446|DRUG|Cannabidiol (CBD)|Oral hemp-derived CBD capsules, 150 mg twice daily (with titration in Cycle 1; dose reductions permitted for tolerability). Administered starting the day before oxaliplatin infusion and continued for 7 days after each chemotherapy cycle.
223482747|NCT07167446|DRUG|oxaliplatin-based chemotherapy|Standard of care oxaliplatin-based regimens per NCCN guidelines (e.g., FOLFOX or CAPEOX), administered in 2-3 week cycles for a maximum of 6 months.
223482748|NCT07168655|DRUG|Mavacamten|According to the product label
223482749|NCT07167290|BEHAVIORAL|Focused Acceptance and Commitment Therapy|Focused Acceptance and Commitment Therapy will be delivered following a facilitators guide. The intervention is adapted for Spinal Cord Injury patients and is to be delivered on an inpatient neurorehabilitation setting over the course of 1-3 sessions.
223482750|NCT07169110|OTHER|SPIN-NA Developmental Observation Grid Assessment via Home-Based Standardized Video Recording|The SPIN-NA intervention consists of an analytical developmental assessment using a standardized clinical observation grid. Infants are filmed once between 1 and 6 months corrected age in their home environment by the grid's creators. Each video includes structured observation scenarios designed to evaluate eight developmental domains (e.g., stress signals, tonic regulation, sensory perception, emotional expressiveness, and parent-infant interaction). The videos are independently assessed by five experienced psychomotor therapists trained in the use of the SPIN-NA grid. No treatment or physical intervention is administered; the intervention is observational and non-invasive, aiming to validate the grid's reproducibility in a real-life setting.
223482751|NCT07167940|DEVICE|Transcranial magnetic stimulation|iTBS; 50 Hz triplets given at 5 Hz frequency with a cycle time of 2 seconds on and 8 seconds off). There will be 60 cycles for a total of 1800 pulses
223482752|NCT07167940|DEVICE|Sham transcranial magnetic stimulation|Sham iTBS; 50 Hz triplets given at 5 Hz frequency with a cycle time of 2 seconds on and 8 seconds off). There will be 60 cycles for a total of 1800 pulses
223482753|NCT07166965|DIETARY_SUPPLEMENT|Hawthorn supplement|Hawthorn oral supplement
223482754|NCT07166965|DIETARY_SUPPLEMENT|Ketones|ketone oral supplement
223482755|NCT07166965|OTHER|Placebo Control|Placebo Control, oral supplement
223482756|NCT07169071|OTHER|Home-based chest physiotherapy program|he program will include breathing exercises, teaching of relaxation positions, cough training, breathing control strategies, and physical activity recommendations.
223482757|NCT07169071|OTHER|Expiratory Muscle Training|Participants perform expiratory muscle training (EMT) using a threshold device at 30% of their maximum expiratory pressure (MEP). The program consists of twice daily sessions, each lasting 20 minutes, at least 5 days per week, for 8 weeks. Resistance will be increased by 10% each week, adjusted according to tolerance and the presence of any complaints for experimental group.
223585514|NCT04670393|DIETARY_SUPPLEMENT|FertyBiotic Woman Plus|4g Myo-Inositol, 421 mg D-Chiro-Inositol, 400 mcg folic acid, 55 mcg selenium, 15 mcg vitamin D, 1,8 mg melatonin,2x109 Lactobacillus rhamnosus, 2x109 Lactobacillus crispatus and 2x109 Lactobacillus plantarum
223585515|NCT04670393|OTHER|Placebo|400 mcg folic acid
224170757|NCT01553591|DRUG|Eluxadoline|Oral tablets twice daily
224170758|NCT01553591|DRUG|Placebo|Oral tablets twice daily
224170759|NCT02871791|DRUG|Palbociclib|
224170760|NCT02871791|DRUG|Everolimus|
224170761|NCT02871791|DRUG|Exemestane|
224170762|NCT01865136|OTHER|Medical Post Abortion Care|Women with incomplete abortion is diagnosed and treated with misoprostol
224170763|NCT04045873|DEVICE|extracorporeal membrane oxygenation|The VA-ECMO procedure will be performed by femoral artery access, and the IABP will then be implanted in the contralateral femoral artery.
224170764|NCT02839512|DEVICE|Jejunal to Ileal Diversion|The Jejunal to Ileal Diversion procedure will be performed using colonoscopes to place magnets to create a side to side compression anastomosis. The colonoscope delivered magnet creates the proximal end of the anastomosis approximately 100 cm distal from the ligament of Treitz. The colonoscope delivered magnets creates the distal end of the anastomosis approximately 100 cm proximal from the ileocecal junction.
224170765|NCT00984919|OTHER|high performance liquid chromatography|
224170766|NCT00984919|OTHER|laboratory biomarker analysis|
224170767|NCT00984919|OTHER|mass spectrometry|
223482758|NCT07167602|BEHAVIORAL|Positional Release Therapy|A manual therapy technique applied to the medial and lateral hamstrings after conventional physiotherapy. In PRT, the affected muscle is placed in a position of maximal comfort and relative shortening, while gentle pressure and controlled joint movements are applied. This position is held for approximately 30 seconds and repeated three times per session. The method aims to decrease neuromuscular tension, reduce pain, and promote muscle relaxation through a reflexive response. Distinct from Active Release Therapy, PRT does not involve active contractions or longitudinal tension but instead relies on positioning and relaxation to achieve therapeutic effects.
223482759|NCT07167602|BEHAVIORAL|Active Release Therapy|A manual therapy technique applied to the hamstrings after conventional physiotherapy. ART combines therapist-applied longitudinal tension with patient movement and brief isometric contractions of both hamstrings and quadriceps. The limb is guided through specific ranges of motion to break down adhesions, restore tissue mobility, and improve flexibility. Unlike Positional Release Therapy, ART is an active technique requiring patient engagement through contractions and controlled movement against resistance, targeting scar tissue and myofascial restrictions.
223482760|NCT07167602|OTHER|Conventional Physiotherapy|Hot pack, TENS, hamstring stretching, ankle pumps (common to both groups).
223482761|NCT07169344|RADIATION|preoperative|The radiotherapy will be delivered 2.85 Gy x 15 for both x-ray or proton radiotherapy. A comparative doseplan will decide if the patient will receive proton og x-ray radiotherapy.
223482762|NCT07169344|OTHER|Quality of life|Questionnaire
223482763|NCT07169344|OTHER|Functional outcome|Questionnaire
223482764|NCT07169305|PROCEDURE|Deep Margin Elevation|The tooth preparation is performed using conventional diamond burs. The extent of caries decides the group into which the participant falls. A precontoured sectional matrix (Palodent) with a properly sized plastic diamond wedge (Bioclear Matrix Systems) is applied and stabilized using a separating ring to ensure closure of deep cervical margins, adaptation of the matrix cervically and attain contact tightness. A 37% phosphoric acid etch gel is used for Selective Enamel Etching technique for 15-20 seconds. Two coats of adhesive are applied to both enamel and dentin using a microbrush and light cured. Flowable bulkfill composite (SDR plus, Dentsply, Sirona) restorative composite is placed using teflon coated hand instruments to perform DME till the level of CEJ and light cured for 20s. Further build up of proximal box is done using packable composite. The restoration is finished using fine grit yellow coded tapered diamond stones. Polishing done by using Composite Polishing kits.
223482765|NCT07167381|DIAGNOSTIC_TEST|xDRIVE Tumor Profiling|Patients and physicians will receive tumor profiling data via xDRIVE Functional Precision Medicine and Artificial Intelligence analysis. As this is a feasibility study, results will be returned to the physician and the physician may use the data to inform the next line of treatment.
223482767|NCT07168187|OTHER|Reflexology|Reflexology, a complementary therapy rooted in ancient practices, involves applying pressure to specific points on the feet, hands, or ears thought to stimulate nerve pathways, potentially promoting relaxation and reducing stress. Evidence supporting reflexology's role in obstetrics is growing, with studies highlighting its ability to reduce anxiety, alleviate pain, and influence the duration of labor. Moreover, when reflexology was applied during the active phase of labor it was related to a significant reduction in labor pain intensity and improvements in maternal satisfaction.
223482768|NCT07169006|DRUG|Group 1|Will receive a single dose of gabapentin 300 mg preoperatively before standard general anesthesia
223482769|NCT07169006|DRUG|Group 2|will receive a placebo before standard general anesthesia
223482770|NCT07169396|OTHER|RNA extraction and gene expression|RNA extraction and gene expression
223585516|NCT02408523|DRUG|Lacosamide Tablet|"* Active Substance: Lacosamide~* Pharmaceutical Form: Film-coated Tablet~* Concentration: 50 mg~* Route of Administration: Oral use"
223585517|NCT02408523|DRUG|Lasosamide Oral Solution|"* Active Substance: Lacosamide~* Pharmaceutical Form: Oral Solution~* Concentration: 10 mg/ml~* Route of Administration: Oral use"
223585518|NCT02408523|OTHER|Placebo Tablet|"* Active Substance: Placebo~* Pharmaceutical Form: Film-coated Tablet~* Concentration: 50 mg~* Route of Administration: Oral use"
223585519|NCT02408523|OTHER|Placebo Oral Solution|"* Active Substance: Placebo~* Pharmaceutical Form: Oral Solution~* Concentration: 10 mg/ml~* Route of Administration: Oral use"
223585520|NCT03025178|PROCEDURE|4Fr central venous catheter insertion|The central venous catheter is placed at left internal jugular vein in infant, and its tip is confirmed by transthoracic echocardiography.
223585521|NCT05002387|DEVICE|NanoScope™ Operative Arthroscopy (Arthrex, Inc)|Needle arthroscopy will be performed in the operating room to visual the medial, lateral, and patellofemoral compartments prior to undergoing either unicompartmental or total knee arthroplasty
223585522|NCT04872517|DEVICE|Meridian Electroacupuncture Analysis Device (MEAD)|use MEAD to detect energy change in patient with head and neck cancer
224170768|NCT02151045|PROCEDURE|Non target epidural infiltration done at L3-L4 stage|For patients included in control arm, a non target posterior epidural space infiltration of corticoids will be done at L3-L4 stage on scan control
224170769|NCT02151045|PROCEDURE|Epidural infiltration on contact of disco radicular conflict|For patients included in experimental arm, an epidural infiltration of corticoids will be done in lateral on contact of disco radicular conflict on scan control.
223585523|NCT03964792|GENETIC|DREPAGLOBE drug product|Each patient will receive a single IV infusion of DREPAGLOBE drug product
223585524|NCT01232153|DEVICE|Non invasive ventilation|Non invasive ventilation
224170770|NCT04917328|OTHER|compression ultrasound|performing a compression ultrasound
224170771|NCT00585507|DRUG|Fulvestrant|500mg into the muscle on days 1, 15 and 29 and then every 28 days thereafter.
224170772|NCT06980181|OTHER|Graded Motor Imagery|Graded Motor Imagery typically 1 to 3 times per day for 5 to 10 minutes for each phase. No physical movement at first only cognitive task, mental rehearsal and visual motor.
223482771|NCT07169097|BIOLOGICAL|free ceftriaxone concentration dosage|The proportion of patients with UTI for whom the time spent with a free ceftriaxone concentration above 1x MIC is 100% will be determined by calculating the ratio of the total number of patients meeting this criterion to the total number of patients included. Plasma ceftriaxone dosages will be integrated into a structural model from the scientific literature using the MonolixSuite 2023R1® package (Lixoft - Saclay) including a modeling module (Monolix) and a simulation module (Simulx). T. Individual pharmacokinetic parameters will be determined by Bayesian estimation by integrating the dosage performed in the protocol.
223482772|NCT07167901|PROCEDURE|Free Gingival Graft|All patients will undergo free gingival graft surgery by the same surgeon using the same surgical protocol.
223482773|NCT07168213|DEVICE|Manual FiO2 titration with Philips oximeter (SpO2 target 90%)|FiO2 titration to reach the SpO2 target (set at 90%) with Philips oximeter
223482774|NCT07168213|DEVICE|Manual FiO2 titration with Nonin oximeter (SpO2 target 90%)|FiO2 titration to reach the SpO2 target (set at 90%) with Nonin oximeter
223482775|NCT07168213|DEVICE|Manual FiO2 titration with Philips oximeter (SpO2 target 94%)|FiO2 titration to reach the SpO2 target (set at 94%) with Philips oximeter
223482776|NCT07168213|DEVICE|Manual FiO2 titration with Nonin oximeter (SpO2 target 94%)|FiO2 titration to reach the SpO2 target (set at 94%) with Nonin oximeter
223482777|NCT07167329|DRUG|Belzutifan|Patients with Von Hippel-Lindau Syndrome presenting with lesions or neoplasms requiring treatment with oral Belzutifan.
223482778|NCT07167563|OTHER|Lithium (LI) based on clinical indication|Participants have for 4 weeks a pill box registering the time for lithium intake. Weekly phone calls will assess whether patients can remember the time for lithium intake.
223482779|NCT07168603|DRUG|aNPC|Eligible subjects must be diagnosed with disc herniation and scheduled for discectomy, nucleus pulposus tissue will be collected for cell culture. Cultured cells will be then reintroduced into the degenerated disc via injection. Subjects will undergo multiple follow-up visits after surgery to evaluate safety and efficacy, supplemented with imaging studies to assess disc height, tissue regeneration, and water-retention capacity.
223482780|NCT07167082|OTHER|Hand Grip Strength Measurement|Hand grip strength will be measured within the first 24 hours of hospitalization using a calibrated hand dynamometer. Measurements will be performed on the dominant hand, with patients seated, following standardized international procedures. Three consecutive measurements will be obtained, and the average value will be recorded. The test is non-invasive, quick, and performed by oncology clinicians trained in the protocol.
223482781|NCT07168031|DEVICE|Active Transcranial Direct Current Stimulation (tDCS)|High definition tDCS will be applied, using a Soterix Medical device and 4x1 ring electrodes. A centre ring electrode overlying the target cortical region (left dlPFC at position F3 according to the 10-20 system) will be surrounded by four return electrodes (position F1, FC3, F5, and AF3).
223482782|NCT07168031|DEVICE|Sham Transcranial Direct Current Stimulation (tDCS)|The same setup and device as in the active tDCS group will be used, but in this case stimulation will be turned off after a ramp-up phase of 30 seconds. This mimics the same sensory feeling as active tDCS.
223482783|NCT07168837|DRUG|Letrozole tablets|to compare between Letrozole withncabergoline and letrozole alone in ovulation induction among PCOS female patients.
223482784|NCT07168395|DRUG|Non-selective beta blockers|Non-selective beta blockers are used in patients who have not had a previous variceal bleed to prevent bleeding by reducing blood pressure in the liver. These drugs also work by blocking beta receptors that reduce cardiac output and by causing vessel constriction in the abdominal organs, which lowers blood flow to the liver and the existing varices.
223482785|NCT07168395|PROCEDURE|Retrograde transvenous obliteration|Pre-emptive retrograde transvenous obliteration will be performed in patients randomized to this arm to evaluate the effectiveness in decreasing gastric variceal bleeding. Either CARTO or PARTO (coil or plug-assisted retrograde transvenous obliteration) will be performed using EMBOLIZATION COILS or VASCULAR PLUGS of different sizes based on the size of the shunt. Additionally, Gelfoam (collagen sponges) slurry will be injected into the shunt and varices to completely obliterate them.
223482786|NCT07167303|OTHER|VR Training)|Participants were first introduced to the VR simulator and briefed on the current scenario. Through the VR headset, nurses experienced the CPR scenario in real time in an interactive environment. Each nurse had sufficient time to practice the skill steps in the given scenario. Participants used the scenario-based VR CPR training game until they felt ready (approximately 30 minutes)
223482787|NCT07167303|OTHER|Traditional Training|Nurses in the control group received traditional training in a hospital training room using an adult plastic CPR manikin
223482788|NCT07167927|BEHAVIORAL|Decision support tool|Decision support tool developed for patients, parents, and providers of children with neuromuscular scoliosis
223482789|NCT07168499|BEHAVIORAL|Diet Management|Visit with IBD dietician for diet management specifically for IBD
223482790|NCT07168499|BEHAVIORAL|Stress Management|Visit with IBD GI psychologist for stress management
223482791|NCT07169565|DRUG|Ibrutinib|Oral Bruton's tyrosine kinase (BTK) inhibitor administered at a fixed dose of 420 mg once daily. Capsules must be swallowed whole with water; do not open, break, or chew. If a dose is missed by ≤6 hours, take immediately; if \>6 hours, skip the dose and resume normal schedule the next day. Avoid grapefruit and Seville oranges (moderate CYP3A inhibitors). Treatment duration: 3 cycles (28 days/cycle) or until disease progression/unacceptable toxicity. Dose reduction is mandated for specific toxicities: 420 mg → 280 mg → 140 mg → discontinuation (per protocol-specified criteria). Use with caution in hepatic impairment (Child-Pugh A: reduce to 80 mg/day; Child-Pugh B/C: contraindicated).
223585525|NCT06437912|DRUG|Botulinum toxin type A|Eligible patients were randomly assigned to the experimental group and the control group. Patients in the experimental group will be randomized to receive injections of 1 U,2.5 U, and 5 U botulinum toxin type A,Patients in the control group received an injection of 0.9% Nacl
223585526|NCT01936493|GENETIC|DNA analysis|At a future time DNA analysis will be performed
223585527|NCT01936493|OTHER|Hormonal analysis|Participants will provide blood samples so that hormonal factors that influence outcomes of leiomyoma treatments can be assayed.
223585528|NCT00701805|DRUG|Paricalcitol|Intravenous (IV) paricalcitol, 3 times weekly, immediately before completion of hemodialysis.
224170773|NCT06980181|OTHER|Mirror Therapy|Mirror Therapy typically involves 1 to 3 sessions per day for 10 to 15 minutes gradually increases as tolerated.Visual and motor training using a mirror placed at the midline.
224170774|NCT06599073|DEVICE|RescueDoppler|Continuous hands-free Doppler ultrasound of the carotid artery during cardiac arrest
224170775|NCT06599073|DEVICE|Rescue|RescueDoppler patch with probe is attached on the left side of the neck during the cardiac arrest. Operative health personell are blinded for the velocity curves that are post-processed by the research team after the cardiac arrest and synchronised with ECG.
224170776|NCT04173481|OTHER|Rood's Group|"ROOD'S sensory motor training~Brushing \& strokings 3-5 strokings after 30sec, joint compressions and slow stretch 10 rep of 3 sets on alternative days for consecutive 6 weeks CIMT training~Writing, combing hairs and using spoon activity 1 hour training concentrated on affected limb along with restraint of non affected limb by cotton sling under supervision of therapist and 5 hours training in home plan 3 times a week on alternative days for consecutive 6 weeks along with conventional physical therapy."
224170777|NCT04173481|OTHER|Conventional Physical Therapy Group|Conventional training Proprioceptive neuromuscular facilitations (PNF) Combination of Isotonics technique 10 rep 3 sets 10 sec hold on alternative days for consecutive 6 weeks Stretching's 10 rep 3 sets on alternative days for consecutive 6 weeks Joint approximation 10 rep of 3 sets on alternative days for 6 weeks
224170778|NCT00263406|DRUG|Administration of an ACE-inhibitor or not|
224170779|NCT04112992|PROCEDURE|Any treatment that is used for a defect of any long bone|Any treatment that is used for a defect of any long bone. All treatments are based on individual clinician's judgement and the patient characteristics. The registry does not dictate any specific treatment.
224170780|NCT00367627|DRUG|Albendazole|
224170781|NCT02204111|OTHER|Intervention|Individualized treatment proposals (e.g. pain therapy, physiotherapy, psychological contact) from expert consensus, based on Patient Reported Outcomes
224170782|NCT06654336|RADIATION|Recurrence-directed therapy (RDT)|RDT options include radiotherapy or surgical resection.
224170783|NCT06654336|DRUG|ELIGARD 22.5mg|ADT in the form of ELIGARD 22.5 mg every 3 months for a total of 12 months.
224170784|NCT04005755|DRUG|Maxigesic® IV|acetaminophen 1000 mg + ibuprofen 300 mg, 100 ml solution for infusion
224170785|NCT02331706|DRUG|Interferon alpha-2B (IFN-α) 3 million units (MU) subcutaneous daily|
224170786|NCT00169338|PROCEDURE|Deep brain stimulation|internal pallidal deep brain stimulation
224170787|NCT02983695|DRUG|TIL-TC150|The active ingredients in TIL-TC150 are tetrahydrocannabinol (THC) and Cannabidiol (CBD), isolated from the Cannabis sativa L. strains produced by Tilray, and formulated into an oral liquid drug product.
224170788|NCT03629483|DRUG|Dexmedetomidine|Patients in this group receive continuous femoral nerve block analgesia for 48 hours after surgery. The formula is a mixture of 0.2% ropivacaine 250ml and 3.75 ug/kg dexmedetomidine. The analgesic pump is set to administer a continuous infusion at a rate of 5 ml/h (equivalent to a dexmedetomidine infusion at a rate of 0.075 ug/kg/h).
224170789|NCT03629483|DRUG|Placebo|Patients in this group receive continuous femoral nerve block analgesia for 48 hours after surgery. The formula is a mixture of 0.2% ropivacaine 250 ml and placebo. The analgesic pump is set to administer a continuous infusion at a rate of 5 ml/h.
223482792|NCT07169565|DRUG|Bendamustine|Intravenous alkylating agent dosed via a 3+3 dose de-escalation design (70 mg/m² → 60 mg/m² → 50 mg/m²). Infused over 60-120 minutes on Days 1-2 of each 28-day cycle for 3 cycles. Starting dose: 70 mg/m² (Dose Level 1); dose reduction triggered by Dose-Limiting Toxicity (DLT) events per protocol. In the dose-expansion phase, all subjects receive the MTD/RP2D established in Part 1. Concomitant live vaccines are prohibited. Dose delays (≤4 weeks) and reductions are required for Grade ≥3 hematologic/non-hematologic toxicities.
223482793|NCT07169565|DRUG|Rituximab|Intravenous anti-CD20 monoclonal antibody administered at a fixed dose of 375 mg/m² on Day 0 of each 28-day cycle for 3 cycles. Initial infusion starts at 50 mg/hour; if tolerated, increase by 50 mg/hour every 30 minutes (maximum: 400 mg/hour). Subsequent infusions start at 100 mg/hour with the same escalation. Premedication with acetaminophen and an antihistamine is required prior to each infusion. Permanently discontinue for Grade 4 infusion-related reactions or severe/life-threatening toxicity.
223482794|NCT01682525|OTHER|Frozen ovarian tissue|Use of ovarian tissue cryopreserved and stored at Boston IVF
224170790|NCT06816368|DEVICE|Catheter ablation using sequential radiofrequency and pulsed field ablation|We are using sequential application of radiofrequency and pulsed field ablation to increase lesion depth and better treat ventricular arrhythmias.
224170791|NCT06986317|OTHER|Positional release techniques|Positional release techniques apply for 90 second with the frequency of 3. This protocol will given 2 times in a week.
223482795|NCT03978767|DRUG|Ibuprofen 600 mg|NSAID pain medication to be used in the experimental bundle for postpartum analgesia
223482796|NCT03978767|DRUG|Ketorolac|NSAID analgesic to be used in the experimental bundle for postpartum analgesia in patients who underwent cesarean section
223482797|NCT03978767|DRUG|Acetaminophen|Analgesic medication to be used in both treatment arms
223482798|NCT03978767|DRUG|Oxycodone|Analgesic medication to be used in both treatment arms
224170792|NCT06986317|OTHER|Graston technique|Graston technique will apply at 45 degree to muscle fiber for 60 sec with the frequency of three. 2 session will be given per week
224170793|NCT04128072|DRUG|Mogamulizumab|• Patients will receive mogamulizumab 1.0 mg/kg IV over at least 1 hour on Days 1, 8, 15 and 22 of the first 28 day treatment cycle (C1) and on Days 1 and 15 of subsequent 28 day cycle (C2).
224170794|NCT04128072|RADIATION|Total Skin Electron Beam Therapy (TSEB)|"* After completion of C2, patients will be administered TSEB at a dose of 12 Gy in 8 fractions (4 fractions per week). TSEB will start 28 days (window of + 7 days) after mogamulizumab (C2 D1).~* In case of toxicity from mogamulizumab, the maximum delay permitted for the start of TSEB is 2 weeks.~* If recovery to at least grade 1 from toxicity exceeds the 2 weeks interval, please contact the medical monitor.~* Mogamulizumab is stopped during TSEB administration."
224170795|NCT04128072|DRUG|Mogamulizumab (subsequent cycles post TSEB)|"• Mogamulizumab will be restarted at a dose of 1.0 mg/kg IV on Days 1, 8, 15 and 22 for cycle 3. Subsequent cycles will be administered as for C2.~Treatment with mogamulizumab will be continued until disease progression (PD) or the occurrence of another withdrawal criterion."
224170796|NCT04717050|BEHAVIORAL|Progressive combine training (PCT)|8 month exercise program with 4 month follow up.
224170797|NCT04717050|BEHAVIORAL|Attention Control (AC)|12 month stretching program
224170798|NCT00611767|DRUG|Thiopental|A 2-day test design involving 2 conditions: saline (Placebo) or Thiopental 1.5mg/kg (loading) with a subsequent infusion rate of 40 mcg/kg/minute (60 minute infusion).
224170799|NCT00611767|DRUG|Placebo|A 2-day test design involving 2 conditions: saline (Placebo) or Thiopental 1.5mg/kg (loading) with a subsequent infusion rate of 40 mcg/kg/minute (60 minute infusion).
224170800|NCT05837234|DEVICE|ULF SCS|Ultra low frequency spinal cord stimulation
224170801|NCT05105529|BEHAVIORAL|Exercise|Cycling at 60% of VO2max on a cycle ergometer for 30 minutes
224170802|NCT05105529|OTHER|Ozone|Breathing 170ppb ozone
224170803|NCT05105529|OTHER|Filtere Air|Breathing filtered air
224170804|NCT03272880|BEHAVIORAL|Arts-Based Programming|This feasibility study includes educational components and an experiential components which are assessed with pre- and post-tests. The topics of these components include: Introduction to the Arts and Health; Music, Well-Being, and Resilience; Movement and Physical Activity; Art and Well-Being; Theater and Socialization; Art Appreciation and a Healthy Brain; and Summary/Integration of the Arts into Daily Lives. The impact of this program will be assessed with qualitative follow-up interviews.
223482799|NCT05084456|DRUG|ModraDoc006/r|Treatment with weekly ModraDoc006 (oral docetaxel) 10mg tablets in combination with ritonavir 100mg tablets in fed or fasting condition
223482800|NCT04898556|DRUG|Prasterone 6.5 MG|The dose to be applied will be one Intrarosa ovule (Prasterone 6.5mg) a day before going to bed for 12 weeks.
223482801|NCT04898556|OTHER|Placebo|Patients with a diagnosis of VVA who will not undergo treatment for 12 weeks.
223482802|NCT02953691|DRUG|Galacto-Oligosaccharide|Mixture produced from lactose utilizing the transgalactosidic activity of Bifidobacterium bifidum NCIMB 41171 beta-galactosidase
223482803|NCT02953691|DRUG|Maltodextrin (Placebo)|Maltodextrin is a polysaccharide commonly used as a food additive. It is produced from starch by partial hydrolysis.
223585529|NCT03865485|BEHAVIORAL|Parenting for Lifelong Health (PLH)|The Parenting for Lifelong Health (PLH) initiative is focused on the development, evaluation, and dissemination of parenting programs to reduce violence against children and improve child wellbeing in LMIC. It was established to address the need to develop low-cost, evidence-based parenting programs that can be integrated within existing service delivery systems in LMIC. The PLH for Young Children from 2-9 y. (PLH 2-9) program includes general content like one-on-one time/child-led play; praising and rewarding children; instructions, household rules, and routines; managing difficult behaviours: ignore and consequences; reflection and moving on. Core activities during sessions include group discussions illustrated vignettes, role-plays, collaborative problem solving, practicing skills at home.
224170805|NCT04255368|OTHER|Water-soluble choline|600 mg choline as choline bitartrate
224170806|NCT04255368|OTHER|Fat-soluble choline|600 mg choline as phosphatidylcholine
224170807|NCT04255368|OTHER|No choline control|No choline
224170808|NCT00475072|DRUG|peginterferon alfa-2a [Pegasys]|180 micrograms sc weekly for 48 weeks
224170809|NCT00475072|DRUG|ribavirin|1000/1200mg po daily for 48 weeks
224170810|NCT03035422|DRUG|Sequential Packaging (SET)|"Sequential chemotherapy:~* Thiotepa 5 mg / kg / day for 1 day (D-13)~* Cyclophosphamide 400 mg / m² / day for 4 days (J-12 to J-9)~* Etoposide 100 mg / m² / day for 4 days (J-12 to J-9) Repos days J-8 and J-6 Reduced-intensity conditioning (RIC)~* Fludarabine 30 mg / m² / day for 5 days (J-5 to D-1)~* Busulfan IV 3.2 mg / kg / day for 2 days (J-5 and J-4)~* Anti-lymphocyte serum (Thymoglobuline) 2.5 mg / kg / day for 2 days (J-3 and J-2)"
224170811|NCT03035422|DRUG|Transfusion graft|Graft of peripheral stem cells is preferred at D0
223482804|NCT01754649|DRUG|Misoprostol|The study group will receive two doses of misoprostol (200mcg each tablet) vaginal 12 and 4 hours prior insertion. After 24 hours of the insertion failure the women will return to the clinic and a new attempt of insertion will be done. At this time we will evaluate if the insertion was able to do or not.
223482805|NCT03395964|PROCEDURE|Hybrid Dyna-CT guided localization|We will perform intraoperative lung tumor localization in CGMH hybrid operation room(Room 51) equipped with the Siemens Artis Zeego system with DynaCT imaging capabilities. The system provides images equivalent to a 16-slice spiral CT scanner in a single 6-s sweep.
223482806|NCT03395964|PROCEDURE|Preoperative CT scan-guided localization|Preoperative localization of the lung nodule will be carried out in the radiology department on the day of surgery using local anesthesia. CT-guided hook-wire or methyl blue dye will be placed percutaneously through a 22-gauge needle with the distal end deep to the nodule. The patient will then be taken to the operating room, where under general anesthesia with lung isolation, the nodule will be removed by wedge excision with endostaplers (Endo-GIA-II, United States Surgical,Norwalk, Conn; Echelon Endostapler, Ethicon Endo-Surgery, Cincinnati,Ohio) under the guidance of preoperative lung marking. If the lesion could not be excised using the VATS technique, the patient underwent an open thoracotomy.
223482807|NCT03070652|BEHAVIORAL|NBO, Newborn behavioral observation|
223482808|NCT03070652|BEHAVIORAL|Practice as usual|
223482809|NCT01331434|DRUG|exemestane|25 mg tablet
223482810|NCT04403633|OTHER|mobile health educational tool|Interactive educational tool delivered on iPad
223585530|NCT00002112|DRUG|Nystatin|
223585531|NCT00002112|DRUG|Fluconazole|
224170812|NCT03035422|DRUG|Prevention of GVHD|"* Cyclophosphamide 50mg / kg / day on days D + 3 and D + 5~* Cyclosporine A (CSA; 3 mg / kg / day IV from D + 6)~* Mycophenolate mofetil (MMF; 30 mg / kg / day, maximum x2 1g / day from day J + 6)"
224170813|NCT03035422|DRUG|Care supports|According to the protocols of each center
224170814|NCT03035422|DRUG|Lymphocyte injection of prophylactic donor (PDLI)|"According to the protocols of each center. In the absence of clinical indication against-disease (GVHD), phasing MMF between days D + 35 and D + 56, then phasing APF between D + 62 and D + 90~\- PDLI: 3 injections from the D + 120 patients who discontinued immunosuppressive therapy for ≥ 1 month and having no active GVHD or history of acute GVHD grade\> II"
224170815|NCT05402111|DRUG|SEP-363856|SEP-363856 will be supplied by 25 mg and 50 mg tablets. Multiple tablets may be required to achieve a single dose.
224170816|NCT05402111|DRUG|Prior antipsychotic (risperidone, olanzapine, quetiapine or aripiprazole)|PA will be prepared by the pharmacy staff according to the patient's prescribed treatment and will be orally administered. Multiple tablets or capsules may be required to achieve a single dose.
224170817|NCT03888976|PROCEDURE|Cholecystectomy|Cholecystectomy with repair of duodenal wall.
224170818|NCT02238236|DRUG|Alesion®|Dry Syrup
224170819|NCT06108440|OTHER|action observation training|Patients in Group A will receive action observation training with conventional treatment. All participants will undergo the training for 25 minutes per session, 5 days per week for 8 weeks.
224170820|NCT06108440|OTHER|motor imagery training|Patients in Group B will receive motor imagery with conventional treatment. All participants will receive interventions for twenty-five minutes per session, five times a week, for eight weeks.
224170821|NCT03148899|DRUG|Oxytocin Intranasal Spray|In human volunteers intranasal administration of oxytocin significantly increases parasympathetic and decreases sympathetic cardiac control. In addition to the classic effects of oxytocin on uterine contraction and milk ejection, recent work indicates oxytocin is present in both males and females and has an important role in both behavior and cardiovascular homeostasis, particularly during anxiety and stress.
224170822|NCT03148899|DRUG|Placebo Intranasal Spray|The placebo has been compounded to be an inactive, blinded comparative to the oxytocin nasal spray.
224170823|NCT04572724|DRUG|Sacubitril / Valsartan Oral Tablet|Sacubitril/Valsartan will start at 50mg bid, when blood pressure can be tolerable, the dose will be gradually increased to 100mg bid after taking for 2-4 weeks, and then the target dose is gradually add to the 200mg bid after another 2-4 weeks. Ensure BP\>90/60mmHg, the minimum dose is 50mg bid if the patient can't tolerate higher dose but the blood pressure is stable at low dose.
224170824|NCT04572724|DRUG|RAS Inhibitors|RAS inhibitor group allows the use of a monodose of any ACEi or ARB. Ensure BP\>90/60mmHg, the minimum dose is half dose if the patient can't tolerate monodose but the blood pressure is stable at half dose.
224170825|NCT00979862|DRUG|Cediranib Maleate|Given PO
224170826|NCT00979862|DRUG|Cilengitide|Given IV
223482811|NCT06116851|OTHER|MRI scan and laboratory visit|Prostate MRI scan is performed according to the protocol used in earlier studies (PMID 31158230). In addition to the PCa diagnostics, the scan will include abdominal imaging to body composition analysis (visceral and subcutaneous fat and psoas muscle). Baseline blood and urine samples are collected in Turku University Hospital laboratory.
223482812|NCT06116851|PROCEDURE|Prostate biopsies|The visit follows routine outpatient clinic protocol. The results from MRI and laboratory findings are discussed and the potential benefits and harms from prostate biopsies are evaluated. After a mutual decision, prostate biopsies are performed.
223482813|NCT06116851|PROCEDURE|Radical prostatectomy and blood, urine and tissue sampling|Baseline blood and urine samples are collected at the time of surgery. Robotic assisted laparoscopic prostatectomy (RALP) is performed according to routine protocol. Routine diagnostic histopathological procedures will be followed, and study tissue samples are obtained in the department of pathology.
223482814|NCT06116851|PROCEDURE|TURP and blood, urine and tissue sampling|Baseline blood and urine samples are collected the time of surgery. TURP is performed according to normal protocol. Routine diagnostic histopathological procedures will be followed in the department of pathology. Additionally, tissue samples (a total of 10 resection chips) will be collected for study analyses. Due to the study, no additional tissue samples are removed, i.e. study samples are from the tissues removed as clinically indicated.
223482815|NCT06116851|PROCEDURE|Radical cystoprostatectomy and blood, urine and tissue sampling|Baseline blood and urine samples are collected at the time of surgery. Radical cystoprostatectomy is performed according to routine protocol. Routine diagnostic histopathological procedures will be followed, and study tissue samples are obtained in the department of pathology.
223482816|NCT02050204|BEHAVIORAL|Intervention|The intervention was a 3-month structural and social change process designed to increase employee control over work time and family supportive supervisory behaviors (Kossek et al., in press). The change process was an integration of two previously evaluated interventions (Hammer et al., 2011; Kelly et al., 2011). A facilitator led 8 hrs of participatory sessions to transition employees from a time-based to a results-based work culture. Supervisors participated in all change activities plus 4hrs of training in supportive supervision. Training in family supportive supervision was implemented with behavioral computer-based training (cTRAIN, NWeta, Lake Oswego, OR) followed by 2 rounds of goal-setting and behavioral self-monitoring using an iPod Touch (Habitrack, OHSU, Portland, OR).
223482817|NCT02930447|DEVICE|Autologous glue|Patients will undergo abdominoplasty according to the procedure routinely used in the Department of Plastic, Reconstructive and Aesthetic Surgery of HUG. At the end of the procedure, patients assigned to the experimental group will be additionally treated with an application of autologous glue prepared with RegenKit®-Surgery in the undermining region space between fascia and skin, just before closure of the surgical wound.
223482818|NCT01111669|DRUG|Tranexamic Acid|The bolus of TA is prepared according to patient weight (10mg / kg loading dose). The patients receiving placebo will receive an infusion of normal saline of the same volume of IV solution. Patients will receive the TA or saline infusion on call to the operating room, approximately 30 minutes before onset of the operation. The patients would also receive a continuous infusion of 1mg / kg per hour or TA preparation or normal saline for the duration of the operation.
223482819|NCT01111669|DRUG|Normal Saline (placebo)|The patients receiving placebo will receive an infusion of normal saline of the same volume of IV solution. Patients will receive the saline infusion on call to the operating room, approximately 30 minutes before onset of the operation. The patients would also receive a continuous infusion of saline for the duration of the operation.
223482820|NCT02634463|DRUG|Aripiprazole|No study agent will be administered as a part of this study. Participants must be on Aripiprazole 5 milligram (mg) (minimum dose) to 30 mg (maximum dose), orally, daily or long-acting injectable versions (300-400 mg once every 4 weeks), as part of the treatment for a psychiatric illness to be eligible for enrollment in this study. Whole Blood and Plasma Samples will be collected for development of antipsychotic immunoassays.
224170827|NCT00979862|OTHER|Laboratory Biomarker Analysis|Correlative studies
224170828|NCT06119568|DEVICE|Robot assisted laparoscopic Radical/simple nephrectomy (RN), Partial nephrectomy (PN) or Radical Prostatectomy (RP).|Three different surgery interventions: 1. Radical Nephrectomy: Complete remove of the kidney; 2. Partial Nephrectomy: Partial remove of a section in the kidney. 3. Radical Prostatectomy: Complete remote of the prostate gland. During each of these procedures removal of regional lymph nodes (lymphadenectomy) and lysis of abdominal lesions may be performed according to patient medical condition and/or surgeon criteria.
224305716|NCT05813366|OTHER|Vitamin B6 Supplementation|All participants in all groups (A, B and C) will receive a tablet of vitamin B6 60mg once/day for 8 weeks, starting from the first day of their menstrual cycle, throughout two menstrual cycles.
223482821|NCT02634463|OTHER|Olanzapine|No study agent will be administered as a part of this study. Participants must be on Olanzapine 5 mg (minimum dose) to 30 mg (maximum dose), orally, daily or long-acting injectable versions (150-405 mg once every 2-4 weeks), as part of the treatment for a psychiatric illness to be eligible for enrollment in this study. Whole Blood and Plasma Samples will be collected for Development of the antipsychotic immunoassays.
223482822|NCT02634463|DRUG|Paliperidone|No study agent will be administered as a part of this study. Participants must be on Paliperidone 3 mg (minimum dose) to 12 mg (maximum dose), orally, daily or long-acting injectable versions (25-150 mg equivalent \[eq.\] once every 4 weeks), as part of the treatment for a psychiatric illness to be eligible for enrollment in this study. Whole Blood and Plasma Samples will be collected for Development of the antipsychotic immunoassays.
223482823|NCT02634463|DRUG|Risperidone|No study agent will be administered as a part of this study. Participants must be on Risperidone 1 mg (minimum dose) to 8 mg (maximum dose), orally, daily or long-acting injectable versions (12.5-50 mg once every 2 weeks), as part of the treatment for a psychiatric illness to be eligible for enrollment in this study. Whole Blood and Plasma Samples will be collected for Development of the antipsychotic immunoassays.
224170829|NCT01859884|BEHAVIORAL|Inform Me: web-based education tool|The purpose of Inform Me is to help kidney transplant candidates understand what kidneys from increased risk donors are and describes the risks and benefits of accepting and refusing a kidney from an increased risk donor. Increased risk donors are donors who engaged in behaviors that increase their chances of having: Human Immunodeficiency Virus, Hepatitis B Virus , Hepatitis C Virus. Inform Me focuses only on increased risk donor kidneys. Inform Me aims to prepare patients to make a decision with their transplant team to accept or to refuse a kidney from an increased risk donor. Inform Me does not try to convince patients to accept or refuse a kidney from increased risk donors.
224170830|NCT03644316|DEVICE|BandGrip skin closure device|topical skin closure device
224170831|NCT04833049|DRUG|TAK-994 Oral Tablet|TAK-994 tablet.
224170832|NCT04833049|DRUG|[14C]TAK-994 Intravenous Infusion|\[14C\]TAK-994 intravenous infusion.
224170833|NCT04833049|DRUG|[14C]TAK-994 Oral Suspension|\[14C\]TAK-994 oral suspension.
224170834|NCT05839899|DRUG|Mifepristone plus one dose Misoprostol|Mifepristone 200mg PO, then 800 mcg of misoprostol 24-30 hours later
224170835|NCT05839899|DRUG|Mifepristone plus two doses Misoprostol|Mifepristone 200mg PO, then 800 mcg misoprostol 24-30 hours later, then another 800 mcg misoprostol 4 hours after that
224170836|NCT02221570|DRUG|Baclofen|Baclofen, a derivative of gamma-aminobutyric acid, is a muscle relaxant and an antispastic agent. It was introduced in 1966 as a possible treatment for spasticity due to corticospinal tract lesions. Baclofen was also tested with promising results in the treatment of other medical disorders such as cluster headaches, gastroesophageal reflux disease,chronic hiccups and cough.
224170837|NCT00090623|DRUG|rhuFab V2 (ranibizumab)|
224170838|NCT04214106|DRUG|intravenous Thiamine|patients who received Thiamine,100-500 mg/day for at least one day
224170839|NCT04589832|DRUG|PAC-1|Pharmacokinetic (PK) and pharmacodynamic (PD) assay for PAC-1 will be performed during Days 1 and 21 of Cycle 1. PAC-1 will be given on Day 1 of Cycle 1, withheld on Day 2 and Day 3 of Cycle 1 then reinitiated on Day 4 of Cycle 1 to continue for 21 days of the 28-day cycle. For each successive cycle, PAC-1 therapy will be initiated on Day 1 and continue for 21 days of the 28-day cycle.
224170840|NCT04589832|DRUG|Entrectinib|Pharmacokinetic and pharmacodynamic assay for entrectinib will be performed during Days 3 and 21 of Cycle 1. Entrectinib therapy will be withheld on Day 1 and Day 2 of Cycle 1, initiated on Day 3 of Cycle 1 and continue for the remainder of the 28 day cycle. For each successive cycle, entrectinib will be intiated on Day 1 and continue for 28 days of the 28-day cycle.
224170841|NCT00397631|DRUG|sitagliptin 100 mg q.d./pioglitazone 30 mg q.d|Patients will receive initial combination therapy with blinded sitagliptin 100 mg q.d. and open- label pioglitazone 30 mg q.d. for up to 24 Weeks. Sitagliptin 100 mg q.d. and pioglitazone 30 mg q.d. will be administered as oral tablets.
224170842|NCT00397631|DRUG|Comparator: placebo to match sitagliptin 100 mg q.d./pioglitazone 30 mg q.d.|Patients will receive placebo to match sitagliptin 100 mg q.d. (blinded) and open label pioglitazone 30 mg q.d. for up to 24 Weeks. Placebo to match sitagliptin 100 mg q.d.(blinded) and open-label pioglitazone 30 mg q.d. will be administered as oral tablets.
224170843|NCT05353218|PROCEDURE|Intermediate cervical plexus block|Intermediate cervical plexus block will be applied in transverse plane using posterior approach at C4.
224170844|NCT05353218|PROCEDURE|Deep cervical plexus block|Deep cervical plexus block will be appliedin transverse plane using anterior approach at C2-3-4.
224170845|NCT05319886|DRUG|Anlotinib and Penpulimab|Anlotinib 12mg, po, qd, with 2 weeks off for 1 week. Penpulimab 200mg, ivgtt, q3w. Efficacy was evaluated every 2 cycles. Efficacy evaluation was performed every 2 cycles during the follow-up study. Patients with disease control (CR+PR+SD) and tolerable adverse reactions continued to take the drug until the investigator considered that the patient was not suitable to continue the drug or the efficacy was evaluated as PD. Safety evaluations were performed concurrently with the dosing period. No other antitumor therapy can be administered until PD.
224170846|NCT01666353|RADIATION|PET/CT imaging with [18F] 2-deoxy-2-(18F)fluoro-D-glucose (FDG)|PET/CT imaging with \[18F\] 2-deoxy-2-(18F)fluoro-D-glucose (FDG) is a potent diagnostic tool and is able to detect melanomas and other tumors, some of which are undetectable by CT.
224170847|NCT02202161|DRUG|GSK2330672|GSK2330672 will be available in 10 mg, 20 mg, 30 mg, and 90 mg oral solution to be administered BID for 14 days. Subjects are to drink contents of dosing bottle (45 ml) followed by 2 x 50 ml rinses of bottle and then an additional 95 ml water for a total volume of 240 ml consumed
224305717|NCT04223531|DRUG|Normal Saline 0.9% Infusion Solution Bag|Participants will receive a normal saline infusion at a rate of 10ml per unit of body surface area per minute for 120 minutes.
223482824|NCT06086795|OTHER|Whole eggs|3 large whole eggs per day for 4 weeks
223482825|NCT06086795|OTHER|Egg yolks|3 large egg equivalent of egg yolks per day for 4 weeks
223482826|NCT06086795|OTHER|Egg whites|3 large egg equivalent of egg whites per day for 4 weeks
223482827|NCT00359684|DRUG|Cysteamine|Cystine-depleting agent
223482828|NCT04955691|OTHER|low carbohydrate diet|Participants will engage in a diet that limits carbohydrate intake to 15% of total daily calories for 2 weeks.
223482829|NCT04955691|OTHER|standard carbohydrate diet|Participants will engage in a diet that recommends standard carbohydrate intake with respect to total daily calories for 2 weeks.
224170848|NCT02202161|DRUG|Placebo|Matching placebo will be available as oral solution to be administered for 14 days, BID. Subjects are to drink contents of dosing bottle (45 ml) followed by 2 x 50 ml rinses of bottle and then an additional 95 ml water for a total volume of 240 ml consumed
224170849|NCT02202161|DRUG|Sitagliptin|Sitagliptin will be available as film-coated tablets Tablet of 50 mg to be administered orally, BID, for 14 days
223482830|NCT06420271|DEVICE|Real (real iTBS/tACS + exergaming)|Stimulation will be applied to the cerebellum. The tACS session duration will be 190 seconds with a frequency of 5 Hz coupled with iTBS (coil positioned tangentially with respect to the scalp)(600 pulses consisting of bursts of 3 stimuli at 50 Hz, repeated at intervals of 200ms, with an intensity of 80% of active motor threshold -AMT-) (Huang et al., 2005) for a total duration of 190 seconds. The exergaming will be performed with an adaptive system, comprising a force platform connected to a computer. The system is designed to enhance standard balance rehabilitation programs by guiding the user's performance of prescribed physical exercises through a video interface. Patients will perform 3 different exercises (10 minutes of training for a total of 30 minutes): 1) latero-lateral load shift; 2) antero posterior load shift; 3) omnidirectional displacement (combined latero-lateral and antero-posterior loading).
223482831|NCT06420271|DEVICE|Sham (sham iTBS/tACS + exergaming)|Stimulation will be applied to the cerebellum. The tACS session duration will be 10 seconds with a frequency of 5 Hz coupled with sham iTBS (coil positioned perpendicularly with respect to the scalp)(600 pulses consisting of bursts of 3 stimuli at 50 Hz, repeated at intervals of 200ms, with an intensity of 80% of active motor threshold -AMT-) (Huang et al., 2005) for a total duration of 190 seconds. The exergaming will be performed with an adaptive system, comprising a force platform connected to a computer. The system is designed to enhance standard balance rehabilitation programs by guiding the user's performance of prescribed physical exercises through a video interface. Patients will perform 3 different exercises (10 minutes of training for a total of 30 minutes): 1) latero-lateral load shift; 2) antero posterior load shift; 3) omnidirectional displacement (combined latero-lateral and antero-posterior loading).
223482832|NCT05399680|DEVICE|S.M.A.R.T. RADIANZ™ Vascular Stent System|The S.M.A.R.T. RADIANZ™ Vascular Stent System is designed to deliver the S.M.A.R.T.™ self-expanding stent (S.M.A.R.T.™ stent) to the iliac arteries, superficial femoral arteries and/or proximal popliteal arteries using a 6F (2.0 mm) sheathed delivery system introduced through the radial artery.
223482833|NCT05399680|DEVICE|BRITE TIP RADIANZ™ Guiding Sheath|BRITE TIP RADIANZ™ is a catheter guiding sheath that facilitates percutaneous entry of an intravascular device into the peripheral vasculature through the radial artery.
223482834|NCT05399680|DEVICE|SABERX RADIANZ™ PTA Balloon Catheter|SABERX RADIANZ™ is a catheter with a distal inflatable balloon.
223482835|NCT02659865|DRUG|Placebo|Administered orally
223482836|NCT02659865|DRUG|LY3039478 Capsule Formulation (Formulation 3)|Administered orally
223482837|NCT02659865|DRUG|LY3039478 Drug-in Capsule (Reference, Formulation 1)|Administered orally
223482838|NCT02659865|DRUG|LY3039478 Formulated Capsule (Test, Formulation 3)|Administered orally
223482839|NCT05084404|DRUG|Experimental: 4 mg/day of WY-8678 (guanabenz acetate)|Patients with nonalcoholic fatty liver disease are administered 4 mg/day of WY-8678 (guanabenz acetate) twice daily for 16 weeks
223482840|NCT05084404|DRUG|Experimental: 8 mg/day of WY-8678 (guanabenz acetate)|Patients with nonalcoholic fatty liver disease are administered 8 mg/day of WY-8678 (guanabenz acetate) twice daily for 16 weeks
223482841|NCT05335161|DEVICE|Home-based leg heat therapy|The Aquilo system consists of a garment that contains an inner water-circulating pad that is compressed by air bladders. The volume of air inflating the air bladders is pressure-controlled so the garment automatically adjusts to the shape and size of all legs. The touch screen console contains pre-programmed settings for ease of use. After baseline characteristics are established, patients will be provided with the Aquilo device and will be instructed on how to operate the equipment and how to rapidly remove the system if the alarm sounds or if they have any unusual feeling. Patients in both groups will also receive a logbook to record their sessions. Patients will undergo daily home-based leg HT (90 min/day, 7 days/week) for 12 weeks. Water at 42ºC will be perfused through the water-circulating garment for 90 min, with the goal of increasing skin temperature in the calf to \~37ºC.
223482842|NCT00133796|DRUG|Herceptin|IV
223482843|NCT06502158|DRUG|Mifepristone|200 milligrams (mg)
223482844|NCT06502158|DRUG|Misoprostol|600 micrograms (ug)
223482845|NCT01288430|DRUG|DS-2248|Oral capsules, of various strengths (1, 5 , 20 ,or 50 milligrams), once daily during 21-day cycles, until unacceptable treatment-related toxicity or tumor progression are observed.
223482846|NCT04131803|DRUG|Bifico combined with chemotherapy plus targeted therapy|Bifico combined with chemotherapy plus targeted therapy
223482847|NCT04131803|DRUG|chemotherapy plus targeted therapy|chemotherapy plus targeted therapy
223482848|NCT04607096|BEHAVIORAL|Intermittent fasting|The intermittent fasting intervention consists of a decreased daily caloric intake of 400 kcal below individual requirements (Harris Benedict Formula) combined with early time restricted fasting according to the schema 16:8. fasting will be performed over 4 weeks.
223482849|NCT04607096|BEHAVIORAL|Control diet|Control group will be advised to reduce daily caloric intake of 400 kcal below individual requirements (Harris Benedict formula)
223482850|NCT02970864|DEVICE|Polynerve|Polymer biomaterial nerve conduit
223482851|NCT05795335|DRUG|CDK4/6 inhibitor|CDK4/6 inhibitors
223482852|NCT04639063|OTHER|Microscopic examination using H&E stained slides|Reexamination of the stained slides of the patients from the hospital archive and adding a CD10 stain when required
224170850|NCT02202161|DRUG|Metformin|Metformin will be available as 850 mg white to off-white, film-coated tablets; to be administered BID orally during run-in through Day 14
224170851|NCT00003716|BIOLOGICAL|rituximab|
224170852|NCT06187051|DEVICE|FEVAR|Relining the EVAR with FEVAR
224170853|NCT06187051|DEVICE|Explantation|open surgery to explant the previous EVAR
224170854|NCT04211857|DEVICE|Round XTENDOBUTTON Fixation Device used in suture fixation of ligaments and tendons in conjunction with an ULTRABUTTON™ product or ENDOBUTTON™ device.|Round XTENDOBUTTON Fixation Device used in suture fixation of ligaments and tendons in conjunction with an ULTRABUTTON™ product or ENDOBUTTON™ device.
224305718|NCT00968786|DEVICE|Home monitoring|automated measuring devices for patients using at home
224170855|NCT00832091|DRUG|Thymosin Beta 4|There were 3 groups of patients with venous stasis (VS) ulcers. Each group included 18 patients receiving active drug and 6 receiving placebo. There were three concentrations of gel used for topical administration to the active groups: 0.01% weight/weight (w/w), 0.03% w/w, and 0.1% w/w thymosin beta 4 gel applied once daily for up to 84 days
224170856|NCT00832091|DRUG|Placebo|There were 3 groups of patients with venous stasis (VS) ulcers. Each group included 18 patients receiving active drug and 6 receiving placebo. There was one concentration of placebo gel for topical administration to the placebo group. The concentration was 0.0% weight/weight (w/w) thymosin beta 4 gel applied once daily for up to 84 days
224170857|NCT01782612|PROCEDURE|Multimodal analgesic techniques|Postoperative pain was controlled for all patients routinely by intravenous sulfentanil patient-controlled analgesia (PICA) in combination with Parecoxib(40 mg, every 12 h). PICA was continued with sulfentanil (1.25 µg.h-1) and 1.25 µg sulfentanil bolus with a 8-min lockout time. Oral oxycodone 0.2 mg was administered necessarily.
224170858|NCT01782612|PROCEDURE|Total uni-Hip Replacement|All subjects will undergo standard Total uni-Hip Replacement
224170859|NCT02750501|DEVICE|RELiZORB (immobilized lipase) cartridge|Hydrolyzing fats from enteral formula, ex vivo, with in-line enteral feed RELiZORB (immobilized lipase) cartridge
224170860|NCT02750501|OTHER|Impact Peptide 1.5|Impact Peptide 1.5 at a volume of administration from 500 mL to 1,000 mL per enteral feeding
224170861|NCT05986006|PROCEDURE|Anterior Cervical Disc Fusion (ACDF) Surgery w/ machined bone allograft|Participant will undergo primary, elective one-level to four-level ACDF using machined bone allograft
224170862|NCT05986006|PROCEDURE|Anterior Cervical Disc Fusion (ACDF) Surgery w/ Iliac Crest Bone Graft|Participant will undergo primary, elective one-level to four-level ACDF using iliac crest bone allograft
224170863|NCT06359886|PROCEDURE|B-Lynch Transverse Compression Suture|closure of uterine and utero ovarian arteries bilaterally with one suture
224170864|NCT04759612|OTHER|Action Observation|Participants will watch an upper extremity functionality test.
224170865|NCT01738594|DRUG|carfilzomib|Given IV
224170866|NCT01738594|DRUG|romidepsin|Given IV
223482853|NCT04853290|DEVICE|Ultrasound-guided peripheral venipuncture|Ultrasound-guided peripheral venipuncture performed by a proficient vascular access registered nurse. The procedure will be performed according to the standard operational protocol for ultrasound guided peripheral venipuncture instituted at the hospital where the study will be conducted. Site Rite 8 or Site Rite 5 ultrasound machines (Bard Access Systems, Inc., USA) will be used on the procedures.
223482854|NCT04853290|DEVICE|Conventional peripheral venipuncture|Conventional peripheral venipuncture performed by the registered nurse at the clinical inpatient unit. The procedure will be performed according to the standard operational protocol for peripheral venipuncture protocol instituted in the hospital where the study will be conducted
223482855|NCT06832878|DRUG|Oral Tranexamic Acid|Subjects will receive a 1.95 g dose of oral TXA at the following timepoints: (1) following ambulation, (2) postoperative day 1, (3) postoperative day 2, and (4) postoperative day 3
224170867|NCT01738594|OTHER|laboratory biomarker analysis|Correlative studies
224170868|NCT01481428|BEHAVIORAL|Computer-facilitated HIV intervention|Individuals assigned to the experimental condition will complete the self-directed CARE HIV intervention during each of their first three sessions. The 20 minute intervention sessions involve several components including a brief risk assessment, review of identified risks, structured skill building videos, and the development of a risk prevention action plan. Because of the adaptive nature of the CARE program, the content of each session will be tailored to address the current risks of the participant. While the main focus of the intervention is on risk, individuals who report being HIV infected will receive a referral to treatment if they are not currently receiving medical care and their session will address, among other things, adherence to HIV care.
224170869|NCT01481428|BEHAVIORAL|Attention Control|Life skills training DVDs that match the duration of the anticipated experimental condition. The DVDs address topics such as positive listening skills, anger management, and stress reduction.
224170870|NCT02508506|DRUG|ALKS 5461|Single dose, given orally
224170871|NCT05232344|DRUG|Estradiol / Progesterone|Treatment with estradiol (Provames®, 3 mg morning and evening, or 6 mg per day) will start on the 1st or 2nd day of her period. This treatment is continued until the end of the study (discontinuation treatment after the blood test taken on Day 7). After ten days of minimum estradiol treatment (and up to 7 days later to be working days), vaginal progesterone treatment will start in the evening on Day 0 (400 mg, Progestan®, evening and morning, ie 800 mg per day).
223482856|NCT06833788|DRUG|Ferric carboxymaltose IV|Single dose of Ferric carboxymaltose 1000 mg (20mL) IV infusion (20ml vial of 1000mg iron or two 10ml vials of 500mg)
223585532|NCT03035682|OTHER|Augmented Media Group|The intervention group will receive traditional PT services deemed clinically appropriate via examination plus home exercise prescription augmented via a mobile health application. The augmented media group will receive digital exercise prescription via a mobile health application source (Physitrack) that includes: high definition video and pictures, education material and written instruction, reminder notification and in-app logging of completion.
224170872|NCT05232344|BEHAVIORAL|Sexual event|A sexual intercourse (protected or not protected by condoms) will take place in a pre-defined order for each participant within one hour of the administration of the progesterone ovum on the evening of Day 2 and Day 6.
224170873|NCT04752631|DRUG|Tenecteplase|The participants received TNK-tPA thrombolytic therapy
224170874|NCT00875966|DRUG|Azithromycin for Oral Suspension 200mg/5mL Eon Pharma, LLC|
224170875|NCT00875966|DRUG|Zithromax (azithromycin for oral suspension) 200mg/5mL Pfizer|Subjects randomized to Zithromax received a single oral dose of Zithromax 600mg (15mL), administered with 240mL of water under fed conditions
224170876|NCT02021864|DRUG|vitamin D3 50,000 unit|vitamin D3 50,000 unit/week for 8 weeks
224170877|NCT02021864|DRUG|prenatal multivitamin|daily prenatal multivitamin containing elemental calcium 250 mg/day and vitamin D3 400 unit
223482857|NCT06833788|DRUG|TIMOFÉROL®|100 mg once a day (2 pills of TIMOFÉROL® 50mg)
223482858|NCT04097561|BIOLOGICAL|Belimumab|Belimumab 10 mg/kg once every 2 weeks for 3 doses, and then once every 4 weeks for 5 doses, delivered via 1-hour intravenous (IV) infusion.
224170878|NCT00403390|DRUG|Brand Name Levothyroxine (Synthroid)|Randomized crossover study using 8 weeks of brand name levothyroxine (Synthroid, manufactured by Abbott), then 8 weeks of the generic formulation of levothyroxine (manufactured by Sandoz). The dose of medication does not change throughout the duration of the study.
224170879|NCT00403390|DRUG|Generic formulation of Levothyroxine|Randomized crossover study using 8 weeks of the generic formulation of levothyroxine (manufactured by Abbott, then 8 weeks of brand name levothyroxine (Synthroid, manufactured by Abbott). The dose of medication does not change throughout the duration of the study.
224170880|NCT04145505|PROCEDURE|COLORECTAL CANCER SURGERY|SENTINEL NODE DETECTION
224170881|NCT06135142|OTHER|Connective Tissue Massage|It involves manipulating the soft and deep tissues of the body.
223482859|NCT03768999|DIAGNOSTIC_TEST|Non-contrast magnetic resonance coronary angiography (MRCA)|Scan non-contrast MRCA and compare the image with clinically scanned coronary computed tomography angiography (CTA).
223482860|NCT05802940|BEHAVIORAL|Electronic health record best practice alert|The electronic health record will identify patients at high-risk for preeclampsia and candidate for low dose aspirin (LDA) prophylaxis. For those in the intervention group, a best practice alert will notify the healthcare provider within the patient's chart during a prenatal visit that LDA should be recommended.
223482861|NCT05652101|OTHER|collection of medical data|"The data collected concerns:~* Sex~* Age~* Socio-professional category of patients or parents / level of education of the parents~* Family history~* Neonatal patient data (pregnancy, childbirth)~* Clinical data (age of onset of symptoms, evolution of these symptoms over the years, psychomotor development, schooling, learning difficulties, rehabilitation)~* Therapeutic data (treatments tried, their dosage and effectiveness, changes in dosage over the years)~* Paraclinical examinations (Magnetic Resonance Imaging (MRI), scanner, Electroencephalography (EEG))~* Genetic data if available"
223482862|NCT05652101|OTHER|Vineland Adaptive Behaviour Scales (VABS2) questionnaire|"This is a standardized semi structured interview that measures adaptative skills in 4 areas, in the fields of communication, socialization, daily living, and motricity (for children under 7 years). It can be used for children and adults.~Rating: 2 = yes, usually, 1 = sometimes or partly, 0 = no, never, N = not applicable (when a child is not yet of sufficient age, for example), NS = don't know. The results by domain and by sub-domain are given in raw scores which are then transformed into equivalent ages using a grid provided for this purpose."
223482863|NCT06125743|BEHAVIORAL|Usual Care|Participants will conduct self-care activities prescribed by their treating lymphedema therapists.
223482864|NCT06125743|BEHAVIORAL|In-Person LEF-SMP|Participants will receive the in-person LEF-SMP intervention.
223482865|NCT06125743|BEHAVIORAL|Telehealth LEF-SMP|Participants will receive the telehealth LEF-SMP intervention.
223482866|NCT06056102|DRUG|Cyclophosphamide|"* Safety Run-in: 375mg/m\^2 daily x 3~* Cohort 1: 375mg/m\^2 daily x 3~* Cohort 2: 375mg/m\^2 daily x 3~* Cohort 3: 375mg/m\^2 daily x 3"
223482867|NCT06056102|BIOLOGICAL|CART-BCMA|"* Safety Run-in: 5 x 10\^7 CAR T cells~* Cohort 1: 1.5 x 10\^8 CAR T cells~* Cohort 2: 1.5 x 10\^8 CAR T cells~* Cohort 3: 5 x 10\^8 CAR T cells"
223482868|NCT06056102|BIOLOGICAL|huCART19|"* Safety Run-in: 5 x 10\^7 CAR T cells~* Cohort 1: 1.5 x 10\^8 CAR T cells~* Cohort 2: 1.5 x 10\^8 CAR T cells~* Cohort 3: 5 x 10\^8 CAR T cells"
223482869|NCT06056102|DRUG|Fludarabine|• Cohort 3: 24mg/m\^2 daily x 3
223482870|NCT05874271|COMBINATION_PRODUCT|Revised case management package|"1. Point-of-care quantitative G6PD testing using G6PD STANDARD (SD Biosensor) prior to use of primaquine (Day 0)~2. Prescription of short course primaquine (7 mg/kg total) (Day 0):~   * PQ7 (1 mg/kg/day for 7 days) if G6PD activity greater than 70 percent~  * PQ14 (0.5 mg/kg/day for 14 days) if G6PD activity is 30-70 percent~  * PQ8w (0.75 mg/kg/week for 8 weeks) if G6DP activity less than 30 percent~3. Participant counselling at the health facility (Day 0):~   * Supervision of first dose of primaquine~  * Education regarding importance and risks of primaquine therapy and necessity to take primaquine with food~4. Community based clinical review on Day 3 (and Day 7 for the first 300 participants) to detect and manage gastrointestinal or haemolytic adverse effects of treatment and encourage adherence to full treatment regime~5. Improved malariometric surveillance and pharmacovigilance to support wider scale use of the revised case management"
223482871|NCT03166709|BEHAVIORAL|Preventing Addiction Related Suicide (PARS)|PARS is a module designed for a single session of an Intensive Outpatient Program (IOP) including a specified combination of didactic presentations and group discussions. PARS topics include: Goals and Objectives; Suicide Overview; The Strong Link Between Addiction and Suicide; Suicide Myths and Facts; Common Triggers of Suicidal Thoughts and Behaviors; Warning Signs of Suicide; Suicide Risk Factors; Suicide Protective Factors; How You Can Prevent Addiction Related Suicide; Action Steps to Take if You or Someone You Know Becomes Suicidal
224170882|NCT06135142|DEVICE|Transcutaneous Electrical Nerve Stimulation (TENS)|The sum of therapeutic modalities of physical medicine capable to change the threshold of elicitation of nerve or muscle.
224170883|NCT06135142|OTHER|Classical Massage|It involves manipulating the soft tissues of the body.
224170884|NCT06135142|DEVICE|Therapatic Ultrasound|The sum of therapeutic modalities of physical medicine capable to change the threshold of elicitation of nerve or muscle.
224170885|NCT06135142|OTHER|Heat Treatment|Applying heat to an affected area to treat damaged muscles, joints or tissues in the body.
224170886|NCT04146870|OTHER|not have|not have
224170887|NCT01941212|BEHAVIORAL|Music therapy|Music therapy will be given to patients 24 hours prior and for the first 48 hours after surgery
224170888|NCT06859281|DRUG|Grammidin neo|Grammidin neo, lozenges, 1 lozenge to be taken once under fed conditions.
224170889|NCT06859281|DRUG|Grammidin, a metered dose topical spray|Grammidin, a metered dose topical spray, 4 sprays to be taken once under fed conditions.
224170890|NCT01522196|DRUG|Varespladib|48 hour continuous infusion delivered intravenously (IV)at a rate of 110µg/kg/hr.
224170891|NCT01522196|OTHER|Placebo (Normal Saline)|48 hour continuous infusion delivered intravenously (IV)at a rate of 110µg/kg/hr.
224170892|NCT05015062|BEHAVIORAL|Mobile-based HIV-related educational message delivery|HIV/AIDS awareness-raising and behavior-related cyclic messages will be delivered by the village doctors on a biweekly basis for 18 months.
224170893|NCT05015062|BEHAVIORAL|Incentive policies evaluation|village doctors in Intervention A and B will receive different types of monetary compensation. Doctors in Intervention A will receive standardized compensation for completing their assigned tasks. Doctors in Intervention B will receive performance-based compensation whose amount depends on how well the participants perform on the follow-up questionnaires.
224170894|NCT03112499|PROCEDURE|PCNL|Under general anesthesia and patient in prone position, with the use of a flexible cystoscope an open-ended ureteral catheter 5F / 70cm is positioned to the proximal ureter. Retrograde pyelography is performed and the most appropriate calyx is accessed with the use of ultrasound, under fluoroscopic guidance. A 0.035 guide wire is inserted into the ureter and then replaced with an extra stiff wire. Using either balloon (20 atm) or Amplatz serial dilators a 30F access channel is created. Lithotripsy is performed using ultrasound lithotripter and stone fragments are removed by grasping forceps. At the end of the operation a 18F Council type catheter is placed into the kidney for drainage of urine and an indwelling JJ catheter is inserted in the ipsilateral ureter. Council and JJ catheter are removed,in the absence of complications, the second and tenth postoperative day, respectively.
224170895|NCT03112499|PROCEDURE|mini-PCNL|Under general anesthesia and patient in prone position, with the use of a flexible cystoscope an open-ended ureteral catheter 5F / 70cm is positioned to the proximal ureter. Retrograde pyelography is performed and the most appropriate calyx is accessed with the use of ultrasound, under fluoroscopic guidance. A 0.035 guide wire is inserted into the ureter and then replaced with an extra stiff wire. Using Amplatz serial dilators a 16F access channel is created. Lithotripsy is performed using using 270mm Ho: YAG laser fiber and stone fragments are removed by grasping forceps. At the end of the operation a 10F nephrostomy tube is placed into the kidney for drainage of urine and an indwelling JJ catheter is inserted in the ipsilateral ureter. Nephrostomy tube and JJ catheter are removed, in the absence of complications, the second and tenth postoperative day, respectively.
224170896|NCT03112499|PROCEDURE|RIRS|Under general anesthesia and patient in lithotomy position, a 0.035 hydrophilic safety wire is inserted in the ureter under fluoroscopic guidance. Subsequently 8-10 F dilators are used for dilation of the ureter.Insertion of a second working wire follows above which a 14F ureteral sheath is placed. Lithotripsy with a flexible ureteroscope using 270mm Ho: YAG laser fiber follows.Remaining stone fragments are removed by a 2,2F nitinol basket. At the end of the operation a JJ indwelling ureteral catheter is placed over the safety wire. Discharge is performed in the absence of complications, the first postoperative day while JJ catheter is removed on the 10th postoperative day.
224170897|NCT01393665|DRUG|PENNEL capsule|"hard capsule DDB 25mg \& GO 50mg in cap .......... 1 capsule~1 or 2 capsule, T.I.D"
223482872|NCT03166709|BEHAVIORAL|Intensive Outpatient Program standard session|Intensive Outpatient Program (IOP) substance abuse group session focused on depression, grief, or managing emotions. Site-specific session topic is what that IOP usually provides and was chosen by agency leads prior to start of study.
223482873|NCT00003720|DRUG|semaxanib|
223482874|NCT05942313|DRUG|Buprenorphine/ Methadone exposure|Validate candidate genes- and prenatal opioid exposure- related maternal relapse and NOWS outcome associations in pregnant women and their newborns.
223482875|NCT03836053|DRUG|AMG 420|28 day continuous Intravenous infusion of either 400 mcg/d or 600 mcg/d followed by 2 treatment free weeks
223482876|NCT05357651|DRUG|LB1410|anti-PD-1 and anti-TIM-3 bispecific antibody
223482877|NCT04006457|DRUG|PF-06651600|50 mg oral tablets/capsules
223482878|NCT04006457|BIOLOGICAL|Tetanus and diphtheria toxoids and acellular pertussis (Tdap) vaccine|Single intramuscular injection administered to patients participating in the vaccine sub-study
223482879|NCT04006457|BIOLOGICAL|Meningococcal (groups A, C, W-135 and Y [ACWY]) oligosaccharide diphtheria CRM197 conjugate vaccine|Single intramuscular injection administered to patients participating in the vaccine sub-study
223482880|NCT05172960|DEVICE|SAPIEN X4 THV|Implantation of the SAPIEN X4 valve
223482881|NCT04669197|DRUG|Paclitaxel protein bound|combination therapy
223482882|NCT04669197|DRUG|Gemcitabine|combination therapy
223482883|NCT04669197|DRUG|Cisplatin|combination therapy
223482884|NCT04669197|DRUG|Hydroxychloroquine|combination therapy
223482885|NCT06049212|BIOLOGICAL|Sacituzumab tirumotecan|Sacituzumab tirumotecan injection powder for intravenous (IV) infusion.
223482886|NCT06049212|BIOLOGICAL|Pembrolizumab|Pembrolizumab solution for IV infusion.
223482887|NCT06049212|DRUG|Supportive care measures|Participants are allowed to take supportive care measures at the discretion of the investigator. Prophylactic supportive care measures may include but are not limited to antiemetic agents, antidiarrheal agents, granulocyte and erythroid growth factors, and blood transfusions
223482888|NCT04486716|DRUG|Ofatumumab|Investigational drug will be provided in an autoinjector for subcutaneous administration containing 20 mg ofatumumab (20 mg/0.4 ml)
224170898|NCT01393665|DRUG|Placebo|Placebo
224170899|NCT02180464|DRUG|LAS41004|
224170900|NCT02180464|DRUG|control|
224170901|NCT00301236|DRUG|Dexmethylphenidate HCl extended-release capsules|
223482889|NCT05633550|DIAGNOSTIC_TEST|Flexion-extension radiographs|Participants will undergo (regular) flexion-extension radiographs.
223482890|NCT05518162|DEVICE|InBloom|The Rose Program (RPv2) application will be built for iOS and Android devices (including tablets) and will feature a video-based Learning Management System (LMS) which provides resources for people with postpartum depression to improve their wellbeing. Each InBloom session will contain 4-5 video modules with specific themes contained in each ROSE session which are 3-5 minutes each.
223482891|NCT05518162|BEHAVIORAL|ROSE|"ROSE will be offered as a psychoeducational course on adjusting to parenthood by a health professional embedded in the obstetric clinics. There are five 90-minute group sessions which provide interpersonal rationale for the program, a review of the course outline, ground rules for the group, and the signs and symptoms of baby blues and postpartum depression, stress management skills. managing role transitions with an emphasis on transition to motherhood and the development of a support system, identifying types of interpersonal conflicts common around childbirth and techniques for resolving them, skills for resolving interpersonal conflicts and an opportunity to review and reinforce the content of the previous sessions."
223482892|NCT06398158|DRUG|Ravulizumab|All study participants will receive commercially covered ravulizumab consistent with the indication, dose and frequency contained within the approved label.
223482893|NCT02602262|OTHER|HIV-infected deceased donor organ|HIV-infected deceased donor organ transplant
223482894|NCT05479461|OTHER|Digital Hypertension Management System|Mobile health technology using physician- directed, semi-automated management of hypertension
223482895|NCT05479461|OTHER|Usual Care|The participants will receive usual care
223482896|NCT05685303|DEVICE|Alleviant ALV1 System|Creation of interatrial shunt
223482897|NCT05685303|OTHER|Sham-Control|Cardiac imaging
223482898|NCT06565559|DEVICE|Wearable Wireless Sensor|Stage III is a shadow mode evaluation of the device with participants wearing sensors pre-, intra-, and post-operatively. Sensor and clinical data will be collected contemporaneously in the clinical environment. No sensor data is made available to clinical teams for decision making, with no change in patient care.
223482899|NCT06814236|BEHAVIORAL|Three-Stage Informed Consent Conversation Model for Anaesthesia Risk profiling|"Stage 1 Pre-information queries~Do you know about the risks involved in Anaesthesia?~If yes, where did you get information about the risks involved with Anaesthesia??~Which of these do you already know of and what concerns you most?~Why are you concerned more about that particular risk factor?~Stage 2 Informing Risks~The probability or chances of supposed anaesthesia risks could be:~Probable risk Possible risk Remote risk~We have the following risk management strategy in place for your reassurance and safety:~Employing ERAS protocol~The surgery you are going to undergo, also may have its own set of risks~Stage 3 Post-information Informing Risks~In view of the above conversation we had, do you have other point of concern or query on what we have talked about."
223482900|NCT06775379|DRUG|Azetukalner|Azetukalner 20 mg taken orally once a day with food (with the evening meal when possible) for 6 weeks
223482901|NCT06775379|DRUG|Placebo|Placebo taken orally once a day with food (with the evening meal when possible) for 6 weeks
223482902|NCT05611307|DIAGNOSTIC_TEST|Lipid profile|Advanced lipid profile
223482903|NCT05611307|DIAGNOSTIC_TEST|Coronary artery assessment|Coronary artery assessment via CT scans
223482904|NCT05611307|DIAGNOSTIC_TEST|Hormone levels for hypogonadism|Hormone levels for hypogonadism
223482905|NCT06110624|OTHER|Survey|A survey study will be conducted to evaluate if GHCPs have the Intention to Use (IU) MuSt-PC in daily practice.
223482906|NCT04484441|OTHER|Blood and placenta specimen collection.|Collection of maternal and paternal blood. Collection of infant cord blood and placenta.
223482907|NCT06788262|OTHER|Cerebral MRI|Cerebral MRI
223482908|NCT00488878|PROCEDURE|Biospecimen Collection|Patients' residual tissue samples are collected
223482909|NCT00488878|OTHER|Electronic Health Record Review|Medical records are reviewed
223482910|NCT05292313|PROCEDURE|Single distal femur implant|Single implant fixation
223482911|NCT05292313|PROCEDURE|Dual distal femur implants|Dual implant fixation
223482912|NCT04864171|DEVICE|near-infrared spectroscopy|Near-infrared spectroscopy is an intravascular imaging device to visualize lipid-rich plaque of coronary artery.
223482913|NCT06835530|DRUG|Rituximab + Golcadomide (CC-99282)|A combination of Rituximab and CC-99282 as front-line therapy for older frail patients with Diffuse Large B-cells non-Hodgkin Lymphoma evaluated with a simplified Geriatric Assessment (sGA).
223482914|NCT04184050|DRUG|MK-4002|IV infusion
223482915|NCT00879177|DRUG|Varenicline|Varenicline: 1 tab 0.5mg once a day for 3 days; 1 tab 0.5mg twice a day for 4 days; followed by 1 tab 1mg twice a day for 11 weeks.
223482916|NCT00879177|BEHAVIORAL|behavioral therapy|confirmed negative smoking status at different time points
223482917|NCT02332707|DRUG|Grazoprevir|One GZR 100 mg tablet (Part A), or 2 FDC tablets containing GZR 50 mg per tablet (Part B), taken q.d.by mouth.
223482918|NCT02332707|DRUG|Uprifosbuvir|Two or 3 UPR 150 mg (300 mg and 450 mg total daily dose) tablets (Part A), or 2 FDC tablets containing UPR 225 mg (Part B), taken q.d. by mouth.
223482919|NCT02332707|DRUG|Elbasvir|One EBR 50 mg tablet (Part A), taken q.d. by mouth.
223482920|NCT02332707|DRUG|Ruzasvir|Six RZR 10 mg (60 mg total daily dose) capsules (Part A), or 2 FDC tablets containing RZR 30 mg per tablet (Part B), taken q.d. by mouth.
223482921|NCT02332707|DRUG|Uprifosbuvir (+) Grazoprevir (+) Ruzasvir|Two FDC tablets, each containing GZR 50 mg + UPR 225 mg + RZR 30 mg (Part B), taken q.d. by mouth.
223482922|NCT02332707|DRUG|Ribavirin|RBV 200 mg capsules taken b.i.d. at a total daily dose of 800-1400 mg based on participant body weight.
223482923|NCT02887001|OTHER|Pharmacist consultation|
223482924|NCT05848063|OTHER|Global hip muscles strengthening exercises|Strengthening exercises will be given to all hip muscles
223482925|NCT05848063|OTHER|Hip abductors strengthening exercises|Strengthening exercises will be given to hip abductor muscles
223482926|NCT05695287|DRUG|Propofol|To maintain anaesthesia in Group 1 P, propofol was used as an anaesthetic in a dose of 4-6 mg/kg/h intravenously on a perfusor
223482927|NCT05695287|DRUG|Isoflurane|Isoflurane
223482928|NCT05695287|DRUG|Sevoflurane|Sevoflurane
223482929|NCT05435508|OTHER|Pain Neuroscience Education|A total of 1 PNE sessions (Neuroscience pain education) will be carried out, in addition medical treatment similar to control group (Usual care). The PNE sessions will be conducted by an experienced PNE certified proffesional in 35 minute face-to-face sessions. In PNE, the patient is taught about the physiology of pain, central sensitization, representation of the different body regions in the brain, pain-related changes in body perception, and the psychosocial dimensions of pain.
223482930|NCT05435508|OTHER|Usual care|The control group (Usual care) is treated with pre-anesthetic assessment + usual treatment, management for analgesic medication pre, during and post hysterectomy. Depending on the medical needs and criteria of patients´s care physician.
223482931|NCT04761822|BIOLOGICAL|Moderna COVID-19 Vaccine|Intramuscular injection
223482932|NCT04761822|BIOLOGICAL|Pfizer-BioNTech COVID-19 Vaccine|Intramuscular injection
223482933|NCT04761822|BIOLOGICAL|Placebo|Intramuscular injection
223482934|NCT02700841|DRUG|Melphalan|Given IV
223482935|NCT02700841|PROCEDURE|Peripheral Blood Stem Cell Transplantation--CD34 HSCT|Undergo autologous CD34 HSCT
223482936|NCT02700841|PROCEDURE|Peripheral Blood Stem Cell Transplantation--AHSCT|Undergo AHSCT
223482937|NCT02700841|BIOLOGICAL|T Cell-Depleted Hematopoietic Stem Cell Transplantation|Undergo autologous CD34 HSCT
223482938|NCT02700841|BIOLOGICAL|Tetanus Toxoid Vaccine|Given IM
223482939|NCT06136585|DRUG|2 mg/kg sugammadex|All participants will be given rocuromium for neuromuscular blocks during the procedure. Per randomization, patients in this group will be reversed with 2 mg/kg sugammadex.
223482940|NCT06136585|DRUG|0.07 mg/kg neostigmine|All participants will be given rocuromium for neuromuscular blocks during the procedure. Per randomization, patients in this group will be reversed with 0.07 mg/kg neostigmine (to a maximum of 5 mg).
223482941|NCT04598113|DEVICE|Cervical Traction Device|"While The patient is lie on the back his or her head is housed within the specific head portion of the device. The investigator inflate progressively the device using a valve and ensuring the patient's relaxation. The process of inflation is continued until the level of 12 Kg of pressure is reached. This maximum level of traction is maintained for 10 minutes then the process of deflation is started until the pressure decreased to 0 Kg. This maneuver is reproduced once again after 5 minutes of rest.~The balance assessment using the force plate-from is done just before the intervention and 5 minutes after its end."
223482942|NCT06021522|DRUG|Ecopipam|Selective dopamine D1 and D5 receptor antagonist
223482943|NCT03238534|DEVICE|Neobianacid®|Oral administrations of Neobianacid® (30' after meals and on demand)
223482944|NCT03238534|DRUG|Omeprazole 20mg|Daily administration Omeprazole 20mg (per os, 30' before breakfast).
223482945|NCT03238534|OTHER|Neobianacid® placebo|Oral administrations of Neobianacid® placebo (30' after meals and on demand)
223482946|NCT03238534|OTHER|Omeprazole placebo|Daily administration Omeprazole placebo (per os, 30' before breakfast).
223482947|NCT05296278|DRUG|IBI-323 combined with bevacizumab plus Platinum|IBI-323 (30 mg/kg) ccombined with bevacizumab (15 mg/kg) plus platinum based chemotherapy ivgtt, every 21 days until disease progression
223482948|NCT05718674|PROCEDURE|Extracorporeal Photopheresis|ECP is performed by collecting leucocytes from the patient through leukopheresis and incubating them with 8-MOP and UVA in extracorporeal circulation. The treatment steps are the collection of leucocytes, photoactivation and subsequent reinfusion of the treated cells.
223482949|NCT06215911|DRUG|Tovinontrine (CRD-750)|Tablets administered orally
223482950|NCT06215911|DRUG|Placebo|Tablets administered orally
223482951|NCT04213261|BIOLOGICAL|FCX-007 (dabocemagene autoficel; see below for FCX-007 description)|FCX-007 is comprised of fibroblasts isolated from the subject's skin biopsies which are genetically corrected with the full length COL7A1 gene encoding for type VII collagen.
224205412|NCT03094949|PROCEDURE|microwave ablation|Microwave ablation is a technique that uses thermal therapy to induce complete necrosis of tumor in situ by using microwave ablation device.Antenna in the microwave ablation device was percutaneously inserted into the tumor and placed at designated place under US guidance. For tumors less than 1.5 cm, one antenna was inserted and for tumors measuring 1.5 cm or greater, two antennae were inserted in parallel with an inter-antenna distance of 1.0-2.5 cm, which were used simultaneously during MWA to obtain larger ablation zone. A 20G thermocouple was inserted about 0.5-1 cm away from the tumor for real-time temperature monitoring during MWA. MW emission didn't stop until the heat-generated hyperechoic water vapor completely encompassed the entire tumor and the measured temperature reached 60°C or remained above 54°C for at least three minutes.
223482952|NCT04658355|OTHER|Chlorhexidine Gluconate|4% Chlorhexidine Gluconate vaginal cleansing solution as a surgical preparation.
223482953|NCT04658355|OTHER|Povidone-iodine|10% povidone-iodine vaginal cleansing solution as a surgical preparation.
223482954|NCT01898416|DRUG|5-AMINOLEVULINIC ACID (5-ALA), is a non fluorescent prodrug.|"60 mg/kg 5-ALA prepared solution given orally, 3-5 hours before induction of anesthesia.~Red light laser given by a Dye laser system, wave length of 635nm, in s dose of 150J/cm for 2000 seconds (33 minutes) will be given to tumor bed. In case of positive margins a second operation and 5-ALA administration or irradiation will be given."
223482955|NCT03283917|BIOLOGICAL|Daratumumab|Given IV
223482956|NCT03283917|DRUG|Dexamethasone|Given IV or PO
223482957|NCT03283917|DRUG|Ixazomib|Given PO
223482958|NCT00947544|DRUG|HPN-100|HPN-100 is a triglyceride that has a similar mechanism of action as NaPBA. It is a liquid with minimal taste and odor. Three teaspoons of HPN-100 (\~17.4mL) delivers equivalent amount of PBA that 40 tablets of NapBA do.
223482959|NCT00947544|DRUG|NaPBA|NaPBA tablets for oral administration and NaPBA powder for oral, nasogastric, or gastrostomy tube administration contain the active ingredient sodium phenylbutyrate. NaPBA is a prodrug and is rapidly metabolized to PAA, the metabolically active compound that conjugates with glutamine via acetylation to form PAGN, which is excreted by the kidneys.
223482960|NCT04542941|BIOLOGICAL|COVID Convalescent Plasma|Plasma collected from recovered COVID 19 individuals
223482961|NCT03095235|DIETARY_SUPPLEMENT|Dietary riboflavin|Dietary riboflavin is vitamin B2. It has been shown to be safe in children in the treatment of migraines at doses of 400 mg per day. There are no known documented side effects
223482962|NCT04920669|PROCEDURE|erector spinae block with bupivacaine|Patients will receive a sonar-guided erector spinae plane block with 20 ml of bupivacaine 0.5%
223482963|NCT04920669|PROCEDURE|erector spinae block with bupivacaine + dexmedetomidine|Patients will receive a sonar-guided erector spinae plane block with 19 ml of bupivacaine 0.5%+ 1 ml dexmedetomidine
223482964|NCT01240746|BIOLOGICAL|Licensed 2010-2011 Trivalent Influenza Vaccine, No Preservative|0.25 mL (6 to 35 months) or 0.5 mL (3 to \<9 years), Intramuscular
223482965|NCT01240746|BIOLOGICAL|Investigational Trivalent Influenza Vaccine with alternate B strain, No Preservative|0.25 mL (6 to 35 months) or 0.5 mL (3 to \<9 years), Intramuscular
223482966|NCT01240746|BIOLOGICAL|Quadrivalent Influenza Vaccine, No Preservative|0.25 mL (6 to 35 months), or 0.5 mL(3 to \<9 years), Intramuscular
223482967|NCT05127460|OTHER|AI-enabled ECG-based Screening Tool|Primary care clinicians in the intervention group had access to the report, which displayed whether the AI-ECG result was positive or negative. The system will send a message to corresponding physicians if positive finding.
224170902|NCT04829864|BEHAVIORAL|STEP|"The program is offered by two facilitators to groups of three to seven women, in-person or online. The program is divided in three phases entitles Becoming a mother; A look at my own history and Looking ahead. The first phase aims to explore and normalize the emotions experienced by the participants in the course of their pregnancy and to support the use of healthy emotion regulation strategies. The second phase aims to support mentalization of trauma, by discussing the nature of trauma and its impact; by validating participants' feelings as understandable responses to trauma; by supporting a reflection on positive and harsh experiences with significant others and the ways both types of experiences influenced participants' mental states; and identifying how participants coped with trauma. In the last phase, discussions focus on participants' needs and strengths, on available resources to support resilience and envision positive and challenging moments with the child."
224170903|NCT05162833|DEVICE|TheraNova Neuromodulation Device|TENS device
224170904|NCT05140486|PROCEDURE|Rehabilitation: shortwave diathermy and perceptual training|All subjects in the rehabilitation group received shortwave diathermy therapy 5 days per week for 4 weeks and perceptual training 5 days per week for 10 weeks.
224170905|NCT06246864|OTHER|Hydrocolloid dressing|After the oral gastric tube is placed on the premature baby and fixed with a Hydrocolloid dressing, the fixed patch will be removed after 24 hours using a silicone-based spray remover.
223482968|NCT01204242|DRUG|Placebo|"ALL subjects will receive lidocaine up to 1.5mg/kg IV (in the vein) as a rapid injection.~Then the continuous IV infusion of the study medication (containing lidocaine 8 mg/ml or placebo) will be started and will continue for up to two hours in the recovery room."
224170906|NCT06246864|OTHER|Hypoallergenic Flexible|After the oral gastric tube is placed on the premature baby and fixed with a hypoallergenic flexible patch, the fixed patch will be removed after 24 hours using a silicone-based spray remover.
224305719|NCT05061186|OTHER|Resistive Expiratory muscle Training Group|"Mild Resistive Expiratory Technique \[Expiratory Muscle Strength Training (EMST150)- six-week training protocol approximately 20 min per day\] The EMST requires the participant to forcibly blow into the device for 5 seconds with sufficient pressure to open the one-way valve. Each blow is one repetition. The device will be set at a resistance of 30 cmH2O. Participants will be instructed to complete five sets of five repetitions (total of 25 times and approximately 20 minutes per day), any five days per week, for six weeks. Whole exercise will be done in sitting position. Rest between repetitions will be given according to comfort level of patient."
223482969|NCT01204242|DRUG|Lidocaine|"ALL subjects will receive lidocaine up to 1.5mg/kg IV (in the vein) as a rapid injection.~Then the continuous IV infusion of the study medication (containing lidocaine 8 mg/ml or placebo) will be started and will continue for up to two hours in the recovery room."
223482970|NCT05491577|OTHER|Filling in the SF-36, FAAM-F, PHQ-9, PHQ-2 and the simplified version of the EPICES score questionnaire|The SF-36, FAAM-F, PHQ-9, PHQ-2 and the simplified version of the EPICES score questionnaire will all be filled in by the patients.
223482971|NCT02398344|DEVICE|tDCS active|Transcranial direct current stimulation (tDCS) the active tDCS and placebo will be applied to the temporal cortex (T3) associated Cardiac Frequency Variability (HRV).
223482972|NCT02398344|DEVICE|tDCS Sham|Active stimulation application time or placebo 20 minutes. In all sham stimulation, electrode placement procedures will also be performed like the procedures with anodic tDCS, the left and right temporal cortex, however, the stimulator is turned on for 30 seconds only, and the patient will be told that he will feel a slight initial tingling, but it will reduce, disappear or remain during the 20 minutes of application. Thus, individuals will feel it initially, but receive no stimulation in the remaining time. This procedure is a valid form of control in challenge studies transcranial direct current ³³. The equipment itself has a sham configuration.
223482973|NCT02631057|DRUG|Dabigatran|Dabigatran 110 mg capsule twice a day or 75 mg x 2 capsules twice a day
223482974|NCT02631057|DRUG|Warfarin|Warfarin tablet (adjustment by each patients)
224170907|NCT02061163|DEVICE|Contrast Enhanced Ultrasound|Subjects with Crohn's disease will undergo contrast enhanced ultrasound imaging with shear wave elastography. Both CEUS and shear wave elastography will be performed using FDA approved ultrasound machines.
224170908|NCT02061163|DRUG|Optison|Optison is a microbubble contrast agent (dye) that will be injected during the CEUS imaging. Optison is FDA-approved for use in heart ultrasounds but not approved for use in bowel ultrasounds. Its use in this study is considered investigational (off-label).
224170909|NCT00152841|DRUG|Iron supplement 300-600 mg/day|
224170910|NCT00152841|DRUG|Vitamin E 800IU|
224170911|NCT03238209|DIAGNOSTIC_TEST|Exercise testing|The test consisted of a steady-state resting period of 3 min followed by 1 min of unloaded pedaling at 60 cycles/min for each individual; the exercise load was increased by 10 W each min until the test had to be stopped because symptoms prevented further exercise. After test results were recorded, EMGdi,es and each surface inspiratory EMG of maximal exercise capacity were analysed.
224170912|NCT00942422|DIETARY_SUPPLEMENT|defined green tea catechin extract|Polyphenon E, an oral capsule form of EGCG extracted from green tea, 800 mg administered daily on an empty stomach (at least 1 hour before or 2 hrs after a meal)Patients receive oral green tea catechin extract (Polyphenon E) daily on days 1-28. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
224170913|NCT00942422|GENETIC|gene expression analysis|Blood and bone marrow samples will be obtained prior to the start of treatment and at the conclusion of the study for correlative studies. An additional peripheral blood sample will be obtained on day 8 of the first cycle of therapy.
224170914|NCT00942422|GENETIC|protein analysis|Blood and bone marrow samples will be obtained prior to the start of treatment and at the conclusion of the study for correlative studies. An additional peripheral blood sample will be obtained on day 8 of the first cycle of therapy.
224170915|NCT00942422|OTHER|laboratory biomarker analysis|Blood and bone marrow samples will be obtained prior to the start of treatment and at the conclusion of the study for correlative studies. An additional peripheral blood sample will be obtained on day 8 of the first cycle of therapy.
224170916|NCT05246007|DRUG|Dexmedetomidine|Dexmedetomidine will be infused at a rate of 0.02 ml/kg/h (0.025 μg/kg/h) during the night before surgery, the night of surgery, and the first 2 nights after surgery (from 9:00 pm-6:00 am).
224170917|NCT05246007|DRUG|Normal Saline|Placebo (normal saline) will be infused at a rate of 0.02 ml/kg/h during the night before surgery, the night of surgery, and the first 2 nights after surgery (from 9:00 pm-6:00 am).
224170918|NCT04237610|BEHAVIORAL|behavioral assessment|Probabilistic learning task
224170919|NCT03602521|OTHER|Interpersonal stress|"Through an interview the evaluator will make a 1 to 2 pages script, written in first-person and in present tense. It will involve an interpersonal conflict between the participants and the person who once trigger their feeling of abandonment.~After reading the script the participants will have to close their eyes and imagine the event as if was happening to them, now, in real time, and think about it during 3 minutes.~To evaluate the stress efficiency, the evaluator will ask 2 questions :~* 1\) from 0 (no distress at all) to 10 (maximal unimaginable distress), to wich point this script bring distress to you?~* 2\) from 0 (I can not at all) to 10 (I can completely), to wich point are you able to imagine the scenario in real time, as if you were living it?"
224170920|NCT06602869|OTHER|Scheduled visit (V1)|During the scheduled visit (V1), as part of routine care, a blood draw will be performed. On this occasion, an additional 7 ml tube will be collected to perform serology and culture. This will help define the group (NTM+ Cases/NTM- Controls) and measure cellular biomarkers.
224170921|NCT02483715|DRUG|High-dose dual therapy (rabeprazole, amoxicillin)|High-dose dual therapy ( rabeprazole 20 mg qid + amoxicillin 750 mg qid for 14 days)
224170922|NCT02483715|DRUG|Bismuth-containing quadruple therapy (rabeprazole, tripotassium dicitrate bismuthate, metronidazole, tetracycline)|Bismuth-containing quadruple therapy (rabeprazole 20 mg bid + tripotassium dicitrate bismuthate 300 mg qid + metronidazole 250 mg qid + tetracycline 500 mg qid for 10 days)
223482975|NCT04841889|DIAGNOSTIC_TEST|Associated factors with decannulation|All factors potentially associated with successful tracheostomy removal will be prospectively collected: severity factors related to the ICU stay, ventilatory factors, respiratory and extra-respiratory factors. Lung and diaphragm ultrasound, swallowing, muscles and functional assessment will be performed.
224170923|NCT06615349|BEHAVIORAL|DigiPall|DigiPall is an intervention combining a sensor-equipped wearable with a chatbot communicating via WhatsApp on the patient's smartphone. Patients will be asked two questions daily for their subjective rating through WhatsApp on their smartphone, worded slightly differently depending on the measured values for steps, heart rate and compliance as well as the patient's answer the day before.
224170924|NCT06992934|DRUG|Gilteritinib|Administration of Gilteritinib
223482976|NCT01795612|OTHER|physical activity|
223482977|NCT00409825|DRUG|17-OHPC|Intra-muscular injection of 250 mg 17-OHPC administered weekly between the second and third trimesters of pregnancy, until time of delivery.
223482978|NCT00409825|PROCEDURE|Blood Draws|10 cc of blood will be drawn prior to the fifth weekly administration of 17-OHPC during second trimester of pregnancy, and then once daily for seven consecutive days post-dose. 10 cc of blood also will be drawn prior to weekly administration of 17-OHPC from sixth weekly dose in the second trimester until the last scheduled dose in the third trimester. Prior to this last scheduled dose, 10 cc of blood will be drawn, as well as once daily for seven consecutive days post-dose.
223482979|NCT03173339|PROCEDURE|Endotracheal intubation using laryngoscope|Endotracheal intubation was done using laryngoscope for general anesthesia.
223482980|NCT03173339|DRUG|High remifentanil|Remifentanil was started as 0.25 mcg/kg/min. Remifentanil dose was adjusted to maintain blood pressure (20% of preoperative blood pressure) and bispectral index (40-60) by 0.05 mcg/kg/min.
223482981|NCT03173339|DRUG|Low remifentanil|Remifentanil was administered as 0.1 mcg/kg/min.
223482982|NCT03173339|DRUG|High sevoflurane|Sevoflurane was started as 0.5 MAC. Sevoflurane dose was adjusted to maintain blood pressure (20% of preoperative blood pressure) and bispectral index (40-60) by 0.2 %.
224170925|NCT06996730|DRUG|Donanemab|IV Infusion
224170926|NCT06996730|DRUG|RG6289|Oral tablet
224170927|NCT06996730|DRUG|Donanemab placebo|IV placebo
224170928|NCT06996730|DRUG|RG6289 placebo|Oral tablet placebo
224170929|NCT05442515|BIOLOGICAL|CD19/CD22-CAR-transduced T cells|CD19/CD22-CAR-transduced T cells on D0 after lymphodepleting preparative regimen
223482983|NCT03173339|DRUG|Low sevoflurane|Sevoflurane was administered as 0.5 MAC.
223482984|NCT04610775|OTHER|Order of cuff sizes during blood pressure measurements|Each participant will have 4 sets of 3 blood pressure measurements taken. The participants will be randomized to the order in which the cuff sizes are used.
223482985|NCT03642314|DIAGNOSTIC_TEST|HIV self test kit|HIVST receptor will be invited to priority access to PrEP sites
223482986|NCT06153550|OTHER|preparation in Respiratory Physiotherapy|"preparation in Respiratory Physiotherapy consist to:~* 3 sessions per week with the physiotherapist~* spirometry and pulse oximetry test 3 weeks before surgery, the day before surgery and the day after surgery."
223482987|NCT01926210|OTHER|mild stimulation protocol|letrozole is used from cycle day 3 to 7 and low dose recombinant FSH(no more than 150 IU/d) is used on cycle day 4,6 and 8 onwards. GnRH antagonist is only applied in case of premature LH rise might happen.
223482988|NCT01926210|OTHER|controlled ovarian stimulation|After fully downregulation by using short-acting GnRH agonist, 300 IU/d recombinant FSH is administrated for 5 days, then the dose is adjusted according to ovarian response.
223482989|NCT04521868|DRUG|Sulforaphane|Sulforaphane is a compound that can be extracted from broccoli, Brussel sprouts, cabbage, and other cruciferous plants.
223482990|NCT04521868|DIETARY_SUPPLEMENT|placebo|Placebo is made of starch
223482991|NCT00293891|DRUG|Tacrolimus Cream|
223482992|NCT00187551|OTHER|Interruption of enfuvirtide|treatment interruption
223482993|NCT00187551|OTHER|enfuvirtide interrupton|enfuvitide will be interrupted in patients harboring resistant virus
223482994|NCT03636633|OTHER|Standard respiratory physiotherapy|Standard respiratory physiotherapy content; diaphragmatic breathing, pursed lip breathing, segmental breathing, incentive spirometer exercises (Triflo) and coughing techniques.
224170930|NCT05442515|DRUG|cyclophosphamide|Cyclophosphamide will be diluted in an appropriate solution and infused over one hour. The dose will be based on the patient s body weight, at 900 mg/m2/dose after fludarabine infusion.
224170931|NCT05442515|DRUG|fludarabine|Fludarabine is administered as an IV infusion in an appropriate solution over 30 minutes. To prevent undue toxicity the dose will be based on BSA (25 mg/m2/dose).
224170932|NCT03115021|DEVICE|Active tPCS|A current intensity of 2na and a stimulation frequency range of 6-10 Hz will be used with a peri-auricular ear-clip electrode montage for 20 minutes.
223482995|NCT03636633|OTHER|Standard respiratory physiotherapy and inspiratory muscle training|Standard respiratory physiotherapy content; diaphragmatic breathing, pursed lip breathing, segmental breathing, incentive spirometer exercises (Triflo) and coughing techniques. Addition to that, threshold IMT device will be used for the training. Training intensity will set at 40% of the maximum inspiratory pressure.
224170933|NCT03115021|DEVICE|Active tDCS|A current intensity of 2mA will be used for 20minutes. The electrodes that will be used will be standard sponge electrodes. The anode will be place over the left prefrontal cortex and the cathode over the right supraorbitofrontal area.
224170934|NCT03115021|DEVICE|Sham tPCS|Sham tPCS will consist of applying the same parameters as for active but the corresponding device will be turned off after 30 seconds as to simulate the initial sensation of the active current. A current of 2mA will still be used (but turned off after 30 sec). The electrodes that will be used will be the same as for the active tPCS condition and the electrodes placement as well.
224170935|NCT03115021|DEVICE|Sham tDCS|Sham tDCS will consist of applying the same parameters as for active but the corresponding device will be turned off after 30 seconds as to simulate the initial sensation of the active current. A current of 2mA will still be used (but turned off after 30 sec). The electrodes that will be used will be the same as for the active tDCS condition and the electrodes placement as well.
224170936|NCT06384807|DRUG|BHV-1510|BHV-1510 will be administered as an IV infusion on Day 1 every 3 weeks
223482996|NCT00793975|BIOLOGICAL|IMC-1121B|"Cohort 1~2 mg/kg I.V. once a week for 4 weeks, followed by a 2-week observation period."
224170937|NCT06384807|DRUG|Cemiplimab|cemiplimab (350mg) will be administered as an IV infusion on Day 1 every 3 weeks
224170938|NCT06384807|DRUG|BHV-1510|BHV-1510 will be administered as an IV infusion on Day 1 every 2 weeks
224170939|NCT06384807|DRUG|BHV-1510|BHV-1510 will be administered as an IV infusion on Day 1 and Day 8 every 3 weeks
224170940|NCT06384807|DRUG|Cemiplimab|cemiplimab (350mg) will be administered as an IV infusion on Day 1 and Day 8 every 3 weeks
224170941|NCT06997627|BIOLOGICAL|GC3111B|0.5 mL, Intramuscular injection
224170942|NCT06997627|BIOLOGICAL|Boostrix®|0.5 mL, Intramuscular injection
224170943|NCT06864650|OTHER|Ergonomics training|"Each of the control group participants will receive separate ergonomics training. The content of this training will include the topics of what is ergonomics, the purpose of ergonomics, musculoskeletal diseases in employees, work-related musculoskeletal risk factors."
223482997|NCT00793975|BIOLOGICAL|1121B|"Cohort 2~4 mg/kg I.V. once a week for 4 weeks, followed by a 2-week observation period."
223482998|NCT00793975|BIOLOGICAL|1121B|"Cohort 3~6 mg/kg I.V. once a week for 4 weeks, followed by a 2-week observation period."
223482999|NCT00793975|BIOLOGICAL|1121B|"Cohort 4~8 mg/kg I.V. once a week for 4 weeks, followed by a 2-week observation period."
223483000|NCT00793975|BIOLOGICAL|1121B|"Cohort 5~10 mg/kg I.V. once a week for 4 weeks, followed by a 2-week observation period."
223483001|NCT00793975|BIOLOGICAL|1121B|"Cohort 6~13 mg/kg once a week for 4 weeks, followed by a 2-week observation period."
223483002|NCT00793975|BIOLOGICAL|1121B|"Cohort 7~16 mg/kg once a week for 4 weeks, followed by a 2-week observation period."
223585533|NCT03035682|OTHER|Traditional Group|The Traditional Group will receive traditional PT services deemed clinically appropriate via examination plus traditional home exercise prescription.
223585534|NCT02606357|DRUG|INSULIN GLARGINE|"Pharmaceutical form:Solution~Route of administration: Subcutaneous"
224170944|NCT06864650|OTHER|exercise program|stretching exercises strengthening exercises waist exercises core exercises relaxation exercises
224170945|NCT06517732|OTHER|Secukinumab|This is an observational study. There is no treatment allocation. The decision to initiate secukinumab will be based solely on clinical judgement.
223483003|NCT01632319|BEHAVIORAL|Combined Motivational Interviewing and Cognitive Behavioral Therapy|"8 sessions with study clinician, which focus on depressive symptom treatment and alcohol use Both courses teach coping skills for depression (CBT). However, one course focuses only on treatment for depression whereas the other provides also information tailored to the students' level of drinking and experience with regard to alcohol use.~In one course students are asked questions about their drinking, receive personalized feedback about it and are taught coping skills for their depressive symptoms"
223483004|NCT01632319|BEHAVIORAL|Cognitive Behavioral Therapy|Cognitive behavioral therapy is a type of therapy in which students will be taught coping skills for their depressive symptoms but they may or may not talk about alcohol consumption depending on the students' preference.
223483005|NCT02598310|DRUG|nab-paclitaxel|nab-paclitaxel 260mg/m2 q3w
223483006|NCT02598310|DRUG|Trastuzumab|trastuzumab 6 mg/kg (8 mg/kg as the loading dose)
223585535|NCT02795325|DRUG|DCR-PH1|IV infusion of DCR-PH1
223585536|NCT02795325|OTHER|Placebo|
223585537|NCT03926988|DEVICE|NeVa Stent Retriever|mechanical neurothrombectomy
224170946|NCT01930487|DIETARY_SUPPLEMENT|dietary supplement with antioxidants|Formulation contains vitamins, a mineral, dietary antioxidants, amino acids, polyphenols and polyunsaturated fatty acids
224170947|NCT01930487|DIETARY_SUPPLEMENT|Placebo|Placebo - Softgels manufactured to mimic the appearance of active, dietary supplement with antioxidants
224170948|NCT02485405|OTHER|Trier social stress test|Volunteers perform Trier social stress test
224170949|NCT00601653|BEHAVIORAL|Cognitive behavioral therapy plus general nutrition counseling (CBT+GN)|CBT+GN includes 21 sessions over 6 months. Each treatment session includes 40 minutes of CBT and 20 minutes of nutritional counseling.
224170950|NCT00601653|BEHAVIORAL|Cognitive behavioral therapy plus low energy density diet counseling (CBT+LED)|CBT+LED includes 21 sessions over 6 months. Each treatment session includes 40 minutes of CBT and 20 minutes of nutritional counseling that centers upon eating higher volumes of low-calorie foods.
224170951|NCT06300788|OTHER|PPI and T50 dosing|Sampling for PPI determination and T50 in blood and urine.
224170952|NCT02711553|DRUG|Ramucirumab|Administered IV
224170953|NCT02711553|DRUG|Merestinib|Administered orally
224170954|NCT02711553|DRUG|Cisplatin|Administered IV
224170955|NCT02711553|DRUG|Gemcitabine|Administered IV
224170956|NCT02711553|DRUG|Placebo Oral|Administered orally
224170957|NCT02711553|DRUG|Placebo IV|Administered IV
224205413|NCT03940742|DRUG|Tirzepatide|Administered SC
223585538|NCT00418977|BEHAVIORAL|"Family-Based Therapy (Maudsley Method)"|The goal of FBT is to resolve the eating disorder and return the patient to healthy psychosocial and physiological development through active family involvement across three treatment phases. In Phase I, therapy is focused on the disordered eating. The therapist primarily makes careful, persistent requests for united parental action toward re-feeding and/or regulating eating habits and directs the discussion so as to create and reinforce a strong parental alliance around their efforts at feeding their child. In Phase II, the goal is to gradually transfer control over eating back to the participant, with the parents still maintaining general oversight and responsibility for continued progression toward healthy habits. In Phase III, the central goal is establishment of a healthy child or adolescent relationship with the parents where disordered eating is not the basis of interaction.
223585539|NCT00418977|BEHAVIORAL|Individual Supportive Psychotherapy|The goal of ISP is for the patient to understand and address the psychological issues underlying the origin and maintenance of the eating disorder. This work is done directly with the child/adolescent. In this treatment, eating disorders are seen as complicated (e.g., they tend to mask other underlying difficulties). In Phase I, the aims are to establish a sound therapeutic relationship, obtain a comprehensive description of the eating problem and its development, identify underlying problems that might be responsible for the disordered eating, and inform the patient about the dangers of eating disorders. Phase II encourages participants to explore underlying emotional problems, facilitates self-disclosure and expression of feelings, and fosters independence. Phase III focuses on how other underlying issues might affect future adjustment.
223585540|NCT00877370|DRUG|ertapenem|One gram ertapenem will be infused intravenously in subjects receiving continuous hemodialysis (CVVHD). Pharmacokinetic sampling in this study will occur with the first dose of ertapenem. While on CVVHD, enrolled subjects will receive ertapenem 1 g intravenously administered over 30 minutes. Two blood samples (5 mL each) will be collected from the arterial (pre-diafilter) port of the CVVHD tubing at time 0 (baseline), ½ hour (end of infusion), 1, 1½, 2, 3, 6, 12, and 24 hours. Effluent (5 mL) will also be collected at these predefined time points from the effluent port of the CVVHD tubing. If ertapenem is discontinued after the first dose then additional samples will be collected at 36 and 48 hours, otherwise ertapenem will be administered as soon as the 24 hour sample is obtained.
223585541|NCT00468988|DRUG|Travatan® Z|
224170958|NCT02332694|DEVICE|The Whole Body Hyperthermia system uses water-filtered infrared-A (wIRA) heat radiation|The Whole Body Hyperthermia system uses water-filtered infrared-A (wIRA) heat radiation. The rise in the body's core temperature is correspondingly rapid and well-tolerated. There are two phases of the thermal challenge, 1) Irradiation phase during which the patient lies recumbent with his/her head positioned outside the tent. The wIRA irradiators are arranged above the exposed upper part of the body; and 2) Heat retention phase during which the patient lies in the chamber with the walls of the tent positioned to retain heat. Core body temperatures will be raised to those comparable to a mild fever 37.8-38.5°C.
223585542|NCT00468988|DRUG|Xalatan®|
223585543|NCT03106285|DIETARY_SUPPLEMENT|Lactobacillus reuteri DSM17938|5 drops of active oil drops. The active dose consists of 10\^8 CFU L retueri DSM17938
224170959|NCT06996574|OTHER|Randomization|The all-in-one (NTG) procedure versus the established two-phase closed-loop SCS procedure with at-home screening trials (TG) under everyday clinical practice, that can be used for clinical decision-making and to inform health policy decisions.
224170960|NCT07000162|RADIATION|Lattice radiation therapy|"A total dose will be 20 Gy, with a simultaneous boost to selected tumor regions (hot spots) reaching a minimum median dose of 50 Gy.~Peripheral blood (PB) samples for the immune cell characterization and quantification of immune-related circulating factors will be collected at baseline (pre-therapy) and within 7 -14 days after the end of the treatment (post-therapy)."
224170961|NCT06204926|DIAGNOSTIC_TEST|AI diagnostic algorithm|The SMILE procedures collected would be assessed by the algorithm. The performance of the algorithm would be assessed, including accuracy, AUC, sensitivity and specificity.
224170962|NCT01771718|DEVICE|Multiphoton microscopy-based tomograph.|non-invasive optical biopsy
224170963|NCT03100006|DRUG|Nivolumab|240mg of IV Nivolumab is administered over 30 mins every 2 weeks
224170964|NCT03100006|DRUG|Oregovomab|IV Oregovomab is administered over 20 mins every 4 weeks at dose levels: 2mg, 1mg, or 0.5mg
224170965|NCT00648492|DRUG|Metformin Hydrochloride ER Tablets 500 mg|500mg, single dose fed
224170966|NCT00648492|DRUG|Glucophage® XR 500 mg|500mg, single dose fed
224170967|NCT04346368|BIOLOGICAL|BM-MSCs|Participants will receive conventional treatment plus BM-MSCs(1\*10E6 /kg body weight intravenously at Day 1).
224170968|NCT04346368|BIOLOGICAL|Placebo|Placebo
224170969|NCT07004751|DIAGNOSTIC_TEST|Additional laboratory analysis|Additional lab tests will be done to establish the diagnosis of Murine typhus, Bartonellosis, Q-fever, Chikungunya, Zika, Japanese B encephalitis, West Nile virus
224170970|NCT07004751|DIAGNOSTIC_TEST|Standard of Care (SOC)|Standard of care evaluation of a febrile patient is done by the treating medical team as Standard of care evaluation of a febrile patient is done by the treating medical team which includes clinical, basic laboratory, radiological and microbiological evaluations
224170971|NCT06861647|OTHER|sample collection|sample collection of surplus samples not needed for diagnostic or pathological requirements
224170972|NCT06861647|OTHER|Discussing study/seeking consent|An NHS or CRN staff member will inform patients of the nature and objectives of the study, go through the participant information sheet, highlighting possible risks associated with their participation and reiterate the voluntary nature of this study. Patients will be given opportunities to ask questions pertaining to the study. If the potential participant is still interested in taking part, written informed consent for the study will then be received and a copy of the informed consent will be given to the participant to keep.
224170973|NCT06861647|OTHER|Completion of Study Questionnaire|Patient will complete in own time. To take place in a routine outpatient clinic appointment
224170974|NCT06861647|OTHER|Blood Sample|To take place in an outpatient clinic.
223585544|NCT03106285|DIETARY_SUPPLEMENT|Placebo|5 drops of placebo drops
223585545|NCT03610009|DEVICE|2D ultrasound|The timing of final follicle maturation and oocyte retrieval based on follicle tracking with use of conventional two-dimensional (2D) ultrasound.
223585546|NCT03610009|DEVICE|SonoAVC|The timing of final follicle maturation and oocyte retrieval based on follicle tracking with use of SonoAVC.
224170975|NCT04272801|DRUG|tamoxifen, letrozole, anastrozole, or exemestane|choice and dose of neoadjuvant endocrine therapy at the discretion of the treating medical oncologist
224170976|NCT04272801|BEHAVIORAL|Patient reported outcomes|"Questionnaire inquiries include the following:~* how cancer affects daily living~* beliefs about medicines and sensitivity to medicine~* symptoms~* adherence to endocrine therapy~* general health and well being~* depression and anxiety~* preference regarding radiation therapy"
224170977|NCT06998784|DEVICE|taVNS|"Patients will receive taVNS at left tragus (a device developed by the Engineering Research Center of Molecular and Neuro Imaging, Ministry of Education (School of Life Science and Technology, Xidian University), in collaboration with the Wearable BCI and Intelligent Rehabilitation Innovation Lab (Guangzhou Institute of Technology, Xidian University)) twice daily (morning and night) for 30 minutes per session over a period of up to 7 days. The stimulation parameters are as follows:~* Duty circle: 30s on periods alternating with 30s off periods;~* Frequency: 25 Hz;~* Amplitude: 0-2 mA (adjusted to the maximum tolerated level for each patient);~* Pulse width: 0.5 ms."
224170978|NCT06998784|DEVICE|Sham-taVNS|"Patients will receive taVNS at left earlobe (a device developed by the Engineering Research Center of Molecular and Neuro Imaging, Ministry of Education (School of Life Science and Technology, Xidian University), in collaboration with the Wearable BCI and Intelligent Rehabilitation Innovation Lab (Guangzhou Institute of Technology, Xidian University)) twice daily (morning and night) for 30 minutes per session over a period of up to 7 days. The stimulation parameters are as follows: \*Duty circle: 30s on periods alternating with 30s off periods; \*Frequency: 25 Hz; \*Amplitude: 0-2 mA (adjusted to the maximum tolerated level for each patient); \*Pulse width: 0.5 ms."
224170979|NCT07006064|DEVICE|SUPERNOVA|In the intervention group, oxygen is delivered using the SuperNO2VA™ nasal positive airway pressure mask (Vyaire Medical, USA), which differs from conventional nasal oxygen delivery systems by providing continuous positive airway pressure (CPAP) through a sealed nasal interface. This mask also includes an integrated sampling port for accurate end tidal carbon dioxide (EtCO2) monitoring. The aim is to reduce the incidence of hypoxia and allow for better detection and prevention of hypo/hypercapnia during sedation in elderly patients undergoing TAVI without intubation. The use of positive pressure is intended to prevent upper airway collapse, maintain functional residual capacity, and improve gas exchange during sedation.
224170980|NCT07006064|DEVICE|NASAL MASK|Traditional nasal cannulas only provide passive oxygen flow. End-tidal CO2 measurement is being conducted with Capnostream™ 35 Portable Respiratory Monitor.
224170981|NCT04060706|RADIATION|Radical Image-Guided Radiotherapy|Questionnaires administered will monitor the clinical toxicity experienced by each patient up to 5 years post radiotherapy
224170982|NCT05559203|BEHAVIORAL|danceSing Care|The programme was a digital movement and music programme with resources from danceSing Care and consisted of three movement sessions and one music session each week, the recommended dose agreed between danceSing Care and the Advisory group, each lasting about 20 minutes. Also, the danceSing care resources were designed to suit older adults with physical and cognitive impairments (residents with mobility aids and/or dementia). Movement sessions included chair and standing fitness, which started with a warm-up and finished with stretching exercises. Sessions were managed and supervised by care home activity coordinators.
224170983|NCT04655963|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|MagVenture MagPro TMS System would be utilized to deliver 3-minute sessions of intermittent theta burst to left dorsolateral prefrontal cortex.
224170984|NCT06625073|DRUG|Empagliflozin|A starting dose of empagliflozin 10 mg or matching placebo will be initiated after randomization and completion of the baseline testing. Participating subjects will remain at this dose for the whole study duration of 12 months.
223483007|NCT04571203|BIOLOGICAL|Combined Deceased Donor Kidney and Hematopoietic Cell Transplants|This combined kidney and hematopoietic cell transplants with a conditioning regimen with irradiation and ATG creates an environment of immune-tolerance. This promotes hematopoietic cell engraftment.
223483008|NCT05727644|DRUG|NNC0194-0499|Participants will receive a single subcutaneous injection of 30 mg NNC0194-0499.
223483009|NCT05997745|DIETARY_SUPPLEMENT|study group|Patients will receive early enteral locally nutrition postoperatively following surgery for peritonitis
223483010|NCT04129541|OTHER|Same Day Discharge|Patients in the planned same day discharge (SDD) cohort will be discharged from the PACU once they meet standard discharge criteria.
223483011|NCT04129541|OTHER|Overnight Hospitalization|Patients in the planned overnight hospitalization (OH) group will be discharged on post-operative day 1 once they meet standard discharge criteria.
223483012|NCT04017377|DRUG|Drug: Cisplatin; nab-paclitaxel|Drug: Paclitaxel for Injection（Albumin Bound). Other Name: Ke ai li, ZhusheyongZishanchun(Baidanbai Jiehexing)
223483013|NCT03773783|DEVICE|Button and Bead appliance|Button and Bead appliance
223483014|NCT03773783|DEVICE|Twin Block appliance|Twin Block appliance
223483015|NCT04275037|OTHER|Isometric Handgrip Training|The 8-week exercise program will include three sessions of isometric handgrip training per week
223483016|NCT04275037|OTHER|Aerobic Exercise Training|The 8-week exercise program will include three sessions of aerobic exercise per week
223483017|NCT02332642|OTHER|Immuno-monitoring|
223483018|NCT02471183|DRUG|Selexipag|Tablets for oral administration containing 200 micrograms (mcg) of selexipag to be administered twice a day. The individual dose is to be established during the first 12 weeks of the study. Doses are in the range from 200 micrograms (1 tablet) to 1,600 micrograms (8 tablets).
223483019|NCT00532467|DRUG|SRX251|
223483020|NCT02690727|DRUG|RP6530|Single oral dose
223483021|NCT00097435|DRUG|Albuferon|
223483022|NCT00097435|DRUG|Ribavirin|
223483023|NCT04032938|PROCEDURE|extracorporeal circulation during cardiac surgery|We will observe the cardiopulmonary bypass status and time of patients undergoing cardiac surgery and extracorporeal circulation due to their medical needs.
223483024|NCT04416789|OTHER|Exercise programme|1 session of trampolining/dry sports (1.5 hours) and 1 session of supervised swimming (1.5 hours) per week for 10 weeks.
223483025|NCT01295411|DEVICE|Magnetic Resonance Imaging|
223483026|NCT01295411|OTHER|EVALUATION NEUROPSYCHOLOGICAL|
223483027|NCT03784495|DRUG|Melatonin 1mg|1 mg/day 30 minutes before sleep
223585547|NCT00837603|BEHAVIORAL|Training|Controlled home ergometer training
224170985|NCT06625073|DRUG|Placebo|A starting dose of empagliflozin 10 mg or matching placebo will be initiated after randomization and completion of the baseline testing. Participating subjects will remain at this dose for the whole study duration of 12 months.
224170986|NCT07009886|OTHER|Communication|Participants meet with clinician
224170987|NCT07012915|DIAGNOSTIC_TEST|Blood testing|Blood sample will be collected twice for each participants procedding and following dental implant removal. Cone Beam Computed Tomography will be applied to evaluate the shape, severity of bone defect in direct viscinity of the implant.
224170988|NCT03117309|DRUG|Nivolumab 240 mg|PART A Nivolumab 240 mg IV every 2 weeks x 6 then initial disease assessment
224170989|NCT03117309|DRUG|Ipilimumab 1mg/kg|Ipilimumab 1 mg/kg every 3 weeks x 4
224170990|NCT03117309|DRUG|Nivolumab 3mg/kg|In combination with Ipilimumab
224170991|NCT03117309|DRUG|Nivolumab 360mg|Continue Nivolumab 360 mg IV every 3 weeks
224170992|NCT05007301|DEVICE|geko device|Neuromuscular electrostimulation of the peroneal nerve, 12h per day, for up to 12 weeks.
224170993|NCT04568382|OTHER|CI-PVP (context-informed pre-visit planning)|may experience a single additional phone call from clinic staff in addition to the standard clinic staff chart review, email and/or phone call prior to diabetes office visit
224170994|NCT04568382|OTHER|Standard PVP (pre-visit planning)|standard clinic staff chart review, email and/or phone call prior to diabetes office visit
224170995|NCT02227901|DRUG|Tipifarnib|Given PO
224170996|NCT02227901|RADIATION|External Beam Radiation Therapy|Undergo EBRT
224170997|NCT02227901|DRUG|Temozolomide|Given PO
224170998|NCT02227901|OTHER|Laboratory Biomarker Analysis|Correlative studies
224170999|NCT04048876|DRUG|CC-90001|oral
224171000|NCT04048876|DRUG|Placebo|oral
224171001|NCT01089075|DRUG|Hydrocortisone|20 mg po for 7 days (2 tablets)
223483028|NCT03784495|DIETARY_SUPPLEMENT|Essential Aminoacids (eAA)|4g/day of Essential Aminoacids during breakfast. Packets of powdered amino acid supplements (42.0% leucine, 14.0% lysine, 10.5% valine, 10.5% isoleucine, 10.5% threonine, 7.0% phenylalanine, and 5.5% other) were provided for the participants to be taken with water or milk, and they were instructed to take the 4-gram supplement once a day every day for 4 weeks.
224171002|NCT01089075|DRUG|Placebo|2 tablets po
224171003|NCT06145763|PROCEDURE|Biospecimen Collection|Ancillary studies
223483029|NCT03784495|COMBINATION_PRODUCT|Essential Aminoacids + melatonin|4g/day of Essential Aminoacids during breakfast + 1 mg/day of Melatonin 30 minutes before sleep. Packets of powdered amino acid supplements (42.0% leucine, 14.0% lysine, 10.5% valine, 10.5% isoleucine, 10.5% threonine, 7.0% phenylalanine, and 5.5% other) were provided for the participants to be taken with water or milk, and they were instructed to take the 4-gram supplement once a day every day for 4 weeks.
223483030|NCT03784495|OTHER|Placebo|an isocaloric amount of maltodextrin with the same flavor and appearance as the intervention product
223483031|NCT06094647|DEVICE|Altitudes USA|Experimental participants will be onboarded to the digital platform, including the different spaces and how to use the site. The site includes educational and therapeutic content that is tailored to each individual and their current needs and experiences, including psychoeducation, supporting their loved one, self-care, social support, and so on. Further, the platform includes a moderated social media function, where users and family peer workers can post text, images, videos, and comments to connect and share their experiences. The site is monitored by graduated students and trained clinicians.
224171004|NCT06145763|BEHAVIORAL|Smoking Cessation Intervention|Use iCanQuit smartphone app
224171005|NCT06145763|BEHAVIORAL|Smoking Cessation Intervention|Use NCI QuitGuide smartphone app
224171006|NCT06145763|OTHER|Survey Administration|Ancillary studies
224171007|NCT06627816|DRUG|Nefopam|efficacy of 3 drugs in preventing post-spinal anesthesia shivering
224171008|NCT04192760|PROCEDURE|Stenting|Comparison of two technical approaches in the interventional treatment on de-novo non-left main coronary lesions
224171009|NCT02685124|DIETARY_SUPPLEMENT|Orange juice|Three days before the start of the study, all participants will restrict their diet avoiding citrus fruits (orange, tangerine, lemon) and its derivatives (washout period), red fruits and vegetables (strawberry, red lettuce, red grape, tomate). The day before the sample collection will be provided a controlled dinner. A fasting for 8 hours will be required before blood and urine collection. All participants will divided into three groups: I (Cara Cara), II (Bahia), III (Isocaloric control drink). They will consume 250 ml of each drink twice daily for 7 consecutive days, with a washout period of 7 days among each intervention.
224171010|NCT06043934|OTHER|Neural Mobilization with Intermittent Cervical Traction|This group will receive Neural Mobilization with Intermittent Cervical Traction along with routine physical therapy. The patient will be positioned in a supine position with 10 to 15 degrees of flexion on a comfortable treatment table. A suitable pillow will be arranged to support their head. The cervical traction device's integrity and readiness will be confirmed by the therapist. The starting weight will be about 10% of the patient's body weight, and this will slowly increase up to an appropriate level. The on-and-off times will be decided based on the patient's comfort and specific condition. Generally, a ratio of 3:1 or 4:1 (hold: rest) is used. For instance, 60 seconds of traction followed by 20 seconds of rest. The total treatment time will generally range between 15-20 minutes for 3 to 4 times per week. Participants will be scheduled to attend 12 treatment sessions ( 3-4 sessions every week for 4 weeks; 45 min each session).
224171011|NCT06043934|OTHER|Neural Mobilization|"This Group will receive Neural Mobilization with routine physical therapy. Each nerve glide exercise will be performed ideally around 2-3 times, depending on the patient's comfort and tolerance levels. The intensity of the exercise is governed by the degree of stretch applied to the nerve. This should be within the patient's comfort level, causing a mild stretching sensation rather than pain. Each nerve glide will be performed in a set of 10-15 repetitions. Rest periods should be provided between each repetition and set, ensuring the patient's comfort.~In median nerve glide the patient will be seated comfortably. Their arm will be guided into shoulder depression, elbow extension, forearm supination, and wrist and finger extension. The patient will then be instructed to slowly flex and extend their wrist while maintaining the other positions. Participants will be scheduled to attend 12 treatment sessions ( 3-4 sessions every week for 4 weeks; 45 min each session)."
223585548|NCT03350555|DEVICE|Additioned Endoscopy|To evaluate the use of additioned endoscopy in ERCP treatment.
224171012|NCT02177214|PROCEDURE|MRI scan|Visualization of the mesh surface observed with MRI scan at 3 weeks and 13 months after ventral hernia repair with a visible IPOM prosthesis (Dynamesh®)
224171013|NCT01861613|BIOLOGICAL|HBV vaccine (Engerix-B, recombinant hepatitis B surface antigen, 20µg/mL/vial, GlaxoSmithKline, Belgium)|
224171014|NCT02120560|PROCEDURE|Atrial Fibrillation Ablation|Both treatment arms will undergo atrial fibrillation ablation.
224171015|NCT05856279|PROCEDURE|mulligan SNAG and mulligan lion position|manual therapy techniques for lumbar spine
224171016|NCT07020702|DEVICE|Implantation of an ICD|Implantation of an ICD
224171017|NCT03103776|OTHER|Comparison of Positive PCR Frequencies for Polyomavirus in Blood, Urine and / or Thyroid Tissue vs Basedow / Hashimoto|Comparison of Positive PCR Frequencies for Polyomavirus in Blood, Urine and / or Thyroid Tissue vs Basedow / Hashimoto
224171018|NCT03764462|DRUG|AD-101 45mg|Raloxifene 45mg tablet
224171019|NCT03764462|DRUG|Raloxifene 60mg|Raloxifene 60mg tablet
224171020|NCT03435276|DRUG|AZD9977|Randomized subjects will receive AZD9977 oral suspension at a dose of 50 mg in Cohort 1, 150 mg in Cohort 2 and 300 mg in Cohort 3
224171021|NCT03435276|OTHER|Placebo|Randomized subjects will receive orally AZD9977 matched placebo in Cohorts 1, 2 and 3
224171022|NCT05381389|DRUG|Bupivacaine Hydrochloride in-plane approach for the interscalene block|20 ml of 0.5% bupivacaine added to them 50 μg adrenaline in a concentration of 1:400,000, were prepared by an assistant immediately before administration and injected in an in-plane approach to the brachial plexues
224171023|NCT05381389|DRUG|Bupivacaine Hydrochloride out of-plane approach for the interscalene block|20 ml of 0.5% bupivacaine added to them 50 μg adrenaline in a concentration of 1:400,000, were prepared by an assistant immediately before administration and injected in an out of-plane approach to the brachial plexues
224171024|NCT03949010|OTHER|Kinesiotaping with space correction technique|Kinesiotaping with space correction technique twice per week for two weeks along with home exercise program
224171025|NCT03949010|OTHER|Kinesiotaping with muscle inhibition technique|Kinesiotaping with muscle inhibition technique twice per week for two weeks along with home exercise program
224171026|NCT03949010|OTHER|Home exercise program|Home exercise program which consists of stretching exercises towards neck area
224171027|NCT01524926|DRUG|Crizotinib (PF-02341066)|For patients of 15yo and older, Capsules of 200 and 250 mg Daily dose of 500, 400 or 250 mg/day depending on toxicitie; for patients younger than 15yo, 280 mg/m²/dose BID, with reductions allowed to 80% as first reduction and to 60% as second reduction respectively of the initial dose.
224171028|NCT03874104|DIETARY_SUPPLEMENT|Extensively Hydrolysed Formula containing Pre- & Probiotics|Extensively Hydrolysed Formula containing Pre- and Probiotics
224171029|NCT02187224|DRUG|Progesterone|
224171030|NCT02187224|DRUG|Placebo (for Progesterone)|
224171031|NCT00329459|DRUG|sumatriptan succinate/naproxen sodium|
224171032|NCT00329459|DRUG|placebo|placebo to match
224171033|NCT06144567|DRUG|Upadacitinib|As this is an observational study, AbbVie is not involved in the product supply since the drug is being used according to the approved marketing label and is to be prescribed by the physician under usual and customary practice of physician prescription.
224171034|NCT01159886|PROCEDURE|Ileal intubation|"After confirmation of cecal intubation, patient will undergo randomization to either the left-lateral decubitus or supine position. Then terminal ileal intubation will be attempted. Partial suction and scope manoeuvres for ileal intubation will be allowed.~Use of anti-peristalsis agents, use of biopsy forceps, as a guidewire or an ''anchor'' to facilitate the IC- valve intubation, and intubation in the retroflexed position will not be allowed."
224171035|NCT06245304|DEVICE|Dual chamber Medtronic pacemaker implantation.|"All patients will undergo a dual chamber Medtronic pacemaker implantation meeting approved indications for pacemaker implantation per Centers for Medicare \& Medicaid Services (CMS) guidelines.~Pacemaker Model: Azure XT W1DR01. Right ventricular lead model: Medtronic 3830."
224171036|NCT06245304|OTHER|DDD-50 pacing program|This device programming attempts to increase the amount of ventricular pacing via the Medtronic 3830 lead. Since the enrolled patients have a prolonged PR interval, this programming attempts to synchronic atrial and ventricular contractions.
224171037|NCT06245304|OTHER|AAI-DDD 50 pacing program|This device programming attempts to encourage native conduction and minimize ventricular pacing via the Medtronic 3830 lead. This programming attempts to minimize ventricular pacing, which has been associated with worse outcomes by causing ventricular dyssynchrony between the left and right ventricles.
224171038|NCT01208818|DRUG|Cyclophosphamide + Bortezomib + Dexamethasone regimen|"Dosing regimen (21 day-cycle):~* Bortezomib 1.3 mg/m2 I.V. on days 1, 4, 8, and 11. An interval of at least 72 hours between each administration of bortezomib is required.~* Dexamethasone 20 mg on days 1, 2, 4, 5, 8, 9, 11 and 12.~* Cyclophosphamide 900 mg/m2 on day 1, through a short I.V. infusion The regimen is given for 3 cycles in the absence of serious side-effect."
224171039|NCT01208818|DRUG|Bortezomib +Dexamethasone regimen|"Dosing regimen (21 day-cycle):~* Bortezomib 1.3 mg/m2 I.V. on days 1, 4, 8, and 11. An interval of at least 72 hours between each administration of bortezomib is required.~* Dexamethasone 20 mg on days 1, 2, 4, 5, 8, 9, 11 and 12. The regimen is given for 3 cycles in the absence of serious side-effect."
224171040|NCT01208818|DEVICE|HCO group|TheraliteTM dialyzer of 2.1 m2 in surface
224171041|NCT01208818|DEVICE|conventional high-flux dialyzer|conventional high-flux dialyzer; polyacrylonitrile, polysulfone, or PMMA dialysers, with an ultrafiltration coefficient \> 14 ml/min and ≥ 1.8 m2 in surface, are recommended.
224171042|NCT01039038|RADIATION|curietherapy and radiotherapy|boost of curietherapy(40 Gy)and external radiotherapy (34 Gy)
223585549|NCT02252965|DRUG|Metformin IR|Subjects will receive Metformin Immediate Release (IR) tablets, orally once daily at a dose of 500 milligram (mg) for 1 week, and then dose will increase with increments of 500 mg every week in first 2 weeks to 1500 mg. After that dose will increase up to maximum dose of 2000 mg for the next 2 weeks and will be maintained at 2000 mg until Week 16.
224171043|NCT04101370|DRUG|Bosentan 125 mg|Single administered dose of Bosentan (125 mg tablet immediate release) in a fasting condition
224171044|NCT04101370|DRUG|Tracleer 125Mg Tablet|Single administered dose of Tracleer® (125 mg tablet immediate release) in a fasting condition
224171045|NCT03527303|BEHAVIORAL|Meditation|10 minute per day, 8 week digital meditation
224171046|NCT04173403|DRUG|450mg AK102|AK102 Q4W
224171047|NCT04173403|DRUG|300mg AK102|AK102 Q4W
224171048|NCT04173403|DRUG|150mg AK102|AK102 Q2W
223483032|NCT05413642|DRUG|Recommended treatment schedule|Non-steroidal anti-inflammatory drugs (NSAIDs) Corticosteroids (Dexamethasone), Anticoagulants (LMW heparin), Gentle oxygen therapy
223483033|NCT05413642|DRUG|Usual care|Treatment regimens different from the recommended one according to family physician personal practice
223483034|NCT03229603|OTHER|Cluster of 3000 women|An evaluation of the feasibility, reach, adoption and implementation of a cervical cancer screening program where we diagnose HPV using the GeneXpert point of care testing kit prior to VIA and cryotherapy.
223483035|NCT05876065|DRUG|XC|Capecitabine (bid po, d1-14) and cyclophosphamide (qd po, d1-d14) every 21 days
223483036|NCT05876065|DRUG|TPC|Any physician's choice as maintenance therapy (except for XC regimen)
224171049|NCT04173403|DRUG|Statins and/or Ezetimibe|Lipid-lowering therapies
224171050|NCT00373464|DRUG|etoricoxib|
224171051|NCT01925482|DRUG|6%CO2, 25%O2, balance N2|exposure of middle ear to gas
224171052|NCT01925482|DRUG|6% CO2, 0%O2, balance N2|exposure of middle ear to gas
224171053|NCT01925482|DRUG|20%CO2, 6%O2, balance N2|exposure of middle ear to gas
224171054|NCT01925482|DRUG|0%CO2, 6%O2, balance N2|exposure of middle ear to gas
224171055|NCT01925482|DRUG|6% CO2, 6%O2, balance N2|exposure of middle ear to gas
224171056|NCT01925482|DRUG|6%CO2, 6%O2, 0%N2, balance argon|exposure of middle ear to gas
224171057|NCT00388375|PROCEDURE|Ultrasound|limited ultrasound examination to evaluate the following areas: Examination of the subclavian and internal jugular veins to assess proper catheter placement PTX detection, using lung sliding and comet-tail artifact Visualization of the heart (right atrium and ventricle) and the inferior vena cava through the subcostal window
224171058|NCT00906334|DRUG|ON 01910.Na|The original dosing regimen was 800 mg/m\^2 ON 01910.Na.
224171059|NCT00906334|DRUG|ON 01910.Na|Per Amendment 3 to the Protocol, the dosing regimen was changed to 1800 mg ON 01910.Na. Patients enrolled at the original dosing regimen could choose to remain in the original regimen or switch to the new regimen.
224171060|NCT02031627|DEVICE|pneumatic compression - 1 hour per day|Pneumatic compression treatment once per day (1 hour)
224171061|NCT02031627|DEVICE|pneumatic compression - 2 hours per day|pneumatic compression treatment twice per day in the AM \& PM (2 hours)
224171062|NCT02031627|DEVICE|pneumatic compression - 4 hours per day|pneumatic compression treatment twice per day consisting of 2 consecutive 1 hour treatments in the AM \& PM (4 hours)
224171063|NCT01804660|OTHER|No study treatments administered|
224171064|NCT02237365|DRUG|81mg aspirin|1 tablet of 81mg aspirin and 2 tablets of placebo (visually matched to 500mg aspirin) daily for 60 days
224171065|NCT02237365|DRUG|1000mg aspirin|1 tablet of 81mg placebo (visually matched to 81mg aspirin) and 2 tablets of 500mg aspirin daily for 60 days
224171066|NCT02237365|DRUG|Placebo|1 tablet of 81mg placebo (visually matched to 81mg aspirin) and 2 tablets of 500mg placebo (visually matched to 500mg aspirin) daily for 60 days
224171067|NCT02377076|DIETARY_SUPPLEMENT|Dietary calcium supplementation|Dietary calcium supplementation as milk powder
224171068|NCT02377076|DIETARY_SUPPLEMENT|Control|Control (Whey protein, vitamin D, sugar and salt)
224171069|NCT05375240|DRUG|Propranolol|Propranolol will be given at a dose of 10 mg orally, 3 times per day, for 7 consecutive days after stroke onset.
223483037|NCT00869596|DRUG|fluticasone propionate|Single dose of fluticasone 440 mcg (2 x 220 mcg) or 1980 mcg (9 x 220 mcg) by metered dose inhaler in two of three treatment periods
224171070|NCT05375240|DRUG|Ceftriaxone|Intravenously 2.0g/day for 7 consecutive days.
224171071|NCT05007340|OTHER|Blood draws|Blood draws will be performed by personnel that are both qualified and authorized by their employer/institution to perform the procedures. The procedures will be performed with standards expected in the context of clinical care. 40 mL (2-3 tbsp) of blood will be drawn in order to collect DNA, RNA, serum and PBMCs. Blood tubes will be sent to the Bank as per the SOP for patient blood sampling and processing. The blood will be processed, centrifuged and stored by a trained laboratory technician.
224171072|NCT05007340|OTHER|Other biological samples to biobank (skin, lung and muscle biopsies; bronchoalveolar lavage (BAL fluid)|If the patient's medical care or their participation in a research project involves a biopsy or surgery to remove tissue, the tissue not required for diagnosis (excess tissue) or hospital archives will be included in the biobank. This may include healthy tissue as well as tissue affected by the patient's health condition. The Investigators will not conduct extra procedures in order to obtain samples for the sole purpose of this study and will only operate on what's available. These may include blood samples, skin, lung and muscle biopsies, and bronchoalveolar lavage, all of which will be obtained from the pathology department.
224171073|NCT05007340|OTHER|Clinical data collection|Participant's relevant medical information from medical records, general health questionnaires and clinical assessments. The data includes gender, date of birth, race/ethnicity, habits, height, weight, vital signs, medical history, family history, pregnancy history, imaging data pertinent to ILDs and SARDs, results of routine blood tests, environmental exposures, medication and treatment exposures and adherence, function and quality of life, patient's assessment of their own health, clinical symptoms.
224171074|NCT05007340|OTHER|Genetic data/DNA/RNA|Results of the DNA or RNA sequencing, conducted for the Biobank and will be made available to future research; possible single nucleotide polymorphism (SNP) assays (including single SNP, low-plex or microarray-based assays).
223483038|NCT00869596|DRUG|Comparator: Placebo to fluticasone|Single dose of placebo to fluticasone (9 x 0 mcg) by metered dose inhaler in one of three treatment periods
223483039|NCT00869596|DRUG|Comparator: Lipopolysaccharide (LPS)|20,000 EU LPS by inhalation 1 hour postdose of fluticasone or placebo in each of three treatment periods
223483040|NCT00869596|DRUG|Comparator: albuterol|Albuterol two 100 mcg inhalations by metered dose inhaler prior to sputum induction at screening, twice during each of the three treatment periods, and at the post-study follow up visit.
223483041|NCT02320409|DRUG|Sulfatinib|250mg Sulfatinib ,single dose,oral
223483042|NCT00795340|DRUG|carboplatin|Given IV
223483043|NCT00795340|DRUG|cediranib maleate|Given orally
223483044|NCT00795340|DRUG|paclitaxel|Given IV
223483045|NCT00795340|OTHER|placebo|Given orally
224171075|NCT00484367|BEHAVIORAL|Adolescent group therapy|Adolescent group therapy
224171076|NCT00484367|BEHAVIORAL|Transitional family therapy|Transitional family therapy
224171077|NCT00928304|DRUG|Florbetaben (BAY94-9172)|300 megabecquerels (MBq) as single IV injection of 2 to 10 mL
224171078|NCT04162912|BEHAVIORAL|Motivational Interviewing tailored Advance Care Planning|The trained interventionist who is experienced in MI techniques will explore their illness experiences, emotions and beliefs about their health conditions and future care in an empathetic manner and explore their ambivalence for ACP behaviours.
224171079|NCT03402360|OTHER|Virtual Reality rehabilitation group|"Three hours rehabilitation sessions every day that will consist in two hours of physiotherapy and one hour of neurocognitive rehabilitation, for 15 consecutive working days (3 weeks).~1 hour: conventional physiotherapy~1 hour: virtual reality upper extremity motor rehabilitation~1 hour: virtual reality neurocognitive training"
224171080|NCT03402360|OTHER|Control group rehabilitation|"Three hours rehabilitation sessions every day that will consist in two hours of physiotherapy and one hour of neurocognitive rehabilitation, for 15 consecutive working days (3 weeks).~1 hour: conventional physiotherapy~1 hour: upper extremity motor rehabilitation~1 hour: neurocognitive training"
224171081|NCT01010776|DRUG|Paliperidone Extended Release (ER)|Paliperidone ER tablets in the flexible dose ranging from 3 to 12 mg will be administered orally once daily for 26 weeks of Main Phase and for additional 26 weeks of Extension Phase to participants who continued with Extension Phase. Dosage was adjusted as per the Investigator's discretion.
224171082|NCT01386229|DRUG|Ketamine|During standard anesthesia induction with fentanyl and midazolam, ketamine 2 mg/kg IV will be administered
224171083|NCT01386229|DRUG|Etomidate|During standard anesthesia induction with fentanyl and midazolam, etomidate 3 mg/kg IV will be administered
224171084|NCT06693726|DRUG|Angiotensin II Infusion|Angiotensin II continuous infusion
224171085|NCT03622216|DRUG|Bradanicline|Three different doses over the course of the study
223483046|NCT02082951|BEHAVIORAL|Empathic behaviour by nurses.|The empathic behaviour in group 1 was performed by a trained nurse.
223483047|NCT02082951|BEHAVIORAL|Empathic behaviour by family.|Considered the empathic behaviour performed by family as a hospital visit with greater than 45 minutes duration, a person with whom the patient had a good relationship, he considered it to be important and welcome. It is emphasized that these families did not have any prior training and after the visit, patients were asked about how the visit had been seeking to detect the presence of any conversations that have been unpleasant for patients and, if present, the patients were excluded from the study.
223483048|NCT00775034|DRUG|Tisseel®|Mesh repair for open incisional hernia repair with fibrin sealant
223483049|NCT00775034|PROCEDURE|Drainage|Mesh repair for open incisional hernia repair with drainage
223483050|NCT05302050|DEVICE|BT-001|"BT-001is a software application that delivers treatment to participants with type 2 diabetes, using behavioral therapy. BT-001 is accessed via the participants' smartphone.~The behavioral intervention process involves:~Identifying maladaptive thoughts based on misinformed core beliefs that lead to disease-promoting behaviors; replacing maladaptive core beliefs with adaptive ways of thinking; and providing collaborative construction of behavioral exercises to test core beliefs.~Each week, BT-001 asks participants to complete a new lesson, along with one skill exercise. The lessons are expected to take between 10-20 minutes to complete. In addition to completing a lesson and skill, participants will be directed to report plant-based meals consumed and minutes of exercise completed and to measure their blood sugar daily."
224171086|NCT03622216|DRUG|Placebo|Matching placebo for Bradanicline
223483051|NCT05302050|DEVICE|Control Mobile Application|The app asks patients brief questions about their health but does not include any behavioral therapy.
223483052|NCT03850626|BIOLOGICAL|Immunotherapy|subcutaneous injection
223483053|NCT02233257|DRUG|Lorenzo's Oil|Oral use of Lorenzo's oil to lower very long chain fatty acids
223483054|NCT03134807|OTHER|Observation prospective|No intervention
223483055|NCT00818844|DRUG|Nepafenac 0.1%|NSAID
223483056|NCT00818844|OTHER|BSS|BSS
223483057|NCT03710811|DRUG|Insulin|Continuous Subcutaneous Insulin Infusion
223483058|NCT03491592|BEHAVIORAL|Enhanced Physical Activity Intervention|Participants in the Enhanced Intervention arm will receive all the intervention components of the Original Intervention described above plus: 1) text messages and adaptive goal-setting to drive participants back to the website and keep them there longer, and 2) data-driven, technology supported enhanced intervention content targeting theoretical constructs that influenced PA behavior in Latinas from the parent study.
223483059|NCT03491592|BEHAVIORAL|Original Physical Activity Intervention|Participants in the Original Physical Activity intervention arm of the study will receive the original Spanish language, motivationally-tailored, Internet-based physical activity intervention that specifically addresses the Physical Activity barriers and intervention needs/preferences of Latinas.
223483060|NCT02730130|DRUG|Pembrolizumab|
224205414|NCT00903942|RADIATION|radiation therapy|1\) PTV = CTV (GTV + 1.5-cm margins and the most adjacent nodal regions) + 0.5 cm margins to 5,040 cGy in 180 cGy daily fractions; and (2) Cone Down PTV = GTV +1.5 cm margins to 6,480 cGy.
224205415|NCT00903942|DRUG|Paclitaxel Protein-Bound, and CARBOPLATIN|Induction Chemotherapy Abraxane(260 mg/m2) / Carboplatin (AUC of 6) x one cycle Concurrent Chemotherapy(with radiation)--for first 3 pts--20 mg/m2 Abraxane, 3 times per week then for next group of 3 pts--30 mg/m2 Abraxane twice a week
223483061|NCT02730130|RADIATION|Radiotherapy|
223483062|NCT01788514|OTHER|Videogame|Subject will play an interactive educational videogame that is designed to increase their knowledge on influenza and the influenza vaccination.
223483063|NCT03403049|RADIATION|Carbon Ion|Study subjects will receive carbon ion radiotherapy (CIRT), with daily fraction sizes of 3 GyE. The total CIRT dose will increase with each dose level. Subjects in dose level 1 and 2 will receive photon radiotherapy as well.
223483064|NCT03403049|DRUG|Gemcitabine + Cisplatin|"Combined chemotherapy regimen before/after radiotherapy: gemcitabine-based chemotherapy regimen.~All patients will have received 2-4 cycles of gemcitabine-based chemotherapy prior to study registration, with post-chemotherapy imaging demonstrating locally-advanced disease without evidence of distant metastatic disease spread. Patients who received chemotherapy regimens other than those listed above may be considered for study enrollment at the discretion of the lead investigators, provided that all other eligibility criteria are satisfied. Gemcitabine-based chemotherapy will be continued starting 3-5 weeks after completion of radiotherapy until disease progression, intolerability, or the patient's decline of chemotherapy."
223483065|NCT03403049|DRUG|Gemcitabine + Capecitabine|"Combined chemotherapy regimen before/after radiotherapy: gemcitabine-based chemotherapy regimen.~All patients will have received 2-4 cycles of gemcitabine-based chemotherapy prior to study registration, with post-chemotherapy imaging demonstrating locally-advanced disease without evidence of distant metastatic disease spread. Patients who received chemotherapy regimens other than those listed above may be considered for study enrollment at the discretion of the lead investigators, provided that all other eligibility criteria are satisfied. Gemcitabine-based chemotherapy will be continued starting 3-5 weeks after completion of radiotherapy until disease progression, intolerability, or the patient's decline of chemotherapy."
223483066|NCT03403049|DRUG|Gemcitabine + Erlotinib|"Combined chemotherapy regimen before/after radiotherapy: gemcitabine-based chemotherapy regimen.~All patients will have received 2-4 cycles of gemcitabine-based chemotherapy prior to study registration, with post-chemotherapy imaging demonstrating locally-advanced disease without evidence of distant metastatic disease spread. Patients who received chemotherapy regimens other than those listed above may be considered for study enrollment at the discretion of the lead investigators, provided that all other eligibility criteria are satisfied. Gemcitabine-based chemotherapy will be continued starting 3-5 weeks after completion of radiotherapy until disease progression, intolerability, or the patient's decline of chemotherapy."
223483067|NCT03403049|DRUG|Gemcitabine|"Combined chemotherapy regimen before/after radiotherapy: gemcitabine-based chemotherapy regimen.~All patients will have received 2-4 cycles of gemcitabine-based chemotherapy prior to study registration, with post-chemotherapy imaging demonstrating locally-advanced disease without evidence of distant metastatic disease spread. Patients who received chemotherapy regimens other than those listed above may be considered for study enrollment at the discretion of the lead investigators, provided that all other eligibility criteria are satisfied. Gemcitabine-based chemotherapy will be continued starting 3-5 weeks after completion of radiotherapy until disease progression, intolerability, or the patient's decline of chemotherapy."
223483068|NCT03403049|RADIATION|Photon|During this study, the prescribed dose shall be administered according to the dose escalation shown in the table, starting with dose level 1. The carbon ion dose shall be gradually escalated while gradually reducing the dose of photons until eventually administering a full dose of 56 GyE/14 Fx carbon ions (fractional dose of 4 GyE). Dose escalation will be performed in parallel for two patient groups: patients whose pancreatic tumors are greater than 5 mm from the duodenum (Group A) and those whose tumors are within 5 mm of the duodenum (Group B). Enrolled patients will be monitored for 90 days after radiotherapy starts for any acute toxic reaction and to explore the maximum tolerated dose, in addition to being observed for any related long-term toxic reactions in accordance with the protocol.
223483069|NCT05598970|OTHER|Digital application supported CHW Parenting Intervention|"All pregnant women served by the trained CHW will be invited to participate in the Parenting program, from when the mother is at least 20 weeks pregnant and less than 32 weeks pregnant with the target child for a period of 15 months. CHWs will visit pregnant women at least 3 times during their pregnancy and at least 16 times following delivery. In addition to the individual home visits, the CHWs will organise bi-weekly in-community group sessions for children aged 6-12 months and their primary caregivers, focusing on caregiver-child interaction and stimulation activities.~The immediate supervisors Health Care Workers (HCWs) of the CHWs will be trained to closely monitor CHWs activities and progress made. HCWs and CHWs will in turn be supervised and supported by district level Council Health Management Team (CHMT).~Parenting services will be provided to all target children of these eligible caregivers, irrespective of their learning or physical abilities."
223483070|NCT05598970|OTHER|Unconditional Cash Transfer only Intervention fixed amount|The fixed cost for delivering the Parenting only Intervention was calculated to be 32,000 TZS. This cost is added to the average of maximum and minimum amount transferred on a bi-monthly basis to similar pregnant women under TASAF: 77,000 TZS. Therefore, in the 'Unconditional Cash Transfer fixed amount' treatment arm, the transfer will be 109,000 TZS (32,000 TZS + 77,000 TZS).
223483071|NCT05598970|OTHER|Unconditional Cash Transfer Intervention|Families will receive from 5-7 months pregnancy over a period of 15 months a bi-monthly unconditional cash transfer, which equals the average of maximum and minimum amount transferred on a bi-monthly basis to similar pregnant women under Tanzania Social Action Fund (TASAF), i.e., Tanzania's National Cash Transfer program.
223483072|NCT05598970|OTHER|Unconditional Cash Transfer only Intervention vary amount|The rationale for the levels of the varying UCT amounts is to keep them comparable with i) the bi-monthly cost of the parenting program per family, ii) the bi-monthly cash transfers disbursed under TASAF, and iii) the sum of the bi-monthly cost of the parenting program and the bi-monthly cash transfer disbursed under TASAF. The fixed cost for delivering the Parenting Intervention was calculated to be 32,000 TZS. This cost is added to the average of maximum and minimum amount transferred on a bi-monthly basis to similar pregnant women under TASAF: 77,000 TZS. Therefore, in the 'Unconditional Cash Transfer only vary amount' group, each of the amounts vary individually (32,000 TZS; 77,000 TZS; 109,000 TZS).
223483073|NCT02585206|BEHAVIORAL|Personalization|"Phase I Factor~Personalized text messages using the participant's username and gender (Check out the EX Community for tips/support from other men who have quit. They've been there and can help you do this, QuitForever!). Both data points will be pulled from BecomeAnEX registration data."
223585550|NCT02252965|DRUG|Metformin XR|Subjects will receive Metformin Extended Release (XR) tablets, orally once daily at a dose of 500 mg for 1 week, and then dose will increase with increments of 500 mg every week in first 2 weeks to 1500 mg. After that dose will increase up to maximum dose of 2000 mg for the next 2 weeks and will be maintained at 2000 mg until Week 16.
223585551|NCT01705093|DIETARY_SUPPLEMENT|flavonoid-rich freeze-dried strawberry powder|50g of flavonoid-rich freeze-dried strawberry powder
223585552|NCT01705093|DIETARY_SUPPLEMENT|macronutrient-matched control powder|50g macronutrient-matched powder that will lack strawberry flavonoids
223585553|NCT06249906|DEVICE|Commercial bone implant product Group|Commercial bone implant product Group with a smooth surface （without particular microstructures）.
223585554|NCT06249906|DEVICE|Mirco-structured Bioceramic Group|β-tri-Calcium phosphate with microstructures such as grooves, patterns and so on.
223585555|NCT00867555|DIETARY_SUPPLEMENT|Effect of the green tea extract TEAVIGO, high in EGCG, on postprandial fat oxidation|green tea extract TEAVIGO, high in EGCG
224205416|NCT06313697|BIOLOGICAL|GR2102 injection|single dose
224205417|NCT06313697|BIOLOGICAL|placebo|single dose
223483074|NCT02585206|BEHAVIORAL|Integration|"Phase I Factor~Interactive messages to facilitate engagement via text with the 6 interactive intervention components of the BecomeAnEX web intervention:~Set your quit date Cigarette tracker Beat your smoking triggers Build your support system Choose a quit smoking aid Community~Integration will allow interaction with the web-based program via text message; for example, when a user sets a quit date via the website, it will trigger text messages tailored to the quit date; likewise, if a user sets a quit date via the text system, it will be populated in the website and drive the user experience online."
223483075|NCT02585206|BEHAVIORAL|Dynamic Tailoring|Individually tailored message to remind/reinforce users about BecomeAnEX information/tools they have already used, or to prompt users to take actions they have not yet taken.
223483076|NCT02585206|BEHAVIORAL|Message Intensity|"Phase I Factor~Varying levels of text message intensity over a 12-week period."
223483077|NCT02585206|BEHAVIORAL|Optimal-Adherence Text|Optimal-adherence text message intervention developed in Phase I
223483078|NCT01478646|OTHER|conventional breathing therapy|duration: 60 minutes.
223483079|NCT01478646|OTHER|reflectory breathing therapy|duration: 60 minutes.
223483080|NCT03085303|DEVICE|Full Body Blue Light Device|Full body blue light irradiation (phototherapy) of atopic dermatitis patients.
223483081|NCT02181595|OTHER|Group reading and discussion|
223483082|NCT02122419|OTHER|lateral|spinal anesthesia performed during lateral position
223483083|NCT02122419|OTHER|sitting|spinal anesthesia performed during sitting position
223483084|NCT03448848|DRUG|BCAA preparation Intravenous infusion|BCAA IVi in a dose 0.5-1 gm/Kg/day for 2-5 days post liver surgery versus sterile normal saline in a volume equal to the study drug
223483085|NCT03448848|DRUG|sterile normal saline|sterile normal saline in a volume equal to the study drug
223483086|NCT01548235|DRUG|biphasic insulin aspart 30|Prescribed biphasic insulin aspart 30 as part of routine care. Starting dose, dose titration and injection frequency determined individually by each physician.
223585556|NCT05035433|PROCEDURE|First lithotripsy and then EPBD|After successful selective bile duct intubation, contrast agent was injected to measure the thickness of the bile duct and the size of bile duct stones under fluoroscopy. For those meeting the inclusion criteria, sphincterotomy was performed first.Papillary sphincter incision after indwelling godet in bile duct, anti-popular character silk will be crushed stone on top into rubble after biliary tract, broken line to suitable size after the switch to expanding balloon EPBD and further kidney stones, papillary sphincter incision after indwelling godet in bile duct, anti-popular character silk will be crushed stone on top into rubble after biliary tract, broken balloon to suitable size after the switch to expansion, expansion size 10-12 mm, according to the lower bile duct diameter, expansion time of 30 seconds.Then, the stones were removed with a net basket or balloon, and the nasobiliary duct was placed to end the operation.
223585557|NCT05035433|PROCEDURE|First EPBD and then lithotripsy|After puncture of the papillary sphincter, the guide wire was indwelled in the bile duct, and the columnar dilating balloon was inserted in exchange. The dilation size was 10-12mm, and the dilation time was 30 seconds according to the diameter of the lower end of the bile duct.At the end of the expansion, the stones were broken to a suitable size using a one-piece gravel net basket.The calculi were removed by using a stone net basket or balloon, and the nasobiliary duct was placed to end the operation.
224171087|NCT04655846|BEHAVIORAL|Nursing intervention outcome: Breastfeeding Counseling (5244)|"Educational sessions: The nursing professional will carry out 1 educational session per week, for 4 weeks; each lasting between 45 and 60 minutes. The topics that make up each of the activities are:~1. Educational Session: Awareness towards the process of breastfeeding. Inform about the psychological and physiological benefits of breastfeeding.~2. Educational session: Teach the composition of breast milk. Teach the baby's correct alignment, latch, and areolar understanding of the breast. Instruct on breastfeeding positions.~3. Educational Session: Explain the extraction and conservation of breast milk.~4. Educational session: Explain the signs, symptoms, and management strategies for duct obstruction, mastitis, and nipple trauma. Talk about your needs for rest, hydration, and diet during breastfeeding."
223483087|NCT00527995|DRUG|Sildenafil|Orally administered, Sildenafil 100mg, unique administration
223483088|NCT01110941|DRUG|S-1, leucovorin, oxaliplatin|S-1(20mg、25mg), capsule, 40\~60mg, Bid,p.o., day1\~7； LV (25 mg), tablet, 25mg,Bid,p.o., day1\~7； L-OHP (50 mg),injection 85mg/m2, day1. repeated at every 2 weeks cycle till disease progression.
223483089|NCT05142735|DIETARY_SUPPLEMENT|N-Acetylcysteine|2000 mg (4 x 500-mg tablets) every morning
223483090|NCT05142735|DIETARY_SUPPLEMENT|Placebo|4 placebo tablets every morning
223483091|NCT06437756|OTHER|Theraband resistance training|Three sessions of 30 minutes each was used to complete the intervention over the course of six weeks (two sets of 12 repetitions). The participants were warmed up by stretching for 10 minutes before each session Participants were advised to take 5 mins rest before moving to next movement if they would feel fatigued after one movement. Thera-Band was utilized in only three different colors for the workouts.
223483092|NCT06437756|OTHER|Conventional Resistance Training|The intervention was carried out over the course of six weeks in three sessions of 30 minutes each (two sets of 12 repetitions). The participants were warmed up by stretching for 10 minutes before each session. The resistance-training program was performed with Universal weights.
223483093|NCT01946867|DEVICE|NBTXR3 activated by IMRT|
223483094|NCT00635505|DRUG|albuterol HFA (Armstrong's)|180 mcg QID 12 weeks
223483095|NCT00635505|DRUG|albuterol HFA (Proventil HFA)|180 mcg QID 12 weeks
223483096|NCT00635505|DRUG|HFA placebo|2 actuations QID 12 weeks or until use of rescue drug
223483097|NCT05042492|DEVICE|gekoTM|The gekoTM device is a small, transcutaneous nerve stimulator that is placed non-invasively on the skin, whereby the surface electrodes will be attached close to the peroneal nerve. Activation of the peroneal nerve causes contraction of the calf muscle pump, which will increase blood circulation that corresponds to 60% of walking. The increased blood circulation reduces the pressure difference between capillaries and the surrounding tissue and transfers the tissue fluid back into the veins and lymph fibers
223483098|NCT01461551|DRUG|Sevoflurane|anesthesia was maintained with sevoflurane (end-tidal concentration 1.0-1.5 minimum alveolar concentration)
223483099|NCT01461551|DRUG|Propofol|anesthesia was maintained with propofol (2-4 μg/ml via target-controlled infusion)
224171088|NCT04655846|BEHAVIORAL|Nursing education about maternal care and usual education in maternity preparation course|Educational intervention by a nursing professional on the provision of adequate care at the level of growth and development in infants under one year of age, activities not related to the breastfeeding process
224171089|NCT01229410|DRUG|400 µg Brimonidine Tartrate Implant|400 µg brimonidine tartrate implant in the study eye on Day 1 (2, 4 or 8 weeks prior to undergoing a pars plana vitrectomy).
224171090|NCT01229410|DRUG|200 µg Brimonidine Tartrate Implant|200 µg brimonidine tartrate implant in the study eye on Day 1 (2, 4 or 8 weeks prior to undergoing a pars plana vitrectomy).
224171091|NCT04485936|DEVICE|Epitomee Device|medical Device designed to enhance the feeling of early satiation and prolonged satiety
223483100|NCT01461551|DRUG|combine of sevoflurane and propofol|anesthesia was maintained with a combine of propofol (1 μg/ml via target-controlled infusion) and sevoflurane (end-tidal concentration 0.7-1.0 minimum alveolar concentration)
224171092|NCT03131011|OTHER|UV fluorescent ink|"The use of UV tattoo ink results in a tattoo that is visible only under an ultraviolet light. Conventional black tattoo ink is replaced with UV ink for the application of radiotherapy dot tattoos. Handheld UV flashlights are used to make the tattoos visible for use during radiotherapy treatment set-up."
224171093|NCT03334656|BIOLOGICAL|biological dressing|to test a biological dressing on the wound healing of the split-thickness skin graft donor site
224171094|NCT03334656|OTHER|Paraffin gauze dressing|standard intervention : Paraffin gauze dressing on the wound healing
224171095|NCT00902057|DRUG|desmopressin|single desmopressin subcutaneous injection, 1.5mcg
223483101|NCT00827567|DRUG|RAD 001|RAD 001-10 mg by mouth once everyday
223483102|NCT01155141|DRUG|H.P. Acthar Gel|Patients were treated with 40 units subcutaneously (SC) weekly for 2 weeks, then dose increased to 80 units SC weekly for 2 weeks followed by 80 units SC twice weekly to complete 16 weeks of therapy.
223483103|NCT05052905|DEVICE|LibraVR|"LibraVR is a standalone VR-based rehabilitation software for use in physiotherapy. It is designed to work with standard off-the-shelf hardware that is tested and approved for use in conjunction with the software.~LibraVR system consists of the software (LibraVR Clinic) running on a PC (database of patients, creation of protocols, uploading protocols to mobile), and the LibraVR Mobile APP that runs on commercial mobile smartphones embedded in a lightweight cardboard or plastic VR viewer that the child wears as they would eyeglasses. The software displays a range of immersive VR exercises."
223483104|NCT00847028|OTHER|glucose 10%|2 minutes prior to the venipuncture, a 10% glucose concentration was administered orally
224171096|NCT00902057|DRUG|desmopressin|single desmopressin subcutaneous injection, 3mcg
224171097|NCT00902057|DRUG|desmopressin|single desmopressin subcutaneous injection, 15mcg
224171098|NCT00902057|DRUG|placebo|saline subcutaneous
224171099|NCT03286881|OTHER|Brief individual psychotherapy|"Individual brief psychological intervention by adaptation of the Guide NICE Common Mental Health Disorders (ISBN 978-1-84936-585-7) and the unified protocol for the trasndiagnostic treatment of the emotional disorders of Barlow (Boisseau, Farchione, Fairholme, Ellard, y Barlow, 2010). This intervention is provided by clinical psychologist in secondary care."
224171100|NCT03286881|OTHER|Brief group psychotherapy|"Group brief psychological intervention by adaptation of the Guide NICE Common Mental Health Disorders (ISBN 978-1-84936-585-7) and the unified protocol for the trasndiagnostic treatment of the emotional disorders of Barlow (Boisseau, Farchione, Fairholme, Ellard, y Barlow, 2010). This intervention is provided by clinical psychologist in primary care."
223483105|NCT00847028|OTHER|20% glucose|2 minutes prior to the venipuncture, a 20% glucose concentration was administered orally
223483106|NCT00847028|OTHER|glucose 30%|2 minutes prior to the venipuncture, a 30% glucose concentration was administered orally
223483107|NCT00847028|OTHER|sterile water|2 minutes prior to the venipuncture, sterile water was administered orally
224171101|NCT03286881|OTHER|Combined intervention|Traditional psychotherapy and medication provided by a clinical psychologist and a psychiatrist in secondary care.
224171102|NCT03286881|OTHER|Minimum psychological intervention|Psychoeducation and bibliotherapy provided by a trained general practitioner in primary care.
224171103|NCT03286881|OTHER|Usual treatment|Medication provided by a general practitioner.
224171104|NCT05232292|BIOLOGICAL|Ultrix Quadri|vaccination by Ultrix Quadri against flu
224171105|NCT04222257|DRUG|Antibiotics|Patients allocated to this group will receive a short course of antibiotic therapy for 2 weeks.
224171106|NCT04222257|DRUG|Antibiotics|Patients allocated to continue with standard parenteral treatment will maintain the same antibiotic treatment for 4 to 6 weeks.
224171107|NCT04140682|DEVICE|PAV+ mode|PAV+ mode by using Puritan-Bennett 840 ventilator
223483108|NCT04507113|OTHER|DTI sequence acquisition|DTI sequence acquisition
223483109|NCT01720966|PROCEDURE|Liver resection|Liver resection performed for metastatic disease from colorectal carcinoma
223483110|NCT04055883|DRUG|DA-1229|All participants are administered one tablet per day for 96 weeks
223483111|NCT00733434|DRUG|Prostaglandin E1|PGE 1 80mcg/500 ml saline continuous intravenous infusion per day after head and neck microsurgery for 5 days
223483112|NCT00733434|OTHER|Saline|500 ml saline continuous intravenous infusion per day after head and neck microsurgery for 5 days
224171108|NCT04140682|DEVICE|PSV mode|PSV mode by using Puritan-Bennett 840 ventilator
224171109|NCT06331273|PROCEDURE|"Liver transplantation with No-touch technique"|"The core principle of no-touch tumor surgery revolves around avoiding direct contact with the tumor or surrounding tissues as much as possible to minimize the release of cancer cells into the bloodstream or nearby tissues."
223483113|NCT02016118|DEVICE|Ialuril|The treatment is an intravesical administration of combined hyaluronic acid (HA) 1.6% and chondroitin sulphate (CS) 2.0% once per week for the first month, followed by one instillation every two weeks for the second month and one instillation per month until stable remission of the symptoms.
223483114|NCT00440843|DRUG|Olanzapine (Zyprexa)|OLZ
223483115|NCT00440843|DRUG|Typicals|Stay on typicals regimen
224171110|NCT00004889|BIOLOGICAL|rituximab|375 mg/m2 given as an intravenous (IV) infusion once weekly for four doses (days 1, 8, 15, and 22). For purposes of this study 4 weekly courses will constitute one cycle of therapy.
224171111|NCT02929381|DEVICE|Innovative colonoscopy (Olympus CF-HQ190L, NBI + Dual Focus)|NBI and Dual Focus options will be used to classify lesions according to Kudo and NICE classifications.
223483116|NCT03473197|DRUG|Diacerein 1% ointment|During the 3-week Induction Phase, diacerein 1% ointment and vehicle ointment were applied under fully occlusive patch conditions to two randomly assigned skin sites on the infrascapular region of the back twice each week for approximately 24 hours (±4 hours). After patch removal, one application site and an untreated control site was irradiated, and all sites were evaluated 24 hours, 48 hours, and 72 hours later. Following a rest period, during the Challenge Phase, the study products were applied to two naive sites once for approximately 24 hours (±4 hours). After patch removal, one application site and an untreated control site was irradiated, and all sites were evaluated 24 hours, 48 hours, and 72 hours later. A Re-Challenge was to be performed if a response observed during the Challenge Phase indicated photosensitization.
223483117|NCT00014014|DRUG|Lamivudine/Zidovudine|
223483118|NCT00482833|DRUG|arsenic trioxide|"Induction Arsenic Trioxide (As2O3=ATO), 0.15 mg/Kg IV over 2 hours daily starting on day 1. ATO will be continued until hematological CR or for a maximum of 60 days.~Consolidation ATO, 0.15 mg/Kg IV over 2 hours daily for 5 days every week. Treatment will be continued for 4 weeks on and 4 weeks off, for a total of 4 cycles (last cycle administered on weeks 25 - 28)."
223483119|NCT00482833|DRUG|idarubicin|"Induction~Idarubicin, 12 mg/m² on days 2, 4, 6 and 8 by short (20') intravenous infusion .~If no hematological CR is achieved by 60 days after start of induction, patient will go off-study.~Consolidation~1st cycle Idarubicin, 5 mg/m2/day by short (20') intravenous infusion on days 1, 2, 3, 4.~3rd cycle Idarubicin, 12 mg/m2/day as short (20') intravenous infusion only on day 1."
223483120|NCT00482833|DRUG|mercaptopurine|Maintenance therapy 6-Mercaptopurine (6-MP), 50 mg/m2/day orally. The dose will be adjusted according to hematopoietic toxicity during the follow-up period
223483121|NCT00482833|DRUG|methotrexate|Maintenance therapy Methotrexate (MTX), 15 mg/m2/weekly intramuscularly. The dose will be adjusted according to toxicity during the follow-up period.
223483122|NCT00482833|DRUG|all-trans retinoic acid|"Induction ATRA, 45 mg/m²/day will be administered orally in two equally divided doses and rounded to the nearest 10 mg increment, starting on day 1. ATRA treatment will be continued until hematological CR and for a maximum of 60 days.~Consolidation~1. st cycle ATRA, 45 mg/m2/day, will be administered orally in two equally divided doses and rounded to the nearest 10 mg increment, starting from day 1 to day 15.~2. nd cycle ATRA, 45 mg/m2/day will be administered orally in two equally divided doses and rounded to the nearest 10 mg increment, starting from day 1 to day 15.~3. rd cycle ATRA, 45 mg/m2/day will be administered orally in two equally divided doses and rounded to the nearest 10 mg increment, starting from day 1 to day 15.~Maintenance therapy~ATRA, 45 mg/m2/day orally, for 15 days every three months until a two year period is completed."
223483123|NCT00482833|DRUG|all-trans retinoic acid (ATRA)|"Induction All-trans retinoic acid (ATRA), 45 mg/m²/day will be administered orally in two equally divided doses and rounded to the nearest 10 mg increment, starting on day 1. ATRA treatment will be continued until hematological complete remission (CR, see below for definition) or for a maximum of 60 days.~Consolidation ATRA, 45 mg/m²/day will be administered orally in two equally divided doses and rounded to the nearest 10 mg increment. Treatment will be administered for 2 weeks on 2 weeks off and for a total of 7 cycles (last cycle administered on weeks 25 - 26)."
223483124|NCT01946945|GENETIC|Next Generation Sequencing after Blastocyst biopsy|PGD using blastocyst biopsy and testing of the biopsy by NGS
223483125|NCT00267670|DRUG|Pentoxifylline|400mg PO TID
223483126|NCT00267670|DRUG|Placebo|1 pill PO TID
223483127|NCT00785629|DRUG|Calcium acetate|
223483128|NCT00785629|DRUG|Lanthanum Carbonate|
223483129|NCT00785629|DRUG|Sevelamer Carbonate|
223483130|NCT00785629|DRUG|Placebo|
223483131|NCT06397482|DIETARY_SUPPLEMENT|Encapsulated Calcium Butyrate|Contains at minimum 35% butyric acid
223483132|NCT03200821|BIOLOGICAL|G17DT|250 µg/0.2 mL administered by intramuscular injection at Weeks 0, 2 and 6. 125 µg booster administered at Week 24.
223483133|NCT03200821|DRUG|Gemcitabine|1000 µg/m\^2 intravenously administered once weekly for seven weeks starting at Week 0 followed by one week of rest. After, treatments will occur in cycles of 3 weeks of treatment followed by one week of rest.
223483134|NCT05241951|OTHER|Structured hand-off|Use of standardized checklist to provide synchronous or asynchronous handoff that conveys medication recommendations to the SNF clinical teams
223483135|NCT05241951|OTHER|Medication reconciliation during transitional period|Comprehensive medication reconciliation conducted during transitional period between hospital and SNF, focused on SNF-specific requirements for medication delivery (e.g., stop dates, titration instructions)
223483136|NCT05241951|OTHER|Transitional medication monitoring|Review of medication orders during first 7 days of SNF admittance to address barriers to translation of medication orders and appropriate medication delivery
223483137|NCT05241951|OTHER|Teleconsultation|Ad hoc consultation to provide additional clarification to SNF clinical teams
223483138|NCT03736304|DEVICE|AKI alert|An AKI alert will send to the doctor in charge. The team of nephrologists would give suggestions if the doctor in charge need a renal consultation.
223483139|NCT03736304|OTHER|Usual care|Patients will receive standard clinical care by the doctor in charge.
223483140|NCT03797729|DRUG|Tirofiban|Upon being diagnosed as ST Elevation Myocardial Infarction, if informed consent is obtained, patients start to receive Tirofiban(0.05mg/ml) intravenous drip in a dosage of 4ml/hour (patients weight\<50kg) or 6ml/hour (patients weight \> 50kg) lasting for 24 hours.
223483141|NCT03797729|DRUG|Normal saline|Upon being diagnosed as ST Elevation Myocardial Infarction, if informed consent is obtained, patients start to receive normal saline intravenous drip in a dosage of 4ml/hour (patients weight\<50kg) or 6ml/hour (patients weight \> 50kg) lasting for 24 hours.
223483142|NCT00006039|BIOLOGICAL|pegylated interferon alfa|
223483143|NCT05062473|BEHAVIORAL|Lifestyle Modification Webinars Focused on Hypertension Control|Participation in a 12-week health education telemedicine curriculum
223483144|NCT02671968|DEVICE|Continuous Glucose Monitoring System|
223483145|NCT05318326|DRUG|placebo group|placebo 400mg (4 tablet) , Q1W, oral, week 1 to week 24; Yogliptin 400 mg (4 tablet), Q1W, oral, week 25 to week 52.
223483146|NCT05318326|DRUG|Yogliptin 400mg group|Yogliptin 400mg (4 tablet) , Q1W, oral, week 1 to week 24; Yogliptin 400 mg (4 tablet), Q1W, oral, week 25 to week 52.
223483147|NCT05318326|DRUG|Yogliptin 200mg group|Yogliptin 200mg (2 tablet) and placebo 200 mg (2 tablet), Q1W, oral, week 1 to week 24; Yogliptin 400 mg (4 tablet), Q1W, oral, week 25 to week 52.
224171112|NCT02929381|DEVICE|Conventional colonoscopy (Olympus CF-H180DL)|Conventional colonoscopy performed without innovative techniques used in experimental arm.
224171113|NCT04446767|RADIATION|polarized light|bioptron light therapy sessions, about 12 minutes on the foot ulcer 3 sessions per week for about 8 weeks
223483148|NCT03320915|DRUG|Cholecalciferol|Cholecalciferol 5mg (200,000 IU) up to maximum of three times during 1 year follow-up period according to measured 25(OH)D3 level.
223483149|NCT00851591|DRUG|fenugreek|3 capsules 3 times per day with a full glass of water each dose for 7 days
223483150|NCT00851591|DRUG|Placebo (Psyllium)|3 capsules 3 times a day with a full glass of water each dose for 7 days
224171114|NCT04446767|OTHER|Medical Care|Appropriate day-care and principles of local ulcer therapy, washing and bandaging, use of anti exudative, anti-inflammatory and disinfection solutions will be administered to this group, topical antibiotics will be administered based on bio-gram and antibiogram results
224171115|NCT00824967|OTHER|Training and valuation of the treating personnel|Training and valuation of the treating personnel
224171116|NCT00169767|OTHER|Comparison study between KTP and HoLAP for BPH|Comparison study between KTP and HoLAp for BPH
223483151|NCT01114555|DRUG|Bevacizumab, Irinotecan and Temozolomide|Patients will initially receive bevacizumab IV at 15mg/kg/dose (this is defined as Day 1 Three days later (starting day 4), they will receive concurrently, IV irinotecan at 50mg/m2/day x 5 days plus PO temozolomide 150mg/m2/day x 5 days. A second dose of bevacizumab will be administered 14 days after the first one(day 15). The treatment schedule may require minor adjustment as clinically indicated (e.g., due to PDH closure for holidays).
223483152|NCT05413772|OTHER|Temocillin|To evaluate the clinical course of patients who received temocillin. To evaluate the efficacy and safety of temocillin in different situations Enterobacteriaceae ESBL infections
223483153|NCT02326883|BEHAVIORAL|Care Management|The Care Management intervention includes routine outreach to assess ongoing risk of suicide attempt and care management to monitor and facilitate ongoing engagement in outpatient follow-up. The Care Manager will coordinate care with treating mental health and primary care providers (ongoing usual care) using Epic Staff Messaging (or telephone contacts if necessary).
223483154|NCT02326883|BEHAVIORAL|Skills Training|The Skills Training intervention uses an online skills training program to support patients in developing and using self-management skills for emotion regulation and crisis management. A Coach will monitor each participant's use of the program and send periodic messages (using Epic secure messaging) to encourage and support use of the program and practice of program skills.
223483155|NCT02326883|BEHAVIORAL|Usual Care|Those assigned to usual care will not be contacted at all by study staff and will continue to receive usual care from treating primary care and mental health providers.
223483156|NCT02458417|DEVICE|ReCell|A split-thickness skin biopsy will be taken from the hip region of the patient. The skin biopsy that is obtained will be treated in the ReCell kit (Avita Medical Europe Ltd, Cambridge, UK): it will be placed in the heated enzyme solution, containing trypsin, in the device for 15-20 minutes to allow cell disaggregation. After that period, the biopsy will be taken from the enzyme solution and will be dipped in sodium lactate buffer solution. The biopsy will then be scraped to disaggregate the cells from the dermal epidermal junction. The epidermal cells are drawn up in a syringe. The prepared suspension will be dripped on both donor and acceptor site.
223483157|NCT02458417|DEVICE|Full surface CO2 laser 200 mJ|Full surface pretreatment with the CO2 laser (Ultrapulse, ActiveFX handpiece, Lumenis Inc., Santa Clara, CA, USA) at 200 mJ (depth 144 µm) and density 3
223483158|NCT02458417|DEVICE|Full surface CO2 laser 150 mJ|Full surface pretreatment with the CO2 laser (Ultrapulse, ActiveFX handpiece, Lumenis Inc., Santa Clara, CA, USA) at 150 mJ (depth 144 µm) and density 3
223483159|NCT02458417|DEVICE|Fractional CO2 laser 7.5 mJ, 20%|Pretreatment with the fractional CO2 laser (Ultrapulse, DeepFX handpiece, Lumenis Inc., Santa Clara, CA, USA) at 7.5 mJ/microbeam (depth 225 µm) and 20% density.
223483160|NCT02460003|BEHAVIORAL|Physiotherapy|A program of physiotherapy including manual therapy, exercise, pain education.
223483161|NCT02460003|OTHER|Home exercise program|Home exercise program
223483162|NCT03921983|OTHER|Oxygen supplementation|short term O2 supplementation during 1 hour
223483163|NCT00722696|OTHER|physical training|8 weeks of hiking downwards. For the opposite way, a cable car will be used.
223483164|NCT02339207|DRUG|AL-335 matching placebo|
223483165|NCT02339207|DRUG|AL-335|
223483166|NCT05627687|BEHAVIORAL|Heart Rate Variability Biofeedback|Practice using the Inner Balance app and device, 10 minutes/day, 4-5 days per week
224171117|NCT02545972|DRUG|tacrolimus extended release|daily dosing of tacrolimus
224171118|NCT03019172|COMBINATION_PRODUCT|Lactobacillus reuteri|Sachet one contains a total of 5\*10\^8 CFU of Lactobacillus reuteri DSM 16666 \& Lactobacillus reuteri DSM 17938, mixed with maltodextrin for flowability during production. Sachet two contains instant cranberry drink composed of Cranberry extract, xylitol, cranberry aroma, monosodium citrate, zink gluconate, silica. The products will be taken twice per day, morning and evening. The daily dose in the active group will be at least 5\*10\^8 CFU of L.reuteri DSM16666 and L. reuteri DSM17938), PAC-A and zinc
224171119|NCT03019172|DIETARY_SUPPLEMENT|Sachet with cranberry + placebo|Sachet one contains placebo for probiotics (maltodextrin). Sachet two contains instant cranberry drink composed of Cranberry extract, xylitol, cranberry aroma, monosodium citrate, zink gluconate, silica.
224171120|NCT03294772|OTHER|hand sanitizer|DCCs received alcohol-based hand sanitizer and a program educational.
224171121|NCT03294772|OTHER|liquid soap|DCCs received liquid soap and a program educational.
224171122|NCT00952952|DRUG|Mesalamine|
224205418|NCT02032823|DRUG|Olaparib|Patients will be administred olaparib orally twice daily (b.i.d.) at 300 mg. Two (2) x 150 mg olaparib tablets should be taken at the same times each morning and evening of each day, approximately 12 hours apart with approximately 240 ml of water.
224205419|NCT02032823|DRUG|Placebo|Patients will be administred matching placebo. Two (2) tablets should be taken at the same times each morning and evening of each day, approximately 12 hours apart with approximately 240 ml of water.
224205420|NCT04461431|PROCEDURE|Arthroscopic anatomical reconstruction of the posterolateral structure of the knee|Arthroscopic anatomical reconstruction of the posterolateral structure of the knee for patients with injury of the posterolateral structure of the knee
224205421|NCT05922540|OTHER|Intravenous thrombolysis|Intravenous thrombolysis with alteplase within the time window of stroke onset in stroke patients
224171123|NCT01637090|DRUG|Everolimus|"The study drug everolimus will be self-administered (by the patients themselves). The investigator will instruct the patient to take the study drug exactly as specified in the protocol. Everolimus should be administered orally once daily, preferably in the morning, at the same time every day with our without food. Everolimus tablets should be swallowed whole with a glass of water. The tablets must not be chewed or crushed.~Everolimus will be administered orally as once daily dose of 10 mg continuously from study day 1 until progression of disease or unacceptable toxicity.~If vomiting occurs, no attempt should be made to replace the vomited dose. All dosages prescribed and dispensed to the patient and all dose changes during the study must be recorded."
223483167|NCT05627687|BEHAVIORAL|Music Listening Control|Listening to music using the Coffeehouse playlist on either Pandora or Spotify app, 10 minutes/day, 4-5 days per week
223483168|NCT02619188|OTHER|PUQE-form inclusion|PUQE-form encompassing last 24 hours completion
223483169|NCT02619188|OTHER|Nutritional form inclusion|Food-list form encompassing last 24 hours completion
223483170|NCT02619188|OTHER|Blood sampling inclusion|Measurement of biochemical nutrition marker(s); Prealbumin
223483171|NCT02619188|OTHER|Intervention at discharge|PUQE-form, nutritional form and Blood sampling
223483172|NCT05173311|BEHAVIORAL|Intervention arm|The intervention arm groups were instructed to use the Mole's Veggie Adventures mobile application for 3-4 weeks.
223483173|NCT04024137|DRUG|ZSP1273 200 mg|1 X 200-mg tablet taken orally
223483174|NCT04024137|DRUG|Placebo|2 tablets taken orally
223483175|NCT04024137|DRUG|ZSP1273-400 mg|2 X 200-mg tablet taken orally
223483176|NCT04024137|DRUG|Placebo|1 tablet taken orally
223483177|NCT04024137|DRUG|ZSP1273-600 mg|3 X 200-mg tablet taken orally
224205422|NCT02183701|DRUG|Telmisartan|
223483178|NCT04024137|DRUG|Placebo|3 tablets taken orally
223483179|NCT04024137|DRUG|Placebo|Subjects will receive matching placebo of ZSP1273
223483180|NCT01543854|DRUG|RLX030|Intravenous infusion of RLX030 over 20 hrs
223483181|NCT01543854|DRUG|Placebo|Intravenous infusion of placebo over 20 hours
223483182|NCT05689437|OTHER|Application of ILD prediction machine learning model to planning imaging|The ILD prediction machine learning model will be applied to the treatment planning imaging of lung cancer patients receiving radiation therapy (RT). The model will score the risk as high risk or low risk for having underlying ILD.
223483183|NCT05689437|OTHER|Routine, automatic presentation of ILD risk level for evaluation by the clinician.|Participating clinicians will be provided with an ILD risk estimate for all lung cancer patients receiving RT who are deemed potentially high-risk based on the model. In these cases, the clinician will receive an email identifying the patient medical record number (MRN) and 'potential high-risk for ILD' flag. Clinicians will then be able to decide whether, based on the information, they want to reassess the patient for ILD prior to starting treatment. Clinicians will also be presented with a short survey each time they are sent an email for a potential high-risk for ILD case so the study team can better understand how that information was used, if at all.
223483184|NCT05689437|OTHER|Application of SGR machine learning model to diagnostic and planning imaging|The SGR machine learning model will be applied to the imaging of lung cancer patients with node negative lung cancer receiving stereotactic RT. The automatic calculation will compare target lesions on the patient's diagnostic images with those same lesions on treatment planning images.
223483185|NCT05689437|OTHER|Routine estimation of tumor specific growth rate (SGR) for lesions being considered for radiation therapy presented to clinician.|Participating clinicians will be provided with an SGR calculation for each lung cancer patient with node negative lung cancer receiving stereotactic RT. This SGR calculation will be presented to clinicians, who will then be able to decide, based on the information, how they want to address and track a patient's overall survival and failure free survival. Clinicians will also be presented with a short survey each time they are provided with a patient's SGR calculation so the study team can better understand how that information was used, if at all.
223483186|NCT05689437|OTHER|Application of CBCT machine learning model to on-treatment imaging|The CBCT machine learning model will be applied to on-treatment imaging as part of routine care for patients with node positive lung cancer receiving standard RT. An indicator of lung density changes will be calculated automatically by comparing cone beam CTs (CBCTs) completed prior to each treatment.
223483187|NCT05689437|OTHER|Routine monitoring of lung density changes during the course of treatment presented to clinician.|Participating clinicians will be provided with a daily indicator of lung density changes for each patient with node positive lung cancer receiving standard RT. This measurement will be presented to the clinical team, who will then be able to decide, based on the information, how they want to address and track relevant outcomes such as pneumonitis. Additionally, this information may provide the clinical team with feedback about the lung reaction occurring as a result of treatment. Density changes will be documented and monitored for future validation studies, which are outside of the scope of this application.
223483188|NCT02419950|DEVICE|Fixation of mesh in TEP|An endoscopic operative technique were mesh for preperitonelal placement in patients with inguinal hernias can be fixated in Place or left without fixation
223483189|NCT00471965|DRUG|Oxaliplatin + 5-Fluorouracil/Leucovorin|"Day 1: Oxaliplatin 85mg/m² 2h IV infusion, leucovorin 200mg/m² 2h IV infusion, 5-fluorouracil 400mg/m² IV bolus, 5-fluorouracil 600mg/m2 22h IV infusion.~Day 2: Leucovorin 200mg/m² 2h IV infusion, 5-fluorouracil 400mg/m² IV bolus, 5-fluorouracil 600mg/m² 22h IV infusion.~Repeated every 2 weeks"
223483190|NCT00471965|DRUG|Doxorubicin|Day 1: Doxorubicin 50mg/m² iv infusion. Repeated every 3 weeks.
223483191|NCT06557681|DEVICE|Virtual Reality-Treadmill Training Group (VTT)|The Virtual Reality-Treadmill Training Group (VTT) will consist of 15 participants who will undergo 12 training sessions over 6 weeks, with each session occurring twice a week. Each session will include 30 minutes of conventional rehabilitation therapy followed by an additional 30 minutes of virtual reality-treadmill training. The sequence of these therapies can vary with each session. The virtual reality-treadmill training, conducted under the supervision of a therapist, will focus on five key components: precision stepping, obstacle negotiation, direction of progression, precision acceleration, and walking velocity. Evaluations of walking and balance abilities will be conducted before and after the intervention.
224205423|NCT02183701|DRUG|Losartan + Hydrochlorothiazide|
224205424|NCT02183701|DRUG|Placebo|
223483192|NCT06557681|OTHER|Conventional Therapy Group (CT)|The Conventional Therapy Group (CT) will consist of 15 participants who will undergo 12 training sessions over 6 weeks, with each session occurring twice a week. Each session will include 30 minutes of conventional rehabilitation therapy, aimed at improving walking and balance functions. The therapy will be administered by a therapist and may include exercises focused on muscle strength increase, gait training for step length and walking speed improvement, and balance training. Evaluations of walking and balance abilities will be conducted before and after the intervention.
223585558|NCT03719989|DRUG|azacitidine plus R-GDP|azacitidine S.C 25 mg/m2 D1,2,3,4,5 rituximab I.V. 375 mg/m2 D8 gemcitabine I.V. 1,000 mg/m2, D8,15 dexamethasone I.V. or P.O. 40 mg D8,9,10,11 every 21 days, up to 6 cycles
223585559|NCT04816318|OTHER|Social and public health measures against COVID-19|"1. Viral spread (for both outcomes) 1.1. Total lockdown 1.2 Partial lockdown (geographical, step-wise/graduated response) 1.3 Curfew 1.4 School closure 1.5 Closure of shopping malls, gyms, churches, parks 1.6 Remote work 1.7 Restrictions to national/subnational mobility 1.8 Prohibition of mass gatherings~2. Health systems response (for COVID-19 deaths outcome) 2.1 Interventions to increase testing capacity 2.2 Interventions to increase the number of ICU/critical beds~3. Mitigation strategies (for both outcomes) 3.1 Direct social assistance (in-kind/cash) 3.2 Cash transfer 3.3 Withdrawal of pension funds"
223585560|NCT04816318|OTHER|Control|The comparator is a counterfactual outcome defined as the projection of the pre-intervention trend to simulate what would have happened if the policy had not occurred (see Statistical Analysis Plan for definitions)
223585561|NCT05595733|DEVICE|Ventilator mode|Neurally Adjusted Ventilatory Assist (NAVA) mode is a new mode of ventilator, using electronic potential of diaphragm to adjust tidal volume. At the same time, this mode can trigger and cycle-off inspiratory time by high sensitivity of electronic potential of diaphragm, increase patient-ventilator synchrony, reduce sedative drug, improve oxygenation, shorten mechanical ventilation day and reduce the rate of diaphragm atrophy. It can improve survival rate and hospital day of patients. Both the animal and human experiment have the effect of lung and diaphragm protection.
224171124|NCT02931747|DIETARY_SUPPLEMENT|Placebo|Subjects are received Placebo once daily for 16 weeks.
224171125|NCT02931747|DIETARY_SUPPLEMENT|Bacopa Monnieri 300 mg/day|Subjects are received Bacopa Monnieri at the dose of 300 mg/day once daily for 16 weeks.
224171126|NCT02931747|DIETARY_SUPPLEMENT|Bacopa Monnieri 600 mg/day|Subjects are received Bacopa Monnieri at the dose of 600 mg/day once daily for 16 weeks.
224171127|NCT01815905|OTHER|Mobile program for occupational and speech therapy|
224171128|NCT01815905|OTHER|Traditional rehabilitation therapy|
224171129|NCT02822352|OTHER|Chromoendoscopy|High definition virtual chromoendoscopy
224171130|NCT04600453|OTHER|Physical Exercise|The intervention will consist of a multicomponent exercise training programme24, which will be composed of supervised progressive resistance exercise training, balance-training and walking for 4 consecutive days. During the training period, patients will be trained in 20 min sessions twice a day. The supervised multicomponent exercise training programme will be comprised of upper and lower body strengthening exercises, tailored to the individual's functional capacity, using weight machines and aiming for 2-3 sets of 8-10 repetitions at an intensity of 40-60 % of 1RM combined with balance and gait retraining exercises that progressed in difficulty and functional exercises, such as rises from a chair. The second part of the session will consist of functional exercises such as knee extension and flexion, hip abduction, balance movements, and daily walking in the hospital.
224171131|NCT01665898|PROCEDURE|Cold Biopsy forceps|removal of polyps using cold biopsy forceps
224171132|NCT01665898|PROCEDURE|Cold snare biopsy|Removal of colon polyps using cold snare biopsy
224171133|NCT04386473|DEVICE|pacemaker|electrode is implanted in left bundle branch in LBBP; electrode is implanted in right ventricular outflow tract septal in RVOP
224171134|NCT00198731|BEHAVIORAL|Care Seeking for Obstetric Complication|This is a descriptive study of knowledge, practices and outcomes related to maternal morbidity during pregnancy, childbirth and postpartum.
224171135|NCT00922038|BEHAVIORAL|Cash reward|Enrollees testing negative for treatable sexually transmitted infections will receive cash rewards.
224171136|NCT02280525|DRUG|Lenalidomide|2.5 mg by mouth daily on Day -2 to Day +14.
224171137|NCT02280525|DRUG|Rituximab|375 mg/m2 by vein on Day -5 for participants with B-cell cancer.
224171138|NCT02280525|DRUG|Fludarabine|"Lymphodepleting Chemotherapy Option #1: Fludarabine 25 mg/m2 by vein on Days -5 to -3.~Lymphodepleting Chemotherapy Option #2: Fludarabine 25 mg/m2 by vein over 1 hour on Day -6 to -2.~Lymphodepleting Chemotherapy Option #3: Fludarabine 30 mg/m2 by vein over 1 hour on Days -6 to -2"
224171139|NCT02280525|DRUG|Cyclophosphamide|"Lymphodepleting Chemotherapy Option #1: Cyclophosphamide 200 mg/m2 by vein on Days -5 to -3.~Lymphodepleting Chemotherapy Option #2: Cyclophosphamide 60 mg/kg by vein over 3 hours on Days -5 and -4."
223483193|NCT06216496|OTHER|dynamic test for amino acid metabolism|"Subjects are fasting, and the dynamic test is performed as follows:~Placement of 1 peripheral venous line (for infusions).~* H0-H1.5: infusion of a 10% glucose solution at increasing flow rate (3 steps of 30 min each: 0.06g/kg/h then 0.12g/kg/h then 0.25g/kg/h of glucose)~* H1,5: initial blood sampling (amino acid assay)~* H1.5-H4.5: infusion of amino acid solution (Aminoven 5%, Fresenius Kabi, Sèvres, France) at constant speed (flow rate 10.5 mg/kg/h of nitrogen or 1.30 ml/kg/H) in Y with glucose infusion (0.25g/kg/h of glucose)~* H4.5: Final blood sampling (amino acid assay) Each amino acid is plotted as a function of its perfusion rate on the abscissa and its variation in plasma concentration on the ordinate."
223483194|NCT00225030|DRUG|antihypertensive drugs according to current guidelines|
224171140|NCT02280525|PROCEDURE|NK Cells|"Participant assigned to a dose level of NK cells based on when joined study. Starting dose level of NK cells 1 x 10\^7 NK cells/kg given by vein on Day 0.~NK Cell Infusion Expansion Phase: Maximum tolerated dose of NK cells from Induction Phase."
224171141|NCT02280525|DRUG|Cytarabine|Cytarabine 2 mg/m2 by vein on Days -6 to -2.
224171142|NCT01761942|DIETARY_SUPPLEMENT|fatty acids preparation- eye-q|3x2 tablets daily by 70 days
224171143|NCT02913833|OTHER|Pain evaluation|Pain will be assessed four times per day on a visual analogic scale.
224171144|NCT03832166|OTHER|Fruits and Vegetables|Fruits and vegetables delivery, once/week for 24 weeks
224171145|NCT03832166|OTHER|Cooking|Nutrition education and cooking instruction class, one class/week for 6 weeks
224171146|NCT05354973|DEVICE|Consilium CareTM|This is an observational study using the Consilium CareTM smartphone ePRO application.
224171147|NCT03903276|OTHER|rehabilitation|Tens
224171148|NCT01542294|DRUG|s1|60-90mg/m2/d P.O. day 1-14, repeated every 21 days
224171149|NCT01542294|DRUG|Oxaliplatin|130mg/m2 d1 repeated every 21 days
224171150|NCT01512329|BEHAVIORAL|pacing|3 one-on-one sessions weekly for 3 consecutive weeks
224171151|NCT01512329|BEHAVIORAL|relaxation|3 one-on-one sessions weekly for 3 consecutive weeks
224171152|NCT04520867|OTHER|STRENGTH|Patients with esophageal (EC) and gastroesophageal junction (GEJC) cancers who are seen in the Esophageal and Gastric Multidisciplinary Clinic (EGMDC) for treatment planning and are recommended to receive neoadjuvant therapy and plan to receive treatment at UCCC Metro will be offered enrollment into the study. Patients will complete the patient reported assessments focused on QOL and physical activity on provided tablet computers during UCCC visits at specified time points. If unable to complete assessments in person they will be e-mailed to the patient via REDCap to complete. Additional data regarding dosing of chemotherapy, radiation, nutrition and surgical outcomes will be collected.
224171153|NCT02825940|DRUG|Atezolizumab|Atezolizumab will be administered at a dose of 1200 mg IV q3w (in 21-day cycles), except for participants with NSCLC who will be administered atezolizumab at a dose of 1200 mg IV on Day 1.
224171154|NCT02825940|DRUG|Gemcitabine|Gemcitabine will be administered to participants with NSCLC at a dose of 1250 mg/m\^2 on Days 1 and 8.
223483195|NCT04335864|PROCEDURE|Laparoscopic salpingectomy|39 patients with hydrosalpinx will have laparoscopic salpingectomy
224171155|NCT02825940|DRUG|Cisplatin|Cisplatin will be administered to participants with NSCLC at a dose of 75 mg/m\^2 on Day 1.
224171156|NCT04050475|DIETARY_SUPPLEMENT|Fasting Mimicking Diet|The Fasting Mimicking Diet is a low-calorie, five-day eating program meant to promote weight loss and provide the same benefits as more traditional fasting methods.
224171157|NCT03890497|BIOLOGICAL|IPV|The inactivated poliovirus vaccine (IPV) developed by Salk was the first available polio vaccine licensed in 1955 in the United States. The current formulation of IPV got licensed in 1987 and has a higher potency than the original Salk IPV. Almost 100% of children two months of age or older who receive 2-3 doses of intramuscular (IM) IPV achieve high antibody levels against the all three serotypes. IPV (.5mL) can be administered subcutaneously (SC) or IM and fractional (0.1 ml) doses of IPV are generally administered intradermally
224171158|NCT03746145|DIETARY_SUPPLEMENT|Bifidobacterium longum 1714|This is a double-blind randomized placebo-controlled pilot study. Participants under extreme conditions of hypoxia, confinement and isolation receive Bifidobacterium longum 1714 on a daily basis over one year in order to test improvements on stress resilience and immune functions.
224171159|NCT03746145|DIETARY_SUPPLEMENT|placebo sachet containing maltodextrin and magnesium stearate.|placebo sachet containing maltodextrin and magnesium stearate.
223483196|NCT04335864|PROCEDURE|Hystroscopic proximal tubal occlusion|39 patients with hydrosalpinx will have hysteroscopic proximal tubal occlusion
223483197|NCT03698461|DRUG|Atezolizumab|"* 1200mg IV on day1 before start of cycle 'atezolizuamb, bevacizumab + FOLFOX(Oxaliplatin, Levoleucovorin, 5-FU')~* 840mg IV D1 of C1-12 (Cycle: every 2 weeks)"
223483198|NCT03698461|DRUG|Bevacizumab|5mg/kg IV D1 of C1-12 (Cycle: every 2 weeks) at least 5 minutes after completion of atezolizumab
223483199|NCT03698461|DRUG|Oxaliplatin|85mg/m2 IV D1 of C1-12 (Cycle: every 2 weeks)
223483200|NCT03698461|DRUG|Levoleucovorin|200mg/m2 IV D1 of C1-12 (Cycle: every 2 weeks)
223483201|NCT03698461|DRUG|5-FU|"* 5-FU Bolus: 400mg/m2 IV bolus D1 of C1-12 (Cycle: every 2 weeks)~* 5-FU infusion: 2400mg/mg continuous IV infusion over 46hours D1-3 of C1-12 (Cycle: every 2 weeks)"
223483202|NCT03337126|DRUG|Metronidazole Tablet|Comparator Drug
223483203|NCT02552602|DIETARY_SUPPLEMENT|Multivitamin A|Multivitamin containing 7 micronutrients at recommended daily allowance (RDA)
223483204|NCT02552602|DIETARY_SUPPLEMENT|Multivitamin B|Multivitamin containing 22 micronutrients at RDA
224171160|NCT00576368|DRUG|INSULIN GLARGINE|The physician will be guided by the prescribing information outlined in the summary of product characteristics. The administration will be done by once daily subcutaneous injection.
224171161|NCT01223690|DRUG|Clarithromycin|1000 mg diluted into 250 ml of dextrose 5% administered intravenously within one hour of continuous infusion for four consecutive days
223483205|NCT02552602|DIETARY_SUPPLEMENT|Multivitamin C|Multivitamin containing 22 micronutrients at three times the RDA
223483206|NCT06412003|BEHAVIORAL|Home-based balance training|This is a family member supported home-based balance training program designed for community-dwelling people with MS to improve balance and walking abilities as well as cognitive functions. The intervention program aims to have participants with MS reach high-intensity balance tasks during the program. A bi-weekly two-on-one, semi-structured, video-chat session with participants and their exercise supporter and research team will be conducted using videoconferencing techniques (e.g., Zoom, Skype, or Facetime).
223483207|NCT03012776|DEVICE|Total Posterior Spine System (TOPS)|Placement of TOPS System to provide posterior stabilization following decompression to treat lumbar spinal stenosis and spondylolisthesis
223483208|NCT03012776|PROCEDURE|Transforaminal Lumbar Interbody Fusion (TLIF)|Fusion with placement of interbody cage and posterolateral instrumentation
223483209|NCT06425016|PROCEDURE|Laparoscopic Sleeve Gastrectomy (LSG)|Bariatric Surgery
224171162|NCT01223690|DRUG|Dextrose 5%|1000 mg diluted into 250 ml of dextrose 5% administered intravenously within one hour of continuous infusion for four consecutive days
224171163|NCT04537572|DIAGNOSTIC_TEST|comparison of sample collection methods|Samples will be collected via finger-stick, saliva collection, and traditional phlebotomy to determine effects on COVID-19 antibody test results.
224205425|NCT06070701|PROCEDURE|Superficial Parasternal Block (SIPB)|Immediately after induction of general anesthesia, ropivacaine 0.5% with dexamethasone 8mg/20ml (maximum dose 1.5 mg/kg ropivacaine per each side) is administered in the superficial parasternal intercostal plane using real-time ultrasound guidance.
224205426|NCT06070701|PROCEDURE|Erector Spinae Plane Block (ESPB)|Immediately after induction of general anesthesia, ropivacaine 0.5% with dexamethasone 8mg/20ml (maximum dose 1.5 mg/kg ropivacaine per each side) is administered in the plane deep to the erector spinae muscle, typically at the level of the 5th thoracic vertebra, under real-time ultrasound guidance.
223483210|NCT06425016|PROCEDURE|Robotic Sleeve Gastrectomy (RSG)|Bariatric Surgery
223483211|NCT00005663|DRUG|Valacyclovir hydrochloride|
223483212|NCT00315367|DRUG|Donepezil HCI (drug)|
224171164|NCT05469152|DIAGNOSTIC_TEST|ds-MCE and EGD|"Procedure of ds-MCE: The ds-MCE system mainly consists of two parts: the NaviCam magnetic capsule endoscopy guidance system and the detachable string part. The capsule, which is partially enclosed within the sleeve, can be actively moved in the esophagus through the control of string. Investigator can examine the entire esophagus several times under real time views. The capsule then could be detached from the string system through injecting air into the hollow string with the syringe after completing the examination of esophagus. Then, the examination of stomach under magnetic control and small bowel under the natural action of peristalsis follows.~Procedure of EGD: The EGD will be performed using conventional upper gastrointestinal video endoscopy, according to the standard procedure at individual centers. EGD will be performed within 48 hours after ds-MCE procedure and usually during the same endoscopic session."
224171165|NCT03566992|PROCEDURE|Gastric|Placement of a nasoenteric tube
224171166|NCT02152540|DEVICE|rTMS|Repetitive Transcranial Magnetic Stimulation
224171167|NCT02152540|DEVICE|Sham rTMS|Placebo Device that simulates active rTMS treatment
224171168|NCT05959915|DEVICE|device e-patch Implantation|"The ePatch device (Phillips) was used. This device is attached to the sternum, using a specific dressing adapted for the device itself. Manufacturer's recommendations for skin preparation and placement will be followed.~The device will remain in place for 4-5 days, at which time the patient will be readmitted for data extraction and reading.~The team of research nurses will analyze the data through the ePatch platform and later, the electrophysiologists will review the results and make a diagnosis."
223483213|NCT01789268|DEVICE|Respiratory Inductive Plethysmography|Respiratory Inductive Plethysmography (RIP) will be used to document thoracoabdominal motion, relative minute ventilation, and apnea during the minimally invasive respiratory assessments (NIRAs). Both Full and Preterm Infants will undergo a respiratory assessment via RIP prior to and after a bronchodilator (albuterol)
223483214|NCT04794998|DRUG|Recommended treatment schedule|Relatively selective Cox-2 inhibitors, Corticosteroids (Dexamethasone), Anticoagulants (LMW heparin), Gentle Oxygen therapy
223483215|NCT04794998|DRUG|Control treatment schedule|Treatment regimens different from the recommended one according to family phisicians personal practice.
223483216|NCT01319968|DRUG|Estriol 0.1% vaginal cream|Patients with both vulvovaginal atrophy (according to cytologic criteria) and dyspareunia will apply 0.5 ml of the cream (0.5 mg) to the vulvar vestibule once daily for one month and will return for check-up visit. In case both atrophy and dyspareunia will resolve, treatment with the cream will be continued 3 times a week.
223483217|NCT03200223|BEHAVIORAL|Personalized healthcare service|Personalized healthcare service, such as exercise recommendation, lifestyle activity coaching, health data monitoring
223483218|NCT03318562|DRUG|eFT508|200 mg eFT508 dosed BID for 3 week cycles
223483219|NCT02494011|OTHER|traditional exercise|mobilization stretching exercise
223483220|NCT02494011|OTHER|Russian current stimulation|stimulation to wrist flexors for 15 minutes
223483221|NCT02494011|OTHER|closed kinetic chain exercise|wall press exercise plyometric exercise
223585562|NCT04228601|DRUG|Fluzoparib|PARP
223585563|NCT04228601|DRUG|Fluzoparib placebo|Placebo
223585564|NCT04228601|DRUG|mFOLFIRINOX|mFOLFIRINOX
223585565|NCT00633828|BEHAVIORAL|Increased physical education in primary school (daily)|Increased physical education in primary school, 40 minutes per day
223483222|NCT05348434|PROCEDURE|3D printed polyether ether ketone facial implants in repairing maxillofacial deformities|All patients underwent Computed Tomography (CT) scans under the condition of providing a large number of slices (more than 200 slices) per axis, and the thickness of each slice is less than 1 mm with 64-bit resolution, Then the design of the required facial implant was carried out in coordination between the designer and the surgical team. The final form of the facial implant was printed from PolyEther Ether Ketone (PEEK), and then surgical work was performed for patients under general anaesthetic according to the appropriate surgical entrance. The implants were fixed in place using titanium screws
223483223|NCT02952417|OTHER|Excess mortality|Relative survival was defined as the observed survival among patients with STEMI and NSTEMI divided by the expected survival in the age, sex and year matched populace of Sweden.
223483224|NCT03409380|DIETARY_SUPPLEMENT|Arginine Drink|10 g of arginine in a formulated drink
223585566|NCT05433597|DRUG|5-fu|5-fu: 200mg/m2/d, continuous intravenous infusion on the 1st to 30th day of each cycle.
223585567|NCT05433597|DRUG|Cisplatin|Cisplatin: 80mg/m2, used on the 1st and 28th day of each cycle.
223585568|NCT05433597|RADIATION|Radiotherapy|Radiotherapy: Radiotherapy was initiated on day 15 of the first cycle of chemotherapy . GTV: 6810cGy (227 cGy/30f) Or 6996 cGy (212 cGy/ 33F); CTV: 5400-6000 cGy (180-200 cGy/f); Radiotherapy once a day, 5 times a week, a total of 30-33 times, a total of about 6 weeks.
224171169|NCT03942172|DEVICE|SpotOn balance glasses|SpotOn Balance Glasses comprising of personalized visual stimuli placed on the glasses's lenses
224171170|NCT04853056|DEVICE|virtual reality|wearing virtual reality glasses
224171171|NCT04853056|DEVICE|Cold vibration|Buzzy
224171172|NCT02812615|DIETARY_SUPPLEMENT|Egg|After enrollment, participants will receive one large egg 6 days a week for 3, 2 and 2 months for stunted children, children at risk of stunting, and malnourished adults, respectively.
224171173|NCT02812615|DIETARY_SUPPLEMENT|Milk|After enrollment, participants will receive 150ml of milk 6 days a week for 3, 2 and 2 months for stunted children, children at risk of stunting, and malnourished adults, respectively.
224205427|NCT06070701|DRUG|General anesthetic|During general anesthesia, fentanyl is administered according to NOL monitoring.
223585569|NCT05433597|DRUG|TNF|TNF (recombinant human tumor necrosis factor for injection) : 1 million IU (BSA\<2.0m2) or 1.5 million IU (BSA≥2.0m2), dissolved in normal saline 1-2mL, intramuscular, QD, 30 days in the first and third months, once a day.
223585570|NCT05433597|DRUG|Placebo|Placebo: 1-2ml normal saline, intramuscular injection, QD, once a day, 30 days in the first and third months.
223585571|NCT06254859|PROCEDURE|Traditional thyroid surgery.|The patient undergoes traditional thyroid surgery with concurrent intraoperative nerve monitoring technology.
223585572|NCT06848023|PROCEDURE|Reverse Total Shoulder Arthroplasty|standard of care treatment reverse total shoulder arthroplasty delivered
223585573|NCT06848023|PROCEDURE|Rotator Cuff Repair|standard of care treatment rotator cuff repair delivered
223585574|NCT06338202|DRUG|Mavacamten|As detailed in the product label
224171174|NCT02812615|DRUG|Albendazole/Pyrantel Pamoate|As per the national guidelines, treatment will be provided based with 200 mg of Albendazole or 10mg/kg Pyrantel Pamoate single dose if the participants have not been treated for helminths in the preceding three months.
224171175|NCT02812615|BEHAVIORAL|Nutritional counselling|Parents/caregivers will be given nutritional counselling
224171176|NCT02812615|DIETARY_SUPPLEMENT|Micronutrient sprinkles|For the child cohort, one sachet of multiple micro-nutrient sprinkles per day to be administered with the mid-day meal for two months
224171177|NCT01012037|DRUG|linagliptin low dose|patient to receive tablets containing low dose linagliptin twice daily
224171178|NCT01012037|DRUG|placebo|patient to receive placebo tablet(s) matching linagliptin
224171179|NCT01012037|DRUG|linagliptin medium dose|patient to receive a tablet containing medium dose linagliptin once daily
224171180|NCT02583711|DEVICE|Activity sensor (3 axis accelerometer)|Patient cohort will wear the activity sensor from pre-admission clinic until discharge after surgical procedure
224171181|NCT05675475|OTHER|Exposure|Higher education students from health technologies field exposed to digital devices.
224171182|NCT05675475|DIAGNOSTIC_TEST|Orthoptic assessment (Outcome measure)|The orthoptic assessment is a non-invasive assessment that will last for 30 min to determine visual parameters related to binocular vision. It will be carried out by the research team in the orthoptics and vision sciences laboratories of the Lisbon School of Health Tecnology.
224171183|NCT05675475|DIAGNOSTIC_TEST|Tear film Break Up Time (BUT) test (Outcome measure)|The BUT test is a tear film rupture assessment test that allows the stability of the tear film to be evaluated. To perform these tests, it is necessary to instill fluorescein and then it is observed in the slit lamp under illumination with a cobalt blue filter, to count the break-up time.
223483225|NCT03409380|DIETARY_SUPPLEMENT|Plain Drink|formulated drink
223483226|NCT03555799|DIAGNOSTIC_TEST|Inferior vena cava ultrasound|Abdominal ultrasound to identify IVC between hepatic veins and right atrium. Measurement of dimensions throughout respiratory cycle (before and after labor epidural)
223483227|NCT04154956|DRUG|SAR408701|Pharmaceutical form: Concentrate for solution for intravenous infusion Route of administration: intravenous (IV) infusion
223483228|NCT04154956|DRUG|Docetaxel|Pharmaceutical form: Concentrate for solution for intravenous infusion Route of administration: IV infusion
223483229|NCT02041572|BEHAVIORAL|Attentional bias retraining|Participants complete a computer-based intervention, which is designed to correct cognitive biases associated with PTSD by training to attend to neutral information rather than the trauma-related cue words.
223585575|NCT06293976|OTHER|Changes in the ventilator respiratory rate and tidal volume|"With the ventilator on volume control and Vt at 6 ml/kg of predicted body weight (PBW) (standard clinical practice), an end-expiratory occlusion of 30 seconds on the ventilator will be performed to search for intrinsic respiratory rate (RR). The set RR will be modified from 6 breaths per minute (bpm) below up to 6 bpm above the clinical RR in steps of 2 bpm every 1 minute (random order). The changes in RR described above will be repeated with Vt set at 5, 7 and 8 ml/kg PBW (random order). The steps described above will be aborted at any point if SpO2 drops below 85% for at least two minutes, mean arterial pressure drops below 60 mmHg, or plateau pressure \>35 cmH2O.~If an intrinsic respiratory rate ≥8 bpm is present and P/F ratio is ≥150, it will be propose to the clinician to place the patient in pressure support at a level preferred by clinicians for 5 minutes. If the patient tolerates well, it will be propose to the clinician to maintain the patient in pressure support ventilation,"
223585576|NCT05294081|BEHAVIORAL|Exposure therapy|10 sessions based on an individualized pain hierarchy
223585577|NCT05294081|BEHAVIORAL|Cognitive behavioral therapy|10 sessions with graded activity, relaxations techniques and cognitive interventions
223585578|NCT03599245|DRUG|Ocrelizumab|Participants will receive a 600-mg infusion of Ocrelizumab every 24 months for two years.
223585579|NCT05791240|BEHAVIORAL|Family Initiated Interpretation|Interpreter tablet will be given to families so they can contact an interpreter themselves.
223585580|NCT05819892|DRUG|Paclitaxel|Given by IV (vein)
223585581|NCT05819892|DRUG|Carboplatin|Given by IV (vein)
223585582|NCT05819892|DRUG|Dostarlimab|Given by IV (vein)
223585583|NCT05819892|DRUG|Cisplatin|Given by IV (vein)
223585584|NCT04795050|BEHAVIORAL|Project POWER|Diabetes health promotion/cardiovascular disease risk reduction educational curriculum
224171184|NCT02237898|BEHAVIORAL|MoMba Live Long app & Sensordrone™ carbon-monoxide sensor|MoMba Live Long application \& Sensordrone™ carbon-monoxide sensor to deliver contingency management remotely
223483230|NCT01859741|DRUG|OMP-59R5|OMP-59R5 administered intravenously
223483231|NCT01859741|DRUG|Etoposide|administered intravenously
223483232|NCT01859741|DRUG|Placebo|administered IV
224171185|NCT02237898|BEHAVIORAL|Office contingency management|A control group which will receive financial incentives at an in-person office/clinic visit based on expired CO levels obtained through the piCO sensor.
224171186|NCT02237898|DEVICE|Sensordrone™ carbon-monoxide sensor|A custom breath CO meter built by Sensorcon Inc. (Sensordrone, part No. SDRONEG1) that uses an electrochemical CO gas sensor to measure environmental CO. The Sensordrone is accurate to within 10% with a resolution of 1 parts per million (ppm). The Sensordrone pairs via Bluetooth with the MoMba Live Long application.
224171187|NCT02237898|DEVICE|MoMba Live Long Smartphone application|The MoMba Live Long app provides an interface for the Sensordrone which allows participants to complete a breath test and see results of smoking status. The app verifies the user is correctly taking the tests by recording pictures using the front facing camera as well as recording audio to verify that the participants where exhaling while taking the test. The app also provided a platform for social interaction based on a previous system where app users can interact with each other and provide support during the quitting process.
224171188|NCT02282930|DRUG|ACTH (Acthar) Gel|Injected dose of 80 units subcutaneously twice weekly for 6 months.
223483233|NCT01859741|DRUG|Cisplatin or Carboplatin|administered intravenously
223483234|NCT05169905|COMBINATION_PRODUCT|RSV MAT vaccine|"Single dose of the RSV MAT vaccine reconstituted with NaCl solution was planned to be administered intramuscularly, in the non-dominant arm, at Day 1 or at Day 31, depending on the vaccination schedule.~RSV MAT vaccine was no longer administered to participants at Day 31. No vaccine was administered in the dTpa\_RSV-P Group, since there were no participants assigned to it."
224171189|NCT01480791|DRUG|Aliskiren vs. hydrochlorothiazide|Aliskiren will be used at increasing doses from 150 to 300 mg per day for 6-12 months.
224171190|NCT01480791|DRUG|Hydrochlorothiazide|Hydrochlorothiazide will be used at increasing doses from 12.5 to 25 mg per day for 6-12 months.
224171191|NCT06330766|PROCEDURE|No preoperative dental screening|Discontinuance of mandatory preoperative dental screening prior TAVI which also can include oral surgery.
224171192|NCT00442130|BIOLOGICAL|GM-K562 vaccine|The vaccine will be administered over 1 cycle of 7 weeks, that begins 1 month after stem cell transplant. The vaccine will be given 6 times over 2 months -- once a week for three weeks then every other week for 3 vaccines.
224171193|NCT00442130|PROCEDURE|stem cell transplantation|Participants will be admitted to the hospital for approximately 8 days to receive chemotherapy and stem cell transplantation
223483235|NCT05169905|COMBINATION_PRODUCT|dTpa vaccine|"Single dose of the dTpa vaccine was planned to be administered intramuscularly, in the non-dominant arm, at Day 1 or at Day 31, depending on the vaccination schedule.~Two formulations of dTpa vaccine are licensed in the US and outside of the US (ex-US), respectively. dTpa-US formulation was administered to participants in centers located in the US, while dTpa-ex-US formulation was planned to be administered to participants in centers ex-US. The dTpa-ex-US formulation was not applicable in this study anymore as no non-US sites were initiated before the decision to stop the study.~The participants in RSV\_dTpa-P and RSV\_dTpa-A study groups were provided with an option to decide to receive dTpa vaccination as part of standard of care/local recommendation on immunization.~No vaccine was administered in the dTpa\_RSV-P Group, since there were no participants assigned to it."
223483236|NCT02412657|DRUG|Dexamethasone|After the performance of inter scalene plexus blockade, patients will either receive dexamethasone 10 mg i.v. (diluted with 17.5 mL normal saline), dexamethasone 4 mg i.v. (diluted with 19 mL normal saline), or normal saline 20 ml i.v.
223483237|NCT02412657|DRUG|Normal Saline|
223483238|NCT03419650|DRUG|ACTHar|Acthar™ 80 units twice a week for 4 weeks followed by 40 units twice a week until week 12.
223483239|NCT03823131|DEVICE|ImmunoPulse|Intratumoral
223483240|NCT03823131|DRUG|Epacadostat|Given PO
223483241|NCT03823131|DRUG|Pembrolizumab|Given IV
223483242|NCT03823131|BIOLOGICAL|CORVax|Intratumoral
223483243|NCT03823131|DRUG|Tavokinogene telseplasmid|Intratumoral
223483244|NCT01842204|DEVICE|Magnetic field therapy device|Therapy device for 1 week.
223585585|NCT05822011|PROCEDURE|Rhomboid intercostal subserratus plane block|Fascial plane block
223585586|NCT05822011|PROCEDURE|Erector spinae plane block|Fascial plane block
223585587|NCT04969341|OTHER|Survey Administration|Complete survey
223585588|NCT04969341|OTHER|Electronic Health Record Review|Review of medical records
223585589|NCT05503225|DRUG|Colchicine 0.5 MG|0.5mg Orally Taken Colchicine
223585590|NCT06960655|BEHAVIORAL|Referral to Pharmacist-Driven Medication Management Program|Medication initiations and titrations are based on an established drug-treatment algorithm that utilizes a statutory-defined Collaborative Drug Therapy Management Agreement (CDTM) approved by the BWH Pharmacy and Therapeutic Committee to initiate and titrate lipid-lowering medications. Scenarios outside the prescribed medication algorithm are routed to the supervising physician, and changes are signed off by a pharmacist and communicated to the patient and care team by a patient navigator under the supervision of physicians. After each change in medication, re-assessment and lab monitoring are collected in an iterative process until targets are achieved. Details of the programs can be found in the references.
223483245|NCT01842204|DEVICE|Non magnetic field therapy device.|Non-active device for 1 week.
223483246|NCT03099525|OTHER|ILD|This is an observational study without any intervention.
223483247|NCT05624853|DRUG|pregabalin sustained release tablet|pregabalin sustained release tablet 150mg qd for 8weeks
223483248|NCT05624853|DRUG|pregabalin immediate release capsule|pregabalin immediate release capsule 75mg bid for 8weeks
223483249|NCT06401291|DEVICE|Transcutaneous Electrical Nerve Stimulation|Device consists of two electrodes that are applied to the chest region and are connected to a battery operated TENS (Frequency 80Hz, pulse width 150us and amplitude variable (patient dependent)). The device will be used a minimum of three times daily for 30 minutes and additionally during symptoms.
223483250|NCT03620162|BIOLOGICAL|Prevnar 13™|Prevnar 13™ contains the pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F (2.2 mcg each) and 6B (4.4 mcg) in each 0.5 mL dose given via IM injection.
223483251|NCT03620162|BIOLOGICAL|V114|V114 contains the pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19F, 19A, 22F, 23F, 33F (2 mcg each), and serotype 6B (4 mcg) in each 0.5 mL dose given via IM injection.
223483252|NCT03620162|BIOLOGICAL|RotaTeq™|RotaTeq™ live, pentavalent Rotavirus vaccine given as background treatment via oral solution.
223483253|NCT03620162|BIOLOGICAL|Pentacel™|Pentacel™ Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus b Conjugate (Tetanus Toxoid Conjugate) Vaccine, given as background treatment via IM injection in the opposite limb to V114 and Prevnar 13™ administration.
224171194|NCT04884386|DEVICE|robot-assisted gait training|RAGT, WALKBOT-G, is a walking training equipment that can reproduce natural motions by adjusting the leg length and adjusting the motion with the actuator of the ankle joint.
224171195|NCT04884386|BEHAVIORAL|conventional locomotion therapy|locomotion exercise, postural control training, balance training, electrotherapy
224171196|NCT01060124|DRUG|Fentanyl D-trans|Fentanyl D-trans will be applied as transdermal patch releasing drug at the rate of 12.5 microgram per hour (mcg/hr) for 3 days with a dose ranging from 12 mcg/hr to 50 mcg/hr.
224171197|NCT04432181|OTHER|ophthalmic examination|ophthalmic examination including; best corrected visual acuity, alternating prism cover test, retinoscopy, fundus examination, ocular vergence evaluation
224171198|NCT05557136|DEVICE|Multistranded stainless steel fixed retainer|Multistranded stainless steel fixed retainer is used for orthodontic patient after completion of orthodontic treatment to achieve stability of alignment.
224171199|NCT05557136|DEVICE|Polyether-Ether-Ketone (PEEK) fixed retainer|Polyether-Ether-Ketone (PEEK) fixed retainer is used for orthodontic patient after completion of orthodontic treatment to achieve stability of alignment.
224171200|NCT04135664|PROCEDURE|esophagectomy|esophagectomy with at least two-field (thoracic-abdominal) lymphadenectomy
224171201|NCT04135664|COMBINATION_PRODUCT|chemoradiation|concurrent chemotherapy and radiotherapy
224171202|NCT04135664|OTHER|active surveillance|No further adjuvant therapy
224171203|NCT03273699|DEVICE|Mindfulness|Clients will use a consumer grade EEG device that provides guided mindfulness home practices
224171204|NCT03939858|PROCEDURE|Cognitive Assessment|Tests have been selected to represent a range of cognitive functions affected by cancer and radiotherapy including basic attention, recent memory, executive functions (spanning verbal fluency, cognitive set-shifting, and abstract reasoning), and visual perceptual/spatial skills.
224171205|NCT03939858|DIAGNOSTIC_TEST|Blood Collection|16 ml of blood will be collected before 10 a.m. and after the participant has fasted for 8 hours. White blood cells and platelets will be used for respirometric analysis. Plasma will be additionally processed and saved in 500uL aliquots(x2) and the remainder in 1mL aliquots at -80°C.
223483254|NCT03620162|BIOLOGICAL|RECOMBIVAX HB™|RECOMBIVAX HB™ Hepatitis B Vaccine (Recombinant), given as background treatment via IM injection in the opposite limb to V114 and Prevnar 13™ administration.
223483255|NCT03620162|BIOLOGICAL|HIBERIX™|HIBERIX™ Haemophilus b Conjugate Vaccine (Tetanus Toxoid Conjugate), given as background treatment via IM injection in the opposite limb to V114 and Prevnar 13™ administration.
223483256|NCT03620162|BIOLOGICAL|M-M-R™ II|M-M-R™ II (Measles, Mumps, and Rubella Virus Vaccine Live), given as background treatment via subcutaneous (SC) injection in the opposite limb to V114 and Prevnar 13™ administration.
223483257|NCT03620162|BIOLOGICAL|VARIVAX™|VARIVAX™ Varicella Virus Vaccine Live, given as background treatment via SC injection in the opposite limb to V114 and Prevnar 13™ administration.
224171206|NCT03939858|DIAGNOSTIC_TEST|Bioenergetic Profiling|Peripheral blood mononuclear cells (PBMCs) and platelets will be separated from the blood. Primary respirometric parameters will be measured with high-throughput respirometry using the Agilent Seahorse 24XFe. Additional parameters will be collected with high-resolution respirometry using the OROBOROS Oxygraph-2k. Both methods will report a variety of mitochondrial parameters resulting in 48 measures per participant, creating robust profiles of bioenergetic health. Additional analysis will include western blots to enumerate protein density for the five major mitochondrial complexes, mtDNA copy number analysis, and citrate synthase activity as these assays provide different but complementary data to respirometry for a more dynamic picture of mitochondrial metabolism.
224171207|NCT03937739|OTHER|Nutritional and constipation questionnaire|Alcohol and smoking habits, daily activity, frequency of food consumption and the constipation scoring according to Agachan et all. were examined using questionnaire
224171208|NCT00974727|OTHER|Garden Fit|8-week summer gardening program. 9am-12pm on Monday, Wednesday, Friday and 9am-12:30pm on Tuesday and Thursday. Activities included gardening (preparing soil for planting, planting seeds and seedlings, mulching, weeding, watering, and harvesting), preparing meals with fresh foods from the garden, and other garden activities and games.
224171209|NCT01267682|BEHAVIORAL|Cognitive Stimulation|Thirty minutes of cognitive stimulation delivered daily for thirty minutes.
224171210|NCT04526262|DEVICE|transcranial magnetic resonance guided focused ultrasound BBB disruption|The ExAblate BBB disruption procedure will be performed with ExAblate 4000 type 2.0 system, and this will be performed twice every 3 months.
224171211|NCT05351970|PROCEDURE|Barbed|Efficacy of barbed and monofilament closure regarding incisional hernia
224171212|NCT00758576|DEVICE|ACRYSOF Multifocal Single-piece Intraocular Lens (IOL) Model SN6AD1|Implantation with the AcrySof ReSTOR Intraocular Lens (IOL) Model SN6AD1 following cataract removal.
224171213|NCT01489449|DEVICE|Stent|bare metal stent implantation, any bare metal stent is allowed from different companies
224171214|NCT01489449|COMBINATION_PRODUCT|SeQuent(R) Please coated balloon|Angioplasty with Drug coated balloon (DCB)
224171215|NCT00514059|DRUG|Boostrix polio|1 dose (0.5 ml) i.m.
224171216|NCT05644782|OTHER|Open wheat challenge|Patients randomized to intervention diet group will have to follow a diet with elimination of wheat and cow's milk products for 2 months; after that they will be exposed to an open wheat challenge, with reintroduction of wheat. After 2 weeks of open diet, or whenever dermatologic, intestinal and/or extraintestinal symptoms should return or intensify, all patients will be revaluated and will end the study.
224171217|NCT05644782|OTHER|Placebo challenge|Patients randomized to control diet group will have to follow a diet with elimination of rice and turkey's meat products for 2 months; after that they will crossover to a wheat and cow's milk products free diet and, finally, after 2 months, they will be exposed to an open wheat challenge, with reintroduction of wheat. After 2 weeks of open diet, or whenever dermatologic, intestinal and/or extraintestinal symptoms should return or intensify, all patients will be revaluated and will end the study.
223483258|NCT06447974|BEHAVIORAL|Exposure mitigations|Behavioural interventions with an aim to reduce exposure by targeting occurrences of high exposure
223585591|NCT06960655|BEHAVIORAL|Best-Practice Alert|This strategy will employ automated, asynchronous, best-practice alerts (BPAs). Provider notifications via electronic health records (EHRs) are clinical tools designed to improve adherence to evidence-based guidelines by providing real-time alerts that have been widely implemented across healthcare systems to enhance patient safety, reduce clinical inertia, and standardize care delivery. However, their effectiveness depends on factors such as alert fatigue, provider engagement, and integration into existing workflows. BPAs are one of the most common types of automated EHR-based provider notifications.
223483259|NCT00952198|DRUG|ARRY-403, glucokinase activator; oral|multiple dose, escalating
223483260|NCT00952198|DRUG|Placebo; oral|matching placebo
223483261|NCT03777241|BEHAVIORAL|Behavioral Intervention Team|Multidisciplinary team to assist with actively identifying and managing mental illness and substance abuse disorders at their earliest possible time during hospitalization.
223483262|NCT03777241|BEHAVIORAL|Standard of care|Participants in this group will receive standard of care.
223483263|NCT02515474|PROCEDURE|Laparoscopy|After removing the gallbladder, Laparoscopic common bile duct exploration (LCBDE) was performed by one fulltime attending in laparoscopy in a routine fashion. Access from the opening of the anterior wall of common bile duct or from the dilated cystic duct was acceptable, removed stone(s) and irrigated the duct followed by choledochoscope detection simultaneously. Cholangiograms were also can be a alternative method to obtain stone clearance. If needed, all fluoroscopy was performed by the principal author in the presence of and concurrence with the ERCP endoscopist. Once the LCBDE was completed, the incision of the bile duct was sewed intermittently by absorbed threads, or ligated cystic duct. T-tube was acceptable if needed.
223483264|NCT02515474|PROCEDURE|Endoscopy|Initially endoscopic retrograde cholangiopancreatography (ERCP) was performed by a fulltime attending and concurrence of the principal author in endoscopy. Patients randomized to ERCP+ LC group were scheduled to undergo the endoscopic procedure using fluoroscopy in the endoscopy center under moderate sedation (principally intravenous midazolam and meperidine) prior to the intended laparoscopy. Gastric intestinal atony during ERCP was routinely achieved using scopolamine butylbromide injection. Sphincterotomy (EST) and Endoscopic papillary balloon dilatation (EPBD) can be choose accordingly. The laparoscopic cholecystectomy was subsequently performed as soon as technically feasible following the ERCP in one month.
224171218|NCT03193918|DRUG|Crenolanib|Crenolanib continuously on Days 1-28 at 1 of 3 BID doses - 60 mg, 80 mg or 100 mg
224171219|NCT03193918|DRUG|Ramucirumab|Ramucirumab IV 8 mg/kg on Days 1 and 15 q28 days
224171220|NCT03193918|DRUG|Paclitaxel|Paclitaxel IV 80 mg/m2 on Days 1, 8 and 15 q28 days
224171221|NCT01855919|DRUG|Duloxetine|Administered orally
224171222|NCT01855919|DRUG|Placebo|Administered orally
224171223|NCT03065010|DRUG|BCD-115|Inhibitor of CDK8/19
224171224|NCT04459416|OTHER|Acupuncture|Acupuncture treatments will be scheduled to cover the period of high symptom burden. Acupuncture will start on Day 0 and continue once daily to Day 15, as long as the patient is inpatient or comes to the clinic for post-transplantation follow-up. Electrical stimulation (e-acupuncture) may be applied to the ST36 and SP6 points when appropriate as per standard acupuncture practice.
224171225|NCT04459416|DRUG|opioid|All study patients will receive the usual HSCT care and pain management regimens (usually opioids) as per standard practice at the study institution.
224171226|NCT04459416|OTHER|Assessments|Participants will be asked to complete patient reported outcomes assessments online using REDCap or, If they prefer, via pencil and paper or over the phone. Assessments at baseline (within 4 weeks before HiChemo) and on or about days 7, 15, 30, and 90 after the first dose of HiChemo.
224171227|NCT05953961|DEVICE|Therasphere 90Y|Transarterial Radioembolization
224171228|NCT05953961|DEVICE|Microwave Ablation|Microwave Ablation
224171229|NCT06109363|BEHAVIORAL|Cognitive behavioral therapy for insomnia (CBT-I)|CBT-I intervention will be provided to participants once their districts are exposed.
224171230|NCT05910320|DEVICE|Wearable Vital Signs Monitoring Device|The prototype will be used to non-invasively measure vital signs. This prototype (preliminary version) is composed of a sensor module, a rechargeable battery, and electrodes. The device is housed in a waterproof, silicone casing.
224171231|NCT05680545|OTHER|Sevoflurane vaporized in ECMO machines|Sevoflurane will be directly vaporized into the ECMO machine through the sweep gas.
224171232|NCT05493982|BEHAVIORAL|Stanford Vaping Prevention curriculum|Stanford vaping prevention curriculum delivered as a 5-session course administered in a school classroom setting.
224171233|NCT04083963|DRUG|Carboplatin|Low dose weekly carboplatin (AUC 2) will be combined with weekly paclitaxel for 12 weeks.
224171234|NCT04083963|DRUG|Paclitaxel|Paclitaxel will be given weekly along with carboplatin for 12 weeks.
224171235|NCT04083963|DRUG|Doxorubicin|Dose dense doxorubicin will be administered in combination with cyclophosphamide for 4 cycles after weekly carboplatin/paclitaxel.
224171236|NCT04083963|DRUG|Cyclophosphamide|Does dense cyclophosphamide will be in combination with doxorubicin for 4 cycles after weekly carboplatin/paclitaxel.
224171237|NCT03455530|OTHER|Industrial Hygiene-Enhance Community Health Worker Intervention|The intervention will be derived from audits and exposure assessments and focus groups with workers and owners in the same business types (excluded from the trial) conducted in an earlier part of the study, as well as a community advisory group (e.g., Hispanic Chamber of Commerce) . From this, we will generate educational materials specific for each small business sector. We will provide the CHWs with a list of industry-specific control options along with potential cost savings and benefits. For example, EPA estimates a cost saving of $13,000 per year for auto body shops that switch to the high-velocity low-pressure spray guns. Each list will be a comprehensive menu of options that contain multiple control measures including simple controls, such as keeping the lids on the solvent containers.
224171238|NCT01747447|DIETARY_SUPPLEMENT|Vitamin D3 placebo|Vitamin D placebo
224171239|NCT01747447|DIETARY_SUPPLEMENT|Fish oil placebo|Fish oil placebo
224171240|NCT01747447|DIETARY_SUPPLEMENT|omega-3 fatty acids (fish oil)|Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid \[EPA\] and 375 mg of docosahexaenoic acid \[DHA\]).
223483265|NCT00437463|DRUG|Ramipril|2.5mg and increase to 5mg if patient do not develop symptomatic hypotension
223483266|NCT04429958|OTHER|GDM|different degrees of hyperglycaemia during pregnancy
224171241|NCT01747447|DIETARY_SUPPLEMENT|Vitamin D3|Vitamin D3 (cholecalciferol), 2000 IU per day.
224171242|NCT04898153|DEVICE|aXess|Patients will be implanted with one Xeltis hemodialysis access device (aXess) in the arm
224171243|NCT06506097|BEHAVIORAL|Family-school Partnership Intervention (FSPI)|"FSPI includes implementation activities across multiple levels.~FSPI Planning Team Meetings will be held monthly to plan project activities, practice staff and parent coaching strategies, and troubleshoot implementation challenges.~FSPI Staff Training (3 hours) will be provided during a single professional development day (3 hours), and attended by members of the FSPI Planning Team and teachers.~FSPI Playgroups. Over the course of the school year, each parent-child dyad will be invited to participate in three FSPI Playgroup events. Typically, teachers from two classrooms will collaborate in hosting playgroup events, and each playgroup will be attended by four parent-child dyads (i.e., two per classroom). Teachers will be provided with a curriculum and learning outcomes to target.~FSPI Debrief Meetings are held after each FSPI Playgroup to debrief, reflect, and improve FSPI implementation."
224171244|NCT06213649|DRUG|Polyhexamethylene biguanide (PHMB)|PHMB is a cationic antiseptic agent used for topical treatment of acanthamoeba keratitis (AK). Both treatment groups will take PHMB at least 4 times daily while on the allocated study drug.
223585592|NCT05766839|DRUG|Patiromer|Patiromer will be given once daily; In Cohort 3, depending on the dose and the study participant's age, the total daily dose might be split
223585593|NCT03790631|OTHER|The study is observational.|The study is observational.
224171245|NCT06213649|DRUG|Topical corticosteroid|Dexamethasone sodium phosphate, 0.1% ophthalmic solution will be administered 4 times daily for 4 weeks, then 2 times daily for 2 weeks, then 1 time daily for 2 weeks.
223585594|NCT04158154|OTHER|Evidence-based fixed-dose combination protocol based treatment|The intervention has been adapted based on a local needs' assessment including exploration of health care workers and patient's knowledge, attitudes, and behaviors related to HTN, causes, consequences, and treatment. Implementation pathways have been developed with particular attention to overcoming modifiable barriers to HTN treatment and control across capability, intentional, and system domains using CFIR. Sites will randomly be assigned to receive either: Step 1 amlodipine 5mg; Step 2 amlodipine 5 mg + losartan 50 mg (as 2 separate pills); Step 3 amlodipine 10 mg + losartan 100 mg (as 4 separate pills); Step 4 amlodipine 10/losartan 100/HCTZ 25 (as 2 single pill combo) or Step 1 amlodipine 5mg; Step 2 amlodipine 5 mg + losartan 50 mg (as 1 single pill combo); Step 3 amlodipine 10 mg + losartan 100 mg (as 2 single pill combo); Step 4 amlodipine 10/losartan 100/HCTZ 25 (as 2 single pill combo).
223585595|NCT06038383|DEVICE|Group A - Intervention with Virtual Reality (VR)|Group of people with kidney disease that performed VR intervention during hemodialysis.
223585596|NCT06038383|DEVICE|Group B - Intervention with Stationary Bike (SB)|Group of people with kidney disease that performed SB intervention during hemodialysis.
223585597|NCT06038383|DEVICE|Group A - Intervention with Stationary Bike (SB) - Crossover|Group of people with kidney disease that performed SB intervention during hemodialysis after the washout period.
223745028|NCT04366037|OTHER|Routine training + proprioceptive exercise in warm-up|"Training will be defined by each club coach, adding four proprioceptive exercises in warm-up:~Exercise Description Duration Antero-posterior bipodal horizontal jump Players will jump forward and backward with both feet together, keeping their hands on their waists 30 seconds Unipodal lateral jump Players will perform single-leg lateral jump on both sides of a previously drawn line on the ground, and keeping their hands on their waists. 30 seconds per limb.~Antero-posterior unipodal horizontal jump Players will jump forward and backward with one foot, keeping their hands on their waists 30 seconds per limb.~Bipodal vertical jump with or whitout ball. Players will perform vertical jumps with both feet carrying a ball in their hands (this added difficulty will be optional). 30 seconds"
223745029|NCT04366037|OTHER|Routine training + proprioceptive exercise in cool-down|"Training will be defined by each club coach, adding four proprioceptive exercises in cool-down:~Exercise Description Duration Antero-posterior bipodal horizontal jump Players will jump forward and backward with both feet together, keeping their hands on their waists 30 seconds Unipodal lateral jump Players will perform single-leg lateral jump on both sides of a previously drawn line on the ground, and keeping their hands on their waists. 30 seconds per limb.~Antero-posterior unipodal horizontal jump Players will jump forward and backward with one foot, keeping their hands on their waists 30 seconds per limb.~Bipodal vertical jump with or whitout ball. Players will perform vertical jumps with both feet carrying a ball in their hands (this added difficulty will be optional). 30 seconds"
223745030|NCT05705492|DRUG|Olanzapine|Given PO
223745031|NCT05705492|DRUG|Placebo Administration|Given PO
223745032|NCT05705492|OTHER|Questionnaire Administration|Ancillary studies
223745033|NCT03088254|DRUG|Group I (Telmisartan 80 mg, Amlodipine 10 mg, Rosuvastatin 20 mg)|Twinstar(80/10 mg) and Rosuvastatin 20 mg for 8 weeks
224171246|NCT06213649|OTHER|Topical placebo|An artificial tear ophthalmic solution will be administered 4 times daily for 4 weeks, then 2 times daily for 2 weeks, then 1 time daily for 2 weeks.
224171247|NCT05200715|OTHER|No intervention is foreseen by the protocol.|Patients will be observed for 10 years at least. Demographic, genetic, clinical, clinimetric, laboratory, radiologic and therapeutic data will be collected both retrospectively and prospectively during routine follow-up visits.
224171248|NCT05119231|PROCEDURE|Pulmonary Vein Isolation|Catheter ablation (radiofrequency ablation or cryoablation) of atrial fibrillation according to local standard
224171249|NCT05119231|OTHER|Sham-Pulmonary Vein Isolation|Sham-Pulmonary Vein Isolation in deep sedation for at least one hour including femoral vein/artery puncture with introduction of sheaths and electrical cardioversion in presence of current atrial fibrillation
223585598|NCT06038383|DEVICE|Group B - Intervention with Virtual Reality (VR) - Crossover|Group of people with kidney disease that performed VR intervention during hemodialysis after the washout period.
224171250|NCT04713657|OTHER|N-thymidine|15N-thymidine will be administered to patients in order to quantify cardiomyocyte proliferation. 15N-thymidine will be administered as 5 separate syringes. Each syringe will contain the recommended daily dose based on participants weight. Subjects will be given the labeled thymidine by mouth once a day for 5 consecutive days. The dosing will begin one week after starting the study drug.The caregiver (parent or nurse) will administer the labeled thymidine by mouth via a syringe once a day for 5 consecutive days. They will be provided with a diary to keep track of study drug dosing.
224171251|NCT04713657|OTHER|Urine Collection|Parents will be asked to keep a diary of the child's feeding and diaper changes during the administration of thymidine. To monitor how the labeled thymidine is processed in the body, investigators will analyze urine from the child's diapers. Each time a diaper is changed, a cotton ball will be placed in the diaper. At the next diaper change, this cotton ball will be removed from the diaper, placed in a Ziploc bag, and stored in the freezer. They will be collected and stored cotton balls starting with the first administration of thymidine until 24 hours after the last administration. The frozen cotton balls may be collected from the home by a nurse or brought by parent to the next clinic visit.
224205428|NCT06070701|DRUG|Morphine|Morphine 0.03 mg/kg is administered postoperatively for NRS scores equal or higher than 4.
223745034|NCT03088254|DRUG|Group II (Telmisartan 80 mg, Amodipine 10 mg, Rosuvastatin placebo)|Twinstar(80/10 mg) and Rosuvastatin placebo for 8 weeks
223745035|NCT03088254|DRUG|Group III (Telmisartan 80 mg, Amlodipine placebo, Rosuvastatin 20 mg)|Twinstar placebo, Amlodipine 10 mg and Rosuvastatin 20 mg for 8 weeks
223745036|NCT05678556|BEHAVIORAL|all2GETHER|all2GETHER is an HIV prevention and relationship education program designed for young MSM and other individuals who have sex, date, and are in relationships with MSM. all2GEHTER consists of 3 online didactic skills modules that include videos, activities, and other self-paced education components and 2 videoconference-based skills coaching sessions The 3 online modules focus on developmental skills related to sexual health and relationship functioning, including HIV and STI prevention in couples, effective communication skills, coping skills for LGBTQ and relationship stress, problem-solving and acceptance. Individualized couple sessions led by facilitators focus on implementation of skills specific to the needs of each couple.
223745037|NCT01848756|DRUG|SNX-5422|Capsule(s) dosed every other day for 21 days (total = 11 doses), out of a 28-day treatment cycle.
223585599|NCT05268042|OTHER|Moderately carbohydrate-restricted diet|For this study, the investigators will use the low glycemic, moderately carbohydrate-restricted diet that the investigators have previously shown is associated with depletion of hepatic lipid content, and improvement in insulin resistance in adolescents with NAFLD. This diet has a macronutrient composition of approximately 25% energy from carbohydrate, 20% energy from protein, and 55% energy from fat. No food group is excluded in this diet prescription; however, the diet emphasizes low-glycemic sources of carbohydrate, and includes mainly whole foods (vegetables, fruits, whole grains) with minimal highly processed grain products and added sugar. Protein foods will include meat, poultry, fish, eggs, and whey protein supplements if necessary. Fat-containing foods will include olive, coconut, and nut oils; butter; tree nuts and nut butters; cheese; cream; coconut milk; avocados; and the fat found in meat. A number of full-fat dairy products will be included.
224171252|NCT04713657|PROCEDURE|Echocardiogram|On Study Day 1 to obtain baseline assessment of cardiac size. A second research dedicated echocardiogram will be done after being anesthetized for surgery. Echocardiography is routinely performed to determine right ventricle (RV) structure of the heart and function in Tetrology of Fallot/ Pulmonary Stenosis (ToF/PS) and is non-invasive.
224171253|NCT04713657|PROCEDURE|Cardiac MRI (CMR)|"A limited study protocol will be performed using the feed-and-bundle technique at the time of study enrollment, The feed and bundle technique is utilized so that the infant will be as comfortable as possible and asleep during the procedure. This is done to prevent the risk of sedation and allow for a more natural sleep. The baby is undressed, prepared with ECG-leads and an oxygen saturation probe, and fed. With this feed, swaddle, and sleep technique, scanning times of 30-60 minutes can be achieved, which provides the stillness needed for accurate visualization of the heart. A second CMR, with the same limited study protocol, will be performed under general anesthesia prior to surgical repair. It does not pose any risk of radiation exposure and will not require IV placement or contrast administration for a limited assessement of the right ventricle."
224171254|NCT04713657|DRUG|Propranolol Hydrochloride|For patients who are randomized to receive propranolol, The target dose for this study will be 4 mg/kg/day divided in 4 doses. The first dose will be given in the Pediatric Clinical and Translational Research Center (PCTRC) at 1mg/kg. Parents will administer propranolol (1 mg/kg po x 4 doses per day). Parents will be instructed to administer propranolol with feeding or soon after feeding, but not before feeding. families will also be given instructions for regarding 15N-thymidine dosing frequency and interval and provided with a log sheet to record administered and missed doses of propranolol and 15N-thymidine.
224171255|NCT04713657|DRUG|Placebo|For patients who are randomized to receive placebo, the first dose will be given in the Pediatric Translational Research Center (PCTRC) and will be based on the patients weight. Parents will administer placebo 4 doses per day. Treatment with placebo will begin at 1 month of age and continue until 4 months of age or 24hrs prior to surgical repair, whichever comes first.
224171256|NCT04713657|PROCEDURE|Physical Exam|On Study Day 1; monthly until surgery in conjunction with patient's clinical cardiology appointment; and at the time of surgery. Will include vital signs.
224171257|NCT04713657|OTHER|Specimen Collection|On the morning of surgery, after IV access is obtained for anesthesia 2 ml of blood will be collected for analysis. A small piece of heart tissue and fat that has already been removed during surgery will be collected for analysis.
223483267|NCT02767531|DRUG|Orlistat|Orlistat is a gastric and pancreatic lipase inhibitor that is approved by the FDA for weight loss. It is available over-the-counter as 60 mg tablets under the trade name Alli, and available by prescription as 120 mg capsules under the trade name Xenical.
223745038|NCT00819338|DIETARY_SUPPLEMENT|Efamax|5g daily as capsules for 3 months
224171258|NCT03093116|DRUG|Oral repotrectinib (TPX-0005)|Oral repotrectinib (TPX-0005) capsules.
224171259|NCT06956508|OTHER|Targeted Brain Rehabilitation|"Patients will be given a virtual reality headset that is pre-loaded with the targeted brain rehabilitation (TBR) software at the time of their major amputation.~The Virtual Reality (VR) environment will consist of a high-fidelity virtual representation of the participant's phantom limb. Participants will use a mounted head display (MHD) to interact with a virtual avatar, with the phantom limb represented as a realistic 3D limb model matching the remaining anatomy and skin tone. The VR system will be set up either in the clinic or at the participant's home, depending on individual circumstances and preferences.~The VR protocol will be standardized and include exercises designed to mimic typical occupational therapy session."
224171260|NCT06835842|OTHER|rib mobilization technique|"rib mobilization technique The patient in experimental group will be relaxed in semi- fowler position while connected to mechanical ventilator, therapist will seat at the patient side, his fingers pads are placed at the position of the patient's rib angles , pulling upward and the lateral position the position is held while wait for the soft tissues to release this take from 15 seconds .Release of the diaphragm through manual contact with hypothenar region of therapist thumb inferior laterally xiphoid process and rest along Antero lateral costal margin below rib7 during exhalation the therapist thumb give pressure posteriorly repeat this steps for 3 to5 respiratory cycle • routine chest physiotherapy percussion on chest wall its frequency should be 3-7 beats per sec. vibration applying a light pressure with hand on affected segment for about 5 min modified postural drainage R. and L. side. U\&L limb passive ex. for R.10 x3 set~.this program for 30 minutes once daily for ten days"
224205429|NCT06415669|DRUG|Paclitaxel for injection (albumin-bound)|100 mg/m2, day 1, day 8, every 21 days for a cycle.
224205430|NCT06415669|DRUG|Adebrelimab|20mg/kg or 1200mg, the first day, every 21 days as a cycle.
223745039|NCT04546347|RADIATION|[14C]AZD9833 Solution for Infusion, (NMT 22.8 kBq/5mL)|Dose of \[14C\]AZD9833 Solution for Infusion
223745040|NCT04546347|DRUG|AZD9833 film-coated tablet A Dose 1|Dose 1 AZD9833 film-coated tablet A Dose 1
223745041|NCT04546347|DRUG|AZD9833 Oral Solution|AZD9833 Oral Solution
223483268|NCT04877964|DEVICE|Ultrasound|Using ultrasound with transverse median and paramedian sagittal oblique approach, the screens that show the target epidural space in the center are obtained and stored for evaluation.
223483269|NCT02232347|DRUG|Ketamine|
223483270|NCT02232347|DRUG|Sufentanil|
223745042|NCT04546347|DRUG|AZD9833 film-coated tablet B Dose 1|AZD9833 film-coated tablet B Dose 1
223745043|NCT04546347|DRUG|AZD9833 film-coated tablet A Dose 2|Dose 1 of AZD9833 film-coated tablet A Dose 2
223745044|NCT04546347|DRUG|AZD9833 film-coated tablet B Dose 2|Dose 1 of film-coated tablet B Dose 2
224171261|NCT06835842|OTHER|routine chest physiotherapy|"routine chest physiotherapy the patient will be laid in half supine position connected to a ventilator applying~* percussion on chest wall its frequency should be 3-7 beats per second or 180-420 beats per minute~* vibration applying a light pressure with flattened hand on affected segment for about 5 minutes~* modified postural drainage (right and left sidling 10 min for each side~* upper and lower limb exercise for 4 limbs (3 sets and each set has 10 repetition~* this program for 30 minutes once daily~* for 10 consecutive days"
224171262|NCT01592773|DRUG|Memantine Hydrochloride (HCl)|"During the 6-week double-blind dosing titration/maintenance period, Memantine extended-release 3-mg and 6-mg capsules; oral administration. Dosing was once daily.~During open-label treatment: Memantine extended-release 3mg capsules; oral administration. The maximum target dosage was identified during the prior studies for each patient. Dosing was once daily."
224171263|NCT05374512|DRUG|Dato-DXd|Experimental drug. Provided in 100mg vials. IV infusion.
224171264|NCT05374512|DRUG|Paclitaxel|IV Infusion. Active comparator
224171265|NCT05374512|DRUG|Nab-paclitaxel|IV infusion. Active comparator
224171266|NCT05374512|DRUG|Carboplatin|IV infusion. Active comparator
224171267|NCT05374512|DRUG|Capecitabine|Tablet. Oral route of administration. Active comparator
224171268|NCT05374512|DRUG|Eribulin mesylate|IV infusion. Active comparator
224171269|NCT00531310|DRUG|Reduced Intensity Conditioning, Busulfan and Fludarabine|Busulfan and Fludarabine
224171270|NCT01183728|OTHER|Autologous bone marrow mesenchymal stem cells (MSV)|Bone marrow collection from patient, mesenchymal cells isolation and expansion under GMP conditions following the IBGM-Valladolid protocol (MSV). Autologous MSV implantation by articular injection.
224171271|NCT05419596|PROCEDURE|Urologic Surgery|Patients undergoing major urologic surgery will be examined with blood samples that will be taken preoperatively and postoperatively. Accordingly several gene variants and proteins will be examined for patients with or without postoperative cognitive dysfunction. These proteins consist of APOE, phosphatidyl-inositol-binding clathrin assembly protein, CR1 - complement receptor 1 , ATP-binding cassette transporter, IL6, Triggering receptor expressed on myeloid cells2 (TREM2).
224171272|NCT01183611|BIOLOGICAL|Experimental recombinant hepatitis B vaccine, HBIG|Experimental 10mcg/0.5 ml recombinant hepatitis B vaccine and 200IU HBIG
224171273|NCT01183611|BIOLOGICAL|Active Comparator hepatitis B vaccine|Active Comparator 10mcg/0.5 ml of recombinant hepatitis B vaccine，200IU HBIG
224171274|NCT01183611|BIOLOGICAL|Experimental recombinant hepatitis B vaccine|Experimental 10mcg/0.5 ml of recombinant hepatitis B vaccine
224171275|NCT01183611|BIOLOGICAL|Active Comparator recombinant hepatitis B vaccine.|Active Comparator 10mcg/0.5 ml of recombinant hepatitis B vaccine.
224171276|NCT01183611|BIOLOGICAL|Placebo Comparator recombinant hepatitis B vaccine|Placebo Comparator 10mcg/0.5 ml of recombinant hepatitis B vaccine.
223483271|NCT03315260|DRUG|Radium-223 dichloride (Xofigo, BAY88-8223)|Ra-223 is a radiopharmaceutical with an indication to treat Castration Resistant Prostate Cancer (approved indication in Japan)
223483272|NCT02481700|PROCEDURE|Third molar removal|The surgical removal of third molars
223483273|NCT02295319|OTHER|Individual discharge|"See previous description in Arms"
223585600|NCT05268042|OTHER|Fat-restricted diet|The fat-restricted, control diet will consist of approximately 60% carbohydrate, 20% protein, 20% fat. Participants will be given low-fat foods, whole-grain foods, fruits, and vegetables. The meal plans will minimize cholesterol, high-fat foods, high-cholesterol foods, processed starches, and added sugar, and will provide \<2300 mg/day sodium. Saturated fat will be limited to 10% of total fat intake, and all dairy products will be fat-free (or low fat).
223585601|NCT03995706|DRUG|Sacituzumab Govitecan|All 20 subjects will receive study drug Sacituzumab Govitecan preoperatively. Intraoperative tissue collection will follow with contemporaneous CSF (depending on tumor location) and whole blood (serum) sampling. Samples will be tested for total SN-38and free SN-38, as well as SN-38G. Following recovery from surgery, patients will resume treatment
224171277|NCT04418427|BIOLOGICAL|6E11 vg/eye of ADVM-022|ADVM-022 (AAV.7m8-aflibercept) is a recombinant, replication-incompetent adeno-associated virus (AAV.7m8) gene therapy vector carrying a coding sequence for aflibercept
224171278|NCT04418427|BIOLOGICAL|2E11 vg/eye of ADVM-022|ADVM-022 (AAV.7m8-aflibercept) is a recombinant, replication-incompetent adeno-associated virus (AAV.7m8) gene therapy vector carrying a coding sequence for aflibercept
224171279|NCT04418427|BIOLOGICAL|Aflibercept|Commercially available Active Comparator
224171280|NCT01004861|DRUG|PLX3397|Capsules administered once or twice daily, continuous dosing
224171281|NCT04361695|PROCEDURE|Hemorrhoidectomy|The patient receives spinal anaesthesia and is placed in lithotomy position. A complex of external and internal haemorrhoid or internal haemorrhoid only is excised with monopolar electrocautery or bipolar electrosurgery device. Haemorrhoid pedicle is tied with absorbable polyfilament suture. One, two or three nodes can be removed per a procedure.
224171282|NCT04361695|DRUG|Ketoprophenum|Ketoprophenum
224171283|NCT04361695|DRUG|Placebo|Placebo
223483274|NCT01682031|DIETARY_SUPPLEMENT|selenomethionine|Given PO
223483275|NCT01682031|OTHER|placebo|Given PO
223483276|NCT01682031|DRUG|cisplatin|Given IV
223483277|NCT01682031|RADIATION|radiation therapy|Undergo radiotherapy
223483278|NCT01682031|PROCEDURE|quality-of-life assessment|Ancillary studies
223483279|NCT04841291|BEHAVIORAL|Diabetes Foot Care Education (DFCE)|Virtual simulation-based DFCE sessions on seven topics (the reasons for inspecting one's feet, risk factors and prevention strategies of diabetic foot ulcer, how to wash and moisturize feet, comfortable sock and shoe choices, what to look for, and what to do during feet inspection, how to trim fingernails, and how to maintain foot health) at University of Gondar computer lab for 30 minutes.
223483280|NCT01809067|OTHER|Lavender aromatherapy inhalers|Patients will self-administer lavender aromatherapy from hand held inhalers containing lavender essential oil.
223483281|NCT00025467|DRUG|thalidomide|Given orally
223483282|NCT00025467|OTHER|laboratory biomarker analysis|Correlative studies
224171284|NCT03436576|DRUG|Autologous Serum 20%|Instillation of 1 drop of Autologous Serum 20% four times a day
224171285|NCT03436576|DRUG|Autologous Serum 50%|Instillation of 1 drop of Autologous Serum 50% four times a day
224171286|NCT02546102|BIOLOGICAL|ICT-107|Autologous dendritic cells pulsed with peptides associated with tumor antigens
224171287|NCT02546102|BIOLOGICAL|Placebo|Control, autologous monocytes-enriched PBMC.
223585602|NCT06004336|DRUG|Pembrolizumab|Given by vein (IV)
224171288|NCT01842282|DRUG|Amlexanox|
224171289|NCT03930225|BEHAVIORAL|Stigma Directed Psycho-educational Intervention program|psycho-educational intervention with emphasis on Stigma
224171290|NCT02554721|DRUG|Cilostazol|
223483283|NCT00435058|DRUG|timolol maleate 0,5%|
224171291|NCT02554721|DRUG|Acetylsalicylic acid|
223483284|NCT00435058|DRUG|brimonidine tartrate 0,2%|
223483285|NCT00435058|DRUG|travoprost 0,004%|
223483286|NCT01101100|DRUG|AMG 827|210 mg SC or 140 mg SC
223483287|NCT03080285|DEVICE|over-glasses patch|Over-glasses patch (Tomato Eye Patch, Tomato Inc., Busan, South Korea) is applied to the patients. They were prescribed 2 hours of patching per day for the sound eye.
223483288|NCT03080285|DEVICE|Conventional patch|Conventional patch (Opticlude Eye Patch, 3M, Maplewood, MN, USA) is applied to the patients. They were prescribed 2 hours of patching per day for the sound eye.
223585603|NCT06004336|RADIATION|Radiation therapy|Given by vein (IV)
223585604|NCT02740361|BEHAVIORAL|Deprexis, DeprexisPlus|Online program Deprexis, either as a stand-alone internet-based intervention (Deprexis) or with added standardized email support by a clinical psychologist (DeprexisPlus). In this trial, we will use a Version of Deprexis that has been adapted to MS-specific needs.
223585605|NCT03748459|OTHER|Closure with Permanent Suture|Skin closure with permanent suture (prolene) (6-0 polypropylene) in open rhinoplasty.
224171292|NCT02554721|DRUG|Clopidogrel|
224171293|NCT02108561|OTHER|Post Surgical Her2 testing|Eligible patients will have post surgical Her2 testing on the primary tumor, a satellite lesion and a tumor positive node. The results will be provided to medical oncologist, who will comment as to whether the additional testing will prompt treatment recommendation changes
224171294|NCT04605068|PROCEDURE|Transverse preputial island flap (Duckett's technique)|
224171295|NCT04605068|PROCEDURE|Double-faced preputial flap (DFPF)|
224171296|NCT00686699|DRUG|Preladenant|capsules
224171297|NCT00686699|DRUG|Placebo|capsules
224171298|NCT04265859|BEHAVIORAL|Cognitive Behavioral Training|The CBT-based regulation training involves using a cognitive strategy that instructs participants to reappraise situations in positive or less negative ways.
224171299|NCT04265859|BEHAVIORAL|Mindfulness|The MBT-based regulation training involves using a mindfulness strategy that instructs participants to notice and accept their feelings without judgment or intent to act upon them.
224171300|NCT04383041|OTHER|No intervention|Completing questionnaires via ePRO app from their own mobile devices
224171301|NCT04399993|OTHER|Intervention Protocol in Diaphragm|"The protocol consists of three techniques. The two first techniques will be applied for 10 respiratory cycles.~Muscle Stretching Technique:~the researcher will perform a cephalic traction on the inferior costal border with the ulnar border during the inspiratory phase.~Phrenic-center inhibition technique:~the researcher, with a hand on the sternum to caudal and other hand on the umbilical region to cranial, will approach his hands on the horizontal plane, when the volunteer exales.~Functional diaphragm technique:~the researcher will perform a vertical pressure on the diaphragm for 5 minutes and will search for the facilitated parameters and maintain them until the release of all the periarticular elements."
223585606|NCT03748459|OTHER|Closure with Resorbable Suture|Skin closure with Resorbable Suture (5-0 fast absorbing plain gut) in open rhinoplasty.
223585607|NCT06261359|DRUG|CEND-1|CEND-1 will be provided as concentrate for solution to be administered via IV injection.
223585608|NCT06261359|DRUG|Gemcitabine|Gemcitabine will be provided as solution to be administered via IV infusion.
223585609|NCT06261359|DRUG|Nab paclitaxel|Nab-paclitaxel will be provided as solution to be administered via IV infusion.
224171302|NCT04399993|OTHER|Sham technique|In the sham group a manual contact without any therapeutic intention will be performed, in a distant region of the diaphragm (for example on the trapezius muscle). This contact will be maintained during the same amount of time as for the treatment group.
224171303|NCT05810324|DRUG|18F-FAPI|Each patient receive a single intravenous injection of 18F-FAPI, and undergo PET/CT scan within specified time.
223483289|NCT01911247|DRUG|Metformin|Metformin 850 mg once daily
223483290|NCT01056536|BEHAVIORAL|Structured intervention for the prevention of sexually transmitted infections (STI).|The structured intervention will include information about the number of travelers engaging in new sexual relationships, the different types of STI and their prevalence in different countries and population groups. The intervention will last approximately 5 minutes. At the end of the structured intervention the subjects will be offered free condoms.
223483291|NCT01056536|DEVICE|Free condoms|Subjects will be proposed free condoms at the end of the pre-travel consultation.
223483292|NCT04335799|BEHAVIORAL|Diabetes Prevention Program Intensive Lifestyle Intervention plus stress management training|12-month evidence based weight loss intervention with additional training on stress management strategies
223483293|NCT04335799|BEHAVIORAL|Diabetes Prevention Program Intensive Lifestyle Intervention plus general women's health topics|12-month evidence based weight loss intervention with an attention control of general women's health topics
223483294|NCT06329596|DIETARY_SUPPLEMENT|Xylitol gum|Two pieces of xylitol gum after meals, thrice a day.
223483295|NCT06329596|DIETARY_SUPPLEMENT|Sorbitol gum|Two pieces of sorbitol gum after meals, thrice a day.
224171304|NCT04437524|OTHER|therapeutic exercises|Treatment that will continue 3 days a week for 6 weeks in female patients with fibromyalgia.
224171305|NCT05940051|DRUG|Zanubrutinib, Polatuzumab vedotin and Rituximab|Zanubrutinib（Z）160 mg bid po Day 1-21; Polatuzumab vedotin（P）1.8 mg/kg ivgtt D1; Rituximab（R）375 mg/m2 ivgtt D1
224171306|NCT00908895|PROCEDURE|Radio-radial fixator|Using the Distal Radius Fixator from Synthes. A single splint for 5 days.
224171307|NCT00908895|PROCEDURE|Percutaneous pinning|Insert two K-wires in the distal radius, one in the fracture line dorsally and one from the styloid. A cast for 6 weeks.
224171308|NCT01662752|DRUG|Indocyanine green|Please see arm description
224171309|NCT06028906|DIAGNOSTIC_TEST|Multimodal physiological monitoring and cerebral autoregulation monitoring|"Patients are monitored routinely during their treatment in ICU. Multimodal physiological monitoring include continuous monitoring of arterial blood pressure (ABP), intracranial pressure (ICP) (if available), ETCO2 (if available), cerebral perfusion pressure (if available), cerebral blood flow velocity (CBFV) and ECG.~Non-invasive cerebral autoregulation index Mx will by calculated as a Pearson correlation coefficient between slow ABP and slow CBFV waves.~Invasive cerebral autoregulation index (Pressure reactivity index PRx) will by calculated as a Pearson correlation coefficient between slow ABP and slow ICP waves.~Non invasive CBFV will be measured by using TCD device DWL Multi Dop-T. Invasive ICP will be measured by using Codman ICP Express or Raumedic ICP monitor."
224171310|NCT06229093|DEVICE|Gamma|For the OAg group, the visual component of multimodal stimulation will have the same properties as for the other group, except it will also be additionally amplitude-modulated in the gamma-band (30-60 Hz) range, resulting in a detectable flicker over-and-above the beat-level modulation.
224171311|NCT06229093|DEVICE|Synchrony|For the OA group, the lights will be tuned to delta-band frequencies (1-4 Hz) in the music, which corresponds to the beat-level frequency in most music. Thus, the lights automatically adapt to the rhythm of the music, pulsing on the beat and changing color on strong beats.
224171312|NCT05765721|BEHAVIORAL|FRAIL-SM Program|Patients in experimental group will receive a 8 week family-based frailty self-management program; patients in control group maintain their usual life activities.
224171313|NCT05214365|DEVICE|Pacemaker implantation and conventional cardiac pacing|Patients will have the pacemaker implanted in the electrophysiology laboratory. Electrode will be implanted (in the apical or septal portion) according to the criteria of the implanting physician.
224171314|NCT05214365|DEVICE|Conduction system pacing implant|Right ventricular lead was placed to get his bundle or left bundle branch.
224171315|NCT00122824|DRUG|duloxetine hydrochloride|
224171316|NCT00122824|DRUG|placebo|
224171317|NCT06039904|DEVICE|Natural rubber knee support|The knee support comprised two parts, the support body and the protective cushion. Which were categorized into four sizes, S, M, L and XL according to widths and lengths, as follows: size S, 8x17 cm; size M, 10x19 cm; size L, 12x24 cm; and size XL, 14x28 cm. The support body was made of stretchable natural cotton fabrics, which were comfortable, breathable, washable, less irritant and flexible. Similarly, the protective cushion was classified into four sizes: S, M, L and XL with diameters (based on the patellar diameters) of 5, 6, 7 and 8 cm, respectively. Cushions were made from either natural rubber and inserted at the front of the support body (to cover the patellar).
224171318|NCT06039904|DEVICE|Sponge knee support|The knee support comprised two parts, the support body and the protective cushion. Which were categorized into four sizes, S, M, L and XL according to widths and lengths, as follows: size S, 8x17 cm; size M, 10x19 cm; size L, 12x24 cm; and size XL, 14x28 cm. The support body was made of stretchable natural cotton fabrics, which were comfortable, breathable, washable, less irritant and flexible. Similarly, the protective cushion was classified into four sizes: S, M, L and XL with diameters (based on the patellar diameters) of 5, 6, 7 and 8 cm, respectively. Cushions were made from either sponge and inserted at the front of the support body (to cover the patellar).
224171319|NCT02411669|OTHER|Operational patient centered care tools|"The FORAP (Fédération des Organismes Régionaux et territoriaux pour l'Amélioration des Pratiques et des organisations) and the la HAS (High Authority of Health) have developed and validated five tools promoting patient centered care at hospital.~They can be implemented one by one or in association according to hospital situation. Hospitals should identify the association of tools fitting the most to their objectives and the actions already done."
224171320|NCT03263169|BEHAVIORAL|Community-based personalized care|volunteer support, health technology, interprofessional care, social network linkage
224171321|NCT03493373|OTHER|Exercise|The exercise program will consist of: 1) warm up - consisting of stretches of large muscle groups of the upper limbs, lower limbs and trunk and by general mobility exercises; 2) strength training of moderate intensity; 3) balance training; 4) Cooling - will consist of performing overall stretching combined with deep breathing.
223483296|NCT01582204|DRUG|124IcG250|Pts will undergo baseline disease assessment with CT scans (chest, abd \& pelvis), 124I-cG250-PET/CT \& Tc99mMDP bone scan. W/I 7 days of their lst 124I-cG250 PET/CT, pts will start tx with sunitinib or pazopanib, dosed in successive 6-week cycles. At selected time points during the sunitinib or pazopanib cycle 1, repeat imaging with CT scan \& 124I-cG250 PET/CT will be performed. After cycle 2, pts will be followed per standard of care, i.e., pts will have a standard CT scan of the chest, abd, \& pelvis with contrast after cycles 2, 3, 4 \& 6 (or at the time of disease progression if prior to cycle 6) for determination of best response using RECIST 1.1. Each pt will have 2 124I-cG250-PET/CT scans: baseline \& week 4 (during sunitinib or pazopanib tx). All experimental imaging will take place during tx cycle 1. There will be a dosimetry sub-study for pts willing to undergo 3 additional PET/CT scans, whole body counts, \& serial blood sampling, following the lst inj of 124I-cG250.
223483297|NCT01066377|DIETARY_SUPPLEMENT|Prebiotic and probiotic mix|The probiotic strain will be Bifidobacterium longum bv. infantis CCUG 52486 (10\^8 - 10\^9 live bacteria per day), which was originally isolated from healthy elderly subjects, and which has been demonstrated to have particular ecological fitness and anti-pathogenic effects in vitro. A suitable prebiotic (8g/day) will be selected on the basis of ability to promote optimal growth and survival of this probiotic (inulin, fructooligosaccharides \[FOS\], galactooligosaccharides\[GOS\] and xylooligosaccharides\[XOS\] will be tested).
223483298|NCT06568679|OTHER|No intervention; observational|No intervention; observational
223483299|NCT05881811|DRUG|HSK16149，probenecid, cimetidine|40mg HSK16149 single dose, fasted; 500mg probenecid QID from D1\~D4 200mg cimetidine QID from D1\~D4
223585610|NCT04256512|DEVICE|Medical Device Usage and Evaluation|Wear Elasto Gel Therapy Mittens and Foot Wraps
223585611|NCT04256512|OTHER|Questionnaire Administration|Ancillary studies
223585612|NCT03913689|DEVICE|StimRouter Neuromodulation System|An implantable neuromodulation device that treats chronic peripheral nerve pain.
223585613|NCT01733771|OTHER|Reflexology|Reflexology intervention involved a 15-minute treatment in the induction room, provided by three reflexologists from the hospital staff. The reflexology protocol was developed through a Delphi method.
224171322|NCT03493373|OTHER|Neural mobilization|Neural gliding mobilization will target mainly the lower limb nerves and will be performed in series of 10 repetitions with 1 minute interval between series.
224171323|NCT01637792|OTHER|Three 2-liter exchanges daily CAPD|CAPD regimen of three 2-liter daily exchanges
224171324|NCT01637792|OTHER|Four 2-liter exchanges daily CAPD|CAPD regimen of four 2-liter daily exchagnes
224171325|NCT01373099|PROCEDURE|Implantation of a static, non-articulating cement spacer.|After diagnosis of infection and informed consent, patients will be taken to the operating room. After anesthetization, patients will be randomized to either an articulating spacer or static spacer. Randomization will be performed by prepared opaque envelopes administered by a nonparticipant in the study. After a complete debridement of devitalized tissue, explantation of infected components and any associated cement, either an articulating or static spacer will be placed. All spacers will be formed using 3.0 g of Vancomycin and 1.0 g of Tobramycin for each 40 g packet of cement. Static spacers will be hand-made with a rod of antibiotic-impregnated cement and cement beads of sufficient quantity to fill the acetabulum.
224171326|NCT01373099|PROCEDURE|Implantation of an articulating spacer.|After diagnosis of infection and informed consent, patients will be taken to the operating room. After anesthetization, patients will be randomized to either an articulating spacer or static spacer. Randomization will be performed by prepared opaque envelopes administered by a nonparticipant in the study. After a complete debridement of devitalized tissue, explantation of infected components and any associated cement, either an articulating or static spacer will be placed. All spacers will be formed using 3.0 g of Vancomycin and 1.0 g of Tobramycin for each 40 g packet of cement. Articulating spacers will be formed of antibiotic-impregnated cement using the Stage One system (Biomet, Warsaw, IN) sized to fit the endosteal and acetabular bone defect.
224171327|NCT04360889|DRUG|Micronised purified flavonoid fraction (diosmin+flavonoids expressed as hesperidin)|Micronised purified flavonoid fraction (diosmin+flavonoids expressed as hesperidin) is prescribed at a dose of 1000 mg / day Tocopherol is prescribed at a dose of 400 ME/ day
224171328|NCT04360889|DRUG|Tocopherol|patients with lower limb lymphedema receiving conservative therapy (elastic compression, to which are added preparations with antioxidant endotheliotropic activity (Tocopherol-400 IU/day)
224171329|NCT04360889|OTHER|Elastic compression|patients with lower limb lymphedema receiving conservative therapy that includes only the use of elastic compression
223483300|NCT05530694|BEHAVIORAL|Clinician communication training|The clinician training is a generic, skills- and attitude-based approach for clinicians to acknowledge their decision making conversations with patients that 1) there is more than one option, and 2) patient's views matter in deciding what to do next. This tools-free approach can be used on the spot when needed and is termed fostering choice awareness (FCA). The one-hour training consists of 4 parts: 1) a knowledge session on evidence and guidelines on effective conversations and SDM, 2) video-review of behaviors which foster or hinder choice awareness, 3) clinical simulations in which clinicians practice fostering choice awareness behaviors, and 4) a reminder card for use in future clinic visits. Video clips will be of patient-clinician conversations around treatment decision making to prompt and probe clinicians' experiences, improve understanding, and improve practice.
223483301|NCT05530694|BEHAVIORAL|Patient activation|"The patient activation component consists of three questions patients can ask their clinician to help them become more involved: 1. What are my options?; 2. What are the possible benefits and harms of those options?; 3. How likely are each of those benefits and harms to happen to me? These questions have been used in studies to promote improved communication in a number of conditions including cardiovascular disease, cancer, and women's health."
223483302|NCT05530694|BEHAVIORAL|RA Medication summary guide and RA Choice|RA Choice presents information on FDA-approved RA treatments in a set of cards, which can be used alone or in combination based on a patient's preference, values, and the clinician's experience. The RA medication summary guide describes options for medication, physical therapy, occupational therapy, and ways to stay healthy with diet and exercise. Tool development followed key principles of creating low literacy materials that featured icons, short phrases written in plain language, and included topics of interest to RA patients faced with a medication decision. For the proposed study, we will include a paper-based version of the tool, or a web-based version available for telephone or VA Video Connect (VVC) visits. The tools will be updated to include new FDA-approved therapies (e.g., JAK inhibitors).
223483303|NCT00117234|DRUG|darbepoetin alfa|
223483304|NCT03173274|BEHAVIORAL|Brief Motivational Intervention|Participants in both groups will be given an BMI intervention in which they will be counseled to quit smoking.
223483305|NCT03173274|BEHAVIORAL|Contingency Management|Contingent Reinforcement for negative breath CO samples
223483306|NCT03173274|BEHAVIORAL|Non-Contingent Reinforcement|Participants will receive reinforcement for submitting samples ona yoked schedule unrelated to CO sample value \[CM control\]
223483307|NCT00970580|DRUG|BIIB022 With Paclitaxel and Carboplatin|Escalating doses of BIIB022 with fixed dose and schedule of paclitaxel and carboplatin
223483308|NCT02729233|OTHER|patients receiving biopsies|Six mucosal biopsies will be collected from each site (terminal ileum and rectum) for histologic verification of pCLE findings at baseline, and again at month 12 for a total of 12 research samples per colonoscopy, or 24 research biopsy samples during the course of the study. The study subjects will be followed for a total of 1 year after initial colonoscopy with pCLE. The primary study end-point is clinical response at 3 months following initiation of golimumab.
223483309|NCT02030873|OTHER|Virtual simulation training|Virtual simulation training in the Visible Ear Simulator.
223585614|NCT01733771|OTHER|Sham reflexology|Sham reflexology intervention were given by two complementary medicine practitioners with knowledge in touch therapy (shiatsu) and included 15 minutes of gentle, nonspecific foot massage. Similarly to the true reflexology protocol, the protocol for this treatment was also determined in a consensus-reaching process among a group of four experienced reflexologists.
223585615|NCT04570683|DRUG|Nivolumab 10 MG/ML|Se previously
224171330|NCT04011462|DEVICE|prewarming 20 minutes|prewarming with a forced air warming system, using a blanket covering the whole body, regulated to the temperature of 38 °C for 20 minutes.
224171331|NCT04011462|DEVICE|prewarming 30 minutes|prewarming with a forced air warming system, using a blanket covering the whole body, regulated to the temperature of 38 °C for 30 minutes.
224171332|NCT03855358|DRUG|TQB2450 Injection and Anlotinib Hydrochioride Capsules|TQB2450 1200mg intravenously (IV) every-3-weeks (Q3W) and Anlotinib QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
223483310|NCT05456672|OTHER|Test meals and food baskets|"Interventional dietary study using standardized test meals and personalized food baskets to investigate the impact of food combination on the glycemic response. The study period is organized as follows:~(Day 1: Continuous blood glucose monitoring system (CGM) activation) Days 2 and 3: Two standardized daily menus (breakfast, lunch, afternoon snack and dinner) provided on a randomized crossover basis.~Days 4 to 7: four standardized test meals, participants will be asked to substitute one meal each day (lunch or dinner) for a test meal according to a pre-defined randomization plan.~Days 8 to 10: Participants will be asked to prepare all meals using a food basket containing a mix of standardized and personal preference items.~Days 11 to 13: Participants will be asked to prepare all meals using a food basket containing a mix of standardized and personal preference items and following dietary recommendations developed by the study staff.~(Day 14: CGM sensor removed)"
223483311|NCT04995159|DRUG|Single anti-platelet therapy|Aspirin in combination with a P2Y12 receptor antagonist (either clopidogrel or ticagrelor will be selected by investigators according to the degree of ischemia) in the first year after PCI. Aspirin will be discontinued one year after surgery and clopidogrel will be continued until 5 years after surgery.
223483312|NCT04995159|DRUG|Dual anti-platelet therapy|Aspirin in combination with a P2Y12 receptor antagonist (either clopidogrel or ticagrelor will be selected by investigators according to the degree of ischemia) in the first year after PCI. Patients continue to take dual antiplatelet (DAPT) drugs, including aspirin and clopidogrel, for 2 more years; then aspirin will be used alone from the 4th year to the 5th year.
223483313|NCT01512654|DEVICE|Personalized Glucose Predictive and Therapy Advisory System (DIAdvisor)|Glucose predictions and therapy advices will not be displayed. Patient will decide his need of insulin according to the results given by the HemoCue glucometer and CGM trends. He/She will inject insulin at mealtimes or program a bolus on his/her pump by him/herself and will adapt his/her basal insulin doses or pump delivery rates as usual. As needed or on request and more particularly if hypo or hyperglycaemia occurs, the subject will be advised and helped by nurses and physicians.
223585616|NCT04570683|DEVICE|Ablative fractionated laser|Se previously
223585617|NCT04691856|DRUG|Morphine Sulfate|Patients will be received morphine with intravenous patient controlled analgesia (IV PCA) device during postoperative 24 hours. The PCA solution will be prepared with 100 mg morphine in 200 mL of saline (0.5 mg/ml). The PCA device was adjusted as infusion: 0 ml/h, bolus: 1 ml, lockout period: 7 min.
223585618|NCT04691856|DRUG|Intravenous paracetamol|1 g paracetamol will be administered 30 minutes before the end of surgery. All administrations will be applied through IV infusion over 30 minutes. Patients will be received morphine with intravenous patient controlled analgesia (IV PCA) device during postoperative 24 hours. The PCA solution will be prepared with 100 mg morphine in 200 mL of saline (0.5 mg/ml). The PCA device was adjusted as infusion: 0 ml/h, bolus: 1 ml, lockout period: 7 min.
223585619|NCT04691856|DRUG|Intravenous ibuprofen|800 mg ibuprofen (diluted with 250 ml saline) will be administered 30 minutes before the end of surgery. All administrations will be applied through IV infusion over 30 minutes. Patients will be received morphine with intravenous patient controlled analgesia (IV PCA) device during postoperative 24 hours. The PCA solution will be prepared with 100 mg morphine in 200 mL of saline (0.5 mg/ml). The PCA device was adjusted as infusion: 0 ml/h, bolus: 1 ml, lockout period: 7 min.
223585620|NCT04691856|DRUG|Morphine|All patients were instructed to use intravenous patient-controlled analgesia (IV PCA). All administrations will be applied through IV infusion over 30 minutes. Patients will be received morphine with intravenous patient controlled analgesia (IV PCA) device during postoperative 24 hours. The PCA solution will be prepared with 100 mg morphine in 200 mL of saline (0.5 mg/ml). The PCA device was adjusted as infusion: 0 ml/h, bolus: 1 ml, lockout period: 7 min.
223585621|NCT03331822|OTHER|Bright Light|high illuminance white lights positioned at each nursing station throughout the hallway to generate a uniform exposure of approximately 1,000-3,000 lux. To achieve this illuminance, a Day\*Light Classic Light will be positioned at each nursing station in the ICU hallway.
223585622|NCT04773990|DEVICE|Biodex Balance System|Subjects will receive several unique training modules using biodex
223585623|NCT04773990|OTHER|specific physical therapy exercise program|Subjects will receive recommended PT program
223745045|NCT01301495|DEVICE|HANAROSTENT TM covered Esophageal Stent|HANAROSTENT covered Esophageal Stent for maintaining esophageal luminal patency in esophageal strictures caused by intrinsic and or extrinsic malignant tumors only and occlusion of concurrent esophageal fistula
223745046|NCT03079609|PROCEDURE|subinguinal microscopic varicocelectomy|During the procedure approximately 1cm long fragment of varicose vein will be taken for further investigation.
224171333|NCT00025194|DRUG|estramustine phosphate sodium|
224171334|NCT00025194|DRUG|ixabepilone|
224171335|NCT02059174|DRUG|MK-1293|MK-1293 0.4 units/kg administered subcutaneously
223745047|NCT03079609|PROCEDURE|open hernia repair|During the procedure approximately 1cm long fragment of spermatic cord vein will be taken for further investigation.
223745048|NCT03245008|DRUG|MT-5547|Solution for injection in pre-filled syringe
223745049|NCT03245008|DRUG|MT-5547-matching placebo|Solution for injection in pre-filled syringe
223745050|NCT00000586|DRUG|hydroxyurea|
224171336|NCT02059174|DRUG|EU-Lantus™|EU-Lantus™ 0.4 units/kg administered subcutaneously
224171337|NCT02059174|DRUG|Novolog™|Participants will receive an intravenous infusion of insulin aspart (Novolog™ or other rapid-acting insulin analog) for several hours prior to MK-1293 or EU-Lantus™ dosing in each dosing period to meet basal insulin requirements
224171338|NCT04778228|DEVICE|mechanical ventilation|"critically ill patients requiring mechanical ventilation (MV) were ventilated using high tidal volumes (Vt) and high airway pressures, until the pivotal ARDS net randomized controlled trial (RCT) demonstrated that a lung-protective MV strategy using a Vt of 4-8 mL/kg predicted body weight (PBW) and moderate levels of positive end-expiratory pressure (PEEP) improved survival (2). Since then, limitation of Vt to 4-8 mL/kg PBW, plateau pressures (Pplat) to a maximum of 30 cm H2O, and application of PEEP 10 -16 cm H2O represent the standard for MV in ARDS patients."
224171339|NCT02306148|OTHER|Foot and ankle strengthening|Group will be trained during 2 months at the university by a physiotherapist and at home with a training software for foot and ankle strengthening.
224205431|NCT06415669|DRUG|Apatinib mesylate|250mg once a day for 5 consecutive days and discontinue for 2 days
224205432|NCT03428217|DRUG|CB-839|Oral glutaminase inhibitor
224205433|NCT03428217|DRUG|Cabozantinib|Oral receptor tyrosine kinase inhibitor
224171340|NCT04561739|DEVICE|Paclitaxel coated balloon|"The Paclitaxel coated balloon is a paclitaxel-eluting rapid exchange balloon catheter for PTCA. Paclitaxel is the pharmacologically active substance for anti-neointima, whereas iopromide, a well-tolerated nonionic x-ray contrast agent, acts as a release-supporting additive.~The active drug coating is located on the surface of the balloon, which contains 3 μg Paclitaxel per 1 mm2. The spray coating of the mixture of paclitaxel and iopromide of the Swide is via ultrasound, with the crystal size\<2um."
224171341|NCT04561739|DEVICE|Sirolimus eluting stents|The device has a backbone of L605 cobalt chromium. The stent has a open cell, in-phase, peak-to-valley design. The strut thickness is 86 μm and has a stent profile less than 1.12mm. The polymer coating of the stent is a styrene-butadiene block copolymer. The antiproliferative drug concentration is at 9 ug/mm, which 80% of the drug is released by 30 days.
224171342|NCT05547828|DRUG|Tislelizumab combined with chemoradiotherapy|"Tislelizumab: According to the instructions of tislelizumab, 200 mg intravenously on the first day of each cycle, 21 days as a cycle.~Nab-paclitaxel: white purple: 100mg/m2 intravenous infusion on d1.8.15 (during chemotherapy) 100mg/m2 intravenous infusion q3w ╳ 3 cycles (during consolidation therapy) Radiotherapy: 40Gy/20f, 5 times/w, (esophageal primary tumor and metastatic lymph nodes)"
224171343|NCT02939456|OTHER|Magnetic Resonance Imaging|Double Inversion Recovery Magnetic Resonance Imaging (DIR-MRI) and Dynamic Contrast Enhanced Magnetic Imaging (DCE-MRI)
223585624|NCT02396394|BEHAVIORAL|Two-Step Adherence Feedback|Intervention subjects will use an electronic pill container to hold their antiretroviral medications. Throughout the 6-month intervention (until subjects are 3 months post-partum), whenever an intervention subject fails to open her electronic pill container within 60 minutes of dose time (as indicated by lack of a pill container opening), she will be sent a text message reminder. Each intervention subject will also participate in monthly counseling sessions informed by the subject's most recent adherence data generated by the electronic pill container. The counselor will review the adherence report with the patient and 1) provide positive feedback when adherence is ≥95% in the previous month, or 2) discuss reasons for lapses and strategies for improving adherence when adherence is \<95%.
223585625|NCT01799434|OTHER|treadmill run|
223585626|NCT01785823|OTHER|FX2-2-2|Their background infusions of fentanyl diluent (2 ml/hr of diluent was equivalent with 0.5 μg/kg/hr of fentanyl) were maintained at the fixed-rate of 2 ml/hr until the postoperative 24 hr (FX2-2-2), or at the decremental rates of 6.0 ml/hr (D6-4-2) and 8.0 ml/hr (D8-4-2) during 1 hr, 4.0 ml/hr during 1\~3 hr and 2.0 ml/hr during 3\~24 hr, postoperatively. The visual analogue scores (VAS), the incidence of inadequate analgesia, the frequency of intervention of PCA, and side effects were evaluated.
223483314|NCT01512654|DEVICE|Personalized Glucose Predictive and Therapy Advisory System (DIAdvisor)|Glucose predictions and therapy advices will be displayed to the patient. Patients will be asked to follow the advices suggested by DIAdvisor system according to their own judgement. Patient will decide his need of insulin according to the results given by the HemoCue glucometer, CGM trends, glucose predictions as well as therapy advices. In case of any doubt with the predictions displayed or the advices suggested, the patients will be invited to ask study personal and/or the study physician for help.
224171344|NCT01901809|DRUG|Furosemide|
223483315|NCT05934019|DEVICE|EMPATIA 1|The internet-program EMPATIA is hosted on a secure website https://selfhelp.psy.unibe.ch run by the Faculty of Human Sciences and is accessible from any regular internet browser. The software is not CE-marked as it has been developed for research purposes only. EMPATIA consists of 8 sessions and 1 booster session 3 weeks after the last session. It targets transdiagnostic mechanisms that have been identified in several mental disorders in adolescents: behavioral avoidance, repetitive negative thinking including intolerance of uncertainty, emotion, self-critical perfectionism and rejection sensitivity. The contents of EMPATIA are evidence-based and well-established cognitive-behavioral interventions dedicated to the respective transdiagnostic mechanism. The self-help program consists of psychoeducation, cognitive restructuring, relaxation and acceptance-based interventions, exposure and behavioral experiments and behavioral activation as treatment components.
223483316|NCT05305859|DRUG|venetoclax combining chidamide and azacitidine (VCA)|information already included in arm/group descriptions
223585627|NCT01785823|OTHER|D6-4-2|Their background infusions of fentanyl diluent (2 ml/hr of diluent was equivalent with 0.5 μg/kg/hr of fentanyl) were maintained at the fixed-rate of 2 ml/hr until the postoperative 24 hr (FX2-2-2), or at the decremental rates of 6.0 ml/hr (D6-4-2) and 8.0 ml/hr (D8-4-2) during 1 hr, 4.0 ml/hr during 1\~3 hr and 2.0 ml/hr during 3\~24 hr, postoperatively. The visual analogue scores (VAS), the incidence of inadequate analgesia, the frequency of intervention of PCA, and side effects were evaluated.
223585628|NCT01785823|OTHER|D8-4-2|Their background infusions of fentanyl diluent (2 ml/hr of diluent was equivalent with 0.5 μg/kg/hr of fentanyl) were maintained at the fixed-rate of 2 ml/hr until the postoperative 24 hr (FX2-2-2), or at the decremental rates of 6.0 ml/hr (D6-4-2) and 8.0 ml/hr (D8-4-2) during 1 hr, 4.0 ml/hr during 1\~3 hr and 2.0 ml/hr during 3\~24 hr, postoperatively. The visual analogue scores (VAS), the incidence of inadequate analgesia, the frequency of intervention of PCA, and side effects were evaluated.
223585629|NCT01883752|PROCEDURE|Goal-directed Therapy group|Fluid administration is based on the respiratory variation in the pulse oximeter waveform
223585630|NCT00702494|BIOLOGICAL|TB-403|Multiple IV
223585631|NCT00167388|OTHER|feed during blood transfusion|babies receiving the intervention are fed during the PRBC transfusion
223585632|NCT06030284|DEVICE|BurstDR-SCS|Spinal Cord Stimulation with a BurstDR-SCS system.
223585633|NCT06030284|DEVICE|BurstDR-SCS|BurstDR-SCS system turned off.
223585634|NCT04058548|DIAGNOSTIC_TEST|Sit to stand test|Participants will complete a sit to stand test in addition to a 6 minute walk test
223745051|NCT05818579|OTHER|Virtual reality experience|The VR experience is launched on the participants using all-in-one VR head-mount devices. Tablet computers are used to optimize the settings by the intervention facilitators. Each session lasts for approximately one hour with 10 minutes spent on the briefing, 20 minutes spent on the VR experience, and 30 minutes spent on the post-VR group discussion. There are two sessions per week. The whole course lasts for six weeks and there are a total of 12 sessions.
224171345|NCT01901809|DRUG|Dopamine|
224171346|NCT00087594|DRUG|peginterferon alfa-2a [Pegasys]|180 micrograms sc weekly for 24 weeks (G 2/3) or 48 weeks (G 1)
224171347|NCT00087594|DRUG|ribavirin|1000/1200mg (\< or \>= 75 kg, respectively), po in two doses daily for 48 weeks (G 1) or 800 mg po in two doses daily for 24 weeks (G 2/3)
224205434|NCT03428217|DRUG|Placebo|Placebo tablets
223585635|NCT04435600|DRUG|Risankizumab|Subcutaneous Injection
223585636|NCT04435600|DRUG|Ustekinumab|Subcutaneous Injection
223585637|NCT03239015|DRUG|Gefitinib|Gefitinib is an FDA/CFDA approved targeted drugs used for EGFR mutation based on NGS results.
223585638|NCT03239015|DRUG|Erlotinib|Erlotinib is an FDA/CFDA approved targeted drugs used for EGFR mutation based on NGS results.
223585639|NCT03239015|DRUG|Afatinib|Afatinib is an FDA/CFDA approved targeted drugs used for EGFR mutation based on NGS results.
223585640|NCT03239015|DRUG|Trastuzumab|Trastuzumab is an FDA/CFDA approved targeted drugs used for Her2 amplification based on NGS results.
223585641|NCT03239015|DRUG|Oxazolidine|Oxazolidine is an FDA/CFDA approved targeted drugs used for ALK or ROS-1 or MET fusion based on NGS results.
223585642|NCT03239015|DRUG|Olaparib|Olaparib is an FDA/CFDA approved targeted drugs used for BRCA1/2 mutation based on NGS results.
223585643|NCT03239015|DRUG|Everolimus|Everolimus is an FDA/CFDA approved targeted drugs used for mTOR or PI3KCA mutation based on NGS results.
223745052|NCT02075658|DEVICE|AirSeal® System-Interventional|The AirSeal® System consists of an insufflation, filtration, and recirculation system (AirSeal® IFS), a triple lumen filtered tube set, and a valve free trocar (AirSeal® Access Port). The device enables peritoneal access with a novel mechanism to maintain pneumoperitoneum without a mechanical seal.
223745053|NCT02075658|DEVICE|Conventional Insufflator and Trocar|Conventional insufflator and trocars are used in standard procedures and will serve as the base for comparison of the study device (AirSeal® System).
223745054|NCT03209427|DRUG|Morphine 100 μg|Intrathecal injection of morphine100 μg
224171348|NCT06292429|OTHER|Complex Training|"Week 1-4: Foundation Phase Lower Body Resistance Training Squats (Back Squats or Goblet Squats) Deadlifts Lunges~Paired with:~Box Jumps Depth Jumps~Upper Body Resistance Training Bench Press Overhead Press~Paired with:~Medicine Ball Chest Pass Medicine Ball Overhead Throw Rows (Barbell or Dumbbell)~Week 5-8: Strength and Power Phase Lower Body Resistance Training Power Cleans Front Squats Romanian Deadlifts~Paired with:~Box Jumps with Barbell Depth Jumps with Medicine Ball~Upper Body Resistance Training Push Press Pull-Ups or Lat Pulldowns Bent Over Rows~Paired with:~Plyometric Push-Ups Medicine Ball Slam~Week 9-12: Power and Speed Phase Lower Body Resistance Training Snatch Split Squats Jumping Lunges~Paired with:~Box Jumps with Barbell Depth Jumps with Medicine Ball~Upper Body Resistance Training Speed Bench Press Face Pulls Plyometric Pull-Ups~Paired with:~Medicine Ball Chest Pass Medicine Ball Overhead Throw"
224171349|NCT06292429|OTHER|Conventional Training|"Week 0-4 Session 1 Rotator cuff wall compression Forearm flexor compression Alpha ball tricep scrape Band assisted pushups Session 2 Soft ball thoracic breathing Neck ball arm rotations ITb compressions Middle quard compressions~Week 4-8 Session 1 Kneeling pall of band hold Kneeling pall of partner proturbations Leg lower with mediball neutral Half lying arm speed and swing drill Session 2 Single leg band hold Trunk activated psoas lowers Split clam Bulgarian split iso hold~Week 8-12 Session 1 Point kneel thoracic rotations Side lying single arm thoracic abduction Banded side lying clams Side lying abduction from glute Session 2 Low back mobility Kneeling pall off band hold Clean and jerks power drill movements Weighted bench press Session 3 Standing band rotations thoracic only Band pull aparts Tennis ball in trap arm flexion ext thumb to floor Bulgarian weighted"
224171350|NCT06292429|OTHER|Control Group|No intervention given
224171351|NCT01289730|DRUG|Etanercept|Etanercept 25 mg subcutaneously twice a week
224171352|NCT01952041|BEHAVIORAL|Device: Smartphone|
224171353|NCT01952041|BEHAVIORAL|Treatment as usual|
223483317|NCT04230434|BEHAVIORAL|Safety Plan Intervention|The SPI has 6 key steps: (1) identify personalized warning signs for an impending suicide crisis; (2) determine internal coping strategies that distract from suicidal thoughts and urges; (3) identify family and friends who are able to distract from suicidal thoughts and urges and social places that provide the opportunity for interaction; (4) identify individuals who can help provide support during a suicidal crisis; (5) list mental health professionals and urgent care services to contact during a suicidal crisis; and (6) lethal means counseling for making the environment safer (Stanley \& Brown, 2012)
223483318|NCT02763566|DRUG|Abemaciclib|Administered orally
223585644|NCT03239015|DRUG|Cabozantinib|Cabozantinib is an FDA/CFDA approved targeted drugs used for RET mutation based on NGS results.
223745055|NCT03209427|DRUG|Morphine 200 μg|Intrathecal injection of morphine 200 μg
223745056|NCT01139736|DIETARY_SUPPLEMENT|VSL#3|IBS Patients will receive VSL#3 (450 billion lyophilized bacteria/sachet) twice daily for 4 weeks
223745057|NCT05511051|DRUG|Fruquintinib|Fruquintinib
223483319|NCT02763566|DRUG|Anastrozole|Administered orally
223585645|NCT03239015|DRUG|Vemurafenib|Vemurafenib is an FDA/CFDA approved targeted drugs used for BRAF mutation based on NGS results.
223585646|NCT03239015|DRUG|Dabrafenib|Dabrafenib is an FDA/CFDA approved targeted drugs used for BRAF mutation based on NGS results.
223585647|NCT03239015|DRUG|Palbociclib|Palbociclib is an FDA/CFDA approved targeted drugs used for CDK4/6 mutation or amplification based on NGS results.
223585648|NCT03239015|DRUG|PD-1/L1 inhibitor plus anti-angiogenic agent|PD-1/L1 inhibitor plus anti-angiogenic agent is a regimen used for refractory tumor without druggable target
223585649|NCT04773236|DRUG|sodium bicarbonate 8.4%|mixing the sodium bicarbonate with 2%lidocaine and 1:80.000 epinphrine using mixing pen (onset buffering system)
223585650|NCT04773236|DRUG|2%lidocaine with 1:80.000 epinphrine|injection
223585651|NCT04773236|DEVICE|Mixing pen (onset buffering system)|Premixing of the two solutions sodium bicarbonate and lidocaine with epinphrine before the local anesthesia adminstration to the patient
223585652|NCT04856254|PROCEDURE|Trial of labor after cesarean section|The pregnant females with history of previous cesarean section will be classified according to clinical and ultrasound score as patient suitable to undergo trial of labor after CS \[TOLAC\]or not suitable for \[TOLAC\] so undergo from the beginning to elective repeated cesarean section.
223585653|NCT00820404|DRUG|BLI-489|
223585654|NCT00820404|DRUG|Placebo|
223585655|NCT03133221|DRUG|Zydelig|Zydelig given at 150mg continuously in 28-day cycles
223745058|NCT05511051|DRUG|HAIC|HAIC
223745059|NCT04476433|OTHER|Ten Vida (10Vida)|10Vida is a psychoeducational and emotional programme for chronic illness in adolescents and their families.
223745060|NCT04909320|BEHAVIORAL|AWARD advice|Ask about smoking history; Warn about the high risk; Advise to quit; Refer smokers to smoking cessation services (with a referral card); Do it again
224171354|NCT05013476|COMBINATION_PRODUCT|Butterfly handheld ultrasound machine|Both arms of study will utilize the Butterfly ultrasound machine. Only the virtual learners will utilize zoom for their virtual education
224171355|NCT00182494|BEHAVIORAL|Modified diabetes prevention protocol & Metformin|
224171356|NCT00578006|BEHAVIORAL|Questioners|The investigators will ask you to fill out a brief paper questionnaire periodically to tell us how you are feeling, and how satisfied you are with your care.
224171357|NCT00578006|BEHAVIORAL|STAR website|You can report your symptoms every time you come to Sloan-Kettering for an appointment or chemotherapy.
224171358|NCT00186121|DRUG|Anastrozole (Arimidex)|Anastrozole is a prescription hormonal treatment that helps fight breast cancer by lowering the amount of estrogen in the body. It is a non-steroidal aromatase inhibitor, which significantly lowers serum estradiol (estrogen) concentrations, without interfering with the formation of adrenal corticosteroids or aldosterone
224171359|NCT00186121|DRUG|Goserelin (Zoladex)|Goserelin is a palliative treatment of advanced breast cancer in pre- and perimenopausal women
224171360|NCT03550976|BEHAVIORAL|The low-GI diet and muscle training|During the 12-28 weeks of pregnancy, the pregnant women received low-GI diet and exercise intervention.Every two weeks, the pregnant women were followed up to assess the dietary situation and analyze the body composition results.Collect birth outcomes
224171361|NCT01632527|DRUG|HuCNS-SC cells|HuCNS-SC cells transplantation directly into the subretinal space of one eye (Study eye) in a single transplant procedure.
224171362|NCT05007366|BEHAVIORAL|Real-time gait biofeedback|The RTGBF interventions will include eighteen step gait training sessions. The intervention will gradually increase to 3,000 steps at the 9th and 10th session with 100% feedback. During the remaining sessions, the intervention will include 3,000 steps, but the feedback will be gradually tapered off starting with the 11th session.
223483320|NCT02763566|DRUG|Letrozole|Administered orally
223483321|NCT02763566|DRUG|Placebo|Administered orally
223483322|NCT02763566|DRUG|Fulvestrant|Administered intramuscularly
223483323|NCT01837745|DRUG|rhTSH stimulation|Intramuscular injections of rhTSH (0.9 mg) on two consecutive days on LT4 treatment
223483324|NCT01837745|DRUG|I131|An activity of 1.1 GBq of I131 is given orally 24 hours after the second injection of rhTSH.
223483325|NCT01837745|OTHER|Follow up|"* 10 (+/- 2 months) after randomization: a neck ultrasound and a serum Tg measurement after rhTSH or LT4 stimulation~* 2 years (+/- 2 months) after randomization: a serum Tg measurement under LT4 treatment (Tg/LT4)~* 3 years (+/- 2 months) after randomization: a neck ultrasound and a serum Tg/LT4~* 4 years (+/- 2 months) after randomization: a serum Tg/LT4~* 5 years (+/- 2 months) after randomization: a neck ultrasound and a serum Tg/LT4~* 8 years (+/- 2 months) after randomization: a neck ultrasound and a serum Tg/LT4~* 10 years (+/- 2 months) after randomization: a neck ultrasound and a serum Tg/LT4~* 12 years (+/- 2 months) after randomization: a neck ultrasound and a serum Tg/LT4"
223483326|NCT03008044|DEVICE|FiberSense system|A novel CGM system based on a FiberSense system placed through the dermis of the patient.
223483327|NCT03864081|DEVICE|Phase Signal Recorder|The Phase Signal Acquisition (PSAQ) System is a medical device system that is being developed to collect phase signals from patients to support the development and testing of machine learned algorithms. The PSAQ System consists of two components that work together to acquire and transmit the phase signals and patient specific data to a secured, cloud-based repository. The PSAQ System is comprised of: 1) the Phase Signal Recorder (PSR) which is a portable instrument, and 2) the Phase Signal Data Repository (PSDR) which is a cloud based data repository. Data collected during this study will not be used to guide treatment.
223483328|NCT01830517|DRUG|Amlodipine, Losartan|
223745061|NCT04909320|OTHER|Brief leaflet on health warning and smoking cessation|The contents of the leaflet include (1) highlights of the absolute risk of death due to smoking; (2) the whole list of diseases caused by active and second-hand smoking; (3) ten horrible pictorial warnings of health consequences of smoking and second-hand smoking in one page to maximize the impacts; (4) benefits of SC and (5) simple messages to encourage participants to quit smoking and remind them to call the Department of Health SC hotline 183 3183.
223745062|NCT04909320|OTHER|Referral card|The contents consist of brief information and highlights of existing SC services, contact methods, motivation information, and strong supporting messages or slogans.
223483329|NCT03747471|BEHAVIORAL|Diabetic Conversation Map|"Diabetic Conversation Map education tools are a series of tools for facilitated group education 5-8that were developed by Healthy Interactions in collaboration with the International Diabetes Federation (IDF) and are sponsored by Lilly Diabetes.~CM-based education guides people with diabetes through a process with the aim of helping them understand and internalize information about their disease and generate insightful conclusions, which may then result in improved self-management decisions and actions."
223483330|NCT02474641|RADIATION|Standard Radiation|"Conventionally fractionated radiotherapy of the breast followed by a tumor bed boost sequentially or~Conventionally fractionated radiotherapy of the breast with simultaneous integrated boost to the tumor bed or~Hypofractionated radiotherapy of the breast followed by a tumor bed boost sequentially"
223483331|NCT02474641|RADIATION|Hypofractionation with SIB|Hypofractionated radiotherapy of the breast with simultaneous integrated boost to the tumor bed
223483332|NCT05406089|OTHER|Medication history|The study was retrospective and did not involve the application of interventions
223483333|NCT01865019|DEVICE|mechanical ventilation|
223483334|NCT00581191|DRUG|SLV-351|SLV-351 capsules taken once
224171363|NCT05007366|BEHAVIORAL|Sham real-time gait biofeedback|The Sham RTGBF interventions will include eighteen step gait training sessions. The intervention will gradually increase to 3,000 steps at the 9th and 10th session with 100% feedback. During the remaining sessions, the intervention will include 3,000 steps, but the feedback will be gradually tapered off starting with the 11th session.
224171364|NCT01569568|OTHER|MRI scanning|1H MRS, DTI, FMRI
224171365|NCT01569568|BEHAVIORAL|Cognitive testing|Behavioral testing
224171366|NCT01370499|DRUG|LY2216684|
224171367|NCT01370499|DRUG|SSRI|Participants were to enter the study taking their current stable SSRI treatment dose and maintain the same dose throughout the study.
224171368|NCT00532233|DRUG|QAX576|
224171369|NCT06485661|DRUG|Captopril Tablets|Patients will be given captopril to see effect on global longitudinal strain
224171370|NCT01449344|DRUG|Rituximab|Rituximab 375mg/m² IV , day 1
224171371|NCT01449344|DRUG|High dose Ara-C|Ara-C 2000 mg/m² (patients \>65 years or s/p myeloablative treatment: 1000 mg/m²) IV, d 2 and 3
224171372|NCT01449344|DRUG|Dexamethasone|Dexamethasone 40 mg PO, day 1-4
224171373|NCT01449344|DRUG|Bortezomib|Bortezomib 1.5 mg/m² IV, day 1 and 4
224171374|NCT01593176|PROCEDURE|Placement of RSA beads|At the time of surgery sets of up to 9 RSA beads will be implanted on sides of the main fractures lines with the use of the inserter instrument and the image intensifier. In AO/OTA type 33A fractures two sets will be implanted - one in the femoral shaft and one in the distal femoral epiphysis. In AO/OTA type 33C fractures with an extra fracture line through the epiphysis, three sets will be implanted - one in the femoral shaft, one in the main lateral condyle segment and one in the main medial condyle segment. No beads will be planted in comminuted bone fragments. The fracture will then be plated with a LISS plate as it normally would.
224171375|NCT01118585|PROCEDURE|TIF Procedure|The TIF procedure results in the creation of an esophago-gastric fundoplication extending up to 4 cm above the Z-line and 270 degrees around the esophagus.
224171376|NCT06295822|DRUG|Nuan-gong-ye|In this study, the ingredients of nuan-gong-ye are myrrh, dragon's blood, yanhu tuber, white mustard seed, asarum root, argy wormwood leaf, holly oil, clove oil, cinnamon bark oil, glycerin, PEG400.
224171377|NCT06295822|OTHER|Placebo|The placebo was 1/20 concentration of nuan-gong-ye plus glycerin and PEG400.
224171378|NCT01871233|DRUG|Perampanel|Patients will enter this program on the same dose of perampanel that they were receiving at the end of their participation in Studies 207, 307, or 235. Doses of perampanel and of concomitant anti-epileptic drugs (AEDs) can be adjusted based on clinical judgment. A minimum daily dose permitted will be 12 mg per day. Treatment will be prescribed as long as clinically appropriate according to the judgment of the treating physician and the approved summary of Product Characteristics (SmPC). Tablets will be available in strengths of 2 mg, 4 mg, 6 mg, 8 mg, 10 mg, and 12 mg. Patients will be instructed to take their perampanel tablets once daily, by mouth, before bedtime, and with food.
224171379|NCT04770259|OTHER|Timely pre-surgical conditioning|Timely pre-surgical conditioning seeks to prepare frail, pre-frail and / or dependent older patients for the surgery process. For which a work plan has been designed according to your needs and health conditions.
224171380|NCT05486689|OTHER|Pulmonary Rehabilitation|"The enrolled subjects will receivePR program. The 3 weeks inpatient PR will include education, exercise training, nutritional and psychological counselling.~Education: individualized session of 20 minutes each and group session of 45 minutes each. Endurance training: at least twelve 30-minute daily sessions of supervised incremental exercise training according to Maltais, continuous cycling at 50-70% of the maximal load calculated on the basis of the baseline 6MWT according to Hill. Strength training: twelve 30-minute daily sessions of peripheral limb muscle strength training: 2 set of 8 repetitions during the first week, increased at 12 from the second. The initial load will be set at 30/50% of maximal voluntary isometric strength (MVS). Psychological intervention: individual tailored intervention will be offered when the Hospital Anxiety and Depression Scale (HADS) score is \>10 or judged necessary by clinicians, after verifying the subject's motivation."
223483335|NCT00315445|DRUG|Buprenorphine transdermal patch|Buprenorphine 5, 10, or 20 mcg/hour patch applied transdermally for 7-day wear.
223483336|NCT00315445|DRUG|Placebo oxycodone/acetaminophen tablets|Placebo oxycodone/acetaminophen tablets; 1, 2, or 3 tablets taken four times/day.
223483337|NCT00315445|DRUG|OXY/APAP|5 mg oxycodone / 325 mg acetaminophen tablets; 1, 2, or 3 tablets taken four times/day.
223483338|NCT00315445|DRUG|Placebo transdermal patch (TDS)|Placebo transdermal patch 5, 10, or 20 applied transdermally for 7-day wear
223483339|NCT01833676|DRUG|Sevoflurane|
223483340|NCT01833676|DRUG|Desflurane|
223483341|NCT01470716|DRUG|Erlotinib|Neo-adjuvant Erlotinib treatment during maximum 8 weeks.
223483342|NCT06283355|BIOLOGICAL|Nasal Microbiota Transplant (NMT)|nasal microbiota transplant
223483343|NCT06283355|BIOLOGICAL|Placebo|Placebo sterile swab
223483344|NCT03783637|OTHER|Whole grain oats|A meal containing whole grain oats
223483345|NCT03783637|OTHER|Whole grain wheat|A meal containing whole grain wheat
223483346|NCT01931384|DRUG|Human chorionic gonadotrophin|luteal phase support using Human chorionic gonadotrophin 1500 IU intramuscular injection will be given on the day of FET and 6 days later.
223483347|NCT01931384|DRUG|Placebo|Normal saline intramuscularly on the day of embryo transfer and 5 days after embryo transfer.
223585656|NCT02797184|DRUG|KNO3, potassium nitrate|Potassium nitrate (KNO3) will be given orally in 2 gelatin capsules, which will be compounded by the Barnes-Jewish Hospital Pharmacy. The doses are 10 mmol and 20 mmol KNO3.
223483348|NCT04315402|OTHER|prospective, descriptive study via survey|"* Survey administered at check out.~* Patient's rate of follow-up data gathered via chart review."
223483349|NCT04830280|PROCEDURE|posterior quadratus lumborum block|administration local anesthetic solution between the middle layer of the thoracolumbar fascia and QL muscle at the posterior edge of the quadratus lumborum muscle
223483350|NCT01010763|DEVICE|Total Hip Arthroplasty|Degenerated hip is replaced with implantable devices, which include femoral stem, acetabular cup, femoral head and acetabular liner(control group only).
223483351|NCT05218694|DIAGNOSTIC_TEST|CCTA guided focused coronary angiography examination.|Focused examination based on Images from CCTA, by choice of optimal catheter used and projection.
223483352|NCT04184141|DRUG|Hydroxyzine Hydrochloride|Hyroxyzine hydrochloride is given to the patient one hour before surgery.
223483353|NCT04184141|DRUG|Alprazolam tablet|Alprozolam is given to the patient one hour before surgery.
223483354|NCT04184141|DRUG|Placebo|Placebo candy
223483355|NCT06125665|DRUG|Aminophylline-Dexmedetomidine|10 minutes after endotracheal intubation, patients will receive intravenous (IV) bolus of dexmedetomidine 0.5 microgm/kg Lean body weight (LBW) over 15 min, followed immediately by intravenous infusion at 0.2 microgm /kg LBW/h and IV bolus of aminophylline of 5 mg/kg based on the ideal body weight (IBW) over 30 min, followed immediately by intravenous infusion at 0.6 mg/kg IBW/h. The study solutions will be diluted in 50 ml normal saline.
223745063|NCT04909320|OTHER|Self-help smoking cessation booklet|The contents include information about the benefits of quitting, smoking and diseases, methods to quit, how to handle withdrawal symptoms, declaration of quitting, etc.
224171381|NCT06410794|DEVICE|Virtual Reality with Beat Saber|The VR activity used in the intervention was an add-on activity that did not replace any other activities in the programme. The off-the-shelf product Beat Saber (Beat Games, Prague, The Czech Republic) is the VR game of choice in our study. In collaboration with the participating clinics a systematic VR activity plan will be developed. This includes the selection of games and designing a plan that is interesting and motivating both for patients and clinicians.
224171382|NCT01741584|BEHAVIORAL|stationary bike exercise|
224171383|NCT01741584|BEHAVIORAL|aerobic|
224171384|NCT02432911|DRUG|CAG regimen (Aclacinomycin, cytarabine, with/w/o G-CSF)|Aclacinomycin 20mg/d for 4 days combined with cytarabine 20mg bid for 10 days with/without G-CSF 6ug/m2 from 1 day before therapy to day 10 of therapy.
224171385|NCT02432911|DRUG|low dose cytarabine|cytarabine 20mg bid for 10 days.
223483356|NCT06125665|DRUG|Dexmedetomidine|10 minutes after endotracheal intubation, patients will receive intravenous (IV) bolus of dexmedetomidine 0.5 microgm/kg Lean body weight (LBW) over 15 min, followed immediately by intravenous infusion at 0.2 microgm /kg LBW/h. The study solutions will be diluted in 50 ml normal saline.
223483357|NCT02771756|DIETARY_SUPPLEMENT|zhen qishen capsule and Oral Supplement of Yuyikang|
223483358|NCT02771756|DIETARY_SUPPLEMENT|zhen qishen capsule placebo and Oral Supplement of Yuyikang placebo|
223483359|NCT02771756|RADIATION|chemotherapy|
223483360|NCT02771756|OTHER|nutrition education|
223483361|NCT03852511|BIOLOGICAL|NG-350A|NG-350A is oncolytic adenoviral vector which expresses a full length agonist anti-CD40 antibody at the site of virus replication.
223483362|NCT00221780|DEVICE|left ventricular pacing|
223483363|NCT00236717|DRUG|Topiramate; Carbamazepine; Valproate|
223483364|NCT01101178|DRUG|Reformulated OXY (oxycodone HCl)|Reformulated OXY 80-mg tablet x 1 dose taken with food.
223483365|NCT01101178|DRUG|Original OxyContin® (OXY) (oxycodone HCl)|Original OxyContin® (OXY) 80-mg tablet x 1 dose taken with food.
223483366|NCT04700865|DIAGNOSTIC_TEST|AF screening|Continous ECG monitoring for minimum 3 days
223483367|NCT05968235|OTHER|Collecting blood samples|Peripheral blood was collected from the study subjects and blood glucose, glycosylated hemoglobin, triglycerides, total cholesterol, high-density lipoprotein and low-density lipoprotein levels were measured in the peripheral blood.
223483368|NCT04237363|BEHAVIORAL|Exercise|Underwater treadmill training and supplemental overground walk training
223483369|NCT04131296|DIAGNOSTIC_TEST|influenza screening|positive influenza screening
223483370|NCT01850641|DRUG|PA21|
223483371|NCT05672719|DIAGNOSTIC_TEST|Right Heart Catheterization|Procedure
223483372|NCT00141817|DRUG|pantoprazole for approximately 9 weeks.|
224171386|NCT00069251|DRUG|Bupropion|
224171387|NCT03853057|OTHER|body positions|positive pressure ventilation at different body positions
224171388|NCT04945499|DRUG|d-glucose|using d-glucose as an contrast agent on CEST MR Imaging
224171389|NCT00118924|BIOLOGICAL|LGT(TP21)/DEN4|Live attenuated LGT(TP21)/DEN4 vaccine (one of two doses)
224171390|NCT00118924|BIOLOGICAL|Placebo|Placebo for LGT(TP21)/DEN4 vaccine
223483373|NCT01643213|DEVICE|Non Boston Scientific SCS Trial Therapy|No procedures will be attempted as part of this study. This intervention refers to connection and activation of a previously implanted and programmed FDA-approved non Boston Scientific SCS trial system for 30 minutes of SCS therapy for pain
223483374|NCT01643213|DEVICE|BSC approved SCS Trial Therapy w/ OMG|No procedures will be attempted as part of this study. This intervention refers to connection and activation of all Boston Scientific commercially approved SCS trial systems for 30 minutes of SCS therapy for pain
223483375|NCT03077217|DRUG|Rifaximin|The investigators use low-dose rifaximin for the treatment of patients with covert hepatic encephalopathy
223483376|NCT00944554|DRUG|Varenicline|Varenicline given twice a day or five weeks.
223483377|NCT00944554|DRUG|Placebo|Placebo given twice a day or five weeks.
223483378|NCT02251847|DRUG|Rosuvastatin/Ezetimibe|Rosuvastatin 5mg
223483379|NCT02525523|DRUG|Alicaforsen|
223483380|NCT02525523|DRUG|Placebo|
223483381|NCT00894192|DEVICE|Izon Wavefront-guided lenses|Subjects will use prescribed eyeglasses for one week. Their visual functioning will be tested at the end of the week.
223483382|NCT00894192|DEVICE|Conventional lenses|We will test the subjects with these lenses after they have worn them for one week. Same procedures will be followed as with the other lenses.
223483383|NCT05836623|DRUG|Radiolabelled CB307|CB307 radiolabelled with 89-Zirconium (89Zr CB307): drug product is formulated at a concentration of 1 mg/mL (37 MBq)
223745064|NCT04909320|BEHAVIORAL|Positive psychological support through 3-people group chat using instant messaging apps|Each IM chat group will consist of a trained SC counselor (HKU staff), a peer supporter (former smoker), and a participant (smoker). The 3-month group chat-based intervention will consist of regular messages and real-time support through group chat. Regular messages will generally include goal setting, health warnings, abstinence support, positive psychological exercises, and encouragement and will be delivered in a tapering style. During the real-time chatting, SC counsellors and peer supporters will provide real-time chat-based support, and peer supporters will share their quitting experience as appropriate.
224171391|NCT01879891|OTHER|Aerobic|Exercise training will consist of bicycle ergometer riding starting at 67% of heart rate max for 20 minutes. Exercise Intensity will be progressively increased every week until 80% of heart rate max for 40 minute sessions is reached.
223483384|NCT05836623|DRUG|CB307|Trispecific Humabody® targeting CD137, prostate specific membrane antigen and human serum albumin
223483385|NCT00846365|DRUG|Azilsartan medoxomil and chlorthalidone|"Azilsartan medoxomil 20 mg and chlorthalidone 12.5 mg, tablets, orally, and olmesartan medoxomil-hydrochlorothiazide placebo tablets once daily for 8 weeks.~If participant does not achieve target blood pressure at Week 4, then the dosage will be increased to azilsartan medoxomil 40 mg and chlorthalidone 25 mg, tablets, orally, once daily for the remaining 4 weeks."
224171392|NCT02353806|DRUG|Amlodipine besylate|Pregnant and postpartum women will continue taking amlodipine besylate 5 mg for treatment of chronic hypertension as prescribed by their clinician.
224171393|NCT05178329|BEHAVIORAL|Lifting exercise|Patients are instructed for a light lifting exercise after mastectomy.
224171394|NCT05178329|BEHAVIORAL|Standard exercise|Standard exercise program after mastectomy
223483386|NCT00846365|DRUG|Azilsartan medoxomil and chlorthalidone|"Azilsartan medoxomil 40 mg and chlorthalidone 12.5, mg, tablets, orally, and olmesartan medoxomil-hydrochlorothiazide placebo tablets once daily for 8 weeks.~If participant does not achieve target blood pressure at Week 4, then the dosage will be increased to azilsartan medoxomil 80 mg and chlorthalidone 25 mg, tablets, orally, once daily for the remaining 4 weeks."
223483387|NCT00846365|DRUG|Olmesartan medoxomil-hydrochlorothiazide|"Olmesartan medoxomil 20 mg/hydrochlorothiazide 12.5 mg, tablets, orally, and Azilsartan medoxomil and chlorthalidone placebo-matching tablets, orally, once daily for 8 weeks.~If participant does not achieve target blood pressure at Week 4, then the dosage will be increased to olmesartan medoxomil 40 mg/hydrochlorothiazide 25 mg, tablets, orally, once daily for the remaining 4 weeks."
223585657|NCT05770037|DRUG|Alectinib|"Adult patients will be administered alectinib orally at a dose of 600 mg (four 150 mg capsules) twice daily.~Paediatric patients with a body weight ≥40 kg and who are able to swallow the capsules, will be administered alectinib orally at a dose of 600 mg (four 150 mg capsules) twice daily.~Each cycle of treatment will consist of 28 days and patients may continue on treatment until disease progression without clinical benefit, unacceptable toxicity or withdrawal of consent."
224171395|NCT05760651|OTHER|Patient Participation Form|A form that consists of revised osteoporosis knowledge test and osteoporosis awareness scale
224171396|NCT05760651|DIAGNOSTIC_TEST|Timed up - and - go test|. The timed up-and-go test involves rising from a seated position, walking a distance of 3 meters, pivoting, returning to the initial point, and resuming a sitting position. It demonstrates strong inter-rater and intra-rater reliability, offering a reliable means of quantifying functional mobility and balance.
224171397|NCT00651911|DRUG|urate oxidase|First injection of Rasburicase will be done the day of initiation of chemotherapy, or the day before, according to hyperuricemia. Additional doses are permitted q12h during the first 72 hours of chemotherapy if hyperuricemia persists or subject is considered to be at significant risk of tumor lysis complications.
224171398|NCT03196206|DRUG|BMS-986177|Oral Suspension
223483388|NCT04583501|BIOLOGICAL|Omalizumab|Omalizumab will used as dose comparable to to 0.016 mg/kg/IU in serum.
223483389|NCT05079971|DIAGNOSTIC_TEST|Group B: aEEG with concurrent multichannel (full) continuous cEEG review by clinical neurophysiology|In group B, the standart-care equivalent aEEG review is undertaken by NICU staff via a 2-channel display. In addition to the standard care, concurrent full EEG is reviewed remotely with regular feedback by a specialist trained clinical neurophysiologist. The clinical neurophysiology reports only on seizure burden, no information or direction is provided regarding clinical management.
223483390|NCT04337788|OTHER|telehealth applications|telehealth applications during 30 days/patient
224171399|NCT03444246|DIETARY_SUPPLEMENT|Iodine free diet group|120 patients with hyperthyroidism relapsed after new diagnosis or treatment were enrolled. They were randomly divided into iodine free diet group and normal iodine diet group. The two groups were treated with routine antithyroid drugs, followed up for 6 months.
224171400|NCT03444246|DIETARY_SUPPLEMENT|Normal iodine diet group|120 patients with hyperthyroidism relapsed after new diagnosis or treatment were enrolled. They were randomly divided into iodine free diet group and normal iodine diet group. The two groups were treated with routine antithyroid drugs, followed up for 6 months.
224171401|NCT04791241|OTHER|check-list including lung ultrasound|"The investigator will follow the checklist which includes the collection of anamnestic data and clinical signs, the performance of a pulmonary embolism clinical probability score and a cardiopulmonary ultrasound with count -standardized rendering. After completing this checklist, the investigator will note their diagnosis (list of proposals on the data collection sheet), the treatments started (closed list of therapeutic classes). If he orders other tests, he will write them down and then note the diagnosis made and the treatments prescribed after obtaining the results of these tests.~The therapeutic management of patients compared to the usual care in the respective departments may be modified depending on the results of the cardiopulmonary ultrasound . The emergency physician may initiate therapy before the results of additional examinations that he would have usually performed without cardiopulmonary ultrasound."
223483391|NCT03640819|PROCEDURE|Tattooing of biopsied node|Tattooing (marking) of biopsied node with carbon dye (SPOT dye) at the time of fine needle aspiration or core biopsy or separate visit under ultrasound guidance. The dye will be injected in the cortex of the node and the perinodal tissue under ultrasound guidance. Patients will undergo standard (routine) armpit surgery and may receive neoadjuvant chemotherapy as planned by the clinical team. This could be removal of a few lymph glands (sentinel node biopsy) or removal of all the lymph glands (axillary lymph node dissection) in the armpit. The surgeon will try to identify and remove the tattooed lymph gland at the time of planned armpit surgery.
223483392|NCT01535885|BIOLOGICAL|Cytotoxic T Lymphocytes|Patients will be studied in cohorts of 3. Eligible patients will receive a single Multi-Virus CTL line infusion 28-100 days after their transplant. The dose will start at dose level 1 (2.0 x 106/kg). After each cohort of 3 patients has been treated at each of the dose levels, decisions will be made if the next high or lower dose level should be used.
223483393|NCT02109757|OTHER|Software intervention and education|Personal attenuation rating measurements will be taken before and after educating the patient using software program
223483394|NCT02109757|OTHER|Education only|
223483395|NCT01089179|DRUG|Metformin|
223483396|NCT00146471|DRUG|Levetiracetam|1500-2000 mg daily add-on or Placebo Diazepam as needed
223483397|NCT00146471|DRUG|Placebo|1500-2000 mg daily add-on or Placebo Diazepam as needed
223483398|NCT03479905|OTHER|Salter nasal cannula|Oxygen will be delivered via standard nasal cannula during colonoscopy
223483399|NCT03479905|OTHER|Face mask|Oxygen will be delivered via face mask during colonoscopy
223483400|NCT03479905|DEVICE|High Flow Nasal Cannula|A high flow nasal cannula will be placed on the patient at a setting of FiO2 100% and titrated up to 60L/min depending on patient tolerance. 60 L/min is the max flow rate and will be used as tolerated for maximum benefit.
223585658|NCT04526691|DRUG|Datopotamab deruxtecan|Intravenous infusion every 3 weeks (Q3W) on Day 1 of each 21-day cycle (starting datopotamab deruxtecan dose of 4.0 mg/kg)
223585659|NCT04526691|DRUG|KEYTRUDA®|Intravenous infusion Q3W on Day 1 of each 21-day cycle (fixed pembrolizumab dose 200 mg Q3W)
223585660|NCT04526691|DRUG|Carboplatin|Intravenous infusion Q3W on Day 1 or Day 2 of each 21-day cycle (AUC 5)
223585661|NCT04526691|DRUG|Cisplatin|Intravenous infusion Q3W on Day 1 or Day 2 of each 21-day cycle (75 mg/m\^2)
224171402|NCT06313658|PROCEDURE|Total brachial plexus exploration and reconstruction|In the adopted strategy, anatomical reconstruction was always performed when feasible and the lower trunk was considered the primary reinnervation target. Anatomical reconstruction of the plexus was attempted in the presence of at least three available roots; the best quality root stump (usually C5) was used for hand reanimation, while the lower ruptured roots were directed towards the upper and middle trunks. If one or more of the remaining root stumps were of doubtful quality, the compromised roots were grafted to the posterior divisions of the upper and middle trunks, while elbow flexion could be restored by transferring the intercostal nerves (T3-5) to the lateral cord. The lateral root of the median nerve was also included in the intercostal nerve transfer to restore hand sensations. In all cases, the spinal accessory nerve was directly sutured to the suprascapular nerve to restore rotator cuff function.
224171403|NCT01713569|DEVICE|Ulthera Treatment|Focused ultrasound energy delivered below the surface of the skin
224171404|NCT02439424|DEVICE|Reactive ATP|"Reactive ATP turned to on"
224171405|NCT03527290|BEHAVIORAL|Time Restricted Eating|The intervention is delivered in a paradigm in which an individual with abdominal obesity would be referred by their physician to receive dietary counseling from a Registered Dietitian (RD). The aim of the intervention is to improve cardiometabolic health and assist with weight management via 4, individualized counseling sessions over the course of 8 weeks. Participants are educated on basic concepts related to circadian rhythms, metabolism and TRE; and the evidence demonstrating benefit of TRE in animal models and humans. The goal is provide rationale for the potential benefits of a TRE approach. In addition, the RD sessions focus on developing a plan for successfully implementing a TRE approach, identifying challenges for adherence, and a plan for dealing with real or potential challenges. The counseling is focused the TRE concept, with no specific direction or counseling related to modifying the content of the participant's diet or any prescription to reduce energy intake.
224205435|NCT06065475|BEHAVIORAL|Ultrasound-guided bilateral Thyroid Cartilage Plane Block|Use a SonoSite high-frequency linear array transducer (5-13 MHz, SonoSite, USA). Place the transducer parallel to the spine on one side of the neck, ensuring clear visualization of the thyroid cartilage plate under ultrasound. Employ ultrasound-guided out-of-plane techniques to display the needle insertion path and tip. Once the needle tip contacts the upper half of the thyroid cartilage plate, injecting 2.5ml of 2% lidocaine on the surface of the thyroid cartilage each side.
224205436|NCT03889197|DRUG|Sodium supplementation guided by urine sodium concentration algorithm|4 mEq/kg/d sodium added the first time urine \[Na\] below threshold; for each subsequent time urine \[Na\] below threshold, add additional 2 mEq/kg/d.
224205437|NCT05899218|BEHAVIORAL|Critical Narrative Development|"Participants are asked to answer two prompts (describe an experience where you have felt seen as an LGBTQ+ person of color and describe an experience where you have felt unseen as an LGBTQ+ person of color)."
224205438|NCT05159713|BEHAVIORAL|dCBI|"The dCBI, RxWell, is a trans-CBT mobile app product addressing depression and anxiety that was developed based on standard CBT techniques. RxWell provides users users with 40 brief (5-10 minute) skill building techniques for anxiety and depression. Users will have access to a goal-setting tab and in the moment relief section which contains over 17 techniques,14 of which are brief audios to help users engage relaxation responses. The user will be provided with the depression path, which has 40 unique techniques, and if the user expresses significant anxiety, the coach will have the ability to personalize the program by pulling in any of the 53 techniques from the anxiety path, so that the individual can utilize the proper CBT techniques that fit with their presentation."
224205439|NCT05159713|BEHAVIORAL|Treatment as Usual|Participants who are randomly assigned to the Treatment as Usual (TAU) group will receive standard care, which will consist of a tiered stepped care model of behavioral therapy offered by the embedded behavioral therapist at each practice as part of routine care, with the provision of augmentation of therapy (or addition of an antidepressant) at the discretion of the clinical team. Psychotropic medications at baseline and previous behavioral treatment will be recorded at baseline. Number of therapy sessions, delivery modality (face to face versus telemedicine), and addition of antidepressant or other psychotropic medication or dose change will be monitored and recorded over the study period.
224205440|NCT06105697|OTHER|Blood flow restriction Running on Treadmill|Soccer players included in experimental group I will carry out this program for 6 weeks, setting the blood pressure to \~ 60% of limb occlusion pressure (AOP). They will run for 4 sets of 5 minutes, separated by 1 minute of rest, at 50-60% of their maximum Aerobic Speed.
223585662|NCT04121286|DRUG|JAB-3312|JAB-3312 will be supplied as 0.25 mg, 1.0 mg and 4.0 mg capsules.
223585663|NCT04642053|BEHAVIORAL|Dynamic Temporal and Tactile Cuing|Dynamic Temporal and Tactile Cuing is based on principles of integral stimulation where the client watches, listens to and imitates the clinician (Strand, 2020). Treatment will begin by training the child to imitate and simultaneously produce syllables/words with the clinician. Sessions will focus on establishing accurate movement transitions in treated words. The child will be asked to imitate the clinician's production of the target. If the child's imitation is inaccurate, they will be instructed to simultaneously produce the target with the clinician. Simultaneous productions will continue to provide practice opportunity with maximal cuing. As the child gains greater accuracy, simultaneous productions will be faded and direct imitation will be attempted again. Over the course of treatment, the movement gesture will be shaped with the goal being accurate production with normal rate and naturalness.
223585664|NCT01878344|DRUG|NAC|
223585665|NCT01878344|DRUG|Saline|
223585666|NCT05149313|BIOLOGICAL|Lebrikizumab|Lebrikizumab solution for injection administered subcutaneously.
223745065|NCT04909320|BEHAVIORAL|E-messages via SMS|Regular e-messages via SMS at twice per month within 3 months (total 6).
223745066|NCT05096507|PROCEDURE|Hip fracture Surgery (Primary)|Surgery for primary hip fracture requiring general or neuro-axial anaesthesia
224205441|NCT06105697|OTHER|Running on Treadmill|Soccer players included in experimental group II will carry out the program for 6 weeks without occlude the blood pressure. They will run for 4 sets of 5 minutes, separated by 1 minute of rest, at 50-60% of their maximum Aerobic Speed.
224205442|NCT05049460|DEVICE|Theta Burst Stimulation|Four sessions of theta burst stimulation (TBS) at 120 % RMT and comprising 7200 pulses, given with functional targeting.
224205443|NCT05049460|DEVICE|Sham TMS|Four sessions of sham TMS, done using the A/P MagVenture coil, with subject's head separated from the coil by foam padding.
223585667|NCT05149313|DRUG|Lebrikizumab-matching Placebo|Matching Placebo solution for injection administered subcutaneously.
223585668|NCT04831424|BEHAVIORAL|Trier social stress test|The Trier social stress test (TSST) is a tool for investigating psychobiological stress responses in a laboratory setting. It is a laboratory procedure used to reliably induce stress in human research participants. The study is not examining or validating the test itself but rather using it as a tool to measure the response/focus of study.
223585669|NCT05800275|DRUG|Tucatinib Oral Tablet|300 mg, twice daily
223585670|NCT05800275|DRUG|Capecitabine tablets|1000 mg/m², twice daily on days 1-14 of each 21-day cycle
223585671|NCT05800275|DRUG|Trastuzumab Injection|Intrathecal by lumbar puncture or Ommaya Reservoir, 150 mg weekly
223585672|NCT00069992|RADIATION|Total Body Irradiation|Total body irradiation of 450cGy as a single dose, day -6
223585673|NCT00069992|DRUG|Fludarabine|Fludarabine 30mg/m2 Day -5 to -2
223585674|NCT00069992|DRUG|Campath 1H|Campath 1H dosing as per institutional SOPs Day -5 to -2
224171406|NCT03527290|BEHAVIORAL|Standard Cardiometabolic Health Diet|The intervention is delivered in a paradigm in which an individual with abdominal obesity would be referred by their physician to receive dietary counseling from a Registered Dietitian (RD). The aim of the intervention is to improve cardiometabolic health and assist with weight management via 4, individualized counseling sessions over the course of 8 weeks. Participants are educated on basic concepts and known benefits related to eating a diet for cardiometabolic health and weight management recommended by the American Heart Association and the Academy of Nutrition and Dietetics as a standard of practice for dietitians in healthcare settings. The RD sessions focus on adopting a dietary pattern aligned with this approach, identifying challenges to adopting this dietary pattern, and education and plans for dealing with real or potential challenges. The counseling gives no direction related to modifying the timing of dietary intake or any prescription to reduce energy intake.
224171407|NCT06447935|OTHER|No intervention|not applicable - no intervention required
224171408|NCT05703789|PROCEDURE|Dental rehabilitation with either composite resin of crown therapy|Patients in group 1 will be treated with minimal invasive treatment, with restorative composite fillings. Patients in group 2 will be treated with prosthetic rehabilitation, dental crowns.
224171409|NCT05703789|OTHER|Waiting list|Waiting list. Patients randomized to this group will not receive any intervention but answer questionnaires after 4 months on waiting list
223483401|NCT01548365|OTHER|Infusion therapy nursing expert service|"The ITNE will assess the patient and treatment characteristics and use an evidence based decision making algorithm for the selection of the most suitable VAD.~If the VAD needed is a PICC or a midline ITNE will place it following hospital's protocols. If needed, ITNE will also educate and support patients and next of keens in the maintenance of the device at home.~If other devices such as peripheral catheters, central venous catheters (jugular or subclavian) or venous subcutaneous reservoirs are the preferable VADs for patients and treatment conditions, ITNE will work together with health professionals in charge of patients to activate the usual procedures to place the according device."
223585675|NCT03095820|BEHAVIORAL|Supportive therapy|
223585676|NCT03095820|BEHAVIORAL|Multidomain intervention|
223585677|NCT06267066|DRUG|Betamethasone Valerate 0.1% Cream|Moderate potency
223585678|NCT06267066|DEVICE|SmartXide® fractional carbon dioxide laser|Ablative
223585679|NCT06267066|DRUG|Vaseline Topical Product|Emollient
223585680|NCT01731067|DRUG|Cocktail probe drugs|
223585681|NCT02915913|BEHAVIORAL|Experimental: High Intensity Interval|Walking on a treadmill 4min at 80-90% peak heart rate and recovery 4 min at 65% peak heart rate until expenditure of 500 kcal
223585682|NCT02915913|BEHAVIORAL|Resistance training|Completing a resistance circuit (including upper and lower muscle groups) as many times as needed according to subject weight until expenditure of 500 kcal
223585683|NCT02915913|BEHAVIORAL|Plus: High Intensity Interval + Resistance Training|Walking on a treadmill as intervention 1 until 50% the energy expenditure prescribed is reached, then completing a resistance circuit until 100% energy expenditure is reached
223585684|NCT02915913|OTHER|Non-exercise|This group will receive the usual clinical care according to the consensus recommendations of the national goals for cardiovascular health promotion and disease reduction of the American Heart Association and Colombian guidelines COLDEPORTES.
223483402|NCT03241693|OTHER|blended-learning in ethics|"Experimental group followed clinical practices in hospital centers during 8 months.~In addition, an online specific syllabus about Professional Ethics was developed. It consisted of 6 themes and included topics as moral values, ethics and moral, bioethics and professional ethics, ecc. Six online related activities were created: to solve situations related to real clinical practices. Six face to face group sessions based on cooperative learning were planned in order to discuss ethical issues detected among clinical practices during 4 months. Students were divided in small groups, 4-5 participants each, and active participation techniques were used."
223585685|NCT04476927|DEVICE|DiaNose|"DiaNose system is an electronic nose device that can smell diseases in the exhaled breath of patients in real time. The recognition of Volatile Organic Compounds (VOCs) in breath samples approach is non-invasive and for safe diagnosis of diseases.~The DiaNose prototype system consists the following elements:~* A Soft Tube connected to a Sensors Chamber - The soft tube is made of medical grade silicon. The subject blows air into the tube for a few seconds and the exhaled air is directed through the sensors chamber. This unit is for single use.~* Sensors Reading Unit- a multi used unit for sensors signals measurement. The Sensor Reading Unit is connected to a Laptop either via a Data Acquisition Instrument - Commercial unit for resistance measurements (https://www.tek.com/keithley-switching-and-data-acquisition-systems/keithley-daq6510) (option A ) or directly by a USB cable (option B).~* Laptop - Laptop is used to activate and save the test measurements."
223585686|NCT00185601|BEHAVIORAL|Internet Diabetes Self-Management Program|
223585687|NCT00422994|DRUG|ropinirole dosing for up to 28 days|
223585688|NCT02248402|BIOLOGICAL|Vax-DC/MM|
223745067|NCT03896243|DIAGNOSTIC_TEST|Uterine artery ligation (UAL)|"Uterine artery ligation (UAL) We will invite the patients to the hospital at least 6 months after surgery who underwent only uterine artery ligation performed due to uterine atony during C-section.~They will evaluated for their ovarian reserve via hormones and antral follicle count (AFC)"
224171410|NCT00499161|BEHAVIORAL|New model of nursing care|
224171411|NCT00039546|DRUG|cyclophosphamide|
224171412|NCT00039546|DRUG|epirubicin hydrochloride|
224171413|NCT00039546|DRUG|gemcitabine hydrochloride|
224171414|NCT00039546|DRUG|paclitaxel|
224171415|NCT00039546|PROCEDURE|adjuvant therapy|
224171416|NCT00416572|BEHAVIORAL|Education Intervention|Sessions were led by two professionals with expertise in the topic. The sessions began a with presentation of informational material followed by guided discussion of related topics. The first session discussed what to say and not say to children about cancer and how to create a safe environment for them; the second session discussed carrying on with life after the diagnosis of breast cancer, including strategies for managing stress and anxiety and developing meaning in life; the third session talked about how to maintain closeness with a partner and ways to talk about breast cancer; the last session focused on the effects of treatment on reproductive status, and the genetic bases of breast cancer. Participants were also given related booklets and brochures to take home to read.
224171417|NCT00416572|BEHAVIORAL|Nutrition Education Intervention|The nutrition sessions were presented by a professional trained in nutritional science. Sessions included the presentation of information and guided discussion of related topics. The first session discussed information on choosing fruits, vegetables, and low-fat foods and incorporating them into a diet; the second session involved a demonstration of low-fat cooking methods; the third session provided information on the nutritional make-up of a healthy diet and how to shop for it; the last session included information on how to maintain a healthy, low-fat diet while eating out. Women were also asked to keep a four-day food diary, to focus them on their dietary intake and control over it.
224171418|NCT04239807|DEVICE|Group 1 GALILEO WBV|3 month home based WBV training
224171419|NCT04239807|OTHER|Group 2 Control|Training on the floor without WBV
224171420|NCT03459963|DEVICE|indwelling urinary catheter|85 women undergoing first elective CS will be catheterized immediately preoperatively using Foley's catheter by applying catheterization precautions.
224171421|NCT01654224|BIOLOGICAL|High Dose Inactivated Influenza Vaccine|0.5 ml HDIV consisting of 180 mcg (60 mcg each strain) of influenza virus hemagglutinin
224171422|NCT01654224|BIOLOGICAL|Standard Dose Inactivated Influenza Vaccine|0.5 ml of standard dose inactivated influenza vaccine consisting of a total of 45 mcg (15 mcg each strain) of influenza virus hemagglutinin
223483403|NCT03241693|OTHER|control group|"Control group followed clinical practices in hospital centers during 8 months as usual.~In the control group, case study method was also used, thus students in control group had to create and perform a public exposition of a real clinical case about professional ethics. Cases had to be related to clinical practices in order to recognize ethical situations in the work environment. Neither online learning nor online activities were carried out."
223483404|NCT02057341|DRUG|ARRY-371797, p38 inhibitor; oral|multiple dose, single schedule
223483405|NCT04002986|GENETIC|Genetic Testing|A blood draw or saliva kit will be provided to collect subject cells
223483406|NCT06014645|OTHER|Rehabilitation|The study group will be given a core stabilization program in addition to education.
223483407|NCT06014645|OTHER|Control|The control group will receive post-operative cognitive training and will be encouraged to move.
223585689|NCT05018026|BEHAVIORAL|Nutri-Grade labels|All beverage products in the arm are displayed with the Nutri-Grade label. This label was proposed by the Ministry of Health in Singapore to be implemented at the end of 2021. It will apply to all pre-packaged non-alcoholic beverages sold in Singapore. It will have four color-coded grades wherein Grade A, corresponding to the lowest sugar and saturated fat thresholds, will be in green and Grade D, corresponding to the highest sugar and saturated fat thresholds, will be in red.
223585690|NCT03199391|DEVICE|BioWick SureLock Implant|The BioWick SureLock implant is a device for shoulder and extremity surgery, constructed of Ultra High Molecular Weight Polyethylene Suture. BioWick SureLock is uniquely designed to minimize these risks by avoiding manual tensioning with an inserter mechanism that ensures that the implant is consistently deployed below the cortex.
223585691|NCT02923076|OTHER|CCR5 delta32/delta32 cord blood transplantation|
223585692|NCT01867086|BIOLOGICAL|Vigil™ Vaccine|Patients meeting eligibility criteria will receive Vigil™ 1.0 x 10e7 cells/intradermal injection once every 3 weeks.
223745068|NCT02813603|PROCEDURE|EBUS|19G and 22G EBUS needles are compared in a randomized prospective way in lung cancer patients with enlarged mediastinal lymph nodes.
223745069|NCT00535548|BIOLOGICAL|Stem cell therapy|Injection of a hematopoietic stem cell suspension (50'000 CD 34+ cells per microliter) into the wound (1 microliter per cm2 of wound surface)
223745070|NCT05347316|DRUG|Colchicine|0.5 mg per day colchicine for 12 months
223745071|NCT01899534|OTHER|E-screening|E-screening will be conducted on a computer tablet with wireless access. The tablet will be configured with the screening tool currently used in each clinic. The content and order of individual questions will be identical to the paper-pen version. Response options will be listed in full view under each question. Women select responses by touching the screen.
223483408|NCT00862992|DRUG|Cariprazine 3 mg|
223483409|NCT00862992|DRUG|Cariprazine 6 mg|
223483410|NCT00862992|DRUG|Cariprazine 12.5 mg|
223483411|NCT02094040|BEHAVIORAL|Receive municipality-based follow-up visit|Systematic electronic referral from hospital to municipality of high risk people at discharge from a medical ward. Contact from municipality service to primary physician and citizen, to arrange first home visit within 7 days with focus on: medication, rehabilitation plan and health care appointments, functional level and need for further health care initiatives. The visit is concluded by planning of further visits (up till tree) and division of responsibilities between primary physician and the municipality service.
223483412|NCT02872441|BIOLOGICAL|blood sample|One blood sample of 50 milliliter 24 hours after the inclusion
224171423|NCT02881918|OTHER|Blood sample|Blood sample with 6 tube of blood (40 mL), after diagnosis and before any specific anticancer treatment
224171424|NCT06379672|OTHER|Resonance breathing|Resonant breathing was used on the subjects, using nasal inhalation and oral exhalation, for a total of 12 weeks.
224171425|NCT02283229|BEHAVIORAL|Newborns with preventive caring advices|Advices to prevent head molding
223483413|NCT03704740|BIOLOGICAL|NBP607-QIV|Purified inactivated influenza virus surface antigens of four strains (quadrivalent)
223483414|NCT03704740|BIOLOGICAL|Agrippal|Influenza virus surface antigens of three strains (trivalent)
223483415|NCT00720759|DRUG|D-cycloserine + distributed treatment|Subjects will receive CIMT 2 hours/day, 3 days a week, for 10 weeks, in conjunction with d-cycloserine 50 mg PO administered before each treatment session
223483416|NCT00720759|BEHAVIORAL|D-cycloserine + condensed treatment|Subjects will receive CIMT 6 hours/day, 5 days a week, for 2 weeks, in conjunction with d-cycloserine 50 mg PO administered before each treatment session
223483417|NCT00720759|DRUG|Placebo + distributed treatment|Subjects will receive CIMT 2 hours/day, 3 days a week, for 10 weeks, in conjunction with placebo administered before each treatment session
223483418|NCT00720759|BEHAVIORAL|Placebo + condensed treatment|Subjects will receive CIMT 6 hours/day, 5 days a week, for 2 weeks, in conjunction with placebo administered before each treatment session
223483419|NCT00910585|BEHAVIORAL|Coaching, providing social support|Active telephone and in person coaching
223483420|NCT02318940|DEVICE|central venous catheter|installation of Central venous catheter ultrasound guided
223483421|NCT02318940|DEVICE|central venous catheter|installation of Central venous catheter landmark guided
223483422|NCT02837159|OTHER|mHealth application|Dietary and physical activity recommendations trough a mobile application
223483423|NCT01047319|DRUG|Laquinimod|One capsule containing 0.6 mg laquinimod to be administered orally once daily.
223483424|NCT02697045|DRUG|Aripiprazole 400mg LAI|Aripiprazole 400mg, IM, Once a month
223483425|NCT04626076|OTHER|Comparative Observational Cohort Study|This is a comparative observational cohort study; therefore, no preventive interventions, visits or laboratory tests are mandated. Dosing and duration of potential prophylactic treatment is at the discretion of the institution and/or healthcare provider, in accordance with regular local practice. However, serology testing for SARS-CoV-2 antibodies will be offered to the first 50% of participating HCWs per country, at enrollment and at the last follow-up (i.e. at Week 12)
223483426|NCT05987384|DIETARY_SUPPLEMENT|Arachidonic acid|D3 ARA group will receive ARA capsules from the third day of the study. D6 ARA group will receive ARA capsules from the sixth day of the study
223483427|NCT05987384|DIETARY_SUPPLEMENT|Sunflower oil|The placebo group and D6 ARA group will receive sunflower oil capsules from the third day of the study. D6 ARA group will stop receiving sunflower oil capsules from the fifth day of the study.
223483428|NCT05987384|BIOLOGICAL|Rabies Vaccine (Vero Cell) for Human Use|Every participant will receive three doses of rabies vaccination.
223483429|NCT00430326|DRUG|Avotermin|
223483430|NCT00374478|DRUG|Scopolamine|
223483431|NCT02072200|DRUG|Lodotra®|Single arm will be received below oral 10mg tablet daily and maximum 10mg/d depending on the clinical symptoms and the patient's response
223483432|NCT03513419|BEHAVIORAL|The AMOR Method|The parent resilience training involves a series of eight weekly 90-minute group sessions with up to 8 parents of young children with ASD (4- 10:11 years old) per group, as well as three individual sessions.
223483433|NCT05503498|OTHER|DATA RECORDING|RECORD PLASMA FIBRI LEVELS AFTER FIBRINOGEN ADMINISTRATION
223483434|NCT01977833|OTHER|High Calorie Breakfast (BTdiet)|High Caloric Breakfast Test Diet (BTdiet): in which the majority of energy load will be consumed in the morning and with reduced dinner
223483435|NCT01977833|OTHER|High Caloric Dinner (DTdiet)|High Caloric Dinner (DTdiet): resembling a skipping breakfast plan, in which the majority of energy load will be consumed in the evening with minimal caloric content at breakfast
223483436|NCT04084015|DEVICE|Axillary Impella®|All enrolled patients will undergo surgical placement of Impella® via axillary artery within 48 hours after peripheral VA ECMO initiation and be managed with early extubation and ambulation strategy
223483437|NCT02696798|DRUG|Ixekizumab|Administered SC
223483438|NCT02696798|DRUG|Placebo|Administered SC
223483439|NCT01277861|DRUG|Fentanyl|FENTANYL PRETREATMENT DURING INDUCTION OF ANESTHESIA
223483440|NCT03311906|DRUG|0.8% Hyaluronic Acid|Application of 0.8% hyaluronic acid after scaling and root planing
223483441|NCT03311906|PROCEDURE|Scaling and Root Planing|Scaling of the teeth using hand and ultrasonic scalers followed by planing of the root with curettes
223483442|NCT03879694|BIOLOGICAL|Incomplete Freund's Adjuvant|Given SC
223483443|NCT03879694|DRUG|Octreotide Acetate|Given IM
223483444|NCT03879694|BIOLOGICAL|Sargramostim|Given SC
223483445|NCT03879694|BIOLOGICAL|SVN53-67/M57-KLH Peptide Vaccine|Given SC
223483446|NCT04399447|RADIATION|Echocardiography|left ventricular systolic function of all participants were measured by tissue motion tracking of mitral annular displacement using PHILIPS
223483447|NCT02735564|PROCEDURE|Bariatric Surgery|
223483448|NCT00857389|DRUG|Thiotepa|5 mg/kg through a central venous catheter (CVC) over 2 hours on Day -8.
223483449|NCT00857389|DRUG|Clofarabine|40 mg/m\^2 through a central venous catheter (CVC) over 1 hour daily on 4 consecutive days (Days -6 through -3).
224171426|NCT02283229|OTHER|Newborns with normal caring advices|Normal handling
224171427|NCT04203290|DRUG|Bupivacaine|%0.25 bupivacaine solution
224171428|NCT04203290|DRUG|Sevoflurane|End tidal sevoflurane concentration
224171429|NCT04121182|OTHER|On-line training|"Nursing teams randomized in the intervention group will benefit from an intervention in the form of a specific training online on the prevention of pneumonia and their management in the nursing home This training focuses on prevention, and management during the infectious period (the false food route and the management of pneumonia)."
224171430|NCT04121182|OTHER|Usual practice|Nursing home with usual practice : The act of comparison is defined by the usual care, as they are performed in the nursing home at the time of the study. No restrictions are placed on residents or caregivers of any kind in the care of the resident.
224171431|NCT04245813|BEHAVIORAL|Interdisciplinary educational program|Interdisciplinary educational component based on the Clinical Practice Guide for Heart Failure
223585693|NCT01867086|DRUG|Carboplatinum|Patients meeting eligibility criteria will receive either carboplatinum alone (AUC 6/30 minute infusion) or carboplatinum (AUC 5/30 minute infusion) and taxol (175 mg/m2 3-hour infusion) one day prior to Vigil™ 1.0 x 10e7 cells/ intradermal injection, once every three weeks. At recurrence, patients allergic to carboplatinum will receive docetaxel 75 mg/m2/1 hour infusion, one day prior to Vigil™ 1.0 x 10e7 cells/intradermal injection every 3 weeks. Patients with stable disease (SD) or better and unable to tolerate continued chemotherapy will be allowed to continue Vigil™ alone for up to 12 cycles or as long as vaccine is available; conversely, patients with SD or better who exhaust Vigil™ supply may continue on chemotherapy alone.
223585694|NCT01867086|DRUG|Carboplatinum and Taxol|Patients meeting eligibility criteria will receive either carboplatinum alone (AUC 6/30 minute infusion) or carboplatinum (AUC 5/30 minute infusion) and taxol (175 mg/m2 3-hour infusion one day prior to Vigil™ 1.0 x 10e7 cells/ intradermal injection, once every three weeks. At recurrence, patients allergic to carboplatinum will receive docetaxel 75 mg/m2/1 hour infusion, one day prior to Vigil™ 1.0 x 10e7 cells/intradermal injection every 3 weeks. Patients with stable disease (SD) or better and unable to tolerate continued chemotherapy will be allowed to continue Vigil™ alone for up to 12 cycles or as long as vaccine is available; conversely, patients with SD or better who exhaust Vigil™ supply may continue on chemotherapy alone.
224171432|NCT05632705|OTHER|Closing pack|A closing pack, new sterile gloves and new sterile drapes will be used when commencing closure of the sheath and skin
224171433|NCT05159063|DEVICE|Ultrasound imaging|"Patients scheduled to undergo right heart catheterization (RHC) as their standard of care will be included in the study.~The patient will be positioned supine at 0 degrees with normal restful breathing and patient looking straight up. After the right sternocleidomastoid muscle is identified, internal jugular vein (IJV) will be imaged at the apex of the triangle formed by the sternal and clavicular heads of the muscle. Similarly, the inferior vena cava (IVC) will be imaged at the caudal end of the sternum. The diameters of both the veins will be noted during normal respiration. The patients will then be asked to sniff and collapsibility of the veins will be noted. No pressure will be applied on the neck. The anticipated duration for image acquisition is between 5 to 10 minutes.~The patients will undergo the scheduled RHC within 1 hour as scheduled."
224171434|NCT04835389|BIOLOGICAL|AlloGen Liquid|Amniotic fluid
224171435|NCT04835389|DRUG|Placebo|0.9% normal saline
224171436|NCT01208025|OTHER|Magnetic Resonance Imaging (MRI), Multidetector Computed Tomography (MDCT), Ultrasonography (US), Transcranial Doppler (TCD)|3 Tesla Magnetic Resonance Imaging (MRI), Multidetector Computed Tomography (MDCT), Ultrasonography (US), Transcranial Doppler (TCD)
224171437|NCT02286336|OTHER|brachial plexus block|brachial plexus block with ropivacaine 40ml
224171438|NCT00120029|BEHAVIORAL|weight loss counseling|
224171439|NCT00575003|DRUG|CYT003-QbG10|6 subcutaneous injections
224171440|NCT00389922|DRUG|lapatinib ditosylate|Given orally for 28 days per dose level (Dose level 1: 250mg; Dose level 2: 500mg; Dose level 3: 1000mg; Dose level 4: 1250mg; Dose level 5: 1500mg; Dose level 6: 1500mg)
224171441|NCT00389922|DRUG|vinorelbine ditartrate|Given IV Days 1, 8 and 15 per dose level (Dose level 1: 20mg/m2; Dose level 2: 20mg/m2; Dose level 3: 20mg/m2; Dose level 4: 20mg/m2; Dose level 5: 20mg/m2; Dose level 6: 25mg/m2)
224171442|NCT00389922|GENETIC|comparative genomic hybridization|Molecular correlative study
224171443|NCT00389922|GENETIC|cytogenetic analysis|Molecular correlative study
224171444|NCT00389922|GENETIC|gene expression analysis|Molecular correlative study
224171445|NCT00389922|GENETIC|mutation analysis|Molecular correlative study
224171446|NCT00389922|GENETIC|polymerase chain reaction|Molecular correlative study
223483450|NCT00857389|DRUG|Busulfan|"Test dose of 0.5 mg/kg through a central venous catheter (CVC)over 30 minutes on Day -7.~High dose 5,000 µMol-min through a central venous catheter (CVC) over 3 hours on Days -5, -4, and -3."
223483451|NCT00857389|PROCEDURE|Allogeneic Stem Cell Transplantation|Infusion of stem cells through through a central venous catheter (CVC) On Day 0.
223483452|NCT00857389|DRUG|Thymoglobulin (ATG)|1.25 mg/kg by vein on Day -4 and 1.75 mg/kg on Day -3.
223745072|NCT04991571|DRUG|Zibotentan (Treatment A)|Zibotentan capsule will be administered orally as multiple doses in Part 1 and as single dose in Part 2.
223745073|NCT04991571|DRUG|Dapagliflozin (Treatment A)|Dapagliflozin tablet will be administered orally as single dose in Part 2.
223745074|NCT04991571|DRUG|Zibotentan/Dapagliflozin - Formulation 1 (Treatment B)|Zibotentan/Dapagliflozin tablet will be administered orally as single dose in Part 2.
223745075|NCT04991571|DRUG|Zibotentan/Dapagliflozin - Formulation 2 (Treatment C)|Zibotentan/Dapagliflozin tablet will be administered orally as single dose in Part 2.
223483453|NCT00857389|DRUG|G-CSF (Filgrastim)|5 µg/kg Injection under the skin once a day, starting 1 week after transplant, until blood cell levels return to normal.
223745076|NCT00032643|DRUG|DITPA|
224171447|NCT00389922|GENETIC|polymorphism analysis|Molecular correlative study
224171448|NCT00389922|GENETIC|proteomic profiling|Molecular correlative study
224171449|NCT00389922|GENETIC|reverse transcriptase-polymerase chain reaction|Molecular correlative study
224171450|NCT00389922|OTHER|immunohistochemistry staining method|Molecular correlative study
224171451|NCT00389922|OTHER|laboratory biomarker analysis|Molecular correlative study
224171452|NCT00389922|DRUG|lapatinib ditosylate|Given orally on Days 2-5, 9-12 and 16-25 per dose level (Dose level 1: 1250mg; Dose level 2: 1500mg; Dose level 3: 1500mg; Dose level 4: 1700mg)
224171453|NCT00389922|DRUG|Vinorelbine ditartrate|Given IV Days 1, 8 and 15 per dose level (Dose level 1: 20mg/m2; Dose level 2: 20mg/m2; Dose level 3: 25mg/m2; Dose level 4: 25mg/m2)
224171454|NCT00166504|DRUG|ezetimibe (+) simvastatin|simvastatin/ezetimibe 10/20 mg
224171455|NCT00166504|DRUG|atorvastatin|atorvastatin 10 mg
224171456|NCT05290935|DRUG|Anti-PD-1 antibody camrelizumab|Camrelizumab: 200 mg every time, every 3 weeks, which would be sustained until the appearance of disease progression on intolerable adverse events, and no more than 24 months
224171457|NCT05290935|DRUG|Albumin-bound paclitaxel|Albumin-bound paclitaxel: 200-300 mg every time, every 3 weeks, no more than 6 courses
224171458|NCT00270010|DRUG|epoetin alfa|
224205444|NCT04094818|DIAGNOSTIC_TEST|TriVerity|Blood collection for mRNA analysis, Procalcitonin and CRP determination, molecular analysis of nasopharyngeal swab collection and sputum/ BAL sample collection
224171459|NCT03773510|DRUG|Trabectedin discontinuation|"Patients who did not progressed after 6 cycles of trabectedin will stop the treatment and resume drug in case of progression for other 6 cycles.~The treatment will be resumed again at progression for other 6 cycles and this scheme of treatment will be proposed until progression under trabectedin."
224171460|NCT03773510|DRUG|Trabectedin continuation|Patients who did not progressed after 6 cycles of trabectedin will continue the treatment until Progressive Disease or unacceptable toxicity
224171461|NCT02243163|BEHAVIORAL|Yoga exercise|Subjects will receive regular 90-minutes yoga classes twice a week for 3 months.
224171462|NCT05617417|OTHER|Local applied injectable platelet-rich fibrin in women with stress urinary incontinence|Injectable platelet-rich fibrin was prepared by centrifuging venous blood taken from women with stress urinary incontinence and applied locally to the anterior vaginal wall of the patients.
224171463|NCT04998175|PROCEDURE|ventriculo-peritoneal shunt|A ventriculoperitoneal shunt is a tube that drains excess cerebrospinal fluid into abdomen
224171464|NCT02015858|PROCEDURE|Chest drain withdrawal|
224171465|NCT02015858|DEVICE|Pain Monitor|
224171466|NCT02641665|PROCEDURE|Cardiac valve surgery|Aortic or mitral valve replacement/repair performed in isolation of in addition to coronary artery bypass graft(s).
224171467|NCT01410331|BIOLOGICAL|JVS-100(4 mg) or placebo/8 injections|4 mg of JVS-100 or placebo delivered in 8 injections
224171468|NCT01410331|BIOLOGICAL|JVS-100(8 mg) or placebo/8 injections|8 mg of JVS-100 or placebo delivered in 8 injections
224171469|NCT01410331|BIOLOGICAL|JVS-100(8 mg) or placebo/16 injections|8 mg of JVS-100 or placebo delivered in 16 injections
224171470|NCT01410331|BIOLOGICAL|JVS-100(16 mg) or placebo/16 injections|16 mg of JVS-100 or placebo delivered in 16 injections
224171471|NCT04474210|DRUG|JNJ-56136379|Participants will receive JNJ-56136379 tablets orally.
224171472|NCT04990999|PROCEDURE|Vestibular Root Extraction|a 1-cm long vestibular access incision was cut, 3-4 mm apical to the mucogingival junction of the involved tooth, then pushing the vestibular pouch in an incisal direction exposing the apical root area, and allowing direct undisturbed access to the root surface
224171473|NCT04990999|PROCEDURE|Atraumatic extractions using periotomes followed by conventional forceps|a sulcular releasing incision suing a micro scalpel was made to detach the surrounding tissues, followed by applying the periotome interproximally into the PDL space, widening the attached periodontal ligaments space.
224171474|NCT03686462|DEVICE|Virtual reality-based interactive treadmill training|During the 30-min training session, VR based interaction and feedback will be provided; the foot location will be visualized in the VR screen (semi-immersive condition), the obstacles will be seen in the screen from which subjects has to avoid, gait speed will be visualized, slopes of the treadmill will be changed according to the slope changes in VR and distractors will be added. Dual tasks will also be provided. Subjects in this group will receive a 30min/session, 3 sessions/week for 4 weeks, the total of 12 sessions of VR-based training.
224171475|NCT03686462|DEVICE|Treadmill training without VR-based interaction|Treadmill training without VR-based interaction
223585695|NCT06584253|OTHER|Musculoskeletal System Health Questionnaire Scale|It is a 14-item scale that evaluates pain intensity, physical function, sleep, fatigue, emotional state, physical activity level, impact on work and social life, independence, self-management ability and general impact.
223585696|NCT06584253|OTHER|International Physical Activity Questionnaire (short form)|"International Physical Activity Questionnaire (short form) -~The IPAQ assesses a range of physical activities, including leisure-time physical activities, indoor and outdoor activities, work-related physical activities, and transportation-related physical activities."
223585697|NCT06584253|OTHER|Pittsburgh Sleep Quality Index|It is a questionnaire that evaluates sleep quality with questions asked under 7 main headings: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disorders, use of sleep aids and daytime functions.
223585698|NCT06584253|OTHER|Cognitive Failures Questionnaire|The questionnaire aims to measure daily cognitive errors. It assesses simple errors made over the last 6 weeks, as well as perception (e.g., are there times when you can't see something you need at the supermarket even though it's there?), memory (e.g., have you ever forgotten people's names?) and motor functioning (e.g., have you ever bumped into anyone?).
224171476|NCT00741910|DRUG|Semapimod|semapimod IV 60 mg x 3 days q 6 - 10 weeks
224171477|NCT03819023|DIAGNOSTIC_TEST|Respilife monitor|Respilife monitor
224171478|NCT03464929|DEVICE|Airtraq indirect laryngoscopy|Attempt to intubation using the Airtraq device
224171479|NCT03464929|DEVICE|King Vision indirect laryngoscopy|Attempt to intubation using the King Vision device
224305720|NCT05061186|OTHER|Conventional Breathing Exercise Group|"Breathing Exercises: (approximately 20 minutes per day)~● Pursed lip breathing: (Sit with your back straight. Inhale through your nose for two seconds. Purse your lips like you're blowing on hot food and then breathe out slowly, taking twice as long to exhale as you took to breathe in. 4-5 times a day)~● Diaphragmatic breathing: (Lie on your back on a flat surface, knees bent and head supported. Use pillow under knees to support your legs. Breathe in slowly through your nose Tighten your stomach muscles, letting them fall inward as you exhale through pursed lips. Practice this exercise 5-10 minutes about 3-4 times per day).~● Incentive spirometer: (Hold in an upright position. Breathe in slowly and as deeply as possible. Hold your breath as long as possible (at least for 5 seconds). Then exhale slowly Rest for a few seconds and at least 10 times every hour)"
224305721|NCT01391741|OTHER|Visual Cues|Walking with visual cues for 30 minutes, 4 times a week for 4 weeks
224305722|NCT01391741|OTHER|Walking without visual cues|Walking without visual cues, but verbal encouragement twice a week to take longer steps, for 30 minutes, 4
224305723|NCT01712737|OTHER|Dietary intervention|
224305724|NCT04452253|DIETARY_SUPPLEMENT|PS128|PS128 belongs to Lactobacillus plantarum subsp. plantarumand. Probiotic capsules contain 10 billion CFU (colony forming units) of PS128
224305725|NCT04452253|DIETARY_SUPPLEMENT|PS23 live|PS23 belongs to Lactobacillus paracasei group.Probiotic capsules contain 10 billion CFU (colony forming units) of PS23
224305726|NCT04452253|DIETARY_SUPPLEMENT|PS23 heat-treated|The PS23 heat-treated probiotic capsule contain 10 billion of PS23 cells.
224305727|NCT04452253|OTHER|Placebo|The placebo capsule contains microcrystalline cellulose.
224171480|NCT03351660|DIAGNOSTIC_TEST|connected ECG|Cardiosecur allows the realization of a 15 or 22 leads ECG with only 4 electrodes connected to a tablet with an automatic interpretation function
224171481|NCT06220227|PROCEDURE|vitrification and thawing procedures|"Vitrification and thawing are crucial steps in infertility treatment. Vitrification solutions are aqueous cryoprotectant solutions that undergo solidification (and not freezing) when cooled at high rates to very low temperatures, thanks to an increase in viscosity.~Thawing consists in remove the cryoprotectants, warm and dilute the blastocyst."
224171482|NCT05743439|BEHAVIORAL|Early Augmentative and Alternative Communication (AAC) Intervention|Caregivers will receive 24, 50 min intervention sessions twice a week for three months. During each intervention session, the therapist provides instruction and coaching on using AAC and a set of evidence-based language support strategies. Strategies are taught sequentially in three phases: (1) Responding to all Communication, (2) Teaching Words, and (3) Creating Communication Opportunities. Caregivers practice using the AAC intervention strategies during three, five-minute routines with their children. Therapists coach the caregiver on using the targeted strategies during these routines, encouraging caregivers to reflect on their implementation, and developing a plan to use the AAC strategies during activities not practiced during the intervention session. The AAC intervention is provided to families using an evidence-based service delivery model, Family Guided Routines Based Intervention.
224171483|NCT03903861|OTHER|Glucose alone|Young men or women will complete a glycogen depleting bout of exercise followed by the provision of glucose-alone over 4 hours of recovery before a subsequent bout of exercise.
224171484|NCT03903861|OTHER|Galactose alone|Young men or women will complete a glycogen depleting bout of exercise followed by the provision of galactose-alone over 4 hours of recovery before a subsequent bout of exercise.
224171485|NCT03903861|OTHER|Glucose and galactose|Young men or women will complete a glycogen depleting bout of exercise followed by the provision of glucose and galactose over 4 hours of recovery before a subsequent bout of exercise.
224171486|NCT04778722|DIETARY_SUPPLEMENT|Oral probiotics|containing four Lactobacillus strains (Lactobacillus crispatus -Lbv88, Lactobacillus rhamnosus -Lbv96, Lactobacillus jensenii -Lbv116, and Lactobacillus gasseri -Lbv150)
224171487|NCT05248646|DRUG|Sibeprenlimab 400 mg|Sibeprenlimab 400 mg s.c. q 4 weeks
224171488|NCT05248646|DRUG|Placebo|Placebo s.c. q 4 weeks
224171489|NCT03062670|OTHER|Retreat|Full day off-site training session
224171490|NCT01776372|DEVICE|Medela Thopaz Thoracic Drainage System|
224171491|NCT01776372|DEVICE|Atrium Express Dry Seal Chest Drain|
224171492|NCT05465668|DRUG|DWP16001 Drug A|DWP16001 Drug A
224171493|NCT05465668|DRUG|DWP16001 Drug C|DWP16001 Drug C
224205445|NCT05246111|DRUG|[14C]Berzosertib|Participants received single intravenous infusion of \[14C\]Berzosertib at a dose of 210 milligrams per square meter (mg/m\^2) on Day 1 in Period 1 and stay in clinical research unit (CRU) is required until the discharge criteria are met with a maximum confinement period of 15 days.
224205446|NCT05246111|DRUG|Berzosertib|Participants received single intravenous infusion of Berzosertib at a dose of 210 mg/m\^2 on Day 2 and Day 5 in period 2 until disease progression or other criteria for study intervention discontinuation were met.
223483454|NCT00857389|DRUG|Tacrolimus|Starting dose of 0.015 mg/kg (ideal body weight) as a 24 hour continuous infusion daily, to be changed to oral dosing when tolerated. Tacrolimus is to be tapered as indicated after transplant day 90, if no GVHD is present. Tacrolimus is adjusted trough level of 5-15 ng/mL.
224205447|NCT05246111|DRUG|Topotecan|Participants received topotecan at a dose of 1.25 mg/m\^2 intravenously on Days 1 through 5 of each 21-day cycle in period 2 until disease progression or other criteria for study intervention discontinuation were met.
224205448|NCT04066192|DRUG|Brexpiprazole|Brexpiprazole will be used in .5mg, 1mg, 2mg, and 4mg doses as described in the study arms.
224205449|NCT04066192|DRUG|Placebo|A medically inert placebo medication will be used as described in the study arms.
224205450|NCT05397119|BIOLOGICAL|BW-1014: 25 µg rH5 in 20% NE - pipette - IN|20% Nanoemulsion and 25 µg recombinant H5 antigen administered intranasally by an electronic pipette (500µL) Two doses administered 4 weeks apart
224205451|NCT05397119|BIOLOGICAL|BW-1014: 50 µg rH5 in 20% NE - pipette - IN|20% Nanoemulsion and 50 µg recombinant H5 antigen administered intranasally by an electronic pipette (500µL) Two doses administered 4 weeks apart
224205452|NCT05397119|BIOLOGICAL|BW-1014: 100 µg rH5 in 20% NE - pipette - IN|20% Nanoemulsion and 100 µg recombinant H5 antigen administered intranasally by an electronic pipette (500µL) Two doses administered 4 weeks apart
224205453|NCT05397119|BIOLOGICAL|rH5 (100 µg) control - pipette - IN|100 µg recombinant H5 antigen (without adjuvant) administered intranasally by an electronic pipette (500µL) Two doses administered 4 weeks apart
224205454|NCT05397119|BIOLOGICAL|Saline (Placebo) - pipette - IN|Saline (negative control) administered intranasally by an electronic pipette (500µL) Two doses administered 4 weeks apart
224205455|NCT05397119|BIOLOGICAL|H5N1 IIV - IM|90 µg H5N1 IIV administered intramuscularly (1 mL) One booster dose administered 6 months following last immunization
224205456|NCT02549833|BIOLOGICAL|GBM6-AD and poly-ICLC before and after surgery|Subcutaneous vaccination with GBM6-AD lysate protein and poly-ICLC combination
224205457|NCT02549833|BIOLOGICAL|GBM6-AD and poly-ICLC after surgery only|Subcutaneous vaccination with GBM6-AD lysate protein and poly-ICLC combination
224205458|NCT06136676|BEHAVIORAL|Arm 1 - Heart-Centred Spiritual Meditation: Christian contemplation|Participants assigned to this condition will receive daily audio instructions of approximately 20 minutes daily over the course of 8 weeks focused on Christian contemplation delivered through a mobile app. The intervention will consist of a core contemplative practice focused on heart visualisation based on Christian tradition and prayer recitation with breathing to focus their attention on and connection to God.
224205459|NCT06136676|BEHAVIORAL|Arm 1 - Heart-Centred Spiritual Meditation: Islamic contemplation|Participants assigned to this condition will receive daily audio instructions of approximately 20 minutes daily over the course of 8 weeks, focused on Islamic contemplation delivered through a mobile app. The intervention will consist of a core contemplative practice focused on heart visualisation based on Islamic tradition and prayer recitation with breathing to focus attention on and connection to God.
224171494|NCT00861302|BEHAVIORAL|Mind-body emotional awareness program|This intervention, developed and offered by Dr. Howard Schubiner of St. John Providence Health System, consists of a single individual session with him, followed by four, classroom group sessions. The intervention includes expressive writing, mindfulness, and other techniques designed to enhance awareness and acceptance of the emotional factors underlying the chronic pain problem.
224171495|NCT00470873|DRUG|Levitra (Vardenafil, BAY38-9456)|Primary care erectile dysfunction patients for whom physician decided to start the treatment with vardenafil
224171496|NCT04725604|DEVICE|pH probe|"Patients who agree to take part will have a pH probe inserted into their injured limb. The pH probe will be attached to a pH monitor which will record pH data for up to a maximum of 72 hours (24 hours per probe). The surgical team will not have access to the pH data. During the time they are considered at risk for ACS, patients will be monitored in the routine way (using regular clinical assessment and pressure monitoring). If ACS is diagnosed in the routine way, then treatment (fasciotomy) will be offered as appropriate."
224171497|NCT03416517|DRUG|Anlotinib|Anlotinib 12 or 8 mg/d po D1-14 q3w
224171498|NCT03416517|DRUG|Irinotecan|Irinotecan 20 or 15mg/m\^2/d IV over 60 minutes on days 1-5 and 8-12, q3w
224171499|NCT04918069|DRUG|Capsaicin|Topical capsaicin ointment
224171500|NCT04918069|DRUG|Placebo|Topical placebo ointment
224171501|NCT00065221|DRUG|Ginger|
224171502|NCT00723489|BIOLOGICAL|Live Yellow Fever Vaccine (YFV-17D)|
224171503|NCT00723489|DRUG|YFV-17D Placebo|
224171504|NCT02274311|DRUG|Clomiphene Citrate|Clomiphene citrate, 50 mg, orally for three months
224171505|NCT03968458|BEHAVIORAL|CON|. Control condition without exercise / rest condition. The adolescents will be asked to remain quiet and at rest during the morning and will receive an ad libitum meal at lunch and dinner times. Their food reward will be assessed before and after lunch. Their appetite feelings will be assessed at regular intervals.
224171506|NCT03968458|BEHAVIORAL|EX-30|Condition with an acute exercise set 30 minutes before lunch The adolescents will be asked to complete a 30 minutes exercise set at 65% of their capacities (cycling), 30 minutes before lunch. Lunch will be served ad libitum as well as diner. Their food reward will be assessed before and after lunch. Their appetite feelings will be assessed at regular intervals.
224171507|NCT03968458|BEHAVIORAL|EX-90|condition with an acute exercise set 90 minutes before lunch. The adolescents will be asked to complete a 30 minutes exercise set at 65% of their capacities (cycling), 30 minutes before lunch. Lunch will be served ad libitum as well as diner. Their food reward will be assessed before and after lunch. Their appetite feelings will be assessed at regular intervals.
224171508|NCT02422381|DRUG|MK-3475|Investigational drug.
224171509|NCT02422381|DRUG|Gemcitabine|Standard care drug.
224171510|NCT04771390|DRUG|Selitrectinib (BAY2731954) Adult tablet|Tablet, oral administration
224171511|NCT04771390|DRUG|Selitrectinib (BAY2731954) Pediatric tablet|Tablet, oral administration
224171512|NCT04771390|DRUG|Selitrectinib (BAY2731954) Oral solution|Oral solution after reconstitution
224171513|NCT04771390|DRUG|Selitrectinib (BAY2731954) Oral suspension|Oral suspension after reconstitution
224171514|NCT01110486|DRUG|ABT-348|An oral dose of ABT-348, once daily on Day 1, Day 8, and Day 15 of each 28 day cycle.
224171515|NCT01110486|DRUG|ABT-348 and carboplatin|An oral dose of ABT-348 will begin in Cycle 2on Day 1 and Day 8; and an IV dose of carboplatin (AUC 5.0) on Day 1 of each 21-day cycle.
224171516|NCT01110486|DRUG|ABT-348 and docetaxel|ABT-348 dosing will begin in Cycle 2. An oral dose of ABT-348 on Day 1 and Day 8; and an IV dose of docetaxel (75 mg/m2) on Day 1 of each 21-day cycle.
224171517|NCT01110486|DRUG|ABT-348|An oral dose of ABT-348, twice daily on Day 1, Day 8, and Day 15 of each 28 day cycle
224171518|NCT01110486|DRUG|ABT-348|An IV administration of ABT-348 two hour infusion on Day 1, Day 8 and Day 15 of each 28 day cycle.
224171519|NCT01985204|DIETARY_SUPPLEMENT|Iodine tablet|Iodine tablets containing 200 ug iodine as potassium iodate
224171520|NCT01985204|DIETARY_SUPPLEMENT|Placebo tablet|Placebo tablet without iodine
224171521|NCT05763472|GENETIC|Next-generation sequencing (NGS) assay TruSight Oncology 500 (TSO 500).|Next-generation sequencing (NGS) analysis with TruSight Oncology 500 (TSO 500) is performed on tumor samples from breast and ovarian cancer of the enrolled patients.
224305728|NCT05094245|PROCEDURE|Stellate Ganglion Block Group|Patients underwent a stellate-ganglion block at the anterolateral aspect of the C6 vertebra. After local analgesia (lidocaine 2%), a 22-gauge Quincke needle was placed in the anterolateral aspect of the C6 vertebral body. When the needle contacted the bone, it was drawn back 1 mm. 5 mL of 0·5% ropivacaine was subsequently injected next to the stellate ganglion to produce a sympathetic block.The effect of the stellate-ganglion block on the sympathetic nervous system was confirmed by the presence of Horner's syndrome (ie, facial anhydrosis, enophthalmos, ptosis, swelling of the lower eyelid, miosis, and blood-shot conjunctiva), and an increase in the temperature of the right hand of at least 2°F from baseline.
224305729|NCT05899751|DRUG|High-dose methotrexate|High-dose methotrexate
224305730|NCT05899751|DRUG|Glucarpidase|Glucarpidase
224305731|NCT02439931|BEHAVIORAL|Remote psychosocial intervention|
224305732|NCT01573169|DRUG|Enoxaparin|enoxaparin 0.4 ml sc per day for 10 days started 72 hours after the stroke
223483455|NCT00857389|DRUG|Methotrexate|5 mg/m2 by vein on Days 1, 3 and 6 and Day +11 post transplant. The Day 11 methotrexate dose may be held as indicated if mucositis is present.
223483456|NCT00857389|DRUG|Cyclophosphamide|Post haploidentical stem cell transplant participants: 50 mg/kg by vein on Days + 3 and + 4.
223483457|NCT00857389|DRUG|Mesna|Post haploidentical stem cell transplant participants: 10 mg/kg by vein just prior to the first dose of cyclophosphamide, repeated every 4 hours for a total of ten (10) doses.
223483458|NCT02251639|BEHAVIORAL|Questionnaire|Participant completes a short questionnaire regarding their awareness of oral cancer and risk factors.
223483459|NCT02251639|DEVICE|POS + PS2 + VELscope|Oral cavity examined with one or more of the widefield imaging devices, such as the VELscope and/or PS2 device.
223483460|NCT02251639|PROCEDURE|Oral Brush Biopsy|If abnormal areas found, a small brush is pressed against an area inside mouth, and turned 5-10 times. The areas that could be biopsied include gums, tongue, roof of mouth, bottom of mouth, or the inside of cheeks.
224305733|NCT01573169|OTHER|Graduated compression stockings and/or intermittent pneumatic compression and/or early mobilization|placebo standard therapy
224171522|NCT01104922|DRUG|Cetuximab|Cetuximab will be administered for 3 weekly doses commencing one week prior to stereotactic radiosurgery treatment as follows: \* Cetuximab 400 mg / m2 day -7 (1 week prior to initiation of radiosurgery) \* Cetuximab 250 mg/m2 days 0 and +8 (i.e. during the first and second week of fractionated stereotactic radiosurgery) Cetuximab will be administered at 400 mg/m2 IV over 120 minutes on day -7 (loading dose) and 250 mg/m2 IV on days 0 and 8 during the course of stereotactic radiosurgery.
224171523|NCT01104922|DEVICE|Stereotactic radiosurgery|Fractionated stereotactic radiosurgery, 8.0 Gy per fraction for 5 fractions (total: 40.0 Gy)
223745077|NCT01498458|DRUG|Pazopanib plus capecitabine|"Patients will receive pazopanib tablets once daily at a dose according to the allocated dose level:~* dose level I: 400 mg~* dose level II: 600 mg~* dose level III: 800 mg~In addition patients receive capecitabine at the same oral dose for all dose levels with 1600 mg/m2 on days 1 to 14 every 3 weeks.~Treatment will be given until disease progression or unacceptable toxicity of the study drug, or withdrawal of consent of the patient.~Six patients will be recruited in each dose level. If less than 2 out of 6 patients experience a DLT within the first 2 cycles (weeks 1 to 6), the next dose level is started. Once the MTD is established, additional 6 patients will be included into this dose level to further characterise the safety of the dose regimen.~If it is reported, that two patients had a DLT, all patients are informed about it and the dose level immediately reduced by one dose level."
224171524|NCT03893994|OTHER|Stretching exercises|Stretching exercises will be applied 6 days a week, 30sec / 5 reps
224171525|NCT04384952|OTHER|Parent-administered reading therapy.|Parent-administered reading therapy program: 15min each day, 5 days a week during 6 weeks during the summer break. Repeted reading with feedback from the parent and time control.
224171526|NCT04384952|OTHER|Dyslexic's Holiday Workbook|Use of a special Dyslexic's holiday book, no parent-guided training.
224171527|NCT03109288|DRUG|Pioglitazone|15-45 mg po qd
224171528|NCT03109288|DRUG|clemastine fumarate|8 mg/day (divided into 3 doses of 2, 2, and 4 mg)
224171529|NCT03109288|DRUG|Dantrolene|Up to 200 mg/day (divided into 3 doses of 50mg, 50mg, and 100 mg)
224171530|NCT03109288|DRUG|Pirfenidone|"Up to 801 mg po tid. Slow titration over weeks based on tolerability:~267mg po tid x \>= 7d 534 mg po tid x \>= 7d 801 mg po tid"
224171531|NCT01739192|DRUG|Bupropion|Subjects will be maintained on oral bupropion or placebo during the study.
224305734|NCT00896155|DRUG|Tamoxifen|260 patients of breast cancer will be accrued into the study. After inclusion in the study, all the patients will be randomized into two arms. ARM 1 will receive Tamoxifen 20 Mg once daily given concurrently with radiotherapy while in ARM-2 radiotherapy followed by tamoxifen 20 mg once daily sequentially.
224305735|NCT00896155|RADIATION|Radiotherapy|260 patients of breast cancer will be accrued into the study. After inclusion in the study, all the patients will be randomized into two arms. ARM 1 will receive Tamoxifen 20 Mg once daily given concurrently with radiotherapy while in ARM-2 radiotherapy followed by tamoxifen 20 mg once daily sequentially.
224305736|NCT00303394|DRUG|IL-1Ra|
224305737|NCT01949961|OTHER|Ultrasound|SonoVue solution 10 ml (2 vials / 80 µl microbubbles) is given as an infusion of 0,3 ml/min for \~30 minutes, using a Bracco infusion pump.
224171532|NCT01138605|DRUG|Darunavir|600mg composed via oral solution or various tablets, twice daily in combination with ritonavir, for body weight as of 40 kg
224171533|NCT01138605|DRUG|Ritonavir|Liquid formulation, 80 mg/ml, taken in combination with Darunavir
224171534|NCT01138605|DRUG|Ritonavir|100 mg capsule, to be taken once or twice daily in combination with Darunavir and following the Darunavir dosing schedule
224305738|NCT01949961|OTHER|Sham ultrasound|Mounting the ultrasound headframe but connecting this to a non-operative channel
224305739|NCT03926481|BEHAVIORAL|Evaluate Healthy Lifestyle Program on cognitive outcomes|The healthy lifestyle program will be delivered once a week for 17 weeks as part as regular clinical care. It will include an group classes taught by health coaches and dieticians. These classes will focus on diet, exercise, and behavior modification. We plan 2 cohorts of 15 subjects (n=30). In-person research assistant-led assessments will occur at baseline and 17 weeks.
224305740|NCT06928961|OTHER|Patient portal with patient-reported outcome measure administration, appointment calendar and reminders, access to lab test results, and educational material|Patients in the intervention will be trained to register on and use the patient portal. The following portal features will be used and studied in this project: the appointment calendar, PROMs administration, reminders (e.g., for appointments), educational materials, and access to personal lab results. Educational materials in the portal will include information on what to expect during HIV clinic visits, how to interpret HIV lab reports, and instructional videos on using the portal. Prior to visiting their HIV physician, patients will have continuous access to several portal features (calendar, education, and lab results, if applicable), and receive reminders (within 48 hours) of their clinic appointment and to complete the PROMs. Physicians will acquire their patients' PROM scores via the patient portal and receive training on how to do so. Patients and physicians are expected to review the PROM results and consider them during each clinic visit.
224305741|NCT01943721|DRUG|VISION5 Product|
224305742|NCT00486616|DEVICE|electrical impedance tomography|
224305743|NCT00486616|PROCEDURE|double-lumen tube placement|
224305744|NCT05463263|DRUG|STP938|Small molecule
224305745|NCT06272747|DRUG|XH-S003|IP: XH-S003 Dose: 25 mg, 100 mg Dose Formulation: Capsule Route of Administration: Oral
224171535|NCT01138605|DRUG|Darunavir|Oral suspension 100 mg/ml, 20 mg/kg twice daily in combination with ritonavir for body weight between 10 and 20 kg
224171536|NCT01138605|DRUG|Ritonavir|100 mg tablet, to be taken once or twice daily in combination with Darunavir and following the Darunavir dosing schedule
224171537|NCT01138605|DRUG|Darunavir|375 mg composed via oral solution or various tablets, twice daily in combination with ritonavir for body weight between 20 and 30 kg
224171538|NCT01138605|DRUG|Darunavir|450 mg composed via oral solution or various tablets, twice daily in combination with ritonavir for body weight between 30 and 40 kg
224171539|NCT01138605|DRUG|Darunavir|400 mg tablet, intake of 2 tablets once daily in combination with ritonavir
224171540|NCT01138605|DRUG|Ritonavir|100 mg tablet, to be taken once or twice daily in combination with Darunavir and following the Darunavir dosing schedule
224171541|NCT01138605|DRUG|Darunavir|375 mg composed via oral solution or various tablets, twice daily in combination with ritonavir for body weight between 20 and 30 kg
224171542|NCT01138605|DRUG|Ritonavir|Liquid formulation, 80 mg/ml, taken in combination with Darunavir
224171543|NCT01138605|DRUG|Darunavir|450 mg composed via oral solution or various tablets, twice daily in combination with ritonavir for body weight between 30 and 40 kg
224171544|NCT01138605|DRUG|Darunavir|600mg composed via oral solution or various tablets, twice daily in combination with ritonavir, for body weight as of 40 kg
224171545|NCT01138605|DRUG|Ritonavir|100 mg capsule, to be taken once or twice daily in combination with Darunavir and following the Darunavir dosing schedule
224171546|NCT01138605|DRUG|Ritonavir|Ritonavir powder for oral suspension 10 mg/mL taken in combination with Darunavir.
224171547|NCT00232531|DRUG|Niaspan|
224171548|NCT05322759|OTHER|aquatic exercises|aquatic polymetric exercises for 30 min including hip abduction/adduction, knee flexion/extension, hip flexion/extension, holding pool from sides, bending forward and picking up objects, shoulder flexion/extension kangroo jumpes, jumping to sides.
224171549|NCT05322759|OTHER|halliwick exercise programme|Halliwick exercise programme for 30 min include sagittal rotations, transversal rotations, longitudnal rotations and combined rotations.
224171550|NCT00141622|DRUG|Slow sodium|
224171551|NCT00904436|DRUG|ipratropium (Atrovent)|Bronchodilator Treatment: Subjects will inhale 1 unit dose vial of aerosolized ipratropium (500 mcg of ipratropium (Atrovent) mixed in 2.5 ml of saline).
224171552|NCT06549699|OTHER|Medically Tailored Meal Program with Traditional Navajo Foods|Patients will receive medically-tailored meals incorporating local traditional Navajo foods
224171553|NCT06549699|OTHER|Usual Care|Usual care plus healthy recipes provided
224171554|NCT02126384|DRUG|pneumovax vaccination|vaccination
223483461|NCT04853485|DEVICE|repetitive transcranial magnetic stimulation (rTMS)|All subjects with early psychosis will be divided into three subgroups determined by their psychotic symptoms and cognition. There are three rTMS strategies: (1) For subgroup 1, characterized by negative symptoms, iTBS over cerebellum and 1 Hz over right DLPFC; (2) For subgroup 2, characterized by cognition deficits, 20 Hz over the left inferior parietal cortex; (3) For subgroup 3, characterized by positive symptoms: 10 Hz over ACC. Ten to twenty sessions of rTMS will be delivered to each patients during the intervention period.
223483462|NCT03226587|PROCEDURE|Blue light|Subjects will be exposed to blue light (453 nm wavelength) for 30 minutes
223483463|NCT03226587|PROCEDURE|control exposure|Subjects will get control exposure to 30 minutes of whole body, which causes only comparable warming of skin as with blue light exposure.
223483464|NCT05297383|DIETARY_SUPPLEMENT|Omega-3 Polyunsaturated Fatty Acid.|4 grams n-3 PUFA (AlaskOmega®) per day (3000 mg EPA and 1000 mg DHA).
223483465|NCT05297383|DIETARY_SUPPLEMENT|Safflower Oil|4 grams safflower oil (AlaskOmega®) per day.
223483466|NCT05297383|BEHAVIORAL|High-Intensity Interval Training|A 4 x 4 high-intensity interval training (HIIT) exercise program 3 days/week for 6 weeks. This will include a 3 min warm up at 15% watt max followed by 4 intervals for 4 min at 65% watt max with 3 min active recovery at 15% watt max.
223483467|NCT05297383|BEHAVIORAL|Flexibility Training|30 min of stretching 3 days/week for 6 weeks
223483468|NCT06701825|DRUG|Tacrolimus|"Tacrolimus at the dosage reccomended by the Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 Genotype and Tacrolimus Dosing based on the subjects pharmacogenetic phenotype."
223483469|NCT06701825|DRUG|Tacrolimus|Subject allocated to this arm will receive tacrolimus according to clinical practice and the drug's product labelling. These subject will not receive a personalised dose based on their pharmacogenetic phenotype.
223483470|NCT03673644|OTHER|Questionnaires|Two questionnaires will be administered, one focusing on life space and the other focusing on low luminance.
223483471|NCT02056678|DRUG|acetaminophen, IV preparation|
223483472|NCT07027813|OTHER|Telemedicine|Provision of Telemedicine support to pediatric patients during ambulance transport.
223483473|NCT07027813|OTHER|Control|Provision of ambulance transport without any telemedicine support.
223483474|NCT05532878|DRUG|Apixaban|Apixaban 2.5 mg daily
224171555|NCT05898659|DEVICE|ABFnoS then ABFS (Cochlear implant)|Cochlear implant with tonotopy-based fitting without synchronization with the contralateral hearing-aid then with synchronization with the contralateral hearing-aid
224171556|NCT05898659|DEVICE|ABFS then ABFnoS (Cochlear implant)|Cochlear implant with tonotopy-based fitting with synchronization with the contralateral hearing-aid then without synchronization with the contralateral hearing-aid
224171557|NCT04717414|DRUG|ACE-536|Subcutaneous Injection
224171558|NCT04717414|OTHER|Placebo|Subcutaneous Injection
224171559|NCT06810544|DRUG|TNG456|A selective PRMT5 inhibitor
224171560|NCT06810544|DRUG|abemaciclib|A kinase inhibitor
224171561|NCT00853112|DRUG|PF-00489791|tablet form, 1 mg, single dose (Day 1)
224171562|NCT00853112|DRUG|PF-00489791|tablet form, 2 mg, single dose (Day 1)
224171563|NCT00853112|DRUG|PF-00489791|tablet form, 4 mg, single dose (Day 1)
224171564|NCT00853112|DRUG|PF-00489791|tablet form, 10 mg, single dose (Day 1)
224171565|NCT00853112|DRUG|PF-00489791|tablet form, 20 mg, single dose (Day 1)
224171566|NCT00853112|DRUG|placebo|tablet form, single dose (Day 1)
224171567|NCT00853112|DRUG|sildenafil|tablet form, 20 mg, single dose (Day 1)
224171568|NCT01762592|DRUG|Iodine (124I) Girentuximab|i.v.
224171569|NCT05535790|OTHER|Naturalistic LED light|Naturalistic LED light (bright light therapy) which affects Melanopic Equivalent Daylight Illuminance.
224171570|NCT05535790|OTHER|Standard/traditional lighting|Standard/tradtional lighting environment with fluorescent tubes
224171571|NCT05439304|OTHER|No intervention|No intervention
224171572|NCT04660006|PROCEDURE|Cataract surgery|Patients undergoing uneventful cataract surgery were recruited to this study if they met the inclusion criteria of the three groups. Postoperative retinal vasculature measures, as recorded by the optical coherence tomography angiography imaging technique, were compared to baseline measures.
224171573|NCT02329860|DRUG|Apatinib|
224171574|NCT02329860|DRUG|Placebo|
224171575|NCT05306262|PROCEDURE|Hypnosis session|Comfort hypnosis: accompaniment of a pleasant memory.
224171576|NCT05306262|OTHER|Catalepsy|Catalepsy of the hand.
224171577|NCT02858596|DIETARY_SUPPLEMENT|Semi-solid feed (Terumo PG soft)|
224171578|NCT02858596|DIETARY_SUPPLEMENT|Liquid feed (Meibalance)|
224171579|NCT02477800|DRUG|Aducanumab (BIIB037)|Low dose
224171580|NCT02477800|DRUG|Aducanumab (BIIB037)|High dose
224171581|NCT02477800|DRUG|Placebo|Placebo
224171582|NCT01633775|PROCEDURE|Implantation of Ahmed glaucoma tube shunt, and Trabeculectomy with MMC|In the Ahmed implant group, the tube shunts used were the valved 184-mm2 surface area (Model FP7; New World Medical, Inc, Rancho Cucamonga, California, USA). In the Trabeculectomy group, a routine trabeculectomy surgery was performed.
224171583|NCT01063699|PROCEDURE|Laparoscopic Kasai operation|the Kasai procedure (hepatoportoenterostomy) is performed laparoscopically, thus not in open surgery.
224171584|NCT05939219|BIOLOGICAL|15-valent pneumococcal conjugate vaccine 202210001|Immunization program and dosage:3 month old group: basic immunization at 0, 1, and 2 months, and strengthened immunization at 12 to 15 months old, with a total of 4 doses administered. 7-11 month old group: baseline immunization at 0 and 2 months; Strengthen one dose after 12 months of age; A total of 3 doses were administered. 12-23 month old group: Immunized with 2 doses of 0 and 2 month program, a total of 2 doses were administered. 2-5 year old group: 1 dose administered
224171585|NCT05939219|BIOLOGICAL|15-valent pneumococcal conjugate vaccineY202210002|Immunization program and dosage: 3 month old group: basic immunization at 0, 1, and 2 months, and strengthened immunization at 12 to 15 months old, with a total of 4 doses administered. 7-11 month old group: baseline immunization at 0 and 2 months; Strengthen one dose after 12 months of age; A total of 3 doses were administered. 12-23 month old group: Immunized with 2 doses of 0 and 2 month program, a total of 2 doses were administered. 2-5 year old group: 1 dose administered
224171586|NCT05939219|BIOLOGICAL|15-valent pneumococcal conjugate vaccineY202210003|Immunization program and dosage: 3 month old group: basic immunization at 0, 1, and 2 months, and strengthened immunization at 12 to 15 months old, with a total of 4 doses administered. 7-11 month old group: baseline immunization at 0 and 2 months; Strengthen one dose after 12 months of age; A total of 3 doses were administered. 12-23 month old group: Immunized with 2 doses of 0 and 2 month program, a total of 2 doses were administered. 2-5 year old group: 1 dose administered
224171587|NCT05939219|BIOLOGICAL|15-valent pneumococcal conjugate vaccineY202210004|Immunization program and dosage: 3 month old group: basic immunization at 0, 1, and 2 months, and strengthened immunization at 12 to 15 months old, with a total of 4 doses administered. 7-11 month old group: baseline immunization at 0 and 2 months; Strengthen one dose after 12 months of age; A total of 3 doses were administered. 12-23 month old group: Immunized with 2 doses of 0 and 2 month program, a total of 2 doses were administered. 2-5 year old group: 1 dose administered
224171588|NCT05939219|BIOLOGICAL|13 valent pneumococcal polysaccharide conjugate vaccine|Immunization program and dosage: 7-11 month old group: baseline immunization at 0 and 2 months; Strengthen one dose after 12 months of age; A total of 3 doses were administered. 12-23 month old group: Immunized with 2 doses of 0 and 2 month program, a total of 2 doses were administered. 2-5 year old group: 1 dose administered
224171589|NCT02699840|BIOLOGICAL|Meningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine|No vaccine will be provided as part of this study
224171590|NCT02699840|BIOLOGICAL|Meningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine|No vaccine will be provided as part of this study
224305746|NCT06272747|DRUG|Placebo|Dose: 25 mg, 100 mg Dose Formulation: Capsule Route of Administration: Oral
224305747|NCT06384534|OTHER|6-minute walk distance (6MWD) test on ambient air|6-minute walk distance (6MWD) test will be performed on ambient air according to clinical standards
224305748|NCT06384534|OTHER|6-minute walk distance test with supplemental oxygen|6-minute walk distance (6MWD) test will be performed according to clinical standards additionally with supplemental oxygen therapy (approximately 3l/min, nasal)
224305749|NCT05052515|DIETARY_SUPPLEMENT|Dihydromiricetin, Vitamin C, E and Choline|Patients with MASLD will be randomly allocated to receive capsules with Dihydromiricetin, Vitamin C, E and Choline
223483475|NCT06883279|OTHER|Intraplexus|The block needle will be advanced from the middle scalene muscle in a posterior-anterior direction and advanced between the C5-C6 nerve roots and the injection will be performed
223483476|NCT06883279|OTHER|Extraplexus|The block needle will first be advanced above the C5 nerve root and towards the anterior part of the brachial plexus and 10 ml of local anesthetic will be injected. Then, the needle will be withdrawn to the posterior surface of the brachial plexus and 10 ml of local anesthetic will be administered.
223483477|NCT06709534|OTHER|Exercise Intervention|Participate in an individualized online home-based exercise intervention
224305750|NCT05052515|OTHER|Placebo|Patients with MASLD will be randomly allocated to receive placebo capsules
223483478|NCT06709534|OTHER|Functional Assessment|Complete functional capacity assessment
223483479|NCT06709534|OTHER|Medical Device Usage and Evaluation|Wear an activity tracker
223483480|NCT06709534|OTHER|Questionnaire Administration|Ancillary studies
223483481|NCT06709534|OTHER|Supportive Care|Receive social support
223483482|NCT03546127|GENETIC|Next Generation Sequencing (NGS): exome, RNA seq|"Tumor and blood samples will be sequenced at medium-high coverage at the whole genome (exome) and transcriptome levels (RNA Seq). This will allow detecting variants in a larger set of samples even though only from the main clone will be precisely measured. The whole exome will be performed at a mean coverage of at least 60x for the normal DNA samples and 120x for the tumor DNA samples. The transcriptome of the tumor will be performed at enough depth of coverage to detect gene fusions, transcriptome variants and measure the digital expression of already annotated isoforms.~For both sequencing configurations:~* Data from each cancer and normal genome will be analysed for the presence of somatic variants.~* DNA and RNA sequencing results will be integrated.~* Technical replication for the mutations / chromosome alterations / transcript fusions that most likely drive the tumour process will be performed via Target Resequencing of the genomic / coding regions of interest."
223483483|NCT07055399|DRUG|neoadjuvant chemo-immunotherapy: Iparomlimab and tuvonralimab plus cisplatin,nab-paclitaxel for 1 cycle and Iparomlimab and tuvonralimab for 2 cycles|"Neoadjuvant chemo-immunotherapy: Iparomlimab and tuvonralimab, cisplatin, and nab-paclitaxel for 1 cycle, then Iparomlimab and tuvonralimab continued for 2 cycles at 3-week intervals. Details:~Iparomlimab and tuvonralimab 5 mg/kg, IV infusion, Q3W for 3 cycles Cisplatin：75-80 mg/m2, IV infusion, (cycle 1) Nab-paclitaxel 260 mg/m2，30min，IV infusion,(cycle 1)"
223483484|NCT06751433|DEVICE|Scar gel|Health care product (scar gel)
223483485|NCT06751433|DEVICE|Scar gel comparator|Health care product (Scar gel comparator)
223483486|NCT02970084|OTHER|Nutraceutical product based on vitamin K2 (PLAK2)|
224171591|NCT02699840|BIOLOGICAL|Meningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine|No vaccine will be provided as part of this study
224171592|NCT04102696|DRUG|Aromatherapy|"Free aromatherapy (70% menthol and 30% propanediol) will be provided for 6 months. All participants will receive the standard inhalation method training before hospital discharge.~The aromatherapy will be given twice daily, one treatment in the morning and one in the evening. At each treatment, 4 deep steady inhalations will be performed, and 10 seconds per inhalation is optimal."
224171593|NCT04102696|DRUG|Placebo|Free placebo (10% menthol and 90% propanediol) will be provided for 6 months. The specific method is the same as aromatherapy.
224171594|NCT04681742|BEHAVIORAL|CO-OP Group|CO-OP focuses on learning of a global problem-solving strategy, Goal-Plan-Do-Check (GPDC), within the performance of participant-chosen goals. Use of a broadly applicable strategy and meaningful activity ensures the intervention is salient to the participant and increases likelihood of transfer. Uniquely, therapists applying CO-OP use guided discovery methods, such as asking a series of probing questions, to support participants in analyzing their own performance of a given task and generating potential solutions for improving performance. Participants become equipped with these skills through repetitive application of the GPDC process. First, participants identify a specific goal (Goal). Then, participants consider a detailed plan (Plan) for accomplishing the goal. By carrying out the plan (Do) and critically analyzing the results (Check), participants determine how the plan worked. The intervention focuses on learning GPDC with gradual withdrawal of guided discovery methods.
224171595|NCT04491045|OTHER|Workshop Training on Multicomponent Collaborative Care for Depression|Hybrid Workshop Trainings on Stepped collaborative care model for depression that involves using a team-based approach to integrating depression care components (screening, psychoeducation, Behavior Activation therapy, and antidepressant medications) into primary care settings. This integration involves task-shifting mental health tasks from mental health specialist to community providers at the commune health stations.
224171596|NCT04491045|OTHER|Supervision|Ongoing supervision and coaching is provided to community health providers by local mental health specialist from the provincial psychiatric hospital for 6-9 months
223483487|NCT06107114|DRUG|Cetuximab|Cetuximab 400mg/m2 (The first week), 250mg/m2(Follow-up weekly) The drug was administered every week (QW). The treatment regimen is recommended for three cycles until the researchers determine that the subjects cannot continue to benefit, until the disease progression (PD), the toxicity cannot be tolerated, the treatment is delayed by more than 14 days, or the patient withdraws the informed consent form or dies.
224171597|NCT04491045|OTHER|Community-Engaged Learning Collaborative|The CELC group will receive support for continuous quality improvement using a province-wide learning collaborative that will meet monthly for 3 months, followed by bi-monthly meetings for 12 months.
224171598|NCT06593379|BEHAVIORAL|Safety planning|Safety planning (SP) is a single-session intervention that consists of developing a written list of individualized coping strategies and sources of support that can be used during a suicidal crisis.
224171599|NCT06593379|BEHAVIORAL|Treatment as usual|This will include continued care with any of the Veterans' current providers. Study staff will also place appropriate referrals for Veterans, as needed (e.g., Trauma Recovery Program referrals for Veterans with PTSD, Sleep Psychology referrals for Veterans with insomnia). Participants will be encouraged to follow up with their providers' recommendations and treatment plans
224171600|NCT06593379|BEHAVIORAL|MIST Intervention|This is a mobile intervention designed to target and modify suicidal cognitions. Veteran in this condition will be asked to use the intervention 5 times a week for 4 weeks.
224171601|NCT01076270|DRUG|plerixafor|Given SC
224171602|NCT01076270|BIOLOGICAL|filgrastim|Given SC
224171603|NCT01076270|PROCEDURE|peripheral blood stem cell transplantation|Infusion of peripheral blood stem cells
224171604|NCT01076270|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Infusion of hematopoietic stem cells
224171605|NCT04473495|DEVICE|educational video|educational video before intervention
224171606|NCT01952613|DEVICE|FES|In phase 1, five subjects (randomly chosen) will be provided the FES device and instructed to use it for ambulation for the 6 months. At the baseline visit, gait data will be collected from this group. On the 6 month follow up visit, same data collection procedure will be performed and the devices will be collected back from the subjects. After performing quality check on these devices, phase 2 of the data collection will start by providing the devices to the other five subjects and their baseline data will be collected.
224171607|NCT00958191|DEVICE|Trident® X3 Polyethylene Insert|Trident® X3 Polyethylene Insert
224305751|NCT06193928|DRUG|Livmarli|The recommended dosage is 380 mcg/kg once daily.
224305752|NCT06193928|DRUG|Livmarli|The recommended dosage us 570 mcg/kg twice daily.
224305753|NCT03145077|PROCEDURE|Dynamic Contrast-Enhanced Magnetic Resonance Imaging|Undergo DCE-MRI
224305754|NCT03145077|OTHER|Questionnaire Administration|Ancillary studies
224305755|NCT05742347|DEVICE|DriGo Skin Protectant Textile|All participants in this study will have the DriGo skin protectant textile applied to their skin fold condition. Erythema, denudation, maceration, odor, and moisture will be assessed following application of the SPT.
223483488|NCT06107114|DRUG|Zimberelimab|Zimberelimab 240 mg, The drug was administered every week (Q3W), and 21 days (Q3W) was a treatment cycle. The treatment regimen is recommended for three cycles until the researchers determine that the subjects cannot continue to benefit, until the disease progression (PD), the toxicity cannot be tolerated, the treatment is delayed by more than 14 days, or the patient withdraws the informed consent form or dies.
223483489|NCT06107114|DRUG|Docetaxel|Docetaxel 75mg/m2. Intravenous infusion was given every 3 weeks (Q3W), and 21 days (Q3W) was a treatment cycle. Treatment regimen is recommended for 3 cycles.
223483490|NCT06107114|DRUG|Cisplatin|Cisplatin 60mg/m2. Intravenous infusion was given every 3 weeks (Q3W), and 21 days (Q3W) was a treatment cycle. Treatment regimen is recommended for 3 cycles.
223483491|NCT01157845|DEVICE|BreathID (Methacetin breath test)|13C-labeled methacetin (75 mg) is given to the patient by mouth in a small volume of water, and expired 13C-labeled carbon dioxide is measured from a nasal cannula.
223483492|NCT05146752|DEVICE|extremely low frequency electromagnetic fields|extremely low frequency electromagnetic fields
223483493|NCT05146752|OTHER|routine care|routine care
224305756|NCT03190330|DRUG|Ibrutinib 420 mg|Ibrutinib capsule administered orally at a dose of 420 mg for CLL participants.
224171608|NCT05929677|DRUG|Placebo|Participants receive placebo (saline) intravenously. They will also have the opportunity to self-administer saline during the 60-minute free-access IV self-administration period in session 3.
224171609|NCT05929677|DRUG|Alcohol|Participants receive alcohol intravenously, clamped at BrACs of 20mg%, 40mg%, and 60mg%. They will also have the opportunity to self-administer alcohol (up to 120mg% BrAC) during the 60-minute free-access IV self-administration period in session 3.
224171610|NCT05728749|OTHER|Non-interventional|As this is a non-interventional trial, only data obtained within the current routine management of asthma at outpatient respiratory centres or GP centres will be documented.
224171611|NCT05518136|BEHAVIORAL|exercise-guidance on rehab APP|Training motions included sitting balance, hand support, crawling and squatting training12-14 were scheduled for 1 to 3 months postoperatively, moreover, climbing over obstacles was for 3 to 6 months.
224171612|NCT04743401|OTHER|Tele-exergaming Tablet|"The Tele-Exergame platform virtually supervises exercise tasks and coaches patients to perform evidence-based foot and ankle exercises that have been designed to improve balance, cognition, and lower extremity vascular health.~The exergame program uses a game-based approach, similar to playing a video game, which helps to increase patient motivation and engagement in the cognitively demanding exercise program."
224171613|NCT01818765|PROCEDURE|Trans-ventricular-septal placement of LV pacing lead|
224171614|NCT01818765|OTHER|Pre-procedure speckle-tracking echocardiography|Assessment of site of latest mechanical activation
224171615|NCT01818765|OTHER|Acute response assessment|Cardiac output monitoring
224171616|NCT00004147|DRUG|incyclinide|
224171617|NCT01730001|PROCEDURE|Early Intubation|
224171618|NCT01730001|PROCEDURE|Late intubation|
224171619|NCT05412160|DRUG|Arginine|During the first assessment the patients will be randomized to receive BioArginine C™ twice daily on top of chronic inhaled therapy or to continue their chronic Inhaled therapy plus placebo for 6 weeks. The main purpose is to compare changes in CRQ from baseline and after 6 weeks in the interventional arm compared with the control group in order to evaluate whether in symptomatic patients with COPD, daily bioarginine on top of chronic inhaled therapy can improve respiratory symptoms and dyspnea. The secondary objective of the study is to determine whether there is any correlation between improvement in respiratory symptoms and distance walked at the 6MWT and lung function parameters.
224171620|NCT05412160|DRUG|Placebo|During the first assessment the patients will be randomized to receive BioArginine C™ twice daily on top of chronic inhaled therapy or to continue their chronic Inhaled therapy plus placebo for 6 weeks. The main purpose is to compare changes in CRQ from baseline and after 6 weeks in the interventional arm compared with the control group in order to evaluate whether in symptomatic patients with COPD, daily bioarginine on top of chronic inhaled therapy can improve respiratory symptoms and dyspnea. The secondary objective of the study is to determine whether there is any correlation between improvement in respiratory symptoms and distance walked at the 6MWT and lung function parameters.
224171621|NCT02010567|DRUG|CRLX101|CRLX101 is an experimental nanoparticle formulation of the anticancer agent camptothecin manufactured by Cerulean Pharma Inc..
223483494|NCT05041400|OTHER|Evaluation of the strength of knee flexors and extensors|Each participant will benefit from a clinical evaluation and an evaluation of the strength of knee flexors and extensors using an isokinetic dynamometer after a 10-minute warm up.
223483495|NCT03311555|DRUG|Apalutamide|240mg tablet daily for 36 weeks
223483496|NCT03311555|DRUG|Androgen deprivation|ADT will consist of treatment with a GnRH agonist or antagonist per physician and institutional preference. Either leuprolide acetate (Lupron Depot, 22.5 mg or 45 mg IM), triptorelin pamoate (Trelstar, 11.25 mg or 22.5 mg IM), goserelin acetate (Zoladex, 10.8mg SC) or degarelix (Firmagon 120 mg or 240 mg SC) will be administered monthly, every 3 months, or every 6 months, depending on institutional standards, for 36 weeks total.
223483497|NCT03311555|RADIATION|Salvage radiation therapy|On week 9 (+/- 28 days), subjects will begin salvage radiation therapy to the prostate bed. The total dose to the prostate bed must be 66-74 Gy in 1.8-2 Gy daily fractions over a total of 6-8 weeks
223483498|NCT03311555|DRUG|Docetaxel|About 4 weeks (+/- 2 weeks, pending recovery of adverse events from radiation to Grade 2 or less) after completing radiation, patients will start docetaxel 75mg/m2 intravenously, every 3 weeks for 6 cycles.
223585699|NCT06584253|OTHER|Jamar hand dynamometer|Jamar hand dynamometer - students will perform grip strength assessments with their dominant hand while seated. As recommended by the American Association of Hand Therapists protocol, students will sit in a comfortable chair with their shoulders neutrally rotated and adducted, elbow flexed to 90°, and wrist and forearm in neutral positions.
223585700|NCT06584253|OTHER|Depression Anxiety Stress Scale - 21 Short Form|DASÖ-21 consists of 3 subcategories (depression, anxiety and stress). Each category consists of 7 separate questions and a total of 21 questions.
223483499|NCT05159934|DRUG|0.05, 0.025, and 0.0125 mg nicotine/pulse of nicotine|Determine if smokers can discriminate 0.05, 0.025, and 0.0125 mg nicotine/pulse of nicotine from saline.
223483500|NCT05159934|DRUG|Saline|Saline will be use to determine if smokers can discriminate from the nicotine/pulse of nicotine and saline
223483501|NCT05685121|DEVICE|Apollo Neuro|The device is a wearable nerve stimulator.
223483502|NCT02164617|OTHER|Wheelchair-bound Senior Elastic Band exercise program (WSEB)|Wheelchair-bound Senior Elastic Band exercise program (WSEB) three times per week, 40 minutes per practice
223483503|NCT03966625|DIAGNOSTIC_TEST|tissue transglutaminase autoantibodies|celiac disease-specific autoantibodies
223483504|NCT03025321|DEVICE|transcranial Direct Current Stimulation (tDCS)|tDCS is an electrical brain stimulation method Participants will receive real-tDCS or sham twice daily for 13 min with an interval of 20 min for five consecutive days.
223483505|NCT05777421|PROCEDURE|Conventional Physical Therapy for Knee Osteoarthriths|Participants of Group A will receive the conventional physical therapy for Knee Osteoarthistis for a duration of 6 weeks atleast 2 times a week
223585701|NCT06584253|OTHER|Body Awareness Questionnaire|The questionnaire aims to determine the level of body composition sensitivity.
223585702|NCT06584253|OTHER|SF-12|This questionnaire consists of two general components related to physical and mental function, consisting of 12 questions and 8 scales measuring physical function (2 questions), bodily pain (1 question), role limitations due to physical problems (2 questions), general health (1 question) vitality (40).
223585703|NCT01786395|DRUG|UF-021|
223585704|NCT01786395|DRUG|Placebo|
224171622|NCT02010567|DRUG|Capecitabine|Capecitabine is an oral fluoropyrimidine pro-drug, metabolically converted to 5-fluorouracil after administration. It is indicated as adjuvant treatment in patients with stage III colorectal cancer (Dukes' C colon cancer), and as first-line treatment of metastatic colorectal cancer.
224171623|NCT02010567|RADIATION|Radiotherapy|"This protocol allows physician discretion as to the use of Intensity Modulated Radiation Therapy (IMRT) or 3D conformal planning techniques.~Radiation begins on Day1 of neoadjuvant chemotherapy and continues for 28 (if \<T4) or 30 (T4 disease) consecutive weekdays. Patient will receive 1.8 Gy daily fractions of radiotherapy without a break except for weekends and holidays.~Dose is to be prescribed to an isodose surface that encompasses the planning target volume (PTV) and that satisfies the dose uniformity guidelines below. The minimum dose to PTV 1 and PTV 2 shall be no less than 95% of the protocol specified dose for that volume."
224171624|NCT02010567|PROCEDURE|Surgery|Surgery will take place at least 6 weeks post completion of chemoradiotherapy in patients with resectable disease; tissue from surgical resection will be preserved for correlative studies in those patients who do not achieve a pCR.
224171625|NCT03094481|PROCEDURE|SCPB|Bupivacaine hydrogen chloride Inj 0.5% epinephrine. 10ml injected for US guided Superficial Cervical Plexus Block at C4 or C5.
224171626|NCT03094481|PROCEDURE|ISB|Bupivacaine hydrogen chloride Inj 0.5% epinephrine. 10ml injected for US guided Interscalene Brachial Plexus Block at C5 or C6.
224171627|NCT03094481|PROCEDURE|SCPB + ISB|Bupivacaine hydrogen chloride Inj 0.5% epinephrine. 10ml injected for US guided SCPB at C4 or C5 + 10ml injected for ISB at C5 or C6.
224171628|NCT03094481|DRUG|Bupivacaine hydrogen chloride , epinephrine|Bupivacaine hydrogen chloride Inj 0.5% (1:200,000) epinephrine
223483506|NCT05777421|PROCEDURE|Virtual Reality-Based Therapeutic Exercise regimes|"* Participants of Group B will receive Virtual Reality Based therapeutic exercises on the Xbox. The difficulty level of the games will progess each week. The duration of training will also also progress at treatment week progresses.~* Frequency: 2-3 times a week for 6 weeks. Minimum 12 sessions in total."
224171629|NCT00657748|DRUG|Lithium Gluconate (drug) Glyceryl Triacetate GTA (drug)|Lithium 1.3 mEq/kg/day (three administrations a day)during the study GTA 500 mg/kg/day in four administrations a day during the study
224171630|NCT02005211|DRUG|AZD3293|Oral solution
224171631|NCT02005211|DRUG|Placebo|Oral solution
224171632|NCT01917136|DRUG|11C-acetate|For each PET/CT imaging session subjects will receive a 15-25 millicurie intravenous injection of 11C-acetate
224171633|NCT01917136|DRUG|[18F]Fluoro-2-deoxy-2-D-glucose|For each PET/CT imaging session subjects will receive a 10 millicurie injection of 18F-FDG
224171634|NCT01917136|OTHER|Cardiac MRI|Cardiac MRI is performed at 6 months to measure any change in structure and function of the treatment groups.
224171635|NCT00006463|DRUG|ECTEINASCIDIN 743|
223483507|NCT00267436|BEHAVIORAL|Community PROMISE|The Community PROMISE begins with a community assessment to identify HIV risk factors. Once risk factors have been identified, individuals from the targeted at-risk community are recruited and trained to be peer advocates. Trained peer advocates interview members of the community about their behavior. Role model stories are written based on the interviews. Role model stories are personal accounts from individuals in the target population which explain how and why they took steps to practice HIV risk-reduction behaviors and the positive effects the choice has had on their lives. Each week, peer advocates distribute role model stories and supplies, such as condoms, to 10 to 20 members of their social networks.
223483508|NCT06054711|OTHER|joint puncture|Patients reporting complications such as pain hindering mobility or affecting quality of life, or any other symptoms suspecting prosthesis failure or infection will undergo joint fluid aspiration.
223483509|NCT01273259|DRUG|DHEA Treatment|DHEA : 200 mg/day hard gelatine capsule
223585705|NCT02472704|DIETARY_SUPPLEMENT|Gluten challenge|gluten (20 g/day) (identical powder sachets than placebo, mixed with meals) rechallenge while on a gluten-free diet
223585706|NCT02472704|DIETARY_SUPPLEMENT|Placebo challenge|placebo (maltrodextrin) (identical powder sachets than gluten, mixed with meals) rechallenge while on a gluten-free diet
223585707|NCT06234215|DEVICE|functional electrical stimulation|electrical stimulation during function
223585708|NCT06234215|OTHER|functional task training|functional exercise
223585709|NCT03722654|BEHAVIORAL|MTFS-I Installation|MTFS-I Installation will focus on introducing MTFS-I components including weekly training modules and mock video segments to be coded, as well as monthly feedback reports summarizing therapist self-reported FT and CBT implementation in active cases. Facilitation will also be included to review progress and provide regular support.
223585710|NCT05605340|BEHAVIORAL|Meal Delivery|10 healthy, home-delivered meals per week + brief weekly remote behavioral support
224171636|NCT03529175|DRUG|Abraxane (nab-paclitaxel)|
224171637|NCT03529175|DRUG|Gemcitabine|
224171638|NCT05398341|DEVICE|The BEAR® Implant|"The BEAR Implant is a bovine collagen-based implant. The bovine tissue is sourced from countries that are free of bovine spongiform encephalopathy \[BSE\] and is further treated to remove bovine cell fragments and DNA.~The BEAR® (Bridge Enhanced ACL Restoration) Implant is a bovine extracellular matrix collagen-based implant for treatment of anterior cruciate ligament (ACL) injuries. The BEAR® Implant is indicated for skeletally mature subjects at least 14 years of age with a complete rupture of the ACL. Subjects must have an ACL stump attached to the tibia to construct the repair."
224171639|NCT06256575|COMBINATION_PRODUCT|Diosmin|A medical food of diosmin and alka4-complex
224171640|NCT06256575|OTHER|Placebo|Corn starch one (1) capsule twice daily
224171641|NCT03678389|OTHER|ESC|USE OF ENDOSPHENOIDAL COIL (ESC) TO OBTAIN MRI IMAGING OF THE PITUITARY GLAND
224171642|NCT01573286|DRUG|Glucagon-Like Peptide 2|Patients will be treated with 20 ug/kg/day GLP-2, in two doses, given subcutaneously for 3 days (Phase 1). If the treatment is well tolerated, GLP-2 will be continued for a total of 42 days.
224171643|NCT01573286|DRUG|Glucagon like peptide-2|"Patients will treated with 5, 10 or 20 ug/kg/day of GLP-2, given twice daily by subcutaneous injection. The initial cohort of patients will be treated at 5 ug/kg (n=6), and if this dose is seen to be safe, and levels appropriate, the next group of 6 will be treated at 10 ug/kg/day. If this dose is seen to be safe, and levels appropriate, the final group of 6 will be treated at 20 ug/kg/day.~Patients will be given GLP-2 at the assigned dose, subcutaneously for 3 days (Phase 1). If the treatment is well tolerated, GLP-2 will be continued, at the same dose, for a total of 42 days."
224171644|NCT00006062|DRUG|oxaliplatin|
224171645|NCT06343129|BEHAVIORAL|Dietary education program|"Jumpstart educational program:~https://www.rochesterlifestylemedicine.com/about-community-jumpstart/"
224171646|NCT03876704|DRUG|High dose of fat-Soluble Vitamin|Supplementation of 5 times current dose of fat-soluble vitamins by intravenous perfusion
224171647|NCT03876704|DRUG|Conventional dose of fat-Soluble Vitamin|Supplementation of the current dose of fat-soluble vitamins by intravenous perfusion
224171648|NCT04969458|OTHER|survey application|"Data collection tools used in the study;~* Clinic and Demographic Evaluation Form~* Oswestry Low Back Pain Disability Index (ODI)~* Patterns of Activity Measure Pain (POAM-P)~* Roland-Morris Disability Questionnaire (RMDQ)~* Hospital Anxiety and Depression Scale (HADS)~* Graded Chronic Pain Scale Version 2.0 (GCPS 2.0)"
224171649|NCT05316350|DEVICE|Electrocardiogram recording|ECG recording with investigational device
224171650|NCT05316350|DEVICE|Electrocardiogram recording|ECG recording with reference device
223483510|NCT01273259|DRUG|DHEA Treatment|DHEA : 25 mg/day hard gelatine capsule
223483511|NCT02830711|OTHER|Positive and Negative Affect Scale for Children|A 36-item instrument, including the Mood and Anxiety Symptom Questionnaire (MASQ)16 developed by Chang and Yeh and the Positive and Negative Affect Scale for Children developed by Watson and Clark
223483512|NCT04481139|DRUG|SHR0302|SHR0302, oral, once daily
223483513|NCT04481139|DRUG|SHR0302 placebo|SHR0302 placebo, oral, once daily
223483514|NCT05883514|BEHAVIORAL|Motivational interviewing|According to the Miller and Rollnick principles, the framework of the motivational interviewing group's sessions was taken from the workbook of the intervention's six sessions of motivational interviewing. A researcher recruited participants in groups of 7 patients for six sessions of 60-90 minutes each (two sessions per week). The training sessions covered topics like stress alleviation, appropriate drug usage, quitting smoking, regular physical activity, healthy eating habits, and regular physical activity. Patients in the control group got standard treatment for PPM, including education on proper medication usage, nutrition, and exercise, as well as regular checking.
223483515|NCT04324229|DRUG|Liraglutide 6 MG/ML [Victoza]|Starting dose of liraglutide 0.6 mg will be administered for one week, after which dose will be escalated to liraglutide 1.2 mg for one week and thereafter liraglutide 1.8 mg s.c. daily injections.
223483516|NCT04324229|DRUG|Placebos|Starting dose of placebo 0.1 ml will be administered for one week, after which dose will be escalated to placebo 0.2 ml for one week and thereafter placebo 0.3 ml s.c. daily injections.
223483517|NCT04309331|DIETARY_SUPPLEMENT|Motion|Amino acid based protein substitute
223483518|NCT05407883|BEHAVIORAL|School traffic warden programme|Trained school traffic wardens placed at school crossing points to help children cross
223483519|NCT01044524|RADIATION|SLV 334|2000 mg via i.v. solution
223483520|NCT06159582|BEHAVIORAL|eSTEP|eSTEP (Electronic Support to Engage with PrEP) is an mHealth intervention to promote engagement on the full PrEP care continuum and is tailored to the unique needs of GBMSM and TW. eSTEP is a mobile app (eSTEP) intervention with interactive components delivered before in-person HIV testing and PrEP initiation visit and interactive components delivered after PrEP is initiated.
223483521|NCT06159582|BEHAVIORAL|Usual Care|Usual HIV testing and PrEP clinical care
223585711|NCT02880527|OTHER|Patients with polymyositis / dermatomyositis|"recruitment of patients with polymyositis / dermatomyositis using :~1. medical specialists , hospital and liberals who support patients with polymyositis / dermatomyositis ( internists , dermatologists, neurologists, pulmonologists , rheumatologists ) ;~2. general practitioners~3. the PMSI data for public and private hospitals ; 4 ) data boxes regional health insurance (primary health insurance fund , MSA Normandy , Social Scheme for Self )~5\) Norman patients, members of an association of patients with polymyositis / dermatomyositis : the French Muscular Dystrophy Association"
224171651|NCT02149186|DEVICE|iCTuS-L|
224171652|NCT03248817|DRUG|single shot phenylephrine|a single shot of phenylephrine (1.5 mcg/Kg) will be administrated intravenously
224171653|NCT03248817|DRUG|fixed infusion phenylephrine|fixed infusion of phenylephrine will be administrated at a rate of 0.75 mcg/Kg/min.
224171654|NCT03248817|DRUG|variable infusion phenylephrine|Variable infusion of phenylephrine will be administrated at a starting rate of 0.75 mcg/Kg/min.
224305757|NCT03190330|DRUG|Ibrutinib 560 mg|Ibrutinib capsule administered orally at a dose of 560 mg for MCL participants.
223483522|NCT05835999|DRUG|Everolimus 0.5 MG once per day|Everolimus is considered an mTOR kinase inhibitor
223483523|NCT05835999|DRUG|Everolimus 5 MG once per week|Everolimus is considered an mTOR kinase inhibitor
223483524|NCT05835999|DRUG|Placebo once per day|No therapeutic effect
223483525|NCT05835999|DRUG|Placebo once per week|No therapeutic effect
223483526|NCT01580956|OTHER|VARIABLE-PSV ventilatory mode|The two ventilatory modes will be studied during 24h in intubated patients in random order.
223483527|NCT01580956|OTHER|STANDARD-PSV ventilatory mode|The two ventilatory modes will be studied during 24h in intubated patients in random order.
223483528|NCT06774235|DRUG|Interferon Gamma 1-b|injection of interferon gamma 1-b
223483529|NCT06774235|DRUG|Placebo|Injection of placebo in the same condition of experimental traitment
223483530|NCT05789485|BEHAVIORAL|structured treadmill walking|Three doses of AT (i.e., 90, 150, or 300 mins/week) will be tested. All doses will consist of individualized walking delivered up to 7 times per week delivered throughout treatment.
223585712|NCT01566578|DRUG|Human recombinant epidermal growth factor|topical
223585713|NCT01566578|OTHER|Placebo cream|Dermal cream without EGF
223585714|NCT05769049|BIOLOGICAL|REC610|administered as 2 intramuscular (IM) injections in healthy adults aged 40 years and older
223585715|NCT05769049|BIOLOGICAL|Shingrix|Shingrix
223585716|NCT06872749|OTHER|Placebo gel|will receive the application of a placebo gel (without active ingredient), under the same conditions described for the experimental gel.
223585717|NCT06872749|OTHER|KF2 (Potassium nitrate gel)|will receive application of potassium nitrate gel on hypersensitive dental surfaces, in an active way, for 10 minutes.
224171655|NCT03248817|DRUG|Bupivacaine|Bupivacaine will be administrated in the subarachnoid space for spinal anesthesia
224171656|NCT00415623|DRUG|Amlodipine|Amlodipine 5mg/ day
224305758|NCT06559176|BIOLOGICAL|PM359|Single dose of PM359 administered autologously by intravenous (I.V.) infusion following myeloablative conditioning with busulfan
224171657|NCT00415623|DRUG|Amlodipine|Amlodipine 10mg/ day
224171658|NCT04261218|DRUG|tomivosertib|Tomivoserib is supplied as a 100 mg capsule, to be taken orally.
224305759|NCT06145737|BEHAVIORAL|HOme-Based Self-management and COgnitive Training CHanges lives (HOBSCOTCH)|"One on one virtual self-management program for cognitive dysfunction associated with Multiple Sclerosis (MS).~HOBSCOTCH is a home-based self-management program to treat cognitive symptoms and improve quality of life, while minimizing the barriers of access to care. The program is based on Problem Solving Therapy (PST) and teaches problem solving strategies and compensatory mechanisms to help manage cognitive dysfunction and enhance quality of life. HOBSCOTCH-MS is an adaptation of the HOBSCOTCH program for people with MS and incorporates education about multiple sclerosis and cognition into the education module."
224305760|NCT04295473|PROCEDURE|Reduced port laparoscopic gastrectomy|The ports were reduced in the surgery of intervention arm.
223745078|NCT05594394|BEHAVIORAL|Orai: Master Public Speaking|"Participants will access the Orai: Master Public Speaking (Sani, Dhamani, \& Gupta, 2020) platform with mobile and web-based applications. Communication skill-building moduleswill be assigned using exercises, case scenarios, and AI-assisted feedback debriefing through the Orai application.~Participants will also complete case scenarios created with specific nursing conflict issues a charge nurse may encounter in an acute care facility. Upon completion of the competency development program, participants will complete the CMCSS to determine the effect on confidence levels and a brief survey (Appendix C) to assess the amicability of the program."
223745079|NCT04414709|OTHER|Double short implant|Patients receives 2 short implants to restore missing posterior teeth, loaded with splinted screw retained crowns.
223483533|NCT03335046|BEHAVIORAL|Home Visit|The intervention will consist of a series of home visitations to chronically absent students with co-morbid asthma. These visits will consist of a home environment evaluation, medication adherence and knowledge assessment, distribution of home environmental allergen reduction items such as mattress and pillow encasements, as well as review and reinforcement of any asthma action plans or care plans provided by patient's primary care physicians or medical home.
223483534|NCT03335046|BEHAVIORAL|Standard Care|Standard care will refer to the procedures carried out by the school district to address students with chronic absenteeism. This includes parent-teacher and parent-school administrator meetings and communications and may also include home visits carried out by classroom teachers or student support center staff.
223483535|NCT03857256|DRUG|CP105F|Natural Health Product
223483536|NCT03857256|DRUG|Placebo|tablet manufactured to mimic the CP105F beta-glucan
223585718|NCT06872749|OTHER|experimental Copaiba gel|will receive the application of the experimental desensitizing gel on the vestibular surfaces of the hypersensitive teeth in an active manner, for 10 minutes.
223585719|NCT06886542|OTHER|Dual task training|Dual task training is based on the simultaneous maintenance of motor-motor or cognitive-motor performance. The exercises given in single task training will be applied by combining them with cognitive and motor cognitive tasks.
223585720|NCT06886542|OTHER|Single task training|Single task training is a training approach that aims to improve the performance of individuals by focusing on only one task at a time.
223585721|NCT06886542|OTHER|Conventional physiotherapy|Range of motion, stretching, resistance exercises, isometric exercise, Before the treatment, a Hotpack will be applied to warm up the muscles, increase flexibility and improve performance. After exercise, transcutaneous electrical stimulation (TENS) will be used to relieve pain, reduce muscle tension and provide faster recovery.
223585722|NCT07087899|OTHER|music|listening music
223483537|NCT07147790|DRUG|After successful revacularization, We will categorize patients into two groups : groups A (The patient's wound will be cleaned and irrigated with silver nanoparticle spray, then we will cover the woun|"After successful revacularization, We will categorize patients into two groups :~groups A (The patient's wound will be cleaned and irrigated with silver nanoparticle spray, then we will cover the wound with silver nanoparticle spray for 15 minutes (time needed for its absorption) before applying NPWT with foam soaked in silver nanoparticle spray) and group B (The patient's wounds will be cleaned and irrigated with a normal saline solution for 15 minutes before applying NPWT.). Standard NPWT setting will be used in both groups, with a continuous negative pressure range from 70 to 125 mmHg. Selection criteria for the application of VAC therapy will be presented by calcaneal, dorsal, or plantar foot ulcers with an area of 4.0 and 10.2 cm2. The NPWT dressing will be changed every 3 days. The endpoint of NPWT will be the appearance of healthy granulation tissue."
223585723|NCT03701997|DEVICE|EXCOR Pediatric|Mechanical circulatory support using ventricular assist device
223585724|NCT06853314|BEHAVIORAL|PrEP for WINGS|The PrEP for WINGS intervention involves three sessions of a self-paced and self-directed intervention delivered via a mobile health platform. Session 1 will focus on HIV risk reduction and provide the PrEP Decision Aid, where participants will learn information about PrEP to help them decide if it is appropriate for them. Sessions 2-3 will involve integrated Screening, Brief Intervention, Referral to Treatment (SBIRT) modules focused on IPV and alcohol reduction. The PrEP for WINGS intervention will also involve peer navigation sessions with Community Health Advocates to help intervention participants trouble shoot any barriers to achieving goals they set during the self-paced sessions. The PrEP for WINGS intervention will take place over a 30 day period and Sessions 2-3, and the peer navigation sessions may be delivered using smart phones or using tablets available at study data collection sites.
224171659|NCT04261218|DRUG|paclitaxel|Taken weekly according to the current market label in combination with experimental tomivosertib.
224171660|NCT01186315|BEHAVIORAL|Prolonged Exposure Therapy|These treatments include repeated exposure to intrusive trauma-related memories in a safe and structured manner designed to reduce emotional arousal and facilitate processing of trauma-related memories.
224171661|NCT01186315|BEHAVIORAL|Prolonged Exposure therapy + VR/ER|The therapy includes repeated exposure to intrusive trauma-related memories in a safe and structured manner designed to reduce emotional arousal and facilitate processing of trauma-related memories and adding in virtual reality (VR)-based exposure to cues for marijuana, cocaine, heroin, cigarette, and/or alcohol use \& CER used outside treatment sessions in response to VR exposure (available 24 hours per day/7 days per week) to high-risk contexts for drug use
224171662|NCT00057928|DRUG|cisplatin|
224171663|NCT00057928|DRUG|gemcitabine hydrochloride|
224171664|NCT00057928|DRUG|paclitaxel|
224171665|NCT03846076|BEHAVIORAL|Cognitive behavioral therapy|Cognitive behavioral therapy
224171666|NCT04864327|BEHAVIORAL|Brief smoking cessation advise|The tobacco cessation protocol consisted of performing a routine assessment (asking) of cigarette use; providing advice on the importance of quitting; performing an assessment of the tobacco user's readiness to quit; assisting in setting a quit date; and making arrangements for follow-up visits. This protocol is popularly known as the 5A's strategy (The first 3A's should be delivered to all smokers regardless of their willingness to quit). Tobacco users were identified by staff nurses. Clinicians provided brief advice on quitting, and the researcher assessed the patient's dependence and readiness to quit. Patients who were not ready to quit were motivated to consider quitting, whereas those who were ready to quit were referred to practitioners who could assist them and follow them in the tobacco cessation clinic
223745080|NCT04414709|OTHER|Single short implant|Patients receives single short implants, loaded with single screw retained crowns.
223745081|NCT03640585|OTHER|Music therapy|Only the neurodevelopmental therapy was applied in the second group without music. A total of 15 treatments were administered for 5 weeks, 3 sessions per week for all patients. The sessions were 45 minutes.
224171667|NCT06156462|DEVICE|ResAppDx v.20|Software device measuring cough sounds to aid diagnosis of respiratory diseases
224171668|NCT00174889|DRUG|Pregnenolone|
224305761|NCT05439278|RADIATION|Hypofractionated radiotherapy|40.05 Gy in 15 fractions (daily treatment, 5 per week)
224305762|NCT05439278|RADIATION|Conventional radiotherapy|60 Gy in 30 fractions (daily treatment, 5 per week)
224305763|NCT05439278|DRUG|Temozolomide|concurrent (75 mg/m2/day qd) and adjuvant (6 cycles)
223483538|NCT07147790|DRUG|Silver Nanoparticles Irrigant|"After successful revacularization, We will categorize patients into two groups :~groups A (The patient's wound will be cleaned and irrigated with silver nanoparticle spray, then we will cover the wound with silver nanoparticle spray for 15 minutes (time needed for its absorption) before applying NPWT with foam soaked in silver nanoparticle spray) and group B (The patient's wounds will be cleaned and irrigated with a normal saline solution for 15 minutes before applying NPWT.). Standard NPWT setting will be used in both groups, with a continuous negative pressure range from 70 to 125 mmHg. Selection criteria for the application of VAC therapy will be presented by calcaneal, dorsal, or plantar foot ulcers with an area of 4.0 and 10.2 cm2. The NPWT dressing will be changed every 3 days. The endpoint of NPWT will be the appearance of healthy granulation tissue."
224305764|NCT06488001|DRUG|pantoprazole|Pantoprazole 40mg given the night before surgery, 2 hours prior to surgery, and the evening after surgery.
224305765|NCT06488001|DRUG|Placebo|Placebo given the night before surgery, 2 hours prior to surgery, and the evening after surgery.
224305766|NCT06314048|OTHER|CGM and RPM|1\. Implement the 4T program as standard of care at Stanford Diabetes clinics, including Continuous Glucose Monitoring (CGM) and Remote Patient Monitoring (RPM) within the first 30 days after T1D diagnosis to reduce the rise in HbA1c trajectory observed 4-12 months post-diagnosis.
224305767|NCT04351737|DRUG|Intracanalicular Dexamethasone, (0.4 mg) Insert|To determine post-surgical resolution of pain and inflammation outcomes with DEXTENZA compared to topical steroid treatment in patients who undergo bilateral pterygium surgery.
224305768|NCT04351737|DRUG|Prednisolone Acetate|To reduce post-surgical pain and inflammation in patients who undergo bilateral pterygium surgery.
224305769|NCT05413915|DRUG|Asciminib|Tyrosine kinase inhibitor
224305770|NCT05413915|DRUG|Imatinib|Tyrosine kinase inhibitor
223483539|NCT00523211|DRUG|Vicriviroc|One tablet of vicriviroc 30 mg once daily.
224305771|NCT04197258|OTHER|Peer support|"The intervention studied is the psycho-social support by a peer-helper to the patients and their main informal caregiver during the return home following a stay in rehabilitation center for a stroke.~Peer support intervention will be based on evidence, Bandura's social learning and social support theory, and the results of our ongoing study of the needs of patients and their caregivers as a result of returning home (Stroke69). It will include a meeting before the discharge and a regular follow-up for 6 months (face-to-face meetings, virtual or by phone), adapted to the needs of the patient and his caregiver, taking into account the social environment and in connection with the devices existing sanitary and social."
223483540|NCT00523211|DRUG|Placebo|One tablet of placebo once daily.
223483541|NCT07155538|OTHER|Assesment test for Validity and Reliability|Assesment test
223483542|NCT07168707|OTHER|Group-based Emotional Awareness & Expression Therapy - Hebrew|"This pilot study will use the eight-session group EAET manual developed by Mark A. Lumley and Howard Schubiner. Several adaptations to this manual were made: a) Manual's translation to the Hebrew language; b) Adaptations to the Israeli context and setting; c) Manual's language was changed from fibromyalgia to chronic pain and adaptations were made accordingly. Group participants will receive a class syllabus and an educational booklet of the EAET approach. Each group meeting will be led by two instructors, a psychologist and a physiotherapist."
223483543|NCT07168226|DRUG|Active Comparator|Megace F suspension 20mL, intake daily for 12weeks
223483544|NCT07168226|DRUG|ASCA101 24.32mg/kg|ASCA101 Inj. 24.32mg/kg, twice a week for 12 weeks
223483545|NCT07168226|DRUG|ASCA101 32.43mg/kg|ASCA101 Inj. 32.43mg/kg, twice a week for 12 weeks
223483546|NCT07168226|DRUG|Placebo|0.9% normal saline injection
223483547|NCT07168629|BEHAVIORAL|Community health worker delivered outreach, shared decision-making, tobacco treatment, and navigation|The CHW will perform: 1) patient outreach 2) patient-centered shared-decision making, 3) smoking cessation counseling, and 4) navigation of logistical barriers
223483548|NCT07168629|OTHER|Enhanced Usual Care|After randomization, the control group will receive the same mailed LCS educational materials as the intervention group and encouraged to discuss screening with their PCP, the typical pathway through which patients enter the LCS program.
223483549|NCT07167667|OTHER|Paraffin Bath|Patients' hands will be dipped into the paraffin bath 8-10 times.
223483550|NCT07167667|OTHER|Extracorporeal Shock Wave Therapy|The patients will be treated with a sound wave pulse frequency of 15 Hz, an intensity of 1.5 bar, and a total number of pulses of 2000 for one session.
223483551|NCT07169500|BIOLOGICAL|CAR-T|Chimeric antigen receptor T cells (car-t) are genetically engineered MHC independent tumor specific killer cells.
223483552|NCT07169513|DRUG|Aspirin 75 mg daily|For group 1 patients
223483553|NCT07169513|DRUG|Clopidogrel 75 mg daily|For group 2 patients
223483554|NCT07169513|DRUG|Clopidgrel 75 mg daily|For group 1 patients
223483555|NCT07169513|DRUG|Aspirin 75 mg daily + Clopidgrel 75 mg daily|For group 2 patients
223745082|NCT05150353|PROCEDURE|MRI|Wrist MRI
224171669|NCT05708729|DEVICE|MCS surgery for CPSP|The investigational devices that will be used for the MCS surgeries are the following: the Vanta with AdaptiveStim Technology Primary cell neurostimulator or the Intellis Implantable Neurostimulator with AdaptiveStim Technology from Medtronic, Inc. (MN, USA). These implantable neurostimulators are intended to generate electrical pulses and to deliver stimulation trough one or more leads as part of a neurostimulation system for pain therapy in adults.
224171670|NCT05708729|DEVICE|Vc-DBS surgery for CPSP|For the deep brain stimulation procedure, we will use Vercise stimulators from Boston Scientific together with the Cartesia Directional Leads or the Percept PC stimulator from Medtronic.
224305772|NCT04018664|DRUG|Nalbuphine HCl solution|nalbuphine solution administered at various strengths
224305773|NCT04018664|DRUG|Placebo solution|Placebo
224305774|NCT05960266|BIOLOGICAL|Polvac Grass+Rye|Aqueous suspension of a co-precipitate of allergen extract and tyrosine
224305775|NCT04141098|DEVICE|All patients that meet the inclusion/exclusion criteria will receive the PerQdisc® Nucleus Replacement Device.|All patients meeting all inclusion criteria and no exclusion criteria will be considered for nucleus replacement surgery following a review by the Medical Advisory Board. Any patient meeting any of the three intraoperative exclusion criteria will receive an alternative standard of care therapy.
223745083|NCT01815125|DRUG|Ondansetron|The intervention of interest will be the administration of one dose of oral ondansetron in the emergency department. The dosage will be 8 mg.
223483556|NCT07168473|DRUG|Experimental|"1. DW1807 Once daily with water regardless of meals without chewing or crushing for up to 4 weeks~2. DW1807-R2 placebo Once daily with water regardless of meals without chewing or crushing for up to 4 weeks"
223483557|NCT07168473|DRUG|Comparator|"1. DW1807 placebo Once daily with water regardless of meals without chewing or crushing for up to 4 weeks~2. DW1807-R2 Once daily with water regardless of meals without chewing or crushing for up to 4 weeks"
223483558|NCT07168512|OTHER|Exercises (Endurance and strengthening)|"Neck Strengthening and Endurance Exercises with Hot Packs~Preparation: A moist hot pack will be applied for 10-15 minutes to the cervical region before exercise to reduce stiffness and enhance tissue extensibility.~Exercise program:~Deep cervical flexor training: Chin tucks in supine and sitting, progressing to sustained isometric holds.~Extensor and scapular stabilizer training: Prone head lifts and shoulder retraction exercises with light resistance.~Endurance training: Low-load, high-repetition exercises focusing on maintaining cervical posture against gravity.~Progression: Intensity and duration will gradually increase, emphasizing endurance over maximal strength to correct postural deficits.~Frequency: 40 minutes per session, 3 times per week for 6 weeks~Rationale: The combined use of heat and targeted exercises improves neuromuscular control, enhances cervical stability, and supports better cervical curvature correction. Myofascial Release Technique"
223483559|NCT07168512|OTHER|Myofascial release technique|"Myofascial Release Technique~Target areas: Suboccipital muscles, upper trapezius, levator scapulae, and deep cervical fascia.~Method: A physiotherapist will perform gentle, sustained manual pressure and low-load, long-duration stretching on restricted cervical and upper thoracic fascia to reduce tension and improve soft tissue mobility.~Duration and frequency: Each session will include 30'to 50 minutes of myofascial release, delivered 3 times per week for the study period for 6 weeks.~Rationale: This technique aims to decrease myofascial restrictions contributing to abnormal cervical alignment and pain, thereby facilitating improved posture and muscle activation."
223483560|NCT07168096|OTHER|Psychosocial and clinical assessment|Participants complete standardized self-report questionnaires and undergo medical record review at three time points (baseline, 3 months, and 6 months) to assess psychological symptoms (anxiety, depression, somatization), coping strategies, quality of life, cognitive difficulties, physical activity, nutrition, supportive care needs, and informed decision-making in the context of cancer treatment. No experimental treatment or therapy is administered.
223483561|NCT07167576|OTHER|Catinfo tool and discussion with physician|Patients in the study group watch a computer presentation with information about the cataract surgery
223483562|NCT07167576|OTHER|discussion with physician|Patients in the control group have a discussion with the physician
223745084|NCT01815125|DRUG|PLacebo|placebo
223745085|NCT04336891|DRUG|Testosterone gel|Transdermal 2% T gel applied once daily to the thighs or lower abdominal/pubic area (300 mcg T per day) for 6 months
223745086|NCT04336891|DRUG|Estradiol ovules|Intravaginal estradiol ovules taken daily for 2 weeks and afterwards twice a week, for 6 months
223745087|NCT04336891|DRUG|Moisturizer|Local non-hormonal moisturizers applied regularly every 2-3 days and lubricants as needed
223745088|NCT04336891|DRUG|Testosterone gel + Estradiol ovules|Transdermal 2% T gel applied once daily to the thighs or lower abdominal/pubic area (300 mcg T per day), plus Intravaginal estradiol ovules taken daily for 2 weeks and afterwards twice a week, for 6 months
223745089|NCT02408393|DRUG|Saline|
223745090|NCT02408393|DRUG|Ropivacaine|
224171671|NCT01855867|DRUG|Single Dose Elivitegravir (150mg), Combicistat (150mg), Emtricitabine (200mg), Tenofovir DF (300mg)|
224305776|NCT04582279|DIAGNOSTIC_TEST|Lung ultrasound|The lung ultrasound will be performed by a trained pulmonologist by gently pressing a probe to various areas of your chest. This is a non-invasive procedure and you should not feel any pain. The ultrasound will take less than 10 minutes.
224305777|NCT03845296|DRUG|Rucaparib|Given PO
224305778|NCT05091307|BIOLOGICAL|Ad26.COV2.S|Ad26.COV2.S will be administered as an IM injection.
224305779|NCT05091307|OTHER|Placebo|Placebo will be administered as an IM injection.
224305780|NCT05091307|BIOLOGICAL|Influenza Vaccine|Influenza vaccine high and standard dose will be administered as IM injection.
224305781|NCT05104073|BEHAVIORAL|Intervention|Provided with educational materials, guidelines and instructions.
224305782|NCT06411899|DRUG|Sonelokimab|Sonelokimab
224305783|NCT06411899|DRUG|Placebo|Placebo
224305784|NCT06956430|DEVICE|Battery-powered rickshaw|A battery-powered rickshaw is a rickshaw where the wheels are turned by a small electric motors powered by a battery.
224305785|NCT06959407|DRUG|oral dexamethasone|Patients in group A will receive oral dexamethasone which will be administered at 0.6mg/kg as single dose
224305786|NCT06959407|DRUG|intramuscular dexamethasone|Patients in group B will receive intramuscular dexamethasone which will be administered in 0.6mg/kg strength as intra-gluteal injection as single dose
224171672|NCT00182234|BEHAVIORAL|Community Interlink Program|The study intervention is a referral to a specialized oncology nursing program. The standardized care provided by this program includes comprehensive assessment and care planning specific to breast and colorectal cancers during the initial phases of treatment, with a minimum of two home visits. Through consultation with the patient, nurses either provide direct (non-medical) care to address needs identified and/or coordinate linkage to services in the community.
224171673|NCT06691698|OTHER|The Cognitive Orientation to Daily Occupational Performance Approach|CO-OP is a client-centred, performance-based, problem-solving focused, occupation-focused and occupation-based intervention. In CO-OP the person is guided to use a meta-cognitive strategy to find his or her own strategies for specific activities. The main purpose is to enable meta-cognitive thinking in every day activities, leading to enhanced self-efficacy, occupational performance and independency.
224171674|NCT04251195|BEHAVIORAL|Cognitive Intervention|Participants will undergo 15 minutes of a cognitively challenging activity in the Virtual Reality environment. (More details about each condition will be added after study completion to protect the blinding of our participants).
224171675|NCT04251195|BEHAVIORAL|Active Control Intervention|Participants will undergo 15 minutes of a cognitively challenging activity in the Virtual Reality environment. (More details about each condition will be added after study completion to protect the blinding of our participants).
224171676|NCT01572636|DRUG|Laronidase|Administered 0.58 mg/kg/dose intravenously (IV) once a week beginning 12 weeks before planned hematopoietic stem cell transplant (HSCT) and resume same dosing regimen for 8 weeks after HSCT.
224171677|NCT00678249|DEVICE|FLAIR Endovascular Stent Graft|Primary balloon angioplasty followed by placement of the FLAIR Endovascular Stent Graft
224171678|NCT00678249|PROCEDURE|PTA|Percutaneous Transluminal Angioplasty
224171679|NCT00678249|DEVICE|FLAIR Endovascular Stent Graft|Primary PTA followed by placement of the FLAIR Endovascular Stent Graft. Roll-in participants were enrolled in the study for training purposes and were not randomized.
224171680|NCT03828864|DEVICE|Pulsed Shortwave Therapy|Pulsed Shortwave Therapy device placed over the site of pain for 16 hrs per day
224171681|NCT03828864|DEVICE|Placebo Pulsed Shortwave Therapy|Placebo Pulsed Shortwave Therapy device placed over the site of pain for 16 hrs per day
224171682|NCT03458403|PROCEDURE|Motions during gastroscopy|Recording of endoscopist and endoscope motions right after the endoscopic exam the patient came for. The endoscope is removed halfway up the esophagus and inserted into the pylorus to the descending duodenum. The gesture is repeated three times.
224171683|NCT02052908|OTHER|Laboratory Biomarker Analysis|Correlative studies
224171684|NCT02052908|DRUG|Naproxen|Given PO
224171685|NCT02052908|OTHER|Placebo Administration|Given PO
224171686|NCT03044743|DRUG|Fludarabine|To modify immune micro-environment
224171687|NCT03044743|DRUG|Cyclophosphamide|To modify immune micro-environment
224171688|NCT03044743|DRUG|Interleukin-2|To sustain the survival of infused T cells
224171689|NCT04071808|DIAGNOSTIC_TEST|ELISA Test|The levels of orphanin and norepinephrine in blood of diabetic patients with painless myocardial ischemia requiring interventional therapy and diabetic patients without interventional therapy were measured.
224171690|NCT02920879|PROCEDURE|PEEP-level, driving pressure|Different levels of PEEP and different levels of driving pressures during mask-ventilation at anesthesia induction.
224171691|NCT01708915|DRUG|nicoboxil|2cm ointment line for a skin area of approximately 20 cm x 20 cm up to 3 times in a 24h period
224171692|NCT01708915|DRUG|placebo matching nonivamide + nicoboxil|2cm ointment line for a skin area of approximately 20 cm x 20 cm up to 3 times in a 24h period
224171693|NCT01708915|DRUG|nonivamide + nicoboxil (Finalgon)|2cm ointment line for a skin area of approximately 20 cm x 20 cm up to 3 times in a 24h period
224171694|NCT01708915|DRUG|nonivamide|2cm ointment line for a skin area of approximately 20 cm x 20 cm up to 3 times in a 24h period
224171695|NCT00108615|DRUG|Metformin|
224171696|NCT00108615|DRUG|Pioglitazone|
224171697|NCT00108615|DRUG|Metformin|
224171698|NCT00108615|DRUG|Pioglitazone|
224171699|NCT00108615|RADIATION|CT scans|To measure changes in adipose tissue volumes
224305787|NCT03611543|DEVICE|Standard of Care Flat Paddle|"X-Ray Mammogram Exam.~Each screening subject will receive a 4-view 2D plus 3D combination imaging: Left Cranial Caudal (LCC), Left Medial Oblique (LMO), Right Cranial Caudal (RCC), and Right Medial Oblique (RMLO) with the current standard of care (SOC) flat paddle.~Each diagnostic subject will have her prescribed diagnostic 2D plus 3D combination imaging (CC or MLO) with the SOC flat paddle. The image view (CC or MLO) will be based on the visibility of the area of interest for which the diagnostic imaging was ordered.~The amount of compression applied in all mammograms will be to achieve tautness."
224305788|NCT03611543|DEVICE|Investigational Curved Paddle|"X-Ray Mammogram Exam.~Each screening subject will receive a CC and an MLO in one of her breasts as determined by a randomization scheme with the investigational (INV) curved paddle.~Each diagnostic subject will have her prescribed diagnostic 2D plus 3D combination imaging (CC or MLO) with the INV curved paddle. The image view (CC or MLO) will be based on the visibility of the area of interest for which the diagnostic imaging was ordered.~The amount of compression applied in all mammograms will be to achieve tautness."
224305789|NCT02081209|DEVICE|The Zeltiq CoolSculpting System|Non-invasive cooling is applied to the treatment area with a defined cooling rate and duration.
224171700|NCT00108615|PROCEDURE|Oral glucose tolerance test|To detect a change in glucose tolerance
224171701|NCT02907411|OTHER|Quadrivas Therapy|Quadrivas therapy will be applied to subjects. Quadrivas therapy is a intensive massage therapy for different tissues. Subjects will receive 12 treatments. The first lasting 2.5 hours and the remaining 11 lasting 1.5 hours.
224171702|NCT02072733|OTHER|Comprehensive geriatric assessment|Intervention is planned to be based on the findings of the geriatric assessment and could include optimizing on comorbidity, planning of physical exercise, improvement of the social situation and nutritional status.
224171703|NCT02171156|DRUG|nintedanib|soft gelatin capsule
224171704|NCT04742140|DRUG|Magnesium sulfate|each patient injected 0.5ml in each TrPs of magnesium sulphate according to the treatment group by the same operator
224171705|NCT04742140|DRUG|Saline|each patient injected 0.5ml in each TrPs of saline according to the treatment group by the same operator
224171706|NCT05956327|PROCEDURE|Aerobic Endurance Training|Aerobic endurance training on a bicycle ergometer (week 1 to 6: three units per week á 40 minutes, week 7 to 12: three units á 45 minutes, in groups of up to three patients over 13 weeks)
224171707|NCT05956327|PROCEDURE|Flexibility, strengthening and balance training|Flexibility, strengthening and balance training (exercises from the areas of stretching, strength, balance and relaxation, 3x40 min from week 1-2, 3x45 min from week 3-4 and 3x50 min from week 5-13, in groups of up to three patients over 13 weeks)
224171708|NCT02802657|PROCEDURE|Treat-and-Extend regimen|For the T\&E regimen,investigators recorded patients' data after retreatment by 3 monthly intravitreal injections of Conbercept. Patients were examined 6 weeks after the third injection, with ETDRS visual acuity testing, fundus ophthalmoscopy and photography, and OCT, and treated on the same day. The interval between treatments was extended by 2-week (12-week was a maximum) provided that OCT and fundus examination did not show either exudative manifestations or new macular hemorrhage or active CNV or reduced by 2 weeks (4-week was minimum) in case of such manifestations or hemorrhage. The persistence of pigment epithelium detachment was not considered a condition that justified shortening the interval between injections.
224171709|NCT02802657|PROCEDURE|Pro Re Nata|For the PRN group, investigators recorded patients'data after retreatment by 3 monthly intravitreal injections of Conbercept.Subsequent reinjections were given as needed according to the changes in patients'visual acuity and/or the exudation shown by OCT. Four to five weeks after the third and last injection, all patients in the PRN group underwent an examination, including ETDRS visual acuity, fundus photography,and OCT. In case of persistent subfoveal or perifoveal fluid, macular intraretinal edema, visual loss of \>5 letters, or the occurrence of a new hemorrhage, patients were retreated. The persistence of hemorrhage without evidence of fluid was not considered a criterion for retreatment. In the absence of retreatment criteria, no further injections were given and another examination was proposed usually 4 weeks later.
224171710|NCT02802657|DRUG|Conbercept|
224171711|NCT04272762|PROCEDURE|Cryoablation|Pulmonary vein isolation with cryoablation
224171712|NCT04272762|PROCEDURE|Placebo|Placebo procedure
224171713|NCT03414268|OTHER|Micronized dHACM|1 mL injection of 40 mg Micronized dehydrated human amnion/chorion membrane (dHACM)
224171714|NCT03414268|DRUG|Saline Injection|Injection of 1mL 0.9% Sodium Chloride Injection, USP
224305790|NCT06847633|BEHAVIORAL|Digital lifestyle intervention|The digital lifestyle intervention provides support to the patient through digital lectures, home assignments and digital group meetings as well as provides the possibility for the healthcare provider to provide personalized digital support and feedback to the patient
223483563|NCT07167095|OTHER|Retrospective Data Collection and Analysis|This intervention refers to retrospective evaluation of clinical and laboratory data of advanced cancer patients who presented to the emergency department between December 2022 and March 2025. Data will be extracted from the hospital information system (HBYS) and national death registry (e-Nabız). Parameters include demographics, ECOG performance status, primary tumor type, metastatic sites, laboratory markers (e.g., NLR, CRP, albumin, LDH), and outcomes such as 90-day mortality, re-admissions, and re-hospitalizations. No experimental treatment, drug, or device is administered as part of the study.
223483564|NCT07167914|DRUG|SFG-02|Transdermal Formulation (SFG-02)
223483565|NCT07167914|DRUG|Placebo|Transdermal Formulation (Placebo)
223483566|NCT07167888|BEHAVIORAL|Clinical Control Group (Group A)|The participants who reported the presence of neck or low back pain and were assigned to the clinical control group (Group A) after randomisation will not receive the intervention of an exercise program. The interventional group (Group B) will be asked to keep the standardised exercise program confidential and not share with the control group (Group A). After eight (8) weeks, Group A participants will receive: the Cornell Musculoskeletal Discomfort Questionnaires (CMDQ) to assess for changes in the frequency, discomfort and interference with work due to musculoskeletal pain; a Questionnaire B, to ascertain any changes in their pain level using the Numeric Rating Scale (NRS); as well as their knowledge, attitude and practice towards musculoskeletal problems of the neck and low back pain, without having received any intervention.
223483567|NCT07167888|BEHAVIORAL|Spine Exercise Program (Group B)|The standardised spine exercise program will be provided in a handout and given only to the intervention group (Group B), and will include simple basic neck or low back exercises to be done three (3) times per week, as well as brief stretching exercises, to be done during periods of sitting for greater than sixty (60) minutes. The selected participants will be asked to comply with instructions on the handout. Participants who experience worsening of their symptoms, or who develop new symptoms will be assessed as having an adverse outcome and will be withdrawn from the study.
223483568|NCT07167784|OTHER|Ecological Momentary Assessment|Participants will be complete four daily EMA surveys via the Avicenna Research app (morning, 11 a.m., 3 p.m., and evening). Participants will be instructed to complete and submit each survey as soon as they see the app notification. If no response is provided within 15 minutes, a reminder notification will be sent. At the end of the 14-day period, devices will be returned using a prepaid envelope provided by the study team and participants will complete an end-of-study questionnaire to assess the acceptability of the study and will be invited to participate in a debriefing interview with a member of the research team.
224171715|NCT04892394|OTHER|Information Types Before Endodontic Treatment|The first aim of this study is to compare the effect of detailed video information or basic verbal information on the anxiety levels of patients by using anxiety scales before treatment. The second aim is to evaluate the effect of pretreatment video or verbal information on the stress level occurring in patients during the endodontic treatment steps by using electrodermal activity. The third aim is to investigate the relationship between patients' pretreatment anxiety levels and socio-demographic characteristics which are thought to play a role in anxiety's etiology.
224171716|NCT00353340|DRUG|n acetylcysteine|
224171717|NCT00353340|DRUG|sodium bicarbonate|
224171718|NCT00353340|DRUG|sodium chloride|
224171719|NCT06412640|DRUG|Keverprazan|Potassium-competitive acid blocker
224171720|NCT06412640|DRUG|Amoxicillin|Antibiotic for H. pylori eradication
224305791|NCT06580925|DEVICE|sham tape|sham
224305792|NCT06580925|DEVICE|kinesio tape|Kinesio taping will be applied to correct shoulder posture and facilitate shoulder external rotators
224305793|NCT06580925|DEVICE|dynamic tape|Dynamic tape will be applied to correct shoulder alignment and assist concentric contraction and eccentric control of external rotators
224171721|NCT02663245|OTHER|Intervention 1|"* Diabetes specific consultation~* Basic training in clinical guidelines~* Platform of communication for professionals~* Training update to review and evaluate actual cases where the coaching strategy has been applied 2-hours training programme to update and review the training of month 0.~* 7-hour training programme in group coaching for primary care professionals with a theoretical and practical approach.~* Intervention based on text messaging to patients to remind them of strategies that promote behaviour change in relation to diabetes."
224171722|NCT02663245|OTHER|Intervention 2|"* 7-hour training programme in group coaching for primary care professionals with a theoretical and practical approach.~* Training update to review and evaluate actual cases where the coaching strategy has been applied 2-hour training programme to update and review the training of month 0.~* Basic training in clinical guidelines.~* Platform of communication for professionals.~* Intervention based on text messaging to patients to remind them of strategies that promote behaviour change in relation to diabetes."
224171723|NCT04697108|OTHER|Shoulder reproduction teste assisted by laser pointer|In the step (1) of Familiarization in which the SRTLP was applied through a single evaluator with the aim of knowledge and understanding of the test. After five minutes, step (2) test started. In this step, the test was applied twice, by different evaluators, with an interval of five minutes between applications (inter-rater reliability). Ten minutes after the end of the tests, step (3) retest (intra-rater reliability) was started, following the same procedures as in step 2. The order of the evaluators was randomized through a draw in Excel, the order of randomization of the steps (2) and (3) was the same in order not to influence intra-rater reliability
224171724|NCT05699044|DIAGNOSTIC_TEST|Amyloidosis screening (bloodtest, DPD-scintigraphy, potentially endomyocardial biopsy)|"Bloodtest: Troponin I, NT-pro-BNP, electrolyte status, renal function, kampda/lambda free chain + ratio, M-komponent.~DPD-scintigraphy. (Echocardiography)"
223483569|NCT07168954|DEVICE|Lumos Glasses|The Lumos Glasses provided tailored blue light therapy and blue light filtering based on the time of day and the user's ambient light conditions. It combines the effect of bright blue light therapy and blue light blocking.
223483570|NCT07168317|DRUG|tislelizumab in combination with cyclophosphamide, mitoxantrone liposomes, chidamide, and prednisone|tislelizumab: 200mg on d1 every 3 weeks; chidamide: 20mg twice a week at least 3 days apart; cyclophosphamide: 750mg/m2 on Day 1 of each cycle, every 4 weeks; mitoxantrone liposomes: 20mg/m2 on Day 1, every 4 weeks; prednisone: 100mg/day on Day 1 to Day 5 of each course, every 4 weeks.
223483571|NCT07167108|OTHER|Conventional program, with addition to Mulligan technique|The Mulligan Concept is a manual therapy approach developed by New Zealand physiotherapist Brian Mulligan in the 1980s. It includes techniques such as Mobilization with Movement (MWM) and the Sustained Natural Apophyseal Glide (SNAG), which have attracted significant attention for their effectiveness in treating neck pain. Recent research has supported the benefits of physiotherapy interventions like SNAGs in improving cervical range of motion (ROM) and reducing pain.
223483572|NCT07167108|OTHER|Conventional Physical Therapy Program|Included exercises, electrical stimulation, and massage.
223483573|NCT07168434|DRUG|Saccharomyces Boulardii 250 MG|Saccharomyces boulardii CNCM I-745, 250 mg, 2 capsules/day
223483574|NCT07168434|DRUG|Placebo 250 mg|Placebo, 250mg, 2 capsules/day
223483575|NCT07167043|DIAGNOSTIC_TEST|AI-assisted diagnostic systems|Diagnosing neurological diseases on CT/MRI with and without AI-assisted tools
223483576|NCT07168681|OTHER|Control group|"Active Comparator: Control group The exercise program to be implemented within the scope of the study is the SHRed (Sports Injury Prevention for the Lower Extremity, focusing on musculoskeletal and head-related injuries) neuromuscular training program. The program will be administered over six weeks, with two sessions per week.~The control group will perform the exercises under normal visual conditions. The exercise program to be implemented within the scope of the study is the SHRed (Sports Injury Prevention for the Lower Extremity, focusing on musculoskeletal and head-related injuries) neuromuscular training program. The program will be administered over six weeks, with two sessions per week. Previous research has shown that the SHRed injury prevention neuromuscular training program reduces ankle and knee injuries in youth basketball players by 36% \[35\]. The program consists of balance, agility, strength, and aerobic exercises."
223585725|NCT06853314|BEHAVIORAL|PrEP Decision Aid|The PrEP Decision Aid will be delivered to participants in the control condition, and focus on helping study participants decide if they should initiate PrEP. This single session will focus on HIV risk reduction, and then launch the patient-centered PrEP Decision Aid. This individual session will be identical to the first session of the PrEP for WINGS three session intervention, and will also be delivered through an online survey platform. In addition, study participants in the control condition will also have one peer navigation session with a Community Health Advocate at the end of the self-paced session to help facilitate linkage to care.
224171725|NCT01636739|BIOLOGICAL|Oral Rotarix®|2 doses administered orally.
224171726|NCT01636739|OTHER|Data collection|Additional information on intussusception will be collected through interview and by phone-contact.
224171727|NCT03943940|BIOLOGICAL|BM-MNC and UC-MSC|"Autologous bone marrow mononuclear cells (BM-MNCs) and allogeneic umbilical cord tissue-derived mesenchymal stem cells (UC-MSCs) under sterile conditions to treat this disease.~UC-MSC: 1-2 x 10\^6 cells/kg"
224171728|NCT03943940|OTHER|Control|Standard medicine
224171729|NCT01432938|BIOLOGICAL|dulaglutide|Administered subcutaneously
224171730|NCT01432938|DRUG|Warfarin|Administered orally
224171731|NCT00566332|DRUG|Chlorambucil|Chlorambucil 8 mg/m² (6 mg/m² if patient aged more than 75 years old) 10 days every 28 days during 12 months By oral route
224171732|NCT00566332|DRUG|Fludarabine|Fludarabine 40 mg/m² (30 mg/m² if patient aged more than 75 years old) 5 days every 28 days during 6 cycles By oral route
224171733|NCT04602299|OTHER|Set the minimum time of gastroscopy|This study contains 2 stages. At the first stage, no interventions are implemented. The researchers just observe the actual procedure time of gastroscopy. At the second stage, a minimal procedure time is set based on the observational results of the first stage.
224171734|NCT01510561|DRUG|90Y-hPAM4|90Y-hPAM4 will be administered weekly for 3 weeks in conjunction with gemcitabine which will be administered weekly x 4.
224171735|NCT01510561|DRUG|90Y-hPAM4|
224171736|NCT01510561|DRUG|90Y-hPAM4 + gemcitabine|
224305794|NCT05105490|DRUG|PerQdisc|Observational trial to collect post-market safety and efficacy information in a limited number of human patients
224171737|NCT03727776|DRUG|Adrenocorticotropic Hormone|Adrenocorticotropic hormone (ACTH) is a melanocortin peptide hormone that is normally produced in the pituitary gland and acts as a major regulator of adrenal cortex function. It stimulates the adrenal cortex to produce and secrete glucocorticoids. ACTH is available for clinical usage as an injectable gel (H.P. Acthar®).
224171738|NCT01601873|DEVICE|PROPATEN|Heparin-bonded graft implantation for hemodialysis vascular access
224171739|NCT01601873|DEVICE|Standard Graft|non-heparin bonded conventional hemodialysis vascular access graft
224171740|NCT04961502|BIOLOGICAL|Blood test to describe the humoral and cellular response to vaccination BNT162b2 in the elderly|3 blood samples taken to compare the immunization response of the elderly with that of younger adults (priority caregivers): the first carried out before the anti-Coronavirus Disease 2019 (COVID-19) vaccination; the second shortly before the vaccination booster injection and the third approximately two months after the first vaccine injection
224171741|NCT04780191|DEVICE|MyoRegulator®|Trans-spinal DC stimulation paired with peripheral DC stimulation
224171742|NCT00268476|DRUG|Celecoxib|
224171743|NCT00268476|DRUG|Docetaxel|
224171744|NCT00268476|DRUG|Prednisolone|
224171745|NCT00268476|DRUG|ADT|
224171746|NCT00268476|DRUG|Zoledronic Acid|
224171747|NCT00268476|DRUG|Abiraterone|
224171748|NCT00268476|RADIATION|Radiotherapy to the prostate|
224171749|NCT00268476|DRUG|Enzalutamide|
224171750|NCT00268476|DRUG|Metformin|
224171751|NCT00268476|DRUG|Transdermal Oestradiol|
224171752|NCT00269620|DRUG|ethinyl estradiol/etonogestrel vaginal ring|vaginal ring for cyclic use (3 weeks in, 1 week out)
224171753|NCT00269620|DRUG|ethinyl estradiol/norelgestromin transdermal contraceptive|contraceptive patch worn for 7 days and replaced for use for 3 consecutive weeks followed by a one-week patch free interval
224305795|NCT04163432|DRUG|Durvalumab|Durvalumab is administered at a dose of 1500mg for patients who weigh \>30 kg. If weight falls to ≤ 30 kg, weight-based dosing at 20mg/kg will be a utilized
223483577|NCT07169279|DRUG|Infigratinib is provided as a single dose of minitablets for oral administration|"* The initial cohort dose of infigratinib will begin at the protocol-specified starting dose, with subsequent cohort escalation based on protocol specific criteria.~* The target dose is the dose that will provide similar exposure to the dose of 0.25 mg/kg/day in participants 3 years old and older.~* The dose and number of minitablets will be calculated based on individual participant age and weight."
223483578|NCT07169279|DRUG|Infigratinib is provided as sprinkle capsules for daily oral administration|"* The cohort dose of infigratinib will be the dose identified in the Single Ascending Dose portion for the age group.~* The dose and number of sprinkle capsules/day will be calculated based on individual participant age and weight. Doses will be adjusted based on age and weight changes approximately every 3 months."
223585726|NCT05502666|BEHAVIORAL|¡Salud! Por la Vida|Lay health worker (LHW) delivered educational intervention for colorectal cancer screening (CRCS). The intervention consisted in having the participant complete a tailored interactive multimedia intervention (TIMI). TIMI consisted of a series of educational videos that addressed common barriers to colorectal cancer screening as well as provided information about colorectal cancer (CRC) and CRCS tests. Participants were able to tailor the TIMI for sex (male/female) and CRC family history. After TIMI completion, the LHW provided participant with a copy of the SPLV newsletter and printed infographics on CRC, CRCS, and an action plan tailored by type of CRCS (FOBT/FIT or colonoscopy). The Intervention Group subject participation took approx. up to 2 hours and Control Group up to 1 hour (half hour for each: baseline and follow-up interview). Follow-up data was collected 6 months post education session (intervention group) or post-baseline survey (control group).
223585727|NCT00300677|DRUG|voriconazole|Multiple oral doses of voriconazole at 400 mg loading twice daily followed by 200 mg maintenance twice daily
224171754|NCT04951817|DRUG|Ga-68 PSMA ligand|For PET/CT PSMA scan, the subject will have catheter(s) placed for intravenous administration of \[68Ga\]PSMA-11. Subjects will receive a single intravenous bolus of 2-5 mCi \[68Ga\]PSMA-11 and received PET/CT scan 60 minutes later.PSMA PET-CT scan was performed on a GE Discovery MI PET/CT system.
224171755|NCT01847872|DRUG|IPV IM Needle|
224171756|NCT01847872|DRUG|IPV ID Needle|
224171757|NCT01847872|DRUG|IPV IM Device|
224171758|NCT01847872|DRUG|IPV ID Device|
224171759|NCT05399836|BEHAVIORAL|Portion size manipulation|The intervention will be administered via changing portion sizes of foods served to participants.
224171760|NCT04220658|OTHER|Biomarker study|Biomarkers of aging including NAD+ levels in whole blood, interleukins, inflammatory cytokines, growth factors, omega-3 polyunsaturated fatty acids, and patterns in DNA methylation
224171761|NCT02096471|DRUG|PD-0325901|
224171762|NCT00073034|DRUG|EAA-090|
224305796|NCT04163432|DRUG|Pemetrexed|Pemetrexed dosing is adjusted for kidney function. Pemetrexed is dosed at 500mg/m2 for patients with a creatinine clearance ≥ 45 mL/min (by Cockcroft-Gault formula). If creatinine clearance is \< 45 mL/min, pemetrexed is dosed at 400 mg/m2.
224171763|NCT03305913|DRUG|TAS 102|TAS-102 tablet
224171764|NCT03305913|DRUG|Regorafenib|Regorafenib tablet
224171765|NCT05797727|DEVICE|LifeChamps Platform HCP|Healthcare professionals that will participate in the study will be introduced will have access to the LifeChamps Dashboard, which will display the data monitored from the patients, thus potentially facilitating patients' follow-up between clinical consultations. The LC Dashboard will provide pseudonymised information regarding the patients' physical activity and PROMs for the purpose of the pilot feasibility trial. They will not be able to view real time processed information, such as risk of frailty, QoL, risk of dependency and psychological condition, from the LIFECHAMPS analytics engine. They will be shown the anonymised outputs of the engine per patient and asked their opinions on the usability, acceptability and on whether such information would have helped better manage their patients' supportive care.
224205460|NCT06136676|BEHAVIORAL|Arm 2 - Action Control: Mindfulness Meditation|Participants assigned to this condition will receive daily audio instructions of approximately 20 minutes daily over the course of 8 week, focused on mindfulness meditation delivered through a mobile app. The intervention will consist of the mindfulness-based stress reduction program which emphasizes focused attention on breathing and sensations as well as the practice of non-judgemental acceptance of the present experience.
224171766|NCT05797727|DEVICE|LifeChamps Platform|Participants will be asked to provide 5 endpoints (PROMS) and will be provided with the study equipment, i.e., a mobile app, smartwatch, smart scale, location home sensor, a smart plug, and a micro-computer, with which they will need to interact with the devices for three months. Specifically, participants should wear the activity tracker wristband (Fitbit Charge 4) as much as possible. Additionally, participants should use the smart scale to weigh themselves and the mobile app to fill in selected PROMs monthly, while the ambient home sensors will be passively collecting information about their everyday living during these three months. At the end of the 3 month period, the participants will return the devices and will be asked to provide the 5 endpoints and their opinions regarding the usability and acceptability of the platform using structured questionnaires
224171767|NCT00238160|DRUG|cisplatin|
224171768|NCT00238160|DRUG|fluorouracil|
224171769|NCT00238160|PROCEDURE|adjuvant therapy|
224171770|NCT00238160|PROCEDURE|chemotherapy|
224171771|NCT00238160|PROCEDURE|conventional surgery|
224171772|NCT00238160|PROCEDURE|hepatic arterial infusion|
224171773|NCT00238160|PROCEDURE|surgery|
224171774|NCT07028385|DRUG|Bariticinib 2 mg|Commercially available tablets containing 2 mg of barticiinib will be used. The tablets will be re-capsulated to keep the study blind.
224171775|NCT07028385|OTHER|Placebo|Maltodextrin capsules with identical weight and appearance (shape, size, colour and flavour) as the bariticinib-containing capsules.
224305797|NCT04163432|DRUG|Carboplatin|Carboplatin dosing is adjusted for kidney function.The total dose (in mg) of carboplatin will be calculated using the Calvert Formula utilizing a target AUC of 5 and a patient's GFR in mL/min.
224305798|NCT06099444|DEVICE|Conventional High Intensity Gait Training|Participants during a training session will complete at least 30 minutes of treadmill walking at the target intensity. The participants will complete 18 training sessions.
223585728|NCT05096754|DEVICE|OCS Liver|Transplant with an OCS preserved liver.
223585729|NCT00487474|DEVICE|DL6049 (injectable poly-L-lactic acid)|Subjects will be treated with SCULPTRA® every 4-6 weeks in accordance with SCULPTRA® package insert
223585730|NCT00483041|OTHER|PLACEBO|Placebo administered as a single intravenous infusion
223585731|NCT00483041|BIOLOGICAL|MEDI528 9 mg/kg|MEDI-528 at a dose of 9 mg/kg administered as a single intravenous infusion
223585732|NCT01224444|OTHER|standard polypectomy snare|Electrocautery snare resection of sessile colonic polyps
224305799|NCT06099444|DEVICE|Standard FES to the Tibialis Anterior (TA)|Participants during a training session will complete at least 30 minutes of treadmill walking at the target intensity while wearing a FES stimulator on the tibialis anterior muscle of their more affected leg. Stimulation will be triggered prior to swing phase to combat drop foot. The participants will complete 18 training sessions.
224305800|NCT06099444|DEVICE|Synergy-Based Multichannel FES (MFES)|Participants during a training session will complete at least 30 minutes of treadmill walking at the target intensity while FES is applied to multiple muscles of the leg throughout the gait cycle based on the healthy muscle synergies. The goal will be to have the FES applied for at least 20 minutes of each gait training session. The participants will complete 18 training sessions.
224305801|NCT06099444|DEVICE|Muscle Synergy Visual Biofeedback|Participants during a training session will complete at least 30 minutes of treadmill walking at the target intensity while receiving visual feedback of the similarity of their muscle synergies to healthy muscle synergies. They will be instructed to try to optimize the similarity score. The participants will complete 18 training sessions.
224305802|NCT05927610|DIAGNOSTIC_TEST|Lumber Puncture|During the lumbar puncture/LP, 20cc will be collected per standard practice in adult patients. LP will be performed either at bedside or under interventional radiology (IR) guidance (due to patient anatomy).
224305803|NCT05205772|DEVICE|transcranial magnetic stimulation|"Transcranial magnetic stimulation (or TMS) is a non-invasive form of brain stimulation in which a magnetic pulse is applied directly to the scalp. This device is FDA approved for treatment of depression and other neuropsychiatric disorders, and is regularly used in neurologic and psychiatric research.~iTBS is a particular TMS protocol which delivers the magnetic field in triplet bursts (three stimulations very close together at a frequency of 50 Hz very quickly). The triplet bursts are repeated at a rate of 5 Hz for 2 seconds (30 pulses), followed by 8 seconds rest, repeated 20 times for a total of 600 pulses. Each treatments lasts approximately 3 minutes."
224305804|NCT05768178|DRUG|Vemurafenib|Patients will receive vemurafenib at a dose of 960 mg orally (4 tablets of 240 mg) on a twice daily schedule throughout a 28-day cycle. Patients may continue until disease progression without clinical benefit, unacceptable toxicity or withdrawal of consent.
224305805|NCT05768178|DRUG|Cobimetinib|Patients will receive cobimetinib at a dose of 60 mg (3 tablets of 20 mg) to be taken orally, once daily for 21 consecutive days (days 1 to 21 in each 28-day cycle); followed by a 7-day break. Patients may continue until disease progression without clinical benefit, unacceptable toxicity or withdrawal of consent.
224305806|NCT05297760|BIOLOGICAL|Polvac Grass+Rye|Suspension of micro crystalline tyrosine with grass and rye pollen allergen
224305807|NCT05297760|DRUG|Saline 0.9%|Physiological saline solution for use as vehicle for the biological drug (Polvac Grass+Rye) or as placebo.
224305808|NCT00946816|BEHAVIORAL|Nutritional Intervention|Nutritional Intervention
224305809|NCT00536692|DRUG|mecamylamine|topical ocular drops
224305810|NCT06222320|OTHER|Kinesiotaping|Kinesiotaping will be applied to patients in this group in addition to painkillers. Kinesiotaping is a physical therapy technique used to treat muscle pain. It is performed with kinesiotaping tapes attached to the skin. These bands are removed after 4-5 days.
224305811|NCT06222320|DRUG|Painkillers|Patients in this group will be treated with painkillers consisting of paracetamol and dexketoprofen.
223585733|NCT03102567|DRUG|GLPG1205 50mg q.d.|oral gelatin capsule containing 50mg GLPG1205 for q.d. administration - compared to placebo
223585734|NCT03102567|DRUG|Placebo oral capsule|oral gelatin capsule containing placebo to match study arm 1 - q.d. administration
224171776|NCT07048587|DIAGNOSTIC_TEST|Beta-hCG levels in the uterine cavity lavage for differential diagnosis in pregnancy of unknown locations and ectopic pregnancy|The intervention in this study centers on utilizing beta-hCG levels in uterine cavity lavage as a diagnostic tool to differentiate between ectopic pregnancy and early pregnancy loss.The procedure includes females aged 18-45 with positive serum beta-hCG, inconclusive clinical findings, and transvaginal ultrasound results, focusing on beta-hCG levels below 1500-2000 mIU/mL and abnormal progression.The intervention performed before probe curettage (P/C). Before the intervention beta-hCG is measured in venous blood. Patients undergo uterine cavity lavage with 5 ml of saline solution administered and 3 ml of aspirated liquid collected for beta-hCG measurement. Data collection involves beta-hCG levels from lavage fluid and venous blood, pathology results.After the samples were collected, each one was frozen at -80 ºC. All uterine lavage samples were then analyzed later on the same day.
224171777|NCT06890559|BEHAVIORAL|financial incentive intervention based on a digital platform|The intervention will span a duration of 12 months. All residents in the 8 intervention subdistricts/townships are available for participation; each participant household needs to register a household account on the digital platform. Each family member who completes targeted vaccine uptake or related health behaviors can earn points through two point-recording routes. Reward points will be accumulated on a household basis to encourage family members' engagement. Points can be redeemed for gifts on the digital platform and are only valid once.
224171778|NCT05911945|PROCEDURE|Flexible Ureterorenoscopy|A guidewire was placed in the ureter in the lithotomy position. Ureterorenoscopy was performed with an 8 Fr ureterorenoscope for active dilatation. An 11 - 13 Fr or 9.5 / 11.5 Fr UAS was attempted to be placed under fluoroscopy by the surgeon of the procedure. In cases where the UAS could not inserted, a 26 cm, 4.8 Fr JJ stent was placed under fluoroscopy and the procedure was terminated. Patients underwent a second f-URS session, 4 - 6 weeks later. After the JJ stent was removed, an 11 - 13 Fr UAS was placed in the ureter. Digital flexible ureterorenoscope was used as the flexible ureteroscope. Stone fragmentation was performed in dusting mode using a Ho:YAG laser with a 272 µ probe. After fragmentation, a 26 cm 4.8 Fr JJ stent was inserted into the ureter. The JJ stent was removed at 4 - 6 weeks postoperatively.
224205461|NCT01421524|DRUG|CC-122|CC-122 dose in both arms will increase by 1 mg increments starting with 3 mg 5/7 days using the 3+3 design in dose escalation phase. A dose-level -1, with a starting dose of 2mg, may also be evaluated if the opening dose level is not tolerated. At all dose levels in MM-2b arm, DEX will be combined with CC-122 at a starting dose dependent on the subject's age: for subjects who are ≤ 75 years of age, DEX 40 mg/day will be given on Days 1, 8, 15 and 22 of a 28-day cycle and for subjects who are \> 75 years of age, DEX 20 mg/day will be given on Days 1, 8, 15 and 22 of a 28-day cycle. Approximately 33 subjects will be enrolled in the dose escalation phase (15 in each treatment arm). An additional intermittent schedule of 21/28 days may be evaluated per Safety Review Committee (SRC) decision. Following dose escalation, one or two arms will be expanded at or below the MTD in up to 28 subjects (14 subjects in each arm).
224305812|NCT02991690|OTHER|Hypothermia|To deliver intravascular hypothermia, an Alsius Icy CoolGuard® catheter (US Food and Drug Administration approved, Premarket Notification \[510(k), K030421\]; Alsius Corporation, Irvine, California) will be inserted through the femoral vein using a sterile technique. Patients will be cooled at a maximum rate (2-2.5 ºC/hr.) until they reach the target temperature (T 33 ºC), which will be maintained for 48 hours, and then re-warmed at 0.1 ºC/hr. until normothermia (T 37ºC) is achieved.
223483579|NCT07169279|DRUG|Infigratinib or placebo comparator is provided as sprinkle capsules for daily oral administration|"* The cohort dose of infigratinib or placebo will be the dose confirmed in the Phase 2 portion for the age group.~* The dose and number of sprinkle capsules/day will be calculated based on individual participant age and weight. Doses will be adjusted based on age and weight changes approximately every 3 months."
223483580|NCT07169279|DRUG|Infigratinib is provided as sprinkle capsules for daily oral administration|"* The dose of infigratinib will be the dose confirmed in the Phase 2 portion and used in the Phase 2b portion for the age group.~* The dose and number of sprinkle capsules/day will be calculated based on individual participant age and weight. Doses will be adjusted based on age and weight changes approximately every 3 months for the first year and every 6 months thereafter."
223483581|NCT07169539|DEVICE|SerenApp Digital Psychological Intervention|SerenApp is a co-created, personalized digital intervention designed to support the mental health of women in breast cancer follow-up or survivorship. The app includes modules targeting stress coping, anxiety, and depression, delivered via smartphone or computer. Content and functionalities were developed collaboratively with patients and healthcare professionals, ensuring usability, clinical relevance, and adherence to regulatory and ethical standards. The intervention is intended for self-guided use over eight weeks, with monitoring of engagement, completion, and user satisfaction.
223483582|NCT07167134|RADIATION|D1-3-5 radiotherapy|23.1 Gray (Gy) delivered in 3 fractions of 7.7 Gy at D1, D3, and D5
223483583|NCT07167134|RADIATION|D1-2-3 radiotherapy|23.1 Gray (Gy) delivered in 3 fractions of 7.7 Gy at D1, D2, and D3
223483584|NCT07167524|BIOLOGICAL|Dosage concentration of piperacillin and tazobactam|The concentration of piperacillin and tazobactam will be quantified by liquid chromatography coupled with tandem mass spectrometry (HPLC-MS² - CIC-CRB 1404) at each of these times by transposition of the method already used in current practice.
223483585|NCT07168005|BEHAVIORAL|Informative Video on LMWH|A short (up to 5 minutes) informative video presented to postpartum women prior to their first LMWH (Clexane) injection. The video explains the rationale, process, and safety of LMWH use for thrombopr
223585735|NCT03102567|DRUG|GLPG1205 250 loading dose and 50mg q.d. maintenance dose|Open label - oral gelatin capsule containing 50mg GLPG1205 for one time 250mg loading dose and subsequent q.d. administration
223585736|NCT04527939|PROCEDURE|three-dimensional endorectal ultrasonography|three-dimensional endorectal ultrasonography
223585737|NCT06095167|DRUG|without concurrent cisplatin chemotherapy|IMRT without concurrent cisplatin chemotherapy
223585738|NCT06095167|DRUG|with concurrent cisplatin chemotherapy|IMRT with concurrent cisplatin chemotherapy
223585739|NCT05650671|DEVICE|instrumented wheelchair|Measurements of pressure, temperature and humidity at the subject/cushion interface
224171779|NCT05911945|PROCEDURE|Mini Percutaneous Nephrolithotomy|A guidewire was placed in the ureter in the lithotomy position. Ureterorenoscopy was performed with an 8 Fr ureterorenoscope for active dilatation. An 11 - 13 Fr or 9.5 / 11.5 Fr UAS was attempted to be placed under fluoroscopy by the surgeon of the procedure. In cases where the UAS could not inserted, patients were positioned in prone position and access was performed to the appropriate calyx with an 18-gauge percutaneous access needle using the triangulation technique accompanied by fluoroscopy, in the same session. After the guidewire was introduced into the pelvicalyceal system, sequential dilatation was applied with Amplatz dilatators, and a 21 Fr metallic sheath was placed. Stones were fragmented with a yttrium-aluminum-garnet (Ho:YAG) Laser lithotripter. At the end of the procedure, a 14 Fr nephrostomy catheter was placed in according to the residual stone, hemorrhage, and perforation status. In other cases, the procedure was concluded as totally tubeless.
224171780|NCT06564051|OTHER|Non-Interventional Study|Non-interventional study
224171781|NCT07058025|BIOLOGICAL|Human Allogenic Umbilical Cord Mesenchymal Stromal Cells|IV administration of uc-MSC every 7 days ± 1 day for 3 weeks. Randomized double blinded
224171782|NCT07058025|OTHER|Sham procedure control|Sham procedure (mimic IV catheter insertion adn cell product infusion behing a screen). Repeated weekly for 3 weeks
224171783|NCT07059286|BEHAVIORAL|Maternal Frailty Inventory (MaFra) Questionnaire|A validated psychometric inventory designed to assess maternal clinical, psychological, and lifestyle risk factors during pregnancy. The composite risk score is used to stratify participants into low- or medium/high-risk categories. Administered during pregnancy, the inventory informs classification and predictive modeling of fetal and child neurodevelopmental outcomes.
224171784|NCT07059286|DIAGNOSTIC_TEST|Fetal Resting-State Functional MRI|Non-invasive resting-state functional MRI scans performed during gestation (fetal) life to assess functional connectivity across sensorimotor, auditory, visual, language, and attention networks. Imaging data are analyzed to derive local and global connectivity measures and indices of segregation and integration among functional brain systems. Structural MRI is used to confirm normal brain morphology.
224171785|NCT07059286|BEHAVIORAL|Maternal Emotional Reactivity|During fetal rs-fMRI acquisition, mothers listen to emotionally evocative musical excerpts while rating their emotional responses. These self-reported ratings (valence and arousal) are later correlated with fetal brain connectivity responses.
224171786|NCT07059286|DIAGNOSTIC_TEST|Neonatal Resting-State Functional MRI|Non-invasive MRI scanning protocol conducted during the neonatal period to acquire resting-state functional MRI (rs-fMRI) data. The scan is performed while the newborn is in a natural sleep state, using motion-optimized sequences to assess functional connectivity between brain regions. The focus is on sensorimotor, auditory, visual, language, and attention networks. Structural MRI is also acquired to verify normative brain morphology. Imaging outcomes are used in longitudinal analyses to link early brain connectivity with cognitive and behavioral development.
224171787|NCT07059286|BEHAVIORAL|Longitudinal Neurodevelopmental Testing Battery|Standardized neuropsychological and behavioral assessments are administered at multiple timepoints between birth and 72 months of age. Domains evaluated include sensorimotor skills, cognitive abilities, language development, executive function, social-emotional regulation, and adaptive behaviors. Data are used to compute specific and composite scores that reflect neurocognitive and behavioral profiles. These are later integrated with prenatal and neonatal brain imaging and maternal risk data to model individual neurodevelopmental trajectories.
224171788|NCT07059468|DIAGNOSTIC_TEST|Bone mineral density/ Bone mineral density (BMD) will be measured on the lumbar spine (L1-L4) and femoral neck by dual X-ray absorptiometry (DXA)|Bone mineral density/ Bone mineral density (BMD) will be measured on the lumbar spine (L1-L4) and femoral neck by dual X-ray absorptiometry (DXA) method
223483586|NCT07168005|BEHAVIORAL|Standard Verbal Explanation|Participants receive the routine verbal explanation regarding postpartum LMWH (Clexane) administration, covering its purpose and method of injection
223483587|NCT07169292|PROCEDURE|Wet-cupping|"The intervention consists of three sessions of wet cupping therapy (Hijama), administered once every month over three consecutive months. This study's protocol is distinguished by its standardized, medically supervised approach, designed to align traditional Hijama practices with modern clinical trial standards.~Key features that distinguish this intervention include:~Standardized Procedure: The Hijama protocol follows a detailed, consistent method including suction, superficial skin incisions, and reapplication of suction, followed by honey dressing. All sessions use disposable, single-use instruments and follow strict infection control measures.~Timing Based on Prophetic Recommendation: Cupping is performed on the 17th, 19th, or 21st day of the Islamic lunar month, which is rooted in Islamic tradition and rarely standardized in scientific studies.~Certified Practitioner and Setting: Procedures are conducted by a licensed Hijama practitioner with"
223483588|NCT07169058|BEHAVIORAL|Vagus Nerve Fascial Mobilization|"Reference Points of the Body Regions for Mobilization~1. Occipito-Mastoid Suture (OM) The occipitomastoid suture is the cranial suture located between the occipital bone and the mastoid part of the temporal bone. The condylus squamosa mastoidea serves as the pivot point. The patient lies in the supine position while the physiotherapist sits at the head of the patient. One hand is placed under the occiput at the suture, while the other hand is placed on the mastoid portion of the temporal bone. The patient's head is turned toward the direction of mobilization, and mobilization is performed using the weight of the head (25). Each application is planned as a single repetition lasting 120 seconds.~2. Anterior Cervical Region (Triangle) Topographically, this region is located at the anterior part of the neck, extending along the seven cervical vertebrae (C1-C7). The anterior triangle is bordered superiorly by the lower margin of the mandible, laterally by the anterior median line of the s"
223483589|NCT07168993|OTHER|Standard medical treatment|Standard of care follow up per institution
223483590|NCT07168993|OTHER|Standard medical treatment|SOC per institution
223483591|NCT07167693|DRUG|Arginine hydrochloride|Single intravenous infusion of arginine hydrochloride 30 g in 300 mL 10% solution (R-Gene® 10), administered over 30 minutes via infusion pump. Given as early as feasible after recognition of DKA and in addition to standard DKA care (fluids, insulin, electrolytes) at the treating clinician's discretion. Investigational pharmacy prepares and dispenses blinded study drug; containers are covered to mask appearance and infusion parameters match placebo. Continuous safety monitoring with prespecified stop criteria. Study blood draws at 0 (pre-infusion), 10, 30, and 90 minutes for C-peptide/glucose and amino acids; clinical labs track β-hydroxybutyrate clearance and total insulin over 24 hours.
224171789|NCT07058246|OTHER|Mime therapy with Conventional therapy|"Experimental group was given mime therapy along with conventional therapy. Mirror therapy, Raising eyebrows as if surprised, Widening eyes in shock, blinking rapidly, Extreme smiling, Eye closure with dramatic expressions, exaggeration nose wrinkling. pouting and mouth opening, expression transitions.~Total sessions given are 4-5 per week in 3 weeks consist of 45 mins.~Number of repetitions are 5-10 with the hold of 5 second x 2 sets."
224171790|NCT07058246|OTHER|Conventional therapy|"Raising and lowering eyebrows, Wrinkling nose, smiling, frowning, massage.~Total sessions given are 4-5 per week in 3 weeks consist of 45 mins.~Number of repetitions are 5-10 with the hold of 5 second x 2 sets."
224171791|NCT07059494|DRUG|Atezolizumab|Atezolizumab is an immune checkpoint inhibitor. It is a monoclonal antibody that works by binding to the protein PD-L1 on the surface of some cancer cells, which keeps cancer cells from suppressing the immune system. It is indicated for usage in Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), Hepatocellular Carcinoma (HCC), Melanoma, and Alveolar Soft Part Sarcoma (ASPS).
224171792|NCT07059494|DRUG|Bevacizumab|Bevacizumab is a vascular endothelial growth factor inhibitor indicated for the treatment of metastatic colorectal cancer, in combination with intravenous fluorouracil-based chemotherapy for first- or second-line treatment. It is also indicated for the treatment of metastatic colorectal cancer, in combination with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy for second-line treatment in participants who have progressed on a first-line bevacizumab product-containing regimen.
224171793|NCT07059494|RADIATION|Y^90 Radioembolization|Radioembolization is a minimally invasive procedure that combines embolization and radiation therapy to treat cancers in the liver. Tiny beads filled with a radioactive isotope are placed inside the blood vessels that supply a tumor. This blocks the supply of blood to the cancer cells and delivers a high dose of radiation to the tumor while sparing normal tissue. It can help extend the lives of participants with inoperable tumors and improve their quality of life.
224171794|NCT07059156|DRUG|Induction Therapy Regimen|"VICP+VEN regimen:~* Vindesine: 3 mg/m²/day (max 4 mg), administered on days 1, 8, 15, 22.~* Idarubicin (IDA): 8 mg/m², days 1, 8, 15, 22.~* Cyclophosphamide (CTX): 500 mg/m², days 7, 21.~* Prednisone: 1 mg/kg/day, days 1-14; 0.5 mg/kg/day, days 15-28~* Venetoclax (VEN) 8-day ramp-up: Day 1: 100 mg, Day 2: 200 mg, Days 3-8: 400 mg/day"
224171795|NCT07059156|DRUG|Pre-Treatment Regimen|"Indications for pre-treatment:~* WBC ≥30×10⁹/L, or significant hepatosplenomegaly/lymphadenopathy.~* Laboratory signs of tumor lysis syndrome (e.g., electrolyte abnormalities).~Pre-treatment protocol:~* Glucocorticoids (e.g., prednisone or dexamethasone): Prednisone 1 mg/kg/day (PO/IV) for 3-5 days.~* Optional addition of CTX: 200 mg/m²/day IV for 3-5 days."
224171796|NCT07059156|OTHER|Post-CR Treatment|"Principles:~1. MRD-positive or rising: Administer blinatumomab (CD19/CD3 bispecific antibody) for residual disease clearance, followed by allogeneic hematopoietic stem cell transplantation (allo-HSCT).~2. MRD-negative/unknown: Continue multi-agent chemotherapy ± blinatumomab consolidation. Allo-HSCT for patients with high-risk clinical/genetic features."
224171797|NCT07059156|DRUG|Post-CR Consolidation Regimens|"① Hyper-CVAD-B (Methotrexate/Cytarabine-based):~* Methotrexate (MTX): 1 g/m² IV over 24h (Day 1) with urine alkalinization (pH \>7.0) and leucovorin rescue.~* Cytarabine (Ara-C): 1 g/m² IV q12h (Days 2-3; total 4 doses).~* Dexamethasone: 40 mg/day (PO/IV, Days 1-4).~* Cycle interval: 21-28 days (alternating with other regimens).~  ② CAM Regimen:~* CTX: 750 mg/m² IV (split over 2 days).~* Ara-C: 75 mg/m²/dose (8 days; 1-2 doses/day IV; if once daily, administer 5 days/week × 2 weeks).~* 6-MP: 50-75 mg/m²/day fasting (7-14 days PO)."
224171798|NCT07059156|OTHER|Transplant-Eligible Subsequent Therapy|"* Allo-HSCT for eligible patients after induction.~* Conditioning regimen: TBI-VP16-CY.~* Donor priority: HLA-matched sibling donor (MSD), Matched unrelated donor (MUD), Haploidentical donor (Haplo).(Consider age/donor health status)."
224171799|NCT07059156|OTHER|Allo-HSCT Protocol|"1.6.1 Conditioning Regimen (TBI-VP16-Cy/ATG):~* TBI: 5 Gy (Days -7 to -6).~* VP16: 10 mg/kg/day (Days -5 to -4).~* CTX: 30 mg/kg/day (Days -3 to -2).~* ATG: 7.5 mg/kg/day (Days -5 to -2). 1.6.2 GVHD Prophylaxis:~* Basiliximab (anti-CD25 mAb): 50 mg (Days +1, +4).~* Standard regimen: Cyclosporine (CsA): IV: 2 mg/kg/day (start Day -9; target level 150-250 μg/L). PO: 3-5 mg/kg/day BID (switch delayed until Day +10 if no aGVHD); Mycophenolate mofetil (MMF) + short-course methotrexate."
223483592|NCT07167693|DRUG|Sodium Chloride 0.9%|Placebo comparator: 0.9% sodium chloride administered as a single 30-minute intravenous infusion using identical tubing, pump settings, and covered container as the active arm to preserve blinding. Initiated as early as feasible after recognition of DKA and provided in addition to standard DKA care at the treating clinician's discretion. Study assessments occur on the same schedule as the active arm (0, 10, 30, and 90 minutes) with continuous safety monitoring during and after infusion and follow-up through 90 days.
223483593|NCT07168850|DEVICE|Exablate MR-guided Focused Ultrasound Pallidotomy|Active Pallidotomy
223483594|NCT07168850|DEVICE|Sham Sham Exablate MRgFUS Pallidotomy|Sham procedure. Identical setup without thermal lesioning. Participants cross over to Active Pallidotomy after 3 months.
223483595|NCT07168538|PROCEDURE|TAP Block Group|Bilateral ultrasound-guided transversus abdominis plane block performed at the end of surgery using 20 mL of 0.25% bupivacaine per side.
223483596|NCT07168538|PROCEDURE|Control Group|Standard ERAS-based multimodal analgesia protocol without regional block.
223483597|NCT07167550|DRUG|Dimephosphon®|1 g/ml, concentrate for solution for intravenous infusion
223483598|NCT07167550|DRUG|Placebo|Placebo IV solution
223483599|NCT07168980|DRUG|Cyclophosphamide, Vincristine, Cytarabine, Doxorubincin, Prednisone|Cyclophosphamide 800mg/m2, D1, then 200mg/m2, D2\~4;Vincristine 1.5mg/m2 (MAX 2mg), D1; Cytarabine 1g/m2/dose, (2 doses, 12-hour interval), D4; Doxorubincin 20mg/m2, D2,3; Prednisone 60mg/m2, D1\~7;Intrathecal injection, D1;
223483600|NCT07168980|DRUG|Drug: Ifosphamide, Etoposide, Methotrexate, Vincristine, Prednisone|Ifosphamide 1.2g/m2, D1\~5; Etoposide, 60mg/m2, D3\~5; Methotrexate, 0.5g/m2, D1;Vincristine 1.5mg/m2 (MAX 2mg), D1; Prednisone 60mg/m2, D1\~7;Intrathecal injection, D1;
223483601|NCT07168980|DRUG|Cyclophosphamide, Vincristine, Cytarabine, Doxorubincin, Prednisone|Cyclophosphamide 800mg/m2, D1, then 200mg/m2, D2\~4;Vincristine 1.5mg/m2 (MAX 2mg), D1; Cytarabine 1g/m2/dose, (2 doses, 12-hour interval), D4;Doxorubincin 20mg/m2, D2,3; Prednisone 60mg/m2, D1\~7;Intrathecal injection, D1,8;
223483602|NCT07168980|DRUG|Ifosphamide, Etoposide, Methotrexate, Vincristine, Prednisone|Ifosphamide 1.2g/m2, D1\~5; Etoposide, 60mg/m2, D3\~5; Methotrexate, 0.5g/m2, D1;Vincristine 1.5mg/m2 (MAX 2mg), D1; Prednisone 60mg/m2, D1\~7;Intrathecal injection, D1
223483603|NCT07168980|DRUG|Cyclophosphamide, Vindelsine, Cytarabine, Doxorubincin, Prednisone|Cyclophosphamide 800mg/m2, D1, then 200mg/m2, D2\~4; Vindelsine 3mg/m2 (MAX 5mg), D1; Cytarabine 2g/m2/dose, (2 doses, 12-hour interval), D4; Doxorubincin 20mg/m2, D2,3; Prednisone 60mg/m2, D1\~7;Intrathecal injection, D1,4(CNS2-3),8
223483604|NCT07168980|DRUG|Ifosphamide, Etoposide, Methotrexate, Vindelsine, Prednisone|Ifosphamide 1.2g/m2, D1\~5; Etoposide, 100mg/m2, D3\~5; Methotrexate, 5g/m2, D1;Vindelsine 3mg/m2 (MAX 5mg), D1; Prednisone 60mg/m2, D1\~7;Intrathecal injection, D1,8
223585740|NCT05354193|OTHER|vasoplegic syndrome|"In all included patients, 3 milliliters of venous blood will be collected before cardiopulmonary bypass, 3 milliliters of venous blood 15 minutes after the reversal of heparin with protamine and a small fragment of aortic tissue. Samples of biological material will be compared between the control and vasoplegic groups for the difference in amount and type of miRNA present.~For the diagnosis of vasospastic syndrome, the following criteria were adopted: mean arterial pressure \< 65 mmHg, cardiac index \< 2.2 L / min / m2, refractory to replacement of at least 1000 milliliters of crystalloid, excluding other causes such as tamponade, bleeding and cardiogenic shock"
224171800|NCT07059156|OTHER|Non-Transplant Maintenance Therapy Options|"① Hyper-CVAD-B (Methotrexate/Cytarabine-based):~* Methotrexate (MTX): 1 g/m² IV over 24h (Day 1) with urine alkalinization (pH \>7.0) and leucovorin rescue.~* Cytarabine (Ara-C): 1 g/m² IV q12h (Days 2-3; total 4 doses).~* Dexamethasone: 40 mg/day (PO/IV, Days 1-4).~* Cycle interval: 21-28 days (alternating with other regimens).~  ② CAM Regimen:~* CTX: 750 mg/m² IV (split over 2 days).~* Ara-C: 75 mg/m²/dose (8 days; 1-2 doses/day IV; if once daily, administer 5 days/week × 2 weeks).~* 6-MP: 50-75 mg/m²/day fasting (7-14 days PO).~  * Maintenance (6-MP/MTX alternating with V-Dex): 6-MP: 75 mg/m²/day at bedtime (Days 1-21); MTX: 20 mg/m² IM weekly × 3 weeks.\*Adjust doses to maintain WBC \~3×10⁹/L, ANC 1.0-1.5×10⁹/L.\*"
224171801|NCT07057856|BIOLOGICAL|Ustekinumab (UST)|The first sufficient dose of UST (6mg/kg) was administered intravenously at weeks 0
224171802|NCT07058337|PROCEDURE|parsplana vitrectomy|23 gauge parsplana vitrectomy
224171803|NCT07058337|PROCEDURE|adjunctive use of Methotrexate|intravitreal methotrexate (200 μg/0.05 ml) at the time of surgery and repeated weekly for four weeks postoperatively
224171804|NCT07058285|OTHER|Speed-dependent treadmill training (SDTT)|This training methodology focuses on adjusting the treadmill's speed according to the individual's walking pace, creating a more dynamic and adaptive exercise environment. SDTT is designed to mimic real-world walking conditions and challenges, promoting neuromuscular coordination, balance, and overall mobility. By tailoring the treadmill speed to match the user's gait, SDTT encourages the development of natural and efficient walking patterns. This training technique has shown promise in various clinical settings, aiding individuals with gait impairments caused by neurological conditions, musculoskeletal disorders, or post-injury rehabilitation. Its adaptability allows for progressive adjustments as a person's walking abilities improve, making it a versatile tool for optimizing gait mechanics and functional mobility. o ensure continued progress and integration into daily life, home-based walking training, supported by a phone application, will be included between T1 and T2.
224171805|NCT07058285|OTHER|SDTT+ anteroposterior perturbations|The SDTT+ anteroposterior perturbations program will trigger reactive gait adaptations by accelerations and decelerations of one of the belts of a split-belt treadmill.
224171806|NCT07058571|OTHER|EXERCISE TRAINING WITH OR WITHOUT MEDICATION|Participating Veterans will engage in bi-weekly, telehealth mediated resistance exercise session. Aerobic exercise will be monitored passively through FitBit data collection. Telehealth exercise sessions will last approximately 45-90 minutes pending the individual Veteran's progress. Participants will also undergo a one-time dietary consultation and recommendations by a Leukemia and Lymphoma Society (LLS) member.
224171807|NCT04281836|BEHAVIORAL|Interoceptive breathing awareness through use of audio and visual virtual technology aid|Participants are asked to focus on their breathing while (a) listening to their breathing sounds with headphones and (b) watching the 3-D image of their lungs inhaling and exhaling in real-time using the Oculus Rift 3D virtual imaging equipment and plethysmography belt. During this time fNIRS and tQST data will be collected (more detail provided below).
224171808|NCT04281836|BEHAVIORAL|Interoceptive breathing awareness without use of audio or visual virtual reality|Participants are asked to focus on their breathing. During this time fNIRS and tQST data will be collected (more detail provided below).
224171809|NCT02422563|PROCEDURE|hysterectomy|radical hysterectomy
223585741|NCT01442805|BEHAVIORAL|Virtual Reality Exposure Therapy|Participants are exposed to the feared situation (flying) through the virtual reality technology
223585742|NCT01442805|BEHAVIORAL|Exposure Therapy through Imagination|Participants are exposed to the feared situation (flying) through exposure technique of imagination.
223585743|NCT05124379|DEVICE|Hemoclin Gel|Non sterile gel for intra-rectal use
223585744|NCT02189707|DIETARY_SUPPLEMENT|Probiotic Bifidobacterium 1x1010 cfu|Participants who pass the initial screening will enter a 2-week placebo-only run-in period. Participants who successfully complete the run-in period will be randomized to daily supplementation with B. lactis HN019 (1 x 1010 cfu), B. lactis HN019 (1 x 109 cfu), or placebo for 4 weeks.
224171810|NCT02422563|RADIATION|Radiation|
223483605|NCT07168980|DRUG|Prednisone,Vincristine, Cyclophosphamide|Prednisone 45mg/m2, D1\~7; Vincristine 1.5mg/m2(MAX 2mg), D1; Cyclophosphamide 300mg/m2, D1; Intrathecal injection, D1
223585745|NCT02189707|DIETARY_SUPPLEMENT|Probiotic Bifidobacterium 1x109 cfu|Participants who pass the initial screening will enter a 2-week placebo-only run-in period. Participants who successfully complete the run-in period will be randomized to daily supplementation with B. lactis HN019 (1 x 1010 cfu), B. lactis HN019 (1 x 109 cfu), or placebo for 4 weeks. One capsule of study product, mixed with provided yogurt, will be consumed once a day.
223585746|NCT02189707|OTHER|Placebo powder in capsules|Participants will consume placebo capsules only during the 2-week run-in period. After randomization, participants will be administered their assigned study product and will continue on the product for 4 weeks.
223585747|NCT02855723|OTHER|Surgery: GS strategy|sentinel node biopsy
223585748|NCT02855723|OTHER|Surgery: Classic strategy|systematic lymphadenectomy
223585749|NCT03670784|OTHER|No intervention|No intervention, epidemiological investigation
223585750|NCT07088237|BEHAVIORAL|Stress Feedback|The stress feedback draws on a skills-based model of emotion regulation that emphasizes the ability to identify and label emotions, followed by either actively modifying negative emotions or accepting negative emotions when necessary. Participants will receive a prompt to identify their current emotion, followed by questions regarding their current context.
223745091|NCT04073381|COMBINATION_PRODUCT|Prehabilitation Program|This is a 4 week prehabilitation program which uses both exercise and nutrition. Exercise will be prescribed at least 6 days a week. Three days a week , for 45 mins, participants will be asked to perform body, leg and arm exercises against light resistance while wearing pneumatic blood flow restriction arm and leg bands. minutes. On the alternate days participants will walk approximately 15 minutes while wearing the leg bands that restrict blood flow. Additionally, a nutrition supplement cocktail will be provided and should be taken every day within 1 hour after completing each exercise session. The 4 Week Nutrition (Sports Drink) Supplement Cocktail: will include whey protein (25 g/day), creatine monohydrate (8 g/day), and L-citrulline (5 g/day). The supplement mixture will be provided in daily packages by the investigators (nutrition supplements are not regulated by the FDA)
224171811|NCT02422563|DRUG|Cisplatin|
224171812|NCT02422563|DRUG|Paclitaxel|
223745092|NCT06824987|COMBINATION_PRODUCT|AZD2373-Arm 1|Accessorized Pre-Filled Syringe (Solution for injection)
223483606|NCT07168460|BEHAVIORAL|Dog-assisted support|Children in the intervention group received dog-assisted support for 30 minutes per session, twice per week for 10-12 weeks. The process began with children meeting school dog with dog handlers either at their home or at school. During the intervention, children had physical contact with dogs as much as they wished and on consideration of dogs' welfare. The dog handler carried out some pedagogical tasks, such as children reading to the dog while the dog was next to the child or when its head was on the child's lap. The dog handler documented the process of each session in a protocol filled in after each session and observed the children on their educational tasks.
223483607|NCT07168460|BEHAVIORAL|Special education teacher support|Children in the control group met special education teachers and received pedagogical tasks involving Swedish, mathematics, etc. Similar to the dog team, special education teachers documented the process and observed the performance of children's educational tasks.
223745093|NCT06824987|COMBINATION_PRODUCT|AZD2373-Arm 2|Accessorized Pre-Filled Syringe (Solution for injection)
223745094|NCT06824987|COMBINATION_PRODUCT|Placebo|Accessorized Pre-Filled Syringe (Solution for injection).
224171813|NCT02422563|DRUG|Carboplatin|
223483608|NCT07168525|DEVICE|Ultrasound spa|Each participant will sit in a bathtub which has been fitted with an ultrasound device which produces low frequency sound waves within the water.
223483609|NCT07168525|OTHER|Sham ultrasound spa|The control group will sit in the same tub for 45 minutes, 3 times per week for 8 weeks but without the ultrasound being turned on.
223483610|NCT07167069|RADIATION|Radiation Therapy|Standard of Care Chemoradiation for Cervical cancer patients in India.
223483611|NCT07167498|BEHAVIORAL|Intermittent midwife absence during remote monitoring of remifentanil PCA in labour|"Midwife absence during remifentanil PCA for labour analgesia.~We aim to include a total of 80 participants. All will receive remifentanil PCA for labour analgesia and be monitored with remote monitoring equipment. First a group of 40 parturients will be included, and the attending midwife will not be allowed to leave the parturient (Group 1). A following group of 40 parturients will then be included and the attending midwife can leave the room in intervals up to 10 minutes (Group 2)."
223483612|NCT05767359|DRUG|Ciltacabtagene Autoleucel|Genetically modified autologous T-cell immunotherapy, via intravenous infusion per protocol.
223483613|NCT05767359|DRUG|Cyclophosphamide|Lymphodepleting conditioning regimen, nitrogen mustard-derivative, via intravenous infusion per standard care.
223483614|NCT05767359|DRUG|Fludarabine Phosphate|Lymphodepleting conditioning regimen, synthetic purine nucleoside, via intravenous infusion per standard care.
223483615|NCT05528848|DRUG|Carfentanil, C-11|Investigational radiotracer to be injected by IV as s a bolus during both study PET/CT scans.
223745095|NCT06824987|DEVICE|APOL1 Genotyping Clinical Trial Assay|The APOL1 Genotyping Clinical Trial Assay, an investigational use only qualitative Polymerase Chain Reaction invitro diagnostic assay, discriminates between the rs73885319 G1(S342G) and rs71785313 G2 genotypes within the APOL1 gene from DNA extracted from whole blood.
223745096|NCT03467113|DRUG|ZX008 0.2 to 0.8 mg/kg/day|ZX008 drug is an oral aqueous solution of fenfluramine hydrochloride. The product is sugar free.
223745097|NCT03467113|DRUG|Cannabidiol|Cannabidiol
223483616|NCT05528848|DRUG|Naloxone|Non-selective opioid antagonist injected by IV parenterally during the second study PET/CT scan only.
223483617|NCT05528848|DRUG|Loperamide Hydrochloride|Loperamide is an FDA- approved, over-the-counter drug for the control and symptomatic relief of acute or chronic diarrhea given orally prior to the optional HC third PET/CT scan only.
223745098|NCT06202781|DRUG|SOX plus PD-1 inhibitor|S-1, Oxaliplatin and nivolumab/sintilimab
223745099|NCT06202781|PROCEDURE|Gastroscopic biopsy|Gastroscopy and biopsy
223745100|NCT01885546|DEVICE|AgaMatrix Blood Glucose Monitor|
223745101|NCT00718328|DRUG|Simvastatin 80 mg|Patients in study arm 1 will receive simvastatin 80 mg once daily for 14 days or until death or discharge.
223745102|NCT00718328|DRUG|Placebo|Patients in study arm II will receive placebo once daily for 14 days or until death or discharge.
223745103|NCT02865915|DRUG|MLE4901|For 80% of subjects randomized to MLE4901 (n=24/30), the dose is 40 mg twice daily. Six subjects (20%) randomized to higher MLE4901 dose cohorts that were promptly discontinued.
223745104|NCT02865915|DRUG|Placebo|Placebo to match active drug
223745105|NCT01876485|BEHAVIORAL|Empowering Patients in Chronic Care (EPIC)|EPIC group training sessions consisting of 6 one-hour group sessions occurring over a 6-month period. Group sessions will consist of behavioral coaching focused on diabetes management. Following each group-session, patients enrolled in the intervention arm will meet with a designated member of their primary care team to personalize diabetes goals and action plans.
224171814|NCT02422563|DRUG|Ifosfamide|
224171815|NCT04873843|BEHAVIORAL|Functional digital game training group|Functional digital game training group is divided in 16 participants. In one session, participants in the functional digital game training group completed 40 minutes of intervention using various functional digital game such as working memory, memory, and attention. (Total 10 session)
224171816|NCT04873843|BEHAVIORAL|Individual cognitive training|Functional digital game training group is divided in 16 participants. In one session, participants in the individual cognitive training group completed 40 minutes of intervention using various cognitive training such as working memory, memory, and attention. (Total 10 session)
223483618|NCT01191749|DRUG|Alemtuzumab|10 mg by vein over 2 hours on Days 1 to 10 of a 28 day cycle.
224171817|NCT07058896|BEHAVIORAL|High intensity task oriented circuit training + Telerehabilitation|"Participants will receive 12 sessions of high-intensity, task-oriented circuit training, three times a week for four weeks. Each session will last 180 minutes, with 108 minutes of active training. Each session will include three rounds, each lasting 51 minutes. During each round, participants will rotate between stations working for six minutes at each station, followed by three minutes of rest. The stations will focus on key motor skills, including sit-to-stand transitions, walking, standing, bed mobility and transfers, stepping, and wheelchair use. If participants are unable to walk, the walking station will be replaced by upper limb function station.~After in-hospital treatment participants will receive 36 sessions of asynchronous telerehabilitation, three times a week for 12 weeks. Including monthly televisits with the physiotherapist. This intervention will be supported by low-cost, off-the-shelf technology for treatment delivery and monitoring."
224171818|NCT06751251|DIAGNOSTIC_TEST|IHC: Immunohistochemistry|Immunohistochemistry will be implied in tissue sections to test the expression of OX4O in sarcoma.
224171819|NCT06751251|GENETIC|RNA-seq|RNA-seq will be implied in tissue sections to test the expression of CD134 RNA expression in sarcoma.
224171820|NCT02449915|DRUG|Bupivacaine|At the completion of the procedure, and at least 20 minutes after the injection of lidocaine with epinephrine (routine for the surgical procedure), those subjects in the liposomal bupivacaine arm will have 30mL dilutional volume injected. Ten mL will be injected into the perineum in the posterior vaginal area and 20 mL will be injected the port site wounds in the abdomen (5 sites, 4 ml per incision).
224171821|NCT02449915|DRUG|Placebo|At the completion of the procedure, and at least 20 minutes after the injection of lidocaine with epinephrine (routine for the surgical procedure), those subjects in the placebo arm will have 30mL total volume injected. Ten mL will be injected into the perineum in the posterior vaginal area and 20 mL will be injected the port site wounds in the abdomen (5 sites, 4 ml per incision).
224171822|NCT07058233|DIETARY_SUPPLEMENT|Oral nutritional supplementation|Oral Nutritional Supplement (ONS) in the form of a soy-based drink (235 kcal/200mL: 10.34 g protein, 7.9 g fat, 30.61 g carbohydrate; Protein)
224171823|NCT06757218|OTHER|empty socket|Patients will be left socket empty without any graft materials for spontaneous healing process after tooth extraction
224171824|NCT06757218|PROCEDURE|Autogenous Dentin Graft with Platelet Rich Fibrin|Patients will be inserting autogenous dentin graft and platelet rich fibrin in the socket after extraction.
224171825|NCT06757218|PROCEDURE|Autogenous Dentin Graft with Albumin Platelet Rich Fibrin|Patients will be inserting autogenous dentin graft and Albumin Platelet Rich Fibrin in the socket after extraction.
224171826|NCT06771648|DEVICE|Daxxin Psoriasis Shampoo|Daxxin Psoriasis Shampoo at least 3 times a week and at most once a day as per instructions for use
224171827|NCT07063446|DEVICE|sTMS|Single pulses of TMS will be delivered over the motor cortex to quantify and map the motor evoked potentials
224171828|NCT07063446|DEVICE|taVNS|taVNS will be used to stimulate the auricular branch of the vagus nerve and paired with CIMT for a total of 40hours of CIMT
224171829|NCT02407691|OTHER|Primary care 101 plus mental health|A facility-based stepped care intervention combining depression case detection by non-physician clinicians with group counselling intervention delivered by lay-health workers.
224171830|NCT02407691|OTHER|Standard Primary Care 101|Standard Primary Care 101 guideline with standard training
224171831|NCT07058675|DRUG|Metformin Hydrochloride 500 MG|metformin (MET) hydrochloride 500 mg three times daily as the standard insulin sensitizer.
224171832|NCT07058675|DRUG|Myoinositol|myoinositol/d-chiro-inositol combination (MYO/DCI) in 40:1 ratiotwice daily
224171833|NCT07063277|DEVICE|Preoperative Evaluation with ORI and Spirometry|"All participants in this single-arm diagnostic study will undergo preoperative evaluation involving two non-invasive respiratory assessment methods: the Oxygen Reserve Index (ORI) and spirometry. ORI will be measured using a multi-wavelength pulse co-oximetry sensor placed on the patient's fingertip. This sensor provides a continuous, real-time index (ranging from 0.00 to 1.00) that reflects the patient's oxygen reserve within a PaO₂ range of approximately 100-200 mmHg.~Spirometry will be performed using standard pulmonary function testing protocols. Each patient will be instructed to perform forced expiratory maneuvers to obtain parameters including forced expiratory volume in one second (FEV₁), forced vital capacity (FVC), and the FEV₁/FVC ratio. These values will be recorded prior to surgery and interpreted according to internationally accepted reference ranges."
224171834|NCT06760156|DRUG|Tafasitamab|The recommended dose of tafasitamab is 12 mg/kg.
224171835|NCT06760156|DRUG|Lenalidomide|The starting dose for lenalidomide will be 25 mg PO daily.
224171836|NCT02717962|DRUG|VAL-083, Dianhydrogalactitol|The dosing regimen for patients will be VAL-083 (30 mg/m2) administered IV for 3 consecutive days at the beginning of every 21-day cycle. Patients will continue to receive VAL 083, for up to 12, 21-day treatment cycles or until they fulfill one of the criteria for study discontinuation.
224171837|NCT06814041|OTHER|Chatbot as an informational coach|"The chatbot acts as an empathic informational coach, performing three main functions: (1) offering short conversation sessions about key topics on living with HIV; (2) responding to users' ad-hoc questions on HIV; (3) reminding users of medical appointments and drug taking.~The chatbot comprises a conversational system, utilizing WhatsApp for user interaction, with messages routed through the backend Voiceflow. User can access the chatbot system via WhatsApp. That means that they access the chatbot like any other contact in their WhatsApp chat list. The bot incorporates mostly text-based input- and output modalities, and a few images, which are more protective of users' privacy than speech. Concretely, chatbot users interact with the chatbot on WhatsApp by selecting from pre-defined options (buttons) or, in some parts, writing text."
224171838|NCT07070440|DRUG|DZD6008|DZD6008 was administered orally at 40/60/90 mg QD.
223483619|NCT06280313|COMBINATION_PRODUCT|Splenectomy+Targeted therapy+ Immunotherapy|Eligible patients with unresectable hepatocellular carcinoma accompanied by cirrhotic portal hypertension were enrolled in the trial, and all participants underwent either open or laparoscopic splenectomy, with or without devascularization around the cardia. Starting two weeks post-surgery, patients began intravenous infusion of PD-1 monoclonal antibody, Tislelizumab, at a dosage of 200mg every three weeks. Three weeks post-surgery, patients commenced oral administration of the targeted therapy, Lenvatinib, with a dosage based on body weight: 8mg (≤60kg) or 12mg (\>60kg), once daily.
224171839|NCT07070440|DRUG|Pemetrexed|Pemetrexed 500 mg/m2, every 3 weeks, intravenous infusion.
224171840|NCT07070440|DRUG|Carboplatin|Carboplatin AUC 5 mg/mL/min, every 3 weeks, intravenous infusion.
224171841|NCT07070440|DRUG|Docetaxel|Docetaxel 75 mg/m2, every 3 weeks, intravenous infusion.
224171842|NCT05227612|DRUG|Psilocybin|Participants will receive two doses of psilocybin (10mg, 25mg).
224171843|NCT05227612|BEHAVIORAL|Cognitive behavioral therapy|Twelve total sessions of therapy, including manualized cognitive behavioral therapy for major depressive disorder, including psychoeducation about depression, cognitive skills, and behavioral skills as well as preparation for psilocybin.
224171844|NCT05227612|BEHAVIORAL|Minimal therapeutic support|Six total therapy sessions. Preparation for psilocybin in the first three sessions plus supportive, nondirective psychotherapy in the final three sessions.
224171845|NCT06899945|DEVICE|a percussion massage gun (Hypervolt device (Hyperice, CA, USA))|Vibration application will be applied to the individuals in this group in addition to conventional methods. Vibration application will be applied to the deltoid, supraspinatus, infraspinatus, and teres minor muscles with a percussion massage gun (Hypervolt device (Hyperice, CA, USA)) along the origo-insertio line for 3 minutes for each muscle group. Vibration application will be performed using the soft head of the percussion massage gun. Vibration therapy will be applied 3 days a week for 3 weeks.
224171846|NCT06899945|OTHER|conventional physiotherapy program|"Participants in the conventional physiotherapy program will follow a 3-week exercise plan, with sessions 5 days per week, each lasting 30 minutes under physiotherapist supervision.~Treatment includes:~TENS therapy (20 min, 100 Hz) on the painful area. Wand exercises for flexion, abduction, extension, internal, and external rotation (10 reps/set).~Codman exercises for flexion, abduction, and circular movements (10 reps/set). Active \& passive stretching for flexion, abduction, internal, and external rotation (10 reps/set).~Finger ladder exercises for flexion and abduction (10 reps/set). Strengthening with a theraband for flexion, abduction, external/internal rotation, and extension, adjusted based on progress (10 reps/set).~This exercise program will be applied to all study groups."
224171847|NCT07074184|OTHER|Radiofrequency 448khz with manual therapy|The intervention in consisted of a total of 12 sessions (twice a week) of treatment. The set duration for each session was 45 minutes, except for those sessions where variable measurements were required, which lasted 60 minutes. Radiofrequency 448 Hz was administered to the affected area in two phases, depending on the electrode applied: 5 minutes of capacitive electrode and 25 minutes of resistive electrode. In addition, a specific joint physical therapy manual therapy treatment was also performed, in which pumping techniques were performed after the radiofrequency treatment.
224171848|NCT07074184|OTHER|Turn off radiofrequency 448khz|Radiofrequency 448 Hz was administered to the affected area in two phases, depending on the electrode applied: 10 minutes of capacitive electrode and 35 minutes of resistive electrode, both with the machine turned off.
223483620|NCT04770805|PROCEDURE|Fetoscopy|After an exteriorization of the uterus through a laparotomy, humidified and warmed gas will be insufflated with low pressure (6 to 8mmHg mmHg). Fetoscopic repair surgery will consist in a dissection of the placode, its reintegration into the spinal canal and the closure of the lesion, through a three ports access. After fetal surgery, the gas will be exsufflated and the trocar ports will be closed. The uterus will be reintegrated before suturing the maternal abdominal wall.
223483621|NCT04530630|DRUG|BIC/F/TAF 50Mg-200Mg-25Mg Tablet|A three-drug fixed dose combination tablet containing 50mg of bictegravir, 200mg of emtricitabine, and 25mg of tenofovir alafenamide.
223483622|NCT00850642|DRUG|GSK2190195 100mg|GSK2190915 is a high affinity 5-lipoxygenase-activating protein (FLAP) inhibitor.
223483623|NCT00850642|DRUG|Placebo|"Placebo :~2% (w/w) Ethanol, sucralose (5 mg/100 mL of oral solution) to 100 % (w/w) aqueous sodium carbonate buffer (0.010 M, pH 9-10)"
223483624|NCT03675308|BIOLOGICAL|Placebo|Placebo for risankizumab administered by subcutaneous injection
223483625|NCT03675308|BIOLOGICAL|Risankizumab|Risankizumab administered by subcutaneous injection
223585751|NCT07088237|BEHAVIORAL|Music Listening|For the music recommendation component, our system suggests music that is tailored to the individual and the specific context. Because we will use machine learning to predict optimal music features based on physiological, contextual, and musical data, the music items will be naturally suggested based on current emotion and level of intensity as well as the current context and problem type. The music recommendation component is an adaptive playlist that is updated as changes in the user's stress level are detected. To provide personalized music recommendations, we use a supervised learning approach to design an algorithm, referred to as music feature prediction, which predicts optimal values of music features (e.g., energy, valence, instrumentalness, acousticness) that are hypothesized to result in reducing stress. These feature values, referred to as effective music features, are then used to generate a personalized music playlist.
223483626|NCT06128954|DRUG|900mg TETA 4HCl Once Daily Formulation|3x300mg trientine base tablets as a single AM dose
223483627|NCT06128954|DRUG|900mg TETA 4HCl Cuprior®|6 x150mg trientine base tablets in two equally divided doses
223483628|NCT03360721|DRUG|Abiraterone Acetate|Given PO
223585752|NCT07089394|PROCEDURE|flexible urs|treating pediatric renal stones with flexible urs+holmium laser fragmentation
223585753|NCT02591459|OTHER|Using the app to assist routine anticipation|Using the app to assist routine anticipation for autistic children in Android mobile devices
223585754|NCT03609476|PROCEDURE|Room temperature saline instillation|Saline is used as room temperature
223585755|NCT03609476|PROCEDURE|Warmed saline instillation|Saline is warmed to 37Celcius prior to instillation
223585756|NCT03609476|PROCEDURE|No saline instillation|No saline is used prior to catheter removal
223585757|NCT01354704|DRUG|Enoxaparin|enoxaparin 4000 IU 1 injection/day in subcutaneous.
223585758|NCT01756443|DRUG|2% lidocaine/adrenaline and 0.5% bupivacaine|
223585759|NCT05314933|DRUG|2-Deoxyglucose|Intranasal administration
223585760|NCT05314933|OTHER|Placebo|Intranasal administration
224171849|NCT07074184|OTHER|Manual therapy|Articulatory pumping techniques were applied towards the painful position with the aim of reducing it.
223483629|NCT03360721|DRUG|Apalutamide|Given PO
223483630|NCT03360721|DRUG|Prednisone|Given PO
224171850|NCT07077460|DEVICE|TIPr|TIPr is a second-generation device, which is originated from Pressing Evaluation and Training System (PETs), developed by NCKU Motion Analysis Lab. This 2nd generation device is a home-based training device, which equipped with single-axis force sensors and displayed visual feedback through a tablet advantages.
224171851|NCT07077460|DEVICE|Mirror Visual Feedback Device|A box with two compartments through a partition with two mirrors installed on each side, which is applied in Mirror therapy.
224171852|NCT07077460|DEVICE|Mirror Visual Feedback Device(Blocked mirror)|Different from Mirror Visual Feedback Device in MVF group, the mirror was blocked by black curtain or paperboard.
224171853|NCT07077460|DEVICE|Graded-Pressure Haptic Device (Passive press-feedback cushion)|A passive press-feedback cushion (Graded-Pressure Haptic Device) would deliver force pulses to the subjects' non-dominant fingertips in synchrony with the TiPR game's force output (matched amplitude)
224171854|NCT06812286|OTHER|Less-volume|In the first 10-week cycle, the less-volume group will perform around 1500 repetitions per intervention. Participants will perform 1-3 sets of 4-7 repetitions per exercise with intensities ranging from 5% to 10% of body weight and 1-10 kg. Strength exercises will include chair squats, seated medicine ball throws, seated knee extensions, seated shoulder presses, standing calf raises, standing biceps curls, seated lateral raises, and chair stand + 4-meter walk. In the second and third 10-week training cycles, volume will increase by 20% with respect to the previous cycles. Two exercise physiologists will supervise training sessions.
224171855|NCT06812286|OTHER|More-volume|In the first 10-week cycle, the more-volume group will perform around 2000 repetitions per intervention. Participants will perform 1-3 sets of 6-10 repetitions per exercise with intensities ranging from 5% to 10% of body weight and 1-10 kg. Strength exercises will include chair squats, seated medicine ball throws, seated knee extensions, seated shoulder presses, standing calf raises, standing biceps curls, seated lateral raises, and chair stand + 4-meter walk. In the second and third 10-week training cycles, volume will increase by 20% with respect to the previous cycles. Two exercise physiologists will supervise training sessions.
224171856|NCT06812286|OTHER|Control|Participants in the control group will undergo sham training twice weekly for 30 weeks, consisting of stretching exercises supervised by two exercise physiologists.
224171857|NCT07081360|DRUG|Neoadjuvant chemotherapy|Neoadjuvant chemotherapy (mFOLFIRINOX) followed by pancreaticoduodenectomy
224171858|NCT07081360|PROCEDURE|Upfront Surgery Group|Pancreaticoduodenectomy followed by adjuvant chemotherapy
224171859|NCT07083817|DRUG|[14C]Xeruborbactam|Carbon Radiolabeled Xeruborbactam
223483631|NCT06568276|PROCEDURE|Additional deep deltoid ligament suture|The deep deltoid ligament will be sutured through a curved incision lifting the tibialis posterior tendon out to be sutured back after tying the ligament to an anchor in the talus.
223483632|NCT04206072|DRUG|D-0316 Capsule|"The initial dose of D-0316 is 75 mg orally once daily (QD) for one cycle, and then increased to 100 mg orally QD in the absence of CTCAE grade ≥ 2 headache or thrombocytopenia during the first cycle, otherwise maintained to 75 mg orally QD until disease progression or meet the discontinuation criteria. A cycle of treatment is defined as 21 days of once daily treatment.~Following objective disease progression according to RECIST 1.1, as per investigator assessment, patients who were confirmed T790M mutation positive may have the option to continuously receive D-0316."
224171860|NCT07123597|OTHER|5mm bioceramic putty coronal plug|Teeth will be treated by regenerative endodontic procedures with placing of 5mm bioceramic putty coronal plug.
224171861|NCT07123597|OTHER|3mm bioceramic putty coronal plug|Teeth will be treated by regenerative endodontic procedures with placing of 3mm bioceramic putty coronal plug.
224171862|NCT07125183|DRUG|Doxorubicin|Doxorubicin is an antibiotic derived from the Streptomyces peucetius bacterium. It has widespread use as a chemotherapeutic agent since the 1960s. Doxorubicin is part of the anthracycline group of chemotherapeutic agents. Doxorubicin may be used to treat soft tissue and bone sarcomas and cancers of the breast, ovary, bladder, and thyroid. It is also used to treat acute lymphoblastic leukemia, acute myeloblastic leukemia, Hodgkin lymphoma, and small cell lung cancer.
224171863|NCT07124117|DRUG|OBI-902|OBI-902 is an antibody-drug conjugate study drug
224171864|NCT06853847|OTHER|The bed levels of the patients in the experimental group changed the patient's position|The bed levels of the patients in the experimental group changed the patient's position
224171865|NCT06779994|DIETARY_SUPPLEMENT|Probiotic|The experimental phase of this study will last 8 weeks and each subject will have three visits (day 0, week 4 and week 8).
224171866|NCT06779994|DIETARY_SUPPLEMENT|Placebo|The experimental phase of this study will last 8 weeks and each subject will have three visits (day 0, week 4 and week 8).
224171867|NCT05083546|DRUG|Gly-low|MGO cocktail containing a combination of alpha-lipoic acid, nicotinamide, thiamine, pyridoxamine, and piperine
224171868|NCT05083546|OTHER|Placebo|sugar pill
223585761|NCT02258529|DRUG|Idelalisib|150 tablets administered orally twice daily
223585762|NCT02258529|BIOLOGICAL|Rituximab|375 mg/m\^2 administered intravenously (weekly for 4 weeks and then every 8 weeks from Week 12 up to Week 100)
223585763|NCT05413122|DRUG|Varenicline|At enrolment, a 12-week course of varenicline in the commercially available package will be dispensed by a study clinician.
223585764|NCT05413122|DRUG|Nicotine patch|A 12-week course of nicotine patches and nicotine gum will be dispensed to the participant by the counsellor according to randomization into the c-NRT condition. c-NRT will be provided per label instructions given number of cigarettes the participant smokes per day and will be provided in the commercially available package.
223585765|NCT05413122|DRUG|Nicotine gum|A 12-week course of nicotine patches and nicotine gum will be dispensed to the participant by the counsellor according to randomization into the c-NRT condition. c-NRT will be provided per label instructions given number of cigarettes the participant smokes per day and will be provided in the commercially available package.
224171869|NCT05076760|BIOLOGICAL|MEM-288 Intratumoral Injection|Intratumoral injection of MEM-288, conditionally replicative oncolytic adenovirus vector encoding transgenes for human interferon beta (IFNβ) and a recombinant chimeric form of CD40-ligand (MEM40).
224171870|NCT05076760|BIOLOGICAL|Nivolumab|anti-PD1 monoclonal antibody
224171871|NCT05076760|DRUG|Docetaxel|75 mg/m2 intravenous administration every 3 weeks
224171872|NCT06313593|DRUG|INCB160058|Oral; Tablet
224171873|NCT06060613|BIOLOGICAL|OBX-115|"A tumor sample is obtained from each participant for autologous OBX-115 manufacture.~After lymphodepletion including cyclophosphamide and fludarabine, participant will receive OBX-115 infusion, followed by short courses of acetazolamide."
224171874|NCT07091565|OTHER|Qualitative interview/Focus group|Participants will take part in a 1:1 interview or focus group
224171875|NCT07091344|BEHAVIORAL|VR-Based Avatar Therapy with Cognitive and Metacognitive Assessments|"VR-Based Avatar Therapy is a 12-week intervention designed to help patients with psychosis manage distressing auditory hallucinations. The therapy consists of 7 individual sessions using virtual reality (VR) technology to externalize the auditory hallucinations, allowing patients to interact with a computer-generated avatar representing their dominant voice.~In addition to standard therapy, participants will undergo assessments of cognition, metacognition, and social cognition to explore their impact on treatment outcomes. These assessments include measures of emotion recognition, attributional style, theory of mind, cognitive flexibility, and trauma history. Sessions are conducted using VR headsets and noise-canceling headphones to enhance immersion, and patients receive ongoing therapeutic guidance throughout the process."
224171876|NCT06858332|DRUG|Atorvastatin|3-Hydroxy-3-methylglutaryl-CoA reductase inhibitors (statins)
224171877|NCT06858332|DRUG|Simvastatin|3-Hydroxy-3-methylglutaryl-CoA reductase inhibitors (statins)
224171878|NCT06858332|DRUG|Rozuvastatin|3-Hydroxy-3-methylglutaryl-CoA reductase inhibitors (statins)
224171879|NCT06858332|DRUG|Ezetimibe|Ezetimibe
224171880|NCT06858332|DRUG|Niacin|Niacin
224305813|NCT06638450|PROCEDURE|Dense Cranial Electroacupuncture Stimulation plus Body Acupuncture (DCEAS+BA)|"DCEAS+BA will be conducted for 2 sessions per week for 8 weeks.~For DCEAS, 6 pairs of acupoints are used: Baihui (GV20) and Yintang (EX-HN3), left Sishencong (EX-HN1) and Toulinqi (GB15), right Sishencong (EX-HN1) and Toulinqi (GB15), bilateral Shuaigu (GB8), bilateral Taiyang (EX-HN5), and bilateral Touwei (ST8). For body acupuncture, the following acupoints are used: Shenmen (HT7). Neiguan (PC6), Zhongwan (CV12), Guanyuan (CV4), Zusanli (ST36), Sanyinjiao (SP6), and Taichong (LV3).~Disposable acupuncture needles (0.25 mm in diameter and 25-40 mm in length) are inserted at a depth of 10-30 mm perpendicularly or obliquely into acupoints. Manual manipulation is conducted to evoke a needling sensation. After that, electrical stimulation is delivered on DCEAS, with continuous waves at 2 Hz through an electrical acupuncture stimulation instrument (Hwarto, SDZ-II). The stimulation lasts 30 minutes."
223483633|NCT04206072|DRUG|Icotinib Hydrochloride Tablets|"Icotinib (125 mg three times daily, orally), treatment should continue until disease progression or meet the withdrawal criteria. A cycle of treatment is defined as 21 days of three times daily treatment.~Following objective disease progression according to RECIST 1.1, as per investigator assessment, patients who were randomized to Icotinib arm and confirmed T790M mutation positive have the option to receive D-0316 (crossover to active D-0316)."
223483634|NCT00672009|DRUG|Ixabepilone|Ixabepilone 35 mg/m\^2 intravenously over 3 hours every 21 days for 4 cycles.
223483635|NCT02702856|OTHER|ExoIntelliScore Prostate|
224171881|NCT06858332|DRUG|Ciprofibrate|Fibrates
224171882|NCT06858332|DRUG|Fenofibrate|Fibrates
224171883|NCT06858332|DRUG|Bezafibrate|Fibrates
224171884|NCT06858332|DRUG|Evolocumab|PCSK9 inhibitor
224171885|NCT06858332|DRUG|Alirocumab|PCSK9 inhibitor
224171886|NCT06858332|DRUG|Inclisiran|Small interfering RNA
224171887|NCT05472545|BEHAVIORAL|Neurofeedback|Real-time functional magnetic resonance imaging dyadic neurofeedback
224171888|NCT07093684|OTHER|Kidney disease|This is a registry-based observational study investigating the association between kidney disease and dementia-related outcomes. Kidney disease is not assigned or manipulated by the researchers but is classified as an exposure based on diagnostic codes (e.g., ICD codes), and related laboratory test recorded in health registers.
223483636|NCT02927626|DRUG|Yang Yin Fu Zheng therapy|Yang Yin Fu Zheng is a Chinese herbal compound.
223483637|NCT02927626|DRUG|Routine medical care|Routine medical care
223483638|NCT05347355|OTHER|Spencer technique along with conventional treatment|"Subjects in this group will receive conventional exercises and 7 stages of Spencer technique: (A) extension, (B) flexion, (C) circumduction with compression, (D) circumduction with traction, (E) abduction, (F) internal rotation, (G) lymphatic pump.~Spencer technique will be used to increase range of motion of the glenohumeral joint. The patient will be positioned lying on the side with the affected shoulder above. The therapist will stabilize the shoulder girdle with the proximal hand and the distal hand will provide force into the restrictive barrier of shoulder in 7 different movements. These will be shoulder extension, circumduction with distraction, abduction, adduction with internal rotation and glenohumeral pump. During all the movements, patient will be asked to use muscle energy against the slight resistance offered by the therapist for 3-5 seconds. The exercise will be repeated 3-5 times with rest intervals over 3 sessions per week on alternate days for 4 weeks."
223585766|NCT05413122|BEHAVIORAL|Intensive Behavioral Counselling|Participants randomized to the Intensive Behavioural Counselling condition will receive in-person intensive (\~45 minutes) behavioural counselling in the clinic at screening and at weeks 2, 4, 8, and 12. Additionally, on non-clinic visit weeks participants will receive (1) one phone call each week from the clinic counsellor, and (2) two text messages each week providing encouragement and advice.
224171889|NCT07093437|DEVICE|GRIP-LOK FOLEY SECUREMENT DEVICE ®|"* Used device: adhesive~* Specific Skin protection: with non alcohol barrier film"
224171890|NCT07093437|DEVICE|CONVEEN, ELASTIC LEG WRISTBAND FOR URINARY CATHETER|The elastic wristband will be adjusted appropriately to minimize catheter movement while allowing normal blood circulation in the limb.
224171891|NCT04039607|DRUG|Nivolumab|Participants will receive nivolumab as intravenous (IV) infusion.
224171892|NCT04039607|DRUG|Ipilimumab|Participants will receive ipilimumab as IV infusion.
224171893|NCT04039607|DRUG|Sorafenib|Participants will receive sorafenib as oral tablets.
224171894|NCT04039607|DRUG|lenvatinib|Participants will receive lenvatinib as oral capsules.
224171895|NCT04960397|OTHER|Placebo|Physiological saline, i.e., 0.9% sodium chloride.
224171896|NCT04960397|BIOLOGICAL|Sing2016 M2SR H3N2|Novel intranasal live attenuated influenza vaccine with a defective M2 gene which renders the virus unable to replicate and generate progeny in animals and in humans, making its infectivity self-limiting. It induces both a mucosal and cell-mediated immune response and is administered intranasally. Supplied by Flugen Inc.
224171897|NCT07101718|OTHER|No intervention|No intervention
224171898|NCT07101770|OTHER|A combined retrospective and prospective observational follow-up|A combined retrospective and prospective observational follow-up
224171899|NCT07101666|RADIATION|Short course radiation therapy|25 Gy in 5 fractions
224171900|NCT07101666|DRUG|Standard of care neoadjuvant chemotherapy|Recommended options are CAPOX, FOLFOX, or FLOT but other standard of care chemotherapy may be given given at the discretion of the treating medical oncologist after consultation with the study Principal Investigator.
224171901|NCT07102004|DRUG|MHB088C for Injection|MHB088C for Injection, an antibody drug-conjugated molecule (ADC) MHB088C will be administered intravenously at a frequency of once every 2 weeks (Q2W) or every 3 week (Q3W).
224171902|NCT07101601|DRUG|DM5167|Once daily for 28 days
223483639|NCT05347355|OTHER|Gongs Mobilization along with conventional treatment|The Gong's mobilization can be done either in high sitting or in side-lying position with the affected shoulder upward. The subject's shoulder will be abducted at 90° so that the humerus will be maintained at vertical position. The elbow joint will be flexed and maintained at 90°; the therapist will maintain this position by placing his/her hand below the subject's elbow. The humeral head will be pressed from anterior to posterior direction with the other hand. The therapist will hold the vertical axis of the humerus by maintaining the shoulder in abduction and the elbow in 90°. The therapist will raise his own body by slightly pulling on the anterior capsule and this pull will be maintained for 10-15 seconds and then relax for five seconds and will be performed for about two to three minutes. At this moment the subject will be asked to perform shoulder abduction with no external rotation, while elbow flexion will be maintained throughout.
223483640|NCT05032183|DRUG|Cyclophosphamide|Given IV
223483641|NCT05032183|DRUG|Cytarabine|Given IT
223483642|NCT05032183|DRUG|Dexamethasone|Given IV or PO
223483643|NCT05032183|BIOLOGICAL|Filgrastim-sndz|Given SC
223483644|NCT05032183|DRUG|Leucovorin|Given IV
223483645|NCT05032183|DRUG|Mercaptopurine|Given PO
223483646|NCT05032183|DRUG|Mesna|Give IV
223483647|NCT05032183|DRUG|Methotrexate|Given IT
223585767|NCT05413122|BEHAVIORAL|Peer Counselling|Participants randomized to the Peer Support condition will be engaged by a peer counsellor over weeks -2 to 12. Peer counselling will follow a flexible framework for contact with participants, which will include in-person and phone-based check-ins, depending upon individual participant preference. Peer counsellors will visit the counsellors' assigned participant in-person at participants' home, workplace, or other setting based on participant preference at least during weeks -2, 2, 4, 8 and 12; additional in-person contact will be provided upon participant request.
223745106|NCT01876485|BEHAVIORAL|Enhanced Usual Care (EUC)|Patients randomized to EUC will be referred to the PACT RN Care Manager for diabetes management, and will also receive a packet of educational materials regarding diabetes management, including a letter delineating the diabetes management resources available at their facility.
223745107|NCT03011359|OTHER|Optimizing B.I (New) PCA mode|In the intervention group, the optimizing B.I PCA mode will be setted. This mode is setted that the amount of administered drug per hour will be increased by 0.3 ml by pressing bolus button (The interval: \~ 6 hr: 1.5 - 3.5 ml, 6-24 hr: 1 - 3 ml, 24 hr \~ : 0.5 - 2.5 ml). Conversely, if the bolus button is not used for 90 minutes, the administered amount of drug per hour is setted to be reduced by 0.1 ml, and the maximum (or minimum) allowable flow rate is 3.5 ml (or 0.5 ml).
224171903|NCT07100860|PROCEDURE|One-Lung ventilation|In this observational study, the naturally occurring duration of intraoperative single-lung ventilation (SLV) during thoracic surgery will be recorded. No intervention is applied or modified for research purposes. The exposure of interest is the total duration (in minutes) of SLV, which will be timed from initiation to termination during surgery. This variable will be analyzed in relation to postoperative pulmonary complications.
224171904|NCT07101055|DRUG|Letermovir 480 mg [PREVYMIS]|A single 480 mg oral dose of letermovir (2 x 240 mg tablets).
224171905|NCT07101731|BEHAVIORAL|Pelvic Floor Muscle Training (PFMT)|Participants in the control group will receive an individualized home-based pelvic floor muscle exercise program. Exercises will be performed once daily for 8 weeks, focusing on voluntary pelvic floor contractions in various positions (supine, sitting, standing). Participants will receive initial training and written instructions from a physiotherapist, and will be contacted weekly to monitor adherence.
224171906|NCT07101731|BEHAVIORAL|Hypopressive Exercises|Participants in the experimental group will attend supervised hypopressive exercise sessions twice per week for 8 weeks. These sessions involve specific postural sequences combined with breathing and apnea techniques aimed at reducing intra-abdominal pressure while activating pelvic floor and abdominal muscles. Sessions will be led by a physiotherapist and adapted based on individual performance and posture tolerance.
224171907|NCT07102472|BEHAVIORAL|"Using the term community immunity instead of herd immunity"|"In the intervention arm, participants are shown the less traditional term community immunity in place of the more traditional herd immunity"
223483648|NCT05032183|BIOLOGICAL|Pegfilgrastim|Given SC
224171908|NCT07102472|BEHAVIORAL|Herd immunity|"Using the traditional term herd immunity"
223483649|NCT05032183|DRUG|Prednisone|Given PO
223483650|NCT05032183|BIOLOGICAL|Rituximab|Given IV
223483651|NCT05032183|BIOLOGICAL|Tagraxofusp-erzs|Given IV
223483652|NCT05032183|DRUG|Vincristine|Given IV
223483653|NCT05045482|DRUG|Saroglitazar Magnesium 1 mg|Group-8: Total of 18 subjects will be enrolled in the Group-8. Group 8A (n=6, consist of mild hepatic impairment subjects); Group 8B (n=6, consist of moderate hepatic impairment), Group 8C (n=3, consist of severe hepatic impairment and Group 8D (n=3, consist of control subjects with normal hepatic functions).
223585768|NCT06046469|DIAGNOSTIC_TEST|CT with contrast|CT abdomen and pelvis with IV contrast
223585769|NCT06046469|DIAGNOSTIC_TEST|MRI pelvis|MRI pelvis with contrast
223585770|NCT06046469|PROCEDURE|TURBT|transurethral resection of bladder tumor
223585771|NCT05275790|DEVICE|Vestal device|Battery powered non-invasive neurostimulation device
224171909|NCT07100613|DRUG|Clobetasol Patch|A mucoadhesive patch containing clobetasol propionate 0.05%. Applied once daily for 30 days to the oral lesion.
224171910|NCT07100613|DRUG|Clobetasol + Resveratrol Patch|A mucoadhesive patch containing clobetasol propionate 0.05% and resveratrol. Applied once daily for 30 days to the oral lesion.
224305814|NCT06638450|PROCEDURE|Minimal Acupuncture Stimulation (MAS)|"MAS will be conducted for 2 sessions per week for 8 weeks.~The following 6 acupoints are used: bilateral Tongtian (BL07), bilateral Shousanli (LI10) and bilateral Fuyang (BL59).~Disposable acupuncture needles (0.25 mm in diameter and 25-40 mm in length) are inserted at a depth of 10-30 mm perpendicularly or obliquely into acupoints. After that, electrical stimulation is performed on bilateral Tongtian (BL07), with continuous waves at 2 Hz through an electrical acupuncture stimulation instrument (Hwarto, SDZ-II). The stimulation lasts 30 minutes."
224305815|NCT06378749|BEHAVIORAL|PreCharge|PreCharge is an intervention for Hereditary Cancer Syndrome Previvors that administers brief assessments and uses multivariate algorithms and tailoring technology to provide timely, individualized, bi-directional text messages to improve resilience and coping. The program uses proven approaches to behavior change tailoring to increase resilience by promoting a positive mindset, strong social connections, and a deep sense of meaning and purpose. It will also proactively provide access to online tools prior to medical appointments to address scanxiety (e.g., management of emotion tips; mindfulness meditation; communication scripts; breathing exercises). At any time, users will be able to text a trigger word to indicate that they need extra support and will receive just-in-time assistance via text message.
223483654|NCT05045482|DRUG|Saroglitazar Magnesium 2 mg|Group-9: Total of 12 subjects will be enrolled in the Group-9. Group 9A (n=3, consist of mild hepatic impairment subjects); Group 9B (n=3, consist of moderate hepatic impairment), Group 9C (n=3, consist of severe hepatic impairment and Group 9D (n=3, consist of control subjects with normal hepatic functions).
223483655|NCT03550885|OTHER|High taurine and saturated fat diet|This is a 3-week (21 day) isocaloric Western-type diet with all meals, snacks, beverages and condiments provided.
223483656|NCT03550885|OTHER|Low in taurine and saturated fat diet|This is a 3-week (21 day) isocaloric largely plant-based diet with all meals, snacks, beverages and condiments provided.
223483657|NCT06480565|DRUG|ADI-270|Anti-CD70 CAR-T
223483658|NCT06480565|DRUG|Fludarabine|Chemotherapy for Lymphodepeletion
223483659|NCT06480565|DRUG|Cyclophosphamide|Chemotherapy for Lymphodepletion
223483660|NCT06122272|OTHER|Test Formula|The duration of the study for each subject from enrolment to final visit, is 12 months. Test Formula will be provided during this 12 month.
223483661|NCT06122272|OTHER|Control Formula|The duration of the study for each subject from enrolment to final visit, is 12 months. Control Formula will be provided during this 12 month.
223483662|NCT05183347|DRUG|BI 1291583|BI 1291583
223483663|NCT05183347|DRUG|Placebo|Placebo
223483664|NCT04254263|DRUG|pyrotinib|pyrotinib 400 mg, orally once daily for one year
223483665|NCT03892200|BEHAVIORAL|Aim2 - Daily Mouth Care|"Nursing assistants will be trained to provide daily mouth care to all residents in nursing homes. Mouth care supplies will also be provided to intervention assisted living communities.~For Aim2 the intervention training is delivered by a research dental hygienist."
224305816|NCT02799095|DRUG|ALKS 4230|Intravenous (IV) infusion over 30 minutes given daily for 5 consecutive days followed by an off-treatment period
224305817|NCT02799095|DRUG|ALKS 4230 + pembrolizumab|IV infusion of ALKS 4230 over 30 minutes given daily for 5 consecutive days followed by an off-treatment period; pembrolizumab administered IV once with ALKS 4230 on the first day of each cycle
223483666|NCT03892200|BEHAVIORAL|Aim3 - Daily Mouth Care|"Nursing assistants will be trained to provide daily mouth care to all residents in nursing homes. Mouth care supplies will also be provided to intervention assisted living communities.~For Aim3 the intervention training is delivered by state public health dental hygienists."
223483667|NCT02310594|OTHER|cytology specimen collection procedure|Undergo blood sample collection
223483668|NCT02310594|OTHER|laboratory biomarker analysis|Correlative studies
223483669|NCT00135655|DRUG|denufosol tetrasodium (INS37217) Intravitreal Injection|
223483670|NCT05750082|DEVICE|CCTA CT-FR CAG OCT|Per the protocol, patients will have a CCTA (coronary computed tomography angiography), CT-FFR (fractional flow reserve derived from CTA), ICA (invasive coronary angiography), OCT (optical coherence tomography).
223585772|NCT05275790|BEHAVIORAL|Lifestyle intervention|All subjects will be prescribed a diet plan and instructed to follow it for the duration of the 12-week study. The diet plan will be designed by the P.I. who is a qualified, obesity management coach.
223745108|NCT03011359|OTHER|Conventional PCA mode|(Mode setting; total volume: 150 ml, flow rate: 2 ml, bolus volume: 0.5 ml, and LOT: 10 minutes)
224171911|NCT07100613|DRUG|Clobetasol in Orabase|Clobetasol propionate 0.05% in orabase-type adhesive paste. Applied once daily for 30 days to the oral lesion.
224171912|NCT07101939|DRUG|(S)-pindolol benzoate|(S)-pindolol benzoate (ACM-001.1) immediate release tablet containing (S)-pindolol benzoate administered BID.
224171913|NCT07101939|DRUG|Semaglutide|Semaglutide, solution for injection in pre-filled pen
224171914|NCT07101939|DRUG|Placebo to (S)-pindolol benzoate|Placebo to ACM-001.1 immediate release tablet administered BID
223483671|NCT06468033|BIOLOGICAL|Ropeginterferon alfa-2b|"Pre-filled Syringe.~Dosage: up to 500mcg"
223483672|NCT06468033|OTHER|Placebo|Placebo is a look-alike substance with the intervention (Ropeginterferon alfa-2b) that contains no active drug.
223483673|NCT00788671|OTHER|Laboratory Biomarker Analysis|Correlative studies
223483674|NCT00788671|DEVICE|Levonorgestrel-Releasing Intrauterine System|Undergo placement of a levonorgestrel-releasing intrauterine system
223483675|NCT00788671|OTHER|Quality-of-Life Assessment|Ancillary studies
223585773|NCT01188616|BEHAVIORAL|Telephone Linked Care-HEAT (TLC-HEAT)|A primary care intervention linked with Telephone Linked Care-HEAT (TLC-HEAT), and delivered through an electronic health record (EHR). The HEAT system will guide children in the early stages of overweight toward healthy weight management and assist the child's parent(s) and primary care provider (PCP) to support the child's efforts.
223585774|NCT06515314|BIOLOGICAL|AFP Specific T Cell Receptor T Cells|"AFP Specific T Cell Receptor T Cells On day 1, the TCR-T cells will be administered intravenously.~Drug: Fludarabine + Cyclophosphamide Fludarabine: 25mg/m²/day×3days; Cyclophosphamide: 250mg/m²/day×3 days"
223585775|NCT02334488|DRUG|Everolimus|Active Comparator
223483676|NCT05165368|OTHER|Intraneural Facilitation® Therapy (INF® Therapy)|INF® Therapy plus dietary education with weekly follow-up by a physical therapist. Includes meal preparation ideas and sample menus promoting a gluten-free diet.
223483677|NCT05165368|OTHER|INF® Therapy|"INF® Therapy only (INF® Therapy is a manual therapy technique that consists of three components. The first is the pressurization or facilitation hold which biases circulation more consistently in the nerves, which is thought to pressurize the entire system The secondary hold attempts to stretch the innervated structure, pulling apart the tough dividing membrane and allowing the pressurized blood flow to transport from the outside holding chamber to the endoneurium and push open the closed capillary beds next to the nerve axons. Once capillaries surrounding the nerves are pressurized, the circulation needs to be induced up the neural connective tissue. A separate set of pressure points or holds are performed distal to the secondary holds to ensure the circulation is drawn up the inflamed capillary beds using the Bernoulli principle.)"
223483678|NCT06469801|DEVICE|Hyperfine|Enrolled subjects will undergo a Hyperfine MRI exam, which is a portable, low-field MRI, at various timepoints during their clinical course on ECMO. Patients will undergo imaging within 36 hours of ECMO initiation/cannulation. Patients that remain on ECMO will have repeat imaging at 72-120 hours of ECMO therapy and again weekly for the duration of their ECMO course. Patients will also undergo a portable MRI within 24 hours of clinical head imaging, if applicable.
223483679|NCT05139173|DEVICE|Smart Physiotherapy Activity Recognition System (SPARS)|Wearable smart watch that records inertial data such as (accelerometer, gyroscope magnetometer) and the exercise is started on the tablet, while patients are performing physiotherapy exercises.
223483680|NCT06114849|BEHAVIORAL|Treatment as usual|Treatment-as-usual will follow the existing RallyPoint procedures for concerning posts on the site. In the current procedures, a RallyPoint staff member sends a supportive message to the member containing resource information on the Veteran's Crisis line, 911, and connecting with a therapist. This information is typically sent within 24 hrs of seeing a concerning post. Participants in both the control and intervention conditions will receive treatment-as-usual.
223483681|NCT06114849|BEHAVIORAL|Barrier Reduction Intervention|"After a post is identified in real-time by the risk algorithm, participants will be shown a pop-up message offering information on mental health resources (e.g., crisis line). Participants will be asked about their likelihood of using these resources. For participants who indicate they are not likely to use these resources, they will then be presented with a list of common barriers to help-seeking, drawing from research in this area (e.g., Treatment is too expensive or I'm concerned about the police or paramedics getting involved.). Participants will be asked to click on any reason that resonates with them. When they click on a particular reason, they will then be presented with psychoeducational information to allay their concerns and encourage professional help-seeking."
223483682|NCT03637543|DRUG|Nivolumab|Nivolumab is an antibody inhibitor of the programmed death-1 (PD-1) pathway. By blocking PD-1, this medication may allow the immune system to recognize and fight cancer
223483683|NCT05172609|BEHAVIORAL|Exposure Based Implementation Strategy (EBIS)|EBIS will include psychoeducation, assessment/hierarchy building. guided practice, and guidance for application to clinical practice.
223483684|NCT05172609|BEHAVIORAL|Implementation as Usual (IAU)|IAU will consist of standard didactic training and ongoing consultation activities for enrolled clinicians
223483685|NCT06063538|COMBINATION_PRODUCT|CardiaMend in Combination with Amiodarone|"The first three patient will receive 600 mg amiodarone into the intact pericardial space. Amiodarone serum levels will be tested at post operative days 2 and 6. The study will only proceed if there is a serum amiodarone level less than 25% of the normal therapeutic level. This should insure lack of systemic toxicity. After the first 3 patients have demonstrated low amiodarone blood levels, a total of up to 60 patients will be enrolled in the study.~The CardiaMend patch will saturated per the instructions and be sutured into place. Amiodarone will be dripped directly over the heart."
223483686|NCT00714818|BEHAVIORAL|Genetic Counseling|One face-to-face genetic counseling session of 1-2hours duration, with a board certified or board eligible genetic counselor which will involve, documentation of a detailed family history, discussion of: the contributors to mental illness pathogenesis, illness risk reduction strategies, chances for family members to develop mental illness (if required), supportive counseling around living with illness/risk of illness/managing illness vulnerability, and referral to support organizations as required
223483687|NCT00714818|BEHAVIORAL|Genetic Counseling|One educational booklet that provides information about the causes of mental illnesses, and the chances for relatives of affected individuals to develop mental illness will be provided to participants.
223585776|NCT02334488|DRUG|Tacrolimus|Active Comparator
223585777|NCT02334488|DRUG|Mycophenolate sodium|Experimental Arm
223585778|NCT06520631|OTHER|Ice packs (cryotherapy)|"One group of patients receives ice pack applied on the site of the cannulation, for 20 sessions (3 sessions per week) it introduced for 5-10 minutes before the beginning of the dialysis.~The second group of patients receives ice pack applied on contralateral to the site of the cannulation, for 20 sessions (3 sessions per week) it introduced for 5-10 minutes before the beginning of the dialysis."
223585779|NCT05728073|PROCEDURE|ERCP|Patients separated to two groups according to having a ERCP history before the operation
223585780|NCT00120055|DRUG|Atorvastatin (Lipitor)|
223745109|NCT06212076|DRUG|IPG1094|IPG1094 Activity: An inhibitor of macrophage migration inhibitory factor (MIF) Dosage form: Tablet Strength: 50 mg and 100 mg
224171915|NCT07100717|BEHAVIORAL|2-days workshop and self-mindfulness practices|Participants will attend 2-days face-to-face workshop on mindfulness-based self-care (MBSC) program. After the completion of the 2-days workshop, the participants will be required to complete self-mindfulness practices within a period of 4 weeks
224171916|NCT07100873|DRUG|ADI-001|Anti-CD20 CAR-T
224171917|NCT07100873|DRUG|Fludarabine|Chemotherapy for Lymphodepletion
224171918|NCT07100873|DRUG|Cyclophosphamide|Chemotherapy for Lymphodepletion
224171919|NCT07102173|PROCEDURE|Intercostal nerve block|Before final lung re-expansion, involving the administration of 20 mL of 0.5% levobupivacaine using a 27G needle into the subpleural space of the thoracotomy access site and adjacent intercostal spaces.
224171920|NCT07102173|PROCEDURE|Ultrasound-guided ESPB|After identifying the target transverse process, a linear ultrasound probe is placed sagittally approximately 2 cm from the midline. The needle (22G, 50 mm) is inserted in-plane in a cranio-caudal direction until contacting the transverse process. After confirming proper injection by observing anesthetic spread between the erector spinae muscle and transverse process, a total of 30 mL of 0.375% ropivacaine is administered.
224171921|NCT07100574|OTHER|atheroma plaque|During the endarterectomy procedure, samples will be collected for study from some of the atheroma plaques routinely taken for pathology from patients.
224171922|NCT07100574|OTHER|dental plaque|Subgingival plaque samples will be collected from patients before the endarterectomy procedure.
223483688|NCT06217809|BEHAVIORAL|The intervention curriculum addresses sexual activity, abstinence, and adulthood preparation topics.|The intervention is youth-co-led, and targets youth in Detroit, Out-Wayne County or geographically similar areas through a 16-unit curriculum totaling 20 hours. Each participant and their parent/guardian will also receive one individual session with a case planner. Parents will receive 3 hours of parental support group. EmpowHer contains lessons and activities focusing on topics relating to abstinence, and teen pregnancy prevention, focusing on adulthood preparation subjects (APS), such as parent-child communication, adolescent development, healthy life skills, and healthy relationships.
223483689|NCT05644834|OTHER|I'm Fully Empowered for Her (IFE4Her)|IFE4Her consists of 2 key components: 1) An awareness-raising messaging campaign with messages about PrEP that includes posters and Peer Networkers; and 2) access via a mobile medical unit outreach delivery model linking women in public housing to care from the PrEP providers of a university healthcare system and other complementary screening services (i.e., blood pressure, blood glucose monitoring, and HIV testing).
223483690|NCT06153459|PROCEDURE|Umbilical Cord Clamping at ~30 seconds|Care team will wait to clamp the umbilical between 1-\<60 seconds after birth. 30 seconds is the ideal time of clamping.
224171923|NCT07100327|PROCEDURE|Band|Laparoscopic sleeve gastrectomy with the placement of a 1.5 x 5.5 cm polypropylene band around the proximal gastric pouch to enhance restriction.
224171924|NCT07100327|PROCEDURE|Non-Band|Standard laparoscopic sleeve gastrectomy where approximately 75-80% of the stomach is resected to form a tubular structure
224171925|NCT07100431|PROCEDURE|Articulating (experimental group)|1\. Surgical procedure On the day of surgery, random allocation to either the experimental or the control group will be perfored just before the start of the procedure. All of the surgery will be conducted laparoscopically. The control group will undergo surgery using a conventional straight laparoscopic instrument, while the experimental group will use an articulating instrument. The surgical procedure will be the same for both groups. The total time of surgery and the time spent on the supra-pancreatic lymph node dissection will be recorded during the procedure. The estimated blood loss during surgery will be also measured.
224171926|NCT07100431|PROCEDURE|Control (control group)|"2\. Postoperative follow-up Patients participating in this study will have the same postoperative care as those not participating in this study. To compare the degree of pancreatic injury, amylase and lipase levels will be measured in the serum and the peritoneal fluid frome the drainage on postoperative days 1 and 3.~Postoperative complications will be classified and recorded according to the Clavien-Dindo classification for all complications occurring within 30 days after surgery. The dissected lymph nodes will be categorized by region, and the number of dissected lymph nodes will also be confirmed."
223483691|NCT06153459|PROCEDURE|Umbilical Cord Clamping at ~120 seconds|Care team will wait to clamp the umbilical cord between 60-180 seconds after birth.120 seconds is the ideal time of clamping
223745110|NCT01234233|PROCEDURE|duration of preoperative active warming|"duration of prewarming by forced air warming"
223745111|NCT04931485|OTHER|Fluid management according to the REDUCE Fluid Protocol|Fluid management according to the protocol will be guided by pre-defined clinical signs for impaired perfusion and fluid overload.
223745112|NCT04931485|OTHER|Standard of care|Fluid resuscitation and de-resuscitation will be managed according to the standard of care
223745113|NCT00084669|DRUG|venlafaxine|
223745114|NCT00084669|DRUG|zolpidem tartrate|
224171927|NCT07101133|DIETARY_SUPPLEMENT|Control group: Energy-limited balanced diet group|"Based on clinical phenotype + energy-restricted diet group：Based on the baseline dietary quality assessment of the subjects and baseline clinical data , a dietary plan was formulated, and the types and proportions of food were adjusted specifically .~Intervention group based on genetic susceptibility：Integrate deep phenotypes (diet quality, physical fitness test results, clinical indicators), superimpose obesity nutrition gene data and nutrient metabolism genes, and customize the macronutrient ratio.~Based on genetic susceptibility + intestinal flora intervention group: Integrating deep phenotypes (diet quality, physical fitness test results, clinical indicators), superimposing obesity nutrition gene + intestinal flora genomic data, including 33 obesity nutrition-related genes and 170 intestinal obesity nutrient metabolic bacterial genera/species test results, to customize the proportion of macronutrients."
224171928|NCT07100275|BEHAVIORAL|Patient education|In addition to the procedures in the control group, the patient will be informed about the surgery while he/she is at home the day before the surgery. Information will be provided about the hospital and surgical process. If there are any questions, the patient will be asked and their concerns will be resolved. T0-T1-T2 procedures will be performed on patients in the intervention group, respectively.
224171929|NCT07100275|BEHAVIORAL|Follow-up via Mobile Health Application|The researcher will create a video depicting the process of transferring patients from the ward to surgery. The video will be created with a volunteer mannequin. It will not be created with a real patient. This video will be recorded during a non-busy Sunday at the hospital. This video will be shown to patients the evening before surgery, following online education, and their questions will be answered.
223745115|NCT00084669|PROCEDURE|management of therapy complications|
223745116|NCT00564655|PROCEDURE|bupivacaine with epinephrine (mid and upper abdomen)|Patients will receive localized infiltration of local anesthesia (0.25% bupivacaine with epinephrine 1:200,000) at the beginning of the procedure as is current standard practice. Localized anaesthetic of the mid and upper abdomen.
223745117|NCT00564655|PROCEDURE|bupivacaine with epinephrine (transversus abdominis plane)|0.6 cc/kg (to a maximum of 20 ccs) of 0.25% bupivacaine with epinephrine 1:200,000 will be injected into the neuro-vascular plane between the internal oblique and transversus abdominis muscles. Regional anaesthetic block of the transversus abdominis plane.
224171930|NCT07101003|PROCEDURE|single visit instrumentation|root canal instrumentation will be done on single visit treatment
224171931|NCT07101003|PROCEDURE|multiple visit instrumentation|root canal treatment will be done on two visits
224171932|NCT07100548|BEHAVIORAL|"ich bin alles (English: I am everything)"|"The web-based information platform ich bin alles (www.ich-bin-alles.de) on depression and mental health in youth as well as its social media channels were developed by the Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy of the Ludwig-Maximilians-University Munich Hospital together with the Prof. Otto Beisheim Foundation. It is aimed at youth with depression, healthy youth, and their parents. The project focuses on education, prevention, low-threshold support, and destigmatisation through the transfer of evidence-based knowledge and hands-on supportive materials. Information material on Instagram is posted four times a week in the form of a post, a longer explanatory video and two reels (i.e., short videos with overlays of text and music; https://www.instagram.com/ich.bin.alles/). All content is evidence-based information created by the research team and is primarily based on the ich bin alles page."
224171933|NCT07100184|DRUG|Disitamab Vedotin combined with Radiotherapy|Disitamab Vedotin (RC-48) injection 2mg/kg, Q2w for 4 circles before radiotherapy and 2mg/kg, Q3w for 8 circles after radiotherapy; Radiotherapy (Whole bladder dose: 25 Gy in 5 doses, QD)
224171934|NCT05543252|DRUG|Minzasolmin (UCB0599)|Minzasolmin (UCB0599) Pharmaceutical form: Granules in capsules Route of administration: Oral use Participants will receive minzasolmin (UCB0599) in a pre-specified sequence during the Treatment Period.
224171935|NCT05337137|DRUG|Relatlimab|Specified dose on specified days
224171936|NCT05337137|DRUG|Nivolumab|Specified dose on specified days
224171937|NCT05337137|DRUG|Bevacizumab|Specified dose on specified days
224171938|NCT05337137|OTHER|Placebo|Specified dose on specified days
224171939|NCT07101562|DEVICE|Tissue-engineered bone|Tissue-engineered bone with autologous bone marrow mesenchymal stem cells
224171940|NCT07100535|BEHAVIORAL|Education and Literacy for an Active Life|This study will assess the effectiveness of a school-based health literacy intervention on the four dimensions of health literacy (i.e., access, understanding, evaluation, and application) on diet, sedentary behaviour, physical activity, sleep, and mental health in 5th and 6th graders (aged 9-12), and explored its implementation feasibility.
224171941|NCT07100834|DEVICE|Single-Shot Pulsed Field Ablation (FARAPULSE™ Pulsed Field Ablation System)|The FARAPULSE™ Pulsed Field Ablation System (Boston Scientific, Inc.) is a CE-marked system consisting of the FARASTAR™ Pulsed Field Ablation Generator that is used with the FARAWAVE™ Pulsed Field Ablation Catheter for cardiac tissue ablation
224171942|NCT07100834|DEVICE|Single-Shot Cryoballoon Devices (Arctic Front Advance PRO, Medtronic Inc., Minneapolis, MN, USA; POLARx and POLARx FIT Balloon Catheter, Marlborough, MA, USA)|The Arctic Front Advance PRO, POLARx and FIT Balloon Catheters are CE-marked cryoablation systems consisting of a cryoballoon device, which is used in conjunction with a CryoConsole, a steerable sheath, and a circular mapping catheter
224171943|NCT07101653|OTHER|Exercise|According to current clinical guidelines for multiple sclerosis patients, the progressive resistance training (PRT) protocol will be implemented as follows: a 12-week intervention consisting of three supervised 60-90 minute sessions per week at 60-80% of one-repetition maximum intensity. All training sessions will be conducted under the direct supervision of a certified physiotherapist to ensure proper technique adherence and safety throughout the intervention period
224171944|NCT07101211|BEHAVIORAL|Video-Based Educational Animation|A short, Turkish-dubbed educational animation video explaining the cystoscopy procedure, including steps of the procedure, expected sensations, and post-procedure care. The video is viewed by patients via QR code on their mobile devices before the cystoscopy to enhance patient understanding and reduce anxiety, stress, and depression.
224171945|NCT07101211|OTHER|Standard Written Informed Consent|A standard written informed consent form describing the cystoscopy procedure, including the purpose, steps, possible sensations, and post-procedure care, provided to all participants before the procedure.
223483692|NCT06153459|PROCEDURE|Umbilical Cord Milking|"For infants who need their cord clamped before the target in the DCC-120 group. Care team may milk the umbilical cord towards the infant four times. Cord milking should NOT be performed if the delay meets or exceeds 60 seconds.~Umbilical cord milking will not be provided among participant-infant dyads in the DCC-30 group."
223745118|NCT05053529|OTHER|Mirror therapy|Session consist of total 1hour,20 min of passive mobilization, 30 minutes for Movement mirror therapy,10 minutes standard ADL activities 5 times a week and for consecutive 3 weeks in a month.
223745119|NCT05053529|OTHER|CIMT group|Session consist of total 1hour ,20 min of passive mobilization, 30 min session to CIMT and 10 minutes standard ADL activities 5 times a week and for consecutive 3 weeks in a month.
223745120|NCT03808168|DRUG|Nivolumab|Protocol dose: 3mg/kg mg as a 30-minute IV infusion on Day 1 (Arm I) or Days 1, 15, 29 (Arm II).
224171946|NCT07102550|BIOLOGICAL|MiMedx AmnioFix|MiMedx Amniofix to be placed on biliary anastomosis of the recipient during living donor liver transplant.
224171947|NCT07100743|DIETARY_SUPPLEMENT|Probiotic Agent|HEXBIO MCP Granule probiotic is prepared in sachets which consist of the following probiotics: Lactobacillus acidophilus (BCMC 1 12130)107mg, Lactobacillus casei (BCMC 1 12313) -107mg, Lactobacillus lactis (BCMC 1 12451)-107 mg, (BCMC 1 02290) -107mg, Bifidobacterium infantis (BCMC 1 02129) -107mg and Bifidobacterium longum (BCMC 102120)-107mg
223745121|NCT04230512|OTHER|Pump prototype|Effects of pump function on gait
224171948|NCT07100743|DIETARY_SUPPLEMENT|Placebo|The placebo sachets will contain the same ingredient as the probiotic sachet but without the Lactobacillus sp. and Bifidobacterium sp. Participants in the placebo group will receive an identical Hexbio sachet (aluminum foil sachet.) with non-microbial material.
224171949|NCT01877005|DRUG|Ruxolitinib|
223483693|NCT04521296|OTHER|Part 1|\- DWJ1248 600mg PO (100mg 2 tab, TID)
223483694|NCT04521296|OTHER|Part 2|\- DWJ1248 600mg PO (200mg 1 tab, TID)
224171950|NCT07100652|PROCEDURE|Threshold FiO₂|"Group 1 (Intervention Group) received the initial dose of pulmonary surfactant immediately upon reaching an inhaled oxygen concentration (FiO₂) \>0.25.~Group 2 (Control Group) received the initial dose of pulmonary surfactant as early as possible within 48 hours, but only when FiO₂ was titrated to \>0.3 based on the infant's clinical condition."
224171951|NCT07102420|OTHER|Questionnaire and Physical Exam|Artificial Intelligence Anxiety Scale, Exercise Benefits/Barriers Scale
224171952|NCT07101614|DRUG|JS004 in combination with toripalimab and chemotherapy|"BTLA inhibitor (JS004):200mg, IV infusion , d1, Q3W;(1-24 week)~Toripalimab:240mg, IV infusion , d1, Q3W;(1-24 week)~Carboplatin: IV infusion,AUC=5, d1,q3w(OR AUC=1.5,d1,qw);(1-12 week)~Paclitaxel:IV infusion,80 mg/m2,qw;(1-12 week)~Doxorubicin:IV infusion,60 mg/m2,q3w(OR Epirubicin:IV infusion,90 mg/m2,q3w);(13-24 week)~Cyclophosphamide:IV infusion,600 mg/m2,q3w(13-24 week)"
224171953|NCT07101614|DRUG|Toripalimab and chemotherapy|"Toripalimab:240mg, IV infusion , d1, Q3W;(1-24 week)~Carboplatin: IV infusion,AUC=5, d1,q3w(OR AUC=1.5,d1,qw);(1-12 week)~Paclitaxel:IV infusion,80 mg/m2,qw;(1-12 week)~Doxorubicin:IV infusion,60 mg/m2,q3w(OR Epirubicin:IV infusion,90 mg/m2,q3w);(13-24 week)~Cyclophosphamide:IV infusion,600 mg/m2,q3w(13-24 week)"
224171954|NCT07101614|DRUG|Chemotherapy|"Carboplatin: IV infusion,AUC=5, d1,q3w(OR AUC=1.5,d1,qw);(1-12 week)~Paclitaxel:IV infusion,80 mg/m2,qw;(1-12 week)~Doxorubicin:IV infusion,60 mg/m2,q3w(OR Epirubicin:IV infusion,90 mg/m2,q3w);(13-24 week)~Cyclophosphamide:IV infusion,600 mg/m2,q3w(13-24 week)"
224171955|NCT07100795|OTHER|No Interventions|This is an observational study. No intervention will be administered. Participants will provide blood samples for micronutrient analysis.
224171956|NCT07100457|DIAGNOSTIC_TEST|Blood Biomarker Profiling and Prognostic Follow-up|Peripheral venous blood collection for in-vitro quantification of serum biomarkers (including octanal, OR6A2, and inflammatory mediators) via mass spectrometry/ELISA/flow cytometry, coupled with longitudinal surveillance of Major Adverse Cardiovascular Events (MACEs) using hospital records, patient interviews, and adjudicated endpoint verification during scheduled follow-up visits.
224171957|NCT07101861|BEHAVIORAL|Survivors RESET|16-session adaptation of the Diabetes Prevention Program Intensive Lifestyle Intervention plus stress management training
224171958|NCT07114276|OTHER|Machine learning models predictions of acute kidney injury and acute kidney disease|Comparison of the performances of machine learning models and clinicians in predicting AKI within 14 days and AKD within 89 days
224171959|NCT07132489|DIAGNOSTIC_TEST|HbA1c/C-peptide ratio Albumin-bilirubin (ALBI) score. Neutrophil/HDL ratio|"1. To investigate whether the HbA1c to C-peptide ratio can serve as a predictive marker for no-reflow, reflecting the impact of chronic glycemic control and pancreatic beta-cell function.~2. To evaluate the neutrophil-to-HDL ratio as a potential indicator of no-reflow, representing the balance between systemic inflammation and endogenous vascular protection.~3. To examine the prognostic value of the albumin-bilirubin (ALBI) score in identifying patients at higher risk for no-reflow, considering the systemic influence of hepatic function and inflammation."
224171960|NCT06933095|DIETARY_SUPPLEMENT|LPC-EPA+DHA capsules containing omega-3 fatty acids EPA and DHA esterified to lysophosphatidylcholine (LPC-EPA+DHA)(Trade name: Lysoveta)|apsules containing omega-3 fatty acids EPA and DHA esterified to lysophosphatidylcholine (LPC-EPA+DHA)(Trade name: Lysoveta)
224171961|NCT03384914|BIOLOGICAL|DC1 Vaccine|"Vaccination Phase: DC1 vaccine will be administered weekly via intranodal injection in weeks 1 to 6 (window 8-21days between vaccines).~Booster vaccines will be administered at approximately 3 month intervals on months 6, 9 and 12 (with a window +/- 1 month)."
224171962|NCT03384914|BIOLOGICAL|WOKVAC Vaccine|"Vaccination Phase: WOKVAC vaccine will be administered via intradermal injection on weeks 1, 4 and 7 (window +21 days).~Booster vaccines will be administered at approximately 3 month intervals on months 6, 9 and 12 (with a window +/- 1 month)."
224171963|NCT05505669|OTHER|One-time blood (up to 100 ml) will be drawn and the amount of blood drawn is based on weight. Saliva and urine will be collected during the blood draw visit.|One-time blood (up to 100 ml) will be drawn and the amount of blood drawn is based on weight. Saliva and urine will be collected during the blood draw visit.
224171964|NCT07140224|OTHER|Korfball-Based Movement Training|"The weekly training content was structured as follows:~* Week 1: Chest pass, overhead pass, right-left hand pass, moving pass, cool-down (15 repetitions).~* Week 2: One-handed pass, penalty shot, defensive follow-up run, lay-up shot, cool-down (20 repetitions).~* Week 3: One-handed pass, diagonal passing, penalty shot, lay-up shot, short and long-distance shooting (25 repetitions).~* Week 4: Lay-up shot, V-cut shot, stationary short-distance shot, defensive follow-up run,penalty shot, cool-down (20 repetitions).~* Week 5: V-cut shot, stationary short-distance shot, front-of-the-basket shot, behind-the-basket short-distance shot (15 repetitions).~* Week 6: V-cut shot, lay-up shot, stationary shot, defensive follow-up run, penalty shot (20 repetitions).~* Week 7: One-handed pass, penalty shot, lay-up shot (right-left), shooting, V-cut shot (10 repetitions).~* Week 8: One-handed pass penalty shot, lay-up shot (right-left), stationary shot, V-cut shot (10 repetitions)."
223585781|NCT00443781|PROCEDURE|functional anesthetic discography|Functional Anesthetic Discography (F.A.D.) involves the placement and anchoring of a small catheter into a disc. After placement, functional testing is performed, in which the subject elicits his/her back pain via functional maneuvers or postures. Local anaesthetic is then delivered into the target disc through the catheter and the effect on functional back pain is noted.
223585782|NCT00443781|PROCEDURE|provocative discography|"Provocative discography (PD) has been used as a preoperative diagnostic tool for patients with back pain attributed to degenerative disc disease considering lumbar disc surgery. During PD, a clinically suspected disc is accessed with a needle and injected under pressure with radiopaque contrast dye. The subject rates his/her experience of pain for intensity and whether the pain is exactly the same as (concordant) or different from (not concordant or discordant) typical back pain."
223585783|NCT02066415|BIOLOGICAL|Erenumab|Administered once a month subcutaneously by authorized investigational site study staff.
223585784|NCT02066415|DRUG|Placebo|Administered once a month subcutaneously by authorized investigational site study staff.
223585785|NCT05105113|PROCEDURE|Zirconia dental implant installation surgery|Dental implant installation surgery using zirconia one-piece implant (Tav-dental)
223745122|NCT01757119|DRUG|Tardyferon 80 mg|Oral administration (2 tablets)
223745123|NCT05619718|BEHAVIORAL|Awareness, Courage, and Love Groups|Groups based on the Awareness, Courage, and Love framework from functional analytic psychotherapy
224171965|NCT07137767|DEVICE|Quantitative refractive crosslinking|Non-invasive corneal crosslinking device delivering controlled UV light through a contact lens platform for refractive reshaping of the cornea.
223483695|NCT04521452|DRUG|Evogliptin|Subjects will receive evogliptin 5 mg daily
224171966|NCT06939946|DEVICE|Parathyroid auto-fluorescence imaging|All enrolled patients for thyroid surgery, once the thyroid gland is removed the device will be used to identify the parathyroid glands.
224171967|NCT06939946|DRUG|Indocyanine green|For a select group of patients when deemed necessary by the surgeon, and when one or more parathyroid gland appear to be de vascularized ICG will be administered, A dosage of 5 mg will be injected into a peripheral IV line, followed by fluorescence imaging to determine the perfusion status of the gland.
224171968|NCT07149051|BEHAVIORAL|Gamified Sensory Integration Exercise Program|This study implemented a gamified physical activity intervention aimed at improving sensory integration abilities among first-grade students with sensory processing difficulties. The intervention program incorporated game narratives, mechanisms, and components into physical education activities, guided by the Octalysis Framework to strategically engage both extrinsic (e.g., rewards, rankings) and intrinsic (e.g., creativity, social interaction, meaning) motivational drives.
224171969|NCT07148843|DRUG|Cannabidiol (CBD)|Cannabidiol
224171970|NCT07148843|DRUG|Placebo|placebo
224171971|NCT07148466|OTHER|Scapular PNF|scapular PNF coupled with upper limb PNF and conventional physiotherapy treatment . It was a 6 week's intervention in which patients got treatment protocol for 30 mints 5 times a week.
224171972|NCT07148466|OTHER|Conventional treatment|Conventional treatment. It includes closed kinematic chain exercises of upper limb, upper and lower extremity range of motion exercises, stretching and strengthening exercises for upper limb, trunk and lower limb, balance \& coordination, manual dexterity exercises (e.g., grasp release), and teaching of ADLs.. It was a 6 week's intervention in which patients got treatment protocol for 30 mints 5 times a week.
223483696|NCT03265964|DRUG|Uridine|Uridine is the active treatment in this clinical trial.
223483697|NCT03265964|DRUG|Placebo|Pill placebo is the inactive treatment comparator in this clinical trial.
223483698|NCT05251428|PROCEDURE|Excision of the A1 pulley|Participants will undergo excision of the A1 pulley. Wounds will then be irrigated and closed in the standard fashion.
223483699|NCT05251428|PROCEDURE|Incision of the A1 pulley in the standard fashion|Participants will undergo incision of the A1 pulley in the standard fashion. Wounds will then be irrigated and closed in the standard fashion.
224171973|NCT07147452|PROCEDURE|Dual tracer: The infiltration of the Supermagnetic Iron Oxide (SPIO) and Methylene Blue|"Participation in the study did not alter the indications or standard surgical technique. The only additional intervention consisted of intraoperative administration of SPIO, performed either laparoscopically or conventionally, as appropriate.~Immediately after removal of the surgical specimen : Submucosal instillation of methylene blue was then performed at the tumour periphery"
223483700|NCT06172660|DRUG|Nirsevimab|Immunoprophylaxis against RSV
223483701|NCT04476043|DRUG|INCB054707|Oral; Tablet
223483702|NCT04476043|DRUG|Placebo|Oral; Tablet
223483703|NCT00223574|DRUG|Control - high carbohydrate, high glycemic index foods|
223483704|NCT00223574|DRUG|high carbohydrate, low glycemic index foods|
224171974|NCT07147452|DIAGNOSTIC_TEST|OSNA AND H-E|Analysed the performance of one-step nucleic acid amplification (OSNA) versus conventional histology and applied pooling analysis with OSNA in non-sentinel nodes
224171975|NCT07147491|DEVICE|Electrically Powered Orthopedic Exercise Device|Participants who pass the screening undergo an evaluation of gait function and balance ability without wearing the Electrically Powered Orthopedic Exercise Device. Afterward, the patient wears the motorized orthopedic exercise device for a total of four adaptation sessions. In each session, the patient performs short-distance walking within 10 meters while wearing the device to explore the appropriate assistive mode and level of support that match their physical condition. No evaluations are conducted while wearing the device during sessions 1, 2, and 3. After the 4th session, an evaluation identical to the one conducted without the device is performed while wearing it, and a satisfaction survey is conducted.
224171976|NCT07147179|RADIATION|Short Course Radiotherapy|Participants will receive a shorter course of radiation therapy across 5 days (20 Gray in 5 fractions).
224171977|NCT07147426|DRUG|Tislelizumab Combined With Chemotherapy for 4 cycles|Tislelizumab: 200mg, day 1, every 3 weeks for 4 cycles Cisplatin: 75mg/m\^2 Nab-paclitaxel: 260mg/m\^2
224171978|NCT07147426|DRUG|Tislelizumab Combined With Chemotherapy for 2 cycles|Tislelizumab: 200mg, day 1, every 3 weeks for 2 cycles Cisplatin: 75mg/m\^2 Nab-paclitaxel: 260mg/m\^2
224205462|NCT01421524|DRUG|CC-122|One or more intermittent schedules of CC-122 either given 5 continuous days out of 7 per week (5/7 days) or 21 continuous days out of 28 days per cycle (21/28 days). Following dose escalation, one or more of these intermittent schedules will be evaluated at a starting dose of 4 mg.
223585786|NCT02767739|BEHAVIORAL|Physical, social and cultural activities|This intervention included two 60-min aerobic exercise sessions per week. Each session was supervised by a physical activity specialist and walking and stretching exercises were performed after programmed exercise sessions. PHC nurses were prepared to advise patients about the health benefits of PA and used different strategies to encourage the adherence of participants to the program. In addition, social and cultural support activities were included in this intervention program. These activities were performed once a month and they included: visits to museums and libraries, cultural exhibitions, tourist attractions and dance lessons.
223483705|NCT00223574|DRUG|low carbohydrate, high monounsaturate fat foods|
223483706|NCT00211367|DRUG|Anecortave Acetate|
223483707|NCT05592366|BEHAVIORAL|Care Partner Hospital Assessment Tool|Complete the adjusted CHAT as well as demographic and caregiving questionnaires during and after loved one's hospitalization.
223483708|NCT03170297|OTHER|Research interventions of blood sampling and data collection|Patient-Specific Functional Scale (PSFS) survey will be administered to patients to record symptoms at both the time of evaluation in the emergency department and in follow up by phone at 3, 7, 14, 21 and 28 days after discharge from the emergency department or hospital. The rest of the patients' care will be as usual care, and patients will have had research interventions of blood sampling and data collection as noted in the previously approved SC2i Tissue Data Acquisition Protocol (TDAP) Pro00054947 (ClinicalTrial.gov ID: NCT02182180).
224171979|NCT07148258|OTHER|Project ImPACT Training As Usual|"Project ImPACT is an evidence-based autism intervention that teaches parents to use a blend of developmental and naturalistic behavioral intervention techniques across a variety of daily routines to enhance their child's social engagement, language, imitation, and play skills.~The typical training model for Project ImPACT includes a 6-hour, interactive online tutorial that walks providers through the core Project ImPACT intervention strategies. After completing the online tutorial, providers attend a live interactive workshop virtually that is spread across 4, 3.5-hour days (14 hours total). Providers receive 1 hour of consultation once every other week for an hour from a trained Project ImPACT consultant (research staff member) following training."
224171980|NCT07148258|OTHER|Project ImPACT Training Plus Co-Production|"Project ImPACT is an evidence-based autism intervention that teaches parents to use a blend of developmental and naturalistic behavioral intervention techniques across a variety of daily routines to enhance their child's social engagement, language, imitation, and play skills.~The second cohort for Project ImPACT training is a model in which providers receive the same typical Project ImPACT training activities, in addition to three supplemental modules on other common areas of concern for families and how best to integrate other topics within Project ImPACT to meet the diverse needs of families."
224171981|NCT07148258|BEHAVIORAL|Routine Project ImPACT|Project ImPACT is an evidence-based autism intervention that teaches parents to use a blend of developmental and naturalistic behavioral intervention techniques across a variety of daily routines to enhance their child's social engagement, language, imitation, and play skills. Project ImPACT is delivered with parents meeting once or twice each week for one hour over 12- 16 weeks. In each session, parents receive: 1) didactic instruction in intervention strategies; 2) modeling of the intervention techniques by the therapist; 3) live coaching from the therapist while practicing the strategies with their child; and 4) homework to practice the strategies at home with their child, 20 minutes each day across meaningful home routines.
224171982|NCT07147387|BEHAVIORAL|Lion Hearts Family-Based Physical Activity Program|The Lion Hearts Family-Based Physical Activity Program is a 12-week, community-based intervention designed to improve cardiovascular health and physical activity behaviors among mother-child dyads. The program consists of twice-weekly, 60-minute group exercise sessions delivered at local CrossFit affiliates. Each session includes scalable functional movement exercises, strength training, cardiovascular conditioning, and flexibility activities appropriate for both adults and children. In addition to physical activity, sessions incorporate goal-setting, family teamwork activities, and health education components to promote sustainable behavior change. The program was co-designed with community members during earlier study phases and is tailored to support engagement, feasibility, and family bonding.
224171983|NCT07148453|OTHER|Experimental Group|The experimental group will receive training through a smartphone-based brain training program using the Lumosity app, as well as aerobic exercise on a bicycle ergometer for 18 sessions other days for 6 weeks, 3 times per week, every session for 40 minutes (20 minutes aerobic training on a stationary bicycle ergometer followed by 20 minutes for Lumosity training application on the smartphone).
223483709|NCT03967834|OTHER|Patient with Soft Tissue Sarcoma|"* Tumor specimens will be collected for the study at diagnosis.~* A blood sample will be collected in all included patients at baseline, after the completion of the treatment (for patients included with a localized disease) or at the time of the first tumoral evaluation (for patients included with a metastatic disease), and at the time of progression.~* Patient's data (clinical, biological and disease data) will also be collected at baseline visit and then at each time point planned in the center for clinical benefit assessment (i.e. every 2 or 3 months) until progression or for a maximum duration of 5 years."
223483710|NCT06217380|DEVICE|Masimo SafetyNet Alert (MSNA)|This study will explore the feasibility of implementing the Masimo SafetyNet Alert (MSNA) oxygen saturation monitoring system and the acceptance of MSNA by individuals living in a supportive housing program, who inject opioids.
223483711|NCT04539236|DRUG|Lenalidomide|Administered daily by mouth on a 21 day cycle. Doses will be administered at 2.5 mg, 5 mg and 10 mg.
223483712|NCT04539236|DRUG|Luspatercept|Administered subcutaneously in the upper arm, thigh and/or abdomen on Day 1 of a 21 day cycle. Starting dose will be at 1.0 mg/kg and can be titrated, dependent on participant response, to doses of 1.33 mg/kg, and 1.75 mg/kg.
223483713|NCT04109963|DEVICE|Remote ischemic conditioning|Remote ischemic conditioning therapy to the upper arm will be delivered by an automated device (RIC VCI) manufactured by Seagull Aps (Denmark).
223483714|NCT05539170|BEHAVIORAL|Immediate positive parenting feedback|Individual positive feedback concerning their parenting and their child's behavior.
223483715|NCT06582524|DRUG|Pegzilarginase|SC administration of pegzilarginase over 12 weeks in subjects with ARG1-D who are \< 24 months of age
223483716|NCT05205811|DRUG|Bupropion|Extended-release bupropion dosing (150 mg each morning days 1-3, then 300 mg/daily) for the remainder of the 7 weeks.
223483717|NCT05205811|DRUG|Zonisamide|Zonisamide (100 mg/daily) for 7 weeks.
223483718|NCT05205811|DRUG|Placebo bupropion|Placebo bupropion for 7 weeks.
223483719|NCT05205811|DRUG|Placebo zonisamide|Placebo zonisamide for 7 weeks.
223483720|NCT05205811|OTHER|E-cigarette|e-cigarette for ad libitum use for two weeks prior to complete switch day and for an additional 10 weeks.
223483721|NCT03054896|DRUG|Venetoclax|Venetoclax is an Antineoplastic Agent; BCL-2 Inhibitor
223483722|NCT03054896|OTHER|DA-EPOCH-R|Intensive chemotherapy regiment
223483723|NCT03054896|OTHER|R-CHOP|Intensive chemotherapy regiment
223483724|NCT04848961|BEHAVIORAL|LungTalk|MSK developed LungTalk, a novel computer-tailored health communication and decision support tool to (1) increase awareness and knowledge about lung screening; (2) decrease perceived barriers to screening based upon misinformation; and (3) increase screening rates.
223483725|NCT02912312|RADIATION|Hypofractionated Radiation Therapy|Undergo hypofractionated RNI
223483726|NCT02912312|OTHER|Laboratory Biomarker Analysis|Correlative studies
223483727|NCT02912312|OTHER|Quality-of-Life Assessment|Ancillary studies
223483728|NCT02912312|OTHER|Questionnaire Administration|Ancillary studies
223483729|NCT02912312|RADIATION|Radiation Therapy|Undergo standard RNI
223483730|NCT00005584|BIOLOGICAL|bleomycin sulfate|
223483731|NCT00005584|DRUG|ABVD regimen|
223483732|NCT00005584|DRUG|BEACOPP regimen|
223483733|NCT00005584|DRUG|epirubicin hydrochloride|
223483734|NCT00005584|DRUG|prednisone|
223483735|NCT00005584|DRUG|vinblastine sulfate|
223585787|NCT01120795|DRUG|Pegylated interferon and ribavirin|Pegylated interferon 180 ug subcutaneous per week Ribavirin 1000-1200 mg /day for genotype 1 and 800 mg /day orally for genotype non 1 Duration: 48 weeks for genotype 1 and 24 weeks for gentoype non 1
223585788|NCT01120795|DRUG|Pegylated interferon and ribavirin|Pegylated interferon 180 ug/ week subcutaneously Ribavrin 1000-1200 mg /day for genotype 1 and 800 mg/day orally for genotype 2 and 3 Treatment duration 48 weeks for genotype 1 and 24 weeks for genotypes 2 and 3
223745124|NCT05619718|OTHER|Mutual Help Meetings|Groups based on treatment as usual where patients gather to discuss how they can help others on the ward, and make requests for how others can help them.
223745125|NCT06073951|OTHER|Best Practice|Receive usual care
223745126|NCT06073951|OTHER|Exercise Counseling|Receive walking step goals
223745127|NCT06073951|OTHER|Exercise Intervention|Participate in Mates in Motion program
223745128|NCT06073951|OTHER|Medical Device Usage and Evaluation|Wear Actigraph
223745129|NCT06073951|OTHER|Medical Device Usage and Evaluation|Wear Garmin activity tracker
223745130|NCT06073951|OTHER|Physical Performance Testing|Undergo walk-test
223483736|NCT00005584|RADIATION|radiation therapy|
223483737|NCT06633965|DEVICE|AIDANET|AIDANET is a fully automated, utilizing a Bolus Priming System (BPS) that recognizes meal ingestion and delivers a quick priming dose of insulin prior to extreme blood sugar excursions.
223483738|NCT06633965|DEVICE|AIDANET|AIDANET is a fully automated, utilizing a Bolus Priming System (BPS) that recognizes meal ingestion and delivers a quick priming dose of insulin prior to extreme blood sugar excursions.
223483739|NCT04661904|DEVICE|Continuous theta burst stimulation (cTBS)|Our active treatment consisted of 600 pulses per session, delivered over the right dorsolateral prefrontal cortex at 80% of resting motor threshold (RMT). Every session cTBS consists of 50 Hz triplets of pulses delivered at 5 Hz for 40 seconds for a total of 600 pulses. Every set simulation includes 3 sessions. All enrolled patient in the cTBS group received 1 set simulation per day with an intersession interval (ISI) of over 30 minutes during the hospitalization after the surgery. The first set of stimulation was given at 4 hours after the end of surgery on the day of surgery. The other sets of stimulation were given at 8 am, 8:30 am and 9:00 am on postoperative day 1and 2, respectively.
223483740|NCT04661904|DEVICE|Sham stimulation|The sham stimulation group received a sham cTBS (600 pulses per session, 3 sessions per day, ISI ≥ 30mins, 3 days) with the coil set at 90 against the skull. The first set of stimulation was given at 4 hours after the end of surgery on the day of surgery. The other sets of stimulation were given at 8 am, 8:30 am and 9:00 am on postoperative day 1 and 2, respectively.
223483741|NCT06529159|PROCEDURE|HEAPE|The stomach is filled with sodium chloride solution which is then treated with APC to activate it into an antibacterial solution.
223483742|NCT06529159|PROCEDURE|Pre-HEAPE|Plasma activated sodium chloride solution (prepared outside of the body) is administered into the patients stomach through an endoscope channel using a syringe.
223585789|NCT01557959|DRUG|cisplatin|Given IV
223585790|NCT01557959|BIOLOGICAL|pegfilgrastim|Given SC
223585791|NCT01557959|DRUG|erlotinib hydrochloride|Given PO
223585792|NCT01557959|OTHER|laboratory biomarker analysis|Optional correlative study
223585793|NCT01557959|GENETIC|polymorphism analysis|Correlative study
223585794|NCT01557959|OTHER|pharmacogenomic studies|Correlative study
223585795|NCT01557959|GENETIC|genetic linkage analysis|Correlative study
223585796|NCT01557959|DRUG|docetaxel|Given IV
223585797|NCT01019837|BIOLOGICAL|Focetria (Monovalent MF59-Adjuvanted vaccine)|Biological: Focetria (Monovalent MF59-Adjuvanted vaccine)
223585798|NCT05690750|OTHER|No intervention|No intervention as this is an observational study.
223585799|NCT00888641|PROCEDURE|Hypothermia|Surround kidney in ice slush for 10 minutes after arterial clamping
223585800|NCT05276895|DIETARY_SUPPLEMENT|Quercetin and Fisetin tab.|1250 mg/day quercetin + 1000mg/day Fisetin for 3 consecutive days every 3 weeks over 15 weeks .
223585801|NCT05276895|DIETARY_SUPPLEMENT|Quercetin Cap/Tab,Fisetin Cap/tab and Glycyrrhizin capsules|quercetin + Fisetin for 3 consecutive days followed by 100mg/day glycyrrhizin for one week every 3 weeks over 15 weeks
223585802|NCT05276895|OTHER|Placebo|Placebo capsule for one week every 3 weeks over 15 weeks
223585803|NCT01012921|DEVICE|barrier membrane|The in situ forming gel serves as a barrier membrane for Guided Bone Regeneration (GBR).
223585804|NCT01012921|DEVICE|MembraGel|Device application at surgery
223585805|NCT01012921|OTHER|Bio-Gide® membrane|Device application at surgery
223585806|NCT02334397|BEHAVIORAL|Total Control Program|Women will be enrolled in Total Control, which is a fitness and education program.
223585807|NCT01072825|OTHER|questionnaires|a descriptive questionnaire, SF-36, , bone questionnaires, Baecke physical activity questionnaire, voice evaluation
223745131|NCT06073951|OTHER|Questionnaire Administration|Complete questionnaires
223745132|NCT05734443|BEHAVIORAL|step training|Participants practice volitional and reactive stepping responses that mimic those needed when recovering balance after tripping.
224171984|NCT07148453|OTHER|Control Group|The control group will participate in aerobic training on a bicycle ergometer as well as mental exercises for 18 sessions every other day for 6 weeks, 3 sessions/week, each for 40 minutes
224171985|NCT07147400|BIOLOGICAL|10µg of R21 with 50µg Matrix-M1|R21 is a portion of Pf circumsporozoite protein fused with hepatitis B surface antigen in the form of non-infectious virus-like particles (VLPs) produced in yeast cells (Hansenula) by recombinant DNA technology. Matrix-M1 (Adjuvanted) is cGMP manufactured by Serum Institute of India, PVD, LTD (SIIPL), Pune.
224205463|NCT01421524|DRUG|CC-122|Dose escalation on a continous schedule will be evaluated at a starting dose of 4 mg. Specifically, dose levels with 1 mg increments (eg 4mg, 5mg, 6mg etc.) will be evaluated using a 3+3 design as detailed in Part A of the protocol .
224171986|NCT07147400|BIOLOGICAL|6µg of Pfs230D1-CRM197 + 10µg of R21 with 50µg Matrix-M1 single vial coformulation|"R21 Malaria antigen is expressed in a recombinant high expressing Hansenula polymorpha production strain. The R21 Malaria drug substance lots/batches were cGMP manufactured at SIIPL, India.~Recombinant CRM197 is a recombinant protein, and its drug substance lots/batches cGMP manufactured using Pseudomonas fluorescens production strain at SIIPL, India.~Recombinant Pfs230D1M drug substance lots/batches of cGMP were manufactured using Hansenula Polymorpha and manufactured at the SIIPL.~A single vial coformulation containing 10µg R21 and 6µg Pfs230D1-CRM197 conjugate mixed with 50µg Matrix-M1 has been developed and is manufactured by SIIPL."
224171987|NCT07147400|BIOLOGICAL|RABIVAX-S|Sterile, purified inactivated rabies vaccine prepared on vero cells, indicated for the prevention of rabies in children and adults.
224171988|NCT07147400|BIOLOGICAL|Conjugated Pfs230D1 Vaccine (Pfs230D1-CRM197) For Bedside Mixing|"Recombinant Pfs230D1M drug substance lots/batches cGMP manufactured using Pichia pastoris manufactured at the Pilot Bioproduction Facility, Walter Reed Army Institute of Research (Silver Spring, Maryland), and at SIIPL respectively.~Recombinant CRM197 is a recombinant protein and its drug substance lots/batches cGMP manufactured using Pseudomonas fluorescens production strain at SIIPL, India."
224171989|NCT07147400|BIOLOGICAL|R21 Malaria Vaccine (Recombinant) For Bedside Mixing|R21 is a fusion protein of hepatitis B surface antigen (HBsAg) to the C-terminus and central repeats of the circumsporozoite (CS) protein of Plasmodium falciparum. R21 VLP, recombinant HBsAg spontaneously self-assembled \& formed a virus-like particle, wherein circumsporozoite protein (CSP) from Plasmodium falciparum is presented on the VLP of recombinant HBsAg particles. R21 Malaria antigen expressed in recombinant high expressing Hansenula polymorpha production strain. The R21 Malaria drug substance lots/batches were cGMP manufactured at SIIPL, India.
224171990|NCT07147400|BIOLOGICAL|MATRIX-M1 (Adjuvant) For Bedside Mixing|active ingredient in Matrix-M1 are saponin-based fractions. Matrix-M1 has a ratio of Matrix-A and Matrix-C of 85:15 (by weight). Both Matrix-A and Matrix-C are individual fractions (separated by chromatography) derived from extracts from the Quillaja saponaria tree. Matrix-M1 (Adjuvanted) is cGMP manufactured by Serum Institute of India, PVD, LTD (SIIPL), Pune.
224171991|NCT07147270|OTHER|side to side and front to back rotation 30 minutes each|side to side and front to back rotation 30 minutes each after pleurodesis
224171992|NCT07148388|DEVICE|Repetitive transcranial magnetic stimulation|Patients in the AiTBS group received 5 consecutive days of AiTBS treatment, with 6 sessions of iTBS interventions per day (1800 pulses per trial, with a 50-minute interval between trials). Patients in the 10Hz rTMS group received 10 consecutive days of 10Hz rTMS treatment within 10 days, with 1500 pulses per day, totaling 15 minutes.
224171993|NCT07147205|OTHER|Therapy|MCGP will be delivered in 8 weekly sessions for 90 minutes over Zoom by a licensed doctoral level psychologist.
224171994|NCT07147218|DEVICE|TMS|transcranial magnetic stimulation - DASH 36 treatment delivered in 5 days
224171995|NCT07149012|OTHER|Artificial Intelligence Awareness and Feasibility Assessment|"A sequential explanatory mixed-methods assessment of surgeons' awareness, readiness, and perceived barriers to adopting artificial intelligence in surgical care during the ongoing Sudan conflict. The intervention consisted of:~A validated, structured online questionnaire adapted from established AI awareness tools, assessing familiarity, perceived benefits, barriers, and ethical concerns.~Semi-structured interviews with senior surgical residents and consultants to explore contextual and ethical perspectives in greater depth.~The study did not implement AI tools in practice but focused on measuring feasibility and identifying requirements for future AI deployment in conflict-affected surgical systems."
224171996|NCT07148544|OTHER|Sedo analgesia protocol|Nurse-Controlled Sedo-Analgesia Protocol
224171997|NCT07148544|OTHER|control group|The clinic's routine sedation analgesia management plan will be implemented.
224171998|NCT07147907|DEVICE|Chest Worn Respiratory Rate Monitor|The Perin Health Patch is a non-invasive, chest-worn wearable device designed to continuously monitor physiological signals, including respiratory rate and other health metrics. In this study, the device will be evaluated for its ability to accurately measure respiratory rate during controlled breathing exercises in healthy adult volunteers. The respiratory rate values recorded by the Perin Health Patch will be compared against respiratory rate measurements obtained via manually scored end tidal carbon dioxide (EtCO2) waveforms from a GE Datex-Ohmeda monitor, following Element Laboratory protocols aligned with clinical validation standards. The intervention in this study is limited to the application and use of the device for data collection during controlled respiratory rate conditions, where participants perform paced breathing exercises at various rates (5-50 breaths per minute) using a breathing app while positioned sitting or lying supine.
224171999|NCT07148739|DRUG|Elexacaftor / Ivacaftor / Tezacaftor|This study will examine different dosing strategies and outcomes for triple combination CFTR modulator therapy using the drug(s) elexacaftor, tezacaftor, and/or ivacaftor in patients with cystic fibrosis.
224172000|NCT07148739|OTHER|therapeutic drug monitoring|Participants who consent to the therapeutic drug monitoring study will have their dose adjusted to remain within estimated effective concentrations.
224172001|NCT07147608|OTHER|actimeter wearing|actimeter wearing during 7 days : recording of physical activity over 7 days using a non-invasive external sensor
223483743|NCT05581030|DRUG|Hyper CVAD Protocol (Standard of Care Multi-Agent Chemotherapy)|"Hyper-CVAD consists of two combinations of drugs (courses A and B) given in an alternating fashion. The term hyper refers to the hyperfractionated nature of the chemotherapy, which is given in small doses, more frequently, to minimize side effects. CVAD is the acronym of the drugs in course a: cyclophosphamide, vincristine, doxorubicin and dexamethasone.~Course A: Cyclophosphamide days 1, 2 and 3. Vincristine days 4 and 11, Doxorubicin day 4, dexamethasone days 1-4 and 11-14, Cytarabine day 7. Mesna is also given orally with cyclophosphamide, to reduce the incidence of haemorrhagic cystitis, a common side effect of cyclophosphamide. Methotrexate, an antimetabolite, may be given when necessary to get chemotherapy past the blood brain barrier.~Course B: Methotrexate Day 1 and Cytarabine Days 2 and 3. Dosage is individualized to the patient."
223483744|NCT05581030|DRUG|Calaspargase Pegol|Calaspargase pegol 2000 IU/m\^2 (capped at 3750 IU) will be administered beginning in cycle 1B of Hyper-CVAD, and will continue at this dose for the duration of the trial.
224172002|NCT07147608|OTHER|physical activities questionnaires|IPAQ and SAPHIR questionnaires
224172003|NCT07148102|DEVICE|Diaphragmatic US|Diaphragmatic thickening fraction (DTF) and diaphragmatic excursion (DE) were measured by ultrasound within the first three hours of life and repeated either 24 hours later in successful cases or immediately before intubation in cases who had NIV failure.
224172004|NCT07148102|DEVICE|EC|TFC was assessed using electrical cardiometry (EC). Measurements were obtained within the first three hours of life and repeated either 24 hours later in successful cases or immediately before intubation in cases who had NIV failure.
224172005|NCT07148427|DRUG|Iparomlimab and Tuvonralimab combination with regorafenib and chemotherapy|Iparomlimab and Tuvonralimab：5mg/kg，Intravenous infusion，Q3W regorafenib：80mg，oral administration once daily from Day 1 to Day 14 chemotherapy：XELOX or SOX
224172006|NCT06949514|OTHER|guided imagery|Participants in this group will receive the guided imagery intervention. They will be approached after being hospitalized for at least 24 hours. The guided imagery audio recording will be played for the pregnant women every evening before sleep for three consecutive days.
224172007|NCT06948955|DRUG|Bezuclastinib|Drug: Bezuclastinib
224172008|NCT06948955|DRUG|Sunitinib|Drug: Sunitinib (locally sourced)
224172009|NCT06951165|BEHAVIORAL|Parent Supported Psychosocial Development Programme|A six-module online program was developed for parents of children ages 1 to 3. The program was provided to parents as a PDF, one module per week, and each module was discussed online.
224172010|NCT07149194|OTHER|CBC derived markers|CBC derived markers against CRP and ESR in detecting active Rheumatoid arthritis
224172011|NCT07149233|DEVICE|Inspiratory Muscle Training|Inspiratory muscle training (IMT) was performed for 4 weeks in patients with moderate to severe OSA. The intervention group used a threshold device with resistance: training occurred twice daily, 7 days per week, with 3 sets of 30 fast inspiratory efforts and 1-minute rest between sets. Load started at 50% of maximal inspiratory pressure (MIP), increased to 60% in week 3, and 75% in week 4. Weekly visits were held for load adjustment. The sham group followed the same schedule using the same device without resistance (spring removed). Both groups recorded adherence in training diaries and received daily follow-up calls from the principal investigator
224172012|NCT07149168|DRUG|Dexmedetomidin|The PENG block will be performed using a mixture of 0.25% bupivacaine (1.25 to 2.5 mg/kg.) combined with dexmedetomidine at a dose of 1.25 mcg/kg
224172013|NCT07149168|DRUG|Bupivacain|a typical dose of 0.5% hyperbaric bupivacaine ranges from 0.1 to 0.15 mg/kg (2 to 3 mL), depending on the patient's height and clinical condition. Lower doses are used for shorter or elderly patients, while taller patients may require higher doses
224172014|NCT07147985|BEHAVIORAL|162 step frequency|The exercise protocol lasted 21 minutes, comprising a 10-minute period of slow-pace running, preceded by a 3-minute quiet resting period and a 3-minute warm-up, and followed by a 5-minute recovery period after the warm-up and slow-pace running. 162 steps per minute crossover to 180 steps per minute and 198 steps per minute.
224172015|NCT07147985|BEHAVIORAL|180 step frequency|The exercise protocol lasted 21 minutes, comprising a 10-minute period of slow-pace running, preceded by a 3-minute quiet resting period and a 3-minute warm-up, and followed by a 5-minute recovery period after the warm-up and slow-pace running. 180 steps per minute crossover to 162 steps per minute and 198 steps per minute.
224172016|NCT07147985|BEHAVIORAL|198 step frequency|The exercise protocol lasted 21 minutes, comprising a 10-minute period of slow-pace running, preceded by a 3-minute quiet resting period and a 3-minute warm-up, and followed by a 5-minute recovery period after the warm-up and slow-pace running. 198 steps per minute crossover to 162 steps per minute and 180 steps per minute.
224172017|NCT07149116|DEVICE|Tracheostomy sealing|A non-classified silicone-based prototype device designed to temporarily seal the tracheostomy tract from within the airway for up to 7 days after decannulation.
224172018|NCT07148570|OTHER|Nursing Care Based on Kolcaba's Comfort Theory|Delivery Room Nursing Care Based on Kolcaba's Comfort Theory
224172019|NCT07100223|OTHER|EDUCATION|"Assignment to the intervention and control groups will be made by randomization method.~Before training is given to the intervention and control groups, Parental Introduction Form, Conscious Awareness Scale, Prenatal Attachment Scale, Prenatal Attachment Scale, Fathers' Fear of Birth Scale, Wijma Birth Expectation/Experience Scale Version A will be applied.~After parents attend a 1-week birth preparation training at Kayseri City Hospital Pregnancy School, they will participate in a 9-week Awareness-Based Parenting and Birth Preparation Training.~After the training is completed; Conscious Awareness Scale, Prenatal Attachment Scale, Prenatal Attachment Scale, Fathers' Fear of Birth Scale, Wijma Birth Expectation/Experience Scale Version A will be applied.~Wijma Birth Expectation/Experience Scale Version B will be administered to mothers on the 1st postpartum day."
224172020|NCT07148908|DIETARY_SUPPLEMENT|Yeast Protein Supplement|Each protein will be consumed at 0.9g/kg/d in n=8 hourly drinks
224172021|NCT07148908|DIETARY_SUPPLEMENT|Whey Protein Isolate Supplement|Each protein will be consumed at 0.9g/kg/d in n=8 hourly drinks
224172022|NCT07148908|DIETARY_SUPPLEMENT|Collagen Hydrolysate Supplement|Each protein will be consumed at 0.9g/kg/d in n=8 hourly drinks
224172023|NCT07147569|DEVICE|GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis|The target patients are those who were attempted to implant the AC during the enrollment period of this surveillance. Patients will also be targeted even if all components of the TAMBE device (devices that can be used in combination with AC specified in IFU) were not used, or if a device other than the component of the TAMBE device was used.
223483745|NCT05581030|DRUG|Rituximab|Rituximab 375mg/m\^2 will be administered once per cycle for patients with CD20+ ALL.
223483746|NCT06257550|BEHAVIORAL|THRIVE Intervention|"THRIVE Intervention includes:~1. Weekly Pulse Surveys~2. Adaptive culturally tailored messages~3. Personalized Dietitian Coaching~4. Produce Prescription FARMacy Mobile Market~5. Linkages to Social Services"
223483747|NCT06257550|BEHAVIORAL|Active Comparator|The Active Comparator arm will receive standard produce bags through our food is medicine partner, and will receive the linkages to needed social and health resources intervention components.
223745133|NCT05734443|BEHAVIORAL|treadmill training|Sudden treadmill changes in speed (from standing) induce trip-like losses of balance, after which participants take steps to recover balance and establish a stable gait pattern. This is repeated over a range of speeds to both provide training variability and to individualize training to each participant's capability.
223483748|NCT04917575|OTHER|Mobile Game|An enhanced life-simulation prototype of a playable interactive game to increase HIV testing.
224172024|NCT07148674|DEVICE|Positive Expiratory Pressure (10cmH2O) in hypobaric hypoxia|The intervention under investigation will be the application of positive expiratory pressure (PEP) at 10 cmH₂O using an Ambu mask. The mask will allow participants to inspire freely while generating a controlled expiratory pressure. The PEP device is a non-pharmacological medical device whose uses in both hospital and pre-hospital settings are part of everyday medical practice.
224172025|NCT07147842|DRUG|Rutin 500 MG|Rutin 500 mg capsules twice daily for 30 days
223483749|NCT04917575|OTHER|Mobile Application|A mobile application that will include basic information on HIV basics (e.g., routes of transmission, data on the epidemiology of HIV among youth), prevention information, and information on HIV testing and PrEP, as well as a link to the HIV risk estimator, and HIV testing and PrEP locators.
224172026|NCT07147842|OTHER|Placebo|Placebo Tablets
224172027|NCT07147842|DIAGNOSTIC_TEST|fecal calprotectin|Fecal calprotectin level was measured using an ELISA kit .
224172028|NCT07148401|DEVICE|Hall technique|Hall technique for placement of crowns on carious primary molars
224172029|NCT07149181|DRUG|SOX plus PD-1 inhibitor|SOX or XELOX plus PD-1 inhibitor
224172030|NCT07149181|DRUG|SOX Chemotherapy|SOX or XELOX
224172031|NCT07148375|PROCEDURE|Anterograde screws for medial Malleolus fractures|Fixation of medial Malleolus fracures by anterograde headless screws
224172032|NCT07148947|DRUG|Pacritinib|Given PO
224172033|NCT07148947|DRUG|Decitabine|Given IV
224172034|NCT07148947|DRUG|Decitabine and Cedazuridine|Given PO
224172035|NCT07148947|DRUG|Azacitidine|Given IV or SC
224172036|NCT07148947|OTHER|Survey Administration|Ancillary studies
224172037|NCT07148947|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
224172038|NCT07148947|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
224172039|NCT07148947|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
224172040|NCT04716920|OTHER|Tai Chi|Attend Tai Chi exercise classes
224172041|NCT04716920|DEVICE|FitBit|Wear FitBit
224172042|NCT04716920|OTHER|Support Group Therapy|Join Tai4Chijoint group
223483750|NCT06438211|PROCEDURE|superficial or deep serratus anterior plane block for mastectomy|group I: superficial SAP Block for postoperative analgesia for mastectomy group II: deep SAP Block for postoperative analgesia for mastectomy
224172043|NCT04716920|OTHER|Questionnaire Administration|Ancillary studies
224172044|NCT04716920|OTHER|Quality-of-Life Assessment|Ancillary studies
224172045|NCT06533930|OTHER|Transorbital Sonography|OND and ONSD of participants in the MS patient group and healthy control group were measured by TOS.
224172046|NCT06533930|OTHER|Orbita Magnetic Resonance Imaging|OND and ONSD of participants in the MS patient group were measured by orbita MRI.
224172047|NCT06533930|OTHER|Visual Evoked Potentials|P100 amplitude and P100 latency values of participants in the MS patient group were measured by VEP.
224172048|NCT06533930|OTHER|Optical Coherence Tomography|pRNFL thickness of participants in the MS patient group were measured by OCT.
224172049|NCT04223778|DRUG|DOR/ISL|A FDC of 100 mg DOR/ 0.75 mg ISL taken in tablet form, orally, once daily
224172050|NCT04223778|DRUG|ART|Baseline ART regimen will be administered as per approved label. ART medication will not be provided by the Sponsor; participants will provide their own ART medications. Allowed drug classes include nucleoside analog reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), integrase strand transferase inhibitors (InSTIs), fusion inhibitors, chemokine receptor 5 (CCR5) antagonists, post-attachment inhibitor, and pharmacokinetic (PK) boosters.
224172051|NCT05726747|DIAGNOSTIC_TEST|Quality of Life surveys|QoL and sarcopenia assessments
224172052|NCT06547112|DRUG|Motixafortide|Dose = 1.25 mg/kg via subcutaneous injection
224172053|NCT06547112|DRUG|G-CSF|Dose = \~10 µg/kg (and maximum of 15 µg/kg) via subcutaneous injection
223483751|NCT06645041|DIETARY_SUPPLEMENT|Vitamin D (Cholecalciferol )|The hypertensive patients with vitamin D deficiency will receive a Vitamin D capsule with a dose of 25,000 IU. They will be asked to receive a capsule per week for 8 subsequent weeks and re-visit the hospital two weeks from the final dose.
223483752|NCT06645041|DIETARY_SUPPLEMENT|Placebo Capsule(s)|The hypertensive patients with vitamin D deficiency will receive a Placebo capsule. They will be asked to receive a capsule per week for 8 subsequent weeks and re-visit the hospital two weeks from the final dose.
224172054|NCT05490849|DRUG|68Ga-HX01|"For pharmacokinetics, healthy volunteer underwent 68Ga-HX01 PET imaging. Blood samples were collected at 25 min, 55 min, and 115 min after imaging agent injection, and urine specimens were collected at 28 min, 58 min, and 118 min after injection to measure radioactivity in blood and urine. PET/MR scans were performed at 30-50 min, 60-80 min, and 120-140 min after injection to understand absorption, distribution, and metabolism.~Cancer patients,~1. Subjects should have 68Ga-HX01 and 18F-FDG PET scans two days apart.~2. Blood tests, liver and kidney function, tumor markers (CA125, CA199, CEA, etc.), and other biochemical markers must be performed one week prior to and after imaging.~3. Tumor biopsies or surgical specimens should be evaluated histopathologically and immunostained for biomarkers associated with angiogenesis."
224172055|NCT06318481|DRUG|Ticagrelor 90 MG|Patients in the treatment group will receive Ticagrelor 180 mg as a loading dose and 90 mg twice daily as a maintenance dose for 30 days. After 30-day doses will be according to standards clinical practice guidelines.
224172056|NCT06318481|DRUG|Clopidogrel|Patients in the control group will receive Clopidogrel 600 mg as a loading dose and 75 mg twice daily as a maintenance dose for 30 days. After 30-day doses will be according to standards clinical practice guidelines.
224172057|NCT00417235|DEVICE|Chlorhexidine Sponge (Biopatch TM)|dressing with chlorexidrine sponge versus dressing without chlorexidrine sponge
224172058|NCT00417235|BEHAVIORAL|7-day catheter dressing frequency|dressing changes every 7 days versus every classical change every 3 days
224172059|NCT01054339|DRUG|rAAV1-CB-hAAT|Recombinant adeno-associated virus vector expressing human alpha-1 antitrypsin
224172060|NCT02442375|RADIATION|standard dose prescription|"* standard elective dose~* no intermediate dose-level~* visual interpretation of FDG-PET-scan"
224172061|NCT02442375|RADIATION|FDG-PET guided gradient dose prescription|"* de-escalation of elective dose~* intermediate dose-level~* standardized methods to evaluate FDG-PET-scan"
224172062|NCT00740116|DRUG|Tranexamic acid|Tranexamic acid, 100 mg/ml; 15 mg/kg body weight added to 100 ml 0.9% NaCl solution given as a single dose intravenously immediately prior to skin incision at surgery
224172063|NCT00740116|DRUG|0.9% NaCl solution|0.9% NaCl solution; 0.15 ml/kg body weight added to 100 ml 0.9% NaCl solution. The volume is given intravenously immediate before skin incision at surgery.
224172064|NCT04678193|DRUG|Coromec Registry with ECL-19|Glycocheck to assess Microvascular Score will be used on all patients. An algorithm-based identification of symptoms and objective evidence using care coordination and remote sensor driven technology
224172065|NCT05315531|DIETARY_SUPPLEMENT|Water Intake|Participants will increase plain water consumption to at least 70% of the daily adequate intake for Americans depending on their sex.
224172066|NCT01567254|BEHAVIORAL|guided imaginary|Auditory guided imagery disk - will be prepared by Ronit Brooks, a clinical psychologist, who is engaged in guided imagery and by Livia Yanai, an art therapist.
224172067|NCT01567254|BEHAVIORAL|music ONLY|music. It will be equal in length to the auditory guided imagery disk
224172068|NCT04422847|DEVICE|3D obturator|Based on this 3D visualization of precise anatomical conditions in the oral cavity, a form (negative unique impression of the upper jaw and palato-alveolar conditions) for casting of a protective obturator (splint), used during intubation to cover the defect of the alveolar arch and palate will be created on a 3D printer
223483753|NCT06295250|BEHAVIORAL|Manualized Group Based Psychotherapy|Manualized Group Based Psychotherapy. Adapted from the World Health Organization (WHO) Problem Management Plus (PM+) intervention, this intervention includes behavioral activation, enhancing social support, and problem management.
223483754|NCT06295250|OTHER|Poverty Alleviation|Modeled on the well-known Graduation Program, a poverty alleviation strategy widely used in low income countries, this intervention includes an asset transfer (agricultural animals), financial literacy education, a 6 month stipend, savings accounts, veterinary support, feed, and agricultural training
223483755|NCT06323954|PROCEDURE|tVNS stimulation|Electrical stimulation to the vagus nerve area.
223483756|NCT06323954|PROCEDURE|Sham stimulation|Electrical stimulation to the non-vagus nerve area.
223483757|NCT03991169|DRUG|Ferrous Sulfate|Oral iron will be given in the form of immediate-release iron sulfate, 3-6 mg/kg/day of elemental iron to children with body weight ≤43 kg, and 65 mg of elemental iron (325 mg of iron sulfate) to children with body weight \>43 kg.
223483758|NCT04232631|DEVICE|SnapshotNIR, Kent Imaging|Vascular imaging device
223483759|NCT06958380|BEHAVIORAL|Corrective exercise and rehabilitation|This is a longitudinal single-subject case study in which one adult patient diagnosed with Fanconi anemia will undergo a structured, supervised corrective exercise and rehabilitation program. The subject will serve as their own control, with baseline measurements compared to post-intervention outcomes.
223483760|NCT02977351|PROCEDURE|Non-surgical periodontal treatment|
223483761|NCT03143452|DRUG|lidocaine gel|2% lidocaine gel in 1 ml syringe, applied to the eye 5 minutes before phacoemulsification
223483762|NCT03143452|DRUG|tetracaine eye drop|0.5% tetracaine eye drop was given 5 minutes before phacoemulsification
223483763|NCT00634517|DRUG|Armstrong Albuterol Sulfate Inhalation Aerosol|Albuterol Sulfate Inhalation Aerosol, 216 mcg albuterol sulfate (108 mcg/actuation) is equivalent to 180 mcg albuterol base (90 mcg/actuation).
223483764|NCT00634517|DRUG|Albuterol Sulfate Inhalation Aerosol|Albuterol Sulfate Inhalation Aerosol, 216 mcg albuterol sulfate (108 mcg/actuation) is equivalent to 180 mcg albuterol base (90 mcg/actuation).
223483765|NCT02517749|DEVICE|Chest Drain Insertion and Talc Pleurodesis|
223483766|NCT02517749|DEVICE|Indwelling Pleural Catheter Insertion and Talc Pleurodesis|
223483767|NCT05106907|BIOLOGICAL|ThisCART19 cells|0.2-60 x 10\^6 CAR T cells per kg body weight
223483768|NCT05129696|BEHAVIORAL|Treatment (T)|Children area offered to participate in bimonthly group sessions. Each session will have materials and activities appropriate for children spanning a 6-month range (6-12 m, 12-18 m, 12-24 m, 24-30 m) and can accommodate a maximum of 10 children per age group. If more households are interested than can be accommodated by the program, interested families will be randomly selected for participation. A total of 40 children per site will be able to participate in the ECD activities at any one time. With bi-monthly meetings, each child will be exposed to 12 sessions for each age group, and is eligible to transition to the next.
223483769|NCT05129696|BEHAVIORAL|Treatment + (T+)|Caregivers/children participating to the group ECD sessions will be invited to play within a play space equipped with books, and homemade/purchased age-appropriate toys. This will be phased in after 6 months of implementation.
223483770|NCT06517381|OTHER|Digital Online Warning Signs of Mental Illness Literacy Program|Digital Online Warning Signs of Mental Illness Literacy Program is comprised of 30-minute pre-recorded video and question-and-answer sessions. The videos were followed by case studies, success stories, and interactive question-and-answer sessions
223483771|NCT02549118|DRUG|Tenoxicam|
223483772|NCT02549118|DRUG|Pethidine|
224172069|NCT04085406|DEVICE|Deep Brain Stimulation of the Subgenus Cingulate Cortex|The Abbott Infinity DBS device will be surgically implanted in the bilateral subgenual cingulate cortex to provide electrical stimulation to this region.
224172070|NCT05515653|GENETIC|Exposure to genetics (polygenic)|The polygenic risk score (PRS) aggregates the effects of genetic variants into a single number that predicts the genetic predisposition to a phenotype. PRS are typically composed of hundreds to millions of genetic variants, usually Single Nucleotide Polymorphisms (SNPs). For each individual, the number of risk alleles computed in each variant is summed and weighted by the estimated value of the obtained effects (log odds ratio for traits with binary values or Beta coefficients for traits with continuous value) obtained from large-scale genomic studies ( GWAS)
224172071|NCT05135637|OTHER|Mobile health services|Mobile health services (MHS) will be deployed with one team per UC. MHS will focus on underserved areas to provide basic health services, immunization, \& health and nutrition counseling for under-five children \& WRAs.
224172072|NCT05135637|OTHER|Private practitioner engagement for immunization|Private healthcare providers (HCPs) will be taken on board to increase coverage of immunization. HCPs will offer routine vaccination to all under-five children visiting their clinics. Project team will liaison with EPI to arrange vaccines for them.
224172073|NCT05135637|OTHER|Community engagement and mobilization|Community engagement \& mobilization will focus on immunization, breastfeeding practices, \& optimal care-seeking for both pregnant women and young children. Opinion leaders will be engaged to gain support for activities.
224172074|NCT05135637|OTHER|Sehat Nishani - a health, nutrition and immunization app|Sehat Nishani App will be launched to assess feasibility of a health, \& immunization app to capture information on birth, nutrition, immunization \& growth records. Lady health workers (LHWs), lady health visitors (LHVs) in government health facilities, EPI vaccinators \& HCPs will be engaged to use app.
224172075|NCT03996993|DRUG|Casodex, Axumin|Patients will receive hormone therapy if Axumin positive area appears.
224172076|NCT03996993|RADIATION|Salvage Radiation, Axumin|Patients will receive salvage radiation therapy if Axumin positive area appears.
224172077|NCT04401488|BIOLOGICAL|Prevenar 7 and Prevenar 13|pneumococcal conjugate vaccines
224172078|NCT03310476|OTHER|Potatoes|Participants will follow the same protocol for each arm with a minimum of 1-week wash-out period between arms. For each arm, fasting blood will be collected then 200 g of potato will be consumed. Postprandial blood will be collected 15, 30, 60, and 120 minutes. Subjective satiety will be assessed using Visual Analogue Scale three times, as well as 48-hour subsequent dietary intake.
224172079|NCT00430924|DRUG|Eplerenone|Once daily administration for 8 weeks and 8 weeks control.
224172080|NCT03782389|OTHER|Preseason Periodic Health Examination Completion|all available players completed a mandatory PHE on one of three days during the first week of the season. Typically, the musculoskeletal and performance components of the PHE included: 1) anthropometric measurements; 2) medical history (i.e. previous injury history); 3) musculoskeletal examination tests; 4) functional movement and balance tests; 5) strength and power tests.
223483773|NCT01408472|DRUG|NT-501 CNTF Implant|Single implantation of CNTF-secreting NT-501 device into one eye
223483774|NCT03112538|DEVICE|Insulin Pump|Medtronic Minimed Paradigm Veo Insulin Pump
223483775|NCT03112538|DRUG|Multiple daily injections of insulin|Multiple daily injections which consist of a single injection of basal insulin(insulin Glargine) and 3 injections of bolus insulin(rapid acting insulin Glulisine or Aspart) before each meal
223483776|NCT05453721|PROCEDURE|Indocyanine green fluorescence imaging method|Using indocyanine green fluorescence imaging method to identify intersegmental plane in segmentectomy
223483777|NCT05453721|PROCEDURE|Modified inflation-deflation method|Using modified inflation-deflation method to identify intersegmental plane in segmentectomy
223483778|NCT03349463|DRUG|Fluciclovine F18|All study participants will receive 10 mCi of 18F-Fluciclovine (Axumin) one time administered through injection through the catheter into participant's arm immediately before PET/CT scan.
223483779|NCT05812404|DRUG|DWP14012|Potassium-competitive acid blocker
223483780|NCT05812404|DRUG|DWC202201|Atorvastatin Calcium Trihydrate
223483781|NCT05322486|PROCEDURE|surgery of the primary tumour|Surgical resection of the colon tumour, R0. No surgical intervention on metastasis.
223483782|NCT05322486|DRUG|chemotherapy|Chemotherapy with or without biological drugs.
223483783|NCT02385318|DRUG|Ingenol Mebutate (Perrigo)|
223483784|NCT02385318|DRUG|Ingenol Mebutate (Reference)|
223483785|NCT02385318|DRUG|Placebo gel|
223483786|NCT05683067|OTHER|Hand Held Capillary Microscopy|The investigator will visualize the blood vessel appearance, number, and size they have in their hands, feet, and under the tongue. This procedure is non-invasive and will not cause any pain.
224172081|NCT04759729|COMBINATION_PRODUCT|Probiotic and vitamin D|"Participants enrolled to PRO + D group will receive probiotics and vitamin D supplements as a intervention product.~Participants enrolled to probiotic group will receive probiotics as well as vitamin D supplements."
224172082|NCT04759729|DIETARY_SUPPLEMENT|placebo and vitamin D|Participants enrolled to PL+D group will receive vitamin D. Additionally they will get placebo instead of probiotics.
224172083|NCT03037489|DRUG|MIV-711|MIV-711 administered orally once daily
224172084|NCT03303131|OTHER|Discharge from community-based management|Comparison of patient characteristics and treatment outcomes between two groups
224172085|NCT00621764|BIOLOGICAL|Japanese encephalitis vaccine (Day 0) Hepatitis A vaccine (Day 28)|≥4.0 Log10 Plaque forming units (PFU), Subcutaneous (SC; Day 0); 0.5 mL intramuscular (IM; Day 28)
224172086|NCT00621764|BIOLOGICAL|Hepatitis A vaccine (Day 0) Japanese encephalitis vaccine (Day 28)|0.5 mL IM (Day 0); ≥4.0 Log10 PFU SC (Day 28)
224172087|NCT00621764|BIOLOGICAL|Japanese encephalitis vaccine (Day 0) Hepatitis A vaccine (Day 28)|≥4.0 Log10 PFU SC (Day 0); 0.5 mL IM (Day 28)
224172088|NCT00621764|BIOLOGICAL|Hepatitis A vaccine (Day 0) Japanese encephalitis vaccine (Day 28)|0.5 mL IM (Day 0); ≥4.0 Log10 PFU SC (Day 28)
224172089|NCT04627389|PROCEDURE|orbicularis oris muscle Z- plasty modification of modified millard technique|After orbicularis oris muscle had been released from the overlying skin, the previously marked points using methylene blue for designing the z-plasty were shown to be followed by back-cut incisions including the OOM and inner mucosa in both medial and lateral elements without involving the overlying skin. This procedure resulted in two triangular flaps in both segments
224172090|NCT04627389|PROCEDURE|modified millard technique|no z-plasty modification
224172091|NCT03362723|DRUG|Idasanutlin|Participants will receive one 300-mg dose of each of the four different oral tablet formulations of idasanutlin (tablet A \[reference\], B, C, D) during Cycle 1, in the order specified for their assigned treatment arm (Treatment Sequence 1-4). Participants who enter the optional treatment extension phase will receive the reference tablet formulation of idasanutlin, as specified in the Optional Treatment Extension Arm description.
224172092|NCT02499172|BIOLOGICAL|Shanchol|
223483787|NCT05683067|OTHER|Mobile 'O' Graph|The aortic stiffness will be measured non-invasively using a special blood pressure monitor called Mobile 'O' Graph, which is about size of a pocket diary. 24 hour blood pressure monitoring is optional.
223483788|NCT05683067|OTHER|quality of life using questionnaires|The investigator will evaluate the quality of life using questionnaires such as EQ-5D-5L questionnaire and the Minnesota Living with Heart Failure Questionnaire (MLHFQ)
223585808|NCT01072825|BIOLOGICAL|blood sampling|LFT (AST, ALT), CRP, creatinine, glucose, Total Cholesterol, Triglycerides, HDL-CH, LDL-CH, 25OH vitamin D, PSA if\> 45 years, Hematocrit, testosterone, sex hormone-binding globulin, free testosterone , oestradiol, prolactin, luteinizing hormone, TSH, androgeengevoeligheids test (CAG RL), oral glucose tolerance test
223483789|NCT01563939|DRUG|Remifentanil|"Remifentanil IV for continuous infusion: 0.025mcg/kg/min, increased by 0.025mcg/kg/min every 15 min if patient is not satisfied, to a maximum of 0.15mcg/kg/min.~Remifentanil IV for demand bolus: 0.2 mcg/kg, lockout 2 min, incrementally increased if patient is not satisfied by 0.2 mcg/kg to a maximum of 1.2 mcg/kg."
224172093|NCT02330731|PROCEDURE|injection sclerotherapy for gastric varices|The intravariceal technique of injection
224172094|NCT01293123|DRUG|Raltegravir|raltegravir 400 mg PO twice daily
224172095|NCT01293123|DRUG|Efavirenz|efavirenz 600 mg PO once daily
224172096|NCT01180829|BEHAVIORAL|Personalized feedback text messages|A series of 12 text messages, each of which contains one personalized feedback item about the person's drinking.
224172097|NCT01180829|BEHAVIORAL|Consciousness raising text messages|A series of 12 text messages, each of which consists of an item designed to get the person to think about his or her drinking
224172098|NCT01567072|DRUG|Ibuprofen|Treatment with Ibuprofen 600mg 3times a day in 7 days after Colles fracture diagnosis
224172099|NCT01567072|DRUG|Ibuprofen|Treatment with Ibuprofen 600mg 3 times daily in 3 days after´diagnosis - Colles fracture
224172100|NCT01567072|DRUG|Placebo|Only placebo treatment instead of NSAID painkillers
224172101|NCT00121485|DEVICE|Left Ventricular Assist System (LVAS)|Implantation of left ventricular assist device for hemodynamic support
224172102|NCT01111331|DRUG|BI 10773 25 mg|25 mg BI 10773 qd for 5 days
224172103|NCT01111331|DRUG|Warfarin 25 mg|25 mg Warfarin single dose
224172104|NCT01111331|DRUG|BI 10773 25 mg|25 mg BI 10773 qd for 12 days
224172105|NCT01111331|DRUG|Warfarin|25 mg warfarin single dose with and without 50 mg BI 10773
224172106|NCT04749303|PROCEDURE|Large Screen|Large screen size is 4x larger than standard screen, we hope that the colonoscopies carried out with large screens will confer to better lesion detection
224172107|NCT04899167|OTHER|MRI 1.5T and 3.0T|Magnetic Resonance Imaging for Renal Fibrosis
224172108|NCT01090167|DRUG|clofarabine|Intravenous, 20 mg/m2, 30 mg/m2, 40 mg/m2
224172109|NCT00724243|DRUG|Infliximab|Infliximab given in accordance with the local summary of product characteristics
224172110|NCT02386605|BEHAVIORAL|Motivational Interviewing and Cognitive Behavioral Therapy|group-based recovery-oriented Motivational Interviewing combined with cognitive-behavioral therapy to target the negative symptoms of schizophrenia
224172111|NCT02386605|BEHAVIORAL|Relaxation Skills|Relaxation and mindfulness skills training group for comparison condition for negative symptoms of schizophrenia
224172112|NCT03031327|DEVICE|Lubricin 20µg/ml|Lubricin 20µg/ml eye drops
224172113|NCT03031327|DEVICE|Lubricin 50µg/ml|Lubricin 50µg/ml eye drops
224172114|NCT03031327|DEVICE|Sodium hyaluronate 0.18%|Sodium hyaluronate (HA) 0.18% eye drops
224172115|NCT02274987|OTHER|Specialized tumor board recommendation|A combination of up to four FDA approved drugs based on the molecular profile of the patient's tumor as determined by gene expression analysis, WES and predictive modeling.
224172116|NCT02274987|RADIATION|Standard radiation therapy|Initial therapy will consist of standard radiation therapy per institutional guidelines followed by molecular based therapy with FDA approved drugs.
224172117|NCT00526760|DRUG|Dexmedetomidine|
224172118|NCT01226758|BIOLOGICAL|Influenza vaccine (FLU-v)|FLU-v (sterile lyophilised mixture of polypeptide T-cell epitope sequences) and adjuvant. Administered by single subcutaneous injection.
224172119|NCT01226758|BIOLOGICAL|Placebo (adjuvant only)|Single subcutaneous injection of adjuvant
224172120|NCT01226602|DRUG|AZD6140|P2Y12 receptor antagonist
224172121|NCT01226602|DRUG|Placebo|
224172122|NCT01938443|DRUG|GSK2256098|GSK2256098 250 mg will be supplied as white to off-white, round, biconvex tablets with no markings. GSK2256098 will be administered 30 minutes after a light meal with approximately 240 milliliter of water.
224172123|NCT01938443|DRUG|Trametinib|Trametinib 0.5 mg will be supplied as capsules with no identifying markings. Trametinib will be administered orally under fasting conditions two hours after a meal.
224172124|NCT03609775|DRUG|ACT-541468|One tablet of 50 mg ACT-541468 will be administered orally.
224172125|NCT03609775|OTHER|ACT-541468 placebo|Matching ACT-541468 placebo will be administered orally as 1 tablet.
224172126|NCT03609775|OTHER|Ethanol 10%|Ethanol 10% w/v solution in 5% glucose will be administered i.v. for 5 h and clamped at an ethanol level of 0.6 g/L.
224172127|NCT03609775|OTHER|Ethanol placebo|Matching placebo for the ethanol infusion (i.e., 5% glucose solution) will be administered i.v. for 5 h.
224172128|NCT03942029|DRUG|LY3154207 Capsule|Administered orally as capsule
224172129|NCT03942029|DRUG|LY3154207 Tablet|Administered orally as tablet
224172130|NCT03942029|DRUG|Placebo|Administered orally as tablet
224172131|NCT03942029|DRUG|Fluconazole Tablet|Administered orally as tablet
224172132|NCT03908658|OTHER|Inspiratory muscle Training and Nasal High Flow|Inspiratory muscle Training will be used to increase respiratory muscle strength. Initial settings will depend on patient's maximal inspiratory pressure. Nasal High Flow will support respiratory muscles and thus reduce the work of breathing. By this mechanism the endurance of the respiratory muscles will increase in parallel with the strenght
224172133|NCT03908658|DEVICE|Inspiratory muscle training and Venturi mask|Inspiratory muscle Training will be used to increase respiratory muscle strength. Initial settings will depend on patient's maximal inspiratory pressure. Venturi mask is usually applied after extubation in every day clinical practice for oxygen supplementation
224172134|NCT02441387|DRUG|Antidepressant|Sertraline 50-250mg/day for 1 year or Escitalopram 10-20mg/day for 1 year or Mirtazapine 15-45mg/day for 1 year or Venlafaxine 37,5-300mg/day for 1 year or Lithium 300-900mg/day for 1 year.
224172135|NCT02441387|OTHER|Psychoeducation|Patients who are in the antidepressant treatment group and does not reach remission (MADRS score \<or =8) until visit 4 will be invited to be part of a psychoeducation program. If the patient accepts the psychoeducation intervention, he will be randomized to psychoeducation (pharmacological treatment plus psychoeducation) or treatment as usual (only pharmacological treatment). The psychoeducation program consists of 10 individual sessions, conducted by a trained psychologist who will explain the main concepts of depression and its symptoms, the importance of adhering to treatment, the main side effects of pharmacological treatment, and how to cope with daily difficulties.
224172136|NCT02441387|OTHER|Treatment as usual (only pharmacological treatment).|Patients who are in the antidepressant treatment group and does not reach remission (MADRS score \<or =8) until visit 4 will be invited to be part of a psychoeducation program. If the patient accepts the psychoeducation intervention, he will be randomized to psychoeducation (pharmacological treatment plus psychoeducation) or treatment as usual (only pharmacological treatment).
224172137|NCT05038306|DRUG|Chinese medicine WT|The Chinese medicine WT is thought to be neurotrophic, and its major constituent may benefit IGF-1 in animal studies, or certain healthy human group. WT is safe in clinical use in Asia.
224172138|NCT00211536|DRUG|Medtronic MiniMed Implantable Pump Human Recombinant Insulin|400 IU per ml - dosage based on the Investigators clinical judgement and the individual subject requirements.
224172139|NCT00211536|DEVICE|Medtronic MiniMed Implantable Pump System|The implantable pump system is intended to provide continuous intraperitoneal delivery of insulin in subjects with diabetes.
224172140|NCT00211536|DRUG|Aventis HOE21PH U400|400 IU per ml - dosage based on the Investigators clinical judgement and the individual subject requirements.
224172141|NCT04104399|DRUG|XC101-D13H|XC101-D13H supplied as 0.4, 0.8, 1.6 or 3.2 mg dose, administered in capsules
224172142|NCT04104399|DRUG|Placebo|Placebo supplied as matching capsules
223483790|NCT01080261|DEVICE|PROMUS Element|PROMUS Element Everolimus-Eluting Coronary Stent System
224172143|NCT02962999|DRUG|Ketamine|After induction, patients will be received 1 mg/kg ketamine bolus, then administered 0,5 mg/kg/hour ketamine infusion intraoperatively.
224172144|NCT02962999|DRUG|Saline|After induction, patients will be received saline bolus, then will be administered saline infusion intraoperatively.
224172145|NCT05500911|PROCEDURE|sinus lift|when residual bone height is \>4 mm sinus lift through crestal approach procedure will be performed and after sinus flor elevation, OSSIX® Bone will be placed in the sinus cavity.
224172146|NCT05500911|PROCEDURE|implant placement|Implant will be placed in edentulous area
224172147|NCT03582631|PROCEDURE|Emergency abdominal surgery|Emergency surgery for high-risk abdominal pathology using a protocol for optimized perioperative care
224172148|NCT04087551|OTHER|Developing the list of items for BRFES|The finalized list of items will be discussed by two researchers who will combine similar items generated by the two focus groups to complete the Balance Recovery Falls-Efficacy Scale. The list of items has been developed by a group of community-dwelling older adults who had demonstrated an understanding of near-falls and will be able to articulate the use of balance recovery strategies used in near-fall experiences.
224172149|NCT05881590|OTHER|Hybrid pulmonary rehabilitation|Technology-enabled 8-week pulmonary rehabilitation programme using the Active+me REMOTE App
224172150|NCT04177940|DRUG|DMAB Discontinuation and Switching|"Investigators will test the hypothesis that an increase in bone turnover markers (e.g. CTX and P1NP) in patients currently taking chronic glucocorticoids will be attenuated more in those who switch from denosumab to late zoledronic acid (9 months after last denosumab dose) compared to participants randomized to early zoledronic acid (6 months after last denosumab dose) or weekly alendronate (6 months after last denosumab dose"
224172151|NCT00189059|DRUG|amitriptyline|
224172152|NCT03188458|OTHER|Blood sample|Blood samples will be collected from infants prior to their first routine primary pertussis vaccination (At Visit 2 \[approximately 4-8 weeks of age\]).
224172153|NCT02735876|DRUG|acalabrutinib|
224172154|NCT02735876|DRUG|ibrutinib|
224172155|NCT02735876|DRUG|rituximab|
224172156|NCT04590976|OTHER|Semi-Structured Interview Healthcare Professional|Interview
224172157|NCT04590976|OTHER|Semi-Structured Interview Patients|Interview
224172158|NCT04590976|OTHER|Think Aloud Interview Patients|Interview
224172159|NCT04590976|OTHER|Discrete Choice Experiment (DCE) Patients|DCE Questionnaire
224172160|NCT00003389|DRUG|Doxorubicin|given IV
224172161|NCT00003389|DRUG|Bleomycin|given IV
224172162|NCT00003389|DRUG|Vinblastine|given IV
224172163|NCT00003389|DRUG|Dacarbazine|given IV
224172164|NCT00003389|DRUG|Vincristine|given IV
224172165|NCT00003389|DRUG|Mechlorethamine|given IV
224172166|NCT00003389|DRUG|Etoposide|given IV
224172167|NCT00003389|DRUG|Prednisone|taken orally
224172168|NCT00003389|DRUG|Cyclophosphamide|given IV
224172169|NCT00003389|RADIATION|Radiotherapy|
224172170|NCT01678469|OTHER|blood sample|
224172171|NCT01234558|DRUG|GLYX-13|single IV dose
224172172|NCT00206752|RADIATION|Radiation therapy|definitive external beam radiation in the ipsilateral neck.
224172173|NCT00206752|RADIATION|definitive external beam radiation in the ipsilateral neck|definitive external beam radiation in the ipsilateral neck
224172174|NCT04401982|DRUG|Netarsudil ophthalmic solution 0.02% one drop nightly for 1-2 weeks|Netarsudil ophthalmic solution 0.02% one drop nightly for 1-2 weeks will be administered
224172175|NCT01797042|BEHAVIORAL|Dietary Compliance|Incorporation of sugar sweetened milk into the usual diet. Instruction on how to account for additional calories provided by sugar sweetened milk Weekly compliance checks
224172176|NCT03790267|OTHER|Questionnaire administration|One questionnaire (Euro Quality 5 Dimensions, EQ-5D) for the general assessment of patient's health status will be administered to all the patients in the study. One joint-specific questionnaires will be administered to patients depending on the surgery procedure they will be undergoing. Hip disability and Osteoarthritis Outcome Score - Short Form (HOOS-PS) for patients undergoing hip replacement (6); Knee injury and Osteoarthritis Outcome Score - Short Form (KOOS-PS) for patients undergoing knee replacement (7); the American Shoulder and Elbow Surgeons Standardized Shoulder Assessment Form (ASES), for patients undergoing shoulder implants.
224172177|NCT05892406|DEVICE|Static guide|A static guide will be designed and fabricated based on CBCT and intra-oral scan. Implant will be placed under the assistance of statistic guide through the whole procedure.
224172178|NCT05892406|DEVICE|Dynamic navigation|Implant will be placed under the assistance of dynamic navigation.
224172179|NCT05892406|DEVICE|Robotic system|Implant will be placed under robotic arm and human collaboration.
224172180|NCT05385172|OTHER|No any intervation.|This research, a quasi-experimental study based on the comparison of the pre-test and post-test results of individuals in a single group is conducted to raise awareness about cervical cancer in women aged 18-65 years.
224172181|NCT04610827|DRUG|Ferrous sulfate|Guideline-recommended 3 mg/kg/day dosing
224172182|NCT03016260|BIOLOGICAL|Infliximab|Anti-TNF alpha originator
224172183|NCT03016260|BIOLOGICAL|Adalimumab|Anti-TNF alpha originator
224172184|NCT03016260|BIOLOGICAL|Etanercept|Anti-TNF alpha originator
224172185|NCT03016260|BIOLOGICAL|Golimumab|Anti-TNF alpha originator
224172186|NCT03016260|BIOLOGICAL|Certolizumab Pegol|Anti-TNF alpha originator
223483791|NCT01922999|DRUG|Melatonin|patients will receive placebo, 1mg melatonin or 3mg melatonin
223483792|NCT00004497|DRUG|UT-15|
223483793|NCT05668455|DRUG|Hydrocortisone|1 drops 4 times a day
223483794|NCT05668455|DRUG|Dexamethasone|1 drops 4 times a day
223483795|NCT05668455|OTHER|Povidone|1 drops 4 times a day
223483796|NCT06550908|OTHER|Lutetia Training Plattform - real images|Training platform Lutetia offers training the Paris classification using real images of colon polyps.
223483797|NCT06550908|OTHER|Lutetia Training Plattform - artifical images|Training platform Lutetia offers training the Paris classification using artificial images of colon polyps.
223483798|NCT05080491|DIAGNOSTIC_TEST|immuno analysis and neuropsychological tests|"A venous blood sample will be taken for assay in immuno-analysis including and for assay in chromatography with mass spectrometry. Patients will participate in computer neuropsychological tests: .~Venous blood collection and the administration : the tubes are transported to the biochemistry laboratory of the University Hospital Center of Nice (CHU Nice) which prepares five aliquots (4 for assays in immuno-analysis including 2 on site, and one for assay in chromatography with mass spectrometry.~Administration of two neuropsychological tests on computer(Attention Network Task and Tower of London)."
223483799|NCT04146701|OTHER|Blood draw|venous blood withdraw (ca. 40ml)
223483800|NCT03023501|DRUG|Gabapentin|
223483801|NCT03023501|DRUG|Placebo Oral Capsule|
223483802|NCT01409473|RADIATION|Prostate SBRT with concurrent boost to intraprostatic lesion(s)|40 Gy in 5 fractions to prostate for low-risk and 45 Gy in 5 fractions to prostate for intermediate-risk patients, and 50 Gy in 5 fractions to intraprostatic lesion(s), delivered over 10-14 days on preferably every other day.
223483803|NCT03773588|DEVICE|Closed-Loop propofol Target controlled infusion by Entropy and SPI|Closed loop target infusion of propofol using BD TCI pumps guided by entropy and Surgical pleth index
223483804|NCT03773588|DEVICE|Open-loop propofol target controlled infusion|Propofol target controlled infusion using Schnider algorithm to determine effect site concentration
223483805|NCT03245606|PROCEDURE|Liver biopsy|Measurement of liver fibrosis
223483806|NCT03245606|DEVICE|Abdominal MRI|Measurement of liver fibrosis
223483807|NCT03245606|DEVICE|Transient elastography|Measurement of liver fibrosis
223483808|NCT02594111|DRUG|Colchicine vs Placebo|Colchicine vs Placebo 1.8 mg PO over 1 hour
223483809|NCT02965482|DEVICE|Wright Nebulizer|Roxon Medi-Tech, Montreal, QC, Canada
224172187|NCT03016260|BIOLOGICAL|Infliximab biosimilar|Anti-TNF alpha Infliximab biosimilars
223483810|NCT02965482|DEVICE|Aerogen Solo Nebulizer|Aerogen Ltd., Galway, Ireland
223483811|NCT05926921|OTHER|music|Brahms' Lullaby will be played from a speaker at 50 decibels
223483812|NCT04132713|DRUG|Capecitabine 150Mg Oral Tablet|Advanced breast cancer patients with first-line medication
223483813|NCT01963611|DRUG|Plovamer acetate 0.5 milligram (mg)|Plovamer acetate was administered at a dose of 0.5 mg as weekly subcutaneous injection for 40 weeks up to a maximum of 14 months.
223483814|NCT01963611|DRUG|Copaxone 20 mg|Plovamer acetate was administered at a dose of 3 mg as weekly subcutaneous injection for 40 weeks up to a maximum of 14 months.
223483815|NCT01963611|DRUG|Plovamer acetate 3 mg|Plovamer acetate was administered at a dose of 10 mg as weekly subcutaneous injection for 40 weeks up to a maximum of 14 months.
223483816|NCT01963611|DRUG|Plovamer acetate 10 mg|Plovamer acetate was administered as two subcutaneous injection of 10 mg weekly for 40 weeks up to a maximum of 14 months.
223483817|NCT01963611|DRUG|Plovamer acetate 20 mg|Copaxone was administered at a dose of 20 mg as subcutaneous injection once daily for 40 weeks up to a maximum of 14 months.
223483818|NCT01241929|BEHAVIORAL|video decision aid|video of CPR
223483819|NCT03526705|DEVICE|NB-UVB|Phototherapy
223585809|NCT01072825|OTHER|clinical evaluation|height, weight, blood pressure, chestcircumference, waist circumference, grip strength, measuring 2 ° and 4 ° finger, and Ferriman Gallwey score
224172188|NCT03016260|BIOLOGICAL|Etanercept biosimilar|Anti-TNF alpha Etanercept biosimilar
223483820|NCT01318434|DRUG|EB-1010 25mg BID|capsule once daily
223483821|NCT01318434|DRUG|SSRI Active|Active Comparator
223483822|NCT01318434|DRUG|EB-1010 50mg BID|Experimental Active
223483823|NCT01318434|DRUG|Placebo|Placebo comparator
223483824|NCT00750334|DRUG|clofarabine|Drug given Daily x 14 days and 7 days of rest for 21 day cycle
223483825|NCT00750334|DRUG|clofarabine|Drug given Daily X 14 days and 7 days of rest for 21 day cycle
223483826|NCT04791176|RADIATION|concurrent lenvatinib and Radiotherapy, followed lenvatinib maintenance|Radiotherapy with IMRT or VMAT with 40-60Gy/20-30f; Concurrent Lenvatinib 12mg/day (for patients≥60 kg) or 8 mg/day (for patients\<60kg ) qd po. (Note: Levatinib can be given to patients in four weeks before Radiotherapy is applied, so that it can control disease during waiting for Radiotherapy). Maintenance Lenvatinib 12mg/day (for patients≥60 kg) or 8 mg/day (for patients\<60kg ) qd po until disease progress or unacceptable adverse events; six months is recommended but not mandatory.
223483827|NCT01759927|BEHAVIORAL|physical activity coaching|After measuring physical actity, physical fitness level, anthropometric and psychosocial variables a personalized 12 week physical activity program is made (=baseline). The intervention consisted of two face-to-face counselling sessions at the start of the intervention, short contacts by e-mail or telephone at weeks 3, 6 and 9, and two face-to-face counselling sessions at the end of the intervention. Employees exercise on their own. After 12 weeks and 6 months all measures are repeated.
223483828|NCT02580656|BEHAVIORAL|Metacognitive Therapy|MCT helps patients to understand the deleterious and counterproductive effects of responding to negative thoughts and feelings with worry and rumination. Treatment aims to enable patients to exert greater metacognitive control over their worry and rumination. The positive and negative metacognitive beliefs that keep perseverative thinking in place are modified, using verbal and behavioural reattribution and through specifically designed therapeutic methods.
223483829|NCT04700943|PROCEDURE|Regional awake anesthesia|We want to assess the impact of regional anesthesia on diaphragmatic function in patients undergoing Video-assisted thoracoscopic surgery pulmonary biopsy in interstitial lung disease
223585810|NCT01072825|OTHER|Dermatology evaluation|Evaluation of the hair pattern, using the Leeds acne classification scale, acne scars through ECCA scale (échelle d'évaluation clinique des cicatrices d'acné), androgenetic alopecia, and sebummetrie
223585811|NCT01072825|OTHER|Bone evaluation|PQCT scanner, BMD assessment
223483830|NCT00128843|DRUG|Exemestane|25mg/day until progression disease
223483831|NCT00128843|DRUG|Anastrozole|1mg/day until progression disease
223483832|NCT01126424|DRUG|Solifenacin|tablet
223483833|NCT01126424|DRUG|Oxybutynin|capsule
223483834|NCT01126424|DRUG|Placebo|tablet
223585812|NCT02861911|OTHER|Current flow between sensory and motor threshold|Artificial strength training by means of neuromuscular electrical stimulation (NMES)
223585813|NCT02861911|DEVICE|Current intensity upper of motor threshold by Kneehab XP technology|Artificial strength training by means of neuromuscular electrical stimulation (NMES)
223585814|NCT00813891|DRUG|Ranibizumab|Intraocular injection of 0.5mg of Ranibizumab one week prior to PDT with verteporfin
223585815|NCT00813891|DRUG|Ranibizumab|Intraocular injection of 0.5mg of Ranibizumab one week after PDT with verteporfin
223585816|NCT00813891|DRUG|Ranibizumab|Intraocular injection of 0.5mg of Ranibizumab with no accompanying PDT with verteporfin
223585817|NCT04723225|OTHER|Cat-Cow Yoga|Cat-Cow is one of the essential postures in yoga for its beneficial reasons. It is an alternate shift of posture from flexion of the back (rounded) to the extension of the back (arched). During each set of movement, inhalation and exhalation will be guided
223585818|NCT03738319|GENETIC|Sequencing of miRNA/lncRNA|Next generation sequencing of micro-RNA (miRNA) and long non-coding RNA (lncRNA)
223585819|NCT01360177|PROCEDURE|124 PET/CT imaging|Standard of Care
224172189|NCT03016260|BIOLOGICAL|Infliximab biosimilar|Anti-TNF alpha Infliximab biosimilar
224172190|NCT03247712|DRUG|Nivolumab|Nivolumab 240mg IV q2wks or 480mg IV q4wks
224172191|NCT03247712|PROCEDURE|Surgical Resection|Surgical Resection of Tumor
224172192|NCT03247712|RADIATION|Radiation (5 days)|8Gy x 5 (Mon-Fri) GTV+3mm
224172193|NCT03247712|RADIATION|Radiation (3 days)|8Gy x 3 (Monday, Wednesday, Friday) GTV+3mm
224172194|NCT00528814|OTHER|Active Hand Sanitizer|Active Hand Sanitizer
224172195|NCT00908050|DRUG|Botulinum toxin type A|Patients are injected with botulinum toxin type A (BOTOX) 60 units in each masseter muscle and 35 in each temporalis muscle, bilaterally.
224172196|NCT00908050|DRUG|Placebo arm|Placebo comparator
224172197|NCT02838186|PROCEDURE|retroflexion|examination of the right colon with scope retroflexion
224172198|NCT02838186|PROCEDURE|forward view|examination of the right colon in forward view
224172199|NCT01659437|DRUG|Clarithromycin Extended Release|oral administration of Clarithromycin extended release
224172200|NCT01659437|DRUG|Streptomycin intramuscular injection|daily intramuscular drug injection
224172201|NCT05195619|BIOLOGICAL|Autologous dendritic cell vaccine loaded with personalized peptides (PEP-DC vaccine)|"Patients will receive six DC vaccinations Q3W (±3 days) in combination with low dose cyclophosphamide the day before vaccination.~Each dose of vaccine (PEP-DC) will be split into two injections, which will be administered on W2D2 of each cycle, subcutaneously. Patients will be vaccinated until vaccine exhaustion, disease progression, major toxicity or patient withdrawal, whichever is earlier. Additional DC vaccines may be administered Q3W (±3 days) if available until vaccine exhaustion or disease progression, whichever is earlier."
224172202|NCT05195619|DRUG|Low dose cyclophosphamide|Patients will receive six DC vaccinations Q3W (±3 days) in combination with low dose cyclophosphamide the day before vaccination.
223483835|NCT05627596|BEHAVIORAL|Ask-Advise-Refer|All patients will be asked if they smoke, advised to quit, and referred to the state quitline
223483836|NCT05627596|DRUG|Nicotine Patch, 14 Mg/24 Hr Transdermal Film, Extended Release|14 mg transdermal nicotine patch
223483837|NCT05627596|DRUG|Nicotine lozenge|4mg nicotine lozenge
223483838|NCT05090254|OTHER|Treatment algorithms targeting cardiac output|Treatment algorithms targeting maximization or personalization of cardiac output
223483839|NCT05970458|OTHER|Quality of life assessment|EQ5D-5L and Stoma QoL
223483840|NCT01323556|BEHAVIORAL|Cognitive Behavioural Therapy (CBT)|12 sessions of CBT including psychoeducation, behavioral analyses, interoceptive exposure and in-vivo exposure with interoceptive exposure during in vivo exposure
223483841|NCT01323556|BEHAVIORAL|Cognitive Behavioural Therapy (CBT)|12 sessions of CBT including psychoeducation, behavioral analyses, interoceptive exposure and in-vivo exposure without additional fear augmenting strategies
223483842|NCT02425553|OTHER|Diet|High calorie (1200 kcal), high fat (50% energy), 400 ml juice (230 kcal)
223483843|NCT02425553|OTHER|Diet|High calorie (1200 kcal), low fat (20% energy), 400 ml juice (230 kcal)
223483844|NCT02425553|OTHER|Diet|Low calorie (600 kcal), low fat (20% energy), 400 ml juice (230 kcal)
223483845|NCT02425553|OTHER|Diet|High calorie (1200 kcal), high fat (50% energy), 300 ml wine (40 g alcohol, 230 kcal), 100 ml water
223483846|NCT02429466|DRUG|Guadecitabine (SGI-110)|SGI-110 will be given subcutaneously, daily, 30 mg/m2 on days (1-5) followed by cisplatin 100mg/m2 on day 8 every 4 weeks.
223483847|NCT04292951|PROCEDURE|Fluid and inotropic/vasoactive management protocol|GDT protocol: keep SVV 10-13% and give fluid when SVV \> 13%, give inotropic to maintain CI 2.5-4 L/min/m2, give vasoactive drugs to maintain SVRI 1,900-2,400 dynes-sec/cm-5/m2 Control protocol: keep CVP 8-12 mmHG and give fluid when CVP \< 8 mmHg, give inotropic/vasoactive to maintain normal blood pressure and heart rate
223483848|NCT03478280|DRUG|Brodalumab|Subjects with moderate-to-severe psoriasis are enrolled consecutively and randomly assigned to either active treatment with brodalumab or placebo during the treatment period
223483849|NCT03478280|DRUG|Placebos|Subjects with moderate-to-severe psoriasis are enrolled consecutively and randomly assigned to either active treatment with brodalumab or placebo during the treatment period
223483850|NCT04013464|DRUG|Escitalopram|Escitalopram 10-20mg/d
223585820|NCT01360177|DRUG|Na134I|25 to 150 mCi
223585821|NCT01360177|DRUG|Tri-iodothyronine|75 ug/8hr x 4 weeks; oral
223585822|NCT01360177|DRUG|Tri-iodothyronine|20 mg/day x 2
223585823|NCT05432167|DRUG|CIN-107|Patients will take CIN-107 tablets by mouth once daily.
223585824|NCT05432167|DRUG|Placebo|Patients will take placebo tablets by mouth once daily.
223585825|NCT02295241|OTHER|No intervention|This is an observational trial, no interventions are being used.
224172203|NCT03139773|DIETARY_SUPPLEMENT|Control Breakfast Beverage|Each participant consumes the breakfast beverage every morning before 10:00 am for 14 days.
224172204|NCT03139773|DIETARY_SUPPLEMENT|Omega-3 Breakfast Beverage|Each participant consumes the breakfast beverage every morning before 10:00 am for 14 days.
223585826|NCT04750980|OTHER|food allergy|food allergy
224172205|NCT01855139|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|15 mg OD or 20 mg OD
224172206|NCT02710422|BIOLOGICAL|Amniotic Membrane Placement|Amniotic membranes will be placed over the neurovascular bundle after extirpative RARP, and before the urethrovesical anastomosis. The membrane will cut into two longitudinal pieces and it will be placed over each neurovascular bundle separately.
224172207|NCT02710422|BEHAVIORAL|EPIC 26|Participants will receive EPIC 26 psychosocial questionnaire at baseline, and post-RARP at protocol-defined intervals.
224172208|NCT02710422|OTHER|PSA Measurement|Measurement of serum PSA levels every three months (+ 1 month) for first year post surgery, and then annually for 5 years.
224172209|NCT02710422|BEHAVIORAL|Sexual History Inventory for Men|SHIM psychosocial questionnaire administered at baseline, and post-RARP at protocol-defined intervals.
224172210|NCT04882826|DRUG|Sildenafil film-coated tablet 100 mg|Sildenafil is manufactured by Pharmtechnology LLC, Belarus. Each tablet contains 100 mg of sildenafil.
223585827|NCT04750980|OTHER|respiratory allergy|respiratory allergy
223585828|NCT04750980|OTHER|healthy controls|healthy controls
224072324|NCT00393874|DRUG|Prazosin|Participants randomized to PRZ will take 4 capsules each night (PRZ dose complemented with placebo capsules ). The target dose of prazosin is 10 mg. Some individuals may require doses up to 15 mg, (Murray Raskind, M.D., personal communication, February 4, 2005). Prazosin will be administered in an initial oral dose of 1 mg (Week 1), with titration to a maximum of 15 mg. The first increment will be of 1 mg (Week 2: 2 mg), and subsequent weekly increments according to the following schedule: Week 3: 4 mg; Week 4: 6 mg; Week 5: 10 mg; Week 6: 15 mg; Week 7: 15 mg; Week 8: 15 mg. A maximum dose of 15 mg may be necessary. Medication will be administered in a single dose to be taken 30 minutes prior to bedtime because the onset of action occurs within 30 to 90 minutes after a single dose.
224172211|NCT04882826|DRUG|Viagra® film-coated tablet 100 mg|Viagra® is manufactured by Fareva Amboise, France. Each tablet contains 100 mg of sildenafil.
224172212|NCT01381289|DRUG|VX-770|150 mg tablet, oral use, twice daily every 12 hours (q12h)
224172213|NCT01935622|DRUG|Doxycycline|Doxycycline 1 tablet every 12 hours for 14 days
224172214|NCT01935622|DRUG|placebo|Placebo 1 tablet every 12 hours for 14 days
224172215|NCT04806165|BEHAVIORAL|Repeated Administration|A discussion with the chatbot, including follow ups over the course of 2 weeks to encourage help seeking for their eating disorder.
224172216|NCT04806165|BEHAVIORAL|Personalized Recommendation|A discussion with the chatbot, including identifying a personalized recommendation for accessing help for their eating disorder.
223585829|NCT03125694|DRUG|Sitagliptin 100mg|Sitagliptin arm took sitagliptin 100 mg daily in combination with metformin 500 mg QID and gliclazide 80 mg TDS for 52 weeks
223585830|NCT03125694|DRUG|Pioglitazone 30 mg|Pioglitazone arm took pioglitazone 30 mg daily in combination with metformin 500 mg QID and gliclazide 80 mg TDS for 52 weeks
223585831|NCT05442177|PROCEDURE|Chemotherapy and Integrated Chinese Medicine With Western Medicine for cancer treatment|
224172217|NCT04806165|BEHAVIORAL|Motivational Interviewing|A discussion with the chatbot, including motivational interviewing techniques to help overcome barriers to seeking care for their eating disorder.
224172218|NCT04806165|BEHAVIORAL|Core Modules Only|A discussion with the chatbot, including only the core modules.
224172219|NCT04806165|BEHAVIORAL|Motivational Interviewing, Personalized Recommendation, Repeated Administration|A discussion with the chatbot, including motivational interviewing techniques to help overcome barriers to seeking care for their eating disorder, identifying a personalized recommendation for accessing help for their eating disorder, and follow ups over the course of 2 weeks to encourage help seeking for their eating disorder.
224172220|NCT04806165|BEHAVIORAL|Motivational Interviewing, Repeated Administration|A discussion with the chatbot, including motivational interviewing techniques to help overcome barriers to seeking care for their eating disorder and follow ups over the course of 2 weeks to encourage help seeking for their eating disorder.
224172221|NCT04806165|BEHAVIORAL|Motivational Interviewing, Personalized Recommendation|A discussion with the chatbot, including motivational interviewing techniques to help overcome barriers to seeking care for their eating disorder and identifying a personalized recommendation for accessing help for their eating disorder.
224172222|NCT04806165|BEHAVIORAL|Personalized Recommendation, Repeated Administration|A discussion with the chatbot, including identifying a personalized recommendation for accessing help for their eating disorder and follow ups over the course of 2 weeks to encourage help seeking for their eating disorder.
224172223|NCT04806165|BEHAVIORAL|Psychoeducation|A discussion with the chatbot, including psychoeducational content to increase knowledge related to eating disorders.
224172224|NCT04806165|BEHAVIORAL|Psychoeducation, Repeated Administration|A discussion with the chatbot, including psychoeducational content to increase knowledge related to eating disorders and follow ups over the course of 2 weeks to encourage help seeking for their eating disorder.
224172225|NCT04806165|BEHAVIORAL|Psychoeducation, Personalized Recommendation|A discussion with the chatbot, including psychoeducational content to increase knowledge related to eating disorders and identifying a personalized recommendation for accessing help for their eating disorder.
224172226|NCT04806165|BEHAVIORAL|Psychoeducation, Motivational Interviewing|A discussion with the chatbot, including psychoeducational content to increase knowledge related to eating disorders and motivational interviewing techniques to help overcome barriers to seeking care for their eating disorder.
224172227|NCT04806165|BEHAVIORAL|Psychoeducation, Motivational Interviewing, Personalized Recommendation|A discussion with the chatbot, including psychoeducational content to increase knowledge related to eating disorders, motivational interviewing techniques to help overcome barriers to seeking care for their eating disorder, and identifying a personalized recommendation for accessing help for their eating disorder.
223585832|NCT00958932|BEHAVIORAL|Speech recognition|The TEAM intervention is a program to increase communication with families, provide feedback to families about their refill adherence, assess asthma symptoms, deliver health communication messages, encourage parents to ask questions of asthma care managers, and facilitate refilling ICS prescription. Speech recognition calls will be tailored to specific situations including new or re-issued ICS prescriptions, failure to fill an initial prescription, failure to refill, or failure to refill following an ED visit, hospitalization, or oral steroid burst resulting from an asthma exacerbation.
223483851|NCT04148456|PROCEDURE|Covered Endovacular Reconstruction of Aortic Bifurcation|"* The occlusive lesion is then passed, either subintimal or endoluminal, using crossing wires and catheters.~* After gaining re-entry into the lumen of the aorta, angiography will be confirmed proper positioning for those with a subintimal passage.~* A 10-12 mm V12 LD balloon expandable ePTFE covered stent (Atrium Medical, Maquet Getinge Group, Hudson, NH) will be expanded in the distal aorta approximately 20 mm above the bifurcation through the 9 Fr sheath.~* The proximal 2/3 part of the aortic stent will be flared with a larger balloon, usually 16 mm, thereby creating a funnel shaped covered stent. Subsequently, two 8 mm V12 balloon expandable ePTFE covered stents (Atrium Medical, Maquet Getinge Group, Hudson, NH) will be placed proximally in the distal 1/3 of the aortic stent, and then simultaneously deployed distally into the common iliac arteries creating a tight connection with the first aortic stent, thereby creating the new aortic bifurcation."
223483852|NCT02127853|DRUG|gabapentin|100 mg tid of gabapentin is prescribed to the patient for 1 week after the first eye surgery
223483853|NCT02127853|DRUG|placebo|the same regimen of placebo drug is prescribed to the patient for 1 week after the first eye surgery
223483854|NCT00248560|DRUG|docetaxel|Gemcitabine given 3000 mg/m2 IV over 30 minutes and Docetaxel given 60mg/m2 IV over 60 minutes. The Docetaxel should be administered after the Gemcitabine.
223483855|NCT00248560|DRUG|Gemcitabine|Gemcitabine given 3000 mg/m2 IV over 30 minutes and Docetaxel given 60mg/m2 IV over 60 minutes. The Docetaxel should be administered after the Gemcitabine.
223483856|NCT00954876|DRUG|capecitabine and cetuximab|"Cetuximab 500 mg/m2 IV infusion over 1-2 hours Once every 2 weeks~Capecitabine 1500 mg/m2 PO BID Days 1-7 followed by 7 days of no treatment and repeated every 2 weeks"
223483857|NCT02758470|DRUG|Acetazolamide|250 mg, taken orally three times per day
223483858|NCT02758470|DRUG|Methazolamide|100mg, taken orally two times per day. A placebo pill will be taken between each dose of methazolamide to match the timing of doses and the number of pills between study arms.
223483859|NCT02758470|OTHER|Placebo|A placebo will be taken three times per day
223483860|NCT05546762|DRUG|Povidone-iodine solution|Pleural irrigation with 2% povidone iodine
223483861|NCT05546762|DRUG|Normal saline|Pleural irrigation with normal saline
223483862|NCT05076929|DIAGNOSTIC_TEST|ultrasound|Ultrasonographic measurement of Inferior Vena Cava Collapsibility Index
223483863|NCT01462604|OTHER|non-drug intervention educational programme|educational programme
223585833|NCT05455177|OTHER|Digital first-line intervention for osteoarthritis including exercise and education|The digital OA management programme was delivered by a smartphone application, including education and exercises based on a face-to-face osteoarthritis self-management programme provided nationwide in Sweden and designed according to national and international guidelines. Over 12 weeks, which is the recommended minimum duration of a self-management intervention for OA, a total of 163 exercise sessions and 31 educational sessions are provided.
223585834|NCT02534116|PROCEDURE|Vacuum-assisted closure (VAC) therapy|Following closure of the incision, patients will either have a gauze dressing placed over the incision (control group), or incisional vacuum-assisted closure (VAC) therapy. The dressing will be removed over a time period of 2 to 5 days after surgery. The gauze dressing will be removed at 2 days and the wound VAC will be removed at 5 days.
224072325|NCT00393874|DRUG|Placebo|Participants randomized to PLA will take 4 capsules each night for eight weeks, all capsules will be identical to prazosin capsules. As for participants randomly assigned to PRZ, they will receive a one-week medication supplies in daily dose dispensers. Similarly, participants will also be instructed to be ready for bed at the time they take the medication, and not to engage in any activities that will prevent them from going to bed.
224072326|NCT03228966|DIAGNOSTIC_TEST|Echocardiogram|Screening echocardiogram
224072327|NCT00454805|DRUG|AZD2171|Oral tablet
224072328|NCT00454805|DRUG|Fulvestrant|intramuscular injection
224072329|NCT04870879|PROCEDURE|Liver Transplant|Liver Transplant from cadaveric donors
224072330|NCT04870879|DRUG|Chemotherapy|Chemotherapy
224072331|NCT00767897|DRUG|Human Papillomavirus Vaccine|The HPV vaccination will be administered by intramuscular injection in three separate 0.5mL doses. The recommended schedule is a 3-dose series with dose #2 and #3 administered 2 and 6 months after dose #1, respectively. The minimum interval between dose #1 and #2 of the vaccine is 4 weeks. The minimum recommended interval between dose #2 and #3 of the vaccine is 12 weeks.
224072332|NCT00802685|DRUG|Early ibuprofen|"IBUPROFEN SCHEDULE: initial dose 10 mg/kg, then 2 doses 5 mg/kg each, after 24 and 48 h, slow IV infusion. Initial therapy is blinded. At PDA diagnosis, infants randomized to early treatment receive blinded ibuprofen. Infants randomized to late treatment receive blinded placebo. Hemodynamically significant PDA criteria: SIGNS OF PDA + pulmonary hemorrhage OR SIGNS OF PDA +: Pulmonary edema, plus a large heart on CXR + one of the following: Hypotension, Respiratory failure (due to PDA) defined as at least two of the following: Need for supplemental O2 \> 50%; need IMV \>40; need for PIP \> 20; or need for HFOV. Once hemodynamically significant PDA criteria met, if echo is positive, infants from both groups can receive open label ibuprofen."
224072333|NCT00802685|OTHER|Late ibuprofen expectant group (placebo)|"Drug: Late ibuprofen expectant group (placebo): DOSING SCHEDULE: At PDA diagnosis infants randomized to late ibuprofen expectant group will receive blinded placebo. If hemodynamically significant PDA develops, infants now receive open label ibuprofen at an initial dose of 10 mg/kg, then two doses 5 mg/kg each, after 24 and 48 h, slow IV infusion. Signs of a hemodynamically significant PDA include: SIGNS OF PDA + pulmonary hemorrhage ALONE OR SIGNS OF PDA +: Pulmonary edema, plus a large heart on CXR + one of the following: Hypotension, Respiratory failure (due PDA) defined as at least 2 of the following settings: Need for supplemental O2 \> 50%; need IMV \>40; need for PIP \> 20; or need for HFOV."
224072334|NCT01487512|DRUG|Treatment A: Hydromorphone 8 mg|type= exact number, unit= mg, number= 8, form= tablet, route= oral use. One tablet of Hydromorphone 8 mg in each of 4 treatment sequences.
224072335|NCT01487512|DRUG|Treatment B: Hydromorphone 16 mg|type= exact number, unit= mg, number= 16, form= tablet, route= oral use. One tablet of Hydromorphone 16 mg in each of 4 treatment sequences.
224072336|NCT01487512|DRUG|Treatment C: Hydromorphone 32 mg|type= exact number, unit= mg, number= 32, form= tablet, route= oral use. One tablet of Hydromorphone 32 mg in each of 4 treatment sequences.
224072337|NCT01487512|DRUG|Treatment D: Hydromorphone 64 mg|type= exact number, unit= mg, number= 64, form= tablet, route= oral use. One tablet of Hydromorphone 64 mg in each of 4 treatment sequences.
224072338|NCT00040755|DRUG|rebimastat|Given orally
223483864|NCT05939167|DRUG|mesenchymal stem cell|Mesenchymal stem cell dose is 0.75-1.0×10\*6/kg and is transplanted by intravenous infusion. For the mesenchymal stem cell standard treatment group, the cells are used for three times(at week 0, 2,4 after recruitment) and the mesenchymal stem cell enhanced treatment group, the cells are used for six times(at week 0, 2,4,24,26,28 after recruitment).
224172228|NCT04806165|BEHAVIORAL|Psychoeducation, Personalized Recommendation, Repeated Administration|A discussion with the chatbot, including psychoeducational content to increase knowledge related to eating disorders, identifying a personalized recommendation for accessing help for their eating disorder, and follow ups over the course of 2 weeks to encourage help seeking for their eating disorder.
224172229|NCT04806165|BEHAVIORAL|Psychoeducation, Motivational Interviewing, Repeated Administration|A discussion with the chatbot, including psychoeducational content to increase knowledge related to eating disorders, motivational interviewing techniques to help overcome barriers to seeking care for their eating disorder, and follow ups over the course of 2 weeks to encourage help seeking for their eating disorder.
223585835|NCT02534116|PROCEDURE|Gauze dressing|Following closure of the incision, patients will either have a gauze dressing placed over the incision (control group), or incisional vacuum-assisted closure (VAC) therapy. The dressing will be removed over a time period of 2 to 5 days after surgery. The gauze dressing will be removed at 2 days and the wound VAC will be removed at 5 days.
223585836|NCT00922805|DIETARY_SUPPLEMENT|guar gum|guar gum (20 g/l of formula) for one week
223585837|NCT00875342|DRUG|DCS|1\. Cognitive behavioral treatment with exposure therapy plus D-Cycloserine (100 mg on days of therapy session (approximately 9 times)
224172230|NCT04806165|BEHAVIORAL|Psychoeducation, Motivational Interviewing, Personalized Recommendation, Repeated Administration|A discussion with the chatbot, including psychoeducational content to increase knowledge related to eating disorders, motivational interviewing techniques to help overcome barriers to seeking care for their eating disorder, identifying a personalized recommendation for accessing help for their eating disorder, and follow ups over the course of 2 weeks to encourage help seeking for their eating disorder.
224172231|NCT05753124|OTHER|Observational|This is an observational study
223745134|NCT04317417|BEHAVIORAL|EMPOWER|"Participants will receive weekly material for a total of 5 weeks consisting of 1-2 days of didactic content and several days of brief, real-life skills practice and reporting taking approximately 10-15 minutes to complete. Adolescents and young adults cannot skip ahead, but they can return to old lessons or exercises if they choose. Most exercises are done in a diary format in which past responses are displayed next to their new ones, so that every time they visit that exercise they see their growing list of past positive experiences. Participants will be permitted up to 8 weeks to complete this self-guided intervention."
224072339|NCT00040755|OTHER|laboratory biomarker analysis|Correlative studies
224072340|NCT02772432|BEHAVIORAL|Relaxation Response Resiliency Training for Parents of SPLD|
224072341|NCT04002544|DRUG|NTG patch|A half-NTG patch (dose calculated at 5-12.5 mcg/kg/hr) will be applied to patients at the site of radial pulsation one hour before induction of anesthesia. The NTG patch will be applied to the right upper in half of the patients and will be applied to the left upper limb in the other half
223483865|NCT05939167|OTHER|saline|saline is used as placebo in the placebo comparator group
223483866|NCT00689741|BIOLOGICAL|Cervarix|3 doses of IM injection
223483867|NCT00689741|BIOLOGICAL|placebo|3 doses of IM injection of Al(OH)3 placebo
223483868|NCT04089319|OTHER|Music recording|Participants will listen to music for 45 minutes while they rest with acupuncture needles in place.
223585838|NCT00875342|OTHER|Placebo|2\. Cognitive behavioral treatment with exposure therapy plus a placebo(sugar pill) (Placebo given on days of therapy session (9 times)
223585839|NCT04357509|BIOLOGICAL|Super circulating tumor infiltrating lymphocytes(ScTIL)|"Peripheral blood mononuclear cells (PBMCs) are used for cell preparation. PD-1(programmed death 1) positive T cells are isolated from peripheral blood by blood cell apheresis method and transduced with lentivirus loaded with enhanced receptor and superamplification factor. The obtained ScTIL is used for one-time intravenous infusion."
223585840|NCT05545202|OTHER|Pentaisomaltose|Each subject will receive 1 or 2 bags with cryopreserved cells according to randomization group.
224072342|NCT04002544|OTHER|gauze cover|A gauze will be applied near the radial artery pulsation to ensure blinding
224072343|NCT01545700|DRUG|Control-saline|Patients are randomized to receive saline 2 cc
224072344|NCT01545700|DRUG|Dexamethasone 4 mg|Patients randomized to receive dexamethasone 4mg and 1 cc saline
224072345|NCT01545700|DRUG|Dexamethasone 8 mg|Patients randomized to receive dexamethasone 8mg
224072346|NCT01545700|DRUG|Control saline|Patients are randomized to receive saline 2 cc
224072347|NCT01545700|DRUG|Dexamethasone 4 mg|Patients are randomized to receive dexamethasone 4 mg and saline 1 cc
224072348|NCT01545700|DRUG|Dexamethasone 8 mg|Patients are randomized to receive dexamethasone 8 mg
224072349|NCT02080793|OTHER|Questionnaire|
224072350|NCT04641442|BIOLOGICAL|MAS825|Experimental drug
224072351|NCT04641442|BIOLOGICAL|Placebo|matching placebo
224072352|NCT06558838|DRUG|acyclovir-penciclovir cream|Patients will treat their cold sore with active study drug based upon their randomization
224072353|NCT06558838|DRUG|Abreva|Patients will treat their cold sore with Abreva based upon their randomization
224172232|NCT04395924|DIAGNOSTIC_TEST|Diagnosis of SARS-Cov2 by RT-PCR and : IgG, Ig M serologies in the amniotoc fluid, the blood cord and the placenta|"During labor and delivery~1. Sample of amniotic fluid~2. 2 samples of blood cord after the birth of the new born~3. 2 samples of placenta~These samples will be tested with A RT-PCR COVID-19 test and / or serology's A sample of blood cord and placenta will be frozen at -80 degree C and studied for PCR and viral proteome, cytokines , D-dimers and others inflammatory markers in the PRIMMO Laboratory (Prof. TOUMI and LESPESSAILLES) and after in the Centre of molecular biophysics of CNRS of Orleans (Prof. PICHON)"
224172233|NCT00601510|DRUG|capecitabine|
224172234|NCT00601510|DRUG|cisplatin|
224172235|NCT00601510|DRUG|imatinib mesylate|
224205464|NCT01421524|DRUG|CC-122|Up to 10 subjects with relapsed or refractory PCNSL will be enrolled to a PCNSL cohort to evaluate intermittent schedules of CC-122 and to further explore preliminary signals of efficacy and biomarker hypotheses.
224205465|NCT00294190|DRUG|Topotecan|Topotecan 6mg/m2 IV weekly x 6 consecutive weeks followed by a 2 week break.
224172236|NCT04865016|DEVICE|Tecnis +2.75 D (ZKB00) and Tecnis Symfony (ZXR00)|This study included 30 eyes of 15 cataract patients undergoing cataract surgery with implantation of a low add (+2.75 Diopters \[D\]) bifocal (Tecnis ZKB00; Johnson and Johnson Surgical Vision Inc., Jacksonville, Florida, USA) IOL (MIOL Group) and 30 eyes of 15 patients with implantation of an EDOF (Tecnis Symfony \[ZXR00\]; Johnson and Johnson Surgical Vision Inc., Jacksonville, Florida, USA) IOL (EDOF Group).
224172237|NCT03318822|DEVICE|Q-Collar|An externally-worn medical device that applies mild jugular compression
224172238|NCT05822349|BEHAVIORAL|picograms-enriched label|The intervention care includes usual care (instructions for using each anti-diabetic drug) plus pictograms that show how much medications should be taken at each time of day (morning, noon, evening, and night), how to take them in relation to meals, the purpose of the drug, and the most important non-pharmacologic interventions for diabetic patients (weight loss, exercise, avoiding smoking, blood sugar controlling).
224172239|NCT00600639|DEVICE|Non-invasive mechanical ventilation using a BiPAP Vision or any other ICU ventilators with NIV option|A mode of ventilation that does not require the insertion of the endotracheal tube, since the support is delivered throgh a full face or nasal mask
223483869|NCT04089319|OTHER|Mindfulness recording|Participants will listen to a recording of mindfulness for 15 minutes and then listen to music for 30 minutes while they rest with acupuncture needles in place.
223483870|NCT03782597|BEHAVIORAL|Semi-structured interviews or focus groups to explore families representations and strategies about their teenagers involved in radicalisation process|A sample of representative French families (parents, siblings, and persons identified as attachment figures) of adolescents or young adults (12-25 years old) involved in the radicalisation process will be asked to participate in semi-structured interviews or focus groups to explore their representations and strategies about radicalisation. It will be supplemented by genogram draw sociodemographic data.
224172240|NCT00600639|DRUG|standard medical therapy plus oxygen that includes salbutamol, prednisolone and antibiotics as needed|Standard medical therapy includes drugs like beta2-agonists, steroids, anthicolinergic agents- antibuiotics as needed
224172241|NCT00600639|DRUG|standard medical therapy that includes salbutamol, prednisolone and antibiotics as needed|oxygen plus medical therapy for ARF
223483871|NCT05203016|OTHER|Hipotermia/Normotermia|The temperature will be measured at the beginning and at the end of the surgery, as well as during admission to the Post-Anesthesia Care Unit, where the temperature normalization time will be noted in the event of hypothermia. In retrospect, those variables corresponding to the late postoperative period will be evaluated and the telephone interview will be conducted to assess the quality of care received. All the data will be reflected in the collection booklet that we present in the annex.
223585841|NCT02892721|OTHER|Training with feedback|"One-day workshop of face to face training, comprising a mixture of theory and real-world CTC cases. Radiologists will complete four interpretation assessments lasting 2 to 3 hours: one set of 10 CTC cases immediately prior to training and a further test set of 10 immediately after, with tests repeated at 6 and 12 months (using different CTC cases for each set). Radiologists will be asked to identify colorectal cancer and polyps on the scans and complete an online answer form, including questions regarding diagnostic confidence, site of abnormality and management.~The intervention group will receive online, confidential, individualised feedback after each test, which will include a case by case breakdown of their performance with explanatory answers and learning points."
223585842|NCT05194527|OTHER|Biomarker validation and VOC profile identification|Validation of a panel of plasma markers for the early diagnosis of acute intestinal ischemia with a panel consists of I-FABP, VIL-1, and SM22. Identification of an acute intestinal ischemia specific VOCs profile and evaluate exhaled breath analysis as a diagnostic tool for intestinal ischemia.
223585843|NCT01878994|BEHAVIORAL|Counselling group|
223585844|NCT01878994|BEHAVIORAL|Nereu group|
223585845|NCT01711593|BIOLOGICAL|Bronchoscopy, Segmental Allergen Challenge and Bronchoalveolar Lavage|On the first bronchoscopy day,BAL will first be performed in the lingual without instillation of diluent or allergen. A 2ml aliquot of isotonic diluent is instilled into the right upper lobe.The procedure is repeated in the right middle lobe with instillation of 2ml of standardized cat or mite allergen solution. A test dose concentration of allergen is administered first consisting of 2 ml of allergen at 1/10th(Cat,D.farinae)or 1/30th(D.pteronyssinus)the threshold concentration.If on visual inspection through the bronchoscope there is no evidence of mucosal inflammation after 2 minutes a second segmental allergen challenge will be done in the right middle lobe using 2ml of full-dose allergen at the threshold concentration(Cat,D.farinae)or 1/3 the threshold concentration(D.pteronyssinus). This dose will be predetermined by quantitative skin prick testing.A second bronchoscopy is performed 24 hours after delivery of allergen extract and diluent to obtain BAL fluid from the RUL and RML.
223745135|NCT01916356|OTHER|educational video|Educational video covering topics of basic reproductive biology, infertility etiologies, risk factors, treatments and common myths.
224172242|NCT02608099|DRUG|Interrupted apixaban|Apixaban dose is administered on the evening prior to the procedure; apixaban dose is held on the morning of the procedure; apixaban dose is administered on the evening after the procedure if there were no peri-procedural complications that necessitated withholding anticoagulation for longer duration.
223483872|NCT03336970|OTHER|EDTA|
223745136|NCT06647953|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
224172243|NCT02608099|DRUG|Uninterrupted apixaban|Intervention description: Apixaban dose is administered on the evening prior to the procedure; apixaban dose is administered on the morning of the procedure; apixaban dose is administered on the evening after the procedure if there were no peri-procedural complications that necessitated withholding anticoagulation for longer duration.
224172244|NCT03968523|PROCEDURE|Novel local infiltration technique|Local analgesic infiltration in the mesh fixation site
224172245|NCT03968523|PROCEDURE|TAP block|TAP block technique
224172246|NCT03536689|DIAGNOSTIC_TEST|Amniotic fluid index|Ultrasonography of the amniotic fluid level in each 4 quadrants of uterus then summerize as one value to measure the quantity of amniotic fluid index
224172247|NCT03040479|DRUG|lasmiditan 200 mg|single dose
223483873|NCT03336970|OTHER|NaOCl|
223483874|NCT03336970|OTHER|CHX|
223483875|NCT03336970|OTHER|Calcium hydroxide|
223483876|NCT00200382|DRUG|PS-341 (Velcade-drug)|
223483877|NCT06302036|OTHER|EFT|EFT
223585846|NCT01711593|PROCEDURE|Phlebotomy|200 (40 teaspoons) ml of blood will be obtained from the subjects to collect different leukocyte populations. A second 200 ml of blood will be obtained from the Track 2 subjects 4 weeks later for isolation of T lymphocytes for functional studies.
223585847|NCT06915376|DEVICE|CPES Monitoring|Noninvasive blood pressure data will be collected using a combined pulse oximeter and ECG signal system (CPES) during elective non-cardiac surgery under general anesthesia. This system is used for observational purposes and does not alter the standard of care. The goal is to compare CPES-derived blood pressure values with invasive arterial blood pressure measurements.
224172248|NCT01969604|BEHAVIORAL|Motivational Lifestyle Counselling|"The intervention will focus on individual goal setting and self-efficacy, where participants describe their everyday life in terms of sitting time and set goals how to reduce their daily sitting time. Project staff will introduce the patients to the possible benefits of reducing their daily sitting time.~The intervention focuses on 4 key messages or themes, which are written in booklets that will be handed to the patients: 1) Reduce daily TV-viewing, 2) Substitute sitting with standing when possible, 3) Break up prolonged sitting and 4) Maximum 30 minutes of sitting.~Based on the patients' own individually goals the patients decide how many weekly SMS reminders they want to receive during the 16-week intervention period.Example:~• Hello X. Raise from your table stand-up and allow gravity to assist your lunch to digest. Bonus: You burn more energy when you stand."
224172249|NCT01211366|OTHER|Cell Saver RBCs|Use of cell saver RBCs to decrease the infusion of allogeneic PRBCs, crystalloid, and colloid in post-operative infants following CPB as needed for hemodynamic instability
224172250|NCT01211366|OTHER|Conventional volume infusion|Infusion of allogeneic PRBCs, crystalloid, and colloid as needed for hemodynamic instability
224172251|NCT05320640|DRUG|Chidamide|Chidamide is a novel and orally active benzamide class of HDAC inhibitor that selectively inhibits activity of HDAC1, 2, 3 and 10, which can induce tumor-cell apoptosis, suppress cell proliferation and enhance immune surveillance.
223483878|NCT05884619|DEVICE|Dual-target deep brain stimulation|DBS electrodes will be implanted into the ALIC and the NAcc, electric stimulation of those areas are used to treat alcohol use disorder and to evaluate the efficacy and safety of DBS system.
223483879|NCT01324752|DRUG|PA21 and Losartan with Food|The maximum dose of PA21 will be 15.0 g/day. The maximum dose of Losartan will be 100 mg/day.
223483880|NCT01324752|DRUG|No PA21; Losartan with food|The maximum dose of Losartan will be 100 mg/day.
223585848|NCT01339117|OTHER|Low fermentable substrate diet|Diet low in fermentable oligosaccharides, disaccharides, monosaccharides, and polyols.
223585849|NCT01339117|OTHER|High fermentable substrate diet|Diet high in fermentable oligosaccharides, disaccharides, monosaccharides and polyols
223585850|NCT02694952|BIOLOGICAL|FAV-Africa|Polyspecific antivenom immunoglobulin F(ab)'2 fragments of equine origin manufactured by Sanofi Pasteur, S.A., Lyon, France. Per undiluted 1 ml, the multivalent serum contains ≥25 times the LD50 for mice exposed to venom of Bitis gabonica, Bitis arietans, Echis leucogaster, Echis ocellatus, Naja haje, Dendroaspis polylepis, Dendroaspis viridis, and Dendroaspis jamesoni, as well as ≥20 times the LD50 for mice exposed to venom of Naja melanoleuca and Naja nigricollis.
224172252|NCT05320640|DRUG|Decitabine|Low-dose decitabine inhibits the activity of DNA methyltransferase, which can increase tumor antigens and HLA expression, enhance antigen processing, promote T cell infiltration, and boost effector T cell function.
224172253|NCT05320640|DRUG|Immune checkpoint inhibitors（anti-PD1/PD-L1/CTLA4 antibodies）|Immune checkpoint inhibitors (ICIs) have emerged as effective therapies for many cancers by promoting the reactivation and restoring function of T cells.
224172254|NCT02776904|OTHER|Immediate Post-concussion Assessment and Cognitive Testing|Computerized assessment that provides information related to visual reaction time and visual memory.
223585851|NCT02694952|BIOLOGICAL|EchiTabPlus-ICP|Polyspecific antivenom immunoglobulin of equine origin manufactured by the Clodomiro Picado Institute, San Jose, Costa Rica. Each 10 ml of undiluted antivenom contains enough antibody fragments to neutralize 30 mg of Echis ocellatus venom, 20 mg of Bitis arietans venom and 5 mg of Naga nigricollis venom.
224172255|NCT02776904|OTHER|Gait with single and dual task|Walking alone and then walking while performing a memory task on a tablet.
224172256|NCT02776904|OTHER|Y-Balance test|Dynamic balance test measuring reaching of the leg to the anterior,postero- lateral, and postero-medial directions.
224172257|NCT02776904|OTHER|Psychomotor Vigilance Task|Assessment measuring reaction time based on auditory cues.
224172258|NCT01822912|OTHER|Heart Failure Disease Management Program|Subjects will be assessed 3 times a week while in SNF.
224172259|NCT01822912|OTHER|Heart Failure Usual Care|Subjects will receive standard of care.
224205466|NCT01030055|DRUG|TKI258 (dovitinib)|bioavailability (anhydrate capsules) food (monohydrae capsules)
224205467|NCT03151226|DEVICE|Capnography monitoring|capnography and pulse oximetry will be initiated in the recovery room and worn for 12-24 hours post delivery
223483881|NCT01324752|DRUG|PA21 with food and Losartan 2 hours later|The maximum dose of PA21 will be 15.0 g/day. The maximum dose of Losartan will be 100 mg/day.
223483882|NCT01659905|DRUG|Montelukast|Chewable Tablet
223483883|NCT01659905|DRUG|Singulair|5 mg Chewable Tablet
223483884|NCT03801252|DRUG|Cefazolin|intravenous drugs used as prophylactic antibiotics
223483885|NCT03801252|DRUG|Placebo|Intravenous saline
223585852|NCT02772900|OTHER|Beetroot-based nutritional gel|100 g of beetroot-based nutritional gel containing approximately 12 mmol of nitrate.
223585853|NCT02772900|OTHER|Placebo|100 g of apple-based nutritional gel containing approximately 0.02 mmol of nitrate.
223585854|NCT02747511|DRUG|Haloperidol|
223483886|NCT03801252|DRUG|Azithromycin|prophylactic antibiotic
223483887|NCT04356651|PROCEDURE|Fu's subcutaneous needling(FSN)|In this study, physician will use a disposable Fu's subcutaneous needling(FSN) to penetrate the subject's skin from anterior superior iliac spine(ASIS) to 1/3 superior border of patella. Then the physician will push forward the needle parallel to the skin surface. The physician will sway the needle 45 times in 30 seconds. After swaying the needle, the physician will instruct the subject to do sole dorsiflexion for 10 seconds resisting the physician's opposite force, then the subject take a rest for 10 seconds. The above actions are 3 repetitions. Then the subject do knee flexion and extension for 10 seconds, and take a rest for 10 seconds. These actions are also 3 repetitions. After the above reperfusion approach of muscles, the physician will take out the needle to finish the treatment.
223585855|NCT02747511|DRUG|Placebo|
224172260|NCT04997564|DRUG|Tenofovir Alafenamide 25 MG|All the patients will use prophylactically TAF for 4 weeks before using SOF/VEL once daily for 12 weeks. Group 1 patients will be discontinued TAF once daily therapy at the end of week 28 if no HBV reactivation occurs during treatment .
224172261|NCT04997564|DRUG|Sofosbuvir / Velpatasvir|All the patients will use prophylactically TAF for 4 weeks before using SOF/VEL once daily for 12 weeks. Group 2 patients will be received TAF once daily for 64 weeks. In this study, after week 64.
224172262|NCT04657003|DRUG|Tirzepatide|Administered SC
224172263|NCT04657003|OTHER|Placebo|Administered SC
224172264|NCT04044625|DEVICE|High-intensity NPPV|In the high-intensity NPPV group, patients will undergo pressure-limited NPPV (eg, NPPV in spontaneous/timed mode) at a higher IPAP level. IPAP is initially set at 10 cmH2O and continuously adjusted by increments and decrements of 1-2 cmH2O (typically ranging between 20 and 30 cmH2O), according to patients' tolerance, to obtain a tidal volume (VT) of 10-15 mL/kg. IPAP should be increased as much as possible to decrease PaCO2 to a normal level. However, if PaCO2 decreases to less than 35 mmHg, IPAP should be decreased to achieve normocapnia.
224172265|NCT04044625|DEVICE|Low-intensity NPPV|In the low-intensity NPPV group, patients will undergo pressure-limited NPPV (eg, NPPV in spontaneous/timed mode) with a conventional IPAP level. IPAP is initially set to 10 cmH2O and is continuously adjusted by increments and decrements of 1-2 cmH2O (up to 20 cmH2O), according to patients' tolerance, to obtain a VT of 6-10 mL/kg.
224172266|NCT01728610|DIETARY_SUPPLEMENT|Probiotic (Active high)|Higher dose of probiotic supplement
224172267|NCT01728610|DIETARY_SUPPLEMENT|Probiotic (Active low)|Lower dose of probiotic supplement
224172268|NCT01728610|DIETARY_SUPPLEMENT|Placebo|Placebo
224305818|NCT05644873|DRUG|magnesium sulfate group|Anesthesia induction was provided with propofol (2mg/kg), fentanyl (2mcg/kg). Intubation was performed after administration of 0.6 mg/kg rocuronium with an appropriate endotracheal tube. Anesthesia was maintained using AIR/O2 (50%/50%), 1 minimum alveolar concentration (MAC) sevoflurane, 0.1-0.25 mcg/kg/min remifentanil infusion. The target BIS value was kept between 40 and 50. Systolic blood pressure (SBP) \<90mmHg or \<20% of baseline was considered hypotension; remifentanil infusion was reduced. If no response was obtained, 5-10 mg of IV ephedrine was administered. HR \< 45 beats/min was evaluated as bradycardia; IV atropine 0.5 mg was planned The magnesium group received a bolus of 20 mg/kg of magnesium sulfate in 100 mL of saline for 15 minutes prior to induction, followed by a continuous infusion of 20 mg/kg/hr until skin closure.
224172269|NCT01192581|DRUG|hydroxyethyl starch 130/0.4 and sodium chloride injection|routine treatment for brain hypoperfusion plus hydroxyethyl starch 130/0.4 and sodium chloride injection 500mg
224172270|NCT01192581|DRUG|hydroxyethyl starch 130/0.4 and sodium chloride injection|routine treatment for brain hypoperfusion plus hydroxyethyl starch 130/0.4 and sodium chloride injection 1000mg
224172271|NCT01192581|DRUG|hydroxyethyl starch 130/0.4 and sodium chloride injection|routine treatment for brain hypoperfusion plus hydroxyethyl starch 130/0.4 and sodium chloride injection 1500mg
224172272|NCT01768624|PROCEDURE|dialysis, kidney transplant|
224172273|NCT02666079|DEVICE|LightPath® Imaging System.|Intra-operative use of the LightPath® Imaging System.
224172274|NCT03288558|OTHER|A comprehensive perioperative mechanical ventilation strategy|"1\) Intervention group.~* Recruitment maneuvers (doubling the tidal volumes for 10 consecutive breaths) every 30min and after every time mechanical ventilation is stopped for surgical reasons, suctioning occurs or the breathing circuit is disconnected~* Mechanical ventilation will be continued during CPB (PEEP 5 cm H2O, respiratory rate 8/min, Tidal Volume 6 ml/kg PBW, FiO2 21%~* Avoidance of lung de-recruitment during patient's transfer (use of PEEP via PEEP valves, endotracheal tube clamps during disconnection from the breathing circuit)~* Avoidance of disconnection from respiratory circuit during respiratory secretions suctioning (applying closed suction circuits)~* For the remaining aspects the mechanical ventilation settings will be the same as in the control group.~Tidal volume 6ml/kg PBW PEEP 5cm H20 FiO2 to target SatO2 of 92-97% Discontinuation of mechanical ventilation during cardiopulmonary bypass"
223483888|NCT04356651|PROCEDURE|Transcutaneous Electric Nerve Stimulation|Transcutaneous electrical nerve stimulation (TENSor TNS) is the use of electric current produced by a device to stimulate the nerves for therapeutic purposes. TENS, by definition, covers the complete range of transcutaneously applied currents used for nerve excitation although the term is often used with a more restrictive intent, namely to describe the kind of pulses produced by portable stimulators used to treat pain. The unit is usually connected to the skin using two or more electrodes. A typical battery operated TENS unit is able to modulate pulse width,frequency and intensity. Generally TENS is applied at high frequency (\>50 Hz) with an intensity below motor contraction (sensory intensity) or low frequency (\<10Hz) with an intensity that produces motor contraction.
223483889|NCT01627717|DRUG|Maraviroc (5 days)|Subjects will receive maraviroc 150 mg tablets (1 tablet) every 12 hours from days 1 to 5 inclusively.
223483890|NCT01627717|DRUG|Maraviroc and boceprevir (14 days)|From days 6 to 19, inclusively, boceprevir 800 mg (4 capsules of 200 mg) every 8 hours with food will be given with maraviroc 150 mg (1 tablet of 150 mg) every 12 hours.
223483891|NCT02521480|DEVICE|Active Transcranial Magnetic Stimulation|TMS is a non-invasive treatment. During TMS treatment, a coil, which creates a magnetic field, will be placed on the left prefrontal area of the head. Active TMS will stimulate for 4 seconds, pause for 26 seconds, and repeat this for approximately 40 minutes. There will be a total of 3000 pulses during treatment. We expect TMS to decrease pain and depression. In order to find out if this is true, we will compare real TMS with sham (inactive) TMS.This will allow us to decide if active TMS is successful because of electrical stimulation, or because of the support, concern, and understanding of the research team.
223483892|NCT02521480|DEVICE|Sham Transcranial Magnetic Stimulation|Inactive treatment (simulation of active TMS)
223483893|NCT02451878|BEHAVIORAL|E-Couch|e-couch is an online CBT based intervention
223483894|NCT00527059|DRUG|Levosimendan in addition to standard therapy|intravenous infusion of levosimendan (10 minutes bolus with 6 mcg/Kg according to physician judgement, followed by 0.1 mcg/Kg/min for 24 hours) in addition to standard therapy
223483895|NCT00527059|DRUG|spironolactone, beta-blockers,ecc|
223483896|NCT03778632|BEHAVIORAL|individualized desensitization exercises|implementing individualized desensitization exercises in standard application of intensive stuttering group therapy for school-age children who stutter
224172275|NCT01736176|DRUG|Levodopa-Carbidopa Intestinal Gel|"Levodopa-carbidopa intestinal gel (LCIG) for upper-intestinal infusion is a suspension of levodopa (20 mg/mL) and carbidopa monohydrate (5 mg/mL) in an aqueous gel, administered continuously by a portable pump via a percutaneous endoscopic gastrojejunostomy (PEG-J) tube.~The rate of LCIG infusion was expected to be within the range of 1 to 10 mL/hour (20 to 200 mg of levodopa/hour) in most instances over a period of 16 consecutive hours."
224172276|NCT01736176|PROCEDURE|Percutaneous Endoscopic Gastrostomy with Jejunal Extension (PEG-J)|
224172277|NCT01736176|DRUG|Levodopa-carbidopa Immediate Release (LC-IR) Tablets|After LCIG initiation, participants could take prescribed oral levodopa-carbidopa immediate or continuous release (i.e., oral LC prescribed by the investigator) for nighttime use.
224172278|NCT06341738|BEHAVIORAL|Video education about HPV and HPV vaccine|video animation in 8 minutes to promote about HPV and HPV vaccine. the video is played in front of class using LCD projector.
224172279|NCT06341738|BEHAVIORAL|Electronic reminder messages|Reseachers send reminder messages twice per vaccination event (e.g., 7 days and 1 day before vaccination event), with a total of four times sending reminder messages using the app on the smartphone.
224172280|NCT06341738|BEHAVIORAL|Usual Information Service|this usual information (e.g., the HPV vaccination event) was delivered face-to-face by staff in front of class
224172281|NCT04288713|DRUG|Eculizumab|A distal complement inhibitor.
224172282|NCT00158275|BEHAVIORAL|Cognitive behavioral therapy|Cognitive behavioral therapy focuses on identifying and eliminating maladaptive beliefs and thoughts.
224172283|NCT00158275|DRUG|Antidepressants|Antidepressant drugs try to eliminate symptoms of depression such as persistent sadness and disinterest in normal or pleasurable activities.
224172284|NCT00158275|BEHAVIORAL|Problem solving therapy|Problem solving therapy identifies problems that interfere with everyday functions and that contribute to depression and disability. The treatment then provides compensatory strategies that are designed to bypass the person's cognitive limitations and to improve adaptive functioning in the home environment.
224172285|NCT01442545|DRUG|JNJ-39758979 / MTX|Day 1: MTX: Route=oral use, single dose of participant's weekly MTX dose; Days 3-15: MTX: Route=oral use, single dose of participant's weekly MTX dose and JNJ 39758979: Type=exact, unit=mg, number=300, form=tablet, route=oral use, administered daily.
224172286|NCT02763605|OTHER|no intervention|
224172287|NCT03398187|DEVICE|cardiac catheterization|diagnostic and interventional cardiac catheterization
224172288|NCT03919682|OTHER|Experimental: Training, Phase 1|Weeklong training in signs, symptoms and treatability of breast cancer, performance of clinical breast exam, and structured algorithms for management of breast complaints followed by regular mentorship for health center nurses. CHWs received a one-day training in breast awareness and how to educate communities about breast health.
224172289|NCT03919682|OTHER|Experimental: Training, Phase 2|Weeklong training in signs, symptoms and treatability of breast cancer, performance of clinical breast exam, and structured algorithms for management of breast complaints followed by regular mentorship for health center nurses. CHWs received a one-day training in breast awareness and how to educate communities about breast health.
223483897|NCT01134042|DRUG|Fluticasone Furoate/Vilanterol Inhalation Powder|Fluticasone furoate/Vilanterol inhalation powder inhaled orally once daily for 24 weeks
223483898|NCT01134042|DRUG|Fluticasone Furoate Inhalation Powder|Fluticasone furoate inhalation powder inhaled orally once daily for 24 weeks
223483899|NCT01134042|DRUG|Fluticasone Propionate Inhalation Powder|Fluticasone propionate inhalation powder inhaled orally twice daily for 24 weeks
223483900|NCT01134042|OTHER|Placebo Inhalation Powder 1|Placebo in novel dry powder inhaler once daily
223483901|NCT01134042|OTHER|Placebo Inhalation Powder 2|Placebo in Diskus inhaler twice daily
223483902|NCT04189523|OTHER|SOC Pain Management|Study subjects will be compared to historical controls selected for same age +/- 5yrs, gender, fracture type who meet the inclusion criteria and do not have historical documentation of one of the exclusion criteria. Controls will be identified by the ICD-10 injury codes selected for use in this study. Clinical course and pain management data will be collected through the EMR only.
223483903|NCT04189523|PROCEDURE|Early US Guided Nerve Block Administration|US-Guided regional anesthesia (fascia illiaca compartment block or brachial plexus block)
223585856|NCT00110461|DRUG|Aripiprazole|Treatment Arm 1 (10 mg treatment arm): Aripiprazole 2 mg QD for 2 days, aripiprazole 5 mg QD for 2 days, and aripiprazole 10 mg QD as the target dose starting on Day 5. Subjects remained on the 10 mg dose for the remainder of the treatment period Subjects reached their target dose through a forced titration schedule and proceeded with treatment at their target dose until Week 4. If the subject reached Week 4, he or she continued into the Extension Phase, a 6-month double-blind treatment period, beginning at the same dose taken at the end of the Acute Phase.
224172290|NCT05140694|DRUG|Empagliflozin|Empagliflozin 10 mg p.o. once daily (available to control over \~25mg)
224172291|NCT05140694|DRUG|Dulaglutide|Dulaglutide 0.75mg s.c. once a week (available to control over \~1.5mg)
224172292|NCT05140694|DRUG|Empagliflozin and Dulaglutide|Empagliflozin 10 mg p.o. once daily with Dulaglutide 0.75mg s.c. once weekly
224205468|NCT03620760|DRUG|Ticagrelor 90 mg|Ticagrelor (AZD6140) 90 mg twice daily dose
224205469|NCT03620760|DRUG|Ticagrelor 45 mg|Ticagrelor (AZD6140) 45 mg twice daily dose
224205470|NCT03620760|DRUG|Aspirin|Aspirin 100 mg once daily dose
224205471|NCT00745459|DRUG|NPO-11|20 mL NPO-11
224205472|NCT00171080|DRUG|valsartan|
224205473|NCT00171080|DRUG|irbesartan|
224205474|NCT05459012|OTHER|follow-up|Questionnaire of Quality of life
224205475|NCT02427425|DEVICE|TENS|
224205476|NCT05800327|DRUG|Levilimab|Subcutaneous or intravenous injection of levilimab with placebo.
224205477|NCT01015456|DRUG|mycophenolate sodium|per oral, twice daily, for 12 months
224205478|NCT01015456|DRUG|cyclophosphamide|intravenous, monthly, for 6 months
224205479|NCT04755426|BEHAVIORAL|AVITA--Aortic Valve Improved Treatment Approaches|AVITA is an interactive shared decision making tool that helps patients clarify their treatment goals and preferences and communicate those preferences to their valve specialist.
224205480|NCT00002560|BIOLOGICAL|monoclonal antibody 3F8|
224205481|NCT00002560|BIOLOGICAL|sargramostim|
224205482|NCT05471063|DRUG|Amphotericin B Colloidal Dispersion|Amphotericin B Colloidal Dispersion 3.0-4.0 mg/kg/d (subject to adjustment, maximum dose not exceeding 6.0 mg/kg/d) . The course of induction therapy is at least four weeks.
224172293|NCT05290389|OTHER|SMART AMI APPLICATION|"SMART AMI allows real-time sharing and review of patient history and ECG between Emergency Department physicians and Interventional Cardiologists to allow for immediate decision-making regarding the need for percutaneous coronary intervention.~Participant physicians will use a smartphone application to communicate, transmit the ECG, and activate the STEMI team. This application enables calling and transmission of up to three images of ECGs, which can be reviewed immediately by the Interventional Cardiologist when communicating with the referring physician."
224172294|NCT04874129|DRUG|YYC506-T and YYC506-A (phase 1)|Comparator
224172295|NCT04874129|DRUG|YYC506 (phase 1)|Test
224172296|NCT04874129|DRUG|YYC506-T and YYC506-A (phase 2)|Comparator
223483904|NCT04448808|DRUG|BX-1|BX-1 (dronabinol), oral solution. All patients enrolled establish their individually tolerable dose by dose Titration.
223483905|NCT04448808|DRUG|Placebo|Placebo of BX-1, oral solution
223483906|NCT03113097|OTHER|Embryo transfer|Transfer of different qualities of embryos at blastocyst stage
223483907|NCT04943783|DRUG|Atorvastatin 20mg|One with the intervention (Atorvastatin, 20mg OD), 20 patients for this arm.
223483908|NCT06541015|DEVICE|InTENSity 10 TENS Stimulator|InTENSity 10 TENS stimulator is a portable electrotherapy device featuring Transcutaneous Electrical Nerve Stimulation (TENS) therapeutic device. The stimulator sends a gentle electrical current to underlying nerves and muscle group via electrodes applied on the skin. The parameters of device are controlled by the buttons.
223483909|NCT04085016|DEVICE|Keratograph 5M, Oculus, Wetzlar, Germany|
223483910|NCT05525468|DRUG|TDM-180935|TDM-180935 topical ointment
223483911|NCT05525468|DRUG|Placebo|Placebo for TDM-180935 topical ointment
223585857|NCT00110461|DRUG|Aripiprazole|Treatment Arm 2 (30 mg treatment arm): Aripiprazole 2 mg QD for 2 days, aripiprazole 5 mg QD for 2 days, aripiprazole 10 mg QD for 2 days, aripiprazole 15 mg QD for 2 days, aripiprazole 20 mg QD for 2 days, aripiprazole 25 mg QD for 2 days, and aripiprazole 30 mg QD as the target dose starting on Day 13. Subjects remained on the 30 mg dose for the remainder of the treatment period. Subjects reached their target dose through a forced titration schedule and proceeded with treatment at their target dose until Week 4. If the subject reached Week 4, he or she continued into the Extension Phase, a 6-month double-blind treatment period, beginning at the same dose taken at the end of the Acute Phase.
223585858|NCT00110461|DRUG|placebo|Placebo tablet
224172297|NCT04874129|DRUG|YYC506 (phase 2)|Test
223483912|NCT00766220|DRUG|SIR-spheres Agent Administration|SIR-Spheres, resin microspheres containing pure Beta emitter Yttrium-90, given through femoral catheter over 10 minutes.
223483913|NCT00766220|DRUG|Cetuximab|"400 mg/m2 by vein over 2 hours once a week.~Cetuximab infusions will be continued weekly at a dose of 250 mg/m2 unless toxicity necessitates interruptions."
223483914|NCT00766220|DRUG|Irinotecan|350 mg/m2 (or 300 mg/m2 in patients who are greater or equal to 70 years of age, or have an ECOG PS of 2 or have had prior pelvic and/or abdominal irradiation), by vein over 90 minutes, every three weeks.
223483915|NCT01905072|OTHER|Education Home Visits|"Intervention will include educational home visits on:~1. Growth monitoring and feedback~2. Feeding: support exclusive breastfeeding until 6 months; delay solid feeding until 6 months; appropriate amounts of food for age; stop bottle feeding at 12 months; have nothing but breast milk/formula/4 oz juice in bottle; limit juice amount to 4 oz day; introduce cup by 10-11 months; no sweetened beverages; limited amounts of sweets.~3. Parenting: recognizing hunger and satiety cues; handling colic/crying; engaging baby in play.~4. Activity: being active with the baby; no screen time for baby and limited to 1 hour for 1-3 year olds; promote active play while maintaining safety.~5. Sleep: at least 10-12 hours sleep per day needed; how to promote sleeping environment for baby."
223745137|NCT06647953|PROCEDURE|Biospecimen Collection|Tumor tissue is collected and centrally reviewed by a study pathologist
223483916|NCT02328105|DRUG|Carboplatin|Dosing: AUC = 6; on Day 1
223483917|NCT02328105|DRUG|Abraxane|100 mg/m\^2; Days 1, 8, 15
223483918|NCT00657566|OTHER|duration of antibiotics|4 +/- 1 days of antibiotics
223483919|NCT00657566|OTHER|duration of antibiotics|active comparator antibiotics given until 2 days after resolution of fever, elevated white blood cell count, and gastrointestinal dysfunction.
223483920|NCT02612857|DRUG|IMO-8400 Dose Group 1|IMO-8400 Dose 1 subcutaneous injections once a week for 24 weeks.
223483921|NCT02612857|DRUG|IMO-8400 Dose Group 2|IMO-8400 Dose 2 subcutaneous injections once a week for 24 weeks.
223483922|NCT02612857|DRUG|Placebo|normal saline subcutaneous injections once a week for 24 weeks.
223483923|NCT01588509|DRUG|Romosozumab|Administered by subcutaneous injection
223483924|NCT03276143|DRUG|Enoxaparin|40 mg enoxaparin administered as subcutaneous injection once daily
223483925|NCT03276143|DRUG|Apixaban|2.5 mg apixaban administered as tablet orally twice daily
223483926|NCT03276143|DRUG|BAY1213790|Single dose of BAY1213790 administered as intravenous infusion
223483927|NCT00165074|DRUG|Infasurf (drug)|Infasurf 3 cc/kg instilled via endotracheal tube q 12-24 hours x 2 doses
223745138|NCT06647953|PROCEDURE|Bone Scan|Undergo bone scan
223745139|NCT06647953|PROCEDURE|Computed Tomography|Undergo CT
224172298|NCT02781662|BEHAVIORAL|Pharmacist Home-Visit|
224172299|NCT02955446|DRUG|PF-03084014|Two patients enrolled in this study will continue receiving 80mg BID doses of PF-03084014, which was the same dose/schedule of their latest cycle on protocol A8641014. PF-03084014 will be administered twice a day in the morning and evening divided by approximately 12 hours. PF-03084014 should be administered in cycles of 21 days continuously.
224172300|NCT00417248|DRUG|Cisplatin|Cisplatin 50 mg/m2 IV, days 1 and 8 of 28 day cycle
224172301|NCT00417248|DRUG|Etoposide|Etoposide 50 mg/m2 IV, days 1-5 of 28 day cycle
224172302|NCT00417248|PROCEDURE|Radiotherapy|Concurrent chest radiation (planned dose is 5940 cGy with an additional, optional boost of 1080 cGy to a total allowed dose of 7020 cGy)
224172303|NCT00417248|DRUG|Sorafenib|Maintenance therapy of Sorafenib 400 mg PO BID, to begin a minimum of 6 and maximum of 9 weeks from completion of chemo-radiotherapy until PD, intolerable toxicity, or up to 6 months
224172304|NCT01344213|DRUG|Pregabalin|Oral single-dose of pregabalin (150 mg) and placebo (P) 1-2 hours before starting spinal anesthesia with intrathecal morphine 0.2 mg.
224172305|NCT01344213|DRUG|Celecoxib|Oral single-dose of celecoxib (400 mg) and placebo(C)1-2 hours before starting spinal anesthesia with intrathecal morphine 0.2 mg.
224172306|NCT01344213|DRUG|Pregabalin with celecoxib|Oral single-dose of pregabalin (150 mg) and celecoxib (400 mg) (PC) 1-2 hours before starting spinal anesthesia with intrathecal morphine 0.2 mg.
224172307|NCT01344213|DRUG|Placebo|Oral single dose of placebo 2 capsules 1-2 hours before starting spinal anesthesia with intrathecal morphine 0.2 mg
224172308|NCT00013689|DRUG|Fansidar (pyrimethamine and sulfadoxine)|
223483928|NCT01983930|BEHAVIORAL|Kundalini yoga and meditation|Participants will participate in a 60 minute yoga and meditation session weekly for 12 weeks and will be assigned a daily Kirtan Kriya meditation (12 minute duration) for 12 weeks.
223483929|NCT01983930|BEHAVIORAL|Memory Training|Participants will attend a weekly memory training class for 12 weeks as well as receive daily memory homework (12 minute duration) for the 12 weeks.
224172309|NCT00537251|DRUG|Insulin glargine|
224172310|NCT03984916|DIETARY_SUPPLEMENT|Hesperidin Pharma|Two capsules with 250 mg of sweet orange extract with a mixture of hesperidin isomers -S and -R.
224172311|NCT03984916|DIETARY_SUPPLEMENT|Hesperidin Pharma_M|Two capsules with 250 mg of sweet orange extract each with a mixture of hesperidin isomers -S and -R and micronized.
224172312|NCT03984916|DIETARY_SUPPLEMENT|Cardiose|Two capsules with 250 mg of sweet orange extract each with more than 90% of hesperidin as isomer -S and micronized.
224205483|NCT05471063|DRUG|flucytosine|Flucytosine 100 mg/kg/d for induction therapy and consolidation therapy of cryptococcal meningitis. The course of induction therapy is at least four weeks, and consolidation therapy for at least 6 weeks.
224205484|NCT05471063|DRUG|fluconazole|Fluconazole (400-600 mg/d) for consolidation therapy for at least 6 weeks.
224305819|NCT05644873|DRUG|control group saline|Anesthesia induction was provided with propofol (2mg/kg), fentanyl (2mcg/kg). Intubation was performed after administration of 0.6 mg/kg rocuronium with an appropriate endotracheal tube. Anesthesia was maintained using AIR/O2 (50%/50%), 1 minimum alveolar concentration (MAC) sevoflurane, 0.1-0.25 mcg/kg/min remifentanil infusion. The target BIS value was kept between 40 and 50. Systolic blood pressure (SBP) \<90mmHg or \<20% of baseline was considered hypotension; remifentanil infusion was reduced. If no response was obtained, 5-10 mg of IV ephedrine was administered. HR \< 45 beats/min was evaluated as bradycardia; IV atropine 0.5 mg was planned The same volume of isotonic saline for the control group was administered as indicated in the magnesium group.
223483930|NCT00158613|BIOLOGICAL|Carticel (autologous cultured chondrocyte) implantation|Each Carticel vial of autologous cultured chondrocytes contains approximately 12 million cells implanted into the defect and secured with a periosteal flap
223483931|NCT01060488|OTHER|GHRH+Arg, GHRH+Arg, ITT|GHRH+Arg repeatability test (2 tests) + comparison with one IT test
223483932|NCT01060488|OTHER|ITT, ITT, GHRH+Arg.|IT repeatability test (2 tests) + comparison with one GHRH+Arg test
223483933|NCT04208932|DRUG|SSRIs|Selective Serotonin Reuptake Inhibitors
223483934|NCT00393367|DRUG|Budesonide inhalation suspension (0.5 mg/2mL) 2mg, albuterol (5mg/mL) 7.5 or 10mg|Patients randomized to budesonide inhalation suspension (BIS) receive 2 nebulized albuterol sulfate (5mg/mL) doses (2mL =10mg for patients over 20kg, 1.5mL =7.5mg for patients 10-20kg) mixed with 8mL (2mg) of BIS(0.5mg/2mL). The albuterol sulfate and BIS mixture is delivered by a medium volume, high flow nebulizer (AirLife Mister FinityTM)with an oxygen flow rate of 8L/min via a tight-fitting face mask.
223483935|NCT00393367|DRUG|Prednisolone, prednisone, or methylprednisolone|All patients are given 2mg/kg of systemic corticosteroids (max 60mg). Patients who can tolerate pills are given oral prednisone, those who cannot are given oral prednisolone, and those who cannot tolerate oral medications are given IV methylprednisolone.
223483936|NCT00393367|DRUG|Albuterol, ipratropium bromide|While guardians are approached for possible participation, patients are given a single nebulized dose of albuterol sulfate (5mg/mL) mixed with ipratropium bromide (500mcg/2.5mL). Patients who weigh 10-20kg receive 3.75mg of albuterol. Patients over 20kg receive 5mg of albuterol. All patients receive 500mcg of ipratropium bromide. Albuterol sulfate and ipratropium bromide are delivered by a medium volume, high flow nebulizer (AirLife Mister FinityTM)with an oxygen flow rate of 8L/min via a tight-fitting face mask.
224205485|NCT03576430|DEVICE|active stress handling|biofeed back stress handling
224205486|NCT00263796|DRUG|Oxytocin|10 international units = 1 cc, IV over 4 hours
223585859|NCT05342337|OTHER|Telerehabilitation Group|"The Telerehabilitation program includes a Biopsychosocial Exercise Therapy (BETY) approach.~BETY approach includes patient education on pain, functional body stabilization exercises (mind-body information management), dance therapy authentic movement (emotion-state information management), and sexual information management.~Telerehabilitation group participate in the sessions that last for one and a half hours, 3 days a week for 12 weeks, video conference over the Zoom program. The investigator, who provides supervision during the sessions, also participates in the exercises simultaneously."
223585860|NCT05342337|OTHER|Control group|The control group participants include those who do not want to receive exercise treatment with telerehabilitation and take their routine medications during the 12 weeks period.
223585861|NCT00531583|DRUG|Autologous peripheral Bld Stem Cell Transplantation with In Vivo Purging as an alternate stem cell transplantation|Autologous PBSCT
223585862|NCT05772078|OTHER|Assess compliance rate and demographics|Records to evaluate attendance rate
223585863|NCT03311984|DIAGNOSTIC_TEST|anti Xa level|monitoring the anti-Xa level according to LMWH emploing
223585864|NCT02616393|DRUG|Tesevatinib|
223585865|NCT02391532|DIETARY_SUPPLEMENT|L. reuteri DSM 17938/ATCC PTA|Ingestion of active lozenge twice daily for 12 weeks
224205487|NCT00263796|DRUG|Placebo|Normal Saline, IV over 4 hours
224205488|NCT03957317|OTHER|Eye mask and ear plugs|Subjects receive one pair of eye mask and ear plugs during their stay in the surgical ICU.
224172313|NCT04162145|DEVICE|Active BRIDGE device placement|The active BRIDGE device will be placed by a blinded medical provider. The severity of opioid withdrawal signs and symptoms will be assessed with the COWS, pain and cognitive functioning tests at several time points. Patients will be dosed with buprenorphine at the blinded provider's discretion. Supportive medications to help manage signs and symptoms of opioid withdrawal will NOT be allowed for one hour after the first dose of buprenorphine. Subjects will be asked to return to clinic for additional visits based on the clinic standard of care. Subjects will be reassessed using COWS, OCS and VAS at each subsequent visit, or remotely (via phone) when unrequired to return to clinic during the 5-day trial. The device will be removed at the clinic visit on Day 5 and disposed of in a sharps container. If the patient cannot come back on day 5, they will be instructed to remove the device at home and bring it back at the next clinic appointment for proper disposal.
224172314|NCT04162145|DEVICE|Inactive BRIDGE device placement|The inactive or sham BRIDGE device will be placed by a blinded medical provider. The severity of opioid withdrawal signs and symptoms will be assessed with the COWS, pain and cognitive functioning tests at several time points. Patients will be dosed with buprenorphine at the blinded provider's discretion. Supportive medications to help manage signs and symptoms of opioid withdrawal will NOT be allowed for one hour after the first dose of buprenorphine. Subjects will be asked to return to clinic for additional visits based on the clinic standard of care. Subjects will be reassessed using COWS, OCS and VAS at each subsequent visit, or remotely (via phone) when unrequired to return to clinic during the 5-day trial. The device will be removed at the clinic visit on Day 5 and disposed of in a sharps container. If the patient cannot come back on day 5, they will be instructed to remove the device at home and bring it back at the next clinic appointment for proper disposal.
224172315|NCT00564759|DRUG|retroviral SF71-gp91phox transduced CD34+ cells|autologous ex-vivo retroviral transduced (SF71-gp91phox) CD34+ cells
224172316|NCT05882487|GENETIC|KL002 injection solution|Neurosurgical delivery of KL002 to the brain
224172317|NCT02949414|PROCEDURE|Cadaveric decellularised tracheal scaffold seeded with autologous mesenchymal cells|The tracheal graft will be manufactured from cadaveric tracheal scaffold and bone marrow derived mesenchymal cells.
224172318|NCT01695928|DEVICE|Extracorporeal shockwave therapy|1000 impulses
224172319|NCT01695928|DEVICE|ESWT placebo|0 impulses, acoustic effect
224172320|NCT00934791|DRUG|Tacrolimus|Tacrolimus 6-10 mg/day (maintain trough levels of 8-10 ng/mL)
224172321|NCT00934791|DRUG|Sirolimus|Sirolimus 3-5 mg/day (maintain high-performance liquid chromatography (HPLC) blood level 10-15 ng/mL)
223483937|NCT00393367|DRUG|Ipratropium bromide|500 mcg/2.5mL. All patients receive a final dose of ipratropium bromide after the intervention or placebo. The ipratropium bromide is delivered by a medium volume, high flow nebulizer (AirLife Mister FinityTM) with an oxygen flow rate of 8L/minute via a tight-fitting face mask.
223483938|NCT05742295|DRUG|Vitamin K|Coadministration of vitamin K with the first dose of cefoperazone/sulbactam
223483939|NCT05330949|DIAGNOSTIC_TEST|Optical coherence Tomography Angiography, Uterine artry doppler|vascular changes in retina by OCT angiography and uterine artry doppler in the first and second trimesters
223483940|NCT02560467|DRUG|Echo and myocardial contrast echocardiography perfusion imaging|"Myocardial blood flow will be assessed by myocardial contrast echo. Perfusion at rest and stress will be quantified and compared to patient sx, degree of dysfunction on echo strain imaging, and degree of fibrosis on magnetic resonance imaging (when available) that was ordered as part of routine clinical care.~Myocardial contrast echocardiography will be performed by intravenous administration of ultrasound contrast agent (Definity or Lumason) using FDA-approved dose limits. Vasodilator stress during MCE imaging will be performed using regadenoson at FDA-approved doses."
223585866|NCT02391532|DIETARY_SUPPLEMENT|Placebo|Ingestion of placebo lozenge twice daily for 12 weeks
224172322|NCT00934791|DRUG|Mycophenolate Mofetil|Mycophenolate Mofetil 750 mg twice daily
224172323|NCT00934791|DRUG|Prednisone|Prednisone tapered to 5 mg/day by day 92
223585867|NCT05481099|BEHAVIORAL|Intervention|Cognitive-behavioural-based intervention combined with mindfulness (attention focus), psychoeducation, and relaxation techniques (short version of Jacobson's progressive relaxation, breathing exercises)
223585868|NCT05516849|DRUG|Oxandrolone|Oxandrolone is a synthetic anabolic androgenic steroid that induces its responses by binding to androgen receptors which modulates gene expression to increase protein synthesis and efficient utilisation of amino acids. Oxandrolone was first synthesized in 1962 through 17alpha-alkylation of testosterone resulting in a formal composition of (4bS,7S,9aS,9bR,11aS)-tetradecahydro-7-hydroxy-4aS,6aS,7-trimethyl- cyclopentanaphthopyran-2(1H)-one and molecular formula of C19H30O3.
223585869|NCT05516849|OTHER|Placebo|As there is currently no approved medication to aid in soft-tissue regeneration, we will be using a placebo control.
223585870|NCT03828474|DRUG|Acetazolamide Pill|Acetazolamide pill
223585871|NCT04112979|BEHAVIORAL|Music|45 dB SL, normalized, high-frequency sampled W.A. Mozart Symphony n°4 in D K19 and n°5 in B-flat K22 (from Mozart Symphonies Vol. I - Adam Fisher, Dacapo Records, Frederiksberg C., Denmark, 2013)
224172324|NCT00162799|DRUG|Triflusal (DCI)|
224172325|NCT03097562|PROCEDURE|Femtosecond cataract surgery|Catalys create a circular opening for accessing and removing the cataract.
224172326|NCT01886144|DEVICE|Knee OA Brace|
224205489|NCT05743686|DEVICE|Application|The participants will have access to an app allowing them to report their adverse effects to oral chemotherapy. Basic advices will be given and the hospital pharmacists will be warned.
224205490|NCT01409018|DRUG|Itraconazole|pharmacokinetics
224205491|NCT00731510|DIETARY_SUPPLEMENT|Carbohydrate energy drink|Complex carbohydrates including maltodextrin (97%) dissolved in water to make a a 10% solution, or dissolved in 25mL gels. Ad libitum. Twenty two days.
224205492|NCT00731510|DIETARY_SUPPLEMENT|Aspartame|Aspartame dissolved in water, ad libitum, 22 days.
224205493|NCT01900379|PROCEDURE|CPAP treatment|This device consists in a nasal continuous positive airway pressure. It will be applied just after CABG and for 3 months for OSA/CPAP patients group.
224205494|NCT01900379|OTHER|Sham CPAP treatment|This device consists in a sham continuous positive airway pressure. It will be applied just after CABG and for 3 months for OSA/sham CPAP patients group.
224205495|NCT05761132|DRUG|Pembrolizumab|neoadjuvant immunotherapy
224172327|NCT06241937|BEHAVIORAL|Expanded Clinical Firearm Safety Counseling Training|Members of the DGSOM class of 2027 will participate in a mandatory 3.5 hour training session as a part of the regular curriculum that will include: (1) didactic information on firearm violence epidemiology; (2) suicide epidemiology and introduction to lethal means restriction; (3) firearm safety counseling techniques; (4) a panel of firearm violence survivors / trauma interventionists; and (5) a small group session with discussions of the aforementioned topics and a demonstration of a patient encounter using a standardized patient actor depicting a clinical scenario warranting firearm safety counseling. The training will be taught by faculty members, invited subject matter experts, senior medical students, and the DGSOM Standardized Patient Program.
223483941|NCT05708664|PROCEDURE|precision breast conserving surgery guided by wire guided localization combined with MDCT guided 3D reconstruction|Local anesthesia was induced by using 1% lidocaine before wire location. The wire (localization set, PAJUNK) was placed in the superior, inferior, lateral and interior edge of the tumor through a 20-gauge needle using US guidance one day before BCS, respectively. Then, the patient underwent an immediate supine contrast enhanced CT (Philips Brilliance iCT) scan of the breast. The radiologist performed 3D reconstruction of CT images prior to surgery. Finally, the surgical procedures were performed by experienced breast surgeons combing 3D reconstruction of CT images and wire localizations one day after the localization.
223483942|NCT03286504|BEHAVIORAL|FANMI - Cohort Care|FANMI includes receiving integrated clinical care, group counseling, and social activities in a single session by the same provider to simplify care and strengthen relationships between peers and providers. FANMI groups consist of 5-10 adolescents meeting once per month.
223483943|NCT06109740|DIETARY_SUPPLEMENT|lactobacillus GG|probiotic
223483944|NCT01459926|DRUG|TD-1211|once daily
223483945|NCT01459926|DRUG|TD-1211|Once daily
223585872|NCT04112979|BEHAVIORAL|Mother's lap|45 dB SL, normalized and filtered, high-frequency sampled heartbeat sound, 75 bpm tempo, looped
224172328|NCT00754273|OTHER|etest susceptability testing|E-test methodology is performed on all MRSA samples using standardized inoculum (0.5 McFarland) for Tigecycline, Vancomycin, Teicoplanin, and Linezolid. E test is performed using heavy inoculum for Vancomycin and Teicoplanin (2.0 McFarland).
224172329|NCT06333535|OTHER|foot massage|foot massage
224172330|NCT06333535|OTHER|abdominal massage|abdominal massage
224172331|NCT06333535|OTHER|foot and abdominal massage|foot and abdominal massage
224205496|NCT05066100|OTHER|Prenatal Use of Supple Cups|For pregnant women identified with FIRN and providing consent to participate in this study, Supple Cup usage will be initiated at 32 weeks gestation to begin to elongate the nipples in preparation for breastfeeding.
224205497|NCT03963856|OTHER|parbolic flight|weightlessness during parabolic flight
223483946|NCT01459926|DRUG|TD-1211|Once daily
223483947|NCT01459926|DRUG|Placebo|Once daily
223483948|NCT06060366|PROCEDURE|Pulmonary endarterectomy|removal of chronic thrombus from pulmonary arterial system
223483949|NCT01965795|DIETARY_SUPPLEMENT|Whole Coffee Fruit Concentrate (WCFC)|Neurfactor is a powder dietary supplement patented by Futureceuticals, in which the active ingredient is WCFC. It is hypothesized that the whole fruit of the coffee plant, Coffea arabica, has very unique, important benefits for healthy aging not available from regular coffee, other coffee extracts, green coffee bean extracts, caffeine, or other leading botanicals. NeuroFactor is thought to increase Brain-Derived Neurotrophic Factor, a protein vital for neuron development, repair and protection and essential for learning, memory, alertness, controlling body weight, and energy metabolism.
223585873|NCT04112979|BEHAVIORAL|Soundproof earplugs|Disposable foam earplugs with a noise attenuation of at least 30 dB
223585874|NCT04066634|DEVICE|Vivio System|The Vivio Analysis Software is an analysis software that assists in identifying suspected systolic murmurs associated with aortic stenosis. The Vivio Analysis Software is used with the Vivio System, a non-invasive device used for the detection and amplification of sounds from the heart and arteries.
223585875|NCT03930875|OTHER|Aspirin Resistance testing|Aspirin resistance will be measured using platelet aggregometry (VerifyNow assay)
223585876|NCT05629507|DEVICE|Virtual Reality|"The Virtual Reality intervention will administer through the use of a Virtual Reality headset. The multimedia contents in VR, will have a video quality from 4K to 8K, 360 degrees, and HD audio stereo.~The scenarios are classified into 12 categories: 1) Artistic cities (60 scenarios); 2) Africa (17 scenarios); 3) Hills (26 scenarios); 4) Rivers, lakes and waterfalls (43 scenarios); 5) Sardinia (13 scenarios); 6) Deserts (21 scenarios); 7) Beaches (20 scenarios); 8) Animals (20 scenarios); 9) Mountains (25 scenarios); 10) Concerts (21 scenarios); 11) Sea (24 scenarios); 12) submarine (20 scenarios)."
223745140|NCT06647953|DRUG|Cyclophosphamide|Given IV
223745141|NCT06647953|BIOLOGICAL|Dactinomycin|Given IV
223745142|NCT06647953|DRUG|Dexrazoxane|Given IV
223745143|NCT06647953|DRUG|Doxorubicin|Given IV
224205498|NCT01741909|BEHAVIORAL|education|after a baseline period, shorter intravenous treatment will be promoted by mail, posters, lectures, and pharmacy monitoring of treatment
223483950|NCT01965795|DIETARY_SUPPLEMENT|Nutrim|Nutrim is an oat bran powder Nutrim is hypothesized to bestow a number of benefits such as cardiovascular health, glucose management and healthy digestion. However, improved cognition is not one of the hypothesized benefits. This product is free of caffeine and stimulants.
223483951|NCT01432327|DEVICE|SenseWear display|"Participants use the self-monitoring device (display) to aid behavior change via real-time lifestyle feedback targeting physical activity.~The display has a versatile design that allows it to be clipped to a shirt, bag or belt loop. The Display can help participants stay in sync with their daily goals."
223483952|NCT01432327|DEVICE|Pedometer|Participants receive a pedometer to determine their daily amount of steps. Every day they write down their amount of steps in a step diary.
223745144|NCT06647953|PROCEDURE|Echocardiography Test|Undergo ECHO
223745145|NCT06647953|DRUG|Ifosfamide|Given IV
223745146|NCT06647953|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
224205499|NCT04408300|PROCEDURE|Ophthalmological exam|Retinophotography, OCT-A (Optical Coherence Tomography- Angiography), OCT-B scan (Optical Coherence Tomography B Scan), Measurement of corrected visual acuity in ETDRS (Early Treatment Diabetic Retinopathy Study), Measurement of intraocular pressure, adaptive optics
223483953|NCT01432327|DEVICE|SenseWear Armband|Participants wear the SenseWear Armband for 4 weeks
223483954|NCT01432327|BEHAVIORAL|Personal Coaching|A weekly meeting with a Personal Coach to evaluate the physical activity patterns in daily life
223483955|NCT04729712|PROCEDURE|Anaesthesiologist-administered ultrasound guided Erector Spinae block with catheter insertion|Erector Spinae block: A bolus of 20 ml 0.375% Levobupivacaine will be administered into the erector spinae plane prior to surgical incision. A further bolus of 10 ml 0.25% Levobupivacaine will be given at skin closure if it has been greater than 1 hour after the first bolus of local anaesthetic medication. A continuous infusion of 0.125% Levobupivacaine will be commenced via the sited nerve catheter for postoperative analgesia. This will be started at 10 ml/hr and titrated to effect to a maximum rate of 15 ml/hr.
223483956|NCT04729712|PROCEDURE|Surgeon-administered video-assisted Paravertebral block with catheter insertion|Paravertebral block: A bolus of 20 ml 0.375% Levobupivacaine will be administered into the paravertebral space after the thoracoscopic ports have been sited. A further bolus of 10 ml 0.25% Levobupivacaine will be given at skin closure if it has been greater than 1 hour after the first bolus of local anaesthetic medication. A continuous infusion of 0.125% Levobupivacaine will be commenced via the sited nerve catheter for postoperative analgesia. This will be started at 10 ml/hr and titrated to effect to a maximum rate of 15 ml/hr.
223483957|NCT03398135|DRUG|risankizumab|subcutaneous (SC) injection
223483958|NCT03398135|DRUG|placebo for risankizumab|subcutaneous (SC) injection
223483959|NCT04706221|DEVICE|CM-1500|Blood volume monitor CM-1500
223483960|NCT05231967|OTHER|Cardioversion|In proper atrial fibrillation patients, cardioversion was performed to provide sinus rhythm
223483961|NCT06847360|DEVICE|Home-based taVNS intervention|Home-based taVNS intervention will be administered using the non-invasive taVNS device, Parasym system (Parasym Health, Inc, London, UK).
223483962|NCT00141921|DRUG|Etanercept|Open-label at a dose of 0.8 mg/kg (up to an intended dose of 50 mg) given once weekly by subcutaneous injection
223483963|NCT02497014|DEVICE|1 Stent|Stenting of main vessel should be undertaken with a wire jailed in the side vessel to preserve side vessel flow and access. Stent diameter should be chosen according to diameter of the main vessel immediately distal to the bifurcation. Distal left main should be dilated with a short non-compliant balloon. Side vessel should be rewired and a kissing balloon inflation should be undertaken. Balloon sizes should be according to the diameter of the main and side vessel with individual high pressure inflation followed by a final lower pressure kiss dilatation. Proximal stented portion in the left main coronary artery should be dilated to full expansion using either low pressure dilatation of the kissing balloon pair or a separate individual balloon. It is preferred that non-compliant balloons should be used to limit overstretching of vessels. In case of specific situations described in the protocol the operator may choose to implant a side vessel stent, using same process as described above.
223483964|NCT02497014|DEVICE|2 Stents|"Coronary guide wires should be passed to LAD and Cx/intermediate arteries respectively. One should be designated the main vessel and one should be designated the side vessel. The planned dual stent technique is at the discretion of the operator but should be one of culotte, minicrush, T or TAP. If a crush procedure is chosen, it should ideally be of the DK variety. Stent diameter should be chosen according to the diameter of the vessel immediately distal to the bifurcation. Wire jail, POT, non-compliant balloons, high pressure individual ostial dilatations and final dilatation of the stented proximal left main should be used in accordance with the advice of the EBC. Further treatment to proximal or distal aspects of the main vessel or side vessel can be continued at the discretion of the operator. At any stage, proximal or distal dissections may be treated as required with further stent implantations. At any stage, post-dilatations may be undertaken to optimise stent expansion."
223483965|NCT05791110|DIAGNOSTIC_TEST|Fecal pancreatic elastase 1 test|Fecal pancreatic elastase 1 test are immunoassays for the quantitative determination of fecal pancreatic elastase in human stool samples.
223585877|NCT01528761|BEHAVIORAL|Prosocial Behavior Physical Activity (PBPA)|The PBPA condition involves a cognitive-behavioral intervention to teach participants the behavioral skills to engage in independent physical activity. Participants will engage in supervised physical activity delivered two times a week during months 1 to 3 at the William G. White, Jr. Family YMCA in Winston-Salem, NC. During months 4 to 6, supervised sessions will be held once per week, and sessions will be held once per month in months 7 to 9. Participants will engage in completely independent physical activity in months 10 to 12. PBPA participants will also be able to earn boxes of food for donation to the Second Harvest Food Bank (SHFB) of Northwest North Carolina based upon their weekly physical activity. Lowe's Foods, a regional grocery chain, will donate the food. Participants in the PBPA intervention also will receive a 12-month membership to the William G. White, Jr. Family YMCA at no cost.
223585878|NCT01528761|OTHER|Healthy Aging (HA)|The HA group will receive a health education intervention based on topics from several sources, including the National Institute on Aging's Age Pages, University of Pittsburgh's 10 Keys to Healthy Aging; and Stanford University's Successful Aging program, among other topics . The HA intervention will receive ongoing staff contact, and will provide participants with excellent information on health-related topics. Biweekly 45-minute lectures will be given during months 1 to 6, and once per month during months 7 to 9. After each session, participants will engage in a 15-minute stretching routine. During months 10 to 12, no lectures will be given. After completion of the 12-month assessments, participants will receive a 12-month membership to the YMCA at no cost.
223585879|NCT00769028|DRUG|Hyperimmune caprine serum|Subcutaneous injection of serum, 1ml twice weekly for 6 months
224172332|NCT03763942|BEHAVIORAL|HealthMindr App|Participants in the intervention arm will receive access to the HealthMindr app with basic prevention services (HIV test planning and test locators; risk assessment; HIV treatment locators; and condom, HIV test kit, and at-home STI specimen collection kit distribution) plus monthly PrEP eligibility assessments, PrEP provider locator, enhanced information about PrEP, and referrals to local PrEP navigators. The app also provides information about obtaining health insurance coverage and paying for PrEP.
224172333|NCT03763942|BEHAVIORAL|Control App|Men in the control arm will have access to an app with information pertinent to their participation in the study, including a study events timeline. The app will also allow participants and study staff to communicate via a messaging feature. The control arm app will not contain HIV prevention information.
224172334|NCT01142362|BIOLOGICAL|VGX-3400X|DNA plasmids delivered via IM injection + electroporation using CELLECTRA device
224172335|NCT01060410|GENETIC|Polymorphism Analysis|Analysis of genetic polymorphisms of the drug metabolic enzymes involving in the bio-activation and elimination of cyclophosphamide
224172336|NCT01060410|DRUG|Cyclophosphamide|intravenous injection, 0.2g, once every two days
224172337|NCT01060410|OTHER|Pharmacokinetic analysis|laboratory analysis of concentration of cyclophosphamide and 4-OH-cyclophosphamide in plasma
224172338|NCT01108224|BEHAVIORAL|Psychosocial support|Psycho-social group intervention including patient-education for 6 h per week for 2 weeks and group therapy 2½ h for 8 weeks
224172339|NCT01218061|OTHER|Pre-diabetes screening|The timing of the study is :- Screening of high metabolic risk patients based on a clinical score : Finnish Diabetes Risk Score ≥ 15- if Diabetes Risk Score ≥ 15 or if history of blood glucose between 1.10 and 1.26 g/l (impaired fasting glucose): measuring fasting glycaemia + HbA1C + lipids profile + creatinemia + liver enzymes- if fasting blood glucose between 1.10 and 1.26 g/l (=V0):\* OGTT (oral glucose tolerance test) to identify subjects with impaired glucose tolerance (optional)\* establishment of a serum bank to identify biomarkers (serum, genomic, proteomic) - to plan for 10 years annual follow-up (V1 to V10) with blood sample (fasting glycemia + HbA1C + lipids profile + creatinemia + liver enzymes + serum bank (not after V5)) Making a total of 11 visits (V0-V10) with 6 blood samples.
224172340|NCT05968794|PROCEDURE|Vaginal cerclage|A vaginal cerclage is a short and minor surgical procedure performed under general or regional anesthesia. An unabsorbable suture is placed around/through the cervix to close the cervical canal and to increase its firmness, in order to reduce cervical insufficiency.
223483966|NCT01255020|DRUG|α-Keto Acid with restricted protein diet|"α-Keto Acid: The daily dose of compound α-Keto Acid is 100mg/kg/d. The total daily dose will be divided into three times a day.~Restricted Protein Diet: Diet contain protein 1.0g/kg/d"
223483967|NCT01255020|DRUG|Placebo plus restricted protein diet|"placebo: The daily dose of placebo is 100mg/kg/d. The total daily dose will be divided into three times a day.~Diet contain protein 1.0 g/kg/d."
224172341|NCT05754372|DIAGNOSTIC_TEST|user-friendly and widely applicable algorithm to tailor the treatment of acute neonatal hyperammonemia|user-friendly and widely applicable algorithm to tailor the treatment of acute neonatal hyperammonemia, based on kinetic modelling
224172342|NCT02008461|PROCEDURE|radiofrequency ablation|
223483968|NCT05608863|OTHER|Lifestyle - group sessions|The Combined Lifestyle Intervention Program consists of a total of 7 individual coaching sessions and 16 group sessions in a 2 year program. The individual coaching sessions will be done in a virtual setting.
223483969|NCT05608863|OTHER|Lifestyle - individual coaching|The Individual Intervention consists of a total of 7 individual coaching sessions in a 2 year program and additional written information. These will be done in a virtual setting.
223483970|NCT06843551|RADIATION|Stereotactic Body Radiation Therapy|"The radiation therapy (RT) prescription biologically effective dose (BED10) goal for tumor (α/β=10) aims to achieve at least BED10= 60 Gy for a single fraction plan and at least BED10=100 Gy for a multi-fraction plan. This equates to a prescription dose of at least 20 Gy in a single fraction, 42 Gy over 3 fractions, 50 Gy over 5 fractions, and 62 Gy over 10 fractions.~Radiation therapy must be completed for up to 10 daily treatments within a 15-day course."
223483971|NCT06843551|DRUG|Botensilimab|Participants will be receive 75mg of Botensilimab immunotherapy administered via intravenous infusion, every six weeks for up to 4 doses, about 24 weeks. Botensilimab therapy will begin no later than seven (7) days after completion of radiation therapy.
223483972|NCT06843551|DRUG|Balstilimab|Participants will receive 240mg of Balstilimab immunotherapy, administered via intravenous infusion, every 2 weeks for up to one (1) year. Balstilimab therapy will begin no later than seven (7) days after completion of radiation therapy.
223483973|NCT05665647|DRUG|Cohort 1: SIM0417/ritonavir and itraconazole|SIM0417/Ritonavir: Dose: 750 mg SIM0417 coadministered with 100 mg ritonavir once: Day1-Day2, Day9-Day10, BID; Day3,Day11(once only in the morning); Itraconazole：Dose: 200mg once；Day6-Day13, QD
223483974|NCT05665647|DRUG|Cohort 2: SIM0417/ritonavir and rifampicin|SIM0417/Ritonavir:Dose: 750 mg SIM0417 coadministered with 100 mg ritonavir once: Day1,Day11(once only in the morning); Rifampicin：Dose: 0.6g once; Day4-Day12, QD
223483975|NCT05665647|DRUG|Cohort 3: SIM0417/ritonavir and midazolam|SIM0417/Ritonavir: 750 mg SIM0417 coadministered with 100 mg ritonavir, Day3-Day6, BID; Day7(once only in the morning) Midazolam：Dose: 2mg once; Day1, Day6, QD
223585880|NCT00769028|DRUG|Albumin|Subcutaneous injection of albumin, 1ml twice weekly for 6 months
223585881|NCT02314364|RADIATION|SBRT with protons or photons|
223585882|NCT00205543|PROCEDURE|uvulopalatopharyngoplasty with or without sutures|standard UPPP
223585883|NCT02188498|PROCEDURE|Polysomnography|Polysomnography, also called a sleep study, is a test used to diagnose sleep disorders. Polysomnography records your brain waves, the oxygen level in your blood, heart rate and breathing, as well as eye and leg movements during the study.
223585884|NCT05513313|BIOLOGICAL|JYNNEOS|smallpox vaccine
223585885|NCT03432416|DRUG|NES-E2 CVR|NES-E2 CVR
223585886|NCT02077543|DEVICE|Brain Tissue Imprint - Medical Device (ProTool)|genomic, transcriptomic and proteomic studies.
223585887|NCT03278431|DRUG|Albendazole|Albendazole (400 mg) from Janssen, donated by the World Health Organization
223585888|NCT03278431|DRUG|Pyrantel Pamoate|Pyrantel pamoate (20 mg/kg), will be purchased by the World Health Organization
223585889|NCT03278431|DRUG|Oxantel Pamoate|Oxantel pamoate (20mg/kg) will be produced by the University of Basel
223585890|NCT03278431|DRUG|Mebendazole|Mebendazole (500 mg) from GlaxoSmithKline, donated by the World Health Organization
223585891|NCT01041443|DRUG|5-fluoro-2-deoxycytidine|Given IV
223585892|NCT01041443|DRUG|tetrahydrouridine|Given IV
223585893|NCT01041443|OTHER|laboratory biomarker analysis|Correlative studies
223585894|NCT01041443|GENETIC|reverse transcriptase-polymerase chain reaction|Correlative studies
223585895|NCT01041443|GENETIC|DNA methylation analysis|Correlative studies
223585896|NCT00975065|DRUG|vildagliptin 50 mg bid plus metformin 1500mg (Galvus+Diabex)|vildagliptin 50 mg bid plus metformin 1500mg
223585897|NCT00975065|DRUG|metformin 1500mg plus metformin 500mg or 1000mg (Diabex)|metformin 1500mg plus metformin 500mg or 1000mg
223745147|NCT06647953|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
224172343|NCT02008461|DRUG|botulinum toxin injection|
224172344|NCT02646891|BIOLOGICAL|Trivalent P2-VP8 Subunit Rotavirus Vaccine|Manufactured and supplied by the Walter Reed Army Institute of Research (WRAIR) Pilot Bioproduction Facility (BPF). The trivalent P2-VP8 vaccine was formulated as a sterile suspension containing a total of 360 µg of protein (120 µg of each P type) per mL adsorbed to aluminum hydroxide (1.125 mg of aluminum per mL in a phosphate buffer, pH 7).
224172345|NCT02646891|BIOLOGICAL|Placebo|Sodium Chloride 0.9%, USP for Injection
224172346|NCT04914091|OTHER|Semi-structured interviews and self-administered questionnaires|Interviews and questionnaires will be performed before administration of CAR-T cells, 3 month after and 6 month after, and will last 60 minutes each time. Semi-structured interview using pre-established questionnaires will be completed with a hospital pharmacist, concerning the patient's perception of his family, socio-professional environment, his knowledge of his illness and his treatment, the consumption of prescribed drugs outside the hospital, self-medication, complementary alternative therapies including herbal medicine. Seven self-administered questionnaires will be completed, concerning quality of life, Assessment of Cancer Treatment-Lymphoma, Beliefs about Medicines, Brief Illness Perception, satisfaction with medication, perceived social support scale, and on Health Literacy.
224172347|NCT00992706|DRUG|antiperspirant cream F511|Placebo and verum cream once daily, in the morning, during the first week of the first PLD treatment only, then once daily, three times per week (in the morning). Tube R for right hand and foot, tube L for left hand and foot.
224172348|NCT00992706|DRUG|pegylated liposomal doxorubicin hydrochloride|According to local practice. 1, 2 and 4 week schedules with at least 10mg/m2 per week are allowed.
224172349|NCT03730870|DIAGNOSTIC_TEST|Pharmacogenomics report|Intervention is the performance of a pharmacogenomics laboratory-developed test (LDT) performed by high-throughput sequencing of 38 genes involved in drug pharmacokinetics or pharmacodynamics. The clinician reviews the report results for each subject.
224172350|NCT04708769|BEHAVIORAL|Smartphone App Participants (APP)|Participants will receive calorie, fat, and physical activity goals, a Smartphone application for self-monitoring their diet, activity and weight, online educational readings, and brief bi-weekly remote health sessions with a Health Promotionist. They will also be provided with a wireless bluetooth scale and portable blood pressure machine.
224172351|NCT04708769|BEHAVIORAL|Diabetes Prevention Program Participants (DPP)|In accordance with the Center for Disease Control curriculum, participants will receive a participant log for tracking physical activity, food intake, and weight, a paper participant guide with worksheets, logs, and psycho-educational materials, and 16 hour long remote sessions with a Health Promotionist. They will also be provided with a wireless bluetooth scale and portable blood pressure machine.
223483976|NCT05849077|OTHER|Sat75|As per the current NRP guidelines, resuscitation will be initiated with 0.3 FiO2. FiO2 will be titrated every 30 seconds by 0.2-0.3 to achieve target SpO2 that approximates the 75th percentile SpO2 observed in healthy term newborns. Percentiles are roughly based on Dawson reference curves of healthy term infants after birth. Apart from the randomly assigned target SpO2, resuscitation will follow the current NRP guidelines. Following NICU admission, all care decisions, including ventilator management, will be at the discretion of the clinical team.
224172352|NCT05053867|DRUG|tranexamic acid|Inhaled
224172353|NCT05053867|OTHER|Usual Care|Standard of Care
224172354|NCT04547491|DEVICE|HPI - hypotension prediction index|treatment of hypotension before the appearance following HPI algorithm
224172355|NCT04547491|DEVICE|GDT|cardiac optimization and treatment of hypotension following standard clinical practice
224172356|NCT02373891|DRUG|Surfolase CR|T1: Surfolase CR (Acebrophylline 200mg) administration after fat intake Surfolase CR(Acebrophylline 200mg) administrated fasting or fat intake at D1 and D8 a.m. 8:00
224172357|NCT02373891|DRUG|Surfolase CR|T0: Surfolase CR(Acebrophylline 200mg) fasting administration Surfolase CR(Acebrophylline 200mg) administrated fasting or fat intake at D1 and D8 a.m. 8:00
224172358|NCT02819583|BIOLOGICAL|PCAR-019 (anti-CD19 CAR-T cells)|
224172359|NCT05481944|DIAGNOSTIC_TEST|MRI in patients|Injected MRI
224172360|NCT05481944|DIAGNOSTIC_TEST|MRI in healthy volunteers|non injected MRI
224172361|NCT04888182|DIETARY_SUPPLEMENT|intervention|a protein intake of ≥25 E%. An oral nutritional supplement (containing 1570 kJ/100 g and 92 g protein/100 g. Atpro 200) was used as supplement to the patients' habitual diet.
224172362|NCT02352428|OTHER|Skin Cancer Screening Training|Topics of the 5.5-hour in-class course include: the screening test, types of skin cancer (signs and symptoms), case history taking, epidemiology of skin cancer, etiology, risk factors and risk groups, communicative aspects of primary and secondary preventive measures, and benefits and harms of cancer screenings.
224172363|NCT02171806|DRUG|BI 1744 CL|
224172364|NCT02171806|DRUG|Placebo|
224172365|NCT01599585|BEHAVIORAL|Behavioral Activation|Behavioral activation(BA)will be delivered in 8 weekly sessions via webcam for the in-home arm or face to face in the in-person arm. Behavioral activation attempts to help depressed individuals reengage in their lives through focused activation strategies.
223483977|NCT05849077|OTHER|Sat50|As per the current NRP guidelines, resuscitation will be initiated with 0.3 FiO2. FiO2 will be titrated every 30 seconds by 0.1-0.2 to achieve target SpO2 that approximates the 50th percentile SpO2 observed in healthy term newborns. Percentiles are roughly based on Dawson reference curves of healthy term infants after birth. Apart from the randomly assigned target SpO2, resuscitation will follow the current NRP guidelines. Following NICU admission, all care decisions, including ventilator management, will be at the discretion of the clinical team.
223483978|NCT01485835|DRUG|Ganetespib|Standard 3+3 design to determine the maximum tolerated dose (MTD) of ganetespib when given in combination with bortezomib and dexamethasone.
223483979|NCT01485835|DRUG|Bortezomib|Standard 3+3 design to determine the maximum tolerated dose (MTD) of ganetespib when given in combination with bortezomib and dexamethasone.
223483980|NCT01485835|DRUG|Dexamethasone|Standard 3+3 design to determine the maximum tolerated dose (MTD) of ganetespib when given in combination with bortezomib and dexamethasone.
223483981|NCT05594160|BEHAVIORAL|Psychotherapy|Patients treated at the inpatient psychotherapy unit of a University Hospital receive 8 to 10 weeks of multimodal psychotherapeutic treatment. Treatment consists of individual as well as group psychodynamic therapy. Additionally, patients receive an individual combination of music, art, relaxation and body-oriented group therapy. Therapeutic treatment is provided by a multiprofessional, interdisciplinary team of psychotherapists with either a medical or psychology degree, art and music therapists, specialist nurses, social workers and physiotherapists.
224172366|NCT05857150|DIAGNOSTIC_TEST|Treadmill Test|Measurement of whole-body fitness level. Walking or running on a treadmill and breathing into a machine that measures oxygen level during test. Heart rhythm is continuously monitored during exercise using an electrocardiogram (ECG).
224172367|NCT05857150|DIAGNOSTIC_TEST|Strength Test|Measure the strength of leg muscles by kicking against a machine with resistance.
224172368|NCT05857150|DIAGNOSTIC_TEST|Dual-Energy X-Ray Absorptiometry|Body composition measurement.
224172369|NCT05857150|PROCEDURE|Muscle Biopsy|Obtain a small piece of muscles from the upper part of the legs
224172370|NCT05857150|PROCEDURE|Fat Biopsy|Fat sample taken from abdomen
223483982|NCT00888082|DRUG|Goserelin acetate|3.6 mg depot injectable preparation
223483983|NCT01951066|DRUG|Dexamethasone Implant|Patients will receive a single injection of a dexmethasone implant
224172371|NCT05857150|DIAGNOSTIC_TEST|Resting Energy Expenditure|Measured by indirect calorimetry. Measures how much energy the body uses at rest by placing a special plastic dome over the head while resting quietly for 30 minutes. Measures oxygen breathed in and carbon dioxide breathed out.
224172372|NCT05857150|DIAGNOSTIC_TEST|Magnetic resonance imaging|MRI on upper leg to look at fat and muscle
223483984|NCT01951066|DRUG|Anti-VEGF injection|Patients will receive PRN injections of an anti-VEGF agent
223483985|NCT04608864|PROCEDURE|varicocelectomy|microsurgical subinguinal varicocelectomy
223483986|NCT04195412|DEVICE|tDCS + upper limb rehabilitation|Stimulation will be applied for 20 minutes by a DC stimulator (NeuroConn, Germany). During each stimulation section, a pair of saline-soaked sponge electrodes (surface 24 cm²) will be placed over C3 and C4, according to the International 10-20 EEG system. Stimulation intensity will be 2 mA with current ramping up and down of 10 seconds each. The stimulation will be followed by 40 minutes of upper limb rehabilitation. Experimental sessions will be repeated five times per week to complete 10 sessions.
223483987|NCT04195412|DEVICE|Sham tDCS + upper limb rehabilitation|Sham stimulation will be applied for 20 minutes by a DC stimulator (NeuroConn, Germany). During each sham stimulation section, a pair of saline-soaked sponge electrodes (surface 24 cm²) will be placed over C3 and C4, according to the International 10-20 EEG system. The anode will be placed to the affected hemisphere, while the cathode will be positioned over the unaffected hemisphere. Sham tDCS will be performed by ramping current flow for the first 10 seconds of stimulation, but switching the stimulator off automatically after 30 seconds. The sham stimulation will be followed by 40 minutes of upper limb rehabilitation. Experimental sessions will be repeated five times per week to complete 10 sessions.
223483988|NCT03427281|BEHAVIORAL|questionnaire|questionnaire to assess the patterns of postoperative bracing use by spinal surgeons in Belgium
223483989|NCT04841174|OTHER|Abdominal massage|The effect on gastric problems by applying abdominal massage to eligible participants in the study will be examined.
223483990|NCT00177489|BEHAVIORAL|multicomponent psychosocial intervention|The intervention addressed caregiver depression, burden, self-care, and social support and care recipient problem behaviors through 12 in-home and telephone sessions over 6 months.
224172373|NCT06163066|OTHER|Newborn Basic Care Training|These talented fathers will be given both face-to-face practical training and the industrial web-based training type of information technologies will be used. In this way, the positive developments provided by the two trainings will be abandoned and the understandability and usefulness of the training from the people's perspective will be increased. A website suitable for mobile phones will be designed by transferring digital materials. With this website, fathers will be able to access information about basic care via phone whenever and wherever they want. Thus, in a short time, without human resources and time, all the fathers in need throughout the country will reach the capacity to obtain appropriate information.
224172374|NCT06390371|OTHER|Spotlight AQ Survey platform|A psychosocial assessment pinpointing the needs of patients divided into four domains: Therapy, Psychological, Social, Knowledge which is delivered to health care providers to guide their in clinic visits
224172375|NCT05840393|OTHER|Discharge training based on Roy adaptation model|The Roy Adaptation Model consists of four main areas of adaptation. In this study, the content of the discharge education given within the scope of the adaptation areas of the Roy Adaptation Model will be continued with information such as home nutrition process, pain, anxiety, fear, stress and coping methods, addressing changing roles and responsibilities, communication, problem solving and utilizing social support. A booklet will be prepared to increase the effectiveness of discharge training based on the Roy Adaptation Model and the booklet will be used as a guide in the training program.
223483991|NCT00177489|OTHER|Control arm|"Caregivers in the control group received 2 brief check-in telephone calls during the 6-month intervention."
223483992|NCT04892667|OTHER|Intervention|"Evaluation of the sensitivity of the cardiac uptake of 18F-FDG measured on D28 +/- 7 days, D42 +/- 7 days ou D56 + 4 days of the administration of ATCs to identify at 1 year the patients at risk of occurrence of a LVSD defined by a drop of more than 10 units of the LVEF and LVEF \&lt; 53%.~The patient participating in the study needs to respect a minimum of 12-hour fasting period, a high protein and a low-carbohydrate diet prior to performing PET/CT in order to limit physiological 18F-FDG myocardial fixation."
223483993|NCT00358488|DRUG|GSK159797 (10, 15, and 20mcg)|GSK159797 (10, 15, and 20mcg)
223585898|NCT00573807|RADIATION|Far Infrared Radiation (5μm to 20μm wavelength)|Far Infrared Radiation (5μm to 20μm wavelength)for 30 to 40 minutes per treatment session.
223585899|NCT04454645|BEHAVIORAL|mABC|Intervention targets parenting sensitivity and nurturance.
223585900|NCT04454645|BEHAVIORAL|mDEF|Intervention targets parenting enhancing infant cognitive development
223585901|NCT02916147|DRUG|Sevoflurane|
223483994|NCT00358488|DRUG|salbutamol|salbutamol
223483995|NCT00358488|DRUG|salmeterol 50mcg|salmeterol 50mcg
223483996|NCT00358488|DRUG|placebo|placebo
223483997|NCT03881774|BIOLOGICAL|CAR-T cells|collecting cord blood for CAR-T cells culture; three days later, FC regimen (fludarabine 30mg/m2/d x 3, cyclophosphamide 600-800mg/m2/d x 2) another two days later, transfusing CAR-T cell with a dose of 0.5-3x106/kg
223585902|NCT02916147|DRUG|Propofol|
223585903|NCT00254683|DEVICE|PET/CT with FDG|PET/CT before start of neoadjuvant CRT, at 6 weeks, 12 weeks, following CRT completion and 12mo, 24mo following CRT for those considered complete responders
223745148|NCT06647953|OTHER|Patient Observation|Undergo observation
224172376|NCT03224832|PROCEDURE|Artery-first Approach|"Dissection at the origin of the superior mesenteric artery and the celiac trunk all along their right side of the vessels. -En bloc resection of the primary tumor and regional lymph nodes through complete excision of the mesopancreatic plane, utilizing the artery-first approach.~* The mesopancreatic plane consists of the pancreas head, the uncinate process of the pancreas, and the meso-pancreatoduodenum.~All the tissues that lay in this triangular space (SMA down, CT up, and SMV-PV anterior) is cleared.~Then the investigators continue the dissection along the right then anterior surface of the SMV and PV until reaching the dissected posterior surface the neck of the pancreas .~Last step is the division of the neck of the pancreas. After the specimen is removed and before it is sent to the pathology we put mark on each boundary of the specimen one towards SMA, another towards PV/SMV area and the last towards the posterior surface of the mesopancreas."
224172377|NCT03224832|PROCEDURE|Standard Approach|In standard approach after kocharization of the duodenum the investigators start to asses the tunnel under the neck of the pancreas whether tumor infilterating PV/SMV axis and if not we cut the neck of pancreas early in the procedure then we continue to dissect the uncinate process and control pancreatoduodenal vessels and draining lymph nodes and LNS around portal vein and up to hepatic artery and we will add to the standard procedure the previously defined mesopancreatic triangle dissection which lies between SMA caudal, Coeliac artery cranial and PV/SMV axis anterior and the specimen will be marked and sent as previous to pathology.
224172378|NCT00298506|DRUG|Multitherapy|Tacrolimus,4mg/d, MMF 1.0g/d
224172379|NCT03899558|DEVICE|Humidified nasal high-flow device|Humidified nasal high-flow device which delivers warmed, humidified air at flow rates of up to 60 litres per minute via a nasal cannula interface. Intended delivery at 30 L/min at 37 degrees Celsius, if tolerated.
224172380|NCT04248972|DEVICE|PBM|A whole body red light therapy (NovoTHOR®) will be carried out during 20 minutes
224172381|NCT04248972|OTHER|PLACEBO PBM|A placebo whole body red light will be carried out during 20 minutes
224172382|NCT06972004|BEHAVIORAL|Preventing Loss of Independence through Exercise (PLIE)|"Preventing Loss of Independence through Exercise (PLIÉ) is a multi-domain, mind-body, group movement program for people with dementia that improves quality of life.~Classes begins and ends with fully body tapping/massaging and breathing exercises that bring participants into awareness of their bodies in the present moment and create a calming ritual. Participants are invited to share appreciations of things in their lives that make them feel happy or grateful. Instructors lead participants through progressive, functional movement sequences that are designed to be repetitive (to build procedural or muscle memory) and to build slowly in functional complexity over time. Movements are tailored to the ability levels of the group. Resting, breathing and mindful body awareness exercises are incorporated throughout each class to provide breaks and to improve focus and attention. A non-judgmental errorless learning process is used, and all movements are performed slowly and purposefully."
224172383|NCT06022497|OTHER|Tidal Model Based Emotion Regulation Interventions|The Tidal Model is a nursing model and was developed by Phil Barker. It is an important model for psychiatric nursing care. In the research, nursing interventions for emotion regulation were structured by using the Tidal Model.At each session, emotion regulation interventions were applied within the Tidal Model care domains.
224172384|NCT02098915|DRUG|intravenous metoclopramide|the experimental arm will receive intravenous metoclopramide dosed according to the current Sick Kids guidelines based upon weight and age
224172385|NCT02098915|OTHER|Placebo|equivalent volume to intravenous metoclopramide (dosed according to the current Sick Kids guidelines based upon weight and age ) of sterile sodium chloride 0.9% injection as a placebo
224172386|NCT05458492|DRUG|Sirolimus|"Sirolimus, tablets 2 mg/day with dose adjustment of 1 to 3 mg/day for residual concentrations between 4 and 10 ng/mL~1 dose daily for 16 weeks"
223483998|NCT03818568|DIETARY_SUPPLEMENT|ketoanalogues of essential amino acids|Patients will receive conventional treatment according to the institution's clinical guidelines, with moderate restriction of proteins 0.6 g protein/kg/day, as recommended to slow renal damage progression), plus ketoanalogues in the established dosage (1 tablet/5 kg weight divided into 3 doses per day).
223483999|NCT02130609|DEVICE|Skintel|
223484000|NCT03316781|DRUG|HLX03|80 mg SC at Week 0, 40 mg SC at Week 1, and 40 mg every other week thereafter.
223484001|NCT03316781|DRUG|adalimumab|80 mg SC at Week 0, 40 mg SC at Week 1, and 40 mg every other week thereafter.
223585904|NCT03464916|BIOLOGICAL|CAR2 Anti-CD38 A2 CAR-T Cells|Autologous IV infusion; dose-escalation
224172387|NCT05780164|OTHER|Research readiness tool|Online/paper based tool containing information about lung cancer clinical trials
223484002|NCT05627804|OTHER|Low-moderate intensity exercise|The participants will perform low-intensity cycling exercise at 90% lactate threshold under moderate hypoxia
223585905|NCT03276949|DEVICE|Blood glucose measurement|Device used to measure blood glucose levels
223585906|NCT03395561|DIETARY_SUPPLEMENT|green coffee|2 capsuls
223585907|NCT03395561|OTHER|control|2 capsuls
223585908|NCT01317511|DIETARY_SUPPLEMENT|Protein|Protein drink
223585909|NCT05736003|PROCEDURE|Laparoscopic cholecystectomy|Removal of gallbladder laparoscopically
223585910|NCT02471781|DEVICE|Zenith TX2 Low Profile TAA Endovascular Graft|Endovascular treatment of patients with aneurysms or ulcers of the descending thoracic aorta having morphology suitable for endovascular repair.
223484003|NCT05627804|OTHER|Sprint interval training|The participants will perform sprint interval cycling exercise at a load of 7.5% bodyweight under moderate hypoxia.
223484004|NCT05627804|OTHER|Functional exercise|The participants will perform bodyweight exercises under moderate hypoxia.
223585911|NCT00364533|DRUG|Tapentadol IR (CG5503)|Fixed Dose 50, 75, \& 100 mg BID for 3 days
223585912|NCT00364533|DRUG|Placebo|Fixed Dose Matching placebo for 3 days
223585913|NCT00364533|DRUG|Oxycodone HCL IR|Fixed Dose 10 mg BID for 3 days
223585914|NCT00364533|DRUG|Tapentadol IR (CG5503)|Flexible Dose q4-6 hr Tapentadol IR 50 \& 100 mg BID for 9 days
223585915|NCT02484924|DRUG|Ticagrelor|No intervention- purely observational
223585916|NCT03675542|DRUG|CUDC-305|Dose-selection treatment with HSP90 inhibitor (CUDU-305)
223585917|NCT02758301|DEVICE|Reveal LINQ™ Insertable Cardiac Monitor (ICM)|Insertable Cardiac Monitor with LINQ™ HF Investigational RAMware download
223585918|NCT05099159|DRUG|Elinzanetant (BAY3427080)|120 mg elinzanetant orally once daily
224172388|NCT02714894|DRUG|Clozapine|Patient participants will be starting clozapine as part of their clinical care.
224172389|NCT02939196|PROCEDURE|office hysteroscopy 3.7|office hysteroscopy with a 3.7 -mm outer sheath
224172390|NCT02939196|PROCEDURE|office hysteroscopy 4|office hysteroscopy with a4-mm outer sheath
224172391|NCT00444639|DRUG|Triptorelin (Decapeptyl®)|Two injections of 11.25mg given every 12 weeks
224172392|NCT05093244|DEVICE|SeQuent Please ReX|The SeQuent Please ReX is a conventional rapid exchange balloon tip catheter with a drug-coated balloon (DCB). The surface of the SeQuent Please ReX balloon is coated with paclitaxel, embedded in a soluble matrix (resveratrol).
224172393|NCT05093244|DEVICE|Plain old balloon angioplasty (POBA)|Any commercially available semi-compliant PTCA balloon may be used per the investigator's discretion.
224172394|NCT03211546|PROCEDURE|Conservative (non-surgical) treatment|Spica cast Traction Traction and spica cast
224172395|NCT03211546|PROCEDURE|Surgical treatment|Elastic Stable Intramedullary Nailing (ESIN) Conventional locking intramedullary nail Plating External fixation
224172396|NCT04981860|DRUG|Betadine|One drop of 5% Betadine will be administered to the inferior conjunctiva of the eye
224172397|NCT04981860|DRUG|Avenova|One drop of 0.01% Avenova will be administered to the inferior conjunctiva of the left eye
224172398|NCT06040099|DRUG|Durvalumab|Durvalumab IV (intravenous)
224172399|NCT06040099|DRUG|Bevacizumab|Bevacizumab IV (intravenous)
224172400|NCT06040099|PROCEDURE|Transarterial Radioembolization (TARE)|Yttrium 90 glass microspheres will be administered
223484005|NCT05627804|OTHER|Control|No exercise will be performed.
223484006|NCT02030600|DRUG|insulin degludec|Administered once daily injected s.c. / subcutaneously (under the skin). Dose is individually adjusted.
223484007|NCT02030600|DRUG|insulin glargine|Administered once daily injected s.c. / subcutaneously (under the skin). Dose is individually adjusted.
223484008|NCT03272152|GENETIC|Genome-wide DNA methylation|Genome-wide DNA methylation was determined using the Infinium Human Methylation 850K BeadChip.
223484009|NCT01155323|DEVICE|etafilcon A|1-day soft contact lens
223484010|NCT01155323|DEVICE|omafilcon A|1-day soft contact lens
223484011|NCT02250638|OTHER|CA 19-9 Assay|Physicians use the CA 19-9 test results to manage their patients
223484012|NCT02490163|DEVICE|Spectra Optia|"The Spectra Optia® Apheresis System is an automated centrifugal system that separates whole blood into its cellular and plasma components. The device is comprised of three major sub-systems, 1) the apheresis machine itself, 2) a sterile, single-use, disposable blood tubing set, and 3) embedded software.~Terumo BCT developed a completely automated apheresis system: the Spectra Optia MNC and CMNC based on an automatic interface-controlled technology that allows MNCs collection without the intervention of an operator. The optical sensors continuously control and adjust the buffy coat layer by adjusting the plasma flow.~The Spectra Optia MNC collects MNCs by intermittent flow: MNCs accumulate and are flushed from a secondary chamber at intervals during the procedure. On the other hand, the very recently released Spectra Optia CMNC (developed especially to collect stem cells that reside in the MNCs layer) is able to collect MNCs by continuous flow."
223585919|NCT05099159|DRUG|Placebo|Matching placebo orally once daily
224172401|NCT05379933|OTHER|Remote health coaching to improve self-care behaviors|Participants will be asked to wear an activity tracker, complete brief surveys, and participate in weekly health coaching sessions remotely for 8 weeks
223484013|NCT03953716|DEVICE|low level light therapy|Start using low level light therapy after the menstrual period, once a day, every 20 minutes \* 5 days ( one treatment cycle), start the next course at intervals of 2 days until the next menstruation
223484014|NCT03953716|DRUG|DING KUN DAN|DING KUN DAN,3.5g BID for 10 days (starting 3-5 days before menstruation) \*3 menstrual cycle
223484015|NCT03953716|DRUG|Simulated drug of DING KUN DAN|Simulated drug of DING KUN DAN，3.5g BID for 10 days (starting 3-5 days before menstruation) \*3 menstrual cycle
223484016|NCT03953716|DRUG|Marvelon|Marvelon 1 pill QD\*21 days (starting on the 5th day of menstruation, continuing the next cycle after 1 week of withdrawal) \*3 menstrual cycle
223484017|NCT03805139|DIETARY_SUPPLEMENT|Ajwa Date (phoenix dactylifera)|Effect of Ajwa on Dyslipidemia
223484018|NCT04530071|BIOLOGICAL|CordSTEM-DD (0.7 x 10^7 cells)|CordSTEM-DD (0.7 x 10\^7 cells)
223484019|NCT04530071|BIOLOGICAL|CordSTEM-DD (2.1 x 10^7 cells)|CordSTEM-DD (2.1 x 10\^7 cells)
223484020|NCT04530071|BIOLOGICAL|Placebo|HA + saline + placebo comparator
223585920|NCT03530085|DRUG|Decitabine|Decitabine was administered at 20mg/m2/day on days -9 to -7.
223585921|NCT03530085|DRUG|Busulfan (BU)|Busulfan was administered at 3.2 mg/kg/day on days -5 to -4.
223745149|NCT06647953|PROCEDURE|Positron Emission Tomography|Undergo PET
224172402|NCT05550857|OTHER|eccentric resistance exercise|The subject will lying prone on a treatment table. One end of eccentric resistance band will tie around the mid of the foot of indvidual, the other end of the resistance band will be attach to the table and the band is adjusted so that it will tight and there will be no slack present in it. It will provide a smooth eccentric resistance throughout the dorsiflexion range
224172403|NCT05550857|OTHER|myofascial release|The subject will lye prone on a treatment table. Deep longitudinal massage with the help of both thumbs reinforcing eachother will be given on the subject's calf muscles.
224172404|NCT03720067|DRUG|Propranolol|40mg to 320mg / day
224172405|NCT03720067|DRUG|Carvedilol|6.25mg to 25mg / day
224172406|NCT03720067|DRUG|Rosuvastatin|20mg / day
224172407|NCT03720067|DRUG|Placebo|Placebo of rosuvastatin
224172408|NCT03646812|OTHER|Glucose Reference 1|Glucose contains 50g of available carbohydrates
224172409|NCT03646812|OTHER|Glucose Reference 2|Glucose contains 50g of available carbohydrates
224172410|NCT03646812|OTHER|Glucose Reference 3|Glucose contains 50g of available carbohydrates
224172411|NCT03646812|OTHER|Semolina Penne|Semolina Penne contains 50g of available carbohydrates
224172412|NCT03646812|OTHER|Wholegrain Penne|Wholegrain Penne contains 50g of available carbohydrates
224172413|NCT03646812|OTHER|Semolina Spaghetti|Semolina Spaghetti contains 50g of available carbohydrates
224172414|NCT03646812|OTHER|Wholegrain Spaghetti|Wholegrain Spaghetti contains 50g of available carbohydrates
224172415|NCT03646812|OTHER|Jasmine Rice|Jasmine Rice contains 50g of available carbohydrates
224172416|NCT03646812|OTHER|Asian Noodles|Asian Noodles contains 50g of available carbohydrates
224172417|NCT06482801|DRUG|ipilimumab+pembrolizumab or ipilimumab+durvalumab, idarubicin, bevacizumab|"This study has 3 subgroups:~Arm 1. Ipilimumab +pembrolizumab or Ipilimumab +durvalumab is administrated with a total dose of 1-2mg/kg via intra-tumor fine needle injection in 10 min, every 3 weeks.~Arm 2. Ipilimumab +pembrolizumab or Ipilimumab +durvalumab combined with idarubicin is administrated via intra-tumor fine needle injection in 15 min, every 3 weeks.~Arm 3. Ipilimumab +pembrolizumab or Ipilimumab +durvalumab combined with idarubicin plus bevacizumab is administrated via intra-tumor fine needle injection in 20 min, every 3 weeks."
224172418|NCT02319564|DRUG|Beclomethasone|
224172419|NCT02319564|DRUG|Beclomethasone and Salbutamol|
224172420|NCT02319564|DRUG|Placebo|
224172421|NCT02319564|DEVICE|Aerochamber Max®|
224172422|NCT04571502|OTHER|My PATI ( Person Assisted Touchscreen Interface)|My PATI was designed to support communication between PWD and their caregiver, and healthcare provide; promotes person centered care by giving the PWD their voice and specifically by supporting the PWD in expressing their experiences , needs, preferences in care activities (e.g., food choices, clothing), and entertainment ( personalized pictures, videos , and music). My PATI has multiple features including allowing the caregiver to assess symptoms of the PWD using clinical assessments, which can be shared with the healthcare provider. The clinical trial evaluates the impact of the My PATI interface that relies on touchscreen technology ( two interfaces one for PWD that can be used independently or with assistance, and a 2nd caregiver interface for customization ). The comparison group will receive usual care.
224172423|NCT06381310|DEVICE|asus-handheld-ultrasound LU710L|Ultrasound-guided group:The nurse uses ultrasound-guide injection. control group: After physical assessment by the nurse, the injection will be carried out according to the conventional injection plan.
224172424|NCT02955940|DRUG|Ruxolitinib|5 mg BID
224172425|NCT02955940|DRUG|Capecitabine|Capecitabine at the same dose provided in the parent study at the time of the rollover.
224172426|NCT02955940|DRUG|Regorafenib|Regorafenib at the same dose provided in the parent study at the time of the rollover.
224172427|NCT03805789|BIOLOGICAL|AAT|AAT is a lyophilized product for IV administration.
224172428|NCT03805789|BIOLOGICAL|Placebo|Albumin solution administered intravenously
224172429|NCT03980340|BEHAVIORAL|Short Nap Intervention|Study participants may be asked to have a 1-2 hour nap in between the breath analysis tests.
224172430|NCT03980340|BEHAVIORAL|No Nap Intervention|Study participants may be asked to sit or lay down remaining awake for 1-2 hours in between breath analysis tests.
224172431|NCT06371404|DRUG|Bavarostat|Up to two injections of ≤ 5 mCi \[F18\] Bavarostat
224172432|NCT00879047|DRUG|Alcohol|Consumed orally as liquid mixed with a juice beverage, 1 g/kg formula, administered once at baseline and again at either 2 or 3 weeks
224172433|NCT00879047|DRUG|Alcohol placebo|Liquid alcohol spritzed on top of juice beverage immediately prior to administration in order to give smell of alcohol, administered once at baseline and again at either 2 or 3 weeks
224172434|NCT00986804|DRUG|Decitabine|
224172435|NCT05925829|BIOLOGICAL|SVF and aaPRP|Stromal vascular fraction and autologous activated platelet-rich plasma
224172436|NCT03809195|BEHAVIORAL|Clinical Hypnosis|See information in arm/group description. Four different audio recordings are provided electronically, each approximately 20 minutes in length. Participants are encouraged to listen to one daily.
224172437|NCT03350802|DIAGNOSTIC_TEST|procalcitonin test|All patients enrolled in this cohort undergo procalcitonin test in addition to basic microbiological test.
224172438|NCT04782492|PROCEDURE|graft configuration in coronary artery bypass grafting|Saphenous vein could be used as Y-composite graft or aortocoronary conduit during coronary artery bypass grafting
224172439|NCT02788825|PROCEDURE|Targeted biopsies using Magnetic Resonance Imaging guiding|Prostate biopsies targeted by findings on MRI where findings are classified according to PI-RADS v2.
223484021|NCT00880217|DRUG|Atomoxetine 80 mg/d|40-mg capsule for 3 days, followed by 80-mg capsule once daily for 39 days
223484022|NCT00880217|DRUG|Placebo|Placebo capsule once daily for 42 days
223484023|NCT00880217|DRUG|OROS methylphenidate HCl 54 mg/d|36-mg capsule for 3 days, followed by 54-mg capsule once daily for 39 days
223484024|NCT00880217|DRUG|JNJ-31001074 3 mg/d|3-mg capsule once daily for 42 days
223484025|NCT00880217|DRUG|JNJ-31001074 1 mg/d|1-mg capsule once daily for 42 days
223484026|NCT00880217|DRUG|JNJ-31001074 10 mg/d|10-mg capsule once daily for 42 days
223484027|NCT02052635|DRUG|ticagrelor|Single loading dose of 180mg of ticagrelor at time of bivalirudin administration. Beginning 12 hrs following study drug administration, all pts in the ticagrelor arm will receive ticagrelor 90 mg (maintenance dose) approximately every 12 hrs until Follow-up telephone contact.
223745150|NCT06647953|DRUG|Topotecan|Given IV
224172440|NCT00537459|DRUG|16448|
224172441|NCT01770119|BIOLOGICAL|MMR vaccination|Unprotected children will be vaccinated with two MMR vaccines
224172442|NCT00971191|DRUG|PF-00299804|Brief exposure (5- 11 days) to study drug prior to surgical resection
224172443|NCT04848129|BEHAVIORAL|Feeding clinic|These children have all attended a multidisciplinary feeding clinic with severe food refusal and were commonly receiving tube feeding or supplement drinks. The clinic helps children progress onto a normal oral diet
224172444|NCT04477668|DEVICE|Helmet non-invasive ventilation|Patients will be allocated to helmet non-invasive ventilation
224172445|NCT04135222|DIAGNOSTIC_TEST|Measurements of gingiva thickness|Measurements were performed at upper canines and incisors in thirty periodontally healthy patients. The CBCT/CAD technology along with the PDIP software were used to measure crestal (CGT in mm ), supracrestal (SGT in mm) and free gingival thickness (FGT in mm ) as well as alveolar crest-gingival margin (AC-GM) and cemento-enamel junction (AC-CEJ) distance and the TLPAC localized 2, 4 and 8mm apically than the edge of the AC. Width of keratinized tissue (WKT) were measured using a periodontal probe. For each patient, the periodontal phenotype was evaluated on the basis of coronal width/length (CW/CL in percentages) ratio of both upper central incisors. For each tooth, the gingival phenotype was assessed on the basis of the GT measurement( in mm).
224172446|NCT02709239|DIETARY_SUPPLEMENT|DHA 200mg|4 50mg capsules of DHA to be taken by mouth daily
224172447|NCT02709239|DIETARY_SUPPLEMENT|DHA 800mg|4 200mg capsules of DHA to be taken by mouth daily
223585922|NCT03530085|DRUG|Fludarabine(Flu)|Fludarabine(Flu) was administered at 30mg/m2/day on days -6 to -3.
224172448|NCT04951219|DRUG|Resmetirom|Tablet
224172449|NCT02258191|DEVICE|telemonitoring|
224172450|NCT02258191|DEVICE|sham telemonitoring|
224172451|NCT03075865|DEVICE|OmniMax MMF system|OmniMax MMF system consists of arch bars and screws that work together to achieve temporary fixation of the maxilla and mandible to provide indirect or passive stabilization of fractures and maintenance of occlusion in the oral and maxillofacial region. The arch bars have hooks designed to accommodate either wires or elastic bands for temporary maxillomandibular fixation (MMF) either intraoperative or postoperative.
224172452|NCT00845533|DRUG|Dihydroartemisinin-Piperaquine|
224172453|NCT05482594|DIAGNOSTIC_TEST|ELISA|During routine blood sampling, serum after centrifugation will be stored and frozen at -80°C in the immunology laboratory in order to carry out analyzes by the ELISA method to measure the levels of SCF.
224172454|NCT05482594|DIAGNOSTIC_TEST|Videocapillaroscopy|Videocapillaroscopy is a non-invasive and safe method for the morphological examination and the analysis of abnormalities of the microcirculation linked in particular to systemic scleroderma. Here it is a digital capillaroscopy used routinely at the CHU Brugmann, in the follow-up of patients and whose results will be collected in this study.
224172455|NCT06983782|OTHER|Exercise and education programme|Participants will complete 8-week online exercise programme consisting of an online exercise class once per week. The exercises will target improving strength, balance and range of movement. In addition, participants will receive educational materials on exercise, nutrition, walking changes, fatigue, optimizing bone health, pain management, mental health, sleep and physical activity maintenance.
224172456|NCT06983782|OTHER|control group|The control group will receive educational materials over 8 weeks
224172457|NCT02881086|DRUG|Rituximab|
224172458|NCT02881086|DRUG|Nelarabine|
224172459|NCT02881086|DRUG|PEG-Asparaginase|
224172460|NCT02881086|PROCEDURE|Cranial irradiation|
224172461|NCT02881086|DRUG|Imatinib|
223484028|NCT02052635|DRUG|clopidogrel|Single loading oral dose of 600 mg of clopidogrel will be given at time of bivalirudin administration. Beginning 4 hrs following study drug administration, all pts in the clopidorgrel arm will receive ticagrelor 180 mg for the loading dose, followed by 90 mg maintenance dose approximately every 12 hours until the Follow-up telephone contact.
223484029|NCT00406237|DRUG|tigecycline|Single intravenous dose of tigecycline 50 mg, as a 30-minute infusion
224172462|NCT02881086|DRUG|Idarubicin|
224172463|NCT02881086|DRUG|Dexamethasone|
224172464|NCT02881086|DRUG|Cyclophosphamide|
224172465|NCT02881086|DRUG|Fludarabine|
223484030|NCT06283017|DEVICE|Hypoglossal nerve stimulation|Device stimulation of the hypoglossal nerve
223484031|NCT04732585|PROCEDURE|Physiotherapy or Surgery|"Physiotherapy: Guidelines suggest a tailored and progressive exercise program to improve muscle strength and control, joint mobility, and patient understanding of the problem and how to manage it. Additional interventions like tape or manual treatment can also be implemented but should not be exclusive~Surgery: ACL surgical reconstruction"
223484032|NCT02721069|DRUG|NRL-1|
223484033|NCT04103840|OTHER|Testing stool mycobiota|Both cohorts of SAH and their family controls will be tested for fecal mycobiota
223484034|NCT04440384|OTHER|Functional evaluation|"Patients will complete these forms and tests :~Box and block test, Purdue peg board, Percival, Nine hole peg, T-GAP, EGF, MAHVIE, DASH, RAND36, CHQ-PF28, CHQ-CF45, CGI-S"
223484035|NCT02742207|OTHER|Electrical atrial fibrillation Cardioversion|Electrical cardioversion for patients admitted for Atrial Fibrillation
224172466|NCT02881086|DRUG|Vincristine|
224172467|NCT02881086|DRUG|Mercaptopurine|
224172468|NCT02881086|DRUG|VP16|
224172469|NCT02881086|DRUG|Daunorubicin (DNR)|
224172470|NCT02881086|DRUG|Methotrexate|
224172471|NCT02881086|PROCEDURE|Stem cell transplantation|
224172472|NCT02881086|DRUG|Cytarabine|
224172473|NCT02881086|DRUG|Vindesine|
224172474|NCT02881086|DRUG|Adriamycin|
223484036|NCT02742207|OTHER|Cardioversion|Electrical cardioversion for patients admitted for Atrial Fibrillation
223585923|NCT02062983|DRUG|Herceptin|"Herceptin will be administered in different way per each setting as follow::total herceptin cycles are 18.~Neu Adjuvant : chemo+herceptin, Surgery (hold herceptin) , Resume herceptin for 1 year period Adjuvant : Surgery, chemo+herceptin for 1 year period Metastatic : chemo+herceptin until progression."
224172475|NCT02881086|DRUG|Prednisolone|
224172476|NCT04419597|DEVICE|HEMOPATCH|The treatment will be performed with the HEMOPATCH collagen patch and hemostatic PEG sealant (Baxter), applying two units of the large patch to reinforce the primary dural closure (HEMOPATCH 4.5x9cm, 1506253).
224172477|NCT04419597|DEVICE|Standard of care|Usual clinical practice techniques for reinforcing primary dural closure.
224172478|NCT02068261|BEHAVIORAL|Computerized Cogmed working memory training|Computerized working memory training with Cogmed QM software. The QM software consists of a set of verbal and visual working memory tasks which is trained for 25-40 minutes each session.
224172479|NCT02068261|BEHAVIORAL|Treatment as usual|Treatment as usual can consist of medication, psychotherapy, counseling, and psychological assessment.
224172480|NCT00675311|BEHAVIORAL|DM-Standard|Device/t+ Medical Diabetes Management System
224172481|NCT00675311|BEHAVIORAL|Disease Management Plus|Plus is one of the randomized arms of the study. Patients assigned to this arm receive support from Disease Management nurses and technology.
224172482|NCT00068549|DRUG|Gemcitabine Hydrochloride|Given IV
224172483|NCT00068549|DRUG|Cisplatin|Given IV
224172484|NCT00068549|RADIATION|Radiation Therapy|Undergo whole pelvis radiotherapy
224172485|NCT00068549|RADIATION|Internal Radiation Therapy|Undergo brachytherapy
224205500|NCT02038959|OTHER|Virtual Visits|Virtual visits will be completed using HIPAA-compliant video conferencing software from SBR Health and Vidyo, designed specifically for use in the healthcare industry. The software is available for Windows and Mac OS, as well as iOS devices (iPad and iPhone).
224205501|NCT00534209|BIOLOGICAL|Allogeneic B7.1/HLA-A1|Dose: At least 4x10\^7 irradiated HLA/B7.1 transfected AD100 cells Given intradermally
224205502|NCT00534209|OTHER|Placebo|Given intradermally
224172486|NCT05477251|PROCEDURE|microwave ablation|MWA procedures were performed under local anesthesia and CT guidance (GE Discovery CT750 HD) was used for the guidance. Using the coaxial system, MWA was performed by the combining of a 17G sharp-tip guide trocar needle and a 15-cm cooled-shaft electrode (18-gauge) with a 1.5-cm expandable blunt-tip (MTC-3CA-II3, Vison Medical Inc.). Firstly, the sharp-tip guide trocar needle was used to puncture through the pleura and then the blunt-tip MWA electrode was advanced into the GGO lesion through the guide needle lumen. Once the target was reached, ablation was performed at a power of 40 watts. Once the lesion was covered by the ablation zone, the ablation completed.
224172487|NCT05477251|PROCEDURE|lobectomy|lobectomy for GGOs located in hilar regions
223484037|NCT06394258|RADIATION|Stereotactic body radiotherapy (SBRT)|Stereotactic body radiotherapy to the vaginal cuff with the aim to reproduce adjuvant high dose rate (HDR) brachytherapy dose distribution by means of external beam radiotherapy in patients operated for intermediate risk endometrial carcinoma
223484038|NCT02471339|BEHAVIORAL|Acceptance and Commitment Therapy (ACT)|Acceptance and Commitment Therapy (ACT), a newer generation of cognitive-behavioral therapy, focuses on encouraging individuals to engage in more adaptive ways of coping with pain.
223484039|NCT04286880|PROCEDURE|PRP injection|"Clinically proven cases of Trigger points in masseter muscle will be randomly and equally divided into test group and control group. The selected subjects will be divided into two groups.~Test group will be administered 0.5 ml of PRP solution per trigger point in masseter muscle according to symptoms of patient at baseline (0 week). PRP will be prepared as per methodology mentioned by Okuda et al 2003."
223484040|NCT04286880|PROCEDURE|Dry needling|In control group all the armamentarium and procedure will remain same except that no PRP solution will be delivered. Only dry needling will be performed on the baseline.
223484041|NCT05356663|OTHER|Mulligan Mobilization|Medial glide MWM for knee flexion (supine) Lateral glide MWM for knee flexion (supine) Medial glide MWM for knee flexion.( prone ) Lateral glide MWM for knee flexion (prone)
223484042|NCT05356663|OTHER|Hold Relax|Hold-relax technique of PNF included, the affected knee will be flexed passively to the end of range with the therapist's hand on the patient's lower leg. Patients then performed 5 s of quadriceps contraction against the resistance of the therapist. Patients will be asked not to let move. At the end of 5 s, the patients will be asked to totally relax for 10 s and the therapist pushed the knee into more flexion and hold at that newly acquired range
223484043|NCT00025337|BIOLOGICAL|bevacizumab|Given IV
223484044|NCT00025337|DRUG|oxaliplatin|Given IV
223484045|NCT00025337|DRUG|leucovorin calcium|Given IV
223585924|NCT00148447|DRUG|escitalopram|
224172488|NCT03955120|BEHAVIORAL|Dayzz mobile sleep training|"1. The dayzz digital sleep program provides each user with relevant educational materials (depending on their sleep condition), sleep tracking, and sleep or health-related tasks or challenges pertaining to their sleep or sleep difficulties.~2. Each app user is matched with a sleep trainer who will communicate with them via a chat option within the dayzz app and who will support the participants with any sleep training issues or technical aspects of all app for the duration of the treatment program.~3. Participants receive a wrist-worn device for monitoring sleep and activity patterns, a Fitbit fitness tracker (www.fitbit.com), to be worn for the duration of the study."
224172489|NCT03955120|OTHER|Treatment as usual|Standard medical care for specific sleep condition
224172490|NCT01948518|DRUG|Oral sildenafil 20 mg|A single dose of sildenafil will be given after recording baseline diffusion capacity and 6 minute walk. Measurements will be repeated one hour after the drug.
224172491|NCT03975049|RADIATION|Chemoradiation|Fluorouracil 225 mg/m2/day continuous intravenous infusion on weekdays for five weeks; local irradiation 2GY/day on weekdays, totally 50GY.
224172492|NCT03975049|DRUG|FOLFOXIRI Protocol|Oxaliplatin 85 mg/m2 on day 1; irinotecan 150 mg/m2 on day 1; leucovorin 400 mg/m2 on day 1; fluorouracil 2400 mg/m2 civ over 46h; treatment will be repeated every 14 days; prophylactic G-CSF support is recommended.
223484046|NCT00025337|DRUG|fluorouracil|Given IV
223484047|NCT05466058|DIAGNOSTIC_TEST|palpation - ultrasonography|Physical therapist will assess patients to detect site of pathology (A1, A2, A3, A4, A5, midpalm or wrist) then patients will be refereed to radiologist who will detect site of pathology by sonography
223484048|NCT05662813|DRUG|Almonertinib|Almonertinib 110mg p.o qd. Patients receive Almonertinib treatment until disease progression, unacceptable toxicity or other discontinuation criteria.
223484049|NCT05513911|OTHER|Acute Intermittent Hypoxia|Acute Intermittent Hypoxia is administered in 30-60 second bouts of 9% O2 concentration, followed by 60-90 seconds of normoxic air concentrations (21% O2, room air). This procedure is repeated 15 times for a 30 minute session
223484050|NCT05144243|DRUG|Venetoclax|Tablet: Oral
223484051|NCT05144243|DRUG|Azacitidine|Subcutaneous Injection (SC)
223484052|NCT00318396|PROCEDURE|Bone preparation technique: compaction|The bone is pressed very hard together before implantation of femoral component.
223484053|NCT00318396|PROCEDURE|Bone preparation technique: conventional technique|Bone is broached before implantation of femoral component.
223484054|NCT03786393|DIAGNOSTIC_TEST|ACR 1990 fibromyalgia critters|ACR 1990 fibromyalgia critters
223585925|NCT03191877|DIETARY_SUPPLEMENT|coffee|"Nescafe brand of coffee made by Nestlé, red mug 100 % pure coffee 12083811"
223585926|NCT01522430|PROCEDURE|Renal angiography followed by renal sympathetic denervation|Radiofrequency catheter based therapy for renal denervation: Symplicity catheter will be advanced into the renal artery and connected to a radiofrequency generator. As previously described, four-to-six discrete, low-power radio frequency treatments will be applied along the length of both main renal arteries. At least four radiofrequency applications will be delivered in each renal artery, unless this is not feasible for anatomical reasons.
223585927|NCT01522430|PROCEDURE|Renal angiography alone|Procedure will start with a local anesthesia of the femoral site to allow the placement of a 4-Fr sheath in the femoral artery, which allows a minimal risk of bleeding to the patient. Using JR-4 or similar diagnostic catheter, a selective renal angiography will be realized.
223585928|NCT06087978|DRUG|14C RPT193|Radiolabelled RPT193
224172493|NCT03975049|DRUG|Folfox Protocol|Oxaliplatin 85 mg/m2 on day 1; leucovorin 400 mg/m2 on day 1; fluorouracil 400 mg/m2 bolus and 2400 mg/m2 civ over 46h; treatment will be repeated every 14 days.
223745151|NCT06647953|PROCEDURE|Ultrasound Imaging|Undergo ultrasound
223745152|NCT06647953|DRUG|Vincristine|Given IV
224172494|NCT03793790|BEHAVIORAL|Conditioning with partial reinforcement|Conditioning with partial reinforcement (PRF) provides an uncertain pairing of unconditioned high pain stimuli and conditioned stimuli (i.e., on-screen messages signaling the activation of a mock medical device). During PRF only 70 percent of unconditioned stimuli are paired to conditioned stimuli. Pain of only moderate intensity is used for control stimuli that are paired to the deactivation of the mock device and are also used in the 30 percent of unreinforced trials.
224172495|NCT03793790|BEHAVIORAL|Conditioning with continuous reinforcement|During conditioning with continuous reinforcement (CRF) unconditioned high pain stimuli are paired to conditioned stimuli (i.e., on-screen messages signaling the activation of a mock medical device) in 100 percent of conditioning trials. Pain of only moderate intensity is used for control stimuli that are paired to the deactivation of the mock device.
224172496|NCT03793790|BEHAVIORAL|Counterconditioning|During counterconditioning, the previously conditioned nocebo effects on pain are attenuated by pairing the same conditioned stimuli (i.e., on-screen messages signaling the activation of a mock medical device) to thermal pain stimuli of low intensity.
224172497|NCT03793790|BEHAVIORAL|Extinction|During extinction, the previously conditioned nocebo effects on pain are attenuated by pairing the same conditioned stimuli (i.e., on-screen messages signaling the activation of a mock medical device) only to control stimuli of moderate intensity (previously paired to the deactivation of the mock device).
224172498|NCT03793790|BEHAVIORAL|Sham Conditioning|In the sham group, participants receive different instructions (namely, that the activation of the device is not expected to affect their pain sensitivity). Additionally, during sham conditioning unconditioned stimuli are not consistently paired to conditioned stimuli, thereby preventing the formation of an association between high pain stimuli and the activation of the mock medical device. In the attenuation phase participants undergo an extinction procedure.
224172499|NCT02207738|DEVICE|microneedling radiofrequency device|Microneedling radiofrequency device is composed of 49 insulated microneedle which emit radiofrequency from the needle tip. This radiofreqeuncy generates dermal heat which evokes biological effect.
224172500|NCT02207738|DEVICE|bipolar radiofrequency|bipolar radiofrequency instrument gives out bipolar radiofrequency from the hand piece tip. This bipolar radiofrequency generates dermal heat which has a lot of bilogical effect.
224172501|NCT02070081|PROCEDURE|Roux-en-Y gastric bypass surgery or sleeve surgery|
224172502|NCT02196090|BEHAVIORAL|Exposure and Response Prevention|A procedure where patients with OCD test out their fears without responding by compulsive act.
224172503|NCT02196090|DEVICE|Cold face gel mask|Temporary application of cold eye mask on the face is commonly used for relaxation purpose.
224172504|NCT01184339|DEVICE|MicroPhage S. aureus/MSSA/MRSA Blood Culture Test|"In vitro diagnostic for the Identification of S. aureus and determination of MSSA or MRSA from a positive blood culture.~Approximately 5 hour rapid test."
224172505|NCT03216668|DRUG|TONKA|Administered orally twice a day, 2 tablets each time, for 6 weeks.
224172506|NCT03216668|DRUG|LEGALON|Administered orally three times a day, two tablets each time, for 6 weeks
224172507|NCT00135993|DRUG|Rotigotine|
224172508|NCT03525821|DRUG|Ketamine Hydrochloride|intranasal use of ketamine 1mg/kg with nitrous oxide
223484055|NCT05675670|OTHER|AI-enabled ECG-based Screening Tool|Primary care clinicians in the intervention group had access to the report, which displayed whether the AI-ECG result was positive or negative. The system will send a message to corresponding physicians if positive finding.
224172509|NCT01898000|BEHAVIORAL|Triphala mouthwash|Subjects were instructed to use 15ml mouthwash twice daily and were instructed not to rinse/eat anything for 30 min after mouthwash use. Subjects were also asked to refrain from all other unassigned forms of oral hygiene aids, including dental floss and chewing gum during the study. No oral hygiene instructions like brushing and flossing were given to the subjects to exclude the influence of improved oral hygiene practices on the results.
224172510|NCT01898000|BEHAVIORAL|Chlorhexidine mouthwash|Subjects were instructed to use 15ml mouthwash twice daily and were instructed not to rinse/eat anything for 30 min after mouthwash use. Subjects were also asked to refrain from all other unassigned forms of oral hygiene aids, including dental floss and chewing gum during the study. No oral hygiene instructions like brushing and flossing were given to the subjects to exclude the influence of improved oral hygiene practices on the results.
224172511|NCT04940741|DRUG|VER-01|standardised cannabis extract (containing 21 mg THC per gram drug product)
224172512|NCT04940741|OTHER|Placebo|comparator without active ingredient
224172513|NCT03166657|PROCEDURE|office hysteroscopy|A speculum is first inserted into the vagina. The hysteroscope is then inserted and gently moved through the cervix into uterus. Carbon dioxide gas or a fluid, such as saline will be put through the hysteroscope into uterus to expand it. The gas or fluid helps see the lining more clearly. The amount of fluid used is carefully checked throughout the procedure
224172514|NCT00598806|DRUG|Apaziquone|A single intravesical dose of Apaziquone 4mg in 40ml instilled into the bladder post-TURBT
224172515|NCT00598806|DRUG|Placebo|A single intravesical dose of placebo instilled into the bladder post-TURBT
224172516|NCT00598806|PROCEDURE|TURBT|TransUrethral Resection of the Bladder Tumor
224172517|NCT01126567|OTHER|Sampling Rate|Both cohorts will have a lumbar catheter placed and CSF samples will be obtained. The only difference between the two arms will be the sampling rate of CSF. One arm will have a high sampling rate and the other will have a low sampling rate.
224172518|NCT06336447|OTHER|Experimental: Group #1: Virtual Reality Headset|Group 1 will be assigned to the Virtual Realtity Headset. Participants will wear the device for at least 10 minutes prior to the planned procedure. Subjects will receive standard procedure. The VR Headset will be removed 10 minutes after the planned procedure.
224172519|NCT06336447|OTHER|Group 2 No Virtual Reality Headset|Group 2 will receive standard care without the use of the Virtuality Reality Heaset.
224172520|NCT01908049|DIETARY_SUPPLEMENT|Probiotic.|
224172521|NCT01908049|DIETARY_SUPPLEMENT|Placebo|
223484056|NCT03934775|DEVICE|Finapres Nova|Non-invasive mesurement of hemodynamic parameters and heart rate variability
223484057|NCT00564356|PROCEDURE|cataract surgery with phacoemulsification|removal of cataract with phacoemulsification technique
223484058|NCT03340883|BIOLOGICAL|BION-1301|a solution for intravenous (IV) administration, diluted and administered Q2W
223484059|NCT03552406|BIOLOGICAL|ISU104|Intravenous Infusion for 1 hour.
224172522|NCT05935475|PROCEDURE|Anatomical landmark guided dialysis catheter insertion|.: Before insertion, the catheter depth was calculated from the insertion point to the catheter tip point (midway the vertical line from the clavicular head of sternocleidomastoid to inter nipple line.
224172523|NCT05935475|PROCEDURE|ECG guided dialysis catheter insertion|after inserting the dialysis catheter into right IJV, the guidewire will be then withdrawn until the tip to be exactly positioned at the entry of the Superior Vena Cava in the right atrium. This will be ECG guided: the p wave appears as biphasic wave in the RA then the catheter will be withdrawn at 0.5 cm intervals until the P-wave returned to a normal configuration. (At that point, the catheter will be secured at the skin with suture and dressed with a transparent dressing
224172524|NCT00811395|DRUG|Teriflunomide|"Film-coated tablet~Oral administration"
223484060|NCT03552406|DRUG|Cetuximab|Intravenous Infusion for 1 hour (2 hours at initial dose)
223484061|NCT01675778|DRUG|Hydromorphone|a fixed dose (1 mg) of hydromorphone will be given to the study subjects
223484062|NCT03453736|OTHER|No intervention|This is a qualitative study involving staff interviews and observations. No intervention is being applied.
223484063|NCT05225662|DIAGNOSTIC_TEST|radiofrequency ablation|Mesuring change in Speckle tracking analysis before and after the radiofreqency ablation
224172525|NCT00811395|DRUG|Placebo (for teriflunomide)|"Film-coated tablet~Oral administration"
224172526|NCT00811395|DRUG|Interferon-β [IFN-β]|Powder for reconstitution, of any licensed strength for either intramuscular or subcutaneous injection
224172527|NCT00811395|DRUG|Glatiramer Acetate [GA]|Solution in prefilled syringe for subcutaneous injection
224172528|NCT05185219|DRUG|Valerian|A natural plant
224172529|NCT02022644|DRUG|nanoliposomal irinotecan|The drug named here (nanoliposomal irinotecan) will be used in varying amounts, based on tumor volume.
223484064|NCT04067999|DRUG|Semaglutide|Patients will be treated with commercially available semaglutide in a prefilled pen injector (FlexTouch® variant) according to routine local clinical practice at the discretion of the treating physician. Other anti-hyperglycaemic treatments will be prescribed at the physician's discretion.The decision to initiate treatment with semaglutide is at the treating physician's discretion, and clearly separated from the decision to include the patient in the study.
223484065|NCT01622322|DRUG|Nitrous Oxide|Nitrous Oxide, 70%, O2 30%) 1-5 L, Sevoflurane 1-2%, ETCO2: 32-35 mmHg.
223484066|NCT01622322|OTHER|oxygen|Subjects will receive General anesthesia: (Air, 70%, O2 30%) 1-5 L, Sevoflurane 1-2%, ETCO2: 32-35 mmHg.
223484067|NCT00626639|DRUG|Placebo|Administered by intravenous (IV) bolus injection
223585929|NCT04519060|DEVICE|phototherapy eye shield|Phototherapy eye shields will be applied to the eyes of infants dilated for scheduled eye exam. They will be worn until four (4) hours after the last dose of dilating eye drops.
223585930|NCT02694497|OTHER|Chlamydia care as usual|
223585931|NCT05839704|PROCEDURE|Bilateral Erector Spinae Plane Block|Patient will receive local ropivacaine 0.75% with lignocaine 1% with adrenaline, administered under ultrasound into the erector spinae plane at the level of T8.
223585932|NCT05839704|PROCEDURE|Abdominal Wall Blocks|Patient will receive local ropivacaine 0.75% with lignocaine 1% with adrenaline, administered under ultrasound into the subcostal transversus abdominus plane bilaterally and the serratus plane on the left side
223585933|NCT00034879|DRUG|ZD1839 (Gefitinib)|
223484068|NCT00626639|DRUG|palifermin|Administered by intravenous (IV) bolus injection
223484069|NCT00626639|RADIATION|Radiotherapy|Once daily irradiation of 20 centigray (cGy)/day x 33 fractions for a total target dose of 6600 cGy (conventional radiation therapy using standard fractionation \[one fraction per day\])
223585934|NCT03622177|PROCEDURE|biopsie|Additional colorectal mucosal biopsies during rectoscopy or colonoscopy
224172530|NCT00102336|BIOLOGICAL|AMG 531|Weekly subcutaneous dosing based on screening weight and platelet count. Starting dose is at 1mcg/kg up to a maximum dose of 15mcg/kg. AMG 531 is supplied in a 5 mL single use glass vial as a sterile, white, preservative-free, lyophilized powder.
223585935|NCT03622177|BIOLOGICAL|blood drawn|Additional blood drawn by venepuncture
224172531|NCT00102336|DRUG|Placebo|Weekly subcutaneous dosing based on screening weight and platelet count. Starting dose is at 1mcg/kg up to a maximum dose of 15mcg/kg. Placebo is supplied as a lyophilized power in a 5 mL single use glass vial.
224172532|NCT04600427|PROCEDURE|Epidural anesthesia|T11-12 epidural blockade with 0.25% bupivacaine continuous infusion.
224172533|NCT03249480|BIOLOGICAL|PEG-somatropin|30IU/10 mg/3ml/kit, 0.1-0.2mg /kg/w, once per day for 26 weeks.
223484070|NCT00626639|DRUG|Cisplatin|100 mg/m\^2 intravenously (IV) on days 1, 22 and 43.
223484071|NCT00989300|DRUG|Treatment A - rabeprazole|20 mg rabeprazole sodium once daily for 7 days, in combination with 75 mg clopidogrel once daily for 7 days, oral dosing
223484072|NCT00989300|DRUG|Treatment B - omeprazole|20 mg omeprazole once daily for 7 days, in combination with 75 mg clopidogrel once daily for 7 days, oral dosing
223585936|NCT06491290|OTHER|No intervention administered|NA (not applicable)
223585937|NCT01889134|DRUG|Sedron (alendronate)|
223585938|NCT01889134|PROCEDURE|Parathyroidectomy|
223585939|NCT02834923|BEHAVIORAL|Enhanced Engagement Protocol for CTH (EE-CTH)|EE-CTH integrates CTH with an efficacious, structured, motivational interview (MI)-informed protocol.
223585940|NCT02834923|BEHAVIORAL|Connection to Health (CTH)|CTH is a comprehensive SMS program that focuses on behavior change.
223585941|NCT06436586|OTHER|No intervention|No intervention
223585942|NCT05077007|PROCEDURE|Percutaneous nephrolithotomy|Endoscopic stone Extraction from the kidney by making a puncture and dilate a tract direct into the kidney through muscle wall and renal parenchyma
224172534|NCT04509297|DIETARY_SUPPLEMENT|high protein milk|This intervention consisted of high protein milk consumption concomitant with 6 weeks of resistance training. Subject ingested consumed 1 x 250 mL immediately after resistance training and 1 x 250 mL half an hour before bedtime.
224172535|NCT04509297|DIETARY_SUPPLEMENT|Placebo|This intervention consisted of the consumption of a maltodextrin drink with a 9% solution with a vanilla flavor concomitant with 6 weeks of resistance training. Subject ingested consumed 1 x 250 mL immediately after resistance training and 1 x 250 mL half an hour before bedtime.
224172536|NCT01228149|DRUG|Trabeculectomy with preoperative Diamox/DexaEDO treatment|Filtrating glaucoma surgery, preoperative treatment with Diamox (acetazolamide) 28 day prior surgery. DexaEDO (dexamethasone) 7 days prior surgery
224172537|NCT01228149|DRUG|Trabeculectomy with preoperative Cosopt S treatment|Filtrating glaucoma surgery, preoperative treatment with Cosopt S (dorzolamide/timolol) 28 day prior surgery.
224172538|NCT00896662|OTHER|immunologic technique|immunologic technique
224172539|NCT00896662|OTHER|laboratory biomarker analysis|laboratory biomarker analysis
223484073|NCT00989300|OTHER|Treatment C - placebo|placebo once daily for 7 days, in combination with 75 mg clopidogrel once daily for 7 days, oral dosing
224172540|NCT00896662|OTHER|pharmacological study|pharmacological study
224172541|NCT01146262|OTHER|cell therapy product|Patients receive for up to 5 doses of apoptotic corpse pulsed dendritic cells after CR1 ou CR2 documentation (9/10 subcutaneously and 1/10 intradermally) every week, except the last injection performed at 2 weeks from the 4th injection.
223484074|NCT02007772|DEVICE|nHF|nasal high-flow is used over a period of 6 weeks (outpatient)
223484075|NCT02007772|DEVICE|BiPAP|BiPAP is used over a period of 6 weeks (outpatient)
223484076|NCT01694134|DRUG|Hydrocortancyl.|Patients will receive an intradiscal injection of hydrocortancyl.
223484077|NCT01694134|DRUG|Lidocaine|
223484078|NCT02240329|BEHAVIORAL|Neuropsychological Testing and Measures of TBI severity|A brief cognitive assessment will be given to each participant when he or she presents for this project.
223484079|NCT02240329|BEHAVIORAL|Respiratory measures|We will collect measures of cough airflow and breathing strength.
223585943|NCT05077007|PROCEDURE|Extracorporeal Shock Wave Lithotripsy|Using Shock waves from outside the body targeted at a kidney stone causing the stone to fragment. The stones are broken into tiny pieces.
224172542|NCT01146262|PROCEDURE|injection of the cell therapy product|Cytapheresis D0: 1st injection of the cell therapy product, J7 2nd injection of the cell therapy product, J14 third injection of the cell therapy product,J17 cutaneous biopsies, J21 fourth injection of the cell therapy product, J35 fifth injection of the cell therapy product
224172543|NCT04591340|DIETARY_SUPPLEMENT|dietary advice, oral nutritional supplement, supplementary parenteral nutrition or total parenteral nutrition|All HSCT(hematopoietic stem cell transplantation) patients should be accepted dietary advice or oral nutritional supplement, if their energy intake will not reach 60% of the goal level during the transplanting, then supplementary parenteral nutrition or total parenteral nutrition.
224172544|NCT00942292|DIETARY_SUPPLEMENT|Lipidem- fish oil emulsion BBraun UK|
224172545|NCT00942292|PROCEDURE|Digital Contrast MRI scan|
224172546|NCT03371394|OTHER|no intervention|no intervention
224172547|NCT04016727|BIOLOGICAL|platelet rich plasma|Platelet rich plasma was prepared using patients own blood. 60 units of PRP was injected on one side of the arch using insulin syringe. Each patient served as his/her own control (the side with PRP injected) and experimental group (the side without PRP injected). Whether the right or left side served as control or experimental was determined by lottery method. Patients were recalled after 4 weeks and the measurements were repeated again between lateral incisors and canines at mid, cervical and incisal of the teeth and their mean was recorded.
224172548|NCT05008367|DRUG|Dexamethasone|24 mg intravenous Dexamethasone (6 ml)
224172549|NCT05008367|DRUG|Isotonic saline|6 ml of isotonic saline
224172550|NCT02240524|PROCEDURE|D2 lymphadenectomy|The dissected lymph nodes were classified according to the Japanese Classification of Gastric Carcinoma, first English edition.
223484080|NCT02240329|DRUG|Capsaicin cough sensitivity testing|Subjects will inhale a saline vapor mixed with various concentrations of capsaicin powder in order to determine how sensitive his or her cough response is.
223484081|NCT01828658|OTHER|Strict bioimpedance guided dry weight prescription|Post dialysis patient dry weight was exclusively prescribed using the ideal weight measured by the BCM device (+/- 1.1 Kg).
224172551|NCT02240524|PROCEDURE|Systemic chemotherapy|
224172552|NCT02240524|PROCEDURE|HIPEC|
224172553|NCT05322538|DIAGNOSTIC_TEST|vitamin D plasma levels baseline|Measuring vitamin D plasma levels at baseline
224172554|NCT05322538|DIAGNOSTIC_TEST|Dual-energy X-ray absorptiometry at baseline|Measuring T-score and Z-score of the femur and lumbar spine at baseline
224172555|NCT05322538|DIAGNOSTIC_TEST|cervical Vestibular evoked myogenic potentials at baseline|cVEMP is a vestibular test for saccular function, an otolith organ in the inner ear. the electrical response of the stermocledomastoid muscle to saccular stimulation is measured via two distinct waves - P13 and N23. the latency, amplitude and peak to peak amplitude will be measured.
224172556|NCT05322538|DIAGNOSTIC_TEST|Audiogram at baseline|hearing measurement will be performed. Hearing level in dB will be performed in the 250-8,000 Hz frequency. The test includes Speech reception threshold and word recognition score.
224172557|NCT05322538|DIAGNOSTIC_TEST|Measuring Orthostatic Blood Pressure at baseline|blood pressure will be measure two minutes after lying supine and repeated 3 minutes after standing. A drop of at least 20mmHg systolic pressure or at least 10mmHg diastolic blood pressure is considered a positive test
223484082|NCT01384656|DRUG|GIK solution|Patients receive 0.3 ml/kg/hr GIK solution or the same volume of normal saline depending on the group during off-pump coronary bypass surgery. GIK solution consist of 50% glucose, potassium 80 mEq, and regular insulin 325 IU/500ml.
223484083|NCT04029844|DEVICE|Colibri TAVI System|Implantation of Colibri heart valve
223484084|NCT00937950|OTHER|Gynaecological follow-up|Subjects received a gynaecological follow-up with cytology and oncogenic HPV DNA testing every 12 months, for up to four years in this gynaecological follow-up study (HPV-052 EXT 008). No vaccine was administered in this extension study. Subjects received 3 doses of Cervarix/Havrix vaccine, administered intramuscularly, according to a 0, 1, 6-month vaccination schedule in the HPV-008 (NCT00122681) primary study.
223484085|NCT00448799|RADIATION|[123-I] AV-83 Injection and Imaging Procedures|Evaluation of \[123I\] AV83 and SPECT as a marker of beta-amyloid protein deposition in subjects with Alzheimer disease in comparison to healthy subjects
223484086|NCT01137786|DRUG|Non ionic contrast media comparator|One time administration for PCI
223484087|NCT01137786|DRUG|Non ionic contrast media comparator|one time administration for PCI
223484088|NCT02711787|DEVICE|Experimental group|Robotic assisted passive mobilization (Gloreha, Idrogenet, Italy) and traditional rehabilitation.
223484089|NCT02711787|DEVICE|Control group|Physiotherapy and occupational therapy.
224172558|NCT05322538|DIAGNOSTIC_TEST|cold pressor test at baseline|The cold pressor test is an indicator for sympathetic system function. A rise of at least 15mmHg of systolic pressure after putting the subject's hand in cold water (4 deg Celsius) is indicative of normal sympathetic function.
224172559|NCT05322538|DIAGNOSTIC_TEST|vitamin D plasma levels one year after recruitment|Measuring vitamin D plasma levels one year after recruitment
224172560|NCT05322538|DIAGNOSTIC_TEST|vitamin D plasma levels two years after recruitment|Measuring vitamin D plasma levels two years after recruitment
224172561|NCT05322538|DIAGNOSTIC_TEST|Dual-energy X-ray absorptiometry one year after recruitment|Measuring T-score and Z-score of the femur and lumbar spine one year after recruitment
224172562|NCT05322538|DIAGNOSTIC_TEST|Dual-energy X-ray absorptiometry two years after recruitment|Measuring T-score and Z-score of the femur and lumbar spine two years after recruitment
224172563|NCT05322538|DIAGNOSTIC_TEST|cervical Vestibular evoked myogenic potentials one year after recruitment|cVEMP is a vestibular test for saccular function, an otolith organ in the inner ear. the electrical response of the stermocledomastoid muscle to saccular stimulation is measured via two distinct waves - P13 and N23. the latency, amplitude and peak to peak amplitude will be measured one year after recruitment
224172564|NCT05322538|DIAGNOSTIC_TEST|cervical Vestibular evoked myogenic potentials two years after recruitment|cVEMP is a vestibular test for saccular function, an otolith organ in the inner ear. the electrical response of the stermocledomastoid muscle to saccular stimulation is measured via two distinct waves - P13 and N23. the latency, amplitude and peak to peak amplitude will be measured two years after recruitment
224172565|NCT05322538|DIAGNOSTIC_TEST|Audiogram one year after recruitment|hearing measurement will be performed. Hearing level in dB will be performed in the 250-8,000 Hz frequency. The test includes Speech reception threshold and word recognition score performed one year after recruitment
224172566|NCT05322538|DIAGNOSTIC_TEST|Audiogram two years after recruitment|hearing measurement will be performed. Hearing level in dB will be performed in the 250-8,000 Hz frequency. The test includes Speech reception threshold and word recognition score performed two years after recruitment
224172567|NCT05322538|DIAGNOSTIC_TEST|Measuring Orthostatic Blood Pressure one year after recruitment|blood pressure will be measure two minutes after lying supine and repeated 3 minutes after standing. A drop of at least 20mmHg systolic pressure or at least 10mmHg diastolic blood pressure is considered a positive test. The test will be performed one year after recruitment
223484090|NCT02711787|DEVICE|traditional rehabilitation|Assisted stretching, shoulder and arm exercises, and functional reaching tasks
223484091|NCT06135038|OTHER|Suprascapular nerve block with physical therapy|"Suprascapular nerve block was applied to the relevant shoulder area of all patients before treatment. Afterwards, a physical therapy program (5 days a week for 3 weeks, a total of 15 sessions) was applied, including 20 minutes of hot pack at 60°C, 20 minutes of conventional TENS at 80 Hz and US at 3 MHz frequency and 1.5 watt/cm2 intensity.~After physical therapy, all the participants received therapeutic exercise program (3 sets of 10 reps with 3- minute intervals between the sets) consisting of active-assisted ROM, passive stretching and Codman exercises for their shoulder joint for 30 minutes in accompany with a physiotherapist."
223484092|NCT06135038|OTHER|Group 2 Physical therapy|"A physical therapy program (5 days a week for 3 weeks, a total of 15 sessions), including a hot pack at 60 ° C for 20 minutes, conventional TENS at 80 Hz for 20 minutes and US at 3 MHz frequency and an intensity of 1.5 watts / cm2, was applied to the relevant shoulder area of all patients.~After physical therapy, all the participants received therapeutic exercise program (3 sets of 10 reps with 3- minute intervals between the sets) consisting of active-assisted ROM, passive stretching and Codman exercises for their shoulder joint for 30 minutes in accompany with a physiotherapist."
223484093|NCT01586325|DRUG|JNJ-47910382 30 mg|JNJ-47910382 30 mg (0.6 mL of an oral suspension of 50 mg/mL of JNJ-47910382) administered once daily as monotherapy for 5 days.
223484094|NCT01586325|DRUG|JNJ-47910382 90 mg|JNJ-47910382 90 mg (1.8 mL of an oral suspension of 50 mg/mL of JNJ-47910382) administered once daily as monotherapy for 5 days.
223484095|NCT01586325|DRUG|JNJ-47910382 200 mg|JNJ-47910382 200 mg (4 mL of an oral suspension of 50 mg/mL of JNJ-47910382) administered once daily as monotherapy for 5 days.
223484096|NCT01586325|DRUG|Placebo|Matching Placebo administered once daily as monotherapy for 5 days.
223484097|NCT01344564|DRUG|Degarelix acetate, Leuprolide acetate|Degarelix acetate, 1 mo depot for 3 months Leuprolide acetate, 3 mo depot once
223585944|NCT04246723|DRUG|Narlaprevir|100 mg oval shaped, concave, yellow film-coated tablets taken as 200 mg per os once daily. 28 tabs/36 tabs/ 56 tabs in bottle.
223585945|NCT04246723|DRUG|Ritonavir|100 mg tablets taken as 100 mg per os once daily. 30 tablets in bottle
223585946|NCT04246723|DRUG|Sofosbuvir|"400 mg yellow, capsule-shaped film-coated tablets debossed with GSI on one side and 7977 on the other side, taken as 400 mg per os once daily. 28 tablets in bottle."
223585947|NCT03562468|DIETARY_SUPPLEMENT|300 mg/day of TRU NIAGEN (nicotinamide riboside)|Treatment with 300 mg/day of TRU NIAGEN (nicotinamide riboside) will be administered daily as 4 capsules in a double-blind, randomized, crossover manner for three 8-week treatment periods. Each subject will receive one placebo and two active treatments in a crossover design. The two active treatments are 300 mg/d TRU NIAGEN (nicotinamide riboside) and 1000 mg/d TRU NIAGEN (nicotinamide riboside).
224172568|NCT05322538|DIAGNOSTIC_TEST|Measuring Orthostatic Blood Pressure two years after recruitment|blood pressure will be measure two minutes after lying supine and repeated 3 minutes after standing. A drop of at least 20mmHg systolic pressure or at least 10mmHg diastolic blood pressure is considered a positive test. The test will be performed two year after recruitment.
223585948|NCT03562468|DIETARY_SUPPLEMENT|1000 mg/day of TRU NIAGEN (nicotinamide riboside)|Treatment 1000 mg/day of TRU NIAGEN (nicotinamide riboside) will be administered daily as 4 capsules in a double-blind, randomized, crossover manner for three 8-week treatment periods. Each subject will receive one placebo and two active treatments in a crossover design. The two active treatments are 300 mg/d TRU NIAGEN (nicotinamide riboside) and 1000 mg/d TRU NIAGEN (nicotinamide riboside).
223585949|NCT03562468|DIETARY_SUPPLEMENT|Placebo|Treatment with placebo capsules will be administered daily as 4 capsules in a double-blind, randomized, crossover manner for three 8-week treatment periods. Each subject will receive one placebo and two active treatments in a crossover design. The two active treatments are 300 mg/d TRU NIAGEN (nicotinamide riboside) and 1000 mg/d TRU NIAGEN (nicotinamide riboside).
223585950|NCT04477057|DRUG|HS-10241|HS-10241 is a tablet in the form of 100 mg, oral, once daily.
223585951|NCT01472744|BEHAVIORAL|Dance Group|Participants will be instructed and learn various forms of dance (i.e. English country, folk, ballroom) and will be led by trained dance instructors and exercise specialists. Participants will for one-hour sessions and meet three times per week for six months.
224172569|NCT05322538|DIAGNOSTIC_TEST|cold pressor test one year after recruitment|The cold pressor test is an indicator for sympathetic system function. A rise of at least 15mmHg of systolic pressure after putting the subject's hand in cold water (4 deg Celsius) is indicative of normal sympathetic function. The test will be performed one year after recruitment.
224172570|NCT05322538|DIAGNOSTIC_TEST|cold pressor test two years after recruitment|The cold pressor test is an indicator for sympathetic system function. A rise of at least 15mmHg of systolic pressure after putting the subject's hand in cold water (4 deg Celsius) is indicative of normal sympathetic function. The test will be performed two years after recruitment.
224172571|NCT00034697|DRUG|temozolomide|
224172572|NCT02003586|DIETARY_SUPPLEMENT|plant-based ingredient|
224172573|NCT02003586|DIETARY_SUPPLEMENT|No plant-based ingredient|
224172574|NCT04801355|PROCEDURE|full-thickness laparo-endoscopic colon adenomas excision|Full-thickness laparo-endoscopic removal of colon adenomas will be performed as follows: an endoscopist during intraoperative colonoscopy visualize the neoplasm, intra-luminary marks the margins of resection and stop at this in some cases. In another one: endoscopist start full-thickness removal of this lesion then the abdominal team during laparoscopy, with using laparoscopic technique, performe full-thickness resection of intestine wall with the tumor. Speciment extracted intralumenary or via minilaparotomy. Defect of the intestinal wall is sutured intracorporeally using laparoscopic technic. Desuflation, suturing of trocar sites.
224172575|NCT04801355|PROCEDURE|laparoscopic colon resection|Standard laparoscopic colon resection
224172576|NCT05346380|DEVICE|Olympus VE2 NIR Imaging System|A prospective, (NSR), single-center feasibility study of the Olympus VE2 NIR Imaging System to assess perfusion using NIR during minimally invasive esophagectomy or pulmonary segmentectomy based on treatment arm.
224172577|NCT05346380|DRUG|Indocyanine green|intravenous delivery of low-dose 0.15 mg/kg of ICG combined with Olympus VE2 NIR Imaging System to assess perfusion using NIR during minimally invasive esophagectomy or pulmonary segmentectomy based on treatment arm
224172578|NCT00103779|DRUG|SGN-40 (anti-huCD40 mAb)|1 mg/kg IV (in the vein) on Day 1; 1-2 mg/kg IV on Day 4; 2-4 mg/kg IV on Day 8; 3-8 mg/kg on Days 15, 22 and 29.
224172579|NCT04062006|DRUG|Interleukin-2|low dose interleukin-2 injected subcutaneously, at a dose of 1 x 10\~6 IU/m2 five days per week for 4 weeks (day1-5, 8-12, 15-19, 22-26) and then once a week for 8 weeks (day33, 40, 47, 54, 61, 68, 75, 82).
223484098|NCT05079087|PROCEDURE|Pericapsular nerve group blockade|The PENG-block will be administered under ultrasound (US) guidance with a low frequency curvilinear probe. The probe will be placed parallel to the inguinal crease at the level of the anterior superior iliac spine. Scanning will be done with gradual caudal movement of the probe. After the anterior inferior iliac spine (AIIS) is visible, the probe will be turned slightly medial until the hyperechoic continuous shadow of the superior pubic ramus is visible. The Psoas muscle with its prominent tendon will be identified just above the pubic ramus. The target is the plane between the 2 structures. While aligning the pubic ramus in the center of the image and targeting the pubic ramus just medial to the AIIS, a 22 Go 10 cm needle will be introduced and 20 ml of anesthetic solution administered.
223484099|NCT05079087|DRUG|Midazolam Ketamine arm|Patients in the second group will undergo sedation and analgesic treatment with Ketamine and Midazolam titrated to the best Verbal Rating Score without respiratory and cardiovascular depressant effect.
223484100|NCT03791931|DIAGNOSTIC_TEST|oxidative stress measurement|oxidative stress measurement
223484101|NCT00310518|DRUG|ARQ 501|
223585952|NCT01472744|BEHAVIORAL|Strength, Stretching, Stability|Exercises focusing on strength, flexibility and balance will be performed at one-hour sessions held three times per week for six months. Classes are led by trained exercise specialists.
223585953|NCT01472744|BEHAVIORAL|Walking|Participants in this moderate aerobic conditioning exercise program will be instructed in a walking program that focuses on having them walk within their target heart rate. They will be provided with heart rate monitors and pedometers for accurate record keeping. They will meet three times per week for one hour for six months. Warm up and cool down stretches will be a part of each walking session and sessions will be monitored and led by trained exercise specialists.
224172580|NCT05646160|OTHER|Ischemic Compression of Myofascial Trigger Points (IC-MTRPs)|IC-MTrPs intervention was made first on the right side and then on the left side and this order was the same in each patient. Before starting the therapeutic procedure, the MTrPs localizations were identified by palpation and pinch pressure in patients lying back on the couch. During the procedure, a qualified physiotherapist sat behind the subject's head. The pressure was sustained for about 5 seconds with a 2-3 seconds pause. In each subject, the intervention lasted 15 minutes on the same measurement day in the morning. The subjects underwent cycle of seven IC-MTrPs therapeutic sessions, with 3 days brakes between each session, that lasted in total about a 3-weeks (25 days).
224172581|NCT01550315|PROCEDURE|Pulsitile Arterial Tonometry (PAT) Protocol|"* A blood pressure cuff will be placed on one upper arm (study arm; non-dominant), while the contralateral arm will serve as a control (control arm).~* RH-PAT probes will be placed on one finger (finger II, III, or IV) of each hand (same finger on both hands). The fingers on either side of the one with the probe will be separated using soft sponge rings.~* Continuous recording of pulsatile blood volume responses from both hands will be initiated.~* After a 10-min equilibration period, the blood pressure cuff on the study arm will be inflated to 60 mm Hg above systolic pressure for 5 min. The cuff will then be deflated to induce reactive hyperemia, PAT recording will be stopped."
223484102|NCT05959291|OTHER|Discontinuation of Anti-HER-2 Maintenance Treatment|Patients assigned to this group will be asked to discontinue anti-HER-2 maintenance treatment.
224172582|NCT01550315|DEVICE|Calf Blood Flow in Reactive Hyperemia (CBF-RH)|Calf blood flow (CBF) will be determined using venous occlusion plethysmography and calibrated mercury strain-gauges during reactive hyperemia after a 5 min of ischemia of the distal limb. Strain-gauges will be applied to the widest part of the non-dominant calf (\~10 cm below patella). Participants will remain quietly supine for 10 min with legs elevated on foam pads above the right atrium to achieve stable baseline measurements of CBF. The venous occlusion cuff is inflated for 4 seconds at 8 seconds intervals, while monitoring the change in resistance in the system, pressure inside the measuring cuff, and 5-10 determinations are performed
224172583|NCT01550315|DEVICE|Evaluation of Forearm-Mediated Dilation|The arm will be kept extended and immobilized at heart level. Brachial artery diameter will be measured using a high resolution ultrasonography using a linear array probe with a 5 to 17 MHz frequency range. The brachial artery will be imaged in longitudinal sections, 5-10 cm proximal to placement of an occlusion cuff in the dominant forearm just below the antecubital fossa. The probe will be held with a stereotaxic holder with micrometer movement capabilities.
224172584|NCT02111954|DIAGNOSTIC_TEST|1 PET/CT with F-18-FCH + 1 PET/CT with Ga-68-NODAGA-MJ9|Each patient will have two PET/CT
224172585|NCT00118040|DRUG|Genistein|Given orally
224172586|NCT00118040|OTHER|Laboratory Biomarker Analysis|Correlative studies
224172587|NCT00118040|OTHER|Pharmacological Study|Correlative studies
224172588|NCT00118040|OTHER|Placebo Administration|Given orally
224172589|NCT00118040|PROCEDURE|Therapeutic Conventional Surgery|Undergo cystoscopic excision, transurethral resection of the bladder tumor, or cystectomy.
223745158|NCT05559749|BEHAVIORAL|collaborative care|a 24-week neurology based collaborative care program consisting of: 1. a series of every 2 weeks care management calls by the care manager to evaluate anxiety, depression, seizures and side effects and deliver brief therapy interventions to the participant, and 2. collaborative care conferences including a psychiatrist to generate expert recommendations for anxiety and depression management and communication of recommendations between the care manger, psychiatrist and neurologist.
224172590|NCT01968915|DRUG|LCL161|Patients will receive oral LCL161 once a week until unacceptable toxicity, disease progression and/or withdrawal of consent.
224172591|NCT01968915|DRUG|Paclitaxel|Patients will receive weekly paclitaxel as intravenous infusion over 1 hour in combination with LCL161, from cycle 2 in dose escalation part or from the first cycle in dose expansion part, and will continue it until unacceptable toxicity, disease progression and/or withdrawal of consent.
224172592|NCT01550614|GENETIC|Alferminogene tadenovec|One-time intracoronary infusion of Ad5FGF-4 (6x10e9 viral particles in buffer)
224172593|NCT02520102|DRUG|sargramostim GZ402664|"Pharmaceutical form: lyophilized powder in vial~Route of administration: subcutaneous"
224172594|NCT00886314|DRUG|midazolam|Children in this group will be premedicated with oral midazolam syrup (0.3 mg.kg) at least 15 minutes before the surgical procedure and one of the parents will be present throughout the anesthesia induction process.
224172595|NCT00886314|OTHER|clown doctor|Children will interact with clowns before entering the operating room and will stay with them and one of the parents throughout the anesthesia induction process.
224172596|NCT02504606|DRUG|Besylsartan|Amlodipin besylate 6.944mg+Losartan K 100mg
224305820|NCT06556251|DEVICE|PIPPEP App|"Digital platform with psichoeducative content in infographics, animated and testimonial videos about:~* psychotic and comorbid symptoms, substance use, available treatments, healthy lifestyle habits, social and health emergency resources and outpatient clinics for young people.~* Regular self-completed questionnaires to measure alarm symptoms, side effects of pharmacological treatment, emotional state, and treatment adherence. There will be a feedback for patients in the form of graphs of the evolution of the different types of questionnaires.~* A bidirectional messaging service with the professional reference team, allowing better accessibility in non-urgent cases.~* A gamification system to encourage use of the application, which includes points, rewards, a leaderboard and mini-games.~* A folder where patients can keep documents they find useful (personal reports, relapse prevention plan, crisis plan)."
223585954|NCT01472744|BEHAVIORAL|Walking + Nutrition|Participants in this moderate aerobic conditioning exercise program will be instructed in a walking program that focuses on having them walk within their target heart rate. They will be provided with heart rate monitors and pedometers for accurate record keeping. They will meet three times per week for one hour for six months. Warm up and cool down stretches will be a part of each walking session and sessions will be monitored and led by trained exercise specialists. These participants will also be provided with a daily nutritionally balanced liquid, milk-based supplement formula.
223585955|NCT00127335|DRUG|cellulose placebo vs. atorvastatin|drug
224305821|NCT06340893|BEHAVIORAL|Exercise|Participants will participate in cardiovascular, agility, balance, strength and coordination training.
223585956|NCT01642758|DRUG|Sodium 2,2 dimethylbutyrate|Oral capsules, dose 20 mg/kg/day, once per day for 26 weeks
223745159|NCT05559749|BEHAVIORAL|usual neurology care|ongoing usual neurology care, without the addition of the collaborative care program
223745160|NCT06420778|OTHER|electroacupuncture|The patient takes the supine position, the whole body relaxes, the facial skin is routinely sterilized. Local acupuncture points along the head and face herpes zoster lesion branches with 0.18 × 25 mm millimetre needle series of shallow stabbing method row stabbing method.Han's Acupoint Neurostimulator (model HANS-200) was selected, local acupoints were chosen as Xiaguan+Quanliao or Xiaguan+Jiache, and distal acupoints were chosen as Hegu+Waiguan connected with electroacupuncture, sparse and dense wave 2/100 Hz was selected, and the treatment time was 60 minutes, and the intensity of the current was all to the extent that the patient could tolerate it. The needles were left in place for 60 minutes each time, once every other day, and the treatment was performed 3 times a week for 4 weeks, for a total of 12 treatments.
224305822|NCT06340893|BEHAVIORAL|Restful Play|This group will engage in restful play activities such as coloring and playing with legos.
224305823|NCT06296901|OTHER|Perineal Wipe|use of perineal wipe
224305824|NCT04702542|DRUG|Enteral oxygen therapy|Enteral oxygen therapy during the rehabilitation period of patients with CGDP.
224172597|NCT02504606|DRUG|Amosartan|Amlodipin besylate 7.841mg+Losartan K 100mg
224172598|NCT00706264|DEVICE|Silicon ring (Arabin Pessary)|Placement of a silicon pessary in the vagina, around the cervix.
224172599|NCT00532064|PROCEDURE|Biospecimen Collection|Undergo collection of blood
223484103|NCT00452569|DRUG|Thalidomide|Oral thalidomide (100mg or 200mg or 400 mg/day) administered to the patient once daily until progression of the disease and for a maximum of 336 + 36 days (12 cycles of 28 +/- 3 days).
223484104|NCT00452569|DRUG|Dexamethasone|High dose oral dexamethasone will be administered at a dose of 40mg/day on days 1-4, 9-12 and 17-20 of each 28-day cycle for cycles 1-4. Beginning with cycle 5, the oral dexamethasone dosing schedule will be reduced to 40mg/day on days 1-4 of each 28-day cycle. Dexamethasone will be administered until progression of the disease and for a maximum of 336 +/- 36 days (12 cycles of 28 +/- 3 days).
223484105|NCT06449157|OTHER|Inhalation induction with parosmia|"The experimental group will then be told that the patient's favorite smell will be put into the face mask via the magical machine. The patient will be asked to take a deep breath thinking about that smell and then introduce sevoflurane. The patient will be asked if the chosen flavor is smelled and their response will be noted."
223484106|NCT03974906|OTHER|Applying goal-directed fluid therapy by continuous hemodynamic monitoring system (LiDCO）|Applying continuous hemodynamic monitoring system ( LiDCO) to monitor Stroke Volume Variation and Cardiac Output and further manage intra-operative fluid therapy.
223484107|NCT03988647|DRUG|Pembrolizumab|Pembrolizumab administered at 200 mg IV every 3 weeks
223484108|NCT03988647|RADIATION|Radiation Therapy|9 Gy X 3 (27 Gy in 3 fractions), or 4-6 Gy X 5 (20-30 Gy in 5 fractions).
223484109|NCT04681300|OTHER|Skin biopsy|a skin sample will be taken using a 4 mm punch biopsy in lesional skin
223484110|NCT04681300|OTHER|Plastic surgery remnants|healthy skin from plastic surgery interventions
223484111|NCT04447365|DIAGNOSTIC_TEST|device interrogation|All patients will have a pre-existing ICD and a diagnosis of cardiomyopathy with left ventricular systolic function of 35% or less by echocardiogram done within 3 years of the time of enrollment.
223484112|NCT01913184|DEVICE|AKITA|
223484113|NCT00460798|OTHER|Sutent: observational study|SUNIKA - A Non-Interventional Study With SUTENT® In The First Line Treatment Of Renal Cell Carcinoma
223585957|NCT05830877|OTHER|the acupuncture group|"The primary choice is to puncture GB20 with a quick puncture, which means regulate the mind and open the way. ①Scalp acupuncture: Du 20(Baihui), EX-HN 3(Yintang), EX-HNl(Sishencong); ②Select acupoints from six acupoints for mind-regulating, ear points (both sides): heart, lung, and Shenmen; body points (both sides): LI20(Yingxiang), EXTRA 12(Anmian), ST36(Zusanli) as the main hole. ③Sleeping three needles(both sides): HT7(Shenmen), PC6(Neiguan), SP6(Sanyinjiao); ④Opening four gates: LI4(Hegu) , LR3(Taichong) ⑤Abdominal four needles:ST25(Tianshu), CV12(Zhongwan), CV4(Guanyuan). For body acupuncture, a 0.3 mm×40 mm needle was used to insert directly for 0.5-1.0 cun, and twisting to gain the qi; for auricular points, a 0.25 mm×40 mm needle was used for 2-3 minutes without manipulating the needle. The acupuncture points were retained for 30 min, and the treatment was performed once every other day, three times a week, and the curative effect was evaluated after 4 weeks of treatment."
223585958|NCT05830877|OTHER|the placebo acupuncture group|Subjects in the placebo acupuncture group will receive non-insertive acupuncture using the sham needle supported by the Park device. This needle has a retractable shaft and a blunt tip, they could not penetrate the skin. We gently placed the sham needle and Park device on the skin. The sham needle is then no longer manipulated to minimize any physiological effects. The selected acupoints and needle retention time were the same as for the acupuncture group. Since oblique insertion is required for acupuncture points on the head, the fixed acupuncture body of the Park device could not be used. Therefore, blunt needles are used to stimulate the head points to reduce the amount of stimulation produced by acupuncture. At the end of the treatment, the acupuncturist also used a dry cotton swab to press the acupoints so that patients could feel the withdrawal of 'real' needles.
223745161|NCT06420778|DRUG|Pregabalin|Subjects in this group will be treated with oral pregabalin capsules only, 150 mg twice daily for 4 weeks.Pregabalin was administered with Lerica (specification: 75 mg\*8 capsules,manufactured by Pfizer Pharmaceuticals Ltd).
223745162|NCT03372733|DRUG|control olive oil (COO)|2 capsules, 2 times a day after meals in a total of 4 capsules a day
223745163|NCT03372733|DRUG|palmitoleate-rich oil (PLO)|2 capsules, 2 times a day after meals in a total of 4 capsules a day
223745164|NCT05997615|DRUG|VIR-5500|Pharmaceutical form: Solution for infusion Route of administration: Intravenous (IV) infusion
223484114|NCT03448003|OTHER|Cancer Prevention|Attend IO prevention program
223484115|NCT03448003|OTHER|Questionnaire Administration|Ancillary studies
223484116|NCT01898130|BIOLOGICAL|bevacizumab|Given IV
223484117|NCT01898130|PROCEDURE|quality-of-life assessment|Ancillary studies
223484118|NCT00154466|BEHAVIORAL|cardiac rehabilitation|Those in the training group participated in a 3-month rehabilitation training program at an exercise intensity of 55% to 70% of peak oxygen uptake (VO2); those in the nontraining group continued their usual lifestyle.
223484119|NCT02724436|PROCEDURE|TACE|
223484120|NCT02724436|PROCEDURE|radioembolization with Y-90|radioembolization with Y-90
223484121|NCT05508802|OTHER|State Counselor-Coordinated Services|"A counselor affiliated with the New Jersey State Division of Vocational Rehabilitation Services coordinates services that consider the participant's condition, needs and goals. Services they may receive include:~* Education on programs designed to help people with spinal cord injury or brain injury pursue employment.~* Advice and guidance from professional counselors who have special training in helping people with disabilities pursue employment.~* Help completing applications for services.~* Assistance communicating with my employer about my needs and ways to accommodate them.~* Referrals to and services from other health care or technology providers."
223484122|NCT05508802|OTHER|Center Facilitator-Coordinated Services|"A facilitator affiliated with Kessler Institute for Rehabilitation coordinates services that consider the participant's condition, needs and goals. Services they may receive include:~* Education on programs designed to help people with spinal cord injury or brain injury pursue employment.~* Advice and guidance from professional counselors who have special training in helping people with disabilities pursue employment.~* Help completing applications for services.~* Assistance communicating with my employer about my needs and ways to accommodate them.~* Referrals to and services from other health care or technology providers."
223484123|NCT02871427|DRUG|Nelotanserin|Once Daily, Oral, at 20, 40, 60, or 80 mg dose
223484124|NCT04922762|BEHAVIORAL|Moderate Intensity, Normal Volume Exercise Training|"Week 1 3 days/week for 20 minutes/day Performed at 70% of heart rate maximum~Week 2 3 days/week for 30 minutes/day Performed at 70% of heart rate maximum~Weeks 3-10 3 days/week for 45 minutes/day Performed at 70% of heart rate maximum"
224172600|NCT00532064|OTHER|Questionnaire Administration|Ancillary studies
224172601|NCT05749874|DRUG|Berberine plus lifestyle intervention|"berberine hydrochloride 500mg twice a day plus lifestyle intervention. Lifestyle intervention is based onChinese guideline on the primary prevention of cardiovascular diseases and Guideline for the prevention and treatment of type 2 diabetes mellitus in China (2020 edition), including health education on smoking, alcohol consumption, diet, physical activity and weight loss, etc."
224172602|NCT05749874|BEHAVIORAL|Placebo plus lifestyle intervention|"Placebo with identical shape, colour, odour and taste twice a day plus lifestyle intervention. Lifestyle intervention is based onChinese guideline on the primary prevention of cardiovascular diseases and Guideline for the prevention and treatment of type 2 diabetes mellitus in China (2020 edition), including health education on smoking, alcohol consumption, diet, physical activity and weight loss, etc."
224172603|NCT02576171|BEHAVIORAL|Group-therapy + ICBT|The group therapy supported ICBT treatment program is a combined web-based and face-to-face intervention that will involve adolescents as well as their parents. The program is founded on and inspired by previously evaluated and evidence-based interventions. Altogether, adolescents go through 12 chapters/sessions, 3 of which are face-to-face group sessions at the research clinic, and 9 of which are web-bases chapters. The program is divided into three different phases, starting with psychoeducation regarding social anxiety and the rationale for a cognitive behavioral intervention. Phase two is the main part of treatment and contains behavioral interventions, mainly exposure and habituation to feared situations and/or stimuli.
224172604|NCT04139421|BEHAVIORAL|Shinrin-Yoku|Shinrin-Yoku is a traditional Japanese practice of getting in touch with nature through walking in the forest in a relaxed way using all five senses.
224172605|NCT04814706|DIETARY_SUPPLEMENT|Carbohydrate drinking|Administration of carbohydrate fluid
224172606|NCT03177954|BEHAVIORAL|Patient Oriented Discharge Summary|Participants will undergo a Patient Oriented Discharge Summary (PODS). The PODS is a personalized summary of the discharge plan presented in an easy to understand worksheet that covers (1) medication instructions; (2) follow-up appointments with phone numbers; (3) normal expected symptoms, warning signs, and what to do if they experience a problem; (4) lifestyle changes and when to resume activities; and (5) information and resources to have handy. The meeting will take place one week prior to discharge.
224172607|NCT02108795|DRUG|Remifentanil|Children randomised to remifentanil group receive remifentanil 0.05 ug/kg/min. Children randomised to control group receive normal saline (placebo)
223484125|NCT04922762|BEHAVIORAL|High Intensity, Normal Volume Exercise Training|"Week 1 3 days/week for 31 minutes/day 10 minute warm up at 50% of heart rate maximum 2 x 4 minute intervals 4 minutes at 90-95% of heart rate maximum 3 minutes at 70% of heart rate maximum REPEAT 7 minute cool down at 50% of heart rate maximum~Week 2 3 days/week for 38 minutes/day 10 minute warm up at 50% of heart rate maximum 3 x 4 minute intervals 4 minutes at 90-95% of heart rate maximum 3 minutes at 70% of heart rate maximum REPEAT 2 TIMES 7minute cool down at 50% of heart rate maximum~Weeks 3-10 3 days/week for 45 minutes/day 10 minute warm up at 50% of heart rate maximum 4 x 4 minute intervals 4 minutes at 90-95% of heart rate maximum 3 minutes at 70% of heart rate maximum REPEAT 3 TIMES 7 minute cool down at 50% of heart rate maximum"
223484126|NCT04922762|BEHAVIORAL|Moderate Intensity, High Volume Exercise Training|"Week 1 5 days/week for 20 minutes/day Performed at 70% of heart rate maximum~Week 2 5 days/week for 30 minutes/day Performed at 70% of heart rate maximum~Weeks 3-10 5 days/week for 45 minutes/day Performed at 70% of heart rate maximum"
223484127|NCT03927391|DRUG|Enzalutamide|enzalutamide treatment
223484128|NCT04747002|DRUG|DSP-7888|Cocktail peptide vaccine designed to induce cytotoxic T lymphocytes that recognize WT1 peptides
223484129|NCT01476072|OTHER|MRI scan|MRI scan only, methodology study with no other intervention
223484130|NCT02909647|PROCEDURE|Preoperative planning|preoperative planning using 3D digital planning software or conventional template
223484131|NCT02909647|PROCEDURE|Osteosynthesis|osteosynthesis using volar locking plate
223484132|NCT06493799|DRUG|LAENNEC (Human Placenta Hydrolysate) IV|Intravenous Injection
223484133|NCT06493799|DRUG|LAENNEC (Human Placenta Hydrolysate) SC|Subcutaneous Injection
223484134|NCT04494815|DRUG|SR419|Each participant will receive 1 dose of 20 mg SR419 oral suspension.
224172608|NCT02108795|DRUG|Placebo|
223484135|NCT04494815|DRUG|active control|Each participant will receive 1 dose of 300 mg active control capsule.
224172609|NCT05064943|DIAGNOSTIC_TEST|2-minute step test|"The participant stands and counts for 2 minutes. The minimum height to raise the knee is determined for each participant by calculating the midpoint between the patella and the anterior superior iliac spine. They are instructed to complete as many steps as possible during the 2-minute period. A verbal command is given every 30 seconds to encourage performance: You're doing great, keep it up. If the claudication symptom becomes unbearable, the patient can stop during the test, but the time is not stopped. Patients who discontinue testing due to symptoms of claudication are encouraged to return to testing as soon as possible. An evaluator records the number of steps in the right leg."
224172610|NCT01970540|DRUG|lurbinectedin (PM01183)|lurbinectedin (PM01183) is presented as powder for concentrate for solution for infusion with two strengths, 1-mg and 4-mg vials.
224172611|NCT01970540|DRUG|Doxorubicin|Commercially available presentations of vials containing doxorubicin will be provided as appropriate.
223484136|NCT04494815|DRUG|SR419 placebo|Each participant will receive 2 doses of SR419 placebo oral suspension.
223484137|NCT04494815|DRUG|active control placebo|Each participant will receive 2 doses of active control placebo capsule.
223484138|NCT03150186|OTHER|SHS exposure in homes|The investigators will recruit 20 non-smoking volunteers living in different homes with at least one smoker: 10 participants living in more deprived neighborhoods and 10 participants living in wealthier neighborhoods. Nicotine vapor phase will be measured using passive SHS samplers. The investigators will contact with participants and make an arrangement for measuring levels of nicotine at homes. First, the investigators will hang up a passive sampler in the main room of the house in accordance with the written protocol of sample collection. One week later, the investigators will come back to the house in a second visit to remove the sample. During the second visit the investigators will administer a specific questionnaire about environmental tobacco exposure to the participant.
223745165|NCT05997615|COMBINATION_PRODUCT|Enzalutamide|Oral administration
223745166|NCT05997615|COMBINATION_PRODUCT|Darolutamide|Oral administration
224172612|NCT01714336|DRUG|tranexamic acid|Tranexamic acid will be administered intravenously in two doses of 15 mg/kg. Each dose will be administered over a period of ten minutes, one dose just prior to incision and the second at initiation of wound closure.
224172613|NCT01714336|DRUG|placebo|A similar dose of 0.9% sodium chloride (NaCL) will be administered intravenously in two doses over a ten minute period, one dose at incision and the other at initiation of wound closure.
223484139|NCT03150186|OTHER|SHS exposure in private cars|The investigators will measure levels of nicotine in 30 cars (two samples per car) in 2 European countries with different smoke-free legislation (Spain and UK). A convenience sampling will be performed considering feasibility. The investigators will recruit 30 drivers: 10 daily-smoking volunteers that usually smoke within their car; 10 daily-smoking volunteers that do not smoke within their car; and 10 non-smoking volunteers. To be eligible, participants have to spend a minimum of 30 minutes per day within the car. Nicotine vapor phase will be measured using passive SHS samplers. Two samplers will be hung up in each car during a period of 24 hours. One sampler will be open during the 24-hour sampling period. The other sampler will be only open during travelling time.
223484140|NCT03150186|OTHER|SHS exposure in outdoor settings|In three types of outdoor settings (children playgrounds, terraces of hospitality venues, and entrances of primary school buildings), nicotine vapor phase will be measured using active SHS samplers. For each country, a convenience sampling of 60 outdoor settings (20 of each of the above mentioned settings) will be performed. Data collection will be conducted from March to October. The measurements will be able to be taken at any time of day providing that there are at least five adults. The investigators will collect nicotine samples using samplers attached to an air pump. Measurements will last 30 minutes. While measurements are being taken, data collectors will also conduct observations in accordance with the protocol of active sampling collection.
223484141|NCT05551988|OTHER|Retrospective observational study of diabetic foot ulcer|This is a retrospective observational study of antibiotic resistance and risk factors of amputation in diabetic foot ulcer patients
223484142|NCT02320396|DRUG|Desloratadine 5 mg|Desloratadine 5 mg tablets
223484143|NCT02320396|DRUG|Placebo|Placebo tablets
223484144|NCT00977977|DRUG|Rituximab Infusion|Drug Rituximab Infusion 2 infusions (each 1000 mg) separated by 2 weeks; repeated after 6 months
223484145|NCT00977977|DRUG|Oral Cyclosporine|Daily therapy for 6 months (3-5 mg/kg), then tapered and discontinued
223484146|NCT06569238|DIAGNOSTIC_TEST|Conventional bacterial culture|Participants will have DFU ulcer tissue collected and sent to the laboratory (per usual care practices) that includes the use of conventional bacterial culture analysis (i.e., plates).
223585959|NCT02445573|OTHER|EA|When acupuncturing, adhesive pads were first pasted on acupoints after sterilization in either group. In EA group, participants were needled at bilateral BL33 at an angle of 30 to 45 degree inward and downward, and at bilateral BL35 slightly toward upside and outside, to a depth of 50 to 60 mm using acupuncture needles of size 0.30×75 mm. Needles were then lifted, thrusted and twirled evenly for 3 times. Paired electrodes of EA apparatus were attached transversely to bilateral BL33 and BL35 (using real electrodes) respectively, with a continuous wave of 50 Hz and a current intensity of 1-5 milliampere (mA) for 30 min. Participants were treated with EA 3 sessions a week on alternate days for 6 successive weeks.
223484147|NCT06569238|DEVICE|Rapid diagnostic group using mNGS technology|Participants will have DFU ulcer tissue collected and have metagenomics sequencing performed. The name of the devices listed for this study are the Illumina MiSeq System with MiSeq Reagent Kit V2 from Illumina and the MinION sequencer (Oxford Nanopore Technologies).
223484148|NCT05970757|DIAGNOSTIC_TEST|Extended MRI|Extension of the brain tumor MRI-protocol
223484149|NCT02171455|DRUG|Dabigatran etexilate low dose|
223484150|NCT02171455|DRUG|Dabigatran etexilate medium dose|
223484151|NCT02171455|DRUG|Dabigatran etexilate high dose|
223484152|NCT02171455|DRUG|Placebo|
223745167|NCT05760300|DRUG|Bulevirtide (BLV)|Administered via subcutaneous (SC) injections
224172614|NCT00952133|DRUG|Palonosetron only|The placebo arm will be given a dose of IV palonosetron only, and saline solution prior to surgery to see how this compares with the other combination.
224172615|NCT00952133|DRUG|Palonosetron with Dexamethasone|Women/Men 18-55 scheduled for surgery 1-3 hours in duration will be given .075 mg IV Palonosetron (Aloxi) with 8mg IV Dexamethasone (Decadron) before surgery to see if this reduces PONV.
224172616|NCT03245944|PROCEDURE|early Angioplasty|Angioplasty is a minimally invasive, endovascular procedure to widen narrowed or obstructed arteries or veins. A deflated balloon attached to a catheter (a balloon catheter) is passed over a guide-wire into the narrowed vessel and then inflated to a fixed size. The balloon forces expansion of the blood vessel and the surrounding muscular wall, allowing an improved blood flow. This is part of standard of care for immature arteriovenous fistulas. Early means pt will get the procedure at 6 weeks from time of initiation of AVFs
223484153|NCT04970940|DRUG|Treatment A|AJU-A51R1: Farxiga 1 Tab., Q.D., single dose, for 5 days
223484154|NCT04970940|DRUG|Treatment B|AJU-A51R2: Trajenta 1 Tab., Q.D., single dose, for 11 days
223484155|NCT04970940|DRUG|Treatment C|AJU-A51R1 1 Tab. and AJU-A51R2 1 Tab., Q.D., co-administration for 5 days
223484156|NCT04640116|PROCEDURE|Transjugular intrahepatic portosystemic shunt (TIPS)|A needle punctured the portal vein through the transjugular approach. After a successful puncture, the parenchymal tract was dilated, and covered stents (GORE® VIATORR) were introduced. The specifications of the covered stents were 8 mm × 50 mm, 8 mm × 60 mm, 8 mm × 70 mm, and 8 mm × 80 mm. All of the diameters of the bare stents were 8 mm, and the lengths were 50-80 mm. The portal vein pressure was measured before and after shunt creation. After the insertion of TIPS, all of the patients received a diuretic treatment and a salt-limited diet until the ascites disappeared.
223484157|NCT04640116|PROCEDURE|microwave ablation (MWA)|MWA: After the patient's ascites disappears, MWA therapy will be performed. A MWA antenna was gradually inserted into the tumor along the predetermined angle under the guidance of Computed Tomography (CT). The whole thermal procedure was conducted under intravenous anesthesia. Vital signs were monitored during the procedure. The settings of the ablation parameters depended upon the manufacturer's recommendation and our experience. Ablation volume was determined by physicians according to liver function, tumor invasion site, and tumor stage. An upper abdominal CT scan was carried out immediately after the procedure to evaluate the ablation area and complications.
224172617|NCT03245944|PROCEDURE|late Angioplasty|Angioplasty is a minimally invasive, endovascular procedure to widen narrowed or obstructed arteries or veins. A deflated balloon attached to a catheter (a balloon catheter) is passed over a guide-wire into the narrowed vessel and then inflated to a fixed size. The balloon forces expansion of the blood vessel and the surrounding muscular wall, allowing an improved blood flow. This is part of standard of care for immature arteriovenous fistulas. Late means the angioplasty is done at 3 months from time of AVF creation if still immature at that time.
224172618|NCT04022291|BIOLOGICAL|Humulin ®70/30|"Humulin® 70/30 is a premixed suspension of human insulin of recombinant deoxyribonucleic acid (rDNA)origin, which contains 30% short-acting human soluble insulin and 70% intermediate-acting isophane insulin.~Human insulin is produced by recombinant deoxyribonucleic acid (rDNA), technology utilizing a non-pathogenic laboratory strain of Escherichia coli."
224172619|NCT04022291|BIOLOGICAL|Biocon Insulin 70/30|"Biocon Insulin 70/30 is a premixed suspension of human insulin of recombinant deoxyribonucleic acid (rDNA)origin, which contains 30% short-acting human soluble insulin and 70% intermediate-acting isophane insulin.~Biocon insulin is produced by recombinant deoxyribonucleic acid (rDNA) technology utilizing a non-pathogenic laboratory strain of Escherichia coli."
224172620|NCT03710291|DRUG|TRC101|Oral, non-absorbed, polymeric hydrochloric acid binder
224172621|NCT03710291|DRUG|Placebo|Placebo comparator
224172622|NCT05692206|OTHER|evaluation|Surveys will be administered to the participants. Participants will be given a stroop TBAG test.
224172623|NCT06084065|DEVICE|CART-I Plus|Photoplethysmography based ring-type blood pressure measurement device
223484158|NCT01348243|DRUG|disodium clodronate 200 mg/4 ml with 1% lidocaine|CLODRONATE 200 MG/4 ML SOLUTION FOR INTRAMUSCULAR USE WITH 1% LIDOCAINE EVERY OTHER WEEK
224172624|NCT00952588|DRUG|AZD1152|1200 mg, iv, 7 day infusion
224172625|NCT00952588|DRUG|LDAC|20 mg, sc, bd, 10 days
224172626|NCT00264511|OTHER|Hyperbaric Oxygen Treatment|Subjects in the HBO treatment group will receive a course of hyperbaric oxygen therapy (HBO) in addition to normal trauma and general care. A total of 12 HBO sessions will be delivered over approximately 8 days. HBO treatment will be provided at 2.4 atmospheres absolute (ATA) pressure for approximately 90 minutes of oxygen therapy. Treatments should be twice daily for the first three days. Minor variability will be allowed with respect to timing and profile of each session.
224305825|NCT05538065|OTHER|Follow-up booster Alert|Once the order entry or open encounter alert displays, the provider will have the option to schedule a follow-up message that will be sent 4 weeks after the alert is triggered
224305826|NCT05538065|OTHER|Pre-commitment|A two-staged pre-commitment electronic health record alert will be used. In the 1st alert, the providers will be prompted to discuss risks of these high-risk medications and share a handout about the risks with their patients, at their own discretion. The second alert will be either an order entry or open encounter alert, depending on the arm the provider is assigned to.
224305827|NCT05538065|OTHER|Enhanced Alert|An enhanced alert (known as a Best Practice Advisory \[BPA\]) will appear on the provider's electronic health record screen and will contain several standard components such as information about why the medication is dangerous for their patient and an order set that will allow providers to order a gradual dose taper for their patient, order alternative medications, place a referral to a behavioral health specialist, provide instructions on how to make lifestyle modifications to improve patient symptoms, and add patient instructions for how to gradually taper off benzodiazepines and sedative hypnotics, as applicable.
224305828|NCT06364696|DRUG|ASP4396|Intravenous (IV) infusion
224305829|NCT04270175|DRUG|Daratumumab SC|Given as 1800mg via injection
224305830|NCT04270175|DRUG|Pomalidomide|Given as 4mg oral capsule
224305831|NCT04270175|DRUG|Dexamethasone|Given as 20mg or 40 mg IV and 20mg or 40mg oral tablet.
224305832|NCT06244745|DRUG|Administration of letrozole|Oral administration of letrozole 5 mg (each capsule is 2.5 mg) once a day for 5 days starting on the night of the follicular puncture.
224305833|NCT04994015|DEVICE|Lab Assay for seven genetic variants for Parkinson's Disease|Counseling provided to participant by site clinician/physician/genetic counselor.
224305834|NCT05474846|DRUG|Melatonin|Given by PO
224305835|NCT05474846|OTHER|Placebo for Melatonin|Given by PO
224305836|NCT05474846|DRUG|Melatonin|Given by PO
224305837|NCT05474846|DRUG|Methylphenidate|Given by PO
224305838|NCT01565655|DRUG|peficitinib|oral
224305839|NCT01565655|DRUG|Placebo|oral
223484159|NCT01348243|DRUG|Disodium clodronate 100 mg/3,3 ml with 1% lidocaine|CLODRONATE 100 MG/3,3 ML SOLUTION FOR INTRAMUSCULAR USE WITH 1% LIDOCAINE ONCE-WEEK
223484160|NCT00058032|OTHER|screening questionnaire administration|
223484161|NCT00058032|PROCEDURE|annual screening|
223484162|NCT01286350|BEHAVIORAL|FL3X: Flexible Lifestyle Empowering Change|The FL3X Adaptive Intervention is designed to increase adherence to T1D self-management including medical management (blood sugar testing and insulin dosing), diet, and physical activity. FL3X relies on MI, and problem-solving skills training (PSST) as the basis for the counseling strategy, and creates a coherent integration across three key components of 1) behavior family systems therapy focused on family communications and teamwork; 2) individualized diabetes education in response to knowledge gaps relevant to behavioral goal attainment; and 3) use of currently available communications technology to support behavioral goal attainment through participant-defined reminders and motivational boosters, and/or peer support.
223484163|NCT00658853|BEHAVIORAL|4 times 4 minutes high aerobic intensity one leg cycling|3 times per week for 10 weeks
223484164|NCT02684175|DEVICE|Remote CI Counseling|The remote setup includes a 500 series teleconference audio and video live set-up. The teleconference set-up will be situated on a telemedicine cart and placed within the sound-proof booth at the testing site (UK ENT practice in Morehead, KY). The audiologist will deliver the session remotely.
223484165|NCT02684175|OTHER|In-Person CI Counseling|The standard face-to-face counseling that will occur between the participant and audiologist is the standard of care. No technology will be used. The audiologist will deliver the session face-to-face with the participant in the same room (standard practice).
223484166|NCT02819817|DRUG|Aloe Vera Gel|The participant will be asked to place the allocated substance onto the wound twice daily and cover with a supplied dressing on each occasion for 1 week.
223484167|NCT02819817|OTHER|Ultrasound gel|The participant will be asked to place the allocated substance onto the wound twice daily and cover with a supplied dressing on each occasion for 1 week.
224172627|NCT01796106|DEVICE|Resin infiltration|Up to two proximal early caries lesions (only if the second lesion is in a separate quadrant) per participant will be included. After radiographic and SFE imaging to assess lesion depth, the study lesions will be treated using the resin infiltrant Icon (DMG, Germany) according to manufactures´ instructions. Essentially, the treatment consists of the following parts: 1) isolating the tooth with a rubber dam and cleaning its surface; 2) removing/ conditioning the surface layer of the lesion (using Icon-Etch) to open the lesion body; 3) drying of the exposed porous enamel; 4) infiltrating the existing pore volume with the resin infiltrant (Icon Infiltrant); 5) light curing of the resin infiltrant; 6) repeating the infiltration step including light curing; followed by 7) finalizing using interproximal finishing/polishing strips.
224172628|NCT01796106|DEVICE|Fluoride varnish & Oral hygiene instruction|Up to two proximal early caries lesions (only if the second lesion is in a separate quadrant) per participant will be included. After radiographic and SFE imaging to assess lesion depth oral hygiene instruction and topical fluoridation therapy will be provided. For topical fluoridation Duraphat Fluoride Varnish (Colgate, USA) will be used according to manufactures´ instructions.
224172629|NCT01066611|DRUG|CAL-263|CAL-263 10 mg or placebo once daily for 7 days
224172630|NCT01066611|DRUG|Placebo|CAL-263 10 mg or placebo once daily for 7 days
224172631|NCT01960764|DRUG|Pre-Treatment with Dial liquid antibacterial soap|This arm will be pre-treated with Dial liquid antibacterial soap and alcohol prior to the autologous microbiome transplant.
224172632|NCT01960764|OTHER|Control|
224172633|NCT03220594|PROCEDURE|hypogastric artery ligation|hypogastric artery ligation is the ligation of the internal iliac artery to stop bleeding related to obstetrics obstetric hemorrhage Hysterectomy is the removal of the uterus if bleeding can't stop by hypogastric artery ligation
223484168|NCT01567410|OTHER|e-learning|Braden scale and pressure ulcer classification
223484169|NCT01567410|OTHER|traditional classroom training|Braden scale and pressure ulcer classification
223484170|NCT04480879|DRUG|AZD8154 nebuliser|Nebuliser suspension
223484171|NCT04480879|DRUG|AZD8154 Monodose DPI presented in capsules|AZD8154 Monodose DPI formulation delivered dose
223484172|NCT04480879|DRUG|AZD8154 Placebo Monodose DPI presented in capsules|The dose correspond to AZD8154 Monodose DPI formulation
223484173|NCT01545336|DRUG|Anastrozole|1 mg tablet to be taken 1 time daily
223484174|NCT01545336|DRUG|Placebo|1 mg tablet to be taken 1 time daily
223484175|NCT02826213|DEVICE|LifePort® perfusion device|Renal Perfusion with LifePort® perfusion device
223484176|NCT02826213|DEVICE|Waves perfusion device|Renal Perfusion with Waves perfusion device
223484177|NCT02682121|DRUG|Metformin|Metformin 850 mg twice daily
223484178|NCT02682121|DRUG|Placebo|Placebo twice daily
224172634|NCT00000642|DRUG|CD4-IgG|
223484179|NCT05775653|OTHER|ADAPT program|The ADAPT program is a structured and individualized group-based program, in which two occupational therapists teach groups of people the skills of problem-solving more efficiently as means to overcome ADL task performance problems. The ADAPT program 3.0 includes 10 two-hour sessions and is followed by two booster sessions to support sustainable gains.
224172635|NCT01766401|DRUG|Placebo|
224172636|NCT01766401|DRUG|Vilazadone|Viibryd
224172637|NCT01523613|DEVICE|Chemfil ROCK Glassionomer restoration|High-viscous glassionomer restoration of Chemfil ROCK used as posterior dental filling material.
224305840|NCT03299088|BIOLOGICAL|Pembrolizumab|Given IV
224305841|NCT03299088|DRUG|Trametinib|Given PO
223484180|NCT05775653|OTHER|UOT|UOT is delivered by one occupational therapist. Sessions are individualised and focus on improving ADL ability e.g. by practicing the performance of ADL task. UOT typiccally includes 7 one-to-one sessions of 60 minutes, delivered over a 10-week period in the clients´ homes. The dose is however not fixed but based on the occupational therapists´ clinical judgement.
223484181|NCT06465056|DRUG|Botulinum toxin type A|Botulinum toxin application between 3-14 days after direct eyebrow lift surgery.
223484182|NCT02341079|DRUG|Bupivacaine Liposome Injection|Intraoperative intracapsular injection of 266mg of bupivacaine liposome injection diluted to 60mL with 0.9% normal saline.
223484183|NCT02341079|DRUG|Indwelling femoral nerve block|Femoral nerve block delivered via indwelling femoral nerve catheter with 0.125% bupivacaine.
223484184|NCT05704712|BEHAVIORAL|Monetary Incentives|Monetary incentives, provided in the form of pre-loaded Visa debit cards are provided to encourage exercise.
223484185|NCT04666298|DRUG|Inclisiran sodium|Subcutaneously injected on Day 1, 90 and 270.
223484186|NCT04666298|DRUG|Placebo|Subcutaneously injected on Day 1, 90, and 270.
223484187|NCT01869374|DEVICE|MagVenture MagPro MST|Brain stimulation by magnetic means versus electrical standard unilateral Electroconvulsive Therapy (RUL ECT). Treatment will be administered 3 times a week.
223484188|NCT01869374|BIOLOGICAL|RUL ECT|RUL ECT using the Somatics Thymatron device with Ultrabrief stimulus. Treatment will be administered 3 times a week.
223484189|NCT01680796|DRUG|Dovitinib|"Dose Level 0: 200 mg daily~Dose Level 1: 300 mg daily~Dose Level 2: 300 mg daily~Dose Level 3: 400 mg daily~Dose Level 4: 500 mg daily"
224172638|NCT01523613|DEVICE|Fuji IX GP Extra Glassionomer restoration|High-viscous glassionomer restoration of Fuji IX GP Extra used as posterior dental filling material.
224172639|NCT00959829|OTHER|Music and message|Experimental group: music and message Control group: silence
224172640|NCT05647928|OTHER|no intervention|no intervention
224172641|NCT00485121|DRUG|Ezetimibe|
224172642|NCT04180475|DEVICE|MedRem application|Medication adherence smartwatch application
224172643|NCT00348192|DRUG|SB-742457|
224172644|NCT00348192|DRUG|donepezil|
224172645|NCT02737371|DRUG|F901318 Dose level A oral|Adverse events days 1-10
223484190|NCT01680796|DRUG|Bortezomib|"Dose Level 0: 1.3 mg/m2 IV on days 1 and 8~Dose Level 1: 1.3 mg/m2 IV on days 1 and 8~Dose Level 2: 1.6 mg/m2 IV on days 1 and 8~Dose Level 3: 1.6 mg/m2 IV on days 1 and 8~Dose Level 4: 1.6 mg/m2 IV on days 1 and 8"
223484191|NCT01680796|DRUG|Dexamethasone|Dexamethasone 20 mg will be given orally on Days 1, 2, 8, and 9 of each 21-day cycle.
223484192|NCT03942588|BEHAVIORAL|High-intensity interval training|
223484193|NCT00844519|DRUG|Maraviroc|For subjects assigned to the maraviroc group, they will receive maraviroc at 300mg by mouth twice daily for 24 weeks in addition to taking their current anti-HIV medications. For subjects on ritonavir, the dose will be reduced to 150mg by mouth twice daily for 24 weeks.
224172646|NCT02737371|DRUG|Placebo dose level A oral|Placebo adverse events days 1-10
224172647|NCT02737371|DRUG|F901318 Dose level B oral|F901318 adverse events days 1-10
223484194|NCT00844519|DRUG|placebo|For subjects assigned to the placebo group, they will receive a matching placebo pill 300mg to be taken by mouth twice daily for 24 weeks in addition to taking their current anti-HIV medications.
223484195|NCT00226655|DRUG|hCRF [XERECEPT (corticorelin acetate injection)]|2mg/day
223585960|NCT02445573|OTHER|sham EA|When acupuncturing, adhesive pads were first pasted on acupoints after sterilization in either group. In sham EA group, participants were needled at sham BL33 and sham BL35, which were about 20 mm lateral to BL33 and BL35, respectively, with blunt needle tips piercing adhesive pads and not piercing the surface of the skin, using placebo needles of size 0.30×25 mm. Needles were then lifted, thrusted and twirled evenly for 3 times. Paired electrodes of EA apparatus were attached transversely to bilateral sham BL33 and sham BL35 (using sham electrodes) respectively. The parameters of sham EA apparatus and the treatment course were the same as in the EA group.
224305842|NCT04809740|OTHER|Evaluate implementation of navigator-delivered Home ePRO for all cancer patients|evaluate implementation of navigator-delivered Home ePRO for all cancer patients across multiple practice sites; 2) examine the barriers, facilitators, and implementation strategies used in implementing navigator-delivered Home ePRO; and 3) assess the impact of Home ePRO on clinical and utilization outcomes
224172648|NCT02737371|DRUG|Placebo dose level B oral|Placebo adverse events days 1-10
224172649|NCT02737371|DRUG|F901318 Dose level C oral|F901318 adverse events days 1-10
224172650|NCT02737371|DRUG|Placebo Dose level C oral|Placebo adverse events days 1-10
224172651|NCT00261378|DEVICE|Transarterialchemoembolisation (TACE)|
224305843|NCT05828745|DRUG|CB06-036|CB06-036 capsule
223484196|NCT01757132|DEVICE|Implantable Miniature Telescope|Device - Implantable Miniature Telescope
223585961|NCT00139217|DRUG|iNO|
223585962|NCT00139217|PROCEDURE|Non-invasive nitric oxide|
224172652|NCT00261378|DEVICE|DC Bead with Doxorubicin|
223484197|NCT06281249|DEVICE|Ultrasound placement device|Device to assist in placement of epidural procedure
223484198|NCT06108921|DRUG|Xylitol Powder|The bilateral nasal cavity was irrigated by using a Sanvic SH903 pulsatile irrigator containing 400 ml of xylitol solution once a day for 2 months.
223484199|NCT06108921|DRUG|Salt Powder|The bilateral nasal cavity was irrigated by using a Sanvic SH903 pulsatile irrigator containing 400 ml of normal saline once a day for 2 months.
223484200|NCT05490082|DRUG|Mirabegron, Propevirine, Solifenacin|Efficacy comparison
223484201|NCT06438601|DEVICE|Lens A (omafilcon A)|15 minutes of daily wear.
223484202|NCT06438601|DEVICE|Lens B (comfilcon A)|15 minutes of daily wear.
223484203|NCT06034184|OTHER|Virtual Reality|The nursing students use glasses and handcontrollers (High Fidelity Simulation) in the VR scenario for training and learning mass casualty incidents.
223585963|NCT04274803|DRUG|Intralipid, 20% Intravenous Emulsion|intralipid 20% (Frezenius, Clayton, NC, USA) in a dose of 4 ml diluted in 250 ml 0.9% regular saline to be infused IV and to be repeated every 2 weeks all over the pregnancy.
223585964|NCT04274803|DRUG|Conventional therapy of antiphospholipis syndrome|the conventional basic treatment of APS (Dual low dose aspirin (LDA) (Ezacard 75mg) once daily and Low molecular weight heparin (LMWH) (clexane 4000 IU) injection once daily.
223585965|NCT01518504|OTHER|Thoracic Mobilization|The subject will be in a prone position and the physical therapist will first identify the upper thoracic spine region. The physical therapist will then cross his or her hands and place them on opposite sides of the spinous processes using the pisiforms as the contact area. The subject will be asked to exhale and upon exhalation the physical therapist will apply a small amplitude, quick thrust at end of range.
224172653|NCT01432665|DRUG|Placebo|Solid Oral Dosage. Maximum every other day (on an as needed basis)
224172654|NCT01432665|DRUG|Sildenafil|Solid Oral Dosage. Maximum every other day (on an as needed basis)
224172655|NCT01432665|DRUG|Testosterone|Solid Oral Dosage. Maximum every other day (on an as needed basis)
224305844|NCT05828745|DRUG|Placebo|Placebo capsule
224305845|NCT03672487|DRUG|Benznidazole|Benznidazole tablet
223484204|NCT04076683|DEVICE|Algodrep|Algorithm computing the volume of blood to be transfused and the interval between apheresis which are necessary to maintain an individual objective of HbS percentage.
224172656|NCT06980168|OTHER|kabat technique|kabat technique include diagonal movements to activate weak muscles through resistance . 3-5 repetetion per muscle for 2-3 sets .session conducted 5 days per week for three weeks each lasting 30 minutes .
224172657|NCT06980168|OTHER|facial nerve mobilization|neural mobilization involves manual traction and circular movement around ear to enhance nerve mobility and function .5-10 repetetions .Session conduted 5 days per week for 3 weeks lasting 30 minutes facial exercises include raising eyebrows-eye closure-lip raising-smiling-snarling flaring of nose-forehead wrinkling-lipspuckering-pouting. 5-10 repetetions 3 times a day .7 days for 3 weeks
224172658|NCT01021553|DRUG|GSK557296|50 mg GSK557296
224172659|NCT01021553|DRUG|GSK557296|150 mg GSK557296
224305846|NCT03672487|DRUG|Placebo Oral Tablet|Sugar pill manufactured to mimic Benznidazole
224305847|NCT03589768|BIOLOGICAL|Tetanus and Diphtheria Toxoids Adsorbed|Used for active immunization of adults and children 7 years of age and older against diphtheria and tetanus.
224305848|NCT03589768|BIOLOGICAL|Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed onto aluminum hydroxide|A sterile isotonic suspension of tetanus and diphtheria toxoids and pertussis antigens adsorbed on Aluminum hydroxide.
224172660|NCT01021553|DRUG|placebo|placebo
224172661|NCT00006493|DRUG|Rosiglitazone|
224172662|NCT06502509|DIETARY_SUPPLEMENT|Commercial Kombucha tea (Brand name E-Ben Organic Kombucha Lemon)|Commercial lemon kombucha tea (Brand:E-Ben Organic Kombucha Lemon), which will be given to participants in opaque bottles for 8 weeks.
224172663|NCT06502509|DIETARY_SUPPLEMENT|Lemon tea|Diluted lemon juice with the same pH as the commercial kombucha tea as placebo, which will be given to participants in opaque bottles for 8 weeks.
224172664|NCT01579526|DRUG|FP01|comparison of different dosages
224305849|NCT06530290|DRUG|Mirtazapine 15 MG|Mirtazapine (15 mg), once a day for 12 weeks
224305850|NCT06530290|DRUG|Placebo|Placebo, once a day, for 12 weeks
223484205|NCT05548907|BEHAVIORAL|sleep restriction treatment|"Treatment consists of sleep restriction treatment for insomnia. In this treatment, participants limit their bedtimes to the time they actually sleep. If they sleep most of the time in bed again then bedtimes are slowly built up again. This treatment technique has already been studied in several trials and found to be effective.~Mode of delivery is an online booklet, online exercises and weekly telephone support"
223484206|NCT05548907|BEHAVIORAL|sleep diary monitoring|As an active control condition people monitor their sleep with a sleep diary (also included in the sleep restriction intervention)
223484207|NCT03803826|DEVICE|CRT-D re-programming|"The previously implanted, ineffective CRT-D is reprogrammed under supervision of Trans-Thoracic Echocardiography (TTE) to:~1. adjust the atrioventricular interval so that E and A waves do not overlap~2. the interventricular interval is subsequently optimized to yield maximum improvement of the sum of longitudinal+radial+circumferential strains."
223484208|NCT03803826|DIAGNOSTIC_TEST|Trans-Thoracic Echocardiography|"This intervention relates to the determination of strains and atrioventricular interval and supplies data for reprogramming the ineffective CRT-D~Transthoracic echocardiography performed to determine the left ventricular ejection fraction as an outcome measure is not considered intervention here (as it is also performed in the control group and that would cause an error cross-referencing."
223484209|NCT02262871|DEVICE|High flow nasal oxygen cannula|HFN will be set with an inspiratory flow rate at 45-55 L/min (maximal tolerated flow), temperature at 37°C or 34°C if perceived as too warm, and fraction on inspired oxygen (FiO2) will be adjusted to achieve an oxygen saturation (SpO2) of at least 92%.
223484210|NCT02262871|DEVICE|Noninvasive ventilation|The setting of NIV will be appropriately adjusted, based on the clinical assessment of the respiratory therapist in charge and will not be modified during the test.
223484211|NCT00397124|DEVICE|PET/CT imaging|
223484212|NCT05579834|PROCEDURE|posterior correction surgery|Cases of hemothorax developing after posterior correction surgery for spinal deformities
223484213|NCT06448780|DRUG|Caffeine citrate 20 mg/kg|Following loading dose of 20 mg/kg of caffeine citrate IV, participants will receive 2 daily doses of 10 mg/kg caffeine citrate IV.
223585966|NCT01518504|OTHER|Sham|The subject will be in a prone position and the physical therapist will first identify the upper thoracic spine region. The physical therapist will then cross his or her hands and place them on opposite sides of the spinous processes using the pisiforms as the contact area. The subject will be asked to exhale and upon exhalation the physical therapist will not apply any other force than light hand contact.
224172665|NCT05384990|DEVICE|Stochastic Resonance Electric Stimulation|Subjects will be asked to perform postural transitions like sit to stand, gait initiation, sit to walk and Timed up and the Go (TUG) functional test. This will entail a subsensory electrical signal with a white noise frequency distribution. Proprioceptive SR electrical stimulation will be delivered by BIOPAC Systems, Inc. stimulators that are current limited to deliver less than 10 milli ampere of current. Electrical stimulation will be delivered to muscles and joints along the legs and hips. The stimulation intensity will be very low, below the sensory threshold of the participant.
224172666|NCT01950364|DRUG|brentuximab vedotin|Brentuximab vedotin will be administered every 3 weeks at a dose of 1.8 mg/kg.
224172667|NCT01950364|DRUG|Brentuximab vedotin and rifampicin|Brentuximab vedotin will be administered every 3 weeks at a dose of 1.8 mg/kg beginning on Cycle 1, Day 1; daily rifampicin (600 mg PO) will be administered during Cycles 0 through 3 only, beginning on Cycle 0, Day 1 (7 days before the Cycle 1, Day 1 dose of brentuximab vedotin) and continuing through Cycle 3, Day 21.
224172668|NCT04372173|DIAGNOSTIC_TEST|analysis of the concentration of the clotting factors in patients who underwent primary hip arthroplasty|"Blood samples were taken before surgery, 6 hours, two, four, and six days after the procedure. Venous blood samples were taken from peripheral veins.~All analyzed parameters (fibrinogen, factor II, factor VIII, factor X, D-dimer) were determined using an ACL TOP 500 CTS automated coagulation analyzer.~All patients were operated on by a single surgical team, with cementless hip replacements implanted, and without tranexamic acid administered in the perioperative period. All patients underwent venous thromboembolic complications prophylaxis.~The following data were collected: age, body mass index, gender, perioperative risk assessment scale according to the American Society of Anesthesiologists score, blood transfusions, hemoglobin levels before surgery and two days post-surgery, instances of thromboembolic complications. Because of the observational nature of this study no changes in the treatment of patients were made."
224172669|NCT00033293|OTHER|Clinical Observation|Undergo observation
224172670|NCT00033293|DRUG|Cyclophosphamide|Given IV
224172671|NCT00033293|OTHER|Laboratory Biomarker Analysis|Correlative studies
224172672|NCT00033293|PROCEDURE|Magnetic Resonance Imaging|Correlative studies
224172673|NCT00033293|DRUG|Prednisone|Given orally
224172674|NCT00033293|BIOLOGICAL|Therapeutic Immune Globulin|Given IV
223484214|NCT06448780|DRUG|Caffeine citrate 30 mg/kg|Following loading dose of 30 mg/kg of caffeine citrate IV, participants will receive 2 daily doses of 10 mg/kg caffeine citrate IV.
223484215|NCT03149770|DRUG|Naloxone then placebo|naloxone intranasal 4mg, then placebo
223484216|NCT03149770|DRUG|Placebo then Naloxone|placebo then naloxone intranasal 4mg
223585967|NCT02855944|DRUG|Chemotherapy|Chemotherapy will be administered per local standard of care and regulations. Specific comparator will depend on platinum status and investigator decision.
224172675|NCT03696498|PROCEDURE|Resin restoration (1 step)|Permanent resin restoration is placed on top of the partial removed caries.
223585968|NCT02855944|DRUG|Rucaparib|Tablets of rucaparib, at a dose of 600 mg, will be taken orally twice a day
223484217|NCT00090688|BIOLOGICAL|meCS6 + LT(R192G)|
223484218|NCT02993809|BIOLOGICAL|BM-ECs and PRPE|
223484219|NCT02993809|BIOLOGICAL|BM-ECs|
223585969|NCT05942118|PROCEDURE|Breast conservative surgery|Every patients with non-palpable breast lesion will undergo to conservative breast surgery after lesion's localization
224172676|NCT03696498|PROCEDURE|Resin restoration (2 steps)|A calcium hydroxide containing base material is used and a temporary glass-ionomer restoration is placed in the entire cavity. After 4-6 months the patients are recalled. The temporary restoration is removed and final excavation is carried out with hand excavators until firm but stained dentine remains. A permanent resin restoration is performed.
224172677|NCT03831607|DRUG|KHK7791|KHK7791 30 mg, 20 mg ,10 mg or 5 mg tablets
224172678|NCT00935701|DEVICE|Acupressure and Acupuncture|Acupressure involves the stimulation of specific acupoints by firm pressure, while acupuncture involves the insertion of very fine needles (the size of a strand of hair). The needles may be quickly inserted and removed or left in up to 5 minutes at a time.
223484220|NCT01311661|DRUG|Placebo twice daily|Inhaled Placebo of Olodaterol twice daily
223484221|NCT01311661|DRUG|Olodaterol low daily dose twice daily|Inhaled Olodaterol medium daily dose administered as low dose twice daily
223484222|NCT01311661|DRUG|Olodaterol medium daily dose twice daily|Inhaled Olodaterol high daily dose administered as medium dose twice daily
223484223|NCT01311661|DRUG|Placebo twice daily|Inhaled Placebo of Olodaterol twice daily
223484224|NCT01311661|DRUG|Olodaterol high daily dose once daily and placebo|Inhaled Olodaterol high daily dose administered as one full dose once daily and placebo once daily
223484225|NCT01311661|DRUG|Olodaterol medium daily dose once daily and placebo|Inhaled Olodaterol medium daily dose administered as one full dose once daily and placebo once daily
223484226|NCT03390153|OTHER|semi flexible socket|The investigators will analyze the subject's gait by trained visual diagnosis and video gait analysis, to determine comfort and safety. Any modifications will be done at this time. Once the subjects, student, and faculty investigators are satisfied with the overall fit of prostheses, a student investigator will insert force sensors into the socket to evaluate pressure. In the 'Comfort Test', walk at a self-selected pace on a treadmill for 10 minutes. Subjects will then perform a single stance activity on a Balance Master. Investigators will remove the force sensors and do one final safety check of prostheses before each subject takes their definitive socket home. Subjects will be required to wear the prosthesis given to them for one week before returning for a follow up appointment.
223484227|NCT03390153|OTHER|rigid fiber socket|The investigators will analyze the subject's gait by trained visual diagnosis and video gait analysis, to determine comfort and safety. Any modifications will be done at this time. Once the subjects, student, and faculty investigators are satisfied with the overall fit of prostheses, a student investigator will insert force sensors into the socket to evaluate pressure. In the 'Comfort Test', walk at a self-selected pace on a treadmill for 10 minutes. Subjects will then perform a single stance activity on a Balance Master. Investigators will remove the force sensors and do one final safety check of prostheses before each subject takes their definitive socket home. Subjects will be required to wear the prosthesis given to them for one week before returning for a follow up appointment.
223484228|NCT06083896|PROCEDURE|Photodynamic nails|stab incision is made at the entry site
223484229|NCT03188822|DEVICE|Bioabsorbable steroid releasing sinus implant|After completion of indicated frontal sinus surgery, patients will have a bioabsorbable steroid releasing implant placed in the frontal sinus opening, which will remain in place for 14 days.
223484230|NCT03188822|DEVICE|Bioabsorbable nasal dressing impregnated with steroid|After completion of indicated frontal sinus surgery, patients will have a bioabsorbable nasal dressing impregnated with steroid placed in the frontal sinus opening, which will remain in place for 14 days.
223484231|NCT05115929|PROCEDURE|Decompressive Laparotomy|As described in the study protocol a long midline laparotomy is performed and open abdomen therapy using negative pressure dressings initiated to lower abdominal pressure and thereby improve venous return from the brain to lower intracranial pressure.
224172679|NCT01592942|DEVICE|Histoacryl|cyanoacrylate glue fixation of mesh 1 ml
224172680|NCT01592942|DEVICE|Progrip|self-gripping mesh
224172681|NCT01592942|DEVICE|sutures (prolene 3-0)|non-absorbable suture fixation 3-0
224172682|NCT05747664|DRUG|DWP16001|0.3mg
224172683|NCT02118402|DIETARY_SUPPLEMENT|Fortified maize porridge|Maize porridge will be home-fortified with either A) MNP, B) MNP+Fe, C) MNP+Fe+GOS
224172684|NCT02657109|OTHER|physical therapy procedure|physiotherapy exercises conducted in early way for the rehabilitation of patients in the postoperative period of cardiac valve replacement.
224172685|NCT00124384|BEHAVIORAL|CBT-I|
224172686|NCT00124384|DRUG|modafinil|
224172687|NCT01778140|OTHER|Patient-specific computerized reminder|The intervention targets are physicians,not patients. This CDSS alerts physicians only when the patient with high risk of contrast-induced-nephropathy(CIN) is encountered. On the contrast, the CDSS will not alert when the patient without CIN risk is encountered.
224172688|NCT01778140|OTHER|Non-patient-specific computerized reminder|The non-patient-specific computerized reminder always pops up to remind physicians to check their patient's CIN risk no matter what CIN risk is.
223484232|NCT05115929|PROCEDURE|Decompressive Craniectomy|As described in the study protocol a sufficiently sized hemi-craniectomy is performed and the skin closed over the bony defect to allow cerebral swelling and thereby lower intracranial pressure.
223484233|NCT05840445|DRUG|Onabotulinum toxin A|Intramuscular application of onabotulinum toxin-A in the upper facial third.
223484234|NCT05840445|DRUG|Prabotulinumtoxin A|Intramuscular application of prabotulinum toxin-A in the upper facial third.
223484235|NCT00911911|PROCEDURE|Blood sampling|Taken at different times : inclusion, at the cycle 4 and at the cycle 6 during the neoadjuvant chemotherapy
223484236|NCT00911911|PROCEDURE|BIOPSY|Biopsy at the moment of inclusion, before neoadjuvant chemotherapy
224172689|NCT06865014|OTHER|Intermittent Ramadan Fasting|Intermittent fasting during the month Ramadan
224172690|NCT05919511|OTHER|Non-Interventional|This is an observational study
224172691|NCT04368741|DIETARY_SUPPLEMENT|SANZ®KINGWILL|20g nutrition product (SANZ®KINGWILL) was used as extra meal at 10:00am and 15:00pm, respectively.
224172692|NCT04368741|DIETARY_SUPPLEMENT|GLUCERNA SR®|17.5g nutrition product (GLUCERNA SR®) was used as extra meal at 10:00am and 15:00pm, respectively.
224172693|NCT05734144|PROCEDURE|The intraoperative ERCP has been performed immediately before LC|combination approach has been used to improve patient compliance and shorten hospital stays. The intraoperative ERCP has been performed immediately before Laparoscopic Cholecystectomy
224172694|NCT05734144|PROCEDURE|POES followed by LC|Treatment in two stages, which combines a preoperative ES followed by LC (sequential treatment).
224172695|NCT01662128|DRUG|Xeloda|Xeloda as Adjuvant Therapy
224172696|NCT00961558|PROCEDURE|Varicocelectomy|Varicocelectomy
224172697|NCT02724280|DEVICE|WLE and then LCI|The gastric mucosa was evaluated with WLE and then LCI by two different endoscopists.
224172698|NCT02724280|DEVICE|LCI and then WLE|The gastric mucosa was evaluated with LCI and then WLE by two different endoscopists.
224172699|NCT00878306|DRUG|Disulfiram|62.5 mg daily x3 days, then 250 mg daily x3 days
224172700|NCT00878306|DRUG|Disulfiram + Efavirenz|Efavirenz 600 mg daily x10 days, then in addition with 62.5 mg daily x3 days, then Disulfiram 250 mg daily x3 days
224305851|NCT06636240|DIETARY_SUPPLEMENT|Mulberry fruit juice|Mulberry fruit juice 200ml/day plus standard therapy for atopic dermatitis including topical Mometasone furoate cream 0.1%
224172701|NCT00878306|DRUG|Disulfiram + Atazanavir|Atazanavir 400 mg daily x8 days, then in addition with 62.5 mg daily x3 days, then Disulfiram 250 mg daily x3 days
224172702|NCT00878306|DRUG|Disulfiram + Ritonavir|Ritonavir 200 mg daily x8 days, then in addition with 62.5 mg daily x3 days, then Disulfiram 250 mg daily x3 days
224172703|NCT03316755|BEHAVIORAL|Exposure|Exposure to pamphlet
224305852|NCT06636240|OTHER|Mometasone furoate 0.1% cream|Standard therapy for atopic dermatitis including Mometasone furoate cream 0.1%
224305853|NCT04911738|OTHER|Virtual Reality , immersion in a virtual titlted room|The immersion in virtual reality will be based on the HTC VIVE® device and the software developed by the Virtualis Society.
224305854|NCT00112866|DRUG|cilengitide|Given IV
224305855|NCT00112866|PROCEDURE|therapeutic conventional surgery|Undergo tumor resection
224305856|NCT00112866|OTHER|pharmacological study|Correlative studies
224305857|NCT00112866|OTHER|laboratory biomarker analysis|Correlative studies
224305858|NCT05635383|OTHER|PERIPHERAL NERVE BLOCK|Observation of rebound pain after peripheral nerve block application
224305859|NCT01539135|DRUG|Methylene Blue|20 cc methylene blue instilled above the cuff once after intubation for the duration of the surgical procedure
224305860|NCT04197817|DRUG|JS002|JS002, Subcutaneous or intravenous injection of a single dose of JS002, dose cohort according to ascending dose design
224305861|NCT04197817|DRUG|Placebo|Placebo,Subcutaneous or intravenous injection of a single dose of placebo, dose cohort according to ascending dose design
224305862|NCT03465826|BEHAVIORAL|PainCOACH Pain Coping Skills Training|Migraineurs will participate in 4 weeks of daily headache monitoring, baseline questionnaires, followed by 8 weeks of the PainCOACH migraine mHealth Pain Coping Skills Training program (developed by Drs. Keefe and Rini based on social cognitive theory and in-person pain coping therapy sessions). Following the 8 week mHealth intervention, participants will immediately complete post-treatment assessments and later will complete follow-up assessments at 3 and 6 months.
224305863|NCT03465826|BEHAVIORAL|Treatment as Usual|Participants will keep headache diaries for 4 weeks, followed by baseline assessments + 8 weeks of daily headache monitoring (as a parallel to the PainCOACH intervention). Post-assessments will immediately follow, and participants later will complete follow-up assessments at 3 and 6 months.
224305864|NCT03898089|OTHER|Core Stability Exercise|The participants in the core stability exercise group will be included in a treatment program for 3 days per week for 6 weeks. Traditional physiotherapy methods will be applied to all participants. Traditional physiotherapy will include heat modality (a hot pack for 15 minutes), electrotherapy (transcutaneous electrical nerve stimulation (TENS), a 50 Hz conventional TENS with a pulse duration \<150 microseconds).Each training session will be lasted 60 min, starting with a 10-min warm up program mainly consisting of core strength exercises and ending with a 5-min cool-down program (stretching). Progression of exercises will be tailored to individual patients' ability, fatigue and pain. Exercises will be designed from 1 set to 3 sets, from 8 to 15 repetitions and contractions from 5 seconds to 10 seconds.
223484237|NCT00911911|PROCEDURE|SURGERY|Surgery after neoadjuvant chemotherapy
224172704|NCT06687876|DRUG|Metformin|Twice a day 500mg of metfomrin orally (1000mg/day) during a 2-week period.
224172705|NCT03338452|BEHAVIORAL|Low energy ketogenic diet|Low energy ketogenic diet lasting 12 weeks with a previous preparation period including detailed instructions during classes and individual counselling by a dietitian. Participants were provided with a list of suitable foods with very low carbohydrate content. Furthermore, the subjects shared cooking recipes and links to helpful webpages. They were free to follow a KD according to their personal preferences but limit their carbohydrate intake to 5-10 % of total energy from carbohydrates, but derive at least 70 % of total energy from fat.
224172706|NCT01836367|DRUG|Ingenol Mebutate 0.015%|Picato
224172707|NCT03616249|OTHER|Sleep|Initially, all volunteers will undergo the following pre and post-intervention tests: Polysomnography; Actigraphy for 10 days; Maximum exercise test; blood collection; Physical performance evaluation; Assessment of muscle strength, assessment of body composition; And application of questionnaires.
224305865|NCT03898089|OTHER|Core Stability Exercise plus Myofascial Release Technique Group|In addition to the core stabilization exercise group myofascial relaxation technique will be performed with roller massager (Theraband®, The Hygenic Corporation, Akron, OH.) for 3 days per week for 6 weeks. The myofascial relaxation technique will be performed along the superficial back line (plantar fascia gastrocnemius muscles, hamstring muscles, sacrolumbar fascia, erector spinae muscles) bilaterally. Myofascial relaxation will be done to the anatomical structures indicated by roller massage technique. Applications will be made in 3 sets of 30sec for each zone (1 min rest between sets) and 7/10 according to VAS.
224305866|NCT03543436|DRUG|Temocillin|Intravenous temocillin disodium 2g intravenously/8h Or Renally Adjusted Equivalent (ORAE) in 30-40 min infusion or continuous intravenous (6g/24h) .
224305867|NCT03543436|DRUG|meropenem or imipenem|Intravenous carbapenem (meropenem 1g intravenously/8h Or Renally Adjusted Equivalent (ORAE) or imipenem 1g intravenously/8h ORAE)
224305868|NCT04465695|DRUG|Interferon beta-1b|Subcutaneous injection of interferon β-1b 1mL (0.5mg; 16 million IU) for 3 days
224305869|NCT04465695|DRUG|Clofazimine|Oral 100mg twice daily on day 1, then 100mg daily for 2 days
224305870|NCT02213510|DEVICE|Zip Surgical Skin Closure Device|The Zip Surgical Skin Closure device is a single use, sterile medical device that replaces sutures, staples, and glue for closure of the skin layer for surgical incisions or laceration repair. The device will applied by the surgeon at the end of the CIED procedure and be worn until the two week post-operative wound check.
223484238|NCT02138383|DRUG|Enzalutamide|The starting dose of enzalutamide will be 80 mg (Level 1) daily, taken orally. The dose escalation schedule is a standard 3 + 3 design. In the first part of the study, different doses of enzalutamide will be tested. In the second part of the study, all patients will be started at the same dose of enzalutamide.
223484239|NCT02138383|DRUG|Gemcitabine|The starting dose of gemcitabine will be 1000 mg/m\^2 administered intravenously on days 1, 8 and 15 of each cycle.
224172708|NCT03616249|OTHER|Resistance Exercise|After these procedures, the sarcophagic elderly will Resistance training, will be performed according to the latest positioning of the American College of Sports Medicine for the training of the elderly . The training will last 12 weeks, 3 times / week, with intervals of 48h between the training sessions, which will have a maximum duration of 60min. The periodization of the training will be done in a linear way, in which the volunteers will be submitted to training with 1 series of 12 to 15 repetitions at 60% of 1RM in the first week; In the second week volunteers will train at 70% of 1RM, performing 2 sets of 10 to 12 repetitions; And from the third week to the end of the training period the volunteers will train at 80% of 1RM performing 3 sets of at most 8 replicates and the intervals between sets may range from 60min to 180min. The training load will be readjusted in the 6th week of training from a new 1RM test and the training will be on the same test equipment.
224172709|NCT01318928|DRUG|Metronidazol|metronidazol. 400mg x 3 per day for 10 days
224172710|NCT06107790|DRUG|HS022|"8 treatment cycles, 3 weeks/cycle, 24 weeks. The first dose is 8 mg/kg , and then 6 mg/kg .3 weeks/cycle, continue until the disease progresses, intolerable toxic reaction occurs, or the subject voluntarily withdraws from the clinical trial, whichever occurs first.~The second stage 9 treatment cycles, 3 weeks/cycle, 27 weeks. 6mg/kg"
224172711|NCT06107790|DRUG|Trastuzumab|"8 treatment cycles, 3 weeks/cycle, 24 weeks. The first dose is 8 mg/kg , and then 6 mg/kg .3 weeks/cycle, continue until the disease progresses, intolerable toxic reaction occurs, or the subject voluntarily withdraws from the clinical trial, whichever occurs first.~The second stage 9 treatment cycles, 3 weeks/cycle, 27 weeks. 6mg/kg"
224172712|NCT06107790|DRUG|Vinorelbine Bitartrate|"Vinorelbine: 25mg/m2 (intravenous infusion, day 1 and 8 of each cycle). 3 weeks/cycle, continue until the disease progresses, intolerable toxic reaction occurs, or the subject voluntarily withdraws from the clinical trial, whichever occurs first.~Second section:9 treatment cycles, 3 weeks/cycle, 27 weeks. Vinorelbine: 25mg/m2 (intravenous infusion, day 1 and 8 of each cycle). The investigator may decide whether to continue treatment with vinorelbine at his discretion.~3 weeks/cycle, continue until the disease progresses, intolerable toxic reaction occurs, or the subject voluntarily withdraws from the clinical trial, whichever occurs first."
224172713|NCT07022457|BIOLOGICAL|Encorafenib + Binimetinib|Participants will have received a clinical decision to begin encorafenib plus binimetinib treatment as a second-line treatment for metastatic melanoma, in accordance with current Summary of Product Characteristics
224172714|NCT01832389|DEVICE|PiCCO|
224172715|NCT01700140|DRUG|SyB D-0701|Study drug patches \[Low dose group (18.75 mg): SyB D-0701 15 cm2 placebo patch + SyB D-0701 25 cm2 patch, High dose group (30.00 mg): SyB D-0701 15 cm2 patch + SyB D-0701 25 cm2 patch\] assigned at the Case Registration Center are applied to either the right or left upper arm at 12 to 24 hours prior to the start of radiotherapy and left as is until 24 hours after completion of the third irradiation.
224172716|NCT01700140|DRUG|Placebo|Study drug patches (Placebo group: SyB D-0701 15 cm2 placebo patch + SyB D-0701 25 cm2 placebo patch) assigned at the Case Registration Center are applied to either the right or left upper arm at 12 to 24 hours prior to the start of radiotherapy and left as is until 24 hours after completion of the third irradiation.
224172717|NCT05740267|PROCEDURE|Natural Orifice Specimen Extraction|After bowel resection, all bowel anastomoses are created via side-to-side intracorporeal anastomosis, either isoperistaltic or antiperistaltic. The surgical steps of NOSE with the transrectal method are illustrated in Figure 1. First, the rectosigmoid colonic lumen is blocked with a bowel clamp. After rectal irrigation with povidone-iodine water, a transanal endoscopic microsurgery (TEM) scope or Alexis wound protector is inserted through the anus, reaching the upper rectum. Enterotomy is performed at the upper rectum, and a suction device is used to clean any fecal spillage. The TEM scope is pushed forward beyond the rectal opening, and the specimen is extracted with the TEM scope. The rectal opening is closed with a barbed suture, and an air leak test is performed to identify anastomotic leakage.
224172718|NCT00164567|BEHAVIORAL|Onsite IPV specialist|
224172719|NCT00164567|BEHAVIORAL|Empowerment focused intervention|
224305871|NCT02213510|DEVICE|Standard Suture Closure|The surgeon will perform standard suture closure for the skin layer following CIED procedure.
224305872|NCT03052010|OTHER|Integrated PrEP as a bridge to ART HIV-1 prevention strategy|The PrEP as a bridge to ART intervention will be introduced into clinics according to Kenya national guidelines using a stepped wedge design, stratified by region. The components of the intervention are: a) Couples' HIV-1 counseling and testing; 2) PrEP as a bridge to ART: PrEP offered prior to ART initiation in couples in which the HIV-1 infected partner is not on ART due to refusal/delay, during the first 6 months after ART start during viral decline, and then discontinuation; 3) ART at any CD4 count, offered to all HIV-1 infected partners, with ongoing promotion/counseling for those delaying/declining;4) Standard of care HIV-1 prevention services
224305873|NCT03052010|DRUG|PrEP|A fixed-dose, oral co-formulation of emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF) is the approved and preferred regimen for HIV-1 prevention in Kenya and the United States. The World Health Organization (WHO) recommends TDF-containing medications as PrEP, which includes TDF combined with FTC as well as potentially TDF alone and TDF combined with lamivudine (or 3TC, a medication closely related to FTC). Any TDF-containing medications that align with WHO and Kenya national guidelines for PrEP will be used. PrEP medication will come from clinic stocks.
224305874|NCT03052010|DRUG|ART|ART medications will be provided according to Kenya national ART policies and will come from clinic stocks.
224305875|NCT04055038|DRUG|Platinum-Based Drug|Reintroduction of platinum-based chemotherapy
224305876|NCT04055038|DRUG|Conventional chemotherapy|Conventional chemotherapy
224305877|NCT00006395|DRUG|St. John's Wort|
224305878|NCT04996550|DRUG|Carvedilol|To compare the efficacy of carvedilol and metoprolol succinate on all-cause mortality or first hospitalization for worsening heart failure in patients with heart failure with reduced ejection fraction with an indication for treatment with beta-blockers.
224305879|NCT04996550|DRUG|Metoprolol Succinate|To compare the efficacy of carvedilol and metoprolol succinate on all-cause mortality or first hospitalization for worsening heart failure in patients with heart failure with reduced ejection fraction with an indication for treatment with beta-blockers.
224305880|NCT05978908|DRUG|FC-12738|Retro enversio pentapeptide of thymopentin
224305881|NCT05978908|DRUG|Saline|placebo
224305882|NCT01844466|PROCEDURE|Physiotherapy and speech therapy|
224172720|NCT00419835|DRUG|enalapril|
223484240|NCT02138383|DRUG|Nab-paclitaxel|The starting dose of nab-paclitaxel will be 125 mg/m\^2 administered intravenously on days 1, 8 and 15 of each cycle.
223484241|NCT06284161|DIAGNOSTIC_TEST|Quadriceps Combined Test|The recording of the motor response on the quadriceps is done using self-adhesive surface electrodes on the motor point of the vastus medialis muscles (active electrodes) and on the patella (reference electrode), using a classic electromyography device that allows calculations and measurements of amplitude, duration and speed.
223484242|NCT01285518|DRUG|PF-05231023|0.5 mg QD IV x 1 day
223484243|NCT01285518|DRUG|PF-05231023|1.5 mg QD IV x 1 day
223484244|NCT01285518|DRUG|PF-05231023|5 mg QD IV x 1 day
223484245|NCT01285518|DRUG|PF-05231023|15 mg QD IV x 1 day
223484246|NCT01285518|DRUG|PF-05231023|50 mg QD IV x 1 day
223484247|NCT01285518|DRUG|PF-05231023|100 mg QD IV x 1 day
223484248|NCT01285518|DRUG|PF-05231023|200 mg QD IV x 1 day
223484249|NCT01285518|OTHER|Placebo|0.9% w/v sodium chloride injection, USP QD IVx 1 day
223484250|NCT02991079|OTHER|Intervention group|"Smartphone with APP (EVIDENT) for 3 months, cardio-health rides and feeding workshop.~Counseling on physical activity and Mediterranean diet."
223484251|NCT02991079|OTHER|Control: Lifestyle counseling|Conseling on physical activity and nutrition (intervention)
223484252|NCT05389267|DRUG|Kinezodianone R hydrochloride|Eyedrops
223484253|NCT05389267|DRUG|Placebo|Placebo
224172721|NCT00419835|DRUG|losartan|
224172722|NCT00177008|DRUG|Aripiprazole|
223484254|NCT04132219|BEHAVIORAL|eHealth Intervention|Every week, each dyad member will receive a tailored text message that provides a new fun fact or that encourages them to log-on to the website to access findings of new research and how the results might apply to them. They will be directed to specific pages in the Web-based program and asked to select strategies from a list that they will practice during the upcoming week. Graphic displays of their progress will be provided along with SCT-based feedback. They will be directed to the website to record their behavioral goals for the upcoming week. Tips also will be provided for effective communication to enhance couple efficacy. All usage will be tracked to assess adherence.
223484255|NCT04111835|DIAGNOSTIC_TEST|Offering an alternative cervical cancer screening method - hrHPV molecular testing.|"Women randomized to this screening strategy group will take a hrHPV molecular test.~hrHPV-positive - reflex LBC:~Abnormal reflex LBC (ASC-US or worse) -\> colposcopy~Normal reflex LBC -\> repeat LBC in 6 months~Positive - colposcopy~Negative - rescreen in 3 years~HPV-negative - rescreen in 5 years"
223484256|NCT01471990|DRUG|Pituitary Adenylate Cyclase-Activating Polypeptide-38|10 pmol/kg/min over 20 mins
223484257|NCT01471990|DRUG|Vasoactive Intestinal Peptide|8 pmol/kg/min over 20 mins
223484258|NCT00764114|DRUG|antibiotic|6 or 12 weeks
223484259|NCT01500980|BIOLOGICAL|P. falciparum infection|P. falciparum (NF54 strain) infection delivered by the bites of 12 - 15 infected A. stephensi mosquitos
223484260|NCT01500980|DRUG|Chloroquine|Weekly chloroquine dosing (600 mg loading dose, 300 mg thereafter)
223585970|NCT04024904|DEVICE|OncomfortTM device|The VHRD (Virtual Reality Hypnosis Distraction) technique is the program of OncomfortTM (Oncomfort Inc, Houston, USA). The OncomfortTM device include the hyper vision 3D virtual reality glasses and disposable single-patient-use headphones. The program is an immersive experience focused on inducing relaxation environment and this program exist in 5,15 and 30 minutes
223585971|NCT03407885|OTHER|Bundled payments for knee and hip replacement|"The bundled payment model holds acute care hospitals (ACHs) financially responsible for the spending and quality of an entire episode of care for two types of hospital admissions: MS-DRG 469 and 470. An episode begins with an ACH stay that results in a discharge in one of the two DRGs, and ends 90 days after discharge. Before each performance year begins, hospitals receive target prices from CMS, determined by historical hospital and regional episode expenditures. Hospitals are eligible for reconciliation payment from CMS if they spend less than the target prices for an episode, provided that they met an acceptable quality standard. Conversely, they are responsible for paying the difference if they spend more than the target prices."
223585972|NCT04191785|DIAGNOSTIC_TEST|plasmatic NGAl and MRI|Determination of plasma NGAL protein during routine blood test Realization of a reno vesical MRI at 48 hours of inclusion
223484261|NCT01500980|DRUG|Primaquine|Primaquine (45 mg) on day 2 or 3 post ITV infection
223484262|NCT01500980|DRUG|Primaquine|Primaquine (45 mg) on day 2 or 3 (pending results of pilot study) post ITV infection
223484263|NCT03805841|DRUG|tarloxotinib bromide|weekly intravenous infusion
223484264|NCT02525068|DRUG|AZD5363|Until confirmed disease progression.
223484265|NCT02525068|DRUG|Enzalutamide|Until confirmed disease progression.
223484266|NCT03048786|BEHAVIORAL|Control|Participants will receive automated text messages used by SmokefreeTXT. The messages are designed to provide encouragement, support, and information about quitting smoking. Participants will receive 1-5 automated messages per day for 6-8 weeks depending on choice of quit date.
224172723|NCT00896350|DRUG|Standard Care Chemoradiation|"External beam radiation to the neck and tumor site of head and neck. Concurrent platinum based chemotherapy. External beam boost at discretion of treating physician."
224172724|NCT00233181|BEHAVIORAL|Home-based adherence monitoring|
224172725|NCT02663947|DEVICE|ultrasonographic measurement of optic nerve sheath diameter|A thick layer of gel is applied on the upper closed eyelid. The linear 7.5-MHz ultrasound probe is then placed in the gel, without exerting pressure on the eye. Three measurements are taken for each optic nerve in the transverse plane, with the probe being horizontal. The final ONSD is the mean of these measurements.
224172726|NCT06695858|DRUG|ESPB|Patients received bilateral ultrasound-guided ESPB using 20 mL bupivacaine 0.25% on each side.
224172727|NCT04520919|OTHER|anesthesia;Radial artery puncture|we chose the patients who need to monitor invasive blood pressure to obtain high-fidelity arterial waveforms
224172728|NCT04174872|DRUG|Dexmedetomidine|it has a sedative effect without significant respiratory depression , anxiolytic, analgesic, antihypertensive and sympatholytic properties. It is now being used as a neuraxial adjuvant that can be used as an effective adjuvant in epidural anaesthesia as it intensifys the motor block and prolongs the duration of postoperative analgesia.
224172729|NCT04174872|DRUG|Midazolam|Midazolam has been reported to have a spinally mediated analgesic effect. Clinically, single-shot epidural or spinal administration of midazolam has been shown to have an analgesic effect on perioperative pain.
224172730|NCT00542425|DRUG|teriparatide|teriparatide 20 µg subcutaneous daily
224172731|NCT00542425|DRUG|Placebo|Placebo subcutaneous daily
224305883|NCT04890301|BEHAVIORAL|CT guided biopsy for pulmonary nodule|"The technical process of the experimental group: ① design of puncture path, positioning and fixation of patients; ② puncture point positioning; ③ installation of navigation frame and template; ④ percutaneous lung biopsy guided by PT combined with CT.~The technical process of the active comparator group: ① planning puncture path, positioning and fixation of patients; ② positioning puncture point; ③ CT guided percutaneous lung biopsy.~The operation related information, complications and postoperative pathological results were collected."
224305884|NCT02969265|DRUG|Amlodipine|Amlodipine Capsules
223484267|NCT03048786|BEHAVIORAL|Peer Mentoring|"Participants will receive a modified version of the automated text messages sent to the control arm plus random assignment to a peer mentor. The modified messages include automated conversation starters, designed to stimulate conversation with the peer mentor. The peer mentor will then send personalized, tailored responses. The peer mentor is a former smoker who has completed a training program developed by the investigator team. Participants will receive 1-5 automated messages per day for 6-8 weeks depending on choice of quit date."
223484268|NCT04501250|DRUG|Rinsulin NPH|subcutaneous injection at a dose of 0.4 IU/kg
223484269|NCT04501250|DRUG|Humulin NPH|subcutaneous injection at a dose of 0.4 IU/kg
223484270|NCT01719653|DRUG|MiraLAX|MiraLAX consumed as described in each arm.
223484271|NCT01719653|OTHER|Gatorade|Gatorade consumed as described in each arm.
223484272|NCT01719653|DRUG|MoviPrep|MoviPrep consumed as described in each arm.
223484273|NCT01719653|DRUG|SUPREP|SUPREP consumed as described in each arm.
223484274|NCT03995563|DRUG|Dexamethasone|"Continous epidural injection will be done during 10 days. D group will be injected a 0.19% ropivacaine 8mL and dexametasone 1mg every other day during 10 days.~."
223484275|NCT03995563|DRUG|Ropivacaine|Continous epidural injection will be done during 10 days Both group will be injected a 0.19% ropivacaine 8mL every other day during 10 days
223484276|NCT03765606|DIETARY_SUPPLEMENT|Cocoa Flavanol beverage mix|Acute consumption of single portion of cocoa powder dissolved in 310g 1% milk.
223484277|NCT03765606|DIETARY_SUPPLEMENT|De-xanthinated Cocoa Flavanol beverage mix|Acute consumption of single portion of cocoa powder dissolved in 310g 1% milk.
223484278|NCT01579214|OTHER|Cellular Phone Text Messages|Cellular phone text message formats to be sent to participants after abnormal laboratory results to communicate information and request early return to clinic.
223484279|NCT02351921|DEVICE|Transcranial magnetic stimulation|Intermittent theta-burst stimulation is a form of repetitive Transcranial magnetic stimulation. ITBS is a non-invasive, non-painful procedure being used worldwide to study brain function and promote short-term changes (\~1 hour) in neural activity in the brain. The delivery of cTBS requires \~ 40 seconds in total.
223484280|NCT02460289|DRUG|Treatment: Minoxidil 5% / Botanical Hair Solution for Men|
223484281|NCT04722406|OTHER|This item is not applicable to our observational study.|This item is not applicable to our observational study.
223484282|NCT03303222|DIAGNOSTIC_TEST|breath|measurement of volatile compounds, such as TMAO in exhaled breath and blood
223484283|NCT00395577|DRUG|VX-702|
223585973|NCT02410265|BEHAVIORAL|Lantern: Guided self-help program|"Subject assigned to the Lantern intervention will receive 3-month access to a web-based, CBT-based guided self-help intervention for GAD. In the program, they receive psycho-education about GAD and the management of symptoms of GAD along with access to an e-coach who can monitor their progress in the program and provide feedback and encouragement via messaging and one voice call."
224172732|NCT00542425|DRUG|BA058 20 µg|BA058 20 µg subcutaneous daily
224172733|NCT00542425|DRUG|BA058 40 µg|BA058 40 µg subcutaneous daily
223484284|NCT02164916|BIOLOGICAL|cetuximab|Given IV
223484285|NCT02164916|DRUG|irinotecan hydrochloride|Given IV
223484286|NCT02164916|DRUG|vemurafenib|Given PO
223484287|NCT03505346|DRUG|68Ga-NODAGA-E[c(RGDyK)]2|200 MBq 68Ga-NODAGA-E\[c(RGDyK)\]2 administered IV.
223484288|NCT04366674|PROCEDURE|cleft palate repair|restoration of tensor veli palatini for the purpose of the muscle function recovery.
223484289|NCT01824667|DIETARY_SUPPLEMENT|B-GOS|
223484290|NCT01824667|DIETARY_SUPPLEMENT|Maltodextrin|
223484291|NCT03229499|DRUG|Anastrozole|"Anastrozole is an aromatase inhibitor indicated for:~* adjuvant treatment of postmenopausal women with hormone receptor-positive breast cancer~* first-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer~* treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy."
223484292|NCT03229499|DRUG|Placebo Oral Tablet|matching placebo tablet
223484293|NCT04501900|DRUG|Clopidogrel|Study subjects diagnosed as stable, unstable ischemic coronary disease or myocardial infarction planning to undergo percutaneous coronary intervention (PCI) and no contradiction to prolonged DAPT are eligible for this trial. All subjects will provide written informed consent to participate. Subjects will be enrolled into the study before or within 24 hours after the index procedure. Subjects will be randomized to either discontinue P2Y12 inhibitor (clopidogrel or ticagrelor) (12 months total) or receive P2Y12 inhibitor for an additional 24 months (36 months total). Aspirin will be maintained in the entire study and can be replaced by cilostazol or indobufen if subjects are intolerant. Dosage of antiplatelet drugs will be according to local standard of practice. Subjects will be treated with XINSORB BRS only.
224172734|NCT00542425|DRUG|BA058 80 µg|BA058 80 µg subcutaneous daily
224172735|NCT04862650|DRUG|Carboplatin|Given IV
224172736|NCT04862650|BIOLOGICAL|Cemiplimab|Given IV
224172737|NCT04862650|DRUG|Paclitaxel|Given IV
224172738|NCT01563952|DEVICE|Non-IVUS guided intervention with Endeavor Resolute stent (zotarolimus-eluting stent, Medtronic)|2x2 randomization by the treatment of IVUS-guided intervention vs. Non-IVUS guided intervention and the types of the implanted DES, Endeavor-R vs. Nobori.
224172739|NCT01563952|DEVICE|IVUS guided intervention with Endeavor Resolute stent (zotarolimus-eluting stent, Medtronic)|2x2 randomization by the treatment of IVUS-guided intervention vs. Non-IVUS guided intervention and the types of the implanted DES, Endeavor-R vs. Nobori.
224305885|NCT02969265|DRUG|TCV-116CCB|TCV-116CCB Tablets
224305886|NCT02969265|DRUG|Amlodipine Placebo|Amlodipine placebo-matching capsules
224172740|NCT01563952|DEVICE|Non-IVUS guided intervention with Nobori stent (biolimus A9-eluting stent, Terumo)|2x2 randomization by the treatment of IVUS-guided intervention vs. Non-IVUS guided intervention and the types of the implanted DES, Endeavor-R vs. Nobori.
224172741|NCT01563952|DEVICE|IVUS guided intervention with Nobori stent (biolimus A9-eluting stent, Terumo)|2x2 randomization by the treatment of IVUS-guided intervention vs. Non-IVUS guided intervention and the types of the implanted DES, Endeavor-R vs. Nobori.
224172742|NCT03552809|DEVICE|Gigaa Cheese 810 nm Diode Laser|Diode Laser assisted frenectomy operation.
224172743|NCT03552809|PROCEDURE|Conventional Frenectomy Operation|Frenectomy operation performed by surgical blades with suturing.
224172744|NCT02098928|BEHAVIORAL|Hand-acupuncture|Use Hand-acupuncture directly. Four acupoints:Tianshu,Zigong,Guanyuan and Sanyinjiao. Every patient are supposed to have 24 times acupuncture treatment. 30 minutes per time.
224172745|NCT02098928|DEVICE|Electrico-acupuncture|Use Electrico-acupuncture device to therapy. Four acupoints:Tianshu,Zigong,Guanyuan and Sanyinjiao. Every patient are supposed to have 24 times acupuncture treatment. 30 minutes per time.
223484294|NCT03869099|OTHER|Pneumonia Case Management Practices|Standard practices of pneumonia case management at three levels of health care; community level, first level care facility and practitioner level, across Pakistan.
223484295|NCT03434288|OTHER|Bone sampling|Bone biopsy in Diabetic patients with foot osteomyelitis
223484296|NCT01715051|DRUG|D-serine|The molecular formula for D-serine is C3H7NO3. D-serine is being used in IND# 71,369 (D Javitt, PI) and in IND#76,940 (H Singer, PI). This approved D-serine will be purchased by the Research Pharmacy at Johns Hopkins and will be encapsulated into capsules containing 500 mg of D-serine.
223484297|NCT01715051|BEHAVIORAL|Cognitive Behavioral Therapy|CBT sessions will be offered weekly to both active medication and placebo arms. The National Institute on Drug Abuse (NIDA) published CBT treatment manual for cocaine dependence, written by Kathleen Carroll, Ph.D., will be utilized. The skills taught in this CBT manual include (1) self-monitoring and functional analysis of situational factors associated with craving or drug use; (2) learning alternative non-drug responses for handling high risk situations; and (3) general lifestyle modifications (e.g., increasing pleasant drug-free events, anger management, interpersonal skills, general problem-solving).
223484298|NCT01715051|DRUG|Placebo|The Research Pharmacy at Johns Hopkins will produce matching placebo capsules.
223484299|NCT06522113|DRUG|Cilostazol|patients were given cilostazol 100mg twice a day with aspirin
223484300|NCT06522113|DRUG|Clopidogrel|patients were given clopidogrel 75mg with aspirin
223484301|NCT04398472|BEHAVIORAL|KIND Challenge|The KIND challenge consists of nominating an activity to complete over a 4 week period. The activities involve doing an activity with others in your neighbourhood. These activities are positive, engaging and feasible to the average individual. Activities adhere to relevant country or state department health and safety guidelines. For example; having a chat with a neighbour online, or bringing in rubbish bins for an elderly neighbour.
223585974|NCT02410265|BEHAVIORAL|Mental Health Online: Self-help program|Subject assigned to the Mental Health Online (MHO) intervention will receive 3-month access to a web-based, CBT-based self-help intervention for GAD. In the program, they receive psycho-education about GAD and the management of symptoms of GAD.
224172746|NCT02930811|DRUG|Sildenafil 100 mg oral morning dose|"Measurement of maximal walking distance on a constant load treadmill test, SF-36 questionnaire, and Edimburg questionnaire at inclusion, 1 month, 3 month and 6 month.~Events occurence questionnaires, Tolerance and adverse events questionnaire, Welch questionnaire and walk recommendation at inclusion, 7 days, 14 days, 1-2-3-4-5-6 and 9 months"
224172747|NCT02930811|DRUG|Placebo oral morning dose|"Measurement of maximal walking distance on a constant load treadmill test, SF-36 questionnaire, and Edimburg questionnaire at inclusion, 1 month, 3 month and 6 month.~Events occurence questionnaires, Tolerance and adverse events questionnaire, Welch questionnaire and walk recommendation at inclusion, 7 days, 14 days, 1-2-3-4-5-6 and 9 months"
224172748|NCT03810261|DIETARY_SUPPLEMENT|Oil-based vitamin D|Participants will receive oil-based VALENS vitamin D, 1000 IU/day for 8 weeks.
223484302|NCT05232890|OTHER|Datterino tomato purée from hydroponic technology|Daily intake of minimum 100ml - maximum 200ml of 100% Italian datterino tomato puree deriving from hydroponic technology (soilless), contained in a 720ml bottle.
223484303|NCT05232890|OTHER|Datterino tomato puree from conventional cultivation|Daily intake of at least 100ml - maximum 200ml of 100% Italian datterino tomato puree deriving from conventional cultivation, contained in a 720 ml bottle.
223484304|NCT01867775|DRUG|Mirtazapine|Mirtazapine 15 mg, at night, once a day for 14 days
223484305|NCT00483665|PROCEDURE|Computed tomography angiography|Computed tomography angiography
223484306|NCT00483665|PROCEDURE|Magnetic resonance imaging|Magnetic resonance imaging after injection of Vasovist
223484307|NCT00774475|DRUG|comparison of different dosage of clopidogrel|clopidogrel 75 mg/day versus clopidogrel 150 mg/day
223484308|NCT00774475|DRUG|doubled therapy|clopidogrel 150 mg/day
224172749|NCT03810261|DIETARY_SUPPLEMENT|Water-based vitamin D|Participants will receive water-based VALENS vitamin D, 1000 IU/day for 8 weeks.
224172750|NCT03810261|DIETARY_SUPPLEMENT|Vitamin D capsules|Participants will receive vitamin D capsules with starch-adsorbed vitamin D (powder), 1000 IU/day for 8 weeks.
224172751|NCT02587104|OTHER|EpiFix|Weekly application of EpiFix and standard of care (moist wound therapy and offloading)
224172752|NCT01281774|BIOLOGICAL|CSL112|reconstituted high density lipoprotein
224172753|NCT01281774|BIOLOGICAL|Placebo|Normal saline (0.9%)
224172754|NCT02544698|BIOLOGICAL|One dose of PCV13a vaccine|
224172755|NCT02544698|BIOLOGICAL|One dose of PCV13a vaccine|
224172756|NCT02544698|BIOLOGICAL|three doses of PCV13a vaccine|
223484309|NCT03385538|DRUG|Clopidogrel|increasing doses of clopidogrel depending on PRU values (75-300 mg)
223484310|NCT00596635|DIETARY_SUPPLEMENT|Once Daily Cranberry Capsule|650mg capsule pure cranberry powder
223484311|NCT00596635|DIETARY_SUPPLEMENT|Twice Daily Cranberry Capsules|One 650mg cranberry capsule administered twice per day
224172757|NCT02544698|BIOLOGICAL|three doses of PCV13a vaccine|
224172758|NCT03324867|DRUG|Regular insulin|40 IU of Humulin-R to be administered via nose using metered nasal dispenser prior to surgery, and up to 7 days after surgery.
224305887|NCT02969265|DRUG|TCV-116CCB Placebo|TCV-116CCB 8/5 mg placebo-matching tablets
224305888|NCT03223792|OTHER|Control|Routine cow's milk-based infant formula
224172759|NCT03324867|DRUG|Normal Saline Flush, 0.9% Injectable Solution|Placebo: Normal Saline to be administered via nose using metered nasal dispenser prior to surgery, and up to 7 days after surgery
224172760|NCT03520426|DEVICE|Votiva RF|The Votiva system is approved by the U.S. Food and Drug Administration for treatment of sexual dysfunction as well as in combination with Kegel exercises for tightening of the muscles of the pelvic floor to increase muscle tone. One part of the system, the fractora handpiece, is approved for tissue coagulation for the purpose of skin rejuvenation. The Votiva has two hand pieces, Forma and Fractora, which have been cleared by the United States Food and Drug Administration (FDA) and are used during dermatological procedures.
224172761|NCT06371326|DRUG|ZT002 Injection|Participants will receive ZT002 by subcutaneous (SC) injection.
224172762|NCT06371326|DRUG|Placebo|Participants will receive Placebo by subcutaneous (SC) injection.
224172763|NCT04272372|DRUG|Ketoprofen|PO and local therapy
224172764|NCT00803296|OTHER|Oral glucose tolerance test (OGTT)|
224172765|NCT00803296|OTHER|Isoglycemic intravenous glucose infusion|
224172766|NCT01321658|OTHER|Geriatric intervention|A comprehensive geriatric assessment (CGA), focusing on co-morbidity, medication, cognitive status, depression, nutritional status and physical status is performed. The intervention is individualized according to the results of the CGA.
224172767|NCT05388734|OTHER|alternative medicine education consultation|The intervention will consist in a 1h30 individual consultation with a GP physician. Patients will be able to ask any questions they have regarding treatments for their breast cancer delivered outside of the hospital. Topics such as benefit-risk ratios, placebo effects and expectancies from CAM will be discussed with the patients. This consultation will promote a shared-decision model to help patients better discuss these matters with their healthcare providers.
224172768|NCT01610414|BIOLOGICAL|Herpes Zoster vaccine GSK1437173A|2 doses administered intramuscularly (IM) in deltoid region of non-dominant arm
224172769|NCT01610414|BIOLOGICAL|Placebo|2 doses administered IM in deltoid region of non-dominant arm
224172770|NCT01607749|BEHAVIORAL|Educational Program|"Schools in the intervention group received the educational program Asthma, Sport and Health, as validated by our group. This program will be taught to students in three lessons with equipment designed and developed by the research group to be taught within the curriculum of physical education subject.~Teachers of physical education specialists responsible for the project at each center will receive the training curriculum for use in a training seminar for a school day by researchers from the health of our group. Once familiar with the educational package of three sessions taught his students and fellow faculty (on different days for teachers and students) within 15-30 days."
224172771|NCT01607749|OTHER|Usual Asthma Information for teachers|Common asthma information for teachers
223484312|NCT02630030|DRUG|Ixazomib|Given PO
223484313|NCT04903301|PROCEDURE|Contoura Vision LASIK|Topography-Guided LASIK using Phorcides Analytic Software
223484314|NCT01484340|DRUG|Nicotine|"The nicotine patch be given in three phases:~* 2 weeks of patches at enrollment~* 6 weeks of patches at two-week follow-up visit~* 2 weeks of patches at two-month follow-up visit~This schedule will cover the entire 10-week course of therapy as per label instructions: 6 weeks at 21mg; 2 weeks at 14mg; and 2 weeks at 7mg."
224172772|NCT02074761|DEVICE|SImmetry|"The SImmetry device is commercially available. The implanted devices consist of a range of threaded, self-tapping, cannulated implants designed to transfix the sacrum and ilium, providing stability for intra-articular fusion.~The SImmetry Surgical Instruments include standard manual surgical instruments used to access and prepare the sacroiliac joint space for intra-articular fusion."
224172773|NCT04432168|PROCEDURE|Fetoscopic Laser Surgery|Fetoscopic Photocoagulation of the connecting vascular anastomoses on the surface of the placenta.
224172774|NCT04432168|OTHER|Standard Treatment|"In the control group, the choices of treatment include expectant management, intrauterine transfusion (IUT) (with or without partial exchange transfusion (PET)) or preterm delivery, depending on the judgment of the fetal surgeon with regard to the gestational age and state of the disease.~* Expectant management will consist of close monitoring with ultrasound including Doppler measurements of the middle cerebral artery peak systolic velocity (MCA-PSV), at least every week.~* IUT: the intrauterine infusion of red blood cells into the circulation of the donor twin treat anemia.~* PET: the intrauterine infusion of saline into the circulation of the recipient twin to treat polycythemia.~* Preterm delivery: Induction of labor or cesarean section before 36 weeks of gestation."
224172775|NCT06245395|DEVICE|Virtual Reality|Meta Quest 2 Headset
224305889|NCT03223792|OTHER|Investigational|Partially-hydrolyzed cow's milk protein infant formula
224305890|NCT04258462|DRUG|Hyperpolarized Carbon C 13 Pyruvate|Given IV
224305891|NCT04258462|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
224305892|NCT04258462|DRUG|Hyperpolarized 13C,15N2-urea|Given IV
224305893|NCT04335786|DRUG|Valsartan (Diovan)|"At the time of randomization each participant will start with study treatment and continue up to 14 days, or up to reaching the primary endpoint, or up to hospital discharge, or up to any of the pre-defined stopping criteria.~Study drug dosages will be titrated to blood pressure with a maximum of 160mg b.i.d."
224305894|NCT04335786|DRUG|Placebo oral tablet|At the time of randomization each participant will start with study treatment and continue up to 14 days, or up to reaching the primary endpoint, or up to hospital discharge, or up to any of the pre-defined stopping criteria.
224305895|NCT05881746|PROCEDURE|anatomical liver resection|Based upon the segmental anatomy of the liver according to Couinaud system, anatomical resection (AR) was defined as resection of 1 or more complete hepatic segments in our study, including bisegmentectomy, right hemihepatectomy, left hemihepatectomy, extended right hemihepatectomy, extended left hemihepatectomy, single segmentectomy, caudate lobectomy, or a combination of these.
223484315|NCT01484340|BEHAVIORAL|Intensive Counseling|"The advice to quit smoking message will follow NCI's 5A's model for smoking cessation counseling. This is a simple smoking cessation counseling strategy with 5 discrete components: (1) Ask about smoking at every opportunity; (2) Advise the patient to quit smoking; (3) Assess readiness to quit; (4) Assist the patient in quitting; and (5) Arrange follow-up.~Visit schedule:~* Baseline~* 2-week follow-up (Quit Day)~* 1-month follow-up~* 2-month follow-up~* 3-month follow-up~* 6-month follow-up~Participants abstinent at 6-month follow-up will be next seen at 12-month follow-up.~Participants still smoking at 6-month follow-up will be offered group-assigned intervention again."
224305896|NCT05881746|PROCEDURE|nonanatomical liver resection|Nonanatomical resection(NAR), known as wedge resection, was defined as resection of the tumor with a margin of normal parenchyma without regard to hepatic anatomy.
223484316|NCT02258672|OTHER|Prehabilitation program|Progressive and individualized physical training aimed at improving core muscles strength and endurance as well as spinal stability.
223484317|NCT00164359|DRUG|Amodiaquine plus artesunate|
223484318|NCT00164359|DRUG|chlorproguanil-dapsone plus artesunate|
223484319|NCT02815761|OTHER|NO intervention, just observation|No intervention.
223484320|NCT03059368|DEVICE|new bone fixation plate with screw|Fracture ends and injured posterior cruciate ligament will be exposed in twenty patients with tibial avulsion fracture of posterior cruciate ligament of knee through posterior approach. Open reduction will be conducted. The posterior cruciate ligament will be reconstructed with a new bone fixation plate with screw(cancellous bone screw).
223484321|NCT01584934|DRUG|Sodium oxybate|Treatment is started and continued for 6 weeks at patient's home. Patients receive 3g/night during the first week, and 4,5 g/night during the second week. After the second week, patients have their dose increased to 6 g/night during 6 weeks. A washout period of 4 weeks is installed to withdraw from treatment. Patients receive 4,5 g/night for 1 week, followed by 3g/night for 1 week. The next 2 weeks, patients are not treated.
223484322|NCT01584934|DRUG|Placebo|Placebo treatment is started and continued for 6 weeks at patient's home. Patients receive 3 g/night during the first week and 4.5 g/night during the second week. After the second week, patients have their dose increased to 6 g/night during 6 weeks. A washout period of 4 weeks is installed to withdraw from treatment. Patients receive 4.5 g/night for 1 week, followed by 3 g/night for 1 week. The next 2 weeks, patients are not treated.
223484323|NCT04745117|BEHAVIORAL|READHY - questionnaire|The READHY tool consists of 70 questions divided into three sections, one with a focus on eHealth literacy, one on self-management and one on the social context. The READHY consists of the eHealth Literacy Questionnaire (eHLQ) that includes seven scales, supplemented with four scales from the Health Education Impact Questionnaire (heiQ) and two scales from the Health Literacy Questionnaire (HLQ). The READHY tool has been validated. Each question presented to the participant as a statement and scored on a 4-point rating, from 1=strongly disagree to 4=strongly agree. The overall score of each scale was calculated as the mean score of the 4-6 items (i.e., statements) that constitute the scale (2).
223484324|NCT00127803|BIOLOGICAL|Placebo (vaccine diluent)|0.5 mL, intramuscular (IM) on Days 0, 28, and 56, respectively.
223484325|NCT00127803|BIOLOGICAL|Clostridium difficile vaccine|0.5 mL, intramuscular on Days 0, 28, and 56, respectively.
223484326|NCT00127803|BIOLOGICAL|Clostridium difficile vaccine|0.5 mL, intramuscular on Days 0, 28, and 56, respectively.
223484327|NCT00127803|BIOLOGICAL|Clostridium difficile vaccine|0.5 mL, intramuscular on Days 0, 28, and 56, respectively.
223585975|NCT04175574|OTHER|Music|The music has no lyrics, has a sustained melodic quality, has no strong rhythms and percussion or base, rate of 60-80 beats per minute, promotes relaxation, calming and soothing, neutral and is unbiased towards any culture or age. The volume of the music will be pre-adjusted to the patients' preference (preferable 30 dB) by the research assistant.
224172776|NCT05947695|BEHAVIORAL|Palliative and Survivorship Care Model|The standard of care comparator arm is usual clinical care using NCCN guidelines and evidence-based practice for palliative and survivorship care.
224172777|NCT01172704|BEHAVIORAL|Skills Building - Motivational Interviewing|"SB-MI incorporates Motivational Interviewing strategies into a psycho-educational HIV risk reduction protocol to help participants identify high-risk behaviors, reduce ambivalence about these behaviors, increase motivation to change behaviors, and develop a specific plan of action for risk reduction. Consistent with MI, information gathered at baseline regarding HIV risk behaviors is systematically reviewed in a personalized way with each participant at the outset of the intervention. This is designed to engage participants in becoming active agents in the change process and to assist participants in recognizing discrepancies between their current risk behaviors and goals and values, which typically do not include HIV infection or transmitting HIV to others. Also consistent with the principles of MI, participants are empowered to choose those educational and skills-based modules which fit their personal risk profile and values."
224172778|NCT01353066|DRUG|Intensive Medical Treatment|
224172779|NCT01353066|OTHER|IMM+Roux-en-Y Gastric Bypass (RYGBP)|
224305897|NCT02590250|BIOLOGICAL|botulinum toxin Type A|Botulinum toxin Type A treatment for Neurogenic Detrusor Overactivity or Overactive Bladder as per local standard of care in clinical practice.
223585976|NCT04467125|DRUG|Eutectic Lidocaine Prilocaine|Subjects randomized to EMLA receive one inch of EMLA cream placed at the removal site and then have an occlusive dressing placed. One hour later they have the Nexplanon device removed.
223585977|NCT04467125|DRUG|Subcutaneous Lidocaine|Subjects randomized to subcutaneous lidocaine have 1% lidocaine injected by the provider at the removal site in an amount decided on by the provider.
224305898|NCT05498181|DRUG|Sacubitril-valsartan|sacubitril/valsartan
223484328|NCT06208501|DIAGNOSTIC_TEST|Urine sample for proteomic analysis|Urine sample for proteomic analysis in screen visit (before renal denervation procedure).
223484329|NCT06208501|DIAGNOSTIC_TEST|ABPM|ABPM in screen visit and 3 months after renal denervation procedure.
223484330|NCT06208501|DIAGNOSTIC_TEST|OBPM|OBPM in screen visit and 3 months after renal denervation procedure.
223484331|NCT02258581|DRUG|GS-4774|Exposure of interest for participants who received GS-4774 (administered as a subcutaneous injection) in a previous Gilead study for chronic hepatitis B virus infection.
223484332|NCT02258581|DRUG|GS-9620|Exposure of interest for participants who received GS-9620 (tablets administered orally) in a previous Gilead study for chronic hepatitis B virus infection.
223484333|NCT02258581|DRUG|Tenofovir disoproxil fumarate (TDF)|Exposure of interest for participants who received TDF (tablets administered orally) in a previous Gilead study for chronic hepatitis B virus infection.
223484334|NCT01348841|OTHER|Systematic referral to MDWCT and comprehensive primary care|Systematic referral to, and follow up, by Multi-Disciplinary Wound Care Teams (MDWCTs), co-ordinated by the Case Manager (CM), will occur.There will be immediate referral to the MDWCT of clients with :1/ diabetic lower extremity ulcers,2/peripheral neuropathy, charcot changes,3/wound present longer than 4 mths. ,4/ Ankle Brachial Index less than 0.6, non-diabetics, and not being seen by a vascular surgeon. Subsequent referral to MDWCT will occur if less than 30% healing by week 4.
223585978|NCT01874938|BIOLOGICAL|LY2875358|Administered IV
224172780|NCT01341236|OTHER|different nutrional regimen|compare bolus versus intermittent nutrition
224172781|NCT01341236|OTHER|comparison of different feeding regimens|compare intermittent versus bolus nutrition
224172782|NCT05830240|DRUG|Recombinant oncolytic herpes simplex virus type 1 (R130)|R130, a modified herpes simplex virus-Ⅰ (HSV-1) containing the gene coding for anti-CD3 scFv/CD86/PD1/HSV2-US11
224172783|NCT01219166|PROCEDURE|Laparoscopic Cholecystectomy|Laparoscopic Cholecystectomy
224172784|NCT02382276|DRUG|Nalmefene hydrochloride|
224172785|NCT05162300|COMBINATION_PRODUCT|Same Day Intervention of VI Peel (Procedure) and Botulinum Toxin (Drug)|Same-Day combination of VI Peel applied to the full face, followed by Botox injection per label to the face.
224172786|NCT02071329|DRUG|Vaccine FP-01.1|
224172787|NCT02071329|DRUG|Placebo|
224172788|NCT02071329|OTHER|Virus Challenge|
224172789|NCT06386367|BEHAVIORAL|Monastery-based health education by Buddhist monks|During the three-month intervention from July to September 2022, a total of 18 health education sessions were conducted across the three intervention villages, with an average of 50 attendees per session, totaling 921 attendees across all sessions.
224172790|NCT03008928|BEHAVIORAL|Alcooquizz|
224172791|NCT05391412|DRUG|Fibrinogen Concentrate Human|Patients in the intervention group will receive single administration of fibrinogen concentrate intravenously at a dose of 20-30 mg/kg (depending on body weight and clinical condition, according to SmPC). The medicinal product will be diluted in a 100 ml infusion bag and administered after induction of anaesthesia prior beginning of surgery. The infusion rate should not exceed approximately 5 ml per minute.
224172792|NCT03849092|BEHAVIORAL|Financial incentives|Cessation programs in municipalities will offer a financial incentive of 1200 DKK to smokers who achieve continuous abstinence from smoking when attending a group-based smoking cessation program. Aimed at smokers with low socioeconomic status but other smokers are also included.
224172793|NCT03849092|BEHAVIORAL|Campaigns|Municipalities will design anti-smoking campaigns targeting smokers, recommending to use a municipal free group-based smoking cessation program. Aimed at smokers with low socioeconomic status but other smokers are also included.
224172794|NCT00518336|PROCEDURE|Blood sampling|Blood sampling at Visit 3, 5 and 7.
224172795|NCT00518336|PROCEDURE|Collection of cervical specimen|Collection of cervical specimen at Visit2, 3, 4, 5, 6 and 7.
223484335|NCT00522834|DRUG|Elesclomol (STA-4783)|213 mg/m2 Elesclomol (STA-4783) plus 80 mg/m2 paclitaxel administered intravenously once a week for the first 3 weeks of a 4 week cycle. Number of cycles: Until progression or unacceptable toxicity develops
223484336|NCT00522834|DRUG|Paclitaxel|80 mg/m2 paclitaxel alone administered intravenously once a week for the first 3 weeks of a 4 weeks cycle. Number of cycles: Until progression or unacceptable toxicity develops
224172796|NCT00518336|BIOLOGICAL|Cervarix|Three doses administered intramuscularly at 0, 1 and 6 months.
224172797|NCT03797794|DEVICE|Pulsating Electrostatic Field|A pulsating electrostatic field is generated by the New Health 9000 (Akern). During the session the patients sits on a chair which contains the apparatus for 30 minutes.
224172798|NCT03797794|DEVICE|SHAM Pulsating Electrostatic Field|The same apparatus which produces the pulsating electrostatic field contains a 'sham-inlet'. This inlet will be used as placebo.
224172799|NCT05882435|OTHER|Organization with AI|X-rays are done in the radiology department and the images are made available to emergency physicians with the AI interpretation. X-rays flagged by IA as anormal or suspicious will be reviewed without delay by the radiologist, non-flagged X-rays will be reviewed by radiologists on a delayed basis.
224172800|NCT03441399|OTHER|Financial incentives|Providing money for taking antidepressant medication
224172801|NCT05350800|DRUG|BMS-986369|Specified dose on specified days
224172802|NCT03756142|DIAGNOSTIC_TEST|Motion Analysis|Analysis of orthostatic posture, initiation of walking and walking by a motion analysis system
224172803|NCT05096442|DEVICE|GENOSS® DCB|Drug Coated Balloon
224172804|NCT05096442|DEVICE|SeQuent® Please NEO|Drug Coated Balloon
224172805|NCT04479306|DRUG|Alisertib|Given PO
224172806|NCT04479306|DRUG|Osimertinib|Given PO
224172807|NCT04479306|DRUG|Sapanisertib|Given PO
224172808|NCT03717727|OTHER|Exergame|16-week home-based exercise intervention with exergaming system and usual treatment.
224172809|NCT03717727|OTHER|Control|16-week home-based exercise by standard protocol and usual treatment.
224172810|NCT01696708|OTHER|31-Phosphorus RMN Spectroscopy|
224172811|NCT04764591|OTHER|Lateral sagittal approach|Lateral sagittal approach for ultrasound guided infraclavicular brachial plexus block
224172812|NCT04764591|OTHER|Costoclavicular approach|Costoclavicular approach for ultrasound guided infraclavicular brachial plexus block
224172813|NCT00125268|DEVICE|MIRE|Monochromatic near infrared photo energy (MIRE). A 30-minute application of MIRE results in a radiant exposure of 43.2 joules per square centimeter (J/cm\^2). The design of the flexible pads allows the infrared energy to be delivered perpendicular to and in contact with the involved site. MIRE applied to the skin facilitates the release of a small molecule of the free radical nitric oxide from hemoglobin and other proteins in surrounding tissue. Increased levels of nitric oxide improve the circulation of blood enhancing wound healing and reducing pain.
224172814|NCT00125268|DEVICE|Sham Device|The sham device is non-active but otherwise identical to the study device.
224172815|NCT04166955|BEHAVIORAL|Promoting Physical Activity through mobile application|Students will be randomly assigned to either the intervention or the control group. WhatsApp groups will be formed within each study group. The control participants will have the WhatsApp group only for communications. And they will keep their usual activity for 10 weeks. The intervention participants will have the intervention WhatsApp group which will be for communication and providing the intervention materials. The intervention group will receive a brief (15-minute) orientation on exercise, and benefits of keeping a healthy life pattern. They will receive 3-4 health-promotional (Physical activity) messages per week via WhatsApp for 10 weeks; group interaction is optional without adding more messages aiming to promote physical activities from any participants.
224172816|NCT03628391|DRUG|Haloperidol|haloperidol for ICU delirium, titrated on validated screening tool-based diagnosis
224172817|NCT03628391|DRUG|Placebo|placebo for ICU delirium, titrated on validated screening tool-based diagnosis
224172818|NCT06875973|DRUG|Pelacarsen (TQJ230)|pelacarsen 80mg s.c. monthly
224172819|NCT01723176|PROCEDURE|Echocardiography|
224305899|NCT05498181|DRUG|Placebo|Placebo
224172820|NCT00879788|DRUG|Ramipril 10mg capsules|
224172821|NCT06711302|DEVICE|Sham RIC|Remote Ischemic Conditioning is given twice a day with 60mmHg pressure.
224172822|NCT06711302|DEVICE|Remote Ischemic Conditioning treatment instrument|Remote Ischemic Conditioning is given twice a day with 200mmHg pressure.
224172823|NCT06713499|DRUG|SHR-1819 injection|SHR-1819 injection.
224172824|NCT07030868|DRUG|LY6249492|Administered orally
223484337|NCT01950962|OTHER|Sampling of blood|
224172825|NCT07030868|DRUG|Placebo|Administered orally
224172826|NCT00286156|DRUG|Rapamune|Group 1- doses of Rapamune aimed at maintaining trough levels 5-8ng/ml Group 2 - doses of Rapamune aimed at maintaining trough levels 2-5ng/ml Group 3- Standard Care
223484338|NCT04224116|DRUG|Tranexamic acid injection|to receive tranexamic acid (25mg/kg) in bolus at induction followed by 2mg/kg/h in continuous infusion until the end of the act.
223484339|NCT04224116|DRUG|SSI|Serum Salin isotonic injected
224172827|NCT06925776|OTHER|CHOOSE Home Intervention|Integration of a CHW (Community Health Worker) in the CKD (Chronic Kidney Disease) care process to augment patient engagement and address HRSNs (Health-Related Social Needs) within the context of an IDC (Interdisciplinary Care) CKD clinic. The multifaceted components of the intervention are tailored to address key care delivery and social barriers to home dialysis utilization before implementation.
224172828|NCT06925776|OTHER|Usual Care|This is the usual interdisciplinary care that patients would typically receive for their chronic kidney disease. A key missing factor here is the lack of a community health worker. Patients in this group will be screened for health-related social needs and receive general information on ways to access social services from a study coordinator. Patients will not receive facilitated peer support and social care navigation from the Community Health Worker.
224172829|NCT00671515|DRUG|Pioglitazone|An open-label 12-week trial of pioglitazone monotherapy. The investigators will titrate pioglitazone to the maximum tolerable dose up to 45mg per day.
224172830|NCT07047482|BIOLOGICAL|Immunohistochemical staining|Immunohistochemical staining of paraffin embedded blocks of colorectal carcinoma tissues by p16 monoclonal antibodies to be evaluated with the positivity, intensity and distribution of the detected stain.
224172831|NCT06334055|DEVICE|Masimo INVSENSOR00073|Noninvasive blood pressure monitor
223484340|NCT01551667|BIOLOGICAL|Antibody assays for S. aureus|Antibody assays for S. aureus at Day 0, Day 2, Day 4, Day 7, Day 30 and Month 6.
223484341|NCT01551667|BIOLOGICAL|Basic blood work|Hemogramme + CRP on Days 0, 2, 4 and 7
223484342|NCT01357772|DRUG|Tamoxifen|
223484343|NCT01357772|DRUG|placebo|
224172832|NCT07052942|DRUG|Inhaled corticosteroid (ICS)|Participants will use either a combination of budesonide/formoterol or mometasone/formoterol as both controller and rescue therapy or a stand alone inhaled steroid (beclomethasone, budesonide, fluticasone, mometasone, ciclesodine) of their choice with their current reliever therapy or be converted to budesonide/albuterol as rescue therapy.
224172833|NCT07052942|DRUG|Azithromycin|Participants will take 500mg of azithromycin three times a week or 10mg/kg if under 50Kg which may be reduced to 250mg/Kg for side effects.
224172834|NCT07052942|OTHER|Asthma Symptom Monitoring Web-based Application|All participants will be provided access to the Asthma Symptom Monitoring (ASM) tools. ASM can be integrated with electronic health records (EHR) or used as a stand alone application. Participants will answer 5 questions about their asthma each week. If symptoms are problematic, participants can request a call back from a person on their care team. Participants can view a graph of their data, watch videos, and record peak flows. Clinicians and members of the care team can view data in the EHR (not for stand alone web app).
224172835|NCT07057973|DRUG|Ferric carboxymaltose|The experimental group was treated with 1000 mg of ferric carboxymaltose
223484344|NCT00063453|DIETARY_SUPPLEMENT|Vitamin E|vitamin E (400 IU/day all rac-α-tocopheryl acetate)
223484345|NCT00063453|DIETARY_SUPPLEMENT|Selenium|selenium (200 μg/d L-selenomethionine)
223484346|NCT00063453|DIETARY_SUPPLEMENT|Vitamin E placebo|placebo
223484347|NCT00063453|DIETARY_SUPPLEMENT|Selenium placebo|placebo
223484348|NCT00262379|DRUG|epoetin beta (NeoRecormon®)|• Prescription of the epoetin beta : when blood concentration of hemoglobin is lower or equal to 12 g/dL in male or lower or equal to 11 g/dL in female
223484349|NCT04788134|DIAGNOSTIC_TEST|Post-rotatory nystagmus test|The test is administrated with the person sit down with cross legs at a rotatory board, with the head positioned by the examiner in 30° of forward flexion. The position was maintained by the administration of the test. The administration consist in two administrations separate by one minute. Each administration consist in rotate the person 10 times in 20 seconds (the first 10 rotations in a counterclockwise direction in 20 s and the second 10 rotations in a clockwise direction in 20 s). After each administration the examiner counts the duration of the reflex in seconds.
223484350|NCT00217451|DRUG|Fosmidomycin-clindamycin|
223484351|NCT01731548|RADIATION|hyperfractionated radiation therapy for both arms|1.5 Gy twice daily to 45 Gy in 30 fractions over 3 weeks for both arms
224172836|NCT07057895|DIAGNOSTIC_TEST|Global Leadership Initiative on Malnutrition (GLIM) Criteria Assessment|Malnutrition was diagnosed according to the GLIM consensus criteria. This required at least one phenotypic criterion (non-volitional weight loss, low BMI, or reduced muscle mass) and one etiologic criterion (reduced food intake/assimilation or inflammation/disease burden). Reduced muscle mass was assessed by bioelectrical impedance analysis (BIA). The assessment was performed once for each patient within 24 hours of hospital admission.
224172837|NCT07057895|DIAGNOSTIC_TEST|Patient-Generated Subjective Global Assessment (PG-SGA)|A comprehensive nutritional assessment administered by trained clinical staff. The tool comprises patient-reported sections (weight history, food intake, symptoms, activities/function) and clinician-assessed sections (disease, metabolic demand, physical exam). For this study, a total score of ≥2 was considered indicative of malnutrition. The assessment was performed once for each patient within 24 hours of hospital admission.
224172838|NCT07057687|OTHER|Conventional Physical Therapy Group|Conventional physical therapy applied to patients consists of Transcutaneous Electrical Nerve Stimulation (TENS), Ultrasound (US) and Hot Pack. TENS will be applied for 20 minutes at a frequency of 100 hertz. US will be applied for 5 minutes at an intensity of 1.2-1.5 W/cm2. Hot Pack will be applied for 20 minutes. Treatment will be applied to the lumbar region. Application will be made 3 days a week for 4 weeks.
224305900|NCT03795038|DEVICE|Lipoprotein Apheresis MONET and DALI|Three apheresis treatments assigned to one type of apheresis system of MONETand DALI
224172839|NCT07057687|OTHER|Relaxation Techniques Group|The individual will be in a sitting or lying position without muscle tension, and progressive relaxation will be provided with verbal commands given for each body part in order. The patient is asked to place their hand on their abdomen and by applying light resistance, they are provided with the direction in which the breath will go. During diaphragmatic breathing, the person breathes deeply and slowly through the nose and out through the mouth for 5-7 seconds, holds it for 2 seconds and exhales for 6-8 seconds. During this time, the abdomen is inflated in 4 directions and care is taken to ensure that there is no auxiliary muscle activity. First, after taking a deep breath, the muscles are tensed, this tension is maintained for 5-7 seconds and then the muscles are relaxed (8-10 seconds). This application will be applied in 3 sets, with 5/6 repetitions and then returning to calm/normal breathing. The treatment will be applied 3 days a week and will last for 4 weeks.
224172840|NCT07057687|OTHER|Mulligan Treatment Group|Application of the Technique: The direction of the technique will be shaped according to the direction of movement of the patient's pain. If the patient's pain occurs during flexion, flexion will be applied, if it occurs during extension, extension SNAGS will be applied. In the flexion SNAGS application, the physiotherapist places the mobilization belt at the patient's spina iliaca anterior superior (SIAS) level while the patient is sitting or standing. The physiotherapist places his hand, thumbs or the hypothenar part of the hand parallel to the spinous processes one level above the relevant segment. Then, he asks the patient to flex until he feels pain. The physiotherapist continues the flexion by applying force towards the cranium with his hand. After waiting for a while at the end point, the starting position is returned. During this time, the physiotherapist maintains the natural shift in the facet joint. If the pain does not disappear, the application is applied unilaterally.
224172841|NCT07059247|BIOLOGICAL|Application of Enamel Matrix Derivatives|After the extraction of the impacted lower third molar, EMD will be applied on the distal site of the second molar
224172842|NCT07059247|PROCEDURE|Extraction of the impacted third molar|Extraction of the impacted third molar
224172843|NCT07059195|PROCEDURE|cervical collar or cervical-thoracic orthosis.|postoperative cervical spine flexion maintained using non-invasive techniques, such as a cervical collar or cervical-thoracic orthosis.
223484352|NCT05623527|DEVICE|cardiac electronic implants|Cardiac electronic implants(CIED) includes permanent pacemaker (PPM), implantable cardioverter defibrillator (ICD), three-chamber pacemaker for cardiac resynchronization therapy defibrillator, lead free pacemaker, etc.
223484353|NCT03795948|OTHER|PROMs|"Introduction and assessment of the ICHOM standard set consisting of demographic and medical data as well as questionnaires filled in by patients, shortly after admission to the stroke unit, at discharge, and at 90 and 360 days after stroke.~Specifically the intervention includes an assembly of clinical records, in particular records of complications, recurrence of disease and mortality. Further patients will be required to complete a questionnaire assessing their situation in terms of housing and symptom burden as well as their self-perceived autonomy and quality of life.~Telephone assessments will be administered to support patients if necessary and validate their responses."
223484354|NCT02629770|DRUG|usual antibiotic treatment|pharmacological studies in patients treated with usual antibiotics, for different types of joint and bone infections
223484355|NCT03702699|DEVICE|Auricular point detector|This device is only for auricular detection. No additional intervention will be delivered.
223484356|NCT01978756|OTHER|Outpatient clinic|The participants are seen at the outpatient clinic by a physician or a physician assistant. To analyse fibrosis clinical examination of the breast will be performed. To analyse shoulder function anteversion / retroversion, abduction / adduction and internal / external rotation will be measured. To analyse edema the arm circumference will be measured 15 cm above and below the medial epicondyle (both sides). Also, a photograph of the breast will be made for cosmetic analysis using standardized procedures. Finally a blood sample or saliva will be obtained, if the patient has given written informed consent to participate in the Biobank.
223484357|NCT00091858|DRUG|Darbepoetin Alfa|6.75 mcg/kg Q4W
223484358|NCT00091858|DRUG|Placebo|Placebo Q4W
223484359|NCT06222307|OTHER|Game-Based Exercises|Week 1: Dough Kneading, Sorting Legumes, Cutting Lines with Scissors, Coloring with Dry Crayons Week 2: Dough Rolling, Scissor Use, Crumpling Paper, Finger Exercises, Tying Knots with Rubber Bands Week 3: Dough Cutting, Dough Rolling, Dough Stretching, Sewing with Needles, Wrapping Thread like a Spool, Sorting Legumes, Untying Knots in String Week 4: Rhythm Exercises, Dough Kneading and Rolling, Scissor Use, Sorting Legumes, Untying Knots in String Week 5: Stringing Beads on Thread, Unlocking, Tearing Paper, Sorting Legumes, Untying Knots in String Week 6: Tying Shoe Laces, Opening-Closing Jar Lids, Sorting Legumes
223585979|NCT04844086|BIOLOGICAL|RPM CD19-mbIL15-CAR-T cells|"Single dose of RPM CD19-mbIL15-CAR-T cells will be infused, and a standard 3+3 design will be applied.~Drug: Fludarabine~Fludarabine is used for lymphodepletion.~Drug: Cyclophosphamide~Cyclophosphamide is used for lymphodepletion"
223585980|NCT01873690|DRUG|Ciprofloxacin|Once, 400 mg IV
223585981|NCT01873690|DRUG|Placebo|5% Dextrose in water
223585982|NCT04795700|BEHAVIORAL|MSC intervention|Patients in the intervention group had access to conventional care, in addition to receiving the 8 weeks MSC intervention sessions. The intervention was provided by trained nurses, including one researcher and one MSC therapist. The intervention is mainly out-of-hospital intervention, supplemented by short-term in-hospital intervention. Among them, the first and second weeks of the intervention project in the hospital phase focus on guiding the research subjects to understand the content of mindful self-compassion and emotions, and carry out basic mindful self-compassion training; the content of the 3-8th week of the intervention program outside the hospital, Focus on the maintenance of mindful self-compassion training and the promotion of mindful life. Each face-to-face group contact lasted about 1 hour, depending on the complexity of the patients' problems.
223585983|NCT00473408|DEVICE|Functional MRI (DCE-MRI)|MRI examination with i.v. gadolinium contrast to assess blood perfusion in remaining tumor tissue.
223585984|NCT00473408|PROCEDURE|Blood sample|See protocol.
223585985|NCT00473408|PROCEDURE|Tumor sample|See protocol.
223585986|NCT00996346|DRUG|Irinotecan&Temsirolimus:Arm1, Level 1|Irinotecan is given first over 60 minutes followed by temsirolimus over 30 minutes. No intrapatient dose escalations are allowed. Treatment continues until disease progression or intolerable side effects develop.
223585987|NCT00996346|DRUG|Irinotecan&Temsirolimus:Arm 1, Level 2|Irinotecan is given first over 60 minutes followed by temsirolimus over 30 minutes. No intrapatient dose escalations are allowed. Treatment continues until disease progression or intolerable side effects develop.
224172844|NCT07059195|DEVICE|chin-to-chest (Grillo) suturing|cervical spine flexion maintained using traditional chin-to-chest (Grillo) suturing
224172845|NCT07058129|PROCEDURE|Deep cervical lymphatic venous anastomosis|The intervention requires to perform bilateral deep cervical lymphatic venous anastomosis (DC-LVA). Through cervical incision, the deep cervical lymphatic tissue is anatomically dissected and anastomosed with the venous system of the neck. Under indocyanine green (ICG) navigation, the flow of lymphatic fluid into the vein could be observed via ICG tracing fluorescence after surgery.
223585988|NCT00996346|DRUG|Irinotecan&Temsirolimus:Arm 2, Level 1|Irinotecan is given first over 60 minutes followed by temsirolimus over 30 minutes. No intrapatient dose escalations are allowed. Treatment continues until disease progression or intolerable side effects develop.
224172846|NCT07057778|DRUG|Iguratimod|oral iguratimod at 25mg twice daily for 26 weeks
224172847|NCT07057778|DRUG|low-dose rituximab|rituximab 100mg once weekly for 6 weeks
224172848|NCT07058493|DRUG|Dexmedetomidine|dexmedetomidine 100 μg as adjuvant to IPACK block with 20 ml of bupivacaine 0.25%.
224172849|NCT07058493|DRUG|Bupivacaine|20 ml of bupivacaine 0.25%.
224172850|NCT07058545|DRUG|CJC-1134-PC Injection|Double-blind Treatment Period: 0.2ml (2mg) once weekly ×24 weeks (Week 1 to Week 24); Open-label Treatment Period: 0.2ml (2mg) once weekly ×28 weeks (Week 25 to Week 52)
224172851|NCT07058545|DRUG|Placebo|Double-blind Treatment Period: 0.2ml (0mg) once weekly ×24 weeks (Week 1 to Week 24); Open-label Treatment Period: 0.2ml (2mg) once weekly ×28 weeks (Week 25 to Week 52)
223484360|NCT02587936|OTHER|Collaborative Model of Primary care and Subspecialty care|Pieces will access Electronic Health Record for all patients receiving care at the participating sites to detect patients with a triad of chronic kidney disease, diabetes and hypertension, facilitate management and monitor outcomes. To maximize successful implementation of care, a Practice Facilitator will be at each site with standardized role training using a curriculum based on the Agency for Healthcare Research and Quality (AHRQ) Practice Facilitation Handbook. Specific interventions are maintaining BP less than 140/90 mmHg, use of angiotensin-converting-enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB), treatment with statins, aiming for glycosylated Hemoglobin (HgA1C) at the recommended target, and avoiding nephrotoxic medications. Additional interventions include chronic kidney disease education for Primary Care Providers (PCP) and patients using National Kidney Disease Education Program (NKDEP) materials.
223484361|NCT06427499|DRUG|Stannous fluoride toothpaste|brush 2 min morning \& night daily
223484362|NCT06427499|DRUG|Colgate Cavity Protection Toothpaste|brush 2 min morning \& night daily
223484363|NCT04270461|BIOLOGICAL|NKG2D-based CAR T-cells|Autologous genetically modified anti-NKG2DLs CAR transduced T cells
223484364|NCT03654417|DRUG|EMLA|Patients undergoing a vulvar biopsy will be randomized to receive EMLA cream or a lidocaine injection as their numbing agent prior to the procedure.
224172852|NCT07054801|DRUG|Lidocaine hydrochloride|A total of 20 mg injected in 10 mg doses will be administered over 5 min into the frontal and parietal branches of each MMA, resulting in a cumulative dose of 40 mg per MMA. The injection will be performed bilaterally, yielding a total dose of 80 mg per patient.
224172853|NCT07054801|DRUG|Methylprednisolone sodium succinate|A total of 10 mg were injected over 5 min into the frontal and parietal branches of each MMA, resulting in a cumulative dose of 20 mg per MMA, yielding a total dose of 40 mg per patient.
224172854|NCT07058090|DRUG|Silymarin 420 mg|silymarin group received silymarin 140mg thrice daily along with antituberculous drugs for 14 days
224172855|NCT07058090|DRUG|N Acetyl Cysteine|N- acetylcysteine group will receive N-acetylcysteine 900mg once daily with antituberculous drugs for 14 days
224172856|NCT07058090|DRUG|Rifampicin (RMP) Ethambutol (E) Isoniazid (H) Pyrazinamid (Z)|Antituberculous drugs only
224172857|NCT07058584|DEVICE|repetitive Transcranial Magnetic Stimulation|Repetitive transcranial magnetic stimulation (rTMS) is administered using a figure-of-eight coil from MagVenture positioned over the left primary motor cortex (M1) in an anteroposterior direction. High-frequency rTMS is delivered at 10 Hz, consisting of 100 trains of 10-second duration (3000 pulses), with 20-second inter-train intervals, at \~90% of resting motor threshold (RMT) depending on participant tolerance and TMS-EEG brain response.
224172858|NCT07058584|DEVICE|Sham repetitive Transcranial Magnetic Stimulation|This intervention involves high-frequency repetitive transcranial magnetic stimulation (rTMS) applied over the primary motor cortex (M1), using a figure-of-eight coil. In the sham condition, the same coil is used, but it is oriented away from the scalp at an angle that prevents effective magnetic stimulation of the brain, while still producing similar auditory and tactile sensations. This allows participants to remain blinded to the intervention type, maintaining the single-blind nature of the study. The active stimulation is delivered at 10 Hz, comprising 30 trains of 10 seconds (9900 milliseconds)(3000 pulses in total), with 20-second inter-train intervals, at \~110% of the individual's resting motor threshold (rMT). Stimulation is delivered while the participant is seated at rest, and the full rTMS protocol takes approximately 15 minutes to complete.
223484365|NCT03654417|DRUG|Lidocaine|Patients undergoing a vulvar biopsy will be randomized to receive EMLA cream or a lidocaine injection as their numbing agent prior to the procedure.
223484366|NCT00177125|DEVICE|ErectAid|
223585989|NCT00450034|PROCEDURE|drug - oriented multifaceted intervention|oriented multifaceted intervention
223585990|NCT04408911|DRUG|Midazolam vs. Lormetazepam|In this retrospective analysis we compared critically ill ICU patients receiving midazolam to those receiving lormetazepam.
224205503|NCT03233737|COMBINATION_PRODUCT|One spray CTY-5339-A|Metered spray bottle with ≈200 uL total spray volume. Contains the active ingredients: 14.0% Benzocaine (USP = 28 mg) and 2.0% Tetracaine Hydrochloride (USP = 4 mg). Administered in a single anesthetic spray.
223585991|NCT05318820|DRUG|HMPL-523|This study plans to enroll 39 healthy Chinese subjects who will be randomized (1:1:1) into one of three sequence groups (Test \[T\]/Reference\[R\]/R group, RTR group and RRT group) to receive a single dose in each cycle with a washout period of at least 7 days, where T is the test product \[i.e., HMPL-523 Tablets manufactured by Hutchison MediPharma (Suzhou) Limited.\], and R is the reference product (i.e., HMPL-523 Tablets manufactured by WuXi STA).
223585992|NCT00329615|DRUG|Insulatard, flexpen|
223585993|NCT03931915|DRUG|TAK-385|TAK-385 40 mg tablets + Leuprorelin acetate placebo injection
223585994|NCT03931915|DRUG|Leuprorelin acetate|TAK-385 placebo tablets + Leuprorelin acetate 1.88 mg / 3.75 mg injection
223484367|NCT05504525|PROCEDURE|Fascia Iliaca block|Ultrasound guided fascia iliaca block done by palpation of anterior superior iliac spine to identify the inguinal crease, then place the ultrasound probe on it to identify the sartorius muscle. Sonographic anatomy will be identified, from superficial to deep, consisting of subcutaneous fat, the internal oblique muscle, the transverse abdominis muscle, the fascia iliaca covering the iliacus muscle and the iliacus muscle itself. The block needle will be advanced in out-of plane to puncture the fascia iliaca. With the needle tip just below the fascia iliaca, 2 ml of a local anesthetic will be injected to confirm the tip location. Once the proper position is confirmed, 40 ml of bupivacaine 0.25% will be injected superficial to the iliacus muscle and deep to the fascia iliaca.
224172859|NCT07059260|DIAGNOSTIC_TEST|Early referral|The intervention involves early referral, allowing patients to be assessed by a cardiologist prior to the standard referral process. During this visit, the cardiologist will perform a comprehensive medical history and a detailed physical examination to assess signs of central and peripheral congestion. A standardized echocardiogram will also be conducted, including a series of objective measurements.
224172860|NCT06769633|DRUG|Givinostat Hydrochloride|Cohort 1 - from 4 to 6 years old
224172861|NCT06769633|DRUG|Givinostat Hydrochloride - Cohort 2|Cohort 2 - from 2 to 4 years old
224172862|NCT06856057|BEHAVIORAL|Caregivers' Aid to Accelerate Recovery after pediatric Emergencies (CAARE)|CAARE is a technology-enhanced stepped model of care that is designed to deliver education at the bedside to caregivers of children under age 12 years hospitalized for pediatric injury about mental health recovery after pediatric injury as well as risk assessment and brief intervention for high-risk patients (Step 1), foster symptom self-monitoring and reinforcement of coping skills via mHealth tools (Step 2), screen for caregivers' and children's PTSD and depression 30 days post-injury (Step 3), and provide a referral and warm hand-off to mental health services if needed (Step 4).
224172863|NCT06879327|BIOLOGICAL|R21 Matrix-M (R21/MM) Malaria Vaccine|Administered by intramuscular injection. Each 0.5 mL dose contains R21 Malaria Antigen (5 mcg) and Matrix-M1 (Adjuvant) (50 mcg).
224172864|NCT06879327|BIOLOGICAL|Placebo|Administered by intramuscular injection. Each dose (0.5 mL) contains Normal saline (0.9%).
223484368|NCT05504525|PROCEDURE|Quadratus lumborum block|The patients will receive anterior ultrasound guided quadratus lumborum block QLB in the lateral position. The transducer will be first placed in a parasagittal orientation 3-4 cm lateral to the midline and over the sacrum to identify the L5 transverse process. The probe will then rotated into a transverse orientation with slight medial and caudal angulation to obtain a transverse oblique view at L5 transverse process .The ultrasound probe will be tilted , so the lateral end of the probe will be more cranial than the medial side of the probe to avoid the acoustic shadow of the iliac crest. Identify the quadratus lumborum and psoas major and inject the local anesthetic above the QL
224172865|NCT06879327|BIOLOGICAL|Hexavalent Vaccine|"Administered by intramuscular injection. Each dose of 0.5 mL contains:~* Diphtheria Toxoid \> 30 IU~* Tetanus Toxoid \> 40 IU~* B. pertussis (whole cell) \> 4 IU~* Hepatitis B surface antigen (HBsAg) (recombinant DNA) 15 mcg~* Inactivated polio vaccine (Salk strains grown on vero cells): Type - 1 (Mahoney strain) 40 D antigen units (DU); Type - 2 (MEF-1 strain) 8 DU; Type - 3 (Saukett strain) 32 DU~* Haemophilus influenzae Type b (Hib) Conjugate Vaccine (Adsorbed) polyribosylribitol phosphate (PRP) 10 mcg conjugated to tetanus toxoid (TT) (carrier protein) 19 to 33 mcg\]"
224172866|NCT06879327|BIOLOGICAL|Pneumococcal Polysaccharide Conjugate Vaccine|Administered by intramuscular injection. Each 0.5 mL dose contains 2 mcg each Saccharide for serotypes 1, 5, 9V, 14, 19A, 19F, 23F, 7F, 6A and 4 mcg Saccharide for serotype 6B.
224172867|NCT06879327|BIOLOGICAL|Rotavirus, Live Attenuated (Oral) Vaccine|Administered orally. Each 2.0 mL dose contains: Live Attenuated Bovine-Human Rotavirus Reassortant \[G1, G2, G3, G4 and G9\], 5.6 focus-forming units (FFU) / serotype.
224172868|NCT06879327|BIOLOGICAL|Measles and Rubella Vaccine|Administered by subcutaneous injection. Each 0.5 mL dose contains not less than 1000 cell culture infectious dose 50% (CCID50) of Measles virus and 1000 CCID50 of Rubella virus.
224172869|NCT06879327|BIOLOGICAL|Meningococcal A conjugate vaccine|Administered by intramuscular injection. Each 0.5 mL dose contains Meningococcal A polysaccharide 10 mcg and tetanus toxoid (TT) (carrier protein) 10 to 33 mcg.
224305901|NCT03795038|DEVICE|Lipoprotein Apheresis DIAMED and DALI|Three apheresis treatments assigned to one type of apheresis system of DIAMOND and DALI
223484369|NCT01047449|PROCEDURE|No-touch SVG harvest vs conventional SVG harvest technique|Saphenous vein harvested using the pedicled (no-touch) technique or using the conventional technique. Fish oil supplements/placebo (1g taken orally twice daily for 1 year post-op)
223484370|NCT01047449|DIETARY_SUPPLEMENT|Fish oil supplementation vs placebo|Fish oil supplementation \[1g tablets (55% fish oils - EPA:DHA 33%:22%)\] taken twice daily for 1 year post-op
223484371|NCT02937441|OTHER|Ultrasonic Measurement|"How we measure;~1. First measurement shall be taken in 4 hours.~2. Second measurement shall be taken at 12 hours in mild and 12-18 hours measurement shall be taken for severe diabetic ketoacidosis,~3. Third measurement shall be taken after fluid treatment.~4. Fourth measurement shall be taken at patients polyclinic control."
223484372|NCT02332759|DEVICE|Materna Medical|
223484373|NCT04131972|DEVICE|REGENERA|REGENERA breast implant
223484374|NCT01925417|BIOLOGICAL|RBX2660 (microbiota suspension)|
223484375|NCT00404313|DRUG|MK0633|Patients will receive 10 mg, 50 mg, or 100 mg MK0633 tablets once daily for 6 weeks. There will be 2 week period during which all patients will receive placebo to MK0633
223484376|NCT00404313|DRUG|Comparator: placebo|Placebo to MK0633 10 mg, 50 mg, or 100 mg tablets once daily for 6 weeks
223585995|NCT06425432|DEVICE|OVITZ xwave aberrometer|wavefront aberrometer
224305902|NCT05443581|BEHAVIORAL|dietary intervention|Dietary guidance will be given to participants through monthly face-to-face interviews and biweekly telephone calls to change their dietary structure and energy intake.
224305903|NCT04312295|BEHAVIORAL|ACP-SCT program|The ACP-SCT program was designed to improve nurses' knowledge and competence in discussing ACP with Chronic Kidney Disease patients.
224305904|NCT06017310|DIAGNOSTIC_TEST|Evaluate the performance of IFN I/III|Evaluate the response in diagnosing non-respiratory viral infection.
224305905|NCT01502410|DRUG|sorafenib tosylate|Given PO dosage 200 mg/m2/dose (max dose:400 mg/dose) given every 12 hours on days 1-28
224305906|NCT01502410|OTHER|pharmacological study|Optional correlative studies
224305907|NCT01502410|OTHER|laboratory biomarker analysis|Optional correlative studies
224172870|NCT06879327|BIOLOGICAL|Yellow Fever vaccine|Yellow fever vaccine will be locally sourced by each trial site in accordance with the countries' EPI program.
224172871|NCT06879327|BIOLOGICAL|Typhoid Conjugate vaccine|Typhoid conjugate vaccine will be locally sourced by each trial site in accordance with the countries' EPI program.
224172872|NCT07072325|DRUG|CD-001|CD-001 administered as an intravenous (lV)infusion.
224172873|NCT06587932|OTHER|brain gym exercises|It is comprised very easy body movements which have been designed to coax the two hemispheres of the brain.
224172874|NCT06587932|OTHER|Traditional treatments|traditional treatment in form of balance training included standing on one leg, standing in tandem mode, walking in a tandem mode (one foot in front of the other), walking on toes and heels, side walk, standing while one upper extremity and the opposite lower extremity were up, rotating the head from side to side, walking backwards for four steps, and shifting weight from one foot to the other
224172875|NCT04470024|DRUG|INCAGN01876|agonistic antihuman GITR mAb
224172876|NCT04470024|DRUG|INCMGA00012|humanized, hinge-stabilized, IgG4κ mAb that recognized human PD-1
224172877|NCT04470024|BIOLOGICAL|DPV-001|autophagosome cancer vaccine
223484377|NCT01134666|DRUG|Cetuximab|FOLFOX Oxaliplatin 100 mg/ m2 day 1 Folinic Acid 400 mg/m² (racemic) or 200 mg/m² (L-form) day 1 5- FU 400 mg/m² bolus on day 1 followed by a 46-hour continuous infusion of 2,400 mg/m² day 1 FOLFIRI Irinotecan 180 mg/ m2 day 1 Folinic Acid 400 mg/m² (racemic) or 200 mg/m² (L-form) day 1 5- FU 400 mg/m² bolus on day 1 followed by a 46-hour continuous infusion of 2,400 mg/m² day 1 CETUXIMAB Cetuximab administered at loading dose of 400 mg/m2/week over 120 min followed by maintenance dose of 250 mg/m2/ week over 60 min, till disease progression or dose limiting toxicity
223484378|NCT03320811|OTHER|Data record|
223484379|NCT02912936|DIETARY_SUPPLEMENT|Ketogenic medium chain triglyceride drink (MCT drink)|10 days supplementation with the MCT drink. Participants in dose group 1 will be assigned to 10 g per day, those in dose group 2 will be assigned 20 g per day, those in dose group 3 will be assigned 30 g per day, those in dose group 4 will be assigned 40 g per day, and those in dose group 5 will be assigned 50 g per day. The drink will be taken in the morning and evening. Participants will be enrolled 8 per group in ascending order.
223484380|NCT02912936|DIETARY_SUPPLEMENT|Placebo|10 days supplementation with the placebo drink. Participants in dose group 1 will be assigned to 10 g per day, those in dose group 2 will be assigned 20 g per day, those in dose group 3 will be assigned 30 g per day, those in dose group 4 will be assigned 40 g per day, and those in dose group 5 will be assigned 50 g per day. The drink will be taken in the morning and evening. Participants will be enrolled 8 per group in ascending order.
223484381|NCT06308783|OTHER|Diaphragmatic Breathing|10 minutes each day during 6 weeks, before sleeping.
223484382|NCT06308783|OTHER|Global Postural Reeducation|10 minutes each day during 6 weeks, before sleeping.
223484383|NCT02880618|DEVICE|Barostim Neo™ System|
223484384|NCT03199105|OTHER|Preoperative education with image illustrations and/or local tetracaine mucilage|The patients were given preoperative education with image illustrations and/or local tetracaine mucilage to alleviate CRBD during the post-operative period.
224172878|NCT06740214|DRUG|0.5% standard bupivacaine only|20ml 0.5% standard bupivacaine only
224172879|NCT06740214|DRUG|1.33% liposomal bupivacaine with 0.5% standard bupivacaine|10ml 1.33% liposomal bupivacaine (133mg) plus 10ml 0.5% standard bupivacaine
224172880|NCT06740214|DRUG|1.33% liposomal bupivacaine only|20ml 1.33% liposomal bupivacaine (266mg)
224172881|NCT06924164|OTHER|Progressive resistance training|The progressive resistance program consist of a five-minute aerobic warm-up on either an ergometer bike, treadmill or rowing machine followed by six resistance training exercises: landmine twist, walking lunges, leg press, hip abduction, hip adduction and hip flexion. All training sessions (three per week) will be supervised for the first two weeks. After that, there will be one weekly supervised training session and two self-directed sessions. The subjects will be scheduled for 36 training sessions over 12 weeks, of which 16 will be supervised. Each training session is designed based on the findings from the feasibility study and is expected to last approximately one hour. If a subject cannot perform all scheduled sessions in a week, additional sessions will be planned for the following week to obtain the 16 supervised sessions.
224172882|NCT06924164|BEHAVIORAL|Waiting time|12 weeks of waiting time
224172883|NCT06924164|BEHAVIORAL|Self guided exercise|12 weeks of self guided exercise
223484385|NCT03443297|OTHER|breast milk|Feeding with breast milk will be started in early feeding group from 24 to 48 hours of age or in late feeding group, from 48 to 72 hours of age. Initially 4 hourly feeding will be started with 0.5ml and 1 ml expressed breast milk in babies with birth weight \<1200 grams and \>1200 grams respectively. gradually volume of milk should be increased
223484386|NCT04913922|DRUG|Azacitidine Injection|s.c. 75 mg/m2 BSA for 7 days
223484387|NCT04913922|DRUG|Nivolumab|480 mg i.v.
224172884|NCT04267887|DRUG|Abiraterone Acetate|Given PO
224172885|NCT04267887|DRUG|Antiandrogen Therapy|Given ADT per standard of care
223484388|NCT04913922|DRUG|Relatlimab|80-160mg i.v.
223484389|NCT03537833|OTHER|pemetrexed-related hematological toxicity|hematological toxicity will be found on biologic data the day or the day before chemotherapy. Classification will based on NCI-CTCAE criteria
223484390|NCT00847314|DRUG|Testosterone Undeconate (Nebido-R, BAY86-5037)|Male patients \> 35yrs in medical practices fulfilling all criteria for documentation.
224172886|NCT04267887|DRUG|Apalutamide|Given PO
224172887|NCT04267887|DRUG|Prednisone|Given PO
224172888|NCT04267887|PROCEDURE|Computed Tomography|Undergo CT scan
224172889|NCT04267887|PROCEDURE|Bone Scan|Undergo bone scan
224172890|NCT04267887|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
224172891|NCT04267887|OTHER|Questionnaire Administration|Ancillary studies
224172892|NCT07095543|BEHAVIORAL|Low-fat, vegan diet|All participants will be asked to follow a low-fat vegan diet for the duration of the study. Participants will attend weekly classes where they we receive education and support.
224172893|NCT07096908|DRUG|Tirzepatide|weekly injections
224172894|NCT07096908|DRUG|Placebo|weekly injections
224172895|NCT03579446|DRUG|Hydrocodone|Given by PO
224172896|NCT03579446|DRUG|Hydromorphone|Given by PO
224172897|NCT03579446|DRUG|Levorphanol|Given PO
224172898|NCT03579446|DRUG|Morphine|Given by PO
224172899|NCT03579446|DRUG|Oxycodone|Given by PO
224172900|NCT03579446|DRUG|Oxymorphone|Given by PO
224172901|NCT03579446|OTHER|Questionnaire Administration|Ancillary studies
224172902|NCT07100769|PROCEDURE|Real-time ultrasound-guided thoracic epidural placement|"Real-time ultrasound-guided thoracic epidural catheter placement is performed by an attending anesthesiologist using paramedian-cross view to approach thoracic epidural space.~The patient is placed in the prone position with a pillow under the upper abdomen. The probe is placed to identify the rib, then moved medially to identify key anatomical structures: costotransverse joint, transverse process, lamina, superior articular process. The probe is rotated clockwise toward the midline to visualize the lamina and base of the spinal process.~A 18G Tuohy needle is advanced under ultrasound guidance from inferior to superior aiming for the interspace between the lamina and base of the upper spinal process.~After the tip of Tuohy needle approaches the interspace, the anesthesiologist will perform a loss-of-resistance test to identify the epidural space. Then a catheter will be inserted into epidural space."
224172903|NCT07101276|OTHER|No intervention|No intervention will be performed in this study.
224172904|NCT07100730|COMBINATION_PRODUCT|TLX-101-Tx + Lomustine|Combination therapy with TLX-101-Tx + Lomustine
224172905|NCT07100730|RADIATION|TLX101-Tx|TLX101-Tx
224172906|NCT07100886|OTHER|long-term follow up visit|Phone call questionnaire- retrospective treatment arm Phone call questionnaire- retrospective control arm
224172907|NCT07101159|DRUG|Dalpiciclib|Dalpiciclib 100 mg orally, daily on days 1-21 of a 28-day cycle, for 3 years.
224172908|NCT07101159|DRUG|Endocrine Therapy (Tamoxifen, Anastrozol, Letrozole, Exemestane)|Standard adjuvant endocrine therapy (e.g., tamoxifen or aromatase inhibitor), as per physician's choice.
224172909|NCT07101159|DRUG|Dalpiciclib|Dalpiciclib 125 mg orally, daily on days 1-21 of a 28-day cycle, for 2 years.
223484391|NCT03451370|DRUG|Capecitabine|"750 mg/sqm/bid, day 2 to 15; if toxicities grade ≥2 do not occur, pts may subsequently receive capecitabine 1000 mg/sqm/bid, day 2 to 15 starting the second cycle based on investigator's choice.~To be repeated every 3 weeks (21 days), for a maximum of 8 cycles.~If no progression occurs, pts will receive maintenance capecitabine (starting at the same dose used at the last cycle of the induction treatment) plus bevacizumab every 3 weeks (21 days), until disease progression, unacceptable toxicity or patient's refusal."
223484392|NCT03451370|DRUG|Oxaliplatin|100 mg/sqm iv over 2 hours, day 1 To be repeated every 3 weeks (21 days), for a maximum of 8 cycles.
223484393|NCT03451370|DRUG|Bevacizumab|"7.5 mg/kg iv over 90 minutes, day 1; if the first infusion is tolerated, then subsequent infusions may be administered in 30 minutes.~If no progression occurs, pts will receive maintenance capecitabine (starting at the same dose used at the last cycle of the induction treatment) plus bevacizumab every 3 weeks (21 days), until disease progression, unacceptable toxicity or patient's refusal. To be repeated every 3 weeks (21 days), for a maximum of 8 cycles."
223484394|NCT01831843|DEVICE|Group C|non-heated, non-humidified conventional breathing circuit was used in group C patient
224172910|NCT07102303|BEHAVIORAL|Online Group Cognitive-Behavioral Therapy (CBT)|"12-session group online CBT treatment for online sexual compulsivity/cybersex addiction. Cognitive-behavioral psychological treatment program applied online and in a group format. The program consists of twelve sessions of approximately 2,5 hour's duration and weekly frequency 1. Psychoeducational module and motivational interviewing. 2. Environmental planning, stimulus control 3. Beginning of training in emotional self-regulation techniques. 4. Cognitive errors and cognitive discussion. 5. Self-talk, thought traps, responsibility vs. guilt and backpack of coping resources. 6. Self-esteem, stigma and life goals 7. Backpack of coping resources, mindfulness and slow breathing training for anxiety 8. Stress coping techniques 9. Lifestyle 10. and 11. Reduction of stimulus control and addressing previously unaddressed relevant issues. 12. Relapse prevention"
224172911|NCT07102303|BEHAVIORAL|Online Individual Cognitive-Behavioral Therapy (CBT)|"12-session individual and online CBT treatment for online sexual compulsivity/cybersex addiction. Cognitive-behavioral psychological treatment program applied online and individually. The program consists of twelve sessions of approximately one hour's duration and weekly frequency 1. Psychoeducational module and motivational interviewing. 2. Environmental planning, stimulus control 3. Beginning of training in emotional self-regulation techniques. 4. Cognitive errors and cognitive discussion. 5. Self-talk, thought traps, responsibility vs. guilt and backpack of coping resources. 6. Self-esteem, stigma and life goals 7. Backpack of coping resources, mindfulness and slow breathing training for anxiety 8. Stress coping techniques 9. Lifestyle 10. and 11. Reduction of stimulus control and addressing previously unaddressed relevant issues. 12. Relapse prevention"
224172912|NCT07101588|COMBINATION_PRODUCT|Ruxolitinib, Decitabine|"1. Decitabine: 20 mg/m²/day, administered from Day -15 to Day -10.~2. Ruxolitinib:~   * 10 mg twice daily (bid), Day -15 to Day -5~  * 5 mg twice daily (bid), Day -4 to Day -3~  * 5 mg once daily (Qd), Day -2"
224172913|NCT07100951|BEHAVIORAL|Brief Psychoanalytic Couple Therapy|Brief Psychoanalytic Couple Therapy (BPCT) consists of 12 weekly online sessions (50 minutes each) focused on uncovering unconscious relational dynamics, symbolic conflict meanings, and early attachment schemas. Techniques include relational interpretations, exploration of projective identification and transference, and analysis of emotional defenses. Therapists maintain a neutral, reflective stance to promote insight and self-awareness within the couple dynamic.
223484395|NCT01831843|DEVICE|Group E|breathing tube which apply humidity and heat (Evaqua™ Breathing Circuits manufactured by Fischer \& Paykel)was used in group E patient
223484396|NCT01831843|DEVICE|Group M|Heated humid tube with a warming device (Mega Acer kit manufactured by Acemedical,Seoul Korea)was used in group M patient
223484397|NCT00805259|BEHAVIORAL|Financial incentives|Financial incentives based on use of software designed to promote cognitive function
223484398|NCT05349305|DRUG|continuous renal replacement therapy|continuous renal replacement therapy
223484399|NCT03186755|DRUG|Hyaluronic acid 0.05% & Ectoine 2.0%|Treatment of 1 drop three times a day in both eyes for 8 weeks
223484400|NCT03186755|DRUG|Olopatadine hydrochloride ophthalmic solution 0.1%|Treatment of 1 drop two times a day in both eyes for 8 weeks
223484401|NCT03020368|BIOLOGICAL|Leeches|
223484402|NCT03020368|DRUG|Diclofenac|
223484403|NCT07152704|DEVICE|Active therapy with non-ablative Er:YAG laser|three intravaginal and vulvar/clitoral treatments within 60 days
224172914|NCT07100951|BEHAVIORAL|Emotionally Focused Therapy|Emotionally Focused Therapy (EFT) involves 12 weekly online sessions (50 minutes each) focusing on repairing emotional bonds and enhancing attachment security. The intervention targets maladaptive emotional interaction cycles and promotes the expression of primary emotions and attachment needs. Therapists actively guide couples through restructuring emotional responses and rebuilding secure, responsive communication patterns.
224172915|NCT07102576|DRUG|MDMA Hydrochloride|Initial dose of 120 mg MDMA HCl in a therapeutic setting, followed 1.5 to 2 hours later by a supplemental dose of 40 mg MDMA HCl. Supplemental doses may be withheld if tolerability issues emerge or it is declined by the participant.
223484404|NCT07168798|DEVICE|Pulse oximeter|OLV-4201 pulse oximeter with sensors: TL-272T3, TL-274T3 and TL-273T3
223484405|NCT07168382|BEHAVIORAL|DAPHNE Chatbot Intervention|The DAPHNE intervention consists of a conversational, AI-powered chatbot designed to identify and address health-related social needs (HRSNs) among caregivers of pediatric patients. Delivered via a secure mobile and web-based application, the chatbot facilitates natural language interactions to assess needs, generate personalized resource recommendations, and support real-time navigation to community-based services. Participants assigned to the intervention arm will have continuous access to the chatbot over a six-month period, including automated nudges, tailored prompts, and context-aware suggestions. The intervention is non-invasive and participant-driven.
223484406|NCT07168382|OTHER|Standard HRSN Screening and Referral (Usual Care)|Participants randomized to the control group will receive the standard-of-care HRSN screening and referral services as currently implemented in Nationwide Children's Hospital Primary Care Clinics. These services include in-clinic social needs assessments conducted during routine visits and referrals to internal or external resources, such as social work or care coordination teams. Participants in this group will not receive access to the DAPHNE chatbot.
223484407|NCT07166900|PROCEDURE|Modified Thoracolumbar Interfascial Plane Block|The TLIP block, introduced as a modification of the lumbar interfascial plane block, targets the dorsal rami of the thoracolumbar nerves by injecting local anesthetic into the fascial plane between the multifidus and longissimus muscles. This technique is designed to provide analgesia to the posterior elements of the spine, which are often the primary sources of pain after laminectomy
223484408|NCT07169370|BEHAVIORAL|SPIRIT Club CBI Pathway|A tailored, on-demand exercise and education program delivered via the SPIRIT Club virtual streaming platform. Content includes progressive adaptive workouts, safety videos, screening checkpoints, and prompts for a support person. Participants choose classes designed specifically for adults ≥9 months post-brain injury and after being placed in the appropriate archetype, complete activity surveys, and earn incentives for adherence. They are instructed on current physical activity guidelines (≥150 min moderate or ≥75 min vigorous activity per week) and to follow the CBI Pathway at their comfort level. Content was co-developed with clinical experts and survivors to ensure both usability and safety.
223484409|NCT05094336|DRUG|AMG 193|AMG 193: Orally via tablet
223484410|NCT05094336|DRUG|Docetaxel|Docetaxel: Intravenous infusion
223484411|NCT05094336|DRUG|Comparator AMG 193 Test Tablet|Comparator AMG 193 test tablet: Orally via tablet. Only participants in the DSPS group of the Part 1a, Phase 1: AMG 193 Monotherapy Dose Exploration, and Part 1j, Phase 1 arms will receive comparator AMG 193 test tablet.
223484412|NCT03365648|DIETARY_SUPPLEMENT|Lertal® + standard therapy|"Lertal® is a novel food supplement. Each tablet contains the following active ingredients:~* Quercetin 150 mg: a natural flavonoid that inhibits the release of histamine, leukotrienes, PGD2, IL (IL-6, IL-8, TNF-alpha).~* Perilla frutescens 80 mg: A dry extract of the seeds containing rosmarinic acid, luteolin, apigenin and crysoeriol that inhibits the release of histamine and expression of interleukins (IL-6, TNF-alpha).~* Vitamin D3 5 mcg (200 IU), which contributes to the normal function of the immune system.~Standard therapy: antihistamine."
223484413|NCT03365648|OTHER|Placebo + standard therapy|"Placebo tablet identical in appearance, size and taste to Lertal® tablets. Standard therapy: antihistamine.~Standard therapy: antihistamine"
223484414|NCT03454555|BEHAVIORAL|Shared Decision Making|The Shared Decision Making (SDM) intervention is a patient-provider communication intervention to explore and compare treatment options, assess a patient's values and preferences, and reach a shared decision about chronic pain treatment. Participants in the SDM arm received their regular pain care visits with a designated SDM-trained clinician over a 12-month period. SDM intervention participants scheduled pain visits as often as needed for pain management (typically quarterly). SDM participants also received an electronic and physical packet of educational materials after randomization.
223484415|NCT03454555|BEHAVIORAL|Motivational Interviewing and Cognitive Behavioral Therapy for Chronic Pain|The Motivational Interviewing and Cognitive Behavioral Therapy for Chronic Pain (MI+CBT-CP) intervention is an empirically based behavioral pain management behavioral therapy intervention, including MI to enhance motivation for active participation in the CBT-CP, and the use of CBT-CP to enhance pain coping skills. MI + CBT-CP participants received one MI session plus up to eight weekly CBT-CP group sessions.
223484416|NCT06387303|DRUG|Methadone|Intravenous Methadone
223484417|NCT06387303|DRUG|Morphine|Intrathecal Morphine
223585996|NCT01581008|OTHER|Collaborative Care to Alleviate Symptoms and Adjust to Illness|A palliative symptom management and psychosocial care intervention named Collaborative Care to Alleviate Symptoms and Adjust to Illness (CASA) that includes (a) evidence-based palliative symptom management of breathlessness, fatigue, and pain, provided by a nurse; (b) a 6-session structured psychosocial care protocol targeting depression and adjustment to illness, supplemented by informal (family) caregiver assessment and support, provided by a social worker or psychologist; and (c) brief weekly team meetings with the nurse, social worker/psychologist and a palliative care specialist, cardiologist, and primary care provider.
223585997|NCT01581008|BEHAVIORAL|Psychospiritual|A psychospiritual intervention that is home-based, self-guided, and requires minimal resources. It will be delivered in written modular form via US Mail along with brief weekly telephone support.
224172916|NCT07100288|OTHER|resection of infundibulopelvic ligament|Therefore, this study also aims to perform bilateral infundibulopelvic ligament resection (at least 8 cm in length) during surgery for ovarian cancer patients
224172917|NCT06309511|DIAGNOSTIC_TEST|Arterial tonometry|Arterial transcutaneous tonometry
224172918|NCT00175422|BEHAVIORAL|The Period of PURPLE Crying Program|There are two treatment arms in the study. The first half of all subjects (n=500) will receive the PURPLE intervention materials (a video and a pamphlet) about infant crying. The second arm will receive comparable materials on infant safety and SIDS.
224172919|NCT05013788|OTHER|Social Media Enhanced Education|Along with usual asthma education received,participants will receive asthma education via various social media platforms ,Facebook, Twitter, Instagram, and/or Snapchat. Topics of education will include background on asthma and pathophysiology, asthma severity classification, asthma triggers, different medications and indications for when to take them, how to use an inhaler technique, and symptom monitoring.Online resources from the American Lung Association and the National Asthma Education and Prevention Program will also be posted.
224172920|NCT05013788|OTHER|Usual Asthma Education|For patients who are admitted to Children's Memorial Hermann for asthma exacerbation, asthma education is provided to patients and families on the day of discharge by the nurse and respiratory therapist on triggers, Signs \& Symptoms, Medication Use, Medication Delivery, Peak Flow, Zones and how to respond to each, and Cleaning equipment.Nursing staff are responsible for printing out education sheets to give to patients and showing an education video that is 20 minutes long. An asthma action plan are given to families on discharge. Patients that are discharged from the emergency room are given the same educational materials by the nurses and/or respiratory therapists except for the asthma video. Patients receive a variable amount of asthma education when going to usual clinic visits. The education provided is dependent on the provider, and usually limited in length to the time of the visit
224172921|NCT07147530|DEVICE|Electrically Powered Orthopedic Exercise Device|Participants who pass the screening undergo an evaluation of gait function and balance ability without wearing the Electrically Powered Orthopedic Exercise Device. Afterward, the patient wears the motorized orthopedic exercise device for a total of four adaptation sessions. In each session, the patient performs short-distance walking within 10 meters while wearing the device to explore the appropriate assistive mode and level of support that match their physical condition. No evaluations are conducted while wearing the device during sessions 1, 2, and 3. After the 4th session, an evaluation identical to the one conducted without the device is performed while wearing it, and a satisfaction survey is conducted.
224172922|NCT05325333|BEHAVIORAL|Retrieval-based word learning: Expanding retrieval practice schedule|Learning sessions: Novel nouns and their meanings are practiced on Day 1. Retrieval trials will initially be immediate. In the expanding condition, the next two retrieval trials will each occur after 1 intervening word and then after 3 intervening words for the remainder of the session. This practice schedule is repeated the next day (Day 2).
223484418|NCT06548750|OTHER|Intrinsic and Ectrinsic Exercise|Intrinsic and extrinsic muscle strengthening exercises
223484419|NCT06548750|OTHER|Intrinsic Exercise|Intrinsic muscle strengthening exercises
223585998|NCT03619135|DEVICE|Buzzy|The Buzzy is a reusable device that applies vibration to the skin surface to override the body's gate control pain pathway. It has been used effectively to reduce the discomfort of intravenous cannulation (IV placement) in pediatric patients. Also, it has been utilized to reduce the discomfort of injections in pediatric and adult patients. We are preforming this study to evaluate the effectiveness of the Buzzy in reducing the discomfort associated with intravenous cannluation (IV placement) in adults.
224172923|NCT05325333|BEHAVIORAL|Retrieval-based word learning: Standard retrieval practice schedule|Learning sessions: Novel nouns and their meanings are practiced on Day 1. Retrieval trials will initially be immediate. In the standard condition, all remaining retrieval trials will occur after 3 intervening words. This practice schedule is repeated the next day (Day 2).
224172924|NCT04845581|PROCEDURE|Diagnostic tests: Determination of the gingival phenotype, measure gingival thickness and width of keratinized tissue|Gingival thickness was measured using UGTM method and CBCT/ CAD with PDIP technology at upper incisors and canines in three points localized midbucally : Free gingival thickness (FGT), supracrestal ( SGT) and crestal (CGT). Width of keratinized tissue was measured using periodontal probe calibrated for 1 mm. The gingival phenotype was determined by both methods according to the following criteria: GT ≤ 0,7 mm - thin gingival phenotype, GT \&gt; 0,7 mm ≤ 1,0 mm - medium gingival phenotype, GT \&gt; 1,0 mm - thick gingival phenotype. Toincrease the repeatability of the results, two researchers tested the same values twice on 2days interval between sessions.
224172925|NCT00522652|DRUG|PX-478|Oral formulation, dose escalation, taken on days 1 to 5 of a 21 day cycle until progression or development of unacceptable toxicity
224172926|NCT04443205|OTHER|Data record|Data record
223484420|NCT02002663|DRUG|ropivacaine 0.2%|PCA morphine 0.5 mg/ml bolus 1 mg LO 5 min max 20 mg in 4 hs
223745168|NCT06181669|DIAGNOSTIC_TEST|Pathogen and Host Directed testing|"This study will compare up to 6 pathogen-directed tests and 3 host biomarker tests. Pathogen-directed tests detect and identify the most common causes of bacterial pneumonia, while host biomarker tests assess the host's immune response to infection. Testing will occur at various testing centers.~Evaluable participant specimens will be sent to a central laboratory for distribution to the testing centers that will perform the index testing. Testing centers will be blinded to whether the samples were collected at baseline or clinical change. Further, each testing center will prepare and test the specimens according to documented procedures, then transfer the testing results to the ARLG Statistics and Data Management Center for analysis. Neither the study sites, participants, nor adjudicators will receive the results from the index testing. After the study, untested aliquots of specimens will be stored in the ARLG Physical Biorepository."
223745169|NCT05616741|DEVICE|Cerebri biofeedback|Daily use of a mobile application connected with two wireless sensors for measurement of muscle tension, heart rate variability, and peripheral finger temperature, to be used for home-based biofeedback treatment.
223484421|NCT02002663|DRUG|Methylprednisolone 1mg/kg|
223484422|NCT02002663|DRUG|saline 0.9%|
223484423|NCT05868265|DRUG|Enfortumab Vedotin|All patients will receive enfortumab vedotin at 1.25 mg/kg on days 1 and 8 of 21 days cycle, for a total of three cycles.
223484424|NCT05868265|PROCEDURE|Radical surgery|Radical surgery, such as radical nephroureterectomy, nephrectomy or ureterectomy is to take place within 60 days from the last dose of treatment end of cycle 3 (i.e., cycle 3 day 22).
223484425|NCT01775098|DRUG|allopurinol|No arms will not be change as the study as been closed.
223484426|NCT00962767|DRUG|gemtuzumab ozogamicin|2 IV infusions 6 mg/m2 administered monthly
223484427|NCT00962767|DRUG|ATRA plus 6-MP and MTX|6-MP 50 mg/m2/day PO; MTX 15 mg/m2/q week IM; ATRA 45 mg/m2/day PO
223585999|NCT03619135|OTHER|Placebo|No use of the Buzzy (standard IV access techniques)
223586000|NCT03032445|OTHER|Alcoholic Beer|Subject will be asked to consume alcoholic beer within 30 minutes. Subject will be monitored for 60 minutes at commencement of study beverage.
223745170|NCT05616741|OTHER|Cerebri headache diary|Daily registration of headache and medication with the Cerebri mobile application. This intervention is identical for both study arms.
224172927|NCT02348671|OTHER|shear- force|19 Newton shear- force and 3,9 kPa pressure for half an hour
224172928|NCT04150523|OTHER|Survey|The study will involve a 22 question online survey, administered through the online survey platform conjoint.ly. Conjoint.ly is a web-based survey tool used to conduct survey research, evaluations and other data collection activities. Participants will complete a conjoint.ly survey and choose between treatment (antibiotic vs no antibiotic) scenarios.
224172929|NCT02491593|DEVICE|fecal occult blood test|
224172930|NCT05465967|PROCEDURE|Quadratus lumborum Block|1-Transverse transmuscular Quadratus lumborum block: ultrasound transducer will placed transverse to the abdominal flank to visualise abdominal muscle layers. moving the probe posteriorly, the transverse process of the lumbar vertebra, Quadratus lumborum, Psoas Major and erector spinae muscles identified as a 'Shamrock sign'. the needle will inserted through the back muscles to fascial plane between the Quadratus lumborum and Psoas Major, local anesthetic will injected .2- paraspinous sagittal Quadratus lumborum block: ultrasound transducer will be directed caudally in a sagittal plane lateral to the spinous process of L4. moving laterally until the Quadratus lumborum is evident in its long axis with a characteristic sonographic image of three muscle layers appearing from posterior to anterior as: erector spinae, Quadratus lumborum, and Psoas major muscle the needle will be advanced through the muscles, until it pierces the Quadratus lumborum. local anesthetic will be injected.
223745171|NCT05227326|DRUG|PCNA Inhibitor AOH1996|Given PO
224172931|NCT00290355|BIOLOGICAL|GSK 249553 vaccine|Intramuscular injection, 13 doses
223484428|NCT04742179|OTHER|Manteinance and care intervention on the green areas.|Manteinance and care intervention on the green areas.
223484429|NCT05538845|DEVICE|Screw fixation|Screw fixation to patients
223484430|NCT05538845|DEVICE|Suture button|Suture button for patients
223484431|NCT03077867|PROCEDURE|sinus floor augmentation with bone graft|sinus floor augmentation with lateral approach with bone graft
223484432|NCT01386385|RADIATION|3-Dimensional Conformal Radiation Therapy|Undergo 3D-conformal RT
223484433|NCT01386385|DRUG|Carboplatin|Given IV
223484434|NCT01386385|OTHER|Laboratory Biomarker Analysis|Correlative studies
223484435|NCT01386385|DRUG|Paclitaxel|Given IV
223484436|NCT01386385|OTHER|Placebo Administration|Given PO
223484437|NCT01386385|DRUG|Veliparib|Given PO
223484438|NCT02617251|OTHER|No intervention|
223484439|NCT04874311|DRUG|Bintrafusp alfa|Bintrafusp alfa will be administered by intravenous infusion on day 1 every 3 weeks at a fixed dose of 2400 mg.
223484440|NCT04874311|DRUG|Doxorubicin|Doxorubicin will be administered by intravenous infusion on day 1 every 3 weeks at a fixed dose of 75 mg/m² for a maximum of 6 cycles
223484441|NCT03199209|OTHER|Behavioral, Psychological or Informational Intervention|Receive information about healthy lifestyles
223484442|NCT03199209|OTHER|Behavioral, Psychological or Informational Intervention|Receive information about healthy homes
223484443|NCT03199209|BEHAVIORAL|Patient Visit|Attend study visit with research staff
223484444|NCT03199209|OTHER|Questionnaire Administration|Ancillary studies
223484445|NCT03199209|OTHER|Text Message|Receive information about healthy lifestyles
223484446|NCT03199209|OTHER|Text Message|Receive texts about healthy homes
223745172|NCT01722240|DRUG|Liraglutide 1.8mg|
224172932|NCT00290355|BIOLOGICAL|Placebo|Intramuscular administration, 13 doses
224172933|NCT01173822|OTHER|Ultrafiltration of residual blood|The inflow line to the hemoconcentrator was connected to the sideport of the arterial filter stopcock, allowing the residual blood in the CPB circuit to be processed through the hemoconcentrator. The outflow line from the hemoconcentrator was connected to a second three way stopcock located on the cardiotomy reservoir. Blood was circulated from the venous reservoir through the hemoconcentrator and returned to the venous reservoir until the desired hematocrit was achieved. The blood was then diverted to a transfer pack until all the blood from the venous reservoir, heat exchanger, and membrane oxygenator had been filtered and hemoconcentrated. This transfer pack was given to the anesthetist for reinfusion into the patient.
224172934|NCT01383551|BEHAVIORAL|"Becoming Parents intervention"|"A Becoming Parents programme consists of: (i) 3 antenatal workshops conducted over a period of 10-14 weeks in prenatal period; and (ii) support provided by trained volunteers for up to 3 months post-delivery; in addition to the usual prenatal education."
224172935|NCT01590524|BEHAVIORAL|Guided Imagery and Progressive Muscle Relaxation|Daily implementation of the guided imagery and progressive muscle relaxation techniques additionally to weekly supervised sessions.
223484447|NCT05399485|DRUG|Rimegepant|Randomization Phase: Rimegepant (BHV3000) 75 mg orally disintegrating tablet every other day until Week 12
223484448|NCT05399485|DRUG|Placebo|Randomization Phase: Placebo tablet to match Rimegepant every other day until Week 12
223484449|NCT06368778|OTHER|Verbal Advice|The participant will receive verbal instructions following the standard physical therapy.
223484450|NCT06368778|OTHER|Bathroom Scale|The participant is given a sense of what a 20 kg load feels like using a scale.
223484451|NCT06368778|DEVICE|Loadsol Biofeedback|Average peak force (N) with be measured during partial weightbearing physical therapy routine for 2-minutes using the Loadsol device.
223484452|NCT06357182|DRUG|Azacitidine|Given SC
223484453|NCT06357182|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223484454|NCT06357182|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
223484455|NCT06357182|PROCEDURE|Echocardiography Test|Undergo ECHO
223484456|NCT06357182|DRUG|Iadademstat|Given PO
223484457|NCT06357182|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
223484458|NCT06357182|OTHER|Questionnaire Administration|Ancillary study
223484459|NCT06357182|DRUG|Venetoclax|Given PO
223484460|NCT06552234|DRUG|Repotrectinib|Repotrectinib 160 mg BID, until progression or unacceptable toxicity
223745173|NCT01722240|DRUG|Placebo|
223745174|NCT03514784|DRUG|BB-12 with LGG (Higher Dose)|BB-12 with LGG - Higher Dose (10 billion CFUs)
223745175|NCT03514784|DRUG|Placebo|Maltodextrin
223745176|NCT03514784|DRUG|BB-12 with LGG (Lower Dose)|BB-12 with LGG - Lower Dose (1 billion CFUs)
224172936|NCT04238286|PROCEDURE|Dry needling|All the participants will be placed in a prone position on the bench. Once the subject is settled, we will localize a nodule within the palpable taut band, confirming its presence after inducing local twitch response by palpation. After placing the MTrPs, the area will be sterilized with an alcohol solution colorless spray \[Skin-des. Agupunt ®\]. The puncture method used in the true dry needling groups will be the Hong's fast in-fast out technique, described as the most aggressive technique in the MTrPs treatment, using a needle of 0.32 x 40 mm. The intervention will be implemented until the subject reports the presence of seven local twitch reactions to the controller.
224172937|NCT01542632|BIOLOGICAL|Takeda's Tetravalent Dengue Vaccine Candidate (TDV)|TDV subcutaneous injection
224172938|NCT01542632|BIOLOGICAL|TDV New Formulation|TDV New Formulation subcutaneous injection
224172939|NCT01542632|DRUG|Placebo|Placebo subcutaneous injection
224172940|NCT01542632|DRUG|New Formulation Placebo|New Formulation placebo subcutaneous injection
224172941|NCT00723515|DRUG|sodium fluoride|sodium fluoride 5%
223484461|NCT05165433|BIOLOGICAL|NG-350A plus Pembrolizumab|Patients receive three doses of NG-350A by intravenous infusion and a single dose of Pembrolizumab by intravenous infusion
223484462|NCT05960175|DEVICE|New telemonitoring approach using 2 connected devices : Scanwatch connected watch + Asten&masanté application|"The home healthcare provider will monitor the treatment remotely and make home visits, as in the control group. However, in the case of technical alerts concerning CPAP treatment (problems with observance, leaks, residual apneas), the provider will send the patient a notification via the mobile application in order to provide advice/instructions so that the patient can resolve the alert independently. The provider will monitor the resolution of alerts remotely and may contact the patient by telephone or come to your home if necessary.~If the connected watch detects an abnormal heart rhythm at night, the patient receives a notification and can undergo an electrocardiogram."
224172942|NCT00723515|DRUG|sodium fluoride calcium fluoride|sodium fluoride 5% + calcium fluoride
224172943|NCT03896087|DIAGNOSTIC_TEST|Abbott RealTime HCV assay from DBS|The trial intervention will consist of testing DBS, PSC and plasma samples obtained from trial participants using the centralised molecular assays for detection of HCV RNA. Results of testing DBS samples on the HCV assay will not be used to make any clinical decisions, and should not be communicated to study participants.
223484463|NCT03768063|DRUG|Atezolizumab|Atezolizumab will be administered as a monotherapy or atezolizumab with other agent(s) as per parent protocol. Dosing regimen will continue in accordance with the parent study or at equivalent dose (if applicable) and at the same schedule as the parent study, or switch to a fixed atezolizumab dose of 1200 mg every 3 weeks (Q3W).
223484464|NCT03768063|DRUG|Bevacizumab|Bevacizumab will be administered as directed per the parent study.
223484465|NCT03768063|DRUG|Alectinib|Alectinib will be administered as directed per the parent study.
223484466|NCT03768063|DRUG|Cobimetinib|Cobimetinib will be administered as directed per the parent study.
223484467|NCT03768063|DRUG|Vemurafenib|Vemurafenib will be administered as directed per the parent study.
223484468|NCT03768063|DRUG|FAP IL2V|FAP IL2V will be administered as directed per the parent study.
223484469|NCT03768063|DRUG|Venetoclax|Venetoclax will be administered as directed per the parent study.
224172944|NCT03896087|DIAGNOSTIC_TEST|HCV for use on the cobas® 6800/8800 Systems from PSC and DBS|The trial intervention will consist of testing DBS, PSC and plasma samples obtained from trial participants using the centralised molecular assays cobas® 6800/8800 Systems for detection of HCV RNA. Results of testing DBS samples on the HCV assay will not be used to make any clinical decisions, and should not be communicated to study participants.
223484470|NCT03768063|DRUG|Enzalutamide|Enzalutamide will be administered as directed per the parent study.
223586001|NCT03032445|OTHER|Non alcoholic beer|Subject will be asked to consume non alcoholic beer within 30 minutes. Subject will be monitored for 60 minutes at commencement of study beverage.
223586002|NCT01105455|OTHER|Nutrition education|Group nutrition classes supplemented by handouts and provision of key study foods.
223484471|NCT03768063|DRUG|Pembrolizumab|Pembrolizumab will be administered as directed per the parent study.
224172945|NCT03896087|DIAGNOSTIC_TEST|Aptima® HCV Quant Dx Assay from DBS|The trial intervention will consist of testing DBS, PSC and plasma samples obtained from trial participants using the centralised molecular assays Aptima® HCV Quant Dx Assay from DBS for detection of HCV RNA. Results of testing DBS samples on the HCV assay will not be used to make any clinical decisions, and should not be communicated to study participants.
224172946|NCT03896087|DIAGNOSTIC_TEST|HCV for use on the cobas® 4800Systems from PSC and DBS|The trial intervention will consist of testing DBS, PSC and plasma samples obtained from trial participants using the centralised molecular assays cobas® 4800 for detection of HCV RNA. Results of testing DBS samples on the HCV assay will not be used to make any clinical decisions, and should not be communicated to study participants.
224172947|NCT02827487|DRUG|Tramadol|Women will receive Tramadol 100mg (Trama®, Global Napi, Giza, Egypt) orally 2 hours before IUD insertion.
224172948|NCT02827487|DRUG|Celecoxib|Women will receive Celecoxib 200mg (Celebrex® 200, Pfizer, USA) orally 2 hours before IUD insertion.
224172949|NCT02827487|DRUG|Placebo 1|Women will receive a placebo similar to Tramadol orally 2 hours before IUD insertion.
224172950|NCT02827487|DRUG|Placebo 2|Women will receive a placebo similar to Celecoxib orally 2 hours before IUD insertion.
224172951|NCT02827487|PROCEDURE|IUD|IUD insertion
223484472|NCT03768063|DRUG|Sunitinib|Sunitinib will be administered as directed per the parent study.
223484473|NCT03768063|DRUG|Niraparib|Niraparib will be administered as directed per the parent study.
223484474|NCT03768063|DRUG|Cabozantinib|Cabozantinib will be administered as directed per the parent study.
223484475|NCT03768063|DRUG|Pemetrexed|Pemetrexed will be administered as directed per the parent study.
223484476|NCT03768063|DRUG|Paclitaxel|Paclitaxel will be administered as directed per the parent study.
223484477|NCT03768063|DRUG|Emactuzumab|Emactuzumab will be administered as directed per the parent study.
223484478|NCT03768063|DRUG|Rucaparib|Rucaparib will be administered as directed per the parent study.
223484479|NCT05895643|DRUG|Semaglutide Injectable Product|Once weekly injections s.c with semaglutide (Wegovy)
223484480|NCT05895643|DRUG|Placebo|Once weekly injections s.c with placebo (BD Posiflush)
223745177|NCT05920577|OTHER|exergames and resistance training|"In each session, the participants will receive 40 minutes of combined use of exergaming and resistance training. The participants will practice the exergames using the gaming system Nintendo Switch (Nintendo Co., Ltd, Kyoto, Japan). The gaming software Nintendo Switch Sports will be adopted in which arrays of exergames are available to strengthen both the upper and lower extremity muscle and improve the balance ability of participants. The exergaming programme will consist of both upper (badminton game and tennis game) and lower (soccer game) extremity games. For week 1 and 2, the participants will first practice 1-minute warm up exercise (stretching exercises) and then the 3 exergames. For week 3 to 12, the participants will receive the same warm up exercise and exergames as if week 1 and 2 but there will be an addition of light cuff weight for resistance training."
224172952|NCT01926652|DRUG|candesartan cilexetil 32mg, amlodipine 10mg|"Part A: Treatment A (candesartan), Treatment B (candesartan + amlodipine) 2-period, 2-treatment crossover.~Part B: Treatment A (Amlodipine), Treatment B (candesartan + amlodipine) 2-period, 2-treatment crossover."
224172953|NCT05747768|DRUG|Midazolam, dabigatran etexilate, pitavastatin, rosuvastatin and atorvastatin|Midazolam, dabigatran etexilate, pitavastatin, rosuvastatin and atorvastatin were provided by the Department of Pharmacy, Peking University Third Hospital, and were dissolved and mixed with normal saline respectively, and the mixing process needed to be fully stirred. Then, according to the concentration of the drug mixed solution, the corresponding volume of mixed solution was given to achieve the dosage of 10 μg midazolam, 375 μg dabigatran etexilate, 10 μg pitavastatin, 50 μg rosuvastatin and 100 μg atorvastatin. In order to avoid the food effect, the test drugs were administered on an empty stomach on the administration day in this experiment.
224172954|NCT00809575|OTHER|questionnaire administration|
224172955|NCT00809575|OTHER|fatigue assessment and management|
224172956|NCT00809575|OTHER|observation|
224172957|NCT00809575|OTHER|quality-of-life assessment|
224172958|NCT03502941|DIETARY_SUPPLEMENT|6.3 g of EAAs mixture and whey protein isolate|A single dose of the mixture of EAAs/whey
223484481|NCT01184807|DRUG|OPB-51602|OPB-51602 at a dose of 2, 5, 10, 20, 40, 60, 80, or 100 mg/day,will be orally administered to subjects once daily for 2 weeks in each cycle of treatment in Dose Escalation Stage.A 2-day treatment-free interval will occur on Days 2 and 3 for PK sampling. Study drug administration will resume on Day 4 and continue until Day 17 in cycle 1.In Expansion stage part 1, OPB-51602 will be administered at recommend dose (4mg) for 3 weeks per cycle 9 2 weeks treatment and 1 week washout). There is also 2-day treatment free interval between Day 1 and Day 4 for PK sampling in cycle 1.In Expansion stage part 2, subject dosing will be started on Day 1 without 2-day treatment free interval and continued until Day 28 at recommend dose (4mg) first in Cycle 1. The same subjects will be treated at MTD(5mg)from cycle 2 onwards for 4 weeks per cycle.
224172959|NCT03502941|DIETARY_SUPPLEMENT|12.6 g of EAAs mixture and whey protein isolate|A double dose of the mixture of EAAs/whey
224172960|NCT03502941|DIETARY_SUPPLEMENT|12.6 g of whey protein isolate|Whey protein isolate alone, which is an equal amount to the double dose of the mixture of EAAs/whey
224172961|NCT00057265|DRUG|telbivudine or lamivudine|
224172962|NCT05617248|BEHAVIORAL|Self-efficacy App|The training starts with a psychoeducational video and instructions to define two autobiographical self-efficacy The individuals will then receive three self-efficacy trainings per day based on their autobiographical memories and combined with a slow breathing exercise. Additionally, they will receive 10 daily EMA questionnaires on mood, social contacts, and virtual context.
224172963|NCT00618865|DIETARY_SUPPLEMENT|Omega-3 fatty acids|
224172964|NCT04444323|OTHER|3D Telemedicine|The intervention is a consultation conducted using a 3D form of telemedicine
224172965|NCT02924766|DRUG|Niraparib|Participants will start with niraparib 200 mg once daily.
224172966|NCT02924766|DRUG|Apalutamide|Participants will receive apalutamide 240 mg (4\*60 mg) once daily orally.
224172967|NCT02924766|DRUG|Abiraterone Acetate|Participants will receive 1000 mg (4\*250mg) once daily.
224172968|NCT02924766|DRUG|Prednisone|Participants will receive 10 mg (1\*5 mg twice daily).
224172969|NCT01631006|DEVICE|CPAP|A low or high CPAP pressure is delivered for 20 minutes
224172970|NCT06041230|DEVICE|Ozone Generator|Ultrasound guided ozone therapy
224172971|NCT06041230|DEVICE|Extracorporeal shock wave therapy device|Extracorporeal shock wave therapy device
224172972|NCT03307395|PROCEDURE|Middel Meningeal Artery Embolization|Blood supply to the subdural hematoma via the middle meningeal artery is interrupted.
224172973|NCT01566006|DRUG|Mycophenolate Mofetil (MMF) ,phosphodiesterase 5 inhibitors , CARNITINE|effect of MMF on diabetic nephropathy patients by evaluating its effect on proteinuria and progression of kidney disease of diabetic origin
224172974|NCT04822090|OTHER|Supportive treatment with or without red cell transfusion/intravenous immune globulin (IVIG)|red cell transfusion; plasma exchange; renal replacement therapy; intravenous immunoglobulin. plasma exchange
224172975|NCT01321736|DIETARY_SUPPLEMENT|dietary fiber|mixture of fiber sources added to liquid nutrition product
224172976|NCT02997111|DEVICE|PFA-100|The PFA-100 will be used to assess platelet function before and after energy drink consumption.
224172977|NCT04465240|OTHER|Virtual reality|Participants are immersed in a neighborhood environment in virtual reality
224172978|NCT04352686|DRUG|Buspirone|Administration of buspirone to assess esophageal sensitivity
224172979|NCT04352686|DRUG|Placebo|Administration of placebo to assess differences in esophageal sensitivity
224172980|NCT00856336|DRUG|DMXAA|DMXAA, given intravenously over 20 minutes. Patients were to each undergo six doses of treatment at weekly intervals, receiving each of six doses (300, 600, 1200, 1800, 2400 and 3000 mg/m2)
224172981|NCT00036816|BIOLOGICAL|MART-1 antigen|
224172982|NCT00036816|BIOLOGICAL|NA17-A antigen|
224172983|NCT00036816|BIOLOGICAL|gp100 antigen|
224172984|NCT00036816|BIOLOGICAL|tyrosinase peptide|
224172985|NCT01126385|DEVICE|DensiProbe Spine|Intraoperative DensiProbe Spine measurements
224172986|NCT03577028|BIOLOGICAL|HPN424 Fixed IV 1.3 to 150 ng/kg|Fixed dose IV cohorts at doses from 1.3 to 150 ng/kg
224172987|NCT03577028|BIOLOGICAL|HPN424 Prime Step IV 36 ng/kg Target|Step-dosing IV cohort at a single Prime Dose followed by the Target Dose (12/36 ng/kg)
224172988|NCT03577028|BIOLOGICAL|HPN424 1 Prime Step IV 225-300 ng/kg Target|Step-dosing IV cohorts who received a single Prime Dose followed by the Target Dose (100/300 ng/kg and 75/225 ng/kg)
224172989|NCT03577028|BIOLOGICAL|HPN424 2 Prime Step IV 300 ng/kg Target|Step-dosing IV cohorts who received 2 Prime Doses followed by the Target Dose (50/150/300 ng/kg with prior chemotherapy and 50/150/300 ng/kg no prior chemotherapy)
224172990|NCT03577028|BIOLOGICAL|HPN424 2 Prime Step IV 450 ng/kg Target|Step-dosing IV cohorts who received 2 Prime Doses followed by the Target Dose (100/300/450 ng/kg and 50/150/450 ng/kg)
224172991|NCT03577028|BIOLOGICAL|HPN424 Fixed SC|Fixed subcutaneous dose 120 ng/kg
223484482|NCT06274021|DEVICE|Transcutaneous spinal stimulation at 100 Hz|Transcutaneous spinal stimulation (TSS) is a non-invasive neuromodulation method that uses electrical currents to stimulate sensory fibers. The procedure involves placing surface electrodes midline on the lower back (T11-12 spinal processes) and on each side of the belly button. The stimulation frequency during the intervention is 100 Hz, performed at a sub-motor threshold for 30 minutes.
223617578|NCT02742831|BEHAVIORAL|Intervention|"The intervention group will receive a 6-session intervention. The overview of the 6 sessions is as follows:~1. Behavioral chain analysis of episode where parent felt stressed with child and episode where things went well. Identification of sources of interpersonal support.~2. Stress relief techniques. Identification of short and long-term goals. Development of a detailed crisis plan.~3. Problem solving techniques.~4. Emotional regulation. Exercises to identify moods and explore connections between feelings, thoughts, and behavior.~5. Positive parenting, review of common and specific parenting challenges, child development, short and long-term effects of different discipline approaches.~6. Reflection, repeat behavioral chain analysis. Update crisis plan."
224172992|NCT03434860|DIETARY_SUPPLEMENT|probiotic|"The multiprobiotic Symbiter which contains of 14 alive probiotic strains of Lactobacillus + Lactococcus (6×1010 CFU/g), Bifidobacterium (1×1010/g), Propionibacterium (3×1010/g), Acetobacter (1×106/g) genera. Over 8 weeks of interventional period, the patient received 1 sachet (10 grams) of probiotic per day."
224172993|NCT03434860|DIETARY_SUPPLEMENT|placebo|Over 8 weeks of interventional period, the patient received 1 sachet (10 grams) of gel per day
224172994|NCT00722735|DRUG|Finafloxacin|Finafloxacin tablets, 300 mg b.i.d., oral administration; Ciprofloxacin placebo capsule, 1 capsule b.i.d.,oral administration; duration: 3 days
224172995|NCT00722735|DRUG|Ciprofloxacin|Finafloxacin placebo, 6 tablets b.i.d., oral administration; Ciprofloxacin capsule, 250 mg b.i.d., oral administration; duration: 3 days
224172996|NCT05305742|OTHER|Instrument Design|Research the effect of different instrument designs on root canal preparation by evaluating bacterial count reduction and post-operative pain
223484483|NCT06274021|DEVICE|Transcutaneous spinal stimulation at 50 Hz|Transcutaneous spinal stimulation (TSS) is a non-invasive neuromodulation method that uses electrical currents to stimulate sensory fibers. The procedure involves placing surface electrodes midline on the lower back (T11-12 spinal processes) and on each side of the belly button. The stimulation frequency during the intervention is 50 Hz, performed at a sub-motor threshold for 30 minutes.
223484484|NCT06274021|COMBINATION_PRODUCT|Transcutaneous spinal stimulation at 50 Hz and single dose of baclofen|"Transcutaneous spinal stimulation (TSS) is a non-invasive neuromodulation method that uses electrical currents to stimulate sensory fibers. The procedure involves placing surface electrodes midline on the lower back (T11-12 spinal processes) and on each side of the belly button. The stimulation frequency during the intervention is 50 Hz, performed at a sub-motor threshold for 30 minutes.~Study participants will receive a single dose of baclofen, a centrally-acting muscle relaxant belonging to the class of gamma-aminobutyric acid (GABA) analogs. Its primary mechanism involves acting on the GABA receptors in the brain and spinal cord to decrease spasticity. Participants will receive baclofen orally at a single dose of 10 mg."
223484485|NCT06274021|COMBINATION_PRODUCT|Transcutaneous spinal stimulation at 50 Hz and single dose of tizanidine|"Transcutaneous spinal stimulation (TSS) is a non-invasive neuromodulation method that uses electrical currents to stimulate sensory fibers. The procedure involves placing surface electrodes midline on the lower back (T11-12 spinal processes) and on each side of the belly button. The stimulation frequency during the intervention is 50 Hz, performed at a sub-motor threshold for 30 minutes.~Study participants will receive a medication called tizanidine, which is an alpha-2 adrenergic agonist. This medication works by inhibiting presynaptic motor neurons, resulting in a reduction of muscle spasticity. It is commonly used to manage spasticity caused by neurological disorders. Each participant will be given a single oral dose of 4 mg of tizanidine as part of this trial."
223484486|NCT06274021|DEVICE|Sham transcutaneous spinal stimulation|Sham Transcutaneous spinal stimulation (TSS) involves placing two surface electrodes midline on the lower back (T11-12 spinal processes). The stimulation frequency during the intervention is 50 Hz, performed for 30 minutes.
224172997|NCT01032057|DRUG|capecitabine|
224172998|NCT01032057|DRUG|gemcitabine hydrochloride|
224172999|NCT01032057|PROCEDURE|quality-of-life assessment|
224173000|NCT01032057|RADIATION|3-dimensional conformal radiation therapy|
224173001|NCT01241643|DRUG|CYT107|repeated cycles of 3 injections of CYT107 at 20 µg/kg/week over 2 weeks, for a maximum of 4 cycles within 21 months and a maximum of 3 cycles within 12 months
224173002|NCT02650518|OTHER|Short-course Antibiotics|3 days of amoxicillin/clavulanate, ciprofloxacin, or cotrimoxazole.
224173003|NCT02650518|DEVICE|Catheter Change|Urinary catheter change once randomization is complete.
224173004|NCT06258161|PROCEDURE|Spinal Fusion|Realignment and fusion of adult spinal deformity
224173005|NCT06258161|OTHER|No intervention|No intervention for control group.
224173007|NCT04880499|DIETARY_SUPPLEMENT|Iron plus folic acid, vitamin B2, B6, B12, C, and E|A number of 30 subjects are supplemented with iron plus folic acid, vitamin B2, B6, B12, C, and E daily for 60+/-15 days before orthopedic surgery.
224173008|NCT05859776|DRUG|AXT107 Low Dose|Single suprachoroidal injection of AXT107 (0.125 mg/eye)
224173009|NCT05859776|DRUG|AXT107 Mid Dose|Single suprachoroidal injection of AXT107 (0.250 mg/eye)
224173010|NCT05859776|DRUG|AXT107 High Dose|Single suprachoroidal injection of AXT107 (0.500 mg/eye)
224173011|NCT01108263|DRUG|INTEGRA™ Flowable Matrix (Collagen)|INTEGRA™ Flowable Wound Matrix is an advanced 3-D porous matrix comprised of granulated cross-linked bovine tendon collagen and glycosaminoglycan. It provides a scaffold for cellular invasion and capillary growth. The collagen and glycosaminoglycan mix is hydrated with saline and applied on the wound bed.
224173012|NCT03683680|OTHER|MPT Test|molecular expression tests at the RNA level using approximately 7 or more genes with RTPCR, nanostring or similar platforms
224173013|NCT03683680|OTHER|CLDN15/VIM Test|molecular expression tests at the RNA level using approximately 7 or more genes with RTPCR, nanostring or similar platforms
224173014|NCT01685372|BIOLOGICAL|Fluzone High Dose|A single-dose of high-dose influenza vaccine will be administered to subjects randomized to this arm
224173015|NCT01685372|BIOLOGICAL|Fluzone|A single-dose of standard-dose influenza vaccine will be administered to subjects randomized to this arm
224173016|NCT05790967|OTHER|Sexual Education|Women in the experimental group will be given education on sexual life during pregnancy. Before the training, preliminary data will be collected and then the participants will be given two hours of individual and face-to-face training.
224173017|NCT05260190|DEVICE|tSMS|30-minute tSMS application in a comfortable seated position. The material used in the stimulation was a MAGxx1.1 helmet (Neurek Spain Toledo), with a Neodymium (NdFeB) magnet of 60mm diameter and 30mm height with Nickel (Ni-Cu-Ni) coating MAG60r+ (Neurek Spain, Toledo), placed over the primary motor cortex (M1) of the left cerebral hemisphere.
224173018|NCT05260190|DEVICE|Sham tSMS|30-minute sham tSMS application in a comfortable seated position. The device used in sham stimulation had the same weight and shape as the real stimulation helmet.
224173019|NCT02117973|PROCEDURE|iAssist Technique using Persona system vs. the conventional technique using Persona system|
224173020|NCT06054594|OTHER|Resistance exercise|After baseline testing, participants followed a progressive resistance training program 3 times a week for 4 months.
223484487|NCT05887973|BEHAVIORAL|The T.R.I.G.G.E.R Project|"The T.R.I.G.G.E.R Project includes the following core components to address root causes of gun violence:~* Summer Employment~* Social and Emotional Learning~* Future Orientation~* Adult and Peer Support~* Critical Consciousness~* Civic Efficacy and Engagement"
223484488|NCT06047119|PROCEDURE|Blood pressure|Blood pressure targets during general anesthesia and 2 hours after
223484489|NCT06047119|PROCEDURE|Positive end expiratory pressure|Positive end expiratory pressure during general anesthesia
223484490|NCT06047119|PROCEDURE|Tidal volume|Tidal volume during general anesthesia
223484491|NCT06047119|PROCEDURE|Fraction of inspired oxygen|Fraction of inspired oxygen during general anesthesia and 2 hours after
223484492|NCT03068910|DRUG|Micronized progesterone|Micronized progesterone 0.8 mg/kg at 0700, 1500, 2300 and 0700 h. Progesterone is a natural hormone.
223484493|NCT03068910|DRUG|Spironolactone|Spironolactone is an androgen-receptor blocker commonly used (off-label) for hyperandrogenism. The spironolactone dose will be 50 mg taken orally twice daily (for two weeks before admission to the Clinical Research Unit).
223484494|NCT03068910|DRUG|Placebo|Placebo contains only inert ingredients and is not expected to exert any direct physiological effects.
223484495|NCT06387979|OTHER|Non-Interventional Study|Non-Interventional Study
223484496|NCT01120197|OTHER|Exercise group|Weekly exercises
223484497|NCT01120197|OTHER|Control Group|No Intervention, control group only
223484498|NCT04058405|BEHAVIORAL|Observational|Cross-sectional observations
223484499|NCT05900245|OTHER|Index of consciousness+Anesthetic（propofol）+Muscle relaxant（Succinylcholine）|EEG monitoring is performed before induction of electrical shock anesthesia（propofol1.5mg/kg+Succinylcholine1mg/kg）, and the timing of electrical stimulation is determined based on the level of consciousness index 1 displayed on the EEG.
223484500|NCT03632447|DEVICE|Leva|Subjects randomized to Leva will use a vaginal probe containing motion-based sensors to direct the performance of pelvic muscle exercises.
223484501|NCT03632447|DEVICE|PFDx|All subjects (in both study arms) will be evaluated using a vaginally placed device that will evaluate pelvic floor motion to document change in pelvic floor muscle function resulting from pelvic floor muscle exercises.
223484502|NCT06463275|DIAGNOSTIC_TEST|SpinChip hs-cTnI|SpinChip Platform, consisting of the SpinChip hs-cTnI test (self-contained cartridge) and SpinChip Analyzer (instrument).
223484503|NCT05542147|DRUG|Fenofibrate 145 mg|1 tablet per day
224173021|NCT02055872|DRUG|Intravenous albumin|
224173022|NCT02055872|DRUG|Normal saline|
224173023|NCT06095349|OTHER|inhalatory treatment with sulfureous aerosol|osteopenic patients are subject to a 12-days cycle of 30 minutes-long inhalatory treatment with sulfureous aerosol
224173024|NCT04966806|PROCEDURE|LASIK refractive surgery|laser vision correction for myopic eyes
224173025|NCT00829010|BIOLOGICAL|Pneumococcal vaccine GSK1024850A|Intramuscular injection, administered as 3 or 4 doses
224173026|NCT00829010|BIOLOGICAL|Tritanrix-HepB/Hib|Intramuscular injection, 4 doses
224173027|NCT00829010|BIOLOGICAL|measles|Intramuscular injection, 2 doses
224173028|NCT00829010|BIOLOGICAL|Rotarix|Oral, 2 doses
224173029|NCT00829010|BIOLOGICAL|Local OPV|Oral 4 doses. Given at any time during the study, routinely given concurrently with DTPw-HBV/Hib vaccine
224173030|NCT02136264|OTHER|PCFA interventional dietary counselling|
224173031|NCT02136264|OTHER|conventional DASH diet counselling|
224173032|NCT03270527|OTHER|High SFA diet (Diet 1)|'Diet 1' will contain \~18% of its total energy as SFA .
224173033|NCT03270527|OTHER|Low SFA diet (Diet 2)|'Diet 2' will contain \~10% of its total energy as SFA. The SFA-replacement fats will be mixture of PUFA/MUFA.
224173034|NCT00324454|BIOLOGICAL|Levetiracetam|Levetiracetam 1500 mg BID
223484504|NCT05542147|DRUG|Placebo|1 tablet per day
223484505|NCT04178018|DEVICE|Photoacoustic imaging|-Emerging technique in which a short-pulsed laser beam penetrates diffusively into a tissue sample
223484506|NCT04178018|DEVICE|Ultrasound|-The ultrasound is being used in conjunction with the photoacoustic imaging
223484507|NCT05489588|DEVICE|GORE® VIAFORT Vascular Stent|Treatment of unilateral symptomatic iliofemoral venous obstruction with the GORE® VIAFORT Vascular Stent.
223484508|NCT04069897|DRUG|Botulinum toxin type A|Botulinum toxin 25 Allergan units in 0.5 ml Sodium Chloride (NaCl) 0.9 % Braun. Two injections, one in each side of the face, and targeting the sphenopalatine ganglion.
223484509|NCT04069897|DRUG|placebo|0.5 ml Sodium Chloride (NaCl) 0.9% Braun. Two injections, one in each side of the face, and targeting the sphenopalatine ganglion.
223484510|NCT04799470|DEVICE|Novel DBS stimulation patterns|Stimulation patterns
223484511|NCT05387980|DRUG|CIBINQO|Patients receiving CIBINQO tablets by mouth for the treatment of Atopic Dermatitis.
223484512|NCT05388474|OTHER|No ibalizumab or Pre-ibalizumab treatment|Patient registry
223484513|NCT05388474|BIOLOGICAL|On ibalizumab treatment|Patient registry
223484514|NCT03970720|DRUG|Metoclopramide|10 mg metoclopramide four times a day
223484515|NCT03970720|DRUG|Placebo|10 mg matching placebo capsules four times a day
223586003|NCT06365983|PROCEDURE|Connective Tissue with Free Gingival Graft|The de-epithelialized free gingival grafting will begin with two horizontal incisions, 1.0 to 1.5 mm apical to the margin of the soft tissue of the adjacent teeth and two vertical incisions to delimit the area to be grafted. Along the coronal horizontal incision, the blade will be oriented almost perpendicular to the bone surface, and once an adequate thickness of soft tissue is obtained, it will be rotated to become almost parallel to the external surface of the palate. The graft thickness will be maintained uniform and the wound will be protected with absorbable collagen sponge derived from swine (Spongostan; Ethicon, Somerville, USA) and maintained with compressive sutures with non-absorbable 5-0 monofilament thread (Microsuture, São Paulo), anchored to the soft tissue apical to the area of the palatal wound. Immediately after suture completion, drops of high viscosity cyanoacrylate adhesive (PeriAcryl 90 HV; Glustitch, Delta, Canada) will be applied.
224173035|NCT04395521|BEHAVIORAL|Diabetic foot self-management support|Daily educational organic or inorganic posts (2 to 5) released in a timed sequence through a Hootsuite application plus peer interactions/support for three months.
224173036|NCT02721290|PROCEDURE|Femoral nerve block using Ultrasound and neurostimulator|
224173037|NCT02721290|PROCEDURE|Femoral nerve block using Ultrasound|
224173038|NCT02721290|DRUG|Ropivacaine 0.5%|Ropivacaine 0.5% (20cc total) will be injected for the performance of the block in the two arms of the study.
224173039|NCT02789800|BEHAVIORAL|DIMAC02|Integrated Approach For Chronic Diseases (DIMAC02) is an integrated approach for chronic disease prevention and management services that aims to improve and coordinate different regional initiatives in 11 Family Medicine Groups(FMG) related to : Self-management, Case management, Patient-centred care for persons with multimorbidity, Motivational approach, Interprofessional collaboration. DIMAC 02 specific objectives are: 1) To make available, in FMG's, an interdisciplinary educational intervention for prevention and management of chronic diseases for patients with low and high risk for complication. 2) To Increase the flow of communications between FMG and hospital facilities to improve continuity of care.
224173040|NCT03151772|DRUG|Disulfiram|200 mg disulfiram two times daily and 2,5 mg copper once daily taken preoperatively
224173041|NCT03151772|DRUG|Metformin|Metformin 850 mg x 3 taken preoperatively
224173042|NCT06234891|DRUG|Nsaid|Medical treatment
224173043|NCT06234891|OTHER|Phsiotheraphy|Nsaid and phsiotheraphy (hotpack-ultrasound therapy- tens)
223484516|NCT05037812|DRUG|Saline injection|Saline
223484517|NCT05037812|DRUG|Multimodal injections|"5mg morphine, 500 micrograms epinephrine, and 4ml normal saline (superficial injection).~2.5mg morphine, 40 micrograms clonidine, 15mg ketorolac, and 4ml normal saline (deep injection)."
223484518|NCT03405870|DRUG|Smoflipid|Administration of lipid injectable emulsion
224173044|NCT05080686|DEVICE|Posthorax Thoraxbelt|The patients will be assisted to put on the ThoraxBelt after surgery or at the emergency room by our research members and will be asked to keep it on except for showering through the whole study period.
224173045|NCT06976775|BIOLOGICAL|"Rush regimen"|"The rush regimen consists of the administration of several incremental doses daily, every day, over the first week of the Induction Phase (Part 1)"
224173046|NCT06976775|BIOLOGICAL|"Conventional regimen"|"The conventional regimen consists of the administration of only one incremental dose every 2 weeks, throughout all the Induction Phase (Part 1)"
224173047|NCT05908422|DEVICE|Alvision™ Interventional Cardiology Diagnostic Catheter|The Alvision™ Interventional Cardiology Diagnostic Catheter is a single use only, thin, flexible single lumen tube, with a proximal hub, sterilized with ethylene oxide (EO) gas, non-pyrogenic. The product is defined as a catheter to inject a contrast medium into selected blood vessels.
223484521|NCT06431763|DRUG|Inclisiran sodium|300 mg s.c. administered at day 1 and day 90
224173048|NCT04236440|DRUG|BAY2586116 (A1)|160 μg BAY2586116 (nasal spray administration)
223617579|NCT02742831|OTHER|Control|The families in the control group will be contacted by a member of the study team 6 times in 12 weeks to approximate the frequency of contact that the intervention group receives. The study team member will check in with families on the telephone or in person and will help them connect with clinic and community resources as needed.
224173049|NCT04236440|DRUG|Placebo (A2)|Placebo matching BAY2586116 (nasal spray administration)
224173050|NCT04236440|DRUG|BAY2586116 (B1)|160 μg BAY2586116 (nasal drops)
224173051|NCT04236440|DRUG|BAY2586116 (B2)|80 μg BAY2586116 (nasal spray)
224173052|NCT04236440|DRUG|BAY2586116 (B3)|160 μg BAY2586116 (pharyngeal spray with direct endoscopic application via a nostril)
224173053|NCT04236440|DRUG|BAY2586116 (C)|160 μg BAY2586116 (pharyngeal spray with direct endoscopic application via a nostril). It is the same procedure as described under part B3.
224173054|NCT03042494|DIETARY_SUPPLEMENT|Control|Isocaloric food without the test prebiotic.
224173055|NCT03042494|DIETARY_SUPPLEMENT|Prebiotic|Prebiotic consumed as 7 g/d in a snack food in Group 1 and consumed as 2.5-3 g/d in a snack food in Group 2.
223484522|NCT06431763|DRUG|BPA|180 mg daily per oral
223484523|NCT04310930|DRUG|Amikacin|Adults: Intravenous amikacin 5mg/kg once daily or 7.5mg/kg twice daily or 20-25 mg/kg thrice weekly. Children:Intravenous amikacin 15-30 mg/kg once daily, maximum dose 1500mg
224173056|NCT02289833|DRUG|Trastuzumab Emtansine|Trastuzumab emtansine will be administered intravenously (IV) at a dose of 3.6 mg/kg on Day 1 of every 21-day cycle until disease progression (as assessed by the investigator), unmanageable toxicity, or study termination by the sponsor, whichever occurs first.
224173057|NCT03501381|DRUG|Entinostat|Entinostat should be taken 1-2 hours prior to the HD IL-2 infusion. Dose reductions for entinostat should be followed. Entinostat will continue after high dose IL-2 every 2 weeks
224173058|NCT03501381|DRUG|Interleukin-2|In the event of clinical benefit after a course of HD IL-2 (stable disease or tumor shrinkage) patients will receive a second treatment course of HD IL-2 therapy. Patients with evidence of tumor shrinkage after the 2nd HD IL-2 treatment course may receive a 3rd treatment course of HD IL-2.
224173059|NCT03017833|OTHER|Laboratory Biomarker Analysis|Correlative studies
224173060|NCT03017833|DRUG|Metformin|Given PO
224173061|NCT03017833|OTHER|Pharmacological Study|Ancillary studies
224173062|NCT03017833|DRUG|Sapanisertib|Given PO
224173063|NCT03527836|DRUG|Lidocaine brachial plexus block|Combined Axillary-supraclavicular approach to brachial plexus with lidocaine
224173064|NCT03527836|DRUG|Bupivacaine brachial plexus block|Combined Axillary-supraclavicular approach to brachial plexus with bupivacaine
224173065|NCT03527836|DRUG|Mixture brachial plexus block|Combined Axillary-supraclavicular approach to brachial plexus with mixture solution of 20 ml bupivacaine 0.5% and 10 ml lidocaine 1%
224173066|NCT03442595|OTHER|Intensive diabetes education and medication management|Patients receive intensive knowledge based diabetes education and algorithm driven medication management over a period of 12 weeks.
223484524|NCT04310930|DRUG|Tigecycline|Adults: Intravenous Tigecycline 25 mg increasing by 5 mg every two doses until either maximum dose reached (50mg) or until patient is unable to tolerate twice daily. Children (≥8 years of age) intravenous tigecycline: Day 1- 0.6mg/kg twice daily to a maximum of 25mg. Day 2- 0.6mg/kg (maximum 25mg) in the morning, 1.2 mg/kg (maximum 50mg) at night. Day 3- 1.2mg/kg (maximum 50 mg) twice daily
223484525|NCT04310930|DRUG|Imipenem|Adults: Intravenous Imipenem (≥50kg) 500mg twice daily (\<50kg) 15 mg/kg twice daily. Children: intravenous imipenem Day 1- 2- 25mg/kg (maximum 1g) twice daily. DAY 3- 25mg/kg (maximum 1g) four times daily (drop to 3 if not tolerated).
223484526|NCT04310930|DRUG|Cefoxitin|Adults: If imipenem is poorly tolerated intravenous cefoxitin 200 mg/kg thrice daily. Children: if imipenem is poorly tolerated intravenous cefoxitin 50mg/kg (maximum 4g) four times daily.
223484527|NCT04310930|DRUG|Azithromycin|"Adults: Oral azithromycin 500mg (≥40kg) once daily, (\<40kg) 250mg once daily.During consolidaiton: 500mg (≥40kg) thrice weekly, (\<40kg) 250mg thrice weekly.~Children: Oral azithromycin:10mg/kg (maximum 500mg) once daily. During consolidation 10mg/kg once daily maximum 500mg."
223484528|NCT04310930|DRUG|Clarithromycin|Adult: If azithromycin is poorly tolerated use oral clarithromycin 500mg twice daily.Children: If azithromycin is poorly tolerated use oral clarithromycin. In children 1 month old- 11years of age the following dosing applies: \<8kg: 7.5mg/kg twice daily, maximum dose 62.5mg, 8-11kg: 62.5mg twice daily, maximum dose 62.5mg, 12-19 kg: 125mg twice daily, maximum dose 125mg, 20-29 kg: 187.5mg twice daily, maximum dose 187.5mg, 30-40 kg: 250mg twice daily, maximum dose 250mg, Children 12-18 years of age: 500 mg twice daily
223484529|NCT04310930|DRUG|Clofazimine|Adult: Oral clofazimine 100mg once daily. Children: Oral clofazimine: 3-5mg/kg once daily. Maximum dose of 50mg once daily if \<40kg or 100mg if ≥40kg once daily.
223484530|NCT04310930|DRUG|Ethambutol|Adults: with confirmed mixed NTM infections (slow growers + MABS) oral ethambutol can be added at either 15 mg/kg once daily or 25mg/kg thrice weekly. Children with confirmed mixed NTM infections (slow growers + MABS) oral ethambutol can be added at 20 mg/kg once daily.
223586004|NCT06365983|PROCEDURE|Connective Tissue with Linear Incision|The linear technique (Lorenzana ER, Allen EP 2000) will begin with a horizontal incision 2 mm apical to the gingival margin, perpendicular to the palate, which is deepened to the bone crest. Next, a second incision is made to divide the flap and expose the connective tissue bed. The thickness of the outer portion of the flap should be at least 1 mm, with uniformity throughout its extension to reduce the risk of epithelial tissue necrosis. Subsequently, internal lateral incisions (mesial and distal) and the base incision will be made, connecting the vertical incisions to delineate horizontal and vertical boundaries. Immediately after graft removal, an absorbable hemostatic collagen sponge derived from swine (Spongostan; Ethicon, Somerville, USA) will be placed and sutured using non-absorbable 5-0 monofilament thread (Microsuture, São Paulo).Immediately after suturing is completed, drops of high viscosity cyanoacrylate adhesive (PeriAcryl 90 HV; Glustitch, Delta, Canada) will be applied.
223586005|NCT00575874|DRUG|Rivoglitazone HCl|0.5 mg rivoglitazone HCl tablets once daily for 12 weeks
224173067|NCT04705428|OTHER|FLUORINE VARNISH|"Participants in all groups will receive written oral hygiene and oral prophylaxis instructions. All groups will receive the application of fluorine varnish every 3 months.~The application of fluoride in the three groups will be done as follows:~-Drying of the teeth, placement of the fluorine varnish on the teeth by quadrants. The varnish will be left to dry for a few seconds according to the manufacturer's instructions. Children in all groups will be asked to avoid brushing and flossing for one day after applying fluoride. They will be instructed to avoid hard food and hot drinks for 4 hours. Children and parents will be instructed on how to care for their teeth at home: brush teeth with conventional toothpaste containing 1000 ppm sodium fluoride, for 3 minutes without rinsing.~In the following reviews (3 and 6 months) the effectiveness of the treatments will be evaluated by visual examination, tactile examination, fluorescence and photography."
223484531|NCT04310930|DRUG|Amikacin|adult: Inhaled amikacin 500mg twice daily. Children: Inhaled amikacin 500mg twice daily
223586006|NCT00575874|DRUG|rivoglitazone HCl|1.0 mg rivoglitazone HCl tablets once daily for 12 weeks
223586007|NCT00575874|DRUG|rivoglitazone HCl|1.5 mg rivoglitazone HCl tablets once daily for 12 weeks
223586008|NCT00575874|DRUG|pioglitazone HCl|30 mg capsules once daily for 12 weeks
223586009|NCT00575874|DRUG|placebo|matching tablets or capsule once daily for 12 weeks
223586010|NCT02108665|RADIATION|Radiographic hysterosalpingography|
223586011|NCT02108665|RADIATION|Magnetic resonance imaging hysterosalpingography|
224173068|NCT02729870|DRUG|Oral Glucose Gel|This group will receive the following: are less than 3 year of age will receive 7.5 gram oral glucose gel 40% (0.66 oz, 20ml) which will be a one time dose and the subjects who are ages 3-7 will receive 15 gram oral glucose gel (1.3 oz, 40ml) which is a one time dose.
224173069|NCT02729870|OTHER|Placebo|This group will receive carboxymethylcellulose (2%) oral gel. The subjects who are less than than 3 years of age will receive carboxymethylcellulose (2%) oral gel, 20ml which will be a one time dose and the subjects ages 3-7 will receive carboxymethylcellulose (2%) oral gel, 40ml which will be a one time dose.
224173070|NCT03181672|PROCEDURE|Stellate ganglion block|Stellate ganglion block with 1% lidocaine 10ml
224173071|NCT03181672|PROCEDURE|control group|Deltoid muscle injection with 1% lidocaine 10ml
224173072|NCT05246644|DRUG|acetaminophen|we will use IV acetaminophen and an oral placebo or IV placebo and active oral acetaminophen
224173073|NCT00170846|DRUG|Everolimus (RAD001)|
224305908|NCT02826538|DEVICE|fracture fixation with patient specific guides|Using the preoperative computed tomography scan, a 3D planning of the fracture Fixation is made and patient-specific guides for fracure fixation are produced using a 3D Printer. These Patient-specific guides are used for fracture fixation
224173074|NCT00170846|DRUG|Calcineurin Inhibitors (CNI)|
224173075|NCT00170846|DRUG|Mycophenolate acid (MPA)/Azathioprine (AZA)|
224173076|NCT00170846|DRUG|Steroids|
224173077|NCT03839056|DEVICE|IC+PIEB+PCEA high flow|"Ropivacaina 0,1 % is used with fentanilo 2ug/ml Also if during the dilation period a greater or equal AVE appears to 4 (inadequate analgesia) the patient can be administered a bolus of PCEA of the same solution.~If the patient is administered PCEA, the programed intermittent epidural bolus is delayed automatically 20 minutes with regard to the time in which it would have to be administrated.~If after two bolus of PCEA the analgesia keeps on being ineffective a clinical bolus is administered by the anaesthetist of 4ml of lidocaína to 1 %.~This intervention is included in the clinical practice routine"
224173078|NCT03839056|DEVICE|PIEB+PCEA high flow|"Ropivacaina 0,1 % is used with fentanilo 2ug/ml Also if during the dilation period a greater or equal AVE appears to 4 (inadequate analgesia) the patient can be administered a bolus of PCEA of the same solution.~If the patient is administered PCEA, the programed intermittent epidural bolus is delayed automatically 20 minutes with regard to the time in which it would have to be administrated.~If after two bolus of PCEA the analgesia keeps on being ineffective a clinical bolus is administered by the anaesthetist of 4ml of lidocaína to 1 %.~In the group of pure boluses 10ml / h of perfusion will be administered through the high flow and standard flow infusion system, and the maximum sensory level achieved will be compared.~This intervention is included in the clinical practice routine"
224173079|NCT03839056|DEVICE|PIEB+PCEA standar flow|"Ropivacaina 0,1 % is used with fentanilo 2ug/ml Also if during the dilation period a greater or equal AVE appears to 4 (inadequate analgesia) the patient can be administered a bolus of PCEA of the same solution.~If the patient is administered PCEA, the programed intermittent epidural bolus is delayed automatically 20 minutes with regard to the time in which it would have to be administrated.~If after two bolus of PCEA the analgesia keeps on being ineffective a clinical bolus is administered by the anaesthetist of 4ml of lidocaína to 1 %.~In the group of pure boluses 10ml / h of perfusion will be administered through the high flow and standard flow infusion system, and the maximum sensory level achieved will be compared.~This intervention is included in the clinical practice routine"
223484532|NCT04310930|DRUG|Linezolid|"Adult: during consolidation in combination with one to three oral antibiotics (co-trimoxazole, doxycycline, moxifloxacin, bedaquiline or rifabutin) guided by participant susceptibility and tolerance. Oral linezolid 600mg once daily.~Children: during consolidation in combination with one to three oral antibiotics (co-trimoxazole, doxycycline, moxifloxacin or rifabutin) guided by participant susceptibility and tolerance. Age 1 week - 9 years 10mg/kg twice daily maximum dose of 300mg. Age 10-12 years 10mg/kg twice daily maximum dose of 600mg. \>12 years 600mg once daily."
223484533|NCT04310930|DRUG|co-trimoxazole|Adult: during consolidation in combination with one to three oral antibiotics (co-trimoxazole, doxycycline, moxifloxacin, bedaquiline or rifabutin) guided by participant susceptibility and tolerance. Oral Co-trimoxazole (TMP-SMX) 160/800mg twice daily. Children: During consolidation in combination with one to three oral antibiotics (co-trimoxazole, doxycycline, moxifloxacin or rifabutin) guided by participant susceptibility and tolerance. Oral co-trimoxazole 5mg TMP/kg maximum dose of 160mg TMP/ 800mg SMX twice daily.
223484534|NCT04310930|DRUG|Doxycycline|Adult: during consolidation in combination with one to three oral antibiotics (co-trimoxazole, doxycycline, moxifloxacin, bedaquiline or rifabutin) guided by participant susceptibility and tolerance. Oral doxycycline 100mg once daily. Children: During consolidation in combination with one to three oral antibiotics (co-trimoxazole, doxycycline, moxifloxacin or rifabutin) guided by participant susceptibility and tolerance. Oral doxycycline (ages ≥ 8 years) 2mg/kg once daily maximum dose 100mg.
223484535|NCT04310930|DRUG|Moxifloxacin|Adult: during consolidation in combination with one to three oral antibiotics (co-trimoxazole, doxycycline, moxifloxacin, bedaquiline or rifabutin) guided by participant susceptibility and tolerance. Oral moxifloxacin 400mg once daily. Children: During consolidation in combination with one to three oral antibiotics (co-trimoxazole, doxycycline, moxifloxacin or rifabutin) guided by participant susceptibility and tolerance. Oral moxifloxacin 10-15mg/kg once daily, maximum dose 400mg
224173080|NCT05843344|DRUG|erector spinae plane block with a combination of ropivacaine and morphine|Before surgery, a US guided ESPB will be performed, and a catheter will be placed. Serratus Anterior Plane Block (SAPB) will be also performed without catheter placement. 20 mL of Ropivacaine 0.375% will be injected in the SAPB. In this group, 19 mL of 0.375% Ropivacaine + 2 mg (1mL) of morphine will be injected in the ESPB. Continuous peripheral nerve catheters will be placed for postoperative analgesia under the Erector Spinae muscle. A pump of 497 ml of 0.2 % ropivacaine + 6 mg of morphine (contained in 3 mL) will be connected to the catheter after the end of the surgery, and the continuous dose will be 10 mL/hr
224173081|NCT05843344|DRUG|erector spinae plane block with a combination of ropivacaine and dexmedetomidine|Before surgery, a US guided ESPB will be performed, and a catheter will be placed. SAPB will be also performed without catheter placement. 20 mL of Ropivacaine 0.375% will be injected in the SAPB. In this group, 19 mL of 0.375% Ropivacaine +0.5 mcg/kg (1mL) of dexmedetomidine will be injected in the ESPB. Continuous peripheral nerve catheters will be placed for postoperative analgesia under the Erector Spinae muscle. A pump of 497 ml of 0.2 % ropivacaine + 200 mcg of dexmedetomidine (contained in 3 mL) will be connected to the catheter after the end of the surgery, and the continuous dose will be 10 mL/hr
224205504|NCT03233737|DEVICE|One spray CTY-5339-CB|Metered spray bottle with ≈200 uL total spray volume. Contains the active ingredient: 14.0% Benzocaine (USP = 28 mg). Administered in a single anesthetic spray.
224205505|NCT03233737|DEVICE|One spray CTY-5339-P|Placebo. Metered spray bottle with ≈200 uL total spray volume. Contains no active ingredient (vehicle control).
223484536|NCT04310930|DRUG|Bedaquiline|Adult: during consolidation in combination with one to three oral antibiotics (co-trimoxazole, doxycycline, moxifloxacin, bedaquiline or rifabutin) guided by participant susceptibility and tolerance. Oral bedaquiline (18-64 years of age) 400mg once daily for the first two weeks followed by 400mg thrice weekly for 22 weeks (maximum duration of 6 months).
223484537|NCT04310930|DRUG|Rifabutin|Adult: during consolidation in combination with one to three oral antibiotics (co-trimoxazole, doxycycline, moxifloxacin, bedaquiline or rifabutin) guided by participant susceptibility and tolerance. Oral rifabutin: 5mg/kg once daily, maximum 300-450mg. Children: During consolidation in combination with one to three oral antibiotics (co-trimoxazole, doxycycline, moxifloxacin or rifabutin) guided by participant susceptibility and tolerance. Oral rifabutin 5mg/kg once daily
223586012|NCT01722435|DRUG|Opiate Substitution Treatment|
224173082|NCT05843344|DRUG|erector spinae plane block with ropivacaine only|Before surgery, a US guided ESPB will be performed, and a catheter will be placed. SAPB will be also performed without catheter placement. 20 mL of Ropivacaine 0.375% will be injected in the SAPB. In this group, 19 mL of 0.375% Ropivacaine +1 mL of normal saline will be injected in the ESPB. Continuous peripheral nerve catheters will be placed for postoperative analgesia under the Erector Spinae muscle. A pump of 497 ml of 0.2 % ropivacaine + 3 mL of normal saline will be connected to the catheter after the end of the surgery, and the continuous dose will be 10 mL/hr
223484538|NCT05444062|BEHAVIORAL|Educational material and treatment recommendations for patients, general practitioners and pharmacists|Educational material and treatment recommendations given to patients, their family doctors and their pharmacists.
223484539|NCT06367439|BEHAVIORAL|Virtual reality exercise condition|Participants will complete a virtual reality exercise (i.e., Supernatural) tutorial (YouTube instruction and in-headset gameplay instruction/practice) and will complete a 18-20 minute affect measurement medium intensity virtual reality exercise (i.e., Supernatural) session in the Behavioural Medicine Lab (UVic).
224173083|NCT04252924|OTHER|lifestyle characteristics|Exposures of interest: Mediterranean diet, orthorexia nervosa, smoking, physical activity, sleep duration, stress level
224173084|NCT02607865|DRUG|semaglutide|Oral administration once-daily
224173085|NCT02607865|DRUG|sitagliptin|Oral administration once-daily
224173086|NCT02607865|DRUG|placebo|Oral administration once-daily
224173087|NCT02612792|PROCEDURE|Open flap debridement (OFD)|Open flap debridement (OFD) alone
224173088|NCT02612792|PROCEDURE|OFD with Platelet rich fibrin (PRF)|Open flap debridement (OFD) with Platelet rich fibrin (PRF) placement
224173089|NCT02612792|PROCEDURE|OFD with Platelet rich fibrin (PRF)+1.2% Atorvastatin (Drug) in gel form|Open flap debridement (OFD) with Platelet rich fibrin (PRF)+1.2% Atorvastatin gel placement
224173090|NCT05258565|DRUG|IV tPA (Activase)|Any patients eligible came with acute ischemic stroke with or without COVID-19 infection within the time window for thrombolytic therapy (within 4 hours of onset)
224173091|NCT00528840|BIOLOGICAL|collagenase clostridium histolyticum|Up to five injections of AA4500 into cord(s) of the affected hand(s). Each injection was separated by at least 30 days.
224173092|NCT00005623|DRUG|cyproterone acetate|
224173093|NCT00005623|PROCEDURE|quality-of-life assessment|
224173094|NCT01657253|DRUG|PRO-148|Instill 1 drop in each eye four times a day, for 60 days
224173095|NCT01657253|DRUG|Systane|Instill 1 drop in each eye four times a day, for 60 days
223484540|NCT06367439|BEHAVIORAL|Virtual reality exercise condition|Participants will be provided a virtual reality headset (Meta Quest 3 Headset) and subscription to a virtual reality exercise game (i.e., Supernatural) for 10 weeks. Participants will be instructed to participate in 75 minutes of medium intensity Supernatural physical activity (equivalent to 75 minutes of vigorous physical activity) per week in their own home.
223586013|NCT04391166|OTHER|Non invasive visual acuity testing|This will be visual acuity at home and visual acuity in clinic both using an ETDRS chart.
223586014|NCT00397007|BEHAVIORAL|Biofeedback-based cognitive-behavioural intervention|
223586015|NCT01196962|DEVICE|Central venous catheter|Central venous catheter insertion to subclavian vein
223586016|NCT00273156|BEHAVIORAL|Telephone quitline|
223586017|NCT01329913|DRUG|MK-6325|Two 100 mg capsules, orally, once per day for 7 days
224173096|NCT02448095|DRUG|Ponatinib|Observation of tolerability and safety profiles
224173097|NCT03720106|OTHER|GOAL therapy plan|The GOAL algorithm designs a therapy plan based on the LIMOS assessment, patient goals and subject-specific treatment pathways. The adherence of this therapy plan is examined.
224173098|NCT00126386|DRUG|Zoledronic acid (Zometa)|
224173099|NCT00207506|BEHAVIORAL|HoMBReS: A lay health advisor approach to STD prevention|
224173100|NCT02016586|DIETARY_SUPPLEMENT|Maternal Nutritional Supplement|S348S0
224173101|NCT03247010|OTHER|Blood sampling|Blood samples are taken before each cycle of Radium 223
224173102|NCT05143736|DIAGNOSTIC_TEST|gut and nasal microbiota detection|The nasal and fecal specimens will be collected by swabs from subjects with sepsis. After that, total DNA of nasal and gut microbiota will be extracted , amplified, and sequenced to determine the gut and nasal microbiota.
224173103|NCT03223740|OTHER|Arm 1 pre-operative chemoradiation|"Chemotherapy 1:~First 2 courses of chemotherapy with the Capacitabine /cisplatin/ combination.Capacitabine1 g/me2 day 1 to 14. Cisplatin will be given at 20 mg/m2 as a one-hour bolus on day1-5.~Chemoradiotherapy:~At the end of the second 21 days of chemotherapy and one week of rest (day 57), a total of 45 Gy(1.8 Gyfx/d) of radiotherapy will be given with concurrent capacitabine 625 mg/m2 and weekly Taxol 45mg/m2 over 3 hours for 5 weeks.~Chemotherapy2:~Four to five weeks after chemoradiotherapy, Restaged and surgical resection, a D2 resection is encouraged. Peritoneal cytology will be obtained. The J-tube will be left in for at least 8 weeks after surgery to supplement patient's nutrition.~2nd courses of chemotherapy with the Capacitabine. Capacitabine1 g/me2 day 1 to 14. Chemotherapy will be repeated beginning on Day 29."
224173104|NCT03223740|OTHER|Arm 2 post operative chemoradiation|"Surgical resection, a D2 resection is encouraged.~Chemotherapy 1:~All patients will first receive two courses of chemotherapy with the Capacitabin /cisplatin/ combination.Capacitabine1 g/me2 day 1 to 14. Cisplatin will be given at 20 mg/m2 as a bolus on day1-5. Chemotherapywill be repeated beginning on Day 22.~Chemoradiotherapy:~At the end of the second 21 days of chemotherapy and one week of rest (day 57), a total of 45 Gy(1.8 Gyfx/d) of radiotherapy will be given with concurrent capacitabine 625 mg/m2 and weekly Taxol 45mg/m2 over 3 hours for 5 weeks.~Chemotherapy2:~2nd courses of chemotherapy with the Capacitabin. Capacitabine 1g/me2 day 1 to 14. Chemotherapy will be repeated beginning on Day 29"
224173105|NCT00757289|BIOLOGICAL|PRP Injection|PRP Injection
224173106|NCT00757289|BIOLOGICAL|Corticosteroid Injection|Corticosteroid Injection
224173107|NCT05006651|DEVICE|McGrath MAC|Intubaion with McGrath MAC
224173108|NCT05006651|DEVICE|Trachway|Intubaion with Trachway
224173109|NCT05624892|DIAGNOSTIC_TEST|Mirror Therapy with Virtual Reality Application|Researchers will apply Mirror Therapy with Virtual Reality Application to increase individuals' quality of life and motor sense gains.
224173110|NCT01603628|BIOLOGICAL|botulinum toxin Type A|Participants received intramuscular injections of botulinum toxin Type A into specified muscles of the lower limb on Day 1.
224173111|NCT01603628|DRUG|Normal Saline (Placebo)|Participants received intramuscular injections of normal saline (placebo) into specified muscles of the lower limb on Day 1.
224173112|NCT04323917|DIAGNOSTIC_TEST|Liquid biopsy|Detection and quantification of EMT-transcription factor mRNA levels in blood
223484541|NCT05713071|PROCEDURE|Bariatric Endoscopic Antral Myotomy|BEAM will be performed using a standard gastric peroral endoscopic myotomy (G-POEM) technique, however with the myotomy targeting only the antrum and leaving the pyloric ring intact. G-POEM is commonly and widely employed for gastric emptying and nutritional issues and is covered by most insurance plans. This involves injecting fluid into the submucosal space, making a mucosal incision to enter the submucosal space, and tunneling along the antrum to the pylorus. A myotomy is then performed, however, in BEAM the pyloric ring is spared and the myotomy is only performed in the antrum. The incision is then closed with clips. No endoscopic suturing will be performed.
224173113|NCT01430364|DEVICE|BIOSS LIM implantation|BIOSS LIM is a dedicated bifurcation stent system with sirolymus elution.
224173114|NCT01430364|DEVICE|BIOSS Lim|
224173115|NCT01430364|DEVICE|CarloS|
224173116|NCT01416506|OTHER|No Drug|It's a surveillance
224173117|NCT03667573|DEVICE|tsDCS Dosage (A)|mild electrical stimulation delivered to lumbosacral spinal cord
224173118|NCT03667573|DEVICE|tsDCS Dosage (B)|mild electrical stimulation delivered to lumbosacral spinal cord
224173119|NCT03667573|OTHER|textured shoe insoles|textured shoe insoles
223484542|NCT00463814|DRUG|AZD6244|Participants will receive single oral dose of AZD6244 as described in arm description.
223484543|NCT06955403|DEVICE|Precision 7 contact lenses|Acuvue Oaysis contact lens wearers have will be refit into precision 7 contact lenses.
223586018|NCT01329913|DRUG|Placebo to MK-6325|Two 100 mg capsules, orally, once per day for 7 days
223586019|NCT01329913|DRUG|MK-6325|Four 100 mg capsules, orally, once per day for 7 days
224173120|NCT04995666|DEVICE|Phonak Audeo hearing aid|Rechargeable hearing aid
224173121|NCT02491528|BIOLOGICAL|insulin Aspart injection|Subcutaneous injection of insulin Aspart prior to three meals every day, while subcutaneous injection of Lantus at bedtime.
223484544|NCT06025539|BEHAVIORAL|Animal-assisted resilience training|Participants take part in 12 sessions (120 minutes each), each session focuses on a topic that is related to resilience. The intervention takes part outdoors on a farm, and includes interactions with several different animals. The training takes place in small groups, and includes exercises, observations, and discussions.
224173122|NCT02491528|BIOLOGICAL|insulin Aspart injection (NovoRapid)|Subcutaneous injection of insulin Aspart injection (NovoRapid) prior to three meals every day, while subcutaneous injection of Lantus at bedtime.
224173123|NCT01756833|DRUG|Doxycycline|100 mg po bid
224173124|NCT01756833|DRUG|Placebo|capsule identical to the doxycycline capsule
224173125|NCT02664740|DRUG|Topical anti-Staphylococcus bacteriophage therapy|Patients randomized to the experimental arm will receive sterile compress dressings impregnated with a phage solution of 10\^7 PFU/ml on days 0, 7 and 14 (unless the wound is already healed, i.e. phage solutions are not applied to healed wounds).
223484545|NCT05119907|DRUG|Sacituzumab Govitecan-hziy|Administered intravenously
223484546|NCT05975216|OTHER|Contact the patient|Phone call, email or letter to contact the patient to relink them.
223484547|NCT06955598|DRUG|SHR-2173|SHR-2173
223484548|NCT06782542|DRUG|Olutasidenib|Olutasidenib will be supplied as 150 mg capsules to be administered orally, twice per day (BID) on an empty stomach (fasting at least 1 hour before or 2 hours after a meal), starting on Cycle 1 Day 1, and will be given continuously.
223484549|NCT06782542|DRUG|Venetoclax|"Participants will receive Venetoclax as a 100mg tablet to be self-administered orally with a meal and water once daily, two hours after starting Olutasidenib administration, starting on Cycle 1 Day 1. The dosing regimen of Venetoclax is as follows:~* Cycle 1: Days 1 - 21 over a 28-day cycle~* Cycle 1 Week 1: Ramp-up dosing schedule up to 400mg (4 x 100mg/tablet)~* For participants with blast clearance: Cycle 2 and beyond: Days 1 - 14 over a 28-day cycle~* For participants with persistent clearance: Cycle 2 through 4: Days 1 - 21"
223484550|NCT06782542|DRUG|Azacitidine|Participants will receive Azacitidine 75 mg/m2 per day via subcutaneous (SC) injection or intravenous (IV) infusion on Days 1-7 of each cycle.
223484551|NCT06274489|DRUG|Setanaxib|Setanaxib (formerly GKT137831) is a first-in-class inhibitor of the human protein NADPH NOX1/4. It is a low molecular weight organic molecule and a member of the pyrazolopyridine dione chemical class.
223586020|NCT01329913|DRUG|Placebo to MK-6325|Four 100 mg capsules, orally, once per day for 7 days
223586021|NCT01329913|DRUG|MK-6325|Eight 100 mg capsules, orally, once per day for 7 days
223586022|NCT01329913|DRUG|Placebo to MK-6325|Eight 100 mg capsules, orally, once per day for 7 days
223586023|NCT04903145|DIAGNOSTIC_TEST|REOM|To compare data generated by the REOM device with data from the tremoflo C-100 device
223586024|NCT03242018|DRUG|Placebo|Placebo tablet (identical to sotagliflozin 200 mg in appearance) orally, once daily.
223586025|NCT03242018|DRUG|Sotagliflozin|Sotagliflozin 200 mg, tablet, orally, once daily.
224173126|NCT02664740|DRUG|Topical placebo corresponding to anti-Staphylococcus bacteriophage therapy|Patients randomized to the placebo arm will receive sterile compress dressings impregnated with a placebo solution on days 0, 7 and 14 (unless the wound is already healed, i.e. placebo solutions are not applied to healed wounds).
224173127|NCT06661902|DRUG|Buffered Lidocaine (1% Lidocaine + 8.4% Sodium Bicarbonate, in a 3:1 ratio)|Given via injection
224173128|NCT06661902|DRUG|Lidocaine|Given via injection
224173129|NCT06661902|PROCEDURE|Biopsy of Prostate|Undergo SOC prostate biopsy
224173130|NCT06661902|OTHER|Questionnaire Administration|Ancillary studies
224205506|NCT02083588|DEVICE|dTMS|All subjects will receive prefrontal deep rTMS of H1 Coil (75 trains of 2 seconds, 20 Hz, with 20 seconds inter-train intervals, up to 120% of motor threshold, a total of 3000 pulses per session), for 4 weeks, 5 days a week, overall 20 sessions.
224205507|NCT02080533|OTHER|Slow-paced respiration therapy|The FDA-approved RESPeRATE device contains headphones and a sensor that attaches to the chest to detect inhalation and exhalation. Musical tones synchronize with the respiratory cycle to slowly guide the user to decrease respirations.
224305909|NCT02826538|DEVICE|standard procedure of fracture fixation|the standard procedure of fracure fixation for each fracture localisation is used as a standard of reference
223586026|NCT01290900|DRUG|NXL104|IV Solution
224205508|NCT00887107|DRUG|Sorafenib (nexavar)|6 months therapy with Sorafenib 800 mg/day
223484552|NCT06274489|DRUG|Placebo|Matching film-coated placebo tablets, containing only excipients
223586027|NCT01290900|DRUG|Ceftaroline|IV Solution
224173131|NCT03132129|DIAGNOSTIC_TEST|Cardiovascular magnetic resonance (CMR) imaging and magnetic resonance spectroscopy|CMR scanning performed on a 3T MRI scanner. Standardised protocol incorporating cine functional assessment to determine LV mass, systolic function and left atrial volumes; global systolic strain and diastolic strain rates will be assessed by tagging and with tissue tracking analysis from cine images, adenosine rest and stress myocardial perfusion to assess reserve index and qualitative perfusion defects as previously described, aortic distensibility and pulse wave velocity to measure aortic stiffness, delayed contrast enhancement for assessment of LV fibrosis and evidence of previous myocardial infarction. Myocardial and liver triglyceride content will be assessed using the modified Hepafat® sequence or 1H MR spectroscopy at the inter ventricular septum. DIXON technique for the quantification of visceral adiposity and subcutaneous adipose tissue.
224173132|NCT03132129|DIAGNOSTIC_TEST|Transthoracic echocardiography|Comprehensive transthoracic echocardiography, including: tissue Doppler indices of diastolic filling and speckle tracking for systolic and diastolic strain/strain rate, exclusion of valvular abnormalities, assessment of LV size and function.
224173133|NCT03132129|DIAGNOSTIC_TEST|Computed tomography coronary artery calcium scoring|Computed Tomography coronary calcium scoring to assess the presence of subclinical atherosclerosis and allow an estimate of atheroma burden in addition to epicardial adipose tissue characterisation and systolic strain.
224173134|NCT03132129|DIAGNOSTIC_TEST|Cardiopulmonary exercise testing|Physician supervised incremental symptom limited cardiopulmonary exercise tolerance test with ECG and haemodynamic monitoring.
224173135|NCT03132129|DIAGNOSTIC_TEST|Manganese-enhanced magnetic resonance imaging (MEMRI)|A subset of the participants will have cardiac MRI scanning with manganese-based contrast agent, lasting approximately 45-50 minutes. After localisers, baseline functions and native T1 maps have been acquired, Mangafodipir (0.1mL/kg) will be administered intravenously at 1ml/min, with additional T1 maps acquired every 2.5 min after administration of the contrast agent for up to 30 minutes.
224173136|NCT03132129|DIAGNOSTIC_TEST|Ambulatory blood pressure monitoring|A 24-hour blood pressure monitor will be worn at the end of the visit to the following day.
224173137|NCT03132129|DIAGNOSTIC_TEST|Accelerometer watch|Watch worn to collect free living physical activity data for 7 days.
223586028|NCT01290900|DRUG|Placebo Infusion|IV Saline
223484553|NCT05654012|DEVICE|MRI|Grey Matter Volume (T1) Resting state BOLD
223586029|NCT01290900|DRUG|Ceftazidime|IV Solution
223586030|NCT01290900|DRUG|Moxifloxacin|Tablet (1)
223586031|NCT06382935|OTHER|Probin Pocket Depth reduction|Probin Pocket Depth reduction in millimetres before and after treatment
223586032|NCT04280874|DRUG|Dinoprostone 0.5 MG|0.5mg dinoprostone applied intracervically
223586033|NCT04280874|DRUG|Dinoprostone 2 MG/2.5 ML Vaginal Gel/Jelly|2mg dinoprostone applied intravaginally
223586034|NCT04129710|DRUG|Ibrutinib|Ibrutinib 560 mg/day daily (starting dose) between days 4 and 28 of each cycle for six cycles. Then Ibrutinib is continued until disease progression, intolerable toxicity, death or up to two years.
223484554|NCT05654012|DEVICE|Thermal Stimuli|The Thermal Sensory Analyzer (TSA-II or PATHWAY platform - Medoc, Ramat Yishai, Israel) will be used to safely deliver heat and cold stimuli. These devices can deliver relatively complex stimuli via computer control. All targeted stimulus temperatures will be less than 50°C, and participants will be free to remove their arm or leg at any time from the thermode. Noxious cold stimuli will also be delivered with a plastic water container or a water bath (FISHER, USA). Participants will be free to pull out of the water bath at any time.
223484555|NCT05654012|DEVICE|Pressure stimuli|Pressure stimuli will be applied by using a handheld algometer (Wagner Instruments) or the Pressure Algometer (Medoc, Ramat Yishai, Israel). These devices have a round probe that allows quantifying the amount of pressure that is being applied. The Pressure Algometer allows a real-time visual feedback to control and monitor applied pressure rates. Pressure will be applied to the lower leg, volar forearm, or trapezius.
223484556|NCT05654012|BEHAVIORAL|Pain ratings|Pain intensity and pain unpleasantness ratings will be assessed by numerical rating scale (ranging from 0- no pain/unpleasantness to- 10 or 100 the most intense/unpleasantness pain imaginable) and by mechanical and computerized visual analog scales (VAS which ranges between ''no pain sensation'' and ''most intense pain imaginable'').
223484557|NCT05654012|BEHAVIORAL|Pressure pain thresholds (PPT)|Pressure will be increased continually and participants will be instructed to press a button the first moment they feel pain from the pressure stimulus.
223484558|NCT05654012|BEHAVIORAL|Conditioned pain modulation (CPM) efficiency|The CPM paradigm assesses endogenous inhibitory pain modulation efficiency related to spatial filtering of nociceptive information.
223586035|NCT04129710|DRUG|Lenalidomide|Oral lenalidomide 25mg/day between days 4 and 24 of each cycle for six cycles. Then lenalidomide is continued until disease progression, intolerable toxicity, death or up to two years.
223586036|NCT04129710|DRUG|Methotrexate|Methotrexate 3.5 g/m2 (0.5 g/m2 in 15 min + 3 g/m2 in 3-hr infusion) on day 1
223586037|NCT04129710|DRUG|Rituximab|Rituximab 375 mg/m2 conventional infusion on day 1
223586038|NCT04129710|DRUG|Etoposide|Etoposide 250 mg/m2 over 3 hours on day3
223586039|NCT04129710|DRUG|PEGylated recombinant human granulocyte colony|PEGylated recombinant human granulocyte colony 100 ug/kg subcutaneous injection on day 5.
223586040|NCT05883722|PROCEDURE|Catheter ablation|The ablation approach includes: pulmonary vein isolation, left side linear ablation, left side driver ablation and right atrial driver ablation
223617580|NCT03741153|DEVICE|slit lamp|"1. Presence of white grayish exfoliation material on the anterior lens capsule and / or the pupillary margin.~2. Poor pupillary dilatation due to atrophy of the dilator pupillae muscle.~3. The presence of pseudoexfoliative material (PXF)in cilliary processes and zonules.~4. presence of PXF material scattered on corneal endothelium.~5. Flecks of the exfoliative material on the anterior chamber which leads to glaucoma."
223617581|NCT06136780|OTHER|Free reading glasses immediately following surgery|Free reading glasses will be given immediately after cataract surgery in the intervention arm and four months after cataract surgery in the control arm.
223617582|NCT00157885|DRUG|Amodiaquine plus artesunate; Artekin|
224173138|NCT03132129|DIAGNOSTIC_TEST|Blood tests|Collection of blood samples from each participant to characterise the participant's health status and to develop a proteomic signature of early heart failure.
224173139|NCT03596320|PROCEDURE|colonoscopy|description of the results of colonoscopy im managment of children with rectal bleeding
224173140|NCT01697189|BEHAVIORAL|Fatigue management training|Experimental group took part in a single half-day (4 hours) fatigue management training grounded on Problem Based Learning (PBL).
224173141|NCT02984735|OTHER|Evaluation|Descriptive characteristics including age, height and weight were recorded. Chewing performance level was determined with the Karaduman Chewing Performance Scale (KCPS). Each child was placed in a sitting position (either on a chair or on his/her mother's arm) with the head upright and with the midline position and arms and legs supported, and required to bite and chew a standardized biscuit, and no clue was given on how to chew. The physical therapist rated the chewing performance according to the KCPS. All children underwent a physical examination by a physical therapist to determine gross motor function by applying the Gross Motor Function Classification System (GMFCS). In addition to GMFCS, number of affected limbs of the children was also noted.
224173142|NCT02147431|DRUG|semaglutide|"2 periods of 12 weeks of once weekly dosing with multiple doses of semaglutide, for subcutaneous (s.c., under the skin) injection, escalated up to 1.0 mg semaglutide.~Each treatment period will be followed by a hypoglycaemic clamp"
224173143|NCT02147431|DRUG|placebo|"2 periods of 12 weeks of once weekly dosing, subcutaneous (s.c., under the skin) injection.~Each treatment period will be followed by a hypoglycaemic clamp."
224173144|NCT01087073|BEHAVIORAL|Patient Activation|Culturally tailored patient activation training classes providing education and communication strategies to empower patients to be proactive in their diabetes self-management behavior. Participants attend a 10 week interactive class. Diabetes support groups after the completion of these classes help patient maintain self-management and adherence to healthy behaviors.
224305910|NCT02068664|BEHAVIORAL|prism adaptation treatment|Prism goggles shift the image one sees toward the left (because the thicker portion of the glass lens is on the right). This will change the perception of where the image is in space, causing the person to adapt. The after-effects of the treatment is what is important. It has been shown to make it easier for people to move in the right space (if have right neglect) or improves ability to complete other functional tasks.
224305911|NCT02903030|DRUG|Maltose (placebo)|Maltose with a trace amount of silicon dioxide
223484559|NCT05654012|DIAGNOSTIC_TEST|Hormonal assessment|Blood samples will be collected for analyses of sex hormone levels
223484560|NCT05654012|BEHAVIORAL|Migraine-related measures|Adolescents with migraine will complete questions regarding their headache frequency and migraine symptoms.
223484561|NCT05654012|BEHAVIORAL|Neural assessments|MRI and fMRI scans
223484562|NCT05654012|DIAGNOSTIC_TEST|Pubertal status|Pubertal status will be assessed using the self-reported Physical Developmental Scale-
223484563|NCT02903108|DRUG|SRP plus boric acid gel|SRP followed by 0.75% boric acid placement into intrabony defect
223484564|NCT02903108|DRUG|SRP plus placebo gel|SRP followed by placebo gel placement into intrabony defect
224173145|NCT01087073|BEHAVIORAL|Provider Training|Provider patient-centered communication training focuses on cultural competency and communication skills training to aid in shared decision-making and tailoring treatment recommendations to the patient's cultural preferences and readiness. Providers attend 4 1-hour monthly modules and one booster workshop 3 months post-class.
224305912|NCT02903030|DRUG|Visbiome Extra Strength|It is a mix of 8 strains of beneficial bacteria that should improve gut flora, improving GI function and hopefully anxiety
224305913|NCT00253695|DEVICE|Wrist Actigraphy|Wrist actigraph will record participants' sleeping patterns.
224305914|NCT03309995|DEVICE|Lozenges|The participants will be instructed to take 6 lozenges daily over the time awake, evenly distributed, allowing the lozenge to dissolve in the mouth as slowly as possible.
224305915|NCT03309995|DEVICE|Placebo lozenges|Placebo lozenges
224305916|NCT06299930|PROCEDURE|Neoadjuvant chemotherapy|Patients received neoadjuvant chemotherapy (either taxane-or anthracycline-based, or any cytotoxic chemotherapy) , followed by surgery and radiotherapy
224305917|NCT06299930|PROCEDURE|Adjuvant chemotherapy|Patients received adjuvant chemotherapy (either taxane-or anthracycline-based, or any cytotoxic chemotherapy) after surgery, followed by radiotherapy
224305918|NCT03582748|PROCEDURE|sleeve gastrectomy|removal of most of stomach as a bariatric surgical procedure
224305919|NCT03582748|PROCEDURE|No sleeve gastrectomy|Non-receipt of sleeve gastrectomy procedure
224305920|NCT05176795|OTHER|Stool sample|Comparaison of the gut microbiota composition
224305921|NCT00125840|DRUG|clofarabine (IV formulation)|
224305922|NCT05984186|DEVICE|High Velocity Therapy|FiO2=100% with Flow=5LPM FiO2=21% with Flow=25-35LPM FiO2=100% with Flow=25-35LPM FiO2=21% with Flow=5LPM
224305923|NCT04113863|DRUG|all-trans retinoic acid|Vesanoid will be supplied orally at the total dosage of 45mg/m2/d (two daily administrations of 22.5 mg/m2 each). Treatment will last 28 days
224305924|NCT04113863|DRUG|Anastrozole 1mg|Anastrozole will be administered orally at the dosage of 1 mg/die.
223484565|NCT03737994|DRUG|Alectinib|Given PO
223484566|NCT03737994|DRUG|Brigatinib|Given PO
223484567|NCT03737994|DRUG|Carboplatin|Given IV
223484568|NCT03737994|DRUG|Ceritinib|Given PO
223484569|NCT03737994|DRUG|Cisplatin|Given IV
223617583|NCT06327698|DRUG|Cadonilimab|Injectable solution
223617584|NCT06327698|DRUG|anlotinib|capsule
223484570|NCT03737994|DRUG|Crizotinib|Given PO
223484571|NCT03737994|DRUG|Ensartinib|Given PO
223484572|NCT03737994|DRUG|Lorlatinib|Given PO
223484573|NCT03737994|DRUG|Pemetrexed|Given IV
223617585|NCT02933788|DRUG|Cilostazol|Cilostazol sustained release capsule is new drugs developed by Otsuka Korea. This drugs have platelet aggregation inhibiting action, peripheral vasodilating action and endothelial function improving action.
224305925|NCT04074629|DIAGNOSTIC_TEST|Diagnosis, skin volatile organic compounds (VOCs)|"The skin related VOCs will be collected by off-line method using Polydimethylsiloxane (PDMS) patches from different body locations for sensor system and\\or GC-MS analysis"
224305926|NCT05101681|DIAGNOSTIC_TEST|Teledentistry|Teledentistry using mobile photographs
223586041|NCT06256146|OTHER|Food allergy desensitization / Oral Immunotherapy|"Participants consume increasing doses of allergenic food daily until they reach a maintenance dose. In the case of the High Dose Arm, participants will progress to a daily dose of either 1200 mg, 300 mg or 200 ml of egg, peanut or milk respectively.~Participants randomized to the Low Dose Arm also begin by consuming small amounts of the allergenic food, gradually increasing the daily dose. However, participants in this group only progress to 300 ml, 30 mg or 50 ml daily dose of egg, peanut or milk respectively.~The Cooked/Transformed Allergen Arm begins the desensitization with a cooked or transformed form of the allergen - muffins in the case of egg or milk, Bamba puffs in the case of peanut. Participants take increasing amounts of these products (one muffin for egg and milk and four Bamba puffs for peanut) then transition to egg, milk or peanut. Participants then continue their dose progression, getting to 1200 mg, 200 ml or 300 mg for egg, milk and peanut respectively."
223586042|NCT00348894|DRUG|[S,S]-Reboxetine|\[S,S\]-reboxetine
223586043|NCT00348894|DRUG|Any|Any standard of care treatment for DPN
223586044|NCT01171586|BEHAVIORAL|mDiet|"The goals of the intervention groups (SMS-only and SMS plus phone counseling) include: 5% weight loss, 500 k/cal per day deficit through reduced caloric intake and increased energy expenditure, 12,00 steps through the use of a pedometer, and a reduction in sedentary behaviors. Participants will receive daily pushed and pulled text messages, self-monitoring tools, and brief health promotion printed or wed materials on physical activity, nutrition, or other weight loss related topics."
224173146|NCT01087073|BEHAVIORAL|Quality Improvement|Participating clinics participate in quality improvement (QI) programs which aim to redesign clinic operations to improve care for diabetes patients. QI initiatives have included instituting group visits, patient medication cards, peer support groups, flow sheets, nurse case management, and patient registries. New initiatives include improving access and tracking of specialists visits, employing community health workers/patient navigators, coordinating care, and implementing other team-based care initiatives. Provider and clinical staff members from all six project clinics attend collaborative quarterly QI sessions with project staff to discuss improvements in QI efforts, share QI methods among clinic teams, and provide brief training sessions.
224173147|NCT01087073|BEHAVIORAL|Community Outreach|The project collaborates with many community based organizations and resources to reach out to communities at high risk for diabetes on the South Side of Chicago and facilitate diabetes education, particularly in the area of nutrition and physical activity. We provide monthly health education events, nutrition tours, and frequently participate in community-based health fairs and health promotion events. We also work to promote nutrition through the Food Rx program, which utilizes a prescription to link patients at our clinics with nutrition resources on the South Side of Chicago through a coupon that gives discounts towards healthy purchases at participating stores, and have initiated a 10-week fitness program to promote physical activity among minority patients with diabetes.
224305927|NCT05456555|PROCEDURE|Flapless with Enamel Matrix Derivatives (EMD)|Experimental sites will receive a closed non-surgical treatment with a combined use of minicurettes and ultrasonic instruments with thin and delicate tips. Teeth will be instrumented until no residual calculus could be detected. A visualization of the root surface will be accomplished under magnification by using dental loups 4.0X. In the test group, the roots will be conditioned with 24% ethylenediaminetetraacetic acid (EDTA) for 2 minutes. After rinsing with sterile saline, enamel matrix derivatives (EMD) will be applied on the dried root surface.
223484574|NCT02340325|DRUG|Acute Application of kynurenic acid cream|Pouches containing 0.00% (placebo), 0.15%, 0.25%, 0.4% and 0.5% of FS2 will be randomly applied to an occlusive, transparent dressing (Tegaderm) and applied to each test area. The pouch order will be random, generated by the www.random.org list generator each application. The study team member applying the cream will randomly choose the application sites of different concentrations of the FS2 creams and mark the corresponding cream code name on a separate sheet. This study member will not be evaluating the results and the evaluating study member will be blinded to the randomization. Patients will be evaluated at 24 hours post application for skin reactions and adverse reactions by a blinded observer recorded. Before and after photographs will be taken.
224305928|NCT05456555|PROCEDURE|Flapless without Enamel Matrix Derivatives (EMD)|Experimental sites will receive a closed non-surgical treatment with a combined use of minicurettes and ultrasonic instruments with thin and delicate tips. Teeth will be instrumented until no residual calculus could be detected. A visualization of the root surface will be accomplished under magnification by using dental loups 4.0X. No adjunct will be administered.
223586045|NCT03532217|BIOLOGICAL|PROSTVAC-V|-Replication-competent vaccinia virus which has been engineered to encode the sequences for a modified human prostate-specific antigen (PSA) and a triad of co-stimulatory molecules (TRICOM)
223586046|NCT03532217|BIOLOGICAL|PROSTVAC-F|-Fowlpox virus which does not replicate in human cells and has been engineered to encode the same sequences present in PROSTVAC-V.
223586047|NCT03532217|DRUG|Nivolumab|-Nivolumab is a human monoclonal antibody (mAb)
223586048|NCT03532217|DRUG|Ipilimumab|-Ipilimumab is a mAb blocking the inhibitory signal mediated by cytotoxic T Lymphocyte-associated antigen 4 (CTLA-4), a protein receptor that downregulates the immune system.
223586049|NCT03532217|BIOLOGICAL|Neoantigen DNA vaccine|Each DNA vaccination will be 1 mL vaccine administered intramuscularly. At each vaccination time point, patients will receive two injections at separate sites.
224305929|NCT05585879|DEVICE|Pure-Vu EVS|"Subjects will be enrolled until 115 inadequate bowel prep cases via SOC are accrued and subsequently treated with Pure-Vu EVS. Inadequate OCs defined as such if any of the following are met:~* Boston Bowel Preparation Score (BBPS) \< 6 (Adequacy is defined as BBPS of 2 or greater in each segment)~* Inability to identify \> 5mm polyps"
224305930|NCT02553759|OTHER|Actions observed|Patients observed movements without realize them. After this actions, movements will be imagined by patients
224305931|NCT00261092|DRUG|Oxaliplatin|
224305932|NCT01354379|BIOLOGICAL|NB-1008|NB-1008 is composed of Fluzone containing 15 micrograms (mcg) of strain-specific hemagglutinin (HA) and 20% W805EC adjuvant.
224305933|NCT01354379|BIOLOGICAL|Fluzone IN|The active control is Fluzone containing 15 micrograms (mcg) of strain-specific hemagglutinin (HA).
224305934|NCT05253963|DEVICE|Continuous Positive Airway Pressure|Continuous Positive Airway Pressure will be used during the second night of polysomnography .
224305935|NCT02205190|DRUG|Fimasartan|
223586050|NCT03532217|DEVICE|TriGrid Delivery System|-Electroporation device
223586051|NCT03532217|PROCEDURE|Tumor biopsy|-Pre-treatment, post-treatment A (optional), and end of treatment
224173148|NCT04093401|OTHER|individualized risk assessment|Individualized risk assessment of developing a second basal cell carcinoma
223484575|NCT02340325|DRUG|Chronic application of kynurenic acid cream|Volunteers will be educated how to apply a pouch of cream to an occlusive, transparent dressing (Tegaderm) and place it on the test site every 24 hours for 30 days. The date and time of first application will be recorded. Baseline urine and serum measurements of drug concentration (presumed absent), as well as complete blood count, liver enzymes, blood urea nitrogen, and creatinine will be taken on Day 0 (the initial enrollment of each part). The volunteers will be seen in follow-up at day 1, day 5, day 15, and day 30
223484576|NCT03846479|DRUG|Itacitinib|for up to 56 days
223484577|NCT04599140|DRUG|CXCR1/2 Inhibitor SX-682|Given PO
223484578|NCT04599140|BIOLOGICAL|Nivolumab|Given IV
223484579|NCT04661228|DIAGNOSTIC_TEST|Composite International Diagnostic Interview 5th version (CIDI 5.0)|Observational study assessing prevalence of mental and substance use disorders in the general population
223484580|NCT00001956|PROCEDURE|Blood draw|
223484581|NCT00001956|PROCEDURE|Oral surgery|
223484582|NCT00001956|PROCEDURE|Tissue biopsy|
223484583|NCT02806076|PROCEDURE|No-touch RFA arm|No-touch RFA arm indicates RFA procedure without direct tumor puncture. In this study, RFA is done by using dual cooled electrode.
223484584|NCT02806076|PROCEDURE|Conventional tumor puncture RFA arm|"Conventional tumor puncture RFA arm indicates RFA procedure using conventional tumor puncture technique. In this study, RFA is done by using dual cooled electrode."
223484585|NCT05536908|BEHAVIORAL|Residential Written Exposure Therapy|Residential Written Exposure Therapy (resWET): TAU plus 5-individual WET sessions (40-60 min each; Marx \& Sloan, 2019) twice a week for two weeks and once a week for the final session, administered by WET trained psychologists, social workers, or postdoctoral residents. Treatment instructions are read, patients write for 30 minutes, and the writing is briefly processed. No formal written homework is required.
223484586|NCT05536908|BEHAVIORAL|Treatment as Usual|Treatment as Usual (DOM SUD): The DOM SUD (TAU) is a 24-bed intensive SUD residential program with a typical 28-day length of stay. The program focuses on evidence-based treatments for SUD such as Cognitive-Behavioral Therapy, Motivational Enhancement Therapy, Medication Assisted Treatment, and Contingency Management therapy. Patients diagnosed with PTSD are typically referred to outpatient PTSD treatment following DOM SUD and often attend Seeking Safety during the program. Most of the programming is group-based though Veterans also have weekly individual case management appointments.
223484587|NCT01473134|DEVICE|Oxford Cementless Partial Knee|Oxford Partial Knee applied without bone cement.
223484588|NCT01473134|DEVICE|Oxford Cemented Partial Knee|Oxford Partial Knee applied with bone cement.
223484589|NCT05194930|BEHAVIORAL|The ABC of Insomnia (Acceptance and the Behavioral Changes to treat Insomnia)|5 individual sessions incorporating behavioral treatment components plus acceptance and commitment therapy (ACT) provided by a trained instructor.
223484590|NCT05194930|BEHAVIORAL|Cognitive-Behavioral Therapy for Insomnia|5 individual sessions incorporating behavioral and cognitive therapy components with a trained instructor.
223484591|NCT05651256|DRUG|Botulinum toxin type A injection|The solution for injection was prepared immediately before the intervention, by dissolving the vials of BTX, kept refrigerated at 5ºC, in 1 ml of sterile saline solution at room temperature. Eight injection sites were marked, three located in the masseter muscle, two in the lateral pterygoid muscle, one in the temporomandibular joint (TMJ) and two in the temporalis muscle. A 1 cc marked insulin syringe was used for intramuscular injection of the prepared solution, according to the locations and amounts proposed by Kim et al. and Ho et al. with a total dose of 100 U in each patient.distributed at the different injection sites.
223484592|NCT05944718|DEVICE|Continuous glucose monitor|"Continuous Glucose Monitoring (CGM) is a technology used to measure glucose levels in people with diabetes. Unlike traditional finger prick self-monitoring of blood glucose (SMBG), CGM devices provide continuous and real-time glucose readings throughout the day and night.~CGM systems consist of a small sensor that is inserted under the skin to measure glucose levels in the interstitial fluid, a transmitter that sends the glucose data to a receiver or smartphone, which shows the glucose readings. The sensor measures glucose levels automatically at regular intervals, eliminating the need for frequent finger pricks.~CGM devices can track glucose trends, identify high or low glucose levels, and provide alerts for hypo- or hyperglycemia. This can help individuals make more informed decisions regarding their diabetes management, such as adjusting insulin doses, dietary choices, or physical activity levels."
223484593|NCT03643848|BEHAVIORAL|Sleep with Sound Cues|Experimental manipulation to observe effects on memory for learned material.
223484594|NCT03643848|BEHAVIORAL|Sleep with Sham Cues|Sham manipulation
223484595|NCT06957275|PROCEDURE|Nasal packing|group c will not receive pharyngeal packing
223484596|NCT06957275|PROCEDURE|Nasal packing|Group (P): will include the patients who will receive pharyngeal packing
224173149|NCT04025749|BEHAVIORAL|Computerized Executive Functions training|Home-based executive function training with adaptive difficulty, through NeuronUp (https://www.neuronup.com) over 12 weeks (30 min/day, 5 days per week, 30h in total).
224173150|NCT04025749|OTHER|Care as usual|Care as usual
224173151|NCT00886587|DEVICE|F# 11054-010|Apply 3 times daily (or as needed) on all body areas, including the affected areas of the body and face throughout duration of study. Massage gently into skin.
224173152|NCT00886587|DEVICE|F# 10495-053|Apply 3 times daily (or as needed) on all body areas, including the affected areas of the body and face throughout duration of study. Massage gently into skin.
224173153|NCT00043199|DRUG|Aroplatin (Liposomal NDDP, L-NDDP)|
224173154|NCT00231491|DRUG|Botulinum Toxin A (Botox )|
224173155|NCT04568629|OTHER|Advice from the PiPS-B14 prognostic tool|"Participants were informed that prognostic advice came from the PiPS-B14 prognostic tool. PiPS-B14 is a validated prognostic algorithm that has been shown to be as accurate as an agreed multi-professional survival estimate.~Participants were further informed that in a previous study the PiPS-B14 risk categories for predicting two-week survival were as accurate as a doctor's or a nurse's prediction."
224173156|NCT04568629|OTHER|Advice from another clinician|"Participants were informed that prognostic advice came from another clinician.~Doctors were told that advice was from a nurse, whereas nurses or other types of HCPs were told that advice was from a doctor."
224305936|NCT02205190|DRUG|Rosuvastatin|
224305937|NCT02205190|DRUG|Fimasartan/Rosuvastatin combination|
224305938|NCT02068235|DRUG|Ponesimod 5mg i.v.|
223745178|NCT05920577|OTHER|Resistance training|The resistance training programme consists of 2 parts, the upper limb and lower limb resistance exercises. For the upper limb resistance exercises, the participants will first practice 5-minute warm up of upper limb using ergometer and then undergo 2 resistance exercises, including handgrip and elbow flexion. For the lower limb exercise, the participants will also first practice 5-minute warm up of lower limb using ergometer and then undergo 3 resistance exercises, including squatting, single-leg standing and knee extension.
224173157|NCT04491331|PROCEDURE|prone position|Unsupported prone position with arms along the body in neutral position will be used first without any supportive device except support of heels with a soft cylindrical device, head will be held in a neutral position using prone head rest. After recording of all measered values, the prone position using the prone position support system will be tested. The support system allows free movement of the lower thorax and abdomenal wall, upper arms are elevated and angled in 90 degrees (in shoulders and elbows). Heels will be positioned at the level of the heart using a supportive cylindrical device. Head will be held in a neutral position using prone head rest.
224173158|NCT05348499|OTHER|Questionnaire/Interview|Questionnaire/Interview
224173159|NCT02795182|DRUG|Zanubrutinib|
224173160|NCT02795182|DRUG|Tislelizumab|
224173161|NCT01365715|PROCEDURE|Arteriography and preoperative embolization|Arteriography and transcatheter arterial embolization of spinal metastasis/metastases 0-48 hours prior to surgery.
224173162|NCT01365715|PROCEDURE|Arteriography|Arteriography of spinal metastasis/metastases without transcatheter arterial embolization prior to surgery.
224173163|NCT04313309|OTHER|Integrative Yoga Therapy|Individualised intervention developed, consists of a six one to one sessions with patients, followed by home self practiced sessions. The intervention includes yoga movements, yoga breathing, relaxation techniques, reasoning, and other techniques designed to enhance awareness and acceptance of the psychological factors underlying the chronic pain problem.
224173164|NCT04107935|BEHAVIORAL|TREAT-ON|"TREAT-ON is a DE-driven self-management and support program that is delivered primarily through a real-time telemedicine videoconferencing platform. Like the usual care intervention, high risk patients with DM receiving care in underserved practices will be identified by a nurse practice-based manager (PCBM) and referred to a DE for self management services. Participants will complete an initial face-to-face visit with the DE to assess needs and develop a self-management treatment plan and goals. Via telemedicine videoconferencing, follow-up visits will be delivered by the DE to participants in their homes. Follow-up visits will be used to evaluate and support progress towards meeting and sustaining self-management goals and outcomes."
224173165|NCT04107935|BEHAVIORAL|Usual Care|"A retrospective control group will be formed from individuals who have previously participated in a program called the Diabetes High Risk Initiative. In this program, patients receiving care in underserved practices are identified by a nurse PBCM to be at high risk for DM complications and/or unplanned care and referred to a DE for self management services delivered through primary care. Patients typically participate in one face-to-face visit with the DE to assess needs and develop self-management goals and then one to two follow-up encounters (generally conducted by telephone) with the PBCM or DE."
224173166|NCT00619216|DRUG|Mycophenolic Acid (Myfortic)|Equimolar conversion from mycophenolate mofetil to mycophenolic acid
224173167|NCT04155190|DRUG|Patidegib Topical Gel, 2%|Patidegib Topical Gel, 2%
224173168|NCT04155190|DRUG|Patidegib Topical Gel, Vehicle|Patidegib Topical Gel, Vehicle
224173169|NCT00398086|DRUG|Gemcitabine|Administered by intravenous infusion over 30 minutes.
224173170|NCT00398086|DRUG|Albumin-bound paclitaxel|Administered by intravenous infusion over 30 minutes.
224173171|NCT02846766|DRUG|Lenvatinib|Lenvatinib is administered orally at a starting dose of 24 mg per day. Lenvatinib is administered in cycles of 28 days.
224305939|NCT02068235|DRUG|Ponesimod i.v.|Dose and infusion rate will be adjusted according to the results of the pilot phase
224305940|NCT02068235|DRUG|Ponesimod 10 mg tablet|
224305941|NCT01509703|PROCEDURE|High flow therapy|Each patient is treated with nasal high flow at different flow rates (15, 30, 45L/min). The order of flow rates is randomized. Each flow rate will be used for 15 minutes. A wash out time of ten minutes is planned after each phase, during which the patient uses his his individual oxygen flow.
224305942|NCT00003602|DRUG|cytarabine|
224305943|NCT00003602|DRUG|etoposide|
224305944|NCT00003602|DRUG|idarubicin|
224305945|NCT00003602|DRUG|mitoxantrone hydrochloride|
224305946|NCT02478203|DEVICE|Airtraq|videolaryngoscope for difficult airway
224305947|NCT02478203|DEVICE|Glidescope|videolaryngoscope for difficult airway
224305948|NCT02478203|DEVICE|direct laryngoscopy|gold standart for intubation
224305949|NCT06232798|OTHER|a dual energy catheter (RF and PFA) or PFA catheter only will be to treat PeAF,Cardiac Pulsed Electric Field Ablation Catheter|This study will be used two catheters, the contact force sensing catheter able to deliver both RF and PFA energy, this catheter provides both the radiofrequency (RF) energy and pulsed field ablation (PFA) energy to the catheter through the toggling of the two energy sources on the generator monitor. Another catheter is PFA catheter only.
223484597|NCT01566370|DRUG|Zonisamide|titration of dose to 500mg oral, daily, over 8 weeks, then 6 weeks of treatment at that dose
223484598|NCT01566370|DRUG|Placebo|placebo
223484599|NCT06244160|OTHER|High flow oxygen therapy|High flow oxygen therapy delivered via nasal cannulae, at 50 litres flow with variable oxygen levels
223484600|NCT05461209|DRUG|Talquetamab|Talquetamab will be administered as subcutaneous injection.
223484601|NCT05461209|DRUG|Belantamab Mafodotin|Belantamab Mafodotin will be administered as intravenous infusion.
223484602|NCT06098846|DIETARY_SUPPLEMENT|Vitamin D phosphate|Application of a Vitamin D phosphate active patch
223484603|NCT06098846|DIETARY_SUPPLEMENT|Placebo transdermal patch|Application of a placebo transdermal patch
223484604|NCT06956586|OTHER|Therapeutic communication techniques|"Therapeutic communication techniques will be applied to children in the intensive care unit for two days."
223484605|NCT03147612|BIOLOGICAL|Blinatumomab|Given via central catheter
223484606|NCT03147612|DRUG|Cyclophosphamide|Given IV
223484607|NCT03147612|DRUG|Cytarabine|Given intrathecally or IV
223484608|NCT03147612|BIOLOGICAL|Filgrastim|Given SC
223484609|NCT03147612|DRUG|Methotrexate|Given intrathecally or IV
223484610|NCT03147612|BIOLOGICAL|Pegfilgrastim|Given SC
223484611|NCT03147612|DRUG|Ponatinib|Given PO
224173172|NCT01406366|BEHAVIORAL|Group 1: Bright Futures Oral Health Curriculum|Residents who are randomized to Group 1 will receive a resident curriculum that exposes them to Bright Futures concepts of health promotion, including partnership building, communication and oral health. Group 1 residents will complete 7 modules, 3 on Bright Futures concepts (health, partnership building and communication), and 4 on oral health promotion. These modules have been developed in collaboration with the Pediatrics in Practice workgroup and the Open Wide modules endorsed by the American Academy of Pediatrics and the Maternal and Child Health Bureau. The oral health modules address dental caries development and prevention, importance of identifying maternal oral health status, duration of bottle-feeding or breastfeeding and discouraging both during sleep.
224173173|NCT01406366|BEHAVIORAL|Group 2: Iron Deficiency Training Module|Our study team opted to include a single 1-hour educational module addressing the identification and prevention of iron deficiency created by the AAP on Pedialink® to the active control group. This educational module addresses screening for and assessing risk for iron deficiency.
224305950|NCT06232798|OTHER|catheter ablation|catheter ablation
224305951|NCT02598687|DRUG|TH-302|TH-302 day 4 (pre-treatment) and weekly during chemo-radiotherapy (CRT)
223484612|NCT03147612|BIOLOGICAL|Rituximab|Given IV
223484613|NCT03147612|DRUG|Vincristine|Given IV
223484614|NCT05231668|DRUG|SAR439459|Powder for solution for infusion; IV infusion
223484615|NCT05231668|DRUG|Placebo|Solution for infusion; IV infusion
223484616|NCT04570410|PROCEDURE|primary focal resection plus lymph node dissection|Primary radical resection plus lymph node dissection was performed in patients with oligometastatic urothelial carcinoma
223484617|NCT04570410|DRUG|Tislelizumab|Tislelizumab IV infusion of 200 mg Q3W
223484618|NCT04570410|DRUG|Gemcitabine plus cisplatin|GC (Gemcitabine plus cisplatin): Gemcitabine 1000mg/m2 D1,D8 iv every 3 weeks Cisplatin70mg/m2,D2,3,4 iv every 3 weeks
223484619|NCT05913804|BIOLOGICAL|YTS104 Cells injection|YTS104 Cell injection(LILRB4 dual STAR-T Cell Injection/BCMA LILRB4 Dual STAR-T Cell Injection)) is a new STAR-T cell transfected by lentivirus.The study required that lymphocytes were collected from the subjects and cultured for 2-3 weeks to obtain YTS104 cell injection. Subjects were treated with fludarabine and cyclophosphamide chemotherapy prior to reinfusion, followed by a 2-day rest period before cell infusion.
223484620|NCT06023563|DEVICE|Virtual reality active video gaming using Nintendo switch sports|Playing 2 pre-selected VR active video games from beach tennis, soccer, volleyball, badminton, bowling, and chambara for 10 minutes each with a 5 minute break in-between. Total duration 30-40 minutes.
223484621|NCT06023563|BEHAVIORAL|Standard physical therapy balance exercises|Balance exercises: Standing with feet together for 10 seconds 5 times, standing with 1 foot in front of other for 10 seconds 5 times on both sides, standing on one leg for 10 seconds 5 times on both sides, walking with one foot in front of other on a 1-meter-long line for 5 repetitions and standing on a balance board for 30 seconds for 3 repetitions. 5 minutes each of warm-up and cool down exercises. Total duration 20-30 minutes.
223484622|NCT06320652|OTHER|Cardiac telerehabilitation (video consultation and home monitoring)|Patients with cardiac disease and earlier experiences with cardiac rehabilitation, family members, and nurses in the Departments of Cardiology at Amager and Hvidovre Hospital will be invited to work in a partnership and through a course of innovative co-creative workshops. It is recommended that usability studies have 5-15 participants, which is why we plan to enroll 3 cardiac patients, 3 relatives and 3 nurses from the outpatient clinic. Through the workshops, a rehabilitation program offering cardiac telerehabilitation will be co-created to comply with the preferences and perspectives of patients and family members and nurses from the outpatient clinic. Through these workshops we will learn which important components and elements should be prioritized when offering cardiac telerehabilitation (how, when, and why?).
223484623|NCT05020015|BIOLOGICAL|TAK-007|TAK-007 intravenous injection.
223484624|NCT05020015|DRUG|Chemotherapy Agents|Fludarabine and cyclophosphamide as per standard of care.
223484625|NCT05612490|DRUG|Furosemide stress test|The FST corresponds to the intravenous single-dose administration of 1 mg/kg (1.5 mg/kg in previously exposed patients) of furosemide and the assessment of resulting diuresis in the following two hours. In the 12 hours following the first RRT liberation, a FST will be performed. The test will be considered positive if urinary output is ≥200 mL in the two hours following furosemide administration.
223484626|NCT04864054|BIOLOGICAL|ECT204 T cells|ECT204 is an autologous T-cell therapy whereby a subject's own T cells are transduced with a lentiviral vector expressing the ECT204 transgene.
223484627|NCT04864054|DRUG|Regorafenib (STIVARGA®, BAY73-4506)|Regorafenib pretreatment before an ECT204 infusion.
223586052|NCT03532217|PROCEDURE|Peripheral blood|-At the time of pre-treatment biopsy, mid-treatment of chemo-ADT, at time of enrollment (prior to POSTVAC administration), mid-treatment A, mid-treatment B (multiple)
223586053|NCT03532217|PROCEDURE|Fecal samples|-Post chemo/pre-treatment A, post-treatment A, pre-treatment B, post-treatment B
223586054|NCT03532217|PROCEDURE|Leukapheresis|"* Post-treatment A/pre-treatment B~* Mid-Treatment B, after Cycle 9 Day 1 and prior to Cycle 10 Day 1~* End of treatment"
223586055|NCT02282904|DRUG|Sirolimus|"For pediatric patients: Begin sirolimus 1 mg/m2 PO q4h for 3 doses, then 1 mg/m2 once a day (QD). For adult patients, begin sirolimus 5 mg PO q4h for 3 doses, then 5 mg once a day (QD).~Doses may be adjusted to maintain trough levels between 8-14 ng/ml. Recipients will take sirolimus from Day +5 to at least Day 100 (minimum)."
223586056|NCT02282904|BIOLOGICAL|Donor peripheral blood stem cells.|Infuse donor graft.
223586057|NCT02282904|DRUG|Cyclophosphamide post transplant|50 mg/kg/d IV infused over 90 minutes. Day +3 and +4
223586058|NCT02282904|RADIATION|Total body 200cGy|Day -1
224305952|NCT02598687|OTHER|HX4 scan|HX 4 scan day 1 and day 8
224305953|NCT02598687|DRUG|Carboplatin|2mg/ml/min
224305954|NCT02598687|DRUG|Paclitaxel|50 mg/m2
223586059|NCT02282904|DRUG|Cyclophosphamide|14.5 mg/kg IV over one hour Day -6 and -5
223586060|NCT02282904|DRUG|Fludarabine|30 mg/m2 over 30 minutes Day -6 through Day -2
223586061|NCT02282904|DRUG|Busulfan|Busulfan 3.2 mg/kg IV once daily over 2-3 hours Day -4,-3,-2
223617586|NCT02933788|DRUG|Acetylsalicylic acid|Aspirin may prevent coronary thrombosis in patients with cardiovascular event risk factors, such as ischemic heart disease family history, hypertension, diabetes mellitus, dyslipidemia and obesity.
224305955|NCT02598687|RADIATION|Radiotherapy|23 x 1.8 Gy
223484628|NCT03994159|DEVICE|"Use of the PARO emotional robot"|PARO is an advanced interactive therapeutic robot designed to stimulate patients with Dementia, Alzheimer's, and other cognition disorders.
223484629|NCT02921100|PROCEDURE|cytology|The conventional cytology was interpreted independently by two cytopathologists, both of whom are blinded to the DIA results. The conventional cytologic diagnosis were classified as no abnormal cells, atypical cells, suspicious malignant cells and malignant cells.
223484630|NCT02921100|PROCEDURE|DNA ploidy|DIA is a form of cytologic analysis that quantifies cellular constituents by using spectro photometric principles and a sister technique to flow cytometry.Quantification of DNA content, chromatin distribution, and nuclear morphology can be determined and suggest features of malignancy
224173174|NCT05260476|OTHER|Reablement|The service provider customizes a training plan and formulates training goals based on the patient's level of disability, family environment, and the needs of the patient and the caregiver.
224173175|NCT01738724|DRUG|Dienogest|Dienogest 2mg pills daily during 6 months
224173176|NCT01738724|DRUG|Goserelin|Goserelin 10.8mg preloaded syringe subcutaneously at the start of the study and after 3 months
224173177|NCT01738724|DRUG|Desogestrel|Desogestrel 75mcg pills daily during six months
224173178|NCT00095134|DRUG|risperidone|
224173179|NCT02744781|DEVICE|Lumbar disc degeneration; LDD|All MR images, taken at 5 lumbar intervertebral disc levels from the first lumbar (L1) vertebra to the first sacral vertebra (S1), were independently evaluated by 2 experienced orthopedic specialists in a random order using a grading system for LDD assessment. Using a comprehensive grading system for LDD, discs were classified into 5 grades, as described by Pfirrman et al. This system uses characteristics of disc structure, distinction between the nucleus and annulus, MRI signal intensity, and intervertebral disc height for grading, and has been accepted as a standardized and reliable evaluation tool for assessment of MRI disc morphology.
224173180|NCT00396344|OTHER|Çontrol|Intravenous saline
224173181|NCT00396344|DRUG|Hydrocortisone|Intravenous stress dose of hydrocortisone
224173182|NCT00396344|DRUG|Hydrocortisone|Intravenous pharmacologic hydrocortisone
224173183|NCT04853264|DEVICE|Ultrasound-guided peripheral venipuncture|Ultrasound-guided peripheral venipuncture performed by a proficient vascular access registered nurse. The procedure will be performed according to the standard operational protocol for ultrasound guided peripheral venipuncture instituted at the hospital where the study will be conducted. Site Rite 8 or Site Rite 5 ultrasound machines (Bard Access Systems, Inc., USA) will be used on the procedures.
224173184|NCT04853264|DEVICE|Conventional peripheral venipuncture|Conventional peripheral venipuncture performed by a registered nurse at the clinical inpatient unit. The procedure will be performed according to the standard operational protocol for peripheral venipuncture instituted in the hospital where the study will be conducted.
223484631|NCT02921100|PROCEDURE|EUS-FNA|All the enrolled participants underwent an operation of EUS-guided fine needle aspiration. Histological and cytological samples were obtained following this step.
223484632|NCT02921100|DEVICE|EUS-guided fine needle|
223617587|NCT04745364|BEHAVIORAL|A 4-week Bharatanatyam course from the organization Mindful Kala|The 4-week Mindful Kala program focuses on three components of Bharatanatyam: nritta (i.e. technical movements), natya (i.e. storytelling), and nritya (i.e. a combination of movements and narration; nritta + natya).
224173185|NCT03938558|OTHER|MS-Dance|The experimental group will perform 10 weeks of dance training
224305956|NCT02598687|PROCEDURE|surgery|minimally invasive transhiatal approach including a one-field node dissection or transthoracic approach with a two-field lymph node dissection
224305957|NCT02470533|RADIATION|Radiation therapy|6 fractions of 8-9Gy
224305958|NCT02470533|DEVICE|chemoembolization|Up to 4 sessions
223484633|NCT02795143|DRUG|Isotretinoin|
223484634|NCT02795143|OTHER|Placebo|
223484635|NCT04646434|PROCEDURE|Electroencephalography|Undergo EEG
223484636|NCT04646434|PROCEDURE|Electromyography|Undergo EMG
223484637|NCT04646434|OTHER|Questionnaire Administration|Complete questionnaire
223484638|NCT04646434|PROCEDURE|Urodynamics (UDS)|Undergo UDS
223617588|NCT00471692|DRUG|Ropivicaine|
224173186|NCT03938558|OTHER|MS-Art|The other group will contribute to the production in various ways (e.g. word art, photography, painting, …)
224173187|NCT02087241|DRUG|AZD1775|AZD1775 is a highly selective, adenosine-triphosphate (ATP) competitive, small molecule inhibitor of the WEE 1 kinase that sensitizes tumor cells to cytotoxic agents and is being developed for the treatment of advanced solid tumors and p53 pathway deficient malignancies
224173188|NCT02087241|DRUG|AZD1775 Matching Placebo|AZD1775 is a highly selective, adenosine-triphosphate (ATP) competitive, small molecule inhibitor of the WEE 1 kinase that sensitizes tumor cells to cytotoxic agents and is being developed for the treatment of advanced solid tumors and p53 pathway deficient malignancies
224173189|NCT02087241|DRUG|pemetrexed|This drug is a part of a general group of chemotherapy drugs called anti-metabolites. It prevents cells from using folate to make DNA and RNA. Because cancer cells need these substances to make new cells, this drug helps to stop the growth of cancer cells.
223484639|NCT06531109|DRUG|Ritlecitinib|As provided in the real world practice.
223484640|NCT00345306|DRUG|Comparison between two different progesterone administration|
223484641|NCT02358629|DEVICE|NovaCross™ microcatheter|successful delivery, crossing, and retrieval of the investigational device as identified by confirmation of guidewire placement in the distal true lumen confirmed by angiography
223484642|NCT00908700|PROCEDURE|Surgical occlusion of the left atrial appendage|Study intervention: Within the trial, occlusion must be performed using either amputation and closure (cut and sew) or stapler device.
224173190|NCT02087241|DRUG|carboplatin|This drug is a platinum chemotherapy drug that acts like an alkylating agent. It stops the growth of cancer cells, causing the cells to die.
224173191|NCT00204802|BEHAVIORAL|Patient-Centered Advance Care Planning|
224305959|NCT00991705|DRUG|Atorvastatin|
224305960|NCT00991705|DRUG|Fimasartan|
224305961|NCT04773301|DRUG|Levobupivacaine|Local anaesthetic drug belonging to the amino amide group. It is the S-enantiomer of bupivacaine
224305962|NCT04773301|DRUG|Ropivacaine|Local anaesthetic drug belonging to the amino amide group. The name ropivacaine refers to both the racemate and the marketed S-enantiomer.
223484643|NCT00908700|PROCEDURE|Best medical practice|Best medical practice for atrial fibrillation related stroke prevention as per guidelines.
223484644|NCT02515253|OTHER|Bra prescription|
223484645|NCT02515253|OTHER|Standard Care|
223484646|NCT04865705|DRUG|tislelizumab|Tilelizumab 200mg d1 Q3W Albumin Paclitaxel 260mg/m2 d1 Carboplatin/Cisplatin 75mg/m2/AUC5 d1 every 3 weeks
223484647|NCT05658237|PROCEDURE|Pars plana vitrectomy|One sheet of PAL-222 is implanted into the subretinal space of either of eyes through pars plana vitrectomy.
223484648|NCT06400810|DEVICE|Analog Devices Inc.|Wearable wrist device that collects Photoplethysmography, accelerometer data among other parameters.
224173192|NCT06042764|DRUG|SA55 Injection|Novel coronavirus broad-spectrum neutralizing antibody SA55 injection (SA55 injection) is developed and produced by Beijing Kexing Zhongwei Biologics Technology Co., Ltd. The main component of SA55 injection is novel coronavirus broad-spectrum neutralizing antibody SA55. Each milliliter contains 150 mg of novel coronavirus broad-spectrum neutralizing antibody SA55. Excipients include histidine hydrochloride, arginine hydrochloride, histidine hydrochloride, sucrose, and polysorbate 80 (II)
224173193|NCT01725919|BEHAVIORAL|CI therapy|constraint induced movement therapy
224173194|NCT01296464|DRUG|Carbidopa|Capsules
224173195|NCT01614951|PROCEDURE|Perfusion of the lungs|Pulmonary perfusion with oxygenated blood during ECC.
224173196|NCT01614951|DRUG|HTK Custodiol|Pulmoplegia before ECC.
224173197|NCT01614951|OTHER|Standard ECC|ECC after standard procedure
224173198|NCT02897011|DRUG|Methotrexate|
224173199|NCT04022590|DEVICE|E-clothes|The E-clothes could prove heart rate or heart rate variability(HRV) information to the participants' smart phone by blue tooth. Then the smart phone will calculate and provide the suitable aerobic training intensity by the microphone when the participants do aerobic training.
224173200|NCT04022590|BEHAVIORAL|Healthy consultation|Healthy consultation will educate the participants do aerobic training three times a week for 3 months. And the each training period is at least 30 minutes.
224173201|NCT03944811|PROCEDURE|piezoelectric device|crestal approach will be used to augment the maxillary sinus with simultaneous implant placement
224173202|NCT03944811|PROCEDURE|Summers technique|Summers technique
224173203|NCT02303470|BEHAVIORAL|Vigorous Exercise|High-intensity interval training alternates 30 seconds of vigorous exercise with 30 seconds of low-intensity recovery for a total of 15 minutes.
224173204|NCT02303470|BEHAVIORAL|Moderate Exercise|
224173205|NCT00829595|BIOLOGICAL|23-valent polysaccharide pneumococcal vaccine (Pneumovax TM)|0.5mL intramuscular, one time
224173206|NCT06088511|BEHAVIORAL|e-Health System with nutritional advice|"A 12-week intervention consisting of a 4-weekly group-based, face-to-face supervised sessions, and an 8-week self-management phase will be arranged to the experimental group. The features of the System will be introduced to the users and their family members in the first two face-to-face sessions. The users and their family members will then be able to start using the System with the mobile app. In the other two sessions, all participants in the experimental group will learn how to accurately complete their dietary records in the e-Health System and will be provided with nutritional advice.~For the 8-week self-management phase, the participants will be recommended to follow the lifestyle interventions to relieve their problems related to sarcopenia. The participants are required to fill in their dietary record in the e-Health System every day, and will be provided with nutritional advice to improve high-quality protein and leucine intake, which is essential for muscle building."
224305963|NCT02873741|PROCEDURE|Perianal and Digital Anorectal Exam|The physician will inspect the outside of the anus and use a gloved finger to feel the anus for any masses.
223484649|NCT03991143|DRUG|ATH3G10|intravenous
223586062|NCT06312241|BEHAVIORAL|Metacognitive Training-Silver BeWell|Metacognitive Training- Silver BeWell is a cognitive behavioral based group intervention, which focuses on helping participants gain (metacognitive) distance from thought and behavioral patterns as well as behaviors and ER-strategies that are implicated in the onset of depression and reduced overall mental well-being. In 10 modules, MCT-Silver addresses issues specific to later life such as coping with physical changes and loss, as well as adapting to new (social) roles. The program also includes modules on identifying and re-defining values in later life, acceptance of negative feelings and resilience. In the training participants are made aware of information processing biases that have been shown to contribute to the onset of depression through engaging exercises using examples from daily life. Groups are comprised of up to 10 participants. Each session is 90 minutes.
223484650|NCT03991143|DRUG|Placebo|intravenous
223484651|NCT01954615|DRUG|5 mg ACT-281959 prodrug formulation I (Group A)|
223484652|NCT01954615|DRUG|20 mg ACT-281959 prodrug formulation I (Group B)|
223484653|NCT01954615|DRUG|ACT-281959 prodrug formulation I (Groups C to G doses to be defined)|
223484654|NCT01954615|DRUG|ACT-281959 prodrug formulation II (Group G dose to be defined)|
223484655|NCT01954615|DRUG|ACT-246475 (Group G dose to be defined)|
223484656|NCT01954615|DRUG|Placebo (Groups A to F)|
223484657|NCT05917379|BIOLOGICAL|fecal microbiota|FMT utilizes stool from a healthy donor and puts them into capsules after processing
223484658|NCT05917379|OTHER|Placebo|Starch into the same outlook capsule with fecal microbiota
223484659|NCT05917379|DIETARY_SUPPLEMENT|synbiotics|Lactobacillus Helveticas+ Bifidobacterial longum + inulin(3g/day)
223484660|NCT01908244|OTHER|Music|Pentatonic music
223484661|NCT04451538|DIETARY_SUPPLEMENT|Nutritional intervention group|Supplemental nutritional support is provided in addition to normal diet during the perioperative period (five days from pre- to postoperative phase). For non-diabetic patients, ENSURE is provided (Abbott; 112.6 g (12 spoons, 500 kcal)/day, twice a day); for diabetic patients, GLUCERNA SR is provided (Abbott; 104 g \[12 spoons, 440 kcal\]/day, twice a day).
223484662|NCT04451538|DIETARY_SUPPLEMENT|Control group|Supplemental nutritional support is not provided in addition to normal diet during the perioperative period (five days from pre- to postoperative phase).
223484663|NCT05611801|DRUG|marstacimab|marstacimab
223484664|NCT06087211|DRUG|Magnesium sulphate and Duloxetine|Patients received Duloxetine 30mg orally and an intravenous infusion of magnesium sulphate 50mg/kg mixed with 200 ml of normal saline.
223586063|NCT04867941|DRUG|ACP-196|All study participants will receive a single oral dose of 50 mg ACP-196 (2 x 25 mg capsules) on Day 1 of the study.
224173207|NCT06088511|BEHAVIORAL|The Exercise Training|For the 8-week self-management phase, the participants will be recommended to follow the lifestyle interventions to relieve their problems related to sarcopenia. The participants in the experimental group will also be suggested to continually practise exercise training at home for 30 minutes at least 5 times per week. Participants can review the self-learning exercise videos embedded in the System. The exercise trainings include: a) progressive resistance training to improve muscle strength; and b) brisk walking exercise to maintain walkability.
224173208|NCT02280265|DRUG|Recombinant Human Coagulation Factor VIII for injection|Subjects will initially be treated standard prophylaxis(20 - 40 IU/Kg body weight 2 times one week) with ADVATE for 1 year.
224173209|NCT03341728|BEHAVIORAL|Optical flow perturbations|Continuous mediolateral (i.e., side-to-side) 20-minute perturbations of optical flow that elicit the visual perception of lateral imbalance via virtual reality during treadmill walking.
224173210|NCT03341728|BEHAVIORAL|Normal walking|Usual treadmill walking without optical flow perturbations
224173211|NCT01031784|DEVICE|holmium-166 poly lactic acid microspheres|Intra arterial administration of radioactive Holmium 166 microspheres; 600 mg with a specific activity ranging from 1260 MBq per kilo liver weight to 5040 MBq in the highest dose
224173212|NCT01031784|DEVICE|holmium 166 microspheres|intra arterial administration of holmium 166 microsphers in the hepatic artery
224173213|NCT00004795|DRUG|dehydroepiandrosterone|
224173214|NCT02325128|BEHAVIORAL|Sleep-enhancement of extinction memory|Recent reports show that sleep promotes memory consolidation. The investigators' preliminary findings suggest sleep may enhance the therapeutic extinction memories acquired during exposure therapy. For sleep-enhancement of extinction memory, the current intervention uses post-exposure naps as a means to provide sleep in close temporal proximity to the encoding of memory for the extinction social exposure fears in individuals with severe social anxiety symptoms.
224173215|NCT00614042|DRUG|TRU-016 (anti-CD37 protein therapeutic)|TRU-016 administered via IV infusion weekly for 8 weeks and then monthly
224305964|NCT02873741|PROCEDURE|Cervical Swabs|A speculum will be inserted into the vagina to visualize the cervix. The sample for research tests will be collected with one ThinPrep cytobroom inserted into the cervix. Collection will be same for the sample to be paced in the RNA storage solution for future biomarker studies.
224305965|NCT02873741|PROCEDURE|Anal Swabs|The anal cytology specimen will be collected by inserting a saline moistened cotton-tipped swab into the anus, rotating it clock-wise for 20 seconds, and placed in SurePath. The first twenty participants will have anal cells collected in two different ways for validation/optimization: 1) saline moistened Dacron swab placed directly in ThinPrep medium and 2) Medscand Cytobrush Plus, a special brush, placed directly into ThinPrep medium. After validation/optimization is complete for up to 20 participants, the best collection method will be selected and will be used for all future enrolled participants.
224305966|NCT02873741|PROCEDURE|High Resolution Anoscopy (HRA)|High Resolution Anoscopy is a procedure that allows for examination and evaluation of the anal canal. Using a small thin round tube called an anoscope, the anal canal is examined with a high resolution magnifying instrument called a colposcope. Application of a mild acidic liquid (acetic acid or diluted vinegar) or a brown iodine-based solution (Lugol's) onto the anal canal facilitates evaluation of abnormal tissue such as anal dysplasia. If abnormal staining is seen using acetic acid (dense white lesion) or Lugol's solution (bright yellow lesion) a biopsy of that area will be obtained.
224305967|NCT03786718|OTHER|Patient-facing Diabetes Dashboard|The Patient-facing Diabetes Dashboard is embedded within a patient web portal and includes graphics to visualize and summarize patients' health data, incorporates motivational strategies (e.g., social comparisons and gamification), provides literacy level appropriate educational resources, and contains secure-messaging capability.
223586064|NCT00560495|DRUG|ammonium tetrathiomolybdate|4 times daily for up to 3 weeks
223586065|NCT00560495|OTHER|immunoenzyme technique|
223586066|NCT00560495|OTHER|laboratory biomarker analysis|
224173216|NCT04518644|DRUG|Nilotinib|The recommended dosing of nilotinib is 400 mg orally twice daily
224173217|NCT00374452|OTHER|ATHENA-CDS-HTN plus Guideline Link|ATHENA display provides guideline-based recommendations to clinicians at the time of patient care.
224173218|NCT00374452|OTHER|Guideline Link Only|Primary care providers were sent, once, a link (URL) to the VA/DoD and JNC7 hypertension guidelines.
224173219|NCT06990776|DRUG|TQA3605 tablets Placebo|Placebo contains no active substance.
223586067|NCT00560495|RADIATION|Tc 99m sestamibi|
224173220|NCT06990776|DRUG|TQA3605 Tablets|TQA3605 tablets is core protein allosteric modulators
224173221|NCT06990776|DRUG|Entecavir dispersible tablets|Entecavir dispersible tablets is an inhibitor of hepatitis B virus replication.
224173222|NCT01586286|DRUG|Nifedipine|Nifedipine - 0.2% concentration in a lanolin base; administered twice per day for 28 days; as a vaginal ointment applied to vulvar and vaginal area
224173223|NCT01586286|DRUG|Placebo Ointment Base|Placebo administered twice per day for 28 days; as a vaginal ointment applied to vulvar and vaginal area
224305968|NCT05258903|PROCEDURE|Ulnar artery cannulation|Ulnar artery will be cannulated under USG guidance
224305969|NCT05258903|PROCEDURE|Radial artery cannulation|Radial artery will be cannulated under USG guidance
224305970|NCT05408936|DRUG|SGLT2 inhibitor|Patients receive an SGLT2 inhibitor as part of theirn routine care.
224305971|NCT00620399|OTHER|lumbar corset|
224305972|NCT01385449|PROCEDURE|interscalene catheter|interscalene catheter
224305973|NCT01385449|PROCEDURE|interscalene block|interscalene block
224305974|NCT01853800|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|
224305975|NCT00945100|DEVICE|Eye Patch|42 hours patching per week (averaging 6 hours patching daily)
224305976|NCT00945100|DEVICE|Eye Patch|2 hours patching daily
224305977|NCT05013437|DRUG|Evomela|16 mg/m\^2 Evomela administered one time via a central line
224305978|NCT05013437|DEVICE|Next Generation Sequencing|Next Generation Sequencing
223484665|NCT06087211|DRUG|Duloxetine|Patients received Duloxetine 30mg orally and 200 ml of normal saline.
223484666|NCT06087211|DRUG|Placebo and normal saline|Patients received a placebo capsule and an intravenous infusion of 200 mL of normal saline.
223586068|NCT00560495|RADIATION|radiation therapy|once daily, 5 days a week, for 6-7 weeks
224305979|NCT05013437|DRUG|Prochlorperazine|10mg once intravenous (IV) within 30 minutes before Evomela
223484667|NCT05978323|BEHAVIORAL|Brief intervention|Short face-to-face intervention interviews will be conducted with individuals in the intervention group. Interviews will be held in primary healthcare organizations' meeting rooms. Brief intervention interviews will be conducted with the intervention group. It was determined as the first evaluation and the follow-ups on the 1st day, 15th day, 1st month, 3rd month, and the last evaluation (6th month). Brief interventions, 5A for those who are ready to change their behavior (Ask, Advise, Assess, Assist, Arrange); Those who are not ready to change their behavior 5R (Relevance, Risks, Rewards, Roadblocks, Repetition) model will be used. Brief intervention interviews will take an average of 20-30 minutes. The talks will include awareness of overweight and obesity, a healthy diet, and exercise. By the researcher's prepared will be used for individuals with low health literacy educational materials.
223484668|NCT02534480|DRUG|NGP 555|Gamma-secretase modulator for the treatment of Alzheimer's disease
223484669|NCT02625740|DEVICE|Local exposition of target lesion to high intensity, low-frequency ultrasound|Target lesion was exposed to 60 seconds of high intensity, low-frequency ultrasound generated by the Genesis™ system ( CardioProlific Inc., Hayward, CA). The ultrasound catheter is removed after the exposition.
223484670|NCT02625740|DEVICE|drug eluting ballon angioplasty|Target lesion was treated with an angioplasty, performed using the INPACT Admiral drug eluting ballon (Medtronic)
223484671|NCT02625740|DEVICE|Flow occlusion with an angioplasty balloon|Inflation of a 2 cm long balloon catheter Admiral (Medtronic) , located distally to the treatment area, in order to obtain a flow cessation
223484672|NCT02625740|DRUG|Local Paclitaxel infusion|Paclitaxel in a mixture with contrast medium at 1.0 µg/mm³ concentration was delivered to the treatment area for 60 seconds. The column of the Paclitaxel mixture filling the vessel was observed under the fluoroscopy and sustained during 60 seconds. The Paclitaxel /contrast medium mixture was then aspired with a 50 cc syringe and the distal balloon was deflated.
223484673|NCT02625740|PROCEDURE|Angiographic control|A final angiographic control was performed with injection of 10 cc of contrast medium and compared with the pre-procedural one.
223586069|NCT01283542|DRUG|Pasireotide LAR|20 and 40 mg of powder in vials and 2 mL of vehicle in ampoules (for reconstitution) administered as a depot intragluteal IM (intramuscular) injection
223586070|NCT03583827|OTHER|Virtual reality|Virtual reality is a simulation of the real world generated by computer software and experienced by users via a man-machine interface, providing them with intensive repetition of complex tasks, directed by visual and auditory stimuli, creating dynamic individual-task interaction, a motivating environment and immediate feedback on performance and results, stimulating motor skill learning and motor control of complex behaviors.
224305980|NCT05013437|DRUG|Acetaminophen|650 mg once orally within 30 minutes before Evomela
224305981|NCT05013437|DRUG|Diphenhydramine|50 mg once intravenously within 30 minutes before Evomela
224305982|NCT00828737|DRUG|Gadobutrol (Gadovist, BAY86-4875)|Gadovist in approved indications at approved dosages
224305983|NCT05958888|BEHAVIORAL|Text only sodium label|"Warning: High in sodium. is shown in a black square label on the can of soup."
224305984|NCT05958888|BEHAVIORAL|Icon sodium label|"Warning: High in sodium. is shown beneath a yellow triangle icon with an exclamation mark all in a black square label on the can of soup."
224305985|NCT05958888|BEHAVIORAL|Pictorial sodium label|"Warning: High in sodium. is shown beneath an image of a spilled salt shaker, all in a black square label on the can of soup."
223586071|NCT03583827|OTHER|Conventional physical therapy|Exercises of stretching and strengthening of the upper and lower limbs, as well as coordination, gait and balance.
223586072|NCT06929962|DRUG|Vonoprazan and Amoxicillin for the first 7 days|20mg Vonoprazan twice times daily and 1g Amoxicillin twice times daily for 7 days
223586073|NCT06929962|DRUG|Vonoprazan and Amoxicillin for the first 5 days|20mg Vonoprazan twice times daily and 1g Amoxicillin twice times daily for 5 days
224173224|NCT06989242|DEVICE|Yoga-Based Therapeutic Device (incorporating guided breathing and movement)|The Fluere™ Therapeutic Device is a computer-guided, electro-mechanical system designed to simulate yoga-inspired spinal movement and rhythmic breathing. Resembling a dental chair, the device dynamically adjusts spinal curvature to replicate motion patterns associated with deep abdominal breathing, similar to Kundalini or Qi Gong breathwork. The device operates automatically, with optional manual adjustments by the researcher.
224173225|NCT02223949|DEVICE|Cook double balloon catheter|
224173226|NCT02223949|DRUG|PGE1 tablet|
224305986|NCT05958888|BEHAVIORAL|Barcode label|Barcode is shown in white square label on the can of soup
224305987|NCT05938907|OTHER|concentrated growth factor|Implanting concentrated growth factor into the area of root apical bone defect
224305988|NCT05938907|OTHER|bone substitute|Implanting bone substitute into the area of root apical bone defect
224305989|NCT05938907|COMBINATION_PRODUCT|concentrated growth factor + bone substitute|Implanting concentrated growth factor + bone substitute into the area of root apical bone defect
223586074|NCT06929962|DRUG|Vonoprazan and Amoxicillin for the second 7 days|20mg Vonoprazan twice times daily and 1g Amoxicillin three times daily for 7 days
223586075|NCT06929962|DRUG|Vonoprazan and Amoxicillin for the second 5 days|20mg Vonoprazan twice times daily and 1g Amoxicillin three times daily for 5 days
223586076|NCT06929962|DRUG|Vonoprazan and Amoxicillin for 14 days|20mg Vonoprazan twice times daily and 1g Amoxicillin three times daily for 14 days
223586077|NCT03552588|DIAGNOSTIC_TEST|Continuous Electrocardiogram|A high-sensitivity, 14-day continuous ECG monitor.
224305990|NCT06548815|DRUG|GZR4|Ascending single doses - 4 dose levels.
224305991|NCT06548815|DRUG|Placebo|Ascending single doses - 4 dose levels.
224305992|NCT01697553|OTHER|home automation pack coupled to teleassistance service|
224305993|NCT01697553|OTHER|Home without automation pack coupled to teleassistance service|
224305994|NCT05252598|DRUG|Psilocybin|1mg encapsulated psilocybin
224305995|NCT05252598|DRUG|Inonotus Obliquus Whole Extract|1mg encapsulated chaga mushroom
224173227|NCT02492542|DEVICE|PHENIX USB 8.|Electrical stimulation program: frequency: 1/4/Hertz (HZ), pulse width: 270/230/270 μs, time: 30min. Electrode piece: 50\*50mm sticky electrode plate. Position: an electrode piece is placed in the S3, and an electrode piece is placed in the bladder region.Current intensity adjusted according to the patient's tolerance, the maximum current intensity of the pain was not appropriate, generally not more than 100milliampere(mA).Devices PHENIX USB 8.
224173228|NCT02261246|PROCEDURE|Spinal manipulation treatment|Up to 4 sessions of spinal manipulation treatment (once per week).
224173229|NCT01250236|DRUG|brimonidine 0.1%|brimonidine 0.1% eye drops twice daily
223484674|NCT05149105|PROCEDURE|Argon plasma coagulation|On D0, in the operating room, argon plasma coagulation will be performed around the perimeter of the anastomosis for a period of 5 to 10 min under general anesthesia. The removal of the catheter and the endoscope will be carried out under control. Patients will be kept under surveillance the night following the procedure. A liquid diet will be prescribed for 10 days. The follow-up will be carried out on an outpatient basis with a control endoscopy at 2 months, followed by a new procedure in the event of an anastomosis larger than 1.5 cm. A new endoscopic check will be carried out at 4 months if an argon plasma coagulation was performed during the previous check, with a third and last argon plasma coagulation if an anastomosis of more than 1.5 cm persists. The number of procedures will therefore be a maximum of 3. A control endoscopy will be performed at one year for the final control of the anastomosis.
223484675|NCT05413941|BEHAVIORAL|Internet-based Cognitive Behavioral Therapy|Cognitive behavioral therapy (CBT) is a form of psychotherapy in which individuals are taught to identify and modify maladaptive thinking and behavior to improve their psychological status and coping skills. CBT in this trial will be delivered digitally (internet-based).
223484676|NCT01798290|BEHAVIORAL|narrative medicine: reading workshop|
223484677|NCT01798290|BEHAVIORAL|critical reading|
223586078|NCT04018742|OTHER|Surgical puncture|Investigators propose to collect 20 abscesses. A collection of abscesses is performed systematically during the diagnostic for bacteriological analysis. There will be no further examination.
223586079|NCT02887755|DEVICE|Near-Infrared Spectroscopy (NIRS) Sensor|These sensors utilize NIRS to evaluate oxygenated and deoxygenated hemoglobin, total oxygenation index and total blood flow. This is done by bouncing infrared light off of chromatophores (located within red blood cells), which is then refracted off of the cells in the capillary beds to the topical sensor.
224173230|NCT01250236|DRUG|placebo|sodium hyaluronate 1.8mg/ml eye drops twice daily
224173231|NCT03639064|DRUG|Cannabis Oil|"Mixed oil cannabis preparation consisting of 3 differing formulations of ∆-9THC and CBD is clinically available in Canada as CanniMed®. The 3 differing formulations of CanniMed® oils contain varying proportions of ∆-9THC and CBD in the following ratios: 18:0; 10:10; 1:20.~All CanniMed® oil formulations consist of cannabinoids extracted from dried cannabis, and diluted in olive oil."
224173232|NCT02996175|BEHAVIORAL|Behavioral Sleep Treatment|"1. Introduction to the treatment program, an overview of common sleep problems in DS, and the basic principles of the behavioral approach as it relates to sleep problems~2. Information on healthy sleep hygiene, preventative techniques, and use of visual supports~3. Information on reinforcement and extinction procedures for bedtime struggles, codependence, night waking, early waking~4. Information on procedures for delayed sleep onset and problematic sleep associations~5. Feedback on implementation of behavioral sleep treatments and strategies for managing sleep hygiene in the future"
224173233|NCT02996175|BEHAVIORAL|Standard of care sleep treatment enhanced with psychoeducation|"1. Introduction to the general-education program, build rapport with family, and review basic information on Down syndrome~2. Introduction to understanding and interpreting results from clinical evaluations~3. Introduction to educational planning, expectations, and transition planning~4. Introduction to lifespan development and advocacy and support services available~5. Feedback on current concerns and methods for obtaining services to manage concerns"
224173234|NCT00003804|BIOLOGICAL|dactinomycin|
224173235|NCT00003804|DRUG|vincristine sulfate|
224173236|NCT00003804|PROCEDURE|conventional surgery|
224173237|NCT05124327|OTHER|QI project- usage of RPM|close monitoring through RPM to analyze feasibility and compare readmission rates
224305996|NCT06633432|OTHER|Acupuncture|Administer medication at each acupoint a total of three times: (1) the night before surgery, (2) the night of surgery, and (3) the first night after surgery. In the acupuncture group, the acupuncture and moxibustion successively acupunctured four points with a depth of 10-20mm. Select the specific depth based on the subject\&#39;s body type (tall, short, fat, thin). After the puncture, the acupuncture and moxibustion lifted and twisted the needle handle, and then retained the needle for 20 minutes.
224305997|NCT06633432|OTHER|Sham-acupuncture stimulation|The sham acupuncture group received non skin breaking comfort needles at the corresponding points for acupuncture and moxibustion and retained the needles for 20 minutes. Non transdermal comfort needles can cause patients to experience a needle like sensation similar to piercing the skin, but in reality, they do not break the skin.
223586080|NCT01964677|DEVICE|Magnetic Resonance Image-guided High Intensity Focused Ultrasound (MR-HIFU)|
224173238|NCT01071941|BIOLOGICAL|administration of rRp450 into the hepatic artery|Administration of rRp450 into the hepatic artery either as a single infusion, or as four infusions administered every one to two weeks.
224305998|NCT03190213|DRUG|Pembrolizumab Injection|Pembrolizumab at a dose of 200 mg will be administered as an IV infusion over 30 minutes every 3 weeks until disease recurrence or discontinuation due to unacceptable toxicity for a maximum of 2 years. We anticipate on average patients will remain on treatment for approximately 24 weeks.
224173239|NCT05869240|DRUG|BPB-101|Subjects will receive an intravenous infusion of BPB-101 in a pre-set dose escalation until confirmed progression, unaccepted toxicity, or any criterion for withdrawal from the trial.
224305999|NCT02024113|OTHER|Venous blood sample|Collection of a venous blood sample to investigate metabolic changes in blood
224306000|NCT02905747|BEHAVIORAL|Medical Exercise Therapy|physiotherapy intervention with Medical exercise therapy (MET) during 3 months
223484678|NCT02630654|OTHER|This is a non-interventional study. Patients will be treated with any intervention deemed appropriate by the patient's physician.|
223586081|NCT04576078|DRUG|Oral nefopam|Oral administration of nefopam 60mg 2 hours before the surgery following by 60mg each 8h for 24h. Oral nefopam is prepared ex-tempore from the intravenous formulation adding a taste masking compound by a non-caring nurse following detailed instructions.
223484679|NCT04118972|BEHAVIORAL|Mirror exposure and text prompt responses|Participants in the active interventions have three weekly mirror exposure sessions that are either guided with specific instructions as to where to look and how (only in functionality condition)
223484680|NCT02478671|DEVICE|TR Band|The radial artery will be compressed using a Terumo TR Band and artery diameter and perfusion will be measured
223484681|NCT04799990|DRUG|Risankizumab|Subcutaneous Injection
223484682|NCT04799990|BIOLOGICAL|Comparator 1|Subcutaneous or Intravenous Injection
223484683|NCT04799990|DRUG|Comparator 2|Oral, Opthalmic, Subcutaneous or Intravenous Injection
223484684|NCT05282784|OTHER|Hyperthermia|"Patients will be treated with hyperthermia 2 or 3 times a week. Treatment will be performed for 1 hours per each visit.~Patients will be treated with radiotherapy 5 times a week."
223484685|NCT05282784|RADIATION|Radiotherapy|Patients will be treated with radiotherapy 5 times a week.
223484686|NCT00804271|DRUG|memantine|memantine tablets, OD, 12 weeks
223484687|NCT03726476|BEHAVIORAL|Patient centered pre-op education|To implement a patient centered education intervention to evaluate post-op narcotic use.
224173240|NCT06868173|DEVICE|Electro-acupuncture|Electroacupuncture at Trigger Points is electroacupuncture at predetermined trigger points. Electroacupuncture at traditional acupoints is electroacupuncture at the following points: Jiaji (L2-L5), Yaoyangguan (GV3), Shendu (BL23), Dachangdu (BL25), and Weizhong (BL40).
224173241|NCT04234399|DIAGNOSTIC_TEST|Fluciclovine PET/CT using a digital PET/CT|Fluciclovine is a radiotracer that will be used in conjunction with the high resolution digital Vereos PET/CT scanner.
224173242|NCT01070628|DRUG|Stalevo (levodopa/ carbidopa/ entacapone)|150mg, 125 mg, 100mg, 75mg of levodopa q.i.d. in 3.5 h interval
224173243|NCT01070628|DRUG|Sinemet (levodopa/carbidopa)|150 or 100 mg levodopa q.i.d. in 3.5 hr interval
224173244|NCT04669106|OTHER|laboratory clinical trial study|The research stage consisted of two stages, the first stage was the initial screening of the primary data of the research subjects, namely by analyzing food intake including mineral intake data, the diet of the research subjects, mineral and enzyme levels, and data on soil conditions in the area. The second stage was to analyze the relationship between the existing variables so that the most significant relationship was seen between the differences in diet, mineral content, enzyme levels, and soil content between the two groups.
224173245|NCT03345875|DIAGNOSTIC_TEST|HPV self collection, followed by visual assessment of the cervix for treatment (VAT) and treatment|Women who test HPV positive are offered visual assessment for treatment, with treatment method (cryotherapy, LEEP, or biopsy) based on visual assessment findings.
224173246|NCT01546090|DRUG|Alprazolam|preoperative administration of an orally 0.50 mg single dose
224173247|NCT01546090|DRUG|placebo|placebo capsules were filled with starch
224173248|NCT05068427|DRUG|Chidamide|20mg or 30mg orally twice per week(BIW)
224173249|NCT05068427|DRUG|Envafolimab|400mg subcutaneous infusions every 4 weeks
224173250|NCT06321640|GENETIC|Cohort A: primarily operable disease, candidate to adjuvant|This cohort includes any patient with nonmetastatic disease, candidate to surgery as primary treatment, for whom adjuvant therapy with targeted or immune therapy is recommended based on prior information obtained on the diagnostic biopsy. This cohort represents a control group, for whom high-throughput DNA/RNA sequencing is considered feasible in the vast majority of cases, and will not be considered in the computation of the primary endpoint
223484688|NCT03726476|BEHAVIORAL|routine preop education|To implement routine patient education intervention to evaluate post-op narcotic use.
223484689|NCT02534961|DRUG|Cefazolin|Patients in the prophylactic group will receive antibiotic treatment right after randomization with intravenous cefazolin 2 g (3 g for patients weighing ≥120 kg) within 60 minutes before ablation therapy. Patients in the on-demand group will receive antibiotic therapy only when infection will be suspected or established. Antibiotics will be changed according to the antibiotic sensitivity test of cultured microorganisms.
223484690|NCT02840565|DRUG|BIA 5-453|Presented as blue hard gelatine capsules (size 2) of 1 mg, 10 mg and 50 mg for oral administration
223484691|NCT02840565|DRUG|Placebo|The composition of the placebo is qualitatively the same but without BIA 5-453 pharmaceutical active ingredient.
223484692|NCT02019069|DRUG|liposomal cytarabine-daunorubicin CPX-351|Given IV
224173251|NCT06321640|GENETIC|Cohort B: locally advanced disease|Patients in this cohort are eligible if diagnosed with or highly suspected of locally advanced (nonmetastatic) neoplasm and candidate to a diagnostic/confirmatory biopsy and subsequent treatment with targeted therapy, immune therapy or radiotherapy, where the treatment is administered with potentially curative intent. Patients in this cohort may be considered for enrolment prior to a formal diagnosis, so the study should be offered on the basis of a high suspicion of invasive cancer upon radiological evidence.
224173252|NCT06321640|GENETIC|Cohort C: metastatic disease|In this cohort, patients are eligible if diagnosed with invasive cancer with radiologically proven metastatic localization and candidate to treatment with targeted or immune therapy.
224173253|NCT06321640|GENETIC|Cohort D: Progressive disease|In this cohort, patients are eligible if a tumor biopsy is considered indicated by the referring physician upon disease progression to prior treatment in the metastatic setting or for hematological neoplasms. Definition of progression is based on the investigator's judgement and does not strictly require RECIST 1.1 definition, although all relevant radiological data will be collected whenever possible. Tumor biopsy must be collected no more than 6 months after the documented date of progression.
223484693|NCT03132389|OTHER|No intervention|All patients included in the study will be offered the same examination and treatment procedure as the patients who are not included. Identical procedures and examinations will be performed in participants and non-participants.
223484694|NCT00000629|DRUG|Valproic acid|
223484695|NCT00000629|DRUG|Zidovudine|
223484696|NCT02544789|DRUG|Clofarabine|Clofarabine (Betta Pharmaceuticals Co., Ltd, Zhejiang, China) was administered intravenously at 52 mg/m2 over 2 hours daily for 5 consecutive days. During the first two induction cycles, patients who did not achieve an objective response were taken off the study, and responsive patients continued to receive consolidation for a maximum 11 cycles if non-hematological toxicity was grade 2 or less.
223484697|NCT00614393|BIOLOGICAL|dalotuzumab|IV infusion
223484698|NCT00614393|DRUG|irinotecan hydrochloride|IV infusion
223484699|NCT00614393|BIOLOGICAL|cetuximab|IV infusion
223484700|NCT00614393|DRUG|placebo|IV infusion
224173254|NCT06321640|GENETIC|Cohort E: Hematological neoplasms|Any patient that is expected to be treated with targeted agents. Special consideration will be given to patients affected by chronic lymphoid leukemia and follicular lymphoma treated with BTKi, PI3Ki, BCL-2i +/- monoclonal antibodies. Any patient that is expected to be treated with immunotherapy. Special consideration will be given to patients affected by Hodgkin lymphoma and Diffuse Large B-cell lymphoma treated with ICIs, Tafasitamab/Lenalidomide, immunoconjugates.
224173255|NCT06321640|GENETIC|Cohort F: Toxicity|In this cohort, patients are enrolled upon experiencing an adverse event of grade 3/4 as per CTCAE v 5.0 that, in the opinion of the investigator, is unequivocally caused by a targeted or immune therapeutic. The event may occur at any time after the last dose of the drug. Events may be of any nature but particular attention will be given to those events for which pathophysiology is currently poorly understood (severe myocardial or neurologic Immune-related events or DS-8201-induced pneumonitis)
224173256|NCT01438359|DRUG|PA21 and Furosemide with food|The maximum dose of PA21 will be 15.0 g/day. The maximum dose of Furosemide will be 40 mg/day
224173257|NCT01438359|DRUG|No PA21; Furosemide with food|The maximum dosage of Furosemide will be 40 mg/day
224173258|NCT01438359|DRUG|PA21 with food and Furosemide 2hrs later|The maximum dose of PA21 will be 15 g/day. The maximum dose of Furosemide will be 40 mg/day
224173259|NCT02946151|DEVICE|UNEEG implantable EEG electrode and data storage device|The implantable EEG electrode will be implanted subcutaneously in the relevant temporal region by a certified neurosurgeon. The EEGgraphical data recorded will be transmitted transcutaneously to the data storage device via an inductive link, providing continuous data on brain activity.
223484701|NCT05796453|DEVICE|Clareon Vivity IOL - Non Toric|Spherical extended vision IOL implanted in the capsular bag of the eye for the visual correction of aphakia in adult patients with less than 1.00 diopter of preoperative corneal astigmatism in whom a cataractous lens has been removed.
223484702|NCT05796453|DEVICE|Clareon Vivity IOL - Toric|Toric extended vision IOL implanted in the capsular bag of the eye for the visual correction of aphakia and for reduction of residual refractive astigmatism in adult patients in whom a cataractous lens has been removed.
224173260|NCT02211950|DRUG|BI 44847|
223484703|NCT05796453|DEVICE|Clareon PanOptix Trifocal IOL - Non Toric|Spherical trifocal IOL implanted in the capsular bag of the eye for the visual correction of aphakia in adult patients with less than 1.00 diopter of preoperative corneal astigmatism in whom a cataractous lens has been removed.
223484704|NCT05796453|DEVICE|Clareon PanOptix Trifocal IOL - Toric|Toric trifocal IOL implanted in the capsular bag of the eye for the visual correction of aphakia and for reduction of residual refractive astigmatism in adult patients in whom a cataractous lens has been removed.
224173261|NCT02211950|DRUG|Acarbose|
224173262|NCT02211950|OTHER|Japanese diet|
223484705|NCT05442112|BEHAVIORAL|Wellness Patient Message|The intervention is a detailed patient message containing information on strategies for exercise in MS, how to maintain proper sleep, and dietary improvements to maximize health. These strategies are derived from information provided by the National MS Society in their website and covers these topics in greater detail than would normally be addressed in a normal clinic visit. The message also directs patients to the National MS Society website if they would like more information.
224173263|NCT04623255|DRUG|OCTAPLAS|plasma exchange
224173264|NCT06507098|OTHER|Video-assisted training|Patients received a QR code and a link for access to a YouTube video recorded to this effect where the process of setting up the respiratory polygraph was explained. The contents of the video were the same as those in the face-to-face instructions. The visualization of the video was at home, and it could be viewed as many times as necessary.
223484706|NCT00739232|DRUG|HSD-016|
223484707|NCT00739232|OTHER|placebo|
223484708|NCT03870386|PROCEDURE|EUS-BD with LAMS|Endoscopic ultrasound guided insertion of lumen apposing metal stent forming a choledochoduodenostomy
224306001|NCT01879163|BIOLOGICAL|MVA85A-IMX313|Intradermal injection of MVA85A-IMX313 (MVA85A-IMX313 combines the candidate TB vaccine MVA85A with the carrier protein IMX313)
223484709|NCT03870386|PROCEDURE|ERCP|Endoscopic retrograde cholangiopancreatography to localize and cannulate the bile duct using the guidewire-assisted technique.
224306002|NCT01879163|BIOLOGICAL|MVA85A|Intradermal injection of MVA85A (recombinant Modified Vaccinia virus Ankara expressing the M. tb antigen 85A)
223586082|NCT04576078|DRUG|Placebo|Oral administration of a placebo 2 hours before the surgery following by one administration each 8h for 24h. Oral placebo is prepared ex-tempore with a taste masking compound by a non-charge nurse following detailed instructions
223586083|NCT05250791|DRUG|Lidocaine hydrochloride 2% for injection|An intravenous bolus of 2% lidocaine will be administered following the induction of anaesthesia at 1.5mg/kg ideal body weight over 20 minutes followed by intravenous infusion of 1.5 mg/kg/hour ideal body weight with a maximum rate of 120mg/hour for 24 hours.
223586084|NCT05250791|DRUG|0.9% sterile Sodium Chloride solution for injection|Administered as lidocaine
223484710|NCT00855582|DRUG|Tadalafil|tablet once daily by mouth for 12 weeks.
223484711|NCT00855582|DRUG|Placebo|Matching 2.5 or 5 mg placebo tablet once daily by mouth for 12 weeks.
223484712|NCT03345004|BIOLOGICAL|Diamyd|Alhydrogel®-formulated recombinant human glutamic acid decarboxylase (rhGAD65)
223484713|NCT03345004|DIETARY_SUPPLEMENT|Vitamin D|Oil suspension of Vitamin D
223484714|NCT03345004|BIOLOGICAL|Placebo for Diamyd|Alhydrogel® only
223586085|NCT04816383|OTHER|"Breastfeeding at AU Apple-Based Smartphone Application"|This is a free Apple-Based Smartphone Application the participant can download. In the application, there is information and tips for breastfeeding success and continuation, as well as information on additional resources both online and in the community as a whole.
223586086|NCT01675362|DRUG|Antioxidant group|They will be receive vitamins A, C, E and selenium (Selenium ACE) Dosage: Two tablets before ESWL Then 2 tablets every 8 hours after ESWL for one week
223586087|NCT01675362|DRUG|Calcium Channel Blockers|They will receive Verapamil (Isoptin 80 mg) Dosage: One tablet 2 hours before ESWL Then one tablet every 12 hours after ESWL for one week
223586088|NCT01675362|DRUG|Angiotensin receptor blocker group|They will receive Losartan (Cozaar 50 mg) Dosage: One tablet 2 hours before ESWL Then one tablet every day after ESWL for one week
223484715|NCT03345004|DIETARY_SUPPLEMENT|Placebo for Vitamin D|Placebo oil suspension for Vitamin D
223484716|NCT06023290|DIAGNOSTIC_TEST|Heart rhythm measurements with Preventicus®|The sequence of the digital heart rhythm measurements is randomly assigned for each patient. The reference heart rhythm is determined by a simultaneous recording with a 12-lead ECG as gold standard.
223484717|NCT06023290|DIAGNOSTIC_TEST|Heart rhythm measurements with FibriCheck®|The sequence of the digital heart rhythm measurements is randomly assigned for each patient. The reference heart rhythm is determined by a simultaneous recording with a 12-lead ECG as gold standard.
223484718|NCT06023290|DIAGNOSTIC_TEST|Heart rhythm measurements with Apple Watch®|The sequence of the digital heart rhythm measurements is randomly assigned for each patient. The reference heart rhythm is determined by a simultaneous recording with a 12-lead ECG as gold standard.
223484719|NCT06023290|DIAGNOSTIC_TEST|Heart rhythm measurements with 6L Kardia Mobile®|The sequence of the digital heart rhythm measurements is randomly assigned for each patient. The reference heart rhythm is determined by a simultaneous recording with a 12-lead ECG as gold standard.
223586089|NCT01675362|DRUG|Placebo|They will receive placebo
223586090|NCT05347940|OTHER|mirror therapy|A Mirror box will be used to easily create illusion. It' is a box with one mirror in the center where on each side of it, the hands are placed in a manner that the affected limb is kept covered always and the unaffected limb is kept on the other side whose reflection can be seen on the mirror.
223586091|NCT05347940|OTHER|traditional physiotherapy protocol for flexor tendon repair|include stretching exercises and active ROM exercises
223586092|NCT05233345|BEHAVIORAL|Occupational Therapy|online occupational therapy sessions are based on the activity training
223586093|NCT00003447|DRUG|gemcitabine hydrochloride|
223586094|NCT00003447|DRUG|vinorelbine tartrate|
224173265|NCT06507098|OTHER|Nurse training|A trained nurse with long experience in home sleep studies explained the setup of the respiratory polygraph. At the end of the intervention doubts about the procedure were addressed. Patients did not have access to the video.
224173266|NCT03850704|DRUG|Selinexor|
224173267|NCT03953690|OTHER|use of e-Health service|use of the e-Health e-Lupus account (at least) once a month and encouraged to advise his doctor to consult the entered data before the following consultation
224173268|NCT00572663|DRUG|ACC (N-acetylcysteine) 1200 mg|N-acetylcysteine (ACC) 1200 mg In the 8-weeks run-in period angiotensin converting enzyme inhibitors and/or angiotensin II subtype 1 receptor antagonists were administered to achieve the target blood pressure below 130/80 mmHg. Next, they were randomly assigned to add (or not) 1200 mg N-acetylcysteine in two active treatment periods lasting 8 weeks each
224173269|NCT04765839|OTHER|Educational, culturally appropriate COVID-19 messages|Educational, culturally appropriate COVID-19 messages will be developed and shared by RHCP.
224173270|NCT04235088|OTHER|Somatosensory intensive intervention|The intensive somato-sensory intervention will take place during 3 weeks, 5 days per week, for 2 hours per day (30 hours of practice). During the week-ends, some somato-sensory written activities will be explained and handed to each family (6 hours of practice) Therapy sessions will be carried out in groups and each child will have his or her own therapist in charge of his or her treatment along the whole intervention. A daily check-list, design for that purpose, will be used by the therapist in order to register the gradually increased complexity of the activities and individual progression. The principal investigator will supervise all the interventions in order to assure their uniformity, adjusting the somato-sensory training protocol to the individual needs of each subject.
224306003|NCT04087434|DEVICE|Brain Gauge Prospective and Healthy Control|The Brain Gauge is a brain health assessment system that takes advantage of the well-documented relationship between the sensory nerves in the fingers and the projection of those nerves to corresponding regions in the brain. The system is composed of a test device (the Brain Gauge) that uses novel fingertip vibration patterns to probe cortical complexity and utilize that complexity to gain more sensitive and specific detection of compromised neural function.
223484720|NCT03238469|DEVICE|Microwave ablation|A one-sided (either right or left axillary area) single MWA treatment using a miraDry system. The miraDry device has a microwave output frequency of 5.8 GHz and microwave energy level settings ranging from 1 to 5, corresponding with a delivery time in seconds between 2.40 sec and 3.00 sec. For this study standard 5 (i.e. 3.00 sec) is set as treatment setting.
223586095|NCT03226977|DEVICE|NIPPV|NIPPV is used as a primary mode of ventilation in premature infants with respiratory distress syndrome
223586096|NCT03226977|DEVICE|NCPAP|NCPAP is used as a primary mode of ventilation in premature infants with respiratory distress syndrome
224306004|NCT01997216|DEVICE|Delefilcon A multifocal contact lens|Investigational silicone hydrogel contact lens dispensed in low, medium, or high ADD per current AIR OPTIX® AQUA MULTIFOCAL fitting guidelines
223484721|NCT03070145|OTHER|Exercise Intervention|12-week moderate-intensity aerobic and strength training exercise intervention
223484722|NCT01531179|DRUG|Lactobacillus reuteri|Lactobacillus reuteri 100 million CFU/day for 3 months
223484723|NCT01531179|DRUG|Placebo|Placebo for 3 months
223484724|NCT01013753|DRUG|Placebo|Determine efficacy and safety of Placebo inhaled once daily from the Respimat inhaler and/or twice daily from the Aerolizer inhaler
223484725|NCT01013753|DRUG|Olodaterol (BI 1744) high|Determine efficacy and safety in 4 different doses of Olodaterol (BI 1744) inhaled once daily via the Respimat
223586097|NCT06175169|DEVICE|Information of Appendix (IA) model|Deep learning model
223586098|NCT04385225|OTHER|Longitudinal follow-up|Longitudinal hearing, vestibular and cognitive follow-up
223586099|NCT05613582|DEVICE|Transcranial Direct Current Stimulation|The flow of DC electric current 1 mA for 20 minutes. The position of the electrode placement follows the international EEG 10/20 system.
223586100|NCT00903331|DRUG|ACT-064992 (macitentan)|ACT-064992 (macitentan) tablet, 10 mg, once daily
223586101|NCT00903331|DRUG|Placebo|matching placebo, once daily
223745179|NCT06095011|DEVICE|UpRight Go|The UpRight Go posture trainer is a commercially available biofeedback sensor that externally attaches to the wearer via a necklace or silicon adhesive. It vibrates when it senses that the wearer is slouching and connects to a smartphone application which sets daily goals, tracks usage, and provides assistance and support. It complies with International Electrotechnical Commission (IEC) standards.
223745180|NCT05663866|DRUG|Dexamethasone|Dexamethasone will be administered orally.
223484726|NCT01013753|DRUG|Olodaterol (BI 1744) medium|Determination of efficacy in 4 different doses of Olodaterol (BI 1744) inhaled once daily via the Respimat
223484727|NCT01013753|DRUG|Olodaterol (BI 1744) very low|Determination of efficacy in 4 different doses of Olodaterol (BI 1744) inhaled once daily via the Respimat
223484728|NCT01013753|DRUG|Formoterol 12 mcg|Determine efficacy and safety of 12 mcg Formoterol dose inhaled orally twice daily from the Aerolizer in comparison to other treatment groups
223484729|NCT01013753|DRUG|Olodaterol (BI 1744) low|Determine efficacy and safety of 4 different doses of Olodaterol (BI 1744) inhaled once daily via the Respimat
223484730|NCT05886881|DEVICE|Lotrafilcon B spherical soft contact lenses|Commercially available silicone hydrogel contact lenses
223484731|NCT05886881|DEVICE|Lotrafilcon B spherical soft contact lenses with comfort additive|Commercially available silicone hydrogel contact lenses
223484732|NCT05886881|DEVICE|Lotrafilcon B toric soft contact lenses with comfort additive|Commercially available silicone hydrogel contact lenses
223484733|NCT05886881|DEVICE|Comfilcon A spherical soft contact lenses|Commercially available silicone hydrogel contact lenses
223484734|NCT05886881|DEVICE|Comfilcon A toric soft contact lenses|Commercially available silicone hydrogel contact lenses
223484735|NCT06583460|OTHER|Early and systematic oncosexological supporting care|"Each patient included in the study will be cared by an anthropologist and a sexologist.~This therapeutic support care will be based on :~* 2 qualitative semi-directive interviews (Baseline and M18),~* 2 individual consultations with questionnaires (Baseline and M18).~The qualitative semi-structured interviews will be conducted with the anthropologist, and the individual consultations with the sexologist.~At the end of the first oncosexology consultation, patients will be given the opportunity to decide whether or not to accept further systematic oncosexology support care, which will be based on :~* 3 individual and/or couple consultations,~* 3 group workshops.~Patients are under no obligation to accept this additional oncosexology support care."
223484736|NCT05201001|DRUG|APX005M|adding immunotherapy with or without radiation therapy to chemotherapy. Low dose radiation therapy is to sensitise tumour cells to immunotherapy.
223484737|NCT02456558|DRUG|Intravenous deferiprone|In Cohort 1, the subjects who were randomized to get active product will receive deferiprone at a dose of 1.5 g per infusion, and if there are no significant safety concerns, the subjects in Cohort 2 who were randomized to get active product will receive it a a dose of 2 g per infusion.
223484738|NCT02456558|DRUG|Placebo|In both cohorts, the subjects who were randomized to get placebo will receive an infusion of placebo solution that is equal in volume to that of the active product.
223484739|NCT05841550|BIOLOGICAL|TG01|All participants will receive the same treatment as described under arm
223484740|NCT00580099|OTHER|assisted exercise|4 weeks of passive range of motion exercise
223586102|NCT04687423|DRUG|FCN-011|FCN-011 will be given orally in ascending doses starting at 50 mg Q12h or 100mg QD until the maximum tolerated dose or recommended dose is reached.
223586103|NCT00257660|BIOLOGICAL|Botulinum toxin type A|500 units
224173271|NCT05391620|OTHER|Cardiac rehabilitation with 3/7 method|"HIIT ( 2 min 80% wmax: 2 min 50% wmax) during 30 minutes 3/7 method 3 rep (15 sec of rest), 4 rep (15 sec), 5 rep (15 sec), 6 rep (15 sec), 7 rep. (total volume : 25 repetitions) at 70 of 1 repetition Leg press, Dips Press, Leg curl, Traction and Leg extension.~1 minute between each machine is planned."
223484741|NCT00580099|OTHER|cuddle|cuddle infant for 20 minutes
223484742|NCT01733953|DRUG|Atorvastatin|6-Months of Atorvastatin (Lipitor); 40mg, oral, once daily.
223484743|NCT01733953|DRUG|Sugar Pill (Placebo)|6-Months of placebo (sugar) pill; oral, once daily
223484744|NCT06080815|DEVICE|CAD/CAM Complete denture|four implant-supported CAD/CAM complete overdenture
223586104|NCT00257660|DRUG|Placebo|500 units
223484745|NCT01784263|BEHAVIORAL|Individual Cognitive Behavioral Therapy|Therapists will work with families for 32 weekly sessions, each lasting 90 minutes (45 minutes with the child and 45 minutes with the family/parents), implementing the CBT manual for children with ASD (Wood et al., 2007).
223484746|NCT01784263|BEHAVIORAL|Standard Community Treatment|In this condition, the child meets with a therapist for 32 weekly sessions, each 90 minutes. Therapists use an established manual to administer a standard community treatment.
223484747|NCT02487121|BEHAVIORAL|variable interval schedule|12 group-based extended care treatment sessions scheduled in 3, 4-week periods over a 12-month period
223484748|NCT02487121|BEHAVIORAL|self-directed treatment|provision of treatment materials with instruction to work through materials at participant's own pace
223586105|NCT03597607|BEHAVIORAL|Intensive Smoking Cessation Group|This group will meet with the pharmacist more frequently and for longer periods than other groups.
223586106|NCT03597607|BEHAVIORAL|Abbreviated Smoking Cessation Group|This group will meet with the pharmacist less frequently and for shorter periods in comparison to the intensive group.
223586107|NCT03101007|DEVICE|ATTUNE Knee Prosthesis by DePuy|Total Knee Replacement (TKR) Surgery with cementless ATTUNE rotating platform Knee Prosthesis by DePuy
223484749|NCT00512668|DRUG|leuprolide acetate|Given intramuscularly
223484750|NCT00512668|DRUG|goserelin acetate|Given subcutaneously
223484751|NCT00512668|DRUG|bicalutamide|Given PO
223484752|NCT00512668|DRUG|nilutamide|Given PO
223484753|NCT00512668|DRUG|flutamide|Given PO
223484754|NCT00512668|DRUG|temsirolimus|Given IV
223484755|NCT00512668|OTHER|laboratory biomarker analysis|Optional correlative studies
223484756|NCT01271972|DRUG|nesvacumab (REGN910/ SAR307746)|
223484757|NCT00742456|DIETARY_SUPPLEMENT|Glucose solution|single oral intake of 250 ml glucose solution (75gr sugar in 250ml of water)
223484758|NCT00742456|DIETARY_SUPPLEMENT|Placebo|single intake of placebo solution (250ml of sweet flavored water, no sugar added), orally
223484759|NCT03320369|OTHER|Elemental Diet Therapy|Elemental diet is a formula composed of amino-acids, carbohydrates, and lipids that is 100% nutritionally complete
223586108|NCT03101007|DEVICE|LCS Knee Prosthesis by DePuy|Total Knee Replacement Surgery with cementless LCS rotating platform Knee Prosthesis by DePuy
223586109|NCT05485883|DRUG|Tislelizumab Lenvatinib|Patients will receive treatment with Tislelizumab in combination with Lenvatinib every 3 weeks unitl tumor progression or serious side effects
224173272|NCT05391620|OTHER|Cardiac rehabilitation with 3X9 method|"HIIT ( 2 min 80% wmax: 2 min 50% wmax) during 30 minutes 3X9 method 9 rep 1 minute of rest, 9 rep (1 min) and 9 rep (total volume : 27 repetitions) at 70 of 1 repetition Leg press, Dips Press, Leg curl, Traction and Leg extension.~1 minute between each machine is planned"
224173273|NCT06063525|OTHER|Structural anatomy|images acquired with 3T MRI system with 32 channel head coil
224173274|NCT01159457|BIOLOGICAL|Hepatitis B vaccination (Sci-B-Vac)|A dose of 5mcg (0.5 ml) (up to 10yr old) and 10mcg (1.0 ml)(above 10yr old) of the recombinant HBV vaccine will be administered intramuscularly at zero, one and six months intervals
224173275|NCT01159457|BIOLOGICAL|Hepatitis B vaccination (EngerixB)|A dose of 10mcg (0.5 ml) of the recombinant HBV vaccine will be administered intramuscularly at zero, one and six months intervals
224173276|NCT00184067|BIOLOGICAL|Montanide ISA 51|
224173277|NCT00186472|BEHAVIORAL|Brief Cognitive Behavioral Treatment|
224173278|NCT04921410|DEVICE|Biofeedback Knee Sleeve|The biofeedback knee sleeve is a device that is artificially-intelligent and utilizes determined cut-off values of knee motion and forces to determine whether a motion is 'good' or 'bad'. A 'bad' knee motion will provide a haptic output to the wearer (biofeedback) so that they can take note of what the previous motion was that caused the device to signal a warning.
223745181|NCT05663866|DRUG|Montelukast|Montelukast will be administered orally.
224173279|NCT04921410|DEVICE|Sham Biofeedback|The biofeedback knee sleeve is a device that is artificially-intelligent and utilizes determined cut-off values of knee motion and forces to determine whether a motion is 'good' or 'bad'. This intervention will provide sham biofeedback during training sessions.
224306005|NCT01997216|DEVICE|Lotrafilcon B multifocal contact lens|Commercially marketed silicone hydrogel contact lens dispensed in low, medium, or high ADD per current AIR OPTIX® AQUA MULTIFOCAL fitting guidelines
224306006|NCT00375895|DRUG|ciclosporin|ciclosporin administered orally twice a day, at the initial dosing of 2.5 mg/kg/d, adjusted to obtain a C2 concentration of 600 ng/ml associated with the usual ribavirin and PEGinterferon bitherapy.
224306007|NCT03724214|COMBINATION_PRODUCT|Pre-hospital interventional care bundle|"The interventional care bundle will include pre-hospital and in-hospital components and core and adaptable components. All seven centres will implement the core pre-hospital and in-hospital components. Implementation of the adaptable components will be decided by the local team to optimise the interventional care bundle to the local environment.~Pre-hospital core components: 1) covering the bowel in clear plastic, 2) administering intravenous fluids, 3) keeping the neonate warm, 4) transferring to a study centre as soon as possible. This will be implemented as a pre-hospital gastroschisis care protocol to district and secondary level hospitals who refer patients with gastroschisis to the study centres.~Pre-hospital adaptable components: 1) the strategy for disseminating the pre-hospital gastroschisis care protocol."
224306008|NCT03724214|COMBINATION_PRODUCT|In-hospital interventional care bundle|"In-hospital core components: 1) use of a standardised care protocol, 2) neonatal resuscitation and ward care including intravenous access, intravenous fluids, maintenance of normothermia, appropriate antibiotics, regular monitoring and infection control, 3) gastroschisis reduction and sutureless closure using a preformed silo and avoidance of neonatal anaesthesia and surgery, 4) early establishment of breastfeeding and an enhanced enteral feeding programme.~In-hospital adaptable components: 1) administration of parenteral nutrition for neonates who have survived for 1-week in hospital, 2) maternal involvement in monitoring and basic management, 3) management of neonates with gastroschisis on the neonatal intensive care unit if available."
224306009|NCT02516943|OTHER|Control|The patient's ABGs were test according to a 4 - hour routine
224306010|NCT02516943|OTHER|Guideline|The patient's ABGs were test according to the guideline for requests Arterial Blood Gas status post cardiac surgery
224306011|NCT02668588|DRUG|extended release of octreotide|1 intramuscular injection of extended release of octreotide 30 mg
224306012|NCT02668588|DRUG|extended release of placebo|1 intramuscular injection of extended release of placebo
224306013|NCT01596660|DRUG|Bupivacaina 0.5%|Bupivacaina 0.5% 20cc
224306014|NCT01596660|DRUG|placebo comparator|20 cc of saline solution 0.9%, to infiltrate each side.
224306015|NCT01531439|DRUG|Naloxone|Naloxone infusion 0.5 mcg/kg/hr
224306016|NCT01531439|DRUG|Naloxone|Naloxone infusion 2.5 mcg/kg/hr
224306017|NCT00476775|BEHAVIORAL|after school ethnic dance program - ballet folklorica|
224306018|NCT00476775|BEHAVIORAL|culturally-tailored, home-based screen time reduction|
224306019|NCT00476775|BEHAVIORAL|culturally-tailored health and nutrition education|
224306020|NCT03796598|DRUG|Fecal Microbial transplant Capsules|Oral capsules of FMT
224306021|NCT03796598|DRUG|Fecal Microbial Transplant Enema|FMT enema
224306022|NCT03796598|OTHER|Placebo|Placebo
223745182|NCT05663866|DRUG|Methotrexate|Methotrexate will be administered subcutaneously.
224306023|NCT04358055|DEVICE|WET® gel|In each application, a puff should be administered in each nostril every two seconds, with minimal inspirations, up to a sensation of lubrication in the external conduct is perceived. Then the patient should proceed with short inspirations and light touching of ala of the nose, to favour the distribution of the gel. A maximum of 4 erogations (2/nostril) is allowed in each application session.
224306024|NCT00072020|DRUG|zoledronic acid|
224306025|NCT00072020|PROCEDURE|adjuvant therapy|
224306026|NCT00072020|PROCEDURE|neoadjuvant therapy|
224306027|NCT02904941|BIOLOGICAL|Amniotic Membrane Dressing|Amniotic membrane dressings will be made out of donated amniotic membranes from elective cesarean sections. Screening for relevant infectious diseases and irradiation will be performed from every included sample in order to minimise infectious risks. Dressings will be provided to attending surgeons during wound care at the operating theatre and removed every 72-96 hours.
224306028|NCT02904941|DEVICE|Synthetic Dressing|Silicone dressings will used as an active comparator in this study. As with the amniotic membrane, dressings will be applied to wound care at the operating room and replaced every 72 to 96 hours.
223745183|NCT05663866|DRUG|Amivantamab|Amivantamab will be administered intravenously.
224173280|NCT04539665|PROCEDURE|Extended mesenteric resection.|Patients will undergo an ileocolic resection involving high ligation of the ileocolic pedicle, complete mobilization of the mesentery off of the retroperitoneum, and resection of the entire mesentery related to the specimen.
224173281|NCT04869189|DEVICE|JJVC Marketed Contact Lens|Acuvue Oasys® 1-Day
223484760|NCT04890990|BEHAVIORAL|Short videos|Intervention videos will each be of 90-second duration and feature two underage professionals (ages 16) acting as a simulated patient. All videos will focus on an empowered presenter with depression sharing her personal story regarding depression and describe how social supports from family, friends, and community, as well as professional help assisted her in overcoming symptoms of the illness. The actors will include a Black girl and a white girl.
224173282|NCT00152789|PROCEDURE|Oxygen measurement - Eppendorf machine|
223484761|NCT06554236|OTHER|physical therapy and sensory training|Physical therapy standard of care and 5 minutes of sensory training.
224173283|NCT02257112|DEVICE|Multistage low-energy stimulation|The parameters of the Multistage waveform will be altered and the response of the atria will be recorded.
224173284|NCT04976478|DRUG|Nimotuzumab|Patients receive Nimotuzumab: 200mg, intravenous infusion, weekly for 6 weeks.
223484762|NCT01732692|DRUG|MOVIPREP|MOVIPREP solution
223586110|NCT05303688|DRUG|iv dexketoprofen trometamol (Arveles 50mg/2mL; UFSA, İstanbul, Turkey)|The primary predictor variable was preventive analgesia group. Patients were randomly divided in two groups. 50 mg iv dexketoprofen trometamol (Arveles 50mg/2mL; UFSA, İstanbul, Turkey) were administrated 30 minutes before incision in the treatment group (dexketoprofen trometamol n= 15
224173285|NCT04976478|RADIATION|EBRT combined with brachytherapy|"IMRT/VMAT are adopted. A total dose of 45-50.4 Gy, 1.8\~2.0Gy/f, 25\~ 28F in pelvic and/or extension filed. For patients with metastasis in pelvic lymph node and abdominal para-aortic lymph node, the dose of radiation in local lesion will be increased to 60\~66Gy. For patients at stage IIIB, concurrent radiation will be given in parametrial extension or in the late course the dose will be increased to 60Gy.~Brachytherapy: Three dimensional high dose rate brachytherapy is used with HR-CTV D90 cumulative dose of 80\~85Gy (EQD2); If the tumor diameter is ≥4cm, HR-CTV D90 cumulative dose is ≥87Gy (EQD2). Brachytherapy combined with external beam radiotherapy will be completed within 8 weeks."
224173286|NCT03976193|BEHAVIORAL|BfitBwell program|Well known behavior change strategies such as goal setting, and identifying barriers to PA can improve long term adherence to PA, and have been shown to enhance PA maintenance after completion of a supervised intervention among cancer survivors
224173287|NCT03976193|BEHAVIORAL|6 bi-weekly PA Behavior Change counseling sessions|Well known behavior change strategies such as goal setting, and identifying barriers to PA can improve long term adherence to PA, and have been shown to enhance PA maintenance after completion of a supervised intervention among cancer survivors
224173288|NCT05839236|COMBINATION_PRODUCT|Atorvastatin Calcium Tablets|The intervention observes the effects of the medicines on the participant's health without the continued interventions on blood pressure. Rescue medicines will be used once if the blood pressure rise again beyond the healthy range.
224173289|NCT04974957|DRUG|SHR-1701；BP102|"Drug: SHR-1701 IV infusion~Drug: BP102 IV infusion"
224173290|NCT06382740|PROCEDURE|Liver transplantation|Liver transplantation
223484763|NCT01617213|DRUG|Melphalan|200 mg/m2/IV
223484764|NCT01617213|DRUG|Lenalidomide|10 mg daily continuously for the first 3 months, then increased to 15 mg daily as long as the patient tolerates the drug.
224173291|NCT00382551|BEHAVIORAL|Moderate daily consumption of Red wine|
224173292|NCT00382551|BEHAVIORAL|Moderate daily consumption of beer|
224173293|NCT00382551|BEHAVIORAL|Moderate consumption of fruit juice rich in polyphenolics|
223586111|NCT05303688|DRUG|Steril Salin (control)|30 minutes before incision in the treatment group (dexketoprofen trometamol n= 15) and iv sterile saline were administrated 30 minutes before incision in the placebo group (saline n= 15).
223586112|NCT00620152|BEHAVIORAL|1|Low glycemic load diet by telephone counseling
224173294|NCT00998985|DRUG|Grazoprevir|10, 30, 50, 100, 200, 400, 600 or 800 mg Grazoprevir tablets, orally, once a day for 7 days
223586113|NCT00620152|BEHAVIORAL|2|Low fat diet by telephone counseling
223586114|NCT03933176|PROCEDURE|Restoration of carious lesions|Selective carious tissue removal followed by restoration of the cavity using composite resin.
223586115|NCT04897607|BEHAVIORAL|Standard Care|Participants will be advised to quit smoking and offered a choice of nicotine replacement patches or varenicline. Participants are free to decline medication.
224173295|NCT00998985|DRUG|Placebo|Placebo tablet, orally, once a day for 7 days
224173296|NCT00333931|DRUG|Phenytoin|
224173297|NCT00333931|BEHAVIORAL|Cognitive Behavioral Therapy|
224306029|NCT02904941|PROCEDURE|Standard Wound Care|Every included participant will receive standard wound care regardless of treatment allocation. Contaminants such as clothes or other materials will be removed, and all burns will be cleaned using sterile saline solutions. Clorhexidine will also be used to clean the skin. Surgical debridement under general anesthesia or procedural sedation/analgesia will be performed to every included participant, in which nonviable tissues and blisters will be removed.
224306030|NCT00754650|DRUG|Bevacizumab|Bevacizumab was supplied as a sterile liquid in single-use vials.
224306031|NCT00805675|DRUG|Telbivudine|600 mg monotherapy supplied in film-coated tablets.
223484765|NCT00507572|OTHER|Medical Chart Review|Medical records are reviewed
223484766|NCT04035083|DEVICE|Laser activated irrigation|Diode laser at 980 nm, power of 1.5W, for 5 seconds inside the canal along with sodium hypochlorite, repeated 4 times with a gap of 10 seconds in between
223484767|NCT04035083|DEVICE|Passive ultrasonic irrigation|ultrasonic activation inside the canal for 1 min
223484768|NCT04159064|DIAGNOSTIC_TEST|Thromboelastometry, Impedance Aggregometry|Study of coagulation changes after cardiac surgery on CPB using Minimal Extracorporeal Circulation
224173298|NCT00253799|DEVICE|Hylan GF-20|
224173299|NCT05093569|DEVICE|K'watch|Patients
224173300|NCT04277052|DEVICE|Determination muscles sections by Ultrasonography|Determination muscles sections by Ultrasonography
224173301|NCT01995786|DEVICE|Goal Directed Fluid Therapy FloTrac/Vigileo|
224173302|NCT03649386|DEVICE|Heated and humidified breathing circuit on|Heated and humidified breathing circuit will be turned on.
224173303|NCT03649386|DEVICE|Heated and humidified breathing circuit off|Heated and humidified breathing circuit will be turned off.
224306032|NCT00805675|DRUG|Tenofovir|Tenofovir disoproxil fumarate was supplied in 300 mg tablets
224306033|NCT00805675|DRUG|Telbivudine plus tenofovir|Telbivudine 600 mg and Tenofovir 300 mg were purchased in commercial packs. Patients were instructed to take medication(s) orally every morning either with or without food.
224306034|NCT04310618|OTHER|No intervention|No intervention
224173304|NCT02637167|DRUG|Rifaximin|Rifaximin has negligible intestinal absorption after oral administration, giving it a good safety profile. Unlike systemically available antibiotics, this antimicrobial allows localized enteric targeting of bacteria and is associated with a minimal risk of systemic toxicity or side effects.
224173305|NCT02637167|DRUG|Saccharomyces boulardii|The same advantage described above to Rifaximin applies to S. Boulardii, which might be therapeutically sufficient with the advantage of being less disruptive to the instestinal microbiota than broad-spectrum antibiotics.
224173306|NCT01595308|DIETARY_SUPPLEMENT|Pomegranate juice|Pomegranate juice
224173307|NCT00549406|PROCEDURE|computerized visual training|two one-hour training sessions per week, for five consecutive weeks
224173308|NCT00549406|PROCEDURE|computerized word puzzles|two one-hour sessions per week, for five consecutive weeks
224173309|NCT00549406|PROCEDURE|video-game based visual training|two one-hour training sessions per week, for five consecutive weeks
224173310|NCT01701856|DRUG|Interferon beta-1b|250 mcg, s.c., each other day for 12 months
224173311|NCT03824964|BIOLOGICAL|Anti-CD19/CD22 CAR NK Cells|Total dose of 50-600 thousand /kg Anti-CD19/CD22 CAR NK cells will be administered at day0
224173312|NCT01040728|DRUG|Olodaterol (BI1744) Low|Low dose inhaled orally once daily from Respimat inhaler
224173313|NCT01040728|DRUG|Olodaterol (BI1744) High|High dose inhaled orally once daily from Respimat inhaler
224173314|NCT01040728|DRUG|Tiotropium 18 mcg|18 mcg inhaled once daily from HandiHaler
224306035|NCT00642694|DRUG|Escitalopram|Escitalopram 10 or 20mg qd based on symptoms at patient visit
223484769|NCT05283837|BIOLOGICAL|Pertuzumab (ZRC-3277)|Pertuzumab in combination with Trastuzumab and Docetaxel will be administered via intravenous (IV) infusion every 3 weeks for 06 cycles.
223484770|NCT05283837|BIOLOGICAL|Pertuzumab (Perjeta®)|Pertuzumab in combination with Trastuzumab and Docetaxel will be administered via intravenous (IV) infusion every 3 weeks for 06 cycles.
223484771|NCT03243019|DRUG|rapamycin|oral administration
223586116|NCT04897607|BEHAVIORAL|Precision pharmacotherapy|Participants will be advised to quit smoking and provided a medication recommendation on the basis of their nicotine metabolite ratio (NMR) test (i.e., nicotine replacement patches for slower metabolizers, varenicline for faster metabolizers). Participants are free to choose either medication or decline any medication.
223586117|NCT02983591|DRUG|Misoprostol after delivery|Patients will receive 1000 mcg Misoprostol per rectum
223586118|NCT02983591|DRUG|Oxytocin after delivery|Patients will receive 20 units oxytocin intravenously in one liter of Lactated Ringer solution at a rate of 150ml/h
223586119|NCT02983591|DRUG|Oxytocin before delivery|All patients will receive oxytocin 0.5-1 milliUnit/min IV, titrated to 1-2 milliUnit/min every 15-60 min before delivery to induce labor
223586120|NCT02439567|DEVICE|Fibroscan: Liver and Spleen elastography|In cirrhotic patients treated with antivirals for HCV infection, repeated liver and spleen stiffness measures with Fibroscan will be performed to predict the presence of clinically significant and severe portal hypertension.
223586121|NCT00002807|RADIATION|radiation therapy|45 Gy in 25 fractions over 5 weeks
223586122|NCT02406352|DEVICE|Multispectral Digital Colposcope with probe|"Cervical images will be obtained with the Multispectral Digital Colposcope. Spectroscopic data will be obtained with the probe from eligible patients who provided consent to participate in the study.~The standard of care for research participants will not change."
223586123|NCT02317952|OTHER|Experimental Extensively Hydrolyzed Formula|
223586124|NCT02317952|OTHER|Active Comparator Formula|
223586125|NCT03781791|DRUG|Active Investigational Treatment ENT-01|ENT-01 will be administered in tablet form, once daily.
223586126|NCT03781791|DRUG|Placebo Treatment|Placebo will be administered in tablet form, once daily.
223745184|NCT05663866|DRUG|Lazertinib|Lazertinib tablets will be administered orally.
224173315|NCT01040728|DRUG|Placebo (for Olodaterol (BI1744)l)|Placebo (olodaterol low and high dose) delivered by Respimat
224306036|NCT00642694|DRUG|Ramelteon|Ramelteon 8 mg qd
223484772|NCT03243019|DEVICE|MRI|cervicofacial MRI
223484773|NCT03243019|BIOLOGICAL|Rapamycin dosage|Biological dosage of Rapamycin level
223484774|NCT01186081|RADIATION|Preoperative chemoradiotherapy|Preoperative chemoradiation with conventional radiotherapy (46 Gy in 23 fractions to the whole pelvis followed by a boost dose of 4 Gy in 2 fractions) and oral fluoropyrimidine (capecitabine 825 mg/m2 twice per day without weekend breaks during whole radiotherapy period)
223586127|NCT00381875|BIOLOGICAL|E1M184V peptide vaccine|
223586128|NCT00381875|BIOLOGICAL|incomplete Freund's adjuvant|
223586129|NCT00381875|BIOLOGICAL|sargramostim|
224173316|NCT01040728|DRUG|Placebo (for Tiotropium)|Placebo (Tiotropium 18 mcg) delivered by HandiHaler
224173317|NCT05609162|PROCEDURE|neurosurgical resection|neurosurgical resection, stereotactic radiosurgery (SRS), whole brain radiotherapy(WBRT), EGFR target drugs, Immune checkpoint inhibitors，cisplatin, temozolomide
224173318|NCT00155467|PROCEDURE|CT|
224173319|NCT05362461|DIAGNOSTIC_TEST|Near Infrared Transillumination|Caries imaging detection technology.
224173320|NCT03445611|DRUG|corticosteroid solution with lidocaine containing parabens.|To identify whether corticosteroid use with anesthetics containing parabens reduces clinical effectiveness relative to para-free preparations.
224173321|NCT03445611|DRUG|corticosteroid solution with lidocaine containing no paraben|To identify whether corticosteroid use with anesthetics containing parabens reduces clinical effectiveness relative to para-free preparations.
224173322|NCT02793206|DEVICE|Imaging|
224173323|NCT03276260|DEVICE|PMD-200|Patient will be connected to PMD-200 by finger-probe before induction of anesthesia or sedation. Recording will continue during surgery until extubation or awakening. Recording will be initiated again as soon as the patient arrives to the PACU until discharge to the surgical ward or home.
224173324|NCT04717167|OTHER|Dry Needling|
224173325|NCT04717167|OTHER|Sham Needling|
224173326|NCT00432289|PROCEDURE|Acupuncture|Acupunture treatment 3x per week for 6 weeks.
224173327|NCT07022002|DRUG|SSGJ-705|anti-PD-1 (programmed cell death protein 1) and anti-HER2 (Human Epidermal GrowthFactor Receptor 2)bispecifc antibody
224306037|NCT00642694|OTHER|Placebo|Matching placebo qd
224306038|NCT03688282|DEVICE|Wearable vibration belt|The device is worn, a wearable vibration belt, for a specified time. This will provide vibration starting at the hips.
224173328|NCT07022002|DRUG|PD-1/L1 inhibitor combined with chemotherapy|Immune checkpoint inhibitors
224173329|NCT07022002|DRUG|SSGJ-705 combined with chemotherapy|anti-PD-1 and anti-HER2 bispecifc antibody
224173330|NCT02029391|OTHER|Manual pressure release|Therapist applied non-painful pressure with slowly increase over the myofascial trigger point until he felts a tissue resistance barrier.
224173331|NCT02029391|OTHER|Kinesio tape|Kinesio tape was adhered from insertion to origin of the upper trapezius muscle
224306039|NCT03688282|DEVICE|Sham, wearing belt|The device is worn, for a specified time. It will not be turned on during this period. It is only sham.
224306040|NCT05483725|BIOLOGICAL|Booster dose of mRNA vaccine|Administration of SARS-CoV-2 mRNA vaccine.
224306041|NCT00486317|DRUG|Oral salmon calcitonin, salmon calcitonin nasal spray|
224306042|NCT00712738|DRUG|Nifedipine|
224306043|NCT00712738|PROCEDURE|Phlebotomy|
224306044|NCT00712738|PROCEDURE|Urinalysis|
224306045|NCT00712738|PROCEDURE|Echocardiogram|
224306046|NCT00712738|PROCEDURE|Electrocardiogram|
224306047|NCT00814918|DRUG|5-ALA with Blu-U Light|20% 5-ALA Levulan Kerastick will be crushed and prepared for application after shaking for at least 3 minutes. Topical 5-ALA will be applied liberally on skin with extra pressure on lesions.Skin will be exposed to DUSA Blu-U light (417nm).
224306048|NCT00814918|DRUG|5-ALA with Candela V-beam Pulse Dye Laser|20% 5-ALA Levulan Kerastick will be crushed and prepared for application after shaking for at least 3 minutes. Topical 5-ALA will be applied liberally on skin with extra pressure on lesions.Skin will be exposed to Candela V-beam Pulsed Dye Laser (595 nm).
224306049|NCT04316507|PROCEDURE|Genetic Counselling and Testing|Oncologist-initiated brief genetic counselling and testing
224306050|NCT03537599|BIOLOGICAL|Daratumumab|Given IV
224306051|NCT03537599|PROCEDURE|Donor Lymphocyte Infusion|Given via infusion
224306052|NCT03537599|OTHER|Laboratory Biomarker Analysis|Correlative studies
223484775|NCT01186081|RADIATION|Postoperative chemoradiotherapy|Postoperative radiotherapy with conventional radiation schedule (50 Gy in 25 fractions to the whole pelvis) and oral fluoropyrimidine (capecitabine 825 mg/m2 twice per day without weekend breaks during whole radiotherapy period)
223484776|NCT00635284|DRUG|ABI-009|nab-rapamycin
224306053|NCT00097877|DRUG|biphasic insulin aspart|
223484777|NCT03837834|OTHER|Functional Electrical Stimulation Leg Cycling Exercise|FES- leg cycling for 45 minutes (3 min warm up + 40 min HIIT + 2 min cooldown). The FES will be applied via surface electrodes and the stimulation intensity based on your tolerance level.
223484778|NCT05113303|DEVICE|Navigated Revision Total Knee Arthroplasty|Patients in the case group receive a Columbus® Revision knee prosthesis, implanted with computer assisted surgery
224306054|NCT00097877|DRUG|insulin glargine|
224306055|NCT01484262|DRUG|liraglutide|Patients will be treated according to routine clinical practice at the discretion of the treating physician according to current labelling.
223484779|NCT05113303|DEVICE|Manual Revision Total Knee Arthroplasty|Patients in the control group will correspond to a historical cohort of patients in which manual jig-assisted knee revision was done.
223586130|NCT00381875|OTHER|immunoenzyme technique|
224173332|NCT06189027|DRUG|MDMA|Adjunctive administration of MDMA to assist psychotherapeutic process
224173333|NCT06189027|BEHAVIORAL|Psychotherapy|Psychotherapy aimed at assisting with PTSD symptom reduction
224173334|NCT03024229|DEVICE|LifePort® perfusion machine|Renal perfusion on LifePort® machine
224173335|NCT04162262|OTHER|Instrumental-assisted soft tissue mobilization (IASTM)|Instrumental-assisted soft tissue mobilization (IASTM) will consist of treatment focused on the plantar surfaces of foot, posterior heel, and lower leg. The IASTM will be implemented using Graston Technique Instruments by clinicians trained and certified in the technique. Each 10-minute treatment will consist of two phases: 1) six-minute static phase, which includes tissue status screening and soft tissue mobilization, and 2) four-minute dynamic tissue mobilization phase. The treatment will focus on the web spaces of each toe plantarly, the metatarsal heads, the spaces between metatarsals, the medial and lateral plantar fascia borders, plantar fascia proximal origin, the heel, and the lower leg muscle groups. The targeted soft tissues are the plantar fascia, ankle plantar flexors, heel fat pad, Achilles tendon, and the gastrocnemius-soleus complex.
224306056|NCT01484262|DRUG|insulin|Any insulin in any device available on the market may be used by patients as part of routine clinical practice according to current labelling.
224306057|NCT06018974|DEVICE|Yetitablet gaming|Playing digital games like bowling, memory games, coordination games ect. with the Yetitablet.
224306058|NCT04799873|DRUG|AAT( Alpha 1 Antitrypsin)|AAT administration based on clinical indication
224306059|NCT05569603|BEHAVIORAL|Chronobiology-guided lifestyle interventions|1\) timed bright light exposure using blue-enriched white light glasses, 2) recommendations for meal timing, and 3) sleep hygiene education
224306060|NCT00058721|DRUG|I-123-5-IA85380|
224306061|NCT05763186|OTHER|Sampling|Comparison of the results of the biological examinations obtained on the 6 tubes collected on the PiccLine with the results of the biological examinations obtained on the peripheral sample.
224306062|NCT05763186|OTHER|Sampling and rinsing|Comparison of the results of the biological examinations obtained on the 6 tubes collected on the PiccLine with the results of the biological examinations obtained on the peripheral sample.
224306063|NCT06445114|DRUG|Cisplatin|"Low risk pathology with post-op HPV DNA (-): cisplatin-based chemoradiation with 30 Gy in 15 fractions and 3 cycles of weekly cisplatin 40mg/m2 IV on Days 1, 8, and 15 of radiation.~Low risk pathology with post-op HPV DNA (+): cisplatin-based chemoradiation with 40 Gy in 20 fractions and 4 cycles of weekly cisplatin 40mg/m2 IV on Days 1, 8, 15, and 22 of radiation.~High risk pathology with post-op HPV DNA (-), excluding patients with both 5 LN+ and ENE+ or pre-op HPV DNA≤12 copies/mL: cisplatin-based radiation with 40 Gy in 20 fractions and 4 cycles of weekly cisplatin 40mg/m2 IV on Days 1, 8, 15, and 22 of radiation.~High risk pathology with post-op HPV DNA (+) OR pre-op HPV DNA≤12 copies/mL OR both 5 or more LN+ and ENE+: cisplatin-based radiation with 50 Gy in 25 fractions with 5 cycles of weekly cisplatin 40mg/m2 IV on Days 1, 8, 15, 22, and 29 of radiation."
224306064|NCT01007942|DRUG|everolimus|Oral everolimus was taken once 5 mg/day (2 × 2.5 mg tablets) and were packaged into blister packs.
224306065|NCT01007942|DRUG|Placebo|Oral everolimus placebo was taken once 5 mg/day (2 × 2.5 mg tablets) and were packaged into blister packs.
224306066|NCT01007942|DRUG|vinorelbine|intravenous vinorelbine (25 mg/m2 weekly)
224173336|NCT04162262|OTHER|High-Load Strength Training|Participants will perform a heel raise exercise used by Rathleff et al (2015). The exercise will be performed twice daily. While standing with the forefoot on a step, the toes will rest on a partially folded towel, placing them in a maximally dorsiflexed position. The exercise will consist of a maximum ankle plantar flexion followed by maximal dorsiflexion. The concentric plantar flexion and eccentric lowering phases will be 3 seconds, with a 2 second isometric pause in between. The exercise will be performed unilaterally if tolerated by the subject. Otherwise, a bilateral calf raise will be performed until the subject is able to perform the unilateral version. The exercise will be performed every other day and progressed throughout the trial as described by Rathleff and colleagues.
224173337|NCT04162262|OTHER|Plantar Flexor and Gastrocnemius Stretching|For the plantar flexor stretch (DiGiovanni et al, 2006), subjects will sit and cross the affected leg over the contralateral leg. Placing the affected side fingers on the plantar toes, distal to the metatarsophalangeal joints, they will passively dorsiflex the toes until they feel stretching in the arch of the foot. Subjects will be instructed to hold this stretch for 10 seconds and repeat it 10 times. The gastrocnemius stretch will be performed in supine with a towel placed around the distal foot and the foot actively inverted. With the knee extended, the subject will flex the hip while passively dorsiflexing the foot using the towel. This stretch will be held for 30 seconds and repeated 3 times. Subjects will be asked to perform both stretches three times each day.
224173338|NCT02388672|DIETARY_SUPPLEMENT|decaffeinated coffee|Decaffeinated coffee with low chlorogenic acid (224mg; low-CGA)
223484780|NCT02846402|OTHER|Oral HIV Self-Testing|The Oral HIV Self-Test is an in-home test that uses an oral swab to collect samples of oral mucosa that is used to detect the presence of HIV antibodies. The test is read after 20 minutes by the user. The test can be done by an individual at any time and place of the user's choosing. The test is read visually.
224173339|NCT02388672|DIETARY_SUPPLEMENT|chlorogenic acid|Decaffeinated coffee with high chlorogenic acid (560mg; high-CGA)
224173340|NCT02388672|DIETARY_SUPPLEMENT|green coffee bean extract supplement|Decaffeinated coffee together with green coffee bean extract supplement (560mg; high-CGA)
224173341|NCT02388672|DIETARY_SUPPLEMENT|placebo|Decaffeinated coffee with placebo capsules as control group for green coffee bean extract supplement (224mg; low-CGA)
224173342|NCT01899001|BEHAVIORAL|Cognitive Behavioral Therapy|Participants will receive weekly, 30 minute sessions with a CBT-trained clinical psychologist for the first 8 weeks. Briefly, the purpose of CBT is to treat mood and associated anxiety disorders by changing dysfunctional thoughts that lead to negative mood states and maladaptive behaviors. Through the use of Socratic questioning, the therapist challenges the patient to observe the relationship between thoughts and feelings and to question the underlying beliefs that perpetuate negative affect. Ultimately, patients learns to recognize maladaptive automatic thoughts and develop a more rational and balanced way of thinking about themselves and the world around them.
224173343|NCT01899001|BEHAVIORAL|Nutrition Counseling|All women will receive nutrition/exercise counseling by a trained counselor. They will consume a self-selected diet of 1500-1800kcal/d of conventional foods based on the Food Guide Pyramid. Participants will also have an exercise goal that starts at 50 minutes per week and increases to 175 minutes per week. Sessions will teach standard weight loss skills, including self-monitoring, problem-solving, enlisting social support, and overcoming negative thoughts. Subjects will be asked to keep daily food intake and exercise logs which will be reviewed at the nutrition counseling sessions. These sessions will occur in person once weekly lasting on average 30 minutes for 16 sessions.
224173344|NCT05474768|OTHER|no intervention|no intervention
224173345|NCT03398174|BEHAVIORAL|Motor Control Exercise|"Exercise aiming at improving function of specific muscles of the lumbopelvic region and the control of posture and movement.~In addition, participants will perform stretching exercises aiming at targeting the postural muscles and connective tissue around the lower back, pelvis and lower limb that tend to get shortened in chronic LBP, and they will be advised to perform aerobic exercise in the form of overground walking at desirable speed at home."
224173346|NCT03398174|BEHAVIORAL|Patient Education|"Patient education to enable patients to better understand their pain, change any unhelpful beliefs about LBP, and integrate self-management and active coping strategies that deals with fear avoidance behavior and catastrophic thought.~In addition, participants will perform stretching exercises aiming at targeting the postural muscles and connective tissue around the lower back, pelvis and lower limb that tend to get shortened in chronic LBP, and they will be advised to perform aerobic exercise in the form of overground walking at desirable speed at home."
224173347|NCT04019197|DRUG|Semaglutide Injectable Product|semaglutide subcutaneous injection
224173348|NCT04019197|DRUG|Placebo|placebo injection
224173349|NCT02573012|DRUG|Placebo matched to prednisone|Participants will receive placebo matched to prednisone orally for 24 weeks.
224173350|NCT02573012|DRUG|Prednisone|Participants will receive prednisone either at a constant dose of 5 mg/day, or 5 mg/day with 1 mg decrements every 4 weeks orally for 24 weeks.
224173351|NCT02573012|BIOLOGICAL|Tocilizumab|Participants will receive tocilizumab at a dose of 162 mg once a week subcutaneously for 24 weeks.
223484781|NCT02866383|DRUG|Nivolumab|3 mg/kg is given over 60 minutes I.V. on day 1 just after radiation and then every 2 weeks (q2w)
223745185|NCT07130734|BEHAVIORAL|Digital Physical Activity|The Pathverse mobile application platform will be downloaded on each participant's smartphone. Participants will be guided on how to download and use the application, as well as how to interact with the application during the intervention period. Participants will choose approximately five types of physical activity they enjoy before the intervention and will be prompted to complete these physical activities throughout the intervention. Participants will also self-report the duration and type of physical activity performed each day of the intervention.
223484782|NCT02866383|DRUG|Ipilimumab|1 mg/kg is given over 90 minutes I.V. on day 1 30 minutes after the completion of nivolumab infusion and then every 6 weeks IV (q6w)
223484783|NCT02866383|RADIATION|Radiotherapy|15 Gy x 1 fraction given on day 1
223484784|NCT01281306|DRUG|LCZ696|LCZ696 was supplied as tablets in blister cards in 100 mg strengths.
223484785|NCT01281306|DRUG|Valsartan|Valsartan was supplied as tablets in blister cards in 160 mg and 320 mg strengths.
223484786|NCT01281306|DRUG|AHU377|AHU377 was supplied in tablets in blister cards in 50 mg and 100 mg strengths.
223484787|NCT01281306|DRUG|Placebo|Placebo was supplied as tablets in blister cards.
223484788|NCT02054195|BEHAVIORAL|Training|Training model is consist of effort to provide intra uterine device post placental by organising a special guided training model for post-placental IUD insertion by pushing the head of IUD using index and middle finger close enough to fundal part of uterus to prevent expulsion.
223484789|NCT02054195|BEHAVIORAL|No Training|Control of Training model is without training on effort of pushing the head of IUD using index and middle finger to uterine fundus.
223484790|NCT03719664|DRUG|Albuvirtide|Intravenous infusion of Albuvirtide
223484791|NCT03719664|DRUG|3BNC117|Intravenous infusion of 3BNC117
223484792|NCT03719664|DRUG|Baseline ART|Subjects continuing on baseline ART
223484793|NCT06418815|OTHER|Concept map group|The intervention group will create a concept map regarding neonatal toxic stress.
223484794|NCT03174522|DRUG|REX-001|REX-001 is administered through an intra-arterial catheter.
223484795|NCT03174522|DRUG|Placebo|Placebo is administered through an intra-arterial catheter.
223484796|NCT05803343|BEHAVIORAL|Regulating Together-Canine|RT-C is an animal assisted, intensive outpatient group intervention for children with autism spectrum disorder and emotion dysregulation. RT-C meets for 1.5 hours, twice weekly for five weeks with concurrent youth and caregiver groups. The children progress through skills including relaxation training, arousal ratings, problem size, mindfulness, problem solving, and cognitive flexibility. The caregivers learn crisis management, reward systems, and coaching strategies for topics taught to the children. Homework is utilized to reinforce use of skills outside the group. The canines are present throughout as both a calming presence and teaching assistant. Children will be able to interact with the dog when practicing relaxation at the beginning of each session and throughout the session. Additionally, the dog will help to emphasize certain curriculum concepts.
223484797|NCT05803343|BEHAVIORAL|Regulating Together-Standard|RT-S an established, intensive outpatient group intervention for children with autism spectrum disorder and emotion dysregulation. It engages both caregivers and children and utilizes evidence-based intervention techniques including cognitive behavioral therapy (CBT), visuals, reinforcements, and scaffolding, and newer interventions such as mindfulness and acceptance-based therapy.
223484798|NCT03188471|DRUG|GnRH antagonist|GnRH antagonist 0.25mg daily from the day of oocyte retrieval for seven days for high risk of ovarian hyper stimulation syndrome patients
223484799|NCT03188471|DRUG|aspirin|aspirin (100 mg daily, plus saline as placebo of GnRH antagonist ) for seven days
223484800|NCT01609192|DRUG|Hydrea® (hydroxyurea )|treatment by hydroxyurea (20-30 mg/kg/day) for 6 months
223484801|NCT03419871|OTHER|Monitoring Sleep|An accelerometer will be placed on the wrist or ankle of the child while the child sleeps in their home. Caregivers will be instructed to keep the accelerometer on their toddler's ankle to measure sleep duration, latency and sleep efficiency. Seven nights of data will be obtained because actigraphy is most reliably measured in young children over this time frame.
223484802|NCT03419871|OTHER|stress biomarkers|"Salivary and hair cortisol measurements were used to obtain a change in baseline from 12 to 24 months. Data on the timing of the saliva collection will be collected using a Medical Electronic Monitoring System (MEMScapTM) - a digital memory cap that records the timing and frequency of opening.~Cortisol will be measure in the morning and bedtime samples. A small amount of hair (30mg) will be cut from the posterior vertex of the child's head. Due to the expected variability in hair length of toddlers, documentation of hair length will be completed. Each centimeter represents 1 month history of stress and ideally 3 cm of hair length will be collected to provide a three month history of stress."
223586131|NCT03443232|PROCEDURE|Cryoballoon ablation|Cryoablation is performed using a single cryoballoon.In general, the cryoablation of each pulmonary vein is carried out twice. According to the objective condition, the operator determine whether or not to carry out an additional cryoablation. Then we will applicate electrophysiological substrate mapping for guiding ablation of atrial fibrillation,If mapping system detect a poor substrate,we should continue to ablate for left atrial roof and posterior line.
224173352|NCT03518580|OTHER|real-time assessment of biopsychosocial functioning|the participants were asked to provide biopsychosocial data using the mobile device
224173353|NCT00422968|DEVICE|Percutaneous coronary intervention|Using silorimus eluting stent
224173354|NCT00422968|PROCEDURE|coronary artery bypass graft|coronary artery bypass graft
224173355|NCT01693289|DRUG|metformin plus letrozole|
223484803|NCT02428153|OTHER|stretching exercises|static stretching exercise of 5 repetitions, with a duration of 45 seconds to the right gastrocnemius muscle and dynamic stretching exercise of 5 repetitions, with a duration of 45 seconds to the cases' left gastrocnemius muscles
223484804|NCT00051506|DRUG|ALIMTA|
223484805|NCT00051506|DRUG|carboplatin|
223484806|NCT00051506|DRUG|cisplatin|
223484807|NCT01597362|PROCEDURE|laparoscopy|Trocar access in laparoscopy
223484808|NCT01597362|PROCEDURE|Laparoscopy|"The angle of the Veress needle insertion is 45 for non-obese women. After insertion of the needle, tests to determinate its correct positioning are: the double click test, the aspiration test, the handing drop test, serial intrabdominal gas pressure measurements.~The volume of CO2 inserted with the Veress needle depends on the intra-abdominal pressure. Adequate pneumoperitoneum should is determined by a pressure of 20 to 30 mm Hg and not by predetermined CO2 volume."
223484809|NCT01597362|PROCEDURE|Laparoscopy|"Direct insertion of the trocar is performed without prior pneumoperitoneum. Infra-umbilical skin incision is wide enough to accomodate the diameter of a sharp trocar/cannual system. The abdominal wall is elevated by pulling on, by hands, two towel clips placed 3 cm on either side of the umbilicus, and the trocar is inserted at a 90°angle.~On removal of the sharp trocar, the laparoscope is inserted to confirm the presence of omentum or bowel in the visual field."
224173356|NCT01693289|PROCEDURE|ovarian drilling|
224173357|NCT05315973|DEVICE|Testing sensor vs glucometer|Will test accuracy of this sensor; there will be no intervention.
224173358|NCT05589623|OTHER|Copenhagen adduction exercise|The CAE is a progressive eccentric training program that enhances hip adduction. The fact that exercises are done with a partner and do not require special equipment makes them more useful in a team setting. The MPCA program, adapted from the original CAE, included six progressive levels for eight weeks, beginning with an assisted isometric adduction hold (level 1) and progressing incrementally to a complete CAE as the original exercise (level 6). The progression in levels will depend on a pain score ≤ 4/10 numeric rating scale (NRS) in the adductor squeeze test and post-session DOMS score ≤ 4/10 NRS.
224173359|NCT05589623|OTHER|Usual rehabilitation program|The usual rehabilitation program will include leg swings extension/flexion, leg swings abduction/adduction, standing hip circles, isometric standing hip adduction using elastic bands, stretching exercises, balance training on a wobble board, and single leg coordination exercises. Difficulty and volume are progressing incrementally.
224173360|NCT03234075|OTHER|Regional organization for promotion of renal transplantation|"Early identification of candidates for renal transplantation~* with the help of a care coordinator Inform all patients appropriately about the techniques of renal function supplementation~* delivered by expert patients and a care coordinator Assist the nephrologists in patient graft pathway~* Multidisciplinary assessment of patients in dedicated web-conferencing meetings bringing together nephrologists and transplant team ( WebRCP of kidney transplant orientation)~* Helping to carry out the pre-graft assessments of patients by a care coordinator"
224173361|NCT04484038|RADIATION|hypofractionated postoperative radiation therapy|The patients included in the study will undergo intensity-modulated radiotherapy, of any modality, and image-guided (IGRT) with an emphasis on tissue preservation and administration precision through the use of devices that guarantee the stability and reproducibility of the same.
224173362|NCT01875874|BIOLOGICAL|ELAD|Continuous treatment with the ELAD System for a minimum of 3 days to a maximum of 10 days. The subject's ultrafiltrated blood is circulated through 4 cartridges, each containing approximately 110 grams of C3A cells (approximately 440 grams total).
224173363|NCT00590031|DRUG|Cisplatin|pts will receive weekly cisplatin 30mg/m2 after hydration on weeks 8,9,11 and 12
223484810|NCT01597362|PROCEDURE|Laparoscopy|A small incision, 1 cm long, is made through the skin of the lower edge of the umbilical fossa. The skin and the subcutaneous adipose tissues are retracted with the Zimmerman dissectors. The anterior rectus fascia is incised with the scalpel. The dissection with the Zimmerman valves allows the exposure of the peritoneum. After the peritoneum is incised, the trocar is inserted under direct vision. The laparoscope is introduced and insufflation is started. At the end of the procedure the fascial defect is closed.
223484811|NCT03171870|DIAGNOSTIC_TEST|high resolution computed tomography|high resolution computed tomography is an essential component of the diagnostic pathway in idiopathic pulmonary fibrosis. Unusual interstitial pneumonia is characterized on high resolution computed tomography by the presence of reticular opacities, often associated with traction bronchiectasis
223484812|NCT03955445|DRUG|LNP023|LNP023 capsules
223484813|NCT02606253|DRUG|tolvaptan|Tolvaptan (Samsca) is a vasopressin 2 receptor antagonist that works in the collecting duct of the nephron to cause diuresis.
223484814|NCT02606253|DRUG|Chlorothiazide|Chlorothiazide (Diuril) is an intravenous thiazide diuretic that works in the distal convoluted tubule of the nephron to cause diuresis.
223484815|NCT02606253|DRUG|Metolazone|Metolazone (Zaroxolyn) is an oral thiazide diuretic that works in the distal convoluted tubule of the nephron to cause diuresis.
223484816|NCT03411538|OTHER|Collect data on clinical history|Collect data on clinical history, clinical manifestation, comorbidity, admission data, use of invasive medical intervention, history of antibiotic treatment and antibiotic susceptibility test results
223484817|NCT02508064|DRUG|BMS-663068|BMS-663068
223484818|NCT00383825|PROCEDURE|Anterior segment indocyanine green angiography|
223484819|NCT06494163|BEHAVIORAL|Exercise|The MICT and HIIT intervention groups will complete supervised virtual exercise sessions for 12 weeks using Zoom care or Microsoft Teams as a backup resource. The appointments will be scheduled and conducted 2 days per week. Initially, exercise intensity will be determined from participants' peak HR achieved during a baseline CPET.
223484820|NCT00890721|DRUG|SKY0402|During the operation, 30cc of SKY0402 are injected into the wound.
223484821|NCT00890721|DRUG|Placebo|During the hemorrhoidectomy, 30cc Placebo injected into the wound.
223484822|NCT00003969|DRUG|tanespimycin|
223484823|NCT03331562|DRUG|Pembrolizumab|pembrolizumab solution for infusion
223484824|NCT03331562|DRUG|paricalcitol|Paricalcitol solution for injection
223484825|NCT03331562|DRUG|placebo|normal saline solution for injection
223484826|NCT06306391|DRUG|Intravenous naloxone|Nyoxid 1.8 mg nasal spray, solution in single-dose container. Study drugs (naloxone nasal spray and naloxone intravenously) will be administered in 8 subjects in two sequences in fasting conditions (10 hours pre-dose and 4 hours post dose): Intranasal -\> washout period -\>intravenous (n=4) and Intravenous -\>washout period -\> intranasal (n=4).
223484827|NCT06306391|DRUG|Intranasal naloxone|Naloxone Kern Pharma 1 mg in total (from 0.4 mg/mL injectable solution). Study drugs (naloxone nasal spray and naloxone intravenously) will be administered in 8 subjects in two sequences in fasting conditions (10 hours pre-dose and 4 hours post dose): Intranasal -\> washout period -\>intravenous (n=4) and Intravenous -\>washout period -\> intranasal (n=4).
223484828|NCT06367179|OTHER|Virtual reality and AI use|The experimental group will receive interventions of virtual reality and artificial intelligence wound detecting system.
223484829|NCT06367179|OTHER|Health education leaflet|The control group maintained the traditional pressure injury health education with oral introduction and health education leaflet.
223484830|NCT03718000|DEVICE|Daily self-weighing (DSW)|DSW was conducted using digital WiFi scales during the holiday season. Participants received electronic graphic feedback of their weight fluctuations immediately after weight measurement.
223484831|NCT03885388|DRUG|MTX|multicourse methotrexate chemotherapy
223484832|NCT03885388|DRUG|MTX+ACTD|combination use of methotrexate and actinomycin
223484833|NCT02234180|OTHER|Placebo|Given PO
224173364|NCT00590031|DRUG|Irinotecan|Irinotecan will be given 65 mg/m2
224173365|NCT00590031|RADIATION|External Beam Radiation Therapy|will be delivered with multiple (\>2) field techniques using mega-voltage radiation therapy. pts will receive 50.4 Gy and will be treated over a 6 week period.
224173366|NCT04583267|DRUG|tenofovir disoproxil fumarate (TDF) 300mg co-formulated with emtricitabine (FTC 200mg) once daily oral administration|Participants will take tenofovir disoproxil fumarate (TDF) 300mg co-formulated with emtricitabine (FTC 200mg) once daily oral administration for preventing HIV infection.
224173367|NCT03773601|OTHER|Sleep Profiler|A 4-days sleep monitoring with the use of the Sleep Profiler. Data on objective sleep behavior will be collected.
224173368|NCT03773601|OTHER|PSQI|Fill the Pittsburgh Sleep Quality Index (PSQI) for the subjective evaluation of sleep.
224173369|NCT03773601|OTHER|TQR|Fill the Total Quality of Recovery Scale (TQR), every morning for 4 consecutive days, to collect data on subjective perception of recovery,
224173370|NCT03270618|DEVICE|CAD/CAM Surgical Template|The templates were designed based on virtual planning and manufactured using three-dimensional printing technique. The template is designed to assist the surgeon to perform the osteotomy and predrill the screw holes to guide the distractor position.
224173371|NCT00572312|DRUG|atorvastatin (Sortis) 40 mg|In the 8-weeks run-in period angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor blockers were administered to achieve the target blood pressure below 130/80 mmHg. Next, they were randomly assigned to add (or not) 40 mg of atorvastatin in two active treatment periods lasting 8 weeks each
224173372|NCT00002749|DRUG|carboplatin|
224173373|NCT04317898|PROCEDURE|serratus plane block by ultra-sound|To perform Serratus block, patients will be placed in the lateral decubitus position with the affected side facing up, or in the prone position with the affected side facing the operator . After sterile preparation, a linear ultrasound probe will be utilized to identify the latissimusdorsi and serratus anterior muscles in a sagittal plane. The plane superficial to the serratus anterior muscle and below the latissimusdorsi muscle will be identified. The skin will be topicalized with 1 mL of 1% lidocaine using a 30-gauge needle. Using an in-plane approach, a 25-gauge 1.5-cm needle will be used to inject a total of 20-mL of 0.25% bupivacaine with 80 mg of triamcinlone under direct ultrasound visualization.
224173374|NCT04317898|PROCEDURE|paravertebral block by ultra-sound|TPVB will be given using high frequency linear US transducer, place the probe parallel to the vertebral spine at T2 level and shifted 2-3 cm laterally to obtain the appropriate visualization. Following the identification of plura, transverse process and paravertebral space, the needle will be inserted in caudocranial direction using in-plane approach. Confirm negative vessel or pleural breach via aspiration then proceed with local anaesthetic 10ml of 0.25% bubivacine and 80mg triamcinlone slowly; the pleura will be seen to be pushed downward.
224173375|NCT03508973|OTHER|Sculpta|
224173376|NCT02268760|DRUG|BILN 2061 ZW single rising doses|
224173377|NCT02268760|DRUG|Placebo|
224173378|NCT02268760|DRUG|BILN 2061 ZW fixed dose|
224173379|NCT02268760|OTHER|Standardized breakfast|
224173380|NCT03260673|OTHER|specular microscope|The corneal endothelial cell density, variation in endothelial cell size (CV), percentage of hexagonal cells, and central corneal thickness(CCT) were recorded at baseline and at 3 months postoperatively.
223484834|NCT02234180|DRUG|Regorafenib|Given PO
223586132|NCT03443232|PROCEDURE|Radiofrequency ablation|Each patient randomly allocated into the radiofrequency ablation group receives circumferential pulmonary vein isolation(CPVI),The default strategy is to create a circle surrounding the two ipsilateral pulmonary veins.We will mapping the left atrial subtrate. If mapping system detect a poor substrate,we should continue to ablate for left atrial roof and posterior line.
223617589|NCT04967976|PROCEDURE|TiLoop Bra mesh in expander-implant breast reconstrution|The tissue expander is inserted with TiLoop Bra mesh in the first stage of reconstruction immediately after nipple/skin-sparing mastectomy. The tissue expander is placed sub-pectoral.
224173381|NCT00369889|DRUG|bevacizumab|iv every 21 days
224306067|NCT01007942|DRUG|trastuzumab|intravenous trastuzumab (2 mg/kg weekly following a 4 mg/kg loading dose on Day 1 of Cycle 1 only)
224173382|NCT00369889|DRUG|Erlotinib|oral daily
224306068|NCT02275130|PROCEDURE|Calcium Hydroxyapatite|Surgical augmentation of the vocal cords with injection of calcium hydroxyapatite
224306069|NCT02275130|DEVICE|Radiesse Voice (Calcium Hydroxyapatite)|
224306070|NCT01020344|PROCEDURE|Lung volume reduction surgery|Lung volume reduction surgery
224306071|NCT02301195|OTHER|Therapeutic horseback riding|Inclusion of horses as part of the therapeutic experience
224173383|NCT05469880|OTHER|moisturizing cream and 5% benzoyl peroxide gel|"Group A: Eclaran 5% every evening and formula 609567 49 every morning, for 3 months.~Then the group is divided: Group A1/ formula 609613 37 and Group A2/ formula 609567 49 every morning, for the next 3 months"
224173384|NCT05469880|OTHER|anti-acne face cream and 5% benzoyl peroxide gel|"Group B: Eclaran 5% every other night and 609613 37 every morning, for 3 months.~Then the group is divided: Group B1/ 609613 37 and Group B2/ formula 609567 49 every morning, for the next 3 months"
224306072|NCT02301195|OTHER|Barn Activity Intervention|Equine-focused educational activities in small group setting without horses
224306073|NCT04170556|DRUG|Regorafenib|Regorafenib 160 mg/day 3 weeks on and 1 week off
223484835|NCT04951960|OTHER|Higher PEEP setting|PEEP levels are determined according to the higher PEEP-FiO2 tables set plateau pressure less than 30 cmH2O. The duration of measurement at each PEEP levels is 1 hour.
224306074|NCT04170556|DRUG|Nivolumab|Nivolumab at the dose of 1.5 mg/kg, 3 mg/kg or 240 mg/infusion every 2 weeks. Dose will be adjusted depending on the incidence of adverse events
224306075|NCT05083585|BIOLOGICAL|Ad26.RSV.preF-based vaccine|Ad26.RSV.preF-based vaccine will be administered as a single intramuscular injection.
224306076|NCT00613535|DEVICE|Mechanical debridement|Mechanical shaver will be used to remove large chondral flaps and loose fragments
224306077|NCT00613535|DEVICE|Paragon T2|Use Paragon device to debride after removal of larger chondral lesion flaps with mechanical shaver.
224306078|NCT00613535|PROCEDURE|Lavage debridement|Remove loose chondral fragments
224306079|NCT00613535|DEVICE|Mechanical Debridement|Use of a mechanical device such as a shaver, punch, or biter to remove large chondral flaps and loose fragments
224306080|NCT00613535|DEVICE|RF- based Debridement|Use of debridement device to remove large fragments followed by use of RF-based debridement to smooth the base of the shoulder of the tear.
224306081|NCT02016313|OTHER|physiotherapy|
224306082|NCT01536158|DRUG|Oral paracetamol|Patients will receive oral paracetamol 15 mg/kg per dose every 6 hours for 3 days.
224306083|NCT01536158|DRUG|Oral ibuprofen|Patients will receive oral ibuprofen at an initial dose of 10 mg/kg, followed by 5 mg/kg at 24 and 48 h.
224306084|NCT03929757|BIOLOGICAL|Ad26.ZEBOV|Participants will receive 0.5 mL IM injection of Ad26.ZEBOV as first vaccination.
224306085|NCT03929757|BIOLOGICAL|MVA-BN-Filo|Participants will receive 0.5 mL IM injection of MVA-BN-Filo as second vaccination.
224306086|NCT03929757|BIOLOGICAL|MenACWY|Participants will receive 0.5 mL IM injection of MenACWY.
223484836|NCT04951960|OTHER|Lower PEEP setting|PEEP levels are determined according to the lower PEEP-FiO2 tables set plateau pressure less than 30 cmH2O. The duration of measurement at each PEEP levels is 1 hour.
224173385|NCT01337791|DRUG|Telbivudine treatment|Two arms in this study, One is Telbivudine 600 mg by mouth daily from late pregnancy to 28 weeks of post partum. Another arm is clinical observation only without telbivudine treatment
224173386|NCT04574765|DIAGNOSTIC_TEST|Nasopharyngeal swab|Nasopharyngeal swab for COVID-19
224173387|NCT04574765|OTHER|Questionnaire collection (CITF)|Fill out questionnaires regarding exposures and travel history, occupation category, any symptoms in the past 21 days, any face-to-face care of a known COVID-19 positive patients in past 14 days or any children at home who are less than 12 years of age.
224173388|NCT04574765|OTHER|Optional blood collection|Provide blood samples to look for COVID-19 specific antibodies and/or proteins at the time of enrollment and after 8 weeks.
224173389|NCT04574765|OTHER|Optional questionnaire completion (mental health)|Fill out an optional mental health questionnaire.
224173390|NCT04574765|DIAGNOSTIC_TEST|Optional saliva sample (for validation)|Provide saliva sample anonymously.
224306087|NCT03734406|OTHER|Videoclips|The images contained in the videoclips show the pathophysiological process underlying the two diseases under study, namely deep vein thrombosis and atrial fibrillation.
224306088|NCT00463242|DRUG|Agomelatine|Either 25 mg or 50 mg agomelatine orally once daily
224306089|NCT00463242|DRUG|paroxetine|
224306090|NCT00463242|DRUG|placebo|
223484837|NCT03641729|OTHER|individualized exercise training program|The exercise training program was performed once daily, included 2- to 5-minute warm-up session (stretching, coordination and balance exercises), 10 to 20 minutes of moderate-intensity aerobic exercise using a cycle ergometer, 3 - to 5-sets to ten repetitions of sit-to-stand exercises with a 1-minute rest interval between each set. A cool-down period of 2- to 5-minutes of stretching and breathing exercises was delivered at the end of the exercise session. The aerobic training target zone was set at 50% to 70% of heart rate (HR) reserve.
223586133|NCT01471912|PROCEDURE|pars plana vitrectomy and fluid gas exchange|A three-port standard pars plana vitrectomy was performed by a single surgeon using a 23-gauge vitrectomy system, either Associate®(Dutch Ophthalmic Research Center. Inc., Zuidland, The Netherlands) or Accurus®(Alcon Laboratories Inc., Fort Worth, USA), with one step scleral tunnel incision. In all cases, the peeling of the internal limiting membrane, approximately 1 disc diameter area from center of MH was conducted without assistance of dyes followed by complete fluid-gas exchange using 25% sulfur hexafluoride gas. Combined cataract surgery was performed in patients with visually significant cataracts or with incipient cataract in the subjects older than 60 years. All patients were instructed to maintain a face-down position for at least 7 days postoperatively.
223586134|NCT01342614|DRUG|Fosinopril|Fosinopril group received fosinopril, 10mg, once per day.
223586135|NCT01342614|DRUG|Metformin|Metformin group was treated with metformin hydrochloride, 500mg, three times per day
223586136|NCT02449018|DRUG|QBW251|QBW251 capsule(s) taken orally twice per day
224173391|NCT04574765|DIAGNOSTIC_TEST|Nasal Swab (rapid antigen test)|Panbio nasal swab rapid antigen test
224306091|NCT03944174|PROCEDURE|Fixation of unstable pelvic fractures|Percutaneous fixation of both iliac bones through the sacrum using one screw
224173392|NCT04570982|BIOLOGICAL|Convalescent Plasma|The objective of this protocol is to provide a coordinated approach for distribution and guidance for safe and effective administration of convalescent serum with antibodies against SAR CoV-2 for treatment of patients with COVID-19 infection who are most likely to benefit from this investigational treatment and monitor them.
224306092|NCT00114166|DRUG|topotecan hydrochloride|
224306093|NCT01049711|DRUG|erythropoietin|
224173393|NCT03603574|DEVICE|EWA through the needle|In the EWA-N group, 5 mL of normal saline are injected through the epidural needle after the occurrence of loss-of-resistance (LOR). The needle is connected to the pressure transducer. A satisfactory endpoint is defined as the presence of waveforms synchronized with arterial pulsations. In the absence of pulsatile waveforms, the operator injects an additional 2.5 mL-bolus of normal saline through the epidural needle and reconnects the latter to the pressure transducer. If no waveforms are detected after the second injection, the operator removes the needle and reattempts the epidural block at a different intervertebral level. A maximum of 3 levels is permitted: if waveforms are still absent at the third level, the operator simply accepts LOR as the technical endpoint.
224306094|NCT01191983|DRUG|Methoxy polyethylene glycol-epoetin beta [Mircera]|Starting dose of 1.2 mcg/kg, adjusted according to Hb values, administered by subcutaneous injection Q4W
224306095|NCT04013230|BEHAVIORAL|Usual care|Visit doctor and nurse at the clinic.
224306096|NCT04013230|BEHAVIORAL|Web-COP|Usual care plus group sessions and a web-based treatment program for 12 weeks for the child and parents.
223484838|NCT03401047|DRUG|Estradiol|Subjects will receive graded doses of transdermal estradiol patches for up to 7 days. Blood estradiol tests will be performed daily, and the number of estradiol patches used will be adjusted to maintain serum estradiol levels of 250-400 pg/ml. Estradiol is a natural hormone.
224306097|NCT06192836|PROCEDURE|Manual Removal 1|"1. Placenta will be removed manually~2. Uterine incision will be repaired as double layered~3. No uterine massage will be performed"
223586137|NCT02449018|DRUG|Placebo|Matching placebo capsule(s) taken orally twice per day
223586138|NCT02505360|OTHER|Measurements of concentration of hyaluronic acid as well as in type 1 collagen and 3|
223586139|NCT00027911|BIOLOGICAL|NY-ESO-1 peptide vaccine|
223586140|NCT00027911|BIOLOGICAL|sargramostim|
223586141|NCT03995355|DEVICE|9618X investigational lipid eye drops|Test Eye Drops
223586142|NCT03995355|DEVICE|Blink® Tears|Control Eye Drops
224306098|NCT06192836|PROCEDURE|Manual Removal 2|"1. Placenta will be removed manually~2. Uterine incision will be repaired as double layered~3. Uterine massage will be performed for one minute duration, after uterine incision is closed"
224306099|NCT06192836|PROCEDURE|Controlled Cord Traction 1|"1. Placenta will be delivered via controlled cord traction~2. Uterine incision will be repaired as double layered~3. No uterine massage will be performed"
224306100|NCT06192836|PROCEDURE|Controlled Cord Traction 2|"1. Placenta will be delivered via controlled cord traction~2. Uterine incision will be repaired as double layered~3. Uterine massage will be performed for one minute duration, after uterine incision is closed"
224306101|NCT06192836|PROCEDURE|Controlled Cord Traction+Uterine Massage 1|"1. Placenta will be delivered via controlled cord traction plus uterine massage~2. Uterine incision will be repaired as double layered~3. No uterine massage will be performed after placental delivery"
224173394|NCT03603574|DEVICE|EWA through the catheter|In the EWA-C group, the epidural catheter is advanced 5 cm beyond the needle tip after the occurrence of LOR. Subsequently, the operator injects 5 mL of normal saline through the catheter and the latter is connected to the pressure transducer via the sterile, rigid extension tubing. A satisfactory endpoint is defined as the presence of waveforms. In the absence of pulsatile waveforms, the operator injects an additional 2.5 mL-bolus of saline through the catheter and reconnects the latter to the pressure transducer. If no waveforms are detected after the second injection are still absent at the third level, the operator simply accepts this position for catheter placement (intent-to-treat analysis).
224173395|NCT03663972|BEHAVIORAL|articulation therapy|children receive instruction in producing new sounds at the isolation, syllable and word level.
224173396|NCT03663972|BEHAVIORAL|phonologic treatment|children receive instruction in producing new sounds at the word level
224173397|NCT01339104|DRUG|Regorafenib (Stivarga, BAY73-4506)|All subjects will receive regorafenib administered from Day 1 -21 at a dose of 160 mg od (4 x 40 mg tablets) followed by a 7 days break in repeating cycles of 28 days. The drug is to be taken in the morning with approximately 240 mL of water after having a low fat breakfast. Holter ECGs with triplicate measurements will automatically be obtained at specified timepoints over 24 hours on days -1 and Cycle 1, Day 21. PK samples will be drawn on Cycle 1, Day 21. PK timepoints are time-matched with Holter ECG timepoints. 24 hour urine will be collected beginning on Cycle 1, Day 21. MUGA scans will be done at screening, Cycle 2 Day 21 (after 42 doses of BAY73-4506), then every 3 cycles starting in Cycle 5, and at end of treatment.
224173398|NCT04520295|GENETIC|ctDNA screening|Molecular events including gene mutation, fusion and amplification will be detected by next generation sequencing platform (OncoScreen Plus panelTM) using ctDNA collected from peripheral blood samples of gastric cancer patients. For HER2 positive patients, samples will be collected at baseline, first surveillance after treatment and disease progression. For HER2 negative patients, samples will be collected at baseline as negative control.
224173399|NCT00409396|PROCEDURE|Urinary PGEm level|Level of PGEm in urine compared to CRP and fecal calprotectin levels in patients with ulcerative colitis.
224173400|NCT00409396|PROCEDURE|fecal calprotectin|Level of fecal calprotectin in comparison to urinary PGEm and serum CRP levels.
223484839|NCT02374983|OTHER|Gamma knife radiosurgery re-planning with convolution algorithm|"The convolution algorithm, which uses the correlation between CT imaging density in Hounsfield units (HU) and electron density (ρe) of the tissues as input to predict dose distribution, can provide a better simulation of real delivered dose for GKR. By more accurately predicting the dose delivered, a better prediction of clinical effects can be made, increasing the potential clinical efficacy of treatment.~Convolution algorithm is now available in Leksell GammaPlan® 10 but there is not enough clinical data to support its use over TMR 10, which is the current clinical standard. Using convolution algorithm to recalculate the dose for the otherwise unaltered TMR 10 plan will provide valuable insight and understanding of the dosimetric differences between these planning algorithms."
223484840|NCT00815737|DRUG|rhubarb|14 days of rhubarb
223484841|NCT00815737|DRUG|Placebo|14 days of Placebo
223484842|NCT05561062|DRUG|Atorvastatin 80mg|Atorvastatin is one of the most effective drugs used to reduce intracellular cholesterol synthesis. it exerts numerous pleiotropic effects including anti-inflammatory, antioxidant properties, endothelial function improvement, and immunomodulation independent of its basic lipid-lowering properties
223484843|NCT03862781|PROCEDURE|Right Hemicolectomy|Minimally invasive approach (robotic or laparoscopic) with the creation of an anastomosis.
223586143|NCT01467388|PROCEDURE|selective laser trabeculoplasty (SLT)|trabeculoplasty with an SLT-Laser to reduce intraocular pressure
223586144|NCT02153814|PROCEDURE|Endometrial Scratch|After cleansing the cervix with Betadine, the procedure will be performed using a 3mm endometrial sampling curette, with three passes made of the endometrium along the length of the fundus. Patients will be given the option to take ibuprofen 600mg one hour prior to the scheduled procedure. The first endometrial scratch procedure or sham procedure will be performed up to two weeks prior to expected menses, and the second endometrial scratch or sham procedure will be performed cycle day 5-11 of the stimulation cycle.
223586145|NCT02153814|PROCEDURE|Sham procedure|For the sham procedure, after cleansing the cervix with betadine, the endometrial sampling curette will be placed 2-3cm into the cervix without entering the uterine cavity
224173401|NCT06376435|DRUG|Herombopag Olamine Tablets|Herombopag Olamine；combined rhTPO;combined IL-11
223586146|NCT00357383|DRUG|Azithromycin (T1225)|
223586147|NCT03426631|DRUG|Placebo oral capsule|Placebo capsule 30 minutes before sleep
224173402|NCT01402375|DRUG|Hydrocodone (first trial)|Patients will take 1 dose of Hydrocodone 5mg / Acetaminophen 500mg every 4 hours as needed for pain
223586148|NCT03426631|DRUG|DAW1033B2 oral capsule|DAW1033B2 capsule 30 minutes before sleep
224173403|NCT01402375|DRUG|Codeine (first trial)|Patients will take 1 dose of Codeine 30 mg / Acetaminophen 300 mg every 4 hours as needed for pain
224173404|NCT01402375|DRUG|Oxycodone (for second trial)|Patients will take 1 dose of Oxycodone 5 mg / Acetaminophen 325 mg every 4 hours as needed for pain
224306102|NCT06192836|PROCEDURE|Controlled Cord Traction+Uterine Massage 2|"1. Placenta will be delivered via controlled cord traction plus uterine massage~2. Uterine incision will be repaired as double layered~3. Additional uterine massage for one minute duration will be performed after uterine incision is closed"
223484844|NCT02022917|DRUG|Bevacizumab|Bevacizumab 15 mg/ Kg (from post-op cycle 2) intravenous infusion for 30 minutes in a 21 days' cycle for at least three cycles (best to 6 cycles) followed by 3-weekly maintenance bevacizumab 15 mg/ Kg intravenous infusion for 17 cycles.
223484845|NCT06018012|DEVICE|MRS and ABR|Magnetic Resonance Spectroscopy and Auditory Brain- stem Response Audiometry
223484846|NCT05522751|DEVICE|DBS|Bilateral DBS electrodes will be implanted into the limbic pallidum of participants with severe alcohol use disorder and advanced but compensated liver disease.
223586149|NCT03530332|DIAGNOSTIC_TEST|PreTRM test|Blood test to determine risk of preterm birth
223586150|NCT05733728|OTHER|any therapy suitable|any therapy suitable
223745186|NCT05958355|OTHER|Functional postural control training|All participants will receive functional postural control training for 30 minutes/ session, 3 sessions/ weeks, for 4 weeks (a total of 12 training sessions).
224306103|NCT05989113|OTHER|Administration of the IPAQ-SF questionnaire|Administration of the IPAQ-SF questionnaire at the patient's consultation and upon return home
224173405|NCT01402375|DRUG|Codeine (for second trial)|Patients will take 1 dose of Codeine 30 mg / Acetaminophen 300 mg every 4 hours as needed for pain
223484847|NCT02251353|PROCEDURE|intervention|hepatic and/or pulmonary resection, radiofrequency ablation (RFA), transcatheter arterial chemoembolization, CyberKnife stereotactic radiosurgery
223484848|NCT02251353|DRUG|systemic treatment|Systemic therapy
223484849|NCT06632301|DEVICE|Primary hip replacement with cementless stem|Total Hip Arthroplasty is today one of the most established surgical orthopaedic procedures worldwide.
223484850|NCT02653105|BIOLOGICAL|OLFM4|patient have an additional blood test every 6 months for dosing OLFM4
223484851|NCT06110793|DRUG|Lenvatinib|20mg orally PO daily
223484852|NCT06110793|DRUG|Pembrolizuma|400mg IV Q6W
223484853|NCT06110793|DRUG|Fulvestrant|500mg IM Q4W
223484854|NCT03441061|BIOLOGICAL|Inotuzumab Ozogamicin|Given IV
223484855|NCT04432623|DRUG|Benserazide Only Product|Investigational drug
223484856|NCT02475213|BIOLOGICAL|Enoblituzumab Schedule 1|enoblituzumab is administered by IV infusion once per week for up to 51 doses.
223484857|NCT02475213|BIOLOGICAL|Pembrolizumab|Pembrolizumab is administered by IV infusion every 3 weeks for up to 17 doses.
223484858|NCT02475213|BIOLOGICAL|Enoblituzumab Schedule 2|Enoblituzumab is administered by IV infusion every 3 weeks for up to 17 doses
224173406|NCT01402375|DRUG|Oxycodone (third trial)|Patients will take 1 dose of Oxycodone 5mg / Acetaminophen 325 mg every 4 hours as needed for pain
224173407|NCT01402375|DRUG|Hydrocodone (third trial)|Patients will take 1 dose of Hydrocodone 5 mg / Acetaminophen 325 mg every 4 hours as needed for pain.
224173408|NCT03827070|DRUG|Afatinib|Used Afatinib particles of which had an average size of 22 μm and a volume concentration of small particles (\<5 μm) - only 19%
224173409|NCT03827070|DRUG|Talcum powder|Used Talcum powder particles of which had an average size of 24.5 μm and a volume concentration of small particles (\<5 μm) - only 11%
224306104|NCT04041349|DRUG|mouse nerve growth factor|mouse nerve growth factor of 20 UG (9000 U)/day for 14 consecutive days by intramuscular injection
224306105|NCT04096508|BEHAVIORAL|Music listening|Patients sit comfortably in a chair for 20 min listening music before the procedure.
223484859|NCT02475213|BIOLOGICAL|retifanlimab|Retifanlimab is administered by IV infusion every 3 weeks for up to 17 doses
223484860|NCT05453539|DRUG|DSPE-DOTA-Gd Liposomal Injection|Single dose, intravenous infusion
223484861|NCT05236010|DEVICE|rTMS|Transcranial magnetic stimulation is a noninvasive form of brain stimulation in which a changing magnetic field is used to cause electric current at a specific area of the brain through electromagnetic induction. During an rTMS session, an electromagnetic coil is placed against the scalp near the forehead. The electromagnet painlessly delivers a magnetic pulse that stimulates nerve cells in the region of the brain being targeted.
223484862|NCT05236010|DEVICE|HD-tDCS|Transcranial direct current stimulation (tDCS), is a non-invasive, painless brain stimulation treatment that uses direct electrical currents to stimulate specific parts of the brain. A constant, low intensity current is passed through two electrodes placed over the head which modulates neuronal activity.
223484863|NCT05236010|OTHER|Attention Process Training|Attention Process Training (APT) is a multi-session exercise designed to help improve the ability to focus on relevant material while ignoring irrelevant distractions. Further, it helps improve the speed of processing information.
224173410|NCT03973632|DRUG|SH-1028 Tablets|200mg of SH-1028 Tablets, orally once every cycle.
224173411|NCT01018615|DRUG|silymarin|capsules, 700 mg, twice daily, 12 days
224173412|NCT01018615|DIETARY_SUPPLEMENT|green tea extract (EGCG)|capsules, 196.5 mg, twice daily, 12 days
224173413|NCT04880460|DIETARY_SUPPLEMENT|Magnesium Glycinate tablet 200mg|Magnesium glycinate tablet 200mg twice daily orally for 8 weeks along with SSRIs
223484864|NCT04571138|BIOLOGICAL|SCRI-CAR22v2|Single infusion of SCRI-CAR22v2
223484865|NCT02537548|OTHER|Laboratory Biomarker Analysis|Correlative studies
223484866|NCT02537548|PROCEDURE|Retroperitoneal Lymph Node Dissection|Undergo RPLND
223484867|NCT05433467|PROCEDURE|CT-guided localization for micro hepatocellular carcinoma before surgical resection|After preoperative preparation was completed, on the day of surgery, disposable pulmonary nodular localization needle (Ningbo Sonjiecang Biological Technology Co., LTD., Model: SS510-10) was used for the localization of micro hepatocellular carcinoma that could be found by preoperative CT enhancement or MRI. After the micro hepatocellular carcinoma was located under the guidance of CT, and then the patient was sent to the operating room. During the operation, the lesion was removed according to the tail line of the positioning needle and the position of the positioning needle.
223484868|NCT02623712|OTHER|More Frequent Surveillance Strategy|Chest CT scans to be repeated at 3, 6, 12 and/or 24 months, depending on patient risk factors and nodule size and attenuation (density)
224173414|NCT04880460|DIETARY_SUPPLEMENT|Placebo tablet 200mg|Placebo tablet 200mg twice daily orally for 8 weeks along with SSRIs
224173415|NCT02736474|DRUG|Naltrexone|3 tablets（15mg） once per day in the first two weeks，then Naltrexone 5 tablets（25mg） once per day during the rest of the study.
224173416|NCT02736474|DRUG|Placebo Naltrexone|Placebo Naltrexone created and masked by the pharmacy to be used as a control.
224173417|NCT02736474|DRUG|Bupropion|1 capsule（150mg） once per day in the first two weeks，then 2 capsules（300mg） once per day during the rest of the study.
224173418|NCT02736474|DRUG|Placebo Bupropion|Placebo Bupropion created and masked by the pharmacy to be used as a control.
224173419|NCT06117072|OTHER|diet plan|One group (n = 30) received the DASH diet and the other group received a salt-free diet (n = 30) and was followed for 2 months
224173420|NCT02409264|OTHER|Individualised Homeopathic Remedy|Sucrose pillules will be medicated with the individualised homeopathic remedy as determined by the researcher, in the potency, dosage and repetition determined by the researcher in accordance with the laws governing homeopathic prescribing.
224173421|NCT01755390|DRUG|Cabazitaxel (XRP6258)|Pharmaceutical form: infusion solution Route of administration: Intravenous
224173422|NCT04071639|DRUG|Haloperidol 2Mg Tab|Haloperidol take 0.5mg\~2mg three time a day.
224173423|NCT04071639|DRUG|Risperidone 1Mg Tab|Risperidone take 1mg once at night.
224173424|NCT04071639|DRUG|Zoloft 50Mg Tablet|Zoloft take 50mg once in the morning.
224173425|NCT04071639|DRUG|Idebenone|Idebebone take 30mg three times a day.
223484869|NCT02623712|OTHER|Less Frequent Surveillance Strategy|Chest CT scans to be repeated at 3, 6, 12 and/or 24 months, depending on patient risk factors and nodule size and attenuation (density). Overall, participants in the less frequent arm are expected to undergo 30% fewer surveillance imaging tests.
223484870|NCT06031272|DRUG|3BNC117-LS-J|Administered by intravenous (IV) infusion
223484871|NCT06031272|DRUG|10-1074-LS-J|Administered by intravenous (IV) infusion
223484872|NCT06031272|DRUG|Placebo for 3BNC117-LS-J|Administered by intravenous (IV) infusion
223484873|NCT06031272|DRUG|Placebo for 10-1074-LS-J|Administered by intravenous (IV) infusion
223484874|NCT05555017|PROCEDURE|PSMA-radioguided surgery|Approximately 15-24 hours prior to surgery, 400-600 Megabecquerel (MBq) of 99mTc-PSMA-I\&S will be intravenously administered to the patient at the Nuclear Medicine department. Following this injection patients will be allowed to return home, and then present for their 99mTechnetium (99mTc)-based PSMA-radioguided salvage surgery the next day.
223484875|NCT05555017|DRUG|ADT|Standard 6 months of ADT according to current clinical guidelines. ADT consists of one subcutaneous depot of 22,5mg triptorelin (Pamorelin), with 4 weeks bicalutamide 50mg per os from 2 weeks before till 2 weeks after the first Pamorelin administration.
223484876|NCT00119639|DRUG|Sorafenib (BAY43-9006, Nexavar)|All subjects were given a open-label, single dose of 400mg sorafenib
223484877|NCT00505921|DRUG|Campath-1H|3 mg through the catheter Day 1 then 10 mg on Day 2, and 30 mg on Days 3 and 10 of chemotherapy treatment.
223484878|NCT00505921|DRUG|G-CSF|10 mg/kg subcutaneously (sc) on day +5 (in a.m.) for Stem Cell Mobilization.
223484879|NCT00505921|DRUG|GM-CSF|250 m/m2 subcutaneously (sc) on Day +5 (in p.m.) for Stem Cell Mobilization.
223484880|NCT00505921|DRUG|BCNU|300 mg/m2 IV over 1 hour on day -6
223484881|NCT00505921|DRUG|Stem Cell Transplant|Stem cell infusion on Day 0.
223484882|NCT00505921|DRUG|Preparative Regimen for Allogenic Stem Cell Transplantation|Campath 15mg/day (days -6 to -4), fludarabine 30 mg/m2 IV/day (days -6 to -4) and cyclophosphamide 750 mg/m2 IV/day (1000 mg/m2 IV/day if unrelated) (days -6 to -4). Low dose total body irradiation of 2 Gy on day 0.
223484883|NCT00505921|DRUG|Cytarabine|200 mg/m2 IV twice a day on day -5 through -2 (total 8 doses),
223484884|NCT00505921|DRUG|Etoposide|200 mg/m2 IV twice on day -5 to -2 (total 8 doses)
223484885|NCT00505921|DRUG|Melphalan|140 mg/m2 IV on day -1.
223484886|NCT00505921|DRUG|Campath|15 mg/day (days -6 to -4) for preparative regimen Allogenic Stem Cell Transplantation
224173426|NCT04071639|DRUG|Deutetrabenazine Oral Tablet [Austedo]|The recommended starting dose of Austedo is 6 mg administered orally once daily, and dose may be increased at weekly intervals in increments of 6 mg per day to a maximum recommended daily dosage of 48 mg.
223484887|NCT00505921|DRUG|Fludarabine|30 mg/m2 IV/day (days -6 to -4)
224173427|NCT04453345|DRUG|thalidomide + prednisone + methotrexate|thalidomide 50-100mg daily at bedtime + prednisone 0.5mg/kg qod to 1mg/kg qd + methotrexate 10mg/m2 per week. 4 months one cycle, up to 3 cycles. After get partial remission, thalidomide maintenance will continue up to 2 years.
223484888|NCT00505921|DRUG|Cyclophosphamide|750 mg/m2 IV/day (1000 mg/m2 IV/day if unrelated) (days -6 to -4).
223745187|NCT05958355|OTHER|Treadmill training|All participants will receive treadmill training for 30 minutes/ session, 3 sessions/ weeks, for 4 weeks (a total of 12 training sessions).
223745188|NCT00966602|DRUG|VX-809|VX-809 capsule, once daily for 14 days
224173428|NCT00603876|DIETARY_SUPPLEMENT|Almonds|100-110 grams (about 3/4 cupful)of almonds consumed daily for 28 days
224173429|NCT03906591|PROCEDURE|allogenic bone ring|allogenic bone ring with simultaneous dental implant placement
224173430|NCT03906591|PROCEDURE|autogenous bone ring|autogenous bone ring with simultaneous dental implant placement
223484889|NCT00505921|RADIATION|Low dose total body irradiation|Low dose total body irradiation of 2 Gy day 0.
223484890|NCT02355223|OTHER|FAST|See information in arm description
223484891|NCT04011852|DEVICE|Electrical Impedance tomography|Monitoring with Electrical impedance tomography during spontaneous breathing trials on T-piece in children
223484892|NCT05255107|COMBINATION_PRODUCT|Standard of Care Therapy + CXL + Riboflavin 0.23% L Solution|Standard Of Care: Moxifloxacin 0.5% eyedrop therapy every 1 hour (q1h) while awake; to be tapered at treating physician's discretion. Following SOC, for subjects randomized to the experimental arm, riboflavin will be administered (1 drop every 2 min for 40 min with PESCHKE-L solution \[0.23%\], or longer as needed to assure adequate corneal penetration). Then the eye will be aligned under the PXL Platinum 330 light (the treatment plane will be at the correct working distance from the PXL Platinum 330 beam aperture when the border of the projected beam is in sharp focus). The correct aperture setting (3 to 12 mm) will be selected for the size of the eye and area needing to be treated (2 mm larger than the maximal ulcer diameter), and the eye will be irradiated at 18 mW/cm2, with pulsed mode (5 seconds on, 5 seconds off) for 10 min, during which time instillation of riboflavin will continue (1 drop every 2 min).
223484893|NCT05255107|OTHER|Standard of Care Therapy + Sham CXL + Artificial Tears|Standard Of Care: Moxifloxacin 0.5% eyedrop therapy every 1 hour (q1h) while awake; to be tapered at treating physician's discretion. Following SOC, for subjects randomized to the Sham comparator group, artificial tears (1 drop every 2 min for 40 min) will be administered. After instillation of artificial tears, the eye will be aligned under the PXL Platinum 330 light. The instrument will be kept off and the subject will be kept under the device for 10 min, during which time instillation of artificial tears will be performed (1 drop every 2 min) to maintain corneal hydration. The operator will keep track of sham exposure time independently to confirm the actual duration.
223484894|NCT05732714|BEHAVIORAL|Healthy lifestyle behaviors around the time of surgery|Healthy lifestyle choices, such as improving diet and beginning to exercise around the time of surgery and it's influence on an individual's long term risk of developing cardiovascular disease.
223484895|NCT06142084|DIETARY_SUPPLEMENT|Oat Protein, low bioavailability|Participants will consume a protein meal consisting of cooked whole oat kernels (amount based on body weight, 0.3g of protein/kg bodyweight).
223745189|NCT00966602|DRUG|VX-770|VX-770 tablet, once every 12 hours for 14 days
224173431|NCT01935167|DRUG|DW1029M 600mg|DW1029M 150mg 2 tablets b.i.d
224173432|NCT01935167|DRUG|DW1029M 1200mg|DW1029M 300mg 2 tablets b.i.d
224173433|NCT01935167|DRUG|Placebo|Placebo 2 tablets b.i.d.
224173434|NCT03932591|PROCEDURE|kinesio taping method|Kinesio tape is an elastic, adhesive, hypo-allergenic, latex-free tape. Kinesio taping method is rehabilitative taping technique. One of the purposes of this technique is to facilitate or inhibit the muscles.
224173435|NCT03932591|PROCEDURE|Sham kinesio taping|Sham kinesio tape will be used for controlled group. 2,5 cm width, 5 cm length, skin color 2 pieces kinesio tape will be applied on medial and lateral head of gastrocnemius muscle without stretch. 5 cm length, 5 cm width, skin color 1 piece kinesio tape will be a
224173436|NCT05774574|DIETARY_SUPPLEMENT|Cannabidiol (CBD) supplementation|Daily supplementation with 1 ml hemp oil containing 60 mg CBD, applied orally
224173437|NCT05774574|DIETARY_SUPPLEMENT|Placebo supplementation|Daily supplementation with 1 ml hemp oil containing 0 mg CBD, applied orally
223484896|NCT06142084|DIETARY_SUPPLEMENT|Oat Protein, high bioavailability|Participants will consume a protein meal consisting of heated oat protein concentrate (amount based on body weight, 0.3g of protein/kg bodyweight).
223484897|NCT06142084|DIETARY_SUPPLEMENT|Pea Protein, low bioavailability|Participants will consume a protein meal consisting of cooked whole yellow peas (amount based on body weight, 0.3g of protein/kg bodyweight).
223484898|NCT06142084|DIETARY_SUPPLEMENT|Pea Protein, high bioavailability|Participants will consume a protein meal consisting of heated pea protein isolate (amount based on body weight, 0.3g of protein/kg bodyweight).
223484899|NCT06142084|DIETARY_SUPPLEMENT|Protein-free meal|Participants will consume a protein-free meal to correct analyses for endogenous protein losses.
223484900|NCT06564974|DRUG|Vamorolone|"Patients on treatment with Vamorolone (AGAMREE®) Dosage: Oral Suspension: 40 mg/mL . Per package insert, the recommended dosage is 6 mg/kg taken orally once daily, up to a maximum daily dosage of 300 mg for patients weighing more than 50 kg.~Decrease dosage gradually when administered for more than one week."
223484901|NCT01644214|OTHER|6 month follow up for pessary check in the clinic setting|The standard of care is considered to be pessary checks every 3 months, therefore those that are checked every 6 months will be considered to be in the intervention group.
223484902|NCT02441283|DRUG|ABT-493|ABT-493 was not administered in this study. This study was a follow-up for participants who received the drug in prior studies.
223484903|NCT02441283|DRUG|ABT-530|ABT-530 was not administered in this study. This study was a follow-up for participants who received the drug in prior studies.
223484904|NCT01458626|DRUG|mirtazapine|mirtazapine 30mg QD
223484905|NCT01458626|DRUG|paroxetine 20mg QD|paroxetine 20mg QD
223484906|NCT05169983|DIAGNOSTIC_TEST|iPad-Based Visual Field Test|In this study, the investigators aim to teach the participants to use the the visualFields easy App . The investigators will be using the app in the clinic with the patients watching, demonstrating its use and discussing and explaining its functions. Having observed how to use the application, the participant will then complete the visual field assessment.
223484907|NCT06547554|DRUG|Xeruborbactam|Experimental
223484908|NCT06547554|DRUG|Cefiderocol|Experimental
223484909|NCT06547554|DRUG|Xeruborbactam/Cefiderocol|A combination of Xeruborbactam and Cefiderocol.
223745190|NCT00966602|DRUG|VX-809 & VX-770|VX-809 capsule, once daily, and VX-770 tablets, once every 12 hours, for 14 days
223484910|NCT06547554|DRUG|Dextrose 5% in water|Placebo
223484911|NCT01325441|DRUG|BBI608|
223484912|NCT01325441|DRUG|Paclitaxel|
223484913|NCT04892407|DEVICE|Algeness® DF 3.5%|dermal filler CE Mark approved for treatment of cheek and midface volume loss
223484914|NCT04892407|DEVICE|Juvéderm Voluma|dermal filler CE Mark approved for treatment of cheek and midface volume loss
223484915|NCT05906862|DRUG|AMT-253|Administered intravenously
223484916|NCT06415721|DEVICE|Active Transcranial Magnetic Simulation|1 session of active continuous theta burst stimulation (3600 pulses, 110% RMT) will be delivered to the cortical region demonstrating maximal functional connectivity with the striatum during alcohol cue presentation. TMS will be delivered using the Magventure MagPro X100.
223484917|NCT06415721|DEVICE|Sham|1 session of sham continuous theta burst stimulation (3600 pulses, 110% RMT) will be delivered to the cortical region demonstrating maximal functional connectivity with the striatum during alcohol cue presentation. The MagVenture MagPro x100 is capable of administering a sham stimulation. The reverse side of the TMS coil is plated with a magnetic shield such that electromagnetic energy cannot stimulate the brain. The device offers compatibility with Transcutaneous Electrical Nerve Stimulation devices such that titrated electrical pulses can be delivered to the scalp location to mimic the sensation of a TMS pulse without stimulating the brain.
223484918|NCT00642486|OTHER|Portable (Embla Embletta X30 system and Respironic REMStar Auto M series with CFlex)|portable, home-based using the Embla Embletta X30 system as the diagnostic device and the Respironic REMStar Auto M series with CFlex as the PAP titration device.
223484919|NCT00642486|OTHER|Standard polysomnography (PSG)|laboratory-based testing
223484920|NCT02040220|DRUG|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|2 mg of Eylea will be treated per one injection at more than one months interval usually.
223484921|NCT00322036|DRUG|MPC-7869|Oral 800 mg BID
223484922|NCT00322036|DRUG|MPC-7869|Oral BID dosing
223745191|NCT00966602|DRUG|Placebo|Matching Placebo
223745192|NCT00772200|PROCEDURE|Cognitive Assessment|Complete COG Standard Neuropsychological and Behavioral Battery
223745193|NCT00772200|OTHER|Quality-of-Life Assessment|Ancillary studies
223745194|NCT06246539|BEHAVIORAL|VR mindfulness|VR-based mindfulness
223745195|NCT05859269|DRUG|Methylprednisolone|"Patients will receive a single intraoperative dose of 10 mg intravenous dexamethasone followed with a 6-day oral methylprednisolone taper course.~Patients will also receive a standardized multimodal postoperative pain management regimen which includes nonsteroidal anti-inflammatory medication (e.g., NSAIDs) and opioid pain medications, both in the hospital and at home as part of standard care."
224173438|NCT01728766|OTHER|Small for gestational age at delivery|Small for gestational age at delivery. gestational age at \>37 weeks by and birth weight \<2500 g
224173439|NCT01728766|OTHER|Post-term Infant, Not Heavy-for-dates|Appropriate for gestational age at delivery. Gestational age at \>37 weeks and birth weight \>2800 g
224173440|NCT02463331|DRUG|Chloroquine diphosphate|One pill of chloroquine diphosphate per day until the end of the study
224173441|NCT02463331|DRUG|prednisone|Prednisone 5-15 mg/day until the end of the study
224173442|NCT02463331|DRUG|azathioprine|azathioprine 1-2mg/Kg/day until the end of the study
224173443|NCT03227601|DEVICE|posture adapter|continued use of the device at home for 2 months after instructions of how to do it
224173444|NCT01315340|PROCEDURE|Ocular rigidity, outflow facility and intraocular pressure measurement|The measurement procedure includes cannulation of the anterior chamber of the eye, under sterile conditions. Infusion of the eye with microvolumes of a saline solution is performed, followed by manometric measurement of intraocular pressure, in order to quantify ocular rigidity. Outflow facility is estimated from recordings of intraocular pressure after the infusion is stopped.
224173445|NCT06259604|OTHER|PIOMI|Babies in this group will be administered PIOMI once a day, 30-45 minutes before feeding, for 14 days.
224173446|NCT06259604|OTHER|PIOMI+kangaroo care|Babies in this group will start using PIOMI once a day, 30-45 minutes before feeding, and kangaroo care for at least 30 minutes during the last 2 minutes of non-nutritive sucking phase of PIOMI, for 14 days.
224173447|NCT00826540|DRUG|sorafenib tosylate|Given orally
224173448|NCT00826540|BIOLOGICAL|bevacizumab|Given IV
224173449|NCT00542217|BIOLOGICAL|Imprime PGG|
223586151|NCT02570880|OTHER|glycemic index (glucose-solution, bread samples)|All participants will test 2 breads, prepared with different fermentation times of dough, both breads will be tested in duplicate. Methode: International Organization for Standardization / Final Draft International Standard 26642, Food products - Determination of the glycaemic index (GI) and recommendation for food classification
223586152|NCT01340508|RADIATION|Intensity Modulated Radiotherapy|Intensity modulated radiotherapy to a dose of 55Gy in 25 fractions
223586153|NCT03305380|OTHER|No interventions|As this is a patient registry, there are no interventions.
223586154|NCT02857101|OTHER|dosage of calprotectin|
224173450|NCT01166386|BEHAVIORAL|FANCI|comprehensive neurobehavioral sessions with therapist administrating treatment components
223484923|NCT04641351|DRUG|Zilretta Injectable Product or Placebo|The purpose of this intervention is to determine the use of extended release steroid knee injection (Zilretta) at the end of the surgery and its effects on your knee pain.In this study Zilretta will be injected intra-operatively for your arthroscopic partial meniscectomy (APM) surgery.Participants will have MRIs x-rays, and provide a sample of the synovial fluid from both knees at the beginning of surgery. This fluid is drained at the beginning of surgery and then usually discarded. Three samples each of blood and urine will be collected over the study period from each participant and sample of joint (synovial tissue) taken. Participants will be asked to answer questions about knee pain.
223484924|NCT05779748|OTHER|Single bout of exercise|isometric wall squat at a knee joint angle of 100 degrees. Instruct participant to place their back against the wall with feet positioned parallel and spaced shoulder-width apart. Lower themselves down until they reached a knee joint angle of 100 degrees. Measure knee joint angle by placing a goniometer on the lateral epicondyle of the knee, in line with the femur whilst the anchor arm was in line with the lateral malleolus.
223586155|NCT01875718|DRUG|UC1010|
223586156|NCT01875718|DRUG|Placebo|
223586157|NCT01771614|BEHAVIORAL|Exercise|
223586158|NCT01771614|PROCEDURE|Hyperglycemia|
223586159|NCT06025799|BEHAVIORAL|Mindfulness-based stress reduction intervention|The Mindfulness-Based Stress Reduction (MBSR) program consists of eight sessions focusing on reducing stress and improving well-being. Participants learn and practice mindfulness techniques such as mindful eating, breathing, body scan, and meditation. The program emphasizes self-responsibility, developing coping strategies, and applying mindfulness daily. Participants engage in formal mindfulness practices, reflect on their experiences, and receive guidance on continuing their mindfulness journey after the program. The goal is to cultivate resilience, enhance well-being, and reduce stress.
223586160|NCT01694979|OTHER|Minimum expiration effort|Subjects perform a forced expiration at minimum effort
223586161|NCT01694979|OTHER|Moderate expiration effort|Subjects perform a forced expiration at moderate effort
223586162|NCT01694979|OTHER|Maximum expiration effort|Subjects perform a forced expiration at maximum effort
223586163|NCT04971941|DEVICE|Dental Vibe|Use of Dental Vibe during dental anesthesia intervention
223586164|NCT04022018|RADIATION|Adaptive radiotherapy|CT repositioning will be performed after 15fractions of external radiotherapy, then new target volume will be contoured and new radiotherapy plan will be formulated with the assistance of artificial intelligence program. New radiotherapy plan will be performed from the 17th fraction external radiotherapy.
224173451|NCT01166386|BEHAVIORAL|FANCI|Watching DVDs chosen by participants on various topics.
223484925|NCT00141609|DRUG|Slow Sodium|
223484926|NCT02382939|DRUG|somapacitan|Administered subcutaneously (s.c., under the skin) with an investigational pen once weekly for a 26 week period (8 weeks' dose titration, 18 weeks' fixed dose treatment) followed by 1 week washout.
223586165|NCT04022018|RADIATION|no adaptive radiotherapy|Concurrent external volumetric rotational intensity modulated radiotherapy and chemotherapy followed by image-guided adaptive brachytherapy is the treatment strategies of control group patients
224173452|NCT05976906|BIOLOGICAL|Universal Chimeric Natural Killer Receptor Modified T-cells (CNK-UT)|"1. Dose Escalation: After enrollment, participants will recieve preconditioning by lymphodepletion or not, and then will be treated with CNK-UT cells with a 3 +3 design to determine the maximum tolerated dose. 3 dose level of CNK-UK cells will be tested: 4.6E6/kg，1.5E7/kg，4.6E7/kg. The participants will first receive a single ascending dose(SAD) mode of administration. During the DLT observation period (21 days), if the participants do not experience DLT, they will receive a multiple ascending dose(MAD) mode of administration.~2. Indications Expansion: It will be carried out after all participants have completed the DLT observation in the Dose Escalation phase. The target population, dosage and frequency of drug administration in the indication expansion stage can be adjusted and determined according to the previous research results."
224173453|NCT00639808|DRUG|5% dextrose in water|60 ml IV infusion over 30 minutes
224173454|NCT00639808|DRUG|TZP-101|1 infusion: IV 2ml/min for 30 minutes for 1 day of either 160, 320 or 600 micrograms/kg
224173455|NCT00454350|DRUG|Hectorol (doxercalciferol injection)|
224173456|NCT00454350|DRUG|Zemplar (Paricalcitol injection)|
224173457|NCT05499208|OTHER|Giving side position with patient turning and movement system|To provide effective breastfeeding by placing the mother in position.
224173458|NCT02540655|BIOLOGICAL|Stemchymal®|Patients will receive Stemchymal® through intravenous infusion
224173459|NCT02540655|PROCEDURE|Excipients|Patients will receive excipients through intravenous infusion
224173460|NCT02587975|DRUG|Evogliptin|10 mg
224173461|NCT02649075|OTHER|Serum-derived Bovine Immunoglobulin / Protein Isolate|Serum-derived bovine immunoglobulin protein isolate (SBI) is a specially formulated light-colored protein powder composed of immunoglobulin (IgG) and other serum proteins similar to those found in colostrum and milk. SBI does not contain any milk products such as lactose, casein, or whey. SBI is gluten-free, dye-free, and soy-free. SBI is manufactured in accordance with current Good Manufacturing Practice (cGMP) and FDA guidelines for medical food ingredients. Two packets (each packet contains 5 g of SBI) BID.
224173462|NCT02649075|OTHER|Placebo|Matching placebo with control hydrolyzed gelatin protein. Two packets BID.
224173463|NCT01550770|DRUG|propofol|peripheral IV of propofol at increasing dose levels
223484927|NCT02382939|DRUG|somatropin|Administered subcutaneously (s.c., under the skin) with a prefilled pen (Norditropin® FlexPro®) daily for a 26 week period (8 weeks' dose titration, 18 weeks' fixed dose treatment) followed by 1 week washout.
224173464|NCT05231928|PROCEDURE|Argon Laser Iridoplasty|"Argon Laser is applied to the anterior iris surface at sites and with parameters tailored according to iris configuration, pupil size, iris colour.~The device used is Nidek Argon Laser device with YAG capsulotomy or Abraham Iridotomy lens as auxilliary lenses.~-Topical Pilocarpine 2% and ocular surface anesthetic are applied prior to the procedure and Brimonidine 0.2% bid is used fo a week after the procedure together with topical dexamethasone ophthalmic solution."
224173465|NCT01079208|OTHER|test starter infant formula|infants are fed for 6 months with this starter formula
224173466|NCT01079208|OTHER|test starter infant formula with synbiotics|infant are fed for 6 months with this formula
224173467|NCT01079208|OTHER|control standard formula|infant are fed 6 months with this formula
224173468|NCT02483611|DRUG|Magnesium Sulfate|
224173469|NCT02483611|DRUG|Lidocaine|
224173470|NCT02483611|DRUG|Isotonic Solution|
224173471|NCT02483611|DRUG|Cisatracurium|
224173472|NCT00675129|BEHAVIORAL|Dialectical behavioral therapy for adolescents (DBT-A)|"Patients randomised to DBT-A will receive 16 weeks treatment, with one weekly session (60 minutes)of individual therapy, one weekly session of multifamily skills training (120 minutes), and telephone coaching outside therapy sessions.~The treatment has been developed by Marsha Linehan (Linehan, 1993a; 1993b)and adapted for adolescents by Alec Miller (Miller, Rathus \& Linehan, 2007). Individual DBT therapists have been trained by drs Alec L Miller and Sarah K Reynolds and have a minimum of one year clinical practise as DBT therapists. The therapists are organised in two consultation teams supervised on a bimonthly basis throughout the entire study by drs Miller and Reynolds respectively."
224173473|NCT00675129|BEHAVIORAL|Treatment as usual|Patients randomised to EUC will received standard care (16 weeks) at five participating child and adolescent outpatient clinics from therapists not trained in or practising DBT. According to pilot study data EUC will most likely consist of psychodynamic therapy, various forms of family therapy and supportive therapy.
223484928|NCT06399718|DRUG|BOTOX|Intramuscular Injections
223484929|NCT06399718|DRUG|Placebo|Intramuscular Injections
223484930|NCT02438579|OTHER|Nasal Irrigation & Gargling|Participants are advised to perform the intervention as frequently as required (expected frequency around 6 times a day for the first two days, reducing in frequency from day 3 as symptoms improve).
223484931|NCT06133257|PROCEDURE|Goal-Directed Fluid Therapy guided by Inferior Vena Cava Collapsibility Index|Measuring Inferior vena cava(IVC) diameter using ultrasound then calculation Inferior vena cava(IVC) collapsibility index and administer fluid accordingly.
223484932|NCT06133257|PROCEDURE|standard fluid management|standard fluid management
223586166|NCT00444977|BEHAVIORAL|Case-management linkage intervention|dental care
223586167|NCT01978444|PROCEDURE|Laparoscopic D2 lymphadenectomy plus CME|
223586168|NCT01978444|PROCEDURE|Laparoscopic D2 lymphadenectomy|
223586169|NCT00721175|DEVICE|biliary stent (self expandable metallic stent)|metallic stent was inserted into right or left hepatic duct which was planed before intervention using CT scan or MRCP
223586170|NCT00721175|DEVICE|PS|plastic stent was inserted into right or left hepatic duct which was planed before intervention using CT scan or MRCP
223586171|NCT02790814|DEVICE|Moyo strap-on|Continous measurements
223586172|NCT02790814|DEVICE|Hand-held fetoscope|Intermittent measurements
223586173|NCT01142024|DRUG|Glutathione|NS 500ml + Glutathione 1.8g intravenously guttae 1-1.5ml/kg per hour,30 minutes before and during coronary angiography
223586174|NCT01142024|DRUG|saline|NS 500ml intravenously guttae 1-1.5ml/kg per hour,30 minutes before and during coronary angiography
223586175|NCT00267150|DRUG|Enteric-coated mycophenolate sodium (EC-MPS)|Experimental
223586176|NCT00876785|OTHER|Rye bread breakfast|A randomised, within-subject comparison design was used. Appetite (hunger, satiety and desire to eat) was rated regularly from just before breakfast at 08:00 until 16:00. Amount, type and timing of food and drink intake during the study period were standardised.
223586177|NCT00876785|OTHER|wheat bread based breakfast|Reference wheat bread breakfast
224173474|NCT02640924|RADIATION|Proton radiotherapy|
224173475|NCT02640924|PROCEDURE|Radiofrequency Ablation|
224173476|NCT04225936|DRUG|BMS-986263|Single Dose
224173477|NCT00975442|OTHER|Eccentric training|A home training program of eccentric training of the wrist extensors to be carried out daily with 3 sets of 15 repetitions. All subjects were instructed to use the forearm band (Epi Forsa 4061, Rehband, Sweden)
224173478|NCT00975442|DEVICE|Forearm band|All subjects were instructed to use the forearm band during all daily activities.
224173479|NCT00975442|DEVICE|Forearm band|All patients were instructed to use a forearm band during all daily activities.
224173480|NCT04993430|DRUG|HRS8807|HRS8807 monotherapy
224173481|NCT04993430|DRUG|HRS8807|HRS8807 monotherapy
224173482|NCT04993430|DEVICE|HRS8807、SHR6390|HRS8807 in combination with SHR6390
224173483|NCT04993430|DRUG|HRS8807、SHR6390|HRS8807 in combination with SHR6390
224173484|NCT06014476|OTHER|questionnaires|Sent questionnaires to caregivers and used CRS-R to assess patients with DoC
224173485|NCT04264182|OTHER|ICD programming|Re-programming of the ICD device for VA detection (see above)
224173486|NCT05528562|OTHER|PrEP Rapid Access|'Rapid PrEP Access' is a low-threshold intervention designed to provide on-site access to HIV self-testing at the Victory Program for persons who use opioids.
224173487|NCT05528562|OTHER|HIV self-testing|After enrollment the research assistant (RA) will provide the participant with a HIV self-test and provide instructions on how to obtain a proper sample for the test. It uses an oral fluid test and yields results within 20 minutes.
224173488|NCT05528562|OTHER|Dried blood spot testing|HIV Dried blood spot (DBS) testing provides an accurate method of measuring the HIV viral load in comparison to plasma viral load.
224173489|NCT01138462|OTHER|intervention|"5 days topical decolonisation including nasal mupirocin tid, chlorhexidine mouth wash tid, chlorhexidine body wash once daily.~Daily direct resident's environmental disinfection during decolonisation."
224173490|NCT01222416|RADIATION|Radiopharmaceutical Administration [18F]-FDG|Adult dose: (0.15 mCi/kg ranging from 3 to 16 mCi,route IV. Time interval between administration and scanning: 60 +/- 10minutes post-injection.
224173491|NCT01222416|RADIATION|Radiopharmaceutical: [18F]-FLT|Adult dose: (0.15 mCi/kg ranging from 3 to 16 mCi), route = IV, Time interval between administration and scanning: 60 +/- 10minutes post-injection.
223484933|NCT04512690|DEVICE|Epidural electrical stimulation (EES) of the cervical spinal cord|All participants enrolled in this group will undergo a surgical procedure to implant a system which provides epidural electrical stimulation (EES) of the cervical spinal cord. Researchers will quantify the ability of EES to recruit arm and hand muscles and produce distinct kinematic movements. The implant will be removed after less than 30 days.
223484934|NCT05822752|DRUG|Budigalimab|Intravenous (IV) Infusion
223484935|NCT05822752|DRUG|Livmoniplimab|Intravenous (IV) Infusion
223484936|NCT05822752|DRUG|Lenvatinib|Oral: Capsule
223484937|NCT05822752|DRUG|Sorafenib|Oral: Tablet
223484938|NCT02026297|DRUG|Tranexamic Acid|1 gram IV over 10 minutes
223484939|NCT02026297|DRUG|Placebo; Normal Saline|0.9% Normal Saline
223484940|NCT00537277|DRUG|biphasic insulin aspart|Treat-to-target dose titration scheme (dose individually adjusted), injected s.c. (under the skin)
223484941|NCT05383209|DRUG|EYP-1901|EYP-1901 will be administered to the study eye by a single injection through the pars plana using a pre-loaded applicator with a 22-gauge needle. Each EYP-1901 IVT insert has been designed to deliver vorolanib into the vitreous humor for approximately 6 to 9 months.
223484942|NCT05383209|OTHER|Sham IVT|Sham injections will be used to maintain masking of investigational EYP-1901 therapy for study subjects.
223586178|NCT03867682|BIOLOGICAL|Lintuzumab-Ac225|In the Phase I, patients will be enrolled into the following dose escalation cohorts: 0.50 μCi/kg, 1.0 μCi/kg, and 1.5 μCi/kg. If the 0.50 μCi/kg dose is determined to exceed the MTD, a 0.25 μCi/kg dose will be explored.
224173492|NCT01748903|DEVICE|Target 360°, 2D Coils, Nano Coils|
224173493|NCT02663206|PROCEDURE|peroral endoscopic myotomy|peroral endoscopic myotomy
224173494|NCT02663206|PROCEDURE|Botulinum toxin injection|endoscopic Botulinum toxin (BTX) injection at lower esophagus
224173495|NCT02685449|DRUG|Insulin glulisine|A kind of study bolus insulin will be insulin aspart if participant used insulin aspart before entering the trial
224173496|NCT02685449|DRUG|Insulin aspart|A kind of study bolus insulin will be insulin lispro if participant used insulin lispro before entering the trial
224173497|NCT02685449|DRUG|Insulin lispro|A kind of study bolus insulin will be insulin lispro if participant used insulin lispro before entering the trial
224173498|NCT03784326|DRUG|Atezolizumab|Given IV (vein)
224173499|NCT03784326|PROCEDURE|Conventional Surgery|Undergo surgical resection
224173500|NCT03784326|DRUG|Fluorouracil|Given IV (vein)
224173501|NCT03784326|DRUG|Oxaliplatin|Given IV (vein)
224173502|NCT03784326|DRUG|Tiragolumab|Given IV (vein)
224306106|NCT01299259|BEHAVIORAL|Text Message Reminders|Patients in the intervention group will receive text messages on their cell phones following discharge from the emergency department reminding them to make an appointment with their primary care provider. Text messages will be sent daily for 4 days after discharge from the ED.
223484943|NCT06411067|DRUG|Erenumab|Monthly injection of erenumab for fibromyalgia
223484944|NCT06411067|DRUG|Saline|Monthly injection of 0.9% saline for control
223484945|NCT05114174|OTHER|mami-educ|The intervention corresponds to sending 3 messages a week through Telegram, with nutritional information, for 12 consecutive weeks (a different nutritional topic each week). The messages address the three domains of learning, cognitive, affective, and psychomotor for each topic.
223484946|NCT01298258|DRUG|Aliskiren|Aliskiren 150mg
223484947|NCT02229838|DRUG|BIBB 1464 MS tablet|
223484948|NCT02229838|DRUG|BIBB 1464 MS solution|
223484949|NCT02229838|DRUG|BIBB 1464 MS placebo|
223484950|NCT02229838|OTHER|Standard dinner|
223484951|NCT01478659|DIETARY_SUPPLEMENT|Control study food with no added fiber|Adults consuming their usual diet modified by incorporating yogurt and snack bars without added fiber.
223484952|NCT01478659|DIETARY_SUPPLEMENT|Study food with added fiber|Adults consuming their usual diet modified by incorporating yogurt and snack bars containing 16 g of chicory root fiber (Frutalose®).
223484953|NCT00382616|DRUG|Phosphatidylserine-Omega3|
223484954|NCT00769418|DRUG|odanacatib|"Panels A, B, C, and D will enroll males only; Panels E, F, and G will enroll females only.~Panel A: odanacatib tablets 2.5 mg qd for 14 days.~Panel B: odanacatib tablets 5 mg qd for 14 days.~Panel C: odanacatib tablets 10 mg qd for 14 days.~Panel D: odanacatib tablets 25 mg qd for 14 days.~Panel E: odanacatib tablets 0.5 mg qd for 21 days.~Panel F: odanacatib tablets 2.5 mg qd for 21 days.~Panel G: odanacatib tablets 10 mg qd for 21 days."
223484955|NCT00769418|DRUG|Comparator: Placebo|"Panels A, B, C, and D will enroll males only; Panels E, F, and G will enroll females only.~Panel A: placebo to odanacatib tablets 2.5 mg qd for 14 days.~Panel B: placebo to odanacatib tablets 5 mg qd for 14 days.~Panel C: placebo to odanacatib tablets 10 mg qd for 14 days.~Panel D: placebo to odanacatib tablets 25 mg qd for 14 days.~Panel E: placebo to odanacatib tablets 0.5 mg qd for 21 days.~Panel F: placebo to odanacatib tablets 2.5 mg qd for 21 days.~Panel G: placebo to odanacatib tablets 10 mg qd for 21 days."
224173503|NCT03631849|PROCEDURE|peri implantitis sanitation surgery|"an intrasulcular vestibular and lingual / palatal incision with respect to the implant-supported restoration involved is performed, it extends to at least one tooth on either side in order to give laxity to the flap. The use of an incision of discharge will be necessary if the muco-periosteal detachment of the flap (that is to say of full thickness) is considered insufficient to access and unclamp the peri-implant lesion.~Then, the debridement will be carried out using manual curettes in titanium: the products (waste) removed with this curette will constitute the peri-implant pocket specimens. This sample will be deposited in a Roswell Park Memorial Institute Medium (RPMI) supplemented with serum.The surface of the titanium implant will then be disinfected with betadine, or with hydrogen peroxide for patients with an allergy to polyvidone iodine.~The flap will then be repositioned and sutured with simple stitches made with a resorbable suture of Vicryl type 5.0."
224173504|NCT03631849|OTHER|Care|descaling and maintenance of implants
224173505|NCT06332183|GENETIC|Presence of polymorphisms|Statistical analysis of GWAS data, Genome-wide methylation pattern analysis, Integration of GWAS data and methylation data (meQTL analysis), Pathway enrichment analysis
224173506|NCT03851224|PROCEDURE|control group|immediate implant with immediate loading using no graft
224173507|NCT03851224|PROCEDURE|study group|immediate implant with immediate loading using autogenous bone graft
224173508|NCT03851224|PROCEDURE|study group 2|immediate implant with immediate loading using (Geistlich Bio-Oss®) xenograft
224173509|NCT02871570|DRUG|Rivipansel|A single dose of IV Rivipansel over 20 minutes
224173510|NCT01758367|DRUG|Deciatbine(DAC)|
224173511|NCT05661838|PROCEDURE|transfusion|transfusion
224173512|NCT02178592|DRUG|DTG 50 mg|DTG is available as 50 mg film-coated tablet. DTG may be administered with or without food
224173513|NCT02178592|DRUG|EFV 600 mg|EFV is supplied as film-coated capsule-shaped oral tablet containing 600 mg of EFV and must be administered without food
224173514|NCT00928499|DEVICE|Interstim (SNS)|Randomized Controlled Trial of Continuous vs. Cyclic Stimulation in Interstim Therapy
224173515|NCT06227416|OTHER|Biopsy|punch biopsy (2-4 mm) depending on the size of the AK lesion.
224173516|NCT05569356|BIOLOGICAL|Prospective|-Additional blood samples -Myocarditis biopsy sample (routine care) -Additional pericardial fluid sample (routine care)
224173517|NCT05569356|OTHER|Retrospective|None (only data collection)
223484956|NCT00474019|DRUG|esomeprazole|IV qd for 4 days
223586179|NCT03867682|DRUG|Venetoclax|400 mg daily will be taken orally on Days 1-21 of a 28-day cycle. There will be a ramp up of venetoclax dosing in the first cycle, with 100 mg administered on Day 1, 200 mg on Day 2, and 400 mg on Day 3 and Day 4 and later. Patients on antifungal azoles should receive one-half these doses, up to a maximum of 200 mg of venetoclax.
224173518|NCT01476553|PROCEDURE|Extensive Intraperitoneal Lavage (EIPL)|"EIPL is performed after completing resection and lymphadenectomy: the abdominal cavity has to be washed ten times with one liter Ringer's solution. Each liter has to be well dispersed manually in the abdominal cavity, and removed and disposed completely. 100 ml of the last liter of lavage fluid will be harvested and sent for analysis.~Contrary to the Japanese trial, Ringer's solution will be used instead of normal saline solution because of a presumed higher likelihood of peritoneal adhesions when employing the latter (7). Ringer's solution is the standard used for all intraperitoneal lavage procedures at the study centre. To avoid hypothermia, the lavage fluid will be warmed to body temperature (37° Celsius)."
224173519|NCT03390127|OTHER|PEEP|After LMA Supreme™ insertion, it's proper position is confirmed. Then, PEEP of 7 cmH2O is applied during mechanical ventilation.
224173520|NCT01320527|DIETARY_SUPPLEMENT|Nutriceutical formulation|Two pills that collectively contain: folic acid (400µg), Vitamin B12 (6µg), Vitamin E (as alpha-tocopherol; 30 IU), S-adenosylmethionine (SAM; 400mg), N-acetyl cysteine (NAC; 600mg) and Acetyl-L-carnitine (ALCAR; 500mg). Taken once daily for duration of study (1 year).
224173521|NCT01320527|OTHER|Placebo|A mixture of 6 vitamins and nutriceuticals
224173522|NCT02045225|BEHAVIORAL|Reduction of social anxiety & substance use in gay/bi men|The study will provide Phase I trial data for a novel and innovative HIV prevention intervention for MSM built upon empirically supported interventions to reduce HIV risk among MSM and cognitive-behavioural therapy to reduce social anxiety. This study will test a novel integrated HIV prevention intervention that combines empirically supported treatments for social anxiety with HIV risk reduction counseling to reduce HIV sexual risk behaviour. Study objectives: 1) to provide data on the acceptability/feasibility of the intervention, 2) to provide data to test the intervention, and 3) to provide data that will allow for a RCT that will test intervention efficacy relative to HIV prevention interventions that do not reduce social anxiety or substance use in sexual situations.
224306107|NCT03712215|OTHER|Rehabilitation|diaphragmatic electrical stimulation
224306108|NCT03554044|DRUG|Anastrozole|Given PO
224306109|NCT03554044|DRUG|Exemestane|Given PO
224306110|NCT03554044|DRUG|Fulvestrant|Given IM
224306111|NCT03554044|DRUG|Letrozole|Given PO
223484957|NCT01805999|DIETARY_SUPPLEMENT|7 g Ispaghula|
223484958|NCT01805999|DIETARY_SUPPLEMENT|7 g placebo|
223484959|NCT01805999|DIETARY_SUPPLEMENT|3.5g Ispaghula + 3.5 g placebo|
223484960|NCT04210518|OTHER|Neuromuscular training|This intervention consisted of a supervised multimodal exercise protocol addressing different aspects of balance including static and dynamic tasks on the injured ankle. The training program comprised 6 exercises that were progressively adapted depending on the patient's execution controlled by an expert physiotherapist
223484961|NCT04210518|OTHER|Stroboscopic glasses|Patients included in this group performed the same protocol described in the balance training group with the addition of the stroboscopic glasses during the intervention.
223586180|NCT03867682|DRUG|Spironolactone|25 mg by mouth daily, administered on Cycle 1 Day 15 and continued for 12 months after the subject's last treatment with lintuzumab-Ac225.
223586181|NCT04065594|PROCEDURE|PRP dressing|PRP dressing gel dressings for treatment of chronic ulcer
223586182|NCT04065594|PROCEDURE|conventional ordinary dressing|conventional ordinary dressing for treatment of chronic ulcer
224306112|NCT03554044|DRUG|Paclitaxel|Given IV
224306113|NCT03554044|BIOLOGICAL|Talimogene Laherparepvec|Given IT
224306114|NCT03554044|DRUG|Tamoxifen|Given PO
224306115|NCT03554044|DRUG|Nab paclitaxel|Given IV
224306116|NCT03554044|DRUG|Gemcitabine|Given IV
224173523|NCT04787835|PROCEDURE|Forearm nerve block|Local anesthesia will be used to perform a forearm block of the median, radial, and ulnar nerves.
224173524|NCT04787835|PROCEDURE|Local anesthetic infiltration|Local anesthesia will be infiltrated at the site of injury
224173525|NCT01628458|PROCEDURE|radiofrequency ablation (RFA)|RFA with CELON bipolar probes. Settings: Power 30 watts, total energy 15 KJ.
224173526|NCT02520141|OTHER|Laboratory Biomarker Analysis|Correlative studies
224173527|NCT02520141|BIOLOGICAL|Ramucirumab|Given IV
224173528|NCT01640067|BIOLOGICAL|Human Neural Stem Cells|Surgical microinjection of human neural stem cells on spinal cord of ALS patients
224173529|NCT01228695|OTHER|sleep study|The polysomnography (PSG) (Alice 3 System; Healthdyne, Atlanta, GA) consisted of continuous polygraphic recording from surface leads for electroencephalography, electrooculography, electromyography, electrocardiography, thermistors for nasal and oral airflow, thoracic and abdominal impedance belts for respiratory effort, pulse oximeter for oxyhemoglobin level, tracheal microphone for snoring, and sensors for leg and sleep position
224173530|NCT00703781|DRUG|bromfenac ophthalmic solution|sterile ophthalmic solution
224173531|NCT00703781|DRUG|placebo|sterile ophthalmic solution
224173532|NCT00192712|DRUG|irinotecan, gemcitabine|
224173533|NCT03714256|DEVICE|Device, patient mobility, powered|Pediatric mobility device
224173534|NCT00112554|DRUG|cytarabine|Given IV
224173535|NCT00112554|DRUG|laromustine|Given IV
223484962|NCT00717886|RADIATION|isosulfan blue dye|"At the time of surgery, each patient will undergo a subareolar injection of isosulfan blue dye into the ipsilateral breast as routinely performed during a sentinel lymph node mapping for breast cancer. The surgeon will then perform an axillary lymph node dissection in the usual, routine manner. The above differs from standard of care in that patients scheduled for an upfront axillary dissection do not routinely undergo sentinel lymph node mapping- therefore these patients would not normally get any isotope or TSC injections since they already need an ALND. Second, standard sentinel lymph node mapping involves injection of TSC into the affected breast the day prior to surgery or 3 hours before surgery versus injection of TSC into the ipsilateral upper extremity. The protocol specifies day of mapping for patient convenience."
223484963|NCT00716417|DRUG|BIBW 2992|In each arm, BIBW 2992 dose will be escalated to determine MTD. Starting dose will be 20mg daily followed by 40 mg (with the option of an intermediary dose of 30 mg) then 50mg daily. Dose escalation will stop at 50 mg. No intra patient dose escalation.
223484964|NCT00716417|DRUG|BIBW 2992|low to high dose, daily
223484965|NCT06210685|DEVICE|Automatic Continuous Effusion Shunt implantation|The catheter pump chamber is placed with part of the chamber between adjacent ribs and part of the chamber under the skin and external to the ribs. The pump chamber is used to transfer pleural fluid into the peritoneal cavity.
223484966|NCT01520753|DRUG|biphasic insulin aspart 70|Administered subcutaneously (s.c., under the skin) at breakfast, lunch and dinner
223484967|NCT01520753|DRUG|biphasic insulin aspart 70|Administered subcutaneously (s.c., under the skin) at breakfast and lunch
223586183|NCT00228865|PROCEDURE|Pulsatile IV insulin therapy|Diabetic pts are given pulsatile iv insulin on a weekly basis determined by weekly phys orders based on pt response and insulin resistance. Cognitive testing is performed quarterly to track progress
223586184|NCT00228865|PROCEDURE|Effects of Pulsatile IV Insulin on Cognitive functions|Diabetic patients receive weekly treatment of Pulsatile Intravenous Insulin therapy. Dosage is determined each week by the patient's Endocrinologist based upon the patient's response and insulin resistance.
224173536|NCT00112554|OTHER|placebo|Given IV
224306117|NCT03554044|DRUG|Carboplatin|Given IV
223586185|NCT04552327|DEVICE|Solcera|Twice daily application for a duration of 4 weeks followed by another 4 weeks without treatment (up to 2 potential repetitions of this 8-week cycle)
224306118|NCT00806286|DRUG|CS7017 tablets|CS7017 tablets, strength 0.25 mg, two tablets, two times daily for twenty-five to thirty months
223586186|NCT04552327|DEVICE|Placebo|Twice daily application for a duration of 4 weeks followed by another 4 weeks without treatment (up to 2 potential repetitions of this 8-week cycle)
223586187|NCT04552327|DRUG|Solaraze|Twice daily application for a duration of 60 days
223586188|NCT00987701|DRUG|Ringer's Lactate|Ringer's Lactate 8 ml/kg was given intravenously before or after epidural, spinal or CSEA in cesarean section
223586189|NCT00987701|DRUG|Six percent hydroxyethyl starch|Hydroxyethyl starch (6%) was given before or after epidural, spinal or CSEA in cesarean section
223586190|NCT06110455|OTHER|Neuromuscular Training exercises|The 8 week exercise intervention consists of 25 minute group sessions of Neuromuscular training supervised by a physical therapist.
224173537|NCT01235494|OTHER|polarised 3 helium|1 inhalation (= 1 litre)
224173538|NCT02943863|DEVICE|HFNC followed by conventional nasal cannula|
224173539|NCT02943863|DEVICE|Conventional nasal cannula followed by HFNC|
224173540|NCT02901106|DRUG|Dimethyl fumarate|"Patient follow-up at 6, 12, 18, 36, and 60 months after the start of Dimethyl fumarate~Systematization of cerebral MRI examination at 18 month and 5 years from the beginning of treatment by Dimethyl fumarate"
224173541|NCT07022639|PROCEDURE|Total pancreatectomy|Total pancreatectomy for any kind of disease
224173542|NCT07022639|PROCEDURE|Proximal pancreatectomy|Proximal pancreatectomy for any kind of disease
224173543|NCT07022639|PROCEDURE|Distal pancreatectomy|Distal pancreatectomy for any kind of disease
224173544|NCT03112343|DEVICE|Algorithm-based feedback messages|ICT-based intervention group have algorithm-based feedback messages in addition to conventional intervention
224173545|NCT03112343|DEVICE|Personal Health Record|Subjects will save and send their health information to the server via the personal health record app
224173546|NCT06462079|DRUG|Sacituzumab Govitecan|Patients were treated with Sacituzumab Govitecan 10 mg/kg in 21-day treatment cycles with intravenous infusions on days 1 and 8 and continued until disease progression or unacceptable toxicity.
224173547|NCT06462079|RADIATION|Radiotherapy|Radiotherapy was administered after the second infusion of Sacituzumab Govitecan, on day 9 after the start of this regimen. The radiotherapy regimen was: brain metastases at a dose of 60 Gy/20 doses. For lesions located adjacent to the brainstem and optic nerve, 54 Gy/20 doses were given. For patients with ≥5 lesions, whole-brain radiotherapy at 40 Gy/20 doses was synchronized with radiotherapy to localized brain metastases.
224306119|NCT00806286|DRUG|Paclitaxel|Intravenous (IV), 200 mg/m\^2, once every three weeks for up to 18 weeks
224173548|NCT04651699|DEVICE|Active Transcranial Direct Current Stimulation|The Starstim tDCS® stimulator will be used by an experienced physical therapist to transfer direct current by a saline-soak pair of surface sponge electrodes (35cm2). The anode electrode will be placed over C3 (EEG 10/20 system) and the cathode electrode over the contralateral supraorbital area (Fp2), in order to enhance the excitability of M1 (32). Regarding the stimulated hemisphere, contralateral M1 will be stimulated in patients with asymmetric pain and the dominant (contrary to the dominant hand determined by the Edinburgh Handedness Inventory) in patients with symmetric pain, due to the widespread changes induced by tDCS in other cortical areas, including contralateral M1. A constant current of 2 milli amps intensity (subthreshold intensity) will be applied for 20 min, with 30 seconds of ramp-up and 30 seconds of ramp-down.
224173549|NCT04651699|DEVICE|Sham Transcranial Direct Current Stimulation|The electrodes will be placed in the same positions as for M1 stimulation, but only applying ramping active current for 30 seconds in the beginning and at the end of the procedure for a reliable blinding.
223484968|NCT01520753|DRUG|biphasic insulin aspart 50|Administered subcutaneously (s.c., under the skin) at dinner
223484969|NCT04224467|OTHER|Intravenous ICG and Real-Time Near-infrared Imaging|Patients will be intravenously injected ICG (Yichuang Pharmaceutical Limited Liability Company, Dandong, China) at a dose of 2-5 mg per kg of body weight before surgery or 0.25-0.5 mg per kg of body weight during surgery. Then real-time near-infrared imaging will be conducted during surgery.
223484970|NCT01369433|DRUG|Tivozanib + paclitaxel|Subjects will continue to receive 0.5 mg, 1.0 mg, or 1.5 mg of tivozanib once daily for 3 weeks beginning on Day 1, followed by 1 week off treatment. On days when paclitaxel and tivozanib (AV-951) are co-administered, tivozanib will be administered immediately following the end of the paclitaxel infusion. All subjects will continue to receive IV paclitaxel 90 mg/m2, administered over 1 hour once a week for 3 weeks, followed by 1 week off.
223484971|NCT01369433|DRUG|Tivozanib + temsirolimus|Subjects will receive 0.5 mg, 1.0 mg or 1.5 mg of tivozanib (AV-951) once daily for 3 weeks, followed by 1 week off. On days when tivozanib (AV-951) and temsirolimus are co-administered, tivozanib (AV-951) will be administered immediately following temsirolimus infusion. Subjects will receive 15 mg or 25 mg temsirolimus IV once weekly.
223586191|NCT06110455|OTHER|Hip and Knee Muscular Strength exercises|The 8 week exercise intervention consists of 25 minute group sessions of progressive resistance training, supervised by a physical therapist.
224173550|NCT02053597|DRUG|Doxorubicin|All patients will receive four cycles of doxorubicin (A) (50 mg/m2)
223484972|NCT01369433|DRUG|Tivozanib|Subjects will receive 1.0 or 1.5 mg tivozanib (AV-951) capsules once daily for 3 weeks, followed by 1 week off.
223484973|NCT01369433|DRUG|Tivozanib (AV-951)|Subjects will receive 1.0 or 1.5 mg tivozanib (AV-951) capsules once daily for 3 weeks, followed by 1 week off.
224173551|NCT02053597|DRUG|paclitaxel|All patients will receive four cycles paclitaxel (P) (200 mg/m2), given on a three-weekly basis for four cycles, followed by weekly paclitaxel (P) (80 mg/m2) for twelve weeks.
224173552|NCT03452397|DRUG|0.2 % hemigalactarate (0.11% free base) 0.2 % OC-02 Low Dose (1.1 mg/mL)|0.2 % hemigalactarate (0.11% free base) 0.2 % OC-02 Low Dose (1.1 mg/mL)
224173553|NCT03452397|DRUG|1.0 % hemigalactarate (0.11% free base) 1.0 % OC-02 Mid Dose (5.5 mg/mL)|1.0 % hemigalactarate (0.11% free base) 1.0 % OC-02 Mid Dose (5.5 mg/mL)
224173554|NCT03452397|DRUG|2.0 % hemigalactarate (0.11% free base) 2.0 % OC-02 High Dose (11.1 mg/mL)|2.0 % hemigalactarate (0.11% free base) 2.0 % OC-02 High Dose (11.1 mg/mL)
223586192|NCT01207245|OTHER|Tobramycin time of administration|Random allocation to time of day of administration of tobramycin
224173555|NCT03452397|DRUG|Placebo (vehicle) nasal spray|Placebo (vehicle) nasal spray
223484974|NCT01369433|DRUG|Tivozanib + capecitabine|Subjects will receive 1.5 mg of tivozanib once daily for 2 weeks beginning on Day 1, followed by 1 week off. Subjects will receive Capecitabine (Xeloda®) 825 mg/m2 or 1000 mg/m² or 1250 mg/m² oral twice daily. Subjects will receive capecitabine twice daily for 2 weeks beginning on Day 1, followed by 1 week off.
223484975|NCT01369433|DRUG|Tivo|Subjects will receive 1.5 mg tivozanib once daily beginning on Day 1 for 3 weeks followed by 1 week off treatment.
223484976|NCT01553851|DRUG|GSK1120212|Trametinib (GSK1120212) is a selective MEK1 and MEK2 inhibitor with selective activity towards BRAF and RAS mutant cancer cell lines and hematopoietic cancer cells from AML and CML origins.
223484977|NCT04429880|DRUG|Oxytocin|Oxytocin given by intravenous route
223484978|NCT01399996|DIETARY_SUPPLEMENT|Yogurt smoothie without probiotic|A daily 8 oz (240 mg) serving will provide 10x\^y5 cfu/ml of the probiotic (Bifidobacterium animalis subsp. lactis BB12).
223586193|NCT03256747|DEVICE|NMES|NMES will be placed at the knee extensors. Stimulation frequency will be 20 Hz. Pulse width will be 0.5 milliseconds and the contraction time will be 10 seconds (TON: 10s) with a 5-second rest interval (TOFF: 5s). Total time application will be 60 minutes. Intensity will be adjusted individually, taking into account the patient's ability to promote the full knee extension and comfort during contractions.
224173556|NCT04613791|BIOLOGICAL|Blood test|Collection of epidemio-clinical, biological, radiological and therapeutic patient data. Study samples collected from 154 patients to determine whether a particular immune profile could identify individuals prone to insulin resistance
224173557|NCT05408676|DEVICE|electric stimulation therapy|Transcutaneous electrical acupoint stimulation (TEAS) was achieved by an electrical neuromuscular stimulation device (JNR2; designed by the Department of Hand Surgery, Huashan Hospital, Fudan University, manufactured by Energy Conservation and Environment Protection Technology Company, Jiatong University, Shanghai,China)
224173558|NCT01943695|BEHAVIORAL|Aerobic Training|
223586194|NCT03256747|DEVICE|NMES-placebo|NMES-placebo will be placed at the knee extensors. Stimulation frequency will be 20 Hz. Pulse width will be 0.5 milliseconds and the contraction time will be 10 seconds (TON: 10s) with a 5-second rest interval (TOFF: 5s). Total time of application will be 60 minutes. Intensity will be adjusted with minimal intensity, utilized to provide a sensory stimulus, but insufficient to elicit a tetanic muscular contraction.
224173559|NCT01943695|BEHAVIORAL|Educational Information|Subjects will be given material regarding cancer and it's impact.
224306120|NCT00806286|DRUG|Carboplatin|IV, area under the curve (AUC) of 6, once every three weeks for up to 18 weeks
224306121|NCT00806286|DRUG|Placebo Tablets|Placebo tablets matching CS-7017 tablets
223484979|NCT01399996|DIETARY_SUPPLEMENT|Yogurt smoothie with probiotic added post fermentation|A daily 8 oz (240 mg) serving will provide 10x\^y5 cfu/ml of the probiotic (Bifidobacterium animalis subsp. lactis BB12).
224173560|NCT01943695|BEHAVIORAL|Supervised Home Based Training|Patients that elect supervised home based training platform or plan to complete unsupervised training sessions will receive a study kit which includes a heart rate monitor, blood pressure cuff, treadmill and tablet to complete aerobic training requirements. The study kit will be given to the patient upon completion of their baseline testing. The treadmill will be shipped to the patient's home and coordinated by the Ex Onc group. The treadmills are MSK owned equipment that will be deployed to the patient's homes via the vendor TechnoGym. A member of Ex Onc will provide an orientation session for the patient to set up all study kit items. If there is a delay in the patient receiving the treadmill , or any other unforeseen circumstance, patients may be assigned a temporary unsupervised training program until the treadmill is delivered.
224173561|NCT05335993|BIOLOGICAL|Oregovomab|2 mg, added to 50 mL of Sodium Chloride infused over 20 ± 5 minutes.
224173562|NCT05335993|DRUG|Niraparib|300mg administered orally once daily starting at the first day of treatment (Day 1 Week 1) to the end of Week 12. Subjects whose baseline weight is \<77 kg or platelet count is \<150,000 μL, the daily dosing will be 200mg.
224173563|NCT04937127|BEHAVIORAL|I-LEARN training|Training of psycho-behavorial disorders care in neurodegenerative diseases: including a theoretical part in e-learning and a practical part
224173564|NCT04937127|OTHER|usual care|usual care
224173565|NCT03357770|DRUG|mesenchymal stem cells|we will enroll three groups of patients, and they will be therapized by high, medium, and low-dose cytotoxic respectively to evaluate the dose-limiting toxicity (DLT) and establish the maximum tolerated dose (MTD). Dose and cell concentration selection will be based on previous literature \[5\]. The low-dose is 1 × 10\^7cells / 3mL, the medium-dose is 5 × 10\^7cells / 3mL and the high dose is 1 × 10\^8cells / 3mL
224173566|NCT01917591|DEVICE|Punch biopsies treated with MariGen Wound ECM dressing|Weekly dressing changes and review of wounds.
224173567|NCT01917591|DEVICE|Punch biopsies treated with Oasis ECM dressing|Weekly dressing changes and wound review
224173568|NCT02691468|DEVICE|PVC DLT|PVC DLT is type of double lumen tube that is composed of PVC
224173569|NCT02691468|DEVICE|silicon DLT|silicon DLT is type of double lumen tube that is composed of silicon
224173570|NCT05742789|DRUG|Propofol|To maintain anaesthesia in Group 1 P, propofol was used as an anaesthetic in a dose of 4-6 mg/kg/h intravenously on a perfusor
223484980|NCT01399996|DIETARY_SUPPLEMENT|Yogurt smoothie with probiotic added pre-fermentation|A daily 8 oz (240 mg) serving will provide 10x\^y5 cfu/ml of the probiotic (Bifidobacterium animalis subsp. lactis BB12).
223484981|NCT01399996|DIETARY_SUPPLEMENT|A capsule containing the probiotic|A capsule taken daily will provide between 10x\^y9 and 10x\^y10 cfu/ml of the probiotic (Bifidobacterium animalis subsp. lactis BB12).
223484982|NCT04068532|DRUG|Placebo|Administered as specified in the treatment arm.
223484983|NCT04068532|DRUG|BIIB104|Administered as specified in the treatment arm.
224173571|NCT05742789|DRUG|Isoflurane|В качестве анестетика использовали изофлуран - 1,1-1,2 MAC.
223484984|NCT04144816|OTHER|Not applicable (no intervention)|Not applicable (no intervention)
223586195|NCT02204852|DRUG|Iloprost+eptifibatide|
223586196|NCT02204852|DRUG|Placebo|
223586197|NCT06217419|DEVICE|Radio Frequency IDentification (RFID) device|"RFID devices monitor breathing patterns by means of temperature measurements of the respiratory airflow. The temperature gradient of the air flow in and out of the airways can be correlated to the flow-based respiratory patterns. Accordingly, a temperature-based breath monitoring can be achieved by means of on-skin RFID sensors attached below the nose. Finally, a bilateral measurement of nostrils respiratory flow can provide more information since nasal cavities do not behave in the same way during a respiratory cycle.~In this project we will evaluate the possibility to perform domestic breath flow analysis by exploiting thin, lightweight and battery-less sensing plasters directly attached under the nose. The system includes a proper external reader interrogating the face sensors that is capable to directly communicate with smartphone/pc/tablet/cloud environment."
223586198|NCT00617955|DRUG|Aprotinin|compare outcomes of Aprotinin versus Amicar
223586199|NCT00617955|DRUG|Amicar|compare outcomes of Aprotinin versus Amicar
224173572|NCT05742789|DRUG|Sevoflurane|в качестве анестетика использовали севофлуран в дозе - 1,7-1,9 ПДК.
224173573|NCT04227119|DEVICE|Irrigated ablation catheter|After completion of ablation, the ablation catheter will be serially positioned in the cardiac chambers (either the left or right side of the heart). The stop cock will be turned to the pressure transducer and waveforms will be stored corresponding to each chamber.
224173574|NCT04227119|DEVICE|Balloon tipped PA catheter|After removal of the irrigated ablation catheter, a 5F balloon tipped PA catheter which will be positioned under fluoroscopic guidance in each previously evaluated chamber and the chambers will be measured again.
224173575|NCT02052154|BIOLOGICAL|Prime-boost pneumococcal immunization|2 months between the 2 vaccines
224173576|NCT06700551|OTHER|Psychoeducation|Each week, the investigator will send participants one topic through the chat function on the Zalo app. Before receiving the topic, participants will vote on which topic they would like to learn about. The topics will be presented as videos and will cover the following seven areas: providing everyday care, being a caregiver, self-care, knowledge about dementia, fall prevention, pressure injury prevention and care, and managing behavior changes.They may ask questions related to providing dementia care or share their feelings via the chat on the Zalo app.
223586200|NCT01477008|DEVICE|BiPhasic Cartilage Repair Implant|1 or 2 BiCRI devices, depending on lesion size
224173577|NCT07030608|BEHAVIORAL|Exercise|Pelvic Floor Muscle Exercise Program Week 1: Contract the pelvic floor muscles for 6 seconds, then relax for 6 seconds. Repeat 25 times. Perform 3 sessions per day (total of 75 contractions per day). Week 2: Contract for 6 seconds, relax for 6 seconds. Repeat 50 times. Perform 3 sessions per day (total of 150 contractions per day). Week 3: Contract for 6 seconds, relax for 6 seconds. Repeat 75 times. Perform 3 sessions per day (total of 225 contractions per day). Weeks 4-24: Contract for 6 seconds, relax for 6 seconds. Repeat 100 times. Perform 3 sessions per day (total of 300 contractions per day). After Week 24: Contract for 6 seconds, relax for 6 seconds. Repeat 50 times. Perform 3 sessions per day (total of 150 contractions per day).
224173578|NCT07102134|PROCEDURE|Suturing-LIFT procedure|This group received conventional ligation with absorbable sutures
224173579|NCT07102134|PROCEDURE|Clipped-LIFT procedure|This group was treated with absorbable clips commonly used for vascular or biliary duct occlusion
224173580|NCT07138430|OTHER|İntervention|Patients participating in the study will be informed about the purpose of the study. Participants will be included in the study after verbally and in writing confirming the informed consent form. Patients will receive training and information about the virtual reality headset before the procedure. Patients will complete a personal information form 1 hour before the coronary angiography procedure. Pain and anxiety levels will be measured using the Visual Analog Scale (VAS) and the State Anxiety Scale 10 minutes before the procedure. Patients in the intervention group will wear virtual reality headsets during coronary angiography. Local anesthesia will not be administered to the femoral intervention site in these patients. Pain and anxiety will be assessed after the coronary angiography procedure (10 minutes later). Patients will also be questioned about their satisfaction with the virtual reality application after the procedure. One week after discharge, the patient will be re-evaluate
224173581|NCT07138430|OTHER|Control|Ten minutes before the coronary angiography procedure, patients will be assessed for pain and anxiety using the Visual Analog Scale (VAS) and the State Anxiety Scale. During the coronary angiography, control group patients will undergo routine interventional procedures. Following the coronary angiography procedure (10 minutes later), patients will be assessed for pain and anxiety. One week after discharge, the patient will be re-evaluated at the hospital for an interventional site examination. The femoral area will be examined for edema, hematoma, pain, and difficulty walking. These assessments will be recorded on forms.
224173582|NCT04839328|DRUG|60mg Hemay005|Hemay005 is a small molecule PDE4 inhibitor.
224173583|NCT04839328|DRUG|Placebo|Placebos are the same as drugs, but contain no Hemay005.
224173584|NCT00000231|DRUG|Buprenorphine|
224173585|NCT05979363|BIOLOGICAL|anti-BCMA CAR-T|Autologous BCMA-directed CAR-T cells, infusion intravenously at a target dose of 2.0-4.0 x 10\^6 anti-BCMA CAR+T cells/kg.
224173586|NCT05979363|DRUG|VRD-based regimen|Bortezomib, Lenalidomide and Dexamethasone
224173587|NCT05874336|DRUG|Aramchol|Aramchol free acid (3β-arachidylamido-7α,12α-dihydroxy-5β-cholan-24-oic acid) is a synthetic small molecule, produced by conjugation of cholic acid (bile acid) and arachidic acid (saturated fatty acid) linked by a stable amide bond.
224173588|NCT00256646|DRUG|Rosiglitazone|ROSIGLITAZONE (roe si GLI ta zone) helps to treat type 2 diabetes. It helps to control blood sugar. Treatment is combined with diet and exercise.
224173589|NCT00716040|BEHAVIORAL|Social-psycho intervention to improve adherence to HAART|The intervention focus on the notion of scenes and scenarios to examine and discussing the experience of taking ARV medicines. In principle, such an approach provides a tool for conscientization, action and the invention of novel group and individual repertoires that may result in individual mobilization for improving adherence to treatment and reducing his/her vulnerability.
224173590|NCT00716040|OTHER|Usual care|The control group will be submitted to the usual care of the health service
224173591|NCT06721975|DEVICE|Thulio pulsed Thulium:YAG (p-Tm:YAG)|A new laser system developed by Dornier, the Thulio pulsed Thulium:YAG (p-Tm:YAG ) is beginning to be studied in vitro and in vivo. Dornier Thulio p-Tm:YAG may represent an attractive new laser platform, with comparable properties to TFL including decreased retropulsion, smaller dust, and improved ablation efficiency relative to Ho:YAG.
224173592|NCT06721975|DEVICE|Thulium Laser Fiber (TFL)|The thulium fiber laser (TFL) has demonstrated effectiveness in this procedure
224173593|NCT06881290|DRUG|Vunakizumab (IL-17A inhibitor)|Vunakizumab combined with glucocorticoid therapy: Vunakizumab is administered subcutaneously at 240 mg at weeks 0, 2, and 4, followed by maintenance dosing every 4 weeks at 240 mg per dose.
224173594|NCT06723405|BIOLOGICAL|EVO301|Intravenous EVO301
223484985|NCT05557214|BEHAVIORAL|Audit and Feedback Letter|Physicians in the Audit and Feedback Letter Arm will receive an initial letter indicating their high prescriber status with guidance on reducing unnecessary antimicrobial use. They will also receive a follow-up letter at the 6 month mark indicating any change in prescribing habits. There will be a study closure letter mailed at the 12 month mark.
224173595|NCT06723405|BIOLOGICAL|Placebo|Placebo
224173596|NCT07044518|DEVICE|Over-the-Counter Hearing Aid|This intervention involves a self-fit, over-the-counter (OTC) hearing aid that is set up by the user with limited to no help from a hearing professional. Amplification is personalized through an app-based hearing test on a smartphone. The device is used during a single study visit (90 minutes) to assess hearing and provide amplification.
224173597|NCT07044518|DEVICE|Hearing aid, air conduction|This intervention uses a prescription hearing aid that is programmed and fitted based on results from a standard hearing test. The device is also used during a single study visit (90 min) for comparison purposes.
224173598|NCT05282186|BEHAVIORAL|Cognitive Enhancement Therapy|CET's group-based exercises are delivered for 1.5 hours each week in a group of 6-8 participants led by a clinician and an assistant, for one year. During each of three modules (basic concepts, social cognition, CET applications), the groups focus on acquisition of adult social milestones in perspective-taking, social context appraisal, and other aspects of social cognition, with psychoeducational lectures, homework assignments, and in-group exercises. Weekly supervision sessions for the clinician trainers will include review of how patients respond to the different demands of computer-based training and group-based exercises and guidance about improving engagement in both.
224306122|NCT04575766|DRUG|FT-7051|"Dose levels: Dose Level -1 through Dose Level 7, assigned per the protocol using a BOIN design. Additional dose levels may be explored as applicable.~Capsules available in strengths of 10mg, 25mg, and 100 mg that are orally administered per the protocol frequency and dose level."
224306123|NCT03402750|BEHAVIORAL|Meds to Beds|Medications will be delivered to patient bedside before discharge
223484986|NCT01200914|DEVICE|GORE VIABAHN® Endoprosthesis with Heparin Bioactive Surface|The 'GORE VIABAHN® Endoprosthesis with Heparin Bioactive Surface' will be deployed at the brachiocephalic stenosis.
223484987|NCT01200914|PROCEDURE|PTA alone without use of the GORE VIABAHN|Subject will receive standard of care PTA alone at the brachiocephalic stenosis without deployment of the'GORE VIABAHN® Endoprosthesis with Heparin Bioactive Surface'
223484988|NCT05093868|DEVICE|Electrographic Flow Mapping|Electrographic Flow Mapping will be collected
223484989|NCT05319678|OTHER|evaluation with Meludia music software|"Measurement instruments:~1. \- MuMu Questionnaire~2. MuRQoL Questionnaire~3. Questionnaire for subjects aged 6-17 years~4. Music tool Meludia (www.meludia.com)~5. Acoustic analysis of the voice: the Praat programme~6. Audiological tests"
224173599|NCT05282186|BEHAVIORAL|Social Skills Training|"The psychosocial component involves weekly skills training classes delivered over one year, with modules including Communicating Effectively, Making and Keeping Friends, Making the Most of Leisure Time, Healthy Living, Using Medications Effectively, and Making the Most of a Health Care Visit (Pratt et al., 2008). Participants attend two sessions each week (normally morning and afternoon of the same day): a 90-minute session focused on a specific skill and a 60-minute session in which the specific skill is used in role-play exercises."
224173600|NCT05439876|DRUG|Melatonin|Melatonin 2 mg daily for 4 weeks
224173601|NCT05439876|DRUG|Placebo|Placebo daily for 4 weeks
223484990|NCT06342882|DIAGNOSTIC_TEST|dysphagia assessment|Twenty-one patients underwent the Modified Barium Swallowing Study and Swallowing Ability and Function Evaluation (SAFE) assessments. The Penetration Aspiration Scale (PAS) and SAFE physical examination, oral phase and pharyngeal phase domains was used to determine the dysphagia severity.
223484991|NCT06342882|DIAGNOSTIC_TEST|functional independence level|Functional independence was evaluated by the Functional Independence Measurement (FIM) motor and cognitive domains.
223484992|NCT05312203|OTHER|the App|The App provides content for mobile-based stress relief that can be used on most Android and iOS-based mobile devices. Content for stress relief consists of three modules; meditation, cognitive approach, and relaxation sounds. Additionally, the App includes the module for objective stress monitoring. The APP was originally designed and developed in Korean, but English, Chinese, and Japanese versions are also available. For use in the treatment environment, the manufacturer also provides a service that allows therapists to check their patients' application usage and their stress level measured by the stress monitoring module.
223484993|NCT04402242|DEVICE|Bispectral index|Anesthesia monitoring
224173602|NCT07046468|DEVICE|Ingestion of sensor capsule (twice)|Ingestion of the GISMO GEN1 System, an ingestible sensor capsule which measures pH, temperature and oxidation reduction potential (ORP) in the intestines.
224173603|NCT07046468|BEHAVIORAL|Device evaluation questionnaire|A 16-item online questionnaire to assess participant's experiences with the ingestible sensor capsule after the study measurements.
224173604|NCT07046468|DEVICE|Wearing device|Participants will wear a small device on a soft belt around their waist during study measurements with the sensor capsules.
224173605|NCT07046468|BEHAVIORAL|Monitoring sensor capsule exit|Participants are instructed to press a button on the wearable device when they use the toilet for defaecation and wait with flushing to toilet until the wearable device indicates (using colored LEDs) that the toilet can be flushed and 1) that the sensor capsule is still in the body and study measurements continue or 2) that the sensor capsule has likely been excreted via the feces and the participant has to contact the research team to confirm exit.
224173606|NCT07046468|DEVICE|Placement of devices at home|Participants do not have to wear the device around the waist during sleeping. For optimal monitoring of sensor capsule exit during the nights, a second device will be placed on the participant's bedside table/close to the bed and a third device will be placed close to the toilet that the participant usually uses during the night.
224173607|NCT07046468|DIAGNOSTIC_TEST|Follow-up intestinal ultrasound|At 3 months after treatment initiation, participants with ulcerative colitis will undergo a follow-up intestinal ultrasound (IUS) (non-endoscopic) outside of routine care to assess treatment response.
224173608|NCT06196905|DRUG|MT-2990|i.v. infusion
224173609|NCT01718119|DRUG|r-hCG|r-hCG(250mcg) injection subcutaneously
224173610|NCT06534164|DEVICE|Full/High Tech Telerehabilitation decision support system|"The TeleRehaB DSS intervention includes balance rehabilitation programme delivered via an augmented reality hologram of a virtual physiotherapist. The system delivers exercises demonstrated via a hologram of the physiotherapist and corrected in real time by the hologram prompts based on performance monitoring via sensors. It includes different multisensory balance and gait exercises, physical activity and memory training and exergames (video games which are also exercises) to improve balance function in older adults. The system can thus assess and remotely monitor how users are performing the exercises.~Exercise progressions will be suggested by the AI-supported TeleRehaB DSS and approved by the clinicians, which will be loaded into the participant's programme."
224173611|NCT06534164|DEVICE|Basic/Low Tech Telerehabilitation decision support system|"The basic system does not inlcude exergames, a smartwatch, or a mobile phone for activity tracking.~It includes different multisensory balance and gait exercise, cognitive training and real-time feedback from motion sensors.~Exercise progressions will be suggested by the AI-supported TeleRehaB DSS and approved by the clinicians, which will be loaded into the participant's programme."
224173612|NCT06534164|PROCEDURE|OTAGO Home exercise program|balance rehabilitation program
223484994|NCT04402242|DEVICE|Bispectral index + NOL index|Anesthesia monitoring
223484995|NCT02935387|OTHER|Taper|Taper
223484996|NCT02321527|DRUG|Perflutren Protein-Type A Microspheres Injectable Suspension|Participants receive a subdermal periareolar injection of 0.2 - 0.5 cc of microbubble contrast Perflutren Protein-Type A Microspheres Injectable Suspension (OPTISON™) before breast ultrasound.
223484997|NCT02321527|DEVICE|Contrast-Enhanced Ultrasound (CEUS)|Ultrasound images of breast and videos of tumor and lymph nodes in underarm area taken after Perflutren Protein-Type A Microspheres Injectable Suspension injection.
223484998|NCT02321527|PROCEDURE|Biopsy + Radioactive Seed Placement|Biopsy of sentinel lymph node that was identified in ultrasound performed, and a titanium clip marker inserted into the node. After biopsy, a radioactive seed may be inserted into the node to allow surgeon to find and remove it during surgery.
223484999|NCT02321527|BEHAVIORAL|Phone Call|Participant called by phone 30 days after seed is removed to check for any side effects. This phone call should take about 10 minutes.
223485000|NCT03315637|PROCEDURE|Fetoscopic repair of spina bifida|Fetoscopic intrauterine repair of open spina bifida
223586201|NCT01477008|PROCEDURE|Marrow Stimulation|Microfracture or Subchondral Drilling
223586202|NCT01576185|OTHER|laboratory biomarker analysis|Correlative studies
223586203|NCT01576185|DRUG|quizartinib|Via gavage
223586204|NCT01576185|DRUG|sorafenib tosylate|Via gavage
223586205|NCT04454736|BEHAVIORAL|"Amateur Group Singing"|45-minute singing session led by a professional choirmaster without a therapeutic background once a week
223586206|NCT04454736|BEHAVIORAL|"Professional Group Singing"|120-minute singing session led by a professional choirmaster without a therapeutic background three times a week. Assessments take place twice a week.
224173613|NCT06534164|PROCEDURE|Vestibular rehabilitation program|vestibular rehabilitation and dizziness program
224173614|NCT02545049|DRUG|Finerenone (BAY94-8862)|10 mg or 20 mg Finerenone tablet to be given orally, once daily.
224173615|NCT02545049|DRUG|Placebo|Matching placebo to be taken orally, once daily.
224173616|NCT07051642|BEHAVIORAL|Incredible Years Dinosaur Child Program|The Incredible Years Dinosaur Child Program is a structured, manualized group intervention designed for children aged 4 to 8 years with elevated or (sub)clinical conduct problems. The program consists of 18 weekly group sessions lasting approximately two hours each. Sessions are delivered in small groups (5-6 children per group) by certified trainers and follow a developmentally appropriate, play-based curriculum. Intervention components include storytelling with puppets, role-play, video modeling, and group discussions. The program aims to enhance emotional regulation, social competence, and problem-solving skills. The Dutch version of the program is used in this study and implemented in both clinical and preventive settings.
224173617|NCT07059338|DRUG|Trastuzumab +Cetuximab β+Irinotecan|Trastuzumab 4 mg/kg , Cetuximab β: 500 mg/m² ,Irinotecan 180 mg/m², repeat once every 2 weeks
224173618|NCT07057674|DRUG|HS-20094 AI pen;|Arm 1: Administered SC The dose is escalated every 4 weeks until the target dose of 15 mg is reached. The dose escalation scheme is as follows: 2.5 mg → 5 mg → 7.5 mg → 10 mg → 12.5 mg → 15 mg.
224173619|NCT07057674|DRUG|HS-20094 MDV pen|The dose is escalated every 4 weeks until the target dose of 15 mg is reached. The dose escalation scheme is as follows: 2.5 mg → 5 mg → 7.5 mg → 10 mg → 12.5 mg → 15 mg.
224173620|NCT07059481|OTHER|Root Canal Treatment and Sample Collection|Single session root canal treatment procedure will be performed with VDW Gold Reciproc device and reciprocal files (Endo T-Must, Dentac, Turkey). Endodontium Samples will be collected from each patient's root canal, with 15 Hedström files (Dentsplay).
224173621|NCT07059481|DIAGNOSTIC_TEST|PAI Score Comparasion|PAI scores of the patients will be determined with periapical films taken before treatment and compared with oxidative stress markers before and after treatment for the epoxyamine group and bioceramic group.
224173622|NCT07057518|BEHAVIORAL|emotional freedom technique|The EFT application will be implemented by the researcher who has been trained in this subject, in the most quiet and calm environment possible, in a position where the individuals are comfortable. There are basic steps to be followed in EFT application. Thought Field Therapy (TFT), developed by Callahan, based on Craig, uses different click points for specific psychological conditions, while EFT has 12 energy click points in the same specified order to treat every emotional problem, It is called 'Basic Recipe'
224173623|NCT07058636|DRUG|2% Lidocaine HCl + saline|The intervention consists of injecting a mixture of 1 ml 2% lidocaine and 1 ml normal saline into trigger points located in the upper trapezius muscle.
224173624|NCT07058636|DRUG|Steroid+lidocaine|The GON block involves injecting a mixture of 1 ml 2% lidocaine and 1 ml betamethasone.
223485001|NCT01838876|DRUG|Cariprazine|Cariprazine capsules 0.5 mg, 1.0 mg, and 1.5 mg; Cariprazine doses 1.5, 3.0, or 4.5 mg/day (d); patients will be titrated to a starting dose of 3.0 mg/d. Patients can stay on 3.0 mg/d or the dose can be adjusted to 1.5 mg or 4.5 mg based on investigator's judgment of response and tolerability. Oral administration.
223485002|NCT01838876|DRUG|Antidepressant Therapy (ADT)|ADT such as citalopram, escitalopram, fluoxetine, sertraline, paroxetine, vilazodone, venlafaxine, desvenlafaxine, duloxetine or bupropion prescribed in accordance with its respective FDA approved package insert for each drug
223485003|NCT02101294|DEVICE|Interossei Lumbricals Neuro Interface|Finger Relief's keyboard home row layout \[actual home row placement order: asdeihotlrn\], plus substitutions on the upper row \[qwfgjyuk;p\] and bottom row \[zxcvb'm,.\] moves or shifts finger and thumb movement from the elbow muscles to the finger muscles. The movement of finger bending toward the palm is shifted to the interosseous and lumbrical muscles of the hand and fingers from the full flexion and extension muscle control to reduce contraction and expansion of tendons and the movement in the carpal canal adjacent to the median nerve and reduces pressure on the median nerve. Pressure on the median nerve compromises the nerve leading to symptoms of the carpal tunnel syndrome of pain, tingling, and numbness.
223485004|NCT02101294|DEVICE|Standard QWERTY keyboard|Report of onset and severity symptoms of carpal tunnel syndrome when typing with QWERTY keyboard and the Finger Relief device.
223485005|NCT01882452|BEHAVIORAL|Memory Specificity Training|This intervention is a manualised, structured treatment delivered over 5 x 60 minute sessions to groups of 5-8 individuals. This treatment involves repeated practice of retrieving specific autobiographical memories in response to positive, negative and neutral cue words. There is a single psychoeducation component in the first session about memory difficulties common in depression which provides the rationale for this treatment. The training is supplemented by weekly homework practice.
223485006|NCT01882452|BEHAVIORAL|Education and Support|The education-and-support comparison condition is matched with the experimental arm for length and format (ie., 5 x 60 minute weekly sessions in groups of 5-8 individuals). Groups receive a single psychoeducation component where information about depression is provided. This is followed by non-directive support where participants are encouraged to raise different kinds of events that occur each week for discussion in the group. The sessions are supplemented by a homework diary where participants will be invited to note down an event that occurs each day, which may be positive, negative, or benign and non-emotional in nature. This material will provide the basis for discussion in the weekly group meetings.
223485007|NCT00000935|BIOLOGICAL|Intravenous immune globulin (IVIG)|given at a dose of 20mL/kg Intravenous Immune Globulin (Human) (IVIG 10% solvent/detergent)
223485008|NCT01241149|PROCEDURE|anti-reflux surgery|Anti-reflux surgery (Laparoscopic Nissen Fundoplication)
223485009|NCT02646163|DRUG|REP 2055|"(First two patients) REP 2055 is administered once weekly by slow IV infusion in dose escalation from 100 to 1200mg until a grade 3 adverse event is observed not to exceed 40 weeks of dosing.~(Subsequent patients) 400mg of REP 2055 is administered by slow IV infusion. First week of infusion to include daily dosing followed by twice weekly dosing for 40 weeks."
223485010|NCT03335527|DRUG|Dexmedetomidine|Dexmedetomidine is administered as a continuous intravenous infusion at a rate of 0.1-0.2 ug/kg/h (0.025-0.05 ml/kg/h) from study recruitment in the ICU during mechanical ventilation, for no more than 72 hours.
224306124|NCT03402750|BEHAVIORAL|Electronic Prescription|Patient or surrogate can pick up medication from pharmacy
224306125|NCT03257514|DRUG|alpha lipoic acid drug (thioctic acid acid)|Alpha lipoic acid has anti-inflammatory, antioxidant effects and plays a role in wound healing process.
223485011|NCT03335527|DRUG|Placebo (normal saline)|Placebo (normal saline) is administered as a continuous intravenous infusion at a rate of 0.025-0.05 ml/kg/h from study recruitment in the ICU during mechanical ventilation, for no more than 72 hours.
223485012|NCT05502731|DRUG|Filgotinib|Filgotinib is a small molecule that reversibly inhibits Janus kinases (JAK, selectively JAK 1), thereby inhibiting downstream signalling events induced by various pro-inflammatory and regulatory cytokines.
223485013|NCT05502731|DRUG|Adalimumab|Adalimumab is a monoclonal antibody selectively inhibiting the pro-inflammatory cytokine TNF-alpha.
223485014|NCT04179214|OTHER|Thoracic manipulation|Session will be performed twice a week for a three week period if a pop sound occurred then the therapist moved on next procedure ,if not subject will be repositioned and technique will performed again. This procedure will be performed for maximum of two attempts. Approximately 3 minutes of time is required to complete thrust manipulation subjects assigned to thrust manipulation also received general exercise program and manual pressure release technique as the control group. General exercise group involve Stretching exercises for the pectoral muscles and resisted strengthening exercises for the scapular retractors and elevators and the glenohumeral abductors and external rotators were performed three times per week for 3 weeks.
223485015|NCT04179214|OTHER|conventional pt protocol|This group will receive manual pressure release technique along with general exercises program. General exercise group involve Stretching exercises for the pectoral muscles and resisted strengthening exercises for the scapular retractors and elevators and the glenohumeral abductors and external rotators were performed three times per week for 3 weeks.
223485016|NCT05340699|DEVICE|Defocus Distributed Multi-point lens|Wear DDM lens
223485017|NCT05340699|DEVICE|Single vision lens|Wear single vision lens
223485018|NCT01654887|OTHER|Lung Ultrasound|Six anatomic areas, delineated by the anterior, posterior, and mid- axillary lines will be systematically examined bilaterally, as per the modified Bedside Lung Ultrasound in Emergency (BLUE) protocol (Lichtenstein 2008). Ultrasound images will be obtained in longitudinal and transverse orientation, and recorded.
223485019|NCT01654887|RADIATION|Chest X-Ray|Posterior-Anterior and lateral views of the chest via chest radiography followed by a lung ultrasound which is comprised of six anatomic areas, delineated by the anterior, posterior, and mid- axillary lines will be systematically examined bilaterally, as per the modified Bedside Lung Ultrasound in Emergency (BLUE) protocol (Lichtenstein 2008). Ultrasound images will be obtained in longitudinal and transverse orientation, and recorded.
223485020|NCT01375101|DRUG|placebo|The patient is directed to use placebo capsule two times a day, ,until the one mouth
223485021|NCT01375101|DRUG|Quercetin|The patient is directed to digest quercetin hydrate capsule two times a day,until one mouth
223485022|NCT03001102|DEVICE|4% Chlorhexidine gluconate|Cationic biguanide - antimicrobial action rubbing in the skin.
223485023|NCT03001102|DEVICE|10% PVPI degermante|Polymer soluble in water of iodine with polyvinylpyrrolidone (PVP) - antimicrobial action rubbing in the skin.
223485024|NCT03001102|DEVICE|Soap without antiseptic|Liquid soap with glycerin, neutral pH. Skin cleansing
223485025|NCT04562558|DRUG|Methotrexate|50mg intramuscularly on Days 1, 3, 5, 7 . Repeat every 14 days
223485026|NCT04562558|DRUG|Leucovorin|15mg intramuscularly on Days 2, 4, 6, 8. Repeat every 14 days
223485027|NCT04562558|DRUG|Dactinomycin|1.25mg/m2 (2mg max dose)intravenous every 14 days.
223485028|NCT04000113|DEVICE|laser acupuncture|low level laser emission on specific acupuncture points
223586207|NCT03994315|OTHER|B. infantis EVC001|"Bifidobacterium longum subspecies infantis strain EVC001, designated a Foods for Special Dietary Use (FSDU)"
223586208|NCT03994315|OTHER|Lacto-N-tetraose (LNT)|LNT is a human milk oligosaccharide (HMO) found in human breast milk and is a selective prebiotic for B. infantis.
223586209|NCT02624336|OTHER|DTC1|15ml DTC1 twice a day, rinse for 30sec refrain from eating or drinking for 30min
223586210|NCT02624336|OTHER|Oradex|15ml Chlorhexidine gluconate 0.12% (w/v) twice a day, rinse for 30sec refrain from eating or drinking for 30min
223485029|NCT04000113|DEVICE|Sham laser|Sham laser
223485030|NCT03199690|DRUG|Dolutegravir|Antiviral (integrase inhibitor)
223485031|NCT03199690|DRUG|Rifampicin|Antibiotic
223485032|NCT02875457|DRUG|apatinib;etoposide and cisplatin|
223485033|NCT02875457|DRUG|placebo;etoposide and cisplatin|
223586211|NCT02624336|OTHER|Distilled water|15ml distilled water twice a day, rinse for 30sec refrain from eating or drinking for 30min
223485034|NCT01658410|DRUG|BQ-123|BQ-123 (Clinalfa, Läufelfingen, Switzerland) Dosage: 15µmol in two equal amounts (7.5µmol); in the first and last cardioplegia Route: intracoronary
223485035|NCT01658410|DRUG|NaCl|NaCl, Route: intracoronary
223485036|NCT05342844|DRUG|Dexmedetomidine 0.5 mcg|0.5 mcg/kg
223586212|NCT03597282|BIOLOGICAL|NEO-PV-01|Personal Cancer Vaccine
223586213|NCT03597282|BIOLOGICAL|Nivolumab|monoclonal antibody against PD-1
223586214|NCT03597282|OTHER|Adjuvant|immune adjuvant
223586215|NCT03597282|BIOLOGICAL|APX005M|monoclonal agonist antibody against CD40
223586216|NCT03597282|BIOLOGICAL|ipilimumab|monoclonal antibody against CTLA4
223586217|NCT03134183|DRUG|Vaginal Misoprostol|Mifepristone 200mg orally 20-24 hours prior and misoprostol 400mcg (two 200mcg tablets) vaginally 1-2 hours prior and placebo (buccal mint powder) buccally 1-2 hours prior to D\&E
223586218|NCT03134183|DRUG|Buccal Misoprostol|Mifepristone 200mg orally 20-24 hours prior and misoprostol 400mcg (two 200mcg tablets) ground with mint into buccal powder and placebo (two lactose tablets designed to appear similar to misoprostol) vaginally 1-2 hours prior to D\&E
223586219|NCT02231385|DRUG|Acetic Acid|"Subjects in Group A (study group) will undergo a standard colonoscopy. Once the right colon has been fully examined, acetic acid 2% will be sprayed and the right colon re-examined from cecum to hepatic flexure with within a frame-time of two minutes.~Subjects in Group B (control group) will undergo a second examination of the right colon without acid acetic and within the same frame-time."
223586220|NCT00724906|DRUG|123 I - ALTROPANE®|8.0 mCi (±1.0 mCi) will be administered intravenously to each subject.
223485037|NCT05342844|DRUG|Dexmedetomidine 1 mcg|1 mcg/kg
223485038|NCT02950571|BEHAVIORAL|Digital Picture Frame|The intervention is the provision of digital picture frames in long stay inpatient rooms in a ward at CAMH.
223485039|NCT02950571|BEHAVIORAL|Standard Care|High level of support from an interdisciplinary team.
223586221|NCT02223481|DRUG|Terbogrel low dose|
224173625|NCT07058701|OTHER|Investigational Serum, Standard Cleanser|"Mode of Group Serum application : On-site single use~Standard cleanser + Investigational Serum (random half-face) \[FLA #2039128 50\]~\- subjects should wash face with standard cleanser \[FLA #730457 36\] on site before measurements.~The technician will apply the Investigational Serum \[FLA #2039128 50\] on the subject's half face (according to the Annex 11.6) at the test site, keep another half face as blank control."
223485040|NCT06525727|OTHER|Falls Decision Rule|The Falls Decision Rule is a rule used to assess the risk of intracranial haemorrhage in geriatric patients and to prevent brain tomography (CT) in low-risk patients. This rule recommends that brain CT is not necessary in patients who do not have significant head trauma, memory loss, newly developing neurological examination disorder, or frailty score lower than 5 after a fall.
223485041|NCT02266485|DRUG|BIBB 515 BS|
223485042|NCT02266485|DRUG|Pravastatin|
223485043|NCT02266485|DRUG|Placebo|
223485044|NCT05002803|OTHER|Otago Exercise Program|A Home-based Exercise Program to improve strength and balance and prevent falls.
223485045|NCT04882800|DEVICE|Lyric extended wear hearing aid device A|Current commercially available extended wear hearing aid
223485046|NCT04882800|DEVICE|Lyric extended wear hearing aid with fitting modification device B|Extended wear hearing aid with fitting modifications
223485047|NCT06219239|GENETIC|KL003 cell injection Drug Product|No conditioning regimen for transfusion of auto-HSC transduced with lentiviral vector encoding βA-T87Q-globin gene
223485048|NCT02597114|DRUG|AGT-181|intravenous infusion over 3-4 hours
223485049|NCT00080418|DRUG|Liposome Entrapped Paclitaxel Easy to Use|
223485050|NCT01001156|OTHER|Comparison of different breathing muscular training|Three times per week for ten weeks, thirty minutes.
223485051|NCT01568541|DRUG|Regular toothpastes|One tooth brushing
223485052|NCT01568541|DRUG|Children's toothpastes|One tooth brushing
223485053|NCT02011178|PROCEDURE|Optimal medical treatment and surgery|
223485054|NCT02011178|PROCEDURE|Optimal medical treatment|
223485055|NCT04952896|DIAGNOSTIC_TEST|Synovitis diagnosis|
223485056|NCT03692806|DIETARY_SUPPLEMENT|Stablor|Stablor sachet
223485057|NCT03692806|DIETARY_SUPPLEMENT|placebo|placebo sachet
223485058|NCT03047252|DEVICE|Home-based rehabilitation with a digital biofeedback system|"The system will be used independently by the patients to perform rehabilitation sessions at home, under remote monitoring from the clinical team. A tailored rehabilitation program will be prescribed, based on the following principles:~STAGE 1 (Weeks 0-2) Open kinetic chain exercises without added resistance: lying, sitting and standing (with support) Strengthening of hip flexors and extensors Ice pack application after each session and throughout the day as needed STAGE 2 (weeks 3-6) Open kinetic chain exercises with added resistance, progressing to closed kinetic chain exercises, with strengthening of knee flexors and extensors and knee stabilization Progression to standing exercises without support lying, sitting and standing (with support) Exercises with steps Ice pack application after each session and throughout the day as needed STAGE 3 (Weeks 7-8) Eccentric strengthening exercises Exercises involving steps Multi-directional exercises"
223485059|NCT03047252|OTHER|Conventional Home-based rehabilitation|"Patients will perform 3 weekly rehabilitation sessions, with a duration of 1 hour, for 8 weeks, provided by a physical therapist. The rehabilitation program will respect the following principles:~STAGE 1 (Weeks 0-2) Soft tissue massage Active assisted mobilisation of the knee to increase range of motion Gait training with bilateral support Open kinetic chain exercises without added resistance Strengthening of hip flexors and extensors Ice pack application STAGE 2 (weeks 3-6) Soft tissue massage Active assisted mobilisation of the knee to increase range of motion Open kinetic chain exercises with added resistance, progressing to closed kinetic chain exercises, with strengthening of knee flexors/ extensors and knee stabilisation Gait training with progressive withdrawal of external support Ice pack application STAGE 3 (Weeks 7-8) Eccentric strengthening exercises Exercises involving steps Weight-bearing exercises on uneven surfaces Ice pack application"
223485060|NCT05893641|BEHAVIORAL|A regular training volume|Participate will maintain their training volume of 35 h/week
223485061|NCT05893641|BEHAVIORAL|A lower exercise volume group|Participate will conduct 85% of the control group weekly training volume (i.e., 30h/week)
223485062|NCT05893641|BEHAVIORAL|A longer rest group|Participate will maintain the 35 h/week of exercise training
224306126|NCT03257514|DRUG|Placebo Oral Tablet|placebo oral drug have the same shape of thiotacid tablet
223485063|NCT04276220|DIAGNOSTIC_TEST|Tenosynovial biopsy|Tenosynovial biopsy taken from the wrist at the carpal tunnel release surgery.
223485064|NCT04934358|BEHAVIORAL|Physical and motivational follow-up treatment|Physical and motivational follow-up treatment
223586222|NCT02223481|DRUG|Terbogrel high dose|
224306127|NCT06015243|DRUG|GR1802 injection|150mg/1ml. 2 ml every two weeks Route of administration: Subcutaneous
224306128|NCT04914858|OTHER|Education|Its validity and reliability is a reliable scale in Turkey
223485065|NCT04934358|BEHAVIORAL|Usual care|Usual rehabilitation program
223485066|NCT06619444|BEHAVIORAL|Aerobic exercise only|Aerobic exercise training will consist of 60 min of treadmill, elliptical, or bike exercise at a moderate to vigorous (50-80% of heart rate reserve). Intensity of the exercise sessions will be built of gradually. Sessions will occur 2 times per week for the duration of the year trial
223485067|NCT06619444|BEHAVIORAL|30 min of resistance exercise|30 min of resistance exercise (RE) will consist of 30 total minutes of resistance exercise each week (15 min each session) in addition to 60 min of aerobic exercise each week (30 min each session). Each 15 min session of resistance exercise will consist of 2 sets of 8-15 repetitions at 50-80% of 1-rep max of 4 exercises. Aerobic exercise will consist of treadmill, elliptical, or bike exercise at moderate to vigorous intensity (50-80% of heart rate reserve). Intensity of the exercise sessions will be increased gradually. With 1 min rest between sets, this plan is estimated to take approximately 45 min per session. Sessions will occur 2 times per week for the duration of 1 year.
223586223|NCT02223481|DRUG|Placebo|
223586224|NCT05808010|BIOLOGICAL|Mononuclear cells|2 times gastric submucosal injection of mononuclear cells (10\^8) at 1 month interval
223586225|NCT05808010|DRUG|Weifuchun+Hydrotalcite/L-Glutamine and Sodium Gualenate Granules|Orally delivered tablets for 7 months. Take it according to the instructions.
223586226|NCT05897697|OTHER|Interview|Structured interview
223586227|NCT01416623|DRUG|henatinib|Henatinib Maleate Tablets
224173626|NCT07058701|DEVICE|Infrared Light for Redness Induction on Face|"Infrared light has high radiation frequency, its permeability is strong, the wavelength of infrared light can penetrate the human dermis to promote blood circulation and induce skin redness.The redness induction process will be done after baseline measurements for each subject.The subject's face was exposed at a distance of 20cm from infrared lamp for minimum 5 - 10 minutes at a temperature of 30-40°C and a wavelength of 760-5000 nm. In general, the skin will not be burned during the induction process. Due to individual differences, if the subjects cannot tolerate or feel uncomfortable during the process, the investigators will stop the process according to the situation; If there is any burn during the process, the on-site dermatologist will treat it in time, and the subject needs to follow the dermatologist's advice for follow-up treatment.~Infrared light type: PHILIPS, IR250 RH IR2, 230-250V, 250W, wave length 760-5000nm, T 30\~40°C"
224173627|NCT07057843|BEHAVIORAL|Sequential Nutrition Intervention|"Participants received a structured, sequential nutrition intervention guided by nutritional risk screening (NRS2002). A multidisciplinary team provided the intervention, which included:~* Pre-CyberKnife phase: Calculation of energy requirements using the Harris-Benedict formula, dietary guidance, and initiation of oral nutritional supplements (ONS). If oral intake was less than 60% of target, partial enteral (PEN) or parenteral nutrition (PPN) was administered for 7-10 days.~* Post-CyberKnife phase: Phased re-introduction of feeding, starting with enteral nutrition via nasojejunal tube (Day 1-2) and transitioning to an oral diet (Day 3 onwards).~* Post-discharge phase: Home energy targets were recalculated, with telephone/WeChat follow-up to ensure adherence. ONS prescribed if intake fell below 60% of targets."
224173628|NCT07057843|DRUG|Enteral Nutrition Emulsion|Fresubin (500 mL/bottle) administered at 30 mL/kg/day during the initial post-CyberKnife phase if required.
224306129|NCT02416024|DEVICE|SphygmoCor system|Carotid-femoral pulse wave velocity (cfPWV) will be determined by applanation tonometry using the Sphygmocor system by sequentially recording ECG-gated carotid and femoral artery waveforms. Pulse wave signals will be recorded by tonometers positioned at the base of the right common carotid artery and over the right femoral artery. The time (t) between the feet of simultaneously recorded waves will be determined as the mean of 10 consecutive cardiac cycles. PWV is calculated by the system software from the distance between measurement points (D) and the measured time delay (t) as follows: cfPWV = D/Δt (m/s) where D is distance in meters and t is the time interval in seconds.
224306130|NCT00146341|DRUG|Telmisartan/HCTZ|
224306131|NCT00146341|DRUG|Telmisartan|
224306132|NCT01020136|DRUG|AG-013736|single oral dose 5-mg tablet (Form IV for Treatment A and Form XLI for Treatment B under fed conditions)
223485068|NCT06619444|BEHAVIORAL|60 min of resistance exercise|60 min of resistance exercise (RE) will consist of 60 total minutes of resistance exercise each week (30 min each session) in addition to 60 min of aerobic exercise each week (30 min each session). Each 30 min session of resistance exercise will consist of 2 sets of 8-15 repetitions at 50-80% of 1-rep max of 8 exercises. Aerobic exercise will consist of treadmill, elliptical, or bike exercise at moderate to vigorous intensity (50-80% of heart rate reserve). Intensity of the exercise sessions will be increased gradually. With 1 min rest between sets, this plan is estimated to take approximately 60 min per session. Sessions will occur 2 times per week for the duration of 1 year.
223485069|NCT06619444|BEHAVIORAL|120 min of resistance exercise|120 min of resistance exercise (RE) will consist of 120 total minutes of resistance exercise each week (60 min each session) in addition to 60 min of aerobic exercise each week (30 min each session). Each 60 min session of resistance exercise will consist of 3 sets of 8-15 repetitions at 50-80% of 1-rep max of 10 exercises. Aerobic exercise will consist of treadmill, elliptical, or bike exercise at moderate to vigorous intensity (50-80% of heart rate reserve). Intensity of the exercise sessions will be increased gradually. With 1 min rest between sets, this plan is estimated to take approximately 90 min per session. Sessions will occur 2 times per week for the duration of 1 year.
223485070|NCT00970554|OTHER|Patching|Patching of the sound eye for 30 minutes a day for 17 weeks.
223485071|NCT00970554|OTHER|Telescopic magnification|Patching of the sound eye plus simultaneous use of a telescopic device by the amblyopic eye for 30 minutes a day for 17 weeks.
223485072|NCT02754453|BEHAVIORAL|Behavioral lifestyle intervention|20 session lifestyle behavioral intervention with the goal of altering diet and physical activity and decreasing problematic behaviors associated with weight regain and session behavioral intervention addressing increasing physical activity, improving adherence to dietary recommendations and altering problematic eating behaviors.
223485073|NCT01952860|OTHER|Hatha Yoga|18 sessions of Hatha yoga over the course of radiation therapy. Each 45 to 60 minute session guided by an instructor. Participant should attend each session together with their caregiving partner. Some sessions videotaped. At first session, participant given a CD and instructions for practicing Hatha yoga at home.
223485074|NCT01952860|BEHAVIORAL|Questionnaires|Questionnaire completion at baseline, during radiation therapy, and at completion of radiation therapy.
223485075|NCT06095193|BEHAVIORAL|menopause education|Women will be taught the physiology of female reproductive organs, physiology of menopause, vaginal symptoms in menopause, sexual myths in menopause and practices that will support sexuality in menopause, in 50 minutes for 4 weeks.
223485076|NCT01410825|BIOLOGICAL|Retrovirus-mediated gene transfer|Two procedures: 1) Bone marrow harvest from the patient's posterior iliac crests or collection of peripheral blood stem cells via apheresis procedure. 2) One time infusion of patient's transduced bone marrow cells.
223485077|NCT01637168|DRUG|Panax Ginseng + Ginkgo Biloba + Polyminerals + Multivitamin|A tablet, 2 times daily (12/12 hours).
223485078|NCT01637168|DRUG|Ginkgo Biloba (Tebonin®)|A tablet, 2 times daily (12/12 hours).
223485079|NCT03575169|DEVICE|BIS Monitor|Unilateral BIS electrode
223485080|NCT02755090|DRUG|Nitrous Oxide|Participants in the nitrous oxide group will receive a scented face mask through which nitrous oxide will be administered. The nitrous content of the gas will be titrated up by 20% every 5 breaths with a goal of 70% N2O/ 30% O2 as tolerated by the participant. This group will also receive saline through an IV. All participants will receive local anesthesia in the form of a paracervical block and ibuprofen pre-operatively.
223485081|NCT02755090|DRUG|IV Saline|
223586228|NCT01969721|DRUG|fluticasone propionate|low dose
223586229|NCT01969721|DRUG|salmeterol|
223586230|NCT01969721|DRUG|placebo|placebo/dummy for blinding purposes
223586231|NCT01969721|DRUG|placebo|placebo/dummy for blinding purposes
224173629|NCT07057843|BEHAVIORAL|Routine Nutritional Intervention|Participants received routine nutritional intervention, which consisted of dietary education focused on balanced, soft, and easily digestible meals rich in protein and other nutrients (e.g., high-protein soups).
224173630|NCT07057869|PROCEDURE|5-minute Ultrasound Group|Pulsed ultrasound therapy applied at 1 W/cm² intensity and 1 MHz frequency for 5 minutes per session, 4 weeks duration.
224173631|NCT07057869|PROCEDURE|10-minute Ultrasound Group|Pulsed ultrasound therapy applied at 1 W/cm² intensity and 1 MHz frequency for 10 minutes per session, 4 weeks duration.
224173632|NCT07057869|PROCEDURE|15-minute Ultrasound Group|Pulsed ultrasound therapy applied at 1 W/cm² intensity and 1 MHz frequency for 15 minutes per session, 4 weeks duration.
223485082|NCT01465269|BEHAVIORAL|Group Interactive Structured Treatment|GIST groups consist of 8 group participants and two group therapists. Group members receive the workbook and are asked to bring it to each session. During each of the 13, 1.5 hour sessions, key concepts from the previous session are reviewed, a new topic is discussed, strategies and skills are practiced interactively, and real-life social problems are addressed. Previously covered topics are integrated into each session through discussion and problem solving to provide repetition and reinforcement of information.
223485083|NCT01465269|BEHAVIORAL|Alternative Intervention|Participants in the alternative treatment will attend 13 weekly classroom sessions, where they will view video presentations of the same curriculum topics covered in the GIST workbook. The group therapists will serve as moderators and will meet with participants individually. Group interaction will not be encouraged. Homework exercises will be offered but participants will not be asked to return their homework and will not receive any feedback.
223485084|NCT04940221|BEHAVIORAL|Shared Decision Making|Telephone delivered non-persuasive shared decision-making for lung cancer screening.
223485085|NCT05043935|PROCEDURE|L-PRF with antimicrobial photodynamic therapy|Application of L-PRF with antimicrobial photodynamic therapy in the defect
223485086|NCT05043935|PROCEDURE|antimicrobial photodynamic therapy without L-PRF|application of antimicrobial photodynamic therapy without L-PRF in the defect
223485087|NCT01138735|DRUG|adapalene/benzoyl peroxide|daily topical application for 12 weeks
223485088|NCT01138735|DRUG|Topical Gel Vehicle|daily topical application for 12 weeks
223485089|NCT04696471|DEVICE|Continuous Theta Burst Stimulation (cTBS)|cTBS is a brief stimulation of a part of the brain with a magnetic field that passes through the scalp and skull safely. It is FDA-approved as a treatment for psychological conditions including depression; however, this device is not approved for the treatment of adults with Bipolar Disorder I or for use in healthy adults. This research study is using the cTBS off label in all participants (those with and without Bipolar Disorder I) to examine research questions
223485090|NCT04696471|DEVICE|Sham Continuous Theta Burst Stimulation (Sham cTBS)|Sham cTBS goes through the motions of applying cTBS to the brain but administers very low current so that the participant feels like cTBS is being administered even though the current is too low to stimulate brain cells. Participants will know that one session will be a sham, but they will be blinded to which session is the sham
223485091|NCT05577000|BIOLOGICAL|Manufactured Anti-BCMA CAR-T cells|Given IV
223485092|NCT05577000|DRUG|Fludarabine|Given IV
223485093|NCT05577000|DRUG|Cyclophosphamide|Given IV
223485094|NCT01041911|DRUG|Euphorbia tablets|50 mg, tablet, once daily, 14 days
224173633|NCT07059169|DRUG|JY231 (JY231 injection)|JY231 injection is administered intravenously and produces autologous CAR-T cells in the patient's body some time after infusion.
223485095|NCT01041911|DRUG|Euphorbia tablets|100 mg, tablet, once daily, 14 days
223485096|NCT01041911|DRUG|Euphorbia tablets|200 mg, tablet, 2 tablets of 100 mg Euphorbia prostrata, 14 days
223485097|NCT01041911|DRUG|Placebo tablets|placebo, tablet, once daily, 14 days
223485098|NCT04928599|OTHER|Electronic Health Record Review|Review of medical records
224173634|NCT07057752|OTHER|Virtual Reality|Virtual reality (VR) will be applied to patients in this group in addition to painkillers. VR is a non-pharmacological method that uses special glasses to create an immersive visual and auditory experience. It helps distract patients from the procedure and may reduce pain and anxiety.
224173635|NCT07057752|DRUG|dexketoprofen + midazolam|Patients in this group will be treated with dexketoprofen as a painkiller and midazolam as an anxiolytic, if needed. This combination aims to reduce both pain and anxiety during the procedure.
224173636|NCT07058688|DRUG|NTRX-07|Orally administered CB2 agonist
224173637|NCT07058688|DRUG|Placebo|Inactive matched comparator
224173638|NCT07058415|OTHER|Stool sample 1|Stool sampling at D0 for having baseline reference
223485099|NCT04928599|OTHER|Interview|Complete interview
223485100|NCT04928599|OTHER|Survey Administration|Complete survey
223485101|NCT05735834|DRUG|Rituximab|Truxima concentrate for solution for infusion 500 mg/50 ml
223485102|NCT05735834|DRUG|Zanubrutinib|Zanubrutinib 80 mg hard capsules
223586232|NCT01969721|DRUG|tiotropium|tiotropium high dose
223586233|NCT01969721|DRUG|olodaterol|
223586234|NCT01969721|DRUG|olodaterol|
223586235|NCT01969721|DRUG|placebo|placebo/dummy for blinding purposes
223586236|NCT01969721|DRUG|placebo|placebo/dummy for blinding purposes
223586237|NCT01969721|DRUG|tiotropium|tiotropium low dose
223586238|NCT01969721|DRUG|fluticasone propionate|low dose
223586239|NCT01969721|DRUG|salmeterol|
223586240|NCT00512291|DRUG|Olanzapine|5 mg subcutaneous injection every 8 hours for 9 doses. Each injection should take about 1 to 2 minutes.
224173639|NCT07058415|OTHER|Stool sample 2|Stool sampling at D5 to study the impact of antibiotics on microbiota
224173640|NCT07058415|OTHER|Stool sample 3|Stool sampling at DX+28 to study the impact of antibiotics on microbiota
224173641|NCT07057700|DEVICE|welwalk training|welwalk training group 30 min of welwalk robot-assisted training + 15 min of walking training + 15 min of other training per session.The intervention lasted a total of 3 weeks, 6 sessions/week, 1 hour/session.
224173642|NCT07057700|OTHER|physical therapy|45 min of walking training + 15 min of other training per session. The intervention lasted a total of 3 weeks, 6 sessions/week, 1 hour/session.
224173643|NCT07054866|BEHAVIORAL|Speech-Gesture combinations|this is a pretest, test, posttest evaluation of language comprehension with and without gestures, to see if gestures can improve language comprehension
224173644|NCT07054632|GENETIC|LX101|Subretinal administration of LX101 to the study eye
224173645|NCT07059143|DEVICE|Nervio-X|An 8-channel TIS device developed by NEURODOME Corporation.
224173646|NCT07057726|DRUG|SSS39|Single oral administration of SSS39
224173647|NCT07057726|DRUG|SSS39|Single oral administration of SSS39
224173648|NCT07058779|DRUG|SSS55|SSS55 is an injection targeting complement C3b
224173649|NCT07058831|DEVICE|Home ECG monitoring|The 30-second home ECG tracings will be obtained using the Omron Complete Hem-7530 T ECG device (Omron Healthcare Co., Ltd., Japan). The connection and smartphone app download will be available from Omron Connect free of charge on the Google Play Store: https://play.google.com/store/apps/details?id=jp.co.omron.healthcare.omron\_connect\&hl=es\_419\&pli=1 and on the iOS App Store: https://apps.apple.com/mx/app/omron-connect/id1003177043. Two duplicate ECG recordings will be required daily: the first in the morning before breakfast and taking the prescribed medication, and another in the evening before dinner and taking the afternoon/evening medication. Additional ECG recordings will be required if the patient experiences any symptoms.
224173650|NCT07058116|DRUG|L-Boronophenylalanine intravenous administration|L-BPA will be complexed with fructose to form L-BPA-fructose (L-BPA-F) to increase solubility, and 400 mg/kg of L-BFA as complexed with fructose (L-BPA-F) will then be administered intravenously at a concentration of L-BPA 30 g/L over 2 hours before neutron irradiation.
224173651|NCT06843967|DRUG|Mirdametinib|Mirdametinib (PD-0325901) is a highly selective non-ATP-competitive inhibitor of MEK1 and MEK2. It significantly inhibits the phosphorylation of the MAP kinases ERK1 and ERK2, leading to impaired tumor cell growth in vitro and in vivo in a broad spectrum of human tumors
224173652|NCT06843967|DRUG|Palbociclib|Palbociclib (IBRANCE®) is a kinase inhibitor FDA approved for the following indications: treatment of adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with an aromatase inhibitor as initial endocrine-based therapy in postmenopausal women or in men or fulvestrant in patients with disease progression following endocrine therapy.
224173653|NCT07057739|DRUG|Superficial cervical plexus block|Patients received superficial cervical plexus block with 1 ml of normal saline with 7ml bupivacaine 0.25% per side without adjuvants.
224173654|NCT07057739|DRUG|Superficial cervical plexus block + Fentanyl|Patients received superficial cervical plexus block with fentanyl 1 ml (50 microgram) as an adjuvant to 7ml bupivacaine 0.25% per side.
224173655|NCT07057739|DRUG|Superficial cervical plexus block + Dexmedetomidine|Patients received superficial cervical plexus block with dexmedetomidine 0.5mcg/kg in 1 ml of normal saline as an adjuvant to 7ml bupivacaine 0.25% per side.
224173656|NCT07057622|DRUG|177Lu-DOTATATE injection|The eligible subjects who participate in 177Lu study are randomly assigned 1:1 to either the test group or the control group to receive treatment. Subjects in the test group are treated with 177Lu-DOTATATE injection, 7.4GBq±0.74GBq (200mCi±20mCi)/cycle, once every 8 to 12 weeks, 4 times in total.
224173657|NCT07057622|DRUG|Octreotide LAR (Long-acting release)|The eligible subjects who participate in 177Lu study are randomly assigned 1:1 to either the test group or the control group to receive treatment. Subjects in the treatment group are treated with 60mg of long-acting octreotide once every 4 weeks±3 days.
224173658|NCT07058259|BEHAVIORAL|Acupuncture|Acupuncture will be administered twice weekly for 5 weeks (10 sessions total) at predefined bilateral acupoints: LU1, LU9, LI18, ST36, GB12, BL13, BL20, and BL23. Single-use, sterile 25 mm × 0.25 mm needles will be inserted at each point for 20 minutes per session.
224173659|NCT07058259|DRUG|Standard COPD Pharmacological Therapy (LAMA + LABA or LAMA + LABA + ICS)|"Patients in this group receive standard pharmacological treatment for COPD according to current clinical guidelines. Treatment includes either dual or triple inhaler therapy:~Dual Therapy (LABA + LAMA): Patients receive a long-acting beta-agonist (LABA) such as Formoterol, Salmeterol, Olodaterol, Vilanterol, or Indacaterol, in combination with a long-acting muscarinic antagonist (LAMA) such as Tiotropium bromide, Umeclidinium, or Glycopyrronium.~Triple Therapy (LABA + LAMA + ICS): Patients receive the above combination of LABA and LAMA plus an inhaled corticosteroid (ICS) such as Budesonide, Fluticasone, or Beclometasone.~These medications may be administered either as fixed-dose combination inhalers or as separate inhalers, depending on patient needs and physician discretion. The treatment regimen is individualized based on clinical condition, prior therapy, and symptom severity."
224173660|NCT07058532|OTHER|Therapeutic Writing Intervention in Pain Rehabilitation|The therapeutic writing intervention is designed to support emotional processing and regulation in individuals with chronic pain and comorbid mental health disorders. It has been developed specifically for use in a clinical rehabilitation setting and is delivered in two phases over a four-week period at the Pain Clinic of Satasairaala Hospital. Sessions are conducted in person, with clinical staff available to support participants. The intervention is non-pharmacological, low-risk, and integrated into the broader multidisciplinary care pathway.
224173661|NCT07058870|BEHAVIORAL|High Intensity Task Oriented Circuit Training + Telerehabilitation|Participants will receive 10 sessions of high-intensity, task-oriented circuit training, three times a week. Each session will last 60 minutes, with minutes of active training. Each session will include three rounds, each lasting 55 minutes. During each round, participants will rotate between stations working for four minutes at each station, followed by three minutes of rest. The stations will focus on key motor skills, including supine to stand transitions, walking speed and functional capacity, walking adaptability and stepping. After in-hospital treatment participants will receive 36 sessions of asynchronous telerehabilitation, three times a week for 12 weeks. This intervention will be supported by low-cost, off-the-shelf technology for treatment delivery and monitoring.
224173662|NCT07059299|DRUG|Tislelizumab|humanized immunoglobulin G4 (IgG4)-variant monoclonal antibody (mAb) against human programmed cell death-1 (PD-1)
224173663|NCT07059299|DRUG|FLOT Chemotherapy|docetaxel 50 mg/m², oxaliplatin 85 mg/m², leucovorin 200 mg/m² and 5-FU 2600 mg/m², all i.v. on day 1 Q2W
224173664|NCT07058766|BEHAVIORAL|positively affects the physical and psychological health of pregnant women in the disaster area.|As time passes after the earthquake, psychological first aid services are not sufficient. Developing a care protocol to provide physical and psychosocial support to pregnant women who are earthquake victims, especially those in the vulnerable group, during the post-disaster disappointment period (months 2-36), is an important unique value of this project.
224173665|NCT07059442|DIAGNOSTIC_TEST|anal HPV screening|From all included women samples will be collected at the out-patient HIV departments including self-sampled vaginal swab for hrHPV testing and self-sampled anal swab for hrHPV. A blood sample will be taken for the analysis of circulating HPV DNA.
224173666|NCT07058818|BEHAVIORAL|Resistance training|Full-body physical therapy and resistance training intervention
224173667|NCT01154738|DRUG|Lidocaine|"bolus dose of lidocaine (1.5 mg.kg-1) followed by an infusion of lidocaine (2 mg.kg-1 h-1) until the end of anesthesia.~start of the induction of anesthesia 10 minutes after the bolus dose of lidocaine"
224173668|NCT01154738|DRUG|Placebo|"NaCl 9/00 (same volume as in the lidocaine group)~start of the induction of anesthesia 10 minutes after the bolus dose of NaCl 9/00"
224173669|NCT06899620|DIETARY_SUPPLEMENT|Probiotic group|The experimental phase of this study lasted for 60 days.
224173670|NCT06899620|DIETARY_SUPPLEMENT|Placebo group|The experimental phase of this study lasted for 60 days.
224173671|NCT04561284|DIETARY_SUPPLEMENT|Indigestible fiber (classified)|Participants will be asked to ingest 12 grams of indigestible fiber powder per day for a period of 8 weeks. Three times daily, they will take 4 grams of powder with their meal.
224173672|NCT04561284|DIETARY_SUPPLEMENT|Placebo|Participants will be asked to ingest 6 grams of placebo powder per day for a period of 8 weeks. Three times daily, they will take 2 grams of powder with their meal.
224173673|NCT01846689|DRUG|ESS (medical food/drug)|Prescription medical food erythropoietin stimulating system
224173674|NCT02364661|BEHAVIORAL|Over night starvation (fasting)|HBV viral load will be analyzed after over-night starvation versus following a morning meal
224173675|NCT01801189|DRUG|Pregabalin|One 300 mg oral dose of Pregabalin given before surgery.
224173676|NCT01801189|DRUG|Placebo (for Pregabalin)|One oral dose of placebo given before surgery.
224173677|NCT01731756|OTHER|Leaf extract of A. indica|Leaf extract of A. indica plus 6% salicylic acid will be applied on palmer keratotic lesion once daily at bedtime for 12 weeks.
224173678|NCT01731756|DRUG|Salicylic Acid (6%)|Salicylic acid (6%) will be applied on palmer keratotic lesion once daily on bedtime for 12 weeks.
224173679|NCT01731756|OTHER|Petroleum jelly|Petroleum jelly will be applied on palmer keratotic lesion once daily at bedtime for 12 weeks.
224173680|NCT06107452|OTHER|training strategy with adaptation of training strategies to the ANS|a training strategy for subjects whose PFVP is in favour of strength or speed with training load adjusted according to SNA
224173681|NCT06107452|OTHER|training strategy (standard practice)|a training strategy for subjects whose PFVP is in favour of strength or speed
224173682|NCT03300557|DRUG|Exemestane|Given PO
224173683|NCT03300557|OTHER|Laboratory Biomarker Analysis|Correlative studies
224173684|NCT03300557|OTHER|Pharmacokinetic Study|Correlative studies
224173685|NCT03300557|OTHER|Questionnaire Administration|Ancillary studies
224173686|NCT04305054|BIOLOGICAL|Pembrolizumab|Administered via IV infusion at a specified dose on specified days
224173687|NCT04305054|BIOLOGICAL|Vibostolimab|Administered via IV infusion at a specified dose on specified days
223586241|NCT02452203|BEHAVIORAL|Floating|Floating in either a pool saturated with Epsom salt or in a zero-gravity chair
223586242|NCT01012323|BIOLOGICAL|NewGam|The dose of NewGam, solvent/detergent treated human normal immunoglobulin 10%, remained the same throughout the study, as long as minimum trough levels of serum immunoglobulin G (IgG) was above 5 g/L. If serum IgG trough levels dropped to 5 g/L or less, the dose was to be adjusted at the investigator's discretion. NewGam was supplied as a solution for infusion.
223586243|NCT02117349|DRUG|Raplixa|Raplixa is a biological product approved for use in adults to help control bleeding from small blood vessels when standard surgical techniques, such as suture, ligature or cautery, are ineffective or impractical. When applied to a bleeding site, Raplixa is dissolved in the blood and a reaction starts between the fibrinogen and thrombin proteins. This results in the formation of blood clots to help stop the bleeding.
224173688|NCT04305054|BIOLOGICAL|Pembrolizumab/Quavonlimab|Administered via IV infusion at a specified dose on specified days
224173689|NCT04305054|DRUG|Lenvatinib|Administered via oral capsule at a specified dose on specified days
224173690|NCT04305054|BIOLOGICAL|Favezelimab/Pembrolizumab|Administered via IV infusion at a specified dose on specified days
224173691|NCT04305054|DRUG|ATRA|Administered via oral capsule at a specified dose on specified days
224173692|NCT06843577|DEVICE|Zona Plus Device|Use of the Zona Plus device involves performing isometric handgrip exercise therapy. Isometric exercise is the type of exercise in which you tense or tighten your muscle without seeing it change in length.
224173693|NCT06843577|OTHER|Relaxing Music App|Relaxing music will be made available through a mobile app that users access via their smart phone or tablet. Subjects will have the option to listen to 5 different music genres that support relaxation (Classical, Nature, Movie Soundtracks, Jazz, Reggae).
224173694|NCT00502398|PROCEDURE|Blood test|
224173695|NCT04581109|BIOLOGICAL|Blood sample|Twenty ml of blood will be drawn from each patient : 10 ml of blood will be drawn on CellSave tubes (fixed cells) for CTC detection using the FDA-cleared CellSearch system (gold standard) and 10 ml of blood will be drawn on EDTA tubes (viable cells) for the detection of functional CTCs using the EPIDROP.
224173696|NCT04929288|DRUG|Alcohol|Participants will complete three experimental sessions. In each session, participants will provide detailed reports of their alcohol consumption over the past five days, and they will provide a blood sample for hormone assays. They will perform tasks during fMRI to assess each of the neurofunctional addiction domains: inhibitory control, negative emotionality, and cue reactivity. Following the fMRI scan, subjects will self-administer intravenous alcohol to provide a controlled assessment of pharmacologically-driven alcohol consumption.
224173697|NCT05690906|DEVICE|ReSpace™|The experimental group subjects will be injected with ReSpace™ hydrogel.
224173698|NCT05690906|DEVICE|gauze packing|The subjects of both groups will be given gauze packing
224173699|NCT06929403|BEHAVIORAL|Diet|Low-fat, low-cholesterol heart-protective diet
224173700|NCT06929403|DIETARY_SUPPLEMENT|Diet supplementation|2 tablets/daily bergamot and plant sterol/stanol supplement (375 mg bergamot fruit extract, 800 mg plant sterols and 150 mg flavonoids) for 12 weeks
224173701|NCT05118789|DRUG|Zidesamtinib (NVL-520)|Oral tablet of zidesamtinib (NVL-520)
224173702|NCT07095855|DRUG|ZM-H1505R 100mg|ZM-H1505R(100mg,QD) will be used in Part A double-blind treatment period for 48 weeks and Part B open-label extension period 144 weeks.
224173703|NCT07095855|OTHER|ZM-H1505R Placebo|ZM-H1505R Placebo(100mg,QD) will be used in Part A double-blind treatment period for 48 weeks.
224306133|NCT01020136|DRUG|AG-013736|single oral dose 5-mg tablet (Form IV for Treatment A and Form XLI for Treatment B under fed conditions)
224173704|NCT07095855|COMBINATION_PRODUCT|"NAs （EntecavirorTenofovirorTenofovir alafenamideorTMF） treatments"|"All eligible subjects will be use NAs （EntecavirorTenofovirorTenofovir alafenamideorTMF） treatments during the study for 148 weeks, including Part A and Part B.~Subjects will continue to use the NAs as combination therapy before enrollment, the dosage will not be adjusted during the study. Subjects use in accordance with medical advice andinstructions."
224173705|NCT07099209|BEHAVIORAL|Delta-Wave Hypnoanalgesia|Binaural beat audio tracks at delta frequencies (1-4 Hz) to induce deep relaxation and reduce perioperative anxiety.
224173706|NCT01365169|BEHAVIORAL|Exercise Intervention|Participate in walking and/or strengthening program
224173707|NCT01365169|OTHER|Health Telemonitoring|Use accelerometers, blood pressure monitor, heart rate monitor, GPS device, and smart phone
224173708|NCT01365169|OTHER|Health Telemonitoring|Use accelerometers, blood pressure monitor, weight scale, and smart phone
224173709|NCT01365169|OTHER|Health Telemonitoring|Use smart phone
224173710|NCT01365169|OTHER|Health Telemonitoring|Use CO monitor and smart phone
224173711|NCT01365169|OTHER|Health Telemonitoring|Use Fitbit, weight scale and iPhone- or web-based app for self-reported data
224173712|NCT01365169|OTHER|Quality-of-Life Assessment|Ancillary studies
223617590|NCT04967976|PROCEDURE|sub-pectoral expander-implant breast reconstruction|The tissue expander is inserted without TiLoop Bra mesh in the first stage of reconstruction immediately after nipple/skin-sparing mastectomy. The tissue expander is placed sub-pectoral and covered by muscle/fascia.
224173713|NCT01365169|OTHER|Questionnaire Administration|Ancillary studies
224173714|NCT01365169|OTHER|Health Telemonitoring|Use Fitbit and Actigraph
224173715|NCT07095751|DEVICE|AI Uro-Cam|As stated in AI Uro-Cam arm description
224173716|NCT07096401|DEVICE|Reverse Curve of Spee Archwire|Orthodontic treatment using a 0.016 × 0.022 NiTi reverse curve of Spee archwire to correct deep bite through posterior extrusion and anterior intrusion.
224173717|NCT07096401|DEVICE|Anterior Bite Turbos|Orthodontic treatment using anterior bite turbos bonded to the palatal surfaces of the upper central incisors to promote posterior extrusion and correct deep bite.
224173718|NCT07096401|DEVICE|Clear Aligners|Orthodontic treatment using clear aligner therapy designed for anterior intrusion and leveling of the curve of Spee to correct deep bite.
224173719|NCT07096739|DIETARY_SUPPLEMENT|High protein shake|Subjects in this study will consume the study product for 1 week. Participants will record GI symptoms over the past 24h on 3 days during the week prior to the intervention, and on days 3, 5, and 7 during the intervention. On the first day, overnight fasted participants will be given the product and symptoms will be followed for 2h. 24h dietary recalls will be collected at the beginning and end of the 7-day treatment period.
224173720|NCT07101380|DEVICE|Tablet-based Physical SuperBrain BOOM|"This intervention is a tablet-based physical activity program designed for patients with Mild Cognitive Impairment (MCI).~Participants receive a personalized exercise plan through a tablet application, with real-time feedback to enhance cognitive function.~Compared to the smartphone-based version, this program is designed to provide a larger interface and structured environment, allowing participants to engage in the program using a tablet at home or in a clinical setting.~The app also helps track progress and encourage adherence to the exercise regimen."
224173721|NCT07101380|DEVICE|Smartphone-based SuperBrain BOOM|This intervention is a smartphone-based physical activity program designed for MCI patients. Participants receive a personalized exercise plan through a smartphone app, with real-time feedback to enhance cognitive function. Unlike the tablet-based intervention, this program is designed to be more portable and flexible, enabling participants to engage in the program from anywhere using their smartphones. The app also helps track progress and encourage adherence to the exercise regimen.
224173722|NCT07102225|DRUG|prolotherapy solution of 20% dextrose|This intervention is open label. Both participants and investigator will know about the intervention. Participants are allocated according to simple randomization by lottery. Two groups with each contain 28 participants. One group will be given a mixture of intra-articular injection of 5.6 ml 25% dextrose and 1.4 ml 2% lignocaine to achieve a final concentration 20% dextrose with 0.4% lignocaine in the involved knee joint. Another group will be given 1.4 ml 2% lignocaine followed by 2 ml high molecular weight hyaluronic acid intra-articularly in the involved joint.
224173723|NCT07102225|DRUG|Hyaluronic Acid (HA)|This intervention is open label. Both participants and investigator will know about the intervention. Participants are allocated according to simple randomization by lottery. Two groups with each contain 28 participants. One group will be given a mixture of intra-articular injection of 5.6 ml 25% dextrose and 1.4 ml 2% lignocaine to achieve a final concentration 20% dextrose with 0.4% lignocaine in the involved knee joint. Another group will be given 1.4 ml 2% lignocaine followed by 2 ml high molecular weight hyaluronic acid intra-articularly in the involved joint.
224306134|NCT02621918|OTHER|Progressive resistance training|
224306135|NCT02621918|OTHER|Aerobic training|
224306136|NCT02621918|OTHER|Placebo training|
224306137|NCT03469336|DRUG|PF-06763809|Three different concentrations will be administered to three different treatment fields: 2.3%, 0.8% and 0.23%
224306138|NCT03469336|OTHER|Vehicle|Vehicle matching PF-06763809.
224306139|NCT03469336|DRUG|Calcipotriene/calcipotriol|Calcipotriene/calcipotriol 50 ug/mL solution
223617591|NCT03306667|DRUG|FYU-981|Oral single dosing
223617592|NCT04633668|BEHAVIORAL|CBT for parasomnias (CBT-p)|Psychoeducation, sleep hygiene, imagery re-scripting, scheduled awakenings, safety planning, cognitive therapy, and stress management for 6 weeks
223617593|NCT04633668|BEHAVIORAL|Self-Monitoring|Monitoring of sleep quality through sleep diary, actigraphy, nightmare experiences for 6 weeks
223617594|NCT06237582|PROCEDURE|epigastric lymph node biopsy|epigastric lymph node biopsy and analysis to evaluate rate dissemination of ovarian carcinomatosis by this way
223617595|NCT02574403|DRUG|eculizumab|eculizumab discontinuation
224306140|NCT03469336|DRUG|Betamethasone|Betamethasone 1 mg/g solution
223617596|NCT04277559|OTHER|Patient preferential music|Patients will listen to their preferred music through the headphones before surgery.
223617597|NCT04277559|OTHER|Classical music|Patients will listen to classical music through headphones before surgery.
223617598|NCT04277559|OTHER|No music|Patients will not listen to music.
223617599|NCT00455299|PROCEDURE|Laparoscopic ventral hernia repair|
224173724|NCT07101016|DRUG|Diclofenac Sodium Gel|I1: Diclofenac sodium : 1 mL of gel, of 1 mL of 3 mL/75 mg Diclofenac sodium and 1% Carbopol 940 gel base, will be passively placed in the osseous cavity I2: Hyaluronidase : 1 mL of gel, of 1 ampoule (1500 IU) Hyalase powder in 2.5 mL of 0.9% sodium chloride, and 1% Carbopol 940 gel base, will be passively placed in the osseous cavity I3: Diclofenac sodium and Hyaluronidase: 1 mL of gel, of 1 ampoule (1500 IU) Hyalase powder and 1 ampoule (3 mL/75 mg) of Diclofenac sodium, Carbopol 940 gel base, will be passively placed in the osseous cavity
224173725|NCT07101341|PROCEDURE|Traditional aerobic training|5 minutes of warm-up at increasing intensity up to 60% of maximum heart rate (HRmax) + 20 minutes between 60-80% of HRmax + 5 minutes of cool-down at decreasing intensity (30-60% HRmax)
224173726|NCT07101341|PROCEDURE|High Intensity Interval Training (HIIT)|5 minutes warm-up at increasing intensity up to 60% maximum heart rate (HRmax) + 20 minutes main part consisting of 10 repetitions of the combination of 1 minute at 75-90% HRmax and 2 minutes of active rest with light pedaling (50% HRmax) + 5 minutes cool-down at decreasing intensity (30-60% HRmax)
224173727|NCT07101341|PROCEDURE|Aerobic training performed with a immersive virtual reality application|5 minutes of warm-up at increasing intensity up to 60% Maximum heart rate (HRmax) + 20 minutes between 60-80% of HRmax + 5 minutes of cooling at decreasing intensity (30-60% HRmax), with the use of virtual reality glasses and an immersive virtual reality application
224173728|NCT07101341|PROCEDURE|High Intensity Interval Training (HIIT) performed with a immersive virtual reality application|5 minutes warm-up at increasing intensity up to 60% Maximum heart rate (HRmax) + 20 minutes main part consisting of 10 repetitions of the combination of 1 minute at 75-90% HRmax and 2 minutes of active rest with light pedaling (50% HRmax) + 5 minutes cool-down at decreasing intensity (30-60% HRmax), with the use of virtual reality glasses for an immersive virtual reality application
224173729|NCT07100470|DIAGNOSTIC_TEST|Sodium MRI|Sodium MRI is used to detect early metabolic alterations in neurodegenerative diseases
224173730|NCT04331314|DEVICE|Use of Symbios Bone Graft Material|Patients will receive Symbios Bone Graft Material according to randomization Group.
224173731|NCT04331314|DEVICE|Algipore Bone Substitution Material|Patients will receive Algipore Bone Substitution Material according to randomization Group.
224173732|NCT00125736|DRUG|E0671|One 50 mg capsule is orally administered three times daily (150 mg/day)
224173733|NCT00125736|DRUG|rabeprazole sodium|One 10mg tablet is administered orally each day
224173734|NCT00125736|DRUG|E0671 placebo|One 50 mg capsule is orally administered three times daily (150 mg/day)
224173735|NCT00703729|DEVICE|Cold Compression (CC)|The device is applied to the shoulder within 60 minutes of arrival to the recovery room following surgery. The device will be applied at one hour intervals (60 minutes on the shoulder, 60 minutes off) during waking hours for the first 72 hours after surgery. For the remainder of the study period, therapy will be applied for one hour treatments 2-3 times a day during waking hours.
224173736|NCT00703729|OTHER|Ice Wrap (IW)|The ice bag is applied to the shoulder within 60 minutes of arrival to the recovery room following surgery. The ice bag is placed on the shoulder and the elastic wrap is used to hold the bag in place. The ice will be applied at one hour intervals (60 minutes on the shoulder, 60 minutes off) during waking hours for the first 72 hours after surgery. For the remainder of the study period, therapy will be applied for one hour treatments 2-3 times a day during waking hours.
224173737|NCT03142984|OTHER|Cosmetic Products|"Phase 1:~Baby Wash \& Shampoo (F# 13217-070) Baby Lotion (F# 13217-071)~Phase 2:~Baby Wash \& Shampoo (F# 13217-070) Baby Lotion (F# 13217-071)"
224306141|NCT03320200|OTHER|CNS-focused treatment|The CNS-focused treatment will last for 10 weeks, conducted in 60-minute sessions on a weekly basis. In addition, participants in this group will complete a home treatment program for 30 minutes, five times a week.
224306142|NCT03320200|OTHER|Standard Care Treatment|The standard physiotherapy group will receive a 10-session treatment program that will include one corticosteroid infiltration provided in the early acute stage followed by a multimodal physiotherapy program including analgesic modalities (e.g. TENS, cryotherapy) and exercise and manual therapy techniques addressing the specific mobility deficits of each patient. This program also include a home treatment based on conventional physiotherapy that involves a training load comparable to that in the CNS-focused group.
224306143|NCT02889471|PROCEDURE|ERCP with NB|ERCP with NB catheter for introperative tans-nasobiliary cholangiography
224306144|NCT02889471|PROCEDURE|ERCP alone|ERCP alone followed with standard laparoscopic cholecystectomy
223586244|NCT02117349|DEVICE|Gelfoam|Gelfoam Sterile Sponge is a medical device (USP, Pfizer) intended for application to bleeding surfaces as a hemostatic. It is a water-insoluble, off-white, nonelastic, porous, pliable product. It may be cut without fraying, used wet or dry, and is able to absorb many times its weight in blood and other fluids.
223586245|NCT02117349|DRUG|Rescue treatment|Thrombin-containing hemostats included in standard care at the site
223586246|NCT00495755|DRUG|Alemtuzumab (Campath)|An escalating dose given over 4 weeks
223586247|NCT00640367|OTHER|Alteplase IA and/or mechanical thrombolysis|loca intra-arterial recombinant tissue plasminogen activator and/or mechanical thrombolysis
223586248|NCT00640367|DRUG|Alteplase IV|intravenous recombinant tissue plasminogen activator
223586249|NCT01560299|DRUG|Methimazole|Methimazole was stopped 24-48 before radio-iodine therapy
223586250|NCT01560299|DRUG|Methimazole|methimazole discontinued 49-72 hours before radioiodine treatment
223485103|NCT02744586|BEHAVIORAL|Strengthening Our Vows (SOV)|"Participants, led by a counselor, will discuss options to keep HIV from entering their relationship including both sex partners remaining monogamous, using condoms every time they have sex with outside partners, and being tested together with outside partners to ensure they are HIV negative (Together HIV Free Plan). Participants will discuss options in the event of an outside exposure to HIV including abstaining from having sex with their spouse or by using condoms every time they have sex with their spouse until they can be retested for HIV after 30 days (Protecting my Spouse Plan).~Participants will be screened for hypertension, diabetes, schistosomiasis, HIV, syphilis, and trichomonas vaginalis and the presence of sperm (women only). Health problems will be treated or referred. Couples will be administered questionnaires that record self-report of sexually transmitted infections, number of outside partners, and reports of sex without a condom with outside partners."
223586251|NCT01560299|DRUG|Methimazole|methimazole discontinued 73-168 hours before radio-iodine treatment
223586252|NCT02201836|OTHER|One time music therapy|
223485104|NCT02744586|BEHAVIORAL|Good Health Package Plus (GHPP)|Participants, led by a counselor, will discuss how to prevent, screen, and treat neglected tropical diseases (helminths and schistosomiasis), non-communicable diseases (hypertension and diabetes) and diarrheal diseases through basic hygiene and sanitation. The facilitator will demonstrate proper handwashing techniques and chlorination of water and discuss diet and lifestyle changes. Participants will be screened for hypertension, diabetes, schistosomiasis, HIV, syphilis, and trichomonas vaginalis and the presence of sperm (women only). Health problems will be treated or referred. Couples will also be administered questionnaires that record self-report of sexually transmitted infections, number of outside partners, and reports of sex without a condom with outside partners.
223485105|NCT02459626|OTHER|Diagnostic P-V-loops and MRI|Invasive assessment of P-V-loops during catheterization for suspected CAD Magnetic resonance Imaging for assessment of myocardial fibrosis and biventricular function
223485106|NCT01346098|PROCEDURE|Pancreaticoduodenectomy with pancreatic anastomosis|Standard lymphadenectomy, end-to-side two-layer pancreaticojejunostomy and duodenojejunostomy will be performed. If the pylorus is preserved, so will be the right gastric artery, unless the artery is damaged or hindering adequate gastric mobilization. No prokinetic agent will be administered routinely, but IV metoclopramide will given on demand (10 mg , three times daily). Prophylaxis will consist of octreotide (0,1 mg three times daily from day 0 to 7), low molecular weight heparin and a single dose of antibiotic (cefazolin 2 g). Early postoperative analgesia will be achieved by epidural or, when contraindicated, patient-controlled analgesia
223485107|NCT01346098|PROCEDURE|Total pancreatectomy with islet autotransplantation|If the patient will be assigned to this group, the surgeon will complete the pancreatectomy preserving the spleen. The body and tail of the pancreas will be sent to the islet isolation facility. Islets will be isolated and purified according to the automated method described by Ricordi. The resulting islet tissue will be suspended in a cold isotonic saline solution and infused into the portal vein during the next 24h.
223485108|NCT00207740|DRUG|CNTO148|Type=exact type, unit=mg, number=50, 75, 100, 150, 200 and 300, form=injection, route=subcutaneous. Every 4 weeks partciapnts will receive injections in 4 parallel treatment arms
223485109|NCT00207740|DRUG|Placebo|Type=exact type, unit=mg, form=injection, route=subcutaneous. Placebo will be given from from Week 0 through Week 52.
223485110|NCT04490460|DIETARY_SUPPLEMENT|WBF-0031|Medical food formulation WBF-0031
223485111|NCT02585440|DRUG|CMX157|Oral tablet
223485112|NCT02585440|DRUG|placebo|Oral tablet
223485113|NCT00624208|DRUG|droperidol and saline|droperidol 20 mcg.kg-1 and saline
223485114|NCT00624208|DRUG|ondansetron and saline|ondansetron 0.1 mg.kg-1 and saline
223485115|NCT00624208|DRUG|droperidol and ondansetron|droperidol 20 mcg.kg-1 and ondansetron 0.1 mg.kg-1
223485116|NCT00624208|DRUG|saline and saline|saline and saline
223485117|NCT05426473|OTHER|QuickDASH form|Patients have to complete these two forms, Quick DASH and SF-36, before surgery then 6 weeks after
223485118|NCT05372367|DRUG|BI 907828|BI 907828
223485119|NCT05372367|DRUG|Rifampicin|Rifampicin
223485120|NCT05372367|DRUG|Itraconazole|Itraconazole
223485121|NCT02591810|PROCEDURE|Serial casting/splinting|Serial Casting involves applying and removing a series of lightweight casts made of fiberglass. The wrist is monitored as healing occurs.
223485122|NCT02591810|PROCEDURE|Percutaneous fixation|Injury is treated by the percutaneous placement of Kirschner wires to promote healing. This is an invasive procedure, involving the placement of Kirschner wires to stabilize the wrist.
223485123|NCT02591810|PROCEDURE|Foveal repair|Injury is treated by open anatomic foveal repair of the ligaments. This is a surgical procedure.
223485124|NCT04815356|BIOLOGICAL|CD22CART cell infusion|The treatment regimen will consist of lymphodepleting chemotherapy followed by CD22CART infusion: Days -4 to -2: fludarabine 25 mg/m2/dose Day -2: cyclophosphamide 900 mg/m2/dose Day 0: CD22CART infusion (starting at dose level 1 \[DL1\]: 1 x 105 transduced CAR-T cells/kg) on Day 0 participants will be evaluated for response at Day 28 post-CD22CART infusion.
223485125|NCT05790135|DEVICE|shear wave elastography|Shear wave elastography and CEUS will be used to evaluate the reliability in diagnosing graft versus host disease of the gut after hematopoietic stem cell transplantation
223485126|NCT05542563|BEHAVIORAL|Healthy Minds Program (HMP) App|The full HMP app includes 5 modules with practices designed to cultivate categories of mental and emotional skills linked to both hedonic and eudaimonic well-being. These include the cultivation of mindful attention (Awareness), positive relationships with self and others (Connection), insight into the nature of self and internal experience (Insight), and purpose, values, and meaning in life (Purpose), as well as an initial module which includes abbreviated introductions to the topics and lessons in all four areas (Foundations). For this study, the active intervention will include 4 weeks of training using the Foundations module followed by 4 weeks of training using the Awareness module.
223485127|NCT05203172|DRUG|Binimetinib only treatment|Binimetinib will be administered at the same dose level (15 mg to 45 mg) as that received in the Parent Studies C4211001 and C4211003 with water irrespective of food, continuously, starting on Day 1.
223485128|NCT05203172|DRUG|Encorafenib only Treatment|Encorafenib will be self-administered at the same dose level as that received in the C4221010 Parent Study.
223485129|NCT05203172|DRUG|Encorafenib & Binimetinib Treatment|Encorafenib will be administered on a 300 mg QD schedule and binimetinib will be administered on a 45 mg BID schedule, both orally as a flat fixed dose. Cetuximab will be administered at either 400 mg/m2 or 500 mg/m2 IV every 2 weeks on Days 1 and 15 of every cycle.
223485130|NCT05203172|DRUG|Treatment of Encorafenib & Binimetinib & Ribociclib|Encorafenib capsule and ribociclib capsules or tablets will be co-administered orally QD with binimetinib tablets BID. The study drugs will be administered as a flat-fixed dose, and not by body weight or body surface area.
223485131|NCT05203172|DRUG|Treatment of Encorafenib & Binimetinib & Cetuximab|Encorafenib will be administered on a 300 mg QD schedule and binimetinib will be administered on a 45 mg BID schedule, both orally as a flat fixed dose. Cetuximab will be administered at either 400 mg/m2 or 500 mg/m2 IV every 2 weeks on Days 1 and 15 of every cycle.
223586253|NCT02201836|OTHER|Group music therapy|
223586254|NCT02265796|DRUG|Ranolazine|"Ranolazine 500mg tablet~1. 500mg tablet two times per day for 7 days then,~2. 500mg tablet (1000mg) two times per day for 15 weeks"
223586255|NCT02265796|DRUG|Sugar pill|"1. 500mg tablet two times per day for 7 days then,~2. 500mg tablet (1000mg) two times per day for 15 weeks"
223485132|NCT00390013|DRUG|Gabapentin|"300 mg. capsules~Dosage schedule for weeks 1 and 2 and weeks 12 and 13:~1. day 1 you will take 1 capsule for the day~2. day 2 you will take 1 capsule 2 times for that day~3. days 3-6 you will take 1 capsule 3 times for those days~4. days 7-9 you will take 1 capsule in am and 1 capsule at noon, 2 capsules at bedtime each day~5. days 10-12 you will take 1 capsule in am and 2 capsules at noon and 2 capsules at bedtime each day~6. days 13-14 you will take 2 capsules 3 times each day~7. continue on 2 capsules 3 times each day for 6 weeks after maximum dose of 1800 mg is reached after weeks 2 and 13.~8. at completion of study treatment you will titrate off study drug over a weeks time."
224173738|NCT03843567|OTHER|Endoscopic characterisation training|"Included in the training material is an overview of Resect and Discard, endoscopic platforms (NBI, BLI and i-Scan), NICE classification, SIMPLE classification, BASIC classification and example still images and videos of both classifications in use. Still images will be used to ensure participants have the best opportunity to observe and learn Kudo Pit Patterns and other polyp features without movement artefact before observing videos, which are more challenging to interpret. The training will last approximately 1 hour."
224173739|NCT03435289|DRUG|CPI 613 in Combination With Gemcitabine and Nab-paclitaxel|"Day 1,15 CPI-613: IV infusion at a rate of 4 mL/min via a central venous catheter starting at 500 mg/m2 (with concurrent D5W infusing at a rate of 125-150 cc/hr). The CPI dose will be determined based on cohort. Day 2,16 Neulasta as clinically indicated~Nab- paclitaxel 125mg/m2 iv over 30 min followed by Gemcitabine 1000mg/m2 iv over 30 min"
224173740|NCT04862351|BEHAVIORAL|exercise training for TechCR|3 times of supervised exercise training at the centre-based, outpatient cardiac rehabilitation clinic
224173741|NCT04862351|BEHAVIORAL|audio/video conference|weekly audio/video conference
224173742|NCT04862351|BEHAVIORAL|educational video|weekly for 6 weeks, duration of video about 10-15 minutes
224173743|NCT04862351|BEHAVIORAL|Daily log|daily dietary and exercise log
224173744|NCT04862351|BEHAVIORAL|exercise training for centre-based|6 times of supervised exercise training
224173745|NCT05830656|BEHAVIORAL|Exposure to nearby nature|Participants spend a minimum of 20 minutes in their favourite place in nearby nature.
224173746|NCT05830656|BEHAVIORAL|Exposure to virtual nature|Participants spend a minimum of 20 minutes watching virtual nature videos.
224173747|NCT05079724|PROCEDURE|Cardiac Surgery|About 3.5-31.0% of Patients undergoing cardiac surgery Complains from Postoperative Acute renal injury (AKI) that is a severe complication increasing the risk factor for mortality about 8-folds, The occurrence of AKI in patients undergoing cardiac surgery raises the mortality rate from 0.4-4.4% to 1.3-22.3%; when those same patients require dialysis.
224173748|NCT03519815|DEVICE|Ectoin® Eye Spray - Colloidal|eye spray to be applied to the closed eye lid
224173749|NCT03519815|DEVICE|Liposomal eye spray Tears Again®|eye spray to be applied to the closed eye lid
224173750|NCT00935766|DRUG|Omega-3|Subjects meeting eligibility criteria will be randomized to receive a supply of omega-3-acid ethyl esters or placebo, and instructed to take 4 capsules daily. A 3-month supply of study drug will be given following randomization and at 3, 6, and 9 months. Subjects will be asked to bring unused supplies to each quarterly visit for ascertainment of adherence.
224173751|NCT00935766|DRUG|Placebo|
224173752|NCT03764904|RADIATION|Airway Ultrasound|Laryngeal US will be performed with a 12 megahertz (MHz) linear probe attached to the ultrasound device. With the probe placed transversely on the midline of the anterior neck over the cricothyroid membrane.
224173753|NCT03420989|OTHER|Active snack food|snack enriched with seaweeds and carob
224173754|NCT03420989|OTHER|Control snack food|the same snack food without seaweeds and carob
224173755|NCT03223129|OTHER|Oral glucose tolerance test|Oral glucose tolerance tests were glucose is administrated orally with an increasing load (25g, 75g, 100 g)
224173756|NCT03223129|OTHER|Graded intravenous glucose infusion|Graded intravenous glucose infusion where glucose is infused in order to receive an plasma glucose pattern comparable to those received during the oral glucose tolerance tests.
224173757|NCT03091569|OTHER|Vitamin K Cream|To be applied topically 3 times in 24 hours (approximately at 8 and 16 hours post initial application) from the appearance of the erythema.
224173758|NCT03091569|OTHER|Placebo Cream|To be applied topically 3 times in 24 hours (approximately at 8 and 16 hours post initial application) from the appearance of the erythema.
224173759|NCT00768040|DRUG|Aliskiren|300 mg once daily
223485133|NCT00390013|DRUG|Placebo oral capsule|"Placebo capsules~Dosage schedule for weeks 1 and 2 and weeks 12 and 13:~1. day 1 you will take 1 capsule for the day~2. day 2 you will take 1 capsule 2 times for that day~3. days 3-6 you will take 1 capsule 3 times for those days~4. days 7-9 you will take 1 capsule in am and 1 capsule at noon, 2 capsules at bedtime each day~5. days 10-12 you will take 1 capsule in am and 2 capsules at noon and 2 capsules at bedtime each day~6. days 13-14 you will take 2 capsules 3 times each day~7. continue on 2 capsules 3 times each day for 6 weeks after maximum dose of 1800 mg is reached after weeks 2 and 13.~8. at completion of study treatment you will titrate off study drug over a weeks time."
223485134|NCT02287077|PROCEDURE|Umbilical Cord Milking|At birth, neonate will be held below the level of placenta and umbilical cord will be milked 3 times before clamping the cord.
224173760|NCT00768040|DRUG|Placebo|Matching placebo once daily
224173761|NCT00000529|DRUG|tamoxifen|
223485135|NCT05653843|DEVICE|Endoscopic clip placement in the gastrointestinal tract.|The placement of a mechanical endoscopic clip in the gastrointestinal tract.
223485136|NCT00722020|DEVICE|VEST|15 minutes of HFCWO via the Vest 2-3 times daily
223586256|NCT03382067|DIETARY_SUPPLEMENT|High Epicatechin/ Melissa|Single consumption of a 55g bar of dark chocolate containing: 42.8g Acticoa chocolate + 7.2g caster sugar + 5g Melissa
223586257|NCT03382067|OTHER|Low Epicatechin/ Oat bran|Single consumption of a 55g bar of white chocolate containing: 50g Lindor chocolate + 5g oat bran
223586258|NCT04155606|DEVICE|microsurgery; endovascular interventions|microsurgery: surgical resection of the aneurysm endovascular interventions: coiling, stenting or both
223586259|NCT04584593|BIOLOGICAL|Sample|Men will give semen, saliva, nasopharyngeal, urine and blood specimens
223586260|NCT00551603|DRUG|switch (epoetinum beta, darbepoetinum)|switching from epoetinum beta once weekly to once-fortnightly darbepoetinum
223586261|NCT00551603|DRUG|continuation (darbepoetinum)|continuation of the previous darbepoetinum administration schedule
223586262|NCT04999527|DRUG|DISC-0974|DISC-0974 is administered (IV infusion or Subcutaneous Injection) as a single dose
224173762|NCT04500626|DRUG|Oxygen|Hyperbaric oxygen therapy delivered in a monoplace or multi-place chamber. Supervised by a hyperbaric oxygen therapy physician and a chamber operator.
224173763|NCT03470506|OTHER|Stool Samples|Stool samples will be collected at baseline and 3 months to assess differences in microbiome composition between groups
224173764|NCT02012257|PROCEDURE|AMSA nerve block injectio|Sites of injection
224173765|NCT05427864|DIAGNOSTIC_TEST|Multiparametric Prostate MRI|Comparison of Ga68 PSMA PET and Multiparametric Prostate MR imaging tests used in staging in patients diagnosed with prostate cancer
224173766|NCT02543606|DRUG|Esomelone|powder for injection/ infusion Esomeprazole 40mg
224173767|NCT02543606|DRUG|Nexium|powder for injection/ infusion Esomeprazole 40mg
223485139|NCT01883167|DRUG|RDEA3170 10 mg|RDEA3170 10 mg once daily (qd)
224173768|NCT06425406|DEVICE|high-flow nasal cannula|In group H, mask ventilation was performed after the patient lost spontaneous breathing until the end-expiratory oxygen concentration reached 90 %. The lower mask was taken and HFNC was used to record the patient 's safe apnea time.
224173769|NCT04337112|DRUG|viltolarsen|Intravenous (IV) infusions, weekly, at 80mg/kg, once weekly (approximately every 7 days).
224173770|NCT00289302|DEVICE|Cardiac resynchronization therapy device|
224173771|NCT02346955|BIOLOGICAL|CM-24 (MK-6018)|humanized IgG4 (kappa) isotype monoclonal antibody against CEACAM1 by intravenous (IV) infusion
224173772|NCT02346955|BIOLOGICAL|Pembrolizumab (MK-3475)|200 mg of Pembrolizumab by IV infusion
224173773|NCT03557801|BEHAVIORAL|Mammography with Community Health Worker (individual)|Immediately following consent and completion of the baseline assessment, alone with the community health worker. Well woman screening will follow the educational session. The community health worker will be available to assist with questions and language interpretation as necessary. After standard delivery of screening results, the community health worker will contact these participants to answer any questions about their screening results and to assist with scheduling any additional tests necessary.
224173774|NCT03557801|BEHAVIORAL|Mammography with Community Health Worker (group)|Immediately following consent and completion of the baseline assessment, women in the intervention arm will participate in a 20-30 minute group educational session from the community health worker. Well woman screening will follow the educational session. The community health worker will be available to assist with questions and language interpretation as necessary. After standard delivery of screening results, the community health worker will contact these participants to answer any questions about their screening results and to assist with scheduling any additional tests necessary.
224173775|NCT03557801|OTHER|Standard of Care Mammography|Immediately following consent and completion of the baseline assessment, women in the control arm will receive standard of care well woman screening. The control arm will receive screening results per standard protocol.
224306145|NCT04948060|OTHER|Enhanced lung cancer screening services|A theoretically sound and evidence-based, multi-component implementation strategy will be applied which includes care quality benchmarking and regular performance feedback, academic detailing provided by specially trained primary care clinicians, practice facilitation provided by trained and certified Practice Facilitators (PFs), health information technology (HIT) support, and facilitated professional networking to promote the cross-pollination and rapid dissemination of solutions and best practices in primary care settings
224306146|NCT00054574|BIOLOGICAL|panitumumab|
223485140|NCT01883167|DRUG|Febuxostat 40 mg|Febuxostat 40 mg qd
223485141|NCT01883167|DRUG|placebo|placebo qd
223485142|NCT01260129|DRUG|Silodosin|Silodosin 8 mg orally, once daily after morning meal
223586263|NCT04999527|DRUG|Placebo|Placebo is administered (IV infusion or Subcutaneous Injection) as a single dose
223586264|NCT06246812|BEHAVIORAL|Deans' Fit Family Challenge|An annual 8-week physical activity and weight loss competition between VCOM-Auburn, AU College of Nursing, and AU Harrison School of Pharmacy
223586265|NCT06246812|BEHAVIORAL|Text message|Three text messages per week to promote and motive physical activity
224306147|NCT05396378|DIETARY_SUPPLEMENT|Oral glucose in liquid form|A glucose containing drink that has a fixed dose of 25 g of glucose per can.
223485143|NCT01260129|DRUG|Silodosin|Silodosin 4 mg orally, twice daily after morning and evening meal
223485144|NCT05318664|OTHER|Cryotherapy|20 minutes of cryotherapy on the dominant shoulder with ice bags
223485145|NCT03509558|DEVICE|Transcutaneous spinal stimulation|Non-invasive electrical stimulation of spinal cord over the skin combined with physical therapy to improve walking and standing functions
223485146|NCT03509558|OTHER|Physical Therapy|physical therapy to improve walking and standing functions
223485147|NCT05760599|DRUG|Candonilimab|10mg/kg, iv.drip, every 3 week
223485148|NCT05760599|DRUG|Bevacizumab|15mg/kg, iv.drip, every 3 week
223485149|NCT02232867|BEHAVIORAL|Arm and Leg Cycling Exercise Program|Participants will perform arm and leg cycling training three times a week, with 30 minutes of aggregate exercise time per session. To evaluate the physiological cost of exercise, heart rate and a rating of perceived exertion will be collected. The progressive element of this training will include increasing the resistance of the ergometer over the six weeks in order to maintain the same relative exercise stress.
223586266|NCT02916251|DRUG|ZP4207(dasiglucagon) glucagon analogue|Cross-over design with single s.c. administration in euglycemic and hypoglycemic T1D
223586267|NCT02916251|DRUG|Glucagon (Native glucagon)|Cross-over design with single s.c. administration in euglycemic T1D
223586268|NCT00169507|BIOLOGICAL|Pneumococcal (vaccine)|
224173776|NCT04652466|DEVICE|farukcicekci2|To compare the incidence of for I-Gel malposition between USG and FOB, and to find the correlation between I-Gel's USG and FOB-detected malposition
224173777|NCT05972668|DEVICE|Smartphone Apps|The intervention group downloaded the asthma smartphone app, and followed up monthly via phone calls and clinic visits
224173778|NCT04631757|DRUG|Camrelizumab + SOX + Radiotherapy|Camrelizumab 200mg,d1,Q3w; oxaliplatin 130mg/m2, d1, Q3w; S-1 40-60mg bid, d1-d14,Q3w; intensity modulated radiotherapy 45Gy/25d
223485150|NCT05558371|OTHER|No intervention.|No intervention administered as part of this study; observational only.
223485151|NCT05745168|DIAGNOSTIC_TEST|OraQuick|The intervention is based on respondent-driven sampling approach. Each selected seed from hotspots and on social networks is provided with two types of coupons for HIVST kit at partner pharmacy: electronic coupons (e-coupons) consisting of a pictured unique anonymous QR code and identifier and the address of pharmacies; paper coupons consisting of similar information to e-coupon. The seeds will then distribute coupons to their networks physically, via social media, and smart phone applications. Each recruited participant will bring the coupon to be scanned at the pharmacies to receive a free access HIVST kit. There, trained community worker will do the study visit including information/consent, e-CRF filling and providing link to send the test results. These recruited individuals will be considered as wave 1 and will each receive 10 additional coupons to recruit new members in the networks. The next round of individuals recruited and enrolled will be considered as wave 2, and so on.
223485152|NCT01211249|DRUG|GLPG0259 oral capsule|Two capsules, each containing 25 mg of GLPG0259 (i.e. 50 mg/day), to be given once daily; in case of adverse events the dose may be split over two administrations, or reduced to 25 mg/day (one single capsule)
223485153|NCT01211249|DRUG|Placebo|Placebo capsules; two capsules to be taken in the morning, in case of adverse events the dose may be split over two administrations, or reduced to one single capsule
223485154|NCT01211249|DRUG|GLPG0259 (Part B)|Capsule, dosage to be established based on results of Part A
223586269|NCT01699568|DEVICE|RFA|Each week since the surgery the implant stability will be measure with the Osstell mentor to verify the resonance frequence analysis, using the smartpeg number 21
223586270|NCT00320463|BIOLOGICAL|DTPa-HBV-IPV/Hib vaccine|
223586271|NCT04868149|PROCEDURE|Associating liver partition and portal vein ligation for staged hepatectomy (ALPPS)|Associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) is a surgical procedure that induces rapid liver regeneration in patients with small liver remnant planning for major liver resection. It is a two-staged operation with stage I including portal vein ligation and splitting the right liver away from the left liver. After stage I, the left liver will undergo rapid liver regeneration and the stage II operation can be performed at 7-10 days after stage I operation when the liver remnant reaches an adequate size. In stage II operation, the right liver that contains the tumor is then removed.
224173779|NCT03665129|BIOLOGICAL|IPH5401 and Durvalumab|IPH5401 and durvalumab
223586272|NCT06549439|RADIATION|Electron FLASH radiotherapy|A nominal electron energy of 9 MeV will be used for both Flash-RT and Conv-RT, which guarantees ≥ 90% dose coverage up to a depth of 2.8 cm. Shallower lesions will be treated with the same electron energy and with a bolus. In order to treat these patients, field sizes between 2x2cm2 and 10x10cm2 will be used, which can be delivered with sufficient flatness (\<5%) and symmetry (\<2%) by the FlashTrueBeam v2.7.5.
223586273|NCT00218699|BEHAVIORAL|Cognitive-Behavioral Intervention|
223586274|NCT05496556|OTHER|Test Leeds Food Preference Questionnaire (LFQP-France)|"The version of this questionnaire has been adapted to French eating habits. and based on the presentation of food photos, each representing one of the four categories below : salty-high in fat / salty-low fat / sugary-high fat / sweet-low fat The answers given to the LFQP predict a more or less caloric food intake. This tool makes it possible to objectify changes in eating behavior according to the nutritional status and protein status of patients.~The implied wanting score for salty-high-fat, salty-low-fat, sweet-high-fat, and sweet-low-fat foods is calculated based on the frequency and speed of choice for one food type out of 150 combinations.~For each of the food modalities, the software will return a score with its standard deviation. The modality preferred by the patient is the one with the highest score"
223586275|NCT01829022|PROCEDURE|E-NOTES|Embryonic-Natural Orifice Transumbilical Endoscopic Surgery for Myomectomy with Traction of Multidirectional Sutures
223586276|NCT04751188|DRUG|Bezafibrate 200 MG Oral Tablet|Bezafibrate one tablet every 12 hours for six months.
223586277|NCT04751188|DRUG|Placebo|Placebo one tablet every 12 hours for six months.
223586278|NCT04751188|DRUG|Ursodeoxycholic Acid|At a dose of 13 to 15 mg per Kg per day.
224173780|NCT00141297|DRUG|PD-0332991|Dose ranging study - evaluating two oral schedule: (1) 3/1 Schedule - PD-0332991 administered days 1-21 of a 28-day schedule, doses ranging from 25 to 150 mg once daily; (2) 2/1 Schedule - PD-0332991 administered days 1-14 of a 21-days schedule, doses ranging from 100 to 225 mg once daily
224173781|NCT00109239|DRUG|rhuMAb VEGF (Bevacizumab)|
223485155|NCT01211249|DRUG|Placebo (Part B)|Capsules, dosage to be established after Part A, and matching GLPG0259 (Part B)
224173782|NCT05510999|OTHER|Placebo|One capsule of placebo will be taken twice daily for 24 weeks.
224173783|NCT05510999|DIETARY_SUPPLEMENT|Water soluble pollen extract fraction|Each capsule contains 180 mg of water soluble pollen extract fraction. One capsule will be taken twice daily (360 mg/day) for 24 weeks.
224173784|NCT05510999|DIETARY_SUPPLEMENT|Lipid soluble pollen extract fraction + water soluble pollen extract fraction|Each capsule contains a combination of 9 mg of lipid soluble pollen extract fraction and 180 mg of water soluble pollen extract fraction. One capsule will be taken twice daily (18 mg/day and 360 mg/day, respectively) for 24 weeks.
224173785|NCT05510999|DIETARY_SUPPLEMENT|Lipid soluble pollen extract fraction|Each capsule contains 9 mg of lipid soluble pollen extract fraction. One capsule of will be taken twice daily (18 mg/day) for 24 weeks.
224173786|NCT05510999|DIETARY_SUPPLEMENT|Water soluble pollen extract fraction + cranberry powder|Each capsule contains a combination of 42 mg of water soluble pollen extract and 125 mg of cranberry powder. One capsule will be taken twice daily (84 mg/day and 250 mg/day, respectively) for 24 weeks.
224173787|NCT03433599|OTHER|Repeated exposure to acute Intermittent Hypoxia (rAIH)|Participants will be fitted with a mask that will be placed over mouth and nose. Tubing will be attached to the front of the mask. The session will last approximately 30-45 minutes with 60-90 seconds of lower oxygen (tubing attached, 9-10% oxygen level), alternating with 60-90 sec of normal room air (no tubing attached).
224173788|NCT03433599|OTHER|Normal Room Air|Participants will be fitted with a mask that will be placed over mouth and nose. Tubing will be attached to the front of the mask. The session will last approximately 30-45 minutes with 60-90 seconds of normal room air (with tubing attached to the mask) and 60-90 sec of normal room air (without the tubing attached to the mask).
224173789|NCT03433599|OTHER|Upper-limb Training by Research Staff|Training sessions will last for approximately 30 minutes, with additional time for set up. During these sessions, participants will be asked to complete a variety of tasks related to general arm/hand movement, gross grasping, fine grasping, and hand cycle using an arm ergometer. The number of repetitions will be monitored and adjust the difficulty to ensure appropriate task difficulty.
224173790|NCT03433599|OTHER|Lower-limb Training by Research Staff|Training sessions will last for approximately 30 minutes, with additional time for set up. During these sessions, participants will be asked to complete a variety of tasks related to general leg/foot movement, over-ground walking, treadmill walking, stair climbing training, leg cycling, standing frame, and NuStep. The number of repetitions will be monitored and adjust the difficulty to ensure appropriate task difficulty.
224173791|NCT01485003|BIOLOGICAL|natalizumab|Natalizumab will not be provided as a part of this study. Participants will receive natalizumab as prescribed by their treating physician.
224173792|NCT04954976|OTHER|Orthodontic retention procedures survey|The survey was composed of eight parts, about sociodemographic status, retention system selection, choice of fixed and removable retention system, retention period, supervision, given instruction and needs for practice guidelines.
223586279|NCT03938324|BEHAVIORAL|PiCASO Intervention Group|This mobile health intervention utilizes an established telephone/text based secure interface to allow AYAs access knowledge, experience, and instrumental/emotional support from a trained peer coach who has already developed independence an active self-manager. Peers with shared experiences provide instrumental (e.g., health maintenance skills) and emotional support that likely lead to improvements in quality of life. Involving peers in supporting AYAs with chronic conditions to promote self-management and patient activation disrupts the typical over-reliance on the parent and health care provider that often impedes developing independence.
223586280|NCT03938324|BEHAVIORAL|Sham Comparator: Attention Control Group|Over 12 months the attention control group participants will receive a monthly electronic newsletter with educational content about childhood onset chronic condition management and the differences between pediatric and adult health care systems, as well as a monthly phone call from study staff to ensure receipt of the newsletter and to answer questions regarding content, and an opportunity to link them to other resources. If participants report health concerns they will be directed to contact their health care team.
224173793|NCT01190280|PROCEDURE|Cholecystectomy operation|Cholecystectomy after randomization
224173794|NCT02200510|BEHAVIORAL|Self-management intervention for Adolescents with SCD|Chronic Disease Self-Management Program
224306148|NCT03825341|DRUG|Hydroxyurea|Drug: Hydroxyurea oral liquid dose administered will be 20mg/kg/day or infants's usual daily dose.
224173795|NCT02200510|BEHAVIORAL|Patient Portal Intervention for Adolescents with SCD|MyChart for SCD intervention
224173796|NCT00495508|DRUG|Quinine|
224173797|NCT00495508|DRUG|artemether / lumefantrine|
224173798|NCT04290767|DIAGNOSTIC_TEST|Sulphur hexafluoride microbubbles SONOVUE (BRACCO, Milan, Italy)|Enhanced-contrast brain ultrasound with intravenously sulphur hexafluoride microbubbles SONOVUE (BRACCO, Milan, Italy) injection and using the time-intensity curve profile to evaluate brain microcirculation.
224173799|NCT00381524|BEHAVIORAL|Increase condom use|Voluntary increase in condom use
224306149|NCT03825341|DRUG|Hydroxyurea Oral Capsule|Drug: Hydroxyurea both a sprinkle formulation and capsules (Droxia 200mg) administered on 2 separate occasions.
223485156|NCT03129646|DRUG|Miltefosine|Miltefosine 10mg and 50mg capsules
223485157|NCT03129646|DRUG|Paromomycin|Paromomycin sulfate equiv to 750mg paromomycin / 2ml amp
223485158|NCT03129646|DRUG|Sodium stibogluconate|Sodium stibogluconate 33% 30 ml inj.
223586281|NCT03401385|DRUG|Datopotamab Deruxtecan (Dato-DXd)|A total anti-TROP2 antibody and MAAA-1181a
223586282|NCT03401385|DRUG|Steroid Containing Mouthwash|A mouthwash containing a steroid ingredient administered in sub-study
224306150|NCT04248218|BEHAVIORAL|Active Rehabilitation Group/Case|If the patient is in the active rehabilitation group, the patient will receive instructions based on the latest CDC concussion management guidelines that specify a symptom-limited progressive return to full activities. This group will be instructed to take at least 10,000 steps a day for five days on their pedometers. In addition, they will also watch a two-minute video by the PI and research team reinforcing the active rehabilitation instructions.
223485159|NCT02540304|BEHAVIORAL|Reducing the Risk|Safer Sex is a clinic-based intervention intended to reduce the incidence of STIs and increase condom use among high-risk sexually active female adolescents and delivered in face-to-face individualized sessions by a female health educator. Reducing the Risk is a sexuality-education curriculum, most often delivered in a school setting that provides instruction and practice in the social skills needed to put into action what students learn about preventing pregnancy and reducing unsafe behavior in future high-risk situations. ¡Cuidate! is adapted from the Be Proud! Be Responsible! curriculum and culturally tailored for Latino youth. It aims to reduce HIV risk and unintended pregnancies by affecting sexual behaviors such as intercourse, number of partners, and condom use.
223485160|NCT00668928|OTHER|Polyphenols (flavon-3-ol monomers and oligomers)|Flavanols
223485161|NCT01998360|PROCEDURE|Surgical Control|The study is quasi-experimental, because the open surgical controls are not contemporaneous. They were performed at the same center as part of Unicirc 001 trial with the same conditions as the subsequent 50 Unicirc circumcisions.
223485162|NCT01998360|PROCEDURE|Unicirc with tissue adhesive|Excision of foreskin with Unicirc device and wound sealing with tissue adhesive
223485163|NCT01307072|PROCEDURE|Vitrectomy|Vitrectomy. Diabetic retinopathy
224306151|NCT04146116|DRUG|intranasal povidone-iodine|povidone-iodine USP, 10% w/w antiseptic
224306152|NCT00289536|BIOLOGICAL|Antihemophilic factor, recombinant, manufactured protein-free|15 IU/kg rAHF-PFM
224306153|NCT00289536|BIOLOGICAL|Antihemophilic factor, recombinant, manufactured protein-free|30 IU/kg rAHF-PFM
224306154|NCT00289536|BIOLOGICAL|Antihemophilic factor, recombinant, manufactured protein-free|50 IU/kg rAHF-PFM
224306155|NCT04645264|DEVICE|Foley Catheter|The patient is catheterized during surgery.
224173800|NCT06246162|DRUG|Lipo-MIT combination regimen|"Initial diagnosis induction treatment regimen Lipo-MIT +VD (VMD):~Mitoxantrone Hydrochloride Liposome: 10 mg, d1, d15, intravenous infusion; Bortezomib: 1.3mg/m2 d1, 4, 8, 11, subcutaneous injection; Dexamethasone: 20 mg/d, orally on days 1, 2, 4, 5, 8, 9, 11, and 12. Every 4 weeks constitutes a cycle, and 4 cycles of VMD regimen induction therapy are performed.~Reinduction therapy regimen after relapse Lipo-MIT + PD (PMD):~Mitoxantrone Hydrochloride Liposome: 10 mg, d1, d15, intravenous infusion; Pomalidomide: 4 mg/d d1-d21, orally; Dexamethasone: 20 mg/d, orally on days 1, 2, 4, 5, 8, 9, 11, and 12. Every 4 weeks constitutes a cycle, and 4 cycles of PMD regimen induction therapy are performed."
224173801|NCT03165799|BEHAVIORAL|Mindfulness Education|Mindfulness Education
224173802|NCT05417581|PROCEDURE|adipose surgery|A quantity of adipose tissue equivalent to 10-20 cubic centimeter will be removed subcutaneously and from the omentum during surgical procedures (oncological, bariatric)
224173803|NCT00033514|BIOLOGICAL|trastuzumab|Day 1 4mg/kg IV 2 mg/kg IV weekly.
224173804|NCT00033514|DRUG|erlotinib hydrochloride|100 mg daily on Course 1 Day 2. After three weeks patients who have not experienced specific adverse events, dose will be escalated to 150 mg daily. Patients who have experienced specific adverse events dose will remain 100 mg daily or dose reduced as necessary per protocol.
224173805|NCT02666118|PROCEDURE|Preemptive Interscalene Block - Single Shot|Interscalene brachial plexus blockade will be performed by the anesthesia team under ultrasound-guidance utilizing 1 ml/kg (to a maximum volume of 20 mls) of 0.2% ropivacaine without epinephrine. Regional anesthesia will be performed following the induction of anesthesia, but prior to the start of surgery. Anesthesia team members determined to be proficient in regional blockade, having performed a minimum of ten successful interscalene brachial plexus blocks previously, will be performing the regional blockade.
224173806|NCT02666118|PROCEDURE|Postoperative Interscalene Block- Single Shot|Interscalene brachial plexus blockade will be performed by the anesthesia team under ultrasound-guidance utilizing 1 ml/kg (to a maximum volume of 20 mls) of 0.2% ropivacaine without epinephrine. Regional anesthesia will be performed following the completion of surgery with the patient still under general anesthesia. Anesthesia team members determined to be proficient in regional blockade, having performed a minimum of ten successful interscalene brachial plexus blocks previously, will be performing the regional blockade.
224173807|NCT02666118|PROCEDURE|Preemptive Interscalene Block - Catheter|Interscalene brachial plexus blockade will be performed by the anesthesia team under ultrasound-guidance utilizing 1 ml/kg (to a maximum volume of 20 mls) of 0.2% ropivacaine without epinephrine. A continuous peripheral nerve catheter will then be placed under ultrasound-guidance for continuous infusion postoperatively. Regional anesthesia will be performed following the induction of anesthesia, but prior to the start of surgery. Anesthesia team members determined to be proficient in regional blockade, having performed a minimum of ten successful interscalene brachial plexus blocks previously, will be performing the regional blockade.
224173808|NCT02666118|PROCEDURE|Postoperative Interscalene Block - Catheter|Interscalene brachial plexus blockade will be performed by the anesthesia team under ultrasound-guidance utilizing 1 ml/kg (to a maximum volume of 20 mls) of 0.2% ropivacaine without epinephrine. A continuous peripheral nerve catheter will then be placed under ultrasound-guidance for continuous infusion postoperatively. Regional anesthesia will be performed following the completion of surgery with the patient still under general anesthesia. Anesthesia team members determined to be proficient in regional blockade, having performed a minimum of ten successful interscalene brachial plexus blocks previously, will be performing the regional blockade.
224173809|NCT03416036|BIOLOGICAL|TetraVax-DV-TV003 (TV003)|TV003 contains 10\^3.3 plaque-forming units (PFU)/mL of rDEN1Δ30, 10\^3.3 PFU/mL of rDEN2/4Δ30(ME), 10\^3.3 PFU/mL of rDEN3Δ30/31-7164, and 10\^3.3 PFU/mL of rDEN4Δ30. Administered by subcutaneous injection in the deltoid region of the upper arm
224173810|NCT03416036|BIOLOGICAL|rDEN2Δ30-7169 (DENV-2)|Administered at a dose of 10\^3 PFU by subcutaneous injection in the deltoid region of the upper arm
224306156|NCT00829803|DEVICE|SNAP monitor; Bispectral Index Monitor (BIS Monitor)|Intended to monitor the state of the brain by data acquisition of EEG signals.
224306157|NCT00002608|DRUG|cisplatin|
224306158|NCT00002608|DRUG|doxorubicin hydrochloride|
224306159|NCT00002608|DRUG|tamoxifen citrate|
223485164|NCT01113242|OTHER|Neuropsychological Assessment|Included patients had clinically idiopathic PD, were over 65 years old and presented with a cognitive complain. A detailed registration of clinical history (including review of motor, cognitive, and neuropsychiatric symptoms, comorbid medical conditions, and medications) and neurologic examination was performed. Exclusion criteria included other conditions than PD that could contribute substantially to the subject's motor and/or cognitive impairment, including neurologic and major psychiatric disorders ( delirium,…) affecting the cognitive functions. Patients with major cognitive impairment (i.e. Mental State Examination (MMSE) \<16/30) were also excluded.). Neuropsychological assessment explores working memory, episodic memory ,verbal fluency, executive functions and visuo constructive functions.
223586283|NCT03401385|OTHER|Non-Steroid Containing Mouthwash|A mouthwash containing a non-steroid ingredient administered in sub-study
224306160|NCT00002608|PROCEDURE|conventional surgery|
224306161|NCT00002608|RADIATION|radiation therapy|
223485165|NCT00302900|BEHAVIORAL|Pre-Donation Water Consumption|Consumption of 500 ml of bottled water 30 minutes prior to donating
223485166|NCT00302900|BEHAVIORAL|Muscle Tensing Exercise During Donation|Alternating leg lifts at 10-second intervals during donation
223485167|NCT00302900|BEHAVIORAL|Muscle Tensing Exercise Prior to Donation|Alternating leg lifts at 10-second intervals prior to insertion of the donation needle
223586284|NCT00837759|DRUG|Insulin|
223586285|NCT00837759|DRUG|Lansoprazole|
223586286|NCT00837759|DRUG|Sitagliptin|
223586287|NCT00837759|BIOLOGICAL|Diamyd|
223586288|NCT00837759|DRUG|GAD65 (Diamyd)|
223586289|NCT02807870|DRUG|Methylphenidate|Methylphenidate treatment with a initial dosage of 0,3 mg/kg per day (weekly dosage adjustments).
223586290|NCT02807870|BEHAVIORAL|Parental training|Weekly parental training conducted by behavioral psychologists.
224173811|NCT03416036|BIOLOGICAL|rDEN3Δ30 (DENV-3)|Administered at a dose of 10\^3 PFU by subcutaneous injection in the deltoid region of the upper arm
224173812|NCT03416036|BIOLOGICAL|Placebo|Administered by subcutaneous injection in the deltoid region of the upper arm
224173813|NCT01814189|DRUG|Sumatriptan+Promethazine (SPr)|
224173814|NCT00218452|BEHAVIORAL|Lifestyle counseling|assigned to a 6-week individual behavioral treatment involving: 1) a novel brief office intervention for cigarette smoking that includes a treatment component intended to eliminate binge drinking
224173815|NCT00881686|DRUG|adenosine|1.5mg/Kg adenosine will be administered intravenously before surgery
224173816|NCT00040911|PROCEDURE|electroacupuncture therapy|
224173817|NCT00040911|PROCEDURE|sham intervention|Undergo electroacupuncture therapy to sham points
224173818|NCT00040911|PROCEDURE|quality-of-life assessment|Ancillary studies
224173819|NCT01914991|PROCEDURE|dynamic extension contracture orthotic|A dynamic orthosis was constructed in the experimental group using the same style of dynamic extension contracture orthotic. A mobilizing force of 250 - 300 gm/cm2 was set in each one. Patients were instructed to wear it for at least 6 hours per day and then removed it for ADL (Activity Daily Living). A static orthosis was constructed using orfitcast material to the maximum, pain-free length allowed by the tissues at night. Static and dynamic orthoses were checked once a week and adjusted as necessary.
224173820|NCT01914991|PROCEDURE|conventional treatment Physical Therapy|Traditional treatment was applied to one control group. The treatment consisted of 10 minutes of local thermotherapy (paraffin), active exercises at the PIPJ and DIPJ (Distal interphalangeal joint), 3 sets of 15 repetitions of each exercise extending and flexing of the PIPJ with metacarpophalangeal joint from 0° to 90° respectively. Distal interphalangeal joint exercises were conducted with identical repetitions. The metacarpophalangeal joint and PIPJ exercises took place at 0 ° and involved stretching (5 sets of 3 reps, holding for 10 seconds) and Therapeutic U.S (0.8 w/cm2 / 7 minutes).
224173821|NCT03807336|BEHAVIORAL|Emotion-Focused Skills Training for Parents - Experiential|The intervention consists of a 2-day work shop given in a group format, in addition to 6 hours of parent supervision within 6 weeks after the work shop.
224173822|NCT03807336|BEHAVIORAL|Emotion-Focused Skills Training for Parents - Psychoeducational|The intervention consists of a 2-day work shop given in a group format, in addition to 6 hours of parent supervision within 6 weeks after the work shop.
224173823|NCT04018716|DEVICE|MTA|Indirect capping with MTA
224173824|NCT04018716|DEVICE|Dycal|Indirect capping with Dycal
224173825|NCT02146885|OTHER|Weight Control|Weight Control
223586291|NCT02807870|OTHER|Psychoeducational groups for parents|Weekly psychoeducational groups conducted by educators.
223586292|NCT02807870|DRUG|Placebo pill|Placebo pill during 8 weeks.
223586293|NCT02555176|DIETARY_SUPPLEMENT|Dietary intervention|Follow a low-carbohydrate diet
223586294|NCT05663671|DIAGNOSTIC_TEST|Diagnostic Test|30% of IBD patients are misdiagnosed. This affects surgical care of patients. Investigators have unveiled a signature discriminator between UC\&CC that also predicts the outcome of IC patients into authentic UC/CC. This is a bioassay that is specific, sensitive, linear, affordable, minimal risk, non-invasive and constitutes an inexpensive, simple to use, point-of-care test format. Investigators published data which have shown robust presence of DEFA5 in the colon crypt mucosa with aberrant expression of apparent crypt-cell-like cells (CCLCs) in areas identified with ectopic colon ileal metaplasia consistent with CC. Investigators propose to validate that UC/CC, the two unsolved medical sub-types of pathology can accurately be distinguished among IC patients by examining CCLCs secreted DEFA5 levels in endoscopy biopsies instantly. Diagnostics relies on the expression/localization/activation of DEFA5 and the ectopic CCLCs in the mucosal crypt of CC patients.
223586295|NCT02081599|DRUG|Teneli (Teneligliptin)|
223586296|NCT02081599|DRUG|Placebo|
223586297|NCT02081599|DRUG|Insulin|
224173826|NCT01488994|BIOLOGICAL|BAX326|All participants underwent a pharmacokinetic evaluation with BAX326 (recombinant Factor IX) followed by twice weekly prophylactic treatment for 6 months or for at least 50 exposure days, whichever occurred last.
223617600|NCT02216669|DRUG|DTP348|Patients will receive a continuous oral dose of DTP348 for 7 days per week for 7 weeks
223617601|NCT05051748|OTHER|Opalescence™ boost™ PF 40%|40% hydrogen peroxide in-office bleaching
223617602|NCT05051748|OTHER|Opalustre™|6.6% hydrochloric acid and silicon carbide microparticles microabrasion paste
223617603|NCT05051748|OTHER|MI-Paste Plus®|casein phosphopeptide amorphous calcium fluoride phosphate (CPP-ACFP) remineralizing tooth crème
224173827|NCT02940158|OTHER|1/4 cup- Small red lentil|
224173828|NCT02940158|OTHER|1/4 cup- Small green lentil|
224173829|NCT02940158|OTHER|1/4 cup- corn|
224173830|NCT02940158|OTHER|1/4 cup- macaroni|
224173831|NCT02940158|OTHER|1/4 cup- white potato|
224173832|NCT02940158|OTHER|1/4 cup- white rice|
224173833|NCT02940158|OTHER|1/2 cup- small red lentil|
224173834|NCT02940158|OTHER|1/2 cup- small green lentil|
223617604|NCT00027170|DEVICE|Siemens MRI scanner|Investigational or research MRI coils may be used in the protocol. The coils are noninvasive devices external to the body. The coils act as antennae to receive small radiofrequency signals out of the body. Coils of the type we use are used daily in clinical MRI practice.
224173835|NCT02940158|OTHER|1/2 cup- corn|
224173836|NCT02940158|OTHER|1/2 cup- macaroni|
224173837|NCT02940158|OTHER|1/2 cup- white potato|
224173838|NCT02940158|OTHER|1/2 cup- white rice|
224173839|NCT00340938|PROCEDURE|Blood testing|
224173840|NCT04264611|OTHER|Experimental: Short Foot Exercise Group|Short foot exercise which was performed under the supervision of physiotherapist for four weeks in 30 repetitions five days a week.
224173841|NCT04264611|OTHER|Experimental: Towel Curl Exercise Group|Towel curl exercise which was performed under the supervision of physiotherapist for four weeks in 30 repetitions five days a week.
224173842|NCT03525912|DRUG|Ketamine|continuous infusion of low dose ketamine for postoperative pain
224173843|NCT01363973|DEVICE|VITALSTIM transcutaneous electrical stimulation|
224173844|NCT03798366|DRUG|GLPG1690|Film-coated tablets of GLPG1690 for oral use.
224173845|NCT03798366|DRUG|Placebo|Film-coated tablets of GLPG1690 matching placebo for oral use.
224173846|NCT02089191|DEVICE|Nelfilcon A contact lenses|
224173847|NCT02089191|DEVICE|Stenfilcon A contact lenses|
224173848|NCT01948089|BEHAVIORAL|Variable Structured Cognitive Exercise|This exercise uses the n-back paradigm in which participants are asked to keep track of one or two series of sequentially presented auditory and/or visual stimuli in order to detect targets that match those presented n-items ago in the sequence. The task begins at 1-back (i.e., watch for targets that match those just presented) and gets harder (e.g., watch for matches with items presented 2 or 3 items ago in the sequence) as performance improves. The stimuli will vary weekly, and include varying auditory letters or words, or varying visual patterns or faces.
224173849|NCT01948089|BEHAVIORAL|Constant Structured Cognitive Exercise|This exercise uses the n-back paradigm in which participants are asked to keep track of one or two series of sequentially presented auditory and/or visual stimuli in order to detect targets that match those presented n-items ago in the sequence. The task begins at 1-back (i.e., watch for targets that match those just presented) and gets harder (e.g., watch for matches with items presented 2 or 3 items ago in the sequence) as performance improves. The stimuli will remain constant throughout the 10 week intervention
224173850|NCT00512928|DRUG|acenocoumarol|max 5 mg per day during 10 weeks
224306162|NCT04283500|DRUG|Buprenorphine Naloxone|Participants will receive the BUP SL 32mg in divided doses rather than all at once. If after the initial 8mg dose a participant experiences over-sedation or another adverse event that would preclude further dosing, such as an allergic reaction, the subsequent dose will not be administered and the patient will be withdrawn from the study. The participant will be reassessed for other possible etiologies for these symptoms.
224306163|NCT02330536|DEVICE|Insufflation of carbon dioxide (CO2)|After patients were positioned, CO2 was insufflated into right pleural cavity at eight or twenty L/min. during video-assisted thoracoscopic surgery, thoracic pressure, hemodynamic and respiratory parameters were recorded.
224306164|NCT01008332|BIOLOGICAL|Toleromune HDM|ToleroMune HDM dose 1x4 administrations 4 weeks apart
224306165|NCT01008332|BIOLOGICAL|Placebo|Placebo comparator, 1x4 administrations 4 weeks apart
224306166|NCT05552170|OTHER|day-case surgery|Patients who underwent loop ileostomy with age ≤ 65 and ASA II or III were enrolled and underwent ALIR after rigorous evaluation.
224306167|NCT00006199|DRUG|R115777 (farnesyl transferase inhibitor)|
224306168|NCT00006199|DRUG|Topotecan|
224306169|NCT03599271|DEVICE|Drug-Coated Device|3000 mcg mometasone furoate-coated sinus dilation device
224306170|NCT03599271|DEVICE|Control Device|Sinus dilation device without drug
224306171|NCT05715983|PROCEDURE|Bascom II procedure|Buttocks are strapped apart with wide adhesive tape. The area is prepared using antiseptic solution twice. Solution of brilliant green with 3% hydrogen peroxide was injected in all orifices to visualize all tracts and sinuses. The proposal area of incision is marked nearby sinus tract openings and the skin with lateralization on one side of the cleft. A vertical-orientated incision of the skin and subcutaneous fat around the primary and secondary orifices is made using a scalpel or a monopolar electrocautery. The sinus tract is excised in en-block till unchanged subcutaneous tissue. The wound is irrigated with antiseptic solution. If postoperative wound is larger than 5 cm then a silicone draining tube is placed through the contraperature in the upper corner. The wound is closed by interrupted sutures Vicryl/Polysorb 2/0 3/0 layer by layer. Aseptic dressing is applied to the closed wound.
224306172|NCT05715983|PROCEDURE|SiLaC|Buttocks are strapped apart with wide adhesive tape. The area is prepared using antiseptic solution twice. Solution of brilliant green with 3% hydrogen peroxide is injected in all orifices to visualize all tracts and sinuses. All visible orifices are excised with a scalpel or dermo punch. After that hairs are removed from the sinus by Volkmann curette. A metallic stylet is used to determine the length and direction of the different tracts. Then laser destruction of the sinus is performed with FiberLase VT laser, wavelength 1460 or 1520 nm, the laser energy 10-12 Watts. The fiber delivers energy homogeneously in a continuous way. Hemostasis by electrocautery. The wound is washed with povidone-iodine solution. Aseptic dressing is applied.
223485168|NCT00924898|DRUG|efavirenz, emtricitabine, and tenofovir|Once daily ART with emtricitabine, tenofovir DF and efavirenz
223485169|NCT05253014|PROCEDURE|sphenopalatine ganglion block|block of the sphenopalatine ganglion using either lidocaine or bupivacaine to relief postdural puncture headache
223485170|NCT05253014|DRUG|paracetamol|intravenous paracetamol every 8 hours
223485171|NCT04975425|DIAGNOSTIC_TEST|Fractional Flow Reserve|Comparison between FFR and NHPR before and after guiding catheter disengagement
223485172|NCT00504400|DRUG|Intravitreal injection ranibizumab|Monthly intravitreal injection of of 0.5mg ranibizumab in one eye over one year
224306173|NCT02006693|DEVICE|XEN® Gel Stent|The XEN® Gel Stent (XEN45 implant) was placed in the study eye.
224306174|NCT02006693|PROCEDURE|Cataract Surgery|Participants diagnosed with a cataract elected to have cataract surgery.
224306175|NCT05250466|PROCEDURE|Radiofrequency technology|The vulva and vagina were routinely disinfected with iodophor, the negative plate was placed on the patient's waist and abdomen, and the vulva module was selected for treatment for 10 minutes per side, for a total of 20 minutes. Parameters: power 10-20W, temperature 38-42C°, once every 10 days, 5 times in total
224306176|NCT05250466|PROCEDURE|Electrical stimulation|Routine vulvovaginal disinfection with iodophor, vaginal probes are placed in channel A, electrode pads are placed in channels B\\C\\D respectively, the frequency of electrical stimulation (the most comfortable amount) is adjusted, 10 times is a course of treatment, and mild lesions are treated for 1-2 courses of treatment , 2 to 3 courses of treatment for moderate to severe lesions.
224306177|NCT00541216|DRUG|Ephedrine|
223485173|NCT01417169|DRUG|micafungin|Eligible patients who provided informed consent form will be administered micafungin at 50 mg/day (1mg/kg/day for patients weighting \<50kg) as 1-h infusion. Infusion of Micafungin will be started on the day -2 of the conditioning course of autologous stem cell transplantation
223485174|NCT02035540|OTHER|Decellularized human valves|
223485175|NCT00199173|DEVICE|SIR Spheres intra-arterial hepatic|
223485176|NCT03907215|DRUG|ACT541468|50 mg; film-coated tablet for oral use
223485177|NCT03907215|DRUG|ACT541468 placebo|film-coated tablet for oral use
223485178|NCT03907215|DRUG|Citalopram|20 mg; tablet tor oral use; for single- or repeated dosing
223485179|NCT04194632|PROCEDURE|Temporary right ventricular pacing|As described previously. Patients will undergo temporary pacing at the site of latest endocardial activation with measurement of hemodynamic effects.
224173851|NCT00512928|DIETARY_SUPPLEMENT|menaquinone-7|In successive weeks (6 weeks) the dosage is increased over the range 10 µg to 20 µg increasing to 45 µg MK-7 for the final week.
224173852|NCT00474539|BIOLOGICAL|13-valent pneumococcal conjugate vaccine|1 dose at 2,4,6 and 15 months of age
224173853|NCT00474539|BIOLOGICAL|7-valent pneumococcal conjugate vaccine|1 dose at 2,4,6 and 15 months of age
224173854|NCT00005066|DRUG|O6-benzylguanine|
224173855|NCT00005066|DRUG|carmustine|
224173856|NCT04265027|DRUG|50 mg BIA 9 1067|Hard Capsule; Oral
224173857|NCT04265027|DRUG|25 mg BIA9 1067|Hard Capsule; Oral
224173858|NCT04265027|DRUG|50 mg Ongentys|Hard Capsule; Oral
224173859|NCT04265027|DRUG|25 mg Ongentys|Hard Capsule; Oral
224173860|NCT02061540|DRUG|LUM001|LUM001 oral dose
224173861|NCT05594667|DRUG|Psilocybin|25mg of psilocybin provided by Filament Health
224306178|NCT03682224|DRUG|Liposomal Bupivacaine|Liposomal Bupivacaine 1.3% (Exparel), 20 ml vial for injection, administered subcutaneously at port site
224306179|NCT03682224|DRUG|Bupivacaine-Epinephrine|Bupivacaine-Epinephrine 0.25%, 1:200,000 (Marcaine with epinephrine), administered subcutaneously at port site
224306180|NCT00886223|PROCEDURE|laparoscopic robot-assisted sacropexy|Repair of vaginal vault prolapse with laparoscopic sacropexy assisted by robotic surgical system (da Vinci®-System)
224306181|NCT01119508|DRUG|Ipilimumab|Induction Phase: 10 mg/kg by vein (IV) over approximately 90 minutes on Day 1 only repeated every 3 weeks until 4 courses of therapy are given over 3 months. For the Maintenance Phase, dose repeated every 12 weeks.
224306182|NCT01119508|DRUG|Temozolomide|Induction Phase, 200 mg/m\^2 by mouth (PO) on Days 1 to 4, repeated every 3 weeks until 4 courses of therapy are given over 3 months. For the Maintenance Phase, dose delivered on Days 1 to 5, repeated every 4 weeks.
224306183|NCT00265395|DRUG|Combination of pegylated interferon alfa-2b (PEG-Intron®) and ribavirin (Rebetol®)|"1. Powder for injection in vial or Redipen (50, 80, 100, 120, and 150 microgram strengths), subcutaneous, dose of 1.5 micrograms/kg, weekly for 48 weeks~2. 200 mg capsules, oral, weight based dose of 800-1400 mg, daily for 48 weeks"
223586298|NCT04500886|DRUG|PEG-rhG-CSF|PEG-rhG-CSF is a sustained-duration form of rhG-CSF, a recombinant methionyl form of human granulocyte colony-stimulating factor (G-CSF), similar to rhG-CSF, PEG-rhG-CSF increases the proliferation and differentiation of neutrophils from committed progenitor cells, induces maturation, and enhances the survival and function of mature neutrophils, resulting in dose-dependent increases in neutrophils.
224306184|NCT00265395|DRUG|Combination of pegylated interferon alfa-2b and ribavirin|"1. Powder for injection in vial or Redipen (50, 80, 100, 120, and 150 microgram strength), subcutaneous, dose of 1.5 micrograms/kg, weekly for 72 weeks.~2. 200 mg capsules, oral, weight based dose of 800-1400 mg, daily for 72 weeks"
224306185|NCT02013479|DIETARY_SUPPLEMENT|SelenoPRECISE|Produced by Pharma Nord ApS, Vejle, Denmark
224173862|NCT05297292|DRUG|MW02|MW02 is a recombinant anti-VEGF humanized monoclonal antibody injection.
224306186|NCT02013479|DIETARY_SUPPLEMENT|Placebo|Produced by Pharma Nord ApS, Vejle, Denmark
224306187|NCT06317090|PROCEDURE|guided bone regeneration|a non-resorbable membrane was used as a space maintainer, filled with a particulated bone graft.
224306188|NCT01910779|PROCEDURE|100 joule as first biphasic shock energy|
224306189|NCT01910779|PROCEDURE|120 joule as first biphasic shock energy|
223586299|NCT04500886|DRUG|rhG-CSF|rhG-CSF can increase the proliferation and differentiation of neutrophils from committed progenitor cells, induces maturation, and enhances the survival and function of mature neutrophils.
224306190|NCT05109806|BEHAVIORAL|problem prevention therapy with CHD|The psychological exercises are based on the evidence-based Fun FRIENDS protocol (Burhanar, 2016) for reducing emotional behavioral issues. Separate workshop of adolescents will be designed based on transition in child cardiology to adult cardiology(Moons et al., 2009) . A cardiologist and psychologist will psycho educate them about self-care, needs of transition period and strength and strains about further life.
224306191|NCT04832516|OTHER|Performing following WHO (World Health Organization)|The CLA group will perform exercises following WHO (World Health Organization) prescription
224173863|NCT05297292|DRUG|Lucentis|a recombinant anti-VEGF humanized monoclonal antibody injection
224173864|NCT00004064|BIOLOGICAL|oregovomab|
224306192|NCT04832516|OTHER|Performing on their needs|The IND group will perform strength, aerobic or flexibility exercises depending on their needs observed during the first assessment.
224306193|NCT01928706|OTHER|Denture liner Mucopren Soft; Group 1|Complete denture wearers had their existing mandibular dentures relined with a soft silicone-based denture liner (Mucopren Soft; Group 1; n=22)
224306194|NCT01928706|OTHER|Denture liner Kooliner; Group 2|Complete denture wearers had their existing mandibular dentures relined with a hard acrylic resin based denture liner (Kooliner; Group 2;n=22) with chairside procedures.
223586300|NCT03795727|DEVICE|MD ring and precontoured sectional matrix by TOR VM|MD ring (separation ring) and precontoured sectional matrix (thickness 0.035mm hard) and a wedge was used to secure matrix in place
224173865|NCT04198311|BEHAVIORAL|CBT-I|CBT-I will be delivered individually, in five weekly sessions. Intervention components include sleep hygiene, sleep restriction, stimulus control, relaxation, cognitive therapy.
224173866|NCT05562700|OTHER|On-line questionnaire|"It is a self-administered questionnaire (20 minutes) with several subparts:~* Socio-demographic questions: age, height, weight, smoking status, etc.~* Care: date of accident, initial treatment, duration of symptoms, complications, return to work, return to sport, recovery of skills, etc.~* Functional results"
224173867|NCT00005555|BEHAVIORAL|Exercise|
224173868|NCT03526692|BEHAVIORAL|Neurofeedback|Neurofeedback experiment will consist of 30 sessions of neurofeedback training, twice or three times a week during maximum 4 months. The two experimental groups will undergo questionnaires, EEG recording and neuropsychological assessments in three-time points, pre-training (T0), post-training (T1) and 3 months follow-up (T2). Electroencephalography will be recorded by a technician in EEGFor each participant, EEG power spectrum will be calculated in pre (T0) and post neurofeedback training/psycho-pedagogical care at T2 and T3.
224173869|NCT06089772|OTHER|Comparing to Manipulation and Myofascial Release Techniques|Randomized Controlled Trials
224173870|NCT04540614|OTHER|Strengthening exercises programme|Strengthening exercises for Deep Cervical Flexors, Shoulder external rotators, scapular adductors and thoracic erector muscles
224306195|NCT01955837|DRUG|TAS-102|TAS-102 (35 mg/m2/dose) orally, twice daily on days 1-5 and 8-12 of each 28-day cycle. Number of cycles: until at least one of the discontinuation criteria is met.
223485180|NCT01242982|PROCEDURE|Closed reduction and fixation with 2 pins|Closed reduction and fixation with 2 antegrade intramedullary Kirschner wires. Cast for 2 weeks. Control after 2 and 5 weeks. Thereafter a control after 3,6 and 12 months
224173871|NCT01227252|DRUG|LY2886721|5 milligrams (mg) up to 35 mg, administered orally as capsules, daily for 14 days
223485181|NCT01242982|PROCEDURE|Reduction and Plaster of Paris|Closed reduction in local anesthesia and a Plaster of Paris for max. 3 weeks. Control after 1 and 3 weeks, thereafter control after 3,6 and 12 months
223485182|NCT00294658|PROCEDURE|thymectomy plus prednisone|The thymectomy will be performed as soon as possible after randomization.
223485183|NCT00294658|DRUG|prednisone alone|Prednisone regimen will be every other day, starting at 10mg. The dose will increase by 10mg every 2 days to a target dose.
223485184|NCT00836108|BEHAVIORAL|breathing strategy|Subjects will practice a rhythmic overhead arm exercise, during which they will be taught to inspire when they elevate their arms or they will be taught to expire when they elevate their arms or, a third group, will practice a rhythmic overhead arm exercise, during which they will not be provided with any instruction regarding a specific breathing pattern. The arm exercise practiced by all groups will be identical.
223485185|NCT02726347|BIOLOGICAL|PPV-23|one hundred forty subjects will have pre-vaccination titers checked. All will be given vaccination as standard of care. Approximately 4 weeks later subjects will have post-vaccination titers checked for the same serotypes.
223485186|NCT00570947|OTHER|CPR Anytime Kit|The study group will be asked to fill the CPR Anytime ™ prescription and complete the program. They will be encouraged to include other friends and family members in the program
223485187|NCT02808988|PROCEDURE|periodontal phase 1 therapy|periodontal phase 1 therapy consisted of scaling and root planning with ultrasonic and hand instruments under local anesthesia and gingival crevicular fluid collection by the same investigator.
223485188|NCT02808988|PROCEDURE|gingival crevicular fluid collection|gingival crevicular fluid collection by periopapers
223485189|NCT02808988|OTHER|zoledronic acid|5 mg/year zoledronic acid (i.v.)
223485190|NCT04642222|BEHAVIORAL|APOLO-Teens web-based intervention|The APOLO-Teens web-based intervention is a 6-month cognitive-behavioral lifestyle program developed to optimize treatment as usual for pediatric obesity in public portuguese hospitals.
223485191|NCT04642222|OTHER|Treatment as Usual for Pediatric Obesity|Treatment as Usual for pediatric obesity in portuguese public hospitals.
223485192|NCT01757548|PROCEDURE|open operation|high ligation of spermatic vein by open operation
223485193|NCT01757548|PROCEDURE|microsurgery|high ligation of spermatic vein by microsurgery
223485194|NCT01910441|DRUG|Vildagliptin|Vildagliptin 50 mg twice daily
224173872|NCT01227252|DRUG|Placebo|Administered orally as capsules, daily for 14 days
224306196|NCT01955837|DRUG|Placebo|Placebo orally, twice daily on days 1-5 and 8-12 of each 28-day cycle. Number of cycles: until at least one of the discontinuation criteria is met.
224306197|NCT04257552|BEHAVIORAL|Healthy Beyond Pregnancy|Web-based application grounded in tenants of behavioral economics.
223485195|NCT01910441|DRUG|Glimepiride|Glimepiride 1-6 mg once daily
224173873|NCT01041586|DEVICE|BTVA System|Unilateral Bronchoscopic Thermal Vapor Ablation for Lung Volume Reduction
224173874|NCT04101786|OTHER|Hip adductors exercise variations|The participants will perform different exercise variations targeting hip adductors in randomized order.
224173875|NCT04849338|DIAGNOSTIC_TEST|Bleeding score ( questionnaire )|Bleeding score is done for children diagnosed as von Willebrand's disease .
224306198|NCT04257552|BEHAVIORAL|Pre-Scheduled Postpartum Visit|Participants will have their postpartum visit scheduled while they are still in the hospital after delivery.
224306199|NCT04257552|OTHER|Attention Control|Participants will receive texts related to infant care to mirror the attention participants receive in the Healthy Beyond Pregnancy intervention.
224306200|NCT06149715|DEVICE|Bottle Filter|The household is given a Sawyer Squeeze Water Filtration System.
224306201|NCT06149715|DEVICE|Bucket Filter|The household is given a Sawyer International Bucket System, which is a Squeeze Water Filtration System that is integrated with a hose and bucket.
224306202|NCT06149715|DEVICE|Tap Filter|The household is given a Sawyer Tap Water Filtration System.
224306203|NCT05597137|DIETARY_SUPPLEMENT|Zinc Gluconate|Each participant should receive a regular zinc diet for weeks 1-2 and take zinc supplements for weeks 3-4.
224306204|NCT00552578|DRUG|buprenorphine/naloxone|sublingual tablets, 2/0.5 mg, three times a day for one month, twice a day for one month, once a day for one month, then every other day for one month. (dose may be adjusted based on an individual's response)
224306205|NCT00552578|DRUG|buprenorphine/naloxone|sublingual tablets, 2/0.5 mg, one tablet three times a day for six months (doses may be adjusted based on an individual's response
223485196|NCT01910441|DRUG|Metformin|Metformin (1000-1500 mg daily)
223485197|NCT03727282|PROCEDURE|adjust dobutamine according to the ejection volume index|adjust dobutamine dose
223485198|NCT03727282|PROCEDURE|adjust dobutamine according to the attending physician|adjust dobutamine dose
223485199|NCT00152022|DRUG|Neutral salts of dextroamphetamine sulfate, USP, amphetamine sulphate, USP, d-amphetamine saccharate, d, l-amphetamine aspartate monohydrate.|
223485200|NCT04711577|BEHAVIORAL|Track clinician-determined symptoms|Participants will track clinician-determined symptoms
223485201|NCT04711577|BEHAVIORAL|Track clinician-determined and self-determined symptoms|Participants will track clinician-determined symptoms and a self-determined symptom
223485202|NCT00478959|DRUG|Lenalidomide (Revlimid®)|25mg PO daily for 21 out of 28days per cycle
223586301|NCT03795727|DEVICE|Circumferential matrix and tofflemire retainer by Kerr|Circumferential matrix (thickness 0.038mm) applied by tofflemire retainer and secured in place with wedge
223586302|NCT02595294|PROCEDURE|Cervical Lateral Glide neural mobilization|Non-surgical non-invasive Cervical Lateral Glide neural mobilization procedure was applied by a physical therapist continuously during 2 minutes in 5 different occasions with 1 minute of rest between each 2 minute application of the Neural Mobilization technique. The intervention was applied during a period of 6 weeks. The correct linear alignment of patient's cervical spine was determined through the baseline use of a Universal Goniometer Device in each application of Cervical Lateral Glide neural mobilization.
223745196|NCT05859269|OTHER|Standard of Care|"Patients will receive a single intraoperative dose of 10 mg intravenous dexamethasone (control group, IV dexamethasone is standard of care).~Patients will also receive a standardized multimodal postoperative pain management regimen which includes nonsteroidal anti-inflammatory medication (e.g., NSAIDs) and opioid pain medications, both in the hospital and at home as part of standard care."
223745197|NCT06985069|PROCEDURE|General anesthesia applying multimodal anesthesia|"In the multimodal anesthesia-group a combination of different opioid-sparing drugs are added for general anesthesia, dosages are as follows:~* Magnesium 2g IV~* Dexmedetomidine IV 0.3mcg/kg IBW bolus over 10 minutes, followed by 0.3mcg/kg IBW until 30 min. before the end of surgery or the maximal dosage of 1.4mcg/kg IBW.~* Ketamine IV 0.3mg/kg IBW bolus, followed by 0.3 mg/kg IBW or a max. Dose of 25mg/h, until 30 min. before the end of surgery.~* Lidocaine IV 1mg/kg IBW bolus, followed by 1mg/kg/h IBW until in PACU/ICU"
223745198|NCT06985069|PROCEDURE|General anesthesia using conventional opioid-based regimen|Opioids (Fentanyl, Methadone, Hydromorphone) at the discretion of the treating anesthetist
223745199|NCT06040567|OTHER|Validity and reliability of outcome measures in polyneuropathy|Patients will be tested, answer patient reported outcome measures, and wear accelerometer at baseline after 2-4 weeks and after 1-2 years.
224173876|NCT03669263|DRUG|Fentanyl buccal soluble film (FBSF)|"After screening, eligible subjects were individually titrated to an adequate dose of FBSF (titration period) and continued on this dose as required to control their BTP throughout the maintenance period of the study.~During the dose titration period, subjects were administered with FBSF in a dose escalation manner until a treatment dose was identified (defined as an adequate relief of BTP observed for at least two consecutive episodes). All patient started with a dose of 200 μg and increased by 200 μg in each subsequent episode until an adequate pain relief with tolerable side effects was achieved. Doses above 1200 μg were not allowed."
224173877|NCT04709406|DRUG|deep neuromuscular blockade in bariatric surgery|obese patients who underwent bariatric surgery
223485203|NCT01807533|BEHAVIORAL|Family-centered intervention program|This program was in-hospital intervention, after-discharge intervention, and neonatal follow-up. Five sessions of in-hospital intervention emphasized in the parental involvements with modulation of the NICU, a teaching of child developmental skills, feeding support, massage, interactional activities, child developmental skills, parent support and education, and transition home preparation. The 7-session after-discharge intervention consisted of 4 clinic visits and 3 home visits with specific care in modulation of home environment, teaching of child developmental skills, feeding support, teaching of interactional activities, and parent support and education
223485204|NCT01807533|BEHAVIORAL|Usual care intervention program|This program was in-hospital intervention, after-discharge consultation, and neonatal follow-up. Five sessions of in-hospital intervention emphasized in the parental involvements with modulation of the NICU, a teaching of child developmental skills, feeding support, massage, interactional activities, child developmental skills, parent support and education, and transition home preparation. The after-discharge service was provided 7-phone calls for the general health consultation.
223485205|NCT05975489|DIETARY_SUPPLEMENT|Acute caffeine supplementation|To evaluate the influence of the time of the day (i.e., morning vs evening) on the effect of caffeine on maximal fat oxidation in women
223485206|NCT03744832|DIAGNOSTIC_TEST|Alere i™ Strep A assay|Point of care (POC) molecular-based, nucleic acid amplification test (NAAT). This isothermal molecular assay is CLIA waived (Clinical Laboratory Improvement Amendments) and Health Canada licensed for POC use, and is anticipated to have approval for use without need for back up culture testing.
224173878|NCT04509024|BEHAVIORAL|Incidental training|Training involving non-speech sounds embedded in a video-game.
224173879|NCT04509024|BEHAVIORAL|Explicit training|Training involving explicit sound and category information
224306206|NCT00001474|DRUG|Interleukin-2|
223485207|NCT03744832|DIAGNOSTIC_TEST|Throat culture|Standard bacterial throat culture.
223485208|NCT05474001|DRUG|Fentanyl|10mg bubivacain intrathecal ( 2ml ) with 20microgram intrathecal fentanyl
223485209|NCT05474001|DRUG|Bupivacain|10mg bubivacain intrathecal (2ml) with 0.5 ml saline with no intrathecal fentanyl
223485210|NCT05474001|DRUG|intravenous graniseton|10mg bubivacain intrathecal ( 2ml ) with 0.5 ml saline with no intrathecal fentanyl with 1mg iv granisetron
223485211|NCT01811238|DRUG|Oxycodone/naloxone|Targin 5mg, 10mg, 20mg up to 40mg b.i.d
223485212|NCT02217956|DRUG|Cisplatin|
223745200|NCT06040567|OTHER|Healthy controls|Healthy controls will be tested, answer patient reported outcome measures, and wear accelerometer at baseline visit. There is no follow-up in the healthy control group.
223745201|NCT05042440|DRUG|Efanesoctocog alfa|Solution for injection Intravenous
223745202|NCT05042440|DRUG|Octocog alfa|Solution for injection Intravenous
223745203|NCT05042440|DRUG|Rurioctocog alfa pegol|Solution for injection Intravenous
224173880|NCT04509024|BEHAVIORAL|Classroom training|Structured adult classroom language training.
224173881|NCT04509024|BEHAVIORAL|Classroom and incidental training|Both classroom and incidental training.
224173882|NCT04509024|BEHAVIORAL|Classroom and explicit training|Both classroom and explicit training.
224306207|NCT06468293|OTHER|Psychological support|Psychological support intervention
223485213|NCT02217956|DRUG|Bevacizumab|
223485214|NCT00067080|DRUG|ICL670, deferoxamine|
223485215|NCT02340949|DRUG|Aflibercept|Administered I.V. at doses of 4 mg/Kg on Day 1 every 14 days. It will be supplied to sites by Sponsor as 4 ml vials at a concentration of 25 mg/ml
223485216|NCT02340949|DRUG|5-Fluoruracil|Once every 14 days. Day 1: 400 mg/m2 I.V. bolus and a 46 h infusion of 5-FU 2400 mg/m2
223745204|NCT04827914|BEHAVIORAL|Enhanced Care|Smokers in the enhanced care group will receive live counseling (either in person or telehealth consult) while hospitalized combined with post-hospital discharge automated calls using interactive voice recognition (IVR) technology.
224173883|NCT00644033|DRUG|Frovatriptan|2.5 mg tablet administered once daily for 6 days starting 2 days before the anticipated onset of a MAM headache
224173884|NCT00644033|DRUG|Frovatriptan|2.5 mg tablet administered twice daily for 6 days, starting 2 days before the anticipated onset of a MAM headache.
223745205|NCT04827914|BEHAVIORAL|Basic Care|Smokers assigned to the basic care group will only receive the post-discharge IVR phone calls.
223745206|NCT06286280|DEVICE|cytokine adsorber (CytoSorb®)|binding of cytokines to the sorbent polystyrene of the adsorber during cardiac surgery with extracorporeal circulation
223745207|NCT05819554|PROCEDURE|Trans-sphenoidal surgery|Surgical removal of pituitary tumor by trans-sphenoidal approach
223745208|NCT06593600|DRUG|REGN7544|Subcutaneous (SC) administration
223745209|NCT06593600|DRUG|Placebo|SC administration
223745210|NCT06654219|OTHER|GLP-1 RA users with prolonged fasting instructions|NPO for solids: 24 hours prior to procedure, clear liquid diet (CLD) for 24 hours with last intake of clears no less than 2 hours prior to a procedure.GLP-1 RA will not be held prior to surgery and usual dosing schedule will be followed prior to procedure.
223745211|NCT06654219|OTHER|GLP-1 RA users with standard NPO instructions|NPO after midnight prior to procedure; Minimum solid fasting duration of 8 hours for solids and 2 hours for liquids. Last dose of GLP-1 RA no less than 7 days prior to procedure.
223745212|NCT01372280|DRUG|Reminyl|Galantamine Hydrobromide Tablets 4 mg
224173885|NCT00644033|DRUG|Placebo|placebo tablet administered for 6 days, starting 2 days before the anticipated onset of a MAM headache.
224173886|NCT04604028|DRUG|Lenalidomide [Leavdo®]|Complete remission and partial remission rate
224173887|NCT02561273|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous stem cell transplant
224173888|NCT02561273|DRUG|Cyclophosphamide|Given IV
224173889|NCT02561273|DRUG|Doxorubicin Hydrochloride|Given IV
224173890|NCT02561273|DRUG|Etoposide|Given IV
224173891|NCT02561273|OTHER|Laboratory Biomarker Analysis|Correlative studies
224173892|NCT02561273|DRUG|Lenalidomide|Given PO
224306208|NCT05369468|DRUG|dexmedetomidine as adjuvant with bupivacaine|to assess efficacy of adding dexmedetomidine as adjuvant with bupivacaine in ultrasound-guided erector spinae plane block in patient undergoing laporoscopic cholecystectomy. primary outcome was the total amount of morphine consumption in the first 24-hour postoperative, and the secondary outcomes were the time of first rescue analgesia ,pain score, and safety.
224306209|NCT05369468|DRUG|Bupivacain only|to assess efficacy of bupivacain alone in ultrasound-guided erector spinae plane block in patient undergoing laporoscopic cholecystectomy. primary outcome was the total amount of morphine consumption in the first 24-hour postoperative, and the secondary outcomes were the time of first rescue analgesia ,pain score, and safety.
224306210|NCT03308266|DIAGNOSTIC_TEST|electromyography|
224306211|NCT01799525|PROCEDURE|Hypercapnia by reduction of respiratory volume|By reduction of the respiratory volume, PaCO2 is raised while paO2 is kept constant by modulation of the oxygen supply through the respirator,
224306212|NCT03872934|BEHAVIORAL|implant anxiety|to determine the type of music that reduces anxiety in patients undergoing implant surgery.
224306213|NCT00749021|DRUG|Ranibizumab|0.5 mg of intravitreal ranibizumab monthly for 12 months
224173893|NCT02561273|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo peripheral blood stem cell transplant
224306214|NCT00749021|DRUG|Ranibizumab|0.5 mg intravitreal injection of ranibizumab for 4 months followed by PRN dosing
224306215|NCT00749021|DRUG|Ranibizumab|2.0mg of intravitreal ranibizumab monthly for 12 months
223745213|NCT00119418|DRUG|TU 025 Keishi Bukuryo Gan|
223745214|NCT02653560|DRUG|Potassium chloride powder|
223745215|NCT02653560|DRUG|Potassium magnesium Citrate (KMgCit)|
224306216|NCT00749021|DRUG|Ranibizumab|2.0mg of intravitreal injection of Ranibizumab for 4 months followed by PRN dosing
224306217|NCT04053465|OTHER|Heat acclimation|14 days of aerobic exercise in a hot environment
224306218|NCT04053465|OTHER|Exercise in a cool environment|14 days of aerobic exercise in a cool environment
224306219|NCT00001049|DRUG|Zidovudine|
224306220|NCT00001049|DRUG|Didanosine|
224306221|NCT05502965|OTHER|dietary pattern|Reprocessed and intolerant foods were removed from the dietary pattern, and the food were cooked at home for experimental subjects.
223485217|NCT02340949|DRUG|Oxaliplatin|Once every 14 days. Day 1: 85 mg/m2 I.V. infusion in 250-500 mL, over two hours, followed by 5-FU
223745216|NCT02653560|DRUG|Potassium citrate powder|
223745217|NCT02653560|DRUG|Placebo|
223745218|NCT06282562|OTHER|High-Intensity Interval Training (HIIT)|Individualized High-Intensity Interval Training (HIIT) program with two exercise sessions per week for 12 weeks. The exercise sessions will be conducted on a stationary bike, with intensity tailored to each participant's maximum exercise capacity.
223745219|NCT06656364|DEVICE|Esprit BTK System|The Esprit BTK System is a resorbable polymeric scaffold with the everolimus drug and a resorbable polymeric coating mounted on a balloon dilatation catheter.
223745220|NCT03628703|DEVICE|Repetitive TMS|Repetitive Intermittent Theta-Burst Transcranial Magnetic Stimulation over the right Pre-supplementary Motor Area
224173894|NCT02561273|DRUG|Prednisone|Given PO
224173895|NCT02561273|DRUG|Vincristine Sulfate|Given IV
224173896|NCT03114709|OTHER|Mindful Movement|The program focuses on enhancing individuals' mindfulness capabilities and skills, specifically attention regulation, body awareness, emotional regulation, and shifts in self-perception, by providing opportunities for education, practice, and social support in mindfulness practices and physical activity.
224173897|NCT03114709|OTHER|10 Keys to Health & Wellbeing|This community-based educational program provides participants useful content focused on general health related topics including common chronic conditions, social support, social participation, cancer screening, immunization and keeping active.
224173898|NCT02616172|GENETIC|Autologous Bone Marrow Infusion|The subjects autologous bone marrow cells harvested at Florida Hospital will be infused intravenously by gravity
224173899|NCT01071369|DRUG|Xylocaine|0.5% Xylocaine
224173900|NCT01071369|DRUG|Xylocaine and Celestone|non-particulate Celestone
224173901|NCT00724646|OTHER|Survey|3 individual surveys
224173902|NCT00724646|OTHER|Focus group|Focus group discussions facilitated by a psychologist
224173903|NCT00262353|DEVICE|Dialysis with different artificial devices|
224173904|NCT01608555|DRUG|tobramycin|inhaled tobramycin 300 mg single dose OD for 28 days
224173905|NCT01619527|DRUG|darunavir|Type=exact number, unit=mg, number=400, form=tablet, route=oral. Two tablets as a single dose or a tablet in combination with cobicistat
223745221|NCT06661850|PROCEDURE|Fusion or TDR determined by investigator.|The surgical treatment will be decided by the treating investigator based on their clinical judgement.
223485218|NCT02340949|DRUG|Leucovorin|Once every 14 days. Day 1: 200 mg/m2 I.V., over two hours, followed by 5-FU
223485219|NCT01104961|DEVICE|Contact lens packaging solution|These test solutions are the intervention being tested.
223485220|NCT01104961|DEVICE|Balanced salt solution (BSS)|BSS is isotonic to the tissues of the eyes.
223485221|NCT02644018|DRUG|Imidazolyl ethanamide pentandioic acid|
223485222|NCT02644018|DRUG|placebo|
223485223|NCT02879058|PROCEDURE|Intraoperative contact ultrasonography|In patients randomized to myomectomy with contact ultrasonography, the laparoscopic or robotic ultrasound probe will be advanced through an existing port site into the pelvis after traditional myomectomy has been performed. The face of the ultrasound transducer will be guided over the uterus (including open hysterotomy sites) in systematic strokes, taking special care to note locations of myomas that may have been missed by the preceding excision. Additional hysterotomy sites will be made as necessary in order to remove persistent myomas. Any number of additional ultrasound passes and excisions may be performed in order to achieve the most comprehensive removal of myomas.
223745222|NCT06198712|DRUG|Etavopivat|Participants will receive oral tablets of etavopivat once daily.
224173906|NCT01619527|DRUG|cobicistat|Type=exact number, unit=mg, number=150, form=tablet, route=oral. One tablet as a single dose or a tablet in combination with darunavir
224173907|NCT03817749|DIETARY_SUPPLEMENT|Exogenous ketone monoester|Participants will consume 20g of the oral ketone monoester supplement 15 minutes prior to each meal of the day for 14 days. All meals will be provided throughout the 14-day supplementation period.
224173908|NCT02077972|DEVICE|High intensity whole-body infrared heating|The Whole Body Hyperthermia system uses water-filtered infrared-A (wIRA) heat radiation. The rise in the body's core temperature is correspondingly rapid and well-tolerated. There are two phases of the thermal challenge, 1) Irradiation phase during which the patient lies recumbent with his/her head positioned outside the tent. The wIRA irradiators are arranged above the exposed upper part of the body; and 2) heat retention phase during which the patient lies in the chamber with the walls of the tent positioned to retain heat. Core body temperatures will be raised to those comparable to a mild fever 37.8-38.5°C.
224173909|NCT04739917|BIOLOGICAL|Vaccine PvCS N+C+R 150 mcg|Vaccine PvCS N+C+R 150 mcg (Montanide ISA-51), freeze dried powder.
223485224|NCT03297632|BEHAVIORAL|Functional resistance exercise|Functional resistance program designed for older individuals with low muscle mass and muscle strength. The goal is to implement exercises that are possible for the participants to also perform in their home environment, through the use of basic equipment.
223485225|NCT00122603|DRUG|Fosamprenavir|ATV (150mg: 2 pills per day) + RTV (100mg: 1 pill twice a day) + FPV (700mg: 1 pill twice a day)
223485226|NCT00122603|DRUG|Saquinavir|ATV (150mg: 2 pills per day) + RTV (100mg: 1 pill per day) + SQV (500mg: 3 pills per day)
223485227|NCT05730426|PROCEDURE|Deep dry needling|Method to decrease pain and improve function in musculoskeletal disorders.
223485228|NCT05730426|PROCEDURE|Muscle energy technique|Method to decrease pain and improve function in musculoskeletal disorders.
223485229|NCT05730426|PROCEDURE|Neck stability exercise|Method to decrease pain and improve function in musculoskeletal disorders.
224173910|NCT04739917|OTHER|Placebo SSN Montanide ISA-51 1 mL|SSN Montanide ISA-51 1 mL
224173911|NCT05165004|BEHAVIORAL|Kangaroo Mother Care|the preterm neonate was carefully put naked except for the head and diaper area on the mothers' bare chest with flexed arms and legs as in froglike position, and the head was turned sideways. The researchers wrapped and secured the mother's gown and put a blanket on the neonates' back to ensure neonatal thermal insulation
224173912|NCT05165004|BEHAVIORAL|Hammock Positioning|After one hour of feeding, the preterm neonate was placed in a supine fetal position in the hammock where the head was supported in a neutral midline position by using rolled towel without neck hyperflexion or hyperextension. Moreover, the spine of the preterm neonate was supported while arms and knees were flexed
224173913|NCT05165004|BEHAVIORAL|Routine Care of NICU|; encircling the neonate in a fetal position using rolled towel inside the incubator.
224173914|NCT05135468|DRUG|CU-40102 Spray|topical application, 1\~4 sprays each time, once daily
223485230|NCT04003909|PROCEDURE|ultrasound-guided Erector spinae plane block|The patients will be in lateral position. A curvilinear array ultrasound probe will be placed in a transverse orientation at L4 level to identify the tip of the L4 transverse process. Local anesthetic infiltration of the superficial tissues, an echogenic 22-G block needle will be inserted inplane to the ultrasound beam in a cranial-to-caudal direction until contact made with the L4 transverse process. Correct location of the needle tip in the fascial plane deep to erector spinae muscle will be confirmed by injecting 0.5-1ml saline and seeing the fluid lifting the erector spinae muscle off the transverse process while not distending the muscle. A total volume of 20ml bupivicaine 0.25% and 20 ml xylocaine 1% will be injected into the ESP on the affected side.
223485231|NCT04003909|PROCEDURE|subarachonoid block|Local anesthesia 2ml of lidocaine 2% will be applied intradermally to the needle entrance point. A 22-G block needle will be inserted, free cerebrospinal fluid flow will be observed and 20mg of hyperbaric bupivacaine 0.5% and 10μg of fentanyl will be injected for 30 seconds.
223485232|NCT06294470|DIAGNOSTIC_TEST|Ballon expulsion test|Rectal latex balloon probe filled with saline solution. Patients expelled balloon and time recorded (\<1 or \>1 min).
223485233|NCT06294470|DIAGNOSTIC_TEST|Colonic transit time|Patients ingested capsules with 24 radiopaque markers and underwent standing abdominal radiographs on Day 3 and Day 5. Over 80% expulsion within five days was considered normal, while retention indicated defecatory obstruction.
223485234|NCT06294470|PROCEDURE|Stapled hemorrhodopexy|Circumferential stapled hemorrhoidopexy with a 34mm circular stapler is a surgical procedure used to treat mucohemorrhoidal prolapse.
223485235|NCT01774526|OTHER|Characterise the molecular epidemiology of lung adenocarcinoma in multi-ethnic asian phenotypes|
223485236|NCT01737801|PROCEDURE|Lung function test|Lung function test.
223485237|NCT01192178|DRUG|FLOVENT™ DISKUS™ 100 mcg BID|FLOVENT™ DISKUS™ 100 mcg, one inhalation twice daily (BID) from the DISKUS device from randomization through the end of study (week 16).
223745223|NCT04460209|OTHER|Standard of Care|Standard of care mapping and/or ablation
223745224|NCT03253107|DRUG|Chemotherapy|"Institutinal standard chemotherapy as first line~: XP (xeloda + cisplantin) or Xelox (xeloda+oxaliplitan) +/- Herceptin"
223745225|NCT06912828|OTHER|Med-LFD intervention|In the beginning of the intervention, blood and stool samples will be collected. All participants of the group at phase 1 (elimination phase), will initially follow the Med- LFD (2-6 weeks). At phase 2 (reintroduction phase), patients will gradually reintroduce foods rich in FODMAPs (6-8 weeks) and test their tolerance. At phase 3 (maintenance phase), following the reintroduction of foods rich in FODMAPs, patients will follow an individualized diet based on their personal tolerance (a combination of high and low FODMAPs). In the end of intervention, stool samples will be collected again.
223485238|NCT01192178|DRUG|ADVAIR™ DISKUS™ 100/50 mcg BID|ADVAIR™ DISKUS™ 100/50 mcg is a combination product containing a 100 mcg fluticasone propionate and a 50 mcg salmeterol. One inhalation from the DISKUS device twice daily (BID) from randomization through end of study (week 16).
223485239|NCT01943617|DRUG|Entecavir|anti-viral therapy
223485240|NCT01943617|DRUG|Thymosin-α|anti-viral and antitherapy
224173915|NCT05001581|PROCEDURE|Arthroscopic partial repair of massive rotator cuff tear|Surgery relies on arthroscopic reconstruction of the rotator cuff tendons. Because of irreparability of Supraspinatus tendon ( always) and infraspinatus tendon ( sometimes) surgeon performed partial repair to cover humeral head by the tendons
224173916|NCT05001581|PROCEDURE|Arthroscopic partial repair of rotator cuff with biceps augmentation|Surgery relies on arthroscopic reconstruction of the rotator cuff tendons. Because of irreparability of Supraspinatus tendon ( always) and infraspinatus tendon ( sometimes) surgeon performed partial repair to cover humeral head by the tendons and because of good quality of the long head of the biceps tendon, its uses as biological reinforcement of the reconstruction to achieve better clinical and radiological outcome
224173917|NCT01253941|OTHER|Mud bath Therapy|patients will be randomized to Mud bath Therapy ( 12 sessions) or no treatment
224173918|NCT03031990|BEHAVIORAL|In-person yoga for fertility group|The participants in this group will complete the Yoga for Fertility class at Pulling Down the Moon: An Integrative Center for Fertility. This consists of a 30 minute discussion session followed by a 60 minute Vinyasa style yoga class one time a week for a total of 6 weeks. Participants must attend at least 5 out of the 6 sessions to be included in the analysis.
224173919|NCT03031990|BEHAVIORAL|Online yoga for fertility group|The participants in this group will complete an online webinar of the Yoga for Fertility class and engage in a home yoga practice with the Pulling Down the Moon Yoga DVD. This will occur one time a week for a total of 6 weeks. Participants must complete at least 5 out of the 6 sessions to be included in the analysis.
224173920|NCT03031990|BEHAVIORAL|In person discussion only group|The participants in this group will attend an in-person 30 minute discussion session at Pulling Down the Moon. This will occur one time a week for a total of 6 weeks. Participants must complete at least 5 out of the 6 sessions to be included in the analysis.
224173921|NCT02114918|BEHAVIORAL|Attention Modification Program|"Each trial begins with a fixation cross presented in the center of the computer screen for 500 ms. The cross is then replaced by a word pair presented in the center of the screen for 500 ms. The word pair disappears and a probe (i.e., the letter E or F) appears immediately in the location of one of the two words. Participants will be instructed to decide whether the letter is an E or an F and press the corresponding mouse button. This paradigm has been modified to facilitate an attention bias away from threatening material. In this case, the probe always replaces the neutral word. Thus, although there will be no specific instruction to direct attention away from the threat word, on all trials, the position of the neutral word will indicate the position of the probe."
224173922|NCT02114918|BEHAVIORAL|Attention Control Condition|"Each trial begins with a fixation cross presented in the center of the computer screen for 500 ms. The cross is then replaced by a word pair presented in the center of the screen for 500 ms. The word pair disappears and a probe (i.e., the letter E or F) appears immediately in the location of one of the two words. Participants will be instructed to decide whether the letter is an E or an F and press the corresponding mouse button. This paradigm is not intended to facilitate an attention bias away from threatening material. In this case, the probe randomly replaces the threat or neutral word."
224173923|NCT06258772|DRUG|Mepolizumab Auto-Injector|Mepolizumab 100 mg in pre-filled injector
224173924|NCT05320224|OTHER|Patient-Oriented Music Intervention (POMI)|The brief name given to this intervention is POMI (Patient-Oriented Music Intervention). In POMI, music is delivered to adult patients either via headphones (Bose) or by music pillow (MusiCure). Adults admitted to the intensive care unit (ICU) will choose the mode of delivery. ICU adult patients who are unable to self-report will hear music via music pillow. Individualized playlists will be created based on the patient music preferences, as self-reported. For patients unable to self-report, a person significant to the patient such as a family member will be asked about the patient music preferences. Questions about preferences will include music genre, track, artist, instrumentalness, acousticness, energy, and valence, as defined by the streaming service Spotify. A POMI web-based tool (https://pomi.glitch.me) will use these preferences to create personalized playlists on Spotify, with a tempo restriction of 60-80 bpm. Music will play for at least 20 minutes, via smart device (iPad).
224173925|NCT03061149|OTHER|Low-level laser therapy|
223485241|NCT04546841|BIOLOGICAL|multipeptide cocktail|"Three groups of participant will be administered the multipeptide cocktail~1. Part I: Age 18-55 at the time of screening~2. Part II: Age 56-74 years at the time of screening~3. Part III: Age ≥ 75 years at the time of screening"
223485242|NCT02868515|OTHER|Hot cereal contain 3 g dietary fiber|Intervention involves consumption of a hot cereal over 14 day period
224173926|NCT03061149|OTHER|Ultrasound treatment|
224173927|NCT04583228|DRUG|HLX71|Single-dose, intravenous infusion
224173928|NCT04583228|OTHER|Placebo|Single-dose, intravenous infusion
224173929|NCT00676806|BIOLOGICAL|Umbilical Cord Blood After Myeloablative Conditioning|cyclophosphamide (60mg/m2 days -6 \& -5), fludarabine (25 mg/m2 days -7, -6, \& -5) and total body irradiation (days -3, -2, \& -1, total 1200 cGy) followed by cord blood infusion on day 0.
224306222|NCT05502965|OTHER|EEN|All energy and nutrients are obtained from exclusive enteral nutrition.
223485243|NCT06213116|DEVICE|MADgic Atomizer|Device to deliver directly lignocaine
223485244|NCT06213116|DEVICE|Lignocaine pump spray|Lignocaine 30 mg (3 puffs) given via 10mg Lignocaine Pump Spray prior to endotracheal intubation
223485245|NCT02812784|DEVICE|Nephrocheck TM|
223485246|NCT00244179|DRUG|interferon-gamma|
223485247|NCT00244179|DRUG|infliximab|
223485248|NCT00244179|DRUG|dmard|
224173930|NCT00676806|BIOLOGICAL|Umbilical Cord Blood After Reduced-Intensity Conditioning|Extracorporeal Photopheresis (days -8 \& -7), cyclophosphamide 50 mg/kg (day -6) pentostatin 4 mg/kg/d (continuous infusion days -5 \& -4), total body irradiation (days -3 \& -2, total 600cGy) followed by Umbilical Cord Blood Infusion day 0.
224173931|NCT02994199|OTHER|Active video gaming|Participants will engage in active video game play using two off-the-shelf (OTS) and two adapted controllers using the Wii gaming console. Controllers are: OTS balance board, OTS gaming mat, Adapted balance board, Adapted gaming mat.
224173932|NCT02192190|DRUG|LY2951742|Administered subcutaneously (SC)
224173933|NCT02192190|OTHER|Placebo- oral|Administered orally
223485249|NCT02683629|BIOLOGICAL|NTCELL Implantation|NTCELL Implantation
224173934|NCT02192190|OTHER|Placebo - SC|Administered SC
224173935|NCT02192190|DRUG|Celecoxib|Administered orally
224173936|NCT05662488|DIAGNOSTIC_TEST|[68Ga]FAPI PET/CT and [18F]FDG PET/CT|To perform \[68Ga\]FAPI PET/CT and \[18F\]FDG PET/CT in patients with advanced liver and biliary cancer before and after treatment with PD-1 Based Combination Therapy
224173937|NCT03227692|DEVICE|Persona Knee System|Osteoarthritis will be enrolled and randomly assigned into one of two treatment groups. Patients in investigational group will be treated with total knee arthroplasty and the accelerometer-based navigational device. Patients in control group will be treated with total knee arthroplasty with conventional instrumentation.
224173938|NCT03227692|PROCEDURE|Total Knee Arthroplasty|Damaged cartilage due to degerative arthritis is replaced by knee joint prosthesis.
224173939|NCT03227692|DEVICE|iAssist Knee|Osteotomy of TKA is navigated by iAssist system, iAssist requires pin inserted in bone.
224173940|NCT02862028|BIOLOGICAL|HerinCAR-PD1 cells|herinCAR-PD1 cells transfusion: (1-5×107/kg herinCAR-PD1 + physiological saline + 0.25% human alloalbumin) 300ml for each infusion. IV (in the vein) for each infusion, 2 cycles, each cycle received one infusions on day 21, 43.
223485250|NCT02683629|OTHER|Sham Surgery|Sham Surgery
224173941|NCT02079311|DEVICE|Active self warming blanket|BARRIER® EasyWarm is a disposable self-warming blanket that produces heat via an exothermic chemical reaction initiated by exposure to air, resulting from the oxidation of iron.
224173942|NCT02079311|DEVICE|Forced air warming device|Forced air warming is a temperature management unit, where heated air is used to warm subjects through convection.
223485251|NCT02825823|DIETARY_SUPPLEMENT|Ketone Salt|
223485252|NCT02825823|DIETARY_SUPPLEMENT|Placebo|
223485253|NCT00611052|BEHAVIORAL|the Adolescent Coping with Stress|A group cognitive intervention, manualized and highly structured. Includes 8 sessions (á 1.5 hours) and a booster session 6 months after termination of the actual intervention. Groups leaders are specifically trained for this course.
223485254|NCT00611052|BEHAVIORAL|Treatment as usual|The usual treatment received by the adolescent with mild to moderate self-reported depressive symptoms in school health care.
224173943|NCT01008228|PROCEDURE|exsufflation|exsufflation will be performed with a specific thoracentesis system after introducing the device into chest pneumothorax, aspiration will be performed during 30 minutes
224173944|NCT01008228|PROCEDURE|thoracic tube drainage|thoracic tube drainage will be performed with a tube Ch 16 or ch 20
224173945|NCT01138293|DEVICE|motion detection with a motion sensor|To asses physical activity and eating habits electronic health technology was used (Fraunhofer-Institute). The system consists in a motion sensor integrated in a mobile phone (DiaTrace). The system analyses kind, intensity and duration of physical activity and eating habits.
224173946|NCT05488327|DRUG|Lenalidomide|All subjects will be treated with lenalidomide 5mg/day with a regular follow-up of 24 weeks.
224173947|NCT04809649|DRUG|SUBA-itraconazole|Participant will receive treatment with SUBA-itraconazole
223485255|NCT00611052|OTHER|usual health education|usual health education given by the school nurses, targeted for healthy controls with no depressive symptoms according to the self-report scale
223485256|NCT01207193|BIOLOGICAL|cell injection|injection of mesenchymal cells to bone cyst defect
223485257|NCT00296517|DRUG|323U66 (Bupropion Hydrochloride Sustained Release)|Subjects with Major Depressive Disorder who were randomized to take 100mg of Bupropion SR in the morning and placebo in the evening for one week. Week 2 subjects were given 100mg dose of Bupropion morning and evening. Weeks 3 thru 12 received 150mg dose morning and evening. Week 1=dose level 1, 100 mg. Week 2=dose level 2, 200 mg. Weeks 3 - 12=dose level 3, 300 mg.
223485258|NCT00296517|DRUG|Placebo|Subjects with Major Depressive Disorder who were randomised to placebo to match Bupropion SR during the treatment period.
223485259|NCT02517658|OTHER|Video|Watching a YouTube video containing post tonsillectomy discharge instructions.
223485260|NCT02517658|OTHER|Standard discharge teaching|Receiving standard post tonsillectomy discharge instructions from the nurse prior to discharge.
223485261|NCT02515929|DIETARY_SUPPLEMENT|Oligomeric Proanthocyanidins|
223485262|NCT02515929|DIETARY_SUPPLEMENT|Placebo|
223485263|NCT00559078|OTHER|Interview|Hour-long, qualitative, phone interview
223485264|NCT05346029|BEHAVIORAL|Lifestyle intervention|Resistance training and nutritional counseling
224173948|NCT00058448|DRUG|docetaxel|
224173949|NCT01363154|OTHER|Mozart K448|Subjects will receive auditory stimulation by exposure to Mozart's Sonata for Two Pianos in D Major, K448.
224173950|NCT01363154|OTHER|Beethoven's Für Elise|Subjects will receive auditory stimulation by exposure to Beethoven's Für Elise.
224173951|NCT01363154|OTHER|No music exposure|Subject's will not receive an intervention and will therefore, not receive auditory stimulation and/or exposure to music.
224173952|NCT04456803|DRUG|Ferric citrate tablet|250mg/tablet, manufactured by Sinomune Pharmaceutical
224173953|NCT04456803|DRUG|Sevelamer carbonate tablet|800 mg/tablet, manufactured by Genzyme Ireland Limited
224173954|NCT02768636|DIETARY_SUPPLEMENT|Omega-3|Omega-3 or Fish oil (1000 mg.) is taken for one capsule a day in 30 days duration. Heart rate variability is tested before at starting day and later follow up it again in the next 30 days appointment.
224173955|NCT04958551|OTHER|No intervention|No intervention
224173956|NCT06355206|COMBINATION_PRODUCT|endoscopic intervention, surgery or conservative treatment|Personal information and treatment of the enrolled subjects will be collected.
224173957|NCT04731194|BEHAVIORAL|Performance-based financial incentive program|"1. Enhance policy awareness through verbal communication with patients, distributing picture-rich fliers to patients, and putting up large posters in public places of the villages.~2. Support patients' registration in the reimbursement system~3. Follow-up patients after the first, third, and sixth months after the start of the study, measuring blood pressure and blood glucose level. Encourage patients to purchase medications from public institutions and to take their medications on time.~4. Receive financial incentives based on performance in the amount of 3 RMB per patient enrolled (first month) and 5 RMB per patient (at third and sixth month) buying medications with reimbursement from the policy."
224173958|NCT05389865|PROCEDURE|Surgery on the proximal aorta (aortic root +/- ascending aorta)|Surgery involving replacing, repairing or reinforcing the proximal aorta (root and ascending aorta)
224173959|NCT05389865|OTHER|Patients diagnosed with thoracic aortopathy but not operated upon|Radiological size criteria or Genetic mutations associated with aortopathies
224173960|NCT00515866|DRUG|KU-0059436 (AZD2281)(PARP inhibitor)|oral
224173961|NCT00515866|DRUG|Gemcitabine|intravenous injection
224173962|NCT00636038|DIETARY_SUPPLEMENT|corn beta-carotene|yellow corn beta-carotene in a 1 mg level to be taken as corn porridge in one meal by volunteers
224173963|NCT00859144|BEHAVIORAL|Be Proud! Be Responsible!|This intervention consists of highly structured modules that involve group discussions, videos, games, brainstorming, experiential exercises, and skill building activities. The program encourages participants to be proud of themselves and their community, to behave responsibly for themselves and their community, and to consider their goals for the future and how risk behaviors may interfere with the attainment of their goals.
224173964|NCT00859144|BEHAVIORAL|Becoming A Responsible Teen (BART)|This program consists of highly structured modules administered using intervention manuals in community-based settings. Each intervention session involves group discussion, videos, games, presentations, demonstrations, role plays, and practice. Youth learn problem solving, decision-making, communication, condom negotiation and use skills, and behavioral self-management. Youth also meet with HIV infected peers to promote risk recognition and improve their perception of vulnerability.
224173965|NCT00859144|BEHAVIORAL|Reducing the Risk|This program consists of instruction on developing social skills to reduce sexual risk-taking behavior and role plays to practice and model skills. Additional activities-such as teaching decision making and assertive communication skills, offering encouragement to obtain relevant health information from stores and clinics, and asking parents about their views on abstinence and birth control-support the premise that students should avoid unprotected intercourse, either by remaining abstinent or using contraceptives.
224173966|NCT05972122|DRUG|Analgesia management; group S and C|Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. A patient-controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol including 10 mcg bolus without infusion dose, 10 min lockout time, and 4-hour limit. If the NRS score is ≥ 4, 0.5 mg kg-1 iv meperidine will be administered as a rescue analgesic. Postoperative patient evaluation will be performed by an anesthesiologist blinded to the procedure.
224173967|NCT00348075|DEVICE|Neurovision|
224173968|NCT03439722|OTHER|Polysomnography|Participants will be admitted for 1 night at the Danish Center of Sleep Medicine for polysomnography.
224173969|NCT00000175|DRUG|Estrogen|
224173970|NCT00000175|DRUG|Testosterone|
223485265|NCT05968378|BEHAVIORAL|Standard healthy eating advice|Subjects in this group will be provided with standard healthy eating advice according to the Irish National Healthy Eating Guidelines and Food Pyramid and will be asked to follow this advice for 8-weeks.
223485266|NCT05968378|BEHAVIORAL|eTRE plus Mediterranean diet|Subjects in this group will be asked to consume all meals between 8am - 4pm and to adhere to a Mediterranean style diet daily for 8-weeks.
223485267|NCT03133676|DRUG|KA34|50 µg - 400 µg intra-articular injection (single or multiple doses)
223485268|NCT03133676|DRUG|Placebo|50 µg - 400 µg intra-articular injection (single or multiple doses)
223485269|NCT05071924|BEHAVIORAL|PLH Teens Original: In-person PLH programme for parents and teens by community-based workers|This in-person intervention is delivered over 14 sessions (10 joint parent and teen sessions and 4 separate parent and teen sessions).
223485270|NCT05071924|BEHAVIORAL|PLH Teens Hybrid: Hybrid delivery for parents and teens by facilitators|The hybrid intervention delivered over 12 sessions (8 sessions delivered via WhatsApp groups to parents only and 4 sessions delivered in-person to parents and teens together).
223485271|NCT03000153|OTHER|Completing the Goals Form|The Goals Form is a personalised outcome measure where clients enter their goals in collaboration with their assessor. Goals are then rated at the start of every session and open the therapeutic dialogue.
223485272|NCT00002846|BIOLOGICAL|aldesleukin|
223485273|NCT00002846|PROCEDURE|conventional surgery|
223485274|NCT00012909|BEHAVIORAL|Hormone Replacement Therapy Decision-Aid|
223485275|NCT05673122|DEVICE|Implant(Flotecno)|"The implants It has a tapered body design and Sandblasting with Large grit that facilitates the osseointergration process.~made in Italy Flotecno srl via.Turati,38 20121 MILANO (Italia)"
223485276|NCT03667287|PROCEDURE|Repair of parastomal hernia|Surgical repair of symptomatic parastomal hernia.
223485277|NCT01009567|DRUG|Cabergoline|Receive cabergoline tablet (0/5 mg) daily until 6 days after oocytes retrieval
223586303|NCT06202040|PROCEDURE|Bilateral Oblique Subcostal Transversus Abdominis Plane Block (OSTAP) will be performed.|The OSTAP block will be conducted in-plane using a 100mm 22 G needle and a linear probe under ultrasound (USG) guidance. The 20cc block will contain 10cc of 0.5% bupivacaine and 10cc of normal saline. Bilateral OSTAP will be administered with 20cc (10cc per side). To apply the block, position the linear probe parallel to the rib edge immediately below it on the anterior abdominal wall. Visible will be the external, internal, transversus abdominis, and rectus muscle junction. The needle tip will move toward the TAP space (between the internal oblique and transversus abdominis muscles). To ensure medication delivery, the needle tip will be visible in the TAP and the drug will be aspirated negatively. USG will also observe drug distribution at the rectus abdominis muscle-TAP space junction.
224306223|NCT04576299|OTHER|Group 1|Survey about social networks, notification of adverse events, multidisciplinary teams, the doctor-patient relationship, the role of the ethics and patient safety committees, protocol compliance and suspension of outpatient procedures
224173971|NCT02783261|OTHER|CT volumetric measurement after Y90 radioembolization|Liver volume will be measure at 3 time points. All patients will undergo CT volumetry at baseline, 4-6 weeks and 8-12 weeks after SIRT. The images are then measured using a commercially available 3D software (Vital's Vitrea Advanced CT Liver Oncology package) and manually corrected, reviewed and resected by a single senior radiologist to ensure consistency in following the same anatomical landmarks.
223485278|NCT01009567|DRUG|Control|Receive human albumin 20% infusion
223485279|NCT02692079|PROCEDURE|T-PRF|Flap Surgery
223485280|NCT02692079|PROCEDURE|Allograft|Flap Surgery
224173972|NCT03773068|DRUG|BAY1817080 - Formulation A|Formulation A
223485281|NCT02538991|DEVICE|Bulkamid|"Urethral injections will be performed policlinically under local anesthesia (10 ml lidocain, two injections on both sides of the urethra). The Bulkamid-injections will be transurethral four injections (0.2 - 1ml) in locations ten, two and five and seven o'clock within 0.5 to 1 cm from the bladder - urethra junction.~Additional injections will be avoided and can be injected only if the first injections fail. After the operation the patient urinates to empty the bladder. The PVR is checked after the treatment with ultrasound simultaneously with evaluation of stability of the Bulkamid-injections. The treatment will be photographed as before and after still pictures for later evaluation."
223485282|NCT02538991|DEVICE|Tension-free Vaginal Tape|TVT will be performed under local anesthesia (70 - 100 ml 0.25% prilocain cum epinephrine) with i.v. pain medication phentanyl two doses and more on request. Operation will be performed with TVT-Exact® kit. Operation can be performed policlinically or in an operation theatre depending on the patient's medical condition. Cystoscopy will be performed after the set of tapes. A cough stress test with 250 to 300 ml bladder fulfillment will show the right tension of the tape. Before the operation a prophylactic antibiotic of Cefuroxime 1.5 g i.v will be given (Dalacin 900 mg i.v in cases of allergy to penicillin). The patient can go home after 2 to 4 hours follow-up, when PVR is under 150 ml. A sick leave of 5 days is recommended.
223485283|NCT05046704|DEVICE|peripartum transperineal Ultrasound|The anovaginal distance (AVD) will be measured by transperineal ultrasound ,The distance between the anal edge of the internal sphincter and the probe will then be measured in millimeters The ultrasound assessment of the anal sphincters at rest and during contraction will be performed postnatally using a dynamic 2-dimensional transperineal ultrasound with the patient in a supine position, an empty bladder.
223485284|NCT03004040|BIOLOGICAL|Flu Vaccine|
223485285|NCT02428400|BIOLOGICAL|TG1050|TG1050: adenovirus serotype 5 vector based immunotherapeutic product in adenovirus reference material (ARM) buffer
223485286|NCT02428400|BIOLOGICAL|Placebo|Placebo: adenovirus reference material (ARM) buffer
223485287|NCT03100747|PROCEDURE|Bilamellar 3 mm|Trichiasis surgery using the bilamellar tarsal rotation procedure with incision 3 mm from the eyelid margin
223485288|NCT03100747|PROCEDURE|Bilamellar 5 mm|Trichiasis surgery using the bilamellar tarsal rotation procedure with incision 5 mm from the eyelid margin
223485289|NCT03100747|PROCEDURE|Trabut 3 mm|Trichiasis surgery using Trabut procedure with incision 3 mm from the eyelid margin
223485290|NCT05475145|PROCEDURE|Resin based sealing [RBS]|
223485291|NCT03261193|DRUG|ITM + Sham QLB|Sham subcutaneous non-anesthetic infiltration with saline
223485292|NCT03261193|DRUG|ITM + Bupivacaine QLB|QL plane block with local anesthesia
223485293|NCT06055374|DRUG|BxC-I17e|Pharmaceutical form : solution for injection
223485294|NCT06055374|DRUG|Placebo|Pharmaceutical form : solution for injection
223485295|NCT00000552|PROCEDURE|angioplasty, transluminal, percutaneous coronary|
223586304|NCT06202040|PROCEDURE|Bilateral Rectus Sheath Block (RSB) will be performed.|When the patient is in the supine position, the ultrasound (USG) linear probe is held in the transverse plane at the level just above the umbilicus, where the posterior rectus sheath is best visualized. Using the in-plane technique with a 100mm 22 G needle under USG guidance, the drug prepared will be administered between the rectus muscle and the posterior rectus sheath. For this block, a volume of 20cc will be prepared, consisting of 10cc of 0.5% bupivacaine and 10cc of normal saline. Bilateral Rectus Sheath Block (RSB) will be applied with a total volume of 20cc, 10cc to each side.
223586305|NCT06244680|DEVICE|MRI of the prostate|Patients with suspicion for prostate cancer underwent mpMRI on a new 3-Tesla-MRI scanner with a maximum gradient strength of 200 mT/m, a slew rate of 200 T/m/s and DL reconstruction for image postprocessing.
223586306|NCT05984485|PROCEDURE|neoadjuvant chemotherapy plus total mesorectal excision|Neoadjuvant chemotherapy regimen recommended FOLFOX6, XELON, FOLFOX, mFOLFOX for 4-6 courses, and TME surgical treatment after preoperative tumor restaging 1-2 weeks after neoadjuvant chemotherapy.
223586307|NCT05984485|PROCEDURE|total mesorectal excision|Standard total mesorectal excision
224173973|NCT03773068|DRUG|BAY1817080 - Formulation B|Formulation B
224173974|NCT03773068|DRUG|[13C715N]-BAY 181708 stable isotope label (SIL)|0.1 mg \[13C715N\]-BAY181708, 15 minutes i.v. infusion at the estimated tmax after administration of Formulation B
224306224|NCT03595631|OTHER|Physical Therapy|Patients will receive 5 session of multimodal physiotherapy treatment of 30min duration including low-load strength exercises, soft tissue mobilization and muscle-tendon stretching exercises twice per week.
223485296|NCT00000552|PROCEDURE|coronary artery bypass|
223485297|NCT00000552|DRUG|thrombolytic therapy|
223485298|NCT03750721|OTHER|Role of rifampin in staphylococcal PJI|the aim is to determine if the dose and the duration of rifampin influenced the prognosis
223485299|NCT00055562|DRUG|CC 5013|
223485300|NCT01866670|BEHAVIORAL|spiritual support|-Spiritual Support: deep breathing + guided image + meditation
223485301|NCT01866670|BEHAVIORAL|relaxation therapy|Relaxation Therapy: deep breathing
223485302|NCT00497107|DRUG|UFT, Calcium Folinate, PSK|
223485303|NCT00497107|DRUG|UFT, Calcium Folinate|
223485304|NCT06737380|DIAGNOSTIC_TEST|Physical examination|The physical examination will be performed at the Screening visit and at each subsequent study and safety in clinic follow-up visit. The exam will include: measurement of vital signs (heart rate, peripheral arterial blood pressure, respiratory rate, and temperature), weight, height (at Screening visit only), cardiovascular and respiratory systems, abdominal examination, skin evaluation, mouth and eye evaluation, and neurological assessment. Abnormal findings will be recorded in the CRF.
223485305|NCT06737380|DIAGNOSTIC_TEST|Electrocardiogram|A twelve-lead electrocardiogram (ECG), including corrected QT interval (QTc interval), will be performed in all participants at the Screening visit.
224173975|NCT05390034|BEHAVIORAL|ART|Session 1: Description of the group \& Psychoeducation Session 2: Breathing and muscle relaxation Session 3: Importance of practice/motivation Session 4: Nonjudgemental awareness Session 5: Acceptance and tolerance Session 6: Self-support Session 7: Analysis of emotions Session 8: Modification of emotions Session 9: Practice and contextual applications + end of group
224173976|NCT05390034|BEHAVIORAL|Relaxation|Session 1: Description of the groupe \& Psychoeducation Session 2: Breathing control 1 Session 3: Breathing control 2 Session 4: Muscle relaxation Session 5: Visualisation Session 6: Stretching Session 7: Schultz relaxation Session 8: Schultz relaxation Session 9: Summary and end of group
224173977|NCT01743066|DIETARY_SUPPLEMENT|Vitamin E|vitamin E (200 IU, caplet) daily orally for 20 weeks
224173978|NCT02280109|DRUG|Tenofovir Gel|single dose of 1% tenofovir gel (equivalent to 40 mg in 4ml's of gel)
224173979|NCT02280109|DRUG|Tenofovir Film|single dose of 1.3% tenofovir film (equivalent to 40 mg)
224173980|NCT02586116|DEVICE|nanOss|nanOss Cervical Interbody Fusion Device with nanOss BA bone void filler.
224173981|NCT02586116|DEVICE|C-Plus|C-Plus PEEK IBF Device with autograft
224173982|NCT00997607|BIOLOGICAL|Ebola vaccine|4 mg of Ebola DNA plasmid vaccine, VRC-EBODNA023-00-VP, delivered via intramuscular injection on Weeks 0, 4, and 8
224173983|NCT00997607|BIOLOGICAL|Marburg vaccine|4 mg of Marburg DNA plasmid vaccine, VRC-MARDNA025-00-VP, delivered via intramuscular injection on Weeks 0, 4, and 8
224173984|NCT00997607|OTHER|Placebo injection|4 mg of saline injection delivered at Weeks 0, 4, and 8
224173985|NCT03607435|DEVICE|Spectroscopy for Analyte Quantification|Diabetic hospital staff participants subjected to the KBS-1 device (Test Article #01) will have a finger on their left hand pricked with a lancet and their blood glucose level read by a POC glucose monitor (Control Article #02). Next, they will have their interstitial fluid glucose level spectroscopically scanned from the palm of their left hand using the KBS-1 device, and blood (approximately 40µl), collected from their finger prick site, will be spectroscopically scanned using the RBA-1 device (Test Article #02). Hospital patients subjected to the RBA-1 device, who must already be prescribed a hospital lab blood test by their physician, will have approximately 40µl of their blood, collected from the venipuncture site, spectroscopically scanned using the RBA-1 device (Test Article #02).
224173986|NCT00890201|PROCEDURE|Gallbladder bile sampling and intraoperative cholangiography|"Interventions were exactly similar for both groups, and that is how it was intended to be:~Gallbladder bile sampling: Sample 5 cc of gallbladder bile after the cystic duct has been clipped or ligated.~Intraoperative cholangiography: Perform cholangiography before the cholecystectomy is finished"
223485306|NCT06737380|OTHER|SF-36 questionnaire|Patients will fill out the SF 36 survey, assessing physical and mental health outcomes prior to dosing and/or any other clinical assessments, on visits 1 (baseline), visit 5 (day 14), visit 6 (day 28), visit 11 (day 168) and early termination visit.
223586308|NCT02364934|DRUG|Propofol|This study was designed to determine the dose requirements for rocuronium, administered by continuous infusion to maintain a stable 90-99% T1 depression (depression of the first twitch in the train-of-four, TOF) in adult, elderly and different sex patients under sufentanil and propoful anaesthesia.
223586309|NCT02364934|DRUG|Sevoflurane|This study was designed to determine the dose requirements for rocuronium, administered by continuous infusion to maintain a stable 90-99% T1 depression (depression of the first twitch in the train-of-four, TOF) in adult, elderly and different sex patients under sufentanil and sevoflurane anaesthesia.
223586310|NCT05270798|DRUG|triiodothyronine|Patients in septic shock who meet the diagnostic criteria for euthyroid sick syndrome will be divided into two groups; patients with low T3 levels and patients with low T3 and T4 levels. Both of these groups will be further randomly divided into patients receiving T3 hormone and patients receiving placebo.
224173987|NCT01335360|DRUG|Nevirapine|200mg twice daily of nevirapine
224173988|NCT04488601|DRUG|Rapamycin|Rapamycin in 2 different dosage forms.
224173989|NCT04488601|DRUG|Placebo|Placebo capsules
224173990|NCT02411006|BEHAVIORAL|Prediction mailing|Ask people to predict their upcoming medication adherence
224173991|NCT02411006|BEHAVIORAL|Commitment mailing|Ask people to commit to their upcoming medication adherence
223485307|NCT06737380|DIAGNOSTIC_TEST|Clinical laboratory evaluations - Serology|Serologic testing for HIV, HBV, HCV, TB, and CMV will be performed; HBV and HCV PCR will be done only if serology is positive. Autoimmune tests (ANA, anti-ENA, total IgG, anti-nucleosome) will be done at Day 0 and end of study; ANA only at Screening if no positive ANA or anti-dsDNA in prior 6 months. Inflammatory markers (hs-CRP, ESR) will be tested at Day 0 and end of study. CBC with differential, biochemistry, anti-dsDNA, and complement C3/C4 will be assessed at each scheduled visit.
223586311|NCT02905669|DEVICE|EndoFLIP|Esophago-gastric junction distensibility will be assessed in patients thanks to impedance planimetry using EndoFLIP device
223586312|NCT02166268|DRUG|AVANZ Phleum pratense 15,000 SQ+|
223485308|NCT06737380|DIAGNOSTIC_TEST|Clinical laboratory evaluations - Biochemistry|The panel will include analysis of albumin, blood urea nitrogen (BUN), creatinine, glucose, uric acid, calcium, phosphorus, potassium, sodium, lactate dehydrogenase (LDH), total protein, magnesium, alkaline phosphatase, alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin and hs-CRP. For biochemistry, 3 mL blood will be collected at each study visit. Results relating to inclusion criteria must be confirmed within 7 days prior to Day 1.
224173992|NCT02411006|BEHAVIORAL|Reminder|Remind people to take their medicine
224173993|NCT02411006|BEHAVIORAL|Anonymity|Keep patient predictions and commitment anonymous
224173994|NCT02411006|BEHAVIORAL|Identification|Ask patients to report their predictions and commitments
224173995|NCT00004127|DRUG|FOLFOX regimen|
224173996|NCT00004127|DRUG|fluorouracil|
224173997|NCT00004127|DRUG|leucovorin calcium|
224173998|NCT00004127|DRUG|oxaliplatin|
224173999|NCT06990828|OTHER|Frenkel Stabilization Exercises|Participants included in the study will undergo a program of Frenkel Stabilization Exercises.
224174000|NCT02181504|DRUG|abicipar pegol|Abicipar pegol administered to the study eye by intravitreal injection at day 1, weeks 4 and 8.
224174001|NCT02181504|DRUG|ranibizumab|Ranibizumab (Lucentis®) 0.5 mg administered to the study eye by intravitreal injection every 4 weeks from day 1 through week 16.
224174002|NCT02181504|OTHER|sham procedure|Sham procedure to the study eye at weeks 12 and 16.
224174003|NCT03068182|DEVICE|Arm crank|Each participant practiced on arm crank (Hudson) from long sitting position for 40 minutes. Seat's height and distance were adjusted to achieve full extension of subject arms at horizontal shoulder-level position
224174004|NCT03068182|DEVICE|Treadmill|Participant practiced on an electronic computerized treadmill for 40 minutes . participant began warming up with lowest speed treadmill exercise for 5 minutes at zero inclination. Treadmill speed was increased gradually to achieve the pre-determined individualized moderate intensity for 30 minutes
224174005|NCT03068182|OTHER|Exercise|
224174006|NCT04849260|BIOLOGICAL|Pexa-Vec combined with ZKAB001|"1. Intratumoral injection of low dose Pexa-Vec (3×10\^8pfu) combined with intravenous of ZKAB001 (5mg/kg), every 2 weeks as one cycle.~2. Intratumoral injection of high dose Pexa-Vec (1×10\^9pfu) combined with intravenous of ZKAB001 (5mg/kg), every 2 weeks as one cycle."
224174007|NCT04849260|BIOLOGICAL|ZKAB001 monotherapy|ZKAB001 monotherapy
224174008|NCT00625027|OTHER|Survey and Chart Review|After obtaining consent the survey will be completed. After a staff physician has assessed the patient, the chart will be consulted to retrieve the triage notes, diagnosis, treatment, and discharge recommendations. The physician will be asked to comment on the 'urgency' of the complaint and whether the patient would have been treated equally well at a walk-in clinic.
224174009|NCT01006915|PROCEDURE|Surgery|Surgical decompression of the common peroneal, tibial, and deep peroneal nerves
224174010|NCT05327309|DRUG|Bleomycin|
224174011|NCT06252831|DRUG|"AS-Probionorm"|"Dosage form - powder for the preparation of a solution for oral administration. Dosage regimen -1 sachet (1 g) take 2 times a day with an interval of 12 hours. Apply 15-20 minutes before meals in the morning and evening. Before use, the medicine is mixed with 30-50 ml of boiled water at room temperature, resulting in a cream-colored suspension. The resulting aqueous suspension should be drunk without achieving complete dissolution. The diluted drug cannot be stored. The duration of taking the medicine is 7 days. The study is carried out on an outpatient basis.~The total duration of each subject's participation in the clinical trial is no more than 21 ± 1 days. Throughout the entire study period, the research subject has the opportunity to contact the research team on all questions relating to the nature of this study. After completion of the entire observation period of 21 days, there is no follow-up of study subjects under the trial protocol."
224174012|NCT00003159|DRUG|carboplatin|
224174013|NCT00003159|DRUG|cisplatin|
224174014|NCT00003159|DRUG|docetaxel|
224174015|NCT00003159|DRUG|gemcitabine hydrochloride|
224174016|NCT00003159|DRUG|ifosfamide|
224306225|NCT03595631|OTHER|Physical Therapy plus Neurodynamic|Patients will receive 5 session of multimodal physiotherapy treatment of 30min duration including low-load strength exercises, soft tissue mobilization and muscle-tendon stretching exercises twice per week. In addition, they will also receive bilateral nerve slider neurodynamic interventions targeting the median, ulnar and radial nerves.
223485309|NCT06737380|DIAGNOSTIC_TEST|Clinical laboratory evaluations - Hematology|The complete blood count (CBC) will include: hemoglobin, hematocrit, white blood cells (WBCs) with complete manual or automated differential (total neutrophils, lymphocytes, monocytes, eosinophils, basophils; absolute or percentage will be acceptable), red blood cells (RBCs), platelet count. For CBC, 1mL blood will be collected at each study visit.
223485310|NCT06737380|DIAGNOSTIC_TEST|Pregnancy Test|"A serum b-hCG pregnancy test will be performed for women of child-bearing potential at the Screening visit;urine pregnancy tests will be performed for women of child-bearing potential at each study visit noted above, including on Day 0 prior to study treatment.~Pregnancy tests are not required for women unable to become pregnant for one of the following reasons: Menopause confirmed by healthcare provider, verbally reported by a participant that she has had her uterus or both ovaries or both fallopian tubes removed."
224174017|NCT00003159|DRUG|mitomycin C|
224174018|NCT00003159|DRUG|paclitaxel|
224174019|NCT00003159|DRUG|vinblastine sulfate|
224174020|NCT00003159|DRUG|vinorelbine tartrate|
224174021|NCT00003159|PROCEDURE|conventional surgery|
224306226|NCT06117878|DRUG|NK510|NK510 will be administered through intravenous infusion.once a week，for a total of six times.
223586313|NCT02166268|DRUG|Placebo|
224306227|NCT06117878|DRUG|NK510|NK510 will be administered through intravenous infusion.Twice infusions on week 1,week 3,week 5 respectively.
223485311|NCT06737380|DIAGNOSTIC_TEST|Urinalysis|General urinalysis will include analysis of pH, specific gravity, protein, glucose, ketones, bilirubin, urobilinogen, leukocytes, erythrocytes. In addition samples will be assessed for presence of urinary casts. Spot urine protein/creatinine measure will be done at each visit. If no casts are observed at Screening, then machine assessment of further urinary samples is allowed. For urinalysis, 10mL urine will be collected at each study visit.
223586314|NCT00255528|DRUG|metoprolol succinate|
223586315|NCT01834079|BIOLOGICAL|STEM CELL THERAPY|Autologous stem cells(MNCs ) intra thecal .Intra thecal transplantation of single arm autologous MNCs 100 millions per dose in 3 divided doses at interval of 7 days,Intrathecal/Intravenous .Follow up will be taken to three Months or as required
223586316|NCT05976347|DRUG|Fluoxetine 20 MG|Fluoxetine 20 mg once daily
223586317|NCT05976347|DRUG|Duloxetine 30 MG|Duloxetine 30 mg once daily
223586318|NCT05976347|OTHER|Observation|Referral to behavioral health and resources for addressing depressive symptoms
224174022|NCT00003159|PROCEDURE|neoadjuvant therapy|
224174023|NCT04036006|BEHAVIORAL|Group-Based Program|The Group-based Program uses an ecologically valid setting in which participants exercise, prepare foods, and eat together to facilitate the emergence of old habits and replace them with healthy alternatives. The intervention team consists of a health psychologist, registered dietitian, and health coach. They co-facilitate group meetings for 15 participants that are held weekly for 3 months, bi-weekly for 3 months, and then monthly in participant-led maintenance meetings. Each session includes: weigh-in and physical activity (20 min), cooking demonstration (20 min), and a shared vegetable dish with discussion (50 min). The maintenance phase (months 7 to 24 post randomization) consists of support and health-related topics of the participants' own choosing. Progress reports with lab results are sent to participants and primary care physicians.
224174024|NCT04036006|BEHAVIORAL|Self-Directed Program|The Self-Directed lifestyle program represents enhanced usual care based upon what is currently offered in primary care in the United States for lifestyle treatments for adults with metabolic syndrome. Usual care is enhanced by: 1) lifestyle education for management of metabolic syndrome provided in evidence-based tip sheets from nationally recognized organizations; 2) provision of a Fitbit for self-monitoring physical activity; 3) access to a website containing all education materials; and 4) progress report letters with lab results sent to participants and primary care physicians after completion of each assessment.
224174025|NCT02270190|DEVICE|Percutaneous Tibial Nerve Stimulation (PTNS)|
224174026|NCT05528068|BEHAVIORAL|supervised lifestyle intervention|Participants will receive personalized dietary and exercise prescription according to the assessment of nutritional status, physical fitness and physiological-biochemical indexes. The participants will use the digital application for the first 3 months with supervised lifestyle intervention. Wearable devices, such as ambulatory blood pressure monitoring, dynamic electrocardio scanner and smart watch, will be worn to provide continuous physiological monitoring for safety. And then, participants will use the application by self-management for the next 6 months. All participants are given questionnaires, nutritional, physical fitness and physiological-biochemical assessment at baseline, 3 months, 6 months and 9 months.
224174027|NCT05528068|BEHAVIORAL|healthy lifestyle education|Participants will receive standard care and healthy lifestyle education for hypertension prevention and control. Wearable devices, such as ambulatory blood pressure monitoring, dynamic electrocardio scanner and smart watch, will be worn to provide continuous physiological monitoring for safety. Participants will use the application by self-management for 9 months. All participants are given questionnaires, nutritional, physical fitness and physiological-biochemical assessment at baseline, 3 months, 6 months and 9 months.
224174028|NCT03200418|OTHER|Standard hydrocolloid adhesive|This patch is made of standard hydrocolloid adhesive
224174029|NCT03200418|OTHER|P-4|This patch is made of new adhesive
224174030|NCT03200418|OTHER|P-15|This patch is made of new adhesive
224174031|NCT03200418|OTHER|P-16|This patch is made of new adhesive
224174032|NCT03600311|OTHER|Caloric Restriction|Participants will consume 15 kcal/kg FFM/day.
224174033|NCT03600311|DIETARY_SUPPLEMENT|Post-Exercise Protein|Participants will ingest 30 g of protein following exercise.
223485312|NCT06737380|DIAGNOSTIC_TEST|SLE activity evaluation|SLE status will be assessed using the Safety of Estrogens in Lupus Erythematosus National Assessment- SLE Disease Activity Index (SLEDAI 2K scale).SLE activity will also be assessed using British Isles Lupus Assessment Group (BILAG), physician global and participant global assessment allowing use of the Systemic Lupus Responder Index (SRI 4) and the BILAG-based Composite Lupus Assessment (BICLA) instruments to assess clinical response.
223485313|NCT06737380|DIAGNOSTIC_TEST|SLE biomarker profiling|"SLE biomarkers will be profiled at the study visit (Day 1) and at every subsequent follow up visit. For this purpose, urine and 10 ml blood will be collected.~Anti-ENA, Anti-dsDNA antibodies, total serum IgG levels, CBC, C3, C4, anti-nucleosome antibodies, erythrocyte sedimentation rate, CRP, protein/creatinine ratio in spot urine, 24-hour urine protein - Day 1 - Baseline and at end of study visit only; Mononuclear cell changes. This analysis includes lymphocyte subsets and innate immune cell subsets"
223485314|NCT06737380|DIAGNOSTIC_TEST|Cytokines and chemokine profiling|Samples will be analyzed for the following cytokines/chemokines: IFNγ, IL-6, IL-10, IL-18, TNFα, TGFβ1, CXCL10, CCL2, N-GAL, urine endothelin, KIM1. Serum and urine samples will be collected on Days 0, 28, 56, 140, 168, and early termination visit.
223586319|NCT06041698|OTHER|Planned Notification|Receive text notification
223586320|NCT06041698|OTHER|Survey Administration|Complete surveys
224174034|NCT03600311|OTHER|Energy Balance|Participants will consume 40 kcal/kg FFM/day.
223485315|NCT06737380|BIOLOGICAL|single dose of UC-MSCs|participants will be treated on Baseline Day 1 with a UC-MSCs product administered subcutaneously. Participants will be observed for 2 to 3 hours after end of study treatment and then followed up for safety assessments over the subsequent 6-month period.
223485316|NCT06737380|OTHER|PROMIS instruments|PROMIS Fatigue, PROMIS, Depression, PROMIS Pain prior to dosing and/or any other clinical assessments, on visits 1 (baseline, day 0), visit 5 (day 14), visit 6 (day 28), visit 11 (day 168) and early termination visit.
223586321|NCT06041698|BEHAVIORAL|Behavioral Intervention|Participate in TXT-Chatbot
223586322|NCT06041698|OTHER|Electronic Health Record Review|Ancillary studies
223586323|NCT06041698|OTHER|Interview|Ancillary studies
223586324|NCT06041698|OTHER|Survey Administration|Complete surveys
223586325|NCT06041698|OTHER|Planned Notification|Receive email notification
223586326|NCT06041698|BEHAVIORAL|Behavioral Intervention|Participate in MyChart/Patient Portal
223586327|NCT06041698|OTHER|Electronic Health Record Review|Ancillary studies
223586328|NCT06041698|OTHER|Interview|Ancillary studies
224174035|NCT03600311|DIETARY_SUPPLEMENT|Post-Exercise Carbohydrate|Participants will ingest 30 g of carbohydrate following exercise.
224174036|NCT03600311|DIETARY_SUPPLEMENT|Calcium and Vitamin D|Participants will be supplied Calcium and Vitamin D supplements throughout the study period matched to the CON condition.
224174037|NCT00082238|OTHER|Stable isotopes|Stable isotopes were used to quantify gluconeogenesis GNG, hepatic glucose production (HGP), and protein breakdown.
224174038|NCT06315322|DRUG|Brivaracetam Film-coated tablet|Drug: Brivaracetam Film-coated tablet Pharmaceutical form: Film-coated tablet Route of administration: Oral use Brivaracetam film-coated tablet \[10, 25 or 50 mg\] will be administered twice per day in equal doses.
224174039|NCT06315322|DRUG|Brivaracetam oral solution|Pharmaceutical form: Oral solution Route of administration: Oral use Brivaracetam oral solution \[10 mg/mL\]) will be administered twice per day in equal doses.
224174040|NCT04533360|DIAGNOSTIC_TEST|VITROS Anti-SARS-CoV-2 IgG test|The VITROS Anti-SARS-CoV-2 IgG test is a lateral flow immunoassay produced by Ortho-Clinical Diagnostics Inc.
224174041|NCT06193733|BIOLOGICAL|Autologous Dendritic Cell|Biological: Immunotherapy with dendritic cells
224174042|NCT00389805|DRUG|bortezomib|
224174043|NCT00389805|DRUG|pemetrexed disodium|
224174044|NCT00389805|GENETIC|gene expression analysis|
224174045|NCT00389805|GENETIC|mutation analysis|
224174046|NCT00389805|GENETIC|protein expression analysis|
224174047|NCT00389805|GENETIC|reverse transcriptase-polymerase chain reaction|
223485317|NCT02965651|BEHAVIORAL|ECA System|"The ECA system, named Gabby, included content pertaining to stress management, nutrition and physical activity as well as dialogue scripts and media such as meditations. The scripts included motivational interviewing dialogue: dialogue to simulate shared decision making interactions and additional longitudinal interaction using techniques such as goal setting, problem solving, tips, and homework. Gabby was available on a web browser through a username and secure password login."
223485318|NCT00001305|DRUG|Humatrope|Patients receive a subcutaneous injection.
223485319|NCT02811770|OTHER|kidney biopsy|
223485320|NCT03510065|DEVICE|Prevision®|One time Evaluation with documentation of one follow-up visit
223485321|NCT01235221|DRUG|BIIB041 (Fampridine-SR)|10 mg twice a day (BID) sustained-release (SR) tablets by mouth for up to 27 months (in addition to treatment in previous studies) or until the product is commercially available, whichever comes first. Doses of study treatment must be spaced at least 12 hours apart.
223485322|NCT05619133|DEVICE|PBM|"In this study, the health benefits of the addition of NIR to the light spectrum of a desk lamp already available in the market will be investigate; Ikea Ypeperlig, to which a module with high power Lumileds NIR-Leds will be attached with beam angle of 90 degrees. They will be attached in such a way that, when the lamp is installed in the right place, a 1sr beam that covers the users face, neck and hands and lower arms on the desk with the required intensity of 5mW/cm2 of NIR at the skin surface.~The device will be equipped with 3 sensors:~1. A distance sensor connected to the driver of the NIR-leds, such that when the user leans forward or backward, the intensity of the NIR is automatically adjusted such that the intensity on the skin remains 5mW/cm2 (see figure below).~2. a presence sensor~3. ambient vertical lux sensor by which amount of light that enters the users' eye will be measured since it is known that these have an effect sleep, mood and performance."
224174048|NCT00389805|OTHER|flow cytometry|
224174049|NCT00389805|OTHER|immunoenzyme technique|
224174050|NCT00389805|OTHER|immunohistochemistry staining method|
224174051|NCT01677676|BIOLOGICAL|FP-01.1|IM injection
224174052|NCT01677676|BIOLOGICAL|FP-01.1-Adjuvant|IM injection
223485323|NCT04877600|OTHER|dual task performance|dual task performance measurement
223485324|NCT04584788|DEVICE|Masimo O3 Regional Oximeter|Study sensors will be placed on somatic tissues. Readings will be taken from the tissues underneath the O3 sensors.
223485325|NCT04480528|OTHER|Blood Flow Restriction Training (BFRT)|A pressurized cuff is applied to the proximal thigh in order to partially occlude blood flow as the patient exercises.
224174053|NCT05111184|BEHAVIORAL|Education groupe|Education
224174054|NCT01315873|DRUG|Bendamustine|"On days 1 and 4 of each cycle, bendamustine is given at 90 mg/m\^2 after bortezomib . Patients will be dose reduced to 75 mg/m\^2, and then to 60 mg/m\^2 bendamustine on days 1 and 4 if ANC is not \>1 x 10\^9/L and platelets are not \>50 x 10\^9/L on day 1 of each cycle.~Patients will be treated until disease progression after at least one cycle of treatment."
224174055|NCT01315873|DRUG|Bortezomib|"On days 1 and 4 of each cycle, bortezomib is given first at 1.3 mg/m\^2 followed by bendamustine given at 90 mg/m\^2. Patients will be dose reduced to 75 mg/m\^2, and then to 60 mg/m\^2 bendamustine on days 1 and 4 if ANC is not \>1 x 10\^9/L and platelets are not \>50 x 10\^9/L on day 1 of each cycle.~Patients will be treated until disease progression after at least one cycle of treatment."
224174056|NCT02558452|DRUG|Tacrolimus once daily (Advagraf)|Antibody induction by antithymocyte Globulin (ATG) or Basiliximab possible but not mandatory
224174057|NCT05877495|BEHAVIORAL|Nutritional Education Intervention|A 14-session training created by the researchers by examining the literature and various guides. This training includes about, prevention food waste with kitchen activities, food safety, food security and waste control. The content of the intervention will be loaded soon.
224174058|NCT05223374|DEVICE|Canvas Dx|Canvas Dx is intended for use by healthcare providers as an aid in the diagnosis of autism spectrum disorder (ASD) for patients ages 18 months through 72 months who are at risk for developmental delay based on concerns of a parent, caregiver, or healthcare provider. The device is not intended for use as a stand-alone diagnostic device but as an adjunct to the diagnostic process. The device is for prescription use only (Rx only)
224174059|NCT04589221|BEHAVIORAL|Ad libitum energy intake|Investigate ad libitum energy intake according to degree of food processing and eating behaviour
224174060|NCT07007091|DRUG|Risankizumab|Subcutaneous (SC) Injection
224174061|NCT07007091|DRUG|Risankizumab|On-Body Injector (OBI)
224174062|NCT01321333|BIOLOGICAL|HuCNS-SC cells|single dose intramedullary transplantation of HuCNS-SC cells in the thoracic spinal cord
224174063|NCT01289028|DRUG|Nilotinib|
224174064|NCT02014285|PROCEDURE|Muscle Ultrasound and Muscle Sample|The muscles to undergo ultrasound will include the biceps brachii, wrist extensors, quadriceps, and tibialis anterior. A muscle sample will be taken from the rectus femoris.
224174065|NCT04276831|DEVICE|Laryngoscope McCoy|Subjects who fulfill inclusion criteria will be intubated using laryngoscope McCoy
224174066|NCT04276831|DEVICE|Laryngoscope Macintosh|Subjects who fulfill inclusion criteria will be intubated using laryngoscope Macintosh
224174067|NCT03208504|DEVICE|Nexus™ Aortic Arch Stent graft|surgical implantation of Nexus™ Aortic Arch Stent graft
224174068|NCT01657214|DRUG|SAR125844|"Pharmaceutical form:Concentrate for solution~Route of administration: intravenous"
224174069|NCT01709604|PROCEDURE|CVVH|Ultrafiltration at 35ml/h/Kg
224174070|NCT01709604|PROCEDURE|Standardized therapy regimens|"Standardized therapy regimens included the followings:~1. Remove all contaminated clothing~2. Gastric lavage~3. Receive activated charcoal as quickly as possible~4. Hemoperfusion with activated charcoal(160g)~5. Immunosuppression with methylprednisolone~6. Antioxidants (glutathione,1.2 gram iv twice a day)~7. Supportive care"
224174071|NCT00382655|PROCEDURE|Education and referral|
224174072|NCT05254587|DEVICE|IOLMASTER 700 TK|4 different intraocular lens (IOL) calculation methods (Haigis TK, ASCRS calculator, Barrett True K Classic K, Barrett True K TK) will be performed using the preoperative biometry and post operative refraction data.
224174073|NCT03515616|DIAGNOSTIC_TEST|TP us in labour|TP US will be made to pregnant lady in first stage of labour with OS and PC angel measurements
223485326|NCT04480528|OTHER|Sham Blood Flow Restriction Training (Sham BFRT)|A minimally pressurized cuff is applied to the proximal thigh in order to mimic the active blood flow restriction unit as the patient exercises.
223485327|NCT06327100|DRUG|Ruxolitinib|Given by PO
223485328|NCT06327100|DRUG|Tasquinimod|Given by PO
223485329|NCT06776510|DRUG|nicotinamide adenine dinucleotid/nicotinamide mononucleotide|"Drug: intravenous nicotinamide adenine dinucleotide (Coenzyme I for Injection) administration This study adopts a prospective, single arm, open design method. Twenty subjects were enrolled in the study and were treated with nicotinamide adenine dinucleotide (100mg/d) for 1 week.~Drug: oral nicotinamide mononucleotide administration This study adopts a prospective, single arm, open design method. Twenty subjects were enrolled in the study and were treated with nicotinamide mononucleotide 450mg BID for 2 weeks.~The first stage is the main research stage (d0-w2), which is the core treatment period. The aim is to observe the safety and efficacy during treatment.~The second stage (w2-w8) is the stage of withdrawal from the visit, mainly to observe the safety and continuous efficacy after treatment."
223485330|NCT01509105|BIOLOGICAL|13-valent pneumococcal vaccine|0.5mL IM (Intramuscular administration) as per recommended schedule
223485331|NCT05595460|DRUG|RYZ101 Dose Level 1|Dose Level 1
223485332|NCT05595460|DRUG|RYZ101 Dose Level 2|Dose Level 2
223485333|NCT05595460|DRUG|RYZ101 Dose Level 3|Dose Level 3
223485334|NCT05595460|DRUG|RYZ101 Dose Level -1|Dose Level -1
223485335|NCT05595460|DRUG|Atezolizumab|Atezolizumab
223485336|NCT05595460|DRUG|Carboplatin|Carboplatin
223485337|NCT05595460|DRUG|Etoposide|Etoposide
224174074|NCT05261594|DIETARY_SUPPLEMENT|Caffeine|Caffeine capsule 150 mg, oral intake
224174075|NCT05261594|DRUG|Placebo|Placebo capsule, oral intake
224174076|NCT06090929|DEVICE|STN-DBS|STN-DBS was implanted according normal process
224174077|NCT02980991|DRUG|Pemetrexed|Two cycles of pemetrexed 500mg/m2 day 1, 21 days per cycle for patients before surgery
223485338|NCT03687359|OTHER|Standard of care|Treatment as per standard practice
223485339|NCT05019430|DRUG|Cocaine|The pharmacodynamic effects of cocaine will be determined during maintenance on placebo and zolmitriptan.
223485340|NCT05019430|DRUG|Placebo oral capsule|The pharmacodynamic effects of placebo will be determined.
223485341|NCT05019430|DRUG|Zolmitriptan|The pharmacodynamic effects of zolmitriptan maintenance will be determined.
223485342|NCT05708521|DRUG|Personalization of dose and frequency and instituting a tapering protocol of hydromorphone post-orthognathic surgery|POP participants will be given a personalized opioid prescription with a tapering protocol based on their last inpatient 24-hour usage of opioids, obtained from the nursing medication administration record. Should a participant stay in the hospital for less than 24 hours (e.g. patient had an early discharge at 18 hours), the 24-hour in-patient opioid usage would be extrapolated from their total amount and frequency of opioid use. The participant will be provided with an instruction card with suggestions on how much opioid to take at various time points following discharge to safely taper their medication.
223745226|NCT01581307|DRUG|FOLFOX7 (Folinic acid, 5-Fluorouracil, and Oxaliplatin)|The usual treatment if gemcitabine chemotherapy has failed is chemotherapy with a drug combination called FOLFOX (folinic acid, 5-FU and oxaliplatin) given through a vein every 2 weeks for 6-10 cycles. Participants will receive this treatment.
224174078|NCT02980991|DRUG|Cisplatin|Two cycles of cisplatin 75mg/m2 day 1 (or 25mg/m2 day 1-3), 21 days per cycle for patients before surgery
224174079|NCT01518634|DRUG|Imipramine treatment|Two-week of wash-out, one week of 10 mg study drug, 10 weeks of 25-75 mg study drug, four weeks of phasing-out and finaly two weeks after ther last dose of study drug to monito adverse events.
224174080|NCT01518634|DRUG|Placebo|Two-week of wash-out, one week of 10 mg study drug, 10 weeks of 25-75 mg study drug, four weeks of phasing-out and finaly two weeks after ther last dose of study drug to monito adverse events.
224174081|NCT04143789|DRUG|AP-002|Dose escalation
224174082|NCT02120469|DRUG|everolimus|Given PO
224174083|NCT02120469|DRUG|eribulin mesylate|Given IV
223485343|NCT05708521|DRUG|Standardized dose and frequency of hydromorphone with no tapering post-orthognathic surgery|SOP participants will be given a standardized dose of hydromorphone (2-4mg orally every 6 hours), and a total amount of 40mg. No further information is provided to them with regards to their pain medication and to tapering.
223485344|NCT06433310|DRUG|L-Phenylalanine 500 mg Veg Capsule product|500 mg Veg Capsule product
223485345|NCT05063916|DRUG|AK104|Given By IV
223485346|NCT06830590|PROCEDURE|Molecular characterisation|All patients treated by surgery were included without any neoadjuvant therapy
223485347|NCT02818257|OTHER|Strip A|Adhesive strip A
223485348|NCT02818257|OTHER|Strip B|Adhesive strip B
223485349|NCT02818257|OTHER|Strip C|Adhesive strip C
223485350|NCT03105401|OTHER|Assessment of hallucinations in Parkinson's disease|Patients participating to the study will be asked to answer a semi-structured questionnaire searching for hallucinations of all modalities, minor psychotic symptoms and delusions. Psychometric scales will be assessed to search for depressive symptoms, cognitive impairment and specific personality characteristics.
224174084|NCT02120469|OTHER|pharmacological study|Correlative studies
224174085|NCT02120469|OTHER|laboratory biomarker analysis|Optional correlative studies
224174086|NCT01092949|DEVICE|MRI|MRI, 45 minutes
223485351|NCT06111625|DRUG|blinatumomab|Blinatumomab was administered via a peripherally inserted central catheter (PICC) with an initial dosage of 8 μg/day. The dosage gradually escalated to 28 μg/day, with a total dose of 175 μg, infused over 5 to 10 days. To mitigate the risk of cytokine release syndrome (CRS), dexamethasone at a dose of 20 mg was administered 12 hours before the onset of blinatumomab infusion.
223485352|NCT03115710|DIAGNOSTIC_TEST|Rotating Scheimpflug camera (Pentacam HR)|One visit to Ophthalmology Department is required from participant. Parents or legal guardians must attend with their child. The interview and test during visit take approximately 15 minutes. Interview includes filling out a questionnaire about risk factors of the disease and double check on understanding the consent form. The child will sit in front of the instrument (Pentacam HR Scheimpflug imaging system). The rotational measuring procedure generates Scheimpflug images in three dimensions. The images taken during the examination are digitalized, and all image data are transferred to the computer. It calculates a 3D virtual model of the anterior eye segment, from which all additional information is derived.
223485353|NCT02462096|DEVICE|ReLeaf|The ReLeaf catheter is expected to enable a physician to create tissue leaflets that, in turn, generate a valve effect in the deep veins of the legs.
223485354|NCT06096870|DRUG|Enzalutamide|Enzalutamide at 160 mg once daily on every day of the cycle (every 28 days)
223485355|NCT06096870|DRUG|PDS01ADC|PDS01ADC at 12.0 microgram/kg by subcutaneous injection (every 28 days)
223485356|NCT06394882|BEHAVIORAL|Family-Centered Healthy Lifestyle Program (FamCe-HLP)|A multidisciplinary-led healthy lifestyle program will provide a seven-month program comprising two primary therapies: a three-month intensive behavioral therapy (IBT) and a four-month maintenance behavioral therapy (MBT). The program will run on scheduled days using one of the center's offices for the IBT and the center's seminar room for the MBT.
223485357|NCT05306340|DRUG|Giredestrant|Participants will receive treatment with giredestrant 30 milligrams (mg) orally once a day (QD) on Days 1-28 of each 28-day cycle until unacceptable toxicity or disease progression as determined by the investigator according to Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST v1.1).
223485358|NCT05306340|DRUG|Exemestane|If exemestane is chosen as the physician's choice of endocrine therapy, the participant will receive exemestane at a dose of 25 mg orally once a day (QD) on Days 1-28 of each 28-day cycle or as per local label, until unacceptable toxicity or disease progression as determined by investigator according to RECIST v1.1.
223485359|NCT05306340|DRUG|Fulvestrant|If fulvestrant is chosen as the physician's choice of endocrine therapy, the participant will receive fulvestrant in the clinic at a dose of 500 mg intramuscularly on Day 1 and Day 15 of Cycle 1, then Day 1 of each cycle thereafter (1 cycle is 28 days) or as per local prescribing information, until unacceptable toxicity or disease progression as determined by investigator according to RECIST v1.1.
223485360|NCT05306340|DRUG|Tamoxifen|If tamoxifen is chosen as the physician's choice of endocrine therapy, the participant will receive tamoxifen at a dose of 20 mg orally QD on Days 1-28 of each 28-day cycle or as per local prescribing information, until unacceptable toxicity or disease progression as determined by investigator according to RECIST v1.1.
223485361|NCT05306340|DRUG|Everolimus|Participants will receive treatment with everolimus 10 mg orally QD during each 28-day cycle until unacceptable toxicity or disease progression as determined by the investigator according to RECIST v1.1.
223485362|NCT05306340|DRUG|LHRH Agonist|Only premenopausal/perimenopausal female participants and male participants will receive a luteinizing hormone-releasing hormone (LHRH) agonist on Day 1 of each 28-day treatment cycle. The investigator will determine and supply the appropriate LHRH agonist locally approved for use in breast cancer.
223485363|NCT05306340|DRUG|Dexamethasone Mouth Rinse|A compounded alcohol-free mouthwash of dexamethasone (0.5 mg in 5 mL) will be supplied, where feasible. It is strongly recommended for prophylaxis or treatment of stomatitis/mucositis. Participants should use the alcohol-free mouthwash of dexamethasone four times QD for 8 weeks started concurrently with study treatment, and use it reactively thereafter with the first appearance of symptoms.
223485364|NCT00328536|DRUG|Omacor|
223485365|NCT00145067|BEHAVIORAL|Disease Management Assessment|
223586329|NCT05873855|BEHAVIORAL|Para ti, para mi, para nosotros (P3)|From day 1 to day 180 (i.e., entire 6-month duration, post baseline) of the pilot trial, participants randomized to the intervention arm will have access to use the five modules as directed. The P3 intervention includes modules focused on topics of: HIV/STI prevention, sexual agreements, communication/decision-making skills, strengthening relationships and creating goals, and physical activity.
223586330|NCT05873855|BEHAVIORAL|Waitlist Control Para ti, para mi, para nosotros (P3)|From day 91 to day 180 (i.e., starting after 3-month assessment) of the pilot trial, participants randomized to the waitlist control condition will have access to use the five modules as directed. The P3 intervention includes modules focused on topics of: HIV/STI prevention, sexual agreements, communication/decision-making skills, strengthening relationships and creating goals, and physical activity.
224174087|NCT04469257|BEHAVIORAL|Sunbathing|the individuals were exposed directly to sun in the nursing home garden on open and sunny days without sunscreen for five days a week for a month with an average of 21.0 ± 5.0 min (min 15 min - max 30 min). About 30-35% of their bodies (hand, face, neck, forearm open up to elbows and legs open up to the knee caps) were open.
224174088|NCT05570357|DIETARY_SUPPLEMENT|Berberine+Cinnamon (TDS)|The supplements contains 400 mg Berberine, and 200 mg Cinnamon extract
224174089|NCT05570357|OTHER|Placebo (TDS)|Placebo contains Maltodexterin
224174090|NCT04369872|PROCEDURE|Microwave ablation|Microwave ablation of lung lesion using Solero Microwave Tissue Ablation system.
224174091|NCT00384449|DRUG|Ranibizumab|Consented, enrolled subjects will receive open-label intravitreal injections of 0.5 mg ranibizumab administered once a month for 3 months
224174092|NCT01271127|RADIATION|CT coronary angiography|patient will undergo one CT coronary angiography
223485366|NCT01212250|DRUG|carvedilol|Carvedilol will be administered orally at a start dose of 3.125 mg twice daily. After 1 week, this will increased if systolic blood pressure does not fall below 90 mm Hg. The patient will receive the maximum tolerated dose of carvedilol with a maximum of 6.25 BD.
224174093|NCT01100762|DEVICE|Cranial Electric Stimulation (CES)|We will follow the procedure described by several investigators as safe and effective. The participant will sit on a standard chair. Two commercially available surface electrodes will be embedded in an elastic head cup. Each electrode will be covered with a water soaked absorbent fabric. One positive (+) electrode will be placed over the primary motor cortex (M1) and pre-motor areas. One negative (-) electrode will be placed over the skin overlying the contra lateral supra-orbital region. The electrodes will be connected via 2 leads to a battery powered direct current stimulator. The stimulator will be programmed to deliver 0.975mA (peak 4mA) over 20 minutes.
224174094|NCT01100762|DEVICE|Treadmill|The participant will walk on a treadmill for 20 minutes at the individually self-selected velocity determined at baseline.
224174095|NCT01100762|DEVICE|CES and Treadmill|Participants will have a combined session with CES while walking on the treadmill for 20 minutes at the individually self-selected velocity determined at baseline.
224174096|NCT00017927|DRUG|Pegvisomant|
223586331|NCT04236791|OTHER|ENDS (vaporizer/e-cig) and smoking cessation counseling|Participants in the intervention group will receive an ENDS and nicotine-containing e-liquids, which they will be allowed to use ad libitum. Additionally, they will receive smoking cessation counseling. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 60-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6, 12, 24 and 60 months, participants will be asked to come to a clinical visit.
223586332|NCT04236791|OTHER|Smoking cessation counseling|Participants in the control group will receive smoking cessation counseling only. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 60-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6, 12, 24 and 60 months, participants will be asked to come to a clinical visit.
224174097|NCT01623856|OTHER|laboratory biomarker analysis|Correlative studies
224174098|NCT02062970|BIOLOGICAL|blood draw|
224174099|NCT01167088|DRUG|Mitoquinone mesylate|2 tablets to be taken daily upon wakening, with a glass of water and at least one hour before food.
224174100|NCT01167088|DRUG|Placebo|Placebo
224174101|NCT06102928|DRUG|Combined therapy of anlotinib and aumolertinib|Participants were treated with anlotinib and aumolertinib.Aumolertinib mesylate tablets are administered 110 mg orally once a day,and anlotinib hydrochloride capsules were given 12 mg once a day, taken for 2 weeks and then discontinued for 1 week, with a treatment cycle every 21 days. If grade 3 or above treatment-related toxicity occurs, anlotinib can be reduced to 10 mg or 8 mg once daily.
224174102|NCT01958268|PROCEDURE|Pretest and validation of a translated questionnaire|
224174103|NCT02141529|PROCEDURE|Unipolar pulsed radiofrequency thermocoagulation|Unipolar pulsed radiofrequency thermocoagulation, intraarticular administration into the knee joint
224174104|NCT02141529|PROCEDURE|Bipolar pulsed radiofrequency thermocoagulation|Bipolar pulsed radiofrequency thermocoagulation, intraarticular administration into the knee joint
224174105|NCT03104829|BEHAVIORAL|Motivational interviewing|
224174106|NCT03104829|DRUG|DSME participants in this arm will receive standard care for diabetes (DSME) at the beginning of the study and 3 months later|
224174107|NCT02597972|PROCEDURE|Fracture repair|
224174108|NCT02597972|PROCEDURE|Fracture repair with joint replacement|
224174109|NCT04930172|DEVICE|Steerable introducers|endografts via total transfemoral approach for visceral vessels cannulation
224174110|NCT06124352|DIAGNOSTIC_TEST|Gross Motor Function Measurement - 66 (GMFM- 66)|GMFM-66 was performed for participants established on self-independent motion, with importance on allocations, and motion. The emphasis is to detect the grade that greatest reveals the current skills and disabilities of the child regarding motor functions. The new Gross Motor Ability Estimator (GMAE) scoring method for test-retest reliability data showed a high level of stability of the GMFM-66 over time (ICC=0.9932) that did not differ since the original GMFM 88-item test-retest reliability
224174111|NCT06124352|DIAGNOSTIC_TEST|Bruininks- Oseretsky Motor Proficiency|The BOT-2 are scale used to evaluate fine and gross motion skill development. It's used to classify children with movement control limitation. The test is appropriate for those aged 4 to 21 years. The interrater reliability ranging from 0.92 to 0.99 and construct validity. r = 0.78 (0.56 - 0.86) (test grades / chronological age)
224174112|NCT06124352|DIAGNOSTIC_TEST|the Peabody Developmental Motor Scale - Second Edition (PDMS-2|The PDMS-2 is a consistent test that evaluates a child's movement skills. It is norm-referenced and consists of three composites: Fine Motor (FM), Gross Motor (GM), and Total movement composites (TM). GM composite incorporates 151 points from four sub-tests: reflexes, stationary, locomotion, and object manipulation. A 3-point scale scored for each item, with 2 being the highest score. Definite criterion for score of 2 is given when the child achieves the item, 1 is given when the behavior is emerging but not fully met, and 0 is given when the child cannot achieve the point. The highest raw scores of the sub-tests range from 16 to 198. The test-retest reliability of PDMS-2 was found to be r = 0.85 \[24, 25\].
224174113|NCT02077036|DEVICE|Kinetic Oscillation Stimulation Device|
224174114|NCT02077036|DEVICE|Kinetic Oscillation Stimulation Device in placebo mode|
224174115|NCT03345173|DRUG|CI-581-a|Two infusions in the context of naltrexone induction protocol.
224174116|NCT03345173|DRUG|CI-581-b|Two infusions in the context of naltrexone induction protocol.
223485367|NCT01212250|DRUG|Placebo|The placebo tablets will be identical to the carvedilol tablets. First the patients will receive placebo in the dose of 1 BD. Then depending on his tolerance it will be increased to a maximum of 2 BD.
224174117|NCT00250029|DRUG|Oxaliplatin|"Oxaliplatin will be administered at the dose of 130 mg/m2 given as a 2 hour intravenous infusion on day 1 of a three week cycle, prior to the 1st dose of capecitabine. 5-HT3 antagonists with or without dexamethasone premedication are strongly recommended. Oxaliplatin may be infused either through a peripheral vein or a central venous line. The infusion lines must be adequately flushed with 5% dextrose solution (D5W) between oxaliplatin infusion \& the administration of any other drug.~Capecitabine is to be administered orally within 30 mins. after the end of a meal. Tablets should be swallowed with approximately 200 mL water (not fruit juices). The first dose of each cycle will be administered as the evening dose on day 1 \& the last dose of each cycle is scheduled the morning of day 15, followed by a 7 day rest period. This provides for a total of 28 single doses per cycle over 15 calendar days."
224174118|NCT04207125|BEHAVIORAL|Multilevel psychotherapeutic intervention programme|"Part 1: Educational Training and Mentoring After transferring the patient from the intensive care unit to the transplant surgery unit, nurses are planning a nursing diagnosis called therapy recommendations and coping strategies, effective implementation. 3 days after the transfer, nurses start to give information twice a day (morning and evening) about the medication, which the patients are currently taking. The nurse is also handing out a folder, which contains information about the multilevel intervention programme.~Individual Treatment Approach Patients, who seem to be non-adherent during their outpatient follow-ups, are contacted through the co-investigators for a one-to-one session. The content of this session is to promote patients engagement in self-management of their chronic illness. The goal of the treatment is to improve the individual's ability to manage symptoms, treatments, physical and psychosocial consequences and lifestyle changes."
224174119|NCT03605225|DEVICE|mobile cellphone application test|Placement of cellphone on the patient´s hand and recording accelerometric data during elicited muscular contractions.
224174120|NCT01736930|DEVICE|Pump suspension|The study laptop will communicate to the pump causing suspension based on output from the algorithm which predicts hypoglycemia based on the continuous glucose sensor trend.
224174121|NCT06198504|PROCEDURE|Protocol using end-tidal oxygen monitoring during preoxygenation before intubation|"According to previous studies a target of EtO2 ≥ 90% is proposed to trigger RSI and intubation. If this target is judged impossible to achieve and/or there is an imperative need to interrupt the pre-oxygenation phase, the operator is free to continue the procedure according to current recommendations.~Before the start of the inclusions, a training session on the use of the module will be organized with a reminder of the recommendations.~During the procedure, preoxygenation modalities and duration, achieved EtO2 level, conduction of the induction and intubation, minimum SpO2 and occurrence of complications will be recorded.~The procedure will stop ten minutes after completion of the orotracheal intubation procedure (defined as inflation of the balloon,clinical and capnography control)."
224174122|NCT05384795|OTHER|Lung ultrasound|Lung atelectasis score
224174123|NCT01908855|BEHAVIORAL|Cognitive-behavioral therapy + emotion regulation training for patients with multiple somatoform symptoms|"Cognitive-behavioral therapy + emotion regulation training for patients with multiple somatoform symptoms:~20 weekly sessions individual therapy (à 50) minutes"
224174124|NCT01908855|BEHAVIORAL|Cognitive-behavioral therapy for patients with multiple somatoform symptoms|"Cognitive-behavioral therapy for patients with multiple somatoform symptoms:~20 weekly sessions individual therapy (à 50) minutes"
224174125|NCT00456924|DRUG|VA2914|
224174126|NCT06022224|BIOLOGICAL|hAd5-S-Fusion+N-ETSD|Clear and colorless liquid. Each vaccine is supplied in a 2-mL vial containing 1.0 mL of extractable vaccine at a concentration of 1 × 10\^11 viral particles/mL.
224174127|NCT06022224|BIOLOGICAL|Placebo (0.9% (w/v) saline)|Clear and colorless liquid.
224174128|NCT01183481|DRUG|Aprepitant|Patients will be given a single dose of Aprepitant 125 mg on Day 0 (at least one hour before on the day of RT) followed by 80 mg of Aprepitant once daily in the mornings on Days 1 and 2 following the radiation treatment.
224174129|NCT01183481|RADIATION|Palliative radiation therapy|Moderately emetogenic palliative radiation therapy (RT) will be administered to all patients on the study.
223485368|NCT03764124|DIAGNOSTIC_TEST|PET/CT imaging|The PET/CT procedure was performed using cross-calibrated Philips Gemini TF Big Bore or TF 16 PET/CT systems (Philips Medical Systems, Cleveland, OH) at 201 18 minutes following intravenous injection of a mean dose of 3.2 0.2 MBq/kg of body weight of 18 F-FDG. A low-dose helical CT (5-mm slice thickness, 120-kV tube voltage, and 40-mAs tube current-time product) centered to the renal transplant was performed, followed by PET scanning with two bed positions, each lasting 240 seconds. Images were reconstructed using iterative list mode time-of-flight algorithms. Corrections for attenuation, dead time and random and scatter events were applied.
223485369|NCT03595397|DRUG|Bupivacaine|20 patients will receive mid-thoracic epidural analgesia with a loading dose of 8 ml of 0.125% bupivacaine, followed by continuous infusion of 8 ml/hour
223485370|NCT03595397|DRUG|Magnesium Sulfate|20 patients will receive mid-thoracic epidural analgesia with a loading dose of 8 ml mixture of 0.125% bupivacaine and 30 mg/kg Magnesium Sulfate, followed by continuous infusion of 8 ml/hour mixture of 0.125% bupivacaine and 20% Magnesium sulfate
223586333|NCT05469139|DIAGNOSTIC_TEST|Portable MRI acquisition|Patients on ECMO will undergo a portable MRI of the brain
224174130|NCT01183481|DRUG|Granisetron|Patients will be given a single dose of both Granisetron 2 mg orally on Day 0 (at least one hour before on the day of RT).
223586334|NCT00331188|DRUG|Sanvar® (vapreotide)|
223586335|NCT04806802|DEVICE|APIOC Sphere and APIOC Astigmatism|Single Vision Contact Lenses
223586336|NCT03086902|DEVICE|Radiofrequency Ablation Catheter|Ablation of PVC with RF energy
223586337|NCT03086902|DEVICE|Cryo Ablation catheter|Ablation pf PVC with Cryo enerygy
223586338|NCT00278616|BIOLOGICAL|Stem Cell Transplantation|Autologous Stem Cell Transplantation
223586339|NCT03105349|DRUG|elbasvir/grazoprevir|16 weeks treatment
223586340|NCT03105349|DRUG|Sofosbuvir|16 weeks treatment
223586341|NCT03105349|DRUG|Ribavirin|16 weeks treatment
223586342|NCT06011369|PROCEDURE|Fluorescence in thyroid surgery|Fluorescence in thyroid surgery
223586343|NCT02908789|RADIATION|Antimicrobial photodynamic therapy (aPDT)|Selective caries removal + Antimicrobial photodynamic therapy (aPDT) is an effective low potency laser that involves the activation of a photosensitizer( 0.01% methylene blue ) by a visible light source that creates chemical reactions, producing cytotoxic reactive oxygen species and causing oxidative stress and inactivation of pathogenic microorganisms + tooth restauration
224174131|NCT00431223|BEHAVIORAL|Cognitive remediation therapy|36 sessions of computerized cognitive skills training over a 12 week duration. 7 patients were assigned to cognitive remediation therapy or CRT Group.
223485371|NCT03595397|DRUG|Fentanyl|20 patients will receive mid-thoracic epidural analgesia with a loading dose of 8 ml of 0.125 bupivacaine and 2 mcg/ml fentanyl, followed by continuous infusion of 8 ml/hour.
223485372|NCT03595397|PROCEDURE|Thoracic epidural|All patients will receive mid-thoracic epidural analgesia
223485373|NCT04092075|DEVICE|RF-utilizing powered toothbrush|RF-utilizing Powered toothbrush
223485374|NCT04092075|DEVICE|Control placebo with no RF|Placebo control, toothbrush with no RF
223485375|NCT03233256|PROCEDURE|Feasibility of measuring 2H:1H and 18O:16O in saliva and breath.|The investigators propose to demonstrate the feasibility of measuring 2H:1H and 18O:16O in saliva and breath. The natural abundances of 2H:1H and 18O:16O of urine, saliva, and breath samples will be determined from samples obtained simultaneously from 50 relatively healthy human subjects. We will also measure 2H:1H and 18O:16O enrichments in urine, saliva, and breath of 10 relatively healthy human subjects obtained after consuming a standard DLW dose and compare the estimates of TDEE using these different matrices.
223485376|NCT06422871|DEVICE|HeRO® Graft System or Super HeRO® System|Treatment attempted with the HeRO® or Super HeRO® device.
223485377|NCT06832891|OTHER|Survey|Patients complete survey
223485378|NCT01224704|OTHER|Hypertonic saline infusion|Three percent saline (0.1ml/kg of the lean mass/min) will be infused for 120 minutes.
223485379|NCT01224704|OTHER|Water deprivation|24 hour water deprivation
223485380|NCT05359237|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
223485381|NCT05359237|DRUG|Vincristine|Given IV per standard of care
223485382|NCT05395039|OTHER|VCHIPS|Participants in this group will have the opportunity to receive virtual visits with the patient during the hospital stay, led by a study nurse.
223586344|NCT02908789|OTHER|Without Antimicrobial phothodynamic therapy|Selective caries removal + tooth restauration
223586345|NCT01286077|DRUG|bortezomib|Each cycle will consist of 5 weeks treatment. Subjects in the treatment group will receive: Velcade® 1.6 mg/m2 as an intravenous bolus injection on Days 1, 8, 15, and 22 of each cycle followed by a 13-day rest period (Days 23 to 35) Cycle will be repeated on Day 36. Subjects in the treatment group will receive up to 4 treatment cycles, unless they experience either unacceptable toxicity or if the subject requests to withdraw from the study.
223586346|NCT02331498|DRUG|Pazopanib|Study drug Pazopanib will be administered once tumoral evaluation has been performed and after Stupp Protocol (TMZ + Radiation) realisation.
223586347|NCT02237638|BIOLOGICAL|hVEGF26-104/RFASE|Three intramuscular injections on days 0, 14 and 28, followed by an observational period of 6 weeks. If hererafter VEGF is not (or no longer) neutralized in serum and there is no sign of disease progression, another booster vaccination can be given. This booster can be repeated until disease progression, death or withdrawal from the study.
224174132|NCT01725295|OTHER|NST|A form of physical therapy
223485383|NCT05666973|PROCEDURE|Open Mesh Hernioplasty|"* Steps of surgery:~  * Injection Ceftriaxone 50 mg/kg iv stat dose will be given pre-operatively~ * Incision:~* Incision given over medial 3/5 and 2.5 cms above and parallel to inguinal ligament extending from pubic tubercle upto 1 cm lateral to mid point of inguinal ligament.~  * bleeding controlled by forcep coagulation.~ * Cut the subcutaneous tissues,external oblique aponeurosis opened in layers~ * Nerve Iliohypogastric \& ilioinguinal will be preserved (by taking aside from the field)~ * Intra-operative Injection Tramadol(50 mg) and ondansetron(4 mg) iv stat dose given~ * Sac ligated with Polygalactin 2-0 suture.~ * Lichtenstein method of repair~* Mesh type: large pore polypropylene mesh~* Mesh size: 3 x 6 inches(7.5 x 15 cms)~* Mesh Fixation: polypropylene 2-0~  * External oblique closure~ * Skin closure: Ethilon 2 - 0 suture"
223586348|NCT00015951|BIOLOGICAL|bevacizumab|
223485384|NCT03095287|BIOLOGICAL|Alphanate|Bolus IV injection.
223485385|NCT04118400|PROCEDURE|NIV-NAVA|NAVA mode during Non-invasive ventilation
223485386|NCT04118400|PROCEDURE|Nasal CPAP or NIMV mode|Nasal CPAP or NIMV mode during Non-invasive ventilation
223485387|NCT00055237|BIOLOGICAL|Bevacizumab|15 mg/kg day intravenously on day 1, day 8, then every 3 weeks.
223485388|NCT03276299|OTHER|six minute walking test|six minute walking test
223485389|NCT03276299|OTHER|six minute walking test|six minute walking test with encouragement
223485390|NCT02625584|BEHAVIORAL|Reading Together - Pausing for Reading|
223485391|NCT02625584|BEHAVIORAL|Reading Together - Dialogic Reading|
223485392|NCT02625584|BEHAVIORAL|Reading Together - Shared Reading Control|
223485393|NCT03829176|GENETIC|Whole Genome Sequencing|Participants in this arm will have their sample analyzed by whole genome sequencing (WGS), and a report will be included in their medical record. Analysis will be phenotype-driven (gene list will be curated based on primary indication for testing and other available medical history information), and may include genes on ACMG 59 list if participant elects for these results. This report will include pathogenic, likely pathogenic, and suspicious VUS results identified in the genes analyzed.
223586349|NCT00015951|DRUG|cytarabine|
223586350|NCT00015951|DRUG|mitoxantrone hydrochloride|
223586351|NCT01841255|DEVICE|Mouthpiece (Umox)|Device used to perform preoxygenation in the operating room context
223586352|NCT01841255|DEVICE|facemask|
223586353|NCT04105868|OTHER|Neurofeedback|Participants will receive feedback during a computerized task that is based on their own visuocortical activity evoked by attention to negative distractors and task-relevant stimuli on the computer screen.
223586354|NCT03079219|DRUG|Experimental drug: Aprepitant|Day 1: 125mg QD; Day 2 to Day 3: 80mg QD
224174133|NCT01725295|OTHER|Hydrotherapy|
224174134|NCT04454749|DIAGNOSTIC_TEST|Blood test|Mesurement of E2, P4, LH, FSH hormones
224174135|NCT04454749|DIAGNOSTIC_TEST|Ultrasound|Follicular measurement and endometrium measurement
224174136|NCT00122070|DRUG|Quetiapine Fumarate|Dosage can vary from 50 to 150 mg at PI's discretion
224174137|NCT01759628|DRUG|H.pylori eradication|The regimen consists of Omeprazole (20 mg/BD)+ Amoxicillin (1 g/day)+ Bismuth subcitrate (240 mg/BD)+ Azithromycin (500 mg/BD)for two weeks
224174138|NCT04396327|DRUG|SM-1|diphenhydramine, zolpidem and lorazepam
224174139|NCT04396327|DRUG|Active Comparator|diphenhydramine and lorazepam
224174140|NCT04851327|BEHAVIORAL|High Energy preload|Tests the extent to which participants reduce their intake at a meal following ingestion of a high energy preload drink
224174141|NCT04851327|BEHAVIORAL|Low energy preload|Tests the amount participants eat at a meal following ingestion of a low energy preload drink
224174142|NCT04851327|BEHAVIORAL|Test meal|Test meal to follow low or high energy preload
224174143|NCT02828189|OTHER|Physical Exercise|The patients were instructed to perform autonomous physical exercise program based preferences (progressive march on flat ground, dancing, cycling, etc.). They will receive written information. The program is 9 weeks with a frequency of 3 days per week and sessions about 50 minutes long.
224174144|NCT02828189|BEHAVIORAL|Therapeutic Education|Individual Therapeutic Education about healthy habits and exercise on breast cancer.
224174145|NCT02828189|OTHER|Therapeutic exercise-Physiotherapy|"1. Cardiovascular exercise~2. Individualized progressive strength and resistance exercises of principals muscle groups of the lower limbs, upper limbs and trunk.~3. Flexibilization exercises"
224174146|NCT04114773|OTHER|SCARF (Survivors of Cardiac Arrest Rehabilitation focused on Fatigue)|"The intervention will be delivered by a multidisciplinary team. There will be individual testing and feedback on physical capacity and cognitive ability. Group sessions will include education on the consequences of cardiac arrest, promotion of techniques to ameliorate these consequences, for example, increasing physical activity or energy conservation. Additional sessions will cover psychological reactions; family life; work life; intimacy; and existential considerations.~Participants will have a course information book with a physical activity training diary and problem-solving therapy worksheets to use at home for 12-weeks. They will receive one phone call from the clinical team during this period. The 2-day return stay will revisit the subjects from the first 5-day stay.~Participating survivors who have a relative that wishes to attend will be included in all the group sessions and individual feedback but will not take part in the physical capacity or cognitive ability tests."
224174147|NCT03905525|DRUG|CFZ533|Biological
224174148|NCT03905525|OTHER|Placebo|liquid placebo for injections
224174149|NCT03973567|DRUG|selective serotonin reuptake inhibitor (SSRI) or serotonin noradrenaline reuptake inhibitor (SNRI) antidepressants|On the basis of routine treatment for 8-12 weeks, according to the characteristics of symptoms, a combination of SSRI or SNRI antidepressant drugs was given for 12 weeks.
224174150|NCT03973567|OTHER|conventional therapy|Anti-HP, acid suppression, gastrointestinal motility regulation, etc.
224174151|NCT03116841|DRUG|Vonoprazan|Vonoprazan 20 mg
223485394|NCT04980729|DEVICE|Acetabular reconstruction after tumor resection.|In the template-guided group (n = 10), a navigation template was designed and applied to assist acetabular reconstruction. In the traditional operation group (n = 14), the patients underwent the same surgery but without the navigation template. To compare the displacement of the hip rotation center before and after surgery between the two groups, an innovative method based on pelvic CT was developed and a validation group of cases was used to assess the effectiveness of this measurement approach. In the validation group (n = 12), patients undergoing periacetabular puncture or curettage without hip joint reconstruction were included. The displacements for the validation group were calculated and compared with 0 cm, the theoretical value. Subsequently, the displacements between the template-guided group and the traditional operation group were compared.
223485395|NCT02705170|PROCEDURE|index of microvascular resistance|Measurement of the index of microvascular resistance in the left anterior descending artery
223485396|NCT02545192|DEVICE|Low Field Magnetic Stimulation|The LFMS Device is an electromagnetic coil situated on a cylinder with an inside diameter of 13.2 inches. It produces weak electromagnetic fields at a frequency of about 1000Hz; the magnetic fields are less than 30 Gauss and the electric fields are up to 1.43 V/m. A fully detailed description of the electromagnetic field distribution and waveform has been presented in the IDE submission to the FDA (and determined to be a non-significant risk device).
223485397|NCT03426150|DRUG|CPP-ACP|The surfaces of specimens were pretreated with CPP-ACP for 3 min
223485398|NCT03426150|DRUG|Placebos|The surfaces of specimens were pretreated with deionized water for 3 min
223485399|NCT05422508|BIOLOGICAL|MG1111 (BARICELA)|0.5ml, single dose, subcutaneous injection
223485400|NCT05422508|BIOLOGICAL|VARIVAX|0.5ml, single dose, subcutaneous injection
224174152|NCT02591836|DRUG|Gemcabene|Gemcabene
224174153|NCT02591836|DRUG|Atorvastatin|Atorvastatin
224174154|NCT02591836|DRUG|Placebo|
224174155|NCT03001791|PROCEDURE|Excisional biopsy with Er:YAG laser|Excisional biopsy of fibrous hyperplasia in the buccal mucosa in local anesthesia with Er:YAG laser (Lite TouchTM, Synergon Dental Lasers, Light instruments Ltd., Yokneam Elite, Israel), λ = 2940nnm. Soft tissue biopsy mode with water cooling, frequency 35 Hz, pulse duration 250-390 µsec, pulse energy of 200 mJ, power 7 Watt . Cylindrical sapphire tip, 400 µm in diameter, without contact to the tissue.
224174156|NCT03001791|PROCEDURE|Excisional biopsy with CO2 laser|Excisional biopsy of fibrous hyperplasia in the buccal mucosa in local anesthesia with CO2 laser (Spectra DENTA Surgical Carbon Dioxide Laser, MAX Engineering Ltd., Gyeonggi-Do, Korea), λ = 10'600nnm. cf mode (frequency 140 Hz, pulse duration 400 µsec, pulse energy 33 mJ,a power 4.62 watts). Laser beam with a spot size of 0.2 mm, non-contact mode.
224174157|NCT03001791|PROCEDURE|Excisional biopsy with scalpel|Excisional biopsy of fibrous hyperplasia in the buccal mucosa in local anesthesia with scalpel (blade 15C). Polyamide sutures (Seralon 5-DS15, Serag Wiessner KG, Naila, Germany).
224174158|NCT03267576|DRUG|Canagliflozin 300 mg|Participants will receive canagliflozin 300 mg oral tablet once-daily for 28 days.
224174159|NCT03267576|DRUG|Sitagliptin 100 mg|Participants will receive sitagliptin 100 mg oral tablet once-daily for 28 days.
224174160|NCT03267576|DRUG|Metformin|Participants will receive metformin at a stable dose of \>= 1500 mg/day throughout the study including the washout period between each intervention.
224174161|NCT01369069|DRUG|IV insulin to maintain target glucose concentration of 80-130 mg/dL|Intervention is to keep glucose concentration 80-130 mg/dL for up to 72 hours after randomization. IV insulin drip will be used to maintain glucose target.
224174162|NCT01369069|DRUG|Standard Care control - sliding scale insulin to keep glucose less than 180 mg/dL|Sliding scale sub q insulin given will be given up to 4 times per day based on glucose concentration. It will be given only if glucose concentration greater than or equal to 180 mg/dL.
224174163|NCT06070727|OTHER|Obturator|Evaluation of patient satisfaction and oral healthy related quality of life of Polyetherketoneketone(PEKK) and metal framework for management of maxillectomy cases.
224174164|NCT04168151|OTHER|lung recruitment protocol|lung recruitment protocol applied to postcardiac surgery hypoxic adult patients with measurement of trans alveolar pressure as an index for lung recruitment
224174165|NCT04363723|OTHER|Pulmonary Rehabilitation|Patients performed a comprehensive pre-lung transplant inpatient pulmonary rehabilitation program for 4 to 5 weeks duration.
224174166|NCT03952689|DEVICE|Serenno Medical Automatic Urine Output measuring device|"Device that measures ongoing urine output will be connecter to the patients catheter. The urine count of the device will be compared to the gold standard measurement technique (nurse count)."
224174167|NCT03248960|DIAGNOSTIC_TEST|iTreat Flu A+B Test|The iTreat Flu A+B Test is a rapid in vitro diagnostic test for the detection of influenza A or influenza B in nasal swab samples. The iTreat Flu A+B Test is designed to be simple to use and generates a result within 15 minutes.
224174168|NCT03248960|DIAGNOSTIC_TEST|ellume.lab Flu A+B Test|The ellume.lab Flu A+B Test is an in vitro diagnostic test intended to be used at point-of-care for the detection of influenza A or influenza B in nasal swab samples. The ellume.lab Flu A+B Test generates a result within 10 minutes.
224174169|NCT03248960|DIAGNOSTIC_TEST|Reverse Transcriptase Polymerase Chain Reaction (RT-PCR)|Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) is a molecular diagnostic technique for the detection and identification of influenza viruses, both for clinical samples and isolates. The reverse transcriptase polymerase chain reaction (RT-PCR) allows template viral RNA to be reverse transcribed producing complementary DNA (cDNA) which can then be amplified and detected.
223485401|NCT05422508|BIOLOGICAL|Suduvax|0.5ml, single dose, subcutaneous injection
223485402|NCT04250480|DIETARY_SUPPLEMENT|beta-alanine|beta-alanine tablet
223485403|NCT04250480|DIETARY_SUPPLEMENT|placebo|rice powder tablet
223485404|NCT02394275|BIOLOGICAL|Fecal Microbiota Transplant|All eligible patients will receive fecal microbiota transplant
223485405|NCT05751967|DRUG|Placebo Combined With Ursodeoxycholic Acid|1 tablet/ day
223485406|NCT05751967|DRUG|Fenofibrate Combined With Ursodeoxycholic Acid|200 mg/day
223485407|NCT03834168|OTHER|standardized Study Diet|Standardized diet consisted with eucaloric meals with 4.5 gm of sodium per day for 5 days.
223485408|NCT04678674|PROCEDURE|tooth root augmentation|Autogenous tooth roots for lateral alveolar ridge augmentation and staged implant placement.
223485409|NCT06343701|OTHER|Implicit motor imagery|Implicit motor imagery is the ability to engage with the projection and manipulation of the body schema from a first-person perspective. Implicit motor imagery skills were evaluated Recognize App Recognize Hand Hand Laterality Task with, developed by NOI group. (http://www.noigroup.com/ Recognise).
223485410|NCT06343701|OTHER|Explicit motor imagery|In explicit motor imagery, the person simulates a specific motor movement, that is, the individual is aware that she is imagining the movement.Explicit motor imagery skills were evaluated with Movement Imagery Questionnaire for Children (MIQ-C), mental chronometry and box block test.
223485411|NCT00539474|PROCEDURE|Radio guided occult lesion localisation|ROLL procedure using the Europrobe (Europrobe, Strassbourg, France) WGL using a hook wire
223485412|NCT03725007|DRUG|Upadacitinib|Upadacitinib is administered as an oral solution or tablet as described in protocol.
223485413|NCT05038254|OTHER|Best Practice|Receive standard of care telemedicine
223485414|NCT05038254|PROCEDURE|Patient Monitoring|Undergo remote monitoring
224174170|NCT03248960|DIAGNOSTIC_TEST|Viral culture|Nasopharyngeal samples will be inoculated into appropriate culture media for influenza viral culture. In this test, the virus is actually grown and further identified in the laboratory as influenza A or B.
224174171|NCT00882362|DRUG|OPC-14597 (Aripiprazole)|administered orally once daily, 3 to 15 mg daily, 52 weeks
224306228|NCT05830149|OTHER|Cryoinsufflation|In cryoinsufflation, local anesthesia will be administered to the tract area with lidocaine hydrochloride 1% or a similar local anesthetic. A needle will be mounted on a liquid nitrogen cryosurgical unit. The needle will be inserted through the entire sinus tract and cryospray will be delivered to the length of the sinus tract as the needle is retracted with the intention to induce local tissue destruction. Each spray will be 5 seconds in duration and each tract will be sprayed 3 times per treatment session. This technique has been shown to be effective in sinus tract obliteration. This intervention may prevent local disease progression and prevent patients from undergoing more invasive surgeries. Overall, this would result in improved cosmesis, decreased pain, decreased bleeding and improved patient satisfaction.
224306229|NCT05830149|OTHER|Deroofing|Deroofing will serve as the control group as this is a minimally invasive procedure that is used for sinus tracts in HS. Studies have demonstrataed the efficacy of deroofing in treating the draining sinus tracts in HS. The control group should have decreased drainage, pain, recurrence, and scarring. In deroofing, local anesthesia will be administered to the tract area with lidocaine hydrochloride 1% or a similar local anesthetic. The sinus tract is probed to clearly defined the sinus tract. The skin overlying the sinus tract is cut using an a scalpel. In this way, the top of the sinus tract is surgically removed. In this way, the top of the sinus tract is surgically removed. The floor of the sinus tract is exposed and left open to heal by secondary intention.
224306230|NCT04360096|DRUG|ZYESAMI™ (aviptadil acetate)|Inhaled ZYESAMI™ (aviptadil acetate) 100μg 3x daily by mesh nebulizer
223485415|NCT05038254|OTHER|Questionnaire Administration|Ancillary studies
223485416|NCT03556683|DEVICE|3% Hypertonic Saline|4 mL of 3% hypertonic saline
223586355|NCT03079219|DRUG|Experimental drug: Ondansetron|Day 1: 8mg BD, First dose 8mg, Second dose 8mg, 8 hours after first dose
223485417|NCT03556683|DEVICE|7% Hypertonic Saline|4 mL of 7% hypertonic saline
223485418|NCT03556683|DRUG|Salbutamol|4 puffs (90 mcg/actuation)
223485419|NCT04163263|DRUG|BOS-356|topical gel
223485420|NCT04163263|DRUG|Vehicle|topical gel
223586356|NCT03079219|DRUG|Experimental drug: Dexamethasone|Day 1: 12mg QD
223586357|NCT03079219|DRUG|Experimental drug: Olanzapine|Day 1 to Day 5: 10mg QD
223586358|NCT03079219|DRUG|Standard: Aprepitant|Day 1: 125mg QD, Day 2 to Day3: 80mg QD
224174172|NCT05069389|OTHER|Data collection|"Some data will be collected for all patients included :~* specific treatment administered in COVID unit~* dosages of treatment~* inclusion in clinical trials~Evolution of French recommendations and the publication of scientific articles"
224306231|NCT04360096|DRUG|Placebo|Normal Saline Inhalation
223485421|NCT03127059|OTHER|Breathing Exercises|"Key points in the intervention are~* Reduction (or normalising) of the respiration rate; use of rhythmic, nasal inspiration, diaphragmatic breathing; reduction of depth of breath, longer expiration; breath-holding at functional residual capacity.~* Relaxation, especially the neck, jaw, tongue, and shoulders. Emphasizing the impact of gravity to the body.~* Inclusion of the breathing modification into walking and other physical activities.~* Daily home exercise of BrEX."
223485422|NCT03127059|OTHER|Usual care|Participants will receive only short information given initially at recruitment. No instruction or booklet will be distributed in the Usual care-Group.
223586359|NCT03079219|DRUG|Standard: Ondansetron|Day 1: 8mg BD, First dose 8mg, second dose 8mg, 8 hours after first dose
223586360|NCT03079219|DRUG|Standard: Dexamethasone|Day 1: 12mg QD ; Day 2 to Day 3: 4mg BD
223586361|NCT05688488|DRUG|Curcumin|Curcumin was applied to both wound sites of bilateral vocal cords. After evenly applied, gently massage the applied site for 3-5 minutes until the drug was fully absorbed.
223586362|NCT05688488|DRUG|Mitomycin-C|Mitomycin-C was applied to both wound sites of bilateral vocal cords. After evenly applied, gently massage the applied site for 3-5 minutes until the drug was fully absorbed.
223586363|NCT02263443|PROCEDURE|Soap suds enema (S.S.E.)|Patients in S.S.E. group will bowel preparation by soap suds enema until clear at night before surgery.
223485423|NCT03175458|PROCEDURE|sinus lift,implant placement,tenting|elevation of the sinus membrane then insertion of the implants without any bone graft material( graft-less) for augmentation
223586364|NCT02263443|PROCEDURE|sodium chloride enema|Patients in unison enema group will Unison enema 100 ml per rectal at night before surgery
223586365|NCT02263443|PROCEDURE|No enema|Patients NPO groups will NPO and no bowel preparation.
223586366|NCT06142617|DRUG|Pembrolizumab, pemetrexed, platinum|Four cycles of platinum and pemetrexed in combination with pembrolizumab will be administered as first line therapy and up to 31 cycles pemetrexed and pembrolizumab maintenance therapy every 3 weeks.
223586367|NCT06142617|DRUG|Osimertinib|Osimertinib will be the sequential treatment strategy at progression until resistance develops.
223586368|NCT05063539|DRUG|LY3372689|given orally
223586369|NCT05063539|DRUG|LY3372689|given orally
223586370|NCT05063539|DRUG|Placebo|given orally
223586371|NCT03505320|DRUG|zolbetuximab|Zolbetuximab will be administered as a minimum 2-hour IV infusion.
223586372|NCT03505320|DRUG|oxaliplatin|Oxaliplatin will be administered as a 2-hour IV infusion.
223586373|NCT03505320|DRUG|leucovorin|Leucovorin will be administered as a 2-hour IV infusion.
223586374|NCT03505320|DRUG|fluorouracil|Fluorouracil will be administered as IV bolus over 5 to 15 minutes and continuous IV infusion over 46 to 48 hours or per institutional guidelines.
224174173|NCT00947089|DEVICE|oxidized regenerated cellulose (Fibrillar SURGICEL)|one gauze made of ORC
224174174|NCT00947089|DEVICE|iodoform gauze|one iodoform gauze
224306232|NCT04360096|DEVICE|Nebulized administration of ZYESAMI™ or Placebo|Use of 510(k) cleared mesh nebulizer to deliver investigational product
224306233|NCT03265418|DEVICE|BioXmark liquid fiducial markers|Before the start of the treatment planning during an extra sigmoidoscopy after enema preparation, 4 liquid marker spots will be placed 1 cm from the tumor; two in the in the cranial and two in the caudal direction of the tumor (4 markers in total per patient).
224306234|NCT03265418|OTHER|Imaging|"As part of standard patient set-up directly before each radiotherapy treatment, kV cone-beam CTs will be acquired. Treatment positioning will be based on the regular clinical decision protocols for treatment of rectal cancer and not on the markers. During treatment potential fiducial movement will be assessed using an externally positioned ultra-sound probe, positioned against the abdominal or perineal skin of the patients depending on de position of the tumor/fiducials in the rectum. For patients in this study 2 orthogonal kV images will be made immediately after each radiation using the electronic portal imaging (EPI) device.~As part of standard clinical practice an MR of the rectum will be made for response evaluation 6-8 weeks after the end of neo-adjuvant chemo-radiotherapy."
224306235|NCT03265418|PROCEDURE|surgery or wait-and-see|"As part of standard clinical practice patients whose tumor has not responded completely will be operated on 8-12 weeks after the end of neoadjuvant chemo-radiotherapy. Patients with a complete response will be follow-upped according to the wait-and-see protocol."
223485424|NCT03175458|PROCEDURE|sinus lift,implant placement,bovine bone|sinus membrane elevation then placement of the implants together with deproteinized bovine bone substitute as a graft material for augmentation
223485425|NCT04757636|BIOLOGICAL|2.0 mg OPT-302|intravitreal injection
223485426|NCT04757636|BIOLOGICAL|2.0 aflibercept|intravitreal injection
223485427|NCT04757636|PROCEDURE|Sham|intravitreal injection
223485428|NCT00494312|DRUG|Pioglitazone|Pioglitazone 15 mg or 30 mg titrated to 45 mg, tablets, orally, once daily and glyburide placebo-matching capsules, orally, once daily for up to 156 weeks.
223586375|NCT03505320|DRUG|Pembrolizumab|Pembrolizumab will be administered intravenously over 30 minutes.
223586376|NCT03505320|DRUG|folinic acid|Folnic acid will be administered as a 2-hour IV infusion.
223586377|NCT03505320|DRUG|nivolumab|Nivolumab will be administered intravenously according to institutional standards.
223586378|NCT03505320|DRUG|Docetaxel|Docetaxel will be administered as a 1-hour IV infusion.
223586379|NCT01522261|OTHER|Mechanical Bowel Prep|Patients randomized to MBP will complete procedure per standard instructions.
223586380|NCT01522261|OTHER|No Mechanical Bowel Prep|Patient randomized to fleets enemas only prior to surgery
223586381|NCT02333890|DRUG|Chloroquine|chloroquine 500 mg daily as an oral capsule during the wait time to surgery.
223586382|NCT02333890|DRUG|Placebo|
223586383|NCT03737331|BEHAVIORAL|Fractal visual cueing|Walking to an external visual fractal (i.e., pink noise) stimulus.
223586384|NCT03737331|BEHAVIORAL|Periodic visual cueing|Walking to an external visual periodic (i.e., invariant) stimulus.
223586385|NCT03737331|BEHAVIORAL|Random visual cueing|Walking to an external visual random (i.e., white noise) stimulus.
223586386|NCT05318196|BIOLOGICAL|Biological samples collection|"SOT patients: samples will be collected at the time of the protocol follow-up visit (registration on the transplant list, on the day of the transplantation, and then at day 15, month 1-3-6-9-12 and then annually, as well as if complications or therapeutic modifications).~Dialysis patients: at the start of the dialysis and then at M3, M12, and if complications or modification of the dialysis protocol.~Non-dialysis or cancer patients: the sampling frequency will be individualized according to the pathology studied (acute or chronic) and the purpose of the sampling (diagnostic, mechanistic, prediction, evaluation of the therapeutic response). Samples for diagnostic and mechanistic purposes will be taken only once. Samples for prognostic purposes will be taken at regular intervals, adapted to the natural history of the disease while respecting the maximum volume of blood samples defined by the French law. Samples will be collected during a sampling performed as part of routine care."
224174175|NCT06189625|OTHER|Control|"All patients included in the study, both in the non-bandaging group and in the bandaging group, will receive a series of general measures as a recommendation, consisting of the following:~* Administration of anti-inflammatory drugs as ibuprofen at 7.5 mg/kg/8 hours for 2-3 days. If pain continues, recommendation of paracetamol 15 mg/kg 4 hours after ibuprofen.~* Application of local ice for a maximum of 10 minutes as required.~* Elevation of the affected limb when resting.~* Early mobilization and load according to tolerance, using crutches if required.~* Sports rest at least for one week or until the patient is able to walk without pain, with gradual incorporation according to tolerance. During the following year, use of elastic ankle brace for sports activities.~The control group will not receive any special intervention."
224174176|NCT06189625|PROCEDURE|Functional bandage|"The functional bandage will consist of a standardized wrapping in several phases. First, with 6 mm silk tape, open anchors were placed in the distal region of the metatarsals of the foot and in the middle third of the affected leg. Next, a strip of tape was applied in stirrup fashion, starting from the proximal anchor and exerting pressure cranially on the side of the affected ligament. This support was interspersed three times with another strip of tape, starting from the foot anchor and wrapping behind the ankle. Once complete, it was covered with a 7.5 cm Tensoplast spiral bandage, taking care to apply gentle pressure. The emergency nurses underwent dual training, consisting of an instructional video and a half-hour practical session. Reminder posters were also displayed in the technique box where such procedures are typically performed.~As the control group, general measures will be recommended."
223586387|NCT05216029|OTHER|Best Practice|Receive standard of care
223586388|NCT05216029|OTHER|Informational Intervention|View oncology dashboard
223586389|NCT05216029|OTHER|Questionnaire Administration|Ancillary studies
223586390|NCT06453291|DRUG|NSAIDs (Nonsteroidal Anti-Inflammatory Drugs):|"Objective: To reduce pain and inflammation associated with chronic low back pain.~Medications: Ibuprofen, Naproxen, or Diclofenac.~Dosage:~Ibuprofen: 400-600 mg every 6-8 hours as needed. Naproxen: 250-500 mg twice daily as needed. Diclofenac: 50 mg three times daily as needed. Administration: Oral tablets. Duration: Daily use as prescribed, for the duration of the study. Monitoring: Regular follow-up visits to monitor pain levels, side effects, and adherence."
223586391|NCT06453291|PROCEDURE|Standard Physical Therapy|"Objective: To improve mobility, strength, and reduce pain.~Techniques:~Stretching exercises. Strengthening exercises for core and back muscles. Manual therapy techniques. Postural training. Frequency: Twice a week sessions. Duration: 45-60 minutes per session. Monitoring: Progress will be assessed during each session and adjusted as necessary"
223586392|NCT06453291|PROCEDURE|Neuromodulation via Dorsal Root Ganglion (DRG):|"Objective: To modulate excitatory pathways and reduce pain through targeted stimulation.~Procedure:~Placement of electrodes near the DRG. Application of pulsed radiofrequency (RF) at 42°C for 3-20 minutes.~Frequency:~Initial treatment: Once a week for the first month. Maintenance: Monthly sessions if needed. Duration: Each session lasts approximately 30-45 minutes. Monitoring: Pain levels and functional improvement will be assessed before and after each session."
224174177|NCT00411840|PROCEDURE|intraarterial and intramuscular injection of BMCs|
224174178|NCT04451694|OTHER|nutritional intervention|nutritional evaluation and intervention and orientation towards adapted care establishment
224174179|NCT01942395|BEHAVIORAL|DASH/sodium-restricted diet (DASH/SRD)|Baseline diet will be assessed via Block Food Frequency Questionnaire, and 24-hour urinary sodium, potassium, and 8-isoprostanes will be measured. Subjects will then be assigned to 21 days of the DASH/SRD, with all food and beverages provided. The target sodium content will be 1,500 mg/2,100 kcal, as per recent American Heart Association population recommendations for sodium intake. Adherence will be assessed through a three-day food diary at the midpoint of the intervention, and at the end of the 21 days urinary sodium, potassium, and 8-isoprostanes will again be measured.
224306236|NCT01714232|DEVICE|Contour® PLUS BGMS|Study staff performed Blood Glucose (BG) tests with capillary fingerstick blood collected from subjects with diabetes and without diabetes (up to 10% of subjects without diabetes were included). All meter BG results were compared with capillary plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).
224306237|NCT01714232|DEVICE|OneTouch® SelectSimple™ BGMS|Study staff performed Blood Glucose (BG) tests with capillary fingerstick blood collected from subjects with diabetes and without diabetes (up to 10% of subjects without diabetes were included). All meter BG results were compared with capillary plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).
224306238|NCT01714232|DEVICE|Accu-Chek® Performa BGMS|Study staff performed Blood Glucose (BG) tests with capillary fingerstick blood collected from subjects with diabetes and without diabetes (up to 10% of subjects without diabetes were included). All meter BG results were compared with capillary plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).
224306239|NCT01714232|DEVICE|Accu-Chek® Active BGMS|Study staff performed Blood Glucose (BG) tests with capillary fingerstick blood collected from subjects with diabetes and without diabetes (up to 10% of subjects without diabetes were included). All meter BG results were compared with capillary plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).
224306240|NCT01714232|DEVICE|Freestyle Freedom® BGMS|Study staff performed Blood Glucose (BG) tests with capillary fingerstick blood collected from subjects with diabetes and without diabetes (up to 10% of subjects without diabetes were included). All meter BG results were compared with capillary plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).
224174180|NCT01942395|BEHAVIORAL|Control Diet|The Control Diet will be patterned on the information we collected using Food Frequency Questionnaires during our pilot study HUM00025253 (i.e., the dietary patterns reported by previously recruited hypertensive HFPEF patients). The target sodium content will be 3,500 mg per 2,100 kcal and target potassium content for the control diet will be 2,000 mg per 2,100 kcal.
224174181|NCT05233423|DEVICE|compressed cold therapy bandage|Compressed cold therapy bandage was applied by wrapping the operated knee of the patients. The patients in the intervention group received 9 cold applications with 30 mmHg pressure for 20 minutes and 40 minutes of rest.
224174182|NCT01846208|DRUG|Egg Oral Immunotherapy|Commercially available egg white solid dispensed by the central manufacturer. Study product will be dispensed in vials for low doses, capsules for mid-range doses, and bulk powder with dosing scoops for the higher doses.
223745227|NCT01581307|DEVICE|TheraSpheres|TheraSpheres are a medical device containing yttrium-90 (Y-90), a radioactive material that has been used previously in the treatment of liver tumors. Y-90 is incorporated into very tiny glass beads called microspheres and is injected into the liver through the blood vessels supplying the liver. TheraSpheres have restricted approval from the United States Food and Drug Administration (FDA) for the treatment of hepatocellular liver cancer; but has not yet been approved for the treatment of pancreatic cancer that has spread to the liver.
224174183|NCT01846208|DRUG|Baked Egg|Predetermined food substances with known amounts of Baked Egg (egg protein) with standardized dosing/consumption instructions.
224174184|NCT01424306|OTHER|Fructose-sweetened beverages|In addition to consuming a standardized diet, subjects will be asked to consume 4 servings per day of a fructose-sweetened beverage for 8 days. The amount of fructose consumed will be 25% of the subject's estimated daily calorie requirement.
224174185|NCT01424306|OTHER|Glucose-sweetened beverages|In addition to consuming a standardized diet, subjects will be asked to consume 4 servings per day of a glucose-sweetened beverage for 8 days. The amount of glucose consumed will be 25% of the subject's estimated daily calorie requirement.
224174186|NCT01424306|OTHER|High-fructose corn syrup-sweetened beverages|In addition to consuming a standardized diet, subjects will be asked to consume 4 servings per day of a high-fructose corn syrup-sweetened beverage for 8 days. The amount of high-fructose corn syrup consumed will be 25% of the subject's estimated daily calorie requirement.
224174187|NCT03371303|OTHER|collection of prescription data|collection of prescription data before and after a hospitalization
224174188|NCT03105375|DRUG|Single ascending dose of X842|Each subject in a the same cohort will be assigned to the same single dose of X842. The subjects in the subsequent cohort will be assigned to a single dose of X842 based on safety and efficacy data generated from the previous cohort.
224174189|NCT03105375|DRUG|Multiple ascending dose of X842|Each subject in a the same cohort will be assigned to the same dose of X842 once daily for five days. The subjects in the subsequent cohort will be assigned to same dose of X842 once daily for five days based on safety and efficacy data generated from the previous cohort.
224174190|NCT03105375|DRUG|Losec|Each subject in one cohort will be assigned to a standard dose of omeprazole once daily for five days.
224174191|NCT04306770|OTHER|OPTIMUM programme|"OPTIMUM programme encompass of telehealth service to support the patient. Study participants will be given devices (Bluetooth-enabled blood pressure machine, weighing scale and glucometer) to monitor their parameters at home. Care team will use the Phillips Vital Health to perform tele-monitoring, tele-management (individualized on-line health coaching and timely interventions), and to deliver education content."
224174192|NCT06154759|OTHER|Watson Human Caring Model-based psychoeducation|It is a psychoeducation program based on the Watson human care model, one of the theories of the nursing profession, that includes healing processes, and consists of sessions that address the hopelessness, death anxiety and care burden of individuals.
224306241|NCT01607307|DRUG|Oral/enteral TJ-100 solution|Oral TJ-100 solution (5 g tid, 15 g/day) given immediately before meals or every 8 h from preoperative day 3 to postoperative day 7 for 10 consecutive days. A diluent TJ-100 solution given immediately after surgery and on postoperative day 1 via Argyle enteral feeding tube (10 Fr), which terminates in the jejunum to prevent aspiration pneumonia.
223485429|NCT00494312|DRUG|Glyburide|Pioglitazone placebo-matching tablets, orally, once daily and glyburide 5 mg or 10 mg titrated to 15 mg, capsules, orally, once daily for up to 156 weeks.
223485430|NCT03972917|DIAGNOSTIC_TEST|Transvaginal ultrasonographic examination|Evaluation of endometrial thickness; myoma size and volume
223485431|NCT04452838|DRUG|Fesoterodine BIC SR4 fasted (Treatment A in Part A, Treatment G in Part B)|4 mg administered under fasted condition.
223485432|NCT04452838|DRUG|Fesoterodine BIC SR7 fasted (Treatment B in Part A, Treatment H in Part B)|4 mg administered under fasted conditions.
223586393|NCT06453291|PROCEDURE|Platelet-Rich-Plasma Therapy|"Objective: To promote healing and reduce inflammation through the application of concentrated platelets.~Procedure:~Blood draw from the patient. Centrifugation to separate platelets. Injection of PRP into the affected area of the lower back.~Frequency:~Initial treatment: Once a week for the first three weeks. Follow-up: Additional injections may be given based on patient response and clinical judgment.~Duration: Each session lasts approximately 30-45 minutes. Monitoring: Pain levels, inflammation markers, and functional improvement will be assessed before and after each injection."
223485433|NCT04452838|DRUG|Fesoterodine BIC SR7 fed (Treatment C in Part A, Treatment F in Part B)|4 mg administered under fed conditions.
223485434|NCT04452838|DRUG|Fesoterodine BIC SR7 on apple sauce (Treatment D in Part A)|4 mg sprinkled on apple sauce administered under fasting conditions
223485435|NCT04452838|DRUG|Fesoterodine BIC SR4 fed (Treatment E in Part B)|4 mg administered under fed conditions
224174193|NCT01961999|PROCEDURE|Early RRT|"In the early arm renal replacement therapy was started on the basis of refractory oliguria: urine output \<0,5ml/Kg/h for \> 6 hours"
223485436|NCT03173963|DRUG|Empagliflozin|10 mg tablet of empagliflozin daily in addition to best clinical practice for management of diabetes.
223485437|NCT03173963|OTHER|Placebo|1placebo tablet per day
223485438|NCT02825810|BEHAVIORAL|Cervical motor control|Intervention will consist in a tailored exercise training following a previous published motor control protocol
223485439|NCT02018107|DIAGNOSTIC_TEST|N-13 ammonia or F-18 fluorodeoxyglucose|PET tracer
224174194|NCT01961999|PROCEDURE|Late RRT|"In the late arm at least one the following criteria must be fulfilled prior to initiation of renal replacement therapy:~persistent and refractory oliguria (\<0,5ml/Kg/h \>12h), despite therapy refractory extravascular fluid overload azotemia \>40mmol/L or 240mg/dL metabolic acidosis (pH\<7,2) hyperkaliemia (k+\>6mmol/L)"
224174195|NCT00193128|DRUG|Oxaliplatin|40 mg/m2 IV over 2 hours on days 1, 8, 15, 22, and 29 in both treatment cohorts
224174196|NCT00193128|DRUG|Docetaxel|20 mg/m2 IV over 30 minutes was administered on days 1, 8, 15, 22, and 29 in both cohorts
223485440|NCT02018107|DIAGNOSTIC_TEST|PET scan|PET scan
223485441|NCT04261166|DRUG|A1|Medical Cannabis oil diluted in Olive oil. CBD 36.6 mg, THC 1.8 mg (6 drops)
223485442|NCT04261166|DRUG|A2|Medical Cannabis oil diluted in Olive oil. CBD 0.6 mg, THC 3.1 mg (1 drop)
223485443|NCT04261166|DRUG|A3|Medical Cannabis oil diluted in Olive oil. CBD 3.1 mg. THC 3.1 mg (1 drop)
223485444|NCT04261166|DRUG|A4|Medical Cannabis (oil diluted in MCT oil). CBD 34.8 mg, THC 1.7 mg (6 drops)
223485445|NCT04261166|DRUG|A5|Medical Cannabis oil (diluted in MCT oil). CBD 0.6 mg, THC 3.1 mg (1 drop)
223485446|NCT04261166|DRUG|B1|Sublingual tablets. CBD 40 mg, THC 2 mg (1 tablet)
223485447|NCT04261166|DRUG|B2|Sublingual tablets. CBD 30 mg, THC 5 mg (1 tablet)
223485448|NCT04261166|DRUG|B3|Sublingual tablets. CBD 40 mg (1 tablet)
223485449|NCT04261166|DRUG|B4|Sublingual tablets. CBD 40 mg (1 tablet)
223485450|NCT05173636|OTHER|cervical lateral glide|A cervical segmental contralateral lateral glide treatment technique is performed at 1 or more motion segments of the cervical spine (C5-T1), including the level(s) of the segmental motion restriction. With the patient in a supine position, the therapist cradled the head and neck above, and including, the level to be treated and performed a lateral translatory movement away from the involved side while minimizing gross cervical side flexion or rotation.
223485451|NCT05173636|OTHER|thoracic mobilization technique|Participants in group B will be given cervical lateral glide along with thoracic mobilization technique in prone position.
223586394|NCT06558877|BEHAVIORAL|pharmacist-led multifaceted intervention|"Based on the blood pressure management model of pharmacist-led multifaceted intervention, clinical pharmacists who have received unified training provide pharmaceutical intervention and lifestyle guidance to subjects in the intervention group according to standard protocol.~Pharmaceutical interventions include health education, medication adherence (medication consultation, medication reminder), medication reorganization, and rational use of medication. At the same time, clinical pharmacists supervise the subjects to change their lifestyle (including reasonable diet, quitting smoking and drinking, moderate exercise, weight control and ensuring sleep, etc.), and guide the subjects to conduct home blood pressure monitoring."
223485452|NCT04596423|DIAGNOSTIC_TEST|Fetal echocardiography|fetal heart examination by medical ultrasound
224174197|NCT00193128|DRUG|Capecitabine|In Cohort 2, capecitabine was administered 1000 mg/m2 orally twice daily on days 1 to 7, 15 to 21, and 29 to 35.
224174198|NCT00193128|RADIATION|Radiation therapy|In both cohorts, radiation therapy began concurrently with day 1 of chemotherapy at a dose of 1.8 Gy/d Monday through Friday to a total of 45 Gy (25 fractions).
224174199|NCT00369928|DRUG|PG-760564|100 mg BID, of oral PG-760564
224174200|NCT00369928|DRUG|Placebo dose|placebo, BID, oral for 12 weeks
224174201|NCT00369928|DRUG|PG-760564|25 mg BID, of oral PG-760564
223485453|NCT01308710|DIETARY_SUPPLEMENT|Omega-3 fatty acid (Eicosapentaenoic acid)|1.0 grams daily for 6 weeks
223485454|NCT00191919|DRUG|Duloxetine Hydrochloride|
223485455|NCT00191919|DRUG|Placebo|
223485456|NCT00674297|DRUG|Fluvastatin|Fluvastatin 40 mg daily for 3 months
223485457|NCT05350423|DEVICE|Thulium Fibre Laser|The TFL is a relatively new laser in the field of urology. First introduced on the market in 2017, it offers theoretically superior stone dusting qualities and smaller fiber sizes to allow for better irrigation.
223485458|NCT05350423|DEVICE|Holmium:Yttrium-Aluminum-Garnet|The Ho:YAG is currently the most commonly used laser in the field of urology and for the better part of the last 3 decades has been considered the gold standard for laser lithotripsy.
223485459|NCT03243799|BEHAVIORAL|Group psychoeducation|Educational group sessions for patients with depression and physical comorbidities in order to improve the degree of control of their illnesses
223485460|NCT00820300|DRUG|Latanoprost-PPDS|Control of IOP compared to baseline for the experimental doses of Latanoprost-PPDS for 4 months or until loss of efficacy.
223485461|NCT02097277|BIOLOGICAL|BMS-986036|
223485462|NCT02097277|BIOLOGICAL|Placebo (Matching with BMS-986036)|
223485463|NCT00195325|DRUG|TTI-237|
223485464|NCT00835926|BIOLOGICAL|Influenza virus vaccine|0.5 mL, Intramuscular
223485465|NCT00835926|BIOLOGICAL|Influenza virus vaccine|0.5 mL, Intramuscular
223485466|NCT01091259|DRUG|Irinotecan|
223485467|NCT01091259|DRUG|Bevacizumab|
223485468|NCT05229081|BEHAVIORAL|vaccine education|The educational content was developed based on research and expert perspectives and included general information about immunization, pneumonia, and pneumococcal vaccines, as well as vaccine myths. This information was first conveyed to the patients verbally, and then booklets with the same material were handed to them. The Pneumococcal Conjugate Vaccine 13 (PCV13) vaccination was recommended based on Infectious Disease Society of America (IDSA), Advisory Committee on Immunization Practices (ACIP), and national adult immunization guidelines.
223485469|NCT00002265|DRUG|Zalcitabine|
223485470|NCT06844110|DRUG|68GA-DOTA-dPNE|Intravenous administration of 68GA-DOTA-dPNE tracer
223485471|NCT00621530|DRUG|ketorolac tromethamine opthalmic solution|ketorolac 2 mg will be added to the patient's routine spinal anesthetic for surgery
223485472|NCT00621530|DRUG|placebo|placebo will be added to the patient's routine spinal anesthetic for surgery
223485473|NCT00811408|DRUG|carboplatin|
223485474|NCT00811408|DRUG|cidofovir|
223485475|NCT00811408|GENETIC|protein expression analysis|
223485476|NCT00811408|OTHER|laboratory biomarker analysis|
224174202|NCT04126460|DRUG|Toripalimab|Toripalimab is a type of PD-1 antibody
223485477|NCT00811408|RADIATION|brachytherapy|
223485478|NCT00811408|RADIATION|radiation therapy|
223485479|NCT00092729|DRUG|etoricoxib (MK0663)|Two etoricoxib 60 mg tablets and one naproxen sodium 550 mg placebo tablet, single-dose, following onset of moderate-to-severe pain due to primary dysmenorrhea
223485480|NCT00092729|DRUG|Comparator: placebo (unspecified)|Two etoricoxib 60 mg placebo tablets and one naproxen sodium 550 mg placebo tablet, single-dose, following onset of moderate-to-severe pain due to primary dysmenorrhea
223485481|NCT00092729|DRUG|Comparator: naproxen sodium|Two etoricoxib 60 mg placebo tablets and one naproxen sodium 550 mg tablet, single-dose, following onset of moderate-to-severe pain due to primary dysmenorrhea
223485482|NCT04753112|DRUG|Sacubitril / Valsartan Oral Tablet [Entresto]|Treatment of Pulmonary Hypertension With Angiotensin II Receptor Blocker and Neprilysin Inhibitor
223485483|NCT04948125|DRUG|camrelizumab|200 mg intravenous (IV) camrelizumab on Day 1 and Day 15 of each 28-day cycle.
223485484|NCT04948125|DRUG|Apatinib Mesylate|250 mg qd
223485485|NCT01719302|DRUG|Gemcitabine|1500 mg/m\^2 given days 1 and 15 of every 28 day cycle for a total of 4 cycles
223485486|NCT01719302|DRUG|Docetaxel|50 mg/m\^2 on days 1 and 15 of each 28 day cycle for a total of 4 cycles
223485487|NCT01719302|DRUG|Pazopanib|Starting dose of 400 mg/day starting 72 hours after docetaxel/gemcitabine administration for 10 days (days 4-13 and 18-27) of each 28 day cycle for a total of 4 cycles. Dose will be increased by 200 mg/day for each cohort until the maximum tolerated dose is identified.
223485488|NCT00026338|DRUG|erlotinib hydrochloride|150 mg po daily
223485489|NCT00026338|DRUG|gemcitabine hydrochloride|1000 mg/m2 IV weekly (Cycle 1 -Day 1, 8, 15, 22, 29, 36, 43 of an 8 week cycle, Cycle 2 and subsequent cycles -Day 1,8 and 15 of a 4 week cycle)
223485490|NCT05609227|OTHER|mobile application|The application, compatible with IOS and android systems for patients candidate for stem cell transplantation, could be applied whenever needed information relating to transplantation process.
223485491|NCT01051804|OTHER|Systane Ultra|Systane Ultra 1 to 2 drops per eye at least 4 times daily for 4 weeks
223745228|NCT03465241|DIAGNOSTIC_TEST|the ctDNA dynamic monitoring|To detect ctDNA in patients using the second generation of high-throughput gene sequencing (NGS)
223586395|NCT06558877|BEHAVIORAL|conventional health education|The subjects receive conventional hypertension health education, standard blood pressure measurement training and regular follow-up in the control group.
223485492|NCT01051804|OTHER|Optive lubricant Eye Drops|Optive Lubricant Eye Drops 1 to 2 drops per eye at least 4 times daily for 4 weeks
223745229|NCT05556239|BEHAVIORAL|Resistance Exercise Training|Supervised resistance training program planned as 3 sessions per week of approximately 60 minutes. The resistance training program comprises 6 exercises for the major muscle groups, starting at 2 sets of 15 repetitions maximum progressing to 4 sets of 8 repetitions maximum. Each session will be supervised by physiotherapist to ensure proper technique, and progression in training load. The participants will choose an exercise ambassador from their network, who during the period will be encouraged to, on a weekly basis, to be in contact with the participant.
223485493|NCT04649424|DEVICE|CanSwab|New nasopharyngeal swab design.
223485494|NCT06091943|DRUG|Tislelizumab IV|Planned doses will be administered intravenously.
223485495|NCT06091943|DRUG|Tislelizumab SC|Planned doses will be administered via subcutaneous injection.
223485496|NCT06091943|DRUG|Histology-Based Chemotherapy Doublet|"Chemotherapy Doublet 1: Cisplatin/carboplatin + pemetrexed.~Chemotherapy Doublet 2: Carboplatin + paclitaxel/nab-paclitaxel.~Choice of histology-based induction chemotherapy doublet will be determined by the investigator and will be administered at standard doses intravenously."
223485497|NCT05632523|OTHER|Blood sample|Blood samples are taken at each visit to the day hospital for a programmed belatacept perfusion
223485498|NCT05632523|OTHER|urinary sample|Urinary samples are taken at each visit to the day hospital for a programmed belatacept perfusion
223485499|NCT04690426|BIOLOGICAL|PRV-101|Coxsackie Virus B vaccine
223485500|NCT04690426|OTHER|Placebo|Placebo
223485501|NCT03353051|OTHER|Observational study|Observational study
223485502|NCT03268187|DEVICE|Biofeedback|The skin conductance of the patient is measured and fed back to the patient via screen.
223485503|NCT03268187|BEHAVIORAL|Self-Alert Training|Self-Alert Training
223485504|NCT03268187|BEHAVIORAL|Relaxation Training|Relaxation Training
223485505|NCT03641365|DEVICE|Test group|Guided Implant placement Positioning/placement of dental implants thought the fully acrylic surgical template without metallic sleeves.
223485506|NCT03641365|DEVICE|Control group|Guided Implant placement Positioning/placement of dental implants thought the acrylic surgical template with metallic sleeves.
223485507|NCT00671060|DRUG|Misoprostol|200 mcg buccal misoprostol administered every 6 hours for up to 48 hours until fetus is delivered.
223745230|NCT04368819|DRUG|Allopurinol 300 MG|Allopurinol 300mg once daily for four weeks followed by allopurinol 300mg twice daily for 12 weeks
223745231|NCT04368819|DRUG|Placebo oral tablet|Placebo 300mg once daily for four weeks followed by allopurinol 300mg twice daily for 12 weeks
223745232|NCT04811313|DRUG|Tranexamic acid|patients treated with TXA will have reduced blood loss and transfusion requirements compared with those who did not receive TXA
223745233|NCT04811313|PROCEDURE|caudal epidural block|regional anesthesia in orthopedic procedures are known to help reduction of intraoperative blood loss
223745234|NCT04811313|OTHER|Placebo|participants will receive standard care but neither TXA nor caudal epidural block
224174203|NCT00487994|DRUG|Lapaquistat acetate|Lapaquistat acetate 100 mg, tablets, orally, once daily and Atorvastatin placebo-matching capsules, orally, once daily for up to 96 weeks.
224174204|NCT00487994|DRUG|Lapaquistat acetate and atorvastatin|Lapaquistat acetate 100 mg, tablets, orally, once daily and Atorvastatin 10 mg, capsules, orally, once daily for up to 96 weeks.
224174205|NCT00487994|DRUG|Atorvastatin|Lapaquistat acetate placebo-matching tablets, orally, once daily and Atorvastatin 10 mg, capsules, orally, once daily for up to 96 weeks.
224174206|NCT04868331|BEHAVIORAL|Exercise|Two trials of 7-min High Intensity Interval Training (HIIT) with 12 different exercises. Each exercise lasts for 30 seconds continuously with 10 seconds rest interval.
224174207|NCT02812394|DRUG|CVT-301 (Dose Level 1)|All subjects will receive a single dose of low-dose CVT-301 with a 1-day washout between the doses.
224174208|NCT02812394|DRUG|CVT-301 (Dose Level 2)|All subjects will receive a single dose of high-dose CVT-301 with a 1-day washout between the doses.
224174209|NCT02812394|DRUG|Sinemet®|All subjects will receive carbidopa/levodopa tablets administered every 8 hours.
224174210|NCT06461195|OTHER|Monitoring of patients|Data from a spirometer and a stethoscope are captured to develop algorithms to detect and classify respiration sounds to support therapists and patients in future therapy.
224174211|NCT00407420|DEVICE|Mandometer|A computerised device, Mandometer, providing real time feedback to participants during meals to slow down speed of eating and reduce total intake; standard lifestyle modification therapy.
224174212|NCT00407420|BEHAVIORAL|Lifestyle|Typical dietary and activity advice as normally provided in clinic (control).
224174213|NCT04527666|DRUG|Anticoagulation Agents|Patients receive anticoagulation agents including low molecular weight heparin, warfarin, rivaroxaban, et al.
224174214|NCT03201744|PROCEDURE|Patients will be randomized to moderate (TOF 1-2) or deep (post tetanic count 1-2) relaxation. Low pressure insufflation (start pressure set at 8 mm Hg)|All procedures will start with low insufflation pressure (8 mmHg). Surgical field assessment (scale 1-5) will be performed every 5 minutes (Martini Br J Anaesth 2014). If conditions are poor (rating 1-2), intraperitoneal insufflation will be incrementally increased (10 mmHg, 12 mmHg, 15 mmHg) every 5 minutes as needed.Reversal of muscle relaxation will be performed at the end of the procedure using established medications used in clinical practice. In theory, deep relaxation may require a more prolonged reversal process, but using contemporary medical agents (sugammadex), reversal from deep relaxation is prompt (2-3 minutes) without any additional delays.
224174215|NCT01528436|BIOLOGICAL|Umbilical Cord Blood Infusion|The subjects will be undertaken allogeneic umbilical cord blood infusion intravenously or intraarterially under non-myeloablative immunosuppression.
224174216|NCT01528436|OTHER|Placebo Umbilical Cord Blood|Placebo Umbilical Cord Blood that resembles cord blood in appearance was designed.
224174217|NCT01528436|OTHER|Active Rehabilitation|All subjects should participate in active rehabilitation. They will receive two physical and occupational therapy sessions per day. Post discharge, each participant should continue to receive rehabilitation therapy at least 3 days per week until the study completion.
224174218|NCT04090515|BEHAVIORAL|Project Health|This intervention involves a one-hour group meeting for six consecutive weeks.
224174219|NCT04090515|OTHER|Educational Video Control|This intervention involves a one-hour educational video control viewing for six consecutive weeks.
224174220|NCT01323933|DRUG|AB0024|Comparison of different dosages of drug
224174221|NCT01809327|DRUG|Canagliflozin 100 mg|One 100 mg capsule taken orally (by mouth) once daily either before the morning meal (for the Canagliflozin 100 mg arm) or with the evening meal (for the Canagliflozin 100 mg + Metformin XR arm).
224174222|NCT01809327|DRUG|Canagliflozin 300 mg|One 300 mg capsule taken orally (by mouth) once daily either before the morning meal (for the Canagliflozin 300 mg arm) or with the evening meal (for the Canagliflozin 300 mg + Metformin XR arm).
224174223|NCT01809327|DRUG|Metformin XR|One 500 mg tablet (Day 1 up to week 1); two 500 mg tablets (Week 1 up to Week 3); three 500 mg tablets (Week 3 to Week 6); four 500 mg tablets (Week 6 to Week 9). Tablets will be administered with the evening meal.
224174224|NCT03196973|DRUG|DF289 plus DF277|1 vial into the affected ear twice daily for 7 days
223745235|NCT04994444|DRUG|Nicoderm CQ 21Mg/24Hr Transdermal System|Nicoderm CQ patch started 3 weeks prior to quit date. Starting on quit date, patch/gum or patch/lozenge will be used for 8 weeks. Patch will be tapered over the 8 week period.
223745236|NCT05706025|DEVICE|EnteroTracker|The EnteroTracker® is a capsule device that includes an absorbent string.
223745237|NCT06865820|BEHAVIORAL|Project UPLIFT|Project UPLIFT is a Mindfulness-based Cognitive Behavioral Therapy program teaching participants methods that include challenging thoughts, behavioral activation, coping, problem-solving, and mindfulness. The program is group-based and provides weekly sessions, delivered remotely via telephone or video conferencing platform, over an 8-week period.
223745238|NCT01498718|BIOLOGICAL|DNA vaccine|VRC-FLUDNA061-00-VP is composed of 3 closed-circular DNA plasmids that encode for the hemagglutinin (HA) from the following 3 strains: A/California/04/2009 (H1N1); A/Perth/16/2009 (H3N2), and B/Brisbane/60/2008. DNA vaccine vials will be supplied at 4 mg/mL and each dose will be 1 mL.
223745239|NCT01498718|BIOLOGICAL|TIV|2012/13 Seasonal Influenza Trivalent Inactivated Vaccine (TIV)
224174225|NCT03196973|DRUG|DF289|1 vial into the affected ear twice daily for 7 days
224174226|NCT03196973|DRUG|DF277|1 vial into the affected ear twice daily for 7 days
224174227|NCT03344562|DEVICE|CES|Patients will receive cranial electrical stimulation once a day for 20 minutes over 7 days. They will be allowed to increase the stimulation level on Day 2. A wrist worn actigraph will record sleep. Patients may elect to receive standard of care sleep medication if not satisfied with sleep.
224174228|NCT03344562|DEVICE|CES|Patient will receive sham electrical stimulation once a day for 20 minutes over 7 days.
224174229|NCT01802294|BEHAVIORAL|Parenting Program|"Goal of the program is reduction in child behavior problems in high-risk South African families. Program will be delivered to caregivers responsible for the wellbeing of the child.~Program activities will be delivered over 12 weekly group sessions with additional individualized in-home sessions. The groups (n = 15 participants per group) will meet weekly with community facilitators (n = 2 per group). Parenting skills will be developed during the sessions through role-plays, group-discussion, storytelling, and home practice activities.~The program is manualized in isiXhosa."
224174230|NCT02717429|BEHAVIORAL|Mindfulness Meditation|The mindfulness meditation-training program is closely modeled after the 8-week mindfulness based stress reduction protocol developed by Dr. Jon Kabat-Zinn. The briefer four weeks of MMT involve the practice of concentrative attention, where different objects are used as the focus of meditative practices. For example, for the first two weeks, the investigators use breath as an anchor for attention. With repeated practices, the objects of sensations, emotions, and thought processes are introduced.
224306242|NCT01607307|DRUG|Oral/enteral placebo solution|Oral placebo solution (5 g tid, 15 g/day) given immediately before meals or every 8 h from preoperative day 3 to postoperative day 7 for 10 consecutive days. A diluent placebo solution given immediately after surgery and on postoperative day 1 via Argyle enteral feeding tube (10 Fr), which terminates in the jejunum to prevent aspiration pneumonia.
224306243|NCT00935688|OTHER|Rapid diagnostic test|Dual species test for P. vivax and P. falciparum malaria
224174231|NCT02717429|BEHAVIORAL|Computerized Cognitive Training|The control group, which will be used to compare the effects of mindfulness training on emotional and cognitive functioning of MS patients, will comprise of a cognitive training group, which will provide an attentional-training based approach. In this group, the focus will be to provide the individuals with cognitive training tasks to complete that have been shown to improve attentional ability. The investigators will also discuss relevant MS-related material on cognitive deficits during these courses.
224174232|NCT02039089|DRUG|E2006 2.5 mg|
224174233|NCT02039089|DRUG|E2006 10 mg|
224174234|NCT02039089|DRUG|E2006 25 mg|
224174235|NCT02039089|DRUG|Placebo|
224174236|NCT03602638|DRUG|Sitagliptin|Sitagliptin 100mg QD
224174237|NCT03602638|DRUG|Acarbose|Acarbose
224174238|NCT01329172|OTHER|polyunsaturated fatty acids n-3|polyunsaturated fatty acids n-3 1 gram per day during two months
224174239|NCT01329172|OTHER|placebo|sun flower oil with Poly Unsaturated Fatty Acid 1g/day
224306244|NCT06455007|DRUG|Propolis|Propolis 3x10 drops (7 days)
223485508|NCT00671060|DRUG|Misoprostol|100 mcg buccal misoprostol administered every 6 hours for upto 48 hours
223485509|NCT01273961|DEVICE|AuraLevée treatment|A single treatment, on day 0, on each of no more than two treatment sites, using the AuraLevée device. Treatment sites are the face, abdomen, upper arm, thigh or neck.
223485510|NCT03695081|PROCEDURE|Patient Pathway Pharmacist intervention|"1. Medication reconciliation at admission to hospital~2. Medication review post surgery~3. Optimised list of drugs in the discharge summary, in accordance with hospital procedures~4. Medication reconciliation, six weeks after discharge~5. Medication review, six weeks after discharge"
223485511|NCT06057064|BIOLOGICAL|Biological: AZD3152|300 mg single dose of AZD3152 IM
223485512|NCT06057064|BIOLOGICAL|Biological: Placebo|Single dose of Placebo IM (0.9% sodium chloride)
223485513|NCT01541748|OTHER|Axis|Coloplast's Axis™ Allograft Dermis is used for anterior, posterior or combined (anterior and posterior) pelvic organ prolapse repair.
224306245|NCT02338193|DRUG|DAPA/MET XR|final dose- 5 mg dapagliflozin/1000 mg glucophage XR BID for 20-24 weeks
224306246|NCT02338193|DRUG|DAPA|10 mg dapagliflozin QD for 20-24 weeks
224306247|NCT02338193|DRUG|MET XR|1000 mg Metformin XR BID for 20-24 weeks
224306248|NCT03715361|DIAGNOSTIC_TEST|SL-ECG|additional SL-ECG measurement
224306249|NCT00540683|DEVICE|Diffuse Optical Spectroscopy|Muscle properties
224306250|NCT03283462|DIETARY_SUPPLEMENT|Mitopure|Mitopure (Urolithin A) containing softgels
224306251|NCT03283462|DIETARY_SUPPLEMENT|Placebo|Placebo containing softgels
224306252|NCT05042544|DIAGNOSTIC_TEST|Point-of-Care Testing|Participants will be offered finger-stick point-of-care testing for HCV
224306253|NCT02902367|OTHER|Outdoor walking and strength exercise|Exercise group: Participants are supposed to perform an outdoor walking exercise program and one strength exercise for 12 weeks. The first 2 weeks start with daily walks. The intensity and frequency of walks will progressively increase performed according to the Borg scale: 12-15, ie, moderate to strenuous. Participants will walk 5-7 days/week. Added to this is a strength exercise, i.e. chair-rising which also should be performed daily.
224306254|NCT02902367|OTHER|control group|Control-Group: Treatment as usual for 12 weeks, without restriction of being physically active.
223485514|NCT00227916|BEHAVIORAL|Behavior Therapy|
224306255|NCT02531750|OTHER|Immobilization due to an Achilles tendon rupture|
224306256|NCT00742924|DRUG|cisplatin|Given IV
224306257|NCT00742924|DRUG|dexrazoxane hydrochloride|Given IV
224306258|NCT00742924|DRUG|doxorubicin hydrochloride|Given IV
223485515|NCT00436761|BIOLOGICAL|anti-thymocyte globulin|
223485516|NCT00436761|BIOLOGICAL|graft-versus-tumor induction therapy|
223485517|NCT00436761|BIOLOGICAL|sargramostim|
223485518|NCT00436761|DRUG|busulfan|
223485519|NCT00436761|DRUG|cyclosporine|
223485520|NCT00436761|DRUG|melphalan|
223485521|NCT00436761|DRUG|methylprednisolone|
223485522|NCT00436761|OTHER|flow cytometry|
223485523|NCT00436761|OTHER|immunologic technique|
223485524|NCT00436761|OTHER|laboratory biomarker analysis|
223485525|NCT00436761|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
224174240|NCT04096404|GENETIC|Genotype- based personalised advice|Following allocation to groups participants will receive appropriate dietary and physical activity advice based on their genotype via email
224174241|NCT04096404|BEHAVIORAL|Non genetic personalised advice|Following allocation to groups participants will receive appropriate dietary and physical activity advice based on their reported intake, BMI and activity via email
224174242|NCT01635244|DEVICE|Aortic valve replacement|Clinically indicated aortic valve replacement will be performed using one of three approved tissue valves (Freestyle, Magna Ease, or Trifecta).
224174243|NCT00408772|BIOLOGICAL|bevacizumab|
224174244|NCT00408772|DRUG|capecitabine|
224174245|NCT00408772|DRUG|oxaliplatin|
224174246|NCT00408772|PROCEDURE|conventional surgery|
224174247|NCT00408772|PROCEDURE|neoadjuvant therapy|
224174248|NCT00408772|PROCEDURE|radiofrequency ablation|
224174249|NCT02647372|PROCEDURE|Subthalamic nucleus|Surgery will be performed in 15 patients with DBS target to the subthalamic nucleus
224174250|NCT02647372|PROCEDURE|Globus pallidus|Surgery will be performed in 15 patients with DBS target to the globus pallidus nucleus
224174251|NCT01287858|DRUG|AC430|Healthy volunteers will either receive AC430 or placebo.
224174252|NCT01555541|DRUG|Ofatumumab|1000 mg IV days 0, 7, 14, 21
224306259|NCT00742924|DRUG|etoposide|Given IV
224306260|NCT00742924|DRUG|ifosfamide|Given IV
224306261|NCT00742924|DRUG|leucovorin calcium|Given IV or orally
224306262|NCT00742924|DRUG|methotrexate|Given IV
224306263|NCT00742924|DRUG|zoledronic acid|Given IV
224306264|NCT00742924|PROCEDURE|adjuvant therapy|
224306265|NCT00742924|PROCEDURE|neoadjuvant therapy|
224306266|NCT00742924|PROCEDURE|therapeutic conventional surgery|Surgery of the primary tumor is scheduled for 12 weeks after the commencement of chemotherapy.
224306267|NCT00742924|BIOLOGICAL|filgrastim|Given SC
224306268|NCT00742924|DRUG|Mesna|Given IV
224306269|NCT02752763|DRUG|%40 diluted Autologous serum|Serum that obtained after centrifugation of blood sample
224174253|NCT01555541|DRUG|Etoposide|10 mg/Kg IV over 24 hours daily, days 1-4
224306270|NCT02752763|DRUG|Preservative free artificial tears(Tears naturale free, Refresh single dose eye drop)|Preservative free artificial tears is a group naming for drops commonly used for drye disease
224306271|NCT00660400|DRUG|5-azacitidine|Once enrolled, the patients will receive pre-transplant 5-azacitidine (Vidaza) 75 mg/M\^2/day subcutaneously for 5-7 days every 28 days). Adjustments in dose and timing may occur based on clinical and hematological parameters.
224174254|NCT01555541|DRUG|Cytarabine|2000 mg/m2 IV twice daily, days 1-4
224174255|NCT02772835|DEVICE|Medin-cno|Medin-cno is a noninvasive ventilator. With this device we can practice either nCPAP and nHFOV ventilation.
224174256|NCT00236106|DRUG|tacrolimus ointment 0.1%|
224174257|NCT00236106|DRUG|mometasone furoate 0.1%|
224174258|NCT01965028|DEVICE|Transcranial random noise stimulation (tRNS)|High frequency tRNS (Neuroconn, Eldith DC-Stimulator Plus): 100-650Hz, 2mA, 20min, 10s ramp time, left and right auditory cortex, 5x7cm electrode with the inferior middle part over T3/T4 Arms: tRNS
224306272|NCT00660400|PROCEDURE|Allogeneic Hematopoietic Cell Transplantation (HCT)|"Patients will receive transplantation if there is either a suitable sibling or an unrelated donor.~* Response will be evaluated by bone marrow biopsy after 4 cycles of 5-azacitidine or prior to HCT whichever comes first. Due to the very high risk of progression to AML or death in this patient population, the HCT will be done as soon as possible.~* The patients may have additional cycles of 5-azacitidine per standard hematology practice until scheduled for transplant or until progression of disease.~* All patients will be followed until time to progression of MDS, AML or death or a maximum of 1 year. For patients that are transplanted, follow up will be to one year post-transplant."
223485526|NCT00436761|PROCEDURE|umbilical cord blood transplantation|
223485527|NCT02832037|DRUG|BI 425809 dose 1|
223485528|NCT02832037|DRUG|BI 425809 dose 2|
224174259|NCT04383171|DEVICE|Motomed cycle ergometer (MOTOmed letto2 - Reck, Reckstr 1-5, Betzenweiler 88422, Germany).|
224174260|NCT04913792|DEVICE|ZXR00|This prospective comparative study included 60 eyes undergoing cataract surgery with implantation of an extended range of vision IOL.(Abbott Medical Optics, Inc.)
224174261|NCT05813405|OTHER|Experimental: Antihypertensive therapy Hypotension and improved ventilation treatment Intervention treatment for other risk factors|Experimental: Antihypertensive therapy Hypotension and improved ventilation treatment Intervention treatment for other risk factors
224174262|NCT02176005|DEVICE|DAV132|DAV132 is associated to moxifloxacin or it is evaluated alone
224306273|NCT03517696|PROCEDURE|Membrane sweeping|Participants assigned to membrane sweeping will have an additional exam during their initial evaluation in which the membranes will be separated from the cervix and lower part of the uterus with a finger inserted into the cervical os. This would be done with at least one rotation counterclockwise and one rotation clockwise.
224306274|NCT03630107|OTHER|WO 5101 Shampoo for Scalp and Hair|Wash the hair at least three times a week for a period of four weeks
224306275|NCT00482183|DRUG|Pioglitazone|
224306276|NCT00752011|DRUG|TAS-106|Starting dose 2.0 mg/m\^2 by vein over 24 hours, Day 1 of 3 Week Cycle.
224306277|NCT00752011|DRUG|Carboplatin|Starting dose AUC of 4, administered by vein over 60 minutes, Day 1 of 3 Week Cycle.
224306278|NCT02387515|OTHER|intensive rehabilitation program|Patients will follow an intensive rehabilitation program (2x/week for 18 weeks), with emphasis on motor control training that is supported by technology. The technological system consists out of motion tracking sensors that register the movements and position of the lumbar spine.
224306279|NCT02208635|OTHER|Biofortified Maize|Participant in this arm were fed zinc biofortified maize (\~30 µg Zn/g).
224174263|NCT02176005|DRUG|Moxifloxacin|Moxifloxacin is used alone or associated to DAV132
224174264|NCT02176005|OTHER|Negative Control|Moxifloxacin is used alone
224174265|NCT02557867|DRUG|Dexmedetomidine|Dexmedetomidine 0.5 μg/kg over 10 minutes and then, 0.5 mcg/kg/h throughout surgery.
224174266|NCT01661725|BIOLOGICAL|Group ACYW135 Meningococcal Polysaccharide Vaccine|60 subjects were divided into three groups (20 subjects each group), adult (16\~30 years of age), early youth (7\~15 years of age) and children (2\~6 years of age) to receive Group ACYW135 Meningococcal Polysaccharide Vaccine, 0.5 ml, one dose regime
223485529|NCT02832037|DRUG|BI 425809 dose 3|
223485530|NCT02832037|DRUG|BI 425809 dose 4|
223485531|NCT02832037|DRUG|Placebo|
223485532|NCT05897554|DRUG|intra-arterial alteplase|For patients in the successful MT plus intra-arterial alteplase group, after successful recanalization, neurointerventionalists administered intra-arterial thrombolysis with alteplase according to protocol. The angiographic scores will be assessed immediately after intra-arterial thrombolysis.
223485533|NCT03039478|DIETARY_SUPPLEMENT|Xylitol 7g|Xylitol 7g in 300mL tap water
223485534|NCT03039478|DIETARY_SUPPLEMENT|Erythritol 10g|Erythritol 10g in 300mL tap water
223485535|NCT03039478|DIETARY_SUPPLEMENT|Xylitol 17g|Xylitol 17g in 300mL tap water
223485536|NCT03039478|DIETARY_SUPPLEMENT|Xylitol 35g|Xylitol 35g in 300mL tap water
223485537|NCT03039478|DIETARY_SUPPLEMENT|Erythritol 25g|Erythritol 25g in 300mL tap water
224174267|NCT04474392|OTHER|N/A (Observational Study)|Observational study, no intervention will be administered.
224174268|NCT03894267|DEVICE|Cutimed Siltec Heel and Sacrum dressing|The dressing has been developed to facilitate exudate management in the treatment of wounds. Newly formed tissue enjoys optimal protection under a moist environment. The foam core with super-absorbers ensures reliable absorption in slightly to heavily exuding wounds. This core has an excellent retention capacity, even under compression. Hydrogen bridges bind the water so securely that, even when subject to pressure, the water is not released. Vertical absorption through the polyurethane foam and the hydro- phobic wound contact layer minimizes the risk of macerations in the peri-ulcer skin.
224174269|NCT02728310|DRUG|Levobupivacaine|An infusion rate of 10 ml/h of 1500 mg of 0.5 % of levobupivacaine for the first 30 h and 5 ml/h for the second 30 h (LCWI) were injected into the surgical wound.
224174270|NCT02728310|DRUG|Saline|An infusion rate of 10 ml/h of 300 ml of saline solution for the first 30 h and 5 ml/h for the second 30 h (LCWI) were injected into the surgical wound.
224174271|NCT03726749|DRUG|Tocilizumab|Tocilizumab is an interleukin-6 (IL-6) receptor inhibitor
224174272|NCT03726749|DRUG|Prednisone|Prednisone is an anti-inflammatory medication
224174273|NCT04957745|BEHAVIORAL|Binocular visual confusion (unilateral opaque)|"The peripheral target was a horizontally drifting grating measuring 10° by 10°, with a spatial frequency of 1 cycle per degree and a temporal frequency of 3 Hz, and located at 10° above the fixation.~For the binocular visual confusion condition, the non-transparent (opaque) peripheral target will be displayed on only one eye (unilateral opaque display)."
224174274|NCT04957745|BEHAVIORAL|Unilateral monocular visual confusion (unilateral see-through)|"The peripheral target was a horizontally drifting grating measuring 10° by 10°, with a spatial frequency of 1 cycle per degree and a temporal frequency of 3 Hz, and located at 10° above the fixation.~For the unilateral monocular visual confusion condition, the half-transparent peripheral target will be displayed on only one eye (unilateral see-through display)."
224306280|NCT02208635|OTHER|Fortified Maize|Participants in this arm were fed zinc-oxide fortified maize (total level of \~60 µg Zn/g).
224174275|NCT04957745|BEHAVIORAL|Bilateral monocular visual confusion (bilateral see-through)|"The peripheral target was a horizontally drifting grating measuring 10° by 10°, with a spatial frequency of 1 cycle per degree and a temporal frequency of 3 Hz, and located at 10° above the fixation.~For bilateral monocular visual confusion condition, the half-transparent peripheral target will be displayed on both eyes (bilateral see-through display)."
224174276|NCT00481377|PROCEDURE|ablation|
224174277|NCT00374062|BEHAVIORAL|relaxation therapy 1|relaxation therapy 1
224174278|NCT00374062|BEHAVIORAL|relaxation therapy 2|relaxation therapy 2
224174279|NCT00374062|BEHAVIORAL|relaxation therapy 3|relaxation therapy 3
224174280|NCT01740765|OTHER|24-hour energy expenditure|To assess 24-hour energy expenditure and substrate utilization subjects will spend 23 hours and 15 minutes each day in the metabolic chamber at the UNC NRI. Subjects will be requested to arrive at the study center each morning following a 10hour overnight fast. During each study day, subjects remained sedentary. All meals were provided and were tailored to each subject's specific energy requirements and the study protocol (i.e. 50% or 150% of calorie requirements).
224174281|NCT01646346|RADIATION|4D Conformal Image-Guided Partial Breast RT|External beam partial breast radiation to target a portion of the breast twice a day for 5 days.
224174282|NCT00748449|PROCEDURE|Colonoscopy|1 Colonoscopy
224174283|NCT00748449|PROCEDURE|CT-colonography|1 CT-colonography; Procedure/Surgery/Radiation
224174284|NCT02676050|OTHER|Optical Imaging Agents (EMI-137, NAP)|Both optical imaging agents (NAP and EMI-137) will be administered to each patient during a bronchoscopy procedure. A novel delivery catheter (to deliver both agents), imaging fibre and endomicroscopy system with viewer software will be used to detect c-MET and activated neutrophil signal in the human lung.
224174285|NCT02676050|DEVICE|Delivery Device Cathetar and Miniaturised imaging fibre|Both optical imaging agents (NAP and EMI-137) will be administered and imaged simultaneously during a bronchoscopy procedure using the devices mentioned above.
224174286|NCT02676050|DEVICE|Optical endomicroscopy system|The signal emitted by both optical imaging agents (NAP and EMI-137) will be visualised using a novel endomicroscopy system.
224174287|NCT01437059|DRUG|ALN-PCS02|Dose levels between 15 and 400 μg/kg by intravenous (IV) infusion
224306281|NCT02208635|OTHER|Control Maize|Participants in this arm were fed maize that was not fortified or biofortified (\~15 µg Zn/g maize).
224306282|NCT00097903|DRUG|Karenitecin (BNP1350)|Phase 1 study,dose-escalation design
224306283|NCT05308082|BEHAVIORAL|Dance Movement Therapy (DMT)|The main Dance Movement Therapy (DMT) methods were dance-movement improvisations, body awareness exercises, and reflection through drawing/painting, writing, and verbalization. There was an orientation to personal space and body awareness, interaction in pairs, and interaction in the whole group. The themes included exploration of boundaries, somatic resources, symbols, pleasant and unpleasant emotions, mindfulness, and body awareness, enriched movement experiences, and safety and touch. In the present study, it consists of six sessions, including (1) Movement for Self-expression, (2) Movement for Emotional Health I, (3) Movement for Emotional Health II, (4) Movement for Connection \& Creativity, (5) Embracing your Dancing Child, and (6) Movement for Self-compassion.
224174288|NCT01437059|DRUG|Sterile Normal Saline (0.9% NaCl)|Calculated volume to match active comparator
224174289|NCT00086242|BEHAVIORAL|Psychosocial Telephone Counseling (PTC)|Eligible patients are randomized to receive psychosocial telephone counseling (PTC) or usual care.The PTC intervention was specifically designed to help women cope with the stressful events and feelings of distress associated with cervical cancer. The PTC arm of the study received six counseling sessions, \~45 to 50 min in length, in their preferred language, consisting of five consecutive weekly sessions and a 1-month booster session, delivered by a psychologist. A review letter, generated by the counselor after each session, recapitulated the session's contents and reinforced adaptive coping strategies.
224306284|NCT03628625|DRUG|Letrozole 2.5mg|total dose 7.5 mg per day for 3 days
224306285|NCT03628625|DRUG|Placebo|Folic acid for 3 days
224306286|NCT03628625|DRUG|Misoprostol|Misoprosrol 800mcg will be given to all patients for induction of abortion
223485538|NCT03039478|DIETARY_SUPPLEMENT|Erythritol 50g|Erythritol 50g in 300mL tap water
224174290|NCT02698852|DEVICE|BuMA Supreme|Stent platform: cobalt-chromium alloy
224174291|NCT04003415|DEVICE|Investigational Device: Contactless heart rate and respiratory rate monitor|Participant will be seated next to the investigational device. The device is contactless, and will measure the patient's heart rate and respiratory rate through use of radio-waves.
224174292|NCT04003415|DIAGNOSTIC_TEST|Heart Rate (EKG) Monitor|Participant will undergo 3-lead EKG testing to measure heart rate during testing.
224174293|NCT04003415|DIAGNOSTIC_TEST|Respiratory rate Monitor|Participant will have an elastic band around their chest for monitoring respiratory rate during testing.
224174294|NCT04003415|DIAGNOSTIC_TEST|Pulse Oximetry|Participants will wear a finger pulse oximeter during the testing for monitoring of heart rate, respiratory rate, and pulse oximetry.
224306287|NCT00024284|DRUG|carboplatin|
224306288|NCT00024284|DRUG|irinotecan hydrochloride|
224306289|NCT02643355|DRUG|Olanzapine|
224306290|NCT02643355|DRUG|Clonidine|
224306291|NCT03495349|OTHER|safety and effectiveness of the usual treatments of diabetic foot infections|clinical and biological follow-up necessary to assess the safety and effectiveness of the medical treatments, MOS-SF survey (36-Item Short Form Survey) to study the quality of life.
223485539|NCT06150547|DIAGNOSTIC_TEST|FDG Positron Emission Tomography|Imaging using an FDG radioactive tracer to look at the head.
224174295|NCT02630485|BEHAVIORAL|Graceful Lifestyle Changes|Participants will be educated in small groups of 8-10. A wellness booklet designed by physicians and researchers at Grace Fertility Centre will be provided.The target diet for our study is 45% carbohydrates and 55 grams of glycemic load. Participants will keep a 3-day food diary at baseline, 4, 8 and 12 weeks. Secondly, participants will be provided a pedometer and a goal to reach 10,000 steps a day. The third aspect of the program will be to decrease overall stress through mindfulness. Educational sessions will be held to teach the relaxation response and meditation techniques such as breathing and grounding exercises. Participants will be required to meditate for at least 20 minutes each day and record this.
224174296|NCT02630485|DIETARY_SUPPLEMENT|Myo-inositol|Myo-inositol will be consumed in juice or water every morning (6 grams) for 12 weeks.
224174297|NCT02630485|DRUG|Letrozole|Letrozole will be administered to patients. The initial dose will be 5 mg daily for five days and the dose can be increased by 2.5 mg to a total daily dose of 7.5 mg if necessary depending on ovulatory response, as in clinical practice. This treatment regimen will continue for three cycles (approximately the same period of time as the treatment group) or until pregnancy is achieved.
224174298|NCT01564485|DIAGNOSTIC_TEST|Cardiac CT|A cardiac CT involves a non-invasive test of the coronary arteries.
224174299|NCT01564485|BEHAVIORAL|Usual medical care|Patients would be treated by their primary care physicians with usual medical care with drugs such as lipid lowering medication, blood pressure lowering medications, and blood glucose lowering medications. The study will not specify which drugs to use and will it up to the individual physician's discretion.
224174300|NCT03665987|BEHAVIORAL|consultation in preoperative assessment clinic|The treatment group will be seen in the preoperative clinic before hospitalization, while the control group will get anesthetic consultation after hospitalization without clinic service. No additional interventions will be given during and after surgery.
223485540|NCT06150547|DIAGNOSTIC_TEST|Chemical Exchange Saturation Transfer Magnetic Resonance Imaging|A noninvasive diagnostic test for measuring biochemical changes in the brain, especially the presence of tumors.
223485541|NCT02214472|BEHAVIORAL|Biofeedback|
223485542|NCT02214472|DRUG|Placebo|
223485543|NCT03864432|DRUG|Gemigliptin 25mg|Gemigliptin 50mg 1/2T
223485544|NCT03864432|DRUG|Gemigliptin 50mg|Gemigliptin 50mg 1T
223485545|NCT03864432|DRUG|Gemigliptin 100mg|Gemigliptin 50mg 2T
223485546|NCT03864432|DRUG|Gemiglptin 50mg multiple dose|Gemigliptin 50mg 1T \* 10days
224174301|NCT01097733|OTHER|Randomization of Pre-knowledge of CT coronary venography|
223485547|NCT00472238|BEHAVIORAL|endurance training|control group.
223485548|NCT00472238|BEHAVIORAL|exercise training|Treadmill exercise training to optimize physical endurance
223485549|NCT00855608|DRUG|adalimumab|intravitreal adalimumab injection 0.03 ml in volume (1.5mg) one dose to one eye
224174302|NCT02227433|DRUG|Brentuximab Vedotin|
224174303|NCT02339454|DEVICE|Active treatment group|Energy Density - 0.09 mJ/mm2 Device: Active Applicator
224306292|NCT00000139|BEHAVIORAL|Stress|
223485550|NCT03329989|BIOLOGICAL|Collagenase Clostridium Histolyticum|During 3 treatment visits 12 injections will be given per treatment area
223485551|NCT06433726|DRUG|BY101921 tablets|An oral PARP7 Inhibitor
223485552|NCT02011399|PROCEDURE|Brain Computer Interface for Mu Rhythm|"Device: Brain Computer Interface Subjects will wear an EEG (electrode) cap for 1-4 hours (1-2 hours typical) per session and use the brain-computer interface to operate a computer. Subjects will be asked to participate in 4-20 sessions.~Arms: Brain Computer Interface Keyboard"
223485553|NCT06548490|DRUG|Semaglutide Pen Injector|Semaglutide will be provided using an injection pen
223485554|NCT06548490|DRUG|Placebo|Placebo will be a dry needle stick; no substances will be injected
224306293|NCT00000139|DRUG|Acyclovir|
224306294|NCT03144310|OTHER|lung ultrasound|lung ultrasound and blood gas
223485555|NCT00193986|DEVICE|Arbitrary Waveform Defibrillator|
223485556|NCT02708056|DRUG|Sugammadex|
223485557|NCT03520530|DEVICE|Mouth Guard|Patient will wear mouth guard while pushing in the second stage of labor
223485558|NCT04358523|DRUG|ASC18|ASC18：ravidasvir and sofosbuvir fixed Dose Combination 200 mg/400 mg
223485559|NCT04358523|DRUG|ravidasvir and sofosbuvir|RDV 200 mg and SOF 400 mg
223586396|NCT06426849|OTHER|Liuzijue Exercise|"LiuzijueExercise includes inhalation and exhalation through various mouth patterns to manage and control the rise and fall of the breath in the body. It is performed by delivering 6 distinct sounds, (xū,hē, hū sī, chuī, and xī) through termination along with comparing body activities.~The following are 6-8 vital parts of body movements:~1. Swaying and twisting~2. Hip rotations~3. Arm movements~4. Knee bends~5. Foot pivots~6. Spine elongation~7. Hand gestures~8. Breath synchronization Frequency: 1 session per day for a week Intensity:In first week 1 set of Luizijue exercise will be performed then progressively increase to 4 sets till 6th week .~Total Time for Session; 40 minutes Warm-up Time: 10 minutes with pursed lip breathing Cool Down Time: 10 minutes with upper body gentle stretching. Exercise Duration: 20 minutes for Luizijue Exercise."
224174304|NCT02339454|DEVICE|Placebo group|Placebo Applicator
224174305|NCT05677854|OTHER|Health literacy based motivaonal interview|Motivational interviewing technique was used based on health literacy.
224174306|NCT05677854|OTHER|Health literacy based health education|Health education based on health literacy was used.
224174307|NCT01841164|DRUG|Montelukast|
224174308|NCT01841164|DRUG|Placebo for montelukast|Sugar pills manufactured to mimic Singulair
223485560|NCT04358523|DRUG|ASC18|ASC18：ravidasvir and sofosbuvir fixed Dose Combination 200 mg/400 mg
223485561|NCT03662568|DRUG|GLS4|Administered GLS4 120 mg orally three times daily in fed state
223485562|NCT03662568|DRUG|RTV|Administered RTV 100 mg orally three times daily in fed state
223485563|NCT03662568|DRUG|ETV|Administered orally ETV 0.5 mg once daily in fasted state
223485564|NCT03662568|DRUG|TDF|Administered TDF 300 mg orally once daily in fasted state
224174309|NCT01841164|OTHER|Inhaled leukotriene E4|Inhalation challenge with aerosolized GMP-grade LTE4 (Cayman Chemical Company 1180 East Ellsworth Road, Ann Arbor, Michigan 48108,USA)
224174310|NCT05664828|DRUG|SN132D|Manganese-based macromolecular MRI contrast agent
224306295|NCT04007432|OTHER|pulse oxymeter|Nocturnal oxymetry data will be continuously collected during nighttime by a pulse oxymeter, covering for 1 to 3 nights.
224174311|NCT05820776|OTHER|pulmonary rehabilitation|The intervention is PR delivered via a telemedicine. The intervention is PR delivered via a telemedicine. The program is delivered by the multidisciplinary via a remote application for two sessions per week for ten weeks. Remotely supervised exercise includes: 1) deep breathing reinforcing pursed lip and diaphragmatic breathing; 2) warm up breathing and stretching exercise; 3) a cardiorespiratory aerobic exercise battery; 4) resistance training, and; stretching cool down. There is also an educational component. The secondary (maintenance) program includes ongoing remotely supervised exercise and education once a week for six months (24 sessions). All patients successfully completing the initial PR are offered the maintenance program.
224174312|NCT05518994|DRUG|Tislelizumab plus Bevacizumab|200mg sintilimab plus 3mg/kg bevacizumab every 3 weeks.
224174313|NCT02462889|DRUG|Intravitreal aflibercept injection|Intravitreal aflibercept injection
224174314|NCT02462889|DRUG|Placebo|Sham injection
224174315|NCT02390362|DRUG|Rituximab|We hypothesize that the anti-CD20 monoclonal antibody Rituximab will be more effective in maintaining remission in children who have already had one relapse while receiving MMF
224174316|NCT02390362|DRUG|MMF|Subjects randomized to MMF, will continue MMF as scheduled by the investigator
224174317|NCT03946189|DIAGNOSTIC_TEST|Obtaining arterial blood gases|Obtaining arterial blood sample
224174318|NCT00294229|PROCEDURE|manipulative therapy|
224174319|NCT00885729|PROCEDURE|stem cells|Stem cells or chondrocytes under a commercial available membrane
224174320|NCT00885729|PROCEDURE|Chondrocytes|Implantation of chondrocytes
224174321|NCT00885729|OTHER|Rehabilitation program|Strength exercises, neuromuscular exercises
224174322|NCT00613340|PROCEDURE|Cervical medial branch blocks|Cervical medial branch blocks done with 0.25 ml of local anesthetic and contrast
224174323|NCT00613340|PROCEDURE|Cervical medial branch blocks|Cervical medial branch blocks with 0.5 ml of local anesthetic and contrast
224174324|NCT03450486|OTHER|exercise|one 30 minute bout of mild exercise
224174325|NCT02499640|OTHER|immersion cold water|immersion cold water at different temperatures and exposure times
224174326|NCT03238040|OTHER|None, observational study|Observational study, no interventions
224174327|NCT04009824|BIOLOGICAL|AGS-v PLUS Vaccine|Administered by subcutaneous injection
224174328|NCT04009824|BIOLOGICAL|Montanide ISA-51 Adjuvant|Administered by subcutaneous injection
224174329|NCT04009824|BIOLOGICAL|Alhydrogel® Adjuvant|Administered by subcutaneous injection
224174330|NCT04009824|BIOLOGICAL|Saline Placebo|Administered by subcutaneous injection
223485565|NCT04502277|DRUG|Fluconazole Powder|The Objective of This Study Was an Open-label, Randomized, 2-way Crossover to Compare the Single-dose Relative Bioavailability of Diflucan 40mgm/ml 35 ml Suspension and to measure AUC at 0, 1 , 4 , 8, 12, 16 , 20 and 24 hours Under Fed Condition
224174331|NCT01855204|RADIATION|Computed tomographic urography|Computed tomographic (CT) urography was done with the protocols of low voltage and low iodine concentration.
224174332|NCT03131258|PROCEDURE|Donor Nephrectomy|48 Donor Nephrectomy Patients
224174333|NCT02311140|OTHER|nasal lavage (routine diagnostic procedure in our centre), assessment of symptoms|
224174334|NCT05704140|OTHER|Catheter based Dialysis|We will conduct a cross-section analysis regarding patients with catheter-based VA in Vienna.
224174335|NCT01024946|DRUG|everolimus|Everolimus will be administered at a dose of 10mg orally once daily continuously. Dose reduction may be required depending on the type and severity of toxicity encountered. One cycle will be considered 28 days. Patients will have CT scans to evaluate for response after cycle 1 and cycle 2, and then every two cycles thereafter.
224174336|NCT03817931|DRUG|Anticholinergic|Tablet taken once daily.
224174337|NCT03817931|DRUG|Beta-3 Agonists, Adrenergic|Tablet taken once daily.
224174338|NCT03817931|DIAGNOSTIC_TEST|Functional magnetic resonance imaging (fMRI)|All subjects have fMRI at baseline and again after 30 days
223485566|NCT03901300|BEHAVIORAL|Fundamental Motor Skills App|Lessons will be provided over the app each week with notifications sent 5 days/week over 12 weeks specific to randomized experimental group.
224306296|NCT06160193|BEHAVIORAL|Brief behavioral parent training with optional care as usual|A brief behavioral parent training program that combines individually-tailored stimulus control and contingency management techniques to treat children's behavioral difficulties in two (bi)weekly training sessions of 120 minutes, and a third session of 60 minutes, in which the training will be evaluated and maintenance training will be provided.
223485567|NCT03901300|BEHAVIORAL|Unstructured Physical Activity App|Lessons will be provided over the app each week with notifications sent 5 days/week over 12 weeks specific to randomized active comparator group.
223485568|NCT06361108|DRUG|YJ001 for Spray Use|Granules for spray use; Preparation of Dosing Solution: Reconstitute with sterile water (50ml)
224174339|NCT03817931|DIAGNOSTIC_TEST|Rey Auditory Verbal Learning Test (RAVLT)|All subjects have RAVLT at baseline and again after 30 days. RAVLT evaluates: short-term auditory-verbal memory, rate of learning, learning strategies, retroactive, and proactive interference, presence of confabulation of confusion in memory processes, retention of information, and differences between learning and retrieval.
224174340|NCT02274766|DRUG|ADS-5102|Oral capsules to be administered once nightly at bedtime, for 13 weeks.
224174341|NCT02274766|OTHER|Placebo|Oral capsules to be administered once nightly at bedtime, for 13 weeks.
224174342|NCT02239029|DRUG|platelet rich plasma|Platelet rich plasma (PRP) is a new and potential treatment for patients with kinds of musculoskeletal disorders.
224174343|NCT02239029|DRUG|Normal saline|The normal salin as the placebo intervention was injection in the other side of knee.
224174344|NCT01528618|DRUG|gemcitabine and cisplatin|The GP regimen consists of gemcitabine at a dose of 1,000 mg/m2 by intravenous (i.v.) infusion over 30 min on day 1 and day 8, and cisplatin 80 mg/m2 by i.v. infusion for 4 h on day 1 only
224174345|NCT01528618|DRUG|5-Fluorouracil and cisplatin|The FP regimen consists of 5-Fluorouracil 1,000 mg/m2/day which was administered as a continuous intravenous infusion for 96 hours after completion of the cisplatin on days 1( 80 mg/m2 i.v. infusion for 4 h)
224306297|NCT06160193|OTHER|Care as usual|Care as usual may include all mental health care that is usually provided within or outside (e.g., at a child mental healthcare institution or at school) the general practitioners practice, except from pharmacological treatment for children's behavioral difficulties and/or behavioral parent training/support, up until the first posttreatment assessment (T1). Care as usual can also imply that there is no support or treatment.
224174346|NCT01620437|DRUG|biphasic insulin aspart 50|A single dose administrated subcutaneously (s.c., under the skin) on two separate dosing visits. A wash-out period of 6-21 days will take place between dosing visits
224174347|NCT04582162|OTHER|Unsplinted implants|Patients received ball abutments on each implant without splinting for retaining an implant retained mandibular overdenture.
224174348|NCT04582162|OTHER|Splinted implants|Patients had their implants splinted using Rhein bars with ball extension for retaining an implant retained mandibular overdenture.
224174349|NCT06375694|DIETARY_SUPPLEMENT|Herbiotics Oral + Ent Probiotic|Chewable Tablets containing Lactobacillus species.
224174350|NCT06375694|DIETARY_SUPPLEMENT|Placebo|Honest Placebo Pills by Zeebo
224174351|NCT01132391|DRUG|Rectogesic® (glyceryl trinitrate 0.4% ointment)|375 mg of ointment(1,5 mg of glyceryl trinitrate ) / 12h DURING 6 MONTHS
224174352|NCT03032523|DIAGNOSTIC_TEST|Standard of care glucose test|If the CGM in the remote monitoring group detects a blood sugar less than 46mg/dl, a confirmatory standard of care glucose test will be performed to confirm the low blood sugar.
224174353|NCT04840849|BIOLOGICAL|nirsevimab|Drug: injection, a single fixed IM dose on day 1 only.
224174354|NCT04840849|OTHER|Placebo|Placebo: injection, 0.9% (w/v) saline, a single fixed IM dose on day 1 only.
224174355|NCT01982669|OTHER|No Intervention|
224174356|NCT04562038|BEHAVIORAL|Young Children's Participation and Environment Measure (YC-PEM) electronic patient-reported outcome (e-PRO)|The Young Children's Participation in Environment Measure (YC-PEM) is an evidence-based option for comprehensive proxy assessment of a young child's current and desired participation in occupations across home, daycare, and community settings. The YC-PEM is an electronic patient-reported outcome (e-PRO) that provides individual caregivers a valid, reliable, and feasible way to communicate information about their child's current participation in home and community activities and areas of participation need. The gained information is then summarized and shared with the child's EI provide team to identify intervention priorities and goal attainment strategies in partnership with families. For quality improvement, EI programs can aggregate the YC-PEM e-PRO data to examine trends in participation as a function of EI service use. It is therefore a promising electronic health systems intervention to enhance the parent-practitioner relationship, and an NIH common data element for trials.
224174357|NCT02839655|DEVICE|Da Vinci Xi|
224174358|NCT00743613|BEHAVIORAL|Sexual Health Inventory for Men (SHIM)|Five question test with maximum score of 25 points administered on the initial visit. Erectile dysfunction is indirectly related to the score.
224174359|NCT00743613|PROCEDURE|Ankle-Brachial Index (ABI)|Measure Ankle-Brachial Index with a hand held doppler and sphygmomanometer to determine the ABI.
224174360|NCT01751243|OTHER|Allo-depleted lymphocyte infusion|Doses: 1x105 CD3/Kg; 3x105 CD3/Kg; 5x105 CD3/Kg; 1x106 CD3/Kg;31x106 CD3/Kg;
224174361|NCT01751243|OTHER|Haploidentical transplantation of hematopoietic progenitors|Haploidentical transplantation of hematopoietic progenitors without subsequent infusion of allo-depleted lymphocytes.
224174362|NCT01243203|DRUG|Champix|Days 1 - 3: 0.5 mg once daily (1 table each day) Days 4 - 7: 0.5 mg twice daily (1 in the morning and 1 in the evening) Days 8 - 12 weeks 1.0 mg twice daily (1 in the morning and 1 in the evening)
224174363|NCT03206606|DEVICE|SPIRO|Participants in the Experimental Group will be asked to use SPIRO mobile application during a period of 4 months.
224174364|NCT04638036|DRUG|Cetuximab-IRDye800|Intravenous administration of a pre-dose of 75 mg unlabeled Cetuximab followed by 15 mg Cetuximab-IRDye800 prior to the study procedures
224174365|NCT04638036|DEVICE|Fluorescent molecular endoscopy and surgery|A flexible fluorescence fiber-bundle is attached to a fluorescence camera platform to enable the detection of fluorescence signals. The fluorescence fiber-probe can be inserted through the standard working channel of the standard clinical endoscope for fluorescent endoscopy. Fluorescence imaging will be performed post the chemoradiotherapy.
224174366|NCT03307213|DEVICE|BioFreedom™ CoCr Biolimus A9™ stent|Stent implantation
223485569|NCT06361108|DRUG|Placebo of YJ001 for Spray Use|Inactive Ingredient: Sterile water; Preparation of Dosing Solution: 50ml Sterile water
223485570|NCT03436719|DRUG|Oral antibiotic|Metronidazole - 500 mg and Erythromycin - 500 mg per os \*3 times at 5 p.m.; 8 p.m., 11 p.m. in a day before surgery
223485571|NCT03436719|DRUG|Intravenous antibiotic|Cefoperazone - 1000 mg intravenously for 30-90 minutes before surgery
223485572|NCT03436719|DRUG|Mechanical Bowel Preparation|Beginning of MBP at 4 p.m. in a day before surgery
223586397|NCT06426849|OTHER|Tai Chi Chuan Exercise|"Tai Chi Chuan Exercise combines deep diaphragmatic breathing and relaxation with many fundamental postures.~Names of the 10 Movements in Sequence~1. Commencing Form~2. Repulsing the Monkey~3. Brush Knee~4. Parting the Horse's Mane~5. Cloud Hands~6. Golden Cockerel Standing on the Left, then the Right~7. Kick Out Right, Kick Out Left~8. Grasping the Bird's Tail~9. Cross Hands or Embrace the Tiger~10. Closing Form Frequency: 3 sessions / week Intensity: Initially each posture will be performed 3 times then progressively leads to 6 or 10 reps according to patient tolorance.~Total Time for Session; 40 minutes Warm-up Time: 10 minutes with pursed lip breathing Cool Down Time: 10 minutes with upper body gentle stretching. Exercise Duration: 20 minutes for Tai Chi Chuan Exercise."
223586398|NCT06222034|DRUG|Filgotinib|Film-coated mini-tablets administered orally once daily
224174367|NCT03307213|DEVICE|BioFreedom™ SS Biolimus A9™ stent|Stent implantation
224174368|NCT05229575|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|Undergo SBRT
224174369|NCT04926870|OTHER|picture archiving and communication system|PACS administration during teaching
224174370|NCT04926870|OTHER|traditional|Clinical experience administration during teaching without PACS
224174371|NCT06064552|DIAGNOSTIC_TEST|blood sugar|"High and low risk women will undergo measuring fasting blood sugar after fasting 6-8hours with good hydration. then measuring blood sugar 1hrs and 2hrs postprandial. for patient with high results (FBS\>95mg/dl, 1hr postprandial\>126mg/dl, 2hrs postprandial \>140mg/dl) should do HA1C if \>5.6 consider it diabetic and dealing with whom positive as regard lifestyle management like diet and exercise 150 min. per week and whom not well controlled will be enrolled in pharmacological regimen as metformin.~For whom measures normal will be tested by the same method at 20- 24 wks of gestation"
224174372|NCT00935662|DRUG|AZD8329|Oral solution, single ascending doses
224174373|NCT00935662|DRUG|Placebo|Oral solution, placebo
224174374|NCT02349776|OTHER|Providing testimonies from survivors of transplants to patients|"Patients will be asked to complete one mood measure (the HADS), the Life Orientation Test (LOT), and a questionnaire about expectations of treatment in clinic once a decision to proceed to transplant has been made.~Patients will receive the testimonies upon admittance to the transplant unit and then receive the HADS and a structured interview within the first week of being admitted to the transplant ward (just prior to receiving the transplant) and within the first two weeks following the transplant."
224174375|NCT01163695|BEHAVIORAL|Children's development account|Children in the experimental condition (the SUUBI program) received, in addition to the usual care, an economic empowerment intervention aimed at promoting asset accumulation for families-and consisting of three major components: 1) workshops focused on asset-building and future planning; 2) a monthly mentorship program for adolescents with peer mentors on life options; and 3) a Child Development Account (CDA), dedicated to paying for secondary schooling, vocational training and/or a family small business. The CDAs were matched savings accounts, with a match rate of 2:1 as an incentive for participants to save, but with a limit on the maximum savings that could be matched (the match cap, in this case, was equivalent to $10 a month).
224174376|NCT00302575|BEHAVIORAL|Collaborative Behavioral Management|
224174377|NCT00302575|PROCEDURE|Integrated parole and outpatient addiction treatment|
224174378|NCT02292888|OTHER|Passive Leg Raising (PLR) test|Passive Leg Raising (PLR) test
224174379|NCT06117956|DIAGNOSTIC_TEST|Rapid urease test for h pylori|"Tonsillectomy will be done with the dissection method and one tonsil per patient will be collected. A 2 mm gross specimen will be washed with normal saline. The specimen will be placed in a test tube well containing Rapid Urease Enzyme (GASTRO CURE SYSTEM RUT DRY TEST Batch No. A1060).~The initial color will be read at 0 min. Subsequent color changes will be read at 30 min, 6 hours, and 24 hours. Any color change from the initial yellow color to either pink or red will be recorded as positive. Any test that will be remained yellow after 24 hours will be recorded as negative.~Tonsillar tissue samples will be fixed in 10% formalin for 24 h Each slide will be separately evaluated for the presence or absence of Helicobacter-like organisms at a high-power magnification"
224174380|NCT00984009|DRUG|Colchicine|A single dose of 0.6 mg colchicine administered alone at 7:15 a.m. on Day 1
224174381|NCT00984009|OTHER|Grapefruit Juice|240 mL of grapefruit juice ingested twice daily at 7:15 a.m. and 7:15 p.m. on Days 15 to 18.
224174382|NCT00984009|DRUG|Colchicine|A single dose of 0.6 mg colchicine administered with grapefruit juice at 7:15 a.m. on Day 18 after an overnight fast of at least 10 hours.
224174383|NCT05129111|DEVICE|PHYSICAL VIBRATION OF THE PAROTID GLANDS|The system will be placed bilaterally in the parotid glands and assessed the efficacy of the salivary secretion by sialometry before and after the stimulation
224174384|NCT03821350|OTHER|Information leaflet|The written and visual information form prepared specifically for the patients was aimed to provide detailed information by clearly expressing the procedure, the suggestions that will be needed before and after injection (what to bring next, what circumstances may not be done, the control visit day after the procedure etc.) to be applied on before the injection day.
224174385|NCT06193837|DRUG|Augmentin|Use of prophylactic antibiotics in lap cholecystectomy
224174386|NCT05086640|OTHER|Lemon foot to prevent blister|The investigators make the hypothesis that the local application of Lemon allows a reduction of the number of blisters on ultra-trail.
224174387|NCT00281528|DRUG|ABI-007 (Abraxane)|30 minute infusions
224174388|NCT00281528|DRUG|bevacizumab|infusions
224174389|NCT02385591|BEHAVIORAL|Telephone Support|telephone-based physical activity advice and support delivered by a trained professional facilitator.
224174390|NCT02385591|BEHAVIORAL|SMS Support|Telephone-based physical activity advice and support delivered by SMS.
224174391|NCT01758640|DRUG|Warfarin|Low dose warfarin of 5mg or less per day
224174392|NCT01758640|DRUG|phenindione|Phenindione of 100mg or less per day
224174393|NCT04812665|BEHAVIORAL|mHealth solution based on emotional and behavioral change techniques|"Adhera supports the empowerment of patients with chronic conditions by supporting the acquisition of healthier lifestyles, improved mental wellbeing and grounded on the principles of behavioral change.~The solution is based on incorporating the principles of personalized health education into a mobile platform which is achieved by applying the Integrated Model of Behavioral Change which is further adapted using recommender systems. Emotional and mental health elements, such as stress, resilience, are crucial part in the acquisition of self-management behaviors and will be the main focus of this intervention. Adhera adapts to provide tailored support to specific users' needs."
224306298|NCT01653717|PROCEDURE|Leukapheresis|Blood drawn through a needle in a vein in one arm, then passed though a machine to collect white blood cells, and then remaining blood returned back to patient through a needle in a vein in other arm. Procedure will take about 3 hours to complete.
223485573|NCT06372236|BIOLOGICAL|UTAA06 injection for treatment of advanced malignant solid tumors|The subjects who sign the informed consent forms and been screened by inclusion/exclusion criteria,will be assigned into 1×10\^8CAR+gdT、3×10\^8CAR+gdT、5×10\^8CAR+gdT、8×10\^8CAR+gdT、1×10\^9CAR+gdT groups inder of sequence.And the subjects will be administered once.
223745240|NCT02117999|DEVICE|Cross-linking with iontophoresis|The procedure involves a constant current source and two electrodes. The active electrode is a bath tube, which includes a stainless steel grid, placed into the cup at a minimal distance from the cornea. The reservoir is filled with dextran-free, hypotonic riboflavin-5-phosphate solution. The generator applies a constant current of 1mA for a preset period of 5 min. After the riboflavin administration by iontophoresis, the cornea is irradiated using a UVA lamp of 10mW/cm2 for 9 minutes.
223745241|NCT02117999|DEVICE|Standard corneal cross-linking|In the standard CL, the epithelium is mechanically removed. Then, a solution of riboflavin is instilled each minute for 30 minutes. Corneas are irradiated using a UVA lamp of 3mW/cm2 for 30 minutes.
224174394|NCT05512195|RADIATION|New delineation approach|New delineation approach
224306299|NCT01653717|DRUG|Fludarabine|25 mg/m2 by vein on Days -5 to Day -3.
224306300|NCT01653717|DRUG|Cyclophosphamide|250 mg/kg by vein on Days -5 to -3.
224306301|NCT01653717|PROCEDURE|T-cell Infusion|Beginning dose of genetically modified cells is \> 5x10\^7/m2 but less than or equal to 5 x10\^8/m2 infused on Day 0.
223485574|NCT03853928|DIETARY_SUPPLEMENT|Probiotics|"Each 50 ml bottle contains Lactobacillus casei 3.3 x 107 CFU / day, Lactobacillus plantarum 3.3 x 107 CFU / day, Streptococcus faecalis 3.3 x 107 CFU / day and Bifidobacterium brevis 1.0 x 106 CFU / day (BIOFLORA®, BIOSIDUS SA, Argentina) .~Medication Reference intervention. Name of the active substance: Placebo. Administration way: Oral 5 ml orally every 12 hours for 10 consecutive days (Cycle, monthly)~Likewise, both branches will explicitly request the non-consumption of alcohol and the consumption of a non-hypercaloric Mediterranean diet throughout the study for all patients in each branch (ANNEXIII)."
224174395|NCT04081051|OTHER|diagnostic algorithm+Point of care rapid diagnostic tests+ Behavior change ( assessed together as a single package of interventions)|Diagnostic algorithm utilizing pathogen specific and non-pathogen specific point of care, rapid diagnostic tests, behavioral change intervention for healthcare workers
223485575|NCT05884450|OTHER|Acupressure|Acupressure is an integrated method of applying physical pressure to acupuncture points on the body surface with hands, elbows or various tools. With good counseling, patients can apply this method, which is non-invasive, easy to apply and safe, on their own.
223485576|NCT03406468|RADIATION|Radiotherapy|Patients continue the same immune therapy they already received and get radiotherapy to one lesion. The lesion may or may not be symptomatic. The preferred radiotherapy dose is 24 Gy in 3 fractions (dosage on the 10 Gy isodose is allowed), but other fractionation schedules (e.g. 30 Gy/ 10 fractions, 20 Gy/ 5 fractions, 20-24 Gy / 1 fraction for SRS (stereotactic radiosurgery)) are allowed if these are standard for a certain location or palliative indication in the body.
223485577|NCT00435643|PROCEDURE|nasal continuous positive airway pressure|After an average interval of three months, 10 patients with severe OSAS (AHI of more than 30 events per hour of sleep) treated with a mean nCPAP pressure of 11.2 ± 0.7 cm of H2O were reassessed and all mentioned measurements above were repeated
223485578|NCT02695459|DRUG|cisplatinum and everolimus|Cisplatinum : 75 mg/m2 days 1,iv Everolimus : 7.5 mg daily: days 1-21 orally
223485579|NCT02385890|OTHER|Control|Non pulse ingredient bagel
223485580|NCT02385890|OTHER|Pea flour|Pulse ingredient bagel
223485581|NCT02385890|OTHER|Pea fibre|Pulse ingredient bagel
223485582|NCT02385890|OTHER|Pea protein|Pulse ingredient bagel
223485583|NCT02385890|OTHER|Pea flour + pea protein|Pulse ingredient bagel
223485584|NCT02385890|OTHER|Pea fibre + pea protein|Pulse ingredient bagel
223485585|NCT03323762|DEVICE|Remote Ischaemic Conditioning (RIC)|The CellAegis auto RIC (automated blood pressure cuff) will be placed on the upper arm and inflated to 200 mmHg for 5 minutes followed by 5 minutes of deflation. The programmed cycle is repeated 4 times in total, summing up to a total treatment length of 35 minutes
223485586|NCT00435942|DEVICE|Relay Thoracic Stent-Graft|implant
223485587|NCT00435942|PROCEDURE|Open Repair|Open surgery
223485588|NCT05766748|DRUG|Azeliragon|Azeliragon is an orally administered inhibitor of Receptor for Advanced Glycation Endproducts (RAGE) which is formulated as a 5mg hard gelatin capsule.
223745242|NCT00378209|DRUG|Bortezomib|Given intravenously on days 1,4,8 and 11 of a 21-day cycle for a minimum of 8 cycles.
224174396|NCT03486769|DEVICE|M1 stimulation|stimulating primary motor cortex with anodal transcranial direct current stimulation
223485589|NCT06304363|BEHAVIORAL|Braining|"Braining is a clinical invention that helps patients in psychiatry to start and execute physical exercise (PE) regularly in psychiatric care. The core components are basic moderate to vigorous aerobic group training session and motivational work led by the psychiatric staff. Braining is used as add-on treatment to regular psychiatric care and is included in the patient care plan."
223485590|NCT02189824|BIOLOGICAL|Partially HLA-matched unrelated donor cells|
223485591|NCT05614076|PROCEDURE|conserved chalky white enamel margins of class V cavities|during cavity preparation, we conserved chalky white enamel margins of class V cavities and then restored them with resin composite restorations,we assessed the restorations with visual inspection using a mirror and explorer according to USPHS Criteria
223485592|NCT05614076|PROCEDURE|Total removal of demineralized enamel margins of class V cavities|during cavity preparation, we removed the total chalky white enamel margins of class V cavities and then restored them with resin composite restorations, we assessed the restorations with visual inspection using a mirror and explorer according to USPHS Criteria
223485593|NCT05134844|OTHER|Hydrotherapy- Snoezelen|Multi sensory approach in water
223485594|NCT05134844|OTHER|Snoezelen|Multu Sensory approach on land
223485595|NCT02908230|BEHAVIORAL|Enhanced Care|8-week (nutrition, physical activity, and mental health) summer curriculum/program
223485596|NCT02908230|BEHAVIORAL|Standard Care|8-week (nutrition and physical activity) summer curriculum/program
223586399|NCT06222034|DRUG|Filgotinib|Commercially developed film-coated tablet administered orally once daily
223586400|NCT06203223|OTHER|Ova-max|use Ova-max 3 months prior to treatment initiation
223586401|NCT06203223|OTHER|placebo|use placebo 3 months prior to treatment initiation
223586402|NCT04304014|DIETARY_SUPPLEMENT|L. reuteri|(10\^8 CFU) once a day
223586403|NCT04304014|DIETARY_SUPPLEMENT|B. longum and P. Pentosaceus|(10\^9 CFU) once a day
223586404|NCT05771675|DRUG|Simvastatin|40Mg Oral Tablet
223586405|NCT05771675|DRUG|Placebo|Matching Simvastatin Placebo tablet
223745243|NCT00378209|DRUG|Lenalidomide|Taken orally once a day for 2 weeks (days 1-14) of a 21-day cycle for a minimum of 8 cycles
223745244|NCT00378209|DRUG|Dexamethasone|Taken orally on days 1,2,4,5,8,9,11,and 12 of a 21-day cycle for a minimum of 8 cycles
224174397|NCT03486769|DEVICE|PMC stimulation|stimulating premotor cortex with anodal transcranial direct current stimulation
224174398|NCT03486769|DEVICE|aIPS stimulation|stimulating anterior intraparietal sulcus with anodal transcranial direct current stimulation
224174399|NCT03486769|BEHAVIORAL|hand motor task|hand motor task for 30 minutes during transcranial direct current stimulation
224174400|NCT02652572|DRUG|Granexin|Granexin® gel will be dispensed directly from a 5 gram laminate tube and will be spread and smoothed directly over the wound surface in full contact with the wound bed to obtain an even, uniform layer on Day 0 (baseline), Day 3, and Day 7.
224174401|NCT00291460|DEVICE|inspiratory muscle training|
224174402|NCT02133144|BEHAVIORAL|overeating fat|
224174403|NCT02133144|BEHAVIORAL|overeating carbohydrate|
224174404|NCT04396106|DRUG|AT-527|One 550 mg tablet of AT-527 administered every \~12 hours (twice a day) for a total of 5 days
224174405|NCT04396106|OTHER|Placebo|One placebo tablet administered every \~12 hours (twice a day) for a total of 5 days
224174406|NCT04396106|DRUG|AT-527|Two 550 mg tablets of AT-527 administered every \~12 hours (twice a day) for a total of 5 days
224174407|NCT04396106|OTHER|Placebo|Two placebo tablets administered every \~12 hours (twice a day) for a total of 5 days
224174408|NCT05057884|BEHAVIORAL|Breathing training|Slow nasal breathing with intermittent end-expiratory apnoea for 15 min twice per day over 12 weeks.
224174409|NCT03781154|BEHAVIORAL|Group Exercise|Patients will exercise in a virtual group for 60 minutes, twice a week. Five social-cognitive theory-based discussion sessions with the group, and group exercise instructor will be held throughout the course of the intervention, lasting 30 to 60 minutes. The goal of these sessions is to enhance long-term physical activity behavior change.
224174410|NCT06481605|DEVICE|C-REX|The C-REX is a CE-marked class IIa device consisting of an invasive surgical part, including two anastomotic rings, intended for short-term use, and surgical instruments LapAid and RectoAid for assisting the placement of the anastomotic ring to intestine. The device is supplemented with a catheter to monitor the anastomosis.
224174411|NCT02783651|OTHER|Other|No intervention other than routine medical care
223485597|NCT02908230|BEHAVIORAL|Active Control|8-week (non-nutrition, physical activity or mental health) summer curriculum/program
224174412|NCT00515905|DRUG|Sevoflurane/propofol|Sevoflurane/propofol
224174413|NCT05592145|DEVICE|ViOptix|ViOptix machine
224174414|NCT03516227|BEHAVIORAL|heart rate variability biofeedback|The HRVBF group received four, one-on-one bedside biofeedback training sessions (20-minutes a day for 4 days), and practiced on their own (10-minutes twice a day) using a FDA-regulated, hand-held mobile biofeedback device (StressEraser, Helico Inc., New York, NY, USA).26 The control group received usual care.Afterwards, all participants were telephoned bi-weekly and encouraged to practice slow breathing (HRVBF group) or to perform self-care (control group) for three months.
224174415|NCT04562727|DRUG|Chemotherapy|perioperative chemotherapy or postoperative chemotherapy
224174416|NCT03315676|DRUG|Oral Bonoprazan|To examine the efficacy of oral Bonoprazan in patients with NSAIDs-induced Erosions and/or Ulcers
223485598|NCT00463424|DEVICE|NeuFlex metacarpophalangeal implant|
223485599|NCT00463424|DEVICE|Swanson metacarpophalangeal implant|
223485600|NCT01161888|DRUG|Imiquimod|250mg sachets to be applied at a start dose of 5 days a week. Dose will be adjusted using an algorithm according to tolerability.
223485601|NCT01756755|DEVICE|PMX-20R Hemoperfusion|Polymyxin B adsorbs and remove endotoxin from the patient's circulating blood.
223485602|NCT00820092|DRUG|Xerecept 1.0|24 hour infusion
223485603|NCT00820092|DRUG|Xerecept 2.0|24 hour infusion
223485604|NCT00820092|DRUG|Xerecept 3.0|24 hour infusion
223485605|NCT04862208|DIETARY_SUPPLEMENT|Maltodextrin supplement|maltodextrin (25g in 12 oz water) 1 hour pre-exercise
223485606|NCT04862208|DIETARY_SUPPLEMENT|Whey supplement|whey (25g in 12 oz water) 1 hour pre-exercise
223485607|NCT04862208|DIETARY_SUPPLEMENT|Water|non-caloric control (12 oz flavored water) 1 hour pre-exercise
223485608|NCT04862208|DIETARY_SUPPLEMENT|Maltodextrin supplement|maltodextrin (25g in 12 oz water) with no exercise
224174417|NCT03315676|DRUG|Oral Esomeprazol|To examine the efficacy of oral Esomeprazol in patients with NSAIDs-induced Erosions and/or Ulcers
224174418|NCT01930669|OTHER|Gravitational sympathetic stimulus|"Autonomic nervous system (ANS) activity is assessed by means of HRV, SAP variability and baroreflex control analysis daily from day 1 to discharge from ICU or day 28.~Analysis is performed (i)at rest in supine position with bed at zero degrees of inclination (ii) during modified tilt (MTILT) and (iii) recovery from MTILT in supine position at zero degrees. In a subgroup of patients motor sympathetic nervous activity (MSNA) is recorded at day 1,2 and 7.~MTILT consists in elevating head and trunk of patients at 60 degrees and lowering legs at 15 degree with a standard critical care bed. MSNA is recorded from the external peroneal nerve with microneurographic technique."
224174419|NCT00652522|DEVICE|ICD/CRT implant|Implantation of a ICD/ CRT device if not yet implanted
224174420|NCT00652522|PROCEDURE|AF ablation|Atrial Fibrillation ablation by pulmonary vein isolation
224174421|NCT00652522|OTHER|Best Medical Treatment|Best medical treatment according to current guidelines for Management of Patients with Atrial Fibrillation and for Management of Chronic Heart Failure.
224174422|NCT06220240|OTHER|Modified Training Programme|Eccentric muscle contractions and 3-minute rest breaks will be used.
224174423|NCT06220240|OTHER|Routine Training Programme|A routine training program will be used.
223485609|NCT06627803|DRUG|Alcohol (Oral)|Participants will drink a beverage that will have alcohol or no alcohol. The amount of alcohol consumed will be similar to consuming around 3-4 drinks, with breath alcohol concentration peaking at or around the legal limit for driving (0.08%).
223485610|NCT05428865|OTHER|correlation study|investigate the correlations between body mass index, spasticity, functional ability and isolated motor control in children with spastic diplegia.
223485611|NCT01618591|DRUG|Single dose rifaximin 1650 mg|Rifaximin 1650 mg as a single dose plus loperamide 4 mg initially followed by 2 mg after each unformed stool, not to exceed 16 mg/day for 2 days
223485612|NCT01618591|DRUG|Single dose azithromycin 500 mg|Azithromycin 500 mg as a single dose plus loperamide 4 mg initially followed by 2 mg after each unformed stool, not to exceed 16 mg/day for 2 days
223485613|NCT01618591|DRUG|Single dose levofloxacin 500 mg|Levofloxacin 500 mg as a single dose plus loperamide 4 mg initially followed by 2 mg after each unformed stool, not to exceed 16 mg/day for 2 days
223485614|NCT01618591|DRUG|Single dose azithromycin 1000 mg plus loperamide|Azithromycin 1000 mg as a single dose plus loperamide 4 mg initially followed by 2 mg after each unformed stool, not to exceed 16 mg/day for 2 days
223485615|NCT01618591|DRUG|Single dose azithromycin 1000 mg plus placebo|Azithromycin 1000 mg as a single dose and placebo in lieu of loperamide
223485616|NCT01859000|OTHER|Multidimensional Family Therapy|MDFT assesses and intervenes in four domains to address comorbid substance abuse and trauma symptoms: 1) adolescent, 2) parent, 3) family, and 4) external systems. MDFT therapists will address trauma symptoms among both teens and parents, aiming to improve coping and reduce the impact of stress on the family. Consistent with a multidimensional approach, MDFT trauma-focused interventions address the needs of both youth and their parents, and MDFT therapists seek collaboration and advocacy from school and court personnel.
224174424|NCT01023139|BEHAVIORAL|Sibutramine|During phase 1, sibutramine is given to all participants, 10mg po q day. If they do not meet a change in BMI of at least 2.5%,then the dosage may be increased to 15mg po q day. The main intervention in the study during phase 1 and 2is the behavioral modification
224174425|NCT01730625|BEHAVIORAL|Cognitive behavioral therapy for anxiety|
224174426|NCT01730625|BEHAVIORAL|Attention Bias Modification Treatment|
224174427|NCT02263924|DIETARY_SUPPLEMENT|Tocotrienol|Subjects in the intervention arm will take one capsule of 200mg tocotrienol twice daily for 6 months
224174428|NCT02263924|DIETARY_SUPPLEMENT|Placebo capsules|Subjects in the placebo arm will take one capsule of placebo twice daily for 6 months
224174429|NCT03822286|OTHER|e-training course|Home care staff received mainly self-study, you can download e-books on your lithography or personal mobile phone reading and learning, with lively animation, sound and video guide home staff Learn the knowledge of demented care. The e-book course sets out the themes of the eight demented care training courses.
224174430|NCT03822286|OTHER|Support group|A counseling master mix 8\~10 resident staff members, through the counselor to lead the symposium to the case home to implement technical guidance and through the set of social network groups to immediately discuss the care and solutions of dementia cases, and hold once a month in gathering, about 40\~60 minutes each time.
224174431|NCT03822286|OTHER|traditional classroom teaching course programs|Home care staff received the traditional demented care traditional classroom teaching course and did not accept any e-training and gathering.
224174432|NCT00859716|BIOLOGICAL|ACE393|ACE393 250 micrograms as intra muscular injection at day 0 and day 21
224174433|NCT00859716|BIOLOGICAL|Placebo vaccine|Placebo 500 micrograms Alhydrogel as intra muscular injection at day 0 and day 21
224174434|NCT00026624|BIOLOGICAL|ALVAC(2)120(B,MN)GNP (vCP1452)|
224174435|NCT00026624|DRUG|Keyhole-Limpet Hemocyanin|
224174436|NCT06065241|DIETARY_SUPPLEMENT|LLP-01|Participants in the experimental group will take 2 capsules daily containing 1,000mg of the formulation, LLP-01, for 60 days.
224174437|NCT06065241|OTHER|Placebo|Participants in the placebo group will take 2 capsules daily containing rice flower and small amount of Curcuma Longa for 60 days.
224174438|NCT01937949|DEVICE|Custom-made Zenith® Fenestrated AAA Endovascular Graft:|The graft will be inserted through arteries in the groin (called endovascular repair). Endovascular repair is a procedure that uses catheters that go inside your blood vessel to place a stent graft above and below the aneurysm. This procedure lines the aneurysm with a new lining (stent) so blood does not fill the artery any more.
223485617|NCT01859000|OTHER|Group CBT|Trauma symptoms will be addressed using techniques designed to reduce cognitions that maintain anxiety and depressive symptoms and improve coping, such as cognitive restructuring, gradual exposure, and helping teens to understand and accept reminders of the event and ongoing stressors (Pynoos et al, 1998).
223485618|NCT00243321|PROCEDURE|high dose-rate brachytherapy|High dose-rate brachytherapy
223485619|NCT00243321|PROCEDURE|intensity-modulated radiation therapy|intensity-modulated radiation therapy
224174439|NCT00921908|OTHER|2 mBq radioactive technetium diluted in 20 mL saline|
224174440|NCT00381836|DRUG|Darbepoetin Alfa|
224174441|NCT01628718|BEHAVIORAL|Adaptive Disclosure (AD)|Adaptive Disclosure (AD) is an eight-session fully manualized and piloted intervention designed specifically for Marines with PTSD stemming from a variety of traumatic deployment experiences. The approach combines imaginal exposure to activate trauma-related emotions and beliefs and cognitive and experiential techniques to modify maladaptive interpretations of the implication of various combat and operational experiences that contribute to symptoms and dysfunction.
224174442|NCT01628718|BEHAVIORAL|Cognitive Processing Therapy, cognitive version only (CPT-C)|"Cognitive Processing Therapy (CPT) is a 12-session manualized therapy for posttraumatic stress disorder. The theory behind CPT conceptualizes PTSD as a disorder of non-recovery in which erroneous beliefs about the causes and consequences of traumatic events produce strong negative emotions and prevent accurate processing of the trauma memory and natural emotions emanating from the event. A significant contributor to the interruption of natural recovery process is the ongoing use of avoidance as a coping strategy. CPT incorporates trauma-specific cognitive techniques to help individuals with PTSD more accurately appraise these stuck points and progress toward recovery."
224306302|NCT05124977|DRUG|Antimicrobial Stewardship|Antimicrobial stewardship based on daily clinical assessment of clinical cure. Discontinuation of appropriate antibiotic therapy antibiotics if criteria of clinical cure of confirmed pneumonia are met. Intensivists will perform clinical assessment daily in order to decide on the pursuit or discontinuation of antibiotic therapy.
223485620|NCT00994539|DRUG|morphine sulfate|morphine sulfate 15 mg and 30 mg tablets
223586406|NCT05623683|OTHER|Intermittent Walking|Wearing comfortable clothes and their usual walking shoes, participants will walk on a treadmill to accrue 30 minutes of walking. Participants will be instructed not to use the treadmill side rails for balance or support during walking. Participants will walk on the treadmill for 3 blocks of 10 minutes with 2 blocks of 5-minute rest (sitting on a chair) in-between. A safety button to stop the treadmill will be available to the participants, so they can stop walking anytime. If participants feel that they are about to lose balance, they are allowed to hold on to the side rails to regain balance and terminate the trial.
224306303|NCT05124977|DRUG|Standard management|Standard management: duration of appropriate antibiotic for confirmed pneumonia fixed for 7 days according to guidelines. In the control group, intensivists will perform clinical assessment daily, but the antibiotic will not be discontinued until 7 days whatever the clinical cure.
224306304|NCT03706833|DEVICE|Edwards PASCAL System|Transcatheter mitral valve repair with the Edwards PASCAL System
223485621|NCT05516069|OTHER|Our Healthbox (smart vending machine or interactive dispensing system)|Our Healthboxes or interactive dispensing systems (IDS) will be placed in various locations across Canada and will house HIV self-test kits (provided by REACH), harm reduction supplies (provided by the provincial governments / local community based organizations; e.g. sterile drug use kits for safer injection, naloxone kits, syringes), other community determined needs (including but not limited to hats, mittens and/or socks, rapid Covid-19 antigen kits, KN95 masks). Individuals will be able to access the HIV self-test kits and harm reduction and other materials directly from the machine. Our Healthbox will also provide health information, and a support services directory for people to find the health care they need - in their community.
223485622|NCT00255333|DRUG|INNO-105|
224174443|NCT04771936|OTHER|Physiotherapy Exercises|All patients shall be randomly assigned to 3 groups: the control group who shall be awaiting surgery and not receiving a regular physiotherapy, the exercise group who shall be subject to a set of conventional exercises and a core exercise group who shall be performing the conventional exercises plus exercises aimed at the activation of core muscles. These exercises shall be carried out 3 times weekly for a period of 3 months. During the first 4 weeks, all sessions shall be supervised by a physiotherapist. From the 5th to the 8th week, patients shall attend 2 supervised sessions and complete the 3rd one at home. Between the 9th and the 12th week, patients shall then attend 1 supervised intervention and complete 2 sessions at home.Patients assigned to the control group shall be given a chance to enrol into the program upon completion of the study if they wish to do so.
224174444|NCT00003687|DRUG|dextromethorphan hydrobromide|
224174445|NCT00003687|DRUG|morphine sulfate|
224174446|NCT03043300|OTHER|Screening Criteria Review|"The screening criteria review is an 8 item instrument collecting information during screening about overall health, including self-reported chronic intestinal conditions, immunocompromising conditions, the use of certain medication types (immunosuppressives and antibiotics), and pregnancy status. The instrument will also collect dates of planned travel to South(east) as well as preferred dates for study visits and reminder contacts.~This instrument will be administered verbally by the study team and completed no more than 4 weeks prior to travel departure from the United States."
224174447|NCT03043300|OTHER|Pre-Travel Questionnaire|"The pre-travel questionnaire is a 29 item instrument collecting information about baseline characteristics, dietary habits, travel plans, and health history.~This questionnaire will be administered verbally by the study team and completed 1 week prior to travel departure from the United States."
224174448|NCT03043300|OTHER|Pre-Travel Stool Specimen Collection|"The pre-travel stool specimen collection will occur 1 week prior to travel departure from the United States.~The processing and analyses of this stool specimen will be performed by the Centers for Disease Control and Prevention."
224174449|NCT03043300|OTHER|Short-Term Post-Travel Questionnaire|"The short-term post-travel questionnaire is a 19 item instrument collecting information about dates and locations of travel, food and beverages consumed while traveling, and illnesses during or following traveling.~This questionnaire will be administered verbally by the study team and completed 2 weeks after returning to the United States from travel."
224174450|NCT03043300|OTHER|Short-Term Post-Travel Stool Specimen Collection|"The short-term post-travel stool specimen collection will occur 2 weeks after returning to the United States from travel.~The processing and analyses of this stool specimen will be performed by the Centers for Disease Control and Prevention."
224174451|NCT03043300|OTHER|Long-Term Post-Travel Questionnaire|"The long-term post-travel questionnaire is a 16 item instrument collecting information about illnesses since last study visit, dietary habits since last study visit, and any traveling since the last visit.~This questionnaire will be administered verbally by the study team and completed 14 weeks after returning to the United States from travel."
224174452|NCT03043300|OTHER|Long-Term Post-Travel Stool Specimen Collection|"The short-term post-travel stool specimen collection will occur 14 weeks after returning to the United States from travel.~The processing and analyses of this stool specimen will be performed by the Centers for Disease Control and Prevention."
224174453|NCT02313506|BEHAVIORAL|Education session, Fitbit Flex, and remote coaching by a PT|Participants will receive a brief education session, use of a commercially available physical activity tracker (Fitbit Flex), and remote counselling by a PT. Intervention will be received immediately.
223485623|NCT06125990|OTHER|Experimental: Study Group (SGr)|For 6 weeks, in addition to institutional conventional exercise 2 days a week, one day a week of home exercise, breathing exercises to increase lung volumes and 7 sets of video-based breathing exercises were applied, each set consisting of 2 minutes of performance and 1 minute of rest.
223485624|NCT06125990|OTHER|Sham Comparator: Control Group (CGr)|Only institutional conventional rehabilitation was implemented.
223485625|NCT02251392|OTHER|Chamomila recutita Gel|Gel formulated with active principles from Chamomilla recutita which dose is being determined in a dose-response curve
223485626|NCT02251392|OTHER|Chamomila recutita Infuse|chamomila infuse in a concentration of 2,5% already determined in a dose response curve
224174454|NCT02313506|BEHAVIORAL|Same intervention with a 1 month delay|The Delayed Intervention Group will receive the same intervention as the Immediate Intervention Group, but with a 1 Month delay.
224174455|NCT04448340|DIAGNOSTIC_TEST|machine learning model|Two classification algorithms, logistic regression and K-Nearest Neighbors (K-NNs), were investigated for their ability to predict successfully whether patients suffered from PDD or DLB.
224174456|NCT02036476|DRUG|Cabozantinib|oral administration
224174457|NCT06117644|DRUG|Furmonertinib|Furmonertinib 40 mg/tablet, 4 tablets, QD
224174458|NCT01768702|BIOLOGICAL|Injection of C3BS-CQR-1|Injection of the C3BS-CQR-1 using the C-Cath® injection catheter.
224174459|NCT01768702|BIOLOGICAL|Sham, no injection|Mimic the injection procedure trough insertion of a sham catheter. No injection actually performed
223485627|NCT02251392|DRUG|Urea cream based|Urea is already using to treat radiodermatitis when it starts to occur, so it will be the usual care
223485628|NCT06328699|PROCEDURE|Spiritual Therapy|Undergo chaplain led compassionate centered spiritual health sessions
223485629|NCT06328699|OTHER|Best Practice|Receive a traditional chaplain consultation and will receive care upon request
223485630|NCT01967875|DRUG|Capecitabine+Cisplatin|Cisplatin 75mg/m2, d1; Capecitabine 1700-2000mg/m2/day on days1-14 every 21 days, 6 cycles.Capecitabine is to be continued until disease progression or intolerable toxicity.
223485631|NCT01967875|DRUG|Docetaxel+Capecitabine|Docetaxel 75mg/m2, d1; Capecitabine 1700-2000mg/m2/day on days1-14 every 21 days, 6 cycles. Capecitabine is to be continued until disease progression or intolerable toxicity.
223485632|NCT04491994|DRUG|HCQ|Tab HCQ 400mg 12 hourly day 0 followed by tab HCQ 200mg 12 hrly for next 5 days
223485633|NCT04329455|PROCEDURE|Endoscopic thyroidectomy|Endoscopic thyroidectomy in Thyroid Nodules
223485634|NCT03589703|OTHER|Target ear points related to chronic low back pain (T-APA)|Light touch using vaccaria seeds on specific points of the ear.
223485635|NCT03589703|OTHER|Non-Target ear Points not related to chronic low back pain (NT-APA)|Light touch using vaccaria seeds on different points of the ear (compared to the APA group).
224174460|NCT02365272|DRUG|Amikacin|Amikacin administered in a single dose for critical care patients
224174461|NCT04211740|DRUG|OCH-NCNP1|OCH-NCNP1 3mg is supplied as granules and take orally once a week.
224174462|NCT04211740|DRUG|Placebo|Placebo is supplied as granules and take orally once a week.
224174463|NCT03640104|BEHAVIORAL|Intervention-Nutrition guidelines|Subjects will receive an individualized dietary plan according to their nutritional status, socioeconomic and cultural preferences. Protein intake 1-1.5g/kg body weight; 30% fat (mono and polyunsaturated fatty acids), vitamin A sources (1300 RAE). Each subject will have 7 interchangeable options for every meal time, all equivalent in macronutrient content, and every two weeks a new menu will be provided by a nutritionist.
224174464|NCT03640104|BEHAVIORAL|Nutrition guidelines|Nutritional recommendations based on international guidelines
224174465|NCT05119244|OTHER|blood and hair sampling|3.5 ml blood sample Hair sample
224174466|NCT05956990|BEHAVIORAL|multidimensional rehabilitation|Multidimensional lifestyle interventions
224174467|NCT02034539|DEVICE|VADOplex system|intermittent automatic pneumatic compression of the sole of the foot by the VADOplex system
224174468|NCT04652349|DRUG|HGP1910|Take it once daily for 8 weeks orally.
224174469|NCT04652349|DRUG|HCP1903|Take it once daily for 8 weeks orally.
224306305|NCT03706833|DEVICE|Abbott Mitraclip System|Transcatheter mitral valve repair with the Abbott Mitraclip System
224306306|NCT06966050|BEHAVIORAL|Quality-of-life Questionnaire|Participants will be asked to fill out a quality-of-life questionnaire, which will take about 10-15 minutes to complete.
224306307|NCT05438459|BIOLOGICAL|Phase I part|Administration of GAIA-102 as a monotherapy or GAIA-102 and pembrolizumab in combination.
223485636|NCT03589703|OTHER|Enhanced Educational Control Group (CG-2)|No contact with the subject. Participants in the enhanced educational control group will be given the cLBP educational booklet.
224306308|NCT05438459|BIOLOGICAL|Phase II part|Randomized into group of administration of GAIA-102 as a monotherapy or GAIA-102 or pembrolizumab in combination, group of standard treatment
224306309|NCT03185442|DEVICE|Pulsed Radiofrequency|Pulsed Radiofrequency is performed if the sensory threshold is below 0.5 volts, the PRF consists of 380 pulses
224306310|NCT00752830|DRUG|AZD0328|Oral capsule, single dose
224306311|NCT06633250|OTHER|Test Formula|Hydrolyzed rice protein formula
223485637|NCT00624260|OTHER|semi-annual systematic PET-TDM|semi-annual systematic PET-TDM
223485638|NCT00624260|OTHER|PET-TDM for current indication|PET-TDM for current indication (high isolated markers or before a metastasis curative resection)
224174470|NCT04652349|DRUG|HGP1909|Take it once daily for 8 weeks orally.
224174471|NCT04652349|DRUG|HGP1911|Take it once daily for 8 weeks orally.
224174472|NCT02168816|DRUG|Intravenous Antibacterial Agent|Individuals in this arm receive an intravenous antibacterial agent. They are not assigned to specific medications. Individuals in this arm will receive an intravenous antibacterial agent as determined by their primary healthcare provider. This therapy is usually one of the following intravenous medications: (i) piperacillin/tazobactam (Zosyn), (ii) cefepime, (iii) metronidazole, (iv) aztreonam, (v) vancomycin, (vi) daptomycin, (vii) linezolid (Zyvox), and/or (viii) meropenem.
224174473|NCT02168816|DRUG|Oral Antibacterial Agent|Individuals in this arm receive an oral antibacterial agent. They are not assigned to specific medications. Individuals in this arm will receive an oral antibacterial agent as determined by their primary healthcare provider. This therapy is usually one of the following oral medications: (i) sulfamethoxazole/trimethoprim (SMX-TMP), (ii) clindamycin (Clindesse), (iii) linezolid (Zyvox), (iv) moxifloxacin (Avelox), (v) ciprofloxacin (Cetraxal), and/or (vi) metronidazole (Flagyl)
224174474|NCT02227290|DRUG|Naftin Cream|
224174475|NCT02227290|DRUG|Placebo Cream|
224174476|NCT02523742|DEVICE|IMRf|
224174477|NCT02523742|OTHER|language task and a reference task (rest and Tamil)|
224306312|NCT06633250|OTHER|Control Formula|Commercially available extensively hydrolyzed cow's milk formula
224306313|NCT05817929|OTHER|blood sample|5 ml blood sample will be withdrawn at the surgery start and at the surgery end
224306314|NCT06354998|BIOLOGICAL|Investigational mRNA-1273.815|Sterile solution for injection
224306315|NCT06354998|BIOLOGICAL|Licensed Spikevax Vaccine|Commercially available formulation
224306316|NCT02800213|DEVICE|Modified Ambu Spur II bag valve mask|Subjects deliver breaths to manikin (IngMar RespiTrainer manikin model) a modified Ambu Spur II bag valve mask with a supplemental external handle
224306317|NCT02800213|DEVICE|Conventional Ambu Spur II bag valve mask|Subjects deliver breaths to manikin (IngMar RespiTrainer manikin model) a conventional Ambu Spur II bag valve mask
224306318|NCT03907384|BEHAVIORAL|Mat Pilates training|This group completed 12-weeks of training
224306319|NCT00826449|DRUG|Dasatinib|Starting dose of 70 mg by mouth daily for 21 day cycle.
224306320|NCT00826449|DRUG|Erlotinib|150 mg by mouth daily every 21 day cycle.
224306321|NCT03490448|BEHAVIORAL|aerobic exercise and appropriate caloric control|The dietary was designed on the basis of ensuring the daily energy physiological requirement, and basal metabolic rate (BMR) was calculated to formulate diet project according to Harris-Benedict formula. The diet was composed of 20% protein, 30% fat and 50% carbohydrates.In the exercise, heart rate was monitored to ensure the small-medial load aerobic exercise. All kinds of sports were conducted indoor, twice per day, 6 days per week, and lasted for 2 hours every time.
224306322|NCT02994940|DRUG|Acetaminophen|already included in arm/group descriptions
224306323|NCT03233230|DRUG|M2591 25 mg QD|Participants received 25 milligrams (mg) of M2951 orally once daily (QD) for 12 weeks.
224306324|NCT03233230|DRUG|M2951 75 mg QD|Participants received 75 mg of M2951 orally QD for 12 weeks.
224306325|NCT03233230|DRUG|M2951 50 mg BID|Participants received 50 mg of M2951 orally twice daily (BID) for 12 weeks.
224306326|NCT03233230|DRUG|Placebo|Participants received placebo matched to M2951 orally for 12 weeks.
224306327|NCT02987959|DRUG|TAK-228|TAK-228 is a novel, highly selective, orally bioavailable adenosine 5' triphosphate (ATP)-competitive inhibitor of the serine/threonine kinase referred to as the mechanistic target of rapamycin (mTOR). TAK-228 (formerly INK128) targets 2 distinct mTOR complexes, mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2).
224306328|NCT04023903|DRUG|Bardoxolone methyl|Bardoxolone methyl 5 mg capsules
224306329|NCT04023903|DRUG|Bardoxolone methyl|Bardoxolone methyl 5 mg capsules
224174478|NCT06722781|BEHAVIORAL|Unified Protocol|The UP is a transdiagnostic treatment that was designed to be relevant to a wide range of emotional disorders, given the common co-occurrence of depression, anxiety, somatoform and dissociative symptoms. It is based on Cognitive and Behavioural Therapy (CBT) and emotion regulation theories, and the aim is to support patients to apply a series of emotion regulation skills that target the core common vulnerabilities that underlie a range of mental health problems: neuroticism, low perceived control, and overestimation of threat. Contents are organised across 8 modules delivered online across 12 weekly 1.5 hour sessions and will include a combination of internet-based resources (self-monitoring questionnaires, psychoeducational videos, skills practices linked to each module) and group therapy sessions delivered by a qualified cognitive behavioural therapist.
224174479|NCT04659447|DRUG|Platelet-Rich Plasma|36 ml of peripheral blood is extracted from patients, and 4 ml of 3.8% sodium citrate is added for anticoagulation. After centrifugation for 2 times, 4 ml platelet-rich plasma will be prepared.Four semitendinosus tendons and gracilis tendons are prepared.
224174480|NCT07043868|DEVICE|Low Level Laser Therapy|Painless, non-invasive treatment
224174481|NCT07046676|DRUG|sodium valproate|All three groups are administered twice a day via oral administration. Patients are given different doses based on their body weight and the therapeutic effect in controlling epilepsy.
224174482|NCT07047378|BEHAVIORAL|ACT Intervention Group|"For Parent ACT Group, parents will participate in a six-week, group-based ACT program integrated with behavioral parenting training based on positive parenting principles. Each session lasts two hours and includes 65 minutes of ACT-based activities (e.g., experiential exercises, guided imagery, mindfulness, values clarification, metaphors) and 25 minutes of parenting education and/or behavioral skills training.~For Children ACT Group, children (aged 6-11) will also receive a child-focused ACT intervention to help them manage emotional challenges. Each session lasts two hours and includes 65 minutes of ACT-based activities (e.g., experiential exercises, guided imagery, mindfulness, values clarification, metaphors) and 25 minutes of behavioral skills training."
224174483|NCT07047378|OTHER|control group|"Participants allocated to the Control Group will not receive the ACT intervention but will continue to receive the standard services originally provided by Harmony House. These services constitute usual care and include initial assessments, individual counselling, group counselling, the provision of community resource information, and referrals. Control group participants will receive these supports as usual. This study will not alter their existing service arrangements in any way, nor will it add to or reduce the support they receive.~Aside from not participating in the ACT program, the control group's experience will be identical to that of clients receiving regular services. After the intervention group completes the program, the control group will be offered the same course content (i.e., a waitlist intervention arrangement)."
224306330|NCT04390659|PROCEDURE|myomectomy|The myomectomy was done by conventional technique but timing of myomectomy either before or after delivery of the baby varied between different cases .Infusion of oxytocin during the operation and for 24 h later.
224306331|NCT02831608|BIOLOGICAL|Influenza vaccine|
224306332|NCT02831608|BIOLOGICAL|Placebo|
224174484|NCT06444997|DRUG|Oxycodone Hydrochloride|Oxycodone hydrochloride will be administered at a continuous infusion dose of 0.03-0.2 mg/kg/h.
224174485|NCT06444997|DRUG|Remifentanil|Remifentanil will be administered at a continuous infusion dose of 2-9 μg/kg/h.
224174486|NCT00881023|PROCEDURE|Microfracture|The microfracture procedure is a standard method for treatment of cartilage damage in which the surgeon will clean the site of your cartilage damage and then will make several small holes in your bone to stimulate your bone marrow with the intention to repair the damaged area with new cartilage tissue
224306333|NCT00117208|DRUG|mannitol|400mg BD for 12 weeks
224306334|NCT00117208|DRUG|mannitol + pulmozyme|combination
224306335|NCT00117208|DRUG|Dornase alpha|2.5mg daily for 2 weeks
224306336|NCT02589314|DEVICE|Mechanical periodontal therapy|
224306337|NCT02589314|PROCEDURE|nonsurgical periodontal therapy|
224306338|NCT00415441|PROCEDURE|Physiotherapy program|
224306339|NCT00415441|PROCEDURE|Placebo physiotherapy treatment|
224306340|NCT04311788|DEVICE|Prophylactic self gripping mesh|Prophylactic self gripping mesh, Propgrip by Medtronic.
224306341|NCT04311788|DEVICE|Slowly absorbable continuous monofilament suture|Fascial closure by continuous slowly absorbable 4:1 suture
224306342|NCT00675753|GENETIC|Blood spot specimens will be drawn|Blood spot specimens will be drawn from mother-baby dyads in the control and experimental groups and sent for genotyping
224306343|NCT00000583|BIOLOGICAL|hepatitis B vaccines|
224306344|NCT03607526|OTHER|Barriers|NGT sessions identifying barriers to vegetable intake.
224306345|NCT03607526|OTHER|Facilitators|NGT sessions identifying facilitators to vegetable intake.
224306346|NCT06053918|OTHER|additional follow-up extension at home|additional interview when leaving the sector, and the extension of follow-up of the patient at home
224306347|NCT05947110|OTHER|Plyometric-based hydro-kinesio therapy|The plyometric-based hydro-kinesio therapy was conducted for 45 minutes, twice weekly, for 8 successive weeks. The training was geared toward the lower body and was conducted under the close supervision of a licensed pediatric physical therapist in accordance with the safety performance guidelines defined by the American Academy of Pediatrics and the US National Strength and Conditioning Association.
224306348|NCT05947110|OTHER|Standard exercise therapy|The program encompassed the standard exercises for patients with JIA (aerobic, weight-bearing, proprioceptive, flexibility, and strengthening exercises). The training was conducted for 45 minutes, two times a week for 8 successive weeks.
224306349|NCT02755155|DRUG|Human serum albumin infusion 4%|Continuous infusion of 15mL/kg of bodyweight over 24h/day
224306350|NCT02755155|DRUG|Human serum albumin infusion 20%|Specify details not covered in associated Arm Description. Intermittent infusion up to 200 ml/8h/day until the plasma albumin concentration is in the range 30+3g/L
224306351|NCT02650479|DRUG|Exenatide|6 hour IV infusion (double infusion of 0.1250 mcg/kg/hour for 30 min followed by infusion rate (1X) of 0.0625 mcg/kg/hour for 5.5 hours).
224306352|NCT02650479|DRUG|Placebo|6 hour IV infusion.
224306353|NCT02650479|DRUG|Moxifloxacin|400 mg oral dose moxifloxacin within 1 min of start of infusion of exenatide
224306354|NCT02650479|DRUG|Palonosetron|0.25 mg administered IV within 30 minutes prior to initiating the infusion of exenatide
224174487|NCT00881023|DEVICE|Cartilage Autograft Implantation System|A surgical treatment of damaged knee cartilage using the subject's own healthy cartilage obtained from a non-weight or low weight-bearing region
224174488|NCT04140474|DEVICE|Archimedes procedure|All patients will initially have a scanner necessary for planning by the Archimedes system of the tunneling path. each patient will then undergo a general anesthesia as for any bronchoscopy. Then start the Archimedes procedure itself to reach the SPN
224174489|NCT06099808|OTHER|Audit and Feedback Emails|Monthly email containing information including their total medication titration encounters over a 3 month period, as well as the site and VISN level for comparison. This will include rates of GDMT utilization and percentage of patients on \>50% of the target dose of GDMT stratified by site, VISN and national. This data will be obtained from VHA national HF dashboard.
224174490|NCT06099808|OTHER|Patient Specific Targets|Monthly emails include a list of 5-7 HF patients who are potentially eligible for pharmacist HF medication titration. This data will be obtained from VHA national HF dashboard.
224174491|NCT06099808|OTHER|Educational Resources|Monthly educational webinars on pharmacist HF management and access to material and protocols on HF medication management.
224174492|NCT07052591|BEHAVIORAL|Zumba Exercise|Participants in the Zumba Exercise group engaged in supervised aerobic dance sessions lasting 60 minutes, twice per week, over an 8-week period. The exercise intensity was set to match aerobic-level activity suitable for improving body composition, muscle strength, and balance. Sessions included warm-up, main Zumba dance routines, and cool-down phases, all conducted by certified instructors.
224174493|NCT07052591|OTHER|Control Group|Participants in this arm did not receive any structured exercise intervention. They continued their usual daily activities throughout the 8-week study period. No physical training or behavioral program was applied.
224174494|NCT07052656|OTHER|Observational study, participants are not assigned an intervention as part of the study.|Observational study, participants are not assigned an intervention as part of the study.
224174495|NCT07052656|OTHER|Transport modality|Transfer modality to tertiary centers
224174496|NCT07053397|PROCEDURE|Serratus Anterior Plane Block (SAPB) group|"The SAP block, which is among the chest wall blocks, provides its effect by blocking the lateral cutaneous branches of the T2-T9 intercostal nerves, n. intercostobrachial , n. longus thoracicus , n. thoracodorsal.~SAP block can be performed in two ways: superficial and deep. The deep SAP block is administered between the serratus anterior and intercostal muscles, at the intersection point of the anterior axillary line and the level of the nipple (at the level of the 4th-5th ribs).~It has a wide range of use for postoperative pain management in trauma surgery, cardiac surgery, thoracic surgery and breast surgery."
224174497|NCT07053397|PROCEDURE|DSAPB|"The SAP block, which is among the chest wall blocks, provides its effect by blocking the lateral cutaneous branches of the T2-T9 intercostal nerves, n. intercostobrachial , n. longus thoracicus , n. thoracodorsal.~SAP block can be performed in two ways: superficial and deep. The deep SAP block is administered between the serratus anterior and intercostal muscles, at the intersection point of the anterior axillary line and the level of the nipple (at the level of the 4th-5th ribs). Following hydrodissection between the serratus anterior and intercostal muscles, a single-shot injection is administered. Subsequently, a peripheral nerve block catheter is placed in the same region under ultrasound guidance."
224174498|NCT06889415|DIAGNOSTIC_TEST|Osteosarcopenia in Patients with Rheumatoid Arthritis|The prevalence of osteosarcopenia will be examined in this group. Sarcopenia will be categorized into 4 groups. Both the prevalence of osteosarcopenia and the subgroups of sarcopenia will be compared with the healthy control group. Through this comparison, we will explain the relationship between sarcopenia and osteoporosis, the factors affecting this relationship, and the changes in fall and fracture risk using various questionnaires and tests.
224174499|NCT06889415|DIAGNOSTIC_TEST|Osteosarcopenia in Healthy Control Group|The prevalence of osteosarcopenia will be examined in this group. Sarcopenia will be categorized into 4 groups. The relationship between sarcopenia and osteoporosis, the factors affecting this relationship, and the risk of falls and fractures will be evaluated using various questionnaires and tests.
224174500|NCT07058181|BEHAVIORAL|Meaning-centered intervention for individuals who tend to feel down or anxious|"Meaning-centered intervention for internalizing symptoms adapted from the intervention Meaning-centered intervention for youth worrying about their weight and shape.~* Six 1-hour individual online sessions, approximately every 4 days~* Sessions led by a certified trainer based on intervention manual~* Four sources of meaning will be explored: personal life story, dealing with life's limitations, creating one's own life, and meaningful experiences~* Participants follow intervention using intervention workbook~* Homework assignments designed to deepen participants' experience and reflection on meaning in their daily lives"
224174501|NCT07058610|DEVICE|Amplifi Vein Dilation System|An investigational extracorporeal blood pump and catheter system designed to promote vein dilation prior to AVF creation.
224174502|NCT00424463|DRUG|MCI-186|Two ampoules (60 mg) of MCI-186 injection are intravenously administered once a day for 10 days during 14 days, followed by 14 days observation period (first cycle). Then treatment (10 days' administration during 14 days ) - observation (14 days) cycle is repeated eight times.
224174503|NCT00424463|DRUG|Placebo of MCI-186|Two ampoules of placebo injection are intravenously administered once a day for 10 days during 14 days, followed by 14 days observation period (first cycle). Then treatment (10 days' administration during 14 days) - observation (14 days) cycle is repeated eight times.
224174504|NCT07058402|PROCEDURE|Retrograde Intrarenal Surgery (RIRS) with Tip-Flexible Suction Access Sheath|Participants undergo retrograde intrarenal surgery (RIRS) using a tip-flexible suction access sheath. The procedure involves the insertion of a flexible ureteroscope through the urethra and ureter into the kidney. A novel access sheath with tip-flexible and suction capabilities is used to facilitate stone fragmentation and removal. The goal is to improve stone clearance and reduce intrarenal pressure during the procedure.
224306355|NCT02205983|DRUG|2 mg hydromorphone|We are administering oral hydromorphone to healthy volunteers to measure its effects on the performance of a verbal task.
224306356|NCT02205983|DRUG|1000 mg Acetaminophen|We are administering sublingual buprenorphine to healthy volunteers to measure its effects on the performance of a verbal task.
224306357|NCT02205983|DRUG|4 mg hydromorphone|We are administering oral hydromorphone to healthy volunteers to measure its effects on the performance of a verbal task.
224306358|NCT02205983|DRUG|dextrose|We are administering dextrose to healthy volunteers for our placebo group.
224174505|NCT07058402|PROCEDURE|Standard Percutaneous Nephrolithotomy (PCNL)|Participants undergo standard percutaneous nephrolithotomy (PCNL). The procedure involves creating a percutaneous tract into the renal collecting system under imaging guidance, followed by nephroscope insertion to fragment and extract 2-3 cm renal stones. This represents the current standard of care for large renal calculi.
224174506|NCT01436357|BIOLOGICAL|AdCh3NSmut1|Stages I and II: Receive AdCh3NSmut1 at 2.5 x 10\^10 total virus particles (vp)/dose, intramuscularly on day 0.
224174507|NCT01436357|BIOLOGICAL|MVA-NSmut|Stages I and II: 1 dose of MVA-NSmut at the dosage 1.8 x10\^8 plaque forming units (pfu) intramuscularly on day 56.
224174508|NCT01436357|OTHER|Placebo|Stages I and II: Two doses of placebo intramuscularly, 1 at day 0 and 1 at day 56.
224174509|NCT06099678|BEHAVIORAL|Elastic Band Training|This training intervention will be 6 weeks of moderate-intensity elastic band training, including whole-body and isolated muscle exercises.
224174510|NCT06099678|BEHAVIORAL|Elastic Band Training with Maximal Mental Effort|This training intervention will be 6 weeks of moderate-intensity elastic band training, including whole-body and isolated muscle exercises, where participants will perform maximal mental effort by imagining maximal muscle contraction during each exercise.
224174511|NCT06926829|DRUG|EB-1020 (Centanafadine) 164.4 mg|164.4 mg, capsule, oral, once daily, for 52 weeks
224174512|NCT06926829|DRUG|EB-1020 (Centanafadine) 328.8 mg|328.8 mg, capsule, oral, once daily, for 52 weeks
224174513|NCT07137182|OTHER|8-week physical activity program|Individuals in the experimental group will be administered an eight-week physical activity program. The researcher who will administer the activity is a specialist in Sports Sciences and holds the necessary certifications. The activity program includes cardio exercises, jumping, stretching, and stretching exercises.
224174514|NCT04975997|DRUG|Dexamethasone|Oral dexamethasone 40mg on days 1, 8, 15, 22 of a 28-day cycle
224174515|NCT04975997|DRUG|Daratumumab|Subcutaneous Daratumumab 1800mg on Days 1, 8, 15 and 22 for Cycles 1 to 2, on Days 1 and 15 for Cycles 3 to 6, and then on Day 1 for Cycle 7+ of a 28-day cycle
224174516|NCT04975997|DRUG|Bortezomib|Subcutaneous Bortezomib 1.3 mg/m2 on Days 1, 4, 8 and 11 of each 21-day cycle for a total of 8 cycles.
224174517|NCT04975997|DRUG|Iberdomide|Oral Iberdomide 1.0mg on Days 1 to 21 of a 28-day cycle
224174518|NCT04975997|DRUG|Iberdomide|Oral Iberdomide 1.3mg on Days 1 to 21 of a 28-day cycle
224174519|NCT04975997|DRUG|Iberdomide|Oral Iberdomide 1.6mg on Days 1 to 21 of a 28-day cycle
224174520|NCT04975997|DRUG|Dexamethasone|Oral dexamethasone 20mg on days 1,2, 4,5,8,9,11,12 of a 21-day cycle from cycles 1-8
224174521|NCT04975997|DRUG|Daratumumab|Subcutaneous daratumumab 1800mg Cycles 1 to 3 on Days 1, 8, 15 of a 21-day cycle, Cycles 4 to 8 on Day 1 of a 21-day cycle and Cycles 9+ on Day 1 of a 28-day cycle.
224174522|NCT07087769|BEHAVIORAL|Treadmill Walking with Split-Belt and/or Tied-Belt Conditions|Participants will walk on an instrumented treadmill under split-belt and/or tied-belt conditions depending on their walking capacity. The belt speeds will be adjusted to facilitate locomotor adaptation and evaluate propulsion symmetry.
224174523|NCT07087769|BEHAVIORAL|Mechanical Resistance (Pelvis and/or Ankle) depending on participant's walking capacity|Participants will walk on a treadmill (Split-belt and/or Tied-belt) with backward-directed resistance applied at the pelvis, ankle, or both. The resistance is used to challenge paretic leg propulsion and assess adaptive gait responses.
224174524|NCT07087769|BEHAVIORAL|Sensory Feedback Training|Real-time feedback-visual, auditory, or combined-will be provided based on the propulsive force generated during split-belt and/or tied-belt treadmill walking, with or without mechanical resistance.
224306359|NCT05231538|OTHER|Neurodevelopmental therapy|NDT is a hands-on, 'problem solving approach'. It is used in the management and treatment of children who have disorders of function, movement or postural control because of damage in their central nervous system.
224306360|NCT05231538|OTHER|Routine physical therapy|stretching, passive range of motion, and active range of motion).
224306361|NCT03764761|DEVICE|AAC Technology - Standard of Care|Story Book is separate from AAC symbols, AAC symbols are arranged on a grid with color backgrounds. This is non-optimal arrangement and non-integrated presentation
224306362|NCT03764761|DEVICE|AAC Technology - non-optimal integrated arrangement|Story Book is integrated on to the AAC display together with the AAC symbols, AAC symbols are arranged on a grid with color backgrounds. This is non-optimal arrangement and but integrated presentation
224306363|NCT03764761|DEVICE|AAC Technology - non-optimal integrated arrangement|Story Book is integrated on to the AAC display together with the AAC symbols, AAC symbols are arranged on a grid with color backgrounds. This is optimal arrangement and but integrated presentation
224306364|NCT04173624|DIAGNOSTIC_TEST|Endosonography|Endosonography (EUS) is endoscopic method for evaluated pancreatic and biliary pathology.
224306365|NCT04173624|DIAGNOSTIC_TEST|Magnetic Resonance Cholangiopancreatography|Magnetic Resonance Cholangiopancreatography (MRCP) is non-invasive method for evaluating pancreatic and biliary pathology
224306366|NCT00239044|DRUG|Enteric-coated Mycophenolate sodium (EC-MPS)|
224306367|NCT03148561|DRUG|Misoprostol|received misoprostol 800 µg (Misotac 200 µg tablets, SIGMA pharmaceutical) once dose vaginally
224306368|NCT04775420|DIAGNOSTIC_TEST|Measurement of mean platelet volume (MPV) and blood neutrophil to lymphocyte ratio (NLR)|MPV and NLR are easily accessible and inexpensive tests
224174525|NCT01841086|DRUG|Anplag|Sarpogrelate HCl 300mg once a day or 100mg three times a day
224174526|NCT01841086|DRUG|UI03SPG300CT|Sarpogrelate HCl 300mg once a day or 100mg three times a day
223586407|NCT05623683|OTHER|Continuous Walking|Wearing comfortable clothes and their usual walking shoes, participants will walk on a treadmill to accrue 30 minutes of walking. Participants will be instructed not to use the treadmill side rails for balance or support during walking. Participants will rest for 10 minutes (sitting in a chair) before walking on the treadmill for 1 continuous block of 30 minutes. A safety button to stop the treadmill will be available to the participants, so they can stop walking anytime. If participants feel that they are about to lose balance, they are allowed to hold on to the side rails to regain balance and terminate the trial.
224174527|NCT07101237|DIAGNOSTIC_TEST|Multi-modal ultrasonic imaging system for liver cancer|Conventional ultrasound, SMI, shear wave /strain elastography, and CEUS will be conducted for HCC/ICC patients. All above the imaging examinations will be conducted at 1/2/3/4/5/6, 9/12/15/18/21/24, and 30/36/42/48/54/60 months after the postoperative/post-conversion therapy.
224174528|NCT07102238|PROCEDURE|muscoloskeletal ultrasound and synovial biopsy|Use of a standardized US evaluation according with OMERACT definition and scoring system; Synovial biopsy; To identify systemic and synovial disease biomarkers in SLE patients that can predict different joint patterns, systemic manifestations and response to therapy through multi-omics technologies.
224174529|NCT07100093|PROCEDURE|Drug serum levels|Ustekinumab trough levels (prior to administration of the next dose of the drug) will be determined by enzyme-linked immunoadsorption assay (ELISA) methodology.
224174530|NCT06522438|COMBINATION_PRODUCT|Hyaluronic Acid (HA) and Octenidine gel|A thermosensitive gel with Hyaluronic Acid (HA) and Octenidine (Pocket-X®, Geistlich, Wolhusen, Switzerland) will be applied in the periodontal pockets ≥5mm immediately after the subgingival PMPR, by means of a pre-filled syringe bearing a thin plastic tip and following manufacturer's instructions.
224174531|NCT06522438|PROCEDURE|Non-surgical periodontal treatment (NSPT)|Full mouth supragingival professional mechanical plaque removal (PMPR) and subgingival PMPR at sites with PPD ≥4mm will be performed with the aid of manual and power-driven instruments under local anaesthesia.
223586408|NCT04137250|PROCEDURE|Hamstring|The intervention will consist of make an incision on the medial side of the proximal portion of the leg approximately 3 centimeters to dissect by planes until the tendons of the hamstrings are located, which will be removed surgically with specialized instruments and the wound will be closed, for later These tendons be used as an autograft for the reconstruction of the anterior cruciate ligament
224174532|NCT06935331|DRUG|Opioid-Free/Opioid-Avoidant|"Managed post-operatively with an opioid-free pain regimen which will include:~Intrafascial injection of clonidine, epinephrine, ropivacaine, and toradol solution, diluted to 100mL and injected during closure of wound~Gabapentin PO 300 mg TID x 30 days~Toradol IV dosed per body weight, max 30 mg q 6 hours for 24-28 hours~Ibuprofen PO dosed per body weight q 6-8 hours once toradol discontinued and discharged home with PO tabs~Acetaminophen PO dosed per body weight and discharged home with PO tabs~Diazepam PO dosed per body weight during stay and discharged home with PO tabs~Non-medicinal therapy: Ice, Aromatherapy, Music therapy, Pet therapy, Early mobilization and PT"
224174533|NCT06935331|DRUG|Opioid-Containing|"Managed post-operatively with a traditional opioid containing pain regimen including:~Intrafascial injection of clonidine, epinephrine, ropivacaine, and toradol solution, diluted to 100mL and injected during closure of wound~Post-operative morphine IV for breakthrough pain~Oral narcotic (hydrocodone/acetaminophen)~Gabapentin PO 300 mg TID x 30 days~Toradol IV dosed per body weight, max 30 mg q 6 hours for 24-28 hours~Ibuprofen PO dosed per body weight q 6-8 hours once toradol discontinued and discharged home with PO tabs~Acetaminophen PO dosed per body weight and discharged home with PO tabs~Diazepam PO dosed per body weight during stay and discharged home with PO tabs~Non-medicinal therapy: Ice, Early mobilization and PT"
224174534|NCT03649581|OTHER|compare the two groups of schizophrenic patients|"Compare two groups of markers relating respectively to psychomotricity and affectivity in two subforms of schizophrenia: periodic catatonia and hebephrenia in order to highlight a possible double dissociation:~1. abnormalities of markers related to affectivity in Hebephrenia (with preservation of these markers in periodic catatonia),~2. abnormalities of markers related to psychomotricity in periodic catatonia (with markers of these tests in Hebephrenia)."
223586409|NCT04137250|PROCEDURE|Quadriceps tendon|orThe intervention consisted in making an incision in the anterior aspect of the distal portion of the thigh of approximately 3 centimeters to dissect by planes until locating the membranous portion of the quadriceps tendon, from which will be removed a portion of surgical way with specialized instruments and the Wound will be closed, for later this tendon to be used as an autograft for the reconstruction of the anterior cruciate ligament.
224306369|NCT00753220|BIOLOGICAL|VDC2008|"Intratumoral injection of VDC2008 post-cryotherapy.~Dosage will depend on cohort: 2.5 x 10\^7, 7.5 x 10\^7 or 1.0 x 10\^8 cells"
224306370|NCT00753220|DRUG|Cyclophosphamide|Cyclophosphamide i.v. given at day -3 (dose: 300mg/m2); Low-dose Cyclophosphamide pill given twice daily (dose: 25 mg, p.o., b.i.d. for 7 days on and 7 days off; a total of 6 cycles \[1 cycle = 4 weeks\] starting Week 2 after cryoablation and going to Week 26)
224306371|NCT01898650|OTHER|MR scan|
223586410|NCT01751139|PROCEDURE|Blood sample collection|Blood samples will be collected at each study visit (Day 0, Month 6, Month 12, Month 24, Month 36 and Month 48) and any time during the study that dengue is suspected. Samples collected at scheduled visits will be tested for anti-dengue antibodies. Samples collected at visits for dengue suspicion will be tested for dengue infection diagnosis.
223485639|NCT04622956|DRUG|Methotrexate Injectable Solution|"Phase 1:~* Level -1: Methotrexate 7.5 mg/m2 on D+6 and D+9\*. Level -1 will be explored only if the starting dose is too toxic (reduced dose).~* Level 0 \[Starting Dose\]: Methotrexate 10 mg/m2 on D+6 and 7.5 mg/m2 on D+9~* Level +1: Methotrexate 10 mg/m2 on D+6 and D+9~* Level +2: Methotrexate 15 mg/m2 on D+6 and 10 mg/m2 on D+9~Phase 2: dose determined in the phase 1 trial"
223485640|NCT05009420|OTHER|Avocado|avocado served with crackers as breakfast
223485641|NCT02941003|DEVICE|microscope|Detection of of histopathological characteristics of OCT treatment or OCT free samples from patients .
223485642|NCT02941003|OTHER|immunostaining|Detection of CD31/CD34, D2-40, Ki67 and p53 immunostaining of OCT treatment or OCT free samples from patients .
223485643|NCT02941003|DEVICE|NGS|The investigators used the device to detect the gene mutations of OCT treatment or OCT free samples obtained from part of the patients.
223485644|NCT00574899|OTHER|Questioners, blood specimens, prostate tissue specimens|"You will be asked to fill out a confidential questionnaire asking for information such as medical history, family history of cancer, and potential exposures.~Each patient will provide 7 unstained paraffin sections from prostate biopsies, one tube of blood for serum, and one tube for plasma and buffy coat."
223485645|NCT00574899|OTHER|Questioners, blood specimens, prostate tissue specimens|"You will be asked to fill out a confidential questionnaire asking for information such as medical history, family history of cancer, and potential exposures.~Each patient will provide 7 unstained paraffin sections from prostate biopsies, one tube of blood for serum, and one tube for plasma and buffy coat."
224174535|NCT03649581|OTHER|compare the two groups of schizophrenic patients versus volunteers|compare the results of the schizophrenic patient group with healthy volunteers
224174536|NCT06169488|PROCEDURE|Lumbar Interbody Fusion|Fusion of one or two lumbar levels with either a transforaminal lumbar interbody fusion (TLIF) or an anterior lumbar interbody fusion (ALIF) procedure.
224174537|NCT06169488|BEHAVIORAL|Multidisciplinary rehabilitation|Outpatient multidisciplinary rehabilitation based on the treatment model described by Brox et al and Hellum et al consisting of a cognitive approach and supervised physical and functional training, but the protocol is somewhat compressed in terms of time and additionally updated in line with recent years' research in cognitive functional rehabilitation.
224174538|NCT04914182|RADIATION|LASER|Laser will be applied in specific points for perineal lacerations.
224174539|NCT04914182|RADIATION|CONTROL|"A control group of sham laser will create for the patients the impression that laser is being played, with the lights of the instrument of on mode turned on, without biological effects."
224174540|NCT00715780|DRUG|soluble human insulin|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
224174541|NCT00715780|DRUG|biphasic human insulin|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
224174542|NCT00715780|DRUG|insulin NPH|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
224174543|NCT00715780|DRUG|insulin aspart|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
224174544|NCT00715780|DRUG|biphasic insulin aspart|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
224174545|NCT00715780|DRUG|insulin detemir|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
223485646|NCT02619513|DRUG|Dexmedetomidine|Group GTD received thoracic continuous paravertebral nerve block with dexmedetomidine (0.5μg/kg) added to ropivacaine before anesthesia induction, and used continuous thoracic paravertebral nerve block patient-controlled analgesia(with dexmedetomidine 100μg）.
223485647|NCT02619513|DRUG|Ropivacaine|Group GE\\GT\\GTD respectively received continuous nerve blocks and postoperative analgesia combined with ropivacaine.
223485648|NCT02619513|DEVICE|Mindray M7 series|Ultrasound real-time guidance have been used in continuous thoracic paravertebral blocks in group GT and group GTD.
223485649|NCT03209960|DIAGNOSTIC_TEST|Bedside Referral Tool|Two Vanderbilt primary care providers (a nurse practitioner and a primary care physician) will examine all consented residents. Each primary care provider will perform elements of a physical exam guided by the bedside referral tool to determine if a referral to a movement disorders neurologist is required for a spasticity consultation.
223485650|NCT03209960|OTHER|Neurological Examination|The subject will undergo elements of the neurological examination during which the movement disorders neurologist will look specifically for the presence of spasticity. If spasticity is found to be present during the examination, the neurologist will rate the severity of the spasticity in all affected limbs and record whether they would recommend treatment for spasticity, and if so, which treatment(s) they believe would be beneficial for the subject.
223485651|NCT03755076|BEHAVIORAL|Perceptual cuing|Participants were provided four perceptual cues (or feedback) in a pseudorandom order: (a) indiscriminate, (b) Altered gain, (c) Coordination, (d) Dual: altered gain and coordination
223485652|NCT06573528|DRUG|CS060380|Tablets administered orally
223485653|NCT04547439|DRUG|Melatonin|Melatonin 3 mg will be taken nightly for 8 weeks
223485654|NCT04547439|OTHER|Placebo|Placebo will be given nightly for 8 weeks
223586411|NCT01751139|OTHER|Data collection|Diary logs will be issued to all subjects at every visit, except Month 48 (Day 0, Month 6, Month 12, Month 24, and Month 36), as required. Any completed diary logs will be verified, as applicable. Subjects will be given a diary log in the event of the occurrence of a symptom that may be associated with suspected dengue.
224174546|NCT00308568|BEHAVIORAL|Mailed educational brochure|
224174547|NCT02489994|DEVICE|ePrime|The main intent of the ePrime for cellulite is to utilize a minimally-invasive approach to directly deliver RF energy into tissue through pairs of micro-electrode needles and use temperature sensors within the needles to reliably create fractional thermal injuries within the skin.
224174548|NCT02185638|OTHER|Appetite suppressant properties of YGD and A20-50|3-arm crossover study for investigation of the effect of herbal supplements A20-50 compared to YGD blend and placebo on subjective appetite sensations, glucose, insulin, ghrelin, GLP-1, CCK and ad libitum energy intake
224174549|NCT02803437|DRUG|Radium-223 dichloride (Xofigo, BAY 88-8223)|Xofigo treatment will be performed according to the product label in Japan under the routine clinical practice.
224174550|NCT00183027|BEHAVIORAL|Dietary composition and energy intake|
224174551|NCT05198284|DIAGNOSTIC_TEST|KidneyIntelX|KidneyIntelX is a blood-based clinical diagnostic tool that assesses the risk of progressive kidney function decline in chronic kidney disease patients with type 2 diabetes.
224174552|NCT02972658|DRUG|Lanabecestat|Administered orally
224174553|NCT02638285|DRUG|LH|
224174554|NCT02638285|DRUG|HCG|
224174555|NCT02638285|DRUG|Clomiphene|
224174556|NCT05170581|DRUG|Sintilimab Combined with Platinum-containing Chemotherapy|Admininster Sintilimab and platinum-containing chemotherapy in neoadjuvant treatment of resectable stage ⅡB～ⅢA Non-small Cell Lung Cancer
224174557|NCT05739890|OTHER|Embryo genome sequencing|This project proposes the testing of a cohort of research embryos to establish the key parameters for amplified trophectoderm biopsied embryos using minimum depth required for genome sequencing (\>depth of 30x per base).The remaining embryo tissue will be whole genome sequenced to validate the results of the biopsy.
224174558|NCT05739890|OTHER|Parents genome sequencing|Analysis will be performed using trio testing of each embryo in addition to the DNA from the genetic parent to facilitate the derivation of de novo mutation rate.
224174559|NCT03958149|DEVICE|spinal collar|cervical collar to immobilise the cervical spine
224174560|NCT01934166|DRUG|Nalmefene 18 mg|One single oral dose of 18 mg
224174561|NCT02785588|DEVICE|3.0 T Neonatal MRI scanner|eligible subjects will undergo neonatal MRI scan procedure
224174562|NCT00461851|DRUG|Gemcitabine|Gemcitabine will be given at a standard dose schedule of 1000 mg/m² on day 1 and 8.
224174563|NCT00461851|DRUG|Carboplatin|Carboplatin will be given on day 1 to an AUC of 5.
224174564|NCT00461851|DRUG|Sorafenib|Sorafenib will be administered orally daily on days 2-19 at 400 mg bid
224174565|NCT02583399|DRUG|Ibuprofen|Ibuprofen, 10 mg/kg
224174566|NCT04235127|OTHER|sociodemographic variables, somatic conditions, mental disorders, treatment and drug use|"* sociodemographic variables~* history of self-injurious behaviours; all types of somatic conditions; neurodevelopmental, mental, behavioural, personality and substance use disorders; all types of medical procedures performed; and number and type of healthcare contacts.~* prescriptions for psychopharmacological products~* the Suicidal Scale of the Mini-International Neuropsychiatric Interview, the type and lethality of the attempt that warranted evaluation, presence and type of mental disorder, hopelessness, impulsivity, aggressiveness, altered state of conscience, use or dependence of alcohol, use or dependence of illicit drugs, serious somatic disease (including chronic diseases, chronic pain, and disabilities), living status, presence of family or social support, social problems, stressful life events, access to lethal means, and family history of suicide"
224174567|NCT00396968|DRUG|AMD3100|
224174568|NCT00396968|PROCEDURE|Allogeneic Stem Cell Transplantation|
224174569|NCT00694265|PROCEDURE|Decompression|Surgical decompression of the median nerve
224174570|NCT00694265|PROCEDURE|Conservative treatment|Conservative treatment typically consisted of splinting and corticosteroid injections
224174571|NCT01804504|BEHAVIORAL|Nutrition education|The intervention group will be sent out a series of education materials, be arranged to attend lectures(once a month), dietary guidance or nutrition consultation at regular intervals(once every 2 weeks).
224174572|NCT05661500|OTHER|Creative Darama Group|Postmortem care training given by creative drama method
224174573|NCT05661500|OTHER|Classical Education Group|Postmortem care training given by classical education method
224174574|NCT05042531|DRUG|Azacitidine|Azacitidine, 75mg/m2,d1-7;Treatment cycles every 28 days
224174575|NCT05042531|DRUG|Dasatinib|dasatinib,20mg,po,qd,treatment cycles every 28 days
224174576|NCT05297240|DRUG|Belantamab mafodotin|At least one dose of belantamab mafodotin as part of the compassionate use or the expanded access program in Spain between November 2019 and June 2021.
224174577|NCT05895422|PROCEDURE|pyeloplasty|repair of the uPJO
224174578|NCT01880489|BEHAVIORAL|MI + CBST Intervention|The intervention focuses on exploring health goals, creating an action plan, learning about the impact stress, stigma, and substance use can have on health, improving personal growth and social support, and connecting with resources. The first two sessions will be primarily Motivational Interviewing and will explore participants' feelings about their sexual risk, substance use, non-medically monitored hormone and silicone use, and any other issues. Group sessions (Sessions 3-6) will incorporate Cognitive Behavioral Skills Training focusing barriers to physical and mental health. The last session will focus on reviewing progress toward health goals, identifying barriers to change, and generating a plan for connection to ongoing care to reach target health goals.
224174579|NCT06296602|OTHER|A prelevement for HPV genotyping and anal cytology will be carried out in addition to the anal swabs taken quarterly to screen for other sexually transmitted infections.|A prelevement for HPV genotyping and anal cytology will be carried out in addition to the anal swabs taken quarterly to screen for other sexually transmitted infections. A questionnaire will be completed by the doctor to record the data of interest.
224174580|NCT01185912|PROCEDURE|Ventricle muscle tissue samples|
224174581|NCT02267460|BIOLOGICAL|AA4500|
224174582|NCT02267460|DEVICE|ErecAid® Esteem® Manual Vacuum Therapy System|
224174583|NCT02267460|PROCEDURE|Investigator Modeling|
224174584|NCT05465850|DIAGNOSTIC_TEST|Modified USPHS criteria|It assess the restorations with visual inspection using a mirror and explorer. It includes Marginal integrity, shade matching, retention, marginal discoloration, gingival inflammation, and recurrent caries.
224174585|NCT01621581|GENETIC|Convection enhanced delivery/AAV2-GDNF|Adeno-Associated Virus Encoding Glial Cell Line-Derived Neurotrophic Factor (AAV2-GDNF) Administered via Bilateral Stereotactic Convection-Enhanced Delivery
224174586|NCT05853926|DIAGNOSTIC_TEST|Spinal Manipulation With Laser Therapy|Spinal Manipulation With Laser Therapy in Chronic Lower Backache
224174587|NCT05853926|DIAGNOSTIC_TEST|Dry Needling|Dry Needling in Chronic Lower Backache
224174588|NCT00364611|DRUG|Bevacizumab|"Bevacizumab (Avastin) 15 mg/kg will be administered prior to chemotherapy on~* On Day 1 of the 1st cycle over 120 minutes~* On Day 1 of the 2nd cycle over 90 minutes, if no reaction on the first dose~* On Day 1 of 3rd cycle over 60 minutes, if no reaction on previous doses~* On Day 1 of subsequent cycles over 30 minutes, if no reaction on previous doses"
224174589|NCT00364611|DRUG|Docetaxel|Docetaxel 75 mg/m\^2 IV infused over 60 minutes after completion of Bevacizumab infusion q3w
224174590|NCT00364611|DRUG|Trastuzumab|"* A loading dose of 8 mg/kg Trastuzumab (Herceptin) IV will be infused over 90 minutes on Day 2 of Cycle 1.~* For all subsequent cycles 6 mg/kg trastuzumab will be administered on Day 1 one hour following completion of docetaxel infusion"
224174591|NCT04547127|BIOLOGICAL|Convalescent anti-SARS-CoV-2 MBT Plasma|Intravenous infusion.
224174592|NCT04547127|DRUG|Standard Medical Treatment|SMT
224174593|NCT04191252|DIAGNOSTIC_TEST|A multi-gene panel testing|A multi-gene panel, which consists of more than 500 hundred genes will be provided for mutation analysis
224174594|NCT03202589|OTHER|FOCUS Echocardiography|FOCUS Echocardiography
224174595|NCT05230069|OTHER|Interview|Patients will be interviewed post an emergency call and evaluation.
224174596|NCT04330794|OTHER|NMFACT|caries index
224174597|NCT04330794|OTHER|DMF index|caries index chart to collect data about decayed missed filled teeth
224174598|NCT04039295|PROCEDURE|ultrasound guided caudal epidural block|dynamic ultrasound imaging of the spread of local anesthetics
224174599|NCT01813630|DRUG|DA-3002|
224174600|NCT01813630|DRUG|Genotropin®|
224174601|NCT05497622|DIAGNOSTIC_TEST|Quantitative Ultrasound|Ultrasound assessment of Trapezius muscle
224174602|NCT05497622|DIAGNOSTIC_TEST|Osteopathic TART Assessment|"Evaluation of the 4 diagnostic criteria:~1. Tissue Texture abnormality~2. Asymmetry~3. Restriction of Motion~4. Tenderness"
224174603|NCT05497622|PROCEDURE|Osteopathic Manipulation Treatment|Use of manual techniques such as soft tissue stretching, resisted isometric stretches, fascial relaxation and counter strain.
224174604|NCT03350724|DEVICE|episil wound dressing|Episil is a wound dressing material intended for the management of pain and relief of pain by adhering to the mucosal surface of the mouth, soothing oral lesions of various etiologies. episil is an oromucosal liquid that transforms in situ to a bioadhesive oromucosal gel by uptake of small amounts of aqueous fluid.
224174605|NCT03350724|DEVICE|PeriAcryl90 wound dressing|PeriAcryl90 is a cyanoacrylate wound dressing.
224174606|NCT04509635|DRUG|Cetuximab|Cetuximab is used for only patients with ctDNA test RAS wild type.
224174607|NCT04509635|DRUG|Chemotherapy|The detailed regimen is determined by a multi-disciplinary team according to the previous use of chemotherapy.
224174608|NCT03933553|OTHER|Aromatherapy with essential oil|the aromatherapy by fragrance inhalation
224174609|NCT02134912|DRUG|crizotinib|Given PO
224174610|NCT02134912|DRUG|pemetrexed disodium|Given IV
224174611|NCT02134912|OTHER|laboratory biomarker analysis|Correlative studies
224174612|NCT02134912|OTHER|pharmacological study|Correlative studies
224174613|NCT04020224|DEVICE|Amustaline/GSH pathogen reduction technology|Whole blood treated with pathogen reduction technology
224174614|NCT04020224|DEVICE|Standard of Care|Red Blood Cell Component or whole blood
224174615|NCT03280186|PROCEDURE|surgery|The minimally invasive surgical treatment methods and new techniques will be adopted such as spinal superselective angiography, preoperative embolization, intraoperative electrophysiological monitoring, intraoperative angiography, etc.
224174616|NCT00561067|DRUG|Erythropoietin|EPO 500 IU/kg diluted in 50 ml saline and infused in 30 minutes; treatment is started within eight hours after the spinal injury; the same drug dosage will be infused at 24 and 48 hours
224174617|NCT00561067|DRUG|Methylprednisolone|MP 30 mg/kg intravenous (iv) in the first hour, followed by 5.4 mg/kg/h for 23 hours if treatment is started within three hours after the spinal injury,or for 48 hours if treatment is started between three and eight hours (protocol NASCIS III, National Acute Spinal Cord Injury Study)
224174618|NCT04033029|DEVICE|Continuous venovenous hemodiafiltration with high adsorption membrane (oXiris®)|CRRT initiation will be determined by the treating physician on charge, according with the current recommendations of clinical practice and prescriptions of CRRT and local management protocols. The CVVHDF mode will be performed by using PrismafleX eXeed™ system and high adsorbent polyethyleneimide membrane (oXiris®). Filtration parameters will be determined following the local protocol (dose of 25-30 ml/kg/h).
224174619|NCT04033029|DRUG|Antibiotics|Antibiotic concentration-time data will be collected and analyzed.
224174620|NCT02759939|OTHER|Video + Prompt Card|"1. A brief video (available in English and Spanish) intended to be viewed by patients immediately before the health care visit. The video aims to enhance patients' motivation, skills, and self-efficacy to ask their health care providers three specific questions: (1) What are my options? (2) What are the pros and cons of those options? and (3) How likely are those pros and cons to happen to me?~2. A prompt card (available in English and Spanish) intended to be provided to patients when they view the video and kept. The card aims to remind patients of the three questions presented in the video."
223586412|NCT03305315|OTHER|Measurements of jaw movement|Jaw mobility will be measured during simple movements of the mouth (opening the mouth, side-to-side and backwards-and-forwards movement of the jaw). These movements will be measured using a specific apparatus, part of which will be placed on the head like a helmet with the other part placed in the mouth and stuck to the teeth using a dental adhesive. The part in the mouth is specifically designed for this purpose. Measurements using this apparatus will take around 30 minutes.
223586413|NCT03305315|OTHER|Measurement of natural electrical activity of facial muscles|Natural electrical activity of the facial muscles will be measured using electrodes placed on the skin.
223586414|NCT06456073|BIOLOGICAL|E-CEL UVEC cells (AB-207)|Allogeneic (consented-maternal donor) E4ORF1+ (pro-survival gene transduced) human umbilical vein endothelial cells (percutaneous injection formulation)
224174621|NCT02759939|OTHER|Decision Aids + Training|"1. Seven one-page decision aids on contraceptive methods (available in English and Spanish) intended to be used by health care providers with patients during the health care visit.~2. A five-minute training video and accompanying written guidance (available in English) intended to be reviewed by health care providers before implementing the decision aids (and as frequently as desired thereafter). The training aims to enhance providers' motivation, skills, and self-efficacy to use the decision aids to facilitate shared decision-making in the health care visit."
224174622|NCT00409149|BEHAVIORAL|CALM Approache|
224174623|NCT00409149|BEHAVIORAL|DASH approach|standard dietary DASH approach in hypertensive patients
224174624|NCT04306835|BEHAVIORAL|Cognitive behavioural therapy for insomnia|a technique for treating insomnia without medications
224174625|NCT04598100|BEHAVIORAL|FOCUS-EC|
224174626|NCT01064518|DRUG|Botulinum Toxin Type A|RT001 (Botulinum Toxin Type A Topical Gel, Dose A) applied topically at Baseline (Day 0) to the lateral canthal lines
224174627|NCT01064518|DRUG|Placebo (Dose B)|Placebo (Dose B), applied topically at Baseline (Day 0) to the lateral canthal lines
224174628|NCT04554888|DRUG|Doxepin Topical|Four of the areas will be treated with doxepin for 1 hour and 30 minutes (with a patch to deposit 1.2 grams of cream). Each patch will be covered with Tegaderm I.V., an occlusive, adhesive dressing (3M), for at least 1½ hours
224174629|NCT04554888|DRUG|Papain|Papain will be applied by 1 SPT prick thought the skin
224174630|NCT04554888|DRUG|Histamine|Histamine will be applied by 1 SPT prick thought the skin
224174631|NCT04554888|OTHER|Cowhage|Cowhage spicules are 1-2 mm in length and have diameter of 1-3 µm at their tip. 30-35 spicules are gently rubbed into a 1 cm diameter skin area.
224174632|NCT04650685|DEVICE|The novel Salvadora persica toothbrush|The novel Salvadora persica toothbrush will be used twice daily without the application of toothpaste. Modified bass technique will be applied. A demonstration by another investigator will be done via video, written instructions and a tell-show-do method using typodont model.
224174633|NCT04650685|DEVICE|The Salvadora persica (miswak) chewing stick|The Salvadora persica chewing stick will be used twice daily without the application of toothpaste. The Salvadora persica chewing sticks need to be prepared prior to use. A five-finger grip technique will be applied. A demonstration by another investigator will be done via video, written instructions and a tell-show-do method using typodont model.
224174634|NCT04650685|DEVICE|Standard toothbrush and toothpaste (control)|The novel Salvadora persica toothbrush will be used twice daily without the application of toothpaste. Modified bass technique will be applied. A demonstration by another investigator will be done via video, written instructions and a tell-show-do method using typodont model.
224174635|NCT03178591|DRUG|vildagliptin|
224174636|NCT03178591|DRUG|Dapagliflozin|
224174637|NCT04397757|BIOLOGICAL|COVID-19 Convalescent Plasma|2 units of COVID-19 convalescent plasma compatible with their blood type
224174638|NCT04686539|DRUG|CBD|CBD oil not containing THC, to be administered sub-lingual.
224174639|NCT04686539|DRUG|Placebo|Placebo Oil
224174640|NCT00880958|DIETARY_SUPPLEMENT|Mixture of various probiotics and fermentation products|
224174641|NCT00880958|DIETARY_SUPPLEMENT|Placebo|
224174642|NCT02561026|BIOLOGICAL|Frozen plasma|patients randomized to receive frozen plasma transfusions
224174643|NCT00850629|BEHAVIORAL|multimodal lifestyle intervention|After an initial weight loss, the weight regain will be measured during multimodal lifestyle intervention in children, adolescents and adults
224174644|NCT00850629|BEHAVIORAL|placebo|no intervention, only follow up
224174645|NCT04277429|DIAGNOSTIC_TEST|Cardiac function assessment|Echocardiography, cardiac enzymes analysis
224174646|NCT02785094|BEHAVIORAL|Observation|Observation of Participants' behaviour
224174647|NCT04185194|DRUG|Lidocaine|transmission of the drug molecules to the underlying muscles
224174648|NCT04185194|DEVICE|pulsed ultrasound|using thermogenic and cavitation effect of ultrasound to reduce tight muscles and relieve pain
224174649|NCT04185194|OTHER|especially designed physical therapy program|by myofascial trigger point release, stretching and strengthening exercises of upper trapezius muscle and infrared radiation by tungsten lamp for upper trapezius
223485655|NCT04033536|RADIATION|Involved Target Stereotacic Spine Radiosurgery|Image guidance spine stereotactic radiosurgery/ablative radiotherapy 1600 cGy in single fraction to Involved Target using IMRT/VMAT/RapidArc
223485656|NCT04033536|RADIATION|Elective Target Stereotacic Spine Radiosurgery|Image guidance spine stereotactic radiosurgery/ablative radiotherapy 1600 cGy in single fraction to Elective Target using IMRT/VMAT/RapidArc
223485657|NCT04740970|DRUG|JNJ-64304500|JNJ-64304500 injection will be administered subcutaneously.
223485658|NCT04740970|DRUG|Placebo|Matching placebo injection will be administered subcutaneously.
223485659|NCT05474820|OTHER|Samples collection and ELISA analyses|"The serum and unstimulated saliva samples were taken from all patients between 8:00 and 10:00 in the morning. Saliva samples were centrifuged at 10,000 rpm (10 min) whereas venous blood samples were centrifuged at 4000 rpm for 10 min.~For the analysis of irisin and IL-6 specific ELISA Kits (Elabscience, Houston, Texas, USA) were used to determine the molecules in both serum and saliva samples in accordance with the manufacturer's instructions. All samples were run in duplicate, and values have been averaged."
223485660|NCT05474820|DIAGNOSTIC_TEST|Evaluating periodontal paramètres|The clinical periodontal parameters (plaque index (PI), probing pocket depth (PD), gingival recession (GR), clinical attachment loss (CAL), and bleeding on probing (BOP)) were recorded on periodontal charts in each patient
223485661|NCT04504760|DRUG|ONO-2910|Single ascending dose of ONO-2910 will be administered orally.
223485662|NCT04504760|DRUG|Placebo|Single dose of placebo will be administered orally.
223485663|NCT04504760|DRUG|ONO-2910|Multiple ascending dose of ONO-2910 will be administered orally.
223485664|NCT04504760|DRUG|Placebo|Multiple dose of placebo will be administered orally.
224174650|NCT03259607|DRUG|Nicorette Extra Mint 2 mg Gum|A single dose of one nicotine gum will be placed on the tongue to be chewed every 2 seconds for 30 minutes.
224174651|NCT03259607|DRUG|Nicorette Mint 2 mg Gum|A single dose of one nicotine gum will be placed on the tongue to be chewed every 2 seconds for 30 minutes.
224174652|NCT03259607|DRUG|Nicorette Extra Mint 4mg Gum|A single dose of one nicotine gum will be placed on the tongue to be chewed every 2 seconds for 30 minutes.
224174653|NCT03259607|DRUG|Nicorette Mint 4 mg Gum|A single dose of one nicotine gum will be placed on the tongue to be chewed every 2 seconds for 30 minutes.
224174654|NCT00697424|DEVICE|SleepStyle 200 Auto Series CPAP Humidifier|The device will record on internal software perceived sleep disordered breathing events. Events will also be scored manually on the polysomnography (PSG. Results will then be compared.
224174655|NCT00209755|PROCEDURE|therapeutic drug monitoring of ribavirin and dose adaptation|
224174656|NCT01844310|DRUG|RAL+TDF+LPV/r|Group A will be assigned with RAL-based regimen (RAL+TDF+LPV/r).
224174657|NCT01844310|DRUG|3TC+TDF+LPV/r|Group B will be assigned with 3TC+TDF+LPV/r
224174658|NCT03097666|DEVICE|C2 CRYOBALLOON SWIPE ABLATION SYSTEM|"The C2 CryoBalloon Swipe Ablation System (CryoBalloon Swipe) is a cryosurgical device with a nitrous oxide cooled balloon probe that is compatible with upper gastrointestinal diagnostic endoscopes."
224174659|NCT00375596|DRUG|Ketotifen/vasoconstrictor|
224174660|NCT01146158|PROCEDURE|Axillary dissection for breast carcinomas|surgery Axillary dissection
224174661|NCT03144596|DRUG|Alfuzosin Hydrochloride 10 MG|Alfuzosin hydrochloride Tablet
224174662|NCT03144596|DRUG|Tamsulosin Hydrochloride 0.4 MG|Tamsulosin Hydrochloride Tablet
224174663|NCT00712764|DRUG|Adenosine|
224174664|NCT00712764|DRUG|Placebo|
224174665|NCT05786404|DRUG|PRIM-DJ2727 - FROZEN|Patients with active UC will receive induction dose of 100 grams of stool via frozen retention enema, Fecal Microbiota Transplantation (FMT) product manufactured as PRIM-DJ2727-FROZEN administered in clinic. This consists of microbiota suspension from well-screened donors. Twice filtered fecal microbiota product diluted in saline to 500 mL containing 100g of study drug will be administered as frozen enema induction dose
224174666|NCT05786404|DRUG|PRIM-DJ2727 - CAPSULES|Patients with active UC will receive induction dose of 100 grams of stool in orally administered enteric-coated capsules Fecal Microbiota Transplantation (FMT) product manufactured as PRIM-DJ2727-CAPSULES.These capsules consists of microbiota from well-screened donors. The induction dose of enteric-coated capsules will be derived from 100 grams stool.
224174667|NCT05129917|DIETARY_SUPPLEMENT|Placebo|consume 1 sachet per day for 14 day
224174668|NCT05129917|DIETARY_SUPPLEMENT|Gojinsen® drinks|consume 1 sachet per day for 14 day
224174669|NCT04829591|OTHER|observational|Heart failure, non interventional
224174670|NCT04950491|OTHER|Modified Dental Anxiety Score (MDAS) questionnaire|MDAS was used to measure the patients' anxiety toward dental treatment before implant surgery (Humphris, Dyer, \&Robinson, 2009). Originally, the MDAS questionnaire included five questions answered with a 5-category Likert scale. The original MDAS questionnaire does not cover anxiety toward implant surgery. Therefore, a question enquiring about patients' feelings towards implant surgery was added.
224174671|NCT04950491|OTHER|Pain questionnaire|Patients were asked to describe the worst pain feeling using a standard 10 cm Visual Analog Scale (VAS) and the proportion of time spent in severe pain using a 5 category Likert scale. The number of analgesics taken per day was also asked.
224174672|NCT04950491|OTHER|Oral Health-Related Quality of Life (OHRQoL) questionnaire|The OHRQoL comprises 14 questions covering problems the patient may in three main categories: oral function, daily activity, and post-operative symptoms (Chaushu, Becker, Zeltser, Vasker, \& Chaushu, 2004). Patients answered using a 5-category Likert scale.
224174673|NCT00173615|PROCEDURE|Extracorporeal membrane oxygenation|
224174674|NCT03066505|DEVICE|Active MeRT Treatment|A personalized biometrics-guided protocol known as magnetic EEG/EKG resonance therapy (MeRT) treatment that is tailored specifically to each patient's higher harmonic frequency of heart rate, which is nearest to the characteristic frequency of alpha EEG frequency.
224174675|NCT03066505|DEVICE|Sham MeRT Treatment|A personalized biometrics-guided protocol similar to MeRT treatment that mimics magnetic EEG/EKG resonance therapy (MeRT) but does not emit active stimulation.
224174676|NCT01790451|PROCEDURE|Irreversible Electroporation|
224174677|NCT03181776|OTHER|left lateral tilting in 15 degrees|The mother will be placed in left lateral tilted position (15 degrees) using a standard wedge
224174678|NCT03181776|OTHER|left lateral tilting in 30 degrees|The mother will be placed in left lateral tilted position (30 degrees) using a standard wedge
224174679|NCT03181776|OTHER|supine position|The mother will be placed in standard supine position
224174680|NCT00012870|BEHAVIORAL|Behavioral Management|
224174681|NCT02705001|OTHER|all admissions except accident and emergency|No additional intervention, retrospective study
224174682|NCT02412826|DEVICE|Abstats sensor|The AbStats abdominal biosensor will be applied to the abdomen of patients who are admitted with acute pancreatitis.
223485665|NCT05492435|DEVICE|transcranial direct current stimulation|tDCS can regulate cortical excitability by influencing membrane polarity, where anodic current increases excitability and cathodic current reduces excitability. Therefore, in post-stroke patients when the anode is applied to the cerebral hemisphere ipsilesional to the lesion or the cathode to the contralesional hemisphere, the balance between the interhemispheres tends to be restored.
223485666|NCT01953237|BEHAVIORAL|MedActive|Participants randomized to the MedActive condition will complete a 1-hour training session on MedActive, which will include ascertaining their antipsychotic administration schedule that will be pre-programmed into the application along with other personalized features. Each participate will be asked to use the medActive application over the following three months. All participants randomized to this condition will also have their antipsychotic medication adherence assessed over the 3-month period.
223485667|NCT01953237|DEVICE|Smartphone|
223485668|NCT03936127|PROCEDURE|Ultrasound (US) Targeted Fusion Biopsy|Ultrasound (US) Targeted Fusion Biopsy
223485669|NCT04167462|DRUG|BMS-986165|Specified dose on Specified Days
223485670|NCT04167462|OTHER|Placebo|Specified dose on Specified days
223485671|NCT05993169|OTHER|Body Composition optimization visits|Patients who are selected into the body composition optimization (BCO) visits group will attend an extra one hour in-person check-up with Olivia Johnson as part of their regular clinic follow-ups. During their initial BCO visit, patients will complete a hard copy intake form. These BCO visits will take place in the same clinic as the regular visits. These visits will focus on individual concerns and goal-setting. These visits may be changed to online/video follow ups if the patients are finding it difficult to return to main campus that often.
223485672|NCT05408221|DRUG|Rulonilimab+Lenvatinib|Rulonilimab, intravenous (i.v.) administration every 3 weeks; Lenvatinib oral administration, once daily
223485673|NCT05408221|DRUG|Rulonilimab placebo +Lenvatinib|Rulonilimab placebo, intravenous (i.v.) administration every 3 weeks; Lenvatinib oral administration, once daily
223586415|NCT04736628|DRUG|Avenciguat|Avenciguat
223586416|NCT04736628|DRUG|Placebo|Placebo
223586417|NCT04279613|DRUG|NNC0361-0041|Recombinant supercoiled plasmid encoding four human proteins: (pre-proinsulin (PPI), transforming growth factor β1 (TGF-β1), interleukin-10 (IL-10), and interleukin-2 (IL-2) is administered s.c. via syringe and needle.
223586418|NCT04279613|OTHER|Placebo|Placebo
224174683|NCT04334876|DIAGNOSTIC_TEST|SARS-CoV-2 IgG Antibody Testing Kit|A, finger prick, at home test for SARS-CoV-2 IgG Antibodies.
224174684|NCT02155166|DRUG|Intracervical anesthesia with lidocaine 2%|5 min before LNG-IUS placemen
224174685|NCT02155166|DRUG|ibuprofen 400 mg|1 hour prior to the LNG-IUS insertion
224174686|NCT05994105|BEHAVIORAL|Art based Augmented Reality|The participants will be provided 14 sessions management plan
224174687|NCT05894187|OTHER|animated video|Participants randomized to the intervention group will receive a link to a short survey gauging parent anxiety levels three days prior to their childs surgery date. If randomly assigned to watch the informative animated video, the survey will be followed by a link to a video which families are free to watch prior to your child's surgery date. Once participants and there family watch the video, they will be asked to rate the quality of the video on a scale of 0 (very bad) to 10 (excellent). Responses to this question will be used to confirm that participants watched the video to the end.
224174688|NCT05638529|DRUG|Pregnyl (1,500) IU|Patients will self-administer a subcutaneous injection of a GnRH agonist (Suprefact 0.5 mg) and a separate intramuscular injection of hCG (Pregnyl 1,500 IU) on their assigned trigger day.
224174689|NCT05638529|DRUG|1.5 mL of normal saline|Patients will self-administer a subcutaneous injection of a GnRH agonist (Suprefact 0.5 mg) and a separate intramuscular injection of normal saline (1.5 mL - sham placebo) on their assigned trigger day.
224174690|NCT06096766|DIAGNOSTIC_TEST|blood test|Detection of serum levels of copper ions, iron ions, ceruloplasmin (CP), CuZn SOD, malondialdehyde (MDA), etc. Blood samples will be retained from the rest samples for sex hormones samples for testing sex hormones, which don't increase times of blood collection.
224174691|NCT02712892|GENETIC|Non Interventional Study|
224174692|NCT02184520|DEVICE|TRANSITION|
224174693|NCT02184520|DEVICE|REVERE|
224174694|NCT05368766|OTHER|VExUS score|The venous excess ultrasound (VExUS) score incorporates hepatic venous, intrarenal venous Doppler, inferior vena cava (IVC) assessment, and portal vein Doppler
224174695|NCT05368766|DRUG|Diuretic Effect|Response to diuretic therapy
224174696|NCT02185040|DRUG|CC-220|0.3 mg oral capsules once every other day with or without food
224174697|NCT02185040|DRUG|CC-220|Subjects will receive 0.3 mg oral capsules every day with or without food
223485674|NCT05651737|BEHAVIORAL|Sui App (SRK)|"The Sui app contains the following chapters:~6 well-being chapters on: stress, sleep, resources throughout the day, chronic pain, emotion regulation, audio exercises 9 Swiss-specific information chapters on: housing, health (two sub-chapters), finances, asylum process, residence status, social integration, occupational integration, family reunification"
223485675|NCT02638441|OTHER|hospital anxiety and depression scale|Detection of infertility effect on emotional status
224174698|NCT02185040|DRUG|CC-220|CC-220 oral capsules 0.6 mg and 0.3 mg on alternating days with or without food
224174699|NCT02185040|DRUG|CC-220|CC-220 oral capsule 0.6 mg QD with or without food
224174700|NCT02185040|DRUG|Placebo|Matching oral placebo daily
224174701|NCT01713257|DIETARY_SUPPLEMENT|Immunoenhancing diet|Enteral feeding until Day 10 or the day of discharge if earlier than Day 10. The goal of caloric intake is 25 kcal/kg/day and protein 1.2 g/kg/day.
223485676|NCT04976257|PROCEDURE|Angiogram|Undergo angiogram
223586419|NCT06597695|DRUG|Ketamine-assisted psychotherapy|Ketamine-assisted psychotherapy delivered in a group format
223586420|NCT06422338|OTHER|IMCI-enhanced by suPAR levels (SoC + suPAR POC)|IMCI-guidelines (standard of care) + Point-Of-Care (POC) based on suPAR quantification
224174702|NCT01713257|DIETARY_SUPPLEMENT|Isocaloric, isonitrogenous diet|Enteral feeding until Day 10 or the day of discharge if earlier than Day 10. The goal of caloric intake is 25 kcal/kg/day and protein 1.2 g/kg/day.
224174703|NCT04697589|DIETARY_SUPPLEMENT|Memophenol 300 mg|300 mg a proprietary, standardized botanical blend rich in polyphenols (SBRP) and especially in monomers of flavanols.
224174704|NCT04697589|DIETARY_SUPPLEMENT|Memophenol 600 mg|600 mg a proprietary, standardized botanical blend rich in polyphenols (SBRP) and especially in monomers of flavanols.
224174705|NCT04697589|DIETARY_SUPPLEMENT|Placebo|Colored maltodextrin
224174706|NCT03640715|OTHER|ENVU|"ENfant VUlnerable: a clinical tool for screening for social and health vulnerability in pediatrics - tool: VUlnerable Child (ENVU) -; to allow for an appropriate orientation of the patient care pathway. The metrological validation of diagnostic performances (sensitivity, specificity, positive and negative likelihood ratios) will be studied in confrontation with the opinion of an expert caregiver in the care of vulnerable populations."
224174707|NCT03977506|DIAGNOSTIC_TEST|On-road driving evaluation|"The data assessed during the road test from the two assessment grids (recommendations of the HAS and Test ride for investigation practical fitness to drive) :~road position, vehicle control, track management, safety distances, speed, visual behavior, traffic signs, vehicle overtaking, anticipatory reactions and capabilities adaptation, attentional skills, decision-making, communication with other road users, assessment of specific situations such as insertion on a 2x2 lane, mechanical management and general impressions."
224174708|NCT04506879|PROCEDURE|Popliteal Sciatic nerve block|Patients schedule for lower limb surgery under regional anesthesia will receive ultrasound guided subparaneural popliteal sciatic nerve block. After identification of the common peroneal nerve and tibial nerve, local anesthetic agents will be injected close to each nerve below the point of divergence at the popliteal fossa. The spread of the drug and the sensory and motor function of that limb will be assessed regularly till it is ready for surgery.
224174709|NCT05804071|DRUG|Niferex|"Daily iron supplement scheme (QD)：Oral polysaccharide iron complex capsule (Niferex)150mg/300mg daily.~Alternative iron supplement scheme（QOD）：Oral polysaccharide iron complex capsule(Niferex) 150mg/300mg every other day.~Intravenous iron supplement(MonoFer):use as instructions"
224174710|NCT01116128|DRUG|dasatinib|100 mg QD continuously (from day 1 to day 28)
224174711|NCT01116128|DRUG|melphalan|0,18 mg/Kg/day from day 1 to day 4 for 6 cycles
224174712|NCT01116128|DRUG|prednisone|1,5 mg/Kg/day from day 1 to day 4 for 6 cycles
224174713|NCT03347279|BIOLOGICAL|Experimental: Tezepelumab|Tezepelumab subcutaneous injection
224174714|NCT03347279|OTHER|Placebo|Placebo subcutaneous injection
223485677|NCT04976257|PROCEDURE|Catheterization|Undergo prostatic arterial catheterization
223485678|NCT04976257|DRUG|Gallium Ga-labeled PSMA-11|Given IV and IA
223485679|NCT04976257|PROCEDURE|Positron Emission Tomography|Undergo PET scan
223586421|NCT06548932|DRUG|GZR33 Injection|A single dose
223586422|NCT06548932|DRUG|GZR101 Injection|A single dose
223586423|NCT06548932|DRUG|Placebo|A single dose
223745245|NCT05447754|OTHER|Combined RAGT and TBT|Combined RAGT and TBT: Participants will be treated with Lokomat for 40 minutes, twice a week for 5 weeks, and RAGT with a body weight support system and combined TBT for 40 minutes each session 3 times a week. During RAGT, 30-40% of each participant's body weight will be taken with the body weight support system. In patients without drop foot and knee instability in the sessions after the first session, the body weight will be reduced by 10% and progression will be achieved. The speed of the treadmill will be adjusted between 1.2-2.6 km/h and the maximum speed tolerated by the patient will be reached during the sessions. TBT exercises 3 times a week for 40 minutes (weight transfer to the paretic leg during sitting and standing, weight transfer during sitting and standing with or without an assistive device) will be personalized according to the patient. Progression of exercises will be provided by adding upper extremity and trunk activities in addition to exercises.
223586431|NCT04878952|OTHER|Garmin Vivofit Activity Tracker|Activity tracker that is worn on the wrist.
224174715|NCT01646151|DRUG|Bimatoprost|Bimatoprost-containing eye drops administered in the affected eye(s) at a dose determined by the physician in accordance with standard of care for up to 12 weeks.
224174716|NCT05392101|DRUG|Deferasirox 360 MG|Deferasirox 360 MG p.o. once daily
224174717|NCT00944476|PROCEDURE|Fat-free MRI images utilizing standard magnetization, Questionnaire before the MRI exam|In addition to the traditional MRI exam for clinical use, a fat-free MRI based on standard magnetization transfer magnetic resonance imaging will be acquired. Pts will spend 20 extra minutes and 20 minutes total for volunteers in the MRI scanner. Patients/volunteers will complete the MR Screening Questionnaire before the MRI exam.
224174718|NCT02385292|DEVICE|Oculeve Intranasal Lacrimal Neurostimulator|The Oculeve Intranasal Lacrimal Neurostimulator applies a small electrical current to gently activate the body's natural tear production system.
224174719|NCT02840903|DRUG|Iopromide (Ultravist, BAY86-4877)|8 settings for CT Angiography as described in group description.
224306372|NCT04641793|DEVICE|Motion and Emg Control|"We will consider two methods for integrating motions and EMG signals:~1. Direct methods. Signals extracted from the latent EMG space will directly contribute to the control of the external device. We will integrate EMG and IMU in two ways. In a first scenario, EMG and IMU will be given variable weight in the control. In a second scenario (perturbative method) the distance of ongoing muscle patterns from a desired set of strategies will modulate the mapping from body to cursor motions in the form of assistive (i.e. the cursor moves faster towards the target) or resistive (i.e. the cursor slows down) influences on cursor movement.~2. Indirect Methods. Signals extracted by EMG will modulate the feedback offered to the learner to penalize deviations from desired muscle patterns. When multiple ways to perform a movement are offered by redundancy, (i.e., by the multiplicity of muscles compared to task demands), the brain chooses solutions that minimize noise and uncertainty."
223485680|NCT02820636|BEHAVIORAL|S-CBT|The SCBT-SB protocol has 3 phases. Phase I, which is fixed (core sessions), includes 9 sessions (1 family, 5 individual \& 3 caretakers sessions). Topics include: understanding the suicidal crisis, identity in adolescence, chain analysis, communication skills, the power of thought and decision making, parenting skills, rearing in a different culture, and family communication. Phase II is flexible and consists of coping skills modules (thoughts, emotional regulation, social interactions, activities, substance abuse, family communication \& trauma). The treatment plan is adjusted to adolescents' needs. Family and primary caregiver sessions are flexible, depending on the family/caregivers' needs. Participants have received an adequate course of treatment if they at least complete the core sessions. This protocol should take 3-6 months. Once the active phase ends, booster sessions are recommended.
224306373|NCT00209989|DRUG|Zarnestra|ZARNESTRA 100 bid (phase II recommended dose defined in phase I)will be administered continuously from one week prior to start of radiation therapy until the last day of radiation therapy.
224306374|NCT00209989|PROCEDURE|standard Radiation therapy|Radiotherapy will be focused on the initial tumour volume with a reasonable margin of safety (2 cm). A total dose of 60 Gray (Gy) will be given to the Clinical Target Volume
224306375|NCT06218121|DIAGNOSTIC_TEST|Instrumental and Functional Tests that Assess Functional Capacity|The correlation between all functional, ultrasound, nutritional, and psychological variables will be analyzed. Through GLIM diagnosis, anthropometric data (weight, height, BMI) as well as analytical data including inflammation information (CRP and albumin) will be used to reach a diagnosis that allows comparison/correlation with the rest of the variable parameters.
224306376|NCT04385966|PROCEDURE|Interscalene brachial plexus block|Interscalene brachial plexus block is a locorregional anaesthesia technique which is indicated in shoulder and upper arm surgery. The goal of this block is to place the needle in the tissue space between the anterior and middle scalene muscles and inject local anesthetic until the spread around the brachial plexus is documented by ultrasound.
224306377|NCT04385966|DRUG|Levobupivacaine Hydrochloride 2.5 MG/ML|"Levobupivacaine Hydrochloride 2.5 MG/ML is an anesthestic product intended for epidural, intradural and perineural administration. Levobupivacaine is chemically described as (S)-l-butyl-2-piperidylformo-2',6'-xylidide hydrochloride. It is a white crystalline powder with a molecular formula of C18H28N2O. HCl, with a molecular weight 324.9.~FDA approval: NDA-20997 (1999)."
223745246|NCT05447754|OTHER|balance exercises|TBT
223745247|NCT06676072|DEVICE|PFA Ablation catheter|Deliver RF and/or PF energy using the TactFlex PFA system
224174720|NCT01792024|DEVICE|Visualase Thermal Therapy|MR guided laser ablation of prostate cancer
224174721|NCT01792024|PROCEDURE|magnetic resonance imaging|Undergo MR-guided LITT
224174722|NCT03818399|DRUG|SUBLOCADE|SUBLOCADE (buprenorphine extended-release) injection is a colorless to amber sterile solution for SC injection designed to deliver buprenorphine at doses of 100 mg or 300 mg at a controlled rate over a one-month period.
224174723|NCT06232187|BEHAVIORAL|Artificial Intelligence feedback for ultrasound EFW standard plane images|AI feedback in two levels, in aid of the participants, to obtain the right standardplane images used in fetal ultrasound EFW calculation.
224174724|NCT02029365|OTHER|Autoquestionnary|autoquestionnary completed during the consultation for infertility
224174725|NCT02029365|OTHER|semi-structured interview|phone interview
224174726|NCT03787901|OTHER|Morula Vitrification|Evaluating the ongoing pregnancy rate following Morula vitrification compared with Blastocyst Vitrification.
224174727|NCT01707940|DRUG|Ketoconazole|Ketoconazole 400 mg / day
224174728|NCT01707940|DRUG|BI 144807|BI144807 oral solution, intermediate dose
224174729|NCT01707940|DRUG|BI 144807|BI144807 oral solution, intermediate dose
224174730|NCT01657149|PROCEDURE|Lymphatic massage and individual physiotherapy|lymphatic massage and individual physiotherapy
224174731|NCT01657149|PROCEDURE|individual physiotherapy only|individual physiotherapy only
224174732|NCT06202313|BIOLOGICAL|Cadonilimab|Participants receive Cadonilimab 10mg/kg IV on Day 1 of each 21-day cycle PLUS Eribulin 1.4mg/m\^2 IV on Days 1 and 8 of each 21-day cycle.
224174733|NCT06202313|DRUG|Eribulin|Participants receive Eribulin 1.4mg/m\^2 IV on Days 1 and 8 of each 21-day cycle.
224174734|NCT02429089|DRUG|LEE011|"The first 12 patients will receive cetuximab associated with LEE011 at doses of 400 mg and 600 mg daily to determine the DLTs and safety.~In the expansion part, besides safety, objective response rate, progression-free survival and overall survival will be calculated with the inclusion of 14 patients."
224174735|NCT02530281|DRUG|glycopyrronium Topical Wipes|Topical wipes containing glycopyrronium
224174736|NCT02530281|OTHER|Vehicle|Vehicle (placebo) topical wipes
224174737|NCT00003684|DRUG|theophylline|
224174738|NCT00003684|PROCEDURE|quality-of-life assessment|
224174739|NCT03272009|DRUG|EYP001a|Capsules administered orally. Number of morning and evening capsules depending on treatment arm
224174740|NCT03272009|DRUG|Placebo|Placebo capsules for oral administration, identical in appearance to the EYP001a capsules
224174741|NCT03272009|DRUG|Entecavir|Tablets administered orally
224174742|NCT03272009|DRUG|peg-interferon alfa-2a|Ready-to-Use pre-filled syringes for subcutaneous injection
224174743|NCT05749276|DRUG|Darzalex|"DARZALEX® = Daratumumab. Solution for injection, 1800 mg/15 mL, single vial. Sub-cutaneous administration.~* Dose level 1 : 1800 mg Day 1~* Dose level 2 : 1800 mg Day 1 and 8 (+/- 2 days)~* Dose level 3 : 1800 mg à Day 1, 8 (+/- 2 days) and D15 (+/- 2 days)"
224174744|NCT06317298|DRUG|Fruquintinib and Everolimus|Fruquintinib and Everolimus
224174745|NCT01930396|DRUG|Tinzaparin|
224174746|NCT01930396|DRUG|Unfractionated Heparin|
224174747|NCT01930396|DRUG|Placebo (for Tinzaparin)|0.9% Normal Saline
223745248|NCT01894581|DIETARY_SUPPLEMENT|LOVAZA|Subjects will be instructed to take 2 grams twice daily of oral omega-3-acid ethyl esters (Lovaza) starting with day 1 to 3 of their menstrual period. Each capsule contains 60mg of other omega-3 FA. On day 1 of their subsequent menstrual period, subjects will be instructed to discontinue.
224174748|NCT01930396|DRUG|Placebo (for Unfractionated Heparin)|0.9% Normal Saline
224174749|NCT02198313|DRUG|BIIX 1 XX - D1|
224174750|NCT02198313|DRUG|BIIX 1 XX - D2|
224174751|NCT02198313|DRUG|BIIX 1 XX - D3|
224174752|NCT02198313|DRUG|Placebo|
224174753|NCT00945685|DEVICE|Endymion Imagine™ System for Skin Tightening|"Based on patient skin type and area of treatment the physician will choose the following parameters (some parameters are fixed):~* Pulse energy (J);~* RF frequency (1MHz);~* Pulse duration (30 sec);~* Treatment hand piece (skin tightening);"
224174754|NCT03515265|OTHER|Fiber reinforced resin composite restoration|a type of resin composite with improved strength due to the fiber's action
224174755|NCT03515265|OTHER|Microhybrid resin composite restoration|a type of conventional resin composite
223745249|NCT01894581|DRUG|GnRH|An intravenous bolus of exogenous GnRH (75 ng/kg dosing based on total body weight) will be administered at 6 hours.
223745250|NCT06872905|DEVICE|GORE VIABAHN® VBX Balloon Expandable Endoprosthesis (VBX)|Treatment of Target Lesions with the VBX Device in the aortic and common iliac positions during the CERAB procedure.
224174756|NCT04799340|BEHAVIORAL|cognitive training|training to improve encoding and recognition of faces
224174757|NCT00003016|DRUG|tamoxifen citrate|
224174758|NCT00003016|PROCEDURE|adjuvant therapy|
224174759|NCT05381194|DRUG|BPaL(M) regimen|"Patients diagnosed with MDR/RR-TB are initially assigned to the BPaLM regimen as a single-arm for treatment initiation. Afterward, if MDR/RR-TB is confirmed to be fluoroquinolone-resistant by molecular or phenotypic DST, the treatment is switched to the BPaL regimen (for 24 weeks). On the other hand, if MDR/RR-TB is confirmed to be fluoroquinolone-susceptible, treatment for MDR/RR-TB is maintained with the BPaLM regimen (for 26 weeks).~The dosage of each medication is as follows:~* Bedaquiline 400mg/day for the 2 weeks, 200mg/TIW afterward~* Pretomanid 200mg/day~* Linezolid 600mg/day for the 9weeks, 300mg/day afterward~* Moxifloxacin 400mg/day"
224174760|NCT00535236|BIOLOGICAL|V212|0.65 ml V212 in 4 dose regimen. Treatment period of 125 days
223485681|NCT02820636|BEHAVIORAL|Treatment as Usual|Intensive outpatient therapy with teens and their parents using a variety of eclectic treatments that characterize standard care for adolescents.
224174761|NCT00535236|BIOLOGICAL|Placebo|0.65 ml V212 Pbo in 4 dose regimen. Treatment period of 125 days
224174762|NCT03568513|DIETARY_SUPPLEMENT|Curcumin|The curcumin food supplement will be administered in the form of capsules. Participants in the treatment arm will take 50 mg twice or three times a day, depending on their body weight. Participants will take the curcumin capsules for eight weeks.
224174763|NCT03568513|DIETARY_SUPPLEMENT|Placebo|The placebo will be administered in the form of capsules. Participants in the placebo arm will take a capsule twice or three times a day, depending on their body weight. Participants will take the placebo capsules for eight weeks. The placebo capsule will be similar in size, shape and color to the curcumin capsule and they will contain inert food powder.
224174764|NCT01921959|BEHAVIORAL|Intervention|Postpartum women are randomized to intervention or control group
224174765|NCT05146531|DEVICE|McCoy laryngoscope|Patients scheduled for general anesthesia were intubated with McCoy laryngoscope.
224174766|NCT05146531|DEVICE|C-MAC D-blade video laryngoscope|Patients scheduled for general anesthesia were intubated with C-MAC D-blade video laryngoscope.
224174767|NCT01146691|OTHER|Alternative Intensivist staffing models|During the study period, each participating ICU alternated (ABAB or BABA) between two distinct intensivist staffing formats: (i) the standard staffing model, an intensivist is responsible for care in that ICU for the entire 7 days, being present during the daytime hours, and taking call from home at night, (ii) the 24-7 in-hospital, shiftwork model, enabled by splitting each 24 hour period into two shifts. There will, as in the standard model, be a single intensivist covering the ICU during the day shifts for one week. The day shift will run 8 am to 5:30 pm on weekdays, and 8 am to 3 pm on Saturday and Sunday. The night shift intensivist will arrive and take over at 5:30 pm on weekdays, and 3 pm on weekends and remain in the hospital until 8 am.
224174768|NCT06322511|BEHAVIORAL|Dialogical Family Guidance (DFG)|DFG is family intervention including six meetings with family members. The individual needs and questions of each family are discussed and issues parents bring up are seemed as important.
224174769|NCT05591573|DIETARY_SUPPLEMENT|Low glycemic index drink|Fruit flavoured drink with low glycemic index sugar (300 ml)
223586432|NCT01754298|PROCEDURE|Retro-articular drilling|"* Drilling must be performed under AP and lateral fluoroscopic guidance, with no additional drilling in 'trans-articular', or intra-articular trans-condylar fashion.~* Use a 0.045 K-wire for drilling.~* Minimum of 8 wire passes per square centimeter with no maximum number of wire passes."
224174770|NCT05591573|DIETARY_SUPPLEMENT|High glycemic index drink|Fruit flavoured drink with high glycemic index sugar (300 ml)
224174771|NCT00871468|PROCEDURE|superior plate|Open reduction internal fixation (ORIF) clavicle with superior plate
224174772|NCT00871468|PROCEDURE|anterior-inferior plate|ORIF clavicle with anterior inferior plate
224174773|NCT02390323|PROCEDURE|Lumbar Sympathetic Block|"A lumbar sympathetic block is an injection in the middle of the lower back, toward the left or right side. The lumbar sympathetic nerves are a small bundle of nerves that carries sympathetic nerve signals from the lower extremities. In some instances, certain injuries to the lower extremities can cause a burning, unusual pain called complex regional pain syndrome or reflex sympathetic dystrophy. Injecting a small amount of local anesthetic on the lumbar sympathetic nerves can identify whether or not this pain is carried by the sympathetic nervous system."
224174774|NCT02390323|DEVICE|Skin conductance algesimeter|The real-time changes in skin conductance indices can be monitored at the skin level, by use of non-invasive electrodes attached to the skin (similar to EKG electrodes) connected to the skin conductance algesimeter. A computer program analyzes the data and produces a real-time graphic and numeric data demonstrating the skin conductance response. The initiation of successful sympathetic blockade can cause rapid cessation of the skin sympathetic activity that leads to a decrease in skin conductance within seconds.
224174775|NCT02293265|DRUG|Short Acting Beta Agonist (SABA)|Participants requiring a spirometry measurement will be administered a SABA in a metered dose inhaler (MDI) during the reversibility assessments
224174776|NCT02008981|DRUG|Curcuma longa|Curcuma longa in capsule form will be given with actual or placebo aspirin, each for a 3 week period. Clotting profile and platelet function test will be done before and after.
224174777|NCT02008981|DRUG|Angelica sinensis|Angelicae sinensis in capsule form will be given with actual or placebo aspirin, each for a 3 week period. Clotting profile and platelet function test will be done before and after.
224174778|NCT02008981|DRUG|Siwu Tang|"TCM formulation Siwu Tang consisting of 4 herbs ( Ligustici chuangxiong, Angelicae sinensis, Rehmanniae praeparata and Paeoniae alba) in tablet form will be given with actual or placebo aspirin, each for a 3 week period. Clotting profile and platelet function test will be done before and after."
224174779|NCT02008981|DRUG|Aspirin|Aspirin (enteric-coated) at 100mg daily will be given one of the actual herb or placebo herb, each for a 3 week period. Clotting profile and platelet function test will be done before and after.
224174780|NCT03309722|OTHER|biomarker study|
224174781|NCT01156857|DRUG|PGL4001, placebo|PGL4001 10mg once daily (oral tablets) for 3 months followed by a period of 10 days of placebo (oral tablets).
224174782|NCT01156857|DRUG|PGL4001, progestin|PGL4001 10mg once daily (oral tablets) for 3 months followed by a period of 10 days of progestin Norethisterone acetate 10mg once daily (oral tablets).
224174783|NCT06292026|DEVICE|ProgenaMatrix Keratin graft|place ProgenaMatrix graft on the wound
224174784|NCT06292026|OTHER|standard of care|apply non adherent dressing
224174785|NCT04921111|DRUG|SCT1000|Recombinant 14 valent human papillomavirus vaccine (6,11,16,18,31,33,35,39,45,51,52,56,58,59) (insect cells)
224174786|NCT04921111|DRUG|Gardasil®9|Recombinant 9 or 4 valent human papillomavirus vaccine
224174787|NCT04921111|DRUG|placebo|aluminium phosphate
224174788|NCT04921111|DRUG|Gardasil®|Recombinant 4 valent human papillomavirus vaccine
224174789|NCT01213342|DIETARY_SUPPLEMENT|Omega-3 Fatty Acid|"Each patient will be instructed to take 4 soft gel capsules per day (2 with the morning meal and 2 with the evening meal). They will continue this regimen for 8 weeks. The total daily amount included in 4 soft gels includes:~* EPA (Eicosapentaenoic Acid) 1300mg~* DHA (Docosahexaenoic Acid) 900 mg~* Other Omega-3's 360mg~* Total Omega 3's 2560 mg"
224174790|NCT01213342|DIETARY_SUPPLEMENT|Soybean Soft Gels|Each patient will be instructed to take 4 soft gel capsules per day (2 with the morning meal and 2 with the evening meal. The main ingredient in the placebos is soybean oil (95.6%).
224174791|NCT01924793|DRUG|DAS181-F02 Dry Powder in Bulk|Administered via DPI
224174792|NCT01924793|DRUG|DAS181-F02 Nebulized Formulation Inhaled Dose|Administered via Nebulizer
224174793|NCT00100542|BEHAVIORAL|Psychiatric interviews|Measures and questionnaires regarding mental health, pain, and adherence to treatment. No actual treatment or intervention is given as part of this study.
224174794|NCT03727685|BEHAVIORAL|Our Care Wishes|A flyer describing the Our Care Wishes platform will be added to the back pocket of admission packets for patients being admitted via the Silverstein 1 Admission Office and the Emergency Department and for patients being seen in the Pre Admission Testing office. Registration reps in these locations will inform all patients seen that Penn has created a free, online resource called Our Care Wishes to help patients with Advance Care Planning and ask if they would like to be sent a link to Our Care Wishes by email or text. For those patients who respond affirmatively, the rep will then complete the necessary fields to refer on www.ourcarewishes.org/refer.
224174795|NCT04454632|OTHER|Mirror therapy|affected arm stay behind the mirror while exercising
224174796|NCT04454632|OTHER|Visual feedback|visual feedback from mirror
223586433|NCT01754298|PROCEDURE|Trans-articular drilling|"* Drilling must be performed, under arthroscopic visualization, directly through the articular cartilage, with no additional drilling in 'retro-articular', 'extra-articular', or trans-condylar (through the intercondylar notch)~* Use a 0.045 K-wire for drilling~* A minimum 4 wire passes per square centimeter, with a maximum of 5 wire passes per square centimeter"
223586434|NCT05036200|DEVICE|pulsed dye laser|four pulsed dye laser sessions were administered every eight weeks in the 21 patients
223485682|NCT01125553|DRUG|insulin degludec/insulin aspart|Each subject will be allocated to two single injections of trial product on two separate dosing visits with each of the two insulin degludec/insulin aspart formulations. The trial products will be administered as a subcutaneous injection (under the skin).
223586435|NCT03632603|RADIATION|No intervention|No intervention during study period.
224174797|NCT05953896|COMBINATION_PRODUCT|Hyaluronic acid gel|For the Hyaluronic acid gel group: HA gel was injected 2-3mm apical to the coronal tip of the involved papillae and the needle was directed coronally with an angulation of 45° to the long axis of the tooth, and the bevel directed apically until papilla became blanched. The injection was given at each papilla at the following intervals baseline, one week and two weeks.
224174798|NCT05953896|COMBINATION_PRODUCT|Multilayer L-PRF membranes|For the multilayer L-PRF group: A single semilunar incision is made in the buccal vestibule, apical to the muco-gingival junction in the mid interproximal area of the papilla to be treated.Tunneling of the incisions has maintained the full height and thickness of the gingiva. Multilayer L-PRF membranes were prepared according to Pinto's protocol immediately prior to the surgery and placed in the tunnel then incision was closed with simple interrupted sutures.
224174799|NCT05249504|OTHER|VIVIFRAIL|"VIVIFRAIL is a set of physical activity programs (designed according to several elderly functional level profiles) aimed to prevent motor disability and improve quality of life. It works endurance, flexibility, balance and strength.~https://web.archive.org/web/20210907041944/https://vivifrail.com/"
224174800|NCT05249504|OTHER|Nutrition|Sessions to learn about personal nutrition habits, offer nutritional advice, and acquire skills to incorporate simple healthy nutrition guidelines into everyday life. A visit to a supermarket to make it easier to read and understand the basic information on nutrition labels.
224174801|NCT05249504|BEHAVIORAL|Psychology|Relaxation techniques to manage mood, a photo-elicitation dynamic to address loneliness, and a dynamic to collectively develop a map of health assets in the neighborhood or territory to obtain information on community resources. Finally, a group visit is planned to a community facility previously agreed upon by the participants.
224174802|NCT05249504|BEHAVIORAL|Personal autonomy|Review practical cases on personal autonomy, the proper use of medications, and discover basic cognitive stimulation strategies.
224174803|NCT05249504|OTHER|Community resources|Learn about community resources
224174804|NCT05249504|OTHER|Standard recommendations|Usual advice provided at primary care office accompanied to booklets about healthy lifestyles
224174805|NCT03288987|DRUG|Bevacizumab + FOLFIRI-3|Bevacizumab 5 mg/kg will be administered at day 1 every 2 weeks. Initially, it will be administered as a 90-min infusion. If the first infusion is well tolerated, the second will be delivered as a 60-min infusion, and if the 60-min infusion is well tolerated, all subsequent infusions will be given over 30 minutes. FOLFIRI-3 regimen consists of irinotecan 100 mg/m2 over 1 hour at day 1, leucovorin 400 mg/m2 at day 1 followed by a 46 hour 5-FU continuous infusion (2000 mg/m2) and irinotecan 100 mg/m2 over 1 hour on day 3 will administer. Induction treatment was administrated every 2 weeks until disease progression, unacceptable toxicities, surgical intervention, or withdrawal of consent.
224174806|NCT01702402|BEHAVIORAL|Educational and Behavior Change intervention|"Integrate post-partum family planning education and counselling into 2nd Antenatal Home visit by CHW (at approximately 32 weeks of pregnancy) Integrate post-partum family planning education and counselling into post-partum visits by CHWs during first month Continue providing family planning education and counselling to women through CHW home visits after first month.~Promote discussion and acceptance of post-partum family planning methods among key household members.~Facility level Ensure availability of postpartum contraceptive methods such as progestin-only pill.~Ensure availability of post-partum family planning and post-natal services. Community level Increase community awareness of the importance of birth spacing and benefits of LAM Educate influential community members on the importance of birth spacing and benefits of LAM."
224174807|NCT01702402|OTHER|Comparison Group|A comparison area received standard government health services.
224174808|NCT00355381|BEHAVIORAL|Information Services (IRx)|Information services tailored to the needs of individual patients. The information prescription (IRx)or service is defined for this study as a combination of: 1)An evidence-based web site for use by patients and their families; 2) A reference interview and assistance in locating relevant general information in response to patient information needs; 3) Documentation of the questions and the information service provided in response to these in the patient's Electronic Patient Record for review by providers as needed; and, 4) Triage of patient's/parents clinical questions to providers.
224174809|NCT04057313|DIETARY_SUPPLEMENT|Coffee|Coffee used will be the boiled unfiltered Arabica coffee
224174810|NCT02397772|DRUG|albendazole|Single dose of albendazole (400 mg)
224174811|NCT02033252|DEVICE|Acupuncture|In the acupuncture treatment group, 10 acupuncture points (bilateral LI4, TE23, ST36, unilateral EHN-1, GV23, LI20 and LI4) will be inserted with 0.20 mm in diameter x 30 mm in length disposal needles. The needle will be inserted to a depth of 10 - 30 mm, according to the points selected. The participating acupuncture doctors will manually manipulate the acupuncture needles with de-qi sensation and maintain the needles for 10 minutes with two times of manual stimulation, at the beginning and at the end.
224174812|NCT02009501|DEVICE|VAC VeraFlo with Dakins Instillation|VAC VeraFlo with Dakins instillation will be placed in the operating room after surgical debridement. Biopsies will be obtained prior to surgical debridement, after surgical debridement, on day 4, and on day 7.
224174813|NCT02009501|DEVICE|VAC Ulta Therapy|VAC ULTA will be placed in the operating room after surgical debridement. Biopsies will be obtained prior to surgical debridement, after surgical debridement, on day 4, and on day 7.
224174814|NCT03802201|DRUG|PTG-300|Subcutaneous (SC)
224174815|NCT04905563|DRUG|Acetaminophen-Hydrocodone|Narcotic
224174816|NCT04905563|DRUG|Acetaminophen and Ibuprofen|Non-narcotic
223485683|NCT04803500|DRUG|Simvastatin|single injection of simvastatin gel in the gap around immediately placed implant
223485684|NCT04803500|DRUG|Placebo|single injection of the solid lipid nanoparticle carrier in the gap around immediately placed implant
223485685|NCT00169325|PROCEDURE|Magnetic resonance imaging|
223485686|NCT05700838|BEHAVIORAL|Cough Skill Training - with Variable Practice|"Variable practice will involve three targets that reflect a range of cough airflows, including strong, moderate, and weak coughs."
223485687|NCT04657900|OTHER|Observational|Observational - no intervention given
223745251|NCT05206617|OTHER|No intervention - pure observational study|No intervention
224174817|NCT03719716|OTHER|Anticipatory care planning letter|Patient letter to take to GP and GP literature
224174818|NCT02503111|DEVICE|The Hyfrecator ® 2000 Electrosurgical System|Lesion is ablated by the The Hyfrecator ® 2000 Electrosurgical System. During electrocautery (EC) with The Hyfrecator, a gentle brushing technique occurs and the tissue is removed with forceps.
224174819|NCT02503111|OTHER|Observation Alone|No treatment to AIN-2 or AIN-3, only active surveillance.
223485688|NCT06344949|DRUG|Ciprofol|The sedation before tracheal intubation with Ciprofol
223485689|NCT06344949|DRUG|Propofol|The sedation before tracheal intubation with Propofol
223485690|NCT03650075|DRUG|MG-S-2525|The investigational product is MG-S-2525, which is an oral, small-molecule, anti-inflammatory agent. MG-S-2525 is being developed by Metagone Biotech Inc. and contains the new molecular entity HL0, an inhibitor of MAP3K19 which is up-regulated in disease pathobiology and in response to inflammatory stimuli in IPF.
224174820|NCT04703712|PROCEDURE|Lens extraction combined with goniosynechialysis|The patients enrolled underwent phacoemulsification combined with goniosynechialysis surgery.
224174821|NCT04703712|PROCEDURE|Trabeculectomy surgery|The patients enrolled underwent trabeculectomy surgery
224174822|NCT03595982|DRUG|Procardia XL 30Mg|Procardia XL 30 mg XL Q 12h
224174823|NCT03595982|DRUG|Procardia XL 60Mg|Procardia XL 60 mg Q 24h
224174824|NCT06135766|BEHAVIORAL|A Lust for Life|A Lust for Life (ALFL) is a universal teacher-led programme which aims to build resilience, increase wellbeing, and enhance emotional literacy of 8-13 year old school children. The programme spans ten 40-minute classes. The ALFL curriculum draws on multiple sources including contemporary positive psychology; traditional, second, and third wave cognitive behaviour therapy (CBT); and developmental, educational, and health psychology. In ALFL children learn the following specific self-regulation skills: naming and rating the intensity of emotions; linking thoughts, feelings and actions; mindfulness; breathing exercises; visualization exercises; progressive muscle relaxation; positive self-talk (gratitude, optimism, and cognitive restructuring); obtaining social support from adults and peers; assertiveness; managing bullying; and using the internet safely. Skills are learned through didactic instruction, video modelling, in-class experiential exercises, and homework practice.
224174825|NCT06135766|BEHAVIORAL|Waiting List Control|Control group placed on a 12-week waiting list for the A Lust for Life (ALFL) programme.
224174826|NCT05108311|OTHER|Manual therapy and therapeutic exercise|"1. Gliding over the deltoid superficial fascia.~2. Anterior-Posterior mobilization of the clavicle.~3. myofascial release of the shoulder joint complex techniques.~4. Myofascial release external rotation with glenohumeral decoaptation will be carry out in prone position facility the triangular space, quadrangular space and triceps hiatus.~5. anterior and posterior, superior and inferior glenohumeral inferior glide mobilization in adduction will perform in a prone position to facilitate glenohumeral re centration.~6. scapular musculature myofascial release including mobilization with a scapulothoracic joint decoaptation, and angular of the scapula.~7. Supine mobilization of the posterior capsule in 90º shoulder flexion and the adduction.~Finally the patient will be instructed to adapt the daily active biological stimulus at home to maximize the benefits of the manual therapy"
224174827|NCT00887094|BEHAVIORAL|Acute aerobic exercise|Aerobic exercise (on a cycle ergometer, for 50 min)
224174828|NCT00887094|BEHAVIORAL|Acute aerobic-resistance exercise|Aerobic-resistance exercise (on a cycle ergometer plus strength training, for 50 min in total)
224174829|NCT03170089|BEHAVIORAL|Oral Health Educational Program|Oral Hygiene methods learned
224174830|NCT02859480|DRUG|Rosuvastatin 5mg|Rosuvastatin 5mg tablet, q.d., for 30 months
224174831|NCT02859480|DRUG|Rosuvastatin 20mg|Rosuvastatin 5mg tablet, q.d., for 30 months
224174832|NCT05768568|DEVICE|Manual Toothbrush and Powered Toothbrush|Manual Toothbrush will be mechanically (hand) driven Powered Toothbrush will be battery operated
224174833|NCT00161746|BIOLOGICAL|Tick-Borne Encephalitis (TBE) Vaccine (Inactivated)|
224174834|NCT02278159|PROCEDURE|Peritoneal dialysis|
224174835|NCT02278159|PROCEDURE|Home hemodialysis|
224174836|NCT05267899|DRUG|WGI-0301|WGI-0301 is a lipid nanoparticle preparation of Archexin® for the treatment of advanced solid tumors.
223485691|NCT05987280|OTHER|eDelphi method|eDelphi method
223485692|NCT02035124|DRUG|BKM 120|
223485693|NCT02035124|DRUG|Cabazitaxel|
223485694|NCT01200641|DRUG|Melatonin|"ninety patients scheduled for cataract surgery by phacoemulsification were randomly allocated to three study groups to receive melatonin 6~mg (Group M, n = 30) , gabapentin 600mg(GroupG, n = 30)or placebo(GroupP, n=30) orally 90 minutes before retrobulbar injection( for all of three groups)."
223485695|NCT01200641|DRUG|Gabapentin|"ninety patients scheduled for cataract surgery by phacoemulsification were randomly allocated to three study groups to receive melatonin 6~mg (Group M, n = 30) , gabapentin 600mg(GroupG, n = 30)or placebo(GroupP, n=30) orally 90 minutes before retrobulbar injection( for all of three groups)."
224174837|NCT02062099|DRUG|[18F]DPA-714 PET/ [18F]AV-45 PET/neuropsychological assessment|
223485696|NCT01200641|DRUG|placebo|"ninety patients scheduled for cataract surgery by phacoemulsification were randomly allocated to three study groups to receive melatonin 6~mg (Group M, n = 30) , gabapentin 600mg(GroupG, n = 30)or placebo(GroupP, n=30) orally 90 minutes before retrobulbar injection( for all of three groups)."
223485697|NCT05849922|DRUG|SAR442970|1 mL extractable volume of 150 mg/mL SAR442970 filled in 2 mL glass vial
223485698|NCT05849922|DRUG|Placebo|1 mL extractable volume of placebo filled in 2 mL glass vial
223485699|NCT03606161|OTHER|Questionnaire Administration|Ancillary studies
224174838|NCT01228084|DRUG|Sulforaphane|Sulforaphane given 200μmol (total daily) orally in four 50μmol capsules taken once daily from Week 1 Day 1 to Week 20 Day 7. On days when clinic visits are required patient must wait to take that day's dose until instructed to do so in clinic.
224174839|NCT01228084|OTHER|Laboratory biomarker analysis|Correlative studies
224174840|NCT01228084|OTHER|Pharmacological study|Correlative studies
223485700|NCT03606161|PROCEDURE|Transcranial Magnetic Stimulation|Undergo nrTMS
224174841|NCT02796495|DEVICE|Operation of hand prosthesis with direct nerve stimulation|"Four TIME-4H electrodes will be implanted in the median and ulnar nerves of the amputees. The electrodes will be connected with the STIMEP electrical multichannel stimulator. The stimulator will be connected with one of the two sensorized hand prosthesis. Afferent and efferent signals will be elaborated and integrated by the ODROID software.~The amputees will be able to control the prosthetic hand movement and receive a sensory feedback from the prosthesis sensors.~The use of the prosthesis during different tasks will be considered the intervention."
224174842|NCT02196389|DEVICE|Nasal dilator Nasanita|Nasal Dilator
223485701|NCT02196831|DRUG|tesamorelin|
224174843|NCT02196389|DEVICE|Nasal dilator Nozovent|
224174844|NCT02196389|DEVICE|Nasal dilator Breath Right|
224174845|NCT02196389|DEVICE|Nasal dilator Airmax|
224174846|NCT06477432|DEVICE|mesofiller® mesotox|The investigated product mesofiller® mesotox was applied by intradermal or subcutaneous injection by the investigator during Session 1 for all subjects and Session 2 for the subjects, for whom a touch-up was considered beneficial. Both sessions were conducted within 14-day intervals.
224174847|NCT05951374|PROCEDURE|Madany triangle|"After dissection of the proximal part of the gallbladder from its bed and scarification of the cystic artery and its branches, the traction applied to the Hartman pouch created an angle between the skeletonized cystic duct and the skeletonized posterior surface of the GB (Fig. 3).~Also, this traction creates a dynamic triangle visualized from both the left and right sides according to the traction applied to the Hartman pouch to the right or left and the direction of the angled scope of the camera lens. From the left-side view, when right traction is applied to the Hartman pouch, it is bound laterally by the skeletonized proximal part of the cystic duct. Superiorly, it is bound by the posterior surface of the proximal part of the skeletonized gallbladder. It was bounded medially by an imaginary line between a point at the junction of the cystic duct with the CBD and a point at the anterior end of the dissected cystic plate (the Madany triangle)"
224174848|NCT04286724|BEHAVIORAL|"Brief behavioural procedure including a computerized visuospatial task (computer game Tetris)"|"Brief behavioural procedure including a computerized visuospatial task (the computer game Tetris) preceded by a reactivation of the traumatic memory of childbirth"
223485702|NCT02196831|DRUG|Placebo|inactive substance that looks like tesamorelin
223485703|NCT00149643|DRUG|Fluoxetine|Gelatin capsules Fluoxetine 10 mg, 1 capsule every a.m. Medication will be increased by one capsule, to a daily dose of fluoxetine 20 mg, 2 capsules barring side effects.
223485704|NCT00149643|OTHER|Placebo|Gelatin capsules Placebo capsules, identical to Fluoxetine capsules, 1 capsule every a.m. Medication will be increased by one capsule, to a daily dose of placebo, 2 capsules barring side effects.
224174849|NCT03880162|OTHER|Low carbohydrate diet|A energy deficient (30% deficit) low carbohydrate diet (10% of carbohydrates)
223485705|NCT01730313|DRUG|Pyridoxine|
223485706|NCT01730313|DRUG|Sodium Valproate|
223485707|NCT01730313|DRUG|Phenytoin|
223485708|NCT01730313|DRUG|Placebo|
224174850|NCT03880162|OTHER|Energy-matched standard diet|Energy-matched (30% deficit) standard diet (50% of carbohydrates)
224174851|NCT04560127|DRUG|Camrelizumab combination with Apatinib|Apatinib (250mg p.o. q.d.) combined with Camrelizumab (200mg, iv, q2w)
224174857|NCT02368158|OTHER|Driving simulation with elevation of medical data in comparison to Lane Change Test plus automotive monitoring via contactless sensors|During a driving simulation medical data are elevated such as electrocardiography (ECG), heart rate breathing rate and oxygen saturation and compared to data of the performed Lane Change Test as a measurement for the quality of driving. Hereby the deviation of the lane from baseline during driving and ordered lane change via signs are determined also when performing cognitive and visual tasks. Also the simulation is simultaneously accompanied by monitoring via contactless camera usage in regard to possible determination of heart and breathing rate according to Eulerian Magnification Method
224174858|NCT03608345|OTHER|space maintainer|Space maintainers are applied after the missing teeth in pediatric dentistry for protection of size of extracted area.
223485709|NCT02632318|DEVICE|Light|30 minutes of dawn simulation
223485710|NCT02722109|OTHER|No intervention|No intervention will be done
223485711|NCT04051580|DRUG|Lactated Ringer|Comparison of Lactated Ringer's Solution and PlasmaLyte-A as a Base Solution for Del Nido Cardioplegia
223485712|NCT05867875|OTHER|Unblinded ORI values|ORI and SpO2 monitoring will be performed using Masimo Rad 7 and both values will be provided to investigator
223485713|NCT05867875|OTHER|Blinded ORI values|ORI and SpO2 monitoring will be performed using Masimo Rad 7 and only SpO2 values will be provided to investigator
223485714|NCT04587713|DRUG|TD-1473 [Tablet A]|TD-1473 \[Tablet A\] (1 Tablet = Dose A) proposed commercial tablet formulation
223586436|NCT01310478|DRUG|recombinant human endostatin (Endostat)|mFOLFOX6:Oxaliplatin 85 mg/m2 d1 Leucovorin 400 mg/m2 d1+5-FU 400 mg/m2 bolus d1+5-FU 2.4 CIV 46h Endostar 7.5mg/m2/d～45mg/m2/d continous intravenous d4～d14
223485715|NCT04587713|DRUG|TD-1473 [Tablet B]|TD-1473 \[Tablet B\] (2 Tablets = Dose A) current clinical tablet formulation
223485716|NCT06053944|DIAGNOSTIC_TEST|fractional flow reserve (FFR); ultrasonic flow ratio (UFR); intravascular ultrasound (IVUS)|UFR is a novel IVUS-derived modality for fast computation of FFR without pressure wires and adenosine.
223586437|NCT02704689|DEVICE|AccuLIF expandable TLIF cage|AccuLIF TL expandable interbody cage used with autogenous bone and/or allograft (cancellous or corticocancellous allograft chips) and supplemental fixation.
224174859|NCT04828850|PROCEDURE|Endobronchial ultrasound transbronchial needle aspiration lymph node staging|EBUS-TBNA in clinical N0 NSCLC patients
224174860|NCT00267657|DRUG|Reserpine|
224174861|NCT01240772|DEVICE|doppler-guided arterial ligation with mucopexy|doppler-guided arterial ligation with mucopexy
224174862|NCT01240772|DEVICE|stapled haemorrhoidopexy according to Longo|stapled haemorrhoidopexy according to Longo
224174863|NCT00738322|DRUG|AZD1305|Solution for iv infusion, single dose
224174864|NCT00738322|DRUG|Placebo|NaCl solution for iv infusion, single dose
224174865|NCT01815866|PROCEDURE|CF with culturable NTM|CF patients who produce culturable aerosols of NTM will receive the following test: pulmonary function test, collecting a sputum culture if possible, coughing for 5 minutes into a tube connected to a canister, hypertonic saline and albuterol will be given after the 5 minutes of coughing and then they would repeat with another 5 minutes of coughing. There can be a break inbetween the coughing if needed.
224174866|NCT00650715|DEVICE|Vibratory platform, PowerPlate®, Badhoevendorp, Netherlands|Six exercises (static and dynamic tasks) while standing on a Whole-body vibration platform. The six exercises (30 seconds each) were repeated six times with a recovery of 3 minutes in between. The Whole-body vibration intensity was kept constant at 30 Hz of frequency and 2 mm of amplitude.
224174867|NCT00650715|DEVICE|Placebo Whole-body vibration exercise|Six exercises (static and dynamic tasks) while standing on a Whole-body vibration platform. The six exercises (30 seconds each) were repeated six times with a recovery of 3 minutes in between. All exercises were performed without the influence of a vibratory stimulus.
224174868|NCT02367157|PROCEDURE|Kenzo Kase Method|
224174869|NCT02367157|DEVICE|Kinesio Taping|
224174870|NCT01072500|BEHAVIORAL|Physical Activity|The physical activity intervention consists primarily of walking at moderate intensity, lower extremity resistance exercises, balance exercises, stretching and behavioral counseling.
224174871|NCT01072500|BEHAVIORAL|Successful Aging|The successful aging intervention consists of health education seminars regarding health-related matters and upper extremity stretching exercises.
224174872|NCT02798809|OTHER|Clinical dental examination|Clinical dental examination and a questionnaire that was filled out by the parents before each clinical examination.
224174873|NCT02509663|PROCEDURE|Functional Endoscopic Sinus Surgery|Balloon Sinuplasty uses a small, flexible, balloon catheter to open up blocked sinus passageways and facilitate drainage of the mucus that builds up in patients suffering from frontal sinusitis symptoms. When the sinus balloon is inflated, it restructures and widens the walls of the sinus passageway while maintaining the integrity of the sinus lining.
224174874|NCT02509663|PROCEDURE|Functional Endoscopic Sinus Surgery using rigide instrumentation|"FESS (Functional Endoscopic Sinus Surgery) using rigide instrumentation is conventional therapeutic strategy.~The procedure works by cutting to remove bone and tissue to enlarge the sinus opening."
224174875|NCT02509663|DEVICE|Sinuplasty balloon|Balloon Sinuplasty uses a small, flexible, balloon catheter to open up blocked sinus passageways and facilitate drainage of the mucus that builds up in patients suffering from frontal sinusitis symptoms. When the sinus balloon is inflated, it restructures and widens the walls of the sinus passageway while maintaining the integrity of the sinus lining.
224174876|NCT02509663|DEVICE|Endoscope|"FESS (Functional Endoscopic Sinus Surgery) using rigide instrumentation is conventional therapeutic strategy.~The procedure works by cutting to remove bone and tissue to enlarge the sinus opening."
223485717|NCT03881371|DRUG|Safinamide|At baseline (Day 1), eligible patients will be randomised to receive safinamide (initial 50 mg titrated to 100 mg the day after the Visit 3/week 2, ideally at day 15). The investigational medicinal product (IMP) will be taken in the morning at breakfast time, in addition to the morning dose of L-dopa and other (if any) PD medications.
223485718|NCT03881371|OTHER|Placebo|At baseline (Day 1), eligible patients will be randomised to receive matching placebo, orally OD. Placebo will be added to the standard stabilized treatment as a control of the safinamide group, hence patients on placebo will have benefit from other ongoing anti-PD medication
223485719|NCT02305979|DRUG|Loratadine|
223485720|NCT03139513|DRUG|Cobimetinib|Participants will receive cobimetinib as per local guidelines and/or routine clinical practice.
223485721|NCT03139513|DRUG|Vemurafenib|Participants will receive vemurafenib as per local guidelines and/or routine clinical practice.
223485722|NCT05565807|BIOLOGICAL|STI-6129|Anti-CD38 A2 human antibody drug conjugate (ADC) containing an antibody covalently bound to a duostatin tubulin inhibitor.
223485723|NCT02508389|DRUG|Low Dose GC4419: 30mg/day|Low Dose GC4419 will be administered by 60 minute IV infusion, within 1 hour prior to daily IMRT fractions, until IMRT is complete (generally M-F for approximately 7 weeks).
223485724|NCT02508389|DRUG|High Dose GC4419: 90mg/day|High Dose GC4419 will be administered by 60 minute IV infusion, within 1 hour prior to daily IMRT fractions, until IMRT is complete (generally M-F for approximately 7 weeks).
223586438|NCT00759525|DRUG|Glycyrrhetic Acid|130 mg daily for fourteen days
223586439|NCT00759525|DRUG|Placebo|Placebo daily for fourteen days
223586440|NCT03543943|PROCEDURE|Individualized treatment of Acute Achilles tendon rupture.|The most proximal border of the calcaneus and the most distal point of the musculotendinous junction of the medial gastrocnemius muscle is identified and marked on the skin. These two points on the un-injured leg defines the original length of the total Achilles tendon \[1\]. The difference in length between the injure and the un-injured leg determines elongation for the ruptured Achilles tendon. The relative elongation of the ruptured tendon together with overlap of the tendon ends on the cross-sectional area determines the treatment for the patients receiving individualized treatment: 1) patients with 0-6% elongation of the tendon and a minimum of 25% tendon are treated non-operatively 2) patients with 7% elongation or more or less than 25% tendon overlap are treated operatively.
223586441|NCT03543943|PROCEDURE|Non-operative treatment|Circulated cast below the knee in maximal, unforced plantar flexion over the ankel.
223485725|NCT02508389|DRUG|Placebo|Placebo will be administered by 60 minute IV infusion, within 1 hour prior to daily IMRT fractions, until IMRT is complete (generally M-F for approximately 7 weeks).
223485726|NCT02508389|RADIATION|Intensity-Modulated Radiation Therapy|Daily fractions of IMRT (2.0-2.2 Gy) to a total of 60-72 Gy over approximately 7 weeks
224174877|NCT03132038|DRUG|Nivolumab|3 mg/kg, every two weeks, during a maximum of one year
224174878|NCT01520727|DRUG|BIA 9-1067|single ascending doses in up to 8 sequential groups of 8 healthy young male subjects
224174879|NCT01520727|DRUG|Placebo|single-dose
224174880|NCT06303011|OTHER|Transcutaneous Electrical Nerve Stimulator|TENS will be applied on sacral and parasacral area. Frequency 10Hz, Pulse duration 200μs, Stimulation duration 20min
224174881|NCT06303011|OTHER|TENS on para sacral area with Abdominal Massage|TENS on para sacral area with Abdominal Massage. Frequency 10Hz Pulse duration 200μs Stimulation duration 20min
223485727|NCT02508389|DRUG|Cisplatin|"Administered 80-100 mg/m2 once every three weeks for 3 doses or 30-40 mg/m2 once weekly for 6-7 doses.~Substitution of other systemic agents due to related toxicities (i.e., carboplatin) would be evaluated to determine eligibility by the Medical Monitor"
224174882|NCT05561192|OTHER|Diaphragmatic breathing exercises|The initial proposal is for the first week to be adaptive, that is, learning to perform the exercises freely. During this period, students will be able to experience the activities and solve any doubts, as well as understand the process of a respiratory cycle, in which they will be initiated through a cycle of 12 times per minute. In the second and third weeks, the exercises will consist of 10 breathing cycles per minute (complete cycle consisting of 6 seconds, 2:2:2). It is important to note that each cycle contains the inspiration time, brief pause and expiration time in seconds. In the last week, each cycle will last 16 seconds, consisting of 4 seconds of inspiration, 4 seconds of pause and 8 seconds of expiration (4:4:8). Thus, the objective is to reduce the number of respiratory cycles per minute, as the intervention progresses.
224174883|NCT05561192|OTHER|Cardiorespiratory and strength exercise|"During the first two weeks, students will complete two laps of the circuit, with a 15-second break between one station and another and a 1-minute break between one lap and another. These first two weeks will focus on adaptation and technical learning of the exercises to be performed. From the third to the sixth week, one lap will be added to the circuit, totaling three laps, maintaining the aforementioned intervals. From week 7 to week 12, progressions will be carried out, reducing the interval time between one lap and another on the circuit to 30 seconds. For the purpose of controlling the intensity of the exercise, a subjective perception of effort scale will be used, composed of values from 1 to 10, the first being equivalent to very light effort activity, and ten, equivalent to maximum effort activity."
224174884|NCT05561192|OTHER|Cooperative sports activities group|"Intervention with cooperative sports activities will be based on the pedagogical model for teaching sports called Cooperative Learning or Cooperative Learning. This pedagogical model has some predominant characteristics, such as student learning occurring with and through other students, through an approach that facilitates and enhances positive interdependence, where teachers and students act as co-learners. Thus, this teaching model encompasses two key points of cooperative learning: promoting interaction between students and interaction between students and teachers.~Also, in the planning of intervention classes with sports, the five points described as fundamental for learning to be considered cooperative will be considered. These are: face-to-face interaction, positive interdependence, individual responsibility, group processing, and social skills."
224174885|NCT05561192|OTHER|Traditional physical education class|The comparator group will take physical education classes normally, following the traditional menu in the discipline, without changes in the conduct of activities.
224174886|NCT02182505|DRUG|Berodual® Respimat®, low dose|
224174887|NCT02182505|DRUG|Berodual® Respimat®, high dose|
224174888|NCT02182505|DRUG|Berodual® MDI|
224174889|NCT04844970|DRUG|Anamorelin Hydrochloride|Anamorelin HCl is an orally-active selective ghrelin receptor agonist which has shown anabolic and appetite-stimulating effects.
224174890|NCT04844970|DRUG|Placebo|Anamorelin placebo
224174891|NCT05488977|BEHAVIORAL|Exercise training|8 weeks of supervised high-intensity interval training (HIIT).
224174892|NCT02689544|OTHER|intervention with static stretching|Members of static stretching group performed three sets of 30 second self hamstring stretch (IT) of both lower limbs, with 30 seconds of rest between sets, totaling 3 minute intervention so.
224174893|NCT02689544|OTHER|intervention with Dynamic Stretching|Each subject contracting antagonist muscle (quadriceps) to the target muscle (hamstring), performing dynamic movements of hip flexion with the knee extended, repeated every 1 second. They amounted to 3 of 30 repetitions completing approximately three minutes of dynamic stretching for each lower.
224174894|NCT02689544|OTHER|Control|The control group volunteers no received intervention
224174895|NCT00155324|DEVICE|Extracorporeal Shock Wave Therapy (Device)|
224174896|NCT04898088|BIOLOGICAL|Mesenchymal Stem Cells Transplantation|Mesenchymal Stem Cells Transplantation applied as three intravenous infusions with 30 days intervals
224174897|NCT01642004|BIOLOGICAL|Nivolumab|
224174898|NCT01642004|DRUG|Docetaxel|
224174899|NCT06302868|BEHAVIORAL|Telemedicine Exposure Therapy Using Photos and Videos|Participants will complete 12 60-minute exposure therapy sessions using photos/videos and progress to in vivo exposures.
224174900|NCT06302868|BEHAVIORAL|Telemedicine-Based Virtual Reality Exposure Therapy|Participants will complete 12 60-minute exposure therapy sessions in a Virtual Reality Clinic using Virtual Reality stimuli and progress to in vivo exposures.
224174901|NCT06593626|DRUG|[18F]Florbetazine|Evaluate the safety of \[18F\]Florbetazine injection in AD and MCI patients, and healthy subjects.
224174902|NCT04233840|DRUG|P1101 (Ropeginterferon alfa-2b)|solution for injection in prefilled syringe, 500 µg/ mL , 450μg /time, subcutaneous injection every 2 weeks
223485728|NCT00933933|DEVICE|ARCHITECT HIV Ag/Ab Combo|Test blood samples with investigational HIV assay. If results for specimens from the normal healthy population or pregnant female population at risk for HIV infection are reactive, samples will be tested with supplemental HIV assays. If all supplemental HIV assays are negative, subject will be asked to return for a follow-up blood draw.
223485729|NCT00933933|DEVICE|ARCHITECT HIV Ag/Ab Combo|Test blood samples with investigational HIV assay. If results for specimens from the at risk population are reactive, samples will be tested with supplemental HIV assays. If all supplemental HIV assays are negative, subject will be asked to return for a follow-up blood draw when possible.
223485730|NCT05707169|PROCEDURE|Saphenous Ablation|Endogenous Laser Ablation (EVLA) uses a laser fibre, which is inserted into the refluxing vein via skin puncture.
223485731|NCT05707169|DEVICE|Endogenous Laser Ablation (EVLA)|Endogenous Laser Ablation (EVLA)
223485732|NCT05707169|DRUG|mixture of 20 mL 2% lidocaine, 1: 200,000 adrenaline and 20 mL 0.5% levobupivacaine in 1 L of 0.9% saline|mixture of 20 mL 2% lidocaine, 1: 200,000 adrenaline and 20 mL 0.5% levobupivacaine in 1 L of 0.9% saline
224174903|NCT04233840|DRUG|Nivolumab|"Phase I study will use 0.3, 0.75, 1.5, 3mg/kg, Q2W for 3 doses after 6 doses of P1101.~Phase II study : Group I will use 3mg/kg, Q2W for 3 doses; Group III will use the dosage that determine from Phase I study 3 doses after 6 doses of P1101"
224174904|NCT04099225|DIAGNOSTIC_TEST|Multiple breath washout (MBW) testing|Lung clearance index (LCI), acinar (Sacin) and conductive (Scond) ventilation heterogeneity were derived from triplicate SF6-MBW measurements. Global ventilation heterogeneity was calculated for the 2.5% (LCI2.5) and 5% (LCI5) stopping points.
224174905|NCT01413867|PROCEDURE|stapled hemorrhoidopexy|stapled hemorrhoidopexy will be performed using the EEA stapler Covidien
224174906|NCT01413867|PROCEDURE|stapled hemorrhoidopexy|stapled hemorrhoidopexy will be performed using the PPH01/03 Ethicon EndoSurgery
224174907|NCT00702741|DRUG|Chondrogen|Intra-articular injection of ex vivo cultured adult human mesenchymal stem cells
224174908|NCT00702741|DRUG|Chondrogen|Intra-articular injection of ex vivo cultured adult human mesenchymal stem cells
224174909|NCT00702741|DRUG|Placebo|Intra-articular injection of Hyaluronan
224174910|NCT04324476|DRUG|Bevacizumab、Oxaliplatin、Irinotecan、Capecitabine|Drug: Bevacizumab 5mg/kg, iv, 30min, d1, 2w; Drug: Oxaliplatin 85mg/㎡, iv, 120min, d1, 4W; Drug: Irinotecan 150mg/㎡, iv, 90min, d15, 4w; Drug: Capecitabine 1000mg/㎡, bid, d2-8, 2w.
224174911|NCT02417129|DRUG|Rituximab|BI 695500 375 mg/M2
224174912|NCT02417129|DRUG|BI 695500|BI 695500 375 mg/M2
224174913|NCT01962909|DRUG|PTP-01|Dose level 1 is 10mCi (50ug of peptide)
224174914|NCT01128855|DRUG|3 mg/kg GSK2402968|Weekly subcutaneous injection
224174915|NCT01128855|DRUG|6 mg/kg GSK2402968|Weekly subcutaneous injection
224174916|NCT01128855|DRUG|9 mg/kg GSK2402968|Weekly subcutaneous injection
224174917|NCT01128855|DRUG|12 mg/kg GSK2402968|Weekly subcutaneous injection
224174918|NCT01128855|OTHER|Placebo|Weekly Placebo
224174919|NCT01832051|DRUG|89Zr-trastuzumab injection|
224174920|NCT03075930|DEVICE|Extended Electrocardiogram|ECG with 3 additional leads and a 5 minute recording
224174921|NCT03075930|DEVICE|Body surface potential map|ECG with 184 leads and a 5 minute recording
224174922|NCT00425191|DRUG|Docetaxel and Gemcitabine|Docetaxel: 40 mg/m², administered IV over 60 minutes (infusion drop by drop during the first five minutes) on day 1 and 8 immediately followed by Gemcitabine: 1200 mg/m2, administered IV over 30 minutes on day 1 and 8
224174923|NCT00425191|DRUG|Docetaxel and Gemcitabine|Docetaxel: 50 mg/m², administered IV over 60 minutes (infusion drop by drop during the first five minutes) on day 1 and 15 immediately followed by Gemcitabine: 1600 mg/m2, administered IV over 30 minutes on day 1 and 15.
224174924|NCT00425191|DRUG|Gemcitabine cisplatin followed by docetaxel|Gemcitabine: 1200 mg/m2, administered IV over 30 minutes on day 1 and 8 followed by Cisplatin 75 mg/m2, administered IV over 30-60 minutes on day 2
223485733|NCT05509504|OTHER|Low-intensity online intervention|The LiON in the current study is comprised of three core modules identified to be core areas of stress and needs of participants based on clinical experiences of the research team. The three modules include (1) stress management, (2) sleep and relaxation, and (3) problem-solving skills. Each module consists of four 1-on-1 sessions which will be conducted through online platforms (such as Zoom) that lasts for \~45 minutes. Participants will attend these sessions once a week.
223485734|NCT04293536|OTHER|Cases study|Patients with a retained device or almost
223485735|NCT01823900|DRUG|Test formulation|Single administration of a combination tablet of Rosuvastatin 20mg and Olmesartan 40mg
223586442|NCT03543943|PROCEDURE|Operative treatment|Open surgery with suture of the ruptured achilles tendon prior to circulated cast below the knee in maximal, unforced plantar flexion over the ankel.
223485736|NCT01823900|DRUG|Reference formulation|Co-administration of Rosuvastatin 20mg tablet and Olmesartan 40mg tablet
223485737|NCT03033888|BEHAVIORAL|Health-Literacy Focused Education Session|
223485738|NCT02924961|DEVICE|Triathlon PS total knee system with mobile-bearing|
223485739|NCT02924961|DEVICE|Triathlon PS total knee system with fixed-bearing|
223485740|NCT00785889|PROCEDURE|water infusion colonoscopy|water infusion in lieu of air insufflation for screening colonoscopy
223586443|NCT02212678|DRUG|N-acetylcysteine capsule|N-acetylcysteine capsule
223586444|NCT02337634|DRUG|Placebo|Taken as two 150mg capsules BID for 2 weeks, then 300mg BID for remainder of the study.
223586445|NCT02337634|DRUG|Milk Thistle|Taken as two 150mg capsules BID for 2 weeks, then 300mg BID for remainder of the study.
223586446|NCT05797662|DRUG|Propranolol|Adults: Propanolol 120 mg tablets by mouth twice daily for up to 24 weeks Children: Propanolol 3 mg/kg suspension, divided dose twice daily for up to 24 weeks
224174925|NCT05714852|BEHAVIORAL|Healthy eating|Promotion of healthy eating
224174926|NCT05161624|DIAGNOSTIC_TEST|Accuracy evaluation|The design of the diagnostic trial will include 160 cases of liver tumors with indications for microwave ablation after a multidisciplinary consultation with clinicians (Multiple Disciplinary Team, MDT), including primary liver cancer and metastatic liver tumors, and the tumor diameter is less than 3 cm. The test subjects consist of three groups: a. path planning model, b. junior ablation specialists, c. senior ablation specialists. The three groups will perform microwave ablation path planning on 160 selected cases of liver tumors. The attending professor of the clinical medical group of the department is responsible for scoring, evaluating whether the design of the plan is reasonable, and then comparing the scoring results by using statistical methods to evaluate the accuracy and effectiveness of the path planning model established in this study.
224174927|NCT06348862|BEHAVIORAL|Listening to either Quran, Music, and or Natural sound|Patients will be assigned into one of the four groups based on their preferences. These groups are people who will listen to either Quran, Music, Natural sound, and or nothing (control group).
224174928|NCT05592444|DIAGNOSTIC_TEST|Low iodine Spectral Detector CT Pulmonary Angiography|Low iodine Spectral Detector CT Pulmonary Angiography
224174929|NCT05352321|DRUG|Gemcitabine|for induction chemotherapy
224174930|NCT05352321|DRUG|Cisplatin|for induction and concurrent chemotherapy
224174931|NCT05352321|RADIATION|regular intensity-modulated radiotherapy|in active comparator arm
224174932|NCT05352321|PROCEDURE|surgery|in experimental arm
224174933|NCT05352321|RADIATION|Target-reduction intensity-modulated radiotherapy|in experimental arm
224174934|NCT06100367|COMBINATION_PRODUCT|11C-Metomidate PET/CT imaging at Clinical Imaging Research Centre|11C-Metomidate PET/CT imaging at Clinical Imaging Research Centre
224174935|NCT00440102|DRUG|Ketamine|Ketamine
224174936|NCT00440102|DRUG|Etomidate|Etomidate
224174937|NCT03232502|DIAGNOSTIC_TEST|Pharmacogenetic testing|Basic pharmacogenetic panel
224174938|NCT02745795|BEHAVIORAL|Motivational Interview|Three face-to-face interviews using motivational interview techniques to elicit motivation for adhesion to a diet and physical activity plan intended to loose weight. The interviews will be done at schools with three months intervals.
224306378|NCT06339320|PROCEDURE|Endoscopic Sleeve Gastroplasty (ESG)|The ESG procedure uses the Apollo OverStitch endoscopic suturing device, which has received FDA authorization as a minimally invasive procedure to facilitate weight loss for adults with who have been unable to lose weight or maintain weight loss through more conservative measures such as diet and exercise. This procedure involves endoscopic suturing to reduce the volume of the stomach endoscopically by approximately 70% to 80% its original size. Using the Apollo OverStitch or APOLLO ESG and ESG SX Systems, the ESG procedure is performed be folding the stomach in on itself (endoscopically) and placing full-thickness sutures through the wall of the stomach to maintain this narrow, smaller size. Following the procedure, the new stomach appears similar to the surgical sleeve stomach, although the procedure is considered less invasive with fewer complications compared to a surgical sleeve gastrectomy.
224174939|NCT02745795|BEHAVIORAL|Conventional Interview|Three face-to-face interviews without using motivational interview techniques to elicit motivation for adhesion to a diet and physical activity plan intended to loose weight. The interviews will be done at schools with three months intervals.
224174940|NCT02447952|DEVICE|Faros Sensor (FS) and LifeInsight Hub|Each subject will be issued one FS and a MAT LifeInsight Hub for use during the study. At each clinic visit in the Pilot and Core Study Phases, the Faros sensor will be placed on the subject just prior to the defined reference tasks and will be worn on the subject's sternum during completion of the tasks. The morning after the clinic visit, the subject will re-attach the sensor and wear it for approximately 3 days. In between visits during the Core Study Phase the subject will wear the FS every month for approximately 3 days to enable data collection on a monthly basis over the 48 week study period. Movement/physical activity data will be collected by the FS throughout the study.
224174941|NCT02447952|DEVICE|Fast Fix electrode patch|The Fast Fix electrode patch will be worn with the FS on the subject's sternum according to the same schedule as the FS. The Fast Fix electrode patch will be replaced by the subject on a daily basis during the 3 day monitoring period. Subjects will be provided instructions on how to operate and wear the Fast Fix electrode patch.
224174942|NCT02447952|PROCEDURE|Quantitative Measure of Speech (Core Phase Only)|Subjects will follow simple prompts on a computer screen instructing them to say a series of vowels, words, and paragraphs which will be recorded using a high definition digital microphone and stored securely on a laptop. The speech waveform data will be sent via secure method to GSK/MAT for processing.
224306379|NCT06339320|DEVICE|Apollo OverStitch endoscopic suturing device|Apollo ESG is the first and only device to be authorized by the FDA to perform the ESG procedure to facilitate weight loss in patients with obesity (BMI 30 to 50 kg/m2). The FDA identifies this generic type of device as an Endoscopic suturing device for altering gastric anatomy for weight loss.
224306380|NCT03026972|BIOLOGICAL|Placebo|The placebo drug contains 20mg mannitol and 10 millimole(mM) phosphate buffer(PB).population I～population IV are coxal muscle injection of placebo.
223485741|NCT04916678|OTHER|R-TEP EMDR intervention|"During the intervention period, trained psychologists are available in the ER and will provide preferentially a short early 1-hour R-TEP EMDR intervention for patients selected with high risk of PCLS. Patient's selection will be conducted using a score developed in previous studies. If therapist considers R-TEP EMDR unsuitable, he could provide another type of intervention (such as reassurance) that will be recorded.~When no high-risk patient is identified, the therapist could assess other patients and treat them if judged necessary. In this context, they could provide either a R-TEP EMDR or short intervention such as reassurance according to therapist assessment."
223586447|NCT03680729|BEHAVIORAL|Adapted Brothers Saving Brothers (aBSB)|This information is listed in the arm description.
223586448|NCT03680729|BEHAVIORAL|Standard Street Outreach|This information is listed in the arm description.
224174943|NCT05613491|DRUG|Intranasal insulin|Put insulin injection into nasal special drug delivery device.Before anesthesia induction, give the first insulin nasal spray, once per hour, 20 IU each time, until the end of the operation
224174944|NCT05613491|DRUG|Intranasal saline|Put 0.9% sodium chloride into nasal special drug delivery device.Before anesthesia induction, give the first equal volume saline nasal spray, once per hour, 20 IU each time, until the end of the operation
224174945|NCT06196372|OTHER|MenoMind intervention group|To implement the MenoMind program, the women in the initiative group were divided into groups of 4-5 according to their convenient days and hours, and it was done via the Zoom© program. MenoMind program was carried out via video on WhatsApp© program for women who could not or did not want to use the Zoom© program. The researcher provided support to the women for eight weeks, in different groups, 2-3 days a week and at different times, depending on their availability. Each session is approximately 50 minutes. lasted. In addition, make-up sessions were organized for women who could not attend the sessions for various reasons or had difficulty complying with the program (day/date).
224174946|NCT04554394|DEVICE|CellFX Device|The CellFX System utilizes non-thermal, localized delivery of a timed series of low energy, nanosecond electrical pulses that can trigger regulated cell death.
224174947|NCT04251949|PROCEDURE|LED photobiomodulation|1 PLED session before each radiotherapy session, until the end of the radio or radio-chemotherapy treatment. Each session will last 7 minutes. The light delivered will be preset on the lamp which will deliver a red light of a wavelength of 630nm, at a fluence of 37J/cm².
224174948|NCT01365104|DRUG|desferrioxamine|intravenous infusion at 10mg/kg/hr for a total of 6 hours at final infused doses of 60mg/kg.
224174949|NCT03011424|DEVICE|Extracorporeal liver support therapy (ELS)|ELS by using the Molecular Adsorbent Recirculating System (MARS) is based on a modified haemodialysis that allows the removal of water-soluble and protein bound toxins over an albumin-coated high flux membrane against recycled exogenous albumin.
224306381|NCT03026972|BIOLOGICAL|Low dose adjuvant|Population I and polulation IV are coxal muscle injection of low dose adjuvant.
223485742|NCT02806999|DRUG|Berberine; Insulin|Participants will receive 500mg Berberine twice a day for 8 days; Meanwhile，participants will also continue to receive intensive insulin therapy.
224306382|NCT03026972|BIOLOGICAL|High dose adjuvant|Population II ,Population III and Population IV are coxal muscle injection of high dose adjuvant.
224174950|NCT03514394|BEHAVIORAL|Usual Care|The clinic's usual care includes counseling, substance use disorder treatment, peer support services, and some elements of traditional BA (not the modified BA).
224174951|NCT03514394|BEHAVIORAL|Modified Behavioral Activation (Task Sharing)|This intervention will include all core elements of Behavioral Activation (BA), which is a behavioral intervention that identifies work, social, health, or family activities that patients have stopped engaging in because of their mood. The intervention will also include a Task Sharing modification, which will allow clinicians and care managers to more efficiently share the tasks involved in BA.
224174952|NCT00002102|DRUG|Trimetrexate glucuronate|
224174953|NCT00002102|DRUG|Leucovorin calcium|
224174954|NCT04052906|OTHER|Training|Planned Inhaler Medication Trainning
223485743|NCT02806999|DRUG|Insulin|Participants will continue to receive intensive insulin therapy; Meanwhile, Participants will also receive a placebo twice a day for 8 days.
223485744|NCT01138046|DRUG|Lapatinib in combination with weekly paclitaxel|These subjects will receive weekly paclitaxel (80 mg/m2 IV for 3 weeks in a 4 week cycle) plus lapatinib (1500 mg once daily, starting on the second day of phase I). Subjects will receive a daily dose of lapatinib until disease progression or withdrawal from study treatment due to unacceptable toxicity or withdrawal of consent. Study completion is defined as deaths after administering study treatment for more than once. Subjects will be treated with paclitaxel for standard of 6 cycles, and may be continued at the discretion of investigators. If the subject experiences progression, an unacceptable toxicity related to paclitaxel, or termination of lapatinib therapy, paclitaxel therapy must be terminated any time of study period, even before 6 cycles of paclitaxel are given.
223485745|NCT02178956|DRUG|BBI608|BBI608 480 mg orally two times daily (960 mg total daily dose)
224174955|NCT02584660|DRUG|Rivaroxaban|Participants will receive Rivaroxaban 15 milligram (mg) twice daily up to Days 21 by orally and Rivaroxaban 20 mg once daily up to Days 90 by orally.
224174956|NCT02584660|DRUG|Standard-of-care|Standard-of-care as per local protocol and defined by the medical team caring for the participant.
224174957|NCT05961761|DRUG|Propranolol|propranolol 40 mg x2 daily
224174958|NCT05961761|DRUG|Pembrolizumab|pembrolizumab 2 mg/kg every 3 weeks
224174959|NCT03907943|PROCEDURE|carotid endarterectomy|Surgical treatment of ICA stenosis.
224174960|NCT05353881|OTHER|No intervention|No intervention
224174961|NCT04998344|BIOLOGICAL|Inactivated influenza vaccine|Vaccines will be administered as a single dose regimen for the pregnant women and two doses for children at 28-day interval as recommended by the vaccine manufacturers.
224174962|NCT04998344|BIOLOGICAL|Inactivated polio vaccine|Vaccines will be administered as a single dose regimen for the pregnant women and two doses for children at 28-day interval as recommended by the vaccine manufacturers.
224174963|NCT00969462|DRUG|Doxorubicin|measurements of serum Doxorubicin levels
224174964|NCT06231004|PROCEDURE|glucocorticosteroid and surgery|Take glucocorticosteroid at once in the morning and use the following course of treatment: 6 tablets/day for 7 days-- 5 tablets/day for 2 days-- 4 tablets/day for 2 days-- 3 tablets/day for 2 days-- 2 tablets/day for 2 days-- 1 tablets/day for 2 days--surgery
224174965|NCT01003067|DEVICE|Mesh implementation|Prophylactic intraperitoneal mesh implantation in laparoscopic surgery to prevent incisional hernia.
224306383|NCT03026972|BIOLOGICAL|Low dose vaccine|Population I and population IV are coxal muscle injection of low dose vaccine.
224306384|NCT03026972|BIOLOGICAL|High dose vaccine|Population II,population III and population IV are coxal muscle injection of high dose vaccine .
223485746|NCT02178956|DRUG|Paclitaxel|Paclitaxel 80 mg/m2 I.V. infusion on Days 1, 8, and 15 of every 4-week cycle
223586449|NCT05841498|DEVICE|Immunoadsorption|Immunoadsorption (IA) is a well-established extracorporeal therapy for several autoimmune diseases such as systemic lupus. Its therapeutic effect is based on the removal of antibodies (ABs) from the plasma including auto-ABs and it is used if an immediate response to therapy is necessary. Side effects (SE) of the IA are rare, but angiotensin-converting enzyme (ACE)-inhibitors are prohibited concomitant medication. Notable SE may include increased susceptibility to infection, transient disorders of blood coagulation, or allergic reactions to materials of the adsorber or tubing system. To ensure an effective therapy, a blood flow of at least 45 ml/min is necessary. In some patients, adequate blood flow can be achieved by cannulation of peripheral veins but in most patients is the placement of a central venous catheter necessary. Central venous catheter placement carries potential risks such as injury to the lung or mispuncture of the carotid artery.
224306385|NCT00134173|DRUG|torcetrapib/atorvastatin|
223485747|NCT02178956|OTHER|Placebo|Orally two times daily
223485748|NCT00022373|DRUG|iseganan HCl oral solution|
223485749|NCT00022373|PROCEDURE|management of therapy complications|
223485750|NCT01510639|BIOLOGICAL|Platelet Rich Plasma|The application of autologous thrombocyte concentrate (PRP). This is a concentrate with a high amount of thrombocytes (containing growth factors), obtained by centrifuging the patient's own blood. The concentrate is applied into the subacromial space after closure.
224174966|NCT03099304|DRUG|Ruxolitinib cream|Ruxolitinib cream is a topical formulation applied as a thin film to affected areas.
224174967|NCT03099304|DRUG|Vehicle cream|Vehicle cream is matching in appearance to ruxolitinib cream and is to be applied in the same manner as ruxolitinib cream.
224174968|NCT02076243|DRUG|nab-paclitaxel|nab-paclitaxel (abraxane) administered weekly (days 1,8, and 15 of 28 day cycle) to patients with unresectable locoregional or distantly metastatic cutaneous squamous cell carcinoma (SCC).
224174969|NCT00002590|BIOLOGICAL|filgrastim|
224174970|NCT00002590|DRUG|cyclophosphamide|
224174971|NCT00002590|DRUG|cytarabine|
224174972|NCT00002590|DRUG|daunorubicin hydrochloride|
224174973|NCT00002590|DRUG|doxorubicin hydrochloride|
224174974|NCT00002590|DRUG|etoposide|
224174975|NCT00002590|DRUG|leucovorin calcium|
224174976|NCT00002590|DRUG|methotrexate|
224174977|NCT00002590|DRUG|pegaspargase|
224174978|NCT00002590|DRUG|prednisone|
224174979|NCT00002590|DRUG|thioguanine|
224174980|NCT00002590|DRUG|vincristine sulfate|
224174981|NCT00002590|RADIATION|radiation therapy|
224174982|NCT02249260|BEHAVIORAL|High intensity interval training|Group-based high-intensity aerobic interval training and lifestyle counseling
224306386|NCT00134173|DRUG|atorvastatin|
224174983|NCT02820480|DEVICE|Rehab in a Crate System|"The therapy gym is Rehab in a Crate with 4 stations for upper and lower limb assessment/therapy. Each station will allow adaptive game-based therapy.~Note: The device is not being used at this moment for diagnostic or evaluation. Users will be asked to explore the device, try the systems, and provide feedback about use."
224174984|NCT03739099|DEVICE|Closed-loop insulin infusion driven by continuous glucose monitoring through an algorithm, in free-life conditions|Continuous subcutaneous insulin infusion according to an automated algorithm from continuous glucose monitoring data
224174985|NCT02203942|OTHER|NAAT testing|comparison of NAAT testing for BV, VVC and trich to Amsel criteria, Nugent score, yeast culture and TV culture.
224174986|NCT04966611|DRUG|Anlotinib|This is an observational study
223485751|NCT05855720|OTHER|FIT model project|Several statutory health insurance (SHI) funds have established contracts with hospitals for an alternative remuneration / financing of patients treated in the hospital (FIT hospital). Some of those contracts already started in 2013 and were prolonged. Some FIT contracts will start freshly (until June 2026). These contracts encourage FIT hospitals to test alternative treatment options for their patients (insured with the involved SHI funds), for example fewer inpatient and more outpatient treatment.
223485752|NCT04010305|DRUG|Sublingual film containing BXCL501 (Dexmedetomidine)|Sublingual film containing BXCL501 (Dexmedetomidine) for the treatment of agitation associated with Schizophrenia
223586450|NCT05841498|DEVICE|Sham-apheresis|Sham-apheresis is a procedure without any known therapeutic effects. As there are no known therapeutic effects there are also no known side effects excepted the risk of an allergic reaction to materials of the tubing system or to citrate, which is necessary to prevent clotting inside the extracorporeal system. To ensure a smooth operation a blood-flow of at least 45ml/min is necessary. In some patients, adequate blood flow can be achieved by cannulation of peripheral veins. However, in most patients, placement of a Shaldon catheter into the internal jugular vein is necessary. Shaldon catheter placement carries other potential risks such as injury to the lung resulting in pneumothorax or mispuncture of the carotid artery. However, since the catheter placement is sonography-guided, the risks for such adverse events are minimized.
224174987|NCT02530827|DRUG|use of lipid-lowering drugs.|The patients shoud be in use of a lipid-lowering drugs previouly, at least one month before of the begining of the study.
224174988|NCT03194204|DRUG|Doxycycline Tablets|MMP-3 and MMP-9 will be done with blood samples using ELISA technique CIMT will be done using colored doppler ultrasound
224174989|NCT02663115|OTHER|Biopsy of the diaphragmatic muscle|
224174990|NCT02663115|OTHER|Skeletal muscle biopsy|
223586451|NCT04068610|DRUG|Durvalumab|Participants will receive IV infusion of durvalumab as stated in arm description.
223745252|NCT07015281|OTHER|Dry Needling with Percutaneous Electrical Nerve Stimulation (PENS) and Therapeutic Exercises.|Patients assigned to this group (n=50) will receive an intervention in which PENS will be applied for 30 minutes with low frequency parameters (2 Hz) and a pulse width of 120 μs. After 30 minutes of PENS in both groups, the needle will be removed and a compression will be applied for 90 seconds. Once the compression will carried out, the technique will be concluded. Patients will develop a session of PENS and a session with therapeutic exercise once a week.
224174991|NCT04460300|OTHER|Aromatherapy-inhalation method|"In addition to the pharmacological treatment prescribed by the physician to individuals in this group, aromatherapy is carried out through the essential oil inhalation method. Individuals who can distinguish odors in the odor sense test before the application is included in the study. Aromatherapy inhalation is applied for three days and every other day (eg Monday-Wednesday-Friday) determined by the researchers for a week. Intervention is made between 07:00 and 08:00 in the morning hours when the blood cortisol value is maximized and homogeneity is provided.~In this method, 5 drops of lavender oil will be dropped directly on a sterile gauze and individuals will be allowed to breathe from a distance of 10 cm for 5 minutes."
224174992|NCT04460300|OTHER|Aromatherapy-foot massage group|"In addition to the pharmacological treatment prescribed by the physician to individuals in this group, aromatherapy is applied through foot massage. Swedish massage protocol is followed in foot massage intervention.The foot massage is performed on three days and every other day (eg Monday-Wednesday-Friday) determined by the researchers for a week.The intervention is performed between 07:00 and 08:00 in the morning hours when the blood cortisol value is maximized and homogeneity is provided.~Foot massage is done with 10 drops (5 drops per foot) of lavender for 10 minutes for each foot for 20 minutes. During the intervention, 20 techniques is used and the application time of each technique is 30 seconds (total 10 minutes per foot)."
224306387|NCT00911807|DRUG|Cerebrolysin + donepezil|"Cerebrolysin (10 ml) was given as IV infusion on five days per week for four consecutive weeks (week 1-4) with repetition of this treatment course (week 13-16) after a two-months treatment free interval, accounting for a total of 40 infusions.~Donepezil was given PO once daily during the whole study duration (28 weeks). After four weeks the daily dosage was increased from 5 mg to 10 mg."
224306388|NCT00911807|DRUG|Cerebrolysin + placebo|"Cerebrolysin (10 ml) was given as IV infusion on five days per week for four consecutive weeks (week 1-4) with repetition of this treatment course (week 13-16) after a two-months treatment free interval, accounting for a total of 40 infusions.~Placebo for donepezil was given PO once daily during the whole study duration (28 weeks)."
223485753|NCT04010305|DRUG|Placebo film|Placebo film for BXCL501
223586452|NCT04068610|DRUG|Oleclumab|Participants will receive IV infusion of oleclumab as stated in arm description.
224174993|NCT00004056|BIOLOGICAL|filgrastim|
224174994|NCT00004056|DRUG|asparaginase|
223485754|NCT05441904|DRUG|PXL770|A single dose of 500 and 750 mg was administered to each subject.
223485755|NCT05316467|BEHAVIORAL|Intensive Lifestyle Intervention (ILI)|"* dietary guidance~* exercise guidance~* lifestyle intervention"
224174995|NCT00004056|DRUG|cytarabine|
224174996|NCT00004056|DRUG|daunorubicin hydrochloride|
223485756|NCT05316467|DRUG|Megestrol Acetate 160 MG Oral Tablet|enrolled participants will take Megestrol Acetate 160mg daily
224174997|NCT00004056|DRUG|melphalan|
224174998|NCT00004056|DRUG|thioguanine|
224174999|NCT00004056|PROCEDURE|peripheral blood stem cell transplantation|
224175000|NCT02689089|DRUG|3HP|An interrupted time series study design will be used to determine if the introduction of the 3HP regimen will result in more people completing LTBI treatment compared to the standard of 9 months INH twice weekly.
224175001|NCT05990140|OTHER|peppermint flavored mouthwash|The Effect of Peppermint Flavored Mouthwash Applied to Patients in the First 30 Days After Bariatric Surgery on Nausea-Vomiting, Anxiety and Biochemical Parameters
224175002|NCT01401101|OTHER|PCM|Care Manager (CM) intervention
224175003|NCT01401101|OTHER|MEU|The MEU condition consists of only the clinician education and patient screening without written feedback.
224175004|NCT00002041|DRUG|Amphotericin B|
224175005|NCT05488106|DIETARY_SUPPLEMENT|Placebo|Placebo
224175006|NCT05488106|DIETARY_SUPPLEMENT|Riboflavin 1.6mg/d|Riboflavin 1.6mg/d
224175007|NCT05488106|DIETARY_SUPPLEMENT|Riboflavin 5mg/d|Riboflavin 5mg/d
224175008|NCT05488106|DIETARY_SUPPLEMENT|Riboflavin 20mg/d|Riboflavin 20mg/d
224175009|NCT03381352|RADIATION|Chemo-radiotherapy with IMRT technique|IMRT radiation technique; 50.4-54Gy/25F
224175010|NCT03381352|DRUG|Capecitabine|Capecitabine 825mg/m2 PO BID
224175011|NCT03381352|DRUG|Mitomycin C|Mitomycin C 10mg/m2 D1,29 iv
224175012|NCT05680090|DIAGNOSTIC_TEST|Artificial intelligent system for eye emergency triage and primary diagnosis|An intelligent triage and diagnostic system for ophthalmic emergencies has been developed. In the prospective test, patients with acute ocular symptoms can achieve remote self-triage and primary diagnosis after uploading metadata and ocular images.
224175013|NCT02437721|OTHER|infant formula containing folic acid|
224175014|NCT02437721|OTHER|infant formula containing MTHF|
224175015|NCT02822924|PROCEDURE|Prostate artery embolization (PAE)|Right femoral arterial puncture is performed under local anesthesia. The blood supply to the prostate is mapped by angiography of the iliac vessels and the prostate arteries. Microcatheters are used for super-selective catheterization of the right and left inferior vesicle arteries. Embolization is performed with a microcatheter to deliver microspheres of 300 micron diameter. The microsphere mixture is slowly injected under fluoroscopic guidance. The endpoint of embolization is flow stasis in the prostatic vessels with prostatic gland opacification, without reflux of the mixture to undesired arteries.
224175016|NCT00715949|OTHER|Immediate Post-concussion Assessment and Cognitive Testing|ImPACT© utilizes a battery of neurocognitive tests to assess neurologic deficits.
224175017|NCT00789659|OTHER|Negative pressure dressing|A completely occlusive dressing that is attached to a device that allows a constant negative pressure of 125 mmHg to be generated.
224175018|NCT03998995|DEVICE|Immersive Virtual Reality|"An Oculus Rift VR Headset and a set of Oculus Touch Controllers was used as interactivity device. Two scenarios of IVR rehabilitation game were offered to the patients: 1) Archery based on behind-the-neck overhead press, using a quiver on the user back to encourage bending their arm and firing the arrow to help with stretching exercises and 2) Climbing based on an overhead arm raise exercise.~Each child will took part in a single IVR trial during their rehabilitation care with the physiotherapist, supported by IP, the games expert/researcher. Timing of participation was approximately 15 minutes of trial with each scenario of game. A short interview was conducted with each child and their parent (together) after each trial, and a focus group was conducted with the clinical staff."
224175019|NCT05206682|DRUG|Leuprorelin|Leuprorelin will be used to postpone period after vaginal repair.
224175020|NCT02790450|DRUG|Benzbromarone|1x200mg Benzbromarone will be applied after baseline measurements during right heart catheterization. The effects of the drug on the pulmonary hemodynamics will be assessed after 2 hours.
223485757|NCT03846791|OTHER|Observational Study Post MAKO Robotic Surgery|To assess clinical outcomes and surgery related resource use in the year post surgery for patients undergoing hip replacement surgery using the MAKO robot
224175021|NCT06096012|DRUG|Anti-MRSA therapy|chart review to determine the clinical outcomes of patients with osteomyelitis who were placed on definitive anti-MRSA treatment, despite no identified MRSA cultures.
224175022|NCT03731910|DIAGNOSTIC_TEST|MRI|liver MRI using standard dose of extracellular agent. It includes dynamic contrast-enhanced MRI and diffusion weighted image.
224306389|NCT00911807|DRUG|Donepezil + placebo|"Placebo for Cerebrolysin was given as IV infusion on five days per week for four consecutive weeks (week 1-4) with repetition of this treatment course (week 13-16) after a two-months treatment free interval, accounting for a total of 40 infusions.~Donepezil was given PO once daily during the whole study duration (28 weeks). After four weeks the daily dosage was increased from 5 mg to 10 mg."
223485758|NCT04228939|BEHAVIORAL|Recovery Record aftercare|"Patients randomized to IG receive a therapist-guided smartphone-based aftercare intervention for a period of 16 weeks. The patients are invited to download for free the German version of Recovery Record at the App Store (iPhone) or the Google Play Store (android) to their smartphone and to link with the aftercare therapist. After discharge, patients are asked to monitor their meals at least three times per day (breakfast, lunch, and dinner), that is, to produce a minimum of three logs per day over the subsequent 16 weeks. Furthermore, patients are instructed to monitor their thoughts and feelings as well as their (disordered) behaviors. The aftercare therapist also sets the patients clinical post-discharge goals and makes coping skill suggestions. Individual therapist feedback is provided in-app twice per week during the first four weeks, once per week in weeks 4-8, every other week in weeks 8-12 and once in week 16."
224175023|NCT03452995|PROCEDURE|PHYSIOTHERAPY|Lymphodreinage and kinesiotaping are current methods of treatment of edema, pain and indirectly recovery of the knee ROM in TKA. Edema, pain and knee ROM are strictly corelated and, by reducing edema, we reduce the pressure by relieving pain, and allowing an improvement in movement.
224175024|NCT02630381|DEVICE|Unfocused extracoporeal shock wave therapy|"Shock waves are acoustical pulses that are characterized by high amplitude (\~500 bar) and short rise time (\~20 ns), which are followed by a longer low-magnitude negative wave (\~-100 bar). Extracorporeal shock waves are widely used to disintegrate kidney stones, which is called lithotripsy. In orthopedics, shock wave therapy, called orthotripsy, is used safely in a variety of musculoskeletal disorders like non unions, osteonecrosis of the hip, Achilles and patellar tendinopathy, lateral epicondylitis of the elbow and fasciitis plantaris.~Until recently extracorporeal shock wave therapy for musculoskeletal disorders was applied with a focused character, in which the waves converge in a focal point similar to lithotripsy. For the prevention of fractures in osteoporosis a focused character is not preferable because large skeletal regions have to be treated, so unfocused shock waves have been developed."
224175025|NCT00391495|PROCEDURE|Blood drawing|
224306390|NCT02489019|DRUG|Sodium chloride|Sodium chloride will be used as a placebo comparator in this trial
224175026|NCT06019390|DEVICE|Presage care|A screening questionnaire completed by the family caregiver focused on functional and clinical autonomy of the patient (ie, activities of daily life), possible medical symptoms (eg, fatigue, falls, and pain), changes in behavior (eg, recognition and aggressiveness), and communication with relative or their surroundings.
224175027|NCT00284609|BEHAVIORAL|Group based non-pharmacological rehabilitation|"6 x 1.5 hours education program in group classes taught by nurse, physiotherapist, dietitian and chiropodist.~24 x 1.5 hours training program (both aerobic and anaerobic exercise) in group classes supervised by a physiotherapist.~3 x 3 hours cooking sessions in group classes supervised by a dietitian.~Intervention period: 6 month"
224175028|NCT00284609|BEHAVIORAL|Individual non-pharmacological rehabilitation|"Individual counseling in Outpatient Clinic, including patient education, physical activity and diet instruction.~4 x 1 hour with a diabetes nurse,~3 x 0.5 hour with a dietitian and~1 hour with a chiropodist.~Intervention period: 6 month"
224175029|NCT04783961|PROCEDURE|Cold snare endoscopic resection|Cold snare endoscopic resection
224175030|NCT01381809|DRUG|Group 2: Placebo|form= solution for injection, route= subcutaneous use, weekly injections for 24 to 48 weeks
224175031|NCT01381809|DRUG|Group 1: Epoetin alfa|type = range, unit= IU/Kg, number= 337.5 to 1050 IU/Kg, form= solution for injection, route= subcutaneous use, weekly injections (max 40,000 IU per week for first 8 weeks of treatment, max 80,000 IU per week later) using pre-filled 1mL 40,000 IU syringes for 24 to 48 weeks
224175032|NCT02890511|DRUG|Paclitaxel|Oral administration on day 1,8,15 of 4-week cycle until progression, unacceptable toxicity or withdrawal of informed consent.
224175033|NCT03701061|BIOLOGICAL|Seasonal Influenza Vaccine|A single dose of the FDA-approved 2018-2019 seasonal influenza vaccine (Fluarix Quadrivalent) will be administered to the subjects participated in HIPCVAX-010 Study
224175034|NCT03701061|BIOLOGICAL|Seasonal Influenza Vaccine|A single dose of the FDA-approved 2018-2019 seasonal influenza vaccine (Fluarix Quadrivalent) will be administered to the subjects participated in HIPCVAX-010 Study
224175035|NCT04176328|DRUG|Teicoplanin Sandoz 200 mg powder and solvent for solution for injection or infusion or oral solution.|Teicoplanin Sandoz administered by inhalation (aerosol).
224175036|NCT04770428|DRUG|MEDI7352|A dose of MEDI7352 will be administered as two 1.5 mL injections in the abdomen. Following an overnight fast of at least 8 hours, each participant will receive a single dose of MEDI7352 on 4 occasions.
224175037|NCT04770428|DRUG|Placebo|Matching placebo will be administered as two 1.5 mL injections in the abdomen. To maintain the double-blind requirements, the placebo volume administered will be equivalent to the MEDI7352 volume administered for each dosing. Following an overnight fast of at least 8 hours, each participant will receive matching placebo on 4 occasions.
224175038|NCT00976261|DRUG|GSK1614235|Glucose lowering in Type 2 Diabetes Mellitus
224175039|NCT00976261|DRUG|Sitagliptin|Glucose lowering in Type 2 Diabetes Mellitus
224175040|NCT00976261|OTHER|Placebo|Comparator
224175041|NCT02902692|OTHER|Brief Mindfulness|15 minutes psycho-education about mindfulness and a small experiential exercise using a raisin. Following this, participants listen to a 30minute pre-recorded sitting meditation which encourages them to focus on their breath and the sounds around them. Participants will be randomly assigned to either receive the brief mindfulness intervention immediately or will be asked to wait one week before receiving the intervention.
224175042|NCT02180191|OTHER|Comparison of the gut microbiota composition|
224175043|NCT03184766|DRUG|Test Nurofen Cold and Flu®, Ibuprofen and pseudoephedrine liquid capsules|2 x 200 mg ibuprofen \& 30 mg pseudoephedrine
224175044|NCT03184766|DRUG|Comparator 1 Nurofen Cold and Flu®, ibuprofen and pseudoephedrine tablets|2 x 200 mg ibuprofen \& 30 mg pseudoephedrine
224175045|NCT03184766|DRUG|Comparator 2 Nurofen Immedia 200 mg Weichkapseln, ibuprofen liquid capsules|2 x 200 mg solubilised ibuprofen
224175046|NCT03988894|DEVICE|mDASHNa App|The functions of the app will include: (a) antihypertensive dietary education; (b) dietary self-assessment; (c) automatic feedback according to dietary self-assessment; (d) blood pressure monitoring; and (e) automatic feedback according to blood pressure data.
224175047|NCT04526444|DEVICE|Fitness tracker|Fitness tracker Mi Smart Band 5 with the computational algorithm PAI
224306391|NCT02489019|DRUG|Fentanyl|Fentanyl is a synthetic opioid analgesic that will be used as the experimental intervention in this trial
224306392|NCT03144102|BEHAVIORAL|Virtual Reality-based therapy for upper-limbs motor rehabilitation|During each session, the subject will perform 4 VR-based exercises that involve reaching, grasping, and intercepting virtual objects. The training will last a total of 30 min per session.
224306393|NCT03144102|DEVICE|Anodal transcranial direct-current stimulation (tDCS)|Concurrent anodal tDCS on sensorimotor cortex on the ipsilesional hemisphere.
224306394|NCT03144102|BEHAVIORAL|Occupational Therapy for upper-limbs motor rehabilitation|During each session, the subject will perform 4 occupational therapy exercises that involve reaching, grasping, and intercepting objects. The training will last a total of 30 min per session.
224175048|NCT04526444|OTHER|Online training|Les Mills On Demand
224175049|NCT04526444|OTHER|Peer support via social media|Facebook group
224175050|NCT03626844|PROCEDURE|Manual Lysis of Placenta after 15 minutes (Intervention)|Manual Lysis of Placenta after 15 minutes: We administer prophylactic antibiotics, under epidural analgesia, under aseptic conditions, we perform manual lysis of placenta by introducing the hand through the vagina to the uterine cavity, separating and removing the placenta.
224175051|NCT03626844|PROCEDURE|Manual Lysis of Placenta after 30 minutes (Control)|Manual Lysis of Placenta after 30 minutes: We administer prophylactic antibiotics, under epidural analgesia, under aseptic conditions, we perform manual lysis of placenta by introducing the hand through the vagina to the uterine cavity, separating and removing the placenta.
224175052|NCT01710904|DRUG|Targinact® (oxycodone/naloxone)|
224175053|NCT04807244|PROCEDURE|Selective Caries Removal with Biodentine™|"1. Rubber dam placement~2. Cleaning of the tooth and rubber dam with ethanol 98%~3. Caries removal: Removal of protruding parts of enamel/dentin with high-speed round bur with continuous water cooling, caries removal with a low-speed round bur; peripheral caries is removed until only hard dentin is left, while the pulp wall is excavated until reaching leathery dentin~4. Disinfection of the leathery dentin 5 ml 1% NaOCl (speed: 1 ml per min)~5. Indirect pulp capping (layer of 1-2 mm) of the carious lesion with Biodentine™ (15 min setting time after mixing)"
223485759|NCT04228939|BEHAVIORAL|Treatment as usual (TAU)|Patients randomized to CG receive TAU i.e. patients and their physicians or therapists decide on post-discharge treatment which is documented at T1 and T2.
223485760|NCT03510936|DIETARY_SUPPLEMENT|Probiotics|the patients in this arm will receive probiotics blend of Bifidobacterium longum, Lactobacillus acidophilus, Enterococcus faecalis with does of 1.5\*10\^7CFU for 2 weeks
224175054|NCT04807244|PROCEDURE|Partial Pulpotomy with Biodentine™|"1. Rubber dam placement~2. Cleaning of the tooth and rubber dam with ethanol 98%~3. Caries removal: Removal of protruding parts of enamel/dentin with high-speed round bur with continuous water cooling, caries removal with a low-speed round bur; before accessing the pulp chamber, the central caries will be left, peripheral caries will be excavated completely~4. Disinfection of the leathery dentin 5 ml NaOCl 1% (speed: 1 ml per min)~5. Accessing the pulp chamber with a high-speed round bur and removal of 2-3 mm pulp tissue; irrigation with 2 ml NaOCl 1%~6. Hemostasis will be achieved with a sterile foam pellet soaked with NaOCl 1% with gentle pressure to the pulp for 3 min~7. If hemostasis could not be achieved within 3 min, step 6 will be repeated once. In case of no hemostasis, transfer of the case to Intervention: full pulpotomy with Biodentine~8. Confirmed hemostasis: pulp capping with Biodentine™ (layer min. 2-3 mm, 15 min setting time after mixing)"
224175055|NCT04807244|PROCEDURE|Full Pulpotomy with Biodentine™|"1. Rubber dam placement~2. Cleaning of the tooth and rubber dam with ethanol 98%~3. Caries removal: Removal of protruding parts of enamel/dentin with high-speed round bur with continuous water cooling, caries removal with a low-speed round bur; before accessing the pulp chamber, the central caries will be left, peripheral caries will be excavated completely~4. Disinfection of the leathery dentin 5 ml NaOCl 1% (speed: 1 ml per min)~5. Accessing the pulp chamber with a high-speed round bur and removal of the entire pulp chamber roof; full pulpotomy to stump level with a high-speed round bur under continuous irrigation with 5 ml NaOCl 1%~6. Hemostasis will be achieved with a sterile foam pellet soaked with NaOCl 1% with gentle pressure to the pulp for 3 min~7. If hemostasis could not be achieved within 3 min, step 6 will be repeated once. In case of no hemostasis, exclusion.~8. Confirmed hemostasis: pulp capping with Biodentine™ (layer min. 2-3 mm, 15 min setting time after mixing)"
224175056|NCT04807244|PROCEDURE|Direct composite filling after selective caries removal/full pulpotomy/partial pulpotomy|"1. Dentin cleaning with a low-speed round bur~2. Use of Scotchbond Universal™ and Filtek Supreme XTE™ according to manufacturer's recommendation"
224175057|NCT06178458|OTHER|No intervention|To collect data of pain score and opioid consumption of index and previous cesarean delivery
224175058|NCT06129006|PROCEDURE|hydrodilatation with steroid in group A versus hyalase in group B|"Hydrodilatation technique:~the ultrasound transducer will be placed on the posterior surface of the shoulder in the longitudinal plane to identify the posterior glenohumeral joint, bony glenoid, humeral head, and infraspinatus muscle.Then, after sterilizing the area to be injected, the needle will be advanced to the target point between the humeral head cartilage and the infraspinatus tendon using the ultrasound-guided in-plane technique.To ensure the injection into the glenohumeral joint, the Doppler mode will be used to confirm the widening of the space between the humeral cartilage and the innermost synovial line of the infraspinatus muscle by the injected solution."
224175059|NCT04905836|BIOLOGICAL|COVI-MSC|COVI-MSC are allogeneic culture-expanded adipose-derived mesenchymal stem cells
224175060|NCT04905836|DRUG|Placebo|Excipient solution
224175061|NCT02334137|BEHAVIORAL|iPad app|"Provided by the Patient Education Institute, the X-plain iPad app includes modules on healthy eating for diabetics, eye complications, foot care, and others."
224175062|NCT02334137|BEHAVIORAL|Educator sessions|A certified diabetes educator and/or registered dietitian will meet with patients for 30-60 minutes prior to their ophthalmology visits, when scheduling permits.
224175063|NCT02334137|BEHAVIORAL|Retinal photos|A resident ophthalmologist will spend approximately 5 minutes showing patient their own retinal photos, compared to a normal retina, and explaining the pathology present (if applicable).
224175064|NCT02130635|DRUG|GSK2269557 100 MCG|100 mcg of GSK2269557 blended with lactose per blister administered using a dry powder inhaler device
224175065|NCT02130635|DRUG|GSK2269557 500 MCG|500 mcg of GSK2269557 blended with lactose per blister administered using a dry powder inhaler device
224306395|NCT03144102|DEVICE|Sham transcranial direct-current stimulation (tDCS)|Concurrent sham tDCS on sensorimotor cortex on the ipsilesional hemisphere.
223485761|NCT04732676|OTHER|Smartphone application|"Ecological Momentary Assessment (EMA)~: ambulatory assessment of behaviors/symptoms in real-time on smartphones"
223586453|NCT04068610|DRUG|FOLFOX|Participants will receive IV infusion of FOLFOX (5-FU, oxaliplatin, and folinic acid) as stated in arm description.
223586454|NCT04068610|DRUG|Bevacizumab|Participants will receive IV infusion of bevacizumab as stated in arm description.
223586455|NCT06292039|OTHER|Human-Centered Injury Thrivorship Pathway|Enrollment in the human-centered injury thrivorship pathway.
223485762|NCT05891444|DEVICE|High frequency transcranial random noise|High frequency tRNS is described as a non-invasive form of brain stimulation that uses a low-intensity, alternating current applied directly to the head through scalp electrodes.
223485763|NCT05891444|DEVICE|Sham high frequency transcranial random noise|In the sham condition, tRNS was delivered only during the ramp-up and ramp-down periods (30s); no current was delivered during the 30-minute intervention.
223485764|NCT02957448|DRUG|BMS 986141|Two single doses BMS 986141 (days 1 and 13) and single daily doses Rifampin (days 7-22)
223586456|NCT06832579|DEVICE|Wearable|semi-continuous heart rhythm monitoring with Wearable
223586457|NCT02428205|DRUG|Propranolol|Participant will receive Propranolol prior to each EIBI session
223586458|NCT02428205|DRUG|Placebo|Participant will receive placebo prior to each EIBI session
223586459|NCT06524479|PROCEDURE|SEEG recordings and SPES|This study will utilize stereoelectroencephalography (SEEG) recordings combined with single-pulse electrical stimulation (SPES) to investigate functional brain connectivity and cortical excitability patterns in patients with epilepsy during both wakefulness and sleep states. The SEEG recordings will provide high-resolution intracranial electrophysiological data, while SPES will be employed to actively probe and quantify cortico-cortical connections. This combined approach will enable characterization of state-dependent neural network dynamics.
223586460|NCT06668389|DRUG|SGLT2 inhibitor (Dapagliflozin 10mg)|Subjects in SGLT2 inhibitor Group will take dapagliflozin 10mg once daily orally from Visit 1 (Week 1) to Visit 3 (Week 12 ± 1)
224175066|NCT02130635|DRUG|PLACEBO|Lactose administered using a matching dry powder inhaler device
224175067|NCT05247515|DEVICE|Endoscopic mucosal resection with nexpowder|At the end of the EMR procedure, the patient will be randomized. In the treated group, Nexpowder will be sprayed thanks to a catheter inserted through the operating channel of the endoscope.
224175068|NCT03319329|DEVICE|Indirect Calorimetry|REE measurements were using IC (Cosmed, Quark RMR 2.0, Indirect Calorimetry Lab, Italy). A standard protocol for conducting the measurement was followed (Schlein \& Coulter, 2014);(P. Singer \& Singer, 2016); (Taku Oshima et al., 2016). Before each measurement, the metabolic monitor was allowed to warm up for 30 min, and then gas and flowmeter calibrations were performed by an experienced dietitian or healthcare professional. The REE was recorded after a 30 min non-fasting steady state according to RMR protocol and manufacturer instructions.
224175069|NCT02378610|OTHER|Observation|Observation of the gut bacterial flora in high- and low-stressed individuals
224175070|NCT06423001|DIETARY_SUPPLEMENT|PostbiotiX Slowing 4 g sachets PostbiotiX Slowing is a food supplement based on Fermented FOS from Lactobacillus paracasei CNCM I-5220.|Each patient will be supplied with the investigational product at Visit 0, PostibiotiX Slowing and at visit 3, based on the outcome of the randomization at V0 (Sequence AB, PostbiotiX Slowing/Placebo; Sequence BA, Placebo/PostbiotiX Slowing).
224175071|NCT04959786|DRUG|Ivermectin,ribavirin ,nitazoxanide and zinc|oral intake of the 3 drugs ivermectin ,ribavirin and nitazoxanide plus zinc
224175072|NCT01212120|BIOLOGICAL|Genetic profiling of bacterial cultures|Genetic profiling of bacterial cultures harvested from both the nose and foot lesions of patients
224175073|NCT01142791|DEVICE|ExAblate|Magnetic resonance image-guided focused ultrasound (MRgFUS) for fibroid ablation
224175074|NCT00656994|DRUG|Ramelteon|Ramelteon 16 mg, tablets, orally, once nightly for up to 6 months.
223485765|NCT02957448|DRUG|Rifampin|Two single doses BMS 986141 (days 1 and 13) and single daily doses Rifampin (days 7-22)
224175075|NCT00656994|DRUG|Placebo|Ramelteon placebo-matching tablets, orally, once nightly for up to 6 months
224175076|NCT02608892|BEHAVIORAL|BSweet2Babies video|Mothers (and partners if possible) will view the brief BSweet2Babies video on electronic notebooks in French or English, as per parent/s' preference.
224175077|NCT04051489|OTHER|Mobile health App - Test|"Beta Testing 1: The Beta test 1 will be performed with participants inside the Research Center. The purpose of this phase is to increase usability, acceptability and reliability of the mHealth App in participants with knee osteoarthritis (KOA).~Beta Testing 2: The Beta test 2 will be performed with patients outside the Research Center, at their houses. The purpose is to focus on the mHealth App remote usability, acceptability, and data collection."
224175078|NCT03450824|OTHER|No intervention|The standardized standing whole-lower-extremity radiographs, the knee lateral view and skyline view of the participants will be taken.
224175079|NCT05819424|DIETARY_SUPPLEMENT|Yeast Fermentate (EpiCor)|"Dietary Supplement: Yeast Fermentate (EpiCor): Postbiotic whole food fermentate made using yeast. Composed of proteins, polyphenols, vitamins, minerals, amino acids, polysaccharides, fibre, and other nutrients.~Placebo: Substance with no therapeutic value to facilitate blinding"
224175080|NCT02590406|PROCEDURE|Beach chair (BC) and ZEEP|Table Position: Beach chair, Inclination of the upper part of the table at 25 degrees, breaking at the patient's hips ZEEP: 3 minutes pre-oxygenation with tidal volumes, FiO2 100%, mouth piece used as a ventilatory interface
224175081|NCT02590406|PROCEDURE|Reverse Trendelenburg and NIPPV|"Table Position: Reverse Trendelenburg, Inclination of the whole table at 25 degrees from an horizontal plane, head up.~NIPPV: 3 minutes of pre-oxygenation with 8 cm H2O positive pressure and 10 cm H2O PEEP. Trigger set at 1,5 L/min, mouth piece is used as a ventilatory interface"
223485766|NCT06201325|OTHER|virtual reality based exercises|play VR games
223485767|NCT06201325|OTHER|conventional physical therapy|streching and strengthening exercises
223485768|NCT06201325|OTHER|home exercises program|home exercises
223485769|NCT01900314|DEVICE|repetitive Transcranial Magnetic Stimulation (rTMS)|20 active sessions, within a 4 week period, where subjects receive the same repetitive Transcranial Magnetic Stimulation (rTMS) treatment parameters as the sham arm.
223485770|NCT05926713|DIETARY_SUPPLEMENT|Sarcojoint®|All participants are administered Sarcojoint® containing leucinine 1 g, arginine 1.5 g, Vitamin D 7.5μg, chondroitin 400 mg, calcium 300 mg, and glucosamine 700 mg per package, and take 1 package twice a day.
223485771|NCT05926713|BEHAVIORAL|supervised exercise|All participants are required to walk 6500 steps every day for 12 weeks, and the data are recorded by Xiaomi-smart-band.
223485772|NCT04277585|OTHER|Telehealth|Early Psychosis Coordinated Specialty Care Services via telehealth.
223485773|NCT03318068|OTHER|Yoga Intervention|The yoga intervention will consist of a combination of yoga postures, gentle stretches, breathing techniques and relaxation. The sessions will be delivered one-on-one and will be adapted to accommodate the patients each day.
223485774|NCT03005756|DEVICE|Needle guiding robot|This intervention is to evaluate the safety and efficacy of a needle guiding robot for assisting targeting in CT-guided radiofrequency ablation of hepatocelluar carcinomas.
223485775|NCT02095288|PROCEDURE|Blood draw|This is a single blood donation, no drugs or devices administered
223485776|NCT06257446|BEHAVIORAL|Task Instructions|Participants will be given cued instructions as to whether they are in a high or low motivation condition
223485777|NCT04225832|BEHAVIORAL|CBT Coping Intervention|A cognitive behavior therapy group intervention for HIV-negative Latinx sexual minority men aimed at increasing HIV testing and prevention strategies.
223485778|NCT03076463|DIETARY_SUPPLEMENT|GRAPOM|The whole intervention will be divided in 2 periods, control (CTR) and dried and milled grape pomace (GRAPOM). The two periods will have a duration of 6 weeks. During the CTR period, subjects will follow their normal dietary habits and samples will be collected at the beginning and at the end. No proper placebo could be found for the product, so this CTR period was chosen. During the GRAPOM period, the subjects will daily consume 8 g of the product solved in water and samples will be collected at the beginning and at the end.
223485779|NCT05730205|DRUG|Nexplanon 68 MG Drug Implant|Progestin contraceptive device
223485780|NCT05698823|DEVICE|Lumoral Treatment|The Lumoral treatment -device is a CE-marked antibacterial home-use device for the treatment and prevention of oral diseases caused by bacteria. It is used in combination with a CE-marked mouth rinse called Lumorinse.
223586461|NCT00412594|DRUG|Cladribine|Given IV
224175082|NCT00957723|DEVICE|Triathlon® CR Total Knee System|The purpose is to evaluate the Triathlon® CR Total Knee System.
224175083|NCT05375838|BIOLOGICAL|mRNA-1073|Sterile liquid for injection
224175084|NCT05375838|BIOLOGICAL|mRNA-1010|Sterile liquid for injection
224175085|NCT05375838|BIOLOGICAL|mRNA-1273|Sterile liquid for injection
224175086|NCT05375838|BIOLOGICAL|Placebo|0.9% sodium chloride (normal saline) injection
224175087|NCT05839002|PROCEDURE|nCRT|ESCC patients that recieved surgery and nCRT.
224175088|NCT04711395|DEVICE|measure the preoperative DLI、 SS-OCT image of the lens,、take photos of the anterior segment and self-scoring of the preoperative visual quality assessment scale.|subjects in the observation group and Healthy used iTrace ocular aberration analyzer（itracey Technologies）and IOL-Master 700 biometer to measure the preoperative DLI(Dysfunctional lens index) and SS-OCT image of the lens, and The researchers used the anterior segment slit lamp to take photos of the anterior segment of the subject's lens in a state of dilated pupils .and self-scoring of the preoperative visual quality assessment scale.
224175089|NCT00740818|OTHER|No Intervention|The patient will lay prone on the adjustment table 5 minutes, the approximate equivalency of a Logan Basic adjustment. Table will be in proper position according to Logan Basic protocol.
224175090|NCT00740818|PROCEDURE|Sham Logan Basic Adjustment|A thumb contact will be used against the sacrotuberous ligament as opposed to underneath the ligament. Auxiliary contacts will also be sham adjustments; the spine will be contacted but no force applied.
224175091|NCT00740818|PROCEDURE|Logan Basic adjustment|Logan Basic adjustment, as well as auxiliary and abdominal contacts, based on the Logan Basic protocol.
224175092|NCT02907801|BEHAVIORAL|Perception-Action Approach|Environmental set-up, gentle manual guidance, and caregiver education
224175093|NCT03113799|DEVICE|Smart External Drain - SED|Subject will be treated on Day 2 with the SED. ICP and CSF volumes will be recorded at prespecified intervals while subject is stationary and while subject is engaged in protocol-driven directed movements.
224175094|NCT05012709|BEHAVIORAL|multisensory stimulation therapy|The intervention group received six 30-minute MST sessions. During MST session, participants can choose their preferred sensory stimuli such as essential oil diffuses, music and so on.
224175095|NCT02149628|DRUG|propofol|
224175096|NCT02149628|DRUG|Desflurane|
224175097|NCT04337528|OTHER|Osteopathic manipulation type thrust|The osteopathic manipulation type thrust is applied to solve the sacroiliac joint dysfunction. This technique applies a high velocity and intensity push in a specified direction to correct the dysfunction produced by a not correct position or movement of one joint.
224175098|NCT04337528|OTHER|Osteopathic manipulation type muscle-energy|The muscle-energy manipulation is applied to solve the sacroiliac joint dysfunction. This technique applies a movement with an intermittent resistance in a specified direction to correct the position or movement of one joint. The therapist applies the movement in the correct direction since he feels a limitation of movement. When he feels the limitation he requests to the participant pushing in the contrary direction without movement. After five or seven seconds the participant finishes the contraction and the therapist continues the correct movement since he feels once again the limitation, and he request to the participant contraction another five or seven seconds. The therapist request to the participant only three times, when he finish the three contraction and the therapy applies the last movement to correct direction the intervention finishes.
224175099|NCT04337528|OTHER|Placebo technique|The therapist simulates a false technique. The therapist applies movement in the sacroiliac joint without dysfunction, he applies movement since ninety degrees of pelvic flexion, and he wait sixty seconds. Whit this placebo technique the sacroiliac joint with the dysfunction is not altered.
224175100|NCT01660529|BIOLOGICAL|hTERT|
223485781|NCT02578797|DRUG|Apalutamide|Study drug will be administered orally at a dose level of 240 mg daily (4 x 60 mg tablets) in treatment cycles of 28 days.
223485782|NCT04443413|RADIATION|Proton Beam Radiation Therapy|Undergo proton beam radiation therapy
224175101|NCT03708029|OTHER|Revita Allograft|Human placental allograft
224175102|NCT00945594|DEVICE|Cystoscopy|A 16 F flexible cysto urethroscope (Storz, Culver city, CA) is used for flexible cystoscopy. When rigid cystoscopy is performed, a 17F, 70° scope (Storz, Culver city, CA)
223586462|NCT00412594|OTHER|Laboratory Biomarker Analysis|Correlative studies
224175103|NCT00688389|OTHER|case/control|case: infected dengue fever people control:healthy people
224175104|NCT05155540|DEVICE|Trevo and or Merci devices for stent retreival|FDA approved devices for stent retrieval during mechanical thrombectomy
224175105|NCT05155540|DEVICE|Penumbra system for stent aspiration|FDA approved devices for stent aspiration during mechanical thrombectomy
224175106|NCT05155540|DRUG|recombinant tissue plasminogen activator|FDA approved drug for treatment of acute ischemic stroke within 4.5 hours of strokeonset
224306396|NCT04732936|DEVICE|Temporary Peripheral Nerve Stimulator|Temporary Peripheral Nerve Stimulator to deliver 1-hr of electrical stimulation to injured nerves.
223485783|NCT04443413|OTHER|Questionnaire Administration|Ancillary studies
223485784|NCT04443413|RADIATION|X-ray Therapy|Undergo x-ray therapy
223586463|NCT00412594|BIOLOGICAL|Rituximab|Given IV
223586464|NCT06545643|DEVICE|Dreem headband|The Dreem headband is an EEG-based wearable tool that can be used to reliably assess the relationship between sleep and epilepsy over extended observation periods.
223485785|NCT06492993|OTHER|Education|The CHN meets with DDBHH participant over sessions to provide navigation support through the cancer screening process.
223586465|NCT02413411|BEHAVIORAL|DA/MI Intervention|Patients randomized to the DA/MI intervention arm will be shown a decision aid video entitled, Treatment Choices for Knee Osteoarthritis. Following the viewing of the decision aid video, the participant will be engaged in a motivational interview by the research study interventionist.
223586466|NCT02413411|BEHAVIORAL|an educational program (an NIH-developed booklet)|
223586467|NCT06567704|BEHAVIORAL|Interviews|Interviews
223485786|NCT05836077|OTHER|Education with pecha kucha method|Education with pecha kucha method
223485787|NCT05635006|OTHER||No special intervention, randomly classify the subjects
223485788|NCT03963388|OTHER|Speech therapy|Online speech therapy, delivered by specialized speech therapists. Speech therapy will be complemented by a real-time visual feedback app (the Voice Trainer app).
223485789|NCT02712853|OTHER|Saliva collection|Collection of saliva via swab for miRNA processing
224175107|NCT03838666|DRUG|Suspension of human autologous MSC 3P|Single administration of the suspension of human autologous MSC 3P in 1.5 ml on the surface of the repaired rotator cuff tendon
224175108|NCT02005718|DRUG|Cholecalciferol|
224175109|NCT02685839|DEVICE|Intelligent POWER Rehabilitation Cluster Machine|
224175110|NCT02685839|OTHER|general physical therapy|
224175111|NCT02815072|OTHER|Skin biopsy|A sample of skin (approximately 0.5cm x 0.5cm) from inner thigh area. The skin biopsy will be conducted and completed with a single stitch to close the wound under local anaesthesia to minimise any discomfort. The skin biopsy will be taken by the medical doctor trained in biopsy collection. The tissue sample will be processed and cells will be grown out of them under appropriate conditions. These cells will only be used for laboratory experiments that include experimental transplantation models and laboratory bench-top research.
224175112|NCT01984294|DRUG|LDV/SOF|Ledipasvir/sofosbuvir (LDV/SOF) 90/400 mg FDC tablet administered orally once daily
224175113|NCT01984294|DRUG|RBV|Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
224175114|NCT01984294|DRUG|GS-9669|GS-9669 tablet(s) administered orally once daily
224175115|NCT01814228|PROCEDURE|transcatheter ablation of ganglionated plexi in right atrium|
224175116|NCT01008098|DRUG|escitalopram (lexapro)|0 - 4 week: 10 mg escitalopram a day 5 - 8 week: 20 mg escitalopram a day
224175117|NCT06188039|DIAGNOSTIC_TEST|Superior vena cava collapsibility index|"After induction of general anaesthesia following interventions will be performed.~1. Insertion of a tranesophageal echocardiography probe~2. Measurement of SVC-CI~3. Measurement of LVOT-VTI prior to fluid bolus~4. Fluid bolus (250ml of crystalloid)~5. Measurement of LVOT-VTI after fluid bolus~Several volume trials per patient will be allowed, until safety criteria are met. In such cases further testing will be stopped."
224175118|NCT06188039|OTHER|PEEP elevation|"A transient elevation of positive end-expiratory pressure (PEEP) will be applied, in order to validate SVC-CI in the setting of elevated PEEP.~A PEEP level of 8-10cmH2O will be applied for 1 minute prior to every measurement of SVC-CI. Then the previous PEEP level will be reinstated."
223485790|NCT02712853|OTHER|Vineland Adaptive Behavior Scale-II Assessment|
223485791|NCT03368430|DIETARY_SUPPLEMENT|Melatonin|After performing scaling and root planing (SRP) in the test group, melatonin 10 mg oral capsule was taken once daily at night prior to bedtime for only 2 months during the 6-month study period
223586468|NCT05958199|DRUG|NPX267|NPX267 will be administered by intravenous infusion every three weeks until documented disease progression or participant withdrawal
223586469|NCT00068094|DRUG|Probiotic-containing powder|
223586470|NCT04373629|BEHAVIORAL|attentional modulation|Attentional instructions when viewing faces will be given
223586471|NCT04373629|OTHER|perceptual modulation|Faces will be presented of varying durations
223586472|NCT04373629|OTHER|naturalistic viewing|Faces will be viewed without specific instructions
224175119|NCT05507086|OTHER|Antimicrobial therapy|Antimicrobial therapy
224175120|NCT05822284|DIAGNOSTIC_TEST|NGS and ctDNA-MRD detection|NGS and ctDNA-MRD detection
224175121|NCT02537275|DEVICE|EyeLIKe Callamatch II, Koryo Eyetech Co, Seoul, Korea|tinted contact lens, daily-wear tinted lens
223485792|NCT03368430|DRUG|Placebo|After finishing scaling and root planing (SRP) in the control group, placebo capsule was taken once daily at bedtime for two months.
223485793|NCT05322343|OTHER|Questionnaires|"Participants will complete a series of three questionnaires at the V1 (at home, by a trained interviewer) repeated at V7 for the follow up phase:~1. A general questionnaire, with collection of general health history and exposure data~2. A nutritional survey (24-hour recall), that will be repeated by telephone twice at 3-month intervals, at the V4 and V5, V6 visits. and V7, V9, V10 et V11 for the follow-up phase~3. An evaluation of cognitive performance using a validated computerized battery (Cantab®), completed of neuropsychological tests to evaluate dementia syndromes, depressive symptoms and anxiety."
223586473|NCT06979973|DRUG|Midazolam|midazolam syrup
223586474|NCT06979973|DRUG|Rosuvastatin|Rosuvastatin
223586475|NCT06979973|DRUG|CKD-508 Tablet|CKD-508
223586476|NCT06980857|OTHER|Control Group|In our study, this group will be placed in hyperextension position and immobilized on postoperative day 0. Postop 1-2. Foot pumping exercises, isometric quadriceps exercises, passive knee extension, straight leg raising, 0-40 degree passive knee flexion, partial/full weight ambulation, respiratory exercises and cold application will be performed daily. On postoperative days 3-6 (depending on discharge time), stretching in passive knee extension, active/assisted quadriceps exercises, isometric-isotonic exercise for leg and hip muscles, 90-0 knee extension, 0-90 degree passive knee flexion exercises will be performed.
224175122|NCT02537275|DEVICE|EyeLIKe Shine, Koryo Eyetech Co|clear lens
224175123|NCT01987609|DRUG|Hylenex|
224175124|NCT01987609|DRUG|Normal Saline|
224175125|NCT01594489|DRUG|Aminophylline|"* 200 mg of aminophylline administrated intravenously as a short infusion, started in emergency department, before primary angioplasty and contrast medium administration~* Sodium bicarbonate (154 mEq/L in dextrose and H20) 3mL/kg for 1 hour before contrast medium, followed by an infusion of 1 mL/kg/h for 12 hours after procedure~* N-acetilcysteine: intravenous bolus of 1200 mg before angioplasty and 1200 mg twice daily for the 48 hours after PCI"
224175126|NCT01594489|DRUG|Hydration plus N-acetylcisteine|"* Sodium bicarbonate (154 mEq/L in dextrose and H20) 3mL/kg for 1 hour before contrast medium, followed by an infusion of 1 mL/kg/h for 12 hours after procedure~* N-acetilcysteine: intravenous bolus of 1200 mg before angioplasty and 1200 mg twice daily for the 48 hours after PCI"
224175127|NCT06425224|DEVICE|Tens therapy|"There will be 3 weekly therapy sessions for 12 continuous weeks, lasting 30 minutes each. 20 Hertz with a pulse width of 200 µsec will be administered in each session. The intensity will be applied to each patient depending on individual tolerance. TENT therapy will be performed as follows:~1\. The active electrode (cathode - red) is placed and adhered 3 - 5 cm above the internal malleolus and 1 cm behind the tibia.~The second reference electrode (anode - black) is attached to the calcaneus.~The equipment must previously be programmed under the following parameters:~Continuous current Frequency: 20 Hz. Pulse width: 200 µsec Time: 30 min. Intensity: to the patient's tolerance, gross motor perception to verify correct application, upon reaching it, increase the intensity to clearly sensory activation."
224175128|NCT06425224|DRUG|Dapoxetine placebo|Patients in this group will receive dapoxetine placebo (capsules with only excipients without active ingredient) as needed, taken 3 to 4 hours before sexual intercourse during the 12 weeks of the intervention.
224175129|NCT06425224|DRUG|Standard treatment (dapoxetine 30 mg as needed)|Patients in this group will receive dapoxetine 30 mg, taken 3 to 4 hours before sexual intercourse, for the 12 weeks of the study
224175130|NCT06425224|DEVICE|Placebo therapy|In addition to the medication, patients will receive three weekly sessions of placebo therapy for twelve continuous weeks, lasting 30 minutes each. For this, the black electrode will be placed on the external malleolus and the red one 4 finger widths towards the head on the lateral edge of the tibia. 20 Hertz with a pulse width of 200 µsec will be administered in each session.
224175131|NCT02396264|OTHER|mediterranean diet|50 pcos women will be assigned to normocaloric mediterranean diet for 6 months
224175132|NCT02396264|OTHER|normocaloric diet|50 pcos women will be assigned to standardized normocaloric diet for 6 months
224175133|NCT03277651|DIAGNOSTIC_TEST|hemodynamics tests|Hemodynamics tests for intrahepatic blood flow by colour doppler ultrasound
224175134|NCT01462851|DRUG|PF-05297909 25 mg|Single oral (PO) dose, PF-05297909 25 mg
224175135|NCT01462851|DRUG|PF-05297909 100 mg|Single oral (PO) dose, PF-05297909 100 mg
224175136|NCT01462851|DRUG|PF-05297909 250 mg|Single oral (PO) dose, PF-05297909 250 mg
224175137|NCT01462851|DRUG|PF-05297909 525 mg|Single oral (PO) dose, PF-05297909 525 mg
224175138|NCT01462851|DRUG|PF-05297909 525 mg|Single oral (PO) dose, 525 mg
224175139|NCT04691011|OTHER|Muscular MRI|MRI (1.5T)
224175140|NCT04691011|OTHER|Electrophysiological exam|MUNIX
224175141|NCT04691011|OTHER|Brain MRI|MRI (7T)
224175142|NCT04691011|OTHER|Spinal cord MRI|7T and 3T MRI
224175143|NCT06184165|PROCEDURE|Personalized rTMS|"5 personalized targets accessible to TMS (at less than 3.5 cm distance from the scalp or the coil's hot spot) are placed in the hyper-perfused premotor regions.~The patient is installed on the robotic device. The technician puts a neuro-navigation tracker on the subject's forehead and proceeds to the co-registration. The motor threshold is defined, and stimulator output's intensity is adjusted accordingly (120%) The robotic system ensures that the actual stimulation is performed according to the personalized protocol. This adequacy will be evaluated secondarily based on the recordings of the coil positions during each"
224175144|NCT00086489|DRUG|CP-675,206|pts treated at 10 mg/kg dose level on a monthly regimen
224175145|NCT00086489|DRUG|CP-675,206|pts treated at 15 mg/kg dose level on a quarterly regimen
224175146|NCT01445002|BIOLOGICAL|BM32|Subcutaneous injection of 10 micrograms each of the BM32 components adsorbed on 0.3 mg of aluminum hydroxide every 4 week for a total of 3 injections
224175147|NCT01445002|BIOLOGICAL|BM32|Subcutaneous injection of 20 micrograms of each of the BM32 components adsorbed on 0.6 mg of aluminum hydroxide every 4 weeks for a total of 3 injections
224175148|NCT01445002|BIOLOGICAL|BM32|Subcutaneous injection of 40 micrograms of each of the BM32 components adsorbed on 1.2 mg of aluminum hydroxide every 4 weeks until a total of 3 injections
224175149|NCT01445002|BIOLOGICAL|Placebo|Subcutaneous injection of 1.2 mg of aluminum hydroxide suspension every 4 weeks until 3 injections
224175150|NCT04340804|BEHAVIORAL|Kcal labelling|Real-time kcal counter synchronised with the food amount changes
224175151|NCT04340804|BEHAVIORAL|PACE labelling|Real-time PACE counter (as minutes needed to walk to burn off the calories) synchronised to the food amount changes
224175152|NCT03860181|PROCEDURE|Subcuticular Sutures - Surgeon 1|This intervention closes incisions after shoulder arthroplasty using subcuticular sutures with Dermabond.The deep layer closure will require interrupted sutures.
224175153|NCT03860181|PROCEDURE|Metal Staples - Surgeon 2|This intervention closes incisions after shoulder arthroplasty with metal staples. The deep layer closure will require interrupted sutures,
224175154|NCT03860181|DEVICE|PRINEO - Surgeon 1|The closure system uses the Dermabond PRINEO (which is similar to clear tape stuck over the wound) placed over running sutures for both the deep and subcuticular layer.
224175155|NCT03860181|DEVICE|PRINEO - Surgeon 2|The closure system uses the Dermabond PRINEO (which is similar to clear tape stuck over the wound) placed over running sutures for both the deep and subcuticular layer.
224175156|NCT05944861|OTHER|Combined ultrasonography and flouroscopy guided injeciton|In the ultrasound+fluoroscopy group, the sacroiliac injection will be started under ultrasound guidance. With the help of ultrasound, when sacral 2 foramen is seen the needle will be advanced to the entrance of the sacroiliac joint under real-time in-plane view. After considering intra-articular placement, fluoroscopy guidance will be initiated. An anteroposterior image will be taken to confirm whether contrast material is within the joint. If intra-articular placement is not achieved after contrast medium infiltration, needle reposition will be performed under fluoroscopy for correct needle placement. After the intraarticular contrast pattern is seen, 1 ml of 40 mg methylprednisolone + 1 ml of 1% lidocaine mixture will be injected.
224175157|NCT05944861|OTHER|Flouroscopy guided injection|In the fluoroscopy group, the advancement of the needle into the sacroiliac joint will be performed by taking anteroposterior and lateral views. In the same way, the needle tip will be placed in the inferior of the sacroiliac joint, and contrast material distribution examination and injection of the drug will be performed as in the ultrasound + fluoroscopy group.
224175158|NCT05791487|OTHER|Ulcerative colitis Exclusion Diet|a limited whole food diet (UCED)
224175159|NCT05791487|OTHER|Partial enteral nutrition (PEN)|"The diet will be supplemented by 3 glasses a day (750 ml) of the formula developed for UC using the UCED principles."
224306397|NCT05706194|DIAGNOSTIC_TEST|Early neurological prognostication with biomarkers, EEG and CT|Biomarker samples collected at 12, 24, 48 and 72 h after randomisation, CT and EEG performed as early as possible after 24 h post randomisation in patients still unconscious (defined as not awake and able to follow verbal commands)
224306398|NCT06455436|DEVICE|Standard healing abutment|Participants will undergo a surgery to place an immediate klockner dental implant and will be receive a standard healing abutment
223745253|NCT07015281|OTHER|Therapeutic Exercise|These participants (n=50) will engage in an exercise protocol with aerobic, isometric, resistence, strength, and stretching exercises. Participants will perform these exercises with a frequency of 3 times a week for 6 weeks, with each session lasting 30 minutes.
224175160|NCT05791487|OTHER|free diet|oral Budeosnide for 6 weeks + free diet
224175161|NCT05791487|DRUG|Oral Budesonide|Oral Budesonide 9 mg
224175162|NCT05466591|DIAGNOSTIC_TEST|Pre-hospital rule-out strategy|Point-of-care troponin measurement for pre-hospital rule-out of acute coronary syndrome
223745254|NCT03084081|DEVICE|CO2 standard therapy|Standard therapy using carbon dioxide for freezing of tissue
224175163|NCT00404326|DRUG|Hydralazine and magnesium valproate|
223485794|NCT05322343|OTHER|Fasting blood sampling.|"In the morning, during the V2 visit by a nurse at the participant's home. Blood collection will include 8 blood tubes (volume approx.. 35.5 mL), plus 2 additional tubes for 500 participants accepting MRI, for a total volume of blood drawn of 41.5 mL for these participants. For the immunological substudy, a second sample will be taken at a distance (after 4 weeks) for 150 volunteer participants meeting the criteria.~The blood collection is repeated at V8 during the follow-up phase (21 mL)."
223485795|NCT05322343|OTHER|Saliva collection and nasal or nasopharyngeal swab|On the day of the V2 visit, the nurse will collect a volume of saliva that has flowed spontaneously for 5 min in a sterile 40-mL polypropylene tube, and a nasal or nasopharyngeal swab using a specific kit.
223485796|NCT05322343|OTHER|Urine and stool samples|During the V2 visit, the nurse will collect urine and stool samples collected by the participant in the week preceding the appointment, using the equipment provided and kept in the refrigerator. Stool sampling os repeated at V8 during the follow-up phase.
223485797|NCT05322343|OTHER|Hair and a tonenail (or hand nail) sampling|During the V2 visit, the nurse will collect some hair and a toenail sample from the participant, in a dedicated envelope. The hair collection is repeated at V8 during the follow-up phase.
223485798|NCT05322343|OTHER|Nasal microbiota|Nasal or nasopharyngeal swab
223485799|NCT05322343|OTHER|Measurements|"In addition to the samples, anthropometric measurements (weight, height,ead, waist, hip, calf and arm circumferences, subjective evaluation of body shape trajectories over the lifecourse), blood pressure, orthostatic hypotension, walking speed, grip strength, and hearing screening of sarcopenia and Parkinson's syndromes will also be collected by the nurse on the day of the V2 visit. Some of these measures (blood pressure, grip strength, screening of sarcopenia and Parkinson's syndromes) are repeated at V8 during the follow-up visit.~Analyses may be performed on the biobank samples. These analyses will include metabolite assays (Metabolon®), and may include genotyping for research purposes (without searching for specific genes."
223745255|NCT03084081|DEVICE|CryoPen|Provides a means of freezing tissue without the use of gases or liquids
223745256|NCT03084081|DEVICE|Thermocoagulator|Thermoablation
223745257|NCT03313804|DRUG|Immune checkpoint inhibitor|Standard of care immune checkpoint inhibitor
223745258|NCT03313804|RADIATION|Radiation Therapy|Stereotactic Body Radiation Therapy OR Fractionated radiation therapy
223745259|NCT03795298|DEVICE|WATCHMAN FLX Implant|Left atrial appendage closure with the WATCHMAN FLX device
223745260|NCT03795298|DRUG|Market-approved OAC|Used per IFU for atrial fibrillation stroke prevention for the duration of the trial.
224306399|NCT06455436|DEVICE|Individualized healing abutment|Participants will undergo a surgery to place an immediate klockner dental implant and will be receive an individualized healing abutment
223485800|NCT05322343|OTHER|Neuroimaging|"A multi-sequence MRI will be performed at the V3 visit. None of the sequences used will require contrast injection. The MRI sequences used will be: a 3D MPRAGE T1-weighted sequence, a T2-weighted sequence (FLAIR), a diffusion EPI sequence, a magnetization transfer sequence, and a resting state functional MRI BOLD sequence. The total duration of the MRI examination will be approximately 50 minutes.~The MRI will be performed at the Bioimaging Institute on an imager dedicated to research activities (3T Prisma Siemens).During V3 visit, a measurement of skin autofluorescence of advanced glycation products will also be performed"
223485801|NCT05322343|OTHER|Medical visit|For the participants with cognitive disorders (evaluated by the neuropsychologist during the V1 visit) or Parkinson's syndrome (evaluated by the nurse during the V2 visit),a complementary visit by a neurologist may be proposed in order to specify the etiology of these disorders and to establish a possible diagnosis and etiology.
223745261|NCT07020494|DIETARY_SUPPLEMENT|Lipase Thera-blend|Participants will be instructed to consume take one capsule three times a day with food for the duration of the study period.
223745262|NCT07020494|DIETARY_SUPPLEMENT|Lipase Thera-blend + tributyrin|Participants will be instructed to consume take one capsule three times a day with food for the duration of the study period.
223745263|NCT07020494|OTHER|Placebo|Participants will be instructed to consume take one capsule three times a day with food for the duration of the study period.
223745264|NCT01252940|DRUG|FTC/RPV/TDF|Emtricitabine (FTC) 200 mg/rilpivirine (RPV) 25 mg/tenofovir disoproxil fumarate (tenofovir DF; TDF) 300 mg single-tablet regimen (STR) administered orally with a meal once daily (QD)
223745265|NCT01252940|DRUG|PI|Protease inhibitors (PIs) included amprenavir, atazanavir, darunavir, fosamprenavir, Kaletra (lopinavir/ritonavir, coformulated), ritonavir, and saquinavir. PIs were administered according to prescribing information.
224175164|NCT00404326|PROCEDURE|Punch biopsy of the primary tumor|
223745266|NCT01252940|DRUG|RTV|Ritonavir (RTV) was administered according to prescribing information.
223745267|NCT01252940|DRUG|NRTIs|NRTIs included abacavir, emtricitabine, Combivir (lamivudine/zidovudine, coformulated), Epzicom (abacavir/lamivudine, coformulated), lamivudine, stavudine, tenofovir DF, Truvada® (emtricitabine/tenofovir DF, coformulated), and zidovudine. NRTIs were administered according to prescribing information.
223745268|NCT05864846|DRUG|Cannabidiol Oral Solution [Epidiolex]|100 mg/ml Cannabidiol Oral solution
223745269|NCT06629259|DRUG|Guanfacine Extended Release (XR)|3mg tablet once daily
224175165|NCT01753843|PROCEDURE|early cord clamping|early ( \<20 seconds)
224175166|NCT01753843|PROCEDURE|Brief Delay in cord clamping|delay in cord clamping 30 to 60 seconds
223745270|NCT06629259|DRUG|Placebo|placebo tablet once daily
224175167|NCT00006242|DRUG|BMS-214662|Given IV
224175168|NCT00006242|OTHER|laboratory biomarker analysis|Correlative studies
224175169|NCT00006242|OTHER|pharmacological study|Correlative studies
224175170|NCT00632372|DEVICE|Cardiac Resynchronization Therapy|Pacing of the left ventricle to resynchronize ventricular contraction.
224175171|NCT00632372|DEVICE|HeartPOD™ System|Left atrial pressure monitoring.
224175172|NCT00026819|DRUG|Rofecoxib|
224306400|NCT00361114|DRUG|sulphadoxine/pyrimethamine|Sulfadoxine/pyremethamine (SP) given as a single dose per manufacturers recommendation (tablets 500mg sulphadoxine and 15mg pyremethamine; child's body weight 5-10Kgs ½ tablet, 11-20Kgs 1 tablet, 21-30 Kgs 1 ½ tablets)
223745271|NCT07022730|DRUG|Noradrenaline 0.2 mcg/kg/min at 5 minutes before induction|noradrenaline will be given at a rate of 0.2 mcg/kg/min that will start 5 minutes before induction
224175173|NCT00074789|BEHAVIORAL|Modified Interpersonal Therapy|Psychiatric mental health nurses will meet with participants 10 times, an hour each time, over a period of 14 weeks. The nurses will continue to work with the mothers over the next 8 weeks by phone, conducting 5 fifteen minute phone sessions.
224175174|NCT00074789|BEHAVIORAL|Attention control/usual care|Participants will receive the usual care for depression.
224175175|NCT04810429|DRUG|Incobotulinumoxin A|"XEOMIN® (incobotulinumtoxinA) is an approved medication that inhibits the release of acetylcholine and muscle blockage. Xeomin is indicated for the symptomatic treatment of blepharospasm and hemifacial spasm, cervical dystonia of a predominantly rotational type (spasmodic torticollis), spasticity of the upper limbs and chronic sialorrhea due to neurological changes. Xeomin comes as a white powder for solution for injection. When dissolved Xeomin is a clear, colorless solution that does not contain particles. Xeomin is reconstituted before use with sterile sodium chloride 9 mg / ml (0.9%) solution, without preservatives, for injections.~The active substance is Clostridium botulinum type A neurotoxin (150 kD), without complexing proteins. The other components are human albumin and sucrose."
224175176|NCT04810429|PROCEDURE|TMJ surgical arthroscopy|TMJ arthroscopy is a minimal invasive surgical technique for different types of temporomandibular joint (TMJ) internal derangements. Besides the acceptable outcomes of TMJ arthroscopy, the authors believe that adding to this treatment a single injection of BTXA into the temporalis and masseter muscles could reduce joint loading, improving TMJ arthroscopic results.
223485802|NCT03282097|BEHAVIORAL|DECAD decision aid|A mammography decision aid directed toward family caregivers of older women with Alzheimer's disease and other dementias to assist with decisions about breast cancer screening.
223485803|NCT03282097|OTHER|Home safety guide|The home safety guide to provide tips about important actions older adults can take to prevent falls, poisoning, and bathroom hazards and protection against abuse, fire and other related hazards.
223745272|NCT07021482|DIAGNOSTIC_TEST|10 mmHg Pneumoperitoneum|Laparoscopic cholecystectomy will be performed with intra-abdominal pressure maintained at 10 mmHg during insufflation. Standard anesthesia and surgical protocols will be followed.
223745273|NCT07021482|DIAGNOSTIC_TEST|14 mmHg Pneumoperitoneum|Laparoscopic cholecystectomy will be performed with intra-abdominal pressure maintained at 14 mmHg during insufflation. Standard anesthesia and surgical protocols will be followed.
224175177|NCT00517673|DRUG|GSK945237|
224175178|NCT00517673|DRUG|Sugar Pill|Placebo
224175179|NCT04647708|DRUG|M5049|Participants will receive low oral dose of M5049, twice daily in Part A.
224175180|NCT04647708|DRUG|M5049|Participants will receive ascending oral dose of M5049, twice daily in Part A.
224175181|NCT04647708|DRUG|M5049|Participants will receive high oral dose of M5049, twice daily in Part B.
224175182|NCT04647708|DRUG|Placebo|Participants will receive placebo matched to M5049.
224175183|NCT05874700|DRUG|Sivelestat sodium was given intravenously|Anesthesia induction began with a 0.2mg/Kg/h pump test drug until 48 hours after endotracheal intubation was removed or up to 7 days. If the patient was judged to have successfully removed the endotracheal tube, drug administration was discontinued; If the endotracheal intubation was not removed successfully up to 7 days, drug administration was also discontinued. During CPB, 0.1mg/100mL of the experimental drug was injected into the circulating pump immediately after CPB began.
224175184|NCT05874700|DRUG|Placebo was given intravenously|Anesthesia induction began with a 0.2mg/Kg/h pump test drug until 48 hours after endotracheal intubation was removed or up to 7 days. If the patient was judged to have successfully removed the endotracheal tube, drug administration was discontinued; If the endotracheal intubation was not removed successfully up to 7 days, drug administration was also discontinued. During CPB, 0.1mg/100mL of the experimental drug was injected into the circulating pump immediately after CPB began.
224175185|NCT04060589|OTHER|Tissue donation|Biopsies will be performed as part of standard of care, additional cores will be performed for research. Access to standard of care prostate biopsy tissue will also be requested after standard of care reporting is complete.
224175186|NCT04060589|OTHER|Blood Donation|Phlebotomy will be performed prior to tissue collection following trust standard operating procedures or drawn when cannula already in situ in preparation for the prostate biopsy.
223485804|NCT02226159|DRUG|Lidocaine|
223485805|NCT02226159|DRUG|Lidocaine with Dexamethasone|
223745274|NCT05828979|DEVICE|UroMems artificial urinary sphincter|Implantation of the device
223745275|NCT00605982|PROCEDURE|MRI|The patient will then undergo a breast MRI as part of their preoperative work-up of DCIS. Biopsy of any suspicious areas by needle biopsy or at the time of surgery. If appropriate, repeat MRI after biopsy or surgery. Follow-up for 10 years (you will be contacted once a year to see how you are doing).
223745276|NCT05230693|BEHAVIORAL|Sarcoidosis Patient Assessment and Resource Companion App|"The first group, called the SPARC group will be asked to download the SPARC app onto the participant's smartphone, will be shown how to use the app, and then will be asked to use the app to do guided meditations for ten minutes twice a day"
223485806|NCT02120326|DEVICE|Transcranial direct current stimulation of the motor cortex|"The area of stimulation is determined by by EEG system 10/20. The two electrodes are soaked in saline and then placed on the scalp.~Stimulation parameters:~* 2 mA intensity~* Continuous stimulation for 20 min with rise times and fall times of 10 seconds each"
223485807|NCT02120326|DEVICE|simulation of Transcranial direct current stimulation of the motor cortex|"The area of stimulation is determined by by EEG system 10/20. The two electrodes are soaked in saline and then placed on the scalp.~Stimulation parameters:~* The intensity of the stimulation current is 2 mA~* The current is applied during the first 30 seconds with rise times and fall times of 10 seconds each. Then the session will be continued without actual stimulation."
224175187|NCT04060589|OTHER|Urine Donation|Urine will be collected prior to prostate biopsy
224175188|NCT04060589|OTHER|Healthcare data linkage|Men will consent to healthcare data linkage via national databases.
224175189|NCT01709240|DEVICE|BioWeld1 System|External skin layer closure of C-section incision by the BioWeld1 system. Removal of Chitoplast on day 4-7 post procedure.
224306401|NCT00361114|DRUG|Chlorproguanil/dapsone|Chlorproguanil/ dapsone (CD) given daily for 3 days per manufacturers recommendations (tablets chlorproguanil 15mg/ dapsone 18.75 mg; 5-7.9Kgs 1 tablet, 8-11.9 Kg 1 ½ tablets, 12-15.9 2 tablets, 16-20.9 Kgs 2 ½ tablets, 21- 40Kg 5 tablets).
224175190|NCT00925522|DEVICE|Therapy Cool Path Duo Cardiac Ablation System|"Cardiac Ablation Procedure for Ischemic VT using a flexible, insulated 7F all braided catheter that contains an internal lumen connected to 12 open conduits at the 4mm tip electrode for infusion of heparinized saline during radiofrequency ablation; records intracardiac electrograms and can be utilized for cardiac simulation during diagnostic electrophysiologic studies/evaluation.~1500T9-VT generator is a microprocessor-controlled device that produces a continuous unmodulated radiofrequency (RF) output of 485 kHz. The Generator will be used in Temperature Control mode only. The catheter delivers the RF power from the generator in a monopolar mode between its distal electrode (tip electrode) and a large indifferent electrode."
224175191|NCT01116726|BEHAVIORAL|Motivational interviewing|MI sessions will involve home visits concentrating on the mitigation of behavioral risk factors for early childhood caries. These will take place shortly after childbirth and at months 6, 12, and 18.
224175192|NCT01116726|BEHAVIORAL|Enhanced community services|Enhanced community services will involve the development of culturally appropriate messages related to the mitigation of behavioral risk factors for early childhood caries through public service announcements and brochures.
224175193|NCT03102164|PROCEDURE|cardiac rehabilitation|The rehabilitation protocol comprises respiratory, assisted, active dynamic, and relaxation exercises, as well as short-term isometric exercises and general strength exercises of very low intensity, short duration and properly adjusted recovery phase; they are conducted in a lying, sitting, or standing position.
224175194|NCT02561572|OTHER|Acupuncture|Yintang point acupuncture
224175195|NCT00795717|DRUG|Lovaza|Lovaza at a dose of 4g per day with each 1g capsule containing approximately 465 mg of eicosapentaenoic acid (EPA) and 375 docosahexaenoic acid (DHA) for 12 weeks.
224175196|NCT00795717|DRUG|Placebo|2 capsules given twice daily
224175197|NCT00211692|DRUG|consensus interferon (Interferon Alfacon-1) and ribavirin|CIFN (15 mcg/day SQ) and RBV (1-1.2 g/d PO) given for either 52 weeks (group A, n = 33) or 52-72 weeks (from time of viral response +48 weeks) (group B)
224175198|NCT00211692|DRUG|Consensus Interferon alfa (CIFN) and ribavirin|CIFN (15 mcg/day SQ) and RBV (1-1.2 g/d PO) given for either 52 weeks (group A, n = 33) or 52-72 weeks (from time of viral response +48 weeks) (group B)
224175199|NCT04108598|OTHER|Quality of life questionnaire|No intervention will be administered, select sites will administer a quality of life questionnaire
224175200|NCT05228704|BEHAVIORAL|activities in the Botanical Garden or in urban|activities in the Taipei Botanical Garden or in Urban
223485808|NCT01732211|BIOLOGICAL|PD 0360324|100 mg Q2W or 150 mg Q2W via intravenous infusion based on protocol determined dose escalation/de-escalation criteria; 12 weeks Active Therapy;
223485809|NCT01732211|OTHER|Normal Saline for injection|normal saline Q2W via intravenous infusion for 12 weeks
223485810|NCT06050993|OTHER|Additional blood sampling at the same time and in addition of samplings already done for the patient's standard of care.|During the preoperative procedure scheduled at the Paul Brousse hospital, 3 additional blood tubes (total volume 12 ml) will be withdrawn in addition of samplings already done for the patient's standard of care.
223485811|NCT05753800|DEVICE|INTORUS|Motor intervention protocol with Intorus consisting of a series of exercises of progressive difficulty
224175201|NCT02481323|DRUG|isosorbide mononitrate|slow release nitric oxide donor that enhances vasodilation and widely used in angina prophyaxis
224306402|NCT00361114|DRUG|Sulfadoxine/pyrimethamine|Sulfadoxine/pyremethamine (SP) given as a single dose per manufacturers recommendation (tablets 500mg sulphadoxine and 15mg pyremethamine; child's body weight 5-10Kgs ½ tablet, 11-20Kgs 1 tablet, 21-30 Kgs 1 ½ tablets)
224306403|NCT01207505|BEHAVIORAL|Enhancing Emotion Regulation|12 week of group therapy 3 modules: 1) mindfulness, 2) emotion regulation, 3)distress tolerance
224306404|NCT00907127|BEHAVIORAL|Exercise and Diet (Metabolic Fitness Program)|6 month program of diet and exercise training and support.
223485812|NCT06001021|DRUG|Psychopharmacological Intervention|Escitalopram 5-10 mg in antenatal period; Sertraline 12.5-25 mg in postnatal period) and/or Benzodiazepine (Alprazolam, 0.25-0.50 mg).
223485813|NCT06001021|BEHAVIORAL|Cognitive Behavioral Couple Therapy|CBCT intervention from a trained psychologist in CBT.
223485814|NCT06001021|OTHER|Combination of Psychopharmacological Intervention and CBCT|Medication will be prescribed by a consultant gynecologist and CBCT (conditions: with or without Zikr) will be provided by a trained psychologist.
223485815|NCT06001021|OTHER|Placebo and No Intervention|Control waitlist group will be provided with either a placebo by a consultant gynaecologist or no intervention by a trained psychologist
223485816|NCT05404100|PROCEDURE|Aortic valve replacement|SAVR or TAVR
223485817|NCT00363740|DRUG|GW685698X Aqueous Nasal Spray|
223485818|NCT06019078|DEVICE|SedLine|Continuous 4 channel processed neurological monitor
223485819|NCT00758888|PROCEDURE|Orthopedic Blocking|Place the blocks under the pelvis for 2 minutes
223485820|NCT00758888|PROCEDURE|Trochanter Belt|Participant is fitted with trochanter belt on the adjusting table and wear it while Investigator checks their flexion and extension strength.
223485821|NCT00758888|OTHER|Blocking Sham|Participant lies on adjusting table, blocks are placed in a similar configuration but distant to actual points of leverage.
223485822|NCT00512434|PROCEDURE|Osteosynthesis|Nail or external fixator Intervention 'Osteosynthesis'
223485823|NCT02926014|DEVICE|Videolaryngoscopy|A rigid 70 degree laryngoscope is inserted into the subject's oropharynx, which allows to visualize the lingual tonsils. The size of the lingual tonsils is evaluated using DelGaudio and Friedman grading systems.
223745277|NCT05230693|BEHAVIORAL|Enhanced Standard Care|Participants will receive education about reducing fatigue associated with sarcoidosis during a normal clinic visit.
223745278|NCT07024784|DRUG|IMGN151|Intravenous (IV) infusion
223745279|NCT07024784|DRUG|Carboplatin|Intravenous (IV) infusion
224175202|NCT02481323|DRUG|cilostazol|phosphodiesterase 3-inhibitor that enhances vessel wall function with weak antiplatelet effects
224306405|NCT02304991|DRUG|Liquid Peanut Extract|5000mcg/ml peanut protein
224306406|NCT02304991|DRUG|Placebo Glycerin SLIT|pure glycerinated saline solution with caramel coloring to match color
224306407|NCT01157780|DRUG|Lovaza (fish oil)|Patients will receive fish supplementation of 1 g/kg/day with a maximum dose of 4 g/day for a 12 week period.
224175203|NCT07050771|OTHER|Comprehensive multimodal prehabilitation (CMMP)|Components of the CMMP intervention (which will be administered for at least 3 weeks from study registration to the Preoperative Reassessment) will include: 1) Motivational interviewing: 2 sessions, 10-15 minutes each. 2) Nutritional prehabilitation (a supplement containing 18-22g high quality protein consumed 2 times/day, 7 days/week). 3) Inspiratory muscle training using a hand-held inspiratory muscle device, 5 minutes of respiratory muscle training twice/day, 5 days per week. 4) Physical prehabilitation a) aerobic exercise (20 minutes of moderate-intensity exercise at least 3 days/week) and b) strength resistance training using resistance bands (3 sets of 10 repetitions at moderate intensity at least 3 days/week).
224175204|NCT07050056|DRUG|Tislelizumab|200mg, iv, Q3W, 3-4 cycle
224175205|NCT07050056|RADIATION|3D-CRT/IMRT|40Gy in 20 fractions
224175206|NCT07058220|OTHER|Cervical proprioceptive training|Study group will receive proprioceptive training through use of a laser pointer in a similar way to the testing. From sitting position, patients were asked to flex, extend and rotate their head and then return to the neutral position . This training was commenced with open eyes. Each direction was repeated 8 times for two sets, 30 seconds rest between sets. Progression of exercise was achieved by closing eyes, and altering the duration (trace shapes for 5 minutes and progress by increasing 2-3 minutes weekly as tolerated), repetitions (2-3 repetitions weekly), sets (1 set weekly) and the degree of difficulty of the task (different shapes and positions as standing and walking)
224175207|NCT07058220|OTHER|Advices|Patients of control group were allowed to stay active, avoid poor cervical ergonomics (poor sleeping habits, improper use of mobile/telephone),hot/cold packs, some range of motion exercises, and local medicines as prescribed by their general practitioner.
224175208|NCT07058389|OTHER|8-week outdoor physical activity program|"EXT group will perform aerobic and resistance exercises with a coach in adapted physical activities on a green environment in a parc.~Sessions will be typically composed as follows:~* Warm-up (20 min)~* Aerobic exercise (30 min) at RPE 4 to 7 on the Borg scale~* Muscular strengthening (25 min) at RPE 4 to 7 on the Borg scale~* Cool-down, stretching and balance (15 min) EXR group will train for 8 weeks, twice a week for 1h30, following WHO recommendation."
224175209|NCT07058389|OTHER|8-week indoor physical activity program|"INT group will perform aerobic and resistance exercises with a coach in adapted physical activities, inside a conventional gym.~Sessions will be typically composed as follows:~* Warm-up (20 min)~* Aerobic exercise (30 min) at RPE 4 to 7 on the Borg scale~* Muscular strengthening (25 min) at RPE 4 to 7 on the Borg scale~* Cool-down, stretching and balance (15 min) INT group will train for 8 weeks, twice a week for 1h30, following WHO recommendation."
224175210|NCT07057804|DIAGNOSTIC_TEST|Lung Ultrasound|Ultrasound was performed at the bedside with the patient in a semi-recumbent position using a 3.5-5 MHz curvilinear probe. Lung ultrasound was conducted across 12 zones (anterior and posterior) to evaluate aeration and calculate the lung ultrasound score (LUS).
224175211|NCT07057804|DIAGNOSTIC_TEST|Diaphragm Ultrasound|Ultrasound was performed at the bedside with the patient in a semi-recumbent position using a 3.5-5 MHz curvilinear probe. Diaphragmatic excursion and thickening fraction were measured on the right hemidiaphragm.
224175212|NCT07058480|BEHAVIORAL|Combined MET and MFC-Based Pelvic Stabilization Training|This intervention consisted of a combination of Muscle Energy Technique (MET) for iliac and sacral dysfunctions (20 minutes per session) and myofascial chain-based pelvic stabilization training (including curl-ups, planks, and anti-rotation exercises; 30 minutes per session), targeting pelvic alignment and neuromuscular control. Sessions were conducted 3 times per week, 50 minutes per session, for 4 consecutive weeks.
224175213|NCT07058480|DEVICE|Interferential current therapy (ICT)|Interferential current therapy (ICT) was applied to the lumbar (lower back), sacroiliac, and iliac crest regions, 3 sessions per week, 20 minutes per session, for 4 weeks.
224175214|NCT07058480|BEHAVIORAL|Deep Friction Massage (DFM)|Deep friction massage was administered to the lumbar, sacroiliac, and iliac crest regions for 30 minutes per session, 3 sessions per week, for 4 weeks.
224175215|NCT06843018|DRUG|Grammidin with anesthetic|Grammidin with anesthetic, a metered dose topical spray
224175216|NCT06843018|DRUG|Septolete Total|Septolete Total, lozenges 3 mg + 1 mg
224175217|NCT04626050|BEHAVIORAL|Medical Music|Participants randomized to this condition will complete 4 medical music sessions over the course of 2 weeks
224175218|NCT04626050|BEHAVIORAL|Narrative Writing|Participants randomized to this condition will complete 4 narrative writing sessions over the course of 2 weeks
224175219|NCT04626050|BEHAVIORAL|Prolonged Exposure Therapy|Psychotherapy including imaginal exposure for PTSD
224175220|NCT04626050|BEHAVIORAL|Interpersonal Psychotherapy|Psychotherapy that focuses on the effects of PTSD on current interpersonal functioning
224175221|NCT06287749|BIOLOGICAL|Blood sample/Liquid Biopsy|ctDNA analysis
224175222|NCT03786276|BEHAVIORAL|VR-WMR-Only|Participants will spend up to 30 minutes in a VR-WMR environment during each training session.
224175223|NCT03786276|BEHAVIORAL|Exercise-only|Participants will ride a stationary recumbent bicycle for up to 30 minutes during each training session.
223485824|NCT02926014|OTHER|Reflux Symptom Index Questionnaire|A validated clinical tool for suspecting laryngopharyngeal reflux (LPR). The questionnaire was proposed by Belafsky et al. (2002) and consists of 9 most common gastroesophageal reflux disease (GERD) and LPR symptoms: hoarseness or a problem with your voice; clearing your throat; excess throat mucus or postnasal drip; difficulty swallowing food, liquids, or pills; coughing after you ate or after lying down; breathing difficulties or choking episodes; troublesome or annoying cough; sensation of something sticking in your throat or a lump in your throat; heartburn, chest pain, indigestion, or stomach acid coming up. Each symptom is evaluated on a scale from 0 to 5 (0 - no complaint, 5 - severe symptom). The sum of all symptom evaluations ranges from 0 to 45.
223586477|NCT06980857|OTHER|ERAS Group|In our study, this group of patients were informed about the surgical procedure to be performed by the orthopedist; detailed information about the postoperative rehabilitation process, prevention of possible complications, preoperative nutrition, smoking and alcohol cessation time will be given. The patient will stop eating solid food 6 hours before the operation and stop drinking fluids 2 hours before the operation. Necessary consultations will be completed before surgery. Preoperative preparation of the patient will be organized according to the ERAS protocol. The patient will be mobilized early, either in bed or in the room, within 6-7 hours after surgery. The exercises of the first group will be continued from the first postoperative day.
223745280|NCT07024784|DRUG|Bevacizumab|Intravenous (IV) infusion
223745281|NCT07024784|DRUG|Olaparib|Oral Tablet
224175224|NCT03786276|BEHAVIORAL|Active VR-WMR|Participants will spend up to 30 minutes in a VR-WMR environment while riding a stationary, recumbent bicycle during each training session.
224175225|NCT01657227|BEHAVIORAL|Intervention to patients|"Multifaceted intervention consisting of:~* Program of education and behavior modification: group sessions conducted by health educators for the patient and a relative (who usually do the food shopping or prepare meals) every 3 months over 2 years (total:8 sessions). Main contents: diabetes, hygiene/nutrition and physical exercise.~* Monitoring of patient conditions by Informational Communication Technologies (ICT): patient will complete at home a web-based short questionnaire once a week and an expanded version once a month.~* Short text messaging to patient's mobile based on information obtained from self-reported questionnaires. 3 types of messages: 1) Reminders for completing web-based questionnaires, the attendance at group sessions and the follow-up appointments, 2) General advice on good habits, 3) Custom messages to reinforce behavior change."
224205509|NCT01561586|DRUG|Weekly cisplatin with RT|"Cisplatin 40mg/m2 IV Weekly For 6 Cycles.(The 6th cycle of cisplatin may be omitted if external beam radiation therapy has been completed) Cisplatin may be diluted and administered per established institutional guidelines. For general suggestion, 40 mg/ m2 of cisplatin may be diluted in 250 ml 0.9% sodium chloride and administered over one or two hours.~Cisplatin will be given on the first day of external RT (Day 1), preferably, and must be given prior to radiation treatment on that day~External beam RT will be followed by intracavitary brachytherapy. The total elapsed time for completion of external beam to the whole pelvis, intracavitary BT, and parametrial / nodal RT shall not exceed eight weeks (56 days)"
223485825|NCT02926014|OTHER|Dysphagia Screening Questionnaire|"A validated questionnaire, proposed by Ohkuma et al. (2002). Lithuanian version of the questionnaire consists of 16 questions: choking during swallowing meals / liquids; difficulty eating solid foods; difficult swallowing; feeling of food getting stuck in the throat; longer than before eating time; feeling of food remaining in the mouth; feeling that food or liquid is going up into the throat from the stomach; feeling of food being stuck in the esophagus; weight loss; food getting stuck in the throat; food falling from the mouth; difficulty coughing during or after meals; occurrence of pneumonia; hoarseness; coughing during the night. Interpretation of dysphagia screening questionnaire:~Advanced symptom - 2 points; Moderate intensity symptom - 1 point; No symptom - 0 point. At least one advanced symptom means - dysphagia. Higher score represents stronger dysphagia intensity. The maximum score is 32 points."
223485826|NCT01938326|PROCEDURE|Approach Method|SIDG : 1 incision (umbilicus 2.5cm) TLDG : 5 incisions (12mm ports X 3, 5mm ports X 2, umbilicus extension up to 3cm for specimen delivery)
223485827|NCT03515746|DEVICE|Exergaming in virtual environment|"The 10 cubes task will be performed in virtual environment - either in 2D on a laptop computer or in 3D using 3D goggles"
224072354|NCT05432856|BEHAVIORAL|Time restricted eating, nutrition education, and sedentary time reduction strategies|"1. TRE: You will be asked to eating as much as you like but only within an 8-10 hour window and then do not eat, or fast by consuming only water, black coffee or tea without milk/sugar for a window of 16 hours per day. This protocol will be required for 5 or more days in a row each week.~2. Nutrition education and individualized recommendations: You will receive an assessment, and one-on-one education on healthy eating according to Canada's dietary guidelines, with individualized small goal each to improve your dietary habits.~3. Sedentary time reduction: Using the provided Fitbit wrist monitor, you will be asked to track and gradually increase your daily step counts, break up periods of inactivity, and try to incorporate ways to decrease sedentary behaviour in everyday life."
223586478|NCT06980857|OTHER|Multimodal physiotherapy group combined with ERAS protocol|In our study, this group of patients who were informed about the surgery by the orthopedist will be examined by the anesthesiologist 1 week before surgery. Patients whose anesthesia preparation is completed will participate in a training program about pain, prevention of postoperative complications, auxiliary devices/equipment and exercises to be used, accompanied by a physiotherapist and a nurse. At the end of the program, patients will be given a 1-week home exercise program prepared by the physiotherapist. NMES device will be connected to the quadriceps muscles for 20 minutes half an hour before surgery, immediately after surgery and every day during hospitalization. Postoperatively, the patient will be mobilized early within 6-7 hours and the knee will be placed in hyperextension position. From the 1st day onwards, the exercises of the first group will be continued.
223586479|NCT06979713|OTHER|yoga, pain education, yoga nidra|Participants will complete a series of yoga postures targeting the lower back combined with pain education. The session will conclude with either yoga nidra with pain acceptance intention. Interventions are completed at home 2x/week for 6 weeks.
223586480|NCT06979713|OTHER|yoga, pain education, relaxing music|Participants will complete a series of yoga postures targeting the lower back combined with pain education. The session will conclude with relaxing music depending on group assignment. Interventions are completed at home 2x/week for 6 weeks.
223485828|NCT01943604|OTHER|Nutella Breakfast|Breakfast composed of bread and Nutella, milk and apple slices
223485829|NCT01943604|OTHER|Waffle Breakfast|Breakfast composed of waffles and syrup, milk, and apple slices
223485830|NCT05389904|OTHER|Arm 1: Routine care|Patients colonized with toxigenic C. difficile, identified by testing routinely collected swabs for vancomycin-resistant enterococcus screening, will receive standard of care.
223485831|NCT05389904|OTHER|Arm 2: Preemptive C. difficile infection prevention bundle|Patients colonized with toxigenic C. difficile, identified by testing routinely collected swabs for vancomycin-resistant enterococcus screening, will receive a preemptive prevention bundle for C. difficile. The prevention bundle will include enhanced room cleaning, C. difficile precautions (staff entering room must wear gown and gloves and wash hands with soap and water upon exiting the room), pharmacist review and optimization of antibiotics and antacids, and consideration of vancomycin prophylaxis.
223485832|NCT01853865|OTHER|Instruction in self-referral|
223485833|NCT03913039|PROCEDURE|Transperineal biopsy Protocol|"1. Transperineal biopsy approach with avoidance of rectal flora~2. MRI-ultrasound fusion-guided biopsies with reduced number of biopsy cores, where clinically indicated~3. Rectal swab to identify the presence of fluoroquinolone resistant (FQR) bacteria~4. Multi-antibiotic prophylaxis~5. Urine culture, prostate tissue culture and rectal swab culture to define contemporary, region-specific antibiotic resistance patterns."
223485834|NCT04797169|BEHAVIORAL|Noom Health|In Noom Health, participants will be encouraged to use the Noom app multiple times a day to log eating episodes, physical activity and weight. They will also have the ability to interact with coaches to receive advice and feedback specific to weight loss.
224175226|NCT01657227|BEHAVIORAL|Intervention to professionals|"Multifaceted intervention consisting of:~* Educational intervention: Two theoretical and practical sessions to update knowledge on T2DM management and provide professionals with techniques to enhance the patient-centered clinical relationship model and the shared decision making model with the ultimate goal of improving patient adherence to treatment and self-care.~* Computer-based clinical decision support system (CDSS): Implementation of an automated tool combining evidence-based knowledge with patient-specific information to assist clinicians in making clinical decisions in the management of T2DM patients.~* Feedback: periodic mailing of personalized feedback reports with data on health results of all T2DM patients who are cared by the professional."
224175227|NCT01657227|OTHER|Usual care|Usual care for T2DM received in primary health care
224175228|NCT06692673|DRUG|Use of Linaclotide as a single agent Colonoscopy prep|We plan to conduct a pilot study to determine the feasibility of a quality bowel preparation with two 290mg doses of Linaclotide (first dose given 36 hours before, and the other 8 hours prior to the procedure) along with 2 Liters of Gatorade (to prevent dehydration) given the day prior to the colonoscopy instead of the current standard 4 liters of PEG regimen. All study participants will be asked to consume a clear liquid diet for 24hours before the procedure.
224175229|NCT01271049|OTHER|Novel Food Product|Novel food product containing essential oil blend
224175230|NCT01271049|OTHER|Control Food Product|Control food product
224175231|NCT00656799|DRUG|sugammadex|At 15 minutes after administration of rocuronium, an IV single bolus dose of 4.0 mg/kg sugammadex was administered.
224175232|NCT00656799|DRUG|Rocuronium|After achieving stable anesthesia an IV single bolus dose of 0.6 mg/kg rocuronium was administered
224175233|NCT07086222|BIOLOGICAL|NVX-CoV2705|NVX-CoV2705 vaccine in a 0.5 mL injection volume at an antigenic dose of 5 µg with 50 µg Matrix-M adjuvant
224175234|NCT07086222|BIOLOGICAL|Placebo|Placebo (normal saline) in a 0.5 mL injection volume.
224175235|NCT05954845|OTHER|biopsies|Biopsies will be obtained from the right and left colon (5 biopsies per colic region)
224175236|NCT05172973|DEVICE|SAPIEN X4 THV|Implantation of the SAPIEN X4 valve
224175237|NCT00468624|DRUG|pegvisomant/placebo loading dose 80mg sc, thereafter 20mg daily for 2 weeks|
224175238|NCT00468624|PROCEDURE|GH sampling - every 20 min over 24 hours after each limb (pegvisomant/placebo)|
223485835|NCT04797169|BEHAVIORAL|Noom Digital Health|In Noom Digital Health, participants will use a simplified version to log eating episodes and weight. Both conditions will receive the same weight loss advice content.
223485836|NCT05429320|PROCEDURE|Local ablative therapy|In part I, 33 patients with metastatic NSCLC with: a) NR-VAF but b) without radiographic progression of disease, will be treated with LAT. In Part II of the study, patients will be randomized to standard of care (continuation of systemic therapy) vs. LAT to all sites of disease
223485837|NCT05429320|OTHER|Blood collection to assess for ctDNA|Participants will undergo ctDNA collection in conjunction with their standard of care therapy.
223485838|NCT05631626|DRUG|CTx-1301 - Dexmethylphenidate 25mg|25mg CTx-1301 (Dexmethylphenidate tablet)
223485839|NCT05631626|DRUG|CTx-1301 - Dexmethylphenidate 37.5mg|37.5mg CTx-1301 (Dexmethylphenidate tablet)
223485840|NCT05631626|DRUG|CTx-1301 - Dexmethylphenidate 50mg|50mg CTx-1301 (Dexmethylphenidate tablet)
223485841|NCT05631626|DRUG|Placebo|Placebo
223485842|NCT04109924|DRUG|Irinotecan|Given IV
223485843|NCT04109924|BIOLOGICAL|Bevacizumab|Given IV
223485844|NCT04109924|DRUG|Trifluridine and Tipiracil Hydrochloride|Given PO
223485845|NCT03498261|DRUG|Gabapentin|Gabapentin has been commonly used as an adjuvant in the treatment of neuropathic pain.
223485846|NCT03498261|DRUG|Placebos|Placebo
223485847|NCT05473039|DIETARY_SUPPLEMENT|Seidivid Ferty4|The patient will start taking the study treatment (multivitamin supplement with probiotics) immediately after inclusion. Throughout the COH period of the protocol (usual mean duration: 11 days) the patient will continue taking the diatary supplement, without interruption until the day of the GnRH-agonist trigger.
223485848|NCT05473039|OTHER|Placebo|The patient will start taking the study treatment (placebo) immediately after inclusion. Throughout the COH period of the protocol (usual mean duration: 11 days) the patient will continue taking the treatment (placebo), without interruption until the day of the GnRH-agonist trigger.
223485849|NCT06450925|DRUG|Vitamin A|Enrolled subjects will receive one observed oral vitamin A dose, prior to their HSCT, in the outpatient clinic or inpatient Bone Marrow Transplant (BMT) floor.
223485850|NCT06450925|OTHER|Placebo|Placebo pills containing microcrystalline cellulose will be dispensed in patients who are randomized to the placebo arm.
223485851|NCT04921943|DRUG|Hypertonic saline|Nebulizing with 7% hypertonic saline twice daily for 12 weeks.
223485852|NCT04921943|DRUG|Azithromycin|Standard of care
223485853|NCT04921943|DRUG|Ethambutol|Standard of care
223485854|NCT04921943|DRUG|Rifampin|Standard of care
223485855|NCT06033846|DRUG|Minocycline|treatment with minocycline combined with first-line drugs for autoimmune encephalitis
223586481|NCT06981416|BEHAVIORAL|Digital education group|Digital training for home accidents and first aid based on the Theory of Planned Behavior (PBT) and the pre-test, post-test and follow-up results will be evaluated.
224175239|NCT00468624|PROCEDURE|blood sampling before and after pegvisomant/placebo|
224175240|NCT00468624|PROCEDURE|arginine stimulation test after each limb|
224175241|NCT05281094|BIOLOGICAL|HIL-214|2 injections - given on Day 1 and the second given between Day 29 - Day 57
224175242|NCT05281094|BIOLOGICAL|Placebo|2 injections - given on Day 1 and the second given between Day 29 - Day 57
224175243|NCT04936529|DIETARY_SUPPLEMENT|β-glucan|"Group 1 participants receive oral β-glucan (40 mg/kg/day) starting week 1 and continue with \~2 weeks on, \~2 weeks off, up to 1 cycle after vaccination #7, then 1 cycle with each subsequent vaccination (#8-#14). This schedule includes annual booster vaccinations, with a 2-week cycle of β-glucan, administered at months 36 (3 years), 48 (4 years), and 60 (5 years).~Group 2 participants receive oral β-glucan (40 mg/kg/day) starting week 1 and continue with \~2 weeks on, \~2 weeks off, up to 1 cycle after vaccination #7, then 1 cycle with each subsequent vaccination (#8-#14).~Group 3 participants will be treated as in Group 1."
224175244|NCT04936529|DRUG|GM-CSF|"Group 1 participants will not receive GM-CSF.~Group 2 participants will receive GM-CSF (250 mcg/m2/day) x3 days with vaccinations #1-#3; x7 days with vaccinations #4-#11; and x5 days with vaccinations #12-#14.~Group 3 participants will be treated as in Group 1."
224175245|NCT04936529|BIOLOGICAL|OPT-821|Vaccine injections must occur a minimum of 6 days apart. After the first four vaccine injections, vaccines can be administered up to two weeks earlier or later than indicated without representing a protocol violation.
224175246|NCT04581382|BIOLOGICAL|Nivolumab|Given IV
224175247|NCT04581382|BIOLOGICAL|Pembrolizumab|Given IV
224175248|NCT04581382|RADIATION|Radiation Therapy|Undergo radiation therapy
224175249|NCT04581382|BIOLOGICAL|Therapeutic Exchange Plasma|Undergo therapeutic plasma exchange
224175250|NCT04581382|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
224175251|NCT04581382|PROCEDURE|Computed Tomography|Undergo CT
224175252|NCT04581382|PROCEDURE|Positron Emission Tomography|Undergo PET
224175253|NCT04581382|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
224175254|NCT02710110|DEVICE|PowerLung trainer|PowerLung trainer will be utilized which has both an inspiratory and expiratory loading capacity for training. A single daily training session will consist of three sets of 10 repetitions for a total of 30 inspiratory repetitions and 30 expiratory repetitions (i.e. 60 repetitions) for 5 days a week, for 3 months.
224175255|NCT02710110|DEVICE|Micro Mouth Pressure Meter|The participant will be seated with the nose occluded using a nose clip. After inhaling to total lung capacity, the participant will place his or her lips around the mouthpiece and blow out as forcefully as possible. A flange rubber mouthpiece will be used to overcome the inability of some individuals to create tight lip seal due to facial muscle weakness. Three trials will be performed and the patients highest Maximum Inspiratory Pressures (MIP) and Maximal Expiratory Pressure (MEP) used.
224175256|NCT02710110|PROCEDURE|Pulmonary Function Testing|Pulmonary Function testing will be performed using conventional methods and will include the following outcomes: forced vital capacity (FVC), sniff nasal inspiratory pressure (SNIP), peak expiratory flow (PEF), forced expiratory volume (FEV1) expressed as a percentage of predicted values.
224175257|NCT02710110|PROCEDURE|Videofluoroscopic swallowing study|Videofluoroscopic swallowing study will be performed to measure the oropharyngeal swallowing.
223485856|NCT05963113|BEHAVIORAL|Pharyngeal Swallowing Exercises|12-weeks of proactive pharyngeal swallowing exercises conducted 5 times per week. The exercise program will include the following four exercises: effortful saliva swallows, tongue-hold swallows, effortful pitch glides and posterior lingual resistance. Each exercise set will include 10 repetitions of each exercise (40 reps per set). The number of sets will be gradually increased as tolerance builds.
223485857|NCT05963113|DIETARY_SUPPLEMENT|Protein Supplementation|12-week supply of the commercially-available Premier Protein Clear ® High Protein (20 grams of protein and 90 calories per 16.9 oz. drink). Participants will be asked to consume one drink per day for the 12-week intervention period.
223586482|NCT06981416|BEHAVIORAL|classical education group|"The training content prepared according to the Planned Behavior Theory will be given as classical training in the form of a flow chart."
224175258|NCT02710110|OTHER|Swallowing Quality of Life Questionnaire|Swallowing Quality of Life Questionnaire (SWAL-QOL) will be used for participant reporting of swallow-related quality of life.
223485858|NCT05963113|DEVICE|MRI|Participants will be scanned using a 3T MRI scanner and a 16-channel phased array neck coil.
224175259|NCT02710110|DEVICE|Iowa Oral Pressure Instrument|The IOPI is a device that measures the peak pressure performance of lingual strength and endurance via the action of a bulb placed on the hard palate.
224175260|NCT02710110|DRUG|Capsaicin|"A capsaicin challenge with three randomized blocks of 0, 50, 100, 200, and 500 μM capsaicin. The capsaicin will be dissolved in a vehicle solution consisting of 80% physiological saline, and 20% ethanol. Participants will be given the instruction cough if you need to prior to capsaicin delivery.The solution will be administered automatically upon detection of an inspired breath and there will be a minimum of one minute between each trial. This is to test the reflexive cough testing for upper airway sensitivity and motor thresholds."
224175261|NCT06912048|OTHER|Oral glucose tolerance test with double-tracer dilution and atropine infusion|Subjects will undergo a 75 g oGTT (180 min) combined with a double tracer dilution. The double-tracer dilution technique will be used to quantify endogenous glucose production, glucose appearance and disappearance rate. \[6,6-2H\]glucose will be infused for a total of 300 minutes, while the infusion will start 120 minutes prior the oGTT and will last until the end of the oGTT. Atropine infusion will be administered 20 minutes before the start of the oGTT. The drink consumed at time point 0 min contains 75 gram glucose, enriched with \[U-13C6\]-glucose.
223485859|NCT05092451|DRUG|Cyclophosphamide|Given by IV
223485860|NCT05092451|DRUG|CAR.70/IL15-transduced CB-NK cells|Given by IV
223485861|NCT05092451|DRUG|Fludarabine phosphate|Given by IV
223485862|NCT04919408|OTHER|telephone survey|telephone survey with a questionnaire to assess pain at 3 months and then 6 months after their cesarean section
223485863|NCT06850051|BIOLOGICAL|TIV-HA Vaccine formulation 1 at low dose|Suspension for injection in a vial. Route of administration: IM injection
223485864|NCT06850051|BIOLOGICAL|TIV-HA formulation 1 at high dose|Suspension for injection in a vial. Route of administration: IM injection
223485865|NCT06850051|BIOLOGICAL|TIV-HA formulation 2 at low dose|Suspension for injection in a vial. Route of administration: IM injection
223485866|NCT06850051|BIOLOGICAL|TIV-HA formulation 2 at high dose|Suspension for injection in a vial. Route of administration: IM injection
223485867|NCT06850051|BIOLOGICAL|RSV/hMPV/PIV3 formulation 2 at low dose|Suspension for injection in a vial. Route of administration: IM injection
223485868|NCT06850051|BIOLOGICAL|RSV/hMPV/PIV3 formulation 1 at high dose|Suspension for injection in a vial. Route of administration: IM injection
223485869|NCT06850051|BIOLOGICAL|RSV/hMPV/PIV3 formulation 2 at high dose|Suspension for injection in a vial. Route of administration: IM injection
223485870|NCT06850051|BIOLOGICAL|RSV/hMPV/PIV3 formulation 1 at low dose|Suspension for injection in a vial. Route of administration: IM injection
223485871|NCT06850051|BIOLOGICAL|RIV4 (Supemtek®)|Solution for injection in a prefilled syringe. Route of administration: IM injection
223485872|NCT05037370|DEVICE|Wave-Front Optimized (WFO) ablation vs Topography-guided (TG) ablation|Patient will undergo PRK or LASIK using WFO ablation in one eye and TG ablation on contralateral eye
223485873|NCT05718219|DRUG|SIM0348|Several dose levels will be evaluated for SIM0348 administered as a single agent . SIM0348 will be given via IV infusion on Day 1, Day 8, Day 15, Day 22 of each cycle (28-day or depending on study cohort and phase) until disease progression or loss of clinical benefit.
223485874|NCT05718219|DRUG|SIM0348 + Sintilimab|Selected doses from Part 1A will be evaluated for SIM0348 when they were combined with Sintilimab (200mg once every 3 weeks).
223485875|NCT02236364|DEVICE|Photographic Image Capture System|Collection of images of the iris along with corresponding fingerstick blood glucose
223485876|NCT02535312|DRUG|Cisplatin|Given IV
223485877|NCT02535312|DRUG|Methoxyamine|Given PO
223485878|NCT02535312|DRUG|Pemetrexed Disodium|Given IV
223485879|NCT04688736|DRUG|Placebo|The tablet resembles chlorpheniramine but has no therapeutic value.
223485880|NCT04688736|DRUG|Chlorpheniramine|An antihistamine that reduces the natural chemical histamine in the body.
223485881|NCT06385132|OTHER|Psychological Tests' administration|to assess global psychological and psychiatric profile of patients affected by GBM and H\&N-C by means of standardized questionnaires
223586483|NCT06981403|BEHAVIORAL|virtual escape room game-based pediatric medication management education|3 period aplied virtual escape room game-based pediatric medication management education
223485882|NCT06441214|DRUG|Zanubrutinib|Patients will be treated with Zanubrutinib as per routine clinical practice.
223485883|NCT06260904|DRUG|Prednisolone|prednisolone 0.75mg/kg/day (a maximum dose of 30mg at baseline) orally
223485884|NCT06260904|DRUG|Apremilast|Apremilast 30 mg twice daily orally
223485885|NCT06260904|DRUG|Methotrexate|Methotrexate 15 mg weekly orally
223485886|NCT06283628|PROCEDURE|Radiofrequency ablation of lumbar medial branch nerves.|"Traditional approach:~The electrode is introduced at a 15-20 degrees' ipsilateral oblique angle to the sagittal plane toward the junction of the superior articular process (SAP) and transverse process (TP) of the vertebral body to target the traversing medial branch nerve.~Parasagittal (new) approach:~The RF cannula is placed parasagittally and more dorsally. The remainder of the procedure does not differ from the traditional method."
223485887|NCT05343013|DRUG|TAS-102|GIven by PO
223485888|NCT03839641|OTHER|High fat meal|60% fat meal
223485889|NCT03839641|OTHER|Low fat meal|20% fat meal
223586484|NCT06980415|DEVICE|Kay Pictures iSight|Tablet-based visual acuity measurement
223586485|NCT06981247|BEHAVIORAL|m-LIfE: mobile based lifestyle intervention for employees to increase their physical activity and promote healthy diet.|"The m-LIfE will primarily deliver healthy lifestyle educational content, provide customized strategies for PA, and offer participants the option to enter their daily intake of fruits and vegetables through Food Log feature. m-LIfE will track PA and diet, send tailored reminders, and provide motivational messages. Participants will receive two text messages daily: a goal reminder in the morning and feedback or reflection on their progress in the evening. Additionally, they will receive one motivational message at the end of each week to sustain their motivation. Personalized feedback will also be provided through the application, featuring graphs to illustrate daily, weekly, and monthly progress.~To support participants further, the application will enable two-way communication, allowing users to seek assistance and ask questions from the research team. A dedicated contact number will be made available within the app to facilitate direct communication."
224072355|NCT06310499|OTHER|Drowning|Drowning is defined as the process of experiencing respiratory impairment from submersion or immersion in liquid.
223485890|NCT04279483|BEHAVIORAL|Tobacco retailer|Assigned to make a small (\~$3.00) purchase from a tobacco retail store(s) using a study-provided debit card during each retail environment visit
223485891|NCT04279483|BEHAVIORAL|Non-tobacco retailer|Assigned to make a small (\~$3.00) purchase from a store that does not sell tobacco (non-tobacco retailer) using a study-provided debit card during each retail environment visit.
224072356|NCT06142643|DEVICE|Dermal Filler Device|Injection of the device by investigators according to the IFU
224072357|NCT03485820|BEHAVIORAL|COMPASS|The data from the baseline assessment will be used to develop an environmental modification intervention plan. Environmental modifications will be installed before discharge if possible. Problem areas addressed are participant specific (tailored), but the process to identify and address the target area is systematic. All participants will receive identical intervention components. The standardized components include assessment, identification of problematic activities (and environmental barriers), identification of three solutions (for each problem), implementation of solution set selected by the participant, training, and active practice of daily activities in one's own home and community.
224072358|NCT03485820|BEHAVIORAL|Stroke education|The control group will experience the same effects of time and attention in the home but no effect on the outcome of interest.
224072359|NCT05700435|BEHAVIORAL|Stress Management and Resilience Training|The Stress Management and Resilience Training (SMART) program focuses on improving the practices of gratitude, mindful presence, kindness, and developing a resilient mindset. In this proposed study, SMART will be provided via either a two-hour, video teleconference (VTC) or in-person training or by completion of a self-paced, on-line version completed over a period of four to eight weeks. The modalities VTC and in-person are the two intervention conditions.
224072360|NCT02959021|BEHAVIORAL|weight loss intervention - self directed|
224072361|NCT02959021|BEHAVIORAL|weight loss intervention - peer coach|
224072362|NCT04907760|OTHER|Personalized care program|It includes the participant follow-up by a nurse during 5 years with a contact every 4 months for the first year, then after every 6 months
224072363|NCT04868604|DRUG|64Cu-SAR-bisPSMA|64Cu-SAR-bisPSMA
224072364|NCT04868604|DRUG|67Cu-SAR-bisPSMA|67Cu-SAR-bisPSMA
224072365|NCT04886089|DEVICE|Pleth variability index for prediction of post-induction hypotension|The use of the baseline Pleth variability index values for prediction of occurrence of post-induction hypotension
224072366|NCT02559778|DRUG|Ceritinib|One of the following drugs will be chosen for each subject based on molecular guided results: Ceritinib, dasatinib, sorafenib or vorinostat. This will be followed by consolidation, immunotherapy +/- DFMO, and then all subjects will receive DFMO for 2 years as maintenance.
224072367|NCT02559778|DRUG|dasatinib|One of the following drugs will be chosen for each subject based on molecular guided results: Ceritinib, dasatinib, sorafenib or vorinostat. This will be followed by consolidation, immunotherapy +/- DFMO, and then all subjects will receive DFMO for 2 years as maintenance.
224175262|NCT06912048|OTHER|Oral glucose tolerance test with double-tracer dilution and saline infusion (placebo)|Subjects will undergo a 75 g oGTT (180 min) combined with a double tracer dilution. The double-tracer dilution technique will be used to quantify endogenous glucose production, glucose appearance and disappearance rate. \[6,6-2H\]glucose will be infused for a total of 300 minutes, while the infusion will start 120 minutes prior the oGTT and will last until the end of the oGTT. Saline infusion will be administered 20 minutes before the start of the oGTT. The drink consumed at time point 0 min contains 75 gram glucose, enriched with \[U-13C6\]-glucose.
224175263|NCT07093983|OTHER|Constraint-Induced Movement Therapy (CIMT)|Participants in this group will receive modified CIMT in combination with conventional physical therapy. The unaffected arm will be restrained to encourage use of the affected upper limb. Task-specific exercises will include fine motor tasks, strengthening, reaching, and functional movement training. Each session will last approximately 45-60 minutes and will be conducted three times per week for 12 weeks.
224175264|NCT07093983|OTHER|Coupling Rehabilitation|Participants in this group will receive Coupling Rehabilitation in addition to conventional physical therapy. This method involves bilateral arm training and functional tasks designed to improve coordination between both upper limbs, using the unaffected limb to guide movement in the affected one. Exercises will include trunk-supported reaching, object retrieval, and posture-supported task practice. Sessions will occur three times per week for 12 weeks, each lasting approximately 45-60 minutes.
224175265|NCT07102485|OTHER|disease-induced immunity|"Using a different label for natural immunity, specifically, disease-induced immunity"
224175266|NCT07102485|OTHER|natural immunity|"Using standard label natural immunity"
224175267|NCT07100067|BIOLOGICAL|LCAR- F33S cells intravenous infusion|Prior to infusion of the LCAR- F33S cell, Subjects will receive a conditioning premedication regimen consisting of cyclophosphamide and fludarabine.
224175268|NCT07101029|DRUG|Bio-C Temp Intracanal Medication|Bio-C Temp Bioceramic intracanal dressing in the form of injectable premixed paste
224175269|NCT07101029|DRUG|Calcium Hydroxide Intracanal medication|Calcium Hydroxide intracanal dressing in the form of injectable premixed paste
224175270|NCT07101692|BEHAVIORAL|Virtual Reality-Based NGT Training|Participants will be given nasogastric catheter application training accompanied by a PowerPoint presentation and then they will be provided with three individual applications on the model.
224175271|NCT07100301|OTHER|Proximal/distal protocol|Proximal/distal exercise program (trunk, hip, knee and ankle) consisting of four stages: warm-up, strengthening, sensorimotor training and relaxation. The intervention will last 12 weeks and will take place twice a week, with an average duration of 50-60 minutes.
224175272|NCT07100301|OTHER|Distal protocol|Distal exercise program available in the literature and previously tested. This will contain warm-up exercises, intrinsic foot muscle strengthening, extrinsic foot-ankle muscle strengthening, and functional exercises. The intervention will last 12 weeks and will take place twice a week, with an average duration of 50-60 minutes.
224175273|NCT07100379|PROCEDURE|Endoscopic Balloon Dilation|Endoscopic balloon dilation is a routine procedure in which a catheter with a balloon is introduced into the esophagus to help treat esophageal strictures via endoscope. The catheter is placed directly across the span of the esophageal stricture and the balloon is inflated to pre-determined volume in order to dilate the esophageal stricture. Balloon will remain inflated for either 30 or 180 seconds based on patient's randomization.
223485892|NCT00643175|BEHAVIORAL|Automated follow up|Treatment of osteoporosis after hip fracture is also being targeted as a future hospital quality assessment measure. Hospitals which have no plan in place to address osteoporosis treatment after hip fracture may be cited, and may have medicare money withheld. The goal of the study is to create an automated in-patient endocrinology consultation for osteoporotic hip fractures. We plan to gather patient data in a prospective manner including the endocrinologist recommendations, adherence to medical therapy after discharge, and future fracture rates. Planned interventions include only appropriate medical therapy for osteoporosis, DEXA bone scanning, and regularly scheduled telephone follow-up.
223485893|NCT02077699|DIETARY_SUPPLEMENT|Lactobacillus casei DG|Lactobacillus casei DG (24 billion of live cells per pill) - 2 pills b.i.d. for 4 weeks
223485894|NCT03160950|DEVICE|LuxaCrown|"Teeth that would be requiring RCT, would be initially treated by a endodontist using the standardized principles of rotary endodontics.~Restoration using the LuxaCrown as a direct composite crown: In short, the impression material will be loaded with the LuxaCrown material (DMG, Germany). Approx. 0:40 minutes after the start of mixing, the filled impression will be placed in the patient's mouth and will stay there for approx. 1:45 - 2:20 minutes, that is, till the material is partially set. The impression will then be taken out and the material will be allowed to set outside patient's mouth up to approximately 5 minutes after the start of mixing. The Crown will then be finished using a fine buff and pumice, followed by application of Glaze and Bond (DMG, Germany). The preparation will then be cleaned and slightly roughened with a bur or sand blaster at the adhesion sites. The crown fabricated will then be cemented using PermaCem 2.0 luting cement (DMG, Germany)."
223485895|NCT06406972|OTHER|Brief Admission by self-referral (BA)|Through means of an individualised contract access to self-referral to inpatient treatment limited to a maximum of three nights, three times per month.
223485896|NCT02255864|DEVICE|AmM FORTITUDE Bioresorbable Drug-Eluting Coronary Scaffold|Placement of the investigational device into the diseased coronary artery to eliminate the vascular stenosis.
223485897|NCT03474575|OTHER|Prevention|The purpose is to establish a safe and effective way of discharging COPD patients from emergency department by providing enhanced home care.
223485898|NCT00125944|BIOLOGICAL|FluMist|
223485899|NCT04289948|DRUG|Phage|The studies will be undertaken using a cocktail of at least 2-3 anti-staphylococcal phages produced by Intralytix Inc, Baltimore, Maryland, USA. The phages will be included in a gel designed for application directly to the wound surface and packaged in 5 ml single use tubes.
223485900|NCT06086249|PROCEDURE|Regeneration using Injectable platelet-rich fibrin|root canals of affected molars will be cleaned and shaped chemo-mechanically, after two weeks I-PRF will be applied.
223485901|NCT06086249|PROCEDURE|Root canal treatment|Conventional root canal treatment using gutta-percha obturation
223485902|NCT02838355|DEVICE|Respiratory Depression Monitoring with End Tidal Carbon Dioxide Nasal Cannula (ETCO2- NC)|The ETCO2-NC is a non-invasive device that monitors the amount of carbon dioxide that is exhaled with every breath.
224175274|NCT07101146|OTHER|Quality of life questionnaire|The NEI-RQL-42 (National Eye Institute Refractive Quality of Life) questionnaire will be self-administered via a secure online platform to assess the impact of pathological myopia on quality of life.
224175275|NCT07101146|OTHER|Performance Outcomes (PerfO)|"Three tests are planned to assess the impact of high myopia on critical aspects of mobility and safety, with the possibility of adjusting their scope based on pilot data.~* The first test involves an assessment of driving on a simulator, designed to evaluate the performance of detecting pedestrians in peripheral vision, with and without glare.~* The second test focuses on assessing mobility and obstacle avoidance under six levels of brightness.~* The third test evaluates visual search ability. It consists of finding spheres in everyday scenes in an apartment with six levels of contrast tested."
224175276|NCT07101146|OTHER|Semi-structured interviews|Semi-structured interviews will only be offered to patients recruited in Phase 1 Qualitative and aim to further explore the information gathered from the NEI-RQL-42 questionnaire responses and the difficulties encountered during the performance tasks in the laboratory, by exploring in more detail the limitations encountered by patients with pathological myopia in their daily activities. These interviews will help identify the specific causes of the difficulties encountered, as well as the environmental conditions that may create discomfort or increased hardship.
224175277|NCT07100756|DEVICE|AI vertebral fracture diagnostics (Flamingo)|The AI (name: Flamingo from Image Biopsy Lab, IBL, Vienna, Austria) screens thoracic and abdominal CT scans for vertebral fractures.
224175278|NCT07101887|PROCEDURE|Implantation of thumb prosthesis|Replacing the articular surface of the trapezo-metacarpal joint with a socked-ball prosthesis.
224175279|NCT07101887|PROCEDURE|Burton-Pellegrini technique|Remove the trapezium bone and perform a suspensionplasty using a hemi-slip of the flexor carpi radialis tendon
224175280|NCT07100236|OTHER|Observational study of 29 - gene - defined HCC subtypes and immunotherapy responsiveness correlation|This is a non - interventional observational study. We will stratify patients with hepatocellular carcinoma (HCC) based on transcriptome sequencing of their tumor samples, specifically using a 29 - gene signature to classify them into different subtypes. Without interfering with patients' existing immunotherapy regimens (which are determined by clinical practice), we will retrospectively collect and analyze data on treatment responses. The goal is to explore the correlation between the 29 - gene - based HCC subtypes and responsiveness to immunotherapy, focusing on differences in outcomes like objective response rate (ORR) and progression - free survival (PFS) across subtypes. This study distinguishes itself by emphasizing observational analysis of pre - existing treatment patterns rather than implementing active interventions, aiming to provide insights into personalized immunotherapy for HCC through genetic subtyping.
224175281|NCT07102199|OTHER|Internal focus of attention instructions- First|Participants first received internal focus instructions, directing their attention to their own body, followed by external focus instructions.
224175282|NCT07102199|OTHER|External focus of attention instructions- First|Participants first received internal focus instructions, directing their attention to their own body, followed by external focus instructions.
224175283|NCT07102199|OTHER|Home exercises|Participants' home exercise program includes cervical and scapulothoracic stabilization exercises and self-mobilization exercises with the self-sustained natural apophyseal glide (SNAG) method.
224175284|NCT02020304|DRUG|combined spinal epidural|Combined Spinal Epidural
224175285|NCT01308489|PROCEDURE|therapeutic conventional surgery|Undergo posterior spinal tumor resection
224175286|NCT01308489|PROCEDURE|therapeutic conventional surgery|Undergo anterior and posterior spinal tumor resection
224175287|NCT01308489|PROCEDURE|quality-of-life assessment|Ancillary studies
224175288|NCT00243490|PROCEDURE|Photodynamic therapy using Photosan and LumaCare™ Lamp Model LC-122M|
224175289|NCT06397157|OTHER|Virtual Reality|Participants will recieve treatment(Virtual reality) for every alternate day (3 days per week) for 6 weeks. Total number of sessions will be 18.
224175290|NCT06397157|OTHER|Motor Imagery|Participants will recieve treatment(Motor Imagery) for every alternate day (3 days per week) for 6 weeks. Total number of sessions will be 18.
224306408|NCT05931666|OTHER|Gong Mobilization|"Patients are treated with Gong mobilization protocol along with conventional therapy including ultrasound therapy, hot pack and conventional exercises consisting of codman exercises, ROM exercises and shoulder stabilization exercises.~Total of 3 sessions per week for 3 consecutive weeks."
223485903|NCT02838355|OTHER|Standard Non-invasive Respiratory Depression Monitoring|Standard non-invasive respiration monitoring includes telemetry of heart rate and rhythm, respiratory rate, blood pressure, CF-LVAD flow, and oxygen saturation (SpO2) via pulse oximetry.
223485904|NCT05693220|DEVICE|Zymot Multi sperm separation device|Sperm preparation with Zymot Multi sperm preparation device
223485905|NCT05693220|OTHER|Density gradient centrifugation|Sperm preparation with density gradient centrifugation
223485906|NCT00843973|PROCEDURE|iliac crest bone graft|iliac crest bone graft procedure
223485907|NCT00843973|PROCEDURE|Reamer Irrigator Aspirator|Reamer Irrigator Aspirator (RIA) Procedure
223485908|NCT04926233|DRUG|Tiotropium bromide + Olodaterol|Tiotropium bromide + Olodaterol
223485909|NCT04926233|DEVICE|Sp(t)iolto® Respimat®|Sp(t)iolto® Respimat®
223485910|NCT05395442|DIAGNOSTIC_TEST|Training on web-based diabetic foot care based on the Health Belief Model|Training on web-based diabetic foot care based on the Health Belief Model will be implemented.Four materials will be used in the research, namely the Introductory Information Form, the Foot Care Behavior Scale, the Diabetic Foot Care Self-Efficacy Scale.
223485911|NCT01887808|OTHER|Cetaphil DermaControl Oil Control Moisturizer SPF 30|
223485912|NCT02550795|DRUG|Dexmedetomidine|administration of dexmedetomidine only
223586486|NCT06981247|OTHER|Routine care arm|Participants in the routine care arm will receive educational material in the form of paper-based pamphlets to ensure they still benefit from basic health information on CVD risk prevention. They will continue their usual work routines without access to the app, but their PA and dietary habits will be assessed at baseline, post-intervention and at follow-up for comparative purposes.
223485913|NCT02550795|DRUG|Dexmedetomidine and dexamethasone|administration of dexmedetomidine and dexamethasone
223485914|NCT02550795|DRUG|Control|administration of normal saline
224175291|NCT06397157|OTHER|Routine Physical therapy|Participants will recieve treatment(Routine physical therapy) for every alternate day (3 days per week) for 6 weeks. Total number of sessions will be 18.
224175292|NCT07101484|DRUG|GD007 Low-dose drug group|"o Eligible patients who provide informed consent will receive:~* First exosome perfusion: 24 hours post-operatively~* Subsequent perfusions: Every 3 days (total 3 perfusions)"
224175293|NCT07101484|DRUG|GD007 Mid-dose drug group|"* Patients diagnosed with moderate-to-severe intrauterine adhesions (IUA) will undergo standard hysteroscopic adhesiolysis.~* Eligible patients who provide informed consent will receive:~  * First exosome perfusion: 24 hours post-operatively~ * Subsequent perfusions: Every 3 days (total 3 perfusions)"
224175294|NCT07101484|DRUG|GD007 High-dose drug group|"* Patients diagnosed with moderate-to-severe intrauterine adhesions (IUA) will undergo standard hysteroscopic adhesiolysis.~* Eligible patients who provide informed consent will receive:~  * First exosome perfusion: 24 hours post-operatively~ * Subsequent perfusions: Every 3 days (total 3 perfusions)"
224175295|NCT07101484|DRUG|GD007 Blank Control drug Group|"* Patients diagnosed with moderate-to-severe intrauterine adhesions (IUA) will undergo standard hysteroscopic adhesiolysis.~* Eligible patients who provide informed consent will receive:~  * First exosome perfusion: 24 hours post-operatively~ * Subsequent perfusions: Every 3 days (total 3 perfusions)"
224175296|NCT02469597|DRUG|Furosemide|1 mg/kg intravenous or oral (will give oral unless patient has peripheral IV access in place), maximum dose 10mg (1ml), x 1 dose
224175297|NCT02469597|DRUG|Placebo|0.1ml/kg intravenous or oral (Normal Saline) (will give oral unless patient has peripheral IV access in place), maximum dose 1ml, x 1 dose
224175298|NCT02558595|DIETARY_SUPPLEMENT|Niacinamide|
224175299|NCT02558595|OTHER|Placebo|Placebo pill that matches niacinamide pill is size, shape and color
224175300|NCT00879593|DEVICE|PtcCO2|Nocturnal assessment will be performed during the initial polysomnography (and at 6 months) with a combined PtcCO2/pulse oxymetry TOSCA500 Radiometer monitoring evaluating different physiological parameters.
224175301|NCT05234463|OTHER|IgAN patients|Adult patients Histologically proven diagnosis of IgA nephropathy Primary and secondary forms of the disease With or without kidney transplantation history Regardless of kidney/graft function Patients followed in the Nephrology Department of Strasbourg University Hospital.
224175302|NCT06940596|OTHER|FODMAP Diet|The intervention is an online diet program. The diet is the low fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAP) diet. It is a 3-phase diet which involves: 1.Phase 1 FODMAP restriction: restrict foods high or moderate in FODMAPs and swap these for low FODMAP alternatives; 2. Phase 2 FODMAP reintroduction: continue to follow a low FODMAP diet and complete a series of food challenges to understand which foods and FODMAPs are tolerated and which trigger symptoms; 3. Phase 3 FODMAP personalization: include well-tolerated foods and FODMAPs back into the diet, and restrict poorly tolerated foods and FODMAPs to a level needed to maintain symptom relief. The online FODMAP program is a self-directed diet program with support from an online clinician (Accredited Practicing Dietitian \[APD\]). The content is delivered over 12 weeks. After each module participants will complete homework activities and questions and submit them to the dietitian for feedback.
224306409|NCT05931666|OTHER|Kaltenborn Mobilization|"Patients are treated with Kaltenborn mobilization protocol along with conventional therapy including ultrasound therapy, hot pack and conventional exercises consisting of codman exercises, ROM exercises and shoulder stabilization exercises.~Total of 3 sessions per week for 3 consecutive weeks."
224306410|NCT00234182|DRUG|Interferon alpha-2b|
224306411|NCT03287973|BEHAVIORAL|Lifestyle modification|A caloric reduction of 10-20% in daily energy intake from the patient's usual diet (i.e. a deficit ≥ 200 calories per day) will be set as the general initial goal, which will be adjusted subsequently based on changes in body weight with target body mass index (BMI) towards 23 kg/m2.
224306412|NCT03287973|DEVICE|Continuous positive airway pressure (CPAP)|Patients randomized into the continuous positive airway pressure (CPAP) group in each arm will be interviewed by the physician on duty and invited to start autoCPAP treatment for 6 months. They will be offered a CPAP education package. Patients will then commence autoCPAP treatment for 6 months at home.
224306413|NCT06104241|BIOLOGICAL|BGT007 Injection|BGT007 injection (d0) were infused intravenously once, and the dose group was 5.0× 10\^7 cells,1.0 ×10\^8 cells, 3.0× 10\^8 cells,1.0 × 10\^9 cells,3.0 ×10\^9 cells.
224306414|NCT04430855|DRUG|Upadacitinib|Tablet; Oral
224306415|NCT04430855|DRUG|Placebo|Tablet; Oral
224306416|NCT04334486|OTHER|Super Smash Brothers Melee (Gamecube)|10 minutes of participation in Super Smash Brothers Melee prior to Eyesi Surgical Simulator evaluation of skills.
223586487|NCT06601192|DRUG|zelicapavir (therapeutic dose)|Subjects will receive zelicapavir (TD) once per treatment period.
223586488|NCT06601192|DRUG|zelicapavir (supratherapeutic dose)|Subjects will receive zelicapavir (SD) once per treatment period.
223586489|NCT06601192|DRUG|Placebo|Subjects will receive zelicapavir matching placebo once per treatment period.
223586490|NCT06601192|DRUG|moxifloxacin|Subjects will receive moxifloxin once per treatment period.
223586491|NCT06979986|PROCEDURE|Endoscopic Submucosal Dissection with Systematically mediastinal Lymph Node Dissection|Participants will be evaluated for inclusion criteria and exclusion criteria, and then sign informal consent if desired. Participants will be randomly assigned to the intervention according to a prepared random tables. Participants in the SLND group will receive Endoscopic Submucosal Dissection with systematically mediastinal lymph node dissection
223586492|NCT06979986|PROCEDURE|Endoscopic Submucosal Dissection without SLND|Participants will be evaluated for inclusion criteria and exclusion criteria, and then sign informal consent if desired. Participants will be randomly assigned to the intervention according to a prepare random tables. Participants in the non-SLND group will just receive Endoscopic Submucosal Dissection treatment, not undergo Systematically mediastinal Lymph Node Dissection.
223586493|NCT06981169|DIAGNOSTIC_TEST|FeNO|FeNO measured with a NIOX VERO device before the respiratory test
223586494|NCT06981169|DIAGNOSTIC_TEST|blood sample|Blood sample for measuring the blood eosinophil count
223586495|NCT06979622|OTHER|ultrasound combined with electromagnetic positioning guidance|TIPS procedure under ultrasound combined with electromagnetic positioning guidance
224306417|NCT02375919|OTHER|PERC based Strategy|work up for diagnosis of PE includes calculation of PERC
224306418|NCT06229821|DEVICE|Intrapulmonary Percussive Ventilation|IPV applied at increasing intervals, starting every 6 hours, and ending at every 24 hours, for a total of 7 days.
224175303|NCT06940596|BEHAVIORAL|Exposure-based Cognitive Behavioral Therapy|The intervention is an online behavioral therapy program. The behavioral therapy is Exposure-based Cognitive Behavioral Therapy (E-CBT) Program. The E-CBT program is organised into six steps to be completed over 12 weekly modules with support from an online clinician (Psychologist). The first step contains a rationale for the treatment and instructions on self-observation. Steps 2, 3 and 4 contain a presentation of a psychological model of IBS and continued self-observation exercises. The fifth step covers exposure exercises, divided into three categories; (1) exercises that provoke symptoms, (2) abolishment of behaviors that serve to control symptoms, (3) exposure to situations where symptoms were unwanted. The final step (Step 6) includes how to handle relapses into avoidance behaviors and how to maintain a widened behavioral repertoire. After each module participants will be directed to complete homework activities and questions and submit them to the psychologist for feedback.
223485915|NCT01971177|DEVICE|Femtosecond laser cataract surgery|"The VICTUS lens fragmentation procedure is part of the femtosecond laser assisted cataract procedure, which generates precise cuts inside the cataractous lens, leading to a softening and fragmentation of the lens.~The correct positioning of the cuts inside the lens can be verified by means of an optical coherence tomograph (OCT) before starting the laser assisted fragmentation process.~Various surgical patterns will be used within this study. For each pattern different geometry/laser parameters can be adjusted individually according to each patient's cataract status.~All the patients who are enrolled in the laser groups (all cataract grades) will be treated with femtosecond laser assisted capsulotomy before the femtosecond laser assisted lens fragmentation by VICTUS femtosecond laser platform."
223485916|NCT01971177|PROCEDURE|Manual cataract surgery|"Manual: manual group acts as a control group where the lens fragmentation are per-formed manually without femtosecond laser assisted lens fragmentation"
223485917|NCT03983031|DRUG|Rituximab|Infusion
223586496|NCT06981442|BEHAVIORAL|Community-based environmental management|This intervention will be performed by the local community, who will have been previously informed and trained on the appropriate environmental management methods for the control of the Aedes mosquito. It will be based on the following elements: i) identification and removal of all artificial sources of reproduction of the Aedes mosquito inside and around the house (i.e. covering abandoned containers and/or storage containers to avoid water accumulation); ii) regular collection and disposal of household waste; iii) identification and resolution of all artificial sources of reproduction of the Aedes vector in or around the house (i.e. natural cavities such as tree holes will be filled to prevent water accumulation). This intervention will be carried out as a single intervention in Arm 1, in combination with a larvicidal intervention in Arm 2 and in combination with the intervention against the adult stage of the Aedes mosquito in Arm 3.
223745282|NCT07034989|OTHER|Exercise|Teach respiratory exercises and function-focused trunk stabilization exercises to individuals with RA-IAH via online platforms. Subsequently, instructional exercise videos will be delivered to the patients online. The respiratory exercise training will include thoracic expansion and diaphragmatic breathing exercises. The program will consist of a warm-up phase including 10 minutes of trunk stabilization exercises, a 40-minute functional exercise session targeting the upper and lower extremities with trunk stabilization, followed by a cooldown phase including 10 minutes of flexibility exercises involving trunk stabilization. The exercise videos related to these phases will be sent to the participants online. Participants will start the exercises with 6 repetitions and will be encouraged to increase to 8 repetitions as the program progresses. The assigned physiotherapist will contact patients once a week by phone to monitor exercise adherence.
224175304|NCT06939075|DIAGNOSTIC_TEST|ROLE OF Cross sectional imaging modalities in the diagnosis and characterization of colonic masses|"Study tools (in detail, e.g., lab methods, instruments, steps, chemicals, …):~* CT Scan: To evaluate mass morphology, size, and lymph node involvement.~* MRI: To assess tissue composition, characterization and diffusion restriction.~* Colonoscopy and Biopsy: Gold standard reference to assess the diagnostic accuracy for different"
224175305|NCT05996809|DEVICE|Coseal|Adhesion reduction
224175306|NCT03030157|DRUG|pirarubicin(THP)|
224175307|NCT05931068|OTHER|Pre- and postoperative assessment|Pre- and postoperative assessment will consist of measurement of energy expenditure (direct and indirect calorimetry), aerobic capacity (cardiopulmonary exercise test), and physical activity (accelerometry).
224175308|NCT06443177|DEVICE|Vectris trial leads and stimulation|The electrode is placed into the epidural space using standard epidural placement techniques with paramedian approach. The initial electrode settings have been adopted from prior studies. Should any significant discomfort be elicited from the stimulation, first the amplitude will be decreased to an acceptable level. If an acceptable level of stimulation is unable to be found, the stimulation will be discontinued.
224175309|NCT06443177|DEVICE|Sham|No electrode is placed.
224175310|NCT06953752|OTHER|Music intervention|Music group patients select preferred genres (classical/pop/rock/jazz; classical default) delivered at 50-60 dB during the procedure.
224175311|NCT06953752|OTHER|Control|Controls receive no music.
224175312|NCT06766604|OTHER|Super-GDF9 supplementation during CAPA-IVM|Group 1: donated COCs will be exposed to Super-GDF9 at 50 ng/ml in both the CAPACITATION and MATURATION culture steps.
224175313|NCT06766604|OTHER|Conventional CAPA-IVM|Group 2: The subject's remaining COCs will be cultured in the CAPA step and the IVM step without the addition of Super-GDF9 during CAPA-IVM.
224175314|NCT05421546|DIETARY_SUPPLEMENT|Spermidine or Placebo|The supplement, Spermidine, is made mainly from wheatgerm and can be bought in health food shops. It is a powder that can be easily dissolved in water and taken as a drink. The 'placebo' is a sugar powder that can be similarly dissolved in water and taken as a drink.
224175315|NCT05630976|DRUG|Isavuconazole|This is a single arm study, all enrolled participants will receive the study intervention.
224306419|NCT03704402|OTHER|Alcohol policy|Introduction of new mutual alcohol policy
224306420|NCT01425723|BIOLOGICAL|rFIXFc|Administered as specified in the treatment arm.
224306421|NCT00317421|DRUG|Sildenafil citrate|
224306422|NCT00186043|DRUG|Quetiapine/Seroquel|Quetiapine/Seroquel
224306423|NCT00186043|DRUG|Placebo|Placebo
223485918|NCT01113099|OTHER|Academic detailing|Education of physicians by pharmacists regarding indications for statins in diabetic patients
223485919|NCT00889434|DIETARY_SUPPLEMENT|ECGC|1 cycle will comprise 28 days of continuous daily treatment with EGCG given once/day(total 375 mg) /day in the morning with food followed by a 14 day wash out period without drug.
224306424|NCT01689818|OTHER|exercise training|exercise training program which included aerobic exercise for 3 times per week.
224306425|NCT01529918|OTHER|CANRISK (Canadian Diabetes Association Assessment)|Self-risk assessment questionnaire for diabetes
224306426|NCT02497313|DRUG|Isotonic saline|
224306427|NCT02497313|DRUG|Metformin placebo|
224306428|NCT02497313|DRUG|Cholecystokinin|
223485920|NCT00889434|DIETARY_SUPPLEMENT|Tocotrienol|One cycle will comprise 28 days of continuous daily treatment with Tocotrienol given 2 times/6 soft gel capsules (total 600 mg) /day (BID) in the morning and in the evening with food followed by a 14 day wash out period without drug.
223586497|NCT06981442|OTHER|Vector control against immature stages of Aedes|Larvicidal control will be carried out through pyriproxifen-based autodissemination stations combined with Beauveria bassiana, implemented according to the manufacturer's recommended procedures.
224306429|NCT02497313|DRUG|Metformin|
223485921|NCT00889434|DIETARY_SUPPLEMENT|EGCG + Tocotrienol|combination of both arms 375 mg EGCG + 600mg/day Tocotrienol
223485922|NCT01868672|BEHAVIORAL|Educational print materials and coaching call|Intervention group participants receive three sets of mailed educational materials about making their home smoke-free and one coaching call.
223485923|NCT04844320|DIAGNOSTIC_TEST|Cobb angle measurements|PA Chest x-rays will be taken in all patients in the preoperative, postoperative 1st year and 2nd year
223485924|NCT05932888|DRUG|QLM3003|1%（10g∶0.1g）or 1.5%（10g∶0.15g）or 2%（10g∶0.2g）
223485925|NCT05932888|DRUG|QLM3003 Placebo|1%（10g∶0.1g）or 1.5%（10g∶0.15g）or 2%（10g∶0.2g）(matching corresponding study medication)
223745283|NCT04814433|DRUG|Tranexamic acid|"FDA-approved usage for intravenous tranexamic acid (TXA) is for heavy menstrual bleeding and short-term prevention in patients with hemophilia.~Total dose of 500 mg (20 mL) total will be given."
223745284|NCT04814433|DRUG|Aminocaproic acid|"FDA notes that aminocaproic acid is useful in enhancing hemostasis when fibrinolysis contributes to bleeding. Aminocaproic acid inhibits both the action of plasminogen activators and to a lesser degree, plasmin activity. The fibrinolysis-inhibitory effects of aminocaproic acid appear to be exerted principally via inhibition of plasminogen activators and to a lesser degree through antiplasmin activity. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.~Total of 1000 mg total will be given."
223745285|NCT04814433|DRUG|Recombinant Human Thrombin|"Topical thrombin is FDA approved as an aid to hemostasis whenever oozing blood and minor bleeding from capillaries and small venules is accessible and control of bleeding by standard surgical techniques is not sufficient.~Recombinant human thrombin is available as 5000-unit and 20,000-unit vials of sterile recombinant topical thrombin lyophilized powder for solution. When reconstituted as directed, the final solution contains 1000 units/mL.~For topical application, a total of 10000 units per open surgical study arm involving use of Thrombin will be given"
223745286|NCT04814433|DRUG|Lidocaine Hydrochloride with Epinephrine|"Topical lidocaine product is FDA approved as an amide local anesthetic in any indication for relief of pain associated with superficial minor surgery and as an adjunct for local infiltration anesthesia. It is frequently used as a standard local anesthetic for surgical procedures.~Each mL contains lidocaine hydrochloride and epinephrine, with 0.5 mg sodium metabisulfite as an antioxidant and 0.2 mg citric acid as a stabilizer.~Total of 5 mLs per open surgical study arm involving lidocaine hydrochloride and epinephrine will be given"
223485926|NCT00879658|DRUG|BAF312|
223485927|NCT00879658|DRUG|Placebo|
223586498|NCT06981442|OTHER|Vector control against the mature stages of Aedes|The control of the adult Aedes mosquitoes will be carried out through mass trapping using BG-GAT traps implemented according to the manufacturer's recommended procedures. In each household, three traps will be deployed.
224072368|NCT02559778|DRUG|sorafenib|One of the following drugs will be chosen for each subject based on molecular guided results: Ceritinib, dasatinib, sorafenib or vorinostat. This will be followed by consolidation, immunotherapy +/- DFMO, and then all subjects will receive DFMO for 2 years as maintenance.
224072369|NCT02559778|DRUG|vorinostat|One of the following drugs will be chosen for each subject based on molecular guided results: Ceritinib, dasatinib, sorafenib or vorinostat. This will be followed by consolidation, immunotherapy +/- DFMO, and then all subjects will receive DFMO for 2 years as maintenance.
224072370|NCT02559778|DRUG|DFMO|DFMO will be given to Arm B during immunotherapy and then for 2 years as maintenance to all subjects completing immunotherapy.
224072371|NCT04685876|DRUG|Liposomal bupivacaine|4-quadrant TAP block with liposomal bupivacaine
224072372|NCT04685876|DRUG|Plain bupivacaine|4-quadrant TAP block with plain bupivacaine
224072373|NCT04685876|DRUG|Normal saline|placebo (normal saline).
224072374|NCT01358864|DRUG|BI 201335|BI 201335 once a day (QD) for 24 weeks
224072375|NCT01358864|DRUG|Pegylated Interferon-alpha (IFN)|Pegylated Interferon-alpha for 48 weeks
224072376|NCT01358864|DRUG|Ribavirin (RBV)|Ribavirin (RBV) for 24 or 48 weeks
224072377|NCT01358864|DRUG|Placebo|Placebo to BI201335 for 24 weeks
224072378|NCT06640036|OTHER|Rapeseed oil|During 1 week, 46 % of total energy intake will come from rapeseed oil, using pre-prepared and blinded meals.
224072379|NCT06640036|OTHER|Butter|During 1 week, 46 % of total energy intake will come from butter, using pre-prepared and blinded meals.
224072380|NCT06640036|OTHER|Coconut oil|During 1 week, 46 % of total energy intake will come from coconut oil, using pre-prepared and blinded meals.
224072381|NCT04479111|PROCEDURE|laparoscopic ileocecus-sparing right hemicolectomy|The ileocecal artery(ICA) is skeletonized. The colic branch of ICA is divided and ligated. Preserve anterior cecal artery, posterior cecal artery and ileocecal branch of ICA. Divide and ligate the right colic artery(RCA) and middle colic artery(MCA) at their roots. Dissect the lymph nodes surrounding the ICA, RCA and MCA accordingly. Head-to-Head colocolic anastomois is done, with circular stapler via making an opening at the bottom of cecum.
224072382|NCT03194373|DRUG|Palbociclib|"Palbociclib (Ibrance) (PO), dose= 125 mg PO daily, days=1-14, cycle length: 21 days~Maintenance Palbociclib:~Palbociclib (Ibrance) 125 mg PO daily, days 1-21, cycle length: 28 days"
224072383|NCT03194373|DRUG|Carboplatin|Carboplatin (IV), dose= AUC 5, day= 1, cycle length: 21 days
224072384|NCT00679705|DRUG|Ritodrine|Ritodrine (Pre-Par), maximum 400 µg/minute, IV
224072385|NCT00679705|DRUG|Atosiban|Atosiban (Tractocile), maximum 300 µg/minute, IV
224306430|NCT02273336|OTHER|cytology specimen collection procedure|Undergo tissue and blood sample collection
224306431|NCT02273336|OTHER|laboratory biomarker analysis|Correlative studies
223485928|NCT02727712|PROCEDURE|bilateral thoracic paravertebral block|group A under TPVB((TPVB T2/3+T5/6) by ropivacaine(0.3%,10ml\*4)program
223485929|NCT02727712|DEVICE|Transesophageal Echocardiography（TEE）|"1. Apply Transesophageal Echocardiography（TEE）after anesthesia induction and draw 400ml autologous blood (Haemonetics®)used for the postoperative transfusion;~2. Goal-directed fluid management"
223485930|NCT02727712|DEVICE|Lung protection measure during the surgery（Dräger Primus）|Protective ventilation strategy(Low tidal volume about 6\~7ml/kg, joint use of PEEP)
223485931|NCT02727712|DRUG|Anesthesia drugs during the surgery|"1. Bilateral thoracic paravertebral block before induction of anesthesia;~2. Fast channel anesthesia • Induction use Sufentanil 0.5\~1ug/kg, Vecuronium for Injection 0.15mg/kg and Etomidate 0.2\~0.6mg/kg; ②. Maintain use Sufentanil Hydrochloride for Injection 0.01\~0.04ug/kg•min, Sevoflurane 0.5\~1.5MAC（minimum alveolar concentration） and Infusing Dexmedetomidine which load dose 0.5μg/kg in 10min then changed into 0.5-1.0μg/kg•h,Vecuronium 0.06\~0.12mg/kg•h; ③. Intravenous hydromorphone Hydrochloride Injection 0.15mg/kg before surgery over."
223485932|NCT02727712|PROCEDURE|thoracic paravertebral block|group B under(TPVB T3/4)by ropivacaine(0.3%,20ml\*2)program
223485933|NCT01794468|OTHER|Dermal blood flow measurements|Dermal blood flow was measured with the Dermal Blood Flow (DBF) monitor (I.S. MedTech, Israel), which consists of a skin probe and a measuring and control feedback unit.
223485934|NCT04529694|OTHER|Psychotherapy|
223485935|NCT05255419|DEVICE|OnCall mobile health peer support app|"Mobile health platform that provides anonymous access to peer support services that has been co-design by and for Canadian public safety personnel. OnCall is for frontline public safety providers; features include links to mental health self-assessment tools, a wellness toolbox, tips to cope articles and peer wisdom videos, and options to reach out to a peer support provider of their choice via telephone or text. The OnCallSupport app is for the peer support providers which includes a list of resources and an opportunity to create post-action reports following the peer support encounter. Connections are made to peer support via a telephone service that disguises the contact information of both parties. The app platform includes options to complete feedback surveys related to the app and to the peer support encounter."
223485936|NCT00580840|DRUG|Certolizumab pegol|400 mg certolizumab pegol given every 4 weeks and placebo given every 4 weeks given as two injections (alternating injections every two weeks)
223485937|NCT00580840|DRUG|Certolizumab pegol|200 mg certolizumab pegol and placebo administered every 2 weeks (one injection of each)
223485938|NCT00580840|OTHER|Placebo|placebo (saline) administered as two injections every 2 weeks
223485939|NCT01955304|DRUG|fruquintinib|Fruquintinib 4 mg capsule, 2 discrete single doses separated by 2-weeks
223485940|NCT02659904|OTHER|Less than 2 mm remaining palatal tissue thickness|The greater palatine and incisive nerves were blocked with 2% lidocaine, 1:100,000 epinephrine injection. After preparation of the recipient bed, free gingival graft was harvested using a handle with knife at palatal donor side with acrylic stent guidance.
223485941|NCT02659904|OTHER|2 mm or more remaining palatal tissue thickness|The greater palatine and incisive nerves were blocked with 2% lidocaine, 1:100,000 epinephrine injection. After preparation of the recipient bed, free gingival graft was harvested using a handle with knife at palatal donor side with acrylic stent guidance.
223485942|NCT01258868|DRUG|Celebrex|400 mg PO BID for 7 days prior to cell administration and then on days 1 through 28 of each vaccine cycle.
223485943|NCT01258868|BIOLOGICAL|Tumor cell vaccine|A minimum of 1x10e7 and a maximum of 1x10e8 patient tumor cells that have been exposed to 1 mcM decitabine for 6 days, exposed to 100 Gy radiation and emulsified in 0.5 ml of the ISCOMATRIX adjuvant at a concentration of 180 ISCO units/mL administered IM every 4 weeks for 6 injections; if subject shows immune response, vaccine will be given every three months from months 9 - 24
223485944|NCT01046942|DRUG|Clopidogrel+acetylsalicylic acid|loading dose clopidogrel 300mg on second postoperative day. Thereafter 75mg clopidogrel daily for 3 months Aspirin 75mg daily, started within 24 hours after surgery
223745287|NCT04814433|DRUG|Bupivacaine Hydrochloride with Epinephrine|"Topical bupivacaine is FDA approved as indicated for the production of local anesthesia for procedures by infiltration injection. It is frequently used as a standard local anesthetic for surgical procedures.~Each mL contains bupivacaine hydrochloride and 0.005 mg epinephrine, with 0.5 mg sodium metabisulfite as an antioxidant and 0.2 mg citric acid (anhydrous) as stabilizer.~Total of 5 mLs per open surgical study arm involving Bupivacaine Hydrochloride with Epinephrine will be given"
223745288|NCT04206969|BEHAVIORAL|Transcultural psychotherapy|In addition to usual care, the participants receive transcultural psychotherapy
224072386|NCT00679705|DRUG|Placebo|Glucose 5%, IV
224072387|NCT02386150|BIOLOGICAL|RVEc|The composition of the final drug product, prior to any dilution, is 0.2 mg recombinant ricin toxin 1-33/44-198 (RVEc) in buffer and 0.2% Alhydrogel® at a final volume of 1 mL per vial
224072388|NCT02428257|PROCEDURE|continuous spinal anesthesia|Spinal puncture performed with a 19-gauge Tuohy needle at the L4-L5 or L3-L4 interspace using a midline approach. 3 cm of a 22-gauge catheter introduced through the needle, directed to the fractured side.
224072389|NCT02428257|DRUG|hypobaric bupivacaine|hypobaric bupivacaine was prepared diluting each 1 ml of 0.5% isobaric bupivacaine with 1 ml of sterile water.
224072390|NCT02428257|DRUG|isobaric bupivacaine|0.5% isobaric bupivacaine
223485945|NCT01046942|DRUG|acetylsalicylic acid|aspirin 75 mg daily, started 6-24 hours after surgery
223485946|NCT01551173|DRUG|Fluvastatin sodium|Fluvastatin sodium Extended Release Tablets 80mg
223485947|NCT00974454|DRUG|Fuzheng 2|Immunity 2 (Fuzheng 2), 6.25g twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days.
223485948|NCT00974454|DRUG|Placebo|Placebo, 6.25g twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days.
224072391|NCT02428257|DRUG|ephedrine|
223485949|NCT01719276|OTHER|Graded Activity|The graded activity program to increase activity tolerance by performing individualized and submaximal exercises.
223485950|NCT01719276|OTHER|Supervised Exercises|The group will perform stretching exercises (gluteus maximus, hamstrings, triceps surae, lumbar paraspinal), strengthening muscles (rectus abdominus, obliques and lower rectus abdominis internal and external) and motor control exercises (muscle transversus abdominis and lumbar multifidus.
223485951|NCT02632942|PROCEDURE|HAQ criteria|"Obliteration of accessory vein which satisfy the HAQ criteria as below:~1. 60% or greater diameter of the main AVF~2. 50% diameter of AVF with at least one more av\>40% in diameter.~3. 50% in diameter and divides into branches of same size.~4. av likely to interfere with cannulation on physical examination.~5. \>30% in diameter and associated with stenosis at site of origin."
223485952|NCT02632942|PROCEDURE|Current Recommendation|Obliteration of accessory vein which satisfy current recommendations defined as the diameter greater than 25% of the AVF diameter.
223485953|NCT05920239|DIAGNOSTIC_TEST|Magnetic resonance imaging (MRI)|MRI imaging is a diagnostic technique that uses magnetic fields and radio waves to create detailed images of the body's internal structures. It provides high-resolution images of soft tissues, organs, and bones, allowing for the detection and evaluation of various medical conditions.Two experienced radiologists specializing in musculoskeletal imaging will evaluate the images obtained through conventional MRI. Cases demonstrating involvement, characterized by findings such as thickening exceeding 4 mm in the inferior glenohumeral capsuloligamentous complex, signal increase indicating edema on fluid-sensitive sequences, and a reduction in axillary recess volume (greater than 0.53 ml), will be included in the study.
223586499|NCT06980246|OTHER|Plyometric Exercise|The Plyo-Ex program was conducted for 45 minutes/session twice weekly over 12 weeks. The program was directed by a pediatric physical therapist in accordance with the safety performance guidelines defined by the American Academy of Pediatrics and the US National Strength and Conditioning Association. The program consisted of ten unilateral and bilateral upper extremity exercises in the form of push-ups and ball slams/throws/passes activities and was preceded by a warm-up for 5 minutes and ended with a cool-down for 5 minutes.
223586500|NCT06980246|OTHER|Standard exercise program|The standard exercise program lasted for 45 minutes/session and repeated two times a week for 12 consecutive weeks. The program was conducted by a pediatric physical therapist and consisted of flexibility exercises, strength training, weight-bearing exercises, proprioceptive neuromuscular facilitation, coordination exercise, and functional training.
224072392|NCT02177201|OTHER|Group 1|Intravenous access was established and 10 ml/kg/h 0.9% saline solution was delivered following the induction of anesthesia and until the end of the operation.
224072393|NCT02177201|OTHER|Group 2|Intravenous access was established and 20 ml/kg/h 0.9% saline solution was delivered following the induction of anesthesia and until the end of the operation.
224072394|NCT01238458|DRUG|[18F]AV-45 PET amyloid binding imaging|"This study will recruit a total of 150 evaluable subjects (30 cognitively normal volunteers, and 60 MCI, and 60 AD, respectively) Each evaluable subject involved in this study must fulfill all the inclusion and exclusion criteria according the subject grouping.~Safety measurement will be evaluated by medical history, vital signs, physical examinations, laboratory examinations and collecting of adverse events."
224072395|NCT01526161|DRUG|inhaled fluticasone propionate|100 micrograms
224072396|NCT01526161|DRUG|salmeterol|50 m
224072397|NCT01526161|DRUG|Montelukast|Double blind double dummy
224072398|NCT05563506|BEHAVIORAL|Healthy Kids +|Three times a week for 30 weeks.
224072399|NCT06368713|BEHAVIORAL|Exercise|"* Frequency: Exercise sessions will occur no less than three times per week.~* Intensity: The intensity will be based on a rating of perceived exertion score ranging from 12 to 16 on a scale of 6 to 20.~* Exercise duration: Each exercise session will last approximately 30 minutes.~* Exercise Type:The exercise regimen will include aerobic exercise, resistance exercise, and flexibility training."
224072400|NCT02954497|DEVICE|Surgical placement of the Jarvik 2015 VAD|The Jarvik 2015 VAD is a miniaturized, fully implantable, continuous flow left ventricular assist device.
224072401|NCT02954497|PROCEDURE|Surgical Placement of Jarvik 2015 VAD|Surgical Implant of the Jarvik 2015 VAD is a miniaturized, fully implantable, continuous flow left ventricular assist device.
224072402|NCT02626507|DRUG|Gedatolisib|adenosine triphosphate (ATP) competitive, highly selective and potent inhibitor of pan-class I isoform phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3-K)
224072403|NCT02626507|DRUG|Faslodex|Faslodex® (Fulvestrant) is a potent anti-estrogen drug that binds and degrades estrogen receptors (ERs).
224072404|NCT02626507|DRUG|Palbociclib|Palbociclib (Ibrance®) is an orally active highly selective reversible inhibitor of cyclin-dependent kinase (CDK) 4 and CDK 6.
224072405|NCT02626507|DRUG|Zoladex|Zoladex is used to render menopause in pre-menopausal subjects, given once every 28 days starting at least 14 days prior to treatment.
224072406|NCT04563494|DRUG|dexamethasone|Prevention of post op nausea and vomiting
224072407|NCT03963011|DIAGNOSTIC_TEST|Bowel Ultrasound|Ultrasound imaging of the bowel
224072408|NCT00105937|DRUG|OraVescent fentanyl citrate|
224072409|NCT00000625|DRUG|Zidovudine|
224072410|NCT00000625|DRUG|Zalcitabine|
224072411|NCT00000625|DRUG|Didanosine|
224072412|NCT02553512|OTHER|Ingestible Sensor and Wearable Sensor|This digital health offering passively acquires and records medication-taking and habits of daily living.
224072413|NCT03042507|BEHAVIORAL|Comprehensive Behavioral Intervention for Tics (CBIT)|The existing CBIT protocol includes a functional assessment procedure designed to identify relevant contextual variables (both antecedent and consequent) impacting tic expression and guide the development of an individualized behavioral program to neutralize these contextual influences in the service of tic reduction and psychoeducational component. Given the central role that negative social reactions typically play in tic exacerbation and maintenance, psychoeducation about tics is systematically provided to parents, siblings, and other caretakers and prominent individuals in the child's life. The other primary CBIT component, Habit Reversal Training (HRT), is used to weaken or eliminate the negative reinforcement cycle created by tic-contingent reduction in premonitory urge.
224072414|NCT01489527|BIOLOGICAL|Gardasil Vaccine|The study vaccine was blindly administered as supplied on Day 1, Month 2, and Month 6. All vaccines were injected intramuscularly into the deltoid muscle by a member of the clinical staff.
224175316|NCT06954857|DEVICE|Cuff pressure monitor|"Participants were allocated to the experimental group and the control group using block randomization.~Experimental group: A pressure monitor was used to continuously monitor and promptly adjust the cuff pressure, seal pressure, and leakage pressure of the laryngeal mask."
224175317|NCT00631969|DRUG|Vardenafil ODT (STAXYN, BAY38-9456)|Subjects will receive 12 weeks of PRN (on demand) treatment with Vardenafil 10mg orodispersible tablet (ODT)
224175318|NCT00631969|DRUG|Placebo|Subjects will receive 12 weeks of PRN (on demand) treatment with matching placebo tablet
224175319|NCT05243940|DRUG|dexmedetomidine-ketamine-lidocaine (DKL)|"patients will be administered 0.25 mcg/kg Dexmedetomidine in 100 mL of normal saline within 10 minutes. Followingly, they will receive 1 mL/10 kg of the solution containing ketamine, lidocaine and dexmedetomidine at predefined concentrations. As maintenance, they will be receiving~1mL/10kg/h of the aforementioned solution."
224175320|NCT05243940|DRUG|remifentanil infusion|remifentanil infusion under the Minto model (target controlled infusion-TCI aiming at 4ng/ml blood concentration
224175321|NCT07101393|PROCEDURE|Intraoperative Epiaortic Ultrasound (EAU)|Intraoperative epiaortic ultrasound (EAU) is a real-time imaging technique used during coronary artery bypass grafting (CABG) to evaluate the presence, location, and severity of atherosclerotic plaques in the ascending and arch aorta. In this study, EAU was performed after median sternotomy but prior to aortic manipulation, using a high-frequency linear transducer directly applied to the exposed aorta. Plaques were classified by thickness, and findings were used to guide surgical strategy, including modification of cannulation site, avoidance of cross-clamping, or alteration of grafting technique. This intervention differs from conventional CABG, in which such imaging is not routinely employed.
224175322|NCT07100340|DEVICE|TAVR using a guidance software|TAVR procedure with TAVIPILOT augmented reality guidance software operating during the procedure, enabling clinicians to assess the live analysis and recommendations provided by the software.
224175323|NCT07101536|BIOLOGICAL|EBV mRNA vaccine|EBV mRNA vaccine
224175324|NCT07101536|BIOLOGICAL|Immune Checkpoint Inhibitors, ICIs|Immune Checkpoint Inhibitors, ICIs
224175325|NCT07101978|BEHAVIORAL|serial whole body hyperthermia|The hyperthermia treatment is carried out in a cycle of two treatments per week, with at least one day in between, over a period of three weeks, according to the manufacturer's instructions. According to the guidelines, the rectal (possibly vaginal) temperature (as body core temperature), heart rate and oxygen saturation (Sp02) are continuously determined during the hyperthermiatreatment. During the treatment, continuous supervision by trained personnel is guaranteed, and a doctor is on call.
224175326|NCT03109535|BEHAVIORAL|Fitbit + Maptrek|Users receive a Fitbit Zip to wear daily. Users aslo receive the mHealth MapTrek game that places users in weekly walking races and sends automated text messages to users on a daily basis for the purpose of increasing daily physical activity.
224175327|NCT03109535|BEHAVIORAL|Fitbit only|Users receive a Fitbit Zip to wear daily.
224175328|NCT05186363|DRUG|Chemopreventive Agent - SPAQ|Seasonal malaria chemoprevention (SMC) is a highly effective community-based intervention to prevent malaria infections in areas where the malaria burden is high and transmission occurs mainly during the rainy season. It involves administering monthly courses of sulfadoxine-pyrimethamine (SP) and amodiaquine (AQ) during this peak transmission period to those most at risk: children 3-59 months.
224175329|NCT05186363|DRUG|Control Test - no drugs given|This is where children aged 3-59 months do not receive any chemoprevention drugs but do receive health promotion messages and visit from health workers similar to the chemoprevention SPAQ arm.
223485954|NCT05920239|DIAGNOSTIC_TEST|Sonoelastography|Sonoelastography is a medical imaging technique that combines ultrasound imaging with elastography. It is used to assess the mechanical properties and stiffness of tissues in the body.The probe will be carefully positioned perpendicular to the anterior part of the glenohumeral capsuloligamentous complex (IGHCC), ensuring no pressure is applied and preventing anisotropy. It will be specifically oriented in the coronal plane towards the axillary recess. The grayscale examination will reveal irregularly thickened and heterogeneous structures at the axillary recess level in the patient group. On the other hand, in the control group, measurements will be taken from the anterior band of the normal, thin, smooth, and homogeneous structure of the IGHCC.
223485955|NCT02998112|DRUG|fecal microbiota transplantation|Fecal microbiota which was purified from fresh stool defecated by a healthy donor
224175330|NCT00284726|DEVICE|Celsior Cold Storage Solution|
224175331|NCT04794075|OTHER|Therapeutic Education and Nursing Support Program for Supportive Care|"In addition to the conventional oncology follow-up, patients will participate in an initial educational assessment day within 15 days before or after their first dose of hormone therapy.~A discussion between the patient and the pivot nurse will then make it possible to define personalized objectives, thus guiding the choice of workshops in the outpatient educational program."
224175332|NCT05315297|DEVICE|PEMF device|PEMF device wear overnight daily for four weeks
224175333|NCT05315297|DEVICE|Sham PEMF device|Sham PEMF device wear overnight daily for four weeks. Sham PEMF devices do not emit a radiofrequency electromagnetic field but are otherwise identical in appearance to the PEMF device
224175334|NCT04901273|PROCEDURE|Homologous PRP injections|Patients will be treated with a single injection of Homologous PRP (5 ml) in the knee joint affected by osteoarthritis.
224175335|NCT04901273|PROCEDURE|Placebo injection (saline solution)|Patients will be treated with a single injections of saline solution (5 ml) in the knee joint affected by osteoarthritis
224175336|NCT05949632|DRUG|INCB099280|Administered as specified in the treatment arm description
224175337|NCT05949632|DRUG|axitinib|Administered as specified in the treatment arm description
223586501|NCT06979570|DEVICE|AttentivU|"A device for continuous brain and physiology monitoring. It includes up to 8 EEG sensors as well as EOG and accelerometry which can be monitored in real-time for changes in attention, sleepiness, alertness, cognitive load, stress, and related psychological traits. The EEG data is analyzed in real-time to identify these states and this information can then be used to modulate countermeasures to the state--to either increase or decrease alertness or help counteract cognitive load sleepiness or stress conditions."
223586502|NCT00527319|DRUG|VT-122 low dose|VT-122 low dose, dose escalated
223586503|NCT00527319|DRUG|VT-122 high dose|VT-122 high dose, dose escalated
223485956|NCT02998112|DRUG|Saline|
223485957|NCT04317027|DEVICE|New Fighting Clothing|VO2max test Clothing examination- 2-hour walk in 6 kph/4% elevation under 30 degrees Celsius and 60% relative humidity
223485958|NCT05237050|OTHER|Sound therapy associated with relaxation|"Each patient will attend a total of 3 sessions of about 15 minutes each, once by week.~Sessions will start with relaxation. Then, sound therapy will be delivered using weighted medical tuning forks which resonate at a specific frequency. At the end of the session, the patient will be invited to take a short rest."
223485959|NCT05237050|OTHER|Relaxation alone|"Each patient will attend a total of 3 sessions of about 15 minutes each, once by week.~The procedure will be exactly the same than the other arm (relaxation, rest time), but the operator will not activate any tuning fork (so there will be no sound delivered during the session)."
224072415|NCT01489527|OTHER|Placebo|The study vaccine was blindly administered as supplied on Day 1, Month 2, and Month 6. All vaccines were injected intramuscularly into the deltoid muscle by a member of the clinical staff.
223485960|NCT04530344|DRUG|ruxolitinib|ruxolitinib cream is a topical formulation applied as a thin film to affected areas BID.
223485961|NCT04530344|DRUG|Vehicle|Vehicle cream is a topical formulation applied as a thin film to affected areas.
223485962|NCT04616521|PROCEDURE|Deep brain stimulation|The surgical intervention named deep brain stimulation is a well-established neurosurgical treatment for moderate-to-advanced stage PD. The targets used in this study are STN and GPi, which are widely accepted and used for symptom control in PD. The devices used for intervention have been approved by Chinese National Medical Products Administration (CFDA). The postoperative drug dosage adjustment depends on the efficacy of DBS and the judgment of the movement disorder specialist.
223586504|NCT06981377|DIAGNOSTIC_TEST|Analysis of cell free DNA, and extracellular vesicles (EVs) and EV-associated molecular components (including RNA, DNA, proteins)|"Plasma and buffy coat samples are shipped from the recruiting clinical sites to the lab of Professor Francesca Demichelis at the University of Trento (UniTN).~At UniTN, samples are stored in dedicated freezers with restricted access and subsequently used as follows:~* the plasma is used for the isolation of cell free DNA and extracellular vesicles (EVs);~* the buffy coat is used for the extraction of genomic DNA.~Nucleic acids sequencing library preparations and all downstream omics analyses are performed by Prof. Demichelis team."
224072416|NCT04901208|DRUG|Nicotine pod|Nicotine pods administered to individuals who use Juul
224072417|NCT04901208|DRUG|Placebo pod|Nicotine-free pods administered to individuals who use Juul
224072418|NCT02097615|PROCEDURE|chlorhexidine gluconate|chlorhexidine gluconate spray of 0.125% . Application in the area of the ulcer every 24 hours for six weeks
224072419|NCT02097615|OTHER|deionized water|application every 24 hours six weeks
224072420|NCT01984268|DRUG|ACTHAR|
224072421|NCT04589104|BEHAVIORAL|Expressive writing|"The expressive writing intervention consists of a 6-week, virtually-delivered writing program. Each week, participants meet for 90 minutes via Zoom and will be guided through writing prompts designed to encourage emotional expression and enhance personal resilience. The progression of writing exercises flows as follows:~* Week 1: Writing to expressive difficult emotions~* Week 2: Writing to release \& integrate difficult emotions~* Week 3: Writing to nurture gratitude~* Week 4: Writing to enhance strengths \& resources~* Week 5: Writing to cultivate positive meaning \& savor goodness~* Week 6: Writing to invite insight, perspective, \& growth"
224072422|NCT02566746|DEVICE|Chait Trapdoor caecostomie catheter|implantation of the Chait Trapdoor caecostomie catheter
224072423|NCT02566746|DRUG|continuation of optimal medical therapy|continuation of treatment with laxative and / or suppositories and / or enemas retrograde At 12 months : implantation of the Chait Trapdoor caecostomie catheter
224072424|NCT05405283|BIOLOGICAL|2nd booster with Comirnaty® (Pfizer-BioNTech)|In participants previously vaccinated with 3 doses of mRNA vaccine, he/she will receive one dose of Comirnaty® (Pfizer-BioNTech) vaccine as a second booster
224072425|NCT05405283|BIOLOGICAL|CoV2 preS dTM adjuvanted vaccine (B.1.351), Sanofi/GSK|In participants previously vaccinated with 3 doses of mRNA vaccine, he/she will receive one dose of CoV2 preS dTM adjuvanted vaccine (B.1.351), Sanofi/GSK vaccine as a second booster
224072426|NCT00800501|DRUG|sNN0029|Continuous ICV infusion at one of three dose levels
224072427|NCT00800501|DRUG|Placebo|Continuous ICV infusion
224072428|NCT03264300|OTHER|MRI|MRI scans to include: scout images, transmitter tuning, shimming, slice prescription - 5 min; conventional structural MRI; T1-weighted anatomic MRI scan - 7 min; and, T2-weighted anatomic MRI scan - 5 min. Advanced MRI to include: Diffusion Weighted MRI (DW-MRI) - 7 min; Chemical Exchange Saturation Transfer (CEST) - 9 min; Dynamic Susceptibility Contrast / Dynamic Contrast Enhanced MRI - 8 min; and, other advanced imaging, as needed, to be determined. Post-contrast conventional MRI to include T1-weighted anatomic MRI scan - 7 min. Repeat within 1 month.
224072429|NCT03264300|OTHER|MRI|MRI scans to include: scout images, transmitter tuning, shimming, slice prescription - 5 min. Conventional structural MRI to include: T1-weighted anatomic MRI scan - 7 min; and, T2-weighted anatomic MRI scan - 5 min. Serial DSC-MRI: staged injections of Gd-based contrast and Ferumoxytol - 20 min. Post-contrast conventional MRI: T1-weighted anatomic MRI scan - 7 min.
224072430|NCT01394146|OTHER|Research diet|Participants will be provided specially prepared meals to eat at home for two weeks. During the first week, participants will eat foods that do not have any phosphorus-based food additives in them (this is called the control diet). During the second week, participants will eat foods that all have phosphorus-based food additives in them (called the intervention diet).
224072431|NCT03312959|DRUG|hyperbaric bupvacaine in Peribulbar block|hyperbaric bupivacaine in Peribulbar block will be injected in the posterior segment surgery
224072432|NCT03312959|DRUG|isobaric bupvacaine in Peribulbar block|isobaric bupivacaine in Peribulbar block will be injected in the posterior segment surgery
224175338|NCT05244733|BEHAVIORAL|Social Engage (S-ENGAGE)|S-ENGAGE uses the process of action planning to foster sustained behavior change. Action planning involves: 1) select a goal; 2) develop ideas to meet this goal; 3) choose one or more of these ideas; 4) identify concrete steps to implement the goal (i.e., form an action plan); 5) identify and address barriers if needed.
224175339|NCT05244733|BEHAVIORAL|The Healthy Lifestyles Education Program|The healthy lifestyles education program is a self-guided psychoeducational program, including a notebook containing evidence-based educational material on mental health, physical activity, and information on community resources.
224175340|NCT05524584|DRUG|Fulvestrant|Given intramuscularly
224175341|NCT05524584|DRUG|Anastrozole|Given orally
224175342|NCT05524584|DRUG|Abemaciclib|Given orally
224175343|NCT05973565|OTHER|Musicokinetic Training|The intervention protocols are either a) synchronous learning format, b) asynchronous remote video- based, and c) control.
224175344|NCT03350763|DEVICE|Tannenbaum 10 Fr biliary stent|Tannenbaum 10 Fr biliary stent
224175345|NCT03350763|DEVICE|Self-expandable metallic biliary stent|ie WallFlex biliary RX
224175346|NCT04362514|BEHAVIORAL|MEPC - Multi-component exercise program related to cycling|Structured and progressive multicomponent exercise program with and without bikes. Training period will last over 3 months with 8 sessions à 60 minutes. Training sessions will address motor competence (balance, strength, cycling skills and techniques) and cognitive skills required during cycling. Furthermore, fall-related psychological concerns will be addressed.
224175347|NCT04362514|OTHER|HRP - health-related presentations|HRP include 3 presentations on healthy aging (one per month) with a duration of 60 minutes
223485963|NCT05031221|BEHAVIORAL|Yoga + behavioral weight loss|A 12-week, one-arm proof-of-concept and feasibility study will be conducted at the University of Colorado Anschutz Medical Campus (CU-AMC) to assess the processes critical for the success of future randomized trials including: a) Evaluating the feasibility and acceptability of adding a multi-component yoga program to a standard BWL intervention and b) Examining pre-post changes in relevant clinical/cardiometabolic, psychological, and energy balance/behavioral outcomes to inform the design of future trials. Participants will receive a comprehensive, group-based BWL intervention consistent with current guidelines for obesity treatment and a carefully designed multi-component yoga intervention delivered through pre-recorded videos delivered through a cloud-based platform that will be completed in-person and at-home (BWL+yoga).
223485964|NCT01402700|DEVICE|Visi-Pro™ Balloon Expandable Stent System|Implantation of one or more study devices in the common and/or external iliac artery.
223586505|NCT06979947|BEHAVIORAL|Structured Menopause Education Program|The structured education program was developed by midwifery researchers and delivered face-to-face by a certified midwife over four weekly sessions. Each session lasted approximately 20-25 minutes and covered topics such as menopausal symptoms, lifestyle changes, and coping strategies. Educational materials were individualized based on participants' MENQOL pre-test scores.
224175348|NCT01150149|BEHAVIORAL|No face touch|
224175349|NCT01150149|DEVICE|Surgical face mask|
224175350|NCT01150149|DEVICE|Surgical face mask + no face touch|
224175351|NCT05025306|DRUG|ziziphus honey|ziziphus honey obtained form ziziphus spina-christi trees also called sidr tree
224175352|NCT01376115|DRUG|Nelarabine|
224175353|NCT05487807|DRUG|Nicotine patch|Will be receiving nicotine therapy
224175354|NCT05487807|BEHAVIORAL|text messaging|Will be enrolled in an texting app
224175355|NCT02316782|DEVICE|Blinded IVUS assessment|Only the angiogram is used for stent placement
224175356|NCT02316782|DEVICE|Nonblinded IVUS|Angiogram, Grayscale IVUS and VH IVUS used for stent placement pre and post intervention
224175357|NCT02207127|PROCEDURE|MRI, DISE, and Surgery|MRI, DISE, and Surgery
224175358|NCT00738231|BEHAVIORAL|Training|The training materials were randomly distributed to study participant groups. The list of names was systematically divided into two groups: odd-numbered individuals were given brochures only, and even-numbered individuals were given both letters and brochures. Since we could not have prevented an illustrated material to be passed by in a closed environment, it was deemed appropriate to distribute both the letter and brochure instead of just the brochure.
224175359|NCT00738231|BEHAVIORAL|Training|The training materials were randomly distributed to study participant groups. The list of names was systematically divided into two groups: odd-numbered individuals were given brochures only, and even-numbered individuals were given both letters and brochures. Since we could not have prevented an illustrated material to be passed by in a closed environment, it was deemed appropriate to distribute both the letter and brochure instead of just the brochure.
224175360|NCT05206201|DRUG|ZY19489 Capsule|Two part study with single and multiple dose
224175361|NCT05206201|DRUG|Placebo Capsule|Two part study with single and multiple dose
224175362|NCT00491062|PROCEDURE|Biopsies|
224175363|NCT03646929|DIAGNOSTIC_TEST|MEP using standard facilitation technique|measuring of MEP using standard facilitation technique according to the Guidelines of International Federation of Clinical Neurophysiology
224175364|NCT03646929|DIAGNOSTIC_TEST|MEP using modified facilitation technique|measuring of MEP using modified facilitation technique (application of additional 8-12x magnetic stimuli for arms and legs)
224175365|NCT01240629|OTHER|laboratory biomarker analysis|Correlative study
224175366|NCT01240629|OTHER|questionnaire administration|Correlative study
224175367|NCT01240629|DRUG|doxorubicin-GnRH agonist conjugate AEZS-108|Given IV
224175368|NCT03459092|DRUG|Botulinum toxin type A|Botulinum toxin injection in the horizontal extraocular muscles.
224175369|NCT03459092|PROCEDURE|Strabismus surgery|Strabismus surgery on the horizontal extraocular muscles
224175370|NCT02107716|PROCEDURE|Lidocaine injection with bicarbonate|bicarbonate added to change pH
224175371|NCT02107716|PROCEDURE|lidocaine injection|Lidocaine injection with pH unchanged
224175372|NCT05457712|DIETARY_SUPPLEMENT|protocol|The energy and protein value of the prescribed diet will be followed according to the original protocol considering plans A, B or C, via a hypercaloric formula with a caloric density of 1kcal/ml for infants starting 60 days preoperatively. The return for nutritional monitoring will take place after evaluation: weekly, biweekly or monthly.
224175373|NCT05457712|OTHER|Control|Afterwards, they will be evaluated through the standard nutritional protocol of the nutrition clinic of the Instituto de Cardiologia de and Hospital Santo Antonio de Porto Alegre, whose standard nutritional prescription is a polymeric formula with a caloric density of 0.67 kcal/ml. Nutritional monitoring will take place through telephone contact for information on the baby's clinical data and in person before the surgery is performed.
224175374|NCT05951881|OTHER|Emergency Care Unit - medicines|"The same group of patients admitted to the emergency room will respond separately to a pharmacist and a pharmacy assistant about their daily medication.~The two medical records will be compared in order to evaluate the work of the pharmacy assistant on the basis of 3 sources :~* the Electronic Medical Record~* the patient's medication history~* the reference pharmacy"
224175375|NCT06224491|OTHER|Reflex locomotion according to Vojta|Tactile stimulation according to Vojta´s reflex locomotion
224175376|NCT02879968|OTHER|Non-interventional study|
223485965|NCT05814835|DRUG|2-4 mCi 68Ga/64Cu-FAPI-XT117|68Ga/64Cu-FAPI-XT117 and 18F-FDG PET/CT were performed for each patient(the interval was more than one day and less than four weeks). PET/CT images were acquired 30min, 60min, 120min after 2-4 mCi 68Ga/64Cu-FAPI-XT117 injection.
223485966|NCT05814835|DRUG|4-6 mCi 68Ga/64Cu-FAPI-XT117|68Ga/64Cu-FAPI-XT117 and 18F-FDG PET/CT were performed for each patient(the interval was more than one day and less than four weeks). PET/CT images were acquired 30min, 60min, 120min after 4-6 mCi 68Ga/64Cu-FAPI-XT117 injection.
223485967|NCT05814835|DRUG|6-8 mCi 68Ga/64Cu-FAPI-XT117|68Ga/64Cu-FAPI-XT117 and 18F-FDG PET/CT were performed for each patient(the interval was more than one day and less than four weeks). PET/CT images were acquired 30min, 60min, 120min after 6-8 mCi 68Ga/64Cu-FAPI-XT117 injection.
223485968|NCT00936819|BIOLOGICAL|Plasma-Lyte A and 25% Autologous Plasma|Single dose of 8 mls given by investigator via intracoronary injection into stent of infarct-related artery
223485969|NCT00936819|BIOLOGICAL|Autologous EPCs|Single dose of 20 million cells in 8 mls given by investigator via intracoronary injection into stent of infarct-related artery
223485970|NCT00936819|BIOLOGICAL|Autologous EPCs Transfected with human eNOS|Single dose of 20 million cells in 8 mls given by investigator via intracoronary injection into stent of infarct-related artery
223485971|NCT03453216|BEHAVIORAL|neuropsychological tests|"Part 1: to determine the cognitive capacity, the subjects undergo different neuropsychological tests To determine individual characteristics children, adolescents and adults complete self-assessment questionnaires .~Adults spend a semi-directive interview. Part 2: while the subject 1 (S1) is installed in the MRI, he perform behavioral tasks with the subject 2 (S2) (familiar peer of the same age ± 2 years) installed in an adjacent room, alternating periods when S1 is observed by S2 (condition Social) and periods when S1 is not observed by S2 (condition Alone)."
223485972|NCT04442048|BIOLOGICAL|IMM-101|Three doses of IMM-101 on days 0, 14, and 45.
223485973|NCT04442048|OTHER|Observation|No active treatment. Observation only
223485974|NCT04638517|DRUG|Danazol|Danazol up to 800mg daily in two-divided doses.
223485975|NCT04638517|DRUG|Placebo|Matching placebo.
224175377|NCT06388538|OTHER|Conservative treatment (non-operative treatment)|Conservative treatment consists of medical therapy (see fluid, anti-pain drugs and antibiotics, except for radiologic drainage)
224175378|NCT06388538|OTHER|Surgical treatment (operative treatment)|"Surgical treatment (operative treatment) is explained as follows:~1. Open surgery management, i.e. traditional open surgery approach with any kind of technique: either reconstructive (with or without ileal/colonic stoma protection) or non-reconstructive (see Hartman procedure)~2. Laparoscopic approach, i.e. emergency laparoscopic resection with the characteristics mentioned above"
223485976|NCT05449002|BEHAVIORAL|Practicing the Opposite (PTO)|This 30-45-minute digital program is designed to help youths on the waitlist feel better prior to treatment and may also improve their treatment engagement and outcomes.
223485977|NCT05449002|OTHER|Usual Clinical Care|Usual care provided by participating youth mental health clinics in the United States.
224175379|NCT03846895|DEVICE|Microablative Fractional CO2 laser|3 therapies intravaginally administered will be applied at monthly intervals
224175380|NCT03582254|RADIATION|[18F]-FDG PET/MR|"\[18F\]-FDG PET/MR will be performed in the Department of Nuclear Medicine - Pitié-Salpêtrière Hospital:~* prior to initiation of chemotherapy (rituximab, methotrexate, procarbazine, vincristine and cytarabine) (PET#1),~* after two chemotherapy cycles (PET#2),~* at the end of the first-line chemotherapy regimens (PET#3)."
224175381|NCT04408105|BEHAVIORAL|Primary Care Provider Survey|To assess PCP demographics, attitudes, and perceived barriers to BE screening, we have developed a PCP survey using a theoretical model of physician behavior based on Social Cognitive Theory and the Theory of Reasoned Action. This approach has proven effective in colorectal cancer and hepatocellular carcinoma screening. This model includes domains of provider background and experience, screening practices, perceptions of screening, physician influences, and practice environment and practice patterns. To assess PCP knowledge of BE screening, we have designed 9 clinical vignettes that will categorize provider responses into under-, appropriate, and over-use of BE screening. Survey questions and vignettes have been adapted from earlier validated surveys. Prior to distribution, the survey and vignettes will be pretested and refined based on a cognitive interview about the survey among a convenience sample of 10 PCPs.
223485978|NCT05484804|OTHER|Data Accountability and Transparency|Collaboration with Practice Facilitators; Maternal Early Warning System; Disparities Dashboard; Racial Equity Training
223485979|NCT05484804|OTHER|Community-Based Doula (CBD) Support|Community-Based Doula support for high-risk patients; Racial Equity Training
223485980|NCT05783323|DRUG|Larotrectinib monotherapy|Patients will receive larotrectinib monotherapy for 6 months at the FDA-approved dose.
223485981|NCT05783323|RADIATION|131I therapy|Patients will receive 131I therapy after 6 months of larotrectinib.
223485982|NCT06008587|DEVICE|AIRVO3 TM|A device that provides high flows of heated and humidified respiratory gases to patient who breath spontaneously. Patients will be treated with the device up to 15 days or until the occurrence of respiratory acidosis defined by pH\<7.35, whichever come first.
224175382|NCT04408105|BEHAVIORAL|Gastroenterologist Survey|To assess GI demographics, attitudes, and perceived barriers to BE screening, we have developed a GI survey using a theoretical model of physician behavior based on Social Cognitive Theory and the Theory of Reasoned Action. This approach has proven effective in colorectal cancer and hepatocellular carcinoma screening. This model includes domains of provider background and experience, screening practices, perceptions of screening, physician influences, and practice environment and practice patterns. To assess GI knowledge of BE screening, we have designed 9 clinical vignettes that will categorize provider responses into under-, appropriate, and over-use of BE screening. Survey questions and vignettes have been adapted from earlier validated surveys. Prior to distribution, the survey and vignettes will be pretested and refined based on a cognitive interview about the survey among a convenience sample of 10 GIs.
224175383|NCT04408105|BEHAVIORAL|Patient Survey|To assess patient knowledge, attitudes, and barriers to completion of BE screening, we will use a theoretical model of patient behavior on the Health Behavior Framework to guide selection of relevant variables for survey development including 4 domains: knowledge about BE and EAC, potential barriers to BE screening completion, patient attitudes and demographic information. Prior to distribution, the survey will be refined and pretested among a sample of 10 patients with each participant completing a cognitive interview prior to distribution.
224175384|NCT04809415|OTHER|Photobiomodulation|Photobiomodulation consists of irradiation by light in order to achieve photochemical and photophysical outcomes.
224175385|NCT04809415|OTHER|Sham|Simulation of the application of photobiomodulation therapy.
224175386|NCT01648517|DRUG|chemotherapy|A1: docetaxel 60mg/m2 on Day 1 vinorelbine 20mg/m2 on Day 1 and Day 8 (DV) A2: gemcitabine 1000mg/m2 on Day 1 vinorelbine 25mg/m2 on Day 1 and Day 8 (GV) A3: docetaxel 75mg/m2 on Day 1 carboplatin AUC5 on Day 1 (DC) A4: gemcitabine 1000mg/m2 on Day 1 and 8 carboplatin AUC5 on Day 1 (GC)
224175387|NCT01648517|DRUG|chemotherapy|Drug: Docetaxel 75mg/m2 IV on Day 1 Drug: Carboplatin AUC5 IV on Day 1
224175388|NCT03688191|DRUG|Sirolimus|Patients will receive oral sirolimus at a starting dose of 2 mg per day for 3 days and a sequential dose of 1mg per day, with dose adjusted according to tolerance and to maintain a therapeutic range of 6-15 ng/mL.
224175389|NCT02844829|OTHER|Prostate MRI|MRI of the prostate prior to prostate biobsy
224175390|NCT01966029|DRUG|BMN 110|All pateints receive treatment with BMN 110
224175391|NCT02008162|DRUG|Bronchodilators|Administration of both albuterol and tiotropium bromide after a 48h period of washout from all bronchodilators, followed by spirometry and plethysmography
224175392|NCT00387829|DEVICE|DuraGen Plus Adhesion Barrier Matrix|Application of DuraGen Plus Adhesion Barrier Matrix in spine surgery
224175393|NCT04997291|DRUG|Dexrazoxane|Twelve enrollees will be consecutively assigned to a dosing regimen of 400 mg/m2/dose. The medication will be administered in the operating room 30 minutes prior to starting cardiopulmonary bypass (dose #1), prior to aortic cross clamp removal (dose #2), and on the morning after surgery in the cardiac intensive care unit (dose #3).
223485983|NCT06008587|OTHER|Standard therapy|Standard therapy depends on the acute respiratory failure etiology. Treatments will be administered at the investigator's discretion in accordance with the standard of care.
223485984|NCT06304792|PROCEDURE|Immediate FET in a stimulated or programmed cycle|Patients will undergo FET in the cycle immediately following oocyte retrieval and a failed fresh embryo transfer or freeze all.
224175394|NCT03613974|DRUG|Lidocaine|patients will receive different lidocaine concentrations
224175395|NCT06722313|DIAGNOSTIC_TEST|Gametes (sperm or second polar bodies, MI eggs) or arrested embryos were reserved for identification of a proband|"1. Targeted deep sequencing for mosaicism detection for patients with suspected gonadal mosaicism, eg. Repeated similar abortion due to the same variant while the couple were tested negative for the variant in the peripheral blood.~2. Ovarian stimulation, embryo culture, biopsy and vitrification as routinely used in the IVF clinical practice.~3. Gametes and arrested embryo preservation by the embryo laboratory during embryo culture.~4. Genetic testing, including multiple displacement amplification for WGA, variant sequencing in WGA products and Infinium Chip protocol for amplified DNA and haplotype analysis"
224175396|NCT00452166|DRUG|rosiglitazone|
224175397|NCT00511706|DRUG|dexamethasone|Intravitreal injection of dexamethasone 700 µg at Day 1.
224175398|NCT00511706|BIOLOGICAL|ranibizumab|Ranibizumab 500 µg at day -30 and Day 7-14.
224175399|NCT00511706|OTHER|sham|Sham needle-less injection administered in the study eye at Day 1.
224175400|NCT04144140|DRUG|E7766|E7766, solution, intratumorally
224175401|NCT01465958|BIOLOGICAL|GAMUNEX-C|GAMUNEX-C Immune Globulin Injection (Human), 10%, Caprylate/Chromatography Purified, Intravenous Administration: 200-600 mg/kg per intravenous infusion every 3-4 weeks
224175402|NCT01465958|BIOLOGICAL|GAMUNEX-C|GAMUNEX-C Immune Globulin Injection (Human), 10%, Caprylate/Chromatography Purified, Subcutaneous Administration: weekly subcutaneous infusion at a mg/kg dose based on subject's intravenous dose and dosing interval x 1.37 conversion factor
224175403|NCT04427423|OTHER|physical therapy treatment|the experimental group received positional distraction plus stabilization exercises and the control group received stabilization exercises only.
224175404|NCT05275166|BEHAVIORAL|Induction of alcohol craving|Presentation of images that may induce craving for alcohol. Recording of brain activity
223485985|NCT03279952|DRUG|CNS Stimulant|Participants will be stabilized by any FDA approved CNS stimulant medication during open label trial.
223485986|NCT06208878|OTHER|Non Interventional|Safety and Efficacy Assessment
223485987|NCT06582849|OTHER|Standard assistance|Standard assistance includes all community and institutional resources currently available for which the participant qualifies.
223485988|NCT06582849|OTHER|Enhanced assistance|Enhanced assistance includes gift cards and checks to support food, housing, utilities, transportation, pharmacy, and other non-medical costs
223485989|NCT03868540|DRUG|BI 1291583|tablet
223485990|NCT03868540|DRUG|Placebo|tablet
224175405|NCT05275166|OTHER|Questionnaires|Questionnaires related to alcohol, quality of life, anxiety and depression
224175406|NCT06199193|DIETARY_SUPPLEMENT|Personalized diet|Personalized supplement designed by artificial intelligence based on the intestinal microbiota and incorporated into diets
224175407|NCT06199193|DIETARY_SUPPLEMENT|Dietary counseling|Dietary advice will be provided to adapt the diet to the nutritional objectives and recommended intakes.
224175408|NCT04922814|DRUG|muscle relaxation|They will receive muscle relaxation treatment for at least 48 hours. Cisatracurium will be given. Short term infusions up to 24 hours will be given in a dose rate of 2-3 mic/Kg/min followed by intervallic shots of 2-5 mg.
224175409|NCT03109418|DRUG|Ketamine|OSA patients receiving standard inhaled anesthesia combined with a low-dose ketamine infusion in which dosage will be based on ideal or adjust body weight
223485991|NCT01883674|OTHER|Resistance training|All group will exercise 3x/week. Each session of resistance training will last 60min. and will target main muscular groups.
223485992|NCT00808704|DRUG|recombinant human erythropoietin|r-hu-EPO were administered either 300 U/kg or 500 U/kg, subcutaneously the first time and then intravenously every other day for 2 weeks.
224175410|NCT03109418|PROCEDURE|Control|OSA patients receiving standard inhaled anesthesia combined with normal saline
224175411|NCT02043704|DRUG|IV Acetaminophen|Details covered in arm description.
224175412|NCT01986166|DRUG|Cobimetinib|In Stage 1, cobimetinib will be administered at a starting dose of 80 mg q2w. The doses will be escalated to identify MTD. In Stage 2, participants will receive cobimetinib at the established MTD.
224175413|NCT01986166|DRUG|MEHD7945A|MEHD7945A will be administered as IV infusion at a dose of 1100 mg q2w until disease progression or unacceptable toxicity.
224175414|NCT04552340|OTHER|Patient with SAR-CoV-2 infection|Study population The study cohort will be enrolled among patients referred to our the Humanitas Research Hospital, the Hospital Cliniche Gavazzeni (Bergamo) hospitals for SARS-CoV-2 screening who will/will not be hospitalized in wards dedicated to COVID-19 patients or admitted to intensive care unit.
224175415|NCT00050505|BIOLOGICAL|Live vaccinia virus vaccine|Dryvax undiluted. Cohort A receives undiluted dose of Dryvax vaccine
224175416|NCT00050505|BIOLOGICAL|Live vaccinia virus vaccine|Dryvax with diluent (50% glycerin and 0.25% phenol in sterile water). Cohort A-C receives diluted dose of Dryvax vaccine.
224175417|NCT00982267|DRUG|SU014813|Escalating doses of SU014813 from 50 to 250mg/day . Capsules administered daily either as continuous dosing or in cycles of 4 weeks on 1 week off
224175418|NCT01816516|BEHAVIORAL|Healthy Babies|"Each lesson is designed to promote the development of healthy infant eating, and incorporates research-based information, opportunities for mothers to develop and practice skills, and a discussion of strategies to overcome challenges and problem-solving techniques. During lessons, mothers engage in activities in support of lesson goals. Intervention strategies focusing on feeding practices will include modification of the feeding environment (e.g., television off during feeding).~The telephone contacts, 10 minutes in length, made at 6, 8, and 10 months, reinforce key concepts in the lessons after conclusion of the intervention to maintain effects."
224175419|NCT01816516|BEHAVIORAL|Expanded Food and Nutrition Education Program|Core EFNEP concepts are United States Department of Agriculture (USDA) My Pyramid, fruits, vegetables, meats, whole grains, food safety, and food resource management. Educators for the EFNEP group will use the EFNEP lessons which address basic knowledge customized for families with infants. Mothers in the EFNEP group will receive a series of six lessons from the nutrition education program offered in each state; they provide a series of lessons focused on nutrition education for families and do not include extensive content on feeding infants.
224175420|NCT04322799|PROCEDURE|Device: Randomization between prosthetic components|Patients are randomized between two types of cup components in total hip arthroplasty. Identical cups made of either highly-crosslinked polyethylene or conventional polyethylene.
223485993|NCT02080416|DRUG|Nelfinavir|Nelfinavir will be given 3000 mg orally twice daily on days 1-14 of a 14-day cycle. NFV will be continued in patients tolerating therapy for 4 cycles (8 weeks).
223485994|NCT05148728|PROCEDURE|Endoscopic fulguration|already included. WE will use Storz monopolar device for fulguration
223586506|NCT06983522|DEVICE|Toilet training booklet|Education on the subject of motherhood, the concept of motherhood and the role of motherhood. Education on parental attitudes, types of attitudes. Education on education in school, the age of starting education, the duration of education, signs of readiness for child toilet training, Brazelton's child-focused approach and characteristics of toilet training, the effects of parents' attitudes on toilet training and education on problems that may be encountered during toilet training. It covers the topics.
224175421|NCT00699361|DRUG|Pantoprazole|Pantoprazole 160 mg I.V.
224175422|NCT00699361|DRUG|Pantoprazole|Pantoprazole 160 mg intravenously (IV)
224175423|NCT01493024|DRUG|Zirconium silicate (ZS)|Randomized escalating doses (0.3g, 3g and 10g) of ZS (fractionated, protonated microporous Zirconium Silicate, an oral sorbent) administered 3 times daily (tid) with meals.
224175424|NCT01493024|DRUG|Placebo|Randomized to mimic escalating doses of experimental drug administered 3 times daily (tid) with meals.
224175425|NCT04384276|OTHER|The Weigh Easy System|By use of a small user-friendly luggage scale, the family can easily and safely obtain a weight within the comfort of their own home. Using the Weigh Easy eClipboard, a message will be sent to the family on a weekly basis via Cerner's Message Center that will include a link. The link will be used by parents to enter and submit the patient's current weight. Upon submission, the weight will be transmitted into the patient's EMR after it's reviewed and accepted by a member of the study team. When the weight is received in the system, an alert will be triggered that will notify the study team of its arrival. While the Weigh Easy eClipboard function does qualify as a device, as the investigators will be making clinical decisions based off of the data received through the form, the device is not being used investigationally on this study. The eClipboard function is a standard part of the Cerner framework and has been previously investigated and vetted by for safety and efficacy.
224175426|NCT04384276|OTHER|Retrospective Control|No interventions will be administered to the historical control group.
224175427|NCT02221258|BIOLOGICAL|FURESTEM-RA Inj.|Patients will be treated FURESTEM-RA Inj.+DMARDs(Disease-Modifying antirheumatic drugs)
223586507|NCT06980883|OTHER|Dry Needling|dry needles Administered to patients in Group 1 as part of their treatment regimen( 2 days per week).
223485995|NCT06354608|BEHAVIORAL|Audio Book Group|Audiobook will be applied during the entire IM injection procedure and until the end of the procedure. After the procedure is over, the children will be taken to the waiting area. After being allowed to rest for 1-2 minutes, the child will be asked to rate their level of pain and fear during the procedure. A parent who is with the child and observes the child's behavior, and the same nurse who is independent from the study, will independently rate the child's pain and fear level during the procedure.
223485996|NCT06354608|DEVICE|Local Vibration Group|In the local vibration group, IM injection will be performed with a vibrating massage device. After the procedure is finished, the children will be taken to the waiting section. After being allowed to rest for 1-2 minutes, the child will be asked to rate their level of pain and fear during the procedure. A parent who is with the child and observes the child's behavior and the same nurse who is independent from the study will independently rate the pain and fear level of the child during the procedure.
223485997|NCT06550648|PROCEDURE|Right Heart Catheterization (Swan Ganz Catheter)|Swan Ganz Catheter only for PAH patients, Using the swan ganz and pressure transducer
223485998|NCT00040638|DRUG|TLK286|
223485999|NCT00002470|BIOLOGICAL|recombinant interferon alfa|
223486000|NCT00002470|DRUG|fluorouracil|
223486001|NCT06434350|DRUG|Enfortumab Vedotin|Given by IV
223486002|NCT06434350|RADIATION|Radiation Therapy|Given by Radiation Therapy
223486003|NCT06378047|DRUG|Pembrolizumab|Pembrolizumab is an immunotherapy that will be administered via IV infusion.
223486004|NCT06378047|DEVICE|Irreversible Electroporation|Participants will undergo IRE as standard of care treatment.
223486005|NCT06468137|BEHAVIORAL|Swedish I-ACE|Rehabilitative programme with focus on communication strategies and problem solving for people with hearing loss.
223486006|NCT06468137|BEHAVIORAL|Clinical visit|Visit in the clinic with focus on audiologic rehabilitation.
223486007|NCT06468137|OTHER|No follow-up|Participants choosing no follow-up.
223486008|NCT05827835|DRUG|CD7 CAR-T cells injection|CD7 CAR T cells treat patients with refractory or relapsed CD7 positive Malignant Hematologic Diseases
223486009|NCT05827835|OTHER|Allogeneic hematopoietic stem cell transplantation|In this study, Allogeneic hematopoietic stem cell transplantation is used as a bridge therapy to CD7 CAR T cells infusion to treat patients with refractory or relapsed CD7 positive Malignant Hematologic Diseases
223486010|NCT05325034|BEHAVIORAL|Early Intervention|"Participant and clinician lipid score card to increase the likelihood of effecting guideline-directed change in lipid lowering therapy through two key actors - both the patient and their clinician(s).~The Score Card documents four key fields to be completed by the participant, study team and participant's regular clinician including 1) 'current' LDL-C level, 2) participant's level of adherence to lipid-lowering therapy using modified Voil's criteria, 3) lipid-lowering management decisions made at the clinician's appointment and 4) currently prescribed lipid-lowering therapies."
223486011|NCT05019638|DRUG|Regional anesthesia group|bupivacaine 0.25% with epinephrine 1:400,000.
223486012|NCT05019638|DRUG|Local multimodal analgesia group|5mg of morphine, 500 mg of epinephrine, 15mg of ketorolac, and 20mg of bupivacaine.
223486013|NCT04862286|DRUG|Risankizumab|Subcutaneous (SC) injection.
223486014|NCT06366269|OTHER|Acupuncture|traditional and electroacupuncture
223486015|NCT06366269|BEHAVIORAL|Behavioral management|based on American urologic association guidelines
223486016|NCT06366269|OTHER|Physical therapy|pelvic floor with biofeedback
223486017|NCT02489539|DEVICE|GORE® EXCLUDER® Conformable AAA Endoprosthesis|Endovascular Aneurysm repair (EVAR) is a minimally invasive procedure designed to exclude an aneurysmal segment of the aorta from blood circulation. The EVAR procedure involves delivery of a stent- graft compressed onto a catheter to an aneurysmal segment of the aorta from a remote access site, generally the femoral artery. Arterial access may be done by either percutaneous or cut-down technique.
224072433|NCT00898560|DRUG|eslicarbazepine acetate and Microginon®|"eslicarbazepine acetate: once-daily oral dose of 800 mg on days 1- 15 of treatment period.~Microginon®: single oral dose on day 14 of treatment period"
224072434|NCT00898560|DRUG|Microginon®|Single oral dose of Microginon® (30ug ethinyloestradiol and 150ug levonorgestrel)
224072435|NCT04248439|BIOLOGICAL|RP-L102|CD34+ enriched cells from subjects with Fanconi anemia subtype A transduced ex vivo with a lentiviral vector carrying the FANCA gene
224072436|NCT00248248|DRUG|liposomal doxorubicin|Doxil at 50mg/m2 infused over one hour every 3 or 4 weeks for 3-6 cycles
224072437|NCT02201407|DRUG|Peginterferon alfa-2a|Peginterferon alfa-2a treatment according to standard of care, current summary of product characteristics and in line with the local labeling.
224072438|NCT01344876|DRUG|OPB-51602|once daily during the treatment period
224072439|NCT03116932|BEHAVIORAL|PrEP knowledge and acceptability questionnaire|This questionnaire consists of 187 items and evaluates socio-demographic variables, sex conducts, PrEP knowledge and PrEP acceptability.
224072440|NCT06107062|DRUG|Cannabidiol - fsCBD|Full-spectrum (i.e., fsCBD, 7.8mg THC (3.4mg BID)), plant-derived CBD capsules produced by Ecofibre/Ananda Hemp will be used.
224072441|NCT06107062|DRUG|Placebo|Placebo arm
224072442|NCT06107062|DRUG|Cannabidiol - bsCBD|Broad-spectrum (i.e., bsCBD, 0% THC), plant-derived CBD capsules produced by Ecofibre/Ananda Hemp will be used
224072443|NCT05798338|DIAGNOSTIC_TEST|Blood sample|Analysis of plasma in order to quantify and characterize EVs
224072444|NCT06659146|DEVICE|Superficial hyperthermia|Superficial hypothermia will be delivered using a CE-marked water-filtered infrared A (wIRA) machine (hydrosun® TWH1500)
224072445|NCT02926950|DRUG|Sotagliflozin (SAR439954)|Pharmaceutical form: tablet. Route of administration: oral.
224072446|NCT02926950|DRUG|Placebo|Pharmaceutical form: tablet. Route of administration: oral.
223486018|NCT05402761|BEHAVIORAL|Nurse-guided BBTi group|On the arrival for the baseline appointment, participants will receive workbooks which include an outline and content of BBTi. In the end of week 1 and 3, nurse interventionist will meet participants to review their sleep diary data and negotiate their bedtime and wake-time schedule. During the weeks 2 and 4, participants will receive planned follow-up phone calls to assess their adherence and review progress and challenges.
224175428|NCT04209140|DRUG|lithium treatment|"Decisions relating to treatment are also considered the clinician's responsibility to be made according to bipolar treatment guidelines and international standards of care (e.g. discontinuation, co-prescriptions, and according to SmPC in force). After the clinician has confirmed the indication of Lithium treatment as well as the absence of contra-indicated concomintant medication (NSAIDs and Diuretics) and after pre-~Lithium evaluations confirm the absence of contra-indication, Lithium is initiated following standard of care:~progressive titration to reach therapeutic plasma levels. Clinicians will use the therapeutic range provided by the laboratory they use in their usual clinical practice and according to the type of Lithium they prescribe."
224175429|NCT04034342|OTHER|RaceRunning|RaceRunning (www.racerunning.org) is a growing disability sport that provides an opportunity for people with moderate-to-severe CP to participate in exercise in the community. It allows those who are unable to walk independently, to propel themselves using a RaceRunning bike, which has a breastplate for support but no pedals. Participants sit on the saddle and use their legs to propel themselves forward.
224175430|NCT00003855|PROCEDURE|axillary lymph node dissection|
224175431|NCT00003855|RADIATION|whole breast irradiation|
224175432|NCT00669240|DRUG|Varenicline|According to the approved Summary of Product Characteristics (SmPC), patients will be required to orally take 0.5 mg once daily for the first 3 days and titrate up to 0.5 mg twice daily for days 4 - 7. From day 8 to the end of treatment patients should take 1 mg twice daily. Patients who cannot tolerate adverse effects of Champix may have the dose lowered temporarily or permanently to 0.5 mg twice daily. Patients should be treated for 12 weeks. Treatment should start 1 - 2 weeks prior to quitting smoking.
224175433|NCT06037863|OTHER|Best Practice|Undergo bladder filling prior to CT
224175434|NCT06037863|PROCEDURE|Computed Tomography|Undergo CT
224175435|NCT06037863|OTHER|Electronic Health Record Review|Ancillary studies
224175436|NCT06037863|PROCEDURE|Imaging Procedure|Undergo bladder emptying prior to CT
224175437|NCT06037863|OTHER|Questionnaire Administration|Ancillary studies
224175438|NCT06037863|RADIATION|Radiation Therapy|Undergo radiation therapy
224175439|NCT03334994|PROCEDURE|Intervention group:(Group B) connective tissue graft combined with immediate implant.|Patients will be treated with connective tissue graft combined with immediate implant.
224175440|NCT05366686|BEHAVIORAL|NICE Support Program|Patients in experimental group will receive a 12 week NICE Support program; patients in control group maintain their usual life activities.
224175441|NCT00247052|DRUG|diclofenac|diclofenac 50 mg bid versus placebo bid
224175442|NCT00247052|DRUG|diclofenac|diclofenac 100 mg per day for 14 days
224175443|NCT00247052|DRUG|matching placebo|
224175444|NCT02132169|DRUG|Drug: AC-170 0.24%|
223486019|NCT05402761|BEHAVIORAL|Mobile-delivered BBTi group|They will use the app in conjunction with the standard BBTi procedures provided by the app, such as stimulus control, sleep restriction and audio-guided relaxation techniques (suggest to use before bedtime).
223486020|NCT05371158|BEHAVIORAL|Online intervention|The first module includes psychoeducation on neuropathic pain and CIPN (Table 1). Participants acquaintance themselves with intervention goals and mindfulness exercises central to ACT. In subsequent modules, participants learn about the aversive effects of pain avoidance, gain insight into their personal values, and work on pain acceptance. Participants exercise to recognize unhelpful thoughts about their pain and learn the difference between the subjective (judging) and objective self, and think about concrete actions to prevent relapse. The intervention primarily consists of text and experiential exercises, complemented with illustrations, metaphors and audio (mp3) files. Additional functionalities may be an outline of experiences by other CIPN patients and/or the ability to keep a diary. Participants in the experimental condition will receive therapist guidance.
223486021|NCT06242795|DRUG|7% Hypertonic Saline via nebulization|Twice a day treatment with nebulized 7% HS for 2 weeks as part of airway clearance
224175445|NCT02132169|DRUG|AC-170 0%|
224175446|NCT03724799|DEVICE|Intravascular laser irradiation of blood for the patients with cerebral infarction|Intravenous low level therapy has been a variety of applications in many different areas of medicine with a growing interest. It possesses laser specific biomodulation, analgesic, spasmolytic and even sedative effects among many other.
224175447|NCT02359500|DRUG|68Ga-DOTATOC PET|68Ga-DOTATOC as a diagnostic PET/CT imaging agent for the detection of NETs, mainly carcinoid tumors.
224175448|NCT02841254|OTHER|Non interventional study|
224175449|NCT05832866|OTHER|Clinical Based Isometric contraction strengthening Exercises using Thera band|Patients did isometric contraction exercises using thera band in the clinic physically. They did not need to be monitored by telephone
224175450|NCT05832866|OTHER|Telemonitored Home based Isometric Cntraction strengthening exercises using Thera band|Patients did isometric contraction exercises using thera band at home, they were monitored by telephone three times in a week for 8 weeks
224175451|NCT00840931|DRUG|lenalidomide|Patients will take 10 mg capsules of lenalidomide per day for 21 days followed by 7 days of rest. This 28 day period is considered 1 cycle. Patients will receive 4 treatment cycles with 28 days in each cycle.
224175452|NCT00840931|BIOLOGICAL|bystander vaccine|In addition to lenalidomide, during each 28 day cycle patients will also receive GM.CD40L bystander vaccination injections in 2-week intervals on days 8 and 22 for a total of 8 immunizations during the 4 cycle treatment period.
224175453|NCT01075022|DRUG|Colecalciferol (Vitamin D3) 300.000 UI|Colecalciferol (Vitamin D3) 300.000 UI Capsule, Single Dose
224175454|NCT01075022|DRUG|Placebo|Placebo Capsule, Single Dose
224175455|NCT01432236|DRUG|Pregabalin|Pregabalin 300 or 450 mg/day dosed BID ( twice a day) for 14 weeks; 150 mg/day starting dose
224175456|NCT01432236|DRUG|placebo|placebo capsules twice a day for 14 weeks
224175457|NCT05782660|OTHER|Cash Benefit|Spending from the cards was not restricted to food but could be spent on anything and anywhere Visa was accepted. The debit cards were credited with the first payment on November 18th, 2020 and the second payment on December 18th, 2020. The program continued with monthly credits through August 2021.
224175458|NCT05782660|OTHER|No Cash Benefit|No monthly cash benefit.
224175459|NCT03206190|OTHER|SPRS Score and clinical signs|Patients will clinically characterized by using the SPRS Score and the inventory V3
224175460|NCT03206190|BEHAVIORAL|Cognition Testing using CANTAB|Patients will be tested using the CANTAB
224175461|NCT03206190|DIAGNOSTIC_TEST|Lumbar Puncture and blood draw|Biomaterial will be collected (not obligate) to compare e.g. Nfl levels in serum and CSF
224175462|NCT03206190|DIAGNOSTIC_TEST|MRI|MRI will be used to reveal presymptomatic brain morphology changes (not obligate)
224175463|NCT03206190|DIAGNOSTIC_TEST|Electrophysiology|Electrophysiological tests will be used to characterize patients better.
224175464|NCT03206190|DIAGNOSTIC_TEST|Testing functional performance|By using the 3 minute walk, 5 stair-climb test, and 10m walking test we will try to identify and measure subclinical progression prior to disease onset
224175465|NCT03206190|DIAGNOSTIC_TEST|Non motor symptoms|By using a number of different tests we try to identify other non-motor symptoms which might manifest prior to disease onset.
224175466|NCT00959192|BIOLOGICAL|ACC-001|IM injection, dose of 3, 10 and 30 micrograms, at Day 1, month 1, 3, 6 and 12
224175467|NCT00959192|OTHER|QS-21|IM injection, dose of 50 micrograms, at Day 1, month 1, 3, 6 and 12
224175468|NCT00959192|OTHER|QS-21|IM injection, dose 50 micrograms, at Day 1, month 1, 3, 6 and 12
224175469|NCT03607461|DEVICE|Smartphone App|Smartphone App Users will engage with the app at least daily and follow along with the prescriptive exercises as instructed.
224175470|NCT03607461|COMBINATION_PRODUCT|Control Group|Home Health users will have received traditional home health physical therapy and skilled nursing services.
224175471|NCT00532441|DRUG|Erlotinib|Erlotinib 150 mg p.o. daily, days 2-7, 9-14, 16-28
224175472|NCT00532441|DRUG|Docetaxel|Docetaxel 30 mg/m2 IV over 30 min weekly x 3 weeks on days 1, 8 and 15
224175473|NCT03985358|OTHER|Opioid counseling plus standard of care instructions|Same counselor (investigator on the study) will use the same counseling script at the randomization visit as well as at the visit where they come in for pre-admission testing prior to surgery (as a refresher) to counsel patients
224175474|NCT01967134|BIOLOGICAL|H56:IC31|H56:IC31 contains a fusion protein (referred to as H56 antigen, or H56) of 3 mycobacterial antigens (the early secreted antigens Ag85B and ESAT-6, and the latency antigen Rv2660c) formulated in the Th1-stimulating IC31 adjuvant.
224175475|NCT00336466|DRUG|Human recombinant erythropoietin|
224175476|NCT03231592|OTHER|CSA Group|Already included in the arm descriptions.
224175477|NCT03231592|OTHER|Enhanced Usual Care Group|Already included in the arm descriptions.
224175478|NCT00278967|DRUG|HalfLytely with Bisacodyl Tablets Bowel Prep Kit|
224175479|NCT00278967|DRUG|HalfLytely - Reformulation|
224175480|NCT05637073|DRUG|Dienogest|Some women in the cohort will be treated with dienogest for one year after consensus with the physician
224175481|NCT05637073|PROCEDURE|Laparoscopic cystectomy|Some women in the cohort will be treated with laparoscopic cystectomy after consensus with the physician
224306432|NCT01544738|OTHER|Aponeurotic stimulation (the diacutaneous fibrolysis method)|Treatment consisted of manipulating, with a hook, the aponeurotic tissues enrobing the heads of the upper-limb muscles. The manipulation consisted of back and forth mobilization, applied perpendicularly to the axis of the muscular fibers. The mobilization is performed with both hands; the therapist's non-dominant hand performs a manual mobilization whereas the dominant hand follows the movement with the hook. The hook allows the therapist to be very precise about the location of the tissues that are stretched. This stretch is realized at the level of the aponeurotic fibers presenting the greatest resistance to perpendicular movement. The shape of the hook is chosen to avoid discomfort or pain during manipulation. To spread the pressure exerted by the spatula on a very local point, it is important to fill completely the curved part of the hook with the adjacent soft tissues. We manipulated muscle from the proximal insertion towards the distal, giving special attention to the tendons.
223486022|NCT06275477|DIAGNOSTIC_TEST|68Ga-FAPI46|Depending on the situation, it is planned that this evaluation will be transversal (performing \[68Ga\] Ga-FAPI PET/CT at baseline) or longitudinal (performing \[68Ga\] Ga-FAPI PET/CT at baseline and at 3/6 months for patients benefiting from an intensification of therapeutic management at inclusion).
223486023|NCT06505811|BEHAVIORAL|Guaranteed Income ($500/monthly)|Participants receive $500 monthly for up to 18 months.
223486024|NCT06505811|BEHAVIORAL|Active Comparison ($20/monthly)|Participants receive $20 monthly for up to 18 months.
223486025|NCT04467593|DEVICE|Whole body hyperthermia|Whole body hyperthermia to treat stage IV cancer patients
223486026|NCT04467593|DRUG|Standard of Care (SOC) chemotherapy according to the NCCN guidelines.|Whole body hyperthermia to treat stage IV pancreatic cancer patients combined with standard of care chemotherapy
224175482|NCT05637073|OTHER|Control with ultrasound without other type of intervention|Some women in the cohort will be followed with ultrasound control, without other intervention, after consensus with the physician
224175483|NCT00443534|DRUG|SU011248|Administered orally in doses ranging from 25 to 50 mg once daily; dosing schedule and dosage depends on the patients dosing from the prior protocol
224175484|NCT02531919|DRUG|Sodium Bicarbonate|Given PO
224175485|NCT01773616|DRUG|Oral prednisolone|
224175486|NCT01773616|DRUG|Rituximab|
224175487|NCT01773616|DRUG|Mycophenolate mofetil|
224175488|NCT01773616|DRUG|Methyl prednisolone|
224175489|NCT05212623|BIOLOGICAL|quadrivalent influenza split vaccine|This vaccine is produced by Changchun Sponsor Institute of Biological Products Co., Ltd. Subjects will receive two doses of quadrivalent influenza vaccine administered 4 weeks apart by intramuscular injection
224175490|NCT05212623|BIOLOGICAL|quadrivalent influenza split vaccine|This vaccine is produced by Changchun Sponsor Institute of Biological Products Co., Ltd. Subjects will receive two doses of quadrivalent influenza vaccine administered 4 weeks apart by intramuscular injection
224175491|NCT05212623|BIOLOGICAL|Influenza virus split vaccine|This vaccine is produced by Changchun Sponsor Institute of Biological Products Co., Ltd. Subjects will receive two doses of quadrivalent influenza vaccine administered 4 weeks apart by intramuscular injection
224175492|NCT05212623|BIOLOGICAL|Influenza virus split vaccine|This vaccine is produced by Changchun Sponsor Institute of Biological Products Co., Ltd. Subjects will receive two doses of quadrivalent influenza vaccine administered 4 weeks apart by intramuscular injection.
224175493|NCT05516264|BEHAVIORAL|Dog visits/control visits|See arm description above
224175494|NCT05516264|BEHAVIORAL|Control visits/dog visits|See arm description above
224175495|NCT03479840|PROCEDURE|PCI|treatment of coronary arteries and evaluation of SYNTAX score pre and post (to quantify severity of disease)
224175496|NCT03362216|DRUG|Compound Methyl Salicylate Liniment|Compound Methyl Salicylate Liniment, apply to the affected area, 3 times a day.Course of treatment: 7 days
224175497|NCT03362216|DRUG|Diclofenac Sodium Liniment|Diclofenac Sodium Liniment, apply to the affected area, 3 times a day. Course of treatment: 7 days
224175498|NCT04607291|OTHER|Community Health Service|Receive Witness CARES services
223486027|NCT04727944|OTHER|Reach and grasp tasks in healthy participants using MEG technique (Experiment 1)|"Human participants will perform reach and grasp movements to various objects (e.g. a cube, sphere, or rod) driven either by perceived action affordances, or instruction cues. A rotating carousel will be used to present subjects with various objects affording different types of grasps (e.g. a precision pinch, a whole hand 'power' grasp, or a tripod grasp).~Prior to the experiment, subjects will be tested outside the scanner by asking them to grasp each object as they would naturally to ensure that each object elicits the expected grasp type. Subject-specific, 3D-printed head-casts will be created based on high resolution MRI scans from each subject, and worn by subjects during the MEG experiment (Experiment 1) to reduce within-session head movement associated with reaching and grasping.~At the end of this session an experimental task is added: detection of tons in presence of multitonal masks, in order to verify how beta peaks might be generated by a stimulus auditory."
223486028|NCT04727944|OTHER|Reach and grasp tasks in healthy participants using EEG technique (Experiment 2)|Experiment 2 consists of a task of reaching for and grasping several objects (e.g. a cube, sphere, or rod) ; the task used for experiment 2 is the same as that used for experiment 1. EEG signals will be measured.
223586508|NCT06980883|OTHER|myofascial release|"Myofascial Release: Provided to patients in Group 2 along with traditional treatment( 2 days per week).~Evaluation of fascial restriction was assessed using the therapists elbow. Any restrictions felt were assessed and given treatment.Myofascial chain release- Position of the patient- Supine lying, prone lying and side lying Position of the therapist- Side of the patient limb to be treated~\- Technique-Using the therapist elbow a vertical release proximal to the attachment of the muscle belly or fascia was applied. Once an end-feel was reached a slow stroke down the length of the target tissue was performed along with monitoring the indirect feedback and tissue tension to identify any additional restrictions. The long stroke was repeated in a line parallel to the first stroke. It was continued until an end-feel is reached throughout the entire muscle belly or fascia on the most restricted/ painful points."
223586509|NCT06980883|OTHER|(traditional exercises)|comprising straight leg raising and isometric quadriceps exercises (2 days per week).
224072447|NCT02926950|DRUG|Metformin|Pharmaceutical form: tablet. Route of administration: oral.
224072448|NCT06746831|DRUG|S-(+)-methamphetamine|15 mg
224072449|NCT06746831|DRUG|R-(-)-methamphetamine|15 mg
224072450|NCT06746831|DRUG|1:1 racemic mixture of two isomers|15 mg R-Meth + 15 mg S-Meth
224072451|NCT06527391|DRUG|choline bitartrate|Daily supplementation for 9 months with 200 mg choline bitartrate
224072452|NCT06527391|OTHER|placebo drug|Daily supplementation for 9 months with identical placebo
224072453|NCT02905578|DRUG|Gemcitabine|"Administered intravenously the same day as nab-paclitaxel and ascorbate Administered after nab-paclitaxel and before ascorbate~* given for 3 weeks out of the 4 week cycle~* standard dose reductions are used~* up to 2 cycles are administered before standard of care CT scan~* decision to continue therapy is based disease response to therapy as measured from the CT scan~* treatment continues until disease progression is identified"
224072454|NCT02905578|DRUG|nab-paclitaxel|"Administered intravenously the same day as nab-paclitaxel and ascorbate Administered after before gemcitabine and ascorbate~* given for 3 weeks out of the 4 week cycle~* standard dose reductions are used~* up to 2 cycles are administered before standard of care CT scan~* decision to continue therapy is based disease response to therapy as measured from the CT scan~* treatment continues until disease progression is identified"
224072455|NCT02905578|DRUG|Pharmacological ascorbate|"Administered intravenously the same day as nab-paclitaxel and gemcitabine Administered after nab-paclitaxel and gemcitabine~* given 3 times weekly~* given for 4 weeks out of the 4 week cycle~* no dose reductions are used~* up to 2 cycles are administered before standard of care CT scan~* decision to continue therapy is based disease response to therapy as measured from the CT scan~* treatment continues until disease progression is identified"
224072456|NCT07001748|DRUG|Standard of Care Chemotherapy|The most common regimens are FOLFOX, CAPOX, FLOT, CF, and CX. Other local institutional standard of care regimens as well as targeted agents for gastric/GEJ adenocarcinoma are allowed.
224072457|NCT07001748|PROCEDURE|Biospecimen Collection|Plasma is to be submitted at baseline and every three months for the first year or until progression, whichever comes first. For patients who have progression, their last plasma sample should be at time of progression.
224072458|NCT07001748|PROCEDURE|Computed Tomography|Restaging imaging with CT and/or diffusion weighted MRI with contrast will be obtained after completion of 12 weeks (+/- 2 weeks) of assigned treatment (restaging will occur at this timepoint, regardless of if the patient completed all 4 cycles or not). At this point, patients with stable disease or a response will continue assigned treatment. In the absence of radiological or clinical progression, if clinically indicated by treatment team, patients may undergo diagnostic laparoscopy to assess surgical candidacy at which time a PCI assessment and biopsies of peritoneal nodules, peritoneal lavage could be performed. Cytoreduction can be offered to patients with a PCI \< 7 and if complete cytoreduction is feasible based on treating surgeon's discretion. If deemed a candidate for surgical cytoreduction, surgery should be performed within 6 weeks of the last study treatment in both arms.
224072459|NCT07001748|PROCEDURE|Diagnostic Laparoscopy|After induction of general anesthesia, administration of preoperative antibiotics and placement of appropriate laparoscopic ports, peritoneal lavage will be performed by instillation of 200 ml of normal saline in the left upper quadrant and allowed to dwell for 5 minutes after which it will be aspirated for cytology. Extent of peritoneal disease burden will be ascertained as per the Peritoneal Cancer Index (PCI) scoring system as outlined in Appendix V.
224072460|NCT07001748|PROCEDURE|Intraperitoneal Port Placement|Patients assigned to Arm B will undergo placement of indwelling tunneled intraperitoneal port with Teflon cuff following Step 1 randomization and during the diagnostic laparoscopy procedure.
223586510|NCT06663046|BIOLOGICAL|Single dose injection of certain dose of UWD-00B|Eligible participants will undergo FC lymphodepleting chemotherapy preconditioning after signing an informed consent form, followed by a one-time injection of certain dose of universal UWD-00B cells
224175499|NCT04607291|OTHER|Survey Administration|Ancillary studies
224175500|NCT04765176|DEVICE|Endovascular Repair|Endovascular repair of the infrarenal aorta using a AAA stent graft.
224175501|NCT03755362|PROCEDURE|Standard Treatment|Dental evaluation at baseline, 3, 6, and 9 months.
224175502|NCT03755362|PROCEDURE|Intensive Treatment|Dental evaluation at baseline, 3, 6, and 9 months. Plus one or more sessions as needed at baseline of full mouth supra- and sub-gingival scaling and root planing, plus oral hygiene instruction. Additional sessions as necessary to remove remaining local factors and treat inflammation and bacteria overgrowth. Additional evaluations and therapy at 2 months or as needed based on therapeutic response. If bleeding on probing levels do not decrease to \<20% of sites following initial therapy or at subsequent visits, intermediate treatment visits will be scheduled. Each participant will be instructed to use half of a capful of 0.12% chlorhexidine twice a day during active treatment including two weeks beyond the treatment visit.
224175503|NCT02450240|BEHAVIORAL|standardized diagnostic assessment|
224175504|NCT02450240|BEHAVIORAL|self-report questionnaires|
224175505|NCT02450240|BEHAVIORAL|behavioral tasks|
224175506|NCT02450240|OTHER|physiological measurements|
224175507|NCT02450240|OTHER|structural and functional magnetic resonance imaging and EEG|
224175508|NCT02450240|OTHER|biomarker and microbiome assessments|
224175509|NCT02450240|OTHER|blood to derive induced pluripotent stem cells|
224175510|NCT02450240|OTHER|genetic and epigenetic assessments|
224175511|NCT03748875|BEHAVIORAL|mindfulness-based relapse prevention|mindfulness-based relapse prevention, 8 weeks
224175512|NCT06399068|DRUG|CKD-387|1 Tablet
224175513|NCT06399068|DRUG|D484|1 Tablet
224175514|NCT02798172|DRUG|Alogliptin and Metformin|The patients in the control group were given metformin (1,000 mg, bid po) and the patients in the intervention group were given metformin (500 mg, bid po) combined with alogliptin (25 mg, qd po)
224175515|NCT03299621|DEVICE|PLE (Phase Lag Entropy)|Monitoring of PLE value using the monitoring of PLEM™ device during propofol anesthesia.
224175516|NCT03299621|DRUG|Muscle Relaxant|Monitoring of PLE value using the monitoring of PLEM™ device before and after the injection of muscle relaxant that used for tracheal intubation.
224175517|NCT03763292|BEHAVIORAL|Specific information brochure|A purpose-designed brochure about anesthesia and surgery in the ear in children is developed by the investigators. This brochure has photos and describes the procedures the child is going through.
224306433|NCT01544738|OTHER|Placebo stimulation|Placebo stimulation (PS) consisted of manipulating the skin along the same paths over the trunk, shoulder and arm muscles that were the targets for treatment in the AS group
224306434|NCT05020613|PROCEDURE|Procedure: Early removal group|Participants assigned this arm will have their urethral catheters removed at 2 days after low anterior resection of the rectum
224175518|NCT05514093|DEVICE|Beyond Silence App|"The Beyond Silence app is designed to be a mental health coach in your pocket for healthcare workers. It provides opportunities to build mental health literacy and reduce barriers to seeking support, including access to peer support either within or outside the organization."
224175519|NCT02737514|PROCEDURE|Air insufflation|Insufflation during colonoscopy including insertion phase
224175520|NCT02737514|PROCEDURE|water immersion|Water will infused during insertion phase and removed during withdrawal phase of colonoscopy
224175521|NCT02737514|PROCEDURE|water exchange|Water will infused and removed during insertion phase of colonoscopy
224306435|NCT05020613|PROCEDURE|Procedure: Late removal group|Participants assigned this arm will have their urethral catheters removed after 48.th hours after Low anterior resection of the rectum
224306436|NCT04874636|DRUG|LY3556050|Administered orally
224306437|NCT04874636|DRUG|Placebo|Administered orally
224175522|NCT02143336|PROCEDURE|subcuticular suture|
224306438|NCT06404164|PROCEDURE|Wedge resection under watershed analysis method|"* Compare the preoperative 3D reconstruction model, and use electrocautery to directionally separate and expose the target artery;~  * Auxiliary devices (unlimited) to block the target artery, but should not be severed; ③ Peripheral intravenous injection of ICG, electrocautery to mark the border of counter-staining; ④ Evaluate the actual incisal margin according to the preoperative planning, and use the cutting stapler to wedge resection of the pulmonary nodule"
224175523|NCT02143336|PROCEDURE|Skin staples|
224175524|NCT00184366|DRUG|efalizumab|efalizumab
224175525|NCT03710460|DRUG|Dapagliflozin|10 mg, one per day before breakfast during 12 weeks.
224175526|NCT03710460|DRUG|Dapagliflozin plus Metformin XR|10/1000 mg, one per day before breakfast during 12 weeks.
224175527|NCT03710460|DRUG|Metformin XR|1000 mg, one per day before breakfast during 12 weeks.
224175528|NCT00103935|DRUG|placebo|Subcutaneously injected placebo 0.02 mL twice daily as lead-in followed by once weekly injected amount equivalent to exenatide LAR 0.8 mcg
224175529|NCT00103935|DRUG|placebo|Subcutaneously injected placebo 0.02 mL twice daily as lead-in followed by once weekly injected amount equivalent to exenatide LAR 2.0 mcg
224175530|NCT00103935|DRUG|Exenatide LAR|Subcutaneously injected exenatide 5 mcg (0.02 mL) twice daily as lead-in followed by once weekly injected exenatide LAR 0.8 mcg.
224175531|NCT00103935|DRUG|Exenatide LAR|Subcutaneously injected exenatide 5 mcg (0.02 mL) twice daily as lead-in followed by once weekly injected exenatide LAR 2.0 mcg.
224175532|NCT00025090|DRUG|cisplatin|
224175533|NCT00025090|DRUG|fluorouracil|
224175534|NCT00025090|DRUG|mitomycin C|
224175535|NCT00025090|RADIATION|radiation therapy|
224175536|NCT04321590|DIETARY_SUPPLEMENT|Combination of oat beta-glucan of different richness (35 and 70%) at low (3g) and high (5g) doses with green coffee bean extract (600 mg)|Dose-response study on the effect of two different types of oat beta-glucan with different b-glucan content (35% vs. 70%) in combination with a green coffee bean extract rich in polyphenols. Consumption of 2 sachets/day (providing 3 or 5 g/d beta-glucan plus 600 mg polyphenols) during 6 weeks
224175537|NCT05326672|DRUG|Benvitimod Cream|Benvitimod cream, 1%, applied twice daily for 8 weeks after enrolment.
224175538|NCT05326672|DRUG|Placebo|Placebo, applied twice daily for 8 weeks after enrolment.
224175539|NCT03198585|DRUG|Empagliflozin 10 MG|Capsule, once a day for 90 days
224175540|NCT03198585|OTHER|Placebo|Capsule, once a day for 90 days
224175541|NCT02959736|BEHAVIORAL|MATADOC and CRS-R|Behavioural assessments for Disorders of Consciousness
224175542|NCT00478530|PROCEDURE|ELECTRORETINOGRAM|Bevacizumab 1.25 mg/0.05 ml unilaterally into the vitreous cavity as part of the standard management for choroidal neovascular AMD. ERG responses form both eyes will be measured at baseline and 1 month after intravitreal injection
224175543|NCT00370825|DRUG|Combination therapy with AmBisome and miltefosine|
224175544|NCT03095157|DIETARY_SUPPLEMENT|fractionated marine lipid concentrate derived from anchovy and sardine oil|Patients will be randomized to receive perioperative treatment versus placebo
224175545|NCT04097925|DRUG|Doravirine|Doravirine 100 mg tablet
224175546|NCT04097925|DRUG|Descovy|Tenofovir alafenamide 25 mg / emtricitabine 200 mg tablet
224175547|NCT02083822|PROCEDURE|term MRI, executive EF functions testing|An MRI will be realized at term born between 25 and 32 weeks GA
224175548|NCT04646850|OTHER|Color duplex ultrasound of the carotid arteries|Examinations carried out according to the American Society of Echocardiography guidelines 25 using a Vivid 7 US instrumentation with a linear M12L probe (14 MHZ; General Electric).
224175549|NCT02636049|DRUG|Triferic|Triferic is supplied as sterile 5 mL ampules containing 5.44 mg/mL of iron in water for injection. Each 5 mL ampule contains 27.2 mg of Triferic iron.
224175550|NCT00958230|DEVICE|dCell Vascular Patch|Implantation of a dCell Vascular Patch as part of an Endarterectomy
224175551|NCT01749930|DRUG|BOL-303259-X|BOL-303259-X will be administered QD in the evening and its vehicle administered QD in the morning
224175552|NCT01749930|DRUG|Timolol|Timolol will be administered BID once in the morning and once in the evening.
224175553|NCT01749930|DRUG|BOL-303259-X|All participants will receive a topical ocular BOL-303259-X QD in the evening from 3 months (Visit 6) through 6 months (Visit7).
224175554|NCT00427739|PROCEDURE|Cardiac CT|64 slice spiral computerized tomography
224175555|NCT04735432|BIOLOGICAL|efgartigimod PH20 SC|Subcutaneous injection with efgartigimod PH20 SC
224175556|NCT04735432|BIOLOGICAL|efgartigimod IV|Intravenous infusion of efgartigimod
224175557|NCT00901849|DRUG|Tarceva and Rapamycin|Tarceva will be administered once a day for 28 days without interruption. THen Rapamycin will be administered, orally twice daily, in combination with the Tarceva for the remainder of the study.
224175558|NCT01204489|BEHAVIORAL|Intensified dietary counseling at child wellfare clinics.|The intervention is completed by public health nurses who receive updating education in nutrition. A special training in a family-centred lifestyle counseling method in implemented. The nutrition intervention consists of tailored dietary counseling, information leaflets and self-evaluation card given to the families in the intervention arm. In the control clinics, public health nurses continue their usual dietary counseling.
223486029|NCT06382883|BEHAVIORAL|Individually tailored lifestyle and physical activity intervention|"Focus of the SEMC-protocol is on increasing PA gradually towards the national recommendations. Emphasis of counseling is on incidental exercise, endurance, and strength training. Techniques of motivational interviewing are utilized.~Baseline; MD+PT counseling, medical clearance, mapping lifestyle \& life situation, goal setting, measurements, questionnaires, feedback. weeks 1-6: guided group resistance training 1hr, 1x/week. 5-10-minute warm-up, 9 exercises with weight stack equipment on large muscle groups. 2-3 sets, 12-15 repetitions. Modified individually, e.g. according to musculoskeletal problems. Emphasis on learning the basics and safety aspects. After 6 weeks unsupervised training. 3-month: MD counseling and questionnaires. 6-month: MD+PT counseling, assessing safety of PA, measurements, questionnaires, feedback. 12-month: MD+PT counseling (feedback, ensuring continuity of lifestyle changes; redirecting to municipality/NGO activities), measurements, questionnaires, feedback"
223486030|NCT06382883|BEHAVIORAL|Individually tailored lifestyle and physical activity intervention combined with enhanced behavioral support -intervention (EBS)|"In addition to the SEMC-protocol, the participants will be contacted 3 times during the first 3 months (live / online as preferred). Themes:~Session 1: Motivation and illness perceptions. Exploring CPAP use, PA, and SB. Session 2: Self-regulation (feedback, goal setting, self-monitoring, action planning, problem solving), activating social support, prompts/cues, and preparatory behaviors. (Included BCTs from Michie et al 2013 taxonomy: 3.2, 12.2, 8.3,) Session 3: Assessing progress and agenda setting, self-regulation, maintenance of PA.~Measurements and questionnaires as with SEMC-protocol."
223486031|NCT06173791|DEVICE|DFDBA fibers|Bone Allograft fibers used in dental sinus reconstruction surgery
223486032|NCT06173791|DEVICE|DFDBA particles|Bone Allograft particles used in dental sinus reconstruction surgery
223486033|NCT06173791|DEVICE|DBBM|DBBM is routinely used in sinus augmentation to support dental implant placement and restoration of missing teeth.
223486034|NCT06665217|DRUG|Glofitamab, Polatuzumab Vedotin, Zanubrutinib, Lenalidomide and Prednisone as Induction Therapy|Patients were treated by Glofitama(Cycle 1: D8, 2.5mg, D15, 10mg; followed by the target dose of 30mg on D1 of Cycle 2-12), Polatuzumab Vedotin(1.8mg/kg iv qd d1), Zanubrutinib(160mg po bid d1-21), Lenalidomide(25mg po qd d1-14) and Prednisone(60mg/m2 po qd d1-5) as induction therapy.
223486035|NCT06350526|DIAGNOSTIC_TEST|Complete Blood Count|blood sample
223486036|NCT06350526|DIAGNOSTIC_TEST|C-reactive protein|serum sample
223486037|NCT06350526|DIAGNOSTIC_TEST|O2 saturation|blood sample
223486038|NCT06350526|DIAGNOSTIC_TEST|Serum ferritin and D-dimer|Blood sample
223486039|NCT06350526|DIAGNOSTIC_TEST|Liver and renal function tests|Blood sample
223486040|NCT06350526|DIAGNOSTIC_TEST|Lactate dehydrogenase|Blood sample
224175559|NCT04312958|DIAGNOSTIC_TEST|Quantra System|Diagnostic device to monitor coagulation properties of a whole blood sample at the point-of-care.
224175560|NCT01876056|BEHAVIORAL|Brief CaCBTp|Brief CBT for psychosis is comonly used in the West and had an established evidence base. Recently this therapy has been culturally adapted for use with clients from Pakistan.
224175561|NCT05143294|BEHAVIORAL|Conectar Jugando Classroom Program|Modern Board Games Intervention in Elementary Classrooms
223486041|NCT06350526|DIAGNOSTIC_TEST|coronavirus (SARS-CoV-2) swab|Throat swab
223586511|NCT06663722|BIOLOGICAL|Axatilimab|Axatilimab will be administered intravenously (IV) at a dose of 0.3 mg/kg, beginning as a pre-phase dose two weeks prior to initiation of Extracorporeal Photopheresis (ECP) therapy. Thereafter, Axatilimab will be administered with a frequency of one treatment session bi-weekly during each treatment cycle.
224306439|NCT06048666|BIOLOGICAL|Intra ovarian by platelet rich plasma|On the day of PRP infusion (within 10 days after completion of menstrual bleeding) we will take 20 cc of venous blood from each participant of group A to prepare PRP. The blood will be transferred to a tube containing sodium citrate and centrifuged at 800 RPM for 15 min and 2000 RPM for 5 min in two stages, respectively. Then, by discarding part of the plasma, PRP will be prepared with a final concentration of one million platelets per microliter. The PRP will be injected into the ovary under spinal anesthesia and a transvaginal ultrasound guide.
223586512|NCT06663722|PROCEDURE|Extracorporeal Photopheresis|"Mandatory ECP therapy will be administered at a frequency of two treatment sessions per week during Cycles 1 through 3, two treatment bi-weekly during Cycles 4 through 6, and two treatments during week 1 of Cycle 7.~Optional ECP therapy will be administered at a frequency of two treatment sessions during weeks 2 and 4 of Cycles 4 through 6, when mandatory ECP is not administered. Optional ECP therapy will also be administered as two treatment sessions during week 3 of Cycle 7.~After Cycle 7, participants may receive ECP therapy only at the Investigator's discretion for a maximum Treatment Period of 12 months."
224175562|NCT03757702|OTHER|Evaluation|Trunk position sense will be evaluated with a digital inclinometer. Trunk reposition test will be used in evaluation.The postural stability will be evaluated with a special balance device in eyes opened and closed position. Ellipse area (mm2) and perimeter (mm) parameters will be recorded.The angles of thoracal kyphosis and lumbar lordosis will be evaluated with a digital inclinometer.
224175563|NCT05022303|DRUG|Larazotide Acetate|AT1001 10 μg/kg/dose up to 500 μg/dose (rounded to the nearest 50 μg) will be administered orally four times a day (QID) to the standard of care for MIS-C.
224175564|NCT05022303|DRUG|Placebo|Matching placebo will be administered orally four times a day (QID) to the standard of care for MIS-C.
224175565|NCT01320774|DRUG|Daivobet® Gel|Once daily on areas with plaque psoriasis, treatment duration up to 8 weeks for body skin areas except scalp (scalp up to 4 weeks), treatment may be repeated under medical surveillance.
224175566|NCT03294343|PROCEDURE|salpingo-oophorectomy only by laparoscopy|Salpingo-oophorectomy are provided for carriers with mutation genes of BRCA1, BRCA2 (both belonging to mutation genes of hereditary breast and ovarian cancer syndrome, HBOCS) and ATM, BRIP1, RAD51, RAD51C, and RAD51D (all belonging to mutation genes of other hereditary ovarian cancer syndrome). Detailed multi-disciplinary counseling, decision-making analysis before surgeries, and long-term follow-up and health management after surgeries are provided for all participants.
224306440|NCT02754466|OTHER|Subjective vs objective criteria in selective excavation|Subjective vs Objective criteria (Polymer burs) to perform selective excavation of dentin caries in deep lesions
224306441|NCT02754466|OTHER|Glass-ionomer vs Bulk fill composites in the ART approach|High-viscosity glass-ionomer vs Bulk fill composite to restore shallow and medium depth dentin lesions using the ART approach
224306442|NCT05060133|PROCEDURE|Orthognathic Surgery|Surgical corrections of dentofacial deformities and malocclusions.
224306443|NCT04238988|DRUG|Pembrolizumab|Humanized antibody used in cancer immunotherapy. It targets the programmed cell death protein 1 (PD-1) receptor of lymphocytes.
223486042|NCT06350526|RADIATION|CT chest|Radiation
223486043|NCT02401230|DRUG|Truvada|Truvada is a combination of 200 mg of emtricitabine and 300 mg of tenofovir disoproxil fumarate taken orally.
223486044|NCT02401230|DEVICE|Gel lubricant|Five ml of an over the counter sexual lubricant will be dispensed using an applicator.
223586513|NCT06658496|DEVICE|Near Infrared Spectroscopy|Application of regional NIRS sensors to brain and kidney sites in the first 72 hours after birth to monitor regional tissue oxygenation.
224175567|NCT03294343|PROCEDURE|salpingo-oophorectomy with hysterectomy by laparoscopy|Salpingo-oophorectomy with hysterectomy are provided for carriers with mutation genes of MLH1, MSH2, MSH6, PMS2, EPCAM (all belonging to mutation genes of Lynch syndromes) and STK11. Detailed multi-disciplinary counseling, decision-making analysis before surgeries, and long-term follow-up and health management after surgeries are provided for all participants.
224175568|NCT03294343|OTHER|Follow-up|Detailed multi-disciplinary counseling, decision-making analysis and long-term follow-up are provided for carriers with any mutation genes but refusal to any risk-reducing gynecologic surgeries
224306444|NCT04238988|DRUG|Carboplatin|Chemotherapy medication
224175569|NCT03230266|PROCEDURE|Collection of intra-peritoneal catheters for insulin infusion|Collection of intra-peritoneal catheters for insulin infusion
224175570|NCT02249858|PROCEDURE|Cranial Vault Hold|
224175571|NCT02249858|PROCEDURE|Cervical HVLA|
224175572|NCT00626327|BIOLOGICAL|MenACWY-CRM + MMRV|One injection of MenACWY-CRM vaccine at 7-9 months of age; the second injection of MenACWY-CRM vaccine concomitantly administered with MMRV (Measles, Mumps, Rubella and Varicella) vaccine at 12 months of age.
224175573|NCT00626327|BIOLOGICAL|MMRV|one injection of MMRV (Measles, Mumps, Rubella and Varicella) vaccine at 12 months of age
224306445|NCT04238988|DRUG|Taxol|Chemotherapy medication
224306446|NCT04310956|DEVICE|Y-Knot all-suture anchor|Y-knot all-suture anchor will be implanted to participants
224306447|NCT04310956|DEVICE|Biocomposite suture anchor|Biocomposite suture anchor will be implanted to participants
224306448|NCT04359576|DIAGNOSTIC_TEST|Primary and secondary hemostasis|Focus on platelet aggregation, primary and secondary hemostasis parameters
224306449|NCT04350320|DRUG|Colchicine Tablets|standard therapy for COVID-19 according to the stablished hospital protocols.
223486045|NCT03076879|BEHAVIORAL|Promoting participation in cervical cancer screening|"Nursing education: Women in the experimental group will be trained three times in total, one for the cervical cancer screening and the other two for the individual.~Reminders by phone; Short messages and calls will be reminiscent of women's participation in cervical cancer screenings.~Home visit; The content of the training is the key to cervical cancer and screening. After the group training, it is aimed to be an interactive education and counseling service in the form of question-answer method which is not understood by home visiting method.~Brochure; The brochure for cervical cancer and screening will be given after group training."
224175574|NCT00626327|BIOLOGICAL|MenACWY-CRM|Two injections of MenACWY-CRM at 7-9 months and 12 months of age; one injection of MMRV (Measles, Mumps, Rubella and Varicella) at 13.5 months of age
224175575|NCT01868126|DRUG|DE-117 ophthalmic solution|
224175576|NCT01868126|DRUG|latanoprost ophthalmic solution|
224175577|NCT01868126|OTHER|Placebo|
224175578|NCT01823991|DRUG|VitaBlue™|"Self administration of nutritional supplement COGNUTRIN for 3 months.~The supplement to be used will be a combination of the following: (1) VitaBlue (40% polyphenolics, 12.5% anthocyanins from blueberries (BB) and (2) n-3 fatty acids - Lovaza."
224175579|NCT01823991|OTHER|Placebo|"Self administration of placebo for 3 months.~Investigators use a placebo to make sure that it really is the study medicine that is making a difference in the participant's condition. It does not have anything in it that would normally help or harm most people."
224175580|NCT01823991|DRUG|Lovaza®|"Self administration of nutritional supplement COGNUTRIN for 3 months.~The supplement to be used will be a combination of the following: (1) VitaBlue (40% polyphenolics, 12.5% anthocyanins from blueberries (BB) and (2) n-3 fatty acids - Lovaza."
224175581|NCT05158244|DRUG|PF-07081532|Study Drug, once daily for 42 days
224175582|NCT05158244|DRUG|Placebo|Placebo, once daily for 42 days
224175583|NCT01066819|DRUG|Peginterferon alfa-2a [Pegasys]|Peginterferon/ribavirin treatment period as prescribed by treating physician (e.g. 24 or 48 weeks) and treatment-free follow-up period of 24 weeks.
224175584|NCT01066819|DRUG|Peginterferon alfa-2b [PegIntron®]|Peginterferon/ribavirin treatment period as prescribed by treating physician (e.g. 24 or 48 weeks) and treatment-free follow-up period of 24 weeks.
224306450|NCT04350320|DRUG|Standard therapy for COVID-19 according to the stablished hospital protocols.|standard therapy for COVID-19 according to the stablished hospital protocols.
224306451|NCT02737527|PROCEDURE|24G intravenous route for Lumbar Sympathetic Block (LSB):|Enrolled subjects enter the operative room with a 24G intravenous route, and then non-invasive blood pressure and pulse oxygen saturation level are continuously monitored during and after the procedure.
224306452|NCT02737527|DEVICE|15-cm Chiba needle for Lumbar Sympathetic Block (LSB)|The skin entry point is infiltrated using 1% lidocaine. A curved 21 G, 15-cm Chiba needle (Cook Inc., Bloomington, IN, USA) is then advanced toward the anterolateral edge of target vertebral body by posterolateral approach in patients with prone position.
223486046|NCT00683995|DRUG|KW-2246 (fentanyl citrate)|KW-2246 (fentanyl citrate)
223486047|NCT03505775|DIAGNOSTIC_TEST|23Na magnetic resonance imaging|Imaging/diagnostic: Evaluation of the muscular and cutaneous sodium storage by 23Na magnetic resonance imaging. 23Na magnetic resonance imaging: 23NA-MRI protocol on a 3T scanner (Magnetom PRISMA, Siemens, Erlangen) implementing a 3D sequence.
223486048|NCT06376136|DRUG|BAT8010 for Injection|Intravenous
223486049|NCT06376136|DRUG|BAT1006 for Injection|Intravenous
223486050|NCT05402059|DRUG|surgery (any volume) and / or pharmaceuticals treatment initiated or planned or only dynamic observation, in accordance with current clinical guidelines|Any kind of treatment or observation (no treatment) initiated or planned in accordance with current clinical practice
223486051|NCT00830765|DRUG|Progesterone (OHP17)|100mg of OHP17 or comparable amount of placebo administered by IM injection weekly until either 34 weeks' gestation or delivery has been achieved, whichever occurs first.
223586514|NCT05445518|BEHAVIORAL|Jump Start Plus COVID Support|The Jump Start Plus COVID Support intervention is a resiliency program that provides behavior management and safety programs administered weekly via zoom.
223586515|NCT05445518|BEHAVIORAL|Healthy Caregivers-Healthy Children (HC2)|The HC2 intervention is an obesity prevention program that provides nutrition and healthy activities programs administered weekly via Zoom.
224175585|NCT03466528|DRUG|Magnesium Sulfate|Intravenous (Magnesium Sulphate) MgSO4 2 grams IV over 20 minutes
224175586|NCT03466528|DRUG|Pabrinex|standard treatment
224175587|NCT00867594|DRUG|ORMD 0801|1 capsule ORMD 0801 3 times a day, before each meal
224175588|NCT01409642|BEHAVIORAL|Individual Child CBT|12 sessions of individual child focused cognitive behavior therapy with a parent component
224175589|NCT01409642|BEHAVIORAL|Positive Family Interaction Therapy|Six sessions of family-focused treatment for childhood OCD administered as an adjunct to 12 sessions of child CBT
224175590|NCT01409642|BEHAVIORAL|Positive Family Interaction Therapy|Positive Family Interaction Therapy (PFIT) is a 6-session treatment designed to be used as an adjunct to standard child CBT in cases where OCD is complicated by challenging family dynamics.
224175591|NCT03713242|DRUG|ACT-541468 25 mg|Administered as a tablet.
224175592|NCT03713242|DRUG|ACT-541468 25 mg (or 10 mg depending on interim results)|Administered as a tablet.
224175593|NCT03395613|DEVICE|NPWT|Negative pressure wound thearpy on closed surgical wounds
224175594|NCT02172326|DRUG|Tiotropium inhalation capsules for oral inhalation|Powder inhalation via HandiHaler®
224175595|NCT03703609|BEHAVIORAL|Tele-yoga|Participants will get a 60 min tele-yoga session biweekly led by a certified medical yoga instructor via live videoconference link on the participants tablet. Each participant will perform a total of 20-24 yoga instructor-led sessions over a 12-week period. A session will contain 10 min breathing exercises, 40 min of yoga and 10 min relaxation/meditation. Before and at the end of each session, participants can discuss their experiences or ask questions to the instructor online. The tablet also includes an app with instructions (text, pictures, and sound files) for yoga positions, breathing and meditation. Participants are encouraged to practice yoga at home individually with one goal of one session a day for a minimum of 10 minutes.
224306453|NCT02737527|DEVICE|Ultrasound for Lumbar Sympathetic Block (LSB)|Using Ultrasound, the L3 is identified by locating the lumbosacral junction on a paramedian sagittal scan and then counting cranially. After marking the level of L3 vertebra, the modified transverse scan through lumbar intertransverse space (ITS) is obtained with the transducer positioned 4-6 cm lateral to the mid-line at the L2-L3 intervertebral level. The needle is inserted from a lateral to medial direction using in-plane technique. The needle tip is inserted towards the anterior fascia of the psoas major muscle as close as paravertebral space.
224175596|NCT06076863|OTHER|Pharmacist Care|Management of Paxlovid e-visits per regional protocol
224175597|NCT06076863|OTHER|AFM Pool Care|Management of Paxlovid e-visits per regional and local protocols
223486052|NCT00830765|DRUG|Placebo|2cc of placebo liquid formulated by pharmacy personnel at the University of Mississippi Medical Center injected IM weekly until 34 weeks' gestation has been reached or delivery, whichever occurs first.
223486053|NCT06201312|OTHER|COP exercise|crossover point intensity exercise
223486054|NCT03959657|OTHER|No intervention performed by authors|Observational and retrospective study, no intervention performed
223486055|NCT01087060|PROCEDURE|partial or radical nephrectomy|
223486056|NCT01299909|BEHAVIORAL|Integrated Training for Smokers|8 classes in smoking cessation strategies, 2 weeks of nicotine patches, and access to the Freedom From Smoking online program
223486057|NCT01299909|BEHAVIORAL|Mindfulness Training for Smokers|8 classes of training in mindfulness meditation, 2 weeks of nicotine patches, and access to the MTS website.
223486058|NCT01299909|BEHAVIORAL|Quitline|Telephone-based smoking cessation treatment via the Wisconsin Tobacco Quit Line (WTQL) consisting of 2 weeks of nicotine patches, self-help materials, an interactive website, and unlimited follow-up calls to the WTQL at no cost.
223486059|NCT03023995|PROCEDURE|CAF with Platelet rich fibrin|In test group, preparation of PRF was carried out, after which the flap was coronally positioned over the membrane to completely cover it and secured with 4-0 non resorbable sutures.
223486060|NCT03023995|PROCEDURE|CAF with connective tissue graft|In control group, connective tissue graft was harvested, after which the flap was coronally positioned over the graft to completely cover it and secured with 4-0 non resorbable.
224175598|NCT04296344|OTHER|Acupuncture Therapy Treatments|10 consecutive weekly group acupuncture therapy treatments
224175599|NCT04296344|OTHER|Yoga Therapy Sessions|8 consecutive yoga therapy sessions that occur immediately following in a room adjacent to acupuncture therapy.
224175600|NCT00577421|DRUG|risedronate|5 mg tablet of risedronate once a day for 2 years
224175601|NCT03480620|OTHER|Online Telerehabilitation Platform Access|Participants will have 24/7 access to a standardized set post-discharge exercise videos and self-management instructions across multiple internet connected devices (e.g. computer, tablet, smartphone). Standardized exercises include a flexibility routine that participants learned and performed with a physical therapist while in the pain management program. Self-management instructions are also written versions of concepts learned and practiced with a member of the multidisciplinary team during the pain management program.
224175602|NCT03480620|OTHER|Usual care|Participants are given a DVD of the standardized post-discharge exercise videos and a written copy of the self-management instructions as described in the experimental group.
224175603|NCT00336960|DRUG|celecoxib|twice daily beginning 5 days prior to radiotherapy and continuing until completion of radiotherapy
224306454|NCT02737527|DEVICE|Fluoroscope for Lumbar Sympathetic Block (LSB)|Briefly, fluoroscopic guided LSBs are performed at the lower third of the L2 or the upper third of the L3 vertebra. A targeted lumbar vertebral is identified by AP fluoroscopic imaging and the fluoroscopic C-arm is adjusted 25-35° laterally to avoid the transverse process over the needle pathway. After the skin infiltration, the needle is advanced toward the anterolateral edge of the target lumbar vertebra under fluoroscopic guidance using the tunnel vision technique.
223486061|NCT02435134|OTHER|no intervention|
223486062|NCT01256515|BEHAVIORAL|Health Education|CDs, techniques, advice, and group training pertaining to a healthier lifestyle. Both groups will have this intervention, but the specific type of health education training will vary between groups.
223486063|NCT01256515|BEHAVIORAL|Health Education Training|8 weeks of group training regarding health education techniques.
223486064|NCT00460967|DEVICE|Rheopheresis|8 rheopheresis treatments over 10 wks.
223486065|NCT00460967|DEVICE|Rheopheresis|Sham treatment
223486066|NCT03305718|OTHER|Meal sequence: 3C1A2B4D|Participants receive test meals in the sequence 3C1A2B4D
223486067|NCT03305718|OTHER|Meal sequence: 2A3D4C1B|Participants receive test meals in the sequence 2A3D4C1B
223486068|NCT03305718|OTHER|Meal sequence: 2D4B3A1C|Participants receive test meals in the sequence 2D4B3A1C
223486069|NCT03305718|OTHER|Meal sequence: 3B2C1D4A|Participants receive test meals in the sequence 3B2C1D4A
223486070|NCT03305718|OTHER|Meal sequence: 4C2B1A3D|Participants receive test meals in the sequence 4C2B1A3D
223486071|NCT03305718|OTHER|Meal sequence:1B4D3C2A|Participants receive test meals in the sequence 1B4D3C2A
223486072|NCT03305718|OTHER|Meal sequence:4A1C2D3B|Participants receive test meals in the sequence 4A1C2D3B
223486073|NCT03305718|OTHER|Meal sequence:1D3A4B2C|Participants receive test meals in the sequence 1D3A4B2C
223486074|NCT03305718|OTHER|Meal sequence: 4D3B2C1A|Participants receive test meals in the sequence 4D3B2C1A
223486075|NCT03305718|OTHER|Meal sequence: 3A4C1B2D|Participants receive test meals in the sequence 3A4C1B2D
223486076|NCT03305718|OTHER|Meal sequence: 1C2A3D4B|Participants receive test meals in the sequence 1C2A3D4B
223486077|NCT03305718|OTHER|Meal sequence: 2B1D4A3C|Participants receive test meals in the sequence 2B1D4A3C
223486078|NCT03905083|OTHER|Exercise Rehab|Participants who do the Exercise Rehab will engage in up to four center-based exercise rehab sessions each week for approximately 12 weeks; each session lasting roughly 1-hour with a stimulus (exercise) phase and a mix of warm up and cool down. Cycle ergometer and treadmill exercise may be used.
223486079|NCT00742950|PROCEDURE|Nasal 2.8-mm corneal incision|Phacoemulsification through a nasal 2.8-mm incision
223486080|NCT00742950|PROCEDURE|Temporal 2.8-mm corneal incision|Phacoemulsification through a 2.8-mm temporal incision
223486081|NCT00742950|PROCEDURE|Superior 2.8-mm incision|Phacoemulsification through a superior 2.8-mm corneal incision
223486082|NCT06251804|OTHER|Water exercise program|The exercise program includes a short foot exercise and will be given in water.
223486083|NCT06251804|OTHER|Land-based-program|The exercise program includes a short foot exercise and will be given on land.
223586516|NCT06579183|DIETARY_SUPPLEMENT|Extra Strength VitaJoy (ES/VJ)|Extra Strength VitaJoy Capsule, 2 capsules in the morning
224175604|NCT00336960|DRUG|fluorouracil|Patients receive concurrent fluorouracil IV continuously for 5 weeks.
224175605|NCT00336960|PROCEDURE|conventional surgery|4-10 weeks after completion of chemoradiotherapy
224175606|NCT00336960|RADIATION|radiation therapy|Patients undergo radiotherapy 5 days a week for 5 weeks
224175607|NCT00336960|PROCEDURE|tumor biopsy|at baseline and then at the time of surgical resection
223486084|NCT00587093|OTHER|CA 125 and CT scan|Within 14 days prior to surgery serum for CA125 will be obtained. The patient will also undergo a CT scan of the abdomen and pelvis with oral and intravenous contrast within 35 days prior to the procedure.
223486085|NCT03342066|DIAGNOSTIC_TEST|reproducability of caries risk assessment|reproducability of caries risk assessment CAMBRA verses cariogram
223486086|NCT02359240|PROCEDURE|therapy according to SSC guidelines and muscle biopsy|Septic patients will be treated according to the international guidelines for management of severe sepsis and septic shock 2012. Skeletal muscle biopsies, blotted free from blood, are frozen within 30 seconds in liquid nitrogen, and stored in liquid nitrogen until processing.150-300 mg muscle (wet weight) was routinely obtained , which is more than sufficient for the analyses proposed, with some muscle remaining for any additional validation assays that may arise during the course of the research. Muscle will be processed either for isolation of mRNA/microRNA or protein
224175608|NCT00336960|OTHER|laboratory biomarker analysis|blood and urine collected at baseline, 5 days after initiation of celecoxib, 7 days after initiation of celecoxib in combination with fluorouracil and radiotherapy, and at the time of surgical resection. specimens are evaluated for COX-2 expression, eicosanoid production, and gene and protein expression using immunohistochemistry, microarray, and mass spectrometry.
224175609|NCT02388750|DRUG|Palonosetron|Palonosetron 0.5 mg every other day until completion of radiation and at least one hour prior on days of RT
224175610|NCT02388750|RADIATION|Low or moderate risk radiotherapy|Low or moderately emetogenic radiotherapy will be given to all patients on study.
224175611|NCT05580107|DRUG|MDPK67b|24 mg or 48 mg
224175612|NCT04168359|DEVICE|absorbable semi-barbed suture|Positioning the intrapulmonary nodules of patient in this group with a absorbable semi-barbed suture positioning device
224175613|NCT04522986|BIOLOGICAL|Mesenchymal stem cell|1\*10\^8 cells are administered once a week, total four times intravenously.
224175614|NCT05908162|DIAGNOSTIC_TEST|Bood leukocyte subsets|Determination of blood leukocyte subpopulations, subpopulation of monocytes and expression CD64 on neutrophils
223486087|NCT02359240|PROCEDURE|standard surgery for femoral fracture and muscle biopsy|Patients with femoral fracture will under standard surgery for fracture fixation. Percutaneous needle muscle biopsies will be performed. Skeletal muscle biopsies, blotted free from blood, are frozen within 30 seconds in liquid nitrogen, and stored in liquid nitrogen until processing.150-300 mg muscle (wet weight) was routinely obtained , which is more than sufficient for the analyses proposed, with some muscle remaining for any additional validation assays that may arise during the course of the research. Muscle will be processed either for isolation of mRNA/microRNA or protein
224306455|NCT02737527|DRUG|10 ml of 0.25% levobupivacaine injection for LSB|After excluding vascular injection with contrast media by a C-arm image intensifier on anteroposterior (AP) and lateral view, 10 ml of 0.25% levobupivacaine is injected through the Chiba needle.
224306456|NCT02737527|PROCEDURE|Temperature measurement for Lumbar Sympathetic Block (LSB)|Temperature monitoring and measurement: skin-surface temperatures are monitored with small, adhesive thermocouple probes attached bilaterally to the plantar surface of the feet using transparent patches at 1-min intervals for a maximum of 20 min.
223486088|NCT06472648|OTHER|Proprioception training exercise plan with BOSU|"A 5' conventional warm-up (stationary cycling and active ankle mobility exercises) was performed.~Ankle proprioception training exercise plan included:~1. A 30-second series of maintaining the single-leg stance position on the BOSU with extended knee and hip holding the ball with the arms stretched out above the head~2. A series of 10 reps on the BOSU where the subject was asked to pass from the supporting-leg hip and knee starting position to a 90º knee flexion squat, keeping the ball above their heads~3. A single series of 10 reps on the BOSU where the subject started with full limb extension of the supporting member and the ball held with both hands at chest height; from this position subjects were asked to bring the free leg from 45º hip extension to 45º hip flexion~4. 10 passes between the subject and a partner where the participants started with a total extension of the supporting limb on the BOSU and the ball held in both hands in front of them.~2' rest between exercises."
223486089|NCT06472648|OTHER|Proprioception training exercise plan with Blackboard (BB)|"A 5' conventional warm-up (stationary cycling and active ankle mobility exercises) was performed.~Ankle proprioception training exercise plan included:~1. A 30-second series of maintaining the single-leg stance position on the BB with extended knee and hip holding the ball with the arms stretched out above the head~2. A series of 10 reps on the BB where the subject was asked to pass from the supporting-leg hip and knee starting position to a 90º knee flexion squat, keeping the ball above their heads~3. A single series of 10 reps on the BB where the subject started with full limb extension of the supporting member and the ball held with both hands at chest height; from this position subjects were asked to bring the free leg from 45º hip extension to 45º hip flexion~4. 10 passes between the subject and a partner where the participants started with a total extension of the supporting limb on the BB and the ball held in both hands in front of them.~2' rest between exercises."
223586517|NCT06579183|DIETARY_SUPPLEMENT|Extra Strength Vita Calm (ES/VC)|Extra Strength Vita Calm Capsule, 2 capsules in the evening
223586518|NCT06579183|DIETARY_SUPPLEMENT|Placebo|Placebo Capsule, 4 capsules in the morning and evening respectively
224175615|NCT05626465|OTHER|Blood test|Proteomic analyses on serum
224175616|NCT00161720|DRUG|Protein C Concentrate (Human) Vapor Heated|Protein C Concentrate (Human) Vapor Heated
224175617|NCT00282607|DRUG|DA-8159|
224175618|NCT01424865|GENETIC|fluorescence in situ hybridization|
224175619|NCT01424865|OTHER|immunohistochemistry staining method|
224175620|NCT01424865|OTHER|immunologic technique|
224175621|NCT01424865|OTHER|laboratory biomarker analysis|
224175622|NCT03297554|BEHAVIORAL|m-Health Intervention|Parent/child dyads attend remote counseling sessions delivered over Internet-connected device (e.g. smartphone, iPad/tablet, laptop, or desktop computer). A counselor will deliver the lesson, review progress based on the objectively measured data, and provide individualized advice and problem-solving strategies for parent and child. Families will receive weekly contact via smartphone. Each lesson will include an interactive component for parent and child related to healthy eating and active play, as well as an interactive parenting training component. Lessons are based on the family treatment methods that effectively promote child and parent weight loss that is sustained for 10 years (Epstein et al., 1990; Epstein et al., 1981).
224175623|NCT05675124|DEVICE|Needlescopic laparoscopic adrenalectomy|Compared with traditional laparoscopic surgery using 5-12 mm instruments, the wound of needlescopic laparoscopic surgery is smaller. Postoperative pain and recovery are also better than traditional laparoscopic surgery.
224175624|NCT05675124|DEVICE|conventional laparoscopic adrenalectomy|conventional laparoscopic adrenalectomy
224175625|NCT03574987|OTHER|Diet|Macronutrient composition (specifically type and/or amount of carbohydrate) is manipulated
224175626|NCT01676649|BIOLOGICAL|Ipilimumab|3 mg/kg
224175627|NCT01676649|DRUG|Carboplatin|AUC = 6
224175628|NCT01676649|DRUG|Paclitaxel|175 mg/m2
224175629|NCT04928521|PROCEDURE|bilateral erector spinae plane block with 30 mL 0.25 % bupivacaine|Preoperative, awake, bilateral, ultrasound-guided erector spinae plane block with 30 mL 0.25 % bupivacaine
224175630|NCT04928521|PROCEDURE|bilateral erector spinae plane block with 20 mL 0.25 % bupivacaine|Preoperative, awake, bilateral, ultrasound-guided erector spinae plane block with 20 mL 0.25 % bupivacaine
224175631|NCT03036891|DRUG|Naloxegol 25 MG Oral Tablet [Movantik]|Patients will be given the study drug (Movantik 25 mg).They will take this daily in the morning 1 hour before breakfast for four weeks.
224175632|NCT03036891|DRUG|Placebo Oral Tablet|Patients will be given Placebo (Placebo 25 mg).They will take this daily in the morning 1 hour before breakfast for four weeks.
224175633|NCT04465513|DIETARY_SUPPLEMENT|Best Standard of Care + CARDIO|Combination of dietary supplement with clinical care
224175634|NCT04465513|DIETARY_SUPPLEMENT|Best Standard of Care|Combination of placebo with clinical care
224175635|NCT03894501|BEHAVIORAL|Mindfulness Oriented Recovery Enhancement|MORE sessions involve mindfulness training to prevent opioid relapse and reduce pain, cognitive reappraisal to decrease negative affect and regulate opioid craving, and savoring to augment natural reward processing and evoke positive emotion. Each session begins with a mindful breathing meditation, followed by a debriefing session. The therapist then debriefs participants' homework practice of using mindfulness, reappraisal, and savoring skills to cope with pain and enhance well-being in everyday life. During this debrief of the homework. Next, new psychoeducational material is introduced. Sessions culminate with an experiential exercise, and close with a brief mindful breathing meditation. Participants are asked to practice 15 minutes of mindfulness/reappraisal/savoring skills each day.
224175636|NCT03894501|BEHAVIORAL|Methadone program behavioral treatment as usual|In the methadone programs, clients typically come to the clinic regularly to get their methadone dose. Clients see their clinic substance abuse counselor for individual counseling, usually weekly at the beginning of treatment, with decreasing frequency if they remain abstinent and progress through treatment. Depending on clients' stage of MMT and success with remaining abstinent from drugs, they may be required to attend clinic treatment groups. Also, some clients may choose to go to voluntary counseling, educational, or support groups.
224175637|NCT04656769|PROCEDURE|Peridural analgesia|We attempted to evaluate the effectiveness of peridural analgesia through cancer survival and recurrence outcomes.
224175638|NCT03154918|DRUG|GLIDE|The dose and schedule of GLIDE chemotherapy was as follows: gemcitabine 800 mg/m 2 days 1, 8; Peg-ASP 2500 U/m 2 days 4; ifosfamide 1000 mg/m 2 days 1 - 3; dexamethasone 20 mg days 1 - 4; etoposide 100 mg/m 2 days 1 - 3.
224175639|NCT00044811|DRUG|Fexofenadine|
224175640|NCT06321796|COMBINATION_PRODUCT|MTP-101P|"MTP-101P is comprised of standardized dose of total fecal microbiota purified from the stool of healthy donors. Donors are carefully screened via health status questionnaires, physical examinations, reviews of comprehensive medical history, clinical laboratory evaluations, serologic and genomic tests for infectious diseases and metabolic health, and stool-related pathogen testing. The material from the donors is purified to remove the majority of non-bacterial material, washed, lyophilized, and provided to the patient in a sachet contained within a mixing bottle.~Duration: 12.5 Weeks"
223486090|NCT02554396|DRUG|PRX-100|ophthalmic solution
224175641|NCT06321796|COMBINATION_PRODUCT|Vancomycin|"Oral vancomycin is an antibiotic used for treating C. difficile-associated diarrhea and staphylococcal-induced enterocolitis.~Duration: 10 Days"
224175642|NCT06321796|COMBINATION_PRODUCT|Magnesium Citrate|"Magnesium citrate is a common over-the-counter laxative and bowel cleanse.~Duration: 1 Day"
224175643|NCT06321796|COMBINATION_PRODUCT|Antacid|"The antacid will be aluminum/magnesium hydroxide, 1x/day, 5 minutes before the MTP-101P. Each 5 ml consists of Aluminum Hydroxide - 200 mg, Magnesium Hydroxide - 200 mg, and Simethicone - 20 mg. If some participants cannot tolerate the aluminum/magnesium hydroxide, we will allow calcium carbonate alternatives equivalent in acid neutralizing capacity.~Duration: 12.5 weeks"
224175644|NCT06321796|COMBINATION_PRODUCT|Placebo MTP-101P|"The same packaging will be used as for MTP-101P, but the sachets will contain a freeze-dried mixture of normal saline containing 10% Trehalose.~Duration: 12.5 weeks"
224175645|NCT06321796|COMBINATION_PRODUCT|Placebo Vancomycin|"Same packaging and liquid carrier and flavoring used as for the oral vancomycin, but no vancomycin.~Duration: 10 days"
224175646|NCT00999882|DRUG|AZD8055|Dose escalation phase: Tablet taken orally, a single dose of AZD8055 on Day 1, followed by twice daily continuous dosing from Day 3 onwards, till discontinuation or withdrawal.Expansion phase: twice daily continuous dosing from Day 1 onwards till discontinuation or withdrawal.
224175647|NCT00628680|DEVICE|AAT-023 solution (Zuragen)|Amount equal to the catheter lumen plus 0.3mL. Three times per week (after each Hemodialysis) for 26 weeks
224175648|NCT00628680|DRUG|Heparin|Hepaarin 5000 units diluted with normal saline to the exact catheter lumen volume.
224175649|NCT01245972|PROCEDURE|PDL Treatment|Pulsed-dye laser (PDL) treatment at one of two settings.
223486091|NCT02554396|DRUG|Placebo|saline ophthalmic solution
223486092|NCT00964782|DRUG|Sildenafil|oral suspension, 0.5mg/kg, taken once prior to exercise stress test. Enrolled patients will be randomized to receive Sildenafil first and then crossed over to receive the opposite intervention, placebo.
223486093|NCT00964782|DRUG|Placebo|Patient will receive a look-alike placebo. Enrolled patients will be randomized to receive Placebo first and then crossed over to receive the opposite intervention, Sildenafil.
223486094|NCT00964782|DRUG|Sildenafil 2|oral suspension, 0.5mg/kg, taken once prior to exercise stress test. Enrolled patients will receive Sildenafil, the crossed over intervention from their initial intervention (Placebo).
223486095|NCT00964782|DRUG|Placebo 2|Patient will receive a look-alike placebo. Enrolled patients will receive Placebo, the crossed over intervention from their initial intervention (Sildenafil).
223486096|NCT05442658|OTHER|Microbiota|
223486097|NCT02033512|DRUG|Transdermal Hormone Replacement Therapy|"The Blood samples were collected from the subjects early in the morning after an overnight fast. After serum testing, the identification hormone deficiencies, was determined and then, if necessary, additional transdermal progesterone was prescribed. The patients were evaluated 3 months after THRT treatment protocol.~All the patients were instructed about how to use the progesterone pump for transdermal application, performed in the presence of an experienced physician, in order to guarantee standardization and correct use of the THRT. Compliance was defined as completing seventy percent or more of the transdermal applications."
223486098|NCT02033512|DRUG|Transdermal Nanoformulation|The Blood samples were collected from the subjects early in the morning after an overnight fast. After serum testing, the identification hormone deficiencies, was determined and then, if necessary, additional transdermal hormones were prescribed.
223486099|NCT02033512|DRUG|Transdermal formulation|66 patients completed the study. In the present analysis, the subjects received daily in the right and left forearm a transdermal nanostructured formulation of Estriol (0.1%) + Estradiol (0.25%) and Progesterone (10%) respectively (Biolipid B2®, Evidence, SP, Brazil) for sixty months. The effects of transdermal hormone formulation were analyzed.
223486100|NCT03513952|DRUG|Atezolizumab|Given IV
223486101|NCT03513952|PROCEDURE|Biopsy|Undergo biopsy of tumor
223586519|NCT06587230|BEHAVIORAL|Teachers Leading the Frontlines|"1. During 3-day training, Knowledge and attitudes toward child mental health care are measured pre-training, post-training, and post-intervention.~2. The teachers select students whom they believe have the highest mental health needs to receive care.~3. Teachers analyze chosen students' symptoms.~4. Teachers analyze students' behavior with the AABC Chart.~5. Teachers develop a targeted response using a behavior plan called the 4Cs plan (Cause, Change, Connect, and Cultivate). In the 4Cs, teachers select therapeutic techniques to deliver from a menu of evidence-based therapeutic options for each category of behavior.~6. Throughout the year, teachers receive supervision through monthly site visits supplemented by as-needed telephone and digital discussions to guide their care from the study team. Teachers encourage the use of the 4Cs plan at home."
224175650|NCT04005885|DEVICE|comfilcon A|Contact Lens
224175651|NCT04005885|DEVICE|somofilcon A|daily disposable contact lens
224175652|NCT04005885|DEVICE|stenfilcon A|daily disposable contact lens
224175653|NCT03098576|OTHER|Matched targeted drug treatment|Matching a specific genetic abnormality (i.e. mutation) with the appropriate targeted drug.
224175654|NCT03098576|OTHER|Unmatched standard of care|"All patients with either no identified mutation or no available matching treatment but undergoing a systemic treatment will be enrolled in the control group."
224175655|NCT03706144|OTHER|Prodigy Math Training|https://www.prodigygame.com/
224175656|NCT03166189|BIOLOGICAL|bone marrow-derived MSC and HRT|"* Transplantation procedure to endometrial cavity is performed with ultrasound guidance on menstrual cycle day 5-6 through uterine cervix using cater for embryo transfer with 1 ml of suspension containing 5 millions of autologous bone marrow-derived mesenchymal stem cells~* Three cycles of HRT following MSC transplantation;~* Pipelle-biopsy of endometrium on day 20 of hormonal replacement therapy of the last (third) cycle;~* Frozen/thawed embryo transfer 3-6 months after transplantation."
224175657|NCT03166189|OTHER|hormonal replacement therapy|"standard treatment of hypoplastic endometrium or Asherman's syndrome:~* Three cycles of HRT preceding frozen/thawed embryo transfer;~* Frozen/thawed embryo transfer."
224175658|NCT05959239|DRUG|TB006|TB006 will be provided as single-use injectable glass vials.
224175659|NCT00696644|DRUG|Teriparatide|20 mcg daily subcutaneous for 18 months.
224175660|NCT01427855|OTHER|High saturated fat red meat diet|4 weeks of a high saturated fat red meat diet (38% carbohydrate; 25% protein (12% kcal from red meat protein); 37% fat (15% kcal from saturated fat))
224175661|NCT01427855|OTHER|High saturated fat non-meat diet|4 weeks of a high saturated fat non-meat diet (38% carbohydrate; 25% protein (16% kcal from non-meat protein); 37% fat (15% kcal from saturated fat))
224175662|NCT01427855|OTHER|High saturated fat white meat diet|4 weeks of a high saturated fat white meat diet (38% carbohydrate; 25% protein (12% kcal from white meat protein); 37% fat (15% kcal from saturated fat))
224175663|NCT01427855|OTHER|Low saturated fat red meat diet|4 weeks of a low saturated fat red meat diet (38% carbohydrate; 25% protein (12% kcal from red meat protein); 37% fat (7% kcal from saturated fat))
224175664|NCT01427855|OTHER|Low saturated fat white meat diet|4 weeks of a low saturated fat white meat diet (38% carbohydrate; 25% protein (12% kcal from white meat protein); 37% fat (7% kcal from saturated fat))
223486102|NCT03513952|PROCEDURE|Biospecimen Collection|Undergo collection of blood and stool samples
223486103|NCT03513952|PROCEDURE|Computed Tomography|Undergo CT
223486104|NCT03513952|BIOLOGICAL|Glycosylated Recombinant Human Interleukin-7|Given IM
223486105|NCT03513952|OTHER|Laboratory Biomarker Analysis|Correlative studies
224175665|NCT01427855|OTHER|Low saturated fat non meat diet|4 weeks of a low saturated fat non-meat diet (38% carbohydrate; 25% protein (16% kcal from non-meat protein); 37% fat (7% kcal from saturated fat))
224175666|NCT00003572|BIOLOGICAL|peripheral blood lymphocyte therapy|
224175667|NCT00003572|DRUG|mycophenolate mofetil|
224175668|NCT00003572|DRUG|tacrolimus|
224175669|NCT00003572|PROCEDURE|allogeneic bone marrow transplantation|
224175670|NCT00003572|RADIATION|radiation therapy|
224175671|NCT05001672|DRUG|Tenofovir alafenamide|Tenofovir alafenamide (TAF, brand name: Vemlidy) is a hepatitis B virus nucleotide reverse transcriptase inhibitor oral medication for the treatment of chronic hepatitis B virus infection. It is a prodrug of tenofovir. Closely related to the commonly used reverse-transcriptase inhibitor tenofovir disoproxil fumarate, TAF has greater antiviral activity and better distribution into lymphoid tissues than that agent. Vemlidy was approved by the U.S. Food and Drug Administration (FDA) in November 2016 and the TAIWAN Food and Drug Administration (TFDA) in April 2017.
224175672|NCT00826787|DRUG|Levetiracetam|750 mg tablet
223486106|NCT03513952|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
224306457|NCT02737527|PROCEDURE|Postprocedure care for LSB|Adverse events such as genitofemoral nerve block, lumbar plexus block (transient unilateral leg weakness), or others are documented during and after the procedure for 30 min.
224306458|NCT01770392|DRUG|Nintedanib|single dose administration
224306459|NCT01770392|DRUG|Rifampicin|single dose once daily for 7 days
224306460|NCT01770392|DRUG|Nintedanib|single dose administration
224175673|NCT06372405|BEHAVIORAL|Cognitive reappraisal|Cognitive reappraisal is a psychotherapeutic strategy utilized to regulate emotions by reinterpreting the meaning of stimuli. Participants will receive instructions on generating and implementing cognitive reappraisal (distancing and reframing) in both misophonic and non-misophonic contexts and will be practicing it within psychotherapeutic sessions. The program consists of four weekly online psychotherapeutic sessions: the first session will be a 90-minute group session, followed by three individual sessions, each lasting 30 minutes.
224175674|NCT06372405|BEHAVIORAL|Schultz Autogenic Training|Schultz Autogenic Training is a relaxation technique aimed at promoting relaxation and reducing physiological arousal. It consists of six exercises focusing on sensations of heaviness, warmth, heartbeat, breathing, abdominal warmth, and coolness of the forehead. The program consists of four weekly online psychotherapeutic sessions: the first session will be a 90-minute group session, followed by three individual sessions, each lasting 30 minutes.
224175675|NCT00031824|DRUG|cyclosporine|
223486107|NCT03513952|PROCEDURE|Positron Emission Tomography and Computed Tomography Scan|Undergo PET/CT
223486108|NCT05553717|DRUG|Carvedilol|Carvedilol 12.5mg\\12hr
224175676|NCT00031824|DRUG|hydroxychloroquine|
223486109|NCT01583881|PROCEDURE|renal denervation|Renal denervation
223486110|NCT02938663|BEHAVIORAL|Questionnaires and Measurements|Participants completed anthropometric measurements and questionnaires assessing psychosocial stress, habitual dietary intake and physical activity as well as cultural identity, identity-based motivation and socioeconomic status. At home, participants recorded their habitual physical activity and food intake. Participants then returned to the laboratory to complete an assessment of identity-based motivation and received personalized information regarding their habitual physical activity and dietary patterns.
223486111|NCT02703766|BEHAVIORAL|overfeeding induced weight gain|
223486112|NCT01093417|DRUG|Vitamin D|Vitamin D 4000 IU will be administered to enrollees on the active comparator arm
223486113|NCT01093417|OTHER|Placebo|Placebo pills will be administered to enrollees in this arm
223586520|NCT06587230|BEHAVIORAL|Responding to Students' Emotions Through Education|"All processes for RE-SEED are the same as in Tealeaf except...~1. Teachers receive only 1 day of training~2. The study team does not provide supervision to the teachers, allowing only the school counselor to provide supervision~This less resource-intensive approach will allow for an ethical comparator to Tealeaf, where the schools would like for teachers to have some skills to support identified students."
223586521|NCT06980675|DEVICE|Activated Ozonized Olive Oil Gel|It is a natural oil which has been ozonized to improve the antimicrobial activity against periodontopathogenic bacterias
223586522|NCT06980675|OTHER|Placebo gel|Placebo gel with same texture, color, way of administration and taste of Activated Ozonized Olive Oil Gel
224175677|NCT00031824|DRUG|prednisone|
224175678|NCT00031824|DRUG|tacrolimus|
224175679|NCT03597789|BEHAVIORAL|Helping the Noncompliant Child (HNC)|HNC is a mastery-based, family-focused, clinic-based treatment for young children aged 3-8 years with problem behavior.
224175680|NCT02718625|BIOLOGICAL|Santyl|Collagenase ointment applied topically
224175681|NCT02718625|BIOLOGICAL|SoloSite®|SOLOSITE is a hydrogel wound dressing with preservatives. It can donate moisture to rehydrate non-viable tissue. It absorbs exudate while retaining its structure in the wound.
224175682|NCT02681068|OTHER|Fecal microbiota transplantation (FMT)|Fecal microbiota transplantation (FMT) for patients with Clostridium difficile associated diarrhea
224175683|NCT03704090|BEHAVIORAL|Occupational therapy intervention|Prevention of postoperative delirium by occupational therapy intervention
223486114|NCT04793568|DRUG|Recombinant Interferon gamma 1b (IMUKIN®)|100 µg/0,5ml subcutaneous injections from day 1 to day 9 (5 injections, i.e. 1 injection of 100 µg every 48h)
224175684|NCT03704090|BEHAVIORAL|Standard non-pharmacological prevention intervention|Prevention of postoperative delirium using standard non-pharmacological prevention measures
223486115|NCT04793568|DRUG|Recombinant Interferon gamma 1b placebo|5 subcutaneous injections from day 1 to day 9 (i.e. 1 injection of 0,5ml every 48h).
223486116|NCT01143324|DEVICE|MAST™ procedure|Single or double level instrumented fusion receiving the CD Horizon® Spinal System using PLIF or TLIF techniques via a MAST™ procedure.
223486117|NCT01091610|OTHER|no intervention|purely observational retrospective study. no interventions are planned.
223486118|NCT00447408|BEHAVIORAL|Standard hemodialysis dietary instruction|Participants receive standard hemodialysis dietary instruction via a PowerPoint presentation delivered during routinely scheduled dialysis treatments.
223586523|NCT06981364|DIETARY_SUPPLEMENT|Fish Oil|Upon completion of baseline testing both groups will be instructed not to alter their normal diet and activity levels throughout the study period. Zach Townsend, an individual who will not be directly involved with the data analysis, will create a spread sheet containing the weight of the subjects and separate identifier generated via algorithm. The spread sheet will be provided to the principle and co-investigators who will partition the supplements out into 42 separate sealable bags per subject. The bags will be dispersed by Mr. Townsend to maintain the double-blind standard. Subjects will either consume 4 g/day GNC Triple Strength Fish Oil Mini, General Nutrition Corporation, Pittsburgh, PA, or placebo (dextrin) of equal volume for six weeks. They will be instructed to consume fish oil or the placebo with a glass of water at the same time every day. These protocols are similar to ones used in previous investigations1-7.
223486119|NCT00447408|BEHAVIORAL|Behavioral counseling plus PDA-based self-monitoring of diet|Participants receive standard hemodialysis dietary instruction via a PowerPoint presentation delivered during routinely scheduled dialysis treatments. In addition they receive behavioral counseling paired with PDA-based self-monitoring of dietary sodium intake.
223486120|NCT01694680|DIETARY_SUPPLEMENT|Lutein-enriched-egg beverage (NWT-02)|Lutein, zeaxanthin and DHA-enriched-egg yolk combined with buttermilk beverage
223486121|NCT01694680|DIETARY_SUPPLEMENT|Placebo|color-, taste- and energy-matched powder without enriched egg-yolk
223486122|NCT06026397|DRUG|SK10|Participants will be randomized to receive oral suspension of SK10 powder, includes SAD on Day 1 and 14-days MAD from Day 4 to Day 17.
223486123|NCT06026397|DRUG|Placebo|Participants will be randomized to receive oral suspension of placebo, includes SAD on Day 1 and 14-days MAD from Day 4 to Day 17.
223486124|NCT02530541|DRUG|CHG|Varied application times
224175685|NCT00779116|DRUG|Desloratadine|SCH 34117: desloratadine RediTabs, 1 tablet (2.5 mg), oral administration, single dose, single day
224175686|NCT00779116|DRUG|Zyrtec® (cetirizine)|Zyrtec® (cetirizine) Chewable Tablets, 1 tablet (5 mg), oral administration, single dose, single day
224175687|NCT04050540|DRUG|Doxycycline|200 mg of doxycycline to be taken orally within 24 hours and up to 72 hours after each condomless sex act
224175688|NCT00984152|DRUG|TDF/FTC Once-Daily + Raltegravir 400 mg Orally Twice-Daily|TDF/FTC Once-Daily + Raltegravir 400 mg Orally Twice-Daily
224175689|NCT00984152|DRUG|TDF/FTC + Efavirenz (Atripla) Once-Daily|TDF/FTC + Efavirenz (Atripla) Once-Daily
224175690|NCT00554424|DRUG|lignocaine|20 mls of 1% lignocaine solution for injection, 10mls into each side of upper vagina, under ultrasound guidance immediately prior to transvaginal oocyte retrieval under ultrasound guidance from each ovary
223486125|NCT04872283|PROCEDURE|great toe (1st metatarsophalangeal joint) fusion|Great Toe joint fusion surgery
224175691|NCT00554424|DRUG|normal saline|20mls of normal saline solution, 10mls injected each side into upper vagina under ultrasound guidance, immediately prior to ultrasound guided transvaginal oocyte retrieval from each ovary
224175692|NCT01836549|DRUG|imetelstat sodium|Given IV
223486126|NCT04872283|DRUG|IV Ketorolac|Participants will receive 30mg of intravenous (IV) ketorolac will be given during surgery
223486127|NCT04872283|DRUG|Ketorolac Pill|Participants will receive 20 tablets of 10mg ketorolac, with instructions to take 1 tablet orally every 6 hours for pain
223486128|NCT04872283|DRUG|5/325mg Oxycodone-Acetaminophen|Participants will receive 30 tablets of 5/325mg oxycodone-acetaminophen with instructions to take 1 or 2 tablets by mouth every 4 to 6 hours as needed for pain
223586524|NCT06980064|DIAGNOSTIC_TEST|Smartwatch + GP|Participants in the intervention group will be required to wear a smartwatch continuously for 24 hours. After this period, the collected data will be processed using a pre-trained foundational model for disease diagnosis, generating preliminary diagnostic suggestions. GPs will then integrate these smartwatch-derived findings with clinical interviews and aforementioned baseline examination results to formulate a final diagnosis.
223586525|NCT06980064|DIAGNOSTIC_TEST|GP only|GPs will make diagnosis with clinical interviews and aforementioned baseline examination results to formulate a final diagnosis.
223486129|NCT04872283|DRUG|Aspirin 81Mg Ec Tab|Participants will receive 81 mg aspirin twice daily as a preventive measure against deep venous thrombosis (DVT)
223486130|NCT04130841|PROCEDURE|Internal Limiting Membrane Peeling|After removal of the epiretinal membrane, indocyanine green staining will be used to determine the internal limiting membrane (ILM) peeled off with the epiretinal membrane. (Group 1: spontaneous ILM peeling) If it is confirmed that the internal limiting membrane is not peeled together, the investigators determine whether the active Internal limiting membrane peeling is performed by 1:1 randomization immediately during surgery. (Group 2: Active ILM peeling, Group 3: no ILM peeling) The outcomes of the three groups will be compared.
223486131|NCT02353780|DRUG|TNF Antagonist (enbrel, humire, remicade, cimzia, symponi)|TNF Antagonist; treating rheumatologist selects specifics for the therapy chosen.
223486132|NCT02353780|DRUG|Abatacept|Abatacept; SQ; specifics to be determined by the treating rheumatologist.
223486133|NCT02353780|DRUG|Tocilizumab|Tocilizumab; SQ; specifics determined by the treating rheumatologist.
223486134|NCT03133013|DEVICE|SLEEPSCOPE|Brainwave measurement device which is connected to the participant by an electrode attached to the forehead and another electrode behind one ear
223486135|NCT00056680|BEHAVIORAL|Psychoeducational video|
223486136|NCT00056680|BEHAVIORAL|Infant massage|
223486137|NCT00056680|BEHAVIORAL|Brazelton Neonatal Behavioral Assessment Scale|
223486138|NCT03265795|DEVICE|Poly Ether Ether Ketone PSI (patient specific implant).|reconstruction of the bone and the original volume of maxillary sinus accurately (in terms of clinical and radiographic parameters).
223486139|NCT04025424|GENETIC|Genetic tests of the available tumor and plasma samples|Only available samples or samples obtainted for other reasons will be used for molecular testing. No special intervention is preplanned
223486140|NCT02608619|RADIATION|F-choline PET Scan|
223486141|NCT02608619|DEVICE|FDG-PET|
223586526|NCT06086483|DRUG|Ropivacaine 0.2% Injectable Solution|"20 mL 0.5% ropivacaine was injected into the PENG block~20 mL 0.5% ropivacaine was injected into the Adductor Canal block"
224175693|NCT00003465|DRUG|temozolomide|
224175694|NCT01500421|DEVICE|TH - Endovascular alone (Alsius®, Zoll, USA)|Patients are cooled with an endovascular (Alsius®, Zoll, USA) groin catether (9,3 french).
224175695|NCT01500421|DEVICE|TH - Endovascular + nasopharyngeal induction (Alsius®, Zoll, USA) (Rhinochill®, Benechill, USA)|Patient are cooled with a groin endovascular catheter (Alsius®, Zoll, USA) + a nasopharyngeal induction catheter (Rhinochill®, Benechill, USA) in the nostrils. The nasopharyngeal induction is designed to give a more quick and localised brain cooling.
224175696|NCT01500421|DEVICE|Intravenous cold saline and surface cooling (Arctic Sun, Medivance, USA)|Infusion of ice cold saline of 4°C (25 mL/kg body weight)followed by surface cooling
224175697|NCT00476502|GENETIC|identify genetic polymorphism in Thai HIV infected|Gene sequencing of Cyp450 metabolic pathway
224175698|NCT04182165|DEVICE|Gili BioSensor System/ Gili Pro X BioSensor System|Usability study
224175699|NCT04652102|BIOLOGICAL|CVnCoV|Intramuscular (IM) injection.
224175700|NCT04652102|BIOLOGICAL|Placebo|Intramuscular (IM) injection.
224175701|NCT04652102|BIOLOGICAL|Authorized/licensed vaccines for preventing COVID-19 (AV) as standard of care through their national vaccination program|Intramuscular (IM) injection will be received as standard of care (SoC) outside the study.
224175702|NCT03906006|DRUG|ABP-671|Drug: ABP-671, single oral dose
224175703|NCT03906006|OTHER|Placebo|Other: Placebo, single oral dose
224175704|NCT05157178|BIOLOGICAL|Covid-19 (recombinante) vaccine|Administration of the Covid-19 (recombinante) vaccine
224175705|NCT00266799|DRUG|Pegylated liposomal doxorubicin (SCH 200746)|pegylated liposomal doxorubicin (50 mg/m\^2 q 28 days) was administered intravenously until disease progression or unacceptable toxicity
224175706|NCT00266799|DRUG|Capecitabine|capecitabine (1250 mg/m\^2 BID x 14 days q 21 days) in tablets of 150 mg and 500 mg was administered orally, until disease progression or unacceptable toxicity
224175707|NCT03202667|DRUG|Empagliflozin 25mg|Treatment with empagliflozin 25mg once daily for 28 days
224175708|NCT03202667|DRUG|Placebo|Treatment with Placebo oral tablet once daily for 28 days
223486142|NCT02608619|PROCEDURE|biopsy|
223486143|NCT02774889|BEHAVIORAL|Stepping Online|"Stepping Online is a password-protected website with Stepping On graduates, whose groups are randomized to Stepping Online and will have access to and training in a password-protected website. The website includes:~1. Fall prevention tips~2. Fall prevention exercise videos with narrations for proper technique and safety precautions~3. Guest expert videos with online access to the guest expert to ask questions~4. Tools to set exercise goals, get reminders and track progress~5. Access to a fall prevention specialist for personal feedback and suggested group homework~6. Group discussion and messaging (one-to-one and with their fellow Stepping On workshop participants group, or with all Stepping Online participants and leaders)~7. Fall prevention resources"
223486144|NCT00858988|DRUG|Rifaximin|100mg of rifaxin for 7 consecutive days, twice daily
223486145|NCT00858988|DRUG|Placebo|twice daily for 7 consecutive days
223486146|NCT04155801|DIETARY_SUPPLEMENT|Salix Probiotic Blend|Oral capsule. The probiotic strains comprise the Salix Probiotic Blend include 3 strains of Bifidobacterium lactis (Bl-04®, Bi-07®, HN019) and 2 strains of lactobacillus (Lactobacillus acidophilus \[NCFM\]® and Lactobacillus paracasei \[Lpc-37\]®).
223486147|NCT00416273|DRUG|Bortezomib|Bortezomib will be administered as 1.6 mg/m2 per body surface area on the days 1, 8, 15, 22 for the duration of 4 therapy cycles.
223486148|NCT00416273|DRUG|No intervention|Participants in the observation group will be observed and will not receive any consolidation therapy.
223486149|NCT01349595|DRUG|Bortezomib|"Patients randomized to bortezomib treatment will receive 2, 4-dose cycles of drug followed by a 2 month hiatus. At the end of this time, subjects will be re-evaluated for the appropriateness of receiving a 3rd and 4th cycle of bortezomib. Bortezomib will be given subcutaneously (under the skin). If unable to give subcutaneously, bortezomib will be given as a single IV (injection into vein) over a time of 3 to 5 seconds. Patients will receive up to 4, four-dose cycles of 1.3 mg/m(2) (based on body surface area)."
223486150|NCT01885065|OTHER|Gel-based artificial saliva|"Gel-based artificial saliva is an edible non-nutritious gel intended to relieve dry mouth.~Taking orally 1-2 teaspoon each time, 5 times / day (30-50 ml/ day) for four weeks."
223486151|NCT00337883|DRUG|Erlotinib HCl (OSI-774)|
223486152|NCT00492869|DRUG|AEB071|
223486153|NCT00355927|PROCEDURE|Sedation with IV propofol|Propofol(50 microgram/kg/min.), I.V. for 5-10 minutes, Until a level of light sedation is achieved
223486154|NCT02857868|DRUG|ABL001|
223586527|NCT06086483|DRUG|0.9%sodium chloride|"20 mL 0.9% sodium chloride was injected into the PENG block~20 mL 0.5% sodium chloride was injected into the Adductor Canal block"
223586528|NCT06825546|DRUG|Icaritin|"Icaritin soft capsules, 600 mg, taken twice daily, should be swallowed with warm water within 30 minutes after breakfast and dinner. If a patient misses a dose and cannot take it within 2 hours after a meal, they should continue with the next scheduled dose without needing to make up for the missed dose.~Gemcitabine, 1000 mg/m², is administered on days 1 and 8, followed by a 14-day pause, constituting a 21-day treatment cycle. Nab-paclitaxel, 125 mg/m², is also administered on days 1 and 8, with a 14-day pause, making up a 21-day treatment cycle."
223586529|NCT06825546|DRUG|AG chemotherapy|"Gemcitabine (1000 mg/m²) + saline (100 mL), infused intravenously over 30 minutes, followed by a 100 mL saline flush.~Nab-paclitaxel (125 mg/m²) + saline (100 mL), infused intravenously over 30 minutes, followed by a 100 mL saline flush"
224175709|NCT03312075|OTHER|Sputum and blood samples|The cystic fibrosis patient will have a first series of sputum as well as a blood sample. On the same day of consultation, a second expectoration will be performed as far as possible.
224175710|NCT05949463|OTHER|Intermittent teaching unit|The intermittent group students performed an intermittent teaching unit twice a week for eight weeks aimed at promoting healthy physical activity habits. Specifically, the last 15 minutes of each lesson were used. The rest of lessons' time other contents were worked on with no relation to any health physical activity habit (i.e., acrosport, badminton, basketball, volleyball, soccer and athletics).
224175711|NCT05949463|OTHER|No intervention group|The control group students also carried out two Physical Education lessons a week during the intervention period. During these lessons, contents of handball, basketball, alternative sports and traditional games were developed. However, this group did not wear physical activity activity wristbands or receive any behavior modification specific strategy.
224175712|NCT01969565|DRUG|Carfilzomib|
224175713|NCT01969565|DRUG|Dexamethasone|
224175714|NCT03737344|DRUG|IL-1Ra Kineret®|Kineret® 100 mg in 0.67 ml Prefilled Syringe
224175715|NCT03737344|OTHER|IL-1Ra Placebo|Placebo identical to Kineret® 100 mg in 0.67 ml Prefilled Syringe
224175716|NCT01551485|DRUG|Zolpidem|The effect of Zolpidem 10 mg for the first night after surgery is asssessed using PSG
224175717|NCT01551485|DRUG|Placebo|Pacebo tablet, blinded given on the first night after surgery
224175718|NCT04440306|PROCEDURE|Mini-Gastric Bypass - Original Technique|Mini-Gastric Bypass - Original Technique is widely used form of bariatric surgery and includes a tailored BPLL
224175719|NCT03089489|DIAGNOSTIC_TEST|lung biomarkers in organ donor for PGD in lung recipient|Lung biopsies in organ donor before and after cold ischemia
224175720|NCT02258841|BEHAVIORAL|Setting Priorities for Safety|Participants rate the importance of 5 priorities to decision-making about their unsafe relationship by comparing the relative importance of each pair of priorities. Weights for each priority are computed and provided to the woman, along with examples of safety strategies that fit with her top ranked priority.
223586530|NCT06980207|DRUG|LY03017|administered orally
223586531|NCT06980207|DRUG|LY03017-Placebo|administered orally
223586532|NCT06981104|DRUG|0.05% cyclosporine eyedrops|0.05% cyclosporine, one drop each time, twice a day
223586533|NCT06981104|DRUG|0.1% sodium hyaluronate eye drop|0.1% sodium hyaluronate, one drop each time, three times a day
224175721|NCT02258841|BEHAVIORAL|Danger Assessment|Participants complete a calendar to show episodes of physical and/or sexual violence they have experienced in the past 12, along with 20 questions assessing risk of serious or lethal violence. A standardized weighted score is provided, along with a brief explanation about her level of danger and appropriate actions she may take.
224175722|NCT02258841|BEHAVIORAL|Personalized Action Plan|Women create a tailored action plan for themselves by selecting strategies from 8 different groups, including those which are recommended to them based on their responses to previous questions.
224175723|NCT02258841|BEHAVIORAL|General risk and safety information|Participants receive general information about the importance of priorities in making safety decisions and risk factors for intimate partner violence.
224175724|NCT02258841|BEHAVIORAL|Basic Emergency Safety Plan|Participants are provided with a basic emergency plan including information about local DV resources. The information is not personalized but is consistent with online information which women could find on their own (usual care)
224175725|NCT06402149|OTHER|dexamethasone|Use of dexamethasone in infraclavicular block
224175726|NCT02411266|OTHER|ischemic conditioning group|application of a blood pressure cuff around a leg and inflating the cuff to 200mmHg to induce limb ischemia for 10min followed by 5min reperfusion. this will be done for 3 cycles every 24-48hours during the first 14 days after subarachnoid hemorrhage
224175727|NCT01007318|PROCEDURE|Single port laparoscopic appendectomy|Single port through the transumbilical 2-cm incision
224175728|NCT01007318|PROCEDURE|3 port laparoscopic appendectomy|3 trocars was inserted in infraumbilical, left lower quadrant, and suprapubic area
224175729|NCT03021707|DEVICE|WaveLight® Ultraviolet Femtosecond (FS) Laser System|Utilizes ultraviolet (UV) light with a wavelength of 347 nanometers (nm) for refractive error correction
224175730|NCT03021707|PROCEDURE|Laser Assisted Lenticular Extraction|Used for refractive error correction
224175731|NCT03087474|OTHER|Non-Interventional|Non-Interventional
224175732|NCT04220645|OTHER|Opportunstic treatment|opportunistically treating HCV infection immediately when hep C patients are hospitalized for acute care in psychiatric, addiction treatment or somatic wards
224175733|NCT04220645|OTHER|Standard of care|Referral at discharge
224175734|NCT00696774|DRUG|Duloxetine|"Study Period II (Acute Therapy): 60 mg capsules, QD, for 4 weeks.~Study Period III (Optimization): Responder group - 60 mg capsules, QD, for 4 weeks more. Non-responder group - 120 mg capsules, QD, for 4 weeks more."
224175735|NCT02444611|DRUG|BCG Vaccine|intradermal vaccination
223486155|NCT05257616|OTHER|Traction Mobilization technique|Traction Mobilization was given by Researcher at the cervical spine followed by a one minute interval before post vitals were taken, that marked the end of the first session. Three similar sessions succeeded the first, each at an interval of 2 days for 2 weeks between the first and second session; third and fourth session respectively. At the end of the fourth session, cervical ranges and pain intensity were noted again. Participant sits comfortably or leans against a chair backrest. Palms of the hands are placed on the mastoid processes of the patient's skull while pressing the elbows in a caudal direction. It was held for 5 seconds then relaxed.
223486156|NCT05257616|OTHER|Traction Mobilization technique with SNAGS|Traction Mobilization with SNAGS were given at the cervical spine followed by a one minute interval before post vitals were taken, that marked the end of the first session. Three similar sessions succeeded the first, each at an interval of 2 days for 2 weeks between the first and second session; third and fourth session respectively. At the end of the fourth session, cervical ranges and pain intensity were noted again The position of the therapist is behind him or her, medial border of therapist's right thumb is used to contact the spinous process of C6 vertebrae i.e. level above the suspected painful or hypo mobile region. Therapist's left thumb reinforces his/her (right) contact thumb. Therapist fingers are gently placed along the patient's mandible or thorax. Following the treatment plane towards the eye, lift comes from the mobilizing thumb not the contact thumb. While the glide is maintained, the patient is asked to rotate his/her head towards the side of pain or hypo mobility.
223486157|NCT01692574|BEHAVIORAL|Behavior Modification for Weight Loss|
223486158|NCT01692574|BEHAVIORAL|Alternative Approach to Weight Loss|
223486159|NCT01692574|BEHAVIORAL|Cognitive-Behavior Therapy for Depression|
223486160|NCT01692574|BEHAVIORAL|Depression Support and Education|
223486161|NCT05578339|DEVICE|Biometry|Lens thickness, lens shape, anterior chamber depth, axial eye length and angle-to-angle will be used as explanatory variables (independent variables) and the size of the capsular bag will be used as main outcome parameter (dependent variable).
223486162|NCT03955315|BIOLOGICAL|IDCT|Discogenic Cells + Sodium Hyaluronate Vehicle
223486163|NCT03955315|PROCEDURE|Sham|Needle puncture under the muscular layer in front of the intervertebral disc
223486164|NCT02715453|OTHER|Intervention on frailty|"Multidisciplinary team (physicians, nurses, physiotherapists, and nutritionists):~* Nutritional evaluation and intervention after randomization and regularly during follow-up~* Physiotherapy sessions for 3 months after randomization and home exercise program for 1 year~* Psychiatrist or psychologist assistance for 1 year after discharge"
223486165|NCT04696198|OTHER|Manual Therapy Intervention|Manual Therapy Interventions to improve range of motion and decrease pain
223486166|NCT04696198|OTHER|Standard care|standard care
224175736|NCT02444611|DRUG|Hepatitis B Vaccine|intramuscular vaccination
224175737|NCT02908945|DRUG|Ketamine|Bolus dose before induction of anesthesia and infusion during maintenance of anesthesia.
224175738|NCT02908945|DEVICE|NeuroSENSE monitor|NeuroSENSE monitors the brain using electroencephalography (EEG) and produces an index called the WAVCNS. WAVCNS is a measure of depth of hypnosis (DoH).
224175739|NCT01884935|BIOLOGICAL|Natalizumab|As specified in the treatment arm
224175740|NCT03389659|DRUG|vitamin D3|vitamin D3 400IU\*5pills po. qd continue to disease progression
224175741|NCT03389659|DRUG|Placebo|placebo 5 pills po. qd continue to disease progression
224175742|NCT03289442|PROCEDURE|supine position|patients were positioned on their supine position to receive colonoscopy insertion
224175743|NCT00372580|PROCEDURE|blood test|
224175744|NCT00663533|DEVICE|Vas-X|mechanical vasectomy device
224175745|NCT02073227|DRUG|Canagliflozin, 300 mg|Each tablet contains canagliflozin (CANA) of 300 mg to be taken orally (by mouth).
224175746|NCT02073227|DRUG|Metformin XR, 500 mg|Each tablet contains metformin extended release (MET XR), 500 mg, to be taken orally (by mouth).
224175747|NCT02073227|DRUG|CANA/MET XR FDC, Formulation 1, 150 mg/1,000 mg|Each tablet contains 150 mg of canagliflozin and 1,000 mg of metformin HCl granulate formulation 1, in release-controlling polymers to obtain the XR granulation, to be taken orally.
224175748|NCT02073227|DRUG|CANA/MET XR FDC, Formulation 2, 150 mg/1,000 mg|Each tablet contains 150 mg of canagliflozin and 1,000 mg of metformin HCl granulate formulation 2, in release-controlling polymers to obtain the XR granulation, to be taken orally.
224175749|NCT00436722|DRUG|ATG (Fresenius Biotech)|ATG-Fresenius 9 mg/kg at induction
224175750|NCT02455596|DRUG|Recombinant anti-tumor and anti-virus protein for injection (Novaferon)|Recombinant anti-tumor and anti-virus protein for injection, 10μg, im, 3 times for first week,followed by 20μg for two weeks, and followed a maintenance dose of 30μg, the frequency of administration is three times per week.
224175751|NCT00003958|BIOLOGICAL|dactinomycin|Given IV
224175752|NCT00003958|DRUG|vincristine sulfate|Given IV
224175753|NCT00003958|DRUG|cyclophosphamide|Given IV
224175754|NCT00003958|PROCEDURE|therapeutic conventional surgery|Undergo surgery
224175755|NCT00003958|RADIATION|radiation therapy|Undergo radiotherapy
224175756|NCT00003958|DRUG|topotecan hydrochloride|Given IV
224175757|NCT00003958|BIOLOGICAL|filgrastim|Given SC
224175758|NCT00003958|BIOLOGICAL|sargramostim|Given SC
224175759|NCT00003958|OTHER|laboratory biomarker analysis|Correlative studies
224175760|NCT06178835|DRUG|Erythropoietin|500 IU/kg of erythropoietin is given 3 times for each patient: the day before surgery, start of surgery and on postoperative day 1.
224175761|NCT06178835|DRUG|normal saline|The same amount of normal saline is given 3 times for each patient: the day before surgery, start of surgery and on postoperative day 1.
224175762|NCT02442765|DRUG|AVP-786|
224175763|NCT02442765|DRUG|Placebo|
223486167|NCT04161196|PROCEDURE|tonsil pillars suturing|The technique of suturing the faucial pillars is used routinely as part of uvulopalatopharyngoplasty, after performing the tonsillectomy, with postsurgical haemorrhage occurring rarely.
223486168|NCT04161196|PROCEDURE|tonsillectomy without tonsil pillars suturing|tonsillectomy without The technique of suturing the faucial pillars is used routinely as part of uvulopalatopharyngoplasty, after performing the tonsillectomy, with postsurgical haemorrhage occurring rarely.
223486169|NCT04901624|BEHAVIORAL|Family Risk Messaging|"Family risk framing may engender concern for loved ones. It may also make it easier to mentally simulate family burdens with COVID-19 such as knowing how several people in the family becoming sick could adversely affect the lives of everyone in the family. Households randomized to family risk messaging will receive the following message: Antibody testing will help you understand your family's risk of getting COVID-19."
223486170|NCT04901624|BEHAVIORAL|Personal Risk Messaging|"Personal risk framing may engender concern for oneself. Households randomized to personal risk messaging will receive the following message: Antibody testing will help you understand your risk of getting COVID-19."
223486171|NCT04901624|BEHAVIORAL|Loss Protection|Household members are offered a baseline incentive with a 90% (9 in 10) chance of $60 and receive insurance on winning the baseline incentive for repeat antibody testing.
223486172|NCT04901624|BEHAVIORAL|Lottery Incentive|Household members are offered a baseline incentive with a 90% (9 in 10) chance of $60 and receive a bonus lottery incentive with a 4 small (1 in 25) chance of winning $150 for repeat antibody testing.
223486173|NCT00602485|OTHER|Action Control Education|30 minute educational intervnetion
223486174|NCT04488952|DEVICE|nerve block combined with general anesthesia|Patients in this group receive nerve block combined with general anesthesia.
223486175|NCT04488952|DEVICE|spinal anesthesia|Patients in this group receive spinal anesthesia.
223745289|NCT06762392|OTHER|Blood Flow Restriction|Blood Flow Restriction (BFR) therapy in this study involves the application of a pneumatic cuff around the proximal thigh to restrict arterial blood flow during specific rehabilitation exercises. The cuff will be inflated to achieve 70-80% of arterial occlusion, while participants perform low-intensity resistance exercises at 15-20% of their one-repetition maximum (1RM). BFR therapy will be used during Phase 2 of rehabilitation (weeks 2-12) alongside a standardized rehabilitation protocol. The intervention will be closely monitored by trained Physical Therapists to ensure safety and efficacy, with pressure adjustments made in real-time based on the participant's exercise performance. This intervention distinguishes itself by its use of BFR, a technique that is not part of conventional ACL rehabilitation
224175764|NCT04642911|OTHER|Long term follow up|Undergo long term follow up, including copy number measurement safety evaluations diseases specific product (Mesenchymal Stem Cell) in a Ukraine Association of Biobank bio-sponsored clinical trial who agree to participate in this study
223486176|NCT00873652|BIOLOGICAL|Engerix B®, a recombinant hepatitis B vaccine|Single 0.5 ml dose intramuscularly into the deltoid muscle
223486177|NCT02655003|OTHER|TIME|
224175765|NCT01185613|DEVICE|Therapy™ Cool Flex Ablation Catheter|"The device under evaluation is the 4mm Therapy™ Cool Flex Ablation Catheter. The Therapy™ Cool Flex catheter is a flexible tip, insulated, 7F catheter constructed of thermoplastic elastomer material and noble metal electrodes.~The following CE Mark devices will be used in conjunction with the Therapy™ Cool Flex Ablation Catheter~* IBI-1500T11 Cardiac Ablation Generator (RF ablation generator) with software version 3.0 or higher.~* Cool Point™ Irrigation Pump~* Cool Point™ Tubing set~* Data Logger"
224175766|NCT03962413|PROCEDURE|Endoscopic Approaches To Maxillary Sinus|"The first group (group A):~The middle meatal antrostomy approach.~The second group (group B):~The endoscopic prelacrimal recess approach~The third group (group c):~The canine fossa approach."
224175767|NCT02715089|GENETIC|Precise treatment|During screening stage, all patients should accept next-generation sequencing (NGS) test.
224175768|NCT01200758|DRUG|Rituximab SC|First cycle of rituximab IV infusion (375 mg/m\^2) + 7 cycles of rituximab SC (1400 mg; rituximab induction) in administered every 3 weeks. Participants achieving at least PR entered rituximab SC (1400 mg) maintenance therapy once every 8 weeks for 24 months.
224175769|NCT01200758|DRUG|Rituximab IV|Eight cycles of rituximab IV infusion (375 mg/m\^2; rituximab induction) administered every 3 weeks. Participants achieving at least PR during induction, entered rituximab IV maintenance therapy (375 mg/m\^2) once every 8 weeks for 24 months.
224175770|NCT01200758|DRUG|Cyclophosphamide|Eight cycles of cyclophosphamide (750 mg/m\^2 IV) administered every 3 weeks.
224175771|NCT01200758|DRUG|Doxorubicin|Eight cycles of doxorubicin (50 mg/m\^2 IV) administered every 3 weeks.
224175772|NCT01200758|DRUG|Vincristine|Eight cycles of doxorubicin (1.4 mg/m\^2 IV) administered every 3 weeks.
224175773|NCT01200758|DRUG|Prednisone/Prednisolone|Eight cycles of prednisone/prednisolone (100 mg/day or 40 mg/m\^2/day IV/orally) administered Days 1 to 5 of every 21 days cycle.
224175774|NCT01371721|DRUG|DVS SR|Subjects will receive a flexible-dose of 20, 25, 35 or 50 mg/day as prescribed by the investigator.
223486178|NCT02655003|OTHER|Education-only intervention|The staff and physicians in the control nursing homes will receive a 2 hours education session about dementia and neuropsychiatric symptoms
223486179|NCT03087240|PROCEDURE|Dental Prophylaxis|Prevention and treatment of periodontal diseases by cleaning of the teeth in the dental office using the procedures of dental scaling and dental polishing. The treatment includes plaque detection, removal of supra- and subgingival plaque and calculus, as well as motivation and demonstration for establishing a sufficient oral hygiene.
223586534|NCT06993974|DRUG|Mesalamine|Mesalamine or 5-amino salicylic acid (5-ASA), plays a crucial role in the treatment of ulcerative colitis (UC). It is the first-line therapy for mild to moderate cases of UC and is considered a cornerstone in its management.
223586535|NCT06993974|DRUG|Nitazoxanide|Nitazoxanide is an FDA-approved oral medication used to treat protozoal infections and is also effective against metronidazole-resistant Clostridium difficile colitis.
223586536|NCT06673407|BEHAVIORAL|Group Exposure for Social Anxiety|Group exposure therapy for social anxiety and public speaking fears.
224175775|NCT05818176|DEVICE|NAVIRFA® Navigation System|radiofrequency ablation by NAVIRFA® Navigation System.
224175776|NCT05818176|DEVICE|ultrasound|radiofrequency ablation by ultrasound
224175777|NCT01825759|DRUG|danshen dripping pill|
224175778|NCT03033290|DRUG|Bu-Zhong-Yi-Qi-Tang|Qi-tonifying regimen of traditional Chinese herbal medicine
224175779|NCT03033290|DRUG|placebo|placebo control
224175780|NCT04126759|DEVICE|P0.3|Subjects will perform daily measurements on the IMD (Prototype 0.3) for 35 days.
224175781|NCT02276690|BIOLOGICAL|hepcidin|"In order to assess iron deficiency by innovative method (dosage of Hepcidin), an additional collection of blood will be done at day 0 (and weekly until Intensive Care Unit discharge) and at Day 15 after Intensive Care Unit discharge.~Treatement of Iron deficiency anaemia and anaemia of chronic disease using intravenous iron (± erythropoietin) will be encouraged (or not) according to hepcidin levels"
224175782|NCT02276690|BIOLOGICAL|ferritin and transferrin saturation|"In order to assess iron deficiency by using usual biomarkers (ferritin and transferrin saturation), collection of blood will be done at day 0 (and weekly until Intensive Care Unit discharge) and at Day 15 after Intensive Care Unit discharge.~Treatement of Iron deficiency anaemia and anaemia of chronic disease using intravenous iron (± erythropoietin) will be encouraged (or not) according to ferritin levels."
224175783|NCT01652027|DRUG|FVIII concentrate|usual treatment as directed by treating physician
224175784|NCT00169273|BEHAVIORAL|Structured behavioral weight loss group|Structured group weight loss program
223745290|NCT06762392|OTHER|Standard Rehabilitation|The Standard Rehabilitation (RHB) intervention in this study consists of a structured, evidence-based protocol designed to optimize recovery after anterior cruciate ligament (ACL) reconstruction. This rehabilitation protocol is implemented across four phases. The rehabilitation will be supervised by experienced Physical Therapists, and participants will be given a tailored home exercise program to complement the supervised sessions. The intervention aims to optimize recovery, restore function, and reduce the risk of re-injury.
223745291|NCT07059962|DEVICE|Bodyport Cardiac Scale|The Bodyport Cardiac Scale captures several physiological signals, which are used to derive multiple biomarkers that reflect a user's hemodynamic and fluid status.
223745292|NCT02928289|DEVICE|VISCO360 ab interno canaloplasty surgery|360 degrees of viscodilation of Schlemm's canal
223745293|NCT02928289|DEVICE|Selective Laser Trabeculoplasty (SLT)|360 degrees of selective laser trabeculoplasty
223745294|NCT05782907|DRUG|Upadacitinib|Oral Solution/ Tablets
224175785|NCT00169273|BEHAVIORAL|Weight loss and cognitive-behavioral depression group|Structured group program for weight loss and depression
224175786|NCT03475173|DEVICE|LSFG-NAVI|laser-speckle blood flow of ocular arteries and veins
224175787|NCT00545584|DRUG|sitagliptin phosphate|sitagliptin 100 mg once daily. Duration of treatment: 26 Weeks
224175788|NCT00545584|BEHAVIORAL|Comparator: Diet|Diet
224175789|NCT00545584|BEHAVIORAL|Comparator: Physical Activity|Physical Activity
224175790|NCT03958695|DEVICE|Tunable-tension transobturator tape, Urosling-T (Lintex, LLC)|A transobturator mid-urethral sling with the possibility of non-invasive tuning of its tension in the early postoperative period
224175791|NCT03958695|DEVICE|Transobturator mid-urethral tape, Urosling (Lintex, LLC)|A transobturator tension-free mid-urethral sling
223486180|NCT05545917|OTHER|Experimental: APP care|The experimental arm will receive advanced physiotherapy care (APP) care. Patients will be independently managed (assessment and intervention) by a PT. The PT will make a diagnosis and initiate an intervention plan (e.g. education and exercise). If relevant, the PT will make recommendations for medical imaging tests or medication. PTs will also recommend the proper discharge from the emergency department (ED), such as hospitalization, discharge without medical consultation/follow-up or discharge with a medical follow-up or rehabilitation in an outpatient setting.
223586537|NCT06673407|BEHAVIORAL|Self-Compassion Enhanced Group Exposure Therapy for Social Anxiety|Group exposure therapy for social anxiety and public speaking fears plus piloted exercises from the investigators' previous studies among socially anxious undergraduates (Slivjak et al., 2022; Slivjak \&amp; Arch, in preparation), refined during the investigators' quality improvement project, that are designed to enhance compassion.
224175792|NCT04449016|OTHER|High intensity interval training|Repeated, brief, and intense exercise bouts separated by active recovery
224175793|NCT01795716|DRUG|mesylate imatinib capsule|Single and multiple oral mesylate imatinib capsule 400mg qd
224175794|NCT01795716|DRUG|Glivec|Single and multiple oral Glivec 400mg qd
224175795|NCT05990257|PROCEDURE|HHB+TAPB+and LA|Hepatic Hilar Block (HHB), Transversus Abdominis Plane Block (TAPB), and Local Anesthesia (LA)
224175796|NCT05990257|PROCEDURE|HHB+LA|Hepatic Hilar Block (HHB) and Local Anesthesia (LA)
224175797|NCT05990257|PROCEDURE|TAPB+LA|Transversus Abdominis Plane Block (TAPB) and Local Anesthesia (LA)
224175798|NCT01784081|OTHER|Palliative care with decision aids|Participant is followed by the palliative care team, and at each visit, patient will assess their distress and symptoms. Patients facing a treatment decision will receive a Patient Information Program link to review the diagnosis, prognosis, specific benefits and risks with the proposed chemotherapy.
223486181|NCT05545917|OTHER|Control - Usual physician care|The control arm will receive usual ED physician care delivered only by an ED physician. This will include independent assessment, treatment and discharge by an ED physician with no physiotherapy within the ED but physician's referral to outpatient physiotherapy or other professionals/medical specialists will be possible; overall care offered by the ED physician will not be standardized but will be systematically documented.
224175799|NCT03525613|DRUG|APL-2|Complement (C3) Inhibitor
223486182|NCT00658619|DRUG|400 µg Brimonidine Tartrate Implant|400 µg brimonidine tartrate implant in the study eye on Day 1 and Month 6.
223486183|NCT00658619|DRUG|200 µg Brimonidine Tartrate Implant|200 µg brimonidine tartrate implant in the study eye on Day 1 and Month 6.
223486184|NCT00658619|OTHER|Sham (no implant)|Sham in one or both eyes on Day 1 and Month 6.
223486185|NCT06403371|OTHER|Fluoride varnsh|Fluoride varnish was applied to the teeth surfaces before aligner therapy
223486186|NCT06403371|OTHER|Normal saline|Normal saline was applied to the teeth surfaces before aligner therapy
223586538|NCT06673407|BEHAVIORAL|Peer-Enhanced Group Exposure Therapy for Social Anxiety|Group exposure therapy for social anxiety and public speaking fears facilitated by a pair of doctoral student and undergraduate student co-facilitators who explicitly use appropriate self-disclosure to establish the co-facilitators as individuals with lived experiences of social anxiety and public speaking fears.
223586539|NCT06673407|BEHAVIORAL|Peer and Self-Compassion Enhanced Group Exposure Therapy for Social Anxiety|Group exposure therapy for social anxiety and public speaking fears plus piloted exercises from the investigators' previous studies among socially anxious undergraduates (Slivjak et al., 2022; Slivjak \&amp; Arch, in preparation), refined during the investigators' quality improvement project, that are designed to enhance compassion. These groups are facilitated by a pair of doctoral student and undergraduate student co-facilitators who explicitly use appropriate self-disclosure to establish the co-facilitators as individuals with lived experiences of social anxiety and public speaking fears.
223586540|NCT03298841|DEVICE|Zeiss|"This study proposal will highlight the advanced technology features of the Zeiss Lumera surgical operating microscope which include but are not limited to:~Stereo Coaxial Illumination for improved visualization High resolution video screen/co-observation tool to help OR staff anticipate next steps Integrated toric alignment tool Surgical microscope touch screen Cordless foot control for faster turnover between cases"
223745295|NCT04873661|BEHAVIORAL|Hypnosis group intervention|See arm description
223745296|NCT04873661|BEHAVIORAL|Cognitive trance group intervention|See arm description
223745297|NCT04873661|BEHAVIORAL|Meditation group intervention|See arm description
223745298|NCT05737706|DRUG|MRTX1133|KRAS G12D Inhibitor
223486187|NCT04019639|DEVICE|application of CG Paste+EasyFoam|Prior to application of CG paste, sharp debridement can be performed first in the operating room under local anesthesia or general anesthesia. After this, hemostasis is performed by an electrocoagulator and the medical device is applied to the affected area. During the procedure, remove the packaging material and remove the syringe to remove the protective cap in front of the syringe. Slowly push the syringe plunger and apply the contents to the area where you want to use. Depending on the location and size of the wound area, an injection cap can be used. Apply CG paste and apply Easyfoam to finish the dressing.
223486188|NCT04019639|DEVICE|application of EasyFoam|Prior to applying EasyFoam, sharp debridement can be performed first in the operating room under local anesthesia or general anesthesia. Marginal resection is performed until the necrotic tissue is removed sufficiently and pin point bleeding is seen on the wound. After that, hemostasis is done with an electrocoagulator and EasyFoam is applied to the affected area.
223486189|NCT00112229|BIOLOGICAL|group 1|Melan-A analog peptide + CpG + Montanide
223486190|NCT00112229|BIOLOGICAL|group 2|Melan-A natural peptide + CpG + Montanide
223486191|NCT00112229|BIOLOGICAL|group 3|Melan-A natural peptide + Tyrosinase YMD peptide + CpG + Montanide
223486192|NCT00112229|BIOLOGICAL|group 4|Melan-A analog peptide + Tyrosinase YMD peptide + CpG + Montanide
223486193|NCT03882632|DEVICE|Fat Grafting for Fecal Incontinence|Autologous adiopse tissue harvesting/grafting using Lipogems
223486194|NCT01740206|DRUG|Amphetamine and/or methylphenidate|Patients who took their stimulant medication the day of surgery.
223745299|NCT02496533|PROCEDURE|Hand Massage|The hand massage procedure comprises 4 minutes of manipulation of the subject's hands (2 minutes per hand) by a skilled massage therapist or appropriately trained staff.
223745300|NCT06300463|DRUG|Botensilimab|75 mg IV Q6W
223745301|NCT06300463|DRUG|Balstilimab|450 mg IV Q3W
223745302|NCT06300463|DRUG|AGEN1423|30 mg/kg IV Q3W
224175800|NCT03525613|DRUG|APL-2|Complement (C3) Inhibitor
224175801|NCT03525613|OTHER|Sham Procedure|Subjects will receive a Sham procedure every month
224175802|NCT03525613|OTHER|Sham Procedure|Subjects will receive a Sham procedure every other month
224175803|NCT05948800|DIETARY_SUPPLEMENT|Nasal irrigation with seawater isotonic solution|Isotonic sea water: product from the market, Aqua Maris nasal spray (manufacturer JGL, Rijeka), applied in accordance with the approved Instructions for Consumers.
224175804|NCT01317368|DRUG|Naropine|"20 mL of 0,75% Naropin is deposited on each side (40 mL in total) in the TAP.~At the same time 40 mL of saline 0,9% will be deposited subcutaneously as wound infiltration.~Both procedures is carried out at the end of the surgery while the patient is still anaesthetized and only this once."
224175805|NCT01317368|DRUG|Naropine|"20 mL Saline 0,9% is deposited on each side (40 mL in total) in the TAP.~At the same time 40 mL Ropivacaine 0,75% will be deposited subcutaneously as wound infiltration.~Both procedures is carried out at the end of the surgery while the patient is still anaesthetized and only this once."
224175806|NCT01317368|OTHER|Placebo|"20 mL 0,9% Saline is deposited on each side (40 mL in total) in the TAP.~At the same time 40 mL Saline 0,9% will be given as wound infiltration.~Both procedures is carried out at the end of the surgery while the patient is still anaesthetized and only this once."
224175807|NCT01206894|PROCEDURE|Transthoracic Ultrasound|1 transthoracic ultrasound will be performed the evening before the thoracic surgery
224175808|NCT04307264|PROCEDURE|Esophagogasrtoduodendoscopy, liver stiffness measurement|Time frame between liver stiffness measurement and esophagogastroduodendoscopy is less than 2 weeks.
224175809|NCT01322711|DRUG|Atorvastatin|Atorvastatin 40 mg day
224175810|NCT01322711|DRUG|Placebo|Diet
224175811|NCT01682343|DIETARY_SUPPLEMENT|Calcium|Milk-calcium supplement
224175812|NCT02960802|PROCEDURE|kidney transplantation|
224175813|NCT01019733|PROCEDURE|Intrathecal Autologous Stem Cells|Patients will be stimulated with Granulocyte Colony Stimulating Factor (G-CSF) 5 times, harvest bone marrow and infused 8 to 10 mL of stem cells (CD34+) by intrathecal via.
224175814|NCT05992051|BEHAVIORAL|Exercise Therapy|Exercise therapy is considered as the integral component of interventions for chronic non-specific neck pain. It includes different type resistance training, range of motion exercises and stretching exercises to improve neck condition and release symptoms.
224175815|NCT02067208|DEVICE|wedged insole|Wedged insoles are designed to reduce frontal plane knee joint mechanical loads during gait. Specifically, they can alter the knee adduction moment during gait - a variable associated with progression of knee osteoarthritis. In the experimental arm of this study, participants will undergo biomechanical gait analysis to identify the wedged insole that reduces the moments the most. The two options are medial wedge, where the medial aspect of the foot is elevated relative to the lateral aspect, and the lateral wedge, where the lateral wedge is elevated relative to the medial aspect.
224175816|NCT03006952|DRUG|Pentoxifylline|pentoxifylline arm took 400 mg pentoxifylline twice daily plus 50mg losartan daily for 12 weeks.
224175817|NCT03006952|DRUG|Losartan|losartan arm took 100mg losartan daily for 12 weeks.
224175818|NCT03900182|DEVICE|Hyperbaric Oxygen Therapy|The Hyperbaric Oxygen Therapy (HBOT) patients were placed in a chamber that was pressurized with air to 2.5 ATA during 15 min and were supplied 100% oxygen for 25 mins, followed by a 5-min air break. This cycle was repeated once and followed by 100% oxygen for 10 min, after which time the chamber was depressurized to 1 ATA over 15 min with 100% oxygen for a total treatment time of 100 min.
224175819|NCT02528461|DRUG|Galactose|A test to investigate the liver's ability to metabolize galactose to glucose by injecting galactose followed by measurements of blood glucose and the quantification of galactose in the urine.
224175820|NCT02528461|PROCEDURE|Gastroscopy|
224175821|NCT02528461|PROCEDURE|Liver biopsy|
224175822|NCT02528461|PROCEDURE|Fibroscan|
224175823|NCT02528461|PROCEDURE|Liver vein catheterization|
224175824|NCT02528461|DRUG|Sofosbuvir|
224175825|NCT03953794|DEVICE|Fitbit Charge 3|Smart watch monitoring activity and movement, heart rate, sleep, and more
224175826|NCT05536934|DRUG|Nω-hydroxy-nor-arginine|
224175827|NCT00461552|DRUG|Leptin|weight based, sub-cutaneous injection, twice daily
224175828|NCT00461552|OTHER|Placebo|weight based, sub-cutaneous injection, twice daily
224175829|NCT05233319|OTHER|There is no intervention|There is no intervention
224175830|NCT05475119|DEVICE|Continuous Positive Airway Pressure (CPAP)|Continuous Positive Airway Pressure (CPAP) is a form of positive airway pressure ventilation in which a constant level of pressure greater than atmospheric pressure is continuously applied to the upper respiratory tract of an individual.
224175831|NCT05475119|DEVICE|High Flow Nasal Cannula (HFNC)|High Flow Nasal Cannula (HFNC) is an oxygen supply system capable of delivering up to 100% humidified and heated oxygen at a flow rate of up to 60 liters per minute
224175832|NCT06594406|DIETARY_SUPPLEMENT|Creatine|The dosing schedule of creatine administration is 3 g daily for 4 weeks, and administration of a placebo.
224175833|NCT06594406|DIETARY_SUPPLEMENT|Bifidobacterium and creatine|The dosing schedule of creatine administration is 3 g daily for 4 weeks. In parallel, the dosing schedule of bifidobacterium administration is 200 million colony-forming units (CFU) /day for 4 weeks.
224175834|NCT06594406|DIETARY_SUPPLEMENT|Placebo|Administration of creatine placebo and bifidobacterium placebo for 4 weeks,
224175835|NCT02887508|BEHAVIORAL|HINTS Intervention|HINTS is a four-session, group-based behavioral intervention delivered exclusively online and developed using the IMB model of health behavior change focused on sexual risk reduction.
224175836|NCT02887508|BEHAVIORAL|Healthy Living Control|The Healthy Living Control is a four-session, group-based behavioral intervention delivered exclusively online and developed using the IMB model of health behavior change focused on non-sexual health topics.
224175837|NCT02369757|BEHAVIORAL|Navigator intervention|peers sharing common characteristics with the target population whose mission is to accompany towards OCCS
224175838|NCT01563224|DRUG|Baclofen 10mg|Baclofen 10mg single dose po
224175839|NCT01563224|DRUG|Baclofen 60mg|Baclofen 60mg single dose po
224175840|NCT01563224|DRUG|placebo|placebo
224175841|NCT03366935|OTHER|EPL and CEI|"Procedure: Standard epidural placement(EPL)~Drug: ropivacaine Drug: sufentani 0.1% ropivacaine + sufentanil 0.3μg/mL~Device: Infusion pump Infusion pump set to continuous epidural infusion(CEI) plus patient-controlled epidural analgesia (PCEA)."
224175842|NCT03366935|OTHER|DPE and CEI|"Procedure: Dural puncture epidural (DPE) Epidural with spinal needle placed to create a single dural puncture and confirm free flow of cerebral spinal fluid (CSF) , without direct medication administration into the subarachnoid space.~Drug: ropivacaine Drug: sufentani 0.1% ropivacaine + sufentanil 0.3μg/mL~Device: Infusion pump Infusion pump set to continuous epidural infusion(CEI) plus patient-controlled epidural analgesia (PCEA)."
224175843|NCT03366935|OTHER|DPE and PIEB|"Procedure: Dural puncture epidural (DPE) Epidural with spinal needle placed to create a single dural puncture and confirm free flow of cerebral spinal fluid (CSF) , without direct medication administration into the subarachnoid space.~Drug: ropivacaine Drug: sufentani 0.1% ropivacaine + sufentanil 0.3μg/mL~Device: Infusion pump Infusion pump set to programmed intermittent epidural boluses (PIEB) plus patient-controlled epidural analgesia (PCEA)."
224175844|NCT06617689|OTHER|Various levels of patient education|"The three interventions:~GROUP BASED TEACHING In groups of 8-12 patients, 30 minutes of standardised teaching is given. The teaching focuses in particular on the changes in diet and the impact this has on oral pH, enamel erosion and caries; recommended oral hygiene; and good drinking habits.~WEBSITE Website providing recommendations for oral hygiene and drinking habits, as well as in depth information on the topic.~DENTAL HYGIENE SAMPLES These are samples relevant for maintaining proper oral hygiene, distributed free, together with a description of how to use them."
223745303|NCT06300463|RADIATION|Radiation|8Gy x 3 between Day 0 - 18; Allowed techniques for radiation are 3D conformal, intensity modulated radiotherapy (IMRT), or SBRT
223745304|NCT06844357|DRUG|tirapazamine|Intra-arterial injection into the tumor feeding artery
224175845|NCT07002008|OTHER|Scapular Stabilization Exercise|"Intervention Description:~The intervention consists of a structured, physiotherapist-supervised scapular stabilization exercise program developed specifically for athletes engaged in traditional archery. The program is designed to enhance scapular alignment, motor control, and dynamic stability by targeting key stabilizing muscles such as the serratus anterior and lower trapezius.~Participants in the intervention group will continue their standard traditional archery training and will additionally perform the scapular stabilization protocol three times per week for 8 consecutive weeks, with each session lasting approximately 40 minutes.~The exercise regimen includes:~Scapular Retraction Exercise (prone position with arm elevation)~Push-Up Plus Exercise (with scapular protraction emphasis)~Scapular Retraction and Depression with Elastic Band Resistance~Dipping Exercise (shoulder elevation and scapular control in seated position)~Forward Lean Exercise on Therapy Ball (scapular pro"
224175846|NCT02251782|DEVICE|Epi proColon Test|Subjects assigned to the Epi proColon arm will receive information on the Epi proColon test outlined in a template script. They will then be offered a blood draw for Epi proColon testing. The blood draw can be fulfilled at the clinic or at a specified blood draw station, at the convenience of the patient. Epi proColon plasma samples will be sent to a central laboratory for testing. If no test result is recorded within 4 weeks, patients will be mailed a reminder to complete testing. If no result is recorded within 2 weeks of the mailed reminder, subjects will be recorded as non-adherent to screening. Subjects with negative test results will be mailed a notice of result and reminder to continue screening. Subjects with positive tests will be contacted and counseled to undergo colonoscopy.
224175847|NCT02251782|DEVICE|Fecal Immunochemical Test (FIT)|Subjects assigned to the FIT arm will receive information on the FIT test outlined in a template script. They will then be provided a FIT kit to take home and asked to send a stool sample to the testing lab following the kit instructions. If no test result is recorded within 4 weeks, subjects will receive a mailed reminder to complete testing. If no result is recorded within 2 weeks of the mailed reminder, subjects will be recorded as non-adherent to screening. Subjects with negative test results will be mailed a notice of result and reminder to continue screening. Subjects with positive tests will be contacted and counseled to undergo colonoscopy.
224175848|NCT04971759|DRUG|Levobupivacaine|Levobupivacaine 5%
224175849|NCT04971759|DRUG|Dexmedetomidine Hydrochloride|Levobupivacaine 5% + 1 µg/kg dexmedetomidine.
224175850|NCT04971759|DRUG|Fentanyl|Levobupivacaine 5% + 1µg/kg fentanyl
224175851|NCT00523744|DRUG|Amlodipine|Amlodipine supplied as 5 mg tablets, taken orally once a day during Treatment Phase 1 only.
224175852|NCT00523744|DRUG|Olmesartan medoxomil|Olmesartan medoxomil supplied as 10 mg tablets taken once a day during Treatment Phase 1 only.
224175853|NCT00523744|DRUG|Amlodipine+valsartan|Fixed-dose combination of amlodipine 10 mg plus valsartan 160 mg tablet taken orally once a day during Treatment Phase 2 and Extension Phase.
224175854|NCT00523744|DRUG|Hydrochlorothiazide|Hydrochlorothiazide (HCTZ) 12.5 mg tablets taken once a day during the Extension Phase.
224175855|NCT06370494|BEHAVIORAL|Living Healthier with Diabetes|Interventions are different aspects of digital health utilizing American Diabetes Association recognized diabetes programs/applications or a combined approach. All participants were randomly assigned to their education arm and received an A1c kit, glucometer, testing strips, and surveys.
224175856|NCT06356441|DIAGNOSTIC_TEST|AI|An artificial intelligence model predicts the risk and contours of local recurrence for MR images and triages them before radiologists interpret them.
224175857|NCT03478592|OTHER|reference technique|Slow-freezing procedure is the reference technique, actually use at the Toulouse hospital, to cryopreserve embryos. Embryon are frozen with a slow freezing.
223745305|NCT06844357|PROCEDURE|Transarterial Embolization (TAE)|Lipiodol and Gelfoam used to embolize tumor vessels and induce tumor hypoxia
223745306|NCT06844357|PROCEDURE|TACE|TACE with epirubicin
224175858|NCT03478592|OTHER|vitrification technique|Vitrification is the new technique to freeze embryons. In this study, the GAVI system will be use for for embryos automatically vitrification
224306461|NCT03476863|PROCEDURE|Alveolar Recruitment Maneuver|Patients in the Experimental Group will be submitted to ARM, immediately after abdominal desinflation of the pneumoperitoneum (PNP). The ARM will be performed with PEEP of 15 cmH2O for thirty seconds, 20 cmH2O for thirty seconds, 25 cmH2O for thirty seconds, 30 cmH2O for one minute and a inspiratory plateau pressure of 15 cmH2O above PEEP, totaling two minutes and thirty seconds.The data of the TIE will be continuously recorded and the hemodynamic and respiratory function variables such as heart rate (HR), respiratory rate (RF), mean arterial pressure (MAP), peripheral oxygen saturation (SpO2) and final gas expiratory pressure carbon dioxide (PETCO2) will be recorded in several moments: immediately after the monitoring, and the patient is still on spontaneous ventilation, 5min after orotracheal intubation, after the installation of the pneumoperitoneum, before and after the execution of the MRA and in the Post-OP, in the first 24h, along with new lung function tests.
224306462|NCT03476863|PROCEDURE|Conventional mechanical ventilation|Immediately after intubation, patients will undergo mechanical ventilation with the ventilator (Dixtal DX 5020) in volume controlled mode with an ideal tidal volume of 7 ml / kg body weight, a set frequency to maintain a carbon dioxide of 35-42 mmHg, and an inspiratory / expiratory ratio of 1: 2. The inspiratory oxygen fraction (FIO2) will be 0.5.
224306463|NCT04625595|DRUG|350mg BID (700mg total daily) IMT-002, D-methyldopa, active formulation in capsule or Placebo, microcrystalline cellulose in capsule|Oral drug or placebo self-administered by subject as a capsule by mouth once-daily or twice-daily
223486195|NCT01740206|OTHER|Hold stimulant medication|Patients who held their stimulant medication the day of surgery.
223486196|NCT04705090|DRUG|YY-20394 treatment|Each treatment cycle is comprised of 28-day consecutive dosing of YY-20394, 80mg QD (days 1 to 28). Upon completion of each cycle, patients may continue to receive oral YY-20394 tablets if they are benefit from the treatment and the toxicity is tolerable.
223745307|NCT06900153|OTHER|phone questionnaire|the investigator calls the patient and asks her questions about her parental project and her pregnancies
223745308|NCT03488420|DRUG|Edoxaban Pill|Subjects will be taking edoxaban 30 or 60 mg
223486197|NCT03194477|BEHAVIORAL|Mobile-enhanced Engagement Intervention|Mobile phone based enhanced case management intervention for HIV positive \& HIV negative young Black men who have sex with men.
223486198|NCT04573920|DRUG|Atrasentan|Film-coated tablet
223486199|NCT06376526|BIOLOGICAL|Linvoseltamab|"Participants will be administered Linvoseltamab intravenously (IV), using a step-up dosing schedule as follows:~* Cycle 1, Day 1: 5mg~* Cycle 1, Day 8: 25mg~* Cycle 1, Days 15 and 22: 200mg~* Cycles 2 and 3, Days 1, 8, 15 and 22: 200mg~* Cycle 4, Days 1 and 15: 200mg.~For participants who are MRD-positive after four (4) cycles of study treatment:~* Cycles 5 and 6, Days 1 and 15: 200 mg"
224175859|NCT01336257|OTHER|SEBASTIAN Clinical Decision Support System (CDSS)|SEBASTIAN is an example of a clinical decision support technology that supports the latest, service-based architectural approach to CDSS implementation. Developed at Duke University, SEBASTIAN is a clinical decision support Web service whose interface is now the basis of the HL7 Decision Support Service draft standard SEBASTIAN places a standardized interface in front of clinical decision support knowledge modules and makes only limited demands on how relevant patient data are collected or on how decision support inferences are communicated to end-users
224175860|NCT01118884|DRUG|Promethazine|Syrup ,1 mg/kg, oral , 30 minutes before dental procedure , its duration is 4-6 hours
223486200|NCT03910959|OTHER|Animal-assisted therapy|Therapy in the presence and with interaction with an animal. Involved animals can be all species that live at REHAB Basel and are part of the AAT program. All animals are trained for the specific service with vulnerable patients.
223486201|NCT03910959|OTHER|Conventional therapy|Parallelled conventional therapy sessions (treatment as usual)
223486202|NCT06791291|DRUG|Teplizumab|Pharmaceutical form:Solution for injection-Route of administration:Intravenous infusion
223486203|NCT06111586|DRUG|Frexalimab|Intravenous (IV) Infusion at Day 1 and subcutaneous (SC) Injection from W2 to W102
223486204|NCT06111586|DRUG|Placebo|IV Infusion at Day 1 and SC Injection from W2 to W102
223586541|NCT07002645|OTHER|Web-based conflict resolution training program|"Researchers developed the content of the web-based conflict resolution training program. First, ten experts were consulted to check the program's clarity and suitability. Second, the program was revised and finalized according to the experts' feedback.~A web page was obtained from the World Wide Web (www) by using hosting and domain services. Technical support and consultancy were received from a professional web design company during the implementation of the website. The content of the training program, for which expert opinions were obtained, was transferred to the web page. Web-based conflict resolution training program will be applied to the intervention group for 2 week."
223586542|NCT03029507|BEHAVIORAL|ACT Enhanced ShipShape|The ACT components focus on: a) thoughts, feelings, and bodily sensations that are often present in the context of efforts to lose weight or improve fitness; b) limitations of previous efforts to control or eliminate negative thoughts or emotions, stress, or food cravings; c) changing expectations and goals from elimination of stress or cravings to living as well as possible with such feelings; d) mindfulness exercises to increase awareness of experiences; and e) identification of personal values and setting and pursuing values-consistent goals in order to achieve improved quality of life.
223586543|NCT03029507|BEHAVIORAL|Standard ShipShape (SS)|The materials and format of the Standard SS-only protocol are based on recommendations from the Navy and Marine Corps Public Health Center. These include: a) education for nutrition and physical activity; b) creating and documenting goals for weight loss and physical fitness; c) a food diary to track eating habits throughout the program; d) developing behavioral strategies to initiate/maintain an exercise program; e) monitoring of physical activity (pedometer provided by the study); and f) identifying and overcoming personal triggers for over-eating.
223586544|NCT03772054|DRUG|Sevoflurane|Inhalation anesthetic agent
223586545|NCT03772054|DRUG|Propofol|Intravenous anesthetic agent
224175861|NCT03756636|PROCEDURE|"Underwater mucosectomy with submucosal injection of viscous solution -SIC 8000 (EleviewTM)"|"Underwater mucosectomy with submucosal injection of viscous solution -SIC 8000 (EleviewTM)"
224175862|NCT04561050|OTHER|Comparison of score performances (Overall performance, discrimination and calibration)|"Our Study is an observational non-interventional study based on a multicentric anonymized registry. It's an external validation of pre-existing prognostic scores of traumatic haemorrhages at different times of care (Scene of Injury, admission at the trauma room) in order to assess their overall performance, discrimination and calibration in the prediction of massive transfusion and haemorrhagic death.~The statistic intervention will be a comparison of score performances (Overall performance, discrimination and calibration)."
224175863|NCT03035058|DRUG|Vedolizumab|Vedolizumab intravenous infusion
224175864|NCT03035058|DRUG|Placebo|Placebo
223486205|NCT06111586|DRUG|Insulin|SC injection, dose and frequency will be established and/or adjusted by investigator
223486206|NCT00549055|DRUG|Macugen|Dosage form: solution for injection (intravitreal) Dosage: 0.3mg Frequency: every 6 weeks (9 injections/year)
223486207|NCT06406309|BEHAVIORAL|Power Down manipulation|The Power Down is a bedtime manipulation protocol targeting elevated arousal level at bedtime due to a hypothesized effect of sensory over-responsivity (a common experience for children with ADHD). The Power Down incorporates sensory-based tools (gentle tactile pressure and auditory cues) to support nervous system regulation prior to attempting sleep onset. Caregivers will lead a nightly gentle massage with guided relaxation script just prior to the child trying to fall asleep during the 2-week intervention phase. The child will also wear a watch-like activity monitor (ActiGraph GT9x) for the 2 week period throughout the day and night to measure changes in sleep and activity patterns. Caregivers will complete daily diary questions in the morning and evening reporting their child's emotions and sleep timing.
223486208|NCT06551805|DRUG|Safety assessment of Ferumoxytol.|"Observe the injection site for skin invagination, rash, or urticaria during injection. Patients and their relatives were asked about any subjective adverse events before, during, and after drug injection, and all adverse events were recorded on the case report forms, and adverse events were scored according to the Common Terminology Criteria for Adverse Events (CTCAE) from Grade 1 mild to Grade 5 death, Observe the vital signs of patients. Patients undergoing MRI underwent electrocardiogram (ECG) monitoring before and within 60 minutes after ferumoxytol administration, specifically including: biochemical panel, iron metabolism, liver and kidney function, cytokines, blood routine, urine routine, 24-hour urine volume, glycosylated hemoglobin and so on. All patients received a total of 3 blood and urine collections at 7 days before injection, 48 hours after injection, 1month to 3months after injection."
223486209|NCT06551805|DRUG|Assessment of the diagnostic value of Ferumoxytol for MR angiography.|steady-state, high-spatial-resolution, three-dimensional fast low-angle shot acquisition technique, T2W-MDIR imaging, polysaccharide superparamagnetic iron oxide injection enhanced T1W and T2W, T2\* mapping, and Steady state free precession sequence, T2 weighted black blood sequence, T2 preparation single shot steady state free precession sequence, T2\* weighted multi-echo/gradient echo sequence, polysaccharide superparamagnetic iron oxide injection enhanced imaging, Breath-triggered Transverse 3D Balance-Vortex Field Echo (b-TFE) Magnetic Resonance Angiography, iMSDE-SPGR Sequence, 4D Flow MRI. the MRI anxiety questionnaire.
224175865|NCT06205979|DRUG|Ranibizumab Injection [Lucentis]|Three consecutive monthly intravitreal injections of Ranibizumab at a dosage of 0.5mg/0.05ml were administered in a sterile manner using a 30-G needle toward the center of the vitreous at 4mm in phakic or 3.5mm in pseudo phakic eyes from the limbus.
224175866|NCT06205979|DRUG|Aflibercept Injection [Eylea]|Three consecutive monthly intravitreal injections of Aflibercept at a dosage of 2mg/0.05ml were administered in a sterile manner using a 30-G needle toward the center of the vitreous at 4mm in phakic or 3.5mm in pseudo phakic eyes from the limbus.
224175867|NCT00933387|DRUG|Cetuximab,Paclitaxel,Cisplatin|Cetuximab 500 mg/m2 iv infusion (120 min for the 1st infusion, 90 min for the 2nd , and 60 min for the subsequent) Paclitaxel 120 mg/m2 3-hour iv infusion Cisplatin 50 mg/m2 2-hour iv infusion
224175868|NCT06256094|DIETARY_SUPPLEMENT|a2 Platinum Premium Infant Formula Stage 1|Oral intake of a2 Platinum Premium Infant Formula Stage 1 milk powder (dissolved in water)
224175869|NCT06256094|DIETARY_SUPPLEMENT|Frisolac Infant Formula Stage 1 (Dutch Edition)|Oral intake of Frisolac Infant Formula Step 1 (Dutch Edition) milk power (dissolved in water)
223486210|NCT02655341|DEVICE|Body Composition Monitoring|using Fresenius device; two measurements before and after coronary intervention;
223486211|NCT02655341|PROCEDURE|Coronarography|Preprocedural coronary arteriography is obtained after sterile preparation and draping of the patient, conscious sedation, infiltration of local anesthetic (lidocaine solution) at the femoral access site, placement of an arterial sheath in the femoral artery, and advancement of the renal guide catheter over a 0.035-in guidewire under fluoroscopic guidance. After the tip of the guide catheter is positioned at the ostium of the left coronary stem, an angiogram is obtained. After the guidewire is removed, the proximal end of the catheter is connected to a manifold, and 4-8 mL of contrast is manually injected during cineangiographic recording.
223486212|NCT02655341|PROCEDURE|Primary Percutaneous Coronary Intervention|An intravenous antithrombotic agent, usually heparin, is administered before the clinician proceeds with angioplasty.
223486213|NCT02655341|PROCEDURE|Renal Angiography|After the tip of the guide catheter is positioned at the ostium of the renal artery, an angiogram is obtained. After the guidewire is removed, the proximal end of the catheter is connected to a manifold, and 4-8 mL of contrast is manually injected during cineangiographic recording. This procedure is performed in the same time with primary PCI
223486214|NCT03481049|BEHAVIORAL|Usual CM|Behavioral reinforcement for alcohol abstinence
223486215|NCT03481049|BEHAVIORAL|High-Magnitude CM|Behavioral reinforcement for alcohol abstinence
223486216|NCT03481049|BEHAVIORAL|Shaping CM|Behavioral reinforcement for alcohol abstinence
223486217|NCT00770809|OTHER|Laboratory Biomarker Analysis|Correlative studies
223486218|NCT00770809|DRUG|Lapatinib Ditosylate|Given PO
223586546|NCT06870526|BEHAVIORAL|Food box delivery|"* Time Needed: 12 weeks (duration of intervention)~* Description: Participants will receive grocery boxes containing a selection of food items tailored to their cultural and nutritional needs. They will be asked to utilize the groceries provided and provide feedback on the quality and quantity of items received. The pilot study will partner with Instacart, utilizing Instacart Care Carts for the medically tailored grocery delivery in which researchers order and deliver groceries on behalf of participants. Although families are not able to modify the order, they select when and where they want the grocery box delivered."
223486219|NCT00770809|DRUG|Paclitaxel|Given IV
223486220|NCT00770809|BIOLOGICAL|Trastuzumab|Given IV
223486221|NCT03748329|DEVICE|Ultrasound|Will deposit local anaesthetic intra-orally with the aid of ultrasound to guide the location of the final deposition.
223486222|NCT06225739|OTHER|Electronic pregnancy register|Electronic pregnancy register will be created based on local ANC register to monitor pregnancy outcomes across all sites. Pregnant women of all ages attending antenatal care (ANC) facility will be registered
223486223|NCT06225739|OTHER|In-depth interviews and focus group discussions|In-depth interviews (IDIs) and focus group discussions (FGDs) will be used to assess the user experience and the perceptions of pregnant women and health workers on the feasibility, usability, and acceptability of open-source mobile applications for tracking pregnancy outcomes
223586547|NCT05327972|DRUG|The investigational medicinal product is incobotulinumtoxinA (XEOMIN®).|Two milliliters of a mixture comprised of XEOMIN® 100 U and saline solution 0.9% will be once injected in the supra-spinatus muscle using ultrasonography guidance.
223586548|NCT05327972|OTHER|PLACEBO|Two milliliters of a saline solution containing an inactive lyophilisate will be once injected in the supra-spinatus muscle using ultrasonography guidance.
223586549|NCT03344172|DRUG|Gemcitabine, Nab-Paclitaxel, hydroxychloroquine and Avelumab|Days 1, 8, 15 of Cycles 1 and 2: gemcitabine (1000mg/m\^2) and nab-paclitaxel (125mg/m\^2) Beginning on Day 8 of Cycle 1: hydroxychloroquine (600mg/BID) daily until day of surgery Day 1 of Cycle 3: avelumab (10mg/kg)
223586550|NCT03344172|DRUG|Gemcitabine, Nab-Paclitaxel, and hydroxychloroquine|Days 1, 8, 15 of Cycles 1 and 2: gemcitabine (1000mg/m\^2) and nab-paclitaxel (125mg/m\^2) Beginning on Day 8 of Cycle 1: hydroxychloroquine (600mg/BID) daily until day of surgery
224175870|NCT04335357|DRUG|TBR-760|TBR-760 is intended for SC administration. The target dose to be studied in this study is 6 mg SC given once weekly.
224175871|NCT04335357|DRUG|Placebo|Placebo
224175872|NCT02161224|DRUG|FG-4592|Oral
224175873|NCT02438670|DEVICE|PID control algorithm|
224175874|NCT02438670|DEVICE|MPC control algorithm|
224175875|NCT03194256|BEHAVIORAL|Spectrum Research Cigarettes|Participants will be assigned to either normal nicotine content cigarettes or very low nicotine content cigarettes.
224175876|NCT00740688|PROCEDURE|Logan Basic Apex Contact|A Logan Basic Apex Contact, which is a contact that is placed on the anterior surface of the sacrotuberous ligament with a light force directed posterior with varying degrees of laterality.
224175877|NCT00740688|PROCEDURE|Sham Logan Basic apex contact|light force contact applied to the inferior surface of the sacrotuberous ligament, directed straight superiorly.
224175878|NCT03086954|BIOLOGICAL|The Chimeric Antigen Receptor T Cell Immunotherapy (CAR-T)|This study have only one arm that is CAR-T experimental arm. Firstly all participators will be attended the screening, who passed the screening for the treatment of CAR-T cells, the CAR-CD19-modified T cells can recognize and kill tumor cells in the body，follow-up 35 months.
224175879|NCT00671411|DRUG|Ultrasound with intravenous microbubble contrast injection|"Intravenous line will be inserted. After the ultrasound microbubble contrast has been suspended into solution, contrast will be injected intrav via hand bolus with a total activated suspension of 0.2 mL (30 uL octaflouropropane),followed by 10 mL saline flush, with option to rebolus 4 addit time's for tot dose of 150 uL. Post contrast cine images of renal mass will be obtained on commercially available US units primarily using low mechanical index settings \& Contrast Pulsed Sequence (CPS®) technique. Images will be acquired at predetermined intervals, for up to 8 min post contrast admin. Manufacturer's guidelines incl immediate post flush image capture, as well as post admin image capture at intervals as 1 min, 2 , 4 \& 8 mins. Additional, temporary higher mechanical index imaging of kidney for the purpose of flash bubble destruction may be optionally triggered using manufacturer's preset settings \& energy w/i FDA guidelines. This will only be performed while imaging the kidney."
224175880|NCT00005054|DRUG|temozolomide|
224175881|NCT00784160|DRUG|Lactic Acid (Dermacyd PH_DETINBACK Tangerine Mix)|Lactic Acid
224175882|NCT02993783|DRUG|Vedolizumab|Vedolizumab IV infusion
224175883|NCT06250192|OTHER|Virtuel education|Randomization to virtuel education based on a tool of small videos accessible via smartphones
224175884|NCT02117492|PROCEDURE|Cuff Closure|Closure of the vaginal cuff following hysterectomy.
224175885|NCT02660073|DEVICE|NMES+FES|12 weeks of electrically evoked resistance training followed by 12 weeks of functional electrical stimulation cycling.
224175886|NCT02660073|DEVICE|Control+FES|12 weeks of passive movement followed by 12 weeks of functional electrical stimulation cycling.
224175887|NCT00939146|OTHER|Outlook Attention Control|Subjects in the relaxation meditation group will meet with a facilitator three times, for a period of forty-five minutes each; they will listen to a non-guided relaxation CD.
224175888|NCT00939146|OTHER|Outlook Intervention|The Outlook intervention is designed to assist patients self-manage role changes by guiding them through life review, current issues of forgiveness and conflict resolution, and future orientation, with planning heritage and legacy.
224175889|NCT05008718|OTHER|38% SDF group|Participants will be randomized and will receive either 38% SDF treatment or 5% NaF treatment
224175890|NCT05008718|OTHER|5% NaF group|Participants will be randomized and will receive either 38% SDF treatment or 5% NaF treatment
224175891|NCT00766272|DEVICE|Lokomat|Body-weight will be supported using a harness, which suspends the subject above a motorized treadmill (Lokomat, Hocoma, Zurich, Switzerland). The system also incorporates a robot-driven gait orthotic, called the Lokomat, which will be secured to the subject's lower extremity and pelvis using adjustable cuffs and pads. The Lokomat uses computer-controlled motors to drive the hips and knees toward more normative kinematic patterns for gait.
224175892|NCT01202643|DRUG|G-CSF|One infusion of G-CSF 300 units administered by intrauterine infusion
224175893|NCT01202643|DRUG|Saline|One intrauterine saline infusions of 1 cc
224175894|NCT03198884|DRUG|Darunavir 800 MG, Norvir 100 MG, Dolutegravir 50 MG|
223486224|NCT03187470|DEVICE|Different programming of a CRT defibrillator|Different programming of a CRT defibrillator using pacing modalities of a quadripolar left ventricular lead
223586551|NCT03606772|OTHER|Questionanniare|Filling printed questionnaire + Pelvic examination
223586552|NCT00309062|BIOLOGICAL|Recombinant birch pollen|
223617605|NCT05195229|DEVICE|COVID-19 Aerosol Collection|"Step 1: A nasal and oral swab will be obtained to establish the nasopharyngeal viral load.~Step 2: Study staff will use the CCI and/or UPAS to collect aerosol samples for viral load. Staff will sample the room aerosol for 30 minutes while the participant does not wear a mask, and then if the participant is interested, staff will sample room aerosol while the participant wears different types of masks. If the participant does not tolerate wearing a surgical mask, or if the providers believe this is contraindicated, researchers will forego this portion of the study procedures. If an accompanying family member chooses to stay in the patient room during testing, they will be provided with an N95 respirator."
224175895|NCT05965999|DEVICE|EsoCheck|EsoCheck® (EC) is an FDA 510(k) cleared device that is indicated for use in the collection and retrieval of surface cells of the esophagus in the general population 12 years of age and older.
224175896|NCT04755699|DEVICE|Transcutaneous Electrical Stimulation|The study involves the administration of various electrical pulses being delivered to muscles and/or the spinal column with an investigational neurostimulator to evoke various limb movements in order to improve functional movement.
224175897|NCT01371799|DRUG|Drug|Placebo
224175898|NCT01371799|DRUG|Drug|4mg and 8mg Study drug
224175899|NCT03049852|DRUG|CBT-001 single dose|One drop in the study administered one time
224175900|NCT03049852|DRUG|Vehicle|One drop in the study administered three times daily (TID) for 4 weeks
224175901|NCT03049852|DRUG|CBT-001 Multi-dose|One drop in the study administered three times daily (TID) for 4 weeks
224175902|NCT04678349|DIETARY_SUPPLEMENT|PHGG|Subjects will be given 4 scoops (40g) PHGG, which provide 160kcal, 0.24g protein, 30.4g soluble fibre, 40g carbohydrate and 0g sugar, once allowed orally.
224175903|NCT04678349|OTHER|conventional care|follow low fibre diet and anti-diarrhea drugs
224175904|NCT03602742|DEVICE|EZYPRO®|Wear two devices including 24-hour Holter and 14-day continuous EZYPRO® to evaluate the performance
224175905|NCT01393561|DRUG|Group 1|Brompheniramine + phenylephrine
224175906|NCT01393561|DRUG|Group 2|Placebo
224175907|NCT03700866|PROCEDURE|Functional splinting time|Functional splinting time is the time needed for the final healing and organization of Peridontal ligament of tooth with extrusive luxation injury to reattach to the alveolus and function normally in the oral cavity
224175908|NCT01050140|DIETARY_SUPPLEMENT|high sugar diet|25% of dietary energy from fructose or glucose
224306464|NCT04625595|DRUG|700mg BID (1400mg total daily) IMT-002, D-methyldopa, active formulation in capsule or Placebo, microcrystalline cellulose in capsule|Oral drug or placebo self-administered by subject as a capsule by mouth once-daily or twice-daily
224175909|NCT03046329|BEHAVIORAL|Carevive CPS|This intervention will focus on the use of the Carevive CPS at the point of care to enable providers to deliver evidence-based and personalized supportive care and symptom management plans to their MM patients receiving active treatment. The Carevive CPS collects electronic patient reported outcomes (ePROs) and clinical data, reported and entered by clinical staff and/or extracted from the electronic medical record (EMR), and uses these to auto-generate the personalized care plans. Care plan content is driven by practice guidelines and other peer-reviewed evidence, and includes patient education, resources, and referrals developed by expert cancer clinicians and researchers.
224175910|NCT02610231|DRUG|Istradefylline 20 mg or 40 mg|Istradefylline 20 or 40 mg
224175911|NCT06305169|DIAGNOSTIC_TEST|Gastropanel|Gastropanel is a commercially available blood test which given serum levels of pepsinogen I and II and gastrin 17 along with helicobacter pylori infection status
224175912|NCT00806494|DRUG|Fesoterodine|Fesoterodine 4mg for 4 weeks, escalating to fesoterodine 8mg if tolerated
224175913|NCT00266149|DRUG|Oral contraception|
224175914|NCT00266149|DRUG|Lamotrigine|
224175915|NCT05237414|DEVICE|Active tDCS|20 minutes of 2.0 mA direct current applied over the right DLPFC
223486225|NCT04957394|BEHAVIORAL|Family Partner|"The Family Partner intervention is based on well-known elements for preventing child abuse and neglect, such as 1) high intensity intervention with home visitations, 2) coordination of services, 3) an ecological perspective, 4) parental guidance, and 5) an emphasis on a therapeutic relationship with parents to create trust, change and agency.~Family Partners must have relevant professional background and education, such as social work, child welfare services and other health/welfare occupations. They must have a personal attitude for relation-based service delivery in a home-setting, a long work experience and in-depth knowledge of municipal welfare services.~Each practitioner will follow five families. The estimated duration of the intervention is 12 months, but might go over longer stretches of time if it is considered beneficial for the families. The minimum duration of the intervention is 3 months."
223486226|NCT04301284|DRUG|CAD-1883|150 mg filled capsules
223486227|NCT04301284|DRUG|Placebos|capsules
223486228|NCT03618277|PROCEDURE|Biopsy|Micro-biopsies will be performed using a punch of 1 mm in diameter, by pulling the skin at the time of sampling, after disinfection and anesthesia.
223486229|NCT06267391|DEVICE|ReCET Treatment|Treatment arm will receive the ReCET therapy. The ReCET procedure utilizes the ReCET catheter to deliver non-thermal pulsed electric field to the first portion of the small intestine (duodenum) to induce cell regeneration. The catheter is introduced to the duodenum through the mouth using a guide wire and the therapy is applied to treat the duodenum. Participants will be followed for 12 months post procedure.
223586553|NCT05063201|DRUG|Cariprazine 1.5 MG|Subjects will attend two visits per week during the 8-week Outpatient Treatment Phase. Counseling services, in the form of Medication Management (MM) will be provided weekly. A urine sample for drug testing, vitals, AEs, and COWS will be collected/assessed at each visit. At the first weekly visit attended, concomitant medications, medication compliance, AIMS and a blood sample for later analysis of plasma levels of cariprazine and its metabolites will also be collected. The TLFB, C-SSRS, CSSA, SOWS, BSCS, DTS and a UPT (females only) will be collected once weekly. On the final appointment of week 8 only, a physical exam and ECG will be performed and standard laboratory measures (blood chemistry, CBC with differential, fasting glucose and lipids, serum prolactin, medical urinalysis) will be assessed. During week 8, additional assessments will be collected, including the ASI, HAM A/D and Treatment Opinion Form (TOF).
224175916|NCT05237414|DEVICE|Sham tDCS|15 seconds of 2.0 mA direct current applied over the right DLPFC
224175917|NCT05237414|BEHAVIORAL|Active CT|Active memory inhibition CT (i.e., training of memory inhibition specifically for alcohol-related memories).
223617606|NCT03111563|OTHER|Warm saline distension media in office hysteroscopy|warm saline distension media in office hysteroscopy
224175918|NCT05237414|BEHAVIORAL|Sham CT|Sham memory inhibition CT (i.e., participants have to categorize alcoholic and non-alcoholic images but they do not have to inhibit the memories related to these images).
224175919|NCT01084811|PROCEDURE|biopsy|One or more biopsies from nasal mucosa will be harvested during surgery
224306465|NCT04625595|DRUG|1050mg QD (1050mg total daily) IMT-002, D-methyldopa, active formulation in capsule or Placebo, microcrystalline cellulose in capsule|Oral drug or placebo self-administered by subject as a capsule by mouth once-daily or twice-daily
224306466|NCT04625595|DRUG|1050mg BID (2100mg total daily) IMT-002, D-methyldopa, active formulation in capsule or Placebo, microcrystalline cellulose in capsule|Oral drug or placebo self-administered by subject as a capsule by mouth once-daily or twice-daily
224306467|NCT02099695|DRUG|Oxybutynin|The doses will increase due to the absence/ lack of therapeutic response of the previous dose assessed during the study visits.
223486230|NCT06267391|DEVICE|Sham Procedure|The Control arm will receive a sham procedure. The sham procedure consists of placing the ReCET catheter as described above without therapy applied. Participants will be followed for 12 months post procedure and will be offered cross-over to receive the ReCET therapy after 12 months.
224175920|NCT01774838|DRUG|Prasugrel|3 months treatment
224175921|NCT01774838|DRUG|Clopidogrel|3 months treatment
224175922|NCT01215877|DRUG|Tesetaxel|"Tesetaxel capsules orally once every 21 days; duration of therapy not to exceed 12 months~In Cycle 1, a dose of 27 mg/m2 will be administered. In subsequent cycles,~* the dose will be increased to 35 mg/m2 in Cycle 2 for subjects who did not have an ANC \< 1,500/mm3, a platelet count \< 100,000/mm3, or a Grade 3 (or higher grade) nonhematologic adverse event considered by the Investigator to be related to protocol therapy (excluding alopecia, nausea, and vomiting) in Cycle 1. The dose is not to exceed the dose of 35 mg/m2 in any cycle subsequent to Cycle 2.~* for all other subjects, the dose administered in Cycle 1 (27 mg/m2) will be administered in all subsequent cycles."
224175923|NCT04737551|OTHER|Follow-up only|Only routine follow-up but no treatment
224175924|NCT04737551|DRUG|Adjuvant chemotherapy|Chemotherapy regimens will be decided by physicians or MDT teams, basing on patients' physical status, income status, and/or desire. Toxicity was evaluated every cycle and efficacy was evaluated every two cycles. The treatment course of adjuvant chemotherapy was followed the recommendation of NCCN guideline.
224306468|NCT02099695|DRUG|Placebo|The quantity of tablets will increase due to the absence/ lack of therapeutic response.
224306469|NCT03050008|OTHER|FLACS USFREE|Cataract Surgery with Femtosecond Laser Without Ultrasound
224175925|NCT04737551|RADIATION|Adjuvant chemoradiotherapy|"Adjuvant CRT could be delivered before or simultaneously with adjuvant chemotherapy. Radiation used 6 MV or 15 MVX-ray beams delivering daily fractions of 180-200cGy to a total dose of 45-55Gy in 25-28 fractions using CT-based, three-dimensional conformal radiation therapy (3DRT), intensity-modulated radiation therapy (IMRT) or tomotherapy (TOMO).~S-1 was administered orally at a dose of 40mg twice a day during radiation day as radiosensitizer through radiotherapy. Antiemetic medications and proton pump inhibitor were prophylactic used to reduce the occurrence of nausea and inhibit gastric acid secretion."
223486231|NCT06963606|DIAGNOSTIC_TEST|Artificial intelligence-assisted chest X-ray in TB screening|After the completion of the chest DR Examination, the chest X-ray was analyzed by the artificial intelligence-assisted system (JF CXR-1) to identify the potential signs of tuberculosis. Meanwhile, the doctor analyzed the results of the chest X-ray. After the analysis results were confirmed, the initial judgment results of the doctor and the analysis results of the artificial intelligence-assisted system were recorded, and the reading results of the artificial intelligence-assisted system were fed back to the doctor. Review the doctor's comprehensive analysis results of the artificial intelligence-assisted system, make a final judgment on the chest X-ray results, and determine whether further relevant examinations (such as etiological examination, CT examination, etc.) are needed. Record the doctor's judgment results. Follow up and record the time of diagnosis reported by the tuberculosis specific disease system.
223486232|NCT06963606|OTHER|Routine doctors analyze the process of chest X-rays|After the chest DR Examination is completed, a regular doctor reviews the films without using an artificial intelligence-assisted system. Once the results of the regular doctor's review are confirmed, a final judgment is made on whether further related examinations (such as etiological tests, CT scans, etc.) are needed, and the doctor's judgment is recorded. Follow up and record the time of diagnosis reported by the tuberculosis specific disease system
223486233|NCT02323009|DEVICE|Esophageal Balloon|Esophageal balloon was used to measure esophageal pressure (Paux) which was used as an estimate of pleural pressure. Transpulmonary pressure (Ptp) was calculated as the difference between airway pressure (Pao) and Paux. Applied PEEP was then adjusted to overcome negative Ptp which we maintained between 0 to 10 cm H20. All measurements were made at end-expiration.
223486234|NCT02323009|OTHER|Cstat|PEEP was adjusted to achieve the best CStat in this group of patients
224175926|NCT04737551|RADIATION|Adjuvant chemoradiotherapy + Adjuvant chemotherapy|See as above (adjuvant chemotherapy and adjuvant chemoradiotherapy).
224175927|NCT01279954|DRUG|Abatacept|"Subjects will receive approximately 10 mg/kg rounded to the nearest 25 mg for the first 6 months of the trial. At 6 months subjects will then be randomized to receive either 5 mg/kg or 10 mg/kg.~Abatacept will be administered as a 30-minute intravenous infusion. Following the initial administration, abatacept will be given at 2 and 4 weeks after the first infusion and every 4 weeks thereafter for up to 2 years."
224175928|NCT03803176|PROCEDURE|Open Flap Debridement|Full thickness flaps are elevated to fully expose the periodontaldefects. Defects are then fully debrided and the roots are carefully planned. Flaps are repositioned and sutured to obtain primary closure of the interdental space. This will be done for chronic periodontitis patients
224175929|NCT03919760|BEHAVIORAL|NAVIGATE|"NAVIGATE was developed in consultation with clinical and research experts, biostatisticians, health economists, consumers, family members, advocacy groups, and government officials. It is a form of coordinated specialty care for first episode psychosis consisting of 4 key intervention components:~1. individualized medication management using a decision support tool;~2. a package of psychoeducation and a blend of evidence-based psychotherapies called individual resiliency training (IRT);~3. supported employment and education (SEE);~4. a family education program"
224175930|NCT02709889|DRUG|Rovalpituzumab tesirine|
224175931|NCT02709889|DRUG|Dexamethasone|Dexamethasone will be provided through a participant's local prescription by Investigator or other provider (i.e., dexamethasone will not be provided by the Sponsor).
224175932|NCT02397980|BEHAVIORAL|Behavioral intervention|"* What the dementia is~* How to deal with behavioral problems in patients with dementia~* How to manage caregiver's stress~* How to care dementic patients as well as caregivers themselves"
224175933|NCT04255329|OTHER|Montessori reading roundtable|Such book is written in a way to adaptate to people with cognitif and sensory impairments. Indeed, text is written in large characters and structured to not involve episodic memory. Each person read one page aloud in his turn. After the reading phase, the participants discuss the questions about their opinions and distant memories.
224175934|NCT04255329|OTHER|Usual reading|The readen text is a normal, currently used in a everyday life support such as a journal article.
224175935|NCT04437329|DRUG|Docetaxel, nedaplatin, fluorouracil|Induction chemotherapy. Docetaxel 60 mg/m2 intravenous day1. Nedaplatin 60 mg/m2 intravenous day1. Fluorouracil 3000 mg/m2 continuous intravenous infusion 120 hours from day1. Every 21 days, 3 cycles.
224306470|NCT03050008|OTHER|Traditional Surgery|Traditional phacoemulsification cataract surgery using ultrasound.
223486235|NCT06214741|DRUG|survodutide|once weekly subcutaneous injection
223486236|NCT06214741|DRUG|Placebo matching BI 456906|Once weekly subcutaneous injection
223617607|NCT04965142|BEHAVIORAL|Exercise Training|The intervention group will be asked to complete aerobic exercises 3 to 5 times per week (≥ 150 minutes of at least moderate aerobic intensity) and resistance training at least twice a week over a 12-week period.
223617608|NCT04595552|OTHER|language therapy|auditory training and language therapy for 6 months up to 2 years in 2 session per week the duration of session 30 minuets
224175936|NCT04437329|DRUG|Docetaxel, cisplatin, fluorouracil|Induction chemotherapy. Docetaxel 60 mg/m2 intravenous day1. Cisplatin 60 mg/m2 intravenous day1. Fluorouracil 3000 mg/m2 continuous intravenous infusion 120 hours from day1. Every 21 days, 3 cycles.
224306471|NCT04639713|DEVICE|Tixel 2|Thermo-mechanical technology for fractional treatment of human skin. Dermal heating and coagulative effect that occur during the treatment session provide dermal remodeling and collagen restructuring that promote wrinkles appearance improvement.
224306472|NCT01580813|DRUG|Acipimox|Subjects will take acipimox 250mg (randomized and double-blinded) by mouth four times a day for six days prior to the visit and one dose the morning of study visit.
224306473|NCT01580813|DRUG|Placebo|Subjects will take a placebo pill 250mg (randomized and double-blinded) by mouth four times a day for six days prior to the visit and one dose the morning of study visit.
223486237|NCT02308878|BEHAVIORAL|Mobile health cognitive stimulation|
223486238|NCT02505061|BEHAVIORAL|Hospital-based Program|"The research team will discuss with the clinical therapists who will provide training program in a hospital for 120 minutes/per session, 2 sessions/per week for a total of 9-week intervention. In addition, the research team will videotape the childs natural play and driving performance at the hospital for 20 minutes/per session, 1 session/per week during the 9-week intervention phase. The treatment program of the two sessions will be preplanned and adjusted by the occupational therapist through clinical observation of participant's performance in the previous session. Training will still concentrate on building the concept of casual-effect on the switch and car motion, goal-oriented driving (e.g., driving 200 meters and reach for a toy or contact with a person), and upper limb use in functional tasks with driving in a hospital,discussed by the family, the treating therapist and the research team."
224175937|NCT04437329|DRUG|Nedaplatin|Concurrent chemotherapy. Nedaplatin 100 mg/m2 intravenous at day1, 22, 43 of radiotherapy.
223745309|NCT07078656|BEHAVIORAL|Postoperative management|"The patients who agreed to participate in the study will be asked to fill out a Patient Introduction Form by the researchers after obtaining permission from the experimental group with the Informed Consent Form the day before the surgery. On the 2nd day after laparoscopic colorectal surgery, virtual reality glasses will be worn by the patients and they will watch a 10-minute training video on the care of the patient after colorectal surgery. The training content will consist of topics such as dressing the surgical area, signs of infection in the surgical area (redness, swelling, discharge, color, temperature increase), pain management, unexpected situations (fever, nausea, abdominal pain, shivering, chan)"
223486239|NCT02505061|BEHAVIORAL|Regular Therapy Program|"The regular therapy group will continue the regular therapy, including physical, occupational and speech therapy. The general propose of the training is to improve the developmental scales, mobility, socialization and upper limb use in functional tasks. The research team will videotape the childs natural play and driving performance at the hospital for 20 minutes/per session, 1 session/per week during the 9-week intervention phase"
224175938|NCT04437329|DRUG|Cisplatin|Concurrent chemotherapy. Cisplatin 100 mg/m2 intravenous at day1, 22, 43 of radiotherapy.
223486240|NCT05824585|DRUG|DZD8586|DZD8586 treatment starting from 50 mg once daily. If tolerated, subsequent cohorts will test increasing doses of DZD8586.
223486241|NCT06378476|BEHAVIORAL|IMPaCT Community Health Worker Program|The IMPaCT intervention consists of three stages: goal-setting, tailored support, and connection with long-term support. CHWs first seek to understand the patient's individual circumstances, life histories, and priorities by using a semi-structured interview guide inquiring about social and behavioral determinants of health. CHWs will then partner with patients to create customized action plans based on patient needs.
223486242|NCT06378476|OTHER|Trauma-Informed Care Training|Primary care providers and staff at two General Internal Medicine clinics will receive training in providing supportive care to patients who have experienced trauma. The trainings are all action focused and include a review of racism in medicine, understanding intergenerational trauma and its impact on care, naming and mitigating barriers to health equity, and the basics of motivational interviewing
223486243|NCT06775782|DEVICE|Remote Ischemic Conditioning (RIC) treatment|RIC will be given twice a day for 10-14 days. RIC will be applied using an automated RIC device. The cuff of the RIC medical device will be placed around the bilateral upper limbs. Five cycles of cuff inflation (200mmHg for 5 minutes) and deflation (for 5 minutes) for a total procedure time of 50 minutes.
223486244|NCT06775782|DRUG|Medical Management|Patients will receive standard guideline-directed medical therapy, which will include monitor vital signs, management of blood pressure, glucose and lipids, antithrombotic therapy if appropriate.
223486245|NCT06782386|DEVICE|OneStep Foot Scanner|Daily scans with the OneStep Foot scanner will provide thermal and visual data of the soles of the feet to assist in early identification of risk factors associated with Diabetic Foot Ulcers
223486246|NCT05631899|BIOLOGICAL|KRAS-EphA-2-CAR-DC|5\~10 × 10\^6 CAR-DCs per dose will be administered by intravenous injection.
223486247|NCT05631899|DRUG|Abraxane|Intravenous abraxane 125 mg/m\^2/day on day-5.
223617609|NCT00831961|PROCEDURE|Conjunctival and nasopharyngeal bacteria cultures|Conjunctival and nasopharyngeal bacteria cultures
223617610|NCT00708292|DRUG|AUY922|
223617611|NCT00708292|DRUG|Bortezomib|
223617612|NCT00708292|DRUG|Dexamethasone|
223617613|NCT00884364|OTHER|Aerobic exercise|The patients will carry out an aerobic exercise program consisting of walking on a treadmill for 30 minutes at an intensity of 80% of the maximum heart rate. The training will be carried out three times a week.
223745310|NCT02556333|DRUG|FTC/TAF|Tenofovir alafenamide (TAF) is an investigational oral prodrug of tenofovir. This trial will explore the safety and efficacy of TAF in a fixed combination with emtricitabine (FTC) (F/TAF, Gilead Sciences Inc.) as part of a salvage antiretroviral regimen for HIV-1-infected adults and adolescents (greater than or equal to 14 years) who experienced virologic failure.
223745311|NCT06892496|OTHER|Visual Analog scale (VAS) questionnaire|"A Visual Analog Scale (VAS) questionnaire is a type of self-report tool where respondents mark a point on a continuous line to indicate the intensity of a subjective experience, like pain, fatigue, or happiness, between two extreme anchor points (e.g., no pain at one end and worst possible pain at the other), allowing for a more nuanced response compared to a standard Likert scale; essentially, it measures the degree of a symptom along a visual continuum."
224175939|NCT04437329|RADIATION|Intensity modulated-radiotherapy|Intensity modulated-radiotherapy (IMRT) is given as 2.0-2.33 Gy per fraction with five daily fractions per week for 6-7 weeks to a total dose of 66 Gy or greater to the primary tumor.
224175940|NCT00403689|DIETARY_SUPPLEMENT|Beta-D-Glucan|1,5 g Beta-D-Glucan daily
224175941|NCT00403689|DIETARY_SUPPLEMENT|placebo|1.5 g waxy maize starch daily
224175942|NCT02898792|DRUG|Targeted infusion of remifentanil|Remifentanil dosing will be calculated using ideal body weight and infused to achieve brain concentrations of 0.5, 1, 2, 3, and 4 ng/ml; approximately 10 minutes at each concentration.
224175943|NCT04961125|GENETIC|germline variants|Variants of 139 genes associated with different hereditary cancers and polyposis were screened by next-generation sequencing.
224175944|NCT01729481|DRUG|Gemcitabine|1000 mg/m² iv weekly
224175945|NCT01729481|DRUG|Erlotinib|100mg, once per day
224175946|NCT01729481|DRUG|Oxaliplatin|85mg/m², q2weeks
224175947|NCT01729481|DRUG|Folinic Acid|400 mg/m², q2weeks
224175948|NCT01729481|DRUG|Irinotecan|180 mg/m², q2weeks
224175949|NCT01729481|DRUG|5-FU|400 mg/m² Day 1; 2400 mg/m² 46 hour invusion, q2weeks
224175950|NCT00537810|DRUG|Sibutramine|15 mg daily
224175951|NCT00537810|DRUG|Placebo|Daily
224175952|NCT00537810|BEHAVIORAL|Self-help CBT + Sibutramine|Cognitive behavioral treatment manual for binge eating Sibutramine 15 mg daily
224175953|NCT00537810|BEHAVIORAL|Self-help CBT + Placebo|Cognitive behavioral treatment manual for binge eating Placebo daily
224175954|NCT03453346|DRUG|Sofosbuvir|Generic sofosbuvir tablet 400 mg
224175955|NCT03453346|DRUG|Ribavirin|Ribavirin was provided in 100-mg tablets.
224175956|NCT00304681|DRUG|OROS*-Methylphenidate|
224175957|NCT04040166|DIAGNOSTIC_TEST|PET/MRI of carotid arteries with 68Ga DOTATATE|PET/MRI of carotid arteries with 68Ga DOTATATE in patients post head and neck radiation therapy
224175958|NCT01066546|DRUG|Dimebon tablet for oral administration|10 mg TID for Week 1, followed by 20 mg TID for remainder of study
224175959|NCT01349842|BIOLOGICAL|Blood sampling|20ml of patient peripherical blood will be collected
224175960|NCT01349842|OTHER|Usual clinical and radiological criteria|Clinical examination, tumoral evaluation
224175961|NCT03560479|DRUG|alpha1H, 7.4 mg/mL|Intravesical instillations on 6 occasions during 22 days (Days 1, 3, 5, 8, 15 and 22)
224175962|NCT03560479|OTHER|placebo|Intravesical instillations on 6 occasions during 22 days (Days 1, 3, 5, 8, 15 and 22)
224175963|NCT03560479|DRUG|alpha1H, 37 mg/mL|Intravesical instillations on 6 occasions during 22 days (Days 1, 3, 5, 8, 15 and 22)
224175964|NCT03560479|DRUG|alpha1H, 74 mg/mL|Intravesical instillations on 6 occasions during 22 days (Days 1, 3, 5, 8, 15 and 22)
223486248|NCT05631899|DRUG|Cyclophosphamide|Intravenous cyclophosphamide 300 mg/m\^2/day on day -4.
223486249|NCT05631899|DRUG|Anti-PD-1 antibody|Intravenous anti-PD-1 antibody 200 mg/day.
223486250|NCT05631899|DRUG|Anti-CTLA4 Monoclonal Antibody|Intravenous anti-CTLA4 antibody 1 mg/kg/day
223486251|NCT03154606|OTHER|Micellar Casein (#1)|The study participants will be provided with breakfast meals to consume. The energy content of the breakfast meals will be standardized to \~250 kcal. The meals will include the same fat content but will contain protein sourced predominantly from micellar casein. All ingredients are GRAS listed and approved.
223745312|NCT06892496|OTHER|Vacuum-formed retainer (VFR) technique|On the day of surgery, the stent will be positioned to cover the palate and the anterior and posterior teeth, including their occlusal and buccal surfaces bilaterally, to provide retention. Vacuum-formed retainers are a common clinical practice used after harvesting a palatal graft, in order to provide a mechanical barrier to reduce post-operative pain.
223745313|NCT06892496|OTHER|3-D printed acrylic resin stent (3DS) technique|On the day of surgery, the previously made palatal stent (3DS) will be placed in position and stabilized by mechanical retention in the palate and palatal surface of the maxillary teeth, bilaterally.
224175965|NCT01512849|DRUG|TA-7284 Low|Low
224175966|NCT01512849|DRUG|TA-7284 High|High
224175967|NCT00320619|DRUG|Epsilon-Aminocaproic Acid (EACA)|Participants will receive EACA intravenously during surgery and for 8 hours following surgery in the intensive care unit (ICU).
224175968|NCT00320619|DRUG|Placebo|Participants will receive placebo intravenously during surgery and for 8 hours following surgery in the intensive care unit (ICU).
224175969|NCT05649046|DEVICE|thoracic scan Low dose|within 3 months after the V0 visit
224175970|NCT05649046|BIOLOGICAL|BLOOD SAMPLE|within 3 months after the V0 visit
224175971|NCT05649046|BIOLOGICAL|FECES SAMPLE|within 3 months after the V0 visit
224175972|NCT03210415|OTHER|Observational Study Model|There is no intervention for the study.
224175973|NCT02006394|DIETARY_SUPPLEMENT|Fish Oil|fish oil capsules
224175974|NCT02006394|DIETARY_SUPPLEMENT|Polyphenol Capsules|delphinidin polyphenol capsules
224175975|NCT02006394|DIETARY_SUPPLEMENT|Corn Oil Capsules|Corn Oil Capsules
224175976|NCT02006394|DIETARY_SUPPLEMENT|Corn starch capsules|Maltodextrin capsules
224175977|NCT02006394|OTHER|Reduced glycemic index bread products|Made by Zone Labs
224175978|NCT02006394|OTHER|Market variety bread products|placebo bread products
224175979|NCT00204763|DEVICE|Air filled balloon catheter|The new air filled balloon catheter will be tested against the solid state catheter
224175980|NCT00204763|DEVICE|Solid state catheter|The standardly used solid state catheter will be tested against the new air filled balloon catheter
224175981|NCT04930627|DRUG|Empagliflozin|dosis depending on body weight: \<20 kg 5 mg 1x/day; 20-40 kg 2 x 5 mg; \>40 kg 2 x 10 mg
224175982|NCT04375007|OTHER|Routine care|Physiotherapy intervention in routine care
224175983|NCT03506828|PROCEDURE|Surgical sympathectomy|thoracoscopic sympathectomy
224175984|NCT03506828|PROCEDURE|Radiofrequency ablation with phenol injection|All patient in this group will have radiofrequency ablation of T2 and T3 sympathetic ganglia with phenol injection
224175985|NCT03258762|DRUG|Pyrimethamine|Pyrimethamine will be available as 25 mg tablets. Subjects will be orally administered two pyrimethamine tablets on Day 1 in a fasted condition with 240 mL of water.
224175986|NCT03258762|DRUG|Calcium folinate|Calcium folinate will be available as 5 mg tablets. Subjects will be orally administered three calcium folinate tablets on Day 1 along with pyrimethamine followed by once daily administration of calcium folinate until Day 8. Each administration will be with 240 mL water.
224175987|NCT03066492|OTHER|Northwestern Follow Up Care Coordination|Each patient is provided with information by telephone and mail, offering assistance to receive a follow-up appointment at the Northwestern Transitional Care Follow Up Clinic.
224175988|NCT03066492|OTHER|Federally Qualified Health Center|Each patient is provided with information by telephone and mail, offering assistance to receive a follow-up appointment at a nearby Federally Qualified Health Center.
224175989|NCT00624741|DRUG|Pergolide|Pergolide tablets should be initiated with a daily dosage of 0.05 mg for the first 2 days. The dosage should then be gradually increased by 0.1 or 0.15 mg/day every third day over the next 12 days of therapy. The dosage may then be increased by 0.25 mg/day every third day until an optimal therapeutic dosage is achieved.
224175990|NCT01711359|DRUG|Baricitinib|Administered orally
224175991|NCT01711359|DRUG|Methotrexate|Administered orally
224175992|NCT01711359|DRUG|Baricitinib Placebo|Baricitinib placebo administered orally once daily.
224175993|NCT01711359|DRUG|MTX Placebo|MTX placebo administered orally once weekly.
224175994|NCT01711359|DRUG|Folic Acid|Administered orally every day
224175995|NCT02913885|DRUG|Curodont Repair|composed of biomimetic regeneration scaffold self-assembling peptides (P11-4) used for remineralization
224175996|NCT02913885|DRUG|fluoride varnish|fluoride inhibit the progression of white spot lesion
224175997|NCT00564135|PROCEDURE|on Foley time|A-no Foley B-remove Foley at 7AM in the morning of postoperative day 1 C-remove Foley at 7AM in the morning of postoperative day 2
224175998|NCT04864184|BEHAVIORAL|Normal physiologic rate breathing|2-minute breathing exercises will be completed every 15 minutes.
224175999|NCT04864184|BEHAVIORAL|Slow breathing|2-minute breathing exercises will be completed every 15 minutes.
224176000|NCT00267267|DRUG|torcetrapib/atorvastatin|
223486252|NCT03154606|OTHER|Micellar Casein (#2)|The study participants will be provided with breakfast meals to consume. The energy content of the breakfast meals will be standardized to \~250 kcal. The meals will include the same fat content but will contain protein sourced predominantly from micellar casein. All ingredients are GRAS listed and approved.
223486253|NCT03154606|OTHER|Calcium Caseinate|The study participants will be provided with breakfast meals to consume. The energy content of the breakfast meals will be standardized to \~250 kcal. The meals will include the same fat content but will contain protein sourced predominantly from calcium casein. All ingredients are GRAS listed and approved.
223486254|NCT03154606|OTHER|Sodium Caseinate|The study participants will be provided with breakfast meals to consume. The energy content of the breakfast meals will be standardized to \~250 kcal. The meals will include the same fat content but will contain protein sourced predominantly from sodium caseinate. All ingredients are GRAS listed and approved.
223486255|NCT03154606|OTHER|Milk Protein Isolate|The study participants will be provided with breakfast meals to consume. The energy content of the breakfast meals will be standardized to \~250 kcal. The meals will include the same fat content but will contain protein sourced predominantly from milk protein caseinate. All ingredients are GRAS listed and approved.
223586554|NCT05063201|DRUG|Placebo|Subjects will attend two visits per week during the 8-week Outpatient Treatment Phase. Counseling services, in the form of Medication Management (MM) will be provided weekly. A urine sample for drug testing, vitals, AEs, and COWS will be collected/assessed at each visit. At the first weekly visit attended, concomitant medications, medication compliance, AIMS and a blood sample for later analysis of plasma levels of cariprazine and its metabolites will also be collected. The TLFB, C-SSRS, CSSA, SOWS, BSCS, DTS and a UPT (females only) will be collected once weekly. On the final appointment of week 8 only, a physical exam and ECG will be performed and standard laboratory measures (blood chemistry, CBC with differential, fasting glucose and lipids, serum prolactin, medical urinalysis) will be assessed. During week 8, additional assessments will be collected, including the ASI, HAM A/D and Treatment Opinion Form (TOF).
223586555|NCT06123754|DRUG|Envalfolimab subcutaneously injected+Platinum-based doublet chemotherapy intravenous injection|The subjects receive Envafolimab/placebo treatment with a dosage of 600 mg/3 ml subcutaneously injected every 3 weeks.It will last about 3-4 cycles before surgery and 16 cycles after surgery.
224176001|NCT00267267|DRUG|ezetimibe/simvastatin|
224176002|NCT03351582|BEHAVIORAL|Grief and Communication Family Intervention|This intervention is an integrative approach which uses techniques from systemic family therapy as well as cognitive behavioral therapy.
224176003|NCT01385098|DIETARY_SUPPLEMENT|Vitamin D3 and Calcium|1500 mg of calcium citrate plus 1000 IU of vitamin D3 and 1000 IU of vitamin D3 bariatric supplements per day
224176004|NCT00554840|DRUG|varenicline|Subjects will be randomized to receive either active drug or matching placebo capsules using the following titration schedule: 0.5mg for three days, 0.5mg twice daily for the next four days, then 1mg twice daily for the rest of the treatment phase. Subjects will be evaluated weekly for abstinence through self report, end expired CO and urine dipstick for cotinine.
224176005|NCT00554840|DRUG|placebo|At the end of Pre-med week 1, subjects will receive study medication with the target quit date being the following week. Subjects will be randomized to receive either active drug or matching placebo capsules using the following titration schedule: 0.5mg for three days, 0.5mg twice daily for the next four days, then 1mg twice daily for the rest of the treatment phase. Subjects will be evaluated weekly for abstinence through self report, end expired CO and urine dipstick for cotinine.
223486256|NCT03154606|OTHER|Pure Protein Blend|The study participants will be provided with breakfast meals to consume. The energy content of the breakfast meals will be standardized to \~250 kcal. The meals will include the same fat content but will contain protein sourced predominantly from pure protein blend. All ingredients are GRAS listed and approved.
223586556|NCT06123754|DRUG|placebo subcutaneously injected +Platinum-based doublet chemotherapy intravenous injection|The subjects received platinum-based doublet chemotherapy on day 1 of every cycle. It's 3 weeks per cycle and lasts 3-4 cycles before surgery.
224176006|NCT01420523|DRUG|Raltegravir-Maraviroc|Raltegravir 400 mg twice a day + Maraviroc 300 mg twice a day
224176007|NCT04619563|DRUG|Anlotinib Hydrochloride plus Docetaxel|Anlotinib Hydrochloride (12mg, QD PO d1-14, 21days per cycle) and Docetaxel (75mg/m2 IV d1)
224176008|NCT02698176|DRUG|Birabresib|Administered as an oral capsule in a fasted state
224176009|NCT02430298|DRUG|Melatonin|Drug: Melatonin 20 mg/ 10 ml melatonin suspension gargle for 2 minutes before radiation 15 minutes and 20 mg melatonin gelatin capsule taken orally after 21:00 hours each night throughout the study
224176010|NCT02430298|DRUG|Matched Placebo|Drug: Melatonin 20 mg/ 10 ml placebo suspension gargle for 2 minutes before radiation 15 minutes and 20 mg placebo gelatin capsule taken orally after 21:00 hours each night throughout the study
224176011|NCT04303247|BIOLOGICAL|CD19 and CD22 targeted CAR-T cells|The T cells aphesis from subjects then been manufactured to express CAR to binding CD19 and CD22 on B-cell lymphoma.
224176012|NCT02449694|DEVICE|OCS Liver|OCS Liver will be used to preserve the donor liver
224176013|NCT03474172|DEVICE|Cloak Shape Device for Sham Tuina|The Cloak Shape Device for Sham Tuina is exactly the same as the real one, which is opaque and big enough to cover the whole body and arms of a child who is under 6 years old. Two narrow holes are required on the cover, so that the therapist's hands can touch the child through these holes and a sham Tuina will be manipulated
224176014|NCT03474172|DEVICE|Cloak Shape Device for Genuine Tuina|The Cloak Shape Device for Genuine Tuina is opaque and big enough to cover the whole body and arms of a child who is under 6 years old. Two narrow holes are required on the cover, so that the therapist's hands can touch the child through these holes and a genuine Tuina will be manipulated.
224176015|NCT03699501|OTHER|Questionnaires|"* A validated oral health-related quality of life self-assessment questionnaire: the GOHAI~* A validated oral health-related quality of life self-assessment questionnaire to be validated: SOHP~* A validated depression scale: the Beck scale~* A self-assessment questionnaire for oral health coping to be validated: the SCOOHP~* A validated self-assessment questionnaire for coping: The Brief cope)"
224176016|NCT03699501|PROCEDURE|Oral examination|"* An evaluation of dental health using the CAO index~* An evaluation of oral hygiene with the IHO-S index"
224176017|NCT03699501|OTHER|questionnaires (test-retest)|SCOOHP and SOHP questionnaires
224176018|NCT05872243|DEVICE|active rTMS|Each participant will receive two 1800 pulse active rTMS in each session, with a 50-minute break in between. Participants will receive two separate sessions daily (a sum of 7200 pulses per day). The intervention will take place for 15 continuous days.
224176019|NCT05872243|DEVICE|sham rTMS|Each participant will receive two 1800 pulse sham rTMS in each session, with a 50-minute break in between. Participants will receive two separate sessions daily (a sum of 7200 pulses per day). The intervention will take place for 15 continuous days.
224176020|NCT03621111|BEHAVIORAL|Patient-counseling|After one month from the hospital discharge, the pharmacist will give to the patient general advices and suggestions regarding disease, therapy and drugs.
224176021|NCT03621111|BEHAVIORAL|Patient self-administered questionnaire|The pharmacist will submit the questionnaire to the patient for the evaluation of drug adherence, life style, feelings and approach to therapies, at 30 days, 3, 6, 9 and 12 months from the enrollment. This self-questionnaire of 13 questions contains the 8 multiple choice questions of the Morisky medication adherence scale (MMAS-8-Item, Italian version).
224306474|NCT04068636|PROCEDURE|Radioactive tracer injection via flexible endoscopy and SPECT scan for visualization of lymph nodes.|Flexible endoscopy will be performed by one of two experienced head and neck surgeons. Inspection of larynx and pharynx will be performed to determine the extensions of the tumor in all directions. After local anesthesia, 2-4 peritumoral injections of Tc-99m-nanocolloïd will be given. Ten minutes after injection of Tc-99m-nanocolloïd a SPECT scan will be performed.
223486257|NCT03154606|OTHER|Whey Protein Isolate|The study participants will be provided with breakfast meals to consume. The energy content of the breakfast meals will be standardized to \~250 kcal. The meals will include the same fat content but will contain protein sourced predominantly from whey protein blend. All ingredients are GRAS listed and approved.
223486258|NCT03154606|OTHER|Native Whey Protein Isolate|The study participants will be provided with breakfast meals to consume. The energy content of the breakfast meals will be standardized to \~250 kcal. The meals will include the same fat content but will contain protein sourced predominantly from Native Whey Protein Isolate. All ingredients are GRAS listed and approved.
223586557|NCT07031804|OTHER|Saline Nasal Spray|A saline nasal spray will be introduced as saline on the first day (no induced expectations) and as oxytocin on the second day (induced positive expectations)
224176022|NCT03621111|BEHAVIORAL|Pills counts|At the time of the monthly drug re-supply at the community pharmacy, the patient will bring the boxes of the drugs taken in the previous month (empty or not), for the pill counts. The pharmacist will verify the correct assumption of the pharmacological therapies.
224176023|NCT01943396|PROCEDURE|rheohemapheresis|Each treated patient will receive a series of 8 rheohemaphereses (cascade filtration) within 10 weeks. One plasma volume will be washed.
224176024|NCT04715867|DRUG|Rabix-VC|Rabix-VC will be locally manufactured by Incepta Vaccine Ltd
224176025|NCT02253173|DRUG|Estradiol|
224306475|NCT00106236|BEHAVIORAL|exercise|
224306476|NCT00955136|DEVICE|Use of intermittent high MI impulses during echocardiogram|Using the transthoracic three dimensional imaging probe, low mechanical index (MI) will examine wall motion. Intermittent high MI impulses will be administered over the microvasculature where there are wall motion abnormalities using an imaging plan that best aligns itself with the risk area. One vial of MRX 801 to be infused intravenously during echocardiography with high mechanical index impulses.
224306477|NCT00808964|DRUG|NU172|NU172 administered IV bolus followed by continuous infusion during CABG surgery
223586558|NCT07031804|OTHER|Saline Nasal Spray|A saline nasal spray will be introduced as oxytocin on the first day (induced positive expectations) and as saline on the second day (no induced positive expectations)
224176026|NCT02253173|DRUG|Placebo|
224176027|NCT02010489|OTHER|12 week Exercise Program|Patients will be provided with a tour of the Reh-Fit Centre, exercise prescription, and supervised exercise session. The exercise prescription consists of 3 weekly 60-minute sessions, each with 10 minutes warm-up, 30 minutes endurance, 20 minutes strength training and 5 minutes cool-down. The program is overseen by an accredited Exercise Physiologist. Initial exercise intensity is determined by the kinesiologist and based on the patient's baseline fitness level. Goal intensity of endurance activity is based on the heart rate reserve (HRR) method. This is captured with a heart rate monitor at initial assessment and recorded on exercise logs. There are check-ins at each exercise session to determine progress (time, reps, weight, sets, etc). Endurance activities include treadmill, elliptical, walking, and aerobics. Strength training includes upper body, lower body, and trunk circuits. Patients will be asked to attend three weekly sessions at the Reh-Fit Centre.
224176028|NCT00410514|DRUG|Mirabegron|oral
224176029|NCT00410514|DRUG|Placebo|oral
224176030|NCT05312385|DRUG|Isoflurane|Inhaled isoflurane administered by Sedaconda ACD-S
224176031|NCT05312385|DRUG|Propofol|Intravenous infusion of propofol
224176032|NCT01477073|DRUG|FSH-GEX™|
224176033|NCT01477073|DRUG|recombinant FSH|
224176034|NCT01477073|DRUG|urinary FSH|
224176035|NCT01477073|DRUG|Placebo|
223486259|NCT03154606|OTHER|Soy Protein|The study participants will be provided with breakfast meals to consume. The energy content of the breakfast meals will be standardized to \~250 kcal. The meals will include the same fat content but will contain protein sourced predominantly from soy protein. All ingredients are GRAS listed and approved.
223486260|NCT03154606|OTHER|Pea Protein|The study participants will be provided with breakfast meals to consume. The energy content of the breakfast meals will be standardized to \~250 kcal. The meals will include the same fat content but will contain protein sourced predominantly from pea protein. All ingredients are GRAS listed and approved.
224176036|NCT05474885|BIOLOGICAL|BCMA-CD19 cCAR T cells|BCMA-CD19 cCAR T cells are used to treat patients. Patient will be administered either fresh or thawed CAR T cells by IV injection after receiving lymphodepleting chemotherapy.
224176037|NCT01317264|OTHER|no β-glucan|daily consumption of non-β-glucan containing milk drinks together with the 3 main meals for 21 days
224176038|NCT01317264|OTHER|oat β-glucan|daily consumption of 5g of oat β-glucan in the form of milk drinks with the 3 main meals for 21 days
224176039|NCT01317264|OTHER|barley β-glucan|"daily consumption of 5g β-glucan extracted from the barley-mutant mother Bomi in the form of milk drinks with the 3 main meals for 21 days"
224176040|NCT01317264|OTHER|mutant-barley β-glucan|"daily consumption of 5g β-glucan extracted from the high β-glucan barely mutant lys. 5.f in the form of milk drinks with the 3 main meals for 21 days"
224176041|NCT01661231|DEVICE|Astron/Pulsar-18 stent|Peripheral Vascular Intervention
223486261|NCT03154606|OTHER|Native Whey: Micellar Casein (50:50) blend|The study participants will be provided with breakfast meals to consume. The energy content of the breakfast meals will be standardized to \~250 kcal. The meals will include the same fat content but will contain protein sourced predominantly from native whey: micellar casein (50:50) blend. All ingredients are GRAS listed and approved.
223486262|NCT03154606|OTHER|Carbohydrate Control|The study participants will be provided with breakfast meals to consume. The energy content of the breakfast meals will be standardized to \~250 kcal. The meals will include the same fat content but will contain predominantly carbohydrates as a control. All ingredients are GRAS listed and approved.
224176042|NCT03171142|DRUG|Heliox|Heliox (21:79) via nasal cannula 2 litter per minutes
224306478|NCT05652959|DEVICE|Cerviron®|Cerviron® is a medical device manufactured by PFC Pharma Manufacturing SL formulated following the provisions of the European Regulation 2017/745 on Medical Devices. Cerviron® is an invasive medical device of short-term use classified under annex VIII of the European Regulation 2017/745 as class IIb according to Rule 21. Cerviron® has a complex composition consisting of three topical pharmaceutical products - hexylresorcinol, collagen and bismuth subgallate - and four phytotherapeutic extracts - Calendula officinalis, Hydrastis canadensis, Thymus vulgaris extract and Curcuma longa. The Instructions for use specify its field of use as adjuvant in the treatment of acute and chronic vulvovaginitis of mechanical etiology, caused by changes of vaginal pH and changes of the vaginal flora and of cervical lesions of mechanical origin.
223486263|NCT03987048|OTHER|Measure of short- and long-term mortality and analysis of independent predictors of short- and long-term mortality.|"Data were collected regarding medical background, medical condition and management, both at admission and during the ICU stay. These included demographics, clinical, biological and therapeutic data.~Outcome at ICU discharge and at one year were also recorded."
223486264|NCT02235740|DRUG|Afuresertib|Afuresertib will be dosed orally in morning, and will be sourced as opaque, white, size 4, 25 mg capsule and size 1, 100 mg capsules.
223486265|NCT02235740|DRUG|Carfilzomib|Intravenous (IV) Carfilzomib will be sourced in the US from commercial stock. It will be a single-use 60 mg vial as a sterile, white to off-white lyophilized cake or powder
223745314|NCT06892496|OTHER|Flowable resin composite stent (FRC) technique|On the day of surgery, a layer of flowable composite will be added, covering all the wound dimensions, restricted to the wound (no extension to the adjacent teeth). Flowable composite has been shown to help reduce pain using the same principal of providing a mechanical barrier to protect the palatal wound from the oral cavity
224176043|NCT03171142|DRUG|Air|Air 21% via nasal cannula 2 litter per minutes
224176044|NCT06199791|DRUG|Lamotrigine 100 MG|tablets
224176045|NCT01021423|DRUG|Lenalidomide|15 mg orally once daily on Days 1-21 of every 28-day cycle for a maximum of 2 years or until disease progression, unacceptable toxicity develops or voluntary withdrawal.
224176046|NCT01021423|OTHER|Placebo|Placebo (identical matched capsule) orally once daily on Days 1-21 of every 28-day cycle for a maximum of 2 years or until disease progression, unacceptable toxicity develops or voluntary withdrawal.
224176047|NCT04097106|DIETARY_SUPPLEMENT|Synbiotic|Synbiotic dietary supplement in capsule form
224176048|NCT00355251|DRUG|Atorvastatin 40 mg/Atorvastatin 80 mg|Atorvastatin 40 mg/80 mg
224176049|NCT03351062|DRUG|Tamoxifen|Patients will be given 10mg Tamoxifen twice a day.
224176050|NCT03351062|DRUG|Toremifene|Patients will be given 60mg Toremifene once a day.
224176051|NCT00284336|DRUG|Caelyx|
224176052|NCT00284336|DRUG|endoxan|
224176053|NCT01132768|DRUG|Atenolol|Atenolol (ATE) 50 mg and/or 100 mg tablets, oral, once daily
224176054|NCT01132768|DRUG|olmesartan medoxomil|Olmesartan medoxomil (OM), 20 mg and/or 40 mg, oral, once daily
224176055|NCT03087110|BIOLOGICAL|Matched sibling donor cord blood cell infusion|Single dose intravenous infusion of 12/12 HLA matched sibling donor cord blood cells (\>1x10\^7 cells/kg)
224176056|NCT06263400|BEHAVIORAL|psychoeducation and follow-up study|In the study, we hypothesized that the caregiver psychoeducation program (consisting of six sessions over a 3-week period) would improve depressive symptoms in depressed patients, increase recovery levels, reduce the caregiver's burden, and reduce emotional expression levels in the family.
224176057|NCT01800162|DRUG|Methotrexate|Two Dose Protocol: The patient will receive the first dose of MTX 50mg/m2 on treatment day 0. She will receive a second dose of MTX 50mg/m2 on treatment day 4 and a serum hCG level will be drawn. Subsequent doses of MTX will be administered based on hCG levels.
224176058|NCT01800162|PROCEDURE|Uterine Evacuation|Uterine evacuation or dilation and curettage. At the clinician's discretion, this can be performed using local anesthesia, sedation or general anesthesia and can use a manual or electrical evacuation.
224176059|NCT01800162|OTHER|Expectant Management|Pregnancy will be expectantly managed using serum hcg monitoring.
224176060|NCT05651412|OTHER|Dynamic gait index and 5 time sit to stand test|dynamic gait index and 5 time sit to stand test was administered to all sample size of 400
224176061|NCT03378284|DRUG|Tegoprazan|Tegoprazan QD for 7 days
224176062|NCT03378284|DRUG|Revaprazan|Revaprazan QD for 7 days
224176063|NCT06225830|DEVICE|Eksobionics Eksoskeleton NR|During treatment sessions, the therapist will guide the participant's progress using a specific plan. The therapist will set a trajectory for each leg, determining the appropriate step height and length, and program it into the Ekso device. The Ekso will then assist the participant by following this trajectory, with varying levels of assistance for each step. As the participant improves, the therapist will gradually reduce the assistance provided until the participant reaches a point where they no longer require assistance or reach a plateau. In the final phase, the trajectory will be removed, and the participant will walk using their own movements. The therapist may add resistance or assistance based on the participant's needs, but it will be in line with their self-generated movements rather than a predetermined path.
224176064|NCT04250610|OTHER|Survey|On-line survey.
224176065|NCT02184390|OTHER|On LIne Parent Training Tutorial|Interactive on line tutorial for parenting skills for autism
224176066|NCT02393989|PROCEDURE|posterior restoration|restorations for caries effected teeth
224176067|NCT04481711|PROCEDURE|Total Knee Arthroplasty|Osteoarthritis (OA) is one of the most common chronic peripheral joint diseases increasing among the aging population.Pathogenesis is not fully known.One of the most common risk factors and causes are loss of pain and function. Knee joint osteoarthritis adversly affects the person's life quality. Total Knee Arthroplasty (TKA) is a surgical approach to restore tibiofemoral joint alignment, especially in the severe level of knee OA.
224176068|NCT01440829|DRUG|L-ornithine-L-aspartate|The patients will be treated with LOLA (30g per day) for a week after TIPS procedure.
224176069|NCT01518140|DEVICE|Oxygen Delivery Devices|"Participants receive air through VapoTherm for 1 hour, and then on an as needed basis for up to 4 hours. Participants then receive air through bilevel positive airway pressure (BiPAP) for up to 30 minutes, followed by 30 minutes using non-rebreather mask."
224176070|NCT01518140|BEHAVIORAL|Questionnaires|2 Questionnaires completed at baseline taking about 10 minutes to complete. At end of visit, questionnaire completion taking about 5 minutes to complete.
224176071|NCT06720545|DEVICE|No HGNS therapy (HGNS-off)|Prior to enrollment in this study, participants will have been utilizing HGNS at a therapeutic voltage setting confirmed via overnight sleep study. As part of the trial, they will undergo a study arm that involves turning off HGNS therapy (HGNS-off) for between 2-4 weeks.
224176072|NCT07045870|DRUG|group L : will receive lidocaine|group L : will receive 1.5 mg/kg bolus of iv lidocaine 10 minutes before anaesthesia induction then continuous iv infusion rate 1.5 mg / kg / h
224176073|NCT07045870|DRUG|group k : will receive Ketamine|patients will receive .25 mg / kg bolus of iv ketamine 10 minutes before anaesthesia induction then continuous iv infusion of ketamine at .25 mg /kg /h
224176074|NCT07045870|DRUG|group c: will recieve .9% saline|group c will be injected with equivalent volumes and rates of .9% saline using the same application scheme as the lidocaine and ketamine as a control group
224176075|NCT06719362|DRUG|M3T01|Subjects will be treated with M3T01 through an IV infusion over 1 hour given every 3 weeks.
224176076|NCT06719362|DRUG|Pembrolizumab|Pembrolizumab will be given as standard of care to Cohort DL 5+ under Part 1 of the study. Subjects will receive 200 mg IV once every 3 weeks.
223486266|NCT05843565|DEVICE|Cobalt video laryngoscope blade|Non-standard hyperangulated Cobalt video laryngoscope blade
224176077|NCT06719362|RADIATION|Chemoradiation|Subjects will be treated with standard of care chemoradiation therapy consisting of TMZ 75 mg/m2 daily with concurrent radiation therapy (60 Gy administered over 6 weeks). Following chemoradiation therapy, subjects will have a 4-week break from TMZ before starting standard adjuvant TMZ 150-200 mg/m2 days 1-5 of 28-day cycles for 6 cycles. Subjects will be treated with M3T01 at the RP2D through an IV infusion every 3 weeks that will begin concurrently with chemoradiation therapy.
224176078|NCT06719362|DRUG|FOLFOX regimen|FOLFOX will be given as standard of care on 14 day cycles. Subjects will receive oxaliplatin 85 mg/m2 IV on Day 1, leucovorin 400 mg/m2 IV on Day 1, fluorouracil 400 mg/m2 IV push on Day 1, and fluorouracil 1,200 mg/m2 IV continuous infusion on Days 1-2 every 14 days for up to 9 cycles.
224176079|NCT00362141|DRUG|levetiracetam (add-on)|
224176080|NCT00262561|DRUG|Aspirin|The effect of Aspirin on platelet function was assessed.
224176081|NCT03378128|PROCEDURE|Diagnostic laparoscopy|The patient will initially undergo a diagnostic laparoscopy by a minimally invasive approach and entry method. The decision of which approach and entry to perform will be dictated by the primary surgeon of record's preference and their assessment of pre-operative patient factors. Once the primary surgeon determines the areas of macroscopic disease, he/she will make an assessment as to the need to convert to a laparotomy or continue laparoscopically. At the completion of the procedure, it will be noted whether an optimal cytoreduction (≤ 1 cm residual disease) or a sub-optimal cytoreduction (\>1 cm residual disease) was performed.
224176082|NCT04522193|DEVICE|Glycemic Holter|Continuous glycaemia monitoring,
223486267|NCT05843565|DEVICE|Miller video laryngoscope blade|Standard Miller video laryngoscope blade
223486268|NCT04781673|DRUG|Ketamine|Will receive titratable infusion.
223486269|NCT04781673|DRUG|Lidocaine|Will receive titratable infusion, will have daily lidocaine level labs drawn daily.
223486270|NCT04968106|DRUG|Doxorubicin|Doxorubicin will administered by intravenous infusion on day 1 every 3 weeks (75 mg/m²) up to 3 cycles
223486271|NCT04968106|DRUG|Ifosfamide|Ifosfamide will be administered by intravenous infusion over 3 days every 3 weeks (9 g/m²) up to 3 cycles
223486272|NCT04968106|DRUG|INCMGA00012|Retifanlimab will be administered by intravenous infusion on day 1every 3 weeks (375 mg) up to 3 cycles
224176083|NCT04522193|RADIATION|gastric emptying scintigraphy|Fasting administration of a Technecium-labelled milk bottle and quantification of the remaining radioactivity by a camera every 30 minutes for 4 hours.
224176084|NCT04522193|DEVICE|Holter ECG|continuous cardiac monitoring
224176085|NCT05743413|PROCEDURE|Armeo Spring physiotherapy|Study subjects will undergo physiotherapy sessions using the Armeo Spring device.
224176086|NCT05743413|PROCEDURE|Standard physiotherapy|Study subjects will undergo standard physiotherapy sessions.
223586559|NCT06876740|BEHAVIORAL|Project Safe Guard - Trauma|Project Safe Guard-Trauma (PSG-T) is a brief (15- to 20-minute), single-session lethal means safety counseling intervention (LMSC) for firearm-owning individuals with posttraumatic stress disorder (PTSD). PSG-T is designed to promote secure firearm storage practices by (1) using motivational interviewing techniques and (2) addressing the functional link between PTSD symptoms and unsafe firearm storage practices. In motivational interviewing-based LMSC, the clinician uses a guided approach to help individuals identify their values and motivations for secure firearm storage, rather than prescribing a certain set of actions. The focus is on respecting patients' autonomy and normalizing responsible firearm ownership by developing discrepancies, amplifying ambivalence, expressing empathy, rolling with resistance, and supporting self-efficacy. PSG-T combines PSG-proven motivational interviewing techniques with PTSD- and firearm-specific psychoeducation.
224176087|NCT02289521|DEVICE|Transcranial Direct Current Stimulation|"We will use a non-invasive, reversible transcranial direct current stimulation (tDCS) using a low-intensity electrical current. We will use Anodal and Sham tDCS.~* Anodal: Active anodal electrode over F3 (EEG system) and return electrode over right supraorbital area. A 1.5mA current will flow between the electrodes for 20min. To decrease current-induced injuries, at the beginning, the current reaches from 0 to 1.5mA during 30 seconds (fade-in), and decreases from 1.5mA to 0 in 15 seconds at the end (fade-out).~* Sham: The parameters mimics the A-tDCS (i.e. electrode placement, fade-in and current intensity), except the duration of stimulation: the current will reach to 1.5mA in 30 seconds (fade-in) and lasts only for 30 seconds (to give the initial sensation of stimulation)."
224176088|NCT02985684|DEVICE|GORE® CARDIOFORM ASD Occluder|Percutaneous Atrial Septal Defect Closure
224176089|NCT01875666|DRUG|Trastuzumab|8 mg/kg IV, single dose
224176090|NCT01875666|DRUG|pertuzumab|840 mg IV single dose
224176091|NCT01875666|DRUG|lapatinib|1000 mg daily for 7 days
224176092|NCT04118140|OTHER|Somatic Acupressure|7-week self-acupressure plus usual care (an education booklet)
224176093|NCT04118140|OTHER|Sham acupressure|Same dose as the true acupressure group but on the sham acupoints plus usual care (an education booklet)
224176094|NCT04118140|OTHER|Usual care|Usual care only (an education booklet)
223486273|NCT04278690|OTHER|HELPix|HELPix parents will receive usual care as above, after which trained staff will generate HELPix patient-/regimen-specific medication instruction sheets and review them with the parent. Instruction sheets include optimized instructions (mL-only, doses appropriately rounded, visuals of recommended tool (e.g. 1-mL syringe best for doses of \<1 mL), explicit frequency information (e.g. 'morning and night' instead of '2x/day') reinforced by pictograms (e.g. sun/moon icons)). For each medication, staff will: 1) review the dose (refer to the pictographic dose diagram, which illustrates optimal dosing tool filled to correct amount), 2) demonstrate the dose using optimal dosing tool, 3) ask parent to 'teachback'/'showback' dose (e.g. parent shows provider how much they would give by pulling back plunger on syringe to right level), 4) provide optimal dosing tool for the parent to take home. We anticipate this process will take \~5-10 minutes.
223486274|NCT04278690|OTHER|HELPix+Tech|After parent receives usual care and HELPix , trained staff will walk parent through the app on-boarding process to overcome initial barriers to use. Steps: 1) Parent texted link to personalized on-line instructions. 2) Parent clicks link to app. For each medicine: A. Dosing module with optimized instructions (c/w HELPix); parent teachback/showback of dose B. Frequency module supports simplified, explicit intervals (e.g. 'morning and night'), parent chooses convenient times (text reminders sent based on preferences). Time for TECH depends on # medicines and parent baseline knowledge; structured protocol used to see # teachback rounds needed .
223486275|NCT03712943|DRUG|Regorafenib|Regorafenib orally 80 mg daily for 21 days (3 weeks on, 1 week off).
223486276|NCT03712943|DRUG|Nivolumab|Nivolumab 240 mg administered intravenously every 2 weeks.
224176095|NCT07052331|DEVICE|Birth Mobility System|Participants receive standard obstetric care and have access to a birth mobility system installed on the birthing bed. Use of the system is voluntary and guided by medical professionals. Participants view a video explaining the system's operation. Birth mobility data is collected passively.
224176096|NCT07052240|BEHAVIORAL|Gatekeeper Training Program (GTK)|"Behavioral: Gatekeeper Training Program (GTK)~The GTK program is a suicide prevention intervention for university students. It includes two sessions of 3 hours each (total: 6 hours), delivered over one week, either face-to-face or online. Content is organized into six modules:~1. Introduction to suicidal behavior.~2. Warning signs and risk/protective factors.~3. Crisis intervention and suicide first aid.~4. Safety planning and community resources.~5. Ethics and gatekeeper self-care.~6. Practical simulations and skill application.~The program includes interactive exercises, role-plays, take-home materials, and a booster session plus a focus group at the 2-month follow-up."
224176097|NCT07051707|DEVICE|Targeted Lung Denervation (TLD)|Targeted Lung Denervation (TLD)Therapy is a bronchoscopically guided, minimally invasive procedure using the Nuvaira™ Lung Denervation System.
224176098|NCT07051707|DRUG|Standard medical care|Continuing standard of care COPD maintenance medication that minimally includes LABA/ICS, LAMA/LABA or LABA/LAMA/ICS.
224176099|NCT07052981|DRUG|Telitacicept|The study duration was 24 weeks, with the experimental group receiving subcutaneous injections of Telitacicept once weekly for a total of 24 weeks.
224176100|NCT01041001|BIOLOGICAL|Cartistem|allogeneic-unrelated umbilical cord blood-derived mesenchymal stem cell product
224176101|NCT01041001|PROCEDURE|Microfracture treatment|
224176102|NCT01586962|DRUG|IFF flavor 316 282, Paracetamol, Pseudoephedrine|Single dose syrup containing a warmingflavor IFF 316282 in a syrup containing Paracetamol and pseudoephedrine
224176103|NCT07059130|BIOLOGICAL|Mirikizumab|Mirikizumab will be administered to participants according to FDA-approved dosing guidelines for moderate-to-severe Crohn's Disease and Ulcerative Colitis. Participants will receive scheduled doses throughout the study period at predefined intervals. Clinical assessments, patient-reported outcomes, biomarker analyses, and safety monitoring will occur at baseline and at Weeks 12, 24, and 48.
224176104|NCT07058857|DEVICE|Parasym Neuromodulation Device (Treatment Group)|Participant will undergo stimulation in their left tragus for 60 minutes by using Parasym device
224176105|NCT07058857|DEVICE|Parasym Neuromodulation Device (Sham Group)|Participant will undergo implantation of Parasym device lead in their left tragus but without any stimulation for 60 minutes
224176106|NCT07058597|DEVICE|Twinfork plate|Twinfork plate
224176107|NCT07058597|DEVICE|3D-interlocking plate|3D-interlocking plate
224176108|NCT07058597|DEVICE|Miniplate|Miniplate
224176109|NCT07057934|PROCEDURE|ESPB Block|Under sterile conditions and ultrasound guidance, 20 mL of local anesthetic solution (10 mL of 0.5% bupivacaine and 10 mL of 2% lidocaine) was injected bilaterally into the erector spinae plane at the T7-T8 level before incision. The block was performed after induction of general anesthesia but before the start of laparoscopic cholecystectomy.
223486277|NCT05955651|DIAGNOSTIC_TEST|Peritoneal washings|"Peritoneal washing will be done at designated point in the surgical procedure. one hundred cc of normal saline, will be used to irrigate the peritoneal cavity. Samples of the fluid will be collected, with the goal to collect as much fluid as possible for the study, with minimum of 60 cc should be collected. Samples will be sent to the pathology lab.~1. First washing will be collected after obtaining entry into the peritoneal cavity with placement of the first laparoscopic trocar, before any manipulation of the uterus.~2. Second washing will be done after the hysterectomy and containment of the uterus in the bag.~3. Third washing will be collected after scalpel morcellation of the uterus in the containment bag, extraction and closure of the vaginal cuff."
223486278|NCT06133140|DEVICE|Unblinded postoperative vital sign monitoring|Unblinded postoperative GE Portrait monitoring
223486279|NCT06133140|DEVICE|Blinded postoperative vital sign monitoring|Blinded postoperative GE Portrait monitoring
223486280|NCT06045611|DIETARY_SUPPLEMENT|Isolated Pea Protein|Participants will consume the protein supplement dissolved in water in an opaque mug wearing a nose clip.
223486281|NCT06045611|DIETARY_SUPPLEMENT|Isolated Whey Protein|Participants will consume the protein supplement dissolved in water in an opaque mug wearing a nose clip.
223486282|NCT06045611|DIETARY_SUPPLEMENT|Isolated Faba Bean Protein|Participants will consume the protein supplement dissolved in water in an opaque mug wearing a nose clip.
223486283|NCT06045611|DIETARY_SUPPLEMENT|Placebo|Participants will consume the placebo in an opaque mug wearing a nose clip.
223486284|NCT04923542|RADIATION|Stereotactic Radiosurgery (SRS)|Patients will receive single session SRS to intact brain metastases and post-operative cavities. For intact brain metastases, this will be 15 Gy to lesions between 31-40 mm, 18 Gy to 21- 30 mm, and 24 Gy to lesions measuring ≤ 20 mm.
223486285|NCT04923542|DRUG|Abemaciclib|Abemaciclib is an orally administered selective small-molecule inhibitor of CDK4 and CDK6 that is 14 times more potent against CDK4 than CDK6 in enzymatic assays that is approved for the treatment of advanced or metastatic breast cancers. Abemaciclib will be administered at a dose of 150 mg twice daily.
223486286|NCT04923542|DRUG|Endocrine therapy|Abemaciclib will be administered with standard of care endocrine therapy. Endocrine therapy can consist of fulvestrant or an aromatase inhibitor. Dosing of concurrent endocrine therapy with abemaciclib should follow standard dosing and safety guidelines.
223486287|NCT05897788|BEHAVIORAL|Text Message Check-ins|Patients will receive automated text-message check-ins up to once per day for 30 days to see if the patient needs help with anything AND patients can call or text the on-call substance use navigators (SUN) from 9a-9p, 7 days a week.
223486288|NCT05897788|BEHAVIORAL|Contingency Management|Patients will receive incentives for engagement with treatment. Participant will receive compensation for filling their buprenorphine scripts at discharge and attending their follow-up care appointments.
223486289|NCT04625647|DRUG|Sotorasib|Given PO
223486290|NCT04534153|DRUG|Fexofenadine Hydrochloride without sodium lauryl sulfate|without sodium lauryl sulfate
223486291|NCT04534153|DRUG|Fexofenadine Hydrochloride with sodium lauryl sulfate|with sodium lauryl sulfate
223486292|NCT01606475|BIOLOGICAL|Allogeneic islets of Langerhans|Up to 3 intraportal infusions of cadaveric pancreatic islets of Langerhans. Each infusion to contain at least 5,000 islet equivalents/kg body weight.
223486293|NCT03862950|DRUG|Placebo Medication|Placebo liquid or capsules given in parallel to active medication.
223486294|NCT03862950|DRUG|Metformin|Active medication
223486295|NCT05358938|OTHER|Exercise|30 minutes of moderate exercise on an arm ergometer, a cycle ergometer, or a treadmill prior to each administration of standard of care checkpoint blockade immunotherapy across all cycles
223486296|NCT05358938|DRUG|Checkpoint Blockade, Immune|Participants will receive clinical care following Moffitt standards for the patient's disease type and therapeutic setting.
223586560|NCT06876740|BEHAVIORAL|Project Safe Guard|Project Safe Guard-Trauma (PSG) is a brief (15- to 20-minute), single-session lethal means safety counseling intervention (LMSC) for firearm-owning individuals. PSG-T is designed to promote secure firearm storage practices by using motivational interviewing techniques. In motivational interviewing-based LMSC, the clinician uses a guided approach to help individuals identify their values and motivations for secure firearm storage, rather than prescribing a certain set of actions. The focus is on respecting patients' autonomy and normalizing responsible firearm ownership by developing discrepancies, amplifying ambivalence, expressing empathy, rolling with resistance, and supporting self-efficacy.
224176110|NCT07057934|PROCEDURE|EOPB Block|Under ultrasound guidance, 20 mL of local anesthetic mixture (10 mL of 0.5% bupivacaine and 10 mL of 2% lidocaine) was injected into the fascial plane between the external oblique and internal intercostal muscles at the level of the 6th rib. The procedure was done after anesthesia induction but prior to laparoscopic cholecystectomy.
224176111|NCT07057934|DRUG|Standard Systemic Analgesia|No regional anesthesia technique was applied. Postoperative pain was managed using systemic rescue analgesia: 50 mg dexketoprofen trometamol IV when VAS ≥4, followed by 50 mg tramadol IV if pain persisted.
224176112|NCT07059416|BEHAVIORAL|Oncology nurses carried out hand hygiene awareness activities with positive affirmation words and breathing exercises while washing hands or providing hand hygiene with hand antiseptic.|positive affirmation, focus on the moment
224176113|NCT06731894|PROCEDURE|Biospecimen Collection|Undergo urine sample collection
224176114|NCT06731894|DRUG|Cannabidiol|Given PO
224176115|NCT06731894|DRUG|Dronabinol|Given PO
224176116|NCT06731894|DRUG|Placebo Administration|Given PO
224176117|NCT06731894|OTHER|Survey Administration|Ancillary studies
223586561|NCT06879171|PROCEDURE|Alveolar ridge preservation|Grafting of the socket with Autogenous tooth graft mixed with simvastatin immediately after tooth extraction
223586562|NCT06879171|PROCEDURE|Alveolar ridge preservation|Grafting the socket with Autogenous tooth graft immediately after tooth extraction
223586563|NCT07037381|OTHER|KN95 mask|AIR+ KN95 mask
223586564|NCT01137019|DEVICE|Biolimus-eluting stent|The biolimus-eluting coronary stent contains a stainless steel platform on which an abluminally coated polylactic acid (PLA) biodegradable polymer is placed that eludes biolimus-A9.
224176118|NCT07057765|DRUG|Observational Assessment of Standard R-CHOP Treatment|Patients will receive R-CHOP chemotherapy (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) as part of routine clinical care. The study does not assign or modify treatment. Data will be collected to assess the association between inflammatory markers and clinical outcomes.
224176119|NCT07058844|BEHAVIORAL|High-BPM Line Dance|A structured aerobic dance program set to music with tempos of 130-140 BPM, designed to improve cognitive and physical function in older adults with MCI.
224176120|NCT07058844|BEHAVIORAL|Low-BPM Line Dance|A structured aerobic dance program set to music with tempos of 90-100 BPM, using the same choreography but slower rhythm and reduced rest intervals.
224176121|NCT07058844|OTHER|Usual Daily Activity|No structured intervention will be provided. Participants will continue their routine lifestyle.
224176122|NCT07059390|BEHAVIORAL|Nature Immersion Therapy|During the length of inpatient stay at Changi General Hospital (CGH), which ranges from 5 to 10 days, the patients and caregivers will be enrolled for a set of 3 nature-based sessions. Each session will be conducted in groups of 4 to 6 patients incorporating a relational multi-sensory experience as well as mind-body connectedness while spending time in nature. Each of the 3 sessions will be 45 minutes each. The nature-based therapy/green social prescription plan will be conducted in groups guided by a trained CGH staff (Allied Health Professionals/Nurse). This Green social prescribing plan (Playbook) will be integrated into inpatient's care plan. Caregivers of the enrolled patients will also be part of the therapy group following the necessary consent.
224176123|NCT07058012|DRUG|Cemiplimab|Cemiplimab 350mg intravenously
224176124|NCT07058012|DRUG|cemiplimab plus fianlimab|Cemiplimab 350mg + Fianlimab 1600mg intravenously
223486297|NCT06838962|DRUG|Daratumumab Injection|"intravenous Daratumumab administration~This study adopts a prospective, single arm, open design method. Thirty subjects were enrolled in the study and were treated with CD38 monoclonal antibody (Daratumumab 16mg/kg/w) for 4 weeks.~The first stage is the main research stage (d1-w4), which is the core treatment period. The subjects will receive intravenous infusion of 16mg/kg Daratumumab once a week for 4 weeks to observe the safety and efficacy during treatment.~The second stage (w5-w24) is the stage of withdrawal from the visit, mainly to observe the safety and continuous efficacy of Daratumumab after treatment."
223486298|NCT03819322|DRUG|sofosbuvir/velpatasvir|12 week, oral, fixed dose
223586565|NCT01137019|DEVICE|Everolimus-eluting coronary stent|The everolimus-eluting coronary stent is a cobalt chromium platform stent with a permanent fluorinated copolymer matrix that eludes everolimus
223586566|NCT02074813|OTHER|Inspiratory muscle training|Inspiratory muscle training
224176125|NCT07058012|DRUG|cemiplimab + REGN7075|Cemiplimab 350mg + REGN7075 2700mg intravenously
224176126|NCT07058012|OTHER|ctDNA testing|Eligible patients using results for ctDNA-positivity as obtained from a commercial assay run in any CLIA-certified lab will proceed to enrollment and begin treatment. All patients will have confirmation of ctDNA-positivity via the Signatera\^TM assay (Clinical Trial Assay), but treatment may proceed while awaiting confirmatory results.
223586567|NCT05092373|BIOLOGICAL|Atezolizumab|Given IV
223586568|NCT05092373|DRUG|Cabozantinib S-malate|Given PO
223586569|NCT05092373|DRUG|Nab-paclitaxel|Given IV
223586570|NCT05092373|PROCEDURE|Tumor Treating Fields Therapy|Receive TTF
223586571|NCT04495868|DRUG|Bacteriostatic Normal Saline|A skin wheal will be made with bacteriostatic normal saline (BNS). BNS contains 0.9% benzyl alcohol and benzyl alcohol is an opium alkaloid that is sometimes added to physiologic normal saline for its bacteriostatic properties. The skin wheal will be created by injecting the medication intra-dermally with a 26 gauge needle.
224176127|NCT07057713|PROCEDURE|Total Arterial Grafting|Coronary artery bypass grafting using only arterial conduits in the left coronary artery system. The left internal thoracic artery (LITA) is grafted to the LAD, and the radial artery is anastomosed to the obtuse marginal or diagonal branches. This approach avoids the use of saphenous vein grafts for the left coronary system.
224176128|NCT07057713|PROCEDURE|Conventional Mixed Grafting|A standard coronary artery bypass grafting (CABG) procedure where the left internal thoracic artery (LITA) is grafted to the LAD, and saphenous vein grafts are used for the obtuse marginal or diagonal branches of the left coronary system. This approach represents the conventional mixed arterial-venous strategy.
224176129|NCT07058142|BEHAVIORAL|Interaction Standard Theory-Based Multi-Care Program|A comprehensive nursing program based on King's Theory of Goal Attainment and Satir's model, focusing on structured nurse-patient communication, shared goal-setting, and multi-dimensional care addressing cognitive, psychological, behavioral, and dietary aspects. Delivered daily during hospitalization (30-45 min sessions) with post-discharge follow-up.
224176130|NCT07058142|BEHAVIORAL|Conventional Nursing Intervention|Standard hospital protocol for postpartum hemorrhage management including physiological monitoring, emergency measures as needed, and basic postpartum care education.
224176131|NCT07059533|OTHER|Verum|anodal transcranial direct current stimulation: 20 minutes of stimulation with 1 mA (ramp-up/ramp-down times of 8 seconds)
223486299|NCT03624543|DRUG|CFI-400945|32mg; 28 day cycles; Cycle 1: Days 1-7 then 15-21 Cycle 2 onward: Daily
223486300|NCT00392353|DRUG|Azacitidine|Given SC
223486301|NCT00392353|OTHER|Laboratory Biomarker Analysis|Correlative studies
223486302|NCT00392353|OTHER|Pharmacological Study|Correlative studies
223486303|NCT00392353|DRUG|Vorinostat|Given PO
223586572|NCT04495868|DRUG|1% Lidocaine|A skin wheal will be made with 1% lidocaine. The skin wheal will be created by injecting the medication intra-dermally with a 26 gauge needle.
223586573|NCT04862728|OTHER|- Strong kids screening tool - Stamp screening tool - PYMS screening tool|Screening Tool for the Assessment of Malnutrition in Pediatrics (STAMP) evaluates patient's clinical diagnosis, nutritional intake during hospitalization and anthropometric measurements, developing a care plan based on the child's overall malnutrition risk (low, medium or high).Screening Tool for Impaired Nutritional Status and Growth (STRONG kids). It consists of four items: subjective clinical assessment, high-risk diseases, nutritional intake and losses, weight loss or poor weight gain. Patients classified at high nutritional risk have a longer hospitalization and a negative standard deviation score (SDS) for weight-for-height (WFH), which indicated a state of acute malnutrition.The Pediatric Yorkhill Malnutrition Score (PYMS) is adopted among medical and surgical patients between 1 and 16 years of age. The PYMS assesses four items: BMI, history of recent weight loss,
224176132|NCT07059533|OTHER|Placebo|anodal transcranial direct current stimulation with 40 seconds of stimulation delivered at the beginning of training (with 8 seconds ramp-up and 5 seconds ramp-down times)
224176133|NCT04714554|DRUG|Relugolix/E2/NETA FDC|Relugolix/E2/NETA (40 mg/1 mg/0.5 mg) FDC tablet; oral administration.
224176134|NCT04714554|DRUG|Relugolix|Relugolix 120-mg tablets; oral administration.
224176135|NCT04714554|DRUG|Erythromycin|Erythromycin 500-mg tablets; oral administration.
224176136|NCT05263401|DIETARY_SUPPLEMENT|3-hydroxybutyrate|Orally administered pre-meal drinks.
224176137|NCT01560754|DRUG|nicotine transdermal patch|Transdermal patches containing 7 or 14 mg nicotine or placebo with subjects titrating up until reaching their highest tolerated dose of 7 to 28mg/day.
224176138|NCT01749865|BIOLOGICAL|Cytokine-Induced Killer Cells|Cytokine-Induced Killer Cells treatment for 4 cycles
224176139|NCT07058363|OTHER|Progressive Relaxation Exercises|"Progressive Relaxation Exercises are defined as a method that provides relaxation throughout the body by voluntary, regular relaxation of large muscle groups in the human body. The main purpose of relaxation exercises is for individuals to feel the difference between tension and relaxation in the muscles and to learn to relax on their own in cases of tension."
224176140|NCT07100171|OTHER|Biological: GM101|Neurosurgical delivery of GM101 to the putamen
224176141|NCT06910254|DEVICE|Overground Robot-Assisted Gait Training (o-RAGT)|This group receives a combination of overground robot-assisted gait training (o-RAGT) and recumbent bicycle training. The o-RAGT is delivered using the Angel Legs M20 wearable exoskeleton with the MW10 suspension system for safety and gait assistance. Each o-RAGT session lasts 30 minutes and is performed overground, with support gradually reduced based on patient tolerance. Recumbent bicycle training uses the TBR9000 device (DRAX, Korea) for 30 minutes per session, focusing on lower limb strength and aerobic conditioning. Resistance is progressively increased based on patient tolerance using an RPE scale (11-14). Training is provided 5 times per week for 4 weeks. The combined program aims to improve muscle mass, physical function, and cardiopulmonary endurance in subacute stroke patients with pre-sarcopenia.
224176142|NCT06910254|DEVICE|Recumbent Bicycle Training|This group receives 30-minute recumbent bicycle training sessions using the TBR9000 device (DRAX, Korea), 5 times per week for 4 weeks. Resistance is gradually increased based on patient tolerance and monitored using an RPE scale (11-14). The intervention targets lower limb muscle strengthening and aerobic conditioning to promote physical recovery. No robotic gait training is provided in this group.
223486304|NCT06839794|BEHAVIORAL|Cognitively challenging physical activity for paediatric cancer patients|"The intervention is a structured cognitively challenging physical activity (PA) program specifically designed for pediatric cancer patients undergoing acute therapy. It stands out from other interventions by combining motor and cognitive tasks simultaneously. Therefore, the target executive functions are inhibition, shifting, and updating. Additionally, the whole body is addressed by enhancing PA.~The PA program spans 12 weeks, with each participant engaging in guided, supervised 45-minute sessions three times weekly. Each session includes a warm-up, the cognitive challenging PA task and a subsequent multimodal sports programme with a cool-down. Exercises are adaptive and tailored to each participant's physical and health condition by offering three levels of intensity in both cognitive and physical difficulty. In addition, exercise counselling in maintenance therapy or aftercare supports young patients to reintegrate into the life after the disease."
224176143|NCT06857890|DRUG|Grammidin with anesthetic neo|Grammidin with anesthetic neo, lozenges, 1 lozenge to be taken once under fed conditions.
224176144|NCT06857890|DRUG|Grammidin with anesthetic, a metered dose topical spray|Grammidin with anesthetic, a metered dose topical spray, 4 sprays to be taken once under fed conditions
223586574|NCT05080634|OTHER|Patients who underwent POEM|chalasia patients were recruited from a single center. The pre- and postoperative assessments included Eckardt scores, GerdQ questionnaire, high-resolution esophageal manometry, esophagogastroscopy and pH monitoring.
223586575|NCT01988545|OTHER|1,5 nmol/kg,GLP-1 sc injection|
223586576|NCT01988545|OTHER|1,5 nmol/kg GLP-1 9-36amide, sc injection|
223586577|NCT01988545|OTHER|Exendin-4 ;10 ug,sc injection|
224176145|NCT05779176|PROCEDURE|Therapeutic hypothermia|The study intervention is therapeutic hypothermia. After intubation, patients assigned to therapeutic hypothermia will receive central venous catheterization through right jugular vein or femoral vein depending on the cooling application and the unique needs, a flexible catheter will be inserted and iced saline was circulated through the multiple balloons of the catheter in a closed-loop design to induce therapeutic hypothermia. This system also has a hydrophilic coating with heparin and a triple-lumen central venous catheter to satisfy the need of fluid or drug infusion, blood draw and central venous pressure monitoring. After central venous catheterization, patients assigned to TH will receive intravascular temperature management to achieve the target temperature of 34-35 °C.
224176146|NCT02897076|DRUG|betamethasone 24 mg|
224176147|NCT02897076|DRUG|12mg betamethasone +placebo|
224176148|NCT02951728|DRUG|Rituximab|
223486305|NCT06839794|OTHER|Physical activity recommendations|The children and adolescents receive general physical activity recommendations at the baseline measurement (t0). At the end of the intervention (after 12 weeks), i.e. after the final measurement (t3), they receive individualised and tailored exercise recommendations based on the test results from t0-t3.
223486306|NCT03420963|BIOLOGICAL|Cord Blood-derived Expanded Allogeneic Natural Killer Cells|Given IV
223486307|NCT03420963|DRUG|Cyclophosphamide|Given IV
223586578|NCT01988545|OTHER|saline|
223586579|NCT03434314|PROCEDURE|Minimally-Invasive Segmental Artery Coil-Embolization|During one single MISACE session 3-7 segmental arteries will be occluded. The procedure is conducted through a peripheral artery access in local anaesthesia. Microcoils or vascular plugs will be used for the occlusion itself.
223586580|NCT02047097|DRUG|dimethyl fumarate|Provided under routine clinical care
223586581|NCT00757692|DRUG|Vandetanib|Vandetanib at 300 mg in combination with Bicalutamide at 50 mg will be administered orally, daily and continuously
223586582|NCT00757692|DRUG|Bicalutamide|Bicalutamide at 50 mg will be administered orally, daily and continuously.
223586583|NCT01293981|BIOLOGICAL|PureGen Osteoprogenitor Cell Allograft|PureGen Osteoprogenitor Cell Allograft.
224176149|NCT02951728|DRUG|Cyclophosphamide|
224176150|NCT02951728|DRUG|Doxorubicin|
224176151|NCT02951728|DRUG|Vincristine|
224176152|NCT02951728|DRUG|Prednisone|
224176153|NCT02951728|DRUG|Decitabine|
224176154|NCT00938197|DRUG|Fimasartan|Fimasartan (1d\~7d) Amlodipine (12d\~14d) Fimasartan + Amlodipine(15d\~21d)
223486308|NCT03420963|DRUG|Etoposide|Given IV
223486309|NCT05895604|BEHAVIORAL|Nurse-Family Partnership|Nurse-Family Partnership is a prenatal and infancy home visiting program providing regular visits to first-time mothers until the child is two years old
223486310|NCT04693403|PROCEDURE|HFNC|40-60l/min humidified oxygen by nasal cannula
223486311|NCT04693403|PROCEDURE|CPAP|Oxygen therapy by boussignac Continuous positive airway pressure face mask
223486312|NCT04693403|PROCEDURE|Standard Oxygen|Oxygen therapy by low flow (upto 15l/min) by Non-rebreather face mask
223486313|NCT06831188|OTHER|daily life exercise group|random games which includes physical activity
223486314|NCT06831188|OTHER|specific type exercise group|10 minutesTreadmill Walk, Playdough or ball squeeze, Towel wring,Throwing to target, catching the tennis ball, bouncing a ball inside borders without losing control, dribbling a ball inside borders without losing control, tandem walk, Single leg stance balance on balance pad or pillow, rolling forward, Jumping exercises, Side stepping, etc
223486315|NCT02469233|BEHAVIORAL|Transdiagnostic Intervention for Sleep and Circadian Dysfunction|The intervention is a modular treatment composed of core modules that are given to all participants and modules that are delivered based on the need/s of the participants. The interventions are all cognitive behavioral.
223486316|NCT04131829|DRUG|Fluoxetine - immediate treatment|Following the Baseline assessment, OCD subjects will be randomized to receive either immediate fluoxetine monotherapy or delayed fluoxetine, after a 6-week placebo lead-in.
223486317|NCT04131829|DRUG|Fluoxetine - delayed treatment|Following the Baseline assessment, OCD subjects will be randomized to receive either immediate fluoxetine monotherapy or delayed fluoxetine, after a 6-week placebo lead-in.
223486318|NCT06792019|BIOLOGICAL|CM313(SC) injection-low dose|Phase IB:CM313(SC) administered at low dose according to the protocol. Phase II:CM313(SC) administered at different doses based on Phase IB's results.
223586584|NCT01798030|OTHER|Vitamin D|N/A, frozen specimen study
223486319|NCT06792019|BIOLOGICAL|CM313(SC) injection-high dose|Phase IB:CM313(SC) administered at high dose according to the protocol. Phase II:CM313(SC) administered at different doses based on Phase IB's results.
223486320|NCT03474107|DRUG|Enfortumab Vedotin|Intravenous infusion
223486321|NCT03474107|DRUG|Docetaxel|Intravenous infusion
223486322|NCT03474107|DRUG|Vinflunine|Intravenous infusion
223486323|NCT03474107|DRUG|Paclitaxel|Intravenous infusion
223486324|NCT02127671|OTHER|IDEAL intervention|
223486325|NCT02127671|OTHER|Control|
223486326|NCT04825522|DRUG|Vancomycin|During spinal surgery, participants will receive intrawound vancomycin powder in their wound before closure.
223486327|NCT05284253|OTHER|Gold microparticles|Metallic gold microparticles, 20-micron diameter, 1 % w/v in petrolatum
223486328|NCT05284253|OTHER|Gold thiosulphate|Gold Sodium Thio Sulphate, 1 % w/v in petrolatum
223586585|NCT00450073|DRUG|ergocalciferol (vitamin D2)|50,000 IU weekly
223586586|NCT00450073|DEVICE|Sperti Del Sol Lamp|5 times a week for 12 weeks
223486329|NCT05395585|PROCEDURE|Manual placental separation|Manual separation of the placenta from uterus
223586587|NCT00450073|DRUG|Vitamin D3|50,000 IU weekly
223586588|NCT06066073|DRUG|Lavender Oil|Twenty drops of lavender oil was added the distal water which fill the vaporizer which were placed in the waiting room. The patients inhaled the vapors of the lavender oil 20 minutes before starting the dental procedures
223586589|NCT06066073|DRUG|Distal Water|The patients inhaled vapors of the distal water in the waiting room 20 minutes before starting dental procedures
223586590|NCT03120377|OTHER|Platform|Whole body vibration training will consist of 12 consecutive weeks with two sessions per week on alternate days. Initially, before training with the vibratory platform, stretches lasting 5 to 10 minutes will be performed, with a series of 60 seconds for each of the following muscle groups: pectorals, sternocleidomastoids, scalenes, quadriceps and ischiatibial muscles. Patients will be monitored through vital signs for follow-up.
223586591|NCT03120377|OTHER|Platform sham|will receive the treatment without the therapeutic effect of the platform, but with vibrating platform connected with the display lit and a sound device coupled with a noise recording generated by the vibration, but without therapeutic purposes.
224176155|NCT00938197|DRUG|Amlodipine|Amlodipine (1d\~10d) Amlodipine (25d\~27d) Fimasartan + Amlodipine(28d\~34d)
224176156|NCT02912962|BEHAVIORAL|Self-Regulation Intervention adapted from the Alert Program ®|
224176157|NCT04728815|BEHAVIORAL|TAU - Phase 1|4-8 weeks of TAU treatment
224176158|NCT04728815|BEHAVIORAL|CAMS - Phase 1|4-8 weeks of CAMS treatment
224176159|NCT04728815|BEHAVIORAL|DBT - Phase 1 and 2|up to 16 weeks of DBT treatment
224176160|NCT04728815|BEHAVIORAL|CAMS - Phase 2|Up to 8 weeks of CAMS treatment
224176161|NCT04728815|BEHAVIORAL|DBT - Phase 2|Up to 8 weeks of DBT treatment
224176162|NCT00508469|DRUG|Travoprost 0.004%/timolol 0.5% fixed combination eye drops (DuoTrav)|One drop in the study eye once daily at 9 p.m. for six months using the Travalert device.
224176163|NCT00508469|DRUG|Travoprost 0.004% eye drops|One drop in the study eye once daily at 9 p.m. for six months using the Travalert device.
224176164|NCT00508469|DRUG|Timolol 0.05% eye drops|One drop in the study eye twice daily at 9 a.m. and 9 p.m. for six months using the Travalert device.
224176165|NCT00508469|DEVICE|Travalert Dosing Aid|Approved device used with study medication to record time of instillation and quantify dosing
224176166|NCT06953479|DRUG|Sofosbuvir / Velpatasvir Oral Tablet [Epclusa]|Individuals will receive a full course (i.e., 84 tablets) of Sofosbuvir / Velpatasvir 400/100mg tablets.
224176167|NCT06953479|OTHER|Community Health Worker|Participants will receive support from a Community Health Worker which may include assistance with basic needs (transportation, housing, employment, vital documents, insurance re-activation) as well as medication adherence, patient navigation, and peer recovery support.
224176168|NCT06949033|DRUG|Neoadjuvant cadonilimab combined with perioperative SOX|Cadonilimab: 10 mg/kg, iv, day 1 of every 3 weeks Oxaliplatin: 130 mg/m², iv, day 1 of every 3 weeks S1: 40-60 mg/m², po, day 1-14 of every 3 weeks (BSA \< 1.25 m², 40 mg \* 2/day, 1.25 m² ≤ BSA \< 1.5 m², 50 mg \* 2/day, BSA ≥ 1.5 m², 60 mg \* 2/day)
224176169|NCT06949033|DRUG|Neoadjuvant placebo plus perioperative SOX|Placebo: iv, day 1 of every 3 weeks Oxaliplatin: 130 mg/m², iv, day 1 of every 3 weeks S1: 40-60 mg/m², po, day 1-14 of every 3 weeks (BSA \< 1.25 m², 40 mg \* 2/day, 1.25 m² ≤ BSA \< 1.5 m², 50 mg \* 2/day, BSA ≥ 1.5 m², 60 mg \* 2/day)
224176170|NCT00957034|DRUG|placebo|placebo patch
224176171|NCT00957034|DRUG|testosterone|300 or 450 micrograms/day transdermal testosterone patch
224176172|NCT06241144|DEVICE|Information and communication technology -based health behavior change support system|Information and communication technology -based health behavior change support system addition to conventional postpartum lifestyle education
223486330|NCT06139653|DEVICE|Moment 1: IMT. Moment 2 CardioBreath.|"Participants will have PowerBreath device for IMT adjusted for 30% with weekly adjustment of maximal inspiratory pressure and will perform the exercise at home for five days/week. They will perform 5 sets of 10 repetitions twice a day for five weeks.~CardioBreathApp group will have the app settings of profile and spontaneous respiratory rate to determine the exercise rate of exercises, which will be performed at home for five days/week during 5 sets of one minute with 30' of rest between the sets twice a day. respiratory rate of exercise will be determined by 80% of spontaneous respiratory rate twice a day for five weeks. An once a week meeting will provide readjustment of respiratory rate to perform exercises. One week washout will be taken between the two interventions in order to cleanse motor memory of respiratory act."
223486331|NCT06139653|DEVICE|Moment 1: CardioBreath and moment 2: IMT.|"CardioBreathApp group will have the app settings of profile and spontaneous respiratory rate to determine the exercise rate of exercises, which will be performed at home for five days/week during 5 sets of one minute with 30' of rest between the sets twice a day. respiratory rate of exercise will be determined by 80% of spontaneous respiratory rate twice a day for five weeks. An once a week meeting will provide readjustment of respiratory rate to perform exercises. One week washout will be taken between the two interventions in order to cleanse motor memory of respiratory act.~Participants will have PowerBreath device for IMT adjusted for 30% with weekly adjustment of maximal inspiratory pressure and will perform the exercise at home for five days/week. They will perform 5 sets of 10 repetitions twice a day for five weeks."
223486332|NCT01599962|DRUG|Cinacalcet|single administration, 90mg
223486333|NCT01599962|DRUG|Placebo|single administration
223486334|NCT06240182|PROCEDURE|conventional surgery|Surgery performed using conventional rotary burs
223486335|NCT06240182|PROCEDURE|piezoelectric device|surgery performed using piezoelectric device.
223486336|NCT01656499|DIETARY_SUPPLEMENT|Arabinoxylanoligosaccharides|
223486337|NCT01656499|DIETARY_SUPPLEMENT|Maltodextrine|
223486338|NCT00142753|BIOLOGICAL|Engerix B|Standard adult dose for A1; increased adult dose for A2. Doses at Entry, Weeks 4 and 24. Non-responders (\<10 IU/mL of antibody at week 28/4 weeks after dose #3) will receive Engerix-B increased adult dose at Week 48.
223586592|NCT02489812|BEHAVIORAL|Music|This cross over trial aimed to analyze the use of music as a distraction resource during children dental treatment, evaluating their cardiac and respiratory frequency. Thirty-four children took part in this study, 16 boys and 18 girls, from 4 to 6 years old, with no previous dental experience, who had two carious lesions on occlusal surfaces of molars,
223586593|NCT00430937|DRUG|Daptomycin|4 mg/kg intravenous once daily
223586594|NCT00430937|DRUG|Vancomycin|1 g intravenous twice daily
223586595|NCT00430937|DRUG|Teicoplanin|400 mg intravenous once daily following a loading dose of 400 mg administered at 0, 12, 24 hours on day one.
223586596|NCT00329927|BIOLOGICAL|Surface Antigen, Inactivated, (Adjuvanted with MF59C.1), form. 2006-07|
223486339|NCT00142753|BIOLOGICAL|Twinrix for ATN 024|Standard adult dosage, taken at Entry, Weeks 4 and 24. Non-responders (\<10 IU/mL of antibody at week 28/4 weeks after dose #3) will receive Engerix-B increased adult dose at week 48.
223486340|NCT00142753|BIOLOGICAL|Recombivax|Dosage at entry and week 24; non-responders ((\<10 IU/mL of antibody at week 28/4 weeks after dose #3) will receive 3rd dose of Recombivax during weeks 48-72.
223486341|NCT00142753|BIOLOGICAL|Twinrix for ATN 025|Doses at Entry and Week 24. Non-responders (\<10 IU/mL of antibody at week 28/4 weeks after dose #3) will receive a dose of Recombivax during week 48-72.
223586597|NCT06368934|PROCEDURE|sub-lobectomy|Combined with previous research and our team's precise neurosurgery concept, we define the surgical strategy based on lobectomy and further preserving the brain parenchyma in functional areas according to anatomical landmarks and electrophysiological boundaries as sub-lobectomy.
223586598|NCT06368934|PROCEDURE|imaging total resection|Imaging total resection (T1-enhanced borders) will met the RANO criteria
223586599|NCT02514005|OTHER|Manual therapy|\- Manual Therapy. Study treatment consists of a comprehensive joint treatment of the lumbar region and the lower limbs that are related to the biomechanics of the knee. In this way, the aim is to globally balance the possible dysfunctions that may exist in the lower lumbar region and sacroiliac joint, hip, knee and ankle.
223586600|NCT02514005|DEVICE|Dry needling|"* Manual therapy. Study treatment consists of a comprehensive joint treatment of the lumbar region and the lower limbs that are related to the biomechanics of the knee. In this way, the aim is to globally balance the possible dysfunctions that may exist in the lower lumbar region and sacroiliac joint, hip, knee and ankle.~* Dry needling (DN). Dry needling is performed in the MTrPs of the vastus lateralis and vastus medialis muscles of the quadriceps."
223586601|NCT02955459|DRUG|VNRX-5133|
223586602|NCT02955459|DRUG|Placebo|
224176173|NCT06154044|BIOLOGICAL|CD34+ stem cell therapy|After 5-days GCSF stimulation all patients will undergo apheresis to obtain CD34+ cell which will subsequently be injected in the target coronary artery using microcatheter.
224176174|NCT02390167|DEVICE|ONYX NEXT BGMS|Untrained Persons WITH Diabetes Use the ONYX NEXT BGMS (Blood Glucose Monitoring System). Subjects tested capillary fingerstick and palm blood (and study staff tested subject fingerstick blood) using the ONYX NEXT BGMS. All BG results were compared to reference method results obtained with subject capillary plasma. Also, study staff tested venous blood from subjects WITH Diabetes and BG results were compared to reference method results obtained from the subjects' venous plasma.
224176175|NCT03200041|PROCEDURE|Blood sample|20 ml blood sample taken from vein in arm
224176176|NCT00876902|DRUG|recombinant P-selectin glycoprotein ligand Ig fusion protein|The active study drug dose includes both a 1 mg/kg IV infusion for the recipient and a 20 mg \[approximately 0.27 mg/kg\] as an ex vivo flush. The doses will be administered via 2 separate infusions of study agent: one 20 mg dose into the portal vein of the liver prior to implantation as an ex vivo flush with Viaspan®; and the second infusion of 1 mg/kg intravenously into the recipient, when technically feasible, prior to the hepatic artery anastomosis. Those patients that experience an intraoperative blood loss of \>10 units, will receive an additional 1 mg/kg IV infusion of study agent at the end of the transplant surgery.
224176177|NCT00876902|DRUG|Viaspan® and saline|Placebo of a volume equivalent to active study drug will be prepared for administration to the control group to help maintain the blind. Those patients that experience an intraoperative blood loss of \>10 units, will receive an additional 1 mg/kg IV infusion of placebo equivalent at the end of the transplant surgery.
224176178|NCT02549261|DRUG|nimotuzumab|the nimotuzumab treatment: 200mg/w weekly, for 16 weeks. A treatment:nimotuzumab for 3 levels (100mg/w, 200mg/w, 400mg/w, weekly, for 16 weeks).
223486342|NCT04381715|GENETIC|Epigenetic signatures|Epigenetic signatures (Dr Sadikovic' lab, London, Ontario, Canada)
223586603|NCT04028466|DRUG|Vonoprazan|Patients will be randomized to receiving vonoprazan 20mg tablet or omeprazole 40mg capsule, either of which will be taken 30 minutes before the first meal of the day for 14 days
224176179|NCT02549261|DRUG|Cisplatin|Concurrent Chemotherapy,50mg/m2 (d1,d8),4 weeks/cycle, for 2 cycles. the consolidation chemotherapy: Cisplatin: 50mg/m2 (d1,d8)4 weeks/cycle, for 2 cycles.
224176180|NCT02549261|DRUG|Etoposide|"Concurrent Chemotherapy, Cisplatin: Etoposide: 50mg/m2 (d1-5)，4 weeks/cycle, for 2 cycles.~the consolidation chemotherapy:Etoposide: 50mg/m2 (d1-5)，4 weeks/cycle, for 2 cycles."
224176181|NCT02549261|RADIATION|radiotherapy|the tolerance trial of treatment A and B of treatment;95％PTV,60-66Gy/30-33/fraction,6-7weeks.
224176182|NCT03622294|DEVICE|Bella Blankets protective coverlets|Bella Blankets protective coverlets is a Class II 510(k) Cleared (2008) single-use, adhering, non-woven fabric sheet applied to the mammography equipment receptor plate to provide a more comfortable mammogram.
224176183|NCT02033369|DRUG|Pramipexole|Dose will be started at 0.125 mg bid, and increased by 0.25 mg/day every 3-4 days to a target range of 1.0 - 2.5 mg/day.
224176184|NCT02249273|OTHER|Diagnostic approaches|General practitioners will register the diagnostic process in patients with a suspected urinary tract infection
223586604|NCT04028466|DRUG|Omeprazole|Patients will be randomized to receving vonoprazan 20mg tablet or omeprazole 40mg capsule, either of which will be taken 30 minutes before the first meal of the day for 14 days
224176185|NCT01928186|DRUG|Fluorothymidine F-18|Undergo FLT PET
224176186|NCT01928186|PROCEDURE|Positron Emission Tomography|Undergo FLT PET
224176187|NCT01928186|OTHER|Laboratory Biomarker Analysis|Correlative studies
224176188|NCT01928186|DRUG|Run-in (short pre-surgery course) of endocrine-targeted therapy|Patients undergo run-in (short pre-surgery course) of endocrine-targeted therapy with aromatase inhibitor between the two (baseline and repeat) FLT PET scans. This is not an experimental therapy. This is a standard of care therapy that patients will continue after surgery, when the study is completed.
224176189|NCT02286206|DRUG|Clozapine|One-half baseline dose po bid (or one-third baseline dose po qam and two-thirds baseline dose po qhs at the discretion of the treating clinicians and principal investigator)
224176190|NCT04968327|OTHER|Micro-osteoperforations (MOPs)|MOPs included shallow perforations of the buccal cortical plate surrounding the tooth that requires orthodontic tooth movement, with no flap reflection was performed using a surgical bur using the special calibrated device called PROPEL
224176191|NCT04968327|OTHER|Conventional canine retraction|using nickel-titanium (NiTi) closed coil-springs delivering a force of 150 grams per side
224176192|NCT04114227|BEHAVIORAL|Acceptance and Commitment Therapy adapted for Cystic Fibrosis (ACT with CF)|Subjects learn new ways to manage uncomfortable experiences and feelings and to engage in positive behaviors
224176193|NCT04114227|BEHAVIORAL|Supportive Psychotherapy (Treatment as Usual Control)|Subjects talk about their experiences to date in a cohort of adult Cystic Fibrosis patients.
224176194|NCT04540627|DRUG|Palivizumab|Liquid solution in sterile water for injection (final concentration of 20mg/mL), intravenous infusion, single dose of 8mg/kg or 15mg/kg, administered at a rate of 1mL/min
223586605|NCT05521633|DRUG|Metformin and Pioglitazone|Every participant in Group-A took tablet metformin 500 mg daily and every participant in Group-B took tablet pioglitazone 30 mg daily.
223586606|NCT02668029|DRUG|oxygen|information already included in arm/group descriptions.
224176195|NCT04540627|DRUG|Placebo|Sodium Chloride 0.9% Solution (Normal Saline), intravenous infusion, single dose of 0mg/Kg, administered at a rate of 1mL/min
224176196|NCT04540627|OTHER|RSV-A Memphis 37b virus|Single Intranasal Virus Dose (challenge dose is approximately 4.5log10 PFU)
224176197|NCT03220620|OTHER|GDT|individualized fluid therapy
223486343|NCT03555786|OTHER|minimum effective volume|"The determination of MEV90 and its 95% confidence interval (CI) will be based on a biased coin up-and-down sequential design"
223586607|NCT02668029|DRUG|medical air|Placebo
223486344|NCT03600792|GENETIC|whole exome sequencing (WES)|"WES analysis will be performed in the UF de Génomique du Développement (APHP, Pitié-Salpêtrière hospital), using DNA extracted from amniotic fluid for the foetus (also used for chromosomal studies) and DNA extracted from peripheral blood for both parents. There will be no supplemental invasive sampling for this study. The result of WES will be returned during a consultation with the geneticist and the associated prognosis will be explained in case of molecular diagnosis"
223486345|NCT00764517|DRUG|Cladribine|Given IV
223486346|NCT00764517|OTHER|Laboratory Biomarker Analysis|Correlative studies
223486347|NCT00764517|BIOLOGICAL|Rituximab|Given IV
223486348|NCT00764517|DRUG|Vorinostat|Given PO
223486349|NCT02090257|BEHAVIORAL|TRANSIT|Educational Modules, staff follow up.
223486350|NCT00520468|DRUG|Erythropoietin|40,000 units injected under the skin (SQ) weekly
223617614|NCT00884364|BEHAVIORAL|Fatigue counseling|The patients will receive a counseling regarding the causes of fatigue, how to cope with this symptom, and general recommendations about exercise. However, they will not participate at a structured exercise program.
224176198|NCT02502591|DRUG|Pudendal Nerve Block|An injection of local anaesthetic (3 ml of 0.25% bupivacaine) will be administered around the trunk of the pudendal nerve.
224176199|NCT02048501|OTHER|Resting Metabolic Rate (RMR)|Each subject will have their resting metabolic rate (RMR) measured. The RMR is assessed by indirect calorimetry measured with the metabolic cart. Oxygen consumption is converted into kilocalories. Subjects will be advised to avoid strenuous exercise for at least 48 hours prior to participation in the study and to sleep at least 6-8 hours the night before. Smoking and consuming caffeine will be prohibited 12 hours before the study begins.
224176200|NCT02048501|OTHER|Duel-energy x-ray absorptiometry (DEXA)|During a separate appointment on the same day, or within 7 business days if same day is not possible, a body compositions analysis, including fat mass and fat free mass, will be assessed by dual-energy x-ray absorptiometry (DEXA), using a Hologic system.
223486351|NCT00520468|DRUG|Cyclosporin A|300 mg (tablets) by mouth daily for 6 months
223486352|NCT00520468|DRUG|G-CSF|300 mcg injected under the skin (SQ) two times per week
223486353|NCT00520468|DRUG|Prednisone|60 mg per day for 7 days, taper over 1 month
223486354|NCT01433913|DRUG|metformin hydrochloride|Given PO
223486355|NCT01433913|OTHER|placebo|Given PO
223486356|NCT01433913|OTHER|laboratory biomarker analysis|Correlative studies
223486357|NCT05499936|DRUG|68Ga-FAPI|68Ga-FAPI were injected into the patients before the PET/CT scans
223486358|NCT03115970|PROCEDURE|capillary and venous lactate level measurement|capillary and venous lactate level measurement
223486359|NCT02556450|DRUG|Spironolacton|Administration of Spironolacton 25 mg per day
223486360|NCT05743855|DIETARY_SUPPLEMENT|Nutritional Supplement|Nutritional Supplement + Chiropract sessions
223486361|NCT05743855|OTHER|Placebo|Placebo + Chiropractic sessions
223486362|NCT01890577|DRUG|Aranesp|Observational study; minimum single dose of Aranesp required for eligibility; no protocol-specified regimen; study must not influence normal clinical practice.
223586608|NCT03567018|DEVICE|MRI Scan|Study participants will be scanned with a 3.0 Tesla Phillips Ingenia CX whole body clinical MRI system located at the Wright Center of Innovation at The Ohio State University Medical Center. Anatomical and angiographic MR images will be acquired for one of the most commonly used flap surgery donor perforators including but not limited to: the deep inferior epigastric perforators (DIEP); the superior gluteal arter perforators (SGAP); the inferior gluteal artery perforators (IGAP); the thoracodorsal artery perforators (TDAP); the anterolateral thigh perforators (ATL).
223586609|NCT04922905|OTHER|NEURO +|"The participants will undergo several questionnaires after their classic clinical evaluation allowing to determine the Clinical Assessment Scale in Autoimmune Encephalitis (CASE) score :~* The dissociative peri-traumatic experiences questionnaire (Birmes et al., 2005)~* the Peri traumatic distress inventory (Jehel et al., 2005)~* and the Shortness, Trembling, Racing, Sweating (STRS) (Bracha et al., 2004)~Neuro + patients will also have a Brain MRI, cerebrospinal fluid analysis, EEG, as well as an ambulatory sleep recording and electromyography depending on the symptoms observed."
224176201|NCT02048501|OTHER|Visual Analog Scale (VAS)|Subjects will be asked to complete a 100-mm Visual Analog scale (VAS) to assess their appetite. The VAS will be completed prior to the meal stimulation test and at 30-minutes, 1-hour, 90 minutes and 2-hours after the meal. The VAS will contain questions assessing food intake, appetite, and hunger.
223486363|NCT04159155|RADIATION|External Beam Radiation|Radiation therapy given outside the patient to a particular part of the body.
223486364|NCT04159155|DRUG|Niraparib|Oral drug
223486365|NCT04159155|RADIATION|Vaginal high-dose rate brachytherapy|Internal radiation to the vagina
223486366|NCT04159155|OTHER|Observation - no drugs|Observation
223486367|NCT06847230|DEVICE|Dailies total 1 contact lenses|successful refit into dt1 will be determined
223586610|NCT04922905|OTHER|NEURO -|"The participants will undergo several questionnaires after their classic clinical evaluation allowing to determine the Clinical Assessment Scale in Autoimmune Encephalitis (CASE) score :~* The dissociative peri-traumatic experiences questionnaire (Birmes et al., 2005)~* the Peri traumatic distress inventory (Jehel et al., 2005)~* and the Shortness, Trembling, Racing, Sweating (STRS) (Bracha et al., 2004)"
223486368|NCT00469547|OTHER|62% ethanol in emollient gel|62% ethanol in emollient gel used as a topical male microbicide
223486369|NCT00469547|DRUG|Placebo|15% ethanol in emollient gel used as a topical male microbicide
223486370|NCT00469547|OTHER|15% ethanol in emollient gel|15% ethanol in emollient gel used as a topical male microbicide
223486371|NCT04433598|BEHAVIORAL|Nutrition Education Intervention|Each participant were interviewed by face- to- face using Arabic language, after 1 hour when they finish their assessment by medical doctors. The researcher was collected the data from the participants in a special room for 10-15 minutes, after only one hour of completing the necessary tests with the treating physician to allow participants to go for a meal before the nutrition education starts.12 classes (1:30 hour each session):- 100 participants / 5 days = 20 participants each class was offered twice per day to cover the number of participants and to enhance attendance for them can not attend at first morning. the classes was designed according to health belief model (HBM). The topics were about the type 2 diabetes and its complications,the benefits of diabetes plate and eating vegetables before carbohydrates.
223486372|NCT05360953|DRUG|Clonidine|All patients enrolled establish their individually tolerable dose by dose Titration. Dosage up to a maximum of 0.375 clonidine. Using capsules of 0,075 mg clonidine.
223486373|NCT05360953|DRUG|Doxazosin|"All patients enrolled establish their individually tolerable dose by dose. Dosage up to a maximum of 10 mg doxazosin. Using capsules of 2 mg doxazosin.~Titration."
223486374|NCT05360953|DRUG|Placebo|All patients enrolled establish their individually tolerable dose by dose Titration. Dosage up to a maximum of 5 capsules. Using capsules of placebo.
223486375|NCT00693264|DIETARY_SUPPLEMENT|Hoodia Gordonii|750 mg capsule will be taken one time
223486376|NCT00693264|DIETARY_SUPPLEMENT|Placebo|Placebo capsule to be taken one time
223486377|NCT03813654|BEHAVIORAL|8-h Afternoon-Evening Sleep|8 consecutive hours time in bed during the afternoon/evening.
223486378|NCT03813654|BEHAVIORAL|8-h Free Sleep|8 consecutive hours time in bed at any time.
223486379|NCT01044667|BEHAVIORAL|GI and Quality of Life Assessment|
223486380|NCT03609840|DRUG|Thiotepa|Given IV
224176202|NCT02048501|OTHER|Meal Stimulation Test|Subjects will consume a mixed-nutrient liquid meal 240-ml in 20 minutes. Prior to the meal stimulation test, a baseline 10-ml blood sample will be collected. The, during the meal stimulation test, 10-ml venous blood sample will be collected at 30 minute intervals up to two hours, for a total of 5 samples including the baseline sample. The blood samples will be used to measure fasting blood glucose, adipokines, myokines, gut hormones, amino acids, bile acids, vitamin B and vitamin D analysis with the appropriate assay method.
224176203|NCT03618576|PROCEDURE|Balance specific exercise|Balance specific exercise consists of total 10 days' physical therapy (PT) sessions (twice per day for 60 min) after surgery. It will be conducted with a computed posturographic system for diagnostics of balance and movement skills (Balance Master® System NeuroCom®) designed to objectively quantify balance and postural function of different origin. PT (weight-bearing, strengthening, gait training, aerobic, and functional exercises) was gradually increased based on the patient's functional level. Intensive patient education by multidisciplinary rehabilitation members was also provided.
224176204|NCT02308839|DEVICE|GORE® EXCLUDER® Endoprosthesis|Endovascular therapy to treat abdominal aortic aneurysms
224176205|NCT00610922|DIETARY_SUPPLEMENT|Docosahexaenoic acid (DHA)|DHA 20 mg per day through 12 months of life
224176206|NCT04951596|OTHER|Investigate the current situation|Investigate the current situation of infusion treatment for acute and critical patients in 2 hospitals in the province
224176207|NCT05584917|BEHAVIORAL|tegner acticity scale|phone call to complete the tegner activity scale after surgery
224176208|NCT03102541|OTHER|None intervention|
224176209|NCT01401179|DRUG|cefazolin, erythromycin, clarithromycin|Antibiotics regimen was one of cefazolin or cefazolin plus erythromycin or cefazolin plus clarithromycin. Intravenous 1g cefazolin was given every 6 hours after negative result skin test for allergic reaction. With cefazolin plus erythromycin group or cefazolin plus clarithromycin, cefazolin was given with same protocol and 250mg oral erythromycin every 6 hours or 500mg oral clarithromycin every 12 hours was added. All antibiotics were given for 7 days or until delivery.
224176210|NCT00205010|PROCEDURE|Lymphoscintigraphy|
223586611|NCT04190004|DRUG|Vasopressins|40 International units of vasopressin or placebo will be given intra-nasally. The order of the administration will be counterbalanced
224176211|NCT01265719|OTHER|No intervention other than routine medical care|Subjects continuously treated with Latanoprost for at least one month Latanoprost treatment during the study period.
224176212|NCT01265719|OTHER|No intervention other than routine medical care|Subjects not treated with any topical prostaglandin analogues or continuously treated with topical prostaglandin analogues for less than one month before the baseline examination, and unlikely to be treated with topical prostaglandin analogues during the study period.
223486381|NCT04330872|DRUG|Enteric Coated Aspirin Tablet|Study participants will be assigned to receive either EC Aspirin and will be required to continue taking them throughout the study (three days).
223486382|NCT04330872|DRUG|Plain Aspirin|Study participants will be assigned to receive either Plain Aspirin and will be required to continue taking them throughout the study (three days).
223486383|NCT04991961|DIAGNOSTIC_TEST|withdraw antihypertensive drugs|patients need to withdraw of all antihypertensive drugs or change therapy to Doxazosin/Diltiazem for 2-4 weeks prior
223486384|NCT06431607|BIOLOGICAL|Flu Seasonal mRNA Formulation 1|1 dose of Flu mRNA Formulation 1 is administered intramuscularly in the non-dominant upper deltoid to YA participants at Day 1.
223486385|NCT06431607|BIOLOGICAL|Flu Seasonal mRNA Formulation 2|1 dose of Flu mRNA Formulation 2 is administered intramuscularly in the non-dominant upper deltoid to YA at Day 1.
223486386|NCT06431607|BIOLOGICAL|Flu Seasonal mRNA Formulation 3|1 dose of Flu mRNA Formulation 3 is administered intramuscularly in the non-dominant upper deltoid to YA participants at Day 1.
223486387|NCT06431607|BIOLOGICAL|Flu Seasonal mRNA Formulation 4|1 dose of Flu mRNA Formulation 4 is administered intramuscularly in the non-dominant upper deltoid to YA participants at Day 1.
223486388|NCT06431607|BIOLOGICAL|Flu Seasonal mRNA Formulation 5|1 dose of Flu mRNA Formulation 5 is administered intramuscularly in the non-dominant upper deltoid to OA participants at Day 1.
223486389|NCT06431607|BIOLOGICAL|Flu Seasonal mRNA Formulation 6|1 dose of Flu mRNA Formulation 6 is administered intramuscularly in the non-dominant upper deltoid to OA participants at Day 1.
223486390|NCT06431607|BIOLOGICAL|Flu Seasonal mRNA Formulation 7|1 dose of Flu mRNA Formulation 7 is administered intramuscularly in the non-dominant upper deltoid to OA participants at Day 1.
224176213|NCT04411316|COMBINATION_PRODUCT|Catheter directed thrombolysis plus anticoagulation|"Patients will be randomized to pharmacomechanical catheter directed thrombolysis plus anticoagulation.~PCDT will be AngioJet along with alteplase."
223486391|NCT06431607|BIOLOGICAL|Flu Seasonal mRNA Formulation 8|1 dose of Flu mRNA Formulation 8 is administered intramuscularly in the non-dominant upper deltoid to OA participants at Day 1.
223486392|NCT06431607|COMBINATION_PRODUCT|Active Comparator 1|1 dose of active comparator 1 is administered intramuscularly in the non-dominant upper deltoid to YA participants at Day 1.
224176214|NCT04411316|DRUG|Anticoagulation|Patients will receive anticoagulation alone. Anticoagulation will be heparin only.
224176215|NCT03604016|DRUG|Besifovir dipivoxil|Besifovir dipivoxil 150 mg
224176216|NCT03604016|DRUG|L-carnitine|Besifovir dipivoxil 150 mg
224176217|NCT03604016|DRUG|Tenofovir Alafenamide|Tenofovir Alafenamide 25mg
223486393|NCT06431607|COMBINATION_PRODUCT|Active Comparator 2|1 dose of active comparator 2 is administered intramuscularly in the non-dominant upper deltoid to OA participants at Day 1.
223486394|NCT06431607|BIOLOGICAL|Flu Seasonal mRNA Formulation 9|1 dose of Flu mRNA Formulation 9 is administered intramuscularly in the non-dominant upper deltoid to YA participants at Day 1.
223486395|NCT06431607|BIOLOGICAL|Flu Seasonal mRNA Formulation 10|1 dose of Flu mRNA Formulation 10 is administered intramuscularly in the non-dominant upper deltoid to OA participants at Day 1.
223586612|NCT04190004|DRUG|Placebo|40 International units of vasopressin or placebo will be given intra-nasally. The order of the administration will be counterbalanced
223586613|NCT03973905|OTHER|Not applicable / dataset analysis|Not applicable / dataset analysis
224176218|NCT04162717|BEHAVIORAL|The Effect of Telephone Symptom Triage Protocols on Symptom Management, Quality of Life and Self-Care Maintenance in Patients with Cancer Who Applied Systemic Treatment|"Symptom management, quality of life and self-maintenance were assessed by scales at the first interview and 3 months later.~Intervention group received symptom triage application with telephone, which consisted of guiding in line with symptom triage protocols. The patients who were included in the intervention were followed up by telephone on the 3rd, 7th and 10th day of after chemotherapy total of nine times during three chemotherapy cycles."
224176219|NCT03981523|DRUG|Benznidazole|50 mg and 100 mg tablet taken orally
224176220|NCT03981523|DRUG|Nifurtimox|120 mg tablet taken orally
224176221|NCT03176823|DEVICE|CellAegis Technologies autoRIC device|The autoRIC device from CellAegis technologies will be applied as per the manufacturer's instructions on an upper extremity. The device will automatically inflate and deflate a blood pressure cuff to supra-systolic blood pressures, maintaining an occlusive pressure for a period of five minutes, followed by five minutes of re-perfusion with cuff deflation, completing a ten minute cycle. This cycle will repeat four times for a cumulative total of twenty minutes of occlusive conditioning over forty minutes of intervention time.
224176222|NCT03176823|OTHER|Best Practice Management of Traumatic Brain Injury|Standard treatment of TBI in a dedicated trauma-neuro intensive care unit will include a tiered management strategy corresponding to many published treatment algorithms, including the American College of Surgeons Trauma Quality Improvement Program (ACS TQIP) guidelines for the management of intra-cranial hypertension. Standard practice without limitations will be applied to both cohorts of patients in this study.
224176223|NCT02831595|DEVICE|GKS Prime Flex Bioloy by Permedica, a TiNbN coated fixed-bearing cruciate-retaining total knee prosthesis|
224176224|NCT05829018|DIAGNOSTIC_TEST|Mixed meal test|Nutridrink 270 mL 405 kcal, 49 Energy% carbohydrates, 35 Energy% fat, 16 Energy% protein, vitamins, and minerals
224176225|NCT03031613|PROCEDURE|PEEP group|Application of 5cmH20 positive end expiratory pressure
224176226|NCT03031613|PROCEDURE|ZEEP group|No application of positive end expiratory pressure
224176227|NCT03051906|BIOLOGICAL|Durvalumab|Durvalumab given intravenously at 1500 mg every 4 weeks; first two cycles concurrent with RT + cetuximab, 6 cycles after the end of RT as adjuvant treatment; treatment will be continued for a maximum of 8 months (concurrent phase included).
224176228|NCT03051906|BIOLOGICAL|Cetuximab|Cetuximab given intravenously weekly at 400mg/m2 loading dose 1 week before RT start, then 250 mg/m2 weekly thereafter.
224176229|NCT03051906|RADIATION|Intensity modulated radiation therapy (IMRT)|A total dose of 69.9 Gy will be given with 2.12 Gy dose per fraction, delivered in 33 fractions over 7 weeks.
224176230|NCT02114736|PROCEDURE|Tenotomy of the proximal rectus femoris tendon|Surgical release of the proximal tendon of the rectus femoris
224176231|NCT02114736|DRUG|Botulinum Toxin injection in the rectus femoris muscle|Injections of 200U of Botox in the rectus femoris muscle with a 2ml/100U dilution
224176232|NCT00627913|PROCEDURE|Healon 5 injection|Healon 5 (2.3% Sodium hyaluronate) ophthalmic viscoelastic device will be injected into the anterior chamber as needed for pupillary dilation and adequate cataract extraction with intraocular lens placement.
224176233|NCT00627913|PROCEDURE|Retrobulbar anesthetic injection|3-4cc of anesthetic (1% lidocaine/0.75% bupivicaine) will be injected with a 25 gauge needle into the extraocular muscle cone prior to patient and microscope positioning. Cataract extraction with intraocular lens placement will then proceed in standard fashion.
224176234|NCT04805242|OTHER|Dextrose Prolotherapy Injection|"Subacromial injection: 5 cc solution (15% dextrose + saline + 1% lidocaine solution) will be injected into the subacromial bursa using a sterile 21 gauge injector.~Extra-articular injection: Previously marked using a sterile 27 gauge injector (dental needle); A total of 10 cc solution (15% dextrose + saline + 1% lidocaine solution) will be injected into the infraspinatus, teres minor, supraspinatus insertion on the tuberculum majus, the subscapularis insertion on the tuberculum minus, the coracoid process and the long head of the biceps.~As a home exercise program, shoulder range of motion and stretching, shoulder isometric and isotonic strengthening exercises will be given at least three days a week with 3 sets of 10 repetitions."
224176235|NCT04805242|OTHER|Saline Injection|"Subacromial injection: 5 cc solution (saline + 1% lidocaine solution) will be injected into the subacromial bursa using a sterile 21 gauge injector.~Extra-articular injection: 5 cc solution (saline + 1% lidocaine solution) will be injected to the attachment areas of the previously marked tendons to the bone using a sterile 30 gauge injector.~As a home exercise program, shoulder range of motion and stretching, shoulder isometric and isotonic strengthening exercises will be given at least three days a week with 3 sets of 10 repetitions."
224176236|NCT05638009|DIETARY_SUPPLEMENT|Salt substitute 66%33%|Salt substitute composed of 66% potassium chloride and 33% sodium chloride
224176237|NCT05638009|DIETARY_SUPPLEMENT|Salt substitute 33%/66%|Salt substitute composed of 33% potassium chloride and 66% sodium chloride
224176238|NCT00283153|BEHAVIORAL|Facial Affect Recognition Training|A series of pictures of faces displaying various emotions are presented one at a time using a computerized training program.Participants are taught to recognize how emotions affect facial features such as the mouth and eyes.Participants are also taught how to recognize their own emotions.
224176239|NCT00283153|OTHER|Stories of Emotional Inference|Participants are presented with a series of short stories one at a time. Each story presents various contextual cues regarding the emotions the characters are likely to experience. Participants learn to connect the cues to specific emotions.
224306479|NCT06462859|OTHER|Sensory Integration Therapy Group|The experimental group received sensory integration therapy in addition to the NDT program. The NDT program is customized for each child, featuring a unique blend of static and dynamic balance exercises, coordination exercises, mobility exercises, and strength training exercises. Participants attended 45-minute NDT and sensory integration sessions three times a week for 8 weeks. Sensory integration therapy, visual perception activities (block design, shape recognition in pictures, puzzles, matching geometric shapes and letters, numbers and classification exercises), body awareness activities (showing body parts, drawing life-size drawings, turning left and right, recognizing body parts by touching ), tactile perception exercises (feeling and touching various textures and shapes) and visual-motor coordination training (eye tracking exercises, activities with moving objects and panel activities).
223586614|NCT03247959|BEHAVIORAL|Video game distraction and video distraction|video game distraction and video distraction will be advocated during the extraction procedure
223486396|NCT06431607|COMBINATION_PRODUCT|Active Comparator 3|1 dose of active comparator 3 is administered intramuscularly in the non-dominant upper deltoid to YA participants at Day 1.
223486397|NCT06431607|COMBINATION_PRODUCT|Active Comparator 4|1 dose of active comparator 4 is administered intramuscularly in the non-dominant upper deltoid to OA at Day1.
223486398|NCT01208051|DRUG|Cediranib|Given PO
223486399|NCT01208051|DRUG|Cediranib Maleate|Given PO
224176240|NCT04335929|BEHAVIORAL|Internet-based Cognitive Behavior Therapy|The intervention offered is a CTB-based internet intervention, providing an opportunity to learn about new ways of coping with tinnitus during everyday life. It is 8-week long e-learning intervention, with new modules introduced weekly and assignments are given to practice techniques learned.
224176241|NCT02318082|DRUG|Interleukin-2|
223486400|NCT01208051|OTHER|Laboratory Biomarker Analysis|Correlative studies
223486401|NCT01208051|DRUG|Lenalidomide|Given PO
223486402|NCT02646059|OTHER|Text message|Text messages would be sent via the messaging platform of Guangzhou Blood Center. The feedback of sending status (received, failed to receive, or unknown) would be marked on every number. Four to six months follow-up, blood donation rate would be checked.
223486403|NCT02646059|OTHER|Telephone|Status (response, no answer, line issue, wrong number or refused to be interviewed) of every donor in this groups would be marked. Four to six months follow-up, blood donation rate would be checked.
223486404|NCT06290817|DRUG|Orelabrutinib combined with R-CDOP regimen|All participants were treated with the orelabrutinib combined with R-CHOP regimen (O-RCDOP). The treatment plan involved orelabrutinib tablets at 150mg QD (once daily) from day 1 to day 21, Rituximab at 375mg/m2 on day 1; Cyclophosphamide at 750mg/m2 on day 1; Liposomal Doxorubicin at 30mg/m2 on day 0; Vincristine at 25mg/m2 on day 1 (maximum dose 40mg); and Prednisone at 100mg from day 1 to day 5. The treatment cycles were set every 21 days for a total of 6-8 cycles. Dose adjustments were made for elderly patients for Cyclophosphamide and Liposomal Doxorubicin based on age: 70-80% of the dose for those aged 70-80 years old, and 50-60% of the dose for those older than 80 years.
223486405|NCT03277040|OTHER|CSA membership|Bi-weekly fresh food delivery
223486406|NCT02515786|OTHER|oxygen humidification|humidification for oxygen delivered by nasal catheter
223486407|NCT00455624|DRUG|Androgen deprivation therapy|According to standard medical care
223486408|NCT01691664|RADIATION|Only radiation therapy|Patients only radiation therapy after surgery
223486409|NCT01691664|OTHER|Radiation therapy plus DC-CIK cellular therapy|Patients receive radiation therapy plus DC-CIK cellular therapy after surgery
223486410|NCT01821313|OTHER|Moderate exercise|
224176242|NCT04471532|BEHAVIORAL|Behavior change intervention|"It is a 3-month, multimodal, minimal contact, pedometer-driven, behavior change intervention to promote and support physical activity, that is initiated 3 months after THA. There is one initial, physiotherapist-led, face-to-face, physical activity counselling including 1) a brief motivational interviewing regarding physical activity, 2) patient education regarding physical activity after THA including recommendations and safety based on an orthopedic surgeon guided video and leaflet, 3) handling out pedometer and educational material i.e. a practice-oriented leaflet with advice on how to use a pedometer, a step-calendar and goal setting as well as strategies to incorporate physical activity into daily life. This initial counselling is followed by two, physiotherapist-led, telephone-assisted counselling after respectively three and seven weeks."
224176243|NCT03287726|DIETARY_SUPPLEMENT|probiotics|NYCOPRO, a multistrain probiotic (7 strains of Lactobacilli and Bifidobacteria) sold in the Norwegian pharmacies. 2 capsules/day (one with lunch and one with dinner). 2 text messages daily as a reminder. Follow up meeting at ObeCe (St. Olavs hospital) every month with a research nurse, for weighing, blood pressure measurement and collection of probiotics dose for the following month.
223486411|NCT01821313|OTHER|High Intensity Interval Exercise|
223486412|NCT02433717|DRUG|Paliperidone ER|Fixed dose (9 mg/day) of paliperidone ER will be given in the first two weeks of trial (from day 1 to day 14). Since the third week (day 15), the dosage can be adjusted in the range of 6 to 12 mg per day.
223486413|NCT00131300|DEVICE|Synvisc (hylan G-F 20)|
223486414|NCT02476162|DEVICE|iHealth Wireless Blood Pressure Monitor|"Participants will be provided with an iHealth Wireless Blood Pressure (BP) Monitor and instructions for proper use (based on a standard protocol). The iHealth device pairs easily with a cell phone or other mobile device equipped with the iHealth app (freely available on app stores for both Apple and Android devices). Participants place the cuff on their arm and press start on their mobile device. The device measures BP using the oscillometric method and automatically downloads measurements and timing to a cloud-based server.~Participants will be educated that individual BP readings can be highly variable and that any one high or low reading has little or no significance. They will also be encouraged not to measure their blood pressure more than twice in the morning and twice in the evening."
223486415|NCT05564923|DRUG|there is no intervention|there is no intervention
223486416|NCT06486701|BEHAVIORAL|have a sing|Singing
223486417|NCT00552838|BEHAVIORAL|Academic Detailing by the Antimicrobial Utilization Team (AUT)|Physicians caring for patients who were prescribed one of three antimicrobials were randomly assigned to academic detailing by the AUT. The AUT would review the antimicrobial prescription and provide consultation to the ordering physician if the prescription is appropriate and provide feedback on a better alternative if inappropriate.
223486418|NCT01038765|BEHAVIORAL|Mindfulness Based Cognitive Therapy|8-weeks group based intervention of mindfulness and cognitive behavioural techniques
223486419|NCT03931122|DEVICE|Ear Size Based Method (Ambu® AuraOnce™ Laryngeal Mask Airway)|"The Laryngeal Mask Airway (LMA) is one of the devices used to maintain airway during general anesthesia. Its appropriate size is selected according to patients body weight as recommended by the manufacturer.~However its appropriate size can also be selected via several other methods and one of them is patients external ear size. In this study the investigators will compare external ear size based method for LMA selection with the standard weight based method for LMA size selection.~Vertical Ear length: will be measured from the most dependent portion of the lobule to the furthest portion of the auricle.~Horizontal Ear length (width): from the tragus to the furthest part of the helix horizontally.~Dimension(cm2): Vertical length (L) × Horizontal length (width-W)~LMA Size LMA Cuff Length (cm) corresponding to vertical ear length.~LMA Cuff Width (cm) corresponding to horizontal ear width."
223586615|NCT01471210|DRUG|Urelumab (BMS-663513)|
223486420|NCT00107588|BEHAVIORAL|Reinforcement for homework completion|Provides contingent reinforcement for engaging in homework activities designed to enhance coping skills
223486421|NCT00107588|BEHAVIORAL|Reinforcement for Abstinence|Provides contingent reinforcement for submitting marijuana-free urine specimen
223486422|NCT00107588|BEHAVIORAL|Case Management|Will control for the effect of therapist-client contact by providing supportive case management as an active control condition.
224176244|NCT03287726|DIETARY_SUPPLEMENT|placebo|Placebo 2 capsules/day (one with lunch and one with dinner). 2 text messages daily as a reminder. Follow up meeting at ObeCe (St. Olavs hospital) every month with a research nurse, for weighing, blood pressure measurement and collection of probiotics dose for the following month.
223486423|NCT03868800|OTHER|SDM-DC|The SDM-DC intervention is designed for patients with kidney failure who must make a decision regarding type of dialysis: haemodialysis or peritoneal dialysis. SDM-DC consists of patient and his or her relative(s) being given a patient decision aid called 'Dialysis choice' and booked for meetings with a dialysis coordinator. There were optional videos describing other patients' experiences making this decision. The dialysis coordinators were trained in the why, what and how in relation to SDM-DC and to deliver the intervention by tailoring to patients' needs and using three different communication skills: mirroring, active listening and value clarification.
223486424|NCT02107898|DRUG|Placebo (for alirocumab)|Solution for injection, one subcutaneous injection in the abdomen, thigh, or outer area of upper arm with an auto-injector.
223486425|NCT02107898|DRUG|Alirocumab|Solution for injection, one subcutaneous injection in the abdomen, thigh, or outer area of upper arm with an auto-injector.
223486426|NCT02107898|DRUG|Lipid-Modifying Therapy (LMT)|Statin (pravastatin, simvastatin, fluvastatin, atorvastatin, pitavastatin, rosuvastatin) at stable dose with or without other LMT as clinically indicated.
223486427|NCT02569983|OTHER|Observational cohort|No intervention - observational study
223486428|NCT01555775|DIETARY_SUPPLEMENT|P-CHO supplement|In the first trial, this group will drink a protein (P)-carbohydrate (CHO) supplement and in the second trial the fruit milk shake.
223486429|NCT01555775|DIETARY_SUPPLEMENT|Fruit Milk Shake|The fruit content of the milk shake will be 100 g of strawberry and the amount of banana necessary to guaranty 0.8-1.2 g CHO • kg-1 BW • h-1.
223486430|NCT04272515|OTHER|blood sampling|collection of blood sample for preparation of DNA
223486431|NCT04272515|OTHER|skin biopsy sampling|preparation of primary cultures of dermal fibroblasts from skin biopsy sample
223486432|NCT04272515|OTHER|explanted liver of BA patients sampling|cryoconservation of liver tissue for molecular analyses
223486433|NCT01534793|PROCEDURE|Holmium Laser Enucleation of the Prostate (HoLEP)|Under regional or general anaesthesia Urethroscopy to check the location of the prostatic capsule Enucleation of the prostatic lobes (median if present, then lateral lobes)Hemostasis Morcellation Device : LUMENIS Laser
223486434|NCT01426126|DRUG|Genexol PM|Genexol-PM at a dose of 240 mg/㎡ was diluted in 500 ml of 5% dextrose solution and infused i.v. for 3 hours on day 1. Specialized i.v. infusion sets or in-line filter was not required for the administration. The dose of Genexol-PM was escalated to 300 mg/㎡ from the second cycle when pre-specified criteria were fulfilled (nadir ANC ≥ 1,000/ mm3, nadir platelet count ≥ 100,000/ mm3, and no grade 2 or worse non-hematologic toxicities with the exception of alopecia)
223486435|NCT03573856|BEHAVIORAL|Active Living|Participants will be provided with education and support for diet and lifestyle modification related to healthy eating and active living.
223486436|NCT03573856|OTHER|Health and Safety|Participants will be provided with education related to general health and safety topics.
223486437|NCT00525304|BEHAVIORAL|Self-management program for chronic illness|Self-management program for chronic illness will include between 10 and 16 psychoeducational and supportive group sessions.
223486438|NCT06063928|PROCEDURE|Archive Sample Retrieval|Undergo collection of archival tumor tissue
223486439|NCT06063928|PROCEDURE|Biospecimen Collection|Undergo stool and blood sample collection
223586616|NCT05023148|PROCEDURE|Electroacupuncture|Stimulating acupoints using electric stimulator
224176245|NCT05466240|DRUG|AT-752|AT-752 for 5 days
224176246|NCT05466240|DRUG|Placebo|Placebo for 5 days
224176247|NCT06496789|DRUG|Serplulimab+SOX|Serplulimab+Oxaliplatin+S1
223486440|NCT06063928|OTHER|Electronic Health Record Review|Medical records reviewed
223486441|NCT06063928|OTHER|Genetic Testing|Undergo genetic testing
223486442|NCT06063928|OTHER|Questionnaire Administration|Complete questionnaires
223486443|NCT01283386|DRUG|Chlorambucil|10 mg/m\^2 orally on Days 1-7 of each 28-day cycle for 6 cycles
223586617|NCT05023148|PROCEDURE|Thread embedded acupuncture|Stimulating acupoints using thread embedded
223586618|NCT05693454|DRUG|Infiltration with NaCl|Local wound infiltration at the end of spine surgery with NaCl
223586619|NCT05693454|DRUG|Infiltration with Ropivacain|Local wound infiltration at the end of spine surgery with Ropivacain
223486444|NCT01283386|DRUG|Cyclophosphamide|150 mg/m\^2 IV or orally on Days 1-3 of each 28-day cycle for 6 cycles
223486445|NCT01283386|DRUG|Fludarabine|20 mg/m\^2 IV or 32 mg/m2 orally Days 1-3 of each 28-day cycle for 6 cycles
223486446|NCT01283386|DRUG|Rituximab|375 mg/m2 IV on Day 1 of Cycle 1; 500 mg/m2 IV on Day 1 of Cycles 2-6 (28-day cycles)
223486447|NCT02689778|DRUG|Pirfenidone|Oral pirfenidone 600 mg with breakfast and 1200 mg pirfenidone with dinner for 12 months.
223486448|NCT02689778|DRUG|Placebo|Identical tablets without active substance
223486449|NCT02078167|OTHER|nutraceutical combination (red yeast rice, policosanols and berberine)|
223586620|NCT05693454|DRUG|Infiltration with a combination of Levobupivacaine and Tramadol|Local wound infiltration at the end of spine surgery with a combination of Levobupivacaine and Tramadol
223617615|NCT01815944|DRUG|0.75% Ropivacaine|
223617616|NCT01815944|DRUG|Normal saline|
223617617|NCT01815944|DRUG|Dextrose 5%|
224176248|NCT05993585|OTHER|Test Of The Frank Starling Mechanism - Adjustment Of Av Delay And Measurement Of Pre-load -Control|(Control Group): One test of the Starling mechanism Visit 1: Sign consent form, doctor assessment, electrocardiogram (ECG), Starling Test. If patients are in this category, this will be their only research visit
223486450|NCT05994807|DRUG|DC-806|Oral tablets
223486451|NCT05994807|DRUG|Itraconazole|Oral capsules
223486452|NCT05994807|DRUG|Carbamazepine|Oral tablets
223486453|NCT01285089|DRUG|activated recombinant human factor VII|Data collection of the use of activated recombinant human factor VII observed through real-world treatment practices
223486454|NCT03339362|PROCEDURE|Active Procedure|"If they pass the diagnostic injection with a 50% or more in pain reduction, they are randomised to receive either the active procedure or sham procedure.~Active: 4 X-ray guided intra-articular lumbar facet-joint injections via a spinal needle at 2 bilateral lumbar levels using 0.5ml bupivacaine + 20mg methylprednisolone per joint"
223486455|NCT03339362|PROCEDURE|Sham procedure|"If they pass the diagnostic injection with a 50% or more in pain reduction, they are randomised to receive either the active procedure or sham procedure.~Sham: 4 X-ray guided peri-articular injections via a spinal needle at 2 bilateral lumbar levels using 0.5ml of 0.9% sodium chloride per joint."
223586621|NCT02133365|BEHAVIORAL|Mindfulness and Interoceptive Exposure|The Mindfulness and Interoceptive Exposure intervention will be delivered in 4-5 manualized, individualized therapy sessions, of 1.5 hours - 2 hours each. The intervention is comprised of four established cognitive-behavioral strategies: psychoeducation, mindfulness, interoceptive exposure and skills generalization.
223617618|NCT04380506|PROCEDURE|Surgical Drains Management|The Role of Amylase Drain Level in the Management of Surgical Drains after Pancreratoduodenectomy
223617619|NCT00908986|DRUG|Rituximab|375mg/m2 q week x 4; repeated in 6 months
224176249|NCT05993585|OTHER|Other: Test Of The Frank Starling Mechanism - Adjustment Of Av Delay And Measurement Of Pre-load -CRT|(CRT Group): Two tests of the Starling mechanisms Visit 1: Sign consent form, assessment by doctor, electrocardiogram (ECG), Test of the Starling mechanism Visit 2: CRT upgrade procedure - your Cardiologist will explain this procedure to you. Visit 3: CRT pacing check at 6 weeks post-procedure Visit 4: Assessment by doctor, ECG, Echocardiogram, Test of the Starling mechanism at 6 months post-procedure.
224176250|NCT05143853|PROCEDURE|non-absorbable tape fixation around AC joint|fixation around AC joint with tape in different configurations
224176251|NCT05143853|PROCEDURE|no fixation around AC joint|there will be no additional fixation around AC joint in this group
224176252|NCT05143853|PROCEDURE|coracoclavicular (CC) fixation|mandatory coracoclavicular fixation with to suspensory systems, comprised of non-absorbable tapes and metal buttons
224176253|NCT00154895|DRUG|intrapleural minocycline instillation|
224176254|NCT02355860|BEHAVIORAL|assessment|assessment
224176255|NCT03430726|OTHER|Probiotic yogurt drink|Food product; yogurt drink containing a multi-strain probiotic.
224176256|NCT00245726|DEVICE|FES Cycle|Subjects will use electrical stimulation of the leg muscles to pedal a cycle for 1 hour / 3x week
224176257|NCT00245726|DEVICE|ES therapy|Subjects will electrically stimulate the leg muscles for 1 hour/ 3x week
224176258|NCT00245726|DEVICE|Passive (Motor Assist) Cycle|Subjects will use a cycle that moves the legs for 1 hour/3x per week
224176259|NCT00772980|DRUG|Neramexane mesylate|Double-blind treatment period of 17 weeks up to 75 mg Neramexane mesylate per day, 12 weeks follow-up.
224176260|NCT00772980|DRUG|Placebo|Double-blind treatment period of 17 weeks placebo, 12 weeks follow-up.
224176261|NCT05970146|DRUG|Ultrasound guided Stellate ganglion block|Under visualization with ultrasound, a 22-gauge, 5-cm needle inserted perpendicular to the skin to rest anteriorly to the precervical fascia. 6 mL lidocaine 0.125% and 8 mg dexamethasone in a total volume of 8 mL is used. After injection of a 0.5-mL test dose to exclude intravascular positioning, the remainder of the appropriate dose was administered. The patient will be encouraged to lie flat for 3 minutes after the injection and then to sit up.
224176262|NCT05970146|DRUG|unilateral cervical epidural|Aseptic betadine skin preparation will be performed and sterile drapes will be applied. Local anesthetic infiltration of the skin at C7-T1 interspace will be done using 2-3 mL of lidocaine 2% with guidance of the C-arm an 18-gauge. Tuohy needle will be inserted at C7-T1 interspace and directed towards either right or left epidural recess according to the site of the operation. Identification of entering the epidural space will be confirmed by hanging drop technique. The position of the needle is the confirmed by injection of 1 mL of non-ionized diluted dye (omnipause 300) to confirm unilateral spread of the dye. After that, a test dose was administrated, consisting of 2 mL of 2% lidocaine with 1:200,000 epinephrine.
223486456|NCT01531153|DRUG|Galantamine|8mg or 16mg
223486457|NCT01531153|DRUG|Placebo|Placebo dose.
223486458|NCT00494117|DEVICE|ApneaLink|A two channel sleep screening device for the assessment of Sleep Disordered Breathing.
223486459|NCT05075369|DIAGNOSTIC_TEST|water drinking test|Water drinking test-glaucoma diagnostic test - marker for outflow facility reserve to detect IOP instability when the body ingests 800 ml of water within a 5 minute period of time
223486460|NCT00770367|DRUG|Pioglitazone then Placebo|Subjects will take the pioglitazone 30mg tablet daily for 3 months. This will be followed by a 4-week period during which subjects will not be taking either the study drug or placebo. During the final 12-week period the group will take a placebo.
223486461|NCT00770367|DRUG|Placebo then Pioglitazone|Subjects will take the placebo for the first 12 weeks of the study. This will be followed by a 4-week period during which subjects will not be taking either the study drug or placebo. During the final 12-week period the group will take the pioglitazone 30mg tablet daily for 3 months.
223486462|NCT02786966|OTHER|Canadian C-Spine Rule|Paramedic assessment for potential cervical spine injuries using the Canadian C-Spine Rule
223486463|NCT03406676|DRUG|Methylene Blue|2mg / Kg of methylene blue in volume of 50ml is administrated I.V before anesthesia induction.
224176263|NCT00504452|DRUG|KP-1461|Oral dosage, 1600 mg bid for 124 days
224176264|NCT00979004|DRUG|ICA-105665|Oral tablet. Dose forms of 50 and 100 mg or placebo will be used. A single dose will be administered that can range from placebo or 100 to 600 mg.
224176265|NCT00305773|DRUG|vorinostat|Given orally once daily
224176266|NCT00305773|DRUG|vorinostat|Given orally three times daily
224176267|NCT01547494|OTHER|Vegan Diet|Vegan diet, which is devoid of animal products and minimal in fat
224176268|NCT01547494|DIETARY_SUPPLEMENT|mixture of omega3 and vitamins|mixture of omega3 and vitamins
223486464|NCT00920816|DRUG|Axitinib (AG-013736)|axitinib will be given at a starting dose of 5 mg BID with continuous dosing
223486465|NCT00920816|DRUG|Sorafenib|sorafenib will be given at a dose of 400 mg BID continuous dosing
224176269|NCT01577927|OTHER|Usual home care|Usual home care consists in supporting drug and oxygen therapy, mechanical ventilation, GP's assistance,and periodical in-hospital visit.
224176270|NCT01577927|BEHAVIORAL|PT-assisted home rehabilitation|"Patient performs 50 min physical activity/working day autonomously by the help of a DVD. The physical activity consists in cyclette, calisthenic exercises, and training of the respiratory muscles.~Every two weeks, PT phones the patient for an educational reinforcement."
224176271|NCT05737004|DIAGNOSTIC_TEST|functional magnetic resonance imaging examination、Zung Self Rating Anxiety Scale and Beck Depression Inventory-II|fMRI examination 、Zung Self Rating Anxiety Scale and Beck Depression Inventory-II were performed in these patients within 1 week before biopsy .
224176272|NCT03313440|OTHER|High wheat fiber|Daily increased fiber intake by 18-22 grams/day. Products are provided in boxes that must be consumed each day during the intervention.
224176273|NCT03313440|OTHER|Low fiber|Control low fiber intervention. Products are provided in boxes that must be consumed each day during the intervention.
224176274|NCT00501930|DRUG|GSK189075|
224176275|NCT02679222|DIETARY_SUPPLEMENT|Coconut oil|20 g of coconut oil
224176276|NCT02679222|DIETARY_SUPPLEMENT|Coconut oil + MCT|10 g of coconut oil + 10 g of MCT (60 of C8 + 40 of C10)
224176277|NCT02679222|DIETARY_SUPPLEMENT|MCT|20 g of MCT (60 of C8+40 of C10)
224176278|NCT02679222|DIETARY_SUPPLEMENT|Coconut oil + tricaprylin|10 g coconut oil + 10 g tricaprylin
224176279|NCT02679222|DIETARY_SUPPLEMENT|Tricaprylin|20 g tricaprylin
224176280|NCT02679222|DIETARY_SUPPLEMENT|Tricaprin|20 g tricaprin
224176281|NCT02679222|DIETARY_SUPPLEMENT|Control|No supplement taken on this visit
224176282|NCT03942536|OTHER|Focus Group Discussion|At 12-month follow-up, a purposeful, convenience sample of study participants and their significant others, Community Health Workers trained as Health Navigators, and local program staff, will be invited by research staff to participate in focus group discussions to collect qualitative data on pregnancy care, experience of navigating obstetrical emergencies, financial hardships, and Health Navigation program feasibility/acceptability. Particular attention will be paid to recruiting study subjects involved in complex obstetrical emergencies, cases that involved significant delays in transfer of care, cases resulting in significant morbidity/mortality, as well as cases that involved efficient/successful care coordination, referral, and transportation.
224176283|NCT02879435|DRUG|Bupivacaine|pre-operative wound infiltration with 10 ml of numbing medicine
224176284|NCT02879435|OTHER|Placebo|pre-operative wound infiltration with 10 ml of sterile water
224176285|NCT00073541|DRUG|EMD 72000|
224176286|NCT03495999|DIAGNOSTIC_TEST|hyperuricemia|serum uric acid of 7mg/dl or more in men or 6mg/dl or more in women
224176287|NCT06168929|DRUG|SHR4640|SHR4640, 2.5mg\*4 - 10mg\*1
224176288|NCT06168929|DRUG|SHR4640|SHR4640, 10mg\*1 - 2.5mg\*4
224176289|NCT05956080|DIAGNOSTIC_TEST|Allergy testing|University Medicine Greifswald
224176290|NCT00002494|DRUG|cyclophosphamide|
223486466|NCT03976128|BEHAVIORAL|Nordic Walking Training|The excursions will take place predominantly in flat pathways, beginning in a local park and progressing to roadside footpaths. Each session will last an hour including a warm up, NW and a cool down with stretching exercises.
223486467|NCT03976128|BEHAVIORAL|Conventional endurance training|15 minutes of Treadmill training with progressive increase of velocity followed by 20 minutes of cycloergometer with progressive increase of resistance. Each session will last an hour including a warm up, training with treadmill and cycloergometer and a cool down with stretching exercises.
223486468|NCT01180777|DEVICE|etafilcon A (A)|Daily wear contact lens
223486469|NCT01180777|DEVICE|etafilcon A (B)|Daily wear contact lens
223486470|NCT01180777|DEVICE|etafilcon A (C)|Daily wear contact lens
223486471|NCT05758792|OTHER|Muscle Quality Index|Evaluations are applied to older adults to compare the results of muscle quality.
223486472|NCT05029947|PROCEDURE|Microsurgical Clipping of Unruptured Intracranial Aneurysm|Microsurgical Clipping of Unruptured Intracranial Aneurysm
223486473|NCT05956093|RADIATION|FAPI PET CT|the utilization of Gallium 68 labelled Fibroblast Activation Protein Inhibitor (68Ga-FAPI) PET/CT to accurately stage high-grade epithelial ovarian cancers.
223486474|NCT00350220|OTHER|transfusion strategy|For the High Hb group; transfusions will be given to keep the Hb \>13.0 g/dl
223486475|NCT00350220|OTHER|Low Hb transfusion group|RBCs will not be transfused unless the Hb \< 9.0 g/dl
223486476|NCT03988660|DIAGNOSTIC_TEST|Circulating fibrocytes|Peripheral blood samples were taken from the patients presented with right iliac fossa pain. Samples were collected in sodium heparin (EDTA). Circulating fibrocyte levels were determined by dual staining peripheral blood samples for CD4 and Col-1 using Fluorescence-Activated Cell Sorting (FACS) and correlated with histopathological diagnosis.
223617620|NCT04277949|DEVICE|Erbium:YAG|Treatment with Erbium:YAG laser
223617621|NCT04277949|DRUG|UV endonuclease from Micrococcus luteus|Application of topical DNA repair enzymes
224176291|NCT00002494|DRUG|cytarabine|
224176292|NCT00002494|DRUG|dexamethasone|
224176293|NCT00002494|DRUG|doxorubicin hydrochloride|
224176294|NCT00002494|DRUG|etoposide|
224176295|NCT00002494|DRUG|ifosfamide|
224176296|NCT00002494|DRUG|leucovorin calcium|
224176297|NCT00002494|DRUG|mesna|
224176298|NCT00002494|DRUG|methotrexate|
224176299|NCT00002494|DRUG|prednisone|
224176300|NCT00002494|DRUG|therapeutic hydrocortisone|
223617622|NCT02454790|RADIATION|Radiotherapy|
224176301|NCT00002494|DRUG|vincristine sulfate|
224176302|NCT00002494|RADIATION|low-LET cobalt-60 gamma ray therapy|
224176303|NCT00002494|RADIATION|low-LET photon therapy|
224176304|NCT05564364|DEVICE|Recumbent Bike|The first group will exercise with a recumbent bike for 20 minutes, 3 sessions/week for 6 weeks.
224176305|NCT05564364|DEVICE|Upright Bike|The first group will exercise with a upright bike for 20 minutes, 3 sessions/week for 6 weeks.
224176306|NCT00794235|DRUG|Sorafenib (Nexavar), Dacarbazine (DTIC)|"Sorafenib: 2x400 mg daily PO (2 tablets (200 mg each) each AM and PM). DAY 1-56.~DTIC: 1-hour IV infusion 1000mg/m2 DAY 14 and 42."
224176307|NCT04984252|BEHAVIORAL|Self-compassion comprising compassionate body scan-1, compassion body scan-2 and short noticing practice|This intervention includes 3 short meditations that are identified as the active component in the previous study (ID: NCT04665167)
224176308|NCT04984252|BEHAVIORAL|Self-compassion comprising self-compassion break, loving kindness meditation, and breathing exercise.|This intervention includes 3 short meditations that are identified as the inactive component in the previous study (ID: NCT04665167)
224176309|NCT04984252|BEHAVIORAL|Distraction group|Participants will be asked to listen recording on irrelevant topic.
224176310|NCT01599611|PROCEDURE|Movement assessment battery for children - 2|A standardised test developed to identify developmental difficulties in children.
224176311|NCT03703661|PROCEDURE|Needle-Aspirated Negative Pressure Dressing|dressing consisting of Needle-Aspirated Negative Pressure dressing with gauze and adhesive/occlusive dressing, placed over wound after primary closure
224176312|NCT03703661|PROCEDURE|Control|dressing consisting of gauze and adhesive/occlusive dressing, placed over wound after primary closure
224176313|NCT03974711|OTHER|"In this evaluation, no interventions are performed. It is a data collection effort only. The procedure for this study is the data collection effort."|There is no intervention performed in this evaluation. Data is being collected in an on-label standard of care lateral lumbar interbody fusion procedure.
224176314|NCT02840760|DEVICE|Repetitive Transcranial Magnetic Stimulation|Stimulate the primary motor cortex for 2 weeks.
224176315|NCT01017991|OTHER|Milk based infant formula with probiotic|formula supplied as a powder to be constituted as commercially available formula ad libitum daily 28 days duration
224176316|NCT01017991|OTHER|Milk based infant formula|supplied as a powder to be constituted as commercially available formula ad libitum daily 28 days
224176317|NCT04383691|DRUG|Lurasidone HCl|Subjects will be administered orally, once daily, in the evening. Subjects will be treated with Lurasidone 20 mg/day for Days 1-2-3, 40 mg/day for Days 4-5-6, and 60 mg/day on Day 7. Flexible dosing of study drug will be permitted beginning on Day 8.
223486477|NCT02369926|PROCEDURE|Multiple Sclerosis Functional Composite|The MSFC is a diagnostic test that measures multiple sclerosis symptoms. It includes a timed walk test, 9-hole peg test, and paced auditory serial addition test. The MSFC is administered in-person at the study site.
223486478|NCT02369926|PROCEDURE|Mobile Multiple Sclerosis Functional Composite|The mMSFC is a diagnostic test that measures multiple sclerosis symptoms from. It includes a timed walk test, 9-hole peg test, and paced auditory serial addition test. All aspects of this exam are completed from a participant's home using remote sensing technology and video conferencing.
224176318|NCT04383691|DRUG|Placebo|Subjects will be administered orally, once daily, in the evening. Subjects will be treated with Placebo.
224176319|NCT00872586|DRUG|olmesartan medoxomil + hydrochlorothiazide|olmesartan medoxomil 20mg oral tablets, once daily for 4 weeks then olmesartan medoxomil 20mg oral tablets + hydrochlorothiazide 12.5 mg oral tablets, once daily for up to 8 weeks
224176320|NCT00872586|DRUG|olmesartan medoxomil|olmesartan medoxomil 20mg oral tablets, once daily for 4 weeks then olmesartan medoxomil 40mg oral tablets, once daily for up to 8 weeks
224176321|NCT03807258|OTHER|Transcranial magnetic stimulation (TMS)|Evaluations by TMS
224176322|NCT04581057|BIOLOGICAL|Specific blood sampling|"A 30 ml blood sample (6 EDTA tubes) will be taken at inclusion in the study, in addition to the blood sample taken as part of the routine care.~This sampling is carried out for :~* Search for CHIP-associated mutations in circulating leukocytes~* Plasma determination of IL-1β, IL-6, IL-10 and TNF-α"
224176323|NCT02458989|PROCEDURE|Scalpel|Use of a scalpel as a first incision during thyroid operation
224176324|NCT02458989|PROCEDURE|Electrocautery|Use of an electrocautery as a first incision during thyroid operation
224176325|NCT01939067|DEVICE|Heated Humidified High Flow Nasal Cannula|Biweekly measurement of lung mechanics (dynamic compliance, airway resistance, work of breathing) and chest wall asynchrony measures while on HHHFNC and weekly when weaned off until 40 weeks post conceptional age or discharge. Recording of the level and the type of respiratory support and all cross over respiratory support devices. Recording of all growth parameters, neonatal morbidities and therapies.
224176326|NCT01939067|DEVICE|Nasal Continuous Positive Airway Pressure|Biweekly measurement of lung mechanics (dynamic compliance, airway resistance, work of breathing) and chest wall asynchrony measures while on NCPAP and weekly when weaned off until 40 weeks post conceptional age or discharge. Recording of the level and the type of respiratory support and all cross over respiratory support devices. Recording of all growth parameters, neonatal morbidities and therapies.
223486479|NCT02022930|DEVICE|Hydros|
223486480|NCT02022930|DEVICE|Hydros-TA|
224176327|NCT00094640|DRUG|Intramuscular Olanzapine Depot|
224176328|NCT00413231|DEVICE|Valiant Thoracic Stent Graft System|Surgical procedure in which a device is implanted inside the aorta, isolating the diseased area (aneurysm).
223486481|NCT02022930|DRUG|Triamcinolone Acetonide|
223486482|NCT00360204|BEHAVIORAL|Home Nurse Visit|Home nurse visit by maternal child health nurse within first 24-48 after post-partum hospital discharge.
223486483|NCT03479151|DEVICE|Magnetic Resonance Image-guided High Intensity Focused Ultrasound (MR-HIFU)|MRgHIFU treatment will be delivered using a Philips Sonalleve system, which integrates a high intensity phased array focused ultrasound transducer with our Philips 3T Achieva imaging system. An electromechanical transducer positioning system is used to deliver spatially and temporally controlled ultrasound energy and thermal heat to tissues non-invasively. The MR system is used to provide images to plan the therapy, and to guide and monitor the thermal ablation with thermal imaging during the treatment.
223486484|NCT02595710|OTHER|skin punch biopsy collection|Four-mm skin biopsies from non-lesional skin will be acquired from the patients, processed using our published techniques with Bartonella biomarkers, and imaged using confocal microscopy.
223486485|NCT02595710|OTHER|Blood collection|Blood will be tested for presence of Bartonella DNA and Bartonella antibodies using the Alpha Proteobacterium Growth Medium (BAPGM) multi-platform testing, including liquid culture, enriched agar plating and molecular techniques.Blood smears will be analyzed for presence of intra-erythrocytic Bartonella spp. by immunostaining.
223486486|NCT02595710|OTHER|Urine sample collection|Urine samples will be collected and analyzed for Bartonella spp specific microRNAs.
223486487|NCT03934801|OTHER|Brainstorming 1|Expert recommendation statements will be collected for peer evaluation.
223586622|NCT06130982|BEHAVIORAL|Health Qigong·Yijinjing|1-2weeks:learning stage, the frequency is 1 time/day, 5times/week,30 min /time,the total duration controlled within 50 minutes,and includes 4 intervention contents.Warm up activity:take a slow walk around the track and field to activate body and activate small joints (5min).Basic Skills learning of HQ·Yijinjing:breathing exercises,hand exercises,trunk exercises,step exercises,stake exercises(10min).Learning a single action of a routine (30min).Cool down (5min).3-8weeks:practice stage,the frequency and duration of intervention remain unchanged, and the intervention components still include 4 parts.Based on the first two weeks,the intervention content emphasizes more on the practice of complete routine movements, as well as learning and experience the theories and functions of movements.8-12weeks:stop intervention phase,the subjects resume their daily activities and stop intervention. After this, the final data measurement and collection are conducted again.
223586623|NCT06130982|BEHAVIORAL|Health Qigong·Wuqinxi|1-2weeks:learning stage, the frequency is 1 time/day, 5times/week,30 min /time,the total duration controlled within 50 minutes,and includes 4 intervention contents.Warm up activity:take a slow walk around the track and field to activate body and activate small joints (5min).Basic Skills learning of HQ·Wuqinxi:breathing exercises,hand exercises,trunk exercises,step exercises,stake exercises(10min).Learning a single action of a routine (30min).Cool down (5min).3-8weeks:practice stage,the frequency and duration of intervention remain unchanged, and the intervention components still include 4 parts.Based on the first two weeks,the intervention content emphasizes more on the practice of complete routine movements, as well as learning and experience the theories and functions of movements.8-12weeks:stop intervention phase,the subjects resume their daily activities and stop intervention. After this, the final data measurement and collection are conducted again.
224176329|NCT03474380|BEHAVIORAL|iHI-FIVES|Implementation of iHI-FIVES caregiver skills training
224176330|NCT01773057|OTHER|NHGDoc domain Heart Failure|Healthcare providers receive patient specific alerts in terms of diagnosing and treatment of patients with heart failure
224176331|NCT05162534|OTHER|effect of COVID-19 exposure|effect of COVID-19 exposure
223486488|NCT03934801|OTHER|Ranking Round 1|Each participant will rank each statement using a likert scale: strongly disagree -- disagree -- neutral -- agree -- strongly agree.
223486489|NCT03934801|OTHER|Ranking Round 2|Each participant will rank each statement using a likert scale: strongly disagree -- disagree -- neutral -- agree -- strongly agree.
223486490|NCT03934801|OTHER|Ranking Round 3|Each participant will rank each statement using a likert scale: strongly disagree -- disagree -- neutral -- agree -- strongly agree.
223486491|NCT06571045|DRUG|Ranibizumab|Ranibizumab is a commercially available anti-VEGF treatment formulated for intravitreal administration for use in patients with diabetic macular edema
223486492|NCT06571045|DRUG|EYE103|EYE103 is a humanized antibody formulated for intravitreal administration
223486493|NCT01772771|PROCEDURE|Biospecimen Collection|Undergo collection of blood, saliva/buccal swab samples
223486494|NCT01772771|OTHER|Genetic Testing|Correlative studies
223486495|NCT01772771|OTHER|Medical Chart Review|Review of medical records
223486496|NCT06306742|OTHER|Open-label placebo|Light pressure manual therapy
223617623|NCT02908022|DEVICE|Electroacupuncture Analgesia|"For the MRI sessions, acupuncture needles will be inserted next to the cuff placed on the left leg and will be connected to electrodes. Low-amplitude electrical current will be activated when a button is pressed via a handheld device, controlled by the acupuncturist, in order to reduce pain, acting as an analgesic.~Additionally, electroacupuncture-induced analgesia will be used for the treatments. During the treatment sessions the acupuncturist will insert needles in several locations aimed to reduce the patient's fibromyalgia pain. Low-amplitude electrical current will be activated by the acupuncturist using the same electroacupuncture device as in the MRI machine."
224176332|NCT01627379|DRUG|Cisplatin, 5-FU|"Arm A: Cisplatin 80 mg/m2 IV infusion over 2 hours on Day 1, followed by 5-FU 1000 mg/m2 IV daily as continuous infusion over 24 hours, Day 1-4.~Chemotherapy will be administered every 3 weeks until progression of disease or any other reason for treatment withdrawal is fulfilled."
224176333|NCT01627379|DRUG|Panitumumab|"Arm B: Cisplatin 80 mg/m2 IV infusion over 2 hours on Day 1, followed by 5-FU 1000 mg/m2 IV daily as continuous infusion over 24 hours, Day 1-4.~Panitumumab will be administered on Day 1 of each treatment cycle at a dose of 9 mg/kg prior to administration of chemotherapy.~Each treatment cycle is defined as 21 days. Patients are treated until progression of disease occurs or any other reason for treatment withdrawal is fulfilled."
224176334|NCT00134199|DRUG|CP-945,598|
224176335|NCT00134199|DRUG|sibutramine|
224176336|NCT06187519|DEVICE|Uric Acid and Metabolite Monitor System (UR+AIMS) skin patch|The intervention tested is the system (patch and mobile device/phone for reporting) that provides patients with better knowledge (test results) about the impact of their daily dietary choices on their uric acid levels.
224176337|NCT01287507|DIETARY_SUPPLEMENT|Lactoferrin (bovine origin)|Bovine lactoferrin 200 mg/daily, given with either human milk or preterm formula
224176338|NCT00756223|DRUG|Arm A|Dose escalation Arm A (4 weeks)
224176339|NCT00756223|DRUG|Arm B|Dose escalation Arm B (3 weeks)
224176340|NCT02063958|DRUG|SNX-5422|Capsule dosed every other day for 21 days out of a 28 day cycle. Dose escalation based on safety not to exceed a dose of 100 mg/m2. Maintenance therapy of SNX-5422 at the MTD will be allowed for all patients not experiencing significant toxicity.
224176341|NCT03484780|DEVICE|VisONE ADS|VisONE stimulator and leads for delivering continual Synchronized Diaphragmatic Stimulation
223486497|NCT06306742|OTHER|Osteopathic manipulative treatment|Manual therapy
223486498|NCT05787223|OTHER|Baseline Treatment|Control Group that will be provided with be given baseline treatment of static balance training (static exercise like standing on balance board, bounce on one foot, heel rises/toe rises, standing on one foot, jumping on trampoline)
223486499|NCT05787223|OTHER|Dynamic Training|Experimental Group that will be provided with base line treatment along with dynamic balance training (cross, side \&tandem walking, step up and down, jumping \&hopping on floor). Exercises Will be given the 40 minutes with 2 sessions per week over the period of 08 weeks
223486500|NCT03517137|DRUG|Brentuximab Vedotin|For PET positive (score of 4-5 following Deauville Criteria) patients: Brentuximab vedotin is administered as an IV infusion over a period of 30 minutes at 1.8 mg/kg on day 1, every 3 weeks (6 cycles); For PET negative (score of 1-3 following Deauville Criteria) patients: Brentuximab vedotin is administered as an IV infusion over a period of 30 minutes at 1.2 mg/kg on day 1 and 15, every 4 weeks (5 cycles)
224176342|NCT00945945|DRUG|Duloxetine (DLX)|dose daily by mouth
224176343|NCT00945945|DRUG|Placebo (PLA)|Placebo Comparator daily by mouth
224176344|NCT00210067|DRUG|denufosol tetrasodium (INS37217) Intravitreal Injection|
224176345|NCT04822389|DEVICE|Telerehablitation using heart rate monitor|Eligible participants will undergo 12 weeks of physical exercise using a heart rate monitor and internet platform at home. The participants will regularly (minimum once per week) upload the exercise data from the heart rate monitor into the internet platform. An exercise telerehabilitation session consists of the warm-up phase, aerobic phase (30 - 50 minutes gradually increasing exercise duration; heart rate zone based on baseline cardiopulmonary exercise test) and cool-down phase. The exercise training period is set to 3 times a week for 12 weeks. Study participants will receive user guides developed by research team with detailed instructions regarding equipment set-up, training protocol, and contact information. Also, participants will receive weekly phone calls from week 0 to week 12 to monitor adverse events, encourage compliance and adherence to the study protocol, address any subject questions or concerns, and collect information regarding participants' current symptomatology.
223486501|NCT03517137|DRUG|Adriamycin|For PET positive (score of 4-5 following Deauville Criteria) patients: Adriamycin is administered as an IV infusion over a period of 15 minutes at 40 mg/m² on day 2, every 3 weeks (6 cycles); For PET negative (score of 1-3 following Deauville Criteria) patients: Adriamycin is administered as an IV infusion over a period of 15 minutes at 25 mg/m² on day 1 and 15, every 4 weeks (5 cycles)
223486502|NCT03517137|DRUG|Vinblastine|For PET negative (score of 1-3 following Deauville Criteria) patients: Vinblastine is administered as an IV infusion over a period of 15 minutes at 6mg/m² on day 1 and 15, every 4 weeks (5 cycles)
223486503|NCT03517137|DRUG|Dacarbazine|For PET positive (score of 4-5 following Deauville Criteria) patients: Dacarbazine is administered as an IV infusion over a period of 60 minutes at 250 mg/m² on day 3 and 4, every 3 weeks (6 cycles); For PET negative (score of 1-3 following Deauville Criteria) patients: Dacarbazine is administered as an IV infusion over a period of 60 minutes at 375 mg/m² on day 1 and 15, every 4 weeks (5 cycles)
223486504|NCT03517137|DRUG|Etoposide|For PET positive (score of 4-5 following Deauville Criteria) patients: Etoposide is administered as an IV infusion over a period of 60 minutes at 150 mg/m² on day 2,3 and 4, every 3 weeks (6 cycles)
223486505|NCT03517137|DRUG|Cyclophosphamide|For PET positive (score of 4-5 following Deauville Criteria) patients: Cyclophosphamide is administered as an IV infusion over a period of 30 minutes at 1250 mg/m² on day 2, every 3 weeks (6 cycles)
223486506|NCT03517137|RADIATION|Radiation Therapy|Patients with residual lymphoma mass(es) showing metabolic activity of Deauville score 4 or 5 after completion of chemotherapy will be offered consolidation radiotherapy.
223486507|NCT04836936|DEVICE|Auriculotherapy cryopuncture device without nitrogen gas|Auriculotherapy cryopuncture device without nitrogen gas will be administered. Application of this placebo device will be performed in the same manner as the treatment, but without the expulsion of nitrogen gas.
223486508|NCT04836936|DEVICE|Auriculotherapy cryopuncture device with nitrogen gas|Auriculotherapy cryopuncture device with nitrogen gas will be administered. The tip of the cryopuncture will be sanitized and placed on each treatment point of the ear, releasing a spurt of nitrogen gas for 2 seconds on each point (6 points total).
223486509|NCT05653271|DRUG|Cyclophosphamide|Lymphodepleting agent
223486510|NCT05653271|DRUG|Fludarabine|Lymphodepleting agent
223486511|NCT05653271|DRUG|ACE1831|Allogeneic gamma delta T (gdT) cell therapy
223486512|NCT05653271|DRUG|Obinutuzumab|Anti-CD20 monoclonal antibody
223486513|NCT05681819|DRUG|SHR-1707|Multiple-ascending Dose
223486514|NCT05681819|DRUG|SHR-1707 placebo|Multiple-ascending Dose
224176346|NCT04885660|DRUG|compound lisinopril tablet|The subjects randomly received single oral administration of compound lisinopril tablet(Lisinopril 10mg/Levamlodipine besylate 5mg)
223486515|NCT05983952|DRUG|Anti-CD38 antibody Injection|"intravenous Anti-CD38 antibody administration~This study adopts a prospective, single arm, open design method. Ten subjects were enrolled in the study and were treated with Anti-CD38 antibody (16mg/kg/w) for 8 weeks.~The first stage is the main research stage (d1-w8), which is the core treatment period. The subjects will receive intravenous infusion of 16mg/kg Anti-CD38 antibody once a week for 8 weeks to observe the safety and efficacy during treatment.~The second stage (w9-w24) is the stage of withdrawal from the visit, mainly to observe the safety and continuous efficacy of Anti-CD38 antibody after treatment."
223486516|NCT01582451|DRUG|LY2605541|
223486517|NCT01582451|DRUG|Insulin glargine|
223486518|NCT03658525|DEVICE|MR LINAC|MR GUIDED PROSATE RADIOTHERAPY
223486519|NCT06193382|BEHAVIORAL|PCIT|Participants will receive the adapted Pocket PCIT Online via a web-based learning platform for up to 5 weeks. Participants will engage in this intervention weekly for about 1 hour per week. During engaging with the adapted Pocket PCIT Online version of PCIT, caregivers will learn positive parenting skills to increase the warmth of the parent-child relationship as well as strategies to effectively set limits. Participants will also participate in 15-minute check-in phone calls with a therapist each week throughout the course of treatment.
223486520|NCT03318341|DEVICE|Real Stimulation|The device applies wrist vibration at a subthreshold (imperceptible) level.
223486521|NCT03318341|DEVICE|Sham Stimulation|The device applies no vibration.
223486522|NCT03954171|OTHER|Patients treated with platinum based-chemotherapy|"Blood samples, tumor biopsy specimens and ascites samples will be collected at different time points (if feasible, according to the samples taken in the standard practice):~* before treatment initiation (blood sample),~* during hospitalisation for surgery (blood sample),~* during follow-up consultations (blood sample).~If tumor biopsy and/or ascites sampling are performed during the standard care, a sample will be collected for the study."
223486523|NCT05472974|DEVICE|Use of a powered alternating pressure air mattress|Patients with a medium to high risk of pressure injury, without pressure injury, up during the day, will ly a on a specific P-APAM (DOMUS 4 /AUTO)
223486524|NCT04885608|OTHER|PReGe|There will be two weekly sessions of 45 minutes, outdoors in outdoor fitness parks. The components of balance, gait, resistance, strength and elasticity will be worked on and breathing exercises will be performed. The sessions will be guided and dosed by physiotherapists, considering the level of perception of effort. Indications will be given to carry out other sessions of 60 to 120 minutes of therapeutic walking (minimum speed of 4 km/hour) during the week, to complete the 150-300 minutes per week of physical activity recommended by the WHO.
224176347|NCT04885660|DRUG|compound lisinopril tablet(Lisonorm®)|The subjects randomly received single oral administration of compound lisinopril tablet(Lisonorm®)
224176348|NCT02400268|OTHER|7 days course of antibiotic treatment|Standard antibiotic treatment approved for enterobacteraciae infections
224176349|NCT02400268|OTHER|14 days course of antibiotic treatment|Standard antibiotic treatment approved for enterobacteraciae infections
224176350|NCT04697199|DRUG|Lactobacillus Reuteri Oral Drops|Subgingival delivery of probiotic suspension
224176351|NCT04697199|PROCEDURE|Scaling and root planing|Scaling and root planing using hand and ultrasonic instruments
224176352|NCT00551200|DRUG|HPN-100|Subjects will be taking prescribed dose of Buphenyl® TID (not to exceed 20g/day) at least two weeks prior to enrollment. Subjects will take prescribed dose of Buphenyl® TID for first week of study, and then switch over to HPN-100 TID during a dose-escalation phase. The dose of HPN-100 will be increased and the dose of Buphenyl® will be decreased each week by 50 mg/kg until entire daily dose of phenylbutyrate is HPN-100. Target HPN-100 dose will contain the same amount of phenylbutyrate as the subject's prescribed daily dose of Buphenyl®. Subject will take HPN-100 alone for one week and then switch back to previous dose of Buphenyl for the last week of the study.
223486525|NCT00540917|PROCEDURE|cooling spray during laser treatment|skin temperature measurement
224176353|NCT00551200|DRUG|BUPHENYL®|BUPHENYL® (sodium phenylbutyrate) tablets and powder have been approved for marketing in the United States since 1996 as an adjunctive therapy in the long-term management of patients with UCDs involving deficiencies of CPS, OTC, or ASS.
224176354|NCT06253624|PROCEDURE|All Arthroscopic ATFL Repair Surgery|The patients undergo surgery with spinal block, general anesthesia, or a combination of both. During the diagnostic arthroscopy, the anterior compartment is examined with a 4 mm 30-degree camera, and lateral ankle instability is diagnosed arthroscopically
224176355|NCT02408016|BIOLOGICAL|Aldesleukin|Given SC
224176356|NCT02408016|BIOLOGICAL|Autologous WT1-TCRc4 Gene-transduced CD8-positive Tcm/Tn Lymphocytes|Given IV
224176357|NCT02408016|DRUG|Cyclophosphamide|Given IV
224176358|NCT02408016|OTHER|Laboratory Biomarker Analysis|Correlative studies
224176359|NCT02408016|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgical resection
224176360|NCT04143828|BEHAVIORAL|mobile mindfulness programme|"The mobile mindfulness programme adheres to a standardized protocol developed from the MBSR curriculum (Kabat-Zinn, 1990). The program consists of six modules. Each module consists of a short movie (talking head) explaining the content and two audiofiles to guide experiential mindfulness meditation exercises. Participants can follow the different modules based on their own time-schedule.~Key objectives are: (1) to increase awareness of one's present moment experience; (2) to teach an attitude of openness and acceptance (non-judging) toward one's experience."
224176361|NCT01388205|BEHAVIORAL|Family-based Outdoor program|2 to 3 hour outdoor activities organized in conjunction with National Parks, Singapore
224176362|NCT06021912|DRUG|Immunotherapy|Sublingual immunotherapy
224176363|NCT00805194|DRUG|placebo plus docetaxel|placebo matching BIBF 1120 2 times daily along with standard therapy of docetaxel
223486526|NCT03479827|DEVICE|Monofocal Contact Lens|A monofocal contact lens will be used for this measurement.
223486527|NCT03479827|DEVICE|Bifocal Contact Lens|A bifocal contact lens will be used for this measurement.
223486528|NCT01807455|DEVICE|Restylane Vital Lidocaine|
223486529|NCT00487188|DRUG|Enfuvirtide|90 mg subcutaneous injection twice a day
223486530|NCT00487188|DRUG|Highly active antiretroviral treatment (HAART)|An oral HAART regimen of 3-5 antiretrovirals was chosen by the physician and patient, based on the patient's prior treatment history and genotypic antiretroviral resistance testing.
223486531|NCT04098835|BEHAVIORAL|ASCEND|ASCEND is a behavioral intervention that combines computer-based cognitive exercise, strategy coaching with a neuropsychologist, and homework exercises in order to improve attention, working memory, and cognitive control after stroke.
223486532|NCT02759640|DRUG|HS-10241|HS-10241 is administered orally starting at 100 mg/day.
224176364|NCT00805194|DRUG|BIBF 1120 plus docetaxel|BIBF 1120 2 times daily along with standard therapy of docetaxel
224176365|NCT03502265|OTHER|Otteroo|Otteroo will be provided for 4 weeks of use, to supplement any standard care. Standard care is not provided.
224176366|NCT04746170|OTHER|Labor Dance|Pregnant women in the experimental group will be given a birth dance with music for 15 minutes per hour until the cervical opening starts from 3 cm (latent phase) and the cervical opening reaches 8 cm. The massage application will be made by the researcher to their waist and sacrum area with a ball massage glove.
224176367|NCT03891199|PROCEDURE|Robotic-Arm Assisted THA|The study will examine the acetabular cup placement of THA patients and compare results for patients who undergo THA with robotic-arm assistance with those who undergo traditional THA.
224176368|NCT04627805|BEHAVIORAL|MyPath tool|MyPath is a reproductive decision support tool that utilizes a patient-centered approach to help women frame their reproductive decisions in the context of their goals, preferences, and health needs. This tool was developed by Dr. Lisa Callegari with funding from the Veterans Administration (VA) Health Services Research \& Development to be used in primary care settings with women veterans. It is conceptually grounded in Self-Determination Theory, which postulates that health care that meets patients' psychological needs in three key domains - autonomy, competence, and relatedness - will result in improved health behaviors and health outcomes. This is particularly relevant in reproductive health care, given the highly individualized and personal nature of these decisions, and the importance of centering a woman's aspirations and goals in her health care decision making.
224176369|NCT00216346|DRUG|Paromomycin sulfate|
224176370|NCT00216346|DRUG|Amphotericin B|
223486533|NCT04718701|DRUG|Anlotinib+Toripalimab+Nab-paclitaxel|Using combination treatment of anlotinib (12 mg, po. qd.) plus toripalimab (240 mg, ivgtt. q3w.) and nab-paclitaxel (260 mg/m2, ivgtt, q3w) with every 3 weeks as a cycle.
223486534|NCT04818801|BIOLOGICAL|Recombinant two-component COVID-19 vaccine (CHO cell)|The spike (S) protein is the main surface antigen of SARS-CoV-2, mediates entry of SARS CoV-2 into cells expressing the angiotensin-converting enzyme 2 (ACE2). The RBD interacts with ACE2 and can generate potent neutralizing anti-RBD antibodies.
223486535|NCT04818801|OTHER|Placebo|Normal saline (0.9% sodium chloride solution),
224176371|NCT02206958|BEHAVIORAL|Defeating Urinary Incontinence with Exercise Training|"12 week multi-component program. Continence program administered by a nurse practitioner during 4 home visits. Participants do pelvic floor muscle exercises 5 days/week using a 13-minute instructional audio CD. Based on participant symptoms and preferences the following strategies are taught: bladder training, urge and suppression techniques, caffeine reduction, eliminating bladder irritants, medication adjustment, adequate fluid intake, constipation management, and reducing nocturia.~2\. Physical activity program including moderate intensity walking (30 minutes, 5 days weekly) and twice weekly group strength training sessions using Therabands led by a trained exercise instructor."
224176372|NCT04246918|DIETARY_SUPPLEMENT|Branched Chain Amino Acid|Branched chain amino acid is a group of three amino acids known for there role in muscle growth.
224176373|NCT04246918|DIETARY_SUPPLEMENT|Whey Protein concentrate powder|Whey protein will be given to the standard treatment arm including in the same amount of 1.5gm/kg/IBW.
224176374|NCT04802395|DIAGNOSTIC_TEST|KidneyIntelX|KidneyIntelX is an in-vitro diagnostic that enables accurate risk prediction of progressive decline in kidney function in patients with type 2 diabetes and existing CKD at stages 1-3 (eGFR of 30 to 59 ml/min/1.73m2, or eGFR ≥ 60 ml/min/1.73m2 and uACR ≥ 30 mg/g).
224176375|NCT01671176|DEVICE|Wide diameter bone anchored implant|4.5 mm wide diameter bone anchored implant
224176376|NCT01807442|OTHER|Qualitative Interview and Adherence|All participants receive the same intervention. The intervention involves two qualitative interviews per participant. The first interview occurs in the hospital, and the second interview occurs at 12 weeks. Participants also receive a pill bottle that tracks when they take their aspirin. They will also receive a step counter to use for two weeks at the end of the study.
224176377|NCT02275052|DRUG|UMEC/VI DPI|The DPI will contain a total of 30 doses. Each DPI will be comprised of two double-foil, laminate blister strips. Each blister of one strip will consist of 62.5mcg of UMEC blended with lactose and magnesium stearate while each blister of other strip will consist of 25 mcg of VI blended with lactose and magnesium stearate. Each actuation of the DPI will deliver the contents of one blister from each strip simultaneously
224176378|NCT02275052|DRUG|Placebo DPI|The placebo DPI, identical in appearance to the inhaler containing active study medication, will have two blister strips, each containing 30 blisters of lactose and magnesium stearate.
224176379|NCT02275052|DRUG|Albuterol/salbutamol MDI|Albuterol/salbutamol MDI (metered-dose inhaler) or nebules will be permitted throughout the study as rescue medication, for use as-needed. Albuterol/salbutamol will be sourced from local commercial stock or provided centrally from GlaxoSmithKline. Nebules will not be supplied.
224176380|NCT01143116|DEVICE|"Silver-nitrate coated catheter (Catheter A)"|Catheter A releases silver ions into the urethra and urinary bladder upon catheterization.
224176381|NCT01143116|DEVICE|"Degradable silver particle-coated catheter (Catheter B)"|Catheter B releases both silver ions and degradable silver particles into the urethra and urinary bladder upon catheterization.
224176382|NCT03858855|PROCEDURE|Aromatherapy and Essential Oils|Use bergamot essential oil
224176383|NCT03858855|PROCEDURE|Aromatherapy and Essential Oils|Use chamomile essential oil
224176384|NCT03858855|PROCEDURE|Aromatherapy and Essential Oils|Use ginger essential oil
224176385|NCT03858855|PROCEDURE|Aromatherapy and Essential Oils|Use almond essential oil
224176386|NCT03858855|OTHER|Subject Diary|Complete journal
224176387|NCT02807376|DEVICE|Surgeon's 'standard of care' stapler|
224176388|NCT02807376|DEVICE|Ethicon Powered Vascular Stapler|
224176389|NCT01444144|OTHER|Fracture union|Retrospective records review post-operatively until fracture resolved.
224176390|NCT00003410|DRUG|motexafin gadolinium|
224176391|NCT00003410|PROCEDURE|magnetic resonance imaging|
223486536|NCT00484510|DRUG|Ascorbic acid (Vitamin C)|Eight 500 mg capsules/day of ascorbic acid. Subjects will take four (4)capsules each morning and four (4) capsules each evening for 24 months. (Total 4 gr/day).
223486537|NCT00484510|DRUG|placebo|Eight 500 mg capsules/day of placebo. Subjects will take four (4)capsules each morning and four (4) capsules each evening for 24 months.
223486538|NCT02412943|OTHER|Fresh Frozen Plasma|Liquid portion of human blood that was centrifuged, separated, and frozen solid within 6 hours of collection
224176392|NCT00003410|PROCEDURE|surgical procedure|
224176393|NCT00846027|DRUG|Bevacizumab|Bevacizumab was supplied as a sterile liquid in glass vials.
224176394|NCT00846027|DRUG|Paclitaxel|Paclitaxel was supplied as a sterile liquid in glass vials.
224176395|NCT00846027|DRUG|Gemcitabine|Gemcitabine was supplied as a sterile liquid in glass vials.
224176396|NCT03673631|DEVICE|NIV|NIV setting: minimal FiO2 0.3; tidal volume 6-8ml/kg (theoretical body weight)
224176397|NCT03673631|DEVICE|NFHC-O2|NFHC-O2 setting: minimal FiO2 0.3; minimal flow 40l/min
224176398|NCT03322592|DIAGNOSTIC_TEST|Rapid on-site evaluation (ROSE)|On-site evaluation of the acquired samples will be performed by pathologist
224176399|NCT03322592|DIAGNOSTIC_TEST|Histologic evaluation|Samples collected in the EUS-FNB without ROSE will be processed as histologic samples
224176400|NCT05833061|OTHER|The Stroke-Specific Quality of Life (SS-QoL) scale|The Stroke-Specific Quality of Life (SS-QoL) scale is a questionnaire-based tool that is used to assess the quality of life of individuals who have experienced a stroke. It was developed to evaluate the impact of stroke on various domains of life, including physical, psychological, and social aspects. The SS-QoL scale contains 49 items, which are organized into 12 domains such as mobility, self-care, work/productivity, language, social roles, and emotional well-being. The scale has been validated and is widely used by healthcare professionals and researchers to assess the effectiveness of interventions and treatments for stroke patients, as well as to evaluate the long-term impact of stroke on their quality of life.
223486539|NCT04426032|DIAGNOSTIC_TEST|Renal Doppler Ultrasound|Measurement of Renal resistive index
223486540|NCT01932606|DRUG|Nitrite|Study drug (NaNO\_2 50 mcg/kg/min) will be infused for 5 minutes during the cardiac catheterization procedure.
224306480|NCT06462859|OTHER|Neurodevelopmental Treatment Group|The NDT program is customized for each child, featuring a mix of static and dynamic balance exercises, coordination exercises, mobility exercises, and strength training exercises. He attended 45-minute NDT sessions three times a week for 8 weeks. There is no treatment or medication other than NDT.
224306481|NCT03727659|BEHAVIORAL|SHADE therapy + CONNECT FaceBook support|"See study arms description."
224176401|NCT05833061|OTHER|The Stroke Self-Efficacy Questionnaire (SSEQ)|The Stroke Self-Efficacy Questionnaire (SSEQ) is a tool used to measure an individual's perceived self-efficacy or confidence in managing the consequences of a stroke. It consists of 13 items that assess an individual's ability to manage various stroke-related challenges, such as physical, emotional, and social difficulties. The SSEQ is designed to help healthcare professionals and researchers understand how an individual's perceived self-efficacy influences their ability to cope with the consequences of a stroke and manage their recovery effectively. By measuring an individual's perceived self-efficacy, the SSEQ can help identify areas where additional support and interventions may be needed to improve their overall recovery and quality of life.
224176402|NCT01587599|BEHAVIORAL|counseling|The patients grouped to the intervention cohort receive pharmaceutical care by a pharmacist during the study period.
224176403|NCT00808028|BIOLOGICAL|meningococcal B rLP2086 vaccine.|vaccine, 0.5 mL, 0 - 2 - 6 to 9 months
224176404|NCT00808028|BIOLOGICAL|meningococcal B rLP2086 vaccine.|vaccine, 0.5 mL, 0 - 2 - 6 to 9 months
224176405|NCT00808028|BIOLOGICAL|meningococcal B rLP2086 vaccine.|vaccine, 0.5 mL, 0 - 2 - 6 to 9 months
224176406|NCT00808028|OTHER|normal saline (placebo)|vaccine, 0.5 mL, 0 - 2 - 6 to 9 months
224176407|NCT02582619|OTHER|Focus groups, semistructured interviews and Delphi rounds|
224176408|NCT01183130|DEVICE|Compliance monitoring with electronic device|Electronic compliance monitoring with monitoring device (Pharma DDSi, Stora Enso) is used in control group (n=6) and device with mobile phone in intervention group (n=6). Patients in intervention group send every day the information of their medication intakes with the mobile phone to the clinic. This intervention is tested in pilot study (n=2-3) before the actual study begins.
224176409|NCT01797302|DIETARY_SUPPLEMENT|Vitamin D3|Tablet form
224176410|NCT03228836|DRUG|Sintilimab|Sintilimab (IBI308) 200mg IV Q3W
224176411|NCT05644613|OTHER|aerobic exercise on land|aerobic exercise on land in form of walking on the treadmill
224176412|NCT05644613|OTHER|aerobic exercise in water|aerobic exercises in water in form of walking on the treadmill
224176413|NCT02114359|DRUG|Capecitabine/cisplatin|Capecitabine/cisplatin (XP) : cisplatin 50mg/m2 (80% dose of 60mg/2m) iv over 15min D1, capecitabine 1000mg/m2 (80% dose of 1250mg/m2) po bid D1-14, q 3wks
224176414|NCT02114359|DRUG|S-1/cisplatin|S-1/cisplatin (SP) : cisplatin 50mg/m2 (80% dose of 60mg/2m) iv ov 15min D1, S-1 30mg/m2 (80% dose of 40mg/m2) po bid D1-14, q3wks
224176415|NCT02114359|DRUG|Capecitabine/oxaliplatin|Capecitabine+oxaliplatin (XELOX): oxaliplatin 100mg/m2 (80% dose of 130mg/m2)iv ov 120min D1, capecitabine 800mg/m2 (80% dose of 1000mg/m2) po bid D1-14, q3wks
224176416|NCT02114359|DRUG|5-fluorouracil/oxaliplatin|5-fluorouracil/oxaliplatin (FOLFOX): oxaliplatin 80mg/m2 (80% dose of 100mg/m2) iv ov 120min, leucovorin 80mg/m2 (80% dose of 100mg/m2) iv ov 120min, 5-fluorouracil 1900mg/m2 (80% dose of 2400mg/m2) iv ov 46h D1, q 2wks
224176417|NCT02114359|DRUG|Capecitabine|Capecitabine : 1250mg/m2 po bid D1-14 q3wks (if Ccr \<60ml/min, 1000mg/m2 po bid)
224176418|NCT02114359|DRUG|S-1|S-1 : 40mg/m2 po bid D1-14 q3wks (if Ccr \<60ml/min, 30mg/m2 po bid)
224176419|NCT02114359|DRUG|5-fluorouracil|5-fluorouracil (FL) : leucovorin 100mg/m2 iv ov 2h, 5-fluorouracil 2400mg/m2 iv ov 46h D1, q2wks
224176420|NCT01866839|DEVICE|Graft Manipulation (CD34+ Selection)|
224176421|NCT05516316|DRUG|EP395|Capsule for oral use
224176422|NCT05516316|DRUG|Placebo|Capsule for oral use
223745315|NCT06892496|OTHER|Photographs of the patient's palate|At the 14-day, 30-day and 3-month follow-up visits, photographs of the patient's palate (Canon EOS 60D DSLR, Canon, USA) will be taken for healing evaluation as well as intraoral scans (TRIOS 4, 3Shape) of the palatal wound for linear and volumetric changes analysis.
224176423|NCT02773849|BIOLOGICAL|ADSTILADRIN|
224176424|NCT02288663|OTHER|measurement of morphological parameters|measurement of morphological parameters : thigh perimeter, leg perimeter, arm perimeter.
224176425|NCT02288663|BIOLOGICAL|a blood sample|One single blood sample to assay SCr (enzymatic), BUN (blood urea nitrogen), cystatin C, CRP, Na, K, Cl, albuminemia.
224176426|NCT02288663|BIOLOGICAL|albumin or blood in urine|dipstick analysis for albumin or blood in urine
224176427|NCT02288663|DEVICE|Dual X-ray absorptiometry (DXA)|measurement of lean body mass by whole-body DXA
224176428|NCT02288663|DEVICE|Bioelectric Impedance Spectroscopy (BIS)|measurement of lean body mass by BIS
224176429|NCT02288663|BIOLOGICAL|51Cr-EDTA plasma clearance|measurement of 51Cr-EDTA plasma clearance to determine GFR
224176430|NCT05042804|OTHER|Machine learning models predicting postoperative death and acute kidney injury|The machine learning display uses data from the electronic health record to predict the likelihood of postoperative death and postoperative acute kidney injury.
224176431|NCT02058186|DRUG|oral vitamin D|
224176432|NCT02058186|DRUG|Placebo|
224176433|NCT00001116|DRUG|Tumor Necrosis Factor soluble receptor-immunoadhesin complex|
224176434|NCT05883566|BEHAVIORAL|experimental|During the procedure, the chairside assistant can capture video recordings of the child's behavior and facial expressions. These videos can be later reviewed by a trained observer who can evaluate the child's pain experience
224176435|NCT00948389|DRUG|Dasatinib|Tablets, Oral, 100 mg, Once or Twice daily (depending on safety cohort), Until progression or toxicity
224176436|NCT00948389|DRUG|Lomustine|Tablets, Oral, 110 mg/m², Every 6 weeks, until progression or toxicity
223745316|NCT06892496|OTHER|Measuring graft dimensions|The graft dimensions will be measured with the use of a periodontal probe and recorded on the data collection form. The professional preference in regard to technique applied and the time spent by the surgeon to adjust the stent intraorally will also be recorded in the same form.
224176437|NCT02831894|DRUG|0% Hypnotic Medication Taper|Participants will not have their soporific hypnotic medication dosage changed during a 20 week blinded tapering period
224176438|NCT02831894|DRUG|25% Hypnotic Medication Taper|Participants will have their soporific hypnotic medication dosage reduced by 25% every two weeks during a 20 week blinded tapering period.
224176439|NCT02831894|DRUG|10% Hypnotic Medication Taper|Participants will have their soporific hypnotic medication dosage reduced by 10% every two weeks during a 20 week blinded tapering period.
224176440|NCT00289510|BIOLOGICAL|Inactivated influenza vaccine (whole virion, Vero cell-derived)|
224176441|NCT00289510|BIOLOGICAL|Inactivated influenza vaccine (egg derived) [licensed control vaccine]|
224176442|NCT06432361|BEHAVIORAL|Resource Allocation|Those in the intervention condition will receive weekly personalized information summarizing the previous week's resource allocation (e.g., personalized information on how they spent their time and money) in relation to their personal goals, interests, and alcohol use. They will also see a summary of how they spent their time and money in relation to their set goals for the week The information in the intervention feedback will be obtained from participant's responses to the daily surveys on how they spent their time and money each day. Reviewing the intervention feedback should take no longer than 10 minutes.
224176443|NCT06432361|OTHER|assessment only control|participants will complete a 3 week monitoring period of daily surveys assessing time spent in various domains during the time, alcohol use, personal goals, and money spent on alcohol and substance-free activities. Each daily survey should take no longer than 5 minutes to complete.
224176444|NCT01601093|DRUG|High dose|Ceftazidime 3g, iv, bid and Sulbactam Sodium 1.5g, iv, bid for 5-14days.
224176445|NCT01601093|DRUG|Low dose|Ceftazidime 2g, iv, bid and Sulbactam Sodium 1g, iv, bid for 5-14days.
224176446|NCT01601093|DRUG|Cefoperazone and Sulbactam Sodium (CFP/SUB)|Cefoperazone 2g, iv, bid and Sulbactam Sodium 1g, iv, bid for 5-14days.
223486541|NCT01932606|DRUG|Saline Placebo for Nitrite|Normal saline placebo will be infused for 5 minutes during the cardiac catheterization procedure. Hemodynamics will then be measured at baseline after study drug infusion and again during low level exercise (20 Watts).
223486542|NCT02598115|OTHER|Collaborative Pharmaceutical Care|The pharmacist performs collaborative pharmaceutical care in the ward: reconciliation of drug treatments and revision of drug prescriptions indicated on the admission drug prescription. He/she emits pharmaceutical interventions recorded on the standardized support provided by the French Society of Clinical Pharmacy. The pharmaceutical interventions are discussed during a collaborative interview.
223486543|NCT04315324|DRUG|AKR1C3-activated Prodrug AST-3424|Given IV
223486544|NCT04315324|PROCEDURE|Biopsy Procedure|Undergo biopsy
223486545|NCT04315324|PROCEDURE|Biospecimen Collection|Undergo blood and CSF sample collection
223486546|NCT04315324|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspirate
223486547|NCT04315324|PROCEDURE|Computed Tomography|Undergo CT scan
223486548|NCT06115122|OTHER|Pre-eclampsia screening program|Pregnant women will be devided into risk-, control- and PCOS groups according to first trimester screening program.
223486549|NCT04809753|DEVICE|Eustachian tube dilation|Dilation of the eustachian tube with an endovascular balloon
223745317|NCT06907186|OTHER|Psychological Support|Carrying out a systematic and organized path of psychological support interviews on a monthly basis in person or remotely.
224176447|NCT01142011|DRUG|Belimumab|"The first cycle of Belimumab (10mg/kg by intravenous (IV) infusion) is a loading cycle of 3 doses over 28 days (days 1, 15, 29). After the first cycle, additional cycles of belimumab (10mg/kg by intravenous (IV) infusion) will be administered every 28 ± 1 days (cycle 2 and all subsequent cycles).~The infusion will be administered over a minimum period of 1 hour."
224176448|NCT03331393|OTHER|Non-interventional|Non-interventional
223486550|NCT03822416|DRUG|Nicotine patch|Nicotine patch (dose based on number of cigarettes per day) (4-week, 8-week, or 12-week supply) depending on participant preference and how much they are smoking based on FDA guidelines for use
223486551|NCT03822416|DRUG|Nicotine lozenge|Nicotine lozenge (2 or 4 mg if less or greater than 30 minutes to first cigarette in the morning respectively) (4-week, 8-week, or 12-week supply) depending on participant preference and how much they are smoking based on FDA guidelines for use
223486552|NCT03822416|BEHAVIORAL|Therapy|In-person meeting at baseline, 6 phone counseling sessions with participants over 8 weeks after initial in-person meeting, possible additional phone counseling (3 phone calls) from 8 weeks to 6 months after initial in-person meeting, and possible text messages when agreed to by participants during the 8 week to 6 month phase
223486553|NCT03822416|OTHER|Information|Information about smoking and mental illness and referrals to both the QUITPLAN helpline and additional resources in the community
224176449|NCT00514241|DEVICE|The GPS™ II Platelet Concentrate Separation Kit|The GPS™ II Platelet Concentrate Separation Kit system is designed to be used for the safe and rapid preparation of autologous platelet-rich-plasma (PRP) from a small sample of blood at the patient's point of care. The PRP can be mixed with autograft and allograft bone prior to application to an orthopedic surgical site as deemed necessary by the clinical use requirements.
224306482|NCT04731870|OTHER|Survey research|This is not an intervention study. It involves social science research of surveys and focus groups.
224306483|NCT02606175|OTHER|Taking questionnaires and tests|"At predefined timepoints:~* 2 tests for health literacy: New Vital Sign-Dutch version (NVS-D) and Functional, Communicative and Critical Health Literacy (FCCHL)~* 1 test for medication adherence: BAASIS~* 1 questionnaire about demographic factors (weight, income, sex, age, financial situation,...)~* 1 test about medication knowledge"
223486554|NCT00080340|DRUG|TLK286 (Telcyta) HCl for Injection|
223486555|NCT00080340|DRUG|gefitinib (Iressa)|
223486556|NCT04700436|DRUG|Rosuzet tablet 10/5 mg (Ezetimibe 10 mg/Rosuvastatin 5 mg)|Test drug: Rosuzet tablet 10/5 mg (Ezetimibe 10 mg/Rosuvastatin 5 mg)
223486557|NCT04700436|DRUG|Suvast tablet 10 mg (Rosuvastatin 10 mg)|\- Control drug: Suvast tablet 10 mg (Rosuvastatin 10 mg)
223486558|NCT03057418|DRUG|Aurixim|Administration will be performed once a week during 4-week induction period, and then once per 12 weeks during supporting period, if necessary. Total maximum duration of the investigational therapy - 1 year, during which patients will receive up to 8 infusions of Aurixim.
223486559|NCT01809652|OTHER|Remote Implant Support Capability|Use of audio and video telepresence and remote control of device programmer to allow implant to be supported from a remote location
223486560|NCT02032485|DRUG|Indocyanine Green|An iv injection will be performed for the colorectal cancer patient before the operation.
223486561|NCT01532089|BIOLOGICAL|Bevacizumab|Given IV
223486562|NCT01532089|DRUG|Erlotinib|Given PO
223745318|NCT06909058|BEHAVIORAL|Study Postoperative Care|The study group will be given general postoperative instructions. They will also receive liberal activity restrictions instructing the patient to resume normal activities of daily living at their own discretion without specific restrictions.
223586624|NCT06130982|BEHAVIORAL|Health Qigong·Baduanjin|1-2weeks:learning stage, the frequency is 1 time/day, 5times/week,30 min /time,the total duration controlled within 50 minutes,and includes 4 intervention contents.Warm up activity:take a slow walk around the track and field to activate body and activate small joints (5min).Basic Skills learning of HQ·Baduanjin:breathing exercises,hand exercises,trunk exercises,step exercises,stake exercises(10min).Learning a single action of a routine (30min).Cool down (5min).3-8weeks:practice stage,the frequency and duration of intervention remain unchanged, and the intervention components still include 4 parts.Based on the first two weeks,the intervention content emphasizes more on the practice of complete routine movements, as well as learning and experience the theories and functions of movements.8-12weeks:stop intervention phase,the subjects resume their daily activities and stop intervention. After this, the final data measurement and collection are conducted again.
223617624|NCT02908022|DEVICE|Hokanson Rapid Cuff Inflator|The Hokanson Rapid Cuff Inflator will be placed on the lower right leg of the subject and utilized for pain testing purposes according to the protocol. Ascending pressures will be administered using the cuff to elicit different pain intensities.
224176450|NCT04390360|PROCEDURE|Protective ventilation implementation|In this condition, we will implement the protective ventilation related with gender and height . A blood gas will be performed at before protective ventilation implementation and at the end of this condition.Time condition 30 minutes
224176451|NCT04390360|PROCEDURE|Protective ventilation with HME|In this condition, the patient will received protective ventilation with a Heat Moisture Exchanger (HME). A blood gas will be performed at the end of this condition.Time condition 30 minutes
224176452|NCT04390360|PROCEDURE|Protective ventilation with Heated humidifier|In this condition, the patient will received protective ventilation with a Heated humidifier. A blood gas will be performed at the end of this condition.Time condition 30 minutes
224176453|NCT04390360|PROCEDURE|Tidal Volume reduction|n this condition, we will reduce Tidal volume (with smartphone application calculation) to obtain the same alveolar ventilation (PaCO2) obtained on the HME condition
223486563|NCT01532089|DRUG|Erlotinib Hydrochloride|Given PO
223486564|NCT01532089|OTHER|Laboratory Biomarker Analysis|Correlative studies
223486565|NCT06003764|OTHER|Pulsed electromagnetic field|low-frequency PEMFT (15 Hz, 50% intensity output for 5 s/min for 20 minutes)
223486566|NCT06003764|OTHER|traditional skin care|traditional skin care( the patients received the institutional standard skin care, which encompassed 3×/day application of topical, hydroactive colloid gel, from the first day of RT. In case of a painful skin reaction and/or moist desquamation, a foam, absorbent, self-adhesive silicone dressing was used. Additionally, the patient was advised to follow the general skin care guidelines (e.g., no tie, no electric shaving, no aftershave, gentle washing with or without mild soap, patting dry with a soft towel instead of rubbing
223486567|NCT01995201|DRUG|DMARD|non-biological disease-modifying antirheumatic drugs at stable dose
223486568|NCT01995201|DRUG|methotrexate|stable dose
223486569|NCT01995201|DRUG|tocilizumab [RoActemra/Actemra]|162 mg subcutaneously (SC) qw, Weeks 1-24
223486570|NCT01995201|DRUG|tocilizumab [RoActemra/Actemra]|162 mg SC qw or q2w, Weeks 24-48
223486571|NCT01995201|DRUG|tocilizumab [RoActemra/Actemra]|162 mg SC qw, Weeks 24-48
223486572|NCT04994964|DIAGNOSTIC_TEST|Electromyography|Needle vocal cord electromyography using Medtronic NIM monitor
223486573|NCT04619537|DRUG|Anlotinib Hydrochloride plus Docetaxel|Anlotinib Hydrochloride (12mg, QD PO d1-14, 21days per cycle) and Docetaxel (75mg/m2 IV d1)
223617625|NCT02620501|DRUG|Lidocaine|topical lidocaine
224176454|NCT01619176|DRUG|methotrexate|methotrexate: 7.5mg/week to 15mg/week for 3 months
223486574|NCT00137319|DEVICE|Impedance threshold device|
223486575|NCT03329001|DRUG|Niraparib Tablet|Niraparib tablet formulation
223486576|NCT03329001|DRUG|Niraparib Capsule|Niraparib capsule formulation
223486577|NCT00622518|DRUG|Hyland's earache drops|3-4 drops in affected ear 3 times a day as needed for up to 5 days
223486578|NCT00134576|BEHAVIORAL|Computer Assisted Education for Behavioral Change|TLC-Detect will provide subjects in the intervention group with information about each diagnosed mental health disorder. TLC-Detect will then give the Treatment Module and will tell the intervention subjects that it will call back in one month for a follow-up or the next week if a subject is comorbid with other disorders.
223486579|NCT02513875|DIETARY_SUPPLEMENT|vitamin D|60,000 IU per week for 8 weeks
223486580|NCT02513875|DIETARY_SUPPLEMENT|Placebo|placebo +diet and lifestyle
223486581|NCT00782444|PROCEDURE|Computer navigated knee replacement|Total knee replacement performed with the use of navigation system from Brainlab with the Profix total knee implant.
223486582|NCT00782444|PROCEDURE|Conventional knee replacement|Conventional total knee replacement performed in a traditional way with the use of intramedullary rods, with the Profix implant.
223486583|NCT00809198|OTHER|Sodium Hyaluronate|
223486584|NCT00809198|OTHER|Carboxymethylcellulose sodium|
223486585|NCT01034423|DIETARY_SUPPLEMENT|Omega-3|Capsules with omega-3 fatty acids.
223486586|NCT01034423|DIETARY_SUPPLEMENT|sun flower oil|Capsules with sun flower oil.
223486587|NCT06467734|DEVICE|Joint aspiration|Joint puncture to extract joint fluid.
223486588|NCT01592838|OTHER|Data collection|The participating centre will be requested to generate a coded list of all hospitalisations taken place during the study period (June 1st 2004- May 31st 2010) and analysed for changes in hospital pattern pre- versus post-rotavirus vaccination, in children aged ≤15 years.
223617626|NCT02620501|DRUG|Placebo|0.45% Normal Saline
224176455|NCT01619176|DRUG|non-steroidal anti-inflammatory drug (NSAID)|NSAID: 100mg twice a day for 3 months
224176456|NCT01619176|DRUG|leflunomide|leflunomide: 20mg/day for 3 months
224176457|NCT01619176|DRUG|methotrexate|methotrexate: 7.5mg/week to 15mg/week for 3 months
224176458|NCT01619176|DRUG|non-steroidal anti-inflammatory drug (NSAID)|NSAID: 100mg twice a day for 3 months
224176459|NCT01619176|DRUG|leflunomide|leflunomide: 20mg/day for 3 months
224176460|NCT01619176|PROCEDURE|Acupuncture|"30 minutes acupuncture every other day for 3 months.~Basic acupoints: Zusanli, st36; Taixi，KI3）; Shenxu, BL23 Additional acupoints due to personal condition: Waiguan，SJ5; Baxie，Ex-UE9;Yinlingquan，(SP9）; Quchi，LI11; Yanglingquan，GB34; Xuehai，SP10; Dazhu，BL11; Dazhui，DU14; Pixu，BL20."
224176461|NCT02432924|BEHAVIORAL|Instant + Multidimensional Physical Activity Feedback|
224176462|NCT02911324|DRUG|Nabilone|"Nabilone is a synthetic cannabinoid that is thought to be a Cannabinoid receptor type 1 (CB 1) agonist. It acts on the brain's endocannabinoid system, which has been hypothesized to play a role in OCD."
224176463|NCT02911324|BEHAVIORAL|Exposure and Response Prevention Therapy|Exposure and Response Prevention Therapy (EX/RP) is a type of Cognitive-Behavioral Therapy for OCD that involves intentionally confronting situations that trigger obsessional distress while refraining from doing compulsions.
224176464|NCT02418000|DRUG|E6201|Single Group Assignment
224176465|NCT04309175|DEVICE|base rate programming of a permanent cardiac pacemaker|Base rate of a subject's pacemaker is set to a slower, and after wash-out, to a faster pacing rate (Slow-Fast Arm) or to a faster, and after wash-out, to a slower pacing rate (Fast-Slow Arm)
224176466|NCT02772042|OTHER|Intervention Group|
224176467|NCT02772042|OTHER|Control Group|
224176468|NCT01990001|OTHER|enrollment in online reminder system|Study personnel enrolled members in the online reminder system during their office visit.
224176469|NCT01722552|BEHAVIORAL|adherence feedback|
224176470|NCT01722552|BEHAVIORAL|standard of care|
224176471|NCT06056245|PROCEDURE|Preoperative step|"* Explanation of the surgery and use of the IV-PCA pump.~* Signed informed consent."
224176472|NCT06056245|DRUG|Intraoperative|Bolus of methadone 0.1mg/kg based on ideal body weight (up to a maximum dose of 20 mg), at the beginning of surgery.
224176473|NCT06056245|DRUG|Post-operative|Installation of IV-PCA of methadone. Program to be used with no background infusion, boluses of 1 mg, and the intervals between boluses of 8 minutes.
224176474|NCT04703959|OTHER|polysomnography|polysomnography is already done for all patients
224176475|NCT05288764|DEVICE|Bispectral Index|Comparing Bispectral index values (usually adopted during general anaesthesia monitoring) to Ketamine concenetration at the effector site calculated with Domino model pump (usually adopted for Ketamine infusion during general anaesthesia)
224176476|NCT03261739|BIOLOGICAL|RYI-018|Anti-CB1 monoclonal antibody
224176477|NCT03261739|BIOLOGICAL|Placebo|Placebo
224176478|NCT03993002|OTHER|Normoxia with Normocarbia|PaO2 \< 100 (FiO2 \>= 21%) PaCO2 of 30-40
224176479|NCT03993002|OTHER|Normoxia with Hypercarbia|PaO2 \< 100 (FiO2 \>= 21%) PaCO2 of 50-60
224176480|NCT03993002|OTHER|Hyperoxia with Normocarbia|PaO2 \> 250 (FiO2 \>= 70%) PaCO2 of 30-40
224176481|NCT03993002|OTHER|Hyperoxia with Hypercarbia|PaO2 \> 250 (FiO2 \>= 70%) PaCO2 of 50-60
224176482|NCT02056249|OTHER|Norepinephrine Transporter (NET) ligand|Norepinephrine Transporter (NET) ligand for iv administration during Positron Emission Tomography scan to measure changes in brain NET concentration based on insulin levels.
224176483|NCT01845766|OTHER|exercise rehabilitation|
224176484|NCT00327834|DRUG|atomoxetine|
224176485|NCT00508001|DRUG|Vandetanib|ZD6474 300mg
224176486|NCT00508001|DRUG|Vandetanib|ZD6474 100 mg
224176487|NCT00508001|DRUG|Best Supportive Care|Placebo + Best Supportive Care
224176488|NCT00946829|DRUG|telmisartan|
224176489|NCT05850429|DIETARY_SUPPLEMENT|Seaweed protein|Novel protein extracted from seaweed
224176490|NCT05299112|DIETARY_SUPPLEMENT|Arginine|The intervention parenteral nutrition contains additional arginine (18% arginine content) as compared to standard parenteral nutrition (6.3% arginine content).
224176491|NCT04035369|PROCEDURE|Tap and Inject (TAI)|"Patients randomized to the TAI group will have a 0.2 mL vitreous specimen collected and a 0.1 mL anterior chamber paracentesis performed to be sent for standard cultures, Gram stain, and sensitivities.~Intravitreal injection of the following antibiotics: Vancomycin 1.0 mg/0.1 mL, ceftazidime 2.25 mg/0.1 mL (amikacin 400 mcg/0.1 mL instead of Ceftazidime if severe penicillin allergy) and an intravitreal injection of dexamethasone 400 mcg/0.1 mL"
224176492|NCT04035369|PROCEDURE|Pars Plana Vitrectomy (PPV)|Patients randomized to the PPV group will undergo a three-port PPV. The patient should be added to the OR list as an A-case (maximum 6 hours wait) and no intravitreal injection should be performed prior to the surgery. A 0.1 mL aqueous humor simple immediately before the surgery. A 0.2 mL vitreous specimen will be obtained after the sclerotomies are placed. The PPV procedure should be limited to core vitrectomy, air fluid exchange and intravitreal injections (antibiotics and dexamethasone - Vancomycin 1.0 mg/0.1 mL, ceftazidime 2.25 mg/0.1 mL or amikacin 400 mcg/0.1 mL instead of Ceftazidime if severe penicillin allergy and an intravitreal injection of dexamethasone 400 mcg/0.1 mL). Other tamponades such as silicone oil should be avoided if possible. The PPV will then be completed by the surgeon and the vitreous specimen will be sent for standard cultures, Gram stain, and sensitivities.
223617627|NCT01647165|DRUG|Bortezomib|Cycle 1-8: 1.0 mg/m2 SC at a concentration of 2.5 mg/ml or 1 mg/ml to the thighs or abdomen on days 1, 4, 8, 11 of a 21 day cycle for 8 cycles.
223617628|NCT01647165|DRUG|Lenalidomide|Cycle 1: 15 mg oral daily on days 2-14 of 21 day cycle; Cycle 2-8: 15 mg oral daily on days 1-14 of a 21 day cycle
223617629|NCT01647165|DRUG|Dexamethasone|Cycle 1: 10 mg oral or IV daily on days 2,4,5,8,9,11,12 of a 21 day cycle; Cycle 2-8: 10 mg oral or IV on days 1, 2, 4, 5, 8, 9, 11, 12 of a 21 day cycle
224176493|NCT02422537|DIETARY_SUPPLEMENT|Unmodified wheat bran|
224176494|NCT02422537|DIETARY_SUPPLEMENT|Wheat bran with reduced particle size|
224176495|NCT02422537|DIETARY_SUPPLEMENT|Destarched pericarp-enriched wheat bran|
224176496|NCT02422537|DIETARY_SUPPLEMENT|No wheat bran fraction|
224176497|NCT00114400|DRUG|folic acid|
224176498|NCT00114400|DRUG|vitamin B12|
224176499|NCT00114400|DRUG|vitamin B6|
224176500|NCT00848172|DRUG|Octanoic Acid|4mg/kg
224176501|NCT00848172|DRUG|Placebo|identical capsules
224176502|NCT03100929|DIAGNOSTIC_TEST|Ultrasound|Pre-operational ultrasound for the detection of fetal heart rate, fetal presentation and presence of nuchal cord.
224176503|NCT05033106|DRUG|Bevacizumab, Ranibizumab|• A dose of 0.25 mg/0.025 mL ranibizumab (Lucentis) is injected in the right eye of the infant and 0.625 mg/0.025 mL bevacizumab is injected into the vitreous cavity of the left eye 1 mm posterior to the superior/inferior temporal limbus via 30 G needle. The two injections are done sequentially on two consecutive days starting with the eye of more advanced disease.
223617630|NCT02893566|BEHAVIORAL|Mi Band Step Challenge|
224176504|NCT05763030|BEHAVIORAL|Adapted Sleep Well, Bee Well (SWBW)|The SWBW is a 3-week multilevel behavioral sleep intervention that targets organizational (daycare worker-parent), interpersonal (parent-child, daycare worker-child), and individual (child) levels. It provides parent education supporting parent-child interaction at bedtime, helps to adopt a bedtime routine and early bedtime (Table 4). At the beginning of the 3-week intervention period, the parent and teacher co-develop tailored sleep health goals towards meeting the Bedtime, Environment, and Duration (BED) recommendations139-141 for the child. Parents receive an inexpensive bedtime kit, a storybook, and an informational brochure. The parent and child select four activities from the kit to perform at bedtime every night. The brochure has a section for the parents to write sleep goals. During the intervention, daycare teachers provide daily feedback support to parents at pick-up or drop-off. The program has a manualized structured curriculum suitable for use by paraprofessionals.
224176505|NCT03128372|DEVICE|Desaturation|The delivered gas mixture will be adjusted to decrease the displayed saturation of peripheral oxygen. Each desaturation steps are of approximately 5 minutes duration with reduction in pulse oximeter oxygen saturation from 100 to 70%.
224176506|NCT03530059|OTHER|Home-based rehabilitation|Observational study
224176507|NCT03399331|DIETARY_SUPPLEMENT|Manuka honey|5 for children or 10cc of honey for adults was ordered directly from a New Zealand company
224176508|NCT03399331|DIETARY_SUPPLEMENT|olive oil|5 cc of extra virgin olive oil for adults and 2 cc for children directly from a local distributor in south Lebanon will be given.
224176509|NCT03399331|COMBINATION_PRODUCT|Control group|Control at our institution is 5cc sodium bicarbonate, 5cc rinsidin and 5cc of mycostatin 4 times daily for children. For adults it is Caphosol in the BMT unit and in the Basile inpatient unit it is the magic solution (without xylocaine).
224176510|NCT02709941|OTHER|Inspiratory muscle strength training|Breathing training designed to augment inspiratory muscle strength, and thus targeted muscle groups may benefit from improved force generating capability result in improved breathing.
224176511|NCT02709941|OTHER|Placebo|
224176512|NCT05841615|OTHER|Renal Denervation operation|RDN: Percutaneous renal artery sympathetic radiofrequency ablation for both sides. For each side, a total of 13 targets were ablated. The ablation power was 8W\~12W for 40 seconds
224176513|NCT05841615|OTHER|Pulmonary vein isolation|PVI: Pulmonary vein isolation was performed until the potential of each pulmonary vein disappeared under the guidance of the CARTO mapping system. Ablation of the top line and the bottom line of the left atrium was performed at the same time.
224176514|NCT05510791|DIETARY_SUPPLEMENT|Nuun Sport Drink|Subjects will consume a total of 24 ounces water and 1.5 tablets of Nuun SPORT. Specifically, subjects will drink 12 ounces of Nuun drink 15 minutes prior to the 60 min run and 4 ounces of Nuun drink at 15 min, 30 min, and 45 min during the run.
224176515|NCT05510791|DIETARY_SUPPLEMENT|Control|Subjects will consume a total of 24 ounces water. Specifically, subjects will drink 12 ounces of water 15 minutes prior to the 60 min run and 4 ounces of water at 15 min, 30 min, and 45 min during the run.
224176516|NCT00869063|DRUG|Diclofenac Sodium Patch|Topical 1% diclofenac sodium patch, applied once daily for 7 days
224176517|NCT00869063|DRUG|Matching Placebo Patch|Matching placebo patch, containing identical constituents to the active drug arm except for diclofenac sodium; applied once daily for 7 days
224176518|NCT00519220|OTHER|Symptom questionnaire|Patients will answer questionnaires evaluating their symptoms of achalasia.
224176519|NCT03823963|COMBINATION_PRODUCT|Mepilex® Border dressing|Soft silicone self-adherent dressing (5-layers)
224306484|NCT06024200|OTHER|transcutaneous electrical acupoint stimulation|Electrical stimulation is performed within 24h before surgery, 30min before anesthesia induction and 3 days after surgery, each stimulation was 30min. Patients are treated bilaterally at two groups of distal acupoints: one group consisted of Hegu (LI4) and Neiguan (PC6), the other contained Zusanli (ST36) and Shanyinjiao (SP6). Stimulation is delivered with adisperse-dense wave, 2Hz in frequency. The stimulation intensity is adjusted in accordance with the maximal level tolerated by each patient.
224176520|NCT03823963|OTHER|Standard care|The control group will receive pressure ulcer prevention standard care
224176521|NCT04302363|OTHER|Fecal microbiota detection and exfoliated cell gene detection|Fecal microbiota detection and exfoliated cell gene detection
224176522|NCT01199640|DRUG|MLN1202|Patients received 5 intravenous (IV) infusions of the study drug. The first 3 infusions were administered at 15-day intervals, followed by 2 infusions at 30-day intervals. Patients were randomized to receive 1 of 2 doses of MLN1202 (4mg/kg or 8mg/kg).
224176523|NCT01509066|OTHER|Diet|Dietary approaches for PCOS
224176524|NCT02995018|DRUG|BAY987521|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation Code: Z09-174)
224176525|NCT02995018|DRUG|SPF Control|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.
224176526|NCT00721136|DRUG|continue warfarin through the procedure|The usual dose of warfarin (resulting in a therapeutic INR) is taken throughout the peri-procedural period.
224176527|NCT00721136|DRUG|Hold warfarin|For moderate risk patients, warfarin will be held for 4-5 days prior to the procedure.
223486589|NCT04557774|OTHER|Cognitive function test|"Laboratory and imaging test~* Biochemical serum test: total bilirubin, alanine aminotransferase (ALT), haptoglobin, aspartate aminotransferase (AST), gamma glutamyltranspeptidase (GGT), alkaline phosphatase (ALP), albumin, blood urea nitrogen, creatinine, α-fetoprotein (AFP), prothrombin time, blood glucose, triglycerides, and total cholesterol.~* Baseline evaluations: family and alcohol history, X-ray, electrocardiography, blood tests for electrolyte, liver function, and viral markers~Neuropsychological test~-Attention, Language, Visuospatial, Memory, Frontal/executive"
224176528|NCT00721136|DRUG|Warfarin held with heparin transition.|For high risk patients, warfarin is held for 4-5 days prior to the procedure and heparin is given to provide anticoagulation while the INR is subtherapeutic.
224306485|NCT06024200|OTHER|transcutaneous electrical acupoint stimulation sham stimulation|Patients are treated bilaterally at four sham acupoints of LI4, PC6, ST36 and SP6. These four pseudo-acupoints were located 1 cun ulnarlateral, and 7 cun and 9 cun proximal to Shenmen (HT7) ;and 9 cun and 12 cun proximal of Kunlun (BL60). These sham points are picked because there are no meridians or channels through these four sites. The stimulation intensity is adjusted in the lowest level felt by each patient. Other intervention details are similar to those of the experimental group.
224306486|NCT02397642|PROCEDURE|IVF/ICSI|
224176529|NCT00732199|OTHER|1) hyperventilation via noninvasive positive pressure ventilation 2) multiple trials of episodic hypoxia|1\) noninvasive hyperventilation to determine apneic threshold; 2) episodic hypoxia to determine ventilatory long term facilitation
224176530|NCT03293706|OTHER|CHO Control 1 and 2 Glucose|mixed in 237 ml/8 fl. oz. of a flavored non-caloric beverage; 1 time consumption
224176531|NCT03293706|OTHER|CHO Experimental 1 Slowly Digested|mixed in 237 ml/8 fl. oz. of a flavored non-caloric beverage; 1 time consumption
224176532|NCT03293706|OTHER|CHO Experimental 2 Digestion Resistant|mixed in 237 ml/8 fl. oz. of a flavored non-caloric beverage; 1 time consumption
224176533|NCT03293706|OTHER|CHO Experimental 3 Low Sugar|mixed in 237 ml/8 fl. oz. of a flavored non-caloric beverage; 1 time consumption
224176534|NCT03293706|OTHER|CHO Experimental 4 Maltodextrin|mixed in 237 ml/8 fl. oz. of a flavored non-caloric beverage; 1 time consumption
224176535|NCT04171752|DRUG|elafibranor|elafibranor 120mg is a coated tablet for oral administration
224176536|NCT03588949|DIETARY_SUPPLEMENT|Dietary Supplement with L-carnitine (FertilHom)|1 stick of the TDS (vitamins, trace elements with carnitine) will be given 1 time daily in the evening before meals for 6 months or until pregnancy, depending whatever comes first
224176537|NCT03588949|DIETARY_SUPPLEMENT|Control Dietary Supplement|1 stick of the TDSwill be given 1 time daily in the evening before meals for 6 months or until pregnancy, depending whatever comes first
224176538|NCT02303535|PROCEDURE|Cardiac Surgery|All patients with congential and acquired heart disease treated by cardiac surgery procedures.
224176539|NCT02303535|PROCEDURE|Therapeutic cardiac catheterisations procedures|All patients with congential and acquired heart disease treated by therapeutic cardiac catheterisations procedures .
224176540|NCT01747928|OTHER|dual-chamber syringe|dual-chamber syringe for mock injection
224176541|NCT01070654|PROCEDURE|40/30 recruitment manoeuvre|The ventilator will be switched to the continuous positive airway pressure (CPAP) mode and the pressure will be increased to 40 cmH20 for 30 seconds.
224176542|NCT01070654|DEVICE|continuous positive airway pressure (CPAP)|continuous positive airway pressure (CPAP)
223486590|NCT03769493|BEHAVIORAL|Mobile After-Care Support (MACS) app|The MACS app assesses and intervenes by fostering increased treatment adherence (medication/appointments) and self-coping with illness (active, planned, problem-solving focused) to reduce symptoms and improve functioning. Additionally, MACS encourages participants who are already reporting adherence and healthy coping by using positive reinforcement strategies to maintain efforts and promote additional goal setting. MACS app strategies are linked to participants' specific assessment responses, allowing for a highly personalized self-management intervention experience. The MACS app provides interactive exercises delivered by the device designed to teach patients coping skills that they can use now and in the future.
224176543|NCT01986049|DRUG|Bupivicaine|
224176544|NCT03011164|PROCEDURE|Walk and Run|Once participants are eligible, they will undergo the experimental procedure. Before data collection, they will walk or run on a treadmill in barefoot for ten minutes to adapt the condition. The a gait analysis system will collect the data while they walk or run on the treadmill in barefoot at selected gait speed.
224176545|NCT05152836|DEVICE|Vibrotactile stimulation at tremor frequency|Mechanical vibrations are applied at brief bursts of 80Hz that occur at the individual tremor frequency. Vibrations are delivered via a small device, which is worn on the wrist of the most-affected arm.
224176546|NCT05152836|DEVICE|Vibrotactile stimulation at tremor frequency*1.5|Mechanical vibrations are applied at 80Hz bursts at individual tremor frequency\*1.5. Vibrations are delivered via a small device, which is worn on the wrist of the most-affected arm.
223486591|NCT00084630|DRUG|imatinib mesylate|Given orally
223486592|NCT00084630|OTHER|laboratory biomarker analysis|Correlative studies
223486593|NCT02456064|BEHAVIORAL|Lifestyle counseling|"* Group medical visits~* Telephone medical consultations~* Expert patient~* Training workshops"
223486594|NCT06168214|DRUG|Rabeprazloe+bismuth+amoxicillin+clarithromycin|PBAC: 14D: PPI: Rabeprazole 10mg bid; B: bismuth potassium citrate240mg bid/ colloidal bismuth pectin 300mg bid/ colloidal bismuth tartrate 220mg bid; A:amoxicillin1000mg bid; C: clarithromycin 500mg bid.
224176547|NCT05152836|DEVICE|Vibrotactile stimulation at continuous stimulation|Continuous 80Hz stimulation is applied via a small device worn on the wrist of the most-affected arm.
224176548|NCT05152836|DEVICE|Vibrotactile stimulation 10% below and above step frequency|This intervention is applied during assessment of gait. Two devices are worn on both ankles which allows alternating stimulation of both ankles with brief bursts of 80 HZ at the individual step frequency plus or minus 10%.
224176549|NCT01343940|BEHAVIORAL|Project dulce|"Participating families are assigned to a legal/developmental specialist who joins health care team during well-child visits and home visits. The specialist (a Dulce family partner) supports parent around child development issues, addresses unmet basic needs (e.g., housing, utilities, food, etc.), and makes referral to existing agencies and services. Specialist meets with family during all routine well-child visits scheduled in primary care between birth and 6 months (1-mo, 2-mo, 4-mo, 6-mo). Parent may meet with specialist before or after scheduled appointment, and may request a home visit. Specialist will be available by phone for consultation."
224176550|NCT01343940|BEHAVIORAL|Safety intervention|Participating family is assigned a safety specialist. Meeting with the safety specialist will occur before or after a routine well-child visit or at a separately agreed upon time. The specialist will discuss infant injury risks associated with transportation and sleep. The specialist will provide safety equipment (car seat and pack-and-play) and instruct the parent in their proper use.
223486595|NCT06168214|DRUG|Vonoprazan+amoxicillin+clarithromycin 14 days|VAC14: 14D: V: vonoprazan 20mg bid; A: amoxicillin1000mg bid; C: clarithromycin 500mg bid.
223486596|NCT06168214|DRUG|Vonoprazan+amoxicillin+clarithromycin 7 days|VAC7: 7D: V: vonoprazan 20mg bid; A: amoxicillin1000mg bid; C: clarithromycin 500mg bid.
224176551|NCT02404792|OTHER|High-intensity cardiovascular and resistance exercise|
224176552|NCT02404792|OTHER|Moderate-intensity cardiovascular and resistance exercise|
224176553|NCT01295632|DRUG|ridaforolimus|10 mg enteric-coated tablets, orally, starting dose 2 tablets and escalating to 4 tablets each day for 5 days per week.
224176554|NCT01295632|DRUG|MK-0752|300 mg capsule, orally, 6 capsules per dose, once each week.
224176555|NCT01295632|DRUG|MK-2206|Tablets (5 mg, 25 mg, and 200 mg) to equal starting dose of 90 mg and escalating to 200 mg per dose, orally, once each week.
224176556|NCT04563624|DRUG|composite blocks|cad cam composite blocks
224176557|NCT04563624|DRUG|ceramic cad cam blocks|ceramic cad cam blocks
224176558|NCT04510844|DRUG|Evolocumab|Evolocumab is commercially available in the United States and is manufactured by Amgen. Drug and placebo, will be supplied by the manufacturer. The SureClick® pre-filled auto injector contain Evolocumab (140 mg) acetate (1.2 mg), polysorbate 80 (0.1 mg), proline (25 mg) in water for Injection. Evolocumab will be administered at a dose of 420 mg subcutaneously once monthly.
224176559|NCT04510844|OTHER|Placebo|Placebo will be supplied by the manufacturer. Placebo auto injectors will be identically packaged but will lack the active ingredient. Placebo will be administered at an equivalent volume to Evolocumab and given subcutaneously once monthly.
224176560|NCT04952116|OTHER|Eyelid reconstruction|Assessment of differrent techniques in anterior and posterior lamella reconstruction after periocular defects
224176561|NCT06238349|DRUG|Oral bifidobacterium triple live powder|The newborns in the Bifidobacterium group will receive all interventions prescribed for the control group, and also were assigned to orally be given Bifidobacterium triple viable powder (Shanghai Xinyi Pharmaceutical Company, Peifeikang powder, 0.5 g/dose, 3 times/day. Bifidobacterium triple viable powder contains live bacteria of long Bifidobacterium at no less than 1.0 × 107 CFU/g, stored at 2.8℃ away from light) beginning within 24 hours after birth and continuing for 1 week. No sunbathing will be prescribed.
224176562|NCT06238349|OTHER|Sunbathing|The sunbathing group will receive all interventions prescribed for the control group and be assigned to sunbathing (placement in a bed next to a sunny window) after birth for one week according to the following plan: Every morning and afternoon neonates sunbath for 0.5 to 1 hour to avoid excess sun exposure. Healthcare workers will guide and assist families in their preparations. The caregiver will place a black eye patch on the infants to protect the retina, and a cloth will be wrapped around the hands and feet to prevent scratching, but care will be taken that the wrap is not too tight to avoid circulation disorders. Baby boys will have their genitals covered to protect them from sun damage. After feeding, the newborn will be placed on a sunny platform with fully exposed skin and frequent position changes, while the glass of the window prevent injury from UV light exposure.
224176563|NCT06238349|OTHER|Sunbathing and the Oral bifidobacterium triple live powder|The combination group will receive all interventions of both the group sunbathing and the Bifidobacterium group as well as all interventions prescribed for the control group.
223486597|NCT06168214|DRUG|Vonoprazan+tetracycline+furazolidone 14 days|VTF14: 14D: V: vonoprazan 20mg bid; T: tetracycline 500mg tid; F: furazolidone 100mg bid.
223486598|NCT06168214|DRUG|Vonoprazan+tetracycline+furazolidone 7 days|VTF7: 7D: V: vonoprazan 20mg bid; T: tetracycline 500mg tid; F: furazolidone 100mg bid.
223486599|NCT06168214|DRUG|Vonoprazan+amoxicillin+furazolidone 7 days|hVAF: 7D: V: vonoprazan 20mg bid; A: amoxicillin1000mg tid; F: furazolidone 100mg bid.
223486600|NCT06168214|DRUG|Vonoprazan+amoxicillin+tetracycline 14 days|hVAT: 14D: V: vonoprazan 20mg bid; A: amoxicillin1000mg tid; T: tetracycline 500mg tid.
223486601|NCT06168214|DRUG|Vonoprazan+amoxicillin 7 days|hVA7: 7D: V: vonoprazan 20mg bid; A: amoxicillin1000mg tid.
223486602|NCT06168214|DRUG|Vonoprazan+amoxicillin 14 days|hVA14: 14D: V: vonoprazan 20mg bid; A: amoxicillin1000mg tid.
223486603|NCT00884988|DRUG|Lymphomyosot|20 drops X3/day, until discharge
223486604|NCT00884988|DRUG|Placebo remedy|20 drops X3/day, until discharge
223486605|NCT01986998|DRUG|Methylprednisolone 1250 mg/24h x3 days|Oral Methylprednisolone 1.250 mg daily, over 1 hour and during 3 consecutive days. 13 capsules will be administered (12 capsules of 100 mg and 1 capsule of 50 mg)
223486606|NCT01986998|DRUG|Oral Methylprednisolone 625 mg/24h x3 days|Oral Methylprednisolone 625 mg daily, over 1 hour and during 3 consecutive days. 13 capsules will be administered (6 capsules of 100 mg, 1 capsule of 25 mg and 6 capsules of placebo with the same appearance of capsules of 100 mg)
223486607|NCT01431742|DRUG|BEMA Buprenorphine|buccal soluble film; applied to the buccal mucosa twice daily
223486608|NCT01294540|DRUG|Drug: E2609|E2609 orally at varying ascending doses
223486609|NCT01294540|DRUG|Placebo|Matching Placebo
224176564|NCT06238349|OTHER|Conventional treatment|Conventional treatment: Neonates will be placed in an incubator (Ningbo David Medical Device Co., LTD, XHZ model) at 30℃ and relative humidity at 55%. Throughout the study, exclusive breastfeeding and professional care will be provided for the newborns. Newborns requiring phototherapy receive it in the following manner: Phototherapy eye masks (Foshan Forman Medical Technology Co., LTD., Yuesun Mechanical Equipment No. 20160015) and phototherapy diapers (Foshan Baojusheng Medical Equipment Co., LTD., GB/T33280) will be used to cover the eyes and perineum, respectively. Phototherapy was provided via LED blue light continuous irradiation with a wavelength of 425-475nm. All treated neonates will receive continuous phototherapy for 12 hours, then allowe to rest for 6-8 hours, then receive another 12 hours of continuous phototherapy. The decision to continue with further treatment depends on changes in the neonate's jaundice.
224176565|NCT03137524|DEVICE|Hand Held Fan Therapy|Hand-Held fan therapy used to generate airflow directed to face during specific exercise test
224176566|NCT00818636|BEHAVIORAL|Expressive writing (in addition to group therapy as usual).|Participants in the expressive writing condition write about their feelings about an issue of their choosing three times, for at least 20 minutes each time, during a two week period.
223486610|NCT04837170|DRUG|Conventional therapy + S (+)-Ketamine|Patients who undergo general anesthesia using S(+)-ketamine hydrochloride for anesthesia induction,maintenance or postoperative analgesia.
223486611|NCT04837170|DRUG|Conventional therapy|Receiving conventional therapy without S (+)-Ketamine hydrochloride injection. There is no restrictions in drugs, doses and incompatibility, the researchers can choose appropriate medication regimens based on clinical practice, but other NMDA receptor antagonists are not be allowed to use, such as dextromethorphan and amantadine.
223486612|NCT02709369|DEVICE|HIRREM|HIRREM is a noninvasive, closed-loop, allostatic, acoustic stimulation neuro-technology to facilitate recipient-unique relaxation, auto-calibration, and self-optimization of cortical neural oscillations by reflecting auditory tones in near real time. After an initial HIRREM assessment, evaluating patterns of brain electrical rhythms, subjects get a series of 90-120 minute HIRREM sessions, including 5 to 9 individualized protocols. A protocol is a combination of sensor montage and specific software design, during which dominant brain frequencies, recorded at high spectral resolutions, are translated to audible tones, and reflected back via earphones with as little as 8 milliseconds delay. Protocols are received sitting or reclining in a chair, some with eyes open, others eyes closed.
224176567|NCT00474552|DRUG|SAM-315|Multiple Ascending Doses of SAM-315 (treatment duration: 14 days): 0.2 mg; 0.5 mg; 1 mg; 2 mg;
224176568|NCT04771650|OTHER|CAMI|The CAMI is a culturally adapted motivational interview. It is a single 75 minute session that focuses on promoting motivation to change drinking and drug use behavior.
224176569|NCT01533285|BIOLOGICAL|Placebo|Placebo is Treatment A and C. Form=saline solution for intramuscular (IM) injection (Injection of a solution into a muscle), route = IM, Unit = mL, number = 0.5 administered on Day 1 of Period 1 and Period 2.
224176570|NCT01533285|BIOLOGICAL|Salmonella typhi vaccine (Typhim Vi)|Salmonella typhi vaccine (typhoid vaccination) in Treatment B and D; Unit = mg, number = 0.025, form = solution for intramuscularly (IM) injection, route = IM administered on Day 1 of Period 1 and Period 2.
224176571|NCT01157962|PROCEDURE|Lymphadenectomy in cervical cancer|Sentinel lymphadenectomy vs systematic pelvic lymphadenectomy
224176572|NCT04586127|OTHER|AYA NA-SB Questionnaire|Questionnaire identifying cancer needs so that providers can connect subjects with services that might address them.
224176573|NCT05844592|DRUG|INV-101|subjects will be randomized 3:1 ratio
224176574|NCT02870348|BIOLOGICAL|Alpha-1 MP|Alpha-1 MP is a stable, sterile, lyophilized preparation of human alpha1-PI, also known as alpha1-antitrypsin.
224176575|NCT01051856|DEVICE|SEAMGUARD with bioabsorbable staple|In the SEAMGUARD group, pancreatic resection and transection of the pancreatic body will be executed using an endoscopic linear stapling device.
224176576|NCT01051856|PROCEDURE|TissueLink with radiofrequency ablation|After pancreatic transection with the method of choice of the operating surgeon, the pancreatic remnant will be treated with Tissuelink alone for an ablation depth (thickness) of approximately 7 mm.
224176577|NCT04340089|BEHAVIORAL|squatting on the toilet|the patients could go to squatting on the toilet at any time as they want to after taking the capsule
224306487|NCT02397642|DRUG|Human Chorionic Gonadotropin|given in different doses and timing to support the luteal phase
224306488|NCT00429156|DEVICE|Home non-invasive ventilation|Continuation of home non-invasive ventilation after acute NIV for AHRF in COPD. Daily nocturnal treatment by home NIV for 1 year.
224306489|NCT00429156|DEVICE|Home non-invasive ventilation (sham)|Continuation of home non-invasive ventilation after acute NIV for AHRF in COPD. Daily nocturnal treatment by home sham NIV (CPAP 5 cm H2O) for 1 year.
223486613|NCT00963235|BIOLOGICAL|13-valent pneumococcal conjugate vaccine|Three doses of 13vPnC given 6 months apart.
223486614|NCT00963235|PROCEDURE|Blood draw|Six blood draws pre-vaccination and 1 month post-vaccination, doses 1-3.
223486615|NCT02749890|DRUG|Insulin glargine/Lixisenatide (HOE901/AVE0010)|"Pharmaceutical form: solution~Route of administration: subcutaneous"
223486616|NCT02749890|DRUG|Lixisenatide (AVE0010)|"Pharmaceutical form: solution~Route of administration: subcutaneous"
223486617|NCT02749890|DRUG|Oral anti-diabetic drugs|"Pharmaceutical form: tablet~Route of administration: Oral"
224176578|NCT02381795|DRUG|Nasal Carbon Dioxide|
224176579|NCT05707520|DRUG|enteric-coated mycophenolate (MPAs)|Immunosuppression protocol with enteric-coated mycophenolate sodium
224176580|NCT05707520|DRUG|None MPA|Immunosuppression protocol without enteric-coated mycophenolate sodium
224176581|NCT02176226|BEHAVIORAL|IntelliCare|Behavioral interventions for depression and anxiety via a mobile phone application, IntelliCare.
224176582|NCT01173874|DRUG|Cognitive Remediation|Cognitive remediation intervention will be administered in small group settings twice weekly for 30 sessions and will utilize computerized and verbal group training exercises to address basic skills such as auditory processing, attention, processing speed, and verbal working memory and learning, as well as intermediate and complex skills such as deductive reasoning, planning and sequencing, set shifting, and complex problem solving.
224176583|NCT05481190|BEHAVIORAL|Tele-Exercise Program|Data collection tools were applied to the tele-exercise group and control group at the beginning of the study. For the tele-exercise group, by the researcher, Exp. A 6-week exercise program was created under the consultancy of a physiotherapist. Children who met the research criteria were asked to do these exercises for 20 minutes, 3 times a week for 6 weeks. The exercises were performed online with the researcher at the scheduled time one day a week, and by the children twice a week. On the days they exercised, diaries consisting of semi-structured questions were sent to the children's addresses by cargo and they were allowed to keep a diary. Phone calls were made once a week to provide motivation and increase compliance with exercise. A smart watch was sent to the children by cargo to increase motivation. The children were asked to fill in the follow-up form, which was sent via weekly google forms.
224176584|NCT05481190|BEHAVIORAL|Just observation|Standard care was given to the children in the control group.
224176585|NCT02908841|DEVICE|Surgicel Snow|
224176586|NCT02908841|OTHER|Standard of Care|
224306490|NCT05259878|OTHER|Adverse Childhood Events|"• The Adverse Childhood Events (ACE) scale is a validated 10-item binary questionnaire (yes or no) that retrospectively measures domains of physical, emotional, and sexual abuse in the first 18 years of life. Scores range from 0 to 10 with higher scores indicating more adverse experiences during patients' childhood."
224306491|NCT05341297|BEHAVIORAL|ParentKIT|The intervention is structured in 9 modules through which parents learn to identify and manage their children's anxiety and depressive symptoms. The Internet intervention is guided by two psychotherapists under supervision training in Cognitive Behavioral Therapy, trained by the first author on the treatment protocol.
223486618|NCT05842291|DEVICE|Active rTMS with short inter-session interval|Participants in this group will receive ten sessions per day of 1800 pulses per session, at an inter-session interval of 20 min for 5 days. The individualized target will be generated using the personalized Brain Functional Sectors (pBFS) method.
224306492|NCT00539227|PROCEDURE|NAC Sparing Mastectomy|A skin-sparing mastectomy performed with preservation of the nipple-areolar complex (NAC).
224306493|NCT00539227|BEHAVIORAL|Questionnaire|Questionnaires taking about 20-30 minutes to complete.
224306494|NCT02991027|DEVICE|DRI OCT Triton|DRI OCT Triton using micro-electro-mechanical short cavity tunable laser
223486619|NCT05842291|DEVICE|Sham rTMS with short inter-session interval|Participants in this group will receive ten sessions per day of 1800 pulses per session, at an inter-session interval of 20 min for 5 days, using sham stimulation coils that comprehensively mimic the active condition. The individualized target will be generated using the personalized Brain Functional Sectors (pBFS) method.
224176587|NCT01611558|BIOLOGICAL|Ipilimumab|
224176588|NCT02465957|BIOLOGICAL|aNK (NK-92)|A natural killer cell line recovered from a patient with large granular lymphoma
224176589|NCT02465957|BIOLOGICAL|aNK (NK-92) + N-803|aNK - A natural killer cell line recovered from a patient with large granular lymphoma and N-803 - Recombinant human super agonist interleukin-15 (IL-15) complex
224176590|NCT01045902|DRUG|Avelox (Moxifloxacin, BAY12-8039)|Moxifloxacin, 400 mg iv, od, switch after 6 doses (6 days) to 400 mg Moxifloxacin oral, od
224176591|NCT01045902|DRUG|Sulbactam/Ampicillin|Sulbactam/Ampicillin, 3 g iv, tid, switch after 18 doses (6 days) to 750 mg Sulbactam/Ampicillin oral, bid
224176592|NCT01412333|DRUG|Interferon beta-1a|
224176593|NCT01412333|DRUG|Ocrelizumab-matching placebo|
224176594|NCT01412333|DRUG|Ocrelizumab|
224176595|NCT01412333|DRUG|Interferon beta-1a-matching placebo|
224176596|NCT00366106|DRUG|bortezomib|Patients will be treated with bortezomib at 1.3mg/m\^2 on Days 1, 4, 15, and 18 every 28 days (cycle).
224176597|NCT00366106|DRUG|dexamethasone|Dexamethasone tablets will be given at 20mg daily on Days 1, 2, 4, 5, 15, 16, 18, and 19 every 28 days (cycle).
224176598|NCT00366106|DRUG|doxorubicin HCl liposome|Patients will receive intravenous doxorubicin HCl liposome injection given at 30 mg/m\^2 on Day 4 every 28 days (cycle).
224176599|NCT03406806|OTHER|Gaitbox|"The walking path will be set according to the directions of the NIH toolbox 4 meter clinic walk test which includes marking the beginning and end of the walking path. A standard manual stopwatch will be used to record time. The examiner will demonstrate the task then instruct the participant to Walk at a comfortable pace and count down by saying: 3, 2, 1, go. The stop watch will be used to time the amount of time it takes to walk between the cones. Subjects will complete 3 timed trials. The time will be recorded in the log. Simultaneously, the Sprint System \[6\] will be operated according to manufacturers instructions. The Gaitbox will be set up at the end of the 4 meter walking path at a height of 4 feet from the floor. Times/speeds will be recorded on log sheet."
224176600|NCT03406806|OTHER|SprintSystem device|"The walking path will be set according to the directions of the NIH toolbox 4 meter clinic walk test which includes marking the beginning and end of the walking path. A standard manual stopwatch will be used to record time. The examiner will demonstrate the task then instruct the participant to Walk at a comfortable pace and count down by saying: 3, 2, 1, go. The stop watch will be used to time the amount of time it takes to walk between the cones. Subjects will complete 3 timed trials. The time will be recorded in the log. Simultaneously, the Sprint System \[6\] will be operated according to manufacturers instructions. The Gaitbox will be set up at the end of the 4 meter walking path at a height of 4 feet from the floor. Times/speeds will be recorded on log sheet."
224176601|NCT03406806|OTHER|NIH toolbox 4 meter walk|"The walking path will be set according to the directions of the NIH toolbox 4 meter clinic walk test which includes marking the beginning and end of the walking path. A standard manual stopwatch will be used to record time. The examiner will demonstrate the task then instruct the participant to Walk at a comfortable pace and count down by saying: 3, 2, 1, go. The stop watch will be used to time the amount of time it takes to walk between the cones. Subjects will complete 3 timed trials. The time will be recorded in the log. Simultaneously, the Sprint System \[6\] will be operated according to manufacturers instructions. The Gaitbox will be set up at the end of the 4 meter walking path at a height of 4 feet from the floor. Times/speeds will be recorded on log sheet."
224176602|NCT00750867|DRUG|intravenous immunoglobulin (IVIg)|The intravenous immunoglobulin (brand Privigen) will be infused intravenously, monthly, 6 times, for 6 months the dose will be 0.4 gram/kg for each infusion.
224176603|NCT00863031|BEHAVIORAL|problem-solving therapy|Three sessions of problem-solving therapy at week 1, 3 and 5.
224176604|NCT00863031|BEHAVIORAL|Video-viewing|Three sessions of viewing health educational videos.
224176605|NCT00661414|BIOLOGICAL|ASONEP (sonepcizumab/LT1009)|"ASONEP \[sonepcizumab/LT1009\] is supplied as a colorless,particulate-free, pH 6.5, sterile solution containing approximately 10 mg/mL or 20 mg/mL of drug.~The candidate drug is intended for single intravenous (iv) use administered over 90 minutes on a weekly basis."
224176606|NCT00000244|DRUG|Dynorphin 1 - 13|
224176607|NCT02027285|DIETARY_SUPPLEMENT|fortified milk|"FortifiedUltra-high temperature (UHT), partly-skimmed milk (1.6% fat), highly digestible (lactose \<0.5%) produced by Granarolo s.p.a. supplemented with long chain unsaturated fatty acids DHA (Docosahexaenoic acid) +EPA (Eicosapentaenoic acid), vitamin D, B12, B6, B9, E,C, Zinc and Selenium versus placebo Ultra-high temperature (UHT), partly-skimmed milk (1.6% fat), highly digestible (lactose \<0.5%) of the same manufacturer.~The nutrients added are: DHA + EPA 1.4 mg/ml; vitamin D3 0.068 mcg/ml; B6 6.4 mcg/ml; B12 0.01 mcg/ml; B9 (folic acid) 0.80 mcg/ml; vitamin E 0.05 mg/ml; vitamin C 0.19 mg/ml; Zinc 0.04 mg/ml; Selenium 0.22 mcg/ml. The protein content of the milk is 0.04 g/ml."
224176608|NCT00346294|DRUG|Etanercept|Intervention type was to study the drug delivery method.
224176609|NCT00462657|GENETIC|polymerase chain reaction|
224176610|NCT00462657|OTHER|bronchoalveolar lavage|
224176611|NCT00462657|OTHER|immunoenzyme technique|
224176612|NCT00462657|OTHER|laboratory biomarker analysis|
224176613|NCT00462657|PROCEDURE|bronchoscopy|
224176614|NCT00462657|PROCEDURE|management of therapy complications|
224176615|NCT00923806|BIOLOGICAL|PG13-CEA_TCR (Anti-CEA TCR PBL)|
224176616|NCT00923806|DRUG|Aldesleukin|720,000 IU/kg intravenous over 15 minutes every 8 hours for up to 5 days
224176617|NCT03960164|COMBINATION_PRODUCT|Dermal regeneration photosynthetic matrix (DRPM)|"Primary Procedure: DRPM implantation~1. Wound bed preparation and cleaning.~2. DRPM implantation.~3. Illumination with LED device.~Secondary Procedure: Autologous partial skin graft"
224176618|NCT05291741|DIETARY_SUPPLEMENT|VLCD|Advice regarding VLCD
224176619|NCT05291741|DIETARY_SUPPLEMENT|Standard care|Standard dietary advice for weight loss before bariatric surgery
224176620|NCT04145193|DRUG|Standard of Care - mFOLFOX6|Parts of mFOLFOX6 are: Oxaliplatin 85 mg/m2 IV infusion Q2W (Day 1 of every 14-day cycle), Folinic acid (leucovorin) 400 mg/m2 IV infusion Q2W (Day 1 of every 14-day cycle), Fluorouracil (5-FU) 400 mg/m2 IV bolus on Day 1 then 2,400 mg/m2 over 46 to 48 hours IV infusion Q2W (Day 1-2 of every 14-day cycle).
224176621|NCT04145193|DRUG|E1 - mFOLFOX and durvalumab|"Parts of mFOLFOX6 are: Oxaliplatin 85 mg/m2 IV infusion Q2W (Day 1 of every 14-day cycle), Folinic acid (leucovorin) 400 mg/m2 IV infusion Q2W (Day 1 of every 14-day cycle), Fluorouracil (5-FU) 400 mg/m2 IV bolus on Day 1 then 2,400 mg/m2 over 46 to 48 hours IV infusion Q2W (Day 1-2 of every 14-day cycle).~Durvalumab 1500 mg IV, Q4W (Day 1 of every other 14-day cycle)"
224176622|NCT04145193|DRUG|E2 - mFOLFOX6, durvalumab and oleclumab|"Parts of mFOLFOX6 are: Oxaliplatin 85 mg/m2 IV infusion Q2W (Day 1 of every 14-day cycle), Folinic acid (leucovorin) 400 mg/m2 IV infusion Q2W (Day 1 of every 14-day cycle), Fluorouracil (5-FU) 400 mg/m2 IV bolus on Day 1 then 2,400 mg/m2 over 46 to 48 hours IV infusion Q2W (Day 1-2 of every 14-day cycle).~Durvalumab 1500 mg IV, Q4W (Day 1 of every other 14-day cycle) Oleclumab 3,000 mg IV Q2W x5 then Q4W (Day 1 of every 14-day cycle through cycle 4 then Day 1 of every other 14-day cycle)"
224176623|NCT04145193|DRUG|E3 - mFOLFOX6, durvalumab and monalizumab|"Parts of mFOLFOX6 are: Oxaliplatin 85 mg/m2 IV infusion Q2W (Day 1 of every 14-day cycle), Folinic acid (leucovorin) 400 mg/m2 IV infusion Q2W (Day 1 of every 14-day cycle), Fluorouracil (5-FU) 400 mg/m2 IV bolus on Day 1 then 2,400 mg/m2 over 46 to 48 hours IV infusion Q2W (Day 1-2 of every 14-day cycle).~Durvalumab 1500 mg IV, Q4W (Day 1 of every other 14-day cycle) Monalizumab 750 mg IV, Q2W (Day 1 of every 14-day cycle)"
224176624|NCT03971019|DRUG|statins|On the basis of dietary intervention. Simvastatin 20mg/d QN Po (half an hour before bedtime) (dosage can be adjusted according to other indicators of blood lipid level in each review), atorvastatin 10mg/d QN Po (half an hour before bedtime) (patients who can not tolerate the side effects of simvastatin can consider replacing this drug).
224176625|NCT03971019|BEHAVIORAL|Dietary intervention group (control group)|Restriction of dietary components that increase LDL-C Saturated Fatty Acids Less than 7% of total energy Dietary cholesterol \< 300 mg/d Increasing Dietary Ingredients for Reducing LDL-C Phytosterol 2\~3 g/d Water soluble dietary fiber 10\~25 g/d total energy Adjusted to maintain ideal weight or lose weight Physical activity Maintain moderate intensity exercise and consume at least 200 kcal of calories per day
224176626|NCT00860704|DRUG|fluidotherapy with ringer-lactate|a bolus of 250ml ringer-lactate is administered, if there is fluid demand monitored by the Esophageal Doppler
224176627|NCT02828462|OTHER|CAPRI|
224176628|NCT00847249|DRUG|AZD9164|Each subject will receive a single-dose starting dose 4µg (lung deposited dose) with up to 8 dose escalations not exceeding AstraZeneca pre-defined exposure limits.
224176629|NCT00847249|DRUG|Placebo|Each subject will receive a single-dose.
224176630|NCT00000641|DRUG|Ciprofloxacin hydrochloride|
224176631|NCT00000641|DRUG|Ethambutol hydrochloride|
224176632|NCT00000641|DRUG|Amikacin sulfate|
224176633|NCT00000641|DRUG|Azithromycin|
224176634|NCT00000641|DRUG|Rifampin|
224176635|NCT00000641|DRUG|Clofazimine|
224176636|NCT04989140|DRUG|Drug: Ixazomib Drug:pomalidomide Drug:dexamethasone|Treatment was continued until disease progression, unacceptable toxicity
224176637|NCT04334902|DEVICE|mPDia|Clinical decision support system for diagnosing neurodegenerative parkinsonism
224176638|NCT01377038|OTHER|Phenotype assessment|Quantitative sensory testing and patient reported outcome measures used to assess patient pain phenotype
224176639|NCT02516306|DRUG|EV06 Ophthalmic Solution|
224176640|NCT02516306|DRUG|Placebo Ophthalmic Solution|
224176641|NCT05235802|DIAGNOSTIC_TEST|Magnetic Resonance Imaging (MRI) (including functional MRI)|"Patients will undergo magnetic resonance imaging including the following protocols:~* 3D T1w MPRAGE~* 3D T2w FLAIR SPACE~* 3D T2w SPACE~* 3D T1w PSIR (cortical visualization)~* 2D synthetic MRI (quantitative T1, T2, PD and myelin quantification)~* Resting-state fMRI (6 min, human connectome protocol, 2 mm iso)~* 3D SWI~* DWI b1000 32 directions and b3000 64 directions."
224176642|NCT05235802|DIAGNOSTIC_TEST|Blood sampling (serum/plasma preparation)|Blood will be screened for genetic modifications. Serum will be analyzed for auto-antibodies and other inflammatory and neurodegenerative biomarkers.
224176643|NCT05235802|DIAGNOSTIC_TEST|Cerebrospinal fluid (CSF)|CSF will be analyzed for inflammatory and neurodegenerative biomarkers.
223486620|NCT05842291|DEVICE|Active rTMS with long inter-session interval|Participants in this group will receive ten sessions per day of 1800 pulses per session, at an inter-session interval of 50 min for 5 days. The individualized target will be generated using the personalized Brain Functional Sectors (pBFS) method.
223486621|NCT05182437|RADIATION|LINAC-based Stereotactic Radiotherapy|Target definition: the target volume is defined as the epileptogenic zone (EZ) on all (non) invasive examinations (e.g. 3, 7 Tesla MRI or Stereo-EEG) of the presurgical path. Planning target volume (PTV) = GTV. A single fraction SRT with a prescribed isotoxic dose of 24 Gy to the 100% surrounding isodose. Dose is depending on the proximity and maximum tolerable dose to the radiosensitive organs at risk and EZ volume resulting in a V12\<= 10 cc reducing the risk on radionecrosis.
224176644|NCT05235802|DIAGNOSTIC_TEST|Clinical assessments / questionnaires|"* Glasgow Outcome Scale Extended (functional outcome)~* Short-Form 36 (quality of life),~* EQ-5D (quality of life),~* Mini-Mental State Extended (MMSE) (mental state assessment).~* Barthel Index (daily living disabilities),~* Montgomery-Åsberg Depression Score (MADRS-S) (level of depression)~* Fatigue Severity Scale (FSS) (level of fatigue)~Other than that, neurological assessments focusing on the Unified Parkinson's Disease Rating Scale (UPDRS) will be performed."
224176645|NCT05314699|BEHAVIORAL|resistance-aerobic exercise, RA|Participants conduct 5-min warm up, 13-min resistance exercise, 12-min aerobic exercise, and 5-min cool down.
224176646|NCT05314699|BEHAVIORAL|aerobic-resistance exercise, AR|Participants conduct warm up for 5-min, aerobic exercise for 12-min, resistance exercise for 13-min, and 5-min cold down.
224176647|NCT02312375|DRUG|Fimasartan|16 weeks of fimasartan vs. amlodipine followed by 2 weeks of wash-out period, then crossover
224176648|NCT02312375|DRUG|Amlodipine|16 weeks of fimasartan vs. amlodipine followed by 2 weeks of wash-out period, then crossover
224176649|NCT01914900|DRUG|docetaxel, cisplatin, 5 fluorouracil|
224306495|NCT02991027|DEVICE|DRI OCT Triton|DRI OCT Triton using micro-electro-mechanical tunable vertical cavity surface emitting laser
224176650|NCT00152997|DRUG|Pramipexole 0.125 mg tablets|
224176651|NCT00152997|DRUG|Pramipexole 0.125 mg tablets Placebo|
224176652|NCT05790499|DRUG|Atorvastatin|Patients are treated with atorvastatin for 2 weeks (40 mg/day), atorvastatin free for 2 weeks, atorvastatin treatment for 2 weeks, atorvastatin free for 2 weeks, a 4-week washout period (no treatment), and atorvastatin treatment for the last 4 weeks.
224176653|NCT01273506|DRUG|tapentadol (CG5503) ER 25-mg TRF|50 mg TRF single oral dose
224176654|NCT01273506|DRUG|tapentadol (CG5503) ER 50-mg TRF|50 mg TRF single oral dose
224176655|NCT00000970|DRUG|Foscarnet sodium|
224306496|NCT01412372|DRUG|Mesalamine|2 1.2g tablets once daily for 8 weeks. Patients randomized 50/50 to either Mesalamine or the Placebo
224176656|NCT00000970|DRUG|Ganciclovir|
224176657|NCT04995042|DRUG|SHR7280|Drug: SHR7280 All participants receive SHR7280 alone.
224176658|NCT00642122|DRUG|Budesonide|0.5mg once daily
224176659|NCT00642122|DRUG|Budesonide|1mg once daily
224176660|NCT00642122|DRUG|Budesonide|1mg twice daily
224176661|NCT00642122|DRUG|Budesonide|2mg once daily
224176662|NCT00642122|DRUG|Budesonide|4.00mcg twice daily
224176663|NCT06303362|OTHER|Elastic band excercise|experimenatal group was given elastic band excercises along with stretching (pectoralis major, minor, trapezius, rhomboids and neck flexors) and conventional therapy. Sessions will be given 3 days in a week for a period of 4 weeks. The assessment was done at baseline, after 2 weeks and at the end of 4 weeks.
224176664|NCT06303362|OTHER|strengthening with conventional physical therapy|control group was given strengthening excercises and stretching (pectoralis major, minor, trapezius, rhomboids (Sessions will be given 3 days in a week for a period of 4 weeks. The assessment was done at baseline, after 2 weeks and at the end of 4 weeks.
224176665|NCT02749643|DEVICE|Vibrotactile feedback system|
224176666|NCT00001343|DRUG|Humatrope|
224176667|NCT00001343|DRUG|Oxandrolone|
224176668|NCT06137989|PROCEDURE|Fill-Up Class ӀӀ restoration|Bulk-fill technique
224306497|NCT01412372|DRUG|Placebo|This is an inactive pill
224176669|NCT06137989|PROCEDURE|QuiXfil Class ӀӀ restoration|Bulk-fill technique
224176670|NCT06137989|PROCEDURE|Tetric N-Ceram Bulk Fill Class ӀӀ restoration|Bulk-fill technique
224176671|NCT04433936|DIAGNOSTIC_TEST|Pentacam tomography|The Pentacam maps were analyzed. The following anterior and posterior corneal surface parameters were evaluated by the Scheimpflug system: Kf, Ks, Kmax. The pachymetric map was analyzed, including CCT at the apex of the geometric center and CTmin. PPIavg, PPI min and PPI max were calculated . The Ambrósio relational thickness (ART) was calculated The posterior corneal elevation maps were evaluated and the posterior corneal elevation values relative to this reference were recorded. The back difference elevation and multimetric D index values were extrapolated from the difference map of the Belin/Ambrósio-enhanced ectasia display of the Pentacam system.
224176672|NCT05754736|DRUG|Ametinib combined with bevacizumab|Ametinib 110mg po qd bevacizumab 15mg/kg ivdrip q3w
224176673|NCT05850962|OTHER|Individualised MAP target|The project will test an intervention that initially targets a patient's own pre-illness mean arterial pressure (MAP) during vasopressor support in ICU. The pre-illness MAP will be estimated from the most recent pre-illness BP readings recorded in medical records.
224176674|NCT02736149|DRUG|ubenimex|
224176675|NCT02814591|DEVICE|spatially offset Raman spectrometer (SORS)|Raman spectra will be collected non-invasively from patients using a lower power 830 nm laser. A probe is brought into gentle contact with the patients skin and measurements taken. The laser power has a pre-defined safe threshold of 30 mW into a 3.5 mm diameter aperture. Built in device safety features prevent this threshold from being exceeded. The probe that comes into patient contact is suitable for disinfecting.
223486622|NCT03104803|DEVICE|long-term paired associative stimulation|Paired associative stimulation (PAS) administered several times per week for 6 weeks to one hand. PAS comprises transcranial magnetic stimulation (eXimia magnetic stimulator, Nexstim Ltd, Helsinki, Finland) and peripheral nerve stimulation (given with Dantec Keypoint® electroneuromyography device (Natus Medical Incorporated, Pleasanton, CA, USA)).
224176676|NCT03325933|OTHER|High Load/Low Rep Resistance Training|Participants will be prescribed High Load/Low Rep resistance training.
224176677|NCT03325933|OTHER|Low Load/High Rep Resistance Training|Participants will be prescribed Low Load/High Rep resistance training.
224176678|NCT01022918|DRUG|Avastin + Campto / radiotherapy + Temodal + Avastin (4 cures)|
224176679|NCT01022918|DRUG|Temodal/radiotherapy|
224176680|NCT02234024|DIETARY_SUPPLEMENT|Supplementation of dairy-derived concentrated gangliosides.|
224176681|NCT00242710|DRUG|Bazedoxifene/Conjugated Estrogen|Subjects will take 1 capsule orally, once daily, at approximately the same time each day continuously for the duration of the study.
224176682|NCT00242710|DRUG|Bazedoxifene/Conjugated Estrogen|Subjects will take 1 capsule orally, once daily, at approximately the same time each day continuously for the duration of the study.
224176683|NCT00242710|DRUG|CE 0.45 mg/MPA 1.5mg|Subjects will take 1 capsule orally, once daily, at approximately the same time each day continuously for the duration of the study.
224176684|NCT00242710|OTHER|Placebo|Subjects will take 1 capsule orally, once daily, at approximately the same time each day continuously for the duration of the study.
224176685|NCT02777034|OTHER|ER|"Preoperative protocols：Multidisciplinary patient information、no bowel preparation、no fasting（drink 10% glucose 1000 at 21：30 night before the surgery）.~Intraoperative protocols：Laparoscopic standardized technique、fluid restriction (max 500 ml/h)、no abdominal drains.~Postoperative protocols：no nasogastric tube、early solid dietary intake and mobilization、urinary catheter removal on postoperative day 1、restrictive fluid management（\<2000ml/d）."
224176686|NCT02777034|OTHER|UR|"Preoperative protocols：Patient information、Mechanical bowel preparation、Fasting since midnight before operation.~Intraoperative protocols：Laparoscopic standardized technique、fluid overload (over 500 ml/h) 、place abdominal drains.~Postoperative protocols：no nasogastric tube、mobilization from postoperative day 1、fluids and solids intake after first passage of stool、Urinary catheter removal on postoperative day 2/3、no restrictive fluid management（\>2000ml/d）."
224176687|NCT01910649|DRUG|Drisapersen|Subcutaneous and Intravenous
224176688|NCT04272996|PROCEDURE|Craniotomy only|evacuation of SDH
224176689|NCT04272996|PROCEDURE|Craniotomy + Endovascular embolization of the middle meningeal vessels|evacuation of SDH + Embolization of middle meningeal vessels using standard techniques.
224306498|NCT00368901|DRUG|Darbepoetin alfa|Aranesp administered every other week SC titrated to not exceed Hb 12 g/dL
223486623|NCT05378152|DEVICE|Pipelle biopsy catheter|A speculum will be inserted into the vagina. A Pipelle biopsy catheter will be inserted through the cervix up to the fundus of the uterus. The internal piston will be withdrawn to create negative pressure. The catheter will be moved back and forth and rotated to collect the biopsy. The catheter will then be removed, followed by the speculum. The sample will be sent to the laboratory for assessment.
224176690|NCT01609673|DRUG|Everolimus|"On the day of conversion (day 1), 2 mg everolimus will be introduced in the morning and at night, as morning dose of CsA or Tac will be maintained and evening dose of CsA or Tac will be reduced by 50%.~In two days, 2 mg everolimus will be associated with 50% of CsA or Tac original dosage, both in the morning and evening. After that, everolimus dose will be adjusted to achieve a C0 target level of 6-10 ng/mL. Once target levels of everolimus are met, the CNI drug will be suspended."
224176691|NCT00579527|BIOLOGICAL|Cultured Thymus Tissue for Implantation (CTTI)|Potential thymus recipient subjects are screened for eligibility. Thymus donor (unrelated donor), and thymus donor's birth mother are screened for safety. CTTI is done under general anesthesia in the operating room. Cultured thymus tissue is implanted into the subject's quadriceps. Two to three months post CTTI, if medically stable, the subject undergoes allograft biopsy. At the time of implantation and biopsy, a skin biopsy is done. Immunosuppression is weaned as per protocol.
224176692|NCT00579527|OTHER|Cultured Thymus Tissue Implantation and Parental Parathyroid Transplantation|For subjects w/ hypoparathyroidism, the subject may receive CTTI and parathyroid transplant. For parathyroid transplant, parental parathyroid donors are screened. Parathyroid is harvested from the parent who shares the most Human Leukocyte Antigens (HLA) alleles with the thymus donor. Parathyroid gland is minced and placed in quadriceps muscle; there is no dose. Parathyroid donors are monitored as outpatients until recipients' discharge. Recipients' calcium and PTH levels are monitored indefinitely. Potential thymus recipient subjects are screened for eligibility. Thymus donor (unrelated donor), and thymus donor's birth mother are screened for safety. CTTI is done under general anesthesia in the operating room. Cultured thymus tissue is implanted into the subject's quadriceps. Two to three months post CTTI, if medically stable, the subject undergoes allograft biopsy. At the time of CTTI and biopsy, a skin biopsy is done. Immunosuppression is weaned as per protocol.
224176693|NCT00579527|PROCEDURE|Blood Draw|Birth mothers of Thymus Recipients are asked to participate in the study and undergo phlebotomy to allow testing of T cell identity in the Complete DiGeorge subjects. If blood is not obtainable then a buccal swab may be done.
224176694|NCT00579527|DRUG|Rabbit anti-thymocyte globulin|Three doses of 2 mg/kg IV (through a central venous catheter) prior to CTTI. Each dose of Rabbit anti-thymocyte globulin (RATGAM) is given over 12 hours. RATGAM is usually given on days-5, -4, and -3 prior to CTTI or CTTI and parathyroid transplantation. Medications (diphenhydramine, steroids, and acetaminophen) are given with rabbit anti-thymocyte globulin.
224176695|NCT00579527|DRUG|Cyclosporine|"In addition to RATGAM, subjects with typical cDGA with PHA responses \>50,000 cpm, or atypical cDGA with PHA response \<75,000cpm (when not on immunosuppression) or \<40,000 cpm to PHA while on immunosuppression, are started on cyclosporine (Csa) as soon as cDGA is diagnosed. Csa is continued with target trough levels of 180 to 220 ng/ml. If subject cannot tolerate Csa, Csa may be changed to tacrolimus (FK506) with target trough level 7 to 10 ng/ml. When trough levels are outside of range, dosing is modified appropriately.~Csa may be given every 8 to 12 hours enterally or IV before and after CTTI. The Csa dose is dependent on T cell numbers and the target Csa trough levels. Csa is weaned as per protocol."
224176696|NCT00579527|DRUG|Tacrolimus|If unable to tolerate cyclosporine, then tacrolimus is given. Tacrolimus may be given every 8 to 12 hours enterally or IV before and after the CTTI transplant. Tacrolimus dose is dependent on the T cell numbers and the target tacrolimus trough levels. Tacrolimus is weaned as per protocol.
224176697|NCT00579527|DRUG|Methylprednisolone or Prednisolone|Steroids IV or enterally may be given before and after CTTI or CTTI and parathyroid transplantation. Administration and dosage depends on T cell numbers and symptoms. Pre-transplant steroids may be used when pre-transplant T cells \>4,000cumm. Steroids are weaned as per protocol.
224176698|NCT00579527|DRUG|Daclizumab|In addition, subjects with Atypical DiGeorge with PHA responses \>75,000cpm while on no immunosuppression or PHA responses \>40,000cpm while on immunosuppression, Daclizumab 1 mg/kg single dose IV may be given depending on T cell counts. Administration of Daclizumab depends on T cell numbers and T cell activation. A single dose may be given after the administration of rabbit anti-thymocyte globulin and before CTTI. If Daclizumab is not given before CTTI, and, depending on the T cell numbers and T cell activation, a single dose of Daclizumab may be given 3-5 days after CTTI.
224176699|NCT00579527|DRUG|Mycophenolate mofetil|In addition, subjects with Atypical DiGeorge with PHA responses \>75,000cpm while on no immunosuppression or PHA responses \>40,000cpm while on immunosuppression, Mycophenolate mofetil 15 mg/kg/dose every 8 hours IV or enterally may be given depending on T cell counts. Mycophenolate mofetil may be given if the T cell count remains elevated 5 days after CTTI. If MMF is given, the dose is 15 mg/kg IV. MMF may be stopped at 35 days after CTTI or continued for up to six months after CTTI.
224176700|NCT02602028|DRUG|colchicine|to compare once daily dosage schema of colchicine and twice daily dosage schema of colchicine
224306499|NCT03905564|DRUG|doxylamine succinate 10 mg/pyridoxine hydrochloride 10 mg combination|Delayed-release tablet containing a fixed-dose combination of doxylamine succinate 10 mg and pyridoxine hydrochloride 10 mg (product of Tecnandina, S.A. TENSA).
224306500|NCT03905564|DRUG|Diclegis (Registered Trademark)|Delayed-release tablet containing a fixed-dose combination of doxylamine succinate 10 mg and pyridoxine hydrochloride 10 mg (product of Duchesnay Inc.).
223486624|NCT05378152|DEVICE|Sham procedure|A speculum is inserted into the vagina and then removed
223617631|NCT00865345|DEVICE|MMT-7003 subcutaneous glucose sensor|All subjects will use the glucose sensor, randomized to participate in a 12-hour frequent (15-minute) blood glucose sampling period on one of six days of sensor wear. Blood samples will be analyzed using a laboratory standard (YSI) for comparison to the glucose sensor to evaluate accuracy.
223486625|NCT01644838|DRUG|Hyoscine|The samples were randomly allocated to inject of 20 mg of hyoscineIM in dilatation 3-5cm.
223486626|NCT01644838|DRUG|Promethazine|The samples were randomly allocated to inject of 25 mg of promethazine IM in dilatation 3-5cm.
223486627|NCT05958303|DIETARY_SUPPLEMENT|Antioxidant Cocktail|Total dosing of 1000 mg vitamin C, 600 IU vitamin E, and 600 mg of alpha lipoic acid.
223486628|NCT05958303|OTHER|Placebo|Placebo
223486629|NCT03797612|DRUG|Brivoligide Injection 660 mg/6 mL|Single preoperative intrathecal injection
223486630|NCT03797612|DRUG|Placebo 6 mL|Single preoperative intrathecal injection
223617632|NCT02718079|BIOLOGICAL|Plasma Exchange|
223617633|NCT02718079|OTHER|Management of cerebral edema/intracranial hypertension:|
223617634|NCT02718079|OTHER|Transfer to Intensive Care Unit|
224176701|NCT02677506|PROCEDURE|Supraclavicular|Brachial plexus block with supraclavicular approach
224176702|NCT02677506|PROCEDURE|Infraclavicular|Brachial plexus block with infraclavicular approach
224176703|NCT00051194|DRUG|Combination IOP Lowering Therapy|
224176704|NCT02612168|DEVICE|Melanoma Image Analysis Algorithm (MIAA)|The images will be analysed by MIAA (Melanoma Image Analysis Algorithm). The MIAA result for PLs that are biopsied will be compared to the diagnosis made from the biopsy. The MIAA result for PLs not biopsied will be compared to clinician diagnosis.
224176705|NCT00867061|DRUG|ON 01910.Na Concentrate|5-day continuous intravenous dosing of ON 01910.Na given every 2 weeks (1 cycle) at a dose of 800 mg/m2/day or 1500mg/m2/day for up to 24 cycles.
224176706|NCT06282952|DIETARY_SUPPLEMENT|Fecal transplant|At delivery, the fecal transplant is thawed and 0.5 mL representing 3.5 mg of the mother's or donors' fecal sample is dissolved in 5 mL of the mother's own milk or when not available pasteurized bank milk. The sample is given orally to newborn infants as soon as possible but not later than 6 h of delivery and not later than two hours after defrosting.
224176707|NCT03279146|DRUG|Tenofovir exalidex (TXL)|Oral formulations
224176708|NCT00808132|DRUG|bazedoxifene 20 mg/ conjugated estrogens 0.45 mg|One capsule, bazedoxifene 20 mg/conjugated estrogens 0.45 mg (over-encapsulated), once a day for one year.
224176709|NCT00808132|DRUG|bazedoxifene 20 mg/ conjugated estrogens 0.625 mg|One capsule, bazedoxifene 20 mg/conjugated estrogens 0.625 mg (over-encapsulated), once a day for one year.
224176710|NCT00808132|DRUG|bazedoxifene 20 mg|One capsule, bazedoxifene 20 mg (over-encapsulated), once a day for one year.
224176711|NCT00808132|DRUG|conjugated estrogens 0.45 mg/ medroxyprogesterone acetate 1.5 mg|One capsule, conjugated estrogens 0.45 mg and medroxyprogesterone 1.5 mg (over-encapsulated), once a day for one year.
224176712|NCT00808132|DRUG|Placebo|One capsule, placebo (over-encapsulated), once a day for one year.
224176713|NCT00474136|DRUG|Intravenous diclofenac sodium (DIC075V) 18.75 mg|DIC075V 18.75 mg
224176714|NCT00474136|DRUG|Intravenous diclofenac sodium (DIC075V) 37.5 mg|DIC075V 37.5 mg
224176715|NCT00474136|DRUG|Oral diclofenac potassium 50 mg|Oral diclofenac potassium 50 mg
224176716|NCT03442933|OTHER|3 hours Road Cycling Time Trial|The road itinerary is a mixed route profile of 90 km, an elevation gain of 900 m, with mixed sections, flat, uphill and down over roads with little traffic.
223486631|NCT00977145|BIOLOGICAL|A combination of intratumoral IFN-gamma plus systemic vaccination with MELITAC 12.1|"Vaccine regimen: The vaccines will be administered in two treatment cycles. During cycle one, three vaccines will be administered over a 3-week period on days 1, 8, 15. During cycle two, three vaccines will be administered over a 9-week period on days 24, 43, 64. All participants will receive 12-MP (100 mcg each peptide) plus Peptide-tet (Peptide-tet; 200 mcg) administered in Montanide ISA-51 VG adjuvant. The vaccine will be administered subcutaneously (1 ml) and intradermally (1ml) at a single vaccination site.~Intratumoral Interferon regimen: On day 22, patients will have one or more tumor sites injected with 0.5-2 million IU of IFN-gamma each, with a maximum dose of 2 million IU of IFN-gamma administered per patient. The number of lesions that are injected will be dependent on the availability and size of the lesions."
223486632|NCT04582071|BEHAVIORAL|Psychotherapy|Psychotherapy is a term that we use to describe the use of the psychological method to understand and improve an individual's well-being and mental health. The Principal Investigator of this study, a clinical psychologist will be leading each of the sessions.
223486633|NCT04652648|DRUG|Hydroxychloroquine|Randomization was 2:1 to HCQ 200 mg BID or 41 observation for 10 days
223486634|NCT06009874|DRUG|Dapagliflozin 10mg Tab|patients will be treated with DAPA 10 mg once daily for three months
223486635|NCT06009874|DRUG|Placebo|patients will be treated with a placebo tab once daily for three months
223486636|NCT00158730|DRUG|AmBisome|
223486637|NCT06197282|PROCEDURE|Major surgery involving general anesthesia|EHR documented SAR-CoV-2 PCR nasopharyngeal swab results confirming Covid-19 status within one year of undergoing surgical procedure at Kern Medical Center.
223486638|NCT00585182|DRUG|Enoxaparin 0.5 mg/kg once daily|Enoxaparin 0.5 mg/kg (kg= actual body weight) subcutaneous once daily for 2 doses.
223486639|NCT05257187|DEVICE|Transcervical foley catheter|The foley catheter is inserted manually by an obstetric provider through the cervix and inflated with 60cc of saline. Once in the correct position, the catheter is inflated, which puts pressure on the cervix, allowing it to release hormones that soften the cervix and help the cervix to open. The foley catheter can be left in place up to 12 hours but typically will fall out when the cervix is dilated to 3-4 centimeters.
224176717|NCT03442933|OTHER|3 hours Mountain Biking Time Trial|The mountain itinerary, is a mixed route of 55 km, an elevation gain of 600 m, with sections of wide tracks and trails, flat, uphill and down, with a medium technical difficulty.
224176718|NCT00191438|DRUG|gemcitabine|
224176719|NCT00191438|DRUG|capecitabine|
223486640|NCT00366769|DEVICE|Wavefront-guided LASIK using CustomVue platform|
223486641|NCT00448045|BEHAVIORAL|Manual and mechanical assisted cough|Individuals will be given a pulse oximeter and taught both manually assisted and mechanically assisted coughing techniques to maximize their cough. Manually assisted coughing consists of air stacking to deep insufflations. An abdominal thrust is then applied upon glottic opening to augment the cough. These subjects will also have rapid access to a mechanical in-exsufflator (CoughAssistTM) and will be trained on how to access and use this device. Mechanically assisted coughing (MAC) involves the use of the CoughAssistTM to expand the lungs and then quickly reverse the pressure to rapidly empty the lungs with expiratory (cough) flows of 600 L/m. An abdominal (manual) thrust is applied in conjunction with the negative pressure (exsufflation) to further increase cough.
223617635|NCT02718079|DRUG|Prophylactic Antibiotics|
224176720|NCT00191438|DRUG|docetaxel|
224176721|NCT01062516|DRUG|esomeprazole 20 mg daily|oral famotidine 40 mg daily vs. oral esomeprazole 20 mg daily for 28 days
224176722|NCT01062516|DRUG|famotidine 40 mg daily|oral famotidine 40 mg daily vs. oral esomeprazole 20 mg daily for 28 days
224176723|NCT01948791|DRUG|ENA713|The following strengths of Rivastigmine capsules were provided: Rivastigmine capsule strengths: 1.5mg, 3mg, 4.5mg. The 6mg dose was administered as one 1.5mg capsule and one 4.5mg capsule, and when necessary, the 3mg dose could also be administered as two 1.5mg capsules. Rivastigmine was administered from 3mg/d at baseline. Then dose escalation was made in 3mg/d increments, at a minimun of 4 weeks between dose increases to a maximum dose of 12mg/d or the individual's best tolerated dose.
224176724|NCT01524094|DRUG|Systemic chemotherapy alone (oxaliplatin, 5-fluorouracil, isovorin)|Oxaliplatin 100 mg/ m2 as a 2 h iv infusion + 5-fluorouracil 400 mg/ m2 iv bolus + Isovorin 100 mg/ m2 as a 2 h infusion followed by 5-fluorouracil 2400 mg/ m2 as a 46 h infusion. Each cycle is given every other week until 12 cycles have been administered.
224176725|NCT01524094|PROCEDURE|Cytoreductive surgery (CRS) plus postoperative intraperitoneal chemotherapy (5-fluorouracil, isovorin)|Cytoreductive surgery has the goal of completely resecting all visible tumor tissue in the abdomen. Sequential postoperative intraperitoneal chemotherapy has the purpose of an adjuvant treatment to eradicate microscopic residual tumor and prevent recurrences in the abdomen. The chemotherapy regimen consisted of intraperitoneal 5-fluorouracil 550 mg/ m2 and intravenous isovorin 30 mg/ m2 day 1-6 med cycles every 4-6 weeks. Six cycles were planned.
224176726|NCT01056601|DRUG|Bortezomib|1.3 mg/m\^2 administered intravenously twice daily on days 1 and 8 for 2 weeks followed by 10 day rest period
224176727|NCT01056601|DRUG|Panobinostat|20 milligrams administered orally 3 times weekly for 2 weeks on Days 1,3,5,8,10 and 12 followed by 9 day rest period
224176728|NCT02139176|BEHAVIORAL|contract referral|A female partner signs a contract saying it is permissible for a community worker to trace a male sex partner in the community.
224176729|NCT02139176|BEHAVIORAL|patient referral|A patient agrees to recruit their partner using the invitation.
224176730|NCT03490734|DIETARY_SUPPLEMENT|Black Cherry and Orange Flavored Beverage with added sugar|10 oz daily for three weeks
224176731|NCT03490734|DIETARY_SUPPLEMENT|Strawberry Kiwi &Lemonade Flavored Beverage with added sugar|10 oz daily for three weeks
223486642|NCT00448045|BEHAVIORAL|Incentive spirometry|These individuals will be given a pulse oximeter and an incentive spirometer (AirLife Company) and taught how to use them.
223486643|NCT01642316|OTHER|washback|students received 8 specific related formative test for that lesson. plus a pre-test and post-test, Michigan English language proficiency test
223486644|NCT01642316|OTHER|routin intervention|students only received two tests, Michigan test of English language proficiency as pre-test and post-test.
223486645|NCT05707325|DRUG|engineered red blood cell|engineered red blood cell
223486646|NCT01104766|DRUG|Cariprazine|Patients who meet eligibility criteria will be administered a once daily oral dose of cariprazine for six weeks. Upon completion of the study or early termination, patients will undergo a two week safety follow-up period.
223486647|NCT01104766|DRUG|Aripiprazole|Patients who meet eligibility criteria will be administered a once daily oral dose of aripiprazole for six weeks. Upon completion of the study or early termination, patients will undergo a two week safety follow-up period.
223486648|NCT01104766|DRUG|Placebo|Patients who meet eligibility criteria will be administered a once daily oral dose of placebo for six weeks. Upon completion of the study or early termination, patients will undergo a two week safety follow-up period.
224176732|NCT03490734|DIETARY_SUPPLEMENT|Black Cherry and Orange Flavored Beverage no added sugar|10 oz daily for three weeks
224176733|NCT03490734|DIETARY_SUPPLEMENT|Strawberry Kiwi & Lemonade Flavored Beverage no added sugar|10 oz daily for three weeks
224176734|NCT03490734|OTHER|Water|Three mL administered per associated logo presentation only during MRI procedure.
224176735|NCT05068726|DRUG|18F Fluoroestradiol Radiopharmaceutical with PET/CT|Administration of one dose of 18F FES for PET/CT imaging
224176736|NCT05357586|BEHAVIORAL|Unified Protocol for Transdiagnostic Treatment of Emotional Disorders|The Unified Protocol for Transdiagnostic Treatment of Emotional Disorders is a manualized, evidence-based form of cognitive behavioral therapy aimed at targeting emotion regulation processes that underlie common forms of emotional disorders such as anxiety, depression, and commonly co-occurring mental health challenges.
224176737|NCT00171327|DRUG|valsartan, fluvastatin|
224176738|NCT05386979|PROCEDURE|Opioid free anesthesia technology|We have adopted a variety of methods to replace the use of opioids in the process of balanced anesthesia.
224176739|NCT06135558|DIAGNOSTIC_TEST|MAI detection|to detect the presence of marginal acute inflammation
224176740|NCT05553886|DRUG|To evaluate whether the efficacy of the study drug is noninferior to that of the positive control drug|To evaluate whether the efficacy of the study drug is noninferior to that of the positive control drug
224176741|NCT03362827|OTHER|Chronic low back pain patients|People must have experienced low back pain for at least 3 months and have reported a minimal pain level of 30 (pain threshold) on the 0-100 pain numerical rating scale (NRS) in the last 7 days.
224176742|NCT03362827|OTHER|Subjects without chronic low back pain|These participants must not have presented episodes of low back pain for more than 7 days in the last 12 months.
224176743|NCT03564210|BEHAVIORAL|Screen time permitted|Cohort will not be directed to abstain from screen time
224176744|NCT03564210|BEHAVIORAL|Screen Time Abstain|Cohort will be directed to abstain from screen time
224176745|NCT05143645|OTHER|Plasma vancoymcin measurements|
224176746|NCT02815982|BEHAVIORAL|NOURISH-T|Overweight/obesity family intervention
224306501|NCT00521027|DEVICE|Versajet Hydrosurgery System|Debridement with Versajet Hydrosurgery System
223486649|NCT03788330|DEVICE|Fresh air system with filtration|Using fresh air ventilation combined with PM2.5 filtration system to reduce the indoor PM2.5 concentration in primarty school classrooms
223486650|NCT02013414|DEVICE|3D ultrasound-guided biopsy|Patients will have a PET/CT prior to the biopsy. The CT images will be combined with the PET images for improved localization of suspicious tumors. During the biopsy, the 3-D ultrasound images will be acquired immediately before the biopsy while the patient is on the table. The ultrasound images together with the PET images will be used to guide the targeted biopsy of the prostate.
223486651|NCT02753673|BEHAVIORAL|qualitative interviews with patients|
223617636|NCT02718079|OTHER|Intubation of trachea|
223617637|NCT02718079|OTHER|Administration of mannitol or 3% saline for severe elevation of Intra Cranial Pressure|
224176747|NCT02815982|BEHAVIORAL|Enhanced Usual Care|Publicly available overweight/obesity materials
224176748|NCT02287363|OTHER|No intervention involved|No interventions will be involved since it is an observational study
224176749|NCT00702949|DRUG|pregabalin|Given orally
224176750|NCT00702949|OTHER|placebo|Given orally
224176751|NCT03653039|DEVICE|Tritube|The ultra thin tribute is used used for the ventilation of the patients in this arm
224306502|NCT00521027|PROCEDURE|Conventional surgical debridement techniques|Conventional surgical debridement with scalpel and pulse lavage
223486652|NCT02753673|BEHAVIORAL|questionnaires|
224176752|NCT03653039|DEVICE|Standard enditracheal tube|A standard endotracheal tube is used used for the ventilation of the patients in this arm
224176753|NCT03815955|BEHAVIORAL|Non-Sedentary Behaviour Modelling|Consistent with social learning theory, the primary care provider and the DIGMA support team will model, demonstrate, and verbalize aspects of increased confidence to perform the 1-hour appointment in a standing position and offer a variety of strategies to cope and overcome any feelings of discomfort. Emphasis will be placed on the strategies the primary care team uses to break sitting with standing and light, incidental movements. It will be anticipated that the participant will observe cues and relevant information specific to their behaviour change and engage in minimal sedentary behaviour.
224176754|NCT04389931|OTHER|Lactose tab|Two tablets containing lactose Procedure: Periodontal treatment Scaling and root planning
224176755|NCT04389931|DRUG|Omega 3|Two tablets containing 1g Omega 3. Procedure:Periodontal treatment Scaling and root planning
224176756|NCT00006037|DRUG|fluorouracil|
224176757|NCT00006037|DRUG|irinotecan hydrochloride|
224176758|NCT00006037|DRUG|oglufanide disodium|
224176759|NCT03524586|PROCEDURE|Ipsilateral rotation of head|Ipsilateral rotation of head against fixed tube
224176760|NCT03524586|PROCEDURE|Contralateral rotation of head|Contralateral rotation of head against fixed tube
224176761|NCT00688194|DRUG|anastrozole|Patients receive aromatase inhibitor therapy according to standard treatment regulations.
224176762|NCT00688194|DRUG|exemestane|Patients receive aromatase inhibitor therapy according to standard treatment regulations.
224176763|NCT00688194|DRUG|fulvestrant|Given intramuscularly
224306503|NCT04067427|OTHER|Mental training|App-based mental training
223486653|NCT06278168|OTHER|Awareness training with using Oculus.|"The protocol consists of 2 phases:one conducted in groups,one individually. In the first session, through interactive activities such as passing a wool ball while sharing passions and interests, and filling out personal cards, participants get to know each other and develop an atmosphere of mutual acceptance.~In the second session,participants explore neurodiversity through viewing videos, guided discussions and creating symbols representative of the group concept. Optical illusions are explored to understand differences in individual perception.In addition, issues of hypersensitivity and hyposensitivity are addressed,encouraging participants to reflect on their special interests and ways of presenting themselves. The second phase consists of 12 individual meetings to promote emotional well-being and self-awareness. During the meetings, the Oculus device will be used in which relaxation videos will be shown. In addition, heart rate will be detected with sensors placed in the chest."
223486654|NCT06278168|OTHER|Awareness training without using Oculus|The control group will carry out the same steps as the experimental group, heart rate will be taken through the use of sensors but in this case the Oculus device will not be used to watch relaxation videos.
223486655|NCT02222324|DRUG|Placebo|8 placebo tablets matching E2609
223486656|NCT02222324|DRUG|E2609|E2609 will be administered as 8 tablets
223486657|NCT02222324|DRUG|Moxifloxacin|Administered as 1 tablet with 7 tablets of placebo matching E2609
223486658|NCT01056679|DRUG|Doxorubicine|50mg/m2 day 1 + 15
223486659|NCT01056679|DRUG|DTIC|375mg/m2 day 1 + 15
223486660|NCT01056679|DRUG|Lenalidomide|day 1 - 21
223486661|NCT01056679|DRUG|Vinblastine|6mg/m2 day 1 + 15
223486662|NCT01341470|DRUG|LY2495655|administered intravenously or subcutaneously
223486663|NCT01341470|DRUG|Placebo|administered intravenously or subcutaneously
223486664|NCT04905277|DRUG|Atenolol 50 MG|50 mg Atenolol daily
223486665|NCT04905277|DRUG|Placebo|one placebo daily
223486666|NCT03716427|DRUG|CT1812|
223486667|NCT03716427|DRUG|tolbutamide|Single-sequence drug-drug interaction study to determine the effect of CT1812 (560 mg) once daily on the pharmacokinetics of tolbutamide
223486668|NCT03716427|DRUG|dextromethorphan|Single-sequence drug-drug interaction study to determine the effect of CT1812 (560 mg) once daily on the pharmacokinetics of dextromethorphan
223617638|NCT02718079|OTHER|Volume Replacement|
223617639|NCT02718079|OTHER|Pressor Support|
223617640|NCT02718079|DRUG|N-acetyl-L-cysteine|
223617641|NCT02718079|OTHER|Correction of metabolic parameters|
223617642|NCT02718079|DIETARY_SUPPLEMENT|Correction of nutrition|
223617643|NCT05359172|DRUG|Tranexamic acid|preoperative intravenous infusion
223617644|NCT03900494|DEVICE|VHC 1|Salbutamol 0.6-0.8 mg given 20-40 min. maximum four times depending on the bronchodilator response delivered via valved holding chamber 1. Same salbutamol dosing protocol for both arms. Only difference is the VHC used.
224176764|NCT00688194|DRUG|lapatinib ditosylate|Given orally
224176765|NCT00688194|DRUG|letrozole|Patients receive aromatase inhibitor therapy according to standard treatment regulations.
224176766|NCT00688194|OTHER|placebo|Given orally
224176767|NCT00887913|DEVICE|Fractional RF treatment with Matrix RF applicator|3 treatments, single pass, 2-50J
224176768|NCT04241536|PROCEDURE|Blood draw and urine collection|Patients will collect blood and urine for metabolome analysis
224176769|NCT02983851|PROCEDURE|Noninvasive mechanical ventilation|Noninvasive mechanical ventilation will be delivered to the patient through a mask. The mask will be adjusted and connected to a ventilation system.
224176770|NCT02983851|PROCEDURE|Invasive mechanical ventilation|Invasive mechanical ventilation will be initially performed by using the volume controlled mode, and could be adjusted to pressure controlled mode or other modes based on clinical situation.
224176771|NCT04460651|DRUG|Icosapent ethyl (IPE)|"Participants in this arm will receive study medication IPE with the following dosage schedule:~8 g of IPE (4 capsules every 12 hours - morning and evening, with food) for the first three days followed by 4 g of IPE (2 capsules every 12 hours - morning and evening, with food) thereafter (days 4-28 for treatment arm and 4-60 for prevention arm)"
224176772|NCT04460651|DRUG|Placebo|Participants in this arm will receive placebo with the following dosage schedule: 8 g of placebo (4 capsules every 12 hours - morning and evening, with food) for the first three days followed by 4 g of placebo (2 capsules every 12 hours - morning and evening, with food) thereafter (days 4-28 for treatment arm and 4-60 for prevention arm)
224176773|NCT01747733|DEVICE|Bispectral Index|use of BiS-monitor in the assessment of the level of sedation in patients receiving sedation in endoscopy procedures when compared to clinical sedation scales, such as the Richmond agitation-sedation score.
224176774|NCT02290990|BEHAVIORAL|"Imaginative Distention technique"|ID is an Imaginative relaxation technique which combines physical and mental relaxation. ID technique reaches physical relaxation through planned alternated movements taken from Jacobson PMRT which consist of specific muscle contractions and subsequent relaxations, with a precise temporal scanning. Psychological relaxation is achieved thanks to mental imagery (motor imagery, body scan, imagination).
224176775|NCT02948998|DRUG|Spironolactone|The participants in this arm will be prescribed to take 20mg spironolactone orally and daily. Serum potassium concentration and creatinine and blood pressure will be monitored regularly to make the participants safe.
224176776|NCT00052494|DRUG|cisplatin|
223486669|NCT03716427|DRUG|Omeprazole|Single-sequence drug-drug interaction study to determine the effect of CT1812 (560 mg) once daily on the pharmacokinetics of omeprazole
223486670|NCT03716427|DRUG|midazolam|Single-sequence drug-drug interaction study to determine the effect of CT1812 (560 mg) once daily on the pharmacokinetics of midazolam
223486671|NCT05969561|PROCEDURE|ultrasound-guided femoral nerve block|The local analgesia is injected and infiltrated around the femoral nerve under ultrasound guidance.
223486672|NCT05969561|DRUG|Intravenous or intramuscular pain medication|Intravenous or intramuscular pain medication is given for patients with hip fracture.
223486673|NCT04744181|DRUG|Ferric carboxymaltose|administration of a single dose of ferric carboxymaltose in those patietns who fulfill the inclusion criteria
223486674|NCT04744181|DRUG|B vitamin|administration of a single dose of B vitamin in those patietns who fulfill the inclusion criteria
223486675|NCT04744181|DRUG|Folic acid|administration of a single dose of folic acid in those patietns who fulfill the inclusion criteria
223486676|NCT03907436|OTHER|USDA Diet|Participants will receive counseling and education on USDA Guidelines for Americans, 2010
223586625|NCT06130982|BEHAVIORAL|Walking|1-8weeks:While the experimental group received intervention, the control group underwent walking exercise. The intervention frequency is the same as the experimental group: 1 time/day, 5times/week,30 minutes/time, the total duration controlled within 50 minutes, and includes 3 contents.Warm up activity:head movements,neck movements,shoulder movements, chest expansion exercise,waist rotation,body rotation, lunge movements,leg movements,knee joint movements,ankle movements(15 min).Walk around the track and field (30 min).Cool down (5min) 8-12weeks:stop intervention phase,the subjects resume their daily activities and stop intervention. After this, the final data measurement and collection are conducted again.
223586626|NCT05614921|OTHER|ultrasound guided external oblique intercostal plane block|ultrasound guided external oblique intercostal plane block 30 ml local anesthetic each side
223586627|NCT05614921|OTHER|Wound infiltration|5 ml local anesthetic for each trocar side
223586628|NCT02133976|BEHAVIORAL|cognitive therapy|
223586629|NCT02133976|BEHAVIORAL|mindfulness training|
223586630|NCT02133976|BEHAVIORAL|behavioral therapy|
223586631|NCT02133976|OTHER|treatment as usual|
224176777|NCT00052494|DRUG|imatinib mesylate|
224176778|NCT00052494|DRUG|irinotecan hydrochloride|
223586632|NCT02087722|DRUG|KI1001|
223586633|NCT02087722|DRUG|Placebo|
224176779|NCT00824746|DRUG|Gefitinib retreatment|phase II trial of Gefitinib retreatment for the advanced or metastatic (IIIb and IV) NSCLC patients who previously responded to gefitinib And progressive disease should be observed with at least one prior regimen following previous EGFR-TKI failure.
224176780|NCT02509195|DRUG|Triumeq|Subjects will take the last dose of their current antiretroviral combination at its usual time on the day before the baseline visit (day 1) and will switch on day 1 to Abacavir/lamivudine/dolutegravir 600mg/300mg/50mg (Triumeq) fixed dose combination once daily between day 1 and day 180.
223486677|NCT03907436|OTHER|Mediterranean Diet|Participants will receive counseling and education on a Mediterranean diet.
223486678|NCT04057235|DEVICE|FlareHawk Interbody Fusion System|Expandable lumbar intervertebral body fusion device
223486679|NCT00389870|BIOLOGICAL|panitumumab|
223486680|NCT00389870|DRUG|cyclosporine|
223486681|NCT00389870|DRUG|irinotecan hydrochloride|
223486682|NCT01579864|DRUG|succinylcholine|Succinylcholine 1 mg/kg and a second dose if necessary. Rocuronium 0,4 mg/kg can be used as a rescue
223486683|NCT01579864|DRUG|rocuronium|rocuronium 0,9 mg/kg with additional boluses of 0,3 mg/kg f necessary
223486684|NCT01136915|DRUG|Iopamidol 370|one time administration for PCI
223586634|NCT04545463|DIETARY_SUPPLEMENT|FIBRACEP|A total intake of 7 g/day of FIBRACEP (provided in 6 cookies of 15 g/each) during two months
224176781|NCT04491591|OTHER|Breast Reconstruction Education and Support Tool (BREASTChoice)|The tool is an interactive website and can be sent through My Chart and integrated into the electronic health record
223486685|NCT01136915|DRUG|Iodixanol 320|Iodixanol 320 single injection for percutaneous coronary injection
223486686|NCT01699828|DRUG|Buspirone|The buspirone will be given once as a tablet and encapsulated for blinding.
223486687|NCT01699828|DRUG|Placebo|Placebo will be lactose and encapsulated for blinding. A single capsule will be given.
223586635|NCT04545463|DIETARY_SUPPLEMENT|INSOLUBLE|A total intake of 7 g/day of wheat bran (provided in 6 cookies of 15 g/each) during two months
223586636|NCT04545463|DIETARY_SUPPLEMENT|SOLUBLE|A total intake of 7 g/day of psyllium plantago (provided in 6 cookies of 15g/each) during two months
223586637|NCT02392403|DEVICE|Nucleus CI532 cochlear implant|
223586638|NCT02541786|DRUG|dexlansoprazole based triple therapy|dexlansoprazole MR 60 mg once daily+clarithromycin 500 mg twice daily+ amoxicillin 1 g twice daily for 7 days
224176782|NCT04491591|OTHER|Attention Control Website|-(https://www.cancer.gov/types/breast/reconstruction-fact-sheet)
224176783|NCT04491591|OTHER|Clinician Survey|-Questions regarding opinions on shared decision-making with answers ranging from 1-7 with 1=strongly disagree or harmful to 7=strongly agree or beneficial. The higher the score the more the physician agrees with shared decision making.
224176784|NCT02000674|DRUG|Succinylcholine : 1mg/kg|
224176785|NCT02000674|DRUG|Rocuronium : 1.2 mg/kg|
224176786|NCT00135694|DRUG|calcineurin inhibitor-based immunosuppression|May be cyclosporine, mycophenolate mofetil, or tacrolimus
224176787|NCT00135694|PROCEDURE|liver transplant|Occurs at study entry
224176788|NCT00135694|DRUG|corticosteroids|3-month course of corticosteroids
224176789|NCT00135694|OTHER|immunosuppression withdrawal|One year after transplantation, participants eligible for withdrawal are randomly assigned in a 4 to 1 ratio to immunosuppression withdrawal or to maintenance.
224176790|NCT06160362|BIOLOGICAL|CART-19 and 20 cells|Double-target CART-19 and 20 cells will be administered on day0 after completion of the chemotherapy.
224176791|NCT06160362|DRUG|Cyclophosphamide|patients will receive a standard pre-conditioning regime with cyclophosphamide 500mg/m2/day IV for 2 days(Day-3 to day-2).
224176792|NCT06160362|DRUG|Fludarabine|Fludarabine 25mg/m2/day IV for 3 days (Day-4 to day-2).
224176793|NCT00834392|BEHAVIORAL|Exercise|Walking exercise
224176794|NCT05458869|PROCEDURE|HPV Self-Collection|Use HPV self-collection kit
224176795|NCT05458869|OTHER|Interview|Attend interview
224176796|NCT05458869|OTHER|Survey Administration|Complete surveys
223486688|NCT02205645|DEVICE|FibroFix™ Meniscus scaffold|"The test article for this study is the FibroFix™ Meniscus scaffold supplied by Orthox Ltd. The FibroFix™ Meniscus scaffold has been developed for repair of defects of the meniscus.~The FibroFix™ Meniscus scaffold used in this study is a silk derived product developed to functionally replace the excised unstable meniscus following a meniscal tear."
223486689|NCT05486468|DRUG|Yutiq 0.18 MG Drug Implant|YUTIQ ® (fluocinolone acetonide intravitreal implant) 0.18 mg, for intravitreal injection
223486690|NCT05486468|OTHER|Sham Injection|Sham injection
223586639|NCT02541786|DRUG|rabeprazole-based triple therapy|rabeprazole 20 mg twice daily + clarithromycin 500 mg twice daily + amoxicillin 1 g twice daily for 7 days
223586640|NCT00678834|DIETARY_SUPPLEMENT|To surgery patients, Tocopherol capsules.|200mg (2 100mg capsules) to take by mouth twice daily to total 400mg daily
223586641|NCT00678834|DIETARY_SUPPLEMENT|Tocotrienol to healthy subjects.|200 mg to take orally two times a day (400 mg a day).
223586642|NCT00678834|DIETARY_SUPPLEMENT|To surgery patients, Tocotrienol capsules.|200mg (2 100mg capsules) to take by mouth twice daily to total 400mg daily
223586643|NCT05808517|BEHAVIORAL|Tai Chi|Tai Chi (TC) is a traditional Chinese exercise, also known as a mind-body exercise. It is suitable as an alternative or supplementary form of routine physical exercise for older adults. TC focuses on gentle and rhythmical movements while maintaining a meditative state. Low to moderate activities have benefits to improve sleep disturbances in older adults. In addition, growing evidence widely supports meditation as a potential intervention to improve sleep disturbances through reducing repetitive negative thoughts such as worry and rumination.
223586644|NCT05808517|OTHER|repetitive transcranial magnetic stimulation|The brain stimulation technique repetitive transcranial magnetic stimulation (rTMS) provides the opportunity to non-invasively modulate cortical excitability. In general, low-frequency rTMS (≤ 1 Hz) is thought to inhibit cortical excitability.
223586645|NCT00273845|BEHAVIORAL|Motivational interviewing|One session
223586646|NCT00273845|BEHAVIORAL|Strengths-Based Case Management|5 sessions
224176797|NCT00597532|DIETARY_SUPPLEMENT|Soy|soy (soy protein supplementation 50 grams/day)
224176798|NCT00597532|DIETARY_SUPPLEMENT|Milk|placebo (milk protein supplementation 50 grams/day)
224176799|NCT05687253|DRUG|BX1000|IV BX1000
223486691|NCT05646992|PROCEDURE|Uterine Allotransplantation|Temporary allogenic uterus transplantation from a living donor with the goal of achieving pregnancy and delivering viable baby.
223486692|NCT05646992|DRUG|Tacrolimus|Used as daily immunosuppression. Started at 3mg twice daily (PO) on post-operative Day 1, adjusted to achieve serum trough concentrations of 8-10ng/ml.
223486693|NCT05646992|DRUG|Imuran|Used as daily immunosuppresion. 100 mg for total body weight less than 75 kg and 150 mg for total body weight greater than or equal to 75 mgs
223586647|NCT05956509|BIOLOGICAL|ABBV-950|Intramuscular (IM) Injection
223586648|NCT05956509|BIOLOGICAL|BOTOX|Intramuscular (IM) Injection
223586649|NCT05956509|DRUG|Placebo for ABBV-950|Intramuscular (IM) Injection
223586650|NCT00657371|DEVICE|Third Eye Retroscope Auxiliary Imaging System|A thin, flexible probe that is inserted in a standard colonoscope in order to display very detailed images of the colon tissue.
223586651|NCT00724529|BIOLOGICAL|Infliximab|Infliximab 5 mg/kg IV given in a schedule according to the official label, based on the indication it is being used for.
224176800|NCT05687253|DRUG|Rocuronium Bromide|IV Rocuronium
224176801|NCT01451957|OTHER|Exercise - caloric balance|90 min exercise on Day 1 with meals afterward resulting in caloric balance for the day (i.e.; extra kcals provided to account for energy expended during exercise)\]
224176802|NCT01451957|OTHER|No Exercise - hyper-caloric diet|Subjects remain sedentary on Day 1 and they ingest meals that are identical to those ingested on the day they performed exercise (i.e.; more calories ingested than expended because no exercise performed).
224176803|NCT01451957|OTHER|No exercise - caloric balance|Subjects remain sedentary on Day 1 and they ingest a similar proportion of macronutrients however, the total calories ingested will be lower than the other two trials, resulting in caloric balance for the day.
224176804|NCT01983046|DRUG|Three different mixture of acetate, butyrate and propionate and palcebo|
224176805|NCT03398252|DRUG|Doxazosin XL|Participants will be randomized to receive increasing doses of doxazosin XL (0, 4, and 8 mg).
224176806|NCT03398252|DRUG|Placebo|Participants will be randomized to receive a placebo for doxazosin XL.
224176807|NCT01525108|BEHAVIORAL|Self monitoring of blood pressure|Electronic blood pressure device is provided for patients and he/she will be trained to measure blood pressure at home once daily(same time each day). A logbook is also provided to document the daily blood pressure level.
224176808|NCT01525108|OTHER|Usual Care|Four visits to the physician's office at 4th, 12th, 24th week in the study period with usual advice giving practice of the staff. At the end of the trial period, an electronic blood pressure device will be given to each patient in this arm.
224176809|NCT04012762|DEVICE|Whole body vibration training|Intermittent whole-body vibration exposure is a training method providing physical stimulation effect on skeletal muscles by increasing gravitational acceleration on the vibration platform.
224176810|NCT06404229|DIAGNOSTIC_TEST|CardioPulmonary Exercise Testing|CardioPulmonary Exercise Testing using an arm ergometer prior to surgery
224176811|NCT00310063|PROCEDURE|acupressure therapy|Acupressure wristband
223586652|NCT00539422|GENETIC|pcr and serum markers for breast cancer|DNA extraction and genotyping of cytochrome P450-2D6\*4 gene using conventional PCR followed by restriction enzyme (Mva1) digestion. Separated plasma was used for measurement of plasma malondialdehyde(MDA)concentration, total plasma antioxidant capacity and plasma ferretin level.
223586653|NCT05577637|DRUG|0.03% tacrolimus twice daily was applied on group A patients with uvb phototherapy thrice daily|0.03% tacrolimus twice daily was applied on group A patients with uvb phototherapy thrice daily
223586654|NCT03474198|DRUG|Rifampicin|10mg/kg
223586655|NCT03474198|DRUG|Isoniazid|5mg/kg
223586656|NCT03474198|DRUG|Pyrazinamide|25mg/kg
223586657|NCT03474198|DRUG|Ethambutol|15mg/kg
224176812|NCT00310063|PROCEDURE|sham intervention|Sham wristband
224176813|NCT03542890|DEVICE|Baska Mask|used in adult low risk females undergoing elective gynecological operations
224176814|NCT03542890|DEVICE|I-gel|used in adult low risk females undergoing elective gynecological operations
224176815|NCT00578890|PROCEDURE|Medical/surgical treatment versus medical treatment|A 12 week course antibiotics versus a limited resection of infected bone associated with a 4 week course antibiotics.
224176816|NCT00472043|DRUG|PDT with Metvix 160 mg/g cream|
224176817|NCT00472043|DRUG|Placebo|
224176818|NCT04995731|BEHAVIORAL|Information about clinical risk factors for endometrial cancer and endometrial hyperplasia (EH)|Bleeding type, age, race, parity, early menarche or late menopause, body mass index, body composition, hypertension, type II diabetes, anovulation, polycystic ovary syndrome and smoking history. Other epidemiologic risk factors including tamoxifen exposure, history of breast cancer, current hormone therapy use, anticoagulant use, oral contraception use, family history of endometrial, breast or colon cancer.
223486694|NCT05989139|PROCEDURE|NPPV/HFNC|"Enrolled patients will receive NPPV and HFNC oxygen therapy in a randomized, cross-over fashion, for 40 minutes each. NPPV will be delivered through a full-face mask with a FiO2 starting at 100% and then titrated to achieve an SpO2 of 92-98%. Expiratory positive airway pressure (PEEP) will be firstly set to 5 cmH2O and then increased to a maximum of 15 cmH2O based on SpO2. Pressure support (PS) will be set to an initial value of 10 cmH2O and then increased if signs of respiratory distress persisted or worsened to a maximum value of 20 cmH2O. After 40 minutes, patient is shifted to HFNC ventilation support for 40 minutes.~At the end of the protocol, the patient will receive the treatment that will be shown as more appropriate for the patient, according to the attending physician, who will be informed about the results of the study on the individual patient."
223486695|NCT05989139|PROCEDURE|HFNC/NPPV|"Enrolled patients will receive NPPV and HFNC oxygen therapy in a randomized, cross-over fashion, for 40 minutes each.~HFNC oxygen therapy will start at a flow rate of 60 L/min and will be gradually decreased by 5 cmH2O at time if the patient experienced discomfort. FiO2 will be started at 100% and then titrated to maintain a peripheral oxygen saturation of 92%-98%. Active heating and humidification were provided using MR850, Fisher and Paykel, with a temperature chamber of 37°C. After 40 minutes, patient is shifted to NPPV ventilation support for 40 minutes At the end of the protocol, the patient will receive the treatment that will be shown as more appropriate for the patient, according to the attending physician, who will be informed about the results of the study on the individual patient."
223486696|NCT06449014|DEVICE|Mini-implants assisted maxillary expansion|The intervention involved the placement of orthodontic mini-screws in the patient's palate, varying in diameter from 2 to 2.3 mm and in length from 11 to 15 mm. After mini-screw insertion, another intraoral scan was taken for the fabrication of the appliance. Approximately three weeks later, the expander was placed in the patient's palate, and maxillary expansion was initiated immediately afterward according to the chosen protocol.
223486697|NCT02959762|DIETARY_SUPPLEMENT|Placebo-Control|two placebo softgel capsules per day (for 8 weeks) containing no vitamin K2 (menaquinone-7)
223586658|NCT03474198|DRUG|Linezolid|600mg
224176819|NCT04995731|PROCEDURE|transvaginal ultrasound examination|All patients will undergo a standard transvaginal ultrasound examination followed by power Doppler endometrial vascularity assessment. After ultrasound examination, all patients will undergo endometrial sampling either through hysteroscopy or dilatation and curettage operation (D, C) or will have histopathological evaluation of biopsy specimens obtained by hysterectomy. Histopathological evaluation will serve as a gold standard for the ﬁnal diagnosis.
224176820|NCT01344304|DRUG|Aprepitant / Fosaprepitant|"Aprepitant:~125 mg PO on day 1 80 mg PO on days 2 to 3~Fosaprepitant:~150 mg IV on day 1"
223586659|NCT03474198|DRUG|Clofazimine|200mg
224176821|NCT02802735|DRUG|Apremilast|Tablet for oral administration
224176822|NCT02802735|DRUG|Placebo|Tablet for oral administration
223586660|NCT03474198|DRUG|Rifapentine|1200mg
223586661|NCT03474198|DRUG|Levofloxacin|1000mg
223586662|NCT03474198|DRUG|Bedaquiline|400mg once daily for 2 weeks then 200mg 3x a week
223586663|NCT03474198|DRUG|Rifampicin|35mg/kg
223586664|NCT01702740|DRUG|1 mg/kg CNTO 136|Type=exact number, unit=mg, number=1, form=powder for solution for infusion, route=intravenous use, every 2 weeks for 6 weeks.
223586665|NCT01702740|DRUG|4 mg/kg CNTO 136|Type=exact number, unit=mg, number=4, form=powder for solution for infusion, route=intravenous use, every 2 weeks for 6 weeks.
223586666|NCT01702740|DRUG|10 mg/kg CNTO 136|Type=exact number, unit=mg, number=10, form=powder for solution for infusion, route=intravenous use, every 2 weeks for 6 weeks.
223586667|NCT01702740|DRUG|Placebo|Form=liquid for infusion, route=intravenous use, every 2 weeks for 6 weeks.
223586668|NCT01160432|DRUG|Methadone, naloxone|Methadone 2 mg/ml in combination with naloxone 0,04 mg/ml daily according to patient's individual dose. At first open label pilot using single (individual) dosage for 2 patients. After that crossover study using methadone 2 mg/ml in combination with naloxone 0,04 mg/ml compared to methadone 2 mg/ml alone in one week's periods for four weeks.
223586669|NCT06487728|DIAGNOSTIC_TEST|Urinary titin|Urinary titin and skeletal muscle index as predictor of muscle wasting in critically ill patient
224176823|NCT00190606|DRUG|Duloxetine|
224176824|NCT00190606|PROCEDURE|Pelvic Floor Muscle Training (PFMT)|
224176825|NCT00190606|PROCEDURE|Imitation PFMT|
224176826|NCT00190606|DRUG|placebo|
224176827|NCT00852761|DRUG|Olux-E Foam|Olux-E (clobetasol propionate 0.05%) foam. Starting at baseline, subjects were to apply twice daily Olux-E foam to the affected elbows and/or knees up to day 15.
224176828|NCT00852761|DRUG|Clobex lotion|Clobetasol propionate 0.05% lotion. Starting at baseline, subjects were to apply twice daily Clobex lotion to the affected elbows and/or knees up to day 15
224176829|NCT00420212|DRUG|BG00012|
224176830|NCT00420212|DRUG|Placebo|
224176831|NCT05554744|PROCEDURE|EUS-guided fine-needle injection|Diagnostic evaluation for suspected MEN1-1-related pNETs is conducted by cytology or immunohistochemistry and genetic testing. EUS-FNA is performed to obtain samples. After puncturing with the needle, ethanol/ lauromacrogol under the guidance of EUS was injected into the tumor The volume of ethanol/ lauromacrogol is administrated based on the tumor size.
224176832|NCT03934489|BEHAVIORAL|PERSIST|12-week group, adapted from Dialectical Behavior Therapy, that focuses on emotion regulation skills training and practice.
224176833|NCT03934489|BEHAVIORAL|Facilitated Peer Support|12-week group, adapted from community-based peer support groups, that focuses on participant-generated topics and facilitated discussion.
224176834|NCT04574791|DRUG|TiZANidine 2 MG Oral Capsule|Tizanidine 2 mg q8h (standing; # 42 tablets) + Multimodal pain regimen
224176835|NCT04992000|OTHER|4-free app + PHN intervention|same mentioned in groups
224176836|NCT01860794|DRUG|Mesencephalic Neuronal Precursor Cells|All the patients are continuously registered for this study. Data monitoring committee inspects the clinical results of first patient and decides whether the treatment for four subjects are appropriate to proceed. 5 subjects of each group are subject to inspection by Data monitoring committee after the end of tracking fifth patients.
223486698|NCT02959762|DIETARY_SUPPLEMENT|Low-Dose Vitamin K2 (menaquinone-7; 45-mcg/d)|one 45-mcg vitamin K2 (menaquinone-7) softgel capsule per day and one placebo softgel per day (containing no menaquinone-7) for 8 weeks
223486699|NCT02959762|DIETARY_SUPPLEMENT|High-Dose Vitamin K2 (menaquinone-7; 90 mcg/d)|two 45-mcg vitamin K2 (menaquinone-7) softgel capsules per day for 8 weeks
223586670|NCT03403309|DRUG|1) Inosine 5'-monophosphate|1\) Subjects are initiated with 1 tablet (500mg of inosine 5'-monophosphate per one tablet) two times per day, and then titrated up by 1 tablet per every visit up to visit 2, i.e. increased up to 2 tablets two times a day by week 6. A maximum limit of elevated serum uric acid level is 9 mg/dL, so that reducing dose of administration may be considered in case of being way over the top of limited level.
223586671|NCT03403309|DRUG|Placebo|2\) Subjects are initiated with 1 tablet (500mg of placebo tablet with inactive therapeutic effect) two times a day, and then titrated up by 1 tablet per every visit up to visit 2, i.e. increased up to 2 tablets two times a day by week 6. A maximum limit of elevated serum uric acid level is 9 mg/dL.
223586672|NCT01639755|DEVICE|new texture shaped breast implants|breast implant surgery
224176837|NCT02375464|DRUG|Gallium-68 DOTATOC|Imaging with Gallium-68 DOTATOC
224176838|NCT01170468|DRUG|Vitamin D3|Vitamin D3 5000 IU orally, daily for 2 years
224176839|NCT01170468|DRUG|Placebo|Placebo orally, daily for 2 years
224176840|NCT00877890|DRUG|exenatide once weekly|subcutaneous injection, 2.0mg, once a week
224176841|NCT00877890|DRUG|exenatide twice daily|subcutaneous injection; 5mcg (4 weeks) and 10mcg (20 weeks); twice a day
223486700|NCT04574713|DRUG|Candesartan Oral Tablet 8 mg|1 over-encapsulated tablet once daily, containing candesartan 8 mg, for 12 weeks (84 days).
223486701|NCT04574713|DRUG|Candesartan Oral Tablet 16 mg|1 over-encapsulated tablet once daily, containing candesartan 16 mg, for 12 weeks (84 days).
223486702|NCT04574713|DRUG|Placebo oral tablet|1 over-encapsulated tablet once daily, containing placebo, for 12 weeks (84 days).
223586673|NCT00517569|GENETIC|GX-12|a mixed plasma DNA (HIV-1 antigen genes and human IL-12 mutant) 4, 8, 16mg, i.m., once every other weeks for 22 weeks (total 12 times)
223486703|NCT05376358|DEVICE|MoodRing App|"Adolescents and parents in the MR arm will receive instructions to download the MR app and AWARE app, customize the app, utilize an app-based self-guided onboarding, and review questions with the research team. The MR app provides the adolescent and their parent a notification to view a weekly report predicting their mood score (i.e. depression severity level similar to the Patient health questionnaire-9). The MR app will provide a library of coping strategies for adolescents and opportunities to self-track their mood.~Clinicians in the MR Arm will get access to a MR portal online. They will be able to view patients they are a provider for. The clinician will receive in-person and/or video-based training to use the portal."
223586674|NCT00517569|DRUG|HAART|Highly active antiretroviral therapy; Discontinuation at 24 weeks; NB: The patients should be treated with 2 NRTIs+1 NNRTI or 2 NRTIs + 1 PI, according to the guidelines published by DHHS in the USA.
224176842|NCT06106685|DRUG|High-dose washed microbiota suspension|The high-dose group will be administered a high dose of washed microbiota suspension。
224176843|NCT06106685|DRUG|Low-dose washed microbiota suspension|The low-dose group will be administered a low dose of washed microbiota suspension.
224176844|NCT06106685|DRUG|Placebo|The control group will be given equal volume placebo (120ml carrier solution matching the volume of WMT-001), which contains 10% sterile glycerol and saline injection. The drug was administered once a day for 4 days.
224176845|NCT04733664|DEVICE|VFI using the FAST PV Technology|The bolus IV administered visible fluorescent injectate (VFI) agent is comprised of a mixture of 2 different molecular weight carboxymethyl dextran molecules (5 kD and 150 kD) with different fluorescent dye molecules attached.
224176846|NCT03742687|RADIATION|Heterogeneously Hypofractionated Radiotherapy|A heterogeneous hypofractionated schedule for the treatment of high-risk locally advanced NSCLC patients in which the central idea is to decrease dose to normal tissue by ascribing a heterogeneous dose to the PTV. The dose to the periphery of the PTV as well as to the majority of lymph node targets is decreased compared to a standard treatment. The gross volume of the primary tumour and bulky lymph nodes receive mean doses of up to 66 Gy in 24 fractions, and thus receive a hypofractionated higher biological effective dose than standard 66 Gy in 33 fractions.
224176847|NCT04322266|DRUG|HCP1701|Ezetimibe / Rosuvastatin / Amlodipine / Losartan potassium
224176848|NCT04322266|DRUG|HCP1306|Ezetimibe /Rosuvastatin
224176849|NCT04322266|DRUG|HGP0904|Amlodipine
224176850|NCT04322266|DRUG|HGP0608|Losartan potassium
224176851|NCT03172013|DIAGNOSTIC_TEST|Platelet indices|MPV, PDW
224176852|NCT01700595|PROCEDURE|new technical intervention|Contractures and broad scars of the subjects are treated by this surgical intervention which is a reconstructive surgery that is performed by the transfer of preexpanded perforator flaps to the recipient sites of skin deficiency.
224176853|NCT06352502|DRUG|Furmonertinib|Patients treated with Furmonertinib mesilate tablets orally
224176854|NCT03377166|DIAGNOSTIC_TEST|Bucket test and Smartphone-based evaluation of SVV|Bucket test and Smartphone-based evaluation of SVV
224176855|NCT02331173|DRUG|Dorzolamide 2% TID or brinzolamide 1% TID|"Dosing of all medications will be based upon standard of care. Standard dosing for the treatment of pediatric and adult patients with XLRS is as follows:~* Topical dorzolamide 2% three times per day~* Topical brinzolamide 1% three times per day"
224176856|NCT01943266|DIETARY_SUPPLEMENT|protein intake|on the study day, the diet will be provided as free amino acids,with calories made up by a liquid diet and protein free cookies. Protein intake will be varied at 0.2, 0.5, 0.7, 0.9, 1.0, 1.2, 1.5, 1.8, and 2.0 g.kg/day
224176857|NCT05663827|DRUG|Ruxolitinib|A dosage of 5mg once daily will be applied as initiation. After one week use, dose escalation or de-escalation would depend on clinical response.
224176858|NCT02845115|DEVICE|Conventional implantation|"Usual implantation technique of a middle ear implant. The principle of the ossicular stimulator middle ear transducer MET 7000 (Middle Ear Transducer, METTM) is to directly transmit sounds on the ossicles bypassing the outer ear. Their constraint is the surgical placement of the implant.~MET 7000 system (OTOLOGICS LLC, USA) is the implant that the investigators will use for their patients. The stimulator is usually placed against the body of the anvil by simple contact in the case of sensorineural hearing loss. In the case of mixed hearing loss, the stimulator will come in contact with the bracket using a titanium clip (ossicular prosthesis used in otologic surgery for ossiculoplasties). The optimized version corresponds to the use of the conventionally used in mixed deafness and applied to neurosensory deafness art. It is screwed onto the mastoid bone, the motor is suspended in the mastoid cavity and transmits vibrations to the body of the anvil by simple contact of the transducer."
223486704|NCT05376358|OTHER|Usual Care|Adolescents and parents in the usual care arm will receive instructions to download the AWARE app. This app will only track data and will not be interactive. Otherwise they will receive care as per routine by their healthcare provider team.
223486705|NCT03841981|DIAGNOSTIC_TEST|Anthropometric and physical examination|"* Weight and height.~* Waist-to-hip ratio.~* Body composition: Bioelectrical impedance and \[Dual energy X-ray absorptiometry (DEXA)\]."
223486706|NCT03841981|DIAGNOSTIC_TEST|Indirect calorimetry, accelerometer and seven-day dietary recall|Energy availability assessment.
223486707|NCT03841981|DIAGNOSTIC_TEST|Biochemical, hormonal and metabolic phenotyping|"* Lipid profile.~* Oral glucose tolerance test: plasma glucose and insulin, insulin sensitivity indices, gastrointestinal hormones, adipokines, oxidative stress markers.~* Sex steroid profile.~* Hypothalamic-pituitary-adrenal axis study.~* Ferrokinetic study.~* Subclinical chronic inflammatory markers."
223486708|NCT03841981|DIAGNOSTIC_TEST|Sonographic studies|"* Polycystic ovarian morphology.~* Carotid intima-media thickness.~* Eco-FAT: Ultrasound measurements of adipose tissue depots including sc, preperitoneal, intraperitoneal (ip), mesenteric, and perirenal fat thickness."
223486709|NCT03841981|DIAGNOSTIC_TEST|24-hour Ambulatory blood pressure monitoring|A\&D TM2430EX oscillometric devices (A\&D Company Limited, Tokyo, Japan).
224176859|NCT02845115|DEVICE|optimized implantation with laser velocimetry|
224176860|NCT00761033|BEHAVIORAL|music|
224176861|NCT03675685|BIOLOGICAL|CCH (collagenase clostridium histolyticum)|A single dose of 3.36 mg of CCH will be administered as subcutaneous injections (CCH 0.84 mg) per quadrant concurrently in 4 quadrants. A quadrant is defined as one of the following: left buttock, right buttock, left posterolateral thigh, or right posterolateral thigh.
224176862|NCT04663828|OTHER|Structured counseling|Structured patient education and counselling is considered as providing information to patients in order to empower them to better manage their disorder
224176863|NCT04663828|DEVICE|Hearing aids|Hearing aids are considered medical devices and are recommended to patients with a certain degree of hearing loss. Hearing aids amplify environmental sounds.
224176864|NCT04663828|OTHER|Cognitive behavioral therapy|This is a structured intervention and consists of a several week program both with noise exposure and structured interviews and expert-patient as well as patient-patient interaction in groups
223486710|NCT03841981|PROCEDURE|Percutaneous biopsy|Subcutaneous fat tissue and muscle tissue for proteomics an gene expression studies.
223486711|NCT03841981|DIAGNOSTIC_TEST|Cardiovascular autonomic function studies|Parasympathetic and sympathetic responses to deep breathing, Valsalva's maneuver and orthostatism.
223486712|NCT03841981|DIAGNOSTIC_TEST|Oral smear and feces specimen|Microbiome studies.
223486713|NCT05056220|DRUG|Human albumin|20% Human Albumin infusions (every 10th day +/- 4 days) with dosing according to the participants bodyweight (1.5 grams of albumin per kg bodyweight with a maximum of 100 grams)
223486714|NCT05056220|DRUG|sodium chloride|0.9% NaCl infusions (every 10th day +/- 4 days) with dosing according to the corresponding volume used of 20% Human Albumin (1.5 grams of albumin per kg bodyweight with a maximum of 100 grams)
223486715|NCT03811561|DRUG|Semaglutide|Participants will get one dose of semaglutide once weekly in addition to their diabetes medicines - which treatment they get is decided by chance. Participants will inject the study medicine using a pre-filled PDS290 pen-injector. The medicine must be injected in a skin fold in the stomach, thigh or upper arm once a week. Participants will start with once-weekly doses of 0.25 mg for 4 weeks, then the dose will be gradually increased to 0.5 mg once weekly for 4 weeks, and finally to 1.0 mg once weekly (maximum dose) up to 260 weeks (5 years).
223486716|NCT03811561|DRUG|Placebo (semaglutide)|Participants will get one dose of placebo (semaglutide) once weekly in addition to their diabetes medicines - which treatment they get is decided by chance. Participants will inject the study medicine using a pre-filled PDS290 pen-injector. The medicine must be injected in a skin fold in the stomach, thigh or upper arm once a week. Participants will start with once-weekly doses of 0.25 mg for 4 weeks, then the dose will be gradually increased to 0.5 mg once weekly for 4 weeks, and finally to 1.0 mg once weekly (maximum dose) up to 260 weeks (5 years).
223486717|NCT02723474|DEVICE|MRI at baseline and over time|Hyperpolarized noble gas MRI has been used to explore structural and functional relationships in the lung in patients with lung disease and healthy controls. In contrast to proton-based MRI, Helium-3 and Xenon-129 gas is used as a contrast agent to directly visualize ventilation. Whereas the normal density of gas is too low to produce an easily detectable signal, this is overcome by artificially increasing the amount of polarization per unit volume using optical pumping.
223486718|NCT05526417|PROCEDURE|Computed Tomography|Undergo CT
224176865|NCT04663828|OTHER|Sound therapy|Several sounds and music are used for tinnitus disorder
224176866|NCT00138853|DEVICE|Tibial component|Tibial component inserted at the time of surgery
224176867|NCT04303091|BEHAVIORAL|Physical Activity for Advanced Cancer Treatment (PAACT)|12-week physical activity intervention. 60 minute group-based exercise classes held once per week. Home-based exercise recommendations provided weekly along with basic take-home exercise equipment. Optional palliative care consultations offered.
224176868|NCT04312061|DRUG|oral tramadol|oral tramadol tablet 5o mg given 1 hour before LNG-IUD insertion
224176869|NCT04312061|DRUG|Placebo oral tablet|oral placebo tablet given 1 hour before LNG-IUD insertion
224176870|NCT01902927|OTHER|Attentional distraction using IAPS protocol (standardized images)|Positive, Negative and Neutral Attentional distraction will be presented using IAPS protocol (standardized images) during exercise tests
224176871|NCT02746991|DRUG|Sham Injection|Placebo
224176872|NCT02746991|DRUG|FAI Insert|Fluocinolone Acetonide
224176873|NCT02582151|DEVICE|EV-906 Digital Transcutaneous electrical nerve stimulation (TENS) machine|Percutaneous patch electrodes are used to deliver low level electrical currents.
224176874|NCT01341574|PROCEDURE|Prism adaptation with optical shift of 10 degrees.|Prism adaptation with optical shift of 10 degrees.
224176875|NCT01341574|PROCEDURE|Prism adaptation optical shift of 0 degrees.|Prism adaptation with optical shift of 0 degrees.
224176876|NCT00669591|DRUG|Bavituximab|Weekly bavituximab infusion of 3 mg/kg combined with up to six 28-day cycles of docetaxel chemotherapy. After treatment phase, weekly bavituximab maintenance is continued until disease progression.
224306504|NCT04271020|DEVICE|UroLift|"The UroLift System is indicated for the treatment of symptoms due to urinary outflow obstruction secondary to benign prostatic hyperplasia (BPH).~During the procedure, an implant is delivered into the prostatic lobe obstructing the urethra and restricting urine flow. The distal end of the device is used to compress the lobe then the implant is delivered to retain the lobe in position, thereby increasing the urethral opening and reducing the fluid obstruction through the prostatic urethra."
224306505|NCT06706427|BIOLOGICAL|NGGT001|Using a recombinant adeno-associated virus (AAV) vector to deliver the gene CYP4V2 via subretinal injection for the treatment of crystalline retinal degeneration.
224306506|NCT02243267|OTHER|sample collection|
223486719|NCT05526417|OTHER|Educational Intervention|Receive educational materials
223486720|NCT05526417|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223486721|NCT05526417|PROCEDURE|Physical Therapy|Receive prehabilitation physical therapy
223486722|NCT05526417|OTHER|Questionnaire Administration|Ancillary studies
223486723|NCT05526417|OTHER|Telemedicine|Attend telemedicine visits
223486724|NCT05736848|DEVICE|OviTex® PRS|OviTex® PRS is a reinforced tissue matrix intended to reinforce soft tissue where weakness exists in patients requiring soft tissue repair or reinforcement in plastic and reconstructive surgery.
223486725|NCT06640426|BEHAVIORAL|Two Messaging Nudges|This intervention involves receiving one personalized email and one personalized text message, which include the provider's name, the patient's name, and a phone number to schedule an Annual Wellness Visit
223486726|NCT06640426|BEHAVIORAL|Five messaging nudges|This intervention involves patients receiving up to five personalized email and text messages, which include the provider's name, the patient's name, and a phone number to schedule an Annual Wellness Visit
223486727|NCT05865314|OTHER|Optimisation of nutrition therapy coupled with early mobilisation|"Optimisation of nutrition therapy coupled with early mobilisation with:~* Optimisation of nutrition therapy during ICU stay~* Optimisation of physiotherapy during ICU stay~* Better communication and closer collaboration between physiotherapy and nutrition teams.~* Optimisation of continuity of the care."
223486728|NCT05865314|OTHER|Standard care|Patients will receive nutritional therapy and mobilisation according to local standard procedures.
223486729|NCT03965923|DRUG|Dapivirine (DPV) Vaginal Ring (VR)|Vaginal ring containing 25 mg of DPV
223486730|NCT03965923|DRUG|Truvada Tablet|Tablet taken orally
223486731|NCT04491799|DIAGNOSTIC_TEST|Fecal calprotectin|Fecal calprotectin is a protein found in human neutrophils, and it is released during active periods of inflammation of intestine. The sensitivity and specificity has been reported at 93% and 96%, respectively in differentiating inflammatory bowel disease from irritable bowel syndrome in outpatient setting.
223486732|NCT02587416|DRUG|Gemcabene 300 mg|1x300 mg gemcabene tablets orally once daily (QD) for 11 days
223486733|NCT02587416|DRUG|Gemcabene 900 mg|3x300 mg Gemcabene tablets orally once daily (QD) for 11 days
223486734|NCT02587416|DRUG|Atorvastatin|2x40 mg Atorvastatin tablets orally once daily (QD)
223486735|NCT05497128|DEVICE|Ultrahigh-speed cut rate 27-gauge system|The ultrahigh-speed cut rate 27-gauge system (27+®GA HYPERVIT® Vitrectomy Probe (Alcon Laboratories, Fort Worth, TX, USA))
224176877|NCT03408457|PROCEDURE|Blood sampling after antibiotic administration|Sampling of 6 x 8 mL (in sum 48 mL) via the central venous line (established for the surgical procedure) until postoperative day 2
224176878|NCT05546957|DRUG|Aspirin|Administered orally once per day (QD)
224306507|NCT01622686|BEHAVIORAL|PictureRx medication label|Reformatted medication labels that adhere to current best practices for label design and also include illustrations
224306508|NCT05953974|OTHER|Clinical score of Granillo and al.|Compare the performance of the clinical prediction score of confirmed autoimmune encephalitis according to the type of antibody isolated from the CSF.
224306509|NCT03984292|PROCEDURE|Teaching of laparoscopic skills on a box simulator|The students shall be trained a laparoscopic simulator for a variable duration and the outcome shall be compared.
224306510|NCT00030992|DRUG|BMS-247550|One hour infusion on five successive days (daily x 5) every three weeks. Starting dose of 6 mg/m\^2/day for a total per cycle dose of 30 mg/m\^2
224306511|NCT00030992|DRUG|Ranitidine|50 mg 30-60 minutes prior to Ixabepilone (BMS-247550)
224306512|NCT00030992|DRUG|Diphenhydramine|50 mg intravenously 30-60 minutes prior to Ixabepilone (BMS-247550)
224306513|NCT06477484|DIAGNOSTIC_TEST|Blood biomarker|Blood biomarker
224176879|NCT05546957|DRUG|rivaroxaban low dose|Administered orally twice per day (BID)
224176880|NCT05546957|DRUG|rivaroxaban high dose|Administered orally QD
224176881|NCT02335567|OTHER|there is no intervention|
224176882|NCT01309581|DRUG|Ketamine|Ketamine 1-2 mg/kg IV as indicated for ECT
224176883|NCT01309581|DRUG|Methohexital|Methohexital 1 mg/kg IV as indicated for ECT
224176884|NCT01389895|DRUG|AMG 557|AMG 557 (210 mg) or (140 mg ) will be administered as subcutaneous injections in the anterior abdomen of the subjects. Twelve subjects will be randomized to receive AMG 557. Beginning on Day 1, subjects will receive either 210 mg AMG 557 or 140 mg AMG 557 once weekly for 3 weeks on Day 1, Day 8, and Day 15 and following with 6 additional doses of AMG 557 every other week on Day 29, Day 43, Day 57, Day 71, Day 85, and Day 99. Subjects will be followed out to Day 253 for safety, efficacy, pharmacokinetic (PK) and pharmacodynamic (PD) assessments.
224176885|NCT01389895|DRUG|AMG 557 Placebo|AMG 557 Placebo (210 mg) or (140 mg )will be administered as subcutaneous injections in the anterior abdomen of the subjects. Twelve subjects will be randomized to receive placebo. Beginning on Day 1, subjects will receive placebo once weekly for 3 weeks on Day 1, Day 8, and Day 15 and following with 6 additional doses of placebo every other week on Day 29, Day 43, Day 57, Day 71, Day 85, and Day 99. Subjects will be followed out to Day 253 for safety, efficacy, pharmacokinetic (PK) and pharmacodynamic (PD) assessments.
224176886|NCT00003606|DRUG|cisplatin|
224176887|NCT00003606|DRUG|cyclophosphamide|
224176888|NCT00003606|DRUG|epirubicin hydrochloride|
224176889|NCT00003606|DRUG|etoposide|
224176890|NCT00003606|RADIATION|radiation therapy|
224176891|NCT02217449|OTHER|Prediction of histology|
224176892|NCT04352049|PROCEDURE|Preoxygenation|
224176893|NCT05219006|DIETARY_SUPPLEMENT|ketogenic dieting|Atkins modified diet: 1.2-1.5 g/kg/day of protein with a ratio 1:1 (fat: carbohydrate + protein)
224176894|NCT05219006|DIETARY_SUPPLEMENT|healthy dieting|Normocaloric diet established by a nutritionist. 1.2-1.5 g/kg/day of protein with a maximum contribution of 50 % carbohydrates of the total calorie intake eliminating industrialized food.
224176895|NCT03128606|DRUG|GLPG3067 single dose|GLPG3067 oral suspension, single ascending doses, daily
223486736|NCT05497128|DEVICE|Standard cut rate 27-gauge system|The current standard cut rate 27-gauge vitrectomy system (27+®GA Advanced ULTRAVIT® Vitrectomy Probe (Alcon Laboratories, Fort Worth, TX, USA))
224176896|NCT03128606|DRUG|Placebo single dose|Placebo, oral suspension, daily
224176897|NCT03128606|DRUG|GLPG3067 multiple dose|GLPG3067 oral suspension, multiple ascending doses, daily for 14 days
223486737|NCT05398588|OTHER|Cyriax Deep Friction Massage|Hotpack : 10 min TENS : 20 min, High frequency(100 Hz pulse ), 3 days/week Kaltenborn mobilization: End range - Anterior, posterior and caudal glides :10 repetitions with 10 sec hold x 3 sets, 3 days/week Cyriax DFM on targeted muscles (Supraspinatus, Infraspinatus, subscapularis, Deltoid and Pectoralis) 3 minutes each muscle (15 mins in total ) x 1 set , 3 days / week
223486738|NCT05398588|OTHER|Spencer Muscle energy technique|"Hotpack : 10 min TENS : 20 min, High frequency(100 Hz pulse ), 3 days/week Kaltenborn mobilization: End range - Anterior, posterior and caudal glides :10 repetitions with 10 sec hold x 3 sets, 3 days/week The Spencer technique will be applied in Abduction, External rotation and Internal rotation for targeting muscles Supraspinatus, Infraspinatus, subscapularis, Deltoid and Pectoralis.~10 repetitions x 3set , 3 days/week."
223486739|NCT03586193|PROCEDURE|Pars plana vitrectomy|pars plana vitrectomy without ICG staining and ILM peeling
223486740|NCT01829607|OTHER|Functional electrical stimulation of peripheral muscles|
223486741|NCT04303078|OTHER|Varying levels of harness support during walking|Participants will complete a standard gait and motion analysis at varying levels of harness support and stabilization (low, moderate, and high levels).
223486742|NCT05874141|DIAGNOSTIC_TEST|HBA1C|blood sample on EDTA
223486743|NCT05874141|DIAGNOSTIC_TEST|Lipid profile, including total, LDL, and HDL cholesterol and Triglycerides|serum sample
224306514|NCT00818129|DRUG|AZD7295|ascending single doses (start dose 90 mg), oral solution and then multiple ascending dose (tbd based on single dose results), oral solution
223486744|NCT05874141|DIAGNOSTIC_TEST|Urine analysis and urinary albumin-to-creatinine ratio|Morning urine sample
223486745|NCT05874141|DIAGNOSTIC_TEST|Serum creatinine and estimated glomerular filtration rate|serum sample
223486746|NCT05874141|DIAGNOSTIC_TEST|Complete blood count|blood sample on EDTA
223486747|NCT05874141|DIAGNOSTIC_TEST|Thyroid-stimulating hormone|serum sample
223486748|NCT05874141|DIAGNOSTIC_TEST|Serum iron, TIBC, Transferrin saturation and serum ferritin if needed|serum sample
223486749|NCT05874141|PROCEDURE|Electrocardiography (ECG)|by electrocardiogram
223486750|NCT05874141|PROCEDURE|Transthoracic echocardiography, Neck ultrasonography if needed and abdominopelvic ultrasound|imaging
223486751|NCT05874141|PROCEDURE|Arterial duplex ultrasound of both lower limbs|imaging
223486752|NCT05874141|DIAGNOSTIC_TEST|Random blood glucose|serum sample
224176898|NCT03128606|DRUG|Placebo multiple dose|Placebo, oral suspension, daily for 14 days
224176899|NCT03128606|DRUG|GLPG3067 oral suspension|GLPG3067 oral suspension, single dose, daily
224176900|NCT03128606|DRUG|GLPG3067 oral tablet|GLPG3067 oral tablet, single dose, daily
224176901|NCT03128606|DRUG|GLPG3067/GLPG2222 multiple dose|GLPG3067 oral suspension and GLPG2222 oral tablet, multiple doses, daily for 14 days
224176902|NCT03128606|DRUG|GLPG3067/GLPG2222 Placebo multiple dose|GLPG3067 matching placebo oral suspension and GLPG2222 matching placebo oral tablet, multiple doses, daily for 14 days
224176903|NCT03128606|DRUG|GLPG3067/GLPG2222/GLPG2737 multiple dose|GLPG3067 oral tablet, GLPG2222 oral tablet and GLPG2737 oral capsule, multiple doses, daily for 14 days
224176904|NCT03128606|DRUG|GLPG3067/GLPG2222/GLPG2737 Placebo multiple dose|GLPG3067 matching placebo oral tablet, GLPG2222 matching placebo oral tablet and GLPG2737 matching placebo oral capsule, multiple doses, daily for 14 days
224176905|NCT02770872|OTHER|Observation of SAA on apoB containing lipoproteins|attempting to elicit the conditions by which SAA shifts from apo-A1 containing lipoproteins to apoB containing lipoproteins
224205510|NCT01561586|DRUG|Tri-weekly cisplatin with RT|"Tri-weekly cisplatin 75mg/m2 three cycles concurrent to radiation therapy~Cisplatin may be diluted and administered per established institutional guidelines. For general suggestion, 75 mg/m2 of cisplatin may be diluted in 500 ml 0.9% sodium chloride and administered over one or two hours (rate of 1 mg of cisplatin per minute).~Cisplatin will be given on the first day of external RT (Day 1), preferably, and must be given prior to radiation treatment on that day.~External beam RT will be followed by intracavitary brachytherapy. The total elapsed time for completion of external beam to the whole pelvis, intracavitary BT, and parametrial / nodal RT shall not exceed eight weeks (56 days)"
224205511|NCT00819091|DRUG|BI 1356|5mg orally (po) tablet qd
224176906|NCT05103540|BEHAVIORAL|Comprehensive SEM-Based Program|The SEM theorizes that there are multiple inter-related levels of influences on human behavior, and a successful preventive program should address factors at each stratum. My intervention addresses three levels; individual, interpersonal, and social. Firstly, the research will collaborate with relevant stakeholders to design and obtain a commitment from the schools to a suicidal behavior prevention policy and protocol document. Secondly, the intervention will train staff and students on best practices to improve students' connectedness thereby, creating a positive school environment. Thirdly, the study will identify and train gatekeepers on the proper response to suicidal thoughts and other suicidal behaviors; and serve as the link between the students and a school-linked mental health specialist. We will train the gatekeepers to use school-based screening tools. Lastly, this research will educate all students on suicidal behaviors.
224176907|NCT05034029|DRUG|Metformin hydrochloride sustained release tablets|Oral
224176908|NCT05034029|DRUG|Placebo|Placebo
224176909|NCT03153124|OTHER|Respiratory muscle training|The intervention group will perform three months of intradialytic training of a physical therapy protocol with PowerBreath
224176910|NCT02563886|OTHER|Electrically Assisted Movement Therapy|Electrically Assisted Movement Therapy (EAMT) is an extension of conventional Constraint-Induced Movement Therapy (CIMT) for moderately-to-severely paralyzed patients. During EAMT, patients use a movement controller with the healthy hand, controlling movements generated through neuromuscular electrical stimulation of the paralyzed arm and hand. During each session three types of exercises can be performed: mobilization, games, and training for activities of daily living, all three involving proper shaping of exercise difficulty at therapist discretion. Therapy consists in 20 sessions of 45 minutes twice per day over five weeks.
224176911|NCT02563886|OTHER|Usual and customary care|Usual and customary care ranges from no treatment to varying amounts of orthotics, home-based and clinic-based occupational therapy, or physiotherapy, but always excludes CIMT and EAMT. Therapy consists in 20 sessions of 45 minutes twice per day over five weeks, whenever possible, to match EAMT amount of therapy.
224176912|NCT04999319|PROCEDURE|PVB|Paravertebral block will be performed before the surgery with 20 mL of %0.5 bupivacaine at T4 level.
224176913|NCT04999319|PROCEDURE|ESPB|Erector spinae plane block will be performed before the surgery with 20 mL of %0.5 bupivacaine at T4 level.
224176914|NCT03099811|BEHAVIORAL|Incentive plan|The caregiver and designated social network member can each receive monthly financial incentives over the 6 month time interval. Additional monthly incentives will be received at 3- and 6-months if the participant's previous two monthly biomarker levels were below the lower-limit cutoff.
224176915|NCT03099811|BEHAVIORAL|Smoking cessation|Participants who wish to quit smoking will be referred upon study recruitment to the smoking cessation program that is provided at no-cost by the Maryland Department of Health and Mental Hygiene (DMMH). The DMMH provides standard counseling and nicotine replacement pharmacotherapies for clients and is offered online or at six health centers throughout Baltimore City.
224176916|NCT04805606|DRUG|CKD-843 A|Single Dose
224176917|NCT04805606|DRUG|CKD-843 B|Single Dose
224176918|NCT04805606|DRUG|CKD-843-R|QD, PO
223486753|NCT05874141|DIAGNOSTIC_TEST|AST, ALT, albumin|serum sample
223486754|NCT04651673|OTHER|This is a non interventional registry|All patients, at listed investigational sites, that get prescription for a knee orthosis indicated for Knee OA symptomatic treatment, get an invite to partake in the evaluation registry.
223486755|NCT05633355|DRUG|Rocatinlimab|Subcutaneous (SC) injection
223486756|NCT01698788|DRUG|Dexamethasone Drug delivery system (Ozurdex)|It is a sustained release intravitreal implant containing 700µg dexamethasone
223486757|NCT03410420|DRUG|Pimonidazole hydrochloride|administration of pimonidazole-HCl
223486758|NCT00029237|BEHAVIORAL|Cognitive-behavioral relaxation (Positively Living)|
223486759|NCT00029237|BEHAVIORAL|Spiritual growth group|
223486760|NCT00029237|BEHAVIORAL|Focused Tai Chi|
223486761|NCT02436707|DRUG|Ibrutinib|
223486762|NCT02436707|DRUG|Rituximab|
223486763|NCT02436707|DRUG|Gemcitabine|
223586675|NCT03629912|BEHAVIORAL|Socially-Based Exercise Intervention for Older Adults|A socially-based app that incorporates exercise and/or health education into a format familiar and engaging to older adults, designed to improve adherence to health-promoting behaviors
223486764|NCT02436707|DRUG|Dexamethasone|
223486765|NCT02436707|DRUG|Cisplatin|
223486766|NCT02436707|DRUG|Mesna|
223486767|NCT02436707|DRUG|Cyclophosphamide|
223486768|NCT02436707|DRUG|Etoposide|
223486769|NCT02436707|DRUG|G-CSF|
223486770|NCT02436707|DRUG|Selinexor|
223486771|NCT06485258|BIOLOGICAL|3.75 µg Dose of CDC-9 Inactivated Rotavirus Vaccine (IRV)|CDC-9 IRV adjuvanted with alhydrogel for IM administration in 0.5 mL is comprised of single human rotavirus for protection against rotavirus infection
223486772|NCT06485258|BIOLOGICAL|7.5 µg Dose of CDC-9 Inactivated Rotavirus Vaccine (IRV)|CDC-9 IRV adjuvanted with alhydrogel for IM administration in 0.5 mL is comprised of single human rotavirus for protection against rotavirus infection
223486773|NCT06485258|OTHER|Placebo|0.5 mL sterile saline administered via IM injection
223486774|NCT04957095|DRUG|Apomorphine Injectable Solution|Apomorphine injected for therapeutic relief
223486775|NCT04957095|OTHER|Subcortical Stimulation|Subcortical simulation of the deep brain stimulation surgery target site will be applied by clinically placed deep brain stimulation electrodes at the previously determined therapeutic setting
223486776|NCT04197440|DRUG|BAM8-22 2mg/ml|20 µl of BAM8-22 will be applied to a previously determined area on the volar forearm followed by a prick through the drop
223486777|NCT04197440|DRUG|BAM8-22 1mg/ml|20 µl of BAM8-22 will be applied to a previously determined area on the volar forearm followed by a prick through the drop
223586676|NCT03070197|OTHER|Exposure of interest: Brain MRI|Brain MRI will be conducted in all participants
224176919|NCT04884009|DRUG|SHR-1701； Famitinib|SHR-1701+ Famitinib
224176920|NCT04884009|DRUG|SHR-1701|SHR-1701
224176921|NCT00060333|RADIATION|radiation therapy|
224176922|NCT04342858|DRUG|Fluoride Varnish|Duraphat varnish®, Colgate-Palmolive (UK) Ltd., Guildford, Surrey, UK
224176923|NCT04342858|DRUG|Fluoride Varnish with tricalcium phosphate|Clinpro white varnishTM, 3M ESPE, St Paul, MN, USA
224176924|NCT04342858|OTHER|Oral health education|Standard oral hygiene instructions every 3 months
224176925|NCT05162495|DEVICE|BioStation T101 and TeraTube|Rapid detection of the novel SARS-CoV-2 (COVID-19) virus in breath samples.
224176926|NCT03584412|BEHAVIORAL|ACT OPEN|Participants will access the ACT OPEN treatment through a secure online platform. Each session consists of brief videos and audio recordings that provide information about pain and guide participants through experiential exercises (e.g., mindfulness, values clarification, goal-setting). Participants will respond to questions assessing their experiences during the session and their progress using online messaging and/or brief telephone calls according to their preference. Therapists will provide individualised feedback. ACT OPEN consists of 12 sessions over 6 weeks. Participants will be given two further weeks to finish any uncompleted sessions, or to complete additional sessions (up to four) as agreed with their therapist.
224176927|NCT03584412|OTHER|Waiting list control|Participants will receive their usual treatment for 5 months, after which they will complete ACT OPEN as described. A waiting list control was chosen as there is no clearly credible active psychotherapy to serve as the comparator in this context, particularly in light of high drop-out rates in two previous studies of CBT for pain in HIV. Providing the online treatment without therapist support may appear to be a logical comparison group instead of a waitlist control. However, there is evidence that therapist support is a key component of online CBT and, therefore, without this support it may not represent a credible treatment against which to judge the full treatment. In the context of the feasibility aims of this trial these reasons, the use of a waiting list control is thus justified.
224176928|NCT00807456|DEVICE|ASTRA TECH Implant System, OsseoSpeed™|ASTRA TECH Implant System, OsseoSpeed™ Profile implants: Ø4.5, 5.0, 5.0S mm in lengths of 9, 11, 13, 15mm.
224176929|NCT04095962|OTHER|Exercise|The MT program will be conducted for 6 months, twice a week in 60 minutes sessions. Sessions will be divided in warm-up (10 minutes, including slow walk, postural and mobility exercises for general activation, and stretching exercises), specific training (35-45 minutes, including balance/coordination training, strength and aerobic exercises) and cool down (5 minutes with breathing and stretching exercises for the main worked joints and muscles) following the main guidelines recommended by the American College of Sports Medicine \[18\] and the WHO \[19\].
224176930|NCT07058753|PROCEDURE|Prehabilitation. An intensive prehabilitation for NACT patients|Patients referred to NACT (neoadjuvant chemotheraphy) for advanced ovarian cancer will undergo an intensive course of prehabilitation including physical exercise, a high-protein diet, protein and vitamin supplementation, optimization of laboratory test results, and psychological support will be provided.
224176931|NCT03039907|PROCEDURE|Total Knee Arthroplasty|Total knee arthroplasty
224176932|NCT01960556|OTHER|Simulation Training|Simulation training provided to one group
224176933|NCT06892925|DRUG|QL1706|Eligible participants will receive QL1706 at 5.0 mg/kg intravenously every 3 weeks, lenvatinib at 8 mg orally once daily every 3 weeks, oxaliplatin at 85 mg/m², and gemcitabine at 1000 mg/m² (on days 1 and 8 of each cycle) for up to 8 cycles. Then, they will continue with QL1706 and lenvatinib until clinical progression, imaging progression per RECIST 1.1, unacceptable toxicity, withdrawal of consent, or other discontinuation criteria are met.
224176934|NCT06899815|DRUG|F230 tablets|"SAD： A1: F230 tablets 3mg;A2: F230 tablets 6mg;A3: F230 tablets 12mg;A4: F230 tablets 20mg;A5: F230 tablets 30mg;A6: F230 tablets 40mg .~MAD： B1: F230 tablets 6mg; B2: F230 tablets 12mg; B3: F230 tablets 20mg; Studies on the effects of food on drugs:Group K-C: The first cycle was fasting administration, and the second cycle was postprandial administration;C-K:The first cycle was given after meals, and the second cycle was given on an empty stomach."
224176935|NCT05880160|OTHER|Phased withdrawal of heart failure medications|As per arm/group description
224205512|NCT00819091|DRUG|Placebo|Placebo matching BI 1356 5mg one tablet daily
224205513|NCT04192786|OTHER|Standard physiotherapy program+50 Hz local vibration|Standard physiotherapy program (strength, balance, gait exercises) for 50 minutes and local vibration applied to gastrocnemius (50 Hz) for 10 minutes will be performed 3 days a week for 8 weeks.
224205514|NCT04192786|OTHER|Standard physiotherapy program+100 Hz local vibration|Standard physiotherapy program (strength, balance, gait exercises) for 50 minutes and local vibration applied to gastrocnemius (100 Hz) for 10 minutes will be performed 3 days a week for 8 weeks.
224306515|NCT00818129|DRUG|Placebo|multiple ascending dose (tbd based on single dose results), oral solution
223486778|NCT04197440|DRUG|BAM8-22 0.5 mg/ml|20 µl of BAM8-22 will be applied to a previously determined area on the volar forearm followed by a prick through the drop
223486779|NCT04197440|DRUG|Placebo|20 µl of water will be applied to a previously determined area on the volar forearm followed by a prick through the drop
223486780|NCT04197440|DRUG|BAM8-22 with 1 SPT|20 µl of BAM8-22 will be applied to a previously determined area on the volar forearm followed by 1 prick through the drop
223486781|NCT04197440|DRUG|BAM8-22 with 5 SPT|20 µl of BAM8-22 will be applied to a previously determined area on the volar forearm followed by 5 prick through the drop
223486782|NCT04197440|DRUG|BAM8-22 with 25 SPT|20 µl of BAM8-22 will be applied to a previously determined area on the volar forearm followed by 25 prick through the drop
223486783|NCT04197440|DRUG|BAM8-22 with inactivate cowhage spicules|20 µl of BAM8-22 will be applied to a previously determined area on the volar forearm using inactivate cowhage spicules
223486784|NCT05019677|DRUG|GP+PD-1+Tight|"Drug: Tislelizumab Tislelizumab 200mg IV Q3W~Other Name:~BGB-A317 Anti-PD-1 therapy~Drug: Ociperlimab Ociperlimab 900mg IV Q3W~Other Name:~BGB-A1217 Anti-TIGIT therapy~Drug: GP chemotherapy gemcitabine 1000mg/m2 + cisplatin 25mg/m2 Q3W"
223486785|NCT04221490|DEVICE|Transcatheter Tricuspid Valve Replacement|Replacement of the tricuspid valve through a transcatheter approach
223486786|NCT02942290|DRUG|Azacitidine|Powder for injection; taken subcutaneously (SC) or intravenous (IV); Administered on Days 1-7 of 28 days cycle or Days 1-5 of Week 1 \& Days 1-2 of Week 2 of 28 day cycle.
223486787|NCT02942290|DRUG|Venetoclax|Oral; Tablet
223486788|NCT05047302|DEVICE|BlueLeaf Procedure|The device is intended to form autogenous tissue leaflets from vein walls without the use of a permanent vascular implant.
223486789|NCT02404142|DRUG|Curare (Atracurium)|Curare (Atracurium) versus saline isotonic solution for tracheal intubation
223486790|NCT02404142|DRUG|saline isotonic solution|
223486791|NCT01416662|DRUG|gemcitabine hydrochloride|
223486792|NCT05308407|OTHER|Focus Groups|No intervention involved in this phase of the study
223586677|NCT03070197|OTHER|Exposure of interest: neurodevelopmental assessments|neurodevelopmental testing will be conducted in all participants.
224176936|NCT06049706|DEVICE|Active Priming|"It will be applied an active priming stimulation in the supplementary motor area previously to the main stimulation to analyse if that will enhance the response to TMSr, compared to inactive priming.~To apply intervention, it will be used Repetitive Transcranial Magnetic Stimulation Model MagPro R20 (MagVenture Brazil, country Brazil) and the butterfly coil MCF-B70 (MagVenture Brazil, country Brazil).~Each session will last around 20 minutes, and it will be used a 1 Hz frequency, 1200 pulses/day, with 100% of Motor Threshold, once a day, 5 days a week, for two consecutive weeks.~Active Priming group participants will be previously stimulated for 10 minutes (20 trains of 5 seconds with intertrain interval of 25 seconds), with 6Hz frequency over Supplementary Motor Area, receiving 80% of Motor Threshold, with a total of 600 stimulations."
224176937|NCT06049706|DEVICE|Sham Priming|Sham Priming group participants will receive a placebo stimulation for ten minutes, with the same parameters and target area as the active group, they will hear the equipament noise and might feel any sensation in the scalp, but there won't be effective stimulation.
224176938|NCT05571852|DEVICE|CogniFit's CCT Post COVID-19|The computerized cognitive training (CCT) program is tailored to each person's specific cognitive strengths and weaknesses detected in the Cognitive Assessment Battery (CAB)™ PRO (CogniFit Inc., San Francisco, US; https://www.cognifit.com/cab) by a patented Individualized Training System™ (ITS) software.
224176939|NCT07078838|DRUG|Tirzepatide|Patients will receive a subcutaneous dose of 5 mg weekly for the 4 weeks prior to surgical staging.
224176940|NCT02689141|DRUG|Bendamustine|Debulking: Cycles 1 - 2, d1 \& 2: 70 mg/m2 i.v.
224176941|NCT02689141|DRUG|Ofatumumab|"Induction:~Cycle 1: Day 1 300 mg i.v.; Day 8 1000 mg i.v.; Day 15 1000 mg i.v. Cycle 2-6: Day 1 1000 mg i.v.~Maintenance: After the induction ofatumumab iv 1000 mg every three months will be continued.~Cycle 1-8: Day 1 1000 mg i.v."
224176942|NCT02689141|DRUG|Ibrutinib|Induction: Cycle 2-6: d1-28: 420 mg p.o. Maintenance: After the induction ibrutinib p.o. 420 mg daily will be continued. Cycle 1-8: d1-84: 420 mg p.o.
224176943|NCT06911008|PROCEDURE|Biospecimen Collection|Undergo tissue and blood sample collection
224176944|NCT06911008|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
224176945|NCT06911008|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
224176946|NCT06911008|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
224176947|NCT06911008|OTHER|Questionnaire Administration|Ancillary studies
224176948|NCT06911008|BIOLOGICAL|SCD1 Inhibitor MTI-301|Given PO
224176949|NCT02729402|OTHER|Cognitive Testing|We will use a battery of neurocognitive tests to assess cognitive function before and after surgery
224176950|NCT06908395|OTHER|10-day ambulatory assessment in everyday life combined with two laboratory office days|Participants undergo a 10-day ambulatory assessment period wearing a continuous glucose monitor and a light logger as a necklace as well as completing short questionnaires through a smartphone app at regular intervals every day. On the first day, participants also undergo an extensive eye examination. Day 11 and 12 are spent in either dim or bright office lighting in randomized order.
224176951|NCT07101042|OTHER|Cold Stimulation|Ice massage using circular movements over the suprapubic and inner thigh areas to stimulate sensory afferents. Each session lasted 20 minutes, delivered 3 times per week for 4 weeks.
223486793|NCT05308407|OTHER|Pilot randomized controlled trial|The intervention is a virtually delivered, 12 weekly group-based active video game-centered lifestyle physical activity intervention (POWER UP) targeting affect to improve function and quality of life in insufficiently active AYAs with central nervous system tumors.
223486794|NCT06553651|DEVICE|Cryotechnology Necrosectomy Procedure|Subjects undergo necrosectomy with 1.7 mm flexible cryoprobes, either concurrently with stent placement or post-placement, at the Investigator's discretion. The cryoprobe will freeze the necrotic tissue and extracted en-bloc. A maximum of 4 cryotechnology procedures will be performed, with each procedure aiming for significant debris removal and clinical improvement of walled-off pancreatic necrosis (WOPN) symptoms.
223586678|NCT01475162|DRUG|Tocilizumab|Tocilizumab will be administered intravenously at a dose of 8 mg/kg once every three weeks for three doses. After Day 56 doses may be decreased to 4mg/kg once every three weeks depending on GVHD response.
223586679|NCT01276366|OTHER|breast feeding|Newborns who are assigned to group one, receive breastfeeding during the blood sample and thereby have skin-skin contact between mother and child.
223586680|NCT01276366|OTHER|supplemental breast milk|In group two, the newborns receive supplemental breast milk, lying in the arms of a nurse during the heel lance.
223586681|NCT01276366|OTHER|sucrose|In the third group, newborns receive sucrose 1ml 24% two minutes before procedure, followed by non-nutritive sucking. During the procedure the newborn lies in his cot.
223486795|NCT06301035|DEVICE|Asymmetric High flow nasal cannula|"* Both the test group and the control group apply high flow oxygen therapy for at least 24 hours from the time of initial excretion (0h), and only the nasal interface is applied differently depending on the allocation group.~* The initial flow rate setting is 10 L/min, and it can be adjusted up to 50 L/min within the range where the subject does not experience discomfort. Except for cases where the patient complains of being hot, the initial temperature setting is 37°C, and the inhaled oxygen concentration (FiO2) may be adjusted to a target of 93% or more of peripheral oxygen saturation (SpO2) in the range of 21 to 100%.~* After 24 hours, high flow oxygen therapy is discontinued and conventional oxygen therapy can be applied if necessary."
223586682|NCT00901797|PROCEDURE|Arthroscopic Bankart repair|Seated in a beach chair position, arm fixed with a skin traction device (Spider shoulder Immobilizer or 3kg traction), arthroscopy through a posterior portal, anterior portal used for inspection and instrumentation, labral lesion released using a suture liberator, full radius and VAPER. Preparation of the glenoid with rasp up and down. Insertion of anchors as necessary into the glenoid and ligation of labral lesion with the sutures. Wound closure with ethilon 4/0 suture, striped dressing, velpeau arm sling.
223617645|NCT03900494|DEVICE|VHC 2|Salbutamol 0.6-0.8 mg given 20-40 min. maximum four times depending on the bronchodilator response delivered via valved holding chamber 2. Same salbutamol dosing protocol for both arms. Only difference is the VHC used.
223617646|NCT00894140|DEVICE|DePuy Silent™ Hip femoral prosthesis|A short cementless, femoral component for use in total hip arthroplasty
223617647|NCT00317551|DEVICE|Aberration controlled contact lens|
223617648|NCT00317551|BEHAVIORAL|Vision training|
223617649|NCT03813888|OTHER|Arsha Vidya chldren's Group|Yoga, Vedic chants, Vedant sessions, Gita sessions and group activities within the Gurukulam (centre)
223586683|NCT00901797|PROCEDURE|ABR+ARIC|Seated in a beach chair position, arm fixed with a skin traction device (Spider shoulder Immobilizer or 3kg traction), arthroscopy through a posterior portal, anterior portal used for inspection and instrumentation, labral lesion released using a suture liberator, full radius and VAPER. Preparation of the glenoid with rasp up and down. Insertion of anchors as necessary into the glenoid and ligation of labral lesion with the sutures. Through additional anterior superior portal a suture is passed inferior and adjacent to the SSP and through the superior portion of the Sub Scapularis tendon while the arm in 30 degree of external rotation. Tightening the suture on top of the capsule underneath the deltoid. Wound closure with ethilon 4/0 suture, striped dressing, velpeau arm sling.
223586684|NCT00490022|DRUG|Dihydrotestosterone (DHT) gel (0.7%)|DHT gel, 70 mg/day for one month
223586685|NCT00490022|DRUG|Placebo gel|Placebo gel for one month
223586686|NCT04079543|OTHER|NPO past midnight|NPO after midnight (solids and liquids), except for a sip of water with medication.
223586687|NCT04079543|OTHER|NPO|No solids after midnight. Clear liquids up to 2 hours prior to procedure. Patients can take medications with a sip of water.
224176952|NCT07101042|OTHER|Paraspinal Electrical Stimulation|Surface electrodes applied bilaterally to the T12-L2 region. Parameters: 20 Hz frequency, 200 µs pulse width, intensity set below motor threshold. Sessions were administered 3 times per week for 4 weeks.
224176953|NCT00498706|BEHAVIORAL|Telephone-administered cognitive behavioral therapy (T-CBT)|Over 18 weeks, participants will receive eighteen 45-minute sessions of T-CBT administered by a therapist. Participants will undergo telephone-administered sessions twice a week for 2 weeks, once a week for 12 weeks, and once every 2 weeks for the last 4 weeks. Participants will be taught ways to modify thoughts and behaviors that contribute to their depression and ways to maintain the lifestyle changes that they have made.
224176954|NCT00498706|BEHAVIORAL|Face-to-face administered CBT (FtF-CBT)|Over 18 weeks, participants will receive eighteen 45-minute sessions of FtF-CBT administered by a therapist. Participants will undergo face-to-face administered sessions twice a week for 2 weeks, once a week for 12 weeks, and once every 2 weeks for the last 4 weeks. Participants will be taught ways to modify thoughts and behaviors that contribute to their depression and ways to maintain the lifestyle changes that they have made.
224176955|NCT06442176|DIAGNOSTIC_TEST|OCT|Enhanced depth imaging optical coherence tomography (EDI-OCT) using the Heidelberg Spectralis HRA + OCT (Heidelberg Engineering, Inc., Franklin, MA, USA)
223486796|NCT06301035|DEVICE|Standard(symmetric) High flow nasal cannula|"* Both the test group and the control group apply high flow oxygen therapy for at least 24 hours from the time of initial excretion (0h), and only the nasal interface is applied differently depending on the allocation group.~* The initial flow rate setting is 10 L/min, and it can be adjusted up to 50 L/min within the range where the subject does not experience discomfort. Except for cases where the patient complains of being hot, the initial temperature setting is 37°C, and the inhaled oxygen concentration (FiO2) may be adjusted to a target of 93% or more of peripheral oxygen saturation (SpO2) in the range of 21 to 100%.~* After 24 hours, high flow oxygen therapy is discontinued and conventional oxygen therapy can be applied if necessary."
223486797|NCT05123625|PROCEDURE|Reduce surgical procedures|In the intervention group, investigators used a reductive approach. That is, for radical cystectomy, investigators did not perform pelvic lymph node dissection.
223486798|NCT05940012|OTHER|Manual Therapy|Hands on treatments including manipulation, mobilization and soft-tissue mobilization with therapeutic intent.
223486799|NCT05776888|OTHER|Ofatumumab|There is no treatment allocation. For both cohorts, only patients that have received Ofatumumab treatment for at least 3 months prior to inclusion in the study will be enrolled.
223486800|NCT06350318|DRUG|Zanubrutinib|Zanubrutinib is an anti-cancer medication administered orally.
223586688|NCT02871089|DEVICE|Closed-loop system (Florence M or CamAPS FX)|"The automated closed-loop system (FlorenceM) will consist of:~* Sensor augmented Medtronic insulin pump 640G (Medtronic Minimed, CA, USA) incorporating the Medtronic Enlite/Guardian 3 real time CGM and glucose suspend feature.~* An Android smartphone containing the Cambridge model predictive algorithm and communicating wirelessly with the insulin pump using a proprietary translator device.~The automated closed-loop system (CamAPS FX) will consist of:~* Dana R or RS insulin pump~* Dexcom G6 real-time CGM~* CamAPS FX App on an unlocked android smartphone.~Rapid acting insulin analogue will be used (insulin aspart, insulin lispro, insulin glulisine or similar or ultra-rapid insulin analogue)."
223617650|NCT03813888|OTHER|Usual Activity group|Usual after school activities at home.
224176956|NCT02814812|PROCEDURE|CT scan|
223486801|NCT06350318|DRUG|Rituximab|Rituximab is a biologic medication administered intravenously or subcutaneously.
223486802|NCT01426451|OTHER|Group tutoring program|Academic in-class intervention that focuses on differentiated academic instruction and improved overall academic adjustment. In each classroom assigned to the tutorship intervention, two academic resource assistants will provide weekly in-class support to students for the same length of time than the drama workshop (75 minutes, once a week), with the teacher present in the classroom.
223486803|NCT01426451|OTHER|Theatre workshops|The theatre expression workshops will run for 12 weeks, with one 75-minute workshop per week. They will be incorporated into the regular class timetable and will be run by the two members of the intervention team who have training in theatre and psychology, and the homeroom teacher, whose level of direct involvement will increase gradually as he or she becomes familiar with the workshops.
223486804|NCT00837889|DRUG|diuretics, inotropica|
223486805|NCT05898204|OTHER|Ketogenic diet|Prescription of a ketogenic diet, 1200 Kcal/die. Patients are encouraged to walk 30 minutes every day.
224176957|NCT01497665|DRUG|GRN1005|650 mg/m2 IV every 3 weeks
224176958|NCT00477867|PROCEDURE|quality-of-life assessment|
224176959|NCT07102277|PROCEDURE|Percutaneous Internal Ring Suturing (PIRS) with peritoneal cauterization|Percutaneous Internal Ring Suturing with peritoneal cauterization at the internal ring.
224176960|NCT07102277|PROCEDURE|Percutaneous Internal Ring Suturing|Percutaneous Internal Ring Suturing (PIRS) without peritoneal cauterization.
224176961|NCT05920655|DIAGNOSTIC_TEST|Optic coherence tomography|Eye examination of patients with optic coherence tomography test by an ophthalmologist
223486806|NCT05898204|OTHER|Balanced diet|Prescription of a balanced diet, 1200 Kcal/die. Patients are encouraged to walk 30 minutes every day.
223486807|NCT05761171|PROCEDURE|Biospecimen Collection|Undergo collection of blood and CSF samples
223486808|NCT05761171|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
223586689|NCT02871089|OTHER|Multiple Daily Injections|"Rapid acting insulin analogue and long acting insulin analogue will be subcutaneously administered using CE-marked insulin pen devices in accordance with the manufacturer's instructions for their intended purposes.~Participants will be given long acting analogue (insulin glargine, insulin detemir or similar) once or twice daily according to their needs and boluses of rapid acting analogue (insulin aspart, insulin lispro, insulin glulisine or similar or ultra-rapid insulin analogue) when carbohydrates are consumed."
224176962|NCT06419790|DEVICE|EIT electrode belt, spirometry|Placing electrode belt for EIT monitoring and measuring tidal volume with spirometer
223486809|NCT05761171|DRUG|Calaspargase Pegol|Given IV
223486810|NCT05761171|DRUG|Cytarabine|Given IV and IT
223486811|NCT05761171|PROCEDURE|Echocardiography Test|Undergo ECHO
223486812|NCT05761171|DRUG|Fludarabine Phosphate|Given IV
224176963|NCT05700994|BEHAVIORAL|Peer Contingency Management|Participants allocated to peer-facilitated contingency management will receive incentives for achieving self-identified harm reduction goals set with peer specialists using a participant-driven harm reduction goal-setting process (e.g. completing overdose prevention and supply training, daily life goals, treatment and care goals, relationship and social support goals)
223486813|NCT05761171|DRUG|Hydrocortisone Sodium Succinate|Given IT
223486814|NCT05761171|PROCEDURE|Lumbar Puncture|Undergo lumbar puncture
223586690|NCT05597072|BEHAVIORAL|Intervention|Less people within the OR but longer waiting time.
223586691|NCT05597072|BEHAVIORAL|Control|More people in the OR but shorter waiting time
223586692|NCT05170789|DRUG|Elotuzumab, Selinexor, and Dexamethasone (ESd)|This is a single-arm, interventional, phase II clinical trial, in which the anticipated 18 enrolled patients will receive the trial drug, a combination of Elotuzumab, Selinexor, and Dexamethasone in monthly cycles. The study tests the theory of synergy between these drugs, as detailed in the study description above.
223586693|NCT01304407|OTHER|Calcium stable isotope|Subjects consume breakfast and 180 ml of calcium-fortified orange juice to which 20 mg of 46Ca stable isotope was added. Immediately after breakfast, subjects receive 5 mg of 42Ca intravenously.
223586694|NCT00559130|DEVICE|CytoSorb Hemoperfusion|Daily hemoperfusion for 6 hours with CytoSorb device
223745319|NCT06906133|OTHER|Urinary-hCG|Ovulation days will be detected using a commercial urine test for luteinizing hormone (LH) (PREGMATE, Ovulation Midstream Test Predictor Kit; sensitivity level:25mlU/mL). Participants will be instructed to use ovulation tests, starting 5 days before the expected ovulation (day 10) and for the next 7-10 days or until the first the first positive results are detected notify the study co-ordinator and share a photo of the results. Then participants will be asked to continue using the ovulation test for 3 more days.
223745320|NCT07095114|OTHER|Magic Ink|A novel ink that is only visible when exposed to Ultraviolet light and can be hidden using white light will be inserted into the dermis to tattoo a radiation guidance tattoo into the skin of the participant
223745321|NCT06913673|OTHER|Bio-c Temp|Intra-canal medication
223745322|NCT06913673|OTHER|Metapex|Intra-canal medication
224176964|NCT05700994|BEHAVIORAL|Standard of Care Contingency Management|Participants allocated to standard of care contingency management will receive incentives for peer encounters.
224176965|NCT00027846|BIOLOGICAL|filgrastim|Given IV or SC (5mcg/kg/day) start on Day 3 and continue until ANC \>1500/μl given subcutaneously or intravenously.
224176966|NCT00027846|DRUG|carboplatin|Given IV (375 mg/m2/day) Day 1 given as an IV infusion over one hour. For patients with BSA \<0.45m2 the dose is 12.5 mg/kg/day.
224176967|NCT00027846|DRUG|cyclophosphamide|Given IV (1000mg/m2/day) Day 1 and 2 given as an IV infusion over one hour following carboplatin administration. For patients with BSA\<0.45m2 the dose is 33mg/kg/day on Day 1 and 2.
224176968|NCT00027846|DRUG|etoposide|Given orally (50 mg/m2/day) orally once daily on Days 1 through 21. For patients with BSA \< 0.45 m2, the dosage is 1.7 mg/kg/day on Days 1 through 21.
224176969|NCT00027846|DRUG|vincristine sulfate|Given IV or orally (1.5mg/m2/day) (maximum dose 2 mg) Day 1 and 8 given as IV bolus. For patients with BSA\<0.45m2 the dose is 0.05mg/kg.
224176970|NCT00027846|RADIATION|radiation therapy|Given once daily 5 days a week for 6-6½ weeks
224176971|NCT00027846|DRUG|Mesna|Mesna (200mg/m2/dose) Day 1 and 2. For patients with BSA\<0.45m2 the dose is (7mg/kg/dose). Combine mesna (200mg/m2) with cyclophosphamide and administer intravenously over one hour followed by mesna (200mg/m2) in 375 cc/m2 D5-1/2NS and run intravenously over 3 hours at 125cc/m2/hr. After 3 hour mesna, administer mesna (200 mg/m2/dose) IV over 15 minutes at hour 5.
224176972|NCT00027846|PROCEDURE|therapeutic conventional surgery|
224176973|NCT01042561|DIETARY_SUPPLEMENT|Vitamin D3|400 IU of vitamin D3 daily. Pts will recieve 1 mL a day with a feeding for 28 days.
224176974|NCT01042561|DIETARY_SUPPLEMENT|vitamin D3 placebo|Placebo designed by research pharmacist. Pts will recieve 1 mL a day with feedings for 28 days.
224176975|NCT05370300|DIAGNOSTIC_TEST|Blood test|Proprietary immunogenomic signature from peripheral blood CD14 and CD2 cells.
224176976|NCT01539473|DRUG|TR-701 FA with Tyramine|TR-701 FA 200 mg oral and Tyramine
224176977|NCT01539473|DRUG|Placebo-controlled withTyramine|Placebo-controlled and Tyramine
224176978|NCT04392531|DRUG|Cyclosporine|In the experimental group, cyclosporine will be started according to patient weight, and then increased depending on patient tolerance (monitoring renal function and blood pressure)
223486815|NCT05761171|DRUG|Methotrexate|Given IT
223486816|NCT05761171|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA scan
223486817|NCT05761171|DRUG|Prednisolone|Given PO or via NG, NJ, ND or G-tube
223486818|NCT05761171|DRUG|Prednisone|Given PO or via NG, NJ, ND or G-tube
223486819|NCT05761171|DRUG|Revumenib|Given PO or via NG, NJ, ND or G-tube
223486820|NCT05761171|DRUG|Vincristine Sulfate|Given IV
223486821|NCT06341114|DRUG|BAT8008 injection|BAT8008 for injection is a sterile, preservative-free lyophilized powder packaged in vials, with each vial containing 100 mg,Prior to infusion, reconstitute with 5 milliliters of sterile water for injection. After reconstitution, a clear to slightly opalescent, colorless to pale yellow solution with a final concentration of 20 mg/mL can be obtained.
223486822|NCT06341114|DRUG|BAT1308 injection|One vial of 4 mL of concentrate contains 100 mg of BAT1308
223486823|NCT00998192|BIOLOGICAL|REOLYSIN|3x10E10 TCID50 1 hour intravenous infusion, administered on Days 1,2,3,4,and 5 of a 21-day cycle
224176979|NCT04392531|DRUG|Standard treatment|Standard of care according to hospital protocol
224176980|NCT00275704|DRUG|Flaxseed|
224176981|NCT01319539|DRUG|Akt Inhibitor MK2206|Given PO
224176982|NCT01319539|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
224176983|NCT01319539|OTHER|Pharmacological Study|Correlative studies
224176984|NCT01319539|OTHER|Laboratory Biomarker Analysis|Correlative studies
224176985|NCT02711163|DIETARY_SUPPLEMENT|Extensively Hydrolyzed formula|
224176986|NCT02711163|DIETARY_SUPPLEMENT|Amino acid formula|
224176987|NCT01337921|DIETARY_SUPPLEMENT|Multi-strain Probiotic|Multi-strain Synbiotic: 1.5 billion CFU of Lactobacillus acidophilus, Bifidobacterium bifidum,and Bifidobacterium lactis WITH galacto-oligosaccharide(GOS)/fructo-oligosaccharide (FOS) combination at 1g/dL (0.9g/dL GOS/ 0.1g/dL FOS)
224176988|NCT05604781|DEVICE|Symfony & Synergy IOL combination|The Symfony IOL will be implanted in the dominant eye while the Synergy IOL will be implanted in the non-dominant eye.
224176989|NCT04697342|BEHAVIORAL|strategy of education|"one of the strategies is microvideo with nursing information system(NIS); another of the strategies is workshop with NIS.~NIS of PI education is the routine education"
224176990|NCT02933333|BIOLOGICAL|GM-CSF|Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a hematopoietic CSFs that decrease the duration and severity of neutropenia for patients receiving chemotherapy. GM-CSF is a stimulator of the growth and differentiation of hematopoietic progenitor cells committed to neutrophils, monocytes or eosinophils.
224176991|NCT02933333|BIOLOGICAL|G-CSF|Granulocyte colony-stimulating factor (G-CSF) is a hematopoietic CSFs that decrease the duration and severity of neutropenia for patients receiving chemotherapy. G-CSF is a relatively specific stimulator of the growth and differentiation of hematopoietic progenitor cells committed to the neutrophil lineage.
224176992|NCT02933333|BIOLOGICAL|GM-CSF and G-CSF|Granulocyte-macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF) are hematopoietic CSFs that decrease the duration and severity of neutropenia for patients receiving chemotherapy. GM-CSF and G-CSF share a number of biologic activities, GM-CSF seems to be more potent against fungi.
224176993|NCT06049511|BEHAVIORAL|oral self care protocol|An oral self-care protocol, grounded in Orem's Self-Care Deficit theory and incorporating self-care behaviors, was implemented for the patients in the treatment group. The protocol consisted of several components, including the assessment of oral mucositis by the researcher and self-assessment of the oral cavity by the patients. It also involved teaching proper tooth brushing techniques, providing written materials, supplying an oral care kit, and offering patient and family education. Interventions were made for 21 days from the beginning of chemotherapy treatment.
224176994|NCT06049511|BEHAVIORAL|standard care|the patients received standard nursing care provided at the clinic to prevent oral mucositis.
224176995|NCT03763448|PROCEDURE|Infrapatellar Fat Pad preservation|In the IPFP preservation group, IPFP (more than 80%) will be preserved by retracting out of the operative field.
224306516|NCT03647683|OTHER|Self-Compassion|"Participants are introduced to the concept of self-compassion. Treating oneself with kindness, while being mindfully aware of the present moment as well as the fact that suffering is part of human life - a shared human experience.~Participants are instructed to use this strategy to cope with the following heat stimulus."
223486824|NCT00998192|DRUG|Paclitaxel|200 mg/m2, 3-hour intravenous infusion, given on Day 1 of a 21-day cycle
223486825|NCT00998192|DRUG|Carboplatin|6 AUC mg/mL min, 30-min intravenous infusion, given on Day 1 of a 21-day cycle
223486826|NCT04633811|DIETARY_SUPPLEMENT|Low Oxalate Diet before Weight Loss|Subjects will be instructed to ingest a controlled diet low in oxalate for a total of 6 days. 2 x 24 hour urines will be collected on days 3 and 4.
223486827|NCT04633811|DIETARY_SUPPLEMENT|Oral load of oxalate and sucralose before Weight Loss|Subjects will ingest 100mg carbon-13 oxalate, and 1 gram of sucralose on day 5 of the 6-day low oxalate diet phase. Following the oral load, blood and urine will be collected every 30 minutes and hourly, respectively
223586695|NCT06031545|OTHER|Long peripheral venous catheters for use|Long peripheral venous catheters for use during the perioperative period in obese patients
223586696|NCT06031545|OTHER|Midline catheter|Midline catheters for use during the perioperative period in obese patients
223586697|NCT06188299|OTHER|Restricted Fluid Administration|Restrictive fluid administration generally consists of partial or no replacement for the intravascular expansion from anesthesia, in which case vasopressors are usually administered, no replacement for the third space loss, and only partial replacement for deficits from preoperative fasting.
223586698|NCT02776592|OTHER|Cow's milk-based formula with added nutrients|
223586699|NCT02776592|OTHER|Cow's milk-based formula|
223586700|NCT01033318|DRUG|MK1809|single oral doses of MK1809
223586701|NCT01033318|DRUG|Comparator: Losartan|single oral doses of 100 mg Losartan
223586702|NCT01033318|DRUG|Comparator: Placebo|Placebo to MK1809
224176996|NCT03763448|PROCEDURE|Infrapatellar Fat Pad resection|In the IPFP resection group, more than 80% IPFP will be resected during the total knee arthroplasty.
224176997|NCT01005966|DRUG|Sodium Fluoride Toothpaste|Test product
224176998|NCT01005966|DRUG|Amine Fluoride Toothpaste|Test product
224176999|NCT01005966|DRUG|Sodium monofluorophosphate/Sodium Fluoride Toothpaste|test product
224177000|NCT01005966|DRUG|Placebo|placebo and washout treatment
224177001|NCT01005966|DRUG|675 ppmf toothpaste|dose response
224177002|NCT00863564|DIETARY_SUPPLEMENT|Caseine|
224177003|NCT00863564|DIETARY_SUPPLEMENT|Cod|
224177004|NCT00863564|DIETARY_SUPPLEMENT|Gluten|
224177005|NCT00863564|DIETARY_SUPPLEMENT|Whey Isolate|
224177006|NCT01451203|DRUG|Placebo|Subcutaneous (SC)
224177007|NCT01451203|DRUG|CZP|SC
224177008|NCT01451203|DRUG|methotrexate (MTX)|oral
224306517|NCT03647683|OTHER|Acceptance|"Participants are introduced to the concept of acceptance. Thoughts, Emotions and Reactions do not need to be related. Being aware of the present moment helps with accepting the present state and reacting contradictory to the thoughts and feelings.~Participants are instructed to use this strategy to cope with the following heat stimulus."
224306518|NCT03647683|OTHER|Distraction|"Participants are introduced to the concept of distraction. Distracting oneself from the present situation helps with not perceiving pain, painful thoughts or feelings.~Participants are instructed to use this strategy to cope with the following heat stimulus."
223486828|NCT04633811|DIETARY_SUPPLEMENT|Optifast VLCD Program|Subjects will go on a 10-week Intestive level Optifast VLCD weight loss program
223486829|NCT04633811|DIETARY_SUPPLEMENT|Optifast VLCD Transition Phase|After completion of the 10-week Optifast VLCD Program, subjects will be weaned off the Optifast products for 4 weeks.
223486830|NCT04633811|DIETARY_SUPPLEMENT|Low Oxalate Diet after Weight Loss|Subjects will be instructed to ingest a controlled diet low in oxalate for a total of 11 days and collect 2 x 24 hour urines on days 8 and 9
223486831|NCT04633811|DIETARY_SUPPLEMENT|Oral load of oxalate and sucralose after Weight Loss|Subjects will ingest 100mg carbon-13 oxalate, and 1 gram of sucralose on day 10 of the 11-day low oxalate diet phase. Following the oral load, blood and urine will be collected every 30 minutes and hourly, respectively
223486832|NCT04903522|BEHAVIORAL|Baroque music listening|"Patients will listen to a 30-minute musical path of baroque pieces. Before and after this, anxiety, depression and consciousness fluidity will be evaluated thanks to different questionnaires"
223486833|NCT03751813|DIETARY_SUPPLEMENT|Supplement|Supplement will be given to this group to take daily for 8 weeks
223486834|NCT06465667|BEHAVIORAL|Dashboard|The Dashboard intervention, representing current standard of care, will consist of a standard e-mail message with a link to the dashboard and text explanation. No performance data will be included in the e-mail, and links will not be monitored for clickthrough with repeat e-mail.
223486835|NCT06465667|BEHAVIORAL|Precision Feedback Push|"The experimental intervention, precision feedback e-mail messaging, will consist of an e-mail with a link to the dashboard along with tailored information about a participant's performance in the quality process measure of interest. For example, e-mail subject lines may read You have room for improvement in stent omission, accompanied by a visual display in the body of the e-mail showing a participant's performance relative to a top performing peer. The behavior change intervention delivery component will also involve modifications to existing procedures. Namely, performance feedback will be reported directly in the e-mail as either plain text, or an embedded or attached image with graphed data."
223486836|NCT05300282|DRUG|Atezolizumab|"In phase I study: Atezolizumab will be administered until the determination of its MTD when combined with BEGEV schedule.~In phase II b study - arm A (standard): Atezolizumab will not be administered. In phase II b study - arm B (experimental): Atezolizumab will be administered at MTD determined in phase I study plus BEGEV regimen (at dosages performed by local practice)."
223486837|NCT05300282|COMBINATION_PRODUCT|BEGEV|"In phase I study: Atezolizumab will be administered until the determination of its MTD when combined with BEGEV schedule.~In phase II b study - arm A (standard): only BEGEV will be administered. In phase II b study - arm B (experimental): BEGEV regimen will be administered in combination with Atezolizumab at MTD determined in phase I."
223486838|NCT04909762|OTHER|Early Rehabilitation and Mobilisation (ERM)|Early rehabilitation/mobilisation (ERM) encompasses patient-tailored interventions, delivered individually or in a bundled package. It is provided by health professionals from multiple disciplines and care-givers within intensive care settings.
223486839|NCT00334308|PROCEDURE|Barley protein bread or control (casein) bread|
223486840|NCT02272270|DRUG|Minocycline with chemoradiation (temozolomide and radiation therapy)|Patients receive minocycline in conjunction with standard chemoradiation and then they receive minocycline with standard chemotherapy.
223486841|NCT03034967|DRUG|Danirixin|Danirixin is available as 5, 10, 25, 35 and 50 mg white, film-coated, oval or round shaped tablets for oral administration.
223486842|NCT03034967|DRUG|Danirixin matching placebo|Danirixin matching placebo will be available as white, film-coated, oval or round shaped tablets for oral administration.
223486843|NCT03034967|DRUG|Standard of care|Participants will continue with their standard of care inhaled medications (i.e. long acting bronchodilators with or without inhaled corticosteroids) during the study treatment.
223486844|NCT03034967|DRUG|Rescue medication|Participants will continue to use rescue medication(s). The following rescue medications may be used: short acting beta agonists, short acting muscarinic antagonists, or short acting combination bronchodilators.
223486845|NCT06556862|DRUG|Dalpiciclib|100 mg/d, po., qd, administered on an empty stomach (fasting should be ensured at least 1 hour before and 1 hour after administration). The drug will be administered in a 28-day cycle, with continuously administration in the first 3 weeks (D1-21), and discontinuation in the fourth week (D22-28).
223486846|NCT06556862|DRUG|Chidamide|25 mg/BIW, po. The interval between doses should not be less than 3 days (e.g. Monday and Thursday, Tuesday and Friday, Wednesday and Saturday, etc.), administered 30 minutes after meals
223486847|NCT06556862|DRUG|Enitinostat|5mg/QW，po.
223486848|NCT06533449|DEVICE|Couplet Care Bassinet|Couplet Care Bassinet
223486849|NCT06533449|DEVICE|Standard Bassinet|Standard Bassinet
223586703|NCT01167166|DRUG|rigosertib|The dose of rigosertib will be 2400 mg/24h as an intravenous continuous infusion over 72 or 120 hours every 2 weeks for 2 cycles then as oral capsules administered at a dose of 560 mg twice daily on a continuous basis.
223586704|NCT00550901|DRUG|cisplatin|
223586705|NCT00550901|DRUG|dexrazoxane hydrochloride|
223586706|NCT00550901|OTHER|high performance liquid chromatography|
223486850|NCT05879432|DRUG|LSALT Peptide|LSALT, a peptide drug with the sequence NH3-LSALTPSPSWLKYKAL-COOH, binds to dipeptidase-1 (DPEP-1) but does not inhibit its biologic enzymatic activity, potentially minimizing off-target or other adverse effects. LSALT peptide inhibits leukocyte recruitment in multiple experimental disease models through the direct inhibition of leukocyte adhesion to DPEP-1 present in lungs, kidney, and liver.
223486851|NCT05879432|DRUG|Placebo|0.9% saline solution
223586707|NCT00550901|OTHER|laboratory biomarker analysis|
223486852|NCT00007748|BEHAVIORAL|Aerobic exercise|
223486853|NCT00007748|BEHAVIORAL|Cognitive behavioral therapy|
223486854|NCT06557460|DEVICE|Surgical implantation of the CPCB-RPE1 implant|Surgical implantation of the CPCB-RPE1 implant
223586708|NCT00550901|OTHER|mass spectrometry|
223586709|NCT00550901|OTHER|pharmacological study|
223586710|NCT05059977|BIOLOGICAL|TAK-881|Participants will receive subcutaneous infusion of TAK-881 on Day 1.
223586711|NCT02358915|DEVICE|FastStart neuromuscular electrical stimulator|
223586712|NCT03833713|BEHAVIORAL|SMS Dialogue|Once-weekly SMS dialogue sessions or micro-interventions and use behavior change techniques (BCTs) including self-monitoring with performance feedback and goal support
223586713|NCT03833713|BEHAVIORAL|SMS Assessments|Once-weekly SMS assessments of motor vehicle risks
223586714|NCT06464523|BEHAVIORAL|Face to face education|In addition to the standard cervical cancer screening programme service, participants in this group received individual face-to-face health education on HPV and cervical cancer prevention through home visits and were given educational brochures. Participants in this group were interviewed a total of four times (four times face-to-face) during the research period.
223586715|NCT06464523|BEHAVIORAL|Online education|In addition to the standard cervical cancer screening programme service, participants in this group received individual health education on HPV and cervical cancer prevention online via video call via WhatsApp application and were given a digital education brochure. Participants in this group were interviewed a total of four times (four times remotely) during the research process.
223586716|NCT03817073|DEVICE|Iowa Oral Performance Instrument (IOPI)|Using biofeedback to attain repetitions of 80% of baseline MIP.
224177009|NCT03890731|DRUG|BAY73-4506 (Regorafenib, Stivarga)|Regorafenib is administered orally as 20 or 40 mg tablets at the dose that each patient received during the last cycle of the feeder trial. The dose may be either 60, 80, 120 or 160 mg once daily for 3 weeks of every 4-week cycle (3 weeks on, 1 week off).
224177010|NCT02553486|OTHER|quality of life evaluation|
224177011|NCT04984824|BEHAVIORAL|Nap duration|A cognitive battery which will be repeated at 1505, 1530, 1600 and 1900. Material for the picture encoding task will be learned at 1630 and will be tested at 2000.
224177012|NCT02430064|OTHER|Low PAMP diet|
224072461|NCT07001748|PROCEDURE|Magnetic Resonance Imaging|Restaging imaging with CT and/or diffusion weighted MRI with contrast will be obtained after completion of 12 weeks (+/- 2 weeks) of assigned treatment (restaging will occur at this timepoint, regardless of if the patient completed all 4 cycles or not). At this point, patients with stable disease or a response will continue assigned treatment. In the absence of radiological or clinical progression, if clinically indicated by treatment team, patients may undergo diagnostic laparoscopy to assess surgical candidacy at which time a PCI assessment and biopsies of peritoneal nodules, peritoneal lavage could be performed. Cytoreduction can be offered to patients with a PCI \< 7 and if complete cytoreduction is feasible based on treating surgeon's discretion. If deemed a candidate for surgical cytoreduction, surgery should be performed within 6 weeks of the last study treatment in both arms.
224072462|NCT07001748|DRUG|Intraperitoneal Paclitaxel|"Patients on Arm B will start systemic therapy + intraperitoneal paclitaxel as early as the day after Step 1 randomization and must start within 30 calendar days (including holidays) after Step 1 randomization as per the schedule shown in the table below.~Therapy will be administered on Days 1 and 8 of a 21-day cycle for 4 cycles."
224177013|NCT02088359|OTHER|Cycled light|We covered the incubator with blanket for darkness approximately 12 hours.
224177014|NCT02088359|OTHER|Continue near darkness|We covered the incubator with blanket all days.
224177015|NCT00722410|DIETARY_SUPPLEMENT|VSL#3|A probiotic preparation.
224306519|NCT03647683|OTHER|Heat pain|Participants receive heat pain stimuli using the Thermo Sensory Analyser (TSA-II), a commonly used device to study pain sensation and analgesic effects.
223745323|NCT06912594|DEVICE|PCOS-App|The PCOS-App helps to implement multimodal self-help measures in the daily lives of PCOS patients through various functions such as symptom diary and interactive exercises.
223745324|NCT06914063|COMBINATION_PRODUCT|Rapid-Onset Cycloplegic Drops|Rapid-Onset Cycloplegic Drops (e.g., tropicamide with phenylephrine) to assess patient comfort, anxiety, and satisfaction with quicker onset and shorter duration.
223745325|NCT06914063|DIAGNOSTIC_TEST|Conventional Cycloplegic Drops|Conventional Cycloplegic Drops (e.g., cyclopentolate) to provide a baseline for comparison with the rapid-onset treatment.
224072463|NCT06918561|OTHER|Standard of Care|Wound cleansing, Sharps debridement, Dressing for moisture balance, Offloading
224177016|NCT00722410|DRUG|Polyethylene glycol|Oral ingestion of 3 liters of polyethylene glycol solution.
224177017|NCT02771782|BIOLOGICAL|BCG vaccine (SSI)|
224177018|NCT02771782|BIOLOGICAL|TDaP-IPV vaccine|
224177019|NCT02241460|DRUG|Placebo|During the Double-Blind Treatment Period, patients randomized to placebo will receive three cycles of Promescent. The first and second cycle consists of three weeks of treatment using 30 mg and 50 mg, followed by one week of washout. The third cycle consists of three weeks of treatment using 70 mg. During the Open-Label Treatment Period, the patient will receive four weeks of Promescent (active treatment) in one-week cycles: 30 mg, 50 mg, 70 mg, and patient's self-selected dose.
224177020|NCT02241460|DRUG|Promescent Lidocaine Spray|During the Double-Blind Treatment Period, patients randomized to active treatment will receive three cycles of Promescent. The first and second cycle consists of three weeks of treatment using 30 mg and 50 mg, followed by one week of washout. The third cycle consists of three weeks of treatment using 70 mg, followed by four weeks of treatment during the Open-Label Treatment Period using patient's self-selected dose.
224177021|NCT01332422|DRUG|Salmeterol and Fluticasone|Collection of safety data
224177022|NCT04631835|DRUG|HS-10352|Participants will receive single dose of HS-10352 on Day 1 of Cycle 1 followed by once daily from Day 8 of Cycle 1. (Cycle length: 35 days for Cycle 1 and 28 days for all other cycles). Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and unequivocal disease progression.
224177023|NCT00816543|DRUG|DOCETAXEL|50 mg/m² IV as a 1 hour infusion on day 1 for each period of 3 weeks for 3 cycles.
224177024|NCT00816543|DRUG|S-1|80mg/m² day 1-14 every 3 weeks for 3 cycles. The curative resection group will receive two oral doses of 40 mg/m²/day for 4 weeks, followed by 2 weeks rest, for 1 year.
224177025|NCT00816543|DRUG|OXALIPLATIN|100 mg/m² on day 1 as a two-hour IV infusion for each period of 3 weeks for 3 cycles.
224177026|NCT04718376|DRUG|Mitoxantrone Hydrochloride Liposome, intravenous injection (IV)|All subjects will receive Mitoxantrone Hydrochloride Liposome 20 mg/m2, IV, on day 1 of each 21-day cycle (q3w).
224177027|NCT00027027|DRUG|rhuMAb 2C4|
224306520|NCT06284577|DIETARY_SUPPLEMENT|Multistrain Probiotic|Participants will recieve a multi-strain probiotic daily for 6 months
224306521|NCT06284577|DIETARY_SUPPLEMENT|Placebo - maltodextrin|Participants will recieve placebo/ maltodextri daily for 6 months
224177028|NCT05358301|DIETARY_SUPPLEMENT|Probiotic|Probiotic food supplement produced by SYNBIOTEC S.r.l. Each capsule of SYNBIO®slim contains the probiotic strain Lactiplantibacillus Plantarum IMC 510 at a concentration of 15 billion live cells (CFU/capsule). The assumption is of n°1 capsule/day, preferably at breakfast, for 3 months. The capsules can be opened and their content can be dispersed in a cold liquid or at intake temperature or in semi-solid food. Always store in original container or in a clean covered container, out of the reach of children. When stored in a dry, clean environment, out of direct sunlight, the product has a shelf-life of at least 24 months. Samples of probiotic supplement in closed and sealed boxes will be provided to subjects participating at the beginning of the study, in quantities sufficient for the entire duration of the study (90 capsules for 3 months).
224177029|NCT05358301|DIETARY_SUPPLEMENT|Placebo|N°1 capsule/day of placebo food supplement (i.e., capsules without added probiotics), with the same intake modalities as probiotic.
224177030|NCT00290329|BIOLOGICAL|Mencevax ACWY|1 subcutaneous injection.
224177031|NCT01809158|DRUG|minocycline|
224177032|NCT01809158|DRUG|placebo|
224306522|NCT03906162|BEHAVIORAL|Motivational interviews|"During the 12-week intervention, the participants will receive seven telephone calls from a physical therapist. The interviews will be held in week 1, 2,3,5,7,9, and 12.~The telephone call will consist of a motivational interview focused on enhancing the daily level of physical activity in the participants.~MI is a form of counselling aiming at prompting increases in self-efficacy, which may leave people more open to and invested in changing their behaviours and shows potential for significant effects for exercise behaviour change.~In addition to the telephone based motivational interviews, the experimental group will also receive the base intervention which is described in detail under the control intervention paragraph."
224306523|NCT03906162|BEHAVIORAL|Base intervention|"The base intervention consists of a physical activity monitor (PAM) for everyday use in the intervention period and a pamphlet with information about Danish recommendations on physical activity in aging populations. The PAM will be the Garmin Vivofit 3 monitor linked to a pre-specified Garmin Connect account. The participants will be asked to install the Garmin Connect application on their smartphone and use the given ID/password in the app. The participants will be asked to wear the monitor 24-hours a day for the 12-week intervention period. The participants can use the PAM as they like but they will be asked to try to use the PAM and the application to enhance their daily level of physical activity."
224306524|NCT00402454|DRUG|isoniazid, rifampin + isoniazid or rifampin + pyrazinamide|
224306525|NCT03870477|DEVICE|THP Hip Fracture Plating System with telescoping lag screws|The fracture plates are contoured plates used in conjunction with telescoping lag screws that are 7.5mm in diameter with lengths ranging from 70mm to 130mm in 5mm increments.
224306526|NCT03258853|DEVICE|Bionic Pancreas|Bionic pancreas system: The bionic pancreas is an autonomous, self-learning system that requires only the subject's weight for initialization, and then autonomously adapts insulin dosing to maintain glycemic control. The bionic pancreas uses continuous glucose monitoring as input to the controller. The bionic pancreas can be used in a bi-hormonal configuration, administering both insulin and glucagon as well as an insulin only setting.
224306527|NCT03258853|OTHER|Usual Care|Subjects will remain on home insulin regimen (either insulin pump or injectable insulin). Subjects in usual care will wear a study CGM even if in typical care does not include CGM use.
224306528|NCT03709459|DRUG|Doxycycline|Participants will be asked to take Doxycycline 100mg/day for 12months duration
224306529|NCT05912439|BEHAVIORAL|SidekickHealth|Usage of mobile application called SidekickHealth.
224306530|NCT00739986|DRUG|Semapimod|semapimod 60 mg IV x 1 day, placebo x 2 days
224306531|NCT00739986|DRUG|Semapimod|Semapimod 60 mg IV x 3 days
224306532|NCT00739986|DRUG|Placebo|placebo IV x 3 days
224306533|NCT00397163|PROCEDURE|Remote ischemic preconditioning|Blood pressure cuff inflation
224306534|NCT00397163|PROCEDURE|Placebo|Deflated cuff on upper arm and thigh for 20 min
224306535|NCT04860063|DRUG|Berberine|Participants randomly assigned to the intervention group will be provided with Berberine 500 mg administrated per os three times a day for six months
224205515|NCT04192786|OTHER|Standard physiotherapy program|Standard physiotherapy program (strength, balance, gait exercises) for 60 minutes will be performed 3 days a week for 8 weeks.
224205516|NCT00650637|DRUG|Calcium Carbonate|Calcium carbonate 500 mg oral tablet twice a day; given in combination with the following antiretroviral combination: nelfinavir 1250 mg twice a day, and lamivudine 150 mg/zidovudine 300 mg twice a day (or stavudine 40 mg twice a day plus lamivudine 150 mg twice a day); If diarrhea develops, loperamide 2 mg oral caplet 3 times weekly; All study drugs continued through to Week 12
224205517|NCT00650637|DRUG|nelfinavir|1250 mg twice a day
224205518|NCT00650637|DRUG|lamivudine|lamivudine 150 mg/zidovudine 300 mg twice a day (or stavudine 40 mg twice a day plus lamivudine 150 mg twice a day);
224306536|NCT04860063|DRUG|Placebo|Participants randomly assigned to the Placebo group will be provided with placebo administrated per os three times a day for six months
224306537|NCT02569112|DEVICE|multipolar RF, varipulse|Multi-polar Radio frequency (RF) technology combining pulsed electro magnetic fields (PEMF) and mild suction stimulation (varipulse).
223486855|NCT06641570|OTHER|Aquatic Exercise Program|This intervention will include 16 sessions of an aquatic-exercise program, twice a week, over 8 weeks at a water temperature between 32-34°C. Each session will be conducted in groups of 8 to 12 patients and will last about 45 minutes.
223486856|NCT06641570|OTHER|Land-based Exercise Program|This intervention will include 8 sessions in 8 weeks, once a week. Each session will last between 25 to 35 minutes and will be divided into two components: core stability exercises and stretching of the trunk and lower limbs.
223486857|NCT04118036|DRUG|Pembrolizumab|intravenously over 30 minutes every 21 days (+/- 3 days)
223486858|NCT04118036|DRUG|Abemaciclib|Oral 2 times a day
223486861|NCT05989048|DRUG|Zavegepant|The participants will receive single active dose sufficient to treat 1 migraine headache of moderate or severe intensity within Treatment Phase.
223486862|NCT05989048|DRUG|Placebo|Single dose of matching placebo taken within Treatment Phase.
223486863|NCT04297917|BIOLOGICAL|ChAdOx1-HBV|chimpanzee adenovirus-vectored hepatitis B virus vaccine
224177033|NCT00459329|BEHAVIORAL|Program to Encourage Active, Rewarding Lives (PEARL)|"Eight 50-minute in-home sessions over 19 weeks with a masters-level social work counselor using Problem Solving Therapy (PST).~PST is a skills-enhancing behavioral depression treatment based on the assumption that an accumulation of problems in living cause and maintain depressive symptoms, and through systematically identifying and addressing these problems, patients achieve decreased depressive symptoms. Counselors also help participants to increase social and physical activities and to incorporate pleasant activities into patients' lives.~Counselors provide education and monitoring for antidepressant use, and work with the participant's physician and PEARL psychiatrist to recommend initiating or adjusting antidepressant medications. The PHQ-9 is administered at each session to track depression change.~After 19 weeks, counselors will maintain monthly telephone calls with participants, administering the PHQ-9 and assessing PST success."
224177034|NCT03518996|DEVICE|rTMS/iTBS/tACS|Subjects with delirium and matched-controls will be receive theta frequency stimulation of the cerebellum. We will target the cerebellar vermis.
224177035|NCT03518996|DEVICE|Sham TMS/tACS|Subjects with delirium and matched-controls will be receive sham stimulation of the cerebellum. We will target the cerebellar vermis.
224177036|NCT04446273|DEVICE|Bi-Manu-Track|The PRI and DRI protocol provide robotic training for 45 minutes and impairment-oriented training for 45 minutes. The PRI group will start from the Bi-Manu-Track proximal mode (i.e., forearm) and then the Bi-Manu-Track distal mode (i.e., wrist). The DRI group will start from the Bi-Manu-Track distal mode (i.e., wrist) and then the Bi-Manu-Track proximal mode (i.e., forearm).In every session of robotic training, the patient will practice bilateral passive range of motion exercise, in which affected upper extremity is assisted by the unaffected side, and bilateral active range of motion exercise. Robotic training will be followed by impairment-oriented training.
224177037|NCT04929782|DEVICE|Resin-based sealant|Etching with 37% phosphoric acid for 30 s (i-GEL N, i-dental, Lithuania), rinsing for 30 s with air-water spray and drying with oil-free air for 15 s, resin sealant (Conceal F, SDI, Australia) application into the occlusal and buccal/palatal pits and fissures with direct placement syringe system and light curing with 460-500 nm wavelength halogen light unit (Hilux Dental Curing Light Unit 250, Benlioğlu Dental Inc, Turkey) for 20s on each surface.
224177038|NCT04929782|DEVICE|Giomer sealants|Self-etch primer (BeautiSealant Primer, Shofu, Japan) application to the occlusal and buccal/palatal pits and fissures with fine microbrush and waiting for 5 s, homogenizing the bond layer with gentle air stream for 5 s, giomer sealant application (BeautiSealant Paste, Shofu, Japan) with direct placement syringe system and light curing with 460-500 nm wavelength halogen light unit (Hilux Dental Curing Light Unit 250, Benlioğlu Dental Inc, Turkey) for 20 s on each surface.
224177039|NCT06043895|DEVICE|EpiFaith CV|The conducting physician will localize the central vein using EpiFaith CV and assess if there is arterial puncture.
224177040|NCT06043895|DEVICE|Conventional|The conducting physician will localize the central vein using Raulerson syringe and assess if there is arterial puncture.
224177041|NCT01829529|DRUG|Amoxicillin|Amoxicillin
224177042|NCT04115020|DRUG|Naltrexone|Naltrexone 4.5 mg oral suspension
224177043|NCT04115020|DRUG|Placebo|Placebo oral suspension
223486864|NCT04913311|PROCEDURE|Biospecimen Collection|Undergo collection of blood, saliva, stool, and bronchoalveolar lavage samples
223486865|NCT04913311|PROCEDURE|Bronchoscopy with Bronchoalveolar Lavage|Undergo bronchoscopy with BAL
223486866|NCT04913311|OTHER|Chemoradiotherapy|Undergo concurrent chemoradiation per standard of care
223486867|NCT04913311|PROCEDURE|Computed Tomography|Undergo computed tomography scan
223586717|NCT00576472|DRUG|Methylphenidate|Please see detailed description for dosing information and study design.
223586718|NCT04285489|DEVICE|Hakim Shunt Programmable System|patient accept Hakim Shunt Programmable System due to HCP
223586719|NCT03465553|RADIATION|Short course radiotherapy|An accelerated hypo-fractionation radiotherapy is delivered for palliation in patients with advanced thoracic cancer
223586720|NCT06331689|OTHER|Mortality ratio|Mortality rates at 30-day, 90-day and 1-year intervals
223486868|NCT04913311|OTHER|Diagnostic Laboratory Biomarker Analysis|Correlative studies
223486869|NCT04913311|DRUG|Immune Checkpoint Inhibitor|Receive CPI per standard of care
223486870|NCT04913311|PROCEDURE|Nasal Wash and Collection|Undergo nasal wash
223486871|NCT04913311|OTHER|Quality-of-Life Assessment|Ancillary studies
223486872|NCT04913311|OTHER|Questionnaire Administration|Ancillary studies
223486873|NCT04913311|PROCEDURE|Spirometry|Under lung spirometry tests
223486874|NCT06643442|DRUG|Empagliflozin Tablets|Empagliflozin 10mg p.o. once daily (commercially available tablet)
223486875|NCT05359861|DRUG|SRF388|SRF388 will be administered by intravenous injection (IV)
223486876|NCT05359861|DRUG|Atezolizumab|Azezolizumab will be administered by IV
223486877|NCT05359861|DRUG|Bevacizumab|Bevacizumab will be administered by IV
223486878|NCT05359861|DRUG|Placebo|Placebo will be administered by IV
223486879|NCT06645236|DEVICE|therascreen® KRAS RGQ PCR Kit|The investigational device, therascreen® KRAS RGQ PCR Kit, will be used to determine the KRAS G12C mutation status of patients during the screening period of Amgen's clinical trial (20210081)
223486880|NCT06492460|DRUG|Drug：Cisplatin|Concurrent Cisplatin chemotherapy (100 mg/m2 intravenous injection,once every 3 weeks, twice in total, on days 1 and 22) will be given plus intensity modulated radiotherapy
223486881|NCT04225039|DRUG|INCMGA00012|500mg IV neoadjuvant treatment; 500 mg adjuvant treatment
223486882|NCT04225039|DRUG|INCAGN01876|300mg IV neoadjuvant treatment; 300 mg adjuvant treatment
223586721|NCT04405245|DRUG|Latanoprost ophthalmic solution|Latanoprost opthalmic solution to be dosed once daily
223586722|NCT04405245|DRUG|AKB-9778 4%|Razuprotafib opthalmic solution
223586723|NCT04405245|DRUG|Placebo|placebo for razuprotafib opthalmic solution
223586724|NCT03150277|BEHAVIORAL|Plyometric exercise|2 sets of 10 ankle hops, 3 sets of 5 hurdle hops, 5 drop-jumps from a height of 50 cm
223586725|NCT03150277|BEHAVIORAL|Heavy resistance exercise|10 single repetitions of back half squats at 90% of 1 repetition maximum
223586726|NCT03088553|DRUG|Therapeutic Drug Monitoring|Trough concentration of ganciclovir and viral load measurement at each follow-up visit.
223586727|NCT01771445|DRUG|IL-1Ra|100mg, s.c, once only
223586728|NCT01771445|DRUG|Placebo|100mg, s.c., once only
223486883|NCT04225039|DRUG|SRS|administered over the course of 3 consecutive business days (8 Gy x 3 fractions, one fraction per day, total dose 24 Gy).
224177044|NCT04067076|OTHER|Self-administered evaluation questionnaire|Smartphone app with MeMind questionnaires
224177045|NCT06182839|DRUG|Canagliflozin 300Mg Tab|Patients will get 1 pill of Canagliflozin 300 mg daily for one year.
224177046|NCT06182839|DRUG|Placebo|Patients will get 1 pill of placebo daily for one year.
224177047|NCT00343161|DRUG|esomeprazole|
224177048|NCT00343161|DRUG|Gelusil-Lac (Aluminum hydroxide gel,magnesium trisilicate)|
224177049|NCT05507515|DRUG|ONO-2020|ONO-2020 tablets
224177050|NCT05507515|DRUG|Placebo|Placebo tablets matching ONO-2020 tablets
224177051|NCT01281592|DRUG|LOR-253 HCl|LOR-253 HCl will be given in ascending doses starting from 20 mg/m2 until the maximum administered dose or appropriate target dose is reached. Patient will be treated on LOR-253 HCl for 2 cycles for the evaluation.
224177052|NCT00053482|BIOLOGICAL|ACAM2000 Smallpox Vaccine|Group 1 dose: 1.0x10-8th PFU/ml, Group 2 dose: 2.0x10-7th PFU/ml, Group 3 dose: 1.0x10-7th PFU/ml, Group 4 dose: 5.0x10-6th PFUL/ml
224177053|NCT00053482|BIOLOGICAL|Vaccinia virus (calf lymph) smallpox vaccine: Dryvax®|Group 5 dose: 1.0x10-8th PFU/ml
224177054|NCT01064973|DRUG|arbaclofen|A flexible dose titration will be utilized during the first four weeks to define the optimal titrated dose (OTD) for each subject. Investigators will use clinical judgment to adjust doses to the oral OTD. The starting dose will be 1 mg BID. The dose may be increased every four to five days to 2 mg BID, 3 mg BID, 5 mg BID and then 10 mg BID
224177055|NCT04001699|OTHER|Preoperative geriatric assessment|In addition to the usual care, patients randomized to the intervention group receive preoperative assessment conducted by an interprofessional team including geriatrician, registered nurse, physiotherapist and pharmacist. Based on the assessment, a preoperative optimization plan is constructed focusing on the treatment of the patient's chronic conditions, nutritional status, medication and physical activity.
224177056|NCT00075634|DRUG|decitabine|Given IV
224177057|NCT00075634|DRUG|doxorubicin hydrochloride|Given IV
223486884|NCT04225039|PROCEDURE|Brain surgery|maximal safe surgical resection of the tumor.
224177058|NCT00075634|DRUG|cyclophosphamide|Given IV
224177059|NCT00075634|BIOLOGICAL|filgrastim|Given SC
224177060|NCT00075634|BIOLOGICAL|pegfilgrastim|Given SC
224177061|NCT00075634|OTHER|laboratory biomarker analysis|Correlative studies
224177062|NCT00075634|OTHER|pharmacological study|Correlative studies
223486885|NCT05453383|DRUG|Anlotinib;Toripalimab|Anlotinib Hydrochloride;Toripalimab injiection
223486886|NCT06343324|BEHAVIORAL|Web-based education|Patients using noninvasive ventilation at home will receive detailed information about accessing, logging in and using web-based training. Pretest data will be collected, then week 4 and week 8 data will be collected.
223486887|NCT00434486|DRUG|SKI-606|
223486888|NCT02620280|DRUG|Carboplatin|Carboplatin AUC 2 will be given i.v. on day 1 and day 8 q 3 weeks for a total of 8 cycles
223486889|NCT02620280|DRUG|Abraxane|Abraxane, 125 mg/m2 will be given i.v. on day 1 and day 8 q 3 weeks for a total of 8 cycles
223486890|NCT02620280|DRUG|MPDL3280A|MPDL3280A, 1200 mg. will be given i.v. infusion on day 1 q 3 weeks for a total of 8 cycles
223586729|NCT00116363|GENETIC|investigational drug INGN 241|
224177063|NCT04459858|OTHER|data analysis|"Data is extracted from the existing medical records and from the Rotator Cuff Repair Database (RCR\_USB). The GTA (determined as the angle between a line parallel to the humerus diaphysis passing through the humeral head center of rotation and a line connecting the upper border of the humeral head to the most superolateral edge of the greater tuberosity) is determined."
224177064|NCT05862675|DIAGNOSTIC_TEST|RNA sequencing of blood samples|Using omics techniques to detect blood samples from patients with acute lung injury and normal children, screen for marker genes related to immune cells in acute lung injury, and verify the protein expression of this molecule in tissues. Analyze the relationship between its phenotype and the degree of inflammation.
224177065|NCT02423733|OTHER|The Journal|"The Journal is a free internet based program for the self-management of depression (www.depression.org.nz) that was developed in New Zealand and capitalizes on the social marketing appeal of Sir John Kirwan, an ex All Black who has described his experiences of depression to help destigmatize mental illness. . The self-help program is based on the cognitive behavioral techniques of behavioral activation and problem solving which teaches patients the skills of problem solving and delivers an evidence based intervention which is personalized for their individual care."
223486891|NCT02620280|PROCEDURE|Surgery|Breast cancer surgery (breast and axilla) either conservative or radical not later than 6 weeks
223486892|NCT02620280|DRUG|Anthra|AC or EC (adriamycin or epirubicin and cyclophosphamide) or FEC (fluorouracil, epirubicin, and cyclophosphamide) on day 1 every three weeks for 4 cycles to be delivered after surgery
223586730|NCT00026377|DRUG|bicalutamide|50 mg daily for 1 month
223586731|NCT00026377|DRUG|flutamide|250 mg 3 times daily for 1 month
223586732|NCT00026377|DRUG|goserelin acetate|3.6 mg once a month for 4 months
223586733|NCT00026377|DRUG|leuprolide acetate|7.5 mg once a month for 4 months
223586734|NCT00026377|DRUG|SU5416|IV infusion at assigned dose
223586735|NCT00026377|RADIATION|radiation therapy|daily for 5 days each week
223586736|NCT02478580|DRUG|Nuvigil|Patients will receive Nuvigil before the surgery
224177066|NCT03845842|BEHAVIORAL|Volitional help sheet|Participants are asked to choose from a list of strategies for avoiding cannabis use.
224177067|NCT00570089|DRUG|Ranolazine|500mg, orally twice daily for 2 weeks, assuming tolerance, followed by 1000mg orally twice daily for an additional 2 weeks. If the participant is unable to increase dose secondary to side effects, she will remain on 500mg twice daily for the second 2-week interval.
224177068|NCT00570089|DRUG|Placebo|Placebo, 500mg, orally twice daily for 2 weeks, assuming tolerance, followed by 1000mg orally twice daily for an additional 2 weeks. If the participant is unable to increase dose secondary to side effects, she will remain on 500mg twice daily for the second 2-week interval.
224177069|NCT00326976|DRUG|FX06|400 mg as intravenous injection in two divided boluses
224177070|NCT00326976|PROCEDURE|Percutaneous coronary intervention|
224177071|NCT01028794|BIOLOGICAL|autologous bone marrow mononuclear cells|intravenous administration of autologous bone marrow derived mononuclear cells obtained from 25ml of bone marrow on day 7-10 after stroke (only once in that period)
224177072|NCT01028794|BIOLOGICAL|autologous bone marrow mononuclear cells|intravenous administration of autologous bone marrow derived mononuclear cells obtained from 50ml of bone marrow on day 7-10 after stroke (only once in that period)
223586737|NCT02478580|DRUG|Placebo|Placebo will be given before surgery
224177073|NCT00188162|DEVICE|CT|
224177074|NCT00740766|BEHAVIORAL|Food diary and behavioral model|"The monitored group is to be placed on a prenatal nutritional program consisting of 18 to 24 kcal. per kg. (according to the patient's actual weight) with monitoring each visit.~The patients will be weighed each prenatal visit with the monitored patients weighed and blinded to their actual weight (being weighed with her back to the scale). The monitored patients will be requested not to weigh at home and all patients will be asked to wear similar clothing at each visit.~All intervention (monitored) group women will be asked to record in a diary all of the foods eaten during each day. These records will be reviewed at each prenatal visit. Six weeks after delivery, the patient will be weighed and will then exit the study. The food diary notebooks will be collected from each patient at the end of the study."
224177075|NCT00250601|DRUG|Saredutant succinate (SR48968C)|
224177076|NCT02115620|OTHER|Telemedicine|Daily updates on symptoms, weight, vital signs, and relevant labs will be communicated by phone with cardiology nurses at Providence Heart Clinic. Concerning changes in symptoms or signs will trigger a telemedicine clinic visit with a HF specialist using remote video/audio, virtual stethoscope technology, and VZ Cloud managed hosting. The consult will include a virtual face-face interview and physical examination between patient and HF clinician using Cisco Yabber Video, Littman e-stethoscope, and Verizon managed hosting. Medication changes, laboratory testing, additional virtual visits, or in-person clinic visits can be arranged as appropriate.
224177077|NCT05488249|DIAGNOSTIC_TEST|Cardiac imaging tests|"* 2D transthoracic echocardiography~* 128-multislice CT coronary angiography with the evaluation of: epicardial fat volume, plaque burden, total and local calcium score, markers for lesion severity; morphological plaque characteristics; plaque components evaluated via volumetric and planimetric units; markers of plaque vulnerability (necrotic core, low attenuation plaque, spotty calcification, napkin ring sign, positive remodeling).~* Shear stress evaluation via computational fluid dynamics."
224177078|NCT05488249|DIAGNOSTIC_TEST|Venous blood sample collection|Venous blood sample collection during CCTA image acquisition for evaluation of serum levels of hsCRP, IL-6, matrix metalloproteases - MMP9, Adhesion molecules (VCAM, ICAM, e-selectin, p-selectin) periostin.
224306538|NCT02569112|DEVICE|cryolipolysis|Cryolipolysis technology uses the sensitivity of fat cells to cold injury, causing them to freeze and undergo cellular apoptosis.
224306539|NCT00306423|PROCEDURE|Other: Exercise|exercise 3 times per week for 12 weeks
223486893|NCT05743894|DEVICE|Symplicity Spyral RENAL DENERVATION (RDN) SYSTEMTM Livewire™ Reflexion™ Catheter|Renal sympathetic denervation (RDN) was considered an effective alternative for patients whose blood pressure (BP) is not optimally controlled. The RDN works mainly by selectively ablating the sympathetic fibres around the renal arteries and damping the sympathetic overdrive. Blood pressure response by renal nerve stimulation (RNS) during the RDN procedure using the previous generation of the Symplicity Flex catheter have been reported to be potential parameter to assess the intra-procedure efficacy and predict the BP response 6 months after RDN
223486894|NCT00734565|BIOLOGICAL|Haemophilus influenzae type b|1 dose monovalent conjugated vaccine against Haemophilus influenzae type b in children aged 16 - 20 months and infants aged 2 - 4 months
223486895|NCT05884593|DEVICE|Pedicle screw instrumentation using Mazor X robotic system|Pedicle screw instrumentation using Mazor X robotic system
223586738|NCT03961412|BEHAVIORAL|family-based intervention|The participants will identify their accompanying influential person(s) (e.g., spouse, partners, parents, children, friends) with whom they will be attending the 1.5-2 hour face-to-face education session on cervical cancer and screening. At the end of the intervention, time will be allowed for questions, as well as distributing fridge magnets and a pamphlet. Fridge magnets contain Pap test guidelines and availability of local clinics. The pamphlet covers the following topics: (a) information about female anatomy and cervical cancer, (b) risk factors for cervical cancer, (c) facts of cervical cancer incidence and mortality, and screening rates among American women, (d) methods to reduce cervical cancer (e.g., HPV vaccination), (e) Pap test procedure, (f) Pap test guidelines, and (g) availability of clinics and cost of Pap test. The participants will be encouraged to spread the message to family members and friends.
223745326|NCT06914310|DRUG|Memantine|Memantine will be given either orally or through a nasogastric tube for 7 days, starting on the first day of admission to the hospital and then continued for 3 weeks. The memantine dose in the first 7 days is 30 mg twice daily, while during the remaining 3 weeks the dose is 10 mg twice daily
224177079|NCT05985616|OTHER|High Intensity Resistance Training|High intensity resistance training will be performed 3 times a day for sixteen weeks
223486896|NCT00384631|OTHER|subconjunctival normal saline|0.1cc normal saline injection in the subconjunctival space repeated twice at monthly intervals
223486897|NCT00384631|DRUG|Avastin|intravitreal injection of avastin 2.5mg repeated twice at monthly intervals
223486898|NCT02869035|DRUG|Escitalopram|Patients will be treated with an antidepressant drug (escitalopram) at flexible standard doses for 12 weeks. If no response after 4 weeks; shift to duloxetine arm.
223486899|NCT02869035|DRUG|Duloxetine|Patients who at 4 weeks of escitalopram have not responded will be shifted to duloxetine at flexible standard dosages.
223486900|NCT03658772|DRUG|grapiprant|Cohort 1 will be treated for 1 week with oral grapiprant as a single agent, followed by 21-day combination treatment cycles of oral grapiprant in combination with IV pembrolizumab.
223486901|NCT03658772|DRUG|grapiprant and pembrolizumab|Cohort 2 will be administered 21-day combination treatment cycles of oral grapiprant in combination with IV pembrolizumab.
223486902|NCT02020642|PROCEDURE|Renal transplantation|Renal transplantation from cadaveric or live donor
224177080|NCT00045565|DRUG|arsenic trioxide|Given IV
224177081|NCT00045565|RADIATION|radiation therapy|Undergo radiation therapy
224306540|NCT02185651|DRUG|Zavesca® Prescription|"Following baseline evaluation, Zavesca® prescription is given.~Week 2, 4, and 6 ERT infusion with pre-medication are completed at local/home infusion center. Travel to site for week 7 study visit includes physical exam, blood collection and punch muscle biopsy. Health survey is completed."
223486903|NCT00000640|DRUG|Primaquine|
223486904|NCT00000640|DRUG|Sulfamethoxazole-Trimethoprim|
223586739|NCT03961412|BEHAVIORAL|Participant only intervention|Only participant will attend the 1.5-2 hour face-to-face education session on cervical cancer and screening. At the end of the intervention, time will be allowed for questions, as well as distributing fridge magnets and a pamphlet. Fridge magnets contain Pap test guidelines and availability of local clinics. The pamphlet covers the following topics: (a) information about female anatomy and cervical cancer, (b) risk factors for cervical cancer, (c) facts of cervical cancer incidence and mortality, and screening rates among American women, (d) methods to reduce cervical cancer (e.g., HPV vaccination), (e) Pap test procedure, (f) Pap test guidelines, and (g) availability of clinics and cost of Pap test. The participants will be encouraged to spread the message to family members and friends.
223586740|NCT05993962|DIETARY_SUPPLEMENT|Fortified yoghurt|Food-grade vitamin B12 in the form of methylcobalamin (purity: 99%) was used for fortification. Yoghurts were Greek-style and locally produced by a yoghurt company in British Columbia, Canada. The pre-measured vitamin B12 was added into yoghurt vats in amounts that corresponded to the chosen dosage (50 µg of B12 per 150 g). The yoghurt was packaged into white cups, each containing 150 grams of yoghurt, labelled with the date of production and study code.
223586741|NCT05993962|OTHER|Control yoghurt|Yoghurts were locally produced by a yoghurt company in British Columbia, Canada. Yoghurts produced were Greek-style and packaged into white cups, each containing 150 grams of yoghurt, labelled with the date of production and study code.
223486905|NCT00000640|DRUG|Dapsone|
223486906|NCT00000640|DRUG|Clindamycin|
223486907|NCT05483647|PROCEDURE|Local infiltrative anaesthesia|In prone position, before the skin incision, patients in G1 underwent local infiltrative anaesthesia et the level of incision. The skin, subcutaneous tissue and muscles up to the foramen intervertebral were anesthetized by the surgeon employing forty millilitre solution of Lidocaine 1% with Dexamethasone 0.02% and Epinephrine 0.00018%.
223486908|NCT05483647|PROCEDURE|Erector spine plane block|The transverse vertebral process of the required level of spine was identified using the mobile C-arm X-ray System. When the tip of the 22G needle reached to the transverse vertebral process 3 cm lateral to the spinous process, a solution of 40 millilitres of Lidocaine 1% with Dexamethasone 0.02% and Epinephrine 0.00018% was injected under the erector spinae muscle bilaterally.
223486909|NCT06265636|PROCEDURE|Percutaneous nerve stimulation|Percutaneous nerve stimulation (PENS) involves inserting a dry needling needle through muscle tissue until it reaches a nerve branch. At this point, a bipolar TENS current with different parameters is applied to the needle with the goal of improving the patient's pain perception.
223486910|NCT06265636|OTHER|Manual therapy|Digital pressure techniques in muscle areas with the aim of reducing the perception of stiffness and pain
223486911|NCT06265636|OTHER|exercise|Exercises for improving mandibular mobility, occlusion coordination and regulation of temporomandibular muscle tone
223486912|NCT05004025|DEVICE|Novocure Optune|Novacure Optune with Opdivo and Yervoy
223486913|NCT05004025|DRUG|Opdivo|Novacure Optune with Opdivo and Yervoy
223486914|NCT05004025|DRUG|Yervoy|Novacure Optune with Opdivo and Yervoy
223486915|NCT05991375|DRUG|DEXmedetomidine|28 mL of Bupivacain 0.25% was mixed with Dexmedetomidine 1 microgram/kg body weight mixed in 2 mL = total volume 30 mL
223486916|NCT05991375|OTHER|saline|28 mL of Bupivacain 0.25% was mixed with 2 mL of Normal saline = total volume 30 mL
223486917|NCT06131021|DRUG|Amoxicillin|Amoxicillin belongs to the penicillin category, and it is a commonly prescribed broad-spectrum antibiotic as a periodontal treatment adjunct.
223586742|NCT06924658|OTHER|placebo|Placebo will have the same look of metformin
223586743|NCT06924658|DRUG|Metformin|Metformin, a biguanide, is used to manage diabetes by reducing insulin resistance and preventing comorbidities such as cerebrovascular and coronary artery disease, as well as providing renal protection to diabetic nephropathy patients
223586744|NCT00439881|DRUG|SB-681323|
223617651|NCT01715181|OTHER|Volunteer visits|Volunteers will visit 3 times per week with a visit duration of 30 minutes for each visit during the study.
223617652|NCT05385666|OTHER|collaborative cares|coordinate care between city medicine and specialized psychiatric care to improve the management of common mental disorders
223617653|NCT02386020|DRUG|aloe vera|After SRP, aloe vera gel was delivered subgingivally into periodontal pockets.
223617654|NCT02386020|DRUG|placebo gel|After SRP, placebo gel was delivered subgingivally into periodontal pockets.
223617655|NCT03460886|DEVICE|Ipsilesional stimulation|anodal stimulation on Ipsilesional leg area of primary motor cortex and supplementary motor area for 30 minutes
224072464|NCT06918561|OTHER|NeoThelium FT|NeoThelium FT is a dehydrated wound covering derived from donated human placental tissue. NeoThelium FT is a dual-layer membrane with amnion and chorion combination layers.
224072465|NCT06679101|DRUG|Belantamab mafodotin|Belantamab mafodotin will be administered.
224072466|NCT06679101|DRUG|Lenalidomide|Lenalidomide will be administered.
224072467|NCT06679101|DRUG|Dexamethasone|Dexamethasone will be administered.
224072468|NCT06679101|DRUG|Daratumumab|Daratumumab will be administered.
224072469|NCT07134114|PROCEDURE|Hall Technique|"Procedure: Hall Technique A preformed stainless-steel crown will be placed on a primary molar using the Hall Technique. This approach does not require local anesthesia, caries removal, or tooth preparation.~Digital Scan and Bite Registration Schedule:~* T0 (Baseline): Immediately before crown placement~* T1 (Immediate): Immediately after crown placement~* T2 (Two Weeks): Two weeks after crown placement~* T3 (One Month): One month after crown placement At each time point (T0-T3), digital scans of both the upper and lower arches will be obtained, and a bite registration will be recorded. These records will be used to generate three-dimensional digital models, which will be analyzed to assess occlusal relationships and monitor changes over time."
224072470|NCT07004205|OTHER|The ARCS Motivation Model Education|The ARCS Motivation Model Education-focused on Attention, Relevance, Confidence, and Satisfaction
224072471|NCT07005505|OTHER|Pressure Support Ventilation (PSV)|Spontaneous breathing trials will be conducted using the mode pressure support ventilation (PSV) with settings of a pressure support of 5 cmH2O and positive end expiratory pressure (PEEP) 5 cmH2O.
224072472|NCT07005505|OTHER|Automatic tube compensation (ATC)|Spontaneous breathing trials will be conducted using the mode automatic tube compensation (ATC) with settings of 100% tube compensation and a positive end expiratory pressure (PEEP) of 5 cmH2O.
224072473|NCT04586010|DRUG|Fenebrutinib|Participants will receive fenebrutinib.
224072474|NCT04586010|DRUG|Teriflunomide|Participants will receive teriflunomide.
224177082|NCT04561960|DRUG|Fluoride toothpaste|Fluoridated paste containing 1450ppm NaF
224177083|NCT04561960|DRUG|Toothpaste Product|Non Fluoridated toothpaste with extract of miswak ( Dabur, miswak tooth paste)
224177084|NCT04561960|DEVICE|Toothbrush|Colgate classic clean Soft bristled toothbrushes, 19.05 x 1.27 x 1.91 cm
224177085|NCT04561960|DEVICE|Miswak Stick|A miswak stick of 15 cm length
224177086|NCT02967562|OTHER|Inflation Breaths|
224177087|NCT02967562|OTHER|Sustained Inflation|
224177088|NCT03260062|BEHAVIORAL|Parent-Child Early Approaches to Raising Language Skills|The PEARLS intervention will teach parents evidence-based language strategies and sensitive parenting (e.g., warmth, respect for autonomy, linguistic stimulation) to promote language development in young deaf children with cochlear implants (CI).
224177089|NCT03260062|OTHER|Standard Care Speech therapy|Families will participate in auditory-verbal therapy, which is the standard speech therapy with children with hearing loss.
224177090|NCT03475355|BEHAVIORAL|Live movement observation (Upper Limbs)|"All participants will be subjected to two 15-minute sessions per day of the Live movement observation of the upper limbs. The activities of the upper limbs will be based on some relevant activities of daily life such as drinking from a glass, combing, opening a box or eating an apple. The tasks will be both unimanual and bimanual.~Every day, before starting the physical training, the patient will be asked to look carefully at the therapist who shows 20 different daily routine activities (actions) performed with the upper limb."
224177091|NCT03475355|BEHAVIORAL|Video Observation (Upper Limbs)|"All participants will be subjected to two 15-minute sessions per day of the video observation of upper limbs movements. The activities of the upper limbs will be based on some relevant activities of daily life such as drinking from a glass, combing, opening a box or eating an apple. The tasks will be both unimanual and bimanual.~Every day, before starting the physical training, the patient will be asked to carefully watch a video showing 20 different daily routine activities (actions) performed with the upper limb."
224177092|NCT03475355|BEHAVIORAL|Live Movement Observation (Lowe Limbs)|"All participants will be subjected to two 15-minute sessions per day of the Live movement observation of the lower limbs. Tasks to avoid freezing will be based on strategies such as touching the thigh, taking side or back steps, counting out loud while walking.~Every day, before starting the physical training, the patient will be asked to carefully watch the therapist who will show 20 different movement strategies to avoid episodes of freezing the pace (FOG)."
224177093|NCT03475355|BEHAVIORAL|Video Observation (Lower Limbs)|All participants will be subjected to two 15-minute sessions per day of the video observation of lower limbs movements. Tasks to avoid freezing will be based on strategies such as touching the thigh, taking side or back steps, counting out loud while walking. Every day, before starting the physical training, the patient will be asked to carefully watch a video that will show 20 different movement strategies to avoid episodes of freezing the pace (FOG).
224177094|NCT03475355|BEHAVIORAL|Static Picture Observation and Upper Limbs Exercise|"Participants will watch for 3 minutes 5 static images that expose objects, none will represent animals or people.~The participant's attention will be kept high through a cognitive task. The patient will be presented a sequence of images for 3 minutes, the images will be displayed separately, each for 30 seconds, and then during the last 30 seconds, they will be displayed together with an intrusive image (intruder) that the patient you will be asked to identify so that your attention span can be controlled in real time. Participants will then be invited to perform limb movements as far as possible for 2 minutes according to a standard sequence involving joint mobilisations of upper limbs, and simulating that performed by the experimental groups."
224177095|NCT03475355|BEHAVIORAL|Static Picture Observation and Lower Limbs Exercise|"Participants will watch for 3 minutes 5 static images that expose objects, none will represent animals or people.~The participant's attention will be kept high through a cognitive task. The patient will be presented a sequence of images for 3 minutes, the images will be displayed separately, each for 30 seconds, and then during the last 30 seconds, they will be displayed together with an intrusive image (intruder) that the patient you will be asked to identify so that your attention span can be controlled in real time. Participants will then be invited to perform limb movements as far as possible for 2 minutes according to a standard sequence involving joint mobilisations of lower limbs, and simulating that performed by the experimental groups."
224177096|NCT02543762|PROCEDURE|Chromoendoscopy|Chromoendoscopy involves the topical application of stains to improve tissue localization and characterization of lessions during endoscopy . Chromoendoscopy has been used in patients undergoing colonoscopy, including those undergoing surveillance for chronic ulcerative colitis. Using pit pattern classifications, chromoendoscopy has a high sensitivity and specificity for differentiating neoplastic from non-neoplastic lesions
224177097|NCT05752591|DIAGNOSTIC_TEST|Diagnostic testing|Blood diagnostic testing for hypothalamic-pituitary-gonadal axis and hypothalamic-pituitary-thyroid axis. In case of gonadal or thyroid dysfunction, genetic testing for known implicated genes
224177098|NCT02332616|DRUG|Methylprednisolone|Comparison of preoperative single high dose of Methylprednisolone 125 mg iv. and isotonic Sodium Chloride
224177099|NCT02332616|DRUG|Isotonic Sodium Chloride|Placebo
224205519|NCT00650637|DRUG|loperamide|If diarrhea develops, loperamide 2 mg oral caplet 3 times weekly;
224205520|NCT00650637|OTHER|Calcium carbonate not administered|Prophylaxis with calcium carbonate not administered in this group; The following antiretroviral combination was administered: nelfinavir 1250 mg twice a day, and lamivudine 150 mg/zidovudine 300 mg twice a day (or stavudine 40 mg twice a day plus lamivudine 150 mg twice a day);
224205521|NCT00650637|DRUG|nelfinavir|nelfinavir 1250 mg twice a day
224205522|NCT00650637|DRUG|lamivudine + zidovudine|lamivudine 150 mg/zidovudine 300 mg twice a day (or stavudine 40 mg twice a day plus lamivudine 150 mg twice a day);
223617656|NCT03460886|DEVICE|Contralesional stimulation|anodal stimulation on contralesional leg area of primary motor cortex and supplementary motor area for 30 minutes
223617657|NCT03460886|OTHER|Walking on treadmill|walking on treadmill for 10 minutes
223617658|NCT00246519|DRUG|Hydrochlorothiazide|atenolol 50 or 100 mg hydrochlorothiazide 12.5 or 25 mg
224205523|NCT03909373|OTHER|PSFS|Patients will complete the patient specific functional scale. no intervention being administered
224205524|NCT02773641|DRUG|Botulinum Toxin Type A|
224205525|NCT02773641|DRUG|Sterile Saline Solution|
224205526|NCT04704817|OTHER|obsevation|prospective data collection for colonic or rectal surgery
223486918|NCT06131021|DRUG|Metronidazole|Metronidazole is effective against anaerobic bacteria, and it is often combined with Amoxicillin for an enhanced antimicrobial effect as a periodontal treatment adjunct.
223486919|NCT06131021|OTHER|Placebo|Placebo in identical drug-safe vials with capsules identical in appearance to the active drugs
223486920|NCT06245499|BEHAVIORAL|Aging Brain Care Virtual Program|The program involves a virtual intervention to be delivered by RN or SW care coordinators over one year. Every care partner will receive monthly virtual visits during the first 3 months and then quarterly or more depending on assessed need. The intervention relies on a tailored approach in which patient and caregiver needs are identified during visits using validated assessment tools and addressed with standardized protocols. Protocols include management of behavioral/psychological symptoms of dementia, caregiver stress, medication management, comorbidity management and advance care planning.
223486921|NCT06124846|BEHAVIORAL|CB-Abst|incentivized, biochemically verified abstinence via contingency management
223486922|NCT06124846|BEHAVIORAL|CB-Mon|monitoring with no required abstinence
223486923|NCT04733534|DRUG|Dasatinib plus Quercetin|Dasatinib (100 mg/day) plus Quercetin (500 mg twice daily) on days 1, 2, 3, 30, 31, 32 taken orally under observation of the study nurse.
223486924|NCT04733534|DRUG|Fisetin|Fisetin (20mg/kg/day) on days 1, 2, 30 and 31 taken orally under observation of the study nurse. Fisetin will be dispensed based on weight of 20 mg/kg/day on the four separate days.
223617659|NCT00246519|DRUG|Atenolol|atenolol 50 mg, then 100 mg if BP \< 120/70, then add HCTZ 12.5 mg if BP \< 120/70, then HCTZ 25 mg if BP \< 120/70
223617660|NCT05720650|OTHER|No intervention|No intervention
223617661|NCT05549895|DRUG|Dexamethasone|8 mg intrathecally
223617662|NCT05549895|DRUG|Bupivacaine Hydrochloride|0.5 % intrathecally
223617663|NCT02204930|DRUG|PeproStat|A solution of PeproStat containing up to 9.25mg protein soaked immediately prior to use onto a Gelita-Spon® gelatin sponge.
223617664|NCT04388111|DRUG|Morphine|10mg of Morphine delivered Intraosseously
223617665|NCT02735239|DRUG|Durvalumab|Anti PD-L1 antibody
223617666|NCT02735239|DRUG|Tremelimumab|Anti CTLA-4 antibody
224072475|NCT04586010|DRUG|Placebo|Participants will receive teriflunomide-matching placebo or fenebrutinib-matching placebo.
224072476|NCT06310525|OTHER|Drowning incident|"Drowning was defined by the WHO in 2002 as the process of experiencing respiratory impairment from submersion or immersion in liquid."
224072477|NCT07025343|OTHER|Lipid emulsion|Patients (\>70kg will receive 100 ml, \<70 will receive 1.5ml/kg) of 20% intravenous lipid emulsion at the end of surgery as a study group.
224072478|NCT07029646|DEVICE|EndoScell™ intraoperative handheld microscope|The research instrument used is the EndoScell™ intraoperative handheld microscope, which employs the principle of epifluorescence. It is a miniaturized microscope that reduces the size of a traditional large optical microscope by approximately a thousand times. It is the world's first handheld micrometer-level intraoperative real-time cell imaging probe microscope. This microscope is equipped with high-definition, real-time, anti-shake, and full-coverage scanning features. It can rapidly investigate the structure and cell morphology of tissues in real-time.
224072479|NCT07029295|OTHER|Sending a link to the video|Sending a link to the educational video (3 min, 34 sec.) prepared as part of the study, explaining the importance of proper preparation and the diet to follow.
224072480|NCT07029295|BEHAVIORAL|Compliance questionnaire|Patient completes a questionnaire on compliance with preparation instructions on the day of the imaging test.
224072481|NCT07029295|BIOLOGICAL|Determination of beta-hydroxybutyrate (BHB) in capillary blood|Determination of beta-hydroxybutyrate (BHB) in capillary blood prior to imaging examination.
224072482|NCT07029113|OTHER|Task-oriented trainig|In addition to MCP, PIP, DIP joint mobilisation and isometric exercises, the task-oriented training group will perform 30 repetitions of face washing, using a fork, drinking water with a glass, sitting and wearing a t-shirt exercises.
224072483|NCT07029113|OTHER|Mulligan mobilization|In patients included in the Mulligan mobilisation group, the therapist will apply a dorsal shift from the distal radius to the carpal bones and the patient simultaneously extends the wrist. It is essential that the movement is painless; if any pain occurs during mobilisation, the direction or technique is re-evaluated. This application is performed in 8-10 repetitions and the frequency of the session is planned according to the patient's symptoms.
224072484|NCT07029113|OTHER|Conventional treatment|Passive range of motion exercises, metacarpopalangeal, proximal interphalangeal and distal interphalangeal joint mobilisation and isometric exercises will be applied. Isometric exercises will be performed as 30 repetitions, while joint mobilisations will be performed by the therapist as moderate anteroposterior and mediolateral shifts.
224072485|NCT03895866|OTHER|The participants were assigned to different groups according to the results of HPV detection.|The participants were assigned to different groups according to the results of HPV detection
224072486|NCT07028151|OTHER|manual therapy|"Participants who meet the inclusion criteria will be evaluated following the acquisition of written informed consent. Treatment will be administered with participants in the supine position. Initially, soft tissue mobilization will be applied to the cervical extensor muscle group, followed by gentle cervical vertebral traction. Subsequently, a classical facial massage will be performed. The massage will include the suprahyoid muscles and the medial pterygoid. Intramuscular stretching and friction massage techniques will be applied to the masseter and anterior temporalis muscles. Each session will last approximately 40 minutes and will be conducted over a total of 10 sessions."
224072487|NCT07028151|OTHER|Conventional Therapy|Participants who meet the inclusion criteria will be evaluated after providing written informed consent. Treatment will be administered with participants in the supine position. Protective goggles will be placed on the participants' eyes prior to the infrared therapy application. Following 20 minutes of infrared treatment, ultrasound (1 MHz) will be applied to the masseter muscle using the full-contact method for 3 minutes. Finally, transcutaneous electrical nerve stimulation (TENS) will be applied to the masseter and anterior temporalis muscles for 15 to 20 minutes. Each session will last approximately 40 minutes and will be conducted over a total of 10 sessions.
224072488|NCT07029139|DRUG|JMT601 Injection|In accordance with the protocol
224072489|NCT07029139|DRUG|Rituximab|In accordance with the protocol
224072490|NCT07029139|DRUG|Cyclosporin Capsules|In accordance with the protocol
224072491|NCT07028411|BEHAVIORAL|Educational board game|The educational board game will be administered once for a duration of 90 minutes, consisting of a gameplay session followed by a debriefing.
224177100|NCT05357924|PROCEDURE|robotic-assisted laparoscopy|Superficial and deep endometriosis resection will be performed in the usual standard fashion. All superficial lesions suspicious for endometriosis (pigmented and nonpigmented) will be completely resected until non-diseased peritoneal margins are visualized around the defect; all deep lesions suspicious for endometriosis will be completely resected until non-diseased margins are visualized in the tissue surrounding the defect. Cystectomy will be performed for endometriomas. Additional procedures are performed as needed to completely resect all endometriosis lesions. The fascia of any port ≥10 mm will be reapproximated. Cystoscopy will be performed when deemed appropriate by the surgeon. If bowel resection and re-anastomosis is necessary this will be performed together with a General Surgeon.
223745327|NCT06914310|DRUG|Mannitol|Mild to moderate TBI patients will receive mannitol in case of brain edema to reduce brain swelling and analgesic for headache such as; acetaminophen.
224177101|NCT05357924|PROCEDURE|Conventional laparoscopy|Superficial and deep endometriosis resection will be performed in the usual standard fashion. All superficial lesions suspicious for endometriosis (pigmented and nonpigmented) will be completely resected until non-diseased peritoneal margins are visualized around the defect; all deep lesions suspicious for endometriosis will be completely resected until non-diseased margins are visualized in the tissue surrounding the defect. Cystectomy will be performed for endometriomas. Additional procedures are performed as needed to completely resect all endometriosis lesions. The fascia of any port ≥10 mm will be reapproximated. Cystoscopy will be performed when deemed appropriate by the surgeon. If bowel resection and re-anastomosis is necessary this will be performed together with a General Surgeon.
224177102|NCT04599543|DRUG|IL3 CAR T-cells|Each subject receive IL3 CAR T-cells by intravenous infusion
224177103|NCT06366854|PROCEDURE|Personalised fluid and haemodynamic resuscitation|individualised resuscitation
224177104|NCT01896596|BIOLOGICAL|Menjugate|Administered with routine vaccinations at 3 months of age
224177105|NCT01896596|BIOLOGICAL|Menitorix|Administered with routine vaccinations at 3 months
224177106|NCT01896596|BIOLOGICAL|NeisVac-C|Administered with routine vaccinations at 3 months
224177107|NCT06022627|BEHAVIORAL|Pranayama Yoga|Doing practice of paranayam yoga which including breathing exercises yoga-life energy
224177108|NCT02399189|DRUG|R-MT followed by auto-HSCT|Four cycles of Induction therapy: Rituximab 375mg/m2 d1; Methotrexate 3.5g/m2 d2;Temozolomide 100mg/m2 d2-6; for patients who reach a CR, PR, or SD, will proceed to autologous stem cell transplantation: Carmustine 400mg/m2 d1; Thiotepa 5mg/kg q12h, d2-3.
224177109|NCT05419791|OTHER|Robot Asisted Gait Training with Lokomat (Endurance)|"* Faster application (using for Endurance) : 3 days in a week for 6 weeks,very season was 40 min.~* Conventional Physiotherapy : 5 days in a week for 6 weeks, every seanson was 40 min."
224177110|NCT05419791|OTHER|Robot Asisted Gait Training with Lokomat (Attention and Motivation)|"* Smile application (using for Attetion and Motivation) : 3 days in a week for 6 weeks,very season was 20 min.~* Gabarello application (using for Attetion and Motivation) : 3 days in a week for 6 weeks,very season was 20 min.~* Conventional Physiotherapy : 5 days in a week for 6 weeks, every seanson was 40 min."
223586745|NCT03775564|OTHER|REMEDRUGBY PROGRAM|"* 1st Session presentation of the programme, its objectives and a common reflection on the concepts of stigmatization/destigmatization.~* 2nd to 4th session devoted to a group reflection on social conventions and their meaning followed by a practice by means of role-playing.~* 5th to 7th session devoted to writing comments about tournaments on the blog by working on the intentions of others and the emotional impact of comments on their recipients.~* 8th, 9th 11th sessions devoted to media relations with group reflection on the image of themselves and their pathology that participants wish to refer to the media, followed by a practice in role-playing games Interviewer-interviewed~* 10th session devoted to planning and organizing the day of matches with writing a program of the day and spreading on the blog~* 12th General Debriefing session Including : - 3 tournaments~* 8 hours of Touch Rugby"
224205527|NCT03596879|BEHAVIORAL|dCBTI|Online access to the digital CBTI program Sleepio based off of traditional face-to-face Cognitive Behavioral Therapy, six weekly sessions done online.
223486925|NCT05220046|DRUG|Psilocybin|Psilocybin, 25mg administered orally drug during an 8-hour monitored session with supportive pre- and post- session counseling
223745328|NCT06913504|DIAGNOSTIC_TEST|Blue cut filter|Group 1 will be prescribe with blue cut filter feature
223745329|NCT06913504|DIAGNOSTIC_TEST|blue cut glasses|Group 2 will be prescribed with blue cut glasses
223586746|NCT03775564|OTHER|TOUCH RUGBY PROGRAM|Practical training Program at Touchrugby at the rate of 12 weekly sessions of 2 hours and 3 inter-institutional tournaments per day
223586747|NCT03775564|OTHER|TAU|Treatment as usual
223586748|NCT00519662|DRUG|SNS-314|"Stage 1 - Escalating doses of SNS-314 Injection on days 1, 8 and 15~Stage 2 - Same as stage 1 except SNS-314 Injection is administered at the maximum tolerated dose established in stage 1"
223586749|NCT05304312|DEVICE|Kegel Exercises guidebook|The Kegel exercises book is consisted of basic explanation about stress urinary incontinence and Kegel exercises, how to do Kegel exercises, table for them to write how many session they did in a day, and lastly their report progress (UDI-6, IIQ-7, periineometer, and 1-hour pad test) that we updated every four weeks
223745330|NCT06914388|OTHER|Self-Management Strategies|Stretching exercises, strengthening exercises, massage, relaxing exercises, breathing exercises, patient education
223586750|NCT02391961|DRUG|Dalfampridine|10-week randomized, placebo controlled, double-blind, crossover trial, which includes a period of wash out of two weeks between treatment with dalfampridine and placebo.
223586751|NCT02391961|DRUG|Placebo|10-week randomized, placebo controlled, double-blind, crossover trial, which includes a period of wash out of two weeks between treatment with dalfampridine and placebo.
223486932|NCT06538337|RADIATION|External beam Radiotherapy|Five fractions of radiation therapy using adaptive planning and CT or MRI guidance (6 Gy per fraction) delivered once every other day excluding weekends and holidays
223486933|NCT06538246|BEHAVIORAL|Blueprint|This is a mobile app-based adaptive coping skills intervention that lasts 1 month
223486934|NCT06538246|BEHAVIORAL|Education program|This is a mobile app-based education program that lasts 1 month
223586752|NCT01437527|BEHAVIORAL|Anamorphic Micro software|Body image therapy with Anamorphic Micro software
223586753|NCT01437527|BEHAVIORAL|therapy as usual|Body image therapy as usual
223586754|NCT03233022|BEHAVIORAL|Happify|An online platform for conveying techniques from positive psychology, cognitive-behavioral therapy, and mindfulness-based stress reduction.
223486935|NCT06700447|BEHAVIORAL|Enhanced inoculation message|"Participants enrolled in the enhanced inoculation message arm will receive messages that warn them about impending HIV vaccine misinformation and explains why those claims are false or misleading, the messages will be enhanced with insights from behavioural economics see Appendix 5: Inoculation message with a BE boost for an example of the inoculation message. As part of the behavioural economics boost, participants may choose to receive a small token (e.g., sticker, badge, bracelet) with a message promoting vaccination as a consistency and commitment prime."
223486936|NCT06700447|BEHAVIORAL|Nutrition information|Participants enrolled in the control group will receive unrelated information on diabetes and nutrition topics of the same length as the inoculation messages. Please see Appendix 6 for an example of how this message will be structured. This will make the control group an attention control group and ensure that findings are not confounded by the intervention group spending more time and attentional resources on participation in the study.
223586755|NCT04608162|OTHER|Pulsed Electromagnetic Field (PEMF)|PEMF was administered to the whole body using a 1.8×0.6m mat
223586756|NCT04608162|OTHER|Exercise Program|Exercise program to facilitate bone health
223586757|NCT04608162|OTHER|Placebo PEMF|Patients received placebo PEMF
223586758|NCT03547934|DEVICE|High Intensity Focused ElectroMagnetic system.|The treatment administration phase will consist of four (4) treatments, delivered twice a week. The applicator will be applied over the abdomen area. Visible contractions will be induced by the device.
223586759|NCT02768753|PROCEDURE|The Axillary Bilateral-breast Approach|
223586760|NCT02768753|PROCEDURE|The bilateral Axillo-breast Approach|
224072492|NCT07028411|BEHAVIORAL|Lecture|The lecture will be administered once for a duration of 90 minutes, consisting of video lecture followed by question and answer (QnA) session.
224072493|NCT06876935|OTHER|Daily avocado|Infants in the daily avocado group will receive a daily exposure amount of avocado ranging from 1/4 (\~37.5 g or 1.25 oz) to 1/2 (\~75 g or 2.5 oz) of a medium-sized avocado. At 6-8 months, infants will be provided 1/4 (\~37.5 g or 1.25 oz) of a medium-sized avocado for daily consumption. Then from 9-12 months, they will begin receiving 1/2 (\~75 g or 2.5 oz) of a medium-sized avocado for daily consumption.
224072494|NCT07137143|OTHER|The rooms of the intervention group patients will be heated before they come to intensive care and the temperature of the room will be increased.|The rooms of the intervention group patients will be heated before they come to intensive care and the temperature of the room will be increased.
224072495|NCT07027995|BEHAVIORAL|Exercise is Medicine (EIM)|During Phase 1 (Weeks 1-12), participants are enrolled in a comprehensive 12-week fitness education and training program.
224072496|NCT07027995|BEHAVIORAL|Culinary Education|During Phase 1 \& 2, participants receive monthly hybrid cooking demonstrations with culinary training.
224072497|NCT07027995|BEHAVIORAL|Food is Medicine|During Phase 1 (Weeks 1-12), participants receive bi-weekly medically tailored grocery vouchers.
224072498|NCT07027995|BEHAVIORAL|Nutrition Counseling|During Phase 1 (Weeks 1-12), participants engage in weekly behavioral nutrition counseling.
224072499|NCT07027995|BEHAVIORAL|Participant Website|During Phases 1 and 2, participants will receive digital behavioral reinforcers and access to a secure web portal that provides evidence-based resources.
224072500|NCT07028541|DEVICE|Magnesium-based bioresorbable DrillPin for fixation of distal radius fractures in children|This is a first-in-child clinical investigation of a bioresorbable magnesium alloy DrillPin (RemeOs™) for fixation of distal radius fractures in children aged 5 to \<14 years. The implant is investigational, not CE-marked or FDA-approved, and represents a novel alternative to traditional metallic implants. It gradually degrades in vivo, eliminating the need for removal. The study focuses on safety and feasibility in a pediatric population, supported by preclinical data from a similar Mg-based RemeOs™ Screw. The DrillPin's material and design are intended to support bone healing without growth disturbances, offering a state-of-the-art, bioresorbable solution tailored for growing patients.
224072501|NCT07028801|BIOLOGICAL|Freeze-dried human rabies vaccine (human diploid cells)|"This vaccine is produced by Ningbo Rongyu Biopharmaceutical Co., LTD. Participants will be administered 5 doses of freeze-dried human rabies vaccine (human diploid cells) by intramuscular injection.~Receive 1 dose on day 0, 3, 7, 14 and 28, total 5 doses"
224072502|NCT07028801|BIOLOGICAL|Freeze-dried human rabies vaccine (human diploid cells)|"This vaccine is produced by Ningbo Rongyu Biopharmaceutical Co., LTD. Participants will be administered 4 doses of freeze-dried human rabies vaccine (human diploid cells) by intramuscular injection.~Receive 1 dose on day 0, 3, 7 and 14, total 4 doses"
224072503|NCT07028801|BIOLOGICAL|Freeze-dried human rabies vaccine (human diploid cells)|"This vaccine is produced by Ningbo Rongyu Biopharmaceutical Co., LTD. Participants will be administered 4 doses of freeze-dried human rabies vaccine (human diploid cells) by intramuscular injection.~Receive 1 dose on day 0, 3, 7 and 28, total 4 doses"
224072504|NCT07028801|BIOLOGICAL|Freeze-dried human rabies vaccine (human diploid cells)|"This vaccine is produced by Ningbo Rongyu Biopharmaceutical Co., LTD. Participants will be administered 4 doses of freeze-dried human rabies vaccine (human diploid cells) by intramuscular injection.~Receive 2 dose on day 0, 1 dose on day 7 and 21, total 4 doses"
224072505|NCT07028801|BIOLOGICAL|Freeze-dried human rabies vaccine (human diploid cells)|"This vaccine is produced by Chengdu Kanghua Biological Products Co., LTD Participants will be administered 5 doses of freeze-dried human rabies vaccine (human diploid cells) by intramuscular injection~Receive 1 dose on day 0, 3, 7, 14and 28, total 5 doses"
224072506|NCT06768463|PROCEDURE|Cytoreductive Gastrectomy|The patients undergo gastrectomy after 4 cycles of systemic therapy
224072507|NCT07132073|RADIATION|Brachytherapy + SBRT|Brachytherapy + SBRT
224072508|NCT07078760|PROCEDURE|CTI radiofrequency ablation.|Cavotricuspid Isthmus ablation
224205528|NCT03596879|BEHAVIORAL|Sleep Education|Six weekly email messages with sleep hygiene recommendations. Subjects are encouraged to read through the information and apply it to their sleep.
223586761|NCT04407104|DIAGNOSTIC_TEST|skin prick-test|retrospective study on data already collected
223586762|NCT01348555|DRUG|Bronchodilatator|
223586763|NCT01348555|DRUG|Bronchodilatator|
223586764|NCT00112177|DRUG|Itopride Hydrochloride|
223617667|NCT02735239|DRUG|Oxaliplatin|IV administered chemotherapy
224072509|NCT05077137|BIOLOGICAL|Tetanus Diptheria Vaccine|tetanus and diphtheria toxoids
224072510|NCT05077137|BIOLOGICAL|Polio Boost Immunization|trivalent inactivated polio vaccine
224306541|NCT00485420|OTHER|Internet based disease management program|Usual Care is augmented with internet-based education, self-monitoring and clinician monitoring
224306542|NCT00324480|DRUG|alvocidib|Given IV
224306543|NCT00324480|DRUG|vorinostat|Given orally
224306544|NCT00324480|OTHER|pharmacological study|Correlative studies
223486937|NCT04546646|OTHER|Elastic Band Exercises|Resistance exercise will be performed using theraband. The color of the band denotes the degree of elasticity and resistance level(yellow , red ,green ,blue, black or silver).Exercise load in terms of individual yielding elasticity (band color) in resistance training will set at a level that a patient perceived as somewhat hard, which is equivalent to a 13-grade rating (moderate intensity exercise) on the RPE, According to American College of Sports Medicine. For each exercise movement 3 sets of 10 repetitions of gentle concentric and eccentric contractions through the full range of motion will be slowly performed using a yellow Thera band initially. The exercise intensity will be increased when the patient is able to achieve a perceived yield strength corresponding to a 13- grade rating on the RPE scale.
223486938|NCT01670006|DEVICE|Cochlear Nucleus Cochlear Implant System|
223486939|NCT06792825|DRUG|Tafasitamab|Tafasitamab 12 mg/kg IV on Day 1, Day 8, Day 15 and day 22.
223486940|NCT06792825|DRUG|Rituximab|Rituximab 375 mg/m2 IV on day 1
223586765|NCT05107466|DIAGNOSTIC_TEST|P300 Visually evoked potential|Measurement of the late cortical response, P300 potential to visually evoked stimuli using an oddball paradigm.
223486941|NCT06792825|DRUG|Lenalidomide|Lenalidomide 20 mg PO Day 1 through Day 21
223486942|NCT04582526|BEHAVIORAL|BMS program|A BMS program with three components: relaxation exercises, healthy eating, expressive arts therapy
223745331|NCT06914219|BEHAVIORAL|Treatment and Evaluation for After Metabolic Surgery with Eating Disorders (TEAM-ED) Program|A combined a) screening/diagnosis, b) Cognitive Behavior Therapy +/- pharmacotherapy, and c) interdisciplinary team approach for managing disordered eating in patients post-weight loss surgery.
223745332|NCT06913036|DEVICE|Low-frequency fatigue - Myocene|Low frequency fatigue will be measured using Myocene
223586766|NCT04560894|DRUG|SCT-I10A|Participants receive SCT-I10A intravenously，200mg，d1，Q3w
223586767|NCT04560894|DRUG|SCT510|Participants receive SCT510 intravenously，15mg/kg，d1，Q3w
223586768|NCT04560894|DRUG|Sorafenib 200mg|Participants receive sorafenib orally，400mg bid
223586769|NCT01065831|BEHAVIORAL|Motivational interviewing (MINT-TLC)|The MINT-TLC lifestyle intervention lead by lay health advisers will be compared to the health education attention control condition (CC). Twenty churches will participate in the study and each church will be randomly assigned to receive either MINT-TLC or CC. They will be compared on blood pressure reduction, physical activity levels, intake of fruits and vegetables, and weight reduction.
224072511|NCT06863480|DRUG|tocilizumab-aazg (TYENNE)|A single dose of tocilizumab-aazg (TYENNE) will be administered by intravenous drip.
224072512|NCT00648635|BEHAVIORAL|Questionnaire|Questionnaires taking 30-60 minutes to complete every 3 months.
224072513|NCT05554133|DEVICE|High Resolution Microendoscope (HRME)|The High Resolution Microendoscope (HRME) take pictures of a very small area of the lining of the mouth, about the size of a pencil tip, but at high magnification.
224072514|NCT05554133|DEVICE|Optical Mapping Scope|The optical mapping scope displays a wide area of the lining of the mouth (about the size of the top of a soda can) by shining different colors of light into the mouth and taking pictures.
224072515|NCT05554133|DRUG|Proflavine hemisulfate|A coloring substance (a fluorescent dye which glows green in the dark), called proflavine hemisulfate, will be painted on areas of the mouth with a cotton tip applicator to help improve the pictures
224072516|NCT06918548|OTHER|Standard of Care|Wound cleansing, Sharps debridement, Dressing for moisture balance, Offloading
224072517|NCT06918548|OTHER|NeoThelium FT|NeoThelium FT is a dehydrated wound covering derived from donated human placental tissue. NeoThelium FT is a dual-layer membrane with amnion and chorion combination layers.
224072518|NCT07110636|DIAGNOSTIC_TEST|Metagenomic plasma-based test for agnostic pathogen detection|Karius Spectrum metagenomic plasma-based test.
224072519|NCT07142759|OTHER|Precision Bred Provitamin D-rich Tomato Soup|Participants will consume one tomato soup every day for 21 days as part of their normal diet.
224072520|NCT07142759|OTHER|Precision Bred Vitamin D-rich Tomato Soup|Participants will consume one tomato soup everyday for 21-days as part of their normal diet.
224072521|NCT07142759|OTHER|Wild-type (store-bought) Tomato Soup|Participants will consume one tomato soup every day for 21 days as part of their normal diet.
224072522|NCT07142759|OTHER|Wild-type (store-bought) Tomato with vitamin D supplementation Soup|Participants will consume one tomato soup everyday for 21 days as part of their normal diet.
224072523|NCT07142694|DIETARY_SUPPLEMENT|Plant Based pudding|Will consume one high protein plant based pudding daily for 7-days per week for 12 weeks
224072524|NCT07144384|PROCEDURE|Biopsy Procedure|Undergo SOC biopsy
224072525|NCT07144384|BIOLOGICAL|Natural Killer Cell Therapy|Given UD expanded NK cells intratumorally
224072526|NCT07144384|PROCEDURE|Surgical Procedure|Undergo SOC excision
224072527|NCT07144384|BIOLOGICAL|Universal Donor Expanded TGF-beta-imprinted NK Cells|Given intratumorally
224072528|NCT07144098|DRUG|GZR18 injection|3 mg-Control group
224072529|NCT07144098|DRUG|GZR18 injection|3 mg-mild liver insufficiency
224072530|NCT07144098|DRUG|GZR18 injection|3 mg-moderate liver insufficiency
224072531|NCT07144098|DRUG|GZR18 injection|3 mg-severe liver insufficiency
224072532|NCT07143136|DRUG|Colchicine|Administration of Colchicine 1 day before and 90 days after PCI in Non-STEMI Patients
224072533|NCT07143136|DRUG|Placebo|Matching Placebo Regimen
224072534|NCT07144124|DIETARY_SUPPLEMENT|Biopro-max 8 Billion Probiotics (Bioserv Healthcare)|Participants in the intervention arm will receive Biopro-Max 8 Billion Probiotics (Bioserv Healthcare). The supplement will be administered as one bottle per day for 15 consecutive days in addition to standard ICU care. The intervention is intended to evaluate whether daily probiotic supplementation reduces the incidence of ICU-acquired infections and improves related clinical outcomes, including inflammatory and immune markers, feeding tolerance, muscle changes, and mortality.
224072535|NCT07143292|DRUG|Famitinib + Camrelizumab|Famitinib + Camrelizumab
223586770|NCT00269204|DRUG|niacin (+) laropiprant|Duration of Treatment - 24 weeks
223486945|NCT06158828|DRUG|Rabbit Anti thymocyte globulin|rATG is administered intravenously over 6-18 hours for a total of 2 to 3 doses. The daily dose is based on body weight and lymphocyte count.
223486946|NCT06158828|DRUG|Busulfan|Busulfan is administered intravenously either Q6H or Q24H, with a recommended target Busulfan AUC of 70-90 mg\*h/L.
224177111|NCT05419791|OTHER|Robot Asisted Gait Training with Lokomat (Activity Timing)|"* High Flyer application (using for Activity Timing) : 3 days in a week for 6 weeks,very season was 20 min.~* Treasures application (using for Activity Timing) : 3 days in a week for 6 weeks,very season was 10 min.~* Curve Pursuit application (using for Activity Timing) : 3 days in a week for 6 weeks,very season was 10 min.~* Conventional Physiotherapy : 5 days in a week for 6 weeks, every seanson was 40 min."
224177112|NCT05419791|OTHER|Conventional Physiotherapy|-Conventional Physiotherapy : 5 days in a week for 6 weeks, every seanson was 40 min.
224177113|NCT06145100|DIAGNOSTIC_TEST|Ultrasound including color doppler ultrasound|Patients with CVID receive color doppler ultrasound of the liver including assessment of portal vein diameter, portal vein flow velocity, hepatic vein diameter and assessment of arterial perfusion. Further liver and spleen stiffness measurement by transient elastography is performed.
223486947|NCT06158828|DRUG|Fludarabine|Fludarabine is administered intravenously at a dose of 40 mg/m\^2/dose once daily for 4 days.
223486948|NCT06158828|DRUG|Thiotepa|Thiotepa is administered intravenously at a dose of 5 mg/kg/dose Q12H for 2 doses.
223486949|NCT06158828|DRUG|Melphalan|Melphalan is administered intravenously at a dose of 70 mg/m\^2/dose once daily for 2 days.
223486950|NCT06158828|BIOLOGICAL|TCR alpha beta / CD19+ depleted haploidentical hematopoietic progenitor cell graft|The HPC product obtained from a haploidentical donor will undergo ex vivo TCR alpha beta and CD19+ depletion, and will be infused fresh on Day 0. There is no maximum limit for CD34+ dose. A maximum dose of 1 x 10\^5/kg recipient weight of TCRαβ cells should not be exceeded in the final HPC product.
223586771|NCT00269204|DRUG|ER-niacin|Duration of Treatment - 24 weeks
223586772|NCT00370513|DRUG|pazopanib|Pazopanib is a potent, multi-target receptor tyrosine kinase inhibitor of VEGFR.
223586773|NCT03263780|DRUG|18F-Fluciclovine|Imaging (comparing standard and experimental high resolution diffusion-weighted imaging \[DWI\] MRI with 18F-Fluciclovine)
223586774|NCT01822613|DRUG|LJM716|LJM716 (10-40 mg/kg) will be given as a once weekly infusion beginning on cycle 1 day 1. The doses of LJM716 will be increased as dose escalation proceeds until a maximum tolerated dose (MTD) and/or recommended phase II dose (RP2D) is established.
224177114|NCT00840528|OTHER|ozone|0.4 ppm ozone for 2 hours
224177115|NCT04701801|DIAGNOSTIC_TEST|MoCA test|Preoperative MoCA test and State-Trait Anxiety Inventory Test (STAI FORM ) questionnaire form will be filled in female patients between the ages of 18-65 by making a one-on-one interview with the patient and the MoCA test will be applied in the early postoperative period (1st week) to ensure its relationship with POCD will be checked.
224177116|NCT05302102|OTHER|Unilateral plyometric training|The paretic-limb-only plyometric training group received a plyometric exercise program performed unilaterally through the paretic leg only for 45 minutes, three times per week for 12 successive weeks. The training was conducted under close supervision of a licensed pediatric physical therapist according to safety performance guidelines defined by the American Academy of Pediatrics and the US National Strength and Conditioning Association.
223486951|NCT06158828|BIOLOGICAL|memory-like natural killer cells|The ML NK cells (dose: max capped at 20 x 10\^6/kg recipient weight, minimum dose allowed is 0.5 x 10\^6/kg recipient weight) will be infused on Day +7.
223486952|NCT06158828|BIOLOGICAL|IL-2|IL-2 is administered subcutaneously at a dose of 1 million units/m\^2 on Days +7, +9, +11, +13, +15, +17, and +19 (7 doses total).
223586775|NCT01822613|DRUG|BYL719|BYL719 (200-400 mg) will be administered orally on a once daily schedule starting cycle 1 day 1. The doses of BYL719 will be increased as dose escalation proceeds until a maximum tolerated dose (MTD) and/or recommended phase II dose (RP2D) is established.
223586776|NCT01822613|DRUG|Paclitaxel|In the Phase II portion of the study Paclitaxel is one of the 3 physician's choice drug which allows single-agent paclitaxel to be used per manufacturer's label.
223586777|NCT01822613|DRUG|Docetaxel|In the Phase II portion of the study Docetaxel is one of the 3 physician's choice drug which allows single-agent docetaxel to be used per manufacturer's label.
223586778|NCT01822613|DRUG|Irinotecan|In the Phase II portion of the study Irinotecan is one of the 3 physician's choice drug which allows single-agent irinotecan to be used per manufacturer's label
223586779|NCT01055678|DRUG|EF5|An infusion of EF5, a fluorinated 2-nitroimidazole, will be administered using the recommended dose of 21mg/kg one day prior to surgical procedure.
223586780|NCT01055678|PROCEDURE|Partial or Total Mastectomy|A small tissue sample will be removed from the excised tissue and will be stored for later analysis.
223586781|NCT05578378|DRUG|Cladribine|Cladribine combine with cytarabine will be intravenous on days 1-5; G-CSF will be hypodermic injection on day0-5,4 weeks per cycle.
223617668|NCT02735239|DRUG|Capecitabine|orally-administered chemotherapy
223617669|NCT02735239|RADIATION|Radiotherapy|
223617670|NCT02735239|DRUG|Paclitaxel|IV administered chemotherapy
223617671|NCT02735239|DRUG|Carboplatin|IV administered Chemotherapy
223617672|NCT02735239|DRUG|5-fluorouracil (5-FU)|IV administered chemotherapy
223617673|NCT02735239|DRUG|Leucovorin|chemo-protective agent
223617674|NCT02735239|DRUG|Docetaxel|IV administered chemotherapy
223617675|NCT06343246|DEVICE|Inspiratory muscle training with device|: A randomized, controlled three-arm study. Forty-five patients with HT randomized three group: Group 1 will receive IMT (7 days/8 weeks) with function and POWERbreathe® Classic LR device, group 2 will reviece only IMT with 50 % maximal inspiratory pressure (MIP), n: 15) and control group will recieve breathing exercises(7 days/8 weeks).
223617676|NCT05227456|DRUG|Etonogestrel 68mg implant|Implant will be inserted
223617677|NCT05227456|DEVICE|Etonogestrel 68mg implant|Implant will be inserted
224177117|NCT05302102|OTHER|Bilateral plyometric training|The double-limb plyometric training group received a plyometric exercise program performed bilaterally through the paretic and non-paretic legs for 45 minutes, three times per week for 12 successive weeks. The training was conducted under close supervision of a licensed pediatric physical therapist according to safety performance guidelines defined by the American Academy of Pediatrics and the US National Strength and Conditioning Association.
224177118|NCT05302102|OTHER|Standard physical therapy|The control group received the standard physical rehabilitation program conducted for 45 minutes, thrice a week for 12 consecutive weeks, and consisted of advanced balance training, gait training, postural and flexibility exercises, and strength training exercises.
224177119|NCT04080700|PROCEDURE|Distal radial approach|Operator puncture the distal radial artery with open needle or venipuncture catheter needle for coronary angiography and percutaneous coronary intervention.
224177120|NCT06077682|DRUG|Cyclopentolate|Well-known eye drop used for cycloplegic refraction among children.
224306545|NCT04326465|DEVICE|Fractional Carbon Dioxide Laser Therapy at 10-15% Laser Density Coverage|Fractional Carbon Dioxide Laser Therapy is an ablative therapy where abnormal collagen in scarred tissue is destroyed to permit the formation of more organized collagen. Previous studies have demonstrated its efficacy in treating medical conditions (ex. hypertrophic scars) similar to Peyronies Disease. There is evidence that Fractional Carbon Dioxide Laser Therapy has the ability to target and alter the molecular pathways that are similar to the ones that lead to Peyronie's Disease.
223486953|NCT06158828|DRUG|Plerixafor|If suboptimal collection of stem cells is predicted, plerixafor may be administered at a dose of 0.24 mg/kg subcutaneous injection once (maximum 40mg/dose). For patients with renal impairment, plerixafor will be administered at a dose of 0.16 mg/kg subcutaneous injection (maximum 27 mg/day).
223486954|NCT06158828|BIOLOGICAL|Granulocyte Colony-Stimulating Factor|G-CSF will be administered at a dose of 10 mcg/kg/day for 5 days, or 6 days if two days of collection are needed.
223486955|NCT06158828|DEVICE|CliniMACS|After stem cells are collected by leukapheresis, in order to create the HPC product, the stem cells will be washed to remove platelets and the cell concentration will be adjusted per laboratory and CliniMACS technology recommendations. The cells are then labeled using the CliniMACS TCRαβ Biotin Kit and CD19+ immunomagnetic microbeads. After labeling, the cells are washed to remove unbound microbeads. The partially processed product is loaded on the CliniMACS device where labeled cells are depleted and the negative fraction is eluted off the device. The negative fraction is centrifuged and volume reconstituted to obtain the final product.
223486956|NCT05050383|OTHER|Pharyngeal Manometry|Catheters will be passed into the nose and advanced to the pharynx to measure airway pressures during drug-induced sleep.
223486957|NCT05050383|OTHER|Submental Ultrasound|Ultrasound of airway soft tissues
223486958|NCT06189352|OTHER|Positive feeding of the preterm infant|Feeding strategy for the preterm infant with description of nutritional needs and based on the infants development and cues.
223486959|NCT06695247|OTHER|Exercise Training|Patients will be recommended to exercise 3 days/week, 20 minutes per session, for 12 weeks using personalized intervention determined by a consultation with a clinical exercise physiologist (CEP)
223486960|NCT05357495|BEHAVIORAL|Affective Posner fMRI frustration induction task|During the frustration induction paradigm, children play a game with monetary reward. The game is rigged, thus inducing frustration. The control task does not have any reward component. All participants complete both the control task scanning session and the frustration induction scanning session.
223486961|NCT03539510|BEHAVIORAL|HF-ACP Website|Each module is broken down into weekly topics and each module takes 3-6 weeks to complete. Participants can access and review the material as often as needed as well as revisiting the information from modules they have completed.
223486962|NCT05802355|OTHER|Manual Diaphragm Release|The participant was supine, with his or her limbs relaxed. With the therapist's forearms aligned toward the participant's shoulders, the therapist gradually increased the depth of contact inside the costal margin during the subsequent respiratory cycles.
223586782|NCT05578378|DRUG|Fludarabine|"Control arm~Patients in the control arm received the investigator's choice of one of the following three regimens:~FLAG:Fludarabine(30mg/m2)should be intravenous use on day 1-5, granulocyte colony-stimulating factor will be hypodermic injection using 300 μg per day on days 0-5,cytarabine (1.5 mg/m2) every 12 hours, intravenous infusion on day1-5,4 weeks per cycle.~a high-dose cytosine arabinoside-based regimen; a high-dose methotrexate-based regimen"
223586783|NCT01504204|DRUG|Adapalene + benzoyl peroxide samples|A sample size tube of the study medication, combination adapalene 0.1% plus benzoyl peroxide 2.5% gel, will be provided with instruction on proper application, including demonstration, at the first visit.
223586784|NCT01504204|DRUG|Adapalene + benzoyl peroxide from standard tube|Subjects are instructed to apply the combination adapalene 0.1% plus benzoyl peroxide 2.5% gel once daily to all affected areas.
224177121|NCT06077682|DRUG|Tropicamide|Well-known eye drop used for cycloplegic refraction among children.
224306546|NCT01709253|RADIATION|proton beam therapy|hypofractionation study using proton beam therapy for prostate adenocarcinoma
224306547|NCT01540773|DRUG|Amino acid supplement|An orally administered supplement of the proprietary amino acid derivative
224306548|NCT01540773|DRUG|Placebo|A non-active orally administered supplement of the proprietary amino acid derivative
224306549|NCT00147849|BEHAVIORAL|mailing of printed educational materials|
224306550|NCT00147849|BEHAVIORAL|a combination of interactive educational meetings, educational outreach visits, and reminders|
224306551|NCT00147849|BEHAVIORAL|identification of local opinion leaders and establishment of local consensus processes|
223486963|NCT05802355|OTHER|control group|Respiratory re-training was given to participants in control group in form of slow and deep diaphragmatic breathing, exhalation through the nose with pursed lips (the participants were trained to emphasis on expiratory pressure against pursed lips), Breathing control and breathing-hold exercises, and Relaxation techniques:
223586785|NCT02723175|DEVICE|Transcranial Direct Current Stimulation|Transcranial Direct Current Stimulation is a minimally invasive technique that uses a small amount of electricity (2mA) to temporarily stimulate specific brain areas in awake people.
223617678|NCT00387881|DRUG|sumatriptan succinate / naproxen sodium|sumatriptan 85mg / naproxen sodium 500mg
223617679|NCT00387881|DRUG|Placebo|Placebo to match Treximet tablets
224306552|NCT01414049|PROCEDURE|On-pump CABG|Use of cardiopulmonary bypass (CPB) with cardioplegic arrest: on-pump CABG.
224306553|NCT01414049|PROCEDURE|Off-pump CABG|CABG performed without the use of cardiopulmonary bypass (CPB) with cardioplegic arrest, surgery performed with the beating heart.
224306554|NCT00192270|BIOLOGICAL|CAIV-T|Each dose of the vaccine was formulated to contain approximately 1 x 10\^7 TCID50 of each of three (two subtype A and one subtype B) reassortant 6:2 influenza strains, as described above, for a total of \~3 x 10\^7 TCID50 per dose.
224306555|NCT00871741|BIOLOGICAL|GSK2202083A vaccine|Intramuscular, three doses
224306556|NCT00871741|BIOLOGICAL|Infanrix hexa|Intramuscular, three doses
224306557|NCT00871741|BIOLOGICAL|Menjugate|Intramuscular, two doses
224306558|NCT06072495|OTHER|real time MRI|ubjects will be scanned in the supine position using ACHIEVA 3T TX DStream Philips® and a 33 channels head and neck coil. An elastic strap will be fixed to the forehead to limits movement during scan. Headset will be used to cancel the loud MRI noise and to communicate with the subjects
223486964|NCT02477449|DRUG|istaroxime|8 subjects in 0.25ug/kg/min group were administrated Istaroxime + 0.9% NS fo12 subjects in 0.5ug/kg/min or 1.0 ug/kg/min group randomly received Istaroxime placebo + 0.9% NS (2 subjects), 0.9% NS alone (2 subjects) and Istaroxime + 0.9% NS (8 subjects).
223486965|NCT02477449|DRUG|9% Saline (NS)|infusion for 24 hours
223486966|NCT05316220|DRUG|Mesalamine|Oral Capsules
223486967|NCT05316220|DRUG|Placebo|Oral Capsule
223486968|NCT06358469|PROCEDURE|Surgery|Re-excision of vulvar cancer margin
223486969|NCT06358469|OTHER|Active Surveillance|The investigator will follow the patient to watch for side effects and keep track of patient's health
224072536|NCT07143344|OTHER|Fermented lingonberry juice sprey|Patented fermented lingonberry juice sprey
224072537|NCT07144397|PROCEDURE|TOLS|"Standard AC plus bilateral lateral suspension using non-absorbable sutures passed through the obturator foramen to support lateral vaginal wall."
224072538|NCT07144085|DRUG|68Ga-FXX489|The dose will be 3 to 8 millicurie (mCi) +/- 10% given intravenously at a single time prior to imaging.
224072539|NCT07144085|PROCEDURE|Positron Emission Tomography (PET) imaging|Participants will be scanned for approximately 30 to 45 minutes.
224072540|NCT07144085|DRUG|Gallium-68 labelled (68Ga-) FAP-2286|The dose will be 3 to 8 millicurie (mCi) +/- 10% given intravenously at a single time prior to imaging.
224177122|NCT05445869|DEVICE|ProSomnus® EVO Sleep and Snore Device|The ProSomnus® EVO Sleep and Snore Device is an intraoral device for snoring and obstructive sleep apnea. It works by repositioning the mandible during sleep, thereby improving the flow of air through the patient's pharyngeal space. The ProSomnus® EVO Sleep consists of maxillary and mandibular device arches that are CAD/CAM designed with twin-mated posts and digitally milled to be patient-specific according to physician prescription. Prescribed advancements can be achieved by simply removing the current upper or lower device arch and inserting the next upper or lower device arch in the mandibular advancement series. The device does not have any adjustment mechanisms to modify or maintain the mandibular position such as pistons, screws, straps, or repositioning elastics. The device is supplied nonsterile.
224177123|NCT05860166|OTHER|Test Scale|Developing an Neurodevelopment Test for evaluating infants in their neonatal period.
224177124|NCT02404324|OTHER|Prescription of spectacles|All children are prescribed full optical correction of refractive errors with special attention to astigmatism up to 0.5 Dptr to achieve maximal clear image on the retina of both eyes.If necessary, direct occlusion or penalization are administered to the children.
224306559|NCT01398943|DRUG|Tetrahydrobiopterin (BH4)|single dose = 5 mg/kg
223486970|NCT04126070|DRUG|Androgen Deprivation Therapy|Given per standard care for duration of study. Regimens include Leuprolide (Lupron Depot) intramuscularly every 3 months, Goserelin acetate (Zoladex) subcutaneously every 4 weeks, or degarelix (Firmagon) subcutaneously every month per standard of care.
223486971|NCT04126070|DRUG|Nivolumab|Given once per every 3 weeks for cycle 1-6 intravenously and then every 4 weeks during subsequent cycles, at predetermined dosage; up to 28 cycles total.
223486972|NCT04126070|DRUG|Docetaxel|Given once every 3 weeks intravenously at pre determined dosage for cycle 1-6.
223486973|NCT00359476|DRUG|Vinflunine|solution for injection, IV, 280/320 mg/m2, every 3 wks, variable duration
224072541|NCT07143799|DRUG|Cisatracurium|Induction of general anesthesia will be done by IV propofol 2-2.5 mg / kg and IV fentanyl lug/kg. After IV Cis-atracurium 0.15mg/kg, endotracheal intubation will be done.
224072542|NCT07143799|OTHER|scalp block|The scalp block will target six pairs of sensory nerves that innervate the scalp: the supraorbital nerve, supratrochlear nerve, auriculotemporal nerve, zygomaticotemporal nerve, greater occipital nerve, and lesser occipital nerve. Local anesthetic (2% lidocaine and bupivacaine) will be infiltrated at specific anatomical landmarks corresponding to the course of each nerve.
224072543|NCT07144449|BEHAVIORAL|Nurse-Led ePRO System|A nurse-designed electronic patient-reported outcome (ePRO) system for chemotherapy patients. Participants complete weekly symptom assessments for 12 weeks through an electronic platform. The system provides automated feedback, evidence-based self-care advice, and alerts to oncology nurses. Nurses follow up with weekly phone calls if severe symptoms are reported. This intervention is intended to improve symptom self-management, quality of life, and health literacy.
224072544|NCT07144449|BEHAVIORAL|Usual Care|Participants will receive standard oncology care without the use of an ePRO system. Symptom monitoring and management will be provided according to routine clinical practice by the treating oncology team, typically during scheduled visits or when patients proactively report problems.
224072545|NCT07142837|DRUG|ZG005|ZG005 20mg/kg; once every 3 weeks；IV infusion
224072546|NCT07142837|DRUG|Gecacitinib|Gecacitinib for dose escalations are set as 100mg Bid po. Gecacitinib for dose expansion will commence after the Recommended Phase 2 Dose (RP2D) is determined during the dose-escalation stage.
224072547|NCT07143500|OTHER|Selected physical therapy program|Passive stretching, active range of motion exercises, isometric strengthening, and functional gripping practice for the hand
224306560|NCT01398943|DIETARY_SUPPLEMENT|Antioxidant Cocktail|1g of vitamin C, 600 IU of vitamin E, and 600 mg of alpha-lipoic acid
224306561|NCT03433755|DRUG|evolocumab|Evolocumab will be administered per pre-filled auto-injector pen (AI/Pen). Participants will receive evolocumab (AMG 145) every 2 weeks or monthly subcutaneously.
224306562|NCT03433755|DRUG|placebo|Placebo will be administered per pre-filled auto-injector pen (AI/Pen). Participants will receive placebo every 2 weeks or monthly subcutaneously.
224306563|NCT02635581|DEVICE|Delta TT acetabular cup|
224177125|NCT01038635|DRUG|5-Azacytidine|75 mg/m\^2 IV daily x 5 days on days 1 to 5.
224177126|NCT01038635|DRUG|Lenalidomide|Starting dose 10 mg orally daily x 5 days on days 6 to 10.
224177127|NCT04048057|OTHER|Exercise|"Modarete Intensity Continous Training: Medium intensity continuous exercise training will be performed. Exercise intensity will be adjusted as 50-70% of maximal power.~High Intensity Interval Training I: It will be four cycles consisting of 4 minute high intensity exercise phase and 3 minute active recovery phase. High intensity phase will be adjusted as 85-100% of maximal power and active recovery phase as 50-70% of maximal power.~High Intensity Interval Training II: It will be 10 cycles consisting of 1 minute high intensity exercise phase and 1 minute active recovery phase. High intensity phase will be adjusted as 85-100% of maximal power and active recovery phase as 50-70% of maximal power."
224177128|NCT00597857|DRUG|Hydrocortisone|Participants will receive a tapering low-dose of hydrocortisone in pill form for 10 days, twice a day, after the trauma.
224177129|NCT00597857|DRUG|placebo|receipt of a placebo pill for 16 days
224177130|NCT00213967|DEVICE|22 gauge 1 1/2 inch needles on a 3 ml syringe|cold needles or needles kept at room temperature
224177131|NCT02355925|DRUG|intrauterine injection of uhCG|40 μL of tissue culture medium (G.2plus ref. 10132, Vitrolife) containing either 500 IU of hCG (Choriomon®, IBSA SA, Switzerland) is injected intrauterine, approximately 7 minutes before embryo transfer.
224177132|NCT02355925|DRUG|Placebo|only 40 μL of tissue culture medium (G.2plus ref. 10132, Vitrolife) is injected intrauterine, approximately 7 minutes before embryo transfer.
224177133|NCT02355925|OTHER|control|the embryonic transfer is done without the intrauterine hCG injection. The ET procedure is performed just like in the other two groups.
224177134|NCT01355094|DEVICE|KCI AbThera|"The time that the dressing will be left in place will be left to the discretion of the attending surgeon, but revised practice guidelines mandate either formal abdominal closure or dressing change at 24-96 hours from placement. Upon the first OA dressing change, the surgeon is free to utilize whatever temporary closure they choose.~Just prior to placement of the dressing, 16 ml (1 table spoon) of blood will be drawn from an existing arterial or venous line (this will qualify as Day 1). The same quantity of blood will be drawn on days 2, 3, 7 and 28 (or hospital discharge, whichever comes first). 15ml of peritoneal fluid will also be collected from the abdomen on the same days or until closure of the abdomen and removal of the dressing."
224205529|NCT06211803|DIAGNOSTIC_TEST|Positron-Emission Tomography Imaging|Examination of radiation distribution in the patient brain and body after completing a routine examination on a PET diagnostic device. J-PET prototype tests will be carried out in patients who have undergone a classic PET examination after administration of \[18F\]FDG), \[68Ga\]Ga-PSMA or \[68Ga\]Ga-DOTATATE). The duration of the additional exam will be approximately 20 minutes.
223486974|NCT00988026|DRUG|Minocycline vs Lymecycline|Minocycline 100 mg OD per mouth for 8 weeks. Lymecycline 300 mg OD per mouth for 8 weeks.
223486975|NCT02845804|DEVICE|Alpine|
223486976|NCT01642368|OTHER|The Optimum Omega-3 Fatty Acid Feeding Study|Assess whether swapping specific food ingredients in the diet can significantly improve polyunsaturated fatty acid blood profiles and improve a person's response to cognitive measures and physical fitness.
223486977|NCT02064062|BIOLOGICAL|Autologous Mesenchymal Stem Cells|
223486978|NCT00177697|BEHAVIORAL|behavioral weight loss program|
223486979|NCT06564389|DRUG|PF-07832837|escalated doses of PF-07832837
223486980|NCT06564389|OTHER|Placebo|placebo
224306564|NCT01850095|DRUG|treatment azelaic acid (azelan)|treatment for 6 months
223486981|NCT00166699|PROCEDURE|ultrasound|The use of ultrasound to guide the insertion of combined spinal epidural needle
223486982|NCT02802228|DRUG|Ifetroban|thromboxane prostanoid receptor antagonist delivered as infusion and oral capsule
223486983|NCT02802228|DRUG|Placebo|matched placebo delivered as infusion and oral capsule
223486984|NCT04620200|DRUG|Nivolumab|3mg/kg
223486985|NCT04620200|DRUG|Ipilimumab|1mg/kg
223486986|NCT05524532|DRUG|Immulina TM|Immulina TM is a highly standardized extract derived from various preparations of Spirulina, a cyanobacterium, marketed as a dietary supplement and has been utilized in several clinical studies describing its immunopotentiiating properties.
223486987|NCT05524532|DIETARY_SUPPLEMENT|Placebo|Placebo is an inert form of cellulose acetate.
223486988|NCT05250232|OTHER|onlays conservative|Partial coverage of cusps with shoulder finish line
223486989|NCT05250232|OTHER|onlays conventional|all coverage of cusps as overlay with shoulder finish line
223486990|NCT03410316|OTHER|No intervention|
223486991|NCT02225587|BIOLOGICAL|Prevnar 13™|Pneumococcal vaccine containing serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F. Injections are to be administered into the deltoid muscle of the upper arm.
223486992|NCT02225587|BIOLOGICAL|Pneumovax™ 23|Pneumococcal vaccine containing serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F. Injections are to be administered into the deltoid muscle of the upper arm.
223486993|NCT02225587|BIOLOGICAL|Placebo|Injections are to be administered into the deltoid muscle of the upper arm.
223486994|NCT05155358|DIAGNOSTIC_TEST|Peripheral blood test|Collect peripheral blood to separate and extract plasma, PBMC, and plasma exosomal miRNA, and sequence to find indicators related to disease deterioration and prognosis
223486995|NCT06294561|DRUG|Itraconazole+TGRX-326|healthy subjects will be given TGRX-326 60 mg orally on Day 1, and Itraconazole 200 mg with TGRX-326 60 mg orally on day 11
223486996|NCT06294561|DRUG|Efavirenz+TGRX-326|healthy subjects will be given TGRX-326 60 mg orally on Day 1, and Efavirenz 600 mg with TGRX-326 60 mg orally on day 20
223586786|NCT03177096|BEHAVIORAL|Peds QL questionnaire and diabetes modulate|Peds QL questionnaire and diabetes modulate is a pediatric questionnaire about quality of life - children's version and parents version : assessed in the 1st visit (enrollment visit) and after ten months ( V6 End of study)
223586787|NCT03177096|BEHAVIORAL|WHO-5 questionnaire|WHO-5 questionnaire is a questionnaire about quality of life : assessed in the 1st visit (enrollment visit) and after ten months (V6 End of Study) by the children
223586788|NCT03177096|BEHAVIORAL|Felt questionnaire|Felt questionnaire completed by parents with regard to the welcome of their child in community and by the staffs in preschool, school or in out-of school center : assessed 2 months (V2) and ten months (V6 End of study) after enrollment visit
223617680|NCT00659412|DRUG|Alefacept|Intramuscular
224177135|NCT01355094|DEVICE|"Stampede VAC"|"The time that the dressing will be left in place will be left to the discretion of the attending surgeon, but revised practice guidelines mandate either formal abdominal closure or dressing change at 24-96 hours from placement. Upon the first OA dressing change, the surgeon is free to utilize whatever temporary closure they choose.~Just prior to placement of the dressing, 16 ml (1 table spoon) of blood will be drawn from an existing arterial or venous line (this will qualify as Day 1). The same quantity of blood will be drawn on days 2, 3, 7 and 28 (or hospital discharge, whichever comes first). 15ml of peritoneal fluid will also be collected from the abdomen on the same days or until closure of the abdomen and removal of the dressing."
224177136|NCT04454840|BIOLOGICAL|Plasma from healthy young people treatment + Riluzole|Intravenous injection: the subjects received 400ml of intravenous plasma infusion every 2 weeks, with a continuous course of 2 treatments and a course of treatment every 3 months. The course of treatment lasted 10 months, with a total of 3200ml of plasma infusion.
224177137|NCT04454840|DRUG|Riluzole|The basic treatment is Riluzole 25\~50mg twice daily
224177138|NCT02337855|OTHER|Placebo|Placebo: normal saline for parenteral administration. Group C. Group F, and Group I: single dose intramuscular (IM) Placebo (normal saline (0.9% NaCl) on Day 1, 57 and 113.
224177139|NCT02337855|BIOLOGICAL|Sm-TSP-2/Alhydrogel|Sm-TSP-2/Alhydrogel. Group A: single dose IM 10mcg Sm-TSP-2/Alhydrogel® on Day1, 57 and 113. Group D: single dose intramuscular (IM) 30mcg Sm-TSP-2/Alhydrogel® on Day 1, 57 and 113. Group G: single dose intramuscular (IM) 100mcg Sm-TSP-2/Alhydrogel® on Day 1, 57 and 113.
224177140|NCT02337855|BIOLOGICAL|Sm-TSP-2/Alhydrogel/GLA-AF|Sm-TSP-2/Alhydrogel/GLA-AF. Group B: single dose intramuscular (IM) 10mcg Sm-TSP-2/Alhydrogel®/GLA-AF on Day 1, 57 and 113. Group E: single dose intramuscular (IM) 30mcg Sm-TSP-2/Alhydrogel®/GLA-AF on Day 1, 57 and 113. Group H: single dose intramuscular (IM) 100mcg Sm-TSP-2/Alhydrogel®/GLA-AF on Day 1, 57 and 113.
224177141|NCT06228365|DEVICE|use of a device incorporating virtual reality software|use of a device incorporating virtual reality software
224177142|NCT06228365|DRUG|Neuroleptanalgesia|Usual neuroleptanalgesic treatment
224177143|NCT03684460|DEVICE|Daytime Bright Light|Daytime Bright Light (DBL) will be delivered by a free-standing apparatus set to deliver 10,000 lux. The device will be placed at the bedside within 36 inches of the patient's head and is expected to provide at least 1,250 lux at the angle of gaze. To remain in the study, the patient must be in the Intensive Care Unit (ICU) through 13:00 on day 2 (e.g., the first day of potential intervention). After day 2, DBL and other study activities will continue if the patient is transferred out of the ICU to the general medical floor.
224177144|NCT03684460|DEVICE|Usual Light|"Usual care lighting in ICU.~To remain in the study usual care patients must also remain in the MICU through 13:00 on day 2."
224177145|NCT03192384|BEHAVIORAL|Educational programme|Educational programme for ward staff
224177146|NCT04451395|DIETARY_SUPPLEMENT|Multiple micronutrients (UNIMMAP composition)|"The intervention is an oral tablet containing 15 different vitamins and minerals at the UNIMMAP composition (includes 30 mg iron, 400 μg folic acid, 15 mg zinc, 2 mg copper, 65 μg selenium, 800 μg RE vitamin A, 1.4 mg vitamin B1, 1.4 mg vitamin B2, 18 mg niacin, 1.9 mg vitamin B6, 2.6 μg vitamin B12, 70 mg vitamin C, 5 μg vitamin D, 10 mg vitamin E and 150 μg iodine). Each tablet is small (approximately 10 mm diameter) and has been procured using the UNICEF supply catalogue. A single MMN supplementation dose will consist of a single tablet.~Other Name: UNICEF, Micronutrient tabs, pregnancy/PAC-1000"
224177147|NCT03070262|DRUG|CA|caffeic acid, 300mg, tid, po
224177148|NCT03070262|DRUG|placebo group|placebo tablet, 3 tablets, tid, po
224177149|NCT00857116|DRUG|Albendazole|Albendazole 400mg per os for three consecutive days at week 2 and week 8 after initiation of chemotherapy against tuberculosis
224177150|NCT00857116|DRUG|Placebo|Placebo 400mg per os for three consecutive days at week 2 and week 8 after initiation of chemotherapy against tuberculosis
223486997|NCT04373941|DRUG|Filgrastim|G-CSF is a glycoprotein produced by monocytes, fibroblasts, and endothelial cells. Filgrastim is a human granulocyte colony stimulating factor (G-CSF) produced by recombinant DNA technology with NEUPOGEN® as the Amgen Inc. trademark for filgrastim. G-CSF regulates the production, proliferation and differentiation of neutrophils and hematopoietic stem cell precursors within the bone marrow leading to dose-dependent increase in circulating neutrophils and hematopoietic stem cells in the blood. It is indicated to reduce the incidence of infection in patients with severe neutropenia, for neutrophil recovery in neutropenic patients with bone marrow depletion, to mobilize hematopoietic progenitor stem cell for collection by leukapheresis in hematopoietic stem cell transplantation.
224205530|NCT04460521|DRUG|N-Acetyl cysteine|In addition to splinting, both groups will receive an oral tablet to take daily for 8 weeks. Participants assigned to the experimental group will receive oral NAC (500 mg PO daily for eight weeks; based on recommended daily dose for use as an antioxidant and dosing in previous human clinical trials and animal studies), and those assigned to the control group will be given a similar looking placebo with identical instructions. Tablets will be provided in a blister pack to assist with compliance.
224306565|NCT01850095|DRUG|dorspirenone/ethynil estradiol|
224306566|NCT04667260|PROCEDURE|Maxillary sinus membrane elevation|Maxillary sinus membrane elevation with blood coagulum
224306567|NCT04667260|PROCEDURE|Maxillary sinus floor augmentation|Maxillary sinus floor augmentation with 1:1 autogenous bone graft and deprotinized porcine bone mineral
224306568|NCT03894748|DRUG|Botulinum Toxin Type A|20U of the investigational drug will be intramuscularly injected to 5 sites of the glabella line. Treatment will be conducted just once in visit 2.
223486998|NCT04525820|DRUG|Single high dose vitamin D|Patient receives either one dose orally of 140'000 IU (7 ml) of this drug once as an intervention treatment additionally to TAU or the patient receives 7 ml of the placebo Solution (7 ml) in addition to TAU
223486999|NCT04525820|DRUG|Placebo|Patient receives a single dose of a placebo solution
224306569|NCT01565850|DRUG|D/C/F/TAF|DRV 800 mg/COBI 150 mg/FTC 200 mg/TAF 10 mg FDC tablet administered orally once daily
223487000|NCT04525820|DRUG|Treatment as usual vitamin D|Both groups receive the treatment as usual after the single high dose or the placebo which will be 800 IU per day
223617681|NCT00659412|DRUG|Methotrexate|Oral
223617682|NCT00659412|DRUG|Placebo|Intramuscular
224306570|NCT01565850|DRUG|DRV|DRV 800 mg (2 × 400 mg tablets) administered orally once daily
223617683|NCT00003994|PROCEDURE|therapeutic conventional surgery|Undergo surgical resection
223617684|NCT00003994|DRUG|cisplatin|Given IV
224177151|NCT01540110|DRUG|Neoadjuvant Docetaxel and Cyclophosphamide|"5.1.1 Docetaxel Docetaxel at a dose of 75 mg/m2 will be administered by intravenous infusion over 90 minutes (AFTER completion of cyclosphosphamide 600 mg/m2) on D1 every 21 days for 6 cycles using nonpolyvinylchloride tubing.~Standard premedication with oral dexamethasone 8 mg bd on D-1, D1 and D2 will be administered. Alternatively, intravenous dexamethasone 8 mg before docetaxel followed by oral dexamethasone 8 mg bd on D1 and D2 can be given.~Routine prevention of chemotherapy induced emesis will be administered (see 5.2.2)~5.1.2 Cyclophosphamide~Cyclophosphamide 600 mg/m2 by slow intravenous infusion over 10 minutes (BEFORE docetaxel) will be administered every 21 days for 6 cycles.~No premedications are required except for routine prevention of chemotherapy induced emesis (see 5.2.2)"
224177152|NCT05633290|DIAGNOSTIC_TEST|CMR|CMR Imaging 6-10 weeks post hospital discharge.
224177153|NCT05633290|DIAGNOSTIC_TEST|hs-troponin|Biomarker of myocardial injury
224177154|NCT05633290|DIAGNOSTIC_TEST|NT-pro BNP|Biomarker for heart failure
224177155|NCT05633290|DIAGNOSTIC_TEST|CRP|Acute phase inflammatory marker
224177156|NCT05633290|DIAGNOSTIC_TEST|IL1-B|Inflammatory biomarker
223487001|NCT05634369|BIOLOGICAL|GEM/DOX + TGFBi expanded NK cells|"8 cycles consisting of gemcitabine, docetaxel, supportive dexamethasone and pegfilagrastim, and universal donor, TGFBi ex vivo expanded NK cells~* Each cycle will be repeated every 21 days based upon disease response and toxicity criteria~* Tumor response assessed after Cycles 2, 4, 6, and 8~  1. Gemcitabine 675mg/m2/dose IV on Days 1 and 8~ 2. Docetaxel 75mg/m2/dose IV on Day 8~ 3. Dexamethasone 3mg/m2/dose (max 8 mg/dose) PO BID on Days 7, 8, and 9~ 4. Pegfilgrastim (Peg-GCSF) 0.1mg/kg/dose (max 6 mg/dose) SQ on Day 9~ 5. NK cells 1 x 10e8 cells/kg/dose IV on Day 12 (+ 1-2 days)"
224177157|NCT05633290|DIAGNOSTIC_TEST|IL-6|Inflammatory Biomarker
224177158|NCT05633290|DIAGNOSTIC_TEST|IL-10|Inflammatory Biomarker
224177159|NCT05633290|DIAGNOSTIC_TEST|TNF-alpha|Inflammatory Biomarker
224177160|NCT05119790|DRUG|[14C] BIIB122 ([14C] DNL151)|Oral dose
224306571|NCT01565850|DRUG|COBI|COBI 150 mg tablet administered orally once daily
224306572|NCT01565850|DRUG|FTC/TDF|FTC 200 mg/TDF 300 mg FDC tablet administered orally once daily
223487002|NCT06026813|DEVICE|test pressure alternating shoes|test pressure alternating shoes
224177161|NCT01060150|DRUG|OROS Methylphenidate HCl|Osmotic Release Oral System (OROS) Methylphenidate HCl tablet will be given orally once daily at a starting dose of 18 milligram (mg) for those less than 30 kilogram (kg) of body weight and 27 mg for those more than or equal to 30 kg; the dose can be increased by 9 mg or 18 mg per week up to Week 6 depending on a participant's treatment effect and tolerability; then a maximum maintenance dose of 72 mg will be given orally once daily up to Week 12.
224306573|NCT01565850|DRUG|D/C/F/TAF Placebo|D/C/F/TAF placebo tablet administered orally once daily
224306574|NCT01565850|DRUG|DRV Placebo|DRV placebo tablet administered orally once daily
224177162|NCT01562327|DRUG|Tocilizumab|Participants received tocilizumab according to individualized physician-prescribed regimens.
224177163|NCT04079322|OTHER|Meal|Participants will consume a meal containing a stable iron isotope following exercise or rest.
223487003|NCT02368509|OTHER|Perform sensory tests|
223487004|NCT02879695|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223487005|NCT02879695|BIOLOGICAL|Blinatumomab|Given IV
224177164|NCT01969227|DRUG|Subanesthetic ketamine|Ketamine drip at a subanesthetic infusion rate (low dose ketamine 5 - 10 mcg/kg/min)
224177165|NCT03018340|DRUG|Pimavanserin|Pimavanserin 34 mg, tablet, taken as two 17 mg tablets, once daily by mouth All patients continued to receive selective serotonin reuptake inhibitor/serotonin norepinephrine reuptake inhibitor (SSRI/SNRI) antidepressants at a stable dose for the duration of the study.
224177166|NCT03018340|OTHER|Placebo|Placebo, taken as two tablets, once daily by mouth All patients continued to receive selective serotonin reuptake inhibitor/serotonin norepinephrine reuptake inhibitor (SSRI/SNRI) antidepressants at a stable dose for the duration of the study.
224177167|NCT03323372|DRUG|3% potassium nitrate and 0.25% sodium fluoride|
224306575|NCT01565850|DRUG|COBI Placebo|COBI placebo tablet administered orally once daily
224306576|NCT01565850|DRUG|FTC/TDF Placebo|FTC/TDF placebo tablet administered orally once daily
224306577|NCT03202901|DIETARY_SUPPLEMENT|B-turmactive|"The treatment consists of daily administration of B-TURMACTIVE®.~Treatment with B-TURMACTIVE® will last 7 days to determine the effects of the product in the short term, during which the volunteers will be visited 4 times:~V0 screening: to evaluate the inclusion and exclusion criteria. V1 inclusion and randomisation (Day 1): 1st day treatment and intervention. Measure primary and secondary variables V2 (Day 3): the primary endpoint will be monitored by telephone (perception of pain).~V3 (Day 7): Day 7 of treatment and final intervention. Measure primary and secondary variable"
224306578|NCT03202901|DIETARY_SUPPLEMENT|Placebo|"The treatment consists of daily administration of placebo capsule with identical format and harmless thant B-turmactive product.~Treatment with placebo will last 7 days to determine the effects of the product in the short term, during which the volunteers will be visited 4 times:~V0 screening: to evaluate the inclusion and exclusion criteria. V1 inclusion and randomisation (Day 1): 1st day treatment and intervention. Measure primary and secondary variables V2 (Day 3): the primary endpoint will be monitored by telephone (perception of pain).~V3 (Day 7): Day 7 of treatment and final intervention. Measure primary and secondary variable"
223487006|NCT02879695|PROCEDURE|Bone Marrow Aspiration and Biopsy|Undergo bone marrow aspiration and biopsy
223487007|NCT02879695|BIOLOGICAL|Ipilimumab|Given IV
223487008|NCT02879695|BIOLOGICAL|Nivolumab|Given IV
223617685|NCT00003994|DRUG|vincristine sulfate|Given IV
223617686|NCT00003994|DRUG|fluorouracil|Given IV
223617687|NCT00003994|DRUG|amifostine trihydrate|Given IV
223617688|NCT00003994|DRUG|carboplatin|Given IV
223617689|NCT02719535|OTHER|Corneal reshaping therapy|Reshaping the corneal curvature from wearing specific designed rigid gas permeable lenses
223617690|NCT00461617|DRUG|Mitiglinide|10mg tablet, 10mg TID
223617691|NCT04558177|DEVICE|Direct current stimulator|HDCprog connected to a direct current stimulator, controls the number of stimulations (maximum 99), the intensity (up to 1.5mA per channel), the duration (maximum 20min), and the minimum interval between two consecutive simulations (max 1168 hours). A sham condition is also available which will ramp the stimulation to a preset maximum level and then immediately reduces the stimulation to 0.
224177168|NCT03323372|DRUG|5% potassium nitrate and 2% sodium fluoride|
224177169|NCT05519891|OTHER|Custom 3D printed device|A 3D printed adaptation for a mobile device.
224177170|NCT04411225|DRUG|Cannabidiol oral solution|Both the active drug (cannabidiol) and placebo will be in oral solution.
224177171|NCT03001765|OTHER|"Intensive Monitoring Strategy: Reveal LINQ™ Insertable Cardiac Monitoring System."|Intensive monitoring strategy of discharge from Emergency Department with 30 day SEEQ external monitor, followed by implantable cardiac Reveal LINQ monitor if negative 30 day result.
224177172|NCT05414669|DRUG|Allopurinol Tablet 300 mg|Allopurinol 300mg was given orally for a total of 3 days, beginning a day before ESWL.
224177173|NCT05414669|DRUG|Control Group|Placebo was given orally for a total of 3 days, beginning a day before ESWL.
224177174|NCT05027711|RADIATION|ITV (Internal target volume)-based Stereotactic Body Radiotherapy (ITV-SBRT)|ITV (Internal target volume)-based Stereotactic Body Radiotherapy (ITV-SBRT)
224306579|NCT04031781|DEVICE|repetitive transcranial magnetic stimulation (rTMS) 100% motor threshold|Each rTMS session consisted of a single train of 900 total pulses over 3 minutes duration.
223487009|NCT06787599|BEHAVIORAL|Home-based Tele Exercise|The participants in the study group will be given an online personalized exercise program at home in non-peritoneal dialysis (PD) days. Synchronous tele-exercise will be delivered using the free teleconference application (app) (Google Meets software). The groups of teleexercises will be private and the professional will send the link for each training session and will control the access of the participants. Each session will be 40 to 45 min in duration for 3 days per week over 12 weeks, 36 sessions in total.
223487010|NCT06425471|DEVICE|KARL STORZ fetoscope arm|The type of fetoscope used in utero(either straight or curved or both ) will depend on the location of the placenta. The fetoscope will be used to cauterize abnormal blood vessels that cause twin-to-twin transfusion syndrome (TTTS)
223487011|NCT06283485|DEVICE|ultrasound examination|"Phase 1 1: Taking ultrasound images from healthy volunteers (150 volunteers) to produce artificial intelligence - How to take PENG and Suprainguinal Fascia Iliaca Block sonoanatomical images is as follows.~Phase 2: In the second phase of the study, Smart Alfa Teknoloji San. and Tic. Inc. Artificial intelligence technology called Nerveblox, which was developed with the data received in the first stage with the support of the company, will be used. It is the validation and accuracy study of the artificial intelligence technology developed in the first stage. The accuracy study will be conducted on 40 healthy volunteers. 20 men and 20 women will be included in the study."
223487012|NCT05595915|DIETARY_SUPPLEMENT|COMP-4|COMP-4 is a novel compound that consists of ginger extract, L-citrulline, and the herbal components Paullinia cupana and muira puama.
223487013|NCT04298541|DRUG|Ga-68- DOTATATE|"The study intervention consists of two PET scans that will be performed using two different radiotracers, 68-Ga-DOTATATE and 68-Ga-DOTATOC. Ga-68-DOTATATE and 68-Ga-DOTATOC are PET radiotracers targeting somatostatin receptors.~The study intervention consists of 2 PET scans that will be performed at least 24h apart using 68-Ga-DOTATATE and 68-Ga-DOTATOC radiotracers, in patients with suspected meningioma that are planned for subsequent surgery."
223487014|NCT04298541|DRUG|Ga-68-DOTATOC|"The study intervention consists of two PET scans that will be performed using two different radiotracers, 68-Ga-DOTATATE and 68-Ga-DOTATOC. Ga-68-DOTATATE and 68-Ga-DOTATOC are PET radiotracers targeting somatostatin receptors.~The study intervention consists of 2 PET scans that will be performed at least 24h apart using 68-Ga-DOTATATE and 68-Ga-DOTATOC radiotracers, in patients with suspected meningioma that are planned for subsequent surgery."
223487015|NCT04442724|PROCEDURE|Fiducial marker placement|placement of 24k gold fiducial markers surrounding the tumor site, at time of primary or re-staging bladder tumor resection
223487016|NCT04442724|DIAGNOSTIC_TEST|Multiparametric MRI (mpMRI)|In this study, mp-MRI is defined as MRI that includes T1 \& T2 weighted sequences, diffusion weighted sequences, and Dynamic contrast enhanced (DCE) MRI sequences.
223487017|NCT04272060|DIAGNOSTIC_TEST|CT angiography|Diagnostic CT angiography
223745333|NCT06912815|BIOLOGICAL|ustekinumab and semi enteral nutrition|Preoperative treatment optimization involves a single intravenous induction with UST, followed by 6 weeks of oral/nasal feeding with semi-enteral nutrition.
224306580|NCT04031781|DEVICE|repetitive transcranial magnetic stimulation (rTMS) 50% motor threshold|Each rTMS session consisted of a single train of 900 total pulses over 3 minutes duration.
224306581|NCT04149795|DIAGNOSTIC_TEST|Online questionnaire|Online questionnaire via SoSciSurvey
224306582|NCT06928792|OTHER|Experimental interventional group A, (MET).|10-minute hot pack application, followed by MET on the Quadratus Lumborum (3 repetitions with a 7-second hold). Flexibility exercises include William flexion with bilateral knee-to-chest stretches (10-second hold, repeated 10 times) and static stretching of the hamstrings, gastrocnemius, and iliotibial band (5 repetitions with a 5-second hold). Strengthening exercises comprise isometric hip flexor activation (5 repetitions with a 15-second hold), side planks (3 repetitions with a 30-second hold), and static side bending (5 repetitions with a 10-second hold). The intervention will be performed once daily, consisting of 3 sets per session, continued for 4 weeks to enhance flexibility, core stability, and muscular balance, ultimately contributing to pain relief and improved functional mobility in CLBP patients
224306583|NCT06928792|OTHER|Control: group B (conventional intervention exercises)|10-minute hot pack application, followed by William flexion with bilateral knee-to-chest stretches (10-second hold, repeated 10 times). Flexibility exercises consist of static stretching for the hamstrings, gastrocnemius, and iliotibial band (5 repetitions with a 5-second hold). Strengthening exercises include isometric hip flexor activation (5 repetitions with a 15-second hold), side planks (3 repetitions with a 30-second hold), and static side bending (5 repetitions with a 10-second hold). The protocol will be performed once daily, with 3 sets per session, continued for 4 weeks to improve flexibility, core stability, and pain management in CLBP patients.
223745334|NCT06912815|OTHER|Exclusive enteral nutrition|Preoperative optimized treatment with 6 weeks of oral/nasal feeding of exclusive enteral nutrition alone.
224177175|NCT05027711|RADIATION|MRgSBRT (Magnetic Resonance-guided Stereotactic Body Radiotherapy)|MRgSBRT (Magnetic Resonance-guided Stereotactic Body Radiotherapy)
224177176|NCT03961529|DRUG|0.3% OPA-15406 ointment|Twice daily
224177177|NCT03961529|DRUG|1% OPA-15406 ointment|Twice daily
224306584|NCT01632761|DIETARY_SUPPLEMENT|Vitamin D3 .|
224306585|NCT01632761|DRUG|omega-3 fatty acids (fish oil)|
224306586|NCT01632761|DIETARY_SUPPLEMENT|Vitamin D3 placebo|
224306587|NCT01632761|DIETARY_SUPPLEMENT|Fish oil placebo|
224177178|NCT03644173|BEHAVIORAL|Personal Resilience Empowerment Program including 5 sessions with health coaches|5 coaching sessions that will take place either in-person or over the phone with a research nurse (RN)-Health Coach. During the sessions, the health coach will focus on introducing the 5 pillars of health and well-being: sleep, activity, purpose, nutrition and resilience. Will introduce breathing techniques participants and will teach patients how to acquire mind-body skills to assist in stress management, learn to thrive by building resilience, feel empowered to manage their health, gain self-care skills to decrease anxiety, pain and nausea naturally, control the stress response and trigger the relaxation response to promote well-being and discover what foods fuel the body in preparation for healing, during recovery and overall health.
224177179|NCT00362440|DRUG|Leptin|
224177180|NCT00362440|DRUG|Pioglitazone or metformin|
224177181|NCT00362440|DRUG|Placebo|
224177182|NCT03157752|BEHAVIORAL|Quality of life questionnaire|Quality of life questionnaire
224177183|NCT03759444|OTHER|Questionnaires|The three questionnaires applied were: the Time Metaphors Questionnaire by Sobol-Kwapinska, the Time Perspective Inventory by Zimbardo, and the UWIST Mood Adjective Checklist (UMACL) by Matthews et al.
224177184|NCT02527291|OTHER|Blood test|Blood test for CMV PCR and IL28
224306588|NCT00923000|DRUG|Nalbuphine|Nalbuphine 10mg with oral administration
223487018|NCT04272060|DIAGNOSTIC_TEST|Invasive coronary angiography|Diagnostic invasive coronary angiography
223487019|NCT06688864|BEHAVIORAL|EPIO App|Participants will receive access to the app-based cognitive-behavioral pain self-management intervention program (EPIO) for 3 months.
223487020|NCT06496607|BIOLOGICAL|NSI-8226|Solrikitug
223487021|NCT06496607|BIOLOGICAL|NSI-8226|Solrikitug
223487022|NCT06496607|BIOLOGICAL|NSI-8226|Solrikitug
223487023|NCT06496607|BIOLOGICAL|Placebo|Placebo
223487024|NCT02401295|DRUG|ATRA|
223487025|NCT02401295|DRUG|Celecoxib|
223487026|NCT02401295|DRUG|Itraconazole|
223487027|NCT04606446|DRUG|PF-07248144|KAT6 Inhibitor
223487028|NCT04606446|DRUG|Fulvestrant|Endocrine Therapy
223487029|NCT04606446|DRUG|Letrozole|Endocrine Therapy
223487030|NCT04606446|DRUG|Palbociclib|CDK4/6 Inhibitor
223487031|NCT04606446|DRUG|PF-07220060|CDK4 inhibitor
223487032|NCT04606446|DRUG|PF-07850327, ARV-471, vepdegestrant|PROTAC (PROteolysis Targeting Chimera) ER degrader
223487033|NCT05217810|OTHER|Atectura inhalation capsule (150/80ug)|There is no treatment allocation. Patients administered Atectura by prescription that have started before inclusion of the patient into the study will be enrolled.
223487034|NCT05217810|OTHER|Atectura inhalation capsule (150/160ug)|There is no treatment allocation. Patients administered Atectura by prescription that have started before inclusion of the patient into the study will be enrolled.
223487035|NCT05217810|OTHER|Atectura inhalation capsule (150/320ug)|There is no treatment allocation. Patients administered Atectura by prescription that have started before inclusion of the patient into the study will be enrolled.
224177185|NCT00381706|BIOLOGICAL|cetuximab|given IV
224177186|NCT00381706|DRUG|ECF|epirubicin and 5-fluorouracil given IV
224177187|NCT00381706|DRUG|IC|cisplatin and irinotecan given IV
224177188|NCT00381706|DRUG|FOLFOX|oxaliplatin , leucovorin and 5-fluorouracil IV
224177189|NCT00792324|DRUG|Etravirine|Four 100mg tablets daily for 12-24 weeks
224306589|NCT00923000|DRUG|Morphine|Morphine 10mg with oral administration
223487036|NCT05045963|OTHER|Electronic Health Record Review|Medical record reviewed
223487037|NCT05536011|DRUG|Pitolisant|Exposure to at least one dose of pitolisant at any time during pregnancy
223487038|NCT05536011|DRUG|Comparator Products|Exposure to at least one dose of a comparator product at any time during pregnancy
223487039|NCT04627688|BEHAVIORAL|Time restricted feeding|Participants will be advised to eat only during a selected window of 8 hours, and no later than 4pm, with no advice on nutrition quality, quantity or caloric intake. The intervention will include no medication, no medical device, and will last for 2 weeks prior to surgery.
223487040|NCT04627688|BEHAVIORAL|Standard dietary advices|Participants will be given standard dietary advices, as recommended by the international nutrition guidelines, and thus are not different from common clinical practice.
223487041|NCT03318198|OTHER|Enhanged Attending Supervision|Attendings were randomized at the start of the study to begin in the enhanced supervision arm where they attended resident work rounds. They then crossed over to the control arm where they did not attend work rounds. The outcomes were assessed between the two periods during which the attending participated in the study; attending work rounds vs. not attending work rounds.
223487042|NCT03318198|OTHER|Standard of Care|Attendings participated directly in new patient rounds but did not see patients previously known to the team with the residents.
223487043|NCT05455775|DEVICE|Camera-based monitoring technology|Unobtrusive, vital sign measurement with remote photoplethysmography and laser speckle vibrometry
223487044|NCT02373865|DRUG|Sitagliptin|Sitagliptin will be given in a daily dosage of 100 mg
223487045|NCT02373865|DRUG|Glimepiride|Glimepiride will be given in a starting daily dosage of 1 mg which will be adapted up to 6 mg
223487046|NCT02373865|DRUG|Sitagliptin-Placebo|Sitagliptin-Placebo will be given additional to Glimepiride (blinded). It will be given in a daily dosage of 100 mg
224177190|NCT00792324|DRUG|Efavirenz|One 600mg tablet daily
224177191|NCT00863135|DEVICE|CPAP|continuous positive airways pressure
224177192|NCT00863135|DEVICE|Control|Patients are 3 months without any change in their treatment, and are in the waiting list to come into the CPAP procedure after that time
224177193|NCT02804386|DRUG|Sofosbuvir|Sofosbuvir (formerly known as GS-7977) is a direct-acting nucleotide polymerase inhibitor that is being developed as an oral drug for the treatment of chronic HCV infection
224177194|NCT02113891|DRUG|Eculizumab|"Eculizumab induction: 900 mg IV every 7 days for 4 doses, a fifth 1200 mg dose 7 days later Eculizumab maintenance: 15 1200 mg doses every 14 days.~(each patient will receive a total of 20 eculizumab doses during the whole treatment period from 3 month to 12 month post-transplant)."
224177195|NCT01873599|BEHAVIORAL|Positive Affect Journaling|
224306590|NCT00923000|DRUG|Morphine with Long dan xie gan tang|Morphine 10mg with oral administration
224306591|NCT00923000|DRUG|Nalbuphine with Long dan xie gan tang|Nalbuphine 10mg with Long dan xie gan tang 3g tid with oral administration
224177196|NCT01396486|DRUG|Omega-3|Children with bipolar spectrum disorders ages 6-12 will receive treatment with omega-3 fatty acids. Study subjects may be randomized to receive 3000mg (6 500mg capsules) of omega-3 fatty acids for the duration of the study. Omega-3 fatty acid capsules are in the form of Nordic Naturals brand, ProOmega Junior, which contains 325mg EPA and 225mg DHA per two capsules.
224177197|NCT01396486|DRUG|Inositol|Children with bipolar spectrum disorders ages 6-12 will receive treatment with inositol, omega-3 fatty acids, or both weekly for 12 weeks. Subjects weighing 25kg or more may be randomized to receive 2000mg (4 500mg capsules) of inositol (80mg/kg for a 25kg child). Children weighing less than 25kg will be dosed at 80mg/kg rounded down to the nearest thousand mg dose. Dosage will remain constant throughout the study.
224177198|NCT00256204|DRUG|Rasagiline Mesylate|tablet, 1mg once daily
224177199|NCT00256204|DRUG|Rasagiline Mesylate|tablet, 2mg once daily
224177200|NCT00256204|OTHER|Placebo|Placebo
224177201|NCT00816894|DRUG|D-serine|6 week fixed dose phase with D-serine 1500 mg/day to be increased starting from week two to 3000 mg/day followed by a 4 week flexible dose phase allowing for two 500 mg/day dose changes
224177202|NCT00816894|DRUG|Olanzapine|6 week fixed dose phase with Olanzapine 15 mg/day to be increased starting from week two to 30 mg/day followed by a 4 week flexible dose phase allowing for two 5 mg/day dose changes.
224177203|NCT00045019|OTHER|quality-of-life assessment|QLQ-C30 SAT32
224306592|NCT00923000|DRUG|Nubian with Long dan xie gan tang|Nalbuphine 10mg with Long dan xie gan tang 3g with oral administration
224306593|NCT04839081|OTHER|questionnaires and inventories|questionnaires and inventories related to primary end secondary outcomes will be applied and physical examination will be performed.
223487047|NCT02373865|DRUG|Glimepiride-Placebo|Glimepiride-Placebo will be given additional to Sitagliptin (blinded). It will be given in a starting daily dosage of 1 mg which will be adapted up to 6 mg
224177204|NCT05043194|DRUG|Ursodeoxycholic Acid 250 Mg Oral Capsule|prevention
224306594|NCT05849038|DRUG|Baricitinib|Patients will receive baricitinib at a dose of 2 mg oral daily.
223487048|NCT00914212|DRUG|Placebo|Single dose placebo to sibutramine in two of three treatment periods.
223487049|NCT00914212|DRUG|Comparator: sibutramine|Single dose sibutramine 30 mg (2 x 15 mg) in one of three treatment periods.
223487050|NCT05166642|DEVICE|Bandgrip Micro-Anchor Wound Closure|This treatment group will utilize a suture closure technique for the deep dermal layers with Bandgrip being applied to the most superficial layer of the surgical incision
223487051|NCT05166642|DEVICE|Suture closure|This treatment gourd will utilize suture closure technique for all layers of the surgical incision.
223487052|NCT03724331|BEHAVIORAL|Light Physical Activity 1|"Light (mild) physical activity program that corresponds with normal every day activities of daily living (\< 3.0 metabolic equivalents, METs), with a time commitment starting at 5 minutes a day 5 days a week gradually increasing to 30 minutes a day 5 days a week as you are able by week 6 as guided by your Registered Nurse researcher.~The program begins approximately within one week after discharge from the hospital with the physical activity program starting approximately within the first week post-discharge from the hospital."
223487053|NCT03724331|BEHAVIORAL|Light Physical Activity 2|"Light (mild) physical activity program that corresponds with normal every day activities of daily living (\< 3.0 metabolic equivalents, METs), with a time commitment starting at 5 minutes a day 5 days a week gradually increasing to 30 minutes a day 5 days a week as you are able by week 6 as guided by your Registered Nurse researcher.~The program begins approximately within one week after discharge from the hospital with the physical activity program starting approximately 7 weeks post-discharge from the hospital."
223487054|NCT03724331|BEHAVIORAL|Support Education Activity|"Participate in a supportive cancer-related education activity including a direct 10 - 15 minute phone conversation with a Registered Nurse researcher each week for 6-weeks after returning home from the hospital. Wear a pedometer each day of the study.~Recording pedometer steps in the daily diary each day."
223487055|NCT06132477|DRUG|GLP-1 receptor agonist|Randomized to continue or discontinue GLP-1 receptor agonists after bariatric surgery
223487056|NCT02371811|DEVICE|uterine manipulator (v care)|
223487057|NCT00005849|DRUG|bryostatin 1|
223487058|NCT00005849|DRUG|paclitaxel|
223617692|NCT01790594|BIOLOGICAL|Belatacept|The first dose of belatacept will be administered approximately 24-48 hours after the last dose of Anti-Thymocyte Globulin (Rabbit).
224177205|NCT03427528|BEHAVIORAL|Fathers and Babies (FAB)|The initial FAB session was delivered in person or by phone by the home visitor working with the mother, and lasted 30 min on average. Subsequent sessions were delivered, in-person, via text message with embedded links to online content, or a mix of both in-person and text messages, depending on the preference and availability of the father. Fathers received three to six text messages per FAB session.
224177206|NCT03427528|BEHAVIORAL|MB 1-on-1 plus TXT|Home visiting clients received the Mothers and Babies with -Text Messages intervention in person during regular scheduled home visits (i.e., MB 1-on-1 plus MB-TXT). After each in person session home visiting clients receive three messages to reinforce skill practice and remind them about their personal projects.
224177207|NCT01889615|OTHER|PET/CT(3hours]|Low dose PET/CT 1 and 3 hours after injection of FDG, followed by a diagnostic CT with iv contrast
224306595|NCT05849038|OTHER|Placebo|A placebo is a sugar pill that has no therapeutic effect and will be administered orally. Participants will receive 1 placebo tablet matching the baricitinib tablet.
224306596|NCT02375620|BIOLOGICAL|PEG-somatropin|
224306597|NCT06218030|DRUG|L-methylfolate|Oral administration of L-methylfolate 15 mg per day for 8 weeks. The study drug will be given in addition to the standard of care (SOC) for GAD.
224306598|NCT06451926|OTHER|Escape room game|Educational escape rooms are live action games where teams use content knowledge to complete tasks and puzzles to reach a final goal, such as escaping from a room or completing a final puzzle
224306599|NCT04685109|DEVICE|Alocross 0.2% Unit Dose|Eye Drops
224306600|NCT04685109|DEVICE|Vismed|Eye drops
224306601|NCT04941729|DEVICE|OR3O™ - Dual Mobility System|OR3O™ Dual Mobility System is comprised of a diffusion-hardened, oxidized zirconium acetabular liner (OR3O™ Liner), and an insert of highly cross-linked polyethylene (OR3O™ XLPE Insert).
224306602|NCT04941729|DEVICE|Conventional|A conventional, single-bearing design Total Hip System comprised of R3™ Acetabular Shell with XLPE liner and a Smith \& Nephew Oxinium (Ox) femoral head.
223617693|NCT01790594|DRUG|methylprednisolone|
224177208|NCT05335785|DEVICE|High-intensity lazer therapy|Patients in the laser group will be given hiltherapy (high-intensity laser) with the HIRO 3 device every other day. One session of laser therapy application consists of 3 phases: the beginning, the middle and the ending phase. The initial phases are fast scanning and the ending phase is slow scanning. A total of 2000 J will be applied to the rotatorcuff muscles, the upper part of the trapezius muscle, the deltoid muscle and the pectoralis major muscle, 1000 J in the rapid scan phase and 1000 J in the finishing phase. In the middle phase, 50 J will be applied for the trigger point (hard intramuscular points that cause referred pain) in each muscle and a maximum of 500 J in total. The total dose prescribed for patients in one session will be 2500 J. Each phase will be 15 minutes on average and the session will last for 45 minutes in total. The laser probe will be applied with 90 degrees. During the application, the practitioner and the patient will have protective glasses.
224177209|NCT05335785|OTHER|Exercises|Exercise program including Codman, Range of motion and streightening exercises three times in a week.
224177210|NCT00793715|PROCEDURE|Decompressive laparotomy with temporary abdominal closure|Surgical intervention including midline incision with temporary abdominal closure and several planed staged relaparotomies
224177211|NCT00793715|PROCEDURE|Percutaneous puncture with placement of abdominal catheter|Installation of abdominal catheter percutaneously via abdominal centesis 2cm bellow the umbilicus
224177212|NCT01503567|OTHER|No treatment given|Subject will only fill out a questionaire
224177213|NCT05686629|DRUG|Jaktinib hydrochloride tablets|2 doses per day, each containing two 50mg Jaktinib or placebo tablets
224177214|NCT06172829|DEVICE|Advantage MX Module|no intervention will be provided.
224177215|NCT00419029|BEHAVIORAL|telephone-administered motivational interviewing|telephone motivational interviewing
224177216|NCT00419029|BEHAVIORAL|control|brief telephone check-in (no motivational interviewing)
224177217|NCT01584115|BIOLOGICAL|NY-ESO-1 combined with MPLA|Each patient will receive six doses of the formulation, administered intra-muscular, with an interval of 4 weeks between doses, and the first immunization performed 6 weeks after the completion of standard treatment. NY-ESO-1 (250 mcg) amd MPLA (100 mcg).
224177218|NCT01584115|BIOLOGICAL|NY-ESO-1 combined with MPLA vaccine|Immunization os cancer patients with NY-ESO-1 combined with MPLA vaccine
224177219|NCT00550615|DRUG|Dasatinib|"Dasatinib will be orally administered once daily for 28 day cycles.~There will be three dose cohorts for the Dasatinib in the Phase I portion of this trial. A minimum of three patients will be enrolled into each of the following dose cohorts:~Dose cohort # 1 will be 100 mg per day Dose cohort # 2 will be 150 mg per day Dose cohort # 3 will be 200 mg per day~The MTD will be determined in the Phase I portion of this trial."
224177220|NCT00550615|DRUG|Dasatinib Maximum Tolerated Dose|An additional 29 patients using the Two-Stage Simon design will be enrolled into Phase II using the MTD determined in Phase I.
224306603|NCT05676918|BEHAVIORAL|Positive Psychology Intervention|PPI includes 2 modules: hedonic well-being and eudaimonic well-being.
224306604|NCT05676918|BEHAVIORAL|Cognitive Behavior Therapy|CBT includes 3 modules: behavioral activation, cognitive restructuring, and interpersonal skills.
223487059|NCT04883853|PROCEDURE|Mild _moderate Ptosis tucking|A modified levator muscle tucking procedure.The level of sutures was determined according to the levator muscle function and the desired eyelid height. The middle (main) suture was taken first at the level of the medial part of the pupil and was tightened to keep the lid height at the superior limbus and the other two sutures (medial and lateral) were then adjusted. A spindle-shaped, horizontal part of the levator aponeurosis (2.5-3 mm wide and 0.5 mm deep) was excised at the site of insertion into the tarsus before tightening the central suture to induce strong fibrosis and adhesion between the tucked levator aponeurosis and the tarsus
223487060|NCT04947501|DRUG|Cyclophosphamide|"Administration of CTV - cycles 1 and 4~Days 1 \& 2: Cyclophosphamide 70 mg/kg/day (2100 mg/m2/day for patients \>10 years old), IV over 6 hrs.~Mesna 70 mg/kg (2100 mg/m2/day for patients \>10 years old) , by 24-hr IV infusion, starting with the cyclophosphamide infusion.~Days 1-4: Topotecan 2 mg/m2/day, IV over 30 minutes. Day 1: Vincristine 0.067 mg/kg (or 2 mg/m2, whichever is less) by IV piggyback; maximum dose is 2 mg.~\*\*\*\*\*\*\* Administration of CDV - cycle 3 Days 1 \& 2: Cyclophosphamide 70 mg/kg/day ((2100 mg/m2/day for patients \>10 years old), IV over 6 hrs.~Mesna 70 mg/kg ((2100 mg/m2/day for patients \>10 years old), by 24-hr IV infusion, starting with the cyclophosphamide infusion.~Days 1-3: Doxorubicin 25 mg/m2/day, by 24-hr IV infusion (total dose over 72 hr is 75 mg/m2).~Days 1-3: Vincristine 0.67 mg/m2/day or 0.022 mg/kg/day (whichever is less), by 24-hr IV infusion (total dose over 72 hr is 2 mg/m2 or 0.067 mg/kg); maximum dose is 0.67 mg/day, or 2mg over 72 hr."
223617694|NCT01790594|BIOLOGICAL|Anti-thymocyte Globulin (Rabbit)|
224306605|NCT03964532|DRUG|Talazoparib|Talazoparib (formerly MDV3800 and BMN673) is an oral small molecule, selective inhibitor of PARP-1 and PARP-2.
224306606|NCT03964532|DRUG|Avelumab|Avelumab (formerly MSB0010718C) is a human immunoglobulin G1 (IgG1) anti-PD-L1 monoclonal antibody131 that utilizes both adaptive and innate immune mechanisms.
224306607|NCT04810871|PROCEDURE|Brain Surgery|Undergo surgery
224306608|NCT05705128|DRUG|Dexmedetomidine|Dexmedetomidine will be given with bupivaciane for postoperative pain control
224306609|NCT06795997|BEHAVIORAL|Tax Conditions|Participants will make hypothetical purchases of tobacco products to use throughout the next 7 days. Participants will complete a total of 21 purchasing trials each for 7 days' worth of products. They will be exposed to 4 conditions with 5 trials each, where products will increase in price: Tobacco Parity, Nicotine-Content, Harm- Reduction, and Modified Risk Tobacco Product-related taxes.
224306610|NCT06795997|BEHAVIORAL|Control Condition|Participants will make hypothetical purchases of tobacco products to use throughout the next 7 days. Participants will complete a total of 21 purchasing trials each for 7 days' worth of products. They will be exposed to a control trial.
224306611|NCT05376696|BEHAVIORAL|Set For Variability|This intervention will focus on training students to use a sound variation of grapheme correspondence rule in order to read an irregular spelling word correctly.
224306612|NCT05376696|BEHAVIORAL|Current Best Practices|This active control intervention will focus on training students to use grapheme-phoneme correspondence rules and sight words in the absence of set-for-variability component
224177221|NCT02136329|DRUG|Sildenafil|"The active study drug, Revatio®, is the citrate salt of sildenafil, a selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type-5 (PDE5). Sildenafil citrate is designated chemically as 1-\[\[3-(6,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo \[4,3-d\] pyrimidin-5-yl)-4-ethoxyphenyl\] sulfonyl\]-4-methylpiperazine citrate.~The active study medication is supplied in single use glass vials and as a clear, colourless, sterile, ready-to-use solution containing 10 mg (12.5 mL) of sildenafil. Each mL of solution contains 1.124 mg sildenafil citrate, 50.5 mg dextrose and water for injection.~Sildenafil is manufactured under Good Manufacturing Practice (EU-GMP) by Pfizer Inc"
224177222|NCT03544385|DRUG|Ringers Solution|Treatment vs Placebo
224177223|NCT03544385|DRUG|Placebo - Concentrate|treatment vs placebo
224177224|NCT02525835|DIETARY_SUPPLEMENT|Low Dietary Sodium|Participants will be randomized to a low sodium diet (50 mmol/24 hours) for 28 days (range allowed 25-31 days) with a 4 week washout period between (range 2-3 weeks).
224177225|NCT02525835|DIETARY_SUPPLEMENT|High Dietary Sodium|Participants will be randomized to a high sodium diet (250 mmol/24 hours) for 28 days (range allowed 25-31 days) with a 4 week washout period between (range 2-3 weeks).
224177226|NCT04194086|DRUG|posaconazole oral suspensions|posaconazole oral suspensions（5mg/kg/d,tid) will be administered specially febrile neutropenia patients four times a day and blood samples will be taken any hours after the first dose at least Day 7.
224177227|NCT04111926|DRUG|Dexmedetomidine|A loading dose of dexmedetomidine (0.6 μg/kg) was administered during a 10-minute period before anaesthesia induction, followed by a continuous infusion at a rate of 0.5 μg/kg/hr till 1 hour before the end of surgery.
224177228|NCT04111926|DRUG|Placebo|Volume-matched normal saline was administered in the same rate for the same duration as in the intervention group.
224177229|NCT01585909|PROCEDURE|Gastroscopy|When gastroscopy is indicated for clinical reasons, duodenal biopsies to determine the activity of the brush border membrane enzymes intestinal alkaline phosphatase, maltase and lactase, as well as assessing brush border morphology are taken
224177230|NCT03266367|DIAGNOSTIC_TEST|Neutrophil gelatinase-associated lipocalin (NAGL)|Serum level of Neutrophil gelatinase-associated lipocalin (NAGL) using the enzyme linked immunosorbent assay kits (ELISA)
224177231|NCT04144933|DRUG|Acetaminophen, Gabapentin|975 mg, 300 mg
224177232|NCT04144933|DRUG|Acetaminophen, Gabapentin|975 mg, 300 mg
224177233|NCT04144933|DRUG|Lidocaine 1% Injectable Solution, Dexmedetomidine, Ketamine|1.5 mg/kg, 0.5 mcg/kg, 0.5 mg/kg
224177234|NCT04144933|DRUG|Dexamethasone, Ondansetron|6 mg, 4 mg
224177235|NCT04144933|DRUG|Sevoflurane, Lidocaine 2% Injectable Solution, Ketamine, Dexmedetomidine, Magnesium Sulfate|Dose titrated to effect, 1.5 mg/kg/hr, 0.15 mg/kg/hr, 0.3 -1 mcg/kg/hr (titrated to effect), 30 mg/kg bolus over 30 minutes
224177236|NCT04144933|DRUG|Lidocaine 1% Injectable Solution, Sufentanil|0.5 mg/kg, 0.25-0.5 mcg/kg (titrated to effect)
223745335|NCT06912932|BEHAVIORAL|Preventive|systematically investigate the acute physiological responses induced by three levels of %Pmax intensities (50% and 75% of Pmax and all-out efforts) with three varying rest periods (15, 30, and 45-s) between thirty 4-s sprints.
224177237|NCT04144933|DRUG|Sevoflurane, Sufentanil|Dose titrated to effect, As needed (dose at anesthesiologist's discretion)
224177238|NCT03013335|DRUG|Nivolumab|"The dose and schedule of nivolumab in this study will be 3 mg/kg every 2 weeks. Infusion of nivolumab will be performed in 30 minutes (± 5 minutes).~Nivolumab will be administered every 2 weeks until death, disease progression, unacceptable toxicity or withdrawal of the informed consent"
223487061|NCT04947501|DRUG|Topotecan|"Administration of CTV - cycles 1 and 4~Days 1 \& 2: Cyclophosphamide 70 mg/kg/day (2100 mg/m2/day for patients \>10 years old), IV over 6 hrs.~Mesna 70 mg/kg (2100 mg/m2/day for patients \>10 years old) , by 24-hr IV infusion, starting with the cyclophosphamide infusion.~Days 1-4: Topotecan 2 mg/m2/day, IV over 30 minutes. Day 1: Vincristine 0.067 mg/kg (or 2 mg/m2, whichever is less) by IV piggyback; maximum dose is 2 mg."
223617695|NCT01790594|DRUG|Tacrolimus|There may be an opportunity to withdraw tacrolimus at week 40
224177239|NCT01896466|DEVICE|Cranial Nerve Non-Invasive Neuromodulation|Portable device delivers electrical stimulation to cranial nerves V and VII via an electrode array placed on the anterior surface of the tongue. Stimulation is combined with rehabilitation exercises targeting walking and balance.
224177240|NCT01896466|BEHAVIORAL|Sham Cranial Nerve Non-Invasive Neuromodulation|Subjects participate in gait and balance rehabilitation exercises while using a device set to sub-threshold levels.
224177241|NCT02405091|DRUG|NBI-98854|
224177242|NCT01742182|OTHER|Light exposure|
224177243|NCT05568966|DIAGNOSTIC_TEST|Venous blood draw|Venepuncture to draw up to 24mL of venous blood.
224177244|NCT05568966|DIAGNOSTIC_TEST|Fingerstick|Capillary blood draw
224177245|NCT06188403|PROCEDURE|Orthognathic surgery (lefort1)|Lefort 1 osteotomy to reposition the maxilla using two different techniques to achieve more accurate results , one with guide for cutting and placing pre bent stock plates and the other method using custom titanium plates with guide for cutting and placing the plate
224177246|NCT00151723|PROCEDURE|treatment with 131I|
224177247|NCT03234257|DEVICE|UF-ultrasound|the carotid plaque stability by UF in order to improve the stroke prediction in case of asymptomatic stenosis. A UF-ultrasound approach is a non-irradiating, easily accessible, and low cost technique
224177248|NCT03371004|DRUG|4-Demethyl-4-cholesteryloxycarbonylpenclomedine|IV administration as described
224177249|NCT01522599|OTHER|ARDS-Net Strategy|Treatment according to the ARDS-Net protocol (The Acute Respiratory Distress Syndrome Network N Engl J Med 2000; 342:1301-1308May 4, 2000)
224177250|NCT01522599|OTHER|ECCO2-R|Ventilation with Tidal Volume of 4 ml/kg PBW and low flow CO2 removal
224177251|NCT01573611|DIETARY_SUPPLEMENT|Grape Powder|36 g of grape powder to be taken twice/day (total of 72 g/day) for 6 months
224177252|NCT01573611|DIETARY_SUPPLEMENT|Placebo Powder|36 g of placebo powder to be taken twice/day (total of 72 g/day) for 6 months
224177253|NCT05801185|OTHER|Unilateral lower limb suspension|Participants will perform a 5-day unloading intervention using the ULLS model. Short-length crutches, aided by handgrip and forearm support distal to the elbow will be used to assist in any upright or ambulatory activity. One foot (randomized in a counterbalance manner) will be equipped with a shoe having a 10-cm thick sole, which permits the unloaded limb to move passively about the hip joint while adopting a near straight position.
224177254|NCT03424616|DEVICE|Suzhou Sceneray® DBS System|We plan to use the SceneRay 1242 (SceneRay, SuZhou, China) electrode with a diameter of 1.27 mm and 4 contacts. The SceneRay 1242 electrode combined with the SceneRay 1181 implantable pulse generator has the advantage of adaptive coverage area for the Ventral Capsule/Ventral Striatum, enabling simultaneous implantation in the nucleus accumbens (NAc; 2 ventral contacts) and the anterior limb of the internal capsule (ALIC; 2 dorsal contacts) with independently programmed parameters such as frequency, amplitude, and voltage; and remote and wireless programing, which allows for convenient and prompt adjustments in emergency situations.
224314205|NCT04327739|OTHER|Intervention 3 Exercise and SMT|"* Exercise programme same as Intervention Group 1 and~* Manipulation Care. Participants allocated to this group received Spinal Manipulation Therapy after the therapeutic exercise programme. Treatment was delivered by 1 chiropractor with a minimum 5-year experience of clinical practice. Pain provocation and static/motion palpation findings were used to determine areas of treatment in the cervical spine. The Manipulation Therapy technique included joint motion using a diversified thrust technique, and mobilization, a low-velocity type of joint oscillation. The type and the force of the applied spinal manipulation were individualized according to the age and physical condition of each participant. Soft passive stretching, light massage and hot packs were applied to the cervical and upper thoracic area before manipulation in order to prepare each participant."
223487062|NCT04947501|DRUG|Vincristine|"Administration of CTV - cycles 1 and 4~Days 1 \& 2: Cyclophosphamide 70 mg/kg/day (2100 mg/m2/day for patients \>10 years old), IV over 6 hrs.~Mesna 70 mg/kg (2100 mg/m2/day for patients \>10 years old) , by 24-hr IV infusion, starting with the cyclophosphamide infusion.~Days 1-4: Topotecan 2 mg/m2/day, IV over 30 minutes. Day 1: Vincristine 0.067 mg/kg (or 2 mg/m2, whichever is less) by IV piggyback; maximum dose is 2 mg."
223487063|NCT04947501|DRUG|Doxorubicin|"Administration of CDV - cycle 3 Days 1 \& 2: Cyclophosphamide 70 mg/kg/day ((2100 mg/m2/day for patients \>10 years old), IV over 6 hrs.~Mesna 70 mg/kg ((2100 mg/m2/day for patients \>10 years old), by 24-hr IV infusion, starting with the cyclophosphamide infusion.~Days 1-3: Doxorubicin 25 mg/m2/day, by 24-hr IV infusion (total dose over 72 hr is 75 mg/m2).~Days 1-3: Vincristine 0.67 mg/m2/day or 0.022 mg/kg/day (whichever is less), by 24-hr IV infusion (total dose over 72 hr is 2 mg/m2 or 0.067 mg/kg); maximum dose is 0.67 mg/day, or 2mg over 72 hr."
223487064|NCT04947501|DRUG|Ifosfamide|Administration of ICE - cycle 2 Days 1-5: Ifosfamide 1500 mg/m2/day (50 mg/kg/day if weight is \<10 kg), IV over 6 hrs. Mesna 1500 mg/m2/day, by 24-hr IV infusion, starting with the ifosfamide infusion. Days 1-2: Carboplatin 400 mg/m2/day (13.3 mg/kg/day if weight is \<10 kg), IV over 1 hr. Days 1-5: Etoposide 100 mg/m2/day (3.3. mg/kg/day if weight is \<10 kg), IV over 2 hrs.
223487065|NCT04947501|DRUG|Etoposide|"Administration of ICE - cycle 2~Days 1-5: Ifosfamide 1500 mg/m2/day (50 mg/kg/day if weight is \<10 kg), IV over 6 hrs. Mesna 1500 mg/m2/day, by 24-hr IV infusion, starting with the ifosfamide infusion. Days 1-2: Carboplatin 400 mg/m2/day (13.3 mg/kg/day if weight is \<10 kg), IV over 1 hr. Days 1-5: Etoposide 100 mg/m2/day (3.3. mg/kg/day if weight is \<10 kg), IV over 2 hrs."
223487066|NCT04947501|DRUG|Carboplatin|"Administration of ICE - cycle 2~Days 1-5: Ifosfamide 1500 mg/m2/day (50 mg/kg/day if weight is \<10 kg), IV over 6 hrs. Mesna 1500 mg/m2/day, by 24-hr IV infusion, starting with the ifosfamide infusion. Days 1-2: Carboplatin 400 mg/m2/day (13.3 mg/kg/day if weight is \<10 kg), IV over 1 hr. Days 1-5: Etoposide 100 mg/m2/day (3.3. mg/kg/day if weight is \<10 kg), IV over 2 hrs."
223487067|NCT04947501|DRUG|Mesna|"Administration of CTV - cycles 1 and 4 Mesna 70 mg/kg (2100 mg/m2/day for patients \>10 years old) , by 24-hr IV infusion, starting with the cyclophosphamide infusion.~Administration of ICE - cycle 2 Mesna 1500 mg/m2/day, by 24-hr IV infusion, starting with the ifosfamide infusion.~Administration of CDV - cycle 3 Mesna 70 mg/kg ((2100 mg/m2/day for patients \>10 years old), by 24-hr IV infusion, starting with the cyclophosphamide infusion."
223487068|NCT03296683|DEVICE|MIRA device imaging|MIRA Device imaging for adjunctive detection of breast cancer
224177255|NCT01009333|DEVICE|InterStim Therapy at rate 5.2 Hz|All subjects enrolled in this study were programmed to this rate setting for a 1-week period.
224177256|NCT01009333|DEVICE|InterStim Therapy at rate 14 Hz|All subjects enrolled in this study were programmed to this rate setting for a 1-week period.
224177257|NCT01009333|DEVICE|InterStim Therapy|All subjects enrolled in this study were programmed to each rate setting (low, medium, high) for a 1-week period.
224177258|NCT00002024|DRUG|Ganciclovir|
224177259|NCT02680366|DEVICE|collagen/ABMNC scaffold|The patients will receive a bone marrow puncture to collect bone marrow cells which are used to isolation of ABMNCs. After that, hysteroscopic adhesiolysis will be done according to the patient's uterine adhesion. Then, the collagen/ABMNCs scaffold was covered on a Foley catheter balloon and placed into the uterine cavity. The catheter balloon was kept for 24 hours and then removed. Oral antibiotics were given to prevent infection in the second and third days after operation. 72 hours after the surgery, a vaginal speculum examinations will be done in order to make patients unknown about their arms. Estrogen will be administrated for 3 cycles to support the endometrial regeneration after the surgery. The clinical follow up will be done at 1, 3 and 6 months after the procedure.
224177260|NCT02680366|DEVICE|Foley catheter balloon|The patients will receive a sham bone marrow puncture which just has a local anesthesia and collects no bone marrow cells to isolation. After that, hysteroscopic adhesiolysis will be done according to the patient's uterine adhesion. And then, a Foley catheter balloon will be placed into the uterine cavity and kept for 72 hours before it is removed. Oral antibiotics were given to prevent infection in the second and third days after operation. Estrogen will be administrated for 3 cycles to support the endometrial regeneration after the surgery. The clinical follow up will be done at 1, 3 and 6 months after the procedure.
224177261|NCT05757466|DRUG|Prolgolimab|Prolgolimab monotherapy 1 mg/kg IV every 2 weeks up to a maximum of 24 cycles
224177262|NCT05757466|DRUG|Combination with prolgolimab and bendamustine|Prolgolimab 1 mg/kg IV D1,15; Bendamustine 90 mg/m2 IV D1,2, 28-day cycle, maximum of 3 cycles;
224177263|NCT03549637|DIAGNOSTIC_TEST|Psychiatric population|Genetic and biological analysis of patients
223487069|NCT04054167|DRUG|Low Dose Radiation Therapy|Undergo ultra low dose radiation
224177264|NCT03986671|DEVICE|Transmembrane EMG Oropharynx Probe|Examination of the electromyographic signal from oropharyngeal muscles obtained using an investigational transmembrane sensor attached to a rigid probe and an FDA-approved very fine concentric needle electrode (Ambu Neuroline 25 mm x 30G).
224177265|NCT00482209|DRUG|Mifepristone, misoprostol|200mg mifepristone followed by 400mcg misoprostol 36-48 hours later
224177266|NCT00482209|DRUG|mifepristone, misoprostol|200mg mifepristone followed by 800mcg misoprostol 36-48 hours later
224177267|NCT01515813|DRUG|Pravastatin sodium|One 40 mg tablet of Pravastatin sodium taken orally once daily.
224177268|NCT01515813|DRUG|Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate|Participant will be administered one tablet of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF)600 mg/200 mg/300 mg taken orally once daily
224177269|NCT01515813|DRUG|Pravastatin sodium|Two 40mg tablets (80 mg total) of Pravastatin sodium taken orally once daily.
224177270|NCT00250094|DRUG|Topotecan and VP16|"Course 1A: On day 1 treatment will start with a continuous infusion of TPT at 0.4 mg/m2/day for 21 days. A pump will be used to deliver the TPT. The bag in the pump will be replaced every week for sterility precautions.~Course 1B: On day 28, if ANC is \>1,500 and platelets \> 100,000, VP-16 will be administered orally at 50 mg/day for 14 days."
224177271|NCT01768039|DRUG|Vitamin D|
224177272|NCT01768039|DRUG|Placebo|
224177273|NCT06028893|DIAGNOSTIC_TEST|Heart rhythm measurements with FibriCheck®|Measurements are performed twice daily, starting 4 weeks before a pulmonary vein isolation procedure (PVI) and ending 4 weeks after the PVI.
224177274|NCT06028893|DIAGNOSTIC_TEST|Heart rhythm measurements with Kardia Mobile®|Measurements are performed immediately before and after every FibriCheck® measurement.
224177275|NCT03459105|PROCEDURE|Ultrasound-assisted paramedian spinal anesthesia|A preprocedural ultrasound scanning will be done, and skin marking will be made. The needle entry point and insertion angle will be determined based on ultrasound scanning. Spinal anesthesia will be performed via paramedian approach.
224177276|NCT03459105|PROCEDURE|Landmark-guided spinal anesthesia|Spinal anesthesia will be done using conventional landmark-guided technique.
224177277|NCT03459105|DRUG|0.5% heavy bupivacaine|0.5% heavy bupivacaine will be administered into intrathecal space. The dose of local anesthetic injected for spinal anesthesia will be at the discretion of the attending anesthesiologist. The dose range of intrathecal bupivacaine will be between 12 and 16 mg.
224177278|NCT01700127|OTHER|Breastfeeding|breastfeeding encouraged versus withheld
224177279|NCT02074436|DRUG|EACA|EACA 1000 mg twice a day. Patients will receive platelet transfusion in case of grade ≥ 2 bleeding.
223487070|NCT02099058|DRUG|Osimertinib|It is administered orally everyday.
223487071|NCT02099058|DRUG|Nivolumab|It is an intravenous infusion administered every 14 days.
223487072|NCT02099058|DRUG|Telisotuzumab vedotin|It is administered by infusion in 21-day dosing cycles.
223487073|NCT02099058|DRUG|Telisotuzumab vedotin|It is administered by infusion in 28-day dosing cycles.
223586789|NCT02297165|BEHAVIORAL|olfactory stimulation program|"8 individual sessions of olfactory stimulation at the rate of 2 sessions per week. 3 semi-directed interviews will be help (one at the beginning of the trial, the second 5 weeks later and the third at 6 month).~For each session, patients have to smell two different odors (previously selected from a panel presented to the patient during first visits) and then they are invited to evoke memories and feelings related to each odor."
224177280|NCT02074436|OTHER|Platelet transfusion|Prophylactic platelet transfusion. Additional platelet transfusions will be administered in case of grade ≥ 2 bleeding.
224177281|NCT02401945|DRUG|DE-120|
223487074|NCT02099058|DRUG|Erlotinib|It is administered orally everyday.
223487075|NCT05041127|BIOLOGICAL|Cetuximab|Given IV
223487076|NCT05041127|OTHER|Questionnaire Administration|Ancillary studies
223487077|NCT01155765|DRUG|Prasugrel|Prasugrel 10 mg/day for 15 days
223586790|NCT04596085|DIETARY_SUPPLEMENT|Investigational Product - ViraCide|Viracide
223586791|NCT04596085|OTHER|Placebo - Starch Powder Soft gels|Starch Powder Soft gels
223586792|NCT02940483|DRUG|5-Azacytidine|5-Azacytidine 10 mg into the fourth ventricle of the brain via the Ommaya reservoir 1 day a week for 12 weeks.
224177282|NCT02401945|DRUG|Aflibercept|
224177283|NCT04065464|DEVICE|Ava Fertility Tracker|All women aged 18 to 40 years using Ava Fertility Tracker to track their cycles.
224177284|NCT02522091|DEVICE|functional brain MRI|
223487078|NCT01155765|DRUG|Clopidogrel|Clopidogrel 150 mg/day for 15 days
223487079|NCT05076838|DRUG|Diazepam Nasal Spray [Valtoco]|5 mg, 10 mg, or 15 mg dose of intranasal VALTOCO will be administered based on the subject's body weight.
223487080|NCT03662373|RADIATION|carbon ions radiation therapy|Carbon ion radiation therapy to treat adenoid cystic carcinoma, skull base (clivus) chordoma.
223487081|NCT03662373|RADIATION|protons radiation therapy|Proton radiation therapy used to treat meningioma and squamocellular rhinopharynx carcinoma
223487082|NCT01738958|BIOLOGICAL|L. retueri|two tablets a day for 6 weeks
223487083|NCT01738958|BIOLOGICAL|Placebo|
223487084|NCT00157755|DEVICE|Enterra Therapy|Gastric electrical stimulation using Enterra Therapy.
223487085|NCT02141555|DRUG|Vaginal Misoprostol|Misoprostol inserted into vagina
223487086|NCT02141555|DRUG|Buccal Misoprostol|Misoprostol placed between the gum and cheek and allowed to dissolve for 30 minutes with the remnants swallowed after this time.
223487087|NCT01217346|OTHER|no intervention is involved in this study|no intervention is involved in this study
224177285|NCT02522091|OTHER|Neuropsychology tests|
224177286|NCT04371757|DRUG|α1-adrenergic block|Ninety minutes before starting the experimental exercise protocol, participants will be offered a capsule containing an α-1 adrenoreceptor blocker (Drozazosin; 0.05 mg / kg-1 body weight) and will be instructed to lie down. All capsules will be handled by a specialized pharmacy.
224177287|NCT04371757|OTHER|Placebo|Ninety minutes before starting the experimental exercise protocol, participants will be offered a capsule containing an placebo (microcrystalline cellulose; 0.05 mg.kg-1 body weight) and will be instructed to lie down. All capsules will be handled by a specialized pharmacy.
224314206|NCT04327739|OTHER|Control|Participants allocated to this group received general consulting istructions and a home based general exercise sheet
224177288|NCT03041493|BEHAVIORAL|Electronic cigarette|During the first encounter, blood pressure and endothelium-dependent relaxation (EDR) will be measured by flow mediated dilatation (FMD), and a small peripheral IV catheter will be placed in the participant's median antecubital or cephalic vein. A blood sample (10 mL) for EPCs and F2-isoprostanes will be collected. One urine sample will also be collected for measurement of urinary F2-isoprostanes, cotinine and creatinine. These will serve as both baseline measures for subsequent acute exposure to nicotine and as measures of chronic nicotine exposure. The second encounter will be scheduled 4 hours after the first encounter. At that time a blood sample (5 mL) for EPCs will be collected followed by harvesting of vascular endothelial cells for eNOS and NF-κB expression.
224177289|NCT03041493|BEHAVIORAL|traditional cigarette|During the first encounter, blood pressure and endothelium-dependent relaxation (EDR) will be measured by flow mediated dilatation (FMD), and a small peripheral IV catheter will be placed in the participant's median antecubital or cephalic vein. A blood sample (10 mL) for EPCs and F2-isoprostanes will be collected. One urine sample will also be collected for measurement of urinary F2-isoprostanes, cotinine and creatinine. These will serve as both baseline measures for subsequent acute exposure to nicotine and as measures of chronic nicotine exposure. The second encounter will be scheduled 4 hours after the first encounter. At that time a blood sample (5 mL) for EPCs will be collected followed by harvesting of vascular endothelial cells for eNOS and NF-κB expression.
224177290|NCT03041493|BEHAVIORAL|(sham cigarette) - no actual exposure to cigarettes|During the first encounter, blood pressure and endothelium-dependent relaxation (EDR) will be measured by flow mediated dilatation (FMD), and a small peripheral IV catheter will be placed in the participant's median antecubital or cephalic vein. A blood sample (10 mL) for EPCs and F2-isoprostanes will be collected. One urine sample will also be collected for measurement of urinary F2-isoprostanes, cotinine and creatinine. These will be compared to the second set of laboratory measurements done at the second encounter that will be scheduled 4 hours after the first encounter. At that time an additional blood sample (5 mL) for EPCs will be collected followed by harvesting of vascular endothelial cells for eNOS and NF-κB expression.
224177291|NCT03859115|PROCEDURE|TENS (transcutaneous electrical nerve stimulation)|transcutaneous nerve stimulation with electrical pulse generation
224177292|NCT03859115|PROCEDURE|sham intervention|sham stimulation without electrical pulse generation
224177293|NCT02169466|DRUG|BIA 9-1067|OPC, Opicapone
224177294|NCT02169466|DRUG|Placebo|PLC, Placebo
224177295|NCT02169466|DRUG|Madopar® HBS|controlled-release levodopa 100 mg/benserazide 25 mg
224177296|NCT03975816|DEVICE|Analgesia nociception index|Monitor the maternity with Analgesia nociception index
224177297|NCT06336694|PROCEDURE|surgery or diagnostic staging laparoscopy|diagnosis of PDAC with peritoneal examination based on the surgical (for tumors treated with surgery) or diagnostic staging laparoscopy findings (for tumors treated with radiotherapy/chemotherapy)
224177298|NCT02033824|OTHER|dHACM|A piece of dHACM placed over any dural defect or dural closure during craniectomy.
223487088|NCT06034743|DRUG|Baxdrostat|"Baxdrostat tablet administered orally, once daily (QD). Unit dose strengths:~* 1 mg per tablet for 1 mg baxdrostat Arm;~* 2 mg per tablet for 2 mg baxdrostat Arm."
223487089|NCT06034743|DRUG|Placebo|Placebo tablet matching baxdrostat, administered orally, once daily (QD).
224177299|NCT02033824|PROCEDURE|Craniectomy|Removal of the skull flap followed by closure techniques per current SOC.
224177300|NCT01694966|DRUG|Methylene Blue MMX®|
224177301|NCT01694966|DRUG|Placebo|Sugar pill manufactured to mimic Methylene Blue MMX® tablet.
224177302|NCT01978548|DRUG|JNJ-54861911 10 mg|JNJ-54861911 10 mg will be administered as two 5 mg oral tablets once daily.
224177303|NCT01978548|DRUG|JNJ-54861911 50 mg|JNJ-54861911 50 mg will be administered as two 25 mg oral tablets once daily.
224177304|NCT01978548|DRUG|Placebo|Matching placebo will be administered as 2 oral tablets once daily.
224177305|NCT03653286|OTHER|NMES and Run|"NMESIn this exercise protocol for quadriceps strengthening using NMES, the medium-frequency alternating current (1KHz with 10% of the work cycle) 4 will be used. The total daily training time is 900sec (15min), it is expected to perform 45 contractions per training, with three workouts per week for six weeks.~RUN: It will be allowed to carry out training drills that comprise 15-40Km per week, being allowed a minimum of 2 and a maximum of 3 training sessions per week, not being able to carry out drills of explosion and during each training must be covered at least 5km and at most 15km. These limitations were based on the American College of Sports Medicine (ACSM) cardiorespiratory training guidelines to minimize confounders of cardiopulmonary performance."
224177306|NCT03653286|OTHER|Only Run|RUN: It will be allowed to carry out training drills that comprise 15-40Km per week, being allowed a minimum of 2 and a maximum of 3 training sessions per week, not being able to carry out drills of explosion and during each training must be covered at least 5km and at most 15km. These limitations were based on the American College of Sports Medicine (ACSM) cardiorespiratory training guidelines to minimize confounders of cardiopulmonary performance.
224177307|NCT04748250|DEVICE|Acupuncture needles|Standard acupuncture needle which is 3 cm long with diameter o.3 mm
224177308|NCT04748250|DIETARY_SUPPLEMENT|Soy phytoestrogens|100 millilitre of soy milk every day or 100 gram of cooked soy beans per day.
224177309|NCT04068220|OTHER|intraoperative FVEPs monitoring|During the surgery, a pair of goggles (similar to the swimming goggles) will be placed on patient's closed eyes. The goggles equipped with red LEDs will apply no pressure or minimal pressure on patient's closed eyes. Patient's left eye then right eye will be stimulated with flashing red light emitted by the goggles. Two subdermal needle electrodes will be placed under the skin behind patient's ears, and one subdermal needle electrode will be placed under the skin above the bridge of patient's nose. The two electrodes placed behind patient's ears, will record intraoperative flash visual evoked potentials (FVEPs) resulted from red light stimulation of patient's visual pathway through the eyes and the electrode above the bridge of the nose will record, at the same time, the activity of each eye's retina.
223487090|NCT04098003|DRUG|Rosuvastatin|rosuvastatin 20 mg daily or placebo for eight weeks
223487091|NCT04098003|DRUG|Placebo|Matched placebo control
223586793|NCT04356482|BIOLOGICAL|convalescent plasma|"In phase 1, different amounts of convalescent plasma will be evaluated depending on the severity of the case.~In phase 2, both clinical, laboratory, imaging and viral presence (effectiveness) and safety will be evaluated."
224177310|NCT03583502|DIETARY_SUPPLEMENT|krill oil and fish oil supplement|Administration of 2 gelatin soft capsules per day of a combined krill and fish oil supplement, providing 250 mg/day of DHA and 70 mg/day of EPA, for overall 30 days.
224177311|NCT04576390|DRUG|Ondansetron 4 mg|Antiemetic drug
224177312|NCT04576390|DRUG|Palonosetron 75 mcg|Antiemetic drug
223487092|NCT06344364|DIAGNOSTIC_TEST|Digital Pathology FibroNest Phenotypic Fibrosis Composite Score (Ph-FCS)|Biomarker name: FibroNest Phenotypic Fibrosis Composite Score Acronym: FibroNest Ph-FCS Type of Biomarker: Histologic based, Digital, Quantitative Image Analysis, Imaging modality Definition: A quantitative, normalized (no unit) and continuous composite score that aggregates quantitative histological features of fibrosis severity measured by high resolution quantitative image analysis.
223487093|NCT00432822|DRUG|tetrahydrobiopterin (BH4)|
223487094|NCT04808921|DIAGNOSTIC_TEST|Xiamen Wiz Biotech Co., Ltd. SARS-CoV-2 Antigen Rapid Test|Rapid Antigen diagnostic device performance comparative to RT-PCR
223487095|NCT05277207|BEHAVIORAL|Personalized Smoking Cessation Facilitation Meetings|Participants will participate in 5-7 meetings in which they will receive cognitive-behavioral therapy for tobacco cessation.
223487096|NCT05277207|DRUG|Personalized Smoking Cessation Pharmacotherapy|Participants may receive pharmacotherapy for smoking cessation based on VA Pharmacy Benefits Management Services guidelines. Medications may include nicotine-replacement therapy, varenicline, and/or bupropion.
223487097|NCT05277207|BEHAVIORAL|Personalized Text Messaging Support|If the participant has a working cell phone and is willing to receive text messages, supportive, personalized text messages will be sent to the participant starting after Session 1 and extending through 6 months post-quit using VA's Annie texting capability.
223487098|NCT05277207|BEHAVIORAL|SmokefreeVET|Participants will receive a referral to SmokefreeVET, a text-messaging intervention designed to help veterans prepare for and attempt quitting smoking.
223487099|NCT05277207|BEHAVIORAL|VA Quitline|Participants will receive a referral to VA Quitline, which is a nationally available telehealth intervention that provides assistance to veterans who wish to quit tobacco use. Quitline includes five sessions of cognitive-behavioral treatment.
223487100|NCT05277207|OTHER|Education about pharmacotherapy|Participants will receive a handout that provides them with information about pharmacotherapies for tobacco cessation.
223487101|NCT02770703|DEVICE|DynaMesh visible mesh|Implantation of a MRI visible mesh
223487102|NCT06377514|DEVICE|Test IOL Model DEN00V|Eligible subjects will be randomized in a 1:1 ratio to receive the Test IOL Model DEN00V in both eyes for the duration of the study
223487103|NCT06377514|DEVICE|Control IOL Model DCB00|Eligible subjects will be randomized in a 1:1 ratio to receive the control IOL Model DCB00 in both eyes for the duration of the study
223487104|NCT06645093|OTHER|Fasting|Fasting implies 0 kilojoule. Water ad libitum is permitted.
223487105|NCT05523297|DRUG|Octaplex|Prothrombin complex concentrate
223487106|NCT05523297|DRUG|Frozen Plasma Product, Human|If additional treatment is required after the maximum dose of IMP is administered or the treatment period has elapsed, patients in both groups will receive frozen plasma
223487107|NCT04014777|BIOLOGICAL|NGM621|NGM621 Dose 1
223487108|NCT04014777|BIOLOGICAL|NGM621|NGM621 Dose 2
223487109|NCT04014777|BIOLOGICAL|NGM621|NGM621 Dose 3
223487110|NCT04014777|BIOLOGICAL|NGM621|NGM621 Dose 4
223487111|NCT04847024|DRUG|Parecoxib|40 mg IV
223487112|NCT04847024|DRUG|Dexketoprofen|50 mg IV
223487113|NCT03347643|DEVICE|tDCS with real stimulation|tDCS is a non-invasive brain stimulation. Real stimulation includes 2mA current for 20 minutes per session. Two sessions a day for 5 consecutive days (Total: 10 sessions) will be applied.
223487114|NCT03347643|DEVICE|tDCS with sham stimulation|Sham stimulation includes 0mA current for 20 minutes per session. Two sessions a day for 5 consecutive days (Total: 10 sessions) will be applied.
223487115|NCT03462680|DIETARY_SUPPLEMENT|niacin|Niacin or nicotinic acid 250 mg tablets
223487116|NCT03462680|OTHER|placebo|placebo tablet
223487117|NCT03203785|DIETARY_SUPPLEMENT|Carbohydrate (maltodextrin)|maltodextrin flavored
223487118|NCT03203785|OTHER|Placebo|non-caloric drink
223487119|NCT04225975|DIAGNOSTIC_TEST|electroencephalogram|Within the 5 min after birth the electroencephalogram of the neonates will be recorded with the aid of a patch on the scalp
223586794|NCT04093804|DEVICE|Glenosphere size for Reverse Shoulder Arthroplasty|Two randomized study groups will be formed with the consented patients (experimental and control). All patients will undergo reverse shoulder arthroplasty by the Principal Investigator. The experimental group patients will receive a 36mm glenosphere and the control group will receive a 32mm glenosphere. All other procedures during the surgery are identical between groups.
224177313|NCT04084210|DEVICE|Juul Electronic cigarette|The juul e-cigarette pods contain 0.7 ml nicotine by volume / 5% nicotine by weight.
223487120|NCT04225975|DIAGNOSTIC_TEST|oxymetry|Within the 5 min after birth the cerebral oxymetry of the neonates will be recorded with the aid of a patch on the scalp
224177314|NCT04084210|OTHER|Very Low Nicotine Cigarettes|These very low nicotine cigarettes (VLNCs) consist of reduced nicotine cigarettes containing 0.03 mg of nicotine; these VLNCs were obtained from National Institute on Drug Abuse (NIDA's) Drug Supply Program (NOT-DA-14-004).
223487121|NCT02333643|DRUG|CLS003|
223487122|NCT02333643|DRUG|Furosemide|
223487123|NCT02333643|DRUG|Digoxin|
223487124|NCT02333643|DRUG|Vehicle topical|
223487125|NCT05345080|BEHAVIORAL|Exposure-Reduction Intervention|The customized exposure-reduction intervention includes a phone-based telehealth visit, collection of self-report information from detailed health and exposure questionnaires, asthma education, assessment for allergies (optional), and a customized asthma self-management and exposure-reduction plan developed using motivational interviewing techniques, support, and exposure-reduction supplies.
223487126|NCT02270268|DIETARY_SUPPLEMENT|Pectin|Pectin （Andeli Ltd. Yantai, China）, 24g/d for six weeks
223487127|NCT02270268|DIETARY_SUPPLEMENT|maltodextrin|
223487128|NCT02576496|DRUG|Tinostamustine|
223487129|NCT02246777|DEVICE|Ex-PRESS® Glaucoma Filtration Device, Model P50PL|
223487130|NCT05844046|BIOLOGICAL|durvalumab, tremelimumab, bevacizumab|durvalumab, tremelimumab and bevacizumab will be administered in the respective arms either as up-front triple treatment or as combined treatment with durvalumab and tremelimumab followed by the addition of bevacizumab
224177315|NCT04084210|DRUG|Active Nicotine Patch|Active nicotine patches, with dosing based on the package insert (\>10 cigs/day = 21 mg patch and \<11 cigs/day = 14 mg patches).
224177316|NCT04084210|OTHER|Placebo Patch|Placebo patch containing no nicotine.
224177317|NCT02715635|BIOLOGICAL|Typhoid vaccine|The typhoid vaccine is composed of purified polysaccharide from S. typhi capsule 25 micrograms contained in 0.5 ml solution
224177318|NCT02715635|DIETARY_SUPPLEMENT|Concentrate beetroot Juice|140 ml containing \~8 mmol of inorganic nitrate
224177319|NCT02715635|DIETARY_SUPPLEMENT|Concentrate beetroot Juice (Placebo)|140 ml which is nitrate-depleted
224177320|NCT05823155|PROCEDURE|Detailed penicillin allergy evaluation|The intervention group will undergo a detailed penicillin allergy evaluation performed by an Infectious Diseases specialist. Components of penicillin allergy evaluation include verification of allergy history (drug involved including dose and route of administration, exact manifestation of labelled allergy and timing of occurrence after use of alleged culprit, history of skin tests or in vitro testing for diagnosis of allergy, subsequent rechallenge of the same or similar antibiotics), followed by skin test (prick test and intradermal test) and oral provocation test as appropriate.
224177321|NCT01881724|BEHAVIORAL|Sleep education|
224177322|NCT05779280|OTHER|THDA + Acetyl Zingerone Topical Product|A skin care product with Acetyl Zingerone (Synoxyl® AZ) and THDA (VitaSynol® C) used twice daily
224177323|NCT05779280|OTHER|THDA|A skin care product with THDA (VitaSynol® C) used twice daily
224177324|NCT04726943|PROCEDURE|Radiofrequency Energy Applications|RF energy applications to the atrial edge of a leak resulting from incomplete LAA occlusion
224177325|NCT02924922|PROCEDURE|Laparoscopic partial nephrectomy|The renal hilus is identified and both vein and artery are dissected. A laparoscopic ultrasound probe is introduced through a 12 mm port to define the tumor resection margins. A laparoscopic Satinsky clamp is used to induce total kidney ischemia, clamping both vein and artery. Athermal resection of the tumor is performed and titanium clips are used to close interlobar or arcuate arteries encountered during resection. The defect is closed with stitches secured by Hem-o-Lok clips and haemostatic glue. Ischemia is interrupted once renorrhaphy is completed
224306613|NCT06185959|BEHAVIORAL|Psychoeducation and Process Group for Asian and Asian American Psychiatric Outpatients|Participants will be individuals enrolling in a 1.5 hour weekly therapy group lasting 12 weeks and will be invited to participate in research on group processes and outcomes. The psychoeducation and process group will be a 12-session weekly closed group with 10-15 participants per group (2-3 groups total) conducted via Zoom to enhance accessibility and reduce barriers to care. Groups will be co-led by licensed clinical psychologists with experience providing both group psychotherapy and culturally responsive services. Group sessions will include brief check-ins, collaborative agenda-setting, a mini-didactic, individual reflection, and group discussion. The didactics curriculum will include topics such as intergenerational trauma, cultural differences in emotional expression, the model minority myth, family dynamics, racism, and positive connections to culture.
223487131|NCT00439621|BIOLOGICAL|RP 01|Active immunotherapy
223487132|NCT00182819|DRUG|temozolomide|Temozolomide 75 mg/m2 daily x 21 days, q 28 days until progression or for max. 12 cycles
223487133|NCT00182819|RADIATION|radiation therapy|50.4 Gy, standard fractionation (28 x 1.8 Gy), conformal techniques
223487134|NCT00825006|DEVICE|Triple site pacing mode|"The experimental Triple site pacing mode includes pacing with Cardiac resynchronization therapy device using two leads; one in the right ventricle (RV) and one in the left ventricle (LV) but stimulates three sites: LV tip, RV tip and RV ring (instead of the usual two sites: LV tip and RV ring.~Patients with evidence of improved LV dyssinchrony parameters during the triple pacing mode (anodal stimulation) will be programmed to anodal stimulation for 3 months."
223487135|NCT00498303|BIOLOGICAL|trivalent split influenza vaccine|
223487136|NCT00870701|RADIATION|Radiotherapy|50 grays in 25 fractions of 2 Gys or 50.4 grays in 28 fractions of 1.8 grays
223487137|NCT00870701|OTHER|absence of radiotherapy|absence of radiotherapy
223487138|NCT00916734|PROCEDURE|MDT (McKenzie Method)|Subjects who perform exercises in their direction of preference.
223487139|NCT00916734|PROCEDURE|Spinal thrust manipulation|Subjects who receive spinal thrust manipulation as an intervention.
223487140|NCT04133909|BIOLOGICAL|Mepolizumab|Mepolizumab was a sterile liquid formulation. It was administered as a subcutaneous injection (100 milligrams per milliliter \[mg/mL\]) delivered once every 4 weeks using a pre-filled safety syringe.
223487141|NCT04133909|DRUG|Placebo|Placebo was a 0.9% sodium chloride solution. It was administered as a subcutaneous injection delivered once every 4 weeks using a pre-filled safety syringe.
223487142|NCT06405919|DIAGNOSTIC_TEST|Histopathology|Thyroidectomy for patients and histological examination of specimen to determine incidence of malignancy.
223586795|NCT06459882|BEHAVIORAL|progressive relaxation exercises|Patients in the intervention group received 30-minute progressive relaxation exercises for 6 weeks
223586796|NCT01205477|DRUG|EXPERIMENTAL|Infiltration of 40 mg of methylprednisolone acetate plus 1 mL of xylocaine and Diclofenac sodium 100 mg PO QD for 10 days
223487143|NCT00493675|PROCEDURE|endoscopic bile duct stenting|
223487144|NCT02860052|DRUG|SB208 2%|Apply once daily to one or both feet for 14 days
223487145|NCT02860052|DRUG|SB208 4%|Apply once daily to one or both feet for 14 days
223487146|NCT02860052|DRUG|SB208 16%|Apply once daily to one or both feet for 14 days
223487147|NCT02860052|DRUG|Vehicle Gel|Apply once daily to one or both feet for 14 days
223487148|NCT06252207|DRUG|Desflurane|General anesthesia with desflurlane
223487149|NCT06252207|DRUG|Isoflurane|General anesthesia with isoflurane
223487150|NCT04356833|DRUG|Nebulised recombinant tissue-Plasminogen Activator (rt-PA) - Cohort 1|"Patients in the rt-PA group received the first dose as soon as possible after registration.~Initial dosing regime: 10 mg of rt-PA dissolved in 5 ml of diluent given every 6 hrs (resulting in a total daily dose of 40mg) for a maximum of 66 hrs, in addition to standard of care for COVID-19 acute respiratory distress syndrome (ARDS). Following protocol amendment, dosing duration was increased from 3 days to up to 14 days of rt-PA treatment."
223586797|NCT01205477|DRUG|PLACEBO|Infiltration of 1 mL of xylocaine and Diclofenac sodium 100 mg PO QD for 10 days
223586798|NCT01146964|PROCEDURE|MSSICS|Manual super small incision cataract surgery
224177326|NCT02924922|PROCEDURE|Robot assisted partial nephrectomy|The renal hilus is carefully dissected, so that the arterial segmental branches are reached. Tumor resection margins are identified through ultrasound. Drop-in bulldog clamps are used to clamp segmental arterial branches and induce selective ischemia. Indocyanine green 0.2-0.3mg/KG is infused intravenously a few seconds after the selective ischemia is induced. The Firefly near infra-red fluorescence system is used to determine the extent of the ischemic area. The ischemic zone can now be tailored to the tumor by adding or removing bulldog clamps according to the vascular anatomical conditions. Athermal resection of the tumor is performed and titanium clips are used to close interlobar or arcuate arteries encountered during resection. The resection defect is closed with stitches secured by Hem-o-Lok clips and haemostatic glue. Selective ischemia will be interrupted once renorrhaphy is completed
224177327|NCT02924922|DEVICE|Conventional laparoscopic instruments|Endoscope, Scissor, Needleholder, Forceps, Suction unit, Ports, Tissel, CO2, Sutures, Needles, Scalpel, Ultrasound-Probe, Monitors
224177328|NCT02924922|DEVICE|Da- Vinci Robot and conventional laparoscopic instruments|Da Vinci Robot, Console, Ports and Instruments; Suction unit, Forceps, Tisseel, Ultrasound Probe, Monitors
224177329|NCT02924922|DRUG|Mannitol|
224177330|NCT00114764|DRUG|filgrastim|Filgrastim given daily after induction chemotherapy
224177331|NCT00114764|DRUG|pegfilgrastim|Pegfilgrastim given once after induction chemotherapy
224177332|NCT00743041|BEHAVIORAL|Emotional Freedom Techniques (EFT)|EFT is an exposure therapy with a cognitive component, consisting of recall of a trauma along with a statement of self-acceptance, in combination with touching or tapping on a series of stress reduction points on the body
224177333|NCT05122442|OTHER|Patients with inherited retinal disease|Patients with inherited retinal disease
224177334|NCT01955005|BEHAVIORAL|My HealtheVet Training|Participants will be asked to watch an on-line training video, review written materials, and print a document containing health information from their My HealtheVet account.
224177335|NCT01955005|OTHER|Internet Skills Training|Participants will review written training materials to learn how to search the Internet for health information and how to decide which Internet sites have good quality information.
224177336|NCT02555722|DEVICE|fanfilcon A (test)|silicone hydrogel lens
224177337|NCT02555722|DEVICE|enfilcon A (control)|silicone hydrogel lens
224177338|NCT00352027|DRUG|Adriamycin®|Given IV on Day 1 of weeks 1, 3, 5, 7, 9 and 11.
224177339|NCT00352027|DRUG|Vinblastine|Given IV, Day 1 of weeks 1, 3, 5, 7, 9 and 11.
224177340|NCT00352027|DRUG|Nitrogen Mustard|Given IV, Day 1 of weeks 1, 5 and 9. Cyclophosphamide may be substituted if nitrogen mustard is unavailable.
224306614|NCT06193772|BEHAVIORAL|Internet-delivered psychodynamic therapy (IPDT)|"IPDT consists of 8 therapist-supported self-help modules delivered over 10 weeks on a secure online platform. Modules consist of texts and video followed by assignments which they send to their therapist and receive feedback within a few days. The intervention IPDT adapted starts with therapist feedback about the patient's predicted progress and continues with adapting the treatment to the individual adolescent, for example adding text chat sessions."
223487151|NCT04356833|DRUG|Nebulised recombinant tissue-Plasminogen Activator (rt-PA) - Cohort 2 IMV|Patients on IMV received 60mg daily over three doses for up to 14 days
223487152|NCT04356833|DRUG|Nebulised recombinant tissue-Plasminogen Activator (rt-PA) - Cohort 2 NIV|NIV patients received 60mg daily over 3 doses for two days, followed by 12 days receiving 40mg daily over two doses.
223487153|NCT06207799|DRUG|Elranatamab|Given by SC
223487154|NCT06207799|DRUG|Lenalidomide|Given by PO
223487155|NCT06207799|DRUG|Plerixafor|Given by SC
223487156|NCT06207799|DRUG|Melphalan|Given by IV
223586799|NCT01146964|PROCEDURE|Phacoemulsification|cataract surgery with Phacoemulsification
223487157|NCT06207799|DRUG|Busulfan|Given by PO
223487158|NCT06207799|DRUG|G-CSF|Given by IV
224177341|NCT00352027|DRUG|Cyclophosphamide|May be substituted if nitrogen mustard is unavailable. Given on Day 1 of weeks 1, 5 and 9.
224177342|NCT00352027|DRUG|Vincristine|Given IV on Day 1 of weeks 2, 4, 6, 8, 10 and 12.
224177343|NCT00352027|DRUG|Bleomycin|Given IV on Day 1 of weeks 2, 4, 6, 8, 10 and 12.
224177344|NCT00352027|DRUG|Etoposide|Given IV on Days 1 and 2 of weeks 1-10.
224177345|NCT00352027|DRUG|Prednisone|Given PO every other day of weeks 1-12.
223487159|NCT06207799|PROCEDURE|Stem cell transplant|Given by IV
223586800|NCT02259985|DRUG|Itasetron tablet|
224177346|NCT00352027|BIOLOGICAL|G-CSF|Given subcutaneously days 3-13, 16-26, 29-39, 42-52, 55-65, and 68-78 (as clinically indicated).
224177347|NCT00352027|PROCEDURE|Radiotherapy|Participants receive radiotherapy after completion of 12 weeks of Stanford V chemotherapy.
224177348|NCT04723342|DRUG|Blinatumomab|"Blinatumomab, intravenously, as continuous 24 hours infusion 1-7 days - 5 μg/m2/day, 8-28 day - 15 μg/m2/day~1 course after induction treatment"
223487160|NCT04817410|DRUG|Emergency Department Initiated Oral Naltrexone|Emergency Department Initiated Oral Naltrexone
223487161|NCT01985984|RADIATION|Radiation alone|Radiation alone
223586801|NCT02259985|DRUG|Itasetron infusion|
223586802|NCT02259985|OTHER|high fat breakfast|
223586803|NCT01081639|DRUG|Follitropin alfa liquid formulation|Follitropin alfa (Gonal-f) liquid pen (300, 450 and 900 IU) was applied by subcutaneous (sc) administration. Regimen of recombinant FSH-stimulation followed the standard protocol of the IVF-center
223586804|NCT01081639|DRUG|Follitropin beta liquid formulation|Follitropin beta (Puregon) liquid cartridge (300 and 600 IU) used with the Pen was applied by sc administration. Regimen of recombinant FSH-stimulation followed the standard protocol of the IVF-center
224177349|NCT00155246|DRUG|pentoxifylline (drug)|
224177350|NCT03181139|OTHER|ERAS pathway for Total Mastectomy|Enhanced Recovery after Surgery (ERAS) pathway for Total Mastectomy
224177351|NCT01238757|OTHER|Non-invasive Ventilation under Pressure Support|"Non-invasive Ventilation under Pressure Support:~15 min with initial settings, 5 min with ETS-%%, 5 min with ETS+10%, in random order"
224177352|NCT01238757|OTHER|Non-Invasive ventilation under NAVA|20 min session under non-invasive ventilation with NAVA
224177353|NCT01884155|PROCEDURE|Allogeneic umbilical cord blood therapy|
224177354|NCT02238392|PROCEDURE|Adenosine test|Testing dormant conduction after PVI
224177355|NCT02238392|PROCEDURE|Termination of AF|Testing AF iducibility and ermination of
224177356|NCT05504018|PROCEDURE|ACL reconstruction|Anterior cruciate ligament reconstruction surgery
223487162|NCT01985984|RADIATION|Radiation in combination with systemic therapy|Radiation in combination with systemic therapy
223487163|NCT06517576|DEVICE|Blood glucose monitor with Digital Platform and Health Coaching|Blood glucose monitors will be used daily to measure blood glucose measurements.
223487164|NCT06517576|DEVICE|Continuous glucose monitor|Continuous glucose monitors will be used daily to measure blood glucose measurements.
223487165|NCT06517576|OTHER|Usual Care|Usual care for type 2 diabetes
223487166|NCT05504070|DEVICE|Venclose System (digiRF generator w EVSRF catheter)|The Venclose System is intended for use in endovascular coagulation of blood vessels in patients with superficial vein reflux.
223487167|NCT05504070|DEVICE|Venclose MAVEN System (digiRF generator w MAVEN catheter)|The Venclose MAVEN System is intended for use in endovascular coagulation of blood vessels in patients with perforator or tributary vein reflux.
223487168|NCT03363035|DRUG|Rivaroxaban 2.5 mg|One 2.5 mg rivaroxaban tablet twice daily until hospital discharge or 12 hours before revascularization therapy for a maximum of 8 days.
223487169|NCT03363035|DRUG|Rivaroxaban 5 mg|One 5 mg rivaroxaban tablet twice daily until hospital discharge or 12 hours before revascularization therapy for a maximum of 8 days.
223487170|NCT03363035|DRUG|Enoxaparin|Enoxaparin 1mg/kg twice daily SC until hospital discharge or 12 hours before revascularization therapy for a maximum of 8 days.
223487171|NCT03595748|BEHAVIORAL|Peer mentorship|Participants randomized to this arm of the study will speak with their dialysis peer mentor once a week about fluid intake and adherence to dialysis.
223487172|NCT05934084|BEHAVIORAL|Lifestyles Implemented-Survivorship Care Plan (LS-SCP)|Patients in the experimental arm will follow the planned intervention (Survivorship Care Plan (SCP), nutritional plan, physical activity) for 6 months. A bi-monthly automatic call to assess the compliance at the experimental arm (LS-SCP, Lifestyles implemented-Survivorship Care Plan) will be performed.
223487173|NCT05700526|DEVICE|Planning of multiplanar and/or multifocal osteotomies in children by using VSP, PSIs and customized structural bone allograft|Preoperative VSP is performed starting from 3D digital models obtained from DICOM data of CT-scan with a segmentation process. If applicable, a model of the contralateral limb is obtained and used as reference for the correction. The surgeon and the engineer together define the surgical strategy, establishing the correction, the design of Patient-Specific Instruments (PSIs) and the hardware to implant. Then, through VSP, an ideal model of the bone graft is designed.
223487174|NCT05700526|DEVICE|Routine preparation of bone graft according to standard protocols|The size dimensions obtained through VSP are used by the tissue bank to manually cut a structural bone graft according to the standard protocols.
223487175|NCT05700526|DEVICE|Preparation of bone graft with virtual bone-matching and GSIs|The best donor bone is identified by matching the 3D models provided by bone bank with the planned graft, considering not only the size but also the most suitable configuration of cortical and medullary bone. Then GSIs are designed and 3D printed to perform the exact cut on the donor bone according to the experimental protocol.
223487176|NCT05700526|PROCEDURE|Corrective osteotomy|The acute surgical correction is performed according to VSP using PSI and the customized bone graft. Preoperative variables (age, sex, disease, deformity), intraoperative variables (operation time, intraoperative complications, use of fluoroscopy, intraoperative bleeding) are registered.
223745336|NCT06914115|COMBINATION_PRODUCT|TANS Group|The TANS Group will receive low-frequency electrical stimulation (20-30 Hz) via a TENS device on the auricular vagus nerve for 30 minutes, 3-4 times per week for 8 weeks. This non-invasive therapy aims to reduce spasticity, enhance neuroplasticity, and improve motor function and independence, assessed through standardized scales.
224177357|NCT01577446|PROCEDURE|cardiac resynchronization therapy|Implantation of a CRT defibrillator with a standard right atrial, right ventricular defibrillator and left ventricular leads
224177358|NCT02690506|DRUG|Placebo|
224177359|NCT02690506|DRUG|Pregabalin|
224177360|NCT02160743|DIETARY_SUPPLEMENT|CJ-30056 20/500mg (atorvastatin/metformin XR 20/500mg)|
224177361|NCT00209079|DRUG|Gleevec, Taxotere|Gleevec taken 4 times daily, 100 mg per tablet. Taxotere intravenously once a week for two weeks.
224177362|NCT01365195|DRUG|Placebo|Loading and Infusion: Saline at infusion rate calculated and adjusted for weight to match ketamine bolus-infusion rate
224177363|NCT01365195|DRUG|Ketamine high-dose|Loading: 1 mg/Kg Infusion: 10 mcg/kg/min
224177364|NCT01365195|DRUG|Ketamine low-dose|Loading: 0.5 mg/Kg Infusion: 5 mcg/kg/min
224177365|NCT00005577|DRUG|gemcitabine hydrochloride|
224177366|NCT04989660|DRUG|6% aqueous phenol|1.5 mL of 6% aqueous phenol will be injected at each target genicular nerve under ultrasound guidance.
224177367|NCT04989660|DRUG|Isotonic saline|1.5 mL of isotonic saline will be injected at each target genicular nerve under ultrasound guidance.
224177368|NCT02505269|DRUG|Brentuximab Vedotin|
224177369|NCT02505269|DRUG|Adriamycin|
224177370|NCT02505269|DRUG|Dacarbazine|
224177371|NCT04275492|DRUG|Praxol hydrochloride sustained release tablet Specification: 0.375mg/ tablet (in pramipexole hydrochloride)|Praxol hydrochloride sustained release tablets, 0.375mg/ tablet, are manufactured by hongguanbio pharmaceutical co., LTD
224177372|NCT04275492|DRUG|Pramipexole hydrochloride sustained-release tablet (Siforl®) Specification: 0.26mg/ tablet (in pramipexole)|Siforl® is produced by Boehringer Ingelheim International Gmbh
224177373|NCT03904004|PROCEDURE|Peroral endoscopic myotomy|Endoscopic myotomy after performing a tunnel to reach the muscular layer through a mucosal incision
224177374|NCT03904004|PROCEDURE|Neumatic dilatation|Inflation of a ballon of specific diameter in the gastro-oesophageal junction
224177375|NCT03904004|PROCEDURE|Botulinum toxin injection|Injection of botulinic toxin to inhibit the contraction of the gastro-oesophageal junction muscular layer
224177376|NCT03904004|PROCEDURE|Laparoscopic Heller Myotomy|Five or six small incisions are made in the abdominal wall and laparoscopic instruments are inserted. The myotomy is a lengthwise cut along the oesophagus, starting above the lower oesophageal sphincter (LOS) and extending down onto the stomach a little way. The oesophagus is made of several layers, and the myotomy only cuts through the outside muscle layers which are squeezing it shut, leaving the inner mucosal layer intact.
224177377|NCT00307892|DRUG|Traumeel S: intra-operative irrigation + oral ingestion|homeopathic remedy
224177378|NCT00307892|DRUG|Placebo|placebo remedy
224177379|NCT05961397|DRUG|baxdrostat|single oral dose of baxdrostat 10 mg
224177380|NCT01135004|PROCEDURE|Thoracoscopic bullectomy|Thoracoscopic wedge resection of the diseased lung
224177381|NCT00199368|DRUG|Istradefylline ( KW-6002)|
224177382|NCT03727386|OTHER|Coconut oil|Participants will receive 30 ml of virgin coconut oil to replace their normal oil intake for a period of 6 months.
224177383|NCT03727386|OTHER|Sunflower oil|Participants will receive 30 ml of sunflower oil to replace their normal oil intake for a period of 6 months.
224177384|NCT05917392|DIETARY_SUPPLEMENT|Fermented Vegetables (Kimchi) supplementation|Fermented Vegetables (Kimchi) supplementation with 50 gm daily for two months and effects of DNA methylation, serum proteome and microbiota
224177385|NCT05917392|DIETARY_SUPPLEMENT|probiotic|Supplementation with Kimchi plus LGG 50 grams daily for two months
224177386|NCT05917392|DIETARY_SUPPLEMENT|polyphenol|Supplementation with Kimchi plus polyphenol 50 grams daily for two months
224306615|NCT05257213|DRUG|Heparin solution|3 ml saline solution containing 5000 IU heparin.
224177387|NCT00641745|DRUG|Lurasidone HCl|40 - 120mg per day
224177388|NCT00641745|DRUG|Risperidone|Risperidone
224177389|NCT00150150|PROCEDURE|Interstitial laser photocoagulation|
224177390|NCT03494946|PROCEDURE|Liver transplantation|
224177391|NCT03494946|DRUG|Chemotherapy|May include chemotherapy, TACE, SIRT or other available treatment options.
224306616|NCT05257213|DRUG|Anti-adhesion barrier gel|2 ml biodegradable barrier gel containing sodium hyaluronate (10 mg/ml), sodium chloride (8.5 mg/ml), disodium hydrogen phosphate (0.34mg/ml), sodium dihydrogen phosphate (0.14 mg/ml) and water for injection (QS to weight).
224306617|NCT06633419|DRUG|Opevesostat|Administered via oral tablet per dosing regimen.
224306618|NCT06633419|DRUG|Prednisone|Administered at a dose of 5 mg or 10 mg dependent on HRT dosing regimen via oral tablets.
224306619|NCT06633419|DRUG|Fludrocortisone acetate|Administered at a dose of 0.05 mg or 0.1 mg dependent on HRT dosing regimen via oral tablets.
224306620|NCT06633419|DRUG|Carbamazepine|Administered at a dose of 100 mg, 200 mg, or 300 mg BID dependent on dosing regimen via oral capsule (extended-release).
223487177|NCT06327048|OTHER|Individual cognitive rehabilitation training based on Remind strategy was given|This training educates and learns patients from the aspects of assessment of cognitive function and strategic compensation for the impact of cognitive impairment on patients, and then conducts attention, memory and executive function training and attention retraining based on patients' cognitive function to improve patients' cognitive function
223487178|NCT05352763|DRUG|simufilam|simufilam 100 mg oral tablet, twice daily
223487179|NCT04809974|DRUG|Niagen|The intervention consists of taking Niagen and completing all tasks divided into 6 visits.
223487180|NCT00805688|BEHAVIORAL|Questionnaires|Questionnaires including symptom review (MDSAI-GI) via personal or telephone interviews (interactive voice response telephone system - IVRS)
224177392|NCT01339676|DRUG|Colecalciferol|Once weekly treatment with peroral colecalciferol capsules (Dekristol®, Swiss-Caps, Switzerland) containing 20 mg of colecalciferol corresponding to 20000 IU or 0.5 mg of vitamin D
224177393|NCT01339676|DRUG|Placebo capsules|Identically appearing once weekly peroral placebo capsules
224177394|NCT03822546|OTHER|Conventional cigarette|Subject's own conventional cigarette brand smoked with puffs taken at 30 seconds intervals
224177395|NCT03822546|OTHER|myblu 25 mg freebase|E-cigarette used for 10 inhalations every 30 seconds
224177396|NCT03822546|OTHER|myblu 16 mg nicotine salt|E-cigarette used for 10 inhalations every 30 seconds
224177397|NCT03822546|OTHER|myblu 25 mg nicotine salt|E-cigarette used for 10 inhalations every 30 seconds
224177398|NCT03822546|OTHER|myblu 40 mg nicotine salt|E-cigarette used for 10 inhalations every 30 seconds
224177399|NCT03822546|OTHER|blu PRO 48 mg nicotine salt|E-cigarette used for 10 inhalations every 30 seconds
224177400|NCT05212467|BEHAVIORAL|AIR-program|This is a guided self management program that is added on the treatment as usual.
224177401|NCT05212467|BEHAVIORAL|HUS Internet therapy|This is a guided self management program that is added on the treatment as usual.
224177402|NCT05212467|BEHAVIORAL|Treatment as usual|The patients receive routine care from their physician which may include drugs, visits or rehabilitation
224177403|NCT03304769|DEVICE|Virtual Reality|Virtual Reality Headset applied to the patient during placement of IV. Control is patient group without headset applied.
224177404|NCT04882124|DRUG|CSJ117|CSJ117 (4 mg and 8 mg) inhaled once daily for 12 weeks. Delivered via Concept1 device.
224177405|NCT04882124|DRUG|Placebo|Placebo inhaled once daily for 12 weeks. Delivered via Concept1 device
224177406|NCT05692986|DIAGNOSTIC_TEST|A vaginal swab for aerobic and anaerobic cultures before antibiotic administration, 30 minutes after vaginal prep and every hour thereafter until the surgery is completed.|This is a randomized control trial that will compare chlorhexidine vaginal prep with iodine vaginal prep. Our primary outcome will be assessed using a vaginal swab test to look for aerobic and anaerobic cultures. Positive cultures will be defined as colony forming count of \>5000cfu. All patients will receive preoperative antibiotics. Patients will receive a vaginal swab for aerobic and anaerobic cultures before antibiotic administration, 30 minutes after vaginal prep and every hour thereafter until the surgery was completed.
224177407|NCT01701349|DRUG|Fosbretabulin + paclitaxel + carboplatin|Fosbretabulin 200 mg/m2 IV infusion
224177408|NCT01701349|DRUG|Placebo + paclitaxel + carboplatin|Paclitaxel 200 mg/m2, Carboplatin AUC 6 IV infusion
224306621|NCT01711463|DRUG|Fluticasone Furoate/Vilanterol|50/25 or 100/25 or 200/25 mcg inhaled once daily for 7 days in each treatment period.
224306622|NCT01711463|DRUG|Placebo|Placebo inhaled once daily for 7 days in each treatment period.
224306623|NCT04220255|DEVICE|Liberty677MY Multifocal IOL|multifocal intraocular lens (IOL)
224306624|NCT06318780|OTHER|three-phase CT angiography|three-phase CT angiography
224306625|NCT06318780|OTHER|CEUS ultrasound|CEUS ultrasound
224306626|NCT04060017|DRUG|Levoleucovorin Calcium|Liquid leucovorin calcium dosed by weight
224306627|NCT04060017|OTHER|Placebo|Placebo
224306628|NCT03833336|OTHER|Placebo|The group assigned to placebo will receive an infusion of normal saline solution plus oral lactose capsules identical to oral medication.
224306629|NCT03833336|DRUG|Ferric carboxymaltose|The group assigned to receive intravenous iron will receive intravenous ferric carboxymaltose ajusted by weight and Hb levels according to study protocol plus oral placebo
224177409|NCT05422833|OTHER|Evaluation and analysis of clinical data|Evaluation and analysis of clinical data (baseline demographic features (sex, age at diagnosis, age at first symptoms, age at first visit), initial presenting symptoms, affected bone sites (monostotic FD or polyostotic FD), renal phosphate wasting, MAS, Mazabraud syndrome, endocrine disease, fractures, bone specific treatment especially bisphosphonate and surgery, pain and disease's severity.
224177410|NCT03922711|DRUG|Pridopidine|Oral capsule
224177411|NCT03922711|DRUG|Placebo|Oral capsule
224177412|NCT01499212|PROCEDURE|I:E ratio|I:E ratio 1:1 Volume controlled ventilation TV:8ml/kg EtCO2:35-40mmHg
224177413|NCT03147495|DIAGNOSTIC_TEST|Standing anteroposterior knee radiographs and special proximal tibiofibular joint radiograph.|Standing anteroposterior knee radiographs and special proximal tibiofibular joint radiographs will be taken for the participants in both groups. The standing anteroposterior knee radiographs will be obtained with the knee extended. The proximal tibiofibular joint radiographs will be acquired with the knee of the participants in approximately 45°-60° of internal rotation.
223487181|NCT00805688|PROCEDURE|Blood Draws|Blood sample (3½ tbs.)to measure levels of cytokines (biomarkers in the blood) and DNA (the genetic material in cells) before treatment starts.
223487182|NCT00805688|DEVICE|Pedometer|Worn daily to measure physical activity.
223487183|NCT05486169|PROCEDURE|Sleeve Gastrectomy|surgery of laparoscopic sleeve gastrectomy
223487184|NCT00003871|BIOLOGICAL|fowlpox virus vaccine vector|
223487185|NCT00003871|BIOLOGICAL|recombinant vaccinia prostate-specific antigen vaccine|
223487186|NCT05814510|BEHAVIORAL|Asthma CHAMPS full program|Full program includes (1) education for staff, students, and caregivers (2) environmental education and intervention (3) asthma care coordination (4) resources
223487187|NCT05814510|BEHAVIORAL|Asthma CHAMPS Wait List Control|Stepped wedge design
223487188|NCT06628323|BEHAVIORAL|Virtual Reality-based Intervention employing Neurofeedback|Virtual Reality-based intervention augmented with real-time EEG-based neurofeedback targeting auditory hallucinations in schizophrenia
224177414|NCT04542395|BEHAVIORAL|Increasing Willingness and Uptake of COVID-19 Testing and Vaccination|Provide/enhance knowledge, modify attitudes, motivate and provide skills and resources to reduce COVID-19 related risk and challenges and increase willingness and uptake in COVID-19 testing and vaccination.
224177415|NCT05405855|BEHAVIORAL|eLIFEwithIBD|eLIFEwithIBD program is a psychotherapeutic programme based on Acceptance, Mindfulness and Compassion for inflammatory bowel disease patients.
224177416|NCT06446050|BIOLOGICAL|MSC-L|Human umbilical cord-derived mesenchymal stem cells (MSCs) genetically modified to express antitumor chemokine and co-stimulatory molecule will be administered intravenously at a dose of 1/2/3 x 10\^6 cells/kg, every 21 days for at least 6 cycles of treatment.
224177417|NCT01072656|DEVICE|Deep Brain Stimulation for Thalamic Pain Syndrome|Patients will be randomized in a 1:1 ratio to one of two groups: the Treatment Group (active stimulation and programmed to the settings found to be optimal during the titration phase) and the Control Group (sham stimulation - IPG is set to ON but the voltage is set to 0V). In order to prevent too many patients from being randomized to ON or to sham early in the study, we will use, for the first 4 patients, randomization blocks of four or six. In this fashion, the first four consecutive patients will have two patients randomized to the Treatment Group and two patients in the Control Group. In the same fashion, the final six patients will have three patients randomized to the treatment group and three patients to the control group.
224177418|NCT00000756|DRUG|Lymphocytes, Activated|
224177419|NCT04111185|DEVICE|Receive Blood Volume Analysis Guided Treatment|The health care team will be given the results of the blood volume analysis along with guidance on how to provide treatment based on the analysis
224177420|NCT05063760|BEHAVIORAL|aerobic-strength exercise intervention (6-months)|6 month supervised exercise intervention in TGCT survivors (1 hour sessions 3 x per week),
224177421|NCT05087563|DEVICE|Neurolens spectacle lens|spectacle lens
223487189|NCT06628323|BEHAVIORAL|Virtual Reality-based Intervention|Virtual Reality-based intervention targeting auditory hallucinations in schizophrenia
223487190|NCT05415215|DRUG|Fixed Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Use (PH FDC SC)|PH FDC SC is administered subcutaneously (SC) as a fixed non-weight-based dose. A loading dose of 1200 milligram (mg) pertuzumab, 600 mg trastuzumab, and 30,000 units of recombinant human PH20 hyaluronidase (rHuPH20) is given in the first cycle (1 cycle is 21 days). In subsequent cycles, maintenance doses of 600 mg pertuzumab, 600 mg trastuzumab, and 20,000 units rHuPH20 are administered once every 3 weeks (Q3W).
223487191|NCT05415215|DRUG|Pertuzumab IV|Pertuzumab is given as a fixed dose of 840 mg intravenous (IV) loading dose and then 420 mg IV for subsequent maintenance doses once every 3 weeks.
223487192|NCT05415215|DRUG|Trastuzumab IV|Trastuzumab is given as an 8 milligram per kilogram (mg/kg) intravenous (IV) loading dose and then 6 mg/kg IV for subsequent maintenance doses once every 3 weeks.
223487193|NCT05415215|DRUG|Trastuzumab Emtansine|Trastuzumab emtansine will be given at a dose of 3.6 mg/kg by intravenous (IV) infusion, once every 3 weeks.
223586805|NCT00784537|DRUG|ABVD|"ABVD courses are scheduled every 28 days:~Doxorubicin 25 mg/m2 i.v. day 1 and 15 Bleomycin 10 mg/m2 i.v. day 1 and 15 Vinblastine 6 mg/m2 i.v. day 1 and 15 Dacarbazine 375 mg/m2 i.v. day 1 and 15~ABVD courses are scheduled every 28 days:~Doxorubicin 25 mg/m2 i.v. day 1 and 15 Bleomycin 10 mg/m2 i.v. day 1 and 15 Vinblastine 6 mg/m2 i.v. day 1 and 15 Dacarbazine 375 mg/m2 i.v. day 1 and 15~Randomization to Arm A (Observation)"
223487194|NCT05415215|DRUG|Investigator's Choice of Chemotherapy|Option 1: Docetaxel and carboplatin once every 3 weeks for 6 cycles; Option 2: Doxorubicin plus cyclophosphamide once every 3 weeks for 4 cycles, followed by a taxane (docetaxel once every 3 weeks for 4 cycles or paclitaxel once every week for 12 cycles); Option 3: Dose-dense doxorubicin plus cyclophosphamide (ddAC) once every 2 weeks for 4 cycles, followed by a taxane (docetaxel once every 3 weeks for 4 cycles or paclitaxel once every week for 12 cycles).
223487195|NCT05415215|PROCEDURE|Surgery|After completing their neoadjuvant therapy, participants will undergo surgical resection for early or locally advanced HER2+ breast cancer (if eligible for surgery). Participants may undergo breast-conserving surgery or mastectomy according to routine clinical practice. The surgery cannot be performed ≤2 weeks from the last systemic neoadjuvant therapy and must be performed ≤6 weeks after the last systemic neoadjuvant therapy.
223487196|NCT05415215|RADIATION|Radiotherapy|After surgery, radiotherapy is to be given as clinically indicated and as per local practice or institutional standards. The selected radiotherapy regimen should be initiated within 4 weeks after surgery.
223586806|NCT00784537|DRUG|ABVD and Radiotherapy|"ABVD courses are scheduled every 28 days:~Doxorubicin 25 mg/m2 i.v. day 1 and 15 Bleomycin 10 mg/m2 i.v. day 1 and 15 Vinblastine 6 mg/m2 i.v. day 1 and 15 Dacarbazine 375 mg/m2 i.v. day 1 and 15~Randomization to Arm B, Radiotherapy, in patients in CR, on the area of initial bulky disease (see above for the definition of nodal and/or mediastinal bulk)."
223586807|NCT05521321|BEHAVIORAL|Stanford Cannabis Awareness and Prevention curriculum|Stanford Cannabis Awareness and Prevention curriculum delivered as a 5-session course administered in a school classroom setting.
224177422|NCT05087563|DEVICE|Placebo spectacle lens|spectacle lens for refractive correction
224177423|NCT05528159|PROCEDURE|Intraabdominal CO2 insufllation|Patients will receive intraabdominal CO2 insufflation and will be operated under trendelenburg position
224177424|NCT03170492|OTHER|RehaCom Computerized Cognitive Training for 480 minutes|Student OT doctoral researchers will guide the subject when participating in the RehaCom program. RehaCom is computer hardware and software designed for assisted cognitive rehabilitation. The program is designed to target specific aspects of attention, concentration, memory, perception, and problem-solving. As the training goes on, the tasks will become easier or harder depending on the subject's performance. The first session will begin with a screening module with an example and a practice session to make sure the client understands the task. After screening, the results page shows the subject's performance compared with age-matched norms. This gives a helpful indication as to the severity of the deficit and advises the researcher on the particular training module to be used. The subject will continue the training modules for a total of 480 minutes of training over 12 weeks.
224177425|NCT03170492|OTHER|Pencil-and-Paper Cognitive Training for 480 minutes|Student OT doctoral researchers will engage the subject in various pen-and-paper exercises designed to improve cognitive functions: attention and concentration, memory, language, calculation, and orientation. These could include, but are not limited to: word puzzles, calculation or number puzzles, and map reading. The subject will continue the training modules for a total of 480 minutes of training over 12 weeks.
224177426|NCT00869375|DEVICE|Endovascular peripheral intervention|Clearway Balloon: percutaneous transluminal angioplasty with simultaneous in situ thrombolysis using the Clearway balloon AngioJet Rheolytic Thrombectomy System: percutaneous transluminal angioplasty with simultaneous mechanical thrombectomy using the Angiojet
224177427|NCT05616052|DRUG|Semaglutide|treatment with different dosage regimes
224177428|NCT00742391|DRUG|PEP005 (ingenol mebutate) Gel|two day treatment
224177429|NCT00742391|DRUG|Vehicle gel|two day treatment
224177430|NCT00225628|BEHAVIORAL|Computerized Reminders Medications Monitoring|
224177431|NCT00225628|BEHAVIORAL|Computerized Test Results Management Application|
224177432|NCT00225628|BEHAVIORAL|Computerized Reminders Hypertension Management|
224177433|NCT00225628|BEHAVIORAL|Computerized Reminders Osteoporosis Screening and Mgt|
223487197|NCT05493111|DRUG|0.003% AR-15512 ophthalmic solution|Active ingredients administered via topical ocular instillation
223487198|NCT05493111|DRUG|AR-15512 vehicle ophthalmic solution|Inactive ingredients administered via topical ocular instillation
223487199|NCT05886842|OTHER|Test-retest|Test-retest
224177434|NCT01706744|OTHER|Intermediate care unit|
224177435|NCT01706744|OTHER|Local health care 1|
223487200|NCT06125964|BEHAVIORAL|Intensity-Based Goals|On days participants plan to exercise, morning and evening goal sessions ask them to provide an activity goal for the day; create a concrete plan; prompt them to anticipate barriers and brainstorm solutions; and reflect on whether they were able to meet this goal. Intensity-based goals ask participants to maintain a target heart rate range during physical activity based on age-adjusted heart rate (HR) max. Goals progressively increase from 55% to 60% HR max across two weeks. Research staff will show participants how to monitor their heart rate using their Fitbit Versa. For each condition, the Fitbit Versa device will feature a custom watch face with a clock (current local time), the date, current device battery levels, and an exercise button. The exercise button can be pressed whenever a subject wants to engage in physical activity, and provides real-time feedback on heart rate (intensity-based goals only) and exercise duration.
223586808|NCT05340803|RADIATION|Ultrasonograghic optic nerve sheath diameter US-ONSD|To compare effect of sedation in 3 groups by follow up of intracranial pressure by US-ONSD
223586809|NCT05340803|DRUG|midazolam|midazolam
223586810|NCT05340803|DRUG|dexmedetomidine|dexmedetomidine
223586811|NCT05340803|DRUG|magnesium sulfate|magnesium sulfate
224177436|NCT01706744|OTHER|Local health care 2|
224177437|NCT03686527|PROCEDURE|stenosis aortic valve|"The exams to be realized :~* a clinical examination with blood pressure~* a 12-lead surface electrocardiogram~* a standard biological assessment including NTproBNP (Brain Natriuretic Peptide)~* Transthoracic echocardiography at baseline and 12 months after the aortic valve intervention on the (according to recommendations)~* a cardiac MRI looking for fibrosis myocardial"
223586812|NCT02219503|DRUG|Ombitasvir/Paritaprevir/Ritonavir|Tablet; paritaprevir co-formulated with ritonavir and ombitasvir
223586813|NCT02219503|DRUG|Dasabuvir|Tablet
223586814|NCT05879575|BEHAVIORAL|weight training|Pregnant women assigned to the intervention group will receive online weight training sessions twice a week, for 60 minutes per session, from the 16th to the 36th week of pregnancy. The Pelvic Girdle Questionnaire will be used to assess the condition of pelvic girdle pain during pregnancy, and to analyze whether weight training can improve this problem. Pelvic floor muscle structure will also be analyzed by pelvic ultrasound to determine whether it has been altered by weight training, leading to an improvement in pain.
223586815|NCT00766974|DEVICE|Anti-embolism Knee High Stocking|Anti-embolism Knee High Compression Stocking
224177438|NCT01176864|PROCEDURE|Double-balloon enteroscopy|Double-balloon enteroscopy
224177439|NCT01176864|PROCEDURE|Single-balloon enteroscopy|Single-balloon enteroscopy
224177440|NCT02239562|DRUG|sPIF|
224177441|NCT02239562|DRUG|Placebo|
224177442|NCT01834469|DRUG|iv injection of ICG|An iv injection will be performed for the ovarian cancer patient before the operation.
224177443|NCT00021281|DRUG|FOLFIRI regimen|
224177444|NCT00021281|DRUG|fluorouracil|
224177445|NCT00021281|DRUG|irinotecan hydrochloride|
224177446|NCT00021281|DRUG|leucovorin calcium|
224177447|NCT00021281|DRUG|semaxanib|
224177448|NCT03918213|DIAGNOSTIC_TEST|High-Resolution anorectal manometry with the use of solid-state catheter|High resolution anorectal manometry with the use of solid-state catheter will be performed to eligible subjects willing to participate in the study
224177449|NCT00600236|PROCEDURE|blood sample|
224177450|NCT00906555|PROCEDURE|modification of hemodialysis parameters on dialysis machine|Modification of hemodialysis parameters such as dialysis time, blood flow rate and dialysate flow rate to reach a Kt/V ≥ 1.7.
224177451|NCT02975206|DRUG|Serlopitant High Dose|serlopitant tablets - high dose
224177452|NCT02975206|DRUG|Placebo Oral Tablet|placebo tablet
224177453|NCT02975206|DRUG|Serlopitant Low Dose|serlopitant tablets - low dose
224177454|NCT02324413|DRUG|Clonidine|Comparison between placebo and 2 different concentrations of clonidine
224177455|NCT02324413|DRUG|Placebo|
224177456|NCT00497159|OTHER|Placebo|Placebo TID x 90 days
224177457|NCT00497159|DRUG|Dimebon|Dimebon 20 mg TID x 90 days
224177458|NCT01694459|DRUG|Low-dose heparin|Bolus of 50 UI/Kg of heparin at the beginning of coronary interventions
224177459|NCT01694459|DRUG|Standard dose heparin|Bolus of 100 UI/Kg of heparin at the beginning of coronary interventional procedure.
224306630|NCT03833336|DRUG|Ferroglycine Sulfate|One group assigned to receive oral iron will receive two 100 mg oral capsule of ferroglycine sulfate plus intravenous placebo (normal saline solution)
224306631|NCT03833336|DRUG|Sucrosomial Iron|One group assigned to receive oral iron will receive or two oral capsule containing 30 mg of pyrophosphate sucrosomial iron plus intravenous placebo (normal saline solution)
224306632|NCT02839915|DRUG|Folinic Acid|Liquid levo-leucovorin via oral route. L-leucovorin is the active isomer.
224306633|NCT02839915|OTHER|Placebo|Inactive placebo comparator
224306634|NCT06540963|DRUG|Tipifarnib|Tablet
223487201|NCT06125964|BEHAVIORAL|Affect-Based Goals|"On days participants plan to exercise, morning and evening goal sessions ask them to provide an activity goal for the day; create a concrete plan; prompt them to anticipate barriers and brainstorm solutions; and reflect on whether they were able to meet this goal. Affect-based goals ask participants to engage in either a type or context of physical activity that allows them to experience positive affect. Goals focused on context are randomly generated to suggest that the participant performs activity in a place, in a social situation, or while listening to something that makes them feel good. For each condition, the Fitbit Versa device will feature a custom watch face with a clock (current local time), the date, current device battery levels, and an exercise button. The exercise button can be pressed whenever a subject wants to engage in physical activity, and provides real-time feedback on exercise duration while featuring a smiley face emoticon."
223586816|NCT00766974|DEVICE|20-30 Knee High Compression Stocking|20-30 mmHg Knee High COmpression Stocking
223586817|NCT06004375|DIETARY_SUPPLEMENT|Neomune|Neomune containing 4.8 g arginine and 2 g glutamine
224177460|NCT04502394|DRUG|KRT-232|KRT-232 is an experimental MDM2 inhibitor anticancer drug taken by mouth
224177461|NCT04502394|DRUG|acalabrutinib|acalabrutinib is a BTK inhibitor anticancer drug taken by mouth
224177462|NCT00656227|DRUG|Avotermin|Comparison of different dose levels (20ng, 50ng, 100ng or 200ng/100 ul) versus placebo
224177463|NCT05673382|BEHAVIORAL|Internet-based cognitive behavioral therapy|The intervention (the treatment) within this study is based on cognitive behavioral therapy principles and adapted to target psychological symptoms related to life crises. The 20 modules that the intervention consists of include psycho-educational texts as well as examples and exercises.
224177464|NCT03389867|DIETARY_SUPPLEMENT|Kaempferia parviflora extract|
224177465|NCT00381472|DRUG|Ropinirole|
224177466|NCT01981096|BEHAVIORAL|Fibromyalgia integrative training|Combined intervention with neuromuscular exercise training and cognitive behavioral therapy
224177467|NCT01981096|BEHAVIORAL|Cognitive Behavioral Therapy|Therapy focused on training in behavioral pain coping skills
224177468|NCT05391295|OTHER|Short daily questionnaire|This study includes 1 survey that needs to be filled out by the patient on his/her phone daily during the course of corticosteroid treatment. The investigators will start the survey few days before the corticosteroid treatment and it will continue till the end of the treatment regime. The treatment regime is regular care and patient specific, but will approximately have a duration of 40 days. In case of prolonged treatment with steroids it is decided to have a limit for our study: either until 7 days after the end of corticosteroid treatment or a maximum of 60 days.
224177469|NCT02633917|BEHAVIORAL|Motor control exercises|exercises to strength the lumbar musculature and control the posture
224177470|NCT02633917|BEHAVIORAL|Standard exercises|general exercises
224306635|NCT06540963|DRUG|Naxitamab|IV
224306636|NCT00901212|DEVICE|Device programming|6-month period
224306637|NCT06520592|BEHAVIORAL|With AR guided CPAP therapy|Participants will received AR training course to utilize the AR guided CPAP therapy
224306638|NCT06526182|BIOLOGICAL|Lebrikizumab|Lebrikizumab solution for injection administered subcutaneously.
224306639|NCT06526182|OTHER|Placebo|Lebrikizumab Matching placebo solution for injection administered subcutaneously.
224306640|NCT05526300|DEVICE|Intelligent Hypertension Management System|The intelligent hypertension management system is used to remotely detect the blood pressure of hypertensive patients
224306641|NCT05526300|OTHER|The standard care|The standard care
224306642|NCT04994483|DRUG|Simufilam|Simufilam is a novel drug candidate designed to treat and slow the progression of AD. Simufilam binds with femtomolar affinity to an altered conformation of filamin A that is present in the brain of patients with AD and critical to the toxicity of Aβ42. In this study, simufilam will be given b.i.d. for 52 weeks at a dose of 100 mg.
224306643|NCT04994483|DRUG|Placebo|Matching placebo given b.i.d. for 52 weeks.
224306644|NCT06170450|DEVICE|Cyclic SNM|SNM cycling: 8 hours on, 16 hours off
224306645|NCT06170450|DEVICE|Continuous SNM|Continuous SNM: on continuously, no 'off' period
224306646|NCT04809168|OTHER|Questionnaires and inventories|questionnaires and inventories related to primary end secondary outcomes will be applied and physical examination will be performed.
224314207|NCT04732624|DRUG|Oral Rehydration Solution|Feasibility study of Enteral-based resuscitation with Oral Rehydration Solution (ORS) vs standard-of-care Intravenous Fluid resuscitation for moderate-sized burn injuries in Nepal
224314208|NCT04732624|DRUG|Lactated Ringer|Standard-of-care Intravenous Fluid resuscitation
224177471|NCT05791669|DRUG|Silver diamine fluoride|Silver diamine fluoride is a topical medication composed of 25% silver, 5% fluoride, 8% ammonia, and 62% Deionized water, used to treat and prevent dental caries and relieve dentinal hypersensitivity.
224306647|NCT05568264|OTHER|Physical Therapy intervention|The intervention is based on five principles: active learning, caregiver engagement, environmental enrichment, strengths-based approach, and dose. The intervention will start in the NICU and continue until 12-months corrected age. Infants in the intervention group will receive up to two therapist visits per week in addition to standard of care physical therapy. Caregivers will be asked to work with their infant on activities provided by the therapist. The therapist will provide resources to support the caregiver in working on these activities with their child, and caregivers will be asked to complete the activities for as much time as possible, throughout the day. Therapists will work with caregivers to identify ways to incorporate activities into their day. Caregiver engagement and caregiver ability to complete sessions and activity recommendations will be monitored.
224177472|NCT05791669|DRUG|Sodium fluoride varnish|It is a topical application with an active ingredient of 5% sodium fluoride(22,600ppm fluoride).it prolongs the contact time between the fluoride and tooth surface and promotes remineralization and inhibits demineralization.
224177473|NCT03973502|DRUG|18F-DOPA PET|One hour later all patient will be injected intravenously with 185 MBq (5mCi) 18F-FDOPA. PET emission data acquisition in 3-dimensional mode will be started at 60 minutes after tracer injection for 30 minutes.
224177474|NCT06059521|DEVICE|Software refraction with Eye Test Technology in a mobilerone|Refraction is done by software App by a mobilerone software installed.
224177475|NCT06059521|DEVICE|Retinoscopy|Retinoscopy is an objective refraction method with retinoscope.
224177476|NCT01160042|DRUG|Metformin|Metformin Tablets 1000 mg
224177477|NCT01160042|DRUG|Glucophage|Glucophage 1000 mg tablets of Bristol-Myers Squibb
224177478|NCT00866606|BIOLOGICAL|Benefix|BeneFIX for on-demand treatment of bleeding episodes were according to investigator prescription. FIX recovery was assessed by determining the FIX activity (FIX:C) levels in individual subjects. BeneFIX dosage for recovery assessments: single 75 IU/kg (±5 IU/kg) IV bolus infusion.
224177479|NCT04690556|DRUG|Lucentis (ranibizumab)|Lucentis® 0.5 mg via intravitreal injection once monthly
224306648|NCT06770712|OTHER|Mirror therapy|The patients were asked to sit in front of a table at an appropriate height and rest their arms on the table. A mirror was placed between both arms. The mirror was positioned so that the reflection of the healthy extremity overlapped with the paralytic extremity. In this way, the movements of the healthy upper extremity were viewed through the mirror, creating a visual movement illusion for the hemiplegic upper extremity. During the mirror therapy, exercises including forearm supination-pronation, wrist flexion-extension, finger flexion-extension, finger counting, grasping and releasing a cup, grasping and releasing a ball, and writing with a pen were performed. First, 30 minutes of bilateral TENS therapy were applied, followed by 30 minutes of mirror therapy
224306649|NCT06770712|DEVICE|Transcutaneous Electrical Nerve Stimulation|Received stimulation on the extensor muscles of the hand fingers of both the intact and paretic sides, with a frequency of 100 Hz, pulse width of 200 microseconds, and a biphasic symmetric pulse for 30 minutes. The intensity of the current was adjusted to a level that produced a visible, comfortable muscle contraction. Self-adhesive electrodes, measuring 5x5 cm, were placed on the extensor surface of the forearm, 5 cm distal to the olecranon, parallel to the long axis of the muscle. Electrical stimulation was applied using the Cefar Rehab X2 device (DJO France SAS).
224306650|NCT03060434|DRUG|Pentoxifylline Oral Tablet|patient will receive for 15 days: Ibuprofen 600 mg bid; pregabalin 75 mg bid; paracetamol 1 g tid; pentoxifylline 400 mg bid
224306651|NCT03060434|DRUG|Ibuprofen|patient will receive for 15 days: Ibuprofen 600 mg bid; pregabalin 75 mg bid; paracetamol 1 g tid
224306652|NCT06185023|BEHAVIORAL|Low-intensity physical exercise|As an active control intervention, a low-intensity non-aerobic exercise program was selected that mirrors more closely the standard-of-care physical therapy currently provided to stroke patients. This control intervention will offer the same level of participant involvement and type of exercises, but without the intensity element, i.e., it will not incorporate the cardiovascular and the strengthening components.
224306653|NCT06185023|BEHAVIORAL|High-intensity physical exercise|We have developed a new exercise program specifically designed for individuals with post-stroke aphasia, Aphasia Physical EXercise (APEX), to provide a safe, stroke- and aphasia-friendly physical exercise intervention to achieve optimal physical fitness and cognitive/language gains. This intervention, based on published research and clinical practice recommendations, is a high-intensity interval training full-body workout optimized to accommodate the range of motor abilities and general deconditioning observed in stroke survivors.
224314209|NCT02679235|DRUG|POST Triheptanoin|The target daily dose of triheptanoin will be 1 g/kg/d, or approximately 70 g/d during 28±2 days. It will be divided into four daily doses, one of which will be consumed at each meal and one with an evening snack.
224314210|NCT03751618|PROCEDURE|Hip arthroscopy|"Suture will be realized with two simple suture knots (non resorbable suture material). These suture knots will be performed at the end of hip arthroscopy. Correct capsular suture will be controlled under arthroscopy video.~Patients randomized in control arm will not received capsular suture at the end of the procedure."
224314211|NCT00620100|DRUG|Docetaxel|
223487202|NCT06125964|BEHAVIORAL|TYPE/CONTEXT Enhancement|The TYPE/CONTEXT enhancement will augment affect-based treatment effects by additionally providing tailored recommendations for activity types and contexts that satisfy personally important psychological needs as rated by each participant at baseline. Ratings from a crowdsourced panel of adults on Amazon Mechanical Turk were used to determine the potential for specific activity types and contexts to satisfy psychological needs; our tailoring algorithm recommends the corresponding activity type or context while accounting for reported constraints. Different psychological needs will be selected each day. Tailored recommendations are incorporated immediately following the morning goal module.
224177480|NCT04690556|DRUG|LUBT010 (proposed ranibizumab biosimilar)|LUBT010 (proposed ranibizumab biosimilar) 0.5 mg via intravitreal injection once monthly
224177481|NCT03271411|BEHAVIORAL|EMDR-based Flash technique|Initial EMDR session (with Flash technique) of up to three hours; about one week later, follow-up session of up to one hour
224177482|NCT03271411|BEHAVIORAL|PC-based Flash technique|Initial PC session (with Flash technique) of up to three hours; about one week later, follow-up session of up to one hour
224177483|NCT01225211|DRUG|Lumacaftor|Tablet
224177484|NCT01225211|DRUG|Ivacaftor|Tablet.
224177485|NCT01225211|DRUG|Lumacaftor Placebo|Matching placebo tablet.
224177486|NCT01225211|DRUG|Ivacaftor Placebo|Matching placebo tablet.
224177487|NCT04735211|PROCEDURE|Surgery|Pediatric Surgery with hospitalized
224177488|NCT04562233|BEHAVIORAL|Online-delivered physical activity intervention.|Participants randomized to the intervention arm will engage in 12, weekly, supervised, exercise sessions using Zoom with the exercise trainer.
224177489|NCT04562233|BEHAVIORAL|Printed, individualized resistance-based physical activity program.|Without the supervision of an exercise trainer, participants will be given a printed, individualized resistance-based physical activity program to complete over the course of 12 weeks.
224177490|NCT05874947|DEVICE|linear measurement|Linear measurements from digital caliper ,CBCT and EOS generated digital dental models
224177491|NCT02933411|OTHER|Genetic Analysis|Blood sample will be drawn to assess the number of participants enrolled that have sequence variation in the von willebrand factor gene and other genes affecting bleeding, clotting and blood vessel biology.
224177492|NCT02933411|OTHER|Medical Record Data Abstraction|"The subject's response to intranasal or intravenous desmopressin (DDAVP) challenge performed as part of standard of care will be recorded. The desmopressin is a drug that increases the clotting factor in blood to prevent bleeding.~Medical and family history including and not limited to age, diagnoses, race/ethnicity, lab values, HMB and low VWF activity diagnoses, and treatment history and outcome will also be recorded."
224177493|NCT02933411|OTHER|Pictorial Blood Assessment Chart (PBAC) score|PBAC is a pictorial tool to assess menstrual blood loss. Study team will complete the PBAC assessment with each study participant evaluating and measure response to different treatments for menstrual blood loss in the clinic setting between those with VWD versus other bleeding disorders.
224177494|NCT02933411|OTHER|Complete Bleeding Symptom ISTH Bleeding Assessment Tool|Study participants will complete the ISTH BAT assessment. The ISTH BAT is a questionnaire to aid in the standardized evaluation of the presence and severity of bleeding symptoms.
224177495|NCT02409628|DEVICE|EktoTherix|The EktoTherix scaffold is applied to the fresh wound resulting from a full thickness excision of non-melanoma skin cancer and then bolstered by the application of a non-adhesive foam dressing (discontinued at the first visit); both scaffold and foam dressing are secured in place using a semi-occlusive film dressing. The EktoTherix-treated wound is assessed weekly as per standard of care.
224306654|NCT06551441|BEHAVIORAL|High Intensity Interval Training (HIIT)|"The HIIT intervention consist of 4 intervals with each lasting 4 minutes (4x4min). If a participant reports discomfort related to the length of the intervals or start to feel unmotivated by performing the same exercise, we will use another HIIT protocol: 10x1min.~The 4x4min HIIT consists of a warm-up period of 10 minutes with a target heart rate at 60-70% of HRmax, followed by 4 HIIT intervals with a target HR ≥85%. The intervals are separated by three minutes of active rest, in which the HR should drop to 60% of maximum. Following this, a cool down period of three minutes at warm up intensity is performed.~The 10x1min HIIT consists of a 10-minute warm-up period.The warm-up is followed by 10 intervals, each lasting 1 min at 100% of maximal workload, separated by three minutes of active rest, in which the HR should drop to 60% of maximum. Following the intervals, a cool down period of three minutes at warm up intensity is performed."
224306655|NCT04190069|BEHAVIORAL|Behavioral interventions/modifications|UPMC Prescription for Wellness is an innovative physician/provider prescribed coaching and feedback program that improves patient engagement and outcomes in healthy behaviors; self-care of chronic disease and condition management; and shared decision-making. The resources available through this program are offered via a telephonic health coach, online or through a digital intervention based on the participant's convenience.
223487203|NCT06125964|BEHAVIORAL|SAVOR Enhancement|The SAVOR enhancement will augment affect-based treatment effects by additionally implementing a brief savoring exercise on the smartphone during the evening goal session (after the self-monitoring module). Participants will respond to questions that are intended to enhance and prolong positive experiences during physical activity. To trigger attentional deployment, a common savoring strategy that involves intensifying experiences by focusing on them, participants will answer open-ended prompts. These prompts are drawn from a prompt pool with slightly varied wording to promote a sense of novelty.
223487204|NCT04997733|DRUG|Fecal Microbiota Transplantation (FMT)|"The colonoscopy for FMT will be planned between 7 and 14 days after the last adalimumab or sub-cutaneous infliximab administration and 6 weeks +/- 7 days after the last intravenous infliximab administration 14 and 28 days following the last sub-cutaneous golimumab administration. After colon cleansing using polyethylene glycol, the patient will have a colonoscopy under general anesthesia. The patient will then receive either FMT (frozen preparation of 50g of stools in 300ml of saline (NaCl 0.9%), (FMT vehicle in the terminal ileum or the colon.~At W12 and W24 after first colonoscopy, the patient receives treatment by capsule (15 capsules contain 0.8g of stools by visit)."
223586818|NCT04234958|OTHER|Osteopathic manipulative treatment|Specific protocol including 4 osteopathic techniques targeting the pericardium
223586819|NCT04234958|OTHER|Sham therapy|Sham therapy mimicking the osteopathic techniques applied to experimental group
224177496|NCT03166228|DRUG|Normal Saline 0.9% Infusion Solution Bag|0.9% saline as distension medium as long as diathermy is not in use
224177497|NCT03166228|DRUG|1.5% Glycine only|1.5% Glycine alone during hysteroscopy as long as diathermy is in use
224177498|NCT03608462|DEVICE|repetitive transcranial magnetic stimulation(DLPFC)|high frequency(20Hz) repetitive transcranial magnetic stimulation on dorsolateral prefrontal cortex(DLPFC) .Duration:10 days.
224177499|NCT03608462|DEVICE|repetitive transcranial magnetic stimulation(LPC)|high frequency(20Hz) repetitive transcranial magnetic stimulation on left parietal cortex(LPC).Duration:10 days
224177500|NCT02619929|DRUG|Vinorelbine oral|
224177501|NCT00794989|DIETARY_SUPPLEMENT|Ground Flaxseed|Given orally
224177502|NCT00794989|OTHER|No Intervention|Participants randomized to Arm 2 do not receive any intervention
224177503|NCT01205646|DRUG|zoledronate therapy|Zometa will be administered at a dose of 4mg IV over 15 minutes. A third PET scan will be obtained within 1-2 weeks after Zometa administration. Intravenous (through a vein in the arm) infusion every four weeks. Dose will be determined by kidney function.
224177504|NCT01205646|DEVICE|PET Scan|2 scans \[about 1-2 weeks apart\] will be obtained over a period of 2 weeks pretherapy to confirm reproducibility.A third PET scan will be obtained within 1-2 weeks after Zometa administration.
224177505|NCT06454565|BEHAVIORAL|Health Qigong - 12-Step Daoyin Health Preservation Exercises|All participants received a six-month intervention consisting of two phases: the first month was a movement learning and consolidation phase of 45 minutes per session, once a day; the second five months were a formal practice phase of 45 minutes per session, once a day. In the first phase, participants learn four new movements per session and consolidate these exercises in the next session. After learning all the movements, the remaining time of the first phase was used to consolidate the exercises. In the second phase, participants perform a full Health Qigong - 12-Step Daoyin Health Preservation Exercises practice in each session.
224177506|NCT06454565|BEHAVIORAL|Locked exercise|All participants received a six-month intervention of 45 minutes once a day. All participants performed blocked aerobic exercise.
224177507|NCT06454565|BEHAVIORAL|Multiplayer open exercise|All participants received a six-month intervention in the form of a balloon game competition. The intervention consisted of two phases: the first month consisted of a movement learning and consolidation phase of 45 minutes per session, once a day; the second five months consisted of a formal competition phase of 45 minutes per session, once a day. In the first phase, coaches taught participants the technical movements and rules. In the second phase, participants competed in groups during each session, with the coaches acting as referees.
224177508|NCT06454565|BEHAVIORAL|Health Qigong - 12-Step Daoyin Health Preservation Exercises combined with locked exercise|All participants received the intervention for six months, 45 minutes each time, once a day. All participants performed blocked exercise followed by Health Qigong - 12-Step Daoyin Health Preservation Exercises. The schedule was consistent with the Health Qigong - 12-Step Daoyin Health Preservation Exercises group and the Blocked Exercise group.
224177509|NCT06454565|BEHAVIORAL|Health Qigong - 12-Step Daoyin Health Preservation Exercises combined with open exercise|All participants received the intervention for six months, 45 minutes each time, once a day. All participants performed multiplayer Open Exercise followed by Health Qigong - 12-Step Daoyin Health Preservation Exercises exercises. The schedule was consistent with the Health Qigong - 12-Step Daoyin Health Preservation Exercises group and the Multiplayer Open Exercise group.
224177510|NCT01646736|DRUG|Tripterygium wilfordii Hook F|Oral T2(Tripterygium wilfordii Hook F) 20mg thrice daily for 24 weeks.
224177511|NCT01646736|DRUG|Cyclophosphamide|Cyclophosphamide 1.0 intravenous every month.
224177512|NCT01646736|DRUG|GC|Prednisone or equivalent 1 mg/kg/d(up to 60 mg), gradually tapering to 7.5mg/d in 24 weeks.
224177513|NCT01893879|DRUG|placebo for study drug|Given PO
224177514|NCT01893879|DRUG|(RS)2-(3-benzoylphenyl)-propionic acid|Given PO
224177515|NCT01893879|OTHER|laboratory biomarker analysis|Correlative studies
224177516|NCT00002336|DRUG|Clarithromycin|
224177517|NCT00075413|DRUG|arsenic trioxide|
224177518|NCT03431623|BIOLOGICAL|CKD-11101(Darbepoetin alfa)|
224177519|NCT03431623|BIOLOGICAL|NESP(Darbepoetin alfa)|
224306656|NCT03226028|PROCEDURE|Music listening|Patient is given an ipod with earphone and with saved playlists of different music genres. Music listening session will be given for 30 minutes before and after surgery. Questionnaires will be asked to fill in. All the earphones will be disinfected following the hospital's infection control guideline.
224306657|NCT04899388|PROCEDURE|Pericapsular Nerve Block|regional anaesthia
224306658|NCT04899388|PROCEDURE|Lumbar Erector Spinae Plane Block|regional anaesthia
224306659|NCT04899388|DRUG|Fentanyl|intavenous
224306660|NCT04759053|PROCEDURE|FNB|Fine needle aspiration from the nodules
223487205|NCT04997733|DRUG|Sham-transplantation (placebo)|"The colonoscopy for sham-transplantation will be planned between 7 and 14 days after the last adalimumab or sub-cutaneous infliximab administration and 6 weeks +/- 7 days after the last intravenous infliximab administration, 14 and 28 days following the last sub-cutaneous golimumab administration. After colon cleansing using polyethylene glycol, the patient will have a colonoscopy under general anesthesia. The patient will then receive either sham transplantation (frozen preparation of NaCl 0.9% with 10% glycerol) in the terminal ileum or the colon.~At S12 and S24 after first colonoscopy, the patient receives treatment by capsule (15 capsules contain placebo)."
223745337|NCT06914115|COMBINATION_PRODUCT|Body Rocking Exercise|Group 2: Body Rocking Exercise Group Participants will perform rhythmic body rocking exercises for 20-30 minutes, 3-4 times per week for 8 weeks to reduce spasticity and improve motor coordination. Group 3: Control Group (Usual Rehabilitation) Participants will receive standard stroke rehabilitation (therapy, stretching, functional training) for 20-30 minutes, 3-4 times per week for 8 weeks as a baseline comparison.
223745338|NCT06913647|DRUG|Canagliflozin 300 MG|Canagliflozin 300 mg once daily
224177520|NCT02668679|PROCEDURE|Sedation of children during gastroscopy with and without the presence of dream doctor|children and their parents with and without the presence of DD upon arrival to the Gastroenterology institute and throughout the induction of sedation, gastroscopy and recovery.
224306661|NCT04759053|PROCEDURE|Core biopsy|Core biopsy from thyroid nodules
224306662|NCT03521466|BEHAVIORAL|Smoking Cessation Counseling|Trained medical students will visit patients inpatient while hospitalized and provide smoking cessation counseling and recommend Nicotine Replacement Therapy. They will continue to follow these patients for 2 months after discharge and provide telephone-based counseling.
224306663|NCT04170751|DRUG|16 mcg / cc of norepinephrine(group N)|In group N, 16 mcg / cc of norepinephrine was infused through the central catheter. Drug titration should be 0.05 mcg / min / kg for norepinephrine and 2 units / hr for vasopressin, until target blood pressure is reached. Drug infusion rate should not exceed 0.3mcg / min / kg for norepinephrine and 10unit / hr for vasopressin for patient's safety.
224306664|NCT04170751|DRUG|0.4 unit / cc of vasopressin(group V)|In group V, 0.4 unit / cc of vasopressin was infused through the central catheter and the respective doses recorded. Drug titration should be 0.05 mcg / min / kg for norepinephrine and 2 units / hr for vasopressin, until target blood pressure is reached. Drug infusion rate should not exceed 0.3mcg / min / kg for norepinephrine and 10unit / hr for vasopressin for patient's safety.
224306665|NCT05804916|DEVICE|Surface Guided Radiation Therapy (SGRT)|SGRT and DIBH those two devices could be combined together to improve the accuracy in radiation therapy position and heart protection
224306666|NCT01451086|BIOLOGICAL|vaccine made by Beijing Minhai Biotechnology Co., Ltd|Subjects receive 0.5 mL/dose of 23-valent pneumococcal polysaccharide vaccine by intramuscular (deltoid) injection on Day 0.
224177521|NCT02668679|DEVICE|evaluation of stress with PPI and GSR|evaluation of stress in children undergoing gastroscopy with sedation with and without the presence of a dream doctor by measurement of PPI and GSR
224177522|NCT02668679|BIOLOGICAL|blood specimens for stress hormones|evaluation of stress in children undergoing gastroscopy with sedation with and without the presence of a dream doctor by measurement of stress hormones.
224177523|NCT02668679|OTHER|Physiological indices for evaluation of stress|evaluation of stress in children undergoing gastroscopy with sedation with and without the presence of a dream doctor by measurement of blood pressure, pulse, saturation and body temperature.
224177524|NCT03686579|RADIATION|chest trauma|clinical and radiological study
224177525|NCT02545686|BEHAVIORAL|Chest wall movement assessment without CPAP|While subject is breathing normally, determine chest wall movement (via RPM waveform) with free breathing, over the course of half an hour.
224177526|NCT02545686|BEHAVIORAL|Breath hold assessment without CPAP|While subject is breathing normally, subject will perform a moderate and a deep inspiratory breath hold. Duration, reproducibility and tolerance of deep inspiratory breath hold will be recorded.
224177527|NCT02545686|PROCEDURE|Chest wall movement assessment with CPAP|While subject is breathing via CPAP machine, determine chest wall movement (via RPM waveform) with free breathing, over the course of half an hour.
224306667|NCT01451086|BIOLOGICAL|vaccine made by Chengdu Institute of Biological Products|Subjects receive 0.5 mL/dose of 23-valent pneumococcal polysaccharide vaccine by intramuscular (deltoid) injection on Day 0.
224306668|NCT03963024|DRUG|"Conditioning treatment Treosulfan-TMI"|Treosulfan i.v.: 14 g/m²/d (day -6 to -4) Fludarabine i.v.: 30 mg/m²/d (day -6 to -2) Antithymocyte globulin (ATG)-Fresenius i.v.: 5/0 mg/kg (day -4 to -2) Mabthera i.v.: 200/0\* mg/m2 (day -1) TMI: (10 Gy) 2 Gy bis in die (BID) (day -2 to -1) or TMI: (12 Gy) 2 Gy BID (day -3 to -1) or TMI: (14 Gy) 2 Gy BID (day -3 to -1)
224306669|NCT03963024|PROCEDURE|SCT|Stem Cell Transplant
223487206|NCT05962957|DRUG|carbidopa-levodopa|Levodopa is typically prescribed to a patient with Parkinson disease once symptoms become more difficult to control with other anti-parkinsonism drugs. The drug can also be used for postencephalitic parkinsonism and symptomatic parkinsonism due to carbon monoxide intoxication
223586820|NCT04496661|DEVICE|Transcranial Direct Current Stimulation on M1 and Peripheral Electrical Stimulation|Patients will be submitted to 10 treatment sessions, five days a week, for 30 minutes, paired to the same PES protocol. The participants will be positioned in ventral decubitus position. The direct current (2 mA) will be transferred through a neuro-stimulator (TransCranial Technologies, Hong Kong, China), with the use of electrodes and 4x4 cm sponges moistened with 0.9% saline solution. The anodic electrode will be placed on C3 to stimulate the left primary motor cortex according to the international 10-20 EEG system. The reference electrode will be positioned in the supra orbital contralateral region. For the PES, four self-adhesive electrodes with dimensions of 5 x 5 cm will be placed at the height between the T12 and S1 vertebrae in order to cover the entire lumbar area. A 20Hz frequency and pulse duration of 330ms will be provided by means of two channels from an electro-stimulator (Neurodyn, Ibramed).
223586821|NCT04496661|DEVICE|Transcranial Direct Current Stimulation on DLPFC and Peripheral Electrical Stimulation|Patients will be submitted to 10 treatment sessions, five days a week, for 30 minutes, paired to the same PES protocol. The direct current (2 mA) will be transferred through a neuro-stimulator (TransCranial Technologies, Hong Kong, China), with the use of electrodes and 4x4 cm sponges moistened with 0.9% saline solution. The anodic electrode will be placed on F3 to stimulate the left dorsolateral cortex according to the international 10-20 EEG system. The reference electrode will be positioned in the supra orbital contralateral region. For the PES, four self-adhesive electrodes with dimensions of 5 x 5 cm will be placed at the height between the T12 and S1 vertebrae in order to cover the entire lumbar area. A 20Hz frequency and pulse duration of 330ms will be provided by means of two channels from an electro-stimulator (Neurodyn, Ibramed).
223586822|NCT04496661|DEVICE|Sham tDCS and PES|For sham tDCS and PES stimulation, patients will be submitted to 10 treatment sessions, five days a week, for 30 minutes. The anodic electrode will be positioned on the left primary motor cortex, but the current will be turned off automatically after 30 seconds. The reference electrode will be positioned in the supra orbital contralateral region. For sham PES stimulations, four self-adhesive electrodes with dimensions of 5 x 5 cm will be placed at the height between the T12 and S1 vertebrae in order to cover the entire lumbar area. A 20Hz frequency and pulse duration of 330ms will be provided by means of two channels from an electro-stimulator (Neurodyn, Ibramed), but the current will be turned off automatically after 30 seconds.
223586823|NCT04932291|DRUG|vafidemstat|1.2mg capsule
223586824|NCT04932291|DRUG|Placebo|placebo capsule
223586825|NCT02285530|DRUG|TPF induction chemotherapy|TPF induction chemotherapy: 2 cycles; docetaxel(75mg/m\^2), cisplatin(75 mg/m\^2), 5-Fu(750 mg/m\^2/day) for 5 days; 16 days later, the 2nd cycle.
223586826|NCT02285530|PROCEDURE|surgery group|Radical resection of the primary lesion and full neck dissection(functional or radical) with proper reconstruction(pedicle or free flap) were performed.
224177528|NCT02545686|PROCEDURE|Breath hold assessment with CPAP|While subject is breathing via CPAP machine, subject will perform a moderate and a deep inspiratory breath hold. Duration, reproducibility and tolerance of deep inspiratory breath hold will be recorded.
224177529|NCT02599324|DRUG|ibrutinib|Ibrutinib administered orally once daily with 8 ounces (approximately 240 mL) of water.
224177530|NCT02599324|DRUG|everolimus|Everolimus 10 mg tablets should be taken orally once daily at the same time every day, either consistently with food or consistently without food. Four (4) x 2.5 mg tablets or two (2) x 5.0 mg tablets may be substituted if 10 mg tablet strength is not available.
224177531|NCT02599324|DRUG|paclitaxel|Paclitaxel should be administered as a 60-minute (±10 minutes) infusion. Paclitaxel should be given at a dose level of 80 mg/m\^2, once weekly, in continual 3 weekly cycles.
223487207|NCT05962957|DRUG|Pentoxifylline 400 MG|Pentoxifylline (PTX) has a well validated immune modulatory and anti-inflammatory efficacy via suppression of the TLR4/NF-κB network signaling pathway. Moreover, Pentoxifylline has a potential antioxidant capacity mostly via nuclear erythroid 2-related factor 2 (Nrf2) activation with subsequent up-regulation and expression of several antioxidant enzymes
223487208|NCT05962957|DRUG|Celecoxib 200mg|Celecoxib is a nonsteroidal anti-inflammatory drug (NSAID) used to treat mild to moderate pain and help relieve symptoms of arthritis
223487209|NCT06034470|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
224177532|NCT02599324|DRUG|docetaxel|Docetaxel administered as a 60 minute infusion (±10 minutes) at a dose level of 60 - 75 mg/m\^2 (according to local institutional standard of care), given continually in 21-day cycles.
224177533|NCT02599324|DRUG|cetuximab|Cetuximab 400 mg/m\^2 administered as a 120-minute IV infusion. The recommended subsequent weekly dose (all other infusions) is 250 mg/m\^2 infused over 60 minutes.
224177534|NCT02599324|DRUG|pembrolizumab|Pembrolizumab 200 mg intravenous (IV) every 3 weeks.
224177535|NCT02473380|DEVICE|Fluorescence spectroscopy guided surgery|A prototype of intraoperative fluorescence spectroscope will be used for fluorescence spectroscopy during a surgical procedure (open surgical approach only). The experimental probe dedicated to the spectroscopic system will be positioned against the surface of the brain, emission spectrum will be acquired and measured, and finally compared with anatomopathology exams. One specific medication will be used as contrast agent in the study: 5 amino-levulinic hydrochloride (GLIOLAN, MEDAC) orally at the dose of 20mg/kg of body weight.
224177536|NCT01579162|DEVICE|Cholate-24-13C (IND 65121) & Cholate-2,2,4,4-d4 (IND 65123)|"The FDA has indicated that liver function diagnostic testing with stable isotope labeled cholates would be considered a drug/device combination product. The drugs administered at each test visit will be:~20 mg Cholate-24-13C, IV (in the vein), dissolved in NaHCO3 and mixed with albumin.~40 mg Cholate-2,2,4,4-d4, oral, dissolved in NaHCO3 and mixed with juice.~The 3 test visits will be on separate days within a span of 30 days"
224177537|NCT02109939|GENETIC|GeneSight Psychotropic|"The GeneSight Psychotropic product is a pharmacogenomic decision support tool that helps clinicians to make informed, evidence-based decisions about proper drug selection, based on the testing for clinically important genetic variants in multiple pharmacokinetic and pharmacodynamic genes that affect a patient's ability to tolerate or respond to medications.~The GeneSight Psychotropic product contains the most commonly prescribed antidepressant and antipsychotic medications, including a full representation of the SSRI and SNRI drug classes.~tricyclic antidepressants, an MAOI, and typical and atypical antipsychotics are also represented."
224177538|NCT00439699|DRUG|Memantine|Mematine administration
224177539|NCT05413356|DRUG|Ruxolitinib|Oral ruxolitinib twice daily
224177540|NCT02995811|OTHER|Observational Cohort|Ultrasound assessment of 4 muscles, activity monitoring, daily global peripheral skeletal muscle strength
224177541|NCT04056715|DEVICE|Zio XT|ambulatory cardiac monitoring device
224177542|NCT00011128|BEHAVIORAL|Antiretroviral Treatment Interruption|
224177543|NCT05220293|DRUG|Betamethasone Dipropionate Nasal Cream 0.0644%|Betamethasone Dipropionate Nasal Cream 0.0644%, up to 5g per sinus.
224177544|NCT05220293|DEVICE|Pre-filled syringe and applicator device|Cream is pre-filled to a syringe and applicator device to facilitate the topical application direct to the sinus under endoscopic guidance.
224177545|NCT04050228|DEVICE|Quantitative ultrasound to guide adaptive chemotherapy|Quantitative ultrasound results will be used to measure chemotherapy response and guide an adaptive chemotherapy strategy for patients who are found to be nonresponders to their chemotherapy.
224177546|NCT01732861|DRUG|CC-292|CC-292-will be given twice daily on Days 8-28 of Cycle 1 and on Days 1-28 of the remaining 28-day cycles.
224177547|NCT01732861|DRUG|Lenalidomide|Lenalidomde will be given once daily on Days 1-28 of 28-day cycles.
224306670|NCT03963024|DRUG|GvHD prophylaxis|Rapamycin p.o.: 4 mg/d, (target 8-15 ng/ml) (starting day -7) Mycofenolate mofetile: 10 mg/kg tid, (Maximum dose 720 mg/tid) (starting from day 0)
224306671|NCT05575258|OTHER|44-Day Diet Conventionally Sourced - YELLOW Diet|Food for the conventional diet will be sourced from local grocery stores (non-organic produce) around Logan, UT, USA.
224306672|NCT05575258|OTHER|44-Day Diet Agro-Ecologically Sourced - GREEN Diet|Food for the agro-ecological diet will be sourced predominantly from the Greenacres farm (Cincinnati, OH, USA) and a limited number of other retailers that sell select foods from agro-ecological producers (Seal the Seasons, General Mills, Pecan Shop, Sol Simple).
224306673|NCT05256524|DRUG|The effect of LMWH|Quantified by aFXa-levels
224306674|NCT05256524|DIAGNOSTIC_TEST|Monitoring frequency of aFXa-levels|The frequency of aFXa-levels being sampled, analysed and integrated as a possible part of the basis for clinical decisionmaking
223586827|NCT02285530|RADIATION|Post-operative radiotherapy|Radiotherapy was arranged 4 to 6 weeks after surgery. Routine external beam radiotherapy, such as conformal or intensity modulated radiotherapy was performed and the dose was 1.8-2 Gy/day, 5 days/week for 6 weeks, and totally 54-60 Gy.
223586828|NCT01786460|OTHER|Blood draw at Days 0, 7, 14, and 21|
223586829|NCT05827601|DIAGNOSTIC_TEST|respiratory specimen|participants will perform self-sampling with a nasopharyngeal swab
224177548|NCT02604628|BEHAVIORAL|Antibiotic Stewardship Intervention|The Antibiotic Stewardship Intervention will consist of education, motivating opinion leaders, adapting a pragmatic disease severity classification and prospective audit and feedback.
224177549|NCT00653198|OTHER|No intervention|
224177550|NCT04671745|BEHAVIORAL|Music|patient receiving care with interactive music
224177551|NCT04671745|BEHAVIORAL|No music|patient receiving care without interactive music
224177552|NCT02620631|DRUG|Morphine|Subjects receive intrathecal morphine pre-operatively to determine its level of efficacy in acute pain control post-operatively when used in conjunction with post-operative PCA morphine
224177553|NCT02620631|DRUG|Placebo|Subjects receive intrathecal, preservative-free normal saline pre-operatively in conjunction with post-operative PCA morphine
224177554|NCT01774227|PROCEDURE|The pops-titration group|The energy delivery is started at a low level and is increased in intervals till an audible pop is heard, following which the power is reduced downward until the pops are no longer audible, then the treatment is completed at these parameters
224177555|NCT01774227|PROCEDURE|The slow-coagulation group|The Gaasterland's slow-coagulation energy delivery technique using the lower power for the longer duration.
224177556|NCT06259591|BEHAVIORAL|Pedometer follow-up|The daily step count will be obtained from the patients using a pedometer app (OutWalk) from day 8 to day 30 after surgery.
224177557|NCT06259591|BEHAVIORAL|Ambulation coaching|Patients will receive coaching text messages every Monday, Wednesday and Friday between day 8 and day 30 after surgery, based on a pre-fixed template.
224306675|NCT04326621|OTHER|Pressure Release Technique (PRT)|A pressure applied on muscles trigger points with the finger of a physiotherapist and exercises
224306676|NCT04326621|OTHER|Control|exercises
224177558|NCT01112189|PROCEDURE|Autologous transplant|Patients will be stimulated 3 days with Filgrastrim 300 micrograms per day. On the 4th day the autologous transplant of stem cells will be performed.
224177559|NCT01112189|OTHER|Compressed sleeve treatment|"Week 1-2: With compressed sleeve treatment.~Week 3 -4: Without treatment.~Week 5 - 6: With compressed sleeve treatment"
224177560|NCT01252927|OTHER|ASIST|The gatekeeper training intervention group will receive the Applied Suicide Intervention Skills Training (ASIST) workshop in addition to training as usual. ASIST is a 2-day intensive, interactive and practice-dominated course aimed at enabling people to recognize risk and learn how to intervene immediately to prevent suicide.
224177561|NCT03030092|OTHER|Maximal Strength Training|leg pres and abduction exercises
224177562|NCT00392210|GENETIC|Voiding Trial|Post-void residual and uroflow study will be done twice
224177563|NCT00606021|DRUG|pemetrexed|500 mg/m², IV, Day 1 of each 21-day cycle for 6 cycles
224177564|NCT00606021|DRUG|Best Supportive Care|Patients will receive best supportive care (dose, frequency, duration) as judged by their treating physician.
224177565|NCT02570581|OTHER|Jelly with:Paracetamol|"A single dose of each drug will be opened (Paracetamol capsule) or crushed (tablets) in 100 ml of jelly (intervention 1-10) and in 100 ml of apple compote A mix of 6 drugs will be added to 100 ml of jelly (intervention 11) and in 100 ml of apple compote A negative control will consists in 100 ml of plain jelly or apple compote Each participant will receive 24 small transparent plastic glasses (verrines) randomly allocated from number 1 to number 24, each verrine containing 5 ml of the initial 100 ml drug preparation. The participant will be blind to the verrine content.~The participant will taste the verrine content with a 1 ml spoon and spit out each spoonful et rinse his or her mouth with plain water (Evian) between two tests.~The participant will score each verrine numbered 1-24 with a mark ranging from 0 to 10 on the results scoring sheet.~Unblinding will take place immediately after the end of the test. Every volunteer will propose alternative solutions."
224177566|NCT02570581|OTHER|Jelly with Furosemide|
224177567|NCT02570581|OTHER|Jelly with Levothyroxine sodium salt|
224177568|NCT02570581|OTHER|Jelly with Memantine|
224177569|NCT02570581|OTHER|Jelly with Zopiclone|
224177570|NCT02570581|OTHER|Jelly with Alprazolam|
224177571|NCT02570581|OTHER|Jelly with Oxazepam|
224177572|NCT02570581|OTHER|Jelly with Donepezil|
224177573|NCT02570581|OTHER|Jelly with Clopidogrel|
224306677|NCT06647394|PROCEDURE|Matrix Dressing|extracellular matrix dressing soaked in 4% topical lidocaine to the skin graft donor site
224306678|NCT00719030|DIETARY_SUPPLEMENT|Pomegranate pill|Pomegranate extract pill
223487210|NCT06034470|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspirate
223487211|NCT06034470|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
223487212|NCT06034470|DRUG|Cytarabine|Given IV
223487213|NCT06034470|PROCEDURE|Echocardiography|Undergo ECHO
223487214|NCT06034470|DRUG|Fludarabine|Given IV
223487215|NCT06034470|DRUG|Granulocyte Colony-Stimulating Factor|Given SC
223487216|NCT06034470|DRUG|Idarubicin|Given IV
223487217|NCT06034470|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA scan
224177574|NCT02570581|OTHER|Jelly with Ramipril|
224177575|NCT02570581|OTHER|Jelly with Paracetamol + Furosemide + Levothyroxine sodium salt + Memantine + Zopiclone + Alprazolam|
224177576|NCT02570581|OTHER|Plain jelly control|
224177577|NCT02570581|OTHER|Apple compote Paracetamol|
224177578|NCT02570581|OTHER|Apple compote Furosemide|
224177579|NCT02570581|OTHER|Apple compote Levothyroxine sodium salt|
224177580|NCT02570581|OTHER|Apple compote Memantine|
224177581|NCT02570581|OTHER|Apple compote Zopiclone|
224177582|NCT02570581|OTHER|Apple compote Alprazolam|
224306679|NCT00719030|DIETARY_SUPPLEMENT|Pomegranate pill placebo|Pomegranate pill placebo
224306680|NCT04391530|BEHAVIORAL|emotional freedom technique, breathing therapy|emotional freedom technique, breathing therapy
224306681|NCT01200992|BIOLOGICAL|EN3348|Induction: 6 weekly instillations. Maintenance: Monthly instillations to Month 12
223487218|NCT06034470|DRUG|Pivekimab Sunirine|Given IV
223487219|NCT00002462|BIOLOGICAL|bleomycin sulfate|
223487220|NCT00002462|DRUG|doxorubicin hydrochloride|
223487221|NCT00002462|DRUG|mechlorethamine hydrochloride|
223487222|NCT00002462|DRUG|prednisone|
223487223|NCT00002462|DRUG|procarbazine hydrochloride|
223487224|NCT00002462|DRUG|vinblastine sulfate|
223487225|NCT00002462|DRUG|vincristine sulfate|
223487226|NCT00002462|RADIATION|low-LET cobalt-60 gamma ray therapy|
223487227|NCT00002462|RADIATION|low-LET photon therapy|
223487228|NCT00002462|RADIATION|radiation therapy|
224177583|NCT02570581|OTHER|Apple compote Oxazepam|
224177584|NCT02570581|OTHER|Apple compote Donepezil|
224177585|NCT02570581|OTHER|Apple compote Clopidogrel|
224177586|NCT02570581|OTHER|Apple compote Ramipril|
224177587|NCT02570581|OTHER|Apple compote + Paracetamol + Furosemide + Levothyroxine sodium salt + Memantine + Zopiclone + Alprazolam|
224177588|NCT02570581|OTHER|Plain apple compote control|
224177589|NCT02402049|DRUG|Natrum muriaticum 30C|3 globules of Natrum muriaticum applied once daily at days 7,8, and 9 after the start of the period.
224177590|NCT02402049|DRUG|Lachesis 30C|3 globules of Lachesis applied once daily at days 7,8, and 9 after the start of the period.
224177591|NCT02402049|DRUG|Sepia 30C|3 globules of Sepia applied once daily at days 7,8, and 9 after the start of the period.
224177592|NCT02402049|DRUG|Nux vomica 30C|3 globules of Nux vomica applied once daily at days 7,8, and 9 after the start of the period.
224177593|NCT02402049|DRUG|Pulsatilla 30C|3 globules of Pulsatilla applied once daily at days 7,8, and 9 after the start of the period.
224177594|NCT02402049|DRUG|Folliculinum 30C|3 globules of Folliculinum applied once daily at days 7,8, and 9 after the start of the period.
224177595|NCT02402049|DRUG|Placebo Natrum muriaticum|3 globules of placebo Natrum muriaticum applied once daily at days 7,8, and 9 after the start of the period.
224306682|NCT01200992|BIOLOGICAL|Mitomycin C|Induction: 6 weekly instillations. Maintenance: Monthly instillations to Month 12
224306683|NCT02808689|BEHAVIORAL|Lifestyle Factors|Will look at nutrition and exercise that influence long-term health and chronic diseases.
224177596|NCT02402049|DRUG|Placebo Lachesis|3 globules of placebo Lachesis applied once daily at days 7,8, and 9 after the start of the period.
224177597|NCT02402049|DRUG|Placebo Sepia|3 globules of placebo Sepia applied once daily at days 7,8, and 9 after the start of the period.
224177598|NCT02402049|DRUG|Placebo Nux vomica|3 globules of placebo Nux vomica applied once daily at days 7,8, and 9 after the start of the period.
224177599|NCT02402049|DRUG|Placebo pulsatilla|3 globules of placebo Pulsatilla applied once daily at days 7,8, and 9 after the start of the period.
224177600|NCT02402049|DRUG|Placebo Folliculinum|3 globules of placebo Folliculinum applied once daily at days 7,8, and 9 after the start of the period.
224177601|NCT03543449|OTHER|Off-Pump Coronary Artery Bypass (OPCAB) surgery|Off-Pump Coronary Artery Bypass (OPCAB) surgery. This study is retrospective study
224177602|NCT06071533|DRUG|Dandshen|Dandshen injection 20ml /day
223487229|NCT05478304|DEVICE|AtriClip LAA Exclusion System|LAAE using the AtriClip concomitant to and at the time of planned cardiac surgery
223487230|NCT05389293|DRUG|Mosunetuzumab|During Cycle 1, mosunetuzumab will be administered SC in a step-up dosing schedule at the dose of 5 mg on Day 1, 45 mg on Day 8, and 45 mg on Day 15). Beginning with Cycle 2, mosunetuzumab will be administered SC at the dose of 45 mg on Day 1. Each Cycle lasts 3 weeks. After the first 8 cycles (approximately 6 months) of therapy, subjects who achieved CR will discontinue therapy, those who attained a PR will receive up to 17 doses (approximately 12 months). Subjects who achieve stable disease (SD) or who experience progressive disease (PD) will be taken off study and subsequent management will be left at the discretion of the investigator.
223487231|NCT05389293|DRUG|Zanubrutinib|In Cohort 2, zanubrutinib is concurrently administered continuously starting on Cycle 1, Day -7 and is given for 12 months in both patients with CR and those with PR
223487232|NCT05030441|DRUG|Ivosidenib|. Patients should take ivosidenib at approximately the same time every day, with or without food, but should be instructed to avoid a high-fat meal as well as grapefruit and grapefruit products.
224177603|NCT02067104|DRUG|Vismodegib|Pulse therapy pattern of 2 months of daily treatment and 2 months of no treatment for 24 months.
223487233|NCT06830642|DRUG|MTR-601|Capsule
223586830|NCT05827601|DIAGNOSTIC_TEST|serum|participants will be invited to get a blood sample taken by a general practitioner or to perform a self sampling of capillary blood
223586831|NCT04409717|PROCEDURE|Type II endoleak treatment|Type II endoleak endovascular treatment
223586832|NCT05207969|PROCEDURE|Instruction to urinate|Cystoscopy procedure will be done based on cystoscopy protocol. During scope procedure, patient will be ask to urinate and this will lead to contraction of urinary bladder and relaxation of external urethral sphincter. Scope will then pass through external urethral sphinter and go to the urinary bladder
223586833|NCT04855071|DEVICE|Non-ablative radiofrequency application|Non-ablative radiofrequency application will be applied with MJS intracavitary probe, in monopolar application, reaching a temperature between 42-45ºC in the tissues (according to the patient's tolerance), and with a power of 50% until the desired temperature is reached. It will be applied with a frequency that will be individualized according to the maximum level of energy absorption by the patient's tissues (between 0.8-1.2MHz) and with a dose of approximately between 3-4 KJ depending on the application time (20 minutes / session). In addition, they will be applied 1 session per week. The treatment will last 8 weeks.
223617696|NCT01790594|DRUG|Mycophenolate mofetil|Mycophenolate mofetil will be administered at a target dose of 1000 mg by mouth twice daily (e.g., BID) beginning on the day of surgery or post-operative day 1 depending upon when during the day the surgery is completed (maximum MMF dosing is 2G per day). MMF will be adjusted based on clinical complications (such as neutropenia). Myfortic® (mycophenolate sodium) may be used as a replacement for MMF. Mycophenolate sodium will be dosed at 720 mg PO BID. Mycophenolate sodium will be adjusted based on clinical complications.
224177604|NCT02067104|DRUG|Placebo|Pulse therapy pattern of 2 months of daily treatment and 2 months of no treatment for 24 months.
224177605|NCT01431794|DRUG|LDE225-600mg|"Phase I: oral LDE225 (Sonidegib), 600mg daily.~Phase II Arm A: LDE225 at the recommended phase 2 dose on Days 1, 8 and 15. Cycles repeated every 28 days."
224177606|NCT01431794|DRUG|Gemcitabine|Four cycles of Gemcitabine 1000 mg/m2 on days 1, 8, and 15 every 28 days.
224177607|NCT01431794|DRUG|nab-paclitaxel|Four cycles of nab-Paclitaxel 125 mg/m2 on days 1, 8, and 15 every 28 days.
224177608|NCT01431794|DRUG|LDE225-400mg|Phase I: oral LDE225 (Sonidegib), 400mg daily.
224177609|NCT01431794|DRUG|LDE225-800mg|Phase I: oral LDE225 (Sonidegib), 800mg daily.
224177610|NCT04585113|RADIATION|CT-scanning|All participants will receive dual-energy CT scanning and cone-beam CT scanning prior surgery.
224177611|NCT01901679|DRUG|Celebrex|200 mg PO BID
224177612|NCT01134328|DRUG|AC-150 Combo|1 drop in each eye for up to 14 days
224177613|NCT01134328|DRUG|AC-150A 0.1%|1 drop in each eye once per day for up to 14 days
224177614|NCT01134328|DRUG|AC-150B 0.005%|1 drop in each eye once per day for up to 14 days
224177615|NCT01134328|DRUG|Vehicle|1 drop in each eye once per day for up to 14 days
224306684|NCT02808689|OTHER|Customized use of Dietary Supplements|Reduce ongoing biologic imbalances from deficiencies in dietary oxidants/ antioxidants via vitamin supplementation. Approach is customized based on results for laboratory testing.
224306685|NCT02808689|OTHER|Currently Accepted Asthma Care Guidelines|Use of asthma care guidelines set forth by the National Institutes of Health/National Heart, Lung and Blood Institute (NIH/NHLBI) and Global Initiative for Asthma
223487234|NCT06830642|DRUG|Placebo|Capsule
223487235|NCT03617432|DRUG|Chidamide|Chidamide 15mg orally BIW. Six cycles of therapy will be administered, and each cycle of treatment is 21 days.
223487236|NCT03617432|DRUG|Cyclophosphamide|Cyclophosphamide(750mg/m2) was administered intravenously on d1. Six cycles of therapy will be administered, and each cycle of treatment is 21 days.
224177616|NCT06449794|DIAGNOSTIC_TEST|Anti Phospholipid antibodies|diagnosis of SLE
224177617|NCT06449794|RADIATION|EEG|EEG for Cases with seizures.
224177618|NCT02140762|BIOLOGICAL|MenABCWY|Subjects received one dose of 0.5 mL MenABCWY vaccine (intramuscular (IM) injection) at day 1 and a second dose after 2 months.
224177619|NCT02140762|OTHER|Placebo|0.5 mL saline solution (IM)
224177620|NCT02140762|BIOLOGICAL|MenACWY|Subjects received one dose of 0.5 mL placebo (IM) at day 1 and one dose of 0.5 mL MenACWY vaccine (IM) after 2 months.
224177621|NCT04815291|DEVICE|Receives SCOUT at biopsy|SCOUT Reflector
224177622|NCT01885962|BEHAVIORAL|iSHIFTup|Internet-delivered program to support behaviors to prevent pressure ulcers and promote healthy skin in adults with spinal cord injury.
224177623|NCT05010291|BEHAVIORAL|Standard of Care (SOC) text message reminder to attend clinic appointment|SOC one-way text message reminding recipient of care to either 1) attend a scheduled clinic appointment or 2) visit the clinic after a missed appointment.
224177624|NCT05010291|BEHAVIORAL|Loss aversion framed text message reminder to attend clinic appointment|Loss aversion framed one-way text message reminding recipient of care to either 1) attend a scheduled clinic appointment or 2) visit the clinic after a missed appointment.
224177625|NCT05010291|BEHAVIORAL|Social norms framed text message reminder to attend clinic appointment|Social norms framed one-way text message reminding recipient of care to either 1) attend a scheduled clinic appointment or 2) visit the clinic after a missed appointment.
224177626|NCT05010291|BEHAVIORAL|Altruism framed text message reminder to attend clinic appointment|Altruism framed one-way text message reminding recipient of care to either 1) attend a scheduled clinic appointment or 2) visit the clinic after a missed appointment.
224177627|NCT05071222|GENETIC|ARTEGENE drug product|Each patient will receive a single intravenous infusion of ARTEGENE drug product at D0.
224177628|NCT04851522|DRUG|Di-Dak-Sol|Topical solution applied externally.
224177629|NCT04851522|OTHER|White Petrolatum|Topical ointment applied externally
224177630|NCT01414439|BEHAVIORAL|Existential Group Therapy|The treatment will be given in two groups of eight to ten participants each one and will consist of one hour weekly sessions over a period of seven weeks. Dividing the subjects into small groups allows reference to all members of the group. The group facilitators will be two psychologists who work in co therapy.
224177631|NCT00542139|DRUG|Betamethasone|Intraarticular injection of 2ml Diprospan (wich contains 4mg Betamethasone sodium phosphate and 10mg Betamethasone dipropionate)
224177632|NCT00542139|DRUG|Bupivocaine|Intraarticular injection of 10ml of Bupivocaine
224306686|NCT01806766|PROCEDURE|Ceramic on Ceramic bearing|cementless Total Hip Arthroplasty with Ceramic on ceramic bearing
223487237|NCT03617432|DRUG|Doxorubicin|Doxorubicin (50mg/m2)was administered intravenously on d1.Six cycles of therapy will be administered, and each cycle of treatment is 21 days.
223487238|NCT03617432|DRUG|Vincristine|Vincristine (1.4mg)was administered intravenously on d1.Six cycles of therapy will be administered, and each cycle of treatment is 21 days.
223487239|NCT03617432|DRUG|Etoposide|Etoposide (100mg/m2) was administered intravenously on d1,2,3.Six cycles of therapy will be administered, and each cycle of treatment is 21 days.
223487240|NCT03617432|DRUG|Prednisone|Prednisone (100mg)was administered by oral on d1-5.Six cycles of therapy will be administered, and each cycle of treatment is 21 days.
223487241|NCT04932109|OTHER|No intervention|No intervention in this group
223487242|NCT04574518|BEHAVIORAL|TeaM OUT Intervention|The TeaM OUT Intervention has 2 elements: 1) a letter that a) describes the nodule and the importance of cessation related to the pulmonary nodule (i.e. teachable moment) and b) notification that a Proactive IVR Quit line will initiate contact and 2) call(s) from the Proactive IVR Quit Line which a) offers smoking cessation resources and b) helps connect the patient to those resources.
223487243|NCT04574518|BEHAVIORAL|Enhanced Usual Care|The Enhanced Usual Care arm also has two elements: 1) a letter that a) describes the nodule without linking it to smoking cessation (i.e. no teachable moment) with b) wording to contact an Optional IVR Quit line if desired and 2) the Optional IVR Quit line which a) offers smoking cessation resources and b) helps connect the patient to those resources.
223487244|NCT05070845|BIOLOGICAL|PF-06835375|CXCR5 inhibitor
223487245|NCT01787838|OTHER|Focused Health Education|"A two-phase quality improvement study was designed to modify staff and patient behaviors. The project incorporated evidence-based strategies of staff education, feedback and incentives for performance and patient education.~The staff received monthly feedback on departmental immunization rates, and incentives for performance. A one-page patient education flyer, written at 3rd grade reading level, was added to encourage patients to inquire about it."
223487246|NCT06284109|DEVICE|Cryoanalgesia|Participants will receive cryoanalgesia with the The iovera° system. . The specific nerves targeted will be both the sciatic, targeted first (as distal as possible, but not more distal than the bifurcation), and femoral, targeted second (as distal as possible, but not more distal than the adductor canal). Cryoanalgesia will result from an 8-minute-long percutaneous cryoneuroablation procedure consisting of several freeze/defrost cycles. Per routine, all patients will have a nerve block with single shot ropivacaine.
223617697|NCT03011008|DRUG|Liraglutide|Dose escalation of liraglutide starts from 0.6 mg up to 1.2 mg per day.
223617698|NCT03011008|DRUG|Insulin|Receive insulin following clinician's instruction.
224177633|NCT01278810|DRUG|Icaritin|50mg,100mg,200mg,300mg,400mg,500mg ascending-multiple oral dose, Qd, single dose and continuing dose 28 days, to assess the safety,tolerance and pharmacokinetics of icaritin
224177634|NCT01914510|DRUG|ENMD-2076|
224177635|NCT06065410|OTHER|Baseline|Walking without any instruction or sound
224177636|NCT06065410|OTHER|Intrinsic focus|Walking focusing on ensuring equal step lengths and step durations on both sides and symmetry between both steps
224177637|NCT06065410|OTHER|White noise|Intrinsic focus accompanied by white noise
224177638|NCT06065410|OTHER|environmental sound|Intrinsic focus accompanied by environmental sound
224177639|NCT01592110|DRUG|risperidone-SABER|25 mg of risperidone-SABER administered as a subcutaneous (SC) injection of 0.25 mL
224177640|NCT01592110|OTHER|ZX003:risperidone-SABER and the DosePro System|50 mg risperidone-SABER administered as 0.5 mL via the DosePro Needle-Free Injection System
224177641|NCT01592110|DRUG|risperidone-SABER|50 mg of risperidone-SABER administered as a SC injection of 0.5 mL
224177642|NCT01592110|DRUG|Risperidone-SABER|100 mg of risperidone-SABER administered as a SC injection of 1.0 mL
224177643|NCT06492421|DRUG|ipilimumab, pembrolizumab, durvalumab, idarubicin, bevacizumab|"This study has 3 subgroups:~Arm 1. Ipilimumab +pembrolizumab or Ipilimumab +durvalumab is administrated with a total dose of 1-2mg/kg via intra-tumor fine needle injection in 10 min, every 3 weeks, total 3-4 times.~Arm 2. Ipilimumab +pembrolizumab or Ipilimumab +durvalumab combined with idarubicin is administrated via intra-tumor fine needle injection in 15 min, every 3 weeks, total 3-4 times.~Arm 3. Ipilimumab +pembrolizumab or Ipilimumab +durvalumab combined with idarubicin plus bevacizumab is administrated via intra-tumor fine needle injection in 20 min, every 3 weeks, total 3-4 times."
224177644|NCT00095836|DRUG|Gefitinib|Taken orally once a day for duration of benefit. Treatment is continuous until there is evidence of disease progression or unacceptable toxicity.
224177645|NCT03000764|OTHER|skin biopsies|"Biopsies (12 G) will be performed :~* in non-irradiated breast skin~* in irradiated breast skin"
224177646|NCT03000764|OTHER|blood samples|"blood samples are collected:~* 10 ml in EDTA tube~* 2,5 ml in PAXgene Blood RNA tube~* 4 ml in EDTA tube"
224177647|NCT00475579|PROCEDURE|tube with subglottic drainage and polyurethane cuff|
224177648|NCT01078779|DRUG|Chloroquine|Chloroquine phosphate 250mg capsule, two capsules daily for 7 days then 2 capsules once a week for a total treatment duration of 12 weeks
224177649|NCT01078779|DRUG|Placebo|Placebo capsules, 2 capsules daily for 7 days then 2 capsules weekly for a total treatment duration of 12 weeks
224177650|NCT02994043|BEHAVIORAL|Mindfulness-Based Relapse Prevention Therapy|An 8-week, outpatient psychotherapy that combines mindfulness components with relapse prevention.
224177651|NCT02994043|BEHAVIORAL|Relapse Prevention Therapy|An 8-week, outpatient psychotherapy that uses cognitive-behavioral components to reduce alcohol-related consequences.
224177652|NCT00989664|BIOLOGICAL|Tositumomab and Iodine I 131 Tositumomab|"Dosimetric Dose: 450 mg of TST infused over 70 minutes (inclusive of a 10-minute flush) immediately followed by I-131 TST (35 mg of TST, of which 1-2 mg had been labeled with 5 mCi of Iodine-131) infused over 30 minutes (inclusive of a 10-minute flush).~Therapeutic Dose: 7 to 14 days after the dosimetric dose, 450 mg of TST infused over 70 minutes (inclusive of a 10-minute flush) immediately followed by I-131 TST (35 mg of TST labeled with enough Iodine-131 to administer the specified whole body radiation dose determined for the subject) infused over 30 minutes (inclusive of a 10-minute flush). The desired total body dose was 65 cGy for subjects with a baseline platelet count of 100,001-149,999/mm3 and 75 cGy for patients with a baseline platelet count ≥150,000/mm3. Obese patients received an attenuated dose by not including subject mass over 137% of their calculated lean body mass in their calculated lean body mass in the dose calculation."
224177653|NCT01481259|BIOLOGICAL|Autologous cytokine-induced killer cell|Subjects receive autologous cytokine-induced killer cell infusion every 21 days in the absence of disease progression or unacceptable toxicity.
224177654|NCT01481259|OTHER|Pemetrexed|Subjects receive pemetrexed infusion at a dose of 500mg/m2 every 21 days in the absence of disease progression or unacceptable toxicity.
224177655|NCT06012266|DRUG|Dapagliflozin tablet|"Patients randomized to Group A will start with Dapagliflozin on Visit 1 and take Dapagliflozin once daily up to the day before Visit 3.~Patients randomized to Group B will start Dapagliflozin once daily on the day of Visit 3, to be continued up to the day preceding Visit 4.~Dose:~* participants ≤12 year old: 5mg once daily p.o. (commercially available tablet)~* participants \>12 year old: 10mg once daily p.o. (commercially available tablet)"
224177656|NCT06012266|DRUG|Empagliflozin Tablets|"Patients randomized to Group A will start with Empagliflozin on Visit 1 and take Empagliflozin once daily up to the day before Visit 3.~Patients randomized to Group B will start Empagliflozin once daily on the day of Visit 3, to be continued up to the day preceding Visit 4.~Dose: Empagliflozin 10mg once daily p.o. (commercially available tablet)"
223487247|NCT06284109|DEVICE|Sham Cryoanalgesia|Participants will receive Sham cryoanalgesia with the The iovera° system. The specific nerves targeted will be both the sciatic, targeted first (as distal as possible, but not more distal than the bifurcation), and femoral, targeted second (as distal as possible, but not more distal than the adductor canal). Per routine, all patients will have a nerve block with single shot ropivacaine.
223487248|NCT04336683|DEVICE|Interstitial and intracavitary brachytherapy|Standard of care in interstitial or intracavitary brachytherapy is to insert the brachytherapy needle and applicator with no standard real-time image guidance. Interstitial brachytherapy is done under general anesthesia. Trans-abdominal and trans-rectal standard 2D ultrasound is used in some cases, but is typically not consistent and therefore its value is limited. Pre-procedure imaging in the form of MRI is used to help guide needles insertion as well as the clinical exam. Post-procedure CT is done for radiation planning
223617699|NCT02907034|PROCEDURE|Virtual reality experimentation sequency (VR)|
223617700|NCT02907034|PROCEDURE|Classical narrative approach (CN)|
224177657|NCT05541159|DRUG|TNO155|Single oral dose of TNO155 on Day 1
224177658|NCT02067806|DRUG|2-chloroprocaine hydrochloride, 1%|Study included male and female adult patients undergoing spinal anesthesia with chloroprocaine, when the planned surgical procedure was not expected to exceeded 40 minutes.
224177659|NCT04628754|OTHER|Exercise and protein|Home based exercise regime and dietary protein guidance
224177660|NCT05910983|PROCEDURE|Bipolar enucleation of the prostate (BipolEP)|Bipolar enucleation of the prostate (BipolEP)
224177661|NCT05910983|DRUG|Intravesical Botox injection|Intravesical botox injection given only in experimental group.100 units of Botox will be used and diluted in 10 mL of normal saline. 0.5 cc injections will be administered in 20 injection sites (trigone sparing).
224177662|NCT04052594|DRUG|LY3475766 - IV|Administered IV
224177663|NCT04052594|DRUG|LY3475766 - SC|Administered SC
224177664|NCT04052594|DRUG|Placebo - IV|Administered IV
224177665|NCT04052594|DRUG|Placebo - SC|Administered SC
224177666|NCT01808040|DRUG|TAK700|dose is dependant on dose escalation timepoint and dose expansion cohort dose will be the RP2D determined based on the dose escalation cohort final dose recommendation
224177667|NCT00962780|BIOLOGICAL|13-valent Pneumococcal Conjugate Vaccine (13vPnC)|13vPnC; 3 vaccinations given at approximately 1 month intervals at visits 1-3
223617701|NCT01772446|BEHAVIORAL|SMS MESSAGING|SMS MESSAGING TO MOBILE PHONE TO REMEMBER THE NEXT CONTROL OF GLYCATED DIABETES
223617702|NCT05528705|BIOLOGICAL|LAENNEC|Subacromial spatial administration
224177668|NCT00962780|BIOLOGICAL|23-valent Pneumococcal Polysaccharide Vaccine (23vPS)|23vPS; 1 vaccination given at visit 4 (approximately 1 month after visit 3)
224177669|NCT00962780|PROCEDURE|Blood draw|Blood draw; 5 blood draws approximately 1 month apart taken prior to vaccination at visits 1-4 and visit 5 (approximately 1 month after visit 4).
224177670|NCT00962780|PROCEDURE|Blood draw|1 or 2 blood draws for CD4+ T cell count and HIV viral load at least 6 weeks apart, if subject does not have 2 CD4+ T cell counts and HIV viral load counts within 6 months before visit 1.
224306687|NCT01806766|PROCEDURE|Ceramic on Highly crosslinked polyethylene bearing|Cementless Total Hip Arthroplasty with Ceramic on Highly crosslinked polyethylene bearing
223617703|NCT05528705|OTHER|0.9% normal saline|Subacromial spatial administration
224177671|NCT03813576|DIAGNOSTIC_TEST|Self-collected HPV vaginal swab|Patients will be instructed on how to collect a vaginal swab on themselves which will then be processed for presence of HPV DNA.
224177672|NCT02485431|DRUG|Deflazacort|
224177673|NCT05028166|DRUG|Mirdametinib (MEK Inhibitor)|Patients will receive oral mirdametinib.
224177674|NCT04559867|PROCEDURE|Needle knife fistulotomy|A needle knife fistulotomy uses a tiny knife to cut directly into the ampulla to gain access to the biliary system in patients undergoing ERCP.
224177675|NCT04559867|PROCEDURE|Sphincterotomy|A sphincterotomy uses a heated metal wire to cut the opening to the bile duct after a wire has been passed into it.
224177676|NCT03619369|PROCEDURE|Circumcision|Early vs. Routine vs. Delayed Circumcision and their impact on exclusive breastfeeding rates
224177677|NCT00519558|DRUG|somatropin|
224177678|NCT02532075|OTHER|Inspiratory Warm Up|Inspiratory muscle warm up. Inhaling against a resistance for two sets of 15 breaths using a PowerLung.
224177679|NCT02532075|OTHER|Expiratory Warm Up|Expiratory muscle warm up. Exhaling against a resistance for two sets of 15 breaths using a PowerLung.
224177680|NCT02532075|OTHER|Combination Warm Up|Combination of inspiratory and expiratory muscle warm up. One set of 15 breaths inhaling followed by one set 15 breaths exhaling.
224306688|NCT00186095|PROCEDURE|autologous followed by nonmyeloablative allogeneic transplant|
224306689|NCT03402555|OTHER|Stool pattern|Collection of stool images
224306690|NCT02183181|DRUG|Meloxicam capsule|
223487249|NCT00058981|DRUG|DiaPep277|
223487250|NCT02367560|PROCEDURE|Needle decompression|Direct manipulation of calcium deposits in the shoulder with a needle to fragment the deposit performed by a radiologist.
223487251|NCT02367560|PROCEDURE|Shockwave therapy|A physiotherapist performs the shockwave therapy procedure. Treatment is completed in 4 weekly sessions. Treatment involves applying soundwaves directly to the affected shoulder area using an ultrasound device.
224177681|NCT02532075|OTHER|Control Trial|Control Trial. No respiratory muscle warm up to act as a comparison to the other three intervention trials.
224177682|NCT05830331|OTHER|ERASS Pathway|Enhanced Recovery After Spinal Surgery
224306691|NCT02183181|DRUG|Meloxicam tablet|
224177683|NCT00560872|DEVICE|remote magnetic catheter navigation|use of the Stereotaxis system
224177684|NCT00560872|PROCEDURE|cavotricuspid isthmus ablation|conventional (manual) approach
224177685|NCT02363322|DRUG|B/Current Standard of Care Plus ZMapp|Triple monoclonal cocktail of antibodies against Zaire species of Ebola virus
224177686|NCT02363322|OTHER|A/Current Standard of Care Alone|Optimized standard of care for Ebola virus infection
224306692|NCT02155543|DRUG|AGN-223575 Formulation A|One drop of AGN-223575 Formulation A administered in the study eye(s) per protocol.
224306693|NCT02155543|DRUG|AGN-223575 Formulation B|One drop of AGN-223575 Formulation B in both eyes on day 1, followed by one drop of AGN-223575 Formulation B twice daily in both eyes for 13 days, and a single drop of AGN-223575 Formulation B in both eyes on day 15.
224177687|NCT02424890|OTHER|MDT simulation sessions of management of life-threatening events over 1 year|9 simulation sessions over 1 year for Repetitive Sim Group and 3 simulation sessions over 1 year for Control Group
223487252|NCT02367560|DRUG|Depo medrol|Subacromial steroid injection (40 mg depo medrol) is given to the patient to limit irritation following needle decompression.
223487253|NCT02367560|DEVICE|Ultrasound device|Ultrasound device is applied directly to the shoulder at 0.2 mJ/mm2.
223487254|NCT00526175|DRUG|Prednisone|60 mg/m2 day, i.v. or oral, dyas 1 to 27 30 mg/m2 day, i.v. or oral, days 28 to 35
223487255|NCT00526175|DRUG|Vincristine|1,5 mg/m2 i.v., days 8, 15, 22 and 28
224177688|NCT04029649|DRUG|Beta-1,3/1,6-D-Glucan|Beta-1,3/1,6-D-Glucan capsule three times daily for 90 days
224177689|NCT04029649|DRUG|Placebo|Placebo capsule three times daily for 90 days
224177690|NCT00623350|OTHER|Telephone|Acute Stroke consult by Telephone for the decision of tPA within 3 hours of symptom onset.
223487256|NCT00526175|DRUG|Daunorubicin|30 mg/m2, i.v., days 8 and 15
223487257|NCT00526175|DRUG|L-Asparaginase|10.000 UI/m2, i.m. or i.v., days 9 to 11, 16 to 18 and 23 to 25. Total: 9 doses.
223487258|NCT00526175|DRUG|Cyclophosphamide|1000 mg/m2, i.v., day 22.
223487259|NCT00526175|DRUG|Methotrexate|Age \<1 year 1-2 years 2-3 years \> 3 years MTX 5 mg 8 mg 10 mg 12 mg
223487260|NCT00526175|DRUG|Cytosine Arabinoside|Edad \<1 year 1-2 years 2-3 years \> 3 years ARA-C 16 mg 16 mg 20 mg 30 mg
223487261|NCT00526175|DRUG|Mercaptopurine|50 mg/m2,oral, days 1 to 7, 28-35 and 56-63
223487262|NCT00526175|DRUG|VP-16|150 mg/m2 i.v., days 14-15 and 42-43
223487263|NCT01431976|DRUG|Lamictal|No comparison
223487264|NCT00608920|OTHER|Single Photon Emission Computed Tomography (SPECT)|
224177691|NCT00623350|OTHER|Two way audio/video telemedicine consult|Acute Stroke consult by two way audio video telemedicine for the decision of tPA within 3 hours of symptom onset.
224177692|NCT01654406|DEVICE|Fractional CO2 laser and pulsed dye laser|Fractional CO2 laser: 50 mJ, 100 spots/cm2, a scan area of 4\_4mm, static mode, and two passes Pulsed dye laser: 5mm,1.5ms,8J,delay cooling device 30/30,one pass
224306694|NCT02155543|DRUG|AGN-223575 Formulation C|One drop of AGN-223575 Formulation C in both eyes on day 1, followed by one drop of AGN-223575 Formulation C twice daily in both eyes for 13 days, and a single drop of AGN-223575 Formulation C in both eyes on day 15.
224306695|NCT02155543|DRUG|AGN-223575 Vehicle|One drop of AGN-223575 vehicle administered in the study eye(s) per protocol.
224306696|NCT00104143|DRUG|A4I Antagonist|
224306697|NCT04645836|BEHAVIORAL|New management mode|"New management mode intervention: Pharmaceutical care~* SMS text messages and Phone Calls~* Behavioural Educational leaflet~* Self-Administered Therapy A financial incentive for mobile use"
224306698|NCT06408948|DRUG|[14C]SHR7280|Patients will receive single dose of orally \[14C\]SHR7280 on Day 1.
224177693|NCT01654406|DEVICE|Pulsed dye laser|Pulsed dye laser: 5mm,1.5ms,8J,delay cooling device 30/30,one pass
224177694|NCT04063059|BEHAVIORAL|PRIDE counseling intervention|Step-by-Step program to create positive lifestyle change geared toward wellness and long term healthy living through group sessions and telephone counseling.
224314212|NCT01567475|DRUG|Everolimus and rituximab|One injection of Rituximab 375 mg/m2 per week during 28 days followed by one Rituximab infusion every other cycle at 375 mg/m2 associated with everolimus at 5mg or 10 mg every day or 5 mg every other day.
224177695|NCT02865278|OTHER|Standard meal|The participants consume the drink, experimental or placebo drink. After 3 hours they consume a standard meal (905 kcal, 15% protein, 46% fat, 39% CHO). Blood samples are taken at fasting, over 3 hours after drink consumption and over 5 hours after the test meal to evaluate metabolic response. Fasting and 48h-urine are collected to evaluate bioavailability of polyphenol.
224177696|NCT01378156|BIOLOGICAL|JS7 plasmid DNA and MVA62B vaccine|JS7 plasmid DNA (3 mg at weeks 1 and 9) and MVA62B vaccine (10(8) TCID(50) at weeks 17 and 25)
224177697|NCT05540015|PROCEDURE|Third molar extraction by cutting and rotary tools|Extraction of the impacted lower third molar will be conducted using cutting and rotary tools under the local anesthesia (Ultracain D-S 1:100000 40 mg/ml, active substance- articaine+epinephrine, registration № П N015119/01 ). Scalpel will be used for the incision of the soft tissues, rotary instruments will be used for the bone tissue and tooth fragmentation. After the extraction the wound will be sutured by the suture material.
224177698|NCT05540015|PROCEDURE|Third molar extraction by erbium laser with wavelength 2.94 nm|Extraction of the impacted lower third molar will be conducted using erbium laser with wavelength 2.94 nm under the local anesthesia (Ultracain D-S 1:100000 40 mg/ml, active substance- articaine+epinephrine, registration № П N015119/01 ). The soft tissue and bone tissue will be dissected by erbium laser with wavelength 2.94 µm (Erbium laser Smart 2940D plus with the wavelength 2,94 µm, company- DEKA, Italy, registration № 2005/1245). After the extraction the wound will be sutured by the suture material (registration № ФСЗ 2010/06040; 07.08.2018)
224177699|NCT01429376|OTHER|Pulmonary function tests|Patients underwent several pulmonary function tests (spirometry, diffusion measurement, body plethysmography) according to the study protocol 1 month after the first blood sample. COPD was diagnosed post-bronchodilation according to GOLD guidelines. Patients with newly diagnosed COPD received standard treatment for COPD. Spirometry was repeated after 3 months of standard treatment for COPD in patients with newly diagnosed COPD to confirm persistent airway obstruction (COPD) and thus exclude asthma.
224177700|NCT01429376|OTHER|Blood tests|"First blood sample (day 1): NT-pro-BNP, sodium, potassium, urea, creatinin, glomerular filtration rate (GFR).~Second blood sample (after 1 month): NT-pro-BNP, sodium, potassium, urea, creatinin, GFR, haemoglobin, and arterial blood gas analysis in patients with GOLD III COPD. For systemic inflammation substudy also high sensitivity CRP, leukocytes, and platelets.~Third blood sample (after 3 months from second blood sample): NT-pro-BNP, sodium, potassium, urea, creatinin, and GFR."
224177701|NCT01429376|OTHER|Questionnaires|"Minnesota Living with Heart Failure Questionnaire (MLHFQ), modified Medical Research Council (MRC) dyspnoea scale, 10-point Borg dyspnoea score.~All questionnaires were completed on the day of initial pulmonary function tests and three months later."
224177702|NCT01429376|OTHER|Chest radiograph|Standard posteroanterior and lateral chest radiographs were performed and evaluated on the presence or absence of congestion and other conditions that belonged to the exclusion criteria.
224177703|NCT04951557|PROCEDURE|Transsphenoidal resection|Transsphenoidal resection of pituitary adenoma
224177704|NCT00654056|DRUG|Actrapid (human insulin)|On day one: 0,5 IU/kg/min for 3 hours, 1,5 IU/kg/min for 3 hours, on day two: 3,0 IU/kg/min for 3 hours, 5,0 IU/kg/min for 3 hours
224177705|NCT00779233|DRUG|Zidovudine tablets 300 mg|
224177706|NCT02055976|DRUG|Bococizumab (PF-04950615;RN316)|Atorvastatin plus PF-04950615 50 mg subcutaneous administration at every two weeks (Q14D SC) for 16 week
224177707|NCT02055976|DRUG|Bococizumab (PF-04950615;RN316)|Atorvastatin plus PF-04950615 100 mg Q14D SC for 16 week
224177708|NCT02055976|DRUG|Bococizumab (PF-04950615;RN316)|Atorvastatin plus PF-04950615 150 mg Q14D SC for 16 week
224177709|NCT02055976|DRUG|Placebo|Atorvastatin plus PF-04950615 Placebo Q14D SC for 16 week
224177710|NCT02055976|DRUG|Ezetimibe|Atorvastatin plus Ezetimibe 10 mg oral administration once daily for 16 week (open)
224177711|NCT02055976|DRUG|Bococizumab (PF-04950615;RN316)|50 mg Q14D SC for 16 week
224177712|NCT02055976|DRUG|Bococizumab (PF-04950615;RN316)|100 mg Q14D SC for 16 week
223487265|NCT00867932|DRUG|Eculizumab|5 mg/mL solution in 5% Dextrose
223487266|NCT05688228|OTHER|questionnaire|Female Sexual Function Index (FSFI) and self-administrative questionnaires on sexuality just after abortion and repeated at 1, 3 and 6 months
223487267|NCT03197727|DIAGNOSTIC_TEST|GC Saliva-Check BUFFER|Evaluating the saliva flow rate, saliva pH and saliva buffering capacity
223487268|NCT05897151|DRUG|Continuous spinal anesthesia|"Preservative free 0.5% Hyperbaric bupivacaine (AstraZeneca) 5mg + 25mcg fentanyl for the initial dose will be followed by top up doses of 2.5 mg boluses of 0.5% Hyperbaric bupivacaine every 10 minutes until the desired block height is obtained considering patient hemodynamics.~Norepinephrine starting. dose 0.01 micg/kg/min will be ready for both groups if needed (Mean arterial pressure \< 70 or Mean arterial pressure decreased more than 20% of preoperative value). The infusion will be through a wide bore Intravenous line. The dose will be titrated up or down according to the patient hemodynamics."
224177713|NCT02055976|DRUG|Bococizumab (PF-04950615;RN316)|150 mg Q14D SC for 16 week
224177714|NCT02055976|DRUG|Placebo|Placebo Q14D SC for 16 week
224177715|NCT00642343|BEHAVIORAL|Evaluation of motor proficiency skills.|The balance subtest of the Bruininks-Oseretsky Test 2nd Ed. will be administered and scored.
223487269|NCT05897151|DRUG|General anesthesia|After establishing of ASA monitoring, a wide bore cannula (18 G) will be inserted. Induction will be done by fentanyl ( 2 mcg/kg ) , titrating dose of propofol according to patient hemodynamic response and atracurium ( 0.5 mg/kg ) to facilitate tracheal intubation maintaining End tidal Co2 between 30-40 mmHg.
223487270|NCT04888416|BEHAVIORAL|I-STROM|I-STROM is a combination of the following implementation strategies: (a) initial and ongoing training, (b) learning collaboratives/knowledge sharing meetings, and (c) outcome measure champions
223487271|NCT04736875|DIAGNOSTIC_TEST|Doppler ultrasound study|Transcutaneous Doppler ultrasound (DUS) study was performed at the mid brachial artery to assess diameter, VF and RI, and at the mid segment of the efferent vein to assess the diameter and wall thickness.
223487272|NCT04539964|PROCEDURE|Implant Procedure|The SetPoint System (study device) contains a miniaturized stimulator (implant) that is surgically implanted inside the left side of the neck on the vagus nerve (implant procedure). All eligible subjects will undergo the surgery under general anesthesia in outpatient settings.
223487273|NCT04539964|DRUG|Conventional Synthetic DMARD|All subjects will continue to take at least one type of conventional synthetic DMARD at the same stable dose as for 4 weeks prior to consent
224177716|NCT00642343|BEHAVIORAL|Evaluation of motor proficiency|The balance subtest of the Bruininks-Oseretsky Test 2nd Ed. will be administered and scored.
224177717|NCT00642343|BEHAVIORAL|Evaluation of motor proficiency|The balance subtest of the Bruininks-Oseretsky Test 2nd Ed. will be administered and scored.
224177718|NCT00642343|BEHAVIORAL|Evaluation of motor proficiency.|The balance subtest of the Bruininks-Oseretsky Test 2nd Ed. will be administered and scored.
224177719|NCT01392079|DRUG|Alemtuzumab|Alemtuzumab 30 mg s.c. 3 × weekly for 28 days (Days 1, 3, 5; 8, 10, 12; etc.)
224177720|NCT02946008|RADIATION|Stereotactic Body Radiation Therapy|Delivered over 5 treatment sessions for approximately 1.5 weeks total.
224177721|NCT02946008|PROCEDURE|Radical Prostatectomy|Open, laparoscopic, or robotic radical prostatectomy and pelvic lymph node dissection to remove the prostate, seminal vesicles, and pelvic lymph nodes.
223487274|NCT04539964|DEVICE|Active stimulation|Active stimulation for 1 min once per day
223487275|NCT04539964|DEVICE|Non-active stimulation|Non-active stimulation for 1 min once per day
223487276|NCT01136954|DRUG|Zonisamide|Transition Period from Study E2090-E044-312: Placebo Open-Label Period: 1 to 8 mg/kg orally per day for approximately 59 weeks.
223487277|NCT00782067|DRUG|Midostaurin (PKC412)|Midostaurin was provided as 25 mg soft gelatin capsules for oral administration.
223487278|NCT04262843|DRUG|Cyclophosphamide|Given IV
223487279|NCT04262843|DRUG|Fludarabine|Given IV
223487280|NCT04262843|DRUG|Fludarabine Phosphate|Given IV
223487281|NCT04262843|BIOLOGICAL|Granulocyte Colony-Stimulating Factor|Growth factor therapy
223487282|NCT04262843|PROCEDURE|Hematopoietic Cell Transplantation|Undergo hematopoietic cell transplantation
223487283|NCT04262843|PROCEDURE|Intensity-Modulated Radiation Therapy|Undergo TMLI
223487284|NCT04262843|DRUG|Mycophenolate Mofetil|Immunosuppressive therapy
223487285|NCT04262843|DRUG|Tacrolimus|Immunosuppressive therapy
223487286|NCT01949272|DEVICE|esophageal pressure mesurement|"EXPRESS study ventilatory setting the optimization of PEEP with esophageal pressure mesurement"
223487287|NCT05883488|OTHER|Robot-assisted upper extremity rehabilitation|The robotic rehabilitation program (with the Armeo Spring Pediatric Robotic Rehabilitation system) will be implemented 3 days a week for 30 minutes in addition to the conventional rehabilitation program. Participants will receive a total of 4 weeks of treatment.
223487288|NCT05883488|OTHER|Conventional rehabilitation|Conventional rehabilitation program will be applied 5 days a week, lasting 60 minutes.
223487289|NCT02703363|DRUG|Minocycline|
223487290|NCT02703363|DRUG|Celecoxib|
223487291|NCT02703363|DRUG|Placebo|
223487292|NCT04681378|PROCEDURE|double layer step up-step down technique|the incision is closed using Vicryl 1-0 stitch starting from one corner. The first layer is transversely passed through the inner myometrium-decidua line, and second layer is transversely passed through outer myometrium-visceral line continuously by alternating continuous stitches through the upper (step up) and the lower (step down) uterine flaps. The original string is returned to the starting point and tied with knot as in Turan technique. Following the double layered step up-step down closure, additional single sutures were added for hemostasis if required
223487293|NCT06161948|OTHER|Time-restricted enteral nutrition therapy group|Control the daily enteral nutrition time to 8-12 hours, enteral nutrition start time: 06:00 \~ 08:00, end time: 16:00 \~ 18:00. Enteral nutrition lasts until the patient discontinues enteral nutrition, the patient dies, the patient is transferred from the ICU, or enteral nutrition is used until 28 days, whichever event occurs first.
223487294|NCT06161948|OTHER|Continuous enteral nutrition control group|The control group was continuous enteral nutrition (24 hours), which lasted until the patient stopped taking enteral nutrition, the patient died, the patient was transferred from the ICU, or enteral nutrition was used until 28 days, whichever event occurred first.
223487295|NCT06182085|DRUG|PRI-002|Oral administration
223487296|NCT06182085|DRUG|Placebo|Oral administration
223487297|NCT05941936|BIOLOGICAL|LM103|Fresh tumor samples will be resected from enrolled patients. Autologous TILs will be extracted and reinfused to corresponding patients after ex vivo stimulation, activation and extensive expansion.
224177722|NCT01230827|DRUG|CNTO 148 (Golimumab)|Patients will receive subcutaneous (SC) (under the skin) injection of golimumab 30 mg per square meter every 4 weeks from Week 0 through Week 248.
224177723|NCT01230827|DRUG|Placebo|Patients who have a clinical response to golimumab at Week 16 and are randomly allocated to placebo, will receive SC injection of placebo every 4 weeks from Week 16 through Week 48.
224177724|NCT01230827|DRUG|Methotrexate|All patients will receive their fixed dose of commercial methotrexate (10 to 30 mg per square meter) weekly throughout the study duration.
224177725|NCT05539742|DIETARY_SUPPLEMENT|Coconut oil|Coconut oil will be given to each participant in the amount of 40 g, which will be incorporated into biscuits.
224177726|NCT05539742|DIETARY_SUPPLEMENT|Palm oil|Palm oil will be given to each participant in the amount of 40 g, which will be incorporated into biscuits.
224177727|NCT01871428|DRUG|aleglitazar|150 mcg orally daily
224177728|NCT01871428|DRUG|placebo|matching aleglitazar placebo orally daily
224177729|NCT05555914|OTHER|Neurostimulation|Implantation of 3 multicontact cuff electrodes in the upper limb of patients with tetraplegia and control of the stimulation by contralateral shoulder movements
224177730|NCT00417898|DRUG|Aspirin|
224177731|NCT05061758|DRUG|LY3056480|LY3056480 is an inhibitor of gamma-secretase
224205531|NCT04460521|DEVICE|Wrist Splint|Participants in both arms will be given a standard prescription for a prefabricated night splint which keeps the wrist in a neutral position and instructed on proper use and the importance of consistent use. To limit splint variability, we will ensure that splint prescriptions are written such that a MedSpec Wrist Lacer II splint is obtained from the patient's pharmacy. This is the most commonly available brand locally and meets the criteria for wrist, metacarpophalangeal, and interphalangeal joint positioning. They will be advised to wear the splint consistently during sleeping hours on their affected wrist for eight weeks, as is the standard of practice.
223487298|NCT04302285|OTHER|PKU type meal and Exercise|"* Exercise was conducted prior to PKU type meal.~* PKU type meal was based on PKU special low protein foods (50% of total energy intake), natural free protein foods (37%) and protein substitute (13%). Calories provided in breakfast were 600 kcal and were not based on individual dietary requirement. 65% of total energy intake was provided from carbohydrate, 13% from protein and 22% from fat."
223586834|NCT04855071|OTHER|Usual intervention|The usual intervention will consist of supervised individualized sessions that will include application of exercises to balance the pelvis and their muscles, treatment of trigger points, teaching activation of the transverse abdominis with ultrasound biofeedback and teaching reflex activation exercises of the transverse abdominis and pelvic floor muscles in different body positions. In addition, standards of water, urination, food, defecation, postural hygiene and physical activity will be provided. It is also recommended different life habit advices related to tobacco use, constipation, etc.
223586835|NCT04093336|BIOLOGICAL|human umbilical cord mesenchymal stem cells|The MSCs was intravenous transplanted to acute cerebral infarction patients as a single dose.
223586836|NCT04093336|BIOLOGICAL|Placebo|Placebo
223586837|NCT04093336|OTHER|standardized treatment|standardized treatment
223586838|NCT01028066|OTHER|Traditional|The control group will have access to the nutritionist to clear any doubts about the diet prescribed when went out the hospital and will be invited to attend a meeting nutrition in dialogic character at the end of 1 year to ensure fairness in action.
224177732|NCT02741336|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia (CBT-I)|"Cognitive-behavioral therapy is a short-term, focused psychotherapy for a wide range of psychological and behavioral issues including depression, anxiety, anger, and non-compliance. The focus of the intervention is on how one thinks, behaves, and communicates in real time, as opposed to a focus on one's early childhood experiences. The therapist assists the patient in identifying specific distortions and biases in thinking and provides guidance on how to modify these beliefs. CBT helps the patient learn effective self-help skills that are used in homework assignments that ultimately help change the way one thinks, feels and behaves. The~￼ intervention is action-oriented, practical, rational, and helps the patient gain independence and effectiveness in dealing with real-life issues. Techniques utilized in CBT-I include psychoeducation, sleep hygiene, cognitive restructuring, stimulus control, sleep restriction, and relaxation training."
224177733|NCT02741336|BEHAVIORAL|Self-Monitoring|
224177734|NCT00805142|DRUG|Tapentadol PR|Tapentadol PR tablets will be administered orally twice daily initiated at dose of 25 mg. Dose will be adjusted as per Investigator's discretion. Maximum dose limit is 500 mg per day. Total duration of treatment is 19 days.
224177735|NCT00394654|BIOLOGICAL|MEDI-528 9 mg/kg|MEDI-528 at a single dose of 9 mg/kg administered as an intravenous infusion
224177736|NCT00394654|OTHER|Placebo|Placebo administered as a single intravenous infusion
224177737|NCT02886338|DEVICE|capsule endoscopy|The magnetic navigated CE would enable detailed investigations of the whole upper gastrointestinal tract, including the esophagus, stomach and duodenum. Using this remote magnetic manipulation, capsule endoscope might improve diagnostic accuracy and extend the examination of specific area of interest in the gastrointestinal tract.
224177738|NCT00122317|DRUG|eculizumab|
224177739|NCT03756285|DRUG|AZD4831|AZD4831 tablet taken orally for 90 days.
224306699|NCT05699486|DRUG|PDNO|PDNO consists of propylene glycol (1,2-propanediol, PD) chemically combined with NO (to be donated). The drug substance is formulated as an inherent mixture of 4 structure analogues. The mixture consists of an equilibrium of the 2 regioisomers 1-(nitrosooxy) propan-2-ol and 2-(nitrosooxy) propan-1-ol. In addition, each regioisomer is a racemic mixture.
223487299|NCT04302285|OTHER|PKU type meal|PKU type meal was based on PKU special low protein foods (50% of total energy intake), natural free protein foods (37%) and protein substitute (13%). Calories provided in breakfast were 600 kcal and were not based on individual dietary requirement. 65% of total energy intake was provided from carbohydrate, 13% from protein and 22% from fat.
223487300|NCT00748800|BEHAVIORAL|Affect Management|5 session group intervention that focused on teaching affect management skills and included HIV prevention and sexual health training
223487301|NCT00748800|BEHAVIORAL|General Health Promotion|5 session group focused on delivering general health promotion information in didactic format
223487302|NCT04607551|PROCEDURE|Prone positionning|4 to 5 persons required for the procedure, one of them being dedicated to the management of the head of the patient, the endotracheal tube, the jugular ECMO cannula and the ventilator lines and another dedicated to the femoral ECMO cannula. The person at the head of the bed will coordinate the steps. The other persons will stand at each side of the bed. The direction of the rotation will be decided giving priority to the side of the central venous lines. The length of vascular and ventilator lines will be checked for appropriateness, the endotracheal tube and gastric tube will be secured, and the patient's knees, forehead, chest, and iliac crests will be protected using adhesive pads. The patient will be then moved along the horizontal plane to the opposite side of the bed selected for the direction of rotation. Patients will be proned at least four times during the first days on ECMO. Each prone session will stand for at least 16 hours
223487303|NCT04607551|PROCEDURE|Supine position|Patients assigned to supine will remain in a semi-recumbent position.
223487304|NCT04398966|DEVICE|Prostatic Artery Embolization (HydroPearl® compressible microspheres)|Embolic material
223487305|NCT02884648|DRUG|Bevacizumab|15 mg/kg by vein on Day 1 of every 21-day study cycle.
223487306|NCT04106037|OTHER|Data extraction from medical files|Data extraction from medical files
223487307|NCT00177411|DRUG|Parathyroid Hormone-related Protein|Parathyroid Hormone-related Protein in doses started at a 4 microgram single bolus intravenous dose. Dose will be increase to a maximum of 400 micrograms or until a dose limiting toxicity occurs at a lower dose.
223487308|NCT01868568|DRUG|insulin degludec|Administered subcutaneously (s.c., under the skin).
223487309|NCT01868568|DRUG|insulin degludec/insulin aspart 30|A single dose administered subcutaneously (s.c., under the skin).
223487310|NCT01868568|DRUG|insulin degludec/insulin aspart 40|A single dose administered subcutaneously (s.c., under the skin).
223586839|NCT01028066|BEHAVIORAL|Behavioral|The intervention group will go through 4 meetings of food education, to be held within the institution, with approximately 1 hour long, composed of 3 to 8 patients, who may or may not be accompanied by a relative. The first three meetings will be monthly and the fourth will be 6 months after the last one. Each meeting will be developed within the context of dialogic and participatory education, directed to the adoption of a healthy diet and prevention and control of cardiovascular risk factors. The meetings will follow the order: Investigation, Contextualization, Awareness and Strengthening the nutritional concepts, according to the didactics of educator Paulo Freire.
223586840|NCT04808271|DIETARY_SUPPLEMENT|Bifidobacterium breve Bif195|1 capsule daily for 8 weeks
224177740|NCT03756285|DRUG|Placebo|Placebo tablet taken orally for 90 days.
224177741|NCT03739060|DEVICE|Transcutaneous electric nerve stimulation|Conventional transcutaneous electric nerve stimulation
224177742|NCT02951585|DEVICE|KARTILAGE CROSS|Intra-articular injection of Kartilage Cross
224177743|NCT02951585|DEVICE|PLACEBO|Intra-articular injection of physiological serum (saline solution)
224177744|NCT05597111|DIAGNOSTIC_TEST|DHA levels of blood and cervical mucus|DHA levels of blood and cervical mucus of the control and the study groups will be measure
224177745|NCT07050212|DRUG|remimazolam group|remimazolam is administered intravenously at a dose of 0.3 mg/kg
224177746|NCT07050212|DRUG|dexmedetomidine group|dexmedetomidine is administered intravenously at a dose of 1 μg/kg
224177747|NCT07050212|DRUG|esketamine group|esketamine is administered intravenously at a dose of 0.5 mg/kg
224177748|NCT00600249|DRUG|Cetuximab|dosage : 5mg/ml one administration per week: 400 mg/m2 then 250 mg/m2 during 18 weeks
224177749|NCT00600249|DRUG|Docetaxel|100mg/m2 every 21 days 6 cycles of 21 days
224177750|NCT07058103|DRUG|tislelizumab in combination with cyclophosphamide, mitoxantrone liposomes, chidamide, and prednisone|tislelizumab: 200mg on d1 every 3 weeks; chidamide: 20mg twice a week at least 3 days apart; cyclophosphamide: 750mg/m2 on Day 1 of each cycle, every 4 weeks; mitoxantrone liposomes: 20mg/m2 on Day 1, every 4 weeks; prednisone: 100mg/day on Day 1 to Day 5 of each course, every 4 weeks.
224177751|NCT07058506|DEVICE|Comparison of 5 interfaces used to capture user intent to operate a neuroprosthesis|No intervention
224177752|NCT07058168|DIETARY_SUPPLEMENT|Other: experimental group (labor diet)|"The data collection tools Personal Information Form, Women's Perception of Supportive Care Provided at Birth Scale, and Pregnant and Infant Monitoring Form (VAS pain, anxiety, fatigue and thirst scales) were applied. The VAS scales contains numbers evenly spaced (0-10) on a line. It's an evaluation scale filled out by pregnants stating their current levels by givig a number. The cut off point of the VAS anxiety and thirst scales were found to be four.In VAS anxiety, scores above this cut-off point indicate deviation from normal and individuals must be handled by professionals. In VAS thirst, patients who score above this score are considered to be experiencing dehydration symptoms. The time of the last meal was learnt according to the information given by the pregnant woman. Spontaneous blood glucose measurement was performed. The labor diet was administered after 6 hours of fasting. Post-prandial blood glucose and tools were measured after the labor diet (at the 2nd hours)"
224177753|NCT07058272|OTHER|Comprehensive corrective exercise protocol|"Initial phase exercises include lying supine on a foam roll with the arms in 3 different abduction angles, side-lying external rotation, side-lying forward flexion, standing diagonal flexion , and military press .Initial phase lasts for 2 weeks, with exercises progressing from 7 Reps of 10-second holds to 10 Reps of 15-second hold.~Improvement phase consist of exercises including side-lying external rotation with a dumbbell , side-lying forward flexion with a dumbbell , standing diagonal flexion with a dumbbell, standing external rotation with Thera-Band, standing diagonal flexion with Thera-Band, abduction while sitting on a training ball, prone lying V, T, and W exercises, and standing abduction on a balance board. The improvement phase lasts for 2 weeks, with exercises progressing from seven sets of 10-seconds hold to 10 sets of 15 secs hold.~The exercises in the maintenance phase are the same as those in the improvement phase, with no increase in intensity and frequency"
223487311|NCT01868568|DRUG|insulin degludec/insulin aspart 45|A single dose administered subcutaneously (s.c., under the skin).
223487312|NCT01868568|DRUG|insulin degludec/insulin aspart 55|A single dose administered subcutaneously (s.c., under the skin).
224205532|NCT00467038|BEHAVIORAL|Dialectical Behavior|Dialectical Behavior Therapy is an empirically validated treatment approach emphasizing the role of emotion regulation in the treatment of suicidal and self-destructive behaviors in BPD
224205533|NCT04218175|OTHER|neuromobilization exercises|Median nerve neuromobilization (stretching and shifting) was performed. For median nerve stretching; The subjects were brought to shoulder depression and 90 degrees of abduction while the dominant side forearms were supination. In this position, median nerve stretching was performed by extending the participant's head to the opposite side while flexing the wrist and finger. After waiting for 30 seconds in this position, the wrist and head were moved to the neutral position and the participants relaxed. For median nerve shift; The subjects were brought to shoulder depression and 90 degrees of abduction while the dominant side forearms were supination. In this position, the participant flexed his wrist and fingers while lateral flexion of his head to the opposite side, and flexed his wrist and fingers while lateral flexion of the head to the same side.
224205534|NCT02719015|DRUG|rAd.CD40L|"Dose Escalation Phase Starting Dose: 5x10\^10 vp per tumor as an injection directly into 1-3 tumors every 3 weeks. Same tumors injected for each of the 4 injections at week 0, 3, 6 and 9. If the dose well tolerated, the rAd.CD40L escalated to 1x10\^11 vp. Subsequently enrolled patients injected at the same dose of 1x10\^11 vp. Number of injected sites/tumors increased to two sites/lesions if patients have \>/=2 injectable lesions, at the same injection dose of 1x10\^10 up to three separate sites/lesions if patients have \> 3 injectable lesions.~Dose Expansion Phase Starting Dose: MTD from Dose Escalation Phase."
224205535|NCT02719015|DRUG|Pembrolizumab|Dose Escalation and Expansion Phases: 2 mg/kg by vein every 3 weeks.
224205536|NCT00367679|DRUG|Pazopanib|Pazopanib is an oral, potent, multi-target receptor tyrosine kinase inhibitor of VEGFR-1, -2, -3, PDGFR-alpha and -beta and c-kit. Subjects were to receive 800 mg oral pazopanib daily for a minimum of 2 weeks to a maximum of 6 weeks.
223487313|NCT01868568|DRUG|insulin aspart|A single dose administered subcutaneously (s.c., under the skin).
223487314|NCT01868568|DRUG|biphasic insulin aspart 30|A single dose administered subcutaneously (s.c., under the skin).
223487315|NCT01868568|DRUG|placebo|A single dose administered subcutaneously (s.c., under the skin).
223487316|NCT06519331|DEVICE|Research FibroScan (FS)|"Patients #1 to #25:~Exam 1: Examination with Research FibroScan. Exam 2: Examination with the Reference FibroScan at the same measurement point and with the same probe used for the Exam 1.~Patients #26 to #75:~Exam 1: Examination with the Research or Reference FibroScan. Exam 2: Examination with the Reference or Research FibroScan at the same measurement point and with the same probe used for the Exam 1.~Patients #76 to #114:~Exams 1 \& 2: 2 consecutive examinations with the Research or Reference FibroScan.~Exams 3 \& 4: 2 consecutive examinations with the Reference or Research FibroScan at the same measurement point and with the same probe used for the Exams 1 \& 2."
223487317|NCT02033798|DRUG|Tamsulosin|Once Daily 0.2mg per oral for 6 months
224306700|NCT05699486|DRUG|Sodium chloride (placebo)|Placebo (NaCl, commercially available dilution solution for parenteral use, 9 mg/mL)
224306701|NCT02098239|DRUG|G17DT|
224306702|NCT00191113|DRUG|Somatropin|0.05 mg/kg/dose by subcutaneous injection 6 times per week, until Core study completion criteria are met (protocol final height).
223487318|NCT00255177|DRUG|VGX-410 (Mifepristone)|VGX-410 tablets taken daily or twice daily for 28 days
223487319|NCT00255177|DRUG|Placebo|Placebo for VGX-410 tablets taken daily or twice daily for 28 days
223487320|NCT00973973|DRUG|Placebo|Matching placebo tablets taken orally once a day
223487321|NCT00973973|DRUG|Elagolix|Immediate release (IR) tablets taken orally once a day
223487322|NCT05775705|DRUG|L-DEP and PD-1 antibody|Doxorubicin (doxorubicin hydrochloride liposome injection) 35 mg/m2 day 1; etoposide 75 mg/m2 day1; methylprednisolone 1.5mg/kg days 1 to 3, 0.25mg/kg day 4 to 14; PEG-aspargase 6000iu/m2 day2, day4; PD-1 antibody injection 200mg day 5.
223487323|NCT02984137|OTHER|testing, evaluation, sampling|neuroimaging biomarkers using positron emission tomography and magnetic resonance imaging, and evaluation of neurological \& neurocognitive status by using a predefined neuropsychological assessment battery.
223487324|NCT04197960|PROCEDURE|Microwave ablation|Use thermal energy to destroy tumor
223487325|NCT04197960|PROCEDURE|Surgical resection|Resect tumors
223487326|NCT06398938|RADIATION|Interventional Radiotherapy|The patients will undergo four IRT fractions in one week
223487327|NCT00988338|BIOLOGICAL|Trinity Evolution|Novel Allogeneic, Cancellous, Bone Matrix Containing Viable Stem and Osteoprogenitor Cells
223487328|NCT05985759|DRUG|N acetyle cystiene|N acetyle cystien is administerd due to its antibacterial action and anti inflamatory action
223487329|NCT03079830|DRUG|Piritramid|Piritramid will be administered i.v., if the patients feel pain after receiving a bolus of Ropivacaine or saline through the catheter.
223487330|NCT03079830|DRUG|Saline|Piritramid will be administered i.v., if the patients feel pain after receiving a bolus of Ropivacaine or saline through the catheter.
223487331|NCT01571791|DRUG|Placebo|to receive saline infusion and intravenous fentanyl boluses, at 30 min before induction of anesthesia
223487332|NCT01571791|DRUG|Ketorolac-Lidocaine|receive ketorolac-lidocaine infusion and intravenous saline boluses , at 30 min before induction of anesthesia
223487333|NCT00120939|DRUG|Motexafin Gadolinium|
223487334|NCT05361759|DEVICE|Cardiac Implantable Electronic Devices|Description of Cardiac Implantable Electronic Devices
223487335|NCT04422132|RADIATION|5 days Radiation Therapy (32.5 Gy in 5 fractions)|Patients will receive treatment to the prostate fossa +/- nodes in either 32.5 Gy in 5 fractions or 55 Gy in 20 fractions.
223487336|NCT04422132|RADIATION|20 days Radiation therapy (55 Gy in 20 fractions)|Patients will receive treatment to the prostate fossa +/- nodes in either 32.5 Gy in 5 fractions or 55 Gy in 20 fractions.
223487337|NCT01016002|DRUG|Temoporfin|"Drug treatment: Temoporfin 0.15 mg/kg body weight, intravenous injection within at least 6 min.~Laser Treatment: 652nm wavelength; 30 Joules/cm diffusor length ( 200 sec at 150mW/cm diffusor length), within 96 h after Foscan"
223487338|NCT03483090|DIETARY_SUPPLEMENT|Swisse High Strength Deep Sea Krill Oil|Krill oil is sourced sustainably from the Southern Ocean and is extracted from the Antarctic Krill, the most abundant marine biomass. Krill oil is a source of omega-3 fatty acids, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) for the maintenance of good health. Omega-3, EPA and DHA are also found in phospholipid form which are much easier absorbed than triglyceride form of omega-3 which is found in fish oil. Omega-3 supports cardiovascular health, brain health and eye health. Preliminary research suggests krill oil can provide temporary relief from symptoms of mild arthritis, help reduce joint inflammation and increase joint mobility.
223487339|NCT03483090|OTHER|Placebo|No therapeutic effect
223487340|NCT02020941|DRUG|carfilzomib|Given IV
223487341|NCT02020941|DRUG|dexamethasone|Given IV or PO
223487342|NCT02020941|OTHER|laboratory biomarker analysis|Correlative studies
224306703|NCT00191113|DRUG|Ethinyl estradiol|escalating doses 2.5-20.0 mcg tablets daily after age 13 and at least one year on study, continuing until Core study completion criteria are met.
223487343|NCT06494956|PROCEDURE|Implant device|A subcutaneous tunnel was established under general anesthesia, the electrode was connected to the stimulator, and the pulse generator was implanted in the skull.
223487344|NCT03572296|DIETARY_SUPPLEMENT|Placebo|Drinks will be delivered in random order at 3 separate study visits immediately before a high carbohydrate meal. A minimum of 4 days (ideally 7 days) wash-out period will be required between study days.
223487345|NCT03572296|DIETARY_SUPPLEMENT|Polyphenol and fibre|Drinks will be delivered in random order at 3 separate study visits immediately before a high carbohydrate meal. A minimum of 4 days (ideally 7 days) wash-out period will be required between study days.
223487346|NCT03572296|DIETARY_SUPPLEMENT|Fibre|Drinks will be delivered in random order at 3 separate study visits immediately before a high carbohydrate meal. A minimum of 4 days (ideally 7 days) wash-out period will be required between study days.
223487347|NCT01820832|DRUG|Calcitriol|Calcitriol 0.5 ug/BIW for 24 weeks.
223487348|NCT04127929|OTHER|Restoration of cavities using glass carbomer material (GCP Dental)|Detection of caries then restoration of cavities
223487349|NCT04127929|OTHER|Restoration of cavities using nanocomposite resin (Tokuyama Estelite Posterior)|Detection of caries then restoration of cavities
224306704|NCT00191113|DRUG|Medroxyprogesterone acetate|10 mg tablets, ten days monthly, after age 15, continuing until Core study completion criteria are met.
224306705|NCT01746459|OTHER|Paper-Based Reminder System|Paper-based reminders include: a) affixing stickers to clients' bedroom doors, beside their beds, or in their bathrooms; b) posting signs in prominent locations; and c) placing colored flags on the documentation flowsheets.
224306706|NCT01746459|OTHER|Peer-Based Reminder System|Healthcare aides will provide formal and informal peer reminders about the mobility activity; the formal reminders will take place either monthly or every three months during change of shift meetings, while the informal reminders will be provided as opportunities arise during the work day.
224314213|NCT04485832|DEVICE|Telehealth care|Patients in the intervention group daily answer 6 questions, which are focused on the recognition of AECOPD, using the electronic healthcare platform Evita by Swisscom, which has been and continuously is developed by the study team and Swisscom. The study team daily analyses all patients online and reacts according to a pre-specified action plan.
224314214|NCT04485832|DIAGNOSTIC_TEST|Weekly CAT measurement|
223487350|NCT05951686|DRUG|Desflurane|In inhalation group, desflurane will be used for general anesthesia maintenance under the screening with Patient State Index (PSI) between a score of 25-50. Remifentanil infusion is used with desflurane with a dose of 0.05-2 mcg/ kg/ min according to PSI . Fresh gas flow is used 2 L/ min with a mixture of 50%- 50% oxygen and medical air in both groups.
223487351|NCT05951686|DRUG|Remifentanil infusion|Remifentanil infusion will be used with a dose of 0.05-2 mcg/ kg/ min under the screening with Patient State Index (PSI) between a score of 25-50 in both groups.
223487352|NCT05951686|OTHER|Fresh gas|Fresh gas flow will be used 2 L/ min with a mixture of 50%- 50% oxygen and medical air in both groups.
223487353|NCT05951686|DRUG|Propofol infusion|Propofol infusion will be used for general anesthesia maintenance with a dose of under the screening of Patient State Index (PSI) between a score of 25-50 in group tiva.
223487354|NCT05604300|DIETARY_SUPPLEMENT|Vitamin E incorporated oat supplement|A twice daily supplementation of Vitamin E incorporated oat for 12 weeks
223487355|NCT05604300|DIETARY_SUPPLEMENT|Oat supplement|A twice daily supplementation of oat for 12 weeks
223487356|NCT00189514|DRUG|pramlintide acetate|Subcutaneous injection, twice a day or three times a day, at doses of 120mcg, 240mcg, or 360mcg
223487357|NCT00189514|DRUG|placebo|subcutaneous injection, three times a day, volumes equivalent to 120mcg, 240mcg, or 360mcg of pramlintide acetate
223487358|NCT04139135|DRUG|HLX10|neoadjuvant treatment phase：HLX10（4.5mg/kg/3w IV） +SOX, adjuvant treatment phase：HLX10（4.5mg/kg/3w IV）
223487359|NCT04139135|DRUG|Placebos|neoadjuvant treatment phase：placebos（4.5mg/kg/3w IV） +SOX, adjuvant treatment phase：SOX
224177754|NCT07058272|OTHER|Proprioceptive Neuromuscular Facilitation (PNF) Techniques|"In this study following PNF Stretching techniques are used~* Hold-relax or Contract-relax~* Hold-relax with agonist contraction In the Hold-Relax or Contract-Relax technique, stretching is performed 4sessions per week for each muscle group, with each session lasting 40 min. The protocol includes a 10-sec hold phase followed by a 10-sec contraction phase, repeated for 7 reps . The total duration of this program is 8weeks including 6 weeks of treatment phase and last 2 weeks of detraining.~In Hold-Relax with Agonist contract, the same procedure is followed as in Hold-Relax method, with 4sessions per week for each muscle group. The patient is asked to hold the initial stretch for 10 sec, followed by a relaxation phase. Afterward, the agonist muscle is contracted to actively move further into the stretch, which is then held for 10 sec. This protocol is performed for 7 reps per session, and the total duration of study is 8 weeks including 6 weeks of treatment program with last 2 weeks"
224177755|NCT05453006|DEVICE|COPAN 552c.80 FLOQSwab|The study will implement HPV self-sampling as an option for cervical cancer screening alongside usual care for Somali women, and evaluate changes pre and post implementation, compared to Fairview non-intervention clinics.
224177756|NCT03869632|DRUG|YL-13027|Daily doses by oral administration on each day of each 28 day cycle. Starting dose is 60mg, with escalation to 360mg, and subsequent dose escalation using a modified Fibonacci algorithm.
224177757|NCT04565535|BEHAVIORAL|Novel donor lifestyle optimisation protocol|Diet based on calorie requirement as calculated by indirect calorimetry. Daily exercise.
224177758|NCT02074475|OTHER|Control group|A group of no Monitoring patients from larger AoA study with no adequacy of anaesthesia monitoring
224177759|NCT03458234|DEVICE|16 French Foley Catheter|"A Foley catheter is a medical apparatus that creates a passageway for the drainage and collection of urine. This type of catheter is made of a pliable material that indwells into an individual's bladder by way of the urethra.~Featuring two separate channels down the tube, Foley catheters allow absolute stability and safe extraction. One channel of the catheter, by method of a balloon, is stabilized in a bladder; the other channel allows for the passage and collection of urine, by means of a leg bag or bedside drainage bag.~Foley catheters are usually constructed out of either silicone or latex."
224314215|NCT04865393|DRUG|SPR206|SPR206 100 mg single-dose IV infused over 1 hour
223487360|NCT04773795|DEVICE|EndoZip System|"The Nitinotes EndoZip system is designed to allow for the creation of multiple internal gastric segmentation (4-8) in the stomach by using an endoscopic approach. The system allows the forming of wall-to-wall longitudinal attachments of the anterior and posterior stomach walls, creating multiple strictures within.~Creation of this segmentation may significantly reduce gastric volume, may affect gastric motility and consequently, reduce weight."
223487361|NCT03396562|OTHER|Assessments of Development and Growth|Longitudinal observational assessments of development and growth at ages: 2 months, 6 months, 12 months, 18 months, 24 months, 36 months, 48 months, 5 years, 6 years, 7 years, 8 years, 9 years of age.
223487362|NCT06114862|BEHAVIORAL|Stigma-reduction intervention|"Participants will be presented with a list of common reasons why people report not wanting to tell other people about their mental health concerns, drawing from research in this area. Participants will be asked to click on any reason that resonates with them or about which they are interested in learning more. When they click on a particular reason, they will then be presented with psychoeducational information to allay their concerns. For example, if a participant replies that they wouldn't reach out to peers because others don't understand what I'm going through, we might present context showing that many of their peers have had similar challenges with mental health and have found peer support helpful. Participants will be able to click on as many reasons on this list that they would like to."
223487363|NCT03344211|DRUG|Enzalutamide|Given PO
223487364|NCT03344211|OTHER|Laboratory Biomarker Analysis|Correlative studies
223487365|NCT03344211|RADIATION|Radium Ra 223 Dichloride|Given IV
223487366|NCT00002818|DRUG|cytarabine|
223487367|NCT00002818|DRUG|deoxycytidine|
223487368|NCT01401166|DRUG|Herceptin|Herceptin will be given on Day 1 of each 3-week cycle for a total of 18 cycles. If study treatment for Cycle 1 is IV Herceptin, the initial dose will be a loading dose of 8 milligrams per kilogram (mg/kg) for de novo participants who start Herceptin treatment in the study. For all other cycles where IV Herceptin is given and for non-de novo participants, the dose will be 6 mg/kg. The SC dose will be 600 milligrams (mg) for both the SID and vial formulations for all cycles where SC Herceptin is given.
223586841|NCT04808271|DIETARY_SUPPLEMENT|Placebo|1 capsule daily for 8 weeks
223586842|NCT00544284|DRUG|bortezomib|
223586843|NCT00544284|DRUG|temozolomide|
223586844|NCT00544284|OTHER|pharmacological study|
223586845|NCT02659319|BEHAVIORAL|Family Lifestyle (FL)|12-week Family Food \& Lifestyle intervention, aimed at improving family nutritional intake, activity levels, weight perception, and parental monitoring of child eating. Material is delivered in psychoeducational groups in the children's schools.
223586846|NCT02659319|BEHAVIORAL|Family Dynamics (FD)|The Family Dynamics intervention focuses on positive parenting (i.e., emotion coaching, praise, limit setting) and on child emotion regulation and positive problem solving. Material is delivered in psychoeducational groups in the children's schools.
223586847|NCT02659319|BEHAVIORAL|Peer Group (PG)|Peer Group intervention conducted throughout one semester of the school year that includes 12 sessions of a guidance-type curriculum during class time sensitizing children to the importance of social inclusion of all children
224177760|NCT02216292|OTHER|Control Group|Infants received preterm formula during their first days of life until breastmilk from their own mother was available
224177761|NCT02216292|OTHER|Preterm Single Donor Milk Group|Infants received preterm single donor milk during their first days of life until breastmilk from their own mother was available
224177762|NCT07072962|DEVICE|home-based self-administered interactive exercise|The Tele-Exergame system delivers a structured foot and ankle exercise program tailored for individuals with cognitive impairment or mild dementia to support balance and cognitive function. Exercises such as leg raising and foot flexion are guided through audio, visual, and text prompts on a tablet. A foot-mounted motion sensor provides real-time feedback to ensure proper range of motion, while exercise data are securely streamed to the cloud for remote monitoring of adherence. The system also includes a telemedicine interface to enable remote support and education when needed.
224177763|NCT06517446|OTHER|Optokinetic Virtual Reality Stimulation|"The optokinetic stimulation protocol is defined as follows:~* Optokinetic stimulation sessions are planned with a balloon rotation speed of 20°/s (degrees per second) during the first four weeks. In the fifth and sixth weeks, the speed will be increased to 25°/s, and in the seventh and eighth weeks, it will be raised to 30°/s.~* The background screen will be set to rotate in the same direction as the balloons, with a rotation speed equal to 30-50% of the balloon rotation speed.~* Session duration will start at 30 seconds and will increase to 150 seconds depending on patient tolerance as the sessions progress.~* Participants will be instructed to focus on the red balloon in a moving visual scene.~Optokinetic stimuli will be applied to participants in various postures: sitting, upright posture (feet together), semi-tandem stance, or tandem stance positions."
224177764|NCT06517446|OTHER|Conventional rehabilitation program based on Cawthorne Cooksey exercises|The program will consist of Tracking, VOR, Neck, Static-Dynamic Balance Exercises and Walking training. These exercises depend on the patient's condition; It will be done in sitting, Romberg, semitandem, tandem and walking positions with eyes open and closed. Hard and soft grounds will be used.
224177765|NCT06517446|OTHER|VR+OKS|"The optokinetic stimulation protocol is defined as follows:~Optokinetic stimulation will be applied over 8 weeks with gradually increasing balloon rotation speeds: 20°/s (weeks 1-4), 25°/s (weeks 5-6), and 30°/s (weeks 7-8). The background will rotate in the same direction at 30-50% of the balloon speed. Sessions will start at 30 seconds and increase to 150 seconds based on tolerance. Participants will focus on a red balloon in a rotating visual scene, and the stimulation will be performed in various postures including sitting, feet together, semi-tandem, and tandem stance.~The program will consist of Tracking, VOR, Neck, Static-Dynamic Balance Exercises and Walking training. These exercises depend on the patient's condition; It will be done in sitting, Romberg, semitandem, tandem and walking positions with eyes open and closed. Hard and soft grounds will be used."
224177766|NCT03080532|OTHER|dietary habits|
224177767|NCT03102424|DEVICE|Transcutaneous Electrical Nerve Stimulator (DW1330)|The 20 weeks of treatment of the DW1330 device, all the patients enrolled should perform 1 treatment within 1 hour after dinner 5 days a week.
224177768|NCT03102424|DEVICE|Sham DW1330 device|The Sham DW1330 device will be masked by the same appearance as the study device (DW1330). The usage of time and location of Sham DW1330 device will be completely the same with study device (DW1330). However, the electronic model, including the frequency and time consistence of electronic stimulation are different between the Sham DW1330 device and the study device (DW1330). The 20 weeks of treatment of the DW1330 device, all the patients enrolled should perform 1 treatment within 1 hour after dinner 5 days a week.
224177769|NCT05713929|OTHER|Recruitment maneuver (RM)|performance of a recruitment maneuver of 30 cm H20 for 30 seconds and measurement of electrical impedance
224177770|NCT05713929|OTHER|Reverse Trend (REV TREND)|Place the patient in the reverse trendelenburg position and measuring the electrical impedance after 5 minutes
224177771|NCT05281549|DRUG|Alteplase|Alteplase 0.9mg/kg are being used.
224177772|NCT05281549|DRUG|Tenecteplase|Tenecteplase 0.25mg/kg are being used.
224177773|NCT05281549|DRUG|Tenecteplase|Tenecteplase 0.4mg/kg are being used.
224205537|NCT01283711|DEVICE|apollo device|RF treatments for wrinkles and rhytides reduction
224205538|NCT02726217|BEHAVIORAL|CareSmarts Mobile Health Diabetes Program|Nurses from Diabetes Clinic will use a web-based enrollment form that includes the patient's mobile phone number, diabetes care plan, and preferred times for receiving messages. Participants in the program receive text messages about diabetes self-care. The contents of the messages that the participants receive are modified through software every two weeks as needed, based on their interactions with the system. Participants follow a flexible education curriculum in which they move from one topic to the next at their own pace.
224205539|NCT02726217|BEHAVIORAL|Standard of Care Reminders and Self Assessments|
224205540|NCT04518319|DRUG|Omega-3 polyunsaturated fatty acids|Omega-3 polyunsaturated fatty acids will be taken 1200mg per day plus on olanzapine.
224205541|NCT04518319|BEHAVIORAL|Xbox aerobic exercise|Patients will do Xbox aerobic exercise 30min per day plus on olanzapine.
224205542|NCT04518319|DEVICE|transcranial direct current stimulation,tDCS|Patients will receive tDCS at 2mA, 20 min for 5 session per week plus on olanzapine.
224205543|NCT04518319|DRUG|Olanzapine|Patients will take only olanzapine pills.
224205544|NCT02237118|DEVICE|Mepitel One|
224205545|NCT02237118|DEVICE|UrgoTul|
223586848|NCT04476394|DRUG|[14C]-Anaprazole Sodium enteric-coated capsule|\[14C\]-Anaprazole Sodium enteric-coated capsule
223586849|NCT04764110|DIETARY_SUPPLEMENT|Cyplexinol|partially hydrolyzed Collagen and its associated proteins including Bone Morphogenetic Proteins (BMPs)
223586850|NCT04764110|OTHER|Placebo|Maltodextrin
224177774|NCT02492789|BIOLOGICAL|INCSHR01210 injection|"Part1: INCSHR01210 injection at a dose of 1, 3 or 10 mg/kg is administered every 2 weeks (3+3,q2w, except in the first cycle, in which subjects will be only dosed once on Day 1 for PK samplings and dose limiting toxicity observation). Response is assessed by every 2 cycles (4 weeks each cycle) by using irRECIST.~Part2: Additional patients (200mg dose cohorts will be enrolled in Part 2, depending on the data outcomes in Part 1, to further explore preliminarily clinical benefits of INCSHR01210 as well as the other objectives of the study."
224177775|NCT06909578|DEVICE|CorFlow Controlled Flow Infusion System - CoFI™|The CorFlow CoFI™ System is intended to assess the dynamic microvascular resistance and to treat microvascular obstruction in the coronary vasculature of patients following PCI with stent placement.
224177776|NCT07101744|DRUG|Iparomlimab and Tuvonralimab|Iparomlimab and Tuvonralimab combined with Nimotuzumab , administered on Day 1 every 3 weeks (D1 Q3W), until disease progression or unacceptable toxicity.
224177777|NCT01021293|BIOLOGICAL|Poliorix™|3 doses, intramuscular administration
224177778|NCT01021293|BIOLOGICAL|Oral Poliovirus vaccine|3 doses, oral administration
224177779|NCT06026137|PROCEDURE|eFisioTrack Group|Application of manual therapy and physical modalities together with completion of the exercise program for functional recovery of the upper extremity using the efisioTrack system without supervision by the physiotherapist.
224177780|NCT06026137|PROCEDURE|Excercises Group|Application of manual therapy and physical modalities together with completion of the exercise program for functional recovery of the upper extremity supervised by the physical physiotherapist in a hospital room.
224177781|NCT00432354|DRUG|atorvastatin|
224177782|NCT00640900|BEHAVIORAL|Usual care|Two individualized weight loss counseling sessions with a dietetics professional, and monthly contacts to maintain communications.
224177783|NCT00640900|BEHAVIORAL|Commercial weight loss program|Active weekly participation until weight loss goals are reached, and monthly participation to maintain the weight loss.
224177784|NCT04929314|BEHAVIORAL|Systematic Interactive Communication Model to Strengthen Self-Care Regardless of Health Literacy Level|The central element of the intervention is the interactive communication model. A website that contains easy-to-understand knowledge and material about various chronic diseases such as chronic obstructive pulmonary disease, diabetes, heart failure, as well as knowledge and material about wound care, compression treatment and prevention of infections has been developed. Information within each topic is given based on the interactive communication model. The idea is that community nurses should not themselves assess what characterizes an easy-to-understand level or the amount of information for each individual citizen, which seeks to ensure a systematic and uniformity in the work with self-care and more self-sufficient citizens. At the same time, the model makes it possible to take into account the individual citizen's knowledge and competencies (level of HL). Further, the nurses receive specialised education regarding HL to complement their use of the interactive communication model.
224177785|NCT01289561|DRUG|Alcohol + Caffeine Beverage|14 g alcohol per 180 ml total beverage combined with 60 mg caffeine per 180 ml total beverage. The alcohol and caffeine will be mixed in a fruit punch beverage. Participants may self-administer as much beverage as they like with several constraints to assure safety (e.g., participants must stop drinking if their blood alcohol content is above .12 g/dl).
224177786|NCT01289561|DRUG|Alcohol + Caffeine-placebo|14 g alcohol per 180 ml total beverage combined with 2.2 mg quinine per 180 ml total beverage. The alcohol and quinine will be mixed in a fruit punch beverage. Participants may self-administer as much beverage as they like with several constraints to assure safety (e.g., participants must stop drinking if their blood alcohol content is above .12 g/dl).
224177787|NCT01247012|DIETARY_SUPPLEMENT|Omegaven|Omegaven 1g/kg/day until infant receiving full enteral feeds
224177788|NCT01247012|DIETARY_SUPPLEMENT|Lipid minimization|"1g/kg/day daily until infant receiving full enteral feeds~IF conjugated bili rises above 100, crossover to Omegaven (1gram/kg/day)"
224177789|NCT00670813|DRUG|Modafinil (Vigil)|Oral application of 2 x 100 mg Modafinil each encapsulated in identical looking gelatine capsules at 12:00, 24:00 and again at 12:00 o' clock during the 40 h sleep deprivation period
224177790|NCT00670813|DRUG|Placebo|Oral application of 2 x 100 mg Placebo each encapsulated in identical looking gelatine capsules at 12:00, 24:00 and again at 12:00 o' clock during the 40 h sleep deprivation period
224205546|NCT01303588|BEHAVIORAL|Yoga|24 group training sessions Yoga, 2 training sessions per week, 45 min duration , over 3 months
224205547|NCT01303588|BEHAVIORAL|Qigong|12 group training sessions Qigong, 1 training per week, 90 min duration , over 3 months
224205548|NCT02143089|DEVICE|Foley's Catheter|Urinary tract infection inpatient catheterized versus non catheterized
224205549|NCT02131337|OTHER|Electrophysiology study|after 3 months to check for pulmonary vein isolation (PVI) status
224205550|NCT00079963|DIETARY_SUPPLEMENT|Vitamin C|1000 mg/day
224205551|NCT00079963|DIETARY_SUPPLEMENT|Vitamin E|800 IU/day
224205552|NCT00079963|DIETARY_SUPPLEMENT|Placebo|
223586851|NCT00099294|DRUG|Glufosfamide|
223586852|NCT05729698|DEVICE|Baby warmer swaddle|Baby Swaddle with Heating System
223586853|NCT05729698|OTHER|polyethylene bag|polyethylene food bag
224205553|NCT03284424|BIOLOGICAL|Pembrolizumab|IV infusion
224205554|NCT03006822|OTHER|Pressure release 90|This is a massage technique that aims is eliminate myofascial trigger points for to treat muscle pain.
224205555|NCT03006822|OTHER|Pressure release 60|This is a massage technique that aims is eliminate myofascial trigger points for to treat muscle pain.
224205556|NCT03006822|OTHER|Pressure release 30|This is a massage technique that aims is eliminate myofascial trigger points for to treat muscle pain.
224205557|NCT06700564|OTHER|PET scan of FDG|The enrolled patients will undergo PET examination, and the radiation dose generated during the examination will not cause physiological damage to the patients
224205558|NCT03336645|DRUG|SHP615|SHP615 oromucosal solution will be administered as a single age-specific dose (2.5, 5, 7.5 and 10 mg).
224205559|NCT06293573|DEVICE|Whole-body vibration|GROUP A : will receive whole body vibration exercises combined with resistance exercises
224205560|NCT06293573|OTHER|aerobic exercises|Group B will receive aerobic exercises training combined with progressive resistance exercises with diet modification life style.
224205561|NCT06293573|OTHER|resistance exercises|Group c: will receive progressive resistance exercises with diet modification life style.
224177791|NCT01318291|BEHAVIORAL|CCRI Group|Cognitive Coping and Relaxation Intervention (CCRI) Cognitive Coping and Relaxation Intervention (CCRI) group who will receive a packet of relaxation and stress management suggestions
224177792|NCT01318291|BEHAVIORAL|Control|Medical treatment alone
224177793|NCT00006185|DRUG|Avandia administration for 6-12 weeks|
224177794|NCT04193137|DIAGNOSTIC_TEST|Oral sodium loading test,Seated saline infusion test and Captopril challenge test|"Oral sodium loading test : Patients received 6g oral sodium every day for 3 days.~Seated saline infusion test: All participants received the infusion of 2 liters of 0.9% saline over 4 h in seated posture.~Captopril challenge test: Patients received 50 mg captopril orally at 8-9 a.m. after sitting or standing for at least 2 h. Blood samples were drawn at time zero and 2 h after the challenge."
224177795|NCT05573022|OTHER|Pre-consultation electronic patient decision aid|This group is invited to access an electronic version before the consultation. The group of colorectal cancer patients is also introduced to a paper-based version by the clinician in the consultation.
224177796|NCT05573022|OTHER|In-consultation paper-based patient decision aid|This group is introduced to a paper-based version by the clinician in the consultation
224177797|NCT05670132|OTHER|Neurocardiac rehabilitation program|Patients receiving a neurocardiac rehabilitation program for 12 weeks.
224177798|NCT05670132|OTHER|Standard of care|No intervention during the neurocardiac rehabilitation program
224177799|NCT05973825|PROCEDURE|Leucapheresis|leucapheresis is a procedure in which a large amount of blood cells are obtained by an apheresis procedure
224177800|NCT06471686|DRUG|Acamprosate|2 pills three times a day
224177801|NCT03463980|BEHAVIORAL|Compassion meditation (CM)|CM session: 30 minute check-in regarding the participants' levels of suicidal ideation, as well as a discussion of current life stress and weekly meditation practice; a 30 minute didactic session that will describe the meditative technique introduced during the week; and a 30 minute guided meditation session. Participants are also encouraged to meditate at least 30 minutes a day.
224177802|NCT03463980|BEHAVIORAL|Support group (SG)|SG session: 90 minutes to talk about current concerns and to receive support and guidance from other group members and the leaders.
224306707|NCT06213272|BEHAVIORAL|Phono-Motor Therapy|The goal of PMT is to build orthographic and phonological awareness and phonological sequence knowledge. During PMT, participants will complete a series of tasks manipulating minimal sound units (consonants (C) \& vowels (V)), combining these units into syllables (CVC, CVCC, CCVC) and syllable sequences (real words and readable nonwords). PMT will aim to engage 5 modalities: visual, acoustic, tactile kinesthetic, motor, and orthographic. Multisyllabic stimuli used during treatment will consist of 40 real words and 68 readable nonword letter strings.
224306708|NCT06213272|BEHAVIORAL|Aerobic Exercise Training (AET)|Stationary ergometer cycling at 60% heart rate range for 20 minutes, plus 5 minutes of warm up and cool down.
223487369|NCT01401166|DRUG|Herceptin|Herceptin will be given on Day 1 of each 3-week cycle for a total of 18 cycles. If study treatment for Cycle 1 is IV Herceptin, the initial dose will be a loading dose of 8 mg/kg for de novo participants who start Herceptin treatment in the study. For all other cycles where IV Herceptin is given and for non-de novo participants, the dose will be 6 mg/kg. The SC dose will be 600 mg for both the SID and vial formulations for all cycles where SC Herceptin is given.
224177803|NCT05238246|BEHAVIORAL|Behavioral guidance with tell-show-do|The effect of tell-show-do technique during dental treatment on behavior in pediatric patients was evaluated and compared.
224177804|NCT05238246|BEHAVIORAL|Behavioral guidance with robot|The effect of the tell-show-do and distraction technique during dental treatment on behavior in pediatric patients was evaluated and compared.
223487370|NCT01401166|DEVICE|Single-Use Injection Device|The SID will be used, containing Herceptin 600 mg per 5 milliliters (mL).
224177805|NCT03345927|OTHER|no intervention|no intervention
224177806|NCT01365026|BEHAVIORAL|PVS: Programa de Vida Saludable|Lifestyle counseling and prescription
224177807|NCT02337816|PROCEDURE|laparoscopic surgery, obtainment of biological samples|
224177808|NCT06369402|DIAGNOSTIC_TEST|Cerebral haemodynamic testing using transcranial Doppler|Measurement of cerebral haemodynamics using transcranial Doppler to insonate the middle cerebral arteries bilaterally testing neurovascular coupling with selected domains from the Addenbrooks cognitive examination III and the digit span forward and backwards.
223487371|NCT01401166|DEVICE|Single-Use Injection Device|The SID will be used, containing Herceptin 600 mg per 5 mL.
223487372|NCT05135533|DEVICE|Portable Neuromodulation Stimulation|The PoNS group will receive electrical stimulation. Net direct current to the tongue electrode less than 1 µA (micro ampere) will be administered three times a week for four weeks in-lab setting, followed by three times a week for eight weeks at-home setting. Participants will continue to be enrolled in the study for additional 12 weeks without any intervention to evaluate long term effects.
223487373|NCT05135533|DEVICE|Sham|The Sham group will not receive electrical stimulation.
224177809|NCT06369402|DIAGNOSTIC_TEST|Ankle-brachial pressure index|Ratio of ankle to brachial blood pressure measured using handheld Doppler at rest and after exercise (six-minute walk test).
224177810|NCT06369402|DIAGNOSTIC_TEST|Six-minute walk test|Supervised brisk walk for six minutes. Time and distance to onset of claudication pain and total distance walked (and total time walked if did not complete the full six minutes).
224177811|NCT03672136|DRUG|Anlotinib|Anlotinib is a novel multi-target tyrosine Kinase inhibitor that inhibits VEGFR2/3, FGFR1-4, PDGFD α/β, c-Kit and Ret.
224177812|NCT03672136|OTHER|Concurrent Chemoradiotherapy|Concurrent chemoradiotherapy as the current standard of care for unresectable stage III non small cell lung cancer patients
224177813|NCT01527760|DRUG|Viscum album ethanolic extract manufactured according to Homoeopathic pharmacopoeia of India (H.P.I.)|Ten drops of Drug in 30 ml of distilled water with a frequency of three times a day for a duration of 12 weeks
224177814|NCT03131856|BEHAVIORAL|Nutritional intervention programme|The intervention consisted of an individual dietary plan conducted by a clinical dietician before discharge in combination with three follow-up visits after discharge (1, 4 and 8 weeks) conducted by a district nurse.
224177815|NCT05543980|DEVICE|Sham device|The leg heat therapy device consists of a water tank coupled with a circulator, a sous-vide water heater and water-circulating trousers. The water heater in the sham device is adjusted to heat up the water to 33ºC.
224306709|NCT06213272|BEHAVIORAL|Stretching|Light stretching activities targeting the head/neck, shoulder, elbow/forearm, hand/wrist, trunk/hip, ankle/foot.
224177816|NCT05543980|DEVICE|Leg heat therapy device|The leg heat therapy device consists of a water tank coupled with a circulator, a sous-vide water heater and water-circulating trousers. The water heater in the sham device is adjusted to heat up the water to 42ºC.
223586854|NCT06416293|OTHER|Questionnaire patients|Completion of a two-part questionnaire with a special focus on communication around the breast cancer diagnosis. Tumor stage and therapies received are also surveyed. The questionnaire can be answered online via a secure tool (REDCap) or in paper form.
224177817|NCT03999203|DRUG|Citric acid|Citric Acid cough challenge to be administered to assess the cough reflex sensitivity in patients
224177818|NCT03999203|DEVICE|Leicester Cough monitor|Ambulatory cough monitor to assess cough frequency over a 24 hour period
224177819|NCT03999203|OTHER|fractional exhaled nitric oxide testing (FeNO)|Measurement of exhaled nitric oxide to give an indication of airway inflammation
224177820|NCT03999203|OTHER|Patient reported outcome measures|A number a patient reported outcome measures will be administered including: Asthma control questionnaire (ACQ-5), mini Asthma Quality of Life Questionnaire (mini AQLQ), Leicester Cough Questionnaire (LCQ), Cough Quality of Life Questionnaire (CQLQ), Cough Hypersensitivity Questionnaire (CHQ) and visual analogue scales for severity og cough (VASc) and Urge to Cough (VASu)
224177821|NCT03138265|BEHAVIORAL|HIIT Device: ergometer|Supervised exercise training.
224177822|NCT04344431|COMBINATION_PRODUCT|Hyperbaric oxygen treatment (HBOT) i.e. inhalation of pressurized oxygen delivered by a hyperbaric chamber (drug/device)|One session per day of HBOT in addition to the standard treatment with normobaric oxygen
224177823|NCT02718365|PROCEDURE|Wedge resection|A wedge resection is the surgical removal of the lung tumor with a small portion of the lung that surrounds the tumor. Hilar and mediastinal lymph nodes should be resected or sampled.
224177824|NCT02718365|PROCEDURE|Segmentectomy|A segmentectomy removes a segment of a lung lobe anatomically, or inclusion of a portion of adjacent segment, but does not remove the whole lung lobe. Hilar and mediastinal lymph nodes should be resected or sampled.
224177825|NCT05471401|DEVICE|Balloon-tipped catheter|Gastric balloon
224177826|NCT05846659|DRUG|IMSA101|Intra-tumoral administration once weekly for the first three weeks of Cycle 1 (Days 1, 8 and 15) and then on Day 1 of Cycles 2 and 3.
224177827|NCT05846659|DRUG|Immune checkpoint inhibitor|1st infusion on Cycle 1 Day 2, and then thereafter as per product label.
224177828|NCT05846659|RADIATION|PULSAR|1st day of Cycles 1, 2 and 3.
224177829|NCT02885506|DRUG|Oral administration of P218 capsules|Oral administration of P218 capsules. The number of capsules is determined by the dose level of the cohort.
224177830|NCT02885506|DRUG|Oral administration of P218 matching placebo|Oral administration of P218 matching placebo. The number of capsules is identical to the corresponding number of P218 capsules administered to the volunteers on the investigational drug.
223586855|NCT06416293|OTHER|Questionnaire physicians|Completion of a questionnaire with a special focus on communication around the breast cancer diagnosis
223586856|NCT06938308|DEVICE|LMA Igel|adults allocated to the LMA Igel group, an LMA Igel device will be inserted intraoperatively
223586857|NCT06938308|DEVICE|LMA Protector|adults allocated to the LMA Protector group, an LMA Protector device will be inserted intraoperatively
223586858|NCT03898128|DRUG|Anti-CD22 Immunotoxin|Clinical data (treatment, survival, adverse events) of patients treated with anti-CD22 immunoconjugates from 2014 will be collected
223586859|NCT01468636|DRUG|Oral Zinc|200 mg BID of oral zinc gluconate x 8 weeks
224177831|NCT06443437|OTHER|bee-buzzy vibrating cold application marionette doll|"* Bee-buzzy will be attached to the arm of the preschool child (who is included in the bee-buzzy group) by the researchers, where the phlebotomy will be performed on the child. It reduces pain through its cold wings and vibration. It helps to distract attention during phlebotomy and reduces the feeling of pain and fear. Bee-buzzy will be tied 5 cm above the area from which blood will be drawn, and after waiting for 15 seconds, the nurse will perform a phlebotomy.~* A marionette doll group; while the nurse is going to perform the phlebotomy operation on the preschool child, one of the researchers will try to distract the child by paly with marionette doll. The researchers will receive training in play therapy"
224177832|NCT06443437|OTHER|Rotuine care|children in control group will receive routine hospital are
224177833|NCT02889861|DRUG|IMCgp100|Bispecific soluble human leukocyte antigen-A2 (HLA-A2) restricted gp100-specific TCR fused to anti-CD3
224177834|NCT01647204|OTHER|trained volunteer mealtime assistance|trained volunteers helped inpatients at lunchtimes with dinner tray preparation, encouragement and feeding if required
224177835|NCT01864746|DRUG|Palbociclib PD-0332991|palbociclib at a dose of 125 mg once daily, day 1 to day 21 followed by 7 days off treatment in a 28-day cycle
223586860|NCT01468636|DRUG|Placebo|200mg BID x 8 weeks
223617704|NCT01473771|BEHAVIORAL|Caring Letter (email)|"Participants will be emailed letters for two years. The first letter will be sent one week afer discharge from the inpatient psychiatric unit. There will be four subsequent email letters sent every month starting from the day of discharge, then another four every two months. The last four email letters will be sent every three months for the remainder of the two year period."
223617705|NCT00445081|DRUG|Prednisolone|
224177836|NCT01864746|DRUG|Placebo|Arm B: Placebo of palbociclib once daily day 1 to day 21 followed by 7 days off treatment in a 28-day cycle for thirteen cycles
223617706|NCT00445081|DRUG|Ciclosporine A|
224205562|NCT04006691|DRUG|UGN-101 instillations|Treatment with UGN-101 once weekly for a total of 3-6 times; in a retrograde fashion.
224205563|NCT03999229|DRUG|SNO|S-nitrosylating agent (SNO) Inhalation
224205564|NCT03999229|DRUG|Normal Saline|Normal Saline transfusion
224205565|NCT03999229|DRUG|Red Blood Cell|Blood transfusion (RBCs)
224205566|NCT02837263|RADIATION|Stereotactic body radiotherapy (SBRT)|"SBRT treatment will consist of 40-60 Gy delivered in five fractions prescribed to the planning target volume (PVT). Image guidance with MRI, megavoltage CT or cone beam CT scans would be required.~SBRT will be initiated on Day 0. This should be initiated within 4 weeks of signing informed consent. An additional 2 weeks will be allowed if necessary due to SBRT treatment planning."
224177837|NCT02635503|PROCEDURE|transrectal specimen extraction|After mobilization of bowel and dissection of lymph nodes, a cross clamp was placed distal to the tumor. Distal rectum was transected after fully disinfecting rectal lumen by 10% povidone-iodine. An anvil head attached to circular stapling device was put into abdominal cavity through rectal stump, and put into colon lumen through a longitudinal incision, then the proximal colon was transected in close proximity to the upper pole of incision by a linear stapling device. During specimen extraction though the rectum, a disposable sterile protective cover was used to avoid cancer cell exfoliation and implantation. The rectal opening was reclosed by a linear stapler. End-to-end colorectal anastomosis was performed with a circular stapler using the double-stapling technique.
224177838|NCT02635503|PROCEDURE|Conventional laparoscopic surgery|High ligation of inferior mesenteric vessel , mobilization of bowel, and dissection of lymph nodes were performed laparoscopically, and total mesorectal excision with nerve-sparing technique was followed for rectal cancer. Conventional laparoscopic-assisted surgery (CLS), a small incision with a 3-7cm length was made in hypogastrium, transection of rectum was completed through abdominal incision, then the specimen was removed and the bowel was prepared for anastomosis. The anastomosis for all rectal cancer and most of sigmoid colon cancer was performed by a double-stapling technique following open resection.
224177839|NCT03741075|PROCEDURE|BUA|bilateral uterine artery ligation (BUAL) after delivery of the fetus which not respond uterotonic and simple hemostatic maneuvers like placental bed hemostatic sutures
223617707|NCT02823509|DRUG|Coppertone (BAY 987517)|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation-SR15-68\_R84-089)
224177840|NCT03741075|DRUG|topical tranexamic acid|topical application of 200ml saline contains 2 gm tranexamic acid to the placental bed after delivery of the fetus which not respond uterotonic and simple hemostatic maneuvers like placental bed hemostatic sutures
224177841|NCT03741075|DRUG|placebo|topical application of 200ml saline to the placental bed after delivery of the fetus which not respond uterotonic and simple hemostatic maneuvers like placental bed hemostatic sutures
224177842|NCT05677516|PROCEDURE|ablation- pulmonary vain isolation- crioablation|Pulmonary vein isolation is the electrical isolation of the pulmonary veins from the left atrium. It can be performed using the cryoablation technique. The procedure begins with venous access through the femoral vein through which catheters and electrodes are inserted. Then, the left atrium is accessed through a transseptal puncture and the pulmonary veins are isolated using a cryoablation balloon. Cryoablation procedures are performed under local anesthesia. The procedure is performed using X-ray fluoroscopy.
224177843|NCT05677516|PROCEDURE|ablation- pulmonary vain isolation- pulsed field ablation (PFA)|Pulmonary vein isolation is the electrical isolation of the pulmonary veins from the left atrium. It can be performed using the pulsed field ablation (PFA) technique. The procedure begins with venous access through the femoral vein through which catheters and electrodes are inserted. Then, the left atrium is accessed through a transseptal puncture and the pulmonary veins are isolated with a PFA electrode. PFA procedures are performed under general anesthesia. The procedure is performed using X-ray fluoroscopy.
224177844|NCT05677516|PROCEDURE|ablation- pulmonary vain isolation- radiofrequency ablation (RF)|Pulmonary vein isolation is the electrical isolation of the pulmonary veins from the left atrium. It can be performed using the radiofrequency ablation (RF) technique. The procedure begins with venous access through the femoral vein through which catheters and electrodes are inserted. Then, the left atrium is accessed through a transseptal puncture and the pulmonary veins are isolated with a RF electrode. RF procedures are performed under local anesthesia. The procedure is performed using X-ray fluoroscopy.
224177845|NCT05677516|PROCEDURE|Electrophysiological study (EPS)|"In the electrophysiological study (EPS), electrophysiological parameters such as the recovery time of sinus rhythm (SNRT), Wenckebach's point, AH and HV intervals are measured. The examination begins with venous access through the femoral vein. Then, diagnostic electrodes are inserted into the right atrium, right ventricle and coronary sinus, with which electrophysiological tests are performed. The SNRT is measured after 60 seconds of atrial pacing with a 600ms cycle. The Wencjabach point is determined by stimulation in the incremental protocol. AV and HV intervals are measured during sinus rhythm using an electrode placed on the bundle of His. EPS is performed under local anesthesia. EPS will be performed both before and after pulmonary vein isolation. In patients with atrial fibrillation, during ablation, only the HV interval will be measured.~The procedure is performed using X-ray fluoroscopy."
224177846|NCT05677516|DIAGNOSTIC_TEST|Holter EKG|Holter ECG is a 24-hour, non-invasive ECG recording using a portable recorder and electrodes placed on the patient's chest. The Holter ECG will be performed three times: on the day preceding and on the first day after pulmonary veins isolation, and after 3 months of observation.
224306710|NCT04129229|DEVICE|LinguaFlex Tongue Retractor (LTR)|The LinguaFlex Tongue Retractor (LTR) is a small, flexible, implanted tongue retaining device that lessens the backward movement of the tongue during sleep. The LTR's flexible shaft and a nubbed tether passes through the center of the tongue beneath the tongue blade (frenulum area) and connects to a disc (head) that rests on the external surface of the tongue base mucosa. Underneath the tongue, on the external surface of the frenulum, a small anchor secures the shaft that can be adjusted to tension the LTR to maximize therapeutic effect and maintain comfort.
224306711|NCT05460481|DRUG|Anlotinib Plus Penpulimab|Anlotinib: 10mg orally daily on day 1 to 14 of a 21-day cycle. Penpulimab: 200mg by intravenous drip on day 1 of a 21-day cycle.
223617708|NCT02439697|OTHER|Darbepoetin alfa|Conversion from Aranesp® to NESP®
224306712|NCT01466010|PROCEDURE|surgical removal of osteoid osteoma|surgery for osteoid osteoma: this may include curettage or en-bloc resection of the lesion
224306713|NCT02263950|DRUG|Artemether|Artemether sublingual spray at 20mg per spray. Dose escalation study design as per protocol; in Phase 1, three dose levels will be given. The Phase 2 dose will be determined from the results of Phase 1. All patients will receive 4 cycles of dosing, 28 days per cycle.
224306714|NCT04914221|DRUG|JLP-2002|administration of JLP-2002
223617709|NCT03291067|DRUG|MT-8554 1mg|MT-8554 1mg QD, oral, 12 weeks
224306715|NCT04914221|DRUG|Comparator|administration of comparator
224306716|NCT00773630|DRUG|Cilostazol|100 mg Cilostazol
223617710|NCT03291067|DRUG|MT-8554 5mg|MT-8554 5mg QD, oral, 12 weeks
223617711|NCT03291067|DRUG|MT-8554 10mg|MT-8554 10mg QD, oral, 12 weeks
224177847|NCT05677516|OTHER|Questionnaire|The survey will be conducted after 3 months of observation and will include questions about the number of hospitalizations due to atrial fibrillation, heart palpitations, changes in pharmacotherapy.
224177848|NCT02783976|DRUG|Sovaldi|Sovaldi 400 mg tablets administered orally once daily
224177849|NCT03308799|DRUG|MC2-01 cream|MC2-01 (calcipotriene/betamethasone dipropionate, w/w 0.005%/0.064%) cream
224177850|NCT03308799|DRUG|Cal/BDP combination|calcipotriene/betamethasone dipropionate, w/w 0.005%/0.064%
224177851|NCT03308799|DRUG|Cream vehicle|Vehicle Cream
224177852|NCT02750436|DEVICE|Ultrasound guided|This group will be treated using an ultrasound imaging device
224177853|NCT02750436|DEVICE|Fluoroscopy guided|This group will be treated using a fluoroscopy imaging device
224177854|NCT05310006|OTHER|Exercise|Exercise sessions were performed in the morning (07:00 am-12:00 am) under the supervision of at least two fitness instructors in the rehabilitation unit of the nursing home.HSRE and TRE were designed according to the peculiarities of each type of resistance exercise (Chodzko-Zajko et al., 2009). During TRE, participants performed four sets of 8-10 repetitions at 70-75% of the maximal strength. The concentric and eccentric phases were carried out for 2 s. For HSRE, exercises were performed eight times (sets) with 4-5 repetitions at 70-75% of the maximal strength. The concentric phase was performed as fast as possible, and the eccentric phase was carried out for 2 s. Bilateral calf raise was performed using the same load as unilateral knee extension.
224306717|NCT03112330|DEVICE|Plasma rich platelet injection|Plasma rich platelet injection with 26-gauge needle and 2cc syringe on inferior turbinate mucosa
224306718|NCT03112330|DEVICE|Saline nasal spray|two puffs of isotonic saline nasal spray twice daily
224306719|NCT04638530|OTHER|Education on breaking bad news to family members remotely|Participants will receive a combination of surveys, pre- and post-tests, lectures and didactics to increase their awareness of techniques to communicate difficult topics with patients remotely as well as skill building exercises.
224306720|NCT04658017|DEVICE|GARNET device|Use of new filter in conjunction with standard of care dialysis.
224306721|NCT05955196|PROCEDURE|BLOOD AND TUMOR|sampling of 24 ml of peripheral blood and samples of colon cancers with healthy tissue in parallel on the surgery piece
224306722|NCT02058550|OTHER|survey administration|Receive reminder email survey
224306723|NCT02058550|OTHER|computer-assisted intervention|Receive reminder email survey
224306724|NCT02058550|BEHAVIORAL|telephone-based intervention|Receive reminder phone call
224306725|NCT04395014|DIAGNOSTIC_TEST|2D Echocardiography|In this echocardiographic imaging acquisition protocol, the pregnancy patients, are colocated in the left lateral decubitus position on a clinical bed with the left arm flex and the hand behind the head. All the echocardiographic measurements are taken by the examiner in this position.
224306726|NCT02087995|DEVICE|Continuous Glucose Monitoring|A prescribed clinic session day for participating subjects.
224306727|NCT00670163|BEHAVIORAL|Enhanced Partner Therapy (EPT)|EPT, a biomedical intervention, is designed to reduce the rate of sexually transmitted infection (STI) reinfection and, therefore, incident STIs. Men who have sex with men (MSM) with incident STIs will be given partner treatment packets that contain informational brochures, reference cards, prophylactic medications, and condoms for their sexual partners.
224306728|NCT00670163|BEHAVIORAL|Communidades Positivas (CPOS)|The behavioral intervention, CPOS, is based on a combination of social-action theory and diffusion of innovation and is designed to reduce the frequency of unprotected sex with nonprimary partners. In CPOS, MSM who are recognized by their peers as leaders will be trained to implement a community center that provides information, support, and empowerment to MSM, their friends, and partners. CPOS will include a training program of at least 14 sessions. During these sessions, MSM leaders will be provided with information about HIV/STIs and their prevention and ways to strengthen leadership skills. The 2-hour group sessions will occur two times a week for 7 weeks. While the training sessions are underway, MSM leaders will be asked to work with community leaders to form a community center from which they will carry out HIV/STI prevention and promotion of sexual health activities for 18 months.
224306729|NCT00670163|BEHAVIORAL|Standard Care|Standard care will consist of usual care for STIs.
224306730|NCT04051034|DIETARY_SUPPLEMENT|Omega 3|"Active: 1.25 g capsules/420 35-count bottles \[1.25 g capsule contains min. 750 mg EPA + 250 mg DHA\] and heat therapy, increase internal body temperature 1.2 C above baseline.~Placebo: 14,700 1.25 g capsules/420 35-count bottles \[1.25-gram high oleic safflower oil capsule\]"
223617712|NCT03291067|DRUG|Placebo|Placebo QD, oral, 12 weeks
224177855|NCT02095444|DRUG|Menstrual blood stem cells|10\*7 cells/kg, intravenous injection for 4 times during two weeks
224177856|NCT04084444|DRUG|T8 tablet 0.5mg|Immune regulation, inhibition of acute nonspecific inflammation and chronic inflammation.
224177857|NCT04084444|DRUG|T8 tablet 1mg|Immune regulation, inhibition of acute nonspecific inflammation and chronic inflammation.
224177858|NCT04084444|DRUG|Placebo|Blank control.
223617713|NCT02038153|OTHER|Laboratory Biomarker Analysis|Correlative studies
223617714|NCT02038153|DRUG|Lenalidomide|Given PO
223617715|NCT05228665|BEHAVIORAL|Heart Rate Variability Biofeedback (HRV-B)|Breathing technique twice every day (10 min each) to increase HRV
223617716|NCT02018341|OTHER|homeopathic remedy in 30C potency|
223617717|NCT02018341|OTHER|Placebo|
224177859|NCT06304493|DEVICE|Alarms|"The ON cohort patients will receive audible and visual signals from the InSee monitor attached to their incentive spirometer every 20 minutes and upon successfully reaching certain achievements."
223617718|NCT01772966|PROCEDURE|Spinal manipulation|
224177860|NCT05534412|OTHER|Academic Detailing|"1. Provider Assessment. Physicians and advance practice providers will complete questionnaires before the intervention that assess their knowledge about the treatment for UI in women.~2. Mealtime Lecture. A group meeting will take place for the physicians in the intervention groups. All aspects of incontinence care will be addressed-including elements of the history and physical examination, initiation of conservative treatment, as well as when to refer for second-line therapies performed by specialists-utilizing the the principles of Academic Detailing.~3. Monthly individual feedback. Physicians and their clinical champion specialist will meet for individual coaching one month after the mealtime lecture to discuss and review the physician's previous performance as measured by the baseline chart abstraction. Physicians will have monthly check-ins with their clinical champion via a combination of quarterly synchronous Zooms and monthly asynchronous emails."
223586861|NCT04371341|PROCEDURE|erector spinae block by 0.25% bupivacaine|A mark will be applied on the required level (T8), the midline (spinous processes) and the injection points 3 cm from midline.While the patient is in a sitting position with support from a member of staff, Preparation of the field with iodine will be made. Using ultrasound guidance with a 6-10 MHz linear probe anatomical landmarks will be identified including the transverse process at T8 level and the three layers of muscles from posterior to anterior: trapezius-rhomboid-erector spinae. After subcutaneous lidocaine 2% injection a 22-G spinal needle will be inserted under ultrasound guidance in plane, aiming towards the transverse process. After a Gentle contact with the transverse process, 0.25% bupivacaine is injected in increments with careful repetitive aspiration to avoid intravascular injection.
223586862|NCT03691779|DRUG|ELX/TEZ/IVA|Fixed-dose combination tablet orally once daily in the morning.
224177861|NCT05534412|OTHER|Electronic Clinical Decision Support|Intervention physicians will have access to electronic clinical decision support consisting of note templates, order sets, interruptive alerts, and a notification of patients who screen positive for UI.
224205567|NCT02837263|DRUG|Pembrolizumab|Pembrolizumab is a potent and highly selective humanized monoclonal antibody (mAb) of the IgG4/kappa isotype designed to directly block the interaction between PD-1 and its ligands, PD-L1 and PD-L2. KeytrudaTM (pembrolizumab) has recently been approved in the United Stated for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilumumab and, if BRAF V600 mutation positive, a BRAF inhibitor.
224205568|NCT05429112|DEVICE|Flexible Tip Bougie|Patients randomised to Flexible Tip Bougie will be intubated with a Videolaryngoscopy and with a Flexible Tip Bougie.
224205569|NCT05429112|DEVICE|Endotracheal Tube with Stylet|Patients randomised to Endotracheal Tube with Stylet will be intubated with a Videolaryngoscopy and with a endotracheal tube + stylet.
224205570|NCT06634407|PROCEDURE|transcatheter closure|using transcatheter closure of PDA to detect outcome of patients with PDA
223487374|NCT05135533|OTHER|Gait and balance training|During each session participants will receive gait training exercises for 20 minutes, 20 minutes of balance training exercises, and 20 minutes of breathing exercise three times a week for four weeks in-lab setting. This will be followed by 20 minutes of gait training exercises, 20 minutes of balance training exercises, and 20 minutes of breathing exercise three times a week for eight weeks at-home setting. Participants will continue to be enrolled in the study for additional 12 weeks without any intervention to evaluate long term effects.
223586863|NCT03691779|DRUG|IVA|IVA tablet orally once daily in the evening.
223586864|NCT02657902|PROCEDURE|Fractures were treated with a Gamma 3 intramedullary nail|
223586865|NCT02657902|PROCEDURE|Fractures were treated with a Gamma 3 intramedullary nail + U-Blade|
223586866|NCT02983422|DRUG|aminophylline|To increase the dose of frusemide until 15mg/h with Syringe pumps. If the urine doesn't reach 1ml/kg/h,then combined with Aminophylline(loading dose of 5mg/kg，and maintenance dose of 0.5mg/kg)
223586867|NCT02983422|DRUG|frusemide|Use frusemide with Syringe pumps,maximum dose to 15mg/h
223586868|NCT02983422|DRUG|normal saline|Placebo bolus followed by IV infusions of normal saline (0.9%) every hour (matched by volume and appearance to the treatment group)
223586869|NCT06312033|DRUG|Estradiol Valerate|To elevate estradiol levels each woman has received 6mg on two consecutive days (total 12mg) of estradiol valerate (Progynova21©)
223586870|NCT06312033|DRUG|Placebo|Placebo (blue-colored hard gelatine capsules completely filled with a mixture of 99.5% mannitol and 0.5% Aerosil (fumed silica)) has been administered (placebo-controlled condition)
223586871|NCT02974894|DIETARY_SUPPLEMENT|Probiotic (Lactobacillus Plantarum)|
223487375|NCT04629833|BIOLOGICAL|MC0518|MC0518 will be intravenously infused immediately after thawing.
223487376|NCT04629833|BIOLOGICAL|BAT|BAT including MMF, ECP, ATG, everolimus, and RUX will be administered based on Investigator's decision.
223487377|NCT02115152|DRUG|fluorouracil|
223487378|NCT02115152|DRUG|capecitabine|
223586872|NCT02974894|DIETARY_SUPPLEMENT|Placebo|
224205571|NCT05165173|DIETARY_SUPPLEMENT|NanoD4CKD|Participants will receive a 7-day supply of the 4-ounce almond milk mixed with 4000 IUs of nanoparticles of D3 and instructed to consume it in the morning with a meal.
224205572|NCT05165173|DIETARY_SUPPLEMENT|MicroD4CKD|Participants will receive a 7-day supply of the 4-ounce almond milk mixed with 4000 IUs of microparticles of D3 and instructed to consume it in the morning with a meal.
223487379|NCT02115152|DRUG|cyclophosphamide|
223487380|NCT02115152|DRUG|Epirubicin|
223487381|NCT05568290|OTHER|Saliva|"individuals' saliva samples will be collected and transferred to eppendorf tubes.~Until biochemical analysis is carried out will be stored in -80ºC."
223586873|NCT00496132|DRUG|PRO131921|Escalating doses by IV infusion
223586874|NCT00837018|OTHER|physical exercise program|45 min, 3times a week
223586875|NCT01760811|DRUG|Erbitux,merck serono|cetuximab loading dosage 400mg/m2 followed by weekly 250mg/m2 2 weeks
224205573|NCT01504152|BEHAVIORAL|questionnaire|The intervention is a self-administered questionnaire that is voluntarily completed by the subject. This questionnaire has been previously validated and demonstrated to be reproducible in English speaking travelers. The final version of the survey questionnaire consists of 49 questions.Patients who never traveled after HSCT will answer only eighteen questions related to their medical and HSCT history in addition to their demographics.
224205574|NCT03660007|PROCEDURE|Fresh or frozen embryo transfer IVF|
224205575|NCT00698607|DEVICE|Everolimus-eluting stent (Xience or Promus)|Use everolimus-eluting stent in the treatment of coronary stenosis
224205576|NCT00698607|DEVICE|Sirolimus-eluting stent (Cypher)|Use sirolimus-eluting stent in the treatment of coronary stenosis
224205577|NCT00698607|DRUG|6-month clopidogrel therapy|Use clopidogrel for 6 months
224205578|NCT00698607|DRUG|12-month clopidogrel therapy|Use clopidogrel for 12 months
224205579|NCT03347474|PROCEDURE|Bilateral surgical implantation of DBS system to NAc|The Medtronic, PINS and SceneRay DBS device will be utilized in the present study.
224205580|NCT06566287|OTHER|Immediate implant|Immediate Implant with Socket Shield Group
224205581|NCT06566287|OTHER|Delayed implant|Delayed Implant with Socket preserved with socket Shield and dentin graft Group
224205582|NCT02993016|PROCEDURE|patient-specific instruments|
224205583|NCT02993016|DEVICE|The Signature™ Vanguard|
224205584|NCT02993016|PROCEDURE|conventional instruments|
224177862|NCT05534412|OTHER|APP Co-management|"To reduce additional burden of care on the PCPs, the investigators will incorporate Advanced Practices Providers into the patient education and self-management portion of care. The APPs will be trained together with the intervention physicians, but they will also undergo additional standardized training on patient education, UI knowledge, providing instruction on Kegel exercises, shared decision making, and self management.~Patients will then be scheduled for a UI education and self-management session with the APP by telemedicine (video visit or telephone visit) within one month of their initial visit. For patients in need of an annual pelvic examination, and if the patient's PCP prefers to have the APP conduct the pelvic exam, a separate visit will be scheduled with the APP. A followup televisit will then be scheduled within three months of the initial APP visit, in order to assess the outcome of non-surgical treatment and determine if a specialist referral is indicated."
224306731|NCT04051034|OTHER|Placebo|Active: 1.25 g capsules \[1.25-gram high oleic safflower oil capsule\] and heat therapy, increase internal body temperature 1.2 C above baseline.
224306732|NCT05200546|DIAGNOSTIC_TEST|molecular assays to screen for eXDR|"VRE detection will be performed using VIASURE Vancomycin resistance Real Time PCR Detection Kit.~BD MAX Check-Points CPO will be used to detect carbapenemase-producing organisms."
224306733|NCT05267743|DRUG|Tegoprazan 50mg QD|Tegoprazan 50mg tablets will be orally administered, once daily, for up to 2 weeks or 4 weeks.
224306734|NCT05267743|DRUG|Lansoprazole 30mg QD|Lansoprazole 30mg tablets will be orally administered, once daily, for up to 2 weeks or 4 weeks.
224306735|NCT05193643|DEVICE|Sonovein Treatment|The Sonovein System provides High Intensity Focused Ultrasound (HIFU) ablation of soft tissue. The energy is delivered via an extra-corporeal treatment probe, which includes an imaging system. The high-energy ultrasound waves propagate through the skin and are focused on a portion of the target tissue, generating intense heat and causing local cell apoptosis and progressive tissue volume reduction over the following months in the tissue within the focal area. The process is then repeated in a stepwise fashion to destroy the targeted tissues.
224306736|NCT05076695|DRUG|Palbociclib|Palbociclib will be given at the dose of 125 mg po q.d. x 21 every 4 weeks (i.e. 1 week rest period for a total of 5 cycles)
224306737|NCT05076695|DRUG|trastuzumab|8 mg/kg loading dose IV, then 6 mg/kg IV, every 3 weeks for a total of 6 administrations.
224306738|NCT05076695|DRUG|pyrotinib|Pyrotinib 400mg, PO daily, continuously
224306739|NCT05076695|DRUG|fulvestrant|Fulvestrant will be administered according to local prescription guidelines and will be given intramuscle at the dose of 500 mg every 4 weeks (repeat for 5 times) with an additional 500 mg dose given two weeks after the initial dose.
224306740|NCT05272748|OTHER|Conventional Exercise + Core Stabilization Exercise|Before and after the treatment, patients' pain, postural control (static and dynamic balance), functional level and fear of falling will be evaluated. In addition to the exercises in the conventional exercise group, patients will perform pelvic tilt, lateral bridge, single leg bridge, plank, extremity exercises in the crawling position, abdominal crunch, oblique crunch, dead bug, superman exercise. Exercises will be applied 3 times a week.
223487382|NCT05568290|OTHER|gingival crevicular fluid|GCF samples of individuals will be collected by paper strips and transferred to eppendorf tubes.Until biochemical analysis is carried out will be stored in -80ºC.
223487383|NCT01422109|DRUG|YH14659|YH14659 capsule by oral
223487384|NCT01422109|DRUG|clopidogrel & aspirin|clopidogrel tablet(75mg) + aspirin capsules(100mg) by oral
223487385|NCT02210195|DRUG|aprepitant|125 mg daily for 8 weeks.
223487386|NCT02210195|DRUG|Placebo|Placebo daily for 8 weeks.
223487387|NCT02210195|BEHAVIORAL|Manual-guided behavioral counseling|Standardized manual-guided behavioral counseling performed 1 time per week for 8 weeks in conjunction with study drug or placebo.
223487388|NCT02388009|BIOLOGICAL|Flexyn2a|Intramuscular doses of 0.5 mL
223487389|NCT02388009|BIOLOGICAL|Placebo|Intramuscular doses of 0.5 mL
223487390|NCT02388009|BIOLOGICAL|Flexyn2a plus adjuvant|Intramuscular doses of 0.5 mL
223487391|NCT04320875|OTHER|Transcranial direct current stimulation|Anode electrode -C3/C4 (International 10-20 electroencephalogram system), contralateral side of the most affected knee) Cathode electrode- contralateral supraorbital area. 2 mA intensity for 20 minutes, one session/day for 3 days/week for 8 weeks)
223487392|NCT04320875|OTHER|Conventional Physiotherapy|"1. Warm-up exercises: Walking at the usual speed on a flat surface for 10 min ( 3sets X10 Reps X 3 min rest in between)~2. Hamstring and calf gentle stretches. ( 3sets X10 Reps X 3 min rest in between)~3. Straight leg raise (SLR) ( 3sets X10 Reps X 3 min rest in between)~4. Quadriceps setting ( 3sets X10 Reps X 3 min rest in between)~5. Pillow squeeze ( 3sets X10 Reps X 3 min rest in between)~6. Heel raise ( 3sets X10 Reps X 3 min rest in between)~7. One leg balance ( 3sets X10 Reps X 3 min rest in between)~8. Step ups ( 3sets X10 Reps X 3 min rest in between)~9. Quadriceps strengthening exercises ( 3sets X10 Reps X 3 min rest in between)"
223487393|NCT05770310|DRUG|JS015|Patient receives specific dose of JS015. The administration method of JS015 is intravenous infusion.
223487394|NCT06323382|PROCEDURE|Locoregional therapy|"TACE procedure The decision to utilize transarterial artery chemoembolization (TACE) was performed through the tumor-feeding artery. The embolization emulsion was a mixture of Epirubicin 30-60 mg, Lobaplatin 30-50 mg, and Lipiodol 10-30 ml, and it was infused into tumor-feeding arteries via a 2.7/2.8 Fr micro-catheter.~HAIC procedure Hepatic arterial infusion chemotherapy (HAIC) procedure was performed with FOLFOX regimen: 85 or 135 mg/m2 oxaliplatin from hour 0 to 2 on day 1400 mg/m2 leucovorin from hour 2 to 4 on day 1, and 400 mg/m2 fluorouracil bolus at hour 5 on the day 1; and 2400 mg/m2 fluorouracil over 46 h on days 1 and 2."
223487395|NCT06323382|DRUG|Bevacizumab|15mg/kg or 7.5mg/kg intravenously every 3 weeks
223487396|NCT06323382|DRUG|Atezolizumab|1200mg intravenously every 3 weeks
223487397|NCT06323382|DRUG|Tislelizumab|200mg intravenously every 3 weeks
223487398|NCT06323382|DRUG|Toripalimab|220mg intravenously every 3 weeks
223487399|NCT06323382|DRUG|Sintilimab|200mg intravenously every 3 weeks
223487400|NCT06323382|DRUG|Camrelizumab|200mg intravenously every 3 weeks
223487401|NCT00689832|DRUG|Tacrolimus 0.03%|ointment
223487402|NCT00689832|DRUG|Fluticasone 0.005%|ointment
223487403|NCT05900427|DRUG|Liposomal bupivacaine|Subjects randomized to the Liposomal bupivacaine group will receive 10 mL (133 mg) of Liposomal bupivacaine and 20 mL (50 mg) of 0.25% bupivacaine and 6 mL of saline (183 mg).
223487404|NCT05900427|DRUG|Bupivacaine|Subjects randomized to the Plain Bupivacaine group will receive 36 mL (180 mg) of 0.5% bupivacaine.
223487405|NCT00082316|DRUG|Capsaicin Dermal Patch|
224177863|NCT05534412|OTHER|Electronic Referral|"In implementing the electronic consultation system in the private sector, the investigators will model the Expected Practice developed by the Los Angeles County Specialty-Primary Care Work Group. This eConsult system utilizes a kickback mechanism by which a specialist, who reviews the referral, can return it if it has not met certain baseline criteria (e.g. for a woman with OAB/urinary urgency: document negative UA, scheduled voids, titrate fluids to thirst, Kegels, antimuscarinics, optimize diuretic control, adjust any diuretics)."
224177864|NCT01403415|DRUG|Dexamethasone|Given PO or IV
224177865|NCT01403415|OTHER|Laboratory Biomarker Analysis|Correlative studies
224177866|NCT01403415|DRUG|Methotrexate|Given IT
224177867|NCT01403415|DRUG|Mitoxantrone Hydrochloride|Given IV
224177868|NCT01403415|DRUG|Pegaspargase|Given IV
224177869|NCT01403415|OTHER|Pharmacological Study|Correlative studies
224177870|NCT01403415|DRUG|Temsirolimus|Given IV
224177871|NCT01403415|DRUG|Vincristine Sulfate|Given IV
223487406|NCT06205589|BIOLOGICAL|ID93 + GLA-SE vaccine|At Step 2 entry, participants will receive one 0.5 mL injection of ID93 + GLA-SE administered intramuscularly (IM) at the Step 2, Day 0 visit and at the Step 2, Day 60 visit per the dosing schedule within the respective group/arm.
223487407|NCT06205589|BIOLOGICAL|Placebo vaccine|At Step 2 entry, participants will receive one placebo injection (sodium Chloride, 0.9%) administered intramuscularly (IM) at the Step 2, Day 0 visit and at the Step 2, Day 60 visit per the dosing schedule within the respective group/arm.
223487408|NCT01525771|OTHER|Docetaxel|"The study medication will be administered every 3 weeks for a maximum of 8cycles. A study medication will be given to the patients.~* Docetaxel (-1 to 3 level)mg/m2 IV(D1) every 21 days (-1 level: 40, 1 level: 60, 2 level: 80, 3 level: 100)~* Xeloda 937.5 mg/m2/ day PO, twice a day(D1-D14) every 21 days~* Cisplatin 60mg/m2 IV (D1) every 21 days"
224177872|NCT06419023|BEHAVIORAL|supervised physical activity intervention using the Pilates Method (exercises on the mat)|"Each Pilates session was consisted of: a) introduction to the goal of training, familiarizing new skills (2-3 min); b) Pre-Pilates warm-up and respiratory exercises (5-10 min); c) mat Pilates exercises with the traditional Pilates repertoire: basic, beginner (40 min); d) cool down and endings exercises (5 min); e) session summary (2-3min). When required, exercises were adapted for breast cancer body needs and restrictions. Depending on the purpose of the exercise, different equipment was used (Pilates small ball 22 cm, Swiss ball, small massage balls, resistance band, towels, rollers, boxes, Magic Circle)."
223487409|NCT06003036|DEVICE|sham stimulation|sham delivery of transcranial magnetic stimulation
223487410|NCT06003036|DEVICE|transcranial magnetic stimulation|accelerated intermittent theta burst stimulation
224177873|NCT00000980|DRUG|Spiramycin|
224177874|NCT04076280|BEHAVIORAL|Sodium Watcher Program-Hypertension|The Sodium Watcher Program -Hypertension intervention consists of 14 weeks of education \[4 weekly education sessions (45 minutes)followed by 5 bi-weekly sessions 5-20 minutes\] that will be held at the dyads' preferred time delivered to their homes using a video conferencing program through an iPad.
224177875|NCT04076280|BEHAVIORAL|Usual Care|Participants in the usual care group receive their routine medical and nursing care for hypertension that consists of a recommendation to follow a sodium restricted diet and take medications as ordered. Usual care consists of recommendations to follow a sodium restricted diet, but without explicit skills training including instructions on gradual adaptation to sodium restricted diet, follow-up of progress or provision of monitoring.
224177876|NCT04849429|BIOLOGICAL|Platelet rich plasma (PRP) with exosomes|Autologous Platelet rich plasma (PRP) with exosomes Following skin disinfection of the back 2 ml from the total PRPex procured will be injected as soon as possible by an fluoroscopy guided lateral approach.
223487411|NCT03483103|BIOLOGICAL|lisocabtagene maraleucel|lisocabtagene maraleucel will be administered as a single dose intravenous (IV) injection
223487412|NCT00004855|DRUG|Lopinavir/Ritonavir|
223586876|NCT01561963|DRUG|Apremilast|Tablets for oral administration
224177877|NCT04849429|DRUG|Normal Saline|placebo : 2 ml normal saline para discal administration
224177878|NCT02176122|DRUG|Meropenem|Meropenem is a carbapenem anti-bacterial used for the treatment of serious infections in patients.
224177879|NCT02176122|DRUG|Piperacillin-tazobactam combination product|Piperacillin-tazobactam is used for the treatment of patients with systemic and/or local bacterial infections.
224177880|NCT00303290|DRUG|Peg Interferon Alpha 2b (Peg Intron)|4.5 micrograms/kg once a week
224177881|NCT00303290|DRUG|Ara-C (cytosine arabinoside)|10 mg under the skin daily
224177882|NCT03521089|DEVICE|Soterix Medical 1x1 Low Intensity Transcranial Electrical Stimulator (tES) Model 2001|Transcranial direct current stimulation works by sending constant, low direct current through the electrodes. When these electrodes are placed in the region of interest, the current induces intracerebral current flow. This current flow then either increases or decreases the neuronal excitability in the specific area being stimulated based on which type of stimulation is being used. This change of neuronal excitability leads to alteration of brain function, which can be used in various therapies as well as to provide more information about the functioning of the human brain.
223487413|NCT00004855|DRUG|Abacavir sulfate|
223487414|NCT00004855|DRUG|Nevirapine|
223487415|NCT00004855|DRUG|Lamivudine|
223487416|NCT00004855|DRUG|Stavudine|
223487417|NCT04622995|DRUG|Benzodiazepine|Benzodiazepine prescribing
223487418|NCT01481779|DRUG|Glargine|Administered by SC injection via a pen device.
223487419|NCT01481779|DRUG|LY2605541|Administered by SC injection with a pen device.
223487420|NCT01481779|DRUG|Insulin Lispro|Administered by SC injection with a pen device.
223586877|NCT01561963|DRUG|Rifampin Oral Capsules|Capsules for oral administration
223586878|NCT01561963|DRUG|Rifampin IV Solution|Intravenous (IV) solution
223586879|NCT01008969|OTHER|SPECT-CT imaging|SPECT/CT for 3-dimensional mapping of 99mTc-sulfur nanocolloid in order to identify personalized lymphatic drainage patterns
223617719|NCT05952232|DIETARY_SUPPLEMENT|PA-GH-01|1 capsule after breakfast once a day
223586880|NCT02017561|BEHAVIORAL|Lifestyle Counseling|Written and individualized information during the interview in all clinic visits, emphasizing the importance of a healthy lifestyle, engaging on regular moderate-intensity physical activity and eating an healthy diet.
223586881|NCT02017561|DRUG|Metformin|Metformin treatment titrated to a maximum dose of 1000mg twice a day. Metformin treatment will start with 500mg at breakfast during the first week and, if well tolerated, increased to 500mg twice a day (breakfast and dinner) in the second week, 1000mg at breakfast and 500mg at dinner in the third week and finally for the target dose of 1000mg twice a day.
223586882|NCT01609413|DIETARY_SUPPLEMENT|AlgaeCal|One dose equals 3 times 180 mg of calcium, to be taken one time on the morning of the examination day.
223487421|NCT03186365|DRUG|Zepatier Oral Product|Grazoprevir, an HCV nonstructural protein 3/4A (NS3/4A) inhibitor 100 mg, plus elbasvir, an HCV NS5A inhibitor 50 mg fixed dose combination,Zepatier Oral Product, will be prescribed for 8-12 weeks
223487422|NCT04547699|COMBINATION_PRODUCT|A single step culture medium|A single step culture medium (SSCM; Global, Life Global)+5mg/ml life global protein, without supplementation of CYK
223487423|NCT02378181|BEHAVIORAL|Health Education Toolkit|An existing evidence-based toolkit intervention will be adapted and redesigned by a patient and provider team into an engaging, narrative graphic novel curriculum. The proven behavioral interventions will be augmented with health education material focused on MAT and HIV risk reduction. Together, these materials will comprise the Health Education Toolkit. The Health Education Toolkit (TK) will employ a shared decision making model to encourage 1) increased recovery engagement by patients, and 2) patient engagement in deciding whether to initiate and adhere to MAT.
223487424|NCT02378181|BEHAVIORAL|Treatment-as-usual|Treatment-as-usual will consist of the same number of counseling sessions as the experimental TK condition, but the counselors working with patients in this condition will not be equipped with the TK materials.
223487425|NCT05355207|DRUG|TRL1068|A human IgG1κ (G1m1,17 (z,a); Km3 allotype) monoclonal antibody
223487426|NCT04890613|DRUG|CX-5461|150 mg sterile lyophilized powder containing 1% sucrose
223487427|NCT05285969|BEHAVIORAL|Motivational interview|The new CR program with MI will be structured in 4 sessions and an optional fifth during the six months after discharge. The methodology of the MI sessions will follow the four phases logical sequence of MI proposed by Rollnick and Millner. 1) engage in a collaborative relationship, 2) focus on a particular change, 3) evoke intrinsic motivations for change, and 4) plan an immediate step for change
223487428|NCT05285969|BEHAVIORAL|Active Comparator: Standard care group|All patients in the control group will receive a kit with informative material with the actions and procedures to follow (diet, physical activity, smoking cessation, and other recommendations about secondary prevention).
223487429|NCT00042146|BEHAVIORAL|Cognitive-behavior therapy|
223487430|NCT00042146|DRUG|zolpidem|
224306741|NCT05272748|OTHER|Conventional Exercise|Before and after the treatment, patients' pain, postural control (static and dynamic balance), functional level and fear of falling will be evaluated. Terminal knee extension, straight leg raise, heel slide, adductor isometric, bridge, mini squat, heel raise, lunge, range of motion and stretching exercises for lower extremities will be performed by the patients. Exercises will be applied 3 times a week.
224306742|NCT02080169|DRUG|midazolam|"If the target sedation level is not obtained using the above recommended dosage, midazolam 0.01-0.05 mg/kg is added every 10-15min, until the target sedation level is obtained.~If it is over sedation (RASS -3 to -5), and reduction of the dosage of the sedation drug could not ease the situation, and then stop the sedation until the target sedation level is obtained."
224306743|NCT02080169|DRUG|Dexmedetomidine|"If the target sedation level is not obtained using the above recommended dosage, midazolam 0.01-0.05 mg/kg is added every 10-15min, until the target sedation level is obtained.~If it is over sedation (RASS -3 to -5), and reduction of the dosage of the sedation drug could not ease the situation, and then stop the sedation until the target sedation level is obtained."
224306744|NCT02080169|DRUG|Fentanyl|Fentanyl is used as analgesic drug in order to obtain the VAS \<3.
223487431|NCT05524129|OTHER|rehabilitation exercise|Conventional rehabilitation exercise.
223487432|NCT05524129|OTHER|electrotherapy|A middle frequency electro-therapy
224306745|NCT03715504|DRUG|TP-3654|oral PIM inhibitor
224306746|NCT01404923|DRUG|anti spasmodic agents|best standard of care prescriptions
224306747|NCT01404923|DRUG|alverine citrate, simeticone|on-demand therapy
223487433|NCT04115059|DRUG|Dasatinib|Oral, daily, dosing per protocol, once a day for cycle
223487434|NCT05593640|OTHER|biological samples|blood and synovial liquid will be sampled
223487435|NCT01635179|PROCEDURE|Cricoid pressure|The patient is intubated twice, once with a cricoid pressure and once with a sham-pressure, when performing a videolaryngoscopy.
223487436|NCT01088789|DRUG|Cyclophosphamide|Cohort 1 (J0810 Arm B), Cohort 3, Cohort 4, and Cohort 5 patients will receive 200mg/m\^2 CY administered IV on day 0 of each Cycle (every 6 months). Cohort 2 patients will receive 200mg/m\^2 CY administered IV on Day 0 of the first 3 cycles (every 28 days) and Day 0 of subsequent Cycles (every 6 months).
223487437|NCT01088789|DRUG|Cyclophosphamide Pill|Cohort 1 patients (J0810 Arm C) will receive 50mg oral CY once a day starting 28 days prior to GVAX and for 28 days post-GVAX (every 6 months).
223487438|NCT01088789|BIOLOGICAL|GVAX Pancreas Vaccine|Cohort 1, 3, 4, and 5 patients will receive GVAX on day 1 of each Cycle (every 6 months). Cohort 2 patients will receive GVAX on Day 1 of the first 3 cycles (every 28 days) and Day 1 of subsequent Cycles (every 6 months).
223586883|NCT01609413|DIETARY_SUPPLEMENT|Caltrate 600|One dose equals 1 capsule of 600 mg calcium, to be taken one time on the morning of the examination day.
223586884|NCT01175395|DRUG|IBI-20089/Lucentis|Combining a single dose of IBI-20089 (6.9 mg or 13.8 mg) intravitreal injection adjunctively with Lucentis 0.5 mg intravitreal injection at baseline and monthly intravitreal Lucentis injection PRN based on clinical and OCT results.
223586885|NCT02286323|DEVICE|Bonfils|Bonfils Intubation Fiberoscope
223586886|NCT02286323|DEVICE|Macintosh|Direct laryngoscopy using Macintosh Laryngoscope
223586887|NCT04454541|PROCEDURE|Ultrasound-guided nerve block for headache management|The study was done to compare the efficacy of two different techniques: multifidus cervicus plan block and greater occipital nerve block in treatment of refractory cervicogenic headache using ultrasound guided.
223586888|NCT04345094|OTHER|Hexylresourcinol|Emulsion containing hexylresorcinol as an active
223586889|NCT04345094|OTHER|Hydroquinone|Emulsions containing hydroquinone as an active
224177883|NCT05771246|DIAGNOSTIC_TEST|Radiographic evaluation|Panoramic and lateral cephalometric radiographs with cephalometric analysis will be performed.
224177884|NCT02956408|DIETARY_SUPPLEMENT|Vitamin D3|Patients will be prescribed either 2000 IU or 6000 IU of vitamin D3 per day. They will go to a pharmacy and purchase a vitamin D3 supplement in their preferred form (eg gummy, liquid, chew, tablet, capsule)
224177885|NCT03941041|BEHAVIORAL|Prenatal Yoga Course|participation in a 12-week prenatal yoga course (optimally), 1 session in duration of 90 minutes per week
224177886|NCT04215159|DRUG|Trastuzumab biosimilar|1st cycle 8 mg/kg by IV infusion over 90 mins, from 2nd cycle 6mg/kg by IV infusion over 30 mins. every 3weeks.
224177887|NCT04215159|DRUG|Gemcitabine Hydrochloride|1000 mg/m2 by IV infusion over 30 minutes on Day 1, Day 8. every 3weeks.
223487439|NCT06571006|OTHER|music|"The musical intervention will start 10 minutes before the lumbar puncture procedure begins and continue for another 20 minutes after the intervention. Babies will be kept away from noise during this study. W.A. It was decided to use the piece Adagio from the Violin Concerto No. 3 in G major, KV 216, composed by Mozart. The track will be played through two speakers on opposite sides, 30 cm away from the baby's ears, to optimize sound perception. High quality digital audio will be used to make babies listen. Music will be played at a level that can be heard in high noise pollution (i.e. the noise of incubator operation and the white noise of the recorder), but taking into account the permissible sound level recommended by the American Academy of Pediatrics, i.e. 65-70 dB"
223487440|NCT00075231|DRUG|Kaletra® (lopinavir/ritonavir)|
223487441|NCT00075231|DRUG|Combivir® (lamivudine, zidovudine)|
223487442|NCT00075231|DRUG|Sustiva® (efavirenz)|
223586890|NCT00668590|BEHAVIORAL|Patient video decision aid & telephone coaching|The decision aid is a 30 minute video program that educates patients about their role in diabetes care. Telephone coaching will assist patients in initiating behavior change.
223586891|NCT00668590|BEHAVIORAL|Printed educational brochure|The printed brochure is an educational brochure developed by the NIH.
224177888|NCT04215159|DRUG|Irinotecan Hydrochloride|100 mg/m2 by IV infusion over 90 minutes on Day 1, Day 8. every 3weeks.
224177889|NCT04698200|OTHER|Cold exposure|Whole body resting cold (+10 degrees centigrade) and heat (+40 degrees centigrade) for 60 minutes.
224177890|NCT02039687|DRUG|ARA 290|A small peptide that activates the innate repair receptor to induce anti-inflammatory and tissue repair mechanisms.
224177891|NCT02039687|OTHER|Placebo|Formulation buffer
224177892|NCT05959278|OTHER|App for vestibular rehabilitation|This app is a platform for performing conventional vestibular rehabilitation remotely
223487443|NCT04152590|DEVICE|Uincare|Interactive digital healthcare system
223487444|NCT01866592|DRUG|Adalimumab|Study participants will receive the FDA-approved dosing schedule for Adalimumab (Humira): an initial dose of 80mg followed by a 40mg maintenance dose every other week up to 52 weeks.
223487445|NCT06420232|DEVICE|weighted blanket|Blanket weighted with 10% or less of body weight applied to child prior to meals for duration no more than 15 minutes
223487446|NCT06033469|DRUG|Infliximab|Pediatric patients with IBD suitable for treatment with infliximab
223487447|NCT06033469|DRUG|Adalimumab|Pediatric patients with IBD suitable for treatment with adalimumab
223487448|NCT05302999|DRUG|Gabapentin|Generic gabapentin
223487449|NCT05302999|DRUG|Placebo|Inert cellulose
223487450|NCT06465810|DRUG|Treatment of transthyretin (ATTR) amyloidosis in observational study setting|Data will be collected on patients with ATTR amyloidosis in a real-world setting
223487451|NCT04194112|DIAGNOSTIC_TEST|immediate urine cytology|Forty-eight hours after primary TURBT, IUC was retrieved and patients were scheduled for repeat TURBT 2 to 6 weeks later according to the predetermined protocol. The primary outcome was to determine the role of positive IUC to predict positive biopsy findings on repeat TURBT.
223487452|NCT00002703|RADIATION|high-LET heavy ion therapy|
223487453|NCT00002703|RADIATION|low-LET photon therapy|
223586892|NCT01981889|DRUG|Prednisone|Participants will be started on oral prednisone 40mg/day for two weeks as per standard of practice in IBD management, before starting a tapering course.
223586893|NCT04326686|OTHER|Dietary intervention: nuts and wholegrains with dietary advice for a blood-pressure lowering diet|30g mixed unsalted tree nuts (almonds, hazelnuts and almonds) per day; 3 portions of wholegrain foods per day (including wholegrain cereal products, wholegrain bread and wholegrain pasta); guidance for following the Dietary Approaches to Stop Hypertension (DASH) diet
224177893|NCT00138892|PROCEDURE|Waiting time (access time to Total joint replacement)|See Detailed Description.
224177894|NCT01349491|DRUG|Ranolazine|Patients will be started on ranolazine 500mg twice daily. The first dose will be administered the day of cardioversion. The dose will be doubled after 2 weeks to 1000mg twice daily as tolerated for a total of six months.
224177895|NCT01349491|DRUG|Matching placebo|Patients will be started on a matching placebo twice daily. The first dose will be administered the day of cardioversion and continued for a total of six months.
224205585|NCT02993016|DEVICE|Vanguard PS(posterior stabilized)|
224205586|NCT00116129|DRUG|Ibutamoren Mesylate (MK-0677)|Ibutamoren Mesylate 25 mg/day
224205587|NCT00164086|DRUG|atorvastatin|
224205588|NCT02102022|DRUG|ADI-PEG 20 plus modified FOLFOX6|
224205589|NCT05348018|DEVICE|Playing Serious Games during a four-week test period in addition to conventional lectures|Playing SGs during a four-week test period in addition to conventional lectures in oral rehabilitation
224205590|NCT05221476|OTHER|retrospective|The investigators retrospectively analyzed the short- and long-term outcome in polytraumatized patients and the possible influence of RDW values on admission as well as preexisting comorbidities on these outcomes.
224205591|NCT00001729|DRUG|Ribavirin|
224205592|NCT03789058|DRUG|Ibuprofen 400 mg|Surgical removal of wisdom teethb with different regimen of Ibuprofen frequency ; three times versus two times .
224205593|NCT04341207|DRUG|Hydroxychloroquine|Hydroxychloroquine 200 mg 3 times a day for 10 days
224205594|NCT04341207|DRUG|Azithromycin|Azithromycin 500 mg on day 1 followed by 250 mg/day for 4 days
224205595|NCT01563393|OTHER|questionnaire STAMP and dietary|Children will undergo a complete evaluation by an investigating dietician and assessment by the STAMP tool in order to determine the extent of the nutritional risk on a numerical scale. According to findings children will get the dietary recommendations.
224177896|NCT02699489|PROCEDURE|Laparoscopic donor nephrectomy|Laparoscopic donor nephrectomy performed via a standard 4-port distribution. Control of the hilar vessels is performed using extra-large Hem-o-Lok clips (Weck- Covidien, Research Triangle Park, NC) and graft extraction is performed via a pre-prepared Pfannenstiel incision
224177897|NCT02699489|PROCEDURE|Open donor nephrectomy|Open donor nephrectomy performed via a supracostal incision above the 11th rib and an extra-pleural extra-peritoneal approach was adopted
224177898|NCT04898036|DEVICE|Blue Light Therapy|This phototherapy device (PTD-1) consists of a Plexiglas hand compartment (cleanable) enclosed in a powder-coated steel cabinet. Within the cabinet are two blue LED panels located above and below the hand compartment to illuminate the hands.
224177899|NCT04898036|DEVICE|Sham Light Therapy|To turn the device into a sham mode, a thin opaque liner can be inserted which will block light from illuminating the hands.
224177900|NCT05064449|DRUG|Soticlestat|Soticlestat tablets.
224177901|NCT05064449|DRUG|Itraconazole|Itraconazole oral solution.
224177902|NCT05064449|DRUG|Mefenamic acid|Mefenamic acid capsule.
224177903|NCT00003649|BIOLOGICAL|Ad5CMV-p53 gene|
224177904|NCT01048736|BEHAVIORAL|Exercise Only|4 d/wk of aerobic exercise
224177905|NCT01048736|BEHAVIORAL|Exercise + Diet|Exercise 4d/wk with moderate caloric restriction (-250 kcal/d deficit) designed for low fat loss (EX+Low CR; \~4.5 kg weight loss).
224177906|NCT01048736|BEHAVIORAL|Exercise + Diet|Exercise 4d/wk with intensive caloric restriction (-600 kcal/d deficit) designed for high fat loss (EX+High CR; \~10.9 kg weight loss)
224177907|NCT03660566|PROCEDURE|Test - Implant with L-PRF|The patient's blood will be collected and the tubes (4) will be inserted into a tabletop centrifuge (Kasvi). Using a 2500rpm for 12 minutes protocol, the leucocyte- and platelet-rich fibrin clot will be prepared using a kit consisting of a perforated metal box where the clots will be positioned and covered by a metal plaque. The pressure exerted on the clot will lead to the formation of L-PRF membranes, which will be used to cover the ridge after placement of the implant. Then, the flap will be sutured.
224177908|NCT03660566|PROCEDURE|Control - Implant without L-PRF|Single implant installation surgery in maxillary esthetic area.
224177909|NCT05372289|DIETARY_SUPPLEMENT|Immuno-nutrition|The experimental group of 68 older adults will be subjected to a preoperative immuno-nutrition for 30 days prior to surgery and up to 3 days after surgery. The oral feed provides energy, omega-3 fatty acids, arginine, nucleotides, and soluble fibre.
224177910|NCT00983944|BIOLOGICAL|bleomycin sulfate|Given IV
224177911|NCT00983944|BIOLOGICAL|rituximab|Given IV
223487454|NCT06451120|DRUG|Platelet-Rich Plasma (PRP) Injections|Bloods will be drawn prior to the PRP injection, and repeated at 2 weeks, 12 weeks, possibly 14 weeks for crossover patients follow up visits. Under aseptic technique with a surgical drape/curtain in place to block the study subject's view of the knee. Syringes will be covered with aluminum foil and subjects will have a cover over their eyes, so that neither subjects nor the clinical investigator will know if the injection delivered is PRP injection or a normal saline injection
223487455|NCT06451120|DEVICE|Centrifuge|The Eppendorf Centrifuge is used to make the PRP. In our opinion, the centrifuge is a nonsignificant risk device. The centrifuge, sterile vials for blood collection and PRP injection syringes do not present a potential risk for serious health, safety or welfare of a subject. It is not needed to support or sustain human life. It is not of substantial importance in diagnosis, curing, mitigating or treating disease for the health, safety and welfare of the patients. There are no potential for serious risk to the health, safety or welfare of a subject.
223586894|NCT03155308|DEVICE|Pentax chromoendoscopy (i-scan and Optical Enhancement)|All lesions will be evaluated using the 3 i-scan modes and the 2 OE modes without magnification. The lesion size data, location and macroscopic shape of the lesions based on the Paris classification will be recorded. Finally all lesions will be classified in real-time into 3 types based on NICE classification (NICE 1, hyperplastic polyps; NICE 2, adenoma and superficial submucosal carcinoma; NICE 3, SM-d invasive carcinoma). A level of confidence (high or low) will be assign in each stage. Polyp's images will be photographically and videotape recorded. All polyps will be resected or biopsied for histopathological examination used as the criterion standard for the analysis.
224177912|NCT00983944|DRUG|EPOCH regimen|Given IV or orally
224177913|NCT00983944|DRUG|cyclophosphamide|Given IV or orally
224177914|NCT00983944|DRUG|doxorubicin hydrochloride|Given IV or orally
224177915|NCT00983944|DRUG|etoposide|Given IV or orally
224177916|NCT00983944|DRUG|prednisone|Given IV or orally
223487456|NCT06451120|DRUG|Control saline injection|A placebo injection of 6 mL of 0.9% saline will be prepared by the unblinded research assistant in an adjacent room. The syringed will be prepared in a 10 mL syringe and covered with Aluminum foil, such that the investigator performing the injection cannot tell if there is PRP or saline to be injected.
223487457|NCT04285086|BIOLOGICAL|Ropeginterferon alfa-2b|Ropeginterferon alfa-2b (P1101) dosage: from 250 mcg to 500 mcg
223487458|NCT04285086|DRUG|Anagrelide|Anagrelide dosage: 0.5 mg per capsule, according to label and physician's judgement
224177917|NCT00983944|DRUG|vincristine sulfate|Given IV or orally
224177918|NCT00898950|DRUG|Aspirin|Aspirin 75mgs/day orally for 2 weeks.
224177919|NCT00898950|DRUG|Aspirin|300mgs/day orally for 2 weeks
224177920|NCT00898950|DRUG|Aspirin|aspirin 900mgs QID orally for 2 weeks
224177921|NCT00898950|OTHER|placebo tablet|placebo tablet with lactose and excipients.
224177922|NCT04779294|DIAGNOSTIC_TEST|STAN ( St wave analysis) and fetal blood sample-lactate|The CTG will be analysed by an expert group additional to the standard procedure that have been done in Labour already. The STAN analysis will be decrypted/ demasked anonymously by the Company producing these machines.
224177923|NCT04754724|DIAGNOSTIC_TEST|GIMate|Use of GIMate to detect lactose malabsorption
224177924|NCT04754724|DIAGNOSTIC_TEST|H2 Check|Use of H2 Check to detect lactose malabsorption
224177925|NCT02258516|BEHAVIORAL|CHIME 3-M|behavioral intervention for self-management in heart failure
224177926|NCT02258516|BEHAVIORAL|attention control|patients will receive phone calls regarding health-related topics not associated with heart failure
224177927|NCT01906814|DRUG|3 cycles chemotherapy|Chemotherapy: vincristine 0.05 mg/kg (or 1.5 mg/m2 for children ≥ 3 years of age) on Day 1, carboplatin 18.6 mg/kg (or 560 mg/m2 for children ≥ 3 years of age) on Day 1, etoposide 5.0 mg/kg/day (or 150 mg/ m2 for children ≥ 3 years of age) on Days 1 and 2 and 2. Cycles were repeated every 21 days for three cycles.
224177928|NCT01906814|DRUG|6 cycles chemotherapy|Chemotherapy: vincristine 0.05 mg/kg (or 1.5 mg/m2 for children ≥ 3 years of age) on Day 1, carboplatin 18.6 mg/kg (or 560 mg/m2 for children ≥ 3 years of age) on Day 1, etoposide 5.0 mg/kg/day (or 150 mg/ m2 for children ≥ 3 years of age) on Days 1 and 2 and 2. Cycles were repeated every 21 days for six cycles.
224177929|NCT01785940|PROCEDURE|Interscalene block|Interscalene catheters will be placed under aseptic precautions in each patient by one of the investigators using combined peripheral nerve stimulation and ultrasound guidance to get twitch in the C5-C6 dermatomes and documented spread of injectate near C5-6 nerve roots. Twenty mL of 0.2% ropivacaine will be injected while documenting adequate drug spread under ultrasound. After 20 min of injection, the interscalene nerve block will be evaluated and considered successful with inability to abduct the shoulder and a decrease in perceived sensation to cold of the skin over the deltoid muscle.
224177930|NCT01927640|DRUG|Dexmedetomidine|Dexmedetomidine (0.3-0.6 mcg/kg) infusion.
224177931|NCT01927640|DRUG|Normal Saline|Normal saline infusion (10 cc)
224177932|NCT01927640|DRUG|Intranasal cocaine|Intranasal cocaine (2 mg/kg)
224177933|NCT04492306|OTHER|Dimethyl Sulfoxide|DMSO \[(CH3)2SO\] is a polar aprotic solvent that dissolves both polar and non-polar compounds.
224177934|NCT04492306|OTHER|3M ESPE Single bond 2|Total etch adhesive bond
224177935|NCT04492306|OTHER|Filtek Z350 XT, 3 M ESPE, St Paul, MN, USA)|Composite Resin
224177936|NCT04492306|OTHER|3m ESPE etch|32% phosphoric acid
224177937|NCT00329199|BEHAVIORAL|Attachment-Based Family Therapy|
224177938|NCT04516629|DIAGNOSTIC_TEST|heart rate variability, pulse diagnosis device|check heart rate and pulse rate
224177939|NCT00303329|DRUG|Deferasirox|Deferasirox available as 125 mg, 250 mg or 500 mg tablets
224177940|NCT03899389|DIAGNOSTIC_TEST|plasma samples collection|Trimethylamine N-oxide (TMAO) concentration will be determined in plasma samples
224177941|NCT00268658|DEVICE|SmartStep(tm) biofeedback device|
224177942|NCT00510406|DRUG|tamsulosin hydrochloride|Alphablocker
224306748|NCT01960712|DEVICE|Transpapillary plastic stent (7-10 Fr)|Duodenoscopy plus transpapillary bile cannulation plus stent insertion.
224306749|NCT06032650|OTHER|Calisthenics exercise and High intensity interval training|"1. The calisthenics exercise focuses on big muscles and can be combined with breathing exercises and applied rhythmically,10-15 for each exercise,1-3 sets,3 days/week for 8 weeks. It will be progressed gradually by increasing the number of sets, repetitions and by using elastic bands and weighted vest progression.~2. High intensity interval training will be on treadmill for eight weeks, three times/week based on the following program:-Warming up period for 5 min at intensity corresponding to 65-75% of heart rate maximum (HRmax).Training phase for 30 min divided into four sets of 4-min length each at intensity equals 85- 90% of HRmax interspersed by 3 minutes low intensity walking at the level of 65-75% of HRmax.Cooling down period for 5 min of at 50-60% of the HRmax"
223487459|NCT02190201|DEVICE|videolaryngoscope|a kind of videolaryngoscopes, which are widely used in difficult airways.
223487460|NCT02190201|DEVICE|Direct laryngoscope|A kind of traditional laryngoscopes
224177943|NCT00510406|DRUG|solifenacin succinate|antimuscarinic
224177944|NCT00510406|DRUG|Placebo|Placebo
223487461|NCT01979900|DRUG|Vaccae|One vial of Vaccae diluted with 1.0ml sterile water for injection, take deep coxal muscle injection after shaking well, once every 2 weeks, 6 times totally.
223487462|NCT01979900|DRUG|placebo|One vial of placebo diluted with 1.0ml sterile water for injection, take deep coxal muscle injection after shaking well，once every 2 weeks, 6 times totally.
223487463|NCT05971589|BIOLOGICAL|LM103|Fresh tumor samples will be resected from enrolled patients. Autologous TILs will be extracted and reinfused to corresponding patients after ex vivo stimulation, activation and extensive expansion.
223617720|NCT05952232|DIETARY_SUPPLEMENT|MK-GH-04|1 capsule after breakfast once a day
223617721|NCT05952232|DIETARY_SUPPLEMENT|TSH-GH-03|1 capsule after breakfast once a day
224177945|NCT00753025|PROCEDURE|Bone marrow aspiration, injection of cells|"Bone marrow is aspirated at patients in all arms.~Arm TNC receives injection of total nucleated cells into ischemic muscle"
224177946|NCT00753025|PROCEDURE|Bone marrow aspiration , injection of isolated CD 133+ cells|"arm CD133 receives injection of isolated CD 133+ cells"
224177947|NCT00753025|PROCEDURE|Bone marrow aspiration, injection of saline|"arm placebo receives injection of saline"
224177948|NCT02424708|DRUG|Reduced Glutathione 100mg|100mg GSH delivered intranasally, three times a day for 12 weeks, in 1 cc sterile saline using a syringe with a Mucosal Atomization Device (MAD) tip.
223617722|NCT05952232|DIETARY_SUPPLEMENT|PA-GH-02|1 capsule after breakfast once a day
223617723|NCT02313259|OTHER|Speed discrimination test|"The participant has to stare in the middle of two screens, i.e the reference screen and the test screen. Dots are moving from the center to the edge of the screens at different speeds. The participant is forced to determine if the dots of the test screen are moving faster or slower than the reference screen.~The test is designed in Psychtoolbox3. Data analyses performed using MATLAB. Two-alternative forced choice paradigm."
224177949|NCT02424708|DRUG|Reduced Glutathione 200mg|200mg GSH delivered intranasally, three times a day for 12 weeks, in 1 cc sterile saline using a syringe with a Mucosal Atomization Device (MAD) tip.
224177950|NCT02424708|DRUG|Placebo|Saline delivered intranasally, three times a day for 12 weeks, in 1 cc sterile saline using a syringe with a Mucosal Atomization Device (MAD) tip.
224177951|NCT03814057|DIAGNOSTIC_TEST|24 hour urine creatinine excretion|two age corrected calculations of creatinine height index were obtained
224177952|NCT02393365|OTHER|Questionnaire|All patients admitted to the one day clinic for surgery and gastroenterology will be asked, after signing an informed consent, to fill in a questionnaire about HCV risk factors.
224177953|NCT02393365|PROCEDURE|HCV serology|"In case of a pre-operative blood sample an HCV serology will also be done as part of a routine pre-operative screening.~In patients where no pre-operative blood sample is done an additional consent will be asked to perform a blood sample for HCV serology. This qualifies the study as 'interventional' according to the Belgian legislation."
224177954|NCT05619939|DIETARY_SUPPLEMENT|Protein isolate|The indicated protein isolates will be given to subjects as their major protein source
224177955|NCT05476094|DRUG|Polyene Phosphatidylcholine|AYP-101 1 - 25 mg of essential phospholipids in 1 mL AYP-101 2 - 50 mg of essential phospholipids in 1 mL Placebo - Essential phospholipids in 1 mL 00 mg
224177956|NCT01888380|PROCEDURE|Minimally invasive, virtual autopsy|Post-mortem cross-sectional imaging with CT-guided biopsy
224177957|NCT01888380|PROCEDURE|Conventional autopsy|
224177958|NCT04126876|DRUG|Tilsotolimod|Intradermal, single injection of 1 ml (8 mg) Tilsotolimod (IMO-2125) at the primary melanoma excision site, one week prior to sentinel node biopsy (SNB).
224177959|NCT04126876|DRUG|Saline (0.9% sodium chloride)|Intradermal, single injection of 1 ml plain saline (0.9% sodium chloride) at the primary melanoma excision site, one week prior to sentinel node biopsy (SNB).
224177960|NCT01164267|DRUG|Everolimus|Everolimus (tablets, 5 mg) is given orally at the dose of 10 mg/day from day 1 to day 28 of each cycle for up to a total of 6 cycles or until progression. Patients with CR or PR may continue treatment until PD if well tolerated
224177961|NCT03000920|OTHER|SMS before invitation|A couple of days before the invitation letter, an SMS will be sent to announce the arrival of the invitation letter to the mammogram
224177962|NCT03000920|OTHER|SMS Reminder 1|If it is necessary for the women to have a reminder 1, the usual mail will be replaced by an SMS.
224177963|NCT04313660|DRUG|Anlotinib In Combination With PD-1/L1 Inhibitor|"At the end of chest radiotherapy (c2d1), the simultaneous administration of androtinib hydrochloride capsule and PD-1 / L1 inhibitor was started. L~Arotinib hydrochloride capsule, 12 mg, Po, QD, was taken orally for two weeks, one week, three weeks as a cycle, completed in the first 14 days until the disease progress;~Durvalumab injection, 1500mg, IV, once every three weeks, completed on the first day until the disease progresses.~Tetraprizumab injection, 240mg, IV, once every three weeks, completed on the first day until the disease progresses.~The choice of durvalumab / trepril mAb was at the discretion of the researchers."
224177964|NCT03359382|OTHER|Resistance or home exercise combined with eccentric exercise|"First year: Progressive resistance exercise (60-80% RM) combined with low intensity eccentric exercise (10%RM).~Second year: Progressive resistance exercise (60-80% RM) combined with progressive eccentric exercise (10-80% RM).~Third year:Home exercise combined with low intensity eccentric exercise (10% RM )"
224177965|NCT02545465|DRUG|Riociguat (Adempas, BAY63-2521)|As per the treating physicians discretion
224177966|NCT00542321|OTHER|Manual turn|Manual turn from side to back to side every 2 hours by nurses while patient receiving mechanical ventilation
224177967|NCT00542321|DEVICE|kinetic therapy bed|Continuous, automated turning to a maximum of 45 degrees in the lateral positions while the patient is receiving mechanical ventilation
224177968|NCT01639599|DRUG|Dexamethasone iv injection|Dexamethasone 5mg iv during anesthesia induction
223487464|NCT00689936|DRUG|Lenalidomide and low-dose dexamethasone|"Lenalidomide - oral, 2.5mg, 5mg, 10mg, 15mg 20mg, or 25 mg capsules, given either days 1-21 of each 28 day cycles or given every other day for 21 days until documentation of PD.~Dexamethasone - oral 4mg tablets for a total dose of 20mg or 40 mg given days 1,8,15 and 22 of each 28 day cycle up to disease progression"
224177969|NCT01639599|DRUG|Dexamethasone, haloperidol|dexamethasone + haloperidol 1mg
223487465|NCT00689936|DRUG|Lenalidomide plus low-dose dexamethasone given for 18 four-week cycles|"lenalidomide - oral, 2.5mg, 5mg, 10mg, 15mg, 20 mg or 25 mg capsules given on days 1-21 of each 28 day cycle or every other day for 21 days for 18 cycles.~Dexamethasone - oral 4mg tablets for a total dose of 20mg or 40 mg given days 1,8,15 and 22 of each 28 day cycle for 18 cycles"
223487466|NCT00689936|DRUG|Melphalan, Prednisone and Thalidomide|Melphalan - oral, 2mg tablets dosed at either 0.25mg/kg, 0.125 mg/kg, 0.20mg/kg or 0.10mg/kg on days 1-4 of each 42 day cycle up to 12 cycles Prednisone - oral, 5mg, 10mg, 20 mg and 50 mg tablets dosed at 2mg/kg daily days 1-4 of each 42 day cycle for up to 12 cycles Thalidomide - oral, 50mg, 100mg and 200 mg capsules dosed at either 100mg or 200 mg daily on days 1-41 of each 42 day cycle for up to 12 cycles
223487467|NCT00636571|BEHAVIORAL|Exercise|Upright bike intervention for post-surgical lung cancer survivors.
223487468|NCT04876937|DRUG|Dexmedetomidine|Dexmedetomidine is infused at a rate of 0.1-0.2 μg/kg/h (0.025-0.05 ml/kg/h) from study recruitment in the ICU during mechanical ventilation, for no more than 7 days.
223487469|NCT04876937|DRUG|Placebo (normal saline)|Placebo (normal saline) is infused at a rate of 0.025-0.05 ml/kg/h from study recruitment in the ICU during mechanical ventilation, for no more than 7 days.
224177970|NCT01639599|DRUG|Dexamethasone, haloperidol|Active Comparator: dexamethasone + haloperidol 2mg
224177971|NCT00034801|DRUG|olanzapine|
224177972|NCT00034801|DRUG|ziprasidone|
224177973|NCT04138758|DRUG|Tiotropium bromide + Olodaterol|Tiotropium bromide + Olodaterol
224177974|NCT04138758|DRUG|LABA/ICS|Long-acting beta2-agonist and Inhaled corticosteroids (LABA and ICS)
224177975|NCT04613752|DEVICE|diaphragmatic function measurements and diaphragmatic ultrasound|A single experimental group in which diaphragmatic function measurements and diaphragmatic ultrasound will be performed.
223487470|NCT00166816|DRUG|sirolimus, cyclosporine, tacrolimus|
223487471|NCT01396564|DRUG|Metformin|850 mg of Metformin daily, increased to 1700 mg after 12 weeks, for the duration of the trial.
223487472|NCT01396564|DRUG|Pioglitazone|15 mg of pioglitazone daily, increased to 60 mg after 12 weeks.
223487473|NCT04144829|PROCEDURE|HIFU|Intravaginal HIFU procedure, lengths 1.5, 3 and 4.5 mm - 200, 200 and 100 impulses respectively
223487474|NCT04144829|PROCEDURE|Fibrin|Injection of 2ml platelet-rich fibrin from centrifuged for 5 min patient's blood under the urethra
224177976|NCT05578820|BIOLOGICAL|Stimotimagene copolymerplasmid|Gene therapy drug, Intratumoral administration
224177977|NCT05578820|DRUG|Ganciclovir|Antiviral drug, Intravenous administration
224205596|NCT01563393|OTHER|No intervention|The Placebo Comparator arm children got the classic care that practiced in hospitalization
224205597|NCT04608656|OTHER|Provision of livestock feeds|Households will receive livestock feeds (ranch cubes) for the select lactating animals during the dry season
224205598|NCT04608656|OTHER|Nutrition counselling|Households will receive livestock feeds (ranch cubes) for the select lactating animals and will also be enrolled in to a nutrition counselling programme
223586895|NCT06473935|OTHER|Questionnaires and focus groups|"Participation in the research involves completing a test battery composed of self-administered questionnaires, all validated in the Italian language.~Additionally, qualitative data will be collected through semi-structured interviews (conducted in person or online, based on individual preferences) and focus groups, both lasting between 90 and 120 minutes."
223586896|NCT01818440|OTHER|3D Roadmap software|Two scanning methods will be used by doctors to position catheters in the blood vessels to deliver the chemotherapy and close the blood supply to the tumor.
223586897|NCT01818440|OTHER|Fluoroscopy|Patients will have the procedure performed with regular fluoroscopy (X-ray). Regular fluoroscopy is the standard method.
223586898|NCT00162240|DRUG|Muraglitazar|
223586899|NCT06263049|PROCEDURE|transurethral resection of prostate|resection of prostate by using bipolar cautarization
224177978|NCT04693858|BEHAVIORAL|Child Anxiety Learning Modules (CALM)|CALM is a cognitive-behavioral intervention for childhood anxiety. CALM consists of five modules. The primary components include psychoeducation, relaxation training (C), behavioral exposure (A), cognitive restructuring (L), and relapse prevention (M). There is also an optional parent psychoeducation module. Students randomized to the CALM condition will receive the 5 modules over 8 weeks.
224177979|NCT04693858|BEHAVIORAL|Child Anxiety Learning Modules--Relaxation (CALM-R)|CALM-R serves as an active comparison condition to CALM and consists of 5 modules of relaxation skills. The key components of CALM-R include psychoeducation, deep breathing, progressive muscle relaxation, guided imagery, and relapse prevention. Students randomized to the CALM-R condition will receive the 5 modules over 8 weeks.
224177980|NCT03553121|OTHER|walking|walking and not walking
224306750|NCT03398070|OTHER|Standard of Care|"The standard of care interventions for Functional Neurological Disorders (FND) include:~1. delivery of a rule-in diagnosis~2. providing educational materials~3. referring to physical therapy (PT) and/or occupational therapy (OT) as clinically indicated~4. referring to FND-related cognitive behavioral therapy (CBT)~5. psychotropic medication management based on standard psychiatric care"
223487475|NCT05375305|DRUG|SHR8554 Injection|SHR8554 Injection; high dose
223487476|NCT05375305|DRUG|SHR8554 Injection|SHR8554 Injection; low dose
223487477|NCT05375305|DRUG|Saline Solution|Saline Solution
223487478|NCT05375305|DRUG|Morphine|Morphine
223487479|NCT01303419|DEVICE|CE-BMRI|Contrast-enhanced breast imaging using Magnetic Resonance
223586900|NCT05718193|DIAGNOSTIC_TEST|DeFrame|The DeFrame system is applicated during colonoscopy. The DeFrame system superimposes a rectangular box on the polyp lesion area in the colonoscopy field of view, notifying the endoscopists of the presence of the lesion.
223586901|NCT05718193|DIAGNOSTIC_TEST|Classified DeFrame|The Classified DeFrame system is applicated during colonoscopy. The Classified DeFrame system superimposes a rectangular box on the polyp lesion area in the colonoscopy field of view, the color of the rectangle box will turn blue when the polyp is considered as an adenoma, notifying the endoscopists of the presence of the lesion.
223586902|NCT05718193|DIAGNOSTIC_TEST|conventional colonoscopy|conventional colonoscopy
223586903|NCT02831790|OTHER|Fontan Education Videos|"The intervention will consist of three brief (\~5 minute) professionally-developed whiteboard videos, available online. The videos will feature lay language at a grade 7 level or below and will be engaging. Topics are based on key findings of the Family Resilience Study, namely:~1. Stress reactions in children and parents post Fontan. This video will be supplemented with existing resources on the topic.~2. Anticoagulation~3. Prolonged pleural drainage"
223586904|NCT02794389|DRUG|N-acetyl cysteine|
223586905|NCT02794389|DRUG|Placebo|
223586906|NCT00994994|DRUG|Tranexamic Acid|50 mg/kg of tranexamic acid was given as a bolus at the induction of anesthesia, followed by 15 mg/kg of continuous infusion and another 50 mg/kg into the bypass circuit in TXA group. same volume of normal saline was given in Placebo group.
223745339|NCT06914258|COMBINATION_PRODUCT|Inhibition Compression|"Group A will receive conventional Physiotherapy treatment along with the scapular mobilization which will include;~* Electrotherapy (TENS and hot pack) for 10 min~* Active and passive ROMs for 5 min~* pectoral stretching for 5min~* shoulder joint mobilization. To mobilize the shoulder joint, distraction of the glenohumeral joint, posterior glide and caudal glide were performed to the patient in supine position at a frequency of two to three oscillations/second for one to two minutes. (10 min)~* Manual scapular mobilization will be done in sideline with their back towards the physiotherapist."
224177981|NCT00231621|DRUG|topiramate|
224177982|NCT01396811|DRUG|33525|Daily for 14 days
224177983|NCT01396811|DRUG|Placebo|Daily for 14 days
223487480|NCT01303419|DEVICE|DE-CEDM|Breast imaging using Dual-energy, contrast-enhanced digital mammography
223487481|NCT00141375|DRUG|Pregabalin|
223487482|NCT04758338|OTHER|VUMC telehealth services|Participants will access the CTS link (sent to them via email), which will connect them directly to a videoconference and enable them to see and hear the facilitators and other patients in the group.
223487483|NCT04758338|OTHER|Interview|25-30 participants will be interviewed
223487484|NCT04758338|OTHER|Educational materials|Participants will be provided educational materials
223487485|NCT03697746|DRUG|paracetamol|paracetamol 1000 mg vial
223487486|NCT03697746|DRUG|Dexketoprofen Trometamol|dexketoprofen trometamol 50 mg bulb
223487487|NCT03697746|DRUG|Ibuprofen|ıbuprofen 400 mg vial
223487488|NCT05676437|DIAGNOSTIC_TEST|Stress radiography|Radiographic examination during clinical stress test of knee laxity
223487489|NCT05740202|DRUG|SHR-7367|The study was divided into three phases, the dose escalation phase and the dose extension phase and therapeutic effect extension of SHR-7367 in subjects with advanced malignant tumors.
223487490|NCT04229576|DEVICE|TENs|Assessing the efficacy of TENs in pain relieve during office hysteroscopy .
224177984|NCT00253747|DRUG|Osmotic-Release Methylphenidate|OROS-MPH dosing strategy will start with 18 mg/day for 3 days, increasing to 36mg/day for the next three days; increasing to 54 mg/day in week two, and to 72 mg/day in week three through the remainder of the study (as tolerated). And, nicotine patch dosing schedule will be 21 mg/day during weeks 4-11; 14 mg/day during weeks 12-13; and 7 mg/day in week 14.
224177985|NCT00253747|DRUG|Placebo|OROS-MPH (placebo) dosing strategy will start with 18 mg/day for 3 days, increasing to 36mg/day for the next three days; increasing to 54 mg/day in week two, and to 72 mg/day in week three through the remainder of the study (as tolerated). And, nicotine patch dosing schedule will be 21 mg/day during weeks 4-11; 14 mg/day during weeks 12-13; and 7 mg/day in week 14.
224177986|NCT05999292|DRUG|68Ga-R8760 injection at pre-defined dose levels|PET/CT imaging at predefined timepoints
224177987|NCT05999292|DRUG|68Ga-R8760 injection|PET/CT imaging at a single timepoint
224177988|NCT03006549|BEHAVIORAL|Emergency Manual (Crisis Checklist)|participants will have an Emergency Manual available to them during the crisis simulation scenario.
224177989|NCT01851824|DRUG|acenocoumarol|4 mg single oral doses on Days 1 and 23
224177990|NCT01851824|DRUG|vemurafenib|960 mg orally bid, 20 days (Days 4-23)
224177991|NCT00816062|DEVICE|Talent Abdominal Stent Graft|The Talent Abdominal Stent Graft is indicated for the endovascular treatment of abdominal aortic aneurysms with or without iliac involvement.
224177992|NCT04465591|DIAGNOSTIC_TEST|troponin T fragmentation test|laboratory test from blood sample
224177993|NCT03701932|BEHAVIORAL|TMS and Lumosity®cognitive retraining|The Lumosity® training includes exercises for speed, memory, attention, flexibility, and problem solving. Subjects will complete this battery while receiving TMS treatment.
224177994|NCT03701932|BEHAVIORAL|TMS and non cognitive computer games|Subjects will play computer games while receiving TMS treatment.
224177995|NCT02672982|OTHER|NUTPSY treatment|The psychosocial component of the new combined treatment involves seven weekly counselling sessions with mothers focused on feeding, emotional attachment, stages of child development, stimulation, emotional responsiveness and interaction, and on concerns/strategies of child care and parenting.
224177996|NCT02672982|OTHER|NUT treatment|Only the standard nutritional treatment in the form of Ready-to-use Therapeutic Food (RUTF) is administered.
224177997|NCT03971227|DEVICE|Acuity 200 (Fluoroxyfocon A) contact lens|Daily wear rigid gas permeable contact lens
224177998|NCT03971227|DEVICE|Acuity 100 (Hexafocon A) contact lens|Daily wear rigid gas permeable contact lens
224177999|NCT00718887|DRUG|Entecavir|Tablets, Oral, 0.5 mg, once daily (QD), 52 weeks
223487491|NCT06475001|DRUG|VER-01|"Herbal medicinal product, containing as active substance a soft extract of Cannabis sativa L., cannabis flos (Cannabis flower), adjusted to a content of 50 mg/g delta-9-tetrahydrocannabinol (THC).~VER-01 is adjusted to a concentration of 19 mg/mL THC by adding the excipient sesame oil."
223586907|NCT05654688|OTHER|graston and muscle energy technique|"Graston technique (Gt) is a technique of mobilization of soft tissue using instruments which consider myofascial release instrument that has been reported to relieve pain, improve overall function, and increase range of motion.~Muscle energy technique (MET) is a term composed of various types of active muscular relaxation and stretching procedures. The two cornerstone forms of MET are reciprocal inhibition and post isometric relaxation. In theory, reciprocal inhibition takes advantage of the neurological phenomena of muscular contraction, which results in an inhibitory effect on the antagonistic muscles."
223586908|NCT03234231|BEHAVIORAL|3-month supervised tooth brushing programme|One or a few dental hygienists, who are trained to teach how to brush and provide scaling, will supervise the students to brush daily in school for three months.
223586909|NCT03234231|BEHAVIORAL|oral health education talk|It is conducted by a dentist, while written materials will be delivered to the students and their carers.
224178000|NCT00718887|DRUG|Adefovir/Entecavir|Tablets, Oral, 10-mg adefovir QD for 12 weeks followed by 0.5-mg entecavir QD for a maximum of 52 weeks
224178001|NCT00156962|DRUG|Epoetin alfa DT|Receive drug at same frequency and dose as at the time of randomization Change dose by+/- 25% in order to maintain Hb between 11.0 - 13.0 g/dL
224178002|NCT00156962|DRUG|Epoetin alfa RB|Receive drug at same frequency and dose as at the time of randomization Change dose by+/- 25% in order to maintain Hb between 11.0 - 13.0 g/dL
224178003|NCT00453635|DRUG|Docetaxel|Docetaxel at the dose of 75mg/m\^2 IV on day 1 every 3 weeks for 6 consecutive cycles
224178004|NCT00453635|DRUG|Carboplatin|Carboplatin at the dose of 5 AUC IV on day 1 every 3 weeks for 6 consecutive cycles
224178005|NCT00453635|DRUG|Herceptin|Herceptin 8 mg/Kg on day 1 for the first cycle and 6 mg/Kg for the 5 remaining cycles, IV, every 3 weeks
224178006|NCT00453635|DRUG|Vinorelbine|Vinorelbine at the dose of 60mg/m\^2 per os,weekly
224178007|NCT05964296|OTHER|The MAURISSE application use|"* Exchanges with the care team via the messaging system,~* Postponement of consumption,~* Monitoring of consumption,~* Access to information on the To Do List,~* Access to personal content to help with management (Socio-professional situation, type of life, personal history..).~* Postponement of a feeling of boredom,~* Access to proposals to fight against this feeling."
223487492|NCT06475001|DRUG|Placebo|Comparator without active ingredient
223487493|NCT00594555|DRUG|Imatinib Mesylate|Imatinib Mesylate: 400mg po BID every day. Imatinib Mesylate will be administered Day 2 to Day 15
223487494|NCT00594555|DRUG|CLAG|"Cladribine: 5mg/m2 administered through a 2 hour intravenous infusion daily for 5 consecutive days starting on Day 2~Cytarabine: 2gm/m2 administered through a 4 hour intravenous infusion starting 2 hours after the ignition of Cladribine for 5 days starting on Day 2~G-CSF: 300mcg sc for 6 days starting at 24 hours (Day 1) before the first dose of Cladribine; administration starting on Day 1 for 6 days"
223487495|NCT02543411|DRUG|Lidocaine 1%|"Intravenous administration as bolus of lidocaine 1.5 mg/kg before sedation and infusion of lidocaine 2 mg/kg/hr during sedation.~Sedation with fentanyl and propofol"
223487496|NCT02543411|DRUG|Normal saline|"Intravenous administration as bolus of normal saline 0.15 mL/kg before sedation and infusion of normal saline 0.2 mL/kg/hr during sedation.~Sedation with fentanyl and propofol"
223487497|NCT05944952|DRUG|buprenorphine/naloxone|Participants will be dosed with buprenorphine/ naloxone strips
223487498|NCT06635447|DRUG|Capivasertib|400 mg, oral, twice daily; 4 days on and 3 days off
223487499|NCT06635447|DRUG|Fulvestrant|Fulvestrant IV
224178008|NCT05964296|OTHER|Usual care|The usual care within the center will consist of appointments with doctors; regular follow-up meetings with nurses, psychologists, social workers, therapeutic groups depending on the evaluation.
224178009|NCT03327740|DRUG|DTG based ARV regimen with ABC|ARV regimens containing DTG and ABC
224178010|NCT03327740|DRUG|DTG based ARV regimen without ABC|DTG based ARV regimens that do not contain ABC
224178011|NCT03327740|DRUG|RAL or EGV based ARV regimens with ABC|RAL or EGV based regimens containing ABC
224178012|NCT03327740|DRUG|RAL or EGV based regimens without ABC|RAL or EGV based ARV regimens that do not contain ABC
224178013|NCT03327740|DRUG|Any other DTG based ARV regimen as monotherapy|Any other DTG based ARV regimens including DTG as monotherapy or two-drug regimens.
224178014|NCT03470272|DEVICE|FB Professional LED Red light therapy|FB Professional LED red light therapy is a non-invasive dermatological aesthetic treatment for the reduction of circumference of hips, waist and thighs. Measure before and after effects of device unit. Three measurements before of circumference of abdomen area and three measurements after comparing the results.
224178015|NCT03470272|DEVICE|Effects of Red Light LED Therapy on Body Contouring|Intervention is to take a sample and measure before and after using a sham unit (placebo) and take three measurements of abdominal before treatment and three measurements after sham treatment and compare to controlled treatment.
224178016|NCT04692285|DRUG|Zolpidem|Patients will undergo transcranial magnetic stimulation, 18F-FDG-PET brain imaging, and clinical testing after a single 5 mg dose of Zolpidem.
224178017|NCT04692285|DRUG|Placebo|Patients will undergo transcranial magnetic stimulation, 18F-FDG-PET brain imaging, and clinical testing after a single dose of placebo.
224178018|NCT04427241|DRUG|Cerebrolysin|30 ml cerebrolysin + 70 ml normal saline, days 4-17, once/day, intravenously
224178019|NCT04427241|DRUG|Control|100 ml normal saline, days 4-17, once/day, IV
224178020|NCT00066274|DRUG|FOLFIRI regimen|
224178021|NCT00066274|DRUG|FOLFOX regimen|
224178022|NCT00066274|DRUG|fluorouracil|
224178023|NCT00066274|DRUG|irinotecan hydrochloride|
224178024|NCT00066274|DRUG|leucovorin calcium|
224178025|NCT00066274|DRUG|oxaliplatin|
224178026|NCT01672827|DRUG|[18F]Flutemetamol|No drug is administered in this intervention. These are scanned images being reviewed, previously acquired in various GE-067 studies.
224178027|NCT04501380|DRUG|AEMCOLO (Rifamycin SV MMX)|Participants will be issued a patient kit containing AEMCOLO (Rifamycin SV MMX) 194 mg tablets for the 1st or the 2nd treatment regimen in a random order.
224178028|NCT04800406|PROCEDURE|Dental Implants|Resorbable blast media surface treated dental implant and Acid etched surface treated dental implant.
224178029|NCT05102734|DRUG|Nitroglycerin Topical Product|Topical nitroglycerin solution
223487500|NCT01580644|DRUG|GLPG0187 prodrug|
223586910|NCT03082014|DRUG|Amlodipine|blood pressure lowering agent - dihydropyridine Ca2+-channel blocker
224178030|NCT05607342|DRUG|Osanetant|To evaluate the effect of Osanetant on the testosterone levels.
224178031|NCT05749159|BEHAVIORAL|physiotherapy|New physical therapy: a disposable cup (soft cup) to take 1/3 cup of room temperature water and place it on a table. The patient takes a sitting or standing position. The middle finger of both hands press tightly against the nose to seal the nasal cavity. At the same time, press the ear screen with both hands to close the ear canal. After that, bite the cup with teeth (hands do not touch the cup), and drink up 1-2 mouthfuls of water.
224178032|NCT01959087|PROCEDURE|single port surgery|Single port surgery can be converted in multiport surgery if necessary
224178033|NCT01959087|PROCEDURE|Multiport surgery|
224178034|NCT01978717|PROCEDURE|epidural anesthesia|
224178035|NCT01978717|PROCEDURE|general anesthesia|Patients received general anesthesia for surgery
223487501|NCT03232944|DEVICE|Cardiac Resynchronization Therapy - MPP|The multiple point pacing feature (MPP) is designed to allow pacing from 2 LV electrodes.
223487502|NCT05972135|DRUG|Teclistamab|Teclistamab will be administered subcutaneously at step-up doses on Day 1, Day 4 and Day 8, one week after first treatment dose and weekly thereafter. In participants who have a partial response (PR) or better after 6 months of therapy, dosing frequency may be reduced to every 2 weeks.
223487503|NCT05972135|DRUG|Talquetamab|Talquetamab will be administered subcutaneously at step-up doses on Day 1, Day 4, Day 8 and Day 15, one week after first treatment dose and every 2 weeks thereafter. In participants who have a very good partial response (VGPR) or better after Cycle 4, dosing frequency may be reduced to every 4 weeks
223487504|NCT05972135|DRUG|Tocilizumab|Tocilizumab will be administered as a pretreatment medication in advance of administration of the first step-up dose of teclistamab or talquetamab on Cycle 1 Day 1.
223586911|NCT03082014|DRUG|Losartan|blood pressure lowering agent - angiotensin-receptor blockers
223586912|NCT03082014|DRUG|Atenolol|blood pressure lowering agent - beta-blocker
223586913|NCT03751514|BIOLOGICAL|Bordetella Pertussis B1917|"The B. pertussis isolate to be used in this human colonisation model is strain B1917, which is representative of current isolates in Europe. The strain, isolated in 2000 from a Dutch patient with B. pertussis disease, expresses Prn, PT and Filamentous Haemagglutinin (FHA). This strain has been extensively characterised in the mouse model as well as by proteomics and transcriptomics and has a closed genome available. It is fully sensitive to azithromycin in vitro.~Providing there are no safety concerns the standard inoculum (SI) will be identified in a dose escalating or de-escalating experiment commencing at 103 colony forming units administered intranasally."
224178036|NCT04235959|DRUG|Tirzepatide|Administered SC
224178037|NCT04235959|DRUG|Placebo|Administered SC
224178038|NCT02702076|DRUG|Apomorphine|Continuous subcutaneous infusion of apomorphine during waking day
224178039|NCT02702076|DRUG|Placebo|Continuous subcutaneous infusion of placebo during waking day
224178040|NCT00608426|BEHAVIORAL|Proactive Outreach with choice of telephone or in-person smoking cessation services|This group of participants is sent a recruitment letter, then receives a phone call to offer them their choice of smoking cessation services (either telephone care or in-person care).
224178041|NCT00275834|DRUG|Zonisamide|zonisamide 400 mg, 200 mg, or placebo
224178042|NCT03068507|BEHAVIORAL|Trimodal prehabilitation management|Trimodal prehabilitation strategy includes physical exercise (moderate aerobic exercise combined with resistance exercise and respiratory training ), nutritional suggestion and optimization（whey protein supplement）, and psychological therapy, as well as conventional guidance (including preoperative anesthesia assessment, drug treatment recommendations for chronic disease, quit smoking and abstinence).
224178043|NCT00142428|DRUG|Cetuximab|The initial dose of cetuximab was 400 mg/m2 (cycle 1 only) given intravenously followed by weekly intravenous infusions at 250 mg/m2. Each cycle was defined as 6 consecutive weekly intravenous treatments. Treatment was continued until 1 of the following criteria was met: disease progression per RECIST criteria, unacceptable toxicity, patient refusal, or the need to delay therapy more than 3 weeks.
224306751|NCT04129359|BEHAVIORAL|FamilieTrivsel|FamilieTrivsel is a modular internet-based low-cost and brief psychoeducation intervention based on the Robusthed (Resilience) programme (RP). Mentalisation approaches are used to increase resilience and ability to handle the challenges of life. The programme is licence free and can be used with low or high intensity and it can be combined with any other interventions. RP provides simple explanations and tools that can be used to discover, understand and regulate one's own thoughts and feelings by activating mental and physical resources and it provides examples and exercises that may promote communication about mental states between parents and the child. The content has been developed to include video-based training sessions based on different stages of pregnancy and early childrearing. RP appears suitable for use in general practice, where the GP sees young parents regularly and thus can direct patients towards components of the programme when need appears greatest.
224306752|NCT04129359|OTHER|enhanced care as usual|Structured assessments of maternal mental health, child neurodevelopment and parent-child interaction in routine preventive health care in general practice
223487505|NCT02792127|BEHAVIORAL|Online Program for Social Anxiety|This program will be completed from participants' homes using their own computers. This online format is based on a Cognitive Behaviour Therapy framework (CBT) and involves seven modules that ask participants to engage in a variety of thinking exercises and activities.
223487506|NCT02342730|BEHAVIORAL|Weight Loss Specialist|Referred to a weight loss specialist
223487507|NCT02342730|OTHER|Quality-of-Life Assessment|Complete EORTC-QLQ questionnaires
223487508|NCT02342730|OTHER|Medical Chart Review|Chart reviews are performed
223487509|NCT04521140|DRUG|Dextenza 0.4Mg Ophthalmic Insert|DEXTENZA is a corticosteroid intracanalicular insert placed in the punctum, a natural opening in the eye lid, and into the canaliculus and is designed to deliver dexamethasone to the ocular surface for up to 30 days without preservatives.
223487510|NCT04521140|DRUG|Prednisolone Acetate 1% Oph Susp|Prednisolone Acetate 1% is a corticosteroid used as a topical drop after corneal transplant to decrease inflammation and prevent graft rejection
223487511|NCT04153136|DRUG|Sacubitril-Valsartan 49-51Mg Oral Tablet|By mouth twice daily
223487512|NCT04153136|DRUG|Placebo oral tablet|Placebo oral tablet By mouth twice daily
223487513|NCT03225482|BEHAVIORAL|Motivationally Enhanced Compensatory Cognitive Training|ME-CCT is a manualized group-based behavioral intervention (8 weeks, 2 hours per week, 20 hours total) designed to improve cognitive and everyday functioning in patients with MCI.
223487514|NCT03225482|BEHAVIORAL|Goal-focused Supportive Contact|SC is a group therapy intervention that provides the same frequency and amount of therapist and other group member contact as ME-CCT, but does not provide training in cognitive strategies, lifestyle strategies, or motivational enhancement. The SC intervention focuses on setting and achieving short or long-term goals.
223487515|NCT03868956|DIAGNOSTIC_TEST|Colour doppler ultrasound with or without D-dimer test|"* Positive CDUS: anticoagulant treatment~* Negative CDUS: no anticoagulant treatment~* Non diagnostic CDUS : reference to routine D-dimer test~  * Negative test : no anticoagulant treatment~ * Positive test : second CDUS 7 days (±2) after first one~    * No change in CDUS : no anticoagulant treatment~   * Change in CDUS : anticoagulant treatment"
223487516|NCT04584671|DIAGNOSTIC_TEST|Hyperpolarized Xenon-129 MRI of the lungs|Participants will be imaged using MRI using hyperpolarized xenon-129 gas as a contrast gas
223487517|NCT04584671|DIAGNOSTIC_TEST|Computed Tomography (CT)|Participants will undergo a CT scan of the thoracic cavity
223487518|NCT04584671|DIAGNOSTIC_TEST|Pulmonary Function Tests (PFT)|Participants will have their lung function evaluated using PFT
223487519|NCT04584671|DIAGNOSTIC_TEST|Six Minute Walk Test (6MWT)|Participants will perform the six minute walk test as a measure of exercise capacity
223487520|NCT04584671|DIAGNOSTIC_TEST|Sputum analysis|Participants will provide a sputum sample that will be analysed for eosinophils
223487521|NCT04584671|DIAGNOSTIC_TEST|Blood analysis|Participants will have their blood drawn and analysed for eosinophil count.
223487522|NCT04584671|OTHER|Questionnaires|Participants will complete questionnaires to assess activity related dyspnea, respiratory symptoms and health status impairment and respiratory related quality of life.
223487523|NCT05290649|DIAGNOSTIC_TEST|clinical assessment|mini mental test, pulmonary function test, respiratory muscle strength test, trunk impairment scale, timed up and go test, barthel index
223487524|NCT04392206|DRUG|Adipose Derived Mesenchymal Stem Cells|The dose will be specifically tailored to each subject's vascular anatomy determined by the surgeon through ultrasound measurements. Approximately 3-5 million cells in 5ml Ringer Lactate (RL) Solution
223487525|NCT02997293|OTHER|Enhanced Recovery protocol|The Enhanced Recovery protocol focuses on many areas or perioperative care, including non-narcotic pain management, optimization of fluid balance throughout the perioperative course, early eating, ambulation, early removal of drains postoperatively, and preoperative patient education.
223487526|NCT00311168|DEVICE|Intervention/treatment|"Device: VIP On~Device: VIP Off"
223487527|NCT05712772|OTHER|Blue Light|Blue light exposure
223487528|NCT05712772|OTHER|Red Light|Red light exposure
223487529|NCT04302025|DRUG|Alectinib|Participants will receive oral alectinib twice per day (BID)
223487530|NCT04302025|DRUG|Entrectinib|Participants will receive oral entrectinib daily
223487531|NCT04302025|DRUG|Vemurafenib (Enrollment closed)|Participants will receive oral vemurafenib BID
223487532|NCT04302025|DRUG|Cobimetinib (Enrollment closed)|Participants will receive oral cobimetinib daily
223487533|NCT04302025|DRUG|Pralsetinib (Enrollment closed)|Participants will receive oral pralsetinib daily
224178044|NCT04953182|OTHER|Pain scale registry|The nurses ask the patient about the pain filling every two hours during the hospitalization.
224178045|NCT02646501|DRUG|Antiarrhythmic drug|Antiarrhythmic drug
224178046|NCT02646501|PROCEDURE|percutaneous stellate ganglion block (PSGB)|percutaneous stellate ganglion block (PSGB)
224178047|NCT02103894|DRUG|[18F]T807 ([18F]MNI-777)|All enrolled subjects will undergo an \[18F\]MNI-777 PET imaging visit. For individuals with AD or CTE, \[18F\]florbetapir imaging may also be performed to serve as a means of correlating disease severity by evaluating the relationship of β-amyloid uptake (measured by \[18F\]florbetapir imaging) and tau protein uptake (measured by \[18F\]MNI-777 PET imaging). For individuals with Parkinsonian symptoms, \[123I\]β-CIT SPECT imaging may be performed to evaluate for a reduction in dopamine transporter uptake.
224178048|NCT01999959|PROCEDURE|Pertubation|a lavage procedure of the intrauterine cavity and bilateral fallopian tubes
224178049|NCT04082494|DEVICE|Music via internet and noise canceling headphones|Optional music via internet and noise canceling headphones will be offered.
224178050|NCT04082494|OTHER|Beverages|Beverages will be optionally offered (with and without sugar, warm or cold).
224178051|NCT06521632|OTHER|transcutaneous electrical acupoint stimulation|Electrodes are placed at acupoints and connected to the stimulator. Electrical stimulation is given for 2 hours.
224178052|NCT04935528|BIOLOGICAL|serology and ELISPOT test|27 mL blood sample to study the humoral and the cellular immune response
224178053|NCT04935528|BIOLOGICAL|serology|7 mL blood sample to study the humoral response
224178054|NCT06525337|BEHAVIORAL|STANDARDCARE (STAND) group|Will receive a device and health coaching
224306753|NCT06425497|OTHER|The dosage of dnDSA|Flow cytometric analysis using FlowPRA Screening Test and/or Luminex Single Antigen Beads class I and II- IgG (cut- positivity off = MFI\> 1000)
224178055|NCT06525337|OTHER|CONTROL (CON) group|Will not use any devices or receive health coaching
224178056|NCT05283161|DRUG|cannabidiol and tetrahydrocannabinol|CBD and THC will be given in the same concentration within a group of 10 participants, while its effects will be compared with the other two groups with 10 participants each and the placebo group.
224178057|NCT05283161|DRUG|Placebo|The placebo will match the study drug in odor, taste, color and appearance to ensure proper masking.
224178058|NCT01560013|DRUG|Naltrexone|Naltrexone, oral 50 mg per day.
224178059|NCT03055806|DRUG|IX-01 400 mg|IX-01 400 mg caplet
224178060|NCT03055806|DRUG|Placebo|Placebo caplet(s)
224178061|NCT03055806|DRUG|IX-01 800 mg|IX-01 800 mg (Two 400 mg caplets)
224178062|NCT03055806|DRUG|IX-01 1200 mg|IX-01 1200 mg (Three 400 mg caplets)
224178063|NCT01480193|OTHER|Sound Based and Educational Therapies|The SBE program will consist of two hour-long individual counseling and sound therapy sessions based on the Department of Veterans Affairs Progressive Audiologic Tinnitus Management approach. SBE treatment incorporates the use of education, counseling, increased relaxation and decreased stress, along with the integration of sound therapy to better manage the impact of tinnitus.
224178064|NCT01480193|OTHER|Integrative Medicine Therapies and Sound Based Education Therapies|3 Cognitive Based Therapy Sessions, 9 Telephonic Health Coaching Sessions, 5 Acupuncture Sessions, and Group-Based 8 week Mindfulness Based Stress Reduction Provided synergistically through an integrative medicine paradigm
224178065|NCT02122965|OTHER|Pharmacist-led medication review|Medication review is a structured, critical examination of a patient's medications with the objective of reaching agreement with the patient about treatment, optimizing the medications' impact, and minimizing the number of medication-related problems and adverse drug events.
224178066|NCT04601194|BEHAVIORAL|Coaching and Virtual Provider Program Practice|4 weekly goal setting/coaching sessions, coupled with Virtual Provider program training and practice
224178067|NCT00314028|BEHAVIORAL|Focus on the Future|Focus on the Future is an educational program designed to promote proper condom use.
224178068|NCT00314028|OTHER|Control standard of care treatment|Standard of care treatment is the normal treatment that someone would receive for the particular sexually transmitted disease or virus.
224178069|NCT03445494|PROCEDURE|Brace|A brace to be weared according to protocol
224178070|NCT03445494|PROCEDURE|Normal sling|A normal sling to be weared according to protocol
224306754|NCT02591186|PROCEDURE|Acupuncture|Participants will receive 3 acupuncture sessions during IVF process
224306755|NCT05339334|DRUG|PF-07321332/ritonavir|PF-07321332/ritonavir will be given by mouth two times a day for 10 days
224306756|NCT00284024|DRUG|domperidone|
224306757|NCT00368979|DRUG|Dutasteride|once daily
224306758|NCT00368979|DRUG|Placebo|once daily
224306759|NCT06328179|DRUG|Venetoclax 100 mg d1，200 mg d2，400 mg d3-14；|VHEA -Induction Phase Regimen/Consolidation therapy after remission
224306760|NCT03987321|DEVICE|Infrarenal vena cava filter placement|Patients who are enrolled in this study are assigned to receive either Denali or Celect filter in the inferior vena cava. All other procedures are the same in both groups
224306761|NCT06349590|DIETARY_SUPPLEMENT|High-fiber/low-fat meals|Meals with Low fat/High fiber
224306762|NCT06484842|OTHER|The combined psychological resilience and self-efficacy intervention|Based on the content of the literature analysis and the group's previous research, a joint intervention programme on psychological resilience and self-efficacy for patients undergoing surgery for oesophageal cancer has been developed. The programme consists of 6 sessions in total, including preoperative period and one month after discharge, covering the period when patients' postoperative symptoms occur most severely. The intervention will be conducted in an individual, offline face-to-face format during the patients' hospital stay; considering the smooth implementation of the intervention after the patient will be discharged from the hospital, we will conduct the intervention in an individual, offline face-to-face format during the patient's outpatient review, and set up a WeChat group in case the patients are at home to conduct the intervention in the form of an online punch card.
223487534|NCT04302025|DRUG|Atezolizumab|Atezolizumab will be administered by intravenous (IV) infusion
223487535|NCT04302025|DRUG|SBRT|Patients will receive SBRT given concurrently starting with the first dose of atezolizumab
223487536|NCT04302025|PROCEDURE|Resection|Participants will receive surgical resection of the primary tumor along with selected lymph nodes
223487537|NCT04302025|DRUG|Chemotherapy|Participants will receive standard of care (SOC) chemotherapy as determined by the treating physician
224178071|NCT02630459|DRUG|Placebo|placebo via subcutaneous injection
224178072|NCT02630459|DRUG|Erenumab|erenumab via subcutaneous injection
224178073|NCT02630459|DRUG|Erenumab|erenumab via autoinjector (AI)/pen
224178074|NCT00125138|DRUG|Melperone HCl|20 mg/day. Strength of melperone syrup is 5 mg/mL
224178075|NCT00125138|DRUG|Melperone HCl|40 mg/day. Strength of melperone syrup is 5 mg/mL
224178076|NCT00125138|DRUG|Melperone HCl|60 mg/day. Strength of melperone syrup is 5 mg/mL
224178077|NCT00125138|DRUG|Placebo|Syrup formulation
224178078|NCT00499395|PROCEDURE|positron emission tomography|All patients will undergo pre RFA PET prior to ablation for intra and extrahepatic staging and to assess FDG avidity of the lesions. When evaluating patients with liver metastases, we routinely obtain a dedicated liver PET study (Liver View) after the whole body PET. Patients will undergo two post RFA PET scans as part of this project: PET # 1) within 32 hours after RFA. The patients having percutaneous RFA will undergo PET on the same day after the clinical studies at the PET facility are completed; this will be within 8 hours after RFA. In case of laparoscopic and intra-operative RFA, PET will be performed on the following day after the clinical studies are completed; this will be within 32 hours after RFA. PET # 2) on day seven after RFA
224178079|NCT00499395|PROCEDURE|radiofrequency ablation|All patients will undergo pre RFA PET prior to ablation for intra and extrahepatic staging and to assess FDG avidity of the lesions. Patients will undergo two post RFA PET scans as part of this project: PET # 1) within 32 hours after RFA. The patients having percutaneous RFA will undergo PET on the same day after the clinical studies at the PET facility are completed; this will be within 8 hours after RFA. In case of laparoscopic and intra-operative RFA, PET will be performed on the following day after the clinical studies are completed; this will be within 32 hours after RFA. PET # 2) on day seven after RFA
224178080|NCT06300866|DRUG|Test|test toothpaste containing 0.45% stannous fluoride
223487538|NCT04302025|DRUG|Divarasib|Participants in the KRAS G12C cohort will receive divarasib for approximately 8 weeks until the day before surgery.
223487539|NCT05994690|DRUG|Standard Intervention Rc|3 consolidation courses (HAM + HA3E + FLA)
223487540|NCT05994690|DRUG|Investigational Intervention Rc|2 consolidation courses (HAM + FLA)
223487541|NCT05994690|DRUG|Standard Intervention Ri|No addition of GO to first induction course
223487542|NCT05994690|DRUG|Investigational Intervention Ri|Addition of GO to first induction course
223487543|NCT02981693|PROCEDURE|Root canal sealer|Patients who required root canal therapy were enrolled and allotted into either iRoot SP arm or AH Plus arm randomly.For Test Arm: iRoot SP was used as a sealer. Obturation was performed with Gutta-percha cones and root canal sealer by continuous-wave condensation technique. For Control Arm: AH Plus was used as root canal sealer. The same steps were followed for obturation as in Test Arm.
223586914|NCT03751514|DRUG|Azithromycin 500 mg|To ameliorate risk of transmission of B. pertussis B1917 to the environment and household contacts, Azithromycin 500 mg once a day for 3 days will be given to eradicate colonisation with B. pertussis. The inoculum strain is fully sensitive to this antibiotic. Previous studies show that azithromycin eradicates colonisation in 97% of people in 48 hours.
224178081|NCT06300866|DRUG|Control|toothpaste containing 0.76% sodium monofluorophosphate
224178082|NCT03629405|OTHER|C - pH 4 Cosmetic Product WO 3741|Application of the product on the pre-defined skin area on the forearms twice daily for four weeks
224178083|NCT03629405|OTHER|D - pH 5.8 Cosmetic Product WO 4081-1|Application of the product on the pre-defined skin area on the forearms twice daily for four weeks
224178084|NCT01572012|DRUG|Ondansetron|Ondansetron solution 4 mg single administration
224178085|NCT01572012|DRUG|Ondansetron + Hylenex|Ondansetron solution (4 mg) single administration + Hylenex recombinant (150 U) single administration
224178086|NCT01572012|DRUG|Zofran ODT|Zofran ODT (8 mg) single administration
224178087|NCT01572012|DRUG|Ondansetron solution|Ondansetron solution (4 mg) single administration
224178088|NCT01694667|DRUG|Omega-3 Fatty Acids|Omega-3 fatty acids will be delivered in orange-flavored pudding packets (Coromega®, Vista, CA). Each packet contains 650 mg of omega-3 fatty acids, 350mg of eicosapentanoic acid (EPA), 230mg of docosahexanoic acid (DHA) and 2,000 mg of fish oil 18/12, and will be given twice daily for a daily dose of 1.3 grams of omega-3 fatty acids (and 1.1 grams of DHA + EPA).
224178089|NCT01694667|OTHER|Placebo|Placebo packets will have same orange-flavored pudding as active Omega-3 fatty acids comparator with an identical appearance and taste, but will include safflower oil instead of the fish oil. One placebo packet will be given twice daily.
224178090|NCT00041119|DRUG|AC regimen|Given IV
224178091|NCT00041119|DRUG|cyclophosphamide|Given IV
224178092|NCT00041119|DRUG|doxorubicin hydrochloride|Given IV
223487544|NCT02483403|OTHER|Hyperpolarized Helium-3|Hyperpolarized noble gas imaging using Helium-3 has been used to explore structural and functional relationships in the lung in patients with lung disease and healthy controls. In contrast to proton-based MRI imaging, Helium-3 gas is used as a contrast agent to directly visualize the airways, and thus ventilation. Whereas the normal density of gas is too low to produce an easily detectable signal, this is overcome by artificially increasing the amount of polarization per unit volume using optical pumping.
223487545|NCT02483403|DEVICE|MRI|
223487546|NCT06314568|RADIATION|Radiochemotherapy plus interventional radiotherapy|All patients with vaginal cancer will undergo radiochemotherapy (45 Gy on pelvis and tumor in association with cisplatinum) plus interventional radiotherapy (28 Gy on residual disease) with exclusive intent
223487547|NCT04041648|DRUG|L606 (Liposomal Treprostinil) Inhalation Solution 51ug|Single ascending dose
223487548|NCT04041648|DEVICE|L606 Inhalation System|Single ascending dose
223487549|NCT04041648|OTHER|Placebo Solution|Single ascending dose
223586915|NCT03751514|OTHER|Sterile Saline|To compare against B. pertussis, some volunteers will be enrolled onto the Sham arm. These volunteers will not receive B. pertussis but instead be given sterile saline
223586916|NCT05806866|BEHAVIORAL|Cognition scores, cognitive instrumental activities of daily living scores|A detailed neuropsychological test battery will be applied. The Functional Activitites Questionnaire (FAQ) subscores will be used to define cognitive and motor instrumental activities of daily living function
224178093|NCT00041119|DRUG|paclitaxel|Given IV
224178094|NCT06159049|DIAGNOSTIC_TEST|68Ga-FAPI dimer(68Ga-LNC1013)|68Ga-LNC1013 was evaluated in a pilot clinical PET imaging study involving seven patients with gastrointestinal cancer.
224178095|NCT06115343|BEHAVIORAL|Mindfulness|Conscious awareness practice was carried out in 6 sessions. Various inventories are used depending on the nature of the session. For example, in the leaf theme, participants are asked to close their eyes and put their thoughts from the past on a leaf and drop them into running water.
224178096|NCT01557140|DRUG|RASi plus carvedilol|Patients were randomly assigned to 2 groups, with 1 group receiving renin-angiotensin system inhibitors (enalapril) plus carvedilol and the other receiving renin-angiotensin system inhibitors (enalapril) plus placebo
224178097|NCT00035412|DRUG|St. John's Wort|
224178098|NCT00284167|BEHAVIORAL|tailored web-based weight management intervention|
224178099|NCT02758106|DEVICE|Vest Airway Clearance System Model 105|HFCWO for 15 minutes then sputum suction.
224178100|NCT02758106|DEVICE|placebo intervention|CCPT for 15 minutes then sputum suction.
224178101|NCT03795051|DEVICE|Navigated Transcranial Magnetic Stimulation|This study is a feasibility trial. Each participant will receive 30sessions of 10 Hz or 20 Hz rTMS over the left DLPFC. The rTMS interventions will be guided by a neuronavigation system (StimGuide TMS Navigation System, Magstim, Ltd. Carmarthenshire, UK) for navigation to the treatment location and to ensure consistent placement and orientation of the coil during and between each session. For the purpose of this protocol, these sessions are referred to as nTMS.
224178102|NCT03603340|OTHER|ENDS (vaporizer/e-cig) and smoking cessation counseling|Participants in the intervention group will receive an ENDS and nicotine-containing e-liquids, which they will be allowed to use ad libitum. Additionally, they will receive smoking cessation counseling. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 24-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6, 12 and 24 months, participants will be asked to come to a clinical visit.
223487550|NCT04559230|DRUG|Sacituzumab Govitecan|Sacituzumab Govitecan will be administered by IV infusion over 3 hours for first administration and over 1 hour if tolerated. Subjects will be allowed to continue treatment until they have evidence of significant treatment-related toxicity or progressive disease.
223487551|NCT05551741|BIOLOGICAL|IBC-Ab002|An anti-PD-L1 monoclonal antibody
223487552|NCT05551741|OTHER|Placebo|Normal Saline
223487553|NCT05658887|DRUG|Gabapentin|One dose of preoperative gabapentin 300 mg prior to vaginal apical support procedure
223487554|NCT05658887|DRUG|Gabapentin Placebo|Gabapentin Placebo
223487555|NCT04731480|DRUG|Propofol|Propofol administration rate will be controlled by a feedback loop facilitated by BIS monitoring using the closed loop anaesthesia delivery system (CLADS). A BIS value of 50 will be used as the target point for induction and maintenance of anaesthesia.
223487556|NCT04731480|DRUG|Propofol|The target controlled infusion (TCI) pump will be programmed to marsh model with the target plasma site concentration of 3-µg/ml. The plasma concentration will be altered to maintain a target BIS of 50 during induction and maintenance of anesthesia
223487557|NCT04731480|DRUG|Propofol|The target controlled infusion (TCI) pump will be programmed to Schneider model with the target effect site concentration of 3-µg/ml. The effect-site concentration will be altered to maintain a target BIS of 50 during induction and maintenance of anesthesia
223586917|NCT01733433|PROCEDURE|Taping the ankle|Subjects will be taped in at the ankle for performing several exercises.
223586918|NCT00162266|DRUG|Abatacept (BMS-188667)|IV, 10 mg/Kg, monthly, for the duration of the trial
223586919|NCT00162266|DRUG|Abatacept (BMS-188667)|Intravenous (IV) infusion, 2 mg/kg, infused intravenously for approximately 30 min, infusions on Days 1, 15, 30 and monthly thereafter for 12 months
224306763|NCT06484842|OTHER|The mindfulness intervention|The oesophageal cancer surgery patients in the single intervention group will receive 5 sessions of mindfulness intervention consistent with the mindfulness intervention component of the combined intervention programme. The intervention will be conducted in an individual, offline face-to-face format during the patients' hospitalisation; we will conduct the intervention in an individual, offline face-to-face format during the patients' outpatient review, and set up a WeChat group in case the patients are at home in the form of an online punch card. Each session will include a pre-session reflection and post-session homework. The whole process will be supervised and reminded by interventionists, who will respond to patients' questions in a timely manner to ensure patients safety and the smooth implementation of the intervention. Adjustments and improvements will be made at any time according to the needs of patients undergoing oesophageal cancer surgery.
224306764|NCT01162707|DEVICE|CardioMEMS HF Pressure Measurement System|Implant sensor into the left or right pulmonary artery. Measure pulmonary artery pressure
224306765|NCT05160233|BEHAVIORAL|Standard implementation|Brief clinician training and an implementation toolkit consisting of job aids, patient educational materials, scripted conversations, electronic health record tools, and a population management workbench.
224306766|NCT05160233|BEHAVIORAL|Health Coaching|The clinic is provided access to a health coach who conducts outreach with patients. The health coach facilitates engagement with the digital therapeutic and encourages contact with the care team.
224306767|NCT05160233|BEHAVIORAL|Practice Facilitation|A trained facilitator provides support for implementation by delivering the following interventions to clinic staff: Bolster Education, Audit and Provide Feedback, Support Plan-Do-Study-Act Cycles, Engage Others in Change.
224306768|NCT06633809|OTHER|Immediate endovascular therapy|The best medical therapy includes intravenous fibrinolysis, anticoagulants or antiplatelet, but NOT any immediate endovascular therapies.
224306769|NCT05707754|DRUG|Bupivacaine|Topically applied to sphenopalatine ganglion
224306770|NCT05707754|DEVICE|angiocatheter|Introduced into nose to reach sphenopalatine ganglion nerve
224306771|NCT03596814|OTHER|No Interventional study|Retrospective data
224306772|NCT05021718|OTHER|Strengthening exercises|Back and hip strengthening exercises. The intensity of exercises was based on the exercise tolerance and pain thresholds of the individual subjects.
224306773|NCT05021718|DRUG|Pharmacological therapy|Naproxen (500 mg) and Baclofen (10 mg) tablet twice a day for three weeks
224306774|NCT05021718|OTHER|Hot compression|Hot moist compression from week 4 to week 6.
224306775|NCT05021718|BEHAVIORAL|Activities to daily living instructions|"* Avoid forward bending.~* Avoid heavy weightlifting.~* Avoid prolong standing.~* Avoid prolong sitting.~* Use a plain firm bed.~* Lie down in a supine position."
224178103|NCT03603340|OTHER|Smoking cessation counseling|Participants in the control group will receive smoking cessation counseling only. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 24-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6, 12 and 24 months, participants will be asked to come to a clinical visit.
224178104|NCT05314530|BEHAVIORAL|ReTA-model|Validating the rehabilitation model ReTA
224178105|NCT03735186|BEHAVIORAL|Exercise|60 min treadmill exercise performed at 60% of maximum oxygen uptake.
224178106|NCT03606889|DIAGNOSTIC_TEST|Quadratus Lumborum block|0.2 ml/kg bupivicaine 0.125% injected bilateraly at the posterior border of the quadratus Lumborum muscle
224178107|NCT03606889|DIAGNOSTIC_TEST|Tranversus Abdominis plane block|0.2 ml/kg bupivicaine 0.125% injected bilateraly between internal oblique and transversus abdominis muscles.
224178108|NCT03606889|DRUG|Bupivacaine|0.2 ml/kg bupivicaine
224178109|NCT02705339|DRUG|Rociletinib|
224306776|NCT05134857|DRUG|Zonisamide|The ZON will be supplied in 100 mg capsules and deposited directly into the TAD device by research staff every 2 weeks. All participants will be told to take 100 mg/day for the first three weeks (Week 1-2 single-blind, placebo-only, induction; end of Week 2, active treatment begins) and increasing by 100 mg/day every other week (Week 4: 200 mg/day; Week 6: 300 mg/day; Week 8: 400 mg/day) up to the target dose of 500 mg/day by Week 10. The participants will be maintained on this dose through Week 14 of active treatment and then tapered off ZON (2 weeks). This dosing schedule is consistent with best practices for ZON. All TAD devices will only dispense the prescribed medication between 4pm and 11pm each night. Participants will be instructed to take the medication at or near bedtime.
224306777|NCT05134857|DRUG|Placebo|The PLO will be supplied at the same schedule and in the same manner (TAD device) as the ZON.
224306778|NCT02684630|DEVICE|Trima Accel System|Platelet Apheresis Procedure
224306779|NCT04792762|OTHER|GIP(1-30)NH2|Intravenous administration of the peptide hormone GIP(1-30)NH2 during a stepwise glucose clamp
224306780|NCT04792762|OTHER|GIP(1-42)|Intravenous administration of the peptide hormone GIP(1-42) during a stepwise glucose clamp
223487558|NCT04731480|DRUG|Propofol|Manual propofol administration will be done using an intravenous infusion pump to maintain a target BIS of 50 during induction and maintenance of anesthesia.
223487559|NCT06641089|DRUG|Sonelokimab|Sonelokimab
223487560|NCT06641089|DRUG|Placebo|Placebo
223487561|NCT06641089|DRUG|Risankizumab|Active comparator
223487562|NCT06640920|BIOLOGICAL|Cohort A|Administered IV High dose
223487563|NCT06640920|BIOLOGICAL|Cohort B|Administered SC Low Dose
223487564|NCT06640920|BIOLOGICAL|Cohort C|Administered SC Mid Dose
223487565|NCT06640920|BIOLOGICAL|Cohort D|Administered SC High Dose
223487566|NCT06476379|PROCEDURE|Testicular sperm extraction (TESE)|Surgical procedure used to retrieve sperm directly from the testicles of men who have low sperm production or no sperm in their ejaculate
223487567|NCT06476379|OTHER|Ejaculate|Ejaculate processing for ICSI
223487568|NCT06639217|OTHER|a comprehensive nursing care protocol|a comprehensive nursing care protocol provided for nurses who provide direct care for women with pelvic organ prolapse and urinary incontinence on their knowledge and practices as well as its impact on the women quality of life
224306781|NCT04792762|OTHER|Saline|Intravenous administration of saline during a stepwise glucose clamp
224306782|NCT00631657|DRUG|Esmirtazapine|One esmirtazapine 4.5 mg tablet once a day
224306783|NCT00631657|DRUG|Placebo|One placebo tablet once a day
223487569|NCT06952751|OTHER|Differential ultracentrifugation|Differential ultracentrifugation
223487570|NCT06952751|OTHER|OptiPrep™ density gradient ultracentrifugation|OptiPrep™ density gradient ultracentrifugation
224178110|NCT02705339|PROCEDURE|Biopsy|Standard of care biopsies will be taken at diagnosis and at the time of disease progression
224178111|NCT02705339|PROCEDURE|Blood draw|-Approximately 4 teaspoons of blood will be drawn before treatment begins and at the time of disease progression to look at cell-free DNA
224178112|NCT03065166|OTHER|Raisin Treatment|Subjects will consume 3.2oz of dried Cabernet grapes during a single intervention time point.
224306784|NCT01670617|OTHER|Particulated Juvenile Articular Cartilage|Treatment of articular cartilage defects up to 7.5 cm2
224306785|NCT03360955|PROCEDURE|Anesthesia|Different anesthesia technique will be compared to find out which one offers better outcome to perform ultrafast track extubation
224306786|NCT00325195|OTHER|placebo|placebo by intravenous infusion every 2 weeks
224306787|NCT00325195|BIOLOGICAL|pegloticase|8 mg pegloticase by intravenous infusion
224306788|NCT02027181|DEVICE|Device FreeO2 v2.0|"* Automatic adjustment of oxygen through the Free O2 device.~* FreeO2 device in mode medical data collecting(SpO2,EtCO2...)."
224306789|NCT02027181|DEVICE|Device FreeO2 v2.0|"* Manual adjustment of oxygen without the assistance of the FreeO2 device.~* Only FreeO2 device in mode medical data collecting(SpO2,EtCO2...)."
224306790|NCT05686083|DIETARY_SUPPLEMENT|C6 ketone di-ester|C6 ketone di-ester
224306791|NCT05686083|DIETARY_SUPPLEMENT|Novel ketone di-ester|Novel ketone di-ester
224306792|NCT05066672|DRUG|NV-5138|NV-5138 is a novel, orally bioavailable, selective, direct activator of mTORC1 cellular signaling
224306793|NCT05066672|DRUG|matched placebo|matched placebo oral capsules
224306794|NCT01248689|OTHER|concentration profile 1|"IOP will be measured under this order of sevoflurane concentrations:~7%, 5%, 2%, 0.5%"
224306795|NCT01248689|OTHER|concentration profile 2|"IOP will be measured under this order of sevoflurane concentrations:~7%, 2%, 5%, 0.5%"
224178113|NCT03065166|OTHER|Bagel Control|Subjects will consume 95g of whole wheat bagel during a single intervention time point.
224306796|NCT01248689|OTHER|concentration profile 3|"IOP will be measured under this order of sevoflurane concentrations:~7%, 0.5%, 5%, 2%"
223487571|NCT06952751|OTHER|Size-exclusion chromatography|Size-exclusion chromatography
223487572|NCT06952751|OTHER|Combined techniques|Combined techniques
223487573|NCT05810948|BIOLOGICAL|efgartigimod IV|Intravenous (IV) infusion of efgartigimod
223487574|NCT05810948|OTHER|Placebo|Intravenous (IV) infusion of placebo
224178114|NCT01002196|BEHAVIORAL|Stimulus fading procedures|"Core elements : 1.Behavior techniques (BT's) are used to gradually master the anxiety (stimulus fading and reward).~2\. Children are first met at home where they feel most safe, and the BT's are first conducted at home in cooperation with the parents.~3.The same interventions are then continued in the environment where the problem primarily exist (kindergarten / school) not at the clinic.~4.Defocused communication- and interaction is a general treatment principle (e.g. avoid looking directly at the child, sit beside not opposite to the child, no direct questioning, and communication is based upon a motivating activity, not about the child).~5.Frequent and short interventions. 6.Information to parents and teachers on how to communicate with children with SM"
224178115|NCT01002196|BEHAVIORAL|Guidance on defocused communication|Guidance and supervision to teachers working with the children with SM. Frequency: Twice during three months
224178116|NCT00915226|PROCEDURE|Suction cup application|The IOP will be raised by an 11 mm diameter, standardized suction cup placed on the temporal sclera with the anterior edge at least 1 mm from the limbus.
224306797|NCT02901964|OTHER|Hip Abductor Exercise|12 treatments sessions at 6 weeks: Heating, lower limb stretching, tibiofemoral and patellofemoral mobilization, strengthening the quadriceps, hamstrings, triceps sural and hip abductors.
224306798|NCT02901964|OTHER|Hip Aductor Exercise|12 treatments sessions at 6 weeks: Heating, lower limb stretching, tibiofemoral and patellofemoral mobilization, strengthening the quadriceps, hamstrings, triceps sural and hip aductors.
224306799|NCT06430359|DIAGNOSTIC_TEST|urine and blood test|3 urine collections of an 8h period. One blood sample for liver function test and copper assessment
223487575|NCT03909477|DIAGNOSTIC_TEST|Hyperpolarized Xenon-129 MRI of the lungs|Participants will be imaged using MRI using hyperpolarized xenon-129 gas as a contrast gas
223487576|NCT03909477|DIAGNOSTIC_TEST|Computed Tomography (CT)|Participants will undergo a CT scan of the thoracic cavity
223487577|NCT03909477|DIAGNOSTIC_TEST|Pulmonary Function Tests (PFTs)|Participants will have their lung function evaluated using PFTs
223487578|NCT03909477|DIAGNOSTIC_TEST|Six Minute Walk Test (6MWT)|Participants \>35 years of age will perform the six minute walk test as a measure of exercise capacity
223487579|NCT03909477|DIAGNOSTIC_TEST|Cardiopulmonary exercise testing (CPET)|Participants \<35 will perform cardiopulmonary exercise testing as a measure of exercise capacity
223487580|NCT03909477|DIAGNOSTIC_TEST|Sputum analysis|Participants will provide a sputum sample that will be analysed for eosinophils
223487581|NCT03909477|DIAGNOSTIC_TEST|Blood analysis|Participants will have their blood drawn and analysed for eosinophil count.
223487582|NCT05778539|PROCEDURE|Lateral retinacular release|During the implantation of a total knee arthroplasty a lateral retinacular release is performed in the intervention group
223487583|NCT04518085|BEHAVIORAL|Medical hypnosis|Single session 20 minutes hypnosis session originally developed and tested by Montgomery et al. (2007) in a similar setting. Delivered by an experienced clinical psychologist.
223487584|NCT04518085|BEHAVIORAL|Internet-based Acceptance and Commitment Therapy (iACT)|Access to an online platform developed to this study containing video clips and audio files with ACT consistent material
223487585|NCT04518085|BEHAVIORAL|Mindfulness session|Single session mindfulness session delivered by audio file
223487586|NCT04518085|BEHAVIORAL|Treatment as Usual (TAU)|Treatment as usual as part of post-surical care
223487587|NCT06415630|PROCEDURE|Type A aortic dissection surgery|Patients with type A aortic dissection undergone surgery.
223586920|NCT00162266|DRUG|Abatacept (BMS-188667)|Intravenous (IV) infusion, 10 mg/kg, infused intravenously for approximately 30 min, infusions on Days 1, 15, 30 and monthly thereafter for 12 months
223586921|NCT00162266|DRUG|Placebo|Intravenous (IV) infusion, 0 mg/kg, infused intravenously for approximately 30 min, infusions on Days 1, 15, 30 and monthly thereafter for 12 months
223586922|NCT02299076|BEHAVIORAL|Behavioral economics incentives|Behavioral economics-informed incentives to promote engagement and outcomes in a smoking cessation intervention.
223586923|NCT02299076|OTHER|Minimal incentives|Minimal financial incentives to promote engagement and outcomes in a smoking cessation intervention.
223586924|NCT05487183|BEHAVIORAL|Medoc cutaneous probe|A computer-controlled probe delivers temperatures to the skin to measure pain, OA, and OH
223586925|NCT05487183|BEHAVIORAL|Quantitative sensory testing|Standard methods involving pinprick, pressure, heat, and cold applied to the skin are used to measure sensation and pain
223586926|NCT05487183|BEHAVIORAL|Computer tasks|QST and computer tasks are used to measure changes in pain intensity
223586927|NCT04208087|DRUG|SI-722|SI-722 will be intravesically instilled.
223586928|NCT04208087|DRUG|Placebo|Placebo will be intravesically instilled.
223586929|NCT02800590|DRUG|ABP-700|
223586930|NCT01451190|BIOLOGICAL|Autologous cultured dermal and epidermal cells|A piece of occipital scalp is taken from the subject. A mixed population of dermal cells from this tissue are expanded in culture. The cells are then harvested. These cells are then injected into the balding area of the scalp of the original subject.
224306800|NCT05494645|DRUG|Exparel|Liposomal bupivicaine
224306801|NCT05494645|DRUG|Peripheral Nerve Block|Peripheral nerve block without Exparel
223487588|NCT06637332|DRUG|Daptomycin for Injection|Daptomycin given by injection at a dose determined by the treating team but not to be less than 6mg/kg
223487589|NCT06637332|DRUG|Vancomycin (IV)|Vancomycin by injection to be given at a dose selected by the treating team to achieve a desired trough level or AUC-based target, as determined by local standards of care
223487590|NCT06950398|OTHER|NMP viability testing|NMP viability testing before transplantation of discarded livers
223487591|NCT05401201|DEVICE|Lumoral treatment|The investigational Lumoral treatment -device provides a constant and repeatable application which can be done at home and is easily available. All subjects in the study group will receive their own Lumoral treatment -device and Lumorinse-mouth rinse tablets for the complete duration of the study.
223487592|NCT05401201|OTHER|Standard oral hygiene self care|Both groups shall be given oral and written instructions for twice-daily standard oral hygiene self care.
223487593|NCT04928391|DRUG|Dexmedetomidine|A single dose of 0.5 µ/kg IV dexmedetomidine at the end of surgery
223487594|NCT04928391|DRUG|Nalbuphine|A single dose of 0.1 mg/kg IV nalbuphine at the end of surgery
223487595|NCT04928391|OTHER|0.9% saline|Same volume of saline placebo IV at the end of surgery
224178117|NCT00915226|PROCEDURE|Squatting|Squatting
224178118|NCT04803656|OTHER|Assessment of COPD patients|Assessments explained in the arm section were made as described in one session.
224178119|NCT02652286|DEVICE|HARMONIC ACE+7|Pulmonary artery sealing with Harmonic Ace+7 in VATS lobectomy in humans
224178120|NCT06381752|DEVICE|Continuous passive motion|Daily application of continuous passive motion
224178121|NCT06381752|OTHER|standard rehabilitation|standard rehabilitation program with group physiotherapy
224178122|NCT00005838|DRUG|shark cartilage extract AE-941|Given orally
224178123|NCT00005838|OTHER|placebo|Given orally
224178124|NCT00005838|DRUG|cisplatin|Given IV
224178125|NCT00005838|DRUG|vinorelbine tartrate|Given IV
223487596|NCT05905536|DEVICE|Vitalstream|The device will be placed on the subject and monitoring started in the holding room on the morning of surgery. Monitoring will continue postoperatively until the pulmonary artery catheter (PAC) is removed (Standard of Care) or discharged, or at study team discretion. At Intensive Care Unit (ICU) admittance and again 3 hours later a straight leg raise will be done to monitor for changes in hemodynamics.
224178126|NCT00005838|DRUG|carboplatin|Given IV
224178127|NCT00005838|DRUG|paclitaxel|Given IV
224178128|NCT00005838|RADIATION|radiation therapy|Undergo radiotherapy
224178129|NCT03552614|DEVICE|Upper limb robot-assisted rehabilitation|"Upper limb robot-assisted rehabilitation is performed with Armeo®Spring. It is a passive exoskeleton with five degrees of freedom that guarantees passive arm weight support with springs.~The treatment was composed by 45 minutes of robotic training (5 times a week for 4 weeks) during which patients performed a customized pull of exergames."
224178130|NCT03552614|OTHER|physiotherapy|Patients undergo 45-minute treatment sessions 5 times a week for 4 weeks of physiotherapy, focused on gross and fine motor ability to promote independence in daily activities, and it is customized on patients' need.
224178131|NCT00498069|DEVICE|Harvest Smartprep2 BMAC System|injection of 40cc bmac
224178132|NCT00498069|DEVICE|SmartPReP2 BMAC System|Injection of autologous bone marrow concentrate prepared with the SmartPReP2 BMAC System
223487597|NCT06328712|DRUG|EN001|"* Cohort 1: EN001 1.25×10\^6 cells/kg administered intravenously (IV) 2 times at 4 week intervals.~* Cohort 2: EN001 2.5×10\^6 cells/kg administered intravenously (IV) 2 times at 4 week intervals."
223487598|NCT04472299|DRUG|Ropivacaine 0.2% Injectable Solution|Patients in the intervention group will have ultrasound guided bilateral T3 paravertebral catheters placed prior to surgery. Prior to surgery, these patients will have 5ml of 1.5% lidocaine with 1:200,000 epinephrine injected in each catheter. Ropivacaine 0.2% will be administered via programmed intermittent bolus of 7ml every 60 minutes through each catheter during and after surgery.
223487599|NCT01234116|DRUG|emtricitabine/tenofovir disoproxil fumarate|Each health care worker will receive one of the Treatment Arms for 28 days.
223487600|NCT00431418|DRUG|Sildenafil|Sildenafil oral solution
223487601|NCT00431418|DRUG|Placebo|Placebo solution
224178133|NCT00498069|BIOLOGICAL|placebo|injection of placebo into ischemic tissue of the lower extremity
223487602|NCT03679793|PROCEDURE|Open Release Group|Open surgical release of the A1 pulley is the gold standard of treating symptomatic trigger finger
223487603|NCT03679793|PROCEDURE|Percutaneous Release Group|Percutaneous release is a minimal invasive alternative surgical procedure
223487604|NCT00332397|DEVICE|Rapamycin-eluting Stent|due to randomization, Cypher stent will be implanted
224178134|NCT03017066|DEVICE|Ultrasound|Ultrasound assessment of gastric volume is performed three times; before ingestion of infant formula or carbohydrate drink; 1 hour prior to the surgery; and before induction of general anesthesia.
224178135|NCT03017066|OTHER|General anesthesia|Scheduled operation under general anesthesia
224178136|NCT03309865|DIETARY_SUPPLEMENT|semi-vegetarian diet|semi-vegetarian dietary intervention: Duration of Therapy: 14 weeks;
223487605|NCT00332397|DEVICE|Zotarolimus-eluting Stent|due to randomization, Endeavor stent will be implanted
223487606|NCT00332397|DEVICE|Rapamycin-eluting Stent|due to randomization, rapamycin-eluting stent will be implanted
223487607|NCT00516607|DRUG|enzastaurin hydrochloride|
223487608|NCT00516607|DRUG|temozolomide|
223487609|NCT00516607|OTHER|pharmacological study|
224178137|NCT03309865|DRUG|Vedolizumab Injection|vedolizumab (300mg) IV infusions at week 0, 2, 6, 14; Duration of Therapy: 14 weeks
223487610|NCT04635345|OTHER|External Vibrator - patient-administered.|Patient provided with external vibrator for self-use, as well as vaginal dilators.
223487611|NCT04635345|OTHER|Standard care|Dilators, lidocaine topical gel, referral to psychotherapy, group therapy or womens health physio if required, self-help resources.
223487612|NCT04528498|OTHER|Preimplantation Genetic Testing|Embryo biopsies will undergo preimplantation genetic testing for aneuploidies as per standard of care, and polygenic disease risk (PGT-P) will be computed for these samples.
224178138|NCT00000576|DRUG|beclomethasone|
224178139|NCT00348686|DRUG|Candesartan|16 mg once daily in oral tablet form
224178140|NCT00348686|DRUG|Candesartan|32 mg once daily in oral tablet form
224178141|NCT00348686|DRUG|Felodipine|5 mg once daily in oral tablet form
224178142|NCT00348686|DRUG|Felodipine|10 mg once daily in oral tablet form
224178143|NCT01258738|BIOLOGICAL|etanercept|In Period 1, subjects will receive in a prefilled syringe with 1.0 ml (test article Etanercept (SC) once weekly . Additionally they will continue to take the background non steroidal anti inflammatory drug(NSAID) in the tolerated dose agreed upon by the attending Physician.
224178144|NCT01258738|DRUG|Background NSAID|Subject will continue to take a concomitant background non steroidal anti inflammatory drug(NSAID)as prescribed by their attending physician. The name and dose of this NSAID is the decision of the attending physician.
224178145|NCT01258738|OTHER|PLACEBO|In Period 1 will receive a prefilled syringe of Placebo for Etanercept Additionally they will continue to take the background non steroidal anti inflammatory drug(NSAID) in the tolerated dose agreed upon by the attending Physician.
224178146|NCT01258738|DRUG|Background NSAID|Subject will continue to take a concomitant background non steroidal anti inflammatory drug(NSAID)as prescribed by attending physician (dose drug selection as tolerated and agreed upon by the attending Physician).
224178147|NCT05503043|DRUG|Lidocaine|Intravenous bolus of 1.5 mg/kg of lidocaine followed by a continuous infusion of 3.0 mg/kg for the frst hour, 1.5 mg/kg for the second hour, 0.7 mg/kg until the end of the surgery.
224178148|NCT05503043|DRUG|Normal saline|Patients are received equal volumes of saline intravenously until the end of the surgery
224178149|NCT04417816|OTHER|Exercise training intervention with ultrasound induced adipose tissue cavitation|Exercise training intervention with ultrasound induced adipose tissue cavitation
224178150|NCT04417816|OTHER|Exercise training intervention without ultrasound induced adipose tissue cavitation|Exercise training intervention with ultrasound induced adipose tissue cavitation
224178151|NCT00121459|DEVICE|Ortho All-Flex diaphragm and Replens lubricant gel|
224178152|NCT01998854|DEVICE|VizAblate System|The VizAblate System is indicated for use in transcervical intrauterine-guided radio frequency ablation of uterine fibroids
224178153|NCT00130754|DRUG|Thymoglobuline|IV 7.5 mg/kg
224178154|NCT03163277|DRUG|emtricitabine, darunavir/cobicistat, maraviroc|Treatment change
224178155|NCT04717154|BIOLOGICAL|Ipilimumab|4 courses of 1mg/kg q3w
224178156|NCT04717154|BIOLOGICAL|Nivolumab|4 courses of 3mg/kg q3w, followed by maintenance flat dose (480mg, q4w, for 10 doses)
224178157|NCT00689611|DRUG|Bupropion HCl ER|150 mg tablets po qd for 3 days and then 150 mg po bid for remainder of 9 weeks
224178158|NCT00689611|DRUG|Placebo|Placebo
224178159|NCT05566366|OTHER|Qualitative research interview|Qualitative research interview Administration of quantitative scales
224178160|NCT04001426|DEVICE|The FemPulse System|Non-invasive monitoring during activation of the FemPulse System
224306802|NCT06423443|BEHAVIORAL|Digital Cognitive Behavioral Therapy|digital cognitive behavioral therapy app
224306803|NCT06423443|BEHAVIORAL|Health Education|traditional on-line health education app
224306804|NCT06423443|DRUG|TAU|treatment as usual
223487613|NCT05496998|DEVICE|Medtronic Intrepid™ TMVR TF System|Patients with moderate-to-severe or severe symptomatic mitral regurgitation, or moderate symptomatic mitral regurgitation combined with mitral stenosis in the presence of MAC will have a Transcatheter Mitral Valve Replacement with the Medtronic Intrepid™ TMVR Transfemoral System
223487614|NCT02115698|PROCEDURE|Heavy Resistance Training|Supervised Heavy Resistance Training three times weekly for 52 weeks.
223487615|NCT02115698|PROCEDURE|Light Intensity Training|Home-based Light Intensity Training three-five times weekly for 52 weeks.
223487616|NCT02115698|DIETARY_SUPPLEMENT|Protein Whey|Two daily 20 g whey protein and 10 g carbohydrate supplementations for 52 weeks.
223487617|NCT02115698|DIETARY_SUPPLEMENT|Protein Collagen|Two daily 20 g collagen protein and 10 g carbohydrate supplementations for 52 weeks.
223487618|NCT02115698|DIETARY_SUPPLEMENT|Carbohydrate|Two daily 30 g carbohydrate supplementations for 52 weeks.
224178161|NCT06263504|PROCEDURE|at correcting malocclusions or restoring the integrity of the dentition|Patients in this group will receive standard treatment aimed solely at correcting malocclusions or restoring the integrity of the dentition without interfering with the musculoskeletal system.
223617724|NCT02313259|BEHAVIORAL|Driving simulation|"25 km simulated car driving session. The participant is seated in the driver compartment of a real car featuring all the actual components (steering wheel, pedals regulating speed and brakes). He is instructed to respect road regulations as well as safety rules and must perform some driving manoeuvres, such has turning at intersections, stopping when necessary, passing another car, etc.~Software Drive 3.0 by Systems Technology Inc., Hawthorne, California, USA. Magnetic head tracker (Flock of Birds, Ascension Technology Corporation, Burlington, Vermont, USA).~A fixed-base driving simulator. 2 driving scenarios: a practice (10 minutes) and a main scenario including rural and urban sections (35 minutes)."
224178162|NCT06263504|PROCEDURE|comprehensive treatment, including not only dental correction of bite or restoration of the integrity of the dentition, but also correction of disorders of the musculoskeletal system.|): Patients will receive comprehensive treatment, including not only dental correction of bite or restoration of the integrity of the dentition, but also correction of disorders of the musculoskeletal system.
224178163|NCT06006676|OTHER|Near Apnoeic ventilation|Near Apnoeic ventilation (with a respiratory rate of 2 breaths per minute, plateau pressure of 30cmH20 and PEEP set according to the mean airway pressure being delivered during mechanical ventilation prior to randomisation) for a 72 hour period following randomisation
224178164|NCT06006676|OTHER|Crossover standardised ECMO weaning trials|"When all patients are eligible for a trial of ECMO weaning, they will have standardised ECMO weaning trials lasting up to 1 hour with 0 sweep gas flow. 1) One-stage weaning- sweep gas flow rate sequentially decreased to zero 2) Two-stage weaning- fraction of oxygen of sweep gas flow decreased to 0.21 sequentially. Then the sweep gas flow rate decreased to 0 sequentially"
224178165|NCT04179266|DRUG|Ketamine|One Cluster headache attack is treated with intranasal ketamine
224178166|NCT01922869|DIETARY_SUPPLEMENT|Flavonoids|
224178167|NCT04035356|DEVICE|Aortic valve repair|Use of a HAART Aortic Annuloplasty Device in patients undergoing aortic valve repair surgery
224178168|NCT00568399|DRUG|sodium thiosulfate|sodium thiosulfate 12.5-25 gm/M2 after each thrice weekly hemodialysis treatments for 5 months.
224306805|NCT01455311|PROCEDURE|EUS Guided Fine Needle Aspiration|EUS-guided fine needle aspiration of the cyst fluid
224306806|NCT01455311|PROCEDURE|EUS Guided EchoBrush Sampling|EUS-guided brushing of the cyst wall
224306807|NCT04136691|OTHER|simulation training|Burn patient scenario was performed with the intervention group.
224306808|NCT04310969|DEVICE|MiBoFlo Thermoflo|Each treatment for each eye takes 10 minutes and is treated every two weeks for a total of three times. The device was preheated to 42.2℃ and the eyelid was cleaned and smeared with a small amount of ultrasound gel in order to reduce friction between the device and eyelid skin. Then massage the outer skin of the upper and lower eyelids for a period of 10 minutes. The patient's eyes keep closed during therapy.
224306809|NCT04310969|PROCEDURE|forceful expression of the meibomian glands|Utilize a cotton swab on the inner surface of the eyelid and the another cotton swab on the outer lid to apply force
224306810|NCT04310969|DEVICE|LipiFlow|LipiFlow treatment applies heat to the palpebral surface of eyelids while simultaneously applying graded pulsatile pressure to the outer eyelid surfaces, thereby expressing the meibomian glands during heating.
224306811|NCT01036139|DRUG|BF2.649 (pitolisant)|1 capsule of BF2.649 (5mg, 10mg , 20 mg) O.D
224306812|NCT01209130|DRUG|DCDT2980S|Intravenous repeating dose
224306813|NCT01209130|DRUG|rituximab|Intravenous repeating dose
224306814|NCT05213455|BIOLOGICAL|booster vaccine for COVID 19|The effect of Booster vaccine will be seen in participants in terms of antibody response IgG
224178169|NCT03876509|DIAGNOSTIC_TEST|Impedance Cardiography|"Impedance Cardiography will be conducted in patients with suspected Pulmonary Hypertension within an interval of 24 hours to right-heart catheterization. Usually, 8 electrodes will be attached on the neck and thorax of the patient. These electrodes will produce current (max 400µA) and measure the voltage which is produced by the current running through the body. The Signal will be analyzed for specific signs of Pulmonary Hypertension.~At the same time electrocardiography and non-invasive continuous blood pressure will be measured."
224178170|NCT02875262|DRUG|Deferoxamine|Patients will be given deferoxamine 32 mg/kg/day (max iv rate 15 mg/kg/hr), patients with ferritin levels between 2,000 and 3,000 ng/ml will receive 32 mg/kg/day and patients with serum ferritin levels below 2,000 ng/ml wil receive 25 mg/kg/day.during 3 days
223586931|NCT04326764|DRUG|Panobinostat|"Panobinostat should be taken orally once on each scheduled day at about the same time, either with or without food. Each dose of panobinostat should be taken with a cup of water.~The capsules should be swallowed as whole. If vomiting occurs during the course of treatment, no re-dosing is allowed before the next scheduled dose. If one dose is forgotten during the morning on a scheduled treatment day then the missed dose should be taken on that same day within 12 hours. After more than 12 hours, that day's dose should be withheld, and the patient should wait to take panobinostat until the next schedule treatment day. The patient should then continue treatment with the original dosing schedule.~Panobinostat will be administered at a dose of 20 mg three times weekly (TIW) every second week and will be dosed on a flat scale of mg/day and not by weight or body surface area.~Panobinostat will be dispensed as a 20 mg capsule or as two 10 mg capsules."
223586932|NCT01073878|DEVICE|Athena Pelvic Muscle Trainer|The Athena PMT is a vaginally inserted electrical stimulator that induces the pelvic floor muscles to contract and relax, similar to Kegel exercises intended to strengthen the pelvic floor muscles.
223586933|NCT01158690|OTHER|resource card|the intervention group receives an envelop with resource card
224178171|NCT02875262|OTHER|placebo|placebo (NaCl 0.9%) in equal dose to treatment
224178172|NCT01411059|BEHAVIORAL|yoga|yoga classes 2 times per week for 32 weeks
224178173|NCT04217174|BEHAVIORAL|My Personal Health Guide|My Personal Health Guide is a theory-based mobile phone app that uses an Avatar as a personal health guide to increase patient knowledge of HIV disease and its complications and rationale for healthy behavior, increase self-efficacy and motivate participants to improve retention in care and medication adherence, and explain and illustrate behavioral skills related to retention in care, and adherence, with a result of improved behavior that leads to personal and population benefits through viral suppression and decreased risk of transmission, respectively. The relational aspect of the Avatar may be a powerful supplement to clinical care. The Avatar can encourage healthy behavior, acknowledge stigma and speak with empathy, audibly teach persons with low literacy, employ credible culturally appropriate phrasing, and invite the user to hear advice and motivational stories of other HIV-positive people and caregivers.
223487620|NCT04949776|DIAGNOSTIC_TEST|Mammograms|"In the women participating in the study, two strategies for reading mammograms will be carried out:~Strategy 1: Standard reading of the program. Double independent and non-consensual reading of all cases, without any artificial intelligence system (standard strategy).~Strategy 2: Reading strategy based on the global Score granted by Transpara® (strategy based on artificial intelligence):~* In studies with a Score \<8 (studies with a low probability of cancer): They will not be evaluated by any radiologist.~* In studies with a Score\> 7 (studies with a high probability of cancer): double reading will be carried out, assisted by Transpara®."
223487621|NCT05052008|DRUG|Erenumab|Erenumab is monoclonal antibody used for management of migraine
223586934|NCT01158690|OTHER|no resource card|the control group receives an envelop without resource card
223586935|NCT03970616|DRUG|Tivozanib|Dose level 1: 1.0mg for 21 days followed by 7 days rest; Dose level -1: 1.0mg every other day
223586936|NCT03970616|DRUG|Durvalumab|1500mg every 28 days
223586937|NCT06213285|DEVICE|Watchman FLX left atrial appendage occlusion|Early (30-120 days) CT follow-up after Watchman FLX LAAO
223586938|NCT06354374|DIAGNOSTIC_TEST|volume survey|All subjects will receive oral hygiene instructions and, if needed. A dental cleaning of plaque and calculus. After calibration using digital photographs and digital intraoral scans, CBCT scans will be taken as a prerequisite for dental implant treatment protocol. one dentist who will not be involved in the screening phase will obtain all clinical parameters (gingival biotype, probing depth, gingival thickness, gingival width) to avoid any bias. After finishing data collection, a customized treatment plan for each patient will be performed and dental implant treatment will be completed for each patient.
223586939|NCT02477553|BEHAVIORAL|DA - Quantitative|
223586940|NCT02477553|BEHAVIORAL|DA - Verbal|
223586941|NCT03757754|DRUG|HPPH 2.5 mg/m2|HPPH was administered as a single, 2.5 mg/m2, slow intravenous infusion over 1 hour , and a fixed light dose of 150 J/cm delivered 48 hours after infusion of HPPH.
223586942|NCT03757754|DRUG|HPPH 3 mg/m2|HPPH was administered as a single, 3 mg/m2, slow intravenous infusion over 1 hour, and a fixed light dose of 150 J/cm delivered 48 hours after infusion of HPPH.
224178174|NCT04217174|BEHAVIORAL|My Personal Food Guide|My Personal Food Guide is a mobile phone app that contains a talking realistic avatar who teaches about food safety, sugar content in selected foods, and some other food related information. The avatar motivates safe food behavior in order reduce the likelihood of food poisoning and promotes a healthy diet.
223586943|NCT03757754|DRUG|HPPH 3.5 mg/m2|HPPH was administered as a single, 3.5 mg/m2, slow intravenous infusion over 1 hour, and a fixed light dose of 150 J/cm delivered 48 hours after infusion of HPPH.
223586944|NCT03757754|DRUG|HPPH 4 mg/m2|HPPH was administered as a single, 4 mg/m2, slow intravenous infusion over 1 hour, and a fixed light dose of 150 J/cm delivered 48 hours after infusion of HPPH.
223586945|NCT03757754|DRUG|HPPH 5 mg/m2|HPPH was administered as a single, 5 mg/m2, slow intravenous infusion over 1 hour, and a fixed light dose of 150 J/cm delivered 48 hours after infusion of HPPH.
223586946|NCT03757754|DRUG|HPPH 6 mg/m2|HPPH was administered as a single, 6 mg/m2, slow intravenous infusion over 1 hour, and a fixed light dose of 150 J/cm delivered 48 hours after infusion of HPPH.
223586947|NCT02079935|BEHAVIORAL|Cognitive Behaviour Therapy|Following group-modified protocol for cognitive behavioral therapy, CBT, first described by Fairburn 2008, modified by Modum Bad, Norway.
223586948|NCT02079935|BEHAVIORAL|Physical Activity and Dietary Therapy|Guided physical activity and dietary therapy, to (re-)introduce a more healthy lifestyle and help stabilizing a healthy weight. A detailed manual will be published.
224178175|NCT03708926|DRUG|Abaloparatide|abaloparatide injection pen
223487622|NCT04467489|OTHER|observational|There is no intervention for any group in this observational study.
223487623|NCT05331144|DRUG|Angiotensin II Receptor Blockers (ARBs, losartan) and Calcium Channel Blockers (CCB, amlodipine)|Angiotensin II Receptor Blockers (ARBs, losartan) and Calcium Channel Blockers (CCB, amlodipine) will be used to treat high blood pressure. Additional antihypertensive medications may be used if needed.
223487624|NCT05331144|OTHER|PCP|Participants will follow their PCP's recommendations for BP control.
223487625|NCT06138275|DRUG|Elranatamab|subcutaneous (under the skin) injection
223487626|NCT04147494|PROCEDURE|Computed Tomography|Undergo PET/CT scan
223487627|NCT04147494|RADIATION|Gallium Ga 68 FAPi-46|Given IV
223487628|NCT04147494|RADIATION|Gallium Ga 68-labeled PSMA-11|Given IV
223487629|NCT04147494|PROCEDURE|Positron Emission Tomography|Undergo PET/CT scan
223487630|NCT04147494|RADIATION|18F-FDG|Given IV
223487631|NCT01966367|BIOLOGICAL|CD34 Stem Cell Selection Therapy|The CliniMACS (PLUS) Reagent System (Miltenyi CliniMACS CD34+ Cell Selection Device) will be used to remove T-cells from the peripheral blood stem cell transplant in order to decrease the risk of acute and chronic graft versus host disease (GVHD).
223487632|NCT06277063|DEVICE|Transcutaneous auricular vagus nerve stimulation|The vagus nerve's auricular branch is primarily distributed in the tragus, tragus sulcus, and concha cavity. It can activate the nucleus tractus solitarius through the vagus afferent fibers, thereby activating various areas of the vagus nerve in the central nervous system. This stimulation technique involves applying a constant current of around 2-3mA to the epidermal terminals of the ear using an electrode. It aims to regulate the vagus nerve, modulate the autonomic nervous system, release neurotransmitters, improve cerebral blood flow, and alleviate headache symptoms. In the implementation, non-invasive transcutaneous vagus nerve stimulation was performed by having the subject wear a vagus stimulator and adjusting the appropriate stimulation intensity.
223487633|NCT06062108|OTHER|Pain evaluation|All included patients will have an evaluation of their pain, if they have no pain, the assessment stop with one date (pain or no pain), if they have pain, an assessment is done (localization of the pain, pain intensity), if they have a pain duration over 3 months, a DN4 questionnaire, HAD scale, ISI scale and SF-1 questionnaire is evaluated.
223487634|NCT05884983|PROCEDURE|participants will undergo dual-energy CT and endoscopy|Diagnostic Test: P85-Ab,EBNA1-IgA,and VCA-IgA. Detect P85-Ab, EBNA1-IgA, VCA-IgA for all participants and select serological high-risk participants DiagnosticTest: dual-energy CT, endoscopy and biopsy. serological high-risk participants will refer to dual-energy CT, endoscopy and biospy
223487635|NCT05513950|BIOLOGICAL|CHF10067 starting dose -- 1000mg (Cohort A)|Intravenous administration of a starting dose of the monoclonal antibody
223487636|NCT05513950|BIOLOGICAL|CHF10067 intermediate dose -- 2000mg (Cohort B)|Intravenous administration of an intermediate dose of the monoclonal antibody
223487637|NCT05513950|BIOLOGICAL|CHF10067 high dose -- 3000mg (Cohort C)|Intravenous administration of a high dose of the monoclonal antibody
223487638|NCT05513950|DRUG|Placebo|Intravenous administration of a physiological solution as placebo
223487639|NCT06121011|BIOLOGICAL|Cipaglucosidase alfa|Enzyme Replacement Therapy (ERT) via intravenous infusion
223487640|NCT06121011|DRUG|Miglustat|Participants received ATB200 co-administered with AT2221 (Miglustat)
223487641|NCT06121011|BIOLOGICAL|Alglucosidase alfa or Avalglucosidase alfa|Patients prescribed other commercially available ERT after local regulatory approval
223487642|NCT06121011|OTHER|Untreated|Patients who are not currently receiving any medical therapy for Pompe disease.
223487643|NCT06001866|BEHAVIORAL|Retrieval-based verb learning: Repeated Spaced Retrieval condition|"A set of novel verbs are practiced on 2 consecutive days (the same verbs are used each day). Half of the novel verbs are learned in the repeated spaced retrieval condition and half are learned in the repeated study condition, with the two conditions interleaved on each day.~The repeated spaced retrieval condition consists of study and retrieval trials. At the start of the sessions, retrieval trials immediately follow study trials. Thereafter, retrieval trials are spaced for each verb, occurring after 3 other words have intervened between the retrieval trial and the last study trial for that verb."
223487644|NCT06001866|BEHAVIORAL|Retrieval-based verb learning: Repeated Study condition|"A set of novel verbs are practiced on 2 consecutive days (the same verbs are used each day). Half of the novel verbs are learned in the repeated spaced retrieval condition and half are learned in the repeated study condition, with the two conditions interleaved on each day.~The repeated study condition consists of study trials only (with no retrieval practice)."
223487645|NCT03504956|DEVICE|Cardiac MRI|MRI with/without administration of a contrast agent and beta-blocker based upon the stage of method development, if no contraindications are present.
223487646|NCT03504956|DRUG|Contrast|The intravenous gadolinium based contrast agent to be used in this study is Gadavist (up to 0.2 mmol/kg).
224072548|NCT07143500|OTHER|Task Oriented Training for Upper limb|Seated in chair with arm and back support, with forearms resting on a table 73 cm high. Functional movements were trained through task-oriented exercises involving simple activities of daily living(ADL), such as eating (using a plate and spoon), personal hygiene (combing hair, brushing teeth), and tasks using household items (e.g., handling a cup and spoon, or opening a bottle and cap). Each task was repeated five times. Patients were allowed rest periods of five minutes as needed during the exercise sessions.
224072549|NCT07143500|OTHER|Action Observation Training Program|sat comfortably in a chair or wheelchair with both arms resting on a table (73 cm high) positioned 50 cm from a 15.6-inch colored laptop screen. They were instructed to attentively observe action videos displayed on the screen and then imitate the observed movements using their affected upper limb. A total of 30 action videos were used, each lasting approximately 50 seconds and demonstrating specific upper limb movements, such as wrist flexion/extension, abduction/adduction, pronation/supination, ulnar/radial deviation, and various grasping and manipulation tasks (e.g., handling coins, pens, a computer mouse, jar lids, bottle caps, typewriting, dialing a phone, and feeding).
224072550|NCT07143032|PROCEDURE|Extropia squint surgery|patients with large angle exotropia will be treated by three different surgical techniques including: 1/ bilateral lateral rectus muscle recession with unilateral medial rectus muscle resection 2/bilateral medial rectus muscle resection, 3/unilateral medial rectus muscle resection with lateral rectus muscle transplantation ,to compare the surgical outcomes between them.
224072551|NCT05429073|DRUG|RGLS8429|solution for subcutaneous injection
224178176|NCT03708926|DRUG|Placebo|placebo injection pen
224306815|NCT02029014|DEVICE|LAA closure system|
224306816|NCT00000114|DRUG|Vitamin E|
223586949|NCT00513396|DRUG|Isoniazid|"High-dose isoniazid (16-18 mg/kg/day) in addition to standardized regimen that included the following: kanamycin (15 mg/kg/day), levofloxacin (7.5-15 mg/kg/day), protionamide (10-20 mg/kg/day), cycloserine (10-20 mg/kg/day) and p-aminosalicylic acid (150 mg/kg/day)~Regular dose isoniazid (5 mg/kg/day) in addition to standard regimen that included the following: kanamycin (15 mg/kg/day), levofloxacin (7.5-15 mg/kg/day), protionamide (10-20 mg/kg/day), cycloserine (10-20 mg/kg/day) and p-aminosalicylic acid (150 mg/kg/day)"
223586950|NCT00513396|DRUG|Placebo|Similar appearing and similarly packaged placebo tablets in addition to the standardized regimen that included the following: kanamycin (15 mg/kg/day), levofloxacin (7.5-15 mg/kg/day), protionamide (10-20 mg/kg/day), cycloserine (10-20 mg/kg/day) and p-aminosalicylic acid (150 mg/kg/day)
223586951|NCT01997190|BIOLOGICAL|AdV-tk + valacyclovir|AdV-tk will be administered intrapleural through pleural catheter followed by oral valacyclovir. Valacyclovir will be administered orally at a fixed dose for 14 days after each AdV-tk administration.
223586952|NCT05793606|PROCEDURE|Deltoid ligament repair|Surgical repair for the deltoid ligament
223586953|NCT06252441|DRUG|Rectal Diclofenac|100 mg Rectal Diclofenac Before ERCP
223586954|NCT06252441|DRUG|Oral N-acetyl cysteine|1200 mg N-acetyl cysteine in 150 cc water orally before ERCP.
223586955|NCT05527886|OTHER|AAROM|AAROM with knee to wall exercise, 3x30 reps
223586956|NCT05527886|OTHER|Slow Load|Single leg heel raise, 3x10 reps
223586957|NCT05527886|OTHER|Plyometric|Double leg 5 inch wall hops, 3x10 sec
223586958|NCT03166072|OTHER|Low-vision rehabilitation program|Low Vision Rehabilitation Program includes functional vision assessments (low-vision refraction), prescription of a variety of visual aids including microscopes, magnifiers, telescopes, absorptive filters and electronic spectacle eyewear, large print books, and automatic self-transcending meditation plus essential skills for daily living and mobility training offered by CNIB including demonstration of visual aids as well as training on proper use of visual aids.
223586959|NCT03166072|OTHER|No Intervention|Participants will continue to receive treatment as usual
223586960|NCT04402541|DRUG|CB-5339|25mg and 75mg capsules
223586961|NCT05529004|DRUG|Oral Capsule pregapalin|oral cap of pregapalin has been administration to patient before surgery to prvent PONV
223586962|NCT05529004|DEVICE|laparoscope device|general anesthesia with complete relaxation under laparoscopic cholecystectomy
223586963|NCT01410708|DRUG|Dasatinib|
224072552|NCT05429073|DRUG|Placebo volume-matching RGLS8429 dose|solution for subcutaneous injection
224072553|NCT07143682|DRUG|Letrozol step up dose|Tablet letrozole 2.5mg one, two, three, and four tablets once daily from 2nd/3rd day of the menstrual cycle for 4 days
224072554|NCT07143682|DRUG|Conventional fixed dose letrozole|Tab letrozole 5mg once daily for 5 days started from the 2nd/3rd day of the menstrual cycle
224072555|NCT07143240|OTHER|Determine patient demographic and clinical characteristics at baseline|Description of demographic data (sex, age), comorbidities (Charlson scores), septic history, clinical data relating to neuropathy, and tedizolid prescription modalities (dose, duration).
224072556|NCT07144488|DIETARY_SUPPLEMENT|Olive Oil Polyphenol Supplement (OOPs, OLEOPROTECT®, Thousand Olives®)|Participants receive two capsules daily (total 10 mg/day) of a standardized olive oil polyphenol extract. Each capsule contains 5 mg of aldehydic phenols: 75% oleocanthal/oleacein and 25% oleuropein aglycon/ligstroside aglycon. Formulated with PEG400, cellulose, silicon dioxide, and magnesium stearate. Duration: 12 weeks.
224072557|NCT07144488|DIETARY_SUPPLEMENT|Placebo capsules|Two capsules taken daily for 12 weeks. Identical in weight, appearance, and taste to the active OOPs capsules. Contain PEG400, cellulose, silicon dioxide, and magnesium stearate, but no active olive oil polyphenols.
224072558|NCT07144423|PROCEDURE|Endoscope-assisted hematoma drainage|The procedure of endoscope-assisted hematoma drainage is performed under local anesthesia with sedation or general anesthesia. During the operation, a single burr hole is drilled at the midpoint of the thickest layer of the hematoma cavity as shown on CT scan. A bone flap measuring 2.0 cm × 2.0 cm is then created using a milling cutter. Under the guidance of a visualized neuroendoscope, the hematoma is thoroughly irrigated and evacuated. A subdural drainage tube is inserted, and postoperatively, continuous subdural drainage of the hematoma is maintained until the drainage ceases naturally or the drainage tube is removed at a maximum of 48 hours postoperatively to terminate the drainage.
224072559|NCT07144423|PROCEDURE|Burr hole hematoma drainage|The procedure of burr hole drainage is performed under local anesthesia with sedation or general anesthesia. During the operation, a single burr hole is drilled at the midpoint of the thickest layer of the hematoma cavity as indicated by CT scan. A subdural drainage tube is then inserted. The hematoma cavity is irrigated intraoperatively until the drainage fluid becomes clear. Postoperatively, continuous subdural drainage of the hematoma is maintained until the drainage ceases naturally or the drainage tube is removed at a maximum of 48 hours postoperatively to terminate the drainage.
224072560|NCT07142720|DIETARY_SUPPLEMENT|A seaweed extract from brown seaweed, containing fucoidan, laminarin, and the antioxidant phlorotannin.|Portions of the seaweed extract were dissolved in rice milk to help camouflage the strong algae-taste. Plain rice milk served as placebo.
224072561|NCT07143357|BEHAVIORAL|Recovering Together after Cardiac Arrest 1|The intervention will teach resiliency skills (mindfulness and coping) to dyads and provider anticipatory guidance and resources to manage stressors specific to cardiac arrest. These sessions will take place in person until the survivor is discharged; remaining sessions will occur over Zoom.
224072562|NCT07143357|OTHER|Recovering Together after Cardiac Arrest 2|In this minimally enhanced usual care control, dyads will participate in one 30-minute session with a clinician at beside to review a pamphlet of available psychosocial resources for cardiac arrest survivors and their caregivers.
224072563|NCT07143773|DRUG|SGLT-2 inhibitor|The intervention in this clinical trial will be treatment with an SGLT2 inhibitor (Forxiga, 10 mg tablet once daily) compared with a matching placebo. A total of 88 non-diabetic kidney transplant recipients will be enrolled. All participants will be randomized in a 1:1 ratio to receive either Forxiga or placebo as an add-on to standard immunosuppressive therapy. This intervention differs from other studies by specifically targeting non-diabetic kidney transplant recipients, a population in which the efficacy and safety of SGLT2 inhibitors have not yet been established.
224178177|NCT01824368|PROCEDURE|Extracorporeal Photopheresis Procedure (FEC)|"The FEC will be held in the Cellex (Therakos), and authorized device in routine use in our unit for performing FEC in the treatment of graft-versus-host and cutaneous T-cell lymphoma. After performing a blood count, will connect the patient to Cellex through a central or peripheral.~1500 mL typically be processed peripheral blood mononuclear fraction obtained by apheresis process. Then be added Uvadex (8-metoxipsolareno, 0.017 mL / mL) to the mononuclear fraction bag and proceed to photoactivation with UVA radiation.~Finally the photoactivated product is again infuse the patient. It will monitor the final blood count to assess hemoglobin and platelets. The entire procedure is performed in a single step and closed mode, with Cellex."
224178178|NCT03274791|DIAGNOSTIC_TEST|Analysis of induced sputum|"Induced sputum was collected and analysed in the three arms (Healthy subjects, Never smokers with COPD and smokers with COPD) The volume of the sputum sample, was treated with an equal volume of 0.1% dithiothreitol. The samples were then vortexed and placed in a shaking water bath at 37°C for 15 min to ensure complete homogeneisation. The suspensions were centrifuged at 400× g and the sputum supernatant stored at -80°C until cytokines analysis. The cell pellet was resuspended in 0.5% bovine serum albumin in phosphate buffered saline and cytospin were made by putting 100 µL of the cell suspension in the funnels.~Slides for differential cell counts were stained with May-Grünwald Giemsa."
224178179|NCT03274791|DIAGNOSTIC_TEST|Lung Function test|"All the subjects underwent pulmonary function tests (Healthy subjects, Never smokers with COPD and smokers with COPD).~Pulmonary function parameters were measured using a portable spirometer (Easy One ndd. Medizintechnik; Zurich, Switzerland) according to the ATS criteria (American Thoracic Society). Reversibility test was performed 15 min after inhalation of 400 µg of Salbutamol (Ventolin, GlaxoSmithKline, Middlesex, UK). All spirometry data were graded for quality and only tests that met high quality scores were used for the final analysis."
224178180|NCT03274791|DIAGNOSTIC_TEST|Enzyme-linked Immunosorbent Assay|"IL-8 and TNF-α were measured in the sputum supernatant of all the subjects (Healthy subjects, Never smokers with COPD and smokers with COPD).~Commercially available kits were used to detect IL-8 (Human IL-8 Immuno-Biological Laboratories ELISA Kit) and TNF-α (Human TNF-alpha Sigma-Aldrich ELISA Kit) concentrations in the sputum supernatants. The absorbance was measured at 450 nm. The lower limits detection were 2 pg/mL for IL-8 and 5 pg/mL for TNF-α. The intra assay coefficients of variability were 8.7% for IL-8 and 7.7% for TNF- α."
224178181|NCT01381237|BEHAVIORAL|game-based balance exercises|16 sessions, scheduled two per week, each lasting 45 minutes.
224178182|NCT04383665|DEVICE|STN DBS 10Hz|Stimulation of existing DBS device at 100Hz, with other parameters at baseline
224178183|NCT04383665|DEVICE|STN DBS 130Hz|Stimulation of existing DBS device at 130Hz, with other parameters at baseline
224178184|NCT04383665|DEVICE|STN DBS off|Existing DBS device turned off
224178185|NCT04051515|OTHER|Intradialysis exercise training|Combined exercise, aerobic and resistance training, implemented by nursing staff
224178186|NCT04051515|OTHER|Home-based exercise training|Combined exercise, aerobic and resistance training, implemented independently home
224178187|NCT04778215|OTHER|A progressive specific lumbar stabilization program|The aim of these programs is to optimize the stabilization and control of segmental motion of the lumbar spine. It is based on the draw-in action, hereafter called the abdominal hollowing, presented by Richardson and Jull (1995). The training program consists of three levels. Level 1 introduces the abdominal hollowing exercise in the prone and four-point kneeling position. Level 2 is a progression of these exercises and the gymnasts are also instructed to perform the abdominal hollowing standing on a balance board with slightly flexed knees while slowly moving the arms. Level 3 takes the training into sports specificity and the abdominal hollowing are to be held during three different basic trampette jumps with emphasis on good trunk and body control during jumping and landing.
224178188|NCT06128642|DEVICE|Toe separator orthosis|"The orthoses to be used during the study will be randomly distributed to the individuals participating in the study. Foot pressure analysis will be evaluated after the participants use the toe separation orthosis for 8 hours a day, for a total of 1 month.~Plantar pressure analysis will be performed again without orthosis, with orthosis and 1 month after the use of orthosis. Additionally, patient orthosis satisfaction evaluation will be made at the end of the 1-month period during which the participants use the orthoses."
224306817|NCT00000114|DRUG|Vitamin A|
224306818|NCT00128050|DRUG|rFactor VIIa (Eptacog alfa, NovoNordisk)|rFVIIa will be admistered as single bolus at the dosage of 100 mcg/Kg b.w.
224306819|NCT00128050|DRUG|rFVIIa|Patients with spontaneous supratentorial ICH will be treated with rFVII after hematoma evacuation
223487647|NCT03504956|DRUG|Beta blocker|Based upon the focus of the study at the time of the scan, a beta- blocker (metoprolol), in pill form based upon blood pressure and heart rate, may be administered to some subjects to improve the heart's ability to relax and slow the heart rate. The slower heart rate may improve image quality and lessen motion artifact.
223487648|NCT02903914|DRUG|INCB001158|Arginase Inhibitor
223487649|NCT02903914|DRUG|Pembrolizumab|PD-1 Inhibitor
223487650|NCT06280638|OTHER|Virtual stent-guided incremental optimization strategy (VIOS)|"PCI is performed according to strategy recommended by Imaging-Heart Team based on VIOS protocol."
223487651|NCT06280638|OTHER|Standard angiographic strategy|PCI is performed based on international guidelines, local protocols and practice.
223487652|NCT04002180|DRUG|Vedolizumab (Genetical Recombination)|Vedolizumab IV infusion
223487653|NCT03401398|DRUG|Hydrocortisone, sodium succinate|Patients randomized to the hydrocortisone treatment arm will receive an initial bolus of 2 mg/kg IV hydrocortisone, followed by 1 mg/kg (maximum 50 mg) of hydrocortisone dosed every six hours for a maximum of seven days or until all vasoactive infusions have been discontinued for at least 12 hours, whichever comes first. When the hydrocortisone course is completed, the medication will be discontinued.
223487654|NCT03401398|DRUG|Normal saline|Patients randomized to the placebo treatment arm will receive an equivalent volume of normal saline, with the identical dosing schedule to the intervention (hydrocortisone) arm.
223487655|NCT04980794|BEHAVIORAL|Parent-child intervention|Families (two adult caregivers, child between 4 and 17) receive four interactive, asynchronous psychoeducation modules to review on their own paired with weekly contact with a communication coach and two live sessions with a communication coach to discuss psychoeducation, receive feedback on their interactions, and practice a communication technique.
223586964|NCT03380767|PROCEDURE|Trauma-induced coagulopathy treatment|Transfusion as needed according to the assay methodology
224178189|NCT06128642|DEVICE|Dynamic orthosis|"The orthoses to be used during the study will be randomly distributed to the individuals participating in the study. Foot pressure analysis will be evaluated after participants use the dynamic orthosis for 8 hours a day, for a total of 1 month.~Plantar pressure analysis will be performed again without orthosis, with orthosis and 1 month after the use of orthosis. Additionally, patient orthosis satisfaction evaluation will be made at the end of the 1-month period during which the participants use the orthoses."
224178190|NCT01904760|DRUG|Dexmedetomidine|Dexmedetomidine(4㎍/mL) : 0.5㎍/kg/hr infusion for 1 hour before operation is completed and 0.2-0.7㎍/kg/hr infusion continuously until 6:00am the next day.
224178191|NCT01904760|DRUG|Saline placebo|Normal saline 0.9% (guess as 4㎍/mL) : 0.5㎍/kg/hr infusion for 1 hour before operation is completed and 0.2-0.7㎍/kg/hr infusion continuously until 6:00am the next day
224178192|NCT03646955|RADIATION|No partial breast irradiation|Omission of radiation therapy
224178193|NCT02581098|OTHER|No interventions|No interventions
224178194|NCT04473989|DRUG|recombinant teriparatide for injection|weekly subcutaneous administration of 40 ug
224178195|NCT04473989|DRUG|Placebo|weekly subcutaneous administration of 40 ug
224178196|NCT03676712|DEVICE|scoliosis brace|Wear at least 18 hours a day
224178197|NCT03202641|PROCEDURE|PEEP ARDSnet|PEEP settings based on the low PEEP/high FiO2 table
224178198|NCT03202641|PROCEDURE|PEEP LRM|A lung recruitment maneuver (LRM) followed by PEEP guided by transpulmonary pressure.
224306820|NCT00128050|OTHER|Sodiun chloride 0.9%|Bolus injection of sodium chloride 0.9% after surgical hematoma removal
224178199|NCT03673150|OTHER|non intervention|Observational study / non intervention
224178200|NCT05959876|OTHER|Training group|Face-to-face perineal care training
224178201|NCT05959876|OTHER|Control group|No intervention
224178202|NCT04594473|BEHAVIORAL|Comprehensive Oncology Rehabilitation and Exercise (CORE) Program|\[see arm/group descriptions\]
224178203|NCT04380480|COMBINATION_PRODUCT|Concurrent chemoradiotherapy combined with enteral feeding by percutaneous endoscopic gastrostomy|"One or two weeks before CCRT, all patients will undergo a percutaneous endoscopic gastrostomy (PEG) to be administered enteral nutrition support(30-35 kcal/kg of energy, 1.2-1.5g/kg of protein and electrolyte supplementation each day). Nutritional supplements will be administered till 1 month after CCRT.~All patients will receive definitive radiotherapy combined with three cycles of S-1 (40mg/2, BID, po) on D1-14, D22-35, D43-56."
224178204|NCT04071899|OTHER|Scale vaidation|It's just filling a scale in order to validate it in French
224178205|NCT00787280|BEHAVIORAL|Low Carbohydrate Ketogenic Diet (LCKD)|participants will follow a low carbohydrate ketogenic diet for six weeks
224178206|NCT00787280|BEHAVIORAL|Low Fat Diet (LFD)|particpants will follow a low fat diet for six weeks
224178207|NCT00705471|BIOLOGICAL|Infliximab|None available in the protocol. This was a chart review study, therefore no Infliximab provided during the study.
224178208|NCT01993290|DRUG|Ropivacaine|20 ml in total of 0,75% Ropivacaine is administered to each patient in all three arms.
224178209|NCT00939861|PROCEDURE|laparoscopy|colorectal resection
224178210|NCT00939861|PROCEDURE|laparotomy|colorectal resection
224178211|NCT06065371|DRUG|Capecitabine|Capecitabine is a fluoropyrimidine that is metabolized to 5-fluorouracil, which inhibits thymidylate synthase. Capecitabine is available in white or off-white tablets with doses of 500mg and 150mg doses. 500mg dose tablets will be used on this trial. Capecitabine will be ordered as a standard of care and provided commercially.
224205599|NCT04832178|DIETARY_SUPPLEMENT|SUMOR|"SUMOR is a food supplement distributed in Italy by ArcaPharma. regularly entered in the register of Food Supplements of the Ministry of Health (number 62590). Formulated in prolonged-release tablets, each tablet contains the following substances:~* S-Adenosyl-L-Methionine sulfate p-toluenesulfonate 250 mg~* Betaine hydrochloride 250 mg~* Vitamin C 80 mg~* Vitamin B1 1.1 mg~* Vitamin B2 1.4 mg~* Vitamin B6 1.4 mg~* Vitamin B12 2,5 µg~* Folic Acid 200 µg~* Selenium 37 µg"
224205600|NCT04832178|OTHER|Placebo|Placebo tablet will be identical in appearance to the experimental product (SUMOR).
224205601|NCT04222556|BEHAVIORAL|Thiwáhe Gluwáš'akapi|Thiwáhe Gluwáš'akapi (TG, sacred home in which family is made strong) is a cultural adaptation of the Strengthening Families Program for Parents and Youth 10-14 (SFP 10-14). TG, like SFP 10-14, is a 7-week family-based prevention program with separate youth and adult sessions followed by family sessions. Videos teach content and spark discussion; games and activities foster interaction and provide opportunities to practice skills. Four key adaptations were made to create TG: (1) cultural kinship teachings and tribal language kinship words were embedded throughout; (2) a parent session on coping with stress was enhanced to teach recognizing and responding to trauma reactions in youth; (3) a session on listening was moved earlier in the curriculum, given cultural oral tradition; (4) session videos were remade with local actors and adapted scenarios. A multiphase optimization strategy design was used to test potential adaptations, resulting in the optimized TG program.
224205602|NCT04222556|BEHAVIORAL|Woyute Waśte|Woyute Waśte (WW) was adapted from the Colorado School of Public Health's Integrated Nutrition Education Program (INEP) for the culture and context of the reservation. Families will meet for 1 session to participate in hands-on activities - preparing healthy meals, family physical activity, and sugary drinks. They will discuss setting healthy goals and tracking progress, receive recipes and water bottles, and for 6 weeks after the session, will get text messages with additional program content.
224205603|NCT01825915|PROCEDURE|Laparoscopic Hysterectomy|
224205604|NCT01825915|PROCEDURE|Laparoscopic Supracervical Hysterectomy|
224205605|NCT01787188|DRUG|Meloxicam Test Capsules|
224205606|NCT01787188|DRUG|Meloxicam Test Capsules|
224205607|NCT01787188|DRUG|Placebo Capsules|
224205608|NCT06568770|DRUG|USG GUIDED SUPRA-INGUINAL FASCIA ILIACA BLOCK|"With the patient in the proper position, the skin will be disinfected and the transducer positioned to identify the femoral artery and the iliopsoas muscle and fascia iliaca. The transducer will be moved laterally until the sartorius muscle is identified. As the needle will eventually pierce the fascia, maybe a pop will be felt. After negative aspiration, 1-2 mL of local anesthetic will be injected to confirm the proper injection plane between the fascia and the ilio-psoas muscle. A proper injection will result in the separation of the fascia iliaca by the local anesthetic in the medial-lateral direction from the point of injection as described. After the spread of the drug will be seen, the rest of the drug volume will be injected"
224178212|NCT06065371|DRUG|Sacituzumab govetican|"Sacituzumab govitecan is an antibody-drug conjugate that targets Trop-2-expressing cells and is covalently attached to the topoisomerase I inhibitor SN-38. Sacituzumab govitecan will be provided by Gilead Sciences.~Sacituzumab govitecan for injection, 180 mg and 200 mg, is available as a powder that is to be reconstituted with 20 mL of 0.9% Sodium Chloride Injection prior to intravenous infusion.~Following reconstitution, each single-dose vial of Sacituzumab govitecan results in a concentration of 10mg/mL with pH of 6.5."
224178213|NCT00498784|DRUG|Mirena|Mirena 52mg during 1 year
223487656|NCT04980794|BEHAVIORAL|Self-study Intervention|Families (two adult caregivers) receive information in a newsletter format to review on their own, paired with weekly contact from a communication coach to answer questions and direct their attention toward specific topics in the newsletter.
223487657|NCT03817970|DRUG|Granisetron|An antiemetic regimen containing granisetron 2 mg oral or IV.
223487658|NCT03817970|DRUG|Ondansetron|An antiemetic regimen containing ondansetron 8 mg oral or IV.
223487659|NCT03817970|DRUG|Palonosetron|An antiemetic regimen containing palonosetron 0.25 mg IV.
223487660|NCT03968406|OTHER|Quality-of-Life Assessment|Ancillary studies
223487661|NCT03968406|RADIATION|Radiation Therapy|Undergo radiation therapy
223487662|NCT03968406|DRUG|Talazoparib|Given PO
223487663|NCT06199726|BEHAVIORAL|REFLECT web-based tool|Partnering with Nest Genomics, Investigators have developed a customizable web-based tool to support AYA patients through their cancer diagnosis journey for topics related to future family building and genetics. This interactive tool will include educational content to organize knowledge, make connections between concepts, and will include web links to more in-depth content and embedded videos. The interface will allow users to document questions that would be helpful in provider discussions and include decision support to assist with determining values and needs for proceeding with consultations related to genetic counseling and testing, and fertility.
223487664|NCT05777408|PROCEDURE|Conventional Physical Therapy|"* 15 mins of TENS (frequency 100 Hz, phase duration 50 μs) with moist heat over the area of pain~* Isomeric Stretching of neck muscles followed by neck isometrics"
223487665|NCT05777408|PROCEDURE|Natural Apophyseal glides|-Will be applied in sitting position Therapist right hand would cradle the head such that the little finger would rest on the spinous process of the vertebra that is to be mobilized. The other hands thumb would be used to apply over pressure. Direction of force will be parallel to highly irritable-grossly restricted cervical facet joints. Intervention would involve 3 sets of 20 repetitions in 15minutes, 3 days a week for 2 weeks comprising of total 6 session.
223487666|NCT05777408|PROCEDURE|Cranial Base Release|Will be performed in lying position. therapist fingers will contact the sub occipital muscles and upward pressure would be given until the tissues and muscles relax. it will be given once daily for 3 days a week and will continue for 2 weeks
223487667|NCT05287113|DRUG|Retifanlimab|Retifanlimab 500mg will be administered intravenously every 4 weeks.
223487668|NCT05287113|DRUG|INCAGN02385|INCAGN02385 350mg will be administered intravenously every 2 weeks.
223487669|NCT05287113|DRUG|INCAGN02390|INCAGN02390 400 mg will be administered intravenously every 2 weeks.
223487670|NCT05287113|DRUG|Placebo|Placebo will be administered intravenously.
223487671|NCT04955249|DRUG|Dexmedetomidine|Patients in this group receive dexmedetomidine-supplemented patient-controlled analgesia for up to 3 days after surgery. The formula is a mixture of dexmedetomidine (1 microgram/ml) and sufentanil (1 microgram/ml), diluted with normal saline to 200 ml. The analgesic pump is programmed to administer a background infusion at a rate of 1 ml/h, with a bolus dose of 2 ml at each time and a lockout interval of 8 minutes.
223487672|NCT04955249|DRUG|Placebo|Patients in this group receive routine patient-controlled intravenous analgesia for up to 3 days after surgery. The formula is a mixture of placebo and sufentanil (1 microgram/ml), diluted with normal saline to 200 ml. The analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with a bolus dose of 2 ml at each time and a lockout interval of 8 minutes.
223487673|NCT06374550|BEHAVIORAL|Jump Start on the Go|Centers will receive the Jump Start On The Go mental health program via a mobile app. This will entail receiving 12-24 mental health consultation sessions in which a licensed mental health consultant will use a mobile app that will provide directors and teachers with access to information such as videos, infographics, and an Artificial Intelligence Chatbot on how to work with children with challenging behaviors. Participants will receive the intervention once per week for up to 1 hour.
223487674|NCT06374550|BEHAVIORAL|Jump Start Plus Coronavirus Support|The Jump Start Plus Coronavirus Support intervention is a resiliency program that provides behavior management and safety programs administered weekly via zoom.
223487675|NCT03948802|DIAGNOSTIC_TEST|Interleukine 33 test in blood plasma|ELISA test for Interleukin 33
223487676|NCT04341636|RADIATION|Bitewing X ray|"Each patients will be exposed to 4 horizontal bitewing for posterior teeth ( standard of care ) and 4 vertical bitewing for the same area ( experimental ) . X ray will be taken using a film holder and a steel wire (3mm ) on the film holders. This steel wire will help to adjust for magnification later on. The x ray tube will be in the same distance (4mm from the x ray).~The bitewing radiographs will be taken with double-packed Ekta speed Plus films on a radiograph machine operating at 0 kilovolt peak and 8 milliampere, having 2.5 aluminium filtration and a 0.860.8 mm focal spot, according to the manufacturer's exposure recommendations, with the parallel technique to obtain an accurate x ray as much as possible . The radiographs will be processed digitally. All the x ray will be taken using the standard protection protocol ."
224178214|NCT04056325|DRUG|Moxidectin|Monotherapy, oral administration, single dose, fixed dose
223487677|NCT04491643|DRUG|Megestrol Acetate|At a dosage of 160 mg/day
223487678|NCT04491643|DRUG|Rosuvastatin|At a dosage of 10 mg/day
223487679|NCT06243510|OTHER|apixaban|Participants will be randomized to receive a prescription for prophylactic apixaban
223487680|NCT06243510|OTHER|enoxaparin|Participants will be randomized to receive a prescription for prophylactic enoxaparin
224178215|NCT04056325|DRUG|Ivermectin|Monotherapy, oral administration, single dose, weight dependent
224178216|NCT04056325|DRUG|Placebo oral tablet|Monotherapy, oral administration, single dose, matching number of tablets
224178217|NCT03929549|DEVICE|RCMP titration|An overnight titration polysomnogram with gradual mandibular protrusion and assessment of polysomnographic parameters (i.e. AHI, oxygen saturation, etc.) at various magnitudes of protrusion.
224178218|NCT06538610|DEVICE|Holter monitor|"Holter monitor fitted from start of 5-FU infusion (Day 1) to 5-FU infusion ending (Day 3).~Holter monitor to be worn for approximately 46-48 hours."
224178219|NCT05731726|DRUG|Serplilumab|"Serplulimab is an innovative monoclonal antibody targeting PD-1, developed by Shanghai Henlius Biotech, Inc.~300 mg, q3w.~For the timing of serplulimab, there is a subgroup developed, all enrolled patients will be divided into 2 subgroups in 1:1 ratio, the fasting group and the control group. For the fasting group patients, fasting starts from 8 p.m. the day before treatment and concludes at 12 p.m. on the treatment day, water is allowed. For the control group patients, they have meals according to their habits."
224306821|NCT04851938|DEVICE|transcutaneous electrical nerve stimulation device|The application of transcutaneous electrical nerve stimulation is a nonpharmacological method that midwives can apply and determining the effect on these factors will be a guide for the future applications.
223487681|NCT06431074|DIETARY_SUPPLEMENT|Placebo Control Form 1|Participants will use their Placebo Control Form 1 as directed for a period of 6 weeks.
223487682|NCT06431074|DIETARY_SUPPLEMENT|Calm Active Study Product 1.1 Usage|Participants will use their Radicle Calm Active Study Product 1.1 as directed for a period of 6 weeks.
223487683|NCT06431074|DIETARY_SUPPLEMENT|Placebo Control 6.1|Participants will use their Placebo Control 6.1 as directed for a period of 6 weeks.
223487684|NCT06431074|DIETARY_SUPPLEMENT|Calm Active Study Product 6.1 Usage|Participants will use their Radicle Calm Active Study Product 6.1 as directed for a period of 6 weeks.
223487685|NCT05142774|DRUG|Tapinarof cream, 1%|Tapinarof cream, 1%, applied daily to affected areas by subjects or their caregivers based on vIGA-AD. Subjects are advised to choose the application time they prefer and apply the study drug at that approximate time each day of study participation.
223487686|NCT06651177|DRUG|Tirzepatide|The tirzepatide pen is a pre-filled, disposable, injection device designed for subcutaneous administration. Each pen is pre-filled with a single dose of tirzepatide and is available in six doses: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg/0.5 mL. A UMC will administer the once-weekly SQ dose of tirzepatide. Consistent with tirzepatide's prescribing guidelines, participants will be initiated at a once-weekly SQ dose of 2.5 mg/week with a dose increase to 5mg/week at week 5. Consistent with tirzepatide's prescribing information, once the participant has received 5 mg/week for 4 weeks they are eligible for a dose increase if needed
223487687|NCT06651177|OTHER|Placebo|"Saline administered subcutaneously with a syringe will be used as the placebo for the trial. The placebo which will be administered by a study UMC. The process for deciding on dose increases will be the same for placebo and tirzepatide."
223487688|NCT06036615|OTHER|Exercise Intervention|Patients that will be randomly assigned to this group will be invited to attend up to 72 exercise sessions (3 sessions per week) for 24 weeks (6 months) following a combined aerobic, strengthening and mobility-flexibility exercise program. After the exercise intervention, the will follow a 3-month de-training period, continuing their normal physical activity.
223487689|NCT06294106|DEVICE|Electroencephalogram personalized Transcranial Magnetic Stimulation (eTMS)|EEG is utilized to determine a personalized frequency to then apply TMS to the frontal lobe.
223487690|NCT06374537|OTHER|Muscle Therapy|Participants will attend 2 muscle therapy sessions a week for 12 months, for one hour each.
223487691|NCT06018428|DRUG|bempikibart (ADX-914)|Subcutaneous administration of bempikibart (ADX-914)
223487692|NCT03112603|DRUG|Ruxolitinib|Ruxolitinib twice daily at the protocol-defined starting dose.
223487693|NCT03112603|DRUG|Extracorporeal photopheresis (ECP)|Best available therapy (BAT) will be selected by the investigator for each participant. BAT may not include experimental agents (ie, those not approved for the treatment of any indication) as well as a limited number of other selected drugs in accordance with the protocol-defined requirements. The BAT in this study will be among the following treatments currently used in this setting (no other types or combinations of BATs are permitted in this study).
223487694|NCT03112603|DRUG|Low-dose methotrexate (MTX)|Patients will receive BAT based on the Investigator's opinion, taking into account the manufacturer's instructions, labeling, subject's medical condition, and institutional guidelines for any dose adjustment.
223487695|NCT03112603|DRUG|Mycophenolate mofetil (MMF)|Patients will receive BAT based on the Investigator's opinion, taking into account the manufacturer's instructions, labeling, subject's medical condition, and institutional guidelines for any dose adjustment.
223487696|NCT03112603|DRUG|mechanistic Target of Rapamycin (mTOR) inhibitors (everolimus or sirolimus)|Patients will receive BAT based on the Investigator's opinion, taking into account the manufacturer's instructions, labeling, subject's medical condition, and institutional guidelines for any dose adjustment.
223487697|NCT03112603|DRUG|Infliximab|Patients will receive BAT based on the Investigator's opinion, taking into account the manufacturer's instructions, labeling, subject's medical condition, and institutional guidelines for any dose adjustment.
223487698|NCT03112603|DRUG|Rituximab|Patients will receive BAT based on the Investigator's opinion, taking into account the manufacturer's instructions, labeling, subject's medical condition, and institutional guidelines for any dose adjustment.
223487699|NCT03112603|DRUG|Pentostatin|Patients will receive BAT based on the Investigator's opinion, taking into account the manufacturer's instructions, labeling, subject's medical condition, and institutional guidelines for any dose adjustment.
223487700|NCT03112603|DRUG|Imatinib|Patients will receive BAT based on the Investigator's opinion, taking into account the manufacturer's instructions, labeling, subject's medical condition, and institutional guidelines for any dose adjustment.
223487701|NCT03112603|DRUG|Ibrutinib|Patients will receive BAT based on the Investigator's opinion, taking into account the manufacturer's instructions, labeling, subject's medical condition, and institutional guidelines for any dose adjustment.
223487702|NCT05733286|DRUG|Suvorexant 20 mg|Administer Suvorexant versus placebo every evening for Post-Operative Day (POD) 0,1, \&2
223487703|NCT05733286|DRUG|Placebo|Administer Suvorexant versus placebo every evening for Post-Operative Day (POD) 0,1, \&2
223487704|NCT02817880|DEVICE|rTMS|
223487705|NCT02817880|DEVICE|tDCS|
223487706|NCT02817880|DEVICE|tsDCS|
223487707|NCT05497401|BIOLOGICAL|MesenCure|Enhanced mesenchymal cell-based product
224178220|NCT05731726|DRUG|Capecitabine|Given PO
224178221|NCT05731726|DRUG|Oxaliplatin|Given IV
224178222|NCT05731726|DRUG|Celecoxib|celebrex
224306822|NCT03322735|DRUG|Fludarabine|25-30mg/m2/day IV for 3 days
224178223|NCT05642884|OTHER|Multi-modal Exercise Regimen|Participants will undergo a total of 16 sessions over 8 weeks. Each therapy session will comprise of patient education, including facilitated goal planning, promotion of physical activity and safe exercise guideline, followed by 30 minutes of preferred aerobic activity such as walking or biking.
224178224|NCT05642884|BEHAVIORAL|Dietary Guidelines|Participants will be contacted once a week to review dietary recommendations per the 2022 American Cancer Society guidelines for cancer survivors.
224178225|NCT05949177|BEHAVIORAL|Graded Exposure and Mindfulness Meditation|Participants will complete graded exposure and will be encouraged to face fear-eliciting situations. Participants will also complete mindfulness meditation guided through the Headspace mobile application. Participants will complete the graded exposure one time per week and will complete the mindfulness meditation 4 times per week.
224178226|NCT05949177|BEHAVIORAL|Waitlist Control|Participants will receive an email stating that they will receive access to 5-weeks of Headspace after 5-weeks. Participants will be also asked to not change their normal routines or download apps for relaxation, meditation, or sleep during 5-weeks. After completion of the outcome assessments at 5-weeks, participants in this group will receive access to 5-weeks of Headspace.
224178227|NCT03108742|DEVICE|INSORB|dermal stapler for skin closure
224178228|NCT03108742|PROCEDURE|classic intradermal suture|intradermal suture for skin closure
224178229|NCT05989815|OTHER|Muscle damage protocol training|The adopted protocol of muscle damage will follow the recommendations from American College of Sports Medicine (ACSM) in 2009 for trained individuals. It consists of 8-12 repetitions above 70% of 1 Repetition Maximum (1RM) with 1 minute of rest between sets and 2 minutes between exercises. The protocol will be composed as follows: 3 sets of 10 repetitions for each exercise, with an emphasis on producing microlesions in the muscle tissue (muscle damage protocol).
224178230|NCT05989815|DEVICE|Photobiomodulation therapy (PBMT)|PBMT will be administered using the Joovv Elite System, which has 6 panels of red LEDs (660±10nm) and 74 panels of infrared LEDs (850±10nm), totaling 900 LEDs covering an area of 12,193 cm². Athletes will stand 20 cm in front of the device, wearing only swim shorts to expose their thigh muscles and other body areas to the light. The total irradiation time will be 20 minutes, with 10 minutes (600 seconds) of irradiation for the anterior region and another 10 minutes (600 seconds) for the posterior region. The active PBMT dose applied in each region (anterior or posterior) will be 48.97 J/cm², with an irradiance of 81.62 milliwatt (mW)/cm². The PBMT Sham dose applied in each region (anterior or posterior) will be 0 J/cm², with an irradiance of 0 mW/cm².
224178231|NCT04249076|DRUG|Clobetasol Propionate|Clobetasol propionate ophthalmic nanoemulsion 0.05% is an oil-in-water (o/w), clear or slightly yellowish nanoemulsion containing the active ingredient clobetasol propionate at a concentration of 0.05% weight per weight (w/w)
224178232|NCT04249076|DRUG|Vehicle|Vehicle is identical in appearance and composition to clobetasol propionate ophthalmic nanoemulsion 0.05% but, without the active substance
224178233|NCT05362825|DRUG|Neo-adjuvant Chemotherapy FOLFOXIRI Regimen|Oxaliplatin 85mg/m2 IV; Irrinotecan 165mg/m2 IV; Leucovorin 400mg/m2 IV; 5-Fluorouracil 2400mg/m2 continuous infusion in 46 hours - every 2-week cycle, up to 12 cycles.
224178234|NCT05362825|PROCEDURE|synchronous resection surgery|Patients undergoing colorectal primary and liver resection in a single operation or staged curative procedure or no surgery
224178235|NCT00783263|DRUG|Comparator: rosuvastatin 5 mg + ezetimibe 10 mg|Participants who received open label rosuvastatin 5 mg tablets once daily for 4 to 5 weeks then received 10 mg ezetimibe tablets once daily plus 5 mg rosuvastatin for an additional 6 weeks.
224178236|NCT00783263|DRUG|Comparator: rosuvastatin 10 mg|Participants who received open label rosuvastatin 5 mg tablets once daily for 4 to 5 weeks then received rosuvastatin 10 mg once daily for 6 additional weeks.
224178237|NCT00783263|DRUG|Comparator: rosuvastatin 10 mg + ezetimibe 10 mg|Participants who received open label rosuvastatin 10 mg tablets once daily for 4 to 5 weeks then received 10 mg ezetimibe tablets once daily plus 10 mg rosuvastatin for an additional 6 weeks.
224178238|NCT00783263|DRUG|Comparator: rosuvastatin 20 mg|Participants who received open label rosuvastatin 10 mg tablets once daily for 4 to 5 weeks then received rosuvastatin 20 mg once daily for 6 additional weeks.
224178239|NCT01894685|DRUG|Mesalazine|Mesalazine 3 grams, once daily for six months
224178240|NCT01894685|DRUG|Placebo|Placebo 3 grams, once daily for six months
224178241|NCT00105833|BEHAVIORAL|Collaborative Care - Depression Decision Support (DDS)|Multifaceted collaborative intervention for depression based in primary care
224178242|NCT00919828|DEVICE|Avivo System|Non invasive external monitoring device
224306823|NCT03322735|DRUG|Cyclophosphamide|cyclophosphamide 0.6-0.8g/m2/day IV for 2 days
224306824|NCT03322735|BIOLOGICAL|BCMA CAR-T|BCMA CAR-T cells will be administered after completion of the chemotherapy.
224306825|NCT04500418|DRUG|Cenicriviroc (CVC)|Treatment with Cenicriviroc tablets of 150mg. (450g/300g on day 1 and 300mg/d on days 2-28).
224306826|NCT04500418|DRUG|Placebo|Optically identical pills without CVC.
224306827|NCT01774552|DEVICE|Photo Acoustic Microscopy and Optical Coherence tomography|Photo Acoustic Microscopy and Optical Coherence tomography
224306828|NCT02702661|PROCEDURE|Fascia Iliaca Compartment Block (FICB)|Fascia Iliaca Compartment Block
224306829|NCT02702661|PROCEDURE|Local Anaesthetic Infiltration (LAI)|Local Anaesthetic Infiltration (LAI) of the portal tracts
224306830|NCT02702661|DRUG|Levobupivacaine|Levobupivacaine 0.125% - 40ml
224306831|NCT04668911|OTHER|Swab|PCR test for SARS-CoV2, oral and nasal swab
224178243|NCT02144662|DRUG|Ranibizumab|0.5mg ranibizumab intravitreal injection
224178244|NCT00460642|DRUG|GnRH Antagonist (Cetrotide)|
224178245|NCT01096966|DRUG|Bupivacaine TTS (Bupivacaine Patch)|Contains bupivacaine base, in a flexible and rectangular-shaped, transdermal, delivery system. Three patches applied to the lower back every 72 hours for 12 weeks.
224178246|NCT01096966|DRUG|Placebo patch|Identical in size and shape to the Bupivacaine Patch. Three patches applied to the lower back every 72 hours for 12 weeks.
224178247|NCT02067065|DRUG|Non-anesthesiologist propofol sedation|Bolus propofol sedation administered according to non-anesthesiologist propofol sedation guidelines of the European Society of Gastrointestinal Endoscopy
224178248|NCT02067065|DRUG|Propofol sedation administered by an anesthesiologist|Propofol sedation by an anesthesiologist
224306832|NCT02346591|BEHAVIORAL|Jauntly|Mobile app designed to encourage positive emotion-enhancing and stress reduction activities.
224178249|NCT02067065|PROCEDURE|Colonoscopy|Elective total colonoscopy with or without biopsies, polypectomies or mucosal resection, as clinically indicated
224178250|NCT00106626|DRUG|vorinostat (Suberoylanilide Hydroxamic Acid [SAHA]) in combination with Pemetrexed and Cisplatin|Dose escalation study starting with vorinostat (Suberoylanilide Hydroxamic Acid \[SAHA\]) capsules 200 mg b.i.d. in combination with Pemetrexed and Cisplatin (see table for Reporting Groups).
224178251|NCT03302923|BEHAVIORAL|Brisk walking|Prospective randomized clinical trial with 2 intervention groups and 1 control group.
224178252|NCT05696613|DRUG|SNP-ACTH (1-39) Gel|Subjects will be randomly assigned in 1:1 treatment allocation ratio to receive the test and reference product.
224178253|NCT05696613|DRUG|Rituximab|Subjects will be randomly assigned in 1:1 treatment allocation ratio to receive the test and reference product.
224178254|NCT03058809|DEVICE|Oncopheresis|Oncopheresis is a type of apheresis incorporating an extracorporeal blood circuit and a filter to separate circulating tumor cells from normal blood components.
224178255|NCT02114723|DEVICE|Medical Taping Concept|"The material used is a lengthways tape bandage of cotton with elastic properties, provided with a layer of anti-allergic adhesive in one of its sides that does not contain latex. This layer of glue is applied according to a special pattern so as to allow adequate transpiration.~The bandage is applied at the time that menstrual pain begins and is stuck to the skin for 4-5 days until menstrual pain disappears"
224178256|NCT04335552|OTHER|Standard of care|Standard of care
224178257|NCT04335552|DRUG|Hydroxychloroquine|Hydroxychloroquine will be administered orally or via feeding tube at a dosage of 800 mg on day 1, followed by 600 mg daily on days 2-5
224178258|NCT04335552|DRUG|Azithromycin|Azithromycin will be administered orally or via feeding tube at a dosage of 500 mg on day 1, followed by 250 mg daily on days 2-5
224178259|NCT01787123|DRUG|Intravenous Cerebrolysin|14-day course of intravenous Cerebrolysin started within 4 days of ictus
224178260|NCT01787123|DRUG|Normal Saline|14-day course of intravenous normal saline started within 4 days of ictus
224178261|NCT03281239|DIAGNOSTIC_TEST|Laser doppler, blood tests, and holter ECG|"Diagnostic tests :~* laser doppler~* blood tests~* Holter ECG. No drug and no placebo were used in this arm."
224178262|NCT02581501|DRUG|GAX - Gemcitabine, Abraxane and Xeloda|GAX represents a novel approach to the development of cancer chemotherapy agents in pancreatic cancer and is based upon extensive laboratory investigations for the induction of apoptosis in pancreatic carcinoma cells. It is our expectation that this combination will induce apoptotic pathways downstream of biochemical mechanisms of resistance and synergistically induce pathways for apoptosis that are non-p53 dependent, which have not been previously explored in chemotherapy trials for this cancer.
224306833|NCT02346591|BEHAVIORAL|Online stress management information|Online educational information about stress management
223487708|NCT05497401|OTHER|Placebo|Saline
223487709|NCT05247047|DEVICE|TENA SmartCare Change Indicator|The intervention is a medical device system that consists of a reusable electronic sensor and an application installed on one or more smart phones. The device estimates the saturation level of an absorbing incontinence product used by a study subject. The device is non-invasive and does not have any effect on the function of the absorbing incontinence product.
223487710|NCT05924594|DRUG|CTx-1301 - Dexmethylphenidate 6.25mg|All subjects will be titrated to their optimal dose during the dose-optimization phase. Possible doses are 6.25mg, 12.5mg, 18.75mg, 25.0mg, 31.25mg, or 37.5mg of CTx-1301.
223487711|NCT05924594|DRUG|CTx-1301 - Dexmethylphenidate 12.5mg|All subjects will be titrated to their optimal dose during the dose-optimization phase. Possible doses are 6.25mg, 12.5mg, 18.75mg, 25.0mg, 31.25mg, or 37.5mg of CTx-1301.
223487712|NCT05924594|DRUG|CTx-1301 - Dexmethylphenidate 18.75mg|All subjects will be titrated to their optimal dose during the dose-optimization phase. Possible doses are 6.25mg, 12.5mg, 18.75mg, 25.0mg, 31.25mg, or 37.5mg of CTx-1301.
223487713|NCT05924594|DRUG|CTx-1301 - Dexmethylphenidate 25.0mg|All subjects will be titrated to their optimal dose during the dose-optimization phase. Possible doses are 6.25mg, 12.5mg, 18.75mg, 25.0mg, 31.25mg, or 37.5mg of CTx-1301.
223487714|NCT05924594|DRUG|CTx-1301 - Dexmethylphenidate 31.25mg|All subjects will be titrated to their optimal dose during the dose-optimization phase. Possible doses are 6.25mg, 12.5mg, 18.75mg, 25.0mg, 31.25mg, or 37.5mg of CTx-1301.
223487715|NCT05924594|DRUG|CTx-1301 - Dexmethylphenidate 37.5mg|All subjects will be titrated to their optimal dose during the dose-optimization phase. Possible doses are 6.25mg, 12.5mg, 18.75mg, 25.0mg, 31.25mg, or 37.5mg of CTx-1301.
223487716|NCT05924594|DRUG|Placebo|Subjects will be randomized (1:1) to their optimal dose or placebo in the 7-day, double-blind, randomized phase.
223487717|NCT02097706|DRUG|NMDA receptor antagonist (active drug)|
223487718|NCT02097706|OTHER|Lactose packed capsule (inert/inactive arm)|
223487719|NCT05752539|DEVICE|CEREC System by Dentsply Sirona|CEREC Tessera blocks achieve exceptional three-way performance through a unique chemistry that incorporates two complementary crystal structures within a glassy zirconia matrix. These two crystals work together to create an unprecedented fusion of strength and beauty in one block while significantly improving overall processing time.
223487720|NCT04696692|OTHER|Patient with histologically confirmed diffuse large B-cell lymphoma with a planned first line treatment by R-CHOP.|"Blood samples will be collected :~* at baseline (before the 1st R-CHOP cycle)~* before the 3d administration of chemotherapy (CT) (i.e. after 2 cycles of CT and same timepoint as interim FDG-PET/CT)~* after the 4th administration of the CT~* at the end of induction (i.e. end of R-CHOP treatment)~* at 24 months after initiation of R-CHOP treatment~* at the time of progression (if progression occurs before 24 months of treatment).~Tumor samples will be collected at baseline (from an archived initial diagnostic tumor specimen) and at the time of progression (if applicable from lymph node biopsy performed as part of a standard of care surgical procedure).~Bone marrow samples will be collected at baseline and at the time of progression (if applicable) only in patients for whom a bone marrow aspiration (BMA) is necessary as part of their standard of care, upon physician's decision."
223487721|NCT06087627|DRUG|Dupilumab SAR231893 (REGN668)|Subcutaneous injection, standard of care as prescribed by treating physician (no investigational drug provided)
223487722|NCT06118411|DRUG|Upadacitinib|Oral Tablets
223487723|NCT06118411|DRUG|Placebo|Oral Tablets
223487724|NCT06118411|OTHER|NB-UVB (narrow-band ultraviolet B) Phototherapy|NB-UVB phototherapy is a commonly used treatment modality in participants with vitiligo and can be administered in an office setting or at home 2 times per week
224178263|NCT04046289|DIETARY_SUPPLEMENT|Low Calcium Milk|50 mg calcium/day
224178264|NCT04046289|DIETARY_SUPPLEMENT|Regular Calcium Milk|400 mg/day
224178265|NCT04046289|DIETARY_SUPPLEMENT|Probiotic 1|regular calcium milk + probiotic
224178266|NCT04046289|DIETARY_SUPPLEMENT|Probiotic 2|regular calcium milk + probiotic
224178267|NCT00405756|DRUG|Lenalidomide: Double-blind Induction|Double-blind Induction: the starting lenalidomide oral dosing regimen was 10 mg once daily on Days 1 through 21 of each 28 day cycle for up to 9 cycles. Dose was reduced if needed due to dose-limiting toxicity.
224178268|NCT00405756|DRUG|Melphalan|Double-blind Induction: the starting melphalan oral dosing regimen in all 3 treatment arms was 0.18 mg/kg daily on Days 1 through 4 of each 28-day cycle for up to 9 cycles. Dose was reduced if needed due to dose-limiting toxicity.
224178269|NCT00405756|DRUG|Prednisone|Double-blind induction: the starting prednisone oral dosing regimen in all 3 treatment arms was 2 mg/kg daily on Days 1 through 4 of each 28-day cycle for up to 9 cycles. Dose was reduced if needed due to dose-limiting toxicity.
224178270|NCT00405756|DRUG|Aspirin|"Double-blind induction: low-dose aspirin 75 mg to 100 mg daily for all treatment arms.~Double-blind maintenance: at the investigator's discretion"
224178271|NCT00405756|DRUG|Placebo|"Double-blind induction: participants in treatment arm MPp+p received placebo once daily on Days 1 through 21 of each 28-day cycle for up to 9 cycles.~Double-blind maintenance: participants in treatment arms MPR+p and MPp+p received placebo once daily on Days 1 through 21 of each 28-day cycle from cycle 10 to disease progression."
224178272|NCT00405756|DRUG|Lenalidomide: Double-blind Maintenance|Single-agent oral lenalidomide 10 mg once daily on Days 1 through 21 of each 28-day cycle from cycle 10 to disease progression.
224178273|NCT00405756|DRUG|Lenalidomide: Open-label|Any study participant who had progressive disease had the option of open-label lenalidomide up to 25 mg daily on Days 1 through 21 of each 28-day cycle.
224178274|NCT02004457|BEHAVIORAL|ABBT|
224178275|NCT02004457|OTHER|TAU|
224178276|NCT02569268|OTHER|Questionnaires and follow-up|Detecting the vascular functional parameters, questionnaire and follow-up: For 2 years or the occurrence of vascular events end time, including cardiovascular events (acute myocardial infarction, angina, coronary reperfusion therapy), stroke, heart failure, peripheral vascular disease.
224178277|NCT03975881|OTHER|application on smartphone|The aim of this study is to test the feasibility of our approach of preventing suicide relapse with the use of a smartphone application.
224178278|NCT00001961|PROCEDURE|MRI|
224178279|NCT04944121|DRUG|RSLV-132|10 mg/kg RSLV-132 administered by intravenous infusion
224178280|NCT04944121|DRUG|Sodium Chloride 0.9%|0.9% sodium chloride administered by intravenous infusion
224306834|NCT06021535|OTHER|No intervention|No intervention
224306835|NCT02089035|DIETARY_SUPPLEMENT|MUFA-rich dairy products (UHT milk, cheese and butter)|
224178281|NCT01265940|DRUG|Pazopanib as add-on to vinflunine|"Patients will receive vinflunine standard regimen (intravenous infusion every three weeks) as specified per drug label plus additional pazopanib as daily oral medication. Doses of pazopanib will be escalated in 200 mg/d steps during phase I up to a maximum of 800 mg/d.~In Phase II the patients will be given pazopanib + vinflunine at maximum tolerated dose."
224178282|NCT03504384|OTHER|questionnaire|All patients will be interviewed using a semi-structured questionnaire detailing patients' demographic characteristics (age, sex, education, occupation, residence), and the factors that could affect their quality of life such as pain and neurological symptoms, orthopedic disorder in another part of the body and history of spinal surgery.
224178283|NCT03099018|DIAGNOSTIC_TEST|Sofia Strep A FIA|Patients who presented with sore throat will be performed throat swab for the new fluorescent immunoasssay (Sofia Strep A FIA), for a standard RADT (Alere Testpack Strep A) and for culture and backup PCR in case of discrepant results.
224178284|NCT01691937|PROCEDURE|Continuous Paravertebral block with ropivacaine|Before anesthesia, continuous right thoracic paravertebral block of T7 is performed. After injection of 5 mL normal saline, a catheter (PAJUNK, Geisingen, Germany) is advanced medially the estimated distance to the paravertebral space. After injection of 1% lidocaine 15ml, the block level is tested by pinprick and recorded 15 minutes later. At the end of operation, syringe contained 0.2% ropivacaine is connected to paravertebral catheter, a 10ml bolus of 0.2% ropivacaine is injected via the paravertebral catheter, followed by an infusion of ropivacaine 0.2% at 6 ml/h for postoperative pain management.
224178285|NCT01691937|PROCEDURE|Patient-controlled analgesia with sufentanil|Once arrival at the PACU, all patients were placed on a postoperative analgesic regimen that included patient-controlled analgesia with intravenous sufentanil (bolus 1μg, lockout time 10 min) and tramadol 100 mg IV for severe pain (NRS 6-10).
224306836|NCT02089035|DIETARY_SUPPLEMENT|Conventional dairy products (UHT milk, cheese, butter)|
224306837|NCT02618135|OTHER|Intervention Group|Each participant will first need to master a simple concentration task before moving on to play a series of training tasks. An eye gaze tracker connected to the computer will detect the location of eye gaze on the computer screen. The game progresses according to how well the participant can focus their eye gaze on correct objects and sustain their attention. Each task employs the BCI system, and is controlled by the child's concentration. As the child attends to activities on a computer screen, their EEG waves will be recorded simultaneously via the EEG sensors through Bluetooth technology.
224306838|NCT02618135|OTHER|Control Group|"Participants will wait for 8 weeks before training intervention begins.~Each participant will first need to master a simple concentration task before moving on to play a series of training tasks. An eye gaze tracker connected to the computer will detect the location of eye gaze on the computer screen. The game progresses according to how well the participant can focus their eye gaze on correct objects and sustain their attention. Each task employs the BCI system, and is controlled by the child's concentration. As the child attends to activities on a computer screen, their EEG waves will be recorded simultaneously via the EEG sensors through Bluetooth technology."
223487725|NCT01771458|DRUG|Targeted therapy based on molecular profiling : Imatinib|
223487726|NCT01771458|PROCEDURE|Tumor biopsy|
223487727|NCT01771458|DRUG|Standard Chemotherapy|
223487728|NCT01771458|DRUG|Targeted therapy based on molecular profiling : Everolimus|
223487729|NCT01771458|DRUG|Targeted therapy based on molecular profiling : Vemurafenib|
223487730|NCT01771458|DRUG|Targeted therapy based on molecular profiling : Sorafenib|
223487731|NCT01771458|DRUG|Targeted therapy based on molecular profiling : Erlotinib|
224178286|NCT01691937|PROCEDURE|Continuous Paravertebral Block with Saline|Before anesthesia, continuous right thoracic paravertebral block of T7 is performed. After injection of 5 mL normal saline, a catheter (PAJUNK, Geisingen, Germany) is advanced medially the estimated distance to the paravertebral space. After injection of 1% lidocaine 15ml, the block level is tested by pinprick and recorded 15 minutes later. At the end of operation, syringe contained 0.9% saline is connected to paravertebral catheter, a 10ml bolus of 0.9% saline is injected via the paravertebral catheter, followed by an infusion of 0.9% saline at 6 ml/h for postoperative pain management.
224178287|NCT02017366|OTHER|Enteral feeding|Target of 1000 kCal/day enteral feeding or glucose 20%, perferably given overnight.
224178288|NCT02781246|DRUG|perineural dexmedetomidine|"Children scheduled for arm and forearm surgery underwent supraclavicle brachial plexus blocks with ropivacaine and dexmedetomidine guided by ultrasound visualisation were randomly assigned five groups: Group A (perineural ropivacaine), Group B (ropivacaine plus 0.5 mcg/kg dexmedetomidine), Group C (ropivacaine plus 1 mcg/kg dexmedetomidine), Group D (ropivacaine plus 1.5mcg/kg dexmedetomidine) and Group E (ropivacaine plus 2 mcg/kg dexmedetomidine). In each group, children received a certain concentration of ropivacaine which adjusted by the Dixon up-and-down method for supraclavicle brachial plexus. The first child received 0.2% ropivacaine , and the concentration of ropivacaine varied by 0.1% according to the up-and-down method. The primary endpoint was the minimum local anesthetic concentration (MLAC)."
224178289|NCT03977363|DRUG|Anticoagulant drugs|Anticoagulant drugs
224178290|NCT02804581|DIETARY_SUPPLEMENT|Gum Arabic|Oral intake of GA in powder from30 grams per day
224178291|NCT05265494|DEVICE|Non invasive neuromodulation NESA (XSIGNAL device)|"The study volunteers are treated with the NXSIGNAL® device in sessions of 60 minutes, twice a week and for 5 weeks (10 sessions).~• The skin must be clean, free of creams and grease, lectrodes are connected to the control console and the targeting electrode located in over the intervertebral area between C7 and T1 (cervical area) and will follow the central treatment pattern with the following combination:~* 2 sessions: Program 1 (30 min), Program 7 (15min) and Program 8 (15min).~* 4 sessions: Program 2 (15min), Program 7 (30 min) and Program 8 (15min)~* 4 sessions: Program 7 (60min)"
224178292|NCT00672139|DRUG|Methylnaltrexone bromide|
224178293|NCT03894306|OTHER|Medication lock box|given a lock box and instructed on how to use the device.
224178294|NCT03894306|OTHER|medication lock bag|given a lock bag and instructed on how to use the device.
224178295|NCT03894306|OTHER|brief counseling|After completing the per-intervention survey, a research assistant or investigator will perform brief counseling, including educational handouts and information on safe medication storage
224178296|NCT00143039|PROCEDURE|Tandem MS test for inborn errors of metabolism|Tandem MS spectrometry test will be done on all maternal blood, amniotic fluid and newborn blood samples for both groups.
224178297|NCT03702452|OTHER|functional rehabilitation nursing program|According to the modified Barthel index score, the patients' function was divided into four parts Level,each level has different kinds of rehabilitation nursing.
224178298|NCT03702452|OTHER|control group|The rehabilitation were given by the rehabilitation therapist based on the patient's condition, such as, bridge movement,limb passive motion, limb active motion,turn over,sit upw,walk, and so on.
224178299|NCT02079701|BIOLOGICAL|23-valent pneumococcal vaccine|randomization, based upon a random-number (block design) double-blind enrollment sequence. 1:1 ratio.
224178300|NCT02079701|BIOLOGICAL|Placebo|
224178301|NCT05520489|DEVICE|Repetitive Transcranial Magnetic stimulation|"Participants received 15 sessions (15 daily session - Monday to Friday) of active rTMS over the 'hotspot M1 area of the unaffected hemisphere leading to a response in the contralateral thenar muscle using Visor2-navigation system and MagstimRapid -magnetic stimulator. . Hot spot localization was performed by stimulation with 50%:n intensity and found the maximum response area, where the coil was placed using the navigator cursor. The motor threshold was found using Maximum-Likelihood Strategy -algorithm of MTAT system.~Low frequency rTMS was applied at 80-90% resting motor threshold (rMT) intensity, 1 Hz, 600+600 pulses, inbetween 10 minutes break. Intensity was increased after each 2-3 treatment to keep motor threshold 90%."
224178302|NCT05520489|DEVICE|Robot Assisted Therapy|"This was delivered using the Diego and Pablo (Tyromotion GmBH) robotic gym system. Participants receive robot-assisted training for up to 60 min per day, four days per week for 3 weeks, in addition to usual care. Robotic devices enable 3D interactive exercising, using weight reducing system in Diego and fine motor training in Pablo. Exercises can be one- or two-handed and/or symmetrical. Patient performs 150-400 repetitions in one therapy session. Estimated time is 2-3 minutes per one exercise section. Standard minimum program includes 4 games: swimming, shooting, ship and apple orchard. The therapist instructs the patient and assure the position of trunk and shoulder girdle."
224178303|NCT05520489|OTHER|Enhanced upper limb therapy programme|Exercises were performed by using different objects for task orientated movements. The therapist provided assistance as needed and encouraged participants to complete the tasks. Training was divided to 3 sessions for fine motor training and complex training and 1 session for shoulder girdle and complex training per week for 3 weeks, in addition to usual care. Each session lasts 1 hour and estimated time is 2-5 min to each exercise section.
224178304|NCT01245296|PROCEDURE|Timing of clamping the umbilical cord|The time passed after delivery until that the midwife stops circulation in the umbilical cord with a clamp.
224178305|NCT03338699|DEVICE|ShangRing|Topical anesthesia based, no-flip ShangRing circumcision.
224178306|NCT03338699|DEVICE|Mogen clamp|Mogen clamp circumcision
224178307|NCT02546739|BIOLOGICAL|Anti-CD19-CAR|Cells extracted, followed by induction chemotherapy before CD19-CAR infusion (dose escalation.)
224306839|NCT06548308|DIAGNOSTIC_TEST|Corneal Incision|Astigmatism will be assessed by objective and subjective refraction by using the Autorefrectometer and retinoscop.Autorefrectometer uses to acsess the refracive state of eye by which we measure the astigmatim in patients eyes .Then after ctaract surgry in the next followup we will again use autorefrectometer to take readings and these both will be compared on visits among patients undergoing two procedures.
223487732|NCT01771458|DRUG|Targeted therapy based on molecular profiling : Lapatinib + Trastuzumab|
224178308|NCT02665039|DRUG|Vinflunine|"Vinflunine will be given intravenously once every 21 days, starting at a dose of:~* 280 mg/m2 in patients with GFR 40-60 ml/min~* 250 mg/m2 in patients aged \>80 years and/or GFR 30-40 ml/min"
224178309|NCT02665039|DRUG|Gemcitabine|Gemcitabine will be given intravenously on day 1 and day 8 of every 21 day cycle, starting at a dose of 1000 mg/m2
223487733|NCT01771458|DRUG|Targeted therapy based on molecular profiling : Dasatinib|
224306840|NCT06548308|OTHER|Toric Intraocular|Two cataract surgery techniques will be used .1 : Toric IOL lenses designed with a unique shape to help provide clear vision at all distances for individuals with astigmatism compared to give better results specially in astigmatic patients.2: Corneal Inscion is which eye surgeon makes a very small opening on the eye, next to the outer corner. to remove the catract during surgry .
224306841|NCT01716715|DRUG|Cabozantinib S-malate|Given PO
223487734|NCT01771458|DRUG|Targeted therapy based on molecular profiling : Tamoxifen (or letrozole if contra-indication)|
223487735|NCT01771458|DRUG|Targeted therapy based on molecular profiling : Abiraterone|
223487736|NCT00950001|RADIATION|Stereotactic Radiosurgery|Undergo SRS
223487737|NCT04680988|DRUG|SHR-1210|SHR-1210 intravenously every 3 weeks
223487738|NCT04680988|DRUG|SHR-1020|SHR-1020 Orally once daily
223487739|NCT04680988|DRUG|Physician's choice chemotherapy|Investigators will declare one of the following regimens:Albumin-bound paclitaxel injection, Pemetrexed disodium for injection, Gemcitabine for injection
223487740|NCT03884413|OTHER|questionnaires|Longitudinal observational study. Collection of health data using self-administered questionnaires online.
223487741|NCT04725188|BIOLOGICAL|Pembrolizumab/Vibostolimab coformulation|Pembrolizumab 200 mg + vibostolimab 200 mg/20 mL vial IV infusion Q3W up to approximately 2 years.
223487742|NCT04725188|DRUG|Docetaxel|Docetaxel 75 mg\^m2 IV infusion Q3W until discontinuation due to progressive disease or unacceptable toxicity. Docetaxel will serve as part of an experimental treatment in Arm 1, and as an active comparator in Arm 3.
223487743|NCT04725188|DRUG|Placebo|Normal saline IV infusion Q3W up to approximately 2 years
223487744|NCT05340673|DRUG|Agent Affecting Integumentary System|Apply Miaderm
223487745|NCT05340673|OTHER|Petrolatum-Mineral Oil-Lanolin-Ceresin Ointment|Apply to skin
223487746|NCT05340673|OTHER|Quality-of-Life Assessment|Ancillary studies
223487747|NCT05340673|OTHER|Questionnaire Administration|Ancillary studies
223487748|NCT03935048|DIETARY_SUPPLEMENT|Higher protein, low glycemic load diet|"All dietary treatments will be designed to be isoenergetic within individual participants. Energy content of the diets will be individualized to ensure weight maintenance throughout the dietary intervention period using the Harris Benedict equation x 1.35. Glycemic load for the treatment groups will be calculated using the following equation:~Glycemic Load = Glycemic Index x Grams of carbohydrates/100. Potatoes, processed potato products, and control carbohydrate foods will be provided."
223487749|NCT04412096|DRUG|Timolol 0.5% ophthalmic solution|1 drop BID
223487750|NCT04412096|DRUG|Latanoprost 0.005% Ophthalmic Solution|1 drop QD
223586965|NCT05304429|BEHAVIORAL|nutrition education|Educational sessions with topics that will address the management and prevention of frailty syndrome focusing on protein intake and physical activity
223487751|NCT06442033|OTHER|High intensity stationary cycling|All community based exercise sessions are: 3x/week for 40 min, which includes a 5-min warm up \& cool down and a 30-minute main exercise set. Exercise parameters will be set by a neurologically trained physical therapist and will be progressed over time with the ultimate goal of the individual reaching moderate-vigorous exercise. Moderate-vigorous exercise for this project is defined as a cadence of 75+ rpms and a target HR of 60-80% of their age-predicted max
223487752|NCT06850610|DIAGNOSTIC_TEST|Pulse oximeter accuracy under hypoxic conditions|This study will specifically evaluate the accuracy of the Owlet pulse oximeter sensor, currently FDA cleared for infants 1-18 months of age in an expanded hypoxia lab trial.
223487753|NCT06558487|OTHER|Cancer Admission Score Prediction Model|A prediction model that calculates the chance for a patient to be admitted after triage and after first blood results
223487754|NCT03422302|DEVICE|Biphasic Positive Airway Pressure|Receive BiPAP
223487755|NCT03422302|PROCEDURE|Computed Tomography|Undergo CT simulation scans
223487756|NCT03422302|PROCEDURE|Continuous Positive Airway Pressure|Receive CPAP
223487757|NCT03422302|PROCEDURE|Deep Inspiration Breath Hold|Complete DIBH
223487758|NCT03422302|RADIATION|Radiation Therapy Treatment Planning and Simulation|Undergo CT simulation scans
223487759|NCT03422302|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
223487760|NCT02337829|DRUG|Acalabrutinib (Arm A)|"* A1a) acalabrutinib, dose A daily: biopsy (T) schedule W;~* A1b) acalabrutinib, dose A daily: biopsy (T) schedule V.~* A2a) acalabrutinib, dose B q 12 hours: biopsy (T) schedule Y;~* A2b) acalabrutinib, dose B q 12 hours; biopsy (T) schedule Z"
223487761|NCT02337829|DRUG|Acalabrutinib (Arm B)|"B1c) acalabrutinib, dose A daily: biopsy (U) schedule W;~• B2c) acalabrutinib, dose B q12 hours: biopsy (U)) schedule Y."
223487762|NCT01696721|OTHER|No intervention|
223487763|NCT06358885|OTHER|Facilitation (FAC)|The facilitation approach will use a flexible clinic level implementation strategy that helps clinics to address common barriers, such as counselor skills, competing priorities, and resource deficits.
223487764|NCT06358885|BEHAVIORAL|Experiential Brief Alcohol Intervention (EBAI)|Clinic staff will be offered the experiential BAI prior to implementation. The BAI comprises 2 in-person sessions and 2 booster phone sessions. Clinic staff responsible for delivering the BAI to PWH participants will be offered 3 additional consolidation sessions to integrate their experiences receiving the BAI with their delivery of the BAI.
223487765|NCT05658549|DRUG|N-acetyl cysteine|N-acetyl cysteine dosage 600 mg and 1200 mg
223487766|NCT06263946|DEVICE|Essilor® Stellest® spectacle lenses|patients will be asked to wear Essilor® Stellest® spectacle lenses more than 12 hours per day for 24 months.
224178310|NCT02665039|DRUG|Carboplatin|Carboplatin will be given intravenously once every 21 days, starting at a dose of AUC 4.5
224178311|NCT02607904|DRUG|GWP42003-P|Clear, colorless to yellow solution containing cannabidiol (CBD) dissolved in the excipients sesame oil and anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring.
224306842|NCT01716715|OTHER|Laboratory Biomarker Analysis|Correlative studies
224306843|NCT01716715|DRUG|Paclitaxel|Given IV
224306844|NCT00000693|DRUG|Zidovudine|
224178312|NCT04139161|PROCEDURE|Q-Factor Intervention|The intervention period will consist of 12 training sessions across four consecutive weeks, with three training sessions held per week. If pain is not increased or reduced and Rating of Perceived Exertion is ≤12, the participant will progress to the next bout. If pain is increased from the pre-bout pain score, participants will repeat the bout, at the same workrate and Q-Factor settings. Following this fashion, participants will progress through three increasing Q-Factors for each given workrate; Q-Factor 1 (Q1, 192mm), Q2 (234mm), Q3 (276mm). After completing bouts of all three Q-Factors for a given workrate, workrate will be increased by 20 Watts and bouts at each Q-Factor will be repeated. For each training session, participants will complete bouts of cycling until 1) the maximum number of bouts (4 bouts) has been accomplished, 2) self-reported Rating of Perceived Exertion \>12, indicating a transition to moderate physical activity, or 3) self-reported pain \>5.
224178313|NCT04629105|BIOLOGICAL|Longeveron Mesenchymal Stem Cells (LMSCs)|Longeveron Mesenchymal Stem Cells (LMSCs)
224178314|NCT04629105|OTHER|Placebo|Placebo
224178315|NCT03244111|BEHAVIORAL|simple memory tool|The goals may be implemented using the simple memory tool. Simple memory tool involves using materials such as checklists or diaries to assist with memory.
224178316|NCT00458601|DRUG|CDX-110 with GM-CSF|Three biweekly intradermal injections over four weeks followed by monthly injections until tumor progression. Each dose will be 0.8 mL containing approximately 500 mcg CDX-110 and 150 mcg GM CSF.
224178317|NCT00458601|DRUG|Temozolomide|Maintenance temozolomide will begin after completion of the three initial injections of CDX-110 plus GM-CSF. 150 to 200 mg/m2 for 5 days during each 28-day cycle for a minimum of six cycles or a maximum of 12 cycles, intolerance or progression.
224178318|NCT06077123|DEVICE|Contigo Application|Contigo, a smartphone application, aims to achieve two main objectives: monitoring cancer patients for early detection of oncology drug toxicity signs and providing educational content to empower patients in handling clinical challenges tied to their diagnosis and treatment. Monitoring involves modules and sub-modules where patients input experiences through oncology-related questionnaires. Weekly checks for chemotherapy toxicity-associated symptoms use a validated questionnaire (PRO-CTCAE). Severe toxicity triggers immediate alerts, while milder cases receive educational guidance. Data collected is shared with healthcare providers. Educational health content has been created by professionals, encompassing cancer-specific topics, healthcare processes, administration, health coverage, self-awareness, and self-care practices. The content is based on scientific evidence, official reports, and group sessions involving healthcare professionals and cancer patients.
224178319|NCT00420823|DRUG|Taurine 4g|
224178320|NCT02757651|DRUG|Hydrogen Peroxide|Hydrogen Peroxide
224178321|NCT03316599|DRUG|Gemcitabine|Gemcitabine is a chemotherapy agent. Chemotherapy agents are medicines that kill cancer cells.
224178322|NCT03316599|DRUG|Nab-paclitaxel|Nab-paclitaxel is a chemotherapy agent. Chemotherapy agents are medicines that kill cancer cells
224178323|NCT03316599|DRUG|Ficlatuzumab|It is selective recombinant humanized hepatocyte growth factor (HGF) inhibitory immunoglobulin G subclass 1 monoclonal antibody which blocks the MET tyrosine kinase receptor.
224178324|NCT05272306|OTHER|Number of attempts for successful transesophageal echocardiography|Transesophageal echocardiography probe will be inserted after induction of anesthesia. Number of attempts for successful transesophageal echocardiography will be recorded.
224178325|NCT05272306|DIAGNOSTIC_TEST|A questionnaire for cardiologist satisfaction|A questionnaire for cardiologist satisfaction will be measured on a grade of 0-4 (1= very bad, 2= bad, 3= good, 4= very good).
224178326|NCT05272306|DIAGNOSTIC_TEST|A questionnaire for patient satisfaction|A questionnaire for patient satisfaction will be measured on a grade of 0-4 (1= very bad, 2= bad, 3= good, 4= very good).
224178327|NCT02504957|PROCEDURE|Photodynamic therapy using polyhematoporphyrin|
224178328|NCT03058276|BEHAVIORAL|Retrieval-Extinction Learning|The intervention consists of the accomplishment of the task of approach-avoidance of alcohol during 4 days of training. Subjects are instructed to respond with an approach movement (pulling a lever) to neutral images and to respond with avoidance movement (pushing the lever) to images of alcohol.
224178329|NCT03058276|OTHER|rTMS|Previous to rTMS completion, MRI scans were performed in order to determinate the motor threshold trough 1Hz stimuli and locate the desired area with the neuronavigator. Motor threshold is defined as the stimulus with less intensity, able to generate a motor potential of at least 50 µV in 10 trials. Next, patients were called for 5 times per week, along 2 weeks, for receiving brain stimulation with Magstim Rapid coil. rTMS is performed at 10 Hz, during 4.9 seconds,for each set of stimuli (20), with a interval between sets of 30 seconds.
224178330|NCT03058276|OTHER|SAM|Previous to rTMS completion, MRI scans were performed in order to determinate the motor threshold trough 1Hz stimuli and locate the desired area with the neuronavigator. Motor threshold is defined as the stimulus with less intensity, able to generate a motor potential of at least 50 µV in 10 trials. Next, patients were called for 5 times per week, along 2 weeks, for receiving brain stimulation with SAM coil.
224178331|NCT05807191|OTHER|Kangaroo care based on kangaroo care guide|Under the supervision of the researcher, a kangaroo care practice was applied to premature babies by their mothers based on the kangaroo care guide. This practice took 65 minutes. In addition, before the application, the kangaroo application information was explained to the mothers through a brochure.
224306845|NCT00000693|DRUG|Acyclovir|
224306846|NCT03343444|DRUG|12 weeks (Sofosbuvir 400mg/Ledipasvir 90mg)|Single Tablet (Sofosbuvir 400mg/Ledipasvir 90mg) daily for 12 weeks
224306847|NCT03343444|DRUG|8 weeks (Sofosbuvir 400mg/Ledipasvir 90mg)|Single Tablet (Sofosbuvir 400mg/Ledipasvir 90mg) daily for 8 weeks
224306848|NCT00704574|DRUG|insulin detemir|No extra intervention, only normal clinical practise for treatment of type 1 diabetes
224306849|NCT04228783|BIOLOGICAL|Ad26.ZEBOV|Participants will receive IM injection (0.5 mL) of Ad26.ZEBOV as Dose 1 (5\*10\^10 vp, Lot A, B, and C) on Day 1 (Groups 1, 2, 3 and 5) and an Ad26.ZEBOV booster dose on Day 177 (Group 5).
224306850|NCT04228783|BIOLOGICAL|MVA-BN-Filo|Participants will receive IM injection (0.5 mL) of MVA-BN-Filo as Dose 2 (1\*10\^8 Inf U, Lot 1, 2, 3 and 5) on Day 57.
224306851|NCT04228783|BIOLOGICAL|Placebo|Participants will receive IM injection (0.5 mL) of placebo (0.9 % saline) as Dose 1 on Day 1, followed by placebo as Dose 2 on Day 57 (Groups 4 and 6) and a booster of matching placebo on Day 177 (Group 6).
224306852|NCT03327792|DRUG|Mavoglurant|200 mg Mavoglurant
224306853|NCT03327792|DRUG|Placebo|Placebo
224178332|NCT03059576|OTHER|Chronobiological status of the subjects|"Participation was completely voluntary and not remunerated. The subjects were organized into groups of 5 pairs, and were given an appointment at a university facility located in the city center, where informed consent was signed prior to the procedures indicated below. An informational letter was sent to pre-selected individuals. Later a phone call confirmed their availability.~* Temperature rhythm was assessed continuously for 7 days using a temperature sensor and programmed to collect information every 10 min.~* Body position and rest-activity rhythm were assessed over the same 7 days using a Acceleration Data Logger that record data every min and placed on the non-dominant arm by means of an elastic band, with its X axis parallel to the humerus bone.~* Diet and sleep record were completed over the same week, their sleep schedules and their nutritional status."
224178333|NCT02498340|DIETARY_SUPPLEMENT|non- fava beans|Patients will be subjected to eat non- fava beans diet at doses of 10 -30 gm (small to moderate amount) of 3 different types of non- fava beans, each one will be given once daily for 3 days.
224178334|NCT03474627|DEVICE|Non-coated HA/TCP particles|Maxillary sinus floor elevation and bone grafting with the use of biphasic hydroxyapatite and beta-tricalcium phosphate bone graft
223487767|NCT06798974|OTHER|Three-dimensional video|Patients who meet the criteria for inclusion in the study will be randomly assigned to intervention and control groups. The intervention group will be shown a 3D lemon video with virtual reality glasses. The video will be created by a company that shoots 3D videos. Opinions of three experts will be obtained for the suitability of the video. The video will be shown to patients for 5 minutes. In order to control the effects that may arise from the practitioner during the study, the virtual reality glasses application will be applied to all patients by the same clinic nurse. The control group will not receive any intervention and will receive standard care. Data collection forms will be given to the patient by the researcher and will be collected after the patient fills them out.
223487768|NCT03330197|BIOLOGICAL|Ad-RTS-hIL-12|2.0 x 10\^11 viral particles (vp) per injection, one intratumoral injection of Ad-RTS-hIL-12
223487769|NCT03330197|DRUG|Oral Veledimex - Arm 1 (Pediatric Brain Tumor)|1 dose level (10mg/day) 15 oral daily doses of veledimex
223586966|NCT05304429|BEHAVIORAL|nutritional counseling|nutritional counseling system based on the com-b model through three strategies: goal setting, self-monitoring and social support
223586967|NCT05226611|OTHER|Counterstrain|Counterstrain is a hands-on OMM technique that involves shortening the muscle to resolve the dysfunctional muscle stretch reflex and holding it for 90 seconds. The patient is then brought back to a neutral position and reassessed.
223586968|NCT00077844|DRUG|Enoxaparin sodium|
223586969|NCT00237263|DRUG|Entacapone|
223586970|NCT00569868|DRUG|Velcade|"Except for the two PCR-based genotyping assays, which will be conducted only on baseline samples, tests will be assessed at baseline, 1-3 hours after the first dose of Velcade day 1 and on day 11 of the first cycle of Velcade.~The platelet Aggregation Test will be done only if Platelet count is 100 000."
223586971|NCT03495791|OTHER|YouTube Video|Educational Video
223586972|NCT02780973|OTHER|Wearing of an intraoral device with bovine tooth samples|Wearing of an intraoral device with bovine tooth samples
224178335|NCT03474627|DEVICE|PLGA-coated HA/TCP particles|Maxillary sinus floor elevation and bone grafting with the use of biphasic hydroxyapatite and beta-tricalcium phosphate bone graft with PLGA coating
224178336|NCT01693666|BEHAVIORAL|Lifestyle intervention|"1. To establish an effective contingency management behavioral program (LIFE), increasing adherence to nutritional recommendations and exercise guidelines during pregnancy.~2. To examine the impact of the LIFE program on weight gain restriction during pregnancy and postpartum weight loss in obese women in comparison to the RC group.~3. To examine the impact of the LIFE program on short- and long-term maternal and offspring outcomes at study enrollment, 34-36 weeks gestation and 3 months postpartum in obese women in comparison to the RC group."
224178337|NCT05750615|OTHER|Uncertain what intervention will be co-created|Uncertain what intervention will be co-created
224178338|NCT01117428|DRUG|Sym004|"In part A, patients in all dose cohorts will continue weekly treatment with the assigned dose of Sym004 until disease progression.~In Part B, patients will continue weekly treatment with the tolerated dose of Sym004 until disease progression.~In Part C, patients will receive weekly doses of Sym004 at the dose level below 12 mg/kg i.e. 9 mg/kg until disease progression.~In Part D and E, patients will receive doses of Sym004 administered every 2 weeks at dose level 12 mg/kg and 18 mg/kg, respectively until disease progression.~In Part F, patients will receive a single loading dose of 9 mg/kg followed by weekly doses of 6 mg/kg."
224178339|NCT00107536|DRUG|lapatinib ditosylate|
224178340|NCT00107536|OTHER|laboratory biomarker analysis|Correlative studies
224178341|NCT01386749|PROCEDURE|vibration platform provide low magnitude and high frequency vibration treatment, which is self-developed by our research team|Stand on a vibration platform at 35Hz, 0.3g, 20mins/day and 5days/week
223487770|NCT03330197|DRUG|Oral Veledimex - Arm 2 (DIPG)|2 dose levels (10mg/day, 20mg/day) 14 oral daily doses of veledimex
223586973|NCT05288140|OTHER|use of diary|a diary is made for the experimental group where the events and events during the period of sedation and intubation are explained
223586974|NCT04784468|OTHER|No intervention|Case-control design, one single investigation
223586975|NCT01107782|DRUG|sildenafil|50 mg TDS orally until birth
223586976|NCT01107782|DRUG|placebo|50mg tid
223586977|NCT05257343|DIETARY_SUPPLEMENT|Liquid Placebo Supplementation|8-weeks of supplementing with a visually identical liquid placebo supplement.
223586978|NCT05257343|DIETARY_SUPPLEMENT|Liquid Iron Supplement (Blood Builder ®)|8-weeks of supplementing with a liquid iron supplement (Blood Builder ®)
223586979|NCT06329024|BEHAVIORAL|Rehabilitation treatment|Both groups are given rehabilitation treatment. The main intervention measures included: 1) non-invasive ventilator treatment, generally at least once every night and typically not exceeding continuous daily usage.; 2) attention to feeding and sleeping positions, with a recommended sleeping position of lateral recumbent and the head of the bed raised by 20-30°; 3) swallowing function training, such as tongue muscle stretching training, assisted anterior jaw protrusion training, lemon ice stimulation to the soft palate, pharyngeal wall, etc., generally 5 days per week, twice per day, 5-20 minutes each time; 4) pulmonary ultrashort wave therapy, generally at least 2-3 times a week, and not more than once a day; 5) physical therapy, such as intensive training for gross motor functions including lifting the head, turning over, sitting, crawling, standing, etc., generally 3-5 days per week, 1-2 times per day, 5-20 min each time.
223487771|NCT02654574|OTHER|IADL administration by phone|The administration of IADL questionnaire by phone consists of a collection of answers given by the caregiver during the interview with the research nurse, trained for this procedure. This method of procurement will be standardized with a listing support for the phone interview to obtain the same conditions for collection of data from a caregiver to another. Questions will be asked in the same order than the questionnaire collected with the reference procedure i.e. face-to-face interview at the Memory Clinic. The IADL questionnaires in paper format used during the ace-to-face interview and by phone will be identical.
223487772|NCT06042140|DEVICE|NEOX Cord 1K applied fetoscopically|Under general anesthesia and tocolysis, in-utero repair begins with a laparotomy that is followed by exteriorization of the uterus. The fetus is then positioned by external cephalic version. Uterine entry will be accessed using 3 cannulas, followed by heated-humidified carbon dioxide insufflation for visualization. Then, fetoscopically the placode will be examined and dissected. The lesion will be repaired using NEOX Cord 1K® (HUC) for closure of the first layer over the neural placode. Primary closure of the skin will then occur, or NEOX Cord 1K® (human umbilical cord) will be used for skin closure at the discretion of the Pediatric Neurosurgeon. Finally, the laparotomy site will be sutured in multiple layers.
224178342|NCT03018028|DRUG|Semaglutide|Oral administration once daily
224178343|NCT03018028|DRUG|Placebo|Oral administration once daily
224178344|NCT03018028|DRUG|Liraglutide|Subcutaneous (s.c., under the skin) injection once daily
224178345|NCT01531764|DRUG|BIBW 2992 in combination with vinorelbine|Patients will receive BIBW 2992 and vinorelbine chemotherapy. BIBW 2992: 40 mg oral (tablet) once daily Vinorelbine: 25 mg/m² on days 1 \& 8 in a 3-weekly course, intravenous, short infusion of about 10 minutes
223487773|NCT04030559|DRUG|Niraparib|Given PO
223487774|NCT04030559|DRUG|Niraparib Tosylate Monohydrate|Given PO
223487775|NCT04030559|PROCEDURE|Radical Prostatectomy|Undergo standard of care surgery
223487776|NCT05869552|OTHER|STAT-PC|STAT-PC is an adapted version of Suicidal Teens Accessing Treatment after an ED Visit (STAT-ED). It is a brief intervention based on motivational interviewing (MI) that focuses on mental health care seeking behavior, problem-solving, and referrals plus brief case management. The intervention will consist of an initial session with the youth focusing on accessing mental health care plus case management calls. The interventionist will also be available to assist with referrals for connection to other services later during the study period as needed for up to three months. The intervention may include contact with the youth's mental health provider to make sure linkages are made.
223487777|NCT05869552|OTHER|YST-III|YST-III is an adapted version of Youth-Nominated Support Team for Suicidal Adolescents (YST-II). The intervention is a brief intervention originally developed for youth who have been psychiatrically hospitalized due to a suicide attempt or suicidal ideation (SI). Participants will nominate supportive adults (age 18 and older) from their lives who agree to provide ongoing contact and support for up to 3 months. YST-III will include an introductory session with the youth who will nominate their support persons plus referrals for mental health services. The support persons will receive training and support on how to best support their youth partner and then ongoing calls to support them in working with their youth partner for up to 3 months.
223487778|NCT04981613|DRUG|Kunxian capsule|Kunxian capsule (2# tid or 2# bid) + irbesartan tablet (150mg qd or 300mg qd) for 48 weeks
223487779|NCT05261425|DEVICE|Monocryl buried|Participants randomized to this group will receive the Monocryl (suture) buried (technique). The surgeon will utilize the randomized material and technique and the research team will utilize two surveys postoperatively to assess wound healing and appearance. Participants will fill out these surveys at each of their clinical follow-up visits.
223487780|NCT05261425|DEVICE|Nylon (FDA Approved) not buried|Participants randomized to this group will receive the Nylon (FDA Approved) (suture) not buried (technique). The surgeon will utilize the randomized material and technique and the research team will utilize two surveys postoperatively to assess wound healing and appearance. Participants will fill out these surveys at each of their clinical follow-up visits.
224178346|NCT02532998|DRUG|AZD9977 oral suspension|AZD9977 oral suspension, single dose
224178347|NCT02532998|DRUG|AZD9977 placebo oral suspension|oral suspension, single dose
224178348|NCT02532998|DRUG|Fludrocortisone, tablets|Loading dose of 0.5 mg and maintenance doses of 0.1 mg every second hour up to a total dose of 1.0 mg per treatment period (may be modified to up to 1.3 mg based on emerging data)
224178349|NCT02532998|DRUG|Eplerenone, tablets|100 mg (2 x 50 mg tablets) single dose, may be modified based on emerging data (will not exceed 500 mg per treatment period)
224178350|NCT00004885|DRUG|FOLFIRI regimen|
224178351|NCT00004885|DRUG|fluorouracil|
224178352|NCT00004885|DRUG|irinotecan hydrochloride|
224306854|NCT00626392|DRUG|niacin extended-release (NER)|Tablets administered once daily; titrated to 2000 mg maximum dose during coadministration period
224306855|NCT00626392|DRUG|aspirin (ASA)|325 mg tablets administered once daily
224306856|NCT00626392|DRUG|aspirin placebo (ASA Pbo)|Tablets administered once daily
224178353|NCT00004885|DRUG|leucovorin calcium|
224178354|NCT01442142|BEHAVIORAL|CAAT: Appetite Awareness|"Participants in this Children's Appetite Awareness Training (CAAT) group learn to get in touch with the internal cues of hunger - aka the hunger meter - and practice skills to get back in touch with these internal cues of true hunger and fullness. Sessions occur once a week for 8 weeks."
224178355|NCT01442142|BEHAVIORAL|CRST: Volcravo|"Participants in this Cue Reactivity and Sensitivity Training (CRST) group learn about how external cues can affect when and how much we eat (aka volcravo - the craving volcano). Over 8 weekly sessions, they practice skills to ride out the cravings external cues can cause."
224178356|NCT01442142|BEHAVIORAL|Combined CAAT and CRST program|Participants meet weekly for 14 weeks to learn about both Children's Appetite Awareness Training (CAAT) and Cue Reactivity and Sensitivity Training (CRST) - i.e. appetite awareness and external cues that affect food intake.
224178357|NCT05379621|OTHER|COVID-19 infection|All persons of legal age or not resident in the Alpes-Maritimes between 03/01/2021 and 14/02/2021 with a COVID-19 diagnosis.
224178358|NCT03640962|OTHER|Evaluation|This cross-sectional study was conducted in 368 postmenopausal women aged between 40 and 65 years. This study was carried out in family health centers in Istanbul. Data were collected via face-to-face interviews by the researchers.
224306857|NCT03624686|OTHER|peripheral blood|draw peripheral blood
224306858|NCT00635063|DRUG|AD 923|
224178359|NCT02519777|DRUG|Placebo for maraviroc (MVC)|Administered orally as one 150 mg tablet BID OR two 300 mg tablet BID OR one 300 mg tablet BID depending upon background ARV regimen
224178360|NCT02519777|DRUG|Placebo for dolutegravir (DTG)|Administered orally as one 50 mg tablet BID OR one 50 mg tablet QD depending upon background ARV regimen
224178361|NCT02519777|DRUG|Dolutegravir (DTG)|Administered orally as one 50 mg tablet BID OR one 50 mg tablet QD depending upon background ARV regimen
224178362|NCT02519777|DRUG|Maraviroc (MVC)|Administered orally as one 150 mg tablet BID OR two 300 mg tablet BID OR one 300 mg tablet BID depending upon background ARV regimen
224178363|NCT03062631|DRUG|3,4-Diaminopyridine|The investigator will prescribe an initial dose of 3,4 diaminopyridine (DAP) by mouth based on the participant's weight. This initial dose may be modified later according to the participant's response to treatment.
224178364|NCT06330727|DIETARY_SUPPLEMENT|Coffee capsule|Take 12 coffee capsules containing 3.6 g instant black coffee powder per day (take 6 coffee capsules twice daily with breakfast and lunch).
224178365|NCT06330727|DIETARY_SUPPLEMENT|Corn starch capsule|Take 12 placebo capsules containing 3.6 g corn starch per day (take 6 placebo capsules twice daily with breakfast and lunch).
224178366|NCT06202677|DEVICE|Self-guided program on obsessive compulsive disorder|This is an 8-day program that provides psychoeducational on what obsessions and compulsions are, and how to identify them. Subsequently, through a series of content learning and daily exercises that increase in difficulty, participants are guided to conduct exposure exercises while tolerating distress and refraining from compulsions. Participants are also guided to set goals and type down the specific content of their intrusive thoughts and compulsive behaviours to keep track of their progress. Each session of the program is estimated to be approximately 5 minutes.
224178367|NCT06202677|DEVICE|Self-guided program on cooperation|This 8-day program on cooperation aims to improve participants' collaborative skills and interpersonal wellness through a series of content learning and practice exercises. The time and duration of this program is matched to the obsessive compulsive disorder program to ensure that participants spend a similar amount of time and effort across both the intervention and active control conditions.
224178368|NCT01804413|DRUG|Pegvisomant|Pegvisomant 1 mg/kg injection 3 days before the glucagon test.
224178369|NCT01804413|DRUG|Regular insulin|0.1-0.15 units/kg
224178370|NCT02413086|PROCEDURE|Early-stage amputation|Individuals with DFU were given early-stage amputation.
224178371|NCT02413086|PROCEDURE|Amputation|Individuals with DFU were given amputation.
224178372|NCT02413086|OTHER|External herbs chitosan|Wound was given external herbs chitosan after amputation.
224178373|NCT02413086|OTHER|Traditional gauze|Wound was given traditional gauze after amputation.
224306859|NCT02123810|OTHER|CPR|Simulated cardiac arrest on a manikin Chest Compression CPR for 6 minutes
223487781|NCT06236516|RADIATION|One fraction stereotactic body radiotherapy|Radiotherapy will consist of one-fraction SBRT using the Ethos linear accelerator and online adaptive treatment planning system.
224178374|NCT01430949|PROCEDURE|Catheter Ablation of Paroxysmal Atrial Fibrillation|Catheter ablation for the treatment of paroxysmal atrial fibrillation. A pulmonary vein isolation procedure will be performed using the OTW MAS and radiofrequency ablation.
224306860|NCT05546112|DEVICE|Transcutaneous Trigeminal Electrical Nerve Stimulation using YPS-401B|A device that improves insomnia symptoms by transcutaneously applying electrical stimulation including a pulse (10 kHz) burst waveform (10 Hz) to the forehead area to the trigeminal nerve
224306861|NCT05546112|DEVICE|Sham Stimulation using YPS-401B|A device that is attached in the same way as a real medical device, but actually applies a shum stimulus
224306862|NCT03062423|DRUG|Sofodelevier|1 tablet contains 400 mg sofosbuvir
224306863|NCT03062423|DRUG|Sovaldi (fist dose)|1 tablet contains 400 mg sofosbuvir
224306864|NCT03062423|DRUG|Sovaldi (second dose)|1 tablet contains 400 mg sofosbuvir
224306865|NCT05395455|PROCEDURE|Non-surgical periodontal treatment|Treatment of patients with periodontitis was performed scaling and root planing by using manual and ultrasonic instruments.
224306866|NCT00050323|DRUG|Allogeneic DCs and Autologous RCC Tumor Derived Cells|
223487782|NCT06236516|DEVICE|HyperSight|HyperSight is a novel on-board imaging platform equipped with rapid-acquisition high-quality CBCT imager capable of acquiring images sufficient for both simulation and treatment.
223487783|NCT06236516|DEVICE|Ethos|Ethos is a unique ring-gantry CT-guided linear accelerator notable for having a dedicated artificial intelligence treatment planning system to allow for online adaptive radiotherapy.
223487784|NCT06409156|PROCEDURE|Oblique Subcostal Transversus Abdominis Plane Block|With the OSTAP block, local anesthetic is injected into the fascial plane between the posterior rectus sheath and the transversus abdominis muscle beneath the subcostal margin.
223487785|NCT06409156|PROCEDURE|External Oblique Intercostal Fascial Plane block|With the EOIF block, local anesthetic targets the terminal part of the thoracoabdominal nerves pass behind the costal cartilage and continue anteriorly in the plane between the internal oblique and transversus abdominis muscle, before piercing the rectus abdominis sheath as anterior cutaneous branches supplying the skin of the midabdomen.
223487786|NCT05086315|DRUG|SAR443579|Powder for solution for infusion; by IV infusion
223487787|NCT05850494|DRUG|HFA MDI|"* Dose formulation: MDI~* Unit dose strength(s): Reference (propellant only)~* Dosage Level: 4 inhalations, single dose~* Route of administration: Oral inhalation~* Participants will receive treatment A in 1 or 2 possible sequences AB or BA"
223487788|NCT05850494|DRUG|HFO MDI|"* Dose formulation: MDI~* Unit dose strength(s): Experimental (propellant only)~* Dosage Level: 4 inhalations, single dose~* Route of administration: Oral inhalation~* Participants will receive treatment A in 1 or 2 possible sequences AB or BA"
223487789|NCT04325386|OTHER|ECHO Intervention|Project ECHO (Extension for Community Healthcare Outcomes) based intervention 26 CME educational sessions. The sessions will include: 1) active dissemination of knowledge and information by an expert followed by 2) clozapine case presentations and vignettes. 1.25 hour long. Also consultation line and ATHELAS device.
223487790|NCT04325386|OTHER|eTAU|Consultation Line and ATHELAS device only
223487791|NCT00452595|DRUG|DVS-233 SR (desvenlafaxine sustained release )|
224178375|NCT02393612|DRUG|DP-R202|Sarpogrelate HCl SR 300mg is administrated to patients with PAD for 12 weeks
224178376|NCT02393612|DRUG|Anplag tab|Anplag tab 100mg is administrated to patients with PAD for 12 weeks
223586980|NCT06329024|BEHAVIORAL|Myofascial Release Therapy|Myofascial release, also known as fascial release or fascial manipulation, is a physical therapy used to treat muscle and fascial tissue tension or pain. It involves applying appropriate pressure and stretching to release tight fascia and soft tissues, improving blood circulation, alleviating pain, and promoting rehabilitation. Myofascial release therapy is commonly used to treat muscle spasms, chronic pain, skeletal and joint issues, among others.
224178377|NCT00159653|DRUG|Xalacom|
224178378|NCT00159653|DRUG|Xalatan|
224178379|NCT00159653|DRUG|Timolol|
224178380|NCT03745391|DIAGNOSTIC_TEST|MULTIMODAL MAGNETIC RESONANCE (Multimodal MR)|After randomization, a MULTIMODAL MR will be performed to select treatment patient
224178381|NCT03745391|DIAGNOSTIC_TEST|MULTIMODAL COMPUTERIZED TOMOGRAPHY (Multimodal CT)|After randomization, a MULTIMODAL CT will be performed to select treatment patient
224178382|NCT04054219|DEVICE|Bone graft substitute|Evaluation of a device made of deproteinized bovine bone material as bone graft substitute in different indications requiring bone grafting procedures before implant placement
223487792|NCT06086275|DRUG|Buprenorphine|At each visit, the participant will receive a single dose of buprenorphine, either 0.15mg IV, 8mg PO, or 16mg PO. The order for the first dose administered will be fixed to the IV dose, and the subsequent doses will be randomized and counterbalanced to 8mg or 16mg PO.
224178383|NCT02404038|DRUG|Nur-Isterate|Nur-Isterate is a progestogen-only injectable contraceptive (POIC) is a long-acting, reversible contraceptive. Nur-Isterate is administered as an intramuscular injection administered bi-monthly (every 8 weeks). Each ampoule of Nur-Isterate contains 1ml/200mg of norethisterone enantate (17alpha-ethinyl-17beta-heptanoyloxy-4-estrene-3-one).
224178384|NCT02404038|DEVICE|Nuvaring|Nuvaring is the trade name for a combined hormonal contraceptive intravaginal ring, inserted once every 28 days, and removed after 21 days. The flexible plastic ring works in a similar way to the oral contraceptive pill to prevent pregnancy. It contains etonogestrel/ethinyl estradion and delivers 0.120mg/0.015mg per day.
223487793|NCT05622149|BEHAVIORAL|Diet Only|Food tracking based on macronutrient goals.
224178385|NCT02404038|DRUG|Triphasil|"Triphasil is a daily oral contraceptive: 21 active tablets followed by 7 inert tablets, starting initially on first day of menstrual cycle~Composition:~The six brown tablets of TRIPHASIL contain 30 µg ethinyl oestradiol and 50 µg levonorgestrel.~The five white tablets contain 40 µg ethinyl oestradiol and 75 µg levonorgestrel.~The ten yellow tablets contain 30 µg ethinyl oestradiol and 125 µg levonorgestrel.~The seven red tablets are inert"
224178386|NCT01711333|DRUG|Pletaal SR capsule|two capsules once a day of Pletaal SR 100mg Capsules
224178387|NCT05731362|OTHER|MDCIT Intervention|"The MidWest Multidisciplinary Community Intervention Teams (MDCIT) comprise of specialist, healthcare teams that provide a rapid and integrated response to a patient with an acute episode of illness who requires enhanced services/acute intervention for a defined short period of time. This is provided in the patient's home after an acute hospital admission, thereby facilitating early discharge. The MDCIT intervention is composed of occupational therapy, physiotherapy, and healthcare assistants, with nursing support as required.~The MDCIT therapists aim to make their first visit to patients within 24-48 hours of hospital discharge. Patients receive two-three visits per week, over a period of two to four weeks dependant on the patient's rehabilitation needs. Upon discharge from the MDCIT service, patients can be referred to community services as indicated by therapists."
223586981|NCT01761812|OTHER|MRI with gadofosveset and MR elastography|
223586982|NCT00637572|DRUG|Megestrol acetate oral suspension nanocrystal dispersion 115 mg/mL|Megestrol acetate oral suspension nanocrystal dispersion 115 mg/mL administered as 575 mg once per day (5 mL dose)
223586983|NCT00637572|DRUG|Megestrol acetate oral suspension 40 mg/mL|Megestrol acetate oral suspension 40 mg/mL administered as 800 mg once per day (20 mL dose)
224178388|NCT02005679|BEHAVIORAL|application of the mini-mental state test|
224178389|NCT00400868|BEHAVIORAL|psycho-educational Joint protection education|individualized psycho-educational joint protection education, 4-times over 3 weeks; one additional booster session 2 months later
224178390|NCT01513694|PROCEDURE|Instrumented posterolateral arthrodesis|"Cell suspension of mesenchymal stem cells (MSCs) obtained from bone marrow aspirate from the patient and expanded in vitro in a specific medium enriched with platelet lysate without addition of animal products.~They used a minimum dose of 0.5 x106 CSM / kg and a maximum of 1, 5x106 CSM / kg of patient weight.~Dosage Form: Suspension cell support hydroxyapatite and calcium phosphate Route of administration: placement in the fusion bed during surgery."
224178391|NCT01428479|DRUG|GR121167 Solution|GR121167 solution will be administered intravenously. For 100 mg subject will receive 10 milliliter (mL) of solution, 30 mL for 300 mg and 60 mL for 600 mg
224178392|NCT01428479|DRUG|Placebo|Placebo solution will be administered intravenously.
224178393|NCT03243981|DEVICE|Sciton SkinTyte (800-1800 nm) with Broadband Light Technology|This device has been used in the clinical setting to reduce cheek and submental laxity. SkinTyte delivers sequentially pulsed light (800-1200 nm, with a filter enabling focus on 590 nm) and broadband light (which can be turned on or off).
224178394|NCT00329992|BEHAVIORAL|Brief Eclectic Psychotherapy for PTSD|16 weekly sessions (50min) of Brief Eclectic Psychotherapy for PTSD
223487794|NCT05622149|BEHAVIORAL|Training Only|Subjects completed 16 weeks of supervised resistance training
223487795|NCT05622149|BEHAVIORAL|Diet plus Training|Food tracking plus resistance training.
223487796|NCT05998642|DRUG|Methotrexate|3.5mg/m2 IV
223586984|NCT00786539|DEVICE|Diffuse Optical Spectroscopy|mitochondria
223487797|NCT05998642|DRUG|Rituximab (where available)|375mg/m2 / 1400mg IV or SC
223487798|NCT05998642|DRUG|Ibrutinib|Dose and schedule assigned at enrollment
223487799|NCT04416269|DRUG|Oral Anti-diabetes Drugs alone|OADs will be continued at same outpatient dosage unless contraindicated. Participants will be switched to the preferred drug within the category of medication they take at home. Dose adjustment for OADs will be based on clinical/laboratory status. The OAD will be held if the participant is placed on strict nil per os (NPO) and is unable to take oral medications after enrollment.
223487800|NCT04416269|DRUG|Basal bolus insulin|Basal insulin with glargine or detemir will be used as per the hospital formulary.
224178395|NCT02429076|DRUG|IV methylphenidate|IV methylphenidate will be administered to induce emergence from general anesthesia.
224178396|NCT02429076|DRUG|Placebo|normal saline
224178397|NCT02429076|DRUG|Sevoflurane|Inhaled anesthetic
224178398|NCT02429076|DRUG|Propofol|IV anesthetic
224178399|NCT00242814|DRUG|Micardis|
224178400|NCT00242814|DRUG|Amlodipine|
224178401|NCT00242814|PROCEDURE|Abdominal biopsy|
223487801|NCT04416269|DRUG|Supplemental insulin|Supplemental (correction) lispro or aspart insulin following the supplemental/sliding scale standard of care protocol for BG \>140 mg/dl.
223487802|NCT04416269|DEVICE|Continuous glucose monitoring (CGM)|"A subset of participants (50 per study arm) will be randomized to take part in an optional study where a CGM device will be placed for the duration of the study. CGM reports will be reviewed at the end of the study to assess parameters of glycemic control and hypoglycemia, and not used for insulin dose adjustment.~The Dexcom CGM is a small sensor that inserts just under the skin to continuously monitor glucose levels. Results are transmitted to the wearer's smartphone every five minutes."
223745340|NCT06914258|COMBINATION_PRODUCT|Scapular Mobilization Technique|"Group B will receive the same baseline physiotherapy treatment as in group A along with the Inhibition compression therapy which is a (MET). MET was performed on shoulder. Patient position: supine lying position. Following are the steps involved in application of MET: (1) stretch the muscle to a felt 'barrier' or to their tolerance of stretching (2) create a voluntary contraction that is isometric of the muscle being stretched while being resisted with equal and regulated counterforce by the physiotherapist for 7-10 seconds. (3) a stretch is held for a set amount of time after the muscle relaxes (4) the physiotherapist takes up the slack once the muscle relaxes Duration of treatment was approximately 15-20 minutes."
224178402|NCT02879864|DEVICE|light therapy|The light therapy, 6 month's program, is occurring at patient's home the day after device's reception and during at least 7 days before chemotherapy's beginning. The ambulatory light program is daily exposure to a high-intensity light (10,000 lux) in the morning, at a time adapted to the patient according to his chronotype for 30 minutes. The light source should be placed at eye level (distance of about 40 cm). A set of questionnaires evaluation of fatigue and quality of life will be given to the patient at baseline and at weeks 12 and 24, which will be completed the same day or the day before, and / or before any chemotherapy. These questionnaires will be also completed during the follow-up visit 1 month after the last visit (week 28).
224178403|NCT02879864|DEVICE|Usual care|The patient will be taken care of according to local chemotherapy in routine care and the recommendations. A set of questionnaires evaluation of fatigue and quality of life will be given to the patient at baseline and at weeks 12 and 24. They will complete the same day or the day before, and / or chemotherapy before. A follow-up visit will be performed 1 month after the last visit (week 28). A set of questionnaires evaluation of fatigue and quality of life will be given to the patient and will complete the same day or the day before.
224178404|NCT05472506|DRUG|IK-175 + nivolumab|IK-175 + nivolumab
224178405|NCT04458311|DRUG|Abiraterone Acetate|Supplied as 125 mg tablets
224178406|NCT04458311|DRUG|Tildrakizumab|Tildrakizumab will be supplied in single-use 100 mg/mL glass vials intended for IV infusion.
224178407|NCT01332006|PROCEDURE|Intrabone injection|All adults patients with hematological malignancies, lacking a HLA matched donor fulfilling the inclusion criteria, will undergo to intrabone HSC infusion of CB.
224178408|NCT01332006|BIOLOGICAL|Intra-bone cord blood hematopoietic stem cell transplantation|
224178409|NCT01332006|BIOLOGICAL|Intra-bone cord blood hematopoietic stem cell transplantation|Intra-bone injection of CB hematopoietic SCs after conditioning regimen
224178410|NCT00372944|DRUG|AZD6244|oral capsule
224178411|NCT00372944|DRUG|capecitabine|oral tablet
224178412|NCT01741285|DRUG|Beclomethasone (QVAR)|Small particle treatment
224178413|NCT01741285|DRUG|Beclomethasone (Clenil)|Course particle beclomethasone
223487803|NCT00392041|DRUG|Eszopiclone|3mg qpm for 12 weeks
223487804|NCT00392041|DRUG|placebo|1 pill qpm for 12 weeks
223487805|NCT06019754|PROCEDURE|one point combined Lumbar and sacral plexus block|performing an ultrasound-guided one-point combined Lumbar and sacral plexus block using a one-point puncture. Block success will be assessed using the perfusion index (PI) before and after performing the block
223487806|NCT05211700|OTHER|This is an observational study, there is no intervention in this study.|There is no intervention in this study
223487807|NCT04194840|OTHER|physical therapy consult|Physical therapy consult to assess physical functioning on a separate office visit prior to attending the Transplant Wellness Clinic. Full evaluation that incorporates several tools to measure the risk of falling and to assess mobility and strength
223487808|NCT04194840|OTHER|Cognitive Assessment|Montreal cognitive assessment (MoCA) and the Blessed Orientation-Memory-Concentration Test (BOMC)
223487809|NCT04194840|OTHER|Cancer Aging Research Group (CARG) assessment|CARG assessment - utilized to capture information about a participant's medical history as well as functional, cognitive, and psychosocial status
223487810|NCT04194840|OTHER|Medication Review|Medication Review via Beers Assessment
223487811|NCT04194840|OTHER|Nutrition assessment|Nutrition assessment Via Mini Nutrition Assessment (MNA)
223487812|NCT04194840|OTHER|Laboratory studies|Laboratory studies including urine toxicology screen, C-reactive protein, albumin, pre-albumin, vitamin D
223487813|NCT04194840|OTHER|Patient satisfaction questionnaire|Patient satisfaction questionnaire
223487814|NCT04194840|OTHER|Physician Questionnaire|"Physician Questionnaire:~Questionnaire to learn about physician satisfaction with information received from reports and participant questionnaires."
223487815|NCT04194840|OTHER|Patient follow-up questionnaire|"Patient follow-up questionnaire:~Questionnaire to learn more about participant opinions concerning the clinic and the quality of care received during visits with specialists"
223487816|NCT03542760|DRUG|Methylene Blue|Administration of methylene blue as per the treating physician's diagnosis and the acute care facility's standard of care
223487817|NCT04800627|BIOLOGICAL|Pembrolizumab|Given IV
223487818|NCT04800627|DRUG|Pevonedistat|Given IV
223487819|NCT02084797|DRUG|V2R (Vasopressin 2 receptor)|All ten subjects were used as their own controls in this double-blind, randomized controlled trial assessing the effect of the V2R on sweat sodium concentration via use of a V2R blocker (antagonist), stimulator (agonist), against a placebo (drug naive state).
224178414|NCT01741285|DRUG|Fluticasone|Course particle treatment
224178415|NCT04075955|DRUG|Zyprexa® (OLANZapine 5MG)|"Olanzapine 5mg orally at bedtime for 4 days (starting the day before the chemotherapy)~Ondansetron 16mg orally pre-chemotherapy on day 1~Dexamethasone 12mg orally pre-chemotherapy on day 1~Dexamethasone 8mg orally twice a day for 6 doses (starting on the morning of day 2)"
224178416|NCT04075955|DRUG|Emend® (Aprepitant)|"Aprepitant 125mg orally pre-chemotherapy on day 1, then 80mg orally once daily on days 2 and 3~Ondansetron 16mg orally pre-chemotherapy on day 1~Dexamethasone 12mg orally pre-chemotherapy on day 1~Dexamethasone 8mg orally once daily for 3 doses (starting on the morning of day 2)"
224178417|NCT01943136|DRUG|papaya 1% extract ointment|
224178418|NCT01943136|DRUG|mupirocin 2% ointment|
224178419|NCT04310267|DEVICE|Petit typeface mask|(Intraoral) Hyrax expander for maxilary sutures disarticulation through expansion, (Extraoral) Face mask for generating maxillary protraction forces and head gear face-bow to act as a connector between both intra and extra oral parts.
224178420|NCT04779476|OTHER|Socket Dressing|Following dental extraction immediately, the socket will be dressed with one of the materials tested
224178421|NCT00271076|PROCEDURE|IVUS|
224178422|NCT00271076|DEVICE|CAS|
224178423|NCT00271076|PROCEDURE|CEA|
224178424|NCT06147544|DRUG|PB-718|Administered subcutaneously once a week
224178425|NCT06147544|DRUG|Placebo|Administered subcutaneously once a week
224178426|NCT03042728|BEHAVIORAL|Dog Interaction|A therapy dog will visit the patients.
223487820|NCT04544917|BEHAVIORAL|SmartManage for HIV+ cancer survivors|Ten weekly therapist delivered group sessions delivered via web conference. Sessions focus on cognitive behavioral stress management, psychoeducation, and management strategies for dual diagnosis of HIV and cancer. Participants will have access to the SmartManage web platform which has all intervention material, resources, and exercises.
224178427|NCT03042728|BEHAVIORAL|Human Interaction|A human will visit the patients.
224306867|NCT02299024|BEHAVIORAL|Additional Opioid Information|Patients receiving this intervention are given additional information about the opioid pain medication that they are receiving in the form of a one page handout. The hand out was written in a health-literacy appropriate manner. A research assistant read the handout to them out loud, and they were given a copy to take home with them.
224306868|NCT05268835|DRUG|Dalacin C|The objective of the intervention is to determine the effect of antibiotic prophylaxis with three different doses of clindamycin on preventing infection and other complications after surgical extraction of impacted mandibular third molars
223487821|NCT04544917|BEHAVIORAL|Educational Control|Participants in the control condition will view ten videos over ten weeks, consisting of informational and educational material relevant to cancer and HIV.
224178428|NCT02773511|PROCEDURE|Surgical treatment|Closed reduction and Kirschner wire fixation
224306869|NCT01211938|RADIATION|single-fraction radiotherapy with concomitant 5FU and Hydrea|single-fraction radiotherapy with concomitant 5FU and Hydrea
224306870|NCT01211938|RADIATION|hyperfractionated radiotherapy with concomitant Cetuximab|hyperfractionated radiotherapy with concomitant Cetuximab
224306871|NCT00592618|DRUG|Oral N-Acetylcysteine 1200 mg x 2/day for 4 weeks|
223487822|NCT00646516|DRUG|budesonide/formoterol (Symbicort)|
223586985|NCT05257369|DEVICE|Blue-Green LED photoherapy|Continuous phototherapy for 24 h, for newborns placed incubators or radiant warmers will interrupted only for feeding and nursing for 20 - 30 min every three hours.
223586986|NCT00896649|OTHER|questionnaire administration|Questionnaire regarding patient satisfaction with mammogram experience and with positron emission mammography experience.
223586987|NCT00896649|PROCEDURE|digital mammography|standard screening mammogram
224178429|NCT01878786|DRUG|Everolimus|One of the immunosuppressants currently being evaluated to replace CNIs in patients with CNI nephropathy is the mammalian Target of Rapamycin (mTOR) inhibitor, Sirolimus. Everolimus is a derivative of Sirolimus and belongs to this class of immunosuppressants, therefore, both drugs have similar side effect profile. The half-life of Everolimus is almost half of Sirolimus (Everolimus 30 hours vs Sirolimus 62 hours), which makes its dose adjustment easier although it would require more frequent dosing. In clinical trials, Everolimus has demonstrated its potential role as a safe alternative in minimizing and/or eliminating CNI such as Cyclosporin A and Tacrolimus .
223586988|NCT00896649|PROCEDURE|positron emission mammography|one-time positron emission mammography to compare recall rates with that of standard mammogram
223586989|NCT00383396|DRUG|Topical Cyclosporine|
223586990|NCT02495493|DRUG|Induction DCS chemotherapy|docetaxel /cisplatin/S-1 followed by chemoradiotherapy (S-1/cisplatin)
224178430|NCT01878786|DRUG|Tacrolimus|One of the immunosuppressants currently being evaluated to replace CNIs in patients with CNI nephropathy is the mammalian Target of Rapamycin (mTOR) inhibitor, Sirolimus. Everolimus is a derivative of Sirolimus and belongs to this class of immunosuppressants, therefore, both drugs have similar side effect profile. The half-life of Everolimus is almost half of Sirolimus (Everolimus 30 hours vs Sirolimus 62 hours), which makes its dose adjustment easier although it would require more frequent dosing. In clinical trials, Everolimus has demonstrated its potential role as a safe alternative in minimizing and/or eliminating CNI such as Cyclosporin A and Tacrolimus.
224178431|NCT01878786|DRUG|Mycophenolate mofetil (MMF/MPA)|Control Drug
224178432|NCT01683058|DRUG|Aripiprazole IM Depot|Aripiprazole IM Depot 400 mg or 300 mg
224178433|NCT01607996|PROCEDURE|Epidural anesthesia|Epidural will be performed using carbostesin (0.1%), fentanyl (2 microg/ml) administered continuously at a rate of 6 to 15 ml/hour
224178434|NCT01607996|DRUG|Patient controlled intravenous analgesia|Fentanyl 10 microg/ml at continuous flow of 10 to 20 microg/hour
224178435|NCT04062240|DEVICE|BIS sensor|BIS sensors will be labeled L and R. The degree of variability between the concurrent use of the sensors will be assessed .
224178436|NCT04212611|DRUG|INFRA ORBITAL BLOCK|Bilateral infra orbital blocks is performed using 2-3 mL of 0.375% levobupivacaine (group L) or ropivacaine (group R).
224178437|NCT01057394|DEVICE|Endoscopically guided PVI Ablation|Endoscopically Guided Ablation using the EAS-AC
224178438|NCT01057394|DEVICE|RF PVI Ablation|Radiofrequency ablation
224306872|NCT01782300|BIOLOGICAL|TV003 Vaccine|TV003 will contain an admixture of the following monovalent dengue vaccines: 10\^3 PFU of rDEN1Δ30, 10\^3 PFU of rDEN2/4Δ30(ME), 10\^3 PFU of rDEN3Δ30/31-7164, and 10\^3 PFU of rDEN4Δ30. TV003 vaccine will be administered by subcutaneous injection in participants' deltoid region of the upper arm.
223745341|NCT06913920|DEVICE|Continuous Passive Motion (CPM)|"Materials: A CPM device configured for wrist flexion-extension with an adjustable range of motion set between 0° and 30°.~Procedure:~The participant's wrist is gently secured in the device. The CPM device is programmed to deliver 20 minutes of continuous, passive motion through the set range.~Device settings (e.g., speed) may be modified if the participant reports pain \>4/10 on the NPRS."
224178439|NCT01027065|DRUG|CYT107+GenHevac+entecavir or tenofovir|4 patients per arm for each dose level. 3 patients receiving experimental treatment (CYT107 and vaccine) in addition to current antiviral treatment and 1 control patient only the current antiviral treatment
224178440|NCT01027065|DRUG|CYT107+ entecavir or tenofovir|4 patients per arm for each dose level. 3 patients receiving experimental treatment (CYT107) in addition to current antiviral treatment and 1 control patient only the current antiviral treatment
224178441|NCT04581291|OTHER|Moderate Intensity Aerobic Exercises|Participants in the exercise group performed a two weeks aerobic exercise program. The exercise program consisted of walking/running on a treadmill or bicycling on a stationary bicycle. Each session is composed of five-minute warm-up slow walking or bicycling. Then the main intervention which composed of thirty-minutes of moderate-intensity aerobic exercises (walking/running or bicycling). Lastly, a five-minute of cool-down exercises (walking/running or bicycling). The exercise intensity was 60-75% of the predicted MHR (calculated as MHR=210-age).
224178442|NCT03257306|PROCEDURE|ureteral double-J stent removal using magnet|Double-J ureteric stent removed using magnet
224178443|NCT03257306|PROCEDURE|ureteral double-J stent removal using cystoscopy|Double-J ureteric stent removed using cystoscopy
224178444|NCT02416466|BIOLOGICAL|anti-CEA CAR-T cells|Gene modified patient T cells.
224178445|NCT02416466|DEVICE|Sir-Spheres|SIR-Spheres microspheres are a medical device used in Selective Internal Radiation Therapy (SIRT) for liver tumors. SIR-Spheres microspheres are a permanent implant and for single use only. The biocompatible resin microspheres containing yttrium-90 have a median diameter of 32.5 microns (range between 20 and 60 microns).
224178446|NCT06378164|BEHAVIORAL|Exercise|For the combined step training group, the participants will receive training on both volitional and reactive stepping. The training will last for 1 hours per session, 2 session per week for 4 weeks.
224178447|NCT06378164|BEHAVIORAL|Active Control|An active control group will be used to minimise the placebo and history effect. The group will also receive a 4-week programme with the frequency and duration of the training and the instructor-to-participant ratio that match the combined step training group. During training, they will perform exercises not specific to reducing fall risk.
224306873|NCT01782300|BIOLOGICAL|Placebo Vaccine|Placebo vaccine will be administered by subcutaneous injection in participants' deltoid region of the upper arm.
224306874|NCT01801631|OTHER|Home visits|In addition to usual care the patients will receive three home visits from a trained diabetes nurse. The first visit (65 minutes) is within three weeks after discharge from the hospital; the second visit (45 minutes) is two weeks later and the third visit (45 minutes) is two months after the second home visit.
224306875|NCT01801631|OTHER|Consultation by telephone|In addition to usual care patients will receive a consultation by telephone within three weeks after discharge to offer them personal attention. In this consultation they will get the opportunity to discuss in ten to fifteen minutes how they feel in the period after discharge.
223487823|NCT05984030|OTHER|PrEP Navigation Services|Trained professional PrEP navigators will connect with intervention arm participants following study onboarding. Primary navigator responsibilities include helping participants engage in PrEP care, assisting with completing necessary paperwork for insurance, referral to PrEP care, and application for drug assistance programs, as needed. Navigation services will be available to participants for the first 6 months of participation (active intervention period). Navigation services are tailored to the individual needs of each intervention arm participant
223487824|NCT05984030|OTHER|Telehealth PrEP Services Referral|PrEP Navigators can link interested intervention arm participants to telehealth PrEP services via self-referral. The study facilitates referral for intervention arm participants to pre-existing telehealth PrEP services. The telehealth PrEP services participants receive are not provided, financed, or staffed by the study. Participants will receive telehealth PrEP services via the technology platform or service that the provider typically employs. PrEP clinical eligibility, visit frequency, monitoring labs, and all other PrEP management will be at the discretion of the established PrEP provider. PrEP navigators can assist with appointment scheduling, reminders, and other provider-access issues, as requested, for the first 6 months of study participation.
223487825|NCT05984030|BEHAVIORAL|HealthMpowerment Digital Health Intervention - Enhanced|The Enhanced version of the HealthMpowerment Digital Health Intervention includes all features from the Basic version, plus the following additional features: Interactive skill-building health activities; social support newsfeed/group chat; Ask the Expert anonymous health question and answer; Medication Tracker; Health Behavior Tracker; Gamification features for participant engagement.
223487826|NCT05984030|BEHAVIORAL|HealthMpowerment Digital Health Intervention - Basic|The Control Arm version of the HealthMpowerment Digital Health Intervention includes: Study Timeline and Calendar, publicly-available PrEP locator feature, Dried Blood Spot self-collection kit ordering, Educational Health Resource Center.
223487827|NCT01879267|BEHAVIORAL|Exercise training|6 months of exercise training (2 times 30 min per week) starting one week after a 6-months natural course observation period
223487828|NCT00695019|DRUG|interferon-alpha lozenges|500 IU lozenges of natural human interferon-alpha for oral dissolution given once or three times per day for 24 weeks
223487829|NCT00695019|DRUG|placebo lozenges|200 mg matching placebo lozenges
223745342|NCT06913920|DEVICE|Intermittent Pneumatic Compression (IPC)|"Materials: An IPC sleeve designed for the forearm-to-hand region with a baseline compression setting of approximately 30 mmHg.~Procedure:~After CPM treatment, the IPC device is applied to the affected limb. The sleeve provides 15 minutes of intermittent compression with programmed intervals of inflation and deflation.~Compression levels may be adjusted based on participant comfort and pain ratings."
224178448|NCT04312737|DEVICE|Self-Collecting Devices|FLOQSwab (Copan) Colli-Pee (Novosanis)
224178449|NCT04312737|DIAGNOSTIC_TEST|In Vitro Diagnostic Assays|Papilloplex (GeneFirst) HPV Oncopredict DNA (Hiantis) HPV Oncopredict RNA (GeneFirst)
224178450|NCT01195636|DRUG|XPF-002|Twice daily application of XPF-002 ointment which contains 8% of the XPF-002 active ingredient
224178451|NCT01195636|DRUG|Placebo|Twice daily application of Placebo ointment
223745343|NCT06913920|BEHAVIORAL|Standard Therapy Program|"Procedures:~Active/active-assisted wrist/forearm range of motion exercises led by a certified hand/physical therapist.~Progressive grip-strengthening exercises using resistance bands or putty. Manual edema management techniques, including gentle massage and manual lymphatic drainage, as well as scar mobilization if needed."
223745344|NCT06913868|BEHAVIORAL|Consensus-Based Physiotherapy Program|Physiotherapy for fibromyalgia (Baroni et al., 2023 Delphi consensus). Includes pain neuroscience education (PNE), tailored aerobic, strengthening, and sensorimotor exercises (graded exposure), and self-management strategies. 8-week program: 1-2 sessions/week (60 min) + home exercise (20 min, 3x/week). Therapist training and fidelity monitoring.Pain Neuroscience Education (PNE): Approximately 20 minutes per session, focusing on explaining the neurobiology of pain in fibromyalgia, emphasizing central sensitization mechanisms, and reconceptualizing pain as an output of the brain rather than solely a marker of tissue damage. PNE aims to reduce threat value associated with pain and improve understanding of pain fluctuations.
224178452|NCT03163290|OTHER|Posterolateral Hip Complex Exercises|The treatment protocol was composed of: Heating, lower limb stretching, strengthening the quadriceps e hip muscles. The following exercises were included: abduction exercise, Clam exercise and external rotation exercise
224178453|NCT03163290|OTHER|Anteromedial Hip Complex Exercises|The treatment protocol was composed of: Heating, lower limb stretching, strengthening the quadriceps e hip muscles. The following exercises were included: hip adduction exercise, adduction with a ring between the thighs and internal rotation exercise.
224178454|NCT00544154|DRUG|CDP870|
224178455|NCT05779410|DIETARY_SUPPLEMENT|Vitamin D|Participants received 5,000 IU of vitamin D orally twice daily for 4 weeks
224178456|NCT05779410|DIETARY_SUPPLEMENT|Medium-chain triglycerides|Participants received the same amount of placebo matching vitamin D orally twice daily for 4 weeks
224178457|NCT01156246|DRUG|Dapagliflozin/Metformin|oral fixed dose combination tablet 5 mg Dapagliflozin / 1000 mg Metformin given on day 1 at visit 2 and 3.
224178458|NCT05804344|DEVICE|Anodal speech motor tDCS|tDCS montage set for Anode: C5; Cathode: Fp2
224306876|NCT04717765|DEVICE|Preventive, LLL Phototherapy and topical Vit E|Interventions will be carried out for patients who have already passed or will undergo anti-neoplastic chemotherapy or radiation therapy.
224306877|NCT04717765|DEVICE|Curative, LLL Phototherapy and topical Vit E|Interventions will be carried out for patients who have already passed or will undergo anti-neoplastic chemotherapy or radiation therapy.
223487830|NCT03116230|DEVICE|Cutaneous Stimulation|A non-invasive external device that will be placed on the leg of the subject. The device consists of a sensing module to determine specific points in the gait cycle, a processor to analyze signal from the sensor, and a stimulus module to provide feedback to the subject.
223487831|NCT03116230|DEVICE|Knee Sleeve|Commercially-available knee sleeve.
223487832|NCT06197204|OTHER|Blood sampling|"* at first visit in the reference center~* at each follow-up visit ( once a year)~* before and after specific treatment~* in case of flare"
223487833|NCT06197204|OTHER|Biopsy|In case of flare
223487834|NCT06197204|OTHER|Blood sampling|Once at inclusion visit
223487835|NCT02323256|OTHER|Auditory steady-state response ASSR|comparison of ASSR amplitudes in response to amplitude-modulated sounds delivered at different intensities
223487836|NCT02323256|OTHER|Speech-ABR|
223487837|NCT02323256|OTHER|Acoustic Change Complex ACC|comparison of ACC complex in response to changes within speech stimulation
223487838|NCT02323256|OTHER|P1-N1-P2 complex and Mismatch Negativity MMN|comparison of amplitudes and latencies of P1-N1-P2 complex and MMN generated in response to the detection of changes in a series of auditory stimulation
224178459|NCT05804344|DEVICE|Cathodal speech motor tDCS|tDCS montage set for Anode: Fp2; Cathode: C5
224178460|NCT05804344|DEVICE|Anodal IFG tDCS|tDCS montage set for Anode: F3; Cathode: Fp2
224178461|NCT05804344|DEVICE|Cathodal IFG tDCS|tDCS montage set for Anode: Fp2; Cathode: F3
224178462|NCT05804344|DEVICE|Sham tDCS|tDCS device set in Sham mode
224178463|NCT00034606|DRUG|Pemetrexed (Alimta) in combination with gemcitabine (Gemzar)|
224178464|NCT03500419|DEVICE|RestoreX|PTT - Penile traction therapy in the straight position.
224178465|NCT03500419|OTHER|No treatment|Control group. No treatment will be given for the 6 months post-prostatectomy
223487839|NCT00207428|DRUG|Carbamazepine|
223487840|NCT03220893|PROCEDURE|Digital Tomosynthesis Mammography|Undergo DBT
223487841|NCT03220893|RADIATION|Scintimammography|Undergo MBI
223487842|NCT00340483|BEHAVIORAL|Smoking cessation|
223487843|NCT05580120|BEHAVIORAL|Online-supervised exercise group|Participants in the online-supervised exercise group were provided with an online-supervised exercise program by using the video conferencing method three times a week for 6 weeks on the Zoom application. The exercise program was carried out synchronously
223487844|NCT05580120|BEHAVIORAL|Unsupervised-exercise training group|The unsupervised-exercise training group was informed about how to do the same exercises by another researcher, a nurse academician, on the online platform by using the lecturing method. Each training intervention took approximately 30 minutes.
223487845|NCT01796522|DRUG|progesterone 200 mg / day vaginally|
223487846|NCT01796522|DRUG|nifedipine (60 mg / day orally)|
223487847|NCT06375993|DRUG|ADI-001|Anti-CD20 CAR-T
223487848|NCT06375993|DRUG|Fludarabine|Chemotherapy for Lymphodepletion
223487849|NCT06375993|DRUG|Cyclophosphamide|Chemotherapy for Lymphodepletion
223487850|NCT04463706|OTHER|Predictors adverse evolution|Predictors adverse evolution in all hospital participant admitted patients
223487851|NCT04463706|OTHER|Predictors of health care provide|Predictors of death, unequity, variability in process of care, cost in all COVID positive patients form the Basque Country
223487852|NCT05998447|DRUG|GEN-001|The capsules taken by mouth. Each capsule will contain ≥ 3x10\^11 colony-forming units (CFU)
224306878|NCT04717765|DEVICE|Preventive, LLL Phototherapy and LPRF|Interventions will be carried out for patients who have already passed or will undergo anti-neoplastic chemotherapy or radiation therapy.
224306879|NCT04717765|DEVICE|Curative, LLL Phototherapy and LPRF|Interventions will be carried out for patients who have already passed or will undergo anti-neoplastic chemotherapy or radiation therapy.
223586991|NCT04726059|DEVICE|Transcutaneous Spinal Cord Stimulation|Therapeutic TSCS will be delivered during ABT using a non-invasive central nervous system stimulator (TESCoN, SpineX Inc., CA, USA). Stimulation will involve charge balanced monophasic rectangular waveforms with 1.0-ms pulses, administered at 30 Hz, with a carrier frequency of 10 kHz and a current ranging from 10 to 130 mA.
224178466|NCT04335227|OTHER|Structured yoga therapy program|Structured yoga therapy prepared according to traditional yoga scriptures of Patanjali yoga sutras will be administered to 32 females with PCOS. The structured yoga therapy which includes, Surya Namaskara (Sun Salutation) and asanas performed in four positions, standing, sitting, supine and prone for total duration of 60 minutes. In addition to this, they will be asked to undergo nutritional management uniquely prepared by dietitian
224178467|NCT04335227|OTHER|Aerobic exercise training program|Thirty two females with PCOS in aerobic exercise (AE) group will be subjected to aerobic training of moderate intensity for 30-60 minutes six days per week for 12 weeks, in the light of guidelines framed by American College of Sports Medicine (ACSM). Aerobic exercise volume for each female recruited will be set at greater than 500 and up to 1000 MET-min/week, which will be approximately equal to 1000 kcal/week. They will be made sure that they exercise for minimum duration of 150 min/week and thereby covering 5400 to 7900 steps/day in pedometer readings. In addition to this, they will be asked to undergo nutritional management uniquely prepared by dietitian
224178468|NCT04335227|OTHER|Combined yoga and aerobic training program|Thirty two females with PCOS in combined yoga therapy and aerobic exercise (cYTAE) group will be subjected to three days of structured yoga therapy and three days of aerobic training of vigorous intensity. In addition to this, they will be asked to undergo nutritional management uniquely prepared by dietitian
223487853|NCT05998447|DRUG|Pembrolizumab|200 mg given by intravenous (IV) infusion once every 3 weeks
223487854|NCT05998447|DRUG|mFOLFOX|mFOLFOX given by intravenous (IV) once every 2 weeks for only cohort 3
223487855|NCT03197129|OTHER|sensory adapted waiting room|The SADE waiting room: a small waiting room (2.5mx2.5m) inside the clinic with 6 seats. A lighting column that children can touch and climb on. Auditory stimuli include rhythmic music, which is heard via loudspeakers.
223487856|NCT05145114|PROCEDURE|THERAPEUTIC POSITIONS|Therapeutic positioning includes placing infants in prone (prone), supine, side (lateral) decubitus, using restraint devices to provide support, reassurance and physiological stability.
223487857|NCT04226677|OTHER|aerobic exercise|Treadmill training is include warming, cooling and training phase according to rating of perceived exertion for participants.
223487858|NCT04226677|OTHER|Video based exercise|Exergame training include virtual reality games by xbox kinect.
223487859|NCT04226677|OTHER|Control group|first and last evaluations will be made
223487860|NCT02943759|DRUG|Neem leaf extract|A natural irrigant solution act as anti-inflammatory and anti bacterial
223487861|NCT02943759|DRUG|Chlorhexidine gluconate|2%chlorhexidine gluconate , anti bacterial root canal irrigant solution
223487862|NCT01564407|DRUG|ICX-RHY-013|"Drug Dosing for Cohorts as follows:~Cohorts (N=4)~Safety Cohort 1:~1. Empty control no injection~2. Vehicle only (0.5 ml of HypoThermosol solution)~3. 5 million cells / cm² , single administration at Day 0~4. 5 million cells/ cm² , single administration at week 4~5. 5 million cells/cm² , single administration at Day 0 , repeat administration of this dose @ week 4~At day 0, the subject will receive a total of 3 different injections and at week 4 the subject will receive a total of 2 different injections.~Cohort 2: 2.5 million cells/ cm2, single administration Cohort 3: 5 million cells /cm2, single administration Cohort 4: 2.5 million cells/ cm2, repeat dose administration @ 4 weeks Cohort 5: 5million cells / cm2 repeat dose administration @ 4 weeks"
223586992|NCT04726059|DEVICE|SHAM (low-intensity) Transcutaneous Spinal Cord Stimulation|Ineffective stimulation will be administered at the same anatomical location as therapeutic TSCS.
223586993|NCT04726059|DEVICE|Activity-Based Therapy|"Using BWSTT, all participants (both arms) will train 3 times per week for 12 weeks with a target to reach 45 minutes of gait training in each session.~For gait training, the level of body weight support and speed of walking will be adjusted to allow the person to bear as much weight as possible while maintaining proper stance limb kinematics."
223586994|NCT06387641|BEHAVIORAL|Life review|Life review is a process that involves a thorough examination and reflection on one's past experiences, memories, and life events. This process often involves the identification and examination of significant themes, patterns, and lessons learned throughout one's lifespan. Through life review, individuals can gain a deeper understanding of their own identity, values, and beliefs, and how these have shaped their present circumstances and future outlooks. It can serve as a tool for personal growth, self-discovery, and the promotion of a sense of meaning and purpose in life.
223745345|NCT06913868|BEHAVIORAL|Standardized Physiotherapy Care|Standardized physiotherapy for fibromyalgia. Includes general exercise (aerobic, stretching), manual therapy (within guidelines), and basic pain education (excluding PNE). 8-week program: 1-2 sessions/week (60 min) + home exercise (20 min, 3x/week). Therapist training and fidelity monitoring.
223745346|NCT06913322|PROCEDURE|flush endovenous laser ablation of great saphenous vein|A 4 French sheath is advanced over the wire and positioned in the great saphenous vein below knee. Diode laser (SmartM; Lasotronix) with a 600-mm radial fiber catheter was used. The tip of the laser was be placed flush at saphenofemoral junction.
223487863|NCT02976389|OTHER|Financial Incentive: High|dlParticipants in this group will receive an additional $40/month to use towards the purchase of SNAP eligible fruits and vegetables. They will be able to access these dollars through an electronic wallet (e-wallet) that is tied to their customer loyalty card. They will also have access to the fruit and vegetable promotions that include discount pricing and SNAP-Ed programming (e.g., in-store cooking classes, tours, and healthy food self-labeling system) to educate and support the purchasing behaviors of SNAP-eligible families.
223745347|NCT06913322|PROCEDURE|standard endovenous laser ablation of great saphenous vein|A 4 French sheath is advanced over the wire and positioned in the great saphenous vein below knee. Diode laser (SmartM; Lasotronix) with a 600-mm radial fiber catheter was used. The tip of the laser was be placed 2 cm distal to saphenofemoral junction.
223745348|NCT06914674|DRUG|Tamoxifen 20 mg|Tamoxifen: 10 mg orally twice daily. Combination therapy: Chemotherapy, radiotherapy, surgery, or other treatments per NCCN guidelines and patient condition.
224178469|NCT04335227|OTHER|Nutritional management|Thirty two females with PCOS will be asked to undergo only nutritional management uniquely prepared by dietitian
223586995|NCT06387641|BEHAVIORAL|Routine community health services|"Routine community health services refer to a comprehensive health care service system that is government-led, community-participated, and guided by superior health institutions. It focuses on grass-roots health institutions and is staffed with general practitioners as the backbone. By rationally utilizing community resources, it provides a series of comprehensive health care services to community residents. These services center on human health, target families as the unit, cover the entire community, and aim to meet the basic health service needs of community residents.~Specifically, routine community health services include the following aspects: Health Education, Prevention and Control, Health Care Services and so on."
223586996|NCT04736134|BIOLOGICAL|BMS-986326|Specified dose on specified days
223586997|NCT04736134|OTHER|Placebo matching BMS-986326|Specified dose on specified days
223586998|NCT04736134|BIOLOGICAL|Multiple Ascending Dose SC|Specified dose on specified days
223586999|NCT04736134|OTHER|Multiple Ascending Dose Placebo|Specified dose on specified days
223587000|NCT00428207|DRUG|Insulin Aspart versus Insulin Lispro|Subjects will be randomly assigned to insulin aspart versus insulin lispro via random number generation. Half of the patients will begin with insulin aspart, and then will be crossed over to insulin lispro. The insulin sequence will be reversed for the other half of the patients.
223587001|NCT00428207|DRUG|Insulin Lispro versus Insulin Aspart|Subjects will be randomly assigned to insulin lispro versus insulin aspart via random number generation. Half of the patients will begin with insulin lispro, and then will be crossed over to insulin aspart. The insulin sequence will be reversed for the other half of the patients.
223745349|NCT06914284|OTHER|Actigraphy and MRI|All participants will wear a wGT3X-BT actigraph (wGT3x-BT) for 4 days. Actigraphs are collected back at Day 4, after full 96 hours, when coming to the MRI platform. There, they will undergo 45 minutes MRI that acquire MRI signals to quantify degenerative, inflammatory, vascular and functional cerebral features.
223745350|NCT02921009|DEVICE|Crosslinking using UV light of two different fluence rates|The treatment of keratoconus involves the application of riboflavin followed by Ultraviolet light of differing intensities. This study will determine the effectiveness of a greater UV light fluence at a shorter treatment time than is currently utilized.
223487864|NCT02976389|OTHER|Financial Incentive: Middle|Participants in this group will receive an additional $20/month to use towards the purchase of SNAP eligible fruits and vegetables. They will be able to access these dollars through an electronic wallet (e-wallet) that is tied to their customer loyalty card. They will also have access to the fruit and vegetable promotions that include discount pricing and SNAP-Ed programming (e.g., in-store cooking classes, tours, and healthy food self-labeling system) to educate and support the purchasing behaviors of SNAP-eligible families.
223745351|NCT01918761|DRUG|Dacomitinib, Pemetrexed|Pemetrexed 500mg/m2 i.v (q21d) Dacomitinib 45mg orally (continuous)
223745352|NCT06913270|BEHAVIORAL|Immersive Virtual Reality Distraction (IVRD)|"Intervention Description:~Participants assigned to this intervention will receive standard analgesic care per institutional protocol in addition to an immersive virtual reality (VR) distraction intervention. During each burn dressing change, participants will wear a head-mounted display (HMD) that delivers an interactive and engaging virtual environment designed specifically to distract from procedural pain and reduce anxiety. The VR session will last for the entire duration of the dressing change (approximately 10-15 minutes) and will be administered during every session. The VR system is calibrated to provide high levels of sensory immersion to effectively divert attention from painful stimuli."
224178470|NCT00203294|DRUG|lidocaine, bupivicaine and saline|lidocaine, bupivicaine and saline-2 cc were injected to each GON and 0.5 cc to each trigger point. Total injected volume = 10 cc.
224178471|NCT00203294|DRUG|lidocaine plus bupivicaine plus triamcinolone (steroid)|lidocaine, bupivicaine and triamcinolone (steroid)-2 cc were injected to each GON and 0.5 cc to each trigger point. Total injected volume = 10 cc.
224178472|NCT04328142|OTHER|Qigong group|Traditional Chinese Medicine exercise programme
224178473|NCT04328142|OTHER|Physiotherapy|Physiotherapy exercise programme
224178474|NCT06277609|DRUG|Lu AF28996|Capsule
224178475|NCT06277609|DRUG|Acetylsalicylic Acid|Tablet
224178476|NCT06277609|DRUG|Mefenamic Acid|Tablet
224178477|NCT06277609|DRUG|Amoxicillin/clavulanic acid|Tablet
224178478|NCT00327210|BEHAVIORAL|Blood Glucose Awareness Training|
224178479|NCT02466906|DRUG|rhGM-CSF|rhGM-CSF was injected subcutaneously of 3± 0.3ug/kg/d per day for 5 days before and 2 days after surgery. During adjuvant therapy of XELOX, rhGM-CSF was continuous injected for 6 days when finishing each cycle of chemotherapy (from d15) or stopped when ANC\>20.0X109/L.
224178480|NCT02466906|DRUG|placebo|Placebo was injected subcutaneously of 3± 0.3ug/kg/d per day for 5 days before and 2 days after surgery. . During adjuvant therapy of XELOX, placebo was continuous injected for 6 days when finishing each cycle of chemotherapy (from d15).
224178481|NCT05441436|PROCEDURE|Allogeneic hematopoietic stem cell transplantation|Allogeneic hematopoietic stem cell transplantation
224178482|NCT05441436|PROCEDURE|Solid organ transplantation|Solid organ transplantation
223487865|NCT02976389|OTHER|Financial Incentive: Low|Participants in this group will receive an additional $10/month to use towards the purchase of SNAP eligible fruits and vegetables. They will be able to access these dollars through an electronic wallet (e-wallet) that is tied to their customer loyalty card. They will also have access to the fruit and vegetable promotions that include discount pricing and SNAP-Ed programming (e.g., in-store cooking classes, tours, and healthy food self-labeling system) to educate and support the purchasing behaviors of SNAP-eligible families.
223487866|NCT03729479|BEHAVIORAL|DASH diet|Participants will be taught to follow a DASH diet (low-sodium and low-fat meal plan, which includes whole grains, fat-free or low-fat dairy products, vegetables, fruits, poultry, fish, and nuts, with processed, high-sodium, regular-fat, and sugar-added foods restricted).
223487867|NCT03729479|BEHAVIORAL|Very low carbohydrate, ketogenic diet|Participants will be taught to follow a very low-carbohydrate diet (non-starchy vegetables, nuts, seeds, meat, fish, and natural fats such as avocado, olive oil, and butter, with starchy and sugary foods restricted).
223487868|NCT03729479|BEHAVIORAL|Extras|Participants will be given training in positive affect, mindfulness, health information seeking and sharing, and cooking practices and behavior.
224178483|NCT06430736|DRUG|Tocilizumab before CAR-T cell infusion|"Tocilizumab will be given at the standard-dose of 8 mg/kg b.w. intravenously, with completion of the infusion 1 hour prior to infusion of CAR-T cells.~Treatment of eventual subsequent CRS/ICANS will be identical as in patients in the standard arm."
224178484|NCT06430736|DRUG|Tocilizumab at emerging CRS|Tocilizumab will be given at the standard-dose of 8 mg/kg b.w. intravenously, and it will be repeated after 8 hours for a maximum of four administrations in patients with ongoing signs of CRS.
224178485|NCT03236649|DRUG|Icaritin|600mg/time, 6 capsules/time(6×100mg/capsule), 2 times/day(30 minutes after breakfast, lunch and dinner), take orally, continuous administration until reach the standard of termination.
224178486|NCT03236649|DRUG|Sorafenib Tosylate Tablets|400mg/time, 2 tablets/time(2×200mg/tablet), 2times/day(Fasting), take orally, continuous administration until reach the standard of termination.
224178487|NCT00082628|DRUG|Placebo|Placebo matched to serostim® as subcutaneous injection.
224178488|NCT00082628|DRUG|Serostim® 4 mg|Serostim® as subcutaneous injection at a maximum dose of 4 milligram (mg) per day based on body weight.
224178489|NCT00082628|DRUG|Serostim® 2 mg|Serostim® 2 mg as subcutaneous injection on alternate days.
224178490|NCT01566981|PROCEDURE|Computerised support to the Diabetes type II patients|The randomly selected group of patients with diabetes type II will get software application and web based support to their usual healthcare process.
224178491|NCT02847000|DRUG|Tetrahydrouridine|"Starting dose is by weight:~THU is supplied as 250 mg/capsule Weight 40-60kg = 2 capsules of Tetrahydrouridine. Weight 61-80kg = 3 capsules of THU. Weight 81-100kg or higher = 4 capsules of THU.~Timing between THU and Dec, Frequency of administration: Oral THU capsules followed 60 minutes later by oral Dec capsules are ingested 2X/week on consecutive days. Treatment on protocol monitoring continues for 52 weeks, however, subjects will have the option to continue beyond this period if it judged to be in their interests."
224178492|NCT02847000|DRUG|Decitabine|"Starting dose is by weight:~DEC is supplied as 5 mg/capsule. Weight 40-60kg = 2 capsules of Decitabine. DEC capsules are ingested \~60 minutes after THU capsules. Weight 61-80kg = 3 capsules of DEC. DEC capsules are ingested \~60 minutes after THU capsules. Weight 81-100kg or higher = 4 capsules of DEC. DEC capsules are ingested \~60 minutes after THU capsules.~Timing between THU and Dec, Frequency of administration: Oral THU capsules followed 60 minutes later by oral Dec capsules are ingested 2X/week on consecutive days. Treatment on protocol monitoring continues for 52 weeks, however, subjects will have the option to continue beyond this period if it judged to be in their interests."
224178493|NCT05713331|BEHAVIORAL|CLS-R|CLS-R Training includes school provider training in CLS via web platform and videoconferencing for workshops, consultation and coaching.CLS is a 10-12 week program and includes school, parent, and student components which are integrated via joint teacher, parent, and student meetings and use of integrated behavioral programs in the classroom and home.
224178494|NCT00352833|DRUG|catumaxomab|
224178495|NCT02541994|DEVICE|Pachette3|Central corneal thickness will be measured with an ultrasound probe. This test will be performed while the corneas are anesthetized. This test will be performed as part of a standard, comprehensive dilated eye examination with optical coherence tomography and visual field testing as the regular care for benign intracranial hypertension.
224178496|NCT02541994|DEVICE|Lenstar-Think|Axial length will be measured with an ultrasound probe. This test will be performed while the corneas are anesthetized. This test will be performed as part of a standard, comprehensive dilated eye examination with optical coherence tomography and visual field testing as the regular care for benign intracranial hypertension.
223487869|NCT06496243|DRUG|obicetrapib 10 mg + obicetrapib/evolocumab 140 mg Q 2 weeks|10 mg obicetrapib for 8 weeks followed by 10 mg obicetrapib/ 140 mg evolocumab (every 2 weeks) combination for 8 weeks
224178497|NCT03549585|OTHER|Criteria for Screening and Triaging to Appropriate aLternative care|CriSTAL Tool (Criteria for Screening and Treatment of Appropriate Long-Term Care) is a multidimensional geriatric tool that lists 18 elements of the literature, under construction and validation by an Australian retrospective study. This tool is a practical questionnaire and easy to use in current care, with items adapted to the geriatric dimension. The investigators chose to target hospitalized geriatric patients through emergencies.
224178498|NCT04615429|BIOLOGICAL|Mesenchymal stromal cells|Administration of one single dose of allogenic Mesenchymal stromal cells
223487870|NCT05682378|DRUG|Inclisiran|Inclisiran sodium 300mg (equivalent to 284mg inclisiran\*) in 1.5mL solution administered subcutaneously in pre-filled syringe
223487871|NCT06087718|DEVICE|Maastro applicator|The dose profile of the Maastro applicator is similar to the dose profile of a CXRT device. Patients will be stratified based on tumor size. The cut-off is set at the maximum diameter of the treatment surface of the Maastro applicator. The boost consists of 3 fractions with a dose equivalent to 30 Gy per fraction prescribed at the surface of the applicator. The 3 boost fractions will be delivered over a 4-week time period. Patients with a tumor size \< 2.5 cm will receive an upfront boost followed by concurrent chemoradiotherapy (25x1.8 Gy combined with capecitabine 825 mg/m2 bd on radiotherapy days). Patients with a tumor size ≥ 2.5cm will first undergo concurrent chemoradiotherapy (25x1.8 Gy combined with capecitabine 825 mg/m2 bd on radiotherapy days) and will afterwards receive the boost.
223587002|NCT03668834|PROCEDURE|Dermabrasion with NCES|"1. The recipient site will be shaved, cleaned with betadine and surgical spirit and anaesthetized with mixture of 2% lignocaine and NS (1:1).~2. Dermabrasion will be done using Manekshaw's dermabrader until tiny pinpoint bleeding spots are seen and extended 5mm beyond margins to prevent halo phenomenon.~3. The denuded area will be washed with PBS and covered with a PBS moistened gauze piece.~4. With 18 G needle attached to tuberculine syringe, few small drops of non cultured epidermal cell suspension will be placed over the denuded surface and spread evenly.~5. Dressing is done in 4 layers in order-collagen(Neuskin F), bactigras, cutisoft(sterile gauze) and dynaplast (elastic plaster)."
223587003|NCT03668834|PROCEDURE|Dermaroller with NCES|"1. The recipient site will be shaved, cleaned with betadine and surgical spirit.~2. Microneedling will be done with a device containing 540 microneedles in 8 rows, each 0.25 mm in length. Microneedling will be extended 5 mm beyond margins to prevent halo phenomenon.~3. The roller will be passed repeatedly over the skin in a star-shaped way for about 10 minutes~4. The noncultured epidermal cell suspension will be carefully transferred to a tuberculin syringe.~5. NCES will be applied to the skin surface with a tuberculin syringe with an 18G needle and spread evenly after dermarolling treatment.~6. Dressing is done in 4 layers in order-collagen(Neuskin F), bactigras, cutisoft(sterile gauze) and dynaplast (elastic plaster)."
224178499|NCT04615429|OTHER|Placebo|Administration of placebo (solution identical to experimental treatment, without the MSC)
224178500|NCT02733276|OTHER|electroacupuncture|Electroacupuncture: Using an electroacupuntor with different frequencies during 20 minutes. Needles are connected to the electrodes.
224178501|NCT02733276|OTHER|Sham: Electroacupuncture sham|Sham comparator (Electroacupuncture sham): Using an electroacupuntor with different frequencies during 20 minutes. Needles are connected to the electrodes.
224178502|NCT01784900|DRUG|Catumaxomab 100µg|
224178503|NCT01784900|DRUG|Catumaxomab 140µg|
224178504|NCT06201585|DEVICE|SHURUI Endoscopic Surgical Robotic System (SR-ENS-600)|SHURUI Endoscopic Surgical Robotic System (SR-ENS-600)
224178505|NCT01041885|DEVICE|INSTRUCT|INSTRUCT PolyActive scaffold implantation
224178506|NCT01749436|OTHER|Lung ultrasound imaging examinations|Lung ultrasound examinations performed at different time-points immediately before surgery, during surgery under general anesthesia and after surgery in the recovery room to detect and monitor atelectasis related to laparoscopic procedures.
224178507|NCT01664585|BEHAVIORAL|Training group|The 60-minute training sessions include a few mobilization techniques for upper neck. In detail, three different exercises concentrated on postural and motor control will be taught during the first two training sessions. Progressively, two additional exercise movements aiming at postural and motor control will be taught in the next session. After eight weeks, two muscle strength exercises utilising therapeutic rubber band will be included into the program. The aim of the rubber band exercises is eventually to achieve the load of 80% of maximal voluntary contraction. The participants in the training group are also instructed to increase their amount of physical activity progressively according to the current physical activity recommendations.
224178508|NCT01664585|BEHAVIORAL|Control|The control group will receive six sessions of Transcutaneous Nervous Stimulation treatment (TNS) as a placebo treatment (0) and the participants in control group are recommended and encouraged to maintain their previous normal level of physical activity and exercise habits throughout the study without any supervision or home training programs.
224178509|NCT02497599|DRUG|Indium-111-DOTA-Girentuximab-IRDye800CW|Indium-111-DOTA-Girentuximab-IRDye800CW tracer injection will be administered 7 days before (partial) nephrectomy
224178510|NCT02497599|RADIATION|SPECT/CT|4 or 5 days after tracer injection a SPECT/CT of the abdomen will be acquired.
224178511|NCT02497599|PROCEDURE|Intraoperative dual-modality imaging|7 days after dual-labeled girentuximab injection standard of care surgery will be performed extended with the use of dual-modality imaging.
224178512|NCT05066802|DRUG|neoadjuvant modified FOLFIRINOX|oxaliplatin 85 mg/m2 D1 + leucovorin 400mg/m2 D1 + irinotecan 150 mg/m2 D1 + 5-FU 2,000 mg/m2 42\~46h continuous infusion, every other week for 6 cycles (12 weeks) before surgery.
224178513|NCT05373186|DRUG|Euglycemic clamp with BC Combo THDB0207|Administration of a single dose of BC Combo THDB0207 during an euglycemic clamp procedure
224178514|NCT05373186|DRUG|Euglycemic clamp with Humalog® Mix25|Administration of a single dose of Humalog® Mix25 during an euglycemic clamp procedure
224178515|NCT05373186|DRUG|Euglycemic clamp with Humalog® and Lantus®|Simultaneous administration of Humalog® and Lantus® during an euglycemic clamp procedure
224178516|NCT03431467|DEVICE|Impella-CP LV Vent|Patients randomised to the experimental arm will have an Impella-CP implanted in addition to VA-ECMO within a maximum of 10 hours of institution of VA-ECMO
224178517|NCT03062605|DRUG|Iodine (Betadine)|
224178518|NCT03062605|BIOLOGICAL|NaOCL|
224178519|NCT01947166|DIETARY_SUPPLEMENT|Nestle Impact Advanced Recovery nutritional supplement|Before Surgery: Consume 1 drink box (8 ounces) three times a day for 5 days (15 servings total) on postoperative day minus 5 through postoperative day 1 in addition to normal diet. After Surgery: Consume 1 drink box (8 ounces) three times a day for 5 days on postoperative day 2 through postoperative day 6.
224178520|NCT01644812|BEHAVIORAL|Aerobic exercise|
224178521|NCT01644812|BEHAVIORAL|Stretching|
224178522|NCT04139603|OTHER|Lumbopelvic kinesio taping|"Kinesio tapes applied to the lumbopelvic region will stay 3 days. They will be removed from the site, and the skin will be checked and cleaned, and then reapplied for the next 3 days.~An ergonomic education program will be given after the baseline measurements, and will last for 45-60 minutes. A brochure including ergonomic principles with images will also be provided."
224178523|NCT04139603|OTHER|Abdominal supported lumbopelvic kinesio taping|"Kinesio tapes applied to the lumbopelvic region and abdominal area will stay 3 days. They will be removed from the sites, and the skin will be checked and cleaned, and then reapplied for the next 3 days.~An ergonomic education program will be given after the baseline measurements, and will last for 45-60 minutes. A brochure including ergonomic principles with images will also be provided."
224178524|NCT04139603|OTHER|Placebo tapng|"Placebo tapes (just like Kinesio tapes) applied to the lumbopelvic region without any tension will stay 3 days. They will be removed from the site, and the skin will be checked and cleaned, and then reapplied for the next 3 days.~An ergonomic education program will be given after the baseline measurements, and will last for 45-60 minutes. A brochure including ergonomic principles with images will also be provided."
224178525|NCT04145310|DRUG|BOL-DP-o-04 + SCO|sublingual drops
224178526|NCT04145310|DRUG|Placebo + SCO|sublingual drops
224178527|NCT02461576|DEVICE|Xpert HIV-1 VL Assay|in vitro diagnostic test to quantify HIV-1 RNA
224178528|NCT04046666|DEVICE|Functional near infrared spectroscopy|Functional near infrared spectroscopy will be adopted to assess the metabolic characteristics of the Heart and Lung meridians. The probes will be left at 4 measurement sites, which include Shenmen (HT7) and Shaohai (HT3) of the Heart meridian, Taiyuan (LU9) and Chize (LU5) of the Lung meridian.
224178529|NCT04046666|PROCEDURE|Moxibustion|"Two sessions of moxibustion will be performed in the Heart meridian and Lung meridian successively.~Intervention in the Heart meridian: moxibustion will be performed above Shaohai (HT3) for 15 minutes. During moxibustion, the probes of near infrared spectroscopy will detect the metabolic characteristics of three measuring sites, which include the midpoint of the Heart meridian along the forearm, Chize (LU5) of the Lung meridian, and the midpoint of the Lung meridian along the forearm.~Intervention in the Lung meridian: moxibustion will be performed above Chize (LU5) for 15 minutes. During moxibustion, the probes of near infrared spectroscopy will detect the metabolic characteristics of three measuring sites, which include the midpoint of the Lung meridian along the left forearm, Shaohai (HT3) of the Heart meridian, and the midpoint of the Heart meridian along the forearm."
224178530|NCT00642824|DRUG|Standard chemotherapy|As prescribed--chemotherapy may be a)gemcitabine/cisplatin, b)vinorelbine + cisplatin/docetaxel + cisplatin or c)vinorelbine or docetaxel.
224178531|NCT00642824|DRUG|bevacizumab [Avastin]|15mg/kg iv or 7.5mg/kg on day 1, and subsequently once every 3 weeks
224178532|NCT02084316|BEHAVIORAL|One4All|Participants with HIV-positive screening results on EIA will immediately have their blood drawn for CD4 and VL tests. Participants will receive post-screening test counseling. Two venous blood samples will be collected-one for immediate numeration of CD4 T-lymphocytes in the same hospital lave using PIMA POC CD4 analyzer and the other for later VL testing at the province CDC which takes 10-15 days. Participant will be notified in person of their CD4 results on the same day and provided post-CD4 test counseling. Counseling in the One4all intervention has been modified from the national SOC guidelines due to the different order of tests and the shortened time period between screening and CD4 testing. The participant will be provided with a tentative assessment of ART eligibility based on CD4 results and other factors. Those who are eligible for ART are encouraged to seek HIV care at the study hospitals via China's National Free ART program.
224178533|NCT02084316|BEHAVIORAL|Standard of Care|"The control condition is the current standard of care (SOC) utilized within the county hospitals in Guangxi China. This SOC has some variability between counties but in general follows the national policies. After the initial positive screening on EIA and subsequent repeat screening, participants will receive post-screening test counseling. Participants will then be tested by WB either at the same visit or a subsequent visit. The WB is sent offsite.~After WB test results are reported to the hospital, the health care provider will contact the participant by phone. The participant will be asked to return to the hospital for results and post-WB test counseling. At this visit, a blood sample will be collected for CD4 testing, and an initial epidemiological investigation will be carried out.~Once CD4 test results are available, participants must be located again to inform them of their results and ART eligibility and to provide post-CD4 test counseling."
223487872|NCT04248244|OTHER|Palliative Care|Early PC Integration - Participants will meet with a member of the outpatient PC team, which consists of board-certified PC physicians, advance practice providers and nurse care coordinators, within three weeks of enrollment. Participants will be scheduled to meet with a PC provider at least once per month. Additional visits may be scheduled at the discretion of participants, oncologists or PC providers. All participants will receive routine oncologic care throughout the study period.
224178534|NCT05569915|BEHAVIORAL|Trauma Expressive Writing|Participants assigned to the trauma condition will write about an experience of trauma for 15 to 20 minutes per day across five consecutive days.
224178535|NCT05569915|BEHAVIORAL|Stigma Expressive Writing|Participants assigned to the stigma condition will write about an experience of stigma or bias for 15 to 20 minutes per day across five consecutive days.
223487873|NCT04248244|OTHER|FACT-MM questionnaire|FACT-MM questionnaires will be administered by a research coordinator upon enrollment and at four time points from the date of enrollment: 3 months, 6 months, 9 months and 12 months. All questionnaires will be administered in handwritten paper-based form, and while patients are in clinic. There is a +/- two-week window for completion of questionnaires to accommodate patient schedules. The assessment battery takes approximately 20 minutes to complete.
223487874|NCT04248244|OTHER|HADS questionnaire|HADS questionnaires will be administered by a research coordinator upon enrollment and at four time points from the date of enrollment: 3 months, 6 months, 9 months and 12 months. All questionnaires will be administered in handwritten paper-based form, and while patients are in clinic. There is a +/- two-week window for completion of questionnaires to accommodate patient schedules. The assessment battery takes approximately 20 minutes to complete.
223487875|NCT04978636|OTHER|Continuous low-tidal volume ventilation with using FiO2 of 0.21|The continuous low-tidal volume ventilation with using FiO2 of 0.21 will be defined as the tidal volume of 3 mL/kg IBW (up to maximum 200 mL), 0.21 of FiO2, respiratory rate of 5 per minute, and PEEP 5 cm H20). A recruitment maneuver with 30 cm H2O for 10 seconds will be performed before starting the selected ventilation mode in all patients. During the sub-study extra blood samples will be drawn before and after CPB.
223487876|NCT04978636|OTHER|Continuous low tidal volume ventilation with using FiO2 of 1.0|The continuous low-tidal volume ventilation with using FiO2 of 1.0 will be defined as the tidal volume of 3 mL/kg IBW (up to maximum 200 mL), 1.0 of FiO2, respiratory rate of 5 per minute, and PEEP 5 cm H20). A recruitment maneuver with 30 cm H2O for 10 seconds will be performed before starting the selected ventilation mode in all patients. During the sub-study extra blood samples will be drawn before and after CPB.
223487877|NCT04978636|OTHER|Apnea During CPB|There will be no ventilation used. But, during the sub-study part of the Apnea CPB extra blood samples will be drawn before and after CPB.
223587004|NCT03668834|PROCEDURE|Liquid nitrogen induced blister with NCES|"1. The recipient site will be shaved, cleaned with betadine and surgical spirit and anaesthetized with mixture of 2% lignocaine and NS (1:1).~2. The site to be grafted is outlined with a surgical marking pen.~3. To induce blisters on the achromic areas, freezing with liquid nitrogen spray was performed during 10 to 20 seconds inside round circles previously drawn on the skin.~4. The patient is asked to visit 24 hours later.~5. The blister fluid is aspirated and NCES taken in tuberculin syringe with 18 G needle is injected into it such that the blister roof is preserved.~6. Dressing is done in 4 layers in order-collagen(Neuskin F), bactigras, cutisoft(sterile gauze) and dynaplast (elastic plaster)."
223587005|NCT00946673|DRUG|Vorinostat|Orally up to 400 mg
223587006|NCT00946673|PROCEDURE|Radiation Therapy|Single fraction stereotactic radiotherapy - Standard of Care
223587007|NCT06540989|BEHAVIORAL|Immediate treatment|Participants will access a web-based app using their phone to record 100 sentences every treatment session. Noise-augmented feedback will be provided to increase accuracy of speech productions.
224178536|NCT05569915|BEHAVIORAL|Control|Participants assigned to the control condition will write about their days for 15 to 20 minutes per day across five consecutive days. This control condition is standard across many expressive writing studies.
224178537|NCT01234337|DRUG|Sorafenib (Nexavar, BAY43-9006)|Capecitabine was administered orally at a dose of 1,000 milligram per square meter (mg/m\^2) twice daily (12 hours apart) on Days 1 through 14 of each 21-day cycle. Sorafenib was administered orally at a dose of 600 mg (200 mg in the morning, 400 mg in the evening) daily, continuously (that is, Days 1 to 21, inclusive). A treatment cycle consisted of 21 days. If tolerability criteria were met for a subject, capecitabine dose was escalated to 1,250 mg/m\^2 twice daily and sorafenib dose to a total daily dose of 800 mg for that subject.
224306880|NCT00405444|DRUG|Fentanyl|The dose of fentanyl that each child will receive will be 2 mcg/kg based on the child's weight. The medication will be administered 10 minutes prior to the procedure and will be dropped into the unoccluded nares over 1-2 seconds.
224306881|NCT00405444|DRUG|Sterile water|The dose of sterile water that each child will receive will be 2 mcg/kg based on the child's weight. It will be administered 10 minutes prior to the procedure and will be dropped into the unoccluded nares over 1-2 seconds.
224306882|NCT00498901|DRUG|goserelin|
224306883|NCT00498901|DRUG|letrozole|
223587008|NCT06540989|BEHAVIORAL|Deferred treatment|This group of participants will receive the same treatment as those in the immediate treatment group. The only difference is the timeline of treatment onset. Therefore, participants will access a web-based app using their phone to record 100 sentences every treatment session. Noise-augmented feedback will be provided to increase accuracy of speech productions.
223587009|NCT02032654|DRUG|Flucloxacillin|
223587010|NCT02032654|DRUG|Placebo (for flucloxacillin)|Sugar capsule manufactured to mimic flucloxacillin 500mg capsules
223587011|NCT00930007|OTHER|Blood sampling|Blood sampling for later hormone measurements
223587012|NCT03990506|PROCEDURE|Epi-on PiXL|Photorefractive intrastromal crosslinking (PiXL) After local anaesthetics, the cornea is soaked in Riboflavin by repeated topical application during 10 minutes. For masking purposes, epithelial debridement is simulated by moving a scraping instrument in front of the cornea. A Riboflavin soaked sponge is used to lightly disrupt the epithelium tight junctions, without epithelium debridement. The cornea is illuminated with PiXL under 16:40 minutes during continuously delivery of humidified high oxygen via specific oxygen goggles. The UV-dosage is individually customized based upon Kmax; \< 45D, 7.2J/cm2; 45-50D, 10J/cm2; \> 50D, 15 J/cm2.
223587013|NCT03990506|PROCEDURE|Epi-Off PiXL|Photorefractive intrastromal crosslinking (PiXL) After local anaesthetics, the corneal epithelium is debrided and the cornea is soaked in Riboflavin by repeated topical application during 10 minutes. The cornea is then illuminated with individually customized topography-guided PiXL under 16:40 minutes. The UV-dosage is individually customized based upon Kmax; \< 45D, 7.2J/cm2; 45-50D, 10J/cm2; \> 50D, 15 J/cm2.
224072564|NCT07143773|DRUG|Placebo|The control intervention in this clinical trial will be a matching placebo tablet, identical in appearance to Forxiga (10 mg), administered once daily as an add-on to standard immunosuppressive therapy. A total of 88 non-diabetic kidney transplant recipients will be enrolled. All participants will be randomized in a 1:1 ratio to receive either placebo or Forxiga. This placebo intervention ensures blinding of both participants and investigators and allows a direct comparison of the safety and efficacy of SGLT2 inhibition versus no active treatment in this unique patient population.
224072565|NCT07144358|BEHAVIORAL|Biological Feeding Position|Biological Feeding Position
224072566|NCT07143929|DRUG|CAR-T|autologous CD7-targeted CAR-T cells, single injection
224072567|NCT07144592|BEHAVIORAL|solution-oriented approach program|The solution-focused nursing intervention applied to the experimental group in the study was planned as individual sessions, consisting of one session per week, lasting a total of six weeks. The interventions were based on the principles of solution-focused brief therapy, focusing on the individual's strengths, past coping experiences, and current resources. The interviews aimed to identify exceptions, build positive future expectations, set small but achievable goals, strengthen hope, and increase the individual's ability to utilize their internal resources. Each session used structured open-ended questions, scaling techniques, and future-oriented solution scenarios to support the individual's psychosocial adjustment and motivation for treatment.
224072568|NCT02007551|BEHAVIORAL|Mealtime Intervention|The mealtime intervention constitutes once a week visits from a trained volunteer for 8 weeks, each visit lasting 90 minutes and comprising of preparing and sharing a meal together with the participant.
224072569|NCT01620541|PROCEDURE|Ankle Arthrodesis|All surgeons will employ a well-established technique of rigid internal fixation. In this technique, the joint is prepared by removing cartilage from the surfaces, the bones are positioned as desired, and screws and/or a plate are attached to compress the bones together and prevent motion. This technique obviates the need for a cast or external support. Patients are allowed to walk with weight bearing aids immediately. Radiographs are performed at 6 weeks to determine weight bearing status. Weight is allowed on the limb in increments over the 6 to 12 weeks after surgery.
224072570|NCT01620541|PROCEDURE|Ankle Arthroplasty|Protocols are similar among participating centers. Each surgeon uses an anterior surgical approach between the tibialis anterior tendon and the toe extensor group, splints the ankles for 2 weeks, and restricts weight bearing for the first 6 weeks. Radiographs are performed at 6 weeks to determine weight bearing status. The study involves only FDA approved implants with which the surgeon has established experience.
224306884|NCT00498901|DRUG|leuprolide acetate|
224306885|NCT00498901|PROCEDURE|conventional surgery|
224306886|NCT01302522|BEHAVIORAL|Mental practice|All patients in the study will be administered a regimen of locomotor therapy (rehabilitative therapy working on walking). Half of the patients will also be administered a regimen in which they mentally rehearse the exercises that they have just physically performed.
224306887|NCT02066948|OTHER|wt loss|subjects will consume a 750 reduced calorie daily diet based on current ht. wt and age
224306888|NCT02066948|OTHER|Meal Pattern|Even or skewed distribution of protein for a 16 week period of wt loss.
224306889|NCT02066948|OTHER|meal pattern|skew or even
224306890|NCT02066948|DIETARY_SUPPLEMENT|even|even amount of protein distributed between each meal
224306891|NCT02066948|DIETARY_SUPPLEMENT|skew|a skewed amount of protein is distributed between each meal
224306892|NCT02767830|BEHAVIORAL|Excercise and Nutrition Program|
224306893|NCT02005263|PROCEDURE|Salpingography|Infusion of typically 1-2 mL of air bubbles in to the uterine cavity to assess whether they disappear through the ostia in to the Fallopian tubes.
224306894|NCT01234922|DRUG|lisinopril|Given orally
224306895|NCT01234922|DRUG|losartan potassium|Given orally
224306896|NCT01234922|OTHER|laboratory biomarker analysis|Correlative studies
224306897|NCT01234922|DRUG|benazepril hydrochloride|Given orally
224306898|NCT01234922|DRUG|ramipril|Given orally
224306899|NCT04122066|DRUG|sofosbuvir \daclatsvir|study the effect of the new oral antihepatitis C drugs on the respiratory system
224306900|NCT05893810|DRUG|Mupirocin Ointment|Patients in the intervention arm will receive a decolonization regimen, consisting of intranasal mupirocin ointment to be applied twice daily to the nares
224178538|NCT01234337|DRUG|Placebo|Capecitabine was administered orally at a dose of 1,000 mg/m\^2 twice daily (12 hours apart) on Days 1 through 14 of each 21-day cycle. Placebo matching to sorafenib was administered orally, 3 tablets (1 tablet in the morning, 2 tablets in the evening) daily, continuously (that is, Days 1 to 21, inclusive). A treatment cycle consisted of 21 days. If tolerability criteria were met for a subject, capecitabine dose was escalated to 1,250 mg/m\^2 twice daily and placebo dose to a total daily dose of 4 tablets (2 tablets twice daily) for that subject.
224178539|NCT01234337|DRUG|Capecitabine|Capecitabine was administered orally at a dose of 1,000 milligram per square meter (mg/m\^2) twice daily (12 hours apart) on Days 1 through 14 of each 21-day cycle.days. If tolerability criteria were met for a subject, capecitabine dose was escalated to 1,250 mg/m\^2 twice daily,
224178540|NCT05489276|DRUG|TQB2825 injection|TQB2825 injection is a bi-specific, humanized antibody against CD3×CD20, with the structure ratio of anti-CD3 to anti-CD20 of 1:2. It has two asymmetric Fab ends and a complete Fc end, and is a natural IgG4 subtype with weak antibody-dependent cell-mediated cytotoxicity or complement dependent cytotoxicityfunction. By bridging CD3 and CD20, TQB2825 injection induces T cell activation to promote T cell proliferation/expansion, promote the formation of cytolytic synapses, and cause cytotoxic T cells to release perforin and granase, thereby killing CD20 positive tumor cells. Therefore, TQB2825 injection is intended for the treatment of CD20 positive hematologic tumors, including but not limited to lymphoma, leukemia and myeloma.
224178541|NCT01491828|DEVICE|Kai Strap|Medical device component that vibrates on a subject's neck.
224178542|NCT02736487|DEVICE|True-Washout-Sham Air Filtration Intervention|This intervention involved three sequential steps: (1) 12 to 20 hours of true air filtration intervention; (2) at least two weeks of washout period; (3) 12 to 20 hours of sham air filtration intervention. In the indoor environment, the portable filtration device drew room air, sent it through filter and active carbon (for true filtration) or active carbon alone (sham filtration) and then delivered processed air back to room air. In the study the portable filtration device processes 2.8 cubic meter of room air per minute. The washout period lasted for at least two weeks where no filtration intervention was implemented.
224178543|NCT02736487|DEVICE|Sham-Washout-True Air Filtration Intervention|This intervention involved three sequential steps: (1) 12 to 20 hours of sham air filtration intervention; (2) at least two weeks of washout period; (3) 12 to 20 hours of true air filtration intervention. In the indoor environment, the portable filtration device drew room air, sent it through filter and active carbon (for true filtration) or active carbon alone (sham filtration) and then delivered processed air back to room air. In the study the portable filtration device processes 2.8 cubic meter of room air per minute. The washout period lasted for at least two weeks where no filtration intervention was implemented.
224178544|NCT00580827|DRUG|Placebo|Matched placebo.
224178545|NCT00580827|DRUG|Disulfiram|disulfiram at 62.5 mg/day for 12 weeks.
224178546|NCT00580827|DRUG|Disulfiram|Disulfiram at 125 mg/day for 12 weeks.
224178547|NCT00580827|DRUG|Disulfiram|disulfiram at 250 mg/day for 12 weeks.
224178548|NCT01634087|DRUG|Itacitinib|Itacitinib administered orally
224178549|NCT01634087|DRUG|Placebo|Placebo administered orally
224178550|NCT02114528|DRUG|Antiarrhythmic Drug Therapy|Either one or more of the following antiarrhythmic drugs: sotalol, mexiletine, procainamide, or amiodarone.
224178551|NCT02114528|PROCEDURE|Catheter ablation|Ventricular tachycardia catheter ablation.
224178552|NCT03481634|DRUG|Brolucizumab|Intravitreal injection
224178553|NCT03481634|DRUG|Aflibercept|Intravitreal injection
224178554|NCT00424736|PROCEDURE|whole body CT scan|
223487878|NCT05302518|BEHAVIORAL|Cognitive behavioral therapy with exposure in virtual reality|"The treatment rationale is based on a model of the maintenance of social phobia by Clark and Wells. The themes of therapy are: a) The general ideas of CBT, b) The maintaining processes of social phobia, c) negative automatic thoughts, d) shifting focus of attention form self-focus to external focus, e) safety behaviors, f) post-processing, g) self-processing, h) schemas and rules for living.~Exposure in VR:~We will use 360° 3D videos for exposure using an HTC Vive Pro headset. Six different videos will be used for exposure: 1) Taking a seat on a bench in a public park, 2) Being introduced as a new employee, 3) Performing a presentation at a meeting, 4) Entering and shopping in a grocery store, 5) Visiting a café and 6) Using public transportation. The therapist can choose the length of the exposure as well as the difficulty of the exposure. While the participant is in the VR-scenario HR and EDA are measured. These data are collected to continuously estimate the anxiety levels."
223487879|NCT05302518|BEHAVIORAL|Cognitive behavioral therapy with exposure in vivo|"The treatment rationale is based on a model of the maintenance of social phobia by Clark and Wells.The themes of therapy are: a) The general ideas of CBT, b) The maintaining processes of social phobia, c) negative automatic thoughts, d) shifting focus of attention form self-focus to external focus, e) safety behaviors, f) post-processing, g) self-processing, h) schemas and rules for living.~Exposure in vivo:~Exposure is taking place at Centre for Telepsychiatry and the surrounding areas. The therapist is planning the exposure with the participant and is accompanying the participant during the exposure."
224306901|NCT03466255|OTHER|Ultrasound|Contrast-enhanced ultrasound (CEUS)
223487880|NCT05328908|DRUG|Nivolumab-relatlimab FDC|Specified dose on specified days
223487881|NCT05328908|DRUG|Regorafenib|Specified dose on specified days
224178555|NCT01309646|BIOLOGICAL|Infanrix™-IPV+Hib|Intramuscular, 3 doses
224178556|NCT01309646|BIOLOGICAL|Infanrix™ IPV|Intramuscular, 3 doses
224178557|NCT01309646|BIOLOGICAL|Hiberix™|Intramuscular, 3 doses
224178558|NCT01309646|BIOLOGICAL|Synflorix™|Intramuscular, 3 doses
224178559|NCT01309646|BIOLOGICAL|Rotarix™|Oral, 2 doses
224178560|NCT01282190|BEHAVIORAL|Motivational interview|Motivational interview
224178561|NCT00994890|DRUG|Tanezumab 2.5 mg|Tanezumab 2.5 mg administered by subcutaneous injection every 8 weeks for a total of 7 injections administered over approximately 1 year
224178562|NCT00994890|DRUG|Tanezumab 5 mg|Tanezumab 5 mg administered by subcutaneous injection every 8 weeks for a total of 7 injections administered over approximately 1 year
224306902|NCT03666650|DRUG|Edoxaban 60 MG|Viscoelastic analysis and standard laboratory tests after edoxaban ingestion
224306903|NCT01085734|DRUG|Avastin|1.25mg intravitreally
224306904|NCT01085734|DRUG|Osurdex|0.7mg intravitreally
224306905|NCT01085734|DRUG|Avastin|1.25mg intravitreally
224306906|NCT05149859|OTHER|Observational|(no intervention)
223487882|NCT05328908|DRUG|TAS-102|Specified dose on specified days
223487883|NCT04129515|DEVICE|NovoTTF-200A|•NovoTTF-200A will be applied continuously, with 21 consecutive days defined as a treatment cycle
223487884|NCT04129515|DRUG|Pembrolizumab|Pembrolizumab will be administered once every 3 weeks, with 21 consecutive days also defined as a treatment cycle
223487885|NCT05952648|PROCEDURE|Lower tract respiratory samples|Within 1 hour from HAP or VAP suspicion, quantitative tracheal aspirate or bronchoalveolar lavage will be performed to confirm the diagnosis. Clinicians will be encouraged to perform BAL whenever possible
223487886|NCT05952648|DIAGNOSTIC_TEST|Multiplex PCR assay (Film-array Pneumonia Panel Plus)|The lower tract respiratory samples will be analyzed with Multiplex PCR assay (Film-array Pneumonia Plus).
223487887|NCT05952648|DIAGNOSTIC_TEST|Lower respiratory tract standard culture|The lower tract respiratory samples will be analyzed using convention microbiological methods (including conventional Gram stain and semiquantitative culture on both selective/differential and screening agar media)
223487888|NCT05952648|DIAGNOSTIC_TEST|Blood sample standard culture|When HAP or VAP are suspected, blood samples from peripheral vein will be collected and analyzed with conventional microbiological methods
223487889|NCT04893798|COMBINATION_PRODUCT|Sayana Press|Sayana Press is a drug-device combination and is considered a medical product in the EU.
223487890|NCT02442349|DRUG|AZD9291|Once daily tablet 80 mg
223487891|NCT06001398|BEHAVIORAL|Parent Acceptance and Commitment Therapy (PACT)|PACT is a 2-session intervention based on the Focused Acceptance and Commitment Therapy treatment literature
223487892|NCT06001398|BEHAVIORAL|Control|The content of the control intervention covers a range of nutrition and healthy lifestyle topics including USDA's MyPlate
223487893|NCT06219226|PROCEDURE|Chlorine dioxide mouthwash|This one rinsing will last 2x15 seconds(2x12,5ml).
223487894|NCT06219226|PROCEDURE|Chlorhexidine mouthwash|This one rinsing will last 2x15 seconds(2x12,5ml).
223487895|NCT05342519|DRUG|Rapamycin|While rapamycin is not approved for the treatment of vitiligo, it has been found to be efficacious in stopping disease progression in animal models. Another recent study in humans showed that doses of 0.5cc daily of 0.001% of the topical formulation are able to achieve improvement in hypopigmented lesions of the skin at both the clinical and histological level. At this dose, improvement in cell function was observed regarding maintenance of proliferative potential and prevention of senescence, with avoidance of total inhibition of cell growth as has been seen at higher potencies used for immunosuppression.
223487896|NCT05342519|DRUG|Rapamycin|Rapamycin is an immunosuppressant that works by inhibiting the mammalian target of rapamycin (mTOR) leading to inhibition of the cell cycle and antibody production. It has also been shown to promote expansion of Treg populations. Although studies evaluating alternative dosing for vitiligo are limited, topical rapamycin has previously been used to treat angiofibromas related to Tuberous Sclerosis, vascular malformations such as port-wine stains, and inflammatory lesions such as plaque psoriasis. In a 2019 meta-analysis, 38 out of 40 reports included used topical formulations of 1% or lower potency rapamycin; the majority of publications were focused on the treatment of Tuberous Sclerosis, where the median concentration of mTOR inhibition was 0.1% dosed twice daily.
223587014|NCT03652675|BEHAVIORAL|Intervention: (Clinician's Guide + HealthCall for HIV/HCV)|This intervention consists of an adaptation of the National Institutes of Health (NIH) Clinician's Guide (CG; NIAAA, 2007) in conjunction with the previously tested HealthCall smartphone app program (Hasin et al., 2013; Hasin et al., 2014). Participants will complete a brief baseline meeting (\~20 minutes) with a counselor to discuss alcohol use, liver function, and HIV medication adherence. They will track their drinking using HealthCall for 60 days, with brief follow-up meetings with their counselor to check in about their drinking 30 and 60 days later.
223587015|NCT03246659|DRUG|111In-CP04|Radiopharmaceutical preparation
223587016|NCT03246659|DRUG|111In-CP04 with co-administration of gelofusine/gelaspan|Radiopharmaceutical preparation with co-administration of gelofusine/gelaspan
224178563|NCT00994890|DRUG|Tanezumab 10 mg|Tanezumab 10 mg administered by subcutaneous injection every 8 weeks for a total of 7 injections administered over approximately 1 year
224178564|NCT00089206|BIOLOGICAL|incomplete Freund's adjuvant|
224306907|NCT01759732|DRUG|Fludarabine|40mg/M2 once daily IV on days -7 to -4
223487897|NCT05342519|DRUG|Placebo|All patients will be assigned to received topical placebo cream to the lesion not being treated with the active study drug.
223587017|NCT04060966|BEHAVIORAL|Cold-Pressor Task (CPT)|The CPT involves participants submerging their dominant forearm in ice-water (0-4°C) for 3 minutes.
223587018|NCT04060966|BEHAVIORAL|Control CPT|The control CPT involves participants submerging their dominant forearm in warm water (\~30°C) for 3 minutes.
223587019|NCT04060966|DEVICE|fMRI|Participants in the neuroimaging cohort will complete up to two fMRI experimental sessions on different days, with at least a day between sessions, each lasting approximately 2 hours. Imaging data will be collected with a Prisma 3T head- only scanner equipped with a head coil from Nova Medical.
224072571|NCT02040298|DRUG|Clemastine|4mg tablet twice daily
224072572|NCT02040298|DRUG|Placebo|Placebo tablet twice daily
224072573|NCT05557760|BEHAVIORAL|Cognitive Control Training (CCT)|"The CCT training group without booster sessions will receive 10 training sessions with the Adaptive Paced Auditory Serial Addition Task (aPASAT). The aPASAT is a Cognitive Control Training where participants need to click on the sum of the last two heard digits.~Task difficulty is modified based on the participants' current task performance, allowing training of cognitive control."
224178565|NCT00089206|BIOLOGICAL|multi-epitope melanoma peptide vaccine|
224178566|NCT00089206|BIOLOGICAL|sargramostim|
224178567|NCT00792922|DRUG|Azithromycin|Comparison of community coverage rate
223487898|NCT06439225|DRUG|Docetaxel|75mg/m2 q21 days
223487899|NCT06439225|DRUG|Carboplatin|AUC5 q21 days
223487900|NCT05609331|OTHER|Simulated Online Adaptive Planning|The results of the MRI-guided radiation therapy will be compared to conventional radiation therapy (guided by CT scans) during this study
223487901|NCT05609331|RADIATION|Stereotactic MRI-guided adaptive radiotherapy-SMART|The results of the MRI-guided radiation therapy will be compared to conventional radiation therapy (guided by CT scans) during this study
223487902|NCT04041154|BEHAVIORAL|Cognitive Fatigue|Participants will perform a cognitively demanding task (spatial attention task), repeatedly, to induce cognitive fatigue.
224306908|NCT01759732|DRUG|Cyclophosphamide|60 mg/kg IV on day-3 and -2
224306909|NCT01759732|BIOLOGICAL|anti-thymocyte globulin|
224178568|NCT00792922|DRUG|Azithromycin|Comparison of coverage levels at baseline treatment followed by annual treatment if prevalence of trachoma is \>5%. In Niger, there will be a comparison of coverage levels in everyone versus in children ages twelve and under who are treated every 6-months.
223487903|NCT04041154|BEHAVIORAL|Physical Fatigue|Participants will perform a physically demanding task (grip force exertion task), repeatedly, to induce cognitive fatigue.
223487904|NCT04041154|BEHAVIORAL|Rewarding Stimuli|Reward-associated stimuli will be used to study how reward-induced changes in motivational state influence effort choices.
224178569|NCT03323385|DRUG|N1539|Once Daily
224178570|NCT03323385|DRUG|Placebo|Once Daily
224178571|NCT03506529|OTHER|questionnary|questionnary on predictif factors about physiological hypermetabolism of anal canal
224178572|NCT04556942|DIAGNOSTIC_TEST|Flow Mediated Dilation (FMD) measurement|FMD measurements will be performed by ultrasound using longitudinal images of the brachial artery using a high-frequency (10.0-MHz) ultrasound scanning probe (VividTM E9 with XDeclearTM; GE Healthcare, Chicago, Illinois, USA) proximal to the antecubital fossa. Two-dimensional images, acquired with electrocardiogram gating, will be obtained at baseline with Doppler ultrasound imaging to assess arterial diameter and flow velocity. Reactive hyperemia will then be induced by inflation of a pneumatic tourniquet around the forearm to at least 200 mm Hg (or \> 50mmHg above systolic pressure) for 5 minutes. Post-deflation diameter and flow velocity will be monitored continuously from deflation for 210 seconds. To assess endothelial-independent vasodilation maximal brachial artery diameter will be measured continuously for 3 minutes after a single sublingual dose of nitroglycerin (NTG, 0.4 mg).
224178573|NCT04556942|OTHER|Blood pressure, pulse and blood oxygen saturation measurement|"Blood pressure measurement will be done with a pneumatic tourniquet on the upper arm, after at least 10 minutes rest of the patient.~Pulse measurement and oxygen saturation measurement will be done using a finger pulseoximeter, after at least 10 minutes rest of the patient."
224178574|NCT04556942|OTHER|ST George Respiratory Questionnaire|The is a validated and standardized Questionnaire designed to measure health impairment in COPD patients
224178575|NCT04556942|OTHER|Physical activity level (PAL) measurement|PAL will be assessed by the number of steps and kilometers per day using a triaxial accelerometer of a multisensory activity monitor (Fitbit Alta HR; Fitbit Inc., San Francisco, CA, USA). The device is worn like a watch on the wrist. The device is worn always, except while showering or swimming.
224178576|NCT04556942|BIOLOGICAL|Withdrawal of a blood sample|5ml of blood will be withdrawn and preserved after centrifugation at -50 degrees celsius for later analysis at a yet unknown time
224178577|NCT04556942|PROCEDURE|Immediate Bronchoscopic Lung Volume Reduction|Bronchoscopic Lung Volume Reduction by using endobronchial valve placement Within 2 weeks after T0
224178578|NCT04556942|PROCEDURE|Delayed Bronchoscopic Lung Volume Reduction|Bronchoscopic Lung Volume Reduction by using endobronchial valve placement Within 6-8 weeks after T0 and 3-4 days after T1
223487905|NCT05982730|BEHAVIORAL|Sensory-Augmented Postural Training|To examine the safety and efficacy of postural training emphasized on the integration of multiple sensory information into motor control and to assess the effectiveness of postural training using Segway
224178579|NCT00247962|DRUG|etanercept|50 mg
224178580|NCT00247962|DRUG|sulphasalazine (SSZ)|Sulphasalazine: The target dose for SSZ is 1.5 g (3 tablets) twice daily orally. Subject start the oral TA at 0.5 g daily for the first week and increase by 0.5 g every week until a daily dose of 3 g. Is achieved by the start of study week 5 of the study.
224178581|NCT00841854|DRUG|pantoprazole|pantoprazole 40mg bid
224178582|NCT00841854|DRUG|bismuth|bismuth 300mg qid
224178583|NCT00841854|DRUG|metronidazole|metronidazole 500mg tid
224178584|NCT00841854|DRUG|tetracycline|tetracycline 500mg qid
223587020|NCT01638559|DRUG|Immunosuppression withdrawal|Participants will undergo gradual ISW in no less than 36 weeks and no more than 52 weeks with frequent monitoring of liver tests. All participants will be followed for 48 months ensuring a minimum of 36 months of follow-up after successful ISW.
223587021|NCT03299361|OTHER|Magnetic resonance image (MRI)|Diffusion tensor magnetic resonance imaging (DTI) of MRI reveals tissue microstructure based on random movements of water molecules. Here we monitored, by means of DTI, median nerve integrity in CTS patients before and after corticosteroid injection. This information may help to explain the hypothesis regarding the effect of corticosteroid to the median nerve, to identify which anatomic location of median nerve relevant to the symptom relief of CTS after corticosteroid injection, and be useful for the clinical follow-up of patients with nerve entrapments following conservative treatment.
223587022|NCT02539511|DRUG|CI-581a|
223587023|NCT02539511|DRUG|CI-581b|
224178585|NCT02963194|DRUG|Oxytocin|
224178586|NCT02963194|DRUG|Placebo|
224178587|NCT04134949|BEHAVIORAL|Cognitive Behavior Therapy|consists of eight weekly treatment sessions of 45 to 60 minutes.
224306910|NCT01759732|BIOLOGICAL|filgrastim|
223487906|NCT05401487|OTHER|Pre-hospital and hospital care|Pre-hospital care not exceeding 60 min and a whole body CT scan within 45 min for patients categorized as unstable or critical by the pre-hospital doctor and 90 minutes for patients deemed potentially serious.
223487907|NCT04386005|DEVICE|Continuous Glucose Monitoring Device|The Dexcom G7 Glucose Monitoring System (San Diego, CA) reports continuous interstitial blood glucose concentrations every 5 minutes, does not require calibration, and involves only 1 needle stick to place the sensor. The manufacturer recommends that a single sensor may be used for up to 10 days. The Dexcom G7 system is the only FDA approved CGM system for children (age \>2 years).
223487908|NCT05835726|DRUG|Daratumumab|NDMM (newly diagnosed multiple myeloma) who fulfill the inclusion criteria, candidate to stem cell mobilization, collection, and autologous stem cell transplant who receive a Daratumumab-containing induction regimen.
223487909|NCT03733535|DRUG|Benralizumab|Benralizumab is an interleukin-5 receptor alpha-directed cytolytic monoclonal antibody
223487910|NCT03733535|DRUG|129 Xenon|1.0 L of 129-Xenon/4-Helium mixture to acquire MRI images
223487911|NCT01926158|DRUG|Denosumb|Prefilled syringe of 1 mL denosumab solution
223487912|NCT01926158|DRUG|Placebo (for denosumab)|
223487913|NCT00314145|BIOLOGICAL|ChimeriVax™-JE|0.5 mL, Subcutaneous (ChimeriVax™-JE); 1.0 mL, (Saline)
223487914|NCT00314145|BIOLOGICAL|JE-VAX®|0.5 mL, Subcutaneous (JE-Vax®); 1.0 mL, (Saline)
223487915|NCT02339636|OTHER|PDUS examination|
223587024|NCT02539511|BEHAVIORAL|Motivational Enhancement Therapy (MET)|
224178588|NCT04134949|BEHAVIORAL|Mindfulness-Based Cognitive Therapy|consists of eight weekly treatment sessions of 45 to 60 minutes.
223487916|NCT00128063|DRUG|succinylated human serum albumin|
223487917|NCT05778565|PROCEDURE|Extraocular muscle stretching|Extraocular muscle stretching to test its efficacy as a weakening procedure
223487918|NCT01641536|GENETIC|HB-110|Each patient will be administered HB-110 by Electroporation for 20 weeks based on the protocol and take one pill of Entecavir(0.5 mg) per day during the study period. The Dose of HB-110 will be determined by the classical 3+3 dose escalation schedule and dose levels are 1mg, 2mg, 4mg respectively. The number of patients will be ranged from 9 to 18.
223487919|NCT00747604|BIOLOGICAL|mecasermin [rDNA origin] injection|As prescribed by the physician.
223487920|NCT01799083|DRUG|Decitabine|A continuous 5-day lower-dose decitabine transfusion will be performed for patients during each treatment cycle, and autologous cytokine-induced killer cells may be transfused or chemotherapy may be also added.
223487921|NCT01799083|BIOLOGICAL|cytokine-induced killer cell|Autologous cytokine-induced killer cells may be used for patients before and after decitabine treatment.
223487922|NCT05223127|OTHER|Aloe vera|The leaves of Aloe vera (Aloe barbadensis) will be identified and verified by Selçuk University Faculty of Agriculture. Aloe vera leaves will be washed with antiseptic solution and cut crosswise using gloves and sterile knife. The thick epidermis will be removed from the middle of the leaf. The gel will be obtained from the parenchyma of the thick juicy leaves of aloe vera.
223487923|NCT05434702|BEHAVIORAL|Digital Diet Diary|Participants will be asked to complete the Fitbit 3-day food record, which consists of inputting each food and beverage consumed for two weekdays and 1 weekend day into the Fitbit application. This digital diary includes taking photos of each food and beverage consumed during the 3 day food record period on the participant's iphone or ipad.
223487924|NCT05434702|BEHAVIORAL|NHANES Food Frequency Questionnaire (FFQ)|Participants will complete the the Food Frequency questionnaire which indicates usual food intake over the past year.
223487925|NCT05434702|BEHAVIORAL|Fitbit data collection|Participants will be asked to wear a Fitbit continuously (24/7) for one week to track steps and activity intensity. The Fitbit is worn on the wrist and uses accelerometer and heart rate technology to quantify steps taken and integrated barometric altimeter to measure activity intensity. The resulting Fitbit data will be automatically pulled from the participant's smartphone or study device.
223487926|NCT05434702|BEHAVIORAL|Quality of Life questionnaire|The European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) includes questions about participant's quality of life during the past week, self-reported general health, self reported chronic conditions and psychological distress using a scale from 1-5, 1=excellent, 5= poor. A lower total score indicates better qualify of life.
223487927|NCT05434702|BEHAVIORAL|Functional Assessment of Cancer Therapy - General (FACT-G) Questionnaire|The Functional Assessment of Cancer Therapy - General (FACT-G) Questionnaire includes questions about participant's physical, social, emotional and functional well being over the past 7 days. This questionnaire uses a 5 point Likert-type scale, 0=not at all, 4=very much. A higher total score indicates better quality of life.
223487928|NCT05434702|BEHAVIORAL|Godin Exercise Leisure-Time questionnaire|The Godin Exercise Leisure-Time questionnaire measures the frequency of strenuous, moderate, and mild exercise for periods of 15 minutes or more during the participant's free time throughout a typical week. The scoring using the formula leisure score index (LSI) which is obtained using the following formula: (frequency of mild × 3) + (frequency of moderate × 5) + (frequency of strenuous × 9).
223487929|NCT05434702|BEHAVIORAL|Zoom interviews|A subset of 30 participants (10 African American, 10 Hispanic, 10 non-Hispanic white) will participate in semi-structured interviews to explore (a) sociocultural, environmental, and individual factors associated with lifestyle behaviors; (b) awareness of American Cancer Society (ACS) guidelines, current practices, and essential intervention modules (ex. integrating cultural foods and preferences) to provide study team with information needed to develop healthy behavior interventions for young adult cancer survivors.
223487930|NCT05495997|BEHAVIORAL|Mental Imagery Training|Participants will practice mental imagery of everyday tasks daily for 6 weeks.
223487931|NCT05495997|BEHAVIORAL|Psychoeducation|Participants will receive psychoeducation on cognition and brain health.
223487932|NCT00922584|DRUG|sorafenib (Nexavar)|oral sorafenib 400 mg, twice daily, until disease progression or unacceptable toxicity
224178589|NCT01087229|DRUG|equimolar oxygen-nitrous oxide mixture|Kinesitherapy is performed with a mask by which patient inhales an equimolar oxygen-nitrous oxide mixture.
223487933|NCT05262101|DRUG|TQB2858 injection|TQB2858 is a dual-function fusion protein that is aProgrammed cell death 1 ligand 1 (PD-L1)/transforming growth factor-β(TGF-β) double antibody.
223487934|NCT06572033|BEHAVIORAL|Simulation|Observational study with simulations.
223487935|NCT05179629|DRUG|M TAPA block|Under aseptic conditions, a high frequency linear probe will be placed on the costochondral angle in the sagittal plane. Then the probe will be slightly angled deeply to visualize the lower view of the perichondrium. We will perform M-TAPA with totally 30 ml (15 ml for each side) of %0,25 bupivacaine.
223487936|NCT03335176|BEHAVIORAL|Endurance ad Resistance Training Exercise|Patients received a 6-week tele-supervised rehabilitation with 3 exercise sessions per week
223587025|NCT05369481|DRUG|Sildenafil 2%|Patients with male androgenic alopecia will be given topical Sildenafil 2% to apply twice daily for 6 consecutive months and then follow up.
224306911|NCT01759732|RADIATION|Total body irradiation|200 cGy per day on D-5 \& -4
224178590|NCT01087229|DRUG|Placebo|Kinesitherapy is performed with a mask by which patient inhales a placebo.
224178591|NCT03618433|OTHER|study group|The treatment protocol will consist of soft tissue massage, passive mobilization, stretching, self-stretching exercises. and shoulder proprioception .In addition to the standart exercise therapy, Kincet® video game program will be applied .
224178592|NCT03618433|OTHER|Control group|The control group included soft tissue massage, stretching, self-stretching, passive mobilization, coordination, posture exercises, progressive active and assisted shoulder exercises, proprioception and strengthening exercises in the exercise therapy protocol
224178593|NCT04657302|DRUG|Obinutuzumab|Participants will receive 1000 mg of intravenous (IV) obinutuzumab on Cycle 1 Day 1.
224306912|NCT01759732|PROCEDURE|CD3-depleted hematopoietic cell transplantation|Immunogenetic depletion on CliniMACS
224306913|NCT01269333|DRUG|omeprazole|omeprazole 20mg for 7 days
224178594|NCT04657302|DRUG|Glofitamab|Participants will receive 2.5 mg of IV glofitamab Cycle 1 Day 8, 10 mg at Cycle 1 Day 15, and 30 mg on Day 1 of Cycles 2-12 Q3W (cycle length = 21 days).
224178595|NCT04657302|DRUG|Tocilizumab|Participants will receive tocilizumab as needed to manage cytokine release syndrome (CRS).
224178596|NCT01849289|DRUG|Insulin Degludec|Administered subcutaneously (under the skin), dose individually adjusted, once daily in combination with metformin at the unchanged, stable, pre-randomisation dose level and dosing frequency.
224178597|NCT01849289|DRUG|Insulin Glargine|Administered subcutaneously (under the skin), dose individually adjusted, once daily in combination with metformin at the unchanged, stable, pre-randomisation dose level and dosing frequency.
224178598|NCT02538705|DRUG|Neovasculgen|
224178599|NCT02142075|DRUG|Daptomycin|
224178600|NCT05947968|OTHER|Scapular PNF|"Scapular proprioceptive neuromuscular facilitation exercise: will be applied in two diagonals:~1. anterior elevation and posterior depression~2. posterior elevation and anterior depression for 3 sets of 10 repetitions, The rest interval between sets will be 20 seconds.~Patients will lay on the unaffected side while the therapist stands in the line of desired motion. Firstly, the therapist will give preparatory instructions. In the beginning of the pattern, the therapist pulls the scapula to the elongated position and then gives instructions for the desired movement."
224178601|NCT05947968|OTHER|Shoulder strengthening exercises|"Shoulder strengthening exercises:~The following four exercises will focus on shoulder and scapular strengthening. Before starting the program, the patients will be thoroughly instructed in the four exercises, and illustrations with specific exercise instructions will be provided. All subjects will perform the exercises with the affected side for three sets of 10 repetitions for each exercise, with a 1-minute rest between sets.~1. Standing shoulder external rotation with elastic resistance.~2. Bilateral external rotation with scapular retraction exercise.~3. Resisted scapular retraction with shoulder external rotation (Middle trapezius muscle).~4. Weighted scapular retraction and downward rotation Y-shape (lower trapezius muscle)."
224178602|NCT05147194|DRUG|Trimetazidine|Oral，35mg bid
223487937|NCT02511756|DEVICE|Computed tomography X-ray system|Contrast-enhanced computed tomography of liver metastases
223487938|NCT01402726|PROCEDURE|renal sympathetic modification|Device: THERMOCOOL® Catheter Renal sympathetic modification with a catheter-based procedure
223487939|NCT06525818|OTHER|Tube weaning therapy intervention|Participants in the intervention group will be invited to weekly virtual group therapy mealtime sessions with the Speech-Language Pathologist and other participants in the intervention group. Additionally, families will engage in individual virtual therapy sessions at least biweekly focused on individualized goals informed by the expertise of the study team and published expert programs. Therapies intervention group participants are already receiving or who begin to receive during the study period will not be stopped during this intervention. The Speech Therapist and Occupational Therapist will be utilized as needed for the child's individualized care plan. They will consult with the registered dietitian and Developmental and Behavioral Pediatrician as needed.
223587026|NCT05369481|DRUG|Minoxidil 5 %|Patients with male androgenic alopecia will be given topical Minoxidil 5 % to apply twice daily for 6 consecutive months and then follow up.
223587027|NCT01345383|PROCEDURE|bronchoscopy|Routine bronchoscopy under local anesthesia (lidocain). Duration: +/- 10 min
223587028|NCT04343118|PROCEDURE|Hardware Removal|elective removal of plate osteosynthesis at the clavicle
223587029|NCT00483002|DRUG|varenicline|As prescribed by physician in usual clinical practice.
223587030|NCT01462890|BIOLOGICAL|Bevacizumab|15 mg/kg, iv on day 1 every 3 weeks up to and including cycle 22 vs cycle 44
224178603|NCT02134340|DRUG|[I-124]-CPD-1028 Injection|A single intravenous dose of \[I-124\]-CPD-1028 Injection will be given at Visit 2 (within 21 days of screening Visit 1), and may be followed by whole body PET/CT imaging approximately 3 hours post-injection. PET/CT imaging will occur at Visit 3 (2-3 days after Visit 2) and Visit 4 (5-7 days after Visit 2). PET/CT imaging may also occur at Visit 5 (16-18 days after Visit 2). Visit 6 (28 +/- 2 days after Visit 2) is a follow-up telephone call for a post-treatment safety assessment. At Visits 2-5, whole body biodistribution and tumour uptake will be assessed. At all visits, safety will be assessed.
224178604|NCT02134340|BIOLOGICAL|CPD-1061|\[Optional\] An intravenous dose of 0.4, 1.4 or 6 mg/kg of body weight of CPD-1061 may be given 1-2 hours prior to injection of \[I-124\]-CPD-1028 at Visit 2. The decision to use CPD-1061 and the dose amount is based on an adaptive design and is dependent on interim reviews of imaging data.
224178605|NCT01469637|DRUG|sulfamethoxazole + MMX placebo|800 mg sulfamethoxazole/160 mg trimethoprim twice daily (BID) + MMX Mesalazine/mesalamine placebo once daily (QD) orally for 3 days, then a single dose of 800 mg sulfamethoxazole/160 mg trimethoprim + single does of MMX Mesalazine/mesalamine placebo orally on Day 4.
224306914|NCT01269333|DRUG|fluvoxamine|fluvoxamine 50mg for 7 days
223587031|NCT01462890|DRUG|Paclitaxel|175 mg/m², iv on day 1 every 3 weeks for 6 cycles
223587032|NCT01462890|DRUG|Carboplatin|AUC 5, iv on day 1 every 3 weeks for 6 cycles
223587033|NCT01462890|OTHER|specialized pathology review (Germany only)|before randomization
223587034|NCT04691908|BIOLOGICAL|QazCovid-in®-vaccine against COVID-19|QazCovid-in® (inactivated) Vaccine manufactured by Research Institute for Biological Safety Problems Republic of Kazakhstan
223587035|NCT04691908|OTHER|Placebo|Placebo (sodium chloride buffs, solvent for the preparation of dosage forms for injection 0.9%)
223587036|NCT00311909|DEVICE|Thalamic deep brain stimulation|
223587037|NCT04464096|OTHER|non|non
223587038|NCT00093821|DRUG|tanespimycin|Given IV
223587039|NCT00093821|OTHER|pharmacological study|Correlative studies
223587040|NCT00093821|OTHER|laboratory biomarker analysis|Correlative studies
223587041|NCT06499883|BEHAVIORAL|Pocket Ark|Pocket Ark (PA) is a mobile e-learning and assessment platform for use by flood remediation workers in the field. The purpose of this mobile application is to provide workers with real-time data to assist with making safe decisions during the planning phase in the flooded zone and provide a communications platform to improve logistics between operational bases and workers during and after the deployment to the flooded zone. Pocket Ark incorporates an action planner, scenario-based PPE training content, assessments (both knowledge and health-risk), personal security protection, and resource location features for workers involved in disaster rescue and recovery. Individual construction worker's readiness to be safely deployed to flooded and post-flood environments will be assessed.
223587042|NCT00251251|DEVICE|Optimal Medical Therapy plus ICD|ICD vs CRT/ICD
223587043|NCT00251251|DEVICE|Optimal Medical Therapy plus CRT/ICD|ICD vs CRT/ICD
223587044|NCT03664583|BEHAVIORAL|ACHRU-Community Partnership Program (CPP)|The intervention is a 6-month community navigation and self-management program for patients with diabetes and at least one additional chronic condition, and their caregivers, to improve health outcomes. The intervention will be provided by an interprofessional team of providers and consists of six core components.
224178606|NCT01469637|DRUG|Sulfamethoxazole + MMX Mesalazine/mesalamine|800 mg sulfamethoxazole/160 mg trimethoprim BID + 4.8 g MMX Mesalazine/mesalamine QD for 3 days, then a single dose of 800 mg sulfamethoxazole/160 mg trimethoprim + a single dose of 4.8 g MMX Mesalazine/mesalamine on Day 4
224178607|NCT00598585|DRUG|Sildenafil (Viagra)|25 mg tid of either Sildenafil(Viagra) for first week. 50 mg tid of either Sildenafil (Viagra) for second week. 100 mg tid of either Sildenafil (Viagra) 3rd,4th, 5th and 6th week of study participation.
224178608|NCT00598585|DRUG|Placebo|Placebo pills 3X/day for 6 weeks
224178609|NCT05798702|PROCEDURE|roux -en-y- gastric bypass|Roux-\&-Y Gastric Bypass (RYGB) involves the use of a surgical stapler to create a small and vertically oriented gastric pouch with a volume of 30 ml. The upper pouch is completely divided by the gastric remnant and is anastomosed to the jejunum, 75 cm distally to the Treitz's ligament, through a narrow gastrojejunal anastomosis in a Roux-en-Y fashion. Bowel continuity is restored by an entero-entero anastomosis, between the excluded biliary limb and the alimentary limb, performed at 100 cm from the gastrojejunostomy.
224178610|NCT05798702|DIETARY_SUPPLEMENT|intensive life style modification|Weight loss will be induced using a VLCD (800-850 kcal/day; 59% carbohydrate, 13% fat, 26% protein, 2% fiber) with replacement meals for 2 months, followed by structured food reintroduction every 2-8 weeks (about 50% carbohydrate, 35% total fat, and 15% protein), and an ongoing structured program with follow-up visits up to 25% body weight loss
224178611|NCT06148025|BIOLOGICAL|BCG vaccine|0.1ml injected intradermally over the distal insertion of the deltoid muscle onto the humerus
223487940|NCT06525818|OTHER|Feeding Group|All participants in the control group will be invited to a weekly virtual group therapy mealtime session with other enrolled control group participants and a speech therapist who is not involved with the intervention. During this informal session, families will have the opportunity to meet other children with feeding tubes and their parents. The investigators will assess level of engagement (frequency of participation) and parental experience at interval assessments. Therapies research participants are already receiving or who begin to receive during the study period (early intervention community therapies, center-based therapies) will not be stopped during this intervention. Data will be collected on the frequency of these standard of care therapies. The assessments used for the control group will be the same assessments as the intervention group and will include the Speech Therapy Assessment; Occupational Therapy Assessment; and Pediatric Eating Assessment Toll.
223487941|NCT05672056|PROCEDURE|Computer guided placement of a stock plate pre-bent on a 3D printed model|We aim to design a novel guide that can secure the construct of the fibular segments and pre bent plate onto the native mandible and effectively and efficiently translate the VSP into the surgical field.
223487942|NCT01542099|DRUG|Remifentanil|"According to previous patient's response, the investigators will allocate the effect site concentration of remifentanil of next patient during double lumen tube intubation. For this allocation of dose of remifentanil the investigators use up-and-down method.~For the first patient, the dose of remifentanil would be fixed at 6.0 ng/ml which we predict as EC50. And, step size of dose is 0.5ng/ml."
223587045|NCT01403116|DRUG|Oral testosterone undecanoate|Starting dose: 200 mg T (as TU) BID. Doses may be titrated up to a maximum dose of 300 mg T (as TU) BID or down to a minimum dose of 100 mg T (as TU) BID based on serum T values collected at 4-6 hours post AM dose on Days 30 and 60.
223587046|NCT01403116|DRUG|topical testosterone gel|Starting dose: 5 g T applied once daily. Doses may be titrated up to a maximum dose of 10 g daily or down to a minimum dose of 2.5 g daily based on serum T values collected at 4-6 hours post AM dose on Days 30 and 60.
223587047|NCT01895309|DRUG|Enbrel (etanercept)|
223587048|NCT01895309|DRUG|SB4 (proposed biosimilar to etanercept)|
223587049|NCT00188903|PROCEDURE|Diastolic measurements during TEE|Transesophageal echocardiography with diastolic measurements
223587050|NCT04268745|BEHAVIORAL|Balance training|Progressive balance training within virtual environments
223587051|NCT04268745|BEHAVIORAL|Traditional Vestibular Rehabilitation|Progressive balance training and gaze stability exercises
223587052|NCT02062203|DRUG|AKB-6548 (therapeutic dose)|Single oral dose of AKB-6548 at a therapeutic dose level
223587053|NCT02062203|DRUG|AKB-6548 (supratherapeutic dose)|Single oral dose of AKB-6548 at a supratherapeutic dose level
223587054|NCT02062203|DRUG|Placebo|Single oral dose of placebo
223587055|NCT02062203|DRUG|Moxifloxacin|Single oral dose of 400 mg moxifloxacin
223587056|NCT04518033|DEVICE|Various commercially available face coverings|Various commercially available face coverings
223587057|NCT00370838|DRUG|Levetiracetam|The initial dose of levetiracetam was 10 mg/kg/day, divided twice daily (rounded to the closest unit of 250 mg). The dose was increased weekly by 5-10 mg/kg/day, to a maximum dose of 50 mg/kg/day (or 2,500 mg/day), if deemed necessary for tic suppression. In any individual, dose escalation may have proceeded more slowly, or the dose may have been reduced as necessary. No changes in dosage occurred during the final week of either treatment phase.
224178612|NCT06148025|BIOLOGICAL|Yellow Fever vaccine|0.5ml injected subcutaneously
224178613|NCT06148025|DRUG|Vancomycin Oral Capsule|500mg every 6 hours for 3 days
224178614|NCT06148025|DRUG|Neomycin Oral Product|1000mg every 6 hours for 3 days
224178615|NCT02872090|DRUG|Indacaterol|inhalation
224178616|NCT02872090|DRUG|Glycopyrronium|inhalation
224178617|NCT02872090|DRUG|Tiotropium|inhalation
224178618|NCT02872090|DRUG|Placebo|
224178619|NCT02872090|PROCEDURE|photoplethysmography|inhalation
224178620|NCT05465785|BIOLOGICAL|Recombinant COVID-19 vaccine (Sf9 cell)|This vaccine is made by using baculovirus as a vector and expressing SARS-CoV-2 S-RBD in Sf9 cells, which is purified
224306915|NCT01269333|DRUG|placebo|placebo for 7 days
224306916|NCT03090607|DEVICE|Aluvra™|Endoscopic injection of bulking agent to the lower esophageal sphincter
224306917|NCT03090607|DRUG|Saline|Endoscopic injection of saline
224306918|NCT02345629|PROCEDURE|Cordotomy|Radiologist performs a spinal tap to inject a contrast drug into the spinal fluid. A 20G spinal needle guided by real-time CT scan to the C1-C2 level opposite to participant's pain. A radiofrequency electrode inserted through the spinal needle into the spinal cord, to the anatomic location of the spinothalamic tract. Once ideal position of the electrode is confirmed, 1 or 2 radiofrequency ablations performed at 70C-80C for 60 seconds. The procedure will take 1-2 hours.
224306919|NCT02345629|BEHAVIORAL|Pain/Symptom Questionnaire|Pain and symptom questionnaire completed at baseline, by phone during first week of study, and once each month by phone during 6 month follow up.
223487943|NCT01542099|DRUG|Remifentanil|"According to previous patient's response, the investigators will allocate the effect site concentration of remifentanil of next patient during single lumen tube intubation. For this allocation of dose of remifentanil the investigators use up-and-down method.~For the first patient, the dose of remifentanil would be fixed at 6.0 ng/ml which we predict as EC50. Step size of dose is 0.5ng/ml."
223487944|NCT00382512|DRUG|Raptiva (efalizumab)|
223487945|NCT01776229|BEHAVIORAL|Exposure, Relaxation, & Rescripting Therapy-Child|Exposure, Relaxation, \& Rescripting Therapy (ERRT) will be conducted once a week for five consecutive weeks for approximately two hours per session. Each treatment session focuses on one of the following topics/skills: psycho-education and investment in treatment, psycho-education, Progressive Muscle Relaxation, diaphragmatic breathing,child-friendly exposure to the trauma-nightmare, and rescription.
223487946|NCT03669471|OTHER|Testing of performance|"The cross-sectional evaluation will involve assessment of:~1. Hip muscle function~2. Single leg jump performance~3. Self-reported hip and groin function~4. Evaluation of return to sport~5. Evaluation of satisfaction regarding usual-care post-operative rehabilitation~The exercise-based treatment will involve criteria-based physiotherapy aiming at improving muscle function around the hip and trunk."
223587058|NCT00370838|DRUG|Clonidine|The initial dose of clonidine was 0.05 mg, twice daily. If needed for tic suppression, the dose was increased weekly by 0.05-0.1 mg, with a maximum dose of 0.4 mg per day. In any individual, dose escalation may have proceeded more slowly, or the dose may have been reduced as necessary. No changes in dosage occurred during the final week of either treatment phase.
223745353|NCT06913270|BEHAVIORAL|Nature Video Distraction (NVD)|"Intervention Description:~Participants in this intervention will receive the same standard analgesic care provided to all subjects and, in addition, will watch a nature video on a tablet device during the burn dressing change. The video distraction serves as an active comparator to the immersive VR. The nature video is selected to be calming and engaging, and it will be played continuously during the dressing change session (approximately 10-15 minutes). This intervention allows evaluation of whether immersive VR provides additional benefit in reducing procedural pain and anxiety over a standard video distraction."
223745354|NCT05040360|DRUG|Capecitabine|Given PO
223745355|NCT05040360|DRUG|Temozolomide|Given PO
223745356|NCT07144800|BEHAVIORAL|Parent Weekly Individual Telephone Support|Interventionists will deliver a 20-30 minute session via videoconference (e.g. Zoom) using the Family COMIDA Intervention Manual
224178621|NCT03343990|PROCEDURE|Interlocking multi-twisted wires in sternal closure|One of many ways in cloure of sternal give more stabilization. At least 6 wires have to be passed. The wirs should run around the sternum in the intercostals spaces except in the manubrium where it has to be passed through the bone . Adjacent wires on the surgeon's side are wrapped around each other. The wires on the surgeon's side are then pulled towards the assistant so that the sternum is re-approximated. Alternatively the surgeon can also pull the wires at the assistant's side towards himself or herself approximating the sternum. Adjacent wires on the assistant's side are then wrapped around each other. The wrapped wires on both sides are then wrapped around each other The wrapped wires are then twisted around with a twister, closing the sternum tightly and the ends of the are burried
224306920|NCT02345629|PROCEDURE|Sharpness Sensory Testing|Sharpness detection determined using 8, 10, 16, 20, 32, 64, and 128g weighted needle devices. Each stimulus applied for about 1 second in ascending order. Participants asked to rate each stimulus as producing the sensation of touch, pressure, sharp, or pain. The sharpness detection threshold defined as the mean force of the stimuli deemed ''sharp'' or ''painful'' from 3 trials separated by an average interval of 30 to 90 seconds.
223487947|NCT05608655|DEVICE|DKutting LL balloon|After pre-dilation balloon is used (if any), DKutting LL balloon is used as final dilatation balloon before Stent implantation or Drug Coated Balloon deployment
223487948|NCT05608655|DEVICE|Chocolate balloon|After pre-dilation balloon is used (if any), Chocolate balloon is used as final dilatation balloon before Stent implantation or Drug Coated Balloon deployment
223487949|NCT01694238|PROCEDURE|Cruciate incision|
223745357|NCT07144800|BEHAVIORAL|Child Education|6 weekly diet/PA education sessions ('Child Education')
224306921|NCT02345629|PROCEDURE|Heat Pain Sensory Testing|Thermal ramps will applied using a 3.6 x 3.6 cm Peltier thermode (Medoc Inc.) from a baseline temperature set at 32C. Skin heated at a rate of 0.30C/s, and participants asked to signal when the stimulus is perceived as first becoming warmer and then painfully hot.
224306922|NCT04808180|OTHER|Biorepair Shock Treatment|Teeth from this group will undergo the application of Biorepair Toothpaste for the first 7 days of the month for 9 months (1 application per day that lasts 10 minutes).
223487950|NCT01694238|PROCEDURE|Circular incision|
223587059|NCT04046250|DRUG|TK-112690|TK112690 treatment pre-methotrexate treatment
223587060|NCT04046250|DRUG|Placebo TK-112690|Placebo
223587061|NCT02166827|DEVICE|NeuroAD|Synchronized TMS and cognitive stimulation to 6 brain areas.
223745358|NCT07144800|BEHAVIORAL|Parent Initial Counseling|Interventionists will deliver a 20-30 minute session via videoconference (e.g. Zoom) using the Family COMIDA Intervention Manual
223745359|NCT07144800|BEHAVIORAL|Parent Monthly Group Support|Parents will be invited to join a Spanish language (English if preferred) weekly group videoconference (can join by phone if preferred).
223745360|NCT07146503|DRUG|Esketamine (Intranasal Spray)|Esketamine Intranasal Spray at a dosage ranging from 28 to 84 mg weekly, with twice-weekly administration during the first month of treatment, according to the approved labeling
224306923|NCT04808180|OTHER|No treatment|Teeth from this group will not be treated with the experimental toothpaste.
224178622|NCT03343990|PROCEDURE|Eight Figure techniqe in sternal closure|The figure-eight closure is described as faster, simpler, and more reliable than its trans-sternal counterpart; with only oblique forces sutures are less likely to loosen or fracture the sternum. The advantage of figure-eight closure is that it allows oblique and horizontal angle of shearing forces instead of direct perpendicular forces. Thus these wires are less likely to loosen or fracture
224178623|NCT03480360|DRUG|Cyclophosphamide|14.5 mg/kg for 2 days (days -6, -5) and then 50 mg/kg for two days (days 3, 4)
224178624|NCT03480360|DRUG|Fludarabine|30 mg/m2 daily for 5 days
224178625|NCT03480360|RADIATION|Total Body Irradiation|200 centigray (cGy) for one day (day -1)
224178626|NCT03480360|DRUG|Tacrolimus|1 mg IV daily, (or the oral equivalent) adjusted to achieve a level between 5 and 15 ng/ml. If there is no evidence of GVHD, discontinue Tacrolimus by Day 180.
224178627|NCT03480360|DRUG|cellcept|dose at 15 mg/kg po three times per day (maximum dose of 3 grams/day). Stop Cellcept at Day 35 following transplantation.
224178628|NCT03480360|DRUG|g-csf|5 mcg/kg/d starting day 5 and continue until Absolute Neutrophil Count (ANC) \> 1000/mcL for 3 days.
224178629|NCT03480360|PROCEDURE|Peripheral Blood Transplant|cell dose goal: \< 5 x 106 Hematopoietic progenitor cell antigen CD34+ cells/kg recipient weight
224306924|NCT02174380|OTHER|Active Household Contact Evaluation|Active evaluation of TB household contacts will be introducted as a new intervention in the district. The intervention will be undertaken by routine public health staff under routine conditions, however the assignment, training, monitoring and supervision of this intervention will occur in a stepped wedge roll out.
223487951|NCT01694238|OTHER|Mesh enforced cruciate incision|
223487952|NCT01767220|PROCEDURE|Strategy 1 - endocardial ablation|VT substrate mapping and VT ablation are done only from endocardial. Therefore the catheters are introduced through the femoral veins/arteries. For mapping and ablation a 3,5 mm irrigated tip catheter (Navistar Thermocool, Biosense Webster, Diamond Bar, CA, USA) will be used.
223487953|NCT01767220|PROCEDURE|Strategy 2 - endocardial and epicardial ablation|VT substrate mapping and VT ablation are done from endocardial and epicardial. Therefore the catheters are introduced through the femoral veins/arteries and into the pericardial space via a pericardial puncture. After endocardial and epicardial mapping, ablation is done from endocardial. In case of an ineffective endocardial ablation and an epicardial substrate an epicardial ablation is done. For mapping and ablation from endo- and epicardial a 3,5 mm irrigated tip catheter (Navistar Thermocool, Biosense Webster, Diamond Bar, CA, USA) will be used.
223487954|NCT04406792|BEHAVIORAL|DPP only|Participation in the online DPP only with a mixed group of participants at risk for type 2 diabetes and doula divas are not the team leaders.
223487955|NCT04406792|BEHAVIORAL|Diabetes Prevention Program (DPP) online + doula divas|Participation in the DPP online intervention with doula divas as team leaders.
223587062|NCT02166827|DEVICE|Sham TMS+Cog|Sham Device, has the same appearance and sound as the real device, combined with sham cognitive exercises.
223587063|NCT04576897|DIAGNOSTIC_TEST|Velacur|Ultrasound elasticity imaging
223587064|NCT01789216|DRUG|NSAID|
223587065|NCT01789216|DRUG|Gabapentinoids|
223587066|NCT01789216|DRUG|placebo|
224178630|NCT02365961|DRUG|ropivicaine|
224306925|NCT02822495|BIOLOGICAL|tabelecleucel|Tabelecleucel is being investigated as an off-the-shelf, allogeneic T-cell immunotherapy for the treatment of EBV+ malignancies and diseases.
224306926|NCT05367583|PROCEDURE|Allogeneic Stem Cell Transplantation|Allogeneic Stem Cell Transplantation
223487956|NCT03884998|DRUG|Copanlisib|Given IV
223487957|NCT03884998|BIOLOGICAL|Nivolumab|Given IV
223487958|NCT03507790|DRUG|CT1812|Active Study Drug
223587067|NCT01380704|DRUG|ABT-436|QD Days 1-7
223587068|NCT01380704|DRUG|Matching Placebo|QD Days 1-7
223587069|NCT00574548|BIOLOGICAL|13 valent Pneumococcal Conjugate Vaccine|0.5 ml dose 13vPnC will be administered into the deltoid muscle at year 0 and year 1
223587070|NCT00574548|BIOLOGICAL|13 valent Pneumococcal Conjugate Vaccine|0.5 ml dose 13vPnC will be administered into the deltoid muscle at year 0 and 0.5 ml dose 23vPS at year 1
223587071|NCT00574548|BIOLOGICAL|13 valent Pneumococcal Conjugate Vaccine|0.5 ml dose 23vPS will be administered into the deltoid muscle at year 0 and 0.5 ml dose 13vPnC at year 1
223745361|NCT07151924|OTHER|Questionnaires answers|Patients will be asked to complete the MScoff and QACD questionnaires during interviews with the dietitian at baseline, 3 months and 6 months.
224178631|NCT02365961|DRUG|clonidine|
223487959|NCT03507790|DRUG|Placebo|Non-active study drug
223587072|NCT00574548|BIOLOGICAL|23-valent Pneumococcal Polysaccharide Vaccine|0.5 ml dose 23vPS will be administered into the deltoid muscle at year 0 and 0.5 ml dose 13vPnC at year 1
223587073|NCT00574548|BIOLOGICAL|23-valent Pneumococcal Polysaccharide Vaccine|0.5 ml dose 13vPnC will be administered into the deltoid muscle at year 0 and 0.5 ml dose 23vPS at year 1
223587074|NCT00527332|DRUG|Bupivacain|5 mg/mL, 4 mL intrathecally as a single dos
223587075|NCT00527332|DRUG|Morphine|0.4 mg/mL; 0.5 mL intrathecally as a single dosage
223587076|NCT00527332|DRUG|Propofol|2-5 mg/kg body weight/hours IV (intravenously) for sedation during the surgery
223587077|NCT00527332|DRUG|Propofol|Induction of anesthesia with 1-2 mg/kg body weight IV (intravenously). After intubation maintenance dosage of 6-10 mg/kg/hour IV during the surgery
224178632|NCT02365961|DRUG|Epinephrine|
224178633|NCT02365961|DRUG|Noropin|
224178634|NCT04576962|OTHER|Immunization Information System Review|Extraction of county- and state-level data on HPV vaccine completion from Indiana's Immunization Information System
224178635|NCT03674385|DIETARY_SUPPLEMENT|vitamin E|Vitamin E is sold as a dietary supplement, either by itself or incorporated into a multivitamin product. it also has anti-oxidant effect
224178636|NCT03674385|DRUG|Metformin|Metformin is in the biguanide class. It works by decreasing glucose production by the liver and increasing the insulin sensitivity of body tissues. It is also used in the treatment of polycystic ovary syndrome (PCOS)
224178637|NCT03674385|DRUG|Clomiphene Citrate|is a medication used to treat infertility in women who do not ovulate
223587078|NCT00527332|DRUG|Fentanyl|100-200 microgram IV (intravenously) at start of anesthesia. 50-100 microgram IV on demand during surgery.
223587079|NCT00527332|DRUG|Rocuronbromid|0.6 mg/kg body weight IV (intravenously) at induction of anesthesia. If additional muscle relaxation is needed during surgery 5-10 mg is injected IV. The drug is given only at induction of anesthesia and during surgery
223587080|NCT00527332|DRUG|Morphine|5 mg is given IV (intravenously) before end of surgery
223587081|NCT03959787|OTHER|Educational|Educational pamphlet will be given to intervention group.
224178638|NCT00852735|DIETARY_SUPPLEMENT|Rapeseed Oil (prevention of cardiovascular diseases)|to assess the effect of optimized oil (enriched with micronutriments) on the prevention on cardiovascular diseases
224178639|NCT01679964|DRUG|Raltegravir switch|Isentress (400mg) bid + 2 NRTI (at least 2 nucleoside or nucleotide reverse transcriptase inhibitors and no other protease inhibitors)
224178640|NCT05916794|OTHER|Modified Cervical Retraction Exercises (MCRE)|Group A includes Modified cervical retraction exercise The patient is in sitting OR standing position and faces the physical therapist. The MCRE program consisted of alternating head position( neutral, side bending and rotation) while pushing their chin backward patients maintained an upright posture and tried to pull back their shoulders while maintaining this retracted position patient side bend OR rotate their head respectively hold the position for 20 sec.subject performed 5 sets of 10 repetition for 3-4 days per week. Rest intervals of 30 seconds were provided after the completion of 10 repetitions for each pattern and between sets, respectively. The total duration of MCRE will be of approximately 15-20 minutes
224178641|NCT05916794|OTHER|Motor Control therapeutic exercise(MCTE)|Motor control therapeutic exercises will be guided for the retraining of cervical muscles.it include craniocervical flexor exercise,craniocervical extensor exercise, co-contraction of flexors and extensor, a synergy exercise for retraining the strength of the deep neck flexors. Each of these four exercises will be performed for 3 sets of 8 to 10 repetitions, taking an approximate total duration of 15-20 minutes for, 3 days a week
224178642|NCT00006082|DRUG|rubitecan|
224306927|NCT01025115|DIETARY_SUPPLEMENT|Diamel|Two Diamel tablets (Orally administered) three times a day (just before each meal: breakfast, lunch and dinner), for 12 months, together with the standard treatment for metabolic syndrome consisting in appropriate diet according to patient's weight and physical activity, and appropriate hypertensive drugs (generally ACE inhibitors) for hypertension. Patient´s were also verbally encouraged to increase physical activity (to walk for 30-45 minutes a day 3-4 days a week).
224306928|NCT01025115|DIETARY_SUPPLEMENT|Placebo|Two Placebo tablets (Orally administered) three times a day (just before each meal: breakfast, lunch and dinner), for 12 months, together with the standard treatment for metabolic syndrome consisting in appropriate diet according to patient's weight and physical activity, and appropriate hypertensive drugs (generally ACE inhibitors) for hypertension. Patient´s were also verbally encouraged to increase physical activity (to walk for 30-45 minutes a day 3-4 days a week).
224306929|NCT06551571|OTHER|Intrapartum Care Model|\- The Intrapartum Care Model was implemented for all primiparous pregnant women assigned to the intervention group during labor and after delivery by the researcher midwife, in accordance with the World Health Organization's positive birth recommendations
223487960|NCT06181799|DIAGNOSTIC_TEST|Mass spectrometry using the PTR TOF-1000 (IONICON PTR-TOF-MS - Trace VOC Analyzer, Eduard-Bodem-Gasse 3, 6020 Innsbruck, Austria (Europe).|"Once enrolled in the study, all participants are scheduled to undergo the following tests:~Analysis of the exhaled breath volatile organic compounds using real-time analytical methods (PTR-TOF-MS-1000; real-time mass spectrometer with ionization by the proton transfer method) before and after the physical exertion test, during 1 minute. Machine learning models will be employed to analyze the patterns identified in the exhaled air volatilome data.~Before and immediately after the physical exertion test, all participants are scheduled to record a single-lead ECG and pulse wave for 3 minutes, using a portable single-lead recorder (Cardio-Qvark) (Russia, Moscow). Single-lead ECG and pulse wave parameters will be analyzed using machine learning models."
223487961|NCT06294548|DRUG|Valemetostat|Valemetostat is an inhibitor of the enzymes enhancer of zeste homolog 1 (EZH1) and enhancer of zeste homolog 2 (EZH2).
223487962|NCT06294548|DRUG|Atezolizumab|Atezolizumab is commercially available. Atezolizumab combined with bevacizumab is approved for frontline treatment of advanced HCC based on IMbrave150 clinical trial. It will be administered as per the package insert and institutional standards.
223487963|NCT06294548|DRUG|Bevacizumab|Bevacizumab is commercially available. Bevacizumab combined with atezolizumab is approved for frontline treatment of advanced HCC based on IMbrave150 clinical trial. It will be administered as per the package insert and institutional standards.
223487964|NCT01426529|DRUG|Para-aminohippuric Acid|"Aminohippurate sodium is an agent to measure effective renal plasma flow (ERPF). It is the sodium salt of para-aminohippuric acid, commonly abbreviated PAH."
223487965|NCT01426529|DRUG|Angiotensin II|Angiotensin II (Ang II) is a naturally occurring hormone whose primary purpose is to regulate the body's internal volume. It accomplishes this task by influencing the function of a variety of organs and tissues. It increases aldosterone secretion from the adrenal gland. It causes blood vessels to contract, particularly renal blood vessels, and it modifies the way the heart works.
223487966|NCT01426529|DRUG|Norepinephrine|A hormone that is normally present in your body, which regulates your blood pressure.
223587082|NCT02666105|DRUG|Exemestane|One 25 mg tablet once daily for a minimum of 6 weeks
223587083|NCT01392612|DRUG|erythropoietin|Subjects received one single intravenous injection of epoetin alpha (Erypo®, rhEPO, Ortho Biotech/Division of Janssen-Cilag Ag, Bridgewater, New Jersey, US) at a dose of 300 Units per kg bodyweight. Blood was sampled at baseline and 4, 24, 48 and 72 hours after administration of rhEPO during a biosimilarity trial.
223587084|NCT01962870|DRUG|Vasopressin|Participants aged 6 to 9.5 years of age will receive the maximum dose of 24 IU (12 IU twice daily). Participants aged 9.6 to 12 years of age will receive the maximum dose of 32 IU (16 IU twice daily).
223587085|NCT01962870|DRUG|Placebo|
223587086|NCT05230485|OTHER|CPAP level|The level of continuous distending pressure (or positive end-expiratory pressure) chosen on CPAP
223587087|NCT00006056|DRUG|anti-thymocyte globulin|
223587088|NCT00006056|DRUG|busulfan|
223587089|NCT00006056|DRUG|cyclophosphamide|
223745362|NCT07151924|OTHER|Biological assessment|Collection of HbA1c level and continuous glucose monitoring data
223587090|NCT00006056|DRUG|cyclosporine|
224306930|NCT02644005|DEVICE|Smart Vent Control|Smart Vent Control (SVC) was designed to automatically control the following ventilator settings: mechanical breathing frequency, inspiratory pressure, pressure support, inspiratory time, trigger sensitivity. SVC adjusts the ventilator settings with the aim to keep a patient stable in a target zone (TZ). Numerous predefined TZs exist that can be set according to the current therapeutic situation. All TZs are adoptable by the user for each individual patient and consist of upper and lower limits for tidal volume and for the partial pressure of end-tidal carbon dioxide (PetCO2). Based on these limits, the system classifies the current quality of ventilation, called Classification of Ventilation, and derives new ventilator settings accordingly. SVC is available as a software option on Zeus Infinity Empowered anesthesia machines (Drägerwerk AG \& Co. KGAa, Lübeck, Germany) and is approved as a medical product according to 93/42/European Economic Community.
223587091|NCT00006056|DRUG|etoposide|
223587092|NCT00006056|DRUG|filgrastim|
223587093|NCT00006056|DRUG|methotrexate|
223587094|NCT00006056|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
223587095|NCT02687516|BEHAVIORAL|Family-based behavioral social facilitation therapy|"Family-based Behavioral Social Facilitation Treatment (FBSFT) is founded on the principles of standard family-based behavioural therapy for obesity. FBSFT targets life-style behaviors (diet, physical activity and sedentary activity) in a family setting. FBSFT includes some cognitive elements that are considered important in relation to behavioural change for instance problem solving and cognitive restructuring. FBSFT has an intensive treatment phase including weekly family meetings with therapists over 17 consecutive weeks. Further monthly or bi-weekly follow-up sessions with a focus on social facilitation and maintenance of healthy habits are recommended. The dietary guidance of FBSFT is based on the Traffic light diet in which foods are organized into GREEN, YELLOW and RED groups. Activity guidance of FBSFT uses the same system: GREEN activities have the highest intensity and should be engaged in most often, YELLOW activities sometimes, and RED activities."
223587096|NCT02687516|BEHAVIORAL|TAU - Treatment as usual|"This is the default treatment at the obesity clinic. After initial evaluation by paediatrician, nurse, nutritionist and physiotherapist, a contract is written including weight goal, nutritional plan and activity plan. Follow up monthly in primary Health care and every 3rd month at the obesity clinic."
223587097|NCT03994198|DIETARY_SUPPLEMENT|Alpha-lactalbumin|A protein fraction of whey protein, higher in tryptophan
223587098|NCT03994198|DIETARY_SUPPLEMENT|Collagen peptides|Collagen peptides from bovine sources
223587099|NCT04171232|OTHER|Balance It|Each patient in group 1 i.e. Balance It group would be given a 15 minutes long session. Each session would start in standing position and the patient would play the game while they would be instructed to balance the objects falling from above on the imaginary bar (and an actual bar at later stages) held with their both hands, and not let those objects fall by opening their arms wide open and by staying or moving according to the target spot for the set time. This session would be repeated three times a week for two months (total 12 sessions/month).
223587100|NCT04171232|OTHER|Bubble Pop|Each patient in group II i.e. Bubble Pop group would be given a 15 minutes long session. Each session would start in standing position and the patient would play the game while they would be instructed to reach for the balloons coming from random directions and pop them by moving their upper limbs and even their whole body if required. They would also be instructed to avoid a specific object that would result in deduction of their overall game score. This session would be repeated three times a week for two months (total 12 sessions/month).
223587101|NCT04171232|OTHER|Scoop'd|Each patient in group III i.e. Scoop'd group would be given a 15 minutes long session. Each session would start in standing position and the patient would play the game while they would be instructed to hold an imaginary ice cream cone (and an actual basket designed similar to an ice cream cone in later stages) with their both hands and move to catch the ice cream scoops falling at random spots from above, one spot at a time. They would also be instructed to avoid a specific object that would result in deduction of their overall game score. This session would be repeated three times a week for two months (total 12 sessions/month).
224306931|NCT00252200|DRUG|Neseritide|Dose of Nesiritide infusion will be 0.005 ug/Kg/min
224306932|NCT04769414|DRUG|Gemcitabine fluorouracil|"chemotherapy protocol given as:~* Gemcitabine 1000mg/m2 IV short infusion~* Leucovorin 400 mg/m2 IV short infusion~* Flourouracil 400 mg/m2 direct IV shot~* Flourouracil 2000 mg/m2 contineous infusion over 46 hours~The whole regimen will be repeated bi-weekly"
224306933|NCT05949710|BEHAVIORAL|aerobic exercise(AE)|The participants will receive AE three times per week.
224306934|NCT03122288|BEHAVIORAL|Individualized Cognitive Training|These are specific computerized exercises that are designed to improve performance in particular cognitive domains (e.g., attention, speed of processing, verbal learning/memory).
224306935|NCT03122288|OTHER|No-Contact Control|This is simply a no-contact control group. Participants in this group will receive no additional contact with the study beyond the baseline and posttest assessments.
224306936|NCT06223087|OTHER|winter swimming|Intervention involves bathing/swimming in cold water during the winter months in open waters
224306937|NCT02032797|DRUG|Progesterone|
224306938|NCT01339338|PROCEDURE|warming the contrast media|warm the contrast media with 37℃ water-bathing
224306939|NCT02513030|PROCEDURE|Defibrillation testing during ICD replacement|
224306940|NCT01715571|DEVICE|Viberect|"Men will be asked to perform vibratory stimulation of the penis in the privacy of their home, while focused on sexual thoughts for approximately 7-10 minutes (depending on erectile response) for 3 times a week, one day apart, throughout the four week period. Men can perform the stimulation once daily, as long as each session is more than 24 hours apart.~Men will record device use and intercourse attempts after device use in a diary."
224306941|NCT02135471|DRUG|acellular dermal matrix graft|On one side, the previously reflected partial-thickness flaps will be coronally positioned to entirely cover the acellular dermal matrix graft (ADMG), and also sutured with sling sutures using 6-0 bioabsorbable sutures.
224306942|NCT02135471|DRUG|enamel matrix derivative|On the other side, the same procedure will be performed, with an additional layer of enamel matrix derivative between the acellular dermal matrix graft (ADMG) and the flap, and between the ADMG and the root surface by using a sterile brush.
224178643|NCT00846352|PROCEDURE|Variation in the time for performing bronchoscopy|The study will compare outcomes amongst patients assigned to receive early bronchoscopy (within 36 hours of enrollment)versus those in whom bronchoscopy is delayed (5 days after enrollment).
224178644|NCT05476757|BIOLOGICAL|rDEN2Δ30-7169|rDEN2Δ30-7169 will be inoculated at Study Day 0. After 6 months of the inoculation, the participants will be vaccinated with Dengvaxia® until completion of 3 doses with 6-month interval between each dose.
224178645|NCT00923962|DRUG|Glucagon like peptide-1|0,1 pmol/kg/min
224178646|NCT00923962|DRUG|Adenosine|20-40 microgram/minute
224178647|NCT00604357|DRUG|anti-CD 25 mAb, Sirolimus, MMF|"Prior to reperfusion: 500 mg Prednisolone After OLT: anti-CD25-mAB (basiliximab 20 mg on day 0 and day 4 after the procedure)~MMF 2 g/d, 2 applications per day i.v., later conversion to oral intake)~Earliest, on day 10 after LT Sirolimus: 5 mg/d, thereafter a dosage of 2 mg/d (4 and 8 ng/mL)~Steroids: 1mg/kg BW (tapered every 2 days for 5 mg to a dosage of 20 mg, 2.5 mg every two days to 7.5 mg, reduced to 5 mg and 2.5 mg for 1 week each and eliminated thereafter)."
224178648|NCT02490904|DRUG|Eplerenone|Double-blinded Eplerenone administered for 4 days at 25mg every 12 hours
224178649|NCT02490904|DRUG|Placebo|Double-blinded Placebo administered for 4 days at 25mg every 12 hours
224178650|NCT04951882|BIOLOGICAL|human derived umbilical cord derived mesenchymal stem cells|intravenous transplantation of human derived umbilical cord derived mesenchymal stem cells
224178651|NCT05078476|OTHER|Manchester Short Splint|3-5 days after tendon repair the patient will start with hand therapy and the described protocol.
224178652|NCT05078476|OTHER|Relative Motion Flexion|3-5 days after tendon repair the patient will start with hand therapy and the described protocol.
224178653|NCT01084096|BEHAVIORAL|Increasing use of Antenatal Corticosteroids (ACS)|"Intervention clusters:~* Increasing administration of ACS to pregnant women at high risk of preterm birth (HRPB) by providing health providers with kits containing dexamethasone, syringes, and instructions. Eligible women receive four injections of 6 mg dexamethasone from the kit or regimen of choice at the site.~* Improving identification of women at HRPB by diffusing recommendations for ACS use to health care providers, training health care providers to identify signs of preterm labor and eligibility criteria for ACS use, providing reminders to healthcare providers on the use of the kits, and using a color-coded tape to measure uterine height to estimate gestational age in women at HRPB with unknown gestational age.~Control clusters: no specific intervention for comparison. Both intervention and control clusters: Birth attendants trained in essential newborn care of LBW infants and instructed to teach mothers how to provide care to premature infants."
224178654|NCT02033720|OTHER|No treatment|No therapeutic hypothermia was induced.
224178655|NCT02033720|OTHER|Therapeutic hypothermia|Hypothermia was induced after successful resuscitation from cardiac arrest.
224306943|NCT04524364|DEVICE|Pulsed Field Ablation (PFA) Therapy|Participants will undergo PFA therapy with a compatible ablation catheter when used with Multi-Channel irreversible electroporation (IRE) Generator (deliver trains of high-voltage bipolar pulses of short duration on separate channels to a multi-electrode ablation catheter) and Circular IRE Catheter (indicated for use in catheter-based cardiac electrophysiological mapping (stimulating and recording) and, when used with an IRE Generator, for cardiac ablation).
224306944|NCT05784532|DEVICE|STERN FIX|Sternotomy closure with STERN FIX and supplemented with wires
224306945|NCT00555152|OTHER|Laboratory Biomarker Analysis|Correlative studies
224306946|NCT00555152|DRUG|Lapatinib Ditosylate|Given PO
224306947|NCT00555152|OTHER|Placebo|Given PO
224306948|NCT03983915|DRUG|Dexmedetomidine|Dexmedetomidine was used as a sedation agent with less side effect on respiratory system.
224306949|NCT03983915|DRUG|Remifentanil|Remifentanil was used to prevent cough induced by bronchoscopy.
223587102|NCT04361240|RADIATION|Proton vs Photon Radiation|Assignment to proton vs photon by randomization on RadComp parent study.
224178656|NCT01354964|DRUG|Vitamin D|
224178657|NCT01354964|DRUG|Placebo|
224178658|NCT02789761|DIETARY_SUPPLEMENT|High-flavanol milk choocolate|
224178659|NCT02789761|DIETARY_SUPPLEMENT|Low-flavanol milk chocolate|
224306950|NCT03983915|DEVICE|Laryngeal mask|Laryngeal mask was used to ensure respiration function during general anesthesia.
223587103|NCT06480149|OTHER|SMALC|Classical shoulder massage was applied to both shoulders of the patient for 10-15 minutes each.
223587104|NCT06480149|OTHER|no application|In the control group, there was no massage application and only pain and sleep quality were evaluated.
223587105|NCT02253485|DRUG|telbivudine|"in telbivudine treatment entire pregnancy group, mothers were treated with telbivudine during entire pregnancy for hepatitis B.~in telbivudine treatment in late pregnancy group, mothers with high serum HBV DNA load receive telbivudine treatment in late pregnancy for preventing MTCT of HBV."
223587106|NCT04416906|DRUG|Biktarvy|Once daily fixed dose combination regimen of Biktarvy will be evaluated as a rapid treatment strategy in newly HIV diagnosed patients HIV diagnosed patients that come for the first time to the Hospital Clínic HIV Unit
224306951|NCT01869985|DRUG|HCP1104 / Mulex Tab. and Airtal Tab.|HCP1104 / Eperisone plus Aceclofenac
224306952|NCT02467478|DRUG|Linagliptin|5 mg tablet once daily for 12 weeks
224306953|NCT02467478|DRUG|Placebo|1 tablet daily for 12 weeks
224306954|NCT06583473|BEHAVIORAL|Interactive digital health application|The study program will provide an integrated interactive digital health application (LINE app on smartphones, incorporating information about biodata recording, health education, questionnaires, and online Q\&A)
224306955|NCT05786716|DRUG|Trastuzumab|An initial loading dose of 8 mg/kg body weight, followed thereafter by a maintenance dose of 6 mg/kg body weight administered intravenously every 21 days. Patients may continue until disease progression without clinical benefit, unacceptable toxicity or withdrawal of consent.
224306956|NCT05786716|DRUG|Pertuzumab|An initial loading dose of 640 mg, followed thereafter by a maintenance dose of 420 mg administered intravenously every 21 days. Paediatric patients will receive an initial loading dose of 14 mg/kg (maximum 840 mg), followed thereafter by a maintenance dose of 7 mg/kg (maximum 420 mg) administered intravenously every 21 days. Patients may continue until disease progression without clinical benefit, unacceptable toxicity or withdrawal of consent.
224306957|NCT02578030|DRUG|SHP465 12.5mg|
224306958|NCT02578030|DRUG|SHP465 25mg|
223587107|NCT00853138|BEHAVIORAL|cognitive-behavioral therapy|"In addition to standard medical care, the children and parents in the family CBT condition will also receive education about chronic pain, pain behaviors and operant strategies as well as training in coping skills using an interactive, engaging format on the Internet.~The Internet site will consist of three main sections: child treatment modules, parent treatment modules, and diary tracking. All users will complete 8 treatment modules (one per week) over the 8-week treatment period. Each module will require approximately 30-40 minutes to complete. There is separate specific content of the intervention for child users and for parent users.~Assignments are incorporated into each module for the participant to work on during the treatment week."
224178660|NCT04099329|BEHAVIORAL|Pre-game Safety Huddles|Coaches will be trained to lead Pre-game Safety Huddles by the RA with the study using a multi-media tool we have developed. Huddles will be brief (1-2 minutes) and will primarily focused on 1) encouraging concussion reporting and 2) encouraging good sportsmanship
224178661|NCT00957736|GENETIC|polymorphism analysis|Will assess the SNPs present in both the donor and to host and correlate the SNPs with outcome based in the NIH consensus criteria for cGVHD. Candidate SNPs will include but are not limited to TGF-β18, mannose binding lectin19, myeloperoxidase, HSP 70, minor histocompatability antigens, KIR, CCL513, NOD2/CARD1512, TNFα11, TNF R II, IL-1010, 11, IL-1317, IL-620, IFN-γ20, IL-1 RA21, IL-2315, and IL-1516. Other candidate genes will be assessed on current review of the literature and candidate SNPs will be added based on their relationship to aGVHD, cGVHD, autoimmune disease, pharmacogenetics, and other immunologic processes. The genes will be assessed for gene frequency using the HapMap and SNP databases prior to statistical analysis.
224178662|NCT00957736|OTHER|laboratory biomarker analysis|Will assess the SNPs present in both the donor and to host and correlate the SNPs with outcome based in the NIH consensus criteria for cGVHD. Candidate SNPs will include but are not limited to TGF-β18, mannose binding lectin19, myeloperoxidase, HSP 70, minor histocompatability antigens, KIR, CCL513, NOD2/CARD1512, TNFα11, TNF R II, IL-1010, 11, IL-1317, IL-620, IFN-γ20, IL-1 RA21, IL-2315, and IL-1516. Other candidate genes will be assessed on current review of the literature and candidate SNPs will be added based on their relationship to aGVHD, cGVHD, autoimmune disease, pharmacogenetics, and other immunologic processes. The genes will be assessed for gene frequency using the HapMap and SNP databases prior to statistical analysis.
224178663|NCT03539666|OTHER|diet|dietary patterns
223487967|NCT06403943|DRUG|BaiDiZiYin Pill, ShenQiYiFei Pill|"Indications of BaidiZiyin Pill: Nourishing the lungs and kidneys, cooling blood and removing steam. Used as an adjunctive treatment for tuberculosis caused by lung and kidney deficiency and qi yin injury, including coughing, shortness of breath, dry cough with less phlegm, hot flashes and night sweats, cold and spontaneous sweating, hoarseness, palpitations, cold limbs, and emaciation.~Indications of ShenqiYifei Pill: expectorant and cough relieving. It is suitable for patients with pulmonary tuberculosis and spleen diseases, as well as phlegm dampness retention. Symptoms include short breath, low sound, clear and thin phlegm, limited appetite, bloating and loose stools, pale complexion, fatigue and chest tightness, emaciation, and fear of cold and spontaneous sweating."
223487968|NCT06403943|DRUG|Anti tuberculosis chemotherapy|2 months' intensive regimen of anti tuberculosis chemotherapy Recommended first-line anti tuberculosis regimen: 2HRZE
223587108|NCT04243733|OTHER|CEM and MTA|Pulpotomy agent
223587109|NCT04243733|OTHER|MTA and CEM|Pulpotomy agent
223587110|NCT05101798|DRUG|5-Aminolevulinic acid Hydrochloride|The closure consists of colorless glass vial (Type II, Ph Eur) and bromobutyl-rubber stopper ø 20 mm (Type I, Ph Eur) and flip cap. The powder for oral solution is intended for single (partial) use. To prepare the ready-to-use solution the content of one vial is dissolved in 50 ml of water or apple juice. The concentration of the reconstituted solution is 3%. Gleolan® is administered orally to patients prior to tumor removal by surgery (20 mg/kg BW). The reconstituted solution may be prepared up to 24 hours prior to use if protected from light. It should be given 3 hours (range 3-5 hours) prior to planned induction of anesthesia for surgery, although its effect is present for up to 8-12 hours. This step is critical for an optimal visualization of tumor tissue due to pharmacokinetic properties of Gleolan®.
223587111|NCT06156748|PROCEDURE|postoperative adjuvant transarterial chemoembolization|HCC patients received hepatectomy and PA-TACE.
223587112|NCT05614037|DRUG|Felodipine sustained release tablets (trade name: plendil®)|Reference preparation (R) : Felodipine sustained release tablets (trade name: plendil ®) Specification: 5 mg Batch number: 2204 a11 Content: 99.1% Valid until March 2025 Storage conditions: below 25℃ Manufacturer: AstraZeneca AB Supplier: Overseas Pharmaceuticals, Ltd. Usage: Oral, 1 tablet at a time, once a day. Take it before bed and swallow it with water. Do not break, press or chew the pill.
224178664|NCT03354065|DIETARY_SUPPLEMENT|TIME OF FEEDING|Liquid ( Re Feeding 8 h ) OR Enteral Feeding ( re feeding 48 h)
224306959|NCT05626855|DRUG|Apitegromab|Apitegromab (SRK-015) is an investigational, fully human immunoglobulin G4 monoclonal antibody that specifically binds to human proforms (i.e., inactive precursor forms) of myostatin, pro- and latent- myostatin, with high affinity, inhibiting activation of myostatin, a negative regulator of muscle growth and strength.
223587113|NCT05614037|DRUG|Felodipine Controlled Release Tablets|Test preparation (T) :Felodipine Controlled Release Tablets Specification: 5 mg Batch number: 22090301 Content: 100.8% Valid until: September 2024 Storage conditions: sealed, room temperature (10\~30℃) Manufacturer: Overseas Pharmaceuticals, Ltd. Supplier: Overseas Pharmaceuticals, Ltd. Usage: Oral, 1 tablet at a time, once a day. Take it before bed and swallow it with water. Do not break, press or chew the pill.
223587114|NCT02100969|DRUG|HIZENTRA ®|Patients must fulfill inclusion criteria and remain stable at week 0, which means QMG does not increase by 3 points, will enter receive Hizentra for 12 weeks.
224306960|NCT06853197|DIETARY_SUPPLEMENT|Mitopure (Urolithin A)|Mitopure (Urolithin A) is gut microbiome derived postbiotic that has been shown to improve muscle and mitochondrial health
224306961|NCT03806842|DEVICE|Easytech group|total shoulder replacement
223587115|NCT01629953|OTHER|Group vocational intervention|Group based manualized vocational rehabilitation
223587116|NCT01629953|OTHER|Supported Employment Condition|Veterans in this condition will receive a proven group based manualized vocational rehabilitation intervention
223587117|NCT05936528|DRUG|Lactoferrin|antioxidant, immunomodulatory, anti-inflammatory, antimicrobial effect
223587118|NCT05936528|DRUG|Antioxidant therapies|Acetyl cysteine 600 mg / 12 hr
223587119|NCT05936528|DRUG|Dexamethasone|dexamethasone I.V 8 mg / day
223587120|NCT05936528|DRUG|Antibacterial therapies|Antibacterial drugs in their approved doses
224306962|NCT00723723|DRUG|Statin|Statin
224306963|NCT05418504|DRUG|Dental anesthesia|Dental anesthesia, used to do any dental procedure
224306964|NCT04480710|DRUG|CRV431 75mg|1 x 75mg softgel capsule
224306965|NCT04480710|DRUG|Placebo (1 softgel)|1 x placebo softgel capsule
224306966|NCT04480710|DRUG|CRV431 225mg|3 x 75mg softgel capsule
224306967|NCT04480710|DRUG|Placebo (3 softgels)|3 x placebo softgel capsule
224306968|NCT01152619|DRUG|Placebo|Subcutaneous repeated dose
223487969|NCT02296125|DRUG|AZD9291 80 mg/40 mg + placebo|"The initial dose of AZD9291 80 mg once daily can be reduced to 40 mg once daily under specific circumstances. A cycle of treatment is defined as 21 days of once daily treatment.~Number of Cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria."
224178665|NCT03836014|COMBINATION_PRODUCT|Daratumumab/Lenalidomide/Dexamethasone for 24 months|"Conditioning regimen: 16 mg/kg IV :~* Weekly (Cycles 1 and C2)~* Every two weeks (C3 to C6)~* Monthly from C7 up to 24 months in total (Arm 1)~Infusion reaction prophylaxis :~* Acetaminophen (paracetamol) 650-1000 mg IV or orally (PO) approximately 1 hour or less prior to infusion~* An antihistamine (diphenhydramine 25-50 mg IV or PO, or equivalent but avoid IV use of promethazine) approximately 1hour prior to infusion; after Cycle 6, if a subject has not developed an infusion-related reaction and is intolerant to antihistamines, modifications are acceptable as per investigator discretion~* Dexamethasone 40 mg IV (preferred) or PO, approximately 1 hour or less prior infusion.~Lenalidomide:~Conditioning regimen: 25 mg per os. From day 1 to day 21 of each cycle up to 24 months in total (Arm 1)~Dexamethasone:~Conditioning regimen: 40 mg at day 1 (preinfusion medication IV preferred), day 8, day 15 and day 22 per os of each cycle up to 24 months in total (Arm 1)"
224306969|NCT01152619|DRUG|RO4989991|Subcutaneous repeated dose
224306970|NCT03761264|DRUG|Odontopaste®|Teeth with abscess will be opened from the crown to allow cleaning of the canals following which the Odontopaste® will be placed in the canals and the pulp chamber. Cavity will be sealed with capsulated Glass ionomer cement.
224306971|NCT03761264|DRUG|Pulpdent|Teeth with abscess will be opened from the crown to allow cleaning of the canals following which the Pulpdent paste will be placed in the canals and the pulp chamber. Cavity will be sealed with capsulated Glass ionomer cement.
223487970|NCT02296125|DRUG|Placebo Erlotinib 150/100mg|The initial dose of Placebo Erlotinib 150 mg once daily can be reduced to Placebo 100 mg once daily under specific circumstances. A cycle of treatment is defined as 21 days of once daily treatment. Number of cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.
223487971|NCT02296125|DRUG|Placebo Gefitinib 250 mg|The initial dose of Placebo Gefitinib 250 mg once daily cannot be reduced. A cycle of treatment is defined as 21 days of once daily treatment. Number of cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.
223487972|NCT02296125|DRUG|Erlotinib 150/100 mg|"The initial dose of Erlotinib 150mg once daily can be reduced to 10 mg once daily under specific circumstances. A cycle of treatment is defined as 21 days of once daily treatment.~Number of Cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.~Following objective disease progression according to RECIST 1.1, as per investigator assessment, patients who were randomized to Standard of Care arm may have the option to receive open-label AZD9291 (crossover to active AZD9291)."
223487973|NCT02296125|DRUG|Gefitinib 250 mg|"The initial dose of Gefitinib 250mg once daily cannot be reduced. A cycle of treatment is defined as 21 days of once daily treatment.~Number of Cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.~Following objective disease progression according to RECIST 1.1, as per investigator assessment, patients who were randomized to Standard of Care arm may have the option to receive open-label AZD9291 (crossover to active AZD9291)."
223587121|NCT02189512|OTHER|blood sampling|cases - blood sampling controles - blood sampling
223617725|NCT01573546|BEHAVIORAL|Aerobic Exercise|Participants will exercise for 6 months. In the initial 3-month supervised phase, patients will exercise 3 times a week at a level of 50-75% of their initial peak heart rate reserve (HRR) or at their peak heart rate without symptoms, or ST-segment depression \> 1 mm, as determined at the time of their initial exercise test. Aerobic exercise consists of 10 minutes of warm-up exercises followed by 30 minutes of continuous walking or (stationary) biking. Each exercise session will conclude with a 10 minute period of cool-down exercises. During weeks 13 to 24 (i.e., home maintenance phase), participants will be asked to perform 3 aerobic sessions per week at home at 60-70% HRR.
224306972|NCT03761264|DRUG|Amoxicillin|Teeth with abscess will be opened from the crown to allow cleaning of the canals . A sterile cotton pellet will be placed in the pulp chamber and cavity sealed with capsulated Glass ionomer cement. The patient will be prescribed oral amoxicillin at 15mg/kg body weight tds for 5 days
224306973|NCT05655221|DRUG|B1344|multi-site abdominal s.c. injections (maximum 2 mL at each site)
224306974|NCT05655221|OTHER|Placebo|multi-site abdominal s.c. injections (maximum 2 mL at each site)
224306975|NCT04686552|DIETARY_SUPPLEMENT|cinnamon|6 g of ground cinnamon
224306976|NCT04823975|BEHAVIORAL|Health Insurance Education Program (HIEP)|\[See arm/group description\]
224306977|NCT05468424|OTHER|tablet (iPad or android) based role-playing game|The intervention is a tablet (iPad or android) based role-playing game called FarmVille. In FarmVille the player assumes the role of a farmer tasked with tending to crops and farm animals and using what is produced to craft goods which can be sold to expand the farm. The participant is required to play FarmVille for 5 or more hours a week for 8 weeks.
224306978|NCT05468424|OTHER|tablet (iPad or android) based word puzzles and image puzzles|"This intervention is a selection of tablet (iPad or android) word puzzles and image puzzles. One word puzzle involves word making (i.e., making words from a set of random letters), and the other word searching (i.e., finding words on a grid of letters). One image puzzle is Flow Free, a game that requires the player to connect pairs of same coloured dots positioned on a grid ranging from 5x5 to 9x9. The other image puzzle is a jigsaw. The participant is required to play these games for 5 or more hours a week for 8 weeks."
223487974|NCT02296125|DRUG|Placebo AZD9291 80 mg/ 40 mg|The initial dose of Placebo AZD9291 80 mg once daily can be reduced to Placebo AZD9291 40 mg once daily under specific circumstances. A cycle of treatment is defined as 21 days of once daily treatment. Number of cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.
224178666|NCT03836014|COMBINATION_PRODUCT|Daratumumab/Lenalidomide/Dexamethasone until progression|"Conditioning regimen: 16 mg/kg IV :~* Weekly (Cycles 1 and C2)~* Every two weeks (C3 to C6)~* Monthly from C7 until disease progression (Arm 2).~Infusion reaction prophylaxis :~* Acetaminophen (paracetamol) 650-1000 mg IV or orally (PO) approximately 1 hour or less prior to infusion~* An antihistamine (diphenhydramine 25-50 mg IV or PO, or equivalent but avoid IV use of promethazine) approximately 1hour prior to infusion; after Cycle 6, if a subject has not developed an infusion-related reaction and is intolerant to antihistamines, modifications are acceptable as per investigator discretion~* Dexamethasone 40 mg IV (preferred) or PO, approximately 1 hour or less prior infusion.~Lenalidomide:~Conditioning regimen: 25 mg per os. From day 1 to day 21 of each cycle until disease progression (Arm 2).~Dexamethasone:~Conditioning regimen: 40 mg at day 1 (preinfusion medication IV preferred), day 8, day 15 and day 22 per os of each cycle until disease progression (Arm 2)."
224178667|NCT01963910|DRUG|30% Mannitol in vehicle cream|applied to one half of the upper lip following removal of capsaicin cream.
224306979|NCT06971367|BEHAVIORAL|Risk assessment messaging|Participants will be shown a brief video message at their baseline visit, containing information related to HIV risk assessment core concepts and encouraging them to return for a repeat HIV test. They will also receive brief SMS follow-up messages at about 8 and 11 weeks after baseline reminding them about HIV retesting and re-emphasizing concepts from the HIV risk assessment content category.
224306980|NCT06971367|BEHAVIORAL|U=U messaging|Participants will be shown a brief video message at their baseline visit, containing information related to U=U core concepts and encouraging them to return for a repeat HIV test. They will also receive brief SMS follow-up messages at about 8 and 11 weeks after baseline reminding them about HIV retesting and re-emphasizing concepts from the U=U content category.
224306981|NCT06971367|BEHAVIORAL|Community benefits messaging|Participants will be shown a brief video message at their baseline visit, containing information related to Community Benefits core concepts and encouraging them to return for a repeat HIV test. They will also receive brief SMS follow-up messages at about 8 and 11 weeks after baseline reminding them about HIV retesting and re-emphasizing concepts from the Community Benefits content category.
223487975|NCT05456503|DRUG|FPI-2620|Radiotracer
223487976|NCT03611738|DRUG|Ceritinib|Ceritinib daily by mouth (PO) with food, according to the dosage schedule outlined in the treatment arm.
223487977|NCT03611738|DRUG|Docetaxel|Docetaxel intravenously (IV) every 3 weeks, according to the dosage schedule outlined in the treatment arm.
223487978|NCT05935787|DRUG|Cytoflavin (Inosine + Nicotinamide + Riboflavin + Succinic Acid)|Cytoflavin (Inosine + Nicotinamide + Riboflavin + Succinic Acid), 20 ml (two ampoules of 10 ml each) once a day intravenously in a dilution of 200 ml of 0.9% sodium chloride solution at a rate 3-4 ml/min, for 15 days + Cytoflavin ((Inosine + Nicotinamide + Riboflavin + Succinic Acid), 2 tablets 2 times a day, for 25 days
223487979|NCT05935787|DRUG|Placebo|Placebo, 20 ml (two ampoules of 10 ml each) once a day intravenously in a dilution of 200 ml of 0.9% sodium chloride solution at a rate 3-4 ml / min, for 15 days + Placebo, 2 tablets 2 times a day, for 25 days
223487980|NCT00481546|GENETIC|rAAV2-CBSB-hRPE65|One or two, uniocular, subretinal injections; relative doses: 0.3X (Cohort 1), 0.6X (Cohort 2), 0.45X (Cohort 3), 0.9X (Cohorts 4 and 5)
223487981|NCT02098772|DRUG|Custodiol-N|comparison of two cardioplegic solutions, Custodiol-N versus Custodiol, in aortic valve surgery
223487982|NCT02098772|DRUG|Custodiol|comparison of two cardioplegic solutions, Custodiol-N versus Custodiol, in aortic valve surgery
223487983|NCT00457353|DRUG|Bacillus Clausii|For 5 days
223487984|NCT00457353|OTHER|Oral rehydration therapy|For 5 days
223487985|NCT01160614|DRUG|Oxycodone hydrochloride controlled-release (ORF) tablets|Oxycodone hydrochloride controlled-release (ORF) tablets (10 mg, 15 mg or 20 mg) taken every 12 hours
223487986|NCT03543163|PROCEDURE|Non- Pedicled Buccal Fat Pad with Coronally Advanced flap|A horizontal incision of 1.5cm in long will be made at the bottom of the vestibule with the #15 blade in the region of maxillary first and second molars, depending on side of the recipient site. A curved hemostat will be used in the blunt dissection through the buccinators muscle to temporarily reposition and loose the surrounding fascia which will allow the buccal fat pad to be exposed in the oral cavity. A portion of adipose tissue equals to the required graft size will be excised with the microsurgical scissors. The grafting material will be placed on a saline-soaked gauze until its transfer to the recipient site. Finally, the patient's check will be compressed, in order to promote the closure of the wound edges then immediately close the donor site with simple 5.0 silk thread interrupted sutures
223487987|NCT03543163|PROCEDURE|sub-epithelial connective tissue graft|a sub- epithelial connective tissue graft is harvested from the hard palate is used to treat area with gingival recession
223487988|NCT06433648|DEVICE|Ottobock CLeg4 + Ottobock foot|Commercially available Ottobock CLeg 4 microprocessor knee unit and Ottobock foot.
223487989|NCT06433648|DEVICE|SRALAB Hybrid Knee + Polycentric Ankle|Experimental powered prosthesis: SRALAB Hybrid Knee and powered polycentric ankle.
223487990|NCT06433648|DEVICE|SRALAB Hybrid Knee + Passive Ankle|Experimental powered prosthesis: SRALAB Hybrid Knee and passive ankle.
223587122|NCT03034330|OTHER|Two-Tier Stroke Family Empowerment|The family-based care management intervention will be implemented in two tiers. The first tier is the Family Care Management that a care manager is responsible for empowering family caregivers to support their stroke survivors through reorganizing family roles, enhancing family functioning, and maximizing their family and community resources. The second tier is led by trained volunteers who are responsible for increasing the capacity of caregivers for the mastery of stroke care by providing psychoeducation, skill-training, and social support. Each caregiver participant will be assigned a care manager and a volunteer. All care managers who are social workers from the participating centres have undergone 4-day training to improve their knowledge of stroke and skills required for the intervention. Similarly, volunteers have undergone 6.5-day training to equip them with the knowledge and skills to conduct the intervention.
223487991|NCT06433648|DEVICE|Ottobock CLeg 4 + Polycentric Ankle|Commercially available Ottobock CLeg 4 prosthetic knee and SRALAB powered polycentric ankle.
224178668|NCT01963910|DRUG|vehicle cream|application to the other half of the upper lip following capsaicin cream removal
224178669|NCT03428490|BEHAVIORAL|Fully integrated treatment|Clinicians will be delivering CBT for Social Anxiety Disorder directly into the context of the Matrix's evidence-based treatment for substance use disorders (i.e., The Matrix Model).
224178670|NCT03428490|BEHAVIORAL|Stand-alone Intensive Outpatient Program|Evidence-based treatment for substance use disorders (i.e., The Matrix Model).
224178671|NCT02793024|BEHAVIORAL|Intervention|Adolescents in the intervention arm will receive 3 face to face session about making smart shopping choices. The following 9 weeks will consist of utilizing social media to improve shopping choices.
224178672|NCT04065412|PROCEDURE|Conventional laryngeal handshake technique|The conventional laryngeal handshake technique is performed with the non-dominant hand, identifying the hyoid bone and thyroid laminae, stabilizing the larynx between thumb and middle finger, and moving down the neck to palpate the cricothyroid membrane with the index finger.
224178673|NCT04065412|PROCEDURE|Modified laryngeal handshake technique|The modified laryngeal handshake is performed with the non-dominant hand, stabilizing the trachea between thumb and middle finger from the suprasternal notch and moving up the neck to palate the cricoid cartilage and cricothyroid membrane with the index finger.
224306982|NCT06971367|BEHAVIORAL|Fresh start effect|Participants will be shown a brief video message at their baseline visit, containing information related to Fresh Start core concepts and encouraging them to return for a repeat HIV test. They will also receive brief SMS follow-up messages at about 8 and 11 weeks after baseline reminding them about HIV retesting and re-emphasizing concepts from the Fresh start effect content category.
224306983|NCT06971367|BEHAVIORAL|Education-based messaging|Participants will be shown a brief video message at their baseline visit, containing information related to HIV education core concepts and encouraging them to return for a repeat HIV test. They will also receive brief SMS follow-up messages at about 8 and 11 weeks after baseline reminding them about HIV retesting and re-emphasizing concepts from the Education-based content category.
223487992|NCT06262438|DRUG|Quizartinib|"Quizartinib is a novel oral Class III receptor tyrosine kinase (RTK) inhibitor exhibiting highly potent and selective but reversible inhibition of FMS-like tyrosine kinase FLT3. The dose will be adjusted for the patient's body weight (BW) as measured at the start of each course. Quizartinib will be administered orally once daily and is taken for 14 consecutive days during induction and consolidation courses.~Induction course 1: Start on day 13; Induction course 2: Start on day 9; Consolidation course 1: Start on day 6; Consolidation courses 2 and 3 (only if no allo-SCT is done): Start on day 6.~Continuation courses 1-6: patients will receive quizartinib for six 28-day courses. For the first 15 days of course 1 a starting dose will be applicable. On course 1 Day 16, the dose will be increased if the average QTc of the triplicate Electrocardiograms is ≤450 msec on course 1 Day 15. Once the dose is increased, the patient may continue on this dose as long as dose reduction is not needed."
223487993|NCT06262438|DRUG|Etoposide|"Induction course 1: 150 mg/m2 once daily by Intravenous (IV) infusion over 2 hours (+/- 30 mins) on days 1-5 inclusive (total 5 doses).~Induction course 2: 150 mg/m2 once daily by IV infusion over 2 hours (+/- 30 mins) on days 6-8 inclusive (total 3 doses).~Consolidation course 2 (only if no allo-SCT is done): 100 mg/m2 once daily by IV infusion over 1 hour (+/- 15 mins) on days 1-5 inclusive (total 5 doses)."
223487994|NCT06262438|DRUG|Dexrazoxane|"Induction course 1: 250 mg/m2 once daily by 15 mins IV infusion shortly before Mitoxantrone on day 6-10 inclusive (total 5 days), per investigator discretion and per institutional guidelines and availability.~Induction course 2: 600 mg/m2 once daily by 15 mins IV infusion shortly before daunorubicin on day 2,4,6 inclusive (total 3 does), per investigator discretion and per institutional guidelines and availability.~Consolidation course 1: 500 mg/m2 once daily by 15 mins IV infusion shortly before Mitoxantrone on 3-5 inclusive (total 3 does), per investigator discretion and per institutional guidelines and availability."
223487995|NCT06262438|DRUG|Mitoxantrone|"Induction course 1: 5 mg/m2 once daily by IV infusion over 1 hour (+/- 15 mins) on days 6-10 inclusive (total 5 doses). Please note that mitoxantrone and cytarabine should not be given concomitantly. Mitoxantrone should be completed before cytarabine is given.~Consolidation course 1: 10 mg/m2 once daily by IV infusion over 1 hour (+/- 15 mins) on days 3-5 inclusive (total 3 doses)."
223487996|NCT06262438|DRUG|Cytarabine|"Induction course 1: 200 mg/m2 once daily by IV infusion over 12 hours (+/- 1 hour) on days 6-12 inclusive (total 7 doses), following mitoxantrone. Induction course 2: 100 mg/m2 once daily by continuous IV infusion on days 1-2 inclusive. And 100 mg/m2 twice daily as a 30min (+/- 10 mins) IV infusion every 12 hours on days 3-8 inclusive (total 12 doses). Consolidation course 1: 1000 mg/m2 twice daily by IV infusion over 2 hours (+/- 30 min) every 12 hours on days 1-3 inclusive (total 6 doses).~Consolidation course 2 (only if no allo-SCT is done): 3000 mg/m2 twice daily by IV infusion over 2 hours (+/- 30 mins) every 12 hours on days 1-3 inclusive (total 6 doses).~Consolidation course 3 (only if no allo-SCT is done): 2000 mg/m2 once daily by IV infusion over 3 hours (+/- 1 hour) starting 4 hours after fludarabine on days 1-5 inclusive (total 5 doses), following fludarabine."
223487997|NCT06262438|DRUG|Methotrexate|"Induction course 1: Methotrexate (MTX) Intrathecal therapy (IT) prophylaxis is age-adjusted. If MTX is given at diagnosis omit IT therapy on day 6 unless in case of CNS involvement (CNS3). For children with initial CNS involvement (CNS3) MTX IT is replaced with triple IT and given more frequently. For children with CNS2, CSF must be investigated on day 22; if leukemic cells persist, treat as CNS3.~Induction course 2, Day 1: MTX (IT) prophylaxis is age-adjusted. For children with initial CNS involvement (CNS3) MTX IT is replaced with triple IT and given more frequently.~Consolidation course 1, Day 1: MTX (IT) prophylaxis is age-adjusted. For children with initial CNS involvement (CNS3) MTX IT is replaced with triple IT and given more frequently.~Consolidation course 2 and 3, Day 1 (only if no allo-SCT is done): MTX (IT) prophylaxis is age-adjusted. For children with initial CNS involvement (CNS3) MTX IT is replaced with triple IT and given more frequently."
223487998|NCT06262438|DRUG|Daunorubicin|Induction course 2: 60 mg/m2 once daily by IV infusion over 1 hour (+/- 15 mins) on days 2,4,6 inclusive (total 3 doses).
223487999|NCT06262438|DRUG|Fludarabine|Consolidation course 3 (only if no allo-SCT is done): 30 mg/m2 once daily by IV infusion over 30 mins (+/- 10 mins) on days 1-5 inclusive (total 5 doses).
223488000|NCT06262438|OTHER|allo-SCT|The SCT procedure is left to the discretion of the investigator and not part of this protocol.
223488001|NCT05950711|OTHER|Combination use of MBCT and IV Ketamine|Group with Major Depression who will receive a single dose of IV Ketamine embedded within a course of MBCT.
224178674|NCT00750360|BIOLOGICAL|FluarixTM|All subjects will receive a single dose of FluarixTM. For children less than 9 years of age who have not previously been vaccinated against influenza, a second dose will be given after an interval of at least 4 weeks (Group B).
223587123|NCT03034330|OTHER|Volunteer Support Psychoeducation|The active control group will receive a standard, non-family-based psychoeducation intervention provided by the trained volunteers under the supervision of care managers. It will provide 4 in-home visits and 2 telephone follow-up interviews about psychoeducation for caregivers of stroke survivors.
223587124|NCT01012544|DRUG|Clopidogrel|both arms of the study (patients with a history of stent thrombosis as well as patients who did not suffer from a stent thrombosis) will be given a 600 mg loading dose of clopidogrel
224178675|NCT06008522|DRUG|Bevacizumab-800CW|Imaging of fluorescently labeled Bevacizumab-800CW using OCT.
224178676|NCT00743639|PROCEDURE|intramyocardial bone marrow stem cells implantation|"Control group: the patients will be monitored with regular medical visits. Echocardiography: baseline,3,6,9 months. Cardiac NMR at baseline, 3 and 9 months.~Interventional group: Bone-marrow was collected from in the anterior-superior iliac crest and mononuclear stem cells were isolated by centrifugation in the density rate Ficoll-Hypaque 1.077 media. Technique - The approach was through a left mini-thoracotomy. Twenty small injections of cellular suspension were directly made through a 21F butterfly needle(total=5ml), in the anterior, lateral, posterior and apical faces of the LV ((average 9.6±2.6 x 10\[7\] cells). After the procedure, the patients were kept in the p.o. for a minimum period of 24hrs. They were released from the hospital in a period that varied from 5-7 days."
224178677|NCT04721626|DRUG|Chlorhexidine Gluconate|"Preoperative: The patient's dentition, or mandibular alveolus in the absence of dentition, will be brushed for two minutes with 0.12% chlorhexidine gluconate.~Intraoperative: The wound will be irrigated for 60 seconds with 0.05% chlorhexidine after it is irrigated with povidone-iodine.~Postoperative: Patients will swish and spit/suction 15mL 0.12% Chlorhexidine Gluconate (CHG) oral rinses for 30 seconds every six hours for two days (8 total administrations)"
224178678|NCT04721626|DRUG|Povidone-iodine|"Preoperative: The oral cavity and oropharyngeal mucosa as well as the nasal vestibules will be coated with 5% povidone-iodine which will stand for at least three minutes prior to incision.~Intraoperative: The wound will be irrigated for 60 seconds with 10% povidone-iodine."
224178679|NCT04721626|DRUG|Tetracycline Ointment|Postoperative: \~10g 3% tetracycline ointment will be placed into the oral cavity to coat the dorsal tongue and any oral suture lines every six hours for two days (8 total doses).
224178680|NCT04866147|PROCEDURE|Cardiothoracic surgery|Cardiac \& large intrathoracic vessels, respiratory, thoracic, mediastinal \& diaphragmatic procedures
223488002|NCT05107375|BIOLOGICAL|Tetravalent influenza virus lysis vaccine|Influenza virus lysis vaccine, one dose at a time, each dose 0.5mL, containing each influenza virus strain hemagglutinin 15μg.
223488003|NCT05107375|BIOLOGICAL|Recombinant new coronavirus vaccine (CHO cell) group|One dose of recombinant Novel Coronavirus vaccine (CHO cells) was administered at 0.5mL each dose, containing 25μg nCP-RBD protein.
223488004|NCT01680614|BEHAVIORAL|CASI|
224178681|NCT04866147|PROCEDURE|Breast surgery|Breast resections \& mastectomies
224178682|NCT04866147|PROCEDURE|Gastrointestinal surgery|Digestive \& spleen
224178683|NCT04866147|PROCEDURE|Genitourinary surgery|Urinary tract, genital \& retroperitoneal tissue
224178684|NCT04866147|PROCEDURE|Orthopaedic surgery|Back \& neck, shoulder \& upper arm, hip \& thigh, knees \& lower leg
224178685|NCT02049385|DRUG|Diazoxide|A nondiuretic vasodilator thiazide-related agent
224178686|NCT02049385|DRUG|Placebo|Placebo
223488005|NCT02149134|DIETARY_SUPPLEMENT|TeHF2013-01|
223587125|NCT01174394|PROCEDURE|DCEAS (Hwato®/ Dongbang®)|Upon insertion of acupuncture needles, dense cranial electro-acupuncture stimulation (DCEAS), is directly delivered on a density of cranial acupoints (in general 6-8 pairs) located on the frontal, parietal, and temporal scalp areas.
224178687|NCT04450394|DRUG|LY3209590|Administered SC
224178688|NCT04450394|DRUG|Insulin Degludec|Administered SC
224178689|NCT03581032|DEVICE|Active reprogam|Reprogram Changes in AV/PV delays
223488006|NCT02998853|OTHER|QFR measurement by dedicated workstation on xrays angio selected runs|The patient undergoes coronary angiography; if at least one stenosis from 40 to 90% in non culprit is present and FFR is indicated by guidelines the patient is enrolled to 3d Angio QFR evaluation; no adjunctive invasive procedures are needed for QFR measurements
223488007|NCT06525168|DRUG|DA414 Granules|DA414 Granules single ascending doses. DA414 will be orally administrated at single ascending doses of 12.5 mg, 25mg, 50 mg, 100mg and 200 mg.
223488008|NCT06525168|DRUG|DA414 placebo|DA414 placebo single ascending doses. DA414 placebowill be orally administrated at single ascending doses of 25mg, 50 mg, 100mg and 200 mg.
223488009|NCT03314935|DRUG|INCB001158|Phase 1: INCB001158 administered orally twice daily at the protocol-defined dose. Phase 2: INCB001158 administered orally twice daily at the recommended dose from Phase 1.
223488010|NCT03314935|DRUG|Oxaliplatin|Oxaliplatin administered intravenously at the protocol-defined dose and schedule.
223488011|NCT03314935|DRUG|Leucovorin|Leucovorin at the protocol-defined dose and regimen.
223488012|NCT03314935|DRUG|5-Fluorouracil|5-Fluorouracil at the protocol-defined dose and regimen.
223488013|NCT03314935|DRUG|Gemcitabine|Gemcitabine at the protocol-defined dose and regimen.
223488014|NCT03314935|DRUG|Cisplatin|Cisplatin at the protocol-defined dose and regimen.
223587126|NCT01174394|PROCEDURE|Body electro-acupuncture (Hwato®/ Dongbang®)|Both study arms received body electroacupuncture on both sides of ipsilateral limb pairs: Hegu (LI4) and Quchi (LI11) , Zusanli (ST36) and Taichong (LR3). Electrical stimulation as DCEAS is applied.
223587127|NCT01174394|PROCEDURE|n-CEA (Strietberger®)|Streitberger's non-invasive acupuncture needles were applied to serve as sham control at the same cranial acupoints and the same stimulation modality, except that the needles only adhere to the skin instead of insertion
224178690|NCT03029494|DEVICE|stabilization splint|Hard acrylic type of splint with full coverage of occlusal surfaces of upper teeth, with a thickness of about 1.5 mm at the level of the first molar.
224178691|NCT03029494|DRUG|Placebo Oral Tablet|sugar pill manufactured to mimic 1000 mg Vitamin C
224178692|NCT03029494|DEVICE|placebo splint|Ineffectively designed oral appliance: an acrylic palatal plate will be used (without influence on occlusion, TMJ and masticatory muscles).
224178693|NCT03029494|DIETARY_SUPPLEMENT|Vitamin C|1000 mg
223587128|NCT01174394|DRUG|Fluoxetine|Subjects of both study arms received orally administered SSRIs for 4 weeks in an open manner. For those who were currently under antidepressant treatment, they would continue the existing treatment regimens. For those who were not medicated at the time of trial, fluoxetine (FLX) was given at an initiate dose of 10 mg/day and escalated to an optimal dose within one week, based on individual response, but the maximum dose was set at 40 mg/day.
223587129|NCT01399216|DIETARY_SUPPLEMENT|Supplement containing fucoidan, EPA, and DHA|75 mg fucoidan per day, for 8 weeks
223587130|NCT01399216|DIETARY_SUPPLEMENT|Placebo|for 8 weeks
223587131|NCT03668990|OTHER|IMUs (Xsens, MVN Studio)|It is a full-body human measurement system based on inertial sensors, biomechanical models and sensor fusion algorithms applied in neurological patients for measuring upper limb movements.
224178694|NCT00104429|DRUG|GW873140|
223488015|NCT03314935|DRUG|Paclitaxel|Paclitaxel at the protocol-defined dose and regimen.
223488016|NCT04597450|DRUG|Lu AG06466|Lu AG06466 - 30 mg/day, capsules, orally, once daily, one capsule will be taken daily for 15 days per treatment period
223587132|NCT05660213|DRUG|Targeted drugs combined with anti-PD-1/PD-L1 antibodies|Targeted drugs combined with anti-PD-1/PD-L1 antibodies
223587133|NCT05660213|DRUG|TACE (transarterial chemoembolization) combined with targeted/immunotherapy|TACE (transarterial chemoembolization) combined with targeted/immunotherapy
223587134|NCT05660213|DRUG|Lenvatinib monotherapy|For patients weighing less than 60 kg, the recommended daily dose of this product is 8 mg (2 capsules of 4 mg), once daily; For patients weighing ≥ 60 kg, the recommended daily dose of this product is 12 mg (3 capsules of 4 mg), once daily. Treatment should be continued until disease progression or intolerable toxic reactions occur.
223587135|NCT05660213|DRUG|Huaier granules combined with any of the above Cohorts for treatment|Oral administration of Huaier granules, 10g each time, 3 times a day, until the end of the study, intolerable toxicity, withdrawal from the study for any reason, or death, whichever occurs first; Or the researcher determines that there is no longer any benefit.It is recommended that the date of first use of Huaier granules be determined by the researchers, and after disease progression, the researchers and patients should jointly decide whether to continue receiving Huaier granules treatment.
223587136|NCT00783913|OTHER|Visumotor Upper Extremity Training|Control
223587137|NCT00783913|OTHER|Anodal/Sham tDCS|Condition
223587138|NCT06747871|BEHAVIORAL|Very Low Nicotine Cigarettes (VLNC)|Spectrum NRC 102/103 (nonmenthol/ menthol) cigarettes, which have a nicotine content of approximately 0.4 mg/g tobacco.
223587139|NCT06747871|BEHAVIORAL|Normal Nicotine Cigarettes (NNC)|Spectrum NRC 600/601 (nonmenthol/ menthol) cigarettes, which have a nicotine content of approximately 15.8 mg/g tobacco.
223745363|NCT07148713|BEHAVIORAL|CGM-Augmented FIM|The intervention arm will receive electronic healthy foods vouchers and unblinded, real-time CGM sensors for 16-weeks, in addition to individualized nutrition counseling with a registered dietician for 5-8 sessions (all participants will attend 5 sessions, with up to three additional sessions scheduled as needed based a set of a-priori decision rules).
223745364|NCT07148713|BEHAVIORAL|FIM only|The comparator arm will receive electronic healthy foods vouchers and healthy eating resources and self-directed nutrition education. This group will not receive unblinded CGM sensors or any nutrition counseling for the first 12 weeks. This group will receive 30-days of unblinded CGM sensors to use in the extension phase only.
223745365|NCT07150806|DRUG|Actinium Ac 225 DOTATATE RYZ101|Given IV
224178695|NCT00104429|DRUG|Combivir|
224178696|NCT04094662|DRUG|Mirogabalin|Mirogabalin tablets for oral administration
224178697|NCT04094662|DRUG|Placebo|Matching placebo tablets for oral administration
224178698|NCT02327182|DRUG|MT-4666|
223488017|NCT04597450|DRUG|Placebo|Placebo - capsules, orally, once daily, one capsule will be taken daily for 15 days per treatment period
223488018|NCT04529408|DEVICE|EarSats Pulse Oximeter Probe|Off-the-shelf pulse oximeter embedded into a memory foam ear plug for measuring blood oxygen saturation (SpO2) from the ear canal; in-ear SpO2 measured at-rest and during 6 minute walk test
223488019|NCT03437954|OTHER|Diet modification|Patients will be randomized to follow the standard post-tonsillectomy diet at our institution, which consists of soft foods for ten days, or will be in the non-restricted diet group following surgery.
223587140|NCT06175156|PROCEDURE|Controlled analgesia/sedation|During the pre anesthesia assessment, explain in detail to the patient the usage of the self-control pump and confirm that each patient can master it. Firstly, connect the self-control analgesic pump with a loading dose of 3 ml. Then, continuously pump in a mixture of propofol and remifentanil at a speed of 0.1 ml/kg/h. After the loading dose is completed, the examination can begin. During the operation, press the self-control handle according to the patient's sensation. Each press can quickly push 1ml of the medication, with a locking time of 1 minute
223587141|NCT06175156|PROCEDURE|Intravenous combined anesthesia|Intravenous slow infusion of fentanyl 1 μ G/kg, midazolam 0.02mg/kg, slowly administer propofol 0.8-1mg/kg after 2 minutes (time greater than 60 seconds), and start the examination when the patient's consciousness disappears and they do not respond. During the surgery, propofol is interrupted to maintain the auditory evoked potential index (AAI) between 30-40.
223587142|NCT03048760|OTHER|MRI scan|All participants will undergo 2 MRI scans - 1 at the time of their radiotherapy planning scans \& 1 after approx. 2 weeks of radiotherapy treatment.
223587143|NCT01650272|DRUG|5% MInoxidil milky lotion|Patient receive 5% MInoxidil milky lotion (Butylene glycol solvent)
223745366|NCT07150806|PROCEDURE|Biospecimen Collection|Undergo blood and urine sample collection
223488020|NCT06202820|BEHAVIORAL|CV Care Program|Comprised of two, in-clinic, counseling sessions with oncology nurse practitioner or physician assistant for education on cardiovascular disease (CVD) and cardiovascular risk factors as well as recommendations for management.
223745367|NCT07150806|PROCEDURE|Computed Tomography|Undergo CT scan
224178699|NCT05536544|OTHER|IBDMED|The IBDMED program will be applied for 8 weeks and include education on MED diet and lifestyle components, focused on increasing and diversifying dietary fiber intake, reduction of ultra-processed food intake and promoting an active lifestyle. This intervention is digitally supported by an interactive website application and step trackers to monitor lifestyle parameters.
224178700|NCT05536544|OTHER|Control|Dietary counseling according to the local dietary guidelines for patients with IBD
224178701|NCT00630760|DRUG|NRX 194204|NRX 194204 capsules given 3mg/m2 daily x 28 days. Repeated until PD
224178702|NCT00968929|DRUG|Recombinant Streptokinase|Recombinant streptokinase: 1.5 million IU continuously intravenous infusion for 2 hours
224178703|NCT00968929|DRUG|Urokinase|Urokinase: 20,000 IU/kg continuously intravenous infusion for 2 hours
224178704|NCT05582382|OTHER|logistic regression of known prognostic markers of severity of COVID19|"An observational longitudinal follow up of all consecutive patients with positive SARS-CoV-2 testing on nasopharyngeal swabs per WHO definitions presenting to the emergency department . The risk assessment score at initial presentation will be calculated for each patient using clinical assessment scoring of ALA \& ALKA and compared with the currently proposed clinical risk assessment scoring system~The utility of the risk score in triaging patients on their initial visits to emergency department (ED) will be validated against the following measured outcomes:~1. Hospital admission on the first encounter to ED~2. Admission to ICU for the duration of the COVID-19 hospitalization~3. In hospital and out of hospital mortality~4. Return to ED following initial discharge (within the current covid illness period, Maximum 30 days from the initial diagnosis)"
224178705|NCT05528965|PROCEDURE|Perpendicular Group|Radiofrequency ablation was applied to the perpendicular group by placing the tip of electrode perpendicularly to contact the genicular nerves.
224178706|NCT05528965|PROCEDURE|Parallel Group|Radiofrequency ablation was applied to the parallel group by placing the electrode lay parallel to contact the genicular nerves.
223488021|NCT05884580|DEVICE|Neuflo BPH Treatment System|The Neuflo BPH Treatment System is designed to treat patients with lower urinary tract symptoms (LUTS) associated with BPH. It is an outpatient-based, minimally invasive treatment option and uses hydrolysis to reduce prostatic tissue in the lateral lobes of the prostate. Reduced pressure and constriction of the urethra alleviates urinary and other symptoms of BPH.
223488022|NCT05667506|BIOLOGICAL|single dose of CNCT19|"Autologous 2nd generation CD19-directed CAR-T cells, single infusion intravenously.~Lymphodepletion treatment:~Drugs:Fludarabine Drugs: Cyclophosphamide"
223488023|NCT05979883|RADIATION|Machine Learning Assisted Radiation (MLAP) RapidPlan|Radiation therapy simulation, target delineation, dosing, localization, and follow-up will be followed per standard of care practices and/or at the discretion of the treating radiation oncologist. To elaborate, patients will receive a treatment planning CT (computed tomography) scan, followed by normal tissue delineation through the physician and/or medical dosimetry assistant, followed by target delineation by the physician, followed by radiation treatment planning with the dosimetrist and medical physicist. The preliminary plan will be run through the RapidPlan module, which will give a list of possible improvements to the plan. The dosimetrist will then make an amendment to the plan according to RapidPlan suggestions, followed by plan change requests and approval by the physician.
223587144|NCT01650272|DRUG|5% Minoxidil solution|Patient receive 5% Minoxidil solution (Propylene glycol solvent )
223587145|NCT00398203|DEVICE|NaviAid™ BGE Device|NaviAid™ Balloon Guided Endoscopy Device
223587146|NCT05757167|DIAGNOSTIC_TEST|Malaria High-Sensitivity Rapid Diagnostic Test (HS-RDT)|"Detection of Plasmodium falciparum HRP-II antigen1~Method: Lateral Flow; Time to Result: 20 minutes; Sample Type: Fingerstick Whole Blood; Sample Volume: 5µl; Storage Conditions: 1-30°C; Shelf Life: 12 months; Sensitivity/Specificity: 99.0%/98.6%"
223587147|NCT05757167|DRUG|Artemether-lumefantrine (AL)|oral tablets: 6 doses of 80/480 mg over 3 days
223587148|NCT06074458|OTHER|Glucosano|Glucosano is a remote patient monitoring diabetes dashboard with a patient facing Smartphone application
223587149|NCT06074458|BEHAVIORAL|Community Health Worker diabetes technology coach|Community Health Workers will work with participants as a diabetes technology coach during scheduled and as needed visits
224178707|NCT03121625|BIOLOGICAL|Autologous CAR-T|Patients will be drawn 50-100 ml blood to obtain enough peripheral blood mononuclear cells (PBMC) for CAR-T manufacturing. The T cells will be purified from the PBMC, transduced with CAR lentiviral vector, expanded in vitro and then frozen for future administration. Chemotherapy will then be given. Following tumor burden reassessment, CAR-T cells will be infused.
224178708|NCT00124696|DRUG|Cocaethylene|
224178709|NCT04282343|BEHAVIORAL|The DISCO App|Patients will receive an individually-tailorable cancer treatment cost education and communication intervention delivered on an iPad just prior to meeting with their oncologist.
224178710|NCT04282343|BEHAVIORAL|Usual Care|Patients randomized to this arm will receive usual care.
224306984|NCT06971367|BEHAVIORAL|Default appointment messaging|Participants will be shown a brief video message at their baseline visit, containing information related to Default Appointment core concepts and encouraging them to return for a repeat HIV test. They will also receive brief SMS follow-up messages at about 8 and 11 weeks after baseline reminding them about HIV retesting and re-emphasizing concepts from the Default Appointment content category.
224306985|NCT06971367|BEHAVIORAL|Reserved for you messaging|"Participants will be shown a brief video message at their baseline visit, containing information related to the Reserved for you core concepts and encouraging them to return for a repeat HIV test. They will also receive brief SMS follow-up messages at about 8 and 11 weeks after baseline reminding them about HIV retesting and re-emphasizing concepts from the Reserved for you content category."
223488024|NCT05979883|RADIATION|Radiation Therapy Standard of Care (SOC)|Radiation therapy simulation, target delineation, dosing, localization, and follow-up will be followed per standard of care practices and/or at the discretion of the treating radiation oncologist. To elaborate, patients will receive a treatment planning CT (computed tomography) scan, followed by normal tissue delineation through the physician and/or medical dosimetry assistant, followed by target delineation by the physician, followed by radiation treatment planning with the dosimetrist and medical physicist, followed by plan change requests and approval by the physician.
223587150|NCT06745583|DRUG|EI-1071 tablet, oral|Dose: 448.2 mg BID for 28 days
223587151|NCT03922087|OTHER|No intervention|No intervention
223587152|NCT06929676|PROCEDURE|Periodontal Treatment|Non-surgical periodontal treatment with scaling and root planing and dental splinting
223587153|NCT06929676|OTHER|assessment of tooth mobility before and after periodontal treatment|Evaluation of dental mobility with a customized device before and after non-surgical periodontal therapy and after stabilization by periodontal splints
223745368|NCT07150806|PROCEDURE|Echocardiography Test|Undergo echocardiography
224178711|NCT00616005|DRUG|Temodar and Irinotecan|Temozolomide-orally 200mg/m2 in fasting state 1hr prior to CPT-11 infusion. Temozolomide-day 1 of treatment cycle \& every 24hrs thereafter for 5days w treatment cycles repeated every 6wks. Treatment cycles repeated up to maxi of 3 cycles until occurrence of either unacceptable toxicity/evidence of disease progression. CPT-11-intravenously in fasting state over 90min. CPT-11 1hr after Temozolomide administration on day 1 of treatment cycle. CPT-11-days 1, 8, 22, \& 29 of 6wk treatment cycle. Treatment cycles may be repeated up to maxi of 3 cycles until occurrence of either unacceptable toxicity/evidence of disease progression. Dose of CPT-11 will be based on whether pt is receiving EIAEDs due to increased drug clearance produced by agents. For pts receiving EIAEDs, CPT-11 dose of 325mg/m2 administered. For pts not receiving EIAEDs, CPT-11 dose of 125mg/m2 administered.
224178712|NCT00374764|DRUG|Risperidone|
224178713|NCT00374764|BEHAVIORAL|ABA|
224178714|NCT03061617|OTHER|VCV mode|set fixed 6ml/kg tide volume
224178715|NCT03061617|OTHER|PCV mode|adjust pressure to achieve tide volume of 6ml/kg
224178716|NCT04033718|DIAGNOSTIC_TEST|Inpatient lab bundling|The investigators will provide patients a package of diagnostic tests at the time of admission to comprehensively assess for HIV coinfections and treatment failure. These labs are all recommended in advanced HIV guidelines but in this study we will provide all tests as a bundle rather than step-by-step as suggested in guidelines.
224178717|NCT04033718|BEHAVIORAL|Inpatient navigation|Participants will be assigned a patient navigator who will support the patient and bedsider (treatment supporter/guardian) during the hospitalization. The navigator will be an HIV counselor who can provide counseling and health education, as well as support specimen transport, obtaining results, booking tests in other departments, linkages to ART clinic, and discharge planning
224178718|NCT05330806|PROCEDURE|Collagenase chemonucleolysis|"After local anesthesia, and the puncture point was 8-12cm on the side of the paraspinous process under C arm fluoroscopy. The needle was punctured though the skin with an angle of 45-60 to the posterior of the vertebral via safe entry zone to the herniated site outside the intervertebral disc under the epidural space. The syringe was drawn back to confirm that no blood or cerebrospinal fluid was flowing out, Contrast agents were injected to make sure no flows out of the spinal canal. 600 unit collagenase was dissolved in 2ml normal saline and injected slowly with rate of 1ml per minute. The needle was removed and keep the dorsal elevated position for 6-8 hours. Keep away from load bear of lumbar for 3 months."
224178719|NCT05330806|PROCEDURE|Percutaneous endoscopic lumbar discectomy (PELD)|For L1-L4 segment, percutaneous endoscopic transforaminal discectomy(PETD) will be performed. An 1cm length incision was made at 8-14cm lateral of the paraspinous process, where a needle puncture to the superior articular process of the lower involved vertebrae of the herniated disc. A series of conical rods are to be introduced, subsequently a reamer is to be introduced through the cannula. After removal of the disc herniation, the cannula and endoscope are to be removed. For L5/S1 segment, percutaneous endoscopic interlaminar discectomy(PEID) was performed. An incision of nearly 7 mm was made at the entry point of the skin, and a series of expansion channels were sequentially inserted into the surface of the ligamentum flavum.Then, the ligamentum flavum and soft tissue around it were removed. Then, the tongue of the working cannula was inserted and rotated into the lateral nerve root. Removed the prominent nucleus pulposus by various nucleus pulposus forceps.
224178720|NCT01434498|DRUG|GS-5885 tablet|GS-5885 tablet, 90 mg, QD
224178721|NCT01434498|DRUG|GS-9451 tablet|GS-9451 tablet, 200 mg QD
224178722|NCT01434498|DRUG|tegobuvir capsule|tegobuvir capsule, 30 mg BID
224178723|NCT01434498|DRUG|ribavirin tablet|ribavirin tablet (weight based: 1000 mg/day \<75 kg; 1200 mg/day ≥ 75 kg) divided twice daily (BID)
224178724|NCT01434498|DRUG|placebo matching ribavirin tablet|placebo matching ribavirin tablet, BID
224178725|NCT01434498|DEVICE|placebo matching tegobuvir capsule|placebo matching tegobuvir capsule, BID
223488025|NCT05845619|BEHAVIORAL|Enhanced virologic monitoring|"The pilot intervention will include the following components:~1. More frequent viral load collection: Participants who enroll in the first 3 months of the pilot study period will be eligible for a 3-month follow-up visit and will have viral load assessed again at that time.~2. Rapid return of viral load results: Mentor mothers (peer counselors) will be trained to return viral load results to patients. Viral loads will will be processed with GeneXpert point of care technology.~3. Enhanced viral load counseling: Mentor mothers will reinforce adherence with all patients with undetectable levels via scripted messaging to reward and encourage healthy behavior. For those with any detectable levels, mentor mothers will be trained to provide targeted counseling with scripted messaging according to viral load level (undetectable, low-level viremia (50-1000), high viral load (\>1000))."
223488026|NCT04217980|DIAGNOSTIC_TEST|Lung ultrasonography (LUS) or Chest X ray (CXR)|pediatrician researcher (PR) will conduct a LUS or CXR at admission time as a first test of lung image depending on randomized group.
223488027|NCT00168298|DRUG|700 µg Dexamethasone|700 µg dexamethasone intravitreal implant administered on Day 0 and/or Day 180.
223488028|NCT00168298|DRUG|350 µg Dexamethasone|350 µg Dexamethasone intravitreal implant administered on Day 0.
223488029|NCT00168298|OTHER|Sham Injection|Sham injection on Day 0.
223488030|NCT03283878|DRUG|Cefazolin|"Cefazolin will be administered intravenously within less than 60 minutes prior to skin incision in elective TKA for Group 1.~Cefazolin will be administered intravenously within less than 60 minutes prior to skin incision in elective TKA. In addition, two weight based doses of cefazolin will be administered within 24 hours postoperatively for Group 2."
224178726|NCT04189198|DRUG|Articaine|Supraclavicular block with 30 ml articaine 2%
224178727|NCT04189198|DRUG|Bupivacaine|Supraclavicular block with 30 ml bupivacaine 0.5%
224178728|NCT00001151|DRUG|1,25-Dihydroxycholecalciferol|Usual doses of 1,25-dihydroycholecalciferol are 0.25-1 ug per day. All patients in this study received very high doses or 5-20 ug per day.
224178729|NCT03508206|DIETARY_SUPPLEMENT|SBRP|SBRP capsules
224178730|NCT03508206|DIETARY_SUPPLEMENT|PLACEBO|Placebo capsules
224178731|NCT00002176|DRUG|Hydroxyurea|
224178732|NCT00002176|DRUG|Nelfinavir mesylate|
224178733|NCT00002176|DRUG|Stavudine|
224178734|NCT00002176|DRUG|Didanosine|
224178735|NCT02155660|DRUG|Benralizumab Arm A|Benralizumab subcutaneously on study week 0 until study week 48 inclusive
223587154|NCT06929676|OTHER|Evaluation of Clinical Parameters|Periodontal: probing depth, bone loss, CAL (clinical attachment level) Clinical: occlusal prematurities and collection of gingival crevicular fluid Questionnaire: quality of life (OHIP-14)
223587155|NCT05215730|DEVICE|MedCu wound dressings with copper oxide (COD)|Patients whose foot wound is indicated for VAC treatment will be randomized to either treatment arm after signing informed consent.
224178736|NCT02155660|DRUG|Benralizumab Arm B|Benralizumab subcutaneously on study week 0 until study week 48 inclusive
224178737|NCT02155660|DRUG|Benralizumab Arm C|Benralizumab subcutaneously on study week 0 until study week 48 inclusive
224178738|NCT02155660|DRUG|Placebo|Benralizumab subcutaneously on study week 0 until study week 48 inclusive
224178739|NCT03104686|OTHER|Short pasta (dry)|50g available carbohydrate of penne pasta
224178740|NCT03104686|OTHER|Long pasta (dry)|50g available carbohydrate of spaghetti pasta
224178741|NCT03104686|OTHER|Bread|50g available carbohydrate of bread
224178742|NCT03104686|OTHER|Glucose|50g available carbohydrate of glucose monohydrate
224178743|NCT05170516|PROCEDURE|4 °C colled saline irrigation|In Experimental Group A , 4 °C colled saline irrigation was used during impacted third molar surgery
224178744|NCT05170516|PROCEDURE|10 °C cooled saline irrigation|Experimental Group B, 10°C colled saline irrigation was used during impacted third molar surgery.
223488031|NCT04253730|OTHER|Cold Stress|60-90 mins of cooling via a liquid perfused suit circulating \~4-10°C liquid.
223488032|NCT03636477|BIOLOGICAL|Ad-RTS-hIL-12|"* 2.0 x 10\^11 viral particles (vp) per injection~* intratumoral injection of Ad-RTS-hIL-12"
223488033|NCT03636477|DRUG|veledimex|"* 2 doses (10mg/day, 20mg/day)~* 15 oral daily doses of veledimex"
223488034|NCT03636477|DRUG|Nivolumab|"* 2 doses (1mg/kg, 3mg/kg)~* Every 2 weeks"
223488035|NCT05705557|DEVICE|ABSOLOK™ Clip System|Use of ABSOLOK™ Clip System during parenchymal transection for open liver resection
223488036|NCT02617277|DRUG|AZD1775|AZD1775 (adavosertib) is available in capsules for oral administration.
223488037|NCT02617277|DRUG|MEDI4736|MEDI4736 (durvalumab) will be administered by IV infusion.
223488038|NCT06270394|DRUG|68Ga-Fibroblast activation protein inhibitor|Fibroblast activation protein (FAP), a type II transmembrane serine protease with dipeptidyl peptidase and endopeptidase activities. FAP is a specific surface marker for activated fibroblasts in the mesenchyme of tumors, which account for 90% of the stroma of epithelial neoplasms. FAP inhibitors (FAPIs) can specifically target and bind to FAP. These inhibitors that are radiolabeled with gallium 68 (68Ga-FAPIs) can be probes for visualization of the FAP tumor stroma. Previous studies have demonstrated that 68Ga-FAPI-04 is not dependent on blood glucose levels, has an equal or better tumor-to-background ratio, and clearly visualizes primary tumors and their metastatic foci. In addition, previous studies on 68Ga-FAPI-04 have focused on PET/CT and the efficacy of PET/MR with FAPI for postoperative evaluation of GI tumors remains to be clarified.
223488039|NCT06011239|BEHAVIORAL|Team-building processes|"All staff in one of the four role groups (medical assistants (MAs); clerical/administrative staff; nursing staff; and physicians/nurse practitioners/physician assistants) will be sent an anonymous survey. The survey will ask staff to consider what help participants wish to ask for and what help participants can offer to staff in the other three roles at times when people are busy or overwhelmed. These ideas will be combined into a typed idea list for each role and then staff in clinics will discuss. Once these are finalized the clinics will implement these.~At several points during the year, the study team will send out brief surveys. These surveys will collect the clinic and job role and ask participant to rate how much effort has been made in different ways, and if there are open-ended comments about what is or is not working. This information will be used to improve the intervention at each clinic."
223488040|NCT04086264|DRUG|Azacitidine|Commercially available formulation given subcutaneously (SC) or intravenous (IV)
223488041|NCT04086264|DRUG|IMGN632|Study formulation given intravenously (IV)
223488042|NCT04086264|DRUG|Venetoclax|Commercially available formulation administered orally
223488043|NCT04762992|DRUG|subcutaneous Enoxaparin|Enoxaparin subcutaneous injections (40 mg, 4000 IU daily) starting immediately after the diagnosis of FGR, and until 36 weeks of gestation or 12 hours before delivery, whichever comes first.
223488044|NCT04762992|OTHER|standard of care|Obsteric standard of care.
223488045|NCT06471933|DEVICE|Juläine|Dermal filler (PLLA)
223587156|NCT06653023|BIOLOGICAL|Universal CAR-T cells injection for treating HCC and NSCLC|A novel universal CAR-T platform to treat cancer patients
223587157|NCT06856330|PROCEDURE|furlow with buccal myomucosal flap|patients were treated with furlow with buccal myomucosal flap
223587158|NCT06856330|PROCEDURE|two flap palatoplasty|patients were treated with two flap palatoplasty
224178745|NCT05170516|PROCEDURE|Room temperature saline irrigation|In Control Group A and B, salin irrigation at room temperature was used during impacted third molar surgery.
223587159|NCT01689545|BEHAVIORAL|Individual level|Index participants will participate in standard HIV VCT supplemented with 2 posttest counseling sessions, followed by 2 post-test skill-building support groups for HIV positive IDUs.
224178746|NCT01192139|DRUG|saxagliptin|Tablets, Oral, 5 mg, once daily, Single dose
224178747|NCT01192139|DRUG|metformin XR|Tablets, Oral, 500 mg. once daily, Single dose
224178748|NCT01192139|DRUG|saxagliptin + metformin XR (FDC tablet)|Tablet, Oral, (saxagliptin 5 mg)(metformin XR 500 mg), once daily, Single dose
224178749|NCT00153699|DRUG|Topiramate|
224178750|NCT05186220|PROCEDURE|Cardioneuroablation|After 3D mapping of the surface of the left and right atrium and the superior vena cava (Ensite Navx, Carto), localization of ganglion plexus (GP) will be performed either anatomically and/or by means of high frequency stimulation (HFS). The anterior and superior right sided GP will always be ablated per protocol. Other GP will be ablated according to interventional electrophysiologist judgement. The endpoint of the ablation procedure will be 1) absence of a vagal response after HFS from the right jugular vein and 2) an increase in at least 10 bpm as compared to baseline.
224178751|NCT05186220|DEVICE|Permanent dual chamber pacemaker implantation|Under local anesthesia and using a subclavian or cephalic vein approach a dual chamber pacemaker implantation with a lead in the right atrium and a lead in the right ventricle will be performed. The device will be programmed in a AAI-DDDR mode to avoid unnecessary ventricular pacing.
224306986|NCT06971367|BEHAVIORAL|Social norms (default) messaging|Participants will be shown a brief video message at their baseline visit, containing information related to Social Norms core concepts and encouraging them to return for a repeat HIV test. The video message will be delivered by the default avatar. They will also receive brief SMS follow-up messages at about 8 and 11 weeks after baseline reminding them about HIV retesting and re-emphasizing concepts from the Social Norms content category.
224306987|NCT06971367|BEHAVIORAL|Social norms (varied) messaging|Participants will be shown a brief video message at their baseline visit, containing information related to Social Norms core concepts and encouraging them to return for a repeat HIV test. The video message will be delivered by an avatar that approximately matches each participant's age and sex. They will also receive brief SMS follow-up messages at about 8 and 11 weeks after baseline reminding them about HIV retesting and re-emphasizing concepts from the Social Norms content category.
224306988|NCT06971367|BEHAVIORAL|Goal-setting messaging|Participants will be shown a brief video message at their baseline visit, containing information related to goal-setting core concepts and encouraging them to return for a repeat HIV test. They will also receive brief SMS follow-up messages at about 8 and 11 weeks after baseline reminding them about HIV retesting and re-emphasizing concepts from the goal-setting content category.
224306989|NCT06971367|BEHAVIORAL|Incentive|Participants will be informed that they will receive a small financial incentive if they return for repeat HIV testing in 3-6 months after enrollment.
224306990|NCT06968325|DEVICE|AI-based TruRoot group:|Participants in this group will receive clear aligner treatment designed using an artificial intelligence (AI)-based system called TruRoot
224178752|NCT03977376|OTHER|Guide of hosting|Guide of hosting with information about hospitalization to decrease anxiety
224178753|NCT04938882|DRUG|Normal saline|Before the induction of anesthesia, normal saline is used for bilateral transversus abdominis plane block in a volume of 20 mL of each side
224178754|NCT04938882|DRUG|Ropivacaine|Before the induction of anesthesia, 0.375% ropivacaine is used for bilateral transversus abdominis plane block in a volume of 20 mL of each side
224178755|NCT04938882|DRUG|Compound lidocaine at low concentration|Before the induction of anesthesia, 0.4% compound lidocaine is used for bilateral transversus abdominis plane block in a volume of 20 mL of each side
224178756|NCT04938882|DRUG|Compound lidocaine at high concentration|Before the induction of anesthesia, 0.6% compound lidocaine is used for bilateral transversus abdominis plane block in a volume of 20 mL of each side
224178757|NCT01278966|OTHER|The Modified Atkins Diet|The Modified Atkins Diet; 10 g carbohydrate per day and a high fat intake
224306991|NCT06968325|DEVICE|Conventional clear aligner group|Participants in this group will receive clear aligner treatment planned manually by expert orthodontists based only on intraoral scans.
224306992|NCT05980741|PROCEDURE|high-quality nursing|High-quality nursing
223745369|NCT07150806|RADIATION|Gallium Ga 68-DOTATATE|Given IV
224178758|NCT01189396|DRUG|A006|Albuterol DPI with 180 mcg Albuterol/inhalation
224178759|NCT01189396|DRUG|Placebo DPI|Placebo DPI with 0 mcg Albuterol/inhalation
224178760|NCT01189396|DRUG|Proventil-HFA|Albuterol MDI with 90 mcg Albuterol/inhalation
223745370|NCT07150806|DRUG|L-lysine/L-arginine-containing Amino Acid|Given IV
223745371|NCT07150806|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223587160|NCT01689545|BEHAVIORAL|Structural level|Community members will participate in 2 community-based HIV and IDU stigma videos combined with a series of visits with community outreach workers.
223587161|NCT01689545|BEHAVIORAL|Individual level standard of care|The education materials that are currently offered in Thai Nguyen will be delivered didactically by health workers on 1) the HIV situation in Vietnam; 2) consequences of drug use; 3) routes of HIV transmission; and 4) options for drug treatment.
223745372|NCT07150806|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA scan
223745373|NCT07150806|PROCEDURE|Positron Emission Tomography|Undergo PET scan
223745374|NCT07150806|PROCEDURE|Somatostatin Receptor Positron Emission Tomography|Undergo SSTR PET scan
223745375|NCT07155889|OTHER|Educational Competition Method|"This study aims to evaluate nursing students' knowledge levels, practical skills, and the effectiveness of the educational competition method regarding medical waste management. The study consisted of three phases. In the first phase, students were informed, their consent was obtained, the Informative Information Form was completed, and the Knowledge Level Test was administered as a pre-test. In the second stage, the researcher gave a two-hour interactive lecture to all students, explaining the waste classification and separation processes. In the third stage, the Educational Competition Method was applied in Section A. In an arrangement prepared with mock waste and color-coded bins, students placed the waste in the appropriate bins within the specified time. The winner was rewarded at the end of the competition. One week later, a final test and satisfaction form were administered to evaluate the effectiveness of the method."
224178761|NCT03812224|DRUG|Erenumab|Administered by subcutaneous injection once a month
224306993|NCT05980741|PROCEDURE|Clinical Care Pathway|Clinical Care Pathway
224306994|NCT05980741|PROCEDURE|Roy Adaptation Model|Roy Adaptation Model
224306995|NCT00643136|DRUG|Pregabalin|Pregabalin capsules 75 mg twice daily on Days 1-4, then 150 mg twice daily on Days 5-28
224306996|NCT00643136|DRUG|Placebo|Matching placebo capsules twice daily for 28 days
224178762|NCT03812224|DRUG|Placebo|Administered by subcutaneous injection once a month
224178763|NCT00307658|DRUG|Intravenous immunoglobulins (human immunoglobulins G)|
224178764|NCT03909035|OTHER|Medication therapy management|"The intervention is in the form of a pharmacist-led medication review aimed at detecting potentially inappropriate prescribing. It includes:~* A patient-pharmacist interview to collect comorbidities, medication, laboratory results, self-medication, adherence, medication patient's knowledge.~* A pharmacist's evaluation of the prescriptions based on the patient's conditions and on the current recommendations for clinical practice.~* Detailed feedback to the general practitioner.~* An appointment with the patient to explain the modifications made by the general practitioner (GP)"
224306997|NCT00392236|DEVICE|2-way pager|Participants will receive messages daily to take their medication via a 2-way pager for 6 months. Once the message is received the participant will respond whether or not he/she took the medication and reason for not taking.
224306998|NCT00392236|BEHAVIORAL|Treatment as usual|Participants will receive treatment as usual.
223745376|NCT07159269|BEHAVIORAL|Cardiac point-of-care ultrasound (POCUS) training and clinical pathway|Participants will complete a cardiac POCUS simulation session and a hands-on observed structured clinical skill exam (OSCE) post-training led by ultrasound-trained faculty. Then as part of standard clinical care, advanced practice providers (APPs) will perform POCUS while supervised by emergency medicine (EM) attending physicians. To assess program feasibility and acceptability, participants will complete a pre/post and 6-month post-survey and semi-structured interview, as well as a knowledge and technical skills assessment.
224178765|NCT00303719|BIOLOGICAL|anti-thymocyte globulin|"ATG dose is 15 mg/kg intravenous (IV) every 12 hours for 6 doses on days -6, -5, and -4.~Those that should/will receive ATG in the preparative regimen:~* Related donor recipients who have not had exposure to combination chemotherapy in the 6 months preceding transplant should~* Unrelated donor recipients who have not had exposure to combination chemotherapy in the 3 months preceding transplant will~* Unrelated donor recipients who have had only a single induction cycle for the treatment of ALL/AML or MDS or CML blast crisis should~* Recipients with a prior autologous transplant in the year prior to second transplant do not require ATG."
224178766|NCT00303719|DRUG|cyclophosphamide|Cyclophosphamide will be given in a two hour infusion, total dose 50 mg/kg on day -6.
224178767|NCT00303719|DRUG|cyclosporine|Patients will receive cyclosporine A (CSA) therapy beginning on day -3 maintaining a level of \>200. For adults the initial dose will be 2.5 mg/kg IV over 2 hours every 12 hours. For children \< 40 kg the initial dose will be 2.5 mg/kg IV over 2 hours every 8 hours. Patients will receive CSA until day +100.
224178768|NCT00303719|DRUG|fludarabine|Fludarabine 30 mg/m\^2/day intravenous (IV) on day -6 through day -2., total dose 150 mg/m\^2 for 5 days.
224178769|NCT00303719|DRUG|mycophenolate mofetil|Mycophenolate mofetil (MMF) 1.5 gram twice a day (BID) or if \< 50 kg will be given 15 mg/kg orally(po) BID,beginning on day -3, and discontinue at day +30 or 7 days after engraftment (3 consecutive days of absolute neutrophil count (ANC) \> 0.5 x 109 /L).
223488049|NCT05503771|BEHAVIORAL|ISA-MI|Parents seen by clinicians randomized to the intervention group will complete the Infant Sleep Assessment (ISA), either prior to their visit using MyChart (Epic patient portal) or on a tablet computer in the exam room while they wait for their clinician; 2) a Clinical Decision Support (CDS) smart form is created in the EMR based on the assessment results, with risks and MI-informed strategies highlighted; this information will be derived from a pre-programmed algorithm and theory-based, tailored communication strategies and messages; 3) the clinician uses the CDS smart form to guide counseling with the parent during the visit, applying their training in MI-informed counseling skills; and 4) Clinician gives the parent an After Visit Summary (AVS) from the EMR (or informs them that they can access the AVS in MyChart if the parent or other caregivers use the patient portal, MyChart), which summarizes and reinforces the safe sleep counseling.
223488050|NCT05503771|OTHER|Standard of Care (SOC)|Parents seen by clinicians randomized to the control group will receive the usual practice that pediatric residents are taught which follows the American Academy of Pediatrics (AAP) Bright Futures Health Supervision Guidelines and includes age and developmentally based anticipatory guidance. As part of their training, residents receive formal teaching on core aspects of providing primary care to infants, including the AAP recommendations on safe sleep. This includes the recommended ABCS: babies should sleep Alone (no objects or people), on their Back (supine), in a Crib (or safe alternative including portable crib or bassinet), and in a Smoke-free environment.
223488051|NCT06482346|BIOLOGICAL|MT-3534|Solution for infusion; Intravenous (IV)
223488052|NCT06482346|BIOLOGICAL|Placebo|Solution for infusion; Intravenous (IV)
223488053|NCT04261192|OTHER|Constitution of tumor and blood samples|Constitution of tumor and blood samples
223488054|NCT04940065|OTHER|Kesimpta|Prospective observational cohort study. There is no treatment allocation.
223488055|NCT05797506|DRUG|Sulforaphane (Avmacol Extra Strength)|4 Tablets of Sulforaphane (Avmacol Extra Strength) per day in patients with Chronic Kidney Disease, stages 3-4.
223488056|NCT05797506|DIETARY_SUPPLEMENT|Placebo|These tablets will be matched placebos and will be provided by Avmacol.
223488057|NCT03621592|DEVICE|Cutimed® Sorbact®|Dialkylcarbomoyl chloride based wound dressing
223488058|NCT03621592|DEVICE|Acticoat®|Silver impregnated contact layer dressing
223488059|NCT05807477|DEVICE|Pulse Oximeter|OLV-4202 pulse oximeter (SW version: 01-15)
223488060|NCT02382380|DRUG|Gadoterate|Patients who choose to receive Gadoterate will receive an MRI exam with standard pre-contrast and Gadoterate-enhanced acquisitions (0.2 mL/kg). The MRI protocol utilized in the study will be comprised of the standard Body protocols (routine abdomen, liver-pancreas, renal, prostate, angiography) as well as the standard Neurologic exam protocols (routine brain, orbital, brainstem, neck, angiography).
223488061|NCT02382380|OTHER|No Gadoterate|Patients who choose not to receive Gadoterate will receive an MRI exam with no Gadolinium contrast. The MRI protocol utilized in the study will be comprised of the standard Body protocols (routine abdomen, liver-pancreas, renal, prostate, angiography) as well as the standard Neurologic exam protocols (routine brain, orbital, brainstem, neck, angiography).
223488062|NCT02984410|RADIATION|Intensity-Modulated Radiation Therapy (IMRT)|IMRT (Simultaneous Integrated Boost (SIB) and accelerated regimen) with selective neck node dissection
223488063|NCT02984410|PROCEDURE|Trans Oral Surgery (TOS)|TOS (Trans Oral Laser Microsurgery (TLM), Trans Oral Robotic Surgery (TORS), conventional) with selective neck node dissection
223488064|NCT05555043|DEVICE|Irrisafe ip|This portion of endodontic treatment includes chemical disinfection of the root canal system with these different devices that activate the disinfection solution and distribute it throughout the root canal system with ultrasonic energy.
223488065|NCT05555043|DEVICE|GentleWave System|Prepare, clean and irrigate root canals including activation of the disinfection solution and distribution throughout the root canal system.
223488066|NCT05555043|DEVICE|Waterlase iPlus|Prepare tooth and root canal, including enlargement, to debride, clean and disinfect after endodontic treatment.
223488067|NCT06166992|DRUG|BI 1291583|BI 1291583
223488068|NCT06166992|DRUG|[14C]-BI 1291583|\[14C\]-BI 1291583
223488069|NCT04401748|DRUG|Venetoclax|Tablet: Oral
223488070|NCT04401748|DRUG|Azacitidine|Subcutaneous (SC) or Intravenous (IV) injection
224178770|NCT00303719|PROCEDURE|stem cell transplantation|On day 0, if related donor, stem cells are infused via central line. If unrelated donor, marrow/PBSC is infused after arrival and processing on day 0.
224178771|NCT00303719|RADIATION|total body irradiation|The dose of TBI will be 200 cGy given in a single fraction on day -1.
223587162|NCT01689545|BEHAVIORAL|Structural level standard of care|Posters and billboards on HIV/AIDS transmission, leaflets on HIV/AIDS transmission available in health station, 15-minute monthly public broadcasts (via the village loudspeaker) on the consequences of HIV/AIDS and the number of HIV cases in the country and province will be delivered in communities.
224178772|NCT00303719|DRUG|filgrastim|Patients with white blood cell (WBC) counts \< 2500 any time after stem cell infusion will be started on G-CSF support at Day +5 at a dose of 5 mcg/kg intravenously or subcutaneously (IV/SQ) daily rounded to vial size until absolute neutrophil count (ANC) \> 2500 for 2 consecutive days.
224178773|NCT03396406|DEVICE|Pulsed radiofrequency (PRF)|received PRF at 42°C for 8 minutes followed by CRF at 60°C for 270s
224178774|NCT03396406|DEVICE|thermocoagulation|received sole CRF at 70°C for 270 s
223488071|NCT04401748|DRUG|Placebo|Tablet; Oral
223488072|NCT04008602|DEVICE|Quick icing|Brief Application of cold, for a period of up to 30 seconds on a body surface which seeks to promote the activation of the nervous system to produce increased excitability.
223488073|NCT04008602|DEVICE|Prolonged Cold|Prolonged application of cold, for at least 5 minutes or more, on a body surface that aims to reduce nervous system activation by reducing the decreased nerve conduction velocity.
223488074|NCT05476497|BIOLOGICAL|VLP Peanut|solution for subcutaneous administration
223488075|NCT05476497|BIOLOGICAL|Placebo|solution for subcutaneous administration
223488076|NCT05476497|BIOLOGICAL|VLP Peanut|solution for Skin-prick testing
223488077|NCT05168800|BEHAVIORAL|Dialogue-Based Webinar|One-time virtual webinars facilitated by a long-term care worker and a physician expert. The webinars will include provision of the existing COVID-19 vaccine Option Grid(TM) conversation aid. The majority of time will be focused on answering participants' questions about COVID-19 and the COVID-19 vaccines. An additional refresher intervention will be delivered several weeks later that will comprise of an email with links to a pre-recorded, shorter webinar available in video and audio-only formats.
223488078|NCT05168800|BEHAVIORAL|Social Media Website|A curated COVID-19 social media website. The website will feature content from different social media platforms. The posts will include information about COVID-19 and the COVID-19 vaccines. Participants will have the ability to like and comment on website content and can re-visit the website as many times as they like. An additional refresher intervention will be delivered several weeks later that will comprise of an email featuring previews and links to a selection of website content.
223488079|NCT05168800|OTHER|Enhanced Usual Practice|COVID-19 vaccine information on the Centers for Disease Control and Prevention (CDC) website. An additional refresher will be delivered several weeks later that will comprise of an email with a link to the COVID-19 vaccine information on the CDC website.
223488080|NCT04751890|BEHAVIORAL|Structured home-based exercise|Low-intensity interval walking program prescribed at hospital and performed at daily at home
223488081|NCT04751890|BEHAVIORAL|Walking advice|Walking advice according to the guidelines for peripheral artery disease patients
223488082|NCT01744587|OTHER|Epigallocatechin Gallate (EGCG)|EGCG 600 mg per day will be provided to the test group.Four capsules will be taken daily (2# bid) by the test individuals.
223488083|NCT01744587|DIETARY_SUPPLEMENT|Placebo|Placebo qd (2# bid) for 3 years
223488084|NCT06472271|DRUG|Polymyxin e|Increased starting colistin dose
223488085|NCT05514535|DRUG|Semaglutide|Participants will receive once-weekly semaglutide s.c. for 40 weeks. Semaglutide 0.25 mg will be given at week 0 and then the dose will be escalated at weeks 4, 8 and 12 to 0.5 mg, 1 mg, 2 mg respectively.
223488086|NCT05514535|DRUG|Insuline glargine U100 (reduced)|Participants will receive insulin glargine U100 s.c. once-daily. Insulin glargine dose will be reduced by 10 U at initiation of semaglutide and then again at each semaglutide dose escalation up to 40 weeks. The dose will be adjusted based on the mean of three pre-breakfast SMPG values (target SMPG: 4.4-7.2 mmol/L).
223488087|NCT05514535|DRUG|Insuline glargine U100 (titrated)|Participants will receive titrated insulin glargine U100 s.c. once-daily up to 40 weeks. The dose will be adjusted based on the mean of three pre-breakfast SMPG values (target SMPG: 4.4-7.2 mmol/L).
223488088|NCT05507866|OTHER|CSNEI|CSNEI is a policy intervention designed to address childhood obesity by modifying lunch and breakfast meal/menu items, changing the school cafeteria environments, and making changes to purchasing and procurement practices.
223587163|NCT04023123|OTHER|Ophthalmic imaging|Optical coherence tomography Topography Ocular Response Analyzer Optical Biometry Slit lamp photos
223587164|NCT04473365|OTHER|Intestinal parasite|Pre-existing intestinal parasite infection present or absent at time of admission
223587165|NCT07088939|BEHAVIORAL|dialectical behavior therapy|This internet-delivered dialectical behavior therapy (iDBT) intervention consists of an e-learning course with 4 modules based on the 4 areas of skills training in dialectical behavior therapy: mindfulness, emotion regulation, distress tolerance, and interpersonal effectiveness. Participants can work through the modules at a self-guided pace to learn more than 30 specific skills using psychoeducational materials. The intervention incorporates psychoeducational elements of skills training with introductory videos, interactive quizzes, practice and homework suggestions, as well as quotes and videos from individuals with lived experience. In preliminary testing, it was estimated to take approximately 8-10 hours to complete all material.
223745377|NCT07162337|BEHAVIORAL|Increased Plant-Based Diet and Decreased Animal-Based Diet|Self-regulated diet; increased plant-based foods with decreased animal-based foods
224178775|NCT02493075|BEHAVIORAL|The operator blinded to the contact force data or not.|"CF guided group: ablation will be performed with the guidance of real-time CF, ablation time, FTI, etc. CF will be controlled in the range of appropriate CF, which has been defined in phase I. Circumferential PV ablation will be performed orderly, isolated segment, acute reconnected segment , and unisolated segment will be also identified as described in phase I.~Usual ablation group:~Operator will be blinded to CF data, the procedure performance is the same as described in phase I."
224178776|NCT01641952|DRUG|Rituximab|Rituximab at a dose determined by the investigator, guided by the recommendation in the Summary of Product Characteristics.
224178777|NCT02626078|OTHER|observation and interview of residents|Residents will be observed during lunch to evaluate their behavior, verbal interactions between residents. The food intake during 24 hours will be evaluated also. In an interview after lunch, the appreciation of the meal by residents will be assessed by a questionnaire and the score of the nutritional state will be defined.
223745378|NCT07162129|BEHAVIORAL|Cognitive Behavioral Therapy for Postpartum Depression (PPD) and Anxiety|Cognitive Behavioral Therapy (CBT) is a type of psychotherapy (talk therapy). Each session will be two hours in duration. The 1st hour involves teaching and practice of CBT skills followed by one hour of unstructured discussion about topics relevant to PPD and PPA (sleep, supports, transitions). Each group will be delivered online via Zoom and guided by our intervention manual.
224178778|NCT05354115|DIAGNOSTIC_TEST|Nasal and Nasopharyngeal Sampling of the Panbio™ COVID-19/ Flu A&B Rapid Panel|Collection procedure will be a mid-turbinate nasal swab (deep nasal swab), by turning the swab five times in each nostril. After the nasal sampling, the operators will collect two nasopharyngeal swab one from each nostril of each subject.
223745379|NCT07171424|OTHER|Behavioral therapy and transcutaneous posterior tibial nerve stimulation|Behavioral therapy included appropriate fluid intake, bladder training, habit training, pelvic floor muscle exercises (Kegel exercises), prompted voiding, and scheduled voiding. TPTNS will be applied in a biphasic square waveform with a frequency of 20 Hz and 200 cycles/sec in 30-minute sessions. The current intensity will be varied between 0.5-20 mA according to the patient's pain threshold.
224178779|NCT03934333|DRUG|BDA MDI 160/180 mcg|Budesonide/albuterol sulfate pressurized inhalation suspension, single dose given as 2 inhalations of 80/90 mcg.
224178780|NCT03934333|DRUG|Pulmicort Flexhaler 180 mcg|Pulmicort Flexhaler aerosol, power, single-dose given as 2 inhalations of 90 mcg.
224178781|NCT04225182|DEVICE|traditional rehabilitation protocol|muscular strengthening protocol with traditional rehabilitation protocol without orthosis
224178782|NCT04225182|DEVICE|with instrumented Orthosis|8 weeks of muscular strengthening with the orthosis connected to the phone app associated
224178783|NCT00872131|DRUG|Sertraline|Oral sertraline will begin at 50 mg per day, then increase to 75 mg per day on Day 8, then increase to 100 mg per day on Day 15. The dose may be increased to 150 mg per day on Week 8, based on clinical response and medication toleration.
224178784|NCT02500901|DRUG|Enzalutamide|Following completion of 28-day lead-in cycle, enzalutamide 160 mg PO daily will continue to be administered in 28-day cycles until documented progression, unmanageable toxicity, or decision to discontinue for any reason.
224178785|NCT02500901|DRUG|Niraparib|Niraparib will be administered daily in three dose-escalation cohorts of 6 subjects per dose levels of 100mg PO, 200mg PO or 300mg PO in 28-day cycles until documented progression, unmanageable toxicity, or decision to discontinue for any reason.
224178786|NCT01773850|DEVICE|Stationary Carbon Nanotube X-ray Digital Breast Tomosynthesis Scanner|All patients will undergo conventional imaging and imaging with the carbon nanotube based x-ray stationary digital breast tomosynthesis scanner device.
224178787|NCT00133640|DRUG|cholecalciferol|
224178788|NCT00133640|BEHAVIORAL|Physiotherapy|
224178789|NCT06245850|BEHAVIORAL|Baduanjin|chinese baduanjin
224178790|NCT06245850|BEHAVIORAL|Rational emotive behavior therapy|Rational emotive behavior therapy
224178791|NCT03579004|DRUG|Paclitaxel|Paclitaxel is used in two cycles of neoadjuvant chemotherapy and concomitant chemoradiotherapy
224178792|NCT03579004|DRUG|Cisplatin|Cisplatin is used in two cycles of neoadjuvant chemotherapy and concomitant chemoradiotherapy
224178793|NCT03579004|DRUG|Fluorouracil|Fluorouracil is used in two cycles of neoadjuvant chemotherapy
224178794|NCT03579004|RADIATION|chemoradiotherapy|Distant 3D radiotherapy, single dose 2 Gray (Gy), total dose 44Gy.
224306999|NCT04126213|BIOLOGICAL|RSV MAT 60 µg|One single dose of RSV MAT 60 µg vaccine administered intramuscularly in the deltoid region of the non-dominant arm on Day 1.
223488089|NCT05129150|OTHER|Ultrasound examination|Ultrasound examination with Tissue Pulsatility Imaging (TPI) TPI is a relatively simple, rapid and non-invasive ultrasound examination which consists of applying a standard ultrasound probe to the acoustic window of the temporal bone to first measure the velocity of the middle cerebral artery in Doppler mode and secondly the cerebral pulsatility (CP) of a region of approximately 10cm2 centred on the middle cerebral artery in B-Echo mode. After collecting the information, the TPI examination will be performed by MRRC staff specially trained in TPI by engineers. The duration of the examination is between 20 and 30 minutes, including hardware installation. Four 30-second PC acquisitions will be collected per examination, with the patient lying supine on the bed in the day hospital room, then one measurement every minute for 3 minutes after standing.
223488090|NCT00647816|DRUG|Propranolol Hydrochloride Extended-Release Capsules 160 mg|160mg, single dose fasting
223488091|NCT00647816|DRUG|Inderal® LA Capsules 160 mg|160mg, single dose fasting
224178795|NCT03579004|PROCEDURE|Ivor Lewis esophagogastrectomy|Open Ivor Lewis esophagogastrectomy
224178796|NCT01273207|DRUG|Cyclosporine Inhalation Solution (CIS)|CIS is a sterile, clear, colorless, preservative-free solution of cyclosporine (USP) in propylene glycol developed specifically for administration by oral inhalation.
224178797|NCT02050256|OTHER|continuing medical education and electronic decision support|
224178798|NCT02050256|OTHER|education and electronic support|Continuing medical education and electronic decision support to General Practitioners.
224178799|NCT01745159|DRUG|tacrolimus|
224307000|NCT04126213|BIOLOGICAL|RSV MAT 120 µg|One single dose of RSV MAT 120 µg vaccine administered intramuscularly in the deltoid region of the non-dominant arm on Day 1.
224307001|NCT04126213|DRUG|Placebo|One single dose of placebo (NaCl solution) administered intramuscularly in the deltoid region of the non-dominant arm on Day 1.
223488092|NCT05552339|DRUG|Finerenone (Kerendia, BAY94-8862)|Following the physicians' decision.
223488093|NCT05552339|DRUG|Type 2 DM drugs|Following the physicians' decision
223488094|NCT03399773|BIOLOGICAL|Dilanubicel|Given IV
223488095|NCT03399773|DRUG|Cyclophosphamide|Given IV
223488096|NCT03399773|DRUG|Fludarabine|Given IV
223488097|NCT03399773|DRUG|Thiotepa|Given IV
224178800|NCT03868085|DIAGNOSTIC_TEST|dual energy x-ray absorptiometry|DXA scan
224307002|NCT04432103|BIOLOGICAL|Anti SARS-CoV 2 Convalescent Plasma in severe COVID-19 patients|Administration of Convalescent Plasma to COVID-19 obtained from donors with prior documented SARS-CoV 2 infection with IgG antibodies to hospitalized COVID-19 severe cases.
224307003|NCT04432103|BIOLOGICAL|Anti SARS-CoV 2 Convalescent Plasma in critical COVID-19 patients|Administration of Convalescent Plasma to COVID-19 obtained from donors with prior documented SARS-CoV 2 infection with IgG antibodies to hospitalized COVID-19 critical cases.
224178801|NCT04717505|OTHER|Gait Assessments|"10 Meter Walking Test: It is applied by walking at a normal walking speed (like walking in a shopping mall) without any assistance at a marked distance of 10 meters.~1- Evaluation of walking under single task conditions is done with the 10 Meter Walk Test and without any cognitive or motor second task. Evaluation of walking under dual task conditions is applied in two different ways: 2-adding a cognitive task to the walking motor task (motor + cognitive dual task) 3-adding one more motor task to the walking motor task (motor + motor dual task). While performing dual tasks, the time-distance (walking speed, cadence, stride length) characteristics of the gait are recorded using with wearable gait device."
224178802|NCT04717505|OTHER|Arthritis Impact Measurement Scales 2|It is a multidimensional, disease-specific, self-administered questionnaire designed to measure health status outcomes in patients with arthritis.
224178803|NCT04717505|OTHER|Visual Analogue Scale|The Visual Analogue Scale is a reliable and easily applicable scale used to measure the pain intensity of patients, accepted in the world literature.
224307004|NCT03986736|DIAGNOSTIC_TEST|Laboratory analysis - upon admission|Laboratory analysis will be performed upon admission of the patient to the hospital. Levels of the following parameters will be determined: HMGB-1, sCK, sMb, serum NGAL, and urine NGAL
224307005|NCT03986736|DIAGNOSTIC_TEST|Laboratory analysis - 24 hours after injury|Laboratory analysis will be performed upon admission of the patient to the hospital. Levels of the following parameters will be determined: sCK, sMb, serum NGAL, and urine NGAL
224307006|NCT02160275|DEVICE|Artificial Pancreas (Inreda Diabetic BV)|Bi-hormonal reactive closed loop system without mealtime announcement, miniaturized prototype
224307007|NCT02160275|DEVICE|Insulin pump therapy|Patients' own insulin pump with fast-acting insulin analog
224307008|NCT02853370|DRUG|Bendamustine and Rituximab|
224307009|NCT03230500|PROCEDURE|Computer guided implant placement|Implant will be placed immediately using computer aided surgical guide
223488098|NCT03399773|RADIATION|Total-Body Irradiation|Undergo TBI
223488099|NCT03399773|PROCEDURE|Umbilical Cord Blood Transplantation|Given IV
223488100|NCT03399773|OTHER|Laboratory Biomarker Analysis|Correlative studies
224178804|NCT04717505|OTHER|Standardized Mini Mental Test|Although the test has limited specificity in terms of differentiating clinical syndromes, it is a short, useful and standardized method that can be used to determine the cognitive level globally.
224178805|NCT05124145|OTHER|No intervention (surveillance system)|The surveillance network will collect data on all consecutive COVID-19 cases
224307010|NCT00406744|DRUG|Intravitreal injection of Bevacizumab|
223488101|NCT03399773|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223488102|NCT03399773|PROCEDURE|Bone Marrow Aspirate|Undergo bone marrow aspirate and biopsy
223488103|NCT03399773|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow aspirate and biopsy
223488104|NCT03399773|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
223488105|NCT03399773|PROCEDURE|Electrocardiography|Undergo ECHO
223488106|NCT03399773|PROCEDURE|Computed Tomography|Undergo CT
223488107|NCT04556097|BEHAVIORAL|Care Ecosystem|"The Care Ecosystem model uses a telephone-based intervention to support persons with dementia and their care partners, screening for common dementia-related problems and providing modular standardized support protocols and caregiver education. Specially trained health care navigators systematically identify needs and address health status, advance care planning, medication management and management of challenging behaviors. Health care navigators receive backup support from a nurse, social worker, dementia specialist, and pharmacist, and maintain close communication with the primary care provider of the persons with dementia.~This Care Ecosystem model will be adapted to augment the dementia care provided by experienced Integrated Care Management Program nurse care managers engaged in the care of high-risk, high-cost patients in a large health system."
223488108|NCT05566171|DIETARY_SUPPLEMENT|Activia Probiotic Yogurt|Activia probiotic Yogurt will be consumed by participants in this group
223488109|NCT03579511|PROCEDURE|External Pop-out|The original techniques of fetal head extraction entail the introduction of the obstetricians' hands or other instruments into the LUS. This puts the LUS at risk of damage and incision extensions with its consequences of increased blood loss, increased operative time,infection adhesions and blood transfusion.To the available, the generated good quality evidence bases practice in CS is anticipated to decrease such morbidities
224178806|NCT04710459|PROCEDURE|cryotherapy|Group 1 included 30 patients, they were subjected to chemoradiotherapy plus endobronchial cryotherapy. Group 2 included include 30 patients, they were subjected to chemoradiotherapy.
224307011|NCT02608138|OTHER|Iodine status among portuguese school children|
224307012|NCT05418530|OTHER|with pause- without pause|start with pause expiration
224307013|NCT05418530|OTHER|without pause-with pause|start without pause expiration
224307014|NCT06417736|DRUG|Megestrol Acetate 40 MG|160mg/one time/day
224307015|NCT06483841|BEHAVIORAL|Parents as Partners|The Parents as Partners program consists of 8 weekly group sessions attended by couples and was developed to strengthen the coparental relationship and promote paternal involvement. After consenting to their participation, couples will be randomly assigned to one of two conditions: intervention group or waitlist-control group. Participants will be assessed before and after the intervention on (co)parental, dyadic and work-family dimensions. Baseline (before intervention), post-test (2 months after baseline) and a follow-up assessment 6 months after the program will be performed. The intervention group will participate in the program, focusing on 5 family domains: Parents as Individuals; Parent-Child Relationships; Couple Relationship; Family of Origin Patterns; Stressors and Supports. Parents in the waitlist-control group will receive the intervention once their participation in the study is finished and if positive outcomes are found.
224307016|NCT02424643|BEHAVIORAL|Monetary Incentive|$20 Amazon.com gift card
223488110|NCT06514859|PROCEDURE|Laparoscopic repair of inguinal hernia|Laparoscopic repair of inguinal hernia
223488111|NCT06514859|PROCEDURE|Open repair of inguinal hernia|Repair of inguinal hernia by open technique-mesh hernioplasty -
223488112|NCT06018103|BEHAVIORAL|MBCT-vision|8-week mindfulness group learning course, using Mindfulness Based Cognitive Therapy customised for visual symptoms (MBCT-vision). Participants meet once weekly only, with daily home practice between sessions.
224178807|NCT04218942|DEVICE|Exime is the name of the single use temporary prostatic stent used instead of the Foley catheter|"Insertion after instillation of a local lubricant anesthetic gel in the urethra like for Foley insertion. Calibration of the urethral meatus with a 22F Bougie. Insertion of the Bougie until abutment against the posterior wall of the bulbous urethra just below the striated sphincter. Note depth of abutment on the scale of the Bougie. Retrieve the Bougie and glide the device to the same depth until abutment against the posterior wall of the bulbous urethra. At this stage the stent is correctly positioned. Stent release: unlock the Luer connection between pusher tube and stylet . Retrieve pusher tube, stylet and flattener tube.~Control of correct positioning: ask patient to stand up to verify the absence of any urine leak. Ask patient to void immediately to control clear urine output."
224178808|NCT04250142|DEVICE|Self-etching Adhesive|A Self-etching adhesive will be used to cover deep carious dentin after a selective removal of caries lesion to soft dentin procedure.
224178809|NCT04250142|DEVICE|Glass Ionomer|A conventional glass ionomer will be used to cover deep carious dentin after a selective removal of caries lesion to soft dentin procedure.
224178810|NCT05637086|DRUG|Phenytoin|Phenytoin remains a highly effective anti-epileptic drug, especially in generalized seizure management. Unfortunately, phenytoin efficacy on epileptic seizure is apparently reduced with its chronic use
224178811|NCT05637086|DRUG|Pentoxifylline 400 MG|Pentoxifylline (PTX) has a well validated immune modulatory and anti-inflammatory efficacy
224178812|NCT05637086|DRUG|Celecoxib 200mg|Celecoxib is a nonsteroidal anti-inflammatory drug (NSAID) used to treat mild to moderate pain and help relieve symptoms of arthritis
224178813|NCT02285699|DRUG|SSRIs|12-weeks of standard SSRi treatment for those interested in Phase II of the study.
224178814|NCT01475942|DIETARY_SUPPLEMENT|Probiotic|4 month probiotic intervention with 1 month run-in and 1 month wash-out. Probiotic given once a day.
224178815|NCT01955642|DRUG|Clopidogrel|75 mg milligrams per days of PLAVIX
224178816|NCT05243199|DRUG|Sacubitril/Valsartan|The initial dose of 50mg Qd was increased to 50mg Bid after 1 week and maintained to 100mg Bid after 2 weeks if the patient could tolerate it (no follow-up exit criteria were found).
224178817|NCT05243199|DRUG|Irbesartan|The Initial dose of 75 mg Qd with sand, such as patients can tolerate and follow-up exit criteria (not appear, to 75 mg Bid to maintain after 1 week, 2 weeks can still be tolerance is raised to 150 mg Bid.
224178818|NCT03931928|DRUG|(Z)-Endoxifen supplementation according to genotype|Group 2: CYP2D6 genotype predicted intermediate metabolizer receive 1.5 mg, poor metabolizer receive 3 mg (Z)-Endoxifen and extensive or ultrarapid metabolizer receive 0 mg endoxifen (Placebo)
224178819|NCT03931928|DRUG|(Z)-Endoxifen supplementation according to plasma levels|Group 3: Patients will receive (Z)-endoxifen according to (Z)-endoxifen steady state plasma concentrations (phenotype) at screening (i.e. ≤ 15 nM receive 3 mg, \> 15 and ≤ 25 nM receive 1.5 mg (Z)-Endoxifen and \> 25 nM receive 0 mg (Placebo)
224178820|NCT00493909|PROCEDURE|intrathecal opioids and thoracic paravertebral analgesia|
224178821|NCT00493909|PROCEDURE|thoracic epidural analgesia|
224178822|NCT00759993|DRUG|chromium piccolinate|1000mg tab
223488113|NCT00569491|DEVICE|TAXUS Express 2™|TAXUS Express™ Paclitaxel-Eluting Coronary Stent System
223488114|NCT00155987|PROCEDURE|Early decompressive craniectomy|Large bifrontotemporal decompressive craniectomy
224178823|NCT00759993|DRUG|placebo for chromium piccolinate|
223488115|NCT04801095|DRUG|WM-S1-030|WM-S1-030 orally administered once daily (QD) for 28 days of each cycle.
223488116|NCT01277029|OTHER|No drug|Psychopathology, personality traits of patients with lower urinary tract symptoms
223488117|NCT02478827|BEHAVIORAL|Cognitive training|The neurocognitive training program will be provided by an online platform called BrainGymmer (https://www.braingymmer.com/en/brain-games/). Users will receive an account where they will only have access to the training games they have been assigned to and where their activity will be logged. Participants randomized one of the cognitive training arms will complete the training games for 30 minutes per day, 5 days a week, for a total of 10 weeks.
224178824|NCT05459987|BEHAVIORAL|Lifestyle changes|"Nutritional advice to progressively integrate a moderate-carbohydrate Mediterranean diet with intermittent fasting 16:8 (5 times/week for 12 weeks).~Personalized exercise prescription and training (3 times per week)~Personalized education and motivational interviewing"
224178825|NCT04435951|OTHER|Evaluation|No attempt was made to the individuals in Group 1 and Group 2. Individuals were only evaluated.
224178826|NCT02073292|PROCEDURE|c-RFA|
224178827|NCT02073292|PROCEDURE|tRFA|
224178828|NCT00262457|DEVICE|Implanted gluteal electrical stimulation system|Implanted electrical stimulation system incorporating BION microstimulators
224178829|NCT04603339|OTHER|Multidisciplinary rehabilitation programme delivered via telehealth|"12 week programme of;~1\) Physiotherapy led aerobic and resistance exercise 2)1:1 Dietetics Counselling 3) Group Multidisciplinary Education Sessions"
224178830|NCT04769258|BIOLOGICAL|Pfizer Comirnaty vaccine|COVID 19 vaccines administered to the patients according to the times and modalities established by the Italian National Vaccination Plan. Further vaccines will be evaluated if and when they are available in Italy during the study period.
224178831|NCT00266331|DRUG|Reduced glutathione|
223488122|NCT06234462|DRUG|Amantadine|Participants that have been randomized to the study group will be instructed to begin taking amantadine on the day after this study visit. They will self-administer amantadine 100 mg twice daily (morning and noon) for four weeks
223488123|NCT06234462|OTHER|Physical, Occupational, Speech Therapy|Physical Therapy (PT) and Occupational Therapy (OT) train patients on breathing exercises and gradual reconditioning. Patients are referred to speech therapy (SLP) for cognitive remediation and metacognitive strategies.
223488124|NCT06234462|OTHER|Provider Counseling|Clinic providers will provide counseling/education on Long-COVID.
223488125|NCT06234462|OTHER|Medications for symptoms management|Clinic providers may recommend targeted pharmacologic management for symptoms the patient is experience. As an example, if a patient reports a headache the provider may recommend over-the-counter or prescription medications to target this particular symptom.
223488126|NCT06229145|BIOLOGICAL|Pegloticase|IV infusion
223488127|NCT06229145|DRUG|Methotrexate|Oral
223488128|NCT00369083|PROCEDURE|Hospital at home treatment|
223488129|NCT06161519|DRUG|PLX038|PLX038 is given intravenously (IV) at the assigned dose level over about 1 hour on day 1 of each 21-day cycle
223488130|NCT06253520|DRUG|Aldesleukin|Aldesleukin 600,000 IU/kg IV (based on total body weight) over 15 minutes approximately every 8 hours beginning within 24 hours of cell infusion and continuing for up to 4 days (maximum 10 doses). Patients in Cohort 3 may receive 72,000 IU/kg IV.
224178832|NCT02990325|DRUG|ABX464 150mg|ABX464 given orally at 150 mg per day from Day 0 to Day 28 (Cohort 1/ HIV infected subjects)
224178833|NCT02990325|DRUG|ABX464 50mg|ABX464 given orally at 50 mg per day from Day 0 to Day 28 (Cohort 2 / non HIV infected subjects)
224178834|NCT02990325|DRUG|ABX464 50mg|ABX464 given orally at 50 mg per day from Day 0 to Day 84 (Cohort 3 / HIV infected subjects)
224178835|NCT05386368|DRUG|ReCell|"The perioral area of the face will be treated with CO2 laser. Randomization would occur before study initiation with subjects assigned either left perioral or right perioral RECELL treatment based on their subject enrollment number. The study team member who prepares and blinds the RECELL will create the list of subject ID numbers with subject ID number randomly assigned to either left perioral or right perioral treatment group. This will be completed prior to any patient enrollment in the study. Intraoperatively, RECELL and Placebo will be provided to surgeons and assistants in opaque application devices prepared by a trained, designated study team member.~Both the treatment and placebo sides, will be dressed with a standard autologous cell suspension post treatment dressing (Telfa Clear and Xeroform)."
224178836|NCT01822886|DRUG|Romidepsin + Gemcitabine|Romidepsin 12 mg/m2 day 1,8, 15 + Gemcitabine 800 mg/m2 day 1, 15 for 6 cycles by 28 days followed by Romidepsin 14 mg/m2 day 1, 15 to PD
224178837|NCT01880320|DRUG|CD0271 0.3% / CD1579 2.5%|
224178838|NCT01880320|DRUG|CD0271 0.1% / CD1579 2.5%|
224178839|NCT01880320|DRUG|Topical Gel Vehicle|
224178840|NCT04117282|OTHER|gait training|training for improving the quality of gait through adjusting gait cycle phases time and improving the functional level and independence during gait
224178841|NCT02502994|DRUG|GEN0101|
224178842|NCT03585829|DRUG|Hydrocortisone|at a substitutive dosage
224178843|NCT03585829|DRUG|Prednisolone|at a substitutive dosage
224178844|NCT02138929|DRUG|Everolimus|Induction and Dose Expansion Phase: 10 mg by mouth daily in a 28 day cycle.
224178845|NCT02138929|DRUG|LDE 225|"Induction Phase Starting Dose: 400 mg by mouth daily in a 28 day cycle.~Expansion Phase Starting Dose: Maximum tolerated dose from Induction Phase."
224178846|NCT00561912|DRUG|Decitabine|15 mg/m\^2 IV Daily over one hour for 5 days
224178847|NCT00561912|DRUG|Interferon Alfa-2b|0.5 million Units Subcutaneously Twice Daily Continuously. Interferon Alfa-2b will be added on cycle three, day one.
224178848|NCT03511222|DRUG|Vorolanib|Patients should take vorolanib at approximately the same time every day with food.
223488131|NCT06253520|DRUG|Fludarabine|Days -7 to -3: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days.
223488132|NCT06253520|DRUG|Cyclophosphamide|Days -7 and -6: Cyclophosphamide 60 mg/kg/day x 2 days IV in 250 mL D5W infused simultaneously with mesna 15 mg/kg/day over 1 hour x 2 days.
223488133|NCT06253520|BIOLOGICAL|KRAS TCR-Transduced PBL|Day 0: Cells will be infused intravenously (IV) over 20-30 minutes (2-4 days after the last dose of fludarabine).
223488134|NCT06253520|BIOLOGICAL|GRT-C903/GRT-R904|Day 0 (GRT-C903): Injection of 1.0 mL at each of 2 bilateral vaccine injections. Weeks 4, 8 and 12 (as applicable, GRT-R904): Injection of 0.25 mL of diluted GRT-R904 at each of 2 bilateral vaccine injections
223488135|NCT05367505|DEVICE|iFuse-3D implant|The iFuse Implant System consists of cannulated triangular titanium implants (Ti 6AI4V ELI, ASTM F136) with a porous coating of commercially pure titanium plasma spray (C.P. Ti, ASTM F1580) and a setting instrument. The coating and special shape of the implants prevent rotation or displacement of the sacroiliac (SI) joint. The placement instrument uses guide pins to achieve precise placement.
224178849|NCT03511222|DRUG|Nivolumab|Standard of care
224178850|NCT03511222|DRUG|Pembrolizumab|Standard of care
224178851|NCT04586608|DIETARY_SUPPLEMENT|MCT/ω-3 fatty acids|The provision of ω-3 fatty acids to premature neonates in the Parenteral Nutrition.
224178852|NCT04586608|DIETARY_SUPPLEMENT|soybean oil-based IVFE|soybean oil-based IVFE
223488136|NCT06478589|BEHAVIORAL|Adapted Patient Priorities Care (PPC) approach|Step 1 is a PPC facilitation encounter, at which the facilitator will help the participant identify patient priorities, such as clarifying values (what matters most); setting meaningful, specific, and realistic outcome goals; describing healthcare preferences (care that is helpful and/or burdensome) and tradeoffs; and discussing priorities with clinicians. The participant's healthcare priorities are then documented and transmitted to clinicians, in order to facilitate changes in the patient's care plan to align it with his/her priorities. In step 2, the clinician considers patient's priorities and potential healthcare options (options might include starting or stopping treatments; adding or removing medications; ordering more or fewer tests; recommending or removing self-management tasks). In step 3, the clinician discusses care options with the participant, using strategies for aligning care with patient priorities.
223488137|NCT06478589|OTHER|Usual Care|Usual care for breast cancer survivorship includes regular visits with the oncology provider and yearly mammograms for surveillance.
224178853|NCT01098019|DRUG|Xeomin|Patients will receive Xeomin only at Day 0.
224178854|NCT01098019|DRUG|Placebo / Xeomin|Patients will receive 0.9% mL NaCl alone at Day 0. After unblinding (at week 12) patients who were randomized to placebo will receive Xeomin.
224178855|NCT03133702|OTHER|Forensic cases|Forensic cases which were admitted to the Emergency Department
224178856|NCT00425165|DRUG|denufosol tetrasodium (INS37217) Inhalation Solution|Denufosol 60 mg is administered as an inhalation solution one time during the study.
224178857|NCT02176031|DRUG|Natalizumab|
224178858|NCT02176031|DRUG|Methylprednisolone|
224178859|NCT01979250|PROCEDURE|DSAEK surgery|"Corneal endothelial transplantation by Descemet's stripping automated endothelial keratoplasty (DSAEK)."
224178860|NCT00055939|DRUG|exatecan mesylate|
224178861|NCT01990417|OTHER|Passive stretching|Passive stretching of the hamstrings was performed only once, lasting 30 seconds, and initiated on the right leg. Participants were in supine position with head, trunk and arms aligned along the body. The researcher remained ipsilateral to the subject´s leg being stretched and applied external force to the limit tolerated by the participant. The researcher performed a hip flexion, knee extension, and dorsiflexion of the ankle while the opposite leg remained extended on the ground.
224178862|NCT00144417|DRUG|Moxifloxacin (with rifampin, pyrazinamide, and ethambutol)|Moxifloxacin 400mg daily, 8 weeks
224307017|NCT02424643|BEHAVIORAL|Altruistic Incentive|"A preliminary statement of the importance of participation, and periodic inspirational messages throughout the length of the survey emphasizing the value to men's health by completing the survey"
224307018|NCT02424643|BEHAVIORAL|Dashboard Incentive|"A sample dashboard will compare data subjects enter in their survey to the data already collected from other men who have taken the survey. For the dashboard, men who complete the survey will be shown how their own reported data about certain topics compared to other men's data."
224307019|NCT02854592|DRUG|rtPA|intravenous thrombolysis with rtPa
224307020|NCT02854592|DRUG|urokinase|intravenous thrombolysis with urokinase
224307021|NCT03681236|PROCEDURE|Alveolar recruitment maneuver|Applying plateau pressure 30cmH₂O for 30 seconds to achieve alveolar inflation
224307022|NCT05965453|DEVICE|the Castor single branch stent graft|Participants who received thoracic endovascular aortic repair by meant of the Castor single branch stent graft from June 2018 to June 2022 were enrolled in our study.
224307023|NCT01108211|DEVICE|Vibration Platform|The patients receive treatment by standing on the Vibration Platform 20 minutes a day, five days a week. The platform will deliver a vibration of 0.3g with a vertical displacement of 0.085mm at 35 Hz.
224307024|NCT03275064|BIOLOGICAL|LNA043|LNA043 intra-articular injection
224307025|NCT03275064|OTHER|Placebo|Placebo intra-articular injection
224307026|NCT03254381|BEHAVIORAL|Resistance Training|Six months of thrice-weekly resistance training that will gradually progress in intensity. Each training session will be 60 minutes (10 minutes of warm-up, 40 minutes of training, and 10 minutes of cool-down). Classes will be group classes, with up to five participants in each.
224307027|NCT03254381|BEHAVIORAL|Balance and Tone Training|Six months of thrice-weekly stretching and relaxation exercises. Each session will be 60 minutes. Classes will be group classes, with up to five participants in each.
224307028|NCT02138058|DRUG|Topiramate|
224307029|NCT02138058|BEHAVIORAL|Cognitive restructuring intervention|4 sessions of a manualized cognitive restructuring intervention for compulsive buying
224178863|NCT00144417|DRUG|isoniazid|isoniazid, oral, 300 mg, daily, 8 weeks
224178864|NCT00167713|DRUG|Ibuprofen|
224307030|NCT00077753|DRUG|enoxaparin sodium|
224307031|NCT01627353|PROCEDURE|Standard of care|Current Standard of Care at Rockyview General Hospital for Post Hysterectomy Pain Prevention(no wound infiltration and routine anesthetic protocol).
224307032|NCT01627353|PROCEDURE|Pre-emptive wound infiltration|"The Wound Infiltration Group will receive 100 mL 0.125% marcaine plain distributed as follows: 50 mL subcutaneously prior to skin incision along entire length of planned incision line, 50 mL subfascially prior to fascial incision, with 10 mL infiltrated directly into the rectus muscles bilaterally.~The Anesthetic will be given as determined appropriate to the patient by the staff anesthetist with the addition of the following: 2 grams of Magnesium Sulphate, 10 mg of Dexamethasone, and 3 mg/kg of Lidocaine, half of which is given on induction and half of which is infused throughout the remainder of the case."
224307033|NCT02340130|BIOLOGICAL|DP/MG/14-1|The administration regimen will consist of a rush build-up régimen and a follow up period
224307034|NCT02340130|BIOLOGICAL|DP/MG/14-2|The administration regimen will consist of a rush build-up régimen and a follow up period
224307035|NCT00615654|OTHER|aquatic physical therapy|The aquatic physiotherapy program for the SG was applied twice a week, in groups of six to seven people, with sessions lasting 40 minutes, over a 12-week period. The Control Group protocol included maintenance of the individuals' medication therapy and absence of any physical activity during the study period.
223488138|NCT04132999|BEHAVIORAL|Family-informed intervention|Multiple face-to-face visits, telephone calls and-person visits with the PAP psychologist and team
223488139|NCT04132999|BEHAVIORAL|Standard Clinical Care|Support which is given as part of the standard clinical care for patients who are currently prescribed PAP.
223488140|NCT06797245|DEVICE|RiSolve App|Participants randomized to intervention will be given access to the RiSolve PDTx app for 10 weeks after initial activation.
223488141|NCT06797245|BEHAVIORAL|AUGS Patient Handouts|"AUGS Overactive Bladder and Pelvic Floor Muscles and Bladder Training Patient Fact Sheets will be provided and reviewed."
224178865|NCT06035341|OTHER|Orofacial Manual Therapy|As orofacial manual therapy, soft tissue (intraoral and extraoral trigger point therapy and myofascial release of painful muscles) and joint mobilization (caudal and ventro-caudal traction, ventral and mediolateral translation), muscle energy technique, fascia mandibularis release, occipital release and ligamentous treatment was planned.
224178866|NCT06446297|OTHER|Focus Group.|Participants in each focus group will attend a face-to-face (or virtual) meeting that lasts approximately 90 minutes. This will be composed of a briefing period, interview period supported and guided by an interview schedule and finishing with a debrief period. The same process will be followed if individual semi-structured interviews are undertaken.
224178867|NCT02643420|DRUG|SPI-2012|Single-use syringes for subcutaneous injection, administered on Day 2 of each cycle
224178868|NCT02643420|DRUG|Pegfilgrastim|Single-dose subcutaneous injection administered on Day 2 of each cycle
224178869|NCT02643420|DRUG|Docetaxel|Standard therapy
224307036|NCT05986591|COMBINATION_PRODUCT|Test Product - Tiotropium Bromide Inhalation Powder 18 mcg|Test Product
224307037|NCT05986591|COMBINATION_PRODUCT|Spiriva Handihaler (Tiotropium Bromide) 18 mcg|RLD
224307038|NCT05986591|COMBINATION_PRODUCT|Placebo|Placebo Product
224307039|NCT05345743|PROCEDURE|Surgery|All types of surgery requiring general anesthesia
224307040|NCT05962203|DIAGNOSTIC_TEST|Multi-factorial geriatric assessment, monitoring & management systems|Multi-factorial geriatric assessment, monitoring \& management systems, e.g. community-based and home-based exercise programs, polypharmacy
224307041|NCT04600102|DEVICE|Structure Sensor|A 3D representation of each participant's lower limb geometry will be obtained using a Structure Sensor scanner (Occipital, Inc.) which uses an infrared structured light projector to construct a 3D image of an object. The scanner is connected to an iPad; to operate the user rotates the iPad camera around the desired object. In seconds, the entire geometry is digitally reconstructed.
224307042|NCT00230074|DRUG|TCH346|
224178870|NCT02643420|DRUG|Cyclophosphamide|Standard therapy
224178871|NCT05109949|DRUG|Dapagliflozin 10Mg Tab|Daily morning dose per oral of Dapagliflozin 10 mg for 7 days
224178872|NCT05109949|DRUG|Empagliflozin 25 MG|Daily morning dose per oral of Empagliflozine 25 mg for 7 days
224307043|NCT02545348|PROCEDURE|Sentinel Lymph Node Biopsy|First, the detection of the sentinel node will be preformed at the beginning of the surgery. Differents detection methods are use and the efficacy of each will be recorded. Second, dissection and extraction of the sentinel node will be performed, to send it to the frozen section examination. Third, other lymph node could be removed if the surgeon evaluate that it is feasible and necessary. In this group, the false negative rate will be also evaluate.
224307044|NCT01341782|DRUG|paricalcitol|
224307045|NCT01341782|DRUG|maxacalcitol|
224307046|NCT01341782|DRUG|paricalcitol placebo|
224307047|NCT01341782|DRUG|maxacalcitol placebo|
224307048|NCT05882994|BEHAVIORAL|rom exercise|At the beginning of the study, participants will be asked to fill out data collection tools consisting of Personal Information Form, Piper Fatigue Scale, Pittsburgh Sleep Quality Index. Data will be collected with data collection tools in the 6th and 12th weeks. Evaluation will be done. At the end of the study, rom exercises will be applied to the patients in the control group.
224307049|NCT00685672|DRUG|adrenalin|adrenalin 2 microgram pr ml placebo
224307050|NCT00685672|DRUG|placebo|Saline instead of adrenaline in the epidural mixture
224307051|NCT00620555|DRUG|gabapentin|Orally administered gabapentin
224307052|NCT00581087|DRUG|DHEA treatment|DHEA : 200 mg/day hard gelatine capsule
223488142|NCT06793475|BIOLOGICAL|anti-BCMA/GPRC5D bispecific CAR-T|Autologous BCMA/GPRC5D bispecific CAR-T cells, infusion intravenously at a target dose of 2-4 x 10\^6 anti-BCMA/GPRC5D bispecific CAR-T cells/kg.
223488143|NCT06793475|DRUG|Apornemin|Apornemin 10mg/kg will be administered by i.v. infusion. Apornemin will be administered on Days 1-5, 15-19 during bridging therapy, and on Days 1-5 every 28-day cycle during maintanance treatment.
223488144|NCT06793475|DRUG|Carfilzomib|Carfilzomib 27mg/m\^2 will be administered by i.v. on Days 1,2,8,9 during bridging therapy.
223488145|NCT06793475|DRUG|Thalidomide|Thalidomide (150mg/d) will be administered by p.o. on Days 1-14 during bridging therapy, and Days 1-28 every 28-day cycle during maintanance treatment.
223488146|NCT06793475|DRUG|Dexamethasone|Dexamethasone (20mg/d) will be administered by i.v. or p.o. on Days 1-4,8,9 during bridging therapy.
223488147|NCT06775626|DEVICE|Implanon NXT® subdermal implant|"Each implant contains 68 mg of etonogestrel. The release rate is approximately 60-70 mcg/day in the 5th-6th week and reduces to approximately 35-45 mcg/day at the end of the first year; 30-40 mcg/day at the end of the second year and 25-30 mcg/day at the end of the third year.~It will be evaluation before, 3, 6, 9 and 12 months after implant insertion.Participants' use of the device will be evaluated for one year"
223488148|NCT06775626|DRUG|Etonogestrel 68mg implant|"Each implant contains 68 mg of etonogestrel. The release rate is approximately 60-70 mcg/day in the 5th-6th week and reduces to approximately 35-45 mcg/day at the end of the first year; 30-40 mcg/day at the end of the second year and 25-30 mcg/day at the end of the third year.~It will be evaluation before, 3, 6, 9 and 12 months after implant insertion.Participants' use of the device will be evaluated for one year"
223488149|NCT04601506|BEHAVIORAL|Choice Architecture Nudge|"Primary Care Providers (PCPs) will be sent alerts in the Electronic Health Record system when they initiate an opioid order for a patient who has not had an opioid prescription within the past six months. The alert provides guidance language about opioid prescribing and prompts the PCP to open the SmartSet to order non-opioid treatment alternatives. When the SmartSet is opened, PCPs can choose to click on a variety of treatment order options, including both non-opioid pharmacological options and non-pharmacological options.~PCPs will also be sent alerts when they initiate an opioid order for a patient will a current opioid prescription. The alerts prompt PCPs to consider tapering the patient's opioid. The alert also displays the MME of the patient's current opioid prescription and automatically calculates what a 10% reduction in MME relative to the current prescription would be. The alert contains options to either cancel the refill order, or to continue with the order."
224178873|NCT05109949|OTHER|Placebo|Daily morning dose per oral of Calcined magnesite 500 mg for 7 days
224178874|NCT02127970|DRUG|Dalbavancin|Dalbavancin IV infusion over 30 minutes.
224178875|NCT02127970|DRUG|Dalbavancin-matching Placebo|Dalbavancin-matching placebo IV infusion over 30 minutes.
224307053|NCT00581087|DRUG|Placebo|Treatment : 200 mg/day hard gelatine capsule
224307054|NCT04175444|DIAGNOSTIC_TEST|VisuALL Field Analyzer|Each participant will conduct a visual field test with the visuaALL headset.
224307055|NCT04175444|DIAGNOSTIC_TEST|Humphrey Field Analyzer|Each participant will conduct a standard of care Humphrey Visual Field.
224307056|NCT01140503|DRUG|Apremilast|Apremilast 20mg PO BID
224307057|NCT00928161|DRUG|Dexlansoprazole|Dissolving tablet taken by mouth (60 mg tablet), once a day. Take dose first thing in morning on empty stomach, then nothing but water for 30-45 minutes afterwards.
224307058|NCT02678650|DRUG|volatile anesthetics(isoflurane)|volatile anesthetics wash-in / wash-out operation
224307059|NCT02678650|DRUG|propofol intravenous anesthesia|propofol infusion 3-5μg / kg / h
224307060|NCT05363514|DRUG|Low Dose Naltrexone|Participant takes Low Dose Naltrexone 4.5mg PO OD for 120 days. Participant will complete a a 4 week titration to target dose of 4.5mg. Week 1-2: 1.5mg PO OD. Week 3-4: 3.0mg PO OD. Week 5-16: 4.5mg PO OD. Participant will be provided with masked capsules in blister packs.
224307061|NCT05363514|DRUG|Microcrystalline cellulose|Participant takes microcrystalline cellulose 4.5mg PO OD for 120 days. Participant will complete a a 4 week titration to target dose of 4.5mg. Week 1-2: 1.5mg PO OD. Week 3-4: 3.0mg PO OD. Week 5-16: 4.5mg PO OD. Participant will be provided with masked capsules in blister packs.
224307062|NCT00724048|DRUG|ACR16|ACR16 will be administered per dose and schedule specified in the arm description.
224307063|NCT00724048|OTHER|Placebo|Placebo matching to ACR16 will be administered per schedule specified in the arm description.
224307064|NCT02548130|OTHER|MELD score|introduction of MELD score
224307065|NCT06059664|DRUG|Finerenone Oral Tablet|Blinded study of finerenone vs. placebo in kidney transplant recipients. Participants will take finerenone or placebo once daily for 12 months. The drug will be up- or down-titrated according to potassium levels.
223488150|NCT04601506|BEHAVIORAL|PMP Integration & Nudge|During the Prescription Drug Monitoring Program (PMP) integration \& nudge intervention, Primary Care Providers (PCPs) will have integrated access to the PMP embedded within the EHR. All clinicians can already access the PMP to look up a patient's prior opioid prescriptions and prescription fills. However, this process involves signing in to the separate PMP website and can be complicated and time-consuming within typical clinical workflow. The integrated PMP tool makes it much easier and faster for a PCP to access the PMP information for a given patient.
223488151|NCT00440687|DRUG|Fluticasone 500mcg BD via accuhaler or identical placebo|
224178876|NCT05002049|BEHAVIORAL|Intervention Group|Teenagers with leadership skills from intervention schools (called ambassadors) and stakeholders will participate in focus groups to gain insights on the barriers and facilitators for healthy lifestyles of teenagers, and how science could help address these. Building on the information of the focus groups, ambassadors, stakeholders and other peers will participate in a collaborative competition event where the SEEDS intervention(s) will be designed. The intervention(s) will be implemented at intervention high-schools during 6 months. Outcomes in health behaviours and science literacy will be assessed by validated questionnaires at the start and end of the project.
224178877|NCT04966442|BEHAVIORAL|GrandAides|Enhanced post acute care for patients recently admitted for congestive heart failure
224178878|NCT05946837|DRUG|Indocyanine green (ICG) dye|ICG (25 mg vial) will be reconstituted with 10 ml sterile water provided by the manufacturer; further dilutions will be made in sterile saline just prior to administration. The final concentration of 0.32 millimolar (mM) will provide 25 μg ICG/injection, with each injection of 0.1 cc to be made . Up to 30 intradermal injections using conventional 30- or 31-gauge needles will be administered to each subject, for a maximum dose of 750 ug ICG, over 200 times less than the maximum allowed dose. Injection sites will be cleaned with alcohol wipes before intradermal injection.
224178879|NCT05946837|DEVICE|NIRF-LI imaging|Near-infrared fluorescence lymphatic imaging (NIRF-LI) imaging will be done to assess the drainage of ICG laden lymph from ICG injection sites toward regional nodal basins for 60 minutes before, during and after the Neuroglide pad treatment
224178880|NCT05946837|DEVICE|Neuroglide pad|After injection of Indocyanine green (ICG) dye and NIRF-LI imaging the subject will lie on the Neuroglide pad for the one-hour PCT treatment session.
224178881|NCT02895477|DEVICE|hearing aid|
224178882|NCT01607489|RADIATION|Dual-energy computed tomography investigation|"1x 20ml Ultravist (370mg J/ml)3-5ml/s,~1x 70ml Ultravist (370mg J/ml)3-5ml/s Contrast agent administration"
224307066|NCT06059664|DRUG|Placebo|Blinded study of finerenone vs. placebo in kidney transplant recipients. Participants will take finerenone or placebo once daily for 12 months. The drug will be up- or down-titrated according to potassium levels.
224307067|NCT06262282|BIOLOGICAL|mycobacteriophage|mycobacteriophage phage that has been found effective in killing participants NTM infection
224307068|NCT00561561|BEHAVIORAL|Acoustic startle testing|recording of eyeblink component of acoustic startle reflex with small surface electrodes during presentation of acoustic stimuli through headphones
223488152|NCT02215759|DRUG|BI 44370 TA|
223488153|NCT02215759|DRUG|Placebo|
223488154|NCT03841513|PROCEDURE|Laparoscopic Burch Colposuspension|The Burch Colposuspension is an anti-incontinence procedure where non-absorbable monofilament suture is used in the retropubic space to form a suture bridge between the anterior vagina and Cooper's ligament, thereby gently elevating the anterior vaginal wall and providing urethral support.
223488155|NCT00408226|DRUG|MKC-1|capsules, twice daily for 14 days in 21 day cycle
224307069|NCT02141035|DRUG|Acetyl-l-carnitine|Those randomized to the treatment arm will receive the medication at 1 g tid for 60 days
224307070|NCT02141035|DRUG|placebo|The control subjects will receive placebo tablets that are identical in appearance and taste to the active medication tid for 60 days
224307071|NCT03833479|OTHER|No Further Treatment|No further treatment
224307072|NCT03833479|DRUG|TSR-042|Fixed 500 mg TSR-042 dose Q3W for the first 4 doses followed by a fixed 1000 mg TSR-042 dose Q6W for up to 24 months
224307073|NCT02754544|PROCEDURE|Direct Electrocortical Stimulation|Undergo direct electrocortical stimulation
224307074|NCT02754544|OTHER|Electrocorticography|Undergo electrocorticography
224307075|NCT06982924|DRUG|Limertinib+bevacizumab|The advanced or metastatic non-small cell lung cancer patients with EGFR mutation and high PD-L1 expression will receive the combination of Limertinib with bevacizuma in first-line treatment
224307076|NCT06982924|DRUG|Limertinib|The advanced or metastatic non-small cell lung cancer patients with EGFR mutation and high PD-L1 expression will receive Limertinib in first-line treatment
224307077|NCT04801667|BIOLOGICAL|Coronavac|The CoronaVac is manufactured by Sinovac Life Sciences Co., Ltd. This vaccine contains the inactivated SARS-CoV-2 virus antigen and is administered intramuscularly.
223488156|NCT00408226|DRUG|pemetrexed|standard dosing of 500 mg/m2 infused every 21 days
223488157|NCT05900284|DRUG|Metformin low dose|If randomized to the 500 mg. Metformin arm, a tablet will be administered orally to the study participant twice a day for the initial five days starting on the date of study enrollment. Clinical research coordinators will collect blood and urine samples from study participants in both treatment arms. The blood will be collected at Baseline, Day 1 thru 7, and at hospital discharge or Day 30, whichever occurs first. On Day 2 and Day 5, the blood will be collected at hour-based intervals of 0.5h, 1h, 2h, 4h, 8h, 12h for a pharmacokinetic profile and delivered to the University of Pittsburgh Medical Center Clinical Laboratory for analysis. The remaining blood collection tubes will be delivered to the Clinical Research Biospecimen Core laboratory to be processed, separated into microtubes, and stored at -80°. Urine samples will be collected at Baseline, Day 1, 3, and 5. The urine will be processed, separated into microtubes, and frozen at -80°.
224178883|NCT04872374|DIETARY_SUPPLEMENT|Parmigiano Reggiano|subjects will receive 50 g/die of the dietary supplement 10 days before performing the eccentric exercise session
224178884|NCT04872374|DIETARY_SUPPLEMENT|Whey Protein|subjects will receive 20 g/die of the dietary supplement 10 days before performing the eccentric exercise session
224178885|NCT00472628|PROCEDURE|Blood samples collected|
224178886|NCT00072085|BIOLOGICAL|aldesleukin|
224178887|NCT00072085|BIOLOGICAL|gp100 antigen|
224178888|NCT00072085|BIOLOGICAL|incomplete Freund's adjuvant|
224178889|NCT05299905|PROCEDURE|Virtual reality using Semi-CAVE|The Semi-CAVE will use two screens positioned at a corner of the room, each with a ceiling-mounted short throw projector in front. The participant will stand in the middle of the area, giving them a viewing angle of roughly 180 degrees. The participant will be wearing a safety harness secured to an overhead guide rail, if necessary. The participant may be standing freely, on a treadmill, or on a step stool depending on the type of activity to be performed. The participant will interact with the system through motion sensors positioned at the corners of the area. To one side of the area will be a sufficiently powerful computer running the software. The projectors will be connected to this computer via HDMI cables or similar.
224178890|NCT05299905|PROCEDURE|Virtual reality using the HMD|The HMD will be a commercially available device that uses handheld controllers to control movement while in the VE. The researchers will use a room-scale set-up where a 3 m x 3 m square space is required. Oculus Quest 2 Controllers will be used to interact with the VE. The user will be positioned at the center of the square by default. A therapist will assist them through a separate program called the Observation Module. This program will let the therapist view what the patient can see in the HMD. This will also be used by the therapist to guide the patient navigate through the VE and give instructions for the activities.
224307078|NCT06984523|RADIATION|Varian Eclipse|Varian TrueBeam linear accelerator with photon beam Volumetric Modulated Arc Therapy (VMAT) capability. Subjects will receive 3000 centigray (cGy) in 10 fractions at 300 cGy per fraction.
223488158|NCT05900284|DRUG|Metformin high dose|If randomized to the 1000 mg. Metformin arm, a tablet will be administered orally to the study participant twice a day for the initial five days starting on the date of study enrollment. Clinical research coordinators will collect blood and urine samples from study participants in both treatment arms. The blood will be collected at Baseline, Day 1 thru 7, and at hospital discharge or Day 30, whichever occurs first. On Day 2 and Day 5, the blood will be collected at hour-based intervals of 0.5h, 1h, 2h, 4h, 8h, 12h for a pharmacokinetic profile and delivered to the University of Pittsburgh Medical Center Clinical Laboratory for analysis. The remaining blood collection tubes will be delivered to the Clinical Research Biospecimen Core laboratory to be processed, separated into microtubes, and stored at -80°. Urine samples will be collected at Baseline, Day 1, 3, and 5. The urine will be processed, separated into microtubes, and frozen at -80°.
223488159|NCT05900284|DRUG|Placebo|If randomized to the Placebo arm, a tablet will be administered orally to the study participant twice a day for the initial five days starting on the date of study enrollment. Clinical research coordinators will collect blood and urine samples from study participants in both treatment arms. The blood will be collected at Baseline, Day 1 thru 7, and at hospital discharge or Day 30, whichever occurs first. On Day 2 and Day 5, the blood will be collected at hour-based intervals of 0.5h, 1h, 2h, 4h, 8h, 12h for a pharmacokinetic profile and delivered to the University of Pittsburgh Medical Center Clinical Laboratory for analysis. The remaining blood collection tubes will be delivered to the Clinical Research Biospecimen Core laboratory to be processed, separated into microtubes, and stored at -80°. Urine samples will be collected at Baseline, Day 1, 3, and 5. The urine will be processed, separated into microtubes, and frozen at -80°.
223488160|NCT05130827|DRUG|Plinabulin|40mg flat dose IV infusion, infused over approximately 30 minutes starting between 1-3 hours after stem cell infusion on day 0.
223488161|NCT02584296|BEHAVIORAL|BSMA|Biobehavioral self-management approach (BSMA) intervention is aligned with information-motivation-behavioral skills (IMB) model and is guided physical activity (PA). Collects demographic, medical, disease, treatment data, blood specimens and the battery of measures. Includes PA self-assessment, 6 minute walk test(6MWT) and chair squat test (CST) with Physical Therapist (PT); provides PA handouts based on American Cancer Society (ACS) guidelines, discusses known benefits, beliefs and goals of PA (IMB health behavior motivation); assess/discuss perceived barriers to PA. PT or Exercise physiologist (EP) works with subject on various exercises (both strength and aerobic, \~30 minutes; IMB behavioral skills);PT or EP reviews exercises, subject practices, and provides a BSMA program (including strength/aerobic training) for subject to begin upon discharge. Subject keeps journal of PA and wears accelerometer (TAA) to record PA levels. 3-weeks at home study nurse calls subjects each week.
223488162|NCT04474002|DRUG|4L Klean Prep®|Patients allocated to the control group shall mix two sachets of PEG in 2L water. At 6pm the evening before examination, they shall consume 250ml solution every 15mins, and finish in 2hours. At 7am the day of examination, drink another 2L Klean-prep in 2 hours.
223488163|NCT04474002|DRUG|1L Klean prep® and 2 sachets Picoprep®|Patients allocated to the study group shall mix each sachet of Picoprep® in 150ml warm water. The patient shall take the 1st dose at 4pm the day before procedure followed by at least five 250ml drinks of clear fluid before the next dose. The 2nd dose shall be taken approximately 6hrs later and followed by at least three 250ml drinks of clear fluid before bed. On 7am the day of procedure, they shall take 1L PEG in 1 hour.
223587166|NCT07087444|BEHAVIORAL|Health education intervention to improve knowledge and uptake of personal protective equipment and visibility materials among commercial motorcycle riders and passengers|This intervention consists of a structured health education program targeting commercial motorcycle riders and passengers in the Limbe Health District. It includes interactive group sessions focused on the importance, benefits, and correct use of personal protective equipment (helmets, reflective jackets) and visibility materials (reflective strips, lights). Educational materials such as leaflets and posters are distributed to reinforce learning. Additionally, participants receive follow-up SMS reminders to encourage consistent and proper use of protective gear. The goal is to increase awareness and uptake of safety measures to reduce road traffic injuries. This intervention is community-based and tailored to the local context in Cameroon.
223587167|NCT07089004|DIAGNOSTIC_TEST|No intervention (observational study)|Observational - Biochemical, Hematological and Clinical Scoring Assessments
223587168|NCT01646203|BIOLOGICAL|IMC-TR1|Administered intravenously
224178891|NCT01398176|DIETARY_SUPPLEMENT|3 ounces of mushrooms|3 ounces of mushrooms consumed daily for 4 weeks
224178892|NCT01398176|DIETARY_SUPPLEMENT|6 ounces of mushrooms|6 ounces of mushrooms consumed daily for 4 weeks
224178893|NCT04905160|OTHER|COMPASSION Digital Biomarker|Vitals data collected by the Vitalbeat workbench for biomarker based algorithm variables will be used to drive intervention based on PAP systolic and diastolic pressures.
224307079|NCT01358552|OTHER|Néevo®/ NéevoDHA®|Néevo®/NéevoDHA® is an orally administered medical food indicated for the dietary management of impaired metabolic processes in women under a doctor's care who face high to intermediate risk pregnancies and are unable to fully metabolize or absorb folic acid. Néevo®/ NéevoDHA® contains L-methylfolate, the biologically active and immediately bioavailable form of folate.
224307080|NCT05217706|DRUG|Ketamine|The treatment group will receive Ketamine 0.2mg/kg IV once
224178894|NCT04374604|DIAGNOSTIC_TEST|Placental growth factor|On admission, the blood samples of consenting participants will be collected and analysed using enzyme linked immunosorbent assay technique to determine the level of PlGF (pg/ml).
224178895|NCT03429569|DRUG|Cross linking|Accelerated cross-linking procedure: (Total duration: 40 minutes)
224178896|NCT06108531|OTHER||
224178897|NCT00923481|DRUG|Fostamatinib disodium|200 mg BID was the administered dose for the initial part of the study and then a phase I dose escalation was added with 100 mg as the starting dose.
224178898|NCT02988115|DRUG|bempedoic acid|bempedoic acid 180 mg tablet
224307081|NCT05217706|DRUG|normal Saline|The placebo group will receive normal saline IV in a matched syringe
224307082|NCT06990243|OTHER|Evaluation Group|An evaluation form will record the participants' socio-demographic characteristics and information about their disease/treatment. Consciousness and cognitive tests will be performed. Then, pain will be assessed with the Visual Analog Scale, 4-Question Neuropathic Pain Questionnaire,, and the Spinal Cord Injury Pain Instrument (SCIPI).
224178899|NCT02988115|OTHER|placebo|Matching placebo tablet
224178900|NCT01731951|DRUG|Imetelstat|Imetelstat sodium administered as IV over 2 hours with treatment as long as participants derive clinical benefit or until end of study.
224307083|NCT06990971|OTHER|No Intervention: Observational Cohort|No interventions will be performed specifically for this study. Samples will be collected from menstrual fluid naturally shed or from biopsies and/or operations that are already taking place.
223488164|NCT06420908|DRUG|Adebrelimab+TP/FP+ radiation therapy|"Induction stage：~Adebrelimab : 1200mg d1, iv, q3w TP : nab-paclitaxel paclitaxel 180mg/m2, or paclitaxel 135-175mg/m2, d1, iv; carboplatin AUC=5-6, d1, iv, q3w FP : fluorouracil 400mg/m2, 2400 mg/m2 (48 hours), d1; cisplatin 75mg/m2, d1, iv, q3w 2 cycles;~Treatment stage:~TP : nab-paclitaxel paclitaxel 60-70mg/m2, or paclitaxel 75mg/m2, d1, iv; carboplatin AUC=5, d1, iv, q3w FP : fluorouracil 300mg/m2/d, iv; cisplatin 75mg/m2, d1, iv, q3w Radiation therapy (50.4Gy-60Gy/28-33f);~Consolidation stage:~Adebrelimab: 1200mg d1, iv, q3w , until disease progression or unacceptable toxicity occurs."
223488165|NCT06420908|DRUG|Adebrelimab+FP/TP+ radiation therapy|"Induction stage：~Adebrelimab : 1200mg d1, iv, q3w TP : nab-paclitaxel paclitaxel 180mg/m2, or paclitaxel 135-175mg/m2, d1, iv; carboplatin AUC=5-6, d1, iv, q3w FP : fluorouracil 400mg/m2, 2400 mg/m2 (48 hours), d1; cisplatin 75mg/m2, d1, iv, q3w 2 cycles;~Treatment stage: (switch to a different chemotherapy drug which not used during the earlier induction phase)~FP : fluorouracil 300mg/m2/d, iv; cisplatin 75mg/m2, d1, iv, q3w TP : nab-paclitaxel paclitaxel 60-70mg/m2, or paclitaxel 75mg/m2, d1, iv; carboplatin AUC=5, d1, iv, q3w Radiation therapy (50.4Gy-60Gy/28-33f);~Consolidation stage:~Adebrelimab: 1200mg d1, iv, q3w , until disease progression or unacceptable toxicity occurs."
224178901|NCT01720901|DRUG|Icotinib|Icotinib will be administered 250 mg one time by month, 3 times per day.
224178902|NCT00700466|DRUG|i.v. beta-blocker infusion (metoprolol)|A beta-blocker (metoprolol) will be infused for treatment of hypertension and/or tachycardia prior to induction of anesthesia aiming at decrease of blood pressure and heart rate to normal limits
224178903|NCT05114031|OTHER|FB101|Microbial intervention using product FB101
224178904|NCT05114031|OTHER|Placebo|Saline water
224178905|NCT05142462|DEVICE|Hip arthroplasty|Hip prosthesis surgical implantation
224178906|NCT03117556|PROCEDURE|Bilateral Thoracoscopic Splanchnicectomy|BTS will be performed on all patients under general endotracheal anesthesia. Patients will be placed in the prone position. A 5 mm trocar should be placed at the inferior scapular apex on the patient's left side. After confirmation of trocar placement with a 30 degree 5 mm thoracoscope, a second trocar will be placed two intercostal spaces below and two cm medial to the first trocar. After the splanchnic nerves are identified inferior and medial to the sympathetic trunk, the pleura will be incised on both sides of each of the nerves. Skin incisions are then closed and the procedure will then be repeated on the patient's right side.
224178907|NCT00775138|DRUG|280 mg Arikayce™|Study subjects will receive Arikace™ 280 mg on Days 1 through Day 28. Drug is administered once a day via a nebulizer.
224178908|NCT00775138|DRUG|Matching Placebo for Cohort 1|Study subjects will receive placebo on Days 1 through Day 28. Drug is administered once a day via a nebulizer.
224178909|NCT00775138|DRUG|560 mg Arikayce™|Study subjects will receive Arikace™ 560 mg on Days 1 through Day 28. Drug is administered once a day via a nebulizer.
224178910|NCT00775138|DRUG|Matching Placebo for Cohort 2|Study subjects will receive placebo on Days 1 through Day 28. Drug is administered once a day via a nebulizer.
224178911|NCT00969735|DEVICE|Pulmonary vein cryoablation|A deflectable over-the-wire cryoablation balloon catheter (Arctic Front®) will be inflated and be positioned at each PV antrum. Then, cryoenergy will be delivered for 300 seconds. During cryoablation of the right PVs, the right phrenic nerve integrity will be monitored by the observation of right hemi-diaphragm contractions in response to right phrenic nerve pacing at the superior vena cava. Once the 4 PVs are cryoablated, the Arctic Front® catheter will be replaced by a decapolar PV mapping circular catheter (Lasso®, Biosense Webster, Diamond Bar, California, EEUU) to evaluate PV conduction. A second cryoablation application may be delivered at each PV, if necessary. Crossover to RF ablation to complete PV isolation is discouraged.
224307084|NCT06156189|DIETARY_SUPPLEMENT|Enteral Feeding|Feeding via Nasogastric tube in intubated and ventilated patients
224307085|NCT03131492|DIAGNOSTIC_TEST|Blood test|C-reactive protein and PCT measured preoperatively, and on the second, fourth and sixth postoperative days.
224307086|NCT06105827|DRUG|Control group|Give antibiotics or diclofenac sodium suppository as needed.
224307087|NCT06105827|DRUG|Ningmitai capsule|Oral Ningmitai Capsule (produced by Guiyang Xintian Pharmaceutical Co., Ltd.), 0.38 g/capsule, 4 capsules each time, 3 times a day for 12 Weeks.
224307088|NCT06105827|DRUG|Combined group (Ningmitai plus tamsulosin)|Tamsulosin capsules, 0.2 mg/capsule, one capsule each time, once a day, were taken on the basis of Ningmitai group for 12 Weeks.
224307089|NCT06989996|DEVICE|Images Acquisition|Acquisition of useable video images
224178912|NCT00969735|DEVICE|Pulmonary vein radiofrequency ablation|Ablation approach is ostial electrical isolation of all PVs with simultaneous use of the CARTO® electroanatomic mapping system (Biosense Webster, Tirat-Ha-Carmel, Israel). PV isolation will be performed by delivering RF energy at ostial sites with earliest PV potentials. Flow rate during the RF applications will be set at 15 mL/min (baseline 2 mL/min). Temperature and power limits will be set at 45ºC and 35 W. It will be allowed a 5 W reduction in power limit setting for small PVs (angiographic supero-inferior diameter \> 12 mm), and a 5 W increase in areas located away from the esophagus, and for focal applications at sites resistant to ablation or recurrent gaps. The end-point of ablation will be to achieve bidirectional PV conduction block.
224178913|NCT02194634|DRUG|Conbercept|Intravitreal injection of 0.5 mg Conbercept at first month, then repeated as needed.
224178914|NCT02194634|OTHER|Sham injection|Sham intravitreal injection at first month, then repeated as needed.
224178915|NCT02194634|PROCEDURE|Laser|Laser treatment at first month, then repeated as needed.
224178916|NCT02194634|OTHER|Sham laser|Sham laser at first month, then repeated as needed.
224178917|NCT06404476|DIAGNOSTIC_TEST|saliva obtaining|The patient was asked to sit upright and tilt his/her head forward to collect saliva samples. İn this way, unstimulated saliva was allowed to accumulate in the floor of the mouth. The accumulated saliva was collected in a sterile container. It was then transferred to a propylene tube. The tubes were centrifuged and the clear part at the top of the tube was taken with a sterile syringe and transferred to a different propylene tube with 0.5 ml in each tube. Tubes were stored at -80ºC until the day of analysis.
224178918|NCT03629834|DIAGNOSTIC_TEST|Epworth Sleepiness Scale|Maintenance Wakefulness Test
224178919|NCT01223560|DRUG|Insulin Aspart|Insulin bolus with and without carbohydrate intake.
224178920|NCT01223560|OTHER|Exercise|Exercise on tread mill
224178921|NCT01223560|DIETARY_SUPPLEMENT|Carbohydrate|Carbohydrate intake
224178922|NCT05323370|OTHER|24h urine|Urine samples will be collected at home over 24 hours
224178923|NCT05323370|OTHER|urine sample|A urine sample of 20cc will be collected
224178924|NCT04787146|OTHER|No intervention|Once the patient is included, a drug assessment is carried out as part of the treatment and then an compliance questionnaire is submitted to him.
224178925|NCT04227561|PROCEDURE|Pudendal nerve block|"Pudendal nerve block will be performed under general anesthesia and guided by neurostimulation.~The local anesthetic solution (chirocaine 2.5mg/ml) will be injected in the ischiorectal fossa with a needle (a BBraun Stimuplex Ultra 360 22G 50mm needle) connected to a neurostimulator (Stimuplex HNS 12 neurostimulator). The neurostimulator will be used to determine the localization of pudendal nerve and to identify the precise site of injection. The contraction of the anal sphincter or bulbocavernosus muscle occurs when the pudendal nerve is reached.~These procedure will be performed bilaterally."
224178926|NCT04227561|PROCEDURE|Penile nerve block|"The local anesthetic solution (chirocaine 2.5mg/ml) will be injected under the fascia of Scarpa with a real-time ultrasound guidance.~These procedure will be performed bilaterally."
224178927|NCT00431132|DRUG|estradiol, 10 mcg|Tablets, administered intravaginally twice weekly
223488166|NCT05374460|BEHAVIORAL|Explanatory diagram|Participant is told there will be a mismatch between their target finger and the visual indicator of target finger position. They will be shown a diagram explaining this.
223488167|NCT05374460|BEHAVIORAL|Direct vision|Foamboard under mirror removed, making the mirror see-through and the hand directly visible. Mismatch between target hand and visual indicator will be directly visible.
223488168|NCT05374460|BEHAVIORAL|Movement feedback, target hand|After the participant points at each target, a cursor indicating final pointing position will be displayed briefly. The visual indicator of the target hand will be displaced.
223488169|NCT05374460|BEHAVIORAL|Movement feedback, pointing hand|After the participant points at each target, a cursor indicating final pointing position will be displayed briefly. The visual indicator of the target hand will not change, but the cursor indicating pointing hand position will change.
223488170|NCT05374460|BEHAVIORAL|No movement feedback|The visual indicator of the target hand will be displaced, but there will be no cursor to indicate the pointing hand's position.
224178928|NCT02950168|PROCEDURE|Edoxaban|Edoxaban according to Summary of Product Characteristic (SMPC)
224178929|NCT01920087|DRUG|ATNC05|Subject will take between two and four capsules of study medication per day, according to the dose titration schedule in the protocol.
224178930|NCT01920087|DRUG|Placebo|Subject will take between two and four capsules of study medication per day, according to the dose titration schedule in the protocol.
223488171|NCT05374460|BEHAVIORAL|Attend to the targets|Participants will not be told anything about the visuo-proprioceptive mismatch. Instead, they will be asked simply to attend to the target positions.
223488172|NCT00620542|DRUG|Rosuvastatin|capsule, oral, once daily
223488173|NCT00620542|DRUG|Atorvastatin|capsule, oral, one daily
223488174|NCT02208440|PROCEDURE|Best Repair of torn Rotator Cuff|
223488175|NCT02208440|DEVICE|InSpace™ system|
223488176|NCT01582347|DRUG|RBP-6300|"Participants randomized to the RBP-6300 treatment arm take either 10, 20 or 30 mg/day RBP-6300 tablets during the Transfer Period (study days 1-7).~Oral RBP-6300 tablets containing 10 mg buprenorphine hemiadipate HCl and 10 mg naloxone HCl dehydrate."
224178931|NCT00602043|RADIATION|F-18 16 alpha-fluoroestradiol|Undergo \[\^18F\] FES PET
224178932|NCT00602043|RADIATION|fludeoxyglucose F 18|Undergo standard clinical FDG PET/CT
224178933|NCT00602043|PROCEDURE|positron emission tomography|Undergo \[\^18F\] FES PET
224178934|NCT00602043|PROCEDURE|positron emission tomography|Undergo standard clinical FDG PET/CT
224178935|NCT00602043|PROCEDURE|computed tomography|Undergo standard clinical FDG PET/CT
224178936|NCT00602043|OTHER|laboratory biomarker analysis|Correlative studies
224178937|NCT01097564|GENETIC|COL4A1 genetic testing|genetic testing
224178938|NCT03169842|DEVICE|pancreatic cyst fluid glucose analysis using a bedside glucometer|Small amount of pancreatic cyst fluid will be analyzed for glucose level using a bedside glucometer from EUS-FNA procedures.
224178939|NCT02114099|DRUG|Atorvastatin|10 mg qd x1 year
224178940|NCT02181335|DRUG|Respimat® Budesonide low dose|
224178941|NCT02181335|DRUG|Respimat® Budesonide high dose|
224178942|NCT02181335|DRUG|Turbohaler® Budesonide|
224178943|NCT02181335|DRUG|Placebo|
224178944|NCT02002637|DEVICE|Latella Knee Implant System|
224178945|NCT01799291|BEHAVIORAL|Decision Making Tutorial|"A web-based presentation focused on key cognitive de-biasing strategies, including helping clinician participants: consider alternative diagnoses (e.g., symptom checklists); decrease reliance on memory (e.g., mnemonics); and incorporate Bayesian reasoning (e.g., actuarial approaches)."
224178946|NCT04912297|BIOLOGICAL|10-valent pneumococcal conjugate vaccine, PCV10|10-valent pneumococcal conjugate vaccine, PCV10
224178947|NCT04191928|DRUG|Apixaban|Apixaban is an orally administered highly selective factor Xa inhibitor, belonging to the class of direct-acting oral anticoagulants (DOAC) along with rivaroxoban and edoxaban. Factor Xa is an essential mediator of the clotting pathway in humans. Apixaban is currently approved by the FDA for treatment of VTE, prophylaxis of DVT in patients undergoing knee and hip replacement surgeries and for reducing the risk of embolic stroke and systemic embolism in patients with nonvalvular atrial fibrillation.
224178948|NCT01815996|OTHER|One time blood draw to look at patient's DNA|One time blood draw to look at patient's DNA
223488177|NCT01582347|DRUG|Subutex®/Suboxone®|"Participants randomized to the Subutex®/Suboxone® treatment arm take the dosage of either drug on which they were previously stabilised during the Run-In, Transfer, and Transition Periods.~Participants randomized to the RBP-6300 treatment arm take the dosage of either drug on which they were previously stabilised during the Run-In and Transition Periods.~Sublingual Subutex® tablets containing 8 mg buprenorphine and and sublingual Suboxone® tablets containing 8 mg buprenorphine and 2 mg naloxone."
223488178|NCT01582347|DRUG|Placebo for RBP-6300|"Participants randomized to the Subutex®/Suboxone® treatment arm take Placebo for RBP-6300 during the Transfer and Transition Periods.~Participants randomized to the RBP-6300 treatment arm take Placebo for RBP-6300 during the Transition Period."
223488179|NCT01582347|DRUG|Placebo for Subutex®/Suboxone®|Participants randomized to the RBP-6300 treatment arm take Placebo for Subutex®/Suboxone® during the Transfer Period.
223488180|NCT02353663|OTHER|Echocardiography|Echocardiography examination
223488181|NCT01359423|DRUG|Percutaneous transluminal angioplasty of femoropopliteal artery lesions with primary long|Patients will be randomized in a two-by-two factorial manner according to the use of IVUS guidance (IVUS guidance vs. no IVUS guidance) for the PCI and the duration of dual anti-platelet therapy (100 mg/day aspirin and 75mg/day clopidogrel for 6 months vs. 12 months) after PCI. Each randomization of the enrolled subjects will be done 1:1.
223488182|NCT01359423|DRUG|short stenting for the primary outcome and use of cilostazol for 12 months for secondary outcome.|Patients will be randomized in a two-by-two factorial manner according to the use of IVUS guidance (IVUS guidance vs. no IVUS guidance) for the PCI and the duration of dual anti-platelet therapy (100 mg/day aspirin and 75mg/day clopidogrel for 6 months vs. 12 months) after PCI. Each randomization of the enrolled subjects will be done 1:1.
223488183|NCT00432120|DRUG|clopidogrel|To compare two different clopidogrel regimens on the outcomes of patients undergoing elective coronary angiography ± ad-hoc percutaneous coronary intervention
223488184|NCT01970371|DRUG|plazomicin|
223488185|NCT01970371|DRUG|colistin|
223488186|NCT01970371|DRUG|meropenem|
223488187|NCT01970371|DRUG|tigecycline|
223488188|NCT01970371|DRUG|antibiotic of Investigator's choice|
223488189|NCT01348269|DRUG|Aclasta|1 x intravenous non-current drip (infusion)
223488190|NCT01348269|DRUG|Placebo|NaCl Solution
223488191|NCT05690243|BEHAVIORAL|Group psychotherapy delivered via video telehealth|Small group psychotherapy using psychoeducation and skills training aimed at addressing modifiable factors in MCI.
223488192|NCT04727749|BEHAVIORAL|Therapy Dog Team Visit|For the intervention group, patient interacts with the therapy dog, handler shares information about the therapy dog, asks about patient's pets, and offers a trading card of the therapy dog at the conclusion of the visit.
223488193|NCT01199770|OTHER|Control, small|control pasta, small portion
224178949|NCT03344874|DEVICE|Stethee®|Stethee® is a new wireless digital stethoscope.
223488194|NCT01199770|OTHER|Experimental B, small|experimental pasta, small portion
223488195|NCT01199770|OTHER|Experimental pasta C, small|experimental pasta C, small portion
223488196|NCT01199770|OTHER|control, medium|control pasta, medium portion
223488197|NCT01199770|OTHER|experimental pasta B, medium|experimental pasta B, medium portion
223488198|NCT01199770|OTHER|experimental pasta C, medium|experimental pasta C, medium portion
223488199|NCT01199770|OTHER|NL|no pasta, water only
224178950|NCT03344874|DEVICE|3MTM Littmann® Classic IIITM|3MTM Littmann® Classic IIITM is the conventional stethoscope.
224178951|NCT03067701|DRUG|Carbon Monoxide|In healthy young adults 18-39 years of age, The investigator will determine if intermittent inhalation of 0.1% CO, from a 1-Liter bag once every minute for 30-40 min at a level that approaches the CO boost with hookah smoking, augments endothelial function.
224178952|NCT00682760|DRUG|Korean Botulinum toxin type A (KbtxA) and Botox injection|Each vial of Botox and KbtxA contained 100 U of BTX-A in a sterile vacuum-derived form without preservatives. Each vial of KbtxA was identical to the placebo (Botox) vial, and all vials were reconstituted with 2.0 mL of 0.9% sterile nonpreserved saline solution to a final dilution of 5 U /0.1 mL. The dose of BTX-A per injection site was 2.5 U to 5 U, and the location, number of injection sites. Using a 30-gauge needle, injections were angled away from the center of lid to reduce the risk of spread into the levator muscle. Injection sites include the upper medial and lateral eyelid margins, lower lateral lid margins, and above the eyebrow.
223488200|NCT02827968|DRUG|KN035|KN035 is a monoclonal antibody drug which is formulated for subcutaneous injection in a single-use vial (brown neutral borosilicate) containing a total of 300 mg antibody in 1.5 ml of solution.
223488201|NCT02664883|PROCEDURE|Computed Tomography|Correlative studies
223488202|NCT02664883|OTHER|Cytology Specimen Collection Procedure|Undergo collection of blood and urine samples
223488203|NCT02664883|OTHER|Laboratory Biomarker Analysis|Correlative studies
223488204|NCT02664883|PROCEDURE|Magnetic Resonance Imaging|Correlative studies
223488205|NCT02145676|BIOLOGICAL|onabotulinumtoxinA|OnabotulinumtoxinA injected into predefined muscles of the study limb on Day 1.
223488206|NCT02145676|DRUG|placebo (normal saline)|Placebo (normal saline) injected into predefined muscles of the study limb on Day 1.
223488207|NCT04626674|GENETIC|delandistrogene moxeparvovec|Single IV infusion of delandistrogene moxeparvovec
224178953|NCT00838968|DRUG|interferon-alpha|interferon-alpha is intramuscularly or subcutaneously injected at 3,000,000-5,000,000 U three times a week for 18 months
223488208|NCT05229588|DRUG|Lurbinectedin 4 MG Injection [Zepzelca]|"Lurbinectedin will be administered with a minimum total volume of 100 mL of solution for infusion (either on 5% glucose or 0.9% sodium chloride).~Lurbinectedin will be administered intravenously through peripheral or central lines at a dose of 3.2 mg/m2 at a fixed infusion rate."
223488209|NCT04599985|OTHER|star excursion balance training (SEBT)|The SEBT is aimed to be maintained the single limb stance on one leg while reaching farthest possible with the swing leg. An individual can reach farthest with the swing leg while maintaining the balance on the stance leg
223488210|NCT04599985|OTHER|Simplified star excursion balance training (SSEBT)|It is one of the training protocols, in a simplified way, with respect to star excursion balance test. It consists a series of reaching tasks for the lower limbs in three-directions i.e., anteromedial, medial and posteromedial.
223488211|NCT03575364|DEVICE|ClotTriever|Thrombectomy
223488212|NCT04849741|DRUG|zilganersen|zilganersen will be administered by ITB injection.
223488213|NCT04849741|DRUG|Placebo|zilganersen-matching placebo will be administered by ITB injection.
223488214|NCT06281392|DEVICE|CADe system|Colonoscopy assisted by an artificial intelligence system (CADe).
223488215|NCT06281392|DEVICE|NBI|Virtual colonoscopy assisted by NBI
223488216|NCT03979417|OTHER|Blood draw and liver resection|The samples are transferred to the research unit for immunological studies.
223488217|NCT05866224|OTHER|Telerehabilitation program|The supervised telerehabilitation program will be performed in the home of each patient and supervised by an experienced physiotherapist with more than 4 years of clinical experience in therapeutic exercise for chronic diseases.
223488218|NCT02313155|DRUG|Subcutaneous injection of TAK-850|TAK-850 0.5 mL, Subcutaneous injection
223488219|NCT02313155|DRUG|Intramuscular injection of TAK-850|TAK-850 0.5 mL, Intramuscular injection
223488220|NCT04684316|OTHER|Electronic survey with selective consultations|Participants complete an online questionnaire, after which the 20% employees that mostly need contact with the occupational physician (based on their survey score) are invited to a consultation with the occupational physician.
223488221|NCT00386828|DRUG|Bevacizumab:|
223488222|NCT02392910|DRUG|Iron Sucrose|At each visit, the patient lay on a stretcher and underwent a vein cannulation in the forearm with a commercial canula no. 16, which was connected to IV tubing that was connected to a bag contained 200 ml isotonic saline solution 0.9% plus 200 mg of Iron Sucrose. Each infusion was administered throughout 60 min. This scheme was followed for 5 consecutive weeks.
223488223|NCT02392910|DRUG|Placebo|At each visit, the patient lay on a stretcher and underwent a vein cannulation in the forearm with a commercial canula no. 16, which was connected to IV tubing that was connected to a bag of isotonic saline solution 0.9% (200 ml). Each infusion was administered throughout 60 min. This scheme was followed for 5 consecutive weeks.
223488224|NCT00691964|BIOLOGICAL|ABT-874|SQ injection 200 mg Weeks 0 and 4; 100 mg Week 8
223488225|NCT00691964|BIOLOGICAL|etanercept|SQ injection 50 mg BIW
223488226|NCT00691964|DRUG|placebo|SQ placebo injections for ABT-874 and etanercept
223488227|NCT01260506|DRUG|VB-111|
223488228|NCT01260506|DRUG|Bevacizumab|Upon progression, subjects will receive a combination therapy of VB-111 and standard of care bevacizumab
223488229|NCT01577121|DRUG|indomethacin|50 mg / 6 hours during 5 days
223488230|NCT01577121|DRUG|placebo|50 mg / 6 hours during 5 days
223488231|NCT04115722|OTHER|IBD ACTIVIT|Effect of IBD disease and activity of disease on coagulation parameters
223488232|NCT05123924|OTHER|Evaluation of respiratory capacity, respiratory muscle strength and fatigue|"The demographic information of the participants will be taken with the form prepared for the people in this group. Then, respiratory function with Minispir Light Spirometer, respiratory muscle strength with MD Diagnostics RP Check and fatigue with Pediatric Quality of Life Inventory (PedsQL)-Multidimensional Fatigue Scale will be evaluated. All assessments will be completed on the same day and will not be repeated after a certain period of time."
223488233|NCT06378970|OTHER|Audio Book Application|The Audio Book Application Preference Form asked about book preferences other than horror and thriller genres. The selected audiobook was played with headphones via tablet/smartphone. Separate headphones were used for each patient. Patient Follow-up Form and Facial Anxiety Scale evaluations; the initial measurement (M0) was evaluated before the intervention, the first measurement (M1) at the 15th minute of the intervention, the second measurement (M2) at the 30th minute of the intervention, and the third measurement (M3) 30 minutes after the end of the intervention. Care was taken to ensure that there was no deterioration in the comfort of individuals due to the intervention. In the selection of audio books, language fluency, spelling rules and accessibility were taken into consideration and audiobook platforms to which the researchers were members were used.
223488234|NCT04391907|PROCEDURE|IPL|Intense pulse light (IPL) laser is used for the treatment of dry eye originated from meibomian gland dysfunction. IPL laser will be performed to patients who are planned to cataract surgery to improve dry eye.
223488235|NCT05508906|DRUG|Palazestrant|Complete estrogen receptor antagonist (CERAN)
224178954|NCT06436170|DIAGNOSTIC_TEST|OCTA|OCTA is a non invasive diagnostic technique to visualize RPC
224178955|NCT00993694|DRUG|chemotherapy|
223587169|NCT06904235|DRUG|IV NEPA (fosnetupitant/palonosetron)|"In NEPA-22-01, different body weight-based dosages of IV NEPA will be applied to patients below and over 3 months of age:~Formulation A (for patients ≥3 months of age; 235 mg fosnetupitant/1.5 mg palonosetron per vial) or Formulation B (for patients \<3 months of age; 235 mg fosnetupitant/2.5 mg palonosetron per vial)."
224178956|NCT00993694|DRUG|dapsone|
224178957|NCT00993694|OTHER|medical chart review|
224178958|NCT00993694|PROCEDURE|assessment of therapy complications|
224178959|NCT03748654|DIAGNOSTIC_TEST|Visual Field Testing|Visual field test using the protocol 24-2 Threshold Test
224307090|NCT06990932|DEVICE|High Intensity Laser|The therapeutic dose of laser therapy depends on power density, tissue color, and type. Darker skin may absorb the laser in the epidermal layer, but HILT can pass through without absorption. Research has improved power density and dose, with the World Association of Laser Therapy recommending a 5-7 J/cm2 dose for optimal therapeutic outcomes.
224178960|NCT04896840|OTHER|Telerehabilitation İntervention, Motor learning|"Telerehabilitation İntervention:~Training videos will be sent to the families of the children in the tele-rehabilitation group before starting to work. With the training videos, it is aimed to teach the exercises to be done to the families. Treatment will be applied by their families for 8 weeks, 2 days a week, 40 minutes a day. Physiotherapist will attend the sessions by video conference method. Video conference calls will be made by phone over the WhatsApp application.~Motor learning:~The first 10 minutes will start with active stretching Functional lying in a sitting position, Functional lying with feet together in a standing position. rolling the pilates ball on the wall, walking on its side. Going up and down stairs at different heights. Walking across different surfaces and obstacles. Getting up from chairs of different heights, sitting and extending the object taken from the ground. Functional exercises suitable for the child's level."
224178961|NCT03402308|DIETARY_SUPPLEMENT|Schisandra chinensis extract|Schisandra chinensis extract 1,000 mg/day for 12 weeks
224178962|NCT03402308|DIETARY_SUPPLEMENT|Placebo|Starch placebo 1,000 mg/day for 12 weeks
224178963|NCT02495584|DIETARY_SUPPLEMENT|Fortified milk (10µg vitamin D3)|
224178964|NCT02495584|DIETARY_SUPPLEMENT|Unfortified milk (placebo)|
224178965|NCT02495584|DIETARY_SUPPLEMENT|10µg vitamin D3 supplement|
224178966|NCT02495584|DIETARY_SUPPLEMENT|Placebo supplement|
224178967|NCT00728572|PROCEDURE|Logan Basic Technique and Surface EMG|Participant will receive a brief Basic Technique and Surface EMG examination and Basic Technique treatment.
224178968|NCT00728572|OTHER|Surface EMG|Surface EMG only, no intervention
223488236|NCT05508906|DRUG|Ribociclib|All subjects in Treatment Group 1 will receive palazestrant in combination with ribociclib.
223488237|NCT05508906|DRUG|Alpelisib|All subjects in Treatment Group 2 will receive palazestrant in combination with alpelisib.
223488238|NCT05508906|DRUG|Everolimus|All subjects in Treatment Group 3 will receive palazestrant in combination with everolimus.
223488239|NCT06403839|PROCEDURE|No preoperative dental screening|Discontinuance of mandatory preoperative dental screening prior surgical valve replacement which also can include oral surgery.
223488240|NCT01319370|DRUG|Minoxidil|1 g of 5% Minoxidil topical foam twice daily over 24 weeks in double-blinded phase and further 80 weeks in open-label-phase
223488241|NCT01319370|DRUG|vehicle of 5% Minoxidil topical foam|1 g of vehicle topical foam twice daily over 24 weeks in double-blinded phase and further 80 weeks in open-label-phase
223488242|NCT05835882|BIOLOGICAL|Red Blood Cell concentrates from organ donor|"Intervention is a 3-step procedure consisting of 1) recovering blood from the donor during organ procurement; 2) processing donor blood to RBC units; 3) transfusing donor blood to recipients, if necessary during surgery.~1. Donor blood recovery. A: Donor evaluation. During the donor workup, the donor coordinator team gathers additional information from the donor relatives. If no contraindication to blood collection exists, the donor-recipient ABO-crossmatch is performed, and if negative the donor is considered eligible. B: Donor blood collection. It is carried out by a trained investigator, through the continuous autotransfusion system CATSmart (Fresenius Kabi) in the surgery room.~2. Donor blood processing, carried out using the continuous flow CATSmart device. About 4 RBC units are collected.~3. Donor RBC unit transfusion to recipients according to procedures usually adopted at our hospital (final hb level 8-9 g/dL)."
224178969|NCT00728572|PROCEDURE|Logan Basic Technique Sham|Participants will receive a sham Basic Technique treatment, not indicated by examination.
224178970|NCT05784558|DEVICE|UroLift System|The UroLift System is a procedure that utilizes tiny implants to lift and hold the enlarged prostate tissue out of the way so it no longer blocks the urethra.
224178971|NCT05784558|OTHER|Watchful Waiting or BPH Medications|Subjects for whom the physician decides the best course of therapy to be either watchful waiting or new or continuing BPH medications.
224178972|NCT05784558|DEVICE|Other Surgical Intervention|Physician decides the best course of therapy to be a surgical intervention other than the UroLift System.
224178973|NCT03884049|PROCEDURE|Embolization|transcatheter arterial embolization of neovessels around the knee
224178974|NCT03884049|PROCEDURE|Sham embolization|Sham transcatheter arterial embolization of neovessels in the knee
224178975|NCT02029885|DEVICE|Investigational Therapy (Surround Sound)|
224178976|NCT02029885|DEVICE|Sham Control|
224178977|NCT00281359|DEVICE|With heat|heat pad followed by dynamic splinting
224178978|NCT00281359|DEVICE|No heat|No heat added to tissue prior to dynamic splinting
223488243|NCT05733689|COMBINATION_PRODUCT|FLOT|"* Oxaliplatin 85 mg/m2 IV on Day 1~* Docetaxel 50 mg/m2 IV on Day 1~* Leucovorin 200 mg/m2 IV on Day 1~* Fluorouracil 2600 mg/m2 continuous infusion over 24 hours daily on Day 1 Every 14 Days"
223488244|NCT05733689|COMBINATION_PRODUCT|FOLFOX|"* Oxaliplatin 85 mg/m2 IV on Day 1~* Leucovorin 400 mg/m2 IV on Day 1~* Fluorouracil 400 mg/m2 IV Push on Day 1~* Fluorouracil 1200 mg/m2 continuous infusion over 24 hours daily on Days 1 and 2 Every 14 Days"
223488245|NCT05733689|COMBINATION_PRODUCT|FOLFIRI|"* Irinotecan 180 mg/m2 IV on Day 1~* Leucovorin 400 mg/m2 IV on Day 1~* Fluorouracil 400 mg/m2 IV Push on Day 1~* Fluorouracil 1200 mg/m2 continuous infusion over 24 hours daily on Days 1 and 2 Every 14 Days"
223488246|NCT05733689|COMBINATION_PRODUCT|FOLFIRINOX|"* Oxaliplatin 85 mg/m2 IV on Day 1~* Irinotecan 150 mg/m2 IV on Day 1~* Leucovorin 200 mg/m2 IV on Day 1~* Fluorouracil 1200 mg/m2 continuous infusion over 24 hours daily on Days 1 and 2 Every 14 days"
223587170|NCT06904235|DRUG|Reference Treatment: IV ondansetron infusion|"IV Ondansetron Dosing Regimen~* Day 1 (before start of chemotherapy): One 30-min infusion of 0.15 mg/kg (ondansetron maximum dose: 8 mg per administration)~* Day 1 at 4 h and 8 h after the end of first administration: Two 30-min infusions of 0.15 mg/kg (ondansetron maximum dose: 8 mg per administration)"
223587171|NCT06904235|DRUG|Reference Treatment: IV fosaprepitant infusion|"Fosaprepitant IV Dosing Regimen~* Patients aged 12 years to \<18 years: a single dose of IV fosaprepitant 150 mg~* Patients aged 2 years to \<12 years: a single dose of IV fosaprepitant 4 mg/kg (maximum dose: 150 mg)~* Patients aged 6 months to \<2 years: a single dose of IV fosaprepitant 5 mg/kg (maximum dose: 150 mg)"
223587172|NCT07088523|DRUG|Xintong Oral Liquid (Sequential Phase)|Xintong Oral Liquid (Lunan Pharmaceutical), 10 mL tid po from week 5 to 52.
223587173|NCT07088523|DRUG|Xintong Oral Liquid (Intensive Phase)|Xintong Oral Liquid (Lunan Pharmaceutical), 20 mL tid po for 4 weeks.
223587174|NCT07088523|DRUG|TCM Syndrome Differentiation Decoction|Individualized herbal decoction based on TCM diagnosis (four diagnostic methods), administered for 14 days during intensive phase.
224178979|NCT01433328|DRUG|Lidocaine|Lidocaine
223488247|NCT05733689|COMBINATION_PRODUCT|PACLITAXEL with or without CARBOPLATIN|"* Paclitaxel 200 mg/m2 IV on Day 1~* Carboplatin AUC 5 IV on day 1 Every 21 Days~OR~\- Paclitaxel 80mg/m2 IV on Days 1,8,15 Every 28 Days"
223488248|NCT05733689|COMBINATION_PRODUCT|DOCETAXEL and IRINOTECAN (alone or combined)|"* Docetaxel 35 mg/m2 IV on Days 1 and 8~* Irinotecan 50 mg/m2 IV on Days 1 and 8 Every 21 Days~* Docetaxel 75 mg/m2 IV on Day 1 Every 21 Days~* Docetaxel 150 mg/m2 IV on Day 1 Every 14 Days"
223488249|NCT05733689|DRUG|NIVOLUMAB (alone or when added to a regimen above)|"* 240 mg IV on Day 1 every 14 days, or~* 360 mg IV on Day 1 every 21 days, or~* 480 mg IV on Day 1 every 28 days"
223488250|NCT05733689|DRUG|PEMBROLIZUMAB (alone or when added to a regimen above)|"* 200 mg IV on Day 1 every 21 days, or~* 400 mg IV on Day 1 every 42 days"
223488251|NCT05733689|DRUG|Durvalumab|\- 1500 mg IV on Day 1 every 28 days
223488252|NCT05733689|DRUG|Trastuzumab|"* 8 mg/kg on Day 1, then 6 mg/kg IV every 21 days, or~* 6 mg/kg on Day 1, then 4 mg/kg IV every 14 days"
223488253|NCT02724579|DRUG|Cisplatin|Given IV
223488254|NCT02724579|DRUG|Cyclophosphamide|Given IV
223488255|NCT02724579|OTHER|Laboratory Biomarker Analysis|Correlative studies
223488256|NCT02724579|DRUG|Lomustine|Given PO
223488257|NCT02724579|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223488258|NCT02724579|RADIATION|Radiation Therapy|Undergo craniospinal radiation therapy
223488259|NCT02724579|DRUG|Vincristine|Given IV or via minibag
223488260|NCT02724579|DRUG|Vincristine Sulfate|Given IV or via minibag
223488261|NCT04287062|DRUG|Suvorexant|Dual orexin receptor antagonist
224178980|NCT01433328|DRUG|Placebo|Placebo
224178981|NCT04093544|DEVICE|Deep brain stimulation|Steered stimulation using directional leads
224178982|NCT06186089|DIETARY_SUPPLEMENT|probiotics|patients undergoing total gastrectomy take probiotics qd for 3 months
224178983|NCT02367690|DRUG|Selinexor|Topical gel
224178984|NCT02367690|OTHER|Standard-of-Care|Surgical debridement, sterile saline rinses, and dressing changes.
224178985|NCT02367690|OTHER|Vehicle Gel|Topical vehicle gel with no active ingredients.
224178986|NCT03553264|DEVICE|Virtual Reality Rehabilitation|Track Speed Racing 3D game will run with HMD 'Revelation' 3D VR Headset and each HMD group patient will be instructed to perform the game protocol uninterruptedly for 20min/day, while sitting on a chair or sofa.
223488262|NCT04287062|DRUG|Placebos|Weight and color matched placebo
223488263|NCT06641869|DIETARY_SUPPLEMENT|procyanidin C1|Proprietarily extracted procyanidin C1
223488264|NCT06641869|DIETARY_SUPPLEMENT|Placebo|Placebo
223488265|NCT06641869|DIETARY_SUPPLEMENT|PCC1 complex|5 mg of procyanidin C1. Frequency: Administered once daily. Duration: 12 weeks.
223488266|NCT06582433|OTHER|Intervention|"1. Process: implementation of pre-tests~2. Process: Solution-focused counseling, 60 minutes once a week for a total of 6 sessions~3. Final test after 2 months"
223488267|NCT02213926|DRUG|ACP-196 (acalabrutinib)|
223488268|NCT05472142|OTHER|UP FOR IT - practice facilitation|"Using Practice Facilitation and Operationalizing Referral Information Technology (UP FOR IT) involves incorporation of health information technology and practice facilitation. The practice facilitation collaborative trains and supports clinical teams to use the Model for Improvement to make breakthrough improvements in diabetes care and DSMES utilization by recognizing barriers and changing clinical systems and care practices."
223488269|NCT05472142|OTHER|UP FOR IT - health information technology|Using Practice Facilitation and Operationalizing Referral Information Technology (UP FOR IT) involves incorporation of health information technology and practice facilitation. The health information technology component provides the scaffolding for quality improvement efforts by automating patient identification and enabling bi-directional referral communication between providers and diabetes self-management education and services (DSMES) programs.
223488270|NCT04596046|PROCEDURE|steroid injecting|Group L: Triamcinolone acetonide was administered to the patients through injecting inside the lesion.Group S: Oral methylprednisolone was administered to the patients.
223488271|NCT05690828|BEHAVIORAL|Cognitive remediation|The cognitive remediation programme shall be run either in video workshops or face to face workshops and in home sessions via a web app. The programme will run for 4 months during which there will be 3 different evaluations. A first evaluation after randomisation, a second evaluation 4 months after inclusion (corresponding to the end of the programme), and a third evaluation 8 months after inclusion for the experimental group (4 months after the end of the programme). The face to face workshops will take 8 to 10 participants and will be led by a neuropsychologist.
223488272|NCT00107289|DRUG|iobenguane I 131|"Patients receive a single dose of iodine I 131 metaiodobenzylguanidine (\^131I-MIBG) IV over 30 minutes to 4 hours or for 15 minutes for smaller patients on day 0. Patients undergo radiation dosimetry following the first dose of \^131I-MIBG to determine if a second dose can be safely administered. Some patients may receive a second dose of iodine I 131 metaiodobenzylguanidine (\^131I-MIBG) 6-8 weeks after the first dose if response is achieved and patients do not experience major toxicity. After blood radioactivity has fallen below 1 μCi/mL, patients may undergo autologous stem cell transplantation.~After completion of study treatment, patients are followed at 4-6 weeks after \^131I-MIBG administration and then every 3 months for up to 1 year. Once patients are off treatment on this protocol, they will begin long term follow up through 5 years from enrollment."
223488273|NCT05096715|DRUG|Atezolizumab|Intravenous Infusion
223488274|NCT05096715|DRUG|Bevacizumab|Intravenous Infusion
223488275|NCT05096715|RADIATION|Stereotactic body radiation therapy (SBRT)|External Beam Radiation
223488276|NCT01697579|DRUG|Fosaprepitant|Administered intravenously (IV) as a single dose
223488277|NCT01697579|DRUG|Fosaprepitant Placebo|Administered IV as a single dose
223488278|NCT01697579|DRUG|Ondansetron|Administered IV according to local labeling and/or local standard of care
224178987|NCT03553264|OTHER|Vestibular Rehabilitation|The home exercise program will include a patient-tailored combination of adaptation (without and with the target moving in pitch and yaw planes for 1min each three times per day), substitution, habituation, and balance exercises
223488279|NCT01697579|DRUG|5-hydroxytryptamine 3 antagonist|Administered IV according to local labeling and/or local standard of care
223488280|NCT03159637|PROCEDURE|Laparoscopic Surgery|Insufflation of a gas (carbon dioxide) into the peritoneal cavity producing a pneumoperitoneum will be done. The positioning of the patients in Trendelenburg position will be done. intraoperative and postoperative outcomes will be assesed
223488281|NCT02452190|DRUG|Reslizumab|Reslizumab will be administered subcutaneously in a dose of 110 mg every 4 weeks.
223488282|NCT02452190|DRUG|Placebo|Matching Placebo
223488283|NCT01863108|BIOLOGICAL|GeniusVac-Mel4|Multiple sub-cutaneous injections (1 injection weekly during 3 weeks) of GeniusVac-Mel4 (3 increasing dose groups) in patients with melanoma
223488284|NCT01044498|DRUG|Tocilizumab|Tocilizumab 8 mg/kg was administered in a single 1-hour infusion on Day 1 of Cycle 2.
223488285|NCT01044498|DRUG|Ortho-Novum® 1/35|Each Ortho-Novum® 1/35 tablet contained 1 mg of norethindrone and 0.035 mg of ethinyl estradiol.
224178988|NCT01021839|PROCEDURE|Grafts placement|Graft placement (upper or lower extremity); surgical or radiographic revision as needed.
224178989|NCT00457158|DEVICE|ALN optional filter|J1 : ALN optional filter M3 : ALN optional filter removed
224178990|NCT00316212|DRUG|INS50589 Intravenous Infusion|
224178991|NCT03949894|DRUG|Tolvaptan|30mg and 15mg of Tolvaptan Tablet
224178992|NCT04542863|OTHER|18F-DX600 PET/CT|DX600, labeled with 18F will be used as a molecular imaging tracer for PET/CT scanning
223488286|NCT00954083|BEHAVIORAL|DIR/Floortime|Developmental, Individual-Difference, Relationship-Bases (DIR) focus more on relationship, social skills, and meaningful, spontaneous use of language and communication and integrated understand of human development
223488287|NCT00954083|BEHAVIORAL|Routine care|Routine care
223488288|NCT04361175|DRUG|Letrozole|Each group will be followed up for ovulation by day 12 ovulation monitoring by Transvaginal ultrasound for mature griffian follicle and measure endometrial thickness and volume then day 21 test serum progesterone level to confirm ovulation and if pregnancy occurred confirm by serum pregnancy test at day 35 of the cycle and follow pregnancy till confirmed by fetal pulsation by ultrasound.
223488289|NCT04361175|DRUG|Clomiphine Citrate|Clomiphine Citrate
223488290|NCT00767871|DRUG|Lexapro|12 week treatment with lexapro
223488291|NCT06052124|DEVICE|Augmented Reality Device|AR device will be used to determine where to place SEPS drain
223488292|NCT04593602|BEHAVIORAL|Early Mobilization|Nurse-driven early mobilization activities twice daily
223488293|NCT04593602|BEHAVIORAL|Usual Mobility Care|Usual mobility care involves following physician orders for mobilization (i.e., bedrest, mobilization to chair with meals, physiotherapy consultation and care) as per local practice.
223488294|NCT00743093|DRUG|acetaminophen|500 mg caplets; 2 caplets (1 g)/dose; 4 doses (4 g)/day, 4 hours apart for 16 to 40 days.
223488295|NCT00743093|DRUG|placebo|placebo caplets, 2 caplets per dose, 4 doses per day, 4 hours apart for 16 to 40 days
223488296|NCT00820534|DRUG|Penciclovir|Penciclovir every 2 hours during waking hours for 96 hours
224178993|NCT00796172|BEHAVIORAL|Medication Adherence System (MAS)|Participants will receive individualized reports from the MAS and counseling from their doctors. The counseling will focus on adherence to blood pressure and cholesterol management medications.
224178994|NCT00796172|BEHAVIORAL|Usual Care|Participants will receive usual care from their doctors and written materials on CVD risk factors.
223488297|NCT00820534|DRUG|Placebo|Placebo every 2 hous during waking hours for 96 hours
223488298|NCT05679505|DEVICE|Auricular transcutaneous vagus nerve stimulation|Transcutaneous vagus nerve stimulation (taVNS) was performed with an FDA-approved Vagustim stimulation device and an electrode-shaped earpiece. In the participants included in the study and randomized to two groups, i) left ear taVNS was applied to the first group and ii) double-ear taVNS was applied to the second group.
223488299|NCT03831997|DRUG|Dextrose 5% W/ Sodium Chloride 0.225%|D5 1/4NS is comprised of 5% dextrose in a 0.225% sodium chloride (NaCl) solution. D5 1/4NS is initially slightly hypertonic to plasma, with an osmolarity of 321 mOSm/L. As the glucose component is rapidly metabolized, 0.225% NaCl solution remains and is hypotonic to plasma at an osmolarity of 77 mOsm/L. Because of the hypotonicity of the 1/4NS, it shifts into the intracellular compartments, followed by free water, and allows for volume expansion.
223488300|NCT02327078|DRUG|Nivolumab|specified dose and dosing schedule
223488301|NCT02327078|DRUG|Epacadostat|oral twice daily continuous at the protocol-defined dose
223488302|NCT02327078|DRUG|Chemotherapy|Specified dose on specified days
223488303|NCT06579612|OTHER|Personalized follow-up and support|After a pulmonary rehabilitation program, an interview with a professional will enable the professional to identify the barriersand enablers of physical activity engagement, and to identify (with the patient) a plan for maintaining a physical activities adapted in daily life. Adapted solutions will then be proposed.
223488304|NCT06366841|OTHER|Psychological tests administration|Psychological tests administration to evaluate stigma, personality characteristics and quality of life of rectal and anal cancer patients.
224178995|NCT01028599|OTHER|Intensive physical exercise|Intensive physical exercise 1 hour three times per week
224178996|NCT02445352|DRUG|Rosuvastatin 5mg|
224178997|NCT02445352|DRUG|DP-R207 5/10mg|
224178998|NCT02445352|DRUG|Rosuvastatin 10mg|
224178999|NCT02445352|DRUG|DP-R207 10/10mg|
224179000|NCT02445352|DRUG|Rosuvastatin 20mg|
224179001|NCT02445352|DRUG|DP-R207 20/10mg|
224179002|NCT02445352|DRUG|Placebo (for Rosuvastatin 5mg and DP-R207 5/10mg)|
224179003|NCT02445352|DRUG|Placebo (for Rosuvastatin 10mg and DP-R207 10/10mg)|
224179004|NCT02445352|DRUG|Placebo (for Rosuvastatin 20mg and DP-R207 20/10mg)|
224179005|NCT01199913|OTHER|The intervention will be Mini-Mental Status Examination (MMSE)|A questionnaire given to the study patient before and after the anesthetic at 1, 6 and 24 hours.
223488305|NCT05428917|BEHAVIORAL|Simple task|"The subject is seated on a chair facing a table, both hands resting on the table.~The subject is asked, for each block of 20 seconds, to perform flexion / extension movements of the fingers of the left hand at 0.5 Hz."
223488306|NCT05428917|BEHAVIORAL|complex task|"The subject is seated on a chair facing a table, both hands resting on the table.~The subject is asked, for each block of 20 seconds, to perform an exercise based on the nine hole peg test"
223488307|NCT03540940|OTHER|PEEP|7cmH2O positive end expiratory pressure
223488308|NCT03540940|OTHER|ZEEP|0 cmH2O positive end expiratory pressure
223488309|NCT04975867|OTHER|Targeted therapeutic hypothermia|Targeted therapeutic hypothermia is then performed at a body temperature of 33±0.5 °C during 24 h using a surface cooling device as soon as possible after the HBO and research consent. After TH ended, rewarming is done slowly between 0.2℃ - 0.5℃/h for 12 hours. After rewarming, it will be held at 36.5 ℃ for 36 hours.
223488310|NCT04975867|OTHER|Targeted therapeutic normothermia|Targeted therapeutic normothermia will be held at 36.5±0.5 ℃ for 72 hours using a surface cooling device after the HBO and research consent.
223488311|NCT04963920|DEVICE|Cytosorb® 300 ml|patients will receive CytoSorb therapy in addition to standard of care therapy according to applicable guidelines
223488312|NCT05756153|DRUG|GFH925|GFH925 tablets administered orally daily.
223488313|NCT05756153|DRUG|Cetuximab|Cetuximab administered intravenously Q2W.
223488314|NCT04716998|BIOLOGICAL|MesenCure|Three administrations of MesenCure in addition to standard care
223488315|NCT04871477|OTHER|Communication Intervention|Audio record part of clinic visit
223488316|NCT04871477|OTHER|Questionnaire Administration|Ancillary studies
223488317|NCT06504446|DRUG|NOC-110|Inhalation powder
223488318|NCT06504446|OTHER|Placebo|Inhalation powder
223488319|NCT00181025|DRUG|Tasonermine (TNFa)|
223488320|NCT00181025|DRUG|Melphalan|
224179006|NCT00630318|DEVICE|MRI|15-20 minutes MR imaging
223488321|NCT04038424|OTHER|Art therapy|Art therapy including coloring, painting and listening to music
223488322|NCT04705831|DRUG|Ruconest|C1 Esterase Inhibitor
223488323|NCT02402244|OTHER|Cytology Specimen Collection Procedure|Undergo cytology specimen collection
223488324|NCT02402244|OTHER|Medical Chart Review|Undergo medical data review
223488325|NCT06566118|DEVICE|Auricular Vagus Nerve Stimülation|After exercise loading, active ear VSS was applied to Group 1. Application was made simultaneously in both ears, with a 300 microsecond pulse duration, a biphasic asymmetric waveform, and a frequency of 25 Hz, for a total of 20 minutes. All assessments were recorded 3 times: at the beginning of the test, after exercise loading, and after active VSS application.
223488326|NCT06566118|DEVICE|Sham Auricular Vagus Nerve Stimülation|After the exercise challenge, Group 2 underwent sham VSS. Device parameters were set to the same as Group 1 (300 microsecond pulse duration, biphasic asymmetric waveform, and 25 Hz frequency). Both headphones were worn for a total of 20 minutes. However, the participant heard only the device's power-on tone and received no current. All assessments were recorded three times: at the beginning of the test, after the exercise challenge, and after sham VSS.
223488327|NCT06220435|RADIATION|Ultra-hypofractionated radiotherapy regimen.|"* Prostate tumor(s): 49 Gray (Gy)/7 fractions~* Prostate gland: 42.7 Gy/7 fractions~* Elective lymph nodes: 29.4 Gy/7 fractions~* Seminal vesicles: 31.15 Gy/7 fractions"
223488328|NCT05238675|DRUG|BI 1291583|BI 1291583
223488329|NCT05238675|DRUG|Placebo|Placebo
223488330|NCT06176235|DRUG|Teriflunomide|Teriflunomide 7 mg orally once daily for 24 weeks. Dose adjustments were made throughout the study based on individual platelet counts.
223488331|NCT06176235|DRUG|Dexamethasone|Dexamethasone 40 mg orally once daily for four consecutive days (the 4-day course of dexamethasone was repeated in the case of lack of response by day 14).
223488332|NCT00967785|DRUG|Mozobil (TM)|twice daily subcutaneous injection or via continuous subcutaneous infusion
223488333|NCT01903226|OTHER|High intensity training|
224179007|NCT02364999|DRUG|Bevacizumab-Pfizer|Bevacizumab-Pfizer: 15 mg/kg IV on Day 1 of a 21-day cycle for each of at least 4 and no more than six (6) 21-day cycles, followed by the assigned blinded bevacizumab monotherapy.
224179008|NCT02364999|DRUG|Bevacizumab-EU|bevacizumab-EU: 15 mg/kg IV on Day 1 of a 21-day cycle for each of at least 4 and no more than six (6) 21-day cycles followed by the assigned blinded bevacizumab monotherapy.
224179009|NCT02364999|DRUG|Paclitaxel|Paclitaxel 200 mg/m2 via IV infusions on Day 1 of a 21-day cycle for each of at least 4 and no more than six (6) 21-day cycles.
224179010|NCT02364999|DRUG|Carboplatin|carboplatin AUC =6.0 via IV infusions on Day 1 of a 21-day cyclefor each of at least 4 and no more than six (6) 21-day cycles.
224179011|NCT03459794|DRUG|Ivermectin|150 mcg/kg ivermectin, by mouth.
224179012|NCT03459794|OTHER|Placebo|An oral placebo will be administered, once
224179013|NCT04812236|DRUG|Wulingsan single decoction granules|Wulingsan single decoction granules, the prescription is Alisma, Polyporus, Atractylodes, Poria, Guizhi. Oral, 2 times a day, 2 sachets each time, rinsed with warm water
224179014|NCT04812236|DRUG|Wulingsan co-decoction granules|Wulingsan co-decoction granules, the prescription is Alisma, Polyporus, Atractylodes, Poria, Guizhi. Oral, 2 times a day, 2 sachets each time, rinsed with warm water
224179015|NCT04812236|DRUG|Wuling Powder|Wuling powder is composed of Alisma, Polyporus, Atractylodes, Poria, Guizhi. 2 times a day, 5g each time, take it with warm water
224179016|NCT04812236|DRUG|Wulingsan granule simulant|Wulingsan granule simulant, the prescription is Alisma, Polyporus, Atractylodes, Poria, Guizhi. Oral, 2 times a day, 2 sachets each time, rinsed with warm water
224179017|NCT01612494|DRUG|Hypertonic Saline|intravenous formulation of 3% hypertonic saline in a bolus dose of 10ml/kg over one hour
224179018|NCT01612494|OTHER|Normal Saline|intravenous formulation of normal saline in a bolus dose of 10ml/kg over one hour
224179019|NCT02177942|OTHER|Test beverage powder (High Proteins and added micronutrients)|High protein and added Micronutrients at recommended dietary allowance levels
224179020|NCT02177942|OTHER|Control beverage powder (Low protein and no added micronutrients)|Low protein and no added micronutrients
224179021|NCT04081987|DEVICE|non-invasive monitoring|Comparing blood pressure (diastolic \& systolic), heart and respiration rates, blood oxygen level and body temperature measurement using the BiPS non-invasive monitor to an arterial line.
224179022|NCT04449185|DRUG|Tegoprazan 50mg bid + amoxicillin 1000mg bid + clarithromycin 500mg bid for 10 days|Tegoprazan 50mg bid + amoxicillin 1000mg bid + clarithromycin 500mg bid for 10 days
224179023|NCT01020994|DRUG|LAS41003|Once daily, topically
224179024|NCT01020994|DRUG|LAS189962|Once daily, topically
224179025|NCT01020994|DRUG|LAS189961|Once daily, topically
224179026|NCT01302535|OTHER|Yoga group with supervision (trainer)|The Yoga-with-trainer group will meet once a week (60 minutes) to practice yoga with a yoga instructor. The participants will be encouraged to practice yoga between the yoga classes at home for 30 minutes a day.
224179027|NCT01302535|OTHER|Yoga at home|The participants in the Yoga-at-home group will get a private doctor appointment (20 minutes) where they get instructions for two yoga exercises which they are encouraged to perform at home 15 minutes a day.
224179028|NCT04493736|BEHAVIORAL|MHSAFE app recording|Participants are asked a series of questions to elicit their feelings and emotions as part of an audio recorded interview along with their normal therapy session.
224179029|NCT04249466|OTHER|Questionnaire|"During this consult, several parameters will be measured :~* nutritional and physical activity parameters: Food Frequency Questionnaire (FFQ), International Physical Activity Questionnaire (IPAQ), Three-Factor Eating Questionnaire (TFEQ-R18), impedance test, anthropometric measurements, resting energy expenditure~* demographic and clinical parameters : Family history, date of birth (month and year), sex, genotype, best forced expiratory volume (FEV) (over the 12 months preceding inclusion), bacterial colonization~* patient treatment and biologic parameters: corticosteroid therapy (with dosage, over the 12 months preceding inclusion), antidiabetic treatment (oral or insulin), IV antibiotic treatment, corrective treatments, pancreatic enzymes, OGTT (blood glucose and insulin levels at three times), lipid balance, vitamin dosage."
224179030|NCT02256150|DRUG|Mizoribine (MZR)|
224179031|NCT02256150|DRUG|Cyclophosphamide (CTX)|
224179032|NCT02246309|DEVICE|Embryoscope Time Lapse System|The EmbryoScope® time-lapse system is a unique platform facilitating improved IVF treatment, flexible work routines and effective communication, through comprehensive documentation of embryo development and evolving improvements in selection.
224179033|NCT02246309|DEVICE|Standard Embryo Culture|Standard embryo culture in a Standard water jacketed carbon dioxide/low oxygen incubator system.
224179034|NCT00561964|DRUG|Irbesartan|Irbesartan capsules strength 150 mg. Irbesartan group will be initiated at one irbesartan and one placebo for 2 weeks and titrated at two capsules if well tolerated after 2 weeks , this dose will be maintained throughout the study without further dose-adjustment (2 capsules daily in the morning will be taken from randomization to study end)
224179035|NCT00561964|DRUG|placebo|Placebo group: 2 placebo capsules daily as a single morning intake
224179036|NCT02746276|DRUG|Ceftriaxone|Ceftriaxone is active against a broad spectrum of gram positive and gram negative bacteria, including intracellular bacteria (e.g. Salmonellae, Staphylococci). Its antibacterial effect is dependent on time above the minimum inhibitory concentration(MIC). Ceftriaxone is highly protein-bound and elimination depends on glomerular filtration rate. In severely ill adults, elimination is highly variable. Alteration in plasma proteins, volume of distribution and renal function in sick severely malnourished children could significantly alter pharmacokinetics (PK). Despite several published studies on the PK of ceftriaxone in children, none have included severe malnutrition.
224179037|NCT02746276|DRUG|Metronidazole|Metronidazole is effective against Giardia, which is common amongst children with SAM; and against other anaerobic infections, including small bowel bacterial overgrowth and Clostridium difficile colitis. Small cohort studies suggest there may be benefits for nutritional recovery. However, metronidazole can cause nausea and anorexia, potentially impairing recovery from malnutrition and may also cause liver and neurological toxicity. Changes in body composition as well as metabolic and drug elimination mechanisms may alter the potential toxicity or effective dose.
224307091|NCT06990932|OTHER|Instrument-assisted Soft Tissue Mobilization|Instrument-assisted soft tissue mobilization is a popular alternative to traditional manual therapy techniques, derived from Cyriax cross-friction massage. It uses hard tools to manipulate soft tissue, varying in direction, force, and pattern, and allowing pressure to disperse to underlying tissues. Modern Instrument-assisted soft tissue mobilization instruments vary in material and design, and are used to improve musculoskeletal conditions and outcomes. Patients receive Instrument-assisted soft tissue mobilization with an M2T blade, positioned at a 45° angle, and instructed to apply an ice pack if experiencing burning sensations.
224307092|NCT06990932|OTHER|Conventional treatment|conventional physical therapy, which includes ultrasound, isometric neck exercises, chin tucks, stretching of neck muscles, and neck stabilization exercises, were used for groups A, B and C
224307093|NCT06988670|DRUG|EXT608|Modified version of parathyroid hormone attached to vitamin D to extend half-life
223488334|NCT01903226|OTHER|Moderate intensity training|
224179038|NCT00699582|DRUG|E2007 (perampanel)|8 mg perampanel in a 1:1:1 ratio, 125 subjects/arm. All subjects will take a maximum of 6 tablets daily for the duration of the study and will be up-titrated weekly in 2-mg increments to their randomized dose.
224179039|NCT00699582|DRUG|E2007 (perampanel)|12 mg perampanel in a 1:1:1 ratio, 125 subjects/arm. All subjects will take a maximum of 6 tablets daily for the duration of the study and will be up-titrated weekly in 2-mg increments to their randomized dose.
224179040|NCT00699582|DRUG|Placebo|Placebo in a 1:1:1 ratio, 125 subjects/arm. All subjects will take a maximum of 6 tablets daily for the duration of the study.
224307094|NCT06988670|OTHER|Placebo|Placebo for injection
224307095|NCT06988995|OTHER|Information|Participants provided handouts with information on self-compassion
223488335|NCT03410121|DEVICE|IPolysite ® Mini série 3108 or Polysite ® Standard, série 4108.|Implantation of intravenous medical device in thoracic location
223488336|NCT03410121|DEVICE|Vital Port®Minititanium|Implantation of intravenous medical device in humeral location
224179041|NCT00743626|OTHER|Diagnostic cervical cancer screening tests (Pap smear, HPV and/or p16)|If positive (Pap smear, HPV and/or p16) patients will be scheduled for 3 colposcopy follow up visits (1,12,18 months)
224307096|NCT06988995|BEHAVIORAL|Meeting|Participants meet with a psychological provider to receive information on self-compassion and training on how to utilize self-compassion
224307097|NCT02044549|DRUG|carbetocin|Oxycontin analogue
224307098|NCT02044549|DRUG|Syntometrine|Uterotonins
224179042|NCT02311634|DEVICE|Electrical pudendal nerve stimulation|Four sacral points are selected. The two upper points are located about 1 cm bilateral to the sacrococcygeal joint. On the upper points, a needle of 0.40 Х 100 mm is inserted perpendicularly to a depth of 80 to 90 mm to produce a sensation referred to the urethra or the anus. The locations of the two lower points are about 1 cm bilateral to the tip of the coccyx. On the lower points, a needle of 0.40 Х 100 or 125 mm is inserted obliquely towards the ischiorectal fossa to a depth of 90 to 110 mm to produce a sensation referred to the urethra. After the sensation referred to the above regions is produced, each of two pairs of electrodes from a G6805-2 Multi-Purpose Health Device is connected with the two ipsilaterally inserted needles.
224179043|NCT02311634|DEVICE|Transvaginal ES|A neuromuscular stimulation therapy system (PHENIX USB 4，Electronic Concept Lignon Innovation, France) is used for TES
224179044|NCT01434927|PROCEDURE|Unsedated colonoscopy|Patients were offered to undergo colonoscopy without routine premedication
224179045|NCT01434927|PROCEDURE|Unsedated colonoscopy|Patients were offered to undergo unsedated procedure. Their demographics and clinical data were recorded
224179046|NCT06514170|OTHER|No intervention|No intervention
224179047|NCT05375058|OTHER|Observational Study|Observational Study; the study did not involve any interventions
224179048|NCT03958461|PROCEDURE|Anti-infective treatment of periodontal pockets|Removing calculi from teeths' periodontal pockets
224179049|NCT04005781|DRUG|Hydroxychloroquine sulphate|After a stabilization period of 20 min and 10 min after the first blood collection, Plaquenil (Hydroxychloroquine sulfate) will be administered per os (total dose of 400 mg) in a randomized, double-blinded fashion.
224179050|NCT04005781|DRUG|Placebo|After a stabilization period of 20 min and 10 min after the first blood collection, Placebo will be administered per os (2 tablets) in a randomized, double-blinded fashion.
224179051|NCT01579994|DRUG|Ganetespib (STA-9090) and crizotinib|Ganetespib (STA-9090) is given intravenously (days 1 and 8 of a 21 day cycle). Crizotinib will be given at the FDA approved dose of 250mg orally twice daily in a continuous fashion.
224179052|NCT00412425|DRUG|Palonosetron|0.25 mg IV (By Vein) Daily for 2 Days or 0.25 mg IV Daily for 3 Days.
224179053|NCT02098291|DRUG|G17DT|
224179054|NCT02259452|PROCEDURE|SPECT Lung Perfusion Scan|
224179055|NCT02259452|PROCEDURE|SPECT Heart Perfusion Scan|
224179056|NCT02259452|PROCEDURE|Pulmonary Function Tests|
224179057|NCT03698695|DRUG|THN 201|THN 201: Donepezil 5 mg and Mefloquine 10 mg/d
224179058|NCT03698695|DRUG|Donepezil|Donepezil 5 mg/d and Mefloquine placebo
224179059|NCT03698695|DRUG|Placebo|Donepezil placebo and Mefloquine placebo
224179060|NCT03284762|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Rivaroxaban is a direct Factor Xa inhibitor. In this non-interventional setting, the prescription and dosing scheme is up to the treatment physician, however, the recommended dosing scheme is 20mg/day (once daily) or 15 mg/day (once daily) in patients with reduced renal function
224179061|NCT00171691|DRUG|Diclofenac Topical Sodium Gel 1%|
224179062|NCT02692560|BEHAVIORAL|I-STAND|Participants receive health coaching, a workbook, an inactivity alert wristband, and feedback charts based on objective measurement of sedentary time.
224179063|NCT02692560|OTHER|Healthy Living|Participants receive enhanced usual care based on general healthy living topics that are available to all Kaiser Permanente Washington enrollees.
224179064|NCT00031915|DRUG|imatinib mesylate|
224179065|NCT01875068|BEHAVIORAL|Consultations between NPs and PAs and their supervising physicians|Required discussion with physician prior to referral by a nurse practitioner or physician assistant
224179066|NCT01875068|BEHAVIORAL|versus NPs and PAs who are not required to discuss patient referrals (control group).|
224179067|NCT03518463|COMBINATION_PRODUCT|Enhanced recovery after surgery (ERAS)|The ERAS arm was exposed to standard preoperative, intraoperative and postoperative ERAS protocols of care. However, some were modified to our local resources and requirements as well as to the emergency nature of the surgeries.
224179068|NCT02825238|OTHER|Supervised exercise program|
224179069|NCT02162264|DRUG|Donepezil Hydrochloride|Initial dose of 3 mg orally once daily. After 1-2 weeks, dosage increased to 5 mg orally once daily. After 4 or more weeks, dosage increased to 10 mg orally once daily for patients with severe dementia of Alzheimer's type. Dose reduced appropriately according to patient's symptoms.
224179070|NCT02924987|DRUG|Aflibercept Injection|Intravitreal injections of 0.05 mL (2mg) of Aflibercept will be injected. The intravitreal between the first 5 treatments sessions is 4 weeks, and the interval for the following treatment sessions up to week 52 is 8 weeks.
224179071|NCT01675856|OTHER|Urgent endoscopy|Defined by oesophagogastroduodenoscopy within 6 hours of first presentation of Prince of Wales Hospital
224179072|NCT01675856|OTHER|Early endoscopy|Defined by oesophagogastroduodenoscopy within 24 hours of first presentation of Prince of Wales Hospital
224179073|NCT06279052|BEHAVIORAL|Phone interview|Phone interview during which the experience of the transition to adulthood among adolescents and young adults with Prader Willi Syndrome will be retrieved
224179074|NCT00804128|PROCEDURE|Magnetic Resonance Imaging (MRI)|Undergo MRI
224179075|NCT00804128|DRUG|Gadavist|Gadavist injection is a paramagnetic macrocyclic contrast agent administered for magnetic resonance imaging
224179076|NCT04700228|DRUG|Bupivacaine Hydrochloride|We are going to see the effects of dexmedetomidine as an adjunct to bupivacaine in caudal block. In first (control) group (group C) only bupivacaine will be given. Group BD1 patients will be given bupivacaine plus 1mcg/kg dexmedetomidine. Group BD2 patients will get bupivacaine plus 0.5mcg/kg dexmedetomidine. All the groups will be given a volume of 0.5ml/kg.
224179077|NCT04700228|DRUG|Dexmedetomidine|We are going to see the effects of dexmedetomidine as an adjunct to bupivacaine in caudal block. In first (control) group (group C) only bupivacaine will be given. Group BD1 patients will be given bupivacaine plus 1mcg/kg dexmedetomidine. Group BD2 patients will get bupivacaine plus 0.5mcg/kg dexmedetomidine. All the groups will be given a volume of 0.5ml/kg.
224179078|NCT05209204|DIAGNOSTIC_TEST|ASOCT|Anterior segment imaging using RTVue XR 100 Avanti OCT platform (Optovue Inc.,Fairmont, CA).
224179079|NCT05209204|DIAGNOSTIC_TEST|Pentacam|Anterior segment imaging using Oculus Pentacam HR (Oculus Optikgeräte, Wetzlar, Germany).
224179080|NCT05141344|DRUG|Melatonin 3 MG Oral Tablet|it will be given orally one hour preoperatively
224179081|NCT05141344|DRUG|Placebo|sugar-coated tablets will be given one hour preoperatively
224307099|NCT05120206|PROCEDURE|Non-surgical periodontal therapy: motivation and instruction in oral hygiene, debridement using handinstrumentation (Hu-Firedy,Chicago, IL, USA;and American Eagle Instruments,Missoula, MT,USA).|Non-surgical and surgical periodontal therapy in cigarette smokers and non-smokers
224307100|NCT06988891|OTHER|'Evidence-based practice' training based on the flipped learning model|The evidence-based practice training, developed using the flipped learning model, was delivered once a week for four weeks. Each session was delivered as an offline training (3-24 February 2025) and a face-to-face training three days later (6-27 February 2025). The offline part of the training was delivered via the Edpuzzle platform. The training duration for each session was 75 minutes in total, 15 minutes offline and 60 minutes face-to-face.
224307101|NCT06988891|OTHER|'Evidence-based practice' training based on web-based education model|Evidence-based practice training, developed based on a web-based training model, was implemented once a week for two weeks (March 17-24, 2025). Each session was conducted offline. The first session was 20.10 minutes, and the second session was 17.44 minutes.
223488337|NCT04624230|DRUG|tofacitinib|Open label tofacitinib 5 mg BID weight based adult equivalent with the option for individual dose increase to 10 mg BID weight based adult equivalent for a limited time if dose escalation criteria are met, prior to returning to 5 mg BID.
224072574|NCT05557760|BEHAVIORAL|Cognitive Control Training (CCT) + Booster Sessions|The CCT with booster sessions group will receive 10 training sessions with the Adaptive Paced Auditory Serial Addition Task (aPASAT). After these training sessions, participants in this condition will be asked to complete additional CCT sessions after reporting two consecutive assessments of increased depressive symptoms during the monitoring period (PHQ-9 scores equal or greater to 9). Specifically, they will then be instructed to perform three additional sessions within one week. This may be repeated when the participant reports multiple consecutive assessments of increased depressive symptoms during the post-training phase, with a minimum of 3 weeks between the booster sessions and a maximum of 9 boosters (3 x 3 sessions) in total.
223587175|NCT07088523|DRUG|Standard Treatment (Guideline-Based)|Combination therapy including: 1. Antiplatelet: aspirin 100 mg/day + clopidogrel 75 mg/day. 2. Lipid-lowering: atorvastatin 20 mg/day. 3. Antidiabetic: metformin 500 mg bid (max 2000 mg/day). \*Doses may be adjusted per local guidelines or patient tolerance.
223587176|NCT07088250|DRUG|Atorvastatin Treatment|Atorvastatin 20 mg once daily for 21 days.
224072575|NCT01535781|DRUG|Tranexamic Acid|1 g of tranexamic acid as a bolus immediately before surgery 3 g of tranexamic acid in 24hours postop.
224072576|NCT01535781|DRUG|Placebo|Identical syringe and drip used as in the intervention, to ensure blinding.
224072577|NCT01891487|DRUG|Track A|Bimatoprost 0.03% solution applied to eyebrow
224072578|NCT01891487|DRUG|Track B|Refresh Tears applied to eyebrows
224072579|NCT05819866|DRUG|Leriglitazone|Leriglitazone at a strength of 15 mg/ml. Once-daily dosing at an initial volume of 10 ml
224072580|NCT05819866|DRUG|Placebo|Placebo will match the study drug visually and by taste
224072581|NCT00049673|DRUG|prednisone|Given orally
224072582|NCT00049673|DRUG|thalidomide|Given orally
224072583|NCT02365168|OTHER|Cod_Double Blind Placebo Controlled Food Challenge|DBPCFC Food Challenge with cod in the following doses: 3µg, 600µg, 12 mg, 120 mg, and 1g covered in chocholate dessert over one day
224072584|NCT02365168|OTHER|Salmon_Double Blind Placebo Controlled Food Challenge|DBPCFC Food Challenge with salmon in the following doses: 3µg, 600µg, 12 mg, 120 mg, and 1g covered in chocholate dessert over one day
224072585|NCT02365168|OTHER|Mackerel_Double Blind Placebo Controlled Food Challenge|DBPCFC Food Challenge with mackerel in the following doses: 3µg, 600µg, 12 mg, 120 mg, and 1g covered in chocholate dessert over one day
224072586|NCT02365168|OTHER|Placebo_Double Blind Placebo Controlled Food Challenge|DBPCFC Food Challenge with placebo covered in chocholate dessert over one day
224072587|NCT02475681|DRUG|Acalabrutinib|
224072588|NCT02475681|DRUG|Obinutuzumab|
224072589|NCT02475681|DRUG|Chlorambucil|
224072590|NCT04077658|BEHAVIORAL|HeartMath|HeartMath is a program where individuals learn heart rate variability biofeedback. Essentially, they learn breathing exercises that reduce their heart rate. The HeartMath program will be administered via an application on the smartphone and ear monitor.
224072591|NCT04077658|BEHAVIORAL|Waitlist Control|Standard of Care Migraine Treatment
224072592|NCT05951608|DRUG|AK127 in combination with AK112|AK127 in combination with AK112 (administered on Day 1 of each cycle, Q3W) up to 2 years
224072593|NCT04693000|DRUG|Arsenic Keratosis lesion or nodular size observation after 12 weeks of therapy with solasodine ointment|An ointment containing solasodine extract of solanum melongena peel origin applied to patients with palmar arsenical keratosis; dose-twice daily for 12 weeks.Keratotic nodular size observation after 12 weeks
224072594|NCT04035317|DRUG|Aesculus Hippocastanum / Horse Chestnut|Treatment for 4 months, washout of 4 weeks, then crossover for another 4 months.
224072595|NCT04035317|DRUG|Placebo|Treatment for 4 months, washout of 4 weeks, then crossover for another 4 months.
224072596|NCT01030510|DRUG|the order of drug administration|In group R, remifentanil was infused first before administrating propofol and rocuronium and in group P, it was administered last after the rocuronium injection. In other words, the order of drug infusion in each group is remifentanil-propofol-rocuronium in group R and propofol-rocuronium-remifentanil in group P, respectively.
224072597|NCT00748579|DRUG|CK-1827452|I.V. infusion for 0.5 hour at 54mg/hr followed by 1 hour at 21mg/hr
224072598|NCT00748579|DRUG|CK-1827452|I.V. infusion for ≤ 1 hour at 72mg/hr followed by 1 hour at 36mg/hr
224072599|NCT04731935|DEVICE|Sparrow Therapy System|Transcutaneous auricular neurostimulation
224072600|NCT03707535|BIOLOGICAL|CT-P13|3 mg/kg, 2-hour infusion per dose co-administered with methotrexate and folic acid
224072601|NCT03707535|BIOLOGICAL|Remicade|3 mg/kg, 2-hour infusion per dose co-administered with methotrexate and folic acid
224072602|NCT04994106|DRUG|AZD5462|Participants will receive AZD5462, at dose levels of 1 to 5 in part A and at 1 to 4 in part B, respectively.
224072603|NCT04994106|DRUG|Placebo|Participants will receive Placebo matched to AZD5462.
224072604|NCT05415449|DEVICE|Gus gear protective wearable device|Gus gear protective wearable device for central line.
224072605|NCT04756375|DEVICE|Virtual Reality|Use of virtual reality in the management of sickle cell patients with VOS
223488338|NCT06278259|OTHER|Telerehabilitation program bases aerobic and Baduanjin exercises|It is an interventional study in which 68 stroke patients are estimated to enroll according to random allocation and divided into two groups. The study group participants involve in Telerehabilitation sessions is based on aerobic exercises, guided by video. The telerehabilitation program is aerobic exercise 3 times per week for 3 months. With the Baduanjin exercise program is delivered individually, at each patient's home, through telerehabilitation, with direct remote supervision by a physiotherapist
223488339|NCT06278259|OTHER|Telerehabilitation program bases aerobic exercises|The telerehabilitation program is aerobic exercise 3 times per week for 3 months.
224179082|NCT02943044|DEVICE|No intervention, this is an observational study|Non interventional, non-invasive measurements of tissue samples suspected of squamous cell carcinoma using an optical probe.
223587177|NCT07088250|OTHER|Best Medical Treatment|Patients in this group will receive best medical treatments in accordance with the guideline-directed management for ICH.
224179083|NCT01326910|DRUG|Colloidal Oatmeal|Topical cream applied twice daily (or as needed)
224179084|NCT01326910|DEVICE|Topical Cream|Topical cream applied twice daily (or as needed)
224179085|NCT03449186|OTHER|Saliva collection|
224179086|NCT03449186|OTHER|GCF collection|
224179087|NCT01723124|PROCEDURE|Molecular Breast Imaging|Molecular Breast Imaging (MBI) utilizes small high resolution gamma camera detectors in a dual-detector configuration to image the breast following the administration of a radiopharmaceutical that accumulates preferentially in breast tumors.
223587178|NCT07089680|DRUG|Nirmatrelvir/Ritonavir|Participants aged 60 years or older residing in long-term care hospitals (LTCHs) in Korea who were diagnosed with COVID-19 and received Paxlovid (Nirmatrelvir/Ritonavir) as part of their clinical care. This group will be assessed for multiple outcomes including mortality, progression to severe disease, worsening of activities of daily living (ADL), and frailty.
223587179|NCT07087431|BEHAVIORAL|Immediate disclosure of non-high CAD PRS|Participants receive their non-high CAD PRS result as soon as it is available after genotyping.
223587180|NCT07087431|BEHAVIORAL|Deferred Disclosure of non-high CAD PRS|Participants receive their non-high CAD PRS result after completion of the 12 month follow up period.
223587181|NCT07088770|BEHAVIORAL|Community Coalition CLS Workgroup/Network of Providers|Community Coalition/Network of Providers TechMPower forms the foundation of community engagement in this approach, with membership including PLWH and SUD, sheriffs, within-jail staff, community service providers or other partners who are able to advance the adoption of EBPs within jail and service settings. All coalitions are trained and prepared to drive a planning process at the local level for efficient identification and allocation of resources needed to link people from CLS to a network of community providers for HIV and SUD care and retention. Community coalitions integrate evidence-based (ERIC) strategies: Build coalition; Promote network weaving; Identify/train champions; Conduct consensus discussions that support needed services.
224072606|NCT04756375|OTHER|Usual Care|Usual management of sickle cell patients with VOS
224072607|NCT01262365|DRUG|Epratuzumab|600 mg infusions delivered weekly for a total of 4 weeks (cumulative dose 2400 mg) over four 12- week treatment cycles
224072608|NCT01262365|DRUG|Epratuzumab|1200 mg infusions delivered every other week for a total of 4 weeks (cumulative dose 2400 mg) over four 12-week treatment cycles
224072609|NCT01262365|DRUG|Placebo|Placebo infusions delivered weekly for 4 weeks over four 12-week treatment cycles
224072610|NCT04864444|DRUG|Dihydroartemisinin-piperaquine|DHA-PPQ will be given over the course of three consecutive days using 160mg/20mg or 320mg/40mg of dihydroartemisinin/piperaquine tablets. DHA-PPQ will be administered via age-based dosing. All three doses will be directly observed and given orally with water and without food.
224072611|NCT04864444|DRUG|Primaquine|Primaquine will be given once with the first dose of DHA-PPQ. Primaquine will be administered in an aqueous solution according to age-based dosing guidelines.
224072612|NCT04018911|DEVICE|Hearing Aid with standard Noise Reduction (NR_1)|Hearing Aid with standard Noise Reduction (NR) Each participant will be fitted with the 4 different Noise Reduction (Sound Changing) principles on the same hearing aid, saved to 4 manual programs (ensures exact same hearing loss compensation for each intervention). Noise Reduction principle is a sound processing algorithm to remove noise from a speech signal to improve the speech intelligibility and comfort. The active comparator condition is the state of the art Noise Reduction principle.
224072613|NCT04018911|DEVICE|Hearing Aid with NR_2|Each participant will be fitted with the 4 different Noise Reduction (Sound Changing) principles on the same hearing aid, saved to 4 manual programs. Noise Reduction principle is a sound processing algorithm to remove noise from a speech signal to improve the speech intelligibility and comfort. The experimental conditions (novel NR principle) vary in their parametrization to result in different degrees of noise suppression and good speech quality.
224072614|NCT04018911|DEVICE|Hearing Aid with NR_3|Each participant will be fitted with the 4 different Noise Reduction (Sound Changing) principles on the same hearing aid, saved to 4 manual programs. Noise Reduction principle is a sound processing algorithm to remove noise from a speech signal to improve the speech intelligibility and comfort. The experimental conditions (novel NR principle) vary in their parametrization to result in different degrees of noise suppression and good speech quality.
224072615|NCT04018911|DRUG|Hearing Aid with NR_4|Each participant will be fitted with the 4 different Noise Reduction (Sound Changing) principles on the same hearing aid, saved to 4 manual programs. Noise Reduction principle is a sound processing algorithm to remove noise from a speech signal to improve the speech intelligibility and comfort. This experimental condition combines standard NR and novel NR principle to result in different degrees of noise suppression and good speech quality.
224179088|NCT02607735|DRUG|SOF/VEL/VOX|400/100/100 mg fixed dose-combination (FDC) tablet administered orally once daily with food
224179089|NCT02607735|DRUG|Placebo|Tablet administered orally once daily with food
224179090|NCT01270113|BEHAVIORAL|contingency management|
224179091|NCT02430389|DRUG|Remifentanil|Ninety seconds before pinning, an IV bolus of 10 mL of remifentanil (0.7 µg•kg-1 based on ideal body weight) will be administered from the study syringe and an IV bolus of propofol (0.7 mg•kg-1) will be administered
224179092|NCT02430389|DRUG|Normal Saline|Ninety seconds before pinning, an IV bolus of 10 mL of normal saline will be administered from the study syringe and an IV bolus of propofol (0.7 mg•kg-1) will be administered
224179093|NCT06410729|OTHER|Observational study, no intervention|
223488340|NCT05618067|BEHAVIORAL|breathing exercise training|Participants will engage in weekly breathing exercises. They will be trained once a week for 4 weeks, and will use an app called Inner Balance and an device called Firstbeat Bodyguard 3 to track data about their hearts while practicing the exercises at home for 10 minutes a day, twice a day, once before bedtime.
224179094|NCT03575780|DRUG|KX2-391 Ointment 1%|The experimental drug, KX2-391 Ointment 1% will be used in subjects with Clinically typical Actinic Keratosis on the face or balding scalp.
224179095|NCT02807155|BEHAVIORAL|Transition Empowerment Program|Participants will receive the 1-year transition empowerment program/curriculum (TEP-CG) alone.
223488341|NCT02329717|DRUG|PBI 05204|PBI 05204 daily dosing
223488342|NCT04433572|DRUG|Temsirolimus|0.1 mg/mL temsirolimus, including contrast medium with approximately 75 mg iodine per mL. The dosage will be delivered in a volume of 0.50 mL per cm of target lesion length, up to 30 cm, with +50% allowance for anatomical considerations; for a total volume of up to 22.5 mL and a total dose of up to 2.25 mg in participants assigned to treatment. The same volumes of comparator agent will be delivered in control participants.
223488343|NCT04433572|DRUG|Saline placebo|Saline placebo, including contrast medium with approximately 75 mg iodine per mL. The dosage will be delivered in a volume of 0.50 mL per cm of target lesion length, up to 30 cm, with +50% allowance for anatomical considerations; for a total volume of up to 22.5 mL and a total dose of up to 2.25 mg in participants assigned to treatment. The same volumes of comparator agent will be delivered in control participants.
223488344|NCT06200961|DEVICE|Transnasal Endoscopy|Unsedated endoscopic evaluation through the nose.
223488345|NCT06200961|PROCEDURE|Esophagogastroduodenoscopy|Sedated endoscopic evaluation through the mouth.
223488346|NCT04418960|DIAGNOSTIC_TEST|Magnetic resonance imaging (MRI)|MRI pre- and postoperatively for detailed analysis of the ventricle and the mitral annulus. The first MRI will be performed on the admission day before surgery. The second MRI will be performed during the hospital stay, between 3 and 7 days after the operation. The MRI images are interpreted through a specialized cardiologist and radiologist.
223488347|NCT05604417|DRUG|TAZEMETOSTAT|Dosage and treatment timings per protocol
223488348|NCT05604417|DRUG|Zandelisib|Dosage and treatment timings per protocol
223488349|NCT04376671|DEVICE|Electroencephalography|The patients underwent EEG recordings according to previously published methods (Bonanni et al., 2008). . EEG recordings were analyzed with methods described in our previous work (Bonanni et al., 2008) by 2 experimenters unaware of the clinical conditions of the subjects. Briefly, quantitative EEGs (QEEGs) were recorded from 21 scalp derivations. Ag/AgCl disk scalp electrodes (19) were placed according to the international 10-20 system, EEG was recorded from Fp1, Fp2, Fz, F3, F4, F7, F8, Cz, C3, C4, Pz, P3, P4, T3, T 4, T5, T6, O1, and O2. Two additional electrodes were placed on A1 and A2. EEG activity was analyzed from single or multiple leads grouped to define the following scalp regions: anterior (Fz, Fp2, F7, Fp1, F3, F4, and F8), central (Cz, C3, and C4), posterior (Pz, P3, P4, O1, and O2), and temporal (T3, T4, T5, and T6).
224179096|NCT02807155|BEHAVIORAL|Transition Empowerment Program (TEP) + Diabetes Wellness Council (DWC)|Participants will receive the identical 1-year Transition Empowerment Program, plus the innovative wellness-based group process (council).
224179097|NCT02807155|BEHAVIORAL|Online Transition Empowement Program Access|Participants assigned to an outside medical home would be followed according to the clinical needs as assessed by their medical provider. They would be given access to the TEP website curriculum, but would not participate in other aspects of the 1-year TEP.
224179098|NCT06049251|OTHER|ELDOA exercises|"The patients will be asked to sit down on a floor in upright position and keep their legs apart and knees semi-flexed, feet in outward and upward position, knees constantly pushing downwards, straight lower back, raise arms with palms facing upward, and chin should be pulled back.~ELDOA stretch for L5-S1 level Patients will be asked to lay on floor and flatten and bring their legs up and straight with the support of wall, straight knees and keep distance between them, connect their toes, raise arm and externally rotate with wrist extension than press their heels and palms out.~ELDOA exercises will be performed with 2 sets of 5 repetitions with 45 second hold and15 sec rest between each set once a day."
224179099|NCT06049251|OTHER|Lumbar SNAGS and motor control exercises|"The patient will be seated and his pelvis will be stabilized with belt at the level of the anterior superior iliac spine while the SNAGs are administered. The ulnar aspect of the therapist's hand will be placed over the spinous processes of the affected segment's superior vertebrae, for flexion glide and inferior vertebrae for extension glide respectively. A passive glide will be applied and kept up until the patient finished a full movement arc. The glides will be given for six repetitions for three sets every session. Glide can be given unilateral for other movements.~Motor Control Exercises:~Exercise training with 7sec Hold and 10 reps"
224179100|NCT00898690|GENETIC|cytogenetic analysis|
224179101|NCT00898690|GENETIC|gene expression analysis|
224179102|NCT00898690|GENETIC|microarray analysis|
223488350|NCT06285643|DRUG|AAV2-GDNF Gene therapy|Bilateral image-guided infusion of AAV2-GDNF into putamen, single dose
223488351|NCT06285643|PROCEDURE|Control Surgery|Bilateral partial burr/twist holes without dural penetration
224179103|NCT00898690|GENETIC|mutation analysis|
224179104|NCT00898690|GENETIC|reverse transcriptase-polymerase chain reaction|
224179105|NCT00898690|OTHER|immunohistochemistry staining method|
224179106|NCT04016506|OTHER|nutritional questionnaire|nutritional questionnaire is given to the patient after the injury
224179107|NCT00493844|OTHER|Exercise testing|Exercise testing
224179108|NCT00493844|OTHER|Clinical evaluation + NTproBNP|Clinical evaluation + NTproBNP levels
224179109|NCT06296043|PROCEDURE|Progressive Muscle Relaxation Exercise Group|Exercise Group
224179110|NCT06296043|PROCEDURE|Su-Jok Intervention|Hand massage with seeds
224179111|NCT01681836|DRUG|15Nitrogen(15N)-labeled sodium nitrite|15Nitrogen(15N)-labeled sodium nitrite 20 mg once
224179112|NCT01681836|DRUG|15Nitrogen(15N)-labeled sodium nitrate|15Nitrogen(15N)-labeled sodium nitrate 1,000 mg once
223488352|NCT06419270|OTHER|Observation|Observational
223488353|NCT04914338|OTHER|Health Promotion|Participate in MDT-intervention
223488354|NCT04914338|OTHER|Quality-of-Life Assessment|Ancillary studies
223488355|NCT04914338|OTHER|Questionnaire Administration|Ancillary studies
224307102|NCT06988891|OTHER|'Evidence-based practice' training based on traditional education model|The evidence-based practice training, developed based on the traditional/face-to-face education model, was delivered once a week for three weeks (7-21 April 2025). Each session consisted of two teaching hours (one teaching hour: 45 minutes).
224307103|NCT02951442|BIOLOGICAL|Biological sample|
224307104|NCT02951442|PROCEDURE|Non invasive Arterial investigations|
224307105|NCT02951442|PROCEDURE|Abdominal tomodensitometry|
224179113|NCT04096469|BEHAVIORAL|Motivational Interviewing|The motivational interviewing strengthens the motivation and commitment to achieve a specific change through the induction and exploration of the reasons for modifying behavior. All this within an atmosphere of acceptance and compassion. It is about extracting the possible solutions to the change that is faced from the individual and his environment and not from the professional. This strategy is achieved by looking for the patient to feel motivated, and to express their problem and thus create discrepancy so that they evaluate their actions and reflect on the changes they should make.
223488356|NCT03093844|DEVICE|Miltenyi CliniMACS® CD34 Reagent System|Miltenyi CliniMACS® CD34 Reagent System will be used to prepare CD34+ enriched/T-cell depleted cells from haploidentical mobilized peripheral blood.
223488357|NCT06791187|DRUG|dabigatran etexilate|dabigatran etexilate
223488358|NCT06791187|DRUG|BI 1291583|BI 1291583
223488359|NCT04123197|OTHER|Stress Challenge|The stress challenge will assess how different parts of the body react to stress. Participants will be given no specific details about the contents of the test before administration.
223488360|NCT03595150|DRUG|Diclofenac|Diclofenac rectally given before the ERCP to prevent pancreatitis
223488361|NCT06273618|OTHER|Micro-Learning|Micro-Learning involves a series of 5-10 minute interactive, gamified learning exercises delivered to smart-phones (or computers) to reinforce and augment knowledge and promote attitudes and behavior to promote children's wellbeing.
224179114|NCT04096469|BEHAVIORAL|Traditional Education|Traditional education refers to the normal care given to breast cancer survivors. That is, they receive recommendations about their physical activity and diet but without any motivational approach.
224179115|NCT02893332|RADIATION|Radiation: SBRT|A first line TKI (Gefitinib 250mg po qd or Tarceva 150mg po qd ) will be administered according to the standard dosing of the drug for metastatic NSCL during a 1-week run-in period after which SBRT will be delivered to the all oligometastatic lesions concurrently with the TKI. The SBRT dose will be , ranging from at 25Gy (5 Gy per fraction) to 40 Gy (8 Gy per fraction).
224307106|NCT01687348|DRUG|lidocaine aguettant|
224307107|NCT00407758|DRUG|enzastaurin hydrochloride|
224307108|NCT01742520|DRUG|multiple doses of sucrose|unlimited number of doses par day- current status in our NICU
224307109|NCT01742520|DRUG|Formula or breast milk|1-3 minutes prior to every painful procedure, breast milk or formula 0.5-1 ml will be given on the anterior part of the tongue
224307110|NCT02245061|OTHER|paired pulses cortical electrical stimulation|
224307111|NCT01955655|DRUG|Baclofen|Since the therapeutic window of Baclofen is narrow, the lowest dose compatible with an optimal response was used.
223488362|NCT06207305|DRUG|Dexamethasone|Given by PO
223488363|NCT06207305|DRUG|Diphenhydramine|Given by PO
223488364|NCT06207305|DRUG|Famotidine|Given by PO
223488365|NCT06207305|DRUG|Paclitaxel|Given by PO
223488366|NCT01336270|OTHER|biological collection|to collect some human cell samples in melanoma
223488367|NCT06833294|DEVICE|GentleFit Mask, Gentlefit Prong, Standard of Care Interface|The subject will be randomized to sequence of interfaces. The subject will wear each of three NIV interfaces for 8 cumulative hours, for a total of 24 hours. Pressure achieved using each GentleFit interface will be compared to pressure achieved by standard of care interface.
223488368|NCT06837857|DRUG|Opioid|Subjects will receive oral oxycodone as needed for pain which will be titrated weekly based on pain response, adverse effects, and patient preference. Subjects with intolerance to oxycodone will receive the equivalent dosing of morphine as an alternative.
223488369|NCT06837857|DRUG|Opioid Placebo|Subjects will receive a placebo capsule identical to oxycodone, which will similarly be titrated weekly. Subjects with intolerance to the first placebo will receive another placebo capsule identical to morphine.
223488370|NCT06551272|DRUG|EXL01|EXL01 contains an unmodified single strain of F. prausnitzii
223488371|NCT06836414|PROCEDURE|Low-dose Computerized tomography (CT) of Chest|Undergo CT for lung cancer screening
223488372|NCT06836414|OTHER|Questionnaires|Participants will complete questionnaires on or before the day of the scan.
223488373|NCT06836414|OTHER|Medical History|Medical history will be obtained in person and via medical record review
223488374|NCT06078683|DIETARY_SUPPLEMENT|C8 Ketone Supplement|"Nutritional and Dietary Manipulation:~Participants will undertake a controlled feeding intervention where they will drink the supplement twice a day for 6 weeks. The supplement is a C8 Ketone Diester supplement. The beverage contains 25 g of C8 Ketone Diester emulsified in a matrix of water, whey protein concentrate, modified gum acacia, natural and artificial flavors and cocoa powder. It contains 210 kcal, 0.5 g fat, 2 g carbohydrate, and 2 g protein. For the proposed studies all participants will drink 5.4 oz of supplement, delivering 50g of C8 Ketone Supplement daily in a split serving fashion where half will be consumed in the morning with breakfast, and the other half with lunch."
224307112|NCT01955655|OTHER|Placebo|
224307113|NCT00599898|DRUG|Atosiban|Atosiban group will receive an atosiban bolus (6.75 mg) over 1 min then an intravenous infusion of 300mcg/min for 3 h followed by 100mcg/min for another 45h. If contractions continue or recur within 48 hours or the dilatation of the cervix progresses by 1 cm or more within 48 hours, atosiban will be stopped and the women will receive nifedipine as a 2nd line (see arm 2). If the second line fails and gestational age is less than 28 weeks, indomethacin will be administered as a 3rd line.
224307114|NCT00599898|DRUG|Nifedipine|Nifedipine group: the initial dose will be 20 mg (one tab) orally every 20 min for 3 doses. If the contractions is inhibited, a maintenance dose of 20 - 40 mg every 6 h up to 48 h will be followed. If contractions continue or recur within 48 hours or the dilatation of the cervix progresses by 1 cm or more within 48 hours, nifedipine will be stopped and the women will receive atosiban as a 2nd line (see arm 2). If the second line fails and gestational age is less than 28 weeks, indomethacin will be administered as a 3rd line.
224179116|NCT02893332|DRUG|TKI (Gefitinib or Tarceva )|A first line TKI (Gefitinib 250mg po qd or Tarceva 150mg po qd ) will be administered according to the standard dosing of the drug for metastatic NSCL, no local therapy apply to oligo-metastatic sites.
224179117|NCT06049628|BEHAVIORAL|FIFA 11+ exercise program|FIFA 11+ program; It consists of simple, easily remembered, and time-consuming, sport-specific exercises underlying fair play. The F 11+ consisted of 3 parts: the first part consisted of running exercises (part 1); the second part included six exercises, which were made up of three levels of difficulty and aimed at enhancing balance, strength, muscle control, and core stability (part 2). The final and the third part covered advanced running exercises (part 3) .
224179118|NCT06049628|BEHAVIORAL|routine program|This program consists of jogging, and stretching exercises.
224179119|NCT02394028|DRUG|Etrolizumab|Etrolizumab will be administered as per regimen specified in individual arms.
224307115|NCT01822275|DRUG|Chemotherapy with Temodar.|Once the patient has had surgery, patients will receive 6 weeks of radiation therapy with concurrent chemotherapy on protcol. This will be followed by a maximum of 12 cycles of adjuvent chemotherapy with Temodar.
224307116|NCT01822275|RADIATION|Radiation therapy|
223488375|NCT06078683|DIETARY_SUPPLEMENT|Placebo|"Nutritional and Dietary Manipulation:~Participants will undertake a controlled feeding intervention where they will drink the placebo twice a day, once at breakfast, and once around lunch time for 6 weeks. The placebo is flavor, energy, volume, and macronutrient matched will be given to patients as part of the placebo arm of the study. This placebo will not contain any ketones (BHB), which will be replaced with a similar caloric content of fat in the form of canola oil."
223488376|NCT06078683|DIETARY_SUPPLEMENT|Ketone Ester Acute|"Nutritional and Dietary Manipulation:~Participants will undertake a controlled feeding intervention where they will drink two servings of the supplement at once (50g total C8 Ketone Supplement), and images obtained before and after consumption. The supplement is a C8 Ketone Supplement. The beverage contains 25 g of C8 Ketone Diester emulsified in a matrix of water, whey protein concentrate, modified gum acacia, natural and artificial flavors and cocoa powder. It contains 210 kcal, 0.5 g fat, 2 g carbohydrate, and 2 g protein."
223488377|NCT06078683|DIETARY_SUPPLEMENT|Placebo Acute|Participants will undertake a controlled feeding intervention where they will drink two servings of the placebo at once (50g total placebo), and images obtained before and after consumption. The placebo is flavor, energy, volume, and macronutrient matched will be given to patients as part of the placebo arm of the study. This placebo will not contain any BHB, which will be replaced with a similar caloric content of fat in the form of canola oil.
223488378|NCT03579888|BIOLOGICAL|Autologous CD19-CD8-CD28-CD3zeta-CAR-mbIL15-HER1t T Cells|Given IV
223488379|NCT03579888|DRUG|Cyclophosphamide|Given IV
223488380|NCT03579888|DRUG|Fludarabine|Given IV
223488381|NCT06836258|OTHER|AI assisted documentation|This study will use Gosta Aide AI-assisted documentation platform
223488382|NCT04301154|BIOLOGICAL|HIVIS DNA/MVA-CMDR|HIVIS DNA IM by needle-free injection at weeks 0 and 4 followed by intramuscular (IM) needle injection of 1 X 108 IU/mL (1ml) MVA-CMDR at weeks 24 and 36 in the same arm as HIVIS DNA.
223488383|NCT04301154|BIOLOGICAL|HIVIS DNA + Cervarix and MVA-CMDR|Cervarix IM by needle injection followed by 1500 micrograms (0.5ml) per injection of HIVIS DNA IM by a needle-free injection device in the skin above (proximal to) the Cervarix injection (within 1.5 cm). They will receive 1 X 108 IU/mL (1ml) MVA-CMDR IM by needle injection at weeks 24 and 36 in the same arm as HIVIS DNA. They will also receive 0.5 ml Cervarix at the time of the first MVACMDR injection in the opposite arm from the MVA injection at week 24.
223488384|NCT04301154|BIOLOGICAL|Cervarix|Cervarix by IM needle injection at weeks 0, 4 and 24.
223488385|NCT04912687|DIAGNOSTIC_TEST|EGFR gene mutation analysis on liquid biopsy|Blood samples will be collected at inclusion for plasma DNA collection and analysis.
223488386|NCT06485245|DRUG|CS060304|Tablets administered orally
224179120|NCT02394028|DRUG|Placebo|Etrolizumab-matching placebo will be administered as per regimen specified in individual arms.
224179121|NCT04671576|OTHER|Control Infant Formula|Powder, standard commercial infant formula.
224179122|NCT04671576|OTHER|Organic Infant Formula|Powder, organic milk-based infant formula.
224179123|NCT03271944|DEVICE|CO2 Laser Treatment|Fractional handpiece with CO2 laser: Fractional Ablative laser Treatment of Vulvovaginal Atrophy
224179124|NCT02981173|DRUG|0.143 mg/kg Psilocybin or 10 mg Psilocybin|0.143 mg/kg psilocybin capsule (weight-based option) or 10 mg psilocybin capsule (fixed-dose option) ingested on each of three test days (5 days apart +/- 1-2 days)
223488392|NCT05219552|BEHAVIORAL|personalized lactation support|Our intervention design aims to address food insecurity and mental health by providing an unconditional cash transfer and lactation support across the perinatal period, when women are out of the workforce caring for their infant child. The study will include pregnant women living with HIV in Kisumu Kenya. The lactation support component will focus on milk insufficiency primarily as that has been a main concern of women we've worked with in this population, in addition to general breastfeeding support which will all be delivered in one-on-one sessions with a professional lactation consultant. The cash transfer will be delivered to women from their third trimester to 6 months postpartum. The amount of the cash transfer is based on preliminary data and consultation with key stakeholders to determine a reasonable and sufficient amount to basic living expenses during this period.
224179125|NCT02981173|DRUG|0.0143 mg/kg Psilocybin or 1 mg Psilocybin|0.0143 mg/kg psilocybin capsule (weight-based option) or 1 mg psilocybin (fixed-dose option) ingested on each of three test days (5 days apart +/- 1-2 days)
224179126|NCT02981173|DRUG|Placebo|Microcrystalline cellulose capsule ingested on each of three test days (5 days apart +/- 1-2 days)
224307117|NCT00146887|PROCEDURE|coronary catheterization|
224307118|NCT05426304|DRUG|Agomelatine|agomelatine 25 mg/day for 180 days
224307119|NCT05426304|DRUG|Placebo Tablets|placebo 25 mg/day for 180 days
224307120|NCT03610568|BEHAVIORAL|Growing up GREAT! Intervention|The Growing up GREAT! intervention is built around the socio-ecological model. For young adolescents, a suite of materials provides information and prompts discussion about puberty, gender equality, healthy relationships, violence, and other related themes during weekly club sessions. For parents, group sessions featuring six testimonial videos foster discussion around non-violent parenting, equal sharing of household tasks, and girls' education. Other materials for teachers, health workers, and community members complement the core toolkit materials.
224179127|NCT00205374|DRUG|Cidofovir|With regard to cidofovir concentration, the FDA has allowed us to inject a concentration of 5 mg/ml into both children and adults. The injection will add less than 2 additional minutes to the surgery time and discharge time will not be affected. Because the volumes of cidofovir injected into the airway will be reasonably small (typically less than 2 mL), the total systemic dose of cidofovir administered per visit will be far below the FDA-approved systemic limit of 5 mg/kg for HIV-related CMV retinitis.
224179128|NCT00205374|DRUG|Placebo|On the baseline study day, patients will be randomized into either a treatment group (cidofovir injection) or a placebo group. A restricted randomization procedure, in groups of 4, will be used to encourage uniformity in sample sizes between groups.
224179129|NCT01763632|DEVICE|Transcutaneous bilirubinometry|Device: JM-103 (Minolta, Osaka, Japan, jaundice assessment) Procedure: Transcutaneous bilirubinometry (TcB)
224179130|NCT02865681|DRUG|Menopur|Nasal versus injectable
224179131|NCT02865681|DRUG|Synarel|nasal
224179132|NCT02865681|DRUG|HCG trigger|injectable
224179133|NCT02865681|DRUG|Clomiphene citrate|oral
224179134|NCT02865681|DRUG|Letrozole|Oral
224179135|NCT00022906|DRUG|Iodine-131 Anti-B1 Antibody|
223488393|NCT03916926|DEVICE|"A simple medical strategy consisting of silver diamine fluoride (SDF)"|Advantage Arrest, Elevate Oral Care LLC., West Palm Beach, FL)
223488394|NCT03916926|DEVICE|"B typical dental strategy consisting of atraumatic restorative treatment (ART) with glass ionomer cement + Fluoride varnish (FV)"|GC Fuji (for ART) and FluoriMax Advantage Arrest, Elevate Oral Care LLC., West Palm Beach, FL (for FV)
223587182|NCT07088770|BEHAVIORAL|Tech-mediated Training and Service Delivery|Researchers will train all staff, healthcare providers and peer navigators to recognize and reduce stigma in CLS and healthcare settings using a training program informed by MPI Frye and colleagues in the CHHANGE (MH102182-01) intervention, which developed an anti-intersectional stigma training program for CBOs and offers comprehensive training to healthcare and social service organizations. Additionally, researchers will train staff and support protocol enhancements as needed to utilize tech mediated service delivery for NCM in-reach and services coordination in the community. These integrate 5 evidence-based (ERIC) implementation strategies: promote consultation; provide clinical/technical supervision; centralize technical assistance; change physical structure and equipment.
224179136|NCT03795545|PROCEDURE|SWL|Shock wave lithotripsy
224179137|NCT02056665|DRUG|MINOCYCLINE|Pill Minocycline 50 mg capsule
224179138|NCT02056665|DRUG|PLACEBO (for Minocycline)|Pill manufactured to mimic Minocycline 50 mg capsule
224179139|NCT04072796|BEHAVIORAL|Questionnaires|Short Form-36 (SF-36), Barthel Index (BI), Functional Ambulation Category (FAC), Mini-Mental Test (MMT) and Beck Depression Inventory (BDI) questionnaires
224179140|NCT02289118|DRUG|[18F]-T807 imaging tracer|Tau Imaging tracer
224179141|NCT03648502|DIAGNOSTIC_TEST|Cognitive tests and hearing tests|Several cognitive and hearing (peripheral and (central) auditory process) tests
224179142|NCT06250452|COMBINATION_PRODUCT|Halotherapy (Salt Therapy)|"Personal Information Form, SPO2 measurement and Asthma Symptom and Treatment Need Scoring / Daily Follow-up Form will be applied to the children in the experimental group before they are taken to the salt therapy room. Scales and SPO2 measurement will be performed before, during and after therapy. The same procedure will be applied to the children in the control group, but no therapy will be applied. In the study planned to be carried out for 6 weeks, it is recommended that children repeat the session for 10 minutes daily, the first 5 sessions every day and the other 5 weeks once a week."
224179143|NCT04383535|OTHER|Convalescent SARS COVID-19 plasma|Convalescent SARS COVID-19 plasma from a pool of 10 donor plasma. The calculation of the volume to be transfused will be from 10 to 15 ml / kg adjusting the volume to the body weight of each patient, at a suggested infusion rate of 5 to 10 ml / kg / h with an intravenous infusion pump. The infusion rate will be adjusted according to the clinical stability of the patient according to the treating physician.
224179144|NCT04383535|OTHER|Placebo|Single infusion of saline solution, in addition to standard care. The calculation of the volume to be transfused will be from 10 to 15 ml / kg adjusting the volume to the body weight of each patient, at a suggested infusion rate of 5 to 10 ml / kg / h with an intravenous infusion pump. The infusion rate will be adjusted according to the clinical stability of the patient according to the treating physician.
224179145|NCT02971072|PROCEDURE|Subacromial injection|A subacromial injection consisting up 6 cc 0.5% Marcaine with Epinephrine and 1 cc DepoMedrol will be administered.
224179146|NCT02971072|OTHER|Physical Therapy|A standardized six-week exercise protocol supervised by a physical therapist
224307121|NCT01594450|BIOLOGICAL|Biological mesh|patients will undergo the implantation of a biological mesh (after debridement and treatment of the infection) at the same time as the primary operation, or within one month of randomization.
224179147|NCT05588076|OTHER|no intervention|no intervention
224179148|NCT05557240|DRUG|NeoPep Vaccine1 plus Poly-ICLC|"NPVAC1： NPVAC1 drug products are composed of 5 peptides from the HCMV warehouse， NPVAC1 vaccine will be applied before maintenance TMZ cycles after completion of chemoradiation therapy (CRT). Beginning on day 14 before the first maintenance TMZ cycle, patients will receive 7 vaccinations with NPVAC1 drug products during 6 weeks. 400 μg per peptide per vial are used.~Poly-ICLC:~Poly-ICLC（500ug）will be used as immunomodulator with all vaccinations."
224307122|NCT01594450|PROCEDURE|without biological mesh|patients undergo traditional wound care (debridement and treatment of infection), without placement of a biological mesh. For arm B, the common wound care used follows the normal practice of the treating surgeon, except the placement of the biological mesh, which must not be performed within 6 months of randomization In cases of treatment failure at 6 months, patients of arm B are allowed to undergo any treatment which the treating surgeon views suitable, including a surgical procedure with implantation of a biological mesh
224307123|NCT00069186|DRUG|Creatine Monohydrate|
223488395|NCT05412394|DRUG|Prednisolone|Liquid, 5mg/kg per week, for one year
223488396|NCT05143671|PROCEDURE|Coronary artery bypass grafting|Coronary artery bypass grafting in coronary revascularization.
223488397|NCT05143671|PROCEDURE|Percutaneous coronary intervention|Percutaneous coronary intervention in coronary revascularization.
223488398|NCT05143671|PROCEDURE|Surgical valve replacement|Surgical mitral and / or aortic valve replacement.
223488399|NCT05143671|PROCEDURE|Carotid artery stenting|Carotid artery stenting.
223488400|NCT05359484|DIAGNOSTIC_TEST|Uroflowmetry|according to urodynamic, patients with weak urine stream were evaluated into 2 groups, either detrusor underactivity or bladder outflow obstruction From uroflowmetry, 5 variables including maximal flow rate (Qmax), average flow rate (Qave), voiding volume (VV), post-void residual urine (PVR), and value of Qmax minus Qaverage (DeltaQ) were obtained.
224072616|NCT02977195|DRUG|NP137 DL and RP2D|"DOSE ESCALATION PART: 7 DL: NP137 was administrated every 2 weeks, as single agent by intravenous injection over 90 min with up to 7 ascending dose levels: Dose level 1: 1 mg/kg Dose level 2: 2 mg/kg Dose level 3: 4 mg/kg Dose level 4: 6 mg/kg Dose level 5: 9 mg/kg Dose level 6: 14 mg/kg Dose level 7: 20 mg/kg~EXPANSION PARTS: NP137 was administered every 2 weeks, as single agent by intravenous injection over 180 min at 14 mg/kg (RP2D defined in the Dose escalation part).~FOR ALL PARTS AND COHORT: Treatment will be administered as long as patient experiences clinical benefit in the opinion of the investigator or until unacceptable toxicity or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status or withdrawal of consent."
224072617|NCT02700737|OTHER|Image-based simulation modelling|"The first dataset will include the imaging parameters currently recommended by clinical practice guidelines (referred to as limited dataset)."
224072618|NCT02700737|OTHER|Imaging parameters currently recommended by clinical practice guidelines|"The second dataset will include an expanded list of parameters, inclusive of information that is available from traditional imaging parameters (as recommended by the guidelines) and simulation modeling (referred to as image-based modelling dataset)."
224072619|NCT03770065|DEVICE|VML-0001|Medical device
224072620|NCT00142883|DRUG|Pregabalin|pregabalin compared to placebo
224072621|NCT00142883|DRUG|placebo|sugar pill compared to pregabalin
224072622|NCT03591380|DRUG|Belimumab|Kidney transplant recipients (n=5) will receive standard of care (SOC) therapy consisting of alemtuzumab and steroid induction with mycophenolic acid and tacrolimus maintenance immunosuppression, plus induction and treatment for 6 months with belimumab.
224072623|NCT00145405|DRUG|Lanreotide Autogel and Octreotide LAR|
224072624|NCT06109480|DEVICE|High definition transcranial direct current stimulation|tDCS is described as a non-invasive form of brain stimulation that uses a low-intensity, constant current applied directly to the head through scalp electrodes.
224072625|NCT06109480|DEVICE|Sham High definition transcranial direct current stimulation|Sham HD-tDCS was delivered using the same protocol and current intensity, but the period of active stimulation was only during the ramp-up and ramp-down periods of 30 and 30 seconds.
224072626|NCT06109480|DEVICE|electroconvulsive therapy device|ECT induces brief generalized epileptic seizures by electric current to stimulate the forehead under general anesthesia
224072627|NCT02322710|DEVICE|Urgotul: Low-adherent dressing|
224072628|NCT02322710|DEVICE|TulleGras M.S.: Vaseline gauze|
224072629|NCT00143585|PROCEDURE|intramyocardial delivery of either VEGF165 or placebo|
224072630|NCT04161131|BEHAVIORAL|ONBOARD|Session 1: Overview; Overcoming Physical Barriers (experiential wear) Session 2: Managing CGM data (cognitive restructuring) Session 3: Social barriers (problem solving) Session 4: Trust in CGM (motivational interviewing, review of prior sessions)
224072631|NCT04619485|DEVICE|CO2 LASER|5 SESSIONS OF CO2 VAGINAL LASER
224072632|NCT04619485|DEVICE|CO2 SHAM LASER|5 SESSIONS OF CO2 VAGINAL SHAM LASER
224072633|NCT06239129|DRUG|Initiation of specific medications|multiple therapies studied within this database
224072634|NCT06239129|PROCEDURE|Undertaking of specific procedures|multiple procedures/surgeries studied within this database
224072635|NCT06239129|DIAGNOSTIC_TEST|Abnormalities in specific laboratory tests|multiple abnormalities in laboratory values (i.e. CRP, cholesterol, eGFR, potassium) studied within this database
224072636|NCT06501755|DEVICE|transcranial alternating current stimulation (tACS)|Transcrainal alternating current stimulation (tACS) is a non-invasive brain-stimulation where weak sinusoidal electric current with frequencies within the EEG-range is applied over electrodes on the scalp. In the study we use the DC-Stimulator MC, neuroConn, Ilmenau for the stimulation.The device is authorized as medical device for the application on humans in Germany with a CE-Identification. We use two circular (area each = ca. 7.07 cm\^2) and two ring-shaped (area each = 40 cm\^2) rubber electrodes. Impedances are kept \< 15 kOhm.
224072637|NCT02472132|DEVICE|POC US|Use of point of care ultrasound in insertion of CVC
224072638|NCT00703638|DRUG|cisplatin|Cisplatin administered intravenously, 75 mg/m\^2 over 1-2 hours on day 1 of a 21 day cycle
224072639|NCT00703638|DRUG|pemetrexed disodium|Pemetrexed 500 mg/m\^2 intravenously (IV) will be given as a 10-minute intravenous infusion (after cisplatin) on day 1 of a 21 day cycle
224072640|NCT00703638|DRUG|sorafenib|daily oral sorafenib (200 mg or 400 mg bid)
224072641|NCT03733392|DEVICE|Advisor HD Grid Mapping Catheter, Sensor Enabled|The Advisor™ HD Grid Mapping Catheter, Sensor Enabled™, is indicated for multiple electrode electrophysiological mapping of cardiac structures in the heart, i.e., recording or stimulation only. This catheter is intended to obtain electrograms in the atrial and ventricular regions of the heart.
224072642|NCT04536597|OTHER|Quince seed jelly group|Quince seed jelly, prepared by the researcher, was given to the mothers belonging to this group. Briefly, 3 g (2-3 pieces) of quince seeds are placed in 100 mL water and heated to boiling for 10 min. The prepared quince kernel was used for 3 days, immediately after cooling.14,15 On the 1st day postpartum, the researcher provided the mothers with practical training at the hospital, regarding the application of quince seed jelly to the nipple and areola and leaving it to dry. This training was repeated on the 3rd, 7th and 10th days, to ensure that the mothers followed it precisely. The training process was completed in 5-10 min, including questions and answers. Every 3-4 days (days 1, 3, 7 and 10), quince seed jelly prepared by the researcher was given to the mothers to continue applying, according to the procedure. The mothers were asked to apply it after every breastfeeding.
224307124|NCT00073021|DRUG|Asacol 800 mg (mesalamine)|tablets, 4.8 g/day for 6 weeks, 2 - 800 mg Asacol tablets and 2 placebo tablets 3 times daily
223488401|NCT06333769|RADIATION|Short-course Radiotherapy|Rectal lesion + metastatic lymph nodes, GTV 30Gy/5Fx. Pelvic lymphatic drainage area, CTV 22.5Gy/5Fx.
223488402|NCT06333769|DRUG|Tislelizumab|Tislelizumab：200mg，d1，q3w，2 cycles.
223488403|NCT06333769|DRUG|Capecitabine|Capecitabine：1000mg/m2，d1-14，bid, q3w, 2 cycles.
223488404|NCT06333769|DRUG|Oxaliplatin|Oxaliplatin：130mg/m2, d1, q3w, 2 cycles
223488405|NCT06650553|PROCEDURE|Clinically diagnosed AA patients are divided into HLA-matched HSCT group and umbilical cord blood-supported haplo-HSCT group.|Conditioning regimen consisted of the following1)Severe aplastic anemia(SAA):FC-ATG:Flu 30 mg/m\^2/d ×4d (- 7d- -4d), CTX 22.5 -25mg/kg/d × 4d (-7d- -4d), ATG 7.5mg in total（- 5d- -2d).2)Transfusion-dependent non-severe aplastic anemia（TD-NSAA) and Paroxysmal nocturnal hemoglobinuria (PNH) acquired clonal-aplastic anemia(AA):BU/FC-ATG:Bu 0.8mg/kg(q6h -8d）+FC-ATG. The GVHD prophylaxis program was Application of Anti-CD25 Humanized Monoclonal Antibody 50mg (+1d,+4d);cyclosporine A + mycophenolate mofetil (MMF)+short course methotrexate (MTX).The infusion time of umbilical cord blood (UCB) stem cells in the UCB-assisted haploidentical hematopoietic stem cell transplantation (UCB-Haplo-HSCT) group: 4 hours before the infusion of peripheral blood stem cells.In the follow-up phase, outcome evaluation indicators must be collected according to the follow-up plan, ensuring data quality.
224179149|NCT05557240|DRUG|NeoPep Vaccine2 plus Poly-ICLC|"NPVAC2： NPVAC2 will be ready for use 2 months after enrollment, as these peptides have to be newly synthesized for each patient following identification of the mutanome and corresponding mutated peptides in the HLA ligandome. NPVAC2 drug products are composed 20 peptides de novo synthesized for an individual patient. Patients will be repeatedly vaccinated with NPVAC2 drug products beginning on day 33 of the 6 maintenance TMZ cycle.Patients will receive 9 vaccinations within 12 weeks. 400 μg per peptide per vial are used.~Poly-ICLC:~Poly-ICLC（500ug）will be used as immunomodulator with all vaccinations."
224179150|NCT02655263|DRUG|Somatropin|Somatropin infusion (Genotropin®)
224179151|NCT02655263|OTHER|Ketone bodies|ketone bodies infusion
224179152|NCT00293319|BIOLOGICAL|filgrastim|
224179153|NCT00293319|RADIATION|iobenguane I 131|
223488406|NCT06559267|BEHAVIORAL|Remaking Recess|Remaking Recess (RR) is a school-based social engagement intervention designed to enhance elementary school contextual factors to better support peer engagement during recess. Remaking Recess is delivered to educators through direct training and in vivo coaching by a certified Remaking Recess Coach.
223488407|NCT06559267|OTHER|TEAM|Schools that are randomized to the TEAM condition will receive an additional implementation support intervention. TEAM will leverage existing human resources in the school to specifically focus on developing an implementation blueprint to foster a supportive implementation context for paraeducators to use Remaking Recess.
223488408|NCT05639556|DIAGNOSTIC_TEST|BMI and lean mass index from DXA|Estimate and compare correlation between lean mass index from DXA and BMI
224179154|NCT05433233|BEHAVIORAL|Walking|Participants will perform 3,000 additional steps/day on 5 days/week.
224179155|NCT05433233|OTHER|HAPA Behavior Change Counseling|Structured dialogue for initiating behavior change.
224179156|NCT03016832|DRUG|Placebo drug that simulates Irbesartan tablets|Placebo drug that simulates Irbesartan tablets 150mg /qd, oral dosing
224179157|NCT03016832|DRUG|irbesartan tablets|irbesartan tablets 150mg /qd, oral dosing
224179158|NCT03016832|DRUG|Placebo drug that simulates HuangKui capsule|Placebo drug that simulates HuangKui capsule 2.5g/tid, oral dosing
224179159|NCT03016832|DRUG|HuangKui Capsule|HuangKui Capsule 2.5g/tid, oral dosing.
224179160|NCT01521637|PROCEDURE|Neuromuscular Electrical Stimulation of m. quadriceps femoris|Neuromuscular Electrical Stimulation of m. quadriceps femoris by using a commercially available muscle stimulator
224179161|NCT01521637|PROCEDURE|Sham-treatment: no NMES|Sham comparator
223488409|NCT05639556|DIAGNOSTIC_TEST|Anthropometric Measurements|Skinfold will be assessed with calipers. Circumference will be measured with a tape measure.
223488410|NCT05639556|DIAGNOSTIC_TEST|Hand-grip strength|A small, handheld dynamometer will be used to measure grip strength, a measure of function, on each hand.
223488411|NCT05639556|DIAGNOSTIC_TEST|Six-minute walk Test|This will be another functional assessment of fitness. Participants will be asked to walk at their normal pace for 6 minutes.The total distance walked in that time will be measured.
223488412|NCT05639556|DIAGNOSTIC_TEST|Sit-to-Stand Test|This will be used as a functional assessment of fitness and lower extremity strength. Participants will start seated on a chair and be asked to complete as many sit-to-stand repetitions without using their arms for one minute.
223488413|NCT05639556|DIAGNOSTIC_TEST|Short physical performance battery (SPPB)|This is an assessment of frailty. The test is completed in approximately 8 minutes. The test consists of 3 assessments: 1) Balance tests where the participant stands and tries to balance with their feet in various positions for 10 seconds each without assistance (side-by-side, heel-to-side, and heel-to-toe); 2) Two 4-meter gait speed tests; and 3) Chair-stand tests (single chair stand, 5 chair stands).
224179162|NCT00807989|DRUG|Carbamazepine|
224179163|NCT00807989|DRUG|Lamotrigine/Valproate|
224179164|NCT02835391|DEVICE|PerClot|Haemostatic device for the control of bleeding from capillary, venous or arteriolar vessels by pressure, ligature or other conventional means is either ineffective or impractical.
224179165|NCT02835391|DEVICE|Floseal, Surgicel, Surgiflo, Arista|Haemostatic device for the control of bleeding
224179166|NCT02835391|PROCEDURE|Electrocautery/Diatermy|Procedure for the control of bleeding
224179167|NCT04728789|DRUG|Avatrombopag 20 MG|Avatrombopag 20mg/week to 60mg/day, starting at 20mg/day and increased by 20 mg/day every 2 weeks if the platelet count remains less than 20×10e9/L and reduced if the platelet count reaches over than 150×10e9/L.
224179168|NCT02067546|DEVICE|Experimental toilet seat|
224179169|NCT02067546|DEVICE|Standard toilet seat|
224179170|NCT00193726|DRUG|Tab Premarin (Ethinyl estradiol)|Tab Premarin 0.625 mg (Ethinyl estradiol) once a day for 5 days prior to each cycle of chemotherapy
224179171|NCT00193726|DRUG|Placebo|Placebo once a day for 5 days prior to each cycle of chemotherapy
224179172|NCT03700931|BEHAVIORAL|Eating recall condition|Recall of eating episodes would increase subsequent intake of fruit or vegetable items
224179173|NCT03700931|BEHAVIORAL|Non-eating recall condition|Recall of non-eating episodes would not influence subsequent intake of fruit or vegetable items
224179174|NCT02271620|PROCEDURE|nasal allergen provocation test|nasal allergen provocation test
224179175|NCT02476903|DRUG|Monovisc|
224179176|NCT04972890|BIOLOGICAL|stem cells|Using umbilical cord stem cells 15x10\^6 cells in 2 cc saline/NaCl 0,9% solution
224179177|NCT04972890|OTHER|placebo|using 2 cc saline/NaCl 0,9% solution
224307125|NCT00073021|DRUG|Asacol 400 mg (mesalamine)|tablets, 2.4 g/day for 6 weeks, 2 - 400 mg Asacol tablets and 2 placebo tablets 3 times daily
223745380|NCT07170631|OTHER|Therapeutic exercise|Participants will follow a 3-month therapeutic exercise program combining general exercises with specific upper limb exercises, including hand proprioception and neurodynamic techniques. Two group sessions per week (1 to 1.15 hours each) will be conducted, with at least 24 hours between sessions. Each session includes warm-up, three progressive work blocks with strength, mobility, and balance exercises, and a cool-down. Strength training uses body weight and equipment, with intensity guided by the Rate of Perceived Exertion (RPE) scale, progressing safely from moderate to higher levels. Mobility and balance exercises target trunk, upper and lower limbs, and postural control. Neurodynamic techniques focus on median, radial, and ulnar nerves using neural sliding and intermittent tension, stopping exercises if pain exceeds 4/10. Supervised by experienced physiotherapists, the program aims to reduce lymphedema and neuropathy symptoms in breast cancer patients undergoing cancer treatment.
223745381|NCT07170189|DRUG|HU6|HU6 tablet or capsule
223488414|NCT05639556|DIAGNOSTIC_TEST|BIA Sub-study|A minimum of 50 individuals will be enrolled. Body composition will be assessed at each study visit using study bioelectrical impendence analysis (BIA).
223488415|NCT05639556|DIAGNOSTIC_TEST|Accelerometry to assess physical activity|Participants will be provided with a wrist-worn accelerometer/heart rate monitor at the baseline study visit and asked to wear it continuously for at least 3-10 days (two weekdays, one weekend day). Approximately every 3 months, the participant will be asked to again wear the accelerometer. Participants will be able to keep their accelerometers.
223488416|NCT05639556|OTHER|Gastrointestinal (GI) and nutrition questionnaires:|Subjects will complete surveys regarding gastrointestinal (GI) symptoms, including the Patient Assessment of Constipation (PAC-SYM) Score, Patient Assessment of Gastrointestinal Symptoms (PACGI-SYM) Score, the Bristol Stool Chart, and the scored Patient-Generated Subjective Global Assessment (PG-SGA).
223488417|NCT05639556|OTHER|Psychosocial questionnaire: PHQ-8|This is an 8-item scale that measures depressive symptoms over the past two weeks.
223488418|NCT05639556|OTHER|Psychosocial questionnaire: GAD-7|This is a 7-items scale that measures anxiety symptoms over the past two weeks, from not at all to nearly every day.
223488419|NCT05639556|OTHER|Psychosocial questionnaire: The Treatment Self-Regulation Questionnaire (TSRQ)|This is a 15-item scale that assesses the degree to which participants' motivation is autonomous or self-regulated.
223488420|NCT05639556|OTHER|Psychosocial questionnaire: CF Fatalism Scale|The CF Fatalism Scale measures the belief in a lack of personal power or control over one's future and has 13 items.
223488421|NCT05639556|OTHER|Psychosocial questionnaire: Body Esteem Scale for Adolescents and Adults (BESAA)|The Body Esteem Scale for Adolescents and Adults (BESAA) is 23-item measurement of self-evaluations of one's body or appearance.
223587183|NCT07088770|BEHAVIORAL|Multidisciplinary Implementation Team with Champion|The multidisciplinary Implementation Team will be comprised of a correctional health nurse, social worker and discharge planner or counselor and corrections officer from the jail. A representative from the community coalition and peer and case manager from NCM will join the team using a tech-mediated platform for conducting the training and for on-going weekly case conferencing addressing system and client level barriers and service planning. The role of the champion from the correctional setting will be to convene meetings focused on fidelity to the intervention components, engagement in shared problem-solving and mediation of administrative issues that may inhibit effective implementation of TechMPower. The champion and implementation team may request technical assistance (TA) or implementation facilitation at any point during implementation. This TA may be provided by the investigative team or outside providers from federal programs.
223488422|NCT05639556|OTHER|12-month Questionnaire|A short questionnaire designed to explore participants' perspectives of the acceptability and feasibility of nutritional assessments used in STRONG-CF will be given to all study participants at the end of the study.
223488423|NCT05639556|OTHER|Oral glucose tolerance testing (OGTT)|For subjects without previously diagnosed CFRD, an OGTT will be performed at baseline and 12-months with samples analyzed at the central lab.
223488424|NCT05639556|DEVICE|Continuous glucose monitoring (CGM)|Subjects will wear a Dexcom G6Pro sensor in blinded mode for three 10-day periods to collect comprehensive glucose data.
224072643|NCT04536597|OTHER|Breast milk group|Mothers in this group received practical training, conducted by the researcher on the 1st day postpartum at the hospital, on applying a few drops of their breast milk to the nipples and areola after each breastfeeding and leaving it to dry. This training lasted 5-10 min. Breast milk application of mothers in this group was recorded on the 1st, 3rd, 7th and 10th days, by the researcher.
224072644|NCT04536597|OTHER|Control group|Any kind of application that the mothers in the control group did for the nipple fissures were recorded on the 1st, 3rd, 7th and 10th days postpartum, by the researcher
224072645|NCT04046679|DRUG|Bleomycin|Skin bleomycin infusion through tattoo machine
224072646|NCT04046679|OTHER|Saline Solution|Saline solution infusion through tattoo machine
224072647|NCT05119712|DRUG|Terbinafine Tablets|500mg oral terbinafine or placebo daily
224072648|NCT05119712|DIAGNOSTIC_TEST|Laboratory Testing|Laboratory testing at screening, baseline, week 8, 16, 24 and 32.
224072649|NCT05119712|DIAGNOSTIC_TEST|Laboratory Testing|Subjects with the potential to become pregnant will have a baseline urine pregnancy test prior to starting study drug.
224072650|NCT01935843|BIOLOGICAL|CART-HER-2|
224072651|NCT01014117|DRUG|Placebo|Matching placebo will be supplied as hard gelatin capsules, with each containing an appropriate amount of placebo.
224072652|NCT01014117|DRUG|SRT2104|SRT2104 will be supplied as hard gelatin capsules, with each containing 250mg of SRT2104.
224072653|NCT05150366|PROCEDURE|Trans thoracic echocardiography|trans thoracic echocardiography at the beggining and at the end of the placement of the Saint Jude Medical AMULET type prosthesis
224072654|NCT03883880|OTHER|Epigallocatechin gallate|Colored solution prepared with epigallocatechin gallate to be consumed daily for two weeks during the epigallocatechin gallate intervention.
224072655|NCT03883880|OTHER|Epigallocatechin gallate control|Colored control solution to be consumed daily for two weeks during the epigallocatechin gallate intervention.
224072656|NCT03883880|OTHER|Linoleic acid|Colored emulsion prepared with linoleic acid to be consumed daily for two weeks during the linoleic acid intervention.
224072657|NCT03883880|OTHER|Linoleic acid control|Colored control solution to be consumed daily for two weeks during the linoleic acid intervention.
224072658|NCT03883880|OTHER|Capsaicin solution|Colored solution prepared with capsaicin to be consumed daily for two weeks during the capsaicin intervention.
224179178|NCT01241318|DRUG|Chlorhexidine gluconate (4%)|Chlorhexidine is a topical antiseptic that has long been tested for safety and widely used in developed country hospitals, pre-surgical antiseptic technique, wound cleaning and disinfection. Mothers will be instructed to apply 10 ml of 4% chlorhexidine once a day following the infants bath every day from birth until three days after the cord completely separates from the infant's body.
224179179|NCT01241318|PROCEDURE|Dry cord care|Mothers will be instructed to keep their infants' umbilical cord stumps clean and dry and to not apply any foreign substances to the cord stump.
224179180|NCT02842255|DEVICE|Calibrate the oximeter ALTITRAINER200®|During normoxic condition and four situations of hypoxia.
224179181|NCT00333736|DEVICE|Biojector|All patients received biojector to use with BID enfuvirtide doses
224307126|NCT04003584|PROCEDURE|Coronary bypass surgery|Reviewed postoperative coronary bypass patients and compared postoperative pain levels
224307127|NCT01644136|PROCEDURE|robot-assisted laparoscopic surgery|Undergo standard robotic assisted laparoscopic prostatectomy
224307128|NCT01644136|PROCEDURE|regional lymph node dissection|Undergo pelvic lymph node dissection
224307129|NCT01644136|DEVICE|microsphere-mediated lymphocele prevention|Undergo microsphere-mediated lymphocele prevention
224307130|NCT01601366|DEVICE|LNG-IUS|"The study includes 2 treatment groups: Group I the LNG-IUS group where they will have a LNG IUS inserted for them"
224307131|NCT01601366|DRUG|Combined oral contraceptives|Group II: will recite combined oral contraceptives for 6 months
224307132|NCT04470336|OTHER|Collagen Supplement|Three capsules post-breakfast Three capsules post-dinner
224307133|NCT04470336|OTHER|Glucosamine chondroitin|Three capsules post-breakfast Three capsules post-dinner
224307134|NCT04470336|OTHER|Placebo|Three capsules post-breakfast Three capsules post-dinner
224307135|NCT00166270|DEVICE|ExAblate 2000|
224307136|NCT02384694|OTHER|Zumba dance|Twelve weeks, 3 times weekly 1 hour training
224072659|NCT03883880|OTHER|Capsaicin control|Colored control solution to be consumed daily for two weeks during the capsaicin intervention.
224072660|NCT01348646|BEHAVIORAL|Brief intervention|The adolescents were shown a series of photographs of discoloured teeth caused by smoking. Then a mirror was given to the adolescent to let him/her see if similar stains could be seen on his/her teeth. Non-smoking adolescents also received positive feedback for being non-smokers. Duration of a single brief intervention was 2-3 minutes.
224072661|NCT04316585|DRUG|GSK2982772|GSK2982772 will be available as MR tablet at a unit dose strength of 480 mg.
224072662|NCT04316585|DRUG|Placebo|GSK2982772 matching placebo tablets will be administered via the oral route.
224072663|NCT04244929|PROCEDURE|Total knee arthroplasty|Total knee arthroplasty using standard anterior approach.
224072664|NCT04244929|DEVICE|Persona Medial Congruent Knee Prosthesis implantation with Posterior Cruciate Ligament retaining|Patients will be implanted with this medial pivoting knee prosthesis. Posterior Cruciate Ligament will be retained
224072665|NCT04244929|DEVICE|Persona Medial Congruent Knee Prosthesis implantation with Posterior Cruciate Ligament sacrifice|Patients will be implanted with this medial pivoting knee prosthesis. Posterior Cruciate Ligament will be sacrificed
224072666|NCT01869647|RADIATION|Ultra low dose CT scan|Ultra low dose CT scan
224072667|NCT01869647|RADIATION|Regular CT or Low Dose CT scan|Regular CT or Low Dose CT scan
224072668|NCT01869647|RADIATION|No imaging|No imaging
224072669|NCT04922411|DEVICE|STN DBS|PD patients with DBS STN will be scanned and tested with DBS ON and OFF
224072670|NCT03408795|PROCEDURE|Laparoscopic distal gastrectomy|Longitudinal testing of The Japanese Operative Rating Scale for Laparoscopic Distal Gastrectomy
224072671|NCT03842930|PROCEDURE|Endovascular embolization|Endovascular embolization of the Lumbar Arteries
224072672|NCT01155115|PROCEDURE|Sputum Collection|Each study participant will be invited to expectorate sputum for culture, sensitivity, cytology and analysis of cytokine levels. Culture and sensitivity will be performed routinely at the beginning of a pulmonary exacerbation, as per standard of care, and will only be performed at subsequent visits if there is clinical indication. A volume of 5ml of sputum will be required at each visit for analysis. If the participant is unable to expectorate this volume of sputum, he/she will be invited to induce sputum instead as per standard protocols.
224072673|NCT01155115|PROCEDURE|Pulmonary Function Testing|Participants will perform spirometry at each visit according to the American Thoracic Society and European Respiratory Society guidelines.
224072674|NCT01155115|PROCEDURE|Exhaled Nitric Oxide|The investigators will measure exhaled Nitric Oxide (eNO) at each visit according to the American Thoracic Society and European Respiratory Society guidelines using a chemiluminescence analyzer. Briefly, single breath exhalation are performed in triplicate at flows of 30, 50, 100, 150, 200 and 250 ml/s and eNO is measured at the end of the exhalation. The higher the flow rate the more peripheral the airways that are being sampled.
224072675|NCT05222217|DEVICE|Gatekeeper|Six polyacrylonitrile prostheses (THD Gatekeeper™ Delivery System, THD SpA, Correggio, Italy) were implanted under 3D-EUS control through a 5mm perianal incision at 1, 3, 5, 7, 9 and 11 o'clock in lithotomy position, and located in the upper-middle intersphincteric space of the anal canal, using a specifically designed system.
224072676|NCT00794209|DRUG|i.v fentanyl, AeroLEF|"* i.v fentanyl~* 5 mL of AeroLEF in Opti-Mist 750E continuous flow nebulizers (Maersk Medical Inc., (USA), McAllen, Texas)~* 5 mL, of AeroLEF in Misty-Neb continuous flow nebulizers (Allegiance Healthcare Corp., McGaw Park, Illinois)~* 5 mL of AeroLEF in PARI LC-Plus continuous flow nebulizers (PARI Respiratory Equipment Inc., London, Ontario)~* 3 mL, of AeroLEF in AeroEclipse breath-actuated nebulizers (Trudell Medical International, London, Ontario) - reference device."
224072677|NCT05026788|OTHER|type of treatment|pathway of management for conservative treatment, operative treatment and type of anaesthesia used
224072678|NCT04775511|OTHER|Heat Therapy with heating pads|20 minutes of heating pads will be applied to the medial gastrocnemius muscle, followed by gastrocnemius muscle stretching for 20 minutes. While the patient is lying in a prone position the towel, which is located between the skin and heating pads, and heating pads will be placed on the gastrocnemius muscle.
224072679|NCT04775511|OTHER|Cold Therapy with ice packs|20 minutes of ice packs will be applied to the medial gastrocnemius muscle, followed by gastrocnemius muscle stretching for 20 minutes. While the patient is lying in a prone position the towel, which is located between the skin and ice packs, and ice packs will be placed on the gastrocnemius muscle.
223488425|NCT05639556|DIAGNOSTIC_TEST|Chest CT scans (When available within the past 6 months in medical records)|Standard of Care chest CT images will be drawn from the medical record, as available, from enrolled participants. FEV1 measurements prior to chest CT scans will be recorded to account for possible illness occurring at the time of scanning. Quantitative assessment of the pectoralis muscle area will be performed on the first single axial image above the aortic arch. Any additional standard of care chest CT's that are performed while the participant is enrolled in the study will also be collected and have a quantitative assessment of the pectoralis muscle performed.
224179182|NCT01957033|BEHAVIORAL|Exercise and education once/week for 6 weeks|Exercises will include specific range of motion, strengthening, and motor control exercises for the neck and shoulder girdle. Education will include prognosis information, advice to stay active, and use of a book
224179183|NCT01957033|BEHAVIORAL|Exercise and education twice/week for 6 weeks|Exercises will include specific range of motion, strengthening, and motor control exercises for the neck and shoulder girdle. Education will include prognosis information, advice to stay active, and use of a book about whiplash.
224179184|NCT01957033|BEHAVIORAL|Exercise and education 3 times/week for 6 weeks|Exercises will include specific range of motion, strengthening, and motor control exercises for the neck and shoulder girdle. Education will include prognosis information, advice to stay active, and use of a book about whiplash.
223488426|NCT05639556|DIAGNOSTIC_TEST|Hologic Dual X-Ray Absorptiometry (DXA)|DXA measurements for whole body, total hip and lumbar spine will be acquired using the Hologic DXA and standard positioning as noted in the DXA Manual of Operations. DXA will be used to estimate total and regional body composition, which will include body fat and lean body mass. This will be used as the gold standard from which to validate BIA and MAMC.
223488427|NCT05639556|DIAGNOSTIC_TEST|Ultrasound Sub-study of assessment of appendage muscles using ultrasound|A minimum of 50 individuals will be enrolled. At each study visit, participants will undergo ultrasound muscle measurements (cross-sectional area and muscle thickness) of the biceps and quadriceps on each (left and right) side of the body (4 total areas). These measurements will be obtained in triplicate for each patient.
224072680|NCT04775511|OTHER|Stretching Exercises|20 minutes of stretching exercises will be applied. In stretching exercises, stretching will be done for 30 seconds. The stretching exercises, which contain the maximal tension to the ankle, will be performed by the same physiotherapist while the patient is in the supine position, hip and knee extension.
224179185|NCT01957033|OTHER|Manual therapy once/week for 3 weeks|Manual therapy will consist of low velocity mobilizations of the cervical and upper thoracic spine based on the findings of the treating physiotherapist.
224179186|NCT01957033|OTHER|Manual therapy twice/week for 3 weeks|Manual therapy will consist of low velocity mobilizations of the cervical and upper thoracic spine based on the findings of the treating physiotherapist.
224179187|NCT01957033|OTHER|Manual therapy 3 times/week for 3 weeks|Manual therapy will consist of low velocity mobilizations of the cervical and upper thoracic spine based on the findings of the treating physiotherapist.
224179188|NCT01957033|OTHER|Manual therapy once/week for 6 weeks|Manual therapy will consist of low velocity mobilizations of the cervical and upper thoracic spine based on the findings of the treating physiotherapist.
224072681|NCT03828279|DIAGNOSTIC_TEST|functional and antigenic C1 inhibitor|Diagnosis of HAE is based on personal and/or family history of angioedema and on C1 inhibitor functional or antigenic plasma levels ≤50% of normal.
224072682|NCT02601924|DRUG|20% Benzocain (Master-Dent, Monroe, NC)|Two topical anesthetic gel groups will receive anesthetic gel at the site of injection with massage on treating tooth.
224072683|NCT02601924|OTHER|Topical pressure massage|Two topical pressure massage groups will receive topical placebo gel with pressure massage at the site of injection.
224179189|NCT01957033|OTHER|Manual therapy twice/week for 6 weeks|Manual therapy will consist of low velocity mobilizations of the cervical and upper thoracic spine based on the findings of the treating physiotherapist.
224179190|NCT01957033|OTHER|Manual therapy 3 times/week for 6 weeks|Manual therapy will consist of low velocity mobilizations of the cervical and upper thoracic spine based on the findings of the treating physiotherapist.
224179191|NCT05681533|PROCEDURE|CT scan|coronary calcium score measurement by CT scan
224307137|NCT04048343|DRUG|Biological: Experimental: Tezepelumab|Tezepelumab subcutaneous injection every 4 weeks
224307138|NCT01918826|DEVICE|TENS|
224307139|NCT04393766|DRUG|Normal Saline|normal saline(crystalloids)
224307140|NCT03780231|OTHER|non-ischemic scar|"non-ischemic LGE with no underlying labelled cardiomyopathy is detected on CMR"
224307141|NCT02254369|DRUG|GC021109|
223488428|NCT05639556|DIAGNOSTIC_TEST|Psychosocial questionnaire: Hunger Vital Sign questionnaire|Screening tool for identifying households at risk of food insecurity and poor health outcomes linked to food insecurity with 3-items over the last 12 months.
223488429|NCT05639556|OTHER|Respiratory symptom questionnaire: CRISS|Chronic Respiratory Infection Symptom Score (CRISS) is an 8-item respiratory symptom questionnaire covering the last 24-hours.
224072684|NCT04240977|BEHAVIORAL|"HOBSCOTCH: Home-Based Self-Management and Cognitive Training Changes Lives"|Home-Based Self-Management and Cognitive Training Changes Lives (HOBSCOTCH) is a novel phone-based intervention that is enables acquisition of cognitive skills in line with problem solving therapy (PST), and is well suited for PWRE who have failed all other treatment alternatives. Sessions #2 through #7 focus on building patient's awareness for their own day-to-day memory problems, brainstorming, implementing and reviewing the outcomes of potential solutions they generate themselves using the PST framework. In each of these sessions, providers will assist patients in generating alternative solutions, in thinking through what the implementation of each strategy would entail, and in helping them review outcomes for adopted strategies to refine their approach for optimized adoption and generalization.
224072685|NCT00775580|DRUG|Atenolol 100mg Tablets|
224072686|NCT03917602|PROCEDURE|human amniotic membrane plug with vitrectomy|using human amniotic membrane plug with vitrectomy to try to close large macular hole
224072687|NCT00694057|DRUG|HE3286|HE3286 10 mg per day (5 mg BID)
224072688|NCT00694057|DRUG|Placebo|Placebo capsules BID
224072689|NCT04357457|DRUG|Almitrine|Intravenous almitrine at a dose of 2 µg.kg-1.min-1 during 5 days
224072690|NCT04357457|DRUG|Placebo|Intravenous glucose 5% during 5 days
224072691|NCT00331500|DRUG|Olopatadine Hydrochloride Ophthalmic Solution, 0.2%|
224179192|NCT04906733|PROCEDURE|Tumor biopsy|Patients with RAS/RAF wild-type metastatic right colon cancer will receive biopsy before the standard treatment of chemotherapy or target therapy.
224179193|NCT02297204|PROCEDURE|Focal Laser Treatment|All subjects receiving PRN IVT aflibercept injections will be evaluated for focal laser treatment beginning at week 12 through the end of the study. If the subject meets any of the criteria for focal laser treatment (FLT), fluorescein angiography (FA) will be performed to guide the focal laser treatment. Focal laser treatment and focal laser re-treatment will be administered no more than once every 90 days.
224307142|NCT02254369|OTHER|Placebo|
223488430|NCT05639556|DIAGNOSTIC_TEST|Spirometry|Spirometry will be performed in accordance with the current American Thoracic Society recommendations for the performance and interpretation of tests.
223488431|NCT05639556|OTHER|Psychosocial questionnaire: Additional Health Questionnaire|Single question over the last 3 months/90 days about cannabis use for GI problems and appetite. The clinical sites will not see the responses to this question. It will be completed by the participant online either during the study visit or at home.
223488432|NCT05639556|OTHER|CF Management Questionnaire|Assessment of prior 12-month management of cystic fibrosis, including treatments, medication intake and hospitalizations. This questionnaire will only be completed at 24- and 36- month visits.
223488433|NCT05639556|OTHER|Food Frequency Questionnaire|Assessment of prior 12-month nutritional intake being completed at Baseline (no later than 6-month visit) and 12-month visit.
223488434|NCT06343792|DRUG|RLS-0071|RLS-0071 will be administered for 7 or 14 days according to the assigned dose group.
223488435|NCT04855851|PROCEDURE|PAIN NEUROSCIENCE EDUCATION AND STRENGTH TRAINING|The subjects of this group will receive an amount of six sessions that will be applied within 12 weeks. Every 15 days, the subjects will come for a consultation to receive a PNE session and review of the exercise program, which will be carried out 3 times a week for 12 weeks.
223488436|NCT04855851|PROCEDURE|USUAL CARE|"Aerobic exercises will consist of a standard table of low intensity stretching exercises, commonly prescribed to fibromyalgia patients. There will be three series of 30 seconds of each stretch, having a total duration of approximately 40 minutes. Each session will be held twice a week, following the recommendations of the American College of Sport Medicine. Monitoring will be performed every 15 days by a physiotherapist."
223488437|NCT01081951|DRUG|olaparib|Tablets Oral BID
223488438|NCT01081951|DRUG|paclitaxel|175mg/m2 iv for 6 cycles (18 weeks) day 1 of 21 day cycle
223488439|NCT01081951|DRUG|carboplatin|AUC6 iv for 6 cycles (18 weeks) day 1 of 21 day cycle
223488440|NCT01081951|DRUG|paclitaxel|175mg/m2 iv for up to 6 cycles (18 weeks)
223488441|NCT01081951|DRUG|Drug: carboplatin|AUC4 iv for up to 6 cycles (18 weeks)
223488442|NCT05579600|BEHAVIORAL|Caring Contacts letters|Caring Contacts involves sending individuals at risk for suicide brief, non- demanding messages of care.
223488443|NCT05579600|BEHAVIORAL|Reports, re-engagement, and training|Behavioral health providers will receive training in reaching out to and re- engaging patients who pass through the justice system, as well as training in suicide risk assessment (the Columbia Suicide Severity Rating Scale; C-SSRS) and response (the Safety Planning Intervention; SPI).
223488444|NCT05320042|DEVICE|kalifilcon A Daily Disposable Toric|kalifilcon A Daily Disposable Toric
223488445|NCT05320042|DEVICE|Ultra for Astigmatism Contact Lenses|Ultra for Astigmatism Contact Lenses
223488446|NCT02993367|DRUG|Butylphthalide Soft Capsules|DL-3-n-butylphthalide (NBP) (Fig. 1) is a synthetic chiral compound containing L- and D-isomers of butylphthalide.Butylphthalide Soft Capsules is the oral preparation.
223488447|NCT02993367|DRUG|Placebo Butylphthalide Soft Capsules|
223488448|NCT04667234|DRUG|AMG 510|Administered as an oral tablet.
224072692|NCT00331500|DRUG|Olopatadine Hydrochloride Ophthalmic Solution Vehicle|Inactive ingredients used as a placebo comparator
223488449|NCT04315142|DEVICE|Experimental TTNS|30-minute TTNS intervention is performed 2 days a week during a treatment period of 6 weeks
224072693|NCT05730179|OTHER|Mechanical Conditioning stimulus|Painful mechanical stimulus
224072694|NCT02574533|BIOLOGICAL|Vigil|Vigil™ 1 x 10e7 cells via intradermal injection on Day 1, 15, 29, 43 and then every 3 weeks thereafter for a minimum of 4 administrations and a maximum of 9 administrations (depending on the quantity of Vigil™ manufactured from surgical specimens)
224072695|NCT02574533|DRUG|Pembrolizumab|Pembrolizumab 2mg/kg by intravenous infusion over 30 minute starting on day 43 and every 3 weeks thereafter
224072696|NCT04508660|DRUG|CGB-400|BID application
224072697|NCT00526682|DIETARY_SUPPLEMENT|Irvingia/cissus combo|
224072698|NCT05684380|DRUG|MAZ-101association|Experimental drug
224072699|NCT05684380|DRUG|DYMISTA®|Active comparator
224072700|NCT06334094|DRUG|Ozanimod|A hard capsule that is taken daily for one year.
224072701|NCT01961479|BEHAVIORAL|Internet-based CBT for patients with PMS|Internet-based cognitive-behavioural self-help treatment
224072702|NCT01961479|OTHER|Waiting list|During the waiting period, participants receive no treatment.
224072703|NCT00697671|OTHER|NK Cell Infusion|All participants will receive a 4 day regimen of chemotherapy (clofarabine, cyclophosphamide, and etoposide) followed by an infusion of HLA partially matched family member donor NK cells processed through the use of the investigational CliniMACS device. Interleukin-2 (IL-2) will be given three times per week post-infusion for a minimum of 2 weeks. IL-2 administration will continue until donor NK cells are no longer detectable in the recipient, and, at that time, will be discontinued
224072704|NCT00697671|BIOLOGICAL|Immunotherapy|All participants will receive a 4 day regimen of chemotherapy (clofarabine, cyclophosphamide, and etoposide) followed by an infusion of HLA partially matched family member donor NK cells processed through the use of the investigational CliniMACS device. Interleukin-2 (IL-2) will be given three times per week post-infusion for a minimum of 2 weeks. IL-2 administration will continue until donor NK cells are no longer detectable in the recipient, and, at that time, will be discontinued.
224072705|NCT00697671|DEVICE|Miltenyi Biotec CliniMACS device|All participants will receive a 4 day regimen of chemotherapy (clofarabine, cyclophosphamide, and etoposide) followed by an infusion of HLA partially matched family member donor NK cells processed through the use of the investigational CliniMACS device. Interleukin-2 (IL-2) will be given three times per week post-infusion for a minimum of 2 weeks. IL-2 administration will continue until donor NK cells are no longer detectable in the recipient, and, at that time, will be discontinued.
224179194|NCT02297204|DRUG|aflibercept 2.0 mg|If a subject has recurrent CR-DME they will receive an IVT aflibercept injection
224179195|NCT04306692|DRUG|Myo-inositol|2 x 1 bag per day, per os (subjects can take myo-inositol during the meal but it is not obliged).
224179196|NCT04306692|DRUG|Clomiphene Citrate|"Each tablet contains 50 mg of clomiphene citrate which means 33,9 mg of clomiphene. Other constituents are sucrose, lactose monohydrate, corn starch, pregelatinized starch, yellow iron oxide (E172) and magnesium stearate (E470b).~Dosing: 1 tablet per day from cycle day 3 until 7 (extremes included), stepping up until a maximum dose of 3 tablets per day for 5 consecutive days."
224179197|NCT04904991|PROCEDURE|Chan-Chuang qigong|"This study applied the Chan-Chuang qigong program, which was a modified form of the manual of Chan-Chuang qigong (Yeh et al., 2006), to tailor to patients with cognitive impairment. The Chan-Chuang qigong program included warmup prior to qigong practice, preparation for qigong practice, core qigong of four moves, and cool down after qigong practice.~The movements should be repeated and maintained for 10 minutes per time, 3 time a day (Yeh et al., 2006), totally 90 minutes per week, for 3 months. The guideline booklet of Chan-Chuang qigong (Chen et al., 2019; Chuang, Yeh, \& Chung, 2017) was modified and provided to the participants, which had major sections of introduction to qigong, preparation and precautions, practical procedures with description and photos, normal physical reactions from practicing core Chan-Chuang qigong, precautions of daily life, a confirmation sheet, and a checklist of qigong performance."
224072706|NCT00697671|DRUG|Interleukin-2 (IL-2)|All participants will receive a 4 day regimen of chemotherapy (clofarabine, cyclophosphamide, and etoposide) followed by an infusion of HLA partially matched family member donor NK cells processed through the use of the investigational CliniMACS device. Interleukin-2 (IL-2) will be given three times per week post-infusion for a minimum of 2 weeks. IL-2 administration will continue until donor NK cells are no longer detectable in the recipient, and, at that time, will be discontinued.
224179198|NCT01520675|PROCEDURE|surgery|Drainage procedure
224179199|NCT01520675|PROCEDURE|Endoscopic therapy|pancreatic sphincterotomy, removal of calculi, stenting, ESWL
224179200|NCT00106366|DRUG|insulin detemir|
224179201|NCT00106366|DRUG|insulin glargine|
224179202|NCT00106366|DRUG|insulin aspart|
224179203|NCT02355665|DRUG|Nicotine Spray|Nicotine Spray
224179204|NCT02355665|DRUG|Placebo|Placebo to match nicotine spray
224179205|NCT00278486|BIOLOGICAL|Hematopoietic stem cell transplantation.|Autologous hematopoietic stem cell transplantation will be performed.
224179206|NCT01209117|DRUG|GSK2248761 WBM Capsule|200 mg GSK2248761 WBM capsule (reference) 2 X100mg
224179207|NCT01209117|DRUG|GSK2248761 WBM Tablet Formulation 1|GSK2248761 WBM Tablet 200mg manufacturing process 1
224179208|NCT01209117|DRUG|GSK2248761 WBM Tablet Formulation 2|GSK2248761 WBM Tablet 200mg manufacturing process 2
224179209|NCT01209117|DRUG|GSK2248761 WBM Tablet Formulation 3|GSK2248761 WBM Tablet 200mg manufacturing process 3
224179210|NCT01209117|DRUG|GSK2248761 WBM Tablet|GSK2248761 WBM tablet 200mg manufacturing process 1, 2, or 3 chosen from Period 1 - 4
224179211|NCT03566563|OTHER|Screening|Patients tested positive for Hepatitis C will be referred to Hospital through the conventional health care services and by an alternative direct access method to determine if this improves linkage to care
223488450|NCT04315142|DEVICE|Sham TTNS|30-minute sham intervention is performed 2 days a week during a treatment period of 6 weeks
224072707|NCT00697671|DRUG|Clofarabine|All participants will receive a 4 day regimen of chemotherapy (clofarabine, cyclophosphamide, and etoposide) followed by an infusion of HLA partially matched family member donor NK cells processed through the use of the investigational CliniMACS device. Interleukin-2 (IL-2) will be given three times per week post-infusion for a minimum of 2 weeks. IL-2 administration will continue until donor NK cells are no longer detectable in the recipient, and, at that time, will be discontinued.
224179212|NCT01265316|DEVICE|There is no intervention for this study.|There is no intervention for this study. The pre-NSR IDE for this study is simply a modification to allow for recording of data without intervention.
223488451|NCT03456778|DEVICE|Shear Wave Elastography|An ultrasound (US) technique, known as shear wave elastography (SWE), is used to examine structure and biomechanical function. The examination takes place in the ultrasound room at the study site and lasts for approximately 20 minutes.
224179213|NCT05386641|OTHER|measurement of tissue stiffness (N/m)|Stiffness values will be measured with myotonPro on centers of coordination located along the myofascial chain
224179214|NCT05386641|OTHER|measurement of passive muscle tone (Hz)|muscle tones will be measured with myotonPro on centers of coordination located along along the myofascial chain
224179215|NCT05386641|OTHER|measurement of creep of tissue|creep of tissue will be measured with myotonPro on centers of coordination located along the myofascial chain
224179216|NCT05386641|OTHER|measurement of the range of shoulder joint motion|The range of shoulder flexion, abduction, extension and external-internal rotation movements will be measured with a universal goniometer.
224179217|NCT05386641|OTHER|measurement of skin temperature|measurements will be taken by the thermographic camera
224179218|NCT05386641|OTHER|measurement of pain|Pain will be evaluated by visual analog scale (VAS)
224179219|NCT05386641|OTHER|measurement of pain pressure threshold|Pain pressure threshold will be evaluated by a digital algometer
224179220|NCT05386641|OTHER|measurement of grip strength|"The grip strength of both hand will be evaluated by hand-held dynamometer."
224179221|NCT04125199|DIETARY_SUPPLEMENT|supplement consumption|"Composition of the Experimental Product: Concentrated oil of Tridocosahexaenoin-AOX® \* (350 mg per capsule), α-tocopherol and coating agent (gelatin). Each capsule is 700 mg, of which 500 mg is oil.~Placebo composition: Olive oil (each capsule is 700 mg).~Number of capsules: 6 per day, for any of the two products. The dose taken daily is 2.1 g / day for DHA.~Supplementation Period: Each group completed two 10-week consumption periods for each of the products, with an intermediate washing period of 4 weeks (28 days)."
224179222|NCT05312099|OTHER|Case control|Case control study
224179223|NCT04129242|DEVICE|Transcutaneous Auricular Vagus Nerve Stimulation (taVNS) + Task Specifc Training|A closed-loop taVNS system that delivers taVNS with upper-limb rehabilitation training in a chronic stroke population.
224179224|NCT06366685|BEHAVIORAL|Exercise and Psychological Intervention|To address the symptoms and severity experienced by esophageal cancer patients after surgery, providing them with exercise or psychological interventions to improve their rehabilitation outcomes.
224307143|NCT00004755|DRUG|allopurinol|
223488452|NCT05935722|BEHAVIORAL|Parenting Young Children|PYC is a home-based intervention programme involving weekly, one-hour sessions over a period of at least six months. The programme has two core modules (1) Parent-Child Interaction and (2) Child Care Skills and Safety. The Parent-Child Interaction module focuses on the parent-child relationship and interaction skills such as parents' responsiveness to the child's signals, giving the child attention and encouragement, and supporting prosocial behaviour. The Child Care Skills and Safety module targets safety at home and the parent's caring skills (e.g. food, health, and hygiene). Checklists are adapted to each parent in order to support the PYC practitioner and the parent. The programme is compiled in a manual that includes work tasks, instructions for how to perform the tasks, and teaching materials.
223488453|NCT05935722|BEHAVIORAL|Treatment as Usual|TAU consists of a variety of interventions from the social services. The support will be logged and classified in accordance with the Swedish National Board of Health and Welfare's guidelines for classifications of its activities. TAU will be divided into the following five categories: 1) conversation counselling or emotional support, 2) practical support, 3) skills training, 4) compensatory strategies, and 5) other support. Support will also be classified based on whether it is home-based or given outside the home and whether it is individualised or in a group setting.
223488454|NCT05776966|BEHAVIORAL|Gender-specific digital intervention (GSDI)|The GSDI is a digital intervention that incorporates factors that are more prevalent in women with opioid use disorder that may affect their treatment outcomes. The content for the intervention was derived from research on gender-specific substance use disorder antecedents, consequences, and treatment outcomes.
223488455|NCT05776966|OTHER|Treatment as usual|Participants will receive treatment as usual for opioid use disorder which is a mix of medication treatment and individual and group therapy services across various levels of care.
223488456|NCT04553718|OTHER|experimental group|provide mHealth program, which has pregnant women using wearable device and app
223488457|NCT06067711|DEVICE|resistance band|The program will consist of six exercises: triceps press, biceps curl, lat pull down, leg press, leg extension and sit-ups using resistance band.
223488458|NCT02290418|PROCEDURE|Roux-en-Y Gastric Bypass|Laparoscopic Gastric Bypass performed with two anastomoses (gastro-enteral and entero- enteral), two limbs (Alimentary limb of length 150cm and Biliary limb of length 75-100cm) and sewing of mesenteric defect.
224072708|NCT00697671|DRUG|Cyclophosphamide|All participants will receive a 4 day regimen of chemotherapy (clofarabine, cyclophosphamide, and etoposide) followed by an infusion of HLA partially matched family member donor NK cells processed through the use of the investigational CliniMACS device. Interleukin-2 (IL-2) will be given three times per week post-infusion for a minimum of 2 weeks. IL-2 administration will continue until donor NK cells are no longer detectable in the recipient, and, at that time, will be discontinued.
224072709|NCT00697671|DRUG|Etoposide|All participants will receive a 4 day regimen of chemotherapy (clofarabine, cyclophosphamide, and etoposide) followed by an infusion of HLA partially matched family member donor NK cells processed through the use of the investigational CliniMACS device. Interleukin-2 (IL-2) will be given three times per week post-infusion for a minimum of 2 weeks. IL-2 administration will continue until donor NK cells are no longer detectable in the recipient, and, at that time, will be discontinued.
224179225|NCT01548729|PROCEDURE|Combined pancreatic islet and lung transplantation|Combined pancreatic islet and lung transplant from the same donor for the treatment of patients with end-stage cystic fibrosis
224179226|NCT01959594|DRUG|3 mg PF-06412562|oral dosing of 3 mg PF-06412562 tablets three times a day for 14 days
224179227|NCT01959594|DRUG|10 mg PF-06412562|oral dosing of 10 mg PF-06412562 tablets three times a day for 14 days
224179228|NCT01959594|DRUG|25 mg PF-06412562|oral dosing of 25 mg PF-06412562 tablets three times a day for 14 days
224179229|NCT01959594|DRUG|PF-06412562 TBD mg|oral dosing of PF-06412562 tablets three times a day for 14 days. Dosage and frequency to-be-determined based on previous cohorts
224179230|NCT01959594|DRUG|PF-06412562 TBD mg|oral dosing of PF-06412562 tablets three times a day for 14 days. Dosage and frequency to-be-determined based on previous cohorts
224179231|NCT02183792|DRUG|Tolvaptan|
224179232|NCT02183792|DRUG|Furosemide|
224179233|NCT00153322|BEHAVIORAL|Nurtition and Physical Activity Education|
223488459|NCT02290418|PROCEDURE|Omega-Loop Gastric Bypass|Laparoscopic Gastric Bypass performed with single anastomosis (gastro-enteral) connecting a long gastric pouch to small bowel with Afferent limb of length 200cm.
223587184|NCT07088770|BEHAVIORAL|Tech-mediated Peer Navigation Enhanced Case management (NCM)|Navigation-Enhanced Case Management (NCM) uses Project START, a CDC best evidence intervention as its HIV risk reduction framework. Prior to release, a case manager and peer navigator via telehealth and in-person provide discharge planning and patient education and serves as a liaison to the courts. After release, patient navigators facilitate reentry into community care and provide referrals to HIV medical and SUD care as appropriate (e.g., ART, PrEP, MOUD) and assistance with food, housing, transportation, employment, substance dependence, mental health treatment, and legal issues. TechMPower planned to enhance tracking of linkage during NCM services by integrating reporting along with a web-based platform that tracks assignment of providers and peers and follows for 6 months to capture PRISM linkage and retention in MOUD, HIV and ancillary care.
223587185|NCT07087405|DEVICE|Striae Distensae Treatment Device|One time deep skin treatment
223587186|NCT06403878|DRUG|Carboplatin|neoadjuvant chemotherapy，2cycles.
223587187|NCT06403878|DRUG|Nab paclitaxel|neoadjuvant chemotherapy，2cycles.
223587188|NCT06403878|DRUG|Sintilimab|neoadjuvant immunotherapy，2cycles.
223587189|NCT04886258|DRUG|DFV890|DFV890
224179234|NCT04267939|DRUG|Elimusertib (BAY1895344)|Elimusertib will be administered in 28-day cycles.
224179235|NCT04267939|DRUG|Niraparib|Niraparib will be administered in 28-day cycles.
223587190|NCT04886258|DRUG|Placebo|Placebo
224179236|NCT02659839|OTHER|Cancer patients admitted to the ICU|There will be no change in the standard ICU treatment.
224179237|NCT01454531|DRUG|AVANZ Phleum pratense|AVANZ Phleum pratense up-dosing phase (300, 600, 3000, 6000 and 15,000 SQ+) + one 15,000 SQ+ maintenance injection
224179238|NCT03819504|PROCEDURE|4-D navigated stereotactic radio surgical ablation|4-D navigated stereotactic radio surgical ablation will be performed in patients with structural heart disease and sustained monomorphic ventricular tachycardia/tachycardias
224179239|NCT02701569|OTHER|Rebound exercise|Repeated jumping on a mini trampoline was administered
224307144|NCT00004755|DRUG|glucantime|
223488460|NCT02222467|DEVICE|KLOX BioPhotonic System|KLOX BioPhotonic System (Multi-LED Light and KLOX Photo Converter Wound Gel) will be administered until wound closure or for a maximum of 16 weeks, followed by a 8-week follow-up period, in association with Standard Of Care for venous leg ulcers.
223488461|NCT01650428|BIOLOGICAL|Bevacizumab|5 mg/kg, IV (in the vein) over 30-90 minutes, on day 1 of each 2 weekly cycles. Number of cycles: 1-5 (bevacizumab should not be administered during cycle 6).
223488462|NCT01650428|DRUG|Irinotecan|165 mg/m2 IV (intravenous) over 1 hour on day 1 of two weekly cycle. Number of cycles: 1-6
223488463|NCT01650428|DRUG|Oxaliplatin|165 mg/m2 IV (intravenous) over 1 hour on day 1 of two weekly cycle. Number of cycles: 1-6
223488464|NCT01650428|DRUG|5-Fluorouracil|3200 mg/m2 IV (intravenous), continuous infusion over 48 hours starting on day 1 of two weekly cycle. Number of cycles: 1-6
223488465|NCT05438511|BEHAVIORAL|Focus group|A semi-structured focus group discussion guide will be developed with question probes that cover 1) contextual factors, 2) barriers to implementation, and 3) facilitators to implementation, with secondary probing questions.
223488466|NCT05438511|BEHAVIORAL|Organizational Readiness for Implementing Change|measures the extent to which organizational members are prepared to implement organizational change. The ORIC tool asks participants to rate their level of agreement with 12 statements pertaining to organizational readiness for change (change commitment and change efficacy) on a 5-point Likert Scale.
223587191|NCT01359605|DRUG|varespladib methyl|500 mg oral suspension
223587192|NCT07087613|DEVICE|Eko CORE 500 Digital Stethoscope|The FDA-cleared Eko CORE 500 digital stethoscope is used to collect phonocardiogram (PCG) and three-lead ECG recordings from participants. This observational study uses these recordings to develop and validate artificial intelligence algorithms to detect pulmonary hypertension and low left ventricular ejection fraction. No modifications to the device or device functionality are being tested.
223745382|NCT07166237|BEHAVIORAL|Cognitive Behavioral Therapy for Paternal Perinatal Depression|Cognitive Behavioral Therapy (CBT) is a type of psychotherapy (talk therapy). The weekly group sessions will be two hours long and take place once a week for 9 consecutive weeks. The first hour of the session will involve teaching and practice of CBT skills, followed by one hour of unstructured discussion around topics relevant to participants with paternal perinatal depression. Each group will be delivered online via Zoom and guided by our intervention manual.
224072710|NCT06414512|DRUG|AMBITION trial control|Induction therapy for control group participants followed the 2018 WHO cryptococcal guidelines with 7 days of 5-FC 100mg/kg/day and 7 days of IV Amphotericin deoxycholate followed by 1200mg fluconazole/day for 7 days.
224072711|NCT06414512|DRUG|Flucytosine|Participants in the trial will receive 60mg/kg/day of 5-FC in 3 divided doses for 10 days. Single-dose liposomal amphotericin (10mg/kg) is preferred, if available. Amphotericin B 0.7-1.0 mg/kg/day may be used if needed.
224072712|NCT01394081|OTHER|Enhanced Engagement and Enrollment (EEE)|Consists of motivational interviewing, educational outreach, and patient navigation.
224072713|NCT01394081|OTHER|Administrative Outreach (AO)|Consists of giving information about enrolling for VA medical care or scheduling an appointment
224072714|NCT03491332|DEVICE|conventional circuit|"The patient enters the operating room without any pretreatment and attaches a standard patient monitoring device. Anesthesia was performed by intravenous anesthesia. After induction of anesthesia, alveolar recruitment is performed in supine position in all groups with 30 cmH2O for 5 seconds. Mechanical ventilator was set with tidal volume of 8 ml / kg, the inspiratory/ expiratory ratio of 1: 2 and respiratory rate was adjusted for targeting EtCO2 around 35mmHg. Keep the fresh air flow of the ventilator at 3 L / min and set the temperature to 37 ° C for the heating circuits of group H and group SH. An arterial cannulation and subclavian jugular vein catheter is inserted.~The circuits were applied to each group as follows; conventional circuit or group C, conventional humidification circuit for group H and new humidification heat circuit for group SH, respectively. All other conditions were same among three groups."
224072715|NCT03491332|DEVICE|conventional humidification circuit|"The patient enters the operating room without any pretreatment and attaches a standard patient monitoring device. Anesthesia was performed by intravenous anesthesia. After induction of anesthesia, alveolar recruitment is performed in supine position in all groups with 30 cmH2O for 5 seconds. Mechanical ventilator was set with tidal volume of 8 ml / kg, the inspiratory/ expiratory ratio of 1: 2 and respiratory rate was adjusted for targeting EtCO2 around 35mmHg. Keep the fresh air flow of the ventilator at 3 L / min and set the temperature to 37 ° C for the heating circuits of group H and group SH. An arterial cannulation and subclavian jugular vein catheter is inserted.~The circuits were applied to each group as follows; conventional circuit or group C, conventional humidification circuit for group H and new humidification heat circuit for group SH, respectively. All other conditions were same among three groups."
224072716|NCT03491332|DEVICE|new humidifaction heat circuit|"The patient enters the operating room without any pretreatment and attaches a standard patient monitoring device. Anesthesia was performed by intravenous anesthesia. After induction of anesthesia, alveolar recruitment is performed in supine position in all groups with 30 cmH2O for 5 seconds. Mechanical ventilator was set with tidal volume of 8 ml / kg, the inspiratory/ expiratory ratio of 1: 2 and respiratory rate was adjusted for targeting EtCO2 around 35mmHg. Keep the fresh air flow of the ventilator at 3 L / min and set the temperature to 37 ° C for the heating circuits of group H and group SH. An arterial cannulation and subclavian jugular vein catheter is inserted.~The circuits were applied to each group as follows; conventional circuit or group C, conventional humidification circuit for group H and new humidification heat circuit for group SH, respectively. All other conditions were same among three groups."
224072717|NCT02831465|BEHAVIORAL|Healthy Subjects|Subjects with normal lung function performed MVV at increasing breathing frequencies and maximal tidal volume, from 10 to 100 cycles per minute. Inspiratory capacity (IC) was measured at rest and after each 12 seconds of MVV in order to detect DH. From the moment DH appeared at a given frequency, only one additional MVV at a higher breathing frequency was conducted to confirm DH.
224072718|NCT01407926|OTHER|Nurse-Led Mental Health Promotion Intervention|The nurse-led intervention is a multi-faceted 6-month program led by a Registered Nurse that involves regular home visits, monthly case conferences, and evidence-based assessment and management of depression using an interprofessional approach.
224072719|NCT00954044|BEHAVIORAL|Randomized Exercise Intervention|"The Exercising Together training group will participate in 6 months of supervised, progressive partnered resistance exercise.~Couples will participate in 2 exercise sessions a week for 6 months."
224307145|NCT05187702|OTHER|Functional exersize|Participants will be given balance and strengthening exercises covering the balance exercise protocol.
224307146|NCT05187702|OTHER|Aerobic exersize|60% of the maximum heart rate is given 3 walking eccentricity per week
224307147|NCT01703936|OTHER|Agricultural and life skills training program|
223488467|NCT06961851|OTHER|aTMS utilizing the MagVenture TMS device|Participants will complete 6 MagVenture TMS sessions per day for 5 days at the SLP Clinic. Sessions will take place with at least 30 minutes between each session. The first session will determine the baseline motor threshold for delivering aTMS. We will be stimulating the dorsolateral prefrontal cortex (DLPFC) which is within the FDA approved uses. Participants will complete a PHQ9 on all 5 treatment days and 1, 2, 4, and 6 weeks post treatment via REDCap Participants will complete daily adverse event logs via REDCap
223488468|NCT06962345|DEVICE|Hormone-free vulvovaginal gel with tested composition XCM® INTIM and PROMs questionnaire.|"Management of GSM in post-menopausal women will be measured with the combination of the application of the hormone-free vulvovaginal gel along the 8 weeks of the study and the use of a PROMs questionnaire. PROMS questionnaire will be delivered to the women at baseline and at the end of the study. Daily living quality of life domains of activities of daily living, emotional well-being, sexual functioning, self-perception and body image will be evaluated."
223488469|NCT06963177|DRUG|GenSci048|Administered SC.
223488470|NCT06963177|DRUG|Placebo|Administered SC.
223488471|NCT02854462|BEHAVIORAL|Language comprehension intervention|
223745383|NCT07167797|DIETARY_SUPPLEMENT|Vitamin D (Cholecalciferol )|Group II (Treatment) group: received vitamin D single oral dose 300000 IU for age \< 1 year and dose of 600000IU for age\> 1 year in addition to standard treatment
223745384|NCT07167797|DRUG|Standard treatment for rotavirus|Standard treatment for rotavirus which includes rehydration therapy and antipyretic therapy including sodium chloride fluid and paracetamol infusion
223488472|NCT02854462|BEHAVIORAL|Counting intervention|
223488473|NCT03765073|BIOLOGICAL|Multivalent Group B streptococcus vaccine|Various formulations at three dose levels
223488474|NCT03765073|BIOLOGICAL|Placebo|Saline control
223488475|NCT04466293|BEHAVIORAL|Choice Architecture|"1. Providers will receive general training on TPT benefits, indications, and contra-indications.~2. Providers will be provided with updated ART and TPT prescribing approach. This will be adapted to the country context and may include a pre-printed prescription pad (Mozambique), adaptations in clinical stationary (Zimbabwe), or adaptations to an electronic prescribing system (Malawi).~3. The pharmacy or clinician (if the clinician dispenses) will dispense ART, cotrimoxazole, and TPT as prescribed"
223488476|NCT02843308|BEHAVIORAL|Facilitated group therapy with behavioral practice; 18 weeks|Facilitated group therapy for hoarding disorder with behavioral practice
223488477|NCT06379321|DEVICE|Triathlon Hinge Knee (THK) System|Participants receive Triathlon Hinge Knee (THK) System during primary or revision knee arthroplasty in accordance with the indications for use
223488478|NCT03765177|BIOLOGICAL|CLIC-1901|Participants will undergo (a) lymphodepletion with cyclophosphamide and fludarabine, followed by (b) infusion of autologous CLIC-1901 CAR-T cells. All treatments will be delivered intravenously.
223745385|NCT07172464|DEVICE|Recross P3 Occluder (P3O) System|The Recross P3 Occluder (P3O) is being developed for the purpose of transcatheter closure of a patent foramen ovale (PFO) to reduce the risk of recurrent ischemic stroke in patients with PFO-associated stroke.
224072720|NCT00954044|BEHAVIORAL|Randomized Exercise Intervention|Couples will continue doing their usual daily activities for 6 months
224072721|NCT04672161|OTHER|Vaccine Education|A baseline educational intervention on vaccination and its role in the health maintenance of patients with IBD will be provided to all participants. Those on immunosuppressive therapies and/or those age 65 or older will also be offered the pneumonia vaccine educational intervention. Finally, patients aged 18-26 and those 27-45 who have never been vaccinated for HPV or those with high risk for HPV will additionally receive the HPV educational intervention.
224072722|NCT02814565|DRUG|Cyclobenzaprine HCl|Cyclobenzaprine HCl extended-release capsules
224072723|NCT02814565|DRUG|Placebo|Cyclobenzaprine HCl extended release placebo-matching capsules
224072724|NCT06549452|DEVICE|mHealth Intervention|Our HIPPA-compliant texting platform is linked to the Fitabase Interface. Real time activity data are transmitted from the participant's smartphone to Fitabase via cellular network. Participants will receive 3-5 texts/day in sync with their preferred schedule defined at enrollment and taking into account school schedules as relevant. These texts use personal, disease-specific, and provider information to deliver two types of messages customized to the current step count and sent in equal proportion. Messages are designed to facilitate self-awareness, reinforce step targets, and link physical activity with a reward or memorable cue.
224072725|NCT06549452|DEVICE|Usual Care|Routine medical care
224072726|NCT05055180|DIAGNOSTIC_TEST|Invasive hemodynamics and myocardial biopsies|Invasive hemodynamic characterization (biventricular pressure volume loop assessment) and biventricular myocardial biopsies
224072727|NCT06362239|OTHER|Study Surveys|Participants will complete study surveys as their participation in the research study. Study staff will collect clinical and demographic information from the electronic medical records. The enrollment in this intervention will not be decided by research enrollment, but would naturally occur regardless of enrollment in the study.
224072728|NCT04747418|PROCEDURE|Diagnostic Hysteroscopy|Collection of first 5 cc of normal saline from the output port during diagnostic hysteroscopy
224072729|NCT04747418|PROCEDURE|Trans-vaginal ultrasound|Trans vaginal ultrasound performed immediately following the diagnostic hysteroscopy ( as sonohysterography)
224307148|NCT00990587|DRUG|Ciclopirox Olamine|Patients will take Ciclopirox Olamine at various doses depending on which dose level they come into the study at. Ciclopirox olamine will be administered orally as an aqueous suspension without food. The starting dose will be 5 mg/m2/day administered as a single dose daily for 5 days (one cycle). Once a MTD has been determined, the new patients that enter into the trial will then take it at that level.
224307149|NCT04481178|OTHER|Laser (QS, Picosecond laser)|QS-Nd Yag Laser, Picosecond laser
224307150|NCT00609388|DRUG|Tacrolimus|Immunosuppression, intraoperative intraportal infusion of 1ml Tacrolimus with a concentration of 20 ug/mL
224307151|NCT00609388|OTHER|Saline solution 0.9% (250mL)|intraoperative intraportal infusion of Saline solution 0.9% (250mL)
224307152|NCT01044654|GENETIC|SB-728-T|Each infusion will be 5-30 billion ZFN modified CD4+ T-cells
223488479|NCT06049927|BIOLOGICAL|Quadrivalent influenza vaccine(0.25ml)|7.5 ug hemagglutinin (HA) of each of the four influenza strains in 0.25 mL of sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate per njection.The routine of administration is Intramuscular injection into deltoid region.And the immunization schedule is two doses on day 0, 28.
223488480|NCT06049927|BIOLOGICAL|Quadrivalent influenza vaccine(0.5ml)|15 ug hemagglutinin (HA) of each of the four influenza strains in 0.5 mL of sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate per njection.The routine of administration is Intramuscular injection into deltoid region.And the immunization schedule is two doses on day 0, 28.
223488481|NCT06049927|BIOLOGICAL|Trivalent influenza vaccine(BV)|7.5μg inactivated influenza antigen (H1N1, H3N2, Victoria) of each of the trivalent influenza vaccine in 0.25 mL of sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate per injection.The routine of administration is Intramuscular injection into deltoid region. And the immunization schedule is two doses on day 0, 28.
223488482|NCT06049927|BIOLOGICAL|Trivalent influenza vaccine(BY)|7.5μg inactivated influenza antigen (H1N1, H3N2, and Yamagata) of each of the trivalent influenza vaccine in 0.25 mL of sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate per injection.The routine of administration is Intramuscular injection into deltoid region.And the immunization schedule is two doses vaccine on day 0, 28.
223488483|NCT02924870|OTHER|Health education program|"2 sessions, at 15 and 30 days after hospital discharge. The first session will consist of four stages:~* Basic formation: basic lung anatomy and physiology, COPD concept, importance of tobacco, diagnostic tests for COPD, and how COPD is treated.~* Care in COPD: diet, breathing exercises, physical exercise (walking, cycle, treadmill ...), lifestyle (clothing, hygiene, preening, exercise, rest, sexuality, social relations).~* Management of conventional treatment: inhalers, oxygen therapy and smoking cessation.~* Action Plan: the patient and the nurse will establish a target about the activities that the patient must perform as well as their frequency and duration, according to WHO guidelines.~Second session: changes from the previous session; compliance with the physical activity plan and the deviation causes; weaknesses of the patient; skills in the management of inhalers, oxygen, and breathing exercises; and a new physical activity plan."
223488484|NCT02924870|OTHER|Conventional management|Treatment and follow-up according to conventional clinical practice (GesEPOC guidelines), including recommendations on healthy habits and lifestyle.
223488485|NCT05985785|OTHER|Autologous bone marrow aspirate concentrate (BMAC)|Bone marrow aspirate concentrate BMAC is a biologically substance harvested from a patient for autologous use. Bone marrow aspirate concentrate (BMAC) has been determined by the FDA to be a minimally manipulated biologic prepared for autologous use and does not require premarket FDA approval for clinical use.
223488486|NCT05985785|DRUG|Corticosteroid injections|Current standard of treatment for OA of the knee is corticosteroid injection.
223488487|NCT05985785|OTHER|Crossover Autologous bone marrow aspirate concentrate (BMAC)|Subjects who participate in this study and who are randomized to receive the BMAC may experience decreased pain and increased functionality after the injection compared to those that receive a corticosteroid injection. As such, participants who continue to have pain after a corticosteroid injection will be allowed to crossover to a BMAC injection at 24 weeks or 6 months post-surgery.(ARM 3)
223488488|NCT06516211|DEVICE|Clara Pregnancy Test|Multi-Level Pregnancy Test
223488489|NCT06516211|DEVICE|Professional Marketed Pregnancy Test|Early Pregnancy Test
223488490|NCT03054519|DRUG|Metformin|Participants will be prescribed up to 2,000 mgs daily of metformin
223488491|NCT03054519|DRUG|Placebo|Placebo pills will appear identical to the metformin to maintain blinding of participants and investigators.
223488492|NCT06553872|DRUG|Pirtobrutinib|Pirtobrutinib is a non-covalent BTKi that has preserved activity in the presence of mutations that drive BTKi resistance.
223488493|NCT06553872|DRUG|Brexucabtagene Autoleucel|Brexucabtagene autoleucel is an autologous CD19-directed chimeric antigen receptor (CAR) T-cell therapy (brexu-cel).
223488494|NCT06015581|BEHAVIORAL|Workforce Development: Tailored Motivational Interviewing and Technical Assistance|TMI training includes an initial 12 hour virtual workshop, standard patient interaction with feedback, group coaching, and a final standard patient interaction and feedback. TMI relies on experiential activities developed by the network while minimizing didactic presentations. Stigma-reducing communication is emphasized by practicing autonomy supportive and empathic statements and improving cultural humility practices. Role plays map on to the Mystery Shopper domains focusing on risk reduction counseling and PrEP referral. TA addresses factors in the EPIS framework.
223488495|NCT06015581|BEHAVIORAL|Quality Management, Mystery Shopper Feedback|Mystery shoppers visit each agency two times per quarter to systematically examine testing clinics' environmental characteristics and their experiences with clinic staff (e.g., quality of testing session, safer sex discussions, perceived provider competency, PrEP discussions and referral). The investigator team meets with each agency once per quarter to review the data and provide technical assistance.
223488496|NCT05039710|DRUG|JNJ-75220795|JNJ-75220795 will be administered as SC injection.
223488497|NCT05039710|OTHER|Placebo|Matching placebo will be administered as SC injection.
224072730|NCT04656652|DRUG|DS-1062a|DS-1062a will be administered as an intravenous (IV) infusion on Day 1 of each 3-week cycle
224072731|NCT04656652|DRUG|Docetaxel|Docetaxel will be administered as an IV infusion on Day 1 of each 3-week cycle.
224072732|NCT01411345|RADIATION|Standard Salvage Radiation Treatment (SSRT)|A total dose of 68 Gy delivered in 34 fractions to the Clinical Target Volume (CTV), 51 Gy in 34 fractions can be given to the pelvic nodes.
224072733|NCT01411345|RADIATION|Mapped Tumor Salvage RT (MTSRT)|Dose escalation to the imaging or Dynamic Contrast Enhanced MRI (DCE-MRI)-defined dominant region(s) by dose painting at 2.25 Gy per fraction, while the rest of the Clinical Target Volume (CTV) receives 2.0 Gy a fraction to 68 Gy. The mapped tumor (MT) boost region will receive an absolute dose of 76.5 Gy. Assuming an α/β ratio of 3.0, this would be equivalent to 80 Gy in 2.0 Gy fractions.
224072734|NCT03802877|BEHAVIORAL|Resource bank|See intervention arm descriptions
224072735|NCT03802877|BEHAVIORAL|ePlatform|See intervention arm descriptions
224072736|NCT03802877|BEHAVIORAL|Health coach|See intervention arm descriptions
224179240|NCT04619381|BEHAVIORAL|CORONARY ARTERY DISEASE AND CLOPIDOGREL: PATIENT SURVEY|Survey is a non-standardized assessment of demographics, medication compliance and reasons for non- compliance.
223587193|NCT07088822|BIOLOGICAL|V4020|The V4020 vaccine was prepared using an iDNA® infectious clone that encodes the full-length rearranged genomic RNA downstream from the optimized CMV promoter. Compared to the wild type VEEV, V4020 contains genetic rearrangement within the genomic RNA, with the capsid gene placed downstream from the glycoprotein genes. V4020 also includes attenuating mutations from the VEE TC83 vaccine, nucleotide A at position 3 in the untranslated region and E2-120Arg in the E2 glycoprotein. Notably, the E2-120Arg attenuating mutation was genetically engineered in V4020 to prevent reversion mutations. The E2-120Arg was encoded in V4020 by a CGA codon instead of AGA in the TC83 virus. Therefore, in the V4020 vaccine, at least two mutations would be needed to revert to the wildtype ACA (E2-120Thr). In contrast, in the TC83 vaccine, an AGA codon encodes the attenuating mutation E2-120Arg, and a single point mutation would be sufficient to revert to the 213 VEEV wild type ACA (E2-120Thr).
224307153|NCT04801953|DRUG|NiMODipine Injectable Solution|nimodipine solution is applied to cranial nerves during resection of vestibular schwannoma
224307154|NCT04801953|OTHER|Placebo|Sodium chloride solution is applied to cranial nerves during surgery
223488498|NCT05993481|DIAGNOSTIC_TEST|Blood Pressure Measurement|"NIBP measurements will be recorded intraoperatively every 2.5 minutes for the group of 2.5 min. Blood pressure management or every 5 minutes for the other group of 5 min. Blood pressure management after providing randomization before the surgery. A calibrated and time-matched same type of standard anesthetic monitor will be used. The monitor will measure blood pressure and display the mean, systolic and diastolic values.~All blood pressure measurements will be discontinued before the PACU transfer. Data will be automatically downloaded from the monitor to a computer using a software interface program."
223488499|NCT04537299|DRUG|Fisetin|\~20 mg/kg/day oral, NG or D tube course for 2 consecutive days twice (Days 0 \& 1 and Days 8 \& 9)
223488500|NCT04537299|DRUG|Placebo|Placebo looks exactly like the treatment drug, but it contains no active ingredient
223488501|NCT00957359|DRUG|Psilocybin|Psilocybin is a serotonergic hallucinogen that will be administered once at a dose of 0.3mg/kg
223488502|NCT00957359|DRUG|Niacin|Psilocybin and niacin will be administered in identically appearing opaque, size 0 gelatin capsules with approximately 180ml of water. The niacin dose will be 250mg
223488503|NCT04513912|DRUG|Seltorexant|Participants will receive seltorexant over-encapsulated tablet orally.
223488504|NCT04513912|DRUG|Matching placebo to Seltorexant|Participants will receive placebo over-encapsulated tablet matching to seltorexant orally.
223488505|NCT04513912|DRUG|Quetiapine XR|Participants will receive quetiapine XR capsule orally.
223488506|NCT04513912|DRUG|Matching placebo to Quetiapine XR|Participants will receive placebo capsule matching to quetiapine XR orally.
223488507|NCT04993846|DIAGNOSTIC_TEST|Dental plaque sampling|Dental plaque sampling
223488508|NCT04993846|DIAGNOSTIC_TEST|qPCR|qPCR
223488509|NCT05470010|BEHAVIORAL|Mindfulness|A psychological behavioral intervention that trains participants in mindfulness techniques, which involves achieving a moment-to-moment non-judgmental awareness of their internal psychosocial-emotional state through meditation and gentle mindful movements.
223587194|NCT07088302|DRUG|lactase administration|1 drop for each 10 ml of formula milk for 14 days
223587195|NCT07088302|OTHER|placebo|10 ml milk without lactase
224072737|NCT03002415|OTHER|Guided water intake|"Verbal and written guidelines will be given for the patient to ingest the daily volume of water calculated by the weight (30 ml / kg / day) for 14 days. Patients will receive an acrylic glass with a mark in 200 ml and will be instructed to take the number of glasses a day corresponding to the calculated volume (30 ml / kg). Patients will also receive a leaflet indicating how many glasses of water they will need to take. They will also be instructed to mark with an X the number of glasses of water that they actually drank daily during the fourteen days of intervention."
224072738|NCT03002415|OTHER|Placebo - free demand water intake|Patients are instructed to drink water and other liquids on demand. Patients are asked to note on a food record food and liquids and quantities consumed throughout the day. Patients are advised to make a four-day food diary out of the 14 days.
224072739|NCT04607083|DIAGNOSTIC_TEST|Polyp carachterization by combing endoscopist evaluation and Ai output|A polyp characterization (adenoma vs. non adenoma) is provided by endoscopist in light of the results of this own evaluation and of the Ai system output. The confidence level (high vs. low) in polyp characterization is recorded. The combined evaluation is compared with histopathology results.
224072740|NCT00435968|DRUG|CVT E002 (Cold-fX)|
224072741|NCT06032949|OTHER|Vialize|Any patients undergoing surgeries involving a groin incision (e.g., femoropopliteal bypass, aortofemoral bypass, loop thigh graft, femoral exposure for delivery of device) will receive Vialize subcutaneously.
224072742|NCT02777216|DEVICE|ConfidenHT system|ConfidenHT Medical system
224072743|NCT06186687|BEHAVIORAL|Myofunctional therapy exercise|Myofunctional therapy involves various exercises to train muscles in the soft palate, tongue, face, and pharynx. Vocal letters are used to train the palatopharyngeus, palatoglossus, uvula, tensor veli palatine, and levator veli palatine muscles. Tongue exercises involve sliding the tongue to the upper and side surfaces of the teeth, placing the tip in front of the palate, and pressing and sucking the tongue up to the palate. Face exercises involve inflating the cheeks, gargling, and sucking the cheeks to exercise the orbicularis oris muscle and the buccinator muscle. Icing stimulates the mouth, producing a cold, chilling, and numbing effect, causing reflexive contraction of the palate, tongue, and pharyngeal muscles.
224307155|NCT01170910|PROCEDURE|Static incubation|"Kidneys in this group are conserved in University of Wisconsin (eg, UW, Belzer® or Viaspan®), IGL-1, or SCOT solution before being transplanted.~."
224307156|NCT01170910|PROCEDURE|Pulsatile perfusion|Kidneys in this group are placed in the pulsatile perfusion machine(RM 3) within two hours and should be kept there at least 6 hours and 8 hours if possible, before being transplanted
223488510|NCT00600496|DRUG|AZD6244|twice daily oral dose
223488511|NCT00600496|DRUG|Dacarbazine|intravenous infusion
223488512|NCT00600496|DRUG|Erlotinib|daily oral dose
223488513|NCT00600496|DRUG|Docetaxel|intravenous infusion
223488514|NCT00600496|DRUG|Temsirolimus|intravenous infusion
223488515|NCT05912244|DRUG|IO102/IO103|IO102/IO103 will be administered subcutaneously on Days 1 and 15 of the first two 28-day cycles, and then on Day 1 only of subsequent cycles for two total years of treatment. Each vaccine contains 85ug.
223488516|NCT05912244|DRUG|Nivolumab-Relatlimab|Nivolumab-relatlimab will be administered as a single infusion 160mg relatlimab and nivolumab 480 mg for all participants. Both agents will be combined in a single fixed-dose combination (FDC) as an intravenous 30-minute infusion every four weeks.
223488517|NCT03806296|OTHER|Increase morning bright light|Participants will wear Re-Timer bright glasses for 30 minutes each morning
223488518|NCT03806296|OTHER|Decrease evening blue light|Participants will wear tinted glasses that block blue wavelength light for 2 hours before bed
223488519|NCT03806296|BEHAVIORAL|Sleep scheduling|Participants will advance their weekday bedtime and maintain their weekday risetime on weekends
223488520|NCT03806296|BEHAVIORAL|Monitor sleep, mood, and substance use|Participants will monitor sleep, mood, and substance use via smartphone-based platform and wrist actigraphy
223488521|NCT01407263|PROCEDURE|Lymph node template|Inclusion of the external iliac, hypogastric and obturator fossa nodal groups in the template undergoing a Radical Prostatectomy. Modifying the template for lymph node dissection may lead to removal of additional affected nodes, reducing the chance of recurrence. .No lymph nodes will be removed in patients randomized to the no PLND arm.
224072744|NCT02870231|DRUG|NNC9204-0530|Once-daily subcutaneous (s.c., under the skin) administration.
224072745|NCT02870231|DRUG|liraglutide|Once-daily subcutaneous (s.c., under the skin) administration.
224072746|NCT02870231|DRUG|placebo|Once-daily subcutaneous (s.c., under the skin) administration
224072747|NCT01859377|DRUG|V0498 - A mg|Single oromucosal administration
224072748|NCT01859377|DRUG|Ibuprofen|Single oral administration
224072749|NCT01495494|DEVICE|Marketed Nasal Strip|Breathe Right Nasal Strips - Clear small/medium strip
224072750|NCT01495494|DEVICE|Prototype Nasal Dilator|Prototype Nasal Dilator AB2R11
224072751|NCT03424447|PROCEDURE|efferent limb stimulation|
224072752|NCT03305107|OTHER|Exercise and Chocolate Milk|High intensity interval exercise Chocolate Milk
224072753|NCT03305107|OTHER|Exercise and Water|High intensity interval exercise Water
224072754|NCT03305107|OTHER|Sitting and Chocolate Milk|Sitting Chocolate Milk
224072755|NCT03305107|OTHER|Sitting and Water|Sitting Water
224072756|NCT00358787|PROCEDURE|Crossed K-wiring of supracondylar fracture of the humerus|Closed reduction of the fracture followed by crossed K wire percutaneous pinning.
224072757|NCT00358787|PROCEDURE|Lateral K-wiring of supracondylar fracture of the humerus|Closed reduction of the fracture followed by lateral K wire percutaneous pinning.
224072758|NCT06501365|OTHER|Post Intensive Care Transitions Rehabilitation and Family Support (PIC-TRFS)|"PIC-TRFS is a complex dyadic intervention consisting of 4 essential elements:~1. rehabilitation;~2. health and symptom management;~3. social support;~4. healthcare coordination~It is delivered by an interventionist team via telehealth from the time of randomization at discharge until 6 months after discharge. This Team partners with survivors, families, and the usual care team to deliver the active ingredients of PIC-TRFS."
224072759|NCT06501365|OTHER|Enhanced Usual Care Control|Dyads randomized to the Control group will receive: (1) the Run-In; (2) an informational brochure on the post-Intensive Care Syndrome; (3) ongoing assessments on the same schedule as the PIC-TRFS intervention; (4) referral for urgent emergent issues identified during the study
224072760|NCT00428675|OTHER|ACI instrument|Following ethics approval, 17 experts in symptom management assisted with content validation during the pilot phase. In the main study, participants complete the FACT-F, the POMS-Vsf, and the ACI Instrument. A research assistant collected demographic information and assigned an ECOG score.
224072761|NCT01885000|DRUG|Brimonidine tartrate was applied cutaneously once daily for 8 days.|
224072762|NCT01885000|DRUG|Brimonidine tartrate vehicle was applied cutaneously once daily for 8 days.|
224072763|NCT06242483|OTHER|Elfie Solution|"The Elfie solution was designed to improve knowledge, adherence, and the quality of care for patients with cardiovascular diseases. The Elfie solution comprises a mobile phone app with the following features related to hypertension:~1. Personalized monitoring plan based on health conditions to guide frequency of monitoring of blood pressure, weight, and step count~2. Digital pillbox with daily medication-taking reminders and refill reminders~3. Clinical measurements graphs for BP, weight, medical adherence and step count~4. Newsfeed with short videos and texts related to cardiovascular diseases~5. Digital coach - Artificial intelligence technology that provides information via a chatbox as well as feedback information via personalized videos. This feature does not provide medical advice.~6. Connection with a health app or wearable for step count~7. Possibility of family peer support~8. Gamification through the Elfie rewards scoring system"
224072764|NCT00497211|PROCEDURE|Intracoronary mononuclear cell infusion|
224072765|NCT01248351|OTHER|autologous stored platelets|Administration of autologous stored platelets
224072766|NCT01248351|OTHER|administration of autologous stored platelets|administration of autologous stored platelets
224072767|NCT01248351|BIOLOGICAL|autologous stored platelets|transfusion of autologous stored platelets
224072768|NCT06092281|BEHAVIORAL|Questionnaire|"Patients after ESD need to complete a questionnaire on compliance-related education before discharge. The questionnaire includes the following information:~1. General information about the patient (e.g., education level, place of residence, economic status, employment status, family history of neoplasms, whether the patient or immediate family member has a medical background, number of previous endoscopic examinations, etc.)~2. Awareness of follow-up examinations (e.g., knowledge about the timing of the first follow-up, the process of follow-up examinations, related educational issues about follow-up, etc.)~3. Awareness of the disease (self-perceived tumor is benign or malignant, whether lifestyle changes are required, etc.)"
224072769|NCT06092281|BEHAVIORAL|Questionnaire without compliance-related education|Patients after ESD need to complete a questionnaire without compliance-related education before discharge. The questionnaire includes only general information about the patient (e.g., education level, place of residence, economic status, employment status, family history of neoplasms, whether the patient or immediate family member has a medical background, number of previous endoscopic examinations, etc.)
224072770|NCT03124784|DEVICE|RD Disposable Sensors|Noninvasive pulse oximeter sensor
224072771|NCT05243927|OTHER|Aerobic exercise program|Aerobic exercise will be performed under the supervision of a physiotherapist with a treadmill during 40-60 minutes 3 days a week for 8 weeks
224179241|NCT06161233|DEVICE|CAPABLE cohort|The CAPABLE cohort receives the mobileapplication and a multi-sensorial smartwatch (ASUS VivoWatch 5 HC-B05). Patients will be asked to use the system for at least 6 months. The CAPABLE app serves three main functionalities for the patient: symptom monitoring, information needs fulfilment and interventions to improve mental- and physical wellbeing
224179242|NCT05245838|BIOLOGICAL|Z-1018|contains gE at a dose of 100 mcg to be combined with a Toll-like receptor 9 agonist adjuvant, CpG 1018 at dose of 3000 mcg
224179243|NCT05245838|BIOLOGICAL|Z-1018|contains gE at a dose of 100 mcg to be combined with a Toll-like receptor 9 agonist adjuvant, CpG 1018 at dose of 3000 mcg with aluminum hydroxide (alum)
224179244|NCT05245838|BIOLOGICAL|Z-1018|contains gE at a dose of 100 mcg to be combined with a Toll-like receptor 9 agonist adjuvant, CpG 1018 at dose of 6000 mcg
224179245|NCT05245838|BIOLOGICAL|Z-1018|contains gE at a dose of 100 mcg to be combined with a Toll-like receptor 9 agonist adjuvant, CpG 1018 at dose of 6000 mcg, with aluminum hydroxide (alum)
224179246|NCT05245838|BIOLOGICAL|Shingrix|a suspension for injection supplied as a single-dose vial of 50 mcg varicella zoster virus (VZV) glycoprotein E (gE) antigen and AS01B adjuvant
224179247|NCT00598884|BEHAVIORAL|Internet-Based Self-Management for Prolonged Grief Symptoms|The treatment consists of empirically derived cognitive behavioral therapy strategies to promote stable and active routines, self-care, accommodation of loss, enhanced self-efficacy, re-engagement in pleasurable activities, and reattachment with significant others. Treatment sessions will be Internet-based and will occur three times per week for 6 weeks.
224179248|NCT06133790|GENETIC|PCR - Immunohistochemistry - Immunolabelling|Genetic analysis will be conducted on biopsy to define molecular profile of head and neck tumors
224179249|NCT00411879|DRUG|Vasopressin, Epinephrine, and Steroids|During resuscitation, study group patients receive vasopresssin \[20 IU IV maximum dose = 100 IU\] and methylprednisolone (40 mg IV). Epinephrine is given to both groups according to guidelines for resuscitation 2005. In the study group, postresuscitation shock is treated with stress-dose hydrocortisone.
224179250|NCT00411879|DRUG|Placebo, Epinephrine, Placebo|Epinephrine is given to both groups according to guidelines for resuscitation 2005. Control group patients receive placebo instead of vasopressin and steroids.
224179251|NCT00408785|DRUG|Botulinum Toxin Type A|botulinum toxin type A 100 units, human serum albumin 0.5 mg, sodium chloride 0.9 mg
224179252|NCT00408785|DRUG|sodium chloride|sodium chloride 0.9 mg
224179253|NCT00856115|OTHER|medical chart review|Patient charts are reviewed to obtain medical data.
224179254|NCT00856115|OTHER|questionnaire administration|Patients undergo a 45-60 minute interview to obtain information on variations in symptom perception, assessment, and patient-physician communication process. Patients are assessed by sociodemographic characteristics (i.e, education, gender, age, insurance status, employment status, income, race/ethnicity, and religiosity), information of close confidants (i.e., relationship, family history of cancer, and caregiver/decision-making status), and physician characteristics. Patients are also assessed by the Trust in the Health Care System, DMPQ, RCS, Brief COPE scale, Lukwago Religiosity scale, and RAND Social Support Survey questionnaires.
224179255|NCT00856115|OTHER|study of socioeconomic and demographic variables|Patients are assessed by sociodemographic characteristics (i.e, education, gender, age, insurance status, employment status, income, race/ethnicity, and religiosity).
224179256|NCT00856115|OTHER|survey administration|Patients are also assessed by the Trust in the Health Care System, DMPQ, RCS, Brief COPE scale, Lukwago Religiosity scale, and RAND Social Support Survey questionnaires.
224179257|NCT02766309|OTHER|Sf12-v2|structured questioner Sf-12v2, developed by Ware.et al (Ware, Kosinski, Turner-Bowker \& Gandeck, 2002).
224179258|NCT01431456|DRUG|Dabigatran|Dabigatran
223488522|NCT01407263|PROCEDURE|Transverse versus vertical closure|Transverse versus vertical closure of the port site incision
223488523|NCT01407263|DRUG|antibiotic prophylaxis|One vs. three days of antibiotic prophylaxis at catheter removal
223587196|NCT07088835|DEVICE|SeizEAR|The in-ear electrode is a two-electrode device that fits snugly into the ear canal of the user. The device electrodes consist of a Ag/AgCl layer over a substrate. In one iteration, the substrate is a silicone rubber. In another iteration, the substrate is copper. The copper iteration consists of a Ag/AgCl ink that is manually applied to the copper, whereas the other iteration is purchased in a finished state with the Ag/Agel already adhered to the silicone. The electrodes are attached to a foam earpiece during the molding process. The foam earbud is made in-house and can be designed to be more firm or less firm.
224179259|NCT01431456|DRUG|Rivaroxaban|Rivaroxaban
224179260|NCT01431456|DRUG|Nadroparin|Nadroparin
224179261|NCT02871232|OTHER|Researched Abuse, Diversion and Addiction-Related Surveillance (RADARS) System of post-marketing surveillance of prescription medication abuse, misuse, and diversion|
223587197|NCT07089121|DRUG|Descartes-08|In part 1, three different doses will be administered to 3 participants with either disease indication to establish maximum tolerated dose In part 2, the MTD established in Part-1 will be administered as six once-weekly infusions to up to 10 participants per each of four baskets (cSLE, AAV, JDM and JMG) in an outpatient setting.
224179262|NCT01158885|DRUG|Clofarabine|20 mg/m2/day intravenously (IV) over 2 hours (given at hours 0 to 2) on days 1 through 5.
224179263|NCT01158885|DRUG|Cytarabine intravenous|1 gram/m2/day intravenously (IV) over 2 hours to be given 4 hours after the initiation of clofarabine on days 1 through 5.
224179264|NCT01158885|DRUG|Methotrexate|"Methotrexate to be given intrathecally (IT) to all acute lymphoblastic leukemia (ALL) patients on day 1 at the dose defined by age below:~* 8 mg for patients age 1-1.99~* 10 mg for patients age 2-2.99~* 12 mg for patients 3-8.99 years of age~* 15 mg for patients \>9 years of age"
224179265|NCT01158885|DRUG|Intrathecal (IT) Cytarabine|"Intrathecal (IT) cytarabine is optional for acute myelogenous leukemia (AML) patients.~If intrathecal cytarabine is to be given, it must be given at least 72 hours but not more than 7 days prior to the initiation of intravenous cytarabine.~Dose should be given according to age as defined below:~* 30 mg for patients age 1-1.99~* 50 mg for patients age 2-2.99~* 70 mg for patients \>3 years of age"
224179266|NCT04558385|DIAGNOSTIC_TEST|IgG SARS CoV2|IgG SARS CoV 2 will be checked in serum of COVID 19 recovered population
224179267|NCT02785861|BEHAVIORAL|supervision of physical activity|
224179268|NCT02785861|BEHAVIORAL|distance supervised physical activity|
224307157|NCT02244879|DIETARY_SUPPLEMENT|resveratrol|arm resveratrol 500: 6 months of resveratrol 500 mg/day arm resveratrol 40: 6 months of resveratrol 40 mg/day
224307158|NCT06309277|DRUG|GM-1020|N-methyl-D-aspartate (NMDA) receptor antagonist
223488524|NCT01407263|DRUG|Hemostatic Agent|For the patients randomized to routine indwelling HA agent use, the operating surgeon may choose to use either Surgicel™, Surgicel SNoW™, Arista™, FloSeal or surgeon's choice HA directed at the prostatic fossa, ligated dorsal vein complex, or neurovascular bundles. Because there is no standard HA or method of application, the surgeon will apply the HA according to the surgeon's experience and document both the HA used, and the location applied in the operative report. For patients randomized to no routine indwelling HA use, surgeons will only apply a HA if they are unable to achieve hemostasis using traditional means or feel it would be unsafe to complete the operation without using a HA for additional hemostasis. Providers in either arm may use HA as needed provided the intention is not to leave the HA indwelling.
223488525|NCT06189313|DEVICE|Cleaner Pro Thrombectomy System|"The Cleaner™ Pro Thrombectomy System (Cleaner Pro) is a catheter-based aspiration thrombectomy device comprised of a handpiece, an aspiration catheter, a dilator, and an aspiration canister."
223488526|NCT06637527|DRUG|OK-101 0.05%|0.05% Ophthalmic Solution
223488527|NCT06637527|DRUG|OK-101 0.1%|0.1% Ophthalmic Solution
223488528|NCT06637527|DRUG|Placebo|Placebo
223587198|NCT07089602|OTHER|Standard of Care DFU|Beginning at the screening visit, participants will receive weekly treatment with standard of care (cleaning, debridement, ulcer moisture balance, and offloading) until ulcer closure, or a maximum of 12 weeks, whichever occurs first.
223587199|NCT07089602|OTHER|Tri-Membrane Wrap™ DFU|Participants will receive weekly applications of Tri-Membrane Wrap™ and Standard of Care until ulcer closure, or a maximum of 12 weeks, whichever occurs first.
224179269|NCT04698954|BEHAVIORAL|Adherence Improving self-Management Strategy|The AIMS intervention is a conversation between a patient and a trained nurse, imbedded in the usual care. It consists of structured modules with visual materials, developed based on a sound understanding of the factors that drive non-adherence and potent behaviour change techniques to modify those. These modules aim to enhance patient knowledge, motivation, self-efficacy, and skills for self-managing their treatment. As part of the intervention, patients use electronic monitors to track their own behaviour, namely a medication and a physical activity monitor. Together with the nurse they examine these results to identify adherence problems and solutions and make a plan.
224179270|NCT04698954|OTHER|Treatment-as-usual|Participants in the control group will receive treatment as usual. They will visit the nurse in the out patient clinic each 3 or 6 months for 30 minutes.
224179271|NCT05709587|OTHER|Virtual reality training|Virtual reality Training for 12 sessions, two to three times for one week, one training session last for 20 minutes
223488529|NCT02734771|DRUG|Brentuximab vedotin|
223488530|NCT02734771|DRUG|Rituximab|
223488531|NCT02734771|DRUG|Cyclophosphamide|
223488532|NCT02734771|DRUG|Doxorubicin|
223488533|NCT02734771|DRUG|Prednisone|
223587200|NCT07089602|OTHER|Membrane Wrap™ DFU|Participants will receive weekly applications of Membrane Wrap™ and Standard of Care until ulcer closure, or a maximum of 12 weeks, whichever occurs first.
224179272|NCT04984811|DRUG|efineptakin alfa|1200 μg/kg NT-I7 administered intramuscularly (IM) once every 6 weeks (Q6W) starting on Cycle 1. The treatment will be continued up to a maximum of 35 cycles (approximately 2 years).
224179273|NCT04984811|DRUG|Atezolizumab|1200 mg atezolizumab administered intravenously (IV) once every 3 weeks (Q3W) starting on Cycle 1. The treatment will be continued up to a maximum of 35 cycles (approximately 2 years).
224179274|NCT03678766|BEHAVIORAL|Regulation of Cues (ROC)|Participants are provided information about basic learning theory and how physiological responses to food cues develop and can be managed. Lack of sensitivity to appetite and satiety cues and increased sensitivity to food cues will be discussed. Coping skills are presented to assist in mastery and toleration of food cue sensitivity. Participants will complete experiential learning exercises with food, and taught to monitor their hunger, satiety, and cravings. The physical activity program will focus on increasing both lifestyle activity and structured exercise programs.
224179275|NCT03678766|BEHAVIORAL|Cognitive Behavior Therapy (CBT)|"Participants are taught to identify problems in eating, thinking, and mood patterns that served to trigger binge episodes through self-monitoring and to gradually develop alternative patterns aimed at facilitating healthy, binge-free eating patterns. Participants are taught to eat a healthy variety of foods and reducing the avoidance of forbidden foods that are typically consumed during a binge."
224307159|NCT01745705|OTHER|Cervical Spine Manipulation|
224307160|NCT01745705|OTHER|Manual Contact|
224307161|NCT01383798|DIETARY_SUPPLEMENT|Placebo|100 mg lactose per day for 6 weeks
224307162|NCT01383798|DIETARY_SUPPLEMENT|Ferrous sulfate|100 mg per day of ferrous sulfate for 6 weeks
224307163|NCT01698827|OTHER|Tube assessment visits|Patients will return every 2 months for clinical questionnaire about leaks, obstructions or other dysfunctions of the tube. Objective tube examination for cracks, rupture, obstruction or dislodgement, along with replacement if necessary, will be carried out (total of 3 visits/6 months)
224307164|NCT03276780|BEHAVIORAL|Counseling|Both groups receive smoking cessation counseling although one is focused on medication adherence and addressing barriers to adherence while the other is focused on standard behavioral strategies to quit smoking
224307165|NCT03276780|DRUG|combination NRT|Both groups will receive combination NRT to help with smoking cessation
223488534|NCT05457556|PROCEDURE|Biospecimen Collection|Undergo collection of blood
223488535|NCT05457556|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
223488536|NCT05457556|DRUG|Busulfan|Given intravenously (IV)
223488537|NCT05457556|DRUG|Cyclophosphamide|Given IV
223488538|NCT05457556|PROCEDURE|Echocardiography Test|Undergo ECHO
223488539|NCT05457556|DRUG|Fludarabine|Given IV
223488540|NCT05457556|PROCEDURE|Haploidentical Hematopoietic Cell Transplantation|Undergo haploHCT
223488541|NCT05457556|BIOLOGICAL|Lapine T-Lymphocyte Immune Globulin|Given IV
223488542|NCT05457556|PROCEDURE|Lumbar Puncture|Undergo lumbar puncture
223587201|NCT07089602|OTHER|Membrane Wrap-Lite™ DFU|Participants will receive weekly applications of Membrane Wrap-Lite™ and Standard of Care until ulcer closure, or a maximum of 12 weeks, whichever occurs first.
224179276|NCT04034069|DEVICE|Theta burst stimulation (TBS)|Theta burst stimulation (TBS) is a potent form of repetitive transcranial magnetic stimulation (rTMS). Standard 600-pulse intermittent theta burst stimulation (iTBS) can enhance the corticomotor excitability, whereas standard 600-pulse continuous theta burst stimulation (cTBS) can suppress the corticomotor excitability. Sham stimulation uses an extreme low stimulation intensity which will not influence with corticomotor excitability. In the present study, real stimulation will be delivered in an intensity of 70% individual resting motor threshold while sham stimulation will be delivered in an intensity of 20% individual resting motor threshold.
224179277|NCT04034069|BEHAVIORAL|Robot-assisted training|Fourier M2 upper limb rehabilitation robot (Fourier Intelligence Co. Ltd., Shanghai, China), will be used for upper limb proximal joints training. Fourier M2 upper limb rehab robot is an end-effector robot-assisted device. The device targets (1) flexion and extension of shoulder joint, (2) flexion and extension of elbow, (3) internal and external rotation of shoulder joint, and (4) abduction and adduction of shoulder joint, supported by tailored interactive TV games in the device. HandyRehab hand robot (Zunosaki Company Ltd., Hong Kong SAR) will be used for upper limb distal joints training. It is an exoskeleton over the hand which provides power-driven extension and grasping force to the fingers and thumb in order to assist the patient to open and close the paretic hand by means of surface electromyography-triggered from the signals through the forearm extensors and flexors.
224179278|NCT02993289|OTHER|Different well-known treatments|
224179279|NCT04888195|OTHER|Questionnaire|Participants will complete a set of validated questionnaires (TRSC-C and demographic sheet) before chemotherapy. They also have to complete the same questionnaires (TRSC-C) again within 1 week after the 1st, 2nd, 3rd, 4th , 5th and 6th courses of chemotherapy via telephone interview by our research assistants.
224179280|NCT01775995|BEHAVIORAL|Meditation-CBT Intervention + Usual Care|"The intervention combines meditation and standard-of-care CBT strategies for chronic low back pain. It consists of eight weekly 2-hour group sessions guided by trained instructors. In addition to session attendance, experimental participants are asked to practice meditation at home at least 6 days/week, 30 minutes/day during the 26-week study.~Control participants will be offered the intervention after completing the study.~All participants receive usual care for opioid-treated CLBP through their regular clinicians, per their recommendations."
224179281|NCT01775995|OTHER|Usual Care Alone|All participants receive usual care for opioid-treated CLBP through their regular clinicians, per their recommendations.
224179282|NCT05763836|DRUG|Ibuprofen 800 Mg in 8 mL INTRAVENOUS INJECTION [Caldolor]|Intravenous ibuprofen infusion
224307166|NCT01884662|BEHAVIORAL|Virtual walking|"As in mirror therapy for amputee phantom pain, there is evidence that neuropathic SCI pain responds to images of the person with SCI's legs walking; we achieve this via a virtual reality approach where the subject perceives it is his/her legs walking."
224307167|NCT01884662|BEHAVIORAL|Wheeling tape|This control condition mirrors the experimental condition in all respects except it shows still legs in a wheelchair traversing the same path as the virtual walking condition
224307168|NCT01150617|DRUG|Insulin glargine plus insulin analogues|"* Intensified insulin therapy: three administrations of regular insulin or short acting insulin analogues before meals combined with long-acting insulin analogue glargine in the evening. The treatment goal will be a fasting blood glucose level of 5.5 mmol/L (99 mg/dl) and a HbA1c\<6.5% at the end of the follow-up.~* Standard care: treatment will be once-daily long-acting insulin and oral antidiabetic agents to achieve HbA1c levels of \< 7.0% at the end of the follow-up."
223488543|NCT05457556|PROCEDURE|Matched Unrelated Donor Hematopoietic Cell Transplantation|Undergo MUD-HCT
223488544|NCT05457556|DRUG|Melphalan|Given IV
223488545|NCT05457556|DRUG|Methotrexate|Given IV
223488546|NCT05457556|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
223488547|NCT05457556|DRUG|Mycophenolate Mofetil|Given IV
223488548|NCT05457556|PROCEDURE|Myeloablative Conditioning|Receive myeloablative conditioning regimen
223488549|NCT05457556|OTHER|Quality-of-Life Assessment|Ancillary studies
223488550|NCT05457556|OTHER|Questionnaire Administration|Ancillary studies
223488551|NCT05457556|BIOLOGICAL|Rituximab|Given IV
223488552|NCT05457556|PROCEDURE|T-Cell Depletion Therapy|Undergo haploHCT with alpha beta T cell depletion
223488553|NCT05457556|DRUG|Tacrolimus|Given IV
223488554|NCT05457556|DRUG|Thiotepa|Given IV
223488555|NCT05457556|RADIATION|Total-Body Irradiation|Undergo TBI
223488556|NCT04776525|DRUG|Ifosfamide|3 g/m2 each day for three days
223488557|NCT04776525|DRUG|Doxorubicin|80 mg/m2 over four hours day 1
223488558|NCT04975763|OTHER|Soybean Oil Foods|Three food product containing 10g of soybean oil each will be consumed each day for a today of 30g of soybean oil consumed each day
224179283|NCT05763836|PROCEDURE|Scalp nerve block|Scalp nerves blocked by using local anesthetics
224179284|NCT00440232|DRUG|Frovatriptan|Frovatriptan 5.0 mg orally one time at the start of the 20 hour fast
224179285|NCT00440232|DRUG|Placebo|Inert tab identical in appearance to Frovatriptan
224179286|NCT01011764|BEHAVIORAL|SKILLS vs ENGAGE|The investigators plan to contrast 2 different models for social skills groups. Each model involves 16 45-minute bi-weekly sessions, twice a week with a small group of children with ASD. Details of the 2 intervention models are described below.
224179287|NCT05567679|DRUG|Tazverik|Tazemetostat (Tazverik) 200 mg oral tablets; 800 mg by mouth twice daily for 28 days
224179288|NCT00892879|DEVICE|Laparoscopic cholecystectomy surgery|Single port laparoscopic cholecystectomy surgery versus a standard four port device.
223488559|NCT04975763|OTHER|Palm Oil Foods|Three food product containing 10g of palm oil each will be consumed each day for a today of 30g of palm oil consumed each day
223488560|NCT02226770|DEVICE|Implantable Cardioverter Defibrillator (ICD)|
223488561|NCT04764045|DRUG|Ropivacaine|Injection of 1 ml Ropivacaine in all trigger points in and around scar. Injection of 1 ml saline in all trigger points in and around scar.
223488562|NCT04578756|DRUG|Cariprazine Flexible Dose|1 capsule to be taken orally at approximately the same time of day (morning or evening)
223488563|NCT04578756|DRUG|Cariprazine Flexible Dose|Dose solution (in milliliters) to be taken orally at approximately the same time of day (morning or evening)
223587202|NCT07089602|OTHER|Membrane Wrap-Hydro™ DFU|Participants will receive weekly applications of Membrane Wrap-Hydro™ and Standard of Care until ulcer closure, or a maximum of 12 weeks, whichever occurs first.
223488564|NCT05823805|OTHER|Community Health Worker|"Physicians will work with a Community Health Worker (CHW) to review the data presented in their Quality Improvement reports, and triage patients for proactive outreach (e.g. No action necessary, Call patient to check-in, Arrange BP, weight and labs, Book for phone appointment, Book for in-person appointment)."
223488565|NCT04750226|DRUG|ABBV-951|Solution for continuous subcutaneous infusion (CSCI).
223488566|NCT01496742|DRUG|Placebo|Matching RO5490258 (MetMAb) placebo iv, Day 1 of each 21-day cycle
223488567|NCT01496742|DRUG|RO5490258|15 mg/kg iv, Day 1 of each 21-day cycle
223488568|NCT01496742|DRUG|bevacizumab [Avastin]|15 mg/kg iv, Day 1 of each 21-day cycle
223488569|NCT01496742|DRUG|cisplatin/carboplatin|standard dose iv, Day 1 of each 21-day cycle, 4 cycles
223488570|NCT01496742|DRUG|paclitaxel|200 mg/m2 iv, Day 1 of each 21-day cycle, 4 cycles
223488571|NCT01496742|DRUG|pemetrexed|500 mg/m2, Day 1 of each 21-day cycle
223488572|NCT02890017|OTHER|postoperative hotel|"Outpatient surgery First night stay in a defined patient-hotel Patient come for consultation the next morning of surgery to remove the catheter and/or the compressive bandage. The absence of adverse events is checked, the discharge is confirmed and the evaluation questionnaire is given to the patient.~Postoperative consultation at 1 and 3 months."
223488573|NCT02890017|OTHER|conventional hospitalization|Hospitalization for surgery and first postoperative night stay. Postoperative consultation at 1 and 3 months
223488574|NCT01070680|DRUG|Precedex|mkg/ml,continuous infusion at rate 0.7 µg/kg/h
223488575|NCT01070680|DRUG|sodium chlorid 0,9%|continuous intravenous infusion
223488576|NCT03304236|DEVICE|Myelopathy Hand|Patients will undergo radiological and clinical examination at the Duchess of Kent Children Hospital. Patients will be required to put on a pair of hand gloves with 18 IMUs located on specific bony landmarks (distal phalanges of fingers, proximal phalanges of index fingers and thumbs, dorsum of the hands and bilateral wrists)
223488577|NCT02320175|BEHAVIORAL|Patient and Family Centered I-PASS|Patient and Family-Centered I-PASS is a bundle of communication interventions to improve the quality of information exchange between physicians, nurses, and families, and to better integrate families into all aspects of daily decision making in hospitals. The intervention included a health literacy-informed, structured communication framework for family-centered rounds; written rounds summaries for families; a training and learning program; and strategies to support teamwork and implementation.
223488578|NCT03258242|DRUG|Keluo Xin capsule|four capsules at a time, three times a day, taken orally and consecutively for 24 weeks or 48 weeks.
223488579|NCT03258242|DRUG|Placebo oral capsule|four placebo capsules at a time, three times a day, taken orally and consecutively for 24 weeks or 48 weeks.
224179289|NCT04184752|DIAGNOSTIC_TEST|Urodynamic study|The urodynamic assessment included uroflowmetry, filling cystometry with 35°C distilled water at a rate of 60 mL/sec, a pressure flow study, and a stress urethral pressure profile with patient in sitting position \[14\]. A 20-minute pad test for each woman was also performed \[15, 16\]. Multichannel urodynamic equipment (Life-Tech, Houston, TX, USA) with computer analysis and Urovision (Urolab Janus System V, Houston) was used. All terminology conformed to the standards recommended by the ICS \[3\]. All procedures were performed by an experienced technician, and the data were interpreted by a single observer to avoid interobserver variability.
224179290|NCT05408403|OTHER|Regional anesthesia TFPB|Transversalis Fascia Plane Block will be performed with 25 mL of 0.25% bupivacaine,after the end of cesarean surgery before extubation.
224179291|NCT05408403|OTHER|Regional anesthesia QLB|Anterior Quadratus Lumborum Block will be performed with 25 mL of 0.25% bupivacaine, after the end of cesarean surgery before extubation.
224179292|NCT05613933|OTHER|Improved practices|A package of tools including: antibiotic prophylaxis guidelines reminders, periodic reminders, the Infectious Endocarditis Prevention Card for patients at risk, practical information targeting both dentists and patients, etc…
224179293|NCT00426842|DRUG|Midodrine Hydrochloride|Alpha1-agonist, exerts its actions via activation of the alpha-adrenergic receptors of the arteriolar and venous vasculature, producing an increase in vascular tone and elevation of blood pressure.
224179294|NCT03998345|DRUG|609A|609A is a recombinant anti-PD-1 humanized IgG4 kappa antibody that targets the human PD-1
224179295|NCT00313742|DRUG|insulin detemir|
224179296|NCT00313742|DRUG|insulin glargine|
224179297|NCT00313742|DRUG|insulin NPH|
224179298|NCT01910142|DIETARY_SUPPLEMENT|vitamin K|A calcium product will be given either with or without vitamin K. Each intervention will last for 5 weeks, each followed by a 5 week wash-out. The first intervention will start about 4 months after inclusion and the single 41Ca bolus.
224179299|NCT01910142|DIETARY_SUPPLEMENT|calcium|
224179300|NCT05285397|DRUG|Liraglutide Pen Injector [Saxenda]|Subcutaneous injection of GLP-1 agonist
224179301|NCT04615728|PROCEDURE|laparoscopic or open appendicectomy|Laparoscopic/open appendicectomy versus conservative management with antibiotic therapy with or without image-guided drainage of appendicular abscess/collection
224179302|NCT03389594|OTHER|Surgical guide|Surgical Guide for this group will designed from 0.4mm voxel size
223488580|NCT03747003|OTHER|No intervention is provided|No intervention is provided
223488581|NCT05498727|DIAGNOSTIC_TEST|Integration of SARS-CoV 2 Testing in HIV, MNCH and TB Clinics|This study employs a quasi-experimental pre-and-post SARS-CoV-2 Ag-RDT integration design in all facilities implementing the 61 facilities in Cameroon and Kenya in Cameroon and Kenya.
223488582|NCT02704858|DRUG|Perillyl alcohol|Intranasal administration
223488583|NCT02646085|DRUG|C11 Methionine positron emission tomography|diagnostic positron emission tomography imaging after intravenous injection of C11 Methionine
223488584|NCT00497510|PROCEDURE|Chiropractic manipulation|
224179303|NCT01558791|OTHER|TBI handout|The intervention is an educational handout which covers key concepts found in the empirical literature and explicated in the VA/DoD mTBI practice guideline; (1) the meaning of a positive screen, (2) symptoms may be due to another condition, (3) most people with mTBI recover.
224179304|NCT05234762|DRUG|ES-481|Dose escalation during two Treatment Periods
224179305|NCT05234762|OTHER|Placebo|Placebo dosed at same dosing as ES-481
224179306|NCT04754867|BEHAVIORAL|Future Self Virtual Reality Image - Normal Aging|Using software developed for this purpose, a current photograph of the subject will be aged and presented through a visual medium. The image (face) will be rendered as a 3D virtual reality avatar.
223488585|NCT05793723|DIAGNOSTIC_TEST|Pulmonary function testing device|Patients will undergo pulmonary function tests with the Exhalyzer D (Ecomedics, Switzerland) device. This device consists of 1) an ultrasonic flow measuring system for measuring flow, volume and molecular mass, 2) a nitrogen washout system to measure functional residual capacity (FRC) and other indices, 3) a carbon dioxide infrared measurement device for monitoring the level of carbon dioxide in exhaled breath.
223488586|NCT04897243|DRUG|Biktarvy|B/F/TAF (Biktarvy®) is a fixed-dose combination of bictegravir (50 mg), emtricitabine (200 mg), and tenofovir alafenamide (25 mg), administered orally, once daily, without food requirements. Participating patients will receive the medication free of charge.
223488587|NCT04897243|BEHAVIORAL|Patient Experience|To capture and integrate the patient experience, this study will collect patient-reported experience measures, conduct qualitative interviews, and engage patients as well as providers.
223488588|NCT01246284|DRUG|Triamcinolone acetonide|Injections will be given within a 3 cm2 area of alopecia which will be divided into 4 quadrants. Three different concentrations of triamcinolone acetonide will be used: 2.5, 5, and 10 mg/ml. Each quadrant will receive injections with either triamcinolone acetonide 2.5 mg/ml, triamcinolone acetonide 5 mg/ml, triamcinolone acetonide 10 mg/ml, or normal saline as a control. Injection of 0.1 ml will be given intradermally using a 30 gauge half inch long needle attached to a 3 ml syringe. Each quadrant will receive approximately 7 injections per treatment session so the total dose of triamcinolone acetonide will be around 13 mg. Injections will be given vertically, with the beveled side of the needle directed to the opposite side and 2 mm away from the margin of the adjacent quadrant to avoid a diffusion effect. The treatment will be repeated every 4 to 6 weeks for a total of 6 treatment sessions.
223488589|NCT01246284|OTHER|Normal saline|
224179307|NCT04754867|BEHAVIORAL|Future Self Virtual Reality Image - Smoking Consequences Aging|Using software developed for this purpose, a current photograph of the participant will be aged showing the results of continued smoking and presented through a visual medium. The image (face) will be rendered as a 3D virtual reality avatar.
224179308|NCT04754867|BEHAVIORAL|Current Self Virtual Reality Image|Using software developed for this purpose, a current photograph of the participant will be rendered as a 3D virtual reality avatar.
224179309|NCT04754867|BEHAVIORAL|Letter - 20 years|"Participants will write a 200-300 word letter to the self they see in that image in 20 years' time. The instructions will read: Think about who you will be in 20 years from now, and write about the person you are now. What things are important and dear to you, and how do you see your life?"
224179310|NCT04754867|BEHAVIORAL|Letter - 3 months|"Participants will write a 200-300 word letter to the self they see in that image. The instructions will read: Think about who you will be in 3 months from now, and write about the person you are now. What things are important and dear to you, and how do you see your life?"
224179311|NCT03191604|OTHER|Video intervention|Video clips of endoscopy footage with just HD-WLE and clips with NBI will be shown to endoscopists.
224179312|NCT01531244|BIOLOGICAL|dactinomycin|Given via ILI
224179313|NCT01531244|DRUG|melphalan|Given via ILI
223488590|NCT02242630|DRUG|Methylprednisolone, 20 mg|Compared with intrabursal triamcinolone
223488591|NCT02242630|DRUG|Methylprednisolone, 40 mg|Compared with intrabursal triamcinolone
223488592|NCT02242630|DRUG|Triamcinolone, 20 mg|Compared with methylprednisolone
223488593|NCT02242630|DRUG|Triamcinolone, 40 mg|Compared with methylprednisolone
223488594|NCT05310136|BEHAVIORAL|BBTi|On the arrival for the baseline appointment, participants will receive workbooks which include an outline and content of BBTi, sleep diaries, and adherence record. In the end of weeks 1 and 3, nurse interventionist will meet participants to review their sleep diary data and negotiate their bedtime and wake-time schedule. During the weeks 2 and 4, participants will receive planned follow-up phone calls to assess their adherence and review progress and challenges.
223488595|NCT06001645|DIAGNOSTIC_TEST|Blood and bronchoalveolar fluid collection and analysis|Blood and bronchoalveolar lavage fluid will be collected within 12 hours after intubation. Blood samples will be centrifuged, and the serum immediately stored at less than 70° C. The following biomarkers will be analysed in the serum and bronchoalveolar lavage fluid: Interleukin-8 (IL-8), Interleukin (IL)-6, IL-1Ra, IL-18, interferon (IFN ), Angiopoietin-2 (Ang-2), Tumour Necrosis Factor receptor-1 (TNFr1), Plasminogen Activator Inhibitor-1(PAI-1), Receptor for Advanced Glycation Endproducts (RAGE), Intercellular adhesion molecule-1 (ICAM-1), Surfactant Protein D (SPD), protein C, Von Willebrand Factor (VWF), CXCL10/CXCR3, and metalloproteases (MMP9, MMP10). Blood samples obtained from the patients will be placed in specimen tubes containing heparin, centrifuged at 1500 G for 10 minutes, and then the plasma will be aspirated and stored at -70° C. Bronchoalveolar lavage fluid will be centrifuged at 1500 G for 10 minutes to remove cellular contents and stored at -70° C.
223488596|NCT06001645|DIAGNOSTIC_TEST|Chest CT scan|Computed Tomography Scan per normal clinical practice
223488597|NCT04070534|OTHER|PALS|patient activated learning system
223488598|NCT01311791|DEVICE|Algisyl-LVR|Algisyl-LVR™ device (implants) administered during a surgical procedure
223488599|NCT01311791|DRUG|Standard medical therapy|as defined per protocol
223488600|NCT01344928|BEHAVIORAL|HIT exercise intervention|
223488601|NCT01344928|BEHAVIORAL|Aerobic exercise intervention|
223488602|NCT03220789|PROCEDURE|Drilling at low speed|
223488603|NCT03220789|PROCEDURE|Drilling at conventional or high speed|
223488604|NCT06801704|BEHAVIORAL|Top Set Resistance Training|Participants will receive four warm-up sets at increasingly higher resistance, followed by three sets of eight repetitions per set on six resistance-training exercises. During training participants will be allowed 1-minute rests between sets. Participants will come in person for up to 12 weeks, twice per week, for approximately 45 minutes per day.
223488605|NCT06801704|BEHAVIORAL|Power Resistance Training|Participants will receive a total of 24 in-person training sessions using three sets of eight repetitions per set on six power resistance-training exercises. During training participants will be allowed 1-minute rests between sets. Participants will come in person for up to 12 weeks, twice per week, for approximately 45 minutes per day.
223488606|NCT00310544|DRUG|Magnevist (Gadopentetate dimeglumine, BAY86-4882)|One intravenous injection per period. Period 1 and 2 are separated by 4 to 14 days.period1:Magnevist 0.1 mmol/kg body weightperiod 2: Magnevist 0.2 mmol/kg body weight
224179314|NCT01531244|BIOLOGICAL|Conditionally replicative adenovirus 3/5-delta|Given via ILI
224307169|NCT03835221|DEVICE|methafilcon A toric contact lenses|Bilateral daily wear of methafilcon A toric contact lenses
223488607|NCT00310544|DRUG|Magnevist (Gadopentetate dimeglumine, BAY86-4882)|One intravenous injection per period. Period 1 and 2 are separated by 4 to 14 days.period 1: Magnevist 0.2 mmol/kg body weightperiod 2: Magnevist 0.1 mmol/kg body weight
223488608|NCT03674138|DIAGNOSTIC_TEST|DNA-guided choice of therapy|Buccal swab for DNA genotyping to identify best antidepressant therapy
223488609|NCT03674138|OTHER|Clinical management|Clinical management to identify best antidepressant therapy
224179315|NCT01015066|DRUG|Buprenorphine/naloxone|Sublingual tablets, 2/0.5mg (ratio buprenorphine:naloxone = 4:1), three times a day for six months (doses may be adjusted based on an individual's response)
224179316|NCT01015066|DRUG|Naltrexone|Oral tables, 50 mg/d, once a day for six months
224179317|NCT01277666|DRUG|GSK1605786A|500 mg twice daily, administered orally for 12 weeks
224179318|NCT01277666|DRUG|GSK1605786A|500 mg once daily, administered orally for 12 weeks
224179319|NCT01277666|DRUG|Placebo|Placebo capsules, administered orally for 12 weeks
224179320|NCT01397331|DRUG|Isoflurane|Anesthesia based on inhalation of 1-1.5 Minimal Alveolar Concentration of Isoflurane with the addition of infusion of remifentanil
224179321|NCT01397331|DRUG|Propofol|Anesthesia based on the infusion of 2-5 mg/kg/h of propofol with the addition of infusion of remifentanil
224179322|NCT02884440|DRUG|TAP block ropivacaine|
224179323|NCT02884440|DRUG|TAP block placebo|
224179324|NCT02884440|DRUG|General anesthesia|Induction PROPOFOL 10mg/ml REMIFENTANIL 50 μg/ml CISATRACURIUM 2mg/ml if necessary DEXAMETHASONE 8 mg KETAMINE 0,15mg/kg Maintenance PROPOFOL 10mg/ml REMIFENTANIL 50 μg/ml
224179325|NCT00423540|DRUG|Intravenous Infusion of Magnesium Sulfate|See Detailed Description.
224179326|NCT01759095|DEVICE|Electronic multidrug blister pack|At hospital discharge, patients will get their prescribed drugs repackaged in an electronic multidrug blister pack with 7x4 cavities. The electronic film affixed on the rear side measures the date and time when a loop is broken, i.e. when a cavity is emptied. Patients will get feedback on their adherence profiles at the community pharmacy.
224179327|NCT02495714|BEHAVIORAL|Active learning|Physical activity one hour a day as part of academic learning
223488610|NCT00876343|DRUG|Aripiprazole (Fixed dose)|administered orally once daily, 3 mg daily, 6 weeks
223488611|NCT00876343|DRUG|Aripiprazole (Titrated dose)|administered orally once daily, 3 to 15 mg daily, 6 weeks
223488612|NCT00876343|DRUG|Placebo|administered orally once daily, 6 weeks
223488613|NCT00001647|PROCEDURE|White blood cell infusion|
224179328|NCT02495714|BEHAVIORAL|Dietary councelling|Teaching children and parents about a healthy diet
224179329|NCT02275559|BEHAVIORAL|Mindfulness Based Stress Reduction (MBSR)|Mindfulness Based Stress Reduction (MBSR) program consists of 8 weekly classes plus an all-day class to train participants in mindfulness and its application, including addressing challenges arising from chronic diseases and life stresses.
224179330|NCT02275559|BEHAVIORAL|Healthy Living Course (HLC)|The Healthy Living Course (HLC) consists of 8 weekly classes plus an all-day class providing lectures and discussions about health-related topics. The purpose of the HLC is to match the MBSR for time, attention and group support
224179331|NCT02243189|DRUG|JNJ-43260295|A single nasal dose of JNJ-43260295, 6400 microgram, will be given.
224179332|NCT02243189|DRUG|Placebo|A single nasal dose of placebo matching to JNJ-43260295 will be given.
223488614|NCT06121674|PROCEDURE|Shaeer-II|"SHAEER-I targets ligation of the internal pudendal vein at the point where the vein exits Alcock's canal, and courses lateral to the ischial tuberosity.~Patient is oriented in the lithotomy position. The ischial tuberosity is marked. An incision is cut medial to the ischial tuberosity. Subcutaneous fat is dissected down to the neurovascular bundle harboring the internal pudendal vein. The vein is then ligated."
223488615|NCT06121674|PROCEDURE|PPI|Penile Prosthesis Implantation will be performed
223488616|NCT05433688|DEVICE|Robotic assisted gastric bypass surgery|The product under investigation and the conventional suture material will be used in routine clinical practice and according to the Instructions for Use (IfU).
223488617|NCT05707806|DEVICE|MRI|Enables the use of custom pulse sequence
223488618|NCT05355337|DRUG|Pramipexole|9 weeks of treatment with Pramipexole
223488619|NCT05355337|DRUG|Placebo|9 weeks of treatment with Placebo
223488620|NCT05512390|DRUG|ABBV-319|Intravenous (IV); Infusion
224179333|NCT02243189|DRUG|Nasal Allergen Challenge|Participants will be challenged by the nasal route with an appropriate allergen based on skin test reactivity.
224179334|NCT04835740|OTHER|High intensity Interval Training|All the participants underwent 5 weeks of High intensity interval training.
224179335|NCT03031873|DEVICE|MRI perfusion imaging|Evaluate the evolution of progressive obliteration of the AVM nidus
224179336|NCT03515031|DEVICE|High Flow Nasal Cannula Oxygenation|Delivery of humidified and heated (37ºC) high flow oxygen
224179337|NCT03515031|DEVICE|Venturi Mask Oxygenation|delivery of high flow oxygen
224179338|NCT05414422|DRUG|PCN-101|Concentrate for solution for infusion
224179339|NCT05414422|DRUG|Placebo|Concentrate for solution for infusion
224179340|NCT01329822|BEHAVIORAL|Caloric restriction|Caloric restriction
224179341|NCT03797391|DRUG|EMB-01|"In part 1, patients will receive intravenous infusions of EMB01 weekly (QW). Dose escalation will continue until the maximum tolerated dose (MTD) or recommended phase II dose (RP2D) is reached or all planned doses are administered.~In part 2, participants will receive intravenous infusion of EMB-01 at RP2D~The duration of each treatment cycle in both part 1 and part 2 is 28 days (4 weeks).~Participants may continue to receive study drug until discontinuation criteria are met."
224179342|NCT01032265|BEHAVIORAL|Web-based treatment with PFMT and elements of CBT|125 women with stress urinary incontinence(SUI) participate in web-based treatment for 3 months. Treatment consists of information, PFMT and uses elements of CBT. It includes regular email contact with urotherapist.
224179343|NCT01032265|BEHAVIORAL|Pamphlet treatment|125 women with SUI receive a pamphlet with information and a programme for PFMT.
224179344|NCT04120025|BEHAVIORAL|Diaphragm Training|training on isolated abdominal breathing with proper effort and hold time to promote strengthening
224179345|NCT04563130|BEHAVIORAL|Cryocompression|Cryocompression will be administered using ice bags and compression socks/ surgical gloves
224179346|NCT02728804|OTHER|Quality-of-Life Assessment|Complete questionnaire
224179347|NCT02728804|OTHER|Questionnaire Administration|Complete questionnaires
223488621|NCT04613453|DRUG|Ketamine Infusion|Participants will receive four Ketamine infusions over two weeks, each 0.5mg/kg over 40 minutes.
224179348|NCT01985035|BEHAVIORAL|Diet|Reduction of energy intake in order to weight loss
224179349|NCT00673075|DRUG|Nebivolol|Encapsulated Nebivolol 5 mg, 10 mg, 20, mg, 40 mg total daily dosage, oral administration once daily
224179350|NCT00673075|DRUG|Carvedilol|Encapsulated Carvedilol 12.5 mg, 25 mg, 50 mg total daily dosage, oral administration twice daily
224179351|NCT04778111|OTHER|Measurement of the actual and perceived maximum reachable distance|A device (a table) will present luminous targets (green circles) to the subjects. Subjects will be asked to determine whether or not they are able to reach this target with their upper limb.
224179352|NCT04327505|DRUG|Hyperbaric oxygen|1.6- 2.4 ATA, 30-60 min (excluding compression/recompression)
224179353|NCT01201291|OTHER|Normobaric oxygen|Fraction of inspired oxygen
224179354|NCT00003874|BIOLOGICAL|monoclonal antibody CD19|
224179355|NCT00003874|BIOLOGICAL|monoclonal antibody CD20|
224179356|NCT00003874|PROCEDURE|in vitro-treated peripheral blood stem cell transplantation|
224179357|NCT00347685|DRUG|tramadol ER|
224179358|NCT04539444|BIOLOGICAL|CD19/22 CART|CD19/22 CART cells are administrated in a 3-day split-dose regimen at dose of 0.5- 2×10\*107 CART cells per kilogram of body weight.
224179359|NCT04539444|DRUG|Tislelizumab|Patients will receive Tislelizumab 200mg/dose every 3 weeks.
224179360|NCT00574340|OTHER|Hyperinsulinemic Hypoglycemic Clamp|all participants received (2) hyperinsulinemic glucose clamp studies separated by 8 weeks
224179361|NCT03446664|DEVICE|Microburst Stimulation|Implantable generator with new stimulation feature under study to determine the safety and effectiveness of device stimulation on different seizure types.
224179362|NCT00840684|DRUG|amsacrine|
224179363|NCT00840684|DRUG|busulfan|
224179364|NCT00840684|DRUG|cytarabine|
224179365|NCT00840684|DRUG|daunorubicin hydrochloride|
224179366|NCT00840684|DRUG|laromustine|
224179367|NCT00840684|DRUG|melphalan|
224179368|NCT00840684|DRUG|mitoxantrone hydrochloride|
223488622|NCT04613453|DRUG|Midazolam Infusion|Participants will receive four Midazolam infusions over two weeks, each 0.045mg/kg over 40 minutes.
223488623|NCT05217446|DRUG|Encorafenib|capsule
223488624|NCT05217446|BIOLOGICAL|Cetuximab|IV
223488625|NCT05217446|BIOLOGICAL|Pembrolizumab|IV
224179369|NCT00840684|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
224179370|NCT00840684|PROCEDURE|autologous hematopoietic stem cell transplantation|
224179371|NCT04627233|DRUG|Human Ezrin Peptide 1 (HEP1)|"HEP-1 will be administrated s.c. into the lower abdominal wall~1. induction dosage: 2 mg Ezrin in 2 ml physiological saline applied s.c.,one injection every 12 hours until symptoms disappear followed by~2. maintenance dosage: 0.2 mg Ezrin in 1 ml physiological saline solution s.c 1/day for 10 days"
224179372|NCT04627233|DRUG|Placebo|placebo group received normal saline in a same volume to match corresponding HEP-1 doses. Study drug was administered by qualified staff in research clinic settings; injections were given to abdominal sites on rotating basis, by anatomic quadrant.
224179373|NCT00198042|PROCEDURE|Surgical reconstruction of the ACL|Surgical reconstruction of the ACL
223488626|NCT01081990|DRUG|cyclobenzaprine|Cyclobenzaprine 5 mg TID for 7 days
223488627|NCT05567458|DRUG|Luspatercept|Specified dose on specified days
223488628|NCT05567458|DRUG|Placebo|Specified dose on specified days
224179374|NCT00074399|DRUG|Nevirapine|Tablet taken orally daily. Dosage depends on age and body surface area
224179375|NCT00074399|DRUG|Nevirapine placebo|Placebo tablet taken orally daily
224179376|NCT01302340|DRUG|Delta-THC|Active treatment consists of THC in tablet form. Patients receive 0.75 mg THC twice daily during the first three treatment blocks (period A) and 1.5 mg THC twice daily during the latter three treatment blocks (period B). Placebo treatment consists of two tablets daily and is matched to the active treatment for taste, color and size. Study medication will be administered at 10 a.m. and 4 p.m., by the primary caregiver. These time points are chosen because NPS often occur later on the day, when fatigue and external signals build up to the stress and result in NPS. The order of administration of THC and placebo (1:1) will be determined by randomization per block: THC followed by placebo or placebo followed by THC.
224179377|NCT01302340|DRUG|placebo|Active treatment consists of THC in tablet form. Patients receive 0.75 mg THC twice daily during the first three treatment blocks (period A) and 1.5 mg THC twice daily during the latter three treatment blocks (period B). Placebo treatment consists of two tablets daily and is matched to the active treatment for taste, color and size. Study medication will be administered at 10 a.m. and 4 p.m., by the primary caregiver. These time points are chosen because NPS often occur later on the day, when fatigue and external signals build up to the stress and result in NPS. The order of administration of THC and placebo (1:1) will be determined by randomization per block: THC followed by placebo or placebo followed by THC.
223488629|NCT06627569|BEHAVIORAL|Exercise|12 weeks of aerobic exercise, with 4 sessions per week.
223488630|NCT01508000|DRUG|FOLFOX6|5-FU, folinic acid, oxaliplatin
223488631|NCT01508000|BIOLOGICAL|Bevacizumab|Targeted therapy
223488632|NCT01508000|BIOLOGICAL|Panitumumab|Targeted therapy
223488633|NCT01508000|PROCEDURE|Surgery|
224179378|NCT01302340|DRUG|Delta-THC|In case either 2 times daily 1 tablet 0,75mg or 2 times daily 1 tablet 1.5mg Delta-THC appeared to be efficacious for a particular patient, this patient can continue the effective dose of delta-THC in an open label extension phase during 6 months.
224179379|NCT02216630|DRUG|Adipose Derived Stem Cell (ADSC) Therapy|Patients undergo a liposuction where 100 cc of fat are extracted. The ADSCs are then isolated and injected intravenously.
224179380|NCT00754312|DRUG|SNDX-275|
224179381|NCT00747942|BEHAVIORAL|Support for Increased Physical Activity|Exercise referral combined with individual support, access to structured group exercise programs, and motivational support
224179382|NCT05723211|BEHAVIORAL|Vinyasa yoga group|Participants will be instructed to perform a pre-recorded 60-minute vinyasa yoga session 3 times a week for 4 weeks.
224179383|NCT05723211|OTHER|Non-active control group|Participants will be instructed to sit quietly for 60 minutes and watch a nature documentary during this time. The participants will be asked to maintain their current lifestyle habits and refrain from starting a new exercise and/or yoga program.
224179384|NCT01586013|DRUG|evaluation of propofol effect using BIS|propofol administered in target controlled infusion using the pharmacokinetic model of White
224179385|NCT00155428|PROCEDURE|rapid prototyping|
224179386|NCT00155428|PROCEDURE|computed tomography|
224179387|NCT01250782|DRUG|Glutamine|0.5 g/kg/day of dipeptide N (2)-L-Alanyl-L-Glutamine
224179388|NCT01250782|DRUG|Physiological serum|100 mL of physiological serum indistinguishable from active comparator
224179389|NCT02119780|DEVICE|YVOIRE® contour|YVOIRE® contour injection into the anteromedial malar region
224179390|NCT02119780|DEVICE|Restylane SubQ™|Restylane SubQ™ injection into the anteromedial malar region
224179391|NCT03444831|DRUG|Buspirone|Buspirone 5mg used QID a day after meal plus 20mg omeprazole before breakfast.
224179392|NCT03444831|DRUG|Placebo Oral Tablet|Buspirone placebo QID after meal plus 20mg omeprazole before breakfast.
224179393|NCT03024944|DRUG|18F-THK-5351|Intravenous (IV) catheter (tube) placed in participant arm. A small amount of 18F-THK-5351 will be injected into the IV enough time has passed for this contrast to collect in the tissue in the brain (approximately one half-hour), and participant will lie on a bed which slides into a PET Scanner to complete Tau imaging.
224179394|NCT02918006|BIOLOGICAL|VXA-A1.1|Enteric coated oral vaccine tablet
224179395|NCT02918006|BIOLOGICAL|Fluzone®|Fluzone Quadravalent (Fluzone®) influenza vaccine (QIV) suspension for intramuscular (IM) injection
223488634|NCT03776045|OTHER|Standard care plus exercise|The exercise was supervised by exercise science staff in the exercise science facilities at the University of East Anglia, UK. Participants competed two weekly sessions for 12 weeks upon initiating ADT. Each session lasted \~60 min and included aerobic interval exercise on a cycle ergometer (Monark 824E; Varberg, Sweden) followed by resistance training. In addition to the supervised exercise sessions, patients were advised on how to increase their habitual physical activity levels and were encouraged to engage in 30 minutes of self-directed exercise on three days each week (e.g. brisk walking, cycling, home-based resistance training).
223488635|NCT01983631|OTHER|Whole body vibration training|
223488636|NCT04447729|DRUG|fremanezumab|Two doses, each dose consists of 4 injections with prefilled syringes
223488637|NCT06487962|DEVICE|CGM Intervention|The intervention has 4 components with CGM uptake and maintenance as a primary focus. (1) Participants will visit their primary care provider (PCP) at baseline and 3- and 6-months post-baseline (or more frequently as needed) for review of CGM data and insulin therapy adjustments as indicated. Intervention providers received rigorous training in T1D management and CGM via Project ECHO (Extension for Community Healthcare Outcomes). (2) After each PCP visit, the CDCES will follow-up with participants to ensure participant understanding of the education/instructions provided at the PCP visit. (3) Next, participants will receive 4-weekly sessions of culturally sensitive, intensive CGM education and training led by a CDCES with accompaniment of a supportive family member or friend. (4) Virtual group support sessions, led by a peer educator, will follow over 5 months. During this period, the peer-led sessions will take place every two weeks and then move to every three weeks.
223488638|NCT06487962|OTHER|SMBG Control Condition|The SMBG control condition consists of 3 components delivered over 6 months. (1) Participants will visit their PCP at baseline and 3- and 6-months post-baseline (or more frequently as needed) for review of SMBG data and insulin therapy adjustments as indicated. Control providers received rigorous training in T1D management via Project ECHO. (2) Commencing after the first PCP visit, participants will have 4-weekly telehealth visits for knowledge and skills reinforcement for SMBG. (3) CDCES support phone calls will follow over 5 months. During this period, the support phone calls will take place every two weeks and then move to every three weeks.
223488639|NCT01933932|DRUG|Selumetinib|Three 25 mg selumetinib capsules (Hyd-Sulfate) be administered orally, twice daily, (total dose 75 mg dose bd) on an uninterrupted schedule.
223488640|NCT01933932|DRUG|Docetaxel|Docetaxel 75 mg/m2 will be administered intravenously on day 1 of each 21 day cycle.
223587203|NCT07089602|OTHER|Standard of Care VLU|Beginning at the screening visit, participants will receive weekly treatment with standard of care (cleaning, debridement, ulcer moisture balance, and compression) until ulcer closure, or a maximum of 12 weeks, whichever occurs first.
223587204|NCT07089602|OTHER|Tri-Membrane Wrap™ VLU|Participants will receive weekly applications of Tri-Membrane Wrap™ and Standard of Care until ulcer closure, or a maximum of 12 weeks, whichever occurs first.
223587205|NCT07089602|OTHER|Membrane Wrap™ VLU|Participants will receive weekly applications of Membrane Wrap™ and Standard of Care until ulcer closure, or a maximum of 12 weeks, whichever occurs first.
224179396|NCT02918006|OTHER|Placebo Tablets|Placebo tablets similar in size, color and number to the active oral tablet vaccine drug product
224179397|NCT02918006|OTHER|Saline Solution for Placebo IM Injection|
224179398|NCT06195033|PROCEDURE|Surgical protocol guided by artificial intelligence software|At present, the indications for internal fixation of intertrochanteric fractures are not clear. We developed an artificial intelligence software to assist surgeons in determining whether to immobilize lateral and medial posterior wall fractures.
224179399|NCT01618929|DRUG|Montelukast|Placebo and montelukast (5 mg for 6-14 years of age and 10 mg for 14-18 years of age once a day) will be given following one another in 4 weeks periods including a 2 weeks wash-out period in between in a cross over design.
224179400|NCT00000829|BIOLOGICAL|Pneumococcal Vaccine, Polyvalent (23-valent)|Administered as an injection at 24 months of age
224179401|NCT00000829|BIOLOGICAL|Pneumococcal Conjugate Vaccine, Heptavalent|Administered as an injection at 0, 2, 4, and 15 months of age
224179402|NCT00000829|BIOLOGICAL|Placebo|Administered at 0, 2, 4, and 15 months of age
224179403|NCT03262285|PROCEDURE|phacoemulsification|removal of cataract using ultrasound waves
224179404|NCT03262285|PROCEDURE|extracapsular cataract extraction|removal of cataract using surgical corneal incision
224179405|NCT00646191|DRUG|adalimumab|40 mg eow through Week 12 followed by OL 40 mg eow through Week 48, permitted to escalate to weekly dosing upon relapse
224179406|NCT00646191|DRUG|adalimumab|40 mg weekly through Week 48 (OL Week 12 - 48)
224179407|NCT00646191|DRUG|adalimumab|80 mg W0, 40 mg eow through Week 12 followed by OL 40 mg eow through Week 48, permitted to escalate to weekly dosing upon relapse
224307170|NCT03835221|DEVICE|fanfilcon A toric contact lenses|Bilateral daily wear of fanfilcon A toric contact lenses
224307171|NCT03252418|DRUG|Ascorbic Acid 500 MG|ascorbic acid is vitamin that can cause gingival depigmentation
224179408|NCT05358158|PROCEDURE|Intraoperative air leak test|A standard 28 Fr chest drain is inserted through the anterior port hole with all port holes closed. With the tip of the chest tube below water, the pleura is emptied from air during continuous ventilation of the lungs. An air leak after 5 minutes of ventilation indicates a negative sealing test, whereas a cessation of air leak within 5 minutes indicates a positive sealing test.
224179409|NCT05358158|PROCEDURE|Intraoperative chest drain removal|Chest drain is removed intraoperatively.
224179410|NCT05358158|PROCEDURE|Standard chest drain placement|Chest drain is left in pleura.
224307172|NCT03252418|DEVICE|diode laser|diode laser is soft tissue laser case photothermolysis of melanoctes
223488641|NCT01933932|DRUG|Placebo|Three placebo capsules will be administered orally uninterrupted twice daily in combination with docetaxel 75 mg/m2 intravenously administered on day 1 of each 21 day cycle.
223488642|NCT01933932|DRUG|Pegylated G-CSF|All patients will receive pegylated Granulocyte Colony Stimulating Factor (G-CSF) at least 24 hours after administration of every docetaxel dose and not within 14 days prior to the next docetaxel administration.
223488643|NCT06636214|BEHAVIORAL|CHATO-I|Online communication education program
223488644|NCT04315558|DRUG|Revefenacin Inhalation Solution [Yupelri]|nebulized drug comparison
223488645|NCT04315558|DRUG|Ipratropium Bromide|nebulized drug comparison
223488646|NCT06634706|DEVICE|RefleXion X1 Radiotherapy System [Imaging Only]|kVCT and FDG-PET imaging using the RefleXion X1 Radiotherapy System in different anatomical regions
223488647|NCT00858546|DEVICE|Repetitive transcranial stimulation|Repetitive transcranial stimulation
223488648|NCT06520163|DRUG|Etoposide|Day 1\~Day 2: 75mg/m\^2
223488649|NCT06520163|DRUG|Cytarabine|Day 1\~Day 2: 200g/m\^2, q12h
223488650|NCT06520163|DRUG|PEG-rhG-CSF|Day 6: 6mg
223488651|NCT06520163|DRUG|G-CSF|Starting from the 9th day, if the white blood cell count is less than 20,000/μL, administer G-CSF at a dose of 5μg/kg by subcutaneous injection until the collection is completed.
224179411|NCT05598840|OTHER|Care for today Mobile Application|"C4T (Care for Today) Education is a digital application (app) designed to offer quality educational materials.~The APP will be provided to the patients in the outpatient centre four months before surgery. Patients will be able to download the APP using a QR code that will be provided during the visit. They'll realize the download immediately or at home, in both cases a detailed explication of how to use the APP and its contents will be provided using an example version."
224179412|NCT01392391|PROCEDURE|Task Oriented Exercise Training|"Treadmill training with safety harnesses begin at 6 to 15 minutes total duration at 40-50% maximal heart rate reserve 3 times per week, increasing to 60-70% maximal heart rate reserve for 30 minutes for 6 months.~Group dynamic balance exercise immediately follow the treadmill training 3 times a week. Participants also receive Best Stroke Care according to Get with the Guidelines"
224307173|NCT01258166|PROCEDURE|Surgery or immobilization|
224307174|NCT00427713|DRUG|capecitabine|
224307175|NCT00427713|DRUG|oxaliplatin|
223488652|NCT06520163|COMBINATION_PRODUCT|CHOP|\[Cyclophosphamide (Cy) + Doxorubicin (ADM) + Vincristine (VDS) + Prednisone (Pred) \]± Rituximab (R)
223488653|NCT06520163|COMBINATION_PRODUCT|Hyper-CVAD|\[Cyclophosphamide + Doxorubicin + Vincristine + Dexamethasone (DXM)\] ± Rituximab
223488654|NCT06520163|COMBINATION_PRODUCT|ID-MTX + Ara-C|\[High-Dose Methotrexate (MTX) + Cytarabine\] ± Rituximab
223488655|NCT06520163|COMBINATION_PRODUCT|DA-EPOCH|\[Etoposide + Doxorubicin + Vincristine + Cyclophosphamide + Prednisone\] ± Rituximab
223488656|NCT06520163|COMBINATION_PRODUCT|GDP|\[Gemcitabine (G) + Cisplatin (P) + Dexamethasone (DXM)\] ± Rituximab
223488657|NCT06520163|COMBINATION_PRODUCT|GDPE|\[Gemcitabine + Cisplatin + Dexamethasone + Etoposide\] ± Rituximab
223488658|NCT06520163|COMBINATION_PRODUCT|ICE|\[Etoposide + Ifosfamide (IFO) + Carboplatin\] ± Rituximab
223488659|NCT06520163|COMBINATION_PRODUCT|DICE|\[Dexamethasone + Ifosfamide + Ifosfamide + Etoposide\] ± Rituximab
223488660|NCT06520163|DRUG|G-CSF|From Day 6, administer G-CSF at a dose of 5μg/kg by subcutaneous injection until the collection is completed.
223488661|NCT03823027|DEVICE|SiPore15™|SiPore15™ is a taste- and odourless white powder, consisting of precisely engineered micrometre sized synthetic amorphous silicon dioxide. The device is made of pure silicon dioxide, SiO2, which has the CAS Number: 112926-00-8 and EC List number: 601-214-2.
223488662|NCT01031082|PROCEDURE|Middle ear fluid, nasopharyngeal aspirate and urine sample.|Middle ear fluid, nasopharyngeal aspirate and urine sample collection.
223488663|NCT06634979|PROCEDURE|Selective lymph node dissection|For 0.5 \< CTR \< 1 and ≤ 2 cm diameter cT1N0M0 invasive non-small cell lung cancer patient sex for selective lymph node (lower mediastinal lymph nodes are not required to be cleared for upper lobe tumors and upper mediastinal lymph nodes are not required to be cleared for lower lobe tumors)
223488664|NCT06635213|OTHER|Desensitisation|This technique is utilized to decrease, or normalize, the body's response to particular sensations.
223488665|NCT06635213|OTHER|Pain neuroscience education|PNE is an educational intervention aiming to alter a patient's beliefs and cognitions regarding their pain experience.
223488666|NCT06548035|BEHAVIORAL|Adapted Relaxation Response Resiliency Program (3RP)|The 3RP intervention is an integrated program of relaxation response (RR) eliciting meditation and mindfulness exercises, social support, cognitive skills training, and positive psychology focused on developing skills to reduce the stress response, elicit the relaxation response and enhance resiliency.
223488667|NCT06216158|DRUG|Iberdomide|Iberdomide p.o. (1.0 mg, day 1-21 of each 29-days cycle)
223488668|NCT06216158|DRUG|Isatuximab|Isatuximab s.c. (1400 mg, cycle 1: day 1, 8, 15, 22; cycles 2-3: day 1 and 15; from C4: day 1)
223488669|NCT06216158|DRUG|Dexamethasone|Dexamethasone p.o. or i.v. (20 mg, cycle 1 only: day 1, 8, 15, 22)
223488670|NCT04941430|DIAGNOSTIC_TEST|Magnetic Resonance Imaging using 7 Tesla MRI|Undergo 7T MRI
223488671|NCT03938389|DRUG|Sacubitril-Valsartan Tab 97-103 MG|Participants will take Sacubitril-Valsartan for 26 weeks
223488672|NCT03938389|DRUG|Valsartan 160mg|Participant will take Valsartan for 26 weeks
223488673|NCT03938389|DRUG|Placebo Oral Tablet|Participant with take placebo for 26 weeks or if blood pressure elevated will receive standard of care blood pressure medication, amlodipine.
223488674|NCT05482022|DEVICE|Shiley™ phonate speaking valve|The device connects to the tracheostomy tube. Usually used to aid vocalization.
223488675|NCT05482022|OTHER|control|no intervention
224179413|NCT01392391|PROCEDURE|"Stroke Care Get with the Guidelines"|"Post-stroke care is applied according to the recommendations of the American Stroke Association Get with the Guidelines adapted for Jamaica"
224179414|NCT03909724|DRUG|Sunitinib Malate|After study inclusion, patients will be randomized (1:1) via a centralized randomization system to receive either oral sunitinib (700 mg once every 2 weeks) or TAS-102 (35 mg per square meter, twice daily, 5 days a week, with 2 days of rest, for 2 weeks, followed by a 14-day rest period). Patients will receive treatment until disease progression or discontinuation due to unacceptable toxic effects, withdrawal of consent, or other reason.
224179415|NCT03909724|DRUG|TAS 102|After study inclusion, patients will be randomized (1:1) via a centralized randomization system to receive either oral sunitinib (700 mg once every 2 weeks) or TAS-102 (35 mg per square meter, twice daily, 5 days a week, with 2 days of rest, for 2 weeks, followed by a 14-day rest period). Patients will receive treatment until disease progression or discontinuation due to unacceptable toxic effects, withdrawal of consent, or other reason.
224179416|NCT02510885|DEVICE|AngioVue SD-OCT|OCT-A allows noninvasive, high-resolution imaging of the microvasculature of the retina and choroid, without intravenous dye administration. SD-OCT units use the light source used in commercially available and FDA-cleared OCT units on a modified platform. Optovue, Inc. has developed a customized SD-OCT system that implements a novel algorithm, the amplitude-based method of split-spectrum amplitude-decorrelation angiography (SSADA) for OCT-A. This detects motion in the blood vessel lumen by measuring the variation in reflected OCT signal amplitude between consecutive cross-sectional scans. Optovue has integrated the novel SSADA algorithm into their commercially approved RTVue SD-OCT unit for their OCT-A unit, the AngioVue. This unit is being conducted under an abbreviated IDE.
224179417|NCT02825589|DEVICE|BIA|BIA or bioelectrical impedance analysis using electric current through body tissues to estimate body composition particularly body fat and total body water calculating to target body weight.
224179418|NCT01425242|DRUG|Aliskiren|Starting dose: Aliskiren 150 mg p.o, if hypertension is insufficiently treated Hydrochlorothiazide 12.5 mg p.o. tablet once daily for maximally 12 months can be added, the next step is to add increase the dosage of Aliskiren to 300 mg p.o. tablet once daily until maximally 12 months after baseline, the final step to take in case hypertension is still present is to increase Hydrochlorothiazide to 25 mg p.o. tablet once daily until maximally 12 months after baseline.
224179419|NCT01425242|DRUG|Amlodipine|Starting dose: amlodipine 5 mg p.o, if hypertension is insufficiently treated Hydrochlorothiazide 12.5 mg p.o. tablet once daily for maximally 12 months can be added, the next step is to add increase the dosage of amlodipine to 10 mg p.o. tablet once daily until maximally 12 months after baseline, the final step to take in case hypertension is still present is to increase Hydrochlorothiazide to 25 mg p.o. tablet once daily until maximally 12 months after baseline.
224179420|NCT02068391|BEHAVIORAL|Stretching Program|The 'Stretching Program' will teach stretching for the upper and lower limbs, and the trunk, as well as breathing exercises for relaxation. Supervised group activities will be performed once per week (45 minutes) and self-directed stretching will be encouraged 4 days per week and monitored by an activity journal. The intensity of stretching and number of stretches will be progressed every 2 weeks. Heart rate and perceived exertion will be monitored. The program will last 6 months.
224179421|NCT02068391|BEHAVIORAL|Exercise Program|The 'Exercise Program' will prescribe specific aerobic exercise to the participants. Supervised group exercise will be performed once per week (60 minutes) and self-directed exercise will be encouraged 4 days per week and monitored by an activity journal. The initial walking prescription will be set at \~1.6 km and an intensity equivalent to the anaerobic threshold and/or 60% of peak oxygen uptake. Progressions will be made every 2 weeks, increasing distance to a maximum of 6.4 km and then increasing to a max intensity of 80% of peak oxygen uptake and/or max duration of 60 minutes. Heart rate and perceived exertion will be monitored. The program will last 6 months.
224179422|NCT02514889|BEHAVIORAL|Calorie-counting|"The Calorie Counting (CC) condition asks obese patients to achieve a daily calorie deficit. For average women consuming 2,000 calories at baseline, the target daily calorie total might be 1,600 calories. Participants are also asked to do at least 150 minutes of moderate to vigorous physical activity per week.~Two community health workers will provide behavior change coaching to 150 TCC obese patients randomly assigned to the CC condition. The intervention protocol is adapted from the Diabetes Prevention Program. Behavior change strategies include: self-monitoring (e.g., calorie-counting, self-weighing), stimulus control, and relapse prevention strategies. The health coaching will occur during two home visits, two group health education sessions, and 7 telephone coaching calls."
224179423|NCT02514889|BEHAVIORAL|MyPlate|"The MyPlate approach asks Americans to limit daily calories but emphasizes eating MORE high-satiation foods by making ½ of daily food choices fruits and vegetables,¼ of daily food choices whole grains. All participants are asked to do at least 150 minutes of moderate to vigorous physical activity per week.~Two community health workers will provide behavior change coaching to 150 TCC obese patients randomly assigned to the MyPlate condition. MyPlate is adapted from the DASH protocol. Behavior change strategies include: progressive goal-setting, stimulus control, and self-monitoring (e.g., % of food choices that are fruits \& vegetables). The health coaching will occur during two home visits, two group health education sessions, and 7 telephone behavior change coaching calls."
224179424|NCT06276712|DEVICE|Implant placement with 3.5 mm diameter KS implants.|Implant placement in edentulous jaws for a prosthetic implant rehabilitation with implant-retained overdenture (mucosally supported), on two implants. with 3.5 mm diameter KS implants.After osseointegration, both dental implants will receive definitive prosthesis.
224179425|NCT06276712|DEVICE|Implant placement with 3.5 mm diameter TS implants.|Implant placement in edentulous jaws for a prosthetic implant rehabilitation with implant-retained overdenture (mucosally supported), on two implants. with 3.5 mm diameter TS implants.After osseointegration, both dental implants will receive definitive prosthesis.
224179426|NCT00337740|PROCEDURE|endoscopic variceal banding|
224179427|NCT00337740|DRUG|propranolol|
224179428|NCT04019860|BEHAVIORAL|High Intensity Interval Training|Three weekly, supervised exercise sessions with high intensity. Each session will last for 30-45 minutes. Intervention period will be seven weeks.
224307176|NCT00427713|PROCEDURE|adjuvant therapy|
223488676|NCT05109650|DRUG|BAT6026|IV infusions
223488677|NCT05109650|DRUG|BAT1308|Ⅳ infusions
223488678|NCT01635088|DRUG|Mometasone furoate 220|dry powder inhaler QD for 28-43 days
223488679|NCT01635088|DEVICE|KoKo Spirometry|
224179429|NCT04019860|BEHAVIORAL|Time-Restricted Eating|Restricted daily window of caloric intake to maximum 10 hours. Intervention period will be seven weeks.
224179430|NCT03037333|PROCEDURE|Transvenous cardiac pacing guided by fluoroscopy|Transvenous cardiac estimulation
224179431|NCT03037333|PROCEDURE|Transvenous cardiac pacing guided by ECG/ECHO|Transvenous cardiac estimulation
224179432|NCT02475564|DRUG|Placebo|40mg of starch
224179433|NCT02475564|DRUG|Resveratrol|40mg of resveratrol (powder)
224307177|NCT00427713|PROCEDURE|standard follow-up care|
224307178|NCT03134443|DRUG|Andrographolide sulfonate|Routine treatment for acute tonsillitis + Xiyanping injection
224307179|NCT03134443|DRUG|Andrographolide sulfonate simulation|Routine treatment for acute tonsillitis + Xiyanping injection simulation
223488680|NCT01635088|DRUG|Mometasone furoate 440|dry powder inhaler QD for 28-43 days
223488681|NCT01635088|DEVICE|Oscillometry|
223488682|NCT05086757|BEHAVIORAL|TRRP|Receive TRRP services
223488683|NCT05086757|BEHAVIORAL|Enhanced Usual Care|Participants will receive an educational flyer with service referrals
223488684|NCT06466551|OTHER|intravenous catheterization|This randomized experimental study was planned to examine the effect of virtual reality goggles and squeezing a stress ball as a distraction method during intravenous catheter application on pain and fear in children aged 6-12 years.
223488685|NCT04468061|DRUG|Sacituzumab Govitecan|Intravenous Infusion
223488686|NCT04468061|DRUG|Pembrolizumab|Intravenous Infusion
223488687|NCT05843994|OTHER|online survey|Participants will complete an online survey and submit photographs.
223488688|NCT03255694|DRUG|PEG-somatropin|After the first stage (52 weeks) of Phase II clinical trial, the initial medication dose of this extension period is 0.2 mg/kg weight/week of PEG-rhGH for high dose group, low dose group and negative control group, and it is adjusted in accordance with yearly height velocity (HV) and IGF-1 SDS of each visit. The maximum dose shall not exceed 0.4 mg/kg weight/week.
223488689|NCT06071442|DRUG|Vemircopan|Participants will receive oral tablets of Vemircopan.
223488690|NCT06071442|DRUG|Rosuvastatin|Participants will receive oral coated tablets of Rosuvastatin.
223488691|NCT06071442|DRUG|Metformin|Participants will receive oral film-coated tablets of Metformin.
223488692|NCT06071442|DRUG|Levonorgestrel / Ethinyl Estradiol|Participants will receive oral tablets of Levonorgestrel/ Ethinyl Estradiol.
223488693|NCT06071442|DRUG|Carbamazepine|Participants will receive oral chewable tablets of Carbamazepine.
223488694|NCT05258721|DRUG|ClōSYS® Sensitive Fluoride Toothpaste|ClōSYS® Sensitive Fluoride Toothpaste is an over-the-counter drug product containing 0.12% stabilized chlorine dioxide (sodium chlorite in an aqueous solution) and 0.13% w/v fluoride ion.
223488695|NCT05258721|OTHER|ClōSYS® Sensitive Rinse|ClōSYS® Sensitive Rinse is a cosmetic product containing 0.1% stabilized chlorine dioxide.
223488696|NCT02818673|RADIATION|labelled human serumalbumin (125-I, Séralb®CisBio)|Intra-veinous injection of 0,015 MBq/Kg ; 0,5 to 2 mL injected over less than a minute
223488697|NCT02818673|RADIATION|labelled albumin (99m-Tc, Vasculocis®, Cisbio)|intra-peritoneal injection of 200 MBq of labelled albumin (99m-Tc, Vasculocis®, Cisbio) ; 5 ml injected over less than a minute
223488698|NCT05973214|BEHAVIORAL|Cognitive Behavioral Therapy|CBT for IEI
223488699|NCT00230737|DRUG|Melatonin 0.4 mg|
223488700|NCT00230737|DRUG|Melatonin 4.0 mg|
223488701|NCT00230737|DRUG|Placebo|
223587206|NCT07089602|OTHER|Membrane Wrap-Lite™ VLU|Participants will receive weekly applications of Membrane Wrap-Lite™ and Standard of Care until ulcer closure, or a maximum of 12 weeks, whichever occurs first.
224179434|NCT02961400|OTHER|PUSH text messages|The intervention is designed to remind participants of treatment components.
224179435|NCT02961400|OTHER|PULL text messages|The intervention is designed to remind participants to recall treatment components.
224179436|NCT02961400|BEHAVIORAL|TranS-C|The Transdiagnostic Sleep and Circadian Intervention (TranS-C) integrates evidence-based treatments derived from basic research on the circadian system.
224179437|NCT02961400|BEHAVIORAL|PE|Psychoeducation on the inter-associations between sleep, diet, exercise and stress.
224179438|NCT01156012|DRUG|T2345|One drop of T2345
224179439|NCT01156012|DRUG|Prostaglandin|One drop
224179440|NCT01665040|DEVICE|Neurostimulation device implantation|"Study subjects will undergo a screening-trial of neurostimulation using the Boston Scientific Corporation Precision Spectra neurostimulation system and may proceed to permanent implantation in the event of a successful screening trial.~Treatment will include spinal cord stimulation and may also include peripheral nerve stimulation, based upon the physician's subject-specific treatment plan."
224179441|NCT01203111|DRUG|INSULIN GLARGINE|Pharmaceutical form: solution for injection Route of administration: sub-cutaneous Dose regimen: once a day in the evening at bedtime
224179442|NCT01203111|DRUG|INSULIN GLULISINE|Pharmaceutical form: solution for injection Route of administration: sub-cutaneous Dose regimen: once a day, 0 to 15 minutes before the main meal
224179443|NCT06010992|DRUG|Nitazoxanide|Nitazoxanide oral capsules 500 mg twice daily
224179444|NCT02705755|DRUG|TD-9855|Administered orally.
224179445|NCT02705755|DRUG|Placebo|Administered orally.
224307180|NCT02426047|DIETARY_SUPPLEMENT|betaquik®|Participants will add betaquik® (a liquid emulsion of medium chain triglycerides) for a 10 day time interval starting 2 days prior to and encompassing the primary catamenial pattern.
224307181|NCT03375294|DRUG|Nitrous Oxide|One hour inhalation of 50% nitrous oxide, an odorless, colorless gas FDA approved as an induction agent for dental sedation
224307182|NCT05335291|OTHER|Questionnaire study|The Turkish validity and reliability of the questionnaire will be examined.
224307183|NCT03250494|DRUG|Dulox capsule (60mg)|each patient received Dulox capsule (60mg) orally with sips of water 2 hours preoperatively and 100 ml 0.9% sodium chloride solution (NS) intravenous infusion (IVI) over 15 min
224307184|NCT03250494|DRUG|combined Dulox capsule (60 mg) orally and Dex 0.1mg/kg diluted in 100 ml 0.9% NS IVI|each patient received combined Dulox capsule (60 mg) orally with sips of water and Dex 0.1mg/kg diluted in 100 ml 0.9% NS IVI over 15 min, 2 hours preoperatively
224307185|NCT03250494|DRUG|a placebo capsule identical to Dulox capsule and 100 ml 0.9% NS IVI over 15 min, as a placebo for dexamethasone|each patient received a placebo capsule identical to Dulox capsule and 100 ml 0.9% NS IVI over 15 min, as a placebo for dexamethasone 2 hours preoperatively.
224179446|NCT05265585|DIAGNOSTIC_TEST|Ultrasound - Cardiac Acquisition|"The evaluation of the algorithm takes place on patients with an indication for echocardiography.~This examination is done in a standard way with the potential specific explorations related to the indication of the examination. During the echocardiography, the operator records the search phase for the following reference views:~* Parasternal window (Parasternal long axis, Parasternal minor axis)~* Apical window (Apical 4 cavities, Apical 3 cavities, Apical 2 cavities~* Sub costal window, Sub costal 4 cavities, Inferior vena cava)"
224179447|NCT02382952|DEVICE|Differential Dissector|
224179448|NCT02382952|OTHER|Standard Dissection Method|
224179449|NCT00490126|OTHER|Laparoscopic Surgery Data Collection|Prospectively and retrospectively collect data on patients who had laparoscopic surgery since January 1, 1990 forward. Data from the initial patient visit note, consultation notes, operative report, discharge summary, and follow-up progress notes will be entered into the database.
224179450|NCT07052708|BEHAVIORAL|No adherence group|Patients with poor adherence was defined as medication possession ratio(MPR) \<50%.
224179451|NCT07052708|BEHAVIORAL|Adherence group|Patients with good adherence was defined as medication possession ratio(MPR) ≥50%.
224179452|NCT07058428|DRUG|Bevacizumab|Bevacizumab starts on day 1 (one week before FSRT treatment), q3w，a total of 4 treatment courses, intravenous injection, with a dose of 7.5mg/kg.
224307186|NCT04001101|COMBINATION_PRODUCT|RT and Anti-PD-1|limited metastatic site radiation
224307187|NCT04001101|DRUG|Anti-PD-1|anti-PD-1 therapy alone
224307188|NCT02362984|DRUG|Placebo|Placebo of DLBS1033 will be given in addition to the standard therapy consisting of: aspirin enteric-coated tablet 1 x 80 mg daily, simvastatin film-coated tablet 1 x 20 mg daily, vitamin B complex 1 x 1 tablet daily, and citicholine injection 250 mg/2 mL twice daily
224307189|NCT02362984|DRUG|DLBS1033|DLBS1033 enteric-coated tablets will be given in addition to the standard therapy consisting of: aspirin enteric-coated tablet 1 x 80 mg daily, simvastatin film-coated tablet 1 x 20 mg daily, vitamin B complex 1 x 1 tablet daily, and citicholine injection 250 mg/2 mL twice daily
224307190|NCT05228821|DRUG|Voxelotor Oral Tablet|During the Treatment Period, participants will receive 1500 mg of voxelotor once daily (administered as tablets) for 24 weeks in addition to ongoing current standard of care (SOC) treatment
224307191|NCT02165865|PROCEDURE|upper extremity/ hand transplantation|hand transplant on unilateral dominant hand or bilateral upper extremity amputees
224307192|NCT00390221|BIOLOGICAL|BIIB019 (Daclizumab High Yield Process)|SC injection
224307193|NCT00390221|DRUG|Placebo|Placebo SC injection
224307194|NCT02533375|DRUG|Adalimumab|Adalimumab pre-filled syringe, administered by subcutaneous injection
224307195|NCT01294475|BEHAVIORAL|Planned Activities Training|Mothers will be provided a parenting intervention, Planned Activities Training (PAT). Some of the mothers will receive the PAT intervention enhanced with a cell phone.
224307196|NCT04791475|PROCEDURE|adding Dexmedetomidine and dexamethasone to bupivacaine in USG guided supraclavicular brachial plexus block.|The linear transducer probe (frequency 4 -12 Hz) of USG machine will be used. A superficial skin wheal will be made by 2ml of 1% lignocaine subcutaneously at the point of needle insertion. USG guided Brachial plexus block will be performed by supraclavicular route via the subclavian perivascular approach in in-plane technique from lateral to medial using 22 gauge spinal needle. Study Drug will be administered via Pressure Monitoring line connected to syringe according to the allocated group with repeated aspiration and incremental dosing. • Intercostobrachial nerve block will be performed to alleviate the tourniquet pain. A 25 G needle will be inserted at the level of axillary fossa. The entire width of the medial aspect of arm, starting at the deltoid prominence and proceeding inferiorly, will be infiltrated with 5ml of 1% Lignocaine with Epinephrine (1:4,00,000) to raise a subcutaneous wheal. •
224307197|NCT06123442|BEHAVIORAL|Cognitive Resilience Intervention|Participants will have 12 weeks to complete the program, and then before the post-assessment, there will be a one-month feedback period \[22\]. This includes twelve components: 1) preliminary routine, 2) significance of knowing yourself, 3) interpreting events and stressors, 4) taking autonomy over events, 5) practicing mindfulness and self-compassion, 6) learning adaptation skills, 7) building connection , 8) purpose in life and personal growth, 9) Regulation and disclosure of emotions, 10) practicing gratitude, and 11) positive Communication both intra and interpersonal, 12) overcoming obstacles and moving forward (in the context of current problems) and the conclusion/retrospection are addressed in 12 sessions while closure and post assessment will be done after a month
224307198|NCT05376670|DRUG|Intravesical aminoglycoside instillations|Overnight instillation of an aminoglycoside (CIC), varying treatment regimens
224307199|NCT01270737|DIETARY_SUPPLEMENT|Whole soy (soy flour)|40g soy flour per day for six months
224307200|NCT01270737|DIETARY_SUPPLEMENT|daidzein|66mg daidzein per day for six months
224307201|NCT01270737|DIETARY_SUPPLEMENT|milk powder|40g low-fat dry milk per day for six months
224307202|NCT02823483|OTHER|Sunscreen Lotion (BAY987521)|50 μl/cm\*2 of each test product is applied to duplicate skin sites (approximately 2 x 2 cm each) on the lower or mid-back.Formulation A: Y49-103, Formulation B: Y71-150.
224307203|NCT02823483|OTHER|Untreated Skin|This site is patched without treatment as irradiated control
224307204|NCT04040153|BEHAVIORAL|Guiding Good Choices|Guiding Good Choices is a 5-session group-based prevention program for parents of early adolescents. Weekly 2.5 hour sessions will be held at participants' primary care clinics and led by two trained interventionists. Through didactic material, video segments, interactive activities, and home practice, the curriculum teaches parents to understand the progression from individual and environmental risk and protective factors to substance use and problem behavior, enhances parenting behaviors and skills, teaches effective family management skills, strengthens parent-adolescent interactions and bonding, broadens opportunities for family involvement, teaches conflict reduction and anger management skills, and teaches adolescents skills to resist peer influences to engage in risky behavior. Parents who opt not to attend groups will be offered a self-guided intervention manual containing the same core content and video access, plus supportive coaching to motivate use and address questions.
224307205|NCT00495547|DRUG|Azacitidine|Azacitidine
224307206|NCT00495547|DRUG|Beta Erythropoietin|Beta Erythropoietin
224307207|NCT00003079|DRUG|bryostatin 1|
223587207|NCT07089602|OTHER|Membrane Wrap-Hydro™ VLU|Participants will receive weekly applications of Membrane Wrap-Hydro™ and Standard of Care until ulcer closure, or a maximum of 12 weeks, whichever occurs first.
224179453|NCT07058428|RADIATION|FSRT|The FSRT group received simple FSRT radiotherapy; FSRT is targeted at visible intracranial lesions, with a total dose of 30Gy, administered once a day for a total of 5 days, with a fraction dose of 6Gy.
224179454|NCT07058428|RADIATION|Whole brain radiotherapy|The WBRT group received whole brain radiotherapy and locally increased dose radiotherapy for visible intracranial lesions, with a total dose of 40Gy for local lesions and 30Gy for the whole brain, once a day for a total of 10 days.
224179455|NCT01565460|OTHER|Sample Collection|Sample Collection: bile and pancreatic duct brushings and fluid samples will be obtained from the pancreatic stricture during endoscopic retrograde cholangiopancreatic procedure.
224179456|NCT02651376|COMBINATION_PRODUCT|Conventional plus AAIT|Participants received conventional (anti-opportunistic infections and ART) treatment and taken i.v., at a roud (3 times) of 2-3\*10E8 MNCs/kg body at baseline, week 1 and 2.
224179457|NCT04773964|DRUG|MET642|MET642 active treatment
224179458|NCT04773964|DRUG|Placebo|Placebo comparator
224179459|NCT03567590|PROCEDURE|Pulsed Radiofrequency treatment|The pulse treatment generator (PMF-21-100-5, Baylis Medical Inc., Montreal, Canada) with a length of 10 cm, 21-gauge, and an active tip length of 5 mm is inserted vertically into the puncture point. The pulse treatment generator is set to the pulsed radiofrequency automatic mode, with a temperature of 42 °C, pulse frequency of 2 Hz, pulse width of 20 ms, and treatment duration of 360s.
224179460|NCT03567590|PROCEDURE|Nerve Block treatment|A mixture of 40 mg Triamcinolone + 2 ml of 1% Bupivacaine + 2 ml of 2% mepivacaine + 1:100000 epinephrine is injected for nerve block treatment using a puncture needle.
224179461|NCT00180349|DEVICE|Endotak Reliance|Endotak Reliance is a defibrillation lead delivering pacing and defibrillation therapy to the ventricle as needed.
224179462|NCT04973722|DRUG|LY06006|60 mg/1 ml, once every 6 months administered subcutaneously
224179463|NCT04973722|DRUG|Prolia|60 mg/1 ml, once every 6 months administered subcutaneously
224179464|NCT03164122|DRUG|injection of microfat and plasma rich platelet PRP|intra-articular injections
224179465|NCT03164122|DEVICE|MRI|MRI 3T
224179466|NCT04211649|DRUG|3 days of antibiotherapy|Reduce at 3 days of antibiotherapy for the treatment of mild leptospirosis
224307208|NCT00003079|DRUG|cytarabine|
224307209|NCT02351544|DRUG|Botulinum Toxin Type A|
224307210|NCT02351544|PROCEDURE|Surgery|
224307211|NCT02351544|OTHER|Daily headache diary|
224307212|NCT02351544|OTHER|Migraine Disability Assessment Test (MIDAS)|
224307213|NCT02351544|OTHER|Migraine Work and Productivity Loss Questionnaire (MWPLQ)|
224307214|NCT02351544|OTHER|Migraine-Specific Quality of Life Questionnaire (MSQ)|
224307215|NCT05600504|OTHER|no intervention|no intervention
224307216|NCT00786279|OTHER|ethanol|15 gm ethanol daily for 6 months
224307217|NCT00786279|OTHER|Ethanol-free beverage|0 grams ethanol daily for 6 months.
224307218|NCT05623943|PROCEDURE|Endovascular treatment|Patients treated with endovascular treatment, including balloon angioplasty alone and balloon angioplasty plus stenting.
224307219|NCT01700166|BIOLOGICAL|Autologous Human Cord Blood derived Stem Cell injection|One time intravenous (in the vein) injection with two year follow-up
224307220|NCT01431859|BIOLOGICAL|Allergovit Birch pollen|Birch pollen specific immunotherapy. Once weekly injection for 7 weeks prior to birch pollen season for 2 consecutive seasons
224307221|NCT01431859|OTHER|Placebo|Placebo injection to be given subcutaneously once weekly for 7 weeks prior to birch pollen season for 2 consecutive years.
224307222|NCT05386082|OTHER|Modified Delphi process|The study involves a brief demographics survey and Delphi process, i.e. three rounds of information and surveys, in which participants will be asked to score/rank potential metrics.
224307223|NCT05476120|BEHAVIORAL|BATHE|The BATHE interview technique was applied 3 times, once every 3 months, for 6 months.
224307224|NCT01647672|DRUG|Abraxane|Abraxane for neoadjuvant chemotherapy
224307225|NCT04384744|DRUG|growth hormone|growth hormone was adjuvanted 2IU/d from previous menstrual period for about six weeks.
224307226|NCT06708364|OTHER|Virtual Reality Training|"Virtual reality training (X-BOX). Table tennis~* Frequency: 3 day per week~* Intensity: Mild to moderate as per Game. Exer-game ( River Rush)~* Time: total 30 minute of training with 5 min warm and 5 min cool down.~* Type: aerobic exercise"
224307227|NCT06708364|OTHER|Cycle Ergometer|"* Frequency: 3 days per week.~* Intensity: 40-60% of HRR~* Time: total 30 minutes with 5 min warm up and 5 min cool down~* Type: aerobic exercise"
224307228|NCT01088802|RADIATION|IMRT|Dose de-escalation (from 70 Gy to 63 Gy and from 58.1 Gy to 50.75 Gy, same number of fractions (N=35) in 7 weeks)
224307229|NCT01088802|DRUG|Cisplatin|Cisplatin will be administered weekly for the first 3 weeks and the last 3 weeks of radiation. Patients will not receive chemotherapy during week 4 of treatment.
224307230|NCT01088802|DRUG|Carboplatin|Carboplatin will be administered weekly during the 7 weeks of radiation. Carboplatin may be given as a substitution for cisplatin when cisplatin-related toxicities occur or when patients present with greater than grade 2 sensory or motor neuropathy, greater than 2 hearing loss, or less than 60 ml/min creatinine clearance.
224307231|NCT05177172|OTHER|High beta glucans|higher dose betaglucans
224307232|NCT05177172|OTHER|Low beta glucans|lower dose beta glucans
224307233|NCT05177172|OTHER|Low beta glucans + low polar lipids|low dose betaglucans in a combination with low dose of polar lipids
224307234|NCT05177172|OTHER|Polar lipids|low dose polar lipids
224307235|NCT05177172|OTHER|Control|No beta glucans or polar lipids
224307236|NCT04754126|BEHAVIORAL|Amazing Me|The Amazing Me Program is an evidence-based program designed to help children between the ages of 9 and 11 build self-esteem, body confidence, and eliminate weight-based bullying and teasing. This school-based curriculum satisfies national educational health requirements and provides tools for teachers to implement in 4th and 5th grade classrooms.
224307237|NCT06352229|BEHAVIORAL|Playful Learning in Infancy Program|Research-based knowledge on play with babies delivered to the parents systematically by public health visitors based on a manual, activity cards, and video clips at four time points from 0 to 12 months postpartum.
224307238|NCT06352229|BEHAVIORAL|Postnatal care as usual|In accordance with Danish national guidelines, health visitors visit families during the infants first year of life, where they weigh and measure the infant. Further, they offer individual guidance and support regarding for instance feeding, sleeping, how to stimulate the infant, and the developmental stages that the infant goes through.
224179467|NCT05439629|DRUG|BAT5906 injection|4.0 mg/eye/time, 50 μl, intravitreal injection
224179468|NCT05439629|DRUG|Lucentis|0.5 mg/eye/time, 50 μl, intravitreal injection
224179469|NCT05259124|DEVICE|positional perfusion index variation|positional perfusion index variation to predict spinal anesthesia-induced hypotension in elderly patients
224179470|NCT03688841|DEVICE|Bridged V.A.C.® with compression therapy|Patients randomised to receive Bridge VAC with compression dressings will be managed using ActiV.A.C. Therapy unit, with a continuous pressure of 125mmHg. A V.A.C.® Granufoam™ Bridge Dressing will be used instead of the tube connector. A Coban™ Lite compression dressing will be placed over the VAC dressing. The Bridge connector of the VAC will be used to tunnel underneath the Coban™ Lite till the upper edge of the dressing.
224179471|NCT03688841|DEVICE|Conventional Compression Therapy|Patients randomised to receive compression dressings will be managed using Coban™ Lite compression dressings with underlying non-adherent wound contact layer (WCL) dressings. Under the supervision of the investigating clinician, the dressings will be applied by a wound care specialist nurse and changed once to three times per week (depending on amount of exudate), until full ulcer healing or up to 12 weeks.
224179472|NCT04622059|BEHAVIORAL|acoustic stimulation|"An auditive stimulus was produced by hitting a diapason on an acoustic surface, at a distance of 2-3 cm from the mother's skin (in order to avoid mechanical vibration to reach the fetus) in the area near the fetus' head.~The same procedure was repeated three times, waiting 30 seconds between one stimulus and the following one. The total duration of stimulation was about 2 minutes."
224179473|NCT01973673|BEHAVIORAL|Bone health educational materials|
224179474|NCT01657994|OTHER|Combined functional electrical stimulation and robotic gait training|up to 18 sessions of approximately 45 minutes occurring over up to 9 weeks
224179475|NCT02147574|PROCEDURE|Anti-peristaltic ileosigmoid anastomosis|1,Laparoscope Sub-total Colectomy： After the entire colon mobilization,the ileum is resected at 10cm from ileocecum and 10-15cm colon up to peritoneal reflection is reserved. The ileocolic artery should be reserved carefully.2, Intestinal tract reconstruction: The terminal ileum is turned over 180°in anti-clockwise direction along the superior mesenteric vein long axis. To avoid the small mesenteric torsion , we should turn the broken edge towards inside. The terminal ileum and 10-15cm colon anastomose in anti-peristaltic direction,the anastomotic length is 8-10 cm.3, Sewn the space between anastomotic Intestine and posterior peritoneum. A drain is placed in the abdominal cavity and another one is placed in anal canal.
224179476|NCT04797364|DIAGNOSTIC_TEST|Pharmacogenetic Testing|Participants will donate a 2ml (teaspoon) sample of saliva. DNA extracted from the saliva sample will be used for genotyping. Genotyping results will be translated into an interpretative clinical report using evidence-based software (Sequence2Script) developed by our group and delivered to the treating physician for use in their clinical decision-making. The report will contain genotyping results, predicted phenotype, and evidence-based drug selection and dosing recommendations relevant to the child's current and future care
224179477|NCT05842590|OTHER|Composite Veneer Restoration|This is a single-arm study. Direct composite veneer Restorations will be performed to all patients.
224179478|NCT01840332|DRUG|L-thyroxin|Low dose of L-thyroxin (50 microg/day) will be used during 4 weeks. If TSH is \< 30 after 4 weeks the study continues up to 6 weeks.
224179479|NCT02609087|DRUG|Sevoflurane|
224179480|NCT02609087|DRUG|Propofol|
224179481|NCT00646737|DRUG|Mycophenolate sodium|Mycophenolate sodium
224179482|NCT04993183|BEHAVIORAL|3-day PLUS Convention|Participants will participate in a 3-day PLUS Convention, comprising an inclusivity education workshop, a service-learning seminar, a disability simulation workshop, and two community contact sessions which will consist of a 60-minute interview with an older adult with a physical disability and an outdoor experience. Discussion sessions will be facilitated throughout to consolidate learning.
224179483|NCT03935074|DRUG|intra-arterial administration of melphalan|
224179484|NCT02551874|DRUG|Saxagliptin, Onglyza|Tablets, Oral, 5mg , Once daily, 24 weeks
224179485|NCT02551874|DRUG|Dapagliflozin, Farxiga|Tablets, Oral, 10mg , Once daily, 24 weeks
224179486|NCT02551874|DRUG|Glargine insulin|100 Units/ml solution for injection in a prefilled SoloStar pen
224179487|NCT02551874|DRUG|Metformin|Tablets, Oral, ≥ 1500mg/≤ 2500mg, Once daily, 24 weeks
224179488|NCT00004173|DRUG|oxaliplatin|
224179489|NCT00004173|DRUG|paclitaxel|
224179490|NCT03841500|DEVICE|Biocomposite intereference screw femoral tunnel fixation|ACL reconstruction using biocomposite intereference screw for femoral tunnel fixation
223488702|NCT06530550|DRUG|PI3K inhibitor|Linperlisib 80mg QD orally, or Duvelisib 25mg BID orally, with a 28-day cycle. Efficacy will be evaluated once per cycle during the first year, and once every two cycles thereafter. Treatment will continue for up to 24 cycles, or until disease progression, lack of response within the first 6 cycles, or the occurrence of intolerable toxicity, whichever occurs first
223488703|NCT02721888|DRUG|Liraglutide|
223488704|NCT02721888|DRUG|MRI/ MRS (Magnetic Resonance Imaging /Magnetic Resonance Spectroscopy)|
223488705|NCT02721888|BIOLOGICAL|Blood sample|
223488706|NCT02721888|OTHER|Kinetic substudy (10 patients)|
223488707|NCT04508816|DRUG|cetuximab (CTX) or nimotuzumab (NTZ)|The patients will receive IMRT combined with anti-EGFR monoclonal antibody concurrent chemoradiotherapy. The specific treatment description is included in arm description.
223488708|NCT03146390|DRUG|Essential oils|all subjects will perform all interventions of all arms
224179491|NCT03841500|DEVICE|Endobutton (Tightrope) femoral tunnel fixation|ACL reconstruction using endobutton (Tightrope) for femoral tunnel fixation
224179492|NCT03957629|DRUG|Tenofovir Disoproxil Fumarate|Oral medication of Tenofovir Disoproxil Fumarate 300mg once per day.
224179493|NCT03957629|DRUG|PEG-Interferon alfa 2a|Subcutaneous injection of Peginterferon Alfa-2a 180 μg once per week.
224179494|NCT01907373|DRUG|olmesartan medoxomil|
224179495|NCT01907373|DRUG|olmesartan medoxomil+probenecid|
224179496|NCT04183868|DRUG|Empagliflozin 10 MG|10 mg tablet daily
224179497|NCT04183868|DRUG|Glimepiride 2 mg|starting dose: 2 mg tablet daily, 1 mg for lunch and 1 mg for dinner, can undergo to up-titration of glimepiride to a maximum of 6 mg daily
224179498|NCT04393259|OTHER|Rainbow Clinic Model of Antenatal Care|Rainbow Clinic Model is an antenatal model of care with initial ultrasound scan at 23 weeks' gestation including uterine artery Doppler, frequency of subsequent scans determined using data from this initial scan. Continuity of care is provided by obstetricians and midwives.
223488709|NCT03146390|DRUG|Alcohol free essential oils|all subjects will perform all interventions of all arms
223488710|NCT03146390|OTHER|Water|all subjects will perform all interventions of all arms
223587208|NCT03860363|DEVICE|Blood drainage post cardiac surgery|Blood drainage post cardiac surgery with Thoraguard Surgical Drainage System.
223587209|NCT02209974|DRUG|Fluticasone|Administration of inhaled corticosteroids (fluticasone, 0.5 mg) each 12 hours to 8 of the 16 COPD patients versus placebo.
223587210|NCT02209974|DRUG|Inhaled Placebo|
223587211|NCT04670783|PROCEDURE|Surgery|Orthopedic surgery (i.e. tenotomy, tendon transfer) or percutaneous neuroablative procedures (i.e. cryoneurotomy) which will be done for upper limb refractory spasticity after being triaged by DNB.
223587212|NCT03144869|BEHAVIORAL|physical activity monitor and feedback|Children will wear a Runscribe accelerometer for two weeks (children in Arm 2 will also wear a CGM). Runscribe will measure activity levels. Activity data will be downloaded by a researcher, analysed and graphs of daily activity levels prepared. At the child's next routine clinic appointment, child and parent will have 1:1 session with researcher acting as 'physical activity champion'. Session content will be informed by Phase 1, but will involve educational support around PA (including barriers and facilitators to participation) and individualised feedback on PA level). Individualised feedback will involve review of daily PA graphs - addressing times of high and low activity levels. For participants in Arm 2, there will also be review of daily line graphs showing BG trends. As part of standard clinical care, CGM data gets downloaded at routine clinic appointments and is visible on the patient's clinic notes in daily graph form.
223587213|NCT00676910|DRUG|JNJ-26854165|
223587214|NCT02214745|OTHER|Questionnaire|Questionnaire developed for this purpose by the investigators
223587215|NCT02707796|PROCEDURE|Hemicolectomy|
224307239|NCT01708629|DRUG|210 mg brodalumab|210 mg brodalumab administered SC
224307240|NCT01708629|DRUG|140 mg brodalumab|140 mg brodalumab administered SC
224307241|NCT01708629|DRUG|ustekinumab|45 mg or 90 mg ustekinumab administered SC per the labeled dosing regimen.
224307242|NCT01708629|DRUG|placebo|placebo administered SC
224307243|NCT00523965|DRUG|amphotericin B deoxycholate|Amphotericin B deoxycholate 1 mg/kg on alternate days for 15 infusions
224307244|NCT00523965|DRUG|Liposomal Amphotericin B with Miltefosine|Liposomal Amphotericin B 5 mg Miltefosine 50 mg twice daily if patient weighs equal to or \> 25 kg Miltefosine 50 mg once daily if patient weighs \<25 mg
224307245|NCT00523965|DRUG|Liposomal Amphotericin B and Paromomycin Sulfate|AmBisome 5mg/kg iv infusion over 2 h x 1 day (single dose) + paromomycin sulfate 15 mg/kg/day i.m for 10 days, on day 2-11
223587216|NCT00562562|OTHER|osteopathic manipulative treatment|Treatment will focus on the thoracolumbar junction, L5, the sacrum, and the pubes. Treatment will primarily utilize two techniques, muscle energy and ligamentous-articular release, but will be tailored to the findings of the individual patient.
223587217|NCT03393507|DRUG|Apatinib|500mg,po, adjusted to 250mg if cannot tolerate, 3 weeks a cycle for a total of 6 cycles
224307246|NCT00523965|DRUG|miltefosine + Paromomycin sulfate|oral miltefosine 50mg once daily (\< 25 kg body weight) or twice daily ( \> 25 kg body weight) or 2.5 mg/kg for children under 12 years, for 10 days + Paromomycin sulfate 15 mg/kg/day im. for 10 days
224307247|NCT02901613|DEVICE|Negative-pressure wound therapy|
224307248|NCT02823652|OTHER|standard genetic education|Undergo usual care
224307249|NCT02823652|OTHER|Genetic Counseling|Complete remote counseling
224307250|NCT02823652|OTHER|Genetic Testing|Undergo germline testing
224307251|NCT02823652|OTHER|Internet-Based Intervention|Complete on-line genetic education
224307252|NCT02823652|OTHER|Survey Administration|Ancillary studies
224307253|NCT00415766|DRUG|rHCG 250ug|Injection of 250 ug Ovitrelle to trigger final oocyte maturation
224307254|NCT00415766|DRUG|uHCG 5000 IU|Injection of 5000 IU Pregnyl to trigger final oocyte maturation
224307255|NCT00415766|DRUG|uHCG 7500 IU|Injection of 7500 IU Pregnyl to trigger final oocyte maturation
224307256|NCT00003179|DRUG|medroxyprogesterone|
224307257|NCT01367652|DRUG|Letrozole|2.5 mg tablet
224307258|NCT01367652|DRUG|Letrozole|2.5 mg Tablet
224307259|NCT01302613|DRUG|Capecitabine|Capecitabine will be delivered concurrently with the radiation therapy, at a dose of 1650 mg/m2 divided in even BID doses. It will only be taken on the days of radiation treatment (Monday-Friday, except for holidays). The A.M. dose of the capecitabine must be taken at least one hour prior to the radiation treatment.
224307260|NCT01302613|DRUG|5-FU|5-FU 400 mg/m2, iv bolus on day 1 followed by 2400 mg/m2 iv over 46 hours of each cycle. A cycle is delivered every two weeks. Three cycles will be given prior to the surgery. Five additional cycles will be given after surgery.
224072772|NCT05243927|OTHER|Spinal stabilization exercise program|Spinal stabilization exercises will be performed with a physiotherapist during 40-60 minutes 3 days a week for 8 weeks.
224307261|NCT01302613|DRUG|Leucovorin|Leucovorin 400 mg/m2, IV, over 2 hours before 5-FU on day 1 of each cycle. A cycle is delivered every two weeks. Three cycles will be given prior to the surgery. Five additional cycles will be given after surgery.
224307262|NCT01302613|DRUG|Oxaliplatin|Oxaliplatin 85mg/m2 IV on day 1 of each cycle. A cycle is delivered every two weeks. Three cycles will be given prior to the surgery. Five additional cycles will be given after surgery.
224307263|NCT01302613|RADIATION|radiation|"28-30 fractions of radiation, given once a day, five days per week (Monday-Friday, except for holidays). The prescribed fraction dose is 180 cGy; the total radiation dose is thus 5040-5400 cGy. The primary treatment fields will be treated with 25 fractions of 180 cGy/fraction with a boost of 3-5 fractions of 180 cGy subsequently delivered."
224307264|NCT01302613|PROCEDURE|total mesorectal excision|Optimal surgical technique involving use of total mesorectal excision (TME) is mandated. The type of surgery, either low anterior resection with sparing of the sphincter mechanism or sphincter-eliminating abdominoperineal resection (APR), will be at the discretion of the attending surgeon.
224307265|NCT03763552|OTHER|arthroscopic wrist arthrodesis|Cases of midcarpal wrist arthritis treated surgically with arthroscopic partial wrist fusion with cannulated screws
224307266|NCT00030043|DEVICE|Penetrating auditory brainstem implant|
224179499|NCT01857570|RADIATION|Volume Computed Tomography of the wrist and carpus|
223488711|NCT04529174|DIETARY_SUPPLEMENT|CardioLux™HDL|"Enrollment will occur according to the inclusion/ exclusion criteria and after the review and signing of the Informed Consent form. Clinical testing will be performed at baseline and each visit (2, 3).~Measurement of height, weight with body composition analysis, body mass index, waist circumference, and vital signs (blood pressure, heart rate) will be measured.~Review of medical history and current medications by clinician; and collection of fasting blood for testing of the complete blood count (CBC), comprehensive metabolic profile (CMP), as well as a urine pregnancy test in females of child-bearing potential.~Visits: Baseline (Visit 1), Week 6 (Visit 2) and Week 12 (Visit 3/End of Study)"
223488712|NCT04529174|DIETARY_SUPPLEMENT|Placebo|"Enrollment will occur according to inclusion /exclusion criteria and after the review and signing of the Informed Consent form. Clinical testing will be performed at baseline and each visit (2, 3).~Measurement of height, weight with body composition analysis, body mass index, waist circumference, and vital signs (blood pressure, heart rate) will be measured.~Review of medical history and current medications by clinician; and collection of fasting blood for testing of the complete blood count (CBC), comprehensive metabolic profile (CMP), as well as a urine pregnancy test in females of child-bearing potential.~Visits: Baseline (Visit 1), Week 6 (Visit 2) and Week 12 (Visit 3/End of Study)"
223488713|NCT05810662|OTHER|Lactated ringer and dextrose 5%|Fluid use perioperative
223488714|NCT05496764|DRUG|Dexamethasone|we planned to inject steroid( 4 mg of dexamethasone acetate combined with 1% lidocaine into the carpal tunnels) directly into the carpal tunnel in group A
223488715|NCT05496764|DRUG|Glucose Injection|inject10 ml glucose 5% into the carpal tunnel in group B
223488716|NCT03923920|PROCEDURE|Biopsy|During clinically-scheduled spinal stenosis surgery, ligamentum flavum tissue (which may contain surrounding tissue and subcutaneous fat) that is removed during the procedure will be sent to pathology to be analyzed with amyloid-specific staining.
223488717|NCT00754780|DRUG|Pirfenidone|Capsule 800 mg TID, oral
223488718|NCT01925794|DEVICE|COBRA PzF|
223488719|NCT02066454|DRUG|Apixaban|2.5mg x 2 per day during 6 months
223488720|NCT05930288|BEHAVIORAL|Walking exercise|The target physical activity level for participants is to walk 10,000 steps per day and to meet or exceed that level (but not exceed 15,000 steps) seven days a week for three to four weeks. Participants will be advised to gradually increase their daily step count in proportion to their physical condition. Exercise will be performed by brisk walking or jogging using the indoor treadmill equipped by the Neurosurgery Department of Xiangya Hospital or outdoors. Each workout will begin with a 5-minute warm-up and end with a 5-minute cool-down.
223488721|NCT00790036|DRUG|Everolimus|Everolimus was formulated as tablets of 5 mg strength, blister-packed under aluminum foil in units of 10 tablets.
223587218|NCT03393507|DRUG|Taxus + platinum|Taxanes are paclitaxel or docetaxel, and platinum is carboplatin or cisplatin. Docetaxel injection dose size of 60-75mg / m2, infusion time of 1 hour; paclitaxel injection dose size 135-175mg / m2, infusion time\> 3 hours; injection of carboplatin dose according to the standard formula Calculated, AUC = 4-5, continued intravenous infusion the next day; cisplatin injection dose size of 75-100mg / m2.
223587219|NCT00994591|DRUG|Pharmacokinetic dosing|Pharmacokinetic testing involves dosing with deuterated cotinine which has an associated IND#61329.
223587220|NCT04354272|OTHER|Questionnaire|Questionnaire for the satisfaction of patients consulting the odontological emergencies of the GHPS during COVID 19.
224072773|NCT01676714|DRUG|Dovitinib|
224072774|NCT04034160|OTHER|vegetarian burger|"A finger prick test will be used to determine baseline levels measurements for serum lipids, glucose, and hs-CRP levels. Group 1 will be given vegetarian burgers to consume. Participants will need to remain in the room for 2 hours, postprandial (they may study, watch a movie, etc). They will not be allowed to consume anything except for water during this time. After consumption of burger, at 30 min, 60 min, 120 min, finger prick tests will be used to obtain blood. Participants will also be asked to try and identify the burger they consumed and rate the taste of the burger. Visit 2 will take approximately 3 hours.~* Participants will be directed to fast for 8 hours prior to Visit 3 (the following week).~* Visit 3: We will repeat the same procedure as Visit 2. However, this time the burgers will be switched."
224179500|NCT02173015|OTHER|Compensatory step training|The training consists of a progression of anterior or posterior treadmill belt movements applied as the subject is standing or walking. This training specifically focuses on aspects important to trip and slip recovery. Subjects will participate in up to 6 sessions in 7 to 30 days. The training intensity (magnitude of disturbance delivered) is progressive and dependent on subject performance. Subjects will be instructed to respond with single or multiple steps in order to prevent a fall. All subjects will be outfitted with a safety harness to prevent injury. Up to 72 disturbances will be delivered each session.
224179501|NCT00207831|DRUG|Tegafur and Uracil|
224179502|NCT05273515|OTHER|Virtual Reality and 3D Reconstruction|Using virtual reality and 3D reconstruction to produce personalise images of what participants may look like after 15% and 25% total weight loss.
224179503|NCT04731740|DRUG|Lenvatinib|PO
224179504|NCT04731740|BIOLOGICAL|Pembrolizumab|IV
224179505|NCT04731740|DRUG|Chemotherapy|Investigators' choice
223488722|NCT00790036|DRUG|Everolimus Placebo|Everolimus placebo was formulated as tablets of 5 mg strength, blister-packed under aluminum foil in units of 10 tablets.
223488723|NCT02511353|DRUG|ivermectin|
223488724|NCT02511353|DRUG|placebo|Placebo for ivermectin.
223488725|NCT02511353|DRUG|dihydroartemisinin-piperaquine|
223488726|NCT02598908|DIAGNOSTIC_TEST|Quality control - enzyme activity|A blood sample will be collected from patients and staff donors, no more than twice per year.
223488727|NCT00859118|DRUG|AG-013736|Axitinib 5 mg PO BID x \~2 weeks (12-14 days), followed by 1 week drug break (for cycle 1 only)
223488728|NCT00859118|DRUG|AG-013736|Axitinib 5 mg PO BID x \~2 weeks (12-14 days), followed by 1 week drug break (for cycle 1 only). After Scan#3 obtained, patients will commence with Axitinib 5 mg PO BID continuously without breaks, repeated in 3 week cycles.
223488729|NCT03073759|DEVICE|dTCS|Direct current (DC) (maximum of 2 mA) stimulation delivered through surface electrodes. One electrode will be positioned above the left or right primary motor cortex, the other electrode over the forehead.
223488730|NCT03073759|DEVICE|Sham device|The device will administer a sham.
223488731|NCT03181997|DEVICE|Native aortic valve|Native valve, with any transcatheter heart valve type
223488732|NCT03181997|PROCEDURE|Transcatheter aortic valve implantation (TAVI)|Percutaneous aortic valve implantation preformed in one of these methods: transfemoral, transapical,subclavian or other.
223488733|NCT05926960|DRUG|encorafenib|encorafenib
223488734|NCT05926960|DRUG|binimetinib|binimetinib
223488735|NCT05926960|DRUG|pembrolizumab|pembrolizumab
223488736|NCT05926960|DRUG|ipilimumab|ipilimumab
223488737|NCT05926960|DRUG|nivolumab|nivolumab
223488738|NCT06616818|OTHER|DASH-FV|12weeks of fruit and vegetable delivery to the home
223488739|NCT06616818|OTHER|nutrition counselling only|nutrition counselling as part of standard of care
223488740|NCT05869955|DRUG|CC-97540|Specified dose on specified days
223488741|NCT05869955|DRUG|Fludarabine|Specified dose on specified days
223488742|NCT05869955|DRUG|Cyclophosphamide|Specified dose on specified days
223488743|NCT05869955|DRUG|Tocilizumab|Specified dose on specified days
223488744|NCT04510415|DRUG|Olmutinib|"600 mg QD continuously in 21-day cycles until disease progression determined by investigator assessment per RECIST version 1.1, and as long as, in the investigators opinion, they are benefiting from study treatment and they do not meet any of treatment discontinuation criteria."
224072775|NCT04034160|OTHER|beef burger|"A finger prick test will be used to determine baseline levels measurements for serum lipids, glucose, and hs-CRP levels. Group 2 will be given beef burgers to consume. Participants will need to remain in the room for 2 hours, postprandial (they may study, watch a movie, etc). They will not be allowed to consume anything except for water during this time. After consumption of burger, at 30 min, 60 min, 120 min, finger prick tests will be used to obtain blood. Participants will also be asked to try and identify the burger they consumed and rate the taste of the burger. Visit 2 will take approximately 3 hours.~* Participants will be directed to fast for 8 hours prior to Visit 3 (the following week).~* Visit 3: We will repeat the same procedure as Visit 2. However, this time the burgers will be switched."
223488745|NCT02973620|DRUG|Levosimendan|levosimendan infusion started at 0.1 mcg/kg/min for 6-12 hours, increased to 0.2 mcg/kg/min for 24-36 hours
223488746|NCT05789797|DRUG|Remaxol|Remaxol®, solution for infusions, by intravenous drop infusion in the dose of 400 ml/day, on everyday basis for 12 days
223488747|NCT03033615|DEVICE|PixelShine|Machine learning algorithm
223488748|NCT03033615|DEVICE|Conventional processing|Iterative reconstruction software
223488749|NCT01542281|DIETARY_SUPPLEMENT|Whey protein and dietary supplements|Whey protein and dietary supplements in addition to pre-hab exercise
223488750|NCT01542281|OTHER|prehab exercise|minimum 4 weeks and maximum 8 weeks; 3 times a week
223488751|NCT00169832|DRUG|Rosiglitazone or placebo|Rosiglitazone 4 to 8 mg/day or placebo, for 12 months
223488752|NCT05750706|OTHER|observation of invasive fungal infections|observation of invasive fungal infections during chemotherapy
223488753|NCT04512287|DRUG|Autologous Platelet Rich Plasma|2 sessions of Autologous PRP will be administered 15 days apart. Each injection will be 0.5 mL of PRP injected into the Peyronie's disease penile plaque.
223488754|NCT04512287|OTHER|Saline Solution|2 sessions of saline injection will be administered 15 days apart. Each injection will be 0.5 mL of normal saline injected into the Peyronie's disease penile plaque.
223488755|NCT03390660|OTHER|WIC program participation|WIC program is a welfare program in the U.S. to provide nutritional supplements to low-income women, infants, and children.
223488756|NCT00000964|DRUG|Ranitidine hydrochloride|
223488757|NCT00000964|DRUG|Foscarnet sodium|
223488758|NCT01014091|BIOLOGICAL|GSK pandemic vaccine GSK2340272A|2 intramuscular injections
223488759|NCT06217549|OTHER|ozone therapy|Medical ozone is a mixture of pure ozone gas (0.05-5%) and pure oxygen (99.95-95%). It is produced from pure medical oxygen by medical ozone generators. It is applied to the participants 10 sessions by the intravenous method.
224072776|NCT04674631|OTHER|The effect of neuropathic pain on quality of life, depression and sleep quality|The effect of neuropathic pain on quality of life, depression and sleep quality
224072777|NCT01272999|OTHER|No intervention|Non interventional
224072778|NCT05912465|OTHER|Stress Reduction Training|A subgroup of patients from Vienna will undergo an additional PET/CT scan after the first follow-up PET/CT, which takes place one month after stress reduction training. The stress reduction training involves performing a breathing technique.
224072779|NCT02554539|PROCEDURE|Endometrial fluid aspiration|Patient will undergo a biopsy to aspirate endometrial fluid from the uterine cavity
224179506|NCT00776828|DRUG|cilostazol|Pletaal (Otsuka Pharm.) 100mg bid for six months
223488760|NCT04724668|DIETARY_SUPPLEMENT|Melatonin (3hrs before DLMO)|Melatonin 3mg (3hrs before DLMO)
223488761|NCT04724668|DIETARY_SUPPLEMENT|Placebo (3hrs before DLMO)|Placebo capsule (3hrs before DLMO)
223488762|NCT04724668|DEVICE|Morning light version 1|Morning light version
223488763|NCT04724668|DEVICE|Morning light version 2|Morning light version
223488764|NCT04545242|DRUG|Dexamethasone|Intravenous dexamethasone (low vs. moderate doses) during 10 days
223488765|NCT04003285|DRUG|Placebo|ALLO 0 nM (placebo: loading dose, 4-hour infusion, taper)
223488766|NCT04003285|DRUG|Allopregnanolone|ALLO 50 nM (lower dose ALLO: loading dose, 4 hour infusion, taper)
223488767|NCT04003285|DRUG|Allopregnanolone|ALLO 150 nM (higher dose ALLO: loading dose, 4 hour infusion, taper)
223488768|NCT06330675|OTHER|Early mobilization|Short-term bed-rest and immobilization
223488769|NCT06330675|OTHER|Standard of care|Bed-rest and immobility until the day-after procedure
223488770|NCT05841056|DRUG|Amiodarone Hydrochloride 200 MG|200 mg daily for 4 weeks
223488771|NCT05703373|DIETARY_SUPPLEMENT|Multiple Micronutrient Supplement|Multiple micronutrient supplementation (MMS) which includes iron, folic acid, and additional micronutrients,
223488772|NCT06433960|DIAGNOSTIC_TEST|Modified Allen Test|"Pre-operative intervention aimed at evaluating if forearm blood vessels (ulnar artery and collateral) would supply an adequate blood flow to the arm if the radial artery was harvested. Duration: 1 minute.~Instruct the patient to clench their wrist while the examiner occlude with three fingers the patients ulnar and radial arteries; instruct the patient to unclench their wrist; release the ulnar artery. The MAT result is negative or positive considering in how long the palm flushes:~≤5 seconds: negative MAT; good collateral hand circulation (suggesting harvestable radial artery).~greater than 5 seconds: positive MAT; poor collateral hand circulation (suggesting not-harvestable radial artery)."
223488773|NCT06433960|DIAGNOSTIC_TEST|Pulse-oximetry guided Modified Allen Test|"Pre-operative intervention aimed at evaluating if forearm blood vessels (ulnar artery and collateral) would supply an adequate blood flow to the arm if the radial artery was harvested. Duration: 1 minute.~A pulse-oximetry probe is positioned on the patients index finger; both radial and ulnar arteries are occluded by the examiner (with three fingers) until flattening of pulse waveform is obtained. Pressure on the ulnar artery is released and the result of the assessment is calculated considering in how long the pulse waveform returns to baseline:~≤5 seconds: negative result (suggesting harvestable radial artery). greater than 5 seconds: positive result (suggesting not harvestable radial artery).~(Busti and Kellogg, 2015)"
223488774|NCT06433960|DIAGNOSTIC_TEST|Barbeau Test|"Pre-operative intervention aimed at evaluating if forearm blood vessels (ulnar artery and collateral) would supply an adequate blood flow to the arm if the radial artery was harvested. Duration: 2 minutes.~A pulse-oximetry probe is positioned on the patients thumb; the radial artery is then compressed by the examiner, and the pulse waveform is analysed for up to 120 seconds, providing four result patterns of ulno-palmar patency:~1. No damping of the pulse tracing immediately after compression (suggesting harvestable radial artery)~2. Damping of the pulse tracing (suggesting harvestable radial artery)~3. Loss of the pulse tracing, followed by recovery within 120 sec (suggesting harvestable radial artery)~4. Loss of the pulse tracing, without recovery within 120 sec (suggesting not harvestable radial artery).~(Zalocar et al., 2020)"
224072780|NCT02022982|DRUG|Palbociclib|Palbociclib will be administered orally once daily, 3 weeks out of every 4 in each cycle. The initial dose for phase 1 of the study will be 75 mg daily. Dosing will be adjusted until Maximum Tolerated Dose (MTD) and the Recommended Phase 2 Dose (RP2D) are established. No pre-medications for palbociclib are required. It should be administered without food with patients fasting for 1 hour prior and 2 hours post drug administration.
224072781|NCT02022982|DRUG|PD-0325901|PD-0325901 will be administered orally twice daily, 3 weeks out of every 4 in each cycle. The initial dose for phase 1 of the study will be 2 mg twice daily. Dosing will be adjusted until Maximum Tolerated Dose (MTD) and the Recommended Phase 2 Dose (RP2D) are established. PD-0325901 will be administered using a flat-dosing plan. No premedications are required. As the effect of food on PD-0325901 is uncertain, patients will be permitted to dose either fasting or after food.
224072782|NCT01777152|DRUG|brentuximab vedotin|1.8 mg/kg every 3 weeks by IV infusion for 6-8 cycles
224072783|NCT01777152|DRUG|doxorubicin|50 mg/m2 every 3 weeks by IV infusion for 6-8 cycles
224072784|NCT01777152|DRUG|prednisone|100 mg on Days 1 to 5 of each 3-week cycle, orally for 6-8 cycles
224072785|NCT01777152|DRUG|vincristine|1.4 mg/m2 (maximum 2 mg) every 3 weeks by IV infusion for 6-8 cycles
224072786|NCT01777152|DRUG|cyclophosphamide|750 mg/m2 every 3 weeks by IV infusion for 6-8 cycles
224072787|NCT03931278|OTHER|learning and recall of a sequence of body movements|The objective of this study to investigate, if learning and recall of a sequence of body movements (steps that realize a pattern on the ground) can be improved by self-produced music (having particular melodic-structures in relation to the pattern), compared to the same sound (a single tone) for each pattern in persons
224072788|NCT02534259|OTHER|Force monitoring of external fixator struts|
224072789|NCT04580290|DEVICE|JewelACL|The JewelACL is a polyester scaffold for anterior cruciate ligament (ACL) reconstruction
224072790|NCT03096509|OTHER|MISSION ABC Integrated Care clinic|The Investigators have developed a model of care incorporating key innovations for patients with asthma, COPD and undifferentiated breathlessness. This service is being implemented within Wessex CCGs.
224072791|NCT02469090|DRUG|APL-130277|"Use to treat up to 5 OFF episodes per day"
224072792|NCT02469090|DRUG|Placebo|placebo
224072793|NCT05359978|BEHAVIORAL|To with significance activities|activities with purpose with people who are diagnosed of dementia 2 days at week during 30 minutes
224072794|NCT02085499|OTHER|non-synchronized NIMV|"During the study each infant will undergo a 2-hour period of NIMV at a frequency of 30 cycles per minute.~NIMV will be provided by a time cycled, pressure limited neonatal ventilator (Puritan Bennett 840, Covidien, Boulder, CO)."
224072795|NCT02085499|OTHER|Synchronized NIMV|"During the study each infant will undergo a 2-hour period of S-NIMV at a frequency of 30 cycles per minute.~S-NIMV will be provided by a time cycled, pressure limited neonatal ventilator, with leak compensation capacity and nasal flow triggered ventilation (Puritan Bennett 840, Covidien, Boulder, CO). Synchronization will be achieved by the leak compensation software and the internal sensor of the ventilator."
224072796|NCT03581851|DEVICE|Simulated Altitude: (FiO2: 15.1)|"Inhalation of deoxygenated air through an altitude simulator (Altitrainer) for approximately 1 hour given by a facemask."
224072797|NCT03581851|DEVICE|Shamed Hypoxia (FiO2: 20.9)|"Inhalation of unmodified air through an altitude simulator (Altitrainer) for approximately 1 hour given by a facemask."
224072798|NCT04405375|DRUG|gemcitabin|1.25g/㎡ d1, repeated every 21 days
224072799|NCT04405375|DRUG|Pegaspargase|2500IU/㎡ d1, total dose=\<3750IU, repeated every 21 days
224072800|NCT04405375|DRUG|Etoposide|75mg/㎡ d1-3, repeated every 21 days
224072801|NCT04405375|DRUG|Dexamethasone|20mg d1-4
224072802|NCT02498873|BEHAVIORAL|Linear Periodization|Linear Intensity Periodization Running
224072803|NCT02498873|BEHAVIORAL|Non Linear Periodization|Non Linear Periodization Running
224072804|NCT05215600|DEVICE|Anaverse Shoulder System|Reverse Shoulder Arthroplasty
224072805|NCT05206838|PROCEDURE|Surgical reconstruction of gluteus medius with Achilles tendon allograft|Achilles tendon allograft i fixed between the gluteus medius muscle and the greater trochanter
224072806|NCT05944432|DEVICE|FreeStyle Libre 3 Continuous Glucose Monitoring System.|Subjects will be randomised to use the FreeStyle Libre 3 system
224072807|NCT05944432|DEVICE|Self monitoring of blood glucose|Subjects will be randomised to continue with their current glucose monitoring system
224072808|NCT05625321|BEHAVIORAL|Educational Group Weight Loss Classes|Participants will be provided with educational materials on weight loss, and have opportunities to increase their exercise and make changes to their diet.
224072809|NCT05625321|BEHAVIORAL|Home Gardening Intervention|Participants will receive tools to establish their own home garden, increasing their access to fresh fruits and vegetables.
224072810|NCT01391507|DRUG|0.9 % sodium chloride|Monthly intravenous injection for 6 months
224072811|NCT01391507|DRUG|COR-1|Monthly intravenous injection for 6 months
224179507|NCT06161766|DRUG|terlipressin or noradrenalin plus albumin|Patients with clinical suspicion of HRS-AKI or HRS-AKI-like syndrome in case of previously diagnosed CKD who had received vasoactive treatment for the management of HRS, as defined by the administration of terlipressin or noradrenalin plus albumin.
224179508|NCT03764241|DRUG|Rivaroxaban|Rivaroxaban 15mg/QD will be applied for 3 months unless severe safety outcome occurs. All patients in both group will take aspirin 100mg/QD, clopidogrel 75mg/QD and proton pump inhibitor during the intervention.
224179509|NCT03764241|DRUG|Vitamin K Antagonist|warfarin (INR 2.0-2.5) will be applied for 3 months unless severe safety outcome occur. All patients in both group will take aspirin 100mg/QD, clopidogrel 75mg/QD and proton pump inhibitor during the intervention.
224179510|NCT03348306|DEVICE|MRI|Brain and cardiac MRI in one time with gadolinium injection.
224179511|NCT03348306|BIOLOGICAL|Blood sample collection|A blood sampling is also collected for hematocrit measure.
224179512|NCT00060320|DIETARY_SUPPLEMENT|black cohosh|
223488775|NCT06433960|DIAGNOSTIC_TEST|Ultrasound examination of the forearm arteries|"Pre-operative intervention aimed at evaluating morphological characteristics (diameter, presence of calcifications) of the radial and ulnar arteries. Duration: 5 minutes.~The radial artery is surgically exposed (negative result) when the following apply:~1. ulnar artery inner diameter ≥2 mm~2. radial artery inner diameter ≥2 mm~3. absence of radial artery intraluminal calcifications and plaques.~(Vukovic et al., 2017)"
223488776|NCT06433960|DIAGNOSTIC_TEST|Measurement of oxygen saturation|"Intra-operative intervention aimed at evaluating the blood oxygen level in the hand if the radial artery was harvested. Duration: 1 minute.~The radial artery is surgically harvested when the oxygen saturation reading (SpO2) from the thumb through pulse-oximetry remains at 95% or above when an occlusive atraumatic clamp is applied on the mobilised radial artery."
224072812|NCT01391507|DRUG|Standard therapy for heart failure|All patients will continue to receive standard therapy for heart failure (ie, in accordance with guidelines) throughout the study.
224072813|NCT02490514|OTHER|No intervention|No intervention was administered in this study.
224072814|NCT02092194|PROCEDURE|High Dose Online HDF|Convection volume; 33-43 L/treatment (140-180 mL/min)
224072815|NCT02092194|PROCEDURE|Standard Dose Online HDF|convection volume; 16.8-21.5 L/treatment (70-90 mL/min)
224072816|NCT02926209|DEVICE|Aer-O-Scope (Colonoscopy)|"Patients in the Aer-O-Scope first arm will undergo a colonoscopy with the Aer-O-Scope, removing any polyps detected, followed by a colonoscopy using a conventional colonoscope, removing any polyps not previously detected with the Aer-O-Scope."
224072817|NCT02926209|PROCEDURE|Colonoscopy (Conventional Colonoscope)|"Patients in the conventional colonoscope first arm will undergo a colonoscopy with a conventional colonoscope, removing any polyps detected, followed by a colonoscopy using the Aer-O-Scope, removing any polyps not previously detected with the conventional colonoscope"
224072818|NCT05148923|PROCEDURE|Direct current cardioversion (DCCV)|DCCV is a safe and effective method of treating atrial fibrillation.
224072819|NCT05462210|OTHER|Mobilization Protocol Assisted with Simulated Clinical Immersion Videos|Mobilization Protocol Assisted with Simulated Clinical Immersion Videos Simulated clinical immersion videos created for the mobilization protocol for patients in the intervention group will be sent to their smartphones once they are admitted to the clinic. The videos prepared within the scope of the mobilization protocol will be watched by patients in company with the researcher the day before the operation, their questions will be answered, and the correct mobilization techniques will be shown practically. It is expected that patients watch the videos at least four times, as twice with the researcher and twice by themselves.
224072820|NCT03961282|OTHER|Doorway Width Test|The first test consists of Doorway Width. Standard level is a doorway width of 30 inches; Enhanced is doorway width of 36 inches; Co-design allows the participant to adjust the width anywhere from 26 to 48 inches.
224072821|NCT03961282|OTHER|Door Frame Color Test|The second test consists of Door Frame Color. Standard level is same color (hue) as light-color wall; Enhanced level is same hue but of higher color intensity for contrast; Co-design allows the participant to adjust the color intensity range from lowest (same as wall) to highest intensity (stronger contrast than in Enhanced).
224072822|NCT01183273|PROCEDURE|Microlaparoscopic gastric bypass|microlaparoscopic gastric bypass will be performed using standard of care procedure.
224072823|NCT01183273|PROCEDURE|Laparoscopic Surgery|laparoscopic gastric bypass will be performed using standard of care procedure.
224072824|NCT04668352|DRUG|Dactolisib|TORC1 inhibitor
224072825|NCT04668352|OTHER|Placebo|Placebo
224072826|NCT00577993|DRUG|Fludarabine|Group 1= 25 mg/m\^2 IV over 15 min. Days 2 through 4 for 8 Cycles; Group 2 = 25 mg/m\^2 IV over 15 min. Days 1 through 3 for 8 Cycles.
224072827|NCT00577993|DRUG|Novantrone|Group 1 = 10 mg/m\^2 IV over 15 min. Day 2 for 8 Cycles; Group 2 = 10 mg/m\^2 IV over 15 min. Day 1 for 8 Cycles; Group 3 = 10 mg/m\^2 IV over 15 min. Day 2 of 3rd Sequence.
224072828|NCT00577993|DRUG|Decadron|Group 1 = 20 mg IV over 15 min. Days 1 through 5 for 8 Cycles, then Days 1 through 3 Every Month for 1 Year; Group 2 = 20 mg IV over 15 min. Days 1 through 5 for 8 Cycles, then Days 1 through 3 Every Month for 1 Year; Group 3 = 40 mg PO Days 1 through 4 of 1st Sequence; After Completion of 3 Sequences, Days 1 through 3 Every Month for 1 Year.
224072829|NCT00577993|DRUG|Rituximab|Group 1 = 375 mg/m\^2 IV Days 1 through 8 of Course 1, then Day 1 Only of Cycles 2 through 5; Group 2 = 4 Months after IFN Starts, 375 mg/m\^2 IV Once Per Month for 6 Months; Group 3 = 375 mg/m\^2 IV Days 1 through 8 of 1st Sequence; 375 mg/m\^2 IV Days 1 through 8 of 3rd Sequence.
224072830|NCT00577993|DRUG|Interferon|Group 1 = After Completion of Fludarabine, Novantrone, \& Rituximab, IFN 3 mcg/ml/m\^2 SQ Days 1 through 14 Each Month for 1 year; Group 2 = After Completion of Fludarabine \& Novantrone, IFN 3 mcg/ml/m\^2 SQ Days 1 through 14 Each Month for 1 year; Group 3 = After Completion of 3 Sequences, IFN 3 mcg/ml/m\^2 SQ Days 1 through 14 Each Month for 1 year.
224072831|NCT00577993|DRUG|Doxorubicin|25 mg/m\^2 IV Days 2 \& 3 of 1st Sequence.
224072832|NCT00577993|DRUG|Vincristine|.7 mg/m\^2 IV Days 2 \& 3 of 1st Sequence; 1.4 mg/m\^2 IV Day 2 of 3rd Sequence.
224072833|NCT00577993|DRUG|Bleomycin|5 unit/m\^2 IV Days 2 \& 3 of 1st Sequence.
224072834|NCT00577993|DRUG|Cyclophosphamide|750 mg/m\^2 IV Day 2 of 1st Sequence.
224072835|NCT00577993|DRUG|Etoposide|40 mg/m\^2 IV Days 1 through 4 of 2nd Sequence.
224179513|NCT00060320|OTHER|placebo|
224179514|NCT02728141|OTHER|Water|2 ml distilled water by syringe one time in the newborn's mouth 2 minutes before heel stick
224179515|NCT02728141|OTHER|Sucrose|2 ml 25% sucrose in distilled water by syringe one time in the newborn's mouth 2 minutes before heel stick
223488777|NCT06433960|OTHER|Radial Artery Quality Evaluation Survey|"Intra-operative intervention (validated structured questionnaire) aimed at evaluating anatomical and physiological characteristics of the radial artery and suitability for coronary graft implantation.~The radial artery is surgically harvested when its morphology and pathology (diameter, calcifications, presence of pulsatile flow), quality of harvesting technique and surgical accessibility are considered satisfactory, good or optimal.~The Radial Artery Quality Evaluation Survey is completed by surgical care practitioners."
223488778|NCT06433960|OTHER|Follow-up Radial Artery Harvesting Scale|"Postoperative intervention (ordinal symptoms scale) aimed at evaluating patients finger movements, cold tolerance sensitivity and tactile/touch perception at post-operative day 2 to 5 and at follow-up appointment (3-6 weeks after surgery). Bilateral comparison between hands and forearms is undertaken. Tactile perception is assessed through monofilaments (single touch). Cold sensitivity is assessed through the use of ice-pack.~The Follow-up Radial Artery Harvesting Scale was developed from a verbal rating scale (VRS) questionnaire documented in the literature. The VRS questionnaire was re-adapted to appreciate people postoperative experience with their finger movements, cold sensitivity and tactile/touch perception of their forearm."
224179516|NCT05208710|BIOLOGICAL|Vaccination with PANHPVAX 10µg|Escalated dosages of c-di AMP (0, 7,5, 15µg) added groupwise to 10µg antigen
224179517|NCT05208710|BIOLOGICAL|Vaccination with PANHPVAX 40µg|Escalated dosages of c-di AMP (0, 7,5, 15µg) added groupwise to 40µg antigen
224179518|NCT05208710|BIOLOGICAL|Vaccination with PANHPVAX 100µg|Escalated dosages of c-di AMP (0, 7,5, 15µg) added groupwise to 100µg antigen
224179519|NCT04456621|RADIATION|PBT|Proton beam radiotherapy 70 gray relative biological equivalent (GyRBE)/10 fractions (Fx) or 60 GyRBE/5 Fx
224179520|NCT03504059|BEHAVIORAL|Long-term educational program|Comprehensive educational school-based intervention in adolescents on cardiovascular health, including obesity/adiposity and metabolic profiles, through classroom intervention, and complementary intervention in the family setting, at school and on teachers.
224179521|NCT03504059|BEHAVIORAL|Short-term educational program|Comprehensive educational school-based intervention in adolescents on cardiovascular health, including obesity/adiposity and metabolic profiles, through classroom intervention, and complementary intervention in the family setting, at school and on teachers.
224179522|NCT05083975|DEVICE|Buzzy System|Vibrating Device
224307267|NCT06002737|DEVICE|Occlusion of blood vessels with a diameter greater than 5mm and less than or equal to 7mm using harmonic scalpel|Screening of lung or esophageal surgery patients who meet the inclusion criteria but do not meet the exclusion criteria, and evaluating the effectiveness and safety of ultrasound scalpel in the process of coagulation of blood vessels with a diameter greater than 5mm but not equal to 7mm.
224307268|NCT01666197|DRUG|diclofenac potassium 25 mg tablet|diclofenac potassium 25 mg tablet
224307269|NCT01666197|DRUG|placebo|placebo
223488779|NCT03126110|DRUG|INCAGN01876|In Phase 1 participants will receive INCAGN01876 administered intravenously (IV) at the protocol-defined dose according to cohort enrollment. In Phase 2, participants will be administered IV study drug at the recommended dose from Phase 1 ().
223488780|NCT03126110|DRUG|Nivolumab|Nivolumab will be administered IV at the protocol-defined dose according to assigned treatment group.
223488781|NCT03126110|DRUG|Ipilimumab|Ipilimumab will be administered IV at the protocol-defined dose according to assigned treatment group.
223488782|NCT06489483|BEHAVIORAL|Action Regulation Movement Task|A joystick is utilized to trace the movement of a visual stimulus on a computer screen. In stop signal task, the subjects are required to move a reference dot to reach to a target dot by controlling a joystick and stop their movements when the target turns red. During the switch task, subjects will be required to switch their joystick movement trajectory when the target location is switched to one of the other target locations.
224179523|NCT05083975|DRUG|Topical anesthetic|20% benzocaine gel (Opahl Topical Gel)
224179524|NCT05083975|DRUG|1.8 ml of 4% articaine hydrochloride with epinephrine 1:100,000|Local dental anesthetic agent
224179525|NCT04766788|OTHER|Wearable devices, saliva samples, survey measures|Provide a self-collected saliva sample, download and use the suite of apps (e.g., Fitbit, Social Rhythms, Roadmap 2.0), and answer online surveys.
224179526|NCT01411761|DIETARY_SUPPLEMENT|Reflor|5 million unit/day, first 15 day of life
224179527|NCT01411761|OTHER|serum physiologic|1 cc added to one feeding in a day
224179528|NCT00354991|DRUG|losartan potassium (+) hydrochlorothiazide|Patients took losartan 50 mg /HCTZ 12.5 mg orally once daily for 13 weeks. At Weeks 0, 4 and 8 if the blood pressure goal was not reached then the losartan/HCTZ combination will be titrated upwards according to the following scheme: losartan 50/HCTZ 12.5 to losartan 100/HCTZ 12.5 to losartan 100/HCTZ 25.
224179529|NCT02531074|BEHAVIORAL|Mobile Application|
224307270|NCT00630097|DRUG|modafinil|Modafinil, 100mg, 400mg, or 600 mg tablets QD for 4 weeks.
223488783|NCT04892901|PROCEDURE|c-ESPB|In the c-ESPB group an ultrasound-guided ESPB will be performed by the attending anaesthesiologist at the end of surgery, immediately after the last surgical stitch and before extubation. After an initial bolus of 20 ml 0,2% ropivacaine, a catheter will be left in place into the fascial plane deep to the erector spinae muscle to ensure continuous infusion (5ml/h for 48 hours) of the local anesthetic.
223488784|NCT04892901|PROCEDURE|c-SAPB|In the c-SAPB group SAPB will be performed by surgeons intraoperatively, immediately before the closure of chest wall muscle planes, by injection of 20 ml 0,2% ropivacaine into the fascial plane above the Serratus Anterior muscle. After the initial bolus, a catheter will be left in place into the superficial fascial plane of the Serratus Anterior muscle to ensure continuous infusion (5ml/h for 48 hours) of the local anesthetic.
224179530|NCT02531074|BEHAVIORAL|Food Journal|
224179531|NCT02531074|BEHAVIORAL|Usual Care|
224179532|NCT01481480|PROCEDURE|Latissimus dorsi tendon transfer|Latissimus dorsi tendon transfer
224179533|NCT01481480|PROCEDURE|Arthroscopic repair|Arthroscopic repair
224179534|NCT01243047|DRUG|Chemotherapy|Erlotinib, Oxaliplatin, Capecitabine
224307271|NCT01159197|BEHAVIORAL|cognitive behavioral therapy|Participants who randomized into the CBT group will receive 18 30-minute tri-weekly treatment sessions of CBT during the 6-week period
224307272|NCT04971798|BIOLOGICAL|Cell-free Stem Cell-derived Extract Formulation (CCM)|Intraarticular injection
223488785|NCT04892901|PROCEDURE|ICNB|"In the ICNB-group ICNB will be performed by surgeons intraoperatively, immediately before chest drain placement, by injection of 20 ml of 0,2% ropivacaine into the intercostal spaces (III-VII), below the parietal pleura, under direct visualization of the neurovascular bundle. The one-shot ICNB will be associated in this group with intravenous administration of tramadol (300 mg/48 h) by elastomeric pump."
223488786|NCT06305676|DIAGNOSTIC_TEST|combined HPV 16 DNA and host gene methylation oral biomarker panel|DNA Methylation Profiling
223488787|NCT04235374|BEHAVIORAL|FFC-AC-EIT|The two intervention arms will receive the same educational information. The education group will not be exposed to any other activities. The FFC-AC-EIT will focus strongly on motivation of staff and patients to get the patients engaged in functional and physical activities.
223488788|NCT05029869|DIAGNOSTIC_TEST|ctDNA|The blood samples for ctDNA and other tumor markers will be first collected within 14 days before surgery, and then be tested after gastrectomy in scheduled interval
223488789|NCT05858164|DRUG|BAY2862789|Oral administration, solution or tablets
223488790|NCT05785845|RADIATION|Computed tomography-guided stereotactic adaptive radiotherapy|Fractions will be delivered on consecutive business days.
223488791|NCT05785845|DEVICE|ETHOS|ETHOS is a unique ring-gantry CT-guided linear accelerator notable for having an on-board cone beam CT (CBCT) imaging unit with improved definition and resolution to enable target and organ-at-risk contouring. It also has a dedicated artificial intelligence treatment planning system to allow for online adaptive radiotherapy.
223488792|NCT05050799|DEVICE|Central Venous Access|The Surfacer® Inside-Out® Access Catheter System is intended to obtain central venous access to facilitate catheter insertion into the central venous system for patients with upper body venous occlusions or other conditions that preclude central venous access by conventional methods.
224072836|NCT00577993|DRUG|Cisplatin|25 mg/m\^2 IV Days 1 through 4 of 2nd Sequence
224072837|NCT00577993|DRUG|Ara-C|1.5 gm/m\^2 IV Day 5 of 2nd Sequence.
224072838|NCT00577993|DRUG|Methyl-Prednisolone|500 mg IV Days 1 through 5 of 2nd Sequence.
224072839|NCT00577993|DRUG|Procarbazine|100 mg/m\^2 PO Days 2 through 11 of 3rd Sequence.
224072840|NCT00577993|DRUG|Prednisone|100 mg PO Days 1 through 5 of 3rd Sequence.
224072841|NCT01515774|DRUG|Mirapex ER|Change Requip or Mirapex to Mirapex ER
224072842|NCT01847885|DEVICE|Smartpatch Peripheral Nerve Stimulation (PNS) System|"The Smartpatch System is an Investigation Device which delivers mild electrical stimulation to the muscles in the shoulder. The Smartpatch System includes a small wire (called a Lead) that is placed through the skin into the muscle of the shoulder. It also includes a device worn on the body that delivers stimulation (called the Smartpatch Stimulator)."
224072843|NCT04397705|DEVICE|Patient Status Engine|Wearable sensors
224072844|NCT00079859|DRUG|Implitapide|
224072845|NCT04123899|DRUG|IGAD→GSTD|"Drug: IGAD First Period: Single oral administration of 1 tablet of Gaster®D Tab 20mg (Famotidine) (Unchanged Manufacturer, Announced Reference Drug)~Other: Washout period 7 days~Drug: GSTD Second Period: Single oral administration of 1 tablet of Gaster®D Tab20mg (Famotidine) (Changed Manufacturer)"
224072846|NCT04123899|DRUG|GSTD→IGAD|"Drug: GSTD First Period: Single oral administration of 1 tablet of Gaster®D Tab20mg (Famotidine) (Changed Manufacturer)~Other: Washout period 7 days~Drug: IGAD Second Period: Single oral administration of 1 tablet of Gaster®D Tab 20mg (Famotidine) (Unchanged Manufacturer, Announced Reference Drug)"
224072847|NCT02424838|PROCEDURE|EUS-FNA of pancreatic masses|EUS-FNA of pancreatic masses will be performed using a 22 or a 25 gauge needle with or without applying suction.
224072848|NCT02424838|DEVICE|22 gauge needle|
224072849|NCT02424838|DEVICE|25 gauge needle|
224072850|NCT01028807|OTHER|Early feeding|after 24 hours fasting period, with good abdominal conditions (once flatus passage of bowel movements without abdominal distention, vomiting, nausea or ileus) the oral fluids during 24 hours and then advanced to a regular diet as tolerated.
224072851|NCT01028807|OTHER|5 day fasting|Obligatory 5-day fasting because it was the therapeutic gold standard at our hospital and our country. Both groups without NGT and antiemetic drug. 5-day antibiotic regimen, ranitidine and appropriate analgesics were used. Once the regular diet was tolerated, the patients were discharged and followed up at clinic 30 days afterwards.
224072852|NCT05997641|DRUG|DF-003|Oral administration by capsules (1 mg, 5 mg, or 25 mg).
224072853|NCT05997641|DRUG|Placebo|Visually matching 0 mg DF-003 capsules.
224072854|NCT05060588|DRUG|Sacubitril/Valsartan 49/51mg/Tab|patients who meet the inclusion criteria are randomized to receive Sacubitril/Valsartan 24/26 mg once every 12 hours for 6 months
224072855|NCT05060588|DRUG|Valsartan 80mg/Tab|Patients who meet the inclusion criteria are randomized to receive valsartan one tablet every 24 hours for 6 months.
224072856|NCT00006479|DRUG|FOLFOX regimen|
224072857|NCT00006479|DRUG|fluorouracil|
224072858|NCT00006479|DRUG|leucovorin calcium|
224072859|NCT00006479|DRUG|oxaliplatin|
224072860|NCT00006479|PROCEDURE|adjuvant therapy|
224072861|NCT00006479|PROCEDURE|conventional surgery|
224072862|NCT00006479|PROCEDURE|neoadjuvant therapy|
224072863|NCT02889458|OTHER|Not Provided|
224072864|NCT01568606|DEVICE|Body Composition Analysis InBody Scale|"Patients will have their ICD interrogated using a pacemaker Programmer specifically designed from one of the 4 pacemaker manufacturers: St. Jude, Medtronic, Guidant, and Biotronik. Depending on the type of pacemaker, interrogation can be done either wirelessly or by placing a wand over the pacemaker. The ICD will be turned to a monitor-only mode to disable risk of ICD shock by the supervising electrophysiologist. Patient will be asked to step on the InBody 520 scale to have their body composition analyzed. Patient will continue to have their ICD actively monitored. Analysis will take approximately 30 - 50 seconds. At the end of analysis, ICD device will be returned to default settings by supervising electrophysiologist."
224072865|NCT05946408|OTHER|Supervised antenatal exercises|"Supervised antenatal exercises along with education twice a week. Protocol consists of warm up (10 min), Aerobic training (20 mins, 60-75% of max. HR), Strength training (25 minutes), followed by a cool down of 15 minutes.~The Interventions to be provided for a period of 12 weeks."
224072866|NCT05946408|OTHER|Antenatal Education|Antenatal education at 12th week of pregnancy. Which consists of education on Posture in pregnancy, Role of pelvic floor muscles, Labor and breathing and relaxation techniques.
223488793|NCT04825132|OTHER|Geriatric assessment tools|Multidimensional Prognostic Index (Living status, medications, ADL, IADL, MMSE mental evaluation, ESS pressure sores, chronic disease, nutritional assessment)
223488794|NCT03426865|DRUG|Axumin PET scan|PET scan prior to RPLND
223488795|NCT06179069|DRUG|ZL-1310|Drug: ZL-1310
223488796|NCT06179069|DRUG|Atezolizumab|Drug Atezolizumab
223488797|NCT06179069|DRUG|Carboplatin|Drug Carboplatin
223488798|NCT06141135|OTHER|Preimplantation genetic testing for aneuploidy (PGTA)|24 chromosome screening for aneuploidy in the preimplantation embryo(blastocyst stage)
223488799|NCT02368496|DEVICE|HR-pQCT|
223488800|NCT04744623|DRUG|large dose of prednisolone plus intra-lesional of Triamcinolone Acetonide followed the systemic combination of mycophenolate mofetil (MMF), dapsone and low dose prednisolone in treatment of MMP|10 patients suffering from MMP were selected after complete diagnosis based on their clinical diagnosis and immunopathologic findings of IgG, IgA, and/or C3 targeting skin basement membranes with a linear deposition pattern refered from dermatology department. These patient were treated using large dose of prednisone 60mg daily plus intrational injection of Triamcinolone Acetonide every week until no further improvement of the lesion occurred (stage I) then the prednisolone is withdrawn gradually and substituted with using 1 g of MMF plus 50 mg dapsone till the lowest dose of prednisone could be reached (stage II).
223488801|NCT04171622|DRUG|Lenvatinib|Given PO
223488802|NCT04171622|BIOLOGICAL|Pembrolizumab|Given IV
223488803|NCT06337552|OTHER|FEED-FF|3-6 servings of any combination of the following fermented foods/day (from 1 week prior to treatment to approximately 12 weeks after the start of treatment): Yogurt, cottage cheese, kefir, kombucha, sauerkraut, and kimchi.
223488804|NCT06337552|OTHER|Standard of Care (SUC)|Standard of Care (SUC) is the treatment that is accepted by medical experts as a proper treatment for a certain type of disease and that is widely used by health care professionals. Standard of Care will comprise general healthy eating handouts that describe typical healthy foods and the suggested level of servings per day.
223488805|NCT00361985|DRUG|Esomeprazole|Esomeprazole 40mg once daily orally.
223488806|NCT00361985|DRUG|Esomeprazole|Esomeprazole 40mg once daily orally
224205609|NCT06568770|DRUG|PERICAPSULAR NERVE BLOCK|"an ultrasound probe will be placed over the line joining anterior superior iliac spine (ASIS) and pubic tubercle (PT) keeping lateral margin at ASIS and adjusted the probe to get a sonoanatomic view for PENG block. The needle entry point will be selected on the skin in such a manner that perpendicular needle entry will guide needle near target point iliopectineal eminence (IPE). The needle entry point will be anaesthetized with 2 ml 1% lidocaine and 22G 80mm stimuplex needle will be inserted out-of- plane to reach the bony rim near IPE avoiding injury to femoral nerve (visible just lateral to femoral artery). On bony contact, 20 ml 0.5% bupivacaine will be injected slowly with repeated aspiration to avoid intravascular injection. The correct needle position will be confirmed by drug spread under ilio-psoas muscle and then the rest of the drug volume will be injected."
223488807|NCT04907266|OTHER|Structured Questionnaire|A structured proforma to assess outcome
223488808|NCT05917340|DRUG|High dose rifampicin (25mg/kg)|Given for 2 months
223488809|NCT05917340|DRUG|Moxifloxacin 400mg|Given for 2 months
223488810|NCT05917340|DRUG|Aspirin 150 mg|Given for 2 months
223488811|NCT05917340|DRUG|Isoniazid|Given for 6 months
223488812|NCT05917340|DRUG|Pyrazinamide|Given for 6 months
223488813|NCT05917340|DRUG|Steroid|Tapering dose of dexamethasone or prednisolone upto 8 weeks
223488814|NCT05917340|DRUG|Rifampicin|Standard dose for 4 months after the initial treatment with high dose
223488815|NCT05917340|DRUG|HRZE|2 months
223488816|NCT05917340|DRUG|HRE|7-10 months as per TB program guidelines
223488817|NCT03274817|DRUG|Escitalopram Pill|Subjects randomized to group A will receive Lexapro (escitalopram), in an initial, baseline dosage of 5 mg daily.
223488818|NCT03274817|DRUG|Venlafaxine Pill|Subjects randomized to group B will receive Effexor XR (venlafaxine extended release capsules), in an initial baseline dosage of 37.5 mg daily.
223488819|NCT03274817|DRUG|Placebo Oral Tablet|Subjects randomized to group C will receive placebo tablets, which will be matched to the Lexapro and the Effexor XR as far as possible, and will also be administered on a once daily schedule at baseline.
223488820|NCT05107115|DRUG|rilzabrutinib|Tablet, oral use
223488821|NCT05107115|DRUG|placebo|Tablet, oral use
223488822|NCT04732234|PROCEDURE|Superior Hypogastric Plexus Block|Pre operative ultrasound guided superior hypogastric plexus block in pelvic surgeries using a curvilinear probe below umbalicus with needle in plane technique to reach the plexus in front of L5 vertebra
223488823|NCT02497066|OTHER|Neuropathic pain cream|Subjects will apply the cream to the painful area.
223488824|NCT02497066|OTHER|Nociceptive pain cream|Subjects will apply the cream to the painful area.
223488825|NCT02497066|OTHER|Mixed pain cream|Subjects will apply the cream to the painful area.
223488826|NCT04834596|OTHER|retrospectives analysis on hepatic scanner|hepatic scanner will be analysed by two radiologist and by the software
223488827|NCT02072616|OTHER|Pancreatic adenocarcinoma diagnosis|
223488828|NCT03179384|DRUG|Ceftriaxone|ceftriaxone (1g intravenous or 1g/35mL intramuscular) will be given to patients during 7 days
223488829|NCT05145972|OTHER|Ultrasound Guided Superior Hypogastric Plexus|The division of abdominal aorta into common iliac arteries will be identified by using longitudinal sonography , and the body of the fifth (5th) Lumbar vertebra will be identified by placing the transducer transversely. A skin wheal will be raised with subcutaneous infiltration with 2% lidocaine solution nearly 3-4 cm below the umbilicus. A 15-cm Long 22-G Chiba needle will be used with out of plane technique, and the needle will be advanced under USG-guidance to reach the anterior- most point of the fifth Lumber vertebral body avoiding the vascular structures. The needle will be withdrawn nearly 1-2 mm after hitting the vertebral body to avoid injecting the drug into the periosteum. After confirming a negative aspiration of blood, known amount of neurolytic agent according to the grouping will be injected for the neurolysis of superior hypogastric plexus. The uniform spread of the drug will be confirmed under real-time sonography.
223488830|NCT03588338|DRUG|Perfalgan|For postoperative pain
223488831|NCT03588338|DRUG|Control|For postoperative nausea and vomiting
223488832|NCT02440867|DEVICE|Active TBS|Non-invasive transcranial magnetic stimulation inducing changes in cortical excitability depending on the cortical target (except for sham stimulation)
224179535|NCT01591577|OTHER|Lapatinib/Temozolomide/radiation|Patients will be treated with a pulse dose of lapatinib every week and temozolomide 75 mg/m2 daily during radiation. Lapatinib will be administered beginning on the first day of radiation and temozolomide (+/-2 days). External beam fractionated regional radiation will be given on consecutive week days at 200 cGy daily doses to a total dose of 6000 cGy. Patients will have rest from temozolomide only for 2-4 weeks. Patients will continue with weekly pulse-dosing of lapatinib. After a 2-4 weeks rest(for temozolomide only) following completion of radiation therapy, temozolomide will be restarted as Cycle 1 at 150 mg/m2/day for 5 days out of every 28.Subsequent cycles can increase to 200 mg/m2/day as tolerated per investigator's judgment. Lapatinib pulse doses will be continued every week without interruption.Treatment will continue for 24 additional 28-day cycles of temozolomide if there is no evidence of progression.
224179536|NCT01443039|DRUG|phenotypical approach|each visit : CAFEINE : (solution orale) 2 ampoules de 2 ml = 100 mg de CAFEINE DEXTROMETHORPHANE : 15 ml de sirop contains 20 mg =\>22,5 ml = 30mg Midazolam : (solution injectable, ampoule 1 ml = 1 mg) : deux ampoules = 2 mg Digoxine nativelle (solution injectable, ampoule de 0.5mg) : 1 ampoule per os = 0.5 mg Losartan 50 mg : 1cp de 50mg
224179537|NCT00603369|BEHAVIORAL|group intervention|13-session intervention
224179538|NCT00603369|BEHAVIORAL|group intervention|2-session intervention
224179539|NCT04301349|DRUG|vaginal dinoprostone|two tablets of vaginal dinoprostone (6 mg) 3 hours prior to IUD insertion
224179540|NCT04301349|DRUG|vaginal misoprostol|two tablets of vaginal misoprostol (400 mcg) 3 hours prior to IUD insertion
224179541|NCT04301349|DRUG|placebo|two tablets of placebo given 3 hours prior to IUD insertion
224179542|NCT05129566|PROCEDURE|IOL Clareon AutonoMe|Phacoemulsification of cataract with implantation of two types of IOLs - Clareon AutonoMe and Hoya iSert 251. Operations will be performed by one surgeon using the Centurion vision system under control of the Verion navigation system. The Verion system will be used for capsulorhexis and IOL centration (limbus centration).
224179543|NCT05129566|PROCEDURE|IOL Hoya iSert 251|Phacoemulsification of cataract with implantation of two types of IOLs - Clareon AutonoMe and Hoya iSert 251. Operations will be performed by one surgeon using the Centurion vision system under control of the Verion navigation system. The Verion system will be used for capsulorhexis and IOL centration (limbus centration).
224179544|NCT04902547|BEHAVIORAL|Patient Education Workshop (PEWs)|The comprehensive workshops will include a combination of didactic and interactive content on general pain and opioid education (1 hour workshop session to be co-presented by Drs Ryan Amadeo and Dana Turcotte) along with significant psychological content (co-presented by Drs Brigitte Sabourin and Gregg Tkachuk) making up the remainder of the day-long workshop. Content presented in PEWs will include opioid-related risks, identifying personal motivation for (or barriers to) tapering, goal setting, pain self-management, sleep hygiene and comprehensive focus on ACT and rethinking pain. During the interprofessionally co-facilitated sessions, participants will be provided with workbooks that will contain session specific content as well as take-home activities and information for their own personal use.
224179545|NCT04902547|PROCEDURE|Multidisciplinary Tapering Program|"The MTP will begin with a Baseline Tapering Visit and will include the same baseline health and well-being questionnaires, a medication review, relevant pain history, relevant opioid use history, discussion re: patient-specific tapering and functional goals, taper start date, and determination if a different opioid formulation will be required for the taper. A detailed taper plan will be prepared and reviewed by the study clinician(s) and provided to the patient. In general, tapers will begin with a 10% reduction of dose every 2 weeks until ⅓ of the original dose is met, or until taper goal has been met. If further tapering is planned once the patient reaches ⅓ of their original dose, the taper will be reduced to half the volume and rate noted above in order to improve tapering success.~Tapering plans and approaches may be changed (slowed, increased, halted etc.) based on follow up."
224179546|NCT00479973|DIETARY_SUPPLEMENT|Cinnamonforce|"Cinnamonforce™ is a proprietary blend of Cinnamomum aromaticum and Cinnamomum verum bark containing 47 mg of hydroethanolic extract (min. 8% total phenolics) and 23 mg supercritical extract (min. 35% cinnamaldehyde) per capsule.~2 capsules after the two largest meals of the day"
224179547|NCT00479973|DIETARY_SUPPLEMENT|Placebo|Placebo. 2 capsules after the two largest meals of the day
224179548|NCT04492514|DRUG|Mavrilimumab|Treatment infusion
223488833|NCT02440867|DEVICE|Sham TBS|Sham stimulation
223488834|NCT04049461|DIAGNOSTIC_TEST|Bone alkaline phosphatase|Hematologic indicators reflecting ossification.
223488835|NCT04049461|RADIATION|Abdominal CT scan|Observe whether HOAI occurs.
223488836|NCT00888836|PROCEDURE|Bariatric surgery: Gastric bypass|Gastric bypass (GBP): A subcardial gastric pouch with a 30±10 ml capacity will be created on a naso-gastric 36F calibrating tube by sectioning the stomach with a linear stapler 3-4 cm horizontally on the lesser curve, 4 cm distal to the e-g junction, and then vertically until attainment of the angle of Hiss. After identification of the Treitz ligament, the jejunum will be transected at 100 cm from the ligament of Treitz and the two stumps will be closed. The distal stump will be anastomosed to the distal end of the gastric pouch. The preferred gastro-jejunal anastomosis is the totally hand-sewn one, but it can be performed using any other the technique the surgeon is more familiar with. Finally, the proximal stump of the transacted bowel will be joined end-to-side to the jejunum 150 cm distal to the gastroenterostomy.
223488837|NCT00888836|PROCEDURE|Bariatric surgery: Bilio-pancreatic diversion|Biliopancreatic diversion (BPD): A distal two-third gastrectomy will be carried out aiming at leaving an about 400 ml gastric remnant. The gastrointestinal continuity will be re-established by sectioning the small bowel 300 cm proximal to the ileocecal valve, closing the intestinal stumps, and joining the proximal one end-to-side to the distal ileum at 50 cm from the ligament of Treitz. The distal stump of the transacted bowel will be anastomosed to the left corner of the gastric stump, preferably in a totally hand-sewn fashion.
224072867|NCT04029519|DEVICE|PN40082|PN40082 (manufactured by Prollenium Medical Technologies) is a clear, colorless gel in 1.0 mL pre-filled syringes with 25 mg/mL of stabilized hyaluronic acid and lidocaine 0.3% w/w.
224072868|NCT02011191|DIETARY_SUPPLEMENT|Biotin Supplementation|10,000 micrograms biotin supplement daily for 8 weeks
224072869|NCT02011191|DIETARY_SUPPLEMENT|Sugar Pill|Identical sugar pill, identical bottle as the biotin supplementation group
224072870|NCT03669315|DEVICE|Transcranial Magnetic stimulation|Neuromodulation tool
224179549|NCT04492514|DRUG|Placebo|Placebo infusion
223488838|NCT00888836|BEHAVIORAL|anti-diabetic drugs and behavioral suggestions|Medical therapies (oral hypoglycemic agents and insulin) are optimized on an individual basis. Lifestyle modification programs, including reduced energy and fat (\<30% total fat and \<10% saturated fat, high fibre content) intake and increased physical exercise (suggested at least 30 minutes of brisk walking every day possibly associated with a moderate intensity aerobic activity twice a week), are tailor made by an experienced diabetologist assisted by a dietitian. After the two years, the patients in control group will be offered the choice to undergo one of the two surgical procedures.
223488839|NCT03833310|DIAGNOSTIC_TEST|Osteoprotegerin marker in serum in inflammatory bowel disease|I will measure Osteoprotegerin and Soluble Receptor activator of nuclear factor kappa-Β ligand markers in serum of patient with inflammatory bowel disease
223488840|NCT05324189|DIAGNOSTIC_TEST|Referable versus Non Referable Diabetic Retinopathy diagnostic test|Artificial intelligence read reports Referable versus Non Referable Diabetic Retinopathy
223488841|NCT04609696|DRUG|Danicopan: Powder-In-Capsule 1|Danicopan (200 milligrams) will be administered orally on Day 1.
223488842|NCT04609696|DRUG|Danicopan: Powder-In-Capsule 2|Danicopan (200 milligrams) will be administered orally on Day 1.
223488843|NCT04609696|DRUG|Danicopan: Tablet|Danicopan (200 milligrams) will be administered orally on Day 1.
223488844|NCT06357767|BEHAVIORAL|Healing Within: Smoking Cessation Intervention for American Indian Women Experiencing Intimate Partner Violence|A culturally-tailored, trauma-informed group intervention to support smoking cessation by leveraging Lakota values, mindfulness, and a storytelling approach.
223488845|NCT03301259|OTHER|One-shape rotationary system|OneShape (MICRO-MEGA) rotary nickel-titanium use roation movement and available in two sizes N°30 - .06 rotary files. , N°25 - .06
224072871|NCT06492044|OTHER|Transthoracic echocardiography (TTE)|"In this pilot study, all included patients will undergo a TTE before (TTEt0) and after (TTEt1) the PLR maneuver, then before (TTEt2) and after the FC (TTEt3).~Passive leg raising is PLR. FC is fluid challenge. TTE, PLR and FC are routine care procedures in patient in septic shock. In this study the patient will undergo repeated image acquisition with TTE at different times as part of the study, resulting in a longer TTE procedure. The advantage of TTE is that it is a non-invasive, painless, non-irradiating procedure that can be easily performed at the patient's bedside and has no known side effects to date. TTE is a non-invasive procedure that poses no infectious or psychological risk to the patient. No additional follow-up or telephone contact will be necessary for the study. The study concludes once TTEt3 is completed."
224072872|NCT00682266|BEHAVIORAL|intensity controlled interval training (AIT)|4 x 4 min intervals at 90% of maximal heart rate, each interval separated by 3 min at 70%, twice a week for 3 months
224072873|NCT00682266|BEHAVIORAL|Multidisciplinary approach (MTG)|exercise, dietary and psychological advice, twice a month for 12 months
224072874|NCT01055002|BIOLOGICAL|Blood stage parasite (BSP) inoculum|Inoculum of human red blood cells infected with falciparum malaria administered intravenously on Day 1
224072875|NCT03591445|DEVICE|Flexible Bronchoscopy|Flexible Bronchoscopy
224072876|NCT05824429|OTHER|Urotherapy|Urotherapy is an umbrella term that includes components such as information about bladder function and problem, lifestyle changes including the regulation of voiding and fluid intake times, correct toilet positions, information about bladder irritants, and motivation. All participants included in our study will be given urotherapy training before starting PFM exercises and CTM with their families.
224072877|NCT05824429|OTHER|Diaphragmatic Breathing Exercises|In our research, diaphragm breathing exercises will be applied to both groups before starting PFM exercises in sessions for 8 weeks, 3 days a week.
224072878|NCT05824429|OTHER|PFM Exercises|PFM exercises will be started after children learn to contract and relax their PFM in isolation without the use of auxiliary muscles. In the exercises, fast and slow contractions targeting type 1 and type 2 muscle fibers will be taught to increase both strength and endurance of PFM.
224072879|NCT05824429|OTHER|Connective Tissue Manipulation|"CTM is a reflex treatment technique that is applied manually by physiotherapists to the skin area and acts on some cells and connective tissue by making short and long pulls (. In our study, CTM will be applied to our study group, where CTM and PFMR will be applied together, 3 days a week, for a total of 8 weeks.~The application will be made to the basic region (sacral), lower thoracic, abdominal and anterior pelvic region."
224072880|NCT03147469|PROCEDURE|Flexion|After changing the position of head and neck of subjects to flexion, the variables were measured.
224072881|NCT03147469|PROCEDURE|Extension|After changing the position of head and neck of subjects to extension, the variables were measured.
224072882|NCT03147469|PROCEDURE|Right rotation|After changing the position of head and neck of subjects to right flexion, the variables were measured.
224072883|NCT00355394|DRUG|Metoclopramide|Intravenous bolus administration.
224072884|NCT00355394|OTHER|Placebo|Standard care including intravenous fluid, but no metoclopramide.
224072885|NCT01389557|DRUG|Dihydroartemisinin-piperaquine with primaquine|"P. falciparum : Treated with fixed doses of 40 mg dihydroartemisinin and 320 mg piperaquine based on weight for 3 days (D0, D1 and D2) with max dose of 1 x 3 tablets for patients weighing ≥ 41 kg; 1 x 2 tablets for patients weighing 31 - 40 kg, 1 x 1.5 tablets for patients weighing 18 - 30 kg, and 1 X 1 tablet for patients with body weight of 11 - 17 kg. A single dose PQ of 0.75 mg/kg BW was provided on Day-3 using 15 mg base PQ tablets. The maximal dose was 3 tablets for subjects weighing ≥ 60 kg. The dose range for subjects weighing 10 - 13 kg was 0.5 tablet; 14 - 18 kg was 0.75 tablet; 19 - 23 kg was 1 tablet, 24 -30 kg was 1.5 tablet; 31 - 40 kg was 2 tablets; 41- 49 kg was 2.25 tablet; 50 - 59 kg was 2.5 tablet and ≥ 60 kg was 3 tablets.~P. vivax: DHP (3 days) + primaquine (14 days)"
224072886|NCT01912209|BEHAVIORAL|My Everyday Health|MyEveryday Health is a web-based nutritional and lifestyle management program. The program includes personalized diet and weight guidance, meal planners, shopping list generator, recipe finder, weight tracker and dining out and fast food guides. Based on specific algorithms, tips and suggestions on how to make changes in their diet and lifestyle will be give each time the subject logs in. The MyEverydayHealth website will also be available as an app for their smart phone to the participants. If they choose to use the app, daily reminders to log in and use their tools will be sent, along with motivating tool/tips/tricks to stay with the program.
224072887|NCT00070941|DRUG|SAM-e|oral SAM-e in two divided doses, 1200mg or 1800mg daily, with placebo escitalopram.
224072888|NCT00070941|DRUG|oral escitalopram|20mg or 30mg daily in two divided doses, along with placebo SAM-e.
223488846|NCT00909467|OTHER|echocardiography, right heart catheterisation|at each patient an echocardiography will be performed at rest and during exercise. For the evaluation of exercise capacity, cardiopulmonary exercise testing and six-minute walk is performed. Right heart catheterisation is recommended to those with suspected pulmonary hypertension.
223488847|NCT02804893|PROCEDURE|VATS|Thorax thoracoscopic surgery (lobectomy)
223488848|NCT02804893|PROCEDURE|RATS|Thorax robotic surgery (lobectomy)
223488849|NCT03120273|DRUG|Dexlansoprazole Injection|15mg q12h,30mg q12h,15mg qd,30mg qd for 5 days
223488850|NCT03120273|DRUG|Lansoprazole Injection|30 mg q12h for 5 days.
223488851|NCT01284543|DEVICE|Use of the Tan EndoGlide to insert donor graft|Using the Tan EndoGlide to insert donor graft into the eye
223488852|NCT01284543|DEVICE|Busin Glide for delivery of the donor graft|Use of the forceps for delivery of the donor graft into the eye
223488853|NCT00998283|DRUG|HM10460A 5μg/kg|Subcutaneously administrate at 0 hour on Day 1
224072889|NCT00070941|DRUG|placebo|oral placebo escitalopram and oral placebo SAM-e daily in two divided doses.
224072890|NCT05883098|PROCEDURE|Wound debridement|The study's wounds will be mechanically debrided before the experimental or active comparator devices are applied. Debridation will be performed by a trained clinician using a curette. Necrotic tissue and slough will be removed during this procedure.
224072891|NCT05883098|DEVICE|Wound closure matrix application|After wound debridement, the patients will receive the application of a wound closure matrix as dictated by their randomization allocation.
224072892|NCT01691469|DRUG|Montelukast sodium|Montelukast Sodium Oral Granules 4mg
224072893|NCT01363869|DIETARY_SUPPLEMENT|green tea extracts 2 gm/day|"Green tea extracts capsule (1 gm per capsule), taken after meal, twice daily for 14 days.~Total dosage is 2 grams per day."
224072894|NCT01363869|DIETARY_SUPPLEMENT|green tea extracts 4 gm/day|"Green tea extracts capsule (1 gm per capsule), taken after meal, twice daily for 14 days.~Total dosage is 4 grams per day."
224072895|NCT01363869|DIETARY_SUPPLEMENT|green tea extracts 6 gm/day|"Green tea extracts capsule (1 gm per capsule), taken after meal, twice daily for 14 days.~Total dosage is 6 grams per day."
224072896|NCT04429815|DIAGNOSTIC_TEST|Serological test for COVID-19.|Serological test for COVID-19 performed as part of standard of care.
224072897|NCT03369145|DIETARY_SUPPLEMENT|High-fat diet|The high-fat diet will provide 7 days of overfeeding comprising of: +50% extra calories above the daily required intake, 65% of which is fat.
224072898|NCT00094055|DRUG|AG013736|AG013736, tablets 5 mg BID daily until tumor progression or toxicity
224072899|NCT01307475|OTHER|PTSD Checklist-Specific|Completed by patients before clinical examination; it is a 17-item survey listing of symptoms of posttraumatic stress disorder.
224072900|NCT01307475|OTHER|Modified Flanagan Quality of Life Scale|Completed by patients before clinical examination; it is a 16-item survey designed for use in persons with chronic illness.
224072901|NCT01307475|OTHER|Center for Epidemiologic Studies Depression Scale|Completed by patients before clinical examination; it is a 20-item survey that asks about depressive feelings and behaviours in the past week.
224072902|NCT01307475|OTHER|Functional Enquiry Form|Completed by patients before clinical examination; it is a checklist of medical problems.
224072903|NCT01307475|OTHER|Strength, Joint ROM, Girth and Length Measurements|Completed during the clinical examination by the researchers, it is a structured approach to evaluation of muscles, joints, arms, thighs, and legs.
224072904|NCT01307475|OTHER|Study Physical Examination|Completed during the clinical examination by the researchers, it is a structured approach to a full physical examination, minus breasts, genitalia or rectum.
224072905|NCT01307475|OTHER|PTSD, Depression, and FSS-Focused Examination|Completed during the clinical examination by the researchers, it is a structured approach to evaluation of symptoms, signs, and perceptions that may be related to FSS, PTSS, or depressive problems.
224072906|NCT01307475|OTHER|Freeman-Sheldon Specific Quality of Life Survey|Completed after data analysis from the existing surveys and clinical examination, it will be a specific quality of life survey developed and tested during the study; it will take into consideration individual's total health outcome.
224072907|NCT01307475|OTHER|Lactate, Glucose, and Adenosine Triphosphate Blood Levels|Completed during the clinical examination by the researchers, lactate, glucose, and free and total adenosine triphosphate blood levels are determined at rest.
224072908|NCT04482335|OTHER|No intervention|No intervention
224072909|NCT01019382|DRUG|Lipidem fish oil infusion + Gemcitabine chemotherapy|500mls intravenous infusion once a week of lipidem in addition to standard starting dose of gemcitabine (1000mg/m2) Dose can be reduced if poorly tolerated
224072910|NCT01232829|DRUG|gamma-secretase/Notch signalling pathway inhibitor RO4929097|Given PO
224072911|NCT04821804|DRUG|Hyaluronic Acid (HYADENT BG)|"the operator topically applied the HYADENT BG on the borders of the graft after stabilization.~on the donor site and injection of HYADENT BG in collagen sponge that was placed over the site, then figure X sutures to close the area using (4-0 polyglycolic acid/ reverse cutting/ 12 mm) resorbable sutures"
224072912|NCT03453983|DEVICE|Transcrainial Direct Current Stimulation (tDCS)|Transcranial direct current stimulation (tDCS) is a safe non-invasive form of brain stimulation, which modulates, through the application of weak direct current, cortical excitability. The applied subthreshold current passes through two externally placed electrodes, an anode and cathode.
224072913|NCT06258070|OTHER|Abobotulinumtoxin A injection for bruxism|Trigger points were detected with careful palpating of the masticatory muscles (masseter and temporalis muscles) of patients suffering from bruxism. Each trigger point received 0,05 lm ol reconstituted solution of Abobotulinumtoxin A. Dysport (Ipsen Pharma, Germany) was reconstituted with 0.9% sodium chloride solution so that 0.1 ml corresponded to 25 U.
224072914|NCT00411554|DRUG|sitagliptin phosphate|sitagliptin 50 mg orally once daily QD. Duration of Treatment: 12 Weeks
224072915|NCT00411554|DRUG|Comparator: voglibose|voglibose 0.2 mg orally three times daily TID. Duration of Treatment: 12 Weeks
224072916|NCT00080509|DRUG|KOS-862|
224072917|NCT00632801|OTHER|chewing gum|The patients in the gum chewing group (intervention group) will chew one stick of gum the first post-operative day, after the nasogastric tube is removed or if they patient does not have a nasogastric tube, with the head of bed elevated a minimum of 30 degrees for 30 minutes, three times a day at set intervals
224179550|NCT01522963|DRUG|Nicotine lozenge|A single dose of nicotine lozenge will be given at various timepoints relative to completion of a somewhat stressful task
224179551|NCT06307210|OTHER|inpatient rehabilitation|physiotherapy (strength and endurance training), occupational therapy and neuropsychological training
224179552|NCT01266811|DRUG|Placebo, Velcade and dexamethasone|Siltuximab 11 mg/kg as 1 hour IV infusion on Day 1 of every cycle
224179553|NCT01266811|BIOLOGICAL|Siltuximab, Velcade and dexamethasone|Given in 21-day treatment cycles
224179554|NCT05535452|DEVICE|Photobiomodulation through LED board|The applications will be performed within 1 hour after radiotherapy, three times a week, by a trained team, consisting of physiotherapists and physiotherapy students, through the sportllux LED plate equipment, medium size, which combines light emitters in two wavelengths: red (660nm) and infrared (850nm).
224179555|NCT03758612|DRUG|TBI-223 oral suspension|TBI-223 oral suspension, orally administered.
224179556|NCT03758612|DRUG|TBI-223 enteric capsule|TBI-223 enteric capsules filled with 150 mg of TBI-223 powder, orally administered.
224179557|NCT03758612|DRUG|TBI-223 SR Tablet Prototype 1|TBI-223 600 mg sustained-release (SR) tablet Prototype 1, orally administered.
224179558|NCT03758612|DRUG|TBI-223 SR Tablet Prototype 2|TBI-223 600 mg SR tablet Prototype 2, orally administered.
224179559|NCT03758612|DRUG|TBI-223 SR Tablet Prototype 3|TBI-223 900 mg SR tablet Prototype 3, orally administered.
224179560|NCT03758612|DRUG|TBI-223 IR Tablet|TBI-223 1000 mg immediate release (IR) tablet, orally administered
224179561|NCT03758612|DRUG|Placebo suspension|Placebo for TBI-223 oral Suspension; orally administered.
224179562|NCT01724164|BEHAVIORAL|Mirror Therapy|This protocol includes 1 hour mirror therapy and 0.5 hour functional training in a session. The treatment intensity is 1.5 hours/day, 5 days/week, for 4 weeks. MT focuses on symmetrical bimanual movements and simultaneously observing the mirror visual feedback reflected by the unaffected upper extremity.
224179563|NCT01724164|BEHAVIORAL|Robotic assisted therapy|This protocol includes 5 to 10 min of warm-up, 1 hr of RR, and 15 to 20 min of functional activities training. The treatment intensity is 1.5 hours/day, 5days/week for 4 consecutive weeks. The RR session uses the robot-assisted arm trainer, Bi-Manu-Track (Reha-Stim Co., Berlin, Germany).
224179564|NCT01724164|BEHAVIORAL|Robotic Rehabilitation with PI|The RR-PI protocol is the same as the RR-FES protocol described above except that the surface electrodes are attached to the same target muscles on the affected upper limb but there is no output of electrical stimulation.
224179565|NCT01724164|BEHAVIORAL|Robotic rehabilitation with FES|This combined RR-FES treatment involves the same protocol as the RR regimen except that patients receive FES concurrently with RR.
223488854|NCT00998283|DRUG|HM10460A 15μg/kg|Subcutaneously administrate at 0 hour on Day 1
223488855|NCT00998283|DRUG|HM10460A 45μg/kg|Subcutaneously administrate at 0 hour on Day 1
223488856|NCT00998283|DRUG|HM10460A 135μg/kg|Subcutaneously administrate at 0 hour on Day 1
223488857|NCT00998283|DRUG|HM10460A 350μg/kg|Subcutaneously administrate at 0 hour on Day 1
223488858|NCT00998283|DRUG|Placebo|Subcutaneously administrate at 0 hour on Day 1
224179566|NCT01724164|BEHAVIORAL|Conventional Rehabilitation|Participants in this group receive a structured protocol based on occupational therapy such as neuro-developmental techniques and task-oriented approach. The treatment dose is matched to RR and MT groups.
224179567|NCT01723527|DRUG|Methadone|Clinic-Based Methadone Maintenance Treatment
224179568|NCT01723527|DRUG|Buprenorphine|Clinic-Based Buprenorphine Maintenance Treatment
224179569|NCT01723527|BEHAVIORAL|Employment-based drug abstinence reinforcement|
224179570|NCT05999773|DRUG|SGLT2 inhibitor|Start of SGLT-2 inhibitors to treat diabetes according diabetology indications.
223488859|NCT04817982|DRUG|Perineural dexamethasone|Dexamethasone 4mg will be added perineurally to an ulnar nerve block with bupivacaine.
224179571|NCT03479203|DRUG|Electronic Cigarette Aerosol|16 two-second-long puffs from a non-nicotinized electronic cigarette.
223488860|NCT04817982|DRUG|Lidocaine|Lidocaine 40 mg will be added perineurally to an ulnar nerve block with bupivacaine.
223488861|NCT04817982|DRUG|Placebo|Saline will be added perineurally to an ulnar nerve block with bupivacaine.
223488862|NCT04817982|DRUG|Systemic dexamethasone|Dexamethasone will be added perineurally to an ulnar nerve block with bupivacaine, some will be reabsorbed and distributed systemically. Thereby, the investigators control for the systemic effects of adding perineural dexamethasone to an ulnar nerve block.
223488863|NCT02135198|DRUG|2 mg AZD7325|A single 2 mg oral dose of AZD7325
223488864|NCT02135198|DRUG|10 mg AZD7325|A single 10 mg oral dose of AZD7325
223488865|NCT02135198|DRUG|Placebo|A single oral dose
224179572|NCT03922919|DRUG|Cefotaxime Injection|Systematic use of cefotaxime.
224179573|NCT03922919|PROCEDURE|Rectal swab|Rectal swab every 3 days during hospitalization and then 30 days after the first antibiotic infusion
223488866|NCT05162092|OTHER|Conventional physiotherapy|Participants will be given Conventional Physiotherapy. It included Passive Soft tissue elongation of tight muscles, Lower limb resistance exercises, Movement transitions, balance board and foam board standing, walking and stair climbing.
223488867|NCT05162092|OTHER|Vestibular stimulation with conventional physiotherapy|Participants in group B will be given conventional physiotherapy and vestibular stimulation exercises. It included conventional is same as given to the conventional and Vestibular Stimulation
223488868|NCT06549985|BEHAVIORAL|PEEPS|Participants will participate in the PEEPS program in addition to usual care.
223488869|NCT06549985|BEHAVIORAL|Education|Participants will receive an educational handout on endometriosis in addition to usual care.
223488870|NCT02767973|OTHER|Wood Smoke Particles (WSP)|After baseline (pre-exposure) assessment (which includes recovery of induced sputum), these volunteers will then undergo an exposure to 500μg/m3 wood smoke particles for 2 hours, with alternating 15 min of exercise (cycle ergometer) with 15 min rest to achieve 25 l/m2 body surface/min minute ventilation, followed by sputum induction after 6 and 24 hours after initiation of the challenge.
223488871|NCT05561543|DIETARY_SUPPLEMENT|Peppermint oil|Peppermint oil
223488872|NCT05561543|OTHER|Placebo|Placebo
224179574|NCT03922919|DRUG|Cefotaxime/ceftriaxone|ceftriaxone or cefotaxime infusion at the discretion of the prescribing physician
224307273|NCT03567382|DRUG|Tenofovir Disoproxil Fumarate|300 mg tablet of TDF once daily from 28-32 weeks gestation through 12 weeks postpartum.
223488873|NCT06569667|BEHAVIORAL|PRC supported text + AI driven SDH-enhanced text|This interventional study evaluates an AI-driven texting tool combined with peer recovery coach support to deliver social services, reduce stigma, and provide patient navigation content. The goal is to enhance the receipt of buprenorphine in primary care among emergency department-enrolled Black and Latinx individuals who use opioids, addressing the disproportionate impact of opioid overdose deaths on these communities.
224179575|NCT01603615|BIOLOGICAL|Botulinum Toxin Type A|Participants received intramuscular injections of botulinum Toxin Type A in the upper and/or lower limb muscles at a minimum of 12 weeks apart for a maximum of 5 treatments.
224179576|NCT02967965|OTHER|Imagery|MRI at year 3
224179577|NCT02683135|BEHAVIORAL|High-carbohydrate diet|Participants will engage in 4 days of high-carbohydrate low fat diet as recommended by the Canadian Diabetes Association. The macronutrients content will go as follow: 55% carbohydrate, 25% protein and 20% fat. Breakfast, lunch and dinner will be provided to the participants as part of an isoenergetic diet. Between interventions there will be at least a one-week washout, where participants are encouraged to return to their baseline dietary habits.
224179578|NCT02683135|BEHAVIORAL|Low-carbohydrate diet|Participants will engage in 4 days of low-carbohydrate high-fat diet. The macronutrients content will go as follow: 10% carbohydrate, 25% protein and 65% fat. Breakfast, lunch and dinner will be provided to the participants as part of an isoenergetic diet. Between interventions there will be at least a one-week washout, where participants are encouraged to return to their baseline dietary habits.
223488874|NCT06569667|BEHAVIORAL|AI driven SDH-enhanced text only|This interventional study evaluates an AI-driven SDH-enhanced texting tool to deliver social services, reduce stigma, and provide patient navigation content. The goal is to enhance the receipt of buprenorphine in primary care among emergency department-enrolled Black and Latinx individuals who use opioids, addressing the disproportionate impact of opioid overdose deaths on these communities.
223488875|NCT06569667|BEHAVIORAL|Treatment as Usual (TAU)|Control Arm-3 will receive treatment as usual (i.e., verbal instructions, NYC Dept of Health pamphlets detailing access to OUD and social services, health system smartphone application EMR patient portal).
223488876|NCT05406167|DEVICE|Registry - Observational|Observation Registry for Medical Device
223488877|NCT05621772|OTHER|Meridian Activation Remedy System for Parkinson's Disease (MARS-PD)|MARS-PD is a complex therapy developed by researchers to enhance the synergistic effects of acupuncture and exercise.
223488878|NCT00619528|BIOLOGICAL|Infusion of Donor Hematopoietic Stem Cells and Campath-1H|Intervention: a four-dose (peri-operative and 3, 6, and 9-month boost) DHSC infusion protocol using two-dose Campath-1H induction combined with transient (conditioning) Tacrolimus/Sirolimus and MMF therapy will result in a high degree of macro-chimerism (\>10%), and a robust prolonged donor-specific (post-thymic) immunoregulatory condition that will allow renal transplant survival in the absence of permanent immunosuppression.
223488879|NCT04526054|DIAGNOSTIC_TEST|ENT exam|ENT examination of the nasal cavity: nasofibroscopy and anterior rhinoscopy.
223488880|NCT04526054|DIAGNOSTIC_TEST|Olfactometry|Olfactometry test using odorous pens (Sniffin's stick test).
223488881|NCT04526054|DIAGNOSTIC_TEST|Brain MRI|Brain MRI focused on the olfactory bulbs (3 teslas).
224179579|NCT02683135|BEHAVIORAL|Low-carbohydrate diet with post-meal walking|Participants will follow the same diet as in the low-carbohydrate diet arm but also perform 15 minutes of walking beginning \~15 minutes after breakfast, lunch and dinner. Approximately 70 kcal (individualized) will be added to main meals to account for exercise energy expenditure. Between interventions there will be at least a one-week washout, where participants are encouraged to return to their baseline dietary habits.
224179580|NCT03419741|DEVICE|Transcranial Magnetic Stimulation Clinical Research System|Transcranial Magnetic Stimulation Clinical Research System is a US FDA approved treatment system for depression. The treatment research system includes motor threshold TMS coil, active TMS coil and sham TMS coil.
224179581|NCT02643316|DRUG|Same day 4 L preparation (Polyethylene Glycol)|Receive 1 gallon (4 L) of Polyethylene Glycol preparation on the morning of the colonoscopy.
224179582|NCT02643316|DRUG|Split dose 4 L preparation (Polyethylene Glycol)|Receive the split-dose regimen. Will take half (2 L) the preparation the evening before colonoscopy and half (2 L) on the morning of the procedure.
224179583|NCT04354870|DRUG|Hydroxychloroquine (HCQ)|Loading dose: 600 mg, oral, 1 day Maintenance dose: 200 mg, oral, daily, for 90 days
224205610|NCT02192541|DRUG|Ziv-Aflibercept|Ziv-aflibercept is a soluble fusion protein with high binding affinity for vascular endothelial growth factor A (VEGF-A), vascular endothelial growth factor B (VEGF-B), and placenta growth factor (PIGF) and thus confers anti-angiogenic activity
224205611|NCT02192541|DRUG|Ganetespib|Ganetespib is a non-geldamycin synthetic inhibitor of Hsp90 with activity against multiple cancer cell lines and tumor xenografts in preclinical models.
224205612|NCT01519895|BEHAVIORAL|Telephone intervention|counseling and education support
223488882|NCT03870490|DRUG|VNRX-5133 + cefepime|IV infusion (3 doses)
223488883|NCT05117996|OTHER|capsule endoscopy|capsule endoscopy
223488884|NCT05117996|OTHER|standard small bowel preparation|2 L of polyethylene glycol and free residue diet the day before the capsule endoscopy. 2 mL of Babyspasmyl after ingestion of capsule
223488885|NCT05117996|OTHER|Simplified small bowel preparation|Liquid diet the evening before and water on the morning of the capsule endoscopy. 2 mL of Babyspasmyl after ingestion of capsule
223488886|NCT02523209|DEVICE|HR-pQCT|HR-pQCT (High Resolution peripheral micro Computerized Tomography) is a device used for 3D bone measurements at the tibia and the radius levels in humans.
223488887|NCT02523209|DEVICE|DEXA|The Lunar DEXA (Dual Energy X-ray Absorptiometry) is a third generation multi-captor DEXA (Dual Energy X-ray Absorptiometry) device that allows short duration measurements ( \<15 min). It measures Bone Mineral Density at the spine (L1-L4) and the femoral neck
223488888|NCT05784675|DEVICE|MOBI-CPR game|Participants use MOBI-CPR game at home environment.
224205613|NCT05353426|PROCEDURE|Paragastric autonomic neural blockade|Paragastric autonomic neural blockade with Bupivacaine
224205614|NCT00196573|PROCEDURE|Shoulder bursectomy alone|
224205615|NCT06563973|OTHER|Milk odor|One hour before feeding time, 2 cc of breast milk was dripped onto a sterile sponge and placed inside the baby's incubator, close to the baby's nose (3 cm).
224205616|NCT06563973|OTHER|Pacifier|To support oral feeding, a pacifier was given for 3 minutes one hour before feeding time and for 2 minutes 10 minutes before feeding time.
224179584|NCT01113411|DEVICE|PHILOS™ locked plate system by Synthes Canada©|The surgery will be performed under standardized general anesthetic with a prophylactic antibiotic. The deltopectoral approach is used in all cases. The fracture will be fixed using the PHILOS locked plate system by Synthes Canada ©. Some additional osteosutures may be used. The wound is irrigated and then closed in two layers at the end of intervention. A splint thoracic brace will be installed in all patients before the end of anesthesia.
224179585|NCT01113411|OTHER|Early and intensive exercise program|"A thoraco brachial brace will be worn for 48 hours following the surgery and then removed for the remainder of treatment. Patients will then start the intensive rehabilitation program without physical therapy. The exercise program will be provided to the patient.~The exercises consist of active and active assisted movements of the shoulder for a period of six weeks, limiting external rotation to 0 °. Patients are encouraged to use their affected limb for daily activities. Strengthening exercises are started the 6th week following surgery and the full program will be completed three months after surgery. Patients who wish can then continue their rehabilitation with a physiotherapist.~The patient will complete a daily diary to validate the frequency and intensity of the exercises."
224179586|NCT01113411|OTHER|Standard rehabilitation program|The patient will wear the thoraco brachial brace for a period of four weeks following the surgery. It may be taken off for hygiene purposes and dressing up. After the four weeks, the patient will take the brace off permanently and begins an exercise program, writing down the frequency and intensity of the exercises. Physiotherapy is allowed for the remaining part of the three months rehabilitation program.
224179587|NCT03936868|PROCEDURE|Tendon transfer|flexor carpi radialis transfer in most of patients and boye-transfer in very few
224179588|NCT03384316|BIOLOGICAL|ETBX-051; adenoviral brachyury vaccine|immunotherapeutic vaccine administered subcutaneously every 3 weeks for 3 doses, and then every 8 weeks for up to a year
224179589|NCT03384316|BIOLOGICAL|ETBX-061; adenoviral Mucin-1 (MUC1) vaccine|immunotherapeutic vaccine administered subcutaneously every 3 weeks for 3 doses, and then every 8 weeks for up to a year
224179590|NCT03384316|BIOLOGICAL|ETBX-011; adenoviral Carcinoembryonic antigen (CEA) vaccine|immunotherapeutic vaccine administered subcutaneously every 3 weeks for 3 doses, and then every 8 weeks for up to a year
224179591|NCT00050440|DRUG|Trabectedin|Trabectedin 1.3 mg/m2 administered intravenously every 21 days.
224179592|NCT00050440|DRUG|Dexamethasone|Dexamethasone 4 mg administered orally (by mouth) the day before the trabectedin dose, 30 minutes before the trabectedin dose, and for 2 days following the trabectedin dose
224179593|NCT03428230|DRUG|30 mg Paracetamol 3% (1 mL)|Single administration by intrathecal injection just before spinal anaesthesia. The injection will be performed according to the hospital procedures. For the intrathecal injection of Paracetamol followed by the intrathecal injection of the anaesthetic, two needles will be used: one introducer needle, which will serve to introduce the second needle through the skin, plus one intrathecal Pencil point needle (27-G or 25-Gauge or Reganesth or Nizell needle) to which the first syringe containing Paracetamol will be attached first, followed by the second syringe with the anaesthetic. In this way only one intrathecal puncture will be performed. Lumbar puncture will be done according to the standard hospital procedures.
224179594|NCT03428230|DRUG|60 mg Paracetamol 3% (2 mL)|Single administration by intrathecal injection just before spinal anaesthesia. The injections will be performed according to the hospital procedures. For the intrathecal injection of Paracetamol followed by the intrathecal injection of the anaesthetic, two needles will be used: one introducer needle, which will serve to introduce the second needle through the skin, plus one intrathecal Pencil point needle (27-G or 25-Gauge or Reganesth or Nizell needle) to which the first syringe containing Paracetamol will be attached first, followed by the second syringe with the anaesthetic. In this way only one intrathecal puncture will be performed. Lumbar puncture will be done according to the standard hospital procedures.
224205617|NCT06701981|OTHER|Filter comparison|Three filters will be compared on light discomfort thresholds using the Lumiz 100™ device
224205618|NCT00003981|DRUG|indisulam|
224205619|NCT02899442|OTHER|collective prevention in workplace|From countermeasures referenced in guidelines, some tools were also created by the committee to standardize all preventive actions and to define measurable indicators. A specific monitoring for checking their applicability and for evaluating the duration of implementation is planned.Collective actions are classified in 7 categories:1)Standardized information of night work risk on health and countermeasure to prevent them, 2)Acknowledgement of the existence of the risk, thereby helping to raise general awareness, 3)Improvement of characteristics of night work (rhythm, rest, time to start and to end, schedule forecasted, duration of night work),4)Improvement of related conditions at night work (Job strain, monotonous or repetitive tasks, manager's help, collective co-operation; Light environment; Occupational physical activities, 5)Sleep improvements ,6)Improvement of dietetic intakes at work, 7)Improvement of leisure physical activity's practice within the work site
224205620|NCT05349188|DIETARY_SUPPLEMENT|Melatonin 3 mg|Participants will be provided with a smart pill bottle containing a 4-week supply of 3 mg melatonin pills.
224205621|NCT05349188|DIETARY_SUPPLEMENT|Melatonin 0.5 mg|Participants will be provided with a smart pill bottle containing a 4-week supply of 0.5 mg melatonin pills.
224205622|NCT05349188|OTHER|Cellulose placebo pill|Participants will be provided with a smart pill bottle containing a 4-week supply of cellulose placebo pills.
224205623|NCT02756078|DEVICE|TEST Contact Lens|
224205624|NCT02756078|DEVICE|CONTROL Contact Lens|
224205625|NCT00005893|DRUG|anti-thymocyte globulin|
224205626|NCT00005893|DRUG|busulfan|
224205627|NCT00005893|DRUG|cyclophosphamide|
224205628|NCT00005893|PROCEDURE|Bone marrow transplantation|
224205629|NCT02528630|OTHER|Progressive resistance strength training program|Patients undergo to strength training for intrinsic muscles of the hand twice a week, during 12 weeks.
224205630|NCT02528630|OTHER|Joint protection and energy conservation advice|A session regarding joint protection and energy conservation for hands was done before randomization.
224205631|NCT04098471|PROCEDURE|transanal local excision following radiotherapy|transanal local excision following radiotherapy
224205632|NCT00574379|DRUG|Bilastine|Bilastine 10 or 20mg, once or twice daily for 14 days. Tablets
224205633|NCT00574379|DRUG|Placebo|Placebo tablets twice daily for 14 days
224205634|NCT04641754|DRUG|WX-0593 Tablets|tablets, 60 mg→180mg, quaque die（QD）
224179595|NCT03428230|DRUG|90 mg Paracetamol 3% (3 mL)|Single administration by intrathecal injection just before spinal anaesthesia. The injections will be performed according to the hospital procedures. For the intrathecal injection of Paracetamol followed by the intrathecal injection of the anaesthetic, two needles will be used: one introducer needle, which will serve to introduce the second needle through the skin, plus one intrathecal Pencil point needle (27-G or 25-Gauge or Reganesth or Nizell needle) to which the first syringe containing Paracetamol will be attached first, followed by the second syringe with the anaesthetic. In this way only one intrathecal puncture will be performed. Lumbar puncture will be done according to the standard hospital procedures.
224179596|NCT03428230|DRUG|Placebo, 0.9% saline solution|Single administration by intrathecal injection just before spinal anaesthesia. The injections will be performed according to the hospital procedures. For the intrathecal injection of Placebo followed by the intrathecal injection of the anaesthetic, two needles will be used: one introducer needle, which will serve to introduce the second needle through the skin, plus one intrathecal Pencil point needle (27-G or 25-Gauge or Reganesth or Nizell needle) to which the first syringe containing Placebo will be attached first, followed by the second syringe with the anaesthetic. In this way only one intrathecal puncture will be performed. Lumbar puncture will be done according to the standard hospital procedures.
224179597|NCT03428230|DRUG|NIMP: Chloroprocaine HCl 1% (10 mg/mL), solution for injection|Immediately after intrathecal administration of the Paracetamol dose or Placebo, all patients will receive a single intrathecal dose of Chloroprocaine HCl 1% according to the Summary of Product Characteristics indications. Time interval between the 2 administrations should not exceed 2 min.
224307274|NCT03567382|BIOLOGICAL|Monovalent HBV vaccine|Infants born to HBsAg-positive women will be given a single dose of monovalent HBV vaccine within 24 hours of life.
224307275|NCT01099527|DRUG|Everolimus (RAD001)|dose escalation of capecitabine, everolimus
224307276|NCT01099527|DRUG|Capecitabine|dose escalation of capecitabine, everolimus
224307277|NCT01385982|OTHER|Actionable Test Result Management/Standardization|The intervention includes enterprise-wide standardization of actionable test result (ATR) definitions with stratification of significant results into alert levels, expected timeframes for clinician responses, a set of policies for ATR follow-up, metrics to measure ATR management and performance feedback.
224307278|NCT02671227|DRUG|intrathecal Mg sulfate.|intrathecal Mg sulfate 50 mg.
224307279|NCT02671227|DRUG|intrathecal bupivacaine 15 mg.|intrathecal bupivacaine 15 mg.
224307280|NCT00039962|DRUG|thymalfasin (thymosin alpha 1)|
224307281|NCT00039962|DRUG|PEGinterferon alfa-2a|
224307282|NCT03550573|DEVICE|CardioInsight™ Noninvasive 3D Mapping System|"The CardioInsight system uses a proprietary, single-use, disposable multi-electrode vest to capture electrical signals from the body surface. The CardioInsight software provides various cardiac signal analyses and displays interactive 3-D color maps including activation, voltage, composite and phase maps. The vest wearing is coupled with a CT scan.~This exam will be performed only at baseline visit."
224307283|NCT03183492|BIOLOGICAL|Havrix®|One challenge dose of Havrix® administered intramuscularly (IM) in the deltoid region of the non-dominant arm.
224307284|NCT06047392|DIAGNOSTIC_TEST|CT coronary angiography|Patients will undergo a CTCA according to local, standard protocol.
224307285|NCT00131872|DEVICE|Expedial Vascular Access Graft|
224307286|NCT05215717|BEHAVIORAL|Self-Administered Hypnosis|Participants randomized to the self-administered hypnosis group will receive five audio-recordings of self-administered hypnosis, specifically targeting sleep improvement, which they will use for daily home practice.
224307287|NCT05215717|BEHAVIORAL|Self-Administered White Noise Hypnosis|Participants randomized to the white noise hypnosis control will receive the same information and contact with the therapist, but will be provided with audio recordings that contain white noise as a sham hypnosis condition. These recordings include instructions and the use of white noise as a hypnotic induction.
224307288|NCT00211120|DRUG|Epoetin Alfa|
224307289|NCT03601650|BEHAVIORAL|Mindful eating|Attending to the sensory properties of food as it is eaten
224307290|NCT03601650|BEHAVIORAL|Eating without distractions|Eating without intentionally attending to something else such as a television, smartphone, computer, book etc
224307291|NCT03055702|OTHER|Mobile phone text message reminder|an SMS remind subjects to come for scheduled clinic appointment 24-72 hours before
224307292|NCT00620659|DRUG|Comparator: MK0249|Patients will be assigned to receive MK0249 film coated tablet (FCT). The doses of MK0249 that are included for possible investigation (depending upon an adaptive allocation process) are 3 mg, 5 mg, 8 mg, 10 mg, and 12 mg. Study medication will be taken for 14 days, during each of the 3 treatment periods, by mouth (po) once a day (qd).
224307293|NCT00620659|DRUG|Comparator: placebo|Placebo; Patients will be assigned to receive placebo, across 3 treatment periods. Study medication will be taken for 14 days, during each of the 3 treatment periods, po qd.
224307294|NCT00620659|DRUG|Comparator: modafinil|Patients will be assigned to receive modafinil 200mg oral compressed tablet (OCT), across 3 treatment periods. Study medication will be taken for 14 days, during each of the 3 treatment periods, po qd.
224307295|NCT02359747|GENETIC|Polymerase Chain Reaction and Whole Genome Amplification|Polymerase Chain Reaction and Whole Genome Amplification
224307296|NCT02753491|BEHAVIORAL|Motivational short interview|New designed motivational short interview model
224307297|NCT01193127|DRUG|OMS302 Solution|
224307298|NCT01193127|DRUG|OMS302 Mydriatic Solution|
224307299|NCT01193127|DRUG|OMS302 Anti-inflammatory Solution|
224307300|NCT01193127|DRUG|Balanced Salt Solution (BSS) Solution|
224307301|NCT03035344|OTHER|Metabolome study|Metabolome study in ALL patients compared to healthy controls
224307302|NCT04366427|COMBINATION_PRODUCT|L-HBO|as previously described.
224307303|NCT04366427|COMBINATION_PRODUCT|HBO|as previously described.
224307304|NCT04366427|COMBINATION_PRODUCT|30% O2|as previously described
224307305|NCT04366427|COMBINATION_PRODUCT|50% O2|as previously described
224307306|NCT03030820|PROCEDURE|Dental Cleaning|This is standard of care dental cleaning as is guided by the initial dental evaluation
224307307|NCT03246646|BEHAVIORAL|Coaching|Telephone coaching was provided in a series of telephone based sessions with CSO participants
224307308|NCT00532038|DRUG|ThermoProfen™ (Matrix Transdermal Ketoprofen/CHADD™ System)|Patients will apply ThermoProfen daily for approximately 12 hours for up to 12 months for treatment of the pain associated with osteoarthritis of the knee.
224307309|NCT03889366|DRUG|Aprepitant 125 mg|Single dose in the fasted state during treatment period 1,2 or 3
224307310|NCT02688426|DEVICE|Sham Low-Level Laser Therapy (Sham LLLT)|perform with the machine off
224307311|NCT02688426|DEVICE|6J Low-Level Laser Therapy (6J LLLT)|irradiation will be perform with 6J
224307312|NCT01331226|BEHAVIORAL|telephone counseling 3 sessions|3 sessions of telephone counseling
224307313|NCT01331226|BEHAVIORAL|telephone counseling 1 session|1 session of telephone counseling
224307314|NCT01331226|BEHAVIORAL|written materials only|written materials only
224307315|NCT04919863|DRUG|NTP42:KVA4|Single ascending dose (SAD) or multiple ascending dose (MAD) of NTP42:KVA4 administered to healthy volunteers as an oral suspension.
224307316|NCT04919863|DRUG|Placebo|Placebo, matched to corresponding doses of NTP42:KVA4 administered to healthy volunteers as an oral solution.
224307317|NCT06309927|PROCEDURE|Operative hysteroscopy (by tissue removal device)|Surgical evacuation of the uterine cavity using the Truclear Mini-Elite hysteroscopic tissue removal device
223488889|NCT06627764|BEHAVIORAL|SER Familia|SER Familia is a six-session intervention co-developed and delivered by community health workers (CHWs) that uses strategies to reduce acculturative stress, promote resilience, improve parent-child and family level health, while simultaneously helping families maintain strong social networks and better navigate community resources to address social determinants of health (SDOH).
223488890|NCT06387069|DRUG|HMPL-306 Regimen|Patients will receive HMPL-306 monotherapy: HMPL-306 PO at 250 mg QD (C1) + 150 mg QD (starting from C2), 28 days as a cycle.
223488891|NCT06387069|DRUG|Salvage Chemotherapy Regimen|"Patients in this regimen will receive treatment with one of the following regimens, and the regimen will be selected by the investigator based on the patient's condition:~* EA±Mitox regimen: etoposide injection 100 mg/m2, cytarabine injection 100-150 mg/m2, mitoxantrone injection 8 mg/m2 QD IV for 5 consecutive days (Days 1-5).~* FLAG ± Ida regimen: G-CSF injection 300 mcg/m2 QD SC for 5 consecutive days (Days 1-5); fludarabine injection 30 mg/m2 QD IV for 5 consecutive days (Days 2-6); cytarabine injection 1000-2000 mg/m2 QD IV for 5 consecutive days (Days 2-6); idarubicin injection 10 mg/m2 QD IV for 3 consecutive days (Days 2-4).~* LoDAC: -Cytarabine Injection 20 mg every 12 hours, subcutaneous or IV for 10 consecutive days (Days 1-10).~* Azacitidine: Azacitidine Injection 75 mg/m2, QD, subcutaneous or IV for 7 consecutive days (Days 1-7)."
223488892|NCT03534323|DRUG|Duvelisib|This drug is designed to stop cancer growth by blocking a protein called phosphatidylinositide 3-kinase (PI3K), which is important for the survival of CLL cells.
224307318|NCT06309927|PROCEDURE|Suction curettage|Surgical evacuation of the uterine cavity with electrical vacuum suction curette
224307319|NCT02352779|DIETARY_SUPPLEMENT|Omega-3 Fatty Acid|Given PO
224307320|NCT02352779|OTHER|Placebo|Given PO
224307321|NCT02352779|OTHER|Questionnaire Administration|Ancillary studies
224307322|NCT02352779|OTHER|Laboratory Biomarker Analysis|Correlative studies
224307323|NCT05695677|PROCEDURE|Capacitive-Resistive Radiofrequency therapy of the neck muscles|Capacitive-Resistive Radiofrequency therapy of the neck muscles as a non-invasive technique for treating PDPH.
224307324|NCT04346420|OTHER|Standard interface|The standard interface for administering oxygen (nasal cannula or oxygen mask) is worn by the patient. Oxygen output is adapted to reach a SpO2 target of 94%.
223488893|NCT03534323|DRUG|Venetoclax|Venetoclax targets a protein called BCL-2, which helps cancer cells survive.
224072918|NCT02462473|DRUG|Aripiprazole|Participants will receive aripiprazole at a dose of 5 milligram (mg) or higher, as oral formulation once daily for 12 weeks as part of participant treatment.
224072919|NCT02462473|DRUG|Olanzapine|Participants will receive olanzapine at a dose of 5 mg or higher, as oral formulation once daily for 12 weeks as part of participant treatment.
224072920|NCT02462473|DRUG|Paliperidone|Participants will receive paliperidone 3 mg or higher dose as oral formulation once daily or 39 mg or higher dose once every 4 weeks for 12 weeks as part of participant treatment.
224072921|NCT02462473|DRUG|Quetiapine|Participants will receive quetiapine at a dose of 150 mg or higher, as oral formulation once daily for 12 weeks as part of participant treatment.
224072922|NCT02462473|DRUG|Risperidone|Participants will receive risperidone 1 mg or higher dose, as oral formulation once daily or as injection of 12.5 mg or higher dose once every 2 weeks for 12 weeks as part of participant treatment.
224072923|NCT03728309|DEVICE|JUVÉDERM VOLITE™ XC|Intradermal, needle in multiple microdepot injections across both cheeks.
224072924|NCT00397683|DRUG|MK0822|
224072925|NCT03950973|BEHAVIORAL|CareAvenue|CareAvenue is an e-health tool providing information about diabetes management and low-cost resources. Participants in this group have access to CareAvenue and receive a weekly automated phone call and text messages related to CareAvenue and its resources as well as diabetes management.
224072926|NCT03950973|BEHAVIORAL|Guest Assistance Program|The Guest Assistance Program (GAP) is a resource, which provides assistance with medical and non-medical needs and resources to patients receiving medical care at University of Michigan health system. Participants in this group are provided with GAP information and receive text messages related to diabetes management.
224072927|NCT03901950|DRUG|XNW7201 tablets|A wnt pathway inhibitor
224072928|NCT04453046|DEVICE|Hemopurifier|Two Hemopurifier treatments on Day 1 and Day 21
224072929|NCT04453046|DRUG|Pembrolizumab 200mg IV|Pembrolizumab 200mg IV will be administered every 21 days. One cycle is 21 days. All patients will be treated with Pembrolizumab for up to 34 cycles
224072930|NCT05047276|BIOLOGICAL|AloCelyvir|Delivery of Icovir-5 by mesenchymal carrier cells in uveal melanoma patients with hepatic metastases.
224072931|NCT02115204|DRUG|Epirubicin|
224072932|NCT02115204|DRUG|Cyclophosphamide|
224072933|NCT02115204|DRUG|Docetaxel|
224072934|NCT02115204|DRUG|Methotrexate|
224072935|NCT02115204|DRUG|5-fluorouracil|
224072936|NCT00953758|DRUG|PF-04449913|Escalating doses of PF-04449913 administered as tablets PO QD continuously in 28 day cycles
224072937|NCT04264247|DIAGNOSTIC_TEST|routine fetal ultrasonography at 11-14 weeks|routine fetal ultrasonography at 11-14 weeks
224072938|NCT02772861|DIETARY_SUPPLEMENT|Amino Acid Supplement - One dose|20gr
224307325|NCT04346420|DEVICE|Double-Trunk Mask|The standard nasal cannula interface accompanied with the DTM is worn by the patient. Oxygen output is adapted to reach a SpO2 target of 94%.
223488894|NCT02627807|RADIATION|IMRT using individualized CTV|Intensity modulated radiotherapy (IMRT) using individualized CTV based on disease extension risk atlas and computer-aided delineation is given as 2.13 Gy per fraction with five daily fractions per week for 6-7 weeks to a total dose of 70.29 Gy to the primary tumor.
223488895|NCT02627807|RADIATION|IMRT using traditional CTV|Intensity modulated radiotherapy(IMRT) using traditional CTV is given as 2.13 Gy per fraction with five daily fractions per week for 6-7 weeks to a total dose of 70.29 Gy to the primary tumor.
223488896|NCT02627807|DRUG|Gemcitabine and cisplatin (induction chemotherapy)|Induction chemotherapy is optional for patients with T2-4N0-3M0 NPC. Patients who participate in another randomized trial (NCT01872962) at the same time receive gemcitabine (1000 mg/m² d1,8) and cisplatin (80mg/m² d1) every 3 weeks for 3 cycles before radiotherapy.
223488897|NCT02627807|DRUG|Docetaxel and cisplatin (induction chemotherapy)|Induction chemotherapy is optional for patients with T2-4N0-3M0 NPC. Patients who haven't participated in other trials receive docetaxel (75 mg/m² d1) and cisplatin (75mg/m²,total dose average to d1-d3) every 3 weeks for 3 cycles before radiotherapy.
223488898|NCT02627807|DRUG|Cisplatin 100mg/m² concurrent chemotherapy|Cisplatin concurrent chemotherapy is required for patients with T2-4N0-3M0 NPC. Patients who participate another clinical trial (NCT01872962) at the same time receive cisplatin (100mg/m² d1) every 3 weeks for 3 cycles concurrently with radiotherapy.
223488899|NCT02627807|DRUG|Cisplatin 80mg/m² concurrent chemotherapy|Cisplatin concurrent chemotherapy is required for patients with T2-4N0-3M0 NPC.Patients who haven't participated in other trials receive cisplatin (80mg/m²,total dose average to d1-d3) every 3 weeks for 3 cycles concurrently with radiotherapy.
223488900|NCT02588365|BEHAVIORAL|Brain Training (Active)|Online computer games targeting attention, EF, and problem-solving
223488901|NCT02588365|BEHAVIORAL|Brain Training (Passive)|Online computer games targeting attention, EF, and problem solving
223488902|NCT02588365|BEHAVIORAL|Brain Training (Active or Passive)|Online computer games targeting attention, EF, and problem solving
223488903|NCT04913298|DEVICE|Cytosorb therapy|Start of Cytosorb therapy is at the discretion of the attending physician
223488904|NCT02595892|DRUG|Berzosertib|Given IV
223488905|NCT02595892|DRUG|Gemcitabine|Given IV
223488906|NCT02595892|DRUG|Gemcitabine Hydrochloride|Given IV
223488907|NCT06292663|DEVICE|Virtual Reality|The subjects get a supplement of information via. a Vitual Reality (VR) headset. The information they get through the VR headset is about their course on the day of their surgery.
223488908|NCT04869280|OTHER|No Intervention|This is a non-interventional study.
223488909|NCT01139879|DEVICE|P400 mattress|The P400 mattress will be placed for a period of 12 weeks.
223488910|NCT03859297|BEHAVIORAL|Rumination-Focused CBT|"RF-CBT targets rumination and other maladaptive forms of emotion regulation such as suppression and avoidance and provides skills training in effectively coping with rumination. RF-CBT specifically targets rumination through psychoeducation, adopting a functional analytic approach to the learned habitual behavior of rumination, and a focus on shifting process style. The adolescent is taught to notice triggers to ruminate as well as the consequences of rumination and to shift into practicing a more adaptive strategy such as an attention training exercise, behavioral activation, thinking in a concrete way, or active problem-solving. RF-CBT directly teaches adolescents to recognize rumination or when the participant gets stuck in their head and to notice the influence this has on their mood."
223488911|NCT03859297|BEHAVIORAL|Relaxation-based Therapy|Sessions will include progressive muscle relaxation, simple breathing techniques, and guided imagery that focus on bodily and somatic relaxation. Adolescents randomized to Relaxation Therapy (RelaxT) will also receive exercises to do as homework in between sessions, parallel to the RF-CBT group.
223488912|NCT04321512|OTHER|There is no intervention given to the subjects|Not appicable
223488913|NCT03867084|BIOLOGICAL|Pembrolizumab|IV infusion of Pembrolizumab 200 mg.
223488914|NCT03867084|DRUG|Placebo|IV infusion of 0.9% normal saline.
224072939|NCT02772861|DIETARY_SUPPLEMENT|3-Methylhistidine|120mgr
224072940|NCT02682901|DRUG|Cycloset|Cycloset 1.6 -3.2 mg/day
224072941|NCT02682901|DRUG|Placebo|Non-active placebo for cycloset
224072942|NCT05749380|DRUG|AmBisome|Reference, dose of 3 mg/kg.
224072943|NCT05749380|DRUG|DKF-5122|Test, dose of 3 mg/kg
224072944|NCT03971110|DRUG|Zoladex and Casodex|The eligible subjects will receive Casodex 50 mg orally per day in combination with Zoladex 10.8 mg implant subcutaneously as neoadjuvant therapy per 12 weeks for up to 24 weeks.
224072945|NCT00257803|DRUG|Oxytocin|See detailed description
224072946|NCT00257803|DRUG|Saline solution|See detailed description
224072947|NCT05753956|DRUG|5 Methoxy N,N Dimethyltryptamine|GH002 administered via i.v. bolus injection(s)
224072948|NCT05753956|DRUG|Placebo|GH002 placebo administered via i.v. bolus injection
224072949|NCT01487915|DRUG|GCb|Gemcitabine 1000 mg/㎡ D1, D8 plus Carboplatin AUC=4.5 D1 every 3 weeks
224072950|NCT01487915|DRUG|GemOx|Gemcitabine 1000 mg/㎡ D1 plus Oxaliplatin 100 mg/㎡ D1 every 2 weeks
224072951|NCT04110665|DRUG|Tramadol|Tramadol 100 mg tablet
224072952|NCT04110665|DRUG|Nefopam 20 MG/ML|120 mg for 24 hours
224072953|NCT04110665|DRUG|Morphine Sulfate|Tablet 10mg
224072954|NCT04110665|DRUG|Oxycodone 20mg|release
224072955|NCT05988801|OTHER|Glass ionomer sealant|glass ionomer-based sealant material
224072956|NCT05988801|OTHER|Resin based sealant|resin-based sealant material
224072957|NCT02313779|BEHAVIORAL|Lovingkindness Meditation (LKM)|Compassionate behavior training (REVISE)
224072958|NCT02313779|BEHAVIORAL|Mindfulness Meditation|
224072959|NCT03298022|BIOLOGICAL|ALTB-168|monoclonal antibody
224072960|NCT03313245|OTHER|No Intervention/Observational Study|No Intervention/Observational Study
224072961|NCT01787916|DRUG|Liraglutide|Liraglutide will be compared to placebo for 24 weeks in a cross-over design
224072962|NCT01787916|DRUG|Placebos|placebo will be compared to liraglutide for 24 weeks in a cross-over design
224072963|NCT05239520|OTHER|3D movement analysis with surface electromyography and ultrasound|Single measurement session of 3D movement analysis with surface electromyography for upper limb movements and ultrasound measurements of upper muscles
224205635|NCT01210885|BIOLOGICAL|Meningococcal Vaccine|MenABCWY combination vaccine containing four different rMenB formulations with MenACWY, intramuscular (IM) administration, vaccination at 0 and 2 months.
224205636|NCT05409599|OTHER|Exercises|Exercises
224205637|NCT00438685|BEHAVIORAL|Outpatient MST/OPTION-A|
224205638|NCT00438685|BEHAVIORAL|Usual Services|
224205639|NCT03265483|DIETARY_SUPPLEMENT|Magnesium glycinate|Oral administration of magnesium glycinate daily for 12 weeks
223488915|NCT06297668|DRUG|Treatment A: BGF MDI HFA|Participants will receive 4 inhalations of BGF MDI HFA as a single dose with AeroChamber Plus Flow-Vu spacer.
223488916|NCT06297668|DRUG|Treatment B: BGF MDI HFO|Participants will receive 4 inhalations of BGF MDI HFO as a single dose with AeroChamber Plus Flow-Vu spacer.
223587221|NCT06190327|BEHAVIORAL|Blended indoor and outdoor multicomponent structured exercise|Participants will receive a 16-week blended indoor and outdoor multicomponent structured exercise program, with 2 sessions per week (90 mins/session). Session 1/week will conduct in indoor setting, while session 2/week will conducted in outdoor setting (park). Each session will comprise 10-min warm-up, 30-min aerobic training, 20-min muscle strength, 20-min postural balance training, and 10-min cool-down.
223587222|NCT06190327|BEHAVIORAL|Indoor-only multicomponent structured exercise|Participants will receive a 16-week indoor-only multicomponent structured exercise program, with 2 sessions per week (90 mins/session). Both two sessions will conducted in indoor setting. Each session will comprise 10-min warm-up, 30-min aerobic training, 20-min muscle strength, 20-min postural balance training, and 10-min cool-down.
223587223|NCT07088432|DRUG|Dexamethasone|Single intravenous injection of 8 mg dexamethasone (2 mL) administered 5 minutes before spinal anesthesia. This intervention was tested for its effect on prolonging the duration of sensory and motor blocks induced by hyperbaric bupivacaine combined with sufentanil. The drug was administered under sterile conditions by an anesthesiologist blinded to group allocation.
223587224|NCT07088432|DRUG|Placebo|Single intravenous injection of 2 mL isotonic saline (0.9% NaCl) administered 5 minutes before spinal anesthesia. This placebo was used to mimic the dexamethasone injection in the control group. The preparation, volume, and timing were identical to the intervention group to maintain blinding. The saline was administered under sterile conditions by an anesthesiologist blinded to group allocation.
223587225|NCT05822050|DRUG|Selinexor|XPO1 inhibitor
223488917|NCT06297668|DRUG|Treatment C: BGF MDI HFO|Participants will receive 4 inhalations of BGF MDI HFO as a single dose without spacer.
223488918|NCT06297668|DEVICE|AeroChamber Plus Flow-Vu spacer|Participants will receive 4 inhalations of BGF MDI HFA (Treatment A) and BGF MDI HFO (Treatment B) as a single dose with spacer.
223488919|NCT04155528|OTHER|Music therapy|The intervention is listening to selected prerecorded music, specific Raga, on the individual CD player.
223488920|NCT05373680|DRUG|Metformin|Patients will receive metformin 1000 mg PO daily added to their usual therapy for the management of CKD (including the management of predisposing causes with other supportive care).
223488921|NCT05373680|DRUG|Empagliflozin|Patients will receive empagliflozin 10 mg daily PO added to their usual therapy for the management of CKD (including the management of predisposing causes with other supportive care).
223488922|NCT05373680|OTHER|Control|Patients will receive their usual therapy for the management of CKD (including the management of predisposing causes with other supportive care).
223587226|NCT02580786|BEHAVIORAL|Breastfeeding peer support|
223587227|NCT05511350|DRUG|TJ210001|
223587228|NCT01011972|DRUG|XMT-1107|6 mg XMT-1107 administered by I.V. (in the vein) administered over 90 min, once every 21 days : until progression or unacceptable toxicity develops
223587229|NCT01714258|PROCEDURE|cardiac output measurement|non invasive cardiac output estimation based on passive induced prolonged expiration in mechanically ventilated patients
224072964|NCT00016666|DRUG|Propranolol|
224072965|NCT00205478|DRUG|VX-702|
224072966|NCT04632498|BEHAVIORAL|Mindfulness Based Intervention|Standardized 8-week Cognitive and Behavioral Psychotherapy group with 26 hrs of in-class training and homework, along with 1 all-day retreat in which core mindfulness skills are developed
224072967|NCT01120119|DRUG|Calcitriol|
224072968|NCT01422239|BEHAVIORAL|Tailored treatment|8 sessions of individual behavioral counseling. The first 3 sessions will be 45 minutes long and include 30 minutes tailored to the perceived risks of quitting most strongly held by each participant. The final 5 sessions will be 30 minutes long and include material from the Mayo Clinic's smoking cessation manual.
224072969|NCT01422239|BEHAVIORAL|Standard Treatment|8 sessions of individual behavioral counseling. The first 3 sessions will be 45 minutes long and include 30 minutes focused on the benefits of quitting smoking. The final 5 sessions will be 30 minutes long and include material from the Mayo Clinic's smoking cessation manual.
224072970|NCT00384020|DRUG|Paroxetine (Seroxat)|
224072971|NCT00384020|DRUG|Escitalopram (Lexapro)|
224072972|NCT02624037|OTHER|Individualized Dosage Precision IFX Dashboard|Pharmacokinetic Dashboard Recommended Dosage and Dosing Frequency of Infliximab
224072973|NCT01051141|BEHAVIORAL|Computer-delivered Brief Intervention (CBI)|"The multimedia, interactive CBI condition will be delivered using touch-screen tablet computers with audio delivered via headphones. The interventions are highly individualized and designed to address the primary target behavior of alcohol use, and will include a tailored review of participants' goals/values, feedback regarding their present alcohol use patterns and consequences (either actual experiences or potential based on risk behaviors), developing a discrepancy between their alcohol use and ability to meet goals and values through a decisional balance exercise, and formulation of a change plan tailored for each participant."
224072974|NCT01051141|BEHAVIORAL|Intervener-delivered Brief Intervention (IBI)|"The IBI condition will be delivered by a master's-level clinician with the aid of graphics. The interventions are highly individualized and designed to address the primary target behavior of alcohol use, and will include a tailored review of participants' goals/values, feedback regarding their present alcohol use patterns and consequences (either actual experiences or potential based on risk behaviors), developing a discrepancy between their alcohol use and ability to meet goals and values through a decisional balance exercise, and formulation of a change plan tailored for each participant."
224072975|NCT01051141|BEHAVIORAL|Adapted Motivational Enhancement Therapy (AMET)|The AMET session will have a similar general outline (\~45 minutes) to the BI in the ED, including a review of participants' goals and values, alcohol use and consequences, decisional balance exercises, and change plan.
224179598|NCT04778995|OTHER|Structured online training program for effective management of nursing services|"An online structured training program was prepared to reach out to manager nurses for increasing their knowledge regarding the effective management of nursing services in crisis periods. A web page was structured with the support of a professional computer engineer.~Participant manager nurses could log into the system via a personal username and password on the main login screen of the site. In this page, there is an Informed Consent Form.~In the Download Training Documents link; the educational content prepared in sections was presented. Educational content consisted of the issues such as: Management of Crises and Emergency Situations, Leadership in Crisis, Planning and Managing Nurse Human Power in Crisis, Supervision and Management of Patient Care, Logistics and Support Services, Communication in Extraordinary Situations, Motivation Tools Used in Extraordinary Situations, Stress Management During Crisis and Employee Adaptation and Training in Crisis."
224179599|NCT00219310|DRUG|Famciclovir|
224179600|NCT01970124|DRUG|KPS-0373, High dose|
224179601|NCT01970124|DRUG|KPS-0373, Low dose|
224179602|NCT02779621|PROCEDURE|Self-collecting a vaginal sample with a swab for HPV testing|The vaginal sample self-collected with the Floq swab will be tested for Human Papillomavirus (HPV) using Abbott RealTime PCR assay.
224179603|NCT02779621|PROCEDURE|Collection of cervical sample for routine cervical screening|This is the routine cervical screening test available to the public through the NHS. This sample is collected by a clinician (usually a Practice Nurse)
224179604|NCT01091116|DRUG|MEN16132 - 0.125 mg|Intra-articular administration of two low doses of MEN16132 at 2-week interval.
224179605|NCT01091116|DRUG|MEN16132 - 0.25 mg|Intra-articular injection of two intermediate doses of MEN16132 at 2-week interval
224179606|NCT01091116|DRUG|MEN16132 - 0.5 mg|Intra-articular injection of two high doses of MEN16132 at 2-week interval
224179607|NCT01091116|DRUG|MEN16132 - 0.5 mg|Single intra-articular injection of one high dose of MEN16132, followed by one dose of placebo at 2-week interval
224179608|NCT01091116|DRUG|Placebo|Intra-articular injection of 2 doses of Placebo control at 2-week interval
224179609|NCT01160458|DRUG|IMC-A12|20 mg/kg intravenous over 60 minutes or not to exceed 25 mg/minute once every 3 weeks (+ or -1 day cycle 3 and beyond)
224179610|NCT04305158|DRUG|Nitrous Oxide|Patient receiving nitrous oxide are evaluated for success of the procedure
224179611|NCT00085189|BIOLOGICAL|gp100 antigen|Given SC
224179612|NCT00085189|BIOLOGICAL|tyrosinase peptide|Given SC
224179613|NCT00085189|BIOLOGICAL|recombinant MAGE-3.1 antigen|Given SC
223488923|NCT05143255|BEHAVIORAL|KNOW|KNow the Optimal Way (KNOW) is a manualized ADRD patient-care partner intervention designed to increase engagement in advance care planning (ACP) and completion of advance directives among early stage ADRD patients and their care partners using theoretically grounded distress tolerance techniques (inhibitory learning theory) and communication skills (cognitive-social processing theory) consistent with recommended guidelines for discussions about ACP in ADRD care.
223488924|NCT05568511|OTHER|App-based exercise program|Remotely-controlled, app-guided exercise program
223488925|NCT05568511|OTHER|Standard of Care|These participants will follow the usual post-sepsis care after returning to home. The participants will be asked to log their daily activities in the app's health diary. The app will be activated for the baseline and follow-up physical function assessments, which will be supervised be a blinded coordinator via a video call.
223488926|NCT04458194|OTHER|Standard Care|Standard Care is used as a control condition. Cancer survivors assigned to this arm continue to receive standard care from their medical providers.
224179614|NCT00085189|BIOLOGICAL|multi-epitope melanoma peptide vaccine|Given SC
224179615|NCT00085189|BIOLOGICAL|incomplete Freund's adjuvant|Given SC
224179616|NCT00085189|DRUG|Montanide ISA 51 VG|Given SC
224179617|NCT00085189|DRUG|agatolimod sodium|Given SC
224179618|NCT00085189|OTHER|laboratory biomarker analysis|Correlative studies
224179619|NCT04841928|BEHAVIORAL|Mindful attention|The Mindful attention treatment component consists of a breathing exercise and is operationalized as two sessions (1 hour each) delivered over two weeks, i.e., one session per week, with homework between sessions. Sessions will be delivered online.
224179620|NCT04841928|BEHAVIORAL|Decentering|The Decentering treatment component consists of a guided imagery exercise and is operationalized as two sessions (1 hour each) delivered over two weeks, i.e., one session per week, with homework between sessions. Sessions will be delivered online.
224205640|NCT03265483|DIETARY_SUPPLEMENT|Placebo|Oral administration of identical-appearing placebo daily for 12 weeks
224205641|NCT01797809|DRUG|EV/DNG (Qlaira, BAY86-5027)|Patients in daily life clinical practice tratment receiving Qlaira according to indication on the label.
224205642|NCT02275039|BIOLOGICAL|modified vaccinia virus ankara vaccine expressing p53|Given SC
224205643|NCT02275039|DRUG|gemcitabine hydrochloride|Given IV
223488927|NCT04458194|BEHAVIORAL|YOCAS©® yoga|Yoga for Cancer Survivors, YOCAS©®, intervention is a low to moderate intensity mode of exercise that draws from two basic types of yoga; gentle Hatha and Restorative yoga. The program includes specific physical postures and mindfulness exercises focused on breathing and meditation. Cancer survivors will participate in 8 virtual YOCAS sessions (75 minutes/session, 2 times a week for 4 weeks) delivered via an electronic platform (e.g., Zoom)
223587230|NCT04386876|DRUG|Lopinavir/Ritonavir 200 mg/50 mg Film Tablet|Lopinavir/Ritonavir film tablet containing 200 mg lopinavir and 50 mg ritonavir (World Medicine-Turkey).
223587231|NCT04386876|DRUG|Lopinavir/Ritonavir 200 mg/50 mg Film Coated Tablet|Lopinavir/Ritonavir film coated tablet containing 200 mg lopinavir and 50 mg ritonavir(AbbVie Deutschland GmbH \& Co.-Germany)
223587232|NCT03968783|OTHER|Monofilament suture|1.0 monofilament synthetic absorbable suture for closure of the low transverse uterine incision
223587233|NCT03968783|OTHER|Multifilament suture|1.0 multifilament synthetic absorbable suture for closure of the low transverse uterine incision
224205644|NCT02275039|OTHER|laboratory biomarker analysis|Correlative studies
224205645|NCT03304990|OTHER|Patients with CA or suspected risk of CA or a family Hx|Patients with Family History of Cancer, (ii) Patients with Clinical and Environmental Risk Factors for Cancer, (iii) Patients with a Suspected or Confirmed Diagnosis of Cancer.
224205646|NCT00835068|OTHER|No intervention|As it is a non interventional study, patient receives his usual treatment (BeneFIX) as determined by the physician
224179621|NCT04841928|BEHAVIORAL|Value-based action|The Values and committed action treatment component consists of identification of personal values and committed action, and is operationalized as two sessions (1 hour each) delivered over two weeks, i.e., one session per week, with homework between sessions. Sessions will be delivered online.
224179622|NCT03167866|BEHAVIORAL|motivational SMS|the participant receives a weekly text message that is aimed to increase motivation
224179623|NCT03167866|BEHAVIORAL|informational SMS|the participant a weekly text message that is provides information on improving lifestyle
224179624|NCT05220020|PROCEDURE|TACE(Transcatheter arterial chemoembolization)|Hepatic arterial chemoembolization treatment
224179625|NCT05220020|DRUG|Lenvatinib|Experimental group(Synchronous treatment group): the first course of TACE treatment was started after 2-3 weeks Lenvatinib treatment.Control group:(Sequential treatment group)patients with uncontrolled TACE progression after TACE treatment were sequentially treated with Lenvatinib.
223488928|NCT03191058|DEVICE|Magnetic Seizure Therapy|"MST treatment will be administered using the MagPro MST with a Cool TwinCoil over the frontal cortex in the midline position using 100 Hz stimulation. The MST determination of seizure threshold will be done using 100% machine output applied at 100 Hz at progressively escalating train durations, commencing at 2 seconds and increasing by 2 seconds with each subsequent stimulation until an adequate seizure is produced. During subsequent sessions, one stimulation will be delivered using a train duration that is 4 seconds longer than the train duration at threshold (with a maximum train duration of 10 seconds).~This will be performed under the effect of anesthesia. The treatment procedure is approximately 10 minutes, followed by a recovery period of approximately 30 minutes."
223488929|NCT03191058|DEVICE|Electroconvulsive Therapy|In the ECT arm treatment, the MECTA spectrum 5000Q or the MECTA Sigma devices will be used, which are FDA approved devices used for providing standard-of-care clinical ECT treatments. The ECT determination of seizure threshold and the adjustment of energy at subsequent sessions will be based on a standard published protocol. All participants will receive RUL-UB ECT at six times the seizure threshold under the effect of anesthesia. The treatment procedure is approximately 10 minutes, followed by a recovery period of approximately 30 minutes
223488930|NCT04967222|BEHAVIORAL|Cognitive Reappraisal by Distancing|Reappraisal-by-distancing treatment. Participants meet 2 times a week for 6 weeks to learn reappraisal by distancing through repeated practice with negative emotional pictures. The therapist will help model and shape the technique. .
223488931|NCT04967222|BEHAVIORAL|Control Downregulate Condition|Participants either meet 2x a week for 6- weeks to gain added practice, under the guidance of a therapist, using their customary emotion regulatory strategies to downregulate their negative reactions to aversive pictures.
223488932|NCT05776069|DRUG|VGA039|Single doses of VGA039
223488933|NCT05776069|OTHER|Placebo|Single doses of Placebo
223488934|NCT05776069|DRUG|VGA039|Multiple doses of VGA039
223488935|NCT05746325|OTHER|Digital Photography|Digital photographs taken of array placement
223488936|NCT05746325|PROCEDURE|Lumbar Puncture|Undergo LP
223488937|NCT05746325|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223488938|NCT05746325|DEVICE|Medical Device Usage and Evaluation|Transducer arrays applied and wear NovoTTF-200T
223488939|NCT05746325|PROCEDURE|Biospecimen Collection|Undergo collection of cerebrospinal fluid (CSF) during screening if no CSF testing for malignancy has been done previously
224307326|NCT03039660|BEHAVIORAL|RefreshMD|Online Sleep Improvement Course
224307327|NCT03039660|BEHAVIORAL|Bond Between Us|Online Educational Course
223488940|NCT01295944|DRUG|Carboplatin|Carboplatin will be given on day 1 of each cycle; the carboplatin dose should be calculated using the Calvert formula: Carboplatin dose (mg) = target Area Under the Curve (AUC) x (Creatinine clearance (CrCl) + 25; The total duration of treatment will be 6 cycles. After cycle 6, carboplatin should be discontinued.
223488941|NCT01295944|DRUG|Bevacizumab|Bevacizumab will be administered on days 1 and 15 of each cycle. Bevacizumab will be administered at a dose of 10 mg/kg; The total duration of treatment will be 6 cycles. After cycle 6, bevacizumab may be continued at the discretion of the treating physician.
223488942|NCT01149083|PROCEDURE|Biopsy|Undergo biopsy
223488943|NCT01149083|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223488944|NCT01149083|DRUG|Carboplatin|Given IV
224179626|NCT03778476|OTHER|Isometric Exercise|Participants will be asked to hold a submaximal voluntary contraction of the quadriceps muscle as long as they can (task failure).
223488945|NCT01149083|PROCEDURE|Computed Tomography|Undergo CT
223488946|NCT01149083|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223488947|NCT01149083|DRUG|Veliparib|Given PO
223488948|NCT05599490|OTHER|Computerized Plasticity-Based Adaptive Cognitive Training|Forty-two minutes of training on computerized exercises that targets processing speed, memory and attention.
223488949|NCT03741127|DRUG|Rimiducid may be administered as indicated|Patients who received P-BCMA-101 in a previous trial will be evaluated in this trial for long term safety and efficacy. Rimiducid (safety switch activator) may be administered as indicated.
223488950|NCT02315612|BIOLOGICAL|CD22-CAR|CD22-CAR cells will be infused on Day 0 after induction chemotherapy regimen.
224179627|NCT05076981|DRUG|human chorionic gonadotropin|once the dominant follicle reaches 17mm or above, a bolus of 6500 rhCG (Ovitrelle, Merck-Serono) will be administered subcutaneously
224179628|NCT04252872|DRUG|HCP0605|
224179629|NCT04252872|DRUG|HGP1405|
224179630|NCT04252872|DRUG|HCP1401|
224179631|NCT04623281|DEVICE|Sixty device|Prototype wearable hydration monitor to be worn by patient during dialysis and at night
224179632|NCT01730768|DRUG|AQW051|
224179633|NCT01730768|DRUG|Placebo|
224179634|NCT05094258|PROCEDURE|unicondylar knee prosthesis with mobile insert|Patients with unicondylar knee replacement using the mobile insert option
224179635|NCT05094258|PROCEDURE|unicondylar knee prosthesis with fixed insert|Patients with unicondylar knee replacement using the fixed insert option
223488951|NCT05984654|PROCEDURE|Platelet rich plasma therapy|"Approximately 30 ml of the patient's blood sample will be drawn from a peripheral vein in ACD (acid citrate dextrose) tubes. A double spin method will be used for the preparation of PRP.~Note this is not a device or a medicine as this is autologous plasma."
224179636|NCT03263767|DRUG|Fludarabine|30 mg/m² Intravenous 5 days from Day-6 to Day-2
224179637|NCT03263767|DRUG|Clofarabine|30 mg/m² Intravenous 5 days from Day-6 to Day-2
224179638|NCT03263767|RADIATION|Full body irradiation|2 grays at Day-1
224179639|NCT03263767|DRUG|Cyclophosphamide|14 mg/kg intravenous 2 days at Day - 6 and day -5
224179640|NCT03263767|DRUG|Cyclophosphamide|50 mg/kg intravenous 2 days at day +3 and day +4
224179641|NCT03263767|OTHER|stem cell transplantation|at D0 intraveinous Depending on donor : the stem cells will be extracted from blood (CD34+) or from bone marrow (CD34+ and nuclear cells)
224179642|NCT03263767|OTHER|nuclear cells|CD3+ cells if needed after transplantation
224179643|NCT03263767|DRUG|Thymoglobulin Injectable Product|At day -2 2.5 mg/kg for patients inclued after 14 dec 2020
224179644|NCT02194699|BIOLOGICAL|Experimental: Tralokinumab|Tralokinumab subcutaneous injection
224179645|NCT02194699|OTHER|Placebo|Placebo subcutaneous injection
224179646|NCT01908335|DRUG|PEG-IFN-SA /RBV low dose|24 weeks for genotype 2,3 and 48 weeks for non-genotype2,3
224179647|NCT01908335|DRUG|PEG-IFN-SA /RBV middle dose|24 weeks for genotype 2,3 and 48 weeks for non-genotype2,3
224179648|NCT01908335|DRUG|PEG-IFN-SA /RBV high dose|24 weeks for genotype 2,3 and 48 weeks for non-genotype2,3
224179649|NCT01908335|DRUG|Pegasys /RBV|24 weeks for genotype 2,3 and 48 weeks for non-genotype2,3
223488952|NCT02783274|DEVICE|Actis Total Hip System|Total Hip Replacement and Hemi-hip Replacement
223488953|NCT06387394|DRUG|BOTOX|Intramuscular Injections
223488954|NCT06387394|DRUG|Placebo|Intramuscular Injections
223488955|NCT04717557|DRUG|Hyperbaric Oxygen|Hyperbaric oxygen (HBO2) 1-2 times daily for up to 10 times after amputation
224072976|NCT05167019|BEHAVIORAL|CODE intervention|The CODE intervention consists of 1) One interactive session of 2 to 3 hrs focusing on the concepts of medical-ethical decision-making, the psychological challenge of dealing with ethically sensitive medical topics, and empowering leadership. 2) Observation and debrief of the interdisciplinary meeting to enhance self-reflection on empowering leadership and managing group dynamics. 3) Individual coaching on the spot in self-reflective and empowering leadership and in managing groups dynamics with regard to ethical decision-making about patients who are perceived to receive excessive treatment during the intervention period, and in absence of such patients, every item with regard to ethical decision-making that is important for the coachee. 4) During the intervention coaches and doctors in charge will be informed of the presence of a patient potentially receiving excessive treatment in their ward by an electronic alert.
223488956|NCT03745287|BIOLOGICAL|CTX001|Administered by IV infusion following myeloablative conditioning with busulfan.
223488957|NCT06265220|DRUG|AB-101|NK Cell Therapy
223488958|NCT06265220|DRUG|Cyclophosphamide|Lymphodepleting chemotherapy
223488959|NCT06265220|DRUG|Fludarabine|Lymphodepleting chemotherapy
223488960|NCT06265220|DRUG|Rituximab|Anti-CD20 antibody therapy
223488961|NCT06265220|DRUG|Obinutuzumab|Anti-CD20 antibody therapy
223488962|NCT04184895|BIOLOGICAL|ASP2390|Intradermal
224072977|NCT05167019|OTHER|Usual care|The control group will receive usual care in which the quality of the ethical decision-making is determined by the clinical team according to their usual practice. Except from a treatment-limitation-decisions guideline which focuses on the legal and deontological framework, no other guideline with regard to ethical decision-making has been implemented at the Ghent University Hospital. In one ward (geriatrics), there is a ongoing project in which a clinical nurse specialist stimulates and performes advance care planning conversations with patient and/or relatives at request of the team and who organizes debriefings when needed based on the ethical concerns of the nurses.
224179650|NCT01143662|DRUG|Ypeginterferon alfa-2b|sc, qw, for 48 weeks.
224179651|NCT01143662|DRUG|Peginterferon alfa-2a|sc, qw, for 48 weeks.
224179652|NCT00298766|DRUG|VELCADE|"Once weekly at: 0.7, 1.0, 1.3 or 1.6 mg/m2~Or~Twice-weekly at: 0.7, 1.0, or 1.3 mg/m2"
224179653|NCT00582842|BEHAVIORAL|Interview|The phone interview will consist of the following items from the follow up questionnaire; 14, 16, 20, 32, 33, 46, 47, 60, and 65. An additional component of this study would be dispensing the HRQOL tool to long-term survivors 10 years or greater after the completion of therapy. The long term QoL study will be a cross-sectional assessment measuring HRQOL in prostate cancer survivors, free of disease at least ten years post-treatment. Patients will complete a questionnaire by selfreport focusing on assessment of HRQOL.
223488963|NCT04184895|BIOLOGICAL|Placebo|Intradermal; normal saline solution
223488964|NCT06440707|DEVICE|High-definition Cathodal Transcranial Direct Current Stimulation (HD C-tDCS)|The active study treatment involves delivering a weak form of electrical stimulation via 5 small electrodes to the brain tissue at risk of infarction.
223488965|NCT06440707|DEVICE|Sham tDCS|Sham patients will have cap and electrodes in place, but no stimulation will be delivered.
223488966|NCT03964116|OTHER|Questionnaires set all 3 months|"This longitudinal study based upon repeated and multicentric measurement will recruit AYA with cancer in care Units dedicated to them or not. Measures will be quantitative, and repeated every 3 months by questionnaires, as well as qualitative (social network questionnaire, psychological research interview) for teenagers declaring a negative event or a death event during treatments.~Those patients presenting a high depression score will be contacted by a research psychologist for semi-directed interview."
224205647|NCT03156426|OTHER|Event of interest: Acute kidney injury|AKI as defined by AKIN staging
224205648|NCT02009072|PROCEDURE|Sutureless and glue free limbal conjunctival autograft|Simple pterygium excision under local anesthesia was performed then closure of the bare sclera by sutureless and glue free conjunctival autograft in 50 eyes of 50 patients (group 1)
224205649|NCT02009072|PROCEDURE|Sutured limbal conjunctival autograft|Simple pterygium excision under local anesthesia was performed then closure of the bare sclera by sutured limbal conjunctival autograft in 100 eyes of 100 patients (group 2).
224205650|NCT02575807|BIOLOGICAL|CRS-207|via IV infusion
224205651|NCT02575807|DRUG|Epacadostat|PO BID
224205652|NCT02575807|BIOLOGICAL|Pembrolizumab|via IV infusion
224179654|NCT00582842|BEHAVIORAL|survey instruments using Web-Based Data Collection System (WBDC) survey content|The content of the WBDC questionnaire will be similar to the paper form, no alteration in the wording, the order, or the formate of the items will be done. In addition, at the time of each outpatient clinic visit to MSKCC, these subjects will be able to login to WBDC using a computer located in the patient waiting-area, and enter their responses to the different items of the questionnaire if their clinic visit corresponds to any of the study time points 3, 6, 9, 12, 15, 18, 24, 36, and 48 following treatment). An additional component of this study would be dispensing the HRQOL tool to long-term survivors 10 years or greater after the completion of therapy. The long term QoL study will be a cross-sectional assessment measuring HRQOL in prostate cancer survivors, free of disease at least ten years post-treatment. Patients will complete a questionnaire by selfreport focusing on assessment of HRQOL.
224179655|NCT05546515|DRUG|Suvorexant (dual orexin receptor antagonist)|Participants will be prescribed up to 30 days of SUVO.
224179656|NCT05546515|DRUG|Placebo|Participants will be prescribed up to 30 days of placebo medication.
224179657|NCT02515604|DRUG|Misoprostol|
224179658|NCT04854603|OTHER|Food|Dairy products with regular and reduced sugar content and water control.
224179659|NCT03851315|DEVICE|permanent left bundle branch area pacing|Implant the pacing lead in the left bundle branch area instead of traditional RV pacing site(septal or apical). Successful LBBAP was defined as the paced QRS morphology of right bundle branch block pattern in lead V1 and QRS duration (QRSd) less than 130ms.
224179660|NCT00386152|DRUG|epoetin alfa|80,000 Units and 120,000 Units of epoetin alfa (PROCRIT) injected subcutaneously once every 3 weeks for up to 13 weeks
224179661|NCT00386152|DRUG|darbepoetin alfa|500 mcg of darbepoetin alfa (ARANESP) injected subcutaneously the skin once every 3 weeks for up to 13 weeks
224179662|NCT00697242|BIOLOGICAL|Engerix™-B|Intramuscular injection, 3 doses
224179663|NCT00697242|BIOLOGICAL|Recombinant HBsAg with different concentrations of Aluminium Salts and/or MPL|Intramuscular injection, 3 doses
224307328|NCT05255874|OTHER|Aromatherapy|Patients in the study group will rest for 5 minutes before and after the urodynamics procedure. All patients will be asked to fill in the 'Spielberger State Anxiety Scale' before and after the urodynamic procedure. Before and after the procedure, blood pressure, heart rate, respiratory rate, peripheral oxygen saturation will be measured. Blood will be drawn for serum cortisol level. In addition to the routine treatment and care practices of the unit, aromatherapy will be applied to the patients included in the study group. Aromatherapy application will be applied to all patients by the same researcher. Aromatherapy application will be started 5 minutes before the urodynamic procedure after the patient is taken to the urodynamic room, and lavender essential oil (3 drops in 300 cc water for 5 cubic meters of room) will be used with a diffuser until the end of the procedure.
224307329|NCT06506162|OTHER|Flavor|The study will compare sweet vs. cool flavors
224307330|NCT06506162|OTHER|Nicotine concentration|The study will compare low vs. high strength Oral Nicotine Products
224307331|NCT02280668|OTHER|Icing Therapy|Participants will be randomly assigned into 3 experimental groups. Icing Protocol 1 has participants apply cold packs under the supervision of the principal investigators to their elbow flexor region for 10 minutes on, 10 minutes off, followed by an additional 10 minutes on, starting at time 0. Icing Protocol 2 follows the same procedure but it begins 6 hours after the participant has completed their eccentric muscle damaging exercise and is to be done at home without the supervision of the principal investigators. Both protocols require the participants to repeat their icing procedures every 24 hours until their involvement with the study is finished, which is 7 days in duration. The third experimental group is the control group and will not participate in an icing therapy during the duration of the study.
224179664|NCT01763099|BIOLOGICAL|Mesenchymal stem cells|Mesenchymal stem cells will be intravenously infused via a central venous catheter(at a dose of 1×10\^6 cells/kg, over 15 min) in day 1 and day 15 of the cycle. If the NEU and PLT levels do not attain the completely response(CR)standards after this cycle, mesenchymal stem cells combined with cord blood will be given. If the NEU and PLT levels attain the completely response(CR)or partly response(PR) standards after this cycle, another cycle with the same strategy will be given.
224179665|NCT01763099|BIOLOGICAL|Mesenchymal stem cells and cord blood|Mesenchymal stem cells will be given (at a dose of 1×10\^6 cells/kg,intravenously infused via a central venous catheter)on day 1.day 15, day 29 and day 43 of the cycle. Cord blood will be given intravenously infused via a central venous catheter on day 2 of the cycle.
224179666|NCT06346639|OTHER|16-day hot and cold acclimation|Acclimation program will consist of 8 brief cold water immersions (CWI; 14°C 5 min) and 8 hot water immersions (HWI; 45°C 5 min). Heat and cold sessions will be performed on separate days (i.e., 1st day hot exposure, 2nd day cold exposure, 3rd day hot exposure, etc.).
224179667|NCT01785342|OTHER|Biosample and Imaging Collection|Collection of listed biosamples and CT imaging.
224307332|NCT02280668|OTHER|the eccentric muscle damage exercise|
224307333|NCT05323331|OTHER|Circuit Training Exercise Program|The participants allocated to this group will perform Circuit Training Exercise Program
223587234|NCT02179541|OTHER|RGB|When a circular area of 30 surrounding pixels are placed exactly upon the above-mentioned standardized points, the Adobe Photoshop Elements 7.0 program automatically measures the numerical values of the RGB color components in that area. The RGB values of the same points on the tympanic membrane images of the two groups were obtained and compared. Diagnostic significance of objectively assessed color changes at the tympanic membrane in OME patients was evaluated.
224179668|NCT06410833|DRUG|Rituximab|Rituximab weekly until B%\<0.5% or B#\<20×10\^6/L
224307334|NCT05323331|OTHER|Aerobic Training Exercise Program|The participants allocated to this group will perform Circuit Training Exercise Program
223587235|NCT01071629|OTHER|Exercise training|Interval training (30 sec 50% of peak Work Rate achieved at the steep ramp test/60 sec recovery no exercise) for 40 min in the interval training group
223587236|NCT01071629|OTHER|Exercise training|Interval training (30 sec 50% of peak Work Rate achieved at the steep ramp test/60 sec recovery no exercise) for 20 min and Strength training of the quadriceps, hamstrings, muscles of the shoulder and biceps brachialis for 20 min 3 times per week for 36 sessions
224307335|NCT04142892|DRUG|Onapristone|50 mg given orally (PO), twice a day (BID), in a continuous schedule (QD) during 3 weeks (+/-3 days)
223587237|NCT05235919|DEVICE|repetitive transcranial magnetic stimulation (rTMS)|30 minutes rTMS session 5 days/week for 3 weeks.
223488967|NCT04592172|BEHAVIORAL|Bedtime Routine Education|The intervention aims to promote healthy sleep and improved developmental outcomes in infants. Individualized bedtime routine education, including such activities as a bath, teeth-brushing, reading stories, singing songs, and cuddling will be implemented by research assistants at the 12-month well-child visit. Reinforcement of the bedtime routine education will be implemented at the 15-month visit. Each individualized bedtime routine will incorporate 3-5 steps and a bedtime routine chart depicting those steps will be created and provided to the families. Families will receive materials for their bedtime routines, including a CuddleBright kit, 1-2 additional bedtime books, toothbrush/toothpaste , and the created bedtime chart. On top of that, families will also receive a children's book provided by Reach Out and Read through the study period.
223488968|NCT06401980|DRUG|Darolutamide|Darolutamide will be supplied in bottles as 300 mg film-coated tablets for oral intake
224179669|NCT06410833|DRUG|Belimumab|Belimumab every four weeks
224179670|NCT00241371|DRUG|Clofarabine|
224179671|NCT04799509|PROCEDURE|VATS lobectomy|VATS lobectomy
224179672|NCT02693405|OTHER|Executive functions|measures of executive functioning with tasks
224179673|NCT02693405|OTHER|social cognition|measures of socio-cognitive functioning with tasks
224179674|NCT02693405|OTHER|quality of life|measures of quality of life with questionnaires
224179675|NCT02950428|DEVICE|ACURATE neo™TA Delivery System|ACURATE neo™ Aortic Bioprosthesis and ACURATE neo™TA Transapical Delivery System on patients with severe aortic stenosis where conventional aortic valve replacement (AVR) via open-heart surgery is considered to be high risk
224179676|NCT05472168|OTHER|Olfactory Stimulation|Participants are exposed to different odours and energy expenditure is assessed via indirect calorimetry.
224179677|NCT04853368|DRUG|ABBV-576|Oral capsules
224179678|NCT04853368|DRUG|Galicaftor|Oral capsules
224179679|NCT04853368|DRUG|Placebo|Oral capsules
224179680|NCT04853368|DRUG|Navocaftor|Oral capsules
223488969|NCT06401980|OTHER|Standard of care|"* Docetaxel~* Cabazitaxel~* LuPSMA~* Radium 223~* Olaparib, in case of BRCA1 or 2 mutated or HRR deficient tumors~The standard of care is chosen by the local investigator and respecting the country specific approvals."
223488970|NCT06549413|OTHER|Non-Interventional Study|Non-interventional study
223488971|NCT02213003|BIOLOGICAL|Islet transplantation|Transplantation of at least 5000 islet equivalents/kg of body weight onto the Omentum.
223488972|NCT05808920|GENETIC|Molecular Analyses|Nucleic acid extraction, protein analysis. Tumour tissue, blood and saliva samples collected.
223587238|NCT05235919|OTHER|Sham stimulation|30 minutes sham stimulation 5 days/week for 3 weeks.
224179681|NCT04853368|DRUG|ABBV-119|Oral capsules
224205653|NCT02180659|DRUG|sublingual buprenorphine tablets|
224205654|NCT02180659|DRUG|Buprenorphine implant|
224205655|NCT02180659|DRUG|placebo implants|
224205656|NCT02180659|DRUG|sublingual placebo tablets|
224072978|NCT01925690|BEHAVIORAL|Motivational Interviewing-Cognitive Behavioral Therapy|A telephone based talk therapy discussing pros and cons of medication use in MS.
224072979|NCT01925690|BEHAVIORAL|Brief Education|Give patients a pamphlet discussing pros and cons of disease modifying therapies
224072980|NCT05926726|BIOLOGICAL|CAR-GPC3 T cells|Subjects will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of JWATM214 . During JWATM214 production, subjects will receive a preconditioning chemotherapy regimen of cyclophosphamide and fludarabine to deplete the lymphocytes. After lymphodepletion, subjects will receive single-dose treatment with JWATM214 by intravenous (IV) injection.
224072981|NCT03167073|OTHER|BreastFeeding Friend (BFF)|A novel android app designed to improve breastfeeding rates among low-income women
224072982|NCT03167073|OTHER|dummy app|A novel android app that looks identical to the intervention app (BFF) but contains limited content.
224072983|NCT04082585|BEHAVIORAL|Total Health Improvement Program|The Total Health Improvement program is a 13 week community based nutrition program designed to assist participants in improving their physical and emotional well being. The program focuses on a plant based diet and increased physical activity.
224072984|NCT01276236|DRUG|Maraviroc|"FDA Recommended dosing will be used in this study. Subjects on an efavirenz or etravirine-based regimen will be dosed at 600 mg orally, twice per day, for 96 weeks.~Subjects on a ritonavir-boosted protease inhibitor based regimen (except for tipranavir/ritonavir) will be dosed at 150 mg orally, twice per day, for 96 weeks.~Subjects that are on regimens that do not include etravirine, efavirenz, or ritonavir will be dosed at 300mg orally, twice per day, for 96 weeks. These doses are based on the recommendations from the company based on drug-drug interactions."
224072985|NCT01400451|DRUG|Ipilimumab (BMS-734016)|Injection, intravenous (i.v.), cohort 1: 3 mg/kg, Escalate to cohort 2: 10 mg/kg, Escalate to cohort 3: at Recommended Phase 2 Dose (RP2D), De-escalate cohort 1A: 3 mg/kg, De-escalate cohort -1B: 10 mg/kg, (every three week) Q3wk, upto 2 yrs
224072986|NCT01400451|DRUG|Vemurafenib|tablets, oral, cohort 1: 960 mg Twice daily (BID) x 28 days after date, cohort 2: 960 mg BID x 28 days after date, cohort 3: at Recommended Phase 2 Dose (RP2D) x 14 days after date, De-escalate cohort 1A: 720 mg BID x 28 days after date, De-escalate cohort -1B: 720 mg BID x 28 days after date , Up to 2 yrs
224072987|NCT00044512|DRUG|Sorafenib (Nexavar, BAY43-9006)|Sorafenib (Nexavar, BAY43-9006) 400 mg administered bis in die (bid, twice a day)
224072988|NCT02673645|OTHER|SAGA Innovations|An intensive math tutoring program.
224072989|NCT01097304|DRUG|Ursodiol|Given PO
224072990|NCT01097304|OTHER|Laboratory Biomarker Analysis|Correlative studies
224072991|NCT03954600|DRUG|NPT520-34 (125 mg)|NPT520-34, 125 mg oral capsules (size 1)
224072992|NCT03954600|DRUG|Placebos (125 mg)|Placebo, 125 mg oral capsules
224072993|NCT04538391|DRUG|local ifiltration Bupivacaine, Meloxican and placebo|no other intervention done
224205657|NCT01991756|DEVICE|Altura Endograft System|Subjects with a documented untreated, unruptured, infrarenal abdominal aorto-iliac aneurysm.
224205658|NCT04265209|DRUG|SPECT|\[123I\]-FP-CIT SPECT imaging procedure
224205659|NCT04265209|DRUG|PET|\[18F\] LBT-999 PET imaging procedure
224205660|NCT01495793|DRUG|Rotigotine|"Rotigotine transdermal patch:~Dose (size): 0.5 mg/24 h (2.5 cm\^2)- 1 mg/24 h (5 cm\^2)- 2 mg/24 h (10 cm\^2)- 3 mg/24 h (15 cm\^2) The patch has to be applied continuously for 24h. After 24h, the patch has to be removed and a new one applied."
224179682|NCT01813136|DRUG|Continuous pazopanib (Arm A)|Daily oral administration of pazopanib 800mg (28 days cycles) from randomization until progression (according to RECIST 1.1) under treatment, after an initial period of 6 cycles (28 days) of daily administration of pazopanib 800mg from inclusion until randomization
224179683|NCT01813136|DRUG|Intermittent pazopanib (Arm B)|"Temporary discontinuation of pazopanib at randomization, after an initial period of 6 cycles (28 days) of daily administration of pazopanib 800mg from inclusion until randomization. Pazopanib will be reintroduced for 6 cycles of 28 days, with daily administration of pazopanib 800mg, as soon as the patient relapses (progressive disease according to RECIST 1.1). At the end of this additional 6 cycles, study drug will be stopped a second time.~This sequential scheme will be maintained until the patient experiences on-treatment progression"
224179684|NCT02187718|PROCEDURE|Sentinel Node Procedure under Local Anaesthesia|
224179685|NCT02187718|PROCEDURE|Sentinel Node Procedure under General Anaesthesia|
223745386|NCT07170969|OTHER|An Enhanced Coping-oriented Supportive Programme (E-COSP) for Community-Dwelling People with Spinal Cord Injury|The intervention group will receive eight weekly online group sessions (6-8 participants per group) with one hour for each session using Zoom videoconferencing software. A detailed intervention manual will be used to guide all intervention delivery. The intervention will be led by a registered rehabilitation nurse (who will be employed as a part-time RA2) who has more than three years of work experience in caring for people with SCI. The nurse who delivers the intervention will receive extensive training from the PI and CI, who are experts in coping interventions and relevant psychosocial intervention skills. The intervention providers will also receive training in group dynamics and group intervention skills, and be supervised by the research team and a psychologist during the whole period of the study. Selected audio-taped intervention sessions will be rated by the PI and CI on the fidelity of the intervention delivery
223488973|NCT05484778|PROCEDURE|Dual tasking paradigm|The dual task methodology is a testing model that requires one person to perform two tasks at the same time. The dual task is divided into two as motor-motor or motor-cognitive. Dual tasks provide an opportunity to examine the attention demands of both tasks and allow possible interference to be observed. The idea behind this design is that central processing capacity has a limit and must be distributed among concurrent tasks.
223488974|NCT06432517|OTHER|Power Bike（Ergoselect 100P）|Changes in the participants' energy balance will be measured through moderate to high intensity exercise. Observation of food intake, body composition, metabolic rate, food assimilation rate.
223488975|NCT05609435|OTHER|REASSURE|REASSURE is comprised of three components that are intended to be integrated into survivorship care at each follow-up visit: 1) An online patient-reported outcome (PRO) assessment to comprehensively evaluate survivors' symptoms and concerns; 2) A tailored follow-up recommendation based on pre-established thresholds for reported symptoms and concerns. Survivors who report symptoms or concerns have a follow-up visit to discuss findings whereas survivors without symptoms or concerns will avoid a follow-up visit; and 3) Online survivorship messaging sent after the visit, which includes reassurance about the low recurrence risk, an overview of what to expect from follow-up, and steps survivors can take to reduce cancer risk.
223488976|NCT06220656|PROCEDURE|Biopsy|Local anesthetic is usually given and a small needle is used to take cells from the thyroid under ultrasound guidance through several 'passes' and placed into specialized media for pathology evaluation.
223488977|NCT06220656|PROCEDURE|Active Monitoring|Ultrasound and a check-up at 6 months. Depending on ultrasound results, either biopsy and further care (as for the treatment arm called 'biopsy'), or continue with active monitoring.
223488978|NCT05861739|BEHAVIORAL|Endometriosis Self-care Support Program|ESSP will be applied to the women in the intervention group in four sessions, one week apart. In the first and second sessions, a self-care training program will be applied. In the third and fourth sessions, motivational interview will be made by contacting the women by phone.
223488979|NCT05484115|DEVICE|endovascular aneurysm repair (EVAR) using the Endurant II/IIs stent graft system|treatment of AAA's with wide proximal neck diameters with Endurant II/IIs endograft system
223488980|NCT05484115|DEVICE|endosuture aneurysm repair (ESAR) using Heli-FX EndoAnchor system|treatment of AAA's with wide proximal neck diameters with the Endurant II/IIs in conjunction with the Heli-FX EndoAnchor system
223488981|NCT02516241|DRUG|MEDI4736 (Durvalumab)|IV infusion
223488982|NCT02516241|DRUG|Tremelimumab|IV infusion
223587239|NCT03826199|DRUG|TDF-FTC|We will investigate the feasibility and acceptability of integrating PrEP into antenatal and postnatal/well-baby services. Upon enrollment in the cascade, all women will be offered PrEP counseling and information, and patients will be followed regardless of their choice to initiate PrEP or not. Participants who initiate PrEP will receive TDF-FTC during the study. At each study visit (every 3-months), women will receive counseling on PrEP adherence or on the risks and benefits of PrEP for women not yet initiated. We will evaluate PrEP initiation and adherence in pregnant and breastfeeding women (N=220) from first antenatal care visit through 12 months post-partum.
223745387|NCT07177885|BIOLOGICAL|Blood collection|Blood sampling. For patients who have had their cerebrospinal fluid sample taken as part of their treatment, a surplus sample will be used to perform the same measurements.
224179686|NCT04329273|OTHER|Sliding leg curl|The exercise protocol consists of the following sets and repetitions Week 1- 2 sessions with 2 sets of 6 repetitions Week 2- 2 sessions with 3 sets of 6 repetitions Week 3- 2 sessions with 4 sets of 6 repetitions Week 4- 2 sessions with 4 sets of 8 repetitions Week 5- 2 sessions with 4 sets of 10 repetitions Week 6- 2 sessions with 4 sets of 10 repetitions Week 7- 2 sessions with 4 sets of 8 repetitions Week 8- 2 sessions with 4 sets of 8 repetitions
224205661|NCT05853276|BEHAVIORAL|Brush DJ app|Brush DJ app is a mobile app which can be freely downloaded. This app was chosen as part of the intervention as it was recognized by the NHS to reduce the risk of gum disease and tooth decay among its users. This app was built around the info given in the public health England Delivering Better Oral Health Toolkit.
223488983|NCT02516241|DRUG|Cisplatin|IV infusion
223488984|NCT02516241|DRUG|Carboplatin|IV infusion
223488985|NCT02516241|DRUG|Gemcitabine|IV infusion
223488986|NCT05330897|PROCEDURE|Implantation of an eCLIPs™ device|Implantation of an eCLIPs™ device and coiling of the bifurcation aneurysm
223488987|NCT05330897|DEVICE|eCLIPs™ Electrolytic Bifurcation Systems|Implantation of an eCLIPs™ device and coiling of the bifurcation aneurysm
223488988|NCT03425526|BIOLOGICAL|Allogeneic Adenovirus-specific Cytotoxic T Lymphocytes|Given IV
224179687|NCT04329273|OTHER|Balance training|"The exercise protocol consists of 2 sessions/week with 4 sets of 30'' single stance.~Week 1 and 2- 1 set of 30'' single leg stance and 3 sets of 30'' single leg stance and ball kicks with contralateral foot Week 3 and 4- 2 sets of 30'' single leg stance while moving the ball around the leg with the contralateral foot and 2 sets of 30'' single leg stance, moving a ball around the knee with hands and kicking a ball with contralateral foot Week 5 and 6- 2 sets of 30'' single leg stance while giving and receiving hand passes with medicine ball (in couples) and 2 sets of 30'' single leg stance with perturbations (in couples) Week 7 and 8- Same as week 5 and 6 with extra 15 in each repetition"
224179688|NCT04329273|OTHER|Core stability|"The exercise protocol consists of the following sets and repetitions Week 1 and 2- 3 sets of 30'' front plank, 3 sets of 20'' side plank, 2 sets of 30'' superman, 2 sets of 30'' supine bridge and 2 sets of 10 repetitions leg lowering exercise Week 3 and 4- increasing difficulty in 2 of the sets Week 5 and 6- adding 1 more set at each exercise Week 7 and 8- adding 15 in each repetition"
224307336|NCT04771663|OTHER|Breathing a mixture of O2, N2 and CO2 and monitoring SpO2 on each finger|The experiment consists of two separate phases. In one phase, the volunteers inhale one of the mixtures for five minutes. After enough time of recovery, the volunteers undergo the other phase in which they inhale the other mixture of gases. Both phases of the measurement will begin with a two-minute stabilization phase, during which the physiological values of the volunteer will be checked. During the experiment, non-invasive SpO2 measurements will be performed continuously on the individual fingers of both volunteer hands throughout the experiment.
224307337|NCT03598868|DRUG|Vortioxetine|Augmentation : Vortioxetine 10 mg p.o. for week 1, Vortioxetine 5-20 mg p.o. for week 2,4,6.
223488989|NCT06551155|DIAGNOSTIC_TEST|Vitality and biological activity of peripheral blood mononuclear cells (PBMCs)|Diagnostic test based on the vitality and biological activity of peripheral blood mononuclear cells (PBMCs) tested analyzing approximately 2-5 mL of blood from healthy patients and from osteopenic and osteoporotic (both fractured and non-fractured) patients of both genders
223488990|NCT05067387|DRUG|Placebo|Oral placebo
223488991|NCT05067387|DRUG|THC|Oral THC (20 mg)
223488992|NCT05067387|DRUG|CBD|Oral CBD (20 mg)
223488993|NCT05067387|DRUG|THC + CBD|Oral THC (20 mg) + CBD (20 mg)
223488994|NCT04743830|OTHER|Neurodevelopmental Treatment (Bobath) + Scapular Training|The Bobath concept for 40 minutes will be formed according to the needs of the individual and involve the upper limb, trunk and lower limb. It will be performed with 20 minutes scapular training including scapular exercise such as Proprioceptive Neuromuscular Facilitation (PNF), dynamic hug, towel-wall slide, scapular punch exercises etc. 3 days a week for 8 weeks.
223488995|NCT04743830|OTHER|Neurodevelopmental Treatment (Bobath)|The Bobath concept for 60 minutes will be formed according to the needs of the individual and involve the upper limb, trunk and lower limb. It will be performed 3 days a week for 8 weeks.
223488996|NCT05634746|DRUG|APT-1011|"APT-1011 is an orally disintegrating tablet that includes fluticasone propionate as its active ingredient.~Other Names:~fluticasone propionate"
223488997|NCT05634746|DRUG|Placebo oral tablet|"Placebo orally disintegrating tablet.~Other Names:~PBO"
223587240|NCT03826199|BEHAVIORAL|Counselling on PrEP in antenatal and postnatal care|Information about PrEP will be integrated into regular group education in ANC by existing health care providers during discussion about HIV testing and treatment. During every study visit, PrEP counseling (including adherence counseling for women already on PrEP) will be provided. For women not on PrEP, counselling will be provided on PrEP and HIV prevention.
223587241|NCT03242252|DRUG|Placebo|"Placebo tablet (identical to sotagliflozin 200 mg in appearance), orally once daily.~Route of administration: Oral"
223587242|NCT03242252|DRUG|Sotagliflozin|"Sotagliflozin 200 mg, tablet, orally once daily.~Route of administration: Oral"
223488998|NCT05634746|PROCEDURE|Esophagogastroduodenoscopy|Esophagogastroduodenoscopy (EGD) is a test that involves an endoscope, a lighted camera on the end of a tube, that is passed down a subject's throat to visualize their esophagus
223488999|NCT05776277|BIOLOGICAL|Iltamiocel|Single external anal sphincter (EAS) injection of 300 x 10\^6 cells.
223489000|NCT05776277|OTHER|Placebo|Placebo control is the vehicle solution used for the study product.
223489001|NCT05493046|BEHAVIORAL|Interactive Hand Exercise Game|Interactive Hand Exercise Game to Improve Vascular Maturity and Grip Strength in Patients undergoing Arteriovenous Fistula Surgery
223489002|NCT05493046|BEHAVIORAL|Soft ball exercise ( routine care)|Soft ball exercise ( routine care)
223489003|NCT04430218|DEVICE|iSens|The study involves a surgical implant of cuff electrodes on the nerves in the amputated limb, and muscle recording electrodes the remaining muscles. These will be connected to an implanted stimulator. The stimulator will connect wirelessly to an advanced prosthesis. This may allow a user to move the prosthetic hand intuitively and feel what your prosthesis is touching.
223489004|NCT06360289|OTHER|Standard of Care|This is an observational study. No study drug will be administered as a part of the study, participants will be treated according to the decision of the treating physician.
224179689|NCT00612573|DRUG|Doxycycline 0.6 mg/kg/day|doxycycline 40 mg/day, oral, 12 weeks
224179690|NCT00612573|DRUG|Doxycycline 1.2 mg/kg/day|doxycycline 80 mg/day, 12 weeks
223489008|NCT06354777|DEVICE|Atrial Ablation|Left atrial radiofrequency ablation for the treatment of atrial fibrillation; this may include Pulmonary Vein Isolation (PVI) with or without additional ablation lesions as warranted during the procedure
223489009|NCT05975983|DRUG|INS018_055|"Pharmaceutical formulation: Capsules~Mode of Administration: Oral"
223489010|NCT05975983|DRUG|Placebo|"Pharmaceutical formulation: Capsules~Mode of Administration: Oral"
224179691|NCT00612573|DRUG|Doxycycline 2.4 mg/kg/day|doxycycline 160 mg/day, 12 weeks
224179692|NCT00612573|DRUG|Placebo|Placebo, 12 weeks
224307338|NCT03598868|DRUG|Placebo|Augmentation : Placebo for week 1,2,4,6
224307339|NCT03467880|OTHER|Clinical Observation|No treatment given but observation with IOS
224307340|NCT00529282|DRUG|Ceftobiprole Medocaril|500 mg every 8 hours
224179693|NCT04920331|BIOLOGICAL|Erenumab|140mg single intravenous administration (60 minutes)
223587243|NCT01983124|DRUG|Fotemustine + Vemurafenib|"Fotemustine 100mg/m2 IV on day 1 of each 21 day cycle. Number of cycles: until progression or unacceptable toxicity.~Vemurafenib administered continuous oral dosing 960 mg twice daily or dose administered at time of progression since progression or unacceptable toxicity."
223587244|NCT04821323|DRUG|Indomethacin|Indomethacin capsules will be administered orally.
223489011|NCT06546813|OTHER|scales and questionnaire administration|evaluation of the quality of prosthetic intervention, verification of the adequacy of assistive devices, and outcomes measurement
223587245|NCT04821323|DIAGNOSTIC_TEST|Lactulose-mannitol|Lactulose-mannitol solution will be administered orally.
223587246|NCT02805231|OTHER|Vitamin D receptor polymorphic analysis|
223587247|NCT01659255|DRUG|Tirabrutinib|Capsules administered orally
223489012|NCT05864144|DRUG|SNS-101 (anti-VISTA)|SNS-101 IV every 21 days.
223489013|NCT05864144|DRUG|Cemiplimab|Cemiplimab IV every 21 days.
223489014|NCT05040568|DRUG|Cetuximab|Given IV
223489015|NCT05040568|DRUG|Expanded CB-NK cells|Given IV
223489016|NCT05040568|DRUG|Fludarabine phosphate|Given IV
223489017|NCT05040568|DRUG|Cyclophosphamide|Given IV
223587248|NCT05323071|OTHER|Sucrose 24%|"According to the age of the newborn:~24-26 weeks : 0.1 mL, 27-31weeks : 0.25 mL, 32-36 weeks : 0.5 mL, \>37 weeks : 1 mL"
223587249|NCT02482402|DRUG|Inhaled Iloprost|Treatment effect will be controlled at each study visit and the dose and/or inhalation frequency will be adapted.
223587250|NCT02482402|DRUG|Placebo|inhalation solution placebo
223587251|NCT03678831|PROCEDURE|tissue|Adipocyte isolation from distal femoral epiphysis and subcutaneous adipose tissue at the surgery site; classical piece removal during prosthetic replacement of the knee
223587252|NCT02192229|DRUG|50.000 IU vitamin D3 (Biodal 50,000 IU)|
223587253|NCT02192229|DRUG|Placebo (to mimic Biodal 50,000 IU)|Placebo Tablet will be manufactured in a pharmaceutical factory to be identical to vitamin D3 Tablet in color, shape, size, and packaging
223745388|NCT07178132|OTHER|tissue floss band|Floss band is wrapped in thigh from distal to proximal for 2 minutes. during this period patient is asked to actively perform movement for 2 minute, after that the band is removed and repeated once more. Immediately followed by flexibility measurements
223745389|NCT07178132|OTHER|Proprioceptive Neuromuscular Facilitation|Proprioceptive Neuromuscular Facilitation (PNF) Stretching using the hold-relax method: participants perform an isometric contraction of the hamstring at the end of its stretch range , followed by relaxation and passive stretch, then flexibility assessed similarly
224179694|NCT03955068|OTHER|Strict Classic Ketogenic Diet|Diet is administered from a 2:1 to 4:1 ratio; this means 2 to 4 parts of fat to 1 part of both protein (calculated based on RDA and whatever remaining portion of carbohydrates.
224179695|NCT00821886|DRUG|Ixabepilone|Ixabepilone 40mg/m2 IV infusion over 3 hours on day 1 of cycles 1-6 (all treatment cycles are 21 days in length)
224179696|NCT00821886|DRUG|Trastuzumab|Trastuzumab 8mg/kg IV over 90 minutes for the first infusion (Cycle 1, Day 1) with a 60 minute post-infusion observation period. Subsequent infusions (Day 1 of Cycles 2-6 with all cycles being 21 days in length) 6mg/kg over 30 minutes if the previous dose was well tolerated; peri-operative trastuzumab 6mg/kg IV every 3-4 weeks; post-operative trastuzumab 6mg/kg IV day 1 every 3 weeks until week 52
223489018|NCT06487195|BEHAVIORAL|Peer-facilitated, Recovery-based Self-illness-management programme|The Peer-RESIM program will consist of 10 1.5-hour sessions (7-12 day intervals; 4 months), based on the modified CORE program workbook/manual and psychoeducation programmes developed by the research team.
223489019|NCT06487195|BEHAVIORAL|Psycho-education group|The psychoeducation group (6 subgroups; 10-12 participants per subgroup) will be led by one experienced psychiatric nurse trained in psychiatric rehabilitation and psychoeducation group programmes.
223489020|NCT06487195|BEHAVIORAL|Treatment-as-usual only|Participants in the TAU group will receive routine community mental healthcare services.
223489021|NCT03182335|OTHER|sedation awakening trial|vital signs and delirium assessment (CAM-ICU) at baseline then following routine sedation awakening trial. Patient will thus serve as their own control for these interventions
223489024|NCT06487273|DEVICE|SIMEOX|Use of the CE-marked SIMEOX medical device. No specific limitation of the number of use but recommendation to use it daily (and more if needed).
223489025|NCT06487273|OTHER|Remote Physiotherapy|Remote Physiotherapy with physiotherapists, once a month for the first 3 months and once every 3 months after
223489026|NCT05818709|DEVICE|HAC 22L|Subcutaneous and/or Supraperiosteal injection
223587254|NCT04221191|DRUG|Dimethyl Fumarate|DMF as prescribed as standard of care.
223587255|NCT04221191|OTHER|PSP|PSPs is to support patient care.
223587256|NCT00012363|DRUG|gemcitabine hydrochloride|1,000mg/m2, IV over 30 min, days 1 \& 8, q 21 days
223587257|NCT00012363|DRUG|irinotecan hydrochloride|100 mg/m2, IV over 90 min, days 1 \& 8, q 21days
223587258|NCT05019989|BEHAVIORAL|Intervention group on diet and physical activity|"The intervention wanted to increase physical activity, controlling weight, promoting healthy diet.~1. Physical activity: achieve and maintain regular participation in a moderate intensity physical activity program of 210 minutes/week (30 min on average per day) over at least 3 days /week; decrease sedentary behaviors by 30 minutes/day on at least 5 days/week~2. Weight control: reducing energy intake relative to expenditure is the primary dietary focus for promoting weight loss in overweight or obese participants, and maintaining a healthy energy balance is the primary focus for normal weight participants. Participants will be encouraged to include whole grains and high-fiber vegetables~3. Healthy diet: reducing calorie intake, through the preferred consumptions of unrefined cereals, pulses and vegetables, reducing high glycemic index food and high insulinemic foods, such as sugar and milk; reducing sources of saturated fat and animal protein (except fish)"
223745390|NCT04919278|PROCEDURE|Chiropractic adjustments|Chiropractic adjustment is a procedure in which trained specialists (chiropractors) use their hands or a small instrument to apply a controlled, sudden force to a spinal joint. The goal of this procedure, also known as spinal manipulation, is to improve spinal motion and improve your body's physical function.
224179697|NCT00821886|DRUG|Carboplatin|Carboplatin AUC=6 IV per institutional guidelines on Day 1 of Cycles 1-6 (all treatment cycles are 21 days in length)
224179698|NCT04725734|OTHER|Pregnant women|The patients will complete a questionnaire for each quarter
224179699|NCT01787019|OTHER|Oral feeding|
223489027|NCT05720130|DRUG|[²¹²Pb]Pb-ADVC001|"Ph1b Escalation~Drug: \[²¹²Pb\]Pb-ADVC001administered intravenously per dose escalation scheme~Dose Level 1~\- 60 MBq, 4 cycles every 6 weeks~Dose Level 2a~\- 120 MBq, 4 to 6 cycles every 4 weeks~Dose Level 2b~\- Optional cohort of 120 MBq, 4 to 6 cycles every 2 weeks~Dose Level 3a~\- 160 MBq, 4 to 6 cycles every 4 weeks~Dose Level 3b~\- Optional cohort of 160 MBq, 4 to 6 cycles every 2 weeks~Dose Level 3c~\- Optional cohort of 160 MBq, 4 to 6 cycles every week~Dose Level 4a~* 200 MBq, 4 to 6 cycles every 4 weeks~Dose Level 4b~\- Optional cohort of 200 MBq, 4 to 6 cycles every 2 weeks~Dose Level 4c~\- Optional cohort of 200MBq, 4 to 6 cycles every week~Ph2a Expansion~Drug: \[²¹²Pb\]Pb-ADVC001 at recommended phase 2 dose and schedule"
223489028|NCT05380947|DRUG|BI 1810631 - trial formulation 1 (TF1)|BI 1810631 - trial formulation 1 (TF1)
223489029|NCT05380947|DRUG|BI 1810631 - new formulation (NF)|BI 1810631 - new formulation (NF)
223489030|NCT05380947|DRUG|Rabeprazole sodium|Rabeprazole sodium
223489031|NCT05394116|DRUG|Garetosmab|Garetosmab is supplied as a liquid drug product and will be administered IV.
223489032|NCT05394116|DRUG|Placebo|Placebo to match garetosmab, is supplied as a liquid solution without the monoclonal antibody (or the protein) and is administered IV.
223489033|NCT00724945|DEVICE|balafilcon A|multifocal contact lens
223489034|NCT00724945|DEVICE|senofilcon A|multifocal contact lens
223489035|NCT00068185|DRUG|Black cohosh|
223489036|NCT04835441|DRUG|ALPN-101|Intravenous infusion via an infusion pump.
223489037|NCT04835441|DRUG|Placebo|Intravenous infusion via an infusion pump.
223489038|NCT06590454|DRUG|Pyrvinium|Pyrvinium (2 mg/kg) per day for 14 days
223489039|NCT06590454|DRUG|Placebo|Placebo for 14 days
223489040|NCT03778671|DRUG|Levobupivacaine|Patients will receive Levobupivacaine 5%
223745391|NCT07182058|DEVICE|Transcranial Electrical Stimulation Device|The Sphere V3.0 is a non-invasive transcranial electrical stimulation device that delivers amplitude-modulated transcranial pulsed random noise stimulation (am-tPRNS).
223745392|NCT07182929|PROCEDURE|Lateral Sinus Floor Augmentation with Deproteinized Porcine Bone Mineral|Lateral Sinus Floor Augmentation Using Deproteinized Porcine Bone Mineral (DPBM, test) with Simultaneous Implant Placement and 6-Month CBCT Follow-Up
223745393|NCT01816893|OTHER|Hypoglycemic hyperinsulinemic clamp|
223745394|NCT01816893|OTHER|Euglycemic hyperinsulinemic clamp|
223489041|NCT03778671|DRUG|Dexmedetomidine Injection [Precedex]|Patients will receive Levobupivacaine 5% + 1 µg/kg dexmedetomedine
223489042|NCT03778671|DRUG|fentanyl|Patients will receive Levobupivacaine 5% + 1 µg/kg fentanyl
223489043|NCT06839989|BIOLOGICAL|Mpox vaccination with MVA-BN|All participants will be vaccinated on day 0 with the MVA-BN vaccine followed by a second injection on day 28.
223489044|NCT05101226|BEHAVIORAL|Yoga attended in person|One or two weekly yoga classes taught and attended in person with a duration of 60 minutes each. The participants can chose if they want to attend one or both classes. The classes will start with a 10 minute Warm Up and a short Meditation, 10 minutes Sun Salutations, 15 minutes standing Asanas, 15 minutes sitting and lying Asanas and 10 minutes Shavasanah and Meditation.
223489045|NCT05101226|BEHAVIORAL|Yoga attended online|One or two weekly yoga classes taught and attended online with a duration of 60 minutes each. The participants can chose if they want to attend one or both classes. The classes will start with a 10 minute Warm Up and a short Meditation, 10 minutes Sun Salutations, 15 minutes standing Asanas, 15 minutes sitting and lying Asanas and 10 minutes Shavasanah and Meditation.
223489046|NCT02900651|DRUG|MAK683|Drug: MAK683
223489047|NCT06366347|DRUG|Abemaciclib|CDK inhibitor, tablet taken orally per protocol.
223489048|NCT06366347|DRUG|Letrozole|Aromatase inhibitor, tablet taken orally per protocol.
223489049|NCT06366347|DRUG|Pembrolizumab|Humanized immunoglobulin G4 monoclonal antibody, 4mL (milliliter) single-dose vial, via intravenous (into the vein) infusion per institutional standard of care.
223489050|NCT06857448|PROCEDURE|Split Thickness Skin Graft (STSG)|Partial thickness skin in STSGs are performed by harvesting via dermatome the donor site. Donor sites are typically taken from a flat surface on the thigh, lower back, or gluteal region to allow for a graft of even thickness and the selection of donor site is to be based on clinical standard practice. These grafts are placed on the prepared recipient site.
223489051|NCT06857448|PROCEDURE|Base of wound fat graft with STSG Reconstruction (Autologous Layered Composite Grafting).|Autologous Layered Composite Grafting consists of the layered strategy of simultaneous fat and skin grafting. Fat is harvested by minimally invasive liposuction and applied directly to the wound base without any chemical or biologic processing. Skin is harvested as a split thickness skin graft by dermatome and applied over the layer of adipose tissue.
223489052|NCT05360212|PROCEDURE|Anatomy-based fitting (ABF)|MAESTRO 9 can display the tonotopic frequency of each individual electrode channel imported from OTOPLAN to further support fitting based on these measures. The audiologist can set a frequency-band distribution that is more closely aligned to the tonotopic frequency distribution as imported from OTOPLAN.
223489053|NCT05360212|PROCEDURE|Standard Fitting|These group is fitted using the standard frequency-band distribution as implemented in MAESTRO 9.
223745395|NCT03103997|PROCEDURE|EUS-guided liver biopsy|EUS-guided liver biopsy using needles with various preparations
223745396|NCT07179887|DEVICE|Remote Ischaemic Conditioning|Cuff inflation to 20mmHg abocve systolic blood pressure for cycles of 5 minutes. Each session will consist of 4 cycles of 5 minte inflation followed by 5 minute deflation. Total session time 40 minutes
224179700|NCT06420024|BEHAVIORAL|Acceptance and Commitment Therapy|See: https://link.springer.com/chapter/10.1007/0-306-48581-8\_1
224179701|NCT05717413|DEVICE|metatarsophalangeal joint endoprosthesis|arthroplasty of 1 metatarsophalangeal joint
224179702|NCT01452685|DRUG|Placebo|TAK-385 placebo-matching tablets, orally, once daily and leuprorelin acetate placebo injection, subcutaneously, once every 4 weeks for up to 12 weeks.
224179703|NCT01452685|DRUG|TAK-385|TAK-385 10 mg, tablets, orally, once daily and leuprorelin acetate placebo injection, subcutaneously, once every 4 weeks for up to 12 weeks.
224179704|NCT01452685|DRUG|TAK-385|TAK-385 20 mg, tablets orally, once daily and leuprorelin acetate placebo injection, subcutaneously, once every 4 weeks for up to 12 weeks.
224307341|NCT00529282|DRUG|Cefepime with or without vancomycin|120-minute infusion \[250 mL\]
224307342|NCT01846013|BEHAVIORAL|Stand|Stand at least half of the workday at work.
223489054|NCT05360212|PROCEDURE|Standard fitting+ ABF|Patients of this group are both fitting using the standard frequency-band distribution and the anatomy-based frequency distribution in MAESTRO 9. So, subjects will have both study maps on their audio processor throughout the whole study. They will have to change weekly between both fittings: standard fitting and anatomy-based fitting. Here, the performance with anatomy-based fitting is assessed by comparing performance with standard fitting and anatomy-based fitting.
223489055|NCT06248268|OTHER|(Neuro-)psychological assessment|The measurement, which takes place 1 week after the informed consent, aims to determine the distinct (neuro-) psychological patterns of suicidal behavior versus suicidal ideation, in comparison to two control groups.
223489056|NCT06249919|BIOLOGICAL|NS101|NS101 is anti FAM19A5 antibody expected to play as a synapse organizer and reversing synapse dysfunction in various neurological diseases
223489057|NCT06249919|BIOLOGICAL|Placebo|Placebo (i.e. fake drug without active pharmaceutical ingredient) of NS101
223489058|NCT06747247|DRUG|MT1013|MT1013 is a dual-agonist polypeptide, not only to control iPTH levels in SHPT patients on maintainence dialysis, but also promote bone formation.
223489059|NCT06747247|DRUG|Placebo|Appear similar to MT1013, but has no treatment effect.
224179705|NCT01452685|DRUG|TAK-385|TAK-385 40 mg, tablets, orally, once daily and leuprorelin acetate placebo injection, subcutaneously, once every 4 weeks for up to 12 weeks.
224179706|NCT01452685|DRUG|Leuprorelin acetate|TAK-385 placebo-matching tablets, orally, once daily and leuprorelin acetate 3.75 mg injection, subcutaneously, once every 4 weeks for up to 12 weeks
223489060|NCT04262219|BEHAVIORAL|iShare|The iShare intervention consists of a two-episode educational podcast series containing information about breast cancer patients' sexual problems, approaches for addressing sexual concerns, and information about discussing sexual concerns with patients, such as initiating a conversation about sexual health and asking questions to assess sexual concern. Both episodes feature expert guests and relevant discussions or case studies.
223489061|NCT02546570|DRUG|Oxytocin|See arm/group descriptions for dosage amount and procedure.
223489062|NCT02546570|DRUG|Placebo|See arm/group descriptions for dosage amount and procedure.
223489063|NCT01772082|BEHAVIORAL|Internet mediated walking program|
223489064|NCT06403800|OTHER|No intervention|No intervention
224179707|NCT06040437|BEHAVIORAL|Be-Prox|Be-Prox is an intervention developed to prevent, uncover and handle negative behavior in kindergartens.
224179708|NCT04987684|DIAGNOSTIC_TEST|SCINSEV and PECAP|To measure PECAP and SCINSEVs. To find whether electrodes are outside of the cochlear or within dead regions within the cochlear.
223489065|NCT00467766|BEHAVIORAL|Psychosocial information, counseling, and support|
223489066|NCT00467766|DRUG|Donepezil (Aricept)|
224179709|NCT06079606|OTHER|Antibiotic treatment|Children will be assigned to groups according to antibiotic exposure in early life. No antibiotics will be given in the study.
224179710|NCT05751421|DRUG|Zynrelef (Bupivacaine 60 MG / Meloxicam 1.8 MG) Per 2.3 ML Extended Release Solution|zynrelef will be administered during surgery
224307343|NCT01846013|BEHAVIORAL|Move|Increase movement time at work. Move more by making small changes (walking meetings, take stairs, etc).
224307344|NCT01846013|BEHAVIORAL|Stand and Move|Increase standing time to half of workday (4h) and increase movement time at work.
224307345|NCT05220189|DIAGNOSTIC_TEST|EarlyTect® Bladder Cancer test|A highly accurate and sensitive real-time PCR employing Linear Target Enrichment and Quantitative Methylation-Specific PCR (LTE-qMSP) for measuring PENK methylation in urine DNA to detect bladder cancer in hematuria patients.
224307346|NCT04555720|BEHAVIORAL|Interdisciplinary Visit|If assigned to the interdisciplinary group, participants will see social work, physical therapy, occupational therapy, speech therapy, and pharmacy in a scheduled rotation for about 45 minutes each. After these evaluations, the team meets with the participants doctor for a discussion of treatment. After this meeting, the participants doctor will meet to discuss a treatment plan and make recommendations.
224307347|NCT03457467|DRUG|Apatinib|Apatinib 500 mg is administered orally daily, until disease progression or untolerable toxicity
223489067|NCT03088397|BEHAVIORAL|Patient Decision Aid|One sheet of postpartum contraceptive information arranged in a grid.
223489068|NCT03088397|BEHAVIORAL|Website|Patient directed to website with information on various contraceptive methods.
223489069|NCT03088397|BEHAVIORAL|Shared- Decision Making Counseling|Counseling using principles of shared-decision making
223489070|NCT03069989|DRUG|GSK3008348|Solution for nebulisation. Available as clear colorless to pale yellow colored solution in a 5mL vial with 20 millimeter (mm) stopper and aluminium seal yellow colored solution in a 5mL vial with 20 millimeter (mm) stopper and aluminium seal.
223489071|NCT03069989|DRUG|Placebo|Solution for nebulisation. Available as clear colorless to pale yellow colored solution in a 5mL vial with 20mm stopper and aluminium seal.
223489072|NCT03069989|DRUG|[18F]-FBA-A20FMDV2|Radio-labeled peptide ligand for PET scan. Available as intravenous (IV) infusion, 20 mL.
223489073|NCT01303484|DIETARY_SUPPLEMENT|Bi2muno® GOS|5.5g/day for 10 weeks
223489074|NCT01303484|DIETARY_SUPPLEMENT|Maltodextrin|5.5g daily for 10 weeks
223745397|NCT07179887|DEVICE|Sham Remote Ischaemic Conditioning|Cuff inlfation to 20mmHg only for cycles of 5 minutes. Each session will consist of 4 cycles of 5 minute inflation followed by 5 minutes of deflation. Total session time of 40 minutes
224179711|NCT05751421|DRUG|Bupivacaine HCl 0.5% Injectable Solution|adductor canal block will be performed using bupivacaine before surgery
224179712|NCT05751421|PROCEDURE|primary total knee replacement|primary total knee replacement
224179713|NCT04276493|BIOLOGICAL|Zanidatamab|Administered intravenously
224179714|NCT04276493|DRUG|Docetaxel|Administered intravenously
224179715|NCT04276493|BIOLOGICAL|Tislelizumab|Administered intravenously
224179716|NCT04276493|DRUG|Capecitabine|Administered orally
224179717|NCT04276493|DRUG|Oxaliplatin|Administered intravenously
224179718|NCT04220502|DRUG|Magic Shave Powder Gold|Depilatory Cream for facial hair removal
224179719|NCT04220502|DEVICE|Traditional Shaving Methods|Continued facial hair removal using traditional razors
224179720|NCT01144897|RADIATION|PET Acetate scan|PET Acetate scans will be done to detect prostate cancer lesions.
224179721|NCT01144897|DRUG|Carbon-11 labeled Acetate|C-11 Acetate is a radiotracer used in PET scanning
224179722|NCT00937703|DEVICE|placebo|paper support for glycaemia face to face visit at T4mounths
224179723|NCT00937703|DEVICE|IVS|"patients transmit their glycaemia to the IVS, which advises them the insulin amount recommended by their physician in this situation.~Face to face visit at T4mounths plus telephone visits each 2 weeks."
224179724|NCT00937703|DEVICE|PDAphone|Patients will receive PDA phone system. They will hace face to face visit at T4mounths and telephone visits each 2 weeks
223489075|NCT06323291|BEHAVIORAL|Coaching Sessions|"Enrolled participants will set up an account through a secure and encrypted web portal managed by Osara Health.~Coaches will follow-up with their designated patients and/or caregivers to schedule individual coaching sessions via phone, text, or email depending on the participant's communication preference. Participants will have an initial coaching consultation by phone to go over the purpose and structure of coaching sessions.~Participants will then have an additional 3-4 coaching sessions (depending on time availability and need) to discuss symptom management, nutrition and exercise, sleep, and mindfulness.~Participants will receive content for each of the modules via email."
223489076|NCT06831409|DIAGNOSTIC_TEST|Coronary computed tomography angiography|Coronary Computed Tomography Angiography (CCTA) is a non-invasive medical imaging test that uses X-rays to create detailed 3D images of the heart and its blood vessels, specifically the coronary arteries.
223489077|NCT04322383|DRUG|binimetinib|Binimetinib will be given orally at a dose of 45mg BID continuously for 28-day cycles with no resting period between cycles.
223489078|NCT04307667|BIOLOGICAL|Whole lung antigen challenge (WLAC)|Whole lung antigen challenge with cat hair, house dust mite, or short ragweed allergen extracts.
223489079|NCT04307667|RADIATION|[18F]FEPPA|\[18F\]FEPPA is a radiotracer selective for translocator protein (TSPO) binding, which is elevated in activated microglia.
223489080|NCT03333343|DRUG|EGF816|Study Drug
223489081|NCT03333343|DRUG|trametinib|Study Drug
223489082|NCT03333343|DRUG|ribociclib|Study Drug
223489083|NCT03333343|DRUG|LXH254|Study Drug
223489084|NCT03333343|DRUG|INC280|Study Drug
223489085|NCT03333343|DRUG|gefitinib|Study Drug
223587259|NCT05019989|BEHAVIORAL|Control group: only public recommendation an lifestyle|"1. Invitation leaflet, explaining the rationale of the study and including basic life-style recommendations, based on the 1997 World Cancer Research Fund recommendations (to be updated in 2007) and the Italian National Institute of Nutrition food pyramid.~2. Dissemination of the information on the study by media~3. Yearly follow-up questionnaire on breast events and dietary and physical activity chang"
224179725|NCT02083406|DRUG|800mg OZ439 prototype formulation 1|
224179726|NCT02083406|DRUG|800mg OZ439 prototype formulation 2|
224179727|NCT02083406|DRUG|800mg OZ439 prototype formulation 3|
224179728|NCT02083406|DRUG|960mg PQP|
224179729|NCT03527875|PROCEDURE|PTBD group|Percutaneous Transhepatic Biliary Drainage, a kind of Preoperative Biliary Drainage methods for hilar cholangiocarcinoma patients
224179730|NCT03527875|PROCEDURE|ENBD group|Endoscopic Nasobiliary Drainage, a kind of Preoperative Biliary Drainage methods for hilar cholangiocarcinoma patients
224179731|NCT03527875|PROCEDURE|EBS group|Endoscopic Biliary Stenting, a kind of Preoperative Biliary Drainage methods for hilar cholangiocarcinoma patients
224179732|NCT05960006|OTHER|No intervention|There are no risks associated with participation because only waste material (blood and ascites) will be used for analysis and no additional blood collection or paracentesis will be performed in addition to standard-of-care. Moreover, hospital admittance and discharge, indication for interventional procedures, indication/initiation/duration/dosing of ceftriaxone, indication/timing/frequency of blood withdrawal for standard of care biochemical analysis and microbiological culturing as the indication, timing, frequency and duration of paracentesis are all decided by the treating physician independent of participation in the study. There are no extra site visits nor extra days of hospital admission. There is no direct benefit for participants of this explorative study. .
223489086|NCT05677139|OTHER|None (Observational Study)|Not applicable since it's an observational study.
223489087|NCT03850574|DRUG|Tuspetinib|Daily (QD), continuous dosing
223489088|NCT03850574|DRUG|Venetoclax Oral Tablet|Venetoclax will be given to study participants in the Part C tuspetinib plus venetoclax combination treatment group either in 50 mg or 100 mg tablets
223489089|NCT03850574|DRUG|Azacitidine for Intravenous Infusion|Azacitidine will be given to study participants in Part D as intravenous infusion at a dose of 75 mg/m\^2
223489090|NCT04375332|DEVICE|HARPOON™ Beating Heart Mitral Valve Repair System|Repair of the chordae tendinae in the mitral valve.
223489091|NCT05337553|DRUG|taldefgrobep alfa|DB Phase: 35 mg/50 mg weekly subcutaneous injection
223489092|NCT05337553|DRUG|Placebo|DB Phase: matching placebo 35 mg/50 mg weekly subcutaneous injection
223489093|NCT05337553|DRUG|taldefgrobep alfa|Extension Phase: 35 mg/50 mg weekly subcutaneous injection
223489094|NCT04070703|BEHAVIORAL|The Go for Exercise & Healthy Aging Project|Exercise and Cognition
223587260|NCT05515289|DRUG|SHR6390|SHR6390 tablet single dose, and subjects will take the SHR6390 on Day 1.
223587261|NCT00131651|DRUG|ATN-161|
223587262|NCT04397965|DEVICE|Cascade Continuous Glucose Monitor|Continuous Glucose Monitoring
223587263|NCT05962359|BEHAVIORAL|Parent-Implemented Communication Treatment|The intervention will be taught by a qualified professional online and/or in-person for about 6 months. Parents will learn strategies to enhance their children's social communication and will receive coaching and feedback.
223587264|NCT00066547|BIOLOGICAL|monoclonal antibody HuHMFG1|
224179733|NCT04584827|OTHER|lactate level|Lactate, a byproduct of glycolysis, is an indicator of weak tissue perfusion and a useful biomarker with prognostic value in various diseases. Lactate value is calculated by blood gas.
224179734|NCT04584827|OTHER|Glasgow Outcome Scale|Glasgow Outcome Scale; It is a scale developed to categorize people suffering from head trauma or non-traumatic acute brain injury into broad outcome categories. It shows postoperative mortality and morbidity of patients who underwent intracranial surgery.
224179735|NCT01917799|DRUG|Aspirin|75mg tab of LDA once daily for 7 months
224179736|NCT01917799|DRUG|Heparin|0.4 mL/day of the Enoxaparin
223489095|NCT05112432|DEVICE|Cognitive and Social Cognitive Training|"The Cognitive Training Module is designed to improve the speed and accuracy of auditory information processing while engaging working memory and cognitive control under conditions of close attention and reward. Exercises continuously adjust difficulty level to user performance to maintain an approximately 80% current performance rate. The goal is to increase the effectiveness by which salient stimuli engage and drive plastic changes in brain systems that in individuals with psychosis exhibit relatively poor temporal response.~The Social Cognition Training Module consists of exercises designed to ameliorate core deficits in social cognition expressed in schizophrenia and Autism Spectrum Disorders. The exercises apply principles of implicit learning to restore the brain's capacity to process and utilize socially-relevant information, and include training to improve affect perception, social cue perception, theory of mind, self-referential style, and emotion labeling and working memory."
224179737|NCT04058782|OTHER|Imaging evaluation for vascular assessment|At 1month after MI, Blood sample for total blood, plasma and PBMC collection, ECG, 3D-trans thoracic echocardiography for ventriculo-arterial coupling assessment, Vascular doppler for peripheral artery disease assessment, Arterial stiffness evaluation, Bilateral transcranial doppler for HITS evaluation
224179738|NCT01658527|DRUG|Orteronel|"Tak-700 will be administered until disease progression, diagnosis of a second malignancy, patient refusal to continue the treatment, excessive toxicity precluding further therapy according to protocol and /or according to the responsible physician.~Upon progression, patient may stay on study medication until the initiation of a new therapy"
223489096|NCT05112432|BEHAVIORAL|Personalized Real-Time Intervention for Motivational Enhancement (PRIME) App|The PRIME smartphone-based app is designed to be used for 12 weeks to enhance motivation in people with early psychosis. Participants work towards self-identified goals with the support of the virtual community of age-matched peers, as well as with motivation coaches. Participants discuss their interests and aspirations with each other and with their coach, and the coach sends daily individualized motivational messages. Coaches also provide tailored interventions to enhance motivation, and post daily discussion topics to the PRIME community to encourage interaction between members. Coaches will maintain close communication and feedback on progress with each individual's clinical team.
223489097|NCT05112432|OTHER|Early Psychosis Coordinated Specialty Care|Participants will continue to receive treatment as usual at their early psychosis coordinated specialty care clinics. These clinics may follow the NAVIGATE model, as an example.
223489098|NCT06835751|BEHAVIORAL|Motivational Interviewing for PreP|Participants will receive MI-PrEP only will receive two 1-hour sessions with an intervention counselor. The first session will include information on PrEP and other HIV prevention and harm reduction strategies, and discussion on PrEP contemplation, importance, and confidence, and problem-solving around identified barriers to PrEP. The session will also include information on other available harm reduction strategies and services, including medications for opioid use disorder. The second session will focus on following up on any PrEP actions taken, challenges encountered, and problem-solving to address any challenges. Those ready to be linked to PrEP and/or harm reduction services will be offered an escort to a designated PrEP and/or opioid treatment clinic site or other harm reduction services.
223512480|NCT05882331|PROCEDURE|Extracorporeal photopheresis|ECP is initiated on study inclusion day by Therakos Cellex system, according to manufacturers' instructions. Each patient receives two ECP cycles for 2 weeks, each consisting of two sessions on consecutive days per week (alltogether four sessions), through a peripheral or central venous route. Cycles 1 and 2 are separated by 5 consecutive days. One ECP session takes \~3 hours, and is separated into 4 phases. On priming, the system performes a series of calibrations to ensure proper operation. During collection, 1500 ml of whole blood is processed to collect a concentrated buffy coat containing white blood cells, while other cells and plasma are reinfused. During the photoactive phase, a prescribed dose of 8-methoxypsoralen is added to the buffy coat, which is then circulated through ultraviolet-A photoactivation. During reinfusion phase, treated cells are automatically reinfused to the patient.
224072994|NCT05199324|DRUG|Oral fluoroquinolones (most commonly, ciprofloxacin) or oral trimethoprim-sulfamethoxazole|Clinically stable / non-critically ill inpatients with uncomplicated Gram-negative bacteraemia randomised to the intervention arm will be switched early to oral antibiotics (within 72 hours from index blood culture collection)
224072995|NCT05199324|DRUG|Standard of care intravenous antibiotics (e.g. ceftriaxone, cefazolin)|Clinically stable / non-critically ill inpatients with uncomplicated Gram-negative bacteraemia randomised to the standard arm will continue to receive an active intravenous antibiotic therapy for at least another 24 hours post-randomisation before clinical re-assessment and decision making by the treating doctor
224072996|NCT01475201|BEHAVIORAL|Step count prescription|Treating physicians will provide a pedometer, pedometer log, and step count prescription. The aim is a net increase of at least 3,000 steps/day over one year. The time frame for this increase will be 10 months for sedentary participants (\<5,000 steps/day), 7 months for low active participants (5,000-7,499 steps/day), and 5 months for somewhat active participants (7,500-9,999 steps/day). If goals are not met, the doctor and participant will review barriers and facilitators, and a more individualized prescription will be formulated (e.g. lower incremental step count targets or slower rate of dose escalation). For participants who meet goals, the doctor and participant will together decide whether to aim for a further increase.
224072997|NCT01475201|BEHAVIORAL|Usual care|The control trial arm will receive usual care alone, over a one-year period (i.e. no step count prescription but, in accordance with guidelines, including advice to engage in 30-60 minutes of activity on most days of the week).
224072998|NCT00035282|DRUG|aprepitant|
224072999|NCT00035282|DRUG|Comparator: placebo (unspecified)|
224073000|NCT05046405|DEVICE|Transcranial Direct Current Stimulation|Transcranial Direct Current Stimulation (tDCS) has been suggested to the peripartum period combining antidepressant eﬀects with low risks. In tDCS a low intensity constant current is delivered to the scalp with sub-threshold eﬀect on neurons' resting membrane potential. Long stimulation sessions lead to lasting eﬀects and neuroplastic changes. Local tDCS eﬀects target calcium-dependent synaptic plasticity and distal eﬀects alter the networks' connectivity, synchronicity and oscillatory patterns. tDCS applications aim to counteract the hypoactivity of the frontoparietal network and the left sided hyperactivity of the default mode network associated with depressive symptoms.
224073001|NCT02799069|DRUG|BF-200 ALA|topical treatment for photodynamic therapy combining drug application and after a 3 h incubation subsequent illumination with a broad or narrow spectrum light source.
224179739|NCT01658527|DRUG|Bicalutamide|Bicalutamide will be given at the standard daily dose of 50 mg PO (per os). Bicalutamide will be maintained until disease progression diagnosis of a second malignancy, patient refusal to continue the treatment, excessive toxicity precluding further therapy according to protocol and /or according to the responsible physician.
224179740|NCT00816712|DRUG|Comparator: Testosterone 300 mg, intramuscular injection|"Day 1 \& 7 - Infusion with radioactive tracer (dye), given over 12 hours, followed by two thigh muscle needle biopsies.~Day 1 \& 7 - Testosterone 300 mg, Intramuscular injection."
224179741|NCT00816712|DRUG|Comparator: Testosterone 100 mg, Intramuscular injection|"Day 1 \& 7- Infusion with radioactive tracer (dye), given over 12 hours, followed by two thigh muscle needle biopsies.~Day 1 \& 7 - Testosterone 100 mg, Intramuscular injection."
224179742|NCT00816712|DRUG|Comparator: Placebo given by Intramuscular Injection|"Day 1 \& 7 - Infusion with radioactive tracer (dye), given over 12 hours, followed by two thigh muscle needle biopsies.~Day 1 \& 7 - Placebo given as intramuscular injection."
224179743|NCT03699774|DRUG|DS-8500a|DS-8500a is provided as three 25-mg tablets for oral administration
224179744|NCT03699774|DRUG|Rosuvastatin|Rosuvastatin is provided as a 10-mg tablet for oral administration
224179745|NCT02076646|DRUG|L19IL2 - Ph I|During phase I part of the study, increasing dose of L19IL2 from one cohort to the next will be performed in steps of 160,000 IU/kg starting at 480,000 IU/kg (i.e., 0.48; 0.64; 0.80 MioIU/kg until MTD is reached).
224179746|NCT02076646|DRUG|L19IL2 at RD - Ph II|L19IL2 at RD will be administered to Arm 1 patients during phase II part of the study.
224179747|NCT02076646|DRUG|DTIC|Dacarbazine: 1 hour intravenous infusion on day 1 of each 21-cycle at a dosage of 1000 mg/m2 (fixed dose).
224179748|NCT04279041|PROCEDURE|root canal preparation|root canal preparation
224179749|NCT03682471|DRUG|Deoxycholic acid Injection|Solution for subcutaneous injection.
224179750|NCT03682471|DRUG|Placebo|Placebo, 10 mM sodium phosphate, 0.9% \[w/v\] sodium chloride in water for subcutaneous injection.
223489099|NCT06835751|BEHAVIORAL|Common Elements Treatment Approach (CETA) + MI-PrEP|Participants will receive CETA+MI-PrEP will receive 7 to 14 weekly one-hour sessions from an intervention counselor. Similar to the MI-PrEP group, women in this study arm will receive the two 1-hour MI-PrEP sessions with an intervention counselor with linkages to PrEP and/or harm reduction services. Women will then begin CETA sessions. The CETA intervention component is a modular and flexible approach comprised of nine elements that can be combined in various ways, including different sequences, to address clients' presenting symptoms and problem areas. CETA currently includes key engagement strategies, including MI, throughout the intervention. The intervention counselor will determine the specific intervention component sessions, sequence of sessions, and dose, or frequency of sessions, based on the primary problem area identified by the participant and intervention counselor as reported in the baseline assessment survey and initial discussions.
223489100|NCT05962424|DRUG|Ketamine Hydrochloride|Ketamine is an FDA-approved dissociative anesthetic.
223489101|NCT04700124|BIOLOGICAL|Pembrolizumab|200 mg of Pembrolizumab IV infusion, on Day 1 Q3W for 4 cycles (each cycle length = 21 days) in preoperative phase (up to approximately 3 months) and on Day 1 Q3W for 13 cycles in postoperative phase (up to approximately 9 months). The total duration of treatment is up to approximately 1 year.
223489102|NCT04700124|BIOLOGICAL|Enfortumab vedotin (EV)|1.25 mg/kg of EV IV infusion, on Day 1 and Day 8 Q3W for 4 cycles (each cycle length = 21 days) in preoperative phase (up to approximately 3 months) and on Day 1 and Day 8 Q3W for 5 cycles (each cycle length = 21 days) in postoperative phase (up to approximately 4 months). The total duration of treatment is up to approximately 7 months.
223489103|NCT04700124|PROCEDURE|RC + PLND|Curative intent RC + PLND surgery will be administered to all participants randomized to Arm A and B after completion of preoperative systemic treatment (RC + PLND to be done approximately at 15 weeks from randomization).
224179751|NCT03633461|DRUG|OC-02 (simpinicline) nasal spray|OC-02 (simpinicline) nasal spray, 11.1 mg/ml
224307348|NCT03457467|RADIATION|SBRT|according to the different treatment sites given the corresponding dose: 1200cGy × 4 times or 800cGy × 7 times, or according to the specific situation dose adjustment
223587265|NCT03883334|DRUG|Metisoprinol|Immunodulator
223587266|NCT04637919|BIOLOGICAL|IN-B001 EV71 A dose|Inactivated vaccine against EV71, three doses, 28 days interval
224179752|NCT03633461|DRUG|Placebo (vehicle) nasal spray|Placebo (vehicle) nasal spray
224179753|NCT05460728|OTHER|Dry needling|A three-weekly session of DNT was administered with an acupuncture needle (0.30 × 50 mm; Huan Qiu, Suzhou, China). For each session, DNT was applied in the deltoid, biceps brachialis, wrist extensors and flexors, thenar muscles, vastus medialis, gastrocnemius medialis, and tibialis anterior (Hong, 1994). Following focal twitch responses (maximum three), the dry needle was left inserted for 15 minutes in each muscle.
224179754|NCT01347515|OTHER|olive oil|"Each volunteer will be given, in random order, a single dose of 30 ml on a base of 80 g bread, of the following functional olive oils (FOO): FOO750 ppm, FOO500 ppm, which are enriched with two different amounts of broad-spectrum phenolic compounds from the virgin FOO250 ppm; all prepared at the Universitat de Lleida.~Post-ingestion the volunteers will rest for 8h in a comfortable warm room. During the run-in period of 2 weeks prior the first postprandial study and 1 week between each FOO treatment period, all subjects will undergo a 2-day pre-treatment wash-out period of a phenol-free diet (saturated fatty acids in the diet will be 10-13% of energy in an isocaloric diet). Volunteers will avoid non-essential physical activity during the 3 days prior to the treatment day."
224307349|NCT00521469|DEVICE|Pro Adjuster|
224307350|NCT02249312|DRUG|BIIL 284 BS|
224307351|NCT02249312|DRUG|Placebo|
223587267|NCT04637919|BIOLOGICAL|IN-B001 CVA16 B dose|Inactivated vaccine against CVA16, three doses, 28 days interval
223587268|NCT04637919|BIOLOGICAL|IN-B001 Bivalent C dose|Inactivated vaccine against EV71/CVA16, three doses, 28 days interval
223587269|NCT04637919|BIOLOGICAL|Placebo|Placebo, three doses, 28 days interval
223489104|NCT04700124|DRUG|Gemcitabine|1000 mg/m\^2 of Gemcitabine IV infusion, Day 1 and Day 8 Q3W for 4 cycles in preoperative phase (up to approximately 3 months)
223489105|NCT04700124|DRUG|Cisplatin|70 mg/m\^2 of Cisplatin IV infusion, Day 1, Q3W for 4 cycles in preoperative phase (up to approximately 3 months)
223489106|NCT06123377|DIAGNOSTIC_TEST|Angiogenic factor|sFLt-1/PGIF below or equal to 33
223489107|NCT03539536|DRUG|Telisotuzumab vedotin|Intravenous (IV) infusion
223489108|NCT06188000|DIETARY_SUPPLEMENT|Extra Virgin Olive Oil|The patients was given extra virgin olive oil, an unrefined (not processed with chemicals or heat) for of olive oil
223489109|NCT06188000|DIETARY_SUPPLEMENT|Olive Oil|The patients was given olive oil.
223489110|NCT06188000|DIETARY_SUPPLEMENT|Placebo|The patients was given empty capsule
223489111|NCT01477983|PROCEDURE|ATP guide additional ablation.|Following successful PV isolation, intravenous ATP of 0.4 mg/body-weight-kg is rapidly is injected, and dormant LA-PV conduction is evaluated. If dormant LA-PV conduction is unmasked, then additional radiofrequency energy applications are delivered to the conduction gaps until disappearance of dormant LA-PV conduction.
223489112|NCT01477983|DRUG|Antiarrhythmic drug (AAD)|Following successful ablation, AAD (Vaughan Williams class I or III) is administered for 90 days. The recommended drugs are flecainide, propafenone, sotalol and amiodarone, but the final choice of drug and dosage is left to the discretion of the attending physician.
223489113|NCT01477983|PROCEDURE|ATP guide additional ablation.|Following successful PV isolation, intravenous ATP of 0.4 mg/body-weight-kg is rapidly is injected, and dormant LA-PV conduction is evaluated. If dormant LA-PV conduction is unmasked, then additional radiofrequency energy applications are delivered to the conduction gaps until disappearance of dormant LA-PV conduction.
223489114|NCT01477983|DRUG|Control|Following successful ablation, AAD (Vaughan Williams class I or III) including flecainide, propafenone, sotalol and amiodarone is not used during the period of 0 - 90 days.
223489115|NCT01477983|PROCEDURE|Control|Following successful PV isolation, intravenous ATP is not administered.
223489116|NCT01477983|DRUG|Antiarrhythmic drug (AAD)|Following successful ablation, AAD (Vaughan Williams class I or III) is administered for 90 days. The recommended drugs are flecainide, propafenone, sotalol and amiodarone, but the final choice of drug and dosage is left to the discretion of the attending physician.
223489117|NCT01477983|PROCEDURE|Control|Following successful PV isolation, intravenous ATP is not administered.
223489118|NCT01477983|DRUG|Control|Following successful ablation, AAD (Vaughan Williams class I or III) including flecainide, propafenone, sotalol and amiodarone is not used during the period of 0 - 90 days.
223489119|NCT00036400|DRUG|epoetin alfa|
223489120|NCT04125459|PROCEDURE|Joint Biopsy|a synovial biopsy of a joint that has been affected by a gout attack
223489124|NCT04935606|BEHAVIORAL|Usual Care|Usual Care participants will receive their standard medical care as usual and all study assessments. Providers will not receive information about their drug use. To reduce Hawthorne effect biases and to mask the study's purpose, RAs will provide the Usual Care arm patients with a cancer screening booklet and have them view a cancer screening Video Doctor. Participants will receive re-contact calls (5 min) to provide attentional control for the Usual Care arm, motivate continued trial participation by reminding next research assessment and study incentives, update contact information, and address participation barriers, but do not provide intervention. At study end, Usual Care will receive the QUIT video doctor and drug use reduction booklet materials including overdose prevention materials and a list of clinic/community resources to help them reduce substance use.
223489125|NCT04935606|BEHAVIORAL|QUIT Intervention (doctor brief advice, video doctor, health coaching sessions at 2- and 6-weeks)|"QUIT's core components include:~1. patient screening with the WHO Alcohol Smoking and Substance Involvement Screening Test (ASSIST, score 4-26);~2. face-to-face brief clinician advice on reducing drug use (2-3 minutes);~3. video doctor reinforcing the clinician message;~4. drug use reduction brochure;~5. 2- and 6-week telephone health coaching sessions to enhance self-efficacy in reducing drug use, via motivational interviewing and cognitive behavior therapy (CBT) techniques (20-30 minutes)."
223489126|NCT04935606|BEHAVIORAL|QUIT-Mobile (QUIT Intervention plus weekly mobile-web app or text message weekly self-monitoring, automated feedback over 12 months)|"The QUIT-Mobile intervention includes QUIT's core components and adds:~1. SMS/IVR/mobile-app self-monitoring survey prompts twice-weekly during the QUIT coaching through 6 weeks, and then weekly self-monitoring and automated feedback via SMS/IVR/app through 12-months.~2. Web-based dashboards will be used by coaches for monitoring of patients' self-monitoring data to enhance 2- and 6-week coaching sessions and for monitoring during the post-coaching self-management and monitoring period from 7-weeks to 12-months and intervening accordingly. The mobile platform will provide the same intervention functions (self-monitoring surveys and feedback messages) and robust data transfer protocols across three mobile technology platforms."
223489127|NCT04428671|BIOLOGICAL|Cemiplimab|Given IV
223489128|NCT04428671|RADIATION|Radiation Therapy|Undergo standard of care radiation therapy
223489129|NCT04428671|PROCEDURE|Therapeutic Conventional Surgery|Undergo standard of care surgery
223489130|NCT02445560|DIETARY_SUPPLEMENT|Probiotic capsule and Fiber Sachet|"A probiotic capsule and fiber sachet will be consumed daily for 2-weeks. The probiotic capsule contains a mixture of Bifidobacterium bifidum, Bifidobacterium breve, Bifidobacterium longum, Lactobacillus acidophilus and Lactobacillus plantarum. The fiber sachet consists of 5 g of chicory root fiber.~During the treatment period, in addition to consuming the probiotic capsule and fiber sachet participants will consume a controlled diet consisting of foods that provide an average of approximately 2 g/kg/day of protein."
223489131|NCT02445560|DIETARY_SUPPLEMENT|Probiotic capsule and Placebo sachet|"A probiotic capsule and placebo sachet will be consumed daily for 2-weeks. The probiotic capsule contains a mixture of Bifidobacterium bifidum, Bifidobacterium breve, Bifidobacterium longum, Lactobacillus acidophilus and Lactobacillus plantarum. The placebo sachet consists of 5 g of maltodextrin.~During the treatment period, in addition to consuming the probiotic capsule and placebo sachet participants will consume a controlled diet consisting of foods that provide an average of approximately 2 g/kg/day of protein."
223587270|NCT05394480|DIAGNOSTIC_TEST|Blood pressure (Systolic, Diastolic), Pulse value, O2 saturations were measured.|Salivary cortisol was measured by electrochemiluminescence (ECLIA) method using the Cobas Cortisol ll kit.
223489132|NCT02445560|DIETARY_SUPPLEMENT|Placebo capsule and Fiber Sachet|"A placebo capsule and fiber sachet will be consumed daily for 2-weeks. The placebo capsule will contain potato starch, magnesium stearate and ascorbic acid. The fiber sachet consists of 5 g of chicory root fiber.~During the treatment period, in addition to consuming the placebo capsule and fiber sachet participants will consume a controlled diet consisting of foods that provide an average of approximately 2 g/kg/day of protein."
223489133|NCT02445560|DIETARY_SUPPLEMENT|Placebo capsule and Placebo sachet|"A placebo capsule and placebo sachet will be consumed daily for 2-weeks. The placebo capsule will contain potato starch, magnesium stearate and ascorbic acid. The fiber sachet consists of 5 g of maltodextrin.~During the treatment period, in addition to consuming the placebo capsule and placebo sachet participants will consume a controlled diet consisting of foods that provide an average of approximately 2 g/kg/day of protein."
223489134|NCT05234567|BIOLOGICAL|Asfotase Alfa|All participants will receive asfotase alfa subcutaneously per standard of care. Unless otherwise specified per the Physician's standard of care, participants aged \< 2 years are recommended for a clinic visit approximately every 3 months after Enrollment until 2 years of age, after which they should have a clinic visit approximately every 6 months. Participants should be followed for 5 years, as possible.
223489135|NCT06176066|PROCEDURE|CEST PH MRI based resection of glioblastoma|Using pre-operative amine chemical exchange saturation transfer pH weighted MRI, regions of interest that correspond to infiltrating glioblastoma will be identified and via intraoperative neuronavigation, guide resection of glioblastoma
223489136|NCT04620499|DEVICE|EEG|PEER EEG
223489137|NCT00002791|BIOLOGICAL|filgrastim|
223489138|NCT00002791|DRUG|dacarbazine|
223489139|NCT00002791|DRUG|doxorubicin hydrochloride|
223489140|NCT00002791|DRUG|ifosfamide|
223489141|NCT00002791|DRUG|mesna|
223489142|NCT00002791|PROCEDURE|conventional surgery|
223489143|NCT00002791|RADIATION|brachytherapy|
223489144|NCT00002791|RADIATION|intraoperative radiation therapy|
223489145|NCT00002791|RADIATION|radioisotope therapy|
223489146|NCT05686694|OTHER|Video Education|"Sharing of Planned Education Videos on Instagram In this research, the platform where planned video education will be shared was determined as Instagram, which is the most used social media platform by pregnant women. In the Instagram user name @ogttegitim account, 6 education videos that will be created and shared."
223489147|NCT06229730|DIAGNOSTIC_TEST|video Head Impulse Test|For v-HIT, the Synapsys v-HIT Ulmer device is used.
223489148|NCT06229730|DIAGNOSTIC_TEST|Cervical Vestibular Evoked Myogenic Potential|For cVEMP, the Eclipse (Interacoustic, Middelfart, Denmark) is used. To bypass the frequent middle ear problems bone conduction stimuli (B-81, Interacoustic, Middelfart, Denmark) are administrated. The bone conductor is placed on the mastoid process and two trials at 70 dB nHL are conducted to check waveform reproducibility. 500 Hz short tone bursts (2-2-2 ms) are applied at 5 per second stimulus repetition rate.
223489149|NCT06229730|DIAGNOSTIC_TEST|Ocular Vestibular Evoked Myogenic Potential|For oVEMP, the Eclipse (Interacoustic, Middelfart, Denmark) is used. To bypass the frequent middle ear problems bone conduction stimuli (B-81, Interacoustic, Middelfart, Denmark) are administrated. The bone conductor is placed on the mastoid process and two trials at 70 dB nHL are conducted to check waveform reproducibility. 500 Hz short tone bursts (2-2-2 ms) are applied at 5 per second stimulus repetition rate.
223489150|NCT06229730|DIAGNOSTIC_TEST|Computerized Dynamic Posturography|To evaluate functional balance of the children and the relative contributions of the vision, proprioception, and vestibular system a CDP from Virtualis (Virtualis, Montpellier, France) is used.
223489151|NCT06229730|OTHER|Dizziness Handicap Inventory for patient caregivers|DHI is a caregiver-reported 21-item questionnaire. It is designed to evaluate the perceived quality of life and handicap resulting from dizziness and unsteadiness for the pediatric population. For each question there are three possible answers: yes, sometimes or no. Each answer provides respectively 4, 2 and 0 points. The total DHI scores range from 0 to 84 with higher score being consistent with more limitation and more severe handicap. Scores under 16 are characterized as no limitation or handicap. A score from 16-26 present a mild perceived handicap and mild limitations. A DHI-score between 26-43 is classified as a moderate problem, and a score above 43 describes a severe perceived handicap and severe limitations.
223489152|NCT05580562|DRUG|Dordaviprone (ONC201)|Participants ≥ 52.5 kg will receive 625 mg of ONC201 (5 × 125-mg capsules) dosing days; participants \< 52.5 kg will receive a dose (and corresponding number of capsules) scaled by body weight and rounded to 125-mg increments.
223587271|NCT00467675|DEVICE|CGM System for Type 1 and Type 2 Diabetes Mellitus|
223587272|NCT01291693|BEHAVIORAL|Personal Counseling|At three time-points, participants receive counseling by health professionals trained in Motivational Interviewing based counseling. To assure that both interventions do not differ in their content, individual manuals generated by a software program are used. Counseling will be face-to-face during the hospital stay, and by phone one and three months later.
224073002|NCT02799069|DRUG|MAL Cream|topical treatment for photodynamic therapy combining drug application and after a 3 h incubation subsequent illumination with a broad or narrow spectrum light source.
224073003|NCT02799069|DRUG|Vehicle|topical treatment for photodynamic therapy combining vehicle application and after a 3 h incubation subsequent illumination with a broad or narrow spectrum light source.
224073004|NCT01307969|DRUG|Ropivacaine|1,8 mL of the local anesthetic formulations were injected at the apex of the maxillary right canine.
224073005|NCT01265680|DRUG|Erythropoietin|80.000 UI of Human Recombinant Erythropoietin and intravenous iron at time of arrival at the hospital.
224073006|NCT06309056|DEVICE|VitalStim|VitalStim is a device that provides neuromuscular electrical stimulation. It will be applied on muscles related to swallowing to stimulate muscle contraction.
224073007|NCT02886416|OTHER|Non interventional study|
224073008|NCT04486092|DRUG|Valproic Acid|
224073009|NCT01277640|DRUG|dapivirine|"* dosage form: gel 0.05%~* dosage: 2.5g~* frequency: once daily~* duration: 7 days"
224073010|NCT01277640|DRUG|matched placebo|"* dosage form: gel, no api~* dosage: 2.5g~* frequency: once daily~* duration: 7 days"
224073011|NCT01277640|DRUG|universal placebo|"* dosage form: gel, HEC-based~* dosage: 2.5g~* frequency: once daily~* duration: 7 days"
224073012|NCT03821740|OTHER|Kinesiotaping|Mc Connel taping and another kinesiotaping technique
224073013|NCT04425187|DRUG|Gefitinib|gefitinib 250mg (1 tablet), once a day，PO
224307352|NCT01043835|PROCEDURE|Laparoscopy-assisted gastrectomy|A 10-mm trocar for laparoscope was inserted below the umbilicus. Another 10-mm trocar was introduced in the left preaxillary line 2 cm below the costal margin as a major hand port，and a 5-mm trocar was placed at the contralateral site for traction. A 5-mm trocar was inserted in the left midclavicular line 2 cm above the umbilicus as an accessory port, and a 15-mm trocar also as an accessory port was placed at the contralateral site. The operator stood on the left side of the patient. Subtotal or total gastrectomy and D2 lymph node dissection will be performed basically. As a general rule, Billroth I, Billroth II or Roux-Y method was used for gastric reconstruction. Dissected stomach and lymph node are collected through additional 5 cm incision at a median superior abdominal incision.
223489153|NCT05580562|DRUG|Dordaviprone (ONC201) + Placebo|Participants ≥ 52.5 kg will receive 625 mg of ONC201 (5 × 125-mg capsules) or matching placebo on dosing days; participants \< 52.5 kg will receive a dose (and corresponding number of capsules) scaled by body weight and rounded to 125-mg increments
223489154|NCT05580562|OTHER|Placebo|Participants will receive placebo (same number of capsules as the ONC201 dose) on dosing days
223489155|NCT06636448|PROCEDURE|the effect of body mass index during low-flow anesthesia|The investigator planned to evaluate the effect of body mass index on patient outcomes during low-flow anesthesia in patients undergoing gynecologic cancer surgery.
223489156|NCT06785636|DRUG|Pocenbrodib|Pocenbrodib is a selective oral inhibitor of CBP/p300 bromodomain interaction with acetylated lysines on histones.
223489157|NCT06785636|DRUG|Cohort 2A (Pocenbrodib monotherapy), Cohort 2B (Pocenbrodib + abiraterone acetate), Cohort 2C (Pocenbrodib + olaparib), Cohort 2D (Pocenbrodib + 177Lu-PSMA-617|Pocenbrodib alone or in combination
223489158|NCT06496620|DRUG|Biological: Solrikitug low dose|Solrikitug subcutaneous injection
223489159|NCT06496620|DRUG|Biological: Solrikitug high dose|Solrikitug subcutaneous injection
223489160|NCT06496620|OTHER|Placebo|Placebo subcutaneous injection
223489161|NCT01940588|BEHAVIORAL|Neuropsychoanalytic therapy|Psychotherapy, medication management
223489162|NCT05614609|DRUG|Lidocaine topical|Comparing lidocaine spray and muscle relaxing medication
223489163|NCT02693535|DRUG|Palbociclib|drug
223489164|NCT02693535|DRUG|Sunitinib|drug
223489165|NCT02693535|DRUG|Temsirolimus|drug
223489166|NCT02693535|DRUG|Trastuzumab and Pertuzumab|drug
223489167|NCT02693535|DRUG|Vemurafenib and Cobimetinib|drug
223489168|NCT02693535|DRUG|Regorafenib|drug
223489169|NCT02693535|DRUG|Olaparib|drug
223489170|NCT02693535|DRUG|Pembrolizumab|drug
223489171|NCT02693535|DRUG|Nivolumab and Ipilimumab|drug
224073014|NCT04425187|DRUG|Bevacizumab Combined With Gefitinib|Bevacizumab Combined With Gefitinib
223489172|NCT02693535|DRUG|Abemaciclib|drug
223489173|NCT02693535|DRUG|Talazoparib|drug
223489174|NCT02693535|DRUG|Atezolizumab and PHESGO|drug
223489175|NCT02693535|DRUG|Atezolizumab and Talazoparib|drug
223489176|NCT02693535|DRUG|Entrectinib|drug
223489177|NCT02693535|DRUG|Larotrectinib|drug
223489178|NCT02693535|DRUG|Tucatinib plus Trastuzumab Subcutaneous (SC)|drug
223489179|NCT02693535|DRUG|Futibatinib|drug
223489180|NCT05492955|BEHAVIORAL|Community Health Worker Care Model|Participants will be given a digital BP Cuff and a standardized training on its operation, and assigned a CHW from their local Community Health Team. The participant will be instructed to take 6-10 measurements BP per week and record them in a logbook. CHWs will return to participant homes every 2-4 weeks to collect BP measurements and enter them into a data collection system, assess for symptoms, and discuss treatment adherence and lifestyle recommendations. BP readings will be brought by the CHW to their assigned nursing supervisors at their local clinic, who will initiate and tailor medications based on a standardized clinical decision support algorithm, based on SA DoH hypertension control guidelines. All treatment decisions will be made by the nursing supervisors. Participants will either obtain medication(s) at the pharmacy or, as possible, have them delivered by a CHW.
223489181|NCT05492955|BEHAVIORAL|Enhanced Community Health Worker-based with Mobile Health Blood Pressure Monitoring Model|Participants in this arm will also be given a BP Cuff, (but with cellular network capability, such that BP data can be directly transmitted to trial server), given training on its operation, and assigned a CHW from their local Community Health Team. The participant will be instructed to take 6-10 measurements BP per week, which will be automatically uploaded onto the server to be made available by the nurse supervisors. CHWs will return to participant homes every 2-4 weeks to ensure functionality of the devices and transmission, collect BP measurements if the system is not functional, assess for symptoms, and discuss treatment adherence and lifestyle recommendations. Nursing supervisors at the clinic will use the remotely collected BP data to initiate and tailor medications based on the same standardized clinical decision support (CDS) algorithm, based on SA DoH hypertension control guidelines. All treatment decisions will be made by the nursing supervisors.
223512481|NCT06045286|RADIATION|Radiation: High- and Low-dose radiotherapy|High-dose radiotherapy (6-8Gy×3-7F) followed by low-dose radiotherapy (0.5-1.4Gy×3-7F) starting within 7 days after completion.
223512482|NCT06045286|DRUG|PD-1 Inhibitors|Immunotherapy (Zimberelimab) is given every three weeks within one week after the end of high-dose radiotherapy.
224073015|NCT06238167|DRUG|Tislelizumab|Tislelizumab, 200mg Q3W, max 16 cycles.
224073016|NCT06238167|DRUG|S-1 therapy|S1 d1-14 bid (\< 1.25m\^2 40mg, 1.25m\^2-1.5m\^2 50mg, ≥ 1.5m\^2 60mg), followed by 7 days off (Q3W, max 16 cycles).
224073017|NCT06238167|DRUG|low dose SOX therapy|Oxaliplatin: 78mg/m\^2, d1, S-1: 50mg d1-14 bid, followed by 7 days off (Q3W, max 8 cycles).
224073018|NCT02302976|DRUG|cocaine hydrochloride|
224073019|NCT02302976|DRUG|exenatide|
224073020|NCT02302976|DRUG|placebo|
224073021|NCT03222791|OTHER|Algorithm-based diet|Personalized nutrition plan based on an algorithm for predicting the personalized glucose response to food. The algorithm's predictions are based on many personal measurements, including blood tests, personal lifestyle and gut bacteria.
224073022|NCT03222791|OTHER|Mediterranean-style low-fat diet|The Israeli standard of care dietary guidelines for prediabetes.
224073023|NCT04906980|DRUG|JNJ-64281802|JNJ-64281802 will be administered orally.
224073024|NCT04906980|DRUG|Placebo|Matching placebo (PEG400) will be administered orally.
224179755|NCT05102773|PROCEDURE|Biospecimen Collection|Undergo collection of blood and stool
224179756|NCT05102773|PROCEDURE|Computed Tomography|Undergo CT
224179757|NCT05102773|OTHER|Laboratory Biomarker Analysis|Correlative studies
224179758|NCT05102773|OTHER|Questionnaire Administration|Complete questionnaire
224179759|NCT05607927|PROCEDURE|Parks surgery|Parks surgery
224179760|NCT05607927|PROCEDURE|PE-Bacon surgery|PE-Bacon surgery
224179761|NCT02530580|DRUG|20 mg AZD7325|A single 20 mg oral dose of AZD7325
224179762|NCT02530580|DRUG|Placebo|A single oral dose
224179763|NCT01247467|OTHER|Breast Tumor Blocks|
224179764|NCT04000412|DEVICE|CardioZ multifrequency impedance recording system|Patients will be submitted to mapping of both voltage and tissue impedance. The accuracy of the two maps identifying the extent and transmurality of the infarction will be assesssed by gadolinium imaging.
224179765|NCT00003524|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Stomach Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
224179766|NCT04558658|DIAGNOSTIC_TEST|Complete Blood Count|neutrophil to lymphocyte ratio
224179767|NCT03971773|OTHER|hypnosis|patient with cancer will undergo sessions of hypnosis
224179768|NCT04022265|DEVICE|implant placement|Full-thickness muco-periosteal flaps will be elevated, and the alveolar bone exposed to prepare the bed for the implant installation
224179769|NCT02512120|DEVICE|volume controlled ventilation|"After induction of anesthesia and intubation, patients will be applied VCV by Zeus®(Dräger, Germany).~\- Tidal volume : 8ml/kg(ieal body weight), inspiration:expiration ratio = 1:2, FiO2 = 0.5, fresh gas flow = 3L/min respiratory rate(RR) : 12/min. After position, RR can changed 2 times each per 5 minutes to maintain end tidal CO2 around 35. Positive end expiratory pressure will not used."
224179770|NCT02512120|DEVICE|autoflow-volume controlled ventilation|"After induction of anesthesia and intubation, patients will be applied autoflow- VCV by Zeus®(Dräger, Germany).~\- Tidal volume : 8ml/kg(ideal body weight), inspiration:expiration ratio = 1:2, FiO2 = 0.5, fresh gas flow = 3L/min respiratory rate(RR) : 12/min. After position, RR can changed 2 times each per 5 minutes to maintain end tidal CO2 around 35. Positive end expiratory pressure will not used."
224179771|NCT03456557|RADIATION|Perfusion computed tomography.|Using specific post treatment imaging software ( Olea® ) we will calculatell permeability parameters : the pancreatic blood flow and the k-trans, capillary membrane permeability factor.
224179772|NCT03834857|DEVICE|Stentrode|Implantation of Stentrode device
224307353|NCT01043835|PROCEDURE|Open gastrectomy|Approximately 15\~20 cm length incision is made from falciform process to periumbilical area. Subtotal or total gastrectomy and D2 lymph node dissection will be performed basically. As a general rule, Billroth I, Billroth II or Roux-Y method was used for gastric reconstruction for all cases.
224179773|NCT00354120|DRUG|Alentuzumab|Alentuzumab
224179774|NCT00354120|DRUG|Globulina antilinfocitaria|Globulina antilinfocitaria
224179775|NCT03749031|OTHER|Orange juice + Orange Pomace|16 oz. orange juice + orange Pomace per day for 4 weeks
224179776|NCT03749031|OTHER|Orange Juice|16 oz. orange juice per day for 4 weeks
224179777|NCT03749031|OTHER|Apple Juice and Apple Pomace|16 oz. apple juice and apple Pomace per day for 4 weeks
224179778|NCT03749031|OTHER|Apple Juice|16 oz. apple juice per day for 4 weeks
224179779|NCT04495166|BEHAVIORAL|Motherly 1.0|A mobile app designed to promote life habits that have been shown to improve physical and mental health in pregnant women. The app consists of a package of specific and customized interventions defined by eight different modules: 1) Mental Health; 2) Sleep; 3) Nutrition; 4) Physical activity; 5) Social support; 6) Prenatal support; 7) Postnatal support, and 8) Library of pre and postnatal content. The app relies on extensive psychoeducational content delivered as tutorials, brief messages, and available as a library that can be read at the users' discretion; behavior monitoring using schedules, checklists, and notifications to help participants keep track of their health care visits, and schedule behavior activation activities; and gaming elements such as changes in background appearance to reflect participant's mood assessment and ratings of activities, and graphical and easy-to-use questionnaires for obtaining information (mood, nutrition habits).
224205662|NCT05307926|DRUG|PD-1 inhibitors|For patients with PVTT, they received adjuvant therapy of PD1 (200mg intravenously every 3 weeks for a total of 18cycles) plus Lenvatinib (8mg orally once a day for 1 year) 2-4 weeks after surgery; for patients with other high-risk factors for recurrence, they PD-1(200mg intravenously every 3 weeks for a total of 9cycles) monotherapy 2-4 weeks after surgery.
224307354|NCT01899443|OTHER|Observation|This is an observational study observing relationship between routine care and outcomes after total hip or knee arthroplasty.
224307355|NCT04418843|PROCEDURE|Standard Endoscopic Mucosal Resection|Use of injected colloidal or saline solution to raise a lesion prior to polypectomy snare closed over a polyp with electrocautery
224205663|NCT05307926|PROCEDURE|TACE|Patients with high-risk factors for recurrence received 1 TACE about a month after surgery.
224307356|NCT04418843|PROCEDURE|Cold Snare Endoscopic Mucosal Resection|Use of injected colloidal or saline solution to raise a lesion prior to polypectomy snare closed over a polyp without electrocautery
224307357|NCT04896749|OTHER|Nerve mobilization|"Moist pack all over cervical spine for 10 minutes. TENS for 10 minutes at frequency of 60 Hz with 2 electrodes. Cervical traction for 10 minutes with 7 sec hold and 5 sec rest time. Cervical isometric exercises with 7 sec hold and 30 repetitions in each direction twice a day.~Median, ulnar and radial nerve stretch with 3 sets of 10 repetitions , with 3 sec hold at final stretched position.~Following nerve mobilizations are used in experimental group/group A:~Median Nerve: Glenohumeral abduction, wrist extension, supination, glenohumeral lateral rotation, elbow extension, neck lateral bending to opposite side. Radial Nerve: Glenohumeral depression, elbow extension, whole arm internal rotation, wrist flexion Ulnar Nerve: Wrist extension, forearm pronation elbow flexion, glenohumeral lateral rotation, glenohumeral depression, shoulder abduction each with 3 sets of 10 repetitions , with 3 sec hold at final stretched position."
224307358|NCT04896749|OTHER|Conventional physical therapy|Moist pack for 10 minutes. TENS for 10 minutes at frequency of 60 Hz with 2 electrodes. Cervical traction for 10 minutes with 7 sec hold and 5 sec rest time. Cervical isometric exercises with 7 sec hold and 30 repetitions in each direction twice a day.
224179780|NCT04495166|BEHAVIORAL|Brief Psychotherapy|Brief Cognitive-Behavioral Therapy (CBT) with a focus on behavioral activation (BA). Participants will be guided by psychotherapists to plan, schedule, and engage in positively reinforcing activities, and will be aided to develop problem-solving strategies for circumventing barriers to completing scheduled activities. Implementation of these techniques will be conducted with the aid of the Motherly 1.0 for participants in the experimental arm; for participants in the control arm, BA will be implemented without the aid of Motherly 1.0. Throughout the four sessions, psychotherapists will monitor participants' adherence, answering questions about the strategies and providing support for solving problems or CBT techniques, such as cognitive restructuring, relaxation techniques, sleep hygiene, stress and anxiety management, among other evidence-based techniques might be used if appropriate to the case.
224179781|NCT04495166|BEHAVIORAL|Educational app|A simplified version of the Motherly 1.0 app consisting of psychoeducational content about various aspects of pregnancy, maternal physical and mental health, and child development. Active intervention functionalities, such as behavioral activation, activity scheduling, sleep hygiene, among others, are NOT present in this simplified version of the app.
224179782|NCT02996162|DEVICE|Massimo Root Monitoring System|The Masimo Root system is a patient monitoring and connectivity platform; Root displays patient monitoring information from the connected modules. This will be used as a non-invasive way to determine infants' pCO2. The equipment will be used in the inpatient portion of the study up to twice weekly for 5 minutes to obtain approximately 150 end tidal CO2 values and recorded over time for each infant. In the outpatient portion, it will be used in each clinic visit in a similar fashion.
224179783|NCT02996162|DEVICE|ISA-Infrared Sidestream Gas Analyzer|The ISA-Infrared Sidestream Gas Analyzer displays end-tidal carbon dioxide waveforms and measurements and trends of end tidal CO2. This will be used as a non-invasive way to determine infants' pCO2. The equipment will be used in the inpatient portion of the study up to twice weekly for 5 minutes to obtain approximately 150 end tidal CO2 values and recorded over time for each infant. In the outpatient portion, it will be used in each clinic visit in a similar fashion.
224179784|NCT03938857|DRUG|Fentanyl|Fentanyl standard of care
224179785|NCT03938857|DRUG|Dexmedetomidine|Dexmedetomidine (0.5 mcg/kg + 0.2 mcg/kg/hr)
224179786|NCT03938857|DRUG|Dexmedetomidine|Dexmedetomidine (0.5 mcg/kg + 0.5 mcg/kg/hr)
224179787|NCT03938857|DRUG|Dexmedetomidine|Dexmedetomidine (0.5 mcg/kg + 0.7 mcg/kg/hr)
224179788|NCT00296569|DRUG|MK0686|
224179789|NCT06497816|OTHER|No intervention|No intervention
224179790|NCT06261658|PROCEDURE|Cryopreserved Ovarian Tissue Reimplantation|Cryopreserved Ovarian Tissue Reimplantation Using Platelet-enriched Autologous Plasma
224179791|NCT02457130|DRUG|Ticagrelor|
224179792|NCT02457130|DRUG|Clopidogrel|
224179793|NCT03328741|BEHAVIORAL|Online Osteoarthritis treatment|6 week online-program
224179794|NCT03328741|BEHAVIORAL|Face-to-face osteoarthritis treatment|3 months face-to-face program
224179795|NCT01527058|DRUG|68Ga-BNOTA-PRGD2|"Cancer patients, single intravenous bolus injection of nearly 111 MBq 68Ga-NOTA-PRGD2 on day one of the treatment period, dynamic whole-body PET/CT for determination of effective dose, kinetics of 68Ga-BNOTA-PRGD2 in blood, organs, and tumors~Healthy volunteers, single intravenous bolus injection of nearly 111 MBq 68Ga-BNOTA-PRGD2 on day one of the treatment period, dynamic whole-body PET/CT for determination of effective dose, kinetics of 68Ga-BNOTA-PRGD2 in blood and organs"
224179796|NCT01698749|DRUG|long acting intravitreal dexamethasone implant|Intravitreal ozurdex was given in diabetic patients with clinically significant macular edema and they were followed up for change in central macular thickness and visual acuity over a period of 6 months
224179797|NCT01809717|OTHER|Weight Lifting Exercises|
224205664|NCT02587117|DRUG|lycopene|Each capsule contain 2 mg lycopene. Each patient was received two capsules of lycopene (total dose was 4 mg) single dose in morning for 2 months. Follow-up was done at base line, 2nd, 4th, 6th and 8th weeks of the therapy.
224205665|NCT02587117|DRUG|Prednisolone|Each capsule contain 20 mg prednisolone. Each patient was received two capsules of prednisolone (total dose was 40 mg) single dose in morning for 2 months. Follow-up was done at base line, 2nd, 4th, 6th and 8th weeks of the therapy.
224205666|NCT04869618|DEVICE|Raman spectroscopy based device (SPECTRA IMDx)|The SPECTRA IMDx system is developed on the basis of Raman spectroscopy. It comprises a laser system, a spectrometer, a computer with an analysis algorithm installed, and other ancillary parts. The SPECTRA IMDx system also comprises a SPECTRA IMDx probe that can be connected with the main system. The SPECTRA IMDx probe is an assembly of optical fibres and optical components arranged for maximal transmission of light energy. When in use, the laser system will emit a 785nm near infra-red laser that will be transmitted through the SPECTRA IMDx probe to the distal end. When the laser is interrogated upon a tissue surface, the light energy is absorbed and reflected. The reflected energy is then collected from the distal end of the SPECTRA IMDx probe, transmitted back to the main system, and passed through the spectrometer. The collected signal is then processed to obtain the clean Raman signal, which is then parsed through an analysis algorithm for diagnosis.
224307359|NCT00968799|PROCEDURE|Hyperthermic intraoperative intraperitoneal chemotherapy|Perfusion of the peritoneum with 42°C warm 25 mg/l cisplatin solution.
224307360|NCT00968799|PROCEDURE|Cytoreduction|"Surgical removal of tumor nodules~including resection of organs infested with tumor"
224307361|NCT00968799|DRUG|Cisplatin|Cisplatin is applied as chemotherapy during surgery
224205667|NCT01857011|DRUG|Intravenous Iron sucrose|Intravenous Iron Sucrose 200 mg in the immediate postoperative period and first day postop.
224205668|NCT01857011|DRUG|Oral Iron|Oral iron(III)-hydroxide polymaltose complex 100 mg twice daily in the fist 8 postoperative weeks.
224205669|NCT04703647|OTHER|Administration of questionnaires for prospective group|Questionnaires: administration at T0, T1,T2,T3 and T4 of Short Form Health Survey (SF-36),Brief Pain Inventory (BPI),Disabilities of the Arm, Shoulder and Hand (DASH) for upper limb,Foot and Ankle Ability Measure (FAAM) for lower limb,Hospital Anxiety And Depression Scale (HADS),Tampa Scale of Kinesiophobia (TSK),Pain Catastrophizing Scale (PCS),Pattern Of Activity Measure - Pain (POAM-P) .
224205670|NCT04703647|OTHER|Blood samples for prospective group|Blood samples at T0,T1,T2 and T3.
224205671|NCT04703647|OTHER|Blood samples for control group|Blood samples just one time
224205672|NCT00116545|DRUG|troglitazone|
223587273|NCT01291693|BEHAVIORAL|Computer-generated feedback letters|At three time points, participants receive feedback letters, tailored to the stages of change according to the TTM, and generated by a computer software program. The first letter is handed out during their hospital stay and includes normative feedback. One and three months later, participants receive ipsative feedback letters by mail.
223587274|NCT04863196|OTHER|Laser therapy Treatment Group|laser in gastric mucosa lesion
223587275|NCT04863196|OTHER|Barrier Dust Treatment Group|barrier powder in gastric mucosa lesion
223587276|NCT01116427|BIOLOGICAL|abatacept|In core/extension phase: administered IV at weeks 0/28, 2/30, and 4/32, and then every 4 weeks until week 24/52; Dosing: less than 60 kg, 500 mg; 60-100 kg, 750 mg; or greater than 100 kg, 1 gram
223587277|NCT01116427|DRUG|Placebo|In core/extension phase: administered IV at weeks 0/28, 2/30, and 4/32, and then every 4 weeks until week 24/52
223587278|NCT03675516|OTHER|No specific intervention|Usual care
224307362|NCT04642651|DRUG|Dexmedetomidine|Patients in the dexmedetomidine group receive single-shot femoral nerve block preoperatively using a mixture of 0.375% ropivacaine and 1.0 μg/kg dexmedetomidine, in a total volume of 20 ml.
224307363|NCT04642651|DRUG|Placebo|Patients in the control group receive single-shot femoral nerve block preoperatively using a mixture of 0.375% ropivacaine and normal saline, in a total volume of 20 ml.
224307364|NCT05940753|OTHER|Survey about travel willingness regarding cancer treatment and follow-up|No intervention. Willingness to travel is examined through a survey. The survey will be conducted digitally, but may also be done on paper. In the survey a minimal set of categorized patient data (e.g. age, gender, level of education) is collected as part of the survey. For patients who cannot independently complete the questionnaire (for example due to low literacy skills), a volunteer, medical student or researcher is allowed to help the patient.
223587279|NCT00601913|DRUG|erlotinib hydrochloride|
224073025|NCT01169155|OTHER|Smoke Alarm Stimuli|See arm descriptions for information about the smoke alarm stimuli interventions.
224307365|NCT03173144|OTHER|Primary exposure variable|"1. Upper tertile (33.3% of the total sample) based on the ratio: fibre/meat intake is associated with better treatment outcome~2. Low intake of red and processed meat (defined as below the lower tertile \[33.3% of the total sample\]) and high intake of dietary fibres (defined as those above the upper tertile \[33.3% of the total sample\]) are independently associated with better treatment outcome, and their synergy (interaction between the factors meat and fibres) gives the best treatment outcome"
223587280|NCT00601913|GENETIC|protein analysis|
223587281|NCT00601913|GENETIC|western blotting|
223587282|NCT00601913|OTHER|immunohistochemistry staining method|
223587283|NCT00601913|OTHER|laboratory biomarker analysis|
223587284|NCT00601913|OTHER|liquid chromatography|
223587285|NCT00601913|OTHER|mass spectrometry|
223587286|NCT00601913|PROCEDURE|neoadjuvant therapy|
223587287|NCT00601913|PROCEDURE|therapeutic conventional surgery|
223587288|NCT02989805|BEHAVIORAL|Care Management|Professionals and peers will each deliver the same intervention. The intervention combines a traditional medical model of care management with a recovery-based approach.
223587289|NCT04037150|DIAGNOSTIC_TEST|Circulating tumor DNA|Circulating tumor DNA
224073026|NCT02774382|DRUG|Vancomycin|Already incl. in arm description
224073027|NCT02774382|DRUG|Fecal microbiota transplantation|Already incl. in arm description
224073028|NCT02774382|DRUG|Rectal bacteriotherapy|Already incl. in arm description
224073029|NCT02595476|DRUG|Remifentanil|
224073030|NCT02595476|DRUG|propofol|
224073031|NCT02595476|DEVICE|TCI|
224073032|NCT02595476|PROCEDURE|Tetanic stimulation|
224073033|NCT02595476|DEVICE|Algiscan|Pupillometry
224073034|NCT02396186|DEVICE|PTCA Balloon Angioplasty|
224073035|NCT04360070|DRUG|Ketamine Hydrochloride|Parenteral General Anesthetic
224073036|NCT03858673|PROCEDURE|VTH via the Tsuzi method with residual uterine ligament ligation|VTH via the Tsuzi method with residual uterine ligament ligation
224073037|NCT02627820|DRUG|Isis 420915/GSK 299872|Open label study in comparison to historic control.
224073038|NCT01290380|DRUG|ASA404, DMXAA, DXAA|ASA404 (5,6-dimethylxantheone-4-acetic acid) DMXAA or DXAA
224073039|NCT02966691|OTHER|VisioCyt® diagnostic test|The cytology slides obtained from the current practice will be compared to the slides obtained with the Visiocyt protocol, for each arm.
224073040|NCT06239311|DRUG|Methotrexate|Solution for injection in prefilled pen
224073041|NCT06239311|DRUG|Placebo|Solution for injection in prefilled pen
224073042|NCT04406909|OTHER|Access to training facility|Access to training facility under national regulations for COVID control
224073043|NCT00301340|DRUG|5% Lice Asphyxiator lotion - Summers Laboratories, Inc.|
224073044|NCT05572775|PROCEDURE|Quadratus lumborum (QL) block|bilateral anterior subcostal quadratus lumborum block
224073045|NCT05572775|PROCEDURE|Erector Spinae Plane (ESP) Block|bilateral erector spinae plane block
224073046|NCT00336947|DRUG|tegafur-gimeracil-oteracil potassium|
224073047|NCT00336947|DRUG|tegafur-uracil|
224073048|NCT00336947|PROCEDURE|adjuvant therapy|
224073049|NCT05347160|PROCEDURE|Biodentine|using of biodentine , calcium hydroxide and platelet rich fibrin as pulpotomy agents
224073050|NCT01666327|DRUG|MT-1303|
224073051|NCT00470600|DRUG|Caldolor|800 milligrams intravenous
224073052|NCT00470600|OTHER|Normal Saline|Placebo comparator
224073053|NCT00985335|OTHER|Neem Based External Application Cream|Apply externally 3-4 times per day
224073054|NCT06017804|OTHER|Muscle energy technique|Participants were required to adopt a supine position. MET's post-isometric relaxation method was chosen. The therapist gently flexed the patient's hip until the limitation bar-rier was detected. At this stage, isometric contractions against resistance were applied. After that, the patients were told to resist the movement with only 25% of their strength. Before the leg was released, the contraction was maintained for 7-10 seconds. On exhale, the knee joint was straightened (extended) towards its new barrier, and a stretch was applied and maintained through that barrier for 30 seconds. This procedure was carried out six times.
224179798|NCT05453318|PROCEDURE|Treatment of cervical neoplasia by thermal ablation|Women screened for cervical cancer by VIA presenting lesions eligible for ablative treatment were treated by thermal ablation. The treatment consisted in applying the probe on the lesion for 45 seconds at 100 degrees Celsius, with one to up to five applications depending on the lesion size. Following treatment, women were inquired about the pain level during the procedure, their satisfaction level of the procedure and whether they would recommend this treatment to their relatives. Women had a follow-up visit at 6 weeks to assess any complication of the procedure. Women were rescreened at 12 months, to evaluate the cure rate and any long-term adverse events.
224179799|NCT06256679|PROCEDURE|superior hypogastric plexus pulsed radiofrequency and transcutaneous tibial nerve stimulation|The L5-S1 intervertebral space was visualized using fluoroscopy. A 22G, 15 cm injection needle was advanced along the bilateral disc, and under lateral imaging, the needle position was confirmed anterior to the vertebral bodies. 2 ml of contrast solution was injected to confirm the correct needle placement, and then 8 mg of dexamethasone and 40 mg of bupivacaine (0.25%) were injected separately on each side. Two weeks later, patients who showed more than 50% improvement from the diagnostic block, as assessed by NRS, underwent a superior hypogastric pulsed radiofrequency procedure using a transdiscal technique with a 22G, 15 cm, 10 mm active-tipped radiofrequency needle at 42°C for 120 seconds. Two 50x50 mm electrode pads were placed on the posterior-superior aspect of the medial malleolus for posterior tibial nerve stimulation. Stimulation was delivered in continuous mode at a frequency of 20 Hz and a pulsed width of 200 ms. It was applied once a week for 30 min for 4 weeks.
224307366|NCT03173144|OTHER|Other (exploratory) exposure variables|"* Lifestyle factors independently or combined (red and processed meat, vegetable, dietary fibre, cereals, gluten, legumes, red wine, dairy products, physical activity, smoking, total protein/ fat, protein/ fat from red and processed meat, glucemic index)~* Pretreatment lifestyle-associated biomarkers~* Combinations of lifestyle factors and lifestyle-associated biomarkers~* Gene-environment interaction analyses~* Pretreatment levels of inflammatory molecules"
224307367|NCT03382730|OTHER|Chlorhexidine Mouth Rinse|Oral chlorhexidine gluconate oral rinse
224307368|NCT03382730|OTHER|Chlorhexidine Mouth Rinse De-Adoption|Multifaceted education and audit/feedback.
224307369|NCT00719849|BIOLOGICAL|anti-thymocyte globulin|30mg/Kg Days -6 to -4
224307370|NCT00719849|DRUG|cyclophosphamide|50 mg/Kg Day -6
224307371|NCT00719849|DRUG|cyclosporine|Patients will receive cyclosporine A (CSA) therapy beginning on Day -3 maintaining a trough level between 250 and 500 ng/mL. For adults the initial dose will be 2.5 mg/kg IV over 1 hour every 12 hours. For children \< 40 kg the initial dose will be 2.5 mg/kg IV over 1 hour every 8 hours.
224307372|NCT00719849|DRUG|fludarabine phosphate|40mg/m2 Days -6 to -2
224307373|NCT00719849|DRUG|mycophenolate mofetil|1 gram every 8 hours for patients who are ≥ 40 kg. Pediatric patients (\<40 kilograms) will receive MMF at the dose of 15 mg/kg/dose every 8 hours. Stop MMF at Day +30 or 7 days after engraftment, whichever day is later, if no acute GVHD.
224307374|NCT00719849|PROCEDURE|umbilical cord blood transplantation|Single or double unit umbilical cord blood transplant
224307375|NCT00719849|RADIATION|total body irradiation|200 cGy Day -1
224073055|NCT06017804|OTHER|Self-myofascial release technique|A foam roller was rolled from the ischial tuberosity to the back of the knee on the side being tested while the participant remained seated in a long sitting position. Individuals were instructed to keep all of their body weight on the leg being evaluated. They spent 30-40 seconds rolling one hamstring at a time in each set (10 times back and forth).
224073056|NCT00473707|PROCEDURE|Active management of the third stage of labor|standardized oxytocin infusion (10 units of oxytocin in 500 mL of Ringers lactate over 20 minutes) immediately following delivery of the fetus with gentle cord traction and fundal massage
224307376|NCT01323049|PROCEDURE|Positive pressure extubation|Positive pressure extubation will be used for patients waking up from general anesthesia
224307377|NCT01323049|PROCEDURE|Aspiration/suction extubation|Aspiration/suction extubation will be used for patients waking up from general anesthesia
224307378|NCT03048253|BIOLOGICAL|OrienX010|Beijing biological technology co., LTD. Research and development of the source and force of recombinant human GM-CSF herpes simplex virus injection (OrienX010), is a genetically engineered type 1 herpes simplex virus (HSV - 1) as the carrier insert GM-CSF gene therapy drug.Its carrier is made of isolated from patients with oral Chinese wild single blister virus type I (CL1), after gene recombination technology successively removing ICP34.5, ICP47 and insert the deactivation ICP6 gene, and at the site of the original ICP34.5 insert guided by IE promoter of hCMV human GM-CSF gene.
224307379|NCT06895902|DEVICE|Polypropylene Suture Eyelid Spring for Paralytic Lagophthalmos|The polypropylene loop eyelid suture spring will be centrally placed without fixation to the bone unlike a metal lid spring.
224307380|NCT03867097|DRUG|Placebo IV infusion|Study drug will be initiated at a starting dose of 0.5 ng/kg/min up to 2.0 ng/kg/min. Subjects will receive study drug for 5 consecutive days as an IV infusion over 6 hours each day via a peripheral line.
224307381|NCT03867097|DRUG|Iloprost Injection, for intravenous use|Study drug will be initiated at a starting dose of 0.5 ng/kg/min up to 2.0 ng/kg/min. Subjects will receive study drug for 5 consecutive days as an IV infusion over 6 hours each day via a peripheral line.
224307382|NCT04328857|DEVICE|pseudoelastic orthosis|The subject will be given specific physiotherapy including activities oriented to multimodal exploration and refinement of gross and fine motor skills, customized according to the functional status of the individual patient.
224307383|NCT01372774|RADIATION|stereotactic radiosurgery|Undergo RT
224073057|NCT00473707|PROCEDURE|Expectant management of the third stage of labor|standardized oxytocin infusion (10 units of oxytocin in 500 mL of Ringers lactate over 20 minutes) in combination with maternal expulsion efforts once spontaneous separation of the placenta had begun
224073058|NCT00473707|DRUG|Oxytocin and gentle cord traction with fundal massage|standardized oxytocin infusion (10 units of oxytocin in 500 mL of Ringers lactate over 20 minutes) immediately following delivery of the fetus with gentle cord traction and fundal massage
224073059|NCT00473707|DRUG|Oxytocin|standardized oxytocin infusion (10 units of oxytocin in 500 mL of Ringers lactate over 20 minutes) in combination with maternal expulsion efforts once spontaneous separation of the placenta had begun
224073060|NCT03712397|DRUG|nanoliposomal irinotecan|combination therapy of nal-IRI , leucovorin and 5-FU in sequence at day 1, every 14 days counted as one cycle
224307384|NCT01372774|RADIATION|whole-brain radiation therapy|Undergo radiotherapy (RT)
224307385|NCT02828059|DRUG|Ropivacaine|Surgical wound Infiltration over 48 hours
223489182|NCT05492955|BEHAVIORAL|Standard of Care Model|Participants in the SOC arm will be referred to their clinic for active care as per standard clinical protocols. All care will be provided at the clinic. Routine care consists of regular visits to the clinic until BP is under control (\<140/90 mmHg) and then at 6 monthly intervals. BP measurements to guide management decisions will be made at the clinic using standard clinic equipment. Symptoms related to hypertension and/or medications will be assessed at each visit. Medications available will include medications on the South African Essential Drug list and which are available in the pharmacy. Prescriptions are picked up at the clinic pharmacy by patients as per routine protocol at the clinics. CHWs may also conduct monitoring as guided by clinical guidelines and as advised by their clinical supervisors during the study period to assess for adherence and provide education.
223489183|NCT04960618|DRUG|Gemcitabine|Participants will receive gemcitabine 1000 mg/m2 on days 1 and 8 on 21-days cycles for up to 6 cycles
223489184|NCT04960618|DRUG|Pembrolizumab|Pembrolizumab 200 mg will be introduced with cycle 2 and will be given on day 1 of each 21-day cycle for up to 35 cycles
223489185|NCT06307665|COMBINATION_PRODUCT|BDA MDI|Participants will receive oral inhalation of BDA MDI 160/180 μg taken as 2 puffs of 80/90 μg as needed.
223587290|NCT02211313|DEVICE|Randomization to size 6 French soft vs. size 6 French hydrophobic ureteral stent.|Subjects will be randomized to one of two study arms according to ureteral stent size and degree of firmness (size 6Fr, soft vs. size 6Fr, hydrophobic) with allocation ratio of 1:1.
223587291|NCT05148416|RADIATION|High intensity laser treatment|20 patients received high power laser therapy . Zimmer High power laser applied by laser probe perpendicular to and in slight contact with the skin around knee joint , the total energy was delivered to the patient during one session was 1060 j in 3 phases of treatment.
223587292|NCT05148416|DEVICE|sham HILT.|"20 patients received placebo laser  sham laser . The same treatment protocol of HILT was given to the sham group, but the laser instrument was switched off during applications. All laser applications were performed by the same physiotherapist."
223587293|NCT05148416|OTHER|knee osteoarthritis conventional exercises program|"knee osteoarthritis conventional exercises program in form of stretching exercises for both vastus medialis and gastrocnemius muscles , ROM exercises for knee flexion and extension , and isometric strengthening exercise of previously mentioned muscles .~all interventions were done under the supervision of physiotherapist for 30 minutes once a day for 3 days per week during a period of 4 weeks."
224073061|NCT03132181|DRUG|Empagliflozin|Patient will be treaded according to standard care but additionally take one tablet Empagliflozin per day
223489186|NCT06307665|COMBINATION_PRODUCT|AS MDI|Participants will receive oral inhalation of AS MDI 180 μg taken as 2 puffs of 90 μg as needed.
223587294|NCT03743064|DRUG|anamorelin HCl|100 mg anamorelin HCl (administered as 100 mg tablets in the fasted condition)
223587295|NCT03743064|DRUG|Placebo Oral Tablet|Placebo (administered as matching placebo tablets in the fasted condition)
223587296|NCT03528005|BEHAVIORAL|Multi-domain intervention|60 minutes cognitive training, 45 minutes physical exercise, 15 diet nutrition and intermittent disease management consultation
223587297|NCT01301105|BEHAVIORAL|Mindfulness Based Stress Reduction (MBSR)|8 week class in stress reduction through instruction in mindfulness related techniques.
224073062|NCT03132181|OTHER|Placebo|Patient will be treaded according to standard care but additionally take one tablet placebo per day
224073063|NCT05789030|DRUG|Diprospan plus iguratimod|Patients are treated with Diprospan (1mL im) and then with iguratimod (25mg bid) for 12 months.
224073064|NCT05789030|DRUG|Diprospan plus leflunomide|Patients are treated with Diprospan (1mL im) and then with leflunomide (10-20mg qd) for 12 months.
224073065|NCT05789030|DRUG|Prednisone plus leflunomide|Patients are treated with prednisone (20 mg qd and taper to ≦ 5mg in 3 months) and leflunomide (10-20mg qd) for 12 months.
224073066|NCT05853614|BEHAVIORAL|Quality of Life Intervention|Comprised of three components: (1) establishment of clinical research nurse (CRN) and patient relationship, (2) assessment and monitoring of physical, psychological, social, and spiritual well-being and patient-reported outcomes, and (3) weekly, interdisciplinary team meetings led by CRN.
224073067|NCT02197676|DRUG|SGI-110 administration|"SGI-110 will be administered SC at 60 mg/m²/day x5 consecutive days for each cycle. Cycle duration is 28 days. Patients with Complete Remission (CR), Partial Remission (PR), marrow CR or Hematological Improvement (HI) after 6 Cycles of therapy (IWG 2006 criteria) may continue treatment until progression.~A dose reduction to 45 and even 30 mg/m²/day will be made in case of haematological toxicity. Patients with no response (NR) to treatment will be withdrawn from the protocol after the last treatment Cycle."
224073068|NCT00746135|DEVICE|Device Implantation|RV apical pacing lead, RV pacing lead at HIS bundle position, LV pacing lead implantation
224073069|NCT02948621|PROCEDURE|Endoscopic sleeve gastroplasty|Endoscopic sleeve gastroplasty is performed using a CE marked endoscopic suture device (Overstitch, Apollo Endosurgery, Austin, Tx. USA). Continuous stitches are placed to create a sleeve-shaped gastric path of 2 cm diameter to reduce stomach volume from the proximal antrum to the oeso-gastric junction.
224073070|NCT01816581|DRUG|Targin|
224073071|NCT01816581|DRUG|Oxynorm|
224073072|NCT01816581|DRUG|Morphine|
224073073|NCT01730235|OTHER|MyMediHealth access|Patients who will be given access to a web-based medication scheduling and SMS-based reminder system.
224073074|NCT02175056|BIOLOGICAL|HL2351|Dose-escalation For 5 level dose groups A \~ E(each 1, 2, 4, 8, 12mg/kg), 10 subjects (8 for the study drug and 2 for placebo) are randomized to each dose group, and the study drug or placebo is subcutaneously administered for the relevant dose group.
224073075|NCT02175056|BIOLOGICAL|Kineret(Anakinra)|Active comparator(group F) is implemented in parallel with dose groups A\~E in an open-label manner and 8 subjects subcutaneously administer Kineret® 100 mg.
224073076|NCT02695628|DRUG|18F-Fluoromisonidazole|Undergo \[18F\] FMISO PET/CT
224073077|NCT02695628|PROCEDURE|Arterial Embolization|Undergo transcatheter arterial embolization
224073078|NCT02695628|DIAGNOSTIC_TEST|Computed Tomography|Undergo \[18F\] FMISO PET/CT
224073079|NCT02695628|DIAGNOSTIC_TEST|Positron Emission Tomography|Undergo \[18F\] FMISO PET/CT
224073080|NCT02520232|BEHAVIORAL|Combination of aerobic and strength exercises|Combination of aerobic and strength exercises
224307386|NCT02201290|DRUG|Eltrombopag Tablets|Eltrombopag tablets will be white, round film coated tablets containing eltrombopag olamine equivalent to 12.5 mg, 25 mg, 50 mg and 75 mg of eltrombopag. The 12.5 mg tablet will be smaller than the 25 mg, 50 mg and 75 mg tablets. Subjects will receive maximum dose of 75 mg once daily (QD).
224307387|NCT02201290|DRUG|Eltrombopag PfOS|Eltrombopag PfOS is a reddish-brown to yellow powder contained inside an elongated sachet. Each sachet will contain eltrombopag olamine equivalent to 20 mg of eltrombopag per gram of powder. Subjects will receive maximum dose of 75 mg once daily (QD)
224307388|NCT00094081|DRUG|tirapazamine (SR259075)|
224307389|NCT00094081|DRUG|cisplatin|
224307390|NCT00094081|PROCEDURE|Radiation Therapy|
223489187|NCT03246932|BEHAVIORAL|Peer-led psycho-education group|A structured, researcher-designed peer-led psycho-education program (6 months), comprising of 12 bi-weekly, 2-hour group sessions.
223489188|NCT03246932|BEHAVIORAL|Profession-led psycho-education group|A psychoeducation group program (12 sessions, bi-weekly).
223489189|NCT03246932|OTHER|Routine psychiatric care|Routine psychiatric outpatient care, or Treatment-as-usual (TAU).
223489190|NCT00340093|BEHAVIORAL|Managing Diabetes|
223489191|NCT04248361|DIAGNOSTIC_TEST|TEM-PCR URI Panel|Target Enriched Multiplex Polymerase Chain Reaction (TEM-PCR™) is a breakthrough molecular multiplex technology that allows rapid DNA/RNA identification of multiple pathogens (i.e., bacteria and viruses) in a single sample, typically within one day of specimen receipt.
223489192|NCT04248361|OTHER|SOC/Empiric Diagnosis|The SOC for upper respiratory infection may include, but is not limited to, rapid strep testing, rapid influenza testing, and sputum cultures. In the event a lower respiratory infection is suspected a chest x-ray or CBC with differential may be performed.
223489193|NCT03295851|DRUG|Ferric carboxymaltose|Patients in the intervention group will receive preoperative IV ferric carboxymaltose, given as a single dose (15 mg/kg body weight, to a maximum dose of 1000 mg) over 30 minutes.
223489194|NCT03295851|DRUG|Ferrous Fumarate|Patients will be given oral iron as per current clinical protocol, which is Ferrous fumarate 200mg twice daily.
223489195|NCT01901562|DEVICE|Ductoscopic papillectomy|Intraductal papilloma extraction through the nipple orifice by interventional ductoscopy
223489196|NCT04055493|DRUG|Ribociclib 200Mg Oral Tablet|3 x 200 MG per os
223489197|NCT04767451|DIAGNOSTIC_TEST|ultrasound assessment|Lead (Pb), Cadmium (Cd), Gadolinium (Gd), Arsenic (As), Mercury (Hg), Cobalt (Co), Vanadium (V), Titanium (Ti), Sulfur (S), Chromium (Cr), Silver (Ag), Molybdenum (Mo), Boron (B), Lithium (Li), and Nickel (Ni) measurements
224073081|NCT02520232|BEHAVIORAL|Stretching and balance exercise program|Stretching and balance exercise program
223489198|NCT06048224|DRUG|HS628+MTX|Participants will receive HS628 SC injections Q4W along with MTX orally for 24-week
223489199|NCT06048224|DRUG|Actemra +MTX|Participants will receive tocilizumab SC injections Q4W along with MTX orally for 24-week
223489200|NCT04761250|DIETARY_SUPPLEMENT|Lifestyle|Lifestyle intervention i.e. diet, exercise, smoking cessation, alcohol limitations, dietary supplementation
223489201|NCT05167539|PROCEDURE|Aortic valve surgery|mechanical aortic valve replacement versus ross procedure and stentless bioprothesis
223489202|NCT00107497|RADIATION|Radiation therapy|
223489203|NCT04589767|BEHAVIORAL|CAPD scale|Two nurses will apply CAPD scale. One nurse will repeat the CAPD evaluation two minutes later
223489204|NCT00088153|DRUG|Physiologic Estrogen/progesterone|Vivelle Dot patch 100 mcg twice weekly; Provera 2.5 mg daily for the first 10 days of the month
223489205|NCT00088153|OTHER|Placebo|Placebo patches twice weekly; Placebo pills daily for the first 10 days of every month
223587298|NCT01301105|BEHAVIORAL|Health Enhancement Program (HEP)|8-week intervention designed to be structurally equivalent to MBSR but without a mindfulness component. Consists of nutrition, functional movement, physical activity, and music therapy.
223587299|NCT00036101|DRUG|aripiprazole|
223587300|NCT04622904|DRUG|lidocaine-magnesium infusion|A bolus dose of lidocaine of 1.5 mg/kg will be administered within 10 minutes preoperatively diluted in 100 mL of saline. Then, 3 mg/kg/h of lidocaine will be administered intraoperatively. A bolus dose of ketamine of 0.35 mg/kg will be administered within 10 minutes preoperatively diluted in 100 mL of saline. Followingly, 0.2 mg/kg/h of ketamine will be administered intraoperatively diluted in a 60 mL syringe and administered at a rate of 20 mL/h
224073082|NCT00679497|BIOLOGICAL|MVA-B|"* Modified Pox virus, strain MVA clade -B (expressing HIV-1 Bx08gp120 and IIIB gagpolnef)~  -\~ 1 x 10e8 pfu/ml~* 3 immunisations at week 0, 4 and 16"
224073083|NCT00679497|BIOLOGICAL|Placebo|-3 immunisations at week 0, 4 and 16
224073084|NCT05068336|DIAGNOSTIC_TEST|desflurane anesthesia|Anesthesia maintenance of the first group will be provided with desflurane, one of the inhalation anesthetics we routinely use. Before and after the operation, blood will be taken from the patients, and the blood will be centrifuged to evaluate the heparan sulfate and syndecan levels.
224073085|NCT05068336|DIAGNOSTIC_TEST|sevoflurane anesthesia|Anesthesia maintenance of the first group will be provided with sevoflurane, one of the inhalation anesthetics we routinely use. Before and after the operation, blood will be taken from the patients, and the blood will be centrifuged to evaluate the heparan sulfate and syndecan levels.
224073086|NCT04326608|OTHER|physiotherapy|manual therapy and sef-care exercises
224073087|NCT00314600|DEVICE|above and below elbow cast|
224073088|NCT04772729|DRUG|Insulin faster aspart (Fiasp, Novo Nordisk)|"Duration of the study: 10 weeks.~It is assumed that the patients will attend 4 visits in Pediatric Diabetology Clinic, and 3 telephone consultations.~W0: The study will start with a 2-week run-in period in order to normalize glycemia.~W1: RT-CGM will be inserted. Subsequently, the participants will be randomly assigned to one of two groups (Fa-A or A-Fa), basing on which the order of insulin use will be determined.~W2: after 2 weeks, diabetology telephone consultation (washout period).~W3: after 2 weeks, diabetology consultation. Changing insulin type according to the allocation.~W4: after 2 weeks, diabetology telephone consultation (washout period).~W5: after 2 weeks, diabetology telephone consultation.~W6: the results obtained throughout the study will be discussed with the patient and the parent."
224073089|NCT02033564|DEVICE|Macintosh/Miller Laryngoscope|
224073090|NCT02033564|DEVICE|Glidescope Laryngoscope|
224073091|NCT00651066|DRUG|rifabutin in combination with lopinavir boosted by ritonavir - dosing schedule 1|3TC(300mg)/D4t(60mg)/LPV/r(800mg/200mg)+INH/PZA/EMT/Rifabutin(150 mg TPW 3 wks switch to 150 mg OD 4 wks);
223489206|NCT00208975|DRUG|Mitoxantrone/Cyclophosphamide, Fludarabine, Rituximab and GM-CSF|"Initial patients (n=9) received fludarabine (25 mg/m\^2 intravenously) and mitoxantrone (10 mg/m\^2 intravenously)with sequential administration of GM-CSF(Granulocyte-macrophage colony stimulating factor) (500 µcg subcutaneously) on days 6 and 7 and rituximab (375 mg/m\^2) on day 8.~After a change in the protocol, all additional patients (n=6) received fludarabine (25 mg/m\^2 intravenously) and cyclophosphamide (250 mg/m\^2 intravenously)with sequential administration of GM-CSF (500 µcg subcutaneously) on days 6 and 7 and rituximab (375 mg/m\^2) on day 8. All patients received additional doses of GM-CSF (days +8 through +14) were given for patients to reduce variability in neutropenic management."
223489207|NCT00976027|BIOLOGICAL|Trivalent inactivated influenza vaccine High Dose|0.5 mL, Intramuscular
224179800|NCT06256679|PROCEDURE|superior hypogastric plexus pulsed radiofrequency|"The L5-S1 intervertebral space was visualized using fluoroscopy. A 22G, 15 cm injection needle was advanced along the bilateral disc, and under lateral imaging, the needle position was confirmed anterior to the vertebral bodies.~After negative aspiration of blood, 2 ml of contrast solution was injected to confirm the correct needle placement, and then 8 mg of dexamethasone and 40 mg of bupivacaine (0.25%) were injected separately on each side.~Two weeks later, patients who showed more than 50% improvement from the diagnostic block, as assessed by NRS, underwent a superior hypogastric pulsed radiofrequency procedure using a trans discal technique with a 22G, 15 cm, 10 mm active-tipped radiofrequency needle at 42°C for 120 seconds."
224179801|NCT06157970|PROCEDURE|Sphenopalatine Ganglion Block|For SPGB, the plastic part of the 16G angiogram is advanced transnasally into both nostrils, with the patient in the supine position and the head in 15-20° extension, until it contacts the posterior mucosa, and after contact, it is withdrawn 1 mm and 2 ml of 0.5% bupivacaine is dripped into the postnasal space within 1 minute. is applied.
224179802|NCT02516605|DRUG|Part 1: LJN452|LJN452 capsules administered once daily for 28 days
223489208|NCT00976027|BIOLOGICAL|Trivalent inactivated influenza vaccine|0.5 mL, Intramuscular
223489209|NCT00073931|BIOLOGICAL|filgrastim|5 µg/kg/day subcutaneously
223489210|NCT00073931|BIOLOGICAL|sargramostim|250µg/m2/d subcutaneously
223489211|NCT00073931|PROCEDURE|autologous bone marrow transplantation|autologous stem cells given via central catheter
223489212|NCT00073931|PROCEDURE|peripheral blood stem cell transplantation|autologous stem cells given via central catheter
223489213|NCT00073931|RADIATION|tositumomab and iodine I 131 tositumomab|given intravenously (test dose of 1.7-10 mg/kg tositumomab antibody radiolabeled with \~10 mCi I-131) or via central catheter (therapy dose of 1.7-10 mg/kg tositumomab radiolabeled with individually calculated therapy dose of I-131)
223489214|NCT00261040|PROCEDURE|Minimally Invasive Surgery|In minimally invasive surgery, the surgeon makes a shorter incision (about 10 cm or less) along the side of the thigh and replaces the hip through this smaller incision. The surgeon is able to do the surgery through a shorter incision by using special instruments which can guide him or her.
223489215|NCT00261040|PROCEDURE|Standard Surgery|The standard way that an orthopaedic surgeon performs a hip replacement surgery is that they make a long incision (about 20 cm) down the side of the thigh and then replaces the hip joint through this long incision.
223489216|NCT01349387|DRUG|Metformin|After inclusion in the study to J0, metformin treatment will be interrupted between J1 and J30, replaced by Januvia 100 mg/day dose, then resumed at J31.
223489217|NCT05791331|OTHER|Surfactant administration following lung mechanics assessment in addition to clinical assessment|Surfactant is administered following oxygenation-based criteria and if the Xrs is ≤ -23.3 cmH2O\*s /L
223489218|NCT05791331|OTHER|Surfactant administration following clinical assessment|Surfactant is administered following oxygenation-based criteria
223587301|NCT04622904|DRUG|lidocaine-ketamine infusion|A bolus dose of lidocaine of 1.5 mg/kg will be administered within 10 minutes preoperatively diluted in 100 mL of saline. Then, 3 mg/kg/h of lidocaine will be administered intraoperatively. A bolus dose of magnesium of 50 mg/kg will be administered within 10 minutes preoperatively diluted in 100 mL of saline. Followingly, 10 mg/kg/h of magnesium will be administered intraoperatively diluted in a 60 mL syringe and administered at a rate of 20 mL/h
224179803|NCT02516605|DRUG|Part 1: Placebo|Matching placebo capsules administered once daily for 28 days
224179804|NCT02516605|DRUG|Part 2: LJN452 Dose level 1|LJN452 capsules administered once a day for 12 weeks
224179805|NCT02516605|DRUG|Part 2: Placebo|Matching placebo to LJN452 administered once a day for 12 weeks
224179806|NCT02516605|DRUG|Part 2: LJN452 Dose level 2|LJN452
224179807|NCT02577107|DRUG|ranibizumab|
224179808|NCT02577107|DRUG|Conbercept|
224179809|NCT00577382|DRUG|Sunitinib|
224179810|NCT05196074|OTHER|Acute hypoxemic respiratory failure patients on VV-ECMO|To describe the prevalence of complete airway closure in patients with acute hypoxemic respiratory failure on VV-ECMO and its association with outcome.
224179811|NCT02463526|OTHER|Mobilization with Movement (MWM) condition/ Sham condition|The treatment condition consists in the application of a posterolateral glide (MWM) in the affected shoulder. Subjects will be seated and the therapist will stay beside the participants on the opposite side to the affected shoulder. One hand will be placed over the scapula posteriorly while the thenar eminence of the other hand will be placed over the humerus head anterior aspect. A posterior glide will be applied to the humeral head. Three sets of 10 repetitions will be applied with a 30 seconds rest interval between each set. Sham condition will replicate treatment condition except for the hand positioning. The therapist will place one hand along the clavicle and the other on the humeral head posterior aspect of the affected shoulder. A simulated anterior glide will be performed.
223587302|NCT04622904|DRUG|lidocaine infusion|A bolus dose of lidocaine of 1.5 mg/kg will be administered within 10 minutes preoperatively diluted in 100 mL of saline. Then, 3 mg/kg/h of lidocaine will be administered intraoperatively. A bolus dose of normal saline 100 mL will be administered preoperatively within 10 minutes. Followingly, normal saline will be administered intraoperatively at a rate of 20 mL/h
223587303|NCT03580824|BIOLOGICAL|R21 in Matrix- M adjuvant vaccine|R21: Protein particle malaria vaccine candidate in Matrix-M: Saponin based vaccine adjuvant.
223489219|NCT04065620|DIAGNOSTIC_TEST|ambulatory blood pressure measurement|24-hour ABPM will be made using validated devices, following ABPM device should be programmed to take measurements every 30 minutes . Patients will be instructed in their use. Periods of activity and rest will be pre-determined in short windows: for Asian and European Countries daytime period will be defined between 10:00 and 8:00 pm; and night-time period between 00:00 am and 6:00 am. For Latin American Countries daytime period will be defined between 08:00 and 06:00 pm; and night-time period between 00:00 am and 6:00 am. For Africa daytime period will be defined between 08:00 and 06:00 pm; and night-time period between 11 PM and 5 AM In addition, the duration of ABPM (hours), the percentage of valid readings, and the mean SBP/DBP values during periods of activity, rest and in 24 hours will be recorded. Records with a duration \<24 hours, those without one good reading per hour and those with \<70% of satisfactory readings will be excluded
223489220|NCT05289882|BEHAVIORAL|PASS Program Condition:|Participants randomized to this condition will be invited to take part in weekly ball hockey games (once per week), that will last approximately 60 minutes, and will be followed by opportunities to socially connect afterwards. The results of our feasibility study indicated that the PASS program acted as an important conduit to direct participants to other support services and resources (e.g., counseling, career transition centre, employment, education). Military veteran men are often reluctant to access such supports, especially if they attach stigma to such services (e.g., mental health services). At each site, a military veteran will be trained as a facilitator to operate as a conduit to refer participants to the relevant support services and agencies.
224179812|NCT02463526|OTHER|Sham condition/ Mobilization with Movement (MWM) condition|The Sham condition consists in the application of a simulated anterior glide in the affected shoulder. Subjects will be seated and the therapist will stay beside the participants on the opposite side to the affected shoulder. The therapist will place one hand along the clavicle and the other on the humeral head posterior aspect of the affected shoulder. A simulated anterior glide will be performed. Three sets of 10 repetitions will be applied with a 30 seconds rest interval between each set. The treatment condition will replicate treatment condition except for the hand positioning. The therapist will place one hand over the scapula posteriorly while the thenar eminence of the other hand will be placed over the anterior humerus head. A posterior glide will be applied to the humeral head.
224179813|NCT04583410|DRUG|Nicotine patch|"NICOPATCHLIB, 7mg/24h Day 1 to day 3 : 3,5 mg/day Day 4 to day 9 : 7 mg/day Day 10 to Day 15 : 10,5 mg/day Day 16 to day 98 : 14 mg/day~Decrease treatment Day 99 to day 105 : 10,5 mg/day Day 106 to day 112 : 7 mg/day Day 113 to Day 119 : 3,5 mg/day"
224179814|NCT04583410|DRUG|Placebo patch|"PLACEBO OF NICOPATCHLIB, 7mg/24h Day 1 to day 3 : 3,5 mg/day Day 4 to day 9 : 7 mg/day Day 10 to Day 15 : 10,5 mg/day Day 16 to day 98 : 14 mg/day~Decrease treatment Day 99 to day 105 : 10,5 mg/day Day 106 to day 112 : 7 mg/day Day 113 to Day 119 : 3,5 mg/day"
224179815|NCT06308796|OTHER|Application of CaP dental mousse|Application of calcium phosphate (CaP) mousse on dental surfaces at home, once a day for 3 months; followed, as maintenance, once a day for just one week a month.
224179816|NCT05108818|BIOLOGICAL|Seasonal influenza vaccine|The seasonal influenza vaccine is administered intramuscularly at a dose of 15 ug of HA per component, as approved by the FDA.
224179817|NCT04030364|BEHAVIORAL|CrossFit group exercise classes|"The group classes will occur at a local CrossFit gym facility. Participants will be free to attend up to 6 regularly-scheduled, free, 1-hr group classes per week at the local exercise facility for a period of 3-months. The recommendation will be to aim to attend at least three classes/week but there will no prescribed minimum. Classes will be supervised by experienced trainers.~Trainers will work collaboratively with participants to adapt the skill and workout of the day within each group class to the individual participant's physical limitations and needs. As such, each participant may complete a slightly different movement or workout on any given day based on their functional status at that time. However, all participants will be actively included in the community of the group class and will experience a relative stimulus that is moderately challenging for them."
224179818|NCT03641690|OTHER|Empirical antimicrobial therapy|All patients with pulmonary symptoms received empirical antimicrobial therapy with ceftriaxone and rovamycin or levofloxacin on admission and this was subsequently adapted to any documented bacterial infection if positive.
224179819|NCT03775642|BEHAVIORAL|Intervention video|The intervention video will employ the debiasing strategies. It will avoid directly articulating contraception-related myths, but instead will provide a limited number of alternative explanations related to IUD and implant safety.
224179820|NCT03775642|BEHAVIORAL|Control video|The video for the control arm will consist of an existing, public-use video on a non-contraception topic of similar duration
223587304|NCT06079151|DEVICE|Nasal high-flow|Nasal high-flow is a respiratory technique which allows the administration of warmed and humidified air, associated with oxygen if necessary
224179821|NCT01710709|DRUG|Aripiprazole|400mg or 300mg, intramuscular injections every 4 weeks.
224179822|NCT03601429|DIETARY_SUPPLEMENT|Lactogyn|capsules
223587305|NCT03805516|BEHAVIORAL|SCOPP-CW|The proposed intervention integrates the Social Cognitive Theory, use of everyday technology (WeChat), and an adaptation of an evidence-based program that is tailored to the behavior patterns, preferences, and cultures of premenopausal Chinese American women. The intervention includes three components: (1) daily tracking of physical activities, (2) 12 weekly educational modules on healthy lifestyle, physical activity, and breast cancer prevention, and (3) 6 bi-weekly tailored messages to include tips for lifestyle modification, stress management, and healthy weight maintenance based on the user's personal characteristics and behavior patterns.
223587306|NCT03805516|BEHAVIORAL|Control|This is the comparative/control group for the intervention. The control group receives daily tracking of physical activity and 12 weekly non-tailored educational information on general health topics.
224179823|NCT03601429|DIETARY_SUPPLEMENT|Placebo|capsules
224179824|NCT04446039|DRUG|Escitalopram|Treatment for depression
224179825|NCT04446039|DRUG|Paroxetine|Treatment for depression
224179826|NCT04446039|DRUG|Fluoxetine|Treatment for depression
224179827|NCT04446039|DRUG|Mirtazapine|Treatment for depression
224179828|NCT04446039|DRUG|Duloxetine|Treatment for depression
224179829|NCT04446039|DRUG|Sertraline|Treatment for depression
224179830|NCT04446039|DRUG|Venlafaxine|Treatment for depression
223489221|NCT05251870|DRUG|autologous mature tolerogenic monocyte-derived Dendritic Cells loaded with the B29 peptide of HSP70|Intranodal administration into an inguinal lymphnode. Two administrations at the same injection site with a four week interval.
223489222|NCT03354377|BEHAVIORAL|Dietary Intervention Meetings|Participants will attend classes once per week for the first 6 months, bi-weekly for the next 6 months; then once a month for the last 12 months.
223489223|NCT03354377|BEHAVIORAL|Physical Activity|Participants will be given the following exercise recommendations: strength training twice per week and ≥75 min of vigorous or ≥150 min of moderate PA per week and will be provided with accelerometers.
223489224|NCT03354377|BEHAVIORAL|Podcasts/Mailings|Participants with receive additional support delivered remotely months 13-24 in the form of audio podcasts and email newsletters.
223489225|NCT05967091|DEVICE|Targeted Lung Denervation|Targeted Lung Denervation (TLD) is a bronchoscopically guided, minimally invasive procedure using the Ryme Medical Lung Denervation System
223489226|NCT04680039|DEVICE|Continuous monitoring|Identifying intradialytic hypotension using a PPG-based wearable monitor
223489227|NCT04612400|OTHER|Oral amino acid tracer|Whole body protein metabolism response to a dose of the supplement will be measured using a continuous oral sip-feeding (every 10 minutes) method of stable isotope tracer.
223489228|NCT04435626|DRUG|Finerenone (BAY94-8862)|"For participants with an eGFR ≤60 mL/min/1.73 m\^2: Starting dose is 10 mg OD and maximum dose 20 mg OD.~For participants with an eGFR \>60 mL/min/1.73 m\^2: Starting dose is 20 mg OD and maximum dose 40 mg OD. Finerenone is administered orally as immediate release tablets."
223489229|NCT04435626|OTHER|Placebo|Placebo tablets matching BAY94-8862 are administered orally.
223489230|NCT00427596|DRUG|Solabegron|
223489231|NCT00643253|BEHAVIORAL|LC and Electronic Prompt|Women will receive: a) International Board of Certified Lactation Consultant (IBCLC) education/counseling during the pre-natal, intra-partum and post-hospital discharge period to promote early and continued exclusive breastfeeding. The protocol specifies 2 prenatal meetings, a hospital visit, and a home visit if indicated and accepted, and; b) Electronic Medical Record Prompts- will appear on the prenatal record 5 times throughout the pregnancy. They are brief discussion points re breastfeeding that the provider is asked to raise with their patients.
224179831|NCT04446039|DRUG|Tianeptine|Treatment for depression
223587307|NCT03594812|DEVICE|Radiofrequency|Radiofrequency protocol - The radiofrequency protocol was performed in dorsal decubitus, with the head elevated at 45º. The application was in capacitive mode, with a 5 cm electrode, always in movement. The duration of the application was established in 20 minutes, maintaining the local temperature between 40ºC to 42 ºC at the epidermis.
223587308|NCT03594812|DEVICE|Radiofrequency without power|Radiofrequency protocol - The radiofrequency protocol was performed in dorsal decubitus, with the head elevated at 45ºC (Celsius degrees). The application was in capacitive mode, with a 5 cm electrode, always in movement. The duration of the application was established in 20 minutes, maintaining the local temperature between 40ºC to 42 ºC at the epidermis. In this group, the radiofrequency device was switched off.
224179832|NCT04446039|DRUG|Vortioxetine|Treatment for depression
224179833|NCT04446039|DRUG|Desvenlafaxine|Treatment for depression
224179834|NCT04446039|DRUG|Bupropion|Treatment for depression
224179835|NCT02210026|DEVICE|Seattle-PAP|We propose to test the hypothesis that by introduction of variation in airway pressure Seattle bubble nasal continuous positive airway pressure (Seattle-PAP) reduces work of breathing in very low birth weight infants more effectively than standard bubble nasal continuous positive airway pressure.
224179836|NCT02298790|BEHAVIORAL|Meal schedule|
224179837|NCT03902158|DEVICE|Glasses|The patient will wear virtual reality glasses during anesthesia
224179838|NCT03902158|BEHAVIORAL|Distraction techniques|The patient will undergo distraction techniques
224179839|NCT02326909|DEVICE|Optical Coherence Tomography|Single Optical Coherence Tomography measurement of upper urinary tract tumour taken during ureterorenoscopy
224179840|NCT02326909|DEVICE|Optical Coherence Tomography|A single 1300 nm OCT measurement will be performed during ureterorenoscopy in patients with upper urinary tract tumour(s)
224179841|NCT02093156|OTHER|Bowel preparation instructions|The same-day preparation method was used as previously reported. Briefly, all patients were instructed to have a regular diet for breakfast and lunch, but only clear liquids for dinner on the day before the colonoscopy. They were asked to drink two bags of PEG-ELP (polyethylene glycol electrolyte powder) dissolved in 2 L of water, or 45 mL of sodium phosphate be diluted in 240 mL of cool water follow with at least 1.5 L of water at 05:00-06:00 h within 2 h on the day of colonoscopy. Patients were encouraged to drink more clear liquids after purgatives for adequate hydration before colonoscopy.
224179842|NCT03773146|OTHER|1X Airtime Incentive|An incentive given in the form of airtime
224179843|NCT03773146|OTHER|Lottery Airtime Incentive|An incentive given in the form of airtime
224179844|NCT03793517|DRUG|Decitabine|Decitabine 200mg.m-2.d-1 intervanously on days -12 and -11
224179845|NCT03793517|DRUG|mBU/CY and ATG|Ara-C 4 g·m-2·d-1 intravenously on days -10 to -9 Busulfan (BU 3.2 mg·kg-1·d-1) intravenously on days -8 to -6, Cyclophosphamide (CY 1.8 g·m-2·d-1) intravenously on days -5 to -4 Simustine (Me-CCNU, 250 mg·m-2) orally once on day -3 ATG (2.5 mg·kg-1·d-1) intravenously on days -5 to -2
224179846|NCT03793517|DRUG|mBU/CY|hydroxycarbamide (80 mg·kg-1) orally on day -10 Ara-C (2 g·m-2·d-1) on day -9 Busulfan (BU 3.2 mg·kg-1·d-1) intravenously on days -8 to -6, Cyclophosphamide (CY 1.8 g·m-2·d-1) intravenously on days -5 to -4 Simustine (Me-CCNU, 250 mg·m-2) orally once on day -3
224179847|NCT01460979|DRUG|Temsirolimus|25mg weekly intravenous until progression
223489233|NCT05129085|DRUG|Dexamethasone 4mg|For the transforaminal epidural injection, a 22-gauge spinal needle will be inserted coaxially via a subpedicular approach to target the upper part of the foramen under fluoroscopic guidance. Correct needle position will be confirmed with appropriate contrast spread (1ml of contrast) in the anteroposterior, oblique, and lateral view. Spread of contrast delineating the nerve root together with proximal epidural spread will be accepted as indicating correct needle position. A single level injection will be performed because there are no clinical trials showing that multilevel injections is superior to single level injection, and a well-positioned injection usually spreads to multiple levels, thus achieving the effect of multi-level injection. 2ml of 1% lignocaine will be given for skin infiltration. Once correct position is confirmed, drug injectate will be administered. For the ESI group, 8mg of dexamethasone (4mg/ml) added to 1 ml of normal saline will be given (total 3ml volume).
223489234|NCT05129085|PROCEDURE|epidural platelet rich plasma injection|For the transforaminal epidural injection, a 22-gauge spinal needle will be inserted coaxially via a subpedicular approach to target the upper part of the foramen under fluoroscopic guidance. Correct needle position will be confirmed with appropriate contrast spread (1ml of contrast) in the anteroposterior, oblique, and lateral view. Spread of contrast delineating the nerve root together with proximal epidural spread will be accepted as indicating correct needle position. A single level injection will be performed because there are no clinical trials showing that multilevel injections is superior to single level injection, and a well-positioned injection usually spreads to multiple levels, thus achieving the effect of multi-level injection. 2ml of 1% lignocaine will be given for skin infiltration. Once correct position is confirmed, drug injectate will be administered. For the EPRP group, 3 ml of PRP will be injected. The total volume of injectate for both groups of patients is 3ml.
223489235|NCT01023321|DRUG|GLPG0555|single ascending doses, oral solution
223489236|NCT01023321|DRUG|placebo|single dose, oral solution
223489237|NCT01023321|DRUG|GLPG0555|multiple dose, oral solution, 7 or 14 days
223489238|NCT01023321|DRUG|placebo|multiple dose, oral solution, 7 or 14 days
223489239|NCT06310135|DEVICE|Filtered Eyewear|Filtered binocular viewing condition will be produced by eyeglasses frames with orange-tinted blue-blocking filter, eliminating all optical radiation for wavelengths shorter than 540 nm. For the filtered monocular condition, only the lens on the eyeglasses frame on the non-dominant eye will be tinted with the blue-blocking filter.
223489240|NCT06310135|DEVICE|Unfiltered Eyewear|For the unfiltered binocular, the subjects will wear transparent eyeglasses frames with no optical power. Unfiltered monocular vision will be produced by an opaque eyepatch occluding the non-dominant eye.
223489241|NCT06310135|OTHER|No Filters|Dim lights with no filters.
223745398|NCT07190417|OTHER|LEDs and laser light|"Experiment 1：Measure the heart rate parameters before, during, and after laser acupuncture or LED light therapy within a 25-minute experimental period, and observe the changes in the subjects' meridian energy before and after the treatment, followed by analysis. Acupoint selections mainly include Daling, Neiguan, and Shenmen.~Experiment 2：randomly assigns subjects to wear either a low-energy LED device or a sham device. The indicators, duty cycles, and sounds of the low-energy LED device and the sham device are all the same.~Experiment 3：Place light sources of different wavelengths on the earlobes or auricles of subjects with different skin tones. By observing the changes in light power before and after, the investigators can infer the effects of skin tone on light attenuation and transmission of light sources with different wavelengths."
224073092|NCT00651066|DRUG|rifabutin in combination with lopinavir boosted by ritonavir - dosing schedule 2|3TC(300mg)/D4t(60mg)/LPV/r(800mg/200mg)+INH/PZA/EMT/Rifabutin(150 mg OD 3 wks switch to 150 mg TPW 4 wks);
223489242|NCT01976208|DRUG|Omalizumab|The recommended dose is 0.016mg/kg/IgE(IU/ml) every 4 weeks. It is administered by subcutaneous injection.If the total dose per 4 weeks is 150\~300mg, the dosing interval will be every 4 weeks; if the total dose per 4 weeks is 450mg\~750mg，then dosing interval is every 2 weeks.
223489243|NCT01976208|DRUG|placebo|
223489244|NCT03739931|BIOLOGICAL|mRNA-2752|Solution for intratumoral injection
224073093|NCT01791192|DRUG|FTY720|Fingolimod
224073094|NCT01791192|DRUG|Oral Corticosteroid|Oral Corticosteroid
224073095|NCT04675866|OTHER|Camrelizumab, Albumin-bound paclitaxel, S-1|Camrelizumab: 200mg, iv, Q3W, d1; Albumin-bound paclitaxel: 125mg/m2, iv, d1, 8, Q3W; S-1: According to the patient's body surface area, the dosage is set to 40, 50, 60 mg/time, bid, po, taking 2 weeks, and stopping the drug for 1 week as a cycle.
224073096|NCT04914208|DEVICE|DIY face mask|Participants are wearing a DIY face mask for 4 hours (beginning between 8 and 9 a.m.). The correct fit of the face mask is checked by the study officials and corrected if necessary.
224073097|NCT04914208|DEVICE|Surgical face mask|Participants are wearing a surgical face mask for 4 hours (beginning between 8 and 9 a.m.). The correct fit of the face mask is checked by the study officials and corrected if necessary.
224073098|NCT04914208|DEVICE|FFP2 respirator mask|Participants are wearing a FFP2 respirator mask for 4 hours (beginning between 8 and 9 a.m.). The correct fit of the face mask is checked by the study officials and corrected if necessary.
224073099|NCT04914208|OTHER|Waiting for 4 hours without wearing a mask|Participants do not wear any face mask for 4 hours (beginning between 8 and 9 a.m.).
224073100|NCT04914208|OTHER|Use of fluoridated toothpaste|Participants use fluoridated toothpaste.
224073101|NCT03027739|BIOLOGICAL|CART-19|CART-19 cells treated
224073102|NCT01681433|DRUG|OGX-427|OGX-427 started within 7 days of randomization, three loading doses of 600 mg IV within Week 1 if possible (up to 10 days of initiating treatment), followed by weekly doses of 800 mg IV
224073103|NCT01681433|DRUG|Abiraterone Acetate|Standard therapy: Abiraterone Acetate 1000 mg PO daily
224073104|NCT01681433|DRUG|Prednisone|Standard therapy: Prednisone 10-20 mg PO daily
224073105|NCT02179333|OTHER|Ataxia rating scale|Administer new rating scale for ataxia. This will be administered by two different raters on two separate occassions, 4 to 6 weeks apart.
224073106|NCT01421550|PROCEDURE|Conservative treatment|Patients that randomize for conservative management of their umbilical hernia will be followed routinely at the polyclinical ward.
224073107|NCT01421550|PROCEDURE|Surgical repair|Patients that randomize for surgical repair of their umbilical hernia will be operated in an elective setting after a careful preoperative work-up.
224073108|NCT03958448|PROCEDURE|Placement of extra short implants|placement of an extra short implant in the posterior edentulous ridge
223489245|NCT03739931|BIOLOGICAL|Durvalumab|Solution for infusion after dilution
223489246|NCT04426656|BEHAVIORAL|Phone application|"The mini-app (used in Part 2) has four main functions:~1. a knowledge center that contains a series of HIV-, sexual health-, and PrEP-related educational articles in Chinese;~2. an HIV self-test toolkit ordering system that allows users to order a finger-prick HIV rapid test toolkit and shipped to home for free (one piece at a time);~3. an asynchronous message function that allows users to chat with a study staff (C.Li); and~4. a user profile page where users can manage all HIV test orders."
223745399|NCT07191275|DEVICE|Experimental continuous 30 Hz thetaburst transcranial magnetic stimulation|"Bilateral continuous theta burst stimulation (cTBS) 30 Hz to the temporo-occipital cortex~* Frequency: trains of 30 Hz (3 pulses) every 167 ms (frequency of 6 Hz, in the range of theta band)~* Intensity: 100% of resting motor threshold (rMT)~* Location: consecutively on left and right temporo-occipital cortex (MNI: -47, -77, 4; 50, -69, -4)~* Duration: 33.3 seconds for each side~* Timing: Immediately before showing IAPS pictures (off-line)"
223489247|NCT05664789|DRUG|N acetyl cysteine|N-acetylcysteine (NAC) is an over-the-counter dietary supplement that is relatively well tolerated and exhibits minimal side effects, even at high dosages. N
223489248|NCT05664789|DRUG|Placebo|matched placebo
223489249|NCT04754074|BEHAVIORAL|Education|Weekly education related to behavior change
223489250|NCT04754074|BEHAVIORAL|Personalized coaching|Weekly calls with personalized coaches in behavior modification, nutrition, and physical activity/exercise.
223489251|NCT04754074|BEHAVIORAL|Weekly behavior modification challenges|Weekly challenges to address behavior change
223489252|NCT01410942|OTHER|Placebo|Capsules by mouth twice daily.
223489253|NCT01410942|DRUG|Methylphenidate|Starting dose 5 mg by mouth twice daily.
224073109|NCT03958448|PROCEDURE|maxillary sinus lift, maxillary sinus elevation, maxillary sinus augmentation|
224073110|NCT03958448|PROCEDURE|placement of standard implant|placement of standard implant in the posterior edentulous ridge after maxillary sinus augmentation
224073111|NCT04687501|DEVICE|Virtual Reality|Virtual reality in gynaecological surgery in the pre- and postoperative setting
224073112|NCT06317480|PROCEDURE|bone resection|patients underwent soft tissue sarcoma excision together with bone resection following either biological or endoprosthesis reconstruction
224073113|NCT06317480|PROCEDURE|subperiosteal excision|patients underwent sub-periosteal tumor excision combining bone and soft tissue ablation without bone excision
224073114|NCT04500327|OTHER|Drive app|The Drive app will be used to monitor sleep metrics for users of CPAP therapy.
224073115|NCT04500327|DEVICE|Non contact motion sensor|The non contact motion sensor will be used as a reference to the Drive app i.e. Drive app overnight recordings will be compared to the non contact motion sensor overnight recordings.
224073116|NCT03933865|DRUG|HYDROmorphone Injectable Solution|Hydromorphone will be given via intramuscular injection (8 mg)
224073117|NCT03933865|DRUG|Ketamine|Ketamine will be given via intramuscular injection (0.1, 0.2 or 0.4 mg/kg)
224073118|NCT03933865|DRUG|Placebos|Placebo will be normal saline solution given via intramuscular injection.
224073119|NCT06107075|DIETARY_SUPPLEMENT|Active|40g bio-active whey protein concentrate powder containing phospholipids
224073120|NCT06107075|DIETARY_SUPPLEMENT|Placebo|around 40g pea protein powder not containing phospholipids
224073121|NCT06257030|DEVICE|Transarterial Radioembolization|(TARE)Transarterial radioembolization is a transcatheter intra-arterial procedure performed by the interventional radiologist for the treatment of primary and secondary hepatic cancers.
224073122|NCT02173795|DRUG|Berodual® Respimat®|
224073123|NCT02173795|DRUG|Berodual® MA HFA|
224073124|NCT02448732|DRUG|ACM-1|intravitreal injection with 50ul ACM-1 at a concentration of 1600ug/ml
224073125|NCT05565469|OTHER|Adjustment of neurostimulator settings|"This is an interventional prospective study. After obtaining informed consent, only necessary information will be extracted through the electronic patient record. Through post-operative imaging, a level determination of the neurostimulator tip will be done. During general consultations, patients will be asked if they experienced abdominal wall stimulation after the procedure and when (YES/NO, NRS). This will include looking at the settings of the neurostimulator. And its adjustments. Furthermore, general epidemiological characteristics such as age, gender, height, weight will be extracted from the electronic patient record.~At the consultation, another active programming will take place (in accordance with clinical programming) on the tip of the electrode to check whether it provokes abdominal wall stimulation. This will also be scored YES/NO + NRS. Then the settings will be returned as they were pre-consultation."
224073126|NCT05998629|DEVICE|a skin-interfaced colorimetric bifluidic sweat device with two synchronous channels|a skin-interfaced colorimetric bifluidic sweat device with two synchronous channels
224073127|NCT05998629|OTHER|Standard of Care laboratory procedure for measurement of sweat|a skin-interface sweat measurement using a smart-watch type device
224073128|NCT01844895|DRUG|Abatacept|
224073129|NCT02471495|DEVICE|Synergo® RITE + MMC|"Synergo® system delivers homogenous microwave hyperthermia to the bladder wall in combination with bladder instillation of cold chemotherapeutic agent - Mitomycin C (MMC).The energy-delivering unit and the intravesical irrigation system are computer-controlled, The irrigation system consists of a disposable tubing line and catheter set. The catheter is a triple-lumen, silicone, transurethral Foley-type catheter.~MMC is constituted as a powder (40 mg) dissolved in 50 ml sterile water for injection."
224073130|NCT03602872|BIOLOGICAL|Human allogeneic mesenchymal bone marrow derived stem cells|Intraarticular administration of 20x10\^6 MSCs
224073131|NCT02122978|BEHAVIORAL|Mindfulness Based Cognitive Therapy|MBCT 8 week course delivered by trained facilitator
224073132|NCT02122978|BEHAVIORAL|MBSC - minimal contact|8 week course in Mindfulness Based Self Compassion delivered remotely by audio guided MP3
224073133|NCT02122978|BEHAVIORAL|Mindfulness Based Self Compassion Therapy|Mindfulness Based Self Compassion Therapy - 8 wee course delivered by trained facilitator
224179848|NCT01298817|DIETARY_SUPPLEMENT|Medifast meal replacement products|A total of 4 meal replacement (MR)products per participant per day will be used. Approximately 2/3rd of the Medifast® MR product line is soy protein-based (i.e. at least 7 g of total protein coming from soy) with the remaining 1/3rd of items deriving total protein content from animal sources (whey and egg). The soy used in Medifast products is Solae SUPRO® water-washed soy protein isolate. Depending on seasonal variations, soy MR products contain approximately 1.5-3.0 milligrams of soy isoflavones for every 1 gram of soy protein. Thus, participants in the soy treatment arm will consume at least 28 g/soy protein and 42-108 mg/isoflavones per day.
223489254|NCT01410942|BEHAVIORAL|Counseling Sessions|8 weekly sessions (1 in person and 7 by telephone) lasting 45 minutes each.
223489255|NCT01410942|OTHER|Sham Exercise|Participants in placebo/sham exercise intervention meet with exercise physiologist in person on first visit to learn stretching exercises and receive written instructions same as those receiving exercise therapy.
223489256|NCT01410942|OTHER|Standardized Exercise Intervention Program|Resistance exercise sessions completed 3 days a week allowing at least 48 hours between each session, and walk minimum of 5 days a week at intensity and duration established by exercise physiologist.
223489257|NCT01410942|OTHER|Cognitive Behavioral Therapy (CBT)|8 weekly sessions (1 in person and 7 by telephone) lasting 45 minutes each, during which review learned relaxation skills and taught new cognitive and/or behavioral skill.
223489258|NCT02156661|DRUG|Oxytocin|
224073134|NCT04868812|DEVICE|SmartXide 2 V 2 LR, MonaLisa Touch, DEKA, Florence, Italy|SmartXide 2 V 2 LR, MonaLisa Touch, DEKA, Florence, Italy; MonaLisa Touch CO2 fractionated laser
223489259|NCT02605239|DRUG|Bleaching teeth|bleaching teeth with carbamide peroxide 10% for 3 weeks
223489260|NCT03952741|BEHAVIORAL|Physical Therapy|
223489261|NCT06504862|DRUG|Zongertinib|Zongertinib
223489262|NCT06504862|DRUG|Dabigatran-etexilate|Dabigatran-etexilate
223489263|NCT06504862|DRUG|Rosuvastatin|Rosuvastatin
223489264|NCT06504862|DRUG|Metformin hydrochloride|Metformin hydrochloride
223489265|NCT06504862|DRUG|Furosemide|Furosemide
223489266|NCT05462873|BIOLOGICAL|QEQ278|Intravenous dosing of QEQ278
223489267|NCT05120271|BIOLOGICAL|CAR-GPC3 T Cells|Five dose levels each with LD chemotherapy
223489268|NCT03757923|DRUG|TAB METFORMIN|INSULIN SENSITIZING AGENTS
223489269|NCT03757923|DRUG|TAB PIOGLITAZONE|INSULIN SENSITIZING AGENT
223489270|NCT05991453|OTHER|Anesthetic technique Propofol TIVA|Propofol TIVA no inhaled agent
223489271|NCT05991453|OTHER|Anesthetic technique inhaled agent|Must administer inhaled agent.
223489272|NCT06526429|PROCEDURE|rapid local ischemic postconditioning|Rapid local ischemic postconditioning (RL-IPostC) is performed immediately (within 5 minutes) after revascularization. A balloon guiding catheter (BGC) positioned on ipsilateral C1 segment of internal carotid artery is inflated and deflated for the temporary occlusion of the antegrade flow.
223489273|NCT02393625|DRUG|Ceritinib (LDK378)|
223489274|NCT02393625|DRUG|Nivolumab|
223489275|NCT03830606|DRUG|Nab-paclitaxel,S-1|Nab-paclitaxel 120 mg/m2 (D1, D8, q3w) and S-1 (40mg BID for body surface area \< 1.25 m2; 50mg BID for body surface area of 1.25-1.5 m2; and 60mg BID for body surface area \>1.5 m2; D1-14, q3w)
223489276|NCT02517489|DRUG|Hydrocortisone|Hydrocortisone will be given in a double-blind fashion for 8 or 14 full days. The intravenous route will be used. The treatment course will include 4 or 7 days of full dose (200 mg/day by continuous infusion), 2 or 4 days of half dose (100 mg/day by continuous infusion), and 2 or 3 days of tapering dose (50 mg/day by continuous infusion). Duration of treatment is chosen upon patient initial improvement.
224073135|NCT04797845|OTHER|teleconsultation|Patients will benefit from a quarterly teleconsultation to assess the study criteria through different questionnaires during 12 months.
224073136|NCT01477931|DRUG|Bupropion extended release|300mg once a daily, PO, 8weeks
224073137|NCT04938258|BEHAVIORAL|Intensive Case Management|Participants will receive an intensive Case Management (CM) intervention conducted by a multidisciplinary team (Psychiatry, Social Work, Nursing) during 2 months. The intervention will encompass attending weekly or biweekly appointments with the CM team, the interviews will last approximately 30 minutes. This CM intervention will include referral to Hospital Clínic de Barcelona Addiction Outpatient Clinic and a personalised assessment of the medical, psychiatric and social situation of each individual by the CM team. An individualised care plan will be established and periodically reviewed by the multidisciplinary team in response to a better understanding of patient needs or to a change in patient health condition. The intervention will offer motivational interviewing psychotherapy to enhance motivation to reduce or to quit alcohol use, in crisis intervention, coordination of care, patient education and self-management support, and assistance to navigate in the healthcare system.
224073138|NCT04904458|OTHER|"Experimental group (enfacement illusion)"|Virtual reality enfacement illusion exposure
224073139|NCT04904458|OTHER|Control Group (Pleasant virtual environment exposure)|Pleasant virtual environment exposure
224073140|NCT00955630|DRUG|ranibizumab|3 monthly injections of ranibizumab followed by prn injections for the remainder of the study
224073141|NCT00955630|DRUG|ranibizumab|prn injections of ranibizumab throughout the study
224073142|NCT01903512|PROCEDURE|TMJ arthrocentesis|lavage of the superior TMJ space with saline and sodium hyaluronate (SH)
224073143|NCT01537757|DRUG|MK-8931|Single dose, administered as oral capsules
224073144|NCT04495309|RADIATION|Metastases-directed Radiotherapy|Ablative radiotherapy (radiosurgery, stereotactic radiotherapy, hypofractionated image-guided radiotherapy (IGRT)) with few high-dose fractions
224073145|NCT00394459|DEVICE|Perifix Epidural Anaesthesia Catheter|Epidural Catheter
224073146|NCT00394459|DEVICE|Perifix Standard|Perifix Standard
224073147|NCT00394459|DEVICE|Perifix New|Perifix New
224073148|NCT05079607|OTHER|Mitopure Topical Formula 1|topical skin cream containing the low dose mitophagy activator Mitopure
224073149|NCT05079607|OTHER|Mitopure Topical Formula 2|topical skin cream containing the high dose mitophagy activator Mitopure
224073150|NCT03286855|DEVICE|Vibrating Mesh Nebuliser|The Aerogen Ultra vibrating mesh nebuliser is an approved 13 485 class II medical device (CE marked) nebuliser licenced for the delivery of physician-prescribed medications for inhalation which are approved for use with a general purpose nebuliser. It has been shown in previous laboratory and clinical studies to have superior drug delivery to standard jet nebulisers.
223745400|NCT07191275|DEVICE|Control continuous 30 Hz thetaburst transcranial magnetic stimulation|"Active control condition using bilateral continuous theta burst stimulation (cTBS) 30 Hz to the superior parietal cortex~* Frequency: trains of 30 Hz (3 pulses) every 167 ms (frequency of 6 Hz, in the range of theta band)~* Intensity: 100% of resting motor threshold (rMT)~* Location: consecutively on left and right superior parietal cortex (MNI: -17, -70, 60; 17, -70, 60)~* Duration: 33.3 seconds~* Timing: Immediately before showing IAPS pictures (off-line)"
224179849|NCT01298817|DIETARY_SUPPLEMENT|Medifast meal replacement products|A total of 4 meal replacement (MR)products per participant per day will be used. Approximately 2/3rd of the Medifast® MR product line is soy protein-based (i.e. at least 7 g of total protein coming from soy) with the remaining 1/3rd of items deriving total protein content from animal sources (whey and egg). This group will receive the non soy supplements.
224179850|NCT03287089|DRUG|Nitrofurantoin 100 MG|Patients will receive nitrofurantoin 100mg twice daily by mouth for 5 days
224179851|NCT03287089|DRUG|Placebo Oral Tablet|Matching placebo
224179852|NCT00864968|DRUG|Nabumetone 750 mg tablets, single dose|A: Experimental Subjects received Actavis Elizabeth LLC formulated products under fasting conditions
224179853|NCT00864968|DRUG|Nabumetone 750 mg tablets, single dose|B: Active comparator Subjects received Teva formulated products under fasting conditions
224179854|NCT02030795|OTHER|Disconnection group|The blocker cuff was deflated, the single lumen tube was disconnected from the ventilator for 60 s allowing the surgical lung to collapse, then the cuff was re-inflated with the same amount of air as determined previously and the ventilator was reconnected to the single lumen tube
224179855|NCT02030795|OTHER|Bronchial Suction group|The barrel part of a 1-mL insulin syringe was attached to the suction port of the bronchial blocker, and connected to -30 cm H2O of suction.
224179856|NCT04529525|DRUG|Ivermectin|Patients will receive the tablet from the branch to which they were randomized only at the time of inclusion and 24 hours after the first dose.
224179857|NCT04529525|DRUG|Placebo|Patients will receive the tablet from the branch to which they were randomized only at the time of inclusion and 24 hours after the first dose.
224179858|NCT04880642|DRUG|C21|C21
224179859|NCT04880642|DRUG|Placebo|Placebo
224179860|NCT00623753|BIOLOGICAL|EnvDNA, PolyEnv1, EnvPro|Description: The vaccine regimen is a series of 6 injections given 28 days apart. EnvDNA is administered intramuscularly as 100 mcg of recombinant DNA in 1.5 mL of PBS as injections #1, 2 and 5. PolyEnv1 is recombinant vaccinia virus administered subcutaneously as 107 pfu in 0.8 mL of PBS as injection #3. EnvPro is administered intramuscularly as 100 mcg of recombinant protein and 500 mcg of aluminum hydroxide (alum) adjuvant in 1.0 mL of PBS as injections #4 and 6.
224179861|NCT00104299|DRUG|Rituximab plus cyclophosphamide placebo (rituximab group)|375 mg/m\^2 infusions once weekly for 4 week
224179862|NCT00104299|DRUG|Cyclophosphamide plus rituximab placebo (control group)|2 mg/kg/day orally for months 1-3
224179863|NCT00104299|DRUG|Azathioprine|2 mg/kg/day orally for months 4-6
224179864|NCT00104299|DRUG|Methylprednisolone (or other glucocorticoid)|1 g/day intravenously for up to 3 days within 14 days prior to receiving rituximab
223745401|NCT07191431|DRUG|Selinexor+Orelabrutinib+Methotrexate/Thiotepa/Temozolomide|"* Orelabrutinib 150mg qd + Selinexor 40mg qw~* Combined chemotherapy (choose one):~  * MTX 3.5g/m² IV d0~ * Temozolomide 150mg/m² PO d1-5~ * Thiotepa 40mg/m² IV d3~* Every 3 weeks for 6 cycles"
224179865|NCT00104299|DRUG|Prednisone|During the remission induction phase, all participants will receive oral prednisone daily (1 mg/kg/day, not to exceed 80 mg/day). Prednisone tapering will be completed by the Month 6 study visit.
224179866|NCT01974414|DRUG|orally administered cedar honey|
224179867|NCT02452034|DRUG|Posaconazole IV solution|Posaconazole by IV solution twice on Day 1, then once daily on Days 2-10.
224179868|NCT02452034|DRUG|Posaconazole powder for oral suspension|Posaconazole once daily by PFS for a minimum of 10 days
224179869|NCT02961231|BIOLOGICAL|PCV 2p+1|introduction of PCV in a reduced dosing 2p+1 schedule
224179870|NCT02961231|BIOLOGICAL|PCV 3p+0|introduction of PCV in a reduced dosing 3p+0 schedule
223745402|NCT07190430|DRUG|PF-08049820|Administered orally
223745403|NCT07190430|DRUG|Midazolam|Administered orally
224179871|NCT02961231|BIOLOGICAL|PCV 1p+1|introduction of PCV in a reduced dosing 1p+1 schedule
223745404|NCT07190430|DRUG|Dabigatran Etexilate|Administered orally
224179872|NCT02961231|BIOLOGICAL|PCV 0p+1|introduction of PCV in a reduced dosing 0p+1 schedule
224179873|NCT04350749|BIOLOGICAL|PRF is added in the test group.|The PRF membrane can be considered as a biological membrane
224179874|NCT05766410|DRUG|Palbociclib|CDK4, 6 inhibitor
223745405|NCT07190430|DRUG|Portia (EE and LN) or equivalent oral tablet|Administered orally
223745406|NCT07190638|PROCEDURE|Medullary-only suturing (single-layer)|Only the base layer (medulla) is sutured after tumor excision, Cortical suturing is omitted. Hemostatic agents are applied.
223745407|NCT07190638|DEVICE|Suture|Synthetic absorbable monofilament suture (Caproyl™ 3-0).
223745408|NCT07190638|PROCEDURE|Medullary and cortical suturing (two-layer)|Both medullary and cortical layers are sutured after tumor excision, Performed with robotic assistance using absorbable sutures. Hemostatic agents are applied
223745409|NCT07190638|DEVICE|Suture|Synthetic absorbable monofilament suture (Caproyl™ 3-0), absorbable braided suture (Vicryl™ 0)
223745410|NCT07190638|DEVICE|Hemostatic Agent|Hemostatic agents (e.g., Bleed Stp Plus, Surgicel® Fibrillar, Hemopatch®).
224179875|NCT05766410|DRUG|Ribociclib|CDK4, 6 inhibitor
224179876|NCT05766410|DRUG|Abemaciclib|CDK4, 6 inhibitor
224179877|NCT05766410|DRUG|Letrozole|Endocrine therapy
224179878|NCT00561795|DRUG|pazopanib (GW786034)|800 mg orally once a day for 6 cycles
224179879|NCT00561795|DRUG|carboplatin|IV over one hour every 3 weeks of 6 cycles
224179880|NCT00561795|DRUG|paclitaxel|IV 175 mg/m\^2 given over 3 hours on day one of a 21 day cycle for six cycles
224179881|NCT00724594|DRUG|N-acetylcysteine|NAC (100 mg/kg/dose) was given intravenously to mothers within 4 hours of diagnosis of chorioamnionitis, and every 6 hours until delivery. NAC was given to preterm (12.5 mg/kg/dose) and term infants (25 mg/kg/dose) every 12 hours for 5 doses after birth.
224179882|NCT00724594|DRUG|Control|Saline was given in the same volume, at the same timing as NAC infusions
223489277|NCT02517489|DRUG|Placebo|Placebo will be given in a double-blind fashion for 8 or 14 full days. The intravenous route will be used. The treatment course will include 4 or 7 days of full dose (200 mg/day by continuous infusion), 2 or 4 days of half dose (100 mg/day by continuous infusion), and 2 or 3 days of tapering dose (50 mg/day by continuous infusion). Duration of treatment is chosen upon patient initial improvement.
223489278|NCT04451785|BIOLOGICAL|blood sample|6 tubes of 4 milliliters (ml) maximum (total: 24 ml) will be sampled for the measurements of the different biological markers. In case of the genetic mutation is already known, only 5 tubes will be collected (total: 20 ml).
223489279|NCT04451785|DIAGNOSTIC_TEST|Pulse wave velocity|Non-invasive measurement of pulse wave velocity between the carotid and femoral arteries with piezo-electric sensors.
223489280|NCT03837704|OTHER|IQOS|AAA patients will switch from cigarette smoking to ad libitum IQOS use, with no flavor variant restrictions.
223489281|NCT03837704|OTHER|Cigarette|AAA patients will continue to smoke their cigarettes ad libitum, with no brand restrictions.
223489282|NCT03837704|OTHER|Smoking Cessation|AAA patients who have completely quit smoking will continue to remain abstinent from smoking cigarettes or using any tobacco or nicotine-containing product(s)
223489283|NCT06416644|DEVICE|Supera Vasculomimetic Stent|Femoral-popliteal revascularization with Supera Stent
223489284|NCT04208529|BIOLOGICAL|CTX001|CTX001 infusion.
223489285|NCT04132778|DEVICE|AsthmaTuner|Conventional treatment was defined as non-digital self-management using paper individual treatment plans, which contained treatment adjustments of prescribed medications according to symptoms of controlled, partly controlled or uncontrolled asthma, along with instructions according to national guidelines.
223489286|NCT05033054|DRUG|SGLT2 inhibitor|Participants will ingest a standard dose of SGLT2i prescribed by the standard of care physician.
223489287|NCT05128383|DRUG|Dupilumab|Dupilumab a human monoclonal antibody of the immunoglobulin G4 subclass that inhibits interleukin (IL)-4 and IL-13 signaling by specifically binding to the IL-4 receptor alpha subunit, which is shared by the IL-4 and IL-13 receptor complexes.
223489288|NCT03838354|DRUG|Chidamide|In the 2.5 mg group, chidamide will be administered orally at an initial dose of 2.5 mg twice per week for 12 weeks. If an initial response was achieved by week 12, the allocated treatment could continue. Patients in 2.5 mg group were allowed to increase dose to 5 mg if platelet counts were less than 30×10\^9 cells per L or less than two-times increase from baseline platelet count at week 12 according to investigators' advice and the patients' decision.
223489289|NCT03838354|DRUG|Chidamide|In the 5 mg group, chidamide will be administered orally at an initial dose of 5 mg twice per week for 12 weeks. If an initial response was achieved by week 12, the allocated treatment could continue. Patients who did not respond to chidamide at 5 mg for 12 weeks would stop the allocated treatment and were continuously followed up.
223489290|NCT05275426|DRUG|LY2880070|Patients will receive treatment in 21-day cycles with LY2880070 50 mg twice daily orally on days 2-6, 9-13, and 16-20
223587309|NCT03594812|DEVICE|Aerobic exercise|Aerobic exercise protocol - 40 minutes of aerobic moderate-intensity exercise (45-55% of reserve heart rate) using Karvonen´s formula, performed on a cycloergometer. The duration of the exercise was divided into three parts: warm-up (from 0 to 5 minutes); body (from 5 to 35 minutes); and cooling (from 35 to 40 minutes). The entire protocol was monitored through the Polar® brand heart rate monitor and watch.
224073151|NCT03286855|DEVICE|Standard Hospital Care|"The standard hospital care refers to the nebuliser in clinical use currently throughout Beaumont Hospital and used for the administration of nebulised medications. This is the Hudson micromist small volume nebuliser."
224073152|NCT00425386|DRUG|erlotinib hydrochloride|"Dose Level 0 = 50 mg/day, continuous daily; 0.5= 75 mg/day, continuous daily;~1. 100 mg/day, continuous daily; 1.5= 125 mg/day, continuous daily;~2. 150 mg/day, continuous daily"
224073153|NCT00425386|DRUG|sunitinib malate|Will be administered at 50 mg daily, 4 weeks on, 2 weeks off
224073154|NCT00425386|PROCEDURE|biopsy|Paraffin block (or unstained slides) of the primary tumor and/or metastatic lesions (as available) and a plasma sample for future correlative studies will be collected. A paraffin block (or at least 10 unstained slides, each of 10 micromillimeter thickness) from the original paraffin-embedded biopsy material taken at the diagnosis will be stored at 4 degrees Celsius.
224073155|NCT06245551|DRUG|Budesonide/albuterol metered-dose inhaler 160/180 μg|Budesonide/albuterol combination aerosol for inhalation, single dose (given as 2 actuations of 80/90 μg)
224073156|NCT06245551|DRUG|Placebo metered-dose inhaler|Placebo aerosol for inhalation, single dose (given as 2 actuations)
224073157|NCT04476238|DIETARY_SUPPLEMENT|Inosine|2 grams of inosine dissolved in 250 ml water taken by mouth
224073158|NCT04476238|OTHER|Placebo|250 ml water taken by mouth
224073159|NCT01387243|DRUG|Orlistat|60 mg
224073160|NCT00968851|DRUG|EVP-6124|Arms: 1
224073161|NCT00968851|DRUG|Placebo|Arm: 3
224073162|NCT00968851|DRUG|EVP-6124|Arms: 2
224073163|NCT03597048|BEHAVIORAL|Curriculum|The curriculum intervention is a three- module, three-hour curriculum delivered by teachers in sixth grade classrooms over a three- to six-day period. The curriculum is designed to increase knowledge and improve attitudes about mental illnesses so as to improve the school climate with respect to mental illness stigma and encourage help seeking for youth in need.
224073164|NCT03597048|BEHAVIORAL|Contact|The contact intervention involves two college students-a 27-year-old male with a history of bipolar I disorder and a 24-year-old female with a history of bipolar II disorder-who each make a ten-minute in-class presentation (20 minutes total) describing onset and course of their symptoms, hospitalizations and treatments, their feelings about the illness, coping strategies, and impact of the illness on social relationships and functioning at school and work.
223489291|NCT05275426|DRUG|Gemcitabine|Participants will receive treatment in 21-day cycles with gemcitabine 100 mg/m2 intravenously on days 1, 8 and optionally on day 15
223587310|NCT02616770|DRUG|S1226 (4%)|3 ml Peflubron nebulized, with Medical Gas containing 4% carbon Dioxide, for 2 minutes as a single dose.
223587311|NCT02616770|DRUG|Saline (for 4%)|3ml saline nebulized, with Medical Air, for 2 minutes as a single dose
224073165|NCT03597048|BEHAVIORAL|Materials|"The materials intervention is implemented by teachers who prominently display posters in the classroom for two weeks and provide students with bookmarks. The materials focus on individuals' with mental illnesses emphasizing their personal traits and abilities as opposed to language that labels a person as mentally ill."
223489292|NCT04379050|DRUG|ABBV-951|Solution for continuous subcutaneous infusion (CSCI).
223489293|NCT05550350|DRUG|Dexycu|103.4 mcg/mcl dexamethasone: equivalent dexamethasone dose: 517 mcg
223489294|NCT05550350|OTHER|Placebo/Vehicle|Placebo/vehicle, 0 mcg/mcl dexamethasone: equivalent dexamethasone dose: 0 mcg
223489295|NCT04528134|DEVICE|Extended Contact RMGI (Resin-modified Glass Ionomer) Varnish|This is a light-cured, durable coating that forms an immediate layer of protection that releases fluoride, calcium and phosphate and can be recharged with fluoride by using fluoride-containing products over the 6-month life of the product.
223489296|NCT04528134|DEVICE|5% Sodium Fluoride Varnish|This is a 5% Sodium Fluoride varnish that hardens on the teeth upon contact with saliva.
223489297|NCT04650581|DRUG|Ipatasertib|400 mg PO QD days 1-21 every 28 days
223489298|NCT04650581|DRUG|Fulvestrant|500 mg IM cycle 1 days 1 and 15 followed by 500 mg IM day 1 q 28 days subsequent cycles
223489299|NCT04650581|OTHER|Placebo|PO QD days 1-21 every 28 days
223489300|NCT01771107|DRUG|Brentuximab Vedotin|Given IV
223489301|NCT01771107|DRUG|Dacarbazine|Given IV
223489302|NCT01771107|DRUG|Doxorubicin Hydrochloride|Given IV
223489303|NCT01771107|OTHER|Pharmacological Study|Correlative studies
223489304|NCT01771107|DRUG|Vinblastine|Given IV
223489305|NCT00700765|DRUG|insulin detemir|For study drug, start dose and frequency of administration to be prescribed by the physician as a result of normal clinical evaluation
223489306|NCT06543173|PROCEDURE|Prophylactic Catheter-based VT Ablation|Prophylactic Catheter-based VT Ablation refers to a treatment strategy where participants undergo a procedure known as catheter-based ventricular tachycardia (VT) ablation shortly after receiving their primary implantable cardioverter defibrillator (ICD).
223489307|NCT04780321|BIOLOGICAL|Recombinant Human Anti-SARS-CoV-2 Monoclonal Antibody(25mg/kg;50mg/kg;100mg/kg)|use dose 1/2/3 60 patients receipt JS016 intravenous infusion on day 1
223489308|NCT04780321|DRUG|Placebo|30 patients receipt placebo intravenous infusion on day 1
223489309|NCT04357795|DRUG|CequaTM (Cyclosporine 0.09%) ophthalmic solution|One drop CequaTM (Cyclosporine 0.09%) ophthalmic solution in each eye twice daily, approximately 12 hours apart.
223489310|NCT03843528|DRUG|Vorinostat|Vorinostat will be administered concurrent with low-dose azacitidine post-transplant, on days 1-7 and 15-21 of 28 day cycles. This is an oral medication.
223489311|NCT03843528|DRUG|Azacitidine Injection|Azacitidine will be administered on days 1-5 of each 28 day cycle, either by IV or subcutaneous injection. The dose of azacitidine will be fixed, with no dose-escalation.
224179883|NCT02107781|DEVICE|AbViser abdominal compartment pressure measuring device|AbViser AutoValve IAP Monitoring Device will be used on all patient enrolled in the research study.
223489312|NCT05644925|DEVICE|PiCSO Impulse System|The PiCSO Impulse System is intended to reduce infarct size by intermittently occluding the coronary sinus outflow in patients undergoing a percutaneous coronary interventional procedure for myocardial infarction and presenting with Thrombolysis in myocardial infarction (TIMI) flow of 0 or 1.
223489313|NCT05644925|PROCEDURE|Percutaneous Coronary Intervention (PCI)|Minimally invasive procedures used to open clogged coronary arteries
223489314|NCT05248386|DRUG|RTX-GRT7039|RTX-GRT7039 intra-articular injection.
223489315|NCT05248386|DRUG|Placebo|Placebo matching RTX-GRT7039 intra-articular injection.
223489316|NCT02571985|DEVICE|Zenith® Branch Endovascular Graft-Iliac Bifurcation System|Zenith® Branch Endovascular Graft-Iliac Bifurcation (Branch Graft) with the ConnectSX™
223489317|NCT02312843|BEHAVIORAL|Exercise/Aerobic|
223489318|NCT02312843|BEHAVIORAL|Exercise/Stretching|
223489319|NCT06174207|OTHER|Oxygen|Standard supplemental Oxygen therapy (5l/min) will be applied with an oxygen concentrator via nasal cannula.
223489320|NCT03303248|BEHAVIORAL|Web-based Educational Intervention|A web-based educational tool, created for patients with congenital heart disease, will be given to patients using an ipad. This additional educational tool will be used with the standard of care visit with provider.
223489321|NCT05242211|OTHER|exercise test|Each participants will conducted an exercise test on treadmill (using Modified Bruce Protocol) and cycle ergometer. Quark CPET metabolic cart (Cosmed, Rome, Italy) will be used to collect and analysis gas exchange. 10 minute after the graded exercise test Supra maximal exercise test (SMT) will be done for 2 minutes one stage (treadmill protocol) or 10% at cycle protocol higher than highest load achieved in the incremental test.
223489322|NCT05348317|BEHAVIORAL|VetReach|Telehealth-delivered MI-CBT substance use disorder care model
223489323|NCT00077818|DRUG|Enoxaparin sodium|
223489324|NCT05754710|DRUG|Xeljanz|Juvenile Idiopathic Arthritis (JIA) patients with Xeljanz
223489325|NCT00287820|DRUG|Olanzapine|olanzapine 5-40 mg/day
223489326|NCT00287820|DRUG|olanzapine|olanzapine 5-40 ,mg/day
223489327|NCT00287820|DRUG|risperidone|risperidone 1-12 mg/day
223489328|NCT05100667|OTHER|Hypoxia|altitude (3800m)
223489329|NCT05100667|OTHER|Normoxia|sea level
223489330|NCT04909138|DEVICE|DRG stimulation 20 Hz 30/90|Stimulation delivered at 20 Hz and 30 seconds ON, 90 seconds OFF
223489331|NCT04909138|DEVICE|DRG stimulation 5 Hz 30/90|Stimulation delivered at 5 Hz and 30 seconds ON, 90 seconds OFF
223489332|NCT03435419|DIAGNOSTIC_TEST|LoopampTM Leishmania Detection Kit|LoopampTM Leishmania Detection Kit is a diagnostic test for Leishmania DNA detection
223489333|NCT03435419|DIAGNOSTIC_TEST|CL DetectTM Rapid Test|CL DetectTM Rapid Test is a diagnostic test for Leishmania antigen detection
223489334|NCT06000670|PROCEDURE|stromal vascular fraction injection in the osteoarthritic knee|stromal vascular fraction harvested from mid abdominal wall under sedation and seperated from fat using mechanical centrifugation .injection of 5 cc of the SVF in the affected knee.
223489335|NCT04928300|DRUG|Dexmedetomidine|low dose dexmedetomidine infusion 0.2 µ/kg/hour IV for 5 days.
223489336|NCT04928300|DRUG|Ketamine|low dose ketamine infusion 2.5 µ/kg/min for 5 days.
223489337|NCT04928300|OTHER|0.9% saline|the same dose and duration of normal saline will be given for 5 days.
223489338|NCT06551675|DIETARY_SUPPLEMENT|Silkworm pupa tablets|Participants will begin taking the silkworm pupa tablets immediately upon enrollment, 1200mg/tablet, two tablets a time, twice a day (BID), with a treatment duration of three months.
224179884|NCT04672200|OTHER|Group exercise|Weekly group exercises delivered online and face to face
224179885|NCT00490815|DRUG|Fluocinolone Acetonide|0.5 mg fluocinolone acetonide intravitreal insert
223489339|NCT06551675|DIETARY_SUPPLEMENT|Control product|The sham comparator contains 0.5% of the active ingredient of the study product, indistinguishable in appearance. Participants will begin taking the control immediately upon enrollment, 1200mg/tablet, two tablets a time, twice a day (BID), with a treatment duration of three months.
223489340|NCT06172361|DRUG|Prednisone+Tofacitinib|"Withdrawal of prednisone (or equivalent dose of methylprednisolone) within 4 weeks: 5mg tid for 2 weeks, 5mg bid for 1 week, 5mg qd for 1 week, then discontinue.~Take Tofacitinib 10mg/d for 3 months, then 7.5mg/d for 2 months, followed by 5mg qd for 2 months, then 5mg qod for 2 months, and finally 5mg every 3 days for 2 months, discontinue the Tofacitinib for 1 month. If there is a relapse during the dose reduction process, resume Tofacitinib at the original dosage."
223587312|NCT02616770|DRUG|S1226(8%)|3 ml Peflubron nebulized, with Medical Gas containing 8% carbon Dioxide for, 2 minutes as a single dose.
223745411|NCT07190612|DRUG|Dexmedetomidine and propofol|"Dexmedetomidine infusion syringe (50mls): will be filled with 2mls of dexmedetomidine (200µg) diluted in 48 ml of 0.9% normal saline to make a final volume of 50mls and a final dexmedetomidine concentration of 4µg/ml. It will be infused as 1µg~/kg/hr iv. Propofol infusion syringe (50mls): will be filled with 20mls of 1% propofol (200mg) diluted in 30mls 0.9% normal saline to make a final volume of 50mls and a final propofol concentration of 4mg/ml. It will be iv administered as 0.5 mg/kg slow iv for 10 minutes, then infused at a rate of 0.5mg/kg/hr."
224179886|NCT00490815|DRUG|Fluocinolone Acetonide|0.2 mg fluocinolone acetonide intravitreal insert
223489341|NCT06172361|DRUG|Prednisone|Prednisone 15mg (or equivalent dose of methylprednisolone) was set as the initial treatment of PMR. When improvement was achieved, the dose of Prednisone was reduced to 10mg daily within 4-10 weeks; When remission was achieved, then taper Prednisone gradually by 2.5mg every 6-8 weeks. Once relapse occurred, the dose increased to the pre-relapse dose. If reducing pred dosage is difficult, Methotrexate (MTX) 10mg qw can be added after 24 weeks.
223489342|NCT04324112|DRUG|binimetinib|Binimetinib will be given orally at a dose of 45mg BID continuously for 28-day cycles with no resting period between cycles.
223745412|NCT07190612|DRUG|Midazolam and propofol|Midazolam infusion syringe (50mls): will be filled with 10mls of Midazolam (50mg) diluted in 40mls 0.9% normal saline to make a final volume of 50mls to reach a final midazolam concentration of 1mg/ml. It will be administered as a bolus dose of 0.05 mg/kg iv over 2 minutes then infused at a rate of 0.025mg/kg/hr. Propofol infusion syringe (50mls): will be filled with 20mls of 1% propofol (200mg) diluted in 30mls 0.9% normal saline to make a final volume of 50mls and a final propofol concentration of 4mg/ml. It will be iv administered as 0.5 mg/kg slow iv for 10 minutes, then infused at a rate of 0.5mg/kg/hr.
223587313|NCT02616770|DRUG|Saline (for 8%)|3ml saline nebulized, with Medical Air, for 2 minutes as a single dose
223587314|NCT02616770|DRUG|S1226(12%)|3 ml Peflubron nebulized, with Medical Gas containing 12% carbon Dioxide, for 2 minutes as a single dose.
223587315|NCT02616770|DRUG|Saline (for 12%)|3ml saline nebulized with Medical Air for 2 minutes as a single dose
223587316|NCT02771626|DRUG|CB-839|Glutaminase inhibitor
223587317|NCT02771626|DRUG|Nivolumab|PD-1 inhibitor
224073166|NCT06194396|OTHER|chlorhexidine|chlorhexidine will be used as skin disinfectant before insertion of CVC, PICC line, and umbilical catheter
224073167|NCT06194396|OTHER|alcohol|alcohol will be used as skin disinfectant before insertion of CVC ,PICC line and umbilical catheter
224073168|NCT01061814|DRUG|mipomersen|30 mg (cohort A), 70mg (cohort B) or 200mg (cohort C) subcutaneous (SC) dose of study drug daily for 3 weeks
224073169|NCT01061814|DRUG|Placebo|30 mg (cohort A), 70mg (cohort B), or 200mg (cohort C) subcutaneous (SC) dose of study drug daily for 3 weeks
224073170|NCT00511355|DRUG|NOMAC-E2|Nomegestrol Acetate and Estradiol (NOMAC-E2) Tablets, 2.5 mg NOMAC and 1.5 mg E2 taken once daily from Day 1 of menstrual period up to and including Day 28 for 6 consecutive 28-day cycles.
224073171|NCT00511355|DRUG|Levonorgestrel and Ethinyl Estradiol|Levonorgestrel and Ethinyl Estradiol (LNG-EE) Tablets, 150 mcg LNG and 30 mcg EE taken once daily from Day 1 of menstrual period up to and including Day 28 for 6 consecutive 28-day cycles.
224073172|NCT04067063|OTHER|Self-administered evaluation questionnaire|Smartphone app with MeMind questionnaires
224073173|NCT01708460|DEVICE|Ulthera System Treatment|Focused ultrasound energy delivered below the surface of the skin.
224073174|NCT00713583|DRUG|levodopa|800mg levodopa and 200mg carbidopa per day
224073175|NCT00713583|DRUG|Placebo|Placebo
224073176|NCT00713583|BEHAVIORAL|Cognitive Behavioral Therapy|Participants received individual cognitive behavioral therapy (CBT) in 50-minute weekly sessions. These sessions were manual-driven and based on the relapse prevention model proposed by Marlatt and Gordon (1985). Trained masters-level therapists, under the supervision of senior therapists and the principal investigator, worked with participants to teach them how to recognize and cope with risky situations that could influence their cocaine use through self-monitoring of situational craving and drug use stimuli, coping skills training, and lifestyle modifications.
224073177|NCT00713583|BEHAVIORAL|Contingency Management|An abstinence-based contingency management (CM) procedure was used. Participants earned vouchers according to the reward schedule recommended by Budney and Higgins (1998), beginning at $2.50 for the first cocaine-negative urine. For each consecutive cocaine-negative urine, voucher values increased by $1.25 with a $10 bonus given for provision of three consecutive cocaine-negative urines within a week. A cocaine-positive urine or failure to provide a scheduled urine sample resulted in a reset of the schedule to the initial value of $2.50. After provision of five negative urines, the voucher returned to the value prior to the reset. Participants were able to redeem their vouchers for small amounts of cash (≤$25) or gift cards for goods and services.
224073178|NCT04654208|DRUG|palbociclib|patients on palbociclib combination treatment
224073179|NCT02803944|DRUG|Azithromycin|
224073180|NCT06383767|DRUG|ESG401|IV infusion on day 1,8, and 15 of each 28 day cycle
224073181|NCT06383767|DRUG|Eribulin, capecitabine, gemcitabine or vinorelbine (Treatment of Physician's Choice)|Eribulin, capecitabine, gemcitabine or vinorelbine
224073182|NCT02868346|OTHER|Anal swab|
224073183|NCT03967548|DRUG|Germinal peptide eye drops|Germinal peptide eye drops of 0.004%
224073184|NCT05199259|DIAGNOSTIC_TEST|Multi-analyte Blood Test|A clinical diagnostic test based upon the detection and quantification of DNA methylation markers in cell-free DNA (cfDNA) isolated from plasma and of tumor-specific proteins isolated from serum.
224179887|NCT01508221|DRUG|Trental|400 mg tid starting first day after last radiosurgery treatment and continuing for 6 months
224179888|NCT01508221|DIETARY_SUPPLEMENT|Vitamin E|400IU twice daily starting the first day after last radiosurgery treatment and continuing for 6 months
224179889|NCT06421363|DRUG|Inclisiran|Implementation of a follow-up program that incorporates Inclisiran treatment in patients with a history of chronic coronary syndrome
224179890|NCT00999453|OTHER|LDL-cholesterol|This is a 2-arm, open label, multi-center, randomized trial comparing aggressive to standard treatment of LDL-cholesterol. After screening, randomization, participants will be seen every 3 months during the follow-up period. An LDL-cholesterol 100 mg/dL is the goal for the standard group and the target for the aggressive group is 70 mg/dL. A lipid lowering algorithm has been developed based on the NCEP-ATP III recommendation which is used as a general guideline, allowing alterations based on the individual participants needs.
224179891|NCT01414686|OTHER|Commercially-Available Interactive Video Games|"Two commercially available gaming platforms were used in this study, the Nintendo Wii and the Sony PS 2. The Wii games included Wii Sports and Wii Fit; PS games included the EyeToy Play 2 and Kinetic. Each of these games provides multiple mini games which pose different movement challenges, including dynamic balance, speed, accuracy, general mobility, and weight shifts.~Game play was performed 1 hour/day, 4 days/ week, for a period of 5 weeks, totaling 20 hours."
224179892|NCT01438281|DRUG|SYL1001|SYL1001 eye drops. topical administration
224179893|NCT02300922|DRUG|Antibody TF2|injection of a recombinant antibody CEA specific. Three injections. Each injection are separate by one week
224179894|NCT02300922|DRUG|90-Y-IMP-288|Injection of the peptide 90-Y-IMP-288, 24 Hours after injection of TF2. 2 injections by patients separated by one week (week 2 and week 3)
224179895|NCT02300922|DRUG|111-In-IMP-288|Injection of the peptide 111-In-IMP-288, 24 Hours after the first injection of TF2 (week 1)
224179896|NCT05618769|COMBINATION_PRODUCT|LONG LOVE Framework|In order to identify modifiable influencing factors, clinical data of the infants included in our multidisciplinary framework will be continuously collected by eHealth (Luscii Healthtech BV, Netherlands). Study visits take place at 1-1,5 3, 6, 12 and 18 months of age. Outdoor air quality measurements will be conducted using RIVM Luchtmeetnet. Indoor air quality measurements will be collected during a period of 6 weeks using a commercial available device. Lung function analysis using impedance pneumatography (Ventica Recorder, Revenio Research LTD, Finland) will take place during 2 nights at 3, 6 and 12 months of age. In the event of modifiable influencing factors medical or lifestyle interventions will be undertaken.
224307391|NCT05909189|OTHER|LEADing Dementia End-of-Life Planning Conversations|The LEAD Intervention is self-administered and delivered through an interactive, web-based platform designed according to recommended functionalities and user-designed principles. Through three distinct modules, the LEAD Intervention will facilitate the advance care planning processes of 1) defining care recipients' values and preferences for care, 2) developing advance care planning congruence within the pair, or a shared understanding of the care recipient's values and preferences, through conversation(s), and 3) encouraging ongoing advance care planning conversation and documentation that can be shared beyond the pair. All modules will include video tutorials to introduce the goals and tasks as well as provide interactive resources to provide support and education relevant to the content of each module. The three modules are intended to be followed in a sequential pattern.
224179897|NCT04815005|OTHER|Demographics, diagnosis type, genotype, lipid profile, treatment allocation, country of residence.|Differences in diagnosis, genotype, lipid profile treatment allocation among HoFH patients worldwide.
224179898|NCT00611351|BIOLOGICAL|anti-thymocyte globulin|
224179899|NCT00611351|DRUG|busulfan|
224179900|NCT00611351|DRUG|cyclophosphamide|
224179901|NCT00611351|DRUG|mycophenolate mofetil|
224179902|NCT00611351|DRUG|tacrolimus|
224179903|NCT00611351|GENETIC|polymerase chain reaction|
224179904|NCT00611351|GENETIC|polymorphism analysis|
224179905|NCT00611351|OTHER|flow cytometry|
224179906|NCT00611351|OTHER|laboratory biomarker analysis|
224179907|NCT00611351|OTHER|pharmacogenomic studies|
224307392|NCT05933343|PROCEDURE|Ethibond suture|An Ethibond™ 1 suture will be placed as a drainage seton for complex anal fistula
223489343|NCT04324112|DRUG|Encorafenib|Encorafenib will be given orally at a dose of 450mg QD continuously for 28-day cycles with no resting period between cycles.
223587318|NCT02648217|DRUG|insulin degludec/insulin aspart|Injected subcutaneously (s.c., under the skin)twice daily. The pre-trial insulin will be discontinued.
224179908|NCT00611351|OTHER|pharmacological study|
224179909|NCT00611351|PROCEDURE|allogeneic bone marrow transplantation|
224179910|NCT00611351|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
224179911|NCT00611351|PROCEDURE|peripheral blood stem cell transplantation|
224179912|NCT02092142|BIOLOGICAL|Q fever Vaccine|Subcutaneous 0.5 mL Q fever Vaccine, Phase I, Inactivated, Dried, NDBR 105
224179913|NCT04882930|PROCEDURE|Functional Near-Infrared Spectroscopy (fNIRS)|All participants will undergo Functional Near-Infrared Spectroscopy (fNIRS). The hemodynamic response in CPF will be measured using an Octomon+ system (Artinis). Eight emission and two detector probes will be arranged on the participant's forehead.
223587319|NCT02648217|DRUG|biphasic insulin aspart|Injected subcutaneously (s.c., under the skin)twice daily. The pre-trial insulin will be discontinued.
223587320|NCT00599508|DIETARY_SUPPLEMENT|Concord grape juice|Several ounces Concord grape juice administered 3 times a day for 12 or 16 weeks. Specific dosage determined by participant's weight.
223587321|NCT00599508|DIETARY_SUPPLEMENT|placebo juice|several ounces placebo juice consumed three times a day for 12 or 16 weeks; dosage determined according to participant's weight
223587322|NCT00599508|DIETARY_SUPPLEMENT|blueberry juice|wild blueberry juice administered daily for 12 weeks, dosage determined according to participant's weight
223587323|NCT00599508|DIETARY_SUPPLEMENT|whole fruit blueberry powder|whole fruit, freeze dried blueberry powder derived from a blend of cultivated blueberries administered daily for 16 weeks
223587324|NCT00599508|DIETARY_SUPPLEMENT|berry placebo powder|berry placebo powder administered daily for 16 weeks
224179914|NCT03331939|OTHER|no stimulation|Vagal nerve stimulator will be set to no stimulation
224179915|NCT03331939|OTHER|beta (25-30 Hz)|Vagal nerve stimulator will be set to beta (25-30 Hz)
224179916|NCT03331939|OTHER|Theta (5 Hz)|Vagal nerve stimulator will be set to beta (5 Hz)
224179917|NCT02791841|BEHAVIORAL|Rhythmic Reading Training|RRT is a child-friendly computerized reading training program designed for Italian students with DD aged 8-14 yrs. The main feature of this intervention is the integration of a traditional remediation approach (sublexical treatment) with rhythm processing. Therefore, all reading exercises are characterized by a rhythmic accompaniment with gradually increasing speed.
224179918|NCT02791841|BEHAVIORAL|Visual Hemispheric-Specific Stimulation + Action Video Games|"This training combines Visual Hemisphere-Specific Stimulation (VHSS) according to Bakker's Balance Model, and Action Video-Games (AVG). Hemispheric-specific stimulation is carried out by tachistoscopic presentation of words to a visual hemifield in order to selectively stimulate right-hemisphere perceptual analysis or left-hemisphere linguistic anticipation. A computerized program is used, in which the word is flashed and presented for less than 350 ms only if the child clicks on the mouse at the exact moment a dot is crossing a central target (control of eye position and fixation).~AVG training involves dyslexic participants in a video-game training, specifically aimed at improving visuo-spatial attentional abilities. A commercial WiiTM video game from UbisoftTM (suitable for children age 7 and older by the Pan European Game Information) called 'Rayman Raving Rabbids' is used."
224179919|NCT02791841|BEHAVIORAL|Action Video Games|AVG training involves dyslexic participants in a video-game training, specifically aimed at improving visuo-spatial attentional abilities. A commercial WiiTM video game from UbisoftTM (suitable for children age 7 and older by the Pan European Game Information) called 'Rayman Raving Rabbids' is used.
224179920|NCT02195531|BEHAVIORAL|Education and feedback|The education leaflets are information concerning Obstructive Sleep Apna (OSA) and CPAP treatment. The feedback reports are CPAP usage patterns.
224179921|NCT05280223|DRUG|Dexmedetomidine|injection of 1 microgram/kg dexmeditomidine + 10 cc saline injection nearby median nerve as hydrodissection
224179922|NCT05280223|DRUG|Hyalase|injection of Hyalase + 10 cc saline injection nearby median nerve as hydro-dissection
224179923|NCT00767494|DRUG|Travoprost/Brinzolamide fixed combination|Eye Drops, suspension once daily
224179924|NCT00767494|DRUG|Azopt|Eye Drop Suspension, 1 drop BID
224179925|NCT00767494|DRUG|Travatan|Eye Drop Solution, 1 drop BID
224179926|NCT03562728|DEVICE|MRP and NMES(neuromuscular electric stimulation)|nutrition supplementation includes addition of essential amino acids 3 times a day to feeding
224179927|NCT03562728|OTHER|Standard of Care|Patients in the control group are going to receive standard of care
224179928|NCT02543801|DRUG|Liposomal Bupivacaine|Periarticular injection
224179929|NCT02543801|DRUG|Ropivacaine|Periarticular injection
224179930|NCT02543801|DRUG|Bupivacaine|Included as an element of the Liposomal bupivacaine intervention periarticular injection
224179931|NCT02543801|DRUG|Clonidine|Included as an element of both interventions as a standard of care periarticular injection
224179932|NCT02543801|DRUG|Ketorolac|Included as an element of both interventions as a standard of care periarticular injection
224179933|NCT02543801|DRUG|Epinephrine|Included as an element of both interventions as a standard of care periarticular injection
224179934|NCT03145428|DIAGNOSTIC_TEST|CBC-Diff Monocyte volume width distribution (MDW)|MDW measurement used to detect sepsis. Results will not be used to manage patients
224179935|NCT00381784|BEHAVIORAL|Printed materials|"Role model stories comprise the heart of printed materials distributed throughout the target community. The role model stories are brief publications that depict personal accounts from individuals in the population of focus who have made or are planning to make a risk-reducing behavioral change. Depending on the population they are meant to reach and what behavior they are trying to influence, the stories may include examples of people who now carry condoms with them, talked to a partner about condom use, use condoms consistently, avoid sharing needles, or exhibited other risk reduction behaviors."
224179936|NCT00381784|BEHAVIORAL|Peer advocates|"Core Element 1 Core group of young gay men and additional volunteers recruited from the community. The core group and volunteers comprise the peer advocates who design and carry out all program activities.~Core Element 2 Designated space where most social events and meetings are held; also serves as a drop in center where young men can meet and socialize during specified hours.~Core Element 3 Social events to attract young gay men and to promote safer sex. Core Element 4 Teams of young gay men go to locations frequented by young gay men to discuss and promote safer sex, deliver appealing informational literature on HIV risk reduction and distribute condoms.~Core Element 5 Meetings of eight to 10 young gay men to discuss factors contributing to unsafe sex among men. Men practice safer sex negotiation and correct condom use skills.~Core Element 6 Publicity campaigns that attract men to the program by word of mouth and through articles and advertisements in gay newspapers."
224179937|NCT04679896|DEVICE|MagnetOs Putty|Procedure: Instrumented posterolateral spine fusion
224179938|NCT03704428|DRUG|SHR-1314|Pharmaceutical form: Injection solution. Route of administration: subcutaneous injection.
224179939|NCT05278611|DRUG|EP-9001A|The initial dose of the study was set as 1 mg, and the doses were escalated sequentially in the order of 1 mg, 2.5 mg, 5 mg, 10 mg, 20 mg, and 25 mg
224307393|NCT05933343|PROCEDURE|Vessel loop|A vessel loop will be placed as a drainage seton for complex anal fistula
223587325|NCT03316950|DEVICE|IntraGen RF|IntraGen is a radiofrequency vaginal rejuvenation device FDA approved for use in dermatological and general surgical procedures for electrocoagulation and hemostasis. The hand piece is a disposable monopolar applicator that is used to apply energy internally and externally.
224179940|NCT05278611|DRUG|placebo|placebo
224179941|NCT04488406|OTHER|No Intervention|Not applicable to these subjects. There is no study-related intervention
224179942|NCT02974023|DEVICE|Pain Gear|PainGear \[ActiPatch®\] (BioElectronics Corporation, MD, USA) has been recently introduced as an 'topical' analgesic for localized musculoskeletal pain. PainGear is a noninvasive, low power, easy to use, pulsed shortwave therapy device for localized musculo¬skeletal pain.
224179943|NCT02316652|PROCEDURE|Scaling and root planing|Mechanical instrumentation
224179944|NCT02316652|PROCEDURE|Scaling and root planing with solution|Mechanical instrumentation with sodium hypochlorite disinfective solution
224307394|NCT02185716|DRUG|Levobupivacaine 0.25 %|
224307395|NCT02185716|DRUG|Levobupivacaine 0.5%|
224307396|NCT03271450|DRUG|Dabigatran: extended treatment (e.g at least 90 days)|90 days
224307397|NCT03271450|DRUG|Dabigatran: extended treatment (e.g at least 180 days)|180 days
224307398|NCT03271450|DRUG|Dabigatran: extended treatment (e.g at least 270 days)|270 days
224307399|NCT03271450|DRUG|Apixaban: extended treatment (e.g at least 90 days)|90 days
224307400|NCT03271450|DRUG|Apixaban: extended treatment (e.g at least 180 days)|180 days
224307401|NCT03271450|DRUG|Apixaban: extended treatment (e.g at least 270 days)|270 days
224307402|NCT03271450|DRUG|Rivaroxaban: extended treatment (e.g at least 90 days)|90 days
224307403|NCT03271450|DRUG|Rivaroxaban: extended treatment (e.g at least 180 days)|180 days
224307404|NCT03271450|DRUG|Rivaroxaban: extended treatment (e.g at least 270 days)|270 days
224307405|NCT03271450|DRUG|Edoxaban: extended treatment (e.g at least 90 days)|90 days
224307406|NCT03271450|DRUG|Edoxaban: extended treatment (e.g at least 180 days)|180 days
224307407|NCT03271450|DRUG|Edoxaban: extended treatment (e.g at least 270 days)|270 days
223587326|NCT03316950|DEVICE|DiVA|DiVA device utilizes a hybrid fractional laser technology in a wand hand piece. The hand piece is covered by a single use strengthened quartz dilator that allows the hand piece to rotate and provide treatment in a uniform manner.
224073185|NCT03847701|OTHER|Balanced diet high in Slowly Digestible Starch|The carbohydrates present in high Slowly Digestible Starch diet were selected according to the general recommendations made for diabetics and according to their SDS content. The diet will be consumed during three months.
224073186|NCT03847701|OTHER|Balanced diet low in Slowly Digestible Starch|The carbohydrates present in low-Slowly Digestible Starch diet were selected according to the general recommendations made for diabetics and according to their SDS content. The diet will be consumed during three months.
224073187|NCT04464980|DRUG|SL-BUP|Daily dosing of sublingual buprenorphine-naloxone
224073188|NCT04464980|DRUG|XR-BUP|Weekly/monthly dosing of extended-release injectable buprenorphine
224073189|NCT04464980|DRUG|XR-NTX|Monthly dosing of extended-release injectable naltrexone
224073190|NCT04464980|BEHAVIORAL|MM|MM consists of standard Medical Management and the usual counseling at the treatment program.
224073191|NCT04464980|BEHAVIORAL|MMR|MMR consists of Medical Management and usual counseling, plus a technology-based behavioral component.
224073192|NCT04464980|BEHAVIORAL|MMD|MMD consists of Medical Management and usual counseling, plus a technology-based behavioral component.
224073193|NCT00538720|DRUG|Vitamin D|Starting dose 50,000 IU by mouth 3 times weekly for three weeks (+/- one week), then 50,000 IU twice weekly for 6 weeks (+/- one week).
224073194|NCT00538720|DEVICE|Four-dimensional computed tomography (4DCT)|Four-dimensional computed tomography (4DCT) scan of the neck.
224073195|NCT00476879|DRUG|Somatropin and pegvisomant|Somatropin are given intravenous, 0.5mg pegvisomant are given subcutaneous, 15 mg NaCl are given subcutaneous, 2 ml
224073196|NCT06057363|OTHER|volumetric evaluation of gingival augmentation around dental implants|objective volumetric and clinical assesment of vestibular gingival soft tissues changes upon treatment with laser-aided pouch roll augmentation technique and implant placement over a 12-month follow-up
224073197|NCT01450423|BEHAVIORAL|Physical activity|Participation in a 10-week supervised cardio exercise program two-three times a week. Each training session consists of 10 minutes of warm-up, 20 minutes treadmill run/walk and 30 minutes cycling. Heart rate (HR) is monitored during each session. Week 1-5: at least 15 minutes above 75% of HRmax in each session. Week 6-10: at least one session above 75% HRmax.
224073198|NCT06390332|BEHAVIORAL|Giving Information for Trauma Support and Safety (GIFTSS) Training|Training for college health center staff and clinicians on GIFTSS intervention which is a universal education and brief counseling to address sexual violence prevention and intervention.
224073199|NCT06390332|BEHAVIORAL|Centering gender Affirming Resources in higher Education (CARE) Learning Modules|Training for college health center clinicians and staff on trans and gender diverse (TGD) affirming clinical practices in addition to sexual violence and alcohol abuse prevention that is inclusive of TGD service users
224073200|NCT04899687|DRUG|Fluoxetine|Fluoxetine 20mg (or previously prescribed dose) will be taken once daily by mouth for 8 weeks
224073201|NCT04899687|DRUG|Dextromethorphan|Dextromethorphan, an over-the-counter cough suppressant, will be taken by mouth twice daily for four weeks of the study, starting at 15mg per dose, and increasing weekly as tolerated to a maximum of 60mg per dose.
224073202|NCT05142826|BEHAVIORAL|Relative Age Effect Intervention|School-based consultation to establish a developmentally appropriate daily behavior report; teacher education regarding developmentally appropriate behaviors; teacher consultation to promote positive behavior supports.
224073203|NCT05142826|OTHER|School as Usual|Interventions and supports as provided through usual care
224073204|NCT05513456|BEHAVIORAL|Randomization to a different factors in the case descriptions|The case descriptions will include factors like age, co-morbid status and acute physiological parameters; but the factor of sex/gender will be randomized. Moreover, randomization to case description of typical vs non-typical national name will be done.
224073205|NCT01627899|DEVICE|One Touch VerioIQ Blood Glucose Monitor|BGM with pattern alert technology and with associated pattern guide
224073206|NCT05693896|BEHAVIORAL|Centering Appetite|A digital treatment of Appetite Awareness Treatment (AAT) and behavioral weight loss treatment (BWL) over 6 months, delivered remotely using Zoom. The goal of AAT is to enable participants to be able to relearn their stomach's hunger signals and begin to obey and monitor functions of satiety. AAT has been successful in helping participants diagnosed with Binge Eating Disorder (BED) and bulimia nervosa reduce binge eating, overeating, urges to eat in response to non-appetite stimuli, and prevent weight gain.
224073207|NCT04770779|DRUG|Placebo Matching Mitapivat|Tablets
224073208|NCT04770779|DRUG|Mitapivat|Tablets
224073209|NCT05271513|DEVICE|non invasive repetitive magnetic stimulation (real Transcranial + real trans-spinal )|repetitive transcranial magnetic stimulation and trans-spinal magnetic stimulation
224073210|NCT05271513|DEVICE|non invasive repetitive magnetic stimulation (real Transcranial + sham trans-spinal )sham trans-spinal magnetic stimulation|sham trans-spinal magnetic stimulation
224073211|NCT01489592|DRUG|curcuma longa|oral administration of 6 grams of curcumin
224073212|NCT04519801|OTHER|Blood Flow Restriction (BFR) therapy|BFR therapy beginning after first MD follow up appointment after ACL reconstruction with quadriceps tendon autograft and the following functional criteria have been met: 1.) incisions healing or healed without signs of infection or dehiscence. 2.) ROM to at least 90 degree flexion. 3.) Able to perform unilateral weight bearing for 5 seconds. 4.) Pain under control and minimal knee effusion.
224179945|NCT00646347|OTHER|Conventional upper limb stroke rehabilitation|"Patient will be given a ten weeks conventional upper limb therapy. 3 sessions will be provided weekly in the first 4 weeks and 2 therapy sessions will be provided weekly in the subsequent 6 weeks. Patients will receive half an hour of conventional therapy in each session.~Patient will be taught to carry out two and half hours conventional self practice exercise daily for a period of ten weeks."
224179946|NCT00646347|DEVICE|Neuro Hand Orthosis Program (NHOP)|"The NHO is based on a design of dynamic hand orthosis for orthopaedic patients after hand surgery. We use it to support CVA patient's wrist and finger to perform grasping to transport an object (ball) from place to place to achieve the follows;~1. NHO can assist stroke patients to experience successful hand grasping with an object and produce voluntary movement from their paralytic arm. This successful experience will positively reinforce the patient to continue to use their paralytic arm and change the patient's behavior and perception in the arm usage.~2. The NHO Program is able to engage patients to perform their exercises and activities by themselves independently with the effect of intensive therapy.~The intervention (NHOP) group will receive same treatment intensity as the control group but with a Neuro Hand Orthosis."
224179947|NCT00820313|BEHAVIORAL|Dr. Dean Ornish Program for Reversing Heart Disease|"Exercise: At least 3 hours of aerobic exercise per week, 30 minutes per session. Additionally, patients are asked to perform a minimum of 2 strength training sessions per week.~Stress Management: Integrates stretching, relaxation, breathing techniques, meditation and guided imagery. Patients are asked to practice these techniques at least 1 hour per day.~Diet: Approximately 10% daily calories from fat, 15% protein and 75% complex carbohydrates (low-fat, whole foods, primarily plant-based).~Group Support: Weekly group support sessions provide social support to help patients adhere to and sustain the lifestyle-change program."
224179948|NCT01183572|DIETARY_SUPPLEMENT|Multivitamins, Folic Acid, and Iron|Daily oral dose containing 2500 IU Vitamin A, 1.4 mg Vitamin B1, 1.4 mg Vitamin B2, 2.6 mg Vitamin B12, 1.9 mg Vitamin B6, 18 mg Niacin, 70 mg Vitamin C, 14.9 IU Vitamin E, 30 mg elemental iron, 0.4 mg folic acid
224179949|NCT01183572|DIETARY_SUPPLEMENT|Folic Acid and Iron|Daily oral dose of 30 mg elemental iron, 0.4 mg folic acid
224179950|NCT01183572|DIETARY_SUPPLEMENT|Folic Acid|Daily oral dose of 0.4 mg folic acid
224179951|NCT03856749|OTHER|Remote wheelchair skills training|"Prior to the first training session, the trainer will be provided with the results from the assessment immediately preceding training to provide him/her time to individualize the training session. Trainer will provide self-study materials (the Caregiver Handbook and caregiver-training video-recording) and an explanation on how these materials should be used.~The wheelchair user and caregiver will be trained together on wheelchair skills, using the principles of the Wheelchair Skills Training Program, as outlined in the Wheelchair Skills Program Manual using remote technology. Each training session will be with a trainer-to-dyad ratio of 1:1 1 dyad = 1 manual wheelchair user + his/her caregiver. Training will continue until the goals have been met and retained (for at least one subsequent session), using up to 4 training sessions that will each last up to 60 minutes at intervals a minimum of 3 days."
224179952|NCT04333875|DEVICE|TAVR or SAVR|Patients with critical aortic stenosis as defined by an AVA \<0.6 cm2 or a transvalvular mean gradient of \>60 mmHg or a history of cardiac decompensation during the previous 3 months or clinical symptoms on minimal exertion (NYHA III) will be allocated to TAVR or SAVR.
224179953|NCT03252262|OTHER|Vitalize 360|A comprehensive geriatric assessment system and wellness coaching program.
224179954|NCT05648006|BIOLOGICAL|OH2|Oncolytic Type 2 Herpes Simplex Virus
224179955|NCT05648006|DRUG|Capecitabine|1000 mg/m2, orally administered twice a day, D1 to D14, repeated every 3 weeks
224179956|NCT05648006|DRUG|Bevacizumab|Bevacizumab: 7.5 mg/kg, intravenously, once every 3 weeks.
224179957|NCT05914233|DEVICE|Non-invasive ultrasound retinal stimulation Device|Record user feelings during the device is working
224179958|NCT06318000|OTHER|Balance test, bilateral coordination test, fundamental motor skills test|Functional assessment
224179959|NCT02295254|OTHER|feces sample|The travelers will give feces sample before and after the travel. The sample microorganisms will be analyzed.
224179960|NCT02065479|DRUG|Prasugrel|Comparison of platelet reactivity between prasugrel and ticagrelor
224179961|NCT02065479|DRUG|Ticagrelor|Comparison of platelet reactivity between prasugrel and ticagrelor
224179962|NCT00001925|DRUG|Alcohol|
224179963|NCT04454281|DRUG|Naloxone Hydrochloride 0.4 MG/ML|Drug will be topically applied to the corneal surface then study evaluations will ensue.
224179964|NCT01122992|PROCEDURE|Limbal relaxing incision|
224179965|NCT06356649|PROCEDURE|extubation|Complications after extubation
224179966|NCT05371249|DRUG|Vonoprazan-based triple therapy|vonoprazan 20mg+amoxicillin 1000 mg + clarithromycin 500 mg twice daily for seven days
224307408|NCT03271450|DRUG|Warfarin: extended treatment (e.g at least 90 days)|90 days
224179967|NCT05371249|DRUG|Extended sequential therapy|Lansoprazole 30mg + amoxicillin 1000mg twice daily for 7 days, followed by lansoprazole 30mg + clarithromycin 500mg + metronidazole 500mg twice daily for 7 days
224179968|NCT06033495|DEVICE|Coronary sinus reduction stent|Percutaneous stent implantation to reduce the dimension of the coronary sinus
224179969|NCT00799370|PROCEDURE|Early weight bearing|Weight bearing performed immediately after surgery
224179970|NCT00799370|PROCEDURE|Delayed weight bearing|Weight bearing performed 2 months after surgery
224179971|NCT01053806|DRUG|5-Azacytidine and Lenalidomide|Induction:5-Azacytidine 75mg/m2/d S.C.or I.V. days 1-5 every 28 days a cycle for 6 cycles and Lenalidomide 10mg/d orally days 6-28 every cycle for 6 cycles Consolidation: 5-Azacytidine 75mg/m2/d S.C.or I.V. days 1-5 every 28 days for 6 cycles Maintenance: Lenalidomide 10mg/d orally days 1-21 every cycle of 28 days for 13 cycles.
224179972|NCT04721275|OTHER|measurement of pronostic sepsis scores|qSOFA, NEWS and MEDS sores are measured to each patient admitted in the emergency department with a suspicion of infection (excluding localized infection as abscess, angina, cystitis).
224307409|NCT03271450|DRUG|Warfarin: extended treatment (e.g at least 180 days)|180 days
224307410|NCT03271450|DRUG|Warfarin: extended treatment (e.g at least 270 days)|270 days
224307411|NCT03450174|DIETARY_SUPPLEMENT|Placebo|In control group, participants will receive only a placebo product
224307412|NCT03450174|BEHAVIORAL|Formative messgaes|In this group, participants will only receive daily formative messages
224307413|NCT03450174|DIETARY_SUPPLEMENT|Fortified product|In this group, participants will receive fortified product on alternate day up till 8 months
224179973|NCT04828928|PROCEDURE|electromyogram|Patients meeting the criteria will be seen in consultation with standardized interview and clinical examination. An electromyogram will be then carried out to check for the presence of neuropathy. Finally, for patients diagnosed with neuropathy, a biological check-up to look for another cause of neuropathy will be performed. In patients who already had an EMG as part of their medical follow-up, the examination will not be repeated if it strictly meets the conditions of the minimum protocol and if it was done within the year prior to inclusion. In patients who already had an identical biological assessment in the year prior to inclusion, the sample will not be taken.
224179974|NCT00198510|DRUG|Vitrase|7.5 IU of Vitrase
224179975|NCT00198510|DRUG|Vitrase|55 IU of Vitrase
224179976|NCT00198510|DRUG|Vitrase|75 IU of Vitrase
224179977|NCT00561028|OTHER|blood sample analysis - mycoplasma and chlamydia antibodies|Anti-Chlamydia and anti-Mycoplasma IgG antibodies were measured by indirect immunofluorescence at baseline (24 hours of hospitalization) and after 6 months (follow-up).
224179978|NCT06094686|DIAGNOSTIC_TEST|epicardial adipose tissue thickness|EATT measured via transthoracic echocardiography
224179979|NCT02698917|OTHER|Low normal PaCO2|4.5-4.7 kPa
224179980|NCT02698917|OTHER|High normal PaCO2|5.8-6.0 kPa
224307414|NCT03450174|COMBINATION_PRODUCT|Fortified product plus|In this group participants will receive fortified product on alternate day and formative messages up till 8 months
224307415|NCT03283319|BIOLOGICAL|3.75 ug Panblok H7|0.5 mL recombinant Panblok H7 influenza vaccine antigen 15 ug/mL.
224307416|NCT03283319|BIOLOGICAL|7.5 ug Panblok H7|Mix 0.5 mL recombinant Panblok H7 influenza vaccine antigen 30 ug/mL.
223587327|NCT03316950|DEVICE|Placebo (DIVA/IntraGen combined)|"(DIVA/IntraGen combined) IntraGen RF: IntraGen is a radiofrequency vaginal rejuvenation device FDA approved for use in dermatological and general surgical procedures for electrocoagulation and hemostasis. The hand piece is a disposable monopolar applicator that is used to apply energy internally and externally.~DiVA: DiVA device utilizes a hybrid fractional laser technology in a wand hand piece. The hand piece is covered by a single use strengthened quartz dilator that allows the hand piece to rotate and provide treatment in a uniform manner."
224179981|NCT02698917|OTHER|Low normal PaO2|10-15 kPa
224179982|NCT02698917|OTHER|High normal PaO2|20-25 kPa
224179983|NCT02698917|OTHER|Low normal MAP|65-75 mmHg
224179984|NCT02698917|OTHER|High normal MAP|80-100 mmHg
224179985|NCT04796454|DRUG|Cisplatin|Cisplatin IV 25 mg/m² on d1 and d8 - always combined with Gemcitabine; maximum treatment 2 years
224179986|NCT04796454|DRUG|Gemcitabine|Gemcitabine IV 1000 mg/m² on d1 and d8 if in combination with Cisplatin; Gemcitabine IV 1000 mg/m² on d1 and d15 if in combination with Oxaliplatin; maximum treatment 2 years
224179987|NCT04796454|DRUG|Oxaliplatin|Oxaliplatin IV 100 mg/m² on d1 and d15 - always combined with Gemcitabine; maximum treatment 2 years
224179988|NCT04796454|DRUG|Pamiparib|Pamiparib 60 mg PO twice a day from d1 to day28 in a 4-week cycle - always combined with Temozolomide; until progression or maximum treatment 2 years
224179989|NCT04796454|DRUG|Temozolomide|Temozolomide 60 mg PO once a day from d1 to d7 in a 4-week cycle - always combined with Pamiparib; until progression or maximum treatment 2 years
224179990|NCT05506306|OTHER|Assessment|Clinical, biological and imagery before and after 6 weeks of using AtalanteTM exoskeleton
224179991|NCT03822689|DEVICE|Ventilator breathing tube F2220|M: Folding D: 22mm; L: 2.0M
224179992|NCT03822689|DEVICE|Ventilator breathing tube F2216|M: Folding; D: 22mm; L:1.6M
224307417|NCT03283319|BIOLOGICAL|15 ug Panblok H7|Mix 0.5 mL recombinant Panblok H7 influenza vaccine antigen 60 ug/mL.
224307418|NCT03283319|BIOLOGICAL|MF59|0.5 mL MF59 (39 mg squalene/mL ) adjuvant.
224307419|NCT03283319|BIOLOGICAL|AS03|0.5 mL AS03 (42.4 mg squalene/mL ) adjuvant.
224307420|NCT05261295|DIAGNOSTIC_TEST|PEEP|PEEP of 7 cmH2O will be applied 5 minutes after classical LMA or i-gel insertion.
224307421|NCT05261295|DIAGNOSTIC_TEST|ZEEP|PEEP of 0 cmH2O will be applied 5 minutes after classical LMA or i-gel insertion.
224307422|NCT03958565|BIOLOGICAL|Tyrosine Kinase Inhibitor|Targeted therapy given as standard of care.
224307423|NCT03958565|DRUG|Zoledronic Acid 4 MG/100 ML Intravenous Solution [ZOMETA]|Given Q4 weeks as standard of care
224307424|NCT03958565|DRUG|Denosumab 120 MG/1.7 ML Subcutaneous Solution [XGEVA]|Given Q12 weeks for bone disease as standard of care
224307425|NCT04505748|DEVICE|Self-transfusion device|The Transfusion filter set for salvaged blood (Summit Medical Ltd, Gloucestershire, UK) has been randomly used in 20 patients postoperatively. Patients, who received autologous blood, transfused with the collected amount of blood, only once, 6h postoperatively
224307426|NCT02290301|DRUG|gemigliptin|
224307427|NCT03887494|DEVICE|Implantation|Implantation of Y-Strut + cementoplasty in the femoral neck
224307428|NCT00224926|PROCEDURE|Scalp Brushing|sterile, soft-head toothbrush massaged on scalp
224307429|NCT05960812|PROCEDURE|skillful neglect Of upper subscapularis tear in Lafosse type 1 and type 2 with long head biceps tenotomy .|"The following technique will be utilized for confirm isolated or combined upper subscapularis border partial tear conservative treatment which is considered the standard technique.~* Semisetting position under GA.~* Standard shoulder arthroscopy with standard portals for RC repair.~* Inspection of articular surface of rotator cuff and biceps tendon.~* Bursectomy, visualization of all rotators.~* Mobilization is done for associated rotator tears by shaver and radiofrequency device.~* Both preoperative Statistics randomization that is used to determine which case will be repaired and intraoperative loss of tension of the elongated aspect of the tendon are used to confirm diagnosis and treatment of upper subscapularis border tear.~* Skillful neglect to the tear.~* Rotator repair technique by RC anchors~* Biceps Tenotomy will be done in all cases by cutting of LHBT."
224179993|NCT03822689|DEVICE|Ventilator breathing tube F1520|M: Folding; D: 15mm; L:2.0M
224179994|NCT03822689|DEVICE|Ventilator breathing tube F1516|M: Folding; D: 15mm; L:1.6M
224179995|NCT03822689|DEVICE|Ventilator breathing tube U1016|M: Unfolding; D: 10mm; L:1.6M
224179996|NCT03822689|DEVICE|Ventilator breathing tube U1516|M: Unfolding; D: 15mm; L:1.6M
223587328|NCT04628065|BEHAVIORAL|#BabyLetsMove|This intervention will use mobile phones to promote the adoption and maintenance of physical activity, exercise and reduced TV time among overweight or obese, Black, pregnant (\<16 weeks) adolescents (15 - 19 years) enrolled in Mississippi's WIC program.
224179997|NCT03822689|DEVICE|Ventilator breathing tube CA20|M: Co-axis; L:2.0M
224179998|NCT03822689|DEVICE|Ventilator breathing tube CA16|M: Co-axis; L:1.6M
224179999|NCT05937503|OTHER|manual therapy|The manual therapy group will receive a 4-week manual therapy plus conventionel physiotherapy.
224180000|NCT05937503|OTHER|conventional physiotherapy|Control group will only receive conventionel physiotherapy intervention.
224180001|NCT04879511|DRUG|metformin|Oral hypoglycemic drug metformin
224180002|NCT04879511|DRUG|Basal/bolus insulin|Basal/bolus insulin
224180003|NCT03453593|OTHER|No intervention|No intervention
224180004|NCT01842191|DIETARY_SUPPLEMENT|Fish Oil|Patients received 4g/day Omega Rx capsules (Dr. Sears zone diet) containing 0.8 g EPA and 1.6 g DHA and excipient (glycerin, water purified, tocopherol, sunflower oil and titanium dioxide), during 12 months.
224180005|NCT01842191|DIETARY_SUPPLEMENT|Placebo|Orally, 4 Capsules per day, (glycerin, water purified, tocopherol, sunflower oil and titanium dioxide), during 12 months.
224180006|NCT03192228|OTHER|Treatment adequacy score|Evaluation of the program rate of success rate by a score evaluating the different criteria that the patient was supposed to modify following the therapeutic education program: practice of a physical activity, reduction of the amount of fat in Diet, practice of self-monitoring blood sugar as a motivational tool and decreased distress related to diabetes
224180007|NCT03775473|DIAGNOSTIC_TEST|progastrin|PROCODE is an interventional study of category 2 (non-medicinal product), with a minimal risks and restrictions, involving only one blood drawn at the screening of colon cancer.
224307430|NCT05960812|PROCEDURE|arthroscopic repair Of upper subscapularis tear in Lafosse type 1 and type 2 with long head biceps tenotomy .|"The following technique will be utilized for confirm isolated or combined upper subscapularis border partial tear repair which is considered the standard technique.~* Semisetting position under GA.~* Standard shoulder arthroscopy with standard portals for RC repair.~* Inspection of articular surface of rotator cuff and biceps tendon.~* Bursectomy, visualization of all rotators.~* Mobilization is done for associated rotator tears by shaver and radiofrequency device.~* Both preoperative Statistics randomization that is used to determine which case will be repaired and intraoperative loss of tension of the elongated aspect of the tendon are used to confirm diagnosis and treatment of upper subscapularis border tear.~* Skillful neglect to the tear.~* Rotator repair technique by RC anchors~* Biceps Tenotomy will be done in all cases by cutting of LHBT."
224307431|NCT00792935|DRUG|MK-0941|MK-0941 will be taken three times a day (TID), within 15 minutes before each meal. MK-0941 will be titrated to a maximally effective dose. The treatment period will be 6 weeks.
224307432|NCT00792935|DRUG|Glimepiride|Glimepiride will be taken once a day (QD) in the morning, within 15 minutes before the breakfast meal. Glimepiride will be titrated to a maximally effective dose. The treatment period is 6 weeks.
224307433|NCT00792935|DRUG|Metformin|The study will include an up to 4-week metformin dose titration/dose stabilization period. Once a participant has reached the maximum tolerated dose of metformin \[(i.e., ≥1500 mg/day and ≤2550 mg/day (or ≤3000 mg/day, where the maximum dose of metformin per the local label is 3000 mg/day)\], the participant should remain on the same metformin dose throughout the study.
224307434|NCT03186781|BIOLOGICAL|VRC-FLUNPF081-00-VP (HA-F A/Sing)|VRC-FLUNPF081-00-VP (HA-F A/Sing) is an investigational influenza HA ferritin vaccine.
224307435|NCT03186781|BIOLOGICAL|VRC-FLUDNA082-00-VP (DNA A/Sing)|VRC-FLUDNA082-00-VP (DNA A/Sing) is an investigational influenza plasmid DNA vaccine.
224307436|NCT04111055|DEVICE|Closed-loop system|the CLV system will correct hypotension by automated adjustment of norepinephrine.
224307437|NCT04663295|DEVICE|MiniMed™ 670G system|Hybrid closed loop insulin pump with associated CGM and blood glucose meter
223587329|NCT06464965|BIOLOGICAL|CB CAR-NK182|To study the maximum tolerated dose (MTD) and dose-dependent toxicity (DLT) of cord blood-derived CAR-NK cells (CB CAR-NK182) targeting Claudin18.2 in patients with advanced gastric cancer and advanced pancreatic cancer
224180008|NCT05807646|OTHER|Vein ligation first|During this procedure, patients undergo laparoscopic rectal cancer surgery with the inferior mesenteric vein ligated first.
224180009|NCT05807646|OTHER|Artery ligation first|During this procedure, patients undergo laparoscopic rectal cancer surgery with the inferior mesenteric artery ligated first.
224180010|NCT03727802|DRUG|TRK-250|single and multiple doses (4 weeks)
224180011|NCT03727802|DRUG|Placebo|single and multiple doses (4 weeks)
224180012|NCT03955211|DRUG|HTX-011|300 mg
224180013|NCT03955211|DRUG|HTX-011|400 mg
224180014|NCT03955211|DEVICE|Luer Lock Applicator|Applicator for instillation.
224180015|NCT03955211|DRUG|Ibuprofen|400 mg
224180016|NCT03955211|DRUG|Acetaminophen|975 mg to 1 g
224180017|NCT01830829|DRUG|Jalyn|study drug
224180018|NCT01830829|DRUG|Placebo|Placebo
224180019|NCT02961049|PROCEDURE|Gingival displacement|Gingival displacement with a gingival cord (#0, #00 or #000) with specific spatula.
224180020|NCT02961049|PROCEDURE|Enamel and dentin etched|Enamel and dentin etched with 35% phosphoric acid for 30 and 15 seconds, respectively.
224180021|NCT02961049|PROCEDURE|Selective enamel etched|Selective enamel etched with 35% phosphoric acid for 15 seconds.
224180022|NCT02961049|PROCEDURE|Wash and dry|Wash and dry with absorbent paper.
224180023|NCT02961049|DEVICE|Total-etch adhesive system|Two layers of pirmer/bond on enamel and dentin with a brush.
224180024|NCT02961049|DEVICE|self-conditioning adhesive system|One layer of acid/pirmer on enamel and dentin with a brush following to one layer of bond with a brush.
224180025|NCT02961049|PROCEDURE|Photoactivated|Photoactivated for 20 seconds
224180026|NCT05656131|DRUG|Fluzoparib|Arms A will be treated with fluzoparib alone
224180027|NCT05656131|DRUG|Fluzoparib+Camrelizumab|Arms B will be treated with fluzoparib in combination with camrelizumab
224180028|NCT05837429|BEHAVIORAL|Low Volume High Intensity Exercise Training|Patients in the intervention group will be given a warm-up phase for 3 minutes at 50% VO2max, 1 minute at 80-100% VO2max and 1 minute at 50% VO2max in 10 cycles, and finally a cool-down phase for 3 minutes at 50% VO2max.
224180029|NCT05837429|BEHAVIORAL|Aerobic Exercise Training|Patients in the control group will be given exercise training on a bicycle ergometer for 5 minutes warm-up phase at 40% of maximal oxygen consumption (VO2max), 20 minutes exercise phase at 60% of VO2max and 5 minutes cool down phase at 40% of VO2max for a total of 30 minutes.
223587330|NCT06438796|DRUG|Blinatumomab|Maintenance therapy with Blinatumomab initiation: 90 days to 120 days post-transplantation
224180030|NCT05454631|DEVICE|surgical mask (5 different types)|All the participants will wear 5 different types of surgical mask, in random order.
224180031|NCT03754842|OTHER|Placebo (twice daily)|Matching placebo
224180032|NCT03754842|OTHER|Nicotinamide Riboside/Pterostilbene (500 mg/100 mg twice daily)|Elysium Basis TM, Elysium Health, Inc., NY, USA
224180033|NCT01161433|BEHAVIORAL|Virtually delivered spirometry quality improvement program|"Sites in the intervention arm receive the virtually delivered QI program.~The program includes:~1. Spirometry Fundamentals™ CD-ROM, a computer-based CD-ROM training program that teaches primary care providers and their staff techniques required to perform high-quality spirometry tests, and proper interpretation of spirometric data;~2. Case-based, interactive webinars; and~3. an Internet-based spirometry quality feedback reporting system."
224180034|NCT04851769|DRUG|PCSK9 inhibitor plus statin|Patients in the alirocumab arm will receive alirocumab 75 mg Q2W added to statin therapy (atorvastatin 20 mg/day or rosuvastatin 10mg/day).
224180035|NCT04851769|DRUG|standard statin therapy|Patients will continue to receive atorvastatin 20 mg/day or rosuvastatin 10 mg/day.
224180036|NCT04851769|PROCEDURE|Coronary imaging follow-up|coronary angiography and OCT imaging at week 36 ± 2 weeks follow-up
224180037|NCT00992615|PROCEDURE|prostate biopsy|prostate cores - 12 or 20
224180038|NCT00004236|DRUG|pegylated liposomal doxorubicin hydrochloride|
224180039|NCT01351415|DRUG|Bevacizumab|Participants will receive bevacizumab 7.5 or 15 milligrams per kilogram (mg/kg) intravenously.
224180040|NCT01351415|DRUG|Docetaxel|Docetaxel 60 or 75 milligram per meter square (mg/m\^2) on Day 1 every 21 days.
224180041|NCT01351415|DRUG|Erlotinib|Erlotinib 150 mg daily taken on an empty stomach at least one hour before or two hours after the ingestion of food.
223489344|NCT06129734|DRUG|Venetoclax|Venetoclax is a BCL2 inhibitor. It is administered at low doses and used in combination with other hypomethylating agents such as decitabine to manage participants with acute myeloid lymphoma who have undergone stem cell transplant. Participants will initiate therapy with decitabine that will be followed by venetoclax 400 mg oral 6-8 hours later. Participants will continue this dose each week. The venetoclax dose will be reduced to 100 mg once per week if the participant is being treated with posaconazole or voriconazole (strong CYP3A4 inhibitors) (considered dose equivalent to venetoclax 400 mg 1X/week). The venetoclax dose will be reduced 200 mg once per week if the participant is being treated with fluconazole or isavuconazole (moderate CYP3A4 inhibitors) (considered dose equivalent to venetoclax 400 mg 1X/week). This clinical trial is administering venetoclax well below the current FDA approved dosing.
223489345|NCT06129734|DRUG|Decitabine|Decitabine is a hypomethylating agent. It is administered at low doses and used in combination with venetoclax to manage participants with acute myeloid lymphoma who have undergone stem cell transplant. Participants initiate therapy with 5 mg/m2 decitabine subcutaneous every week followed by venetoclax.
223489346|NCT04657991|DRUG|Encorafenib|Encorafenib
223489347|NCT04657991|DRUG|Binimetinib|Binimetinib
223489348|NCT04657991|DRUG|Pembrolizumab|Pembrolizumab
223489349|NCT03776630|OTHER|Blood sample|"Two blood samples (2 tubes of 4 ml for each blood sample) will be collected per patient during the study period for EC and OC. One blood sample will be collected for control population. The first sample will be collected prior to any treatment for EC, OC, and control population.~For EC, the second collection will be done one month post-surgery. For OC, the second collection will be done 6 to 9 months after the initial diagnosis, in most cases at the completion of adjuvant chemotherapy. For control population, there will be no second sample."
223489350|NCT04765631|OTHER|Patients with Type 2 diabetes|No intervention
224180042|NCT01351415|DRUG|Pemetrexed|Pemetrexed 500 mg/m\^2 IV over 10 minutes on Day 1 every 21 days.
224180043|NCT03431415|PROCEDURE|Anatomical Segmentectomy, Lobectomy or Bilobectomy|Lung Cancer Anatomical Resection
224180044|NCT03431415|RADIATION|Stereotactic Body Radiation Therapy|SBRT treatment. 48Gy in 4 sessions for peripheral lesions and 50Gy in 5 sessions for central lesions.
224180045|NCT00294528|DEVICE|Nexgen LPS-flex and AGC|
224180046|NCT06093321|DEVICE|SYB PDO Thread|Apply the test device (SYB PDO Thread) and the control device (MINT lift®) with 7±1 lines on each side of the nasolabial fold.
224180047|NCT06093321|DEVICE|MINT lift®|Apply the test device (SYB PDO Thread) and the control device (MINT lift®) with 7±1 lines on each side of the nasolabial fold.
224180048|NCT02350660|DIETARY_SUPPLEMENT|cow's milk|daily consumption of cow's milk
223489351|NCT04765631|OTHER|Placebo|Placebo comparator
223489352|NCT05285527|DEVICE|MiSight 1 Day|Subjects will wear MiSight 1 day lenses for three years.
223489353|NCT02864992|DRUG|Tepotinib|Subjects will receive 500 milligram (mg) of tepotinib once daily in cycles of 21-day duration until disease progression, death, adverse event (AE) leading to discontinuation or withdrawal of consent.
223489354|NCT05139602|BIOLOGICAL|Lutikizumab|Subcutaneous Injection
223489355|NCT05139602|DRUG|Placebo|Subcutaneous Injection
223587331|NCT04382417|OTHER|Observational study|Not required
223587332|NCT01277315|DRUG|Anakinra|Open Safety and Tolerability study to evaluate a subcutaneous application 100 mg of Anakinra in combination with Riluzol in Amyotrophic Lateral Sclerosis.
223587333|NCT03665116|DIETARY_SUPPLEMENT|L-arginine|L-arginine capsule
223587334|NCT04890015|PROCEDURE|Intraoperative transanal decompression tube placement|Intraoperatively under direct vision in the lower rectum, the balloon of the catheter will be inflated with 5-10cc of distilled water and it will be secured with a dressing / tape to the buttock connected to a collection bag.
224180049|NCT02350660|DIETARY_SUPPLEMENT|peanut powder|peanut oral immunotherapy
224180050|NCT04422951|BEHAVIORAL|Wise interventions -- values self-affirmation and growth mindset -- plus usual care behavioral treatment|Addition of two wise wise social psychological interventions-growth mindset and self-affirmation-to a 6-month usual care behavioral intervention for weight control in children with obesity
224180051|NCT04422951|BEHAVIORAL|Education plus usual care behavioral treatment|6-month health education plus usual care behavioral intervention for weight control in children with obesity
224180052|NCT03140150|DEVICE|Follow-up by Carelink express|Followed by the cardiologist exclusively using Carelink Express during the study period: a single visit 1 to 3 months after implantation, then followed by the cardiologist and interrogation of the stimulator by Carelink Express
224180053|NCT03140150|OTHER|Follow-up according to the usual recommendations|According to follow-up recommendations for pacemakers, a visit is planned every 6 months if the patient is dependent on the stimulator (either visits to M6, M12, M18 and M24) or annually if the patient is not dependent on the stimulator (visits to M12 and M24).
224180054|NCT02180854|OTHER|Control group|
224180055|NCT02180854|OTHER|Increased monitoring frequency|
224180056|NCT05136326|RADIATION|External-beam radiation|External-beam radiation 50.4 GY (45 Gy in 25 fractions + Boost 5.4 Gy in 3 fractions over 5 weeks)
224180057|NCT05136326|DRUG|Capecitabine|825 mg/sqm/bid per os (p.o.) 5 days/week for 5 weeks;
224180058|NCT05136326|DRUG|Temozolomide|75 mg/sqm p.o. 5 days/week for 5 weeks
224180059|NCT02363699|DRUG|Lidocaine|Lidocaine was administered in bolus of 1.5 mg.kg-1 at the start of the procedure and maintained at a dose of 3 mg.kg-1.h-1 until one hour after the end of the procedure. Solution of 0,3% lidocaine was used, so that the infusion rate was equal to the weight of the patient.
224180060|NCT02363699|DRUG|Saline solution|Saline solution was administered in bolus of 1.5 mg.kg-1 at the start of the procedure and maintained at a dose of 3 mg.kg-1.h-1 until one hour after the end of the procedure.
224180061|NCT02260609|OTHER|Grafix®|"The treatment indication is for complex diabetic foot wounds with exposed tendon and/or bone that can accommodate up to three 5cm x 5cm pieces of Grafix®.~Patients will be treated for up to 16 weeks.~Patients will be evaluated at screening and then weekly throughout the study or until wound closure."
224180062|NCT04118127|DRUG|2mg conventional tablet, once-weekly tablets|In each cohort, subjects will receive a brexpiprazole 2 mg conventional tablet on Day 1of Period 1, the QW formulation on Day 1 of Period 2 and 3, as single and multiple dose in a fasted state.
224180063|NCT02254694|OTHER|high heeled shoes|see detailed study description
224180064|NCT04955236|DRUG|Partial scalp block|"Partial scalp blocks will be performed bilaterally after assuming the prone position.The Greater occipital will be blocked by injecting 3ml of local anaesthetic at a point half way between the mastoid process the external occipital protuberance along the superior nuchal line, medial to the occipital artery. The Lesser occipital nerve will be blocked by injecting 3ml of local anaesthetic infiltration along the superior nuchal line, 2.5 cm lateral to the greater occipital nerve block. The greater occipital nerve block also will cover the third occipital nerve due to the close location of the two nerves.~A placebo infusion (normal saline) will be administered at the same rate as fentanyl infusion in the active comparator arm(1 µg/kg/hr.)."
224180065|NCT04955236|DRUG|Fentanyl|1µg/kg/hr. of intravenous fentanyl infusion will be administered. A syringe filled with 20 ml of normal saline will be prepared and 3 ml of normal saline will be injected at the same points of the partial scalp block previously described
224180066|NCT02798159|DRUG|TD0025|
224180067|NCT02798159|DRUG|Sildenafil Citrate 50mg|
224180068|NCT02961153|OTHER|death|
224180069|NCT02800096|BEHAVIORAL|Gambling Internet intervention|The gambling Internet intervention consists of a new online version of self-change tools that have previously been translated successfully into an online form and shown to have a significant impact on gambling in three trials. A major focus of this intervention is to provide individuals with clear and concise behavioral and cognitive strategies for meeting the goal of reducing or quitting gambling.
224180070|NCT02800096|BEHAVIORAL|MoodGYM|Internet intervention for depression and anxiety - MoodGYM, an extensively evaluated intervention found to be effective in a variety of different settings.
224180071|NCT04856293|DRUG|Crizotinib|A single 250 mg crizotinib dose of the FC formulation
224307438|NCT03168581|DRUG|CN-105|Patients with supratentorial intracerebral hemorrhage (ICH) will be evaluated for eligibility within 12 hours of symptom onset. Eligible participants will receive CN-105 administered intravenously (IV) for a 30 -minute infusion every 6 hours for up to a maximum of 3 days (13 doses) or until discharge (if earlier than 3 days)
224307439|NCT03925350|DRUG|Niraparib|300 mg PO daily
224307440|NCT03996135|DEVICE|Cannulation with AccuVein AV400|Cannulation using AccuVein AV400 device
224307441|NCT03665441|DRUG|eryaspase|L-asparaginase encapsulated in erythrocytes (red blood cells)
224307442|NCT03665441|DRUG|Gemcitabine plus Abraxane|gemcitabine, Abraxane
224307443|NCT03665441|DRUG|Irinotecan plus 5-FU plus leucovorin|irinotecan, 5-FU, leucovorin
224307444|NCT01600690|OTHER|Statin withdrawal|Patients are instructed to stop taking statin pills for the duration of the study. The rest of therapy will remain unchanged.
224307445|NCT03335449|OTHER|Protective ventilation group|Application of a protective ventilation strategy in order to improve gas exchange and respiratory mechanics during Robotic surgery in deep Trendelenburg position.
224307446|NCT04953936|DIETARY_SUPPLEMENT|HMB-enriched Nutritional Supplements|The participants will receive oral HMB-enriched nutritional supplements (65 g, once daily), which include soybean isolate protein, flaxseed oil powder, yam powder, whey protein, oligomeric isomaltose powder, cocoa powder, medium-chain fatty acid powder, calcium beta-hydroxy-beta-methylbutyrate, sunflower seed oil powder, L-glutamine, wheat germ powder, membrane isolated casein, wheat oligopeptide, konjac flour, vitamin E, vitamin D, stevioside, edible flavors.
224307447|NCT04953936|DIETARY_SUPPLEMENT|Placebo|Placebo (maltodextrin 65 g once daily) with the same package as the intervention.
224307448|NCT04953936|BEHAVIORAL|Caloric Restrition Diet|Caloric restriction diet with individualized nutritional guidance from professional dietitians by video regarding caloric restriction strategies
224307449|NCT04125849|PROCEDURE|Thoraco-laparoscopic esophagectomy|Thoraco-laparoscopic esophagectomy surgery
224307450|NCT04125849|PROCEDURE|Mediastinoscopy-assisted transhiatal esophagectomy|Mediastinoscopy-assisted transhiatal esophagectomy surgery
224307451|NCT05783830|DRUG|ACD856|IV injection 100 mcg
224307452|NCT06634342|DIAGNOSTIC_TEST|HCV RNA Rapid testing|Participants will receive point-of-care hepatitis C RNA testing using the GeneXpert IV Xpress System technology.
224180072|NCT04856293|DRUG|Crizotinib|A single 250 mg crizotinib dose of the encapsulated microsphere (eMS) formulation administered by sprinkling the contents into a dry glass vial
224180073|NCT04856293|DRUG|Crizotinib|A single 250 mg crizotinib dose of the single 250 mg crizotinib dose of the encapsulated microsphere (eMS) formulation (administered as intact capsules) . The intact capsules will be swallowed whole.
224180074|NCT00154674|DEVICE|ICY catheter, Thermoguard device|
224180075|NCT01639846|DRUG|RX-10045|RX-10045 Ophthalmic Solution, 0.09% At Visits 3A and 4, a trained study technician will instill one drop of the assigned, masked study treatment, into each eye.
224180076|NCT01639846|DRUG|Vehicle for RX-10045 arm|Vehicle of RX-10045 Ophthalmic Solution At Visits 3A and 4, a trained study technician will instill one drop of the assigned, masked study treatment, into each eye.
224180077|NCT04131504|DRUG|Infliximab|No standard dosing regimen will be used and the dose will be determined by the treating physician
224180078|NCT04131504|DRUG|Adalimumab|No standard dosing regimen will be used and the dose will be determined by the treating physician
224180079|NCT03341091|OTHER|Tai-chi group|The Tai-chi group received a 16-week 10-step simplified Tai-chi training programme in which additional measures were implemented to enhance participants' engagement.
224180080|NCT00660816|DRUG|erlotinib hydrochloride|Given orally once daily on days 2-19.
224180081|NCT00660816|DRUG|pemetrexed disodium|Given IV over 10 minutes on day 1
224180082|NCT00660816|DRUG|docetaxel|IV over 60 minutes on day 1.
224180083|NCT03400202|DEVICE|Skin imaging|Non-invasive in vivo skin imaging will be taken with the VivoSight Ox Optical Coherence Tomography (OCT).
224180084|NCT03400202|OTHER|Facial cleanser|Facial cleanser prior to procedures.
224307453|NCT05930457|DRUG|2.5-3.5mCi 64Cu-FAPI-XT117|64Cu-FAPI-XT117 and 18F-FDG PET/CT were performed for each patient(the interval was more than one day and less than four weeks). PET/CT images were acquired 30min, 60min, 120min after 2.5-3.5mCi 64Cu-FAPI-XT117 injection.
224307454|NCT05930457|DRUG|3.5-4.5mCi 64Cu-FAPI-XT117|64Cu-FAPI-XT117 and 18F-FDG PET/CT were performed for each patient(the interval was more than one day and less than four weeks). PET/CT images were acquired 30min, 60min, 120min after 3.5-4.5mCi 64Cu-FAPI-XT117 injection.
224307455|NCT05930457|DRUG|4.5-5.5mCi 64Cu-FAPI-XT117|64Cu-FAPI-XT117 and 18F-FDG PET/CT were performed for each patient(the interval was more than one day and less than four weeks). PET/CT images were acquired 30min, 60min, 120min after 4.5-5.5mCi 64Cu-FAPI-XT117 injection.
223489356|NCT05018221|DRUG|Vitamin K1|Vitamin K1 capsule (10mg) to be administered 3 times per week following the subject's hemodialysis session.
223489357|NCT05018221|DRUG|Magnesium citrate|Magnesium Citrate tablet (150mg) to be administered 3 times per per day. On dialysis days, administration of the middle daily dose should occur following the subject's hemodialysis session.
223489358|NCT05018221|DRUG|Sodium Thiosulfate|Sodium Thiosulfate injection (25g/100ml) to be administered intravenously 3 times per week, during the subject's last hour of hemodialysis.
224180085|NCT05184868|DRUG|AT247|Ultra rapid acting prandial insulin aspart
224180086|NCT05184868|DRUG|NovoLog|Rapid acting prandial insulin aspart
223489359|NCT05018221|DEVICE|High Flux Dialyser|Hemodialysis using a high flux dialyser.
224180087|NCT05184868|DRUG|Fiasp|Fast acting prandial insulin aspart
224180088|NCT04192552|OTHER|PAUSE Perioperative DOAC Management|"Apixaban \& Rivaroxaban: Hold DOAC for 2 days before procedure. Re-start DOAC 2+ days post-procedure.~Dabigatran (see below):~CrCl ≥50: Hold DOAC for 2 days before procedure. Re-start DOAC 2+ days post-procedure.~CrCl \<50: Hold DOAC for 4 days before procedure. Re-start DOAC 2+ days post-procedure."
224180089|NCT04192552|OTHER|ASRA Perioperative DOAC Management|"Apixaban \& Rivaroxaban: Hold DOAC for 3 days before procedure. Re-start DOAC 1+ days post-procedure.~Dabigatran (see below):~CrCl \>80: Hold DOAC for 3 days before procedure. Re-start DOAC 1+ days post-procedure.~CrCl 50-80: Hold DOAC for 4 days before procedure. Re-start DOAC 1+ days post-procedure.~CrCl 30-49: Hold DOAC for 5 days before procedure. Re-start DOAC 1+ days post-procedure.~\*Low-dose heparin bridging can be used if at high A-TE risk"
224180090|NCT02122302|DEVICE|CarePrep Online Health Assessment|Patients can utilize a web-based self-assessment system to answer questions that address medical, psychological, social, behavioral, and quality-of-life issues that are relevant to pancreatic disease. Patients can enter and track their symptoms over the Internet from home or clinic. The system is also designed to gather clues to identify neuropathic pain, which occurs when the nervous system fails to properly regulate pain signals.
223489360|NCT05018221|DEVICE|Medium Cut-off Dialyser|Hemodialysis using a medium cut-off dialyser.
224307456|NCT01038440|DIETARY_SUPPLEMENT|Safflower Oil|One softgel consumed daily with food
224307457|NCT01038440|DIETARY_SUPPLEMENT|EPA|Three different doses of EPA (0.5, 1.5 and 3.0 g/d) consumed with food daily.Subjects consuming more than 1 softgel/day (as in the groups with 1.5 and 3.0 g/d) are instructed to consume the softgels in 2 or 3 separate servings.
223489361|NCT05018221|DRUG|Placebo injection (normal saline)|Placebo to be administered intravenously 3 times per week, during the subject's last hour of hemodialysis.
223489362|NCT05018221|DRUG|Placebo capsule (Vitamin K1)|Placebo to be administered 3 times per week following the subject's hemodialysis session.
223489363|NCT05018221|DRUG|Placebo tablet (Magnesium citrate)|Placebo to be administered 3 times per day. On dialysis days, administration of the middle daily dose should occur following the subject's hemodialysis session.
224307458|NCT01038440|DIETARY_SUPPLEMENT|SDA|Four different doses of SDA (0.5, 1.5, 3.0 and 6.0 g/d) consumed with food daily.Subjects consuming more than 1 softgel/day (as in the groups with 1.5 and 3.0 g/d) are instructed to consume the softgels in 2 or 3 separate servings.
224307459|NCT02051400|DEVICE|the McGrath® MAC video laryngoscope|
224307460|NCT02051400|DEVICE|the GlidesScope® Ranger video laryngoscope|
223489364|NCT03785366|DRUG|VeraCept|VeraCept Intrauterine Device (IUD)
223489365|NCT03785366|DRUG|ParaGard|ParaGard intrauterine copper contraceptive
223489366|NCT06340633|DRUG|Ebselen|Glutathione peroxidase mimetic
224180091|NCT01466309|DEVICE|Somnoguard oral appliances|wearing somnogaurd daily at bedtime
224180092|NCT02132416|DRUG|NSAID|Will be used if tolerated.
224307461|NCT02051400|DEVICE|the Macintosh laryngoscope|
224307462|NCT02101593|DRUG|ADI-PEG 20|
224307463|NCT05471492|DRUG|Investigational Product|PF-06480605 150 mg
224307464|NCT05471492|DRUG|Placebo|Placebo
223587335|NCT00521664|BIOLOGICAL|Prophylactic platelet transfusion|In the PP arm platelet transfusion has to be performed when platelet count is below 10.000/µL in any case and when bleeding (more than petechial) occurs.
223587336|NCT00521664|BIOLOGICAL|Therapeutic platelet transfusion|In the TP arm platelet transfusion is only required if bleeding occurs (more than petechial)or in case of pulmonary infections with or without sepsis.
223587337|NCT06245538|BEHAVIORAL|Seated rest|Participants will be resting while seated on a comfortable chair for 20 minutes
223587338|NCT06245538|BEHAVIORAL|Exercise at moderate intensity|Participants will perform a 20-min leg cycling exercise on a cycle ergometer at moderate intensity (60% of VO2max)
223587339|NCT06245538|BEHAVIORAL|Exercise at vigorous intensity|Participants will perform a 20-min leg cycling exercise on a cycle ergometer at vigorous intensity (80% of VO2max)
224073213|NCT04519801|OTHER|Standard REHAB|Standard post-operative rehabilitation regimen (REHAB) beginning after first MD follow up appointment ACL reconstruction with quadriceps tendon autograft and the following functional criteria have been met: 1.) incisions healing or healed without signs of infection or dehiscence. 2.) ROM to at least 90 degree flexion. 3.) Able to perform unilateral weight bearing for 5 seconds. 4.) Pain under control and minimal knee effusion
224073214|NCT03692052|DRUG|AG-348|AG-348 tablet orally BID
223489367|NCT06340633|DRUG|Placebo|Matching placebo containing excipients
223489368|NCT05467215|DRUG|Pure oxygen (99%) from Praxair, Edmonton, DIN# 02014408|Participants will receive oxygen (99%) or room air (placebo) delivered through a face mask at a flow rate of 10 litres/min for 2 minutes. The participants will be exposed twice to both conditions over 4 experiments at a minimum of 2 week intervals between each testing session.
223489369|NCT01962415|DRUG|Hydroxyurea|Oral administration
223489370|NCT01962415|DRUG|Alemtuzumab|Intravenous (IV) administration.
223489371|NCT01962415|DRUG|Fludarabine|IV administration
223489372|NCT01962415|DRUG|Melphalan|IV administration
223489373|NCT01962415|DRUG|Thiotepa|IV administration
223489374|NCT05382091|DRUG|naltrexone implant|3.6 g per implant set each containing 60% naltrexone
223489375|NCT05763797|BEHAVIORAL|Individual Interview|"Group 1, participant will be in a supportive care program with other Black cancer patients in which you will practice meditation.~Group 2, participate will be in a supportive care program with other Black cancer patients that focuses on coping with cancer.~Participants will be asked to participate weekly sessions for 4 weeks (that is a total of 4 sessions) and each session will last about 60 minutes. Both groups will be delivered via Zoom (a web-based videoconferencing service) and led by a master's-level interventionist."
223489376|NCT05763797|BEHAVIORAL|Meditation Exercise|"Group 1, participant will be in a supportive care program with other Black cancer patients in which you will practice meditation.~Group 2, participate will be in a supportive care program with other Black cancer patients that focuses on coping with cancer.~Participants will be asked to participate weekly sessions for 4 weeks (that is a total of 4 sessions) and each session will last about 60 minutes. Both groups will be delivered via Zoom (a web-based videoconferencing service) and led by a master's-level interventionist."
223489377|NCT04140656|OTHER|Plantar sensitive exercises|"Plantar sensitive exercises:~40 minutes / 3 days per week / 8 weeks Warm up exercise (5 minute) Walking on different 4 different textured floors and hot floor (15 minute) Trying to recognize small objects with the soles of the feet (5min) Seated work with barbed ball and balance pad (5min) Massage to the sole of the foot with different textured fabrics (5min) Cooling exercise (5 min)"
224073215|NCT05024097|DRUG|Etrumadenant (AB928)|Patients will receive a radiation therapy dose of 25Gy in 5 fractions in combination with etrumadenant 150 mg orally, once daily as part of a continuous dose regimen.
224073216|NCT05024097|RADIATION|Radiation therapy|Patients will receive a radiation therapy dose of 25Gy in 5fx
224073217|NCT05024097|DRUG|FOLFOX regimen|After completing the radiation therapy, patients will receive FOLFOX regimen for 9 cycles in combination with etrumadenant and zimberelimab. All patients will be offered adjuvant zimberelimab for up to one year.
223587340|NCT02149017|RADIATION|SNUBH-NM-333(18F)|5-10 mCi
223587341|NCT06398717|PROCEDURE|adductor canal block|"group C will receive a unilateral adductor canal block alone, using an ultrasound to identify the location of the nerve.~group H will receive unilateral peri-hamstring injection combined to adductor canal block, After the adductor canal block, the transducer will be moved posteriorly till identifying the site of injection group O will receive unilateral anterior obturator nerve block combined with adductor canal block, The anterior branch of the obturator nerve is located using ultrasound"
223587342|NCT05044624|PROCEDURE|retroperitoneal mass excision|retroperitoneal mass excision
223587343|NCT03782441|DEVICE|Prototype 0.5|Investigational Medical Device collecting spectral Raman data from tissue
223587344|NCT02335424|BIOLOGICAL|pembrolizumab|IV infusion
223587345|NCT03386409|BEHAVIORAL|Free safe firearm storage device distribution|Participants in the experimental phase of the study receive a safe firearm storage device at the time of study enrollment. They are randomized to receive a free device. Safe firearm storage devices include a California Department of Justice-approved lock box, trigger lock and/or cable lock.
223587346|NCT03386409|BEHAVIORAL|Low cost safe firearm storage device|Participants in the experimental phase of the study receive a safe firearm storage device at the time of study enrollment. They are randomized to receive a low cost ($5) device. Safe firearm storage devices include a California Department of Justice-approved lock box, trigger lock and/or cable lock.
224073218|NCT05024097|DRUG|Zimberelimab (AB122)|After completing the radiation therapy, patients will receive FOLFOX regimen for 9 cycles in combination with etrumadenant and zimberelimab. All patients will be offered adjuvant zimberelimab for up to one year.
224073219|NCT05766059|DEVICE|Transcranial Magnetic Stimulation|The standard PAS protocol will be compared with the mirrorPAS protocol.
224073220|NCT06329661|DRUG|Cyclosporine ophthalmic solution, 0.1%|Colorless and clear opthalmic solution containing 0.1% Cyclosporine
224073221|NCT06329661|DRUG|Saline solution, 0.6%|Colorless and clear sodium chloride solution (0.6%)
224073222|NCT05600309|BIOLOGICAL|favezelimab/pembrolizumab|Coformulated favezelimab/pembrolizumab (800 mg/200 mg), IV infusion
224073223|NCT05600309|DRUG|regorafenib|Oral
224073224|NCT05600309|DRUG|TAS-102|Oral
224073225|NCT06179186|DEVICE|Intense Pulsed Light|The axilla will be treated with intense pulsed light, being right or left, depending upon randomization.
224180093|NCT02132416|DRUG|Opioids|Initially intravenous administration and when tolerated oral slow-release pils will be used.
224180094|NCT02132416|DRUG|Thoracic Epidural anaesthesia|Given by specialists in anaesthesiology and intensive care.
223587347|NCT04316000|OTHER|Initial Anxiety and Fear of Cancer Test|Answer to Hospital Anxiety and Depression Scale (HADS), Cancer Worry Scale (CWS) and European Five-Dimension Quality of Live test (EuroQol-5D) before the initial endoscopic procedure.
223587348|NCT04316000|PROCEDURE|Endoscopic band ligation without resection of the subpetihelial tumour.|Correct application of the elastic band in the subepithelial tumor, achieving its removal by self-amputation in the 4-6 weeks endoscopic ultrasonography (EUS) control.
223489378|NCT04140656|OTHER|Textured insole|"Textured insole group.~Plantar sensitive exercises with insole 40 minutes / 3 days per week / 8 weeks (all exercises will be done with insoles) Warm up exercise (5 minute) Walking on flat ground (15 minute) Exercise with roller under the sole of the foot (5 minute) Seated work with barbed balance pad (5 min) Dorsi flexion and plantar flexion and hip flexion exercises (5min). Cooling exercise (5 min)"
223745413|NCT07190612|DRUG|ketamine and propofol|Ketamine infusion syringe (50mls): will be filled with 2mls of ketamine (100mg) diluted in 48mls 0.9% normal saline to make a final volume of 50mls to reach a final ketamine concentration of 2mg/ml. It will be administered as a bolus dose of 0.25 mg/kg iv then infused at a rate of 0.25mg/kg/hr. Propofol infusion syringe (50mls): will be filled with 20mls of 1% propofol (200mg) diluted in 30mls 0.9% normal saline to make a final volume of 50mls and a final propofol concentration of 4mg/ml. It will be iv administered as 0.5 mg/kg slow iv for 10 minutes, then infused at a rate of 0.5mg/kg/hr.
223745414|NCT07189858|DEVICE|Nasal antimicrobial photodisinfection therapy|The Steriwave Nasal Photodisinfection System is applied using a photosensitizer in the nose followed by 2-minutes of light with nasal illuminators. The application is repeated a second time for total treatment time of 5-minutes.
223745415|NCT07189741|PROCEDURE|hemodialysis|Three times a week.
224180095|NCT02132416|DRUG|Paracetamol|1g QID will be given to all patients unless allergies.
224180096|NCT02132416|PROCEDURE|Surgical management|Fracture stabilization
223489379|NCT05884203|DEVICE|Caregiver socket|A prosthetic socket whose shape was captured by a study helper using digital methods (i.e., 3D scanner). The digital file describing the socket dimensions will be sent to a central fabrication facility where the prosthetic socket will be manufactured.
223489380|NCT05884203|DEVICE|Prosthetist socket|A prosthetic socket whose shape was captured by a prosthetist using traditional, hand casting methods. The hand cast will be plaster filled to create a positive model. A prosthetist socket will be fabricated over the positive model using thermoplastic materials.
223489381|NCT05568719|DIAGNOSTIC_TEST|Testing of hepatic AAV Vector integration|Evaluation of AAV vector integration in participants for whom a sample of liver has been obtained through biopsy or surgical resection when clinically indicated
223489382|NCT05621733|OTHER|ruxolitinib|Prospective observational study. There is no treatment allocation. Patients prescribed with ruxolitinib in the commercial setting are eligible to enroll into this study.
223489383|NCT06391918|BIOLOGICAL|GEN2 + Valganciclovir|Gene therapy vector product
223489384|NCT05477069|DEVICE|Innovative medical device for sampling small intestine content|Ingestion of the medical device by the volunteer
223489385|NCT03240874|BEHAVIORAL|SweetMama Focus Groups|Focus groups will assess tool functionality, design, interpretability, and acceptability (initial reaction, attitude, and receptiveness) of SweetMama via qualitative interviewing. The group format will generate feedback on areas that may not be revealed in a one-on-one interview.
223489386|NCT03240874|BEHAVIORAL|SweetMama Individual Testing|"Women will be oriented to SweetMama use on their own Android- or Apple-based phones. The goals of this phase are to collect data from diverse users that will (1) confirm that the mobile apps are functioning (not crashing) across a wide range of devices and operating systems, (2) provide basic information about app usage and user satisfaction (3) inform the development of future iterations by analyzing participant characteristics and use, and (4) collect quality assurance data that will allow the research team to refine the applications. Women will use SweetMama for 2 weeks, engage in periodic check-ins with the research assistant, and participate in a semi-structured interview upon completion of SweetMama usage."
223587349|NCT04316000|OTHER|1-2 Months Anxiety and Fear of Cancer Test|Answer to Hospital Anxiety and Depression Scale (HADS), Cancer Worry Scale (CWS) and European Five-Dimension Quality of Live test (EuroQol-5D) after 1-2 months of the initial endoscopic procedure, knowing whether the tumor has either been removed or not, is a benign entity or has not been observed.
224180097|NCT00379873|DEVICE|ProAdjuster|
224180098|NCT05004389|DIAGNOSTIC_TEST|MRI|white matter integrity and brain structural connectivity metrics
224180099|NCT05004389|DIAGNOSTIC_TEST|blood draw|post-stroke serum/plasma levels of BDNF, VEGF, IL-6, IL-10, CRP, TNFalpha, MMPs, IGF-1, cGP
224180100|NCT05004389|OTHER|Clinical assessments|measures of strength, balance, and mobility
223587350|NCT04316000|OTHER|1 Year Anxiety and Fear of Cancer Test|Answer to Hospital Anxiety and Depression Scale (HADS), Cancer Worry Scale (CWS) and European Five-Dimension Quality of Live test (EuroQol-5D) after 1 year of the initial endoscopic procedure, knowing whether the tumor has either been removed or not.
223587351|NCT04322825|DEVICE|TENS incorporated into the Mollii suit|trans cutaneous electric stimulation,
223587352|NCT01779635|DEVICE|oXiris as first filter|2 arms - each start off CRRT with either oXiris or M150 as first hemofilter, and then do cross-over to either hemofilters in a sequential manner when the former clots
223587353|NCT01779635|DEVICE|M150 as first filter|start off with M150 as first hemofilter, then cross-over to oXiris when former clots, and then to M150, and then lastly to oXiris
224180101|NCT01641341|DRUG|Bifidobacterium infantis|once a day for seven to eight weeks
223745416|NCT07190742|DRUG|TVAX-008|TVAX-008
223745417|NCT07190742|DRUG|Placebo|Placebo
224180102|NCT01641341|DRUG|Pancrelipase|Pancrelipase (one capsule prior to meals or snacks)
224180103|NCT01641341|DRUG|Nitazoxanide|Nitazoxanide (500mg twice a day for 7 days)
224180104|NCT01641341|DRUG|Placebo|Placebo capsule will not contain active treatment ingredients.
224180105|NCT00520091|DRUG|CPT- 11|65mg/m2 given on days 1, 8 ,22 and 29 prior to surgery
224180106|NCT00520091|DRUG|Cisplatin|Cisplatin 30mg/m2 will be administered on days 1, 8, 22 and 29 prior to surgery
224180107|NCT00520091|DRUG|Celecoxib|400 mg, orally, twice per day beginning on day minus 3 and continue until the end of chemoradiation with CPT-11 and Cisplatin
224180108|NCT00520091|RADIATION|Radiation|4,500 cGy in 180 cGy fractions 5 days per week, over a period of 5 weeks
224180109|NCT00520091|PROCEDURE|Surgery|Surgery will occur prior to chemoradiation therapy for those patients with resectable disease
224180110|NCT03088332|PROCEDURE|Endoscopic gastroplasty|Vertical endoscopic gastroplasty
224180111|NCT00417391|DRUG|RR110 (Tamibarotene)|1 mg RR110
224180112|NCT00417391|DRUG|RR110 (Tamibarotene)|4 mg RR110
224180113|NCT05178680|OTHER|relaxation session combining music and soft light|The caregiver will install a device consisting of a light bubble column, a multicolored light projector, and relaxing music chosen by the patient from a proposed panel. This session will last 30 minutes the day after the surgery
224180114|NCT02621008|OTHER|Stress Reduction& Healthy living|Utilizing a stress reduction app (Serenita) and lifestyle intervention App (NewMe) and obtaining the NewMe guideline for healthy living, plus obtaining periodic messages regarding healthy living.
224180115|NCT01646255|DRUG|Rotigotine|"Transdermal Patch~Content:~4 mg /24 h (20 cm\^2), 6 mg /24 h (30 cm\^2), 8 mg /24 h (40 cm\^2)~For advanced-stage Parkinson's Disease, subjects received Rotigotine patches in escalating weekly dose (starting with daily doses 4 mg/24 h to 16 mg/24 h) for a maximum 7-week Titration Period, then 12 week maintenance period"
224180116|NCT01646255|DRUG|Placebo Patch|"Transdermal Patch~Size:~20 cm\^2, 30 cm\^2, 40 cm\^2~Subjects randomized to placebo received matching placebo patches"
224180117|NCT01646255|DRUG|L-dopa|Subject must be on a stable dose of L-dopa (either short-acting or sustained release \[in combination with benserazide or carbidopa\]) of at least 200 mg/day, administered in at least 2 intakes, for at least 28 days prior to Baseline.
224180118|NCT05734703|DRUG|Nutraceutical Topical|Once daily application of the topical nutraceutical to two by two inch area of skin for 90 days.
224180119|NCT03212209|DEVICE|CPAP Fixed Pressure|Continuous positive airway pressure (CPAP) is the gold standard treatment for moderate and severe OSA, and it has been known to apply positive pressure in the upper airways, acting as a pneumatic splint preventing the upper airway collapse during sleep. CPAP C- Flex Plus by Philips - Respironics works just as CPAP Fixed Pressure, but increases the pressure delivered in the begining of inhalation to softens the breathing rhythm of the CPAP user. CPAP with SensAwake by Fisher and Paykel works just as CPAP fixed pressure but when the breathing pattern suggests that patient is awake, a prompt relief in pressure to the lowest most comfortable level is activated, like ramp feature.
224307465|NCT03659292|OTHER|GEA|Thoracic epidural catheterization will be performed and epidural anesthesia will be maintained with 0.25% ropivacaine during surgery. General anesthesia will be maintained with inhalation (sevoflurane) and muscle relaxants will be administered when considered necessary.
224307466|NCT03659292|OTHER|PCEA|Patient-controlled epidural analgesia (0.15% ropivacaine and 0.5ug/ml sufentanil infusion) will be provided after surgery.
224307467|NCT03659292|OTHER|GA|General anesthesia will be maintained with inhalation (sevoflurane) and sufentanil infusion, and muscle relaxants will be administered when considered necessary.
223587354|NCT02220751|DRUG|non-surgical periodontal therapy + systemic doxycycline|"A program of plaque control with dental prophylaxis and oral hygiene instruction, and the scaling and root planning sessions were included in the non-surgical periodontal therapy. The scaling and root planning was performed by the same operator using curettes and an ultrasonic device, and it was inspected for a second operator. Oral hygiene was reviewed after a week and after a month of periodontal disinfection, followed by dental prophylaxis.~Non-surgical periodontal therapy was associated with systemic doxycycline 100 mg/day, for two weeks after an initial dose of 200 mg, started on the day before the first scaling and root planning session. Patients of the PD group had no access to information about antibiotics administration to patients of the PD+DM group."
223587355|NCT02220751|PROCEDURE|Non-surgical periodontal therapy|A program of plaque control with dental prophylaxis and oral hygiene instruction, and the scaling and root planning sessions were included in the non-surgical periodontal therapy. The scaling and root planning was performed by the same operator using curettes and an ultrasonic device, and it was inspected for a second operator. Oral hygiene was reviewed after a week and after a month of periodontal disinfection, followed by dental prophylaxis.
223745418|NCT07189728|DIAGNOSTIC_TEST|MRI|The MagnaSafe-2 Registry is designed to determine the risks of MRI in patients with limited MRI access not previously addressed in peer-reviewed literature and to improve access for approximately 70% of whom are predicted to have a future clinical need for MRI.
224180120|NCT00001685|BIOLOGICAL|Immunodominant peptides from three melanoma antigens, MART-1, GP100 and tyrosinase|
224180121|NCT02807194|OTHER|spinal anesthesia|
224180122|NCT02807194|OTHER|general anesthesia|
224180123|NCT02807194|PROCEDURE|lumbar disc herniation|
224180124|NCT01261494|DRUG|GFT505 80mg|hard gelatin capsules dosed at 20mg,oral administration,4 capsules per day before breakfast
224180125|NCT01261494|DRUG|Placebo|hard gelatin capsules,oral administration,4 capsules per day before breakfast
224180126|NCT03042663|PROCEDURE|USG stellate ganglion block|After verification of proper needle position and aspiration to exclude vascular spread, 1mL of the injectate will be injected to see proper tissue spread as well as patient response. After one minute the remaining volume will be injected under real time ultrasound imaging.
224307468|NCT03659292|OTHER|PCIA|Patient-controlled intravenous analgesia (1ug/ml sufentanil) will be provided after surgery.
224307469|NCT02977312|DRUG|Imatinib|Observation of chronic myeloid leukemia (CML) patients in chronic phase (CP) treated with Cemivil
224307470|NCT06633081|DEVICE|handheld dynamometer|handheld dynamometer is a device that measure muscle strength
223587356|NCT04185415|DRUG|bepranemab|"bepranemab will be administered in a predefined dosage.~* Pharmaceutical Form: Solution for infusion~* Route of Administration: Intravenous"
223587357|NCT04185415|DRUG|Placebo|"* Pharmaceutical Form: Solution for infusion~* Concentration: 0.9% w/v sodium chloride aqueous solution~* Route of Administration: Intravenous"
223587358|NCT04946617|DRUG|undefined|Rinsing with mouthwashes
224180127|NCT03796923|OTHER|Early follow-up visit after discharge|Early follow-up visit and different degrees of specialized care after discharge
224180128|NCT03796923|OTHER|Comprehensive geriatric assessment (CGA)|Comprehensive geriatric assessment (CGA) during admission
224180129|NCT03796923|OTHER|Continued geriatric care|Continued specialized geriatric care after discharge
224307471|NCT04096755|DIAGNOSTIC_TEST|Procedure|serum and urine samples will be taken for analysis
223489387|NCT03240874|BEHAVIORAL|SweetMama Feasibility Testing - Pilot Randomized Trial|"Women will be oriented to SweetMama use on their own Android- or Apple-based phones. The goals of this phase are to collect data from diverse users that will determine acceptability, feasibility, and pilot procedures in anticipation of a fully powered randomized controlled trial. Women will use SweetMama from enrollment (early pregnancy) to up to 8 weeks postpartum, engage in periodic check-ins with the research assistant, and participate in surveys and a semi-structured interview upon completion of SweetMama usage."
223489388|NCT04235686|DRUG|Mydayis Extended-Release Capsule|Randomized, parallel - group, double-blind, placebo-controlled, flexible-dose adjunctive trial of MYDAYIS®
223489389|NCT04235686|DRUG|Placebo|Matching placebo
223489390|NCT05252702|DEVICE|Aveir DR Leadless Pacemaker System|Patients will undergo a dual chamber leadless pacemaker system implant wherein a leadless pacemaker will be implanted in the right ventricle and right atrium
223489391|NCT04153864|BEHAVIORAL|Brief Behavioral Activation Treatment|A manualized 6-8 session BA treatment delivered individually to each participant.
223489392|NCT05322005|PROCEDURE|partial meniscectomy|Arthroscopic procedure
223489393|NCT05322005|DEVICE|Condrotide® (polynucleotides gel: class III medical device)|Condrotide® Polynucleotide gel is a joint lubricating and viscosizing agent, given by intraarticular and intra-meniscal injection
223489394|NCT06271681|DRUG|21-valent pneumococcal conjugate vaccine|FDA approved pneumococcal vaccines 21 valent conjugate vaccine administered at enrollment
223489395|NCT05988528|DRUG|Mesalamine|Mesalamine, also known as 5-aminosalicylic acid (5-ASA), is a medication used to treat ulcerative colitis. It is usually used to induce or maintain remission of mildly to moderately active ulcerative colitis.
223489396|NCT05988528|DRUG|Nifuroxazide|Nifuroxazide is an oral antibiotic that has been approved as an effective antidiarrheal agent with no side effects in several gastrointestinal infections
223489397|NCT05706051|OTHER|posturography|posturography will be performed when diagnosis of ARHL, in need of hearing aid fitting, is done and after information and written approval from patient. Posturography is performed later when hearing aid fitting and 3months after hearing aid use
223489398|NCT05504967|DRUG|Oradexon|With a syringe aspirate 2.5 ml of a 5mg/ml dexamethasone solution, for a total of 12.5mg. Repeat the procedure with another syringe. 2 syringes must be prepared, one for each of the tonsil sites.
223489399|NCT05504967|DRUG|Ropivacaine|With a syringe aspirate 2.5 ml of a 7.5mg/ml dexamethasone solution, for a total of 18.75mg. Repeat the procedure with another syringe. 2 syringes must be prepared, one for each of the tonsil sites.
223489400|NCT05504967|DRUG|Saline solution|With a syringe, aspirate 2.5 ml of a 0.9% NaCl solution. Repeat the procedure with another syringe. 2 syringes must be prepared, one for each of the tonsil sites.
223587359|NCT01264614|BEHAVIORAL|Strengthening exercise|3 months of 3-5 times per week of low-intensity exercises using a chair and small weights
223587360|NCT02776033|DRUG|GSK2982772|GSK2982772 will be supplied as a white to almost white, round, film coated 30 mg oral tablets; two tablets to be taken in the morning and two in the evening, as directed for Cohort 1 and for Cohort 2 two tablets to be taken three times daily as directed.
223745419|NCT07189702|OTHER|Control|Regular Diet with Cancer-Related Wellness Education and Support
223745420|NCT07189702|OTHER|Whole Food, Plant-Based Diet with Behavioral Education and Support|Whole Food, Plant-Based Diet with Behavioral Education and Support
223745421|NCT07190924|BEHAVIORAL|12 week training|Anti-inflammatory and oxidative environment following 12-weeks of CF training by evaluating inflammatory markers and oxidative precursors in untrained participants
223587361|NCT02776033|DRUG|Placebo|Matching placebo will be supplied as a white to almost white, round film coated tablets; two tablets to be taken in the morning and two in the evening, as directed for Cohort 1 and for Cohort 2 two tablets to be taken three times daily as directed.
223587362|NCT00584571|PROCEDURE|Sensory Adaptation Training|This study will last for approximately 3 months and will include 4-6 clinic visits with each visit lasting 2 hours every week or every 2 weeks. At the beginning of each visit we will ask you about your health status and level of satisfaction of your bowel habits. We will then place the pencil-thick probe and balloon inside your rectum and attach it to the barostat device and a computer. We will increase and decrease the volumes of the balloon until the most pressure you can tolerate or a certain level of pressure as measured by the machine is reached, whichever occurs first. You will continue to keep stool diaries and pain diaries for 7 days before and after each visit.
223587363|NCT00584571|DRUG|Escitalopram Therapy|Escitalopram; 10 mg every day, orally.
223587364|NCT02792998|DRUG|IW-1701|IW-1701 Tablet
223587365|NCT02792998|DRUG|Placebo|Matching Placebo Tablet
223587366|NCT04788771|PROCEDURE|Tracheal intubation in laparoscopic extraperitoneal hernia repair|laryngeal mask airway in laparoscopic extraperitoneal hernia repair
224073226|NCT06179186|DEVICE|Diode Laser|The axilla will be treated with diode laser, being right or left, depending upon randomization.
224073227|NCT06545084|PROCEDURE|Leukocyte and Platelet Rich Fibrin|Leukocyte Platelet Rich Fibrin (L-PRF) is a collection of growth factors rich in proinflammatory cells that promote healing after dental surgery. A L-PRF clot is obtained by collecting blood from the subject, similar to a phlebotomist drawing blood via venipuncture. The blood samples are spun in a centrifuge using the recommended settings by the manufacture(1). The resultant product has separated the red blood cells from the L-PRF clot which is placed back into the subject to promote healing of the surgical site.
224073228|NCT06403761|DRUG|Semaglutide|Participants will receive once-weekly semaglutide subcutaneously.
224073229|NCT06403761|DRUG|Cagrilintide|Participants will receive once-weekly cagrilintide subcutaneously.
224073230|NCT06403761|DRUG|Placebo semaglutide|Participants will receive once-weekly placebo matched to semaglutide subcutaneously.
224073231|NCT06403761|DRUG|Placebo cagrilintide|Participants will receive once-weekly placebo matched to cagrilintide subcutaneously.
224073232|NCT04579588|BIOLOGICAL|Flu shot|All participants will receive a single shot of the flu vaccine
224073233|NCT06492070|OTHER|Best Practice|Undergo standard of care
224073234|NCT06492070|DRUG|Cilostazol|Given PO
224073235|NCT06492070|DEVICE|Cryocompression Therapy|Undergo cryocompression therapy
224073236|NCT06492070|DRUG|Paclitaxel|Given by infusion
224073237|NCT06492070|OTHER|Quality-of-Life Assessment|Ancillary studies
224180130|NCT03796923|OTHER|Possible follow-up visit from GP|Usual care: follow up visit from GP within one week after discharge
224180131|NCT05790915|COMBINATION_PRODUCT|Standardized interventions|Standardized interventions according organ dysfunction
224180132|NCT02740036|DEVICE|Hearing Aid (Successor of Phonak Audéo V90)|Successor of Phonak's Receiver-In-the-Canal (RIC) hearing aid Audéo V90.
224180133|NCT05232461|DRUG|PrimeC-ER 748 mg|PrimeC-ER is an extended release formulation of a fixed dose combination of ciprofloxacin and celecoxib
224180134|NCT05232461|DRUG|Ciprofloxacin 750 MG|Ciprofloxacin
224180135|NCT05232461|DRUG|Celecoxib 200mg|Celecoxib
224180136|NCT00198289|DRUG|Aurexis® (tefibazumab)|
224180137|NCT04844892|DEVICE|Lungpacer PROTECT Diaphragm Pacing Therapy|PROTECT diaphragm pacing therapy is intended to stimulate the diaphragm to preserve and improve inspiratory muscle strength in mechanically ventilated patients.
224180138|NCT00846911|DRUG|Moxifloxacin (Avelox, BAY12-8039)|Patients with acute exacerbation of chronic bronchitis for whom the physician decided to prescribe moxifloxacin
224180139|NCT00717561|DRUG|Avelox (Moxifloxacin, BAY12-8039)|IV therapy: every 24 hours, patients will be administered a 400 mg moxifloxacin infusion over 60 minutes. Oral therapy: patients will be administered a single moxifloxacin 400 mg tablet, every 24 hours
224180140|NCT00717561|DRUG|Ceftriaxone; Azithromycin; Amoxicilline/clavulanate; Clarithromycin|IV therapy: every 24 hours patients will be administered a 2 g ceftriaxone infusion over 30 minutes. Following the infusion with ceftriaxone, patients will be administered a 500 mg azithromycin infusion over 180 minutes.Oral therapy: every 8 hours patients will be administered a 1000 mg amoxicillin/clavulanic acid tablet. Every 12 hours patients will be administered a 500 mg clarithromycin tablet.
224180141|NCT01427829|BEHAVIORAL|Computer-assisted Psychosocial Risk Assessment (CaPRA)|The study intervention was a touch-screen self-assessment survey which eligible patients completed on a touch-screen iPad in Dari/Farsi language while waiting to see their medical practitioner. The Computer-assisted Psychosocial Risk Assessment (CaPRA) survey had questions on psychosocial risks (e.g., alcohol, tobacco and street drug use, sexual health, personal violence, post-traumatic stress disorder, depression, and food insecurity), cardiovascular risks (e.g., physical activity, weight, diabetes, and hypertension), road and home safety, stress buffers (e.g., coping and social support) and sociodemographics. The tool generated two tailored print-outs at the point of care. The recommendation sheet for patients summarized their disclosed risks in simple Dari/Farsi language along with contacts of relevant services. The risk-report for medical practitioner summarized patients' risks with possible referrals. This was attached to the medical chart prior to the consult.
223489401|NCT05052957|BIOLOGICAL|P140K-MGMT|Ex Vivo Cultured P140K MGMT CD34+ Cells. The transduced cells are a biological product and production is detailed in the Cellular Therapy Lab standard operating procedures and IND 14099
223489402|NCT05052957|DRUG|O6-benzylguanine|O6BG is a low molecular-weight purine analog which selectively and irreversibly inactivates the DNA-repair enzyme, O6- alkylguanine DNA-alkyltransferase.
223489403|NCT05052957|RADIATION|Photon Based Radiotherapy|Standard of care, photon-based radiotherapy (60Gy in 30 fractions) will be performed in both arms without concomitant TMZ between to 6 weeks post-operatively. Radiotherapy will be performed at UH-SCC.
223489404|NCT05052957|DRUG|temozolomide|Temozolomide is not directly active but undergoes rapid non-enzymatic conversion at physiologic pHto the reactive compoundMTIC. The cytotoxicity of MTIC is thought to be primarily due to alkylationof DNA. Alkylation (methylation) occurs mainly at the O6 and N7 positions of guanine
224073238|NCT05099107|DRUG|Salbutamol (as Salbutamol Sulfate) 2 Mg Oral Tablet|taken 3 times daily for 6 months
224073239|NCT05099107|DRUG|Salbutamol Only Product in Oral Dose Form|taken 3 times daily for 6 months
224180142|NCT04316780|OTHER|Retrospective observational study- no intervention to occur.|Subject data will be grouped based on the anti-fibrotic medication at the time of lung transplant listing eligibility and when medication was stopped relative to the transplant.
224073240|NCT06503172|BIOLOGICAL|Taiwanese whole grain job's tear (red job's tear)|300cc drink made from red job's tear, 2 bottle/day from week 0 to week 8
224073241|NCT06503172|BIOLOGICAL|White job's tear|300cc drink made from white job's tear, 2 bottle/day from week 0 to week 8
224073242|NCT02847130|OTHER|Informational Intervention|Participate in focus group
224073243|NCT02847130|OTHER|Interview|Undergo one-on-one interviews
224073244|NCT02847130|OTHER|Medical Chart Review|Review of medical chart
224073245|NCT02847130|OTHER|Questionnaire Administration|Ancillary studies
224073246|NCT06502171|DRUG|Cabozantinib Oral Tablet|"Cabozantinib will be taken once a day. It must be swallowed whole and not crushed and taken on an empty stomach. The dose will depend on when a participant enrolls on the study. First group will take 20 mg.~If participants are enrolled early in this study, they may receive doses that are lower than those who are enrolled later. Participants will be told what dose they will take when they start the study. Once a dose is started, the dose will not be increased. However, a dose can be reduced up to 2 times if a participant experience adverse events.~Cabozantinib may be taken simultaneously with selumetinib."
224073247|NCT06502171|DRUG|Selumetinib Oral Capsule|"Selumetinib will be taken twice a day, at least 6 hours apart. It must be swallowed whole and not crushed and taken on an empty stomach. The dose will depend on when a participant enrolls on the study. First group will take 15 mg twice a day.~If participants are enrolled early in this study, they may receive doses that are lower than those who are enrolled later. Participants will be told what dose they will take when they start the study. Once a dose is started, the dose will not be increased. However, a dose can be reduced up to 2 times if a participant experience adverse events."
224073248|NCT04261127|GENETIC|Genetic diagnosis (PMDA panel)|Blood samples for DNA study
224073249|NCT04261127|DIAGNOSTIC_TEST|Use of RADIAL algorithm|RADIAL card filling (contains clinical and biological data)
224180143|NCT04745065|BEHAVIORAL|Connect2BWell|Please see the description provided for arm 1.
224180144|NCT04297124|DRUG|CC-90009|0.6 mg \[ 14C\]-CC-90009 administered IV as a single dose
224180145|NCT04297124|RADIATION|[14C]|A single dose of \[ 14C\]-CC-90009 will contain approximately 2 µCi of radioactivity.
224180146|NCT04296721|BEHAVIORAL|Intensive weigh-loss program|Intervention group: Intensive weight-loss program: 0-3 months very low calorie diet, 15 days substituting three meals for low calorie shakes, from 15 to 120 days substituting 1 meal and from 120 days to 12 months on a low calorie diet while starting a progressive exercise programme. Recommendations for good sleep habits will be given. The program will be carried out through group and individual sessions with the hospital dietician. After 3 months: group sessions with a nurse in the basic area. Group sessions led by hospital dietician. From 3 to 12 months: group sessions led by primary care nurse.
224307472|NCT04354116|DEVICE|Rapid maxillary expansion|Palatal expanders of the HYRAX type, with bands on the first permanent molars will be used for patients in both groups. In the experimental group, the expander will be anchored mesially and bilaterally in mini-implants, in a technique known as rapid maxillary expansion assisted by mini-implants (MARPE). The control active group will be with conventional HYRAX expanders. The maxillary expansion protocol will be once a day for 2 weeks.
223489405|NCT05052957|DRUG|Filgrastim|Filgrastim is a 175 amino acid protein manufactured by recombinant DNA technology. Endogenous filgrastim is a glycoprotein produced by monocytes, fibroblasts, and endothelial cells, which regulates the production of neutrophils within the bone marrow.
223489406|NCT05052957|DRUG|carmustine|BCNU is a lipid soluble agent which has alkylating properties, plus an isocyanate metabolite which interferes with DNA and RNA synthesis.
223489407|NCT05111015|DEVICE|Concomitant Open Heart Surgical Ablation Procedures|AtriCure's Concomitant Open Heart Surgical Ablation Devices used for the treatment of Atrial Fibrillation.
223489408|NCT05111015|DEVICE|Hybrid (Convergent) Ablation Procedures|AtriCure's Hybrid (Convergent) Ablation Devices used for the treatment of Atrial Fibrillation.
223489409|NCT05111015|DEVICE|AtriCure Hybrid Totally Thoracoscopic Ablation Procedures|AtriCure's Hybrid Totally Thoracoscopic Surgical Ablation Devices used for the treatment of Atrial Fibrillation.
223489410|NCT05111015|DEVICE|AtriCure LAA Exclusion Procedures|AtriCure's LAA Exclusion Devices used to exclude the Left Atrial Appendage for the treatment of Atrial Fibrillation.
223489411|NCT06287385|DIETARY_SUPPLEMENT|Goat-milk Based Formula|Provided Goat-milk Based Formula for babies 1-2 years old
223489412|NCT05441917|DEVICE|Sanae method with LED|Sanae method (combination of therapies): Manual therapy, Carboxytherapy, and phototherapy.
223489413|NCT05441917|DEVICE|Sanae method with Radiofrecuency|Sanae method (combination of therapies): Manual therapy, Carboxytherapy, and radiofrequency.
223489414|NCT05385861|DRUG|nanoliposomal irinotecan plus carboplatin|"Dose in phase 1 cohort:~Dose level 1= nanoliposomal irinotecan 100 mg/m2 plus carboplatin AUC=4, intravenously both on day 1, q3wk~Dose level 0= nanoliposomal irinotecan 80 mg/m2 plus carboplatin AUC=4, intravenously both on day 1, q3wk~Dose level -1= nanoliposomal irinotecan 60 mg/m2 plus carboplatin AUC=4, intravenously both on day 1, q3wk~Carboplatin dose (mg) is calculated by the Calvert formula: AUC x (eGFR + 25). Cockcroft-Gault equation: eGFR (calculated Ccr)= \[(140-age) x weight x 0.85 (if female)\] / (72 x serum Cr). The maximum eGFR for dose calculation is 125 ml/min.~In Phase 2 Cohort Patients will be treated until disease progression, unacceptable toxicity or other condition meeting the treatment discontinuation criteria."
223489415|NCT05316935|DRUG|GnRHa|Gonadotropin-releasing hormone analogue, intramuscular injection of 3.75mg will be given every 4 weeks , and the maximum using courses will be 6.
223489416|NCT05316935|DRUG|Letrozole 2.5mg|2.5mg po qd and no more than 24 weeks
223489417|NCT05316935|DRUG|Diane-35|Periodic use. Patients will receive one pill po qd for 21 days, and next period should be started after 7 days.
223587367|NCT04159532|DIETARY_SUPPLEMENT|MAG-EPA/MAG-DHA|monoglyceride of eicosapentaenoic acid and docosahexaenoic acid in proportion of 460:200
223745422|NCT07190924|BEHAVIORAL|12 week training|Anti-inflammatory and oxidative environment following 12-weeks of resistance training by evaluating inflammatory markers and oxidative precursors in untrained participants
224180147|NCT04296721|BEHAVIORAL|Standard Dietary recommendations|Patients will be managed according to the usual recommendations: The common written diet (designed by a hospital nutritionist) and an exercise advice will be given according to patient age and level of activity, without any other assessment or additional visits.
223489418|NCT05316935|DRUG|MET|500mg po tid
223489419|NCT04891640|OTHER|Standard TNFi Therapy|Participants randomly assigned to this arm will continue taking their TNFi medication as currently prescribed.
223489420|NCT04891640|OTHER|TNFi fixed longer dosing intervals|"Participants randomly assigned to this arm will increase the time between TNFi medication doses.~* Adalimumab- from every 2 to 3 weeks~* Certolizumab- from every 2 to 4 weeks~* Etanercept- from every 1 to 2 weeks~* Golimumab- from every 4 to 6 weeks~* Infliximab- from baseline to baseline + 2 weeks"
223489421|NCT04891640|OTHER|Stop TNFi treatment|Participants randomly assigned to this arm will stop TNFi medication.
223489422|NCT06460116|BEHAVIORAL|School-Based Community Health Worker (SB-CHW) intervention|The school-based community health worker will support students with chronic poor attendance and their parent/guardian for a minimum of two 30-minute encounters focused on addressing social determinants needs, understanding the range/student encounter varies greatly due to the intensity of the social need(s) (e.g., crisis/noncrisis) and the number of needs being jointly addressed. The SB-CHW will build relationships across encounters and apply trauma-informed best practices.
223489423|NCT06460116|BEHAVIORAL|Enhanced Usual Care (EUC) Methods|The network of school-based health centers without school-based community health workers will receive reminders of the the existing online social services directory.
223587368|NCT04159532|DIETARY_SUPPLEMENT|TG-EPA/TG-DHA|Triglyceride of eicosapentaenoic acid and docosahexaenoic acid in proportion of 460:200
223587369|NCT04159532|DIETARY_SUPPLEMENT|EE-EPA/EE-DHA|Ethyl ester of eicosapentaenoic acid and docosahexaenoic acid in proportion of 460:200
223587370|NCT02712424|BIOLOGICAL|DAR-901|
223587371|NCT02712424|BIOLOGICAL|Sterile saline placebo|
223587372|NCT02355951|OTHER|blood draw|
223587373|NCT04033874|OTHER|kangaroo care|kangaroo care
223587374|NCT04033874|OTHER|holding on the mother's lap|holding on the mother's lap
223587375|NCT04033874|OTHER|white noise listening|white noise listening
223587376|NCT04033874|OTHER|ambient sound listening|ambient sound listening
224307473|NCT04354116|DEVICE|Maxillary Protraction|Protraction hooks will be projected around the upper canine area. In the experimental group (MARPE), the appliance will be anchored mesially and bilaterally in mini-implants. The control active group will be anchored with conventional HYRAX expanders. Both groups will be treated with maxillary protraction with a Petit-type face mask at night (12 hours a day).
223489424|NCT06123052|OTHER|Interview|"This is a descriptive qualitative study using semi-structured individual interviews. The interview will aim to collect more information about the patients' underlying motives that influence their ability or willingness to use IBD-CE. An interview guide has been developed for this purpose, based on topics derived from the Unified Theory of Acceptance and Use of Technology (UTAUT) model, the COM-B model for behavioural change and the model of positive health. This interview guide is divided into four sections, each introduced by an initial question. Subsequent follow-up questions will be formulated based on the patients' responses.~Furthermore, patient characteristics, disease characteristics, and socio-demographic data will be collected from the Electronic Medical Record (EMR). These data will provide insights into various aspects of the patients' profiles and are based on characteristics that seem to be determinants of technology acceptance and/or digital health literacy."
223745423|NCT07189637|OTHER|Face-to-face nutrition education|All participants will receive face-to-face nutrition education from specialist dietitians in accordance with the principles of nutrition for hypertension. Nutrition education will be provided through prepared brochures. The brochures will be given to participants as gifts. Nutrition education will cover topics such as hypertension and nutrition, nutrients, the importance of micronutrients, foods containing salt, reading labels, limiting salt consumption, healthy fat consumption, fibre consumption, water consumption, and healthy cooking methods.
223489425|NCT05666999|DEVICE|FibDex®|To monitor and compare the clinical performance and safety of the CE marked wound care product (FibDex®) when used according to its intended use for patients or individuals with split thickness skin graft (STSG) donor site wounds.
223489426|NCT05666999|DEVICE|Suprathel|To monitor and compare the clinical performance and safety of the CE marked wound care product (FibDex®) when used according to its intended use for patients or individuals with split thickness skin graft (STSG) donor site wounds.
223489427|NCT05666999|DEVICE|Aquacel Foam|To monitor and compare the clinical performance and safety of the CE marked wound care product (FibDex®) when used according to its intended use for patients or individuals with split thickness skin graft (STSG) donor site wounds.
223489428|NCT05717348|DRUG|ES014|ES014 is administered via intravenous infusion, once every 14 days, every 28 days as a treatment cycle for a maximum treatment duration per patient of 2 years.
223489429|NCT05847504|BEHAVIORAL|mSTARS|mSTARS combines inpatient cognitive-behavioral skills training and outpatient use of a mobile app encouraging application of acquired skills to real life situations.
223489430|NCT06493253|DIAGNOSTIC_TEST|Digital Pathology FibroNest Phenotypic Fibrosis Composite Score (Ph-FCS)|Biomarker name: FibroNest Phenotypic Fibrosis Composite Score Acronym: FibroNest Ph- FCS Type of Biomarker: Histologic based, Digital, Quantitative Image Analysis, Imaging modality Definition: A quantitative, normalized (no unit) and continuous composite
223489431|NCT05922202|OTHER|Assessment of cardiovascular events, cardiovascular mortality, all-cause mortality, and mortality due to COPD at 12 and 24 months|At 12 and 24 months of follow up, cardiovascular events (including hospital admissions), deaths due to cardiovascular disease, deaths due to all-cause, deaths due to COPD will be recorded in COPD outpatients group.
223489432|NCT04958707|OTHER|Information including knowledge and skills related to dementia patient care|The intervention will be administered to the participants via a smartphone app (Zalo app). Weekly, the investigator will post one of the eight topics identified in Phase 1 in the chat room. After posting the topic, one investigator will call the participants to ensure they read and understand the contents.
223489433|NCT04958707|OTHER|Usual care|Caregivers will be introduce to the website www.alzheimer.org to search for eligible information
223489434|NCT05239728|DRUG|Belzutifan|Three 40 mg tablets given as a single oral 120 mg dose.
223489435|NCT05239728|BIOLOGICAL|Pembrolizumab|400 mg via IV infusion
223489436|NCT05239728|DRUG|Placebo|Oral tablet
223489437|NCT03653338|BIOLOGICAL|CD3/CD19 depleted leukocytes|Negative selection for CD3+/CD19+ cells will be performed on the CliniMACS® depletion device.
224307474|NCT03954834|DRUG|Tirzepatide|Administered SC
223489438|NCT03653338|BIOLOGICAL|CD45RA depleted leukocytes|Negative selection for CD45RA will be performed on the CliniMACS® depletion device.
223489439|NCT03653338|DRUG|Hydroxyurea|Sickle Cell Disease Conditioning
223489440|NCT03653338|DRUG|Rituximab|Sickle Cell Disease Conditioning
223489441|NCT03653338|DRUG|Alemtuzumab|Sickle Cell Disease Conditioning
223489442|NCT03653338|DRUG|Fludarabine|Sickle Cell Disease Conditioning
223489443|NCT03653338|DRUG|Thiotepa|Sickle Cell Disease Conditioning
223489444|NCT04222751|DEVICE|Ankle Splint|Ankle splint will be slightly modified from the commercial form to include a pneumatic air cell secured under the forefoot below the splint's padded lining. This replaces the foam wedge provided by the manufacturer, allowing a gradual adjustment of the forefoot/toe region.
223489445|NCT04279522|DEVICE|Relivion®DP- Active|Relivion®DP- Active stimulation device
223489446|NCT04279522|DEVICE|Relivion®DP- Sham|Relivion®DP- Sham stimulation device
223489447|NCT04938830|BIOLOGICAL|Clesrovimab|IM injection
223489448|NCT04938830|BIOLOGICAL|Palivizumab|IM injection
223489449|NCT04938830|BIOLOGICAL|Placebo|IM injection
223489450|NCT02282969|BEHAVIORAL|Interviews|Interviews performed by study staff encompassing lung cancer screening and patient decision aids.
223489451|NCT02282969|BEHAVIORAL|Questionnaires|Questionnaires completed after viewing patient decision aid video. Questionnaires also completed regarding lung cancer screening knowledge at first visit, then again in one month.
224073250|NCT04158648|DRUG|Emicizumab|Four loading doses of emicizumab 3 milligrams per kilogram of body weight (mg/kg) will be administered subcutaneously (SC) once a week (QW) for 4 weeks followed by participant's preference of one of the three following maintenance SC dose regimens: 1.5 mg/kg QW, 3 mg/kg once every 2 weeks (Q2W), or 6 mg/kg once every 4 weeks (Q4W).
224307475|NCT03954834|DRUG|Placebo|Administered SC
223489452|NCT04698967|BEHAVIORAL|Purposeful Pathways|Purposeful Pathways is a manualized intervention to assist veterans in aspiring and pursuing meaningful employment. Purposeful Pathways is an individual counseling protocol delivered weekly for up to 12 sessions (50 minutes per session) focused on career exploration, goal clarity, job-searching, and self-regulation.
223489453|NCT04698967|BEHAVIORAL|Transitional Work Experience|Provides Veterans with immediate access to a non-competitive, paid job contracted by the VA. Positions are typically housed within a VA hospital (e.g., housekeeping, grounds, kitchens, and construction), but are sometimes located in the community. TWE is time-limited. TWE is staffed by vocational rehabilitation specialists (VRS).
223489454|NCT04587830|DRUG|ADI-PEG 20|Investigational Medicine
223489455|NCT04587830|DRUG|Temozolomide|Radiotherapy and TMZ are standard front-line therapy for newly diagnosed GBM.
223489456|NCT04587830|DRUG|Placebo|Investigational Medicine
223489457|NCT05470920|BEHAVIORAL|Electronic Decision Aid|Decision aid followed by an appointment with an oncologist. Will complete surveys/questionnaires
223489458|NCT05470920|BEHAVIORAL|Pre-Test Genetic Counseling|Receive pretest counseling with a genetic counselor. Will complete surveys/questionnaires
223489459|NCT04447222|OTHER|Quality-of-Life Assessment|Ancillary studies
223489460|NCT04447222|OTHER|Questionnaire Administration|Ancillary studies
223489461|NCT04447222|OTHER|Survey Administration|Complete survey
224073251|NCT04209855|DRUG|Mirvetuximab Soravtansine|Mirvetuximab Soravtansine will be administered per dose and schedule specified in the arm.
224073252|NCT04209855|DRUG|Paclitaxel|Paclitaxel will be administered per dose and schedule specified in the arm.
224073253|NCT04209855|DRUG|Topotecan|Topotecan will be administered per dose and schedule specified in the arm.
224073254|NCT04209855|DRUG|Pegylated liposomal doxorubicin|Pegylated liposomal doxorubicin will be administered per dose and schedule specified in the arm.
224073255|NCT06443606|DRUG|Bezafibrate 400 mg in addition to UDCA therapy|"* Bezafibrate 400 mg and Placebo of Bezafibrate 200 mg in addition to continued UDCA at minimum dose of 12 mg/kg/d.~* Duration 96 weeks bezfibrate/ UDCA = daily oral dose."
224073256|NCT06443606|DRUG|Bezafibrate 200 mg in addition to UDCA therapy|"* Bezafibrate 200 mg and Placebo of Bezafibrate 400 mg in addition to continued UDCA at minimum dose of 12 mg/kg/d.~* Duration 96 weeks bezfibrate/ UDCA = daily oral dose."
224073257|NCT06443606|DRUG|Placebo in addition to UDCA therapy|"* Placebo of Bezafibrate 400 mg and Placebo of Bezafibrate 200 mg in addition to continued UDCA at minimum dose of 12 mg/kg/d.~* Duration 96 weeks placebo /UDCA = daily oral dose."
224073258|NCT04203615|DEVICE|Transcranial magnetic stimulation- sham rTMS|Transcranial magnetic stimulation- sham figure-eight coil will be used for stimulation. This sham coil will generate only clicking noise and will not generate any magnetic field.
224073259|NCT04203615|DEVICE|Transcranial magnetic stimulation- real rTMS|Transcranial magnetic stimulation- figure-eight coil will be used for stimulation. 1 Hz stimulation, 100% of Resting Motor Threshold will be used.
224073260|NCT03639025|DEVICE|OCS Lung System|"The OCS™ Lung System is a portable organ perfusion, ventilation, and monitoring medical device intended to preserve donor lungs in a near physiologic, ventilated, and perfused state prior to transplantation. This technology was designed to overcome the limitation of cold storage and has the potential to expand the utilization of donor lungs. The OCS™ Lung System accomplishes this by performing 3 key functions:~* Reducing ischemic injury through the use of warm, oxygenated blood based perfusion.~* Optimizing the lung condition by ventilatory recruitment maneuvers and high-oncotic perfusion solution supplemented with hormones and nutrients.~* Allowing for ex-vivo functional assessment of the donor lung during preservation and prior to transplant."
224073261|NCT06479681|BEHAVIORAL|Peer recovery coaching (PRC)|The RC-Link peer recovery coaching intervention provides participants with an introduction to an RC-Link coach during their hospitalization. The RC-Link coach delivers coaching and support services for a 6-month period using a standardized PRC Checklist. During the baseline visit, the RC-Link coach first develops a personalized recovery plan with the participant that emphasizes multiple pathways to recovery, including different types of mutual aid groups, counseling, and alternative recovery tools. The approach empowers the participant with an actionable recovery plan that can be initiated upon discharge, but the plan can be modified as changes arise. After the initial baseline encounter, the RC-Link coach initiates phone, virtual, and/or in-person contact with the participant a minimum of twice weekly using the PRC Checklist to standardize service delivery.
224073262|NCT06479681|BEHAVIORAL|Brief Intervention (SBIRT)|The control will receive a brief intervention, usual care (a referral list), contact information for the study team and hospital case management, and a follow-up contact at the end of the study period. The brief intervention entails (a) using motivational interviewing to gauge the individual's perspective of drinking, how it influences their life, and readiness for change; (b) provide information about the risks of hazardous drinking and potential ways to reduce drinking; (c) elicit their feedback; listen to their concerns; offer encouragement; encourage them to establish goals for behavior change; and (d) provide resources for change (e.g., the referral list). The referral list includes contact information for no-cost peer recovery coach through FAVOR that the participant could choose to call via self-referral. Thus, control participants are able to be linked to PRC, but they must initiate the call and initial visit outside the hospital setting.
224073263|NCT05653752|DRUG|YL202|"YL202 is provided as the lyophilized powder, 200 mg/vial. YL202 will be given intravenously once every 3 weeks (Q3W) as a cycle.~The initial dose of YL202 will be infused IV into each patient for 90 ±10 minutes. If there is no infusion-related reaction after the initial dose, the second and subsequent doses of YL202 will be infused IV into each patient for 60 ±10 minutes."
224073264|NCT03528694|BIOLOGICAL|Durvalumab (MEDI4736)|Investigational product
224073265|NCT03528694|BIOLOGICAL|Bacillus Calmette-Guerin (BCG)|Standard of care
224073266|NCT05442099|BEHAVIORAL|Iso-principle music playlist|Participants listen to the iso-principle music playlist for 30 minutes.
224073267|NCT05442099|BEHAVIORAL|Generic calm music playlist|Participants listen to the calm music playlist for 30 minutes.
224073268|NCT02860312|BEHAVIORAL|Intradialytic exercise on stationary bicycles|Patients are exercising for 30-60 min during dialysis on an Rated Perceived Exertion (RPE) Scale between 12 and 14
224073269|NCT02860312|BEHAVIORAL|Non-exercising group|Patients are having their usual physical activity
224307476|NCT06505070|BEHAVIORAL|Recreational Games|"40 individuals in the intervention group were introduced to 15 games. Researchers conducted these sessions and provided participants with instructions and rules for the games. Then, they were asked to rate the games from 1 to 10. In this form, the elderly individuals evaluated the games by determining the minimum 1 and maximum 10 points according to their interest and willingness to play. Thus, it was ensured that individuals freely choose the games they want to play. As a result, bingo, matching pairs, word challenges and hot-cold games, which received the highest scores from the participants, were selected to be played."
224180148|NCT04957810|BEHAVIORAL|WeChat Mini Program|Through the WeChat applet, it provides services such as visit content configuration, self-image configuration, self-image measurement configuration, and visit reminders.
224180149|NCT04328181|DEVICE|Spectral Photon Counting Computed Tomography (SPCCT)|"For the dual-layer spectral CT scanner (IQon®, Philips, Amsterdam, The Netherlands), the following parameters will be used for the acquisition:~* Tube potential 120 kVp;~* Tube current time product of 150 mAs;~* Gantry revolution time 0.33 s;~* Automatic exposure control (angular and longitudinal) combined xyz-axis;~* Beam collimation geometry 64 x 0.625 mm - scan field-of-view - 22 cm;"
224180150|NCT04328181|DEVICE|DECT (Dual Energy CT)|"The SPCCT scanner is a prototype spectral photon-counting computed tomography system derived from a modified clinical CT system with a field-of-view (FOV) of 168 mm in-plane, and a z-coverage of 20 mm. It is equipped with energy-sensitive photon-counting detectors relying on the direct conversion high band gap semiconductor of cadmium zinc telluride (CZT). The electronics comprises 5 rate counters with 5 different configurable energy thresholds. The SPCCT scanner has the following parameters:~* Base platform : iCT scanner~* Tube Voltage (kVp) : 120, capability for imaging at 80 and 100 kVp~* Tube current (mA) : 10 - 300~* Spatial Resolution : \> 30 lp/cm, ≤ 250 µm~* Z-coverage isocenter (mm) : 20 mm~* FOV (mm) : 500~* Minimum rotation time : 0.33 s/rotation~* Acquisition modes : Axial, Helical, Step \& Shoot"
224180151|NCT02380703|BEHAVIORAL|Aggression Prevention Training (APT)|
224180152|NCT02380703|OTHER|Enhanced Usual Primary Care (EU-PC)|
224180153|NCT01362049|OTHER|Physical Therapy rehabilitation: Stabilization exercises.|The stabilization exercise protocol consists of exercises focused on improving the ability of trunk muscles to stabilize the spine, beginning with training to isolate the deeper abdominal muscles and then incorporation of these isolated contractions into other exercises. The exercise protocol progresses to include trunk flexion and extension strengthening exercises as well as abdominal bracing exercises in supine and quadruped positions, and finally to exercises in more functional positions.
224180154|NCT01362049|OTHER|Physical Therapy rehabilitation. Movement System Impairment (MSI) classification based exercise|The MSI-classification based approach focuses on education and instruction for modifying movement strategies during functional activities, and on exercises that are specific to the classification category. First there is an analysis of and instruction in modifying a subject's direction-specific alignment and movement strategies during symptomatic functional activities. Second, there is education about the principles of tissue injury and healing, and how cumulative tissue stress contributes to microtrauma and LBP. Unique to the education process is the emphasis on how using one's particular movement strategies during functional activities may accelerate tissue stress accumulation because the strategies are used repetitively. Thirdly, there is exercise prescription that includes practice in performing modified versions of the direction-specific impairment tests from the physical exam, with an emphasis on impairments that can be modified to eliminate LBP symptoms.
224180155|NCT02777008|DRUG|CTP-543|
224180156|NCT02777008|DRUG|Placebo for CTP-543|
224180157|NCT02356042|OTHER|Geriatric inclusive art (GIA) activity|The frequency of GIA sessions in this study was from 1 to 2 per month. The time of a session was around 1 hour 30 minutes. Participants of intervention group benefited GIA activity during a 6-month follow-up period.
224180158|NCT02615808|OTHER|Oxygen saturation data visualization|The data visualization contains current and recent (over last 4, 8 or 12 hours) pulse oximetry readings and trends as well as the monitor alarm limits and most recently recorded supplemental oxygen content and flow.
224307477|NCT00306930|DEVICE|Acetabular cup|Acetabular cup replacement
224307478|NCT05337371|DEVICE|ECG patch (Philips ePatch® 2.0)|The ECG patch will be put on the patients chest to monitor cardiac activity for a total time period of 14 days after cardiac arrest.
224307479|NCT03083652|DEVICE|Neuromuscular electrical stimulation|Neuromuscular electrical stimulation (30 minutes per day, 5 days/week) of the quadriceps femoris and gluteus maximus
224307480|NCT03083652|OTHER|Sham|Conventional physiotherapy with NMES device NOT activated
224180159|NCT02808273|DRUG|Bemiparine|Bemiparine 3500 UI as antithrombotic according to a protocol for prevention of postoperative deep venous thrombosis
224180160|NCT03607994|DEVICE|HIRREM-SOP|HIRREM-SOP is an updated version of HIRREM. It is a novel, noninvasive, closed-loop, brainwave mirroring, acoustic stimulation neurotechnology to support relaxation and auto-calibration of neural oscillations, using auditory tones to reflect brain frequencies in near real time.
224180161|NCT03607994|DEVICE|NCC|Nonspecific acoustic stimulation with randomly generated tones not linked to brain activity.
224180162|NCT04919694|PROCEDURE|combination of orbital compression surgery and strabismus surgery|combination of orbital compression surgery and strabismus surgery at the same time
224180163|NCT04919694|PROCEDURE|orbital compression|orbital compression
224307481|NCT01589289|DEVICE|Immunochromatographic HAT tests (DSD)|Immunochromatographic HAT diagnostic tests manufactured by DSD, Korea and FIND
224307482|NCT01589289|DEVICE|Card Agglutination Trypanosoma Test|Card Agglutination Trypanosoma Test on whole blood and as dilution
224307483|NCT01589289|DEVICE|TB POC Nucleic Acid Amplification Test (Molbio Diagnostics)|"TB POC Nucleic Acid Amplification Test: microPCR handheld device (Molbio Diagnostics PVT ltd, India)"
224307484|NCT01589289|DEVICE|TB 3-marker RDT (Tulip diagnostics)|TB 3-marker RDT: ADA2/IFN-g/LAM (Tulip diagnostics, ltd, India) - pending availability for phase 3 validation
224307485|NCT01589289|DEVICE|Cryptococcal Antigen Lateral Flow Assay (Immy)|Cryptococcal Antigen Lateral Flow Assay (Immy, USA)
224307486|NCT04593576|OTHER|Physical activity protocol/out door sports|"Warm up exercise will be administered for 10 minutes, then one-to-five small group of instruction based activity will be administered for 15 minutes. After this whole group will be engaged in ball exercise and cooperative ball games for 20 minutes. At the end cool down and reward activity will be done with participants for 15v minutes.~Total 1 hour physical activity protocol will be administered twice a week."
224180164|NCT00852124|BIOLOGICAL|VSL#3|VSL#3 2 times daily
223489462|NCT05893511|PROCEDURE|Endoscopic ultrasound-guided gallbladder drainage|Prior to the procedure, the patients would be kept fasted for 6 hours and antibiotics would be commenced (2nd generation cephalosporin or equivalent). EUS-GBD would be performed by either the conventional or direct method. A 10mm stent system would be used if the largest gallstone is smaller than 10mm in size and a 16mm stent is used if the largest gallstone is larger than 10mm. The distal flange of the stent would be deployed under EUS guidance, followed by deployment of the proximal flange under endoscopic guidance. Once deployed, the gallbladder is completely emptied by suction and irrigation until the effluent through the stent is clean. The need of inserting an additional double pigtail plastic stent through the LAMS would be decided by the endosonographer. A course of antibiotics will be continued for 7 days after the procedure .
223489463|NCT05893511|DRUG|Antibiotics first|Patients randomized to antibiotics first would be given intravenous antibiotics 2nd generation cephalosporin or equivalent). Antibiotics would first be given parenterally and then switched to oral form when patient can tolerate diet or when sepsis subside. It will be continued for at least a total of 7 days.
223587377|NCT02977845|BEHAVIORAL|Qigong|"Qigong has long been regarded as a form of mind-body intervention in Traditional Chinese Medicine (TCM), which simultaneously exercises the mind and the body for treating many chronic diseases and promoting wellness. About a hundred million people are currently practicing Qigong in China. Qigong is now regarded as a form of self-practise mind-body exercise and recently relevant to sports activity, which is officially known as Health Qigong. It is different from Medical Qigong which involves a TCM practitioner to emit Qi to heal the patients."
223587378|NCT00537407|DRUG|Debio 025|Debio 025 supplied as a 100 mg/mL oral solution
223587379|NCT00537407|DRUG|Peg-IFNα2a|Peg-IFNa2a supplied in 180 μg/0.5 mL prefilled syringes
223587380|NCT00537407|DRUG|Ribavirin|Ribavirin supplied as 200 mg tablets
223587381|NCT01302054|DRUG|Fesoterodine 8 mg|Fesoterodine sustained release tablets once every morning at 4 mg dose for first week, followed by 11 weeks at 8 mg strength.
223587382|NCT01302054|DRUG|Placebo|Matching placebo for fesoterodine 4 and 8 mg for a total of 12 weeks.
224073270|NCT00069498|DRUG|5-aminosalicylic acid|
224073271|NCT02289950|DRUG|Farletuzumab|Farletuzumab will be administered intravenously (IV) weekly
224073272|NCT02289950|DRUG|Placebo|Placebo will be administered intravenously (IV) weekly
224073273|NCT05348057|DRUG|Ivabradine|The starting dose is 5 mg twice a day. Adjust the dose according to the actual situation
224073274|NCT02655965|DRUG|Ropivacaine|Ropivacaine 3.5 mg/ml
224073275|NCT02655965|DRUG|Clonidine|Clonidine 5µg/ml
224073276|NCT02655965|DRUG|Sodium Chloride|Sodium Chloride 0.9 %
224073277|NCT04338009|OTHER|Discontinuation of ARB/ACEI|The randomized intervention will be the discontinuation of ACEI/ARBs. In all participants randomized to discontinuation, treating clinicians will be reminded about the medication discontinuation upon discharge and will be prompted to consider re-initiation of the medication at that time if appropriate, per the clinician's discretion.
224073278|NCT04338009|OTHER|Continuation of ARB/ACEI|The randomized intervention will be the continuation of ACEI/ARBs at the doses previously prescribed for patients during their routine care. Clinicians will be encouraged to continue the randomized treatment but will be allowed to change the dose of ACEI/ARB or discontinue these medications if any compelling clinical reasons are identified (such as hypotension, hyperkalemia, acute kidney injury).
224073279|NCT01250379|DRUG|bevacizumab [Avastin]|10 mg/ kg iv every 2 weeks or 15 mg/kg iv every 3 weeks
224073280|NCT01250379|DRUG|Chemotherapy|Standard chemotherapy (doublets not allowed)
224073281|NCT02358642|DRUG|Angiotensin converting enzyme inhibitor (Lisinopril)|
224073282|NCT02358642|DRUG|Placebo|
224073283|NCT05902364|OTHER|Systane Ultra PF lubricant eye drops|Commercially available preservative free eye drops
224073284|NCT00644787|DRUG|Fentanyl 1-day transdermal patch (Titration Phase)|Fentanyl 1-day application transdermal patch releasing the drug at the rate of 12.5 mcg/hr applied once daily, and maintained for 2 days. Dose escalation or reduction is done as per Investigator's discretion (maximum applied dose is 100 mcg/hr) up to Day 11 and then dose is fixed up to end of treatment period, that is Day 14.
224073285|NCT00644787|DRUG|Fentanyl 1-day transdermal patch (Double Blind Phase)|Fentanyl 1-day application transdermal patch applied once daily releasing the drug at the same dose as maintained at the end of Titration Phase with maximum applied dose of 100 mcg/hr for 10 days.
224073286|NCT00644787|DRUG|Fentanyl 3-day transdermal patch (Double Blind Phase)|Fentanyl 3-day application transdermal patch applied once daily releasing the drug at the same dose as maintained at the end of Titration Phase with maximum applied dose of 100 mcg/hr for 10 days.
224073287|NCT00644787|DRUG|Placebo|Placebo matching to fentanyl 3-day application transdermal patch applied once daily releasing the drug at the same dose as maintained at the end of Titration Phase for 10 days.
224073288|NCT00644787|DRUG|Placebo|Placebo matching to fentanyl 1-day application transdermal patch applied once daily releasing the drug at the same dose as maintained at the end of Titration Phase for 10 days.
224073289|NCT05517876|DEVICE|Vascular abdominal or peripheral surgery|"replacement or bypass of arteries presenting aneurysm or obliterative arterial disease. Their indication is restricted to abdominal and peripheral surgery not crossing the knee flexion crease.~Abdominal vascular surgery includes abdominal aorto-aortic and/or aorto-iliac and/or aorto-femoral vascular repair, i.e. graft implantation with proximal anastomosis to abdominal aorta (supra and/or infra-renal).~Peripheral vascular surgery includes peripheral arteries repair, i.e. graft implantation with no aortic anastomosis, and/or extra-anatomic vascular repair such as axillo-femoral and/or crossover bypass (femoro-femoral and/or ilio-femoral)."
224073290|NCT06222840|OTHER|Electro-clinical analysis of epileptic seizures|Electro-clinical analysis of epileptic seizures
224073291|NCT06222840|OTHER|Electro-encephalographic cases|Electro-encephalographic connectivity analysis compared to controls
224073292|NCT06222840|OTHER|Clinical datas analysis|Clinical datas analysis
224073293|NCT06222840|OTHER|Electro-encephalographic control|Electro-encephalographic connectivity analysis compared to cases
224073294|NCT04485312|BEHAVIORAL|preventive protocol|preventive protocol
224073295|NCT04485312|BEHAVIORAL|chlorhexidine added to the preventive protocol|chlorhexidine varnish added to the preventive protocol
223489464|NCT04880824|BEHAVIORAL|Prehabilitation- new form of care|The participants in the intervention group take part in a shared decision-making (SDM) conference to plan the intervention. The therapeutic content of the prehabilitation is defined individually for each patient in the SDM conference. Prehabilitation will be a structured and individually tailored 3-week program.
224180165|NCT00852124|BIOLOGICAL|VSL#3 or placebo|1 packet 2 x daily of placebo
224180166|NCT01102816|OTHER|Individualized acupuncture treatment|"Individualized acupuncture treatment which focuses on each patient's symptoms and conditions will be provided twice a week for 6 weeks on a non-dialysis access day or before hemodialysis at dialysis-access day. 10-20 acupuncture needles will be inserted on the body except the arteriovenous fistula-located arm(s). Electrical stimulation of acupuncture will be conducted on 4 needles and the remained needles will be manipulated manually to elicit de-qi sensation. Needle retention time will be 20 minutes.~Routine care provided by dialysis staffs, primary physicians and other healthcare providers will be maintained.~Patients who received acupuncture treatment will be interviewed to explore patient's perceptions and experiences of acupuncture for their pain management. (Nested-qualitative study)"
224180167|NCT01102816|OTHER|Routine care|Patients in this group will maintain routine care provided by their dialysis staffs, primary physicians or other healthcare providers for symptomatic care and disease management of end-stage renal disease through 6 weeks. After post-treatment evaluation, acupuncture treatment will be provided to patients who want to receive acupuncture treatment.
224180168|NCT04622163|OTHER|Secondary Mentor|Subjects will be matched with a secondary mentor from the Department of Medicine for 6 months. Mentors and mentees are expected to hold one-on-one meetings monthly for the first 3 months followed by at least once every 3 months thereafter.
224180169|NCT04622163|OTHER|Career Development Resources|Subjects will receive career development resources.
224180170|NCT00538486|DRUG|Telmisartan plus Metformin|Telmisartan 80mg 1/d, Metformin 250mg 2/d
224180171|NCT00538486|DRUG|Telmisartan|Telmisartan 80mg 1/d
224180172|NCT00538486|DRUG|Candesartan|Candesartan 8mg daily
224180173|NCT00538486|DRUG|Candesartan plus Metformin|Candesartan 8mg 1/d Metformin 250mg 2/d
224180174|NCT00538486|DRUG|Amlodipine|Amlodipine 5mg 1/d
223745424|NCT07189637|OTHER|Intermittent Fasting Diet|Training will be provided to all participants through a food and nutrition photo catalogue so that portions can be recorded correctly and within standard limits when keeping a food diary. Participants will restrict their food intake to a 16-hour period by applying the 16/8 Intermittent Fasting Diet model and will eat and drink whatever they want during the remaining 8 hours. During this 16-hour period, they will consume non-energy drinks consisting of water, unsweetened tea, unsweetened herbal teas and black coffee. It will be recommended that intermittent fasting be maintained from 6:00 p.m. to 10:00 a.m. However, participants may also choose other 16-hour periods, such as 7:00 p.m. to 11:00 a.m. or 8:00 p.m. to 12:00 p.m. Participants will be given a tracking chart to record the first and last times they consume food or energy-containing beverages during the day, and their adherence to the diet will be monitored based on their declarations.
223587383|NCT03594214|DIAGNOSTIC_TEST|serum vitamin d level measured by ELISA kit|serum vitamin d level will be measured by a blood sample from newly diagnosed breast cancer patients just after diagnosis (either by surgery specimen or FNA or excisional biopsy specimen) and before receiving any type of treatment for breast cancer
223587384|NCT02713867|BIOLOGICAL|Nivolumab|
223587385|NCT01647334|RADIATION|Adaptive radiotherapy|
224180175|NCT00538486|DRUG|Amlodipine plus Metformin|Amlodipine 5mg 1/d, Metformin 250mg 2/d
224180176|NCT05189535|DRUG|Pentoxifylline|Pentoxifylline 400 mg oral tablet twice daily for 12 weeks.
224180177|NCT05189535|DRUG|Paclitaxel|Paclitaxel I.V 80 mg/m2 weekly
224180178|NCT05189535|DRUG|Placebo|placebo
224180179|NCT01228435|DRUG|IPI-504|Given intravenously twice weekly for 2 weeks followed by 10 day off treatment
224180180|NCT00073515|DRUG|Alfimeprase|
224073296|NCT04053738|DEVICE|Anti-snoring bed|The mattress shape is adjusted using a custom made intelligent anti-snoring bed, which is able to detect snoring sound and change the position of the user whenever snoring occurs.
223489467|NCT05457855|DRUG|Montelukast|Montelukast claim is used as the exposure group.
224180181|NCT00685308|PROCEDURE|Stenting of atherosclerotic intracranial stenosis|"Patients will receive aspirin 300mg and clopidogrel 75mg per day for 3 days or more before stenting,and for at least 1 month after stenting. Modifiable risk factors will be controlled according to major international guidelines.~All stenting procedures will be performed in an elective setting, and under local or general anesthesia. The study will be terminated if stroke or death rate within 30 days of the stenting exceeds 15%."
224180182|NCT04115605|DEVICE|Altis Single Incision Sling|Minimally invasive system including permanently implantable synthetic suburethral sling for the surgical treatment of female Stress Urinary Incontinence
223489468|NCT05457855|DRUG|Fluticasone|Fluticasone claim is used as the reference group.
223587386|NCT05729984|BEHAVIORAL|Paula exercises|The patients will perform Paula exercises after the cesarean delivery
223587387|NCT05729984|BEHAVIORAL|Gum chewing|The patients will be given chewing gum and will be asked to chew it after the cesarean delivery
224073297|NCT02922140|BEHAVIORAL|pharmaceutical care service|
224073298|NCT01327157|PROCEDURE|occlusal adjustment.|It prompted the patient to perform the act of swallowing for 3 times to reach a terminal axis of rotation of the jaw and from this to start. Will be held palpation of the muscles, masseter and temporal on both sides and compared with the marks of carbon found in the teeth. After starts the adjustment following the rules of Guichet with a cylindrical drill with a thin cut . basic principles 1 Occlusive stress maximum distribution in centric relation 2 The occlusive strengths should by the teeth's major axis.3 When the contact is surface to surface, it must be exchanged to another surface point. 4 Once the stability to the centric relation is achieved, it should be kept. The rules to guide the occlusal adjustment selective grinding .
224073299|NCT01327157|BEHAVIORAL|Visual analog scale.|"Visual analog scale-Graduation was held on the visual analogue scale in the first and last query to measure discomfort chewing.Graduation was held on the visual analogue scale .in the first and last query to measure discomfort chewing. After graduating dental cleaning was performed, with the purpose of blinding the study, Dental Cleaning.With engine using low speed, brushes, and prophylactic paste is carried out dental cleaning in the teeth of all patient.~Dental Cleaning.With engine using low speed, brushes, and prophylactic paste is carried out dental cleaning in the teeth of all patient."
224180183|NCT02882451|DIETARY_SUPPLEMENT|pinaverium bromide|
223489469|NCT05728450|DEVICE|Light amplification by stimulated emission of radiation (LASER)|"* The points for application of laser acupuncture will be cleaned before application. All patients in the study group will be submitted to infrared diode laser, wavelength 808 nm, Pulse duration: 200 ms, Power density: 0.4 W/cm2, energy density 4 J/cm2 (Chow, 2001).~* The plug of the laser unit will inserted into the main current supply and on/off switch will be switched on. The therapy form will be selected from the main menu and then the parameters will be set.~* Acupuncture detector (Pointer Excel II) will be used for definite location of acupuncture points"
223489470|NCT02629159|DRUG|Placebo for Adalimumab|Administered by subcutaneous injection once every other week
223489471|NCT02629159|DRUG|Adalimumab|Administered by subcutaneous injection once every other week
223489472|NCT02629159|DRUG|Placebo for Upadacitinib|Tablets taken orally once a day
223489473|NCT02629159|DRUG|Upadacitinib|Tablets taken orally once a day
224180184|NCT02882451|DIETARY_SUPPLEMENT|Vitamin C|
224180185|NCT02850276|DRUG|Pyridostigmine|
223587388|NCT03251586|DIAGNOSTIC_TEST|oVEMP - infra-orbital electrode montage|oVEMPs are short latency (\~10 ms) stimulus-synchronized extra-ocular muscle reflexes produced in response to appropriate stimuli. The response is believed to originate from excitation of the utricular macula with the subsequent neural response relayed to the brain by the superior portion of the vestibular nerve. Changes in the electrical field of the contralateral inferior oblique muscle can be recorded by an electrode placed at the infra-ocular midline of the lower lid while having the subject gaze upward. The conventional electrode montage, the infra-orbital electrode montage, has the active electrode placed directly inferior to the eye and the reference electrode placed 2-3 cm below the active on the cheek. This electrode montage may result in reference contamination, which will cause an artificially reduced amplitude response, as a portion of the response can be measured by the reference electrode.
224180186|NCT02358928|OTHER|Diet Intervention|
224180187|NCT04707027|DRUG|Aflibercept Injection (2 mg/0.05 ml)|Intravitreal aflibercept injections (treat and extend regimen)
224180188|NCT04707027|OTHER|Defer treatment|Follow up with fundus photo and OCT every 4 weeks
224180189|NCT03097497|OTHER|Physiotherapy re-education program|Physiotherapy Program based on the Re-education of Pre-activation of the Transverse Abdominal Muscle
224180190|NCT03097497|OTHER|Conventional treatment by GP|Patients will follow the general practitioner's advice including medication if needed
224180191|NCT04384991|DRUG|HU007|Cyclosporine 0.02% with Trehalose 3%
224180192|NCT04384991|DRUG|Restasis eye drop|Cyclosporine 0.05%
224180193|NCT03433391|DEVICE|Oxiplex|Oxiplex is a clear, viscoelastic gel that is applied to operative site during lumbar spine surgery in order to coat the nerve root with a protective barrier.
224180194|NCT03433391|OTHER|Surgery Only|Single level partial discectomy as per standard of care procedures.
224180195|NCT03486951|PROCEDURE|Orthognathic Surgery:|maxillary/mandibular osteotomies for orthognathic purposes for the treatment of a dento-maxillary dysharmony The choice between outpatient procedure or hospitalization is decided by the surgeon on a case-by-case basis according to data relating to the general state of the patient, the type of surgery, the social context, the distance from the patient's home. a medical center in accordance with the usual and legal standards of outpatient surgery
224180196|NCT01173328|BEHAVIORAL|Pursed-lip breathing|Pursed-lip breathing involves a nasal inspiration followed by expiratory blowing against partially closed lips, avoiding forceful exhalation.
224180197|NCT01173328|BEHAVIORAL|Normal Breathing|
224180198|NCT00820014|DRUG|Placebo|Placebo control (vehicle) eye drops applied 4-times a day for 4 days before ocular surgery
224180199|NCT04450862|OTHER|Cognitive Behavioural therapy self help intervention for anxiety|"The intervention will involve five key components:~Psychoeducation - Increase awareness of how PH may affect emotional health, normalisation of difficulties, and discussion of how symptoms associated with anxiety may add to the burden of the disease.~Cognitions - Identify and challenge negative automatic thoughts associated with anxiety.~Coping skills - Educate and practice a range of behavioural coping methods to help participants better manage their physical symptoms associated with anxiety in PH.~Exposure - Replace avoidance of anxiety provoking situations and activities using graded exposure.~Relapse prevention - Focus on relapse prevention with implementation intentions and promotion of problem solving."
224180200|NCT03034746|OTHER|Physical activity (PA)|It will perform a program consist of 15 min of warm-up, 60 min of aerobic and resistance training, and 15 min of cool-down.
224180201|NCT03034746|OTHER|cognitive treatment (CT)|The cognitive stimulation group will received a rehabilitation program with multimodal repetitive stimulation in order to exercise and reinforce the cognitive skills of the participant to slow/prevent the decline. In particular the treatment will be focused on reorient the patient about his/her-self, his/her history and his/her environment, to improve the memory skill by teaching compensatory and restitutive strategies, to help the patient to the discussion about everyday life and in particular to the everyday problems
224180202|NCT00498927|DRUG|temozolomide|
224180203|NCT00498927|GENETIC|protein expression analysis|
223489474|NCT06052956|DRUG|Methylene Blue|Administration of 0.1 mg/mL methylene blue to the abscess cavity, followed by a 10 minute incubation interval. After this incubation interval, the methylene blue solution will be aspirated from the cavity and flushed twice with sterile saline.
224180204|NCT00498927|GENETIC|reverse transcriptase-polymerase chain reaction|
224180205|NCT00498927|OTHER|diagnostic laboratory biomarker analysis|
224180206|NCT00498927|OTHER|immunoenzyme technique|
224180207|NCT02946268|DRUG|Ropivacaine|Change in administration of ropivacaine. Rate, Volume and Interval of bolus altered.
224180208|NCT06085040|BEHAVIORAL|Multidisciplinary weight loss|12-months multidisciplinary behavioral intervention combining physical activity (3 times 60 minutes per week), nutritional guidance (balanced meals) and psychological support (60 minutes per week)
224307487|NCT04593576|OTHER|Intensive table teaching speech therapy|Control group participants will be given speech therapy session based on intensive table teaching for 30 minutes twice a week.
223489475|NCT06052956|DRUG|Lipid Emulsion|The abscess cavity will be filled with sterile 0.1% lipid emulsion solution to gently distend the cavity and, through efficient light scattering, to homogenize the light dose to the walls of the cavity. After laser illumination, the Intralipid will be aspirated from the cavity.
224180209|NCT04722692|DIAGNOSTIC_TEST|Delayed SLND|"SLND performed after surgery for DCIS or other pre-invasive lesions, where final pathology showed invasive breast cancer. Patients have received SPIO in the breast at the first operation, prior to dissection and resection and the SLN has already been marked with SPIO. These SLNs are to be removed.~SLND is divided into the following steps:~1. Transcutaneous signal~2. Incision in the axilla (skin, subcutaneous fat and fascia) and In situ signal~3. SLN identification in situ~4. SLN excision and signal ex vivo~5. Background axillary counts. For step d the radioactive counts are registered for each SLN that has been excised. When the procedure is completed successfully with SPIO, then background axillary isotope counts are registered and, if present, SLND continues as described above with the isotope as primary tracer."
223489476|NCT06052956|DEVICE|Insertion of optical fiber|A sterile, FDA-approved optical fiber will be advanced to the approximate center of the abscess cavity via the drainage catheter under image guidance. Following laser illumination, the fiber will be withdrawn.
223489477|NCT06052956|DEVICE|Laser Illumination (pre-defined dose)|Laser illumination will be delivered via the optical fiber for a duration of 20 minutes. The optical power will be set such that the fluence rate at the abscess wall due to ballistic photons is 20 mW/cm2.
223489478|NCT06052956|DEVICE|Optical Spectroscopy Measurement|The same sterile optical fiber used for treatment will be advanced through the drainage catheter/needle in order to make gentle contact with the wall of the cavity. Low-intensity, polarized white light will be delivered by a tungsten halogen lamp by the fiber, and captured by the same fiber. Light that has been de-polarized by interaction with tissue will be detected by a spectrometer and analyzed to extract tissue optical properties. Upon completion of these measurements, the fiber optic will be withdrawn, gently wiped with sterile gauze, and returned to the procedure cart.
223489479|NCT06052956|DEVICE|Laser Illumination (patient-specific dose)|Laser illumination will be delivered via the optical fiber for a duration of 20 minutes. The optical power will be set to deliver a fluence rate of 20 mW/cm2 in 95% of the abscess wall, based upon abscess morphology and optical spectroscopy results.
223489480|NCT06052956|PROCEDURE|Standard of care abscess drainage|Following standard practice, a drainage catheter will be placed in the abscess cavity and used to aspirate purulent fluid.
223489481|NCT04529655|DEVICE|Capillary Refill Assessment|Device to quantify capillary refill time
223489482|NCT04383223|BEHAVIORAL|iTransition|Is a mobile website application (app), and it can be used on a range of devices (computer, tablet, smartphone) and operating systems (iOS, Android, Windows). Features of iTransition will include, but are not limited to: medication reminders, calendar tracking of appointments, direct messaging between youth and providers, and privacy password lock.
223489483|NCT04654312|DRUG|Hydrochlorothiazide|Please see arm descriptions
223489484|NCT04654312|DRUG|Placebo|Please see arm descriptions
223489485|NCT05355272|DRUG|Recombinant human growth hormone|recombinant human growth hormone (rhGH)
223489486|NCT05701800|BIOLOGICAL|mRNA-1468|Sterile liquid dispersion for injection
223489487|NCT05701800|BIOLOGICAL|Placebo|Sterile liquid for injection
223587389|NCT03251586|DIAGNOSTIC_TEST|oVEMP - belly-tendon electrode montage|oVEMPs are short latency (\~10 ms) stimulus-synchronized extra-ocular muscle reflexes produced in response to appropriate stimuli. The response is believed to originate from excitation of the utricular macula with the subsequent neural response relayed to the brain by the superior portion of the vestibular nerve. Changes in the electrical field of the contralateral inferior oblique muscle can be recorded by an electrode placed at the infra-ocular midline of the lower lid while having the subject gaze upward. The belly-tendon electrode montage consists of an active electrode placed laterally to the midline of the lower eyelid and a reference electrode placed on the inner canthus. This reference location is believed to be electrically neutral, and should therefore result in larger amplitude responses as the response would not be subject to reference contamination.
223587390|NCT05385445|BEHAVIORAL|Audit and Feedback|The investigators conducted a clustered randomized trial of primary care providers in Manitoba, Canada participating in the Manitoba Primary Care Research Network (MaPCReN) to assess the impact of Audit \& Feedback interventions to change prescribing and laboratory ordering.
223587391|NCT03652467|DRUG|Conventional TACE|Conventional chemoembolization drugs are injected through hepatic artery.
224180210|NCT04722692|DIAGNOSTIC_TEST|Late SLND|"SLND performed after surgery for DCIS or other pre-invasive lesions, where final pathology showed invasive breast cancer. Patients will be injected with radioisotope in the operated breast before SLND according to standard of care. Any SLNs detected with this intervention are to be removed.~SLND is divided into the following steps:~1. Transcutaneous signal~2. Incision in the axilla (skin, subcutaneous fat and fascia) and In situ signal~3. SLN identification in situ~4. SLN excision and signal ex vivo~5. Background axillary counts. For step d the magnetic counts are registered for each SLN that has been excised. When the procedure is completed successfully with the isotope, then background axillary iSPIO counts are registered and, if present, SLND continues as described above with the SPIO as primary tracer."
224180211|NCT05092867|OTHER|Po Tra tool|Healthcare workers filled the 2 VAS of the tool but it did not impact or change the care of the patient. (observational)
223489488|NCT05701800|BIOLOGICAL|Shingrix|Sterile suspension for injection
223489489|NCT04245514|DRUG|Durvalumab|Immunotherapy
223489490|NCT04245514|RADIATION|Radiotherapy|Immune-modulatory radiotherapy to the primary tumor, with either Cohort A: 20 x 2 Gy weekdaily Cohort B: 5 x 5 Gy weekdaily Cohort C: 3 x 8 Gy q2d
223587392|NCT03652467|DRUG|Deferoxamine and conventional TACE|Deferoxamine is injected before conventional transarterial chemoembolization.
224180212|NCT03708042|COMBINATION_PRODUCT|Definitive Radiochemotherapy|Radiotherapy,IMRT, 60Gy; Chemotherapy, Docetaxel （25mg/m2）+Cisplatin (25mg/m2) 1st/8th/15th/22nd day
224180213|NCT03708042|COMBINATION_PRODUCT|Neoadjuvant Radiochemotherapy|Concurrent Radiochemotherapy: Radiotherapy,IMRT, 40Gy; Chemotherapy, Docetaxel （25mg/m2）+Cisplatin (25mg/m2) 1st/8th/15th/22nd day; Receive radical surgery 4 to 6 weeks later.
224307488|NCT03047629|DRUG|ENT-01|Daily dosing with ENT-01. ENT-01 is an orally administered proprietary substance formulated as a small 25mg coated tablet. Dosing will range from 25-200mg, and the dose will be taken upon awakening on an empty stomach with 8oz water simultaneous to dopamine.
224307489|NCT03047629|OTHER|Placebo|Daily dosing with a placebo
224307490|NCT03047330|DRUG|Estradiol withdrawal|one injection of open-label intramuscular dose of leuprolide (3.75-mg depot), a gonadotropin-releasing hormone agonist that rapidly suppresses estradiol and temporarily achieves ovarian suppression.
224307491|NCT03047330|OTHER|Fragmented sleep|Fragmented sleep will be experimentally induced.
223489491|NCT05826418|DIETARY_SUPPLEMENT|MEND diet|Participants will be asked to adhere to their randomized MEND diet for 4 weeks and FMT. The FMT being offered is part of standard clinical care, as recommended by current practice guidelines. They will complete bi-weekly IBS symptom score questionnaires and stool samples collection from consent to week 4. Following the 4-week intervention period patients will not be asked to adhere to a study diet.
223489492|NCT05826418|DIETARY_SUPPLEMENT|mNICE diet|Participants will be asked to adhere to their randomized mNICEdiet for 4 weeks and FMT. The FMT being offered is part of standard clinical care, as recommended by current practice guidelines. They will complete bi-weekly IBS symptom score questionnaires and stool samples collection from consent to week 4. Following the 4-week intervention period patients will not be asked to adhere to a study diet.
223489493|NCT02250352|OTHER|cytology specimen collection procedure|Correlative studies
223489494|NCT02127398|BIOLOGICAL|fecal microbiota|fecal microbiota in capsule form
223489495|NCT04544462|OTHER|M2 Test|DNA will be extracted from saliva samples obtained from participants. Genetic testing will be performed to screen for the M2 mutation and determine the carrier status of each patient and partner.
223489496|NCT05233228|DRUG|Nicotine patch|Provision of nicotine replacement medications in the form of transdermal patches is important to address nicotine withdrawal/craving for smokers who want to quit. Evidence supporting the safety and efficacy of NRT is vast. The PHS Guideline indicates that use of NRT doubles quit rates and should be considered the minimal standard care. Therefore, we will provide NRT to all participants in both groups in the early cessation phase.
223489497|NCT05233228|BEHAVIORAL|Self-help materials (to support smoking cessation)|"The self-help materials were developed by NTCC in Lao, based on the World Health Organization's A guide for tobacco users to quit."
223489498|NCT05233228|BEHAVIORAL|Smartphone-based automated treatment for smoking cessation|The automated treatment(AT) include text messages, images, and videos. The AT content is designed to tap the theoretical mechanisms described in the Phase-Based Model (PBM). That is, treatment content is designed to increase motivation, self-efficacy, use of coping skills, and social support, while reducing nicotine withdrawal symptoms and stress. The AT will begin immediately after enrollment and continue for a 26-week period. The AT approach allows for several levels of personalization for each participant, including tailoring to participants' specific health conditions, individual cessation phases, and participants' self-efficacy level or smoking status in the past week.
223489499|NCT06436651|OTHER|Digital Storytelling|4 stages of digital storytelling will be implemented.
223489500|NCT06484114|DEVICE|Revita Duodenal Mucosal Resurfacing (DMR)|DMR is designed to ablate and re-epithelialize the duodenal mucosal surface, thus allowing nutrients to be exposed to a newly regrown and potentially normalized local mucosa. This implies that the duodenal mucosa surface is abnormal in participants associated with metabolic disorders. The Revita DMR procedure is performed endoscopically with supporting fluoroscopy.
223489501|NCT06484114|DEVICE|Sham|An endoscopic review with non active catheter introduction
223489502|NCT06378398|DRUG|Omeprazole|Two 20 mg/day omeprazole tablets taken before the first meal each day for 25-45 days.
223489503|NCT06378398|DRUG|Aspirin|Two 81 mg/day aspirin tablets taken before the first meal each day for 25-45 days.
223489504|NCT03331341|DRUG|Dacarbazine|Given IV
223587393|NCT01656226|DEVICE|Eryfotona AK-NMSC® cream|Cream, to be applied according to COLIPA standard at 2 mg/cm² in head and neck, twice a day before exposing to sun light morning and around lunchtime (about 4-6 hours later), for up to 6 months.
223587394|NCT01656226|OTHER|Sunscreen SPF 50+|Cream, to be applied according to COLIPA standard at 2 mg/cm² in head and neck, twice a day before exposing to sun light morning and around lunchtime (about 4-6 hours later), for up to 6 months.
224073300|NCT04800536|OTHER|Rapidly declining plasma glucose|Acute plasma glucose decline, divided into the following three phases: 1) Hyperglycaemic phase (plasma glucose 15 mmol/l), 2) Rapid plasma glucose decline phase and 3) Euglycaemic phase (plasma glucose 4.5-5.5 mmol/l).
224073301|NCT04800536|OTHER|Slowly declining plasma glucose|Acute plasma glucose decline, divided into the following three phases: 1) Hyperglycaemic phase (plasma glucose 15 mmol/l), 2) Slow plasma glucose decline phase and 3) Euglycaemic phase (plasma glucose 4.5-5.5 mmol/l).
223489505|NCT03331341|DRUG|Doxorubicin Hydrochloride|Given IV
223489506|NCT03331341|OTHER|Laboratory Biomarker Analysis|Correlative studies
223489507|NCT03331341|BIOLOGICAL|Pembrolizumab|Given IV
223489508|NCT03331341|DRUG|Vinblastine|Given IV
223489509|NCT05599061|OTHER|FFR>0.80+ OCT with findings indicative of vulnerable plaque|Patients received OPTIMAL MEDICAL TREATMENT (OMT)+PCI
223489510|NCT05599061|OTHER|FFR>0.80+ OCT with findings indicative of vulnerable plaque|OPTIMAL MEDICAL TREATMENT (OMT)
223489511|NCT06452719|DRUG|Letrozole|Letrozole 10 mg orally daily for three consecutive days
223587395|NCT03107923|DIAGNOSTIC_TEST|Dobutamine stress test|Test of myocardial reserve
223587396|NCT04569994|DRUG|NNC0363-0845|A single dose administered s.c. (subcutaneously, under the skin)
223587397|NCT04569994|DRUG|Placebo (NNC0363-0845)|A single dose administered s.c.
223587398|NCT04569994|DRUG|Insulin degludec|A single dose administered s.c.
223587399|NCT04040842|DIAGNOSTIC_TEST|Patients undergoing low anterior resection|Patients before the surgery and one year after the surgery will be assessed with questionnaire.
224073302|NCT01380431|DRUG|Lisinopril|Tablets, 40 mg, single oral dose
224073303|NCT01380431|DRUG|lisinopril|Tablets, 40 mg, single, oral dose
224073304|NCT01380431|DRUG|Lisinopril|50% of subjects received the Par formulated product.
224073305|NCT05558540|DEVICE|spinal cord stimulator|By continuous electrical stimulation of the nerve causing endometriosis-related pain, painful inputs to the spinal cord and brain can be reduced or even eliminated. The electrical stimulation is performed by the spinal cord stimulator (SCS).
224073306|NCT04428424|DRUG|Enbrel|As provided in real world practice
224073307|NCT00381264|DRUG|Cesamet™ (nabilone)|
224073308|NCT04760925|DEVICE|CascadeTM, Non-Occlusive Remodeling Net|Temporary assistance device for coil embolization of intracranial aneurysms
224073309|NCT01781494|PROCEDURE|Immobilization followed by protected range of motion|
224073310|NCT01781494|PROCEDURE|Immediate range of motion|
224180214|NCT06423404|BEHAVIORAL|the Experimental Group, receiving a 12-week program of video-guided active breaks with curricular content in the school classroom|The \&#34;Active Classes + School Climate and Mental Health\&#34; program was crafted following a comprehensive review by the research team on active breaks in the child school population. Based on the findings of this review, the optimal type and duration of intervention, frequency and intensity of the most effective exercises, and video-guided modalities with curricular content for active breaks will be established. Subsequently, a collaborative network was formed, involving researchers from education, sports science, social sciences, medicine, primary school teachers within the Chilean public school system, teams of educational leaders, parents, guardians, pedagogy students, and graduate students. The purpose was to create a team that systematically supports the development of various stages of the project from a multi and interdisciplinary perspective
224180215|NCT02878135|PROCEDURE|fast application|
224180216|NCT02878135|PROCEDURE|slow application|
224180217|NCT05151549|DRUG|Camrelizumab|200mg/3weeks
224180218|NCT05151549|DRUG|Cisplatin or Carboplatin|Cisplatin (40mg/m²), every week Carboplatin(AUC 2)
224180219|NCT03566849|OTHER|KC group|"1. 1st week: each 10 rep/set, 3 set/day. PNF scapular pattern: posterior depression (Combination of isotonic, COI), Ball modified prone Cobra, Ball prone V-raise, Ball prone row, Ball side plank, Ball one-leg bridging~2. 2nd week: each 10 rep/set, 3 set/day. Half sit-up with rotation to left/right, Side plank with ER, Prone extension with rotation to left/right, Bilateral one-leg squat with flexion, Squat to row~3. 3rd week: 5 rep/set, 3 set/day (sling exercise). Prone shoulder protraction, Supine shoulder retraction, Side-lying hip ABD/ADD, Supine pelvic lift, Prone bridging~4. 4th week: each 10 rep/set, 3 set/day. Lateral lunges with shoulder ABD/ER, Lunge with trunk rotation, Forward punch plus with serape effect, Spiking exercise, One-quarter vertical squat jump"
224180220|NCT03566849|OTHER|CT group|"1. 1st week: each 10 rep/set, 3 set/day. PNF scapular pattern: posterior depression (Combination of isotonic, COI), Knee push up plus, Modified prone Cobra, Prone V-raise, Prone row, Side-lying ER~2. 2nd week: each 10 rep/set, 3 set/day. Supine punch, Prone horizontal ABD, Prone V-raise, Prone row, Side-lying ER~3. 3rd week: each 10 rep/set, 3 set/day. Sitting chest press, Sitting ABD in scaption, Sitting overhead press, Long-sitting resisted extension, Sitting ER~4. 4th week: each 10 rep/set, 3 set/day. Standing horizontal pull-apart, Standing retraction plus ER, Standing resisted extension, Ball pushed on wall and controlled rolling, Wall push-up"
224180221|NCT01913015|DRUG|abiraterone acetate|Given PO
224180222|NCT01913015|DIETARY_SUPPLEMENT|dietary intervention|Receive low fat breakfast
224180223|NCT01913015|DIETARY_SUPPLEMENT|dietary intervention|Receive high fat breakfast
224180224|NCT01913015|OTHER|pharmacological study|Correlative studies
224180225|NCT01913015|OTHER|questionnaire administration|Ancillary studies
224180226|NCT01913015|OTHER|laboratory biomarker analysis|Correlative studies
224180227|NCT00928733|DEVICE|Gastroduodenoscopy- Intraduodenal intubation|20 g ethanol diluted up to 10% in tap water
224180228|NCT03960593|OTHER|Evaluation of the influence of geriatric factors|Follow-up of patients\> 70 years old with cancer pathologies to evaluate the influence of geriatric factors associated with a review of therapies on their care pathways and health conditions. We will be particularly interested in the main objective, the unplanned hospitalization rate at 3 months in patients\> 70 years old with cancer treated in oncogeriatric HDJ before the initiation of oncological treatment such as chemotherapy (oral or intravenous) and / or targeted therapy and / or immunotherapy and / or new generation hormone therapy.
224180229|NCT03056209|DRUG|KL1333 25 mg|oral administration, single dose, 25 mg 1 tab
224180230|NCT03056209|DRUG|KL1333 50 mg|oral administration, single dose, 25 mg 2 tabs
224180231|NCT03056209|DRUG|KL1333 100 mg|oral administration, single dose, 100 mg 1 tab
224180232|NCT03056209|DRUG|KL1333 200 mg|oral administration, single dose, 100 mg 2 tabs
224180233|NCT03056209|DRUG|KL1333 400 mg|oral administration, single dose, 100 mg 4 tabs
224180234|NCT03056209|DRUG|KL1333 600 mg|oral administration, single dose, 100 mg 6 tabs
224180235|NCT03056209|DRUG|KL1333 800 mg|oral administration, single dose, 100 mg 8 tabs
224180236|NCT03056209|DRUG|Placebo|oral administration, placebo
224180237|NCT01110889|DRUG|Agomelatine (AGO178C)|
224180238|NCT01110889|DRUG|Agomelatine (AGO178C)|
224307492|NCT04899544|BEHAVIORAL|Center-Based Pivotal Response Treatment (PRT) Intervention (PRT-C)|Pivotal Response Treatment in autism center.
223489512|NCT06452719|DRUG|Misoprostol|Misoprostol 800 mcg vaginally within 24 hours of final letrozole dose
223587400|NCT02411929|DRUG|Unlabeled ertugliflozin for oral use|15 mg oral (3 x 5 mg tablets)
224180239|NCT01110889|DRUG|Placebo|
224180240|NCT02022592|DRUG|Lormetazepam|
224180241|NCT02022592|DRUG|Midazolam|
224180242|NCT00002986|DRUG|carmustine|
224180243|NCT00002986|DRUG|topotecan hydrochloride|
224180244|NCT00258596|DEVICE|sirolimus-eluting stent|
224180245|NCT00890396|DRUG|Hydroxyurea|Parents and child's doctor may plan to use or not to use hydroxyurea.
224180246|NCT00751335|DEVICE|CPAP with ThermoSmart, then CPAP without ThermoSmart|"CPAP with ThermoSmart is the application of CPAP with heated humidification and a heated breathing tube.~CPAP without ThermSmart is the application of CPAP with heated humidification without a heated breathing tube."
224180247|NCT00751335|DEVICE|CPAP without ThermoSmart, then CPAP with ThermoSmart|"CPAP with ThermoSmart is the application of CPAP with heated humidification and a heated breathing tube.~CPAP without ThermSmart is the application of CPAP with heated humidification without a heated breathing tube."
224180248|NCT02504424|DEVICE|AeroForm Tissue Expander|The AeroForm Tissue Expander is a breast tissue expander implanted following mastectomy and activated by remote control to release small doses of carbon dioxide from an internal reservoir to fill and inflate the expander.
224307493|NCT04899544|BEHAVIORAL|Home-Based Pivotal Response Treatment (PRT Intervention (PRT-H)|Pivotal Response Treatment in home environment.
224307494|NCT04251572|OTHER|Blood sampling|Blood sampling
224307495|NCT04251572|OTHER|questionaires|Included participants will complete a baseline questionnaire at end of treatment (EOT) and a follow-up questionnaire throughout the follow-up period (Table 1). The questionnaires collect information on socio-demographics (age, gender, ethnicity, employment status, education level, housing status, incarceration, medical history and OST), injecting drug use (drugs injected, injection frequency and sharing of needle/syringe, cookers, cotton/filter or water). Details on the received DAA regime including mode of administration (direct observed therapy, pill box, etc.) and self-reported data on treatment adherence will also be recorded.
223489513|NCT06106360|DEVICE|Locus Health iPhone App|In this pilot study patients are enrolled into three (3) different groups which will vary by the frequency of the queries being sent to the patients during their chemotherapy cycle. The patients will be separated into three groups of 33-34 patients each. Each group will have a different frequency of symptom questions sent to them via the Locus Health iPhone App to determine patient fatigue and the compliance impact of different query cadences. Patients will be assigned to these 3 groups sequentially since the platform could not assign patients to these three cohorts in a random manner.
223489514|NCT03463408|DRUG|nivolumab|240 mg every 2 weeks
223489515|NCT03463408|DRUG|ipilimumab|1 mg/kg every 6 weeks
223489516|NCT05738213|DEVICE|Thermal stimuli|The Thermal Sensory Analyzer (TSA-II or PATHWAY platform - Medoc, Ramat Yishai, Israel) will be used to safely deliver heat and cold stimuli. These devices can deliver relatively complex stimuli via computer control. All targeted stimulus temperatures will be less than 50°C, and participants will be free to remove their arm or leg at any time from the thermode. Noxious cold stimuli will also be delivered with a plastic water container or a water bath (FISHER, USA). Participants will be free to pull out of the water bath at any time.
223489517|NCT05738213|DEVICE|Pressure stimuli|Pressure stimuli will be applied by using a handheld algometer (Wagner Instruments) or the Pressure Algometer (Medoc, Ramat Yishai, Israel). These devices have a round probe that allows quantifying the amount of pressure that is being applied. The Pressure Algometer allows a real-time visual feedback to control and monitor applied pressure rates. Pressure will be applied to the lower leg, volar forearm, or trapezius.
223489518|NCT05738213|BEHAVIORAL|Pain ratings|Pain intensity and pain unpleasantness ratings will be assessed.
223489519|NCT05738213|BEHAVIORAL|Pressure pain thresholds (PPT)|Pressure will be increased continually and participants will be instructed to press a button the first moment they feel pain from the pressure stimulus. The first threshold measurement will be used as a familiarization. The average threshold is calculated from three measurements.
223489520|NCT05738213|BEHAVIORAL|Conditioned pain modulation (CPM) response|"The CPM paradigm assesses endogenous inhibitory pain modulation efficiency. CPM testing includes the application of a test stimulus without conditioning (control run, pressure pain thresholds) and a subsequent application of the same test stimulus together with a conditioning stimulus (conditioning run, a 60 second of foot immersion in cold water). The CPM response is the difference in the pressure pain thresholds between the control and the conditioning runs."
223489521|NCT05738213|BEHAVIORAL|PedMIDAS (Pediatric Migraine Disability Assessment)|Adolescents with migraine will complete questions regarding their headache frequency. Migraine disability will be assessed using PedMIDAS (Pediatric Migraine Disability Assessment). This self-reported questionnaire assesses the number of days that headaches affect participant's daily activities. This is a widely used, reliable and validated tool to assess migraine disability.
223489522|NCT05738213|DIAGNOSTIC_TEST|Hormonal assessment|Blood samples (approximetly 2 tablespoons) will be collected for analyses of sex hormone levels (e.g., testosterone, estradiol, progesterone).
223489523|NCT05738213|OTHER|Pubertal status|Pubertal status will be assessed using the self-reported Physical Developmental Scale-Wave 3 survey, which allows for differentiation between pre-, early-, late-, and post-pubertal status. Early puberty is defined as a score of 3 and no menarche, mid-puberty is defined as 4 and no menarche, late pubertal is defined as a score of 7 points or less and with menarche, and post pubertal is defined as a score of 8 and menarche. For boys, pubertal maturation status will be determined by the Physical Development Scale using the body hair growth voice change and facial hair questions. Early puberty is defined as a score of 4-5, mid-puberty is defined as a score of 6-8, late pubertal is defined as a score of 9-11 points, and post pubertal is defined as a score of 12.
223489524|NCT06327555|OTHER|telerehabilitation|The telerehabilitation group uses smart wearables and mobile apps worn around the knee joint to perform telerehabilitation at home. Both sets of training sessions are identical.
223489525|NCT06327555|OTHER|in-person rehabilitation|The in-person rehabilitation group uses a face-to-face approach, with therapists providing outpatient rehabilitation guidance to patients three times a week for six weeks. After that, patients exercise at home according to the rehabilitation manual.
223489526|NCT06571838|DEVICE|DAISY system|DAISY is a The humanoid robot with an ipad and attached peripheral devices capable of taking blood pressure and temperature
223587401|NCT02411929|DRUG|14^C-labeled ertugliflozin for IV use|100 µg (10 µg/mL solution IV) containing approximately 400 nCi 14\^C (ie, radiolabeled ertugliflozin)
223587402|NCT02411929|DRUG|14^C-labeled ertugliflozin for oral use|100 µg (10 µg/mL solution oral) containing approximately 400 nCi 14\^C (ie, radiolabeled ertugliflozin)
223587403|NCT04634942|DEVICE|Cryos REF 0971 Cold Spray|Cold Spray Coolant spray is manufactured from liquefied gases with high pressure. It acts by rapidly reducing the temperature in the body area where it is applied. The liquefied gas in the tube spreads on the skin in liquid form and takes the heat of the skin by turning into gas. The temperature of the area where it is applied drops from 30-32 degrees to 10-15 degrees. With the effect of the cold, the excitability of the nerve endings decreases, and thus the pain on the skin is felt by the person. Cold sprays, whose analgesic effect occurs immediately, are applied parallel to the muscle fibers in the area to be applied, from a distance of 15-45 centimeters, by squeezing for approximately 5-15 seconds. Cold sprays are suitable for long-term and multiple uses.
223587404|NCT04634942|DEVICE|ShotBlocker BIONIX Press Firmly USA|ShotBlocker ShotBlocker is a plastic tool with a small and flat shape, with short and non-sharp protrusions on one side that connect with the skin. It resembles a horseshoe (C shaped) with its structure designed to expose the area to be injected. It is suitable for all age groups. It does not have any side effects. ShotBlocker can be used for both intramuscular and subcutaneous injections. The protruding surface of the ShotBlocker is held by pressing the skin during the injection and the process is performed from the part where the opening is.
223587405|NCT04356079|DIAGNOSTIC_TEST|International Headache Society Test|Thorough History of Patients and families
224180249|NCT05204901|DEVICE|Insertion and withdrawal of a magnetic-tipped wire into the lumen of the nasogastric tube for tracking of its position|In each participant, the investigator will place sensors on two sites of the sternum and track the location of the magnet as it is inserted and withdrawn from the nasogastric tube in the patients.
224180250|NCT04337879|DRUG|AL2846|AL2846 is a multi-target receptor tyrosine kinase inhibitor, which has obvious selectivity for c-met.
224180251|NCT04337879|DRUG|Calcium folate|Calcium folate 400mg/ ㎡ IV on day 1,15 in 28-day cycle
224180252|NCT04337879|DRUG|5-FU|5-FU 2800mg/ ㎡ IV on day 1, 2, 15, 16 days in 28-day cycle.
224180253|NCT04337879|DRUG|Oxaliplatin|Oxaliplatin 85mg/ ㎡ administered intravenously (IV) on day 1, day 15 in 28-day cycle.
224180254|NCT04337879|DRUG|Irinotecan|Irinotecan 180mg/㎡ administered intravenously (IV) on day 1,15 in 28-day cycle.
224180255|NCT02943876|OTHER|personalized depression risk information|The personalized depression risk information is determined by sex-specific risk prediction algorithms based on one's family history of depression, current health status, childhood traumatic experience and ongoing life stressors. The information is in the form of probability of having a major depressive episode in the next 4 years.
224180256|NCT04531345|DIAGNOSTIC_TEST|Flow cytometric analysis|IL-1β, IFN-α2, IFN-γ, TNF-α, MCP-1 (CCL2), IL-6, IL-8 (CXCL8), IL-10, IL-12p70, IL-17A, IL-18, IL-23, IL-33 cytokine analysis of COvid-19 patients and healthy volunteers
224180257|NCT00543842|DRUG|Bevacizumab|5 mg/kg By Vein Every 2 Weeks x 3 Doses (Weeks 1, 3, 5)
224180258|NCT00543842|DRUG|Capecitabine|Starting Dose 650 mg/m\^2 By Mouth Twice Daily Monday-Friday x 6 Weeks
223489527|NCT00278408|BIOLOGICAL|filgrastim|
223489528|NCT00278408|BIOLOGICAL|rituximab|
223489529|NCT00278408|DRUG|cyclophosphamide|
223489530|NCT00278408|DRUG|doxorubicin hydrochloride|
223489531|NCT00278408|DRUG|prednisone|
223489532|NCT00278408|DRUG|vincristine sulfate|
224180259|NCT00543842|DRUG|Erlotinib|Starting Dose 50 mg By Mouth Daily Weeks 1-3
224307496|NCT05060744|DEVICE|Antacid|The tablets should be kept in the mouth without chewing or swallowing, allowing them to dissolve completely.
224307497|NCT05060744|OTHER|Control|The tablets should be kept in the mouth without chewing or swallowing, allowing them to dissolve completely.
223489533|NCT00278408|RADIATION|radiation therapy|
223489534|NCT05280730|OTHER|No intervention|There is no intervention
223489535|NCT05285891|DRUG|Ocrelizumab|Two 300 mg intravenous (IV) OCR infusions separated by 14 days (i.e., Days 0 and 14) for a total of 600 mg, followed by 600 mg OCR infusions every 6 months from Month 6 through Month 48.
223489536|NCT05285891|DRUG|Placebo for Ocrelizumab|Placebo infusions every 6 months from Month 30 through Month 48.
223489537|NCT03033355|DRUG|Intra-detrusor injection of Onabotulinumtoxin-A|Using cystoscopy, Onabotulinumtoxin-A is injected into the bladder.
223489538|NCT06273865|DIAGNOSTIC_TEST|Several assays|Standard blood draw by venipuncture is performed in all study participants to collect blood samples in four 2.7 mL citrated blood tubes. Tube one is a dummy tube and is discarded. Tube two is used for the FVIII activity and thrombin generation assay on the EnzySystem. Tube three is used to perform conventional FVIII activity and thrombin generation assays. Tube four is used for duplicate measurements of the conventional assays and measurement of prothrombin F1+2 antigen levels, ADAMTS13 activity, FVIII antigen, VWF (von Willebrand Factor) antigen and von Willebrand ristocetin cofactor activity levels.
223587406|NCT06386679|BIOLOGICAL|allogenic amniotic fluid mesenchymal stem cell|Intra-articular AFCC injection will be given for single knee for each patient in single dose, 20 million of AFCC in each dose
223587407|NCT00628147|DEVICE|Narrow band imaging colonoscope|Adult colonoscopes with narrow band imaging capabilities (XCF-H160AY2L and XCF-Q160W6L, Olympus Medical Systems Corporation, Hachioji, Japan). There is an automatic switch on the handle of the endoscope that allows the physician to instantly switch between narrow band imaging and standard full spectrum white light modes.
224180260|NCT00543842|RADIATION|Radiation Therapy|30 minute radiation treatments, dose of 50.4 Gy once daily on 5 consecutive days, for up to 5 weeks and 3 days, totaling 28 treatments
224180261|NCT00543842|PROCEDURE|Surgery|At least 8 weeks after radiation therapy, surgical removal of rectal tumor
223489539|NCT05115474|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|Participants will undergo MRI imaging with and without contrast.
223489540|NCT05776719|BEHAVIORAL|Health & Wellness|PowerPoint slide decks will be shown via shared screen. The wellness group will be largely educational in nature and will encourage discussion, setting goals, and making healthy choices. Similar topics covered in this group have been used previously in health promotion classes.
223489541|NCT05776719|BEHAVIORAL|Warrior Renew|The group format includes warm-up community building exercises, psychoeducational presentation of material standardized by the use of PowerPoint slides, followed by discussion of the information and interactive exercises, and closes with exercises to improve affect management skills, such as mindfulness or guided imagery.
224180262|NCT05131659|BEHAVIORAL|Executive function group therapy|This executive function group therapy curriculum for adolescents uses cognitive behavioral therapy techniques, and focuses on key functions needed for adult success, such as: self-advocacy, flexibility, time management, motivation, goal setting, developing plans, monitoring progress. Guided practice begins with concrete interventionist support and moves to interventionist cueing, self-cueing, and finally automatic use of the skills without support.
224180263|NCT04651647|PROCEDURE|Revision surgery with / without open bone graft|Removal of previous implant and re-alignment and re-fixation using intramedullary nail with (bone graft group) / without (non bone graft group) open bone graft
224180264|NCT00819052|DRUG|Nevirapine XR|Nevirapine XR
224180265|NCT00819052|DRUG|Nevirapine XR|Nevirapine extended release
224180266|NCT00819052|DRUG|Nevirapine IR|Nevirapine Immediate Release
224180267|NCT06247462|DRUG|Ibuprofen 600 mg|600 mg of ibuprofen was ingested 12- and 1-hours prior to exercise.
224180268|NCT06247462|DRUG|Placebo Corn Starch|600 mg of corn starch (placebo) was ingested 12- and 1-hours prior to exercise.
224180269|NCT00090844|DRUG|triptorelin|3.75 mg TRELSTAR DEPOT (triptorelin) administered monthly as single intramuscular injection
224180270|NCT05981872|BEHAVIORAL|rehacom|"Rehacom was carried out at the cognition laboratory at Faculty of physical therapy, Cairo University for training of figural memory, attention concentration.~1. Attention concentration training consists of 24 levels of difficulties .~2. Figural memory training consists of 9 levels of difficulties. In the training session, every patient was starting training from level one and when the patient successfully finished the level, the training then Progress to the level of difficulty."
224180271|NCT04184466|DRUG|Insulin Aspart|insulin aspart in doses 0.3 IU/kg
224180272|NCT04184466|DRUG|NovoRapid® Penfill®|insulin aspart in doses 0.3 IU/kg
224180273|NCT01509157|DEVICE|MDRS System (Remote & Safety diabetes management system)|Participants will be using the MDRS system combined with their regular Continuous Glucose Monitoring during nightime for 2 weeks. The MDRS will allow the supervising personal to get real time remote data of glucose level and to alarm the patients and intervene in cases such as pending hypoglycemia, long standing hyperglycemia or technical faults
224180274|NCT01509157|PROCEDURE|Continuous Glucose Monitoring|Participants will be using their regular Continuous Glucose Monitoring during nightime for 2 weeks, without using the MDRS remote control system
224180275|NCT04151758|DRUG|Docosahexaenoic Acid Supplementation|Docosahexaenoic Acid (DHA) will be given at the dose of 500 mg/day (2 ml per day DHA RICH OIL 25% aroma mandorla FoodAR Limbiate, Italy;50% DHA oil obtained from Schyzochitrium sp ; Martek Biosciences Corporation, Columbia, Maryland, USA) to all participants of the study. DHA 2 ml will provide about 16 kcal of energy.
224180276|NCT04151758|OTHER|Promotion of physical activity|All participants will underwent a visit at t0, t1 and t2 in which physical activity will be promoted according to Italian dietary guidelines for childhood obesity.
224180277|NCT04151758|OTHER|Promotion of healthy food habits|All participants will underwent a visit at t0, t1 and t2 in which healthy food habits will be promoted according to Italian dietary guidelines for childhood obesity.
224180278|NCT04812457|DRUG|Hialucic|A professional not present at the intervention (researcher 2) will proceed to carry out the postoperative cures 48 hours after the intervention. The bandage will be removed, the area will be washed with physiological saline and the drug will be applied according to the group to which it belongs. In the intervention group, an ointment with hyaluronic acid (hyalucic ®) will be used together with a non-stick dressing and a semi-compression bandage to prevent bleeding.
224180279|NCT04812457|DRUG|Betadine gel|A professional not present at the intervention (researcher 2) will proceed to carry out the postoperative cures 48 hours after the intervention. The bandage will be removed, the area will be washed with physiological saline and the drug will be applied according to the group to which it belongs. In the control group, Betadine Gel will be used together with a non-stick dressing and a semi-compression bandage to prevent bleeding.
224180280|NCT02161614|DRUG|Estradiol valerate|
224180281|NCT02161614|DRUG|Placebo|
223489542|NCT04258319|DIAGNOSTIC_TEST|Ultrasound Procedure|Ultrasound technique that uses a compression device integrated with ultrasound imaging to perform in vivo ramp-and-hold uniaxial creep-like test on upper extremity lymphedema (UEL) in vivo.
223489543|NCT03731000|DEVICE|PHIL® device|Using PHIL® device for treatment of intracranial dural arteriovenous fistulas
223489544|NCT03727880|DRUG|Pembrolizumab|Following standard of care neoadjuvant chemotherapy, subjects will receive two doses of pembrolizumab (200mg) IV 3 weeks apart prior to surgery. After surgery, subjects will receive adjuvant standard of care chemotherapy. Following adjuvant chemotherapy, subjects will receive 8 doses of pembrolizumab (200mg) IV 3 weeks apart.
223489545|NCT03727880|DRUG|Defactinib|Following 2 cycles of standard of care neoadjuvant chemotherapy, subjects will receive 400 mg defactinib twice a day up until 2 days preceding their surgery (approximately 6 weeks) during the immunotherapy cycles with pembrolizumab. After surgery, subjects will receive adjuvant standard of care chemotherapy. Following adjuvant chemotherapy, subjects will receive 400mg defactinib twice a day for 24 weeks.
223489546|NCT06242470|BIOLOGICAL|MGC026 Dose Escalation|Escalating doses of MGC026
223489547|NCT06242470|BIOLOGICAL|MGC026 Dose for Expansion|MGC026 recommended dose for expansion
223489548|NCT04837716|BIOLOGICAL|Bevacizumab|Given IV
223489549|NCT04837716|DRUG|Carboplatin|Given IV
224180282|NCT01292733|OTHER|Laboratory Tumor Marker Analysis|Performed every 6 months, these blood samples will be drawn to measure the concentration of CA125 tumor marker. Remaining samples will be stored in a specimen repository for use in future research for ovarian and breast cancer tumor markers.
224180283|NCT01292733|OTHER|Transvaginal Ultrasound|Performed annually, these pelvic ultrasounds will be used used to look for 1) enlargement of one or both ovaries or 2) suspicious or indeterminate morphometric parameters, determined by the presence of intracystic papillations, and/or mural nodularity.
224180284|NCT01292733|OTHER|Health Status Questionnaire|Performed every 6 months, these questionnaires will ask about your health and medical history, environmental exposures, and family history.
223489550|NCT04837716|DRUG|Ensartinib|Given PO
223489551|NCT04837716|DRUG|Pemetrexed|Given IV
223489552|NCT05352399|OTHER|NeuViCare application|Intervention arm participants will engage with NeuViCare AI, including all variations of its 5 components: 1) NeuViCare Planner - enables review of ordered tests and external resources recommended by the care provider; 2) NeuViCare Task-Support Service - provides context-sensitive, personalized text-based assistance to help patients' complete care plan captured in the NeuViCare Planner; 3) NeuViCare Resource Advisor - presents trusted, unbiased advice to locate nearby resources listed within their care plan; 4) NeuViCare Advisor - educates and trains Persons Living With Dementia (PLWD) and their care partners at the moment of need; and 5) NeuViCare Community Hub - a safe virtual space which enables care partners to interact with other peer care partners to gain their experiential knowledge and emotional support.
223489553|NCT06618885|BIOLOGICAL|SUM-101|Three immunizations every 4 weeks for 3 months (total 3 immunizations)
223489554|NCT06374485|DRUG|AU409|Oral administration
223489555|NCT03370224|BEHAVIORAL|Memory retraining exercises|Memory retraining exercises will be administered on a laptop computer twice a week for 5 weeks (10 training sessions).
223489556|NCT03370224|BEHAVIORAL|Placebo control memory exercises|Placebo control memory exercises will be administered on a laptop computer twice a week for 5 weeks (10 training sessions).
223587408|NCT02834286|DRUG|Rituximab|Rituximab 100 mg weekly days 1, 7, 14, 21
223587409|NCT02834286|DRUG|Eltrombopag|Eltrombopag 50 mg PO days 1-28
223489557|NCT05041998|DEVICE|Trans-femoral prosthetic socket|"Unmodified) A custom-made check socket serving as the interface between residual limb and prosthesis~1. Soft socket (Socket made from softer material than unmodified original)~2. Stiff socket (Socket made from stiffer material than unmodified original)~3. moderately lower brim height (Brim of the socket is lowered by 10% of socket length compared to unmodified original)~4. slightly lower brim height (Brim of the socket is lowered by 5% of socket length compared to unmodified original)~5. Oversized socket (The socket volume is 6% larger than the unmodified original)~6. Undersized socket (The socket volume is 6% smaller than the unmodified original)~7. CAT-CAM influenced geometry (The cross sectional geometry of the socket is modelled following the contoured adducted trochanteric-controlled alignment method (CAT-CAM))~8. MAS influenced geometry (The cross sectional geometry of the socket is modelled following the Marlo Anatomic Socket (MAS) template)"
223587410|NCT02834286|DRUG|Dexamethasone|Dexamethasone 40 mg IV/PO days 1-4
224180285|NCT04772287|DRUG|Toripalimab|Toripalimab: 240mg, IV, q3w, 4 cycles in total; Platinum-containing dual-drug chemotherapy: The specific dose is based on the standard of the selected protocol, IV, q3w, a total of 4 cycles.
224180286|NCT04772287|DRUG|Toripalimab mimetic (placebo)|Placebo: 240mg, IV, q3w, 4 cycles in total; Platinum-containing dual-drug chemotherapy: The specific dose is based on the standard of the selected protocol, IV, q3w, a total of 4 cycles.
224180287|NCT00982111|DRUG|Pemetrexed|500 milligram per square meter (mg/m2) administered Intravenously (I.V.) on Day 1 of every 3-week cycle, for a maximum of six cycles
224180288|NCT00982111|DRUG|Cisplatin|75 mg/m2 administered I.V. on Day 1 of every 3-week cycle, for a maximum of six cycles
223489558|NCT04879862|COMBINATION_PRODUCT|Epidural stimulation + Stand Training|Participants may use a standing apparatus or a less assistive device such as walker or cane. In case of upper limbs and trunk control insufficient for safely using the standing apparatus, participants will be placed on the treadmill, and a body weight support system. In this case, the level of body weight support will be continuously reduced as the individuals increase their ability to bear weight. A trainer positioned behind the participant will aid in pelvis and trunk stabilization. Trainer(s) positioned at the lower limb will provide manual facilitation for knee extension during standing. Manual facilitation at the trunk-pelvis and at the legs will be used only when needed.Participants will be encouraged to stand for as long as possible throughout the training session, with the goal to stand for 60 minutes with the least amount of assistance.
223489559|NCT04879862|COMBINATION_PRODUCT|Epidural stimulation + Step Training|Participants may be placed on the treadmill in an upright position and suspended in a harness. All trainers are careful to provide manual assistance only when needed. A trainer positioned behind the research participant will aid in pelvis and trunk stabilization, as well as appropriate weight shifting and hip rotation during the step cycle. Trainers positioned at each limb will provide manual assistance to promote knee extension and knee flexion and toe clearance. Research participants will step at various body weight load and speed. Research participants will take a break and rest at any time they feel the need to during the session. If independence is achieved during stepping, some training might be performed overground with appropriate assistive device and manual assistance to maintain participant safety. Participants will be encouraged to step for 60 minutes with the least amount of assistance. Seated or standing resting periods will occur when requested by the individuals
223587411|NCT02179814|DRUG|AMPT/ Demser|alpha-methyl-paratyrosine (AMPT, trade name: Demser) body-weight adjusted dosage (40 mg/kg body weight, maximum 4000mg) at 4 medication intake time points over 24 hours
223587412|NCT02179814|DRUG|Diphenhydramine|Diphenhydramine (25mg) at the first medication intake time point
223587413|NCT02179814|DRUG|Placebo|Placebo at the second, third and fourth medication intake time point
223587414|NCT02001584|DRUG|Baclofen|
223587415|NCT02001584|DRUG|Memantine|
224180289|NCT00982111|BIOLOGICAL|Necitumumab|800 mg (absolute dose) on Days 1 and 8 of every 3-week cycle, administered as an I.V.
224180290|NCT04143256|OTHER|JUUL ENDS 5% Virginia Tobacco|JUUL ENDS Virginia Tobacco 5% nicotine strength
224180291|NCT04143256|OTHER|JUUL 3% Virginia Tobacco ENDS|JUUL ENDS Virginia Tobacco 3% nicotine strength
224180292|NCT04143256|OTHER|JUUL 5% Mint ENDS|JUUL ENDS Mint 5% nicotine strength
223587416|NCT02001584|DRUG|Placebo|
223587417|NCT01276002|PROCEDURE|pancreatic duct stenting|in case of a disrupted pancreatic duct, patients will undergo pancreatic duct stenting.
223587418|NCT03583736|BEHAVIORAL|Virtual visit|Virtual visit with oncologist following uterine cancer diagnosis prior to scheduled office visit.
223587419|NCT03583736|BEHAVIORAL|Office visit|Scheduled office visit with oncologist following uterine cancer diagnosis.
223587420|NCT06110000|OTHER|pragmatic set of interventipons|"The pragmatic set included 6 interventions as follows.~1. Pragmatic posterior capsular stretch (PPCS)~2. Serratus anterior stretch (SAS)~3. Rotator cuff facilitation (RCF)~4. Acromioclavicular joint mobilization.~5. Pectoralis minor stretch~6. Thoracic manipulation Five to ten sweeps per minute are administered three to four times. The applied force is combined with deep breathing. The subject is asked to report discomfort and the applied force is adjusted."
223745425|NCT07189637|OTHER|Mediterranean Diet|Training will be provided to all participants through a food and nutrition photo catalogue to ensure that portions are recorded correctly and within standard limits when keeping a food diary. In addition, the dietician will provide this group with a diet plan calculated for energy, macro and micro nutrients, which will be different each week for the first four follow-ups. The diet plans provided will be prepared in accordance with the Mediterranean Diet food pyramid. Participants' energy requirements will be calculated using the Schofield Equation for basal metabolic rate, with adjustments made according to their physical activity levels. Energy requirements will be met by 45-50% from carbohydrates, 15-20% from protein, and 25-35% from fats.
224180293|NCT04143256|OTHER|JUUL 3% Mint ENDS|JUUL ENDS Mint 3% nicotine strength
224180294|NCT04143256|OTHER|JUUL 5% Menthol ENDS|JUUL ENDS Menthol 5% nicotine strength
224180295|NCT04143256|OTHER|JUUL 3% Menthol ENDS|JUUL ENDS Menthol 3% nicotine strength
224180296|NCT04143256|OTHER|JUUL 5% Mango ENDS|JUUL ENDS Mango 5% nicotine strength
224180297|NCT04143256|OTHER|JUUL 3% Mango ENDS|JUUL ENDS Mango 3% nicotine strength
224180298|NCT04143256|OTHER|US Cigarette, Non-menthol - Marlboro Gold King Size|US Cigarette, Non-menthol - Marlboro Gold King Size
224180299|NCT04143256|OTHER|US Cigarette, Menthol - Newport King Size|US Cigarette, Menthol - Newport King Size
224180300|NCT05751915|DEVICE|CardioFlux|CardioFlux MCG is a process that observes incremental changes in the heart's electrical activity by the magnetic fields generated by these currents. These magnetic fields have been used for decades via electrocardiogram to help diagnose and treat both acute and chronic cardiac pathology. The CardioFlux device reaches the potential of this phenomenon by sensing a complete magnetic field map. It is equipped with a magnetic shielding chamber and can attenuate magnetic field noise by a factor of nearly 1500 which maximizes signal to noise ratio. CardioFlux is an easy to operate, noninvasive modality that can detect the presence of ischemic cardiac tissue in symptomatic patients in a less than 5-minute scan. The device uses the proprietary software called Faraday which processes MCG scans, create diagnostic functional images, and run analytics.
224180301|NCT00453453|DRUG|Nesiritide|Nesiritide given orally in the emergency department
224180302|NCT02377401|DRUG|Zanamivir|Zanamivir will be supplied as 10 mg/mL sterile clear, colorless, aqueous solution in 20 mL clear glass vials, each containing 200 mg zanamivir. Intravenous solutions will be prepared with normal saline.
223489560|NCT04879862|COMBINATION_PRODUCT|Epidural stimulation + Bladder Capacity Training|We will initially conduct daily training for capacity in a supervised on-site lab setting. Optimal configurations will be used. The storage phase configuration will be used until the time for voiding/catheterization. The training procedure will be repeated for up to 8 hours daily on-site until three consecutive stable days of maintaining a consistent capacity values are achieved and deemed safe. In the home setting, participants will record blood pressure values, voided and residual volumes. Participants will return to the lab the following day for monitoring and testing. If assessments show stable outcomes, participants will be allowed to train at home for 7 consecutive days, prior to returning to the lab for clinical evaluation (urodynamics and questionnaires). On the return visit, if their storage/voiding outcomes remained stable over the 7 days, they will be able to start the home-based training for bladder capacity.
223489561|NCT04879862|COMBINATION_PRODUCT|Epidural stimulation + Bladder Voiding Efficiency Training|We will conduct training for voiding efficiency in a supervised on-site lab setting while the participant continues his/her training for capacity. Voiding without catheterization will be attempted. The training procedure will be repeated for up to 8 hours on-site until three stable days of maintaining a consistent voiding efficiency are achieved and deemed safe. The participant will be sent home for one day to perform the stimulation at home. In the home setting, participants will record blood pressure values, voided and residual volumes. Participants will return to the lab the following day for monitoring and testing. If assessments show stable outcomes, participants will be allowed to train at home for 7 consecutive days, prior to returning to the lab for clinical evaluation and questionnaires. On the return visit, if their storage/voiding outcomes remained stable over the 7 days, they will be able to start the home program integrating bladder training for capacity and voiding
223489562|NCT05477277|DIAGNOSTIC_TEST|MAsS|Add MAsS to standard of care MRI scan
223489563|NCT02846623|DRUG|Atezolizumab|Given IV
223489564|NCT02846623|OTHER|Laboratory Biomarker Analysis|Correlative studies
223587421|NCT06110000|OTHER|scapular strengthening exercise.|• Subjects in Group B receive strengthening exercises (exercise will perform with 15 repetitions for each set- 3sets/day, 3 days /week for 6 weeks. In Scapular strengthening exercises, treatment protocol will involve the individualized for focus muscle Serratus anterior (Dynamic hug, Scaption with external rotation, Diagonal PNF (shoulder flexion horizontal flexion, external rotation),Trapezius - Upper trapezius (unilateral shoulder shrug, rowing, forward shoulder flexion, shoulder abduction in scapular plane above 120 degrees, Middle trapezius (prone shoulder horizontal abduction, scaption, horizontal abduction with external rotation), Lower trapezius (Unilateral scapular retraction, prone bilateral shoulder external rotation at 90 degrees of abduction, prone shoulder abduction), Levator Scapulae (horizontal abduction with shrug, horizontal abduction with ER, prone shoulder extension, Rhomboids (ER at 90° of abduction, ER at 0° of abduction, Horizontal abduction, Shoulder extension)
223587422|NCT05764174|BEHAVIORAL|Factual messages|Messages with descriptive data on COVID-19 vaccines
223587423|NCT05764174|BEHAVIORAL|Narrative message|Messages with emotional descriptions on COVID-19 vaccines
223587424|NCT05764174|BEHAVIORAL|Mixed message|Messages with both descriptive data and emotional descriptions on COVID-19 vaccines
223587425|NCT05614284|DEVICE|Virtuos|Use of autograft or Virtuous Lyograft as an adjunct to spinal fusion in TLIF.
223587426|NCT00301288|PROCEDURE|Autologous stem cell transplant|
223587427|NCT00747409|DRUG|insulin aspart and detemir (NovoRapid, Levemir)|use of basal-bolus therapy with insulin aspart and detemir
224180303|NCT01070381|DEVICE|nelfilcon A contact lens|Commercially marketed, toric, soft contact lens for daily disposable wear
224180304|NCT01070381|DEVICE|ocufilcon D contact lens|Commercially marketed, toric, soft contact lens for daily disposable wear
224180305|NCT04390217|DRUG|LB1148|LB1148 is delivered orally/enterally, 700 mL per day split into two administrations of 350 mL, approximately 12 hours apart, for up to 7 days.
224180306|NCT04390217|DRUG|Placebo|Placebo is delivered orally/enterally, 700 mL per day split into two administrations of 350 mL, approximately 12 hours apart, for up to 7 days.
223587428|NCT00747409|DRUG|human regular insulin and NPH insulin (Actrapid, Protaphne)|basal-bolus therapy with human regular and NPH insulin
223587429|NCT03133923|BIOLOGICAL|≥3.0 lgCCID50/mlbut <3.5lgCCID50/ml Live Attenuated Mumps Vaccine (Human Diploid Cell) in infants(8-24 months old)|≥3.0 lgCCID50/ml but \<3.5lgCCID50/ml;Live Attenuated Mumps (F-genotype) Vaccine (Human Diploid Cell, KMB-17) in 360 infants(aged 8-24 months ) on 0 day
223587430|NCT03133923|BIOLOGICAL|≥4.5 lgCCID50/ml Live Attenuated Mumps Vaccine (Human Diploid Cell) in infants(8-24 months old)|≥4.5CCID50/ml;Live Attenuated Mumps (F-genotype) Vaccine (Human Diploid Cell, KMB-17) in 360 infants(aged 8-24 months ) on 0 day
223587431|NCT03133923|BIOLOGICAL|Measles and Mumps Combined Vaccine，Live(SIBP)( positive control)|Measles and Mumps Combined Vaccine，Live(SIBP) in 360 infants(aged 8-24 months ) on 0 day
223587432|NCT02372422|OTHER|Transvaginal ultrasound determination of cervical length|Transvaginal ultrasound was used to measure the length of the cervix from the internal to external os relying on a standard approach and clinicians caring for the patients were made aware of the results.
223587433|NCT02372422|OTHER|Routine care|Routine prenatal care of twins. Digital exams were permitted, but transvaginal ultrasound assessment of cervical length was not.
223587434|NCT02544997|DRUG|Poziotinib|12mg P.O. for 2wks q21days
223587435|NCT03343600|DRUG|Imatinib|Imatinib 100 mg/tablet, 2 tablets daily
224180307|NCT03700424|DRUG|Trehalose|"Trehalose is a natural disaccharide sugar found extensively among miscellaneous organisms including bacteria, plants, insects, yeast, fungi, and invertebrates. By preventing protein denaturation, it plays various protective roles against stress conditions such as heat, freeze, oxidation, desiccation and dehydration. Owing to this capacity, trehalose is an FDA-approved pharmaceutical excipient that is used as a stabilizer in numerous medicines including parenteral products.~In this study, all injections will be conducted by a trained nurse in the presence of a specialist physician at a duration of 45-90 minutes."
224180308|NCT03700424|DRUG|Normal saline|A solution of 0.90% w/v of sodium chloride (NaCl) in water
224180309|NCT01869686|BIOLOGICAL|Denosumab|60 mg
224180310|NCT02543879|DRUG|FT-1101|FT-1101 will be supplied as 5 mg, 20 mg or 100 mg capsules and will be administered per the protocol defined frequency and dose level
223489565|NCT02846623|BIOLOGICAL|Obinutuzumab|Given IV
223489566|NCT02846623|DRUG|Venetoclax|Given PO
223489567|NCT06195228|DRUG|dabrafenib plus trametinib with or without PD-1 antibody|advanced thyroid cancer patients who harbor BRAF V600E mutation
223489568|NCT06195228|DRUG|entrectinib or larotrectinib with or without anti-PD-1 antibdoy|advanced thyroid cancer patients who harbor NTRK mutation
223489569|NCT06195228|DRUG|pralsetinib or selpercatinib with or without anti-PD-1 antibdoy|advanced thyroid cancer patients who harbor RET fusion or medullary thyroid carcinoma patients who habor RET mutation.
223489570|NCT06195228|DRUG|anlotinib or anlotinib plus anti-PD-1 antibody|For patients with medullary carcinoma, if there is no RET gene mutation or RET gene mutation is unknown
223489571|NCT06195228|DRUG|lenvatinib plus anti-PD-1 antibody|Advanced thyroid cancer patients who don't harbor the above gene mutation or could not afford the cost of precision treatment even with the above gene mutation
223489572|NCT06195228|DRUG|Other Targets: precise treatment based on the target|Advanced thyroid cancer patients who had other treatment targets not included above
223489573|NCT01802281|PROCEDURE|Uterosacral ligament suspension|The USLS procedure used in this protocol is a modification of the technique described by Shull.
223489574|NCT01802281|PROCEDURE|Uphold® LITE|The Uphold® procedure used in this protocol is a modification of the technique described by Vu and Goldberg.
223489575|NCT03314181|DRUG|Dexamethasone|Infusion; Intravenous (IV), or Tablet; Oral
223489576|NCT03314181|DRUG|Daratumumab|Injection; Subcutaneous (preferred), Infusion; Intravenous (IV)
223489577|NCT03314181|DRUG|Venetoclax|Tablet; Oral
223489578|NCT03314181|DRUG|Bortezomib|Injection; Subcutaneous (preferred), Infusion; Intravenous (IV)
223489579|NCT06003166|DRUG|4-Aminopyridine|Study drug will be a one time, 10mg dose of 4-aminopyridine
223489580|NCT06003166|OTHER|Placebo|Matched placebo
223489581|NCT05639231|BEHAVIORAL|INTOMOB intervention|"The intervention will be multilevel, targeting the patients, healthcare professionals (HCPs) and environment:~PATIENTS:~* Information booklet on the importance/benefits of mobility, consequences of low mobility, how to be more active (with concrete information).~* Customizable diary to document mobility goals, results, difficulties and needs.~* Exercise booklet with explanations \& pictures of mobility exercises (supine, sitting, standing).~* iPad 10.2'' with videos of the exercises.~HCPs (physicians \& nursing staff):~* E-learning on the consequences of low mobility, barriers/facilitators to hospital mobility; recommendations, documentation, communication \& interdisciplinary collaboration regarding mobility; implementation.~* Oral presentation on the intervention.~* Checklist to remind HCPs to address mobility.~ENVIRONMENT:~* Posters in the wards about mobility and other topics of interest to older adults.~* Walking itineraries in the wards."
223489582|NCT05884411|DEVICE|Left bundle branch area pacing|A cardiac pacing electrode is inserted into the left bundle branch area of the myocardium via a transvenous approach.
223489583|NCT05884411|DIAGNOSTIC_TEST|Cardiac MRI|A diagnostic imaging test using magnetic resonance imaging to evaluate cardiac function.
223489584|NCT05049837|OTHER|Group Specific Aim 1|600 cases: two normal and two tumor formalin-fixed tissue samples
223489585|NCT05049837|OTHER|Group Specific Aim 2|600 cases: two normal and two tumor formalin-fixed tissue samples.
223489586|NCT05049837|OTHER|Group Specific Aim 3|600 cases, including 150 patients who had received neoadjuvant therapy and 450 patients who had not. Two normal and two tumor formalin-fixed tissue samples
223489587|NCT05049837|OTHER|Group Specific Aim 4|600 cases; including 150 patients who will receive neoadjuvant chemotherapy, 150 patients who received or will receive postoperative adjuvant chemotherapy, and 300 patients who did not receive or will not receive neoadjuvant or adjuvant chemotherapy. Two normal and two tumor formalin-fixed tissue samples
223489588|NCT05049837|OTHER|Group Specific Aim 5|600 cases; two normal and two tumor formalin-fixed tissue samples
223489589|NCT05049837|OTHER|Group Specific Aim 6|210 cases (of the 600 above), one normal and one tumor formalin-fixed histology sections obtained from formalin-fixed and paraffin- embedded tissue samples.
223745426|NCT07190690|DEVICE|ihtDEStiny® DES implanted|ihtDEStiny® DES implanted
223745427|NCT07190690|DEVICE|Xience™ DES implanted|Xience™ DES implanted
223745428|NCT07190950|PROCEDURE|Low Level Laser Therapy|Patients will receive LLLT at one side after third molar extraction surgery. There will be 7 sessions at the day of surgery, then first, third, seventh, fourteenth, twenty first, twenty eighth day after surgery.
223489593|NCT05674929|DRUG|BPL-003|A single dose administered intranasally
223587436|NCT03343600|DRUG|Placebo|Placebos 2 tablets daily
223745429|NCT07189507|OTHER|Simulated indoor temperature upper limit|Older adults exposed to an 8-hour simulated exposure.
223745430|NCT07189923|PROCEDURE|Ablative Fractional CO₂ Laser|Participants will receive ablative fractional CO₂ laser therapy on one side of the face using the SmartXide DOT Fractionated CO₂ Laser system. Treatment parameters: 15 W power, 800 µm spacing, 600 µs dwell time, stack level 2. Sessions: 3, each one month apart.
223745431|NCT07189923|PROCEDURE|Platelet-Rich Plasma (PRP) With Microneedling|Participants will receive intradermal autologous PRP injections prepared by double-spin centrifugation from 8 mL of venous blood, followed by microneedling with a Dermapen (12-needle cartridge, 1.5 mm depth). Endpoint: pinpoint bleeding. Sessions: 3, each one month apart.
223745432|NCT07190495|DRUG|Ginger|Patients will receive 800 mg of oral ginger 2 hours before laparoscopic cholecystectomy
224180311|NCT02543879|DRUG|Azacitidine|Azacitidine will be administered per site's standard of care
224180312|NCT02063932|OTHER|endomicroscopy, targeted biopsy and 16s rRNA gene sequencing|
224180313|NCT04569890|DRUG|Certolizumab Pegol 200 MG/ML [Cimzia]|CZP 200mg twice a week subcutaneous.
224180314|NCT04569890|DRUG|Hydroxychloroquine|400mg HCQ orally daily
224180315|NCT04569890|DRUG|Prednisone|10mg GC orally daily
224180316|NCT00417911|DRUG|bortezomib|Bortezomib 1,3 mg/sqm Days 1,4,8,11 for two 3-week cycles and then once a week for three weeks in 4 4-week cycles
224180317|NCT00000151|DRUG|Aspirin|
224180318|NCT00000151|PROCEDURE|Argon Laser Photocoagulation|
224180319|NCT03512028|BEHAVIORAL|RLIC|See descriptions under arm/group descriptions. RLIC is delivered for 8 visits. Visits 1-3 occur on consecutive work days and visits 4-8 occur on alternating week days.
224180320|NCT03512028|BEHAVIORAL|Sham conditioning|See descriptions under arm/group descriptions. Sham conditioning is delivered for 8 visits. Visits 1-3 occur on consecutive work days and visits 4-8 occur on alternating week days.
224180321|NCT03512028|BEHAVIORAL|Muscle strength training|All participants undergo muscle strength training of the wrist extensor muscles on one side. Strength training follows standard American College of Sports Medicine guidelines for frequency, intensity, progression etc. Strength training is provided at visits 3-8
224180322|NCT03512028|BEHAVIORAL|Driving training|All participants undergo training of a complex cognitive-motor task using a driving simulator. Participants learn to 'drive' on a virtual course, maximizing speed and minimizing errors. Participants perform the driving task once each day for visits 3-8.
224180323|NCT03512028|BEHAVIORAL|Balance training|All participants undergo training on a balance board, learning to hold the board level with equal weight on each leg. Participants perform the balance task for 15, 30-second trials per day at visits 3-8.
224180324|NCT01066637|DRUG|[18F](+/-)NOS|Injection of radiotracer \[18F\](+/-)NOS for PET imaging and kinetic data analysis
224180325|NCT00000894|DRUG|Cidofovir|
224180326|NCT00000894|DRUG|Probenecid|
224180327|NCT00000894|DRUG|Ganciclovir|
224180328|NCT03529162|PROCEDURE|Long head of Biceps Tenodesis|Patients will be randomized into two different groups to compare biceps tenodesis techniques
224180329|NCT02961348|OTHER|Early start of NOAC|Initiation of NOAC up until day 4 after acute ischemic stroke in patients with atrial fibrillation
223489594|NCT02685735|DRUG|Gabapentin|Drug treatment will begin 2 weeks prior to surgery and continue 3 weeks afterwards. Subjects randomized to gabapentin will receive 900 mg/day for the first week, 1800 mg/day for the next 3 weeks, and 900 mg/day for the last week.
223489595|NCT02685735|DRUG|Placebo|Drug treatment will begin 2 weeks prior to surgery and continue 3 weeks afterwards. Subjects randomized to gabapentin will receive 900 mg/day for the first week, 1800 mg/day for the next 3 weeks, and 900 mg/day for the last week.
224180330|NCT02961348|OTHER|Late start of NOAC|Initiation of NOAC between day 5 and day 10 after acute ischemic stroke in patients with atrial fibrillation
223489596|NCT06590792|OTHER|exhaustive exercise training session|Cardiovascular exercise test will be performed by the participants. This test is sustained until the participants feel exhausted.
223489597|NCT06827782|BIOLOGICAL|anti-CD19 CAR-NK cells|lentiviral vector-transducted cord blood-derived NK cells to express anti-CD19 CAR
223489598|NCT06268808|DEVICE|FreeStyle Libre 2 Flash Glucose Monitoring System|Glucose sensors to be worn continuously for 3 months with data used to monitor and manage diabetes treatment and to inform lifestyle choices (diet and exercise)
223489599|NCT04282616|OTHER|Home-based unstructured physical activity program|Counselling on physical activity according to American College of Sports Medicine guidelines
223489600|NCT04282616|OTHER|Home-based structured low-intensity physical activity program|Structured home-based low-intensity intermittent walking program
223489601|NCT04282616|OTHER|In-hospital structured supervised physical activity program|Supervised exercise training program
223489602|NCT06843720|BEHAVIORAL|HR-HPV Testing|Given by Interview and focus groups
223489603|NCT06849726|PROCEDURE|Standard Epidural Analgesia|Administration of conventional epidural analgesia using an 18G Tuohy needle for catheter placement and subsequent administration of a standardized dose of bupivacaine with fentanyl.
223489604|NCT06849726|PROCEDURE|Dural Puncture Epidural Analgesia|Administration of epidural analgesia that incorporates a dural puncture with a 27G spinal needle prior to epidural catheter placement, followed by the same standardized dose of bupivacaine with fentanyl.
223587437|NCT01833000|DEVICE|Cerebral and splanchnic ear infrared spectroscopy (NIRS) and mesenteric Doppler|
223587438|NCT03153488|RADIATION|MRI|All participants will perform one MRI session before initiation of treatment. The imaging session will last about an hour including the structural and functional MRI portions. The subjects lie on a padded scanner couch in a dimly illuminated room, and wear foam earplugs to attenuate scanner sounds.
223587439|NCT03027232|OTHER|No intervention (drugs) will be given. Purpose: collecting blood for in vitro studies|No drugs or interventions are given. Single purpose is to draw blood from healthy subjects to study immune cell biology in vitro. No records about subjects to be kept.
223587440|NCT02095509|DRUG|Enoxaparin|Drug class: Low-molecular weight heparin
223587441|NCT02350738|OTHER|Period I MCET (8 wks)|MCET\_Mock group: Multimodal Cognitive Enhancement Therapy (MCET) (3 sessions/wk) Mock\_MCET group: mock-therapy (3 sessions/wk)
223587442|NCT02350738|OTHER|Washout (4 wks)|4 weeks wash-out period in both arms and cross-over
224180331|NCT00162630|PROCEDURE|Fascia Iliaca Compartment Blockade|
224180332|NCT02769689|DRUG|Methylprednisolone|Included patients will receive either methylprednisolone (1 gramme, 1 day every 4 weeks for a total of 3 grammes) or undistinguishable capsules of placebo
224180333|NCT02769689|DRUG|Placebo|Included patients will receive either methylprednisolone (1 gramme, 1 day every 4 weeks for a total of 3 grammes) or undistinguishable capsules of placebo
224180334|NCT02769689|DRUG|natalizumab (NTZ)|Patients with MS receiving NTZ for at least 18 months and without any disease activity during the previous year will be eligible. Included patients will receive either methylprednisolone (1 gramme, 1 day every 4 weeks for a total of 3 grammes) or undistinguishable capsules of placebo
224180335|NCT02769689|DRUG|fingolimob (FTY)|Every patient will initiate a treatment with FTY 7 weeks after the last NTZ perfusion. Methylprednisolone or placebo will be taken 4, 8 and 12 weeks (W4, W8 and W12) after NTZ discontinuation.
224180336|NCT02116192|BEHAVIORAL|Experimental: Low-fructose, reduced carbohydrate diet|"Low Carbohydrate (Low Fructose and Sucrose) Diet (Prescribed Hypocaloric regimen to promote 7% initial weight loss via 25-30kCal/kg;40-45% CHO, 20-25% Protein, 30-40% Fat)~● Aim for less than 25g fructose daily."
224180337|NCT02116192|BEHAVIORAL|General Healthy Diet|Prescribed Hypocaloric regimen to promote 7% initial weight loss via 25-30kCal/kg; 50-60% CHO, 15-20% Protein, 20-30% Fat
223489605|NCT05157386|OTHER|Braining|Core components of Braining: Personnel-led training sessions, motivating contact with psychiatric staff, measurement and evaluation before and after the training period; usually 12 weeks. PE is added on to treatment as usual (TAU). The training sessions are moderate to intense aerobic group training, 30-45 minutes. Each training session is preceded by a short (5-10 minutes) individual meeting with staff including assessment of daily form, motivational work, and the opportunity to ask questions. The target frequency for participation is preferably at least three training sessions/week during a 12 week period. The training period for each patient begins with an informative and motivating group or individual lecture or and an individual introductory meeting with staff including psychiatric and somatic examination, self-assessment scales for symptoms and quality of life, and blood samples. The training period ends with a meeting with staff with follow-up on the parameters.
223489606|NCT05560685|OTHER|Outcomes4Me|Patient participants will use the outcomes4Me app to answer PROs over the first 12 weeks of endocrine therapy.
223489607|NCT05560685|OTHER|Semi-structured interview|Team member participants will complete a semi-structured interview.
223489608|NCT05965427|OTHER|No intervention|Study is retrospective data collection only
223489609|NCT05514548|DRUG|INV-202|INV-202 is a new generation of CB1R antagonist developed by Inversago for potential use as a therapeutic method for the treatment of metabolic disorders, including nonalcoholic steatohepatitis, diabetes and its complications (such as DKD), and hypertriglyceridemia.
223489610|NCT05514548|DRUG|Placebo|Placebo Matching size and number of tablets
223489611|NCT05620212|BEHAVIORAL|Recovery College participation|Recovery College participation in any way (visitors, course/retreat participants, volunteers, employees).
223489612|NCT02101788|DRUG|Letrozole|Given PO
223489613|NCT02101788|DRUG|Paclitaxel|Given IV
223489614|NCT02101788|DRUG|Pegylated Liposomal Doxorubicin Hydrochloride|Given IV
223489615|NCT02101788|OTHER|Quality-of-Life Assessment|Ancillary studies
223489616|NCT02101788|OTHER|Questionnaire Administration|Ancillary studies
223489617|NCT02101788|DRUG|Tamoxifen Citrate|Given PO
223489618|NCT02101788|DRUG|Topotecan|Given IV
223489619|NCT02101788|DRUG|Trametinib Dimethyl Sulfoxide|Given PO
223489621|NCT06136169|BEHAVIORAL|Reminder-cue scanning training|Auditory reminders to scan when scanning to the side of the field loss is inadequate
223587443|NCT02350738|OTHER|Period II MCET (8 wks)|MCET\_Mock group: mock therapy (MCET) (3 sessions/wk) Mock\_MCET group: Multimodal Cognitive Enhancement Therapy (MCET) (3 sessions/wk)
223587444|NCT04452773|DIETARY_SUPPLEMENT|Manremyc|Manremyc is composed by 10E5 heat-inactivated Mycobacterium s. manresensis bacilli
223489622|NCT05770479|BEHAVIORAL|Motivationally-Enhanced Compensatory Cognitive Training (ME-CCT) Booster Modules|ME-CCT is a traditionally a manualized group-based behavioral intervention (8 weeks, 2 hours per week) designed to improve cognitive and everyday functioning in patients with MCI. Our booster modules will be shortened and distilled from ME-CCT using the IM Adapt protocol (and thus will not be new information but rather 'reminder' content) for a personalized four-session sequence of booster training targeted toward specific everyday functional needs of individual participants.
223489623|NCT05770479|OTHER|Treatment As Usual|Treatment for MCI is generally managed by Primary Care or Neurology. Participants will continue to receive their usual care with their current providers. With no effective pharmacological treatment known for persons with MCI, providers tend to focus on encouraging a healthy lifestyle, prevention and management of modifiable risk factors for cognitive impairment, and treatment of behavioral and psychiatric symptoms.
223587445|NCT04452773|DIETARY_SUPPLEMENT|Placebo|Same excipients than active arm without bacilli.
223587446|NCT00895544|BIOLOGICAL|Influenza vaccine (whole virion, Vero cell derived)|Dose A (Vietnam strain) for priming vaccination (Day 0) - Dose B (Indonesia strain) for booster vaccination (Day 360)
223587447|NCT00895544|BIOLOGICAL|Influenza vaccine (whole virion, Vero cell derived)|Dose A (Vietnam strain) for priming vaccination (Day 0) - Dose A (Indonesia strain) for booster vaccination (Day 360)
223587448|NCT02288988|PROCEDURE|Antireflux Surgery|Collis gasytroplasty Nissen antireflux fundoplication
224180338|NCT05291429|DEVICE|OVR Health's VR experience|Virtual reality experience
223587449|NCT02557984|DRUG|Placebo|Placebo Pill
223489624|NCT05768685|BEHAVIORAL|Affective touch paradigm|Affective touch paradigm: experimental stimuli will include the touch of a soft cosmetic, a hand, which will be both expected to resemble affective pleasant stimulations, and a plastic stick with a rounded tip, as a control (non-affective) condition. Two speeds of stimulation will be adopted i) slow affective stimuli delivered at 3 cm/s and fast non-affective stimuli, delivered at non-optimal speed (18 cm/s). An imagery version of the task will be also administered: blindfolded participants will be asked to image the touches on their left forearm. After each (actual or imagined) tactile stimulus, individuals will rate the experience level of pleasantness. As part of the protocol, they will fill out two psychological questionnaires, assessing the level of social anhedonia and the amount and characteristics of the lifespan experiences of affective touch inclose relationships.
223489625|NCT03943173|DRUG|Chemotherapy|Given standard chemotherapy
223489626|NCT03943173|DRUG|Olaparib|Given PO
223489627|NCT03943173|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
223489628|NCT01292408|DRUG|Hydrochloroquine|800 mg per os once, and then 400 mg per day
223587450|NCT02557984|DRUG|Amisulpride|400 mg Amisulpride
223587451|NCT02557984|DRUG|Naltrexone|50 mg Naltrexone
223587452|NCT00003719|DRUG|irinotecan hydrochloride|
224180339|NCT03040063|PROCEDURE|Combined endovascular approach (EVAR)|"1. puncture of SFA in orthograde position if possible~2. DSA through 4F dilator, proof of occlusion~3. wire test~4. Heparin 70-80 IU/kg i.a.~5. implantation of peripheral stent graft VIABAHN~6. implantation of peripheral stent SUPERA into stent graft~7. insertion of strait flush catheter for local thrombolysis~8. administration of continuous local thrombolysis in the dose of 1 mg/hr., unfractionated heparin continuously (APTT 1,5-2x) according to the department standards~9. control angiography in 12 hrs or earlier according to clinical status and symptoms~10. repeated angiography in 24 hrs"
224180340|NCT03040063|PROCEDURE|Standard optimal therapy (OPT)|"1. puncture of SFA in orthograde position if possible~2. DSA through 4F dilator, proof of occlusion~3. wire test~4. Unfractionated heparin 70-80 IU/kg i.a.~5. insertion of strait flush catheter for local thrombolysis~6. administration of continuous local thrombolysis in the dose of 1 mg/hr., unfractionated heparin continuously (APTTT 1,5-2x)~7. control angiography in 12 hrs or according to clinical status and symptoms~8. repeated angiography in24 hrs~9. Final result review, vascular team consultation and indication for surgical or conservative management of popliteal artery aneurysm."
224180341|NCT05987709|DIAGNOSTIC_TEST|GuardantSHIELD Blood Test|The GuardantSHIELD CRC screening test is a commercially available test which works by finding signs of colorectal tumor in the blood of patients at average risk for CRC
224180342|NCT04134689|DEVICE|DOT Selfie Intervention|This comprises a smart phone, the VDOT App, a prepaid weekly internet bundle and text message medication reminders
224180343|NCT04134689|OTHER|In-person DOT|Directly observed TB treatment by a health-worker either in a patient's home or at an agreed upon location within the community.
223489629|NCT03366246|DRUG|Lidocaine / Prilocaine Cream|according randomized this side received placebo or active product
223489630|NCT03366246|DRUG|placebo|according randomized this side received placebo or active product
223489631|NCT01092377|DIETARY_SUPPLEMENT|DHA and EPA Fish Oil capsule|2 DHA/EPA capsules on 4 days per week containing totally 420 mg DHA and 80 mg EPA, providing an average dose of 285.7 mg n-3 fatty acids per day
223489632|NCT01092377|DIETARY_SUPPLEMENT|Iron tablet|1 iron tablet containing 50 mg of iron as ferrous sulfate will be administered on 4 days per week, providing an average iron dose of 28.6 mg iron per day.
223489633|NCT01092377|OTHER|Placebo tablet|Placebo tablet will be administered on 4 days per week and will be identical in appearance to the iron tablet.
223489634|NCT01092377|OTHER|Placebo capsule|Placebo capsules contain medium chain triglycerides and will be identical in appearance and total fat content to the DHA/EPA capsules.
223489635|NCT05836948|DRUG|SHR-9839|Weekly fixed dose injection of SHR-9839
223489636|NCT04925635|BEHAVIORAL|experimental group|"The arteriovenous fistula care mobile health application will be installed and promoted on the smart phones of the patients in the experimental group. Arteriovenous fistula care mobile health application will be installed in daytime groups during working hours during or at the end of dialysis according to the patient's request. In addition, the information contained in the arteriovenous care mobile health application will be verbally explained to the patients and their relatives, as well as shown in practice. The training results were evaluated by the researcher in the 1st and 3rd months in the Scale for Evaluation of Self-Care Behaviors Related to Arteriovenous Fistula in Hemodialysis Patients, Final Level of Renal Failure Compliance Scale, Arteriovenous Fistula Care Education Knowledge Level Evaluation Form (Post-Training Section) and  Visual Benchmarking Scale ."
223489637|NCT04925635|BEHAVIORAL|control group|"Patients in the control group will receive arteriovenous fistula care training and a training booklet will be given. The information contained in the booklet will be explained orally to the patients and their relatives by the researcher, and will also be shown in practice. The results of the training were determined by the researcher at the 1st and 3rd months of the Self-Care Behaviors Scale for Arteriovenous Fistula in Hemodialysis Patients, End Stage Renal Failure Compliance Scale, Arteriovenous Fistula Care Training Information Level Assessment Form (Post-training section) and Visual It will be evaluated with the Comparison Scale."
223489638|NCT04646629|DEVICE|electroacupuncture treatment|"Participants in the treatment group underwent 60 minutes acupuncture (0.30mm×70mm) at ST36 (Zusanli) and ST37 (Shangjuxu) twice a day for seven days.After Deqi, electroacupuncture stimulation apparatus (HANS G6805-2, Huayi Co, Shanghai, China) is connected with the density wave (2/100 Hz), width 0.25 ms, intensity of 1 \~ 30 mA (gradually increase to the patient's maximum tolerance) and maintained the end of treatment."
223489639|NCT04646629|DEVICE|sham electroacupuncture treatment|"Participants in the sham electroacupuncture group received shallow needling (0.30mm×25mm) at ST36 and ST37(nonacupoints located 1 inch beside acupoints, about20mm). Specifically, the depth of needle insertion into nonacupoints is 3-5mm and avoided manual stimulation and no Deqi without actual current output, and retained the needle for the same time as treatment group"
223587453|NCT03031119|DRUG|Placebo|Tablets administered once or twice daily, with food, in Part A.
223587454|NCT03031119|DRUG|PF-06835919|Tablets administered once or twice daily, with food, in Part A. Tablets administered once or twice daily, with food and atorvastatin in Part B.
223489640|NCT03653481|DIETARY_SUPPLEMENT|Oligofructose-enriched Inulin OI|Consumed as a powder, 8g/d for children \<50kg and 16g/d for children ≥50kg, divided in 2 daily doses.
223489641|NCT03653481|DIETARY_SUPPLEMENT|Maltodextrin|Consumed as a powder, 8g/d for children \<50kg and 16g/d for children ≥50kg, divided in 2 daily doses.
223587455|NCT03031119|DRUG|atorvastatin|In Part B, tablets administered once or twice daily, with food, with and without PF-06835919.
223587456|NCT05105815|BIOLOGICAL|IPM001|IPM001 will be used against tumor cells
223587457|NCT01233388|OTHER|Text message surveillance|Text message surveillance for vaccine adverse events
223587458|NCT02715726|DRUG|Alirocumab|Pharmaceutical form:solution Route of administration: subcutaneous
223587459|NCT02715726|DRUG|Placebo for alirocumab|Pharmaceutical form:solution Route of administration: subcutaneous
223587460|NCT02715726|DRUG|ezetimibe|Pharmaceutical form:capsule Route of administration: oral
223587461|NCT02715726|DRUG|placebo for ezetimibe|Pharmaceutical form:capsule Route of administration: oral
223587462|NCT02715726|DRUG|atorvastatin|Pharmaceutical form:tablet Route of administration: oral
223587463|NCT02715726|DRUG|rosuvastatin|Pharmaceutical form:tablet Route of administration: oral
223489642|NCT03866694|BEHAVIORAL|BRIGHT|Dyadic therapeutic parenting intervention (BRIGHT) beginning in third trimester of pregnancy through six months postpartum focusing on child-parent relationship, mental health, infant social-emotional development, and recovery. Monthly handouts for mothers in recovery with information about child development and recovery from substance misuse while parenting and the standard of care at participant's high risk maternal-fetal medical clinic.
223489643|NCT03866694|OTHER|STAR/TAU+|Monthly handouts for mothers in recovery with information about child development and recovery from substance misuse while parenting and the standard of care at participant's high risk maternal-fetal medical clinic
223587464|NCT02715726|DRUG|simvastatin|Pharmaceutical form:tablet Route of administration: oral
224180344|NCT03943394|OTHER|fresh samples are obtained from patients for detction of PCM1- JAK2 fusion gene|"Samples are dehydrated in ethanol (a 50, 80 and 95% (v/v) series, exposure for 3 min to 300 µl ethanol at each concentration) prior to hybridization.~Samples on tapes are hybridized for 15 minutes at 55?C using a moisture-sealed slide incubation chamber. Briefly, 500 µl volumes of hybridization buffer (0.7 M NaCl, 0.1 M Tris \[pH 8.0\], 0.1% sodium dodecyl sulfate, 10 mM EDTA, containing probe, preheated to 55 ºC) are applied to the surface of the tape and the chamber's lid is sealed, creating a moist, temperature controlled environment within the chamber.~After 15 min, the lid is removed and samples are briefly rinsed with probe-free hybridization buffer, preheated to 55ºC.~Hybridized cells on tapes are counterstained for 10 minutes in the dark with \~30 µl mounting medium containing 1.5 µg ml-1 4',6-diamidino-2-phenylindole (DAPI).~Then tapes are mounted with a coverslip and examined using a fluorescence microscope."
224180345|NCT03960294|OTHER|DOZE Sleep App|DOZE is an evidence-based cognitive behavioural therapy for insomnia app created specifically for use with adolescents and young adults.
224180346|NCT00758420|DRUG|Varisolve (Polidocanol Endovenous Microfoam)|1% polidocanol, up to 15 mL, one treatment session (initially up to 30 ml, reduced to up to 15 ml in Amendment #2)
224180347|NCT00758420|DRUG|Agitated Saline|10 u/mL normal heparinized saline solution, up to 20 mL, one treatment session
224180348|NCT04763824|BEHAVIORAL|Telementoring with Practice Facilitation|We are attempting to provide education and encourage practice change
224180349|NCT02790749|PROCEDURE|Adjunctive hip arthroscopy to accompany PAO|This is the experimental group: those patients who undergo adjunctive hip arthroscopy in addition to periacetabular osteotomy (PAO).
224180350|NCT02790749|PROCEDURE|PAO without adjunctive hip arthroscopy|This is the control group: those patients who undergo periacetabular osteotomy (PAO) alone, without adjunctive hip arthroscopy.
223489644|NCT05839977|OTHER|Individual telerehabilitation|The exercise will consist of strength and balance exercises using the Homebalance ® system
223489645|NCT05839977|OTHER|Home exercises based on videos|intervention include 12 video recordings of exercises created by a physiotherapist for home exercises, according to which they will also exercise
223489646|NCT05853263|DRUG|paracetamol|paracetamol IV to substitute morphine IV.
223587465|NCT03536026|PROCEDURE|Conventional bronchoscopy|-Standard of care
224180351|NCT03374228|DRUG|BMS-986205|Specified Dose on Specified Days
224180352|NCT02215486|OTHER|Head Massage Therapy|Intervention consists of administering head massage therapy according to the Chinese head massage protocol for approximately 10 minutes.
224180353|NCT02215486|OTHER|Simple relaxation (No Head Massage)|Consists of a simple relaxation in the same sitting position as the head massage therapy session.
224180354|NCT02628262|PROCEDURE|Vitrectomy with internal limiting membrane removal and gas tamponade|Vitrectomy with internal limiting membrane removal and gas tamponade
224180355|NCT02571829|DRUG|ribociclib|Oral, 600 mg x 1 a day, duration - according to response
224180356|NCT03783221|OTHER|High-fat diet|The high-fat diet (51% fat, 27% carbohydrates, 21% proteins and 4.7 g fiber) will be administered for two weeks..
223489647|NCT05853263|DRUG|Morphine|standard care
223489648|NCT01470170|DRUG|Alfentanil|Give Alfentanil before TCI Propofol sedative bronchoscope
223489649|NCT01470170|DRUG|Normal saline|Normal Saline (placebo comparator) was given in equivalent amount of alfentanil dosage in each arm, for double blinded purpose.
223587466|NCT03536026|DEVICE|VIDA Pulmonary Workstation 2|-Virtual bronchoscopic navigation system
223587467|NCT03536026|PROCEDURE|Biopsy|-Standard of care
224180357|NCT03783221|OTHER|High-residue diet|The high-residue diet (19% fat, 62% carbohydrates, 16% proteins and 54.2 g fiber) will be administered for two weeks.
224180358|NCT03941327|DEVICE|AxoGuard Nerve Cuff|A porcine collagen implant will be used to make a protective sheath around the participant's exposed spinal accessory nerve during surgery. This will be performed by physically wrapping the exposed nerve with the implant and suturing the ends together. The goal is to protect nerve from adhesions and compression in the absence of normal protective lymphatic soft tissue.
223587468|NCT01378611|DEVICE|Vagus Nerve Stimulator: Neurocybernetic prothesis NCP, Cyberonics Inc., Webster, TX, USA|The study group is stimulated with the following parameters: Output current 0.25 milliampere (to be ramped up to max. 1.75 milliampere), Pulse width 0.5 milliseconds, Frequency 30 Hz, Duty cycle: 30 sec on 5 min off (duty cycle 10%).
223587469|NCT01906112|PROCEDURE|Surgery for primary breast tumor.|Complete resection of primary breast tumor(Lumpectomy or mastectomy)
223587470|NCT04790292|DRUG|group M|10mg morphine in 5ml normal saline + 10ml of 0.25% bupivacaine ( total volume 15 ml) were injected intra-articularly
223587471|NCT04790292|DRUG|group MD|10mg morphine + 8mg dexamethasone completed to 5 ml with normal saline + 10 ml of 0.25% bupivacaine (total volume of 15ml) were injected intra-articularly
223587472|NCT01177969|BEHAVIORAL|Cognitive-Behavioral Therapy|The form of treatment will involve 16 weekly meetings of about 90 minutes each. Sessions involve both the child and parent and involve teaching youth how to cope with their anxiety through a variety of behavioral techniques.
223587473|NCT01177969|BEHAVIORAL|Wait-list|A wait-list essentially involves not receiving treatment for a specified period of time (in this case 16 weeks). No active treatment is provided; rather, the family 'waits'.
223587474|NCT03230292|DRUG|Bimekizumab|Bimekizumab will be administered subcutaneously in 2 different doses.
223587475|NCT03797092|BIOLOGICAL|Allogeneic adipose-derived stromal cells (CSCC_ASC)|Active group
223587476|NCT03797092|OTHER|Control group|No treatment
223587477|NCT04474041|DEVICE|EyeQue Insight|The Insight will be used to measure visual acuity and compared with a standard ETDRS eye chart.
224180359|NCT02286622|DRUG|Deflazacort|Deflazacort, a glucocorticoid with anti-inflammatory and immunosuppressive effects, is used in treating a variety of diseases. Pharmacologically it is an inactive pro-drug which is metabolized immediately to the active metabolite 21-desacetyl-DFZ. The elimination of this metabolite is primarily via the urine in humans. Its potency is approximately 70 to 90% of prednisone and 6 mg of deflazacort has approximately the same anti-inflammatory potency as 5 mg of prednisolone or prednisone
224180360|NCT04146129|DRUG|CDX-0159|Single dose of one of four dosages of CDX-0159
224180361|NCT04146129|DRUG|Normal saline|Single infusion of normal saline
224180362|NCT05488028|PROCEDURE|Piezo-electric surgery of impacted lower third molars|"During lower third molar surgery, osteotomy is performed using piezoelectric instrumentation.~When necessary, tooth sectioning was performed with a high-speed tungsten carbide slit drill under saline irrigation and the tooth removed in single or multiple segments."
224180363|NCT05488028|PROCEDURE|Rotary bur surgery of impacted lower third molars|During lower third molar surgery, osteotomy is performed using rotary instruments
224180364|NCT06496399|BEHAVIORAL|psychoeducation|"-The elderly's preferences for art therapy (art activities such as wood painting, creating shapes with mud) will be taken into account.~2-Expression of emotions through motivational interviewing 3-Conscious Awareness therapy, staying in the moment here and now 4- Hobbies (growing flowers, gardening, handicraft knitting, puzzle solving, card games, chess game, etc., organizing trips, cinema, movie events and so on)"
224180365|NCT00536354|OTHER|Postural Orientation|
223489650|NCT01470170|DEVICE|Targeted controlled infusion|The Propofol dosage was according to the effect site concentration to reach OAAS-3 ( loss of conscious), using Schneider model
223489651|NCT01470170|DRUG|Propofol|The Propofol dosage is according to the effect site concentration to reach OAAS-3 ( loss of conscious), using TCI Schneider model during the whole procedure of bronchoscope
223489652|NCT00055146|DRUG|ONTAK|
223489653|NCT00927472|DRUG|Malathion gel 0.5%|Malathion gel 0.5% applied to scalp for 30 minutes. May be repeated in 1 week if head lice are still present.
223489654|NCT00927472|DRUG|Permethrin 1% rinse|Permethrin 1% shampooed into scalp for 10 minutes. May be repeated in 1 week if head lice are still present.
223489655|NCT02641041|BIOLOGICAL|BIIB033|single or multiple dose
223489656|NCT02641041|OTHER|Placebo|single or multiple dose
223489657|NCT01373619|DRUG|Ivabradine|ivabradine titrated to 7.5 mg BID
223489658|NCT00829153|DEVICE|U Clip|Interuppted nitional clips
223489659|NCT00829153|PROCEDURE|Conventional prolene anastomosis|Continuous prolene anastomosis
223489660|NCT01991951|DRUG|warfarin|
223489661|NCT05973448|OTHER|Novel Lighting Condition|Horizontal and vertical lights over a doorway visible from the bed
223489662|NCT05973448|OTHER|Control Lighting Condition|Standard night light plugged into wall socket
223489663|NCT06530329|OTHER|Classical massage|Classical massage was started by general stroking 3 times. Then, it was continued by kneading 3 times. After the kneading movement, fibrocytic nodules on the muscle were searched and friction was applied to the found nodules one by one. The massage of the muscle was completed by applying stroking 3 times. The application was carried out 3 times a week for 2 weeks to evaluate the short-term effect.
223489664|NCT06530329|OTHER|Ischemic compression|Ischemic compression was applied to the trigger points in the upper trapezius muscle using an average pressure of 1 kg at a right angle, and after compression, passive stretching was applied to the upper trapezius muscle 3 times in 20-second periods. The application was performed 3 times a week for 2 weeks to evaluate the short-term effect.
224180366|NCT05163964|BEHAVIORAL|Lifestyle Intervention|Circadian misalignment contributes to the high glycemic outcome. To adjust meal timing earlier and avoid late-night meal eating patterns, to switch from the evening chronotype to morning chronotype possibility to reverse glucose fluctuation conditions.
224180367|NCT05620849|BEHAVIORAL|Online program|The online program is 4 weeks and focused on topics such as alcohol and sexual health
224180368|NCT02314299|DRUG|MTP-131|
224180369|NCT05248633|RADIATION|radiotherapy|radiotherapy with a dose of 40-50 Gy
224180370|NCT05248633|DRUG|Bortezomib Injection|subcutaneous Bortezomib 1.3mg/m2 d1,8,15,22
224180371|NCT05248633|DRUG|Lenalidomide|Lenalidomide 25mg for 21 days
224180372|NCT05248633|DRUG|Dexamethasone|Dexamethasone 40mg d1,8,15,22
224180373|NCT04830813|DRUG|Chiauranib|Patients take Chiauranib capsules 50mg, orally once daily, 21 days as a cycle until objective disease progression.
223489665|NCT03897621|DRUG|Tranexamic Acid|tranexamic acid will be administered intravenously after induction of anesthesia (a bolus of 10 mg/kg or maximal dose of 1g).
223489666|NCT03897621|DRUG|Placebo|Patients in the placebo group will receive normal saline (a bolus of sodium chloride 0.9%, 0.1 mL/kg or maximal dose of 10 mL).
223489667|NCT03997136|PROCEDURE|Supratentorial high grade gliomas resection.|Total, near total or subtotal/debulking resection of the brain supratentorial high grade gliomas
223489668|NCT01091207|DRUG|Sorafenib|The patients will receive daily oral administration of sorafenib 400 mg twice daily.
223489669|NCT03882099|DIAGNOSTIC_TEST|Determination of Vitamin D by ELISA|Blood samples
223489670|NCT02649699|OTHER|3D MRI Scans|Patients will receive additional MRI scans before commencing their radiation treatment, at 3-4 months, 6 months and 12 months post RT as well as at recurrence or suspected recurrence.
223489671|NCT06388213|DEVICE|Gastric Ultrasonography|Evaluation of cross sectional area of the antrum by gastric ultrasonography in healthy patients and in patient treated by GLP-1 receptor agonists after a fasting period (6 hours for solid and 2 hours for clear liquids). For the GLP-1 receptor agonists group the gastric ultrasonochography will be repeated each 2 days during 7 days. In the non GLP-1 receptors agonists group the evaluation will be executed one time.
223745433|NCT07190495|DRUG|Placebo|Patients will receive an oral placebo capsule identical in appearance to ginger, administered 2 hours before laparoscopic cholecystectomy
224180374|NCT04830813|DRUG|Placebo|Participants received Chiauranib placebo capsule matching Chiauranib orally once daily until objective disease progression.
224180375|NCT04027127|OTHER|netrin-1 value on admission to hospital|
224307498|NCT01345578|DRUG|human hepatocyte transplantation|"Transplantation of hepatocytes into the liver will be through the portal vein. The portal vein will be accessed transhepatically, by umbilical vein, or surgically by a peripheral mesenteric vein.~The subject will be evaluated de novo and if they are a candidate for orthotopic liver transplantation they will receive the transplant. Even if the subject receives the hepatocyte transplant and it does not work, they will be evaluated for orthotopic liver transplantation as if they never received the hepatocyte transplant.~If at 6 months we see an improvement in disease, we will recommend a re-transplantation with a goal of complete correction of disease and until the subject is no longer required to be a candidate for organ transplantation. Subjects will be re-evaluated every 6 months for re-transplantation. Subjects will remain on the waiting list for organ transplantation. Further radiation therapy will not be needed prior to re-transplantation."
224307499|NCT01345578|RADIATION|Preparative Radiation Therapy|Just prior to the hepatocyte transplant, a portion of the right hepatic lobe comprising between 35-50% of the entire liver volume will be irradiated to a dose of 7.5-10 Gy in a single fraction using a linear accelerator-based stereotactic radiosurgery system with intensity-modulated radiation therapy planning (IMRT).
223489672|NCT06468046|BEHAVIORAL|Mama Empoderada [Mom Power]|'Mamá Empoderada' \[Mom Power\] is a theory-based, trauma-informed group intervention to promote mental health and positive parenting among mothers with young children (0-5 years). It has been adapted for migrant mothers, and will conduct a pilot randomized controlled trial (RCT) of the intervention with migrant mothers with young children (MMC). The intervention group (IG) will receive 10 group and 3 individual sessions addressing attachment theory, hands-on parenting skills, linkage to resources (e.g., food, shelter), social support, and self-care and resilience.
223489673|NCT06069908|OTHER|Complex Decongestive Treatment|Complex Decongestive Treatment (manual lymph drainage, skin care, special exercises, compression) approach. It will be applied 5 days a week for 3 weeks
223489674|NCT06069908|OTHER|Sham transcutaneous vagus nerve stimulation|In sham transcutaneous vagus nerve stimulation application, the device electrode will be placed in the superior scapha region of the outer ear, where the vagus nerve has no innervation, and no current will be given.Complex Decongestive Therapy and sham transcutaneous vagus nerve stimulation.It will be applied 5 days a week for 3 weeks.
223489675|NCT06069908|OTHER|Transcutaneous Auricular Vagus Nerve Stimulation|Transcutaneous vagus nerve stimulation will be applied in addition to Complex Decongestive Therapy.It will be applied 5 days a week for 3 weeks.
223489676|NCT06069908|OTHER|Exercise|Patients will undergo lymphedema-specific exercises 5 days a week for 3 weeks.
223489677|NCT06510296|BEHAVIORAL|Digital Mind Body Intervention mobile application|A DMBI mobile application with psychoeducation and skill-building in illness perception, coping, mindfulness, and disease acceptance informed by needs/barriers of Black and Hispanic patients with IBD who have elevated psychological distress and GI professionals caring for IBD patients.
223489678|NCT04812015|DEVICE|transcutaneous auricular vagus nerve stimulation (taVNS) 15 minutes|Sham 60 minutes and taVNS active stimulation for 15 minutes
223489679|NCT04812015|DEVICE|taVNS 30 minutes|Sham 45 minutes and taVNS active stimulation for 30 minutes
223489680|NCT04812015|DEVICE|taVNS 45 minutes|Sham 30 minutes and taVNS active stimulation for 45 minutes
223489681|NCT04812015|DEVICE|taVNS 60 minutes|Sham 15 minutes and taVNS active stimulation for 60 minutes
223489682|NCT04812015|DEVICE|taVNS 75 minutes|Sham 0 minutes and taVNS active stimulation for 75 minutes
223489683|NCT04812015|DEVICE|taVNS 0 minutes|Sham taVNS 75 minutes
223489684|NCT04838444|BIOLOGICAL|VLA1553|Trial participants previously vaccinated with VLA1553 in trial VLA1553-301 will be followed up for safety and immunogenicity.
223489685|NCT05725239|DEVICE|Vagus Nerve Stimulation|All taVNS sessions will use the following parameters: 25Hz, 500us pulse width, on for 7 seconds, off for 12 seconds.The length of VNS treatment sessions will be identical to TMS treatment sessions and will have the same 30 minute break between each treatment session. These treatments (active or sham) will be administered to participants each treatment day, for a total of 6 different treatment days, but only 4 are active.
223489686|NCT05725239|DEVICE|Transcranial Magnetic Stimulation|Participants will receive 20 trains of 30 pulses each for a total of 600 pulses per session. We will repeat this for 6 sessions each day, with at least 30 minutes between each session. These treatments (active or sham) will be administered to participants each treatment day, for a total of 6 different treatment days, but only 4 are active, so participants will get 24 TMS sessions over the course.
223489687|NCT05458128|DRUG|Pitolisant|"Pitolisant 4.45 mg tablets~Pitolisant 17.8 mg tablets"
223489688|NCT02512419|BEHAVIORAL|Text-Enhanced Physical Activity Intervention Arm|Participants in the Text-Enhanced Physical Activity intervention arm of the study receive a Spanish language, motivationally-tailored, print-based + text-message physical activity intervention that specifically addresses the physical activity barriers and intervention needs/preferences of Mexican and Mexican American men.
223489689|NCT02512419|BEHAVIORAL|Health Education Control Arm|Participants will receive a Spanish language, print-based Wellness Contact control intervention addressing relevant health topics other than physical activity.
223489690|NCT02512419|DEVICE|Actigraph GT3X|
224073311|NCT06287034|PROCEDURE|Primary suture|The primary suture can be performed according to the different techniques available at the discretion of the surgeon (vertical, horizontal or T-shaped closure, with continuous suture, according to Connell or with detached stitches)
224073312|NCT00441597|DRUG|atorvastatin|atorvastatine 80mg, during 3 days
224073313|NCT06094257|DIAGNOSTIC_TEST|Sensory testing|Quantitative sensory testing (QST) will be performed. QST was developed to standardize the noninvasive assessment of the somatosensory nervous system and quantify functioning of all aspects of sensation (light touch, pressure, warm, cold, pain, vibration): 1. Thermal detection (Medoc TSA system): Cold detection threshold B) Warm detection threshold C) Heat pain threshold 2. Mechanical detection threshold (MRC Opti Hair von Frey Filaments) 3. Two-point discrimination (MRC Opti Hair von Frey Filaments) 4. Mechanical pain threshold (MRC Pinprick Stimulator) 5. Pressure pain threshold (Medoc Pressure algometer) 6. Tinel sign on physical exam 7. Vibration (tuning fork)
224073314|NCT07131982|OTHER|Informative Animated Video to be Viewed with Virtual Reality Glasses|No study has been found in the literature evaluating the effect of animated videos shown to children through virtual reality glasses on mothers and children. The aim of this study was to determine the effect of animated videos shown through virtual reality glasses before surgery on perioperative anxiety and fear in children and their mothers.
223587478|NCT02388542|BEHAVIORAL|Educational Intervention|Employees above the age of 35 years will be risk stratified into moderate or high risk of developing cardiovascular disease using a simple non-lab based risk scoring system, they will be invited to participate in the pilot intervention study. This is a single arm before-after study.subject education will focus on life style medication and adherence to medication (if applicable).importantly the peer mentor will try to identify barriers to adopting a healthy lifestyle(tobacco, physical acitivity, diet, alcohol and strees) and adherence to cardiovascular disease prevention medication. peer mentors will be trained to interpret blood glucose and lipids, recognize abnormal valves, provide lifestyle counseling and refer to treating physician when appropriate.
223587479|NCT04570189|DEVICE|Auscul-X|The Auscul-X System (AusculSciences Canada, Inc.), is novel, professional grade, touch free, multichannel, touch-free electronic stethoscope with disposable elements designed to protect HCPs from exposure to infection diseases by allowing them to auscultate patients from a safe distance (10 feet away). The sensors can stay in place and enable providers to listen on-demand to a patient's heart and lungs over an extended period of time. This practice of distancing in the workplace is a key CDC and PHAC recommendation to protect the frontline HCP from exposure risk to the highly contagious COVID- 19 virus and other communicable diseases. The Auscul-X not only has the potential to better protect HCPs from infection, but also eliminates the potential transmission of pathogens through the use of conventional stethoscopes. In addition, the Auscul-X allows multiple HCPs to listen to the patient's heart and lung sounds simultaneously
224180376|NCT04273802|DRUG|CPX-351 in cohort A|"Treatment by CPX-351 via intravenous infusion over 90 minutes.~Induction treatment with CPX-351 100 Units/m²/D on days 1, 3 and 5.~If response after this induction treatment, 4 courses of consolidation therapy with CPX-351 100 Units/m²/D on day 1.~If no response after this induction treatment, a second induction course of CPX-351 100 Units/m²/D on days 1 and 3. If response is achieved after this salvage course, 3 courses of consolidation therapy with CPX-351 100 Units/m²/D on day1."
224180377|NCT04273802|DRUG|CPX-351 in cohort B|"Treatment by CPX-351 via intravenous infusion over 90 minutes.~This will be a dose-finding study : CPX-351 100 Units/m²/D on days 1, 3 and 5 or CPX-351 100 Units/m²/D on days 1 and 3 or CPX-351 60 Units/m²/D on days 1 and 3.~In response after induction treatment, 4 monthly courses of consolidation therapy with CPX-351 at the same dose on day 1."
224180378|NCT03374982|DEVICE|DentalVibe|The DentalVibe is a handheld device that delivers vibration to the tissue during local anesthetic administration.
224180379|NCT03478631|OTHER|High-nitrate dehydrated vegetable powder|A mixed combination of vegetable powders that are naturally high in nitrate content, such as beet, spinach, and kale
224180380|NCT03478631|OTHER|Low-nitrate dehydrated vegetable powder|A mixed combination of vegetable powders that are naturally low in nitrate content, such as peas, tomato, broccoli, carrots, and brussel sprouts
224180381|NCT03290274|DEVICE|Deep brain stimulation (fornix)|Deep brain stimulation at fornix
223489691|NCT03568617|DEVICE|rTMS|The subjects will receive 20 trains of 100 stimuli each delivered at 10 Hz and 80% of MT over the left MC (M1), 3 days a week, for 4 weeks.
223489692|NCT05436613|DEVICE|Transcranial Direct Current Stimulation|tDCS at 2mA in 30 minute sessions for 5 sessions per week for 3 weeks and then 2 sessions per week for 3 weeks.
223489693|NCT05202301|DRUG|Darolutamide (Nubeqa, BAY1841788)|Retrospective cohort analysis, using the IQVIA Real-World Data Adjudicated Claims, US claims database
223489694|NCT05202301|DRUG|Enzalutamide|Retrospective cohort analysis, using the IQVIA Real-World Data Adjudicated Claims, US claims database
223489695|NCT05202301|DRUG|Apalutamide|Retrospective cohort analysis, using the IQVIA Real-World Data Adjudicated Claims, US claims database
223489696|NCT02176967|PROCEDURE|Biopsy|Undergo biopsy
223489697|NCT02176967|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
223489698|NCT02176967|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
223489699|NCT02176967|DRUG|Carboplatin|Given IV
223489700|NCT02176967|OTHER|Clinical Observation|Undergo clinical observation
223489701|NCT02176967|PROCEDURE|Computed Tomography|Undergo CT
223489702|NCT02176967|DRUG|Cyclophosphamide|Given IV
224180382|NCT03290274|DEVICE|Deep brain stimulation (Basal nucleus of Meynert)|Deep brain stimulation AT Basal nucleus of Meynert
224180383|NCT05255939|PROCEDURE|distal TRA group|dTRA for PCI procedure to ACS patients.
223489703|NCT02176967|DRUG|Doxorubicin Hydrochloride|Given IV
223489704|NCT02176967|DRUG|Etoposide|Given IV
224180384|NCT05255939|PROCEDURE|conventional TRA group|Conventional TRA for PCI procedure to ACS patients
224180385|NCT05243472|DIETARY_SUPPLEMENT|Protein nutritional supplement|Participants in the intervention group will receive protein-enriched soups (24-30g of protein). Protein may come from either soy, bean or milk products.
224180386|NCT05144269|OTHER|Multimodal exercises|Telehabilitation including pilates, breathing, progressive relaxation training, posture and pelvic floor strengthening exercises
224180387|NCT04630067|DRUG|AZD3427|Participants will receive SC or IV dose of AZD3427 as per the arm they are randomized.
223489705|NCT02176967|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223489706|NCT02176967|PROCEDURE|Ultrasound|Undergo ultrasound
223489707|NCT05679895|BIOLOGICAL|CD1a-CAR T|Autologous T-cells from peripheral blood, expanded and transduced with a lentivirus to express CD1a chimeric antigen receptor administered by intravenous infusion following a dose-escalation approach
223489708|NCT04002362|DRUG|Triamcinolone Acetonide|An intramuscular injection of triamcinolone acetonide (1 mg/kg, up to 40 mg maximum) is administered deep in the gluteal muscle by a trained registered nurse.
223489709|NCT05344157|BIOLOGICAL|XSTEM-OA|XSTEM-OA is an allogeneic, adipose tissue-derived, integrin alpha10beta1-selected and expanded mesenchymal stem cell (MSC) product for the treatment of osteoarthritis.
223489710|NCT05535244|DRUG|Cevostamab|Cevostamab will be administered by IV infusion in 21-day cycles.
223489711|NCT05535244|DRUG|Tocilizumab|Tocilizumab will be administered for the treatment of cytokine release syndrome (CRS) when necessary.
223489712|NCT05278416|DEVICE|Lumoral treatment -device and Lumorinse tablets|Subjects will use Lumoral treatment -device and Lumorinse tablets daily as per protocol.
223489713|NCT03505281|BIOLOGICAL|Blood samples|"Patients:~* 1 tube of 4 ml blood (Lithium Heparinate)~* 3 tubes of 7 ml blood (EDTA)~* 2 tubes of 7 ml blood (EDTA) for 20 NET Covid patients~Healthy volunteers:~* 1 tube of 4 ml blood (Lithium Heparinate)~* 3 tubes of 7 ml of blood (EDTA)~* 1 tube of 4 ml (citrate)"
224180388|NCT04630067|DRUG|Placebo|Participants will receive SC or IV dose of placebo matched to AZD3427 as per the arm they are randomized.
223489714|NCT04325022|DEVICE|Primary Total Hip Arthroplasty|Primary Total Hip Arthroplasty using the OR3O Dual Mobility System in combination with compatible components
223489715|NCT04325022|DEVICE|Revision Total Hip Arthroplasty|Revision Total Hip Arthroplasty using the OR3O Dual Mobility System in combination with compatible components
223489716|NCT05831579|RADIATION|Proton GRID Radiotherapy|The proton GRID radiotherapy prescription dose is 20 Gy x 3 fractions to the tumor, with an integrated dose of 6 Gy x 3 fractions to the PTV. Treatment to multiple lesions within the PTV is allowed (ex. a dominant lesion plus satellites). Multiple proton GRID radiotherapy plans may be delivered on the same day or different days, but they cannot overlap.
223489717|NCT05239403|PROCEDURE|Biospecimen Collection|Undergo collection of blood and stool samples
223489718|NCT05239403|OTHER|Questionnaire Administration|Complete questionnaires
223489719|NCT05442047|DRUG|NNC6019-0001|Participants will receive i.v infusionof NNC6019-0001.
223489720|NCT05442047|DRUG|Placebo (NNC6019-0001)|Participants will receive i.v. infusion of placebo (NNC6019-0001).
223489721|NCT05404490|DRUG|Bupivacain|20 mL of bupivacaine 0.5% will be infiltrated. 10 mL will be infiltrated in the inferior border and 10 mL in the superior border of the subcutaneous cellular tissue.
223489722|NCT05404490|DRUG|Placebo|20 mL of Normal Saline Solution will be infiltrated. 10 mL will be infiltrated in the inferior border and 10 mL in the superior border of the subcutaneous cellular tissue.
223489723|NCT06138821|DEVICE|ESG + lifestyle modification|Endoscopic sleeve gastroplasty - an endoscopic weight loss procedure where an endoscopic suturing device is utilized to reduce the size of the stomach by 70%.
223489724|NCT06138821|BEHAVIORAL|Lifestyle modification|Lifestyle modification program consisting of diet and exercise therapy
223489725|NCT02095366|DRUG|Morphine|"Intravenous administration Patient receives simultaneously IV morphine administration and IN placebo spray.~Pain is controlled by:~* at 0 minute : Placebo IN (2 sprays, one spray in each nostril) + morphine IV 0,1mg/kg~* at 10 minutes and if NPRS\>3 : Placebo IN (1 spray) + morphine IV 0,05mg/kg~* at 20 minutes and if NPRS\>3: Pacebo (1 spray) + morphine IV 0,05mg/kg"
223489726|NCT02095366|DRUG|Sufentanil|"Intranasal spray with one spray, equivalent to an half-dose. Patient receives simultaneously IV placebo administration and IN sufentanil spray.~Pain is controlled by:~* at 0 minute : Sufentanil IN 0,3µg/kg (2 sprays, one spray in each nostril) + NaCl 0,9% IV~* at 10 minutes and if NPRS\>3 : Sufentanil IN 0,15µg/kg (1 spray) + NaCl 0,9% IV~* at 20 minutes and if NPRS\>3: Sufentanil IN 0,15µg/kg (1 spray) + NaCl 0,9% IV"
223489727|NCT02095366|DRUG|Placebo|"Intravenous administration Patient receives simultaneously IV placebo administration and IN sufentanil spray.~Pain is controlled by:~* at 0 minute : Sufentanil IN 0,3µg/kg (2 sprays, one spray in each nostril) + NaCl 0,9% IV~* at 10 minutes and if NPRS\>3 : Sufentanil IN 0,15µg/kg (1 spray) + NaCl 0,9% IV~* at 20 minutes and if NPRS\>3: Sufentanil IN 0,15µg/kg (1 spray) + NaCl 0,9% IV"
223489728|NCT02095366|DRUG|Placebo|"Intranasal spray with one spray, equivalent to an half-dose. Patient receives simultaneously IV morphine administration and IN placebo spray.~Pain is controlled by:~* at 0 minute : Placebo IN (2 sprays, one spray in each nostril) + morphine IV 0,1mg/kg~* at 10 minutes and if NPRS\>3 : Placebo IN (1 spray) + morphine IV 0,05mg/kg~* at 20 minutes and if NPRS\>3: Pacebo (1 spray) + morphine IV 0,05mg/kg"
224205673|NCT03014570|BEHAVIORAL|EIT-4-BPSD|This arm includes the four step intervention: 1. Assessment of the environment and policies; 2. Education of staff; 3. Establishing person-centered care plans; and 4. Mentoring and motivating staff. We provide the sites with a research nurse who works with an identified stakeholder group and champion within the facility and visits the settings monthly, connects by email weekly to complete the four intervention steps. The implementation process is guided by the Evidence Integration Triangle (EIT) framework. The EIT brings together evidence and key stakeholders from the facility to influence care practices. EIT includes: participatory implementation processes, provision of practical evidence-based interventions, and pragmatic measures of progress toward goals.
223489729|NCT06275282|DEVICE|Intramuscular electrodes|Participants will have regenerative peripheral nerve interfaces (RPNIs) created on nerves in their residual thighs. During either the same surgery or a separate surgery, small electrodes will be implanted into these RPNIs.
223587480|NCT01852383|DRUG|Duloxetine|"Patients were evaluated weekly for the first 6 weeks and every two weeks for the next 6 weeks. At 0, 1, 4, 8, and 12 weeks, the study psychiatrist completed the Cornell Dysthymia Rating Scale , Clinical Global Impression (CGI) scale, and side effect ratings using the Treatment Emergent Symptom Scale. The research rater completed a SCID-P at baseline and the 24-item HAM-D at each visit, and the patient completed the Beck Depression Inventory-II at each visit.~Adverse events: All adverse events and serious adverse events were documented.~The maximum duration of delay before active treatment (medication or psychotherapy) was 1 week.~Dropout: Patients who had a CGI score of 6 or 7 for two weeks during the second half of the study were dropped by the investigator from the trial."
223587481|NCT00635089|DRUG|reslizumab|
223489730|NCT06966375|OTHER|WYSH Web Application|Worldwide Yearly Screening for Hypospadias (WYSH) Web Application
223489731|NCT06600152|DEVICE|MAP Wound Matrix|The MAP Wound Matrix is indicated for the management of full thickness wounds, including surgical sites, donor skin graft sites, wound dehiscence, lacerations, and draining wounds. The application of MAP Wound Matrix will occur immediately after Mohs surgery once hemostasis has been achieved
223489732|NCT06600152|DEVICE|DuoDerm|DuoDerm is a hydrocolloid dressing will be topically applied to the wound immediately following Mohs surgery according to the manufacturer\&#39;s instructions.
223489733|NCT06347315|DIETARY_SUPPLEMENT|BrainXpert|sachet/stickpack of 25 g, has no preservatives, no flavors, no sweeteners, and no colorants.
223489734|NCT06347315|OTHER|Placebo|high-oleic acid sunflower oil as a calorie-equivalent, non-ketogenic vegetable oil, non added vitamin product will also be provided in a powder format in a sachet/stickpack of 25 g.
223587482|NCT02565810|DRUG|Adalimumab PFS and Pen|
223587483|NCT02310997|OTHER|Umbilical Cord Blood Transplant|
223587484|NCT02310997|DRUG|Cyclophosphamide|
223587485|NCT02310997|RADIATION|Total body irradiation|
223587486|NCT02310997|DRUG|Busulfan|
223587487|NCT02310997|DRUG|Melphalan|
223587488|NCT02310997|DRUG|Fludarabine|
223587489|NCT01992562|DRUG|Ziconotide|
223587490|NCT01992562|DRUG|placebo|
224180389|NCT05144646|OTHER|MEPENTOL® AND FARMAOLIVA® IN HEALTHY WITH INTRASUBJECT CONTROL|The corresponding product (HFA -Mepentol®- or EVOO - Farmaoliva®- depending on the study group assigned) will be applied to the subject's right heel, while the contralateral, left, heel will remain as a control. To ensure that the product is completely absorbed into the skin, the subject will then be asked to remain lying face up, at an angle of 30º to the bed, for one hour. The Doppler and infrared laser probes will then be placed on each heel (on the calcaneal tuberosity), for approximately four hours. The subjects will be asked to keep their lower body immobile, but will be able to move their arms and neck gently. Average values for capillary blood flow, local temperature and tissue oxygenation will be collected at 15-minute intervals, although the first 15-minute reading, while the parameters are becoming established, will be discarded.
224180390|NCT05144646|OTHER|MEPENTOL® AND FARMAOLIVA® IN PATIENTS WITH INTRASUBJECT CONTROL|In the second, clinical phase, the measurement protocol will be different, although certain aspects will remain unchanged. The product in question (HFA -Mepentol®- or EVOO -Farmaoliva®- according to the randomisation group assigned) will be applied to the intervention heel (right), leaving the contralateral (left) heel as a control. In addition, every patient will receive the standard PU prevention measures described in the protocol applicable for persons at risk of this condition. The intervention will be carried out in the morning, after bathing, as is customary in acute-care hospital units. The data will be collected at 15-minute intervals, although the first interval will be discarded, as described above. This procedure will be repeated every day during hospitalisation, to assess the cumulative action of the barrier cream. Each measurement will last approximately one hour each day.
224180391|NCT02944058|PROCEDURE|Multiloc nail|Intervention is surgery with Multiloc nail
224180392|NCT02944058|PROCEDURE|Philos plate|Intervention is surgery with Philos plate
224180393|NCT06242886|BEHAVIORAL|Oxytocin massage|Oxytocin massage group: The mother was positioned on a chair with her breasts bare and free, placing her arms on the table at her height and her head on her arms. The researcher who applied the massage applied the massage up and down to either side of the spine between the mother's scapula bones with her thumbs in front and pressing her fists tightly and making small circular movements with her thumbs for three minutes. The mothers received four oxytocin massages over the course of 24 hours.
224180394|NCT06242886|BEHAVIORAL|and Breast massage|Breast massage group: The mother's upper clothes were removed by the researcher. With the palms of the hand the breast grasped from the bottom and top. The hands were advanced by pressing slowly from the base of the nipple towards the nipple. With the palms, the breast was grasped from the bottom and top and gently pressed. Using fingertips, the breast was scanned by massaging from the base of the nipple to the nipple in circular movements. The mothers received breast massage four times over the course of 24 hours.
224180395|NCT00368212|BEHAVIORAL|Relaxation response training|The control treatment is relaxation training or attention control. This will be taught in three, 1-hour sessions with a trained therapist.
223489735|NCT05011656|DEVICE|Seraph-100 + State of the Art Care|Seraph® 100 Microbind® Affinity Blood Filter (Seraph 100) manufactured by ExThera Medical Corporation in Martinez, CA. The Seraph 100 filter has been designed and manufactured to reduce residual risks as much as possible to ensure safe usage. Literature search results concluded that heparin-coated medical devices are safe and decrease platelet adhesion without affecting the adsorption of major adhesive proteins. The efficacy, safety, and risk-benefit data of the studies suggest that Seraph 100 is also safe and potentially beneficial by reducing the rate of thrombosis, without its use entailing a risk for patients. The achieved results from the above-mentioned testing and studies support the performance and safety of Seraph 100 consistent with the intended use. ExThera Medical concludes that the known and potential benefits of Seraph 100, when used to treat patients with pathogen associated shock, outweigh the known and potential risks when used according to the intended use.
223489736|NCT05011656|DEVICE|State of the Art Care|"State of the Art careis defined as the treatment algorithms outlined in the Surviving Sepsis Campaign for the treatment of septic shock, available at https://www.sccm.org/SurvivingSepsisCampaign/Home"
223489737|NCT06391242|RADIATION|Standard Conventional Radiotherapy|20Gy in 5 fractions
223489738|NCT06391242|RADIATION|Stereotactic Body Radiotherapy|30 or 35Gy in 5 fractions
223489739|NCT02273375|DRUG|MEDI4736|
223489740|NCT02273375|DRUG|Placebo|
223489741|NCT06138743|DRUG|ARO-DM1 for Injection|single or multiple doses of ARO-DM1 by intravenous (IV) infusion
223489742|NCT06138743|DRUG|Placebo|calculated volume to match active treatment by IV infusion
223587491|NCT04578561|PROCEDURE|Prophylactic mesh use|After laparotomy sutured clousur the abdominal wall wound is reinforced using a suprafascial synthetic mesh.
224180396|NCT00368212|BEHAVIORAL|Psychoeducational counseling|Patients will receive five sessions of psychoeducational counseling from the nurse who works with the primary care physicians. Patients who are interested in continuing treatment or who have not responded to this first treatment step will then be referred for the second step, cognitive behavioral therapy (CBT), for more intensive treatment.
224180397|NCT04460495|PROCEDURE|Arterial Spin Labeling Magnetic Resonance Imaging|Undergo ASL scan
223489743|NCT05756530|OTHER|Affective touch paradigm|"Affective touch paradigm: experimental stimuli will include the touch of a soft cosmetic, a hand, which will be both expected to resemble affective pleasant stimulations, and a plastic stick with a rounded tip, as a control (non-affective) condition. Two speeds of stimulation will be adopted i) slow affective stimuli delivered at 3 cm/s and fast non-affective stimuli, delivered at non-optimal speed (18 cm/s). An imagery version of the task will be also administered: blindfolded participants will be asked to image the touches on their left forearm.~After each (actual or imagined) tactile stimulus, individuals will rate the experience level of pleasantness.~As part of the protocol, they will fill out two psychological questionnaires, assessing the level of social anhedonia and the amount and characteristics of the lifespan experiences of affective touch in close relationships."
223587492|NCT01848847|PROCEDURE|Hysteroscopy|
223587493|NCT00580762|PROCEDURE|Roux-en-y gastric bypass (RYGB)|
223587494|NCT03584555|PROCEDURE|SMILE using 120μm cap thickness|The surgery was performed with standardized techniques with triple centration technique using the 500-KHz VisuMax system (Carl Zeiss Meditec AG, Jena, Germany). The superior cap depth was set as 120 or 140 µm, and the length of the side cut was set to 2 mm. Once the anterior (upper) and posterior (lower) planes of the lenticule were defined, the anterior and posterior interfaces were dissected using a micropetala with a blunt circular tip and extracted with midforceps. The integrity of the lenticule was assessed subsequently.
224180398|NCT04460495|PROCEDURE|pH-Weighted amine CEST|Undergo pH Weighted amine CEST
224180399|NCT04460495|PROCEDURE|Oxygen-weighted SAGE-EPI|Undergo Oxygen-weighted SAGE-EPI
224180400|NCT04179864|DRUG|Tazemetostat|Tazemetostat (EPZ-6438) is a selective small-molecule inhibitor of the histone-lysine methyltransferase EZH2 gene
224180401|NCT04179864|DRUG|Abiraterone/prednisone|1,000 mg (two 500 mg tablets or four 250 mg tablets) orally once daily in combination with prednisone 5 mg administered orally twice daily.
224180402|NCT04179864|DRUG|Enzalutamide|enzalutamide 160 mg (four 40 mg capsules) orally once daily
224180403|NCT06280079|DIETARY_SUPPLEMENT|Ultra-high-caloric fatty diet|100% fat (70g), saturated fatty acids 7,5g, monounsaturated fatty acids 42,6g, polyunsaturated fatty acids 19,9g, long-chain fatty acids 100%, ratio omega-6 to omega-3 fatty acids 5:1, protein 0g, carbohydrates 0g, fiber 0g
223489744|NCT05201534|OTHER|Interventions in Mathematics and Cognitive Skills - Experimental|"After study participants have completed screenings to meet our inclusion criteria, participants will take part in the pre-training MRI brain scan (if eligible) and behavioral assessments and will then be assigned to the intervention for 6 weeks.~During this training, participants will spend three days each week completing a set of problems at their home on a tablet that we provide them. Participants will receive one-to-one training with a member of our research team once a week.~Following the completion of the 6-week training program, participants will be asked to complete a second MRI brain imaging session (for those who completed pre-training MRI) and post-measure appointments in order to assess immediate effects of the training program. Participants will also be invited to return for follow-up testing after six months in order to assess the long- lasting effects of the training program."
224180404|NCT06280079|OTHER|Placebo|\<5% fat (\<3,5g), protein 0g, carbohydrates 0g, fiber 0g
223489745|NCT05201534|OTHER|Interventions in Mathematics and Cognitive Skills - Active Comparator|"After study participants have completed screenings to meet our inclusion criteria, participants will take part in the pre-training MRI brain scan (if eligible) and behavioral assessments and will then be assigned to the intervention for 6 weeks.~During this training, participants will spend three days each week completing a set of problems at their home on a tablet that we provide them. Participants will receive one-to-one training with a member of our research team once a week.~Following the completion of the 6-week training program, participants will be asked to complete a second MRI brain imaging session (for those who completed pre-training MRI) and post-measure appointments in order to assess immediate effects of the training program. Participants will also be invited to return for follow-up testing after six months in order to assess the long- lasting effects of the training program."
223489746|NCT06025838|BEHAVIORAL|positive feedback|The positive feedback game uses techniques relating to established therapies like Behavioral Activation and Acceptance and Commitment Therapy's valued living to encourage positive action in game and outside of the game.
223489747|NCT06147778|DEVICE|MuCopilot mobile application|MuCopilot is a software as medical device with three digital tests, to measure patient's with CF, lung function, global exercise capacity and a questionnaire to address CF symptoms and impacts on some aspects of patient's life
223489748|NCT05949086|BEHAVIORAL|Work Chat|Work Chat will be a simulation training using virtual characters to role-play conversations. It will contain conversations with a coworker, a customer, and a supervisor within a workplace setting.
223489749|NCT05094128|DRUG|Upadacitinib|Tablet; Oral
223489750|NCT06496477|DEVICE|Ayo wearable|Primary study device - the Ayo wearable which are glasses that emit either bright blue-spectrum white light or dim blue-spectrum white light or Mini motion logger AAM-32 - an actigraphy device work during the first and last week of the study on the participants wrist throughout most of the day, measuring activity. This will be used as an indicator of sleep.
223587495|NCT03584555|PROCEDURE|SMILE using 140μm cap thickness|The surgery was performed with standardized techniques with triple centration technique using the 500-KHz VisuMax system (Carl Zeiss Meditec AG, Jena, Germany). The superior cap depth was set as 120 or 140 µm, and the length of the side cut was set to 2 mm. Once the anterior (upper) and posterior (lower) planes of the lenticule were defined, the anterior and posterior interfaces were dissected using a micropetala with a blunt circular tip and extracted with midforceps. The integrity of the lenticule was assessed subsequently.
223587496|NCT03696095|DRUG|Ropivacaine Hcl 0.2% Inj Bag 200Ml (PIB mode)|programmed intermittent bolus 5ml each one hour.
223587497|NCT03696095|DRUG|Ropivacaine Hcl 0.2% Inj Bag 200Ml (CI mode)|continuous infusion 6ml/h
223587498|NCT04934436|OTHER|sleeping glasses and earplug|In this study, the effect of the chronotype-appropriate nursing care on the intervention group will be examined.
223587499|NCT00491608|BIOLOGICAL|rThrombin|1000 U/mL applied directly or in combination with absorbable gelatin sponge or powder
223587500|NCT05992194|OTHER|multimodal oculomotor measurements|"* Visual assessment to ensure that the subject meets the inclusion and non-inclusion criteria, including anamnesis and the following visual tests: Lang stereotest, H-test ocular motility, convergence, masking and accommodative rock.~* Evaluation by experimenter A (60 min)~  * Neuro-ophthalmological tests on screen~ * Neuro-ophthalmological tests in VR headset~* Evaluation by experimenter B (60 min)~  * Neuro-ophthalmological tests on screen~ * Neuro-ophthalmological tests in VR helmet The sequence of experimenters A-B or B-A will be randomized."
223587501|NCT04109976|DRUG|Bimekizumab|Study participants will receive bimekizumab at pre-specified time points.
223587502|NCT00211952|DRUG|celecoxib|
223587503|NCT03572790|DRUG|Prucalopride|1mg prucalopride capsule, once daily for seven days
223587504|NCT03572790|OTHER|Placebo|Lactose placebo capsule, once daily for seven days
223587505|NCT02367404|DRUG|Duloxetine|Duloxetine 60mg OD for 3 months
224180405|NCT01858675|OTHER|Biomarkers, red blood cells and plasma assessment|
224180406|NCT02514642|DRUG|low-dose ticagrelor|low-dose ticagrelor (22.5 mg twice daily) for 7 days,followed by a 2-week washout period then a 7days crossover phase of clopidogrel (75mg once daily)
224180407|NCT02514642|DRUG|Clopidogrel|clopidogrel (75mg once daily) for 7 days,followed by a 2-week washout period then a 7days crossover phase of low-dose ticagrelor (22.5 mg twice daily)
224180408|NCT02349100|DEVICE|Nellix Endoprosthesis|Implantation of Nellix
224180409|NCT02876211|DRUG|Paricalcitol|Paricalcitol 2 capsules/three times per week
224180410|NCT02876211|DRUG|Epoetin beta|epoetin 1-3 times per week
224180411|NCT02876211|DRUG|Placebo|Placebo 2 capsules/three times per week
224180412|NCT01069692|DRUG|SBR759A|SBR759A 6g daily
224307500|NCT03624959|DRUG|Ozanimod|ozanimod
224180413|NCT01069692|DRUG|SBR759A|Placebo Comparator 0g daily
223489751|NCT06967298|DEVICE|T30 Contact lenses|Individuals who have previously dropped out of Contact lenses (CL) due to discomfort will be refit into T30 contact lenses and their comfort with the product will be assessed.
223489752|NCT04336943|BIOLOGICAL|Durvalumab|Given IV
223489753|NCT04336943|DRUG|Olaparib|Given PO
223489754|NCT04336943|OTHER|Quality-of-Life Assessment|Ancillary studies
223489755|NCT04336943|OTHER|Questionnaire Administration|Ancillary studies
223489756|NCT02422654|DRUG|eliglustat|"Pharmaceutical form:liquid formulation~Route of administration: oral without ingestion"
223489757|NCT05081687|DRUG|Folfirinox|5-FU 2400mg/m2; Oxaliplatin 85 mg/m2, Irinotecan 150mg/m2
223489758|NCT02169232|DEVICE|Videolaryngoscope|
223489759|NCT02169232|DEVICE|Fiberoptic|
223489760|NCT02290184|BEHAVIORAL|PilAm Go4Health Weight-loss Program|This is a 3-month lifestyle intervention program promoting weight loss through physical activity and health diet using a mobile health application (app), pedometer to track daily step-counts, and social networking (in-person and virtual social networking through Facebook) to reduce risks for metabolic syndrome in Filipino Americans with type 2 diabetes on metformin. Subjects will be asked: 1) to use a mobile app diary every day to input their weight, and calories (food and drink intake) and 2) wear a pedometer everyday to monitor their physical activity (step-counts).
223489761|NCT02290184|BEHAVIORAL|Active Control|This is a 3-month active control using a pedometer only without any education related to wt loss, physical activity, health eating, or tracking healthy behaviors
223489762|NCT06184282|DRUG|MEBO|MEBO (Julphar®, Ras Al Khaimah, United Arab Emirates) was applied using sterile plastic brush daily and the patients were recalled at 2, 5 and 10 days for evaluating the healing of the ulcer.
223489763|NCT06184282|DRUG|Lidocaine|Lidocaine gel was applied using sterile plastic brush daily and the patients were recalled at 2, 5 and 10 days for evaluating the healing of the ulcer.
223489764|NCT03345823|DRUG|Upadacitinib|Oral; Tablet
223489765|NCT03345823|DRUG|Placebo for Upadacitinib|Oral; Tablet
223489766|NCT01069939|DRUG|Esomeprazole|20mg, capsule, 72 weeks
223489767|NCT01069939|DRUG|Placebo|Placebo, capsule, 72 weeks
223489768|NCT03755817|DEVICE|SCENAR application|Active SCENAR application on the painful area
223489769|NCT03755817|DEVICE|SCENAR application with the device off|Placebo SCENAR application on the painful area
223489770|NCT01982864|DRUG|Gentamicin|"The decision to introduce the antibiotic is made during a session or between two sessions according to both the clinicians usual procedure.~Depending on the number of injections, 8 to 10 blood samples will be drawn per patient. Clinical and biological data will be concomitantly collected (e.g., hemodialysis session duration, creatinine clearance…).~The number of blood sampling and the time schedule will be adapted to the prescription and the possible follow-up of the treatment after the first injection. Whatever the time is between the first injection and the following dialysis session, a sampling will be performed 30 minutes after the end of the injection (T1), 8h after the end of the injection (T2), juste before (TAD), in the middle (TMD) and at the end of the dialysis (TFD)."
223489771|NCT01544231|BIOLOGICAL|Plasma NGAL level|The plasmatic level of Neutrophil Gelatinase Associated Lipocalin is measured in ng/ml/
223489772|NCT02402062|DRUG|TH-302 + Sunitinib|"Combination of the two drugs in cycles of 28 days, described as follows:~Sunitinib: 37,5 mg/day Oral everyday of each 28 day cycle.~TH-302: 340 mg/m2 IV on days 8, 15 and 22 of each cycle."
223587506|NCT02367404|BEHAVIORAL|Pelvic Floor Muscle Training|PMFT weekly for 3 months
223587507|NCT02323152|BEHAVIORAL|psychoeducation|Usual treatment + psychoteraphy focused on problem solving (6 sessions). The psychoeducational programme consists of 6 sessions of 60 minutes, one per week.
224180414|NCT01069692|DRUG|SBR759A|SBR759A 3g daily
224180415|NCT01069692|DRUG|SBR759A|9g daily
224180416|NCT01069692|DRUG|SBR759A|12g daily
224180417|NCT02719028|DRUG|Antroquinonol|Antroquinonol will be provided as capsules of 50 mg
223489773|NCT01994031|DRUG|Paclitaxel liposome injection|
223489774|NCT01994031|DRUG|Paclitaxel injection|
223489775|NCT01390506|DRUG|Sodium-selenite|Di-sodium-selenite-pentahydrate (Na 2SeO3.5H2O) in 0,9% sodium chloride is administered intravenously at a does of 3000µg on day 0, 2000µg on day 1 and 2 and at a dose of 1000µg per day on day 3-6.
223489776|NCT01390506|DRUG|Placebo|0,9% sodium chloride is administered intravenously
223489777|NCT01890993|DRUG|liraglutide|Anonymised patient level data will be collected by the patients' own general practitioner and electronic case report form (eCRF) will be used to capture the data.
223489778|NCT04227834|BEHAVIORAL|Health hygiene education|A cartoon video explaining the etiology, risk factors, clinical symptoms, treatment and prevention of helminthiasis were given to the school-aged children
223489779|NCT04587817|COMBINATION_PRODUCT|camrelizumab+hyperfractionated radiotherapy|Immunotherapy combined with hyperfractionated radiotherapy
223489780|NCT02823119|DEVICE|Mini-hysteroscopy|Hysteroscopy will be performed with the use of the non-touch technique (vaginoscopic approach). The investigators will use a rigid 2.7-mm hysteroscope with a 30° forward oblique lens and an outer sheath diameter of 3.3 mm. All of the procedures will be diagnostic.
223489781|NCT02823119|DEVICE|Conventional Office Hysteroscopy|. Hysteroscopy will be performed with the use of the non-touch technique (vaginoscopic approach). The investigators will use a rigid 2.9-mm hysteroscope with a 30° forward oblique lens and an outer sheath diameter of 5 mm. All of the procedures will be diagnostic.
223489782|NCT03982537|DRUG|N-Acetyl-L-Cysteine dietary supplement|Treatment will be administered on an outpatient basis, either twice daily or 48 hours prior to starting chemotherapy radiation. Eligible participants will start NAC at least 9 days before definitive or adjuvant radiation therapy.
223489783|NCT03982537|RADIATION|Chemotherapy and Radiation|Participants will receive definitive or adjuvant concurrent chemotherapy and radiotherapy s per standard of care.
223587508|NCT02323152|OTHER|Standard care|Puerperal control with their doctor. This group will also be interviewed with the same frecuency of the experimental group but will not receive a psichologycal treatment
224180418|NCT02719028|DRUG|placebo|The matching placebo will be packaged as Antroquinonol with appearance identical in all aspects, however, don't have the active compound(antroquinonol)
224180419|NCT00980850|BIOLOGICAL|Baxter Novel Influenza A H1N1 Whole Virus Vaccine|Two 0.5 ml doses of vaccine given within 3 weeks interval
224180420|NCT00980850|BIOLOGICAL|GlaxoSmithKline Novel Influenza A H1N1 Split Virion Vaccine|Two 0.25 ml doses of vaccine given within 3 weeks interval
223489784|NCT02414061|DIETARY_SUPPLEMENT|Whey Protein (Arla Foods Ingredients Group)|20 g whey protein isolate added to breakfast meal
223489785|NCT02414061|OTHER|Breakfast meal|Carbohydrate breakfast served as a standard portion (1799 kJ, 93/2/9% energy from carbohydrate/fat/protein)
224180421|NCT02179216|OTHER|Hydration|Hydratation the first day in the arm 1 Hydration the second day in the arm 2
224180422|NCT02179216|OTHER|Venous contention|Venous contention the second day in the arm 1 Venous contention the first day in the arm 2
224180423|NCT04923009|PROCEDURE|ICE visualization and map construction|Radio-frequency ablation of atrial fibrillation
224180424|NCT05614362|DIETARY_SUPPLEMENT|Channa Striatus extract|Channa Striatus extract given with a dose of 500 mg three-times-daily for each patient
224180425|NCT05614362|DIETARY_SUPPLEMENT|Maltodextrin|Maltodextrin given three-times-daily for each patient
224180426|NCT00730665|DRUG|PF-00885706|Capsule, 100ug, every 12 hours (twice a day)
224180427|NCT00730665|DRUG|Esomeprazole|Patients entering the run-in phase lasting 6 weeks (42 days) will be switched from their current proton pump inhibitor (PPI) treatment and maintained on a standard background PPI - open label esomeprazole 20 mg to be taken once daily 1 hour before breakfast. Subjects meeting randomization criteria at Visit 4 are randomly assigned to one of the active arms of PF-00885706 or matching placebo, in addition to esomeprazole.
224180428|NCT00730665|DRUG|PF-00885706|Capsule, 300ug, every 12 hours (twice a day)
224180429|NCT00730665|DRUG|Esomeprazole|Patients entering the run-in phase lasting 6 weeks (42 days) will be switched from their current proton pump inhibitor (PPI) treatment and maintained on a standard background PPI - open label esomeprazole 20 mg to be taken once daily 1 hour before breakfast. Subjects meeting randomization criteria at Visit 4 are randomly assigned to one of the active arms of PF-00885706 or matching placebo, in addition to esomeprazole.
224180430|NCT00730665|DRUG|PF-00885706|Capsule, 1mg, every 12 hours (twice a day)
224180431|NCT00730665|DRUG|Esomeprazole|Patients entering the run-in phase lasting 6 weeks (42 days) will be switched from their current proton pump inhibitor (PPI) treatment and maintained on a standard background PPI - open label esomeprazole 20 mg to be taken once daily 1 hour before breakfast. Subjects meeting randomization criteria at Visit 4 are randomly assigned to one of the active arms of PF-00885706 or matching placebo, in addition to esomeprazole.
223489786|NCT03678740|OTHER|Odyssey 2 Survey|Odyssey2 will retain the strengths (simplicity, brevity, confidentiality, and data quality assurance measures) which made Odyssey1 successful. While Odyssey2 adds some refinements based on experience learned from Odyssey1, the basic questions are changed as little as possible to maximize comparability, and the additions are limited. Odyssey1 consisted of between 16 and 23 questions, depending on skip patterns, and took an estimated 15 minutes to complete. Odyssey2 consists of between 23 and 33 questions, depending on skip patterns and we estimate that it will take approximately 20 minutes to complete.
223489787|NCT03504553|OTHER|Noise reduction|All activity will cease when the patient enters the operating room and nonessential personnel will be removed. Ambient lighting will be reduced and communication devices muted.
223489788|NCT00002129|DRUG|Vesnarinone|
223489789|NCT01017250|RADIATION|Stereotactic Radiosurgery (SRS)|Tumor Volume \< 2.0cm receives 24 Gy in 1 fraction Tumor Volume 2.0-2.9cm receives 18 Gy in 1 faction Tumor Volume 3.0-4.9cm receives 25 Gy in 5Gy/fraction
223489790|NCT01017250|DRUG|Bevacizumab|Bevacizumab (Avastin) 10 mg/kg given the day before SRS and 2 weeks after SRS
224180432|NCT00730665|DRUG|PF-00885706|Capsule, 3mg, every 12 hours (twice a day)
224180433|NCT00730665|DRUG|Esomeprazole|Patients entering the run-in phase lasting 6 weeks (42 days) will be switched from their current proton pump inhibitor (PPI) treatment and maintained on a standard background PPI - open label esomeprazole 20 mg to be taken once daily 1 hour before breakfast. Subjects meeting randomization criteria at Visit 4 are randomly assigned to one of the active arms of PF-00885706 or matching placebo, in addition to esomeprazole.
224180434|NCT00730665|OTHER|Placebo|Capsule, Placebo, every 12 hours (twice a day)
224180435|NCT00730665|DRUG|Esomeprazole|Patients entering the run-in phase lasting 6 weeks (42 days) will be switched from their current proton pump inhibitor (PPI) treatment and maintained on a standard background PPI - open label esomeprazole 20 mg to be taken once daily 1 hour before breakfast. Subjects meeting randomization criteria at Visit 4 are randomly assigned to one of the active arms of PF-00885706 or matching placebo, in addition to esomeprazole.
224180436|NCT03338335|DRUG|prolonged DAPT|Dual antiplatelet therapy will be prescribed for more than 12 months
224180437|NCT01539720|DRUG|Ulipristal acetate|30 mg tablet
224180438|NCT01539720|DEVICE|levonorgestrel IUS|Levonorgestrel IUS, 52mg placed intrauterine
224180439|NCT05593185|BIOLOGICAL|Galinpepimut-S|
224205674|NCT03014570|BEHAVIORAL|Education-only Control|This arm includes step 2 only of the EIT-4-BPSD. Facilities are provided with education abouthow to provide behavioral interventions for behavioral symptoms associated with dementia. They can have the education face-to-face or via a powerpoint or webinar.
223587509|NCT00930436|DRUG|sodium bicarbonate|Serum creatinine will be measured on Days 3,7, 30, 90, and 180
223587510|NCT03559894|DIAGNOSTIC_TEST|Trans-thoracic echocardiography|Trans-thoracic echocardiography
223587511|NCT02238015|PROCEDURE|cataract surgery|All patients underwent cataract surgery with 3.0 mm clear corneal incision at 11 o'clock in one eye
223587512|NCT00413374|DRUG|Enoxaparin|Patient takes 1.5 mg per kilogram, once daily, subcutaneous injections until INR is therapeutic, then medication is stopped.
223587513|NCT01431885|PROCEDURE|Diagnosis by cervical length and fibronectin|Diagnosis will be made by MOD Algorithm B
223587514|NCT01431885|PROCEDURE|Cervical change|Diagnosis will be made by digital examination of cervical change
223587515|NCT00096330|DIETARY_SUPPLEMENT|dietary intervention|oral folic acid supplementation once daily on days 57-84
223587516|NCT00096330|DIETARY_SUPPLEMENT|folic acid|oral folic acid supplementation once daily on days 1-56.
224205675|NCT05705349|DRUG|DOR/ISL|Fixed dose combination tablet containing DOR/ISL 100 mg/0.25 mg taken by mouth.
224205676|NCT05705349|DRUG|BIC/FTC/TAF|Fixed dose combination tablet containing BIC/FTC/TAF 50 mg/200 mg/25 mg taken by mouth.
224205677|NCT05705349|DRUG|Placebo to DOR/ISL|Placebo tablet matched to DOR/ISL tablet taken by mouth.
224307501|NCT03624959|DRUG|Gemfibrozil|Gemfibrozil
224180440|NCT06431139|OTHER|INSPIRE intervention protocol|2-week training program with daily sit-to-stand exercises. Each working day the participant's goals will be adjusted, until exercising a minimum of 100 repetitions using an exercise progression table. When participants complete one level, they will progress to the next level the following day. Participants who do not reach the goals at level one will continue to strive to reach the 100 repetitions. The number of repetitions can be split and performed throughout the day. As the participants' capacity for doing the exercises increases, so will the number of repetitions within each bout of sit-to-stand. Participants are allowed to do the number of repetitions from a higher exercise level if they can and will continue by progressing from that level on the next day. The repetitions will be done from a height that makes it possible to accomplish the sit-to-stand movement. Therefore, the height of the sitting surface will be adjusted according to the participant's abilities.
224180441|NCT05995548|OTHER|Interview|The interview will take place face-to-face. It will take place in a quiet room, with the door and windows closed. Only the participant and the investigator will be present. It will be recorded using a dedicated to this research. At the end of the interview, so as not to influence the participant's discourse, the participant will be asked to fill in the self-questionnaire 'EAI' (Exercise Addiction Inventory), which will confirm or refute the diagnosis, thus exploring a possible discrepancy between the participant's feelings and the diagnosis.
224180442|NCT04651153|DRUG|UCB7853|Subjects will receive UCB7853 at pre-specified time-points.
224180443|NCT04651153|OTHER|Placebo|Subjects will receive Placebo at pre-specified time-points.
224180444|NCT01378624|OTHER|Bronchoscopy|"In brief, during the first bronchoscopy a baseline BAL and baseline endobronchial brush and forceps biopsies will be obtained and allergen as well as saline (control segment) will be instilled.~The subjects will undergo a second bronchoscopy in order to obtain BAL from the allergen challenged segments and the saline challenged segment, and endobronchial forceps biopsies."
224180445|NCT04536181|DRUG|Prednisolone|12 weeks prednisolone treatment
224180446|NCT04536181|DRUG|Placebo|12 weeks simulated tablets
224180447|NCT01500538|DRUG|Eltrombopag and Vorinostat|4 week mono-therapy eltrombopag, commencing at 50mg/day, increasing to 200mg. Daily intake of 400mg vorinostat for minimum of 6 cycles, each cycle of 4 weeks, possibly in combination with daily intake eltrombopag commencing at 50mg/day at a maximum dose of 200md/day (150mg/day for subjects of East-Asian ancestry)
224180448|NCT03927703|DRUG|SB206 12%|Topically once daily
224180449|NCT03927703|DRUG|Placebo|Topically once daily
224180450|NCT00581724|BEHAVIORAL|Telephone interview or self report survey.|We estimate that the completion time for the telephone interview or self-report survey will be 45-60 minutes.
224180451|NCT03854552|DRUG|BI 764198|capsule
224180452|NCT03854552|DRUG|Placebo|capsule
224180453|NCT03943602|DRUG|Cabozantinib|Cabozantinib 60 mg/day orally
224180454|NCT01933542|DRUG|Placebo|Two placebo tablets identical to the chlorzoxazone tablets.
224180455|NCT01933542|DRUG|Chlorzoxazone|Two 250 mg chlorzoxazone tablets
224180456|NCT01933542|DRUG|Morphine|Patient controlled intravenous morphine (PCA-pump), bolus 2.5 mg, lock-out-time 10 minutes. Concentration : Morphin 1 mg/ml.
223489791|NCT06319833|BEHAVIORAL|Physical activity interacting with a video|This experimental condition will be implemented five times a week, once per day, over 8 weeks. It will follow a structured format, including seven consecutive 40-second blocks of physical activity. The total video duration will amount to 9 minutes (40 seconds of activity followed by 20 seconds of rest, maintaining a 2:1 work-to-rest ratio). Additionally, participants will engage in 5 minutes of warm-up exercises and 5 minutes of cool-down activities. The experimental condition will consist of 10 videos, each centered around one of five different themes (a different one will be administered every day).
223489792|NCT03687424|DEVICE|high-flow nasal oxygenation (HFNO)|Experimental HFNO: O2 flow 40L/min, FiO2 40%
224180457|NCT01933542|DRUG|Zofran|Zofran 4 mg iv. in case of moderate to severe nausea, supplemented by Zofran 1 mg iv. if needed
224180458|NCT00088660|BIOLOGICAL|PANVAC™-VF|
224180459|NCT02777294|BEHAVIORAL|Online intervention|Therapist-facilitated, multimedia, cognitive-behavioral online intervention targeting rape-related PTSD
224180460|NCT02777294|BEHAVIORAL|Psycho-educational website|Psycho-educational self-help website about rape-related PTSD
224180461|NCT04708366|DRUG|NER1006|Patients will be randomly assigned (1:1:1) to receive 1L PEG (PLENVU; Norgine, Amsterdam, Netherlands), administered as a 2-day evening/morning split-dosing, or the 2L PEG + ascorbate preparation (2LPEG - MOVIPREP; Norgine), or the 4L PEG (SELG-ESSE; Alfasigma Bologna, Italy), both administered as a 2-day evening/morning split-dosing regimen.
224180462|NCT04708366|DRUG|MoviPrep|Patients will be randomly assigned (1:1:1) to receive 1L PEG (PLENVU; Norgine, Amsterdam, Netherlands), administered as a 2-day evening/morning split-dosing, or the 2L PEG + ascorbate preparation (2LPEG - MOVIPREP; Norgine), or the 4L PEG (SELG-ESSE; Alfasigma Bologna, Italy), both administered as a 2-day evening/morning split-dosing regimen.
224180463|NCT04708366|DRUG|Macrogol 400|Patients will be randomly assigned (1:1:1) to receive 1L PEG (PLENVU; Norgine, Amsterdam, Netherlands), administered as a 2-day evening/morning split-dosing, or the 2L PEG + ascorbate preparation (2LPEG - MOVIPREP; Norgine), or the 4L PEG (SELG-ESSE; Alfasigma Bologna, Italy), both administered as a 2-day evening/morning split-dosing regimen.
224180464|NCT02062749|DRUG|Oxaliplatin|Starting dose of Oxaliplatin is 175 mg/m2 delivered by hyperthermic intraperitoneal chemotherapy over 90 minutes.
224180465|NCT00508872|DRUG|5-Fluorouracil|400 mg/m\^2 IV over 15 minutes, followed by 2400 mg/m\^2 IV Over 46 Hours
224180466|NCT00508872|DRUG|Bevacizumab|5 mg/kg IV Over 30-90 Minutes On Day 1 Every 14 Days
223489793|NCT03687424|DEVICE|low-flow nasal oxygenation (LFNO)|Active comparator (LFNO): O2 flow 5L/min, FiO2 40%
223489794|NCT02650583|OTHER|Educational Intervention|Receive Enhancing Connections Program
223489795|NCT02650583|OTHER|Questionnaire Administration|Ancillary studies
223489796|NCT01270659|DRUG|Fentanyl|Fentanyl buccal tablet 100 mcg once
223489797|NCT01270659|DRUG|Fentanyl|Fentanyl buccal tablet 200 mcg once
223489798|NCT01270659|DRUG|Oxycodone/acetaminophen|Oxycodone/acetaminophen 5/325 mg once
223489799|NCT01270659|DRUG|oxycodone/acetaminophen|Oxycodone/acetaminophen tablet 5/325 mg, 2 tablets one time
223489800|NCT01680913|PROCEDURE|Ultrasound guidance|The intervention group's interspaces will be determined using the curved linear probe on a Zonare ultrasound using two views.
224180467|NCT00508872|DRUG|Leucovorin|400 mg/m\^2 IV Over 2 Hours On Day 1 Every 14 Days
224180468|NCT00508872|DRUG|Oxaliplatin|85 mg/m\^2 IV Over 2 Hours On Day 1 Every 14 Days
224180469|NCT02315716|PROCEDURE|Autologous Stem Cell Transplant (ASCT)|Randomisation to melphalan conditioned autologous stem cell transplant
224180470|NCT02315716|DRUG|Consolidation with 4 cycles of CarCyDex|Randomisation to 4 further cycles of Carfilzomib, Cyclophosphamide and Dexamethasone for responding patients following 4 cycles of induction chemotherapy
224180471|NCT02049476|DRUG|Dexamethasone pellet|"Dexamethasone pellet placement occurs within 14 days of baseline examination; for patients with bilaterally active uveitis, placement of a dexamethasone pellet in the second eye should occur within 14 days of the first implantation or within 30 day of the baseline examination.~Repeated placement is permitted every 3 months based on the best clinical judgment of the doctor and the study protocol."
224180472|NCT03007472|DEVICE|CI532|Cochlear implant
224180473|NCT03007472|DEVICE|Nucleus 7|Sound processor
224180474|NCT01743781|BEHAVIORAL|video|view a 10-minute informational video about comprehensive eye examination
224180475|NCT02185443|RADIATION|SBRT|"* 60Gy in 3 fractions (20Gy/fraction) over 14 days~* 60Gy in 5 fractions (12Gy/fraction) over 18 days if organ at risk constraints cannot be met with fractionation above"
223489801|NCT01680913|PROCEDURE|Palpation of Tuffier's line|Current clinical practice. Standard of care would have the attending anesthetist palpate the Tuffier's line to pinpoint the appropriate location for the spinal.
223489802|NCT01680913|PROCEDURE|Spinal anesthetic|Subcutaneous local infiltration with a 25g needle we be performed prior to the spinal. Neuraxial technique will be attempted midline with a 25 gauge whitacre needle in the sitting position. Spinals will be attempted on either L2-L3, L3-L4, L4-L5 interspaces. The amount and type of local anesthetic/intrathecal narcotic will be left to the discretion of the Anesthetist.
223489803|NCT00825240|BEHAVIORAL|One-time Questionnaire + Recorded Qualitative Interview|One-time questionnaire + recorded qualitative interview, approximately 45 minutes total.
223587517|NCT05580068|DEVICE|Hypertension therapy through iATROS medical device|"The intervention to be carried out in the treatment group is the use of the therapy support provided by the iATROS medical device for the treatment of arterial hypertension.~In particular, patients are guided through a structured digital therapy program that enables them to better manage their disease. Patient receive reminders for taking their medication, for performing vital parameter measurements, and receive educational content for them to learn how to manage their disease better."
223745434|NCT07190547|OTHER|ShotBloker|ShotBlocker is a flat, horseshoe-shaped device used to reduce pain during subcutaneous or intramuscular (IM) injections. It features short, blunt, non-sharp projections approximately 2 mm in height and is designed to be placed against the skin, with a central opening that exposes the injection site. The device is applied to the skin just prior to injection, with its textured surface making contact with the skin. Although the projections do not penetrate the skin, they are believed to create a sensory stimulus associated with pain modulation based on the gate control theory.
224180476|NCT00519090|DRUG|Imatinib|Administered orally as a single agent on a continuous daily schedule given 400 mg bid (twice daily) with food. One cycle comprised of 28 days.
224180477|NCT00519090|DRUG|Nilotinib (AMN107)|Administered orally as a single agent on a continuous daily schedule of 400 mg bid (2 x 200 mg twice daily) without food. Once cycle comprised of 28 days.
224180478|NCT04582331|OTHER|Smartphone-based voice and self-reported symptom collection|Voice samples and COVID-19 symptom inventories will be collected on participant smartphone devices. No outcomes or feedback is provided on acquired data during trial conduct but will be used for confirmatory data analysis post study
224180479|NCT06076174|OTHER|6-week home-based exercise programme|All participants will have an in-person session with the physiotherapist for exercise demonstration before beginning the programme. They will carry out the exercises independently at home over a period of six weeks, thrice a week, giving a total of 18 sessions, each lasting 30 minutes.
224180480|NCT03165227|DRUG|BI 685509|Taken orally
224180481|NCT03165227|DRUG|Placebo|Taken orally
223489804|NCT00191100|DRUG|Gemcitabine|
223489805|NCT00191100|DRUG|Cisplatin|
223489806|NCT00191100|RADIATION|Brachytherapy|Brachytherapy, 30-35 Gy over 1 week
223489807|NCT00191100|RADIATION|Pelvic radiation|Pelvic radiation, 1.8 Gy/day, 5 days/week, 6 weeks
224180482|NCT03306589|BIOLOGICAL|Cantharidin|5 microliter (µL) of 0.2 percent Cantharidin solution (diluted in acetone) will be applied to all subjects on forearm by topical route.
224180483|NCT03306589|BIOLOGICAL|Lipopolysaccharide|0.5 to 4 ng/kg body weight of LPS formulated as suspension in normal saline will be administered to randomized subjects via intravenous (IV) route in dose-escalation manner.
223489808|NCT01675726|OTHER|questionary on quality of life|
224180484|NCT03306589|BIOLOGICAL|Granulocyte-Macrophage Colony-Stimulating Factor|5 to 15 µg/kg of GM-CSF will be administered to randomized subjects via subcutaneous (SC) route in the abdominal region in dose-escalation manner.
224180485|NCT03306589|DRUG|Saline Solution|0.9 percent sodium chloride will be administered via IV route to all subjects at a rate of 250 mL/hour for 4 hours prior to dosing with LPS and 8 hours after dosing with LPS.
224180486|NCT04398160|OTHER|HVLA C3/C4 manipulation|The investigator will apply an anterior and lateral translation associated with extension, homolateral inclination and contralateral rotation of the cervical. This procedure will increase the tension of the soft tissues to reduce the remaining slack and, finally, the thrust will be applied in pure rotation. Subsequently the head of the volunteer will be repositioned in the neutral position without applying any pressure and will wait 10 seconds in this position. Finally, the previous procedure will be repeated to the opposite side.
224180487|NCT04398160|OTHER|Sham technique|The investigator will apply an anterior and lateral translation associated with extension, homolateral inclination and contralateral rotation of the cervical until the perception of tissue tension at the point of contact, holding this position for 10 seconds. The investigator then repositions the head of the volunteer in the neutral position without applying pressure, holding again this position for 10 seconds. Finally, the previous procedure will be repeated for the opposite side.
224205678|NCT05705349|DRUG|Placebo to BIC/FTC/TAF|Placebo tablet matched to BIC/FTC/TAF tablet taken by mouth.
223489809|NCT03990974|DRUG|postoperative antimicrobial prophylaxis|The drugs are all common antibiotics used to prevent postoperative infection in each hospital.
224180488|NCT03924960|BEHAVIORAL|High-intensity interval training|Participants in this group will perform a 20-25 minutes of aerobic exercise with a maximum capacity of 3-4 minutes (HRmax 80-95%) and active recovery for 3-4 minutes (HRmax 30-50%), five exercise sessions per week for 6 weeks.
224180489|NCT03924960|BEHAVIORAL|Moderate-intensity continuous training|Participants in this group will perform a 30-45 minute ergometric cycling exercise at 65-70% of the measured maximum heart rate (HRmax), five exercise sessions per week for 6 weeks.
224180490|NCT03924960|BEHAVIORAL|Control|Usual care control group
224180491|NCT01774734|OTHER|Physical therapy|"Physical therapy~* Provided by 2 experienced physiotherapist~* Applied to every patients 3 times weekly"
224180492|NCT01774734|DEVICE|Neck Strength Exerciser (NSE)|"* Neck strength exerciser use 10-20 minutes daily at home~* Plus traditional physical therapy three times weekly provided by two experienced physical therapist"
224180493|NCT02779842|DRUG|Coppertone (BAY 987517)|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. formulation number SR15-39-Z12-002.
224180494|NCT05659875|OTHER|Standard Occupational Therapy Arm Exercise Program|Standard exercise program will be provided addressing shoulder, elbow, forearm, wrist, and hand with expectation that participant will complete 3 times a week. Exercise program will be updated at assessment timepoints as needed with change in arm function.
224180495|NCT05762315|BEHAVIORAL|Audio Storytelling|The audio session is designed to deliver audio narrative developed following the Transformative Storytelling Technique and provide re-structurization of internal caregiver self-stories.
224180496|NCT01977651|DRUG|Enzalutamide|Participants received 4 capsules (40 mg each) of enzalutamide orally once a day, for a total daily dose of 160 mg. Treatment was given with or without food and as close as possible to the same time each day.
224180497|NCT01784172|DEVICE|electroacupuncture group|Procedure: electro-acupuncture;Points: Bilateral Zhongliao (BL33) Huiyang(BL35).Specially-made pad is stick on pierced acupoints. Bilateral BL33 are given acupuncture of 50～60mm with 30～45°angle to inward and downward by 75mm filiform needle. Bilateral BL35 are given acupuncture of 50～60mm to outward and upward by 75mm filiform needle. Twirl, lift and thrust for 3 times, until local sour and heavy feeling coming.The electric stimulator is applied to bilateral BL33 and BL35, with continuous wave,50 Hz and electric current 1- 5mA.Every session lasts for 30 min per day.The participants are treated continuously for 6 weeks for 3 sessions a week, 18 sessions for each patient in all. The treatment is designed based on recent literature research in 10 years, former result and expert consensus.
224180498|NCT01784172|DEVICE|sham electroacupuncture group|Procedure: sham electroacupuncture;Points: Bilateral sham Zhongliao (BL33) sham Huiyang(BL35).Specially-made pad is stick on pierced acupoints. Both sham BL33 and BL35 are given non-penetrating needling with blunt needle. Twirl, lift and thrust for 3 times. The sham electric stimulator is applied to bilateral sham BL33 and sham BL35. The mental wire has been cut off with a same outlook as the treatment group. The electric stimulator is looked normal but with no current output. Length of Treatment and the treatment sessions are the same as treatment group.
224180499|NCT04013906|DIAGNOSTIC_TEST|Rotational atherectomy|Rotational atherectomy
224180500|NCT03724318|PROCEDURE|closure of the left atrium appendage|closure of the left atrium appendage in addition to the planned Heart operation
224180501|NCT04430387|DEVICE|The saliva ejector|A thin suction tube that draws water, saliva, blood, and debris from the mouth to provide patient comfort, preventing patient from constantly having to sit up and spit while maintain a clear operative field. It is connected through the low-volume suction hose in the dental chair. It can be held by the dental assistant, the dental provider or by the patient. In practice, it can be also contoured and hang by the cheek of the patient due to its light weight.
224307502|NCT03624959|DRUG|Itraconazole|Itraconazole
224307503|NCT03624959|DRUG|Rifampin|Rifampin
223489810|NCT03990974|OTHER|No postoperative antimicrobial prophylaxis|Patients will receive no antibiotics after hepatectomy unless necessary.
223587518|NCT04863690|BEHAVIORAL|Meditation|Participants will be asked to use either the Muse Mind Meditation, Muse Sleep Journeys, Go to Sleep Soundscapes or Go to Sleep Guidance each evening as part of their bedtime routine to help them prepare to sleep. In addition, participants may use any part of the Muse App (Mind, Heart, Breath, Body, Guided or Go to Sleep meditations, as often as they like to help them fall asleep, go back to sleep, or as a meditation practice during the daytime. All Participants will also be asked to do the Muse Mind meditation for a minimum of 5 minutes per day, a minimum of 5 days per week, for 6 weeks. If they also wish to use the Muse system more frequently (day or night), they will be encouraged to do so and will be able to choose between several styles of available meditation (Mind, Heart, Breath, Body, Guided or Go to Sleep meditations). Participants will be asked to also wear their Muse device while they sleep, as often as they like in order to track their sleep.
223587519|NCT04863690|BEHAVIORAL|Digital Coaching|All participants will work through the content in the Muse S Sleep Coaching course, and implement the sleep hygiene and habit changes recommended through the course that they find reasonable and effective for their situation.
223587520|NCT04863690|BEHAVIORAL|Digital Coaching plus Human Coaching|All participants will work through the content in the Muse S Sleep Coaching course, and implement the sleep hygiene and habit changes recommended through the course that they find reasonable and effective for their situation. All participants will also be asked to join regular online coaching sessions. Participants will be divided into 9 cohorts of 10 people per cohort. Each cohort will be offered group coaching once per week. Coaches will be versed in Mindfulness, and how to use Muse and how to support sleep. Coaching will take place virtually using Interaxon's Zoom account.
223587521|NCT01065311|BEHAVIORAL|Mindfulness-based Cognitive Therapy|Mindfulness-based Cognitive Therapy is based on an integration of aspects of cognitive behavioral therapy for depression (Beck et al., 1979) with components of the Mindfulness-based Stress Reduction program developed by Kabat-Zinn and colleagues (Kabat-Zinn, 1990). After an initial orientation session, the MBCT program is delivered by an instructor in eight weekly 2.5 hr group sessions
224307504|NCT02131350|PROCEDURE|Photocoagulation|Photocoagulation include focal/grid laser and/or panretinal photocoagulation
224307505|NCT02131350|DRUG|Ranibizumab|
224307506|NCT00663026|DRUG|bapineuzumab|5 mg bapineuzumab subcutaneous injection once per week for 6 months
224307507|NCT00663026|DRUG|bapineuzumab|10 mg bapineuzumab subcutaneous injection once per week for 6 months
224307508|NCT00663026|DRUG|placebo|Placebo subcutaneous injection once per week for 6 months
224307509|NCT01570686|DRUG|Aliskiren|Aliskiren 300 mg once daily
224180502|NCT04430387|DEVICE|The high-volume evacuator|The high-velocity air evacuation device. It is connected through the high-volume suction hose in the dental chair. It is operated by a dental assistant during the dental treatment, owing to the challenge posed by the rigid disposable attachment and bulky high-volume suction hose.
224180503|NCT04430387|DEVICE|The DryShield|The device is attached to the high-volume suction hose to provide continuous suction of intraoral fluid and debris, and also simultaneous isolation to both maxillary and mandibular quadrants on the same side. Other advantages of these devices include retracting the tongue and cheek, and prevention of aspiration.
223587522|NCT01065311|BEHAVIORAL|The Cognitive Behavioral Analysis System of Psychotherapy|The Cognitive Behavioral Analysis System of Psychotherapy integrates behavioral, cognitive, and interpersonal strategies. After two initial orientation sessions, the MBCT program is delivered weekly by an instructor in eight 2.5 hr group sessions.
223587523|NCT01065311|BIOLOGICAL|Standard psychiatric care|"Antidepressant medication and medical care.~Standard psychiatric outpatient care:~All patients were requested to get treated individually either by a psychiatrist or by a licensed psychotherapist (not member of the study team). If patients were already in psychiatric/psychotherapeutic individual treatment at study intake they continued their treatment with this psychiatrist/psychotherapist"
223587524|NCT04764344|DRUG|Haloperidol|2.5mg of IV haloperidol will be diluted to 5ml with 0.9% NS and given over 2 minutes IVP
223587525|NCT04764344|DRUG|Ondansetron|Ondansetron
224180504|NCT00661362|DRUG|Saxagliptin|Oral tablet, once daily for 24 weeks
224180505|NCT00661362|DRUG|Placebo|oral tablet, once daily for 24 weeks
224180506|NCT00661362|DRUG|Metformin|oral tablet, once daily for 24 weeks
224180507|NCT02906644|DRUG|lorcaserin|
224180508|NCT02906644|DRUG|nicotine patch|
224180509|NCT02906644|DRUG|placebo lorcaserin|
224180510|NCT03110497|RADIATION|Single application multi-fraction brachytherapy|Single application brachytherapy procedure to deliver high dose rate fractions of 9Gy, 7Gy and 7Gy with 6-12 hours apart under strict image guidance
224180511|NCT04370041|DEVICE|Dokimos Plus aortic valve|Dokimos Plus aortic valve
224180512|NCT02108158|DRUG|Azzalure|
223489811|NCT06978842|DEVICE|Wearable EEG headband for passive brain signal acquisition|This intervention involves the use of non-invasive, consumer-grade wearable EEG headbands to passively record brain activity from individuals with epilepsy in their natural home environments. The devices include BrainBit Headband, BrainBit Mindo, BrainBit Headphones, Muse 2, and Muse S. These devices transmit EEG signals via Bluetooth to a mobile application developed by the sponsor. The app provides real-time feedback on signal quality and securely uploads data to the cloud for offline analysis. The wearable devices are used solely for passive data acquisition and are not being evaluated for safety or therapeutic effectiveness in this study. No changes are made to clinical care or treatment.
223489812|NCT05406232|PROCEDURE|Biopsy|Undergo tumor punch biopsy
223489813|NCT05406232|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223489814|NCT05406232|RADIATION|Radiation Therapy|Undergo RT
223587526|NCT04547361|DRUG|E2511|E2511 tablets.
223587527|NCT04547361|DRUG|E2511 Matched Placebo|Placebo tablets matching E2511 tablets.
223587528|NCT03681613|OTHER|NEMEX program combined with a CNS-focused protocol|"The NEMEX program will consist of 12-weeks of individualized and supervised exercise sessions applied twice weekly (n=24 sessions). Each exercise session will last approximately 60minutes and include three parts: warming up, a circuit program and cooling down.~The CNS-targeted treatment will consist of 12-week individualized and supervised sessions applied once weekly. Each training session will last approximately 30 minutes and include three parts, which are further explained below: 1) discussion of the participant's knee pain experience from a pain neuroscience perspective, 2) graded SDT and 3) GMI training."
223587529|NCT03681613|OTHER|NEMEX program|The NEMEX program will consist of 12-weeks of individualized and supervised exercise sessions applied twice weekly (n=24 sessions). Each exercise session will last approximately 60minutes and include three parts: warming up, a circuit program and cooling down.
223587530|NCT04507971|BIOLOGICAL|MET-3|Human microbiome supplementation derived from bacterial strains isolated from fecal matter and grown in a laboratory environment
223587531|NCT06000605|OTHER|Fed|Participants will eat a light meal prior to testing and be fed a light meal during testing.
224180513|NCT03672006|BIOLOGICAL|alteplase (recombinant t-PA)|Medication administered to dwell in central venous catheter
224180514|NCT03672006|DRUG|Heparin|Medication administered to dwell in central venous catheter
224180515|NCT00815373|DRUG|Dorzolamide+Timolol Maleate0.5%|Cosopt\* b. i. d.
224180516|NCT00815373|DRUG|Latanoprost+Timolol Maleate0.5%+Lytears|Xalacom\* QHS
224180517|NCT01237665|DRUG|IXO regimen|"IXO regimen is administered as following: irinotecan 160 mg/m2 i.v. (over 60-90 minutes) with oxaliplatin 100 mg/m2 i.v. (over 120 minutes) on day 1, followed by capecitabine 950 mg/m2 PO, b.i.d. on days 2-15, every 3 weeks.~Each cycle of IXO lasts 21 days, with the subsequent cycle to start on day 22."
224180518|NCT02479022|DRUG|Insulin 320|Subjects will be randomised to receive a single dose of Insulin 320 orally, at 7 escalating dose levels from 300 nmol to 21600 nmol. Progression to next dose level will be based on a safety evaluation.
224180519|NCT02479022|DRUG|insulin glargine|As an open label active comparator, subjects will be randomised to receive a single dose of insulin glargine subcutaneously (s.c., under the skin), at all dose levels. The insulin glargine dose will be the same at all dose levels.
224180520|NCT02479022|DRUG|placebo|Subjects will be randomised to receive a single dose of placebo orally as a comparator Insulin 320, at all dose levels.
224180521|NCT05863065|OTHER|Exposure to a Virtual Reality scenarios|Exposure to a personalized, relaxing Virtual Reality scenario deployed by a Head-mounted tool (Oculus Quest 2). The administration was deployed in one session.
224180522|NCT00705627|DRUG|neoadjuvant chemotherapy plus concurrent chemoradiotherapy|Drug: cisplatin,fluorouracil. Patients received cisplatin 80mg/m2 on day 1,fluorouracil 4000mg/m2 civ 120 hours every three weeks for two cycles, then received radical radiotherapy, and cisplatin (80mg/m2 on day 1) every three weeks for three cycles during RT.
224180523|NCT01869920|BEHAVIORAL|Intervention group|Education on breastfeeding
224180524|NCT01869920|BEHAVIORAL|Usual care|Usual care
224180525|NCT00899327|GENETIC|DNA methylation analysis|
224180526|NCT00899327|GENETIC|RNA analysis|
224180527|NCT00899327|GENETIC|cytogenetic analysis|
224180528|NCT00899327|GENETIC|gene expression analysis|
224180529|NCT00899327|GENETIC|mutation analysis|
223489815|NCT05121337|BEHAVIORAL|Dietitian-Assisted DASH groceries|"The DASH (Dietary Approaches to Stop Hypertension), is a healthy dietary pattern that lowers blood pressure without reducing weight. The DASH diet emphasizes fruits, vegetables, and low-fat dairy products; includes whole grains, poultry, fish, and nuts; and is reduced in red meat, sweets, and sugar-containing beverages.~Intervention Phase:~This intervention is a weekly, 12-week DASH dietary intervention. A dietitian will assist participants in ordering groceries in a pattern consistent with the DASH diet to be delivered to their homes. The quantity of groceries will be based on participant Calorie needs and family size.~Observation Phase:~For months 4-12 of the study, participants will be asked to continue following a DASH grocery shopping pattern without the provision of weekly groceries."
223489816|NCT05121337|BEHAVIORAL|Self-directed shopping|"Intervention Phase:~Participants will receive some basic information on healthy eating and a monthly stipend at 4, 8, and 12-weeks of the intervention.~Observation Phase:~For months 4-12 of the study, participants will be asked to follow their typical shopping pattern without the provision of a monthly stipend."
223489817|NCT06645015|DEVICE|AI augmented risk-stratification|A state-of-the-art artificial intelligence (AI) model called AIDPRO manual CRC is used as a decision support tool to estimate the 1-year mortality risk for each patient
223489818|NCT06645015|OTHER|Expert-based Risk-stratification|Experienced colorectal surgeons assess patient risk based on clinical judgment and national guidelines.
223489819|NCT03603613|BEHAVIORAL|YRI|The YRI is designed to assist youth facing complex problems using evidence-based treatments that have been tested and shown to work well in other settings and cultures. The YRI has three specific goals: 1) develop emotion regulation skills for healthy coping; 2) develop problem-solving skills to assist with achieving goals, and; 3) improve interpersonal skills to enable healthy relationships and effective communication. It integrates six CBT-based, empirically-supported practice elements shown to have transdiagnostic efficacy across disorders ranging from major depressive disorder to PTSD and conduct disorders. The YRI's six evidence-based components are delivered in three phases common in trauma-informed interventions: stabilization, integration, and connection.
223489820|NCT03603613|BEHAVIORAL|EPP|The youth capacity development component of GIZ's EPP includes the following core components: financial literacy, entrepreneurship, and vocational training delivered through six modules (agro-processing, solar photovoltaic installation and maintenance, governance and conflict resolution, psychosocial competencies, entrepreneurship, employability). Youth will be trained at training sites and have access to a youth center in the area. These centers will have agricultural equipment and machinery available for youth to use. Our YRI curriculum will be used for the psychosocial competency training module.
223489821|NCT01235377|OTHER|Favor one of two thiazides for new prescriptions & attempt target dose|Providers will be randomized to either Favor Chlorthalidone or Favor Hydrochlorothiazide for patients who are to be newly prescribed a thiazide for hypertension, whether the thiazide is 1st line or add-on therapy. Providers will have agreed to adhere to their assignment for patients for whom there is equipoise, but they are free to deviate if medically indicated for individual patients. There is no requirement to maintain the initial thiazide therapy; it is expected that the regimen may require adjustment over time. The cluster assignment is simply to favor a particular thiazide on initiation of thiazide therapy and attempt to reach the target dose.
223489822|NCT01525589|DRUG|PM01183|PM01183 drug product (DP) is presented as a lyophilized powder for concentrate for solution for infusion with two strengths: 1 mg/vial and 4 mg/vial
223489823|NCT01858961|DRUG|BI 201335|Once a day
223489824|NCT01858961|DRUG|ribavirin|Twice a day
223489825|NCT01858961|DRUG|BI 207127|Twice a day
223489826|NCT01858961|DRUG|Telaprevir|Three times a day
223489827|NCT01858961|DRUG|ribavirin|Twice a day
223489828|NCT01858961|DRUG|Pegylated Interferon|Once a week
223489829|NCT03424148|DEVICE|Excel V™ Laser & Micro-Lens Array Attach|Subjects will receive laser treatments
223489830|NCT03860155|BIOLOGICAL|allo-APZ2-ACLF|Administration of 2 x 10e6 allogeneic ABCB5-positive stem cells/kg bodyweight, each at Day 0, Day 5 (±1) and Day 13 (±1) into peripheral vein (arm) intravenously with a flow rate of 1-2 ml/min. Infusion of the product via a central venous catheter (CVC), a Port-a-Cath (Port) or a similar catheter is also possible. Allo-APZ2-ACLF will be in a concentration of 1 x 10e7 cells/mL in Human Serum Albumin/Ringer-Lactate/Glucose (HRG)-solution.
223489831|NCT03913247|OTHER|Size Measurement using a measuring tape, a caliper and a metric|Each patient will have the following measure: measure of the span, the tibia, the ulna, the distance between the hill and the knee, the head, the trunk and the leg. The different measures will be done using a measuring tape and with a caliper. Before leaving the intensive care unit, each patients will be measured according to the WHO standard, that is to say strictly lengthened, using a metric for patient younger than 2 and stand up using a stadiometer for patient older than 2.
223489832|NCT00872742|BEHAVIORAL|Acceptance enhanced behavior therapy (AEBT)|Ten 1-hour sessions over 12 weeks, enhancing awareness of hair-pulling behavior and teaching strategies to deal with hair pulling
223489833|NCT00872742|BEHAVIORAL|Psychoeducation and supportive therapy (PST)|Ten 1-hour sessions over 12 weeks, teaching the participant about hair pulling and discussing how hair pulling affects those who do it
223489834|NCT06057857|OTHER|conventional oral examination|conventional oral examination
223489835|NCT05626088|OTHER|No Intervention|This is a non-interventional study.
223587532|NCT06000605|OTHER|Fasted|Participants will completely abstain from calories for 72 hours prior to testing and not receive any calories during testing.
223587533|NCT00145691|DRUG|Oxcarbazepine|
224180530|NCT00899327|GENETIC|polymerase chain reaction|
224180531|NCT00899327|GENETIC|protein expression analysis|
224180532|NCT00899327|OTHER|laboratory biomarker analysis|
224180533|NCT03954418|DIETARY_SUPPLEMENT|Acesulfame K, cyclamate, saccharine, aspartame|Intervention group receives a combination of multiple artificial sweeteners
224180534|NCT01453439|BEHAVIORAL|Cognitive Behavioral Therapy|Participants will receive a total of 22 sessions (over 24 weeks) of individual, manual-based CBT. During the sessions, participants will receive education about BDD and CBT, learn to develop more helpful thoughts and beliefs, gradually enter anxiety provoking situations while reducing compulsions (repetitive behaviors), and learn relapse prevention techniques.
224205679|NCT03973086|DIETARY_SUPPLEMENT|Citrus flavonone-O-glycosides- LD|Low Dose of 200 mg
224180535|NCT01453439|BEHAVIORAL|Supportive Psychotherapy|Participants will receive a total of 22 sessions (over 24 weeks) of individual, manual-based SPT. During the sessions, participants will receive education about BDD and SPT, learn about factors that may affect their symptoms (for example, relationships, work, stress), and learn to cope with challenges in their life by improving self-esteem and positive coping skills.
224180536|NCT06138912|RADIATION|plain radiography (x-ray)|Radiographic imaging of the subjects was performed, and anteroposterior, lateral, flexion-extension, and right-left lateral bending radiograph views were obtained
224180537|NCT00964470|DEVICE|AWBAT™-D and XEROFORM™ OR GLUCAN II™ dressings|Dressing, donor site dressings
224180538|NCT04981886|DRUG|Netarsudil Ophthalmic|Subjects will be randomly assigned to this group
224180539|NCT04981886|DRUG|Bimatoprost Ophthalmic|Subjects will be randomly assigned to this group
224180540|NCT01014442|DRUG|mycophenolate mofetil|1.5 g PO BID from Days 2 to 30 post-transplantation, 1 g PO BID Days 31 to 90 post-transplantation
224180541|NCT02141776|DEVICE|Transcranial direct current stimulation (t-DCS)|The subjects randomized to this group will receive anodal t-DCS stimulation daily for four weeks. The stimulation parameters: current 2 mA continuously for 30 minutes.
224180542|NCT02141776|OTHER|Sham Controlled Arm|The subjects randomized to this group will not receive stimulation daily for four weeks.
224180543|NCT03455400|DEVICE|Swisstom BB2 EIT device|Swisstom BB2 EIT device with NEO SensorBelts will be used to measure ventilation distribution during spontaneous breathing and position changes in healthy newborn infants.
224180544|NCT02679430|DEVICE|Prostate Arterial Embolization|The purpose of this study is to demonstrate the safety and efficacy of the device, Embosphere Microspheres, in prostatic arterial embolization (PAE). PAE, is now an accepted form of treatment for BPH outside of the United States, however few studies have been performed demonstrating safety and efficacy in the US. Embosphere Microsphere is a device that may be used to reduce blood flow to targeted organs. With this research, we would like to show that Embosphere Microsphere may be used for patients with benign hyperplasia of prostate (BPH to reduce blood flow to the prostate gland. This current study is designed to understand the rate of improved BPH symptoms.
223489836|NCT06810973|BEHAVIORAL|SUCCESS-E|"SUCCESS-E is a previously developed intervention based on the evidence-based Antiretroviral Treatment and Access to Services (ARTAS) intervention, modified for those detained within a jail system. It is a manualized six-session program delivered by a case management team, composed of a professional case manager and paraprofessional peer navigators.~In Jail Sessions:~1. Build Trust~2. Assess Strengths~3. Explore life on ART~   Post-Release Sessions:~4. Link with care~5. Enhance self-efficacy for HIV care/PrEP~6. Future transitions"
223489837|NCT06810973|BEHAVIORAL|Enhanced Standard of Care|A list of referral sites for follow-up SUD care will be shared. This information sharing without strength-based, longitudinal case management will be an enhancement to treatment as usual. Also, information about HIV/PrEP follow-up in the community will be placed around the jail, such as affixed to the nurses' medication carts that they push from housing unit to unit, twice a day when residents are due for prescription medications.
223489838|NCT06810973|BEHAVIORAL|Key Informant Interviews|Key informant interviews (KII) will be conducted with jail staff and community stakeholders in the R61 phase to examine perceptions, barriers, and facilitators to SUD and HIV/PrEP service and treatment utilization, as well as document the experiences of SUCCESS-E participants from the pilot phase.
223489839|NCT03684889|BIOLOGICAL|SCRI-huCAR19v1|1:1 mixture of CD4:CD8 autologous T cells lentivirally transduced to express a second generation 4-1BB-ζ human CD19-specific CAR and Her2tG
223489840|NCT03684889|BIOLOGICAL|SCRI-huCAR19v2|Mixture of CD4:CD8 autologous T cells lentivirally transduced to express a second generation 4-1BB-ζ human CD19-specific CAR and Her2tG
223489841|NCT06811636|PROCEDURE|Lesion sterilization and tissue repair|Lesion sterilization and tissue repair therapy performed with a triple antibiotic mixture.
223489842|NCT06811636|PROCEDURE|Conventional pulpectomy|Conventional pulpectomy with calcium hydroxide-iodoform based root canal paste.
223489843|NCT05379556|DIAGNOSTIC_TEST|Assessment of andrological profile of LO-COCO-ANDRO male patients|"Assessment of serum prolactin (PRL), luteininzing hormone (LH), follicle stimulating hormone (FSH), 17β-estradiol, testosterone. Physical examination with measurement of body weight, height, body mass index, waist and hip circumference. Andrological physical examination with evaluation of testis volume with Prader orchidometer, testicular consistency and lesions, varicocele. Scrotal ultrasound performed in longitudinal, transverse and oblique scans using a high frequency linear probe with grayscale and color-doppler; transrectal prostate ultrasound performed with transverse, longitudinal and oblique scans using an end fire probe; basal penile ultrasound will be performed in longitudinal and transverse scans using a high frequency linear probe with grayscale and color-doppler; dynamic penile ultrasound performed as described for basal penile ultrasound after intra-cavernous infiltration of 10 mcg of prostaglandin-E1 (PGE1)."
223489844|NCT05379556|DIAGNOSTIC_TEST|Assessment of reproductive function of LO-COCO-ANDRO male patients|Semen samples will be collected on site by masturbation directly into a sterile plastic container after 3-5 days of sexual abstinence. The sample will be analyzed according to World Health Organization (WHO) 2010 guidelines. Semen samples will be stored for biochemical and molecular evaluations.
223489845|NCT05379556|DIAGNOSTIC_TEST|Assessment of sexual function of LO-COCO-ANDRO male patients|Validated questionnaires to assess the prevalence of male sexual disorders, namely erectile dysfunction with International Index of Erectile function 15 (IIEF-15), premature ejaculation with premature ejaculation diagnostic tool (PEDT), hypoactive sexual desire disorder with andrological structured interview on erectile dysfunction (ANDRO-SIEDY). Patients will be also interviewed to evaluate lifestyle habits.
223587534|NCT06507670|DIAGNOSTIC_TEST|Point of care ultrasound|"Point of care medical ultrasound machines will be used to sonographically visualize the esophagus and following sonographic data will be collected:~* Presence/absence of suspected foreign body~* Sonographic esophageal measurements (diameters, area)~* Other relevant secondary sonographic findings"
224180545|NCT03689270|PROCEDURE|Subluxation|One pole of The nucleus is hydrodissected until it lilts above the capsular bag. The tilted nucleus is rotated to face the incision and remaining half nucleus is then tumbled and emulsification continues from the opposite equator outside in until complete.
224180546|NCT03689270|PROCEDURE|Divide and conquer|Cataract nucleus is fragmented into 4 pieces then aspirated by ultrasonic vibration
224205680|NCT03973086|DIETARY_SUPPLEMENT|Citrus flavonone-O-glycosides- HD|High Dose of 400 mg
224180547|NCT01676428|RADIATION|Radiotherapy|"The investigational treatment will be prescribed as a 2-tiered dose scheduled dependant on target size.~For lesions \<5cm, a single fraction of 26Gy will be prescribed. For lesions ≥5cm a fractionated course of 14Gy by 3 fractions will be prescribed, delivered at least 48 hours apart."
224180548|NCT04045314|OTHER|Topical moisturizer|The investigational product is an intensive emollient cream that is applied topically on the skin and is manufactured by Avicanna Inc. This preparation contains widely used ingredients from mineral and botanical origin aimed at soothing and conditioning the skin as well as improving hydration. The moisturizer also contains 1% hemp oil rich in essential fatty acids and antioxidants as well as 0.5% of CBD with regulatory and conditioning effect on the skin
224180549|NCT06326658|OTHER|Bufei Yishen Prescription Granule|The comparison group was given Bufei Yishen Prescription Granule.The course of treatment was the same as that of the experimental group.
224180550|NCT01833299|PROCEDURE|TACE-Sorafenib group|"Transcatheter arterial chemoembolization drugs and dosage:TACE with chemothrapy drugs (E-ADM 50mg, carboplatin 300 mg, MMC 8mg)and followed with embolization with lipiodol and absorbable gelatin sponge particles or polyvinyl alcohol particles.~Oral sorafenib (400 mg BID) will be start the 2-4 weeks after the first TACE treatment and will continue until the patient shows disease progression, until unacceptable toxicity occurs, or until study termination."
224180551|NCT01833299|PROCEDURE|TACE|
224180552|NCT01017640|OTHER|Laboratory Biomarker Analysis|Correlative studies
224180553|NCT01017640|DRUG|Mitomycin|Given IV
224180554|NCT01017640|DRUG|Veliparib|Given PO
224180555|NCT03820518|DRUG|Calcitriol|
223489846|NCT05379556|DIAGNOSTIC_TEST|Assessment of olfactory function of LO-COCO-ANDRO male and female patients|"Brief interview to collect patient's anamnesis relative to olfactory function, with particular reference to hypo / anosmia and hypo/ageusia onset timeline, duration and regression.~Interview for the self-assessment of chemosensory skills and for the evaluation of quality of life in relation to olfactory dysfunction.~Sniffin 'Sticks test for the evaluation of odor threshold (T), odor discrimination (D) and odor identification (I) (TDI score)."
223489847|NCT06815289|RADIATION|MR-informed stereotactic radiotherapy|MR-informed stereotactic radiotherapy for treatment of ultracentral lung tumours utilising a dedicated MR-simulator for daily adaptation followed by CBCT-guided treatment delivery.
223489848|NCT06811038|DEVICE|iCanQuit Smartphone App Smoking Cessation Program|Receive access to iCanQuit app, with daily push notifications
223489849|NCT06811038|DRUG|Nicotine Gum|Receive nicotine replacement therapy gum
223489850|NCT06811038|DRUG|Nicotine Patch|Receive nicotine replacement therapy patch(es)
223489851|NCT06811038|DRUG|Nicotine Lozenge|Receive nicotine replacement therapy lozenge(s)
224180556|NCT04250246|DRUG|Ipilimumab plus nivolumab plus guadecitabine|"Cohort A Melanoma ARM A Guadecitabine: 30-45 mg/m2 s.c./day 1-5 q21 x 4 cycles and from W13 q28 x 6 cycles Ipilimumab: 3 mg/Kg i.v. plus nivolumab 1 mg/Kg i.v. on W1, 4, 7 and 10 and from W14 nivolumab 480 mg i.v. q4 wks for 2 years~Cohort B NSCLC ARM A Guadecitabine: 30-45 mg/m2 s.c./day 1-5 q21 x 4 cycles and from W13 q28 x 6 cycles Ipilimumab: 1 mg/Kg i.v.q 6wks plus nivolumab 3 mg/Kg i.v. q2 wks until W13, then ipilimumab: 1 mg/Kg i.v. q 6wks plus nivolumab 480mg i.v. q4wks for 2 years"
224180557|NCT04250246|DRUG|Ipilimumab plus nivolumab|"Cohort A Melanoma ARM B Ipilimumab: 3 mg/Kg i.v. plus nivolumab 1 mg/Kg i.v. on W1, 4, 7 and 10 and from W14 nivolumab 480 mg i.v. q4 wks for 2 years~Cohort B NSCLC ARM B Ipilimumab: 1 mg/Kg i.v. q 6wks plus nivolumab 3 mg/Kg i.v. q2 wks until W13, then ipilimumab: 1 mg/Kg i.v. q6 wks plus nivolumab 480mg i.v. q4wks for 2 years."
224180558|NCT02501486|OTHER|ACTH stimulation test|An ACTH stimulation test will be done
224180559|NCT02706535|DRUG|GSK525762 Besylate Tablets|GSK525762 is available as a film-coated, white to slightly colored round, biconvex tablets with no markings. It is available in unit dose strength of 5 mg.
224180560|NCT02706535|DRUG|Itraconazole 200 mg|Itraconazole is available as a clear yellow solution with unit dose strength of 10 mg/mL
224180561|NCT02706535|DRUG|Rifampicin 300 mg|Rifampicin is available as a red capsule with printed markings and as a 300 mg unit dose strength.
223489852|NCT06811038|OTHER|Survey Administration|Ancillary studies
223489853|NCT06811038|OTHER|Interview|Ancillary studies
223489854|NCT05630066|DRUG|Alogabat|Alogabat will be administered QD with dose depending on cohort and age of the participant.
223489855|NCT06132802|PROCEDURE|Patients who received treatment involving ARS and arthrocentesis only|A 5mm acrylic anterior repositioning splint (ARS) with maxillary coverage was crafted from alginate impressions. After arthrocentesis, the ARS was worn incrementally over six months, starting at two hours and reaching 14 hours daily. In the second week, wear time was continuous, increasing to 24 hours daily (excluding meals) until the sixth month. The ramp was removed in the seventh week. Follow-ups involved grinding the splint by 1mm every four weeks. Arthrocentesis included anesthesia, betadine prep, and using two 18-gauge needles to inject Ringer's lactate solution (100-200 cc) for joint lavage, freeing the disc by moving the lower jaw in various orientations.
223587535|NCT03463668|DEVICE|uncovered metal duodenal prosthesis|Implantation of an uncovered metal duodenal prosthesis for symptomatic tumor stenosis
223587536|NCT01843270|DEVICE|actual body weight based size|According randomized allocated group, the laryngeal mask airway is inserted based on actual or ideal body weight-based sizes before the surgery.
223587537|NCT01843270|DEVICE|ideal body weight based size|According randomized allocated group, the laryngeal mask airway is inserted based on actual or ideal body weight-based sizes before the surgery.
223587538|NCT02043119|BEHAVIORAL|Breastfeeding Clinic|
223587539|NCT04117763|DRUG|Empagliflozin 25 MG|Empagliflozin once daily, for three months
223587540|NCT03851419|DIAGNOSTIC_TEST|Diagnosis of (Neuro)cysticercosis|"* Serological tests for cysticercosis~* Neurological examination and cerebral CT scan for the diagnosis of neurocysticercosis~* Stool testing for T. solium"
224180562|NCT03010358|DRUG|Entospletinib|Given PO
224180563|NCT03010358|OTHER|Laboratory Biomarker Analysis|Correlative studies
224180564|NCT03010358|BIOLOGICAL|Obinutuzumab|Given IV
224180565|NCT03010358|OTHER|Pharmacological Study|Correlative studies
224180566|NCT05011110|DEVICE|Graduated compression stockings|Both GraduSOX and Sigvaris are graduated compression stockings. These exert the greatest degree of of compression at the ankle, and the level of compression gradually decreases up the garment.
224180567|NCT02344758|DEVICE|Non-invasive lateral flow test for monitoring gluten intake|
224180568|NCT02344758|BEHAVIORAL|gluten-free diet (GFD)|
224180569|NCT02344758|BEHAVIORAL|gluten-containing diet|
224180570|NCT01496924|OTHER|speech therapy|A single oral-motor technique will be used in a 10-times series intercalated with rest. Swallowing training techniques comprised indirect therapy (swallowing of saliva) and direct therapy (swallowing of food).
224180571|NCT03520842|DRUG|Methotrexate|Given PO
224180572|NCT03520842|OTHER|Pharmacokinetic Study|Correlative studies
224180573|NCT03520842|DRUG|Regorafenib|Given PO
224180574|NCT02981745|DRUG|CT-1530|Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Waldenstrom's Macroglobulinemia, FL, Diffuse B-cell lymphoma, Mental-cell lymphoma
224180575|NCT02985385|OTHER|Palliative management|Diagnostic studies for abnormal fetal ultrasounds
224180576|NCT02700932|DEVICE|PicoWay|solid state laser capable of delivering energy at wavelengths of 1064 nm or 532 nm or wave length of 785±20 nm that was added to the system
224180577|NCT04917666|BEHAVIORAL|Horticultural therapy|A structured 8-session group therapy program, in which participants learn about plants, green spaces, plant-human interactions. During the program, the participants are guided by therapist to grow or take care of both indoor and outdoor plants, do small horticulture projects (like cooking, making drinks, herb projects).
224180578|NCT04917666|OTHER|Comparison|4 session of semi-structured and free engagement in activities of their choice. The activities that they could choose are mostly table-top activities which are solitary in nature, and does not require social interaction.
223489856|NCT06132802|PROCEDURE|Patients who received treatment involving ARS, arthrocentesis, and an I-PRF injection|"A 5mm acrylic anterior repositioning splint (ARS) was crafted from alginate impressions, secured with Adam's clasps on upper first molars. After arthrocentesis, patients wore the splint incrementally over six months, starting at two hours and reaching 24 hours daily (excluding meals). The ramp was removed in the seventh week, and follow-ups included grinding the splint by 1mm every four weeks until it reached 3mm, guided by articulating paper.~Arthrocentesis involved administering anesthesia, prepping the area with betadine, and using two 18-gauge needles to inject 2-3 ml of Ringer's lactate solution for joint lavage. The lower jaw was moved to free the disc and release fibrous tissue. I-PRF preparation included centrifuging collected blood for 3 minutes at 700 rpm, and the resulting I-PRF was injected into the superior joint space of the lavaged joints."
223587541|NCT02613169|DRUG|Isoniazid|HIV-exposed uninfected infants will be randomized to receive either INH or no INH daily for 12 months for the prevention of Mycobacterium tuberculosis (MTB) infection.
223587542|NCT00343382|DRUG|pilocarpine hydrochloride|Given orally
223587543|NCT00343382|OTHER|placebo|Given orally
224180579|NCT03384394|DEVICE|high-flow nasal cannula oxygen|high-flow nasal cannula oxygen
224180580|NCT03384394|DEVICE|Conventional oxygen therapy|oxygen by a standard nasal cannula or nonrebreather mask
224180581|NCT03731065|DIETARY_SUPPLEMENT|Fructose-maltodextrin|Fructose plus maltodextrin in a ratio of 1:1.4, diluted in water to produce a 16% carbohydrate solution.
224180582|NCT03731065|DIETARY_SUPPLEMENT|Fructose-maltodextrin hydrogel|Fructose plus maltodextrin in a ratio of 1:1.4, encapsulated in an alginate-pectin hydrogel diluted in water to produce a 16% carbohydrate solution.
224180583|NCT03731065|DIETARY_SUPPLEMENT|Glucose-maltodextrin|Glucose plus maltodextrin in a ratio of 1:1.4, diluted in water to produce a 16% carbohydrate solution.
224180584|NCT03826641|DRUG|HCP1805|Dapagliflozin/Metformin (Xigduo XR) 10/1000mg
224180585|NCT03826641|DRUG|HCP1801|Dapagliflozin/Metformin 10/1000mg
224180586|NCT04306003|OTHER|ERAS pathway|See ERAS pathway arm description.
224180587|NCT04306003|OTHER|Standard Perioperative Care|See control arm description.
224180588|NCT06282731|DRUG|Silodosin|Indications:Benign prostate hyperplasia
224307510|NCT04528030|DEVICE|WAVE device|WAVE applies a transcutaneous vibration to the soles of the foot and palms of the hand to elicit nerve signalling from pressure and other limb proprioceptor sensors to pontine, cerebellar, and medullary brain areas that coordinate limb movement and reflexively activate brain areas controlling breathing. The WAVE device is a battery-operated product to reduce the episodes of Apnoea of Prematurity by vibratory stimulation to the hand and foot.
224307511|NCT04708639|DRUG|Alectinib|Use of ctDNA to establish response and resistance to alectinib.
223489876|NCT03966651|DRUG|PRRT with 177Lu-DOTATATE|Children will receive 2 Peptide Receptor Radionuclide Therapy (PRRT) using 177Lu-DOTATATE administered intravenously at 6 weeks interval.
223489877|NCT03412032|OTHER|assessment|different assessments in both arms
223489878|NCT06371274|DRUG|ATRA|ATRA is the main active metabolite of vitamin A. Studies have shown that ATRA can also reduce the number of MDSC in solid tumor patients, promote their differentiation and maturation, remove the immunosuppressive ability of MDSC, improve the tumor immune microenvironment, and thus improve the tumor treatment efficacy.
223489879|NCT06371274|DRUG|Toripalimab|Toripalimab is a fully human monoclonal antibody injection against PD-1 receptor. The NMPA has accepted the application of Toripalimab for a new indication for the treatment of initial metastatic or relapsed metastatic TNBC with PD-L1 positive (CPS≥1).
223489880|NCT06412601|BEHAVIORAL|RPM|remote patient monitoring by clinic staff
224180589|NCT02027324|DRUG|Chlorhexidine-alcohol group|2% chlorhexidine in 70% isopropyl alcohol in accordance with manufacturer's instructions for safe usage.
224180590|NCT02027324|DRUG|Povidone-Iodine Group|10% Povidone-Iodine for surgical antisepsis according to manufacturer's instructions.
224180591|NCT02671786|OTHER|MAHAN RUTF & MAHAN Vit-Min mix|MAHAN RUTF dishes are locally prepared by local tribal women and each packet of RUTF provides 500-550 calories \& 15-17 gms of proteins.
224180592|NCT01211795|DRUG|topical intraoral ketoprofen gel|20% ketoprofen oral gel is applied once daily by cotton swab to a branch of the trigeminal nerve on the maxillary gingival mucosa above the 2nd and 3rd molars. The swab is held in place for 2 minutes at the same time once daily.
224180593|NCT01211795|OTHER|Placebo Gel|An identical oral gel, without ketoprofen, or 'placebo gel' is applied using a cotton swab, once daily to a branch of the trigeminal nerve on the maxillary gingival mucosa. It is held in place for 2 minutes, once daily.
224180594|NCT03076411|DRUG|Pepsin|
224180595|NCT03252223|DRUG|Recombinant Follicle Stimulating Hormone|A modified dose-response study will be done using recombinant FSH (r-FSH), injected sc for 3 days at any one dose. r-FSH will be administered at weight-adjusted doses equivalent to 37.5, 75, and 150 IU based on an average weight of 70 kg, which approximates the weight of the average woman in the United States according to the Centers for Disease Control. Therefore, the actual dose of r-FSH will be 0.53 IU/kg for the 37.5 dose group. Accordingly, r-FSH will be repeated at doses of 1.1 IU/kg and 2.2 IU/kg that are equivalent to 75 and 150 IU for a 70 kg subject. Each FSH stimulation test will be assigned randomly and be separated by an interval of 8 weeks.
224180596|NCT00859495|DRUG|Doxorubicin|A medication used in cancer chemotherapy, derived by chemical semisynthesis from a bacterial species.
224180597|NCT00859495|DRUG|Cisplatin|Platinum-based antineoplastic
224180598|NCT00859495|DRUG|Pemetrexed|Folate Analog Metabolic Inhibitor
224180599|NCT00859495|RADIATION|Radiotherapy|Standard procedure given 3 weeks after last dose of chemotherapy
224180600|NCT01538680|DRUG|Regorafenib (BAY73-4506)|"Subjects will receive 160 mg regorafenib po every day (qd) for 3 weeks of every 4 week cycle (i.e., 3 weeks on, 1 week off). Subjects will continue on treatment until at least one of the following occurs (main criteria):~Progressive Disease (PD). The subject may continue treatment at the investigator's discretion.~Death Unacceptable toxicity Subject withdraws consent Treating physician determines discontinuation of treatment is in the subject's best interest Substantial non-compliance with the protocol"
224180601|NCT04984668|DRUG|GT90001+KN046|GT90001 7.0mg/Kg， KN046 5mg/Kg
224180602|NCT04984668|DRUG|GT90001+KN046|GT90001 7.0mg/Kg ， KN046 3mg/Kg
224180603|NCT04984668|DRUG|GT90001/KN046|GT90001 4.5mg/Kg / KN046 5mg/Kg
223489881|NCT06412601|BEHAVIORAL|app|use of Happy Bob phone app
223489882|NCT06794112|OTHER|Animated Educational Video|Both arms will receive standard care (written instructions), with the experimental arm receiving an additional animated video intervention.
223489883|NCT06794112|OTHER|Written Instructions|Standard written instructions for bowel preparation before colonoscopy
223489884|NCT06605963|DRUG|PPV-06|6 subcutaneous injections at Day 1, Week 4, Week 24, Week 44, Week 64, Week 84
223489885|NCT06605963|DRUG|Placebo|6 subcutaneous injections at Day 1, Week 4, Week 24, Week 44, Week 64, Week 84
223489886|NCT04501419|PROCEDURE|US-guided breast biopsy|During this study, women with undergo an US-guided breast biopsy by a radiologist instead of what is typically performed in Nigerian hospitals, which is either a blind biopsy or surgical excision. US-guided breast biopsy is the standard of care in the United States of America because the accuracy is better than blind biopsy and equal to surgical excision.
223489887|NCT04501419|OTHER|Ultrasound-guided breast biopsy training program|This program, developed by experts in Nigeria and the United States of America, certifies that they have the skills required to safely perform these biopsies on patients
223489888|NCT04409002|DRUG|Niraparib|Niraparib oral, once a day, predetermined dose.Dosing will commence on cycle 1 day 1 and will continue until the participant is taken off treatment
223489889|NCT04409002|DRUG|Dostarlimab|Dostarlimab by intravenous infusion once every cycle for as long as they remain on the study
223489890|NCT04409002|RADIATION|Radiation|Radiation therapy on every other week day of cycle 2 only. Radiation will begin on Cycle 2 Day 1
223587544|NCT02601547|DEVICE|PET-FDG brain imaging and NPT|PET-FDG brain imaging and NPT should be performed at T0, at Tf (within 1 month after chemotherapy termination), T+12. Several PET parameters should be calculated: minimal SUV (Standard Uptake Value), maximum SUV, and mean SUV for each of 20 cortical and sub-cortical territories.
224180604|NCT04984668|DRUG|GT90001+KN046|GT90001 4.5mg/Kg， KN046 3mg/Kg
224180605|NCT04984668|DRUG|GT90001+KN046|GT90001 3mg/Kg ， KN046 3mg/Kg
224180606|NCT05829434|DRUG|Magrolimab|Patients will receive magrolimab on day 1; 4: IV 1 mg/kg; day 8: IV 15 mg/kg; day 11, 15 and 22: IV 30 mg/kg (plus 30 mg/kg for 5 weeks weekly and then q2w until the end of consolidation)
224180607|NCT05829434|DRUG|7+3|"Patients will receive during Induction cycle 1: cytarabine at 100 mg/m² on study days 1-7 as a continuous infusion over 22-24 hours and daunorubicin at 60 mg/m² on study days 3, 4, 5~* optional during Induction cycle 2: cytarabine at 100 mg/m² on days 1-7 of the second induction cycle (i.e. study days 29-35) as a continuous infusion over 22-24 hours and daunorubicin at 60 mg/m² on days 3, 4, 5 of the second induction cycle (i.e. study days 31, 32, 33)~* optional during Consolidation cycle: cytarabine at 1 g/m² administered on days 1, 3, 5 of each consolidation cycle as an infusion for 2 hours every 12 hours (for patients \< 60 years up to 3 CONS cycles and for patients ≥ 60 years up to 2 CONS cycles)"
224205681|NCT03973086|DIETARY_SUPPLEMENT|Placebo|Placebo (Microcrystalline Cellulose) of 400 mg
224205682|NCT05153590|DRUG|Saxenda®|"Patients will be treated with commercially available Saxenda® according to local label and to routine clinical practice at the discretion of the treating physician.~The indication is for adults who need help managing their weight based on two different body mass index (BMI) groups."
224205683|NCT01138852|DRUG|Ampicillin-sulbactam|Patients were randomly assigned to receive either 1.5g of cefuroxime, or 3g of ampicillin/ sulbactam intravenously after the time the umbilical cord was clamped
224205684|NCT01138852|DRUG|Cefuroxime|Patients were randomly assigned to receive either 1.5g of cefuroxime, or 3g of ampicillin/ sulbactam intravenously after the time the umbilical cord was clamped
224205685|NCT04473729|OTHER|Audiovisual speech training in noise for children|Children will participate in listening training in the form of an iPad app
224307512|NCT01892124|BEHAVIORAL|Motivational Interviewing/Cognitive Behavioral-based Therapy|
224307513|NCT05218941|PROCEDURE|Implant surgery assisted by passive robotics|Implant surgery without flap assisted by passive robotics (X-Guide®)
224307514|NCT05218941|PROCEDURE|Conventional implant surgery|Flap implant surgery
224307515|NCT03801889|DRUG|SP-420|Self-administered by mouth
224307516|NCT00000386|BEHAVIORAL|Exposure and Response Prevention|
223489891|NCT05337241|DEVICE|Saline Enhanced Radiofrequency (SERF) Ablation|The Durablate intramural needle catheter delivers heated saline to target tissue in the left ventricle to target mid-myocardial and epicardial VT substrates
223489892|NCT06816186|BEHAVIORAL|multimedia|When mothers and their spouses reported to the health classroom on the 37-week prenatal check-up day, the researcher explained the motivation and process of the research. After the women and their spouses agreed to join the study, they were randomly assigned to the experimental group and the control group. The control group will be given general care guidance, while the experimental group will receive general care and multimedia birth control education intervention, and the mothers and their spouses will download and watch the video through Line, an instant messaging software on their mobile phones.
223489893|NCT06816186|BEHAVIORAL|Usual Care|When mothers and their spouses reported to the health classroom on the 37-week prenatal check-up day, The control group will be given general care guidance,
223489894|NCT05714293|RADIATION|CT scan with contrast medium|Multi-detector CT scan (if possible with prospective-ECG gated sequential scan) with contrast medium injection of nonionic contrast agent. All CT datasets will be analysed for the qualitative and quantitative assessment of the aortic root. The coronary height will be assessed at baseline in relation to the aortic annulus and in relation to the stent of the bioprostheses after aortic valve replacement.
223489895|NCT04468711|DRUG|Vitamin D|Vitamin D plus topical 1% hydrocortisone cream twice daily
223489896|NCT04468711|DRUG|Placebo|placebo plus topical 1% hydrocortisone cream twice daily
223489897|NCT06656845|DEVICE|Genus, a self-management app for patients with knee osteoarthritis|The self-management app (Genus) will include weekly reminders with information videos on knee osteoarthritis and treatment options, exercise videos, quizzes, questionnaires, and a platform for remote monitoring by health professionals.
224073315|NCT04818593|DEVICE|ZyMot Multi Sperm Separation Device (850 ul)|850 uL of untreated semen will be directly deposited into the inlet port of the ZyMotTM Multi device, followed by placement of 750 uL culture medium in the outlet port and throughout the upper collection chamber. The device will then be incubated in a humidified 37C CO2 incubator for 30 minutes. During incubation, the healthiest and most motile sperm will swim through the microporous filter and into the upper collection chamber, where they will be recovered via the outlet port. 500 uL of the sperm sample will be removed and placed in a separate tube for analysis and insemination.
224073316|NCT04818593|OTHER|Density Gradient Centrifugation|Density gradient centrifugation will be performed using a one-layer preparation of 90% Isolate in 15 mL conical tubes. Semen will be layered over 1 mL of gradient and then centrifuged for 15 min at 300xg. The supernatant will be removed and discarded. The sperm pellet will be washed by mixing with Multipurpose Handling Medium Complete and centrifuging the sample for 5 min at 400xg. After the wash, the supernatant is removed and discarded and the pellet is re-suspended in culture medium, assessed for sperm parameters, and held at room temperature until insemination.
224307517|NCT00000386|BEHAVIORAL|Family Treatment Program|
224307518|NCT00000386|BEHAVIORAL|Relaxation Training|
224307519|NCT00000386|BEHAVIORAL|Behavior therapy|
224307520|NCT00000386|BEHAVIORAL|Family Counseling|
224307521|NCT05808192|DRUG|Immunosuppressive|compare MS development in patients who achieve to suspend IS drugs after LT and in those who could not suspend.
223489898|NCT02712515|PROCEDURE|Deep brain stimulation implantation surgery|Deep brain stimulation is a neuromodulatory therapy in which electrodes are implanted in deep brain structures. Electrical pulses are delivered through these electrodes to suppress pathological activity that are causing the symptoms of essential tremor or Parkinson's disease.
224307522|NCT02815358|OTHER|Segmental Stabilization Exercises|The stabilization program focuses on the reestablishment of motor control and coordination between deep and superficial trunk muscles. The exercise program is based on the following criteria progression: 1) Precise contraction of the transverse abdominal and multifidus muscles, keeping the lumbar spine in a neutral position (as the middle way between maximum flexion and extension, repeated three times); 2) Keep the neutral position for 10 repetitions of 10 seconds; 3) Perform exercises with lower limbs in different postures.
224307523|NCT02815358|OTHER|Home Exercises|Home exercises include passive stretching and active mobilization of the spine.
224307524|NCT03543241|DIAGNOSTIC_TEST|MyoStrain|Prior to cardiac catheterization, patients will be stress testing with low dose Dobutamine to evaluate wall motion, segmental, and global myocardial strain at rest and under stress to determine the accuracy of detecting ischemia and viability of myocardial tissue.
223489899|NCT02712515|DEVICE|Ad-Tech Medical Instrumentation Corp. electrodes/subdural strips|Ad-Tech Medical Instrumentation Corp. electrodes are intraoperative monitoring subdural strips will be placed on the surface of the cortex (non-penetrating).
223489900|NCT02712515|DEVICE|FHC Guideline 4000+ system and/or Medtronic RC+S|Brain signals will be recorded using the clinical Participants in this group with Parkinson's disease will be undergoing deep brain stimulation implantation surgery as part of the standard of care. In addition, the Ad-Tech Medical Instrumentation Corp. device will be used to test responses with wireless sensors placed on the participant's arms, which can record EMG activity. Brain signals will be recorded using the clinical FHC Guideline 4000+ system and/or Medtronic RC+S devices, which are capable of recording during stimulation.
223489901|NCT06663436|BIOLOGICAL|altSonflex1-2-3 Dose A|altSonflex1-2-3 Dose A administered intramuscularly on Day 1 and Day 169
223489902|NCT06663436|BIOLOGICAL|altSonflex1-2-3 Dose B|altSonflex1-2-3 Dose B administered intramuscularly on Day 1 and Day 169
224073317|NCT04147104|DEVICE|Low flow ECCO2R|"Treatment with a medical device called ECCO2R. The device consists of a drainage cannula placed in a large central vein, a membrane lung (artificial gas exchanger), and a return cannula into the venous system. Blood is pumped through the membrane lung, and CO2 is removed by diffusion. A flowing gas known as sweep gas containing little or no CO2 runs along the other side of the membrane, ensuring a diffusion gradient from blood to the other side, hence promoting CO2 removal."
223489903|NCT06663436|BIOLOGICAL|altSonflex1-2-3 Dose C|altSonflex1-2-3 Dose C administered intramuscularly on Day 1 and Day 169
224180608|NCT05829434|DRUG|CPX-351|"Patients will receive during Induction cycle 1: CPX-351 with daunorubicin 44 mg/m² and cytarabine 100 mg/m² on days 1, 3, 5~* optional during Induction cycle 2: CPX-351 with daunorubicin 44 mg/m² and cytarabine 100 mg/m² on days 29 + 30~* optional during Consolidation cycle: CPX-351 with daunorubicin 29 mg/m² and cytarabine 65 mg/m² on days 1, 3"
224180609|NCT03547219|DRUG|Escitalopram|
224180610|NCT04846543|OTHER|MRI Scan|MRI scan
224180611|NCT06401382|DEVICE|A modified aligner appliance with NiTi springs|The modified aligner appliance will be used until the final position is achieved.
224180612|NCT06401382|DEVICE|Conventional fixed appliances|The traditional fixed appliances with a standard prescription will be used.
224180613|NCT04645225|DEVICE|. MEFV genetic testing|For mutation analysis, 2 ml blood will be with drawn from both patient and control groups in order to obtain genomic DNA. Extraction of DNA molecule from peripheral blood lymphocytes will be done using standard procedures, then amplification of MEFV gene will be done by polymerase chain reaction(PCR). Reversed hybridization technique will be used for identification of MEFV gene mutation.
223489904|NCT06663436|BIOLOGICAL|TYPHIBEV|TYPHIBEV administered intramuscularly on Day 1
223489905|NCT06663436|COMBINATION_PRODUCT|Infanrix hexa|Infanrix hexa administered intramuscularly on Day 169
223489906|NCT06663436|BIOLOGICAL|MR-VAC|MR-VAC co-administered subcutaneously on Day 1 and Day 169
223489907|NCT06663527|COMBINATION_PRODUCT|Fumigating-washing Therapy With CPD|All patients underwent anal fistulectomy based on the Parks classification. For postoperative infection prophylaxis, cefuroxime was used at a dosage of 2g per dose, twice daily. Commencing the day following surgery, a fumigating-washing therapy was conducted once daily either after defecation or two hours prior to intravenous infusion. In the study group, a medical solution used for fumigating-washing therapy was prepared by blending 200 ml of CPD with 2 liters of water at 40 °C. This medicinal solution was then transferred into the reservoir of an ultrasonic atomizing fumigating-washing device (Model:TM50-C, Xuzhou Tianma Medical Equipment Factory, China) that was classified by the FDA as Class II (special controls).
223489908|NCT06663527|COMBINATION_PRODUCT|fumigating-washing therapy with a placebo|fumigating-washing therapy with a placebo
223489909|NCT06666257|BEHAVIORAL|Continuous Glucose and E-Monitoring to Support Healthy Weight Gain in Pregnancy|The intervention we are basing our adaptations on is a ecological momentary intervention, meaning it is integrated into participants daily lifestyle and schedule. Using an established framework for tracking daily body weight and physical activity, a gestational weight gain trajectory is estimated. Based on the data, recommendation prompts for exercise and diet will be discussed with participants during motivational interviewing. For the CGM piece, participants will wear unblinded CGM devices and have access to CGM linked app features that allow insights and reactivity to personal glycemic data
223489910|NCT02850835|OTHER|Video Decision Aid|A video decision aid was developed inform patients about pelvic organ prolapse, to include female anatomy, and treatment options.
224180614|NCT00984100|PROCEDURE|NOTES Transvaginal Cholecystectomy|An operation to remove the gallbladder, but instead of removing it via an incision in the abdominal wall, will be removed using an endoscope inserted through an opening in the posterior vagina (which then enters the abdominal cavity).
224180615|NCT01363232|DRUG|BKM120 + MEK162|
224180616|NCT01456559|OTHER|Lower body negative pressure (LBNP)|"The purpose with the planned study is to study pleth variability index (PVI) as a non invasive indicator for mild hypovolemia during spontaneous breathing in healthy subjects. Lower body negative pressure (LBNP), a well established technique, is used to create defined levels of hypovolemia.~Baseline data are recorded with the subjects in the supine position breathing with normal tidal volume without PEEP and without LBNP applied. Data are then recorded with LBNP applied in two steps (40 and 15 mmHg). Recordings are continued 5 minutes after releasing the negative pressure. Data are collected in total in four different series; normal tidal volume without PEEP; normal tidal volume with PEEP 5cm H2O; three doubled tidal volume without PEEP; three doubled tidal volume with PEEP 5 cm H20."
223489911|NCT05676554|OTHER|An Enhanced Psychological Mindset Session for Adolescents|"It is a ten-minute psychoeducation video (animation) delivered on the internet, followed by five minutes of stories from fictional students about how they used the concepts. Participants then complete three multiple choice questions aimed to assess their understanding and ability to apply concepts from the video, followed by 'letter of advice' task where participants have to give advice to a fictional younger student based on the information presented in the animation and videos.~The intervention itself was developed by Perkins et al (2021) based on promoting a growth mindset. It was deemed to be a feasible and acceptable tool to promote mental health (Perkins et al., 2021) in their feasibility trial."
223489912|NCT04166019|BEHAVIORAL|Peer-led self-management program|The program based on completion of a self-management workbook, consisting of the main components: personal recovery goals, plans to re-establish community functioning and support networks following a crisis, identifying early warning signs and creating a relapse prevention plan, and strategies and coping resources to problem-solving and maintain well-being.
223489913|NCT04166019|BEHAVIORAL|Psycho-education group|The psycho-education group program is comprised of six components: introduction and goal-setting; basic understanding of psychosis and symptom and emotion self-care; education workshop of psychosis care, treatment and community support services; learning about self-care skills; establishing social support and effective coping skills; and skills practices, review and future plan.
223587545|NCT02762747|PROCEDURE|preperitoneal suction drainage|preperitoneal suction drainage after laparoscopic totally extra-peritoneal hernioplasty for inguinal hernia
223587546|NCT03945019|BIOLOGICAL|CT-P13 SC (Infliximab)|Subcutaneous injection of CT-P13 SC
223587547|NCT03945019|OTHER|Placebo SC|Subcutaneous injection of Placebo SC
223587548|NCT00933894|DRUG|Telaprevir; Escitalopram|
223587549|NCT04123223|BEHAVIORAL|Cognitive Remediation|Cognitive remediation (CR) is a behavioral treatment designed to address neurocognitive deficits through task practice and/or strategy acquisition.
223587550|NCT04123223|BEHAVIORAL|Computer Games|Sham placebo treatment
224180617|NCT03400228|DIETARY_SUPPLEMENT|Probiotic|The probiotic is composed of a combination of Lactobacillus acidophilus (LA-5®) and Bifidobacterium lactis (BB-12®).
224180618|NCT03400228|DIETARY_SUPPLEMENT|Maltodextrin|Maltodextrin is a supplement feed based carbohydrate powder and tasteless.
224205686|NCT02619370|BEHAVIORAL|Conversation card game|
224180619|NCT02223533|DEVICE|19Gx500-mm Pajunk InfiltraLong® catheter|Before completing the surgery, the surgical team inserted a 19Gx500-mm Pajunk InfiltraLong® catheter with multiple perforations in the last few centimeters before the tip to allow for local anesthetic administration.
224180620|NCT02223533|DRUG|morphine|After the intervention patients had access to intravenous morphine via a patient-controlled analgesia
224180621|NCT01017289|DEVICE|Quantum|Treatment of humerus fracture (according to the mentioned indications) with the Quantum Intramedullary Nailing System.
224180622|NCT02802527|PROCEDURE|Percutaneous Tracheostomy|
224180623|NCT00304421|DRUG|rabeprazole|
224180624|NCT00304421|DRUG|pantoprazole|
224180625|NCT02247726|DRUG|Saline Placebo (0.5mL injection)|
224180626|NCT02247726|DRUG|RSV F vaccine (0.5mL injection)|
224180627|NCT01973205|DRUG|Acetaminophen 250 mg and Aspirin 250 mg|2 tablets each containing Acetaminophen 250 mg and Aspirin 250 mg
224180628|NCT01973205|DRUG|Placebo|2 placebo tablets matching acetaminophen 250 mg and aspirin 250 mg tablets
224180629|NCT05571397|DEVICE|Dexcom G6|Continuous Glucose Monitor
224180630|NCT04741867|OTHER|Education|Patients will be educated to determine their level of coping with stress and their adaptation.
224180631|NCT02135848|DRUG|GSK1278863|GSK1278863
224180632|NCT02135848|DRUG|Placebo|Placebo
224180633|NCT04472962|OTHER|Pre-exercise meal|Mixed meal with low-carbohydrate-high-protein content
224180634|NCT04472962|OTHER|Pre-exercise meal|Mixed meal with high-carbohydrate-low-protein content
224180635|NCT05723172|DEVICE|active tACS|40 mins tACS for 10 consecutive daily sessions
224180636|NCT05723172|DEVICE|sham tACS|40 mins sham tACS for 10 consecutive daily sessions
224180637|NCT03762785|DRUG|nebulized Dexmedetomidine|inhalation of dexmedetomidine by nebulizer. the study drug will be prepared in 3 ml of 0.9% saline and will be administered by standard hospital jet nebulizer via face-mask with continuous flow of 100%oxygen at 6 l/m for 10 to 15 min
224180638|NCT01663155|DEVICE|chest x-ray with or without CAD, lose dose CT scan|PA view, low dose CT scan
224073318|NCT04147104|DEVICE|Invasive mechanical ventilation|Invasive mechanical ventilation deviceto support acute respiratory failure and facilitate exhalation via an endotracheal tube or tracheotomy.
224180639|NCT00089505|DRUG|Emtricitabine|200 mg taken orally
224180640|NCT00089505|DRUG|Emtricitabine/Tenofovir disoproxil fumarate|200/300 mg taken orally
224180641|NCT00089505|DRUG|Lopinavir/Ritonavir|400/100 mg taken orally
224180642|NCT00089505|DRUG|Nevirapine|200 mg taken orally
224180643|NCT00089505|DRUG|Tenofovir disoproxil fumarate|300 mg taken orally
224180644|NCT02868801|DRUG|Placebo|same intervention as the experimental group
224180645|NCT02868801|DRUG|Pregabalin SR tablet 165mg/day|According to the efficacy and safety in titration
224180646|NCT02868801|DRUG|Pregabalin SR tablet 330mg/day|According to the efficacy and safety in titration
224180647|NCT02868801|DRUG|Pregabalin SR tablet 660mg/day|According to the efficacy and safety in titration.
224180648|NCT01739868|OTHER|Biopsies of muscular and fat tissue|"3 half days of metabolic exploration including blood sample, urinary taking, OGTT (oral glucose tolerance test), biopsies of muscular and fat tissue:~* 1 visit the first year (inclusion visit)~* 1 visit at the end of 5 years of follow-up or in the appearance of type 2 diabetes~* 1 intermediary visit (in 3 years) or activated by the following conditions:~  * Escalation of the glycemia (increase of 0.1g / l of the glycemia and/or 0.3 % of the HbA1c)~ * Normalization of the glycemia (fasting blood glucose \< 1 g/l)"
224180649|NCT02742155|BEHAVIORAL|Play2Sleep|Behavioral: Video self-modelling
224180650|NCT02742155|BEHAVIORAL|Comparison|Behavioral: Information only
224073319|NCT04265183|OTHER|Placing preformed metal crowns using Hall technique.|Preformed metal crowns (3M™ ESPE™ STAINLESS STEEL CROWNS) were placed after using separation elastics (Dentalastics® separators, DENTAURUM). The crowns were cemented using is a self-curing, radiopaque, fluoride-releasing, resin-modified glass ionomer luting cement (Ketac™ Cem Plus Luting Cement, 3M™ ESPE™). The technique used to place the crowns was the Hall technique (technique without tooth preparation).
224180651|NCT03634852|DRUG|Moxifloxacin hydrochloride 0.5% eye drops|were prescribed four times a day for 1-month postoperatively
224180652|NCT03634852|DRUG|Dexamethasone 0.1% eye drops|were prescribed four times a day for 1-month postoperatively
224180653|NCT03634852|DRUG|Intracameral Moxifloxacin 0.1%|"Auromox (0.5%): is a sterile clear yellow pale colored preservative free isotonic ophthalmic solution with pH 6.0 to 7.5 and osmolarity 620 -320 milliosmol ( mOsm).The sterile Auromox vial contains 1cc Moxifloxacin hydrochloride 5.45 mg equivalent to 5mg of Moxifloxacin. This product is manufactured by Aurolab an Indian pharmaceutical company. Auromox is available in many countries including Iraq.~Each vial enough for 15 different patients by using a sterile needle and 5cc syringe. By the sterile hand's, the surgeon draws the whole 1cc of Moxifloxacin 0.5% and diluted with 4 cc of balanced salt solution (BSS) to get 5 mg in 5 cc (0.1%) then draw 0.2 cc for each patient."
224180654|NCT03634852|DRUG|Subconjunctival Triamcinolone acetonide 4 mg /0.4 ml|"Aurocort is a preservative-free Triamcinolone acetonide (40 mg /1cc), with along acting depot preparation of triamcinolone in 1cc vial also the product of Aurolab company and commercially available in our country.~The whole 1cc had been drawn and diluted with 3cc of BSS and SC injection of 4 mg in 0.4 cc of Triamcinolone was given (as a final step in the surgery) 6mm from the limbus usually an inferotemporal site that is easily accessible and the plaque that formed will be not visible within palpebral fissure"
224180655|NCT01802242|RADIATION|Volumetric Modulated Arc Therapy (VMAT) and High-Dose Rate (HDR) Radiotherapy|"Patients in this group will receive one of 2 treatment arms of their choice:~* Arm 1: VMAT delivery with integrated VMAT boost (IB-VMAT) GTV: 95Gy in 38fractions~* Arm 2: HDR-boost followed by VMAT GTV: 10Gy HDR + 76Gy in 38 fractions VMAT"
224180656|NCT01802242|OTHER|No Active Treatment - completed Prior Radiation|Already had prior radiation treatment. MRI-guided prostate biopsy at 3 years and PSA per standard practice
224180657|NCT04385667|DEVICE|levonorgestrel intrauterine system (LNG-IUD)|progestin delivery for regression of atypical endometrial hyperplasia
224180658|NCT04385667|DRUG|Oral Megesterol 160 mg daily|progestin delivery for regression of atypical endometrial hyperplasia
224180659|NCT05823389|PROCEDURE|Re-instrumentation with flapless Emdogain application|Teeth with deep probing pocket depths were randomized to receive re-instrumentation with adjunctive flapless administration of EMD
223587551|NCT01167868|DRUG|FosD|oral tablet
223587552|NCT01167868|DRUG|Placebo|oral tablet
223587553|NCT02917915|OTHER|Canadian Standardized PR|Patients attend pulmonary rehabilitation (PR) 3 days per week for 6 weeks or 2 days per week for 8 weeks. Patients receive 2 hours of exercise training (aerobic and resistance) and 1 hour of education designed to promote self-management. In this intervention patients will receive the New Canadian Standardized PR educational approach (experimental).
223587554|NCT02917915|OTHER|Traditional PR|Patients attend pulmonary rehabilitation (PR) 3 days per week for 6 weeks or 2 days per week for 8 weeks. Patients receive 2 hours of exercise training (aerobic and resistance) and 1 hour of education designed to promote self-management. In this intervention patients will receive the Traditional PR education approach (active comparator).
224073320|NCT06981780|DEVICE|Femoral artery Doppler|An experienced operator will conduct femoral artery examination for the change in Doppler indices namely pulsatility index, resisitive index, and waveform morphology
224180660|NCT05823389|PROCEDURE|Re-instrumentation with placebo application|Teeth with deep probing pocket depths were randomized to receive re-instrumentation with adjunctive placebo application
224180661|NCT00536458|PROCEDURE|radiotherapy|mini chep+ radiotherapy
224180662|NCT00536458|DRUG|MINI CHEP|chemotherapy minichep 6 courses
224180663|NCT04542525|DEVICE|ACRYSOF IQ PanOptix Toric Trifocal IOL|Single-piece, ultraviolet and blue-light filtering, foldable, multifocal toric IOL intended to provide vision to aphakic subjects at near, intermediate, and distance and to correct pre-existing corneal astigmatism
223489914|NCT04166019|BEHAVIORAL|Usual care|Routine care services consist of monthly psychiatric consultation and treatments prescribed by psychiatrist, nursing advice on community care, brief education (1-2 hourly sessions) about mental illness/treatments by psychiatric nurses, home visits by case managers, and/or referrals to community/welfare services.
223489915|NCT03923075|DRUG|Dexmedetomidine|INFUSION BEFORE INDUCTION OF ANAESTHESIA
223489916|NCT03923075|OTHER|0.9% saline|INFUSION BEFORE INDUCTION OF ANAESTHESIA
223489917|NCT05710679|BIOLOGICAL|Blood sample|"The intervention consist in a blood sample that will be taken twice :~* at the inclusion (before treatment)~* 3 months after the radiochemotherapy in case of incomplete response (PET-CT)"
223489918|NCT06590350|OTHER|Clinical nutrition counseling|"In the first phase, all patients admitted to the Departmental Simple Operating Unit Admission Room of Policlinico Universitario A. Gemelli will be screened for NRS-2002 upon admission.~Only patients with NRS-2002 ≥ 3 will subsequently be tracked via the Foundation's computer system (TrackCare®).~The patients will be managed by caregivers who may spontaneously request nutritional counseling, as is currently the case.~Patient data (laboratory tests, medical history, reason for admission, any instrumental test reports) and clinical outcomes (average length of hospitalization, complications, antibiotic therapy use, intensive care admission, mortality, re-hospitalization within 30 days) will be obtained from the Foundation's computer system (TrackCare®) and recorded in a dedicated Excel® spreadsheet.~Costs related to hospitalization and management of any complications will also be assessed."
223489919|NCT06597240|DEVICE|AMCOR|Participants will collect biometric and quality of life data for 9 or 10 weeks at home, depending on treatment schedule. Continuous step counting will be used to register physical activity. Participants will be asked to measure their blood pressure, heart rate, oxygen saturation level, pain level and temperature each morning, and weight 3 times a week. These measurements consume little time and are not harmful. Once a week they will perform a finger stick test themselves to determine creatinine concentration in the blood. In addition, patients fill in three questionnaires at four time points which will take approximately 20 minutes to complete per time point. We do not foresee reasonable risks of these diagnostic procedures for the participants.
223489920|NCT06827938|DEVICE|YY-WRY-V01 Infrared thermotherapy apparatus|Infrared hyperthermia（44±1℃） device for 3 consecutive days (times / day), each treatment for 30 minutes After 7-10 days, the lesions of the same target were treated continuously for 2 days (times / day), and then treat every 7-10 days, the method was the same as before. Lesion changes were assessed after 15 treatments.
223489921|NCT06592352|DRUG|Modafinil Generis 100 mg|All participants enrolled in the study will receive the study intervention drug (Modafinil Generis 100 mg). Dose 200 mg once per day (2 tablets of 100 mg) in the morning for 3 months (84 days), Oral administration
223587555|NCT01407523|DRUG|Levetiracetam|"* Formulation: concentrate for solution for infusion~* Strength: Levetiracetam injection (100 mg/mL) will be packed in 5 mL glass vials (500 mg/5 mL)~* Dosage: 1000 mg/day, 1500 mg/day, 2000 mg/day, 2500 mg/day or 3000 mg/day~* Frequency: twice daily"
223587556|NCT00186277|DRUG|Oxaliplatin|Calculated per patient
223587557|NCT00186277|DRUG|Taxotere|Calculated per patient
223587558|NCT05946512|BEHAVIORAL|yoga|yoga breathing techniques for dysfunctional breathing
223587559|NCT05946512|BEHAVIORAL|social contact|social contact as active comparator
223587560|NCT00718341|DRUG|AF056|
223587561|NCT00718341|DRUG|Placebo|
223587562|NCT00787215|OTHER|observational: no treatment involved|observational: no treatment involved
224073321|NCT06818734|OTHER|Clinical Decision Support Tool|The CDS in and AI algorithm that will alert clinicians only if patients have high risk of developing PPD, and provide clinicians with risk score, risk factors, and anticipatory actions with an order set to assist with ordering. Clinicians will make the ultimate clinical judgement after receiving CDS aid, including taking no actions towards PPD prevention. Clinicians will manage patients per usual care, including initiating PPD prevention such as conducting referrals to nutrition and behavioral health, suggest educational readings through patient portals, or no actions. Clinicians in the intervention arm will refer patients based on the CDS.
224073322|NCT06817499|OTHER|Nasal Insert + VNS|Participants will complete olfactory training with scented nose plugs along with VNS
224073323|NCT06817499|OTHER|Nasal Insert|Participants will complete olfactory training with scented nose plugs
224073324|NCT06986993|DRUG|Semaglutide|Participants are randomized to receive either semaglutide or placebo (saline) via sc injection once a week for 12 weeks. Dose will be titrated per recommendations every 4 weeks,starting at .25mg, then 0.5mg and then 1.0mg
224073325|NCT06986993|DRUG|Placebo|Participants are randomized to receive either semaglutide or placebo (saline) via sc injection once a week for 12 weeks. Dose will be titrated per recommendations every 4 weeks,starting at .25mg, then 0.5mg and then 1.0mg
224073326|NCT00603759|DRUG|celecoxib|100 mg qid
224073327|NCT00603759|DRUG|placebo|1 cap qid
224180664|NCT04542525|PROCEDURE|Cataract surgery|Cataract extraction by phacoemulsification, followed by implantation of the IOL per investigator's standard of care and instructions for use
224180665|NCT01162967|DRUG|Benznidazole|Standard dosage
223489922|NCT02324751|BIOLOGICAL|Vi-TCV|Each 0.5mL vaccine dose contains 25μg of purified Vi capsular polysaccharide (S. Typhi Ty2 strain) conjugated to non-toxic tetanus toxoid. The vaccine will be administered 28 days prior to typhoid challenge
223489923|NCT02324751|BIOLOGICAL|Vi-PS Vaccine|Each 0.5 mL vaccine dose contains 25 μg of purified Vi capsular polysaccharide (S. Typhi Ty2 strain). The vaccine will be administered 28 days prior to typhoid challenge
223489924|NCT02324751|BIOLOGICAL|Control (Men ACWY)|Each vaccine dose contains N. meningitidis oligosaccharides (10μg MenA oligosaccharide, 5μg of each of MenC, Men Y and MenW-135 oligosaccharides) conjugated to 32.7 μg to 64.1μg Diphtheria CRM197 protein with residual formaldehyde dose less than 0.30μg. The vaccine will be administered 28 days prior to typhoid challenge
223489925|NCT03672721|DRUG|IA Carbo+ Radiation|combination of intraarterial carboplatin + radiation in dose escalation
223489926|NCT03896334|BEHAVIORAL|Supervised Isometric Handgrip Training|The participants randomized to the experimental group will perform 24 weeks of isometric handgrip exercise training, three times/week for 16 minutes with time to rest.
223489927|NCT03896334|BEHAVIORAL|Sham comparator - stretching and relaxation exercises|The participants randomized to the control group (active comparator) will perform 24 weeks of stretching and relaxation exercise training, three times/week for 16 minutes with time to rest.
223489928|NCT06481579|BIOLOGICAL|IVX-A12|IVX-A12 IM injection.
223489929|NCT06481579|BIOLOGICAL|Licensed RSV Vaccine|Licensed RSV Vaccine (AREXVY) IM injection.
223489930|NCT05492994|DIAGNOSTIC_TEST|Spirometry|Pulmonary function test
223489931|NCT05492994|DIAGNOSTIC_TEST|Diffusing Capacity of the Lung for Carbon Monoxide (DLCO)|Pulmonary function test
223489932|NCT05492994|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|Magnetic Resonance Imaging
223489933|NCT05492994|DIAGNOSTIC_TEST|Chest Computer Tomography|Chest Computer Tomography
223489934|NCT05492994|DIAGNOSTIC_TEST|Blood biomarker analysis|Blood biomarker analysis
223587563|NCT05687513|DRUG|Yisui granule|Yisui granule
223587564|NCT05687513|DRUG|Placebo|placebo
224180666|NCT01162967|DRUG|Posaconazole|
224180667|NCT06415916|PROCEDURE|Cardiac ultrasound|Performed 5 times between 0 and 120 minutes
224180668|NCT06415916|PROCEDURE|Lung ultrasound|Performed 5 times between 0 and 120 minutes
224180669|NCT04187586|OTHER|Extracorporeal shock wave therapy|ESWT was performed around the primary treatment site at 100 impulses/cm2, an energy flux density(EFD) of 0.05 to 0.30 mJ/mm2, frequency of 4Hz, and 1000 to 2000 impulses were administered at 1-week intervals for 6 sessions.
223489935|NCT05860595|GENETIC|KL003 cell injection Drug Product|Transplant of auto-HSC transduced with lentiviral vector encoding βA-T87Q-globin gene.
223489936|NCT05032196|DRUG|SAD: 30mg WVE-003|Single ascending dose of 30mg WVE-003, an allele-selective stereopure antisense oligonucleotide (ASO)
223489937|NCT05032196|DRUG|SAD: 60mg WVE-003|Single ascending dose of 60mg WVE-003, an allele-selective stereopure antisense oligonucleotide (ASO)
223489938|NCT05032196|DRUG|SAD: 90mg WVE-003|Single ascending dose of 90mg WVE-003, an allele-selective stereopure antisense oligonucleotide (ASO)
223489939|NCT05032196|DRUG|SAD: Pooled Placebo|Single dose of placebo
223489940|NCT05032196|DRUG|MD: 30mg WVE-003|Three doses of 30mg WVE-003 Q8WK an allele-selective stereopure, antisense oligonucleotide (ASO)
223489941|NCT05032196|DRUG|MD: Placebo|Three doses of placebo Q8WK
223489942|NCT06992258|DRUG|Fruquintinib+ Lonsurf (trifluridine and tipiracil)|Experimental arm
223489943|NCT06992258|DRUG|Fruquintinib|Standard Of Care Arm
223489944|NCT06597175|DEVICE|ORIGO|The device measurement is first performed on the breast area with the lesion, followed by the measurement of the corresponding area in the contralateral breast for comparison.
224205687|NCT02619370|BEHAVIORAL|Active Control|
224205688|NCT01413152|BIOLOGICAL|blood and semen sampling, specific biological exams and biobank and self administered questionnaires|blood and semen sampling, specific biological exams and biobank and self administered questionnaires
223489945|NCT06983470|DEVICE|SNM based on visual-motor responses (VMRs)|SNM using parameters that elicited the best VMRs in the stage-1 implant procedure
223489946|NCT06983470|DEVICE|SNM based on sacral evoked responses (SERs)|SNM using parameters that elicited the best SERs in the stage-1 implant procedure
223489947|NCT03997422|PROCEDURE|Vertical Sleeve Gastrectomy (VSG)|Vertical Sleeve gastrectomy will be performed using five laparoscopic ports using a 40 French Bougie as a template. If a hiatal hernia is identified it will be repaired. This practice has greatly reduced postoperative reflux disease (see human subjects protection). As VSG for patients with a BMI 30.0-34.9 kg/m2 is not covered by insurance the University hospital will cover costs for up to 24 patients.
223489948|NCT06614374|DIETARY_SUPPLEMENT|Low-dose fish oil capsules|Patients in the low-dose group will receive four fish-oil and refined olive oil mixed capsules containing 1.5 g of marine n-3 PUFAs per day.
223489949|NCT06614374|DIETARY_SUPPLEMENT|High-dose fish oil capsules|Patients in the high-dose group will receive four fish oil capsules containing 3 g of marine n-3 PUFAs (72% EPA and 28% DHA) per day.
223489950|NCT06614374|DIETARY_SUPPLEMENT|Refined olive oil|Participants in the control group will receive 4 g refined olive oil daily
223587565|NCT00681993|OTHER|Standard Dose Dense Doxorubucin and Cyclophosphamide|4 cycles of Standard Dose-Dense Doxorubucin and Cyclophosphamide and concurrent radiation therapy at a dose of 270 cGy per fraction for 15 fractions to a total dose of 40.5 Gy. Treatments will be given Monday through Friday for three weeks. Radiation therapy may start 7 days before, but no later than 7 days after, day 1 of cycle 1 of chemotherapy (C1D1).
223587566|NCT00681993|OTHER|Standard Doxorubucin and Cyclophosphamide|4 cycles of Standard Dose Doxorubucin and Cyclophosphamide and concurrent radiation therapy at a dose of 270 cGy per fraction for 15 fractions to a total dose of 40.5 Gy. Treatments will be given Monday through Friday for three weeks. Radiation therapy may start 7 days before, but no later than 7 days after, day 1 of cycle 1 of chemotherapy (C1D1).
224180670|NCT03928249|DIETARY_SUPPLEMENT|Eriocitrin|"A crossover, double-blind, randomized, placebo-controlled clinical study with a duration of 26 weeks will be performed. All individuals and the principal investigator will remain blind to treatment until all analyzes are completed.~Participants will be invited to attend 12-hour fasting to measure glucose levels, glycated hemoglobin and to perform the glucose tolerance test, in addition to an individual interview (Appendix B) to confirm eligibility according to the inclusion and exclusion criteria . The collection of blood and the glycemic curves will be performed at the beginning of the first, 12th, 14th and 26th week in the Laboratory of Clinical Analyzes ( Araraquara)~At the beginning of the first, 12th, 14th and 26th week the following anthropometric parameters will be evaluated: body weight (kg), muscle mass (kg), fat mass (kg), body fat (%) (InBody 720, Biospace, Tokyo, Japan ) and waist-hip ratio."
224180671|NCT03268395|DIAGNOSTIC_TEST|Arterial Blood Gas and Transcutaneous CO2 Monitor|Each patient will receive both an arterial blood gas and a transcutaneous CO2 monitor test.
224180672|NCT02826083|DIETARY_SUPPLEMENT|XXS|
224180673|NCT02826083|DIETARY_SUPPLEMENT|non-XXS|
224180674|NCT04424589|OTHER|Myofascial release|Myofascial release or induction (IMF) is a widely used manual therapy treatment involving specifically guided, low-load, long-lasting mechanical forces to manipulate the myofascial complex, aimed at restoring optimal length, decreasing pain, and improving function. The experimental group will receive 1 examination session and 6 myofascial induction sessions carried out by a physiotherapist specialized in orthopedic manual therapy, superficial and deep techniques will be applied in the cervical region, for spinal at the level of the lumbar square, sacroiliac region and upper trapezius. 2 sessions per week over the course of 3 weeks.
224180675|NCT04424589|OTHER|Sham therapy|The control group will receive 1 examination session and 6 simulated myofascial induction sessions, where a physiotherapist will apparently apply the same techniques and maneuvers of myofascial induction, however, they will not follow the basic principles of technique execution, which does a procedure with a placebo effect.
224180676|NCT00763373|OTHER|Implementation of antibiotic switch guidelines|Implementation of antibiotic switch guidelines
224180677|NCT01077310|DRUG|Vivitrol- Intramuscular naltrexone (depot-formulation)|Subjects in this arm will receive monthly intramuscular gluteal injections of depot naltrexone 380mg (VIVITROL) for 6 months. The 1st injection will be administered prior to release from prison or jail.
224180678|NCT01077310|DRUG|Placebo|Subjects in this arm will receive monthly intramuscular gluteal injections of placebo for 6 months. The 1st injection will be administered prior to release from prison or jail. Placebo will be provided by Alkermes pharmaceuticals, the manufacturer of VIVITROL. Placebo will be identical in shape and form to active drug.
224180679|NCT02625610|DRUG|Avelumab|Maintenance Phase: Intravenous (IV) infusion (10 mg/kg over 1 hour) once every 2 weeks.
224180680|NCT02625610|DRUG|Oxaliplatin|"Induction Phase: Oxaliplatin was administered at a dose of 85 mg per square meter (mg/m\^2) as a continuous intravenous (IV) infusion on Day 1 along with leucovorin followed by 5-Fluorouracil every 2 weeks up to 12 weeks (or) Oxaliplatin at 130 mg/m\^2 IV on Day 1 along with capecitabine twice daily for 2 weeks followed by a 1-week rest period given every 3 weeks up to 12 weeks.~Maintenance Phase: Participants were continued the same regimen of chemotherapy as they received during the Induction Phase until disease progression, significant clinical deterioration, unacceptable toxicity, or discontinuation."
224180681|NCT02625610|DRUG|5-Fluorouracil|Induction Phase: 5-Fluorouracil was administered at a dose of 2600 mg/m\^2 IV continuous infusion over 24 hours on Day 1 (or) 5-FU at 400 mg/m\^2 IV push on Day 1 and 2400 mg/m\^2 IV continuous infusion over 46-48 hours (Days 1 and 2) along with oxaliplatin and leucovorin every 2 weeks up to 12 weeks. Maintenance Phase: Participants were continued the same regimen of chemotherapy as they received during the Induction Phase until disease progression, significant clinical deterioration, unacceptable toxicity, or discontinuation.
224180682|NCT02625610|DRUG|Leucovorin|"Induction Phase: Leucovorin was administered at a dose of 200 mg/m\^2 IV (or) Leucovorin 400 mg/m\^2 IV on Day 1 along with oxaliplatin and 5-FU every 2 weeks up to 12 weeks.~Maintenance Phase: Participants were continued the same regimen of chemotherapy as they received during the Induction Phase until disease progression, significant clinical deterioration, unacceptable toxicity, or discontinuation."
224180683|NCT02625610|DRUG|Capecitabine|"Induction Phase: Capecitabine was administered at a dose of 1000 mg/m\^2 twice daily for 2 weeks followed by a 1-week rest period given every 3 weeks along with oxaliplatin up to 12 weeks.~Maintenance Phase: Participants were continued the same regimen of chemotherapy as they received during the Induction Phase every 3 weeks until disease progression, significant clinical deterioration, unacceptable toxicity, or discontinuation."
224180684|NCT02625610|OTHER|Best supportive care|Treatment administered with the intent to maximize Quality of Life (QoL) without a specific antineoplastic regimen. These may include for example antibiotics, analgesics, antiemetics, thoracentesis, paracentesis, blood transfusions, nutritional support (including jejunostomy), and focal external-beam radiation for control of pain, cough, dyspnea, or bleeding. Best supportive care were administered per institutional guidelines and participants were visit the clinic every 3 weeks.
224180685|NCT02625610|DRUG|Oxaliplatin|Induction Phase: Oxaliplatin will be administered at a dose of 85 mg per square meter (mg/m\^2) as a continuous intravenous (IV) infusion on Day 1 along with leucovorin followed by 5-Fluorouracil every 2 weeks up to 12 weeks (or) Oxaliplatin at 130 mg/m\^2 IV on Day 1 along with capecitabine twice daily for 2 weeks followed by a 1-week rest period given every 3 weeks up to 12 weeks.
224180686|NCT02625610|DRUG|5-Fluorouracil|Induction Phase: 5-Fluorouracil will be administered at a dose of 2600 mg/m\^2 IV continuous infusion over 24 hours on Day 1 (or) 5-FU at 400 mg/m\^2 IV push on Day 1 and 2400 mg/m\^2 IV continuous infusion over 46-48 hours (Days 1 and 2) along with oxaliplatin and leucovorin every 2 weeks up to 12 weeks.
224180687|NCT02625610|DRUG|Leucovorin|Induction Phase: Leucovorin will be administered at a dose of 200 mg/m\^2 IV (or) Leucovorin 400 mg/m\^2 IV on Day 1 along with oxaliplatin and 5-FU every 2 weeks up to 12 weeks.
224180688|NCT02625610|DRUG|Capecitabine|Induction Phase: Capecitabine will be administered at a dose of 1000 mg/m\^2 twice daily for 2 weeks followed by a 1-week rest period given every 3 weeks along with oxaliplatin up to 12 weeks.
223587567|NCT00681993|OTHER|Standard Docetaxel, Carboplatin, and Herceptin|6 cycles of Standard Docetaxel, Carboplatin and Herceptin chemotherapy with concurrent radiation therapy at a dose of 270 cGy per fraction for 15 fractions to a total dose of 40.5 Gy. Treatments will be given Monday through Friday for three weeks. Radiation therapy may start 7 days before, but no later than 7 days after, day 1 of cycle 1 of chemotherapy (C1D1).
224180689|NCT03000413|DRUG|Ketamine|Active treatment
224180690|NCT03000413|DRUG|Fentanyl|
224307525|NCT01090921|DRUG|Bortezomib|"Bortezomib will be administered at a dose of 1.6 mg/m2 IV push. Treatment will be administered once a week for four weeks followed by one week off. This 5 week period is considered a treatment cycle.~Dexamethasone will also be administered at a dose of 40mg on the day of and day after each dose of bortezomib, with a dose reduction to 20mg on the same schedule if the patient cannot tolerate the higher dose of dexamethasone."
223489951|NCT06670976|PROCEDURE|Biopsy|Undergo tissue biopsy sample collection
223489952|NCT06670976|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223489953|NCT06670976|PROCEDURE|Computed Tomography|Undergo CT scan
223489954|NCT06670976|PROCEDURE|Positron Emission Tomography|Undergo PET scan
223489955|NCT06670976|DRUG|Propranolol|Given PO
223489956|NCT06670976|RADIATION|Radiation Therapy|Undergo RT
223489957|NCT06670976|PROCEDURE|Surgical Procedure|Undergo surgery
223489958|NCT06991530|DRUG|Low Molecular Weight Heparine|the LMWH group received injections of 4100 IU/d LMWH from the day of transplant
223489959|NCT04740593|OTHER|Orthoptic care with the prescription of glasses from age 12-18 months onwards|Children assigned to the intervention group (group 1) will receive orthoptic care, including exams 1-3 (depending on the refractive error) times a year, and glasses, based on accurate determinations of refractive error by retinoscopy in cycloplegia by the study orthoptists at age 12-18 months. The spectacles for the children in this study will be provided by the study via their optician without costs.
223489960|NCT04740593|OTHER|Orthoptic care without the prescription of glasses from age 12-18 months onwards|Children with high refractive error in the control group (group 2) will also receive orthoptic care, including exams 1-3 (depending on the refractive error) times a year, but they will not receive glasses.
223489961|NCT04740593|OTHER|First measurement only|Children who have no or mild refractive error (group 3), the majority of all children, will be examined by the study orthoptists only once at the age of 12-18 months, after which youth health care (YHC) physicians and nurses will continue standard vision screening at CHCs, as part of screening for general health disorders and vaccinations. Visual acuity is measured routinely at 42-48 months as part of standard vision screening.
223489962|NCT05288985|DEVICE|Erector spinae plane catheter group in addition to Systemic Analgesia|Erector spinae plane catheter is placed in the post-interventional surveillance room in the operating theatre by an anaesthetist-intensive care physician or in the MIR department by the intensive care physician in charge of the patient within 2 hours after randomisation. The local anaesthetic injected into the catheter is Ropivacaine, prescribed according to a protocol of continuous flow, bolus and refractory period. The catheter is repositioned if a secondary displacement occurs.
223587568|NCT00681993|OTHER|Standard Docetaxel, Doxorubucin and Cyclophosphamide|3 cycles of Standard Docetaxel, Doxorubucin and Cyclophosphamide chemotherapy with concurrent radiation therapy at a dose of 270 cGy per fraction for 15 fractions to a total dose of 40.5 Gy. Treatments will be given Monday through Friday for three weeks. Radiation therapy may start 7 days before, but no later than 7 days after, day 1 of cycle 1 of chemotherapy (C1D1).
223587569|NCT00681993|OTHER|Standard Docetaxel and Cyclophosphamide|4 cycles of Standard Docetaxel and Cyclophosphamide chemotherapy with concurrent radiation therapy at a dose of 270 cGy per fraction for 15 fractions to a total dose of 40.5 Gy. Treatments will be given Monday through Friday for three weeks. Radiation therapy may start 7 days before, but no later than 7 days after, day 1 of cycle 1 of chemotherapy (C1D1).
223587570|NCT02914561|DRUG|Filgotinib|Filgotinib tablets administered orally once daily.
224180691|NCT01430689|BIOLOGICAL|Inactivated Influenza Vaccine Trivalent Types A and B|"Pregnant Woman: Randomization to receive IM injection of Vaxigrip Influenza Vaccine once~Household and Woman/Infant surveillance~* Home visits weekly until the infant is born and reaches 6 months of age~* If the woman, her infant or other household contact has signs and symptoms consistent with Influenza Like Illness (ILI)a nasal and oropharyngeal swab will be obtained"
223489963|NCT05288985|DRUG|Systemic Analgesia Only Group|Systemic analgesia alone consists only of the 3 levels of analgesic treatment
223587571|NCT02914561|OTHER|Placebo|Placebo administered orally once daily.
224180692|NCT01430689|BIOLOGICAL|Meningococcal Polysaccharide-Diphtheria Toxoid Conjugate Vaccine|"Pregnant Women - Randomized to receive IM injection of Menactra once~Household and Woman/Infant surveillance~* Home visits weekly until the infant is born and reaches 6 months of age~* If the woman, her infant or other household contact has signs and symptoms consistent with Influenza Like Illness (ILI)a nasal and oropharyngeal swab will be obtained"
224307526|NCT01561508|DRUG|gamma-amino-butyric acid|gamma-amino butyric acid will be administered orally at a dose of 80mg/kg/day divided BID for one year.
223489964|NCT06994988|DEVICE|A-Band (Smart Band-Aid)|The A-Band is a smart band-aid placed on the forearm or other designated site that collects interstitial fluid (ISF) from participants using a microneedle patch. ISF is a natural fluid found between your cells that can inform us on your bodily readings and health. A microneedle patch is a safe alternative to standard fluid collection which uses tiny needles to collect the ISF. The patches consist of single-use, sterile (clean) microneedles created from biocompatible materials. These microneedles penetrate the outermost skin layer without causing significant discomfort, pain, or bleeding.
223489965|NCT06994988|COMBINATION_PRODUCT|Empatica Smartwatch|A commercial smart band will be worn by participants for 22+ hours a day for approximately 7 days. The smart band collects biophysical data from the participant. This includes data on biomarkers, heart rate and heart rate variability, galvanic skin response, step count, and temperature fluctuations, among other biophysical data.
223587572|NCT04652674|BEHAVIORAL|Telemedicine visit|A postoperative visit with the patient's surgeon conducted remotely via audio/video smartphone app
223587573|NCT04652674|BEHAVIORAL|In-person postoperative visit|A standard-of-care in-person postoperatively visit with the patient's surgeon
223587574|NCT01640665|DRUG|Sorafenib|One cycle will consist of 4 weeks of treatment. The dose of Sorafenib will be 600 mg administered orally daily in divided doses.
223587575|NCT01640665|DRUG|Capecitabine|Capecitabine will be given at a fixed dose of 2000 mg orally BID x 7 days every 14 days.
223587576|NCT04108728|DIAGNOSTIC_TEST|BRIEF SCORE AT INCLUSION|BRIEF SCALE evaluation
223587577|NCT00043927|DRUG|topotecan/cisplatin|
223587578|NCT00043927|DRUG|etoposide/cisplatin|
223587579|NCT03897036|DRUG|CX-4945|API powder-in-capsule in 200 mg strength
224180693|NCT01085695|DRUG|rabeprazole|10 mg normal tablet
224180694|NCT01085695|DRUG|rabeprazole|Type 1 granule containing rabeprazole 10 mg
224180695|NCT01085695|DRUG|rabeprazole|Type 2 granule containing rabeprazole 10 mg
224180696|NCT01085695|DRUG|rabeprazole|Type 3 granule containing rabeprazole 10 mg
224180697|NCT06030531|OTHER|Measures of spasticity, connectivity and analysis of single nucleotide polymorphisms and biomarkers of inflammation|We will test for presence of biological markers in blood that may correlate with levels of spasticity or neurological recovery and functional improvement, including the presence or absence of neuroplastic genetic polymorphisms (e.g. BDNF Val66Met polymorphism), as well as circulating levels of neuroplastic(e.g. BDNF) or inflammatory factors (e.g. interleukins, TNF) that may affect neuronal growth and functional restoration.
224180698|NCT06030531|OTHER|Analysis of biomarkers|We will test for the presence of biological markers in the blood to compare the distribution of polymorphisms and biomarkers with the spinal cord injury patient population.
224180699|NCT04043676|DRUG|Ponatinib|All patient will take 15 mg/day ponatinib oral during 48 weeks.
224180700|NCT00830479|PROCEDURE|Anti-reflux surgery|Open ureteroneocystostomy for correction of vesicoureteral reflux
223489966|NCT06994988|BEHAVIORAL|Questionnaires: Hospital Anxiety & Depression Scale, Central Sensitization Inventory, Pain Catastrophizing Scale, Somatic Symptom Scale-8, Pain Self-Efficacy Questionnaire-10, Athens Insomnia Scale|HADS- measures anxiety and depression (0-21, higher scores signify greater pathology); CSI- measures central sensitization (0-100, higher scores signify greater central sensitization, PCS- measures catastrophizing (0-52, higher scores signify greater catastrophization), SSS-8- measures somatization (0-32, higher scores signify greater somatization), PSEQ-10- measures self-efficacy (0-60, with lower scores signifying low self-efficacy), AIS- measures sleep (0-28, with higher scores signifying greater sleep dysfunction)
223489967|NCT06748066|BEHAVIORAL|RISE-ACL development|A meeting will be organized with all expert panel members to select relevant items. Before the meeting, experts will review a literature on ACL reconstruction return to sport processes. During round 1, the chairperson will ask panel members to suggest items to be included in the scale. Items with agreement from 5 or more members will be included in round 2. In round 2, redundant items will be identified and grouped, and new items will be added based on the literature and expert experience. Selected items will be randomly ordered to create a preliminary 6-level Likert scale (0 = strongly disagree, 5 = strongly agree).
223489968|NCT06748066|BEHAVIORAL|RISE-ACL scale validation|"The scale validation phase will involve 162 participants who have undergone ACL reconstruction within the past two years and are in the 'Return to Sport' process, with follow-up in the sports medicine department.~These participants will complete the final version of the RISE-ACL Scale in addition with the ACL-RSI scale and the IKDC Subjective Knee Form.~Validation will consist of testing face validity, construct validity, criterion validity (concurrent validity), and reliability, including internal consistency and test-retest reliability."
223489969|NCT06538220|BEHAVIORAL|Questionnaires and focus group|"To evaluate the Chronic Disease Unit care pathway, patients will respond to questionnaires : quality of life (SF-12), personal efficacy scale (GSES), Specific self Efficacy related to Weight Management (SEWM), Rosenberg self-esteem, body image satisfaction (QIC), state of anxiety and depression (HAD), Chronic Disease Unit satisfaction. Some patients will also participate to focus group."
223489970|NCT03132792|GENETIC|Autologous genetically modified AFPᶜ³³²T cells|Infusion of autologous genetically modified AFPᶜ³³²T cells
223489971|NCT00575081|DEVICE|Stereotactic brain procedures|Stereotactic brain procedures
223587580|NCT06939660|DEVICE|BCI-SCS-EXS|"Participants will undergo a BCI-SCS-EXS intervention designed to enhance neurorehabilitation for spinal cord injury (SCI). The intervention includes:~1. BCI Implantation: High-density ECoG electrodes placed over the motor cortex to decode lower limb movement intent.~2. SCS Electrode Implantation: 5-6-5 paddle electrodes implanted at T11-L2 to deliver targeted spinal cord stimulation.~3. System Calibration: BCI-SCS synchronization to trigger stimulation parameters based on decoded motor intent. SCS-EXS integration to provide synchronized gait assistance.~4. Rehabilitation Training: Daily training sessions (60 minutes, 5 times/week for 1 year) combining BCI-SCS-EXS.~5. Follow-Up: Safety and efficacy assessments at 1, 2, 3, 6, and 12 months post-intervention.~This intervention aims to promote neuroplasticity and functional recovery through brain-controlled spinal activation and synchronized exoskeleton assistance."
223587581|NCT01455220|DRUG|Tysabri ® (Natalizumab)|IV, monthly
223587582|NCT04543240|DEVICE|Integra™ dermal regeneration template|Integra a biologic dressing for deep wounds or large soft tissue defects that penetrate to the level of bone
224180701|NCT00830479|PROCEDURE|Endoscopic injection|Endoscopic injection of dextranomer/hyaluronic acid gel (Deflux) for correction of vesicoureteral reflux
224180702|NCT01968629|DRUG|Eovist|
224180703|NCT05289999|DEVICE|Virtual reality headset for first injection|Performing the first ultrasound-guided epidural injection through the sacrococcygeal hiatus using the virtual reality headset
224180704|NCT05289999|DEVICE|Virtual reality headset for second injection|Performing the second ultrasound-guided epidural injection through the sacrococcygeal hiatus using the virtual reality headset
224180705|NCT03925493|BEHAVIORAL|Graded Exercise Stress test (GXT) with Target Heart Rate Range|Patients assigned to one of two intervention groups will complete a GXT prior to the 4th CR session. The GXT will be completed in Baystate Medical Center's stress lab using standard protocols. This test will be used to set the target heart rate range, which will guide exercise intensity for the remainder of exercise training in cardiac rehabilitation.
224180706|NCT03925493|BEHAVIORAL|Heart rate monitors|Heart rate monitors (HRM) will be given to half of the patients randomly assigned to exercise stress testing group. Patients will receive a polar heart rate chest strap and polar watch. Patients will be asked to wear both, the chest strap and the watch during cardiac rehabilitation. Ultimately, we hope that the use of HRM is not necessary, but it may be needed to assure that patients in the THHR are able to consistently know their HR and adjust their exercise prescription. This will also increase the likelihood that there is a difference in heart rates between the THRR group from the RPE group.
224180707|NCT01567046|OTHER|laboratory biomarker analysis|Correlative studies
224180708|NCT00641017|BIOLOGICAL|rHPIV1 84/del170/942A, Lot PIV1 #104A vaccine|Live attenuated Human Parainfluenza Type 1 Virus Vaccine
224180709|NCT00641017|BIOLOGICAL|Placebo|Placebo for rHPIVI1 84/del170/942A, Lot PIV1 #104A vaccine
224180710|NCT05430724|PROCEDURE|Controlled hypotention|"The procedure to be applied to the cases to be included in the study:~Patients randomized by the sealed envelope method will be divided into 2 groups (40 patients in each group).~The sealed envelopes that determine which group the patient will belong to will be randomly selected by the patient.~Standard general anesthesia will be applied to all patients. Before starting the surgical procedure; Group N (Nicardipine infusion) will be administered at a dose of 5-15mg/h, and Group E (Esmolol infusion) at a dose of 50-300mcg/kg/min.~2\) General anesthesia will be applied to all groups. Patients will be administered controlled hypotension (mean arterial pressure 50-60 mmHg)."
224180711|NCT05699382|OTHER|practiced mindfulness through the application for 6 weeks|Physicians working at a tertiary hospital were recruited and randomly divided into two groups, a study group (SG) in which participants practiced mindfulness through the application for 6 weeks
224180712|NCT01334138|OTHER|A 4-week diet, low in sodium.|"Study subjects receive personal advice to decrease sodium consumption and will change his diet for 28 days.~Follow up is performed by measuring blood pressure, a 24-hour urine sample collection, diaries and questionnaires."
224180713|NCT02716207|DEVICE|CyberKnife|Radiation Therapy
224180714|NCT04212221|DRUG|MGD013 monotherapy|MGD013 monotherapy will start from Phase I dose escalation first, starting dose will be 120mg Q2W, the dose level may escalate sequentially following traditional 3+3 dose escalation scheme (120mg, 240mg, 400mg, 600mg) to determine the RP2D(recommended phase II dose) of MGD013 monotherapy. Then Phase II dose expansion study will initiate, patients will receive the fixed dose of MGD013 monotherapy with RP2D determined in Phase I study.
224180715|NCT04212221|DRUG|MGD013 in combination with Brivanib Alaninate|After determining the RP2D of MGD013 monotherapy, MGD013 at the fixed dose will be combined with Brivanib Alaninate. Dose escalation study of the combination therapy in Phase I will adopt traditional 3+3 dose escalation scheme; the dosage of Brivanib will start from 200 mg QD, and may escalate to 400 mg QD, 600 mg QD and a maximum of 800 mg QD to to determine the RP2D of MGD013 in combination with Brivanib Alaninate. Then Phase II dose expansion study will initiate, patients will receive the fixed dose of MGD013 and Brivanib Alaninate combination therapy with RP2D determined in Phase I study.
224180716|NCT02839590|DEVICE|HiFU|Ciliary Ablation Treatment ( HiFu ultrasound treatment)
224180717|NCT02839590|DEVICE|Baerveldt implant|External (sub-conjunctival) Drainage Surgery (Baerveldt implant)
224180718|NCT02839590|DEVICE|Ahmed implant|External (sub-conjunctival) Drainage Surgery (Ahmed Implant)
224180719|NCT02839590|DEVICE|STARflo|Suprachoroidal Shunt Surgery (STARflo)
224180720|NCT02839590|DEVICE|Hydrus Microstent implant|Trans-trabecular meshwork implants (Hydrus Microstent implant).
224180721|NCT02839590|DEVICE|iStent implant|Trans-trabecular meshwork implants (iStent implant).
224180722|NCT02839590|DEVICE|Kahook Dual Blade|It removes part of the trabecular meshwork
224180723|NCT05223478|DRUG|Phentolamine Ophthalmic Solution 0.75%|0.75% phentolamine ophthalmic solution (Nyxol), a non-selective alpha-1 and alpha-2 adrenergic antagonist
224180724|NCT05223478|DRUG|Phentolamine Ophthalmic Solution Vehicle|Phentolamine Ophthalmic Solution Vehicle
224180725|NCT01822249|DRUG|EPI-743|
223489972|NCT06260956|BEHAVIORAL|Consumption|Subjects consume peanut and egg from 27 weeks of pregnancy through the first 4 months feeding breastmilk to their infant.
223489973|NCT06260956|BEHAVIORAL|Avoidance|Subjects avoid eating peanut and egg from 27 weeks of pregnancy through the first 4 months feeding breastmilk to their infant.
223489974|NCT05583071|DRUG|Tafasitamab|IV
224180726|NCT01822249|DRUG|Placebo|
223489975|NCT05583071|DRUG|Lenalidomide|Oral
223489976|NCT05583071|DRUG|Rituximab|IV
223489977|NCT05583071|DRUG|Methotrexate|IV
223489978|NCT03922776|PROCEDURE|Blood sample collection|"Participants will receive the following interventions because they are enrolled in the study: blood sample collection~* at diagnosis, before chemotherapy (pre-CT)~* after chemotherapy (post-ct) Collection of two blood samples (5mL),~* before chemotherapy (pre-CT), at diagnosis, up to 1 month after enrollment~* and then, after chemotherapy (post-CT), up to 3 months after enrollment"
224180727|NCT03114670|BIOLOGICAL|CD123CAR-41BB-CD3zeta-EGFRt-expressing T cells|a single dose of CD123CAR-41BB-CD3zeta-EGFRt-expressing T cells will be infusion after preconditioning.
224180728|NCT00821756|BEHAVIORAL|OPAC (Outreach, Problem solving, Adherence, Continuity)|Assertive outreach immediately after the suicide attempt with about 8 home visits plus contact by telephone, phone messages, e-mails. Duration of intervention 6 months.
224180729|NCT01860131|BEHAVIORAL|Weight Wise Community Modules|Program designed to educate patients regarding proper diet, exercise,and behavioural modification techniques with emphasis on increasing self-management, enhancing self-efficacy and identifying/overcoming barriers to success.
224180730|NCT06136910|DRUG|Recombinant human adenovirus type 5 injection (H101) combined with tirilizumab and platinum-containing two-drug chemotherapy|"1. Recombinant human adenovirus type 5 injection : 21 days is one treatment cycle, in principle, 4 cycles of administration, 1 injection on day 1 (d1) of each cycle; the number of injections is determined according to the patient's tolerance and the ease of operation of the injection site, no less than 2 times.~2. tirelizumab: 200mg intravenous, d1, Q21d, administered until disease progression or intolerable side effects occur~3. platinum-containing two-drug chemotherapy: adenocarcinoma, pemetrexed combined with carboplatin, 4-6 cycles, d2, Q21d; non-adenocarcinoma, paclitaxel/gemcitabine combined with carboplatin, 4-6 cycles, d2, Q21d."
224180731|NCT03810053|BEHAVIORAL|Mobile App/Online Module|Short didactic explainer video that will provide information about cancers and benefits of uptake of cancer prevention and early detection measures.
224180732|NCT01624974|DRUG|MK-1029|MK-1029 150 mg tablets taken QD
224180733|NCT01624974|DRUG|Placebo|Placebo tablets (matching the MK-1029 150 mg tablets) QD
224180734|NCT01624974|DRUG|Montelukast (ML)|ML 10 mg tablets QD
224180735|NCT02837549|OTHER|Occupational therapy treatment|This intervention includes various thermal modalities, manual therapy, Physiotouch (Healthy Life Devices Ltd) and education
224180736|NCT06267495|PROCEDURE|Epithelium-on corneal cross-linking (epi-on CXL)|In epithelium-on corneal cross-linking (epi-on CXL), the cornea is soaked with riboflavin for 10 minutes (Paracel® for 4 minutes and VibeX-xtra® for 6 minutes) . Thereafter, the cornea is subjected to ultraviolet A at a wavelength of 370 nm to give a total dose of 5.4 J/cm² through 10 milliwatt mW/cm² for 9 minutes.
224180737|NCT01481714|DRUG|Sodium picosulphate, magnesium oxid and citric acid|"* A sachet mixed with 250 mL of water at 18:00 pm~* A sachet mixed with 250 mL of water at 21:00 pm~* A minimum of 4 litres of fluid were recommended throughout the preparation"
224180738|NCT01481714|DRUG|Sodium picosulphate/magnesium oxide and citric acid|"The day before the procedure:~\- A sachet mixed with 250 mL of water at 18:00 pm, followed by 2 litres of clear liquids~The day of the procedure:~* A sachet administered at 5:45 am, followed by 1,5 litres of fluid intake up to 7 am for colonoscopies scheduled from 9 to 11 am.~* A sachet administered at 6:45 am, followed by 1,5 litres of fluid intake up to 8 for colonoscopies scheduled after 11 am."
224180739|NCT04830176|OTHER|dentifrice|use of dentifrices for brushing
224307527|NCT01561508|DIETARY_SUPPLEMENT|Xylitol|The placebo group will be provided Xylitol powder dosed per body weight. Participants will be instructed to take powder orally twice a day for one year.
224307528|NCT01752543|DRUG|Conivaptan|Conivaptan treatment: 20 mg bolus followed by infusion of 2 mg/hour
224307529|NCT01752543|DRUG|Placebo (Dextrose)|Placebo treatment: 20 mg bolus followed by infusion of 2 mg/hour
224307530|NCT00686075|BIOLOGICAL|MEDI-534, Cohort 1|Participants aged 6 to less than (\<) 24 months will receive MEDI-534, 10\^5 median tissue culture infectious dose (TCID50) by intranasal route at Month 0, 2, and 4.
224307531|NCT00686075|OTHER|Placebo, Cohort 1|Participants aged 6 to \<24 months will receive placebo matched to MEDI-534, 10\^5 TCID50 by intranasal route at Month 0, 2, and 4.
224307532|NCT00686075|BIOLOGICAL|MEDI-534, Cohort 2|Participants aged 6 to \<24 months will receive MEDI-534, 10\^6 TCID50 by intranasal route at Month 0, 2, and 4.
224307533|NCT00686075|OTHER|Placebo, Cohort 2|Participants aged 6 to \<24 months will receive placebo matched to MEDI-534, 10\^6 TCID50 by intranasal route at Month 0, 2, and 4.
224180740|NCT00854568|DRUG|CEOP regimen|cyclophosphamide 750mg/m2 IV day 1 epirubicin 70mg/m2 IV day 1 vincristine 1.4mg/m2 IV day1 (maximum: 2mg) prednisone 50mg PO days 1\~5 twice per day Or combined with rituximab 375mg/m2 IV day 0
224180741|NCT00854568|DRUG|CHOP regimen|cyclophosphamide 750mg/m2 IV day 1 doxorubicin 50mg/m2 IV day 1 vincristine 1.4mg/m2 IV day1 (maximum: 2mg) prednisone 50mg PO days 1\~5 twice per day Or combined with rituximab 375mg/m2 IV day 0
224180742|NCT04142762|DRUG|ABI-H2158|ABI-H2158 tablets
224180743|NCT04142762|DRUG|Itraconazole|Itraconazole capsules
224180744|NCT04142762|DRUG|Rifampin|Rifampin capsules
224180745|NCT04142762|DRUG|Midazolam|Midazolam syrup
224180746|NCT04142762|DRUG|Ethinyl Estradiol / Levonorgestrel|Ethinyl Estradiol / Levonorgestrel tablets
224307534|NCT00686075|BIOLOGICAL|MEDI-534, Cohort 3|Participants aged 2 months will receive MEDI-534, 10\^4 TCID50 by intranasal route at Month 0, 2, and 4.
224307535|NCT00686075|OTHER|Placebo, Cohort 3|Participants aged 2 months will receive placebo matched to MEDI-534, 10\^4 TCID50 by intranasal route at Month 0, 2, and 4.
224307536|NCT00686075|BIOLOGICAL|MEDI-534, Cohort 4|Participants aged 2 months will receive MEDI-534, 10\^5 TCID50 by intranasal route at Month 0, 2, and 4.
224307537|NCT00686075|OTHER|Placebo, Cohort 4|Participants aged 2 months will receive placebo matched to MEDI-534, 10\^5 TCID50 by intranasal route at Month 0, 2, and 4.
224307538|NCT00686075|BIOLOGICAL|MEDI-534, Cohort 5|Participants aged 2 months will receive MEDI-534, 10\^6 TCID50 by intranasal route at Month 0, 2, and 4.
224307539|NCT00686075|OTHER|Placebo, Cohort 5|Participants aged 2 months will receive placebo matched to MEDI-534, 10\^6 TCID50 by intranasal route at Month 0, 2, and 4.
224307540|NCT03884452|DRUG|Atorvastatin|Tablets taken orally once daily in the morning
224307541|NCT03884452|DRUG|Simvastatin|Tablets taken orally once daily in the morning or evening
223489979|NCT06138886|DEVICE|Pulsed electromagnetic therapy|The appliance will be connected to electrical mains supplying 230V± 10%. The solenoids are adjusted to be over the upper abdominal area. The options of the appliance are adjusted with very low frequency (15 HZ), very low intensity (20 G) for 20 minutes, and 3 sessions / week for successive 3 months.
223489980|NCT06138886|OTHER|calisthenics exercises|This group includes 30 burned patients who will perform calisthenics exercises program for 3 months (3times/week) in addition to their traditional physical therapy program and medical treatment.
223489981|NCT06624046|BEHAVIORAL|Sleep stability intervention|The sleep stability intervention will consist of three theory-based intervention components our team has developed and used in prior interventions: 1) self-monitoring using a wearable sleep tracker (Fitbit). This is well-liked by participants and increases awareness of their sleep goals. 2) Accountability coaching via weekly check-ins and daily monitoring of participants' wearable sleep tracking data and a coaching protocol.
223489982|NCT07008976|DRUG|TQB2102 Injection|TQB2102 Injection is a Human Epidermal Growth Factor Receptor 2 (HER2) bispecific antibody-drug conjugate.
223489983|NCT07008976|DRUG|Trastuzumab Emtansine for Injection|Trastuzumab Emtansine for Injection is HER2-targeting antibody-drug conjugate (ADC).
224180747|NCT04142762|DRUG|Esomeprazole|Esomeprazole capsules
224180748|NCT04142762|DRUG|Placebo matching oral contraceptive|Placebo matching Ethinyl Estradiol / Levonorgestrel tablets
224180749|NCT00444834|DRUG|Carvedilol|50 mg
224180750|NCT00758004|DRUG|Atorvastatin|A single dose of 80 mg atrovastatin tablet
224307542|NCT03884452|DRUG|Ezetimibe|Tablet taken orally once daily in the morning or evening
224307543|NCT03884452|DRUG|Placebo for Ezetimibe|Tablets taken orally once daily in the morning or evening
224307544|NCT02928718|PROCEDURE|ERCP|Two expert endoscopists will perform ERCP. Patients will be sedated with midazolam(2-5mg) and pethidine(25-50mg) with careful monitoring. Duodenoscope (TJF-240 or TJF-260; Olympus Corp., Tokyo, Japan) will be used. Cholangiography or pancreatography will be gathered after selective bile duct or pancreatic duct cannulation. Therapy such as endoscopic sphincterotomy, stent insertion, and etc., will be done.
224307545|NCT03052218|DEVICE|Pupillometry|Pupillometry performed before administration of tramadol, at T0 and then 1 to twice per hour, during the stay of the patient in the emergency department
224307546|NCT04715932|DRUG|Hesperidin|Patients will receive study medication Hesperidin and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water.
224307547|NCT04715932|DRUG|Placebo|Patients will receive study medication Placebo and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water.
224307548|NCT00367549|DIETARY_SUPPLEMENT|Energy-containing soft drink|Commercial energy/sports drink
224307549|NCT00051987|DRUG|VELCADE TM (bortezomib) for Injection, or PS-341|
224180751|NCT00758004|DRUG|Atorvastatin pediatric appropriate formulation|A single dose of pediatric appropriate atorvastatin 80 mg formulation
224180752|NCT03882736|PROCEDURE|gluteal augmentation with flap in circumferential body lift|classic circumferential bodylift surgery, using two different well-known flaps for gluteal augmentation
224180753|NCT03529734|OTHER|12 min running|This was already explained in the description of arm
224307550|NCT00002149|DRUG|Clavulanate potassium|
224307551|NCT00002149|DRUG|Pseudoephedrine hydrochloride|
224180754|NCT03529734|OTHER|Local strengthening exercises|This was already explained in the description of arm
224180755|NCT03735017|OTHER|Non-Interactive Virtual Reality Walking|"Individuals will wear a head-mounted display to allow them to visualize virtual legs in the virtual environment. When wearing the display, individuals will see the legs and arms of their virtual avatar from a first-person perspective.~Individuals will engage in virtual reality sessions in their home twice daily over the course of 10 days in a two-week period. Each daily session will take approximately 30 minutes, with 5-10 minutes dedicated to the virtual walking experience. Additionally, each daily session will be scheduled a minimum of 4 hours apart."
224180756|NCT03735017|OTHER|Interactive Virtual Reality Walking|"Individuals will wear a head-mounted display to allow them to visualize virtual legs in the virtual environment. When wearing the display, individuals will see the legs and arms of their virtual avatar from a first-person perspective.~Individuals will engage in virtual reality sessions in their home twice daily over the course of 10 days in a two-week period. Each daily session will take approximately 30 minutes, with 5-10 minutes dedicated to the virtual walking experience. Additionally, each daily session will be scheduled a minimum of 4 hours apart."
224180757|NCT03592134|OTHER|esophageal pressure measurement|Measurement of esophageal pressure to determine the optimal non invasive respiratory support
224180758|NCT01590446|DRUG|BMN 111|SC injection, Part 1 single dose and Part 2 multiple dose.
224180759|NCT01590446|DRUG|Normal Saline|SC injection, Part 1 single dose and Part 2 multiple dose
224180760|NCT01376908|DRUG|Kuvan®|Kuvan® (sapropterin dihydrochloride) tablets will be administered orally at the dose of 10 mg/kg/day and will be escalated to 20 mg/kg/day if after 4 weeks a subject's Phe tolerance is not increased by at least 20% versus baseline.
224180761|NCT01376908|OTHER|Phenylalanine (Phe)-restricted diet|Phe intake will be adjusted every 2 weeks, based on the mean Phe levels of the previous 2 weeks using pre-defined Phe adjustment criteria.
224180762|NCT04012294|DRUG|Allopurinol Pill|"Individuals who meet the inclusion criteria and also have morphostructural changes suggestive of MSU crystal deposits in their MSUS will start treatment with allopurinol at a dosage of 150 mg to be taken daily, orally for a month and then to be increased to 300 mg. The rest of the individuals' medication is not to be altered. If a participant presents hypersensitivity to allopurinol, they are to stop the medication and will be excluded from the investigation.~Three months after starting treatment, the participants will have a physical exam, confirm the continuation of the treatment (adjust dosage if needed) and take a blood sample for laboratory tests. Six months after treatment is started, the participants will be reevaluated by MSUS and have another blood sample taken, Once the study is finished, continuing or ending treatment with allopurinol will be decided by the medical judgment of the physician of each participant."
224180763|NCT00369408|DRUG|Naltrexone|naltrexone (50 mg orally) for 12-week treatment period; 3 and 6 months post-treatment follow-up
224180764|NCT00369408|DRUG|placebo|placebo for 12-week treatment period; 3 and 6 months post-treatment follow-up
224180765|NCT05193890|GENETIC|retrospective analysis of a panel result|retrospective analysis of a exome clinical solution
224180766|NCT04299750|PROCEDURE|Tooth extraction and Alveolar ridge preservation|Tooth extraction and alveolar ridge preservation with deproteinized bovine bone mineral and a collagen matrix seal
224180767|NCT04299750|PROCEDURE|Tooth extraction|Tooth extraction and socket natural healing
224180768|NCT03610867|DRUG|Furaprevir capsule (SAD)|There are four doses in this part, 100 mg, 200 mg, 400 mg, and 600 mg. Each subject will receive the sample once by oral administration.
224180769|NCT03610867|DRUG|Furaprevir capsule (MAD)|There are three doses in this part, 200 mg, 400 mg, and 600 mg. Each subject will be allocated into one dosing regimen and receive the sample once daily for 5 consecutive days by oral administration.
224180770|NCT03610867|DRUG|Placebo (SAD)|Each subject will receive the sample once by oral administration.
224180771|NCT03610867|DRUG|Placebo (MAD)|Each subject will be allocated into one dosing regimen and receive the sample once daily for 5 consecutive days by oral administration.
224307552|NCT00002149|DRUG|Amoxicillin trihydrate|
224307553|NCT01108406|DEVICE|Sonitus SoundBite System|Non Surgical Bone Conduction Device
224307554|NCT01108406|DEVICE|SoundBite Hearing System|
224307555|NCT00175188|DEVICE|Avanta (PIP joint implant with a titanium porous coating)|Implant is inserted at the time of surgery, after written consent
223489984|NCT05260008|DRUG|ATX-101|ATX-101 (bupivacaine) implant, one-time administration into the surgical site
223489985|NCT05260008|DRUG|ATX-101|ATX-101 (bupivacaine) implant, one-time administration into the surgical site
223489986|NCT05260008|DRUG|bupivacaine hydrochloride without epinephrine|bupivacaine hydrochloride (125 mg) without epinephrine via local infiltration and/or nerve block
223489987|NCT07060755|OTHER|Peppermint oil footbath|This includes a footbath with peppermint oil for 30 minutes each day for 2 weeks
223489988|NCT07060755|OTHER|Warm Water Footbath|This includes a warm water footbath for 30 minutes each day dor 2 weeks
223489989|NCT05742360|DEVICE|CPAP therapy|CPAP treatment of obstructive sleep apnea with the excessively sleepy symptom subtype
223489990|NCT07086677|BIOLOGICAL|PG4 vaccine in Buffer 1 with low dose PA-001|Multivalent pneumococcal conjugate vaccine
223489991|NCT07086677|BIOLOGICAL|PG4 in Buffer 1 with low dose PA-002|Multivalent pneumococcal conjugate vaccine
223489992|NCT07086677|BIOLOGICAL|PG4 in Buffer 1 with high dose PA-001|Multivalent pneumococcal conjugate vaccine
223489993|NCT07086677|BIOLOGICAL|PG4 vaccine in Buffer 1 with high dose PA-002|Multivalent pneumococcal conjugate vaccine
223489994|NCT07086677|BIOLOGICAL|PG4 vaccine in Buffer 2|Multivalent pneumococcal conjugate vaccine
224180772|NCT04429828|OTHER|COVID-19 e-package: Psychological wellbeing for healthcare workers|All healthcare students have access to a COVID-19 educational learning package around psychological wellbeing (usual practice). In this study the investigators will conduct semi-structured qualitative interviews with healthcare students about their mental wellbeing, and use of this e-package.
224180773|NCT01213849|DRUG|Fluticasone furoate 50 mcg (4 inhalations)|4 inhalations of 50 mcg strength
224180774|NCT01213849|DRUG|Fluticasone furoate 100 mcg (4 inhalations)|4 inhalations of 100 mcg strength
224180775|NCT01213849|DRUG|Fluticasone furoate 200 mcg (4 inhalations)|4 inhalations of 200 mcg strength
224180776|NCT01213849|DRUG|Vilanterol 25 mcg (4 inhalations)|4 inhalations of 25 mcg strength
224180777|NCT00415246|DRUG|Triptorelin (Decapeptyl®) - Treatment 8 months (pivotal study) followed by a treatment extension of 8 months (extension study)|
224180778|NCT01468844|DRUG|Minocycline|100 mg pink opaque capsule
224180779|NCT01468844|DRUG|Placebo|Placebo
224180780|NCT01468844|DRUG|Bevacizumab|1.25 mg bevacizumab injection
224180781|NCT02142712|DRUG|Diphenhydramine|Diphenhydramine 12.5 mg BID intravenous or 25 mg BID oral for 4 days along with current standard of care.
223489995|NCT07086677|BIOLOGICAL|20-valent pneumococcal conjugate vaccine|(20vPnC)
223489996|NCT07086677|BIOLOGICAL|Saline injection|Placebo
223489997|NCT06551649|OTHER|Venous blood draw and skin biopsy|The skin tissue will be used to isolate fibroblasts, which will then be reprogrammed into induced pluripotent stem cells (iPSCs). These iPSCs will be differentiated to develop patient-specific and control organoids. The blood samples will be used to isolate peripheral blood mononuclear cells (PBMC) to study the contribution of inflammation in the in vitro models developed.
223489998|NCT06340685|DRUG|Triheptanoin|Open-label design with doses of triheptanoin up to 4.0 gm/kg triheptanoin
223489999|NCT06840535|DRUG|[68Ga]Ga-OncoACP3|Single intravenous bolus injection.
223490000|NCT06781788|OTHER|Making room for climate emotions in the classroom|"The Making room for climate emotions in the classroom program is designed to address emotions as students learn (formally or informally) about climate change. Each session features a drawing, photography, Lego sculpture, rock painting or collage/drawing workshop to address themes, explore emotions/feelings/experiences and initiate discussions on topics related to climate change."
223490001|NCT07091435|BEHAVIORAL|ChatGPT|Phase 2 Involves a quasi-experimental design with 174 participants identified as having low social frailty scores, randomly assigned to one of three groups: a ChatGPT intervention group engaging in daily 15-30-minute app-based conversations with emotional monitoring; a community social participation group attending regular social activities; and a control group maintaining routine activities. Outcomes related to emotional state, physical activity, social frailty, and prognosis will be assessed pre- and post-intervention.
223490002|NCT07091435|BEHAVIORAL|community social|Phase 2 involves a quasi-experimental design with 174 participants identified as having low social frailty scores, randomly assigned to one of three groups: a ChatGPT intervention group engaging in daily 15-30-minute app-based conversations with emotional monitoring; a community social participation group attending regular social activities; and a control group maintaining routine activities. Outcomes related to emotional state, physical activity, social frailty, and prognosis will be assessed pre- and post-intervention.
223490003|NCT06107946|OTHER|USD questionnaire|After a baseline screening symptom assessment, all eligible patients with at least 2 simultaneously occurring symptoms with a numeric rating score ≥4 on the 11 point scale on the Utrecht Symptom Diary, will be asked to fill out the Utrecht Symptom Diary during two weeks. In the first week twice daily (morning and evening), in the second week once daily (evening).
223490004|NCT07095660|DEVICE|Recana procedure|recanalization and debulking of obstructions and occlusions within stented and non-stented segments in veins
223490005|NCT06109272|DRUG|Livmoniplimab|Intravenous (IV) Solution
224180782|NCT02142712|DRUG|Pantoprazole|Pantoprazole intravenous 40mg q daily as part of standard of care for stress ulcer prophylaxis along with current standard of care.
224180783|NCT02142712|DRUG|Famotidine|Famotidine 40 mg intravenous BID (maximum dose of 80 mg/day) for 4 days as part of standard of care for stress ulcer prophylaxis along with current standard of care.
224180784|NCT02142712|DRUG|Dextromethorphan|Dextromethorphan 60 mg QID orally (maximum dose of 240 mg/day) for 2 days (total of 4 doses) along with current standard of care. If the drug can't be given orally, then feeding tube (G-tube, NG Tube or DHT) will be used for drug administration.
224180785|NCT03080441|DEVICE|pressure stockings|pressure stockings worn during dialysis throughout treatment period
224180786|NCT03080441|DRUG|Midodrine|administered Midodrine before each dialysis treatment during treatment period based on PI's judgement. Including consideration of blood pressure.
224180787|NCT03080441|OTHER|pressure stockings and midodrine|combination of Midodrine and pressure stocking before each dialysis treatment throughout treatment period
224180788|NCT05278884|BEHAVIORAL|Advanced Cardiac Life Support Training|Advanced Cardiovascular Life Support (ACLS) is a resuscitation course to teach recognition and treatment of cardiopulmonary arrest in patients.
224180789|NCT05278884|BEHAVIORAL|Vital Anesthesia Simulation Training|The Vital Anesthesia Simulation Training (VAST) Course focuses on core clinical practices and non-technical skills needed to respond to the most common urgent and emergent clinical challenges found in hospitals in resource-limited settings like Rwanda.
224180790|NCT05248542|OTHER|Virtual Reality Usage on Oral Care Knowledge|Virtual Reality Usage on Oral Care Knowledge about independent older adults
224180791|NCT02496390|BIOLOGICAL|Autologous|Patients will have their normal microbiome reduced using an oral preparation (pico-salax) as used for routine colonic preparation for colonoscopy. • Administration of the FMT will be via a nasoduodenal tube inserted at the time of gastroscopy. Dosage - approx 100ml previously frozen fecal sample obtained from the patient prior to colonic preparation.
224180792|NCT02496390|BIOLOGICAL|Allogeneic|Patients will have their normal microbiome reduced using an oral preparation (pico-salax) as used for routine colonic preparation for colonoscopy. • Administration of the FMT will be via a nasoduodenal tube inserted at the time of gastroscopy. Dosage - approx 100ml previously frozen fecal sample obtained from a lean donor prior to colonic preparation.
224180793|NCT03792412|OTHER|Usability Questionnaire|Patients receive the usability questionnaire and a structured nutrition and lifestyle program for post-bariatric follow-up visits. Twice in six months the patients visit their family doctor and hand over the usability questionnaire to evaluate the structured follow-up program for postbariatric patients. Family doctors fill out the questionnaire and returns it to the investigator.
224180794|NCT03480841|BEHAVIORAL|Language ENhancement Assessment/intervention system|The LENA with Feedback intervention will involve mothers running the Language ENhancement Assessment/intervention system, an audiorecorder language pedometer that records adult speech centered on the child, child vocalizations, and parent-child reciprocal turn-taking conversations. Researchers will provide an initial feedback session to mothers, which will include reviewing the LENA visual output from the previous recording and how mothers can access the output on their own for future recordings. Mothers will independently use the LENA system and access the output on their own.
224180795|NCT00266695|DRUG|Ruboxistaurin|32-milligram (mg) tablet, orally, once daily (QD) for up to 2 years.
224180796|NCT04734249|DRUG|Surufatinib(HMPL-012)|"1. Cohort 1:Surufatinib(250mg ,qd,po)+mFOLFOX6/FOLFIRI,14 days for a cycle.The curative effect was evaluated every 4 cycles.~   Cohort 2:Surufatinib(250mg ,qd,po)+FOLFOXIRI,14 days for a cycle.The curative effect was evaluated every 4 cycles.~2. if the first-line chemotherapy was used FoLFOX ,the second-line is FOLFIRI,or the first-line chemotherapy was used FOLFIRI ,the second-line is FoLFOX.~3. Second-line Surufatinib Combined With Chemotherapy in Advanced CRC."
224180797|NCT03152175|DRUG|Propranolol Hydrochloride|1mg / kg of propranolol hydrochloride, oral capsule
224180798|NCT03152175|DRUG|Placebo|1mg / kg of matched placebo, oral capsule
224180799|NCT03519776|DIAGNOSTIC_TEST|Progesterone variation|The potential gain for medical caretakers and patients would be a certainty if the progesterone level is affected by variations during daytime
223490006|NCT06109272|DRUG|Budigalimab|Intravenous (IV) Solution
224180800|NCT02417935|DRUG|Duloxetine|Administered orally
224180801|NCT02417935|DRUG|Pregabalin|Administered orally
224180802|NCT02417935|DRUG|Placebo|Administered orally
224180803|NCT02176434|PROCEDURE|Kidney and hematopoietic stem cell transplantation|Kidney transplantation (day 0) Induction therapy (s. above) Hematopoietic stem cell transplantation (s. above)
224180804|NCT02176434|BIOLOGICAL|hematopoietic stem cell|
224180805|NCT01276873|DEVICE|Tracheal aspiration close system|use of closed system in comparision to open system to tracheal aspiration of nweborns, analyzing pain and climical variations associated.
224180806|NCT05248776|DRUG|CPL207280|IMP is a tablet with CPL207280 as an Active Pharmaceutical Ingredient (API).
224180807|NCT05248776|DRUG|Placebo|Matching placebo tablet.
224180808|NCT01584427|DIETARY_SUPPLEMENT|Healthy Carbohydrate Diet vs. Western Style Diet|Cross over study with two intervention diets. Healthy Carbohydrate Diet with approximally 55 g of dietary fibers (arabinoxylan and resistant starch)compared with western style diet with low content of dietary fibers.
224180809|NCT03701373|DRUG|S-1 maintenance|S-1 maintenance till disease progression or untolerable toxicities, in oral doses of 40 mg (BSA\<1.25 m2), 50 mg (1.25≤BSA\<1.50 m2) and 60 mg (BSA≥1.50 m2) b.i.d. on days 1-14 for each 21-day cycle.
224180810|NCT03701373|OTHER|Observation|Observation without anti-tumor treatment
224180811|NCT06127394|PROCEDURE|Sacral ESP Block|Sacral ESPB median approach, 40 ml %0,25 Bupivacaine
224180812|NCT06127394|PROCEDURE|Pudendal Block|Bilateral pudendal block, 10 ml %0,25 bupivacaine
224180813|NCT01424267|DEVICE|Zenith® Low Profile AAA Endovascular Graft|Treatment of an abdominal aortic or aorto-iliac aneurysm with the CE-marked Zenith(R) Low Profile AAA Endovascular Graft.
224180814|NCT04263129|PROCEDURE|Tracheal, carinal or bronchial transplantation using a stented cryopreserved aortic|Radical resection of the lesions was performed using standard surgical techniques. After resection, airway reconstruction was performed using a human cryopreserved (-80°C) aortic allograft, which was not matched by the ABO and leukocyte antigen systems. To prevent airway collapse, a custom-made stent was inserted into the allograft. In patients with proximal lung tumors, the lung-sparing intervention of bronchial transplantation was used.
223490007|NCT06109272|DRUG|Durvalumab|Intravenous (IV) Solution
223490008|NCT06109272|DRUG|Atezolizumab|Intravenous (IV) Solution
224180815|NCT06039540|DRUG|Captopril Tablets|0.3mg/kg, tid
224180816|NCT06039540|DRUG|Metoprolol Oral Tablet|0.2mg/kg, bid
224180817|NCT06039540|DRUG|Spironolactone Tablets|2-4mg/kg, bid
224180818|NCT06039540|DRUG|Torsemide Tablets|0.2-0.5mg/mg, bid
224180819|NCT06039540|DRUG|Potassium citrate powder|0.06g/kg, tid
224180820|NCT02910492|DEVICE|enLighten Laser|Dual-pulse duration laser for the treatment of skin rejuvenation
224180821|NCT03381144|DRUG|GDC-0334|Part 1: GDC-0334 given orally with dose escalation between cohorts, based on emerging safety and pharmacokinetic (PK) data. Parts 2 and 3: doses to be based on the safety, tolerability, and PK data generated in the study. The dosing duration in Part 3 is planned to be at least 14 days, but no longer than 28 days.
224180822|NCT03381144|DRUG|Placebo|Participants will receive GDC-0334-matching placebo.
224180823|NCT05373810|OTHER|Surgery|all interventions are allowed
224180824|NCT05299411|DRUG|iron (isomaltoside)|iron supplement through intravenous infusion
224180825|NCT05299411|DRUG|Dried Ferrous Sulfate|iron supplement through oral intake
224180826|NCT04451369|OTHER|Prehabilitation program|physical, nutritional and psycho-social supports before surgery
223490009|NCT06109272|DRUG|Bevacizumab|Intravenous (IV) Solution
223490010|NCT06109272|DRUG|Tremelimumab|Intravenous (IV) Solution
223490011|NCT00000352|DRUG|Dextromethorphan|
223490012|NCT04943861|BEHAVIORAL|weCare/Secure|The weCare intervention is based on the social cognitive and empowerment theories and social support and is currently designed to reduce missed HIV care appointments and increase viral suppression among PWH who are newly diagnosed or out of care through the use of peer navigation and mHealth
223490013|NCT04943861|OTHER|Usual Care|There is no peer navigation within usual care.
224180827|NCT01408862|OTHER|venous puncture|Blood for in vitro studies will be drawn
224180828|NCT01886092|DEVICE|Active rTMS 1|repetitive transcranial magnetic stimulation (Figured 8-Coil Cool-B65): 1000 stimuli of 1Hz rTMS over the left dorsolateral prefrontal cortex (110% motor threshold) followed by 2000 stimuli of 1 Hz rTMS over the left primary auditory cortex (110% motor threshold), each consisting of 4 days of rTMS treatment. (20 subjects).
224180829|NCT01886092|DEVICE|Active rTMS 2|repetitive transcranial magnetic stimulation (Figured 8-Coil MCF-B65): 3000 stimuli of 1 Hz rTMS over the left temporal cortex (110% motor threshold), each consisting of 4 days of rTMS treatment. (20 subjects)
224180830|NCT01886092|DEVICE|Active rTMS 3|repetitive transcranial magnetic stimulation (Figured 8-Coil MCF-B65): 3000 stimuli of 1 Hz rTMS over the left dorsolateral prefrontal cortex (110% motor threshold) each consisting of 4 days of rTMS treatment. (20 subjects)
224180831|NCT01886092|DEVICE|sham condition|Sham rTMS, applied with the same combination of parameters as active rTMS, except for the number of stimulations per session. (20 subjects)
224180832|NCT04951726|DRUG|Neostigmine|cholinesterase inhibitor
224180833|NCT04754568|OTHER|Virtual reality instructional design|60 minute immersive VR experience with branching method information delivery, physical therapy assessment, and diagnosis.
224180834|NCT04754568|OTHER|Role-playing instructional design|60 minute traditional role-playing with standardized patient
224180835|NCT06152367|BIOLOGICAL|TAPCells vaccine|Patients are immunized with four doses of TAPCells (20x106), days 0, 10, 20, and 50 complemented with low doses 2·4×106 IU/m2 rhIL-2 (Proleukin®) (Chiron Emeryville, CA, USA), injected s.c. days 2, 3, and 4 after a second, third, and fourth vaccination.
223490014|NCT07097324|BEHAVIORAL|Video- and Game-Based Oral Health Education|A video- and game-based oral health education intervention will be delivered to the participants in the intervention group over three weekly sessions. In the first session, participants will watch a video that highlights key messages on oral health, including the importance of oral health, the consequences of poor oral health and recommended oral health practices. This will be followed by an interactive quiz to reinforce the content of the video. In the second session, a video demonstrating proper tooth brushing and flossing techniques will be shown. Participants will then practice these techniques using tooth models. The third session will feature a video on cariogenic food consumption, followed by an interactive educational game in which participants identify non-cariogenic foods.
223490015|NCT07097324|BEHAVIORAL|Conventional Oral Health Talk|A conventional oral health talk will be delivered to participants in both the control and intervention groups. The talk will cover key messages on oral health, including the importance of oral health, consequences of poor oral health and recommended oral health practices.
223490016|NCT07101783|DRUG|NNC0662-0419|Participants will receive NNC0662-0419 subcutaneously.
223490017|NCT07102459|DRUG|Experimental: LTG-001 High Dose|High Dose Active
223490018|NCT07102459|DRUG|Experimental: LTG-001 Low Dose|Lower Dose Active
224180836|NCT01633567|BEHAVIORAL|Culturally Targeted Cessation Program|The culturally targeted version of the behavioral counseling intervention will consist of six group-based smoking cessation counseling sessions. Each smoking cessation therapy session will last approximately 90 minutes and will begin two weeks before the quit date. In addition, participants will be provided nicotine replacement therapy and peer support sessions will occur between the group sessions.
223490019|NCT07102459|DRUG|Active Comparator: HB/APAP|Active Comparator
223490020|NCT07102459|DRUG|Placebo Comparator|Placebo
223490021|NCT06774144|DRUG|Rezafungin|Rezafungin 400 mg IV once within 24 hours of liver transplant, followed by 200 mg IV weekly for 4 weeks.
223490022|NCT06774144|DRUG|Standard of care antifungal prophylaxis|UPMC uses a tiered approach to antifungal prophylaxis, based on risk factors for IFI. Fluconazole is used for recipients with risk factors for yeast infections: choledochojejunostomy, prolonged transplant time, receipt of \>40 units of blood products within 24 hours of transplant, and Candida colonization or infection within 3 months prior to transplant. Voriconazole is used for recipients with risk factors for mould infections: re-transplantation, renal failure requiring renal replacement therapy, fulminant hepatic failure as indication for transplant, intra-abdominal/thoracic re-exploration within the first month after transplant. No prophylaxis is given if there are no risk factors for yeast or mould infections.
223490023|NCT07103239|BEHAVIORAL|Video Based Visits|Video based visit with Heart Failure team
223490024|NCT07103239|BEHAVIORAL|Remote Self-Care Education|Self Guided Training
224180837|NCT01633567|BEHAVIORAL|Non-Targeted Cessation Program|Behavioral counseling intervention will consist of six group-based smoking cessation counseling sessions. Each smoking cessation therapy session will last approximately 90 minutes and will begin two weeks before the quit date. In addition, participants will be provided nicotine replacement therapy and peer support sessions will occur between the group sessions.
224180838|NCT01086267|DRUG|BMS-908662|Capsules, Oral, escalating doses starting at 25 mg, every 12 hours (Q 12 h), Continuously
224180839|NCT01086267|DRUG|BMS-908662|Capsules, Oral, (TBD) mg, Q 12 h, Continuously
224180840|NCT01086267|DRUG|Cetuximab|Vial, IV, 400 mg/m² loading dose followed by 250 mg/m² maintenance dose, Weekly, Continuously
224180841|NCT03656146|OTHER|Food Insecurity Screening Tablet|The intervention is the type of screening modality used to identify food insecurity: verbal face-to-face, or tablet-based screening
224180842|NCT03656146|OTHER|Food Insecurity Screening Verbal|The intervention is the type of screening modality used to identify food insecurity: verbal face-to-face, or tablet-based screening
224180843|NCT02079506|DRUG|Candesartan|
224180844|NCT02079506|DRUG|Rosuvastatin|
224180845|NCT01813149|DRUG|phenylephrine and clonidine|Subjects will be injected with phenylephrine and clonidine at both affected and unaffected sites.
224180846|NCT01813149|OTHER|punch biopsy|
224180847|NCT02853318|BIOLOGICAL|Bevacizumab|Given IV
224180848|NCT02853318|DRUG|Cyclophosphamide|Given PO
224180849|NCT02853318|OTHER|Laboratory Biomarker Analysis|Correlative studies
224180850|NCT02853318|BIOLOGICAL|Pembrolizumab|Given IV
224180851|NCT01835236|DRUG|Trastuzumab|"First administration (loading dose) 8 mg/kg i.v. infusion over 90 min.~\- then every 3 weeks until progression 6 mg/kg i.v. infusion over 30 to 90 min."
224180852|NCT01835236|DRUG|Pertuzumab|"First administration (loading dose) 840 mg i.v. infusion over 60 min.~\- then every 3 weeks until progression 420 mg i.v. infusion over 30 to 60 min."
224180853|NCT01835236|DRUG|Paclitaxel|Day 1, 8 and 15; every 4 weeks for ≥4 months 90 mg/m2 i.v. infusion
224180854|NCT01835236|DRUG|Vinorelbine|"First administration: Day 1 and 8 25 mg/m2 i.v. infusion~* then day 1 and 8, every 3 weeks for ≥4 months 30 mg/m2 i.v. infusion"
224180855|NCT01835236|DRUG|T-DM1|Every 3 weeks until unacceptable toxicity or progressive disease is observed 3.6 mg/kg i.v. infusion First dose: over 90 min (± 10 min.) Subsequent doses: over 30 min. (± 10 min.)
224180856|NCT06331806|DIAGNOSTIC_TEST|Evaluation of myocardial fibrosis|echocardiogram with left ventricular ejection fraction (LVEF) evaluation (biplane method) and CMR with contrast media agent
224180857|NCT03310099|BEHAVIORAL|Increasing daily unsaturated fatty acid consumption|Investigators will provide participant with detailed information about the consumption of food rich in unsaturated fatty acids (UFA) like extra-virgin olive oil, canola oil or mixed nuts, and they will provide specific recommendations based on the participant's diet. The investigators will follow up with a weekly phone call to assure that the dietary recommendations are clear and that the participants can integrate the suggestions into their daily diets.
224180858|NCT02280382|DEVICE|Femmeze®|Femmeze will be used by women in the intervention group for 8 weeks These women will be measuring against their usual care in a linear design; measurement will include validated questionnaires
224180859|NCT00252499|DRUG|rosiglitazone|PPAR-gamma agonist, insulin sensitizer
224180860|NCT00252499|DRUG|fenofibrate|PPAR-alpha agonist, reduces triglycerides
224180861|NCT00252499|DRUG|placebo for rosiglitazone|placebo tablets that are matched to look like rosiglitazone
224180862|NCT00252499|DRUG|placebo for fenofibrate|placebo matched to look like fenofibrate tablets
224180863|NCT02938975|OTHER|Ultra 30 Insect Repellent Lotion (30% Lipo DEET)|"One application of Lipo DEET protects for up to 12 hours and has a pleasant odour and non-greasy feel on the skin. DEET is a broad spectrum insect repellent and was selected this study because it has been extensively tested for safety and toxicity for human use and its efficacy against a broad variety of arthropod vectors. DEET was first registered in 1957 and has been conclusively proven to be safe for use on adults, children, pregnant and lactating mothers.~This Liposome-based repellent is the newest advancement in insect repellent technology. The Liposome envelops the active ingredient, DEET, and slowly time-releases it as needed, thereby extending the effectiveness of the repellent and reducing dermal absorption."
224180864|NCT02938975|OTHER|Permethrin Factory-Treated Army Combat Uniforms|Permethrin is the U.S., Australian and United Kingdom (UK) military's standard repellent for application to fabric and is considered the most effective clothing treatment available to prevent insect bites through fabric. The Army objective is to provide 90% bite protection for at least 50 launderings; an objective easily met through factory treatment of uniforms, which demonstrates 99-100% bite protection up to 50 launderings (the expected lifetime of the uniform).
224180865|NCT02938975|OTHER|Placebo lotion|A liposome lotion with no DEET
224180866|NCT02938975|OTHER|Army combat uniform|Army combat uniform with no permethrin
224180867|NCT02646332|DRUG|(dexlan+amox+clar+metr)+(dexlan+amox)|a 7-day quadruple regimen with dexlansoprazole MR 60 mg once daily, amoxicillin 1 g twice daily, clarithromycin 500 mg twice daily, and metronidazole 500 mg twice daily, followed by a 7-day dual regimen with dexlansoprazole MR 60 mg once daily and amoxicillin 1 g twice daily
224180868|NCT02646332|DRUG|dexlan+clarith+amox+metro|dexlansoprazole MR 60 mg once daily, amoxicillin 1 g twice daily, clarithromycin 500 mg twice daily, and metronidazole 500 mg twice daily for 14 days
223490025|NCT07103239|BEHAVIORAL|Remote Patient Monitoring|Participant will use home devices to monitor blood pressure and weight; Participant will then send results to RN educator
223490026|NCT07103395|DRUG|Neoadjuvant therapy|The neoadjuvant regimen prior to radiotherapy consists of albumin-bound paclitaxel/pemetrexed, cisplatin, Bevacizumab, iparomlimab and tuvonralimab, and thymosin alpha 1.
224180869|NCT04490499|BIOLOGICAL|HBVAXPRO™|Single 0.5 mL intramuscular dose
224180870|NCT03080506|DEVICE|Elastic abdominal binder|Participants will be fitted with an elastic abdominal binder at the time of procedure completion just before leaving the operating room. The binder will be placed snuggly tight on top of the hospital gown at the infraumbilical level with the incision positioned at the middle part of the binder. The patients will be encouraged to wear binders at all time. However, periods of break from wearing the binder will be allowed at their convenience.
223490027|NCT07103395|RADIATION|Radiotherapy|Definitive dose of hypofractionated radiotherapy was delivered to patients, with concurrent chemotherapy.
224180871|NCT00780676|DRUG|Dasatinib|100 mg tablet by mouth daily
224180872|NCT00780676|DRUG|AZD6244|75 mg by mouth twice daily.
223490028|NCT07103395|DRUG|Consolidative therapy|Consolidation therapy consists of iparomlimab and tuvonralimab and thymosin alpha 1, for a total duration of 1 year.
224180873|NCT05250999|OTHER|Skin stretch sensory stimuli|Skin stretch sensory stimuli will be exerted by a piece of kinesio tape that as applied above right and left lateral malleolus on posterior leg and on both side of spinous process of second thoracic vertebrae till 15cm below for 24 hours a day, 5 days/ week for 6 weeks along with conventional physiotherapy.
224180874|NCT05250999|OTHER|Transcutaneous Electrical nerve stimulation|TENS will be applied to patient while in sitting position for 30 minutes, twice a week, and for 6 weeks (12 treatment sessions along with conventional physiotherapy). A maximum of 25 m amp electrical stimulation with a biphasic square-wave pattern and a pulse width of 0.5ms in a continuous duty cycle will be used. The intensity of the electrical stimulation will be regulated to the high tolerable level without initiating muscle contractions.
224180875|NCT05250999|OTHER|Control Group|This program include balance exercises performed twice a week for 6 weeks, which consists of balance, progressive strength, and functional mobility training. Static exercise consists of heel and toe raises, one-legged stance for each limb, weight shifting forward, backward, sideward and diagonally, and turning the head to the left and then to the right keeping the feet together. This exercise comprises two 10-min sessions each, with eyes opened and eyes closed, respectively. Dynamic exercise comprises of walking, step-ups, and bipedal jumps for 10 min. Progressive balance exercises comprises of narrow walking, walking backward, walking sideward, stepping over obstacles, passing, throwing and catching a ball.
224307556|NCT03881956|BEHAVIORAL|Health-promoting lifestyle education program|The intervention group were included in the health-promoting lifestyle education program. The education program consisted of three 45-min sessions, which included a face-to-face lecture with the dissemination and presentation of written and visual materials. Each participant in the intervention group was given the Health-Promoting Lifestyle Booklet and the Diary of a Woman with GDM card. The booklet features all of the health-promoting practices (self-monitoring of blood glucose, nutrition, physical activity, stress, sleeping, smoking, self-care and breastfeeding). The Diary of a Woman with GDM card features the daily program that women should follow (the hours for main meals and snacks, insulin hours, etc.). The education and counseling were maintained through follow-up via phone for intervention group.
224180876|NCT00599144|PROCEDURE|videolaparocholecystectomy|Group1: a bupivacaine 0,5% (2mg/kg) soaked-tabotamp is placed in gallbladder bed after remove of gallbladder
224180877|NCT00599144|PROCEDURE|videolaparocholecystectomy|Group2: bupivacaine 0,5%(2mg/kg)is infiltrated in trocar incision after their closure.
224180878|NCT00599144|PROCEDURE|videolaparocholecystectomy|Group3: control group without any local anesthetic use.
224180879|NCT01262040|OTHER|Narrow Band Imaging (NBI)|The intervention is visual assessment of the peritoneal or pleural surface with NBI followed by biopsy and photographic documentation of any abnormal lesions. Photograph or video of abnormality(ies) under white light and NBI.
224180880|NCT00527722|DEVICE|Bio-Seal Track Plug|The lung plug will be inserted into the left track when the biopsy needle is removed. The smaller sampling needle is removed, and the lung plug is inserted through the larger needle using a delivery tool that has a plunger to push the plug in place. The lung plug remains in the track left when the larger needle is removed.
224180881|NCT00527722|OTHER|No lung plug|Standard lung biopsy without placement of the plug.
224180882|NCT01882439|DRUG|Tofacitinib|tablets, 5 mg BID x 6 months
224180883|NCT01882439|DRUG|Tofacitinib|tablets, 10 mg BID x 6 months
224180884|NCT01882439|OTHER|Placebo|tablets, to match tofacitinib 5 mg BID x 3 months
224180885|NCT01882439|DRUG|Tofacitinib|tablets, 5 mg BID x 3 months
224180886|NCT01882439|OTHER|Placebo|tablets, to match tofacitinib 10 mg BID x 3 months
224180887|NCT01882439|DRUG|Tofacitinib|tablets, 10 mg BID x 3 months
224180888|NCT05272969|DIAGNOSTIC_TEST|Beck depression inventory fast screen (Questionnaire)|Beck depression inventory fast screen questionnaire to detect severe depression for eligibility.
224180889|NCT05272969|DIAGNOSTIC_TEST|Brief Pain Inventory (BPI) (Questionnaire)|Validated questionnaire for pain.
224180890|NCT05272969|DIAGNOSTIC_TEST|German Pain Inventory (Questionnaire)|German Pain Inventory questionnaire for evaluation of pain. Module A, abbreviated questions of module S (sociodemographic questions S1, S2, S3, S4, S5 and S8) and module L (quality of life) and V (therapies) will be used.
224180891|NCT05272969|DIAGNOSTIC_TEST|Fatigue Severity and Disability Scale (FSS) (Questionnaire)|Validated questionnaire for perceived fatigue
224180892|NCT05272969|DIAGNOSTIC_TEST|Rotterdam Handicap Scale (RHS) (Questionnaire)|validated questionnaire to assess a patient's functional ability and level of handicap
224180893|NCT05272969|DIAGNOSTIC_TEST|R-PAct (Questionnaire)|The R-PAct scale is designed specifically for Pompe disease, which consists of 18 items addressing daily life activities with three response options.
224180894|NCT05272969|DIAGNOSTIC_TEST|Quick Motor Function Test|An evaluator observes the performance of a patient and scores the items separately on a 5-point ordinal scale (ranging from 0 to 4). A total score is obtained by adding the scores of all items and ranges between 0 and 64 points.
224180895|NCT05272969|DIAGNOSTIC_TEST|Handheld Dynamometry (HHD)|To ensure a high level of objective measurement, muscle strength will also be assessed by handheld dynamometry. The following muscle groups will be tested: Arm abduction, elbow flexion, elbow extension, hip flexion, hip extension, knee extension, knee flexion, foot extension, foot flexion.
224180896|NCT05272969|DIAGNOSTIC_TEST|Six-minute walk test (6MWT)|It is a sub-maximal exercise test used to assess aerobic capacity and endurance. The distance covered over a time of 6 minutes is used as the outcome by which to compare changes in performance capacity. If a six-minute-walk-test was performed within the last 3 months within the routine treatment, no additional test will be performed and the distance walked in meters as well as borg scale will be recorded in the study CRF, including the date of the assessment. If not performed within the last six months, a six-minute-walk test will be performed once.
224180897|NCT05272969|DIAGNOSTIC_TEST|Pressure pain threshold|"For diagnosis of myofascial pain, pressure algometers are designed and conventionally used to measure deep pressure pain thresholds or tenderness resistance (Park, Kim et al. 2011), and the reliability of pressure pain thresholds according to raters or measurement frequencies has been proven to be relatively high (Chung, Um et al. 1992). The threshold is then determined as the arithmetic mean of the 3 series (in kPa). The measurement will be stopped immediately as the patient feels sensations of burning, stinging, drilling or aching. Pressure algometry measurements will be performed on the trapezius, deltoid and supraspinatus muscles, the rectus femoris muscles, and the tibialis anterior muscles."
224307557|NCT02649985|DRUG|[F-18]PBR06|PET radiopharmaceutical
224307558|NCT02649985|DRUG|[C-11]PBR28|PET radiopharmaceutical
224307559|NCT03046407|BIOLOGICAL|retinal pigment epithelium transplantation|Transplant retinal pigment epithelium derived from human embryonic stem cells into subretinal space of patients with dry age-related macular degeneration(dry AMD).
224307560|NCT05961865|DIAGNOSTIC_TEST|Markers of inflammation and fibrosis|"Will be analyzed the following inflammation markers:~Interleukin 6, N-terminal propeptide of type 1 procollagen (P1NP), chitinase-3-like protein 1 (YKL-40), tumor necrosis factor (TNF-alpha), GlycA, proprotein convertase subtilisin/kexin type 9 and omega-3 fatty acids."
224307561|NCT04137016|OTHER|Mobile application|
224307562|NCT01467414|DRUG|insulin degludec|Injected s.c. (under the skin) once daily for 6 days
224307563|NCT05199519|DRUG|IBI345|IBI345 CAR-T cell injection by intravenous infusion
224307564|NCT00944619|DEVICE|Closed loop|Subcutaneous delivery of Novorapid insulin, dose calculated by control algorithm, based on continuous glucose sensor readings
224307565|NCT00944619|DEVICE|Conventional insulin pump delivery|Subcutaneous delivery of Novorapid insulin according to usual pump regime
224307566|NCT01616108|DRUG|Bupivacaine|Differences in concentration from 0.75% to 3.0% are compared. Differences in volume for 1.0 mL to 3.0 mL are compared. Differences in compounding with addition of epinephrine will be used and compared to plain bupivacaine.
224180898|NCT05272969|DIAGNOSTIC_TEST|Muscle ultrasound|Muscle ultrasound is an ideal imaging modality that allows for atraumatic, noninvasive, radiation-free point-of-care neuromuscular imaging. Muscular diseases are typically associated with an increase in the echogenicity from the muscle substance, distal attenuation of muscle echo and a corresponding loss of bone echo. A measurement on both sides deltoid, biceps and triceps brachii muscle, quadriceps femoris muscle, tibialis anterior muscle, rectus abdominis muscle and paravertebral muscles of cervical (C5-7), thoracic (Th4-6) and lumbar (L4-5) muscles. Muscle tissue alterations will be classified using the Heckmatt scale I-IV, describing muscle echogenicity. For muscle ultrasound, a linear 17MHz probe will be used. The muscle ultrasound assessment usually takes 15-20 minutes.
224180899|NCT05272969|DIAGNOSTIC_TEST|Vital signs|Vital signs (blood pressure, heart rate, respiratory rate) will be measured before and after the six-Minute-Walk-Test (6MWT).
224180900|NCT05272969|DIAGNOSTIC_TEST|Borg Scale|The Borg scale will be assessed, which is a self-reported questionnaire designed to subjectively assess dyspnea and exertion during activity (Borg 1982). The Borg scale rates dyspnea on a scale of 0 to 10 incorporating nonlinear spacing of verbal descriptors of the level of intensity of dyspnea. A higher Borg score indicates more severe dyspnea. The Borg scale will be administered before starting the 6MWT (≤ 5 minutes) and after completing the 6MWT (≤ 5 minutes).
224180901|NCT05272969|DIAGNOSTIC_TEST|Laboratory assessment: Creatine kinase|CK-Level assessment in peripheral blood (peripheral venous blood draw)
224180902|NCT05272969|DIAGNOSTIC_TEST|Laboratory assessment: Vitamin D Level|Vitamin D Level in peripheral blood (peripheral venous blood draw)
224307567|NCT05819723|OTHER|CAM score|"The CAM scores assess the presence of delirium rapidly and accurately and also differentiates delirium from other cognitive impairment with a sensitivity of 94-100% and specificity of 90-95%.~It is an algorithm that consists of four features:~(i) Acute and fluctuating variation in mental status, (ii) Inattention, (iii) Incoherent or disorganized thinking, and (iv) Altered level of consciousness. CAM scores indicate delirium if the first two features are present and either the third or fourth feature is present."
224307568|NCT06160570|RADIATION|Intensive Modulated Radiation Therapy|Radiotherapy technique: IMRT
224307569|NCT06160570|RADIATION|3-Dimension Conformal Radiation Therapy|Radiotherapy technique: 3DCRT
224307570|NCT01545661|PROCEDURE|Sputum induction|Ultrasonic nebulisation 3% hypertonic saline nebulised for duration of 20 mins
224307571|NCT01545661|PROCEDURE|standard routine expectorated sputum|Patients in the control group are trained by the research staff to produce sputum but no device is utilized. Sputum is spontaneously expectorated where possible
223490029|NCT07103538|BEHAVIORAL|Reflective practices|The intervention was implemented as part of a nursing course consisting of 4 hours of theoretical instruction, 4 hours of laboratory practice, and 8 hours of clinical practice. For 14 weeks, reflective practice was integrated into both the laboratory and clinical components. In the laboratory sessions, clinical scenarios were developed based on five common topics (e.g., infection control, vital signs) that students are likely to encounter during clinical practice. Students performed these scenarios by taking on different roles. Following each role-play, structured reflection sessions were conducted with the students. In the clinical setting, the final hour of each practice day was allocated for reflection. After completing an online reflection form, students had the opportunity to engage in group discussions if they wished to reflect further.
223490030|NCT07104916|COMBINATION_PRODUCT|Psilocybin + MBCT therapy|The experimental arm has psilocybin with support and MBCT sessions.
223490031|NCT07104916|COMBINATION_PRODUCT|Active Comparator: Psilocybin with Support Only|The active comparator has psilocybin with support only.
223490032|NCT07105358|DEVICE|transcranial random noise stimulation (tRNS)|Stimulation location: bilateral human middle temporal complex (hMT+). Stimulation parameters: 1 mA current intensity, with a frequency range of 101-640 Hz.
223490033|NCT07105358|DEVICE|Sham Stimulation|Stimulation location: bilateral human middle temporal complex (hMT+). Stimulation parameters: Ramp up stimulation at 1mA with a frequency range of 101-640Hz for the first 30 seconds followed by no current for the remainder of the duration.
223490034|NCT07105358|BEHAVIORAL|Perceptual learning-based training|A motion discrimination task, judging the global direction of moving dot stimuli with two different coherence levels.
223490035|NCT07108777|DRUG|L-Carnitine Tartrate|L-carnitine 350 mg three times daily by oral.
223490036|NCT07108777|DRUG|Placebo|placebo tablet three times daily by oral.
223490037|NCT07142005|OTHER|Interviews|"* Questionnaires/Survey Measures~* Qualitative Instruments"
223490038|NCT07142590|DIETARY_SUPPLEMENT|Stable Isotopes|15 mg of stable iron isotopes in the form of ferrous sulphate 57FeSO4 will be orally administered to each participant.
224180903|NCT05272969|DIAGNOSTIC_TEST|Laboratory assessment: calcium|calcium level in peripheral blood (peripheral venous blood draw)
224180904|NCT05272969|DIAGNOSTIC_TEST|Laboratory assessment: magnesium|magnesium level in peripheral blood (peripheral venous blood draw)
224180905|NCT05272969|DIAGNOSTIC_TEST|Laboratory assessment: phosphate|phosphate level in peripheral blood (peripheral venous blood draw)
224180906|NCT05272969|GENETIC|Genetic test: ACE polymorphism|peripheral venous blood draw for genetic analysis of ACE polymorphism
224180907|NCT05272969|GENETIC|Genetic test: ACTN3 polymorphism|peripheral venous blood draw for genetic analysis of ACTN3 polymorphism
224307572|NCT04431583|PROCEDURE|Bariatric surgery- single surgeon service|
224307573|NCT04431583|PROCEDURE|Bariatric surgery- multiple surgeon + multidisciplinary team approach|
224307574|NCT04431583|PROCEDURE|Bariatric surgery: formalized streamlined multiple surgeon + multidisciplinary team approach|
224307575|NCT03544424|OTHER|No intervention|No intervention
224307576|NCT03627520|DRUG|[14C]Sulfatinib|300 mg Sulfatinib with 100 µCi \[14C\]
224307577|NCT02316665|DEVICE|continuous positive airway pressure|continuous positive airway pressure treatment during three months with adherence recording
224307578|NCT02316665|DEVICE|Sham-continuous positive airway pressure|Sham-continuous positive airway pressure during three months with adherence recording
224180908|NCT05272969|GENETIC|Blood draw for optional genetic exome sequencing|"Optionally, upon additional informed consent, exome sequencing from peripheral blood will be performed in a second step to assess whether polymorphisms or pathogenic mutations in genes that are associated with chronic pain syndromes contribute to increased pain. This analysis will be performed collectively after enrollment is complete by the Genetikum Neu-Ulm. The selection of the genes is based on the Human Phenotype Ontology (HPO) search terms myalgia, muscle pain, chronic pain, musculoskeletal pain, pain, and nociceptive pain."
224180909|NCT03845010|DRUG|Sotalol|Patients will be titrated to the maximal tolerated dose of sotalol with a targeted dose of 80 thrice daily (TID)
224180910|NCT03845010|DRUG|Flecainide and verapamil|Patients will receive maximal tolerated dose of flecainide and verapamil with titration to a maximal dose of 200 mg of flecainide and 240 mg of verapamil per day
224180911|NCT03845010|PROCEDURE|Catheter ablation|Patients will undergo VPB/VT ablation using a percutaneous transfemoral approach according to standard clinical routine
224180912|NCT00245635|DRUG|Fluoxetine|Tablets varying between 10mg and 80mg on a fixed/flexible dosing schedule based on the subjects' weight and side effects score.
224180913|NCT00245635|DRUG|Placebo|Placebo tablets will be given 1x/day for the duration of the study at a fixed/flexible dosing schedule similar to that for the drug fluoxetine based off of subjects' weight and side effects score.
224180914|NCT04624581|DEVICE|Electrophysiological measurement of reflex nociceptive flexion threshold (RIII reflex) using Nicolet Vicking device|"This intervention measures the response to electrical stimulation of the sural nerve using a pair of percutaneous electrodes placed at the external malleolar retro passage of the nerve (2 cm apart) and connected to the stimulation device (Nicolet Vicking). Reflex muscle responses will be collected using surface electrodes placed on the femoral biceps muscle of the participant and connected to an Electromyogram recording device.~The RIII will be determined twice (rest period between each 10-minute). In order to induce the reflex nociceptive flexion response, repeated cutaneous electrical stimulations (30 to 40) will be applied at the level of the sural nerve following a variable interval of 6 to 10 seconds in order to overcome the phenomena of habituation and predictability. Each stimulus test will consist of a single rectangular pulse of 0.5 ms, of variable intensity (0-100mA) until a reflex nociceptive flexion threshold is detected or a maximum current of 100 mA is reached"
224180915|NCT02297295|OTHER|Physiotherapy|Physiotherapy three times a week for 8 weeks according to a well-defined protocol
224180916|NCT03870646|COMBINATION_PRODUCT|Hypertonic saline of NaCl (7%) in combination with hyaluronic acid|Critical adult tracheostomized patients will receive, in the intervention arm, nebulized Hypertonic saline of NaCl (7%) in combination with hyaluronic acid 5ml twice daily for 10 days from the day of the tracheotomy or until decannulation or discharge from the ICU if it happens before. The treatment will be applied through a jet nebulizer located in the inspiratory branch in patients under mechanical ventilation and in the sole tubulant of patients under T-piece oxygen regimen. Salbutamol 100 micrograms / dose, suspension for inhalation in pressure pack: 2 inhalations through the tracheostomy cannula 10 minutes before the application of the nebulization with hypersaline in order to avoid bronchospasm.
224180917|NCT03870646|COMBINATION_PRODUCT|Isotonic saline of NaCl (0,9%)|Critical adult tracheostomized patients will receive, in the control arm, nebulized isotonic saline of NaCl (0,9%) 5ml twice daily for 10 days from the day of the tracheotomy or until decannulation or discharge from the ICU if it happens before. The treatment will be applied through a jet nebulizer located in the inspiratory branch in patients under mechanical ventilation and in the sole tubulant of patients under T-piece oxygen regimen. Salbutamol 100 micrograms / dose, suspension for inhalation in pressure pack: 2 inhalations through the tracheostomy cannula 10 minutes before the application of the nebulization with isotonic saline in order to avoid bronchospasm.
224205689|NCT04486807|DIAGNOSTIC_TEST|Elite badminton players|The population was all the elite badminton players followed in a University Hospital Centre and the National Institute of Sport, Expertise, and Performance. We excluded players who had SSI in the 3 months prior to the isokinetic test or had shoulder surgery. They were included and followed during the badminton season (Nineteen elite badminton players and followed over the badminton season (from september 2018 to may 2019 or from september 2019 to may 2020)
224205690|NCT04356092|DIAGNOSTIC_TEST|2D perfusion digital subtraction angiography of the foot.|2D perfusion digital subtraction angiography of the foot was performed after infrapopliteal angioplasty and Perfusion Blood Volume (PBV), Mean Transit Time (MTT), and Perfusion Blood Flow (PBF) maps were extracted by analyzing Time-Intensity Curves and signal intensity on the perfused vessel mask.
224205691|NCT03311828|BIOLOGICAL|Daratumumab|Given IV
223490039|NCT07141589|DRUG|Lidocaine + Bupivacaine + Hyaluronidase|Patients will receive a mixture of 3 ml lidocaine 2%, 3 ml bupivacaine 0.5%, and hyaluronidase 60 IU diluted in normal saline to a total volume of 8 ml.
223490040|NCT07141589|DRUG|Fentanyl + Lidocaine + Bupivacaine + Hyaluronidase|Patients will receive a mixture of 3 ml lidocaine 2%, 3 ml bupivacaine 0.5%, and hyaluronidase 60 IU and fentanyl 20 μg diluted in normal saline to a total volume of 8 ml.
223490041|NCT07141589|DRUG|Ketorolac + Lidocaine + Bupivacaine + Hyaluronidase|Patients will receive a mixture of 3 ml lidocaine 2%, 3 ml bupivacaine 0.5%, hyaluronidase 60 IU, and ketorolac 15 mg diluted in normal saline to a total volume of 8 ml.
223490042|NCT04021433|DRUG|Ketamine|Repeated doses of IM/SC ketamine up to 3 times a week
223490043|NCT02664753|DRUG|56 days of weight-adjusted L-Carnitine treatment|"Patients in the experimental arm will receive 10 days of intravenous L-carnitine treatment followed by 46 days of oral L-Carnitine treatment.~Day 1: a first bolus of 6g of L-Carnitine is administered with a syringe driver of 50 ml.~Day 2 to Day 10: Two mini-perfusions are prepared each day, corresponding to 1 administration every 12 hours. 50 mg/kg/day (rounded up to the next gram) L-Carnitine is added to each syringes~For the next 46 days, patients will take oral doses of L-Carnitine as follows:~\< à 60kg : 2g/day \> 60kg : 3g/day If the patient leaves the hospital before D10, oral treatment can be initiated at the end of the hospitalization"
223490044|NCT02664753|DRUG|10 days of intravenous placebo (isotonic saline)|"Patients in the placebo arm will receive 10 days of intravenous isotonic saline in a fashion analogous to the experimental arm (they study is thus blinded for the first 10 days and then open there afterwards).~Day 1: 1 50ml syringe driver of 50 ml isotonic saline solution . Day 2 to Day 10 : Two syringe drivers of 50 ml of isotonic saline solution are prepared each day, one during the morning and one during the evening."
224205692|NCT03311828|DRUG|Imaging Agent|Given Copper 64Cu-DOTA-daratumumab IV
224180918|NCT03773016|BEHAVIORAL|Art apps|Participants will be split into two groups of 6 participants; each group will use one app for two weeks and then change to the other app for another 2 weeks. Participants will be supported to use the app twice a week, with a maximum of 8 individual sessions over the four weeks. The intervention will be delivered to the participants at a quiet room in the care home by two co-investigators, one will be the facilitator, and the other one will be the observer. The intervention is a 30-minutes of individual sessions, with 10 minutes of app use. The additional 20 minutes will include the setup of the equipment and preparation of the participant at the beginning of the session; and questions for the participants at the end.
224180919|NCT03507049|PROCEDURE|iFuse|ifuse will be implanted as described in section on the active comparator arm of the study.
224180920|NCT03507049|PROCEDURE|sham group|sham surgery will be performed as desrcribed in section on sham comparator.
223490045|NCT06963580|DRUG|MI078 capsule dose 1|MI078 capsule dose 1 for 3 days
223490046|NCT06963580|DRUG|MI078 capsule dose 2|MI078 capsule dose 2 for 3 days
223490047|NCT06963580|DRUG|placebo|placebo for 3 days
223490048|NCT04316715|BEHAVIORAL|Lifesteps for PrEP|Four weekly nurse delivered counseling sessions plus two optional booster sessions. Sessions last approximately 40-50 minutes each. Sessions employ cognitive behavioral (CBT) techniques, motivational interviewing (MI), and psychoeducation.
223490049|NCT04316715|BEHAVIORAL|Daily text message reminders|Participants get daily text messages on their cell phone reminding them to take their PrEP medication.
224180921|NCT03507049|RADIATION|fMRI study|Quantitative sensory testing, cerebral MRI and functional MRI will be done to examine pain mechanism and activation in the central nervous system.
224180922|NCT05980390|DIAGNOSTIC_TEST|IL 35 in tissue biopsy|Elisa testing
223490050|NCT06027957|BIOLOGICAL|anti-CD19 CAR T-cells|"For Biological: CD19 CAR T-cells~* Dose: 1-2.10e6 cells/kg of weight~* Route: intravenous infusion~For Chemotherapy Drug:~* Fludarabine (30 mg/m2/day) given intravenously (IV) on day -5 to -3.~* Cyclophosphamide 500 mg/m2/day for NHL and 250 mg/m2/day for ALL given IV from day -5 to -3.~* Mesna 500 mg/m2/day for NHL and 250 mg/m2/day for ALL, divided in three infusions: one day before the cyclophosphamide infusion, and 4 and 8 hours after."
224180923|NCT01997333|DRUG|CDX-011|
224180924|NCT01997333|DRUG|Capecitabine|
224180925|NCT05051306|OTHER|High-load resistance exercise|Subjects in high-load trial performed 4 sets per exercise, 8 repetitions with load of 85%-8RM with 90 sec of rest between sets.
223490051|NCT05977868|DRUG|Amoxicillin, amoxicillin-clavulanate, cefadroxil, cefpodoxime, cefalexin, ciprofloxacin, delafloxacin, doxycycline, levofloxacin, linezolid|COpAT (oral antimicrobial therapy) on hospital discharge
223490052|NCT05977868|DRUG|Ampicillin, ampicillin-sulbactam, cefazolin, cefepime, ceftaroline, ceftazidime, ceftazidime-avibactam, dalbavancin, daptomycin, ertapenem|Standard of care (IV antimicrobial therapy) on hospital discharge
224180926|NCT05051306|OTHER|Low-load resistance exercise|Subjects in low-load trial performed 4 sets per exercise, 15 repetitions with load of 45%-8RM with 90 sec of rest between sets.
224180927|NCT01351233|PROCEDURE|Cataract Surgery|Take the operation of phacoemulsification and implant the AcrySof Toric intraocular lens into the capsular bag in high myopic subjects.
224180928|NCT02655211|PROCEDURE|CO2 laser treatment|Surgical treatment using fractionated ablative carbon dioxide laser (CO2)
224180929|NCT02655211|PROCEDURE|PDL laser treatment|Surgical treatment using flashlamp-excited pulsed dye laser (PDL)
224180930|NCT02655211|OTHER|Usual care|Usual care (i.e., non-surgical) therapy (compression garments, massage, physical therapy, silicone gel sheeting)
224180931|NCT05495009|OTHER|Standard of care+virtual reality glasses|At the beginning of the active and transitional phases of labor, videos were watched with virtual reality glasses.
224180932|NCT00476515|DRUG|Rituximab|the recommended dosage of Rituximab is 375 mg/m2 given as an IV infusion once weekly for four doses (days 1, 8, 15, and 22).
224180933|NCT02269709|DEVICE|ARFI Ultrasound|This research scan uses acoustic radiation force impulse (ARFI) shear wave velocity imaging (SVI). This is a new ultrasound technology in which unique sound waves create the images/pictures of the liver beng examined/scanned. This ultrasound scan will take approximately 10 minutes to complete.
223490061|NCT06784024|DRUG|Lidocaine topical|Topical lidocaine (SPRAY SOLUTION 10 g) 10% will be applied to the cervix and cervical canal prior to the MVA procedure in a number of 20 sprays separated by 3 seconds between each spray (0.06 ml/spray).
223490062|NCT06784024|OTHER|Saline solution|Placebo (0.9% saline) will be applied topically to the cervix and cervical canal prior to the MVA procedure in a number of 20 sprays separated by 3 seconds between each spray (0.06 ml / spray).
223490063|NCT05048797|DRUG|Trastuzumab Deruxtecan|Trastuzumab Deruxtecan administered by intravenous infusion
223490064|NCT05048797|DRUG|Cisplatin|Investigator's choice of platinum chemotherapy (cisplatin) administered by intravenous infusion
223490065|NCT05048797|DRUG|Carboplatin|Investigator's choice of platinum chemotherapy (carboplatin) administered by intravenous infusion
223490066|NCT05048797|DRUG|Pembrolizumab|Pembrolizumab administered by intravenous infusion
223490067|NCT05048797|DRUG|Pemetrexed|Pemetrexed administered by intravenous infusion
223490068|NCT04385888|BEHAVIORAL|Low-calorie sweetener restriction|Participants will avoid low-calorie sweetened beverages and other sources of low-calorie sweeteners for 12 weeks and will instead consume unsweetened alternatives, such as still or sparkling water
223490069|NCT05136677|BIOLOGICAL|Nivolumab|Specified dose on specified days
223490070|NCT05136677|BIOLOGICAL|Ipilimumab|Specified dose on specified days
223490071|NCT05136677|DRUG|Pemetrexed|Specified dose on specified days
223490072|NCT05136677|DRUG|Cisplatin|Specified dose on specified days
223490073|NCT05136677|DRUG|Carboplatin|Specified dose on specified days
223490074|NCT02716441|DEVICE|Radio-opaque Tissue Markers|All participants will undergo implantation of radio-opaque tissue markers on their repaired rotator cuff at the time of surgery.
223490075|NCT06229600|OTHER|Standard rehabilitation|Respiratory rehabilitation
223490076|NCT05162443|DRUG|adagrasib (MRTX849)|adagrasib (MRTX849) will be administered orally twice daily in a continuous regimen
223490077|NCT06299189|BEHAVIORAL|MinADHD|Guided self-help, 7 modules Interventions
223490078|NCT05431101|PROCEDURE|Carpal Tunnel Release|Transection of flexor retinaculum for patients who have carpal tunnel syndrome
223490079|NCT06332534|DRUG|Upadacitinib|Oral Solution/ Extended-Release Tablets
224180934|NCT06390293|BEHAVIORAL|Group-delivered guided written exposure therapy-revised version|Group-Delivered guided WET-R is a manualized exposure-based therapy program consisting of 5-8 sequential sessions. The interval between every 2 consecutive sessions is 0-2 days. There will be 5-8 group-delivered sessions in total (only one index trauma will be discussed), and 1-2 weeks to complete. The first and last sessions are scheduled to last for 1.5 hours each, while the other sessions will be 50 minutes in duration.
224180935|NCT06390293|BEHAVIORAL|Waiting-List (WL) condition|Participants assigned to WL will be asked to not work with other therapists or seek additional treatment for trauma-related difficulties during the 2-week WL period. After the one-month follow-up of the WET-R group, they will receive the same treatment (Group-Delivered guided written exposure therapy-revised version).WL participants will also be given contact information to use in case of worsening symptoms or increasing distress.
224180936|NCT02857205|OTHER|Fecal samples|High throughput sequencing methods and analysis for microbiome analysis on fecal samples from a multicenter cohort of patients at various ages.
224180937|NCT00917878|DIETARY_SUPPLEMENT|Milk|500 mL low-fat milk added to high-fat meal
224180938|NCT00917878|DIETARY_SUPPLEMENT|Protein|Milk protein in 500 mL water added to high-fat meal
224180939|NCT00917878|DIETARY_SUPPLEMENT|Calcium|Milk calcium in 500 mL water added to high-fat meal
224180940|NCT00917878|DIETARY_SUPPLEMENT|Control|Lactose in 500 mL water added to high-fat meal
224180941|NCT00659009|OTHER|Reduced barometric pressure|Sleep in reduced barometric pressure environment.
224180942|NCT00659009|OTHER|Sea level equivalent barometric pressure|Sleep in barometric pressure equivalent to sea level.
224180943|NCT00659009|OTHER|Reduced barometric pressure|Sleep in reduced barometric pressure environment.
224180944|NCT02909504|DRUG|Lithium|Eligible patients will receive lithium 300 mg twice daily and titrated in 300 mg increments every 7 days as tolerated to levels \> 0.6 mEq/L
224180945|NCT03201133|DIAGNOSTIC_TEST|Neuromuscular evaluation|(1) Muscle trunk endurance test; (2) Hip isometric strength (abductor, lateral rotation, extension); (3) Knee extensor isometric strength; (4) unilateral squat; (5) navicular drop test; (6) muscle architecture at rest of gluteus medius, gluteus maximus,vastus lateralis, vastus medialis and rectus femoris; (7) muscle activation during unilateral squat (gluteus and quadriceps muscles); (8) pennation angle of obliques vastus medialis; (9) medial patellofemoral ligament length; (10) knee pain.
224180946|NCT03929614|OTHER|MOBI validation|Final version will be distributed to 176 French speaking subjects, 30 of whom are randomly selected and will fill it a second time, at after 72 hrs. To consider of its kind, Moreover, the Bem Inventory for Children will be completed by everyone as well as the SF-12 and SRS-22.
224180947|NCT05231551|PROCEDURE|Placental tissues|Placental tissues are collected after aspiration of abortion products. They are treated immediately in order to isolate placental stem cells. Organoid culture is established and the obtained embryoids are cultured in monophasic or biphasic oxygen conditions. Extra organoids are cryopreserved in liquid nitrogen
223490080|NCT05756543|BEHAVIORAL|Counterfactual Inference Test|All participants were asked to complete the Counterfactual Inference Test - CIT (McNamara et al., 2003), a neuropsychological test that measures the ability to produce counterfactual-derived inferences. Moreover, the decision-making ability will be specifically tested through ad-hoc questionnaire (i.e., the Decision-Making Questionnaire). Finally, all participants will be screened with an extensive neuropsychological assessment, particularly on executive functioning.
223490081|NCT06104917|DRUG|High Dose Maolactin|Once daily dose of 2 capsules (2 capsules containing 250mg active proteins per capsule; equivalent to 500mg active proteins per day)
223490082|NCT06104917|DRUG|Low Dose Maolactin|Once daily dose of 2 capsules (1 capsule containing 250mg active proteins per capsule and 1 capsule containing maltodextrin only; equivalent to 250mg active proteins per day)
223490083|NCT06104917|DRUG|Maltodextrin|Once daily dose of 2 capsules
223490084|NCT02805491|OTHER|meconium|to evaluate internal exposure to pesticide
223490085|NCT02805491|OTHER|self questionnaires to parents|to evaluate external exposure to pesticide
223490086|NCT03119311|DIAGNOSTIC_TEST|Video-oculography|Diagnostic Method for Exotropia Using Video-oculography
223490087|NCT03119311|DIAGNOSTIC_TEST|APCT|alternative prism cover test
223490088|NCT06847100|DIAGNOSTIC_TEST|Blood withdrawal|Optional collection of 5 mL of blood to assess the contribution of 16 gene polymorphisms AF-associated
223490089|NCT04912869|DRUG|Crovalimab|Crovalimab will be administered as a single dose of 1000 milligrams (mg) IV (for participants with a body weight between 40 kilograms (kg) and 100 kg) or 1500 mg IV (for participants with a body weight \>=100 kg).
223490090|NCT04912869|DRUG|Placebo|Placebo will be administered as a single IV infusion, with an equal volume and over the same duration as weight- based crovalimab
223490091|NCT06165016|DEVICE|Far red light therapy|All participants will receive one far red light device per leg. Participants will be asked to use their two light devices daily, exposing their bare legs to the devices for 10 minutes twice per day. A study coordinator will deliver the light devices to each participant's home, positioning the devices 15 cm behind the participant's heels, using tape on the floor to mark where the light and feet should be positioned. Twice each day, the participant flips a switch on the device to begin each session. A timer will turn off the device after 10 minutes. A power meter will measure the total time that the device was turned on. Participants will also record use of the light in a log.
224180948|NCT02925780|DEVICE|Resin infiltration|"Teeth selected for this group will be treated with the resin infiltrant Icon according to the manufacturer's instructions. In short, teeth will be isolated with a rubber dam and the labial tooth surface cleaned with non-fluoride prophylactic paste and pumice. After an etching and drying step (to open the lesion surface), Icon will be applied following the manufacturer's instructions and subsequently light cured, followed by polishing.~Digital images are taken before and after the treatment as well as at the follow-up visits (3, 6, 9 and 12 months)."
224180949|NCT02925780|DEVICE|Microabrasion|"The labial surfaces of teeth selected for this group will be isolated and precleaned. Subsequently, the microabrasive material, Opalustre, will be applied according to the manufacturer's instructions, using a rubber cup at low speed (5 times each for 5 seconds). Between each of the applications the surface is washed by flushing water using a syringe.~Digital images are taken before and after the treatment as well as at the follow-up visits (3, 6, 9 and 12 months)."
224180950|NCT01641029|OTHER|No intervention|There is no intervention
224180951|NCT03864029|DRUG|KUVAN|retrospective data on the effectiveness of past treatment with KUVAN®. It includes blood Phe level, physical development status, intelligence development status, etc., during treatment with KUVAN
224180952|NCT00902473|DRUG|Topiramate|25mg tablets
224180953|NCT02365740|OTHER|gastric emptying test|gastric emptying rate for solid will be determined using the 13C-OBT. Breath samples will be taken before the meal and then at 15-min intervals for a period of 240 min postprandially. The 13C content will be determined by on-line gas chromatographic purification-isotope ratio mass spectrometry (ABCA; Europe Scientific, Crewe, UK). The 13CO2 excretion curves will be analyzed and the half-emptying time (t½) and lag phase (tlag) calculated.
224180954|NCT02365740|OTHER|gut hormones determination|blood sampling at 0, 15, 30, 60, 90, 120, 180 min for determination of plasma, glucagon and GI hormones (Ghrelin, GLP-1, GIP)
224180955|NCT02365740|OTHER|Continuous Glucose Monitoring|7 days Continuous Glucose Monitoring
224180956|NCT02365740|DRUG|Insulin single bolus|pre-prandial insulin administered as single bolus calculated on the basis of carbohydrate counting and each patient's insulin/glycaemic load
224180957|NCT02365740|DRUG|Insulin double-wave bolus|pre-prandial insulin fractioned into a double-wave bolus
224180958|NCT00862329|DIETARY_SUPPLEMENT|Casein-enriched diet|Subjects consume for 9 days a supplement of 30g/d of casein
224180959|NCT00862329|DIETARY_SUPPLEMENT|Milk soluble protein-enriched diet|Subjects consume for 9 days a supplement of 30g/d of milk soluble protein
224180960|NCT00862329|DIETARY_SUPPLEMENT|Casein and milk soluble proteins-enriched diet|Subjects consume for 9 days a supplement of 30g/d of a mix of casein and milk soluble protein
224180961|NCT00862329|DIETARY_SUPPLEMENT|Soy proteins-enriched diet|Subjects consume for 9 days a supplement of 30g/d of soy protein
224180962|NCT02764931|OTHER|Gluten free oats and gastrointestinal health|Subjects will be served 3 different test meals in a randomized order in the cross-over design
224180963|NCT00682292|DRUG|Thymoglobulin (ATG)|Thymoglobulin: 1.25 mg/kg per day from day 0 to day 7 post transplantation
224180964|NCT00682292|DRUG|Daclizumab|Daclizumab: 1mg/kg at day 0, 14, 28, 42 and 56 post transplantation
223490092|NCT06165016|DEVICE|Sham light therapy|All participants will receive one sham device per leg. Participants will be asked to use their two light devices daily, exposing their bare legs to the devices for 10 minutes twice per day. A study coordinator will deliver the light devices to each participant's home, positioning the devices 15 cm behind the participant's heels, using tape on the floor to mark where the light and feet should be positioned. Twice each day, the participant flips a switch on the device to begin each session. A timer will turn off the device after 10 minutes. A power meter will measure the total time that the device was turned on. Participants will also record use of the light in a log.
223490093|NCT06537401|BEHAVIORAL|Hypercaloric, High Fat Diet|Participants will select meals from a list of sample breakfast, lunch, and dinner options from grocery stores. Typical intake will be estimated as 160-170% of resting metabolic rate, which will then be multiplied by 1.65 as the target calorie intake for the HFD. Target fat intake will be 65% of the HFD calorie target. To ensure participants will achieve the desired calorie and fat intake, they will also be provided with pre-made nutrient shakes and half-and-half. Participants will supplement their food intake with one to three shakes per day for each of the three days, depending on the fat and calorie content of the foods they select. They will be asked to add half-and-half equally between across the shakes.
223490094|NCT06122220|PROCEDURE|ONSD+AF|Measurement of the optic nerve sheath diameter and of sFLT-1/PGIF index
223490095|NCT06330701|DEVICE|Robotic-assisted mini-PCNL|This robotically enabled hybrid procedure called the MONARCH Mini-PCNL will allow the clinician to obtain retrograde and percutaneous access to participant's kidney under continuous visualization for therapeutic applications (i.e., stone removal).
223490096|NCT06540170|BEHAVIORAL|A personalised self-care support program|A personalized care program consists of three 30-minute face-to-face sessions (once every 2 weeks) after patients' routine wound dressings to enhance self-efficacy, support emotional adjustments, and DFU self-care.
223490097|NCT05451862|DEVICE|Holmium-166 treatment|Implantation into hepatic tumors by delivery via the hepatic artery for the treatment of unresectable HCC liver tumors.
223490098|NCT05451862|DEVICE|Holmium-166 work-up|Evaluation of lung-shunt, extrahepatic deposition and intrahepatic distribution of intra-arterially injected microspheres for patients that are eligible for TARE treatment.
224180965|NCT02084940|DRUG|GnRH antagonist depot Degarelix|Women receive 20 mg of Degarelix on the first day of menstrual cycle followed by a fixed dose of 225 IU of recombinant FSH on the second day until the day of ovulation triggering
224180966|NCT04098172|DEVICE|Pressure Guidewire|Fractional Flow Reserve measurement
224180967|NCT04314258|DIETARY_SUPPLEMENT|Moringa oleifera tea|4 grams of Moringa oleifera tea twice daily
224180968|NCT04411472|BIOLOGICAL|Recombinant human alkaline phosphatase|patients with SA-AKI are randomly assigned in a 1:1 ratio to either placebo or 1.6 mg/kg recAP.
224180969|NCT04411472|OTHER|Placebo|Placebo
224180970|NCT05060003|DRUG|Atezolizumab|Atezolizumab is provided by Genentech.
224180971|NCT05060003|DRUG|Tiragolumab|Tiragolumab is provided by Genentech.
224180972|NCT05060003|DEVICE|Signatera Assay|"* To detect residual disease or to determine cancer recurrence with ctDNA~* Step 2 screening (4-12 weeks after date of surgery), cycle 3 day 1, cycle 6 day 1, cycle 9 day 1, cycle 12 day 1, and end of treatment (optional)"
224180973|NCT00652964|DEVICE|CPAP|CPAP treatment for patients with congenital central hypoventilation syndrome
224180974|NCT03481933|DEVICE|Transcranial stimulation|"1. 10 days of stimulation (20min, 1.59mA) in double-blind sham-controlled. 3 arms (N=20 in each arm):~   * left-excitatory tDCS (N=20)~  * right-inhibitory tDCS (N=20)~  * sham tDCS (N=20)~2. 4 language/semantic evaluations: base-line; 3 days; 2 weeks; 4 months post-tDCS~3. 2 MRI/PET acquisitions: pre-stimulation (base-line); 2 weeks post-tDCS"
224180975|NCT00362297|DRUG|acyclovir|800 mg orally three times daily for 7 weeks
224180976|NCT00362297|DRUG|valacyclovir|500 mg orally once daily for 7 weeks
224180977|NCT00062842|DRUG|Irinotecan|
224180978|NCT04321291|OTHER|Generic information leaflet|The information about the biosimiliars is realized only by the transmission of the information leaflet in addition to the information given by the investigator.
224205693|NCT03311828|PROCEDURE|Positron Emission Tomography|Undergo PET
224205694|NCT03311828|OTHER|Pharmacological Study|Correlative studies
224180979|NCT04321291|OTHER|Individual information by nurse on biosimilars|Delivery of the same information leaflet, completed if asked by the patient, by individual meeting with specialist nurse, including generic and standardized informations on specificities, advantages and current scientific knowledge about biosimilars in inflammatory rheumatic diseases. This is in addition to the information given by the investigator
224180980|NCT03102073|DIAGNOSTIC_TEST|Radner test|"* The A5 reading booklet is held by the subject~* The subject is instructed to read sentence by sentence, by turning consecutively the pages of the booklet (on the first side is the number of sentence and the backward side contains the sentence)~* The subject is instructed to read the sentences aloud as quickly and accurately as possible to the end, and to not correct reading errors.~* One assessor is writing the reading time and records any reading errors on the scoring sheet while the second assessor is audio recording the operation~* Stop criterion: reading time longer than 20 seconds or severe errors."
224180981|NCT03046069|OTHER|Telephone interviews|Qualitative concept elicitation telephone interviews will be conducted in subjects with COPD to explore treatment effectiveness, symptoms, quality of life, and features of treatment that are considered to be most important to them when making treatment choices.
224180982|NCT03046069|OTHER|In-person focus groups|Qualitative concept elicitation in-person focus groups will be conducted in subjects with COPD to explore treatment effectiveness, symptoms, quality of life, and features of treatment that are considered to be most important to them when making treatment choices.
223490099|NCT06567691|PROCEDURE|EUS Gastrojejunostomy|Endoscopic Ultrasound (EUS) Gastrojejunostomy. Under live real-time EUS visualization, a solution of normal saline or water and dilute methylene blue will be infused through the nasobiliary drainage catheter to mechanically distend the small intestine and create a suitable, expanded fluid-filled target for transgastric access. Once a suitable target has been identified, a lumen apposing metal stent (LAMS) will then be deployed securely across the newly created gastroenterostomy tract. Appropriate stent placement will be confirmed.
224180983|NCT03046069|OTHER|DCE surveys- cognitive interviews|Draft version of the DCE surveys will be tested with subjects in cognitive interviews to explore the saliency of the attribute choices and assess whether the attributes are understandable, meaningful and comprehensive.
224180984|NCT03046069|OTHER|Modified DCE|The modified DCEs will be piloted with subjects with COPD in each country to refine the underlying design and ensure that information is collected in an efficient way to enable the statistical analysis to be as precise as possible.
224180985|NCT03046069|OTHER|Online DCE survey|An online DCE survey questionnaire will be given to the subjects to identify subject preferences, priorities and treatment goals.
224180986|NCT00743184|DRUG|ozarelix|One single-dose vial contains 16.5 mg of ozarelix. The drug is reconstituted with 1.3 mL of diluent.
224180987|NCT00743184|DRUG|Placebo|Identical placebo is also provided and reconstituted using diluent containing 0.1% saline solution.
224180988|NCT01404884|PROCEDURE|SUPRACOR|The developed software algorithm uses the subjective refraction of the eye to create a treatment for the distance vision correction. In addition to the treatment for the distance vision an additional central ablation component will be added to address the near vision.
224180989|NCT01881906|OTHER|Usual care|
224180990|NCT01881906|OTHER|Exercise|
224180991|NCT02443311|DRUG|Pimecrolimus 1% cream|Patients were instructed to apply a thin layer of mixed equal amounts (½ ml) of the study medication and the adhesive gel base per application guided by the graduation on the plastic syringe on the oral lesions, 4 times daily, for a total of 1month. The patients were asked not to eat, drink, for 30 minutes after each application.
224180992|NCT02443311|DRUG|Betamethasone 17-valerate 0.1% cream|Patients were instructed to apply a thin layer of mixed equal amounts (½ ml) of the study medication and the adhesive gel base per application guided by the graduation on the plastic syringe on the oral lesions, 4 times daily, for a total of 1month. The patients were asked not to eat, drink, for 30 minutes after each application.Topical antifungal Miconazole 2% gel (Miconaz, oral Medical Union Pharmaceutical, Cairo, Egypt) was applied only in the fourth week of treatment period to avoid secondary candidiosis
224180993|NCT03294798|BIOLOGICAL|Human Serum Albumin/interferon alpha2b fusion protein|In experiemental groups, each subject will recieve 600,750,900mg once per two weeks during multiple dose period.
224180994|NCT03294798|BIOLOGICAL|Pegasys|In comparator group, each subject will recieve 180mcg once per week.
224180995|NCT03769753|DEVICE|IRE Device|For use in ablating soft tissue
223490100|NCT06567691|PROCEDURE|Surgical Gastrojejunostomy|Gastrojejunostomy will be performed via an open technique using an upper midline or left sub-costal incision (at the discretion of the surgeon). An antecolic, pro-peristaltic, gastrojejunostomy will be performed using one of two standard techniques: 1) hand-sewn: 2-layer anastomosis using absorbable suture or 2) stapled: single-layer anastomosis using a surgical stapler with closed staple height ranging from 1.0 - 1.5 mm and suture closure of the common enterotomy. Feeding tube placement will be at the discretion of the operating surgeon and if performed, will be performed via a Stamm technique. Abdominal fascial closure will be performed with absorbable, monofilament, suture and skin will be closed using staples or suture at the discretion of the surgeon.
224180996|NCT02197351|PROCEDURE|White light biopsy|Endoscopy with biopsies guided by high definition white light
224180997|NCT02197351|PROCEDURE|Protocolled|Upper Endoscopy with Protocolled Biopsy (i.e. biopsy by predetermined guideline not influenced by white light or narrow band imaging findings)
223490101|NCT06567691|OTHER|Gastric Outlet Obstruction Scoring System (GOOSS)|A previously validated instrument for assessing tolerance of oral intake.
223587583|NCT04157283|DIAGNOSTIC_TEST|MRI brain, visual evoked potential, Cerebrospinal Fluid, Sexual dysfunction measure, Depressive symptoms assessment and Multiple Sclerosis Quality of Life-54(MSQOL-54)|"1. Neurophysiological Evaluation:~   Visual Evoked Potential (VEP).~2. Imaging Evaluation:~   Conventional MRI.~3. Cerebrospinal Fluid (CSF):~4. Sexual dysfunction measure: through the international index of erectile function (IIEF), female sexual function questionnaire (SFQ) and the sexual Quality of life male and female version (SQoL) (American Psychiatric Association, 1994).~5. Depressive symptoms assessment through The BDI (The Beck Depression Inventory) which is the most common instrument measuring the severity of depression.~6. Fatigue symptoms were evaluated through fatigue subscale of Multiple Sclerosis Quality of Life-54(MSQOL-54)."
223587584|NCT01864161|DRUG|gluconate iron|FERLIXIT fl 15mg/kg divided into weekly administrations of 125mg up to a maximum of 1000mg
223587585|NCT01864161|DRUG|Liposomal iron|Sideral forte 30 mg/die
224180998|NCT02197351|PROCEDURE|Narrow Band Imaging Guided Biopsy|Upper Endoscopy with biopsy guided by narrow and imaging
224180999|NCT05934929|OTHER|Circulating tumor DNA detection|biological assessment on operating bed to detect residual circulating tumor DNA
224181000|NCT00018694|DRUG|Chenodeoxycholic Acid|
224181001|NCT05862740|PROCEDURE|Laparoscopic Debulking Surgery in advanced ovarian cancer|Laparoscopic debulking will be conducted until the surgical target is achieved or the operation is converted to laparotomy.
224181002|NCT05862740|PROCEDURE|Standard laparotomic Debulking Surgery in advanced ovarian cancer|Debulking by laparotomy in patients when debulking could not be accomplished by laparoscopy.
224181003|NCT02599740|OTHER|Natural fruit extract|Natural fruit extract consumed with rice
224181004|NCT02599740|OTHER|Assumed active|Assumed key active consumed with rice
224181005|NCT02599740|OTHER|Placebo|Rice only
224181006|NCT05779501|BEHAVIORAL|Internet-delivered strengths use intervention|"The online strengths use intervention program follows the theorized five stages of strengths use interventions: (1) preparation and commitment, (2) identification, (3) integration, (4) action, and (5) evaluation. To increase participant engagement and motivation, gamification components are embedded in several stages.~The intervention was previously tested through a feasibility and acceptability trial (NCT05474807).~The entire intervention will be delivered online via an LMS software solution."
224181007|NCT05779501|BEHAVIORAL|Waiting-list|"The waiting-list arm will serve as the control group, filling in only the outcome measure at the same time as the intervention group participants.~After the intervention group finishes participating in the intervention, the waiting-list participants will benefit from the same internet-delivered strengths use program."
224181008|NCT03702166|BEHAVIORAL|Cognitive Processing Therapy (CPT)|CPT is a cognitive behavioral treatment for PTSD consisting of 12 one-hour sessions. CPT is delivered in three phases: education, processing, and challenging.
224181009|NCT03832712|PROCEDURE|Deep Brain Stimulation|Surgical implantation of intracranial leads for deep brain stimulation, extension cables and implantable pulse generator
224181010|NCT03832712|DRUG|Best Medical Treatment|Unselective β-blockers such as Propanolol
224181011|NCT00005089|BIOLOGICAL|rituximab|375 mg/m\^2 on days 1,8 of cycle 1, then on days 1-3 of cycles 2-3.
224181012|NCT00005089|DRUG|cyclophosphamide|750 mg/m\^2 on day 10 of cycle 1, then on day 21 of cycles 2-3.
224181013|NCT00005089|DRUG|doxorubicin hydrochloride|50 mg/m\^2 on day 10 of cycle 1, then on day 21 of cycles 2-3.
224181014|NCT00005089|DRUG|prednisone|100 mg on days 10-14 of cycle 1, then on days 3-7 of cycles 2-3.
223490102|NCT04803279|DEVICE|Collection of Pure tone thresholds from audiogram measured prior to fitting of Ponto 3 SuperPower|Unmasked and if available masked BC thresholds from audiogram obtained prior to Ponto 3 SuperPower were fitted.
224181015|NCT00005089|DRUG|vincristine sulfate|1.4 mg/m\^2 on day 10 of cycle 1, then on day 3 of cycles 2-3.
224181016|NCT00005089|RADIATION|radiation therapy|4000-5500 cGy given in 25 fractions starting 3 weeks after completion of CHOP + Rituximab.
224181017|NCT01484522|BIOLOGICAL|FluMist|Administered at the manufacture's recommended dose
224181018|NCT01484522|BIOLOGICAL|Fluvirin|Vaccine administered at the manufacturer's recommended dose.
224181019|NCT01484522|BIOLOGICAL|Fluzone|Vaccine administered at manufacturer's recommended dose
224181020|NCT00684073|DRUG|buprenorphine|2 mg buprenorphine and 8 mg buprenorphine tablets at doses from 2 to 16 mg buprenorphine daily for first two days of study
224181021|NCT00684073|DRUG|buprenorphine/naloxone|2/0.5 mg buprenorphine/naloxone and 8/2 mg buprenorphine/naloxone tablets at doses from 2/0.5 mg buprenorphine/naloxone to 16/4 mg buprenorphine/naloxone daily for last 3 days of study
224181022|NCT04229186|DIETARY_SUPPLEMENT|EVOO-C|Each patient will consume 10 mg total daily amount EVOO-C
223490103|NCT04803279|DEVICE|Collection of BC In-situ thresholds from BC In-situ audiogram measured during fitting of Ponto 3 SuperPower|BC In-situ thresholds will be collected from the BC In-situ audiogram obtained when Ponto 3 SuperPower were fitted
223490104|NCT04803279|DEVICE|Collection of Aided sound field thresholds measured with the Ponto 3 SuperPower|Sound field thresholds for frequencies 500Hz, 1kHz, 2 kHz, 3kHz and 4kHz will be collected from sound field audiogram obtained as follow-up after Ponto 3 SuperPower fitting, typically this is collected 3 months post fitting, alternatively from the fitting visit. Thresholds will be obtained aided, and when available unaided
223490105|NCT04803279|DEVICE|Collection of speech intelligibility scores|"Speech intelligibility is measured in a sound treated room using sentence tests. The sentence tests used at Norwich and Norfolk hospital is the BKB (Bamford-Kowal-Bench) and/or the The AB\[s\] Isophonemic Monosyllabic Word test (7).~The sentence tests are measured in quiet and/or with background speech-weighted noise."
223490106|NCT04803279|DEVICE|Skin reaction|Classification of skin reactions around skin penetrating implants will be made using the Holgers score. The Holgers classification is a scale from 0 to 4 that is used to grade skin reactions
223490107|NCT04803279|DEVICE|Collection of Glasgow Benefit Inventory|The Glasgow Benefit Inventory (GBI) contains 18 health status questions, which ask specific questions about how the health problem, in this study hearing loss, has affected their quality of life at the time the GBI is completed. In this study GBI has been collected on patients before intervention and 3 months after fitting of Ponto 3 SuperPower on abutment.
223490108|NCT04803279|DEVICE|Collection of power-on usage time with Ponto 3 SuperPower|Average power-on usage hours from Ponto 3 SuperPower will be collected.
223587586|NCT02068560|DRUG|dDAVP infusion|
223587587|NCT03974672|PROCEDURE|Re-laparotomy|
223587588|NCT04761744|DRUG|Nivolumab|Study treatment consists of nivolumab 3mg/kg, and will be repeated every 2 weeks.
223587589|NCT04102722|DEVICE|MUST device|Imaging with MUST device
224181023|NCT04229186|DIETARY_SUPPLEMENT|ROO|Each patient will consume 10 mg total daily amount ROO
224181024|NCT01070186|DRUG|Sunitinib|50mg/day for 4 weeks
224181025|NCT01070186|OTHER|Tumor biopsy|Conducted prior to administration of sunitinib therapy
224181026|NCT01070186|PROCEDURE|Nephrectomy|Nephrectomy 2-4 weeks after last dose of Sunitinib
224181027|NCT01070186|OTHER|Biomarkers|"Biomarker evaluation of blood prior to treatment, after 4 weeks of Sunitinib administration, and every three months for a year after surgery.~Biomarker evaluation of tissue prior to 4 week administration of Sunitinib"
224181028|NCT01118039|DRUG|sunitinib malate|
224181029|NCT01118039|OTHER|immunohistochemistry staining method|
224181030|NCT01118039|OTHER|laboratory biomarker analysis|
224181031|NCT01118039|OTHER|pharmacological study|
224181032|NCT01118039|PROCEDURE|quality-of-life assessment|
224181033|NCT05675202|DRUG|TQ-B3525|TQ-B3525 is a new PI3K α/δ Kinase inhibitor
224181034|NCT03124524|DRUG|estradiol valerate/dienogest|oral, 28 tablets including 2 tablets of 3mg estradiol valerate, 5 tablets of 2mg estradiol valerate plus 2mg dienogest, 17 tablets of 2mg estradiol valerate plus 3mg dienogest, 2 tablets of 1mg estradiol valerate and 2 non hormonal tablets as placebo, respectively
224181035|NCT03124524|DRUG|ethinylestradiol and drospirenone|oral,0.03 mg ethinylestradiol and 3 mg drospirenone (21 tablets)
224181036|NCT03410641|BEHAVIORAL|Diet and antismoking advice|Dietary advice with the aim of reducing participant's serum cholesterol levels, including reduction in the intake of saturated fat and cholesterol, and increased intake of polyunsaturated fat, fish, vegetables and fruit. Weight reduction was recommended for overweight men, as well as reduced consumption of sugar rich foods and drinks, and alcoholic beverages. Smokers were advised to stop smoking. The advice was given both individually and in group sessions during a five-year time period from 1972/3 until 1977/8.
224181037|NCT01657903|DRUG|Sodium Fluoride|Toothpaste containing 1450 ppm F - EU level as NaF.
224181038|NCT01657903|DRUG|Potassium nitrate|All study treatments contain 5% w/w KNO3.
224181039|NCT03652090|PROCEDURE|cell sampling|nasal brushing to collect cells
224181040|NCT00029666|DEVICE|Neopulse Magnetic Stimulator|
224181041|NCT00953784|PROCEDURE|standard operating management|As previously described
224181042|NCT02517502|DRUG|DHA|4 capsules of 400 mg DHA daily
224181043|NCT02517502|DRUG|Placebo|Matched, blinded placebo
224307579|NCT04915482|DRUG|Combined use of TPO-RAs with low-dose anti-CD20 antibody|Experimental: Combined use of TPO-RAs with low-dose anti-CD20 antibody The starting dose of eltrombopag is 50-75mg once daily. The starting dose of hetrombopag is 5.0-7.5mg once daily. The starting dose of avatrombopag is 20-40mg once daily. Prior to or within 2 weeks after initiation of TPO-RAs therapy, a single dose of Rituximab at 375mg/m2 or divided doses of Rituximab at 100mg once a week for 2-4 weeks, or a single dose of ortuzumab at 1000mg can be administered.. The dosage will be adjusted according to the results of laboratory examinations and patient tolerance.
223490109|NCT04035005|DRUG|Ocrelizumab|The first dose of ocrelizumab will be administered as two 300 milligrams (mg), IV infusions given 14 days apart. For the subsequent doses, ocrelizumab will be administered as a single 600 mg infusion every 24 weeks. A minimum interval of 20 or 22 weeks, depending on if the previous dose was administered in one or two infusion, should be maintained between each infusion.
223490110|NCT04035005|DRUG|Placebo|The first dose of placebo will be administered as two IV infusions given 14 days apart. For the subsequent doses, placebo will be administered as a single infusion every 24 weeks, with a minimum interval of 20 or 22 weeks, depending on if the previous dose was administered in one or two infusions, maintained between each infusion.
223490111|NCT02378246|DIETARY_SUPPLEMENT|Iodine|
223490112|NCT02378246|DIETARY_SUPPLEMENT|Placebo|
223490113|NCT05826873|BEHAVIORAL|Discharge antibiotic stewardship intervention|Hospitalists will be provided with group-level, quarterly feedback reports illustrating the number of prescriptions that had the appropriate antibiotic duration and appropriate antibiotic choice for each of the three conditions.
223490114|NCT01809808|PROCEDURE|Surgery for acromegaly|(non-experimental) standard procedure
223587590|NCT03700814|DRUG|Co-amoxiclav|Patients in this group will receive single dose of intravenous co-amoxiclav (Dose: 25 mg/kg body weight) which was injected 30 minutes prior to the incision during surgery.
223587591|NCT02718040|DEVICE|Emervel Classic and/or Deep Treatment Group|"Severity of Wrinkle Severity treated by product type:~Emervel Classic:~Nasolabial Folds (NLFs): Wrinkle Severity Rating Scale (WSRS) = 2/2, 2/3 or 3/3; Marionette Lines (MLs): Wrinkle Assessment Scale (WAS) = 2/2, 2/3 or 3/3~Emervel Deep Nasolabial Folds (NLFs): Wrinkle Severity Rating Scale (WSRS) = 3/3, 3/4 or 4/4; Marionette Lines (MLs): Wrinkle Assessment Scale (WAS) = 3/3, 3/4 or 4/4~Both products may be used in the same subject, but only in different anatomic locations. The same study product should be used within the same wrinkle or fold type (e.g., left and right NLFs treated with the same product)"
224181044|NCT00207493|BEHAVIORAL|Kit enhancement to referral|
224181045|NCT00207493|PROCEDURE|patient referral versus contract referral|
224181046|NCT01259388|DRUG|Lithium Carbonate|Lithium carbonate is dosed at 150 or 300 mg daily, as tolerated by study subjects, for one year's time.
224181047|NCT00455780|BEHAVIORAL|Weight Loss Phase|Weight loss using CBT and meal replacements
224181048|NCT00455780|BEHAVIORAL|Continued CBT|Using CBT during weight loss maintenance
224181049|NCT00455780|BEHAVIORAL|reduced energy density education|Additional nutritional learning
224181050|NCT00455780|BEHAVIORAL|continued use of meal replacements|continued use of meal replacements during weight loss maintenance
224181051|NCT00309192|DRUG|Triamcinolone Acetonide|Intravitreal Injection 4mg single dose
224181052|NCT00309192|PROCEDURE|Grid laser|Grid laser as specified in ETDRS
224181053|NCT00309192|PROCEDURE|Sham Injection|Simulation procedure for triamcinolone injection
224181054|NCT02572869|OTHER|physical exam|Patients will be examined by the treating physician or his/her designee (Fellow). The examining physician will complete an 11-item clinical examination form about the patient's clinical function. This examination assesses lip competence, tongue movement, oral mucosa, dental state, mouth opening, speech, drooling, diet, appearance, oral sensation, and shoulder movement. Where appropriate, the physician will ask the patient questions regarding items on the questionnaire to ensure the completeness and accuracy of the outcome assessment.
224181055|NCT02572869|BEHAVIORAL|questionnaires|"The participating patients will be asked to complete three questionnaires:~(1) The European Organization for Research and Treatment of Cancer (EORTC) Head and Neck questionnaire (EORTC H\&N 35) to assess their quality of life as it relates to their mandible function and aesthetic appearance (2) The EORTC QLQ-C30, which assesses overall health-related quality of life (3) The FACE-Q Oncology Module: Mandibulectomy, which contains questions regarding both functional and aesthetic outcomes."
224181056|NCT03096691|DEVICE|cervical pessary|Silicone rings known as arabin pessary are used to support the cervix in women with a sonographic short cervix.
224181057|NCT04262674|OTHER|Cognitive-motor training|Simultaneous cognitive-motor training and strength training
224181058|NCT00090246|DRUG|MK0869, aprepitant|
224181059|NCT00090246|DRUG|Comparator: ondansetron IV|
224181060|NCT05875194|DEVICE|active transcranial direct current stimulation (tDCS)|2mA, over the left dlPFC (10-20 position F3), duration 15 minutes
224181061|NCT00807768|RADIATION|3-Dimensional Conformal Radiation Therapy|Undergo pelvic radiation therapy
224181062|NCT00807768|DRUG|Carboplatin|Given IV
224181063|NCT00807768|RADIATION|Intensity-Modulated Radiation Therapy|Undergo pelvic radiation therapy
224181064|NCT00807768|RADIATION|Internal Radiation Therapy|Undergo vaginal cuff brachytherapy
224181065|NCT00807768|OTHER|Laboratory Biomarker Analysis|Correlative studies
224181066|NCT00807768|DRUG|Paclitaxel|Given IV
224181067|NCT00807768|OTHER|Quality-of-Life Assessment|Ancillary studies
224181068|NCT00807768|OTHER|Questionnaire Administration|Ancillary studies
224181069|NCT02411968|OTHER|111In-Girentuximab DOTA SPECT|
224181070|NCT00183976|DRUG|Pegylated Liposomal Doxorubicin (Doxil) and Rituximab|
224181071|NCT02743494|DRUG|Nivolumab|Specified dose on specified days
224181072|NCT02743494|OTHER|Placebo|Specified dose on specified days
224181073|NCT03955731|DEVICE|Magmaris resorbable magnesium scaffold|Implantation of Magmaris resorbable magnesium scaffold
224181074|NCT03534466|DEVICE|Baby treadmill|The newborns who received treadmill intervention were stimulated by running 3 times a week for a total of 10 minutes each time (complete in 5 cycles, 2 minutes per cycle, 2 minutes after the completion of one cycle and rest for 2 minutes to start the next cycle). Until the completion and completion of the five cycles). During the remaining four days of each week, other physical rehabilitation training is carried out by the rehabilitator in accordance with the established rehabilitation plan. The stimulation of running lasted from 3 months of corrected gestational age to being able to walk alone for 3 steps or to correct for 18 months.
224181075|NCT03534466|BEHAVIORAL|Conventional physical rehabilitation training|Suitable for general physical rehabilitation training of all infants with cerebral palsy.
224181076|NCT02559830|GENETIC|transduced CD34+ hematopoietic stem cell|Autologous hematopoietic stem cells (HSCs) collected from the mobilized peripheral blood and transduced ex vivo with a Lentiviral vector encoding the human ARSA(for MLD)/ABCD1(for ALD) cDNA（complementary DNA）. Dose: ≥ 2x10\^6 transduced CD34+ cells/Kg (maximum 20x10\^6) at bedside for infusion.
224181077|NCT00539825|DRUG|GSK704838|
224181078|NCT06198946|DEVICE|External diaphragm pacing（EDP）|After the skin is disinfected, place the small electrode pads on the lower 1/3 of the outer edges of the sternocleidomastoid muscles on the left and right sides, and place the large electrodes on the surface of the pectoralis major muscles on both sides, and fix them with medical tape. Adjust the pacing according to the patient's tolerance. Frequency and stimulation intensity, each treatment time is 20 minutes, treatment is once a day, 5 days a week, and the treatment course is 4 weeks.
224181079|NCT06198946|OTHER|Routine rehabilitation treatment|Participants received comprehensive rehabilitation treatments such as muscle strength training, hemiplegic limb comprehensive training, balance function training, limb neuromuscular electrical stimulation, acupuncture and other comprehensive rehabilitation treatments. Each project was 30 minutes/time, once a day, 5 days a week, and the treatment course was 4 weeks.comprehensive rehabilitation treatments, each item is 30 minutes/time, once a day, 5 days a week, and the treatment course is 4 weeks.
224181080|NCT01174602|BEHAVIORAL|Exposure Therapy for AN (AN-EX/RP)|12 Sessions, 3 times per week. 90 minute sessions. Group therapy twice per week.
224181081|NCT01174602|BEHAVIORAL|Cognitive Remediation Therapy|12 Sessions, 3 times per week. 45 minute sessions. Group therapy twice per week.
223490115|NCT01809808|DRUG|Medications for acromegaly|(non-experimental) standard procedure
224181082|NCT05007912|PROCEDURE|Esophagojejunostomy type|Use of either circular or linear stapler
224181083|NCT02883010|DEVICE|PICO Softport V1.6|PICO is a Single-Use Negative Pressure Wound Therapy (NPWT) System consisting of a small portable pump, 2 lithium batteries, 2 dressings and fixation strips. The system is capable of delivering up to 80 mm Hg negative pressure to a wound or surgical incision site and managing low to moderate levels of exudate or fluid generated by the wound or incision. The therapy may be administered for up to 2 weeks.
224181084|NCT02883010|OTHER|Standard Care|Care path normally used by the hospital
224181085|NCT03070054|DRUG|20ml 0.25% bupivacaine-epinephrine|Extra-capsular local infiltration analgesic (LIA) administration of 20ml 0.25% bupivacaine-epinephrine
224181086|NCT00003556|BIOLOGICAL|ALVAC-hB7.1|
224181087|NCT00003556|BIOLOGICAL|canarypox-hIL-12 melanoma vaccine|
224181088|NCT03469206|PROCEDURE|intra-arterial thrombectomy|It is the emergency surgical removal of emboli which are blocking blood circulation. It usually involves removal of thrombi (blood clots)
223490116|NCT01809808|DIAGNOSTIC_TEST|Total body magnetic resonance imaging|Subjects will undergo total body MRI with spectroscopy of the muscle and liver before and 3-6 months, 12 and 24 months after surgery or medical therapy for acromegaly.
223490117|NCT01809808|PROCEDURE|Adipose Tissue Biopsy|Subjects will undergo biopsy of subcutaneous adipose tissue before and 12 and 24 months after surgery or medical therapy for acromegaly.
223490118|NCT05511324|BEHAVIORAL|Questionnaires|Participants will be asked to complete this assessment on your own time, and it should take about 40 minutes.
223490119|NCT05511324|BEHAVIORAL|Caregiver Assessment|These sessions will involve simulation-based, caregiving skill training, and your caregiver will be taught skills to help support you (such as feeding, hygiene, mobility, medication administration, and care coordination).
223490120|NCT05696847|DRUG|Tirzepatide|Administered SC
223490121|NCT05696847|DRUG|Placebo|Administered SC
223490122|NCT04167748|PROCEDURE|Preimplantation genetic testing for aneuploidy (PGT-A)|24-chromosome screening for aneuploidy in the preimplantation embryo (blastocyst stage)
223490123|NCT04945369|OTHER|clinical and biological measurements and questionnaires|"Blood and urinary samples collection for evaluation of insulin resistance and of renal function analysis.~Assessment of body composition by BOP-POD and by impedancemetry. Assessment of pulse wave by popmetre. Assessment of physical activity by accelerometer and by questionnaire Questionnaires for analysis of eating behaviour"
224181089|NCT03469206|DRUG|Intravenous thrombolysis|alteplase is used in the intravenous thrombolysis. It catalyzes the conversion of plasminogen to plasmin, the major enzyme responsible for clot breakdown.
224181090|NCT00218283|DRUG|Nicotine Lozenge|Oral Nicotine replacement product
224181091|NCT00218283|BEHAVIORAL|Behavioral Counseling|Use of behavioral counseling to reduce tobacco use.
223587592|NCT01573156|DRUG|Light activated WST11|WST11-mediated VTP will consist of the combination of a single IV administration of WST11 at doses of 2 mg/kg, or 4mg/kg using 753 nm laser light at a fixed power (150 mW/cm) and energy (200 J/cm) delivered through percutaneous optical fibres. The fibres are introduced into transparent needles that are positioned in the areas of interest under CT image guidance. After a minimum of 3 patients at each drug dosage (2 \& 4 mg/kg) has been treated with a light energy of 200 J/cm, the general and local safety will be assessed. The safety results of the first 3 patients treated in each drug dose/number of fibres combination will be reviewed by the investigators prior to escalation to a higher drug dose/number of fibres combination.
224181092|NCT03513432|DIETARY_SUPPLEMENT|Beer with 5.20 % alcohol|330 ml beer (5.20 % alcohol)/day during 4 weeks
224181093|NCT03513432|DIETARY_SUPPLEMENT|Non-alcoholic beer with 0.45 % alcohol|330 ml non-alcoholic beer (0.45 % alcohol)/day during 4 weeks
224181094|NCT03513432|DIETARY_SUPPLEMENT|Non-alcoholic beer with 0.00 % alcohol|330 ml nonalcoholic beer (0.00 % alcohol)/day during 4 weeks
224181095|NCT00139373|DRUG|donepezil|
224181096|NCT00983827|DEVICE|Aquatic treadmill training|HydroWorx aquatic therapy pool with an underwater, integrated and adjustable speed treadmill
223587593|NCT02132273|OTHER|Educational Story|Educational story with pictures illustrating overnight polysomnography procedure accompanied by simple narrative.
224181097|NCT04789005|DRUG|Norepinephrine|Norepinephrine 8mcg was administered manually by the anaesthesiologist every time the SBP was 20% lower than baseline and the HR ≥60 bpm.
224181098|NCT04789005|DRUG|Phenylephrine|Phenylephrine 100mcg was administered manually by the anaesthesiologist every time the SBP was 20% lower than baseline and the HR ≥60 bpm.
224181099|NCT00890851|PROCEDURE|Transurethral Needle Ablation (TUNA)|Transurethral needle ablation of benign prostatic hyperplasia by radio frequencies
224181100|NCT01521494|DRUG|PA21|
224181101|NCT01521494|DRUG|PA21|
224181102|NCT01521494|DRUG|PA21|
224181103|NCT01521494|DRUG|PA21|
224181104|NCT01521494|DRUG|Placebo|
224205695|NCT00478673|DEVICE|NexStent Carotid Stent System (Monorail Delivery System)|Self-expanding carotid stent for treating patients at high risk for adverse events from carotid endarterectomy who require carotid revascularization.
224205696|NCT00478673|DEVICE|FilterWire EZ™ Embolic Protection System|Used as a guide wire and embolic protection system to contain and remove embolic material (thrombus/debris) while performing angioplasty and stenting procedures in coronary saphenous vein bypass grafts and carotid arteries.
224205697|NCT03147001|OTHER|Protein ingestion|A protein drink was ingested prior to the 90min bike ride in one of the completed trails (order randomised).
224205698|NCT03147001|OTHER|Non-caloric placebo ingestion|A placebo drink was ingested prior to the 90min bike ride in one of the completed trails (order randomised).
224205699|NCT03597126|DEVICE|Robot-assisted surgery|robot-assisted intersphincteric resection for low location rectal cancer(T=1\&2)
224205700|NCT03597126|DEVICE|Laparoscopic surgery|laparoscopic intersphincteric resection for low location rectal cancer(T=1\&2)
224205701|NCT06342791|DEVICE|laser acupuncture|laser use to stimulate acupuncture points
224205702|NCT02978729|OTHER|Two-way videoconference remote genetic counseling|
224205703|NCT02978729|OTHER|Telephone remote genetic counseling|
224205704|NCT05971732|DRUG|Ferric derisomaltose|After baseline assessments patients will be randomised in a 1:1 ratio to receive ferric derisomaltose IV or placebo (normal saline). In the Treatment group, Ferric derisomaltose will be administered according to the dosing schedule.
224205705|NCT05971732|DRUG|Placebo|In the placebo group, patients will receive the equivalent number of normal saline injections.
224205706|NCT05186727|OTHER|Family History education|The education, developed in partnership with community partners, intends to assist women to collect family history of breast cancer and share it with their providers.
224205707|NCT05186727|OTHER|Patient Ambassador|The support of a Patient Ambassador in addition to the education is also tested.
224205708|NCT03576794|DRUG|Leflunomide 20 mg|During the first 2 weeks after randomization patients will receive Leflunomide 20 mg every other day. After 2 weeks Leflunomide will be increased to 20 mg once daily and this therapy will be continued during 12 months.
224205709|NCT03576794|DRUG|Prednisolone|Patients in both groups will receive prednisolone 15 mg once daily and will be randomized within 4 weeks of the start of glucocorticoid therapy (prednisolone). Prednisolon will be tapered according to a short fixed protocol with a slow gradual taper till 0 in week 27.
224205710|NCT00690846|DRUG|adalimumab|40 mg weekly adalimumab injection.
224205711|NCT02896621|DRUG|Chlorthalidone plus amiloride|A capsule with chlorthalidone plus amiloride was taken once daily in the morning for eight weeks.
224205712|NCT02896621|DRUG|Amlodipine|A capsule of amlodipine was taken once daily in the morning for eight weeks.
224205713|NCT01411475|OTHER|Bifurcation restenosis classification|Classification of restenosis involving coronary bifurcation according to their pattern
224205714|NCT04431622|DEVICE|Hearing aid amplification algorithms|The investigators will use stimulus waveforms that have been amplified and recorded for each individual's hearing loss. These waveforms will be created using Desired Sensation Level, Version 5-C hearing aid targets on a continuum of increased signal manipulation. The NIH-funded open hearing aid platform will be used to provide precise control over hearing aid parameters to create waveforms with linear and fast-acting compression amplification. A third set of waveforms will be created using a current clinical hearing aid that uses typical noise reduction and compression parameters. Investigating the effects of hearing aid algorithms in young normal-hearing and older normal-hearing listeners will aid in interpretation of these effects in the older hearing-impaired listeners.
224205715|NCT03332212|DRUG|Empagliflozin|12 weeks
224205716|NCT03332212|DRUG|Placebo|12 Weeks
224205717|NCT01351194|PROCEDURE|RFA|For PRFA, we used a commercially available system with a 375-KHz computer-assisted radiofrequency generator (Elektrotom HiTT 106, Berchtold, Medizinelektronik, Germany) and an open-perfused electrode (Berchtold, Tuttlingen, Germany) of 15 cm (or 20 cm), 14 Ga, and a 15 mm (or 20 mm) active electrode tip with microbores. The 14 Ga needle was introduced into the center of the tumor; then, 60 W of the radiofrequency energy was delivered by the generator with an 8-minute duration for every single energy application.
223490124|NCT03323502|BEHAVIORAL|APPROACHES ACP Specialist Program|The APPROACHES Advance Care Planning (ACP) Specialist will work with nursing home leaders (in intervention arm facilities) to: i. Consolidate nursing home ACP procedures; ii. Train and educate staff; and iii. Facilitate ACP Specialist Program with patients who have Alzheimer's disease/related dementias and their family caregivers.
224181105|NCT05507294|DRUG|Glumetinib|"Fasting: Subjects are fasted overnight (at least 10 hours before administration) and receive Glumetinib tablets with 240 mL warm water the next morning.~Fed (high-fat meal/low-fat meal): Following an overnight fast for at least 10 hours, subjects finished a high-fat meal, or a low-fat meal within 30 minutes the next morning (eat up all meals). Glumetinib tablets are orally administered by subjects with 240 mL warm water on 30 minutes after starting the meal. Water is allowed as desired except for 1 hour before and 2 hours after administration (including the meal), and no more than 500 mL of water will be consumed including the water intake during the high-fat meals or low-fat meals, and the water for administration. The subjects will be fasted for at least 4 hours after administration, and then have dinner approximately 9 hours after administration."
224181106|NCT06000826|DEVICE|Celsi Warmer|During the study, research participants will receive thermal care via the Celsi Warmer. Aside from thermal treatment, research participants will receive the standard of care from the neonatal unit, and will also be closely monitored by study personnel throughout the study. The results from this study will allow the research team to determine if the Celsi Warmer is an effective tool for warming and monitoring newborns in wards of low-resource hospitals. The research team hopes to demonstrate that the Celsi Warmer is effective for the appropriate treatment of newborn hypothermia in hospitals in low-resource settings.
224181107|NCT04352244|PROCEDURE|Fat biopsy|"The fat biopsy is performed during a scheduled procedure at the Beth Israel Deaconess Medical Center (BIDMC). Routine preoperative procedures will be followed, including local anesthesia (numbing a particular region of the body) or general anesthesia (being put to sleep).~Adipose tissue will be sampled from different depots depending on the procedure. For example, the surgeon will collect adipose tissue from the neck and supraclavicular depots from cervical spine, thyroid, and parathyroid procedures; perinephric fat from adrenalectomies, omental fat from abdominal procedures, and paraspinal fat from lumbar spine procedures. Up to 5 pieces of fat tissue weighing about three to six grams will be removed. All other aspects of the surgical procedure will proceed as planned. Samples will be prepared for subsequent laboratory analysis."
224181108|NCT04352244|DIAGNOSTIC_TEST|Blood sampling|A blood sample will be collected in the fasting state either during preoperative testing or in the preoperative area on the day of planned procedure for measurement of adipose functional markers (leptin, adiponectin) and insulin resistance (insulin, C-peptide), and measures of glycemia (glucose, hemoglobin A1c).
224181109|NCT04352244|GENETIC|Blood sample for DNA analysis|Targeted resequencing of DNA to identify variants associated with adipose phenotypes will be performed.
224181110|NCT04602468|DRUG|Kaftrio|The intervention is the same for both study groups. In addition to all the assessments in the standard arm, the advanced arm subjects will undergo spirometry controlled CT, nasal lavage and sputum sample collection.
224307580|NCT04915482|DRUG|The best available therapy|The best available therapy except for combined use of TPO-RAs with low-dose anti-CD20 antibody includes but not limited to glucocorticoids, intravenous immunoglobulin, recombinant human thrombopoietin, TPO receptor agonists monotherapy, rituximab monotherapy, immunosuppressants, etc., and the researchers will adjust the treatment plan at any time according to the patient's condition.
223490125|NCT03323502|OTHER|Standard of care|Standard of care Advance Care Planning (ACP) procedures
223587594|NCT03113604|OTHER|Study on samples of tumor and peri-tumor tissues from patients with hepatocellular carcinoma|"Retrospective study of samples of tumor and peri-tumor tissues from patients with hepatocellular carcinoma (HCC): three groups of samples will be selected:~Group 1: Tumor and peri-tumor tissue samples from patients with non-treated sorafenib CHC (surgical resection or other) Group 2: Tumor and peri-tumor tissue samples from tumor and peritumor tissues of patients not responding to sorafenib treatment Group 3: samples from patients responding to treatment with sorafenib"
223587595|NCT00521222|DRUG|Fluticasone with salmeterol|Fluticasone 45mcg, 115mcg, or 230mcg with salmeterol 21mcg, via HFA device, 2 puffs every 12 hrs, over 16 week study period.
223587596|NCT00521222|DRUG|Fluticasone HFA|Fluticasone HFA alone at 44mcg, 110mcg or 220 mcg 2 puffs every 12 hrs, over 16 week study period.
223587597|NCT00521222|DRUG|Ipratropium HFA|Primary as-needed rescue medication in all treatment groups
223587598|NCT00521222|DRUG|Albuterol HFA|Secondary as-needed rescue medication in all treatment groups
223490126|NCT06638619|BEHAVIORAL|Biofeedback Fixation Training|This training type involves the use of microperimetry. Microperimetry is a visual field test that incorporates perimetry and retinal imaging and is a standard ophthalmic clinical technology. It allows for direct observation of the fundus, but uses an eye-tracking system to compensate for involuntary eye movements. A program designed to train patients to direct and hold their gaze at an eccentric location programmed by the controller will be used. When the participant directs their gaze towards the pre-programmed location, a sound of increasing frequency is emitted to let them know they are approaching the correct location. The sound stabilizes into a solid tone when the patient is gazing directly at the trained location (biofeedback) and they are asked to attempt to hold their gaze at this location for as long as possible.
223587599|NCT02067494|OTHER|Myofascial Soft Tissue Release|Protocol: Myofascial release on thoracolumbar fascia, Myofascial release on diaphragm, Myofascial release in the psoas fascia, Indirect Myofascial release restrictions in the public area, Myofascial release in lumbo-sacral decompression, Myofascial release on sacrum, and Myofascial release on the lumbar fascia.
223587600|NCT02067494|OTHER|Kinesio taping treatment|"Two bands in I, with anchor onset in sacrum, on paravertebral muscles. Furthermore a strip will be applies on correction space point of maximum pain."
223587601|NCT03147794|DEVICE|MyndMove|A new technology system called MyndMove has been developed by MyndTec Inc. (Missisauga Canada) to administer FES. The purpose of this technology is to improve voluntary upper limb (hand and arm) function (i.e. reaching and grasping) for patients with hemiparesis as a results of stroke or spinal cord injury (7). It is a non-invasive application that delivers electrical stimulation to the affected limb transcutaneously. MyndMove has been licensed by Health Canada and is indicated as a functional electrical stimulator for improvement of arm and hand function and active range of motion in patients with hemiplegia due to stroke or upper limb paralysis due to C3-C7 spinal cord injury.
224181111|NCT01888367|DRUG|DFA-02 Antibiotic Gel|
224307581|NCT01303757|BEHAVIORAL|Dietary counselling|
223490127|NCT06638619|BEHAVIORAL|Saccadic Reading Training|Participants will be assigned to participate in an at-home reading program. The reading exercises consist of worksheets with letter and number combinations of increasing complexity and font sizes. They are intended to increase accuracy in identifying letters and numbers. Worksheets will initially be dispensed with larger font type and spacing and be graded at weekly intervals towards regular, newspaper-size print and spacing over the course of training.
224181112|NCT01888367|DRUG|DFA-02 Placebo Gel|
224181113|NCT04597424|DRUG|Experimental: doxycycline|"2 tablets of doxycycline 100 mg (monohydrate form) will be taken orally after each risk sexual intercourse, ideally within 24 hours after sex and no more than 72 hours. PEP should not be taken more than 3 times over a 7 days' period.~If a participant has risk sexual intercourse for several consecutive days, PEP should be taken at least 48 hours apart and no more than 3 times 2 tablets over 7 days. A maximum of 3 intakes of 2 tablets will be allowed over a period of 7 days."
224181114|NCT04597424|BIOLOGICAL|Bexsero® vaccine|1st injection of Bexsero® vaccine at inclusion visit, 2nd injection at week 8.
224181115|NCT05916534|BEHAVIORAL|WeCAB Intervention|The WeCAB intervention will use a dedicated WeCAB community health worker who will administer a social determinants of health (SDOH) tool and use digital care navigation to monitor closed loop referrals.
224307582|NCT06273930|DRUG|5% CALCIUM SODIUM PHOSPHOSILICATE|Calcium sodium phosphosilicate is a particulate, bioactive glass material that degrades in the aqueous oral environment to release calcium and phosphate ions, leading to formation of hydroxycarbonate apatite on the dentine surface result in reduction in dentine hypersenstivity
224307583|NCT06273930|DRUG|8% Arginine|Arginine contributes to Whole Mouth Health. It also plays a role with respect to dental caries, helping to maintain a pH-neutral environment, and is proven to rapidly help relieve dentin sensitivity. Arginine is truly a remarkable ingredient now being used in oral care products.
224307584|NCT00684892|DEVICE|Chartis System|Assessment of airway flow and pressure
224307585|NCT06133283|BEHAVIORAL|High intensity endurance exercise|High intensity interval exercise on a recumbent stepper for 30 minutes, 3 days per week.
224307586|NCT06133283|BEHAVIORAL|Stretching exercise|Stretches of face, neck, upper extremity, trunk and lower extremity muscles including whole body stretches for 30 minutes, 3 days per week.
224307587|NCT06133283|BEHAVIORAL|Virtual reality (VR)-based gaming|VR games will involve games that challenge balance such as reaching different targets during activities such as sit to stand, dodging obstacles etc. Participants will play approximately 6 games for 30 minutes, 3 days a week.
224307588|NCT03783039|DEVICE|SURGICEL Powder|Surgeon to perform surgical procedure according to standard of care. If randomized to SURGICEL Powder, the product will be be applied to the first appropriate TBS with mild or moderate bleeding in parenchyma or soft tissue where conventional methods of control (i.e. suture, ligature, cautery) are ineffective or impractical.
224307589|NCT03783039|DEVICE|SURGICEL Original|Surgeon to perform surgical procedure according to standard of care. If randomized to SURGICEL Original, the product will be be applied to the first appropriate TBS with mild or moderate bleeding in parenchyma or soft tissue where conventional methods of control (i.e. suture, ligature, cautery) are ineffective or impractical.
224307590|NCT01682863|DRUG|QVA149|QVA149 will be supplied in a capsule form in blister packs for use in the Novartis Concept1 SDDPI
223490128|NCT06300996|DEVICE|Spinal Cord Stimulator (Octopolar Medtronic Vectris Leads)|Spinal cord stimulation is FDA approved for treatment of pain. We are proposing utilizing the same technology to help restore motor control in people who have declining function due to the progression of SMA. These are 2-4 leads that are FDA-approved.
223490129|NCT05307666|OTHER|Medication minimization|During the medication minimization visit, and any necessary follow-up visits, patients and providers work together to gradually minimize medication dosages (e.g. reducing 1/4 or 1/2 dose at a time) using the following approach: 1) Medications Treating Symptoms: Find the minimum dose that controls the symptom, 2) Drugs that Lower Blood Pressure: Reduce dosages until systolic BP is in the upper 10mmHg of the target range (e.g. target 130 - 140 mmHg), 3) Drugs That Lower Blood Sugar: Reduce dosages until HbA1c is in the upper 5% of the target range (e.g. target 7.5 - 8.0%).
223490130|NCT05943678|DEVICE|Siemens Magnetom 7T Plus|Magnetic Resonance Spectroscopy
223490131|NCT05842668|BEHAVIORAL|ESWL Group|Increasing comfort and reducing pain during ESWL
223490132|NCT05691283|DEVICE|trans cranial direct current stimulation (tDCS)|Three weeks of 20-minute tDCS stimulation
223490133|NCT05691283|DEVICE|Sham|Three weeks of sham stimulation
223490134|NCT05419518|BIOLOGICAL|EXTERNAL BEAM RADIATION|A minimum of three daily radiation therapy treatments are required in any given week. Any missed radiation treatments will be made up at the end of the treatment schedule, such that the total number of delivered 5 Gy fractions remains ten.
223490135|NCT05524883|DRUG|DYNE-251|Administered by IV infusion
223490136|NCT05524883|DRUG|Placebo|Administered by IV infusion
223587602|NCT03579173|DIAGNOSTIC_TEST|Infant PFT|Assessed through the raised volume rapid thoracoabdominal compression technique and plethysmography
224181116|NCT01513824|BEHAVIORAL|pressure pain sensitivity measure followed bu acupressure|twice daily measure of pressure pain sensitivity on the chest bone followed by stress management of which acupressure is mandatory.
224181117|NCT00735163|OTHER|enhanced model predictive control algorithm (eMPC)|eMPC (software on a bedside computer) advised insulin titration to establish tight glycaemic control
224181118|NCT01854918|BIOLOGICAL|Evolocumab|Administered by subcutaneous injection either every 2 weeks or once a month (patient preference) using a prefilled autoinjector pen
224181119|NCT01854918|DRUG|Standard of Care|Standard of care therapy as per local practices. This could include prescribed therapies and/or dietary/exercise regimes
224181120|NCT04418908|DRUG|Cetrorelix acetate, 0.25 mg/day|All participants self-administered GnRHant daily between the baseline and follow-up visits (cetrorelix acetate, 0.25 mg/day).
224181121|NCT04418908|DRUG|Estradiol Patch, 0.025 Mg/24 Hours Weekly Transdermal Film, Extended Release|Active estradiol transdermal patch.
224181122|NCT04418908|DRUG|Placebo patch|Placebo patch designed to match active Climara patches.
224181123|NCT02020564|BEHAVIORAL|Speed of Processing Training|
224181124|NCT02020564|BEHAVIORAL|Placebo Control|
224181125|NCT04812821|OTHER|questionnaire|questionnaire post delivery
224181126|NCT04916106|DEVICE|Transcutaneous Electroacupuncture|give diffrent parameter TEA treatment for 4 weeks.
224181127|NCT05853640|OTHER|Usual care|Usual care at the orthopedic department consists of a clinical examination, radiological imaging, and a diagnostic injection. A recommendation to get physical therapy treatment in primary care will be provided, but this intervention will not be controlled by the investigators in any capacity.
224181128|NCT05853640|OTHER|HIPSTER|"Patients will be provided with usual care at the orthopedic department, which consists of a clinical examination, radiological imaging, and a diagnostic injection.~In addition, participants in this group will be referred to physical therapists trained in administering a semi-structured, individualized, progressive treatment. This 16-week intervention targets known physical and psychological impairments in people with long-standing hip and groin pain, using exercise therapy and patient education."
224181129|NCT03452059|DEVICE|AiLegs, AiWalker and HKAFO|5 days. Using their own control method, each morning using AiLegs, AiWalker AiWalker and HKAFO for 6 minutes walk test, three kinds of appliance between at least 30 minutes to determine heart rate, blood pressure and breathing back to quiet level. Repeat the same procedure in the afternoon ，the order is also random. Each participant will complete 10 groups of lower limb exoskeleton rehabilitation Training robot (including AiLegs, AiWalker two models) and HKAFO 6 minutes walking test
224181130|NCT02929836|PROCEDURE|PVI|PVI was the complete isolation of all PVs, which was confirmed by entrance and/or exit block into or from the PV antra.
224181131|NCT02929836|PROCEDURE|LA linear ablation|LA linear ablation include mitral isthmus ablation and roof line ablation. Mitral isthmus ablation (from the mitral annulus to the left inferior PV) was performed first, followed by roof line ablation (between the right and left superior PVs).
223490137|NCT04492670|PROCEDURE|Tui-na|For administering of Tui-na manipulation practice, responsible Tui-na CMP must have at least 2 years of clinical experience. The pre-trial workshops led by a senior practitioner will be organized to ensure standardization of Tui-na treatment manipulation and procedures.
223490138|NCT04492670|DRUG|Du-Huo-Ji-Sheng-Tang (DHJST)|This study medication is derived from Du-Huo-Ji-Sheng-Tang (DHJST) and concentrated Chinese Medicine granules will be used.
223490139|NCT02816021|DRUG|Azacitidine|300 mg by mouth daily for 15 days (Days 1-15) of every cycle.
223490140|NCT02816021|DRUG|Pembrolizumab|200 mg by vein every 3 weeks and after the oral dose of Azacitidine on concurrent treatment days.
223490141|NCT03293524|GENETIC|GS010|GS010 is a recombinant adeno-associated viral vector serotype 2 (rAAV2/2) containing the wild-type ND4 gene (rAAV2/2-ND4). GS010 will be administrated via intravitreal injection containing 9E10 viral genomes in 90μL balanced salt solution (BSS) as a single baseline intravitreal injection.
223490142|NCT03293524|DRUG|Placebo|The placebo is a BSS, sterile, apyrogenic solution and used for ocular surgery. The placebo will be administered via intravitreal injection in a volume of 90 μL.
223490143|NCT06514157|COMBINATION_PRODUCT|budesonide/albuterol sulfate metered dose inhaleor (BDA MDI)|BDA MDI 160 μg/180 μg (single dose administered as 2 actuations of 80 μg/90 μg)
223490144|NCT05889910|PROCEDURE|Health education workshop|"The intervention will consist of 5 initial sessions, plus a reinforcement session at 6 months. The sessions will last 2 hours and will preferably be distributed one day a week.~The objective of the intervention is to reduce the fear of falling and falls in people over 65 years of age who live in the community. To this end, nursing interventions will be included to improve the knowledge, skills and attitudes of the participants regarding the improvement of their functional capacity, the prevention of falls and their preventive measures, as well as the improvement in the management of anxiety and coping with the fear of falling and falls.~The activities carried out during the intervention have been extracted from standardized nursing interventions through the Nursing Interventions Classification (NIC).~The following interventions and activities will be addressed: 1665, 5612, 6490, 6486, 4700, 5820 and 5230."
223490145|NCT06003803|BEHAVIORAL|digital learning in motivational interviewing|Receive digital learning in motivational interviewing for three months, once a week, 40 minutes each time
223490146|NCT05791201|DRUG|VX-264|Allogeneic human stem cell-derived islets.
223490147|NCT04188535|DIAGNOSTIC_TEST|MRI IMAGING|Imaging with MRI will be performed as per disease site standards.
223587603|NCT03579173|DIAGNOSTIC_TEST|Lung Clearance Index|The Lung Clearance Index is derived from the Multiple Breath Washout test. It is the cumulative exhaled volume (the volume of gas needed to wash out resident gas mixture out of the lungs) divided by the FRC. The FRC is the amount of air left in the lungs after normal exhalation.
223587604|NCT03579173|DIAGNOSTIC_TEST|Passive tidal breathing|During quiet sleep, tidal breathing flow-volume curves are obtained. The tPEF/tE is calculated by taking the time it takes to reach peak expiratory flow divided by the total peak expiratory time.
224181132|NCT02929836|PROCEDURE|CFAE ablation|Ablation catheter was maintained in a stable position when the electrograms were being recorded for at least 5 s to avoid artifacts.The procedural endpoint of CFAEs was the complete elimination of fragmented atrial activity in local electrograms.
224181133|NCT02929836|PROCEDURE|linear ablation|Right atrial CTI ablation was performed during SR.
224181134|NCT02929836|DEVICE|CARTO|3 dimensional mapping system
224181135|NCT02146352|DEVICE|AXIOS Stent with Electrocautery Enhanced Delivery System|Endoscopy with ultrasonography to implant AXIOS stent using electrocautery enhanced delivery system to allow drainage of pancreatic pseudocyst. Removal of AXIOS stent after 30 or 60 days.
224307591|NCT01682863|DRUG|QVA149|QVA149 will be supplied in a capsule form in blister packs for use in the Novartis Concept1 SDDPI
224307592|NCT01682863|DRUG|QAB149|QAB149 and matching placebo will be supplied in capsule form in blister packs for use in the Novartis Concept1 SDDPI
223587605|NCT00756951|DRUG|Placebo|Placebo
223587606|NCT00756951|DRUG|SCV-07|0.02 mg/kg
223587607|NCT00756951|DRUG|SCV-07|0.10 mg/kg
223587608|NCT05740319|OTHER|FMT|FMT refers to transplanting healthy donor-derived microbiota to participants via oral capsule or injection of fecal suspension via nasojejunal tube.
223587609|NCT04762524|OTHER|CVVH vs CVVHD|Patients are initiated on CRRT in either the CVVH or CVVHD modality
223587610|NCT00214929|BEHAVIORAL|treatment at home|
223587611|NCT05776628|DEVICE|Plenum® Tissue ortho membrane (polydioxanone membrane)|Membrane addition after flavectomy and spinal nerve and dura mater manipulation.
224181136|NCT02155725|DRUG|Human Fibrinogen concentrate|Injection as soon as possible and within 30 min following the start of prostaglandin infusion
224307593|NCT01682863|DRUG|Placebo|To mimic QAB149
224181137|NCT02155725|DRUG|Placebo|As soon as possible and within 30 min following the start of prostaglandin infusion
224181138|NCT05979857|DRUG|SP-3164|SP-3164, an oral next generation cereblon-binding molecular glue 'protein degrader'
224181139|NCT03053466|DRUG|APL-501|"Subjects will be assigned to a dose level in the order of study entry. Treatment includes a minimum of four 28-day cycles at three planned dose levels (1, 3, and 10 mg/kg). In the Dose Escalation Segment, each treatment cycle is comprised of 2 doses of study drug administered on Days 1 and 15 of a 28-day cycle. In the Cohort Extension, the treatment cycle will consist of 2 doses of study drug administered on Days 1 and 15 of a 28-day cycle.~In Dose and Disease Expansion, the treatment cycle will consist of 2 doses of study drug (non-weight based dosing of 400 mg) administered on Days 1 and 15 of a 28-day cycle."
224181140|NCT01026727|DRUG|MPC-4326 plus a 2-3 drug optimized background regimen (OBR)|For treatment arm #1: the MPC-4326 dose will be selected based on the inclusion of raltegravir (i.e., will be limited to 300 mg BID) or inclusion of darunavir (i.e., will be assigned 400 mg BID) in the OBR. If both raltegravir and darunavir are included in the OBR for a subject, the subject will be limited to 300 mg BID
223490148|NCT06585891|BIOLOGICAL|VRC-HIVMAB0121-00-AB|The CAP256J3LS bispecific antibody (bsAbs) targets the V2-apex and CD4-binding sites of the HIV-1 envelope. It is composed of the light chain of CAP256V2LS, linked to the llama nanobody J3, which has broad CD4-binding site-directed neutralization.
223490149|NCT05918640|DRUG|Lurbinectedin|Lurbinectedin will be administered on a Day 1, Day 4 schedule every 21 days. Doses will be determined in the phase 1 portion of the trial.
223490150|NCT04092777|BEHAVIORAL|Strong Minds|The proposed intervention integrates cognitive behavioral therapy techniques combined with mindfulness exercises and promotion of behavioral activation through pleasant activities and developing supportive relationships. The intervention is led by CHWs and organized into 10 sessions, tailored to the participant using a collaborative approach, to improve mood symptoms, augment self-reported functioning, and increase self-reported quality of care among participants with moderate to severe symptoms of depression and/or anxiety. It is complemented by a care manager that links participant to services for needs related to social determinants of health (i.e. education, housing). The intervention has been tailored for delivery by CHWs in Spanish, Mandarin, Cantonese, and English.
223587612|NCT03332160|DEVICE|Flexitouch head and neck lymphedema treatment system|Pneumatic compression device cleared for use by medical professionals and patients who are under medical supervision, for the treatment of many conditions such as: lymphedema; primary lymphedema; post mastectomy edema; edema following trauma and sports injuries; post immobilization edema; venous insufficiency; reducing wound healing time; treatment and assistance in healing stasis dermatitis, venous stasis ulcers, or arterial and diabetic leg ulcers. The Flexitouch system and garments for head and neck are intended for use by medical professionals and patients who are under medical supervision for the treatment of head and neck lymphedema.
223587613|NCT03332160|OTHER|Standard home lymphedema care|May include daily self manual lymphatic drainage, exercise, skin care, compression garments (as appropriate).
223587614|NCT02315508|DRUG|AUT00063|800 mg orally, once a day, for 4 weeks
223587615|NCT02315508|DRUG|Placebo|orally, once a day, for 4 weeks
223587616|NCT06943404|DRUG|BXCL501 (dexmedetomidine HCl)|BXCL501 (dexmedetomidine HCl) taken sublingually (under the tongue) in the ED and at bedtime over 2 weeks.
223587617|NCT06943404|DRUG|Placebo|Placebo taken sublingually (under the tongue) in the ED and at bedtime over 2 weeks.
223587618|NCT03869333|BIOLOGICAL|Invaplex[AR-DETOX]|Detoxified Shigella flexneri 2a Artificial Invasin Complex (Invaplex\[AR-Detox\]) Vaccine
223587619|NCT03869333|OTHER|Placebo|Saline
223587620|NCT03286179|OTHER|modified HEART score and/or Emergency Department Assessment of Chest pain Risk Score (EDACS)|Provision of estimated risk for major cardiac events at 60 days based on the modified HEART and/or EDACS, using KPNC specific estimates derived from an internal validation study
223587621|NCT00438152|DRUG|Saquinavir (Invirase®)|Saquinavir 1000mg + Ritonavir 100mg Bd for 24 weeks
223587622|NCT00438152|DRUG|Lopinavir/ritonavir (Kaletra®)|Lopinavir/ritonavir 400/100 mg BD 24 weeks
223587623|NCT01927055|DRUG|Droxidopa|Droxidopa at 100 mg, 200 mg, 300 mg
224181141|NCT01026727|DRUG|3-4 commercially available antiretroviral drugs|For treatment arm #2: the antiretroviral regimen, dosage and frequency will be selected by the investigator.
224181142|NCT03782766|PROCEDURE|Piezocision|Piezocesion was performed by making 2 vertical incisions mesial and distal to the extraction space. Piezotome was inserted in the incisions previously made and bone cuts were done with a length up to mucogingival line and depth of 3 mm.
224181143|NCT04467866|BEHAVIORAL|A Ride-on Car with a Standing Posture|The 2-hour training session is composed of two 30-minute driving sessions and two 25-minute natural play sessions, with a 10-minute break. Every week's treatment program will be before planned and adjusted by the therapist and the caregivers through discussion and clinical observation of participant's performance in the previous session. Training will concentrate on building the concept of casual-effect on the switch and car motion, goal-oriented driving in a hospital, and upper limb use in functional tasks with driving and hand use in functional tasks for exploration in natural play session.
224181144|NCT04467866|BEHAVIORAL|Regular Therapy Program|The goals are to improve certain motor skills or psychosocial skills based on each participant's current developmental stage. The general propose of the training is to facilitate the developmental scales and improve mobility, socialization and upper limb use in functional tasks. Each participant will have the opportunity to walk on the hallway/public space and interact with the therapist and caregivers depending on his/her motor abilities.
223587624|NCT01927055|DRUG|Placebo|Placebo to match droxidopa capsules and strength designations
223587625|NCT03612050|BEHAVIORAL|Meaning Centered Psychotherapy|"Manualized, 3-session existential psychotherapy (30-45 minutes/session) with an optional 4th booster session. Content focuses on enhancing patients sense of meaning and purpose in life."
224181145|NCT04225104|BEHAVIORAL|Yogic breathing intervention|Yogic breathing will be completed while following a video provided by the investigative team. Breathing practices consist of slow, deep, relaxation breathing and are led by a certified yoga instructor.
224181146|NCT03846856|OTHER|Biopsy|Biopsy taken during surgical procedure
224307594|NCT04549714|PROCEDURE|High AI in paroxysmal atrial fibrillation|Patients with paroxysmal AF will receive pulmonary vein vestibule ablation with high AI value, the AI target value for the front wall and the top wall is 550, and the rear wall and the lower wall are 400.
223745435|NCT07190547|OTHER|Helfer skin tap|"Helfer Skin Tap Technique:~After determining the injection site, gently tap the skin several times with the fingertips of the dominant (most commonly used) hand for approximately 5 seconds to relax the muscle. After the skin is wiped with antiseptic solution and stretched, the cap of the syringe in the dominant (most commonly used) hand is opened. A large V is made with the thumb and index finger of the non-dominant hand. The skin is tapped three times quickly using the whole hand to stimulate the major muscle fibers. The nurse/midwife counts to 3, and the needle is inserted into the muscle at a 90-degree angle simultaneously. To remove the needle from the skin, the skin is tapped three times quickly (again in a V shape) with the whole non-dominant hand, and the needle is withdrawn simultaneously with the final tap (tapping)."
223745436|NCT07190651|OTHER|Home questionnaire|Administration of a questionnaire at each 28-days cycle, to select patients who need to access to hospital for clinical visit during treatment with CDK4/6i + hormone therapy for advanced breast cancer.
223745437|NCT07189819|DEVICE|Model-Predictive Controller (MPC) Functional Electrical Stimulation (FES)|The model-predictive controller (MPC) determines the timing and intensity of electrical stimulation delivered for FES. MPC combined with real-time ultrasound-based feedback delivers optimal FES intensities and minimizes fatigue. FES is delivered to the ankle dorsiflexor muscles using a commercially available FDA-approved electrical stimulator.
223745438|NCT07189819|DEVICE|Conventional Functional Electrical Stimulation (FES)|For functional electrical stimulation, surface electrodes are placed on the paretic leg on skin overlying the tibialis anterior (TA) muscle, with intensity pre-set to elicit dorsiflexion to neutral against gravity. FES will be delivered to the ankle dorsiflexor muscles using a commercially available FDA-approved electrical stimulator.
224181147|NCT04121637|OTHER|Aerobic Exercise|"Each exercise session;~* 5 min warm-up = 30% of VO2 max~* 20 min exercise = 50-60% of VO2 max~* 5 minutes cooling in the form. The goal of aerobic exercise is to increase physical capacity, which is represented by maximum oxygen uptake (VO2max) and mechanical power generated during exercise. Training programs should be conducted at least 2 to 3 times per week (60-80% maximum work rate or 60% VO2max) for 30 to 60 minutes at moderate concentrations. These programs are effective in increasing aerobic capacity and power output in MS."
224181148|NCT04121637|OTHER|Frenkel coordination exercises|Patients will be given Frenkel Coordination exercises (4 different exercises 4-5 repetitions depending on the individual's functional and motor status) 3 times a week for 6 weeks. 1 minute break between each exercise set
224181149|NCT04382209|PROCEDURE|Erector spinae plane block|The transducer was placed vertically 3cm lateral to the midline to visualize the muscles of the back, transverse process and the pleura in between the two transverse processes. Bilateral ultrasound guided erector spinae plane block with 20 mL of 0.375% bupivacaine each using an in-plane, cranial-to-caudad approach to contact the bony shadow of the transverse process (TP) with the tip deep to the fascial plane of the erector spinae muscle. The correct location of the needle tip was confirmed by injecting 0.5-1 cc of normal saline 0.9% and observing linear fluid spread lifting the erector spinae muscle off the tip of the TP.
224181150|NCT04382209|DEVICE|Intravenous meperidine patient controlled analgesia device|Intravenous meperidine patient controlled analgesia device will be given to the patients postoperatively and 24 hour meperidine consumption will be recorded
224307595|NCT04549714|PROCEDURE|Middle AI in paroxysmal atrial fibrillation|Patients with paroxysmal AF will receive pulmonary vein vestibule ablation with middle AI value, the AI target value for the front wall and the top wall is 500, and the rear wall and the lower wall are 350.
224307596|NCT04549714|PROCEDURE|Low AI in paroxysmal atrial fibrillation|Patients with paroxysmal AF will receive pulmonary vein vestibule ablation with low AI value, the AI target value for the front wall and the top wall is 450, and the rear wall and the lower wall are 300.
224307597|NCT00737750|DEVICE|Kneehab|Program of NMES 3 times per day, five days per week for 12 weeks.
224307598|NCT00737750|DEVICE|Poli-Stim|Poli-Stim is standard NMES which the patients used for 20 minutes, 3 times per day, 5 days per week for 12 weeks.
223490151|NCT04092777|OTHER|Enhanced Usual Care|Participants in this arm will receive a booklet about anxiety and depression in Spanish, English, or Mandarin/Cantonese. The Care Manager will call the participant 4 times over the course of 6 months to administer the PROMIS depression (8 item) and anxiety (7 item) short forms, a suicide questionnaire, and a question about medication side effects to mimic the administration schedule in the intervention group. With patient's permission, the care manager will inform the PCP about screening and other assessments and determine if participants should be referred to mental health or substance services and removed from control group given symptom severity.
223490152|NCT05706116|BIOLOGICAL|Trichuris trichiura Egg Inoculum|Trichuris trichiura Egg Inoculum that will be used in this study is manufactured by obtaining T. trichiura eggs from the feces of a chronically infected human volunteer, who is negative for HIV, HBV, and HCV. Fecal material is processed following a qualified standard procedure, and after isolating eggs, they are stored at 2-8oC until use. Controls for the manufacturing process are tests for viability (microscopy of larval hatching), species identification (PCR), and microbial bioburden of the eggs.
224307599|NCT00737750|BEHAVIORAL|Control|Voluntary quadriceps muscle contractions.
224307600|NCT01381250|BEHAVIORAL|cognitive behavior therapy|The treatment was based on established cognitive behavior therapy methods, as described in self-help books (Hodgins, 2002; Ladouceur \& Lachance, 2006). The text was divided into eight modules and was adapted for Internet use. The first four modules had a motivational interviewing focus and included building motivation for change by letting the participant answer open-ended questions that would evoke talk of change. The participants were encouraged to ask for input from their relatives on different aspects of their gambling. In addition, the first four modules included time line follow-back and mapping of the reasons for gambling. The remaining four modules were based on CBT. Each module included information and exercises and ended with three to eight essay-style questions. Feedback on homework assignments was usually given within 24 hr after participants had sent their answers via e-mail. Once weekly, a telephone call was made by the therapists to each participant.
224307601|NCT04269538|DRUG|PF-06480605|PF-06480605 150 mg and 450 mg SC dosing
224307602|NCT04269538|DRUG|Placebo|Placebo SC dosing
224307603|NCT01673438|DRUG|aldoxorubicin|
224181151|NCT00271362|BEHAVIORAL|Amputation rehabilitation exercise program|participants will be physically exercised with a full array of exercise methodologies.
224181152|NCT00271362|PROCEDURE|Osteomyoplasty vs. routine long posterior flap|participants enrolled randomly in one of two surgical procedures.
223490153|NCT06352606|DIAGNOSTIC_TEST|Spinal anesthesia|Oxygen supply will be done via nasal prong (2 L/min) when necessary. The local anesthetic used will be bupivacaine 0.6 mg/kg.
223490154|NCT06352606|DIAGNOSTIC_TEST|General anesthesia|Patients will receive sevoflurane for induction and maintenance in an air/oxygen mixture along. Endotracheal tube will be inserted. No opioids or nitrous oxide was used intraoperatively.
223490155|NCT05600920|DRUG|Recombinant human interleukin (IL) 7-hyFc|Structural Formula: NT-I7 is a fusion protein comprising human IL-7 fused to the human IgD hinge region. This in turn is fused to the N-terminal region of CH2 from IgD and two key regions of the antibody IgG4: C-terminal region of CH2 and the entire CH3 region. NT-I7 will be administered by IM injection once every 12 weeks for a total of 3 doses, with the final dose at week 24. In the absence of treatment delays due to AEs, a treatment course of 24 weeks will be pursued in all enrolled participants. The dose levels to be used in this study are 240, 480, and 720 microgram/kg. NT-I7 dosing will be determined using the weight recorded at the screening visit. The dose will be based on the participant s actual body weight, unless the participant has a BMI \>=30 kg/m2, in which case adjusted body weight will be used.
223490156|NCT06229704|DIAGNOSTIC_TEST|video Head Impulse Test|For v-HIT, the Synapsys v-HIT Ulmer device is used.
223490157|NCT06229704|DIAGNOSTIC_TEST|Cervical Vestibular Evoked Myogenic Potential|For cVEMP, the Eclipse (Interacoustic, Middelfart, Denmark) is used. To bypass the frequent middle ear problems bone conduction stimuli (B-81, Interacoustic, Middelfart, Denmark) are administrated. The bone conductor is placed on the mastoid process and two trials at 70 dB nHL are conducted to check waveform reproducibility. 500 Hz short tone bursts (2-2-2 ms) are applied at 5 per second stimulus repetition rate.
223490158|NCT06229704|DIAGNOSTIC_TEST|Ocular Vestibular Evoked Myogenic Potential|For oVEMP, the Eclipse (Interacoustic, Middelfart, Denmark) is used. To bypass the frequent middle ear problems bone conduction stimuli (B-81, Interacoustic, Middelfart, Denmark) are administrated. The bone conductor is placed on the mastoid process and two trials at 70 dB nHL are conducted to check waveform reproducibility. 500 Hz short tone bursts (2-2-2 ms) are applied at 5 per second stimulus repetition rate.
223490159|NCT06229704|DIAGNOSTIC_TEST|Computerized Dynamic Posturography|To evaluate functional balance of the children and the relative contributions of the vision, proprioception, and vestibular system a CDP from Virtualis (Virtualis, Montpellier, France) is used.
223587626|NCT03082352|DRUG|BF-Metoprolol Tablet 100mg|BF-Metoprolol Tablet 100mg is a generic product manufactured by Bright Future Pharmaceuticals Factory O/B Bright Future Pharmaceutical Laboratories Limited
223587627|NCT03082352|DRUG|Betaloc Tablet 100mg|Betaloc Tablet 100mg will be used as a comparator drug for the BE study
223587628|NCT00319241|BEHAVIORAL|Parenting Intervention|
223587629|NCT01915823|DRUG|azelastine hydrochloride and fluticasone propionate|
223587630|NCT01915823|DRUG|Dymista vehicle|
223587631|NCT00137189|PROCEDURE|Resource-oriented music therapy|
223587632|NCT00137189|PROCEDURE|Standard care|
223587633|NCT02713516|OTHER|Virtual Reality|Use of virtual reality to deliver exposure therapy
223587634|NCT03002454|DRUG|99mTc MDP Injection:neutron-bombardment|Technetium (99mTc) Medronate Injection USP labeled with 99mTc derived from neutron-activation-produced 99Mo.
223587635|NCT02495688|PROCEDURE|Regional anesthesia|Standard supraclavicular brachial plexus nerve block. Ultrasound-assisted. By an anesthesiologist. A mix of short- and medium lasting local anesthetics will be used.
223587636|NCT02495688|PROCEDURE|General anesthesia|Standard procedure.
223587637|NCT02574741|BEHAVIORAL|Behavioral Therapy|Thrice-weekly individually based language JAE-EMT intervention will be provided by a trained therapist and taught to the child and their caregivers. A total of 36 sessions will be provided over 12 weeks, with 2 per week at UCLA, and one session per week in the home.
223587638|NCT02574741|DRUG|Aripiprazole|50% of the subjects will be randomized to aripiprazole (active study medication)
223587639|NCT02574741|DRUG|Placebo|50% of the subjects will be randomized to placebo (inactive study medication).
223587640|NCT04316156|DEVICE|Uincare Homeplus|Interactive digital healthcare system
224181153|NCT03969589|BEHAVIORAL|Reproductive Life Planning-Mental Health (RLP-MH) Intervention|RLP-MH intervention is comprised of two parts: 1) an in-person interactive session in which the participant works with an RLP-MH facilitator to explore pregnancy intentions and RLP goals, consider important factors that impact those goals (e.g. mental health and physical health conditions, psychosocial and lifestyle factors, values, preferences), and identify personal action steps to address RLP goals and 2) a 15-20 minute follow-up session in person or by phone one month later to discuss progress in addressing RLP goals.
224181154|NCT03969589|OTHER|Written Materials on Reproductive Life Planning|Participants will receive written materials on reproductive life planning, contraception, and VA resources. Participants will be given the materials and study staff will briefly discuss the content with the participant.
223587641|NCT04316156|OTHER|Brochure|Brochure
223587642|NCT02900755|DRUG|Perampanel|The subjects will be administered oral perampanel for six months. Dose will be titrated according to the tolerance and be maintained at least 1 month before second EEG evaluation.
223587643|NCT04506515|DIAGNOSTIC_TEST|Psychological stress and adaptation at work score (PSAS)|completing a survey based on PSAS
223587644|NCT00000480|PROCEDURE|electrophysiology|
223587645|NCT00000480|DRUG|anti-arrhythmia agents|
223587646|NCT00000480|DEVICE|defibrillators, implantable|
223587647|NCT04276155|DRUG|non-systematic prescription of anticoagulant therapy|the prescription of anticoagulant is managed by an implantable device follow up
223587648|NCT00563043|PROCEDURE|PASCAL laser treatment|Patterns Scan Laser treatment in patients with PDR.
223587649|NCT03445390|DRUG|Acetaminophen|Acetaminophen 1 g intravenous given at the beginning and end of surgery.
224181155|NCT06183060|PROCEDURE|endotracheal intubation|all patients will receive laryngoscopy and endotracheal intubation
224181156|NCT02434250|PROCEDURE|Selective Laser Trabeculoplasty|Selective Laser Trabeculoplasty is a laser treatment procedure to enhance trabecular aequous humor outflow and thus decrease intraocular pressure.
224181157|NCT00517634|DRUG|FP|Fluticasone Propionate 100 mcg BD
224181158|NCT00517634|DRUG|SFC|Salmeterol/Fluticasone Propionate Combination 50/100 mcg BD
224181159|NCT00517634|DRUG|Placebo|Matching Placebo
224181160|NCT04543565|DRUG|Pradefovir Mesylate;Placebo of Tenofovir disoproxil fumarate tablet|Once daily
224181161|NCT04543565|DRUG|Tenofovir disoproxil fumarate tablet;Placebo of Pradefovir Mesylate|Once daily
224181162|NCT01172340|BEHAVIORAL|Behavioral and support intervention|Individual counseling session with diet and exercise recommendations, 16 weekly group sessions, 8 weeks of followup phone support
224181163|NCT01172340|BEHAVIORAL|Wait-listed control group|Controls receive the same individual counseling session as intervention group; receive mailed health information; are offered group sessions after last post-measure
224181164|NCT01551381|DRUG|EV-077|twice daily oral administration
224181165|NCT01551381|DRUG|Placebo|twice daily oral administration
224181166|NCT00052013|DRUG|PTK787/ZK 222584|
224181167|NCT04284033|DEVICE|Extended Wear Infusion Set|For two of the 4 weeks, the Extended Wear insulin infusion set will be used
224181168|NCT04284033|DEVICE|Standard Infusion Set|For two of the 4 weeks, the standard insulin infusion set will be used
224181169|NCT02936206|DRUG|Fulvestrant|fulvestrant 750 mg (three 5 ml injections slowly over 1-2 mn per injection in the buttocks) on day 1 only
224181170|NCT02936206|DRUG|Tamoxifen|14 days of treatment with tamoxifen 20mg orally each day
224181171|NCT03091920|DRUG|IW-1973|Oral Tablet
224181172|NCT03091920|DRUG|Placebo|Oral Tablet
224181173|NCT04686110|OTHER|angiographic optical coherence tomography|angiographic optical coherence tomography
224181174|NCT03143855|DRUG|Lorcaserin|Lorcaserin will be administered at a dose of 10 mg twice daily for 5 days
224181175|NCT03143855|DRUG|Placebo|Placebo will be administered twice daily for for 5 days
224181176|NCT02136719|PROCEDURE|bimanual uterine compression|bimanual uterine compression immediately after delivery of placenta for 5 minutes
224307604|NCT02037035|DRUG|Ketamine|
224307605|NCT02003521|DEVICE|Lung Flute|A low frequency wave is generated at the mouth by exhaling through a mouthpiece over a laminar surface (Reed) inside the Lung Flute®. The resulting low frequency acoustic wave that is produced travels retrograde into the lower airways and lung parenchyma and increases mucociliary clearance. Patients expel air with the force required to blow out a single candle. Patients concentrate on producing a low tone through the device while breathing in a proscribed pattern. Twenty repetitions of a single two-breath pattern are performed with the device to complete a diagnostic session.
223587650|NCT03445390|DRUG|Placebo|Placebo to match acetaminophen given at the beginning and end of surgery.
223587651|NCT01472211|DEVICE|zinc enriching filter (LifeStrawFamily)|filter purifies water and enriches it with zinc at 1-4 mg/l.
223587652|NCT01472211|DEVICE|placebo filter|filter purifies water
223587653|NCT01472211|OTHER|disinfection tablets|government promoted tablets disinfect water
223587654|NCT06423560|RADIATION|Computed tomography|Follow-up computed tomography at 3-6 months and 12 months
224181177|NCT03373006|DRUG|Axumin PET/CT|Synthetic amino acid uptake agent injection followed by imaging
224181178|NCT02751606|DRUG|ferumoxtran-10|ferumoxtran-10 will be administered intravenously one day prior to the MRI scan
224181179|NCT02751606|DEVICE|7 Tesla MRI|Subjects undergo a 7 Tesla MRI scan
224181180|NCT02751606|DEVICE|3 Tesla MRI|Subjects undergo a 3 Tesla MRI scan
224181181|NCT05288049|BEHAVIORAL|Enhancing cognitive reserve|The CR enhancement protocol consists of 12 weekly sessions in a group format with audiovisual and technological devices support. All sessions are held separately for parents and children, adolescents and young adults. All material is adapted to different ranges of age. This same protocol will be adapted for patients with a first affective or non-affective episode. Two sessions are about to promote healthy lifestyle by implementing healthy habits, two more sessions about training and practice mindfulness with virtual reality devices, two sessions about improving leisure-time activities, focused on promoting of intellectual and/or cultural activities as leisure time as well as physical exercise, the rest of sessions are about to promote vocational and educational activities, metacognition, social skills, problem-solving techniques and how to detect and act on warning signs, a brief psychoeducative session about the main early warning signs of general psychopathology.
224181182|NCT05288049|BEHAVIORAL|Support therapy|The support control group will have weekly meetings with assistants to talk about the difficulties they had during the week, without receiving a specific intervention.
224181183|NCT00453349|DRUG|Moxifloxacin (Avelox, BAY12-8039)|Moxifloxacin (Avelox, BAY12-8039) 400 mg by mouth (PO) once daily for 14 days
224181184|NCT00453349|DRUG|Levofloxacin & Metronidazole|Levofloxacin 500 mg by mouth (PO) once daily for 14 days plus Metronidazole 500 mg (PO) twice daily for 14 days
224181185|NCT06345287|RADIATION|radical radiotherapy (60Gy)|concurrent chemoradiotherapy (60Gy) after induction therapy
224181186|NCT06345287|RADIATION|radical radiotherapy (66Gy)|concurrent chemoradiotherapy (66Gy) after induction therapy
224181187|NCT06345287|RADIATION|radical radiotherapy (70Gy)|concurrent chemoradiotherapy (70Gy) after induction therapy
224181188|NCT06345287|COMBINATION_PRODUCT|anti-PD-1 or PD-L1 antibody|immunotherapy maintenance with anti-PD-1 or PDL1antibody every three weeks for 1 year after radiotherapy
224181189|NCT05657379|OTHER|Other: Product X moisturizer|Product X moisturizer containing Hyaluronic Acid and Rosa Damascena Flower Water
224181190|NCT03066687|DRUG|Erdafitinib|Erdafitinib 9 mg (provided as one 4-mg tablet \[G-024\] and one 5-mg tablet \[G-025\]) will be administered orally on Day 1 in each Treatment Period of assigned sequence.
224181191|NCT03775733|DIETARY_SUPPLEMENT|Hydrolysed Red Ginseng Extract|Hydrolysed Red Ginseng Extract 2.4g/day for 12 weeks.
224181192|NCT03775733|DIETARY_SUPPLEMENT|Placebo|Placebo for 12 weeks.
224181193|NCT00056628|DEVICE|The COGNIShunt® System|
224181194|NCT04832633|DIAGNOSTIC_TEST|Different contrast media injection methods|Different contrast media injection methods
224181195|NCT03637504|BEHAVIORAL|MedActionPlan®|web-based, mobile medication management application \[MedActionPlan® (MAP)\]
224181196|NCT00381810|DRUG|Rituximab|Rituximab will be supplied as a liquid for intravenous infusion.
224181197|NCT00381810|DRUG|Methylprednisolone|
224181198|NCT00381810|DRUG|Acetaminophen|
224181199|NCT00381810|DRUG|Diphenhydramine|
224181200|NCT03778281|DRUG|Baclofen|Oral baclofen 10mg, 3 times a day for three days, then evaluate the efficacy and side effects
224181201|NCT03778281|DRUG|Methoxyclopramide|Intramuscular injection of metoclopramide 10mg, 3 times a day for three days, then evaluate the efficacy and side effects
224181202|NCT01105429|DRUG|BMS-820132|Oral Solution, Oral, 0.3 mg, once daily, 1 day
224181203|NCT01105429|DRUG|BMS-820132|Oral Solution, Oral, 1.0 mg, once daily, 1 day
224181204|NCT01105429|DRUG|BMS-820132|Oral Solution, Oral, 3 mg, once daily, 1 day
224181205|NCT01105429|DRUG|BMS-820132|Oral Solution, Oral, 10 mg, once daily, 1 day
224181206|NCT01105429|DRUG|BMS-820132|Oral Solution, Oral, 30 mg, once daily, 1 day
224181207|NCT01105429|DRUG|BMS-820132|Oral Solution, Oral , 75 mg, once daily, 1 day
224181208|NCT01105429|DRUG|BMS-820132|Oral Solution, Oral, 150 mg, once daily, 1 day
224307606|NCT00918138|DRUG|Saxagliptin|Tablets, Oral, 5 mg, once daily, 4 weeks
224307607|NCT00918138|DRUG|Metformin XR|Tablets, Oral, 1500 mg, once daily, 4 weeks
224181209|NCT01105429|DRUG|BMS-820132|Oral Solution, Oral, 300 mg, once daily, 1 day
224181210|NCT01105429|DRUG|BMS-820132|Capsule, Oral, (TBD), once daily, 2 days
224181211|NCT01105429|DRUG|Placebo|Oral Solution, Oral, 0mg, once daily, 1 day
224181212|NCT01105429|DRUG|Placebo|Capsule, Oral, (TBD), once daily, 2 days
224307608|NCT00918138|DRUG|Placebo matching Metformin XR|Tablets, Oral, 0 mg, once daily, 4 weeks
224307609|NCT00918138|DRUG|Metformin XR|Tablets, Oral, 500 mg, once daily, 4 weeks
224181213|NCT01513460|DRUG|NVA237 50µg once daily|NVA237 50 μg o.d., delivered via single-dose dry-powder inhaler (SDDPI)
224181214|NCT01513460|DRUG|Tiotropium 18µg once daily|Tiotropium 18 μg o.d. delivered via a proprietary inhalation device
224181215|NCT01513460|DRUG|Flu/Sal|Flu/Sal 500/50 μg b.i.d. delivered via a proprietary inhalation device
224181216|NCT01513460|DRUG|NVA237 placebo + Tiotropium placebo.|Tiotropium 18 μg o.d. delivered via a proprietary inhalation device
224181217|NCT00367380|OTHER|413ABM|+/- 3 bites of Anopheles albimanus mosquitoes infected through membrane feeding with blood of the P. vivax infected volunteers 413ABM
224181218|NCT00367380|OTHER|414WRR|+/- 3 bites of Anopheles albimanus mosquitoes infected through membrane feeding with blood of the P. vivax infected volunteers 414WRR
224181219|NCT00367380|OTHER|418JAL|+/- 3 bites of Anopheles albimanus mosquitoes infected through membrane feeding with blood of the P. vivax infected volunteers 418JAL
224181220|NCT03757026|OTHER|Conventional Physical Therapy|"20-22 participants randomly assigned to receive 10 sessions of balance training. Conventional balance training group (PT) will receive individualized standard of care physical therapy with the goal of improving balance and mobility during sessions 3 through 12. The only instructions to the PT are that the focus of the course of care should be on balance and mobility and that there should be 10 sessions total. The first visit will include an initial evaluation and limited treatment. While the remaining 9 sessions will consist of 45 minutes of PT treatment."
224181221|NCT03757026|OTHER|Slip Training|20-22 participants randomly assigned to 1 session of slip training and 9 sessions of accompanied walking. Reactive slip training group (Slip) will complete a standing slip session using the current protocol of scaling slip distance and force to each individual and modulating the slip intensity across the session based on subject responses. Initial perturbation intensity (percent body weight and slip distance) will be based on the participant's miniBEST score and each subsequent perturbation intensity will be determined based on their response to the previous perturbations. The remaining nine interventional sessions will consist of accompanied walking for up to 45 minutes. Participants will walk at a comfortable pace while accompanied by a researcher around Cleveland State.
224181222|NCT03757026|OTHER|Harnessed gaming|20-22 participants randomly assigned to 10 sessions of harnessed gaming. Multidirectional harness group (MHG) will use a harness with the multidirectional OASUS frame and play selected Kinect™ active video games with varied balance demands, while standing on multiple balance training surfaces (e.g., solid floor, rocker board, foam, slider platform). Participants will wear the fall-arresting harness in the OASUS system for all game play. Motion data will be collected during gaming for Sessions 2, 6, and 10. Each game/surface will be played for about 5 to 6 minutes for 4 game/surface conditions per session. All participants will progress with the prescribed sequence of games and surfaces, progressing based on their rating of the previous three bouts of play.
224181223|NCT04880148|DIETARY_SUPPLEMENT|Thyme and Honey-based oral spray|4 X Sprays in the oral cavity before, immediately after and 6 hours following the radiotherapy session
224307610|NCT00918138|DRUG|Placebo matching Saxagliptin|Tablets, Oral, 0 mg, once daily, 4 weeks
224181224|NCT04880148|DIETARY_SUPPLEMENT|Placebo oral spray|4 X Sprays in the oral cavity before, immediately after and 6 hours following the radiotherapy session
224181225|NCT02731924|PROCEDURE|Ultrasound for Appendicitis|Point-of-care ultrasound to evaluate emergency department patients for suspected appendicitis
224181226|NCT00489216|BIOLOGICAL|efalizumab|"Efalizumab will be administered as a subcutaneous injection once a week for 8 weeks (total of 8 doses). First efalizumab injection will be dosed at 0.7mg/kg. Subsequent weekly injections given on days 8-50 will be dosed at~1mg/kg"
224181227|NCT03479424|OTHER|Observational|The MYIA in-home suite of devices.
224307611|NCT03568279|PROCEDURE|Two-handed jaw thrust|The assistant applied two-handed jaw thrust for intubation.
224307612|NCT03568279|PROCEDURE|Control|The intubation was done without two-handed jaw thrust.
224307613|NCT03653117|DEVICE|Transperineal laser ablation|Minimal invasive coagulation of prostatic tissue by laser
224307614|NCT05500118|OTHER|Patients Decision Aids|Patient Decision Aids (PDAs) are an important way to facilitate making decision by patients, helping patients make specific and prudent choices by providing information about treatment options and corresponding outcomes, including benefits and risks, related to their health status. The purpose of PDAs is to encourage patients to participate in decision-making. It makes it easier for patients and doctors to discuss treatment options. It effectively promotes communication between patients and doctors. It can help patients combine their own needs and professional advice to make better, more individualized diagnosis and treatment options.
224307615|NCT00457899|DRUG|Quetiapine IR (Immediate Release)|oral
223587655|NCT00584129|OTHER|Pre-treatment swallowing exercises|Swallowing exercises will be started pre-treatment with radiation.
224181228|NCT01283724|DRUG|Dienogest (Visanne, BAY86-5258)|Subjects received Dienogest tablet orally at a dosage of 2 mg once daily over a period of 52 weeks.
224181229|NCT01539616|DRUG|ZYH7|ZYH7 4mg given once orally in the morning before breakfast, for 8 weeks.
224181230|NCT01539616|DRUG|ZYH7|ZYH7 8 mg given once orally in the morning before breakfast, for 8 weeks.
224181231|NCT01539616|DRUG|ZYH7|ZYH7 16 mg given once orally in the morning before breakfast, for 8 weeks.
224181232|NCT01539616|DRUG|Fenofibrate|Fenofibrate 160 mg given once orally in the morning before breakfast, for 8 weeks.
224181233|NCT03944096|PROCEDURE|FMT+MTX|FMT is performed at the beginning of the study and is repeated after 4 weeks plus MTX in the same dose.
224181234|NCT04005924|OTHER|arabinogalactan|Arabinogalactan will be mixed into sugar-free blackberry jam and consumed with the provided bread.
224181235|NCT04443855|BEHAVIORAL|Water quality|"Hardware: Free supplies chlorine tablets (Aquatabs; NaDCC) and a safe storage vessel to treat and store drinking water.~Promotion: Local promoters will visit study compounds at least monthly to deliver behavior change messages that focus on the treatment of all drinking water for children \< 36 months of age."
224181236|NCT04443855|BEHAVIORAL|Sanitation|Hardware: Free child potties, sani-scoop hoes to remove feces from household environments, latrine upgrades to a dual pit latrine Promotion: Local promoters will visit study compounds at least monthly to deliver behavior change messages that focus on the use of latrines for defecation and the removal of human and animal feces from the compound.
224181237|NCT04443855|BEHAVIORAL|Hand washing|"Hardware: Hand washing stations, soapy water bottles located at hand washing locations, detergent soap to supply soapy water bottles.~Promotion: Local promoters will visit study compounds at least monthly to deliver behavior change messages that focus on hand washing with soap at critical times around food preparation, defecation, and contact with feces."
224181238|NCT04443855|BEHAVIORAL|Water quality, Sanitation, Hand washing (Combined WASH)|"Hardware: Free supplies Aquatabs; (NaDCC) and a safe storage vessel to treat and store drinking water. Promotion: Local promoters will visit study compounds at least monthly to deliver behavior change messages that focus on the treatment of drinking water for children \< 36 months.~Hardware: Free child potties, sani-scoop hoes to remove feces from household environments, latrine upgrades to a dual pit latrine. Promotion: Local promoters will visit study compounds at least monthly to deliver behavior change messages that focus on the use of latrines for defecation and the removal of human and animal feces from the compound.~Hardware: Hand washing stations, soapy water bottles, detergent soap to supply soapy water bottles. Promotion: Local promoters will visit study compounds at least monthly to deliver behavior change messages that focus on hand washing with soap at critical times as food preparation, defecation, and contact with feces."
224181239|NCT04443855|BEHAVIORAL|Nutrition|"Supplement: Lipid-based Nutrient Supplement (LNS) delivered daily from ages 6 to 24 months.~Promotion: Local promoters will visit study compounds at least monthly to deliver behavior change messages modeled on those recommended in the Guiding Principles for Complementary Feeding of the Breastfed Child and the recent UNICEF Program Guide for Infant and Young Child Feeding Practices.General messages will include (1) practice exclusive breastfeeding from birth to 6 months of age and introduce complementary foods at 6 months of age while continuing to breastfeed; (2) continue breast feeding as you did before receiving LNS; (3) provide your child micronutrient-rich foods such as meat, fish, eggs, and vitamin A rich fruits and vegetables; and (4) feed your child at least 2-3 times per day when 6-8 months old and 3-4 times per day when 9-24 months old."
224181240|NCT04443855|BEHAVIORAL|Nutrition, Water quality, Sanitation, Hand washing|Each of the interventions described above for Water Quality, Sanitation \& Hand washing (Combined WASH) Plus the intervention described above for nutrition.
224181241|NCT02046213|DRUG|E2006|Single oral 10mg dose of 100 uCi \[14C\]E2006
224181242|NCT03573921|DRUG|Gastrograﬁn|Patients will receive a single dose of Gastrografin via the nasogastric tube at 24 hours after hospital admission. After receiving Gastrografin, patients will receive the same standard non-surgical management that patients outside of the trial receive.
224181243|NCT03573921|OTHER|Saline solution (control treatment)|Patients will receive a single dose of saline solution via the nasogastric tube at 24 hours after hospital admission. After receiving saline solution, patients will receive the same standard non-surgical management that patients outside of the trial receive.
224181244|NCT00405795|DEVICE|Envision® Patient Support System|
224307616|NCT06048432|OTHER|Conventional Physiotherapy + telephysiotherapty|Patients assigned to the telephyisiotherapy (TP) group will carry out a half-hour session of conventional therapy, plus a 1-hour session of physical exercise, which will be carried out through the administration of tutorial videos, telephone instructions or by email.
223587656|NCT00584129|OTHER|Post-treatment swallowing exercises.|Patients to start swallowing exercises after completion of radiation therapy.
223587657|NCT03214731|DRUG|Artesunate|Artesunate was produced by pharmaceutical factory for research specifically
224181245|NCT01248923|DRUG|ARRY-520, KSP(Eg5) inhibitor; intravenous|Part 1: multiple dose, escalating; Part 2: multiple dose, single schedule.
224307617|NCT02592083|DRUG|Tamoxifen or Aromatase Inhibitor or Aromatase Inhibitor + goserelin|
224307618|NCT02592083|DRUG|Palbociclib|
224307619|NCT05033093|DRUG|Root Canal Sealants|it is planned to conduct the research described below, on the effect of calcium silicate-based (iRoot SP), silicone-based (GuttaFlow Bioseal) and rezin-based (AH Plus) sealer on postoperative pain
223587658|NCT03214731|OTHER|placebo|placebo was produced by pharmaceutical factory for research specifically
223587659|NCT00240604|DRUG|Rosiglitazone|4 mg rosiglitazone per day
223587660|NCT00431119|DRUG|Azathioprine or Mycophenolate mofetil|
223587661|NCT00120328|DRUG|SPP301|
223587662|NCT03951090|OTHER|Results of the brief geriatric assessment|Providers will receive results of the brief geriatric assessment with recommendations for address deficits identified through the results of the brief geriatric assessment
223587663|NCT03951090|OTHER|No results of brief geriatric assessments|Providers will not receive results of the brief geriatric assessment. Participants will receive standard of care treatment
224307620|NCT00699374|DRUG|sunitinib malate|sunitinib capsules at starting dose of 37.5 mg PO daily, until disease progression, occurrence of unacceptable toxicity, or other withdrawal criteria are met. Sunitinib dosing interruptions and/or reductions are allowed based on patient tolerability.
223587664|NCT06412952|DRUG|68Ga-RM26|Intravenous injection of one dosage of 74-185 MBq(2-5 mCi) 68Ga-RM26. Tracer doses of 68Ga- RM26 will be used to image lesions of glioma by PET/CT.
224181246|NCT01248923|DRUG|Bortezomib, proteasome inhibitor; intravenous or subcutaneous|Part 1: standard of care; Part 2: standard of care determined in Part 1.
224181247|NCT01248923|DRUG|Dexamethasone, steroid; oral|Part 1: standard of care; Part 2: standard of care determined in Part 1.
224181248|NCT01248923|DRUG|Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous|Part 1: standard of care; Part 2: standard of care.
224181249|NCT01248923|DRUG|ARRY-520, KSP(Eg5) inhibitor; intravenous|Part 1: multiple dose, escalating
224181250|NCT01248923|DRUG|Bortezomib, proteasome inhibitor; intravenous or subcutaneous|Part 1: standard of care
224181251|NCT01248923|DRUG|Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous|Part 1: standard of care
224181252|NCT03218943|DEVICE|APRV ventilation mode|They will start on APRV mode with high pressure (Phi) 20 cmH2O , low pressure(Plo) 5 cmH2O with I:E ratio ( Phi phase: Plo phase ratio ) 4:1 for 3 hours
224307621|NCT00699374|DRUG|sorafenib|sorafenib tablets at starting dose of 400 mg PO twice daily, until disease progression, occurrence of unacceptable toxicity, or other withdrawal criteria are met. Sorafenib dosing interruptions and/or reductions are allowed based on patient tolerability.
224307622|NCT05973266|BEHAVIORAL|Mobile Application-Based Bowel Preparation Training|The contents of the training in the mobile application where the patients receive bowel preparation training before the procedure are; short videos, images and slides about colonoscopy, bowel preparation drugs, liquid-clear diet and foods recommendations.A mobile application-based training will be provided to guide patients, where user (patient) usage activities are monitored by the researcher, sending notifications or reminders to the patient in accordance with the colonoscopy procedure date.
224307623|NCT00196625|DRUG|Amprenavir (drug)|
224307624|NCT00196625|DRUG|ABT-378/r (drug)|
224307625|NCT00196625|DRUG|Ritonavir (drug)|
224307626|NCT02043587|DRUG|DNR|Daunorubicin 60 mg/m2 IV (in the vein) daily 1,2,3 Courses 1A, 2A
224307627|NCT02043587|DRUG|VCR|1.4 mg/m2 IV, days 1, 8, 15, 22 (cap at 2mg for ages \>50) during Courses 1A, 2A; Maintenance: Day 1 during months 2-12
224307628|NCT02043587|DRUG|PEG-asp|2,000 IU/m2 IV for ages \</= 50, age \> 50, 1000 IU/m2 IV Day 16, Courses 1A \& 2A; Day 18, Course 1B; Day 17, Course 2B; Day 16, Maintenance, Month 1
224307629|NCT02043587|DRUG|CTX|750 mg/m2 IV, days 1 \&15 for subjects \<40 year of age, substitute cyclophosphamide 500 mg/m2 IV over 60 minutes every 12 hours for 4 doses on days 15 \& 16 for subjects \< 40 years of age if day 14 bone marrow M2 or M3; Courses 1A \& 2A
224307630|NCT02043587|DRUG|Prednisone|60 mg/m2 orally once daily on days 1-28 during Courses 1A \& 2A; Maintenance: Monthly, days 1-5
224307631|NCT02043587|DRUG|Liposomal AraC|25 mg intrathecal (IT), on days 1 \& 15 during Courses 1A \& 2A; 50 mg intrathecal on day 1 during Maintenance Months 1 through 4
224307632|NCT02043587|DRUG|MTX|220 mg/m2 IV bolus over 15 minutes then 60 mg/m2/hour for 36 hours once on days 2-3 and 16-17 during Courses 1B \& 2B; 20 mg/m2 orally one day per week every 7 days during Maintenance Months
223587665|NCT01261169|DRUG|Myfortic|Myfortic in uveitis
223587666|NCT02349490|DEVICE|Seraseal / Fastact Hemostatic agent (combined activated factors IIa, VIIa, IXa, Xa )|Following endoscopic confirmation of a bleeding, 2,5-5ml of liquid Seraseal / Fastact, is topically applied to the bleeding site via catheter
223745440|NCT07191301|BEHAVIORAL|Functional Strength Training, Kinesio Taping, and Proprioceptive Neuromuscular Facilitation|Participants will undergo 8 weeks of supervised treatment, 3 sessions per week (24 sessions). Each session includes a warm-up with stretches, range-of-motion exercises, and Functional Strength Training (mini hops, stair climbing, ramp walking, sit-to-stand). Kinesio Taping will be applied from the foot's dorsum along the tibialis anterior and peroneus longus with 25-50% stretch for ankle support and dorsiflexor facilitation, re-applied every 3-4 days. In addition, Proprioceptive Neuromuscular Facilitation (PNF) lower-limb D1 flexion/extension patterns with manual resistance will be performed in 3 sets of 5 repetitions, lasting 35-40 minutes per session.
224307633|NCT02043587|DRUG|LCV|50 mg/m2 IV over 15-30 minutes every 6 hours for 3 doses to begin immediately after completion of methotrexate infusion, then 10 mg/m2 orally or IV over 15-30 minutes every 6 hours until methotrexate level less than 0.1 micromolar during Courses 1B \& 2B
224307634|NCT02043587|DRUG|AraC|2,000 mg/m2 IV, days 1-4 during Courses 1C \& 2C
224307635|NCT02043587|DRUG|Etoposide|500 mg/m2 IV over 3 hours once daily on days 1-4 during Courses 1C \& 2C
224307636|NCT02043587|DRUG|Dasatinib|140 mg orally daily if BCR/ABL positive and/or Ph+
224181253|NCT03218943|DEVICE|BIPAP ventilation moood|start on BiPAP mode with high pressure (Phi) 20 cmH2O , low pressure(Plo) 5 cmH2O with I:E ratio ( Phi phase: Plo phase ratio ) 1:1 for 3 hours
224181254|NCT03555227|PROCEDURE|USG PECS2 with Drug A (active)|Ultrasound guided Pecs 2 blocks with 0.25% levobupivacaine
224181255|NCT03555227|PROCEDURE|USG PECS2 with Drug P (placebo)|Ultrasound guided Pecs 2 blocks with placebo (0.9% saline)
224181256|NCT03555227|PROCEDURE|Wound infiltration with Drug P (placebo)|Wound infiltration at the end of surgery with Drug P (0.9% saline)
224181257|NCT03555227|PROCEDURE|Wound infiltration with Drug A (active)|Wound infiltration at the end of surgery with 0.25% levobupivacaine
224181258|NCT05870397|DIAGNOSTIC_TEST|HY-IREXB plus carbon 13 breath detector do the breath urea test after eradication at different times|Carbon 13 breath tests are generally performed 4-6 weeks after eradication therapy. The control group will perform breath urea test at 4-6 weeks after treatment. The experimental groups will perform the same test at different times after the same treatment, 6-8weeks and 8-10 weeks, respectively.
224181259|NCT02261402|OTHER|Medisinstart|"Medisinstart is a newly developed pharmacy service for patients about to start a new medicine for a chronic or long-term condition. It consists of two follow-up consultations with a pharmacist. The first at 1-2 weeks and the second at 3-5 weeks after start of the new medicine."
224181260|NCT00939094|DRUG|AZD2066|Capsule, once daily
224181261|NCT00939094|DRUG|Placebo|Capsule, once daily
224307637|NCT02043587|DRUG|Rituximab|375 mg/m2 IV once daily on days 1 \& 15 (precursor B-cell ALL only, administer per institutional protocol) during Courses 1A, 1B, 1C \& 2A
224307638|NCT02043587|DRUG|Hydrocortisone|Randomize patients proceeding to Course 1B to hydrocortisone versus placebo prior to PEG-asparaginase treatments in Courses 1B, 2B, 3B, and Maintenance month 1
224181262|NCT01906489|DRUG|AKB-6548|Oral dose administered once daily for 20 weeks. Dose adjustment based on hemoglobin level as defined in the protocol.
224181263|NCT01906489|DRUG|Placebo|Oral Placebo administered once daily for 20 weeks. Dose adjustment based on hemoglobin level as defined in the protocol.
224181264|NCT02556346|DRUG|MT-3724|Intravenous dosing M-W-F X 2 weeks; MT-3724 infusion over 2 hours on each dosing day over 4 week initial cycle and then 3 week repeat cycles for up to 5 total cycles.
224181265|NCT02556346|DRUG|MT-3724|Intravenous dosing M-W-F X 2 weeks; MT-3724 infusion over 2 hours on each dosing day over 4 week initial cycle and then 3 week repeat cycles for up to 5 total cycles.
224181266|NCT02556346|DRUG|MT-3724|Intravenous dosing M-W-F X 2 weeks; MT-3724 infusion over 2 hours on each dosing day over 4 week initial cycle and then 3 week repeat cycles for up to 5 total cycles.
224181267|NCT02556346|DRUG|MT-3724|Intravenous dosing M-W-F X 2 weeks; MT-3724 infusion over 2 hours on each dosing day over 4 week initial cycle and then 3 week repeat cycles for up to 5 total cycles.
224181268|NCT02556346|DRUG|MT-3724|Intravenous dosing M-W-F X 2 weeks; MT-3724 infusion over 2 hours on each dosing day over 4 week initial cycle and then 3 week repeat cycles for up to 5 total cycles.
224181269|NCT00518739|DRUG|MK2461|Patients will be administered oral MK2461 twice daily and will be treated for 28 day cycles. Patients will be enrolled in cohorts and will be treated at sequentially rising dose levels of MK2461. 60 mg dry filled capsules, escalating to 240 mg ( for dosing in Cohort 4 \& beyond).
224181270|NCT02303730|DRUG|Exenatide|The starting dose of exenatide is 5 ug bid, subcutaneously, for 4 weeks, followed by 10 ug bid, subcutaneously, for 20 weeks. If hypoglycaemia (blood glucose\<2.9 mmol/l or \< 3.9 mmol/l at least 2 times) or serious intolerance occurs, the dose will be adjusted to 5 ug bid, subcutaneously.
223490160|NCT06229704|OTHER|Dizziness Handicap Inventory for patient caregivers|DHI is a caregiver-reported 21- item questionnaire. It is designed to evaluate the perceived quality of life and handicap resulting from dizziness and unsteadiness for the pediatric population. For each question there are three possible answers: yes, sometimes or no. Each answer provides respectively 4, 2 and 0 points. The total DHI scores range from 0 to 84 with higher score being consistent with more limitation and more severe handicap. Scores under 16 are characterized as no limitation or handicap. A score from 16-26 present a mild perceived handicap and mild limitations. A DHI-score between 26-43 is classified as a moderate problem, and a score above 43 describes a severe perceived handicap and severe limitations.
224181271|NCT02303730|DRUG|insulin glargine|"The starting dose of insulin glargine will depend upon the HbA1c level at screening(HbA1c \<8% use 0.1 -0.2 U/kg per day;HbA1c \>8% use 0.2 -0.3 U/kg per day).~Dose adjustment protocol for insulin glargine (at least 3 determinations of fasting blood glucose per week):~fasting blood glucose(FBG) \> 180 mg/dL(10 mmol/l): add 4 U; FBG 140-180 mg/dL(7.8-10 mmol/l): add 2 U; FBG 126-139 mg/dL(7.0-7.8 mmol/l): add 1 U.~If hypoglycemia, reduce insulin glargine by:~blood glucose \<70mg/dl（3.9mmol/l）: 10%-20%; blood glucose \<40mg/dl（2.2mmol/l）: 20%-40%."
224181272|NCT00004654|DRUG|soy protein isolate|
224181273|NCT04202029|DEVICE|thoracic impedance monitoring|Thoracic impedance measurement identifies the respiratory frequence using the changes of impedance during inspiration and expiration via an ECG.
224181274|NCT04202029|DEVICE|pulseoxymetry|Pulseoxymetry is meassuring the heart rate and the oxygen saturation in the arterial blood
224181275|NCT04202029|DEVICE|non-invasive blood preassure monitoring|Non-invasive blood preassure is a method using a blood preassure cuff to identify the blood preassure.
224181276|NCT04606862|DEVICE|Morley Medical Sepsis Software Device|The Morley Medical Sepsis (MMS) Software Device is a predictive analytics, stand-alone, cloud-based software system with no hardware components. The software acquires patient data from the electronic medical record, processes the data using unique artificial intelligence (AI) powered algorithms, and generates clinical decision support outputs that aid in the proactive delivery of customized and efficient care for patients. The software output is made available to the end users (trained medical professionals) via an intuitive user interface displayed on desktop computers or mobile communication devices such as laptops, smartphones or tablets.
224181277|NCT06098976|DEVICE|Water Jet|The water jet works by directing a stream of water towards the gap between your teeth. The stream of water helps to loosen and remove plaque and food particles stuck in this area.
224181278|NCT06098976|DEVICE|Manual toothbrush|Manual toothbrush: The patients were taught to use the modified vertical method, and the patient brushed the teeth of the upper and lower jaws using traditional toothbrushes (Diamond, JolleyDent, Damascus, Syria), and anti-plaque toothpaste (Elgydium, UniPharma Co., Ltd, Ashrafiyat Sahnaya, Syria).
224181279|NCT05981560|OTHER|Group A - Closed Chain Exercise|17 participants were in experimental group giving them closed chain exercise plan of 5 exercises, 10reps x 3sets each, on alternate 3 days per week for duration of 4-weeks, all values measured before and after 4-weeks
224181280|NCT05981560|OTHER|Group B - Neuromuscular Training Exercise|17 participants were in experimental group giving them neuromuscular training plan of 5 exercises, 10reps x 3sets each, on alternate 3 days per week for duration of 4-weeks, all values measured before and after 4-weeks.
224181281|NCT01503229|DRUG|Abiraterone Acetate|Given by mouth
224181282|NCT01503229|OTHER|Laboratory Biomarker Analysis|Correlative studies
224181283|NCT01503229|OTHER|Pharmacological Study|Correlative studies
224181284|NCT01503229|DRUG|Prednisone|Given PO
224181285|NCT04357431|OTHER|self-administered questionnaire|Data will be collected using Google online self-administered questionnaire disseminated in Arabic language
224181286|NCT02101216|DRUG|Prurisol|Experimental Drug
224181287|NCT02101216|DRUG|Ziagen|Active comparator
224181288|NCT02812823|DEVICE|High-resolution anorectal manometry|Recording of conventional manometric parameters after insertion of the catheters.
224181289|NCT05494047|DRUG|Tetravalent influenza vaccine developed by Sinovac Biotech Co.|15μg Hemagglutinin Antigen (HA) of each of the four strains
224181290|NCT00133276|DRUG|Escitalopram|OD 5mg for 2 weeks; OD 10mg for 24 weeks; OD 5mg for 2 weeks
224181291|NCT00133276|OTHER|Placebo|
224181292|NCT00136994|DRUG|Ziprasidone|
224181293|NCT04296331|DIAGNOSTIC_TEST|POC|DC DOC's current testing practice offers opt-out POC testing with the INSTI® finger stick test at entry
224181294|NCT04296331|DIAGNOSTIC_TEST|Ag/Ab|The DC DOC will transition from offering their current POC testing upon entry to offering opt-out HIV testing with Ag/Ab: ARCHITECT® laboratory-based test.
224181295|NCT04296331|DIAGNOSTIC_TEST|POC + Ag/Ab|As the DC DOC transitions to utilizing the Ag/Ab: ARCHITECT® laboratory-based test from their current POC testing, jail nurses will offer new entrants op-out testing with the two methods
224181296|NCT02999295|BIOLOGICAL|Ramucirumab|Ramucirumab (8 mg/kg) is administered.
224181297|NCT02999295|BIOLOGICAL|Nivolumab|Nivolumab (3.0 mg/kg or 1.0 mg/kg) is administered.
224181298|NCT02623569|DRUG|Ivabradine|Not Provided
224181299|NCT02623569|DRUG|Atenolol|Not Provided
224181300|NCT03152643|PROCEDURE|blastocyst-stage embryo transfer|All the participants will receive a long GnRH-agonist, ultra-long GnRH-agonist, short GnRH-agonist or GnRH antagonist protocol in combination with recombinant FSH. HCG will be administered for final oocyte maturation. Patients will have a single blastocyst-stage embryos transferred. The outcomes of all the embryo transfers within 1 year after randomization will be followed up. Single embryo transfer (SET) is required for the first 3 embryo transfers within 1 year after randomization. For embryo transfers beyond the third within the 1 year, patients' treatment must follow their randomized allocation, and SET is no longer mandatory. Luteal phase support will be administered before embryo transfer. If pregnancy is confirmed, luteal phase support will be continued until 10 weeks of gestation. The follow up will be continued until 6 weeks after delivery.
224307639|NCT05358470|OTHER|Exercise therapy and adapted physical activity-based program|Exercise therapy and adapted physical activity program based on racket sports
224307640|NCT00899990|OTHER|Laboratory Biomarker Analysis|Correlative studies
223490161|NCT03326336|COMBINATION_PRODUCT|Gene therapy: GS030-DP AND Medical device: GS030-MD|GS030-Drug Product (GS030-DP) - Recombinant adeno-associated viral vector, derived from serotype 2 (rAAV2.7m8), containing the optimized channelrhodopsin ChrimsonR-tdTomato gene under the control of the ubiquitous CAG promoter (rAAV2.7m8-CAG-ChrimsonR-tdTomato) GS030-Medical Device (GS030-MD) - Visual Interface Stimulating Glasses (that amplify the external visual stimulus to the optogenetically engineered retina)
223490162|NCT06005103|DEVICE|Treatment with MoodHeadBand (T-PEMF treatment)|The patients will receive treatment with T-PEMF using a headband containing 20 coils placed symmetrically around the head of the patient. The device delivers 55 Hz magnetic field. Duration of treatment is 30 minutes once a day for 8 weeks.
223490163|NCT06005103|DEVICE|Inactive treatment with MoodHeadBand (Placebo)|Patients will use an identical device, which does not deliver T-PEMF treatment. The patients will use the headband as the active group for 30 minutes, once a day, for 8 weeks.
223490164|NCT06409260|OTHER|Acceleromyography (AMG)|Philips IntelliVue NMT Module
223490165|NCT06409260|OTHER|Electromyography (EMG)|Senzime TetraGraph
223490166|NCT05728775|DRUG|Remimazolam|Remimazolam is administered intravenously for induction and maintenance of general anesthesia.
223490167|NCT05728775|DRUG|Propofol|Propofol is administered intravenously for induction and maintenance of general anesthesia.
223490168|NCT05551949|DRUG|Vaginal estradiol tablets|Vaginal estradiol tablets (10mcg).
223490169|NCT04443452|DIAGNOSTIC_TEST|Quantitative Sensory Testing|"PPT: An electronic data collection unit will be used featuring an electronic algometer connected with a laptop where the amount of pressure will be displayed on the screen. When the pressure pain detection threshold is reached (the point where the pressure sensation starts to be experienced as pain), the individual will press a button at a handheld device, that will automatically store the pressure value in the system and serve as an indication, for the examiner, to stop the testing.~TS: A pinprick stimulator (Weight: 256mNewton) will be used. The examiner will apply the pen that features a retractable blunt needle in a repetitive manner (once per second for ten seconds). The individual will be asked for the intensity of pain (NRS) at the first and at the last time and the given score will be noted.~CPM: A manual blood pressure sphygmomanometer will be used in conjunction with the electronic algometer described above (PPT)."
223490170|NCT04443452|RADIATION|Radiographic Evaluation|Tibiofemoral and patellofemoral radiographs of the most painful knee will be taken using a standardised protocol (standing posterior-anterior (PA) and skyline views) and will be scored by a single experienced observer in order to generate data for correlation analyses with the primary and secondary outcomes. A Perspex Rosenberg template with lead beads is used for the standing PA view to standardising the degree of knee flexion, foot rotation and magnification. PA radiographs are taken with the participant facing the x-ray tube while standing on the Rosenberg jig and leaning forwards with their thighs touching the anterior aspect of the jig, the x-ray beams passing from the posterior aspect through to the anterior aspect of the knee. Variable jigs are used for the skyline view to obtaining 300 of knee flexion with the participant lying in a reclined supine position on a couch. Grading of radiographs for changes of OA will be based on the Kellgren and Lawrence (K/L) score.
223490171|NCT04443452|PROCEDURE|Ultrasound-guided Aspiration|Ultrasound scanning will be conducted on the most painful knee to identify synovial effusion. During the ultrasound scan, the supra-patellar pouch, medial and lateral recess of the knees will be assessed for synovial thickening, synovial fluid/effusion and for positive power Doppler. An ultrasonic probe will be used to direct ultrasonic waves onto the knee joint during sonography, and a computer converts the signals received so that they can be presented on the screen. During skin application, a sterile probe cover and sterile acoustic gel will be used. Once the best aspiration location is identified and the location of the needle insertion marked, the skin will be prepared with a cleansing agent such as iodine or chlorhexidine. The needle may be introduced into the skin either parallel to the probe or perpendicular to the probe. Once the aspiration is completed, the needle will be removed, the skin cleansed, and a bandage will be applied.
223490172|NCT04443452|DIAGNOSTIC_TEST|Muscle Strength Assessment|Isometric testing will be done at 30 and 60 degrees of flexion as done in the previous study and the participant will be in sitting position with hips and knees strapped to keep the position standardised.
223490173|NCT04443452|DIAGNOSTIC_TEST|Function Assessment (A)|"The participant will start in a seated position. The participant will stand up upon therapist's command, walk 3 meters, turn around, walk back to the chair and sit down. The time will stop when the participant is seated. The subject can use an assistive device. If the assistive device is used, it will be documented.~Important Note: A practice trial will be completed before the timed trial."
224307641|NCT01788618|OTHER|Cognitive exams|"Psychopathological assessment (T0 and T3):~* Scale of Spielberger~* The self-administered questionnaire CES-D~Cognitive assessment(T0 and T3):~\- MMS, Grober and Buschke test, memory for numbers (WAIS IV) sequence of numbers and letters (WAIS IV), arithmetic (WAIS IV), Trail Making Test, verbal Fluence, D2, Code (WAIS IV)~Quality of Life: FACT-G and FACT-An Fatigue Module (T0 and T3):~Self-assessment FACT-COG (T0,every months until T3)"
224181301|NCT03152643|PROCEDURE|cleavage-stage embryo transfer|All the participants will receive a long GnRH-agonist, ultra-long GnRH-agonist, short GnRH-agonist or GnRH antagonist protocol in combination with recombinant FSH. HCG will be administered for final oocyte maturation. Patients will have a single cleavage-stage embryos transferred. The outcomes of all the embryo transfers within 1 year after randomization will be followed up. Single embryo transfer (SET) is required for the first 3 embryo transfers within 1 year after randomization. For embryo transfers beyond the third within the 1 year, patients' treatment must follow their randomized allocation, and SET is no longer mandatory. Luteal phase support will be administered before embryo transfer. If pregnancy is confirmed, luteal phase support will be continued until 10 weeks of gestation. The follow up will be continued until 6 weeks after delivery.
224181302|NCT01884675|DRUG|Ambrisentan 5 mg|White, film-coated, immediate-release tablets, containing 5 mg ambrisentan for single dose oral.
224181303|NCT01884675|DRUG|Placebo|White, film-coated, ambrisentan-matching placebo tablet for single oral dose
224181304|NCT02361307|PROCEDURE|Seamless ADL training|The experimental group receive the seamless ADL training which occupational therapist and nurse work with effective communication and cooperate in dressing and bathing training
224181305|NCT02361307|PROCEDURE|Conventional ADL training|The control group receive the conventional ADL training programme
224181306|NCT04192292|DRUG|Sulfonylurea|Given at very low dose as a physiological stimulus on the beta cell not as medical treatment. 20mg gliclazide is being used in this study.
224181307|NCT04192292|DRUG|DPP4 Inhibitor|Given as a physiological stimulus to augment endogenous incretin hormone levels, not as a medical treatment. 100mg sitagliptin is being used in this study.
224181308|NCT00944762|BEHAVIORAL|Ecosystem Focused Therapy (EFT)|12 therapist-led sessions over 25 weeks, in which a participant will learn problem-solving skills, the participant's physical environment will be modified, and the family or caregiver will facilitate the participant's adaptation. Active participation in treatment and rehabilitation for stroke will also be targeted by EFT's problem-solving approach, creating synergy among treatments.
224181309|NCT00944762|BEHAVIORAL|Education in stroke and depression|Information and resources on living with stroke and depression will be provided in 12 sessions over 25 weeks.
224181310|NCT05656729|DIETARY_SUPPLEMENT|DefensePlus|Multistrain probiotic:L. plantarum PBS077, L. acidophilus PBS066, B. lactis BL050, Maltodextrins, Vitamin B12, Vitamin, B6 Folic acid, Magnesium, silicon dioxide
224181311|NCT05656729|DIETARY_SUPPLEMENT|Placebo|Maltodextrins, Vitamin B12, Vitamin, B6 Folic acid, Magnesium, silicon dioxide
224181312|NCT00182572|DRUG|buprenorphine|
224181313|NCT00182572|DRUG|naltrexone|
224181314|NCT00182572|PROCEDURE|behavior therapy|
224181315|NCT00182572|PROCEDURE|voucher-based contingency management|
224181316|NCT00684658|BEHAVIORAL|TeenCope|Teencope consists of a series of 5 sessions designed to increase children's sense of competence and mastery by retraining inappropriate or non-constructive coping styles and forming more positive styles and patterns of behavior. Each week a new 30-45 minute session is uploaded to a password-protected website on the Yale server for youth to complete. Youth are grouped with 8-12 peers who complete the same weekly sessions in an asynchronous manner. Youth interact with each other on an online discussion board moderated by a clinical psychologist
224181317|NCT00684658|BEHAVIORAL|Managing Diabetes|Managing Diabetes consists of 5 sessions on educational content related to diabetes self management targeted to adolescents. As with the TeenCope program, each week a new 30-45 minute session is uploaded to a password-protected website on the Yale server for youth to complete. Youth complete educational sessions independently over 5 weeks. There is no online discussion board or peer interaction.
224181318|NCT04474717|DIAGNOSTIC_TEST|Breath Condensate Collection|Breath Condensate Collection
224307642|NCT01788618|OTHER|standardized cognitive rehabilitation|Patients will achieve 9 standardized cognitive rehabilitation sessions with the RehaCom ® software (over 3 months), and a self-assessment of their monthly experienced cognitive functioning using the self-administered questionnaire FACT-Cog
223745441|NCT07191301|BEHAVIORAL|Functional Strength Training and Kinesio Taping|Participants will undergo 8 weeks of supervised treatment, 3 sessions per week (24 sessions). Each session includes a warm-up with stretches, range-of-motion exercises, and Functional Strength Training (mini hops, stair climbing, ramp walking, sit-to-stand). Kinesio Taping will be applied from the foot's dorsum along the tibialis anterior and peroneus longus with 25-50% stretch for ankle support and dorsiflexor facilitation, re-applied every 3-4 days. No PNF techniques will be applied.
224181319|NCT04474717|DIAGNOSTIC_TEST|clinical examination, spirometry|spirometry
224181320|NCT04474717|DIAGNOSTIC_TEST|blood monocyte assay|study of blood monocytes in the laboratory of cell technology
224181321|NCT01138995|DEVICE|Ness L300|The Ness L300 delivers functional electrical stimulation (FES), which improves gait function, stroke-specific quality of life, functionality, and safety for persons with stroke.
224181322|NCT01138995|DEVICE|Ankle-foot orthosis|"The Control Group will walk with a usual ankle-foot orthosis (AFO)."
224181323|NCT02730312|BIOLOGICAL|XmAb14045|Administered IV weekly up to 8 weeks, with or without step-up dosing
224181324|NCT04259749|OTHER|Flavor Ban|Only flavored tobacco products are banned
224181325|NCT04259749|OTHER|Menthol Ban|Mentholated products are banned
224181326|NCT04259749|OTHER|All flavored and mentholated products available|No bans: All tobacco products are available
224181327|NCT00303602|DRUG|Sublingual orally disintegrating olanzapine (SODO)|5 to 20mg dose, supplied in 5mg tablet strength, tablet should be placed under tongue for at least 60 seconds, daily for 16 weeks.
224181328|NCT00303602|DRUG|Oral olanzapine|5 to 20mg dose, supplied in 5mg tablet strength, oral administration (tablets swallowed), daily for 16 weeks.
224181329|NCT04442932|DEVICE|Blood Collection|K3-EDTA venous whole blood 9 mL 1 venous draw
224181330|NCT06184100|OTHER|Virtual Self-Management Program (SMP)|Four sessions, 60-90 minutes each, will be conducted over eight weeks with a group size of 4-6 participants via videoconferencing platforms such as Zoom or Microsoft Teams. Each session will include Power Point delivered presentations, interactive activities, and group discussions. This is a multifaceted program that includes JIA disease education, self-management strategies, and peer support.
224181331|NCT06184100|OTHER|No Intervention|No intervention. Participant only receives standard of care.
224181332|NCT02103400|OTHER|Experimental group|Exercise Training Group
224181333|NCT02103400|OTHER|Control group|Exercise control group
224307643|NCT01788618|OTHER|Standardized home exercise|These patients will take part in 9 sessions standardized home exercise (over 3 months), and a self-assessment every month felt their cognitive functioning using the self-administered questionnaire FACT Cog
224307644|NCT01788618|OTHER|Follow up by phone|These patients receive follow-up by phone (9 telephone calls over a period of 3 months) standardized optics to know the evolution of the disorder and felt the same way as for the other groups, a monthly self-assessment the feeling of cognitive functioning using the self-administered questionnaire FACT-Cog
224307645|NCT06113926|OTHER|Bystander Acknowledgment|"The experimenter said That is so messed up that they excluded you in the task. And honestly, I would say it was racist… acknowledgment of the participants experience, …this shouldn't have happened, and I'm really sorry it did… an apology, and …I'm going to talk to the primary investigators of the study to figure out how we can make sure that this won't happen to other people a plan of action."
224307646|NCT02226757|DRUG|Paclitaxel-trastzumab|"Trastuzumab~* Dose:~  * First dose: 4 mg/kg IV~ * Subsequent doses: 2 mg/kg every week IV.~* The patient must be monitored for at least 6 hours after the start of the first infusion and for at least 2 hours after the start of subsequent infusions.~Paclitaxel~\- Dose: 60 mg/m2 IV in 30 minutes, every week, after trastuzumab"
224307647|NCT05211414|BEHAVIORAL|Yoga Based Daily Excercise|Subjects will be trained to perform 30 minutes of moderate level yoga daily, with instruction on breathing, self-awareness, and ways to modify poses to avoid pain. Subjects will be instructed in use of the email links to access the 30-minute instructive video. Subjects will attend weekly Zoom classes to learn additional postures and techniques, which will be reflected in their 30 minutes video (i.e. a new video for each week). At these weekly remote yoga classes, they will be asked about difficulties encountered and given advice about their personal home practice.
224307648|NCT01996449|DRUG|Eplerenone|The subject will be started on Eplerenone (Inspra) 50-200mg daily, which he or she will continue for a period of 8 weeks. Following the 8-week treatment period, the procedures listed below will be performed. After completion of the study procedures, the medication will be discontinued
224307649|NCT01996449|DRUG|Amlodipine|The subject will be started on Amlodipine (Norvasc) 2.5 -10mg daily, which he or she will continue for a period of 8 weeks. Following the 8-week treatment period, the procedures listed below will be performed. After completion of the study procedures, the medication will be discontinued.
224307650|NCT01996449|PROCEDURE|Microneurography|Investigators will measure sympathetic nerve activity from the peroneal nerve by inserting a tiny needle directly into the nerve in the leg. Investigators will localize the nerve by electrical stimulation over the skin using a blunt probe. With this stimulation, subject will notice either involuntary twitching or a tingling sensation, which may be annoying but not painful. Investigators will then introduce a tiny, sterile wire needle (an electrode) through the skin at the same location. When the tip of the needle enters the nerve, subjects may again notice involuntary muscle twitches or tingling in the leg. Investigators will then turn the electrical stimulator off and make minor adjustments in the position of the needle until investigators begin to record the nerve signals. The recording needle will remain in position throughout the study.
224307651|NCT01996449|PROCEDURE|Rhythmic handgrip exercise|Subjects will perform a rhythmic handgrip exercise at 30% or 45% of maximal voluntary contraction for 3 minutes. Investigators will measure cardiac output (non-invasive impedance plethysmography), blood pressure, and sympathetic nerve activity (SNA) at baseline and following this handgrip exercise
224307652|NCT01996449|PROCEDURE|Sustained hand grip|Subjects will perform a sustained handgrip exercise at 30% of maximal voluntary contraction for 3 minutes. Investigators will measure cardiac output (non-invasive impedance plethysmography), blood pressure, and sympathetic nerve activity (SNA) at baseline and following this handgrip exercise.
224307653|NCT01996449|PROCEDURE|Forearm blood flow|Using high-resolution ultrasound, investigators will measure skeletal muscle blood flow in the forearm at rest, following sustained handgrip exercise
223745442|NCT07189832|PROCEDURE|Intralesional Injections|Intralesional Injections
224181334|NCT03029793|OTHER|Biomarkers Testing|CRT resistance biomarkers will be detected before CRT, 2-3 weeks after the initiation of CRT, and 4 weeks post-CRT.
224181335|NCT03029793|OTHER|Functional Imaging analysis|The SUV value and texture parameters of 18F-FDG PET-CT as well as ADC values DWI-MRI will be measures before CRT, 2-3 weeks after the initiation of CRT, and 4 weeks post-CRT.
224181336|NCT04766528|OTHER|3 maximal aerobic tests|Maximal aerobic tests will be performed before diet intervention, after the first diet and after the second diet
224181337|NCT00481533|DRUG|Methyl-Ergonovine-Oxytocin|
224181338|NCT00481533|DRUG|Oxytocin|
224181339|NCT00201682|DRUG|Etanercept|25 mg SQ twice weekly weeks 1-5
224181340|NCT00201682|DRUG|Rituximab|(375 mg/m2) Using Stepped-Up Dosing Thrice Weekly, weeks 2-5
224181341|NCT01061346|OTHER|40% Fat Diet, 20% Fructose Beverage|40% fat, 45% carbohydrate (with 20% fructose beverage), 15% protein
224181342|NCT01061346|OTHER|20% Glucose Beverage|40% fat, 45% carbohydrate (with 20% glucose beverage), 15% protein
224181343|NCT01061346|OTHER|20% Glucose Beverage|20% fat, 65% carbohydrate (with 20% glucose beverage), 15% protein
224181344|NCT03702192|DEVICE|novel anticoagulation protocol used in conjunction with the Berlin Heart EXCOR|novel antithrombotic management protocol
224181345|NCT02564627|PROCEDURE|Self-applied patch|An ambulatory self-applied patch will be placed weekly by the patients for PENS of dermatome T6.
224181346|NCT02564627|PROCEDURE|Conventional procedure|PENS of dermatome T6 will be applied by the MD in the Outpatient Clinic.
224181347|NCT02564627|DIETARY_SUPPLEMENT|1200 Kcal/day diet|A 1200 Kcal/day diet will be prescribed.
224181348|NCT01938027|PROCEDURE|Transanal total mesorectal excision|Laparoscopy-assisted transanal total mesorectal excision
224181349|NCT05487027|BEHAVIORAL|Goldilocks work principle|"Using the Goldilocks work principle we have tried to find the just right distribution of physical strain in the home care sector. This is an intervention to test if it possible to distribute the physical strain experienced in the home care sector in a way that may be more health promoting for the workers."
224181350|NCT02160262|DRUG|Dasotraline|Dasotraline 4 mg, 6 mg, 8 mg, flexibly dosed, once daily
224181351|NCT03429894|DEVICE|Percutaneous Coronary Intervention|Drug eluting stent implant
224181352|NCT00005874|DRUG|rubitecan|
224181353|NCT02061020|DRUG|Cannabis (THC) in cigarettes of 30mg, 10mg and placebo|"Smoked THC containing cigarettes. Randomly allocated dosage 30mg, 10mg et placebo.~Both chronic and occasional cannabis consuming volunteers will be allocated to smoking a cigarette containing (1) no THC (placebo), (2) a joint containing 1% THC (10 mg THC, i.e. low-dose) and (3) a joint containing 3% (30 mg THC) mixed with 1 g tobacco.~Each cigarette will be followed by 24 hours testing in laboratory conditions. Each period is separated by 7 days (3 testing periods over 3 weeks). Each volunteer will undergo performance testing (driving simulator and PVT) before administration of the substance (T0).~Blood samples and repeat performance testing will be carried out at 1 hour, 2 hours, 4 hours, 6 hours, 8 hours, 12 hours and 24 hours."
224181354|NCT03914131|DRUG|Xinnaoning Capsule|Xinnaoning Capsule used in study group(treatment period) is the true drug that the investigators are to evaluate.
224181355|NCT03914131|OTHER|Xinnaoning Capsule Simulator|Xinnaoning Capsule Simulator used in control group and introduction period(both groups) is the placebo to reduce the risk of bias.
224181356|NCT02984631|PROCEDURE|Preventing pulm HTN during exercise|Balloon catheter is inflated within the IVC to maintain pulmonary pressures during exercise.
224307654|NCT01996449|PROCEDURE|Arm cycling exercise|Subjects will perform a cycling arm exercise with a stationary cycling device. Investigators will measure cardiac output (non-invasive impedance plethysmography), blood pressure, and sympathetic nerve activity (SNA) at baseline and following this exercise.
224307655|NCT01996449|PROCEDURE|Cold Pressor test|Subjects will place hand in cold water with ice for 3 minutes. Investigators will measure cardiac output (non-invasive impedance plethysmography), blood pressure, and sympathetic nerve activity (SNA) at baseline, during and 2 minutes after the test.
224307656|NCT00553306|BIOLOGICAL|therapeutic autologous lymphocytes|Given IV
223745443|NCT07190716|BIOLOGICAL|GR2301 injection|IL15 monoclonal antibody
224307657|NCT00553306|BIOLOGICAL|aldesleukin|Given subcutaneously
224307658|NCT00553306|DRUG|cyclophosphamide|Given IV
224307659|NCT00553306|PROCEDURE|biopsy|Optional correlative studies
224307660|NCT00553306|OTHER|immunohistochemistry staining method|Optional correlative studies
224307661|NCT00553306|OTHER|flow cytometry|Correlative studies
224307662|NCT00553306|GENETIC|polymerase chain reaction|Correlative studies
224307663|NCT06263712|BEHAVIORAL|Attempted Suicide Short Intervention Program (ASSIP)|"The Attempted Suicide Short Intervention Program (ASSIP) is a specific therapy for patients with a suicide attempt in their biography. The brief therapy ASSIP consists of three to four sessions of approximately 50 minutes each.~Session 1: A narrative interview is conducted, in which the patient is asked to tell her\*his personal story which led to the suicidal crisis. The narrative is video-recorded.~Session 2: Using video-playback of the recorded narrative, patient and therapist explore further details of the suicidal process.~Session 3: A case conceptualization focusing on the patient's vulnerability and the trigger of the suicidal crisis is formulated in writing. A list of safety strategies for the prevention of future suicidal behavior is developed jointly with the patient.~Regular letters are sent to patients over a period of 2 years."
224307664|NCT06263712|BEHAVIORAL|Standard of care plus resource interview group (STAR)|The standard of care plus resource interview group (STAR) will be offered a clinical interview, a risk assessment, and a non-specific resource focused intervention over three face-to-face sessions. In this resource focused intervention, the patient is asked to name her\*his resources, describe them, and give examples.
224307665|NCT05915975|BEHAVIORAL|Behavioral Care Coordinated with Medical Care Intervention|Participants will be meeting with a behavioral health provider during their clinic visit. Subsequent visits can be held either via telehealth or in-person. Participants should expect weekly visits during the first two months and less frequent visits (biweekly or monthly) for the last two months. Some sessions that are provided via telehealth might be video recorded and later reviewed to ensure that the program is being delivered as intended.
224307666|NCT05915975|BEHAVIORAL|Behavioral Care Not Coordinated with Medical Care Intervention|Participants will meet with a study team member during their in-person visit and will receive a list of clinics that are panelled with their insurance. The participants will be responsible for calling the clinics to set up their appointments. Services might be provided in person or via telehealth based on the participant's preference and the clinics' availability.
224307667|NCT06351436|BEHAVIORAL|Mindfulness|The mindfulness-based intervention will last for three months, with 6-8 weekly sessions lasting 1.5 hours each. Participants will attend the sessions in a group format, and the sessions will be administered by registered social worker who are specialized in counseling. The intervention is delivered using an immersive virtual reality cave system. The intervention content is designed by a registered clinical psychologist accredited for delivering mindfulness-based intervention and nurses who are experienced in mindfulness training. To ensure protocol adherence, the social workers administering the intervention will receive close supervision from the clinical psychologist. Weekly meetings will be held to discuss and resolve any difficulties or challenges encountered by the social workers.
224307668|NCT02469259|DRUG|Oxytocin|
224307669|NCT02469259|OTHER|Placebo|
224307670|NCT04758975|DRUG|Venetoclax|VENETOCLAX: Ramp-up than 400 mg QD
224307671|NCT04758975|DRUG|Rituximab|RITUXIMAB: Cycle 7 Day 1 375 mg/m2; Cycles 8-12 Day 1 500 mg/m2
223745444|NCT04689048|DRUG|18F fluciclovine|Patients will receive a standard 5 millicuries dose of 18F-fluciclovine intravenously as a bolus injection. They will be required to fast for at least four hours prior to 18F-fluciclovine injection. Patients will be positioned for PET/CT brain imaging and will be injected with 18F-fluciclovine immediately prior to PET data acquisition. PET data will be collected in list mode up to 25 minutes post-injection. PET images will be reconstructed in two ways: as a standard static image of data acquired between 10 to 20 minutes post-injection, and as a dynamic series of four 5-minute frames between 5 to 25 minutes post-injection to allow for motion assessment and correction and time-dependent observations.
224307672|NCT04758975|DRUG|Ibrutinib|IBRUTINIB 420 mg QD
223745445|NCT02650401|DRUG|Entrectinib|TRKA/B/C, ROS1, and ALK inhibitor
223745446|NCT00002417|DRUG|Amprenavir|
224181357|NCT02581657|DRUG|PE0139 Injection|PE0139 Injection
224181358|NCT02581657|DRUG|Placebo Injection|Placebo Injection
223587667|NCT04712552|PROCEDURE|deep brain stimulation|"On the day of surgery, under general anesthesia, a Fischer ZD frame will be attached to the skull. A T1-weighted 3D MRI with gadolinium will be performed.~Investigators will plan on this MRI, anatomical targets and deep brain trajectories using the NeuroInspire surgical planning software.~The patient will be attached to the base of the robot through the frame. Registration will be performed using the Neurolocate method after the acquisition of 3D CT images using the O-arm. The Neurolocate recording is based on radiographic images.The 3D MRI will be merged with the 3D tomography images taken with the O-arm to co-register the trajectories planned on the MRI in the robot space The surgical procedure will be performed as usual by milling the bone at the entry point and inserting under robotic guidance an electrode through a guide tube to the intended target."
223587668|NCT03063190|DRUG|Vitamin D|patients will receive vitamin D supplementation according to guidelines
223587669|NCT03063190|DRUG|Placebo Oral Tablet|patients will receive placebo oral tablets
223587670|NCT04663334|OTHER|inverse myocardial remodeling|a myocardial reverse remodeling is described, generating a decrease in hypertrophy, interstitial oedema, and inflammation. Its effect on coronary microcirculatory reserve is not known. Some studies have shown improvement in coronary reserve immediately after TAVI and this effect seemed to last long after treatment
224181359|NCT01493440|DRUG|atosiban|Atosiban was administered as a 6.75mg IV bolus dose 30 minutes prior to embryo transfer followed by a 1-hour IV infusion at dose of 18 mg/h then a 2-hour IV infusion at 6 mg/h.
224181360|NCT01933269|DRUG|FACBC|
224181361|NCT00107601|DRUG|Insulin|
224181362|NCT04508504|PROCEDURE|Preop PENG block|Ultrasound-guided injection of 20 mL 0.5% ropivacaine according to the method described by Giron-Arango L in 2018. A needle is inserted at the inguinal level under ultrasound guidance to pass beneath the psoas tendon on top of the iliopubic eminence where the local anesthetic is injected.
224181363|NCT04508504|PROCEDURE|Placebo block|Ultrasound-guided placebo injection of 5 mL 0.9% normal saline. Using the same landmarks as for the PENG group, a needle is inserted in the inguinal region under ultrasound guidance, whereby a subcutaneous injection of 5 mL of 0.9% saline is made.
224181364|NCT04508504|DRUG|Ropivacaine 0.5% Injectable Solution|20 mL 0.5% ropivacaine will be injected for the preop PENG block
223490174|NCT04443452|DIAGNOSTIC_TEST|Function Assessment (B)|The 30-Second Chair Test is administered using a chair. The participant is seated in the middle of the chair with arms crossed at the wrists and held against the chest. The participant will practice a repetition or 2 before completing the test. If a participant must use their arms to complete the test, they are scored 0. The participant is encouraged to complete as many full stands as possible within 30 seconds. The participant is instructed to fully sit between each stand. While monitoring the participant's performance to ensure proper form, the tester silently counts the completion of each correct stand. The score is the total number of stands within 30 seconds (more than halfway up at the end of 30 seconds counts as a full stand). Incorrectly executed stands are not counted. The 30-second chair stand involves recording the number of stands a person can complete in 30 seconds rather than the amount of time it takes to complete a pre-determined number of repetitions.
223490175|NCT04443452|DIAGNOSTIC_TEST|Balance Assessment|Static balance and postural sway either in the medial-lateral or antero-posterior direction will be assessed using the RS Scan force plate. The participant will be asked to stand on the plate looking straight forward for 30 seconds in two conditions: first with their eyes open and then with eyes closed. Medial-lateral, antero-posterior and total sway will be recorded.
223587671|NCT01150643|GENETIC|gene expression analysis|
223587672|NCT01150643|GENETIC|microarray analysis|
224181365|NCT04508504|DRUG|Normal Saline|5 mL 0.9% Normal saline will be injected for the Placebo block
224181366|NCT03713112|OTHER|Weekly MDT deprescribing rounds for certain drugs|"* Weekly deprescribing round (from randomization to day of discharge)~* Conducted by a multidisciplinary team (non-ward doctors, pharmacist, ward nurse)~* Using the 5 steps of de-prescribing~* De-prescribing targets:~  1. Beer's list of potentially inappropriate medications (American Geriatric Society 2015 version)~ 2. Supplements of questionable benefits (glucosamine, chondroitin, vitamin B complex and multivitamins)~ 3. Symptomatic medications (laxatives, gastro-protectives, painkillers, anti-emetics and steroid creams) (Standardized verbal script to initiate de-prescribing by the team)~* On top of usual care"
223587673|NCT01150643|GENETIC|polymerase chain reaction|
223587674|NCT01150643|GENETIC|polymorphism analysis|
223587675|NCT01150643|OTHER|immunohistochemistry staining method|
223587676|NCT01150643|OTHER|laboratory biomarker analysis|
224181367|NCT02978404|DRUG|Nivolumab|Nivolumab is administered to patients to a maximum of 2 year.
223587677|NCT02064608|DRUG|AZD2014|mTOR inhibitor
223587678|NCT05117203|DEVICE|WB-EMS (Whole body electrostimulation)|Application of physical exercise and electrical stimulation on the abdominal muscles through the WB-EMS during 20 minutes training session with specific exercise (CORE)
223587679|NCT05117203|DEVICE|EMS|Application of physical exercise and electrical stimulation on the abdominal muscles through the EMS during 20 minutes training session with specific exercise (CORE)
223587680|NCT05117203|DEVICE|WB-EMS off|Application of physical exercise without electrical stimulation on the abdominal muscles through the WB-EMS off during a 20 minutes training session with specific exercise (CORE).
223587681|NCT00421642|DRUG|Adalimumab|The loading dose will be 160 mg. A dose of 80 mg will be given at Week 2 and 40 mg every other week starting at Week 4 until completion at Week 24. If it is found that they are not responding to 40 mg of adalimumab at Week 8 or later, the dose may be increased to 40 mg weekly.
224181368|NCT02978404|RADIATION|Radiosurgery|Up to 10 cubic centimeter of brain metastases will be treated with radiosurgery. The dose of radiosurgery depends on the size of individual metastases.
224181369|NCT03517150|DEVICE|mandibular advancement device|
224181370|NCT00313716|DRUG|recombinant human erythropoietin, rhEpo|The study design is 2x2 factorial with randomization to erythropoietin or placebo and to transfusion trigger 10 gm/dl or 7 g/dl. Erythropoietin or placebo was initially dosed daily for 3 days and then weekly for 2 more weeks (first 74 patients, Epo1 dosing regimen), and then the 24- and 48-hour doses were stopped for the remainder of the patients (remaining 126 patients, Epo2 dosing regimen).
224181371|NCT00313716|OTHER|placebo|an inactive substance
224181372|NCT03744858|PROCEDURE|Peripheral blood draw|Peripheral vein blood draw will be performed to all participants in order to collect blood samples to be evaluated.
224181373|NCT05997134|DRUG|Ketamine|patients will receive ketamine parenteral infusion (0.35 mg/kg/h or maximum 24mg/h) at post anesthetic care unit(PACU) over 6 hours for 3days .
224181374|NCT05997134|DRUG|Ketamine|patients will receive ketamine parenteral infusion (0.35 mg/kg/h or maximum 24mg/h ) at post anesthetic care unit(PACU) over 6 hours for 5 days
224307673|NCT02984085|DRUG|Genetically corrected cultured epidermal autograft (ATMP)|"Genetically corrected cultured epidermal autograft (Hologene 7) is intended for transplantation onto surgically prepared blistering skin areas of RDEB patients and permanent regeneration of a healthy, functional and renewing epidermis sustained by the engraftment of transduced epidermal stem cells.~By taking some autologous epidermal cells, a new layer of transgenic tissue is grown in the laboratory. This layer of tissue is then implanted by a surgeon into the damaged area. The implantation can be done in one or more areas and repeated in case of failure of the first surgery."
224307674|NCT04918498|BEHAVIORAL|early physiotherapy programs|establishment of multidisciplinary teams, safety assessment, early activity physiotherapy and respiratory physiotherapy
224307675|NCT04918498|BEHAVIORAL|routine treatment|provide routine nursing and rehabilitation program
224307676|NCT02485171|DEVICE|SAFEWALKER|Medical device walking aids.
224307677|NCT02885181|DRUG|GS-9876|One tablet administered orally once daily
223490176|NCT05464095|DEVICE|mHealth Intervention|The Health Insurance Portability and Accountability Act (HIPPA) compliant texting platform is linked to the Fitbit Application Program Interface. Real time activity data will be transmitted from the subject's smartphone to the mHealth platform via cellular network. Participants assigned to the texting arm will receive 3 texts/day in sync with their preferred morning, lunch, and evening leisure schedule, which is defined at enrollment. These texts will use personal, disease-specific, and provider information to deliver 2 types of messages customized to the current step count and sent in equal proportion. Messages are designed to facilitate self-awareness, reinforce step targets, and link physical activity with a reward or memorable cue.
223490177|NCT05464095|DEVICE|Usual Care|The HIPPA-compliant texting platform is linked to the Fitbit Application Program Interface. Real-time activity data will be transmitted from the subject's smartphone to the mHealth platform via cellular network.
223490178|NCT04801329|DRUG|Vyndamax (tafamidis 61mg)|As prescribed in real world practice
223490179|NCT06229717|DIAGNOSTIC_TEST|video Head Impulse Test|For v-HIT, the Synapsys v-HIT Ulmer device is used.
223490180|NCT06229717|DIAGNOSTIC_TEST|Cervical Vestibular Evoked Myogenic Potential|For cVEMP, the Eclipse (Interacoustic, Middelfart, Denmark) is used. To bypass the frequent middle ear problems bone conduction stimuli (B-81, Interacoustic, Middelfart, Denmark) are administrated. The bone conductor is placed on the mastoid process and two trials at 70 dB nHL are conducted to check waveform reproducibility. 500 Hz short tone bursts (2-2-2 ms) are applied at 5 per second stimulus repetition rate.
223490181|NCT06229717|DIAGNOSTIC_TEST|Ocular Vestibular Evoked Myogenic Potential|For oVEMP, the Eclipse (Interacoustic, Middelfart, Denmark) is used. To bypass the frequent middle ear problems bone conduction stimuli (B-81, Interacoustic, Middelfart, Denmark) are administrated. The bone conductor is placed on the mastoid process and two trials at 70 dB nHL are conducted to check waveform reproducibility. 500 Hz short tone bursts (2-2-2 ms) are applied at 5 per second stimulus repetition rate.
224307678|NCT02885181|DRUG|Filgotinib|Two tablets administered orally once daily
224307679|NCT02885181|DRUG|GS-9876 placebo|One tablet administered orally once daily
223490182|NCT06229717|DIAGNOSTIC_TEST|Computerized Dynamic Posturography|To evaluate functional balance of the children and the relative contributions of the vision, proprioception, and vestibular system a CDP from Virtualis (Virtualis, Montpellier, France) is used.
223587682|NCT04515953|DRUG|ND-340|ND-340: Subjects will receive a single administration of ND-340 at the specified dose in each arm after TKA.
223587683|NCT04515953|DRUG|IV-PCA|IV-PCA: Intravenous patient-controlled analgesia (IV-PCA), morphine, will be administered in subjects of control group after TKA for postoperative pain management as standard practice.
223587684|NCT01494519|PROCEDURE|Surgery with an external ring fixator|Modern ring external fixator is defined as any fixator that has at least 1 ring proximal and 1 ring distal to the fracture site. The rings may be connected to the tibia using any combination of external fixation pins or wires at the surgeon's discretion. There must be at least two pins or wires connected to each ring, and typically there will be at least three pins or wires. Any FDA approved ring fixator meeting this definition from any manufacturer is allowed.
224181375|NCT05997134|DRUG|Ketamine|patients will receive ketamine parenteral infusion (0.35 mg/kg/h or maximum 24mg/h ) at post anesthetic care unit(PACU) over 6 hours for 7 days
224181376|NCT06037486|DIAGNOSTIC_TEST|Glucometer Test|measurement of the blood glucose concentration using the blood glucose monitor for personal use
224181377|NCT04387812|DEVICE|Xtrodes home PSG system|Wireless, convenient and relies on actual recording of EMG, EOG and EEG in a home setting
224181378|NCT00663208|DRUG|Daclatasvir|Capsule, Oral, Approximately 182 days from initial dosing
224181379|NCT00663208|DRUG|Placebo|Capsule, Oral, After 28 days from initial dosing and unblinding of the dose panel
224181380|NCT00231959|DRUG|Pramipexole (Mirapex)|pramipexole 0.5mg tablets qd and titrated per protocol
224181381|NCT00231959|DRUG|Placebo|sugar pill
224307680|NCT02885181|DRUG|Filgotinib placebo|Two tablets administered orally once daily
224307681|NCT02885181|DRUG|Methotrexate|Background therapy with methotrexate administered orally or parenterally once weekly
224307682|NCT04930419|DEVICE|Videolaryngoscopy group|Tracheal intubation will be performed using Videolaryngoscope in first intention and will be performed using standard pre-hospital intubation procedures : preoxygenation before intubation, maintenance of oxygenation throughout procedure, standard sedation technique (using rapid sequence intubation (RSI)), correct position confirmation using a capnogram and conditioning (hemodynamic monitoring, respirator settings, securing). If the first attempt at intubation is unsuccessful, further management will be left to the discretion of the clinician according to the procedures and algorithm of usual standard care
224307683|NCT04930419|DEVICE|Direct laryngoscopy group|Tracheal intubation will be performed using Direct laryngoscopy with Macintosh blades in first intention. and will be performed using standard pre-hospital intubation procedures : preoxygenation before intubation, maintenance of oxygenation throughout procedure, standard sedation technique (using rapid sequence intubation (RSI)), correct position confirmation using a capnogram and conditioning (hemodynamic monitoring, respirator settings, securing). If the first attempt at intubation is unsuccessful, further management will be left to the discretion of the clinician according to the procedures and algorithm of usual standard care
224307684|NCT02212613|DRUG|Brexpiprazole|Treatment (6 weeks) Up to 2 mg/day, once daily dose, tablets, orally
224307685|NCT04475835|DRUG|Bivalirudin|Bivaliruding 0.75 mg/kg intravenous bolus loading dose, and immediately followed by intravenous infusion of 1.75 mg/kg/h until 4 hours after PCI. A prolonged infusion of 0.2 mg/kg/h for ≤20h could be considered at the operator's discretion. It is recommended that ACT be monitored 5 minutes after the first administration, and if ACT is \<225 s (Hemotec method), intravenous injection of 0.30 mg/kg of bivalirudin should be administered.
224307686|NCT04475835|DRUG|Heparin|Heparin is dosed at 100 U/kg. ACT is monitored 5 min after the first administration, and if the ACT \<225 s (Hemotec method), an intravenous injection of heparin should be administered by need.
224307687|NCT00095316|DRUG|Caspofungin|Caspofungin is an antifungal agent of the echinocandin class of glucan synthase inhibitor. Subjects receive Caspofungin acetate 50mg/day IV for 28 days.
224307688|NCT00095316|OTHER|Placebo|Normal saline equivalent to that used to deliver the caspofungin given intravenously as a single daily dose infused over approximately 1 hour for 28 days
223490183|NCT06229717|OTHER|Dizziness Handicap Inventory for patient caregivers|DHI is a caregiver-reported 21- item questionnaire. It is designed to evaluate the perceived quality of life and handicap resulting from dizziness and unsteadiness for the pediatric population. For each question there are three possible answers: yes, sometimes or no. Each answer provides respectively 4, 2 and 0 points. The total DHI scores range from 0 to 84 with higher score being consistent with more limitation and more severe handicap. Scores under 16 are characterized as no limitation or handicap. A score from 16-26 present a mild perceived handicap and mild limitations. A DHI-score between 26-43 is classified as a moderate problem, and a score above 43 describes a severe perceived handicap and severe limitations.
223587685|NCT01494519|PROCEDURE|Definitive fixation with a locked IM nail or plate|"Eligible patients with tibial diaphyseal fractures will typically receive a standard locked IM Nail. The nail must use at least one static interlock proximal to and one static interlock distal to the fracture site. The nail may be placed with either a reamed or unreamed technique.~Methaphyseal fractures, especially those with fracture lines extending into the joint may be more commonly treated with plate fixation. The plate may be applied in an open or percutaneous fashion. Any combination of locked and/or non-locked screws may be used."
224181382|NCT03492242|DRUG|Immune checkpoint inhibitor|Immune checkpoint inhibitor targeting either PD-1, PD-L1 or CTLA-4, and included in the following list (ATC classification) as a monotherapy or in combination: Ipilimumab (L01XC11), Nivolumab (L01XC17), Pembrolizumab (L01XC18), Durvalumab (L01XC28), Avelumab (L01XC31), Atezolizumab (L01XC32).
224181383|NCT02356770|DEVICE|Collagen Matrix 10808|At the day of the Intervention (day 0) sulcular incisions will be made around the neighbouring teeth and a straight incision from the lingual/palatal line angle of the distal tooth to the lingual/palatal line angle of the mesial tooth. A full thickness flap will be elevated on the lingual side, whereas a split flap will be made at the buccal aspect preparing a soft tissue pouch without the preparation of horizontal release incisions. The Collagen Matrix 10808 will then be positioned in the pouch under the elevated buccal flap. A horizontal mattress suture will be made to immobilize graft to the flap followed by four to five single sutures to close the wound.
224181384|NCT02356770|PROCEDURE|Connective tissue graft|At the day of the Intervention (day 0) sulcular incisions will be made around the neighbouring teeth and a straight incision from the lingual/palatal line angle of the distal tooth to the lingual/palatal line angle of the mesial tooth. A full thickness flap will be elevated on the lingual side, whereas a split flap will be made at the buccal aspect preparing a soft tissue pouch without the preparation of horizontal release incisions. The Connective tissue graft (Gold Standard) will then be positioned in the pouch under the elevated buccal flap. A horizontal mattress suture will be made to immobilize graft to the flap followed by four to five single sutures to close the wound.
224181385|NCT01024270|DRUG|Misoprostol|
224181386|NCT04533932|DIAGNOSTIC_TEST|Elastography|Endosonographic shear wave elastography
224181387|NCT05069909|PROCEDURE|Denture Fabrication technique|Each patient received two sets of dentures fabricated using the two different techniques and their satisfaction and OHIP-EDENT were compared
224181388|NCT01208376|OTHER|Fibroscan|Fibroscan and Serum Fibrose-marker
224181389|NCT01041027|DRUG|Paclitaxel|Given IV
224307689|NCT05837013|PROCEDURE|Spinal anesthesia (with nerve block)|Spinal Anesthesia and Nerve Block: No premedication will be applied. Spinal anesthesia will be administered to the patients in this group in the sitting position with a 27G Quincke needle (15 mg hyperbaric 0.5% bupivacaine) to be entered through the L2-L3 or L3-L4 interval. If hypotension develops, it will be corrected with a crystalloid infusion and ephedrine. These patients will be administered intravenous sedation with increasing doses of midazolam to provide adequate sedation. According to Hadzic, II and IH nerve block will be performed by applying 10 mL of 0.75% ropivacaine 2 cm above and 2 cm medial to the anterior superior iliac spine.
223490184|NCT01963234|BEHAVIORAL|Seva|Patients were given access to use Seva. This is a mobile application that uses social and behavioral theories to help support people after alcohol use disorder recovery.
223490185|NCT02693067|DRUG|Rose bengal disodium|Percutaneous intralesional injection to NET tumor
223490186|NCT01124253|DRUG|recombinant human endostatin|recombinant human endostatin 15mg per ampul for injection 7.5mg/m2 IV (in the vein) on 1st to 14th days of a 21- day cycle, totally 4 cycles are needed
223587686|NCT01063088|BIOLOGICAL|Seasonal influenza vaccine (split virion, inactivated, prepared in Vero Cell cultures)|Single 0.5 mL intramuscular injection
223587687|NCT00969072|DRUG|GI198745 0.05mg|GI198745 (drug) - benign prostatic hyperplasia
223587688|NCT00969072|DRUG|GI198745 0.5mg|GI198745 (drug) - benign prostatic hyperplasia
223587689|NCT00969072|DRUG|GI198745 2.5mg|GI198745 (drug) - benign prostatic hyperplasia
224181390|NCT01041027|DRUG|Carboplatin|Given IV
224181391|NCT01041027|RADIATION|Internal Radiation Therapy|Undergo HDR brachytherapy
223490187|NCT06962904|BIOLOGICAL|3.75 µg Dose of CDC-9 Inactivated Rotavirus Vaccine (IRV)|CDC-9 IRV dissolving MNP for intradermal administration is comprised of a single human rotavirus strain for protection against rotavirus infection
223490188|NCT06962904|BIOLOGICAL|7.5 µg Dose of CDC-9 Inactivated Rotavirus Vaccine (IRV)|CDC-9 IRV dissolving MNP for intradermal administration is comprised of a single human rotavirus strain for protection against rotavirus infection
223490189|NCT06962904|OTHER|Placebo|Placebo MNP (containing sucrose, sorbitol, maltodextrin, methylcellulose, HEPES, sodium chloride, and calcium chloride) administered intradermally
223490190|NCT00835718|DRUG|Comparator: MK0594 5 mg/day|MK0594 5 mg tablets taken orally once daily for 12 weeks. At the randomization visit, a loading dose of 15 mg MK0594 will be administered.
223587690|NCT02597088|OTHER|Laboratory studies of the effect of human milk handling using a rage surface area bottle (study device)|Using laboratory studies of the effect of storage and heating on expressed human milk, the investigators will compare milk handled in regular bottle and bottle warmer and milk handled using the study device (large surface area bottle)
223587691|NCT02858557|BEHAVIORAL|Mediterranean diet|The Mediterranean diet is rich in complex carbohydrates and fibers and low in animal proteins and fats.
224181392|NCT01041027|RADIATION|External Beam Radiation Therapy|Undergo EBRT
224181393|NCT01041027|OTHER|Laboratory Biomarker Analysis|Correlative studies
224181394|NCT01249404|BIOLOGICAL|Botulinum toxin type A|I.M. injection on day 1 (single treatment cycle)
224181395|NCT01249404|DRUG|Placebo|I.M. injection on day 1 (single treatment cycle)
224181396|NCT01951833|DEVICE|EasyOne Pro and Ecomedics|LCI will be assessed with 2 different devices : EasyOne Pro and Ecomedics
224181397|NCT04431856|BEHAVIORAL|Unified Protocol for COVID-19 Parenting Stress (UP-COVID)|UP-COVID is a group therapy session with each session lasting approximately 60-90 minutes. The sessions will focus on cognitive and behavioral strategies for managing their own distress, anxiety and sadness related to COVID-19, as well as, strategies related to parenting in the midst of the crisis.
223490191|NCT00835718|DRUG|Comparator: MK0594 1 mg/day|MK0594 1 mg tablets taken orally once daily for 12 weeks. At the randomization visit, a loading dose of 3 mg MK0594 will be administered.
223490192|NCT00835718|DRUG|Comparator: MK0594 1 mg/week|MK0594 1 mg tablets taken orally once every 7 days for 12 weeks. At the randomization visit, a loading dose of 3 mg MK0594 will be administered.
223587692|NCT02858557|BEHAVIORAL|Specific Carbohydrate Diet|The specific carbohydrate diet is a dietary program popular among patients with IBD. The diet allows carbohydrate foods consisting of mono-saccharides only, and excludes di-saccharides and most polysaccharides.
223587693|NCT00952614|DEVICE|fluocinolone acetonide (Retisert Implant, Bausch and Lomb)|sustained release device consisting of 0.59 mg of fluocinolone acetonide
224181398|NCT04431856|BEHAVIORAL|SHG|Brochure that details techniques for coping with stress.
224181399|NCT02648152|DEVICE|Osteoarthritis|Total Hip Arthroplasty
223587694|NCT00086645|DRUG|citalopram hydrobromide|10mg/5ml solution
223587695|NCT00086645|OTHER|placebo|up to equivalent of 20 mg of active comparator daily
224181400|NCT05538507|DRUG|smart soup|Severe AD, mild or moderate AD and MCI will be given smart soup
224181401|NCT05538507|DRUG|Donepezil|Severe AD and mild or moderate AD will be given donepezil
224181402|NCT05538507|DRUG|Memantine|Severe AD will be given memantine
223490193|NCT00835718|DRUG|Comparator: Placebo to MK0594|Matching placebo to MK0594 tablets taken orally once daily for 12 weeks.
223490194|NCT02170714|OTHER|Clinical and laboratory assessment|Clinical assessment through PUCAI and laboratory data (Erythrocyte Sedimentation Rate, C-Reactive Protein, hemoglobin, albumin, hematocrit, ferritin) were recorded at admission and at day 3 and 5. All patients were treated according to the 2011 ECCO-ESPGHAN guidelines for ASC: all patients received intravenous (iv) corticosteroids (methylprednisolone 1.5-2 mg/Kg/day) for 5 days. Patients not responding to corticosteroids (i.e. PUCAI\>65 at day 5) started Infliximab (IFX, 5 mg/Kg 0,2,6 then every 8 weeks) as second-line therapy. All therapies were decided at the discretion of the referral gastroenterologist and recorded on standardized case report forms
223587696|NCT03871972|DRUG|Umbilical Cord Blood Unit|3 infusions of umbilical cord blood (UCB) unit (TNC \> 2.0ⅹ107cells/kg) each 4 months apart and take oral Sirolimus (1 mg/m2/day) for 7 days (from 3 days before UCB infusion until 3 days after UCB infusion)
223587697|NCT04023682|DRUG|Provodine Hand Sanitizer|Intervention with Provodine
223587698|NCT00272116|DRUG|Zinc and vitamin A single dose at enrollment|10 mg/day of elemental zinc as zinc gluconate to infants and 20 mg/day to older children
223587699|NCT00272116|DRUG|Placebo and vitamin A single dose at enrollment|Placebo was plain glucose. Vitamin A 100,000 IU to infants and 200,000 IU to older children
223587700|NCT04185506|BEHAVIORAL|DBT+BWL|DBT skills include a focus on emotion regulation, distress tolerance, and mindfulness techniques. BWL includes a focus on monitoring of food intake, calorie reduction, and dietary and physical activity education.
223587701|NCT04378296|OTHER|Teledermatology|The experimental group will be made up of dermatological patients monitored asynchronously.
223587702|NCT05777239|PROCEDURE|Dental Implant Approach for Crestal Sinus Elevation|Crestal Sinus Elevation by elevating the sinus membrane with a blunt ended dental implant approach
223587703|NCT02264080|DRUG|WAL2014|
223587704|NCT02264080|DRUG|Placebo|
224181403|NCT05538507|DRUG|Placebo|patients with MCI will be given placebo
224181404|NCT05141110|DRUG|NVP-1705|NVP-1705
224181405|NCT05141110|DRUG|NVP-1705-R|NVP-1705-R
224181406|NCT03885349|BEHAVIORAL|SBIP+ ADAPs-IMP|Standard batterer intervention program plus Individualized Motivational Plans adapted to alcohol and/or drug abuse problems. The SBIP consist of 70 hr of a cognitive-behavioral intervention including discussion topics such as sexism, sex roles, and gender equality. The intervention phase consisted of six modules in which different intervention techniques were applied (i.e., group dynamics, roleplaying, videos, training in cognitive restructuring, emotion management skills). The IMP included a set of motivational strategies to increase treatment compliance and motivation for change and had four main strategies: (a) five individual motivational interviews, to identify IPV related personal goals and follow up their achievement (in this case, one of the goals has to be related to ADAPs); (b) three group sessions where participants share their goals; (c) therapists follow-up and reinforcement of participants' goals; and (d) use of retention techniques.
224181407|NCT03885349|BEHAVIORAL|SBIP+IMP|Standard batterer intervention program plus Individualized Motivational Plans. The SBIP consist of 70 hr of a cognitive-behavioral intervention including discussion topics such as sexism, sex roles, and gender equality. The intervention phase consist of six modules in which different intervention techniques are applied (i.e., group dynamics, roleplaying, videos, training in cognitive restructuring, emotion management skills). The IMP include a set of motivational strategies to increase treatment compliance and motivation for change and has four main strategies: (a) five individual motivational interviews, to identify IPV related personal goals and follow up their achievement; (b) three group sessions where participants share their goals, explain their progress to the group, and receive feedback, support and advice from the group; (c) therapists follow-up and reinforcement of participants' goals; and (d) use of retention techniques.
224181408|NCT06269042|OTHER|Inspiratory muscle training|The subjects will perform deep inspirations against a threshold device with varying resistances,
224181409|NCT03824106|OTHER|Control|Participants randomized to the control arm will not receive any of the Frailty Management Interventions.
224181410|NCT03824106|BEHAVIORAL|Group Exercise|A recent meta-analysis suggests 180 min/week of exercise (with a high challenge to balance) is most effective for fall prevention. Combined strength and endurance training performed at a moderate weekly frequency (i.e., two times per week) may promote marked gains on muscle hypertrophy, strength and power gains in frail older adults. Balance training is a key component of successful exercise programs for vulnerable older adults.
224181411|NCT03824106|COMBINATION_PRODUCT|Nutrition and Medication review|"Nutrition review: Conduct nutritional screening flow and review any questions, provide some additional counseling/coaching. Protein supplements will be provided to all participants unless contraindicated.~Medication review: Review/update current medication list and forward the list and medical history to the consultant study pharmacist."
224181412|NCT03824106|DIETARY_SUPPLEMENT|Protein Supplement|Protein supplementation will be provided.
224181413|NCT03824106|DIETARY_SUPPLEMENT|Vitamin D|1000 IU of oral vitamin D
223490195|NCT00975923|BEHAVIORAL|Collaborative Group|"In addition to the Tool Kit materials and web site support, facility leaders and managers in this group agreed to participate in a Collaborative to improve critical care. The Collaborative differed from the IHI BTS model in that teams did not come together for face-to-face educational and planning sessions but instead attended web seminars and teleconferences. Between these virtual learning sessions, teams implemented some of the suggested change ideas, measured the results of those changes, and reported back to the larger group. Teams were supported through monthly educational and troubleshooting conference calls, individual coaching by faculty members, and an e-mail listserver designed to stimulate interaction among teams."
223490196|NCT00975923|BEHAVIORAL|Tool Kit|Hospitals received a tool kit:evidence-based guidelines, CLABSI/VAP fact sheets, change ideas,quality improvement and teamwork methods, standardized data collection and charting tools. Periodic reminders of their commitment to the Safe Critical Care Initiative and access to web site containing all of the educational seminars, clinical tools, and quality improvement tools. ICUs in this group were on their own to initiate and implement a local hospital quality improvement initiative preventing CLABSI and VAP.
223490197|NCT05168904|DRUG|fadraciclib|Fadraciclib is a highly selective, orally- and intravenously- available, 2nd generation amino-purine inhibitor of CDK2 and CDK9.
223490198|NCT06025110|BIOLOGICAL|TCD601|Investigational Product
223490199|NCT06025110|OTHER|Placebo|Comparator
223490200|NCT03941821|DRUG|Glecaprevir/Pibrentasvir|Chronic hepatitis C patients will be given Glecaprevir/Pibrentasvir treatment
223490201|NCT02455622|DRUG|Elaprase for intravenous (IV) infusion|Patients enrolled in this study will receive once-weekly IV infusions of Elaprase at a dose of 0.5 mg/kg and will be followed for a minimum of 5 years after initiation of Elaprase treatment, or until they reach their 10th birthday, whichever is longer.Height and weight data from HOS will be utilized in the Primary Growth Analysis for this study.
223490202|NCT04161898|DRUG|Upadacitinib|Upadacitinib will be administered as oral tablet
223490203|NCT04161898|DRUG|Placebo for Upadacitinib|Placebo for upadacitinib will be administered as oral tablet
223587705|NCT03898076|DEVICE|Flash Glucose Monitoring|Continuous Glucose Monitoring (CGM) values will be downloaded from CGM device for a period of 90 days.
224181414|NCT03029754|PROCEDURE|Passive leg raise|A baseline vein diameter will be obtained using ultrasound by the sub-investigator. Then a nurse will raise the child's legs using a bolster while a second measurement of the child's vein diameter is recorded by the sub-investigator. The anesthesiologist will then place the IV and rate the degree of difficulty encountered.
224181415|NCT01928810|BEHAVIORAL|Cognitive Behavioural Therapy|12 sessions of CBT including psychoeducation, interoceptive exposure and in-vivo exposure
224181416|NCT00161291|DRUG|Letrozole in combination with Bevacizumab|Patients will be administered Letrozole at 2.5 mg PO a day and Avastin at 15 mg/kg IV every 3 weeks for 24 weeks. Patients will then undergo surgical treatment and receive adjuvant therapy according to the treating physician.
224181417|NCT05376657|DIETARY_SUPPLEMENT|Cherry collagen drink|consume 1 sachet per day
224181418|NCT05376657|DIETARY_SUPPLEMENT|Placebo drink|consume 1 sachet per day
224181419|NCT02714413|DIETARY_SUPPLEMENT|D-allulose|Subjects will be their own controls as they will be studied sequentially for the effects of varying amounts of D-allulose given in a random order associated with standardized oral sucrose load of 50 gms. In order to limit the possibility of carry-over effect, patients will be randomized to different treatment sequences. In each sequence all four doses (2.5, 5, 7.5, and 10 gm) and placebo will be present only one time and will be administered in a different order.
224181420|NCT02714413|DIETARY_SUPPLEMENT|sucrose|All subjects will receive a standardized oral sucrose load of 50 gms
223490204|NCT04161898|DRUG|Prednisolone|Prednisolone will be administered as oral tablet
223490205|NCT04896385|DRUG|Ruxolitinib cream|Ruxolitinib cream is a topical formulation applied as a thin film to affected areas.
223490206|NCT04896385|DRUG|Vehicle Cream|Vehicle cream is matching in appearance to ruxolitinib cream and is to be applied in the same manner as ruxolitinib cream.
223490207|NCT03386227|OTHER|Withholding antibiotic prophylaxis|Our intervention will be a deviation from our current standard of care which is universal antibiotic prophylaxis, even in low risk populations. Our intervention will be withholding antibiotic prophylaxis in low risk populations.
223587706|NCT03898076|OTHER|A1c|A1c levels will be collected from Hospital EMR prior to CGM data downoad
224181421|NCT02714413|OTHER|Placebo|Subjects will be their own controls as they will be studied sequentially for the effects of varying amounts of D-allulose given in a random order associated with standardized oral sucrose load of 50 gms. In order to limit the possibility of carry-over effect, patients will be randomized to different treatment sequences. In each sequence all four doses (2.5, 5, 7.5, and 10 gm) and placebo will be present only one time and will be administered in a different order.
224181422|NCT04487782|OTHER|Focus Groups|The investigators are enrolling up to 56 women (total) to participate in semi-structured focus groups of 6-8 women per group conducted either in-person or virtually (online) to help us tailor a lifestyle intervention for midlife women during perimenopause.
224181423|NCT02368860|DRUG|oxaliplatin, irinotecan, capecitabine|fixed doses of intravenous oxaliplatin 50 mg/m2, and intravenous irinotecan administered on days 1 and 8 in a 21 day-cycle while xeloda will be administered daily at around midnight from day 1 to day 14
224181424|NCT02645682|DEVICE|anti-infection CVC|
224181425|NCT02645682|DEVICE|normal CVC|
224181426|NCT02738931|DRUG|Dolutegravir 50 mg tablet|A white, film-coated, round tablet debossed with SV 572 on one side and 50 on the other side. Single dose of one tablet will be administered with 240 mL of water.
224181427|NCT02738931|DRUG|Lamivudine 300 mg tablet|"Gray, diamond-shaped tablet, engraved GX EJ7 on one side and plain on the other side. Single dose of one tablet will be administered with 240 mL of water."
224181428|NCT02738931|DRUG|Dolutegravir/Lamivudine 50 mg/300 mg Tablet (Product Code AA)|Immediate release oval tablet embossed 'gsk' on one face with white film coat. Single dose of one tablet will be administered with 240 mL of water.
224181429|NCT02738931|DRUG|Dolutegravir/Lamivudine 50 mg/300 mg Tablet (Product Code AB)|Immediate release oval tablet embossed 'gsk' on one face with white film coat. Single dose of one tablet will be administered with 240 mL of water.
224181430|NCT04504292|DRUG|SUPREP Bowel Prep Kit|Bowel prep prior to colonoscopy
224181431|NCT04504292|DRUG|Golytely Oral Product|Bowel prep prior to colonoscopy
224181432|NCT00336531|DRUG|itraconazole|2.5 mg/kg twice daily for the first two days --\> once daily
224181433|NCT03107065|DEVICE|Thermi Radiofrequency|Percutaneous-Temperature Controlled-Radiofrequency Electrocoagulation
224181434|NCT02927990|OTHER|Percutaneous Coronary Intervention|Percutaneous Coronary Intervention according to standard of care
224181435|NCT04663646|OTHER|Optokinetic stimulation|"Participants are placed in a standing position, with support products, if necessary, and virtual reality glasses will be placed where the visual stimuli will be projected.~The study will be carried out for 10 weeks with a frequency of two weekly sessions. During them, the participants will receive stimulation with OKS.~Stimulation will be performed at 1 cm/second, the vertical black bars will move to the left. The bars change color and the participants will be asked to detect the changes that will occur in the stimulus."
224181436|NCT04663646|OTHER|Placebo|Participants are placed in a standing position, with support products, if necessary, and virtual reality glasses will be placed where the visual stimuli will be projected. In this group, stimulation consists of a video with static vertical bars that change their colour at a randon intervals, in the same way that in the intervention group. The difference between groups is that in control group, bars are not in movement, preventing from generating optokinetic stimulation.
224181437|NCT00960323|DRUG|Colchicine|A single dose of 0.6 mg colchicine administered alone in the morning on Day 1.
224181438|NCT00960323|DRUG|Atorvastatin|Atorvastatin (1 x 40 mg tablet) administered once daily on Days 15-28.
224181439|NCT00960323|DRUG|Colchicine|A single dose of 0.6 mg colchicine administered with a single dose of 40 mg atorvastatin in the morning on Day 28 after an overnight fast.
224181440|NCT06412471|DRUG|SSGJ-707|bispecific antibody
224181441|NCT06412471|DRUG|carboplatin|chemotherapy
224181442|NCT06412471|DRUG|Pemetrexed|chemotherapy
224181443|NCT06412471|DRUG|paclitaxel|chemotherapy
224181444|NCT06412471|DRUG|PD-1/L1|Immune checkpoint inhibitors
223490208|NCT06492252|DEVICE|fMRI|To assess functional connectivity patterns between regions that predict learning.
223490209|NCT06492252|BEHAVIORAL|Adaptation|Auditory adaptation in speech
224181445|NCT06412471|DRUG|Paclitaxel-albumin|chemotherapy
224181446|NCT04321525|BEHAVIORAL|Cognitive-behavioral therapy|10 individual one-hour sessions, with one or two booster sessions at about three months after the tenth session
224181447|NCT04321525|BEHAVIORAL|Personal Construct Therapy|10 individual one-hour sessions, with one or two booster sessions at about three months after the tenth session
224181448|NCT04321525|BEHAVIORAL|Personal Construct Therapy with virtual reality|10 individual one-hour sessions, with one or two booster sessions at about three months after the tenth session
224181449|NCT02788890|PROCEDURE|Scaling without LA|The patient will undergo a supragingival scaling procedure without local anesthesia
224181450|NCT02788890|PROCEDURE|Simple restoration under LA|The patient will undergo a simple dental restoration procedure under local anesthesia
223490210|NCT06492252|BEHAVIORAL|Adaptation|Auditory baseline in speech
223490211|NCT05034289|BEHAVIORAL|PINPOINT Digital Educational Tool|"The intervention prototype called the PINPOINT Digital Educational Tool will be comprised of four main sections that include information about: 1) precision oncology; 2) clinical trials; 3) Learn More screens; and 4) discussion points and questions for the treating clinician. The intervention prototype will also include a search function, short videos of patient testimonials, patient-provider interaction about immunotherapy and clinical trials, as well as a list of questions/concerns that the patient could print (or save electronically) and take with them to their provider visit. An optional chatbot will be available in the corner of the screen. Users can ask the chatbot questions about any of the material on the website or request additional information. The chatbot will also be able to help patients search for molecularly targeted and immunotherapy clinical trials and offer additional resources (such as websites and online support groups)."
224181451|NCT02788890|PROCEDURE|Simple exodontia under LA|The patient will undergo a simple dental extraction procedure under local anesthesia
224181452|NCT00000528|BEHAVIORAL|diet, sodium-restricted (Phase III) diet, sodium-restricted|
224181453|NCT00000528|BEHAVIORAL|diet, reducing (Phase III)|
224181454|NCT05578664|DRUG|Pembrolizumab injection plus metastasis directed treatment (surgery or RT)|Pembrolizumab 400 mg will be administered as a 30 minute IV infusion every 6 weeks for a total of 9 cycles (one year of therapy) and metastasis directed treatment (surgery or RT) from day 21 of cycle 1 to day 42 of cycle 1
223490212|NCT05543941|DEVICE|XPERIENCE Advanced Surgical Irrigation|The patient will undergo THA, TKA, or HR with irrigation of the deep wound prior to fascial closure consisting of XPERIENCE Advanced Surgical Irrigation (XP). XP solution will be applied prior to fascial closure and left to soak for up to 3 minutes. Remaining product will be suctioned away throughout the procedure. No rinsing should take place after irrigation and surgical site will be closed according to site standard operating procedures.
224181455|NCT05578664|OTHER|Tumor resection or RT|Tumor resection or RT will be applied within 42 days from randomization.
224181456|NCT01134458|BEHAVIORAL|Web-Based Intervention|"1. Health Dialog Cardiac Risk Calculator~2. Health Dialog's Living with Coronary Heart Disease~3. Tailored intervention including health behavior modules such as smoking cessation, exercise, diet, and weight"
224181457|NCT06279169|BEHAVIORAL|Heart Sound|In the Heart sound group, this sound will be played to the newborn 5 minutes before Hep B vaccine administration, during the procedure (at 1 minute) and 5 minutes after Hep B vaccine administration
223490213|NCT05543941|DEVICE|Dilute Betadine|The patient will undergo THA, HR or TKA with irrigation of the deep wound prior to fascial closure consisting of Dilute Betadine (DB). DB concentration will be standardized at 0.3% povidone-iodine. DB will be prepared by combining 30 mL of sterile 10% povidone-iodine (from a sterile catheter pack) with 1 L of 0.9% saline in a sterile splash basin. Solution will be left to soak for up to 3 minutes and remaining povidone-iodine solution will be suctioned away. Area will then be rinsed with 1L of normal saline. Surgical site will be closed according to site standard operating procedures.
223490214|NCT06023225|BEHAVIORAL|Pain|Postoperative pain levels
223490215|NCT06023225|BEHAVIORAL|Opioid use|Postoperative opioid use
223490216|NCT04457258|PROCEDURE|Computed Tomography|Undergo PET/CT
223490217|NCT04457258|DRUG|Gallium Ga 68 FAPi-46|Given IV
223490218|NCT04457258|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
223490219|NCT04457258|RADIATION|18F-FDG|Given IV
223490220|NCT06770400|OTHER|Temperature Optimized for Sleep|Using the cloud-controlled thermostat, we will prescribed bedroom temperature based on the observed relationship between the individual's sleep quality and the temperature of their bedroom.
223587707|NCT03898076|OTHER|Predictive A1c|Predictive A1c will be calculated based on the first 15 days of CGM data using time in range (TIR), coefficient of variation (CV), mean amplitude of glycemic excursion (MAGE), mean of daily differences (MODD), continuous overall net glycemic action (CONGA). Predictive A1c will be correlated with actual A1c.
223587708|NCT01291277|DEVICE|Endoscopic Variceal Ligation|Ligation of esophageal varices
223587709|NCT00651963|DRUG|ezetimibe|"Ezetimibe 10 mg daily was added during 4 weeks.~The patients continued taking their usual Statin without titrating the dose."
223587710|NCT02116998|BIOLOGICAL|GEN-004 with Aluminum Hydroxide Adjuvant|"GEN-004: 100 µg of each antigen, with adjuvant, 350 µg aluminum hydroxide, administered as a 0.5 mL intramuscular (IM) injection.~GEN-004 is a recombinant S. pneumoniae protein subunit vaccine consisting of 3 recombinant T cell antigens:~* GB104: ABC transporter, substrate-binding protein~* GB144: Maltose/maltodextrin binding protein, ABC transporter~* GB152: Hypothetical protein~GEN-004 is filled in 2 mL vials containing 0.5 mL (350 µg/mL of each antigen).~Aluminum hydroxide adjuvant is filled in 2 mL vials containing 1 mL at a concentration of 5 mg/mL."
223587711|NCT02116998|BIOLOGICAL|Placebo|Placebo: normal saline, 0.5 mL per dose, IM.
224181458|NCT06279169|BEHAVIORAL|White Noise|"Musician Osman Orhan's song Bebeğiniz Ağlamasın from his album Kolik will be used for white noise. The volume will be set to 45 db."
224181459|NCT04892095|OTHER|No intervention|This is an observational cross-sectional study. No intervention is considered.
224181460|NCT03414372|BEHAVIORAL|Tough Talks Online|Those randomized to the online condition will receive information about how to access Tough Talks online and be given their unique log-in and password information and information on how to contact study personnel for any technical issues. Arm 1 participants will have 24-hour access to all of the intervention features and will be able to access the program for additional sessions at any time. Study staff will provide reminders using text or email (participant preference) if they have not accessed the intervention at the specified time intervals.
224181461|NCT03414372|BEHAVIORAL|Tough Talks Clinic|Those randomized to the in-clinic condition (Arm 2) will immediately begin the Tough Talks intervention. Study staff will ensure participants are logged on and will also be available to answer technical issues should they arise. After completion, those in this arm will have an in-person follow-up visit scheduled for approximately two weeks. The in-person sessions were adapted to be delivered via Zoom or a similar HIPAA compliant platform due to the COVID-19 pandemic.
223490221|NCT06770400|OTHER|Participant's Preferred Temperature|Temperature is set by the individual based on their own habits and preference.
223490222|NCT04512924|BEHAVIORAL|Enhanced mobile app with standard of care and education|Group 1 will download an enhanced mobile app that will include education and support resources related to food allergy and its management.
223490223|NCT04512924|BEHAVIORAL|Enhanced mobile app with standard of care, education and support resources|Group 2 will download an enhanced mobile app that will include education and support resources related to food allergy and its management, a symptom monitoring and tracking system that allows mobile app users to log symptoms they may experience as caregivers of children newly diagnosed with food allergy, e.g. fatigue and anxiety, and symptom based interventions (recommendations) that may improve a caregiver's ability to self-manage experienced symptoms.
223490224|NCT05291689|DRUG|MORF-057|MORF-057 is a small molecule that is designed to selectively inhibit integrin α4β7 and is administered orally.
223490225|NCT01931098|DRUG|topotecan|Taken .25 mg orally, daily continuous until progression up to one year.
223490226|NCT01931098|DRUG|pazopanib|600 mg orally, daily until progression, up to one year.
223490227|NCT05091242|DRUG|Clonidine|Clonidine injection 3 mcg/kg once
223490228|NCT05091242|DRUG|Sodium chloride|Sodium chloride 0.9 % injection 0.2 mL/kg once
223490229|NCT00559000|BEHAVIORAL|KIDNET|Narrative Exposure Therapy for Children
223587712|NCT02116998|BIOLOGICAL|Streptococcus pneumoniae inoculation|Intranasal inoculation of S. Pneumoniae (80,000 CFU/100μl per nostril) serotype 6B.
223587713|NCT01238965|DRUG|panobinostat|Given orally
223587714|NCT01238965|DRUG|fluorouracil|Given IV
223587715|NCT01238965|DRUG|leucovorin calcium|Given IV
223587716|NCT01238965|PROCEDURE|biopsy|Correlative studies
223587717|NCT01238965|GENETIC|reverse transcriptase-polymerase chain reaction|Correlative studies
223490230|NCT03831724|DEVICE|EndoFLIP™ System with FLIP Topography Module|The EndoFLIP system with the EF-322N catheter will be used. The EndoFLIP system is a tool that assesses esophageal, esophago-gastric junction (EGJ)/lower esophageal sphincter (LES), and pylorus function. It allows the measurement of LES and pylorus distensibility as well as esophageal contractile activity in response to distension. The system uses impedance planimetry to measure luminal cross-sectional area (CSA) along an axial plane during volume-controlled distention.
224181462|NCT03414372|BEHAVIORAL|Standard of Care|Those randomized to the control arm (SOC) will receive a paper-based disclosure informational packet based on available Centers of Disease Control (CDC) guidance. At one-month, all participants will complete an online survey to assess intervention acceptability as well as to assess Social Cognitive Theory (SCT model) constructs.
224181463|NCT05199389|DEVICE|Multiwave Locked System® (M6 laser, ASA srl, Arcugnano (VI), Italy)|MLS® Laser M6 is a PBM device that allows the patients to be treated in various positions, either sitting, lying down or at a distance, without risk of contamination. Treatment times are carefully calibrated to deliver the best possible energy dose to the tissue being treated.
224181464|NCT00213668|DIETARY_SUPPLEMENT|glutamine (dipeptiven)|
224181465|NCT02540811|DEVICE|dCELL® ACL Scaffold|
224181466|NCT03154424|PROCEDURE|External fixation in treatment the distal radius fracture|Compare two techniques
224181467|NCT01494753|DRUG|T2345|One drop at 8.00pm.
224181468|NCT01494753|DRUG|Prostaglandin|One drop at 8.00pm.
224181469|NCT05696184|DIAGNOSTIC_TEST|Concurrent manometry/impedance/pH with video pharyngo-laryngoscopy|"Combined manometric/impedance/pH recording: we will use combined solid-state high-resolution manometry and impedance catheter with 36 circumferential pressure sensors, spaced 1 cm apart, 18 impedance sensor couplets spaced 2 cm apart, 3 pH sensors spaced 7 and 10 cm respectively. The catheter will be introduced trans-nasally.~Concurrent video-pharyngo-laryngoscopy: to monitor concurrently the pharynx and larynx for entry of simulated refluxate we will use a laryngo-pharyngo-scope passed through the other nostril and positioned within the pharynx such that the UES inlet, vocal cords and pyriform sinuses are visualized. The laryngo-pharyngo-scope images will be synchronized with manometric/impedance/pH recordings by importing and superimposing the endoscopic images onto high resolution manometric recordings. A specially designed timer will be superimposed on the video images for durational analyses of endoscopic images."
224181470|NCT05696184|DIAGNOSTIC_TEST|Slow and rapid intra-esophageal infusion|A 3 mm outer diameter injection tube will be placed through the nose in a fashion that the injection port will be located 5-7cm above the manometrically determined upper border of lower esophageal sphincter (LES). With this arrangement gastroesophageal reflux events will be simulated by intra-esophageal injection of body temperature1/2 normal saline (its ionic nature helps impedance recording and identification of intra-esophageal distribution), 0.1 N HCl. Infused liquid will be colored green using food dye for ease of recognition of pharyngeal reflux. Esophageal clearance will be verified by the presence of an effective peristalsis and return of intra-esophageal impedance and pressure to baseline. Endoscopic views of pharynx will be watched carefully during infusions. At the first sign of reflux, perfusion will be stopped, and participants will be instructed to swallow to avoid any potential airway compromise.
224181471|NCT01551043|BIOLOGICAL|CART-19|
224181472|NCT04534868|OTHER|taking macroscopic and dermoscopic pictures of suspicious skin lesions|"If there is any diagnostic doubt about a skin lesion, teledermoscopy will be used, if the patient agrees.~* A table containing the useful information about the patient for the lesion's analysis will be completed.~* The pictures will be taken with a Fotofinder Handyscope. The photos will be integrated into the patient's electronic medical record (CareConnect program).~* The photo is anonymized via a serial number assigned by the Handyscope application.~* Sending photos and information via a secure email address to the dermatologists.~* Response from the dermatologist (Prof. Tromme or Dr Harkemanne) in the following days also via email.~* Contact (consultation or telephone call depending on the diagnosis) with the patient to communicate the results and the procedure to be followed.~* This information (emails containing the dermatological report) will be saved in the patient's computerized medical file (CareConnect program) then deleted from the mailbox"
224181473|NCT05863039|OTHER|Blood flow restriction|Strength training of the lower leg muscles using blood flow restriction
223490231|NCT04649307|BEHAVIORAL|MI-CBT|Education, Interoceptive exposure, Exposure in-vivo, Behavioral activation, Relapse prevention
223490232|NCT05179512|DRUG|Tiotropium|Tiotropium dispensing claim is used as the reference group.
223490233|NCT05179512|DRUG|salmeterol-fluticasone|Salmeterol/Fluticasone dispensing claim is used as the exposure group.
223490234|NCT02278354|DRUG|Flortaucipir F18|IV injection, 370 megabecquerel (MBq) (10 mCi)
223490235|NCT02278354|PROCEDURE|Brain PET scan|positron emission tomography (PET) scan of the brain 75-105 minutes post injection
223490236|NCT00562328|BIOLOGICAL|Alemtuzumab|"Week 1 (dose escalation):~Day 3: 3mg subcutaneously; Day 4: 10mg subcutaneously; Day 5 30mg subcutaneously~Weeks 2-5:~30mg subcutaneously three times a week."
223490237|NCT00562328|BIOLOGICAL|Rituximab|"Weeks 2-5:~375 mg/m\^2 by IV once weekly"
223490238|NCT00562328|BIOLOGICAL|Sargramostim|"Week 1-6:~250 mcg subcutaneously three time as week"
223490239|NCT04194970|DEVICE|With WBM smart insole system to monitor compliance of specified weight bearing limits data in live feedback on and off situations|"Weight Bearing Protocol (Duration: Post-Op. 6 week)~* Post-op 3 week non-weight bearing (%0 body weight of patient)~* Post- op 3 week touch down weight bearing (%10-%20 body weight of patient) Group I - monitoring with device while the live feedback mechanism turned on Group II- monitoring with device while the live feedback mechanism turned off"
223490240|NCT05191186|DRUG|Grass pollen extract - Alutard Phleum pratense, ALK|injection in lymph node
223490241|NCT03012243|PROCEDURE|Gallbladder aspiration|Percutaneous ultrasound-guided aspiration of bile from the gallbladder. This is performed without leaving a drain in the gallbladder. The aspiration is performed with the intention to relief the pressure in the gallbladder, without drain.
223490242|NCT03012243|PROCEDURE|Cholecystostomy|Ultrasound-guided insertion of drain in the gallbladder. The drain is left in the gallbladder until clinical assessment and laboratory analyses show that the acute cholecystitis has been successfully treated.
223490243|NCT02612155|BIOLOGICAL|Infusion of autologous cord blood|Infants who meet study enrollment criteria will receive up to 2 infusions of their own volume reduced cord blood cells. The number of doses will be determined by the amount of available cord blood cells.
224181474|NCT05863039|OTHER|Regular training type 1|Strength training of the lower leg muscles using high loads
224181475|NCT05863039|OTHER|Regular training type 2|Strength training of the lower leg muscles using low loads
224181476|NCT05937295|DRUG|Fusion-VAC-XS15|"FusionVAC-22 peptide will be administered subcutaneously (s.c.) adjuvanted with the Toll-like receptor 1/2 ligand XS15 (50 μg) emulsified in Montanide ISA 51 VG (1:1).~Vaccination will take place every 4 weeks at the beginning of Cycle 1 and 2. A total of two vaccinations are planned.~After 11 months a booster vaccination can be applied depending on T-cell responses.~Immune checkpoint inhibition (ICI):~Atezolizumab (TecentriqTM, Roche Pharma AG) is a humanized immunoglobulin (Ig) G1 monoclonal antibody that targets PD-L1 and will be applied intravenously (i.v.).~The anti-PD-L1 antibody Atezolizumab (TecentriqTM) 1680 mg will be applied every 4 weeks as a 30-minute infusion (60-minute first dose) starting on day 15 after the first vaccination. Anti-PD-L1 treatment will be continued after the end of vaccination phase throughout the complete study period until End of Treatment (EOT) or until disease progression or other reasons for study termination."
224181477|NCT03265431|DRUG|18F-TPP|Imaging with 18-F-TPP (18F-BFPET)
224181478|NCT00492739|BIOLOGICAL|Vaccination with VZV vaccine|Varicella vaccination 2 doses 2 months apart.
224181479|NCT03810599|OTHER|Early cardiac rehabilitation|"This is an early cardiac rehabilitation programme starting 1-2 weeks after hospital discharge (Phase 2A rehabilitation). The programme provided by a multidisciplinary team includes individual counseling, educational sessions and discussion in groups, and exercise training sessions three days a week for five weeks.~For additional analysis there will be a comparison group that did not receive the intervention for practical reasons."
224181480|NCT02843113|BEHAVIORAL|4 Your Child Program|Integrates the provision of responsible parenting, economic stability, and relationship education services to fathers at risk for paternal disengagement.
224181481|NCT03789864|DIAGNOSTIC_TEST|Biodynamic imaging (BDI) of mycosis fungoides|Skin punch biopsy samples from cutaneous lesions will be profiled for sensitivity to gemcitabine using ex vivo Biodynamic imaging (BDI). A biodynamic profile, of either phenotypic responder or phenotypic non-responder, will be assigned.
224181482|NCT05471453|DIETARY_SUPPLEMENT|DHEA|75 mg DHEA supplementation per day for 3 months before IVF
224181483|NCT05471453|DIETARY_SUPPLEMENT|DHEA+CoQ10+Tocotrienol|75 mg DHEA supplementation + 30 mg CoQ10 + 300 mg Tocotrienol per day for 3 months before IVF
224181484|NCT01031368|DRUG|cytarabine|Given IV
223490244|NCT02612155|BIOLOGICAL|Placebo|Infants who meet study enrollment criteria will receive up to 2 placebo infusions composed of an equivalent volume (volume of product that would have been administered if the infant randomized to the intervention arm) of packed red blood cells (PRBCs) from the red cell compartment of the separated cord blood unit.
223490245|NCT04767750|OTHER|Blood sample collection|"5ml of peripheral blood samples will be collected into tubes containing EDTA from all subjects and the following procedures will be performed:~* Peripheral blood mononuclear cells (PBMCs) will be isolated from blood samples.~* Total RNA extraction from PBMCs by Trizol reagent and spin column.~* Reverse transcription to cDNA.~* The expression levels of lncRNA H19, IGF-1R mRNA and GAPDH gene (control gene) will be determined by Real-Time Quantitative PCR"
223490246|NCT02876081|DRUG|Afatinib|to evaluate the efficacy of afatinib, an EGFR TKI, on lung adenocarcinomas, EGFR wild-type, bearing the NTS/NTSR1 complex with a high level of expression
223490247|NCT06493747|DEVICE|Combined Low- and High-Frequency rTMS Intervention|This intervention involves the application of rTMS using an 8-shaped coil with a frequency of 1Hz for low-frequency stimulation and 5Hz for high-frequency stimulation, in accordance with the study protocol.
223490248|NCT06493747|DEVICE|Combined High- and Low-Frequency rTMS Intervention|Similar to Arm A, but the sequence of low and high-frequency rTMS is reversed.
224181485|NCT01031368|DRUG|clofarabine|Given IV
224181486|NCT01031368|DRUG|filgrastim|Given SC
223490249|NCT06493747|DEVICE|rTMS|Participants receive an individualized rTMS therapy plan based on integrated analysis of assessment data, targeting specific brain areas to enhance language function recovery post-stroke.
223490250|NCT06493747|DEVICE|rTMS + Acupuncture|"Participants undergo a combined treatment of rTMS as described for the rTMS Experimental Group and traditional Chinese acupuncture based on the Kaiqiao Jieyan method, targeting specific acupoints to facilitate recovery."
223490251|NCT06493747|DEVICE|rTMS|Participants receive a conventional rTMS treatment as per established guidelines, serving as an active comparator to the experimental interventions.
223490252|NCT06493747|DEVICE|Acupuncture|"Participants receive Kaiqiao Jieyan acupuncture therapy alone, without rTMS, following traditional Chinese medicine protocols for post-stroke aphasia rehabilitation."
223490253|NCT05484947|DIAGNOSTIC_TEST|Elisa HIV testing|HIV testing on a voluntary basis
223490254|NCT06237881|DRUG|KSQ-001EX|Given by IV
223490255|NCT06237881|DRUG|Interleukin-2|Given by IV
223587718|NCT01238965|GENETIC|western blotting|Correlative studies
223587719|NCT01238965|OTHER|laboratory biomarker analysis|Correlative studies
223587720|NCT01238965|GENETIC|gene expression analysis|Correlative studies
224181487|NCT01031368|BIOLOGICAL|Ex-vivo expanded cord blood progenitor cell infusion|Undergo ex vivo-expanded cord blood progenitor cell infusion
224181488|NCT01031368|OTHER|laboratory biomarker analysis|Correlative studies
224181489|NCT00004058|DRUG|tetradecanoylphorbol acetate|
224181490|NCT00847951|PROCEDURE|3D Ultrasound Imaging|Ultrasound scanning with power Doppler is used to determine the fractional blood volume of the kidneys in pre-mature and/or very low birth weight babies. This is a measure of perfusion and an indication of how well the kidneys are working.
223490256|NCT06237881|DRUG|Cyclophosphamide|Given by IV
223490257|NCT06237881|DRUG|Fludarabine|Given by IV
223490258|NCT05687110|PROCEDURE|Biopsy Procedure|Undergo tumor biopsy
223490259|NCT05687110|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223490260|NCT05687110|PROCEDURE|Diagnostic Imaging Testing|Undergo medical imaging scans
223490261|NCT05687110|BIOLOGICAL|Novobiocin Sodium|Given PO
223587721|NCT01238965|GENETIC|RNA analysis|Correlative studies
223587722|NCT01238965|GENETIC|polymorphism analysis|Correlative studies
223587723|NCT02963701|DRUG|Ibuprofen|Fixed dose combination
223587724|NCT02963701|DRUG|Pseudoephedrine-HCl|Fixed dose combination
224181491|NCT06580756|OTHER|Short training program|Training in the early identification of addictive disorders in primary care
224181492|NCT05609188|OTHER|Guaranteed Income|Monthly cash transfer of $500 per month for 12 months.
224181493|NCT05609188|BEHAVIORAL|Peer learning circles|Participants can opt-in to attend peer learning circles (also called My Money Hour), which are discussion groups of 10-12 participants about financial topics co-led by a peer (Black youth) with experience in financial programming and an adult financial coach. My Money Hour sessions will be offered on-line multiple times throughout every month of the project, with rotating themes, to ensure that the 50-minute sessions are available different days of the week and times of the day.
224181494|NCT05609188|BEHAVIORAL|Financial coaching|Participants can opt-in to receive financial coaching sessions with a trained financial mentor. Meetings will occur monthly and typically include six one hour sessions. The mentor will be responsive to individual needs, but will touch on the following priority areas: building credit (credit repair, improving credit scores, credit products); savings (emergency savings plans, savings habits and strategies, understanding savings accounts); money management (creating budgets, understanding income vs expense, assessing spending, making better financial decisions); financial products (credit building products, auto loans, credit cards); and long-term goals (home ownership, investments).
224181495|NCT01214382|DRUG|Sertraline|Single dose sertraline 100 mg, tablet and solution
224181496|NCT04749316|PROCEDURE|AcuTENS|Stimulation of acupuncture points with TENS machine
224181497|NCT05794217|BEHAVIORAL|This is a non-interventional study|This is a non-interventional study
224181498|NCT02812550|PROCEDURE|colonoscopy procedure|endoscopy performed with a standard forward view colonoscopy or with full-spectrum endoscopy
224181499|NCT00153452|BEHAVIORAL|perpetration of intimate partner violence|
224181500|NCT04197999|DRUG|GMI-1359|Injection 10 mg/mL
224181501|NCT05312528|PROCEDURE|endometriosis surgery|Laparoscopy was performed in the follicular phase of the woman's menstrual cycle and all recognizable endometriotic lesions were treated by bipolar coagulation, resection of endometriotic nodules and ovarian cystectomy.
224181502|NCT05312528|PROCEDURE|other benign condition surgeries|ovarian cystectomy, bilateral tubal ligation, myomectomy etc.
224181503|NCT04819711|BEHAVIORAL|Thinking Healthy Programme|The Thinking Healthy Programme (THP) is an evidence-based intervention that is based on principles of cognitive behavioral therapy. It includes strategies that incorporate behavioral activation, active listening, collaboration with the family, guided discovery, and homework. The adapted THP consists of 5 integrated sessions. Session 1 introduces the programme and focuses on engagement of participants, introduction of THP, and breathing exercises. Session 2 focuses on psychoeducation and problem solving. Session 3 focuses on the mother's well-being and introduces activities such as physical exercises, good sleep practices and ensuring a balanced diet. Session 4 focuses on the mother's relationship with the unborn baby. Session 5 focuses on activating social support from family, friends and peers and provides closure of therapy.
223490262|NCT05710640|DEVICE|Active tcVNS or Sham tcVNS|tcVNS is administered with a study device that gives off mild electrical impulses through the skin to stimulate the vagus nerve (a nerve that travels underneath the skin in your neck and head). This stimulation triggers a chemical response through the nerves and has been found to be effective in reducing pain and inflammation in several diseases.
223490263|NCT05710640|DEVICE|Active tcVNS|tcVNS is administered with a study device that gives off mild electrical impulses through the skin to stimulate the vagus nerve (a nerve that travels underneath the skin in your neck and head). This stimulation triggers a chemical response through the nerves and has been found to be effective in reducing pain and inflammation in several diseases.
223490264|NCT01601977|DEVICE|AVAPS-AE|Novel ventilation mode (Omnilab - AVAPS AE algorithm)
223490265|NCT01601977|DEVICE|Usual care|Non-invasive ventilation with standard ventilator
223490266|NCT03590327|DEVICE|Transcranial Magnetic Stimulation|rTMS
223490267|NCT03324113|DRUG|SAR408701|"Pharmaceutical form: solution for infusion~Route of administration: intravenous"
223490268|NCT03324113|DRUG|dexamethasone|"Pharmaceutical form: solution for eye drop~Route of administration: eye drop"
223490269|NCT03324113|DRUG|naphazoline|"Pharmaceutical form: solution for eye drop~Route of administration: eye drop"
223490270|NCT03324113|DRUG|diphenhydramine|"Pharmaceutical form: tablet~Route of administration: oral"
223490271|NCT00379041|BIOLOGICAL|bleomycin sulfate|
223490272|NCT00379041|DRUG|doxorubicin hydrochloride|
223490273|NCT00379041|DRUG|mechlorethamine hydrochloride|
223490274|NCT00379041|DRUG|prednisone|
223490275|NCT00379041|DRUG|procarbazine hydrochloride|
223490276|NCT00379041|DRUG|vinblastine sulfate|
223490277|NCT00379041|DRUG|vincristine sulfate|
223490278|NCT00379041|RADIATION|radiation therapy|
223490279|NCT05007925|DEVICE|Intravascular Lithotripsy|Localized peripheral intravascular lithotripsy
223490280|NCT05558761|DRUG|Pentoxifylline 400 MG|Pentoxifylline (PTX) is a methyl-xanthine derivative that possesses antioxidant and anti-inflammatory characteristics. PTX exerts anti-inflammatory effects by inhibiting phosphodiesterase and activating the adenosine 2 receptor
223490281|NCT04543383|DRUG|Milvexian|Milvexian will be administered orally.
223490282|NCT04543383|BIOLOGICAL|4-Factor Prothrombin Complex Concentrate (4F-PCC)|4F-PCC will be administered intravenously.
223490283|NCT04543383|BIOLOGICAL|Recombinant Human Factor VIIa (rFVIIa)|rFVIIa will be administered intravenously.
223490284|NCT04543383|BIOLOGICAL|Placebo matching to 4F-PCC|Placebo matching to 4F-PCC will be administered intravenously.
223490285|NCT04543383|BIOLOGICAL|Placebo matching to rFVIIa|Placebo matching to rFVIIa will be administered intravenously.
224181504|NCT03857165|DRUG|SAP-001|SAP-001 or placebo treatment in a 3:1 randomization ratio.
224181505|NCT00101790|DRUG|pamidronate|There will be four study groups, each with 7 subjects randomly assigned to pamidronate and 4 to placebo. The groups will occur in succession, not parallel. The dosage for group 1 will be 30 mg , 60 mg for group 2, and 90 mg for group 3. Group 4 will receive 2 treatments of 90mg IV pamidronate or placebo.
224181506|NCT03146195|OTHER|Dynamic Magnetic resonance imaging|
224181507|NCT03844581|DEVICE|interferential current|Treatment was applied using four vacuum electrodes with wet sponge, two of them were put under the patient lumber region on a distance from lumber spinous process by five cm on each side and the other two were applied over the suprapubic region parallel to iliac crest.
224181508|NCT03844581|DRUG|Propiverine Hydrochloride|propiverine hydrochloride 20 mg/once per day in the morning
224181509|NCT02478658|OTHER|exercise training|high-intensity resistance training
224181510|NCT03824704|DRUG|Rucaparib|Oral rucaparib will be administered twice daily
224181511|NCT03824704|DRUG|Nivolumab|IV nivolumab will be administered once every 4 weeks
224181512|NCT02529358|BEHAVIORAL|standardized text messages|Messages consist of relaxation techniques and mindfulness exercises as well as emotion regulation strategies
223490286|NCT01833182|OTHER|Tailored home intervention|The occupational therapist (OT) interventionist will develop a set of environmental modification choices to improve performance in problematic activities identified during the clinical evaluation. A plan for resolving the barriers identified during clinical assessment will be developed. The participant will review the barrier removal options and will make an informed choice resulting in a final treatment plan. Modification installation which will be provided, at no cost to the participant, by a contractor trained by the study PI. The tailored intervention includes training in the use of the new equipment or architectural changes. Photographs of identified barriers, study measures, and intervention plans will be reviewed by the principal investigator during team meetings to ensure treatment fidelity.
223490287|NCT01833182|OTHER|Sham intervention|We have developed a kit containing 12 standard adaptive equipment (AD) items (e.g., jar opener). The AD kit has been specifically designed to address fine motor function and will not influence fall outcomes. Two pieces of AD will be provided during each session, and the individual will be instructed to use each AD by the OT interventionist
223490288|NCT00261521|DRUG|epoetin alfa|
223490289|NCT03625128|DRUG|F-18|This is an open-label study to evaluate the performance of a novel tau imaging ligand in up to 36 subjects (12 AD, 3 FTD, 3 PSP, 3 CBS, 3 VCI and 12 HV).
223490290|NCT05383378|DRUG|si-544|Subcutaneous injection in the abdomen
223490291|NCT05383378|DRUG|Placebo|Subcutaneous injection in the abdomen
223490292|NCT00712504|DRUG|sunitinib|25, 37.5 and 50 mg/day, oral, administered on an outpatient basis in two different dosing regimens: schedule 2/1 (2 weeks on, 1 week off) and schedule 4/2 (4 weeks on, 2 weeks off)
223490293|NCT00712504|DRUG|docetaxel|60, 75, and 100 mg/m2 docetaxel administered every 21 days as a 1-hr IV infusion
223490294|NCT04031950|DEVICE|Novel wearable paediatric device|The patient will wear the novel wearable paediatric device at the same time as polysmnography
223490295|NCT05975645|DRUG|Penpulimab injection|Penpulimab is an inhibitor of programmed cell death 1 (PD-1).
223490296|NCT05975645|DRUG|TQB2618 injection|TQB2618 injection is an inhibitor of T cell immunoglobulin and mucin domain-containing protein 3 (TIM-3).
223490297|NCT05975645|DRUG|Anlotinib Hydrochloride Capsules|Anlotinib hydrochloride is a muti-target tyrosine kinase inhibitor.
223490298|NCT02572167|DRUG|brentuximab vedotin|1.8 mg/kg by intravenous (IV) infusion for up to 4 cycles
223490299|NCT02572167|DRUG|nivolumab|3 mg/kg by intravenous (IV) infusion for up to 4 cycles
223490300|NCT00992875|BEHAVIORAL|Mindfulness-Based Stress Reduction|Behavioral intervention, mindfulness meditation in form of yoga, sitting meditation, body scan and mindfulness to routine activities
223490301|NCT02789748|DEVICE|Kinesthetic stimulation|Activation of mechanoreceptors by vibration bursts
223490302|NCT04878900|OTHER|Survey|Survey
223490303|NCT06254339|PROCEDURE|OAGB|using OAGB procedure as metabolic bariatric surgery
223490304|NCT06254339|PROCEDURE|DJB-SG|using DJB-SG procedure as metabolic bariatric surgery
223490305|NCT01124240|DRUG|Cilengitide|"Cilengitide 2000 mg flat i.v. twice weekly is administered over a period of 18 months without interruption.~Starting one week after the initiation of Cilengitide, RTX (60 Gy, 2 Gy per fraction) with concurrent daily temozolomide (60 mg/m2 p.o.) and daily procarbazine (PCB, 50 mg p.o. if BSA \< 1.7; 100 mg p.o. if BSA ≥ 1.7) is given over a period of 6 weeks (RTX Monday to Friday, both TMZ and PCB seven days a week).~After a break of 4 weeks, adjuvant TMZ (50mg/m2 p.o in first cycle, 60 mg/m2 p.o. in subsequent cycles) and PCB (50 mg p.o. if BSA \< 1.7; 100 mg p.o. if BSA ≥ 1.7) are then given daily D1 to 20. This TMZ/PCB cycle is repeated every 28 days over a total period of 6 cycles."
223490306|NCT06059599|OTHER|active informed consent|new preoperative information method, based on multimedia tools and on the objective control of understanding by the patient candidate for vertebral or urological surgery.
223490307|NCT04866160|DRUG|BI 1291583|BI 1291583
223490308|NCT04866160|DRUG|Placebo|Placebo
223490309|NCT01500551|DRUG|Tofacitinib|"Tofacitinib will be administered orally BID (twice daily) approximately 12 hours (±2 hours) apart, once in the morning and once in the evening, based on body weight for all subjects for all three index studies (A3921103, A3921104, and A3921165)~5 mg BID Dose Level:~Body Weight (Dose in tablet \[mg BID\] or solution \[ml BID\]) 5 - \< 7 kg (2 mg or 2 ml) 7 - \< 10 kg (2.5 mg or 2.5 ml) 10 - \<15 kg (3 mg or 3 ml) 15 - \<25 kg (3.5 mg or 3.5 ml) 25 - \<40 kg (4 mg or 4 ml) \>=40 kg (5 mg or 5 ml)~Oral solution (1 mg/mL concentration) will be used for subjects weighing \<40 kg. Oral tablets (5 mg) will be used for subjects weighing \>=40 kg; subjects who are unable to swallow tablets will have the option of taking oral solution.~Subjects will swallow study tablets whole and will not manipulate or chew tablets prior to swallowing."
223587725|NCT05546073|OTHER|Advanced point-of-care technology|"The intervention consists of:~* focused lung ultrasound scan(FLUS)~* venous blood samples for leucocytes with 5-part differential count, creatinin, sodium, potassium, urea"
224181513|NCT02529358|BEHAVIORAL|Personalized text messages|Patients write their own messages
224181514|NCT02529358|BEHAVIORAL|Standardized text messages after 10 weeks|Messages consist of relaxation techniques and mindfulness exercises as well as emotion regulation strategies which are send to the patients 10 weeks after completing inpatient therapy
224181515|NCT04963738|DRUG|JNJ-73763989|JNJ-73763989 will be administered as a single SC injection.
223490310|NCT01500551|DRUG|Tofacitinib|For subjects rolling over from study A3921103 and actively participating in this study at the time of Protocol Amendment 6 and receiving a dosage of tofacitinib in accordance with the dosing scheme specified in Protocol Amendment 5, investigators will have the option of maintaining the subject's current dosage regimen from index study A3921103 (if the desired clinical response has been attained with no safety concern) or adjusting the dosage regimen in accordance with the dosing scheme specified in this section.
223490311|NCT05785611|DRUG|Filgotinib|Tablets administered orally once daily
224181516|NCT00145379|DRUG|Tablet Metformin 500 mg|
224181517|NCT00145379|DRUG|Placebo|
224181518|NCT00865176|DRUG|Eplerenone 50 mg Tablets Sandoz Inc., USA|
224181519|NCT00865176|DRUG|Inspra 50 mg Tablets GD Searle LLC, USA|
224181520|NCT05262842|DRUG|JS001+IMP4297|"Phase I: Dose Escalation The primary endpoints are the safety and tolerability of the combination, including the incidence and nature of DLTs and the determination of the MTD and RP2D. A 3 + 3 dose-escalation (60mg,80mg,100mg)design will be used. Patient in each dose level will be treated with toripalimab 240mg in combination with senaparib.~Phase Ib: Dose Expansion This part will commence after the RP2D is determined and will further evaluate the safety and anti-tumor activity of toripalimab and senaparib in patients with specific types of advanced solid tumors. Patients will be enrolled concurrently into 5 exploratory cohorts with approximately 20 patients each cohort."
224181521|NCT01402999|DEVICE|easypod™|Saizen (Somatotropin) as per Summary of Product Characteristics (SmPC) administered by easypod™
224181522|NCT05751850|DRUG|HR070803; Oxaliplatin; 5Fluorouracil; Calcium folinate|HR070803 in combination with oxaliplatin, 5-fluorouracil, calcium folinate
224181523|NCT05751850|DRUG|nab-paclitaxel; gemcitabine|nab-paclitaxel in combination with gemcitabine
224181524|NCT00182793|BIOLOGICAL|trastuzumab|Cycle 1: 6 mg/kg on day -2 from PBSC reinfusion Cycle 2: 6 mg/kg on day -7 from PBSC reinfusion
224181525|NCT00182793|DRUG|carboplatin|Cycle 2: 800 mg/m2/96 hours on days -7 to -3 from PBSC reinfusion
224181526|NCT00182793|DRUG|cyclophosphamide|Cycle 2: 6000 mg/m2/96 hours on days -7 to -3 from PBSC reinfusion
224181527|NCT00182793|DRUG|melphalan|Cycle 1: 150 mg/m2 on day -1 from PBSC reinfusion
224181528|NCT00182793|DRUG|thiotepa|Cycle 2: 500 mg/m2/96 hours on days -7 to -3 from PBSC reinfusion
224181529|NCT00182793|PROCEDURE|adjuvant therapy|Tandem high-dose chemotherapy comprising melphalan, carboplatin, thiotepa, and cyclophosphamide with or without trastuzumab (Herceptin®) followed by autologous peripheral blood stem cell transplantation and helical tomotherapy or loco-regional radiotherapy.
224181530|NCT00182793|PROCEDURE|autologous-autologous tandem hematopoietic stem cell transplantation|Tandem high-dose chemotherapy comprising melphalan, carboplatin, thiotepa, and cyclophosphamide with or without trastuzumab (Herceptin®) followed by autologous peripheral blood stem cell transplantation.
224181531|NCT00182793|PROCEDURE|bone marrow ablation with stem cell support|Tandem high-dose chemotherapy comprising melphalan, carboplatin, thiotepa, and cyclophosphamide with or without trastuzumab (Herceptin®) followed by autologous peripheral blood stem cell transplantation
224181532|NCT00182793|RADIATION|radiation therapy|"After recovery from high-dose chemotherapy and autologous PBSC transplantation; patients with stage IIIB or IIIC disease undergo radiotherapy to the chest wall and lymph nodes. Treatment should be delivered daily M-F @ 180-200 cGY/day to a total of 4,500 to 5,040 cGy.~Patients with stage IV disease undergo radiotherapy using helical tomotherapy or standard radiotherapy to oligometastatic sites. Treatment should be delivered daily @180-220 cGY/day to a total of 4,000-5,000 cGy."
224181533|NCT03117686|DIAGNOSTIC_TEST|lung ultrasound|"lung ultrasound with positive B-line pattern in patients after lung transplantations and healthy volunteers at sea level and high altitude (4600 m) at Mountb Kilimanjaro"
224181534|NCT02793531|OTHER|Stable isotope amino acid infusion|such as glycerol, D2O, tyrosine, phenylalanine, glucose, arginine, and citrulline
224181535|NCT03287960|DRUG|Setmelanotide|Once daily subcutaneous injection
224181536|NCT03287960|DRUG|Placebo|Once daily subcutaneous injection
224181537|NCT00237146|DRUG|Zoledronic acid|
224181538|NCT03048981|DRUG|Fish oil|Blood samples before and after 10 day intake of maximum dose fish oil
224181539|NCT05707403|DRUG|BI 1015550|Treatment T
224181540|NCT05707403|DRUG|BI 1015550 mixed with [C-14]-BI 1015550|Treatment R
224181541|NCT03730987|BEHAVIORAL|HoMBReS intervention|Adapted intervention based on social cognitive theory and empowerment education that aims to reduce risky sexual behaviors, substance abuse and HIV among recently immigrated rural and urban men.
223490312|NCT05785611|DRUG|Placebo|Tablets administered orally once daily
224181542|NCT03730987|BEHAVIORAL|Families Talking Together (FTT)|The brief intervention, is a parent-based intervention to teach parents effective strategies proven to reduce adolescent sexual risk behavior. The intervention specifically targets the parent (not the adolescent) to: promote communication skills, build parent-adolescent relationships, develop effective monitoring strategies, reduce alcohol use, risky sexual behaviors and prepare them to teach adolescents assertiveness and substance abuse refusal skills.
223490313|NCT05347225|DRUG|Nemtabrutinib|Nemtabrutinib tablets will be administered orally QD.
223490314|NCT06193512|DEVICE|SwishKit + Oral care treatment as usual|SwishKit + Oral care Treatment as usual (TAU) group, instillation of chemical antimicrobial agents care and tooth brushing will be performed as in Oral Care TAU, but SwishKit care will be conducted after other oral care interventions, and prior to instillation of the chemical antimicrobial agent.
224181543|NCT03730987|BEHAVIORAL|Diabetes Prevention Intervention|Session content will focus on the importance of physical activity, healthy eating and maintaining a healthy weight.
224181544|NCT04435093|OTHER|MFM-Play|Neuromuscular patients will complete five items of the MFM (items 18 to 22) either conventionally or using the MFM-Play with 2 different therapists, on the same day. The order of the MFM type completion will be determined by randomization. Both therapists will rate items 18 to 22 blindly.
224181545|NCT02600715|DRUG|Onabotulinumtoxin A (BoNT)|
224181546|NCT02600715|DRUG|belladonna|Part of dosage of the compounded active B\&O suppository of belladonna 16.2mg and morphine 7.5mg.
224181547|NCT02600715|DRUG|Morphine|Part of dosage of the compounded active B\&O suppository of belladonna 16.2mg and morphine 7.5mg.
224181548|NCT02600715|DRUG|Placebo|matching placebo to B\&O suppository
224181549|NCT02600715|DRUG|Active B&O suppository of belladonna|belladonna 16.2mg and morphine 7.5mg
224181550|NCT04605341|DEVICE|miniplate|comparison between k wires and miniplate in metacarpal fractures
224181551|NCT01191190|DRUG|Ofatumumab/HDMP|"High dose methylprednisolone sodium succinate (HDMP) at 1gm/m2 daily as infusion for 3 consecutive days every cycle.~Ofatumumab 300mg administered Day1 of cycle 1 followed by 12 doses of 1000mg administered based on specific schedule.~Each patient will receive a maximum of 3 cycles (one cycle is 28 days)"
224181552|NCT00000649|DRUG|Nevirapine|
224181553|NCT00000649|DRUG|Zidovudine|
224181554|NCT03103464|OTHER|Standard-of-Care Therapy + Sit-to-Stand Therapy|Standard-of-care physical therapy 3x/wk for approximately 30 minutes each time + sit-to-stand training using the Movi chair 3x/wk for approximately 10 minutes each time.
223490315|NCT06193512|PROCEDURE|Oral care treatment as usual|Oral care will be delivered per standard operating procedure of the ICU, which may include the instillation of chemical agents for the purpose of reducing bacterial load, will be administered at 4-hour intervals, and tooth brushing performed twice daily (morning and evening).
223490316|NCT00569127|BIOLOGICAL|Bevacizumab|Given IV
223490317|NCT00569127|OTHER|Laboratory Biomarker Analysis|Correlative studies
223490318|NCT00569127|DRUG|Octreotide Acetate|Given IM
223490319|NCT00569127|BIOLOGICAL|Recombinant Interferon Alfa-2b|Given SC
223490320|NCT06442800|BEHAVIORAL|Liver Cancer|Participants will view messages about the risk of liver cancer from alcohol consumption.
223490321|NCT06442800|BEHAVIORAL|Throat and Mouth Cancer|Participants will view messages about the risk of throat and mouth cancer from alcohol consumption.
223490322|NCT06442800|BEHAVIORAL|Colorectal Cancer|Participants will view messages about the risk of colorectal cancer from alcohol consumption.
223490323|NCT06442800|BEHAVIORAL|Multiple Cancers|Participants will view messages about the risk of multiple cancers from alcohol consumption.
223490324|NCT06442800|BEHAVIORAL|Liver Disease|Participants will view messages about the risk of liver disease from alcohol consumption.
223490325|NCT06442800|BEHAVIORAL|Hypertension|Participants will view messages about the risk of hypertension from alcohol consumption.
223490326|NCT06442800|BEHAVIORAL|Dementia|Participants will view messages about the risk of dementia from alcohol consumption.
223490327|NCT06442800|BEHAVIORAL|Drinking Guidelines|Participants will view messages about guidelines for alcohol consumption.
223490328|NCT06442800|BEHAVIORAL|Current Warning|Participants will view the current warning that is required on most alcoholic beverage containers sold in the US.
223490329|NCT06442800|BEHAVIORAL|Control|Participants will view neutral messages unrelated to the harms of alcohol consumption.
223490330|NCT03834688|DRUG|Venetoclax|"Cycle 1: Venetoclax by mouth daily. The dose will gradually increase during Cycle 1. (Day 1-7: 20 mg; Day 8-14: 50 mg; Day 15-21: 100 mg; Day 22-28: 200 mg.)~Cycles 2-6: Venetoclax 400 mg by mouth daily on Days 1-10 (1 cycle = 28 days)."
223490331|NCT03834688|DRUG|Bendamustine|Cycle 1-6: Bendamustine 90 mg/m² intravenous (IV) on Days 1 and 2 of each cycle. Bendamustine may be started at 70 mg/m² in patients over the age of 75 years with comorbid conditions or patients over the age of 80 years without comorbid conditions.
223490332|NCT03834688|DRUG|Rituximab|Cycle 1-6: Rituximab 375 mg/m² IV on Day 1 of each cycle. After 2 consecutive cycles of Rituximab IV are well tolerated, Rituximab may be given subcutaneously.
223490333|NCT05039164|BEHAVIORAL|Coping Power Program (CPP)|CPP is an evidence-based intervention designed for students with externalizing behavior disorder. CPP consists of twelve 45-minute sessions. This EBP has been found to be effective at reducing aggressive behavior, covert delinquent behavior and substance abuse among aggressive boys, with gains maintained at one-year follow-up. Growth curve analyses showed that CPP had linear effects for three years after intervention on reductions in aggressive behavior and academic behavior problems.
223490334|NCT05039164|BEHAVIORAL|CBT for Anxiety Treatment in Schools (CATS)|CATS is an adaptation of Friends for Life (FRIENDS). The adapted protocol retains the core elements of evidence-based CBT for anxiety and the FRIENDS group format. Investigators implemented planned adaptations to the protocol based on collective experience. Changes were made to the language, cultural methods, number of sessions, and activities while maintaining the 5 essential components of the treatment. This resulted in a briefer (8-session) and more feasible, engaging and culturally appropriate protocol for urban under-resourced schools than the original FRIENDS.
223587726|NCT01548742|BEHAVIORAL|Mindfulness-Based Stress Reduction (MBSR)|Mindfulness Based Stress Reduction (MBSR) is a group based treatment focused on progressive training in mindfulness meditation.
223587727|NCT01548742|BEHAVIORAL|Present-Centered Group Therapy (PCGT)|Present-Centered Group Therapy (PCGT) is a group therapy focused on current problems.
224181555|NCT03103464|OTHER|Standard-of-Care Therapy|Standard-of-care physical therapy 3x/wk for approximately 30 minutes each time.
224181556|NCT04461899|BIOLOGICAL|Blood test|additional blood test will be done 3 and 12 months after endometrioma sclerotherapy.
224181557|NCT04493658|DIAGNOSTIC_TEST|Questionnaires|Cognitive ability questionnaires, dry eye symptom questionnaires (Ocular Surface Disease Index, Impact of Dry Eye in Everyday Life, Visual Function Questionnaire-25, Eye Dryness Visual Analog Scale, Visual Fatigue Visual Analog Scale, Visual Tasking Questionnaire, Short Form Survey-36, Profile of Fatigue and Discomfort, European League Against Rheumatism Sjögren's Syndrome Patient Reported Index) will be completed by the subjects
224181558|NCT04493658|DIAGNOSTIC_TEST|Tear fluid sampling|Using microcapillary tubes, 1 microliter of tear fluid will be collected in both eyes of each subject.
224181559|NCT04493658|DIAGNOSTIC_TEST|Impression Cytology|Under topical anesthesia, impression cytology sampling will be performed in the temporal bulbar conjunctiva of both eyes of each subject.
224181560|NCT05627999|PROCEDURE|doppler endoanal ultrasound|The primary aim was to assess the reduction in the blood supply by comparing the hemorrhoidal arterial systolic peak (overall and sectorial) before and after Emborrhoid.
224181561|NCT02619942|PROCEDURE|D2 radical operation|In D2 radical operation group(D2), the lymph node dissection is based on ligating the supplying vessels close to the right-side of superior mesenteric vein and clean up the surrounding lymph node and adipose tissue.
224181562|NCT02619942|PROCEDURE|Complete mesocolic excision (CME)|In complete mesocolic excision group (CME), the dissecting extent includes the lymphatic and fat tissues surrounding the root of ascending mesocolon, which situated on the surface of superior mesenteric vein, and the root of right half of transverse mesocolon, which situated on the surface of pancreas neck.
224181563|NCT00499733|DRUG|cyclophosphamide|500 mg/m\^2 of cyclophosphamide is infused via intravenous route three days post cryoablation surgery.
224181564|NCT00499733|DEVICE|Cryoablation|Per treating physician's discretion, largest and most accessible lesion will be treated with cryoablation surgery on day 0 of the study.
223490335|NCT05039164|BEHAVIORAL|Check-in/Check-out (CI/CO)|CI/CO is a targeted, Tier 2 intervention for students at risk of developing externalizing and internalizing mental health disorders. CI/CO is designed to provide immediate feedback (i.e., at the end of each class period) to students, based on the use of a daily report card. This feedback is developmentally sensitive. CI/CO implementers meet individually with students for a brief 'check-in' in the morning and a brief 'check-out' in the afternoon. Research on the use of CI/CO has shown it to be effective in reducing externalizing and internalizing problems with elementary school students. CI/CO will be offered to individual students for a three-month period of time, which is the same time-frame needed for the implementation of CPP.
223490336|NCT05039164|BEHAVIORAL|Initial Training (CC)|School personnel will participate in an initial live remote training.
223490337|NCT05039164|BEHAVIORAL|Initial Training plus Video (RV)|School personnel will participate in an initial live remote training and receive access to asynchronous video training modules.
223490338|NCT05039164|BEHAVIORAL|Initial Training plus Video plus Coaching (RV+)|School personnel will participate in an initial live remote training, receive access to asynchronous video training modules, and receive coaching support from study staff.
224181565|NCT04766411|OTHER|Unresisted sprint training|"Particiapants will perform:~2 sets of 3 x 20m sprint~1 set of 3 x 30m sprint"
223490339|NCT03537690|OTHER|Laboratory Biomarker Analysis|Correlative studies
224181566|NCT04766411|OTHER|Resisted sprint training with load equal to 10% of body weight|"Particiapants will perform:~2 sets of 3 x 20m sprint~1 set of 3 x 30m sprint"
224181567|NCT04766411|OTHER|Resisted sprint training with load equal to 20% of body weight|"Particiapants will perform:~2 sets of 3 x 20m sprint~1 set of 3 x 30m sprint"
224181568|NCT04766411|OTHER|Control trial|Participants will not perform any sprint training protocol
224181569|NCT01753765|DEVICE|Device: Cryo-Touch III Study treatment at Day 0.|Device: Cryo-Touch III Study treatment at Day 0.
223490340|NCT03537690|DRUG|PEOX-based Polymer Encapsulated Paclitaxel FID-007|Given IV
223490341|NCT03537690|OTHER|Pharmacokinetic Study|Correlative studies
223490342|NCT04990726|BEHAVIORAL|Assessment|Undergo medical assessments
223490343|NCT04990726|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
223490344|NCT04990726|OTHER|Quality-of-Life Assessment|Ancillary studies
223490345|NCT04990726|OTHER|Questionnaire Administration|Complete questionnaires
223490346|NCT04289142|DRUG|Dexmedetomidine Hydrochloride Group|Dexmedetomidine will be initiated prior to transfer to the CVICU with loading dose of 1.2 ug/kg over approximately 20-60 minutes. This will be followed by an infusion at 0.3 ug/kg/h in CVICU for up to 12 hours from the time DEX infusion started or until the patient is ready for discharge from the CVICU (whichever is earlier). Any additional sedatives necessary at the discretion of ICU.
223490347|NCT03036254|DEVICE|HBOT intervention|"HBOT is a treatment in which oxygen-enriched air (up to 100%) is administered to patients at a pressure.~HBOT intervention arm - 3 months of HBOT treatment, 9 months observation~all participants receive HBOT treatment for 3 months at year 2"
223587728|NCT03480009|DRUG|Dextromethorphan Hydrobromide|Dextromethorphan capsule
223587729|NCT03480009|DRUG|Avicel PH101 (Microcrystalline Cellulose NF) for Compounding|Placebo capsule
224181570|NCT01667731|DRUG|SOF|Sofosbuvir (SOF) 400 mg tablet administered orally once daily
224181571|NCT01667731|DRUG|RBV|Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)
224181572|NCT01425268|DEVICE|AeroForm Tissue Expansion|The AeroForm Patient Controlled Tissue Expander is a breast tissue expander implanted following mastectomy and activated by remote control to release small doses of carbon dioxide from an internal reservoir to fill and inflate the expander.
224181573|NCT01425268|PROCEDURE|Saline Tissue Expansion|A saline tissue expander is a breast tissue expander which is implanted following mastectomy and inflated over time using needle injections to fill and inflate the expander with saline.
224181574|NCT00771420|DRUG|CAM-3001|A single patient shall be dosed with a dose of 0.01mg/kg of CAM-3001 followed no sooner than 24 hours later by a second patient at a dose of 0.03mg/kg.
224181575|NCT00771420|DRUG|CAM-3001|Dosed at 0.1mg/kg.
224181576|NCT00771420|DRUG|CAM-3001|Dosed at 0.3mg/kg
224181577|NCT00771420|DRUG|CAM-3001|Dosed at 1.0 mg/kg.
224181578|NCT00771420|DRUG|CAM-3001|Dosed at 3.0 mg/kg.
224181579|NCT00771420|DRUG|CAM-3001|Dosed at 10 mg/kg.
224181580|NCT00771420|OTHER|Placebo|Active: Placebo 5:1 for arms 2-6
224181581|NCT02387827|BEHAVIORAL|Diet+ short term versus long -term physical activity|
224181582|NCT02839330|BIOLOGICAL|aH5N1c|Intramuscular (IM) administration, containing 7.5 mcg H5N1 hemagglutinin antigen (HA) + 0.25 mL MF59 (approximately 0.5 mL total volume).
224181583|NCT02839330|BIOLOGICAL|Placebo|Placebo: Saline injection
224181584|NCT05957315|DEVICE|Mobile Cardiac Outpatient Telemetry Device (MCOT)|Application of a Philips/Biotel MCOT device
224181585|NCT04918251|PROCEDURE|128 electrode electroencephalography (EEG)|128 electrode EEG will be non-invasively recorded from electrodes placed in a montage over the scalp while the participant is resting or performing tasks designed to engage specific cortical motor networks of interest (cognitive, behavioural, motor and sensory)
224181586|NCT04918251|PROCEDURE|Transcranial magnetic stimulation (TMS)|Single and paired pulse TMS protocol will be delivered while surface bipolar EMG is recorded over hand muscles to interrogate corticospinal tract function and cortical motor network component functions
224181587|NCT03242291|OTHER|Conventional resin-based flowable composite|assessment of marginal integrity of Conventional resin-based flowable composite
224181588|NCT03242291|OTHER|Hydroxyapatite Nanofiber reinforced flowable composite|assessment of marginal integrity of Hydroxyapatite Nanofiber reinforced flowable composite
224181589|NCT02373176|DRUG|[14C]PRC 4016 (Icosabutate)|Single oral dose
224181590|NCT01024816|BEHAVIORAL|Restorative yoga|"Group yoga sessions: Participants will attend 90 minute yoga group classes for 48 weeks: twice a week for 6 weeks, then once weekly during weeks 7 to 12, then every other week for weeks 13 - 24, and once a month for 6 months. We plan a progressive series of classes, with a subset of poses for each class and then selecting individual poses to focus on in each class.~Home yoga practice: Participants will be given a video disk (DVD) of the yoga postures at the start of the yoga intervention practice. We will also provide the yoga participants with a written manual with pictures and descriptions of each posture that they will be taught in the group sessions. The participants will be asked to practice the postures taught during their group sessions at home at least three times a week with the assistance of the DVD and manual. Each participant will be given a set of yoga props for their use at home. We will ask all participants to keep a log of their home practice sessions"
224181591|NCT01024816|BEHAVIORAL|Stretching|"Group classes: Participants will attend 90 minute group stretching classes for 48 weeks: twice a week for 6 weeks, then once weekly during weeks 7 to 12, then every other week for weeks 13 - 24, and once a month for 6 months. The stretches will address all body parts, including cervical, upper extremity, thoracic, lumbar, pelvic, and lower extremity musculature.~Home stretching practice: Each participant will receive a written manual with pictures and descriptions of each stretch that they will be learning in group sessions and a DVD with instruction on each of the stretches. The participants will be asked to practice the stretches taught during their group sessions at home at least three times a week with the assistance of the DVD and manual. Each participant will be given stretching supplies. We will ask all participants to keep a log of their home practice sessions."
224181592|NCT01403324|DRUG|TSH stimulation|rh TSH stimulation followed by thyroid hormon withdrawal
224181593|NCT02615158|BEHAVIORAL|Maternal Physical Activity and Nutrition|At each session, mothers will identify a dietary goal for the next session (e.g., reduce soda intake). They will learn to track and evaluate their progress, setting new goals or modifying existing ones as necessary. Mothers will be given pedometers and shown how to keep a pedometer tracking chart. As with dietary choice, our objective is to have the mothers identify personal goals and strategies to achieve those goals, so they are more likely to continue to engage in physical activity after the intervention ends.
224181594|NCT02615158|BEHAVIORAL|Parenting|Behavior and Development Related to Diet and Physical Activity. The toddler parenting intervention will include modules on toddler behavior and development. We will devote sessions to topics involving parenting toddlers, limit setting, and child development.
224181595|NCT02615158|BEHAVIORAL|Child Safety|The intervention will focus on child safety issues, including car seat safety, fire safety, fall prevention, and poison prevention. Participants will set weekly child safety goals.
224181596|NCT00876759|RADIATION|whole brain radiotherapy|WBRT in 10 fractions to a total dose of 30Gy
224181597|NCT00876759|RADIATION|whole brain radiotherapy with simultaneous boost|Total dose: 10 fractions: whole brain total dose: 30Gy, metastases: total dose 50Gy
224181598|NCT04495400|PROCEDURE|Thoracolumbar Fracture Fixation|The is surgery is preformed on patients who have had a blunt trauma fractures between the T10 and the L2. The surgical management for more severe/unstable fractures usually involves posterior instrumentation with percutaneous or open pedicle screw fixation. While the traditional open pedicle screw fixation technique has demonstrated good radiologic and clinical outcomes, a minimally invasive percutaneous approach has been increasingly used in recent years.
224307690|NCT05837013|PROCEDURE|General anesthesia (GA)|General anesthesia: No premedication will be applied. In the waiting room, 10 mL/kg of Ringer's lactate solution will be infused IV in 30 minutes. In Group I, 2-2.5 mg/kg propofol and 1 μg/kg fentanyl IV will be given for induction; 0.6 mg/kg rocuronium will then be used to provide the muscle relaxation needed for intubation. After intubation, the tidal volume will be set to 6-8 mL/kg and the respiratory frequency PetCO2 32-36 mmHg in volume-controlled ventilation (VCV) mode. Anesthesia will continue to be provided with sevoflurane (1.5%-2%), oxygen-air mixture (FiO 2 = 0.4) and repeated doses of rocuronium (0.015 mg/kg). At the end of the surgery, neostigmine (2-2.5 mg) and atropine (1 mg) will be given IV to antagonize the residual neuromuscular block.
223490348|NCT03036254|DEVICE|Sham intervention|"Sham was selected as the control condition rather than usual care to equate intervention groups with respect to other variables that could influence cognition and functional status, such as a new challenge (completing an activity program), peer socialization, and attention from staff."
224181599|NCT02257970|DRUG|Ketoprofen|
224181600|NCT02257970|DRUG|Placebo|Placebo to match ketoprofen.
224181601|NCT01345162|DRUG|Ketorolac postoperative|Ketorolac 10mg 1cp x 3/die
224181602|NCT01345162|DRUG|postoperative Patrol|acetaminophene 325mg+tramadol 37.5mg, 1cp x 3/die
224181603|NCT01345162|DRUG|intraoperative analgesia|ketorolac 30 mg iv
224181604|NCT01345162|DRUG|intraoperative analgesia|Tramadol 100 mg if Weight over 50 kg, 50 mg if weight below 50 kg
224181605|NCT02301468|OTHER|Dry Needling|(experimental- physiotherapy intervention) - will be performed during 4 weeks (1 treatment/week) on the 4 most painful trigger points (determined/selected at the first session - see above). The same 4 trigger points will be treated during the 4 weeks. DN will be performed by locating the taut band and the trigger point. Once the trigger point is located, the overlying skin will be cleaned with alcohol. A certified and experienced therapist will penetrate the needle through the skin 10-15mm. into the TrP until the local twitch response will be obtained.
223490349|NCT05386914|DRUG|Sirolimus|1 mg of Sirolimus taken orally once a day for 4 weeks.
223490350|NCT04768972|DRUG|ION363|ION363 will be administered by IT bolus injection.
223490351|NCT04768972|DRUG|Placebo|Placebo will be administered by IT bolus injection.
223587730|NCT03480009|DRUG|Oxycodone|Participants may opt for the narcotic receiving arms of the study, before being randomized to dextromethorphan/placebo.
223587731|NCT01954316|DRUG|CFI-400945|Polo-like kinase 4 (PLK4) inhibitor
224307691|NCT04436887|PROCEDURE|positioning of polypropylene strips for prophylactic purposes in closing the middle laparotomies to prevent the incisional hernia|Sub-lay mesh supported closure A 4 cm space is created between posterior rectus sheath and rectus muscle, widening 2 cm at each side of midline. Both posterior rectus sheath edges are sutured using a running slowly absorbable suture. Above arcuate line, posterior layer was performed suturing peritoneum and posterior rectus sheath; below arcuate line, posterior layer was performed suturing peritoneum and trasversalis fascia. Anterior layer was performed suturing anterior rectus sheath. A suture length to wound length ratio of 4:1 is recommended. A 4-cm Parietex Progrip Mesh strip was placed between the posterior rectus sheath and rectus muscle with an overlap of at least 2 cm at each side, suture less. In laparotomies \>20 cm two stripes of 15 cm each were designed. The midline anterior rectus sheath was closed using a running slowly absorbable suture, covering the mesh. A suture length to wound length ratio of 4:1 is recommended.
224307692|NCT05645159|OTHER|Blended learning in heart disease|The intervention included face-to-face classes and online resources (Moodle, online syllabus, videos, websites, podcasts, activities, apps, forums, emails, tutoring).
224307693|NCT01152151|DEVICE|Postal reminder letters|Postal reminder letters if adherence is not obtained (up to four)
224307694|NCT01152151|DEVICE|Electronic reminder letters|Electronic reminder letters if adherence is not obtained (up to four)
223587732|NCT03433534|OTHER|Pharmacokinetic of Nivolumab|Nivolumab residual concentration is measured 14 days after administration of nivolumab 3 mg/kg as an intravenous infusion just before the new administration.
223587733|NCT03197909|OTHER|Determination of pro-inflammatory plasma factors|Determination of pro-inflammatory plasma factors at COPD patients aged from 35 to 85 years old and Healthy subjects aged from 35 to 85 years old
224307695|NCT01152151|DEVICE|Reminder letters|up to four reminder letters in september - december 2010
224307696|NCT05371860|OTHER|Omit breast radiation|Omit breast radiation for 3 years after surgery
224307697|NCT02483208|DRUG|BAY81-8973|BAY81-8973 infusion to analyze pharmacokinetics
224307698|NCT02483208|DRUG|Advate|Advate infusion to analyze pharmacokinetics.
224307699|NCT00996775|BEHAVIORAL|brief alcohol intervention|this intervention consists of brief assessment and feedback
224307700|NCT00996775|BEHAVIORAL|standard care|education about harmful effects of alcohol use and NIAAA recommended drinking limits
224307701|NCT02866006|DRUG|BVAC-C|Autologous B cells and monocytes transfected with E6E7 gene of HPV
224307702|NCT02866006|DRUG|Topotecan|
224307703|NCT05935111|BEHAVIORAL|Physical Activity Self-efficacy (PAS) intervention|The PAS intervention will be a web-based intervention to address the unique barriers to physical activity in adults with obesity, based on self-efficacy theory and effective behavioral change techniques. Self-efficacy is specified as a mediating psychological variable in the conceptual model for the promotion of physical activity. Self-efficacy refers to domain-specific beliefs (e.g., job-, transport-, domestic-, leisure-related physical activity) about their ability to execute differing levels of performance given situational demands. There is a rich literature on the importance of targeting self-efficacy as a modifiable mediating variable in PA-promoting interventions. Also, the PAS intervention will consist of effective behavioral change techniques (e.g., action planning, teach to use prompts/cues, goal setting, etc.).
224307704|NCT01086397|PROCEDURE|Urine sample collection|All subjects have non-invasive urine sample collection performed
224307705|NCT02164474|BEHAVIORAL|High-Intensity Interval Training|Specifically, individuals randomized to HIIT will begin the intervention with four intervals lasting 1-minute each at \~85-90% peak oxygen uptake \[VO2peak\] and increasing to 10 X 1-min intervals by day 10 of the intervention. Individuals randomized to moderate-intensity exercise condition will begin the intervention with 20 minutes of continuous activity at \~55-60% V02peak and gradually increase the duration to 50 minutes by day 10 of the intervention.
224307706|NCT01069276|OTHER|No intervention in this study|No intervention in this study
224307707|NCT01517373|DRUG|Placebo|Combination of tablets and capsules, a total of 3 pills/dose, administered once daily for 84-days
224307708|NCT01517373|DRUG|PF-04937319 10 mg|Combination of tablets and capsules, dose of 10 mg, a total of 3 pills/dose, administered once daily for 84-days
223587734|NCT00449449|DRUG|Pertubation with Lidocain Solution|
223587735|NCT00809653|DEVICE|No Face Mask|Subjects will not wear a face mask to reduce their personal air pollution exposure
223587736|NCT00809653|DEVICE|Face Mask|Subjects will be asked to wear a simple face mask to reduce personal exposure to particulate air pollution. Subjects will be asked to wear the mask for 24 hours prior to the study day and the 24 hours of the study day. They will be instructed to wear the mask at all times when outdoors and as much as possible when indoors.
223587737|NCT02998034|DEVICE|Uncemented Furlong Hemiarthroplasty|A furlong uncemeneted hyroxyapatite coated prosthesis.The hydroxyapatite stimulates bone ingrowth around the prosthesis and is this is thought to reduce loosening of the implant, residual pain and the long-term revision rate.
223587738|NCT02998034|DEVICE|Cemented tapered stem hemiarthroplasty|A cemented double tapered stem hemiarthroplasty
224307709|NCT01517373|DRUG|PF-04937319 50 mg|Combination of tablets and capsules, dose of 50 mg, a total of 3 pills/dose, administered once daily for 84-days
224307710|NCT01517373|DRUG|PF-04937319 100 mg|Combination of tablets and capsules, dose of 100 mg, a total of 3 pills/dose, administered once daily for 84-days
224307711|NCT01517373|DRUG|Glimepiride|Combination of tablets and capsules, dose of up to 6 mg, a total of 3 pills/dose, administered once daily for 84-days
224307712|NCT01284946|DRUG|Exjade|Orodispersible Tablet, 10 mg/Kg/day ± 5 mg/Kg/day during 24 weeks Deferasirox should be taken daily 30 minutes before breakfast
224307713|NCT02712060|OTHER|No intervention|
224307714|NCT04447950|PROCEDURE|Type 2/posterior Quadratus Lumborum block|Injection of local anaesthetic into posterior boundry of Quadratus Lumborum muscle.
224307715|NCT04447950|PROCEDURE|Placebo block with Saline|Injection of saline into posterior boundary of Quadratus Lumborum muscle.
224181606|NCT02301468|OTHER|Ischemic Compression|(experimental - physiotherapy intervention) will be performed during 4 weeks (1 treatment/week) on the 4 most painful trigger points (determined/selected at the first session - see above). IC will be performed by applying a pressure with a wooden stick on the 4 individually determined most painful trigger points. The duration of the pressure will be about 60s, (increase of pressure 10N/s) until the highest tolerable pressure will be reached and this pressure will be held even when the pain is decreasing during the intervention. The subject will always be treated by the same clinician.
224181607|NCT01871870|DEVICE|Artificial Pancreas Control Software|This master controller software is used in conjunction with two subcutaneous continuous glucose monitoring systems and two Omnipod pumps, one for administering aspart insulin (NovoLog) and one for administering glucagon (GlucaGen), to control blood glucose levels. The insulin and glucagon infusion rates are determined by an outpatient automated version of the Adaptive Proportional Derivative (APD) insulin and glucagon control algorithm programmed into a smart phone.
224181608|NCT05795127|PROCEDURE|First metatarsophalangeal joint arthrodesis|Surgery leadin to bony uninon in firts metatarsophalangeal joint
224307716|NCT06232330|DEVICE|Group A|This group will receive TOA which include Weight transfers from a standing position and stepping in various star-type directions, Sit-ups from different heights with the hemiplegic lower limb behind the normal lower limb, From a kneeling position alternately projecting the lower limb forward, From a standing position with a limited base of support turning head and trunk right to left, Continuous walking on a treadmill for 10 minutes, Ascending and descending of stairs, Crossing 4 obstacles with continuous walking, Walking while simultaneously pushing a stroller, Walking while holding an object, Walking on different surfaces and slopes, The intervention took place for 5 days a week for 6 week for 20 minutes. Pre measurement was taken before the intervention and after 6 weeks post measurement was taken.
224307717|NCT06232330|DEVICE|Group B|This group will receive PNF techniques for trunk control. Rhythmic initiation and Rhythmic stabilization for a span of 20 minutes on both sides. In rhythmic initiation patient will move passively from trunk flexion into extension and then back to the flexed position When the patient is relaxed and moving easily, ask for active assisted motion Then begin resisting the motion then patient will perform independently in rhythmic stabilization Resist an isometric contraction of the patient's trunk flexor muscles patient will match the resistance in front and then in back
224307718|NCT04024839|OTHER|Active Isolated Stretch|In supine position, participant was asked to lock the knee and slowly lift leg using the quadriceps muscles. gentle assistance was given by the rope at the end of the movement, as the quadriceps muscles continue to move the leg. strech was applied for 2 sec and then release to starting position. two sets of 10 repetitions were performed.
224307719|NCT04024839|OTHER|Post Isometric Relaxation|In supine line, participant was asked to do SLR until resistance was met in hamstring muscles and then was asked to do isometric contraction (10-20% of maximum) for 5 - 10 sec and inhale. After this, patient was asked to exhale while doing so gentle stretch was applied till the new barrier. Starting from this new barrier, the procedure was repeated 2 - 3 times.
223490352|NCT06114875|BEHAVIORAL|Peer support intervention|"Flags will appear beside posts that the risk algorithm has identified as containing descriptions of distress or mental health concerns (these flags will not be visible to the original poster). Next to these flags, users will also see a brief blurb such as: This person might be going through something difficult. To learn more about what to say to peers who may be experiencing distress, click this banner. RallyPoint users will then have the option of clicking on these flags, where they will be directed to a psychoeducational information page on how to provide support to peers who may be experiencing distress."
223490353|NCT06500078|BEHAVIORAL|Intermittent dietary restriction|"Intermittent dietary restriction will include the ILCD and ICR, which will be self-administered interventions in daily lives. The ILCD intervention will ask participants to restrict carbohydrate intake to ≤ 50 g/d on two consecutive or discontinuous days per week. The ICR intervention will ask participants to restrict caloric intake to 600 kcal/d for boys and 500 kcal/d for girls on two consecutive or discontinuous days per week.~At baseline, participants will receive face-to-face oral dietary instructions (e.g., principle of dietary restriction, sample menus, food list with macronutrients). Participants will receive the intervention booklets containing dietary advice and sample menus for diet according to the requirements of the dietary intervention.~Participants will be required to record dietary and physical activity data on a regular basis. The total intervention duration will be 12 months, including a 3-month intervention phase and a 9-month self-maintenance phase."
223490354|NCT06500078|BEHAVIORAL|General health education|General health education based on dietary and physical activity guidelines for Chinese children and adolescents, will regularly send offline and online promotional materials to participants.
223490355|NCT05351580|DEVICE|DiSCERN|Smart watch Monitoring
223490356|NCT05667324|DRUG|Ropivacaine|A single injection into the pterygopalatine fossa bilaterally of 0.5% ropivacaine at a dose of 20 mg (each side)
223490357|NCT05667324|DRUG|Dexamethasone|Plus 4 mg dexamethasone
223490358|NCT05667324|DRUG|Placebo|A single injection into the pterygopalatine fossa bilaterally of a balanced crystalloid intravenous solution (4 ml of normal saline)
223490359|NCT06354257|DRUG|Microgynon|Participants received 1 dose of Microgynon (0.03 mg EE/0.15 mg LNG) on Day 1 of Treatment Period 1 and 1 dose co-administered with GSK3036656 20 mg on Day 15 of Treatment Period 3.
223490360|NCT06354257|DRUG|GSK3036656|Participants received 1 loading dose of 40 mg on Day 4 and a dose of 20 mg on Days 5 to 14 once daily in Treatment Period 2. In Treatment Period 3, participants received one 20 mg dose along with Microgynon (0.03 mg EE/0.15 mg LNG) on Day 15 after which a 20 mg dose on Days 17 and 18 once daily.
223490361|NCT05108519|OTHER|Electronic Health Record Review|Medical records are reviewed
223490362|NCT03168672|DEVICE|Global ICON|The study device is the GLOBAL ICON stemless humeral component, consisting of the Anchor Plate and Humeral Head.
224181609|NCT02990273|BIOLOGICAL|Blood transfusion|
224181610|NCT00411892|DRUG|pioglitazone|Tablets, 45 mg/day.
224181611|NCT00411892|DRUG|inhaled human insulin|Treat-to-target dose titration scheme, inhalation.
224181612|NCT00883896|OTHER|Placebo|Part 1: Placebo SC administration every 2 weeks X 10 weeks.
224181613|NCT00883896|DRUG|ILV-094|Part 1: ILV-094 100 mg SC every 4 weeks (alternating ILV-094 100 mg and placebo every 2 weeks) X 10 weeks.
223587739|NCT06184958|DRUG|Lidocaine group|Group A: Lidocaine group( 25 patients) will receive 5 mg/Kg lidocaine in 100 ml normal saline given in 40 minutes with 20 minutes follow up to obverse any delayed complication. This procedure will be repeated weekly for 3 weeks.
223587740|NCT06184958|DRUG|Ketamine group|Group B:Ketamine group(25 patients) will receive 0.5 mg/Kg ketamine sulphate in 100 ml normal saline given in 40 minutes with 20 minutes follow up to obverse any delayed complication. This procedure will be repeated weekly for 3 weeks.
223587741|NCT06184958|DRUG|Placebo group|Group C:placebo group (25 patients) will receive placebo 100 ml normal saline given in 40 minutes with 20 minutes follow up to obverse any delayed complication. This procedure will be repeated weekly for 3 weeks
223587742|NCT06156501|PROCEDURE|ACL Reconstruction|Reconstruction of the anterior cruciate ligament
223587743|NCT04672421|DEVICE|Medicurtain®|Anti-adhesion barrier (Medicurtain® 5ml prefilled syringe after laparoscopic surgery)
223587744|NCT04672421|DEVICE|Placebo|No device after laparoscopic surgery
223587745|NCT01424280|DRUG|1440115|Single dose of either 750 mg or 500 mg administered as 250 mg tablets.
223490363|NCT04324619|OTHER|Online interactive learning activities|"1. 3-hour video-storyline-based interactive learning program~2. Micro-learning activities that can be completed on mobile devices (eg, smartphones)"
223490364|NCT04487548|OTHER|Remote smoking cessation bundle|"The bundle is a remote version of what has previously been described in prior literature, which includes:~1. A brief (\<5 minutes) advice~2. Preoperative smoking cessation video prepared by QuitNow~3. Patients will be provided brochures on smoking cessation~4. A referral will be faxed (or internet-registered) to the Quitnow.ca Smokers' Helpline~5. All patients will be requested to participate in the provincial Smoking Cessation program that provides a free 12-week supply of NRT once per year."
223490365|NCT06208267|DRUG|Tranexamic acid|This is a 3 arm RCT using the three dosage regimens mentioned above. Placebo doses will be provided for the 0, 8, 16 and 24 hours without TXA
223490366|NCT02807922|DRUG|Zopiclone|
223490367|NCT02807922|DRUG|Placebo|
223490368|NCT06521242|OTHER|Patient Education|The intervention group was given 120 minutes of training.
223490369|NCT02619201|DRUG|Ondansetron|An intravenous dose of ondansetron ( 0.15mg /kg / doses ) .
223490370|NCT02619201|DRUG|metoclopramide|An intravenous dose of metoclopramide ( 0.15mg /kg / doses ) .
223490371|NCT00952913|DRUG|Bosutinib|4 x 100-mg oral tablets, single dose
223490372|NCT00952913|DRUG|Bosutinib|4 x 100-mg oral tablets, single dose
223490373|NCT00952913|DRUG|Lansoprazole|2 x 30-mg oral tablets, single daily doses for 2 days
223587746|NCT01424280|DRUG|Placebo|Single dose of matching placebo tablets
223587747|NCT04186507|COMBINATION_PRODUCT|Smartwatch with integrated Li+ sensor (provided by Spectrophon LTD)|"To confirm that Li+ is detectable in sweat using Macroduct Sweat Collection System for sweat collection.~Current studies demonstrate that Li+ can be detected in saliva and in sweat. To confirm it, patients that are on treatment with Li+ will be recruited for this aim; sweat will be collected and checked for Li+ levels.~To develop the algorithm for Spectrophon LTD biosensors for Li+ levels measurement in sweat that will allow assessing the level of Li+ in blood.~To evaluate the accuracy and the efficacy of biosensors developed by Spectrophon LTD for Li+ detection in sweat.~Following positive results in previous objectives, clinical trial will be conducted to estimate the suitability, efficacy and accuracy of developed biosensors for non-invasive detection of Li+ in sweat."
224181614|NCT00883896|DRUG|ILV-094|Part 1: ILV-094 100 mg SC every 2 weeks X 10 weeks.
224181615|NCT00883896|OTHER|Placebo|Part 2: Placebo SC administration every 2 weeks X 10 weeks
224181616|NCT00883896|DRUG|ILV-094|Part 2: ILV-094 200 mg SC every 2 weeks X 10 weeks
224181617|NCT02935816|RADIATION|Whole body MRI|We have developed and assessed the feasibility of performing whole---body multi---parametric MRI for staging metastatic disease. We hypothesize that a whole body multi---parametric MRI will be more sensitive and specific than conventional imaging staging for detection of metastatic disease in patients with biochemical failure following local therapies. We therefore propose a comparative trial of conventional imaging verses whole---body multi---parametric MRI within this population of men
223490374|NCT03930433|DRUG|Nebivolol|Patients are randomly assigned to a ratio of 1: 1: 1, divided into 3 groups.
223490375|NCT03930433|DRUG|Diltiazem|Patients are randomly assigned to a ratio of 1: 1: 1, divided into 3 groups.
223490376|NCT03930433|DRUG|Nebivolol+Diltiazem|Patients are randomly assigned to a ratio of 1: 1: 1, divided into 3 groups.
223490377|NCT06008002|PROCEDURE|M-TAPA block|ultrasound guided Modified thoracoabdominal nerves block through perichondrial approach(M-TAPA) block (0.3 ml/kg , %0.25 bupivacaine) will be performed
223490378|NCT06008002|PROCEDURE|EXORA block|Ultrasound guided External Oblique And Rectus Abdominis Plane (EXORA) Block block (0.3 ml/kg , %0.25 bupivacaine) will be performed
223490379|NCT06008002|DRUG|Tramadol|400 mg tramadol, IV 4 mg/ mL tramadol solution into 100 mL normal saline; Patient-controlled analgesia settings: 0.3 mg/kg bolus, 10 mg Demand dose and 20 min lock out interval, six-hour limit infusion to attain 100 mg. Maximum daily dose was set at 400 mg.
223490380|NCT00555191|BEHAVIORAL|diet restriction|each meal should contain less than 2 gm fructose
223490381|NCT01725399|OTHER|Apple Juice|
223490382|NCT01725399|OTHER|Water|
224181618|NCT01461018|BIOLOGICAL|Immune globulin subcutaneous (Human)|IgPro20 is a 20% (weight per volume \[w/v\]) liquid formulation of human immunoglobulin for subcutaneous (SC) use.
224181619|NCT03506165|COMBINATION_PRODUCT|Periodontal treatment|oral hygiene instructions, periodontal debridement and removal of other etiologic factors
224181620|NCT02889926|BIOLOGICAL|a swab according to the method of Levine|A swab according to the method of Levine: choose the pathological area by pressing the swab over the area, with a rotation supported on at least 1 cm² for 5 seconds, to well up from the liquid.
223490383|NCT01757847|BEHAVIORAL|Acceptance and Commitment Therapy (ACT)|The ACT group protocol consists of four 2-hour weekly sessions focusing on a) thoughts, feelings, and bodily sensations in the context of efforts to lose weight; b) limitations of efforts to control or eliminate negative thoughts or emotions, stress, or food cravings; c) changing expectations and goals from elimination of stress or cravings to living as well as possible with such feelings; d) mindfulness exercises to increase awareness; and e) identification of personal values and goals to achieve improved quality of life.
224181621|NCT02889926|BIOLOGICAL|Bacteriological referred to biopsy|Bacteriological referred to biopsy: (This is the hole protocol) Choose the pathological area, debridement of the wound to the pad and a scalpel, cleaning with betadine followed by rinsing with saline, local anesthesia with xylocaine, 6 mm punch for drawing a carrot, put into a sterile container
224181622|NCT01256424|DRUG|HAL 5% with illumination|Treatment with a singe dose of 2g, HAL 5% ointment followed by photoactivation
224181623|NCT01256424|DRUG|HAL 1% with illumination|Treatment with a singe dose of 2g, HAL 1% ointment followed by photoactivation
224181624|NCT01256424|DRUG|HAL 0.2% with illumination|Treatment with a singe dose of 2g, HAL 0.2% ointment followed by photoactivation
224181625|NCT01256424|DRUG|Placebo ointment without illumination|Treatment with a singe dose of 2g placebo ointment, no photoactivation
224181626|NCT03722641|OTHER|Bread reference|Commercially available white wheat bread
224181627|NCT03722641|OTHER|Product 1: Milk|Developed reference product based on milk
224181628|NCT03722641|OTHER|Product 2: Full fat milk + oat|Developed product based on full fat milk with addition of oat
224181629|NCT03722641|OTHER|Product 3: Skim milk + oat, high fibre|Developed product based on skim milk with addition of oat giving a high fiber content to the product
223587748|NCT02986815|OTHER|[11C]Acetate Brain Imaging|Patients will be imaged on a Siemens Biograph 64 slice PET CT scanner. After placing the patient on the scanner and securing the head in a head restraint, a low dose CT of the brain will be acquired. Images with 3 mm slice thickness and spaced at 1.5 mm intervals will be reconstructed in a 300 mm field of view. The purpose of the CT is for image localization and attenuation correction and it is not considered to be a diagnostic quality CT. Following the completion of the CT, the \[11C\]Acetate will be administered. A dynamic PET image will be acquired in 3D list mode for a total of 30 minutes.
224181630|NCT03722641|OTHER|Product 4: Skim milk + oat, low fibre|Developed product based on skim milk with addition of oat giving a lower fiber content to the product
224181631|NCT05222841|DIETARY_SUPPLEMENT|Spermotrend|Patients who are treated with Spermotrend (536,62g) are given 3 capsules every day for 3 months, taken orally every 8 hours.
224181632|NCT00991458|DRUG|Cyclosporine 0.010% eye drops|Cyclosporine 0.010% eye drops administered as 1 drop to each eye twice daily (morning and evening) for at least 2 weeks prior to LASIK surgery and up to 7 months post-LASIK surgery.
224181633|NCT00991458|DRUG|Cyclosporine 0.005% eye drops|Cyclosporine 0.005% eye drops administered as 1 drop to each eye twice daily (morning and evening) for at least 2 weeks prior to LASIK surgery and up to 7 months post-LASIK surgery.
224181634|NCT00991458|DRUG|Placebo (Vehicle for Cyclosporine)|Placebo eye drops administered as 1 drop to each eye twice daily (morning and evening) for at least 2 weeks prior to LASIK surgery and up to 7 months post-LASIK surgery.
224181635|NCT01585285|PROCEDURE|LIMA to SVG Bridge Technique|This surgical design use a composite-sequential venous graft to distribute left internal mammary artery (LIMA) inflow directly to the left anterior descending (LAD), but also to the other branches of the anterolateral territory thereby promoting a higher flow through the LIMA pedicle. It is constructed using a short saphenous vein graft (SVG) bridge interposed between the LAD and one (or more) other anterolateral targets, with the LIMA grafted on the hood of the SVG just above the LAD anastomosis.
224181636|NCT01585285|PROCEDURE|Conventional CABG|Conventional coronary artery bypass grafting (CABG) strategy with left internal mammary artery (LIMA) graft to the left anterior descending (LAD) and separate sequential aorto-coronary saphenous vein grafts (SVG) to the others anterolateral targets
224181637|NCT04311515|RADIATION|Tau Positron emission tomography (PET)|Tau PET imaging enables the longitudinal assessment of the spatial pattern of tau deposition. Tau accumulates with progression of AD dementia and may be sensitive to disease related changes, particularly those due to intervention with a drug thought to work through a tau related mechanism. Quantitative assessments will be utilized to evaluate the target engagement and pharmacological effects of PU-AD after 6 months of treatment
224181638|NCT04311515|RADIATION|Fluorodeoxyglucose (FDG) Positron emission tomography (PET)|Measurement of neuronal function with FDG PET can help to understand the relationship between target engagement and potential clinical effects. FDG PET will be acquired using stringent quality control. Since glucose metabolism captures all neuronal activity, in order to isolate effects due to treatment, patients will be maintained in a consistent state during the tracer uptake period. Subject motion during image acquisition will be minimized and monitored. Images will be quality controlled, processed, and measured quantitatively using methods that maximize signal to noise associated with technical and physiologic variability
224181639|NCT04311515|DIAGNOSTIC_TEST|Cerebrospinal fluid (CSF) Biomarkers|A broad set of biomarkers are being assessed in this study to indicate whether this treatment is able to impact multiple pathways associated with AD related to neurodegeneration
224181640|NCT04311515|DIAGNOSTIC_TEST|Blood Biomarkers|Changes in blood biomarkers may be observable if treatment affects cerebral amyloidosis and loss of nerve cells
224181641|NCT04311515|BEHAVIORAL|Rating Scales|Alzheimer's Disease composite score (ADCOMS+), CDR sb, Alzheimer's Disease Assessment Scale Cognitive (ADAS cog), Alzheimer's Disease Cooperative Study Activities of Daily Living (ADCS ADL), Mini Mental State Examination (MMSE), Alzheimer's Disease Assessment Scale Cognitive (ADAS-COG 12)
224307720|NCT04226326|OTHER|Directly measure microvascular function using direct coronary flow measurements|The study will enroll subjects who have been scheduled for a clinically-indicated cardiac catheterization, and will evaluate coronary microvascular function in all subjects meeting inclusion criteria with a coronary flow wire. Evaluation of coronary microvascular function may be performed using indirect methods, however the rationale behind the present study is to directly measure microvascular function using direct coronary flow measurements, since the subjects in the study are to undergo a clinically-indicated cardiac catheterization. The overall purpose of the study is to define the presence and severity of coronary microvascular dysfunction subjects with CTO.
224307721|NCT00375830|PROCEDURE|Bone scan|Scan to diagnose a number of bone conditions including cancer or metastasis
224181642|NCT04311515|DRUG|PU-AD|PU-AD 30mg daily for 6mos
224181643|NCT04311515|DRUG|Placebo|Placebo 30mg daily for 6mos
224307722|NCT00375830|DRUG|99mTc-methyl diphosphonate|Radiolabel for bone scan procedures
224307723|NCT00375830|PROCEDURE|Positron Emission Tomography (PET) scan|Scan to detect gamma rays emitted by a positron-emitting radioligand such as 18F
224307724|NCT00375830|DRUG|18F-Fludeoxyglucose (18F-FDG)|Radiolabel for positron emission tomography scan procedures
224181644|NCT02835989|OTHER|CP@Home|Community paramedics (CPs) will be assigned to visiting the participants for a first time the week following the initial EMS call. Participants will complete the informed consent process with a CP on their first visit. This visit will also include a full assessment and risk analysis that will take approximately 90 minutes and will be located in the participant's home. As a result of the initial visit, the CP will make all relevant clinical referrals and decisions based on predetermined @Home algorithms. A second visit will be made to the participant 2-4 weeks following the initial call for a streamlined follow-up and reassessment during a 30 minute period. A final visit will be made 6-8 weeks following the initial call for a final evaluation of their situation. It is anticipated the patient will be discharged from the CP@Home program at this point. If the patient calls EMS following the third visit, if they meet the inclusion criteria, they will be re-entered into the CP@Home program.
224307725|NCT00375830|PROCEDURE|Computed Tomography (CT) scan|Scan to detect \& analyze X-rays
224307726|NCT00375830|DRUG|18F-Sodium Fluoride (18F-NaF)|Radiolabel for CT and PET scans, \& as a contrast agent for MRI scans.
224307727|NCT00375830|PROCEDURE|Whole Body Magnetic Resonance Imaging (WB-MRI) scan|Whole Body Magnetic Resonance Imaging (WB-MRI) scan: Scan that uses strong magnetic fields \& radio waves to generate images of the organs in the body.
224307728|NCT00375830|DRUG|Gadopentetate dimeglumine|A gadolinium-based contrast agent for MRI
224307729|NCT00375830|DRUG|Gadofosveset|A gadolinium-based contrast agent for MRI
224307730|NCT00375830|DRUG|Gadobutrol|A gadolinium-based contrast agent for MRI
224307731|NCT00236366|DRUG|fentanyl|
224307732|NCT04330716|BEHAVIORAL|Standard Genetic Counseling|Standard of care genetic counseling
224307733|NCT04330716|BEHAVIORAL|Educational Video|Video tutorial about genetic testing
224307734|NCT01054235|BEHAVIORAL|training|The intervention consisted of 1) training township midwives, 2) informing women and men in the community of the importance of prenatal care, 3) providing intervention township hospitals with basic medical instruments used in prenatal care (i.e. blood pressure monitors, weighing scales for mothers and newborns, stethoscopes).
224307735|NCT04066595|DRUG|Cabozantinib|60 mg cabozantinib oral daily. When dose reduction is necessary, it is recommended to reduce to 40 mg daily, and then to 20 mg daily.
224307736|NCT00759850|DEVICE|Drug Eluting Stent (DES)|Open-label randomization was performed after initial angiography by the treating physician when eligibility criteria were met. All patients received in the CCU 70U/Kg i.v. bolus of UFH plus 1000U/h infusion (to maintain an ACT of at least 200 seconds), aspirin intravenously (500 mg) and clopidogrel (300 mg loading dose). All patients received upstream Gp IIb-IIIa inhibitors administration as a routine adjunctive therapy before primary PCI. Postinterventional antiplatelet therapy for all patients included in the three study group, consisted of aspirin (100 mg) indefinitely and clopidogrel (75 mg for six months). Stenting procedures were performed according to standard techniques. The number and length of stents, and the type of BMS to be implanted, were left to the operator's discretion. The operator was allowed to implant DES to cover the entire length of the lesion with coverage of the entire stented segment and of 5 mm proximal and distal segments.
224307737|NCT05826795|PROCEDURE|Early goal-directed therapy (EGDT)|The principle of hemodynamic optimization to achieve the defined goals.
224307738|NCT00002825|BIOLOGICAL|filgrastim|
224307739|NCT00002825|DRUG|docetaxel|
224307740|NCT04842838|DEVICE|paclitaxel DCB|Drug-coated balloon is a new kind of coronary interventional device. The balloon coated with anti-cell proliferation drugs (paclitaxel, etc.) is sent to the stenosis site. The balloon is closely adhered to the vascular wall during the expansion, and the drug is rapidly and evenly coated on the disaffected vessels.In recent years, DCB has gradually become an alternative for the treatment of in-stent restenosis (ISR), small vessel disease (SVD) and bifurcation disease.
224307741|NCT04842838|DEVICE|DES|Provisional T technique is the preferred method for the treatment of bifurcation lesions with the existing stent.According to the 2018 European Guidelines on revascularization and the consensus group of the European Bifurcation Club (EBC), Provisional T technique is still the first choice for the treatment of Bifurcation, despite the problems related to side branches.
224307742|NCT04187417|DRUG|topical tetracaine hydrochloride 1%|topical ophthalmologic anesthestic
224307743|NCT04187417|DRUG|Placebo|Placebo
224307744|NCT05999058|PROCEDURE|Dacryoendoscopic-assisted laser dacryoplasty with silicone intubation|The dacryoendoscopy was inserted into the lacrimal duct through the upper or lower lacrimal punctum. When the dacryoendoscopy reached the postsaccal obstruction, laser dacryoplasty (FOX diode laser, A.R.C. Laser, Nürnberg, Germany) was performed by widening the stenotic or obstructed section. After removing the dacryoendoscopy, a silicone tube inserted into lacrimal passage. Double bicanalicular silicone intubation was performed as previously described.
223490384|NCT01757847|BEHAVIORAL|Brief MOVE-II control group intervention|The MOVE-II protocol was designed to reinforce the weight-loss principles that patients learn in MOVE! and to provide support in continued weight loss. The brief MOVE-II active control group protocol will be delivered in four 2-hour weekly group sessions. This protocol includes a psycho-educational component that reinforces the key information from the medical, nutrition, and weight loss strategies modules of the MOVE! program. After review of the psycho-educational components, patients have the opportunity to share their challenges with binge eating and weight loss. Patients will then be able to receive support and feedback from other group members and the therapist. In addition to reinforcing the strategies taught during MOVE! and to provide support in implementing those strategies, the active control group focuses on increasing self-esteem and self-efficacy by exploring patient strengths and maintaining therapeutic alliance and optimism.
224181645|NCT01463059|BIOLOGICAL|Placebo|Placebo solution for injection, administered as subcutaneous injections
224307745|NCT00715936|BEHAVIORAL|Control|
224307746|NCT00715936|BEHAVIORAL|ECD|
224307747|NCT00715936|BEHAVIORAL|Enhanced Nutrition|
224307748|NCT04032236|OTHER|caffeine|At room temperature (18-25 ° C) the same place and standard environment will be done. All involved cases will undergo a dental examination and within 30 minutes three samples of saliva will be taken, including first sample, after coffee drink and after drinking water. The pH of samples will be measured and the smoking cessation rate of the smoking cigarette smoker with simultaneous VAS (VISUAL ANALOG SCALA) will be measured. This data will be compared in-house and non-smoking control group
224307749|NCT02135835|DRUG|Shenfu Zhusheye|
224307750|NCT02135835|DRUG|5% glucose injection|
224307751|NCT03216070|DRUG|Dasatinib 50 MG|50mg of dasatinib orally daily
223587749|NCT01949519|DRUG|Lycopene and Docetaxel|During administration of standard of care Docetaxel at 75 mg/m2 on day 15 and every 21 days, study patients will also receive Lycopene at the dose specified per the dose cohort they are enrolled. There are three dose cohort levels as follows: Dose level 1 = 30 mg PO every day; Dose level 2 = 90 mg PO every day; Dose level 3 = 150 mg PO every day.Treatment will continue until disease progression or toxicity or patient withdrawal.
223587750|NCT01105377|DRUG|entinostat|Given orally
223587751|NCT01105377|DRUG|azacitidine|Given SC
223587752|NCT01105377|OTHER|laboratory biomarker analysis|Correlative studies
224181646|NCT01463059|BIOLOGICAL|Olokizumab 60 mg|Olokizumab 60 mg solution for injection, administered as subcutaneous injections
224181647|NCT01463059|BIOLOGICAL|Olokizumab 120 mg|Olokizumab 120 mg solution for injection, administered as subcutaneous injections
224181648|NCT01463059|BIOLOGICAL|Olokizumab 240 mg|Olokizumab 240 mg solution for injection, administered as subcutaneous injections
224181649|NCT01693640|DRUG|Abatacept|Weekly injections with Abatacept 125 mg over 6 months
224181650|NCT03182673|DRUG|SHR7390|SHR7390 is provided as white, film-coated,immediate release tablets containing SHR7390 at dosage strengths of 0.125 mg,0.5 mg and 2mg. Multiple tablets of SHR7390 will be administered orally to achieve targeted doses of SHR7390: 0.125 mg-4 mg. Tablets will be administered once daily or for 21 days and discontinued for 7 days with 240 ml water after 2 hours of the meal.
224181651|NCT03182673|BIOLOGICAL|SHR-1210|SHR-1210 is a humanized anti-PD1 immunoglobulin G4 (IgG4) monoclonal antibody. SHR-1210 is provided as the lyophilized powder,200 mg/vial.SHR-1210 was given with 200mg fixed dose intravenously per 2 weeks at the D1 and D15.Intravenous infusion over 30 min
223490387|NCT05334836|DIAGNOSTIC_TEST|MRI for pancreatic fat and liver fat quantitation|MR imaging would be performed using a 3.0 T scanner (Achieva X series, Philips Healthcare, Best, The Netherlands) with a 16-channel SENSE-XL-Torso array coil. 3D spoiled chemical-shift water-fat mDixon sequence (TR = 5.7 ms, first TE/echo spacing = 1.2-1.4 (ms)/1.0-1.2 (ms), number of echoes = 6, flip angle = 3°, SENSE acceleration = 2, a breath hold technique would be employed to acquire co-registered water, fat, fat-fraction and T2\* image series and would be reconstructed with slice thickness/number of slices = 3.0 mm/50. The field of view (FOV) covered the upper abdomen, i.e. region from the dome of the diaphragm to the iliac crest covering the entire extent of the liver and pancreas. Image reconstruction would be completed online using Philips mDixon product implementation with the multi-peak spectral model of fat to increase accuracy and sensitivity.
223587753|NCT02495454|DRUG|Ga101|
223587754|NCT04198675|BEHAVIORAL|Supervised EMG Biofeedback Exercise Training Group|Posture training and ergonomic arrangements in the workplace. EMG biofeedback training will be carried out with electromyography-controlled video game combined with PNF exercises. Each game sessions comprising the work-rest cycle covers performing the upper trapezius muscle contraction simultaneously the upper extremity PNF patterns.
224181652|NCT03182673|DRUG|SHR3162|SHR3162 is provided as capsules containing SHR3162 at dosage strengths of 10mg,40mg and 100mg. The capsule of SHR3162 will be orally administered with 240ml water twice a day to achieve targeted doses of SHR3162 and the interval of SHR3162 capsules taken twice a day is about 12 hours.
224181653|NCT01404104|DRUG|Temsirolimus (pre surgery)|Temsirolimus will be given to patients 12 weeks prior to surgery (with a one week off period right before the surgery date).
224181654|NCT01698606|BEHAVIORAL|Multidisciplinary, family-centered lifestyle intervention with behavioral counseling|Parent/caregiver education with skill training and practical activities revolving around healthy dietary choices, establishing an active versus a sedentary lifestyle, and behavioral aspects, while children will be engaged in active play.
224181655|NCT05718921|DRUG|YR001 Dose A on low body surface area|Part A: Single topical dose
224181656|NCT05718921|DRUG|YR001 Dose A on middle body surface area|Part A: Single topical dose
224181657|NCT05718921|DRUG|YR001 Dose A on high body surface area|Part A: Single topical dose
223490388|NCT05749822|DRUG|Fenofibrate 200mg|Fenofibrate 200mg/day
223490389|NCT05749822|DRUG|Placebo|1 tablet/ day
223490390|NCT05749822|DRUG|UDCA|UDCA 13-15mg/kg/day
223490391|NCT03495388|DRUG|Oxycodone|Post-op pain management medication
223490392|NCT04796857|DRUG|PD-1 Antibody|Tislelizumab will be administered every 4 weeks up to 6 cycles during induction phase if patients get CR or PR after induction phase.
223490393|NCT04796857|DRUG|Lenalidomide|"Phase I: dose escalation phase. Patients will oral dosage as 10mg, 20mg, per day. Aim to evaluate MTD and DLT, RP2D.~Phase II：Patients continuous oral lenalidomide as RP2D up to 6 cycles during induction phase"
223490394|NCT00010998|PROCEDURE|Yoga|
223490395|NCT02337127|DRUG|Lamivudine|Lamivudine, 100mg/day, per os
223587755|NCT04198675|BEHAVIORAL|Home-Based Exercise Training Group|Posture training and ergonomic arrangements in the workplace. Posture correction exercises, contains strengthening, stretching, mobility and relaxation exercises, will be given as a home exercises program. Exercise diary and weekly calls will be use to maintain the exercise adherence
223490396|NCT02607072|DRUG|Acetylsalicylic acid (ASA)/aspirin 200 mg daily|
223490397|NCT02607072|DRUG|Acetylsalicylic acid (ASA)/aspirin 100 mg daily|
223490398|NCT02607072|DRUG|Placebo|
223490399|NCT00831844|BIOLOGICAL|cixutumumab|Given IV: Week 1 day 1, 9 mg/kg/dose over 1 hour. Week 2 Day 8, 9 mg/kg/dose over 1 hour. Week 3 Day 15, 9 mg/kg/dose over 1 hour. Week 4 Day 22, 9 mg/kg/dose over 1 hour.
223490400|NCT00831844|OTHER|laboratory biomarker analysis|Correlative studies
223587756|NCT04198675|BEHAVIORAL|Posture Training/Ergonomic Regulations Group|Posture training and ergonomic arrangements in the workplace.
223587757|NCT00696969|DRUG|Amphotericin B Deoxycholate|1 mg/kg e.o.d for 30 days
223587758|NCT00696969|DRUG|Ambisome + Miltefosine|Ambisome (i.v. single dose 5 mg/kg)+ Miltefosine 7 days
223587759|NCT00696969|DRUG|Ambisome and Paromomycin|Ambisome 5 mg/kg single dose + Paromomycin Sulphate 15mg/kg/day for 10 days
223587760|NCT00696969|DRUG|Miltefosine and Paromomycin|Miltefosine (standard dose) and Paromomycin Sulphate 15mg/kg/day for 10 days
224181658|NCT05718921|DRUG|YR001 Dose B on low body surface area|Part A: Single topical dose
224181659|NCT05718921|DRUG|YR001 Dose B on middle body surface area|Part A: Single topical dose
224181660|NCT05718921|DRUG|YR001 Dose B on high body surface area|Part A: Single topical dose
224181661|NCT05718921|DRUG|Placebo on low body surface area|Part A: Single topical dose
224181662|NCT05718921|DRUG|Placebo on middle body surface area|Part A: Single topical dose
224181663|NCT05718921|DRUG|Placebo on high body surface area|Part A: Single topical dose
224181664|NCT05718921|DRUG|YR001 Dose A on high body surface area twice daily|Part B: Multiple topical dose
224181665|NCT05718921|DRUG|YR001 Dose B on high body surface area twice daily|Part B: Multiple topical dose
224181666|NCT05718921|DRUG|Placebo on high body surface area twice daily|Part B: Multiple topical dose
224181667|NCT02547064|PROCEDURE|Glidescope guided intubation|
224181668|NCT02547064|DEVICE|GlideScope®|
224181669|NCT02079376|DEVICE|DIAMOND System|DIAMOND Implantable Pulse Generator (IPG)
224181670|NCT01856920|BIOLOGICAL|GI-6207 [Recombinant Saccharomyces cerevisiae-CEA (610D)]|GI-6207 is a heat-killed, recombinant yeast-based vaccine engineered to express the full length human carcinoembryonic antigen (CEA), with a modified gene coding sequence to code for a single amino acid substitution (asparagine to aspartic acid) at the native protein amino acid position 610, which is designed to enhance immunogenicity. A plasmid vector containing the modified human CEA gene is used to transfect the parental yeast strain (S. cerevisiae W303 - a haploid strain with known mutations from wild-type yeast) to produce the final recombinant vaccine product.
224181671|NCT02427542|OTHER|CBT for Depersonalization/Derealization|In addition to treatment as usual, six sessions of Cognitive Behavioural Therapy for Depersonalization/Derealisation covering psychoeducation, formulation, coping strategies.
224181672|NCT02427542|OTHER|Treatment as usual|Treatment as usual - in most cases case management/care coordination and may include medication
224181673|NCT03707106|BEHAVIORAL|CBT smoking cessation|an established protocol for smoking cessation based on cognitive behavioral therapy
223745447|NCT06518746|OTHER|Cryopreservation of gonadal tissue|Patients at risk for primary gonadal tumors will undergo unilateral or bilateral gonadectomy for clinical purposes as a standard of care, and a portion of the surgically removed tissue will be cryopreserved for fertility preservation. The pathologist will assess the tissue using sterile technique and every other section will undergo histologic analysis, including evaluation for the presence of tumor or viable germ cell elements. The sections of the tissue for fertility preservation will be refrigerated and held until a final diagnosis is made on the tissue sections that are being processed for histologic analysis. If no tumor is identified and viable germ cell elements are identified, the tissue sections allotted for preservation will be sent in holding media for processing and cryopreservation.
223587761|NCT02966470|DEVICE|Obtain grip strength from a standardized gripometer|Obtain grip strength from a standardized gripometer, 3 times on each hand
223587762|NCT00226070|PROCEDURE|interview and advising|
223587763|NCT00226070|BEHAVIORAL|3 follow up interviews and personal advising|
223587764|NCT00226070|PROCEDURE|interview SF-36 self rated health|
223587765|NCT02532985|OTHER|Negative Control|No added fiber beverage
223587766|NCT02532985|OTHER|Positive Fiber Control|positive control fiber supplemented beverage provided over 4 servings
224181674|NCT03707106|BEHAVIORAL|virtual reality based cue exposure|smoking cue exposure in virtual reality
224181675|NCT03707106|BEHAVIORAL|progressive muscle relaxation|Progressive muscle relaxation for unspecific stress reduction
224181676|NCT02545270|PROCEDURE|Level of pneumoperitoneum 12-9-6 mmHg|Elective laparoscopic inguinal hernia procedures will be used to make video-recordings under 3 different levels of pneumoperitoneum (12-9-6 mmHg) during desufflation.
224181677|NCT02545270|PROCEDURE|Level of pneumoperitoneum 11-8-5 mmHg|Elective laparoscopic inguinal hernia procedures will be used to make video-recordings under 3 different levels of pneumoperitoneum (11-8-5 mmHg) during desufflation.
224181678|NCT02545270|PROCEDURE|Level of pneumoperitoneum 10-7-4 mmHg|Elective laparoscopic inguinal hernia procedures will be used to make video-recordings under 3 different levels of pneumoperitoneum (10-7-4 mmHg) during desufflation.
224181679|NCT02282839|DIETARY_SUPPLEMENT|Glutamine|Powder that soluble in water for drinking, 10g TID (total 30 g per day)
224181680|NCT02282839|DIETARY_SUPPLEMENT|Placebo|Powder that provided by manufacturer with the same ingredients yet without glutamine, TID use
224181681|NCT05399823|OTHER|Exercise|Strecthing exercises will given for 15-20 minutes everyday for four weeks
224181682|NCT00212615|DRUG|Oxaliplatin (Eloxatin)|
224181683|NCT00212615|DRUG|Capecitabine (Xeloda)|
224181684|NCT01028131|BEHAVIORAL|Computer-delivered brief intervention (5As)|After completing the brief assessment battery, participants will interact with the computer for approximately 20 minutes, with structure being based on the Five A model and Motivational Interviewing.
224181685|NCT01028131|BEHAVIORAL|Contingency Management|Participants randomized by the computer into this condition will view a 20-minute music and tv videos after completing the brief assessment. The research assistant will then briefly describe the CM process, with a period for questions to assure understanding. The CM condition will involve participant-initiated submission of urine samples at prenatal visits. Clinic staff will have no responsibility for the CM component other than calling research staff when a participant wishes to submit a sample. Clinic staff will not schedule any new, additional, or unnecessary prenatal visits.
223587767|NCT02532985|OTHER|Novel Fiber|novel fiber supplemented beverage provided over 4 servings
223587768|NCT02532985|OTHER|Novel Fiber|novel fiber supplemented beverage provided over 4 servings
223587769|NCT02532985|OTHER|Novel Fiber|novel fiber supplemented beverage provided over 4 servings
223745448|NCT04995523|DRUG|AZD2936|Anti-TIGIT/Anti-PD-1 Bispecific Antibody
224181686|NCT01869231|DIETARY_SUPPLEMENT|olive oil|
224181687|NCT01869231|DIETARY_SUPPLEMENT|olive oil and chewing gum|
224181688|NCT01869231|DIETARY_SUPPLEMENT|chewing gum|
224181689|NCT01869231|DIETARY_SUPPLEMENT|water|
224181690|NCT00017108|DRUG|chlorambucil|
224181691|NCT00017108|DRUG|cyclophosphamide|
224181692|NCT00017108|DRUG|fludarabine phosphate|
224181693|NCT05943340|OTHER|Proprioceptive exercises|Specific proprioceptive exercises for the shoulder that the patient has to do during the immobilization period.
224181694|NCT04438642|PROCEDURE|shoulder finishline|tooth will be prepared having shoulder finishline.
224181695|NCT04438642|PROCEDURE|butt joint with bevel|tooth will be prepared having butt joint with bevel finishline.
224181696|NCT00468013|BEHAVIORAL|Resilience Building Exercises|Weekly exercises for 6 weeks
224181697|NCT00468013|BEHAVIORAL|Journaling|Weekly exercises for 6 weeks
224181698|NCT00004937|DRUG|acridine carboxamide|
224181699|NCT00207363|DRUG|Ribavirin, Peg interferon alfa 2b|Peg interferon alfa 2b 1.5mcg/kg/wk for 48 weeks ribavirin 13+/-2 mg/kg daily for 48 weeks
224181700|NCT00207363|DRUG|induction therapy|Peg Intron 3.0mcg/kg/wk for 12 weeks then Peg interon 1.5mcg/kg/week for 36 weeks
224181701|NCT04761835|BIOLOGICAL|Peanut powder or peanut butter|Commercially available peanut powder or peanut butter.
224181702|NCT05177861|DIAGNOSTIC_TEST|EMG|Electromyelography
224181703|NCT02698020|PROCEDURE|Room-air|Provision of room-air
224181704|NCT00513331|PROCEDURE|Endoscopy|Initial Assessment for lesions can be based on information obtained from previous upper endoscopies and or pathology reports. Repeat Endoscopic assessments are based on initial and follow-up assessments.
224181705|NCT00513331|PROCEDURE|Radiofrequency ablation protocol|Ablation using the HALO 360 system according to protocol established by BARRX, Inc.
224181706|NCT00513331|PROCEDURE|Endoscopic mucosal resection protocol|Excision of lesion using DUETTE, marketed by Wilson-Cook
224181707|NCT02477631|DRUG|Deferiprone|This is a single-arm, open-label, multi-center study in 20 patients with MDS. All participants will be treated with deferiprone for up to 4 months.
224181708|NCT01511211|DRUG|Dexamethasone|2 cc of 4 mg/cc dexamethasone will be added to 38 cc of 0.5% ropivacaine solution. Of this combination, 15 cc will be used for a femoral nerve block, 20 cc for the popliteal nerve block, and 5 cc for the obturator nerve block. In addition, 2 cc of normal saline will be added to the patient's IV to maintain blinding.
224181709|NCT01511211|DRUG|Ropivacaine|2 cc of normal saline will be added to 38 cc of 0.5% ropivacaine solution. Of this combination, 15 cc will be used for the femoral nerve block, 20 cc for the popliteal nerve block, and 5 cc for the obturator nerve block. In addition, 2 cc of 4 mg/cc dexamethasone will be added to the patient's IV.
224181710|NCT00667381|DEVICE|Real-time Ultrasound Guidance (Site-Rite 5 or 6 machine)|Real-time ultrasound guidance will be used to aid in femoral artery cannulation. This will occur with a 7 MHz ultrasound probe covered with a sterile cover.
224181711|NCT00038116|PROCEDURE|embryonic dopamine cell implant surgery|Half of the participants received the cell implant surgery, while the other half received the placebo. After the double-blind phase of the study, patients in the placebo group had the option of receiving tissue implants. Fourteen of these patients eventually had transplants.
224181712|NCT00038116|PROCEDURE|placebo|sham surgery
224181713|NCT03390049|DEVICE|Fractional CO2 Laser Treatment|After obtaining a negative urine pregnancy test, each subject assigned to the fractional CO2 laser treatment arm will undergo laser sessions with the fractional microablative CO2 laser system (SmartXide 2 V 2 LR, MonaLisa Touch, DEKA, Florence, Italy) using the flat vulvar probe with the following settings: dot power 26 Watts, dwell time 1000 μs, dot spacing 1000 μm, and smart stack parameter from 1 to 3. Stack 1 is used at baseline; stack 3 is used 6 and 12 weeks after.
224181714|NCT03390049|DEVICE|Sham Laser Treatment|After obtaining a negative urine pregnancy test, each subject assigned to the sham laser treatment arm will undergo laser sessions with the fractional microablative CO2 laser system (SmartXide 2 V 2 LR, MonaLisa Touch, DEKA, Florence, Italy) using the flat vulvar probe. However, these sham laser sessions will administer no fractional CO2 laser energy. To increase the likelihood that subjects assigned to sham laser remain blinded to treatment arm assignment during the study, MonaLisa Touch will provide a software package with settings that allow for reproduction of the sounds generated during a regular fractional CO2 laser session but using 0 Watts of power.
224181715|NCT03467035|OTHER|Inflammasone|Serum level of cytokine and RT-PCR for PBMC
224181716|NCT01716585|DRUG|ABT-450/r/ABT-267, ABT-333|ABT-450 coformulated with ritonavir and ABT-267, ABT-333 tablet
224181717|NCT01716585|DRUG|Ribavirin|Capsule (double-blind treatment period), tablet (open-label treatment period)
224181718|NCT01716585|DRUG|Placebo for ABT-450/r/ABT-267|Tablet
224181719|NCT01716585|DRUG|Placebo for ABT-333|Tablet
224181720|NCT01716585|DRUG|Placebo for ribavirin|Capsule
224181721|NCT01298011|DRUG|Gemcitabine and Abraxane|3 treatments for gemcitabine and abraxane every 28-days for 3 months, prior to surgery.
223490402|NCT03771716|BEHAVIORAL|African Dance|Basic principles and guidelines for exercise programming will be followed including adequate warm-up and cool-down, progressive and gradual increments in duration, and instruction regarding avoidance of physical activity (PA) related injury. The African dance group will receive moderate intensity dance 1 hour per day, twice per week, for 6 months. The prescribed intensity will begin at light to moderate and progress to a moderate to high intensity level. Frequent assessment of heart rate and ratings of perceived exertion will ensure appropriate levels of intensity during each dance session. Levels of exertion during the dance will be prescribed and monitored based on baseline assessments of heart rate and cardiorespiratory fitness.
224181722|NCT04646668|COMBINATION_PRODUCT|E-cigarette and Heat not burn|Current smokers will be randomized to session order and complete a standardized 10-puff bout (5 minutes) followed by a 60-minute ad libitum session with each product (usual brand cigarette, e-cigarette, heat-not-burn).
224181723|NCT04527458|OTHER|Patient Characteristics|Characteristics of the patients
224181724|NCT04527458|OTHER|COVID-19 treatments|Specific treatments used on COVID-19 patients
224181725|NCT04527458|OTHER|Differences in triage|Triage criteria for treating COVID-19 patients
224181726|NCT04527458|OTHER|Surge capacity|Capacity of hospitals
224181727|NCT02503956|DEVICE|Perforated Punctal plugs|Perforated punctal plugs
224181728|NCT02503956|PROCEDURE|Crawford tube insertion|
224181729|NCT02503956|DEVICE|Crawford lacrimal tube|
224181730|NCT04264949|OTHER|Education in the use of smartphone app (Mon coach dos)|In addition to conventional care and the therapeutic education program, GA will benefit from three education sessions (one per week) on the use of the smartphone app mon coach dos
224181731|NCT04264949|OTHER|conventional care|conventional care and the therapeutic education program
224181732|NCT03792230|BEHAVIORAL|Video|Video group receive body mechanic education via CD material,
224181733|NCT03792230|BEHAVIORAL|Brochure|Brochure group receive body mechanic education via written material (brochure)
224181734|NCT01148108|DRUG|Canfosfamide HCl for injection|30 min. intravenous infusion of canfosfamide HCl (1000 mg/m2) every 2 weeks
224181735|NCT03677752|OTHER|GP_Posit|Mother-infant dyads allocated to this arm will receive the GP\_Posit intervention. The intervention consists of a guided participation intervention to positioning. Mothers will meet with the intervention nurse twice a week for the two first weeks after birth and then one a week until the infant will reach 35 weeks of gestational age. During these encounters, mothers will learn how to interpret their infant's stress and stability cues and participate in his/her care and positioning while being guided by the intervention nurse.
224181736|NCT02028052|PROCEDURE|ROSE|The procedure will proceed with conventional EBUS-TBNA sampling of the target lesion with 22 gauge Vizishot needles. Each subject will be randomized to either ROSE by cytopathologist or no ROSE.
224181737|NCT02028052|DEVICE|22 gauge Vizishot needles|
224181738|NCT02784665|DEVICE|577-MPL|All treatments were provided by a single practitioner with the 577-nm yellow laser system(Supra 577nm affected area in micropulse model.The power titration was started at 700 milliwatt(mW) and then gradually increased until a just visible burn was seen. When this threshold was reached, the power was reduced by 50%, using a 100-μm spot diameter and a 200-ms duration with 5 % duty cycle LaserSystem) in 577-MPL arm. The individual power for the patient was titrated at a normal area of near the
224181739|NCT02784665|DEVICE|577-TL|"All treatments were provided by a single practitioner with the 577-nm yellow laser system(Supra 577nm LaserSystem) in 577-TL arm.~100 microns light spot size, 0.05 seconds duration, 80 \~ 200 milliwatts of power"
224181740|NCT02118909|DRUG|Pracinostat|
224181741|NCT02118909|DRUG|Itraconazole|
224181742|NCT02118909|DRUG|Ciprofloxacin|
224181743|NCT03150706|DRUG|Avelumab|"Patients will receive 10 mg/kg of avelumab via intravenous infusion every 2 weeks.~Response evaluation will be performed every 6 weeks (± 1-week window period). Treatment will be continued until disease progression, unacceptable adverse events or the patient's refusal.~Treatment through progression is at the investigator's discretion, and the investigator should ensure that patients do not have any significant, unacceptable, or irreversible toxicity that indicate that continuing treatment will not further benefit the patient. The Investigator should ensure that patients still meet all of the inclusion criteria and none of the exclusion criteria for this study."
224181744|NCT04371705|PROCEDURE|Erector spinae plane block|The ESP block will be performed into a fascial plane between the deep surface of erector spinae muscle and the transverse processes using ultrasound guide.
224181745|NCT04371705|OTHER|control|placebo
224181746|NCT04647006|PROCEDURE|thyroid|Conventional Thyroidectomy and Transoral endoscopic thyroidectomy vestibular approach
224181747|NCT06230107|BEHAVIORAL|Mindful Eating|Analyze the impact of Mindful Eating on changes in dietary habits, episodes of binge eating, body image dissatisfaction, quality of life and anthropometric data (weight, BMI and waist circumference) in Participants with obesity and BED.
224181748|NCT02291952|BEHAVIORAL|Meal schedule|
224307752|NCT02169700|PROCEDURE|Ischemic compression. Dry Needling|Ischemic compression was carried out after dry needling. Dry needling was performed with a solid filament needle. Subjects were asked to lie in a prone position. The MTrP was held firmly in a pincer grasp. Before inserting the needle, the patient was advised about the possible sharp pain and muscle twitching. The needle was inserted perpendicular to the skin. Then, the muscle fibers were repeatedly perforated by rapidly inserting and partially withdrawing the needles from the MTrP until two local twitch responses were elicited from the muscle. On removal of the needle, the area was compressed firmly with a cotton bud for two minutes. Immediately after the needling, subjects were randomly assigned to one of three groups (IC, sham and control).
224307753|NCT05178433|COMBINATION_PRODUCT|Use baby moisturizers by NeoChine|During continuous phototherapy, use skin basic care and protection in combination with baby moisturizing products, use the whole body twice a day, and the amount of each time is not less than 5 grams.
224307754|NCT05984875|OTHER|Collection of tumor samples, blood and vaginal and rectal swabs|The following biological samples will be collected at different time points, according to the specified cohort and after signing the inform consent form: tumor tissue (fresh and archival) or normal tissue (cohort E), ascites (when present), peripheral blood, rectal swab, vaginal swab.
224307755|NCT02449096|DEVICE|Arthroscope|AORIF - arthroscopically assisted open reduction and internal fixation of acute ankle fractures
223745449|NCT01883414|DEVICE|Ultherapy™|All subjects will receive an Ultherapy™ treatment at triple depth using the 4-4.5mm, 7- 3.0mm, 10-1.5mm transducers on one half of the scar and no treatment on the other half of the scar. Treatments will be provided to the defined scar area, treating with a density of lines that is equivalent to 30 lines per transducer per 2.5cm in scar length for a total of 90 lines in a 2.5cm X 2.5cm square area.
224181749|NCT02014753|DEVICE|cobalt-chromium everolimus-eluting stent (CoCr-EES)|
224181750|NCT06518330|DRUG|Intake of Methylphenidate|Intake of Methylphenidate
224181751|NCT06050707|RADIATION|Radiotherapy - Low risk group|20 fractions completed in 4 weeks
224181752|NCT06050707|RADIATION|Radiotherapy - Standard risk group|25 fractions completed in 5 weeks
224181753|NCT06050707|RADIATION|Radiotherapy - Intermediate risk group|30 fractions completed in 6 weeks
224181754|NCT06050707|RADIATION|Radiotherapy - High risk group|35 fractions completed in 7 weeks
224307756|NCT02449096|OTHER|No arthroscope|ORIF - open reduction and internal fixation of acute ankle fractures
224307757|NCT04470687|DEVICE|contrast enhanced ultrafast ultrasound imaging|"Ultrasound contrast medium: SonoVue 8µL/mL (Bracco International BV) Ultrasound scanner: Aixplorer® device marketed by SuperSonic Imagine©, CE Doppler UltraFast™Doppler, contrast ultrasound (CEUS), color Doppler and ultra-sensitive energy Doppler, high-performance directional energy Doppler, Elastography ShearWave™ UF-Doppler (UltraFast-Doppler) and microbubble injection (SonoVue) Apparatus for performing the UF Doppler sequence: Aixplorer, manufacturer : Supersonic Imagine, Aix-en-Provence, France, CE Marking.~3D RCA dedicated vascular probe with dedicated Doppler sequences"
224181755|NCT02104726|OTHER|Fluoroscopy guided steroid injection|We want to compare if there is a difference between the two arms, with the assumption that with fluoroscopy will deliver the steroid more accurately and see better outcomes.
224307758|NCT06148415|BEHAVIORAL|Fetal Heartbeat Monitoring Group|Fetal Heartbeat Monitoring Group
223745450|NCT00047021|BIOLOGICAL|sargramostim|Sargramostim (GM-CSF) subcutaneously beginning on day 14 and continuing until blood counts recover.
223745451|NCT00047021|DRUG|cytarabine|high-dose cytarabine IV over 1 hour on days 1-5
223745452|NCT00047021|DRUG|mitoxantrone hydrochloride|high-dose mitoxantrone IV over 15-30 minutes on day 5.
223587770|NCT01531751|DEVICE|High Cut-off Hemodialysis|During dialysis the patients will undergo the first cycle of chemotherapy according to the current standard of care for subjects with advanced cardiac AL amyloidosis. Measurements of FLC and cardiac biomarkers will be done before and after each dialysis session. High cutoff HD will be continued during the first chemotherapy cycle. After the first cycle the end-of-treatment evaluation will take place.
224181756|NCT02104726|OTHER|Blind Steroid Injection|Want to compare it to fluoroscopy guided, with assumption that it will be less effective in reducing pain
224181757|NCT03616782|DRUG|Ixazomib|Ixazomib 3mg on day 1, 8, 15 q 4 weeks for 24 months or until progression
224181758|NCT01768182|DIETARY_SUPPLEMENT|Folinic Acid|Participants were randomly assigned to a 4-week treatment with either folinic acid (n=15) or placebo (n=15). The study supplementation regimens consisted of the capsules containing 5 mg of folinic acid or placebo. Participants were provided with 1 bottle, which contained 30 capsules. Subjects were instructed to take 1 capsule daily, in the morning
224181759|NCT01768182|OTHER|Placebo|The study supplementation regimens consisted of the capsules containing 5 mg of folinic acid or placebo. Participants were provided with 1 bottle, which contained 30 capsules. Subjects were instructed to take 1 capsule daily, in the morning
224181760|NCT02348710|BEHAVIORAL|Exercise OE workbook|The workbook will aim to make participants aware of the breadth and depth of OEs by first providing a global overview of the many and diverse positive outcomes breast cancer survivors may experience. Participants will then be asked to focus on the three OEs they would most like to experience. Each section of the OE guide contains activities to target specific OE dimensions. Importance will be increased through elaboration of why outcomes are important to the participant; and certainty will be increased by narrative messages from other breast cancer survivors and an oncologist. Accessibility will be increased by having the participant think about the association between exercise and its outcomes
224181761|NCT02348710|BEHAVIORAL|Diet workbook|The workbook will contain the same activities as the intervention workbook but be focused on diet instead of exercise.
224181762|NCT04149145|DRUG|M4344+Niraparib|The first phase will be a 3+3 design of fixed dose Niraparib by mouth (PO) every day (QD) and M4344 will be escalated from 100-200 mg PO QD (28-day cycle). There will be a 4-week lead in with niraparib only.
224181763|NCT04149145|DRUG|M4344+Niraparib|In the second phase eligible patients will receive combination Niraparib + the determined dose of M4344 from the first phase.
224181764|NCT04605120|PROCEDURE|Cervical fusion|1- or 2-level ACDF (Anterior Cervical Discectomy and Fusion) combined with bone graft
224181765|NCT02182856|DRUG|Ipratropium bromide 500 µg/salbutamol sulphate 3 mg|
224181766|NCT02182856|DRUG|Ipratropium 500 µg|
224181767|NCT02182856|DRUG|Salbutamol sulphate 3 mg|
224181768|NCT02182856|DRUG|Salbutamol sulphate 6 mg|
224181769|NCT01276795|DIETARY_SUPPLEMENT|Oral Nutrition Support|The patients will sip the oral nutrition support (in the form of a drink) over the course of 4 hours within each 6 hour study. Each patient will be studied once before surgery and once after surgery.
224181770|NCT05774886|COMBINATION_PRODUCT|Implantable Microdevice (IMD)|"* Small, implantable device with 30 reservoirs for drug and drug combinations.~* Placement of 2 microdevices into tumor will be performed via needle, percutaneously, and guided by interventional radiologic techniques.~* Drugs include all or a subset of the following: Doxorubicin, Paclitaxel, Carboplatin, Eribulin, Pembrolizumab, Atezolizumab, Tazemetostat, Panobinostat, Olaparib, Capecitabine, Sacituzumab govitecan, Abemaciclib, Venetoclax, Doxorubicin + cyclophosphamide (combination), Doxorubicin + cyclophosphamide + paclitaxel + carboplatin (combination), Carboplatin + paclitaxel (combination), Doxorubicin + cyclophosphamide + pembrolizumab (combination), Doxorubicin + cyclophosphamide + paclitaxel + carboplatin + Pembrolizumab (combination), Paclitaxel + atezolizumab (combination), Paclitaxel + pembrolizumab (combination), Carboplatin + gemcitabine + pembrolizumab (combination), Carboplatin + paclitaxel + pembrolizumab (combination), Trastuzumab deruxtecan"
223587771|NCT01531751|DRUG|Chemotherapy|Chemotherapy will be based on alchilators, proteasome inhibitors, steroids, IMiDs.
223587772|NCT06393881|DRUG|UI059|take UI059 once a day for 7 days
224181771|NCT01466439|PROCEDURE|high-frequency of repetitive transcranial magnetic stimulation (rTMS)|frequency of stimulation of 20 Hz
224181772|NCT01466439|PROCEDURE|low frequency of repetitive transcranial magnetic stimulation (rTMS)|frequency of stimulation of 1 Hz
224181773|NCT01020929|DEVICE|Blunt Coude|Type of needle tip
224181774|NCT01020929|DEVICE|Quincke|Type of needle tip
224181775|NCT01020929|DEVICE|Trucath|Type of needle tip
224181776|NCT05553652|DIETARY_SUPPLEMENT|ASTARTE™ oral capsules|1 Capsule daily for 6 months
224181777|NCT05553652|DIETARY_SUPPLEMENT|Placebo oral capsules|1 Capsule daily for 6 months
224181778|NCT05099718|PROCEDURE|palatal soft tissue harvesting|A 6x2mm palatal soft tissue graft will be harvested.
224181779|NCT05099718|DEVICE|Hyaluronic acid|application 3-times per day for 7 days
224181780|NCT05099718|OTHER|Saline solution (placebo)|application 3-times per day for 7 days
223587773|NCT06393881|DRUG|UIC202201|take UIC202201 once a day for 7 days
223587774|NCT00745797|RADIATION|Radiotherapy|blood transfusions, platelet transfusions, antibiotics, antipyretic analgesics and anesthetics
224181781|NCT06028763|PROCEDURE|Injection of biocomposite hydrogel into ankle's cartilage lesion under arthroscopic control|Surgical treatment involves the use of an injectable biocomposite hydrogel containing autologous mesenchymal stem cells (MSCs), adipose tissue-derived cells, and chondroinductive growth factors (TGF-β1 and BMP-4) under arthroscopic control
224307759|NCT06158256|OTHER|Voluntary apnoea|Series of static apneas at low lung volume with a density of 30 seconds, followed by a normal breath of 10 seconds until completing the 6 minutes.
224307760|NCT04471337|DRUG|BAY1817080|BAY1817080 will be administered orally as tablet.
223587775|NCT01120990|OTHER|Blood Pressure Measurement|All patients have their blood pressure measured simultaneously by two observers using parallel connected mercury sphygmomanometers and by a supervisor using the tested device, NISSEI DM 3000. Six sets of measurements are performed.
223587776|NCT05945303|PROCEDURE|Coronary Artery Bypass Grafting surgery|Assessing the reliability of predicting fluid responsiveness in adults undergoing coronary artery bypass graft surgery using ultrasonography of the internal jugular vein for assessment of vessel distensibilty in relation to stroke volume variation (SVV) measured by electrical cardiometry.
224307761|NCT03201432|DEVICE|Drug eluting stent (DES)|Polymer-free paclitaxel eluting stents
223587777|NCT03950310|DEVICE|Excimer laser catheter|The excimer laser catheter is equipped with multiple optical fibers on the periphery of the guide wire lumen corresponding to 0.014 inch, which is used for the purpose of reperfusion of barrier site of coronary artery. The connector on the front side is connected with the CVX-300 laser generator, and the tip at the top contact directly with the lesion. The laser catheter consisting of multiple optical fibers transmits the energy in the ultraviolet region from the CVX300 laser generator to the blockage in the blood vessel. The ultraviolet energy is transmitted from the tip of laser catheter, transpires the fibrous, calcified and arteriosclerotic lesion by light, and enables reperfusion in the lesion. The laser catheter has appropriate hydrophilic coating and easily follows the inside of coronary artery.
223587778|NCT02950376|OTHER|DSM-5 +Virtual reality-based addiction assessment system|The patients who used the amphetamine type stimulants will be diagnosed by the chief physician、associate chief physician or attending physician first to evaluate their addiction severity. And then the patients will finish the test in the virtual environment, at the same time their eye movement index and other physiological data will be recorded .Physiological data includes cardiac rate、galvanic skin response and electroencephalogram and so on.The test will proceed at the beginning of withdrawl、3 months later、 6 months later and 1 year later and record the information synchronously.
223587779|NCT02950376|OTHER|Virtual reality-based addiction assessment system|The healthy controls will finish the test in the virtual environment, at the same time their eye movement index and other physiological data will be recorded .Physiological data includes cardiac rate、galvanic skin response and electroencephalogram and so on.The test will proceed at the baseline and 1 month later and record the information synchronously.
223587780|NCT02950376|OTHER|DSM-5 +Virtual reality-based addiction assessment system|The patients who used the amphetamine type stimulants will be diagnosed by the chief physician、associate chief physician or attending physician first to evaluate their addiction severity. And then the patients will finish the test in the virtual environment, at the same time their eye movement index and other physiological data will be recorded .Physiological data includes cardiac rate、galvanic skin response and electroencephalogram and so on.In this group which is designed to construct the norm of assessment system, the test will record the information synchronously and proceed after baseline assessment.
223587781|NCT04115982|DRUG|Cholecalciferol|One vial every 15 days during 2 months
223587782|NCT04115982|DRUG|Placebos|One vial every 15 days during 2 months
223587783|NCT00712582|DRUG|Etoposide, carboplatin, ifosfamide|Patients in consolidation A will receive three drugs in a regimen called ICE. You will have 3 cycles. Each new cycle begins 2 to 3 weeks after the last one.
223587784|NCT00712582|DRUG|Rituximab, Ifosfamide, Etoposide, Carboplatin|It consists of four drugs in a regimen called augmented RICE (augRICE). It is given every 3 weeks for 2 cycles.
223587785|NCT00712582|DRUG|Rituximab, Ifosfamide, Etoposide, Carboplatin, Stem Cell Collection, Mitoxantrone, Cyclophosphamide and etoposide, Carmustine|"It consists of four drugs in a regimen called augRICE. It is given every 3 weeks for 2 cycles. After the rituximab on day 3, you will then be admitted to the hospital for 2 to 3 nights.~Part 2: Stem Cell Collection, Part 3: High dose chemoradiotherapy and stem cell transplant. Your doctor may want you to get radiation therapy. If so, it will start 2 weeks before the highdose chemotherapy. This regimen is called CBV-N chemotherapy. It is given by vein in the hospital."
223587786|NCT02858921|DRUG|Dabrafenib|Dabrafenib, a 4-(3-aminosulfonylphenyl)-5-(pyrimidine-3-yl) thiazole, is a potent and selective inhibitor of B-RAF kinase activity with a mode of action consistent with adenosine triphosphate (ATP)-competitive inhibition, and is approved as monotherapy in BRAF V600E-mutant advanced/metastatic melanoma.
223587787|NCT02858921|DRUG|Trametinib|Trametinib, a pyrido - pyrimidine derivative, is a potent and highly selective allosteric non-competitive inhibitor of MEK1/MEK2 activation and kinase activity has been approved as monotherapy in BRAF (V600E)-mutant and BRAF (V600K)-mutant melanoma.
223587788|NCT02858921|DRUG|Pembrolizumab|Pembrolizumab is a potent and highly selective humanized monoclonal antibody (mAb) of the IgG4/kappa isotype designed to directly block the interaction between PD-1 and its ligands, PD-L1 and PD-L2.
223587789|NCT01084681|DEVICE|Endovascular treatment of intracranial aneurysms|Endovascular treatment with the SILK Artery Reconstruction Device for occluding intracranial aneurysms.
223587790|NCT01084681|DEVICE|Endovascular treatment of intracranial aneurysm with coils|Endovascular treatment with commercially available intracranial coils for occluding intracranial aneurysms.
223587791|NCT00094432|DRUG|Aripiprazole|Tablets, Oral, 10mg (2 5mg tablets), Once daily, 8 weeks.
223587792|NCT00094432|DRUG|Placebo|Tablets, Oral, 0 mg, Once daily, 8 weeks.
224181782|NCT06028763|PROCEDURE|Microfracture of ankle's cartilage lesion under arthroscopic control|Microfracture involves creating tiny perforations in the damaged cartilage, exposing the underlying bone. This encourages the formation of a healing response, where blood and bone marrow cells fill the holes, forming a repair tissue known as fibrocartilage. This newly formed tissue aims to improve joint function and alleviate symptoms associated with cartilage damage. The procedure is performed under arthroscopic guidance, allowing for precise targeting of the lesion while minimizing trauma to the surrounding tissues.
223745453|NCT03836547|BEHAVIORAL|Coaching and Weight Loss for patients with dyspnea|Patients with lung disease and a BMI of 35 or greater who suffer from shortness of breath will be invited to participate in a study involving a commercial weight loss application with health coaching. The patients will subscribe on their own to the weight loss application. The patients will be provided with a blue tooth scale so that they may weigh themselves weekly. A health coach will call them weekly for 8 weeks.
223745454|NCT03836547|BEHAVIORAL|Active Control|Participants will receive usual care for 12 weeks followed by the active intervention.
224181783|NCT04210141|BIOLOGICAL|lyophilized BPI viper antivenom|Antivenom
224181784|NCT03651960|OTHER|ROBOT PROTOTYPE|The intervention consists of 12 45-minute sessions of balance and gait training with a mobile and interactive robot prototype for 4 weeks.
224181785|NCT03589794|OTHER|AP10-602|Glucopyranosyl Lipid A -liposome-Quillaja Saponaria 21 (GLA-LSQ).
224181786|NCT03589794|OTHER|Malaria challenge|Exposure to mosquitoes infected with P. falciparum.
224181787|NCT03589794|BIOLOGICAL|rCSP|The rCSP malaria vaccine is a recombinant full-length P. falciparum circumsporozoite protein comprised of an amino terminus that binds heparin-sulfate proteoglycans, a four-amino-acid repeat region and a carboxy-terminus that contains a thrombospondin-like Type I region domain.
224181788|NCT00097916|DRUG|memantine HCl|
224307762|NCT03201432|DEVICE|Bare metal stent (BES)|Bare metal stent
224181789|NCT00701181|PROCEDURE|Laser Treatment|Necessity of laser treatment is assessed every three months.
224181790|NCT00701181|DRUG|PF-04523655 high|3 mg intravitreal injection
224307763|NCT02875015|DRUG|Liposomal Bupivacaine|20 mL of Liposomal Bupivacaine (EXPAREL) will be diluted in 80 mL of injectable saline used for hydro-dissection of the vesicovaginal space and along the track of the sling trocars
224307764|NCT02875015|DRUG|Bupivacaine Hydrochloride and Lidocaine|Bupivacaine Hydrochloride (HCL) and Lidocaine. Fifty mL of 0.05% Marcaine and 30 mL of Lidocaine will be diluted in 100 mL of injectable saline used for hydro-dissection of the vesicovaginal space and along the track of the sling trocars during the placement of a suburethral sling.
223490403|NCT03771716|BEHAVIORAL|African Cultural Immersion|The Culture group will participate in activities, including cooking, art and games, music, traditional crafts, and lectures and discussions about other aspects of Africana culture and customs. Topics will vary from session to session to maintain interest and engagement. The sessions will be held in a small group format and will be lead my personnel with training in each topic. Participants will meet 1 hour per day, 3 times per week, for 6 months.
223490404|NCT03188198|DRUG|rituximab, etoposide, cyclophosphamide, doxorubicin, vincristine,prednisone, filgrastim|
223490405|NCT04926545|DRUG|Xiao Chai Hu Tang (XCHT)|"XCHT 9g, po qd, 3 days before each cycle of chemotherapy for 5 days, except the 1st cycle of chemotherapy for irinotecan used cohort patients.~Additional XCHT, 9g qd will be orally administrated for 4 days during the Round 0 study for irinotecan naive cohort patients."
224181791|NCT00701181|DRUG|PF-04523655 middle|1 mg intravitreal injection
224307765|NCT02875015|PROCEDURE|Suburethral Sling|A retropubic, transobturator or mini-sling will be placed in the usual fashion followed by diagnostic cystoscopy.
224307766|NCT05665829|PROCEDURE|Awake transnasal laser-assisted surgery (TNLS)|The experimental intervention would be awake transnasal laser-assisted surgery under local anesthesia, carried out in minor operation theater as a day-case basis in ENT ambulatory center.
224307767|NCT05665829|PROCEDURE|Microlaryngeal surgery (MLS)|For traditional MLS under general anesthesia, laryngeal lesions are visualized and removed with under microscopic or endoscopic approach.
223490406|NCT04926545|OTHER|Raloxifene|Raloxifene 60mg po, used as probe for pharmacokinetic testing. For irinotecan naive cohort patients, raloxifene 60mg will be orally administrated on Day 1 and Day 5 (4th day of XCHT administration) during round 0 study, Day 3 (the day before chemotherapy) during round 2 and round 3 study. For irinotecan used cohort patients, raloxifene 60mg will be orally administrated on Day 1 (irinotecan using day) during round 1 study, Day 4 (irinotecan using day) during round 2 study, and Day 3 (the day before chemotherapy) during round 3 study.
223490407|NCT04926545|DRUG|FOLFIRI regimen|Patients will receive 3 cycles of FOLFIRI regimen for chemotherapy. Irinotecan intravenous (IV) infusion (180 mg/m2) through a drip into the bloodstream over 90 minutes. Folinic acid (400 mg/m2) IV infusion through a drip into the bloodstream over 2 hours. 5-fluorouracil (5-FU) IV bolus (400 mg/m2) into the bloodstream over 5 minutes, followed by 5-FU (2400 mg/m2) continuous IV infusion through a drip or pump into the bloodstream for 46-48 hours.
223490408|NCT04930991|DRUG|Omeprazole|Treatment will consist of Omeprazole 12-14 days prior to surgical therapy of pancreatectomy.
223490409|NCT05879718|DRUG|Placebo|Placebo (intravenous infusion)
223490410|NCT05879718|DRUG|PF-06823859|PF-06823859 (intravenous infusion)
223490411|NCT04738487|BIOLOGICAL|Pembrolizumab/Vibostolimab|Coformulation of pembrolizumab (MK-3475) 200mg and vibostolimab (MK-7684) 200mg. Participants receive the coformulation by intravenous (IV) infusion every 3 weeks (Q3W) for up to 35 administrations (up to \~2 years).
224181792|NCT00701181|DRUG|PF-04523655 low|0.4 mg intravitreal injection
224181793|NCT04850066|BEHAVIORAL|Equine-assisted intervention|Usual care including an equine-assisted intervention carried out on foot, next to the horse, in 3 sessions of 3 hours each, spread over 4 weeks. This program is based on self-awareness, communication, assertiveness and adaptability.
224181794|NCT03990168|DEVICE|Anodal tDCS|1 mA anodal tDCS positioned over left superior temporal gyrus and the cathode placed over the occipital lobe. The tDCS stimulation will be delivered for 20 minutes on 6 intervention days.
224181795|NCT03990168|BEHAVIORAL|fluency intervention/ Delayed Auditory Feedback|Each participant complete three tasks include reading, conversation, and narration. Delayed auditory feedback will be used during these tasks. Each treatment session will take 20 minutes.
224181796|NCT03990168|DEVICE|Sham tDCS|The anodal tDCS positioned over left superior temporal gyrus and the cathode placed over the occipital lobe. The current of sham stimulation will involve 30 seconds of stimulation at the beginning of the 20 minutes on 6 intervention days.
224181797|NCT01220024|DRUG|Bupivacaine Collagen Sponge|Drug: Bupivacaine Collagen Sponge
224181798|NCT01220024|DRUG|Placebo collagen Sponge|Drug: Placebo Collagen Sponge
224307768|NCT01103830|DRUG|Eurartesim™|3 or 4 tablets of Eurartesim™ (40mg Dihydroartemisinin and 320 mg Piperaquine phosphate), depending of body weight (3 tablets for subjects weighting less than 75 kg, 4 tablets for subjects weighting 75 kg or more), once daily from Day 1 to Day 3
224307769|NCT01103830|DRUG|Riamet®|4 tablets of Riamet® (20mg artemether/120mg lumefantrine) on Day -1 evening, 4 tablets of Riamet® bid (with an interval of 12 ± 0.5 h), in the morning and in the evening of Day 1 and Day 2, 4 tablets of Riamet® in the morning of Day 3.
224307770|NCT01103830|OTHER|Placebo and finally Moxifloxacin|"3 or 4 tablets of Eurartesim™ placebo, depending of body weight, (3 tablets for subjects weighting less than 75 kg, 4 tablets for subjects weighting 75 kg or more), once daily from Day1 to Day 3.~1 tablet of Izilox® (400 mg moxifloxacin) on Day 4 morning."
223490412|NCT04738487|BIOLOGICAL|Pembrolizumab|Participants receive 200 mg of pembrolizumab by intravenous (IV) infusion every 3 weeks (Q3W) for up to 35 administrations (up to \~2 years).
223490413|NCT06567847|OTHER|Neurocognitive Enriched Exercise|An intervention planned, progressed, and conducted under the supervision of a physiotherapist, which enriches strengthening, balance, range of motion, stretching, and mobilization exercises with neurocognitive elements.
223490414|NCT06567847|OTHER|Multimodal Exercise|Supervised and progressively advanced interventions that include strengthening, balance, range of motion, stretching, and mobilization exercises.
223490415|NCT03873831|BEHAVIORAL|Animal-assisted intervention|The therapy dog is present during the session.
223587793|NCT01975610|DRUG|CC-292|375 mg PO daily (250 mg in the AM and 125 mg in the PM for 28 days)
223587794|NCT01975610|DRUG|Placebo|Twice daily for 28 days
224181799|NCT00174460|DRUG|Somatropin|Controlled, prospective, randomized, multicenter study with an untreated (control) group during the first year. The children will be randomized into treatment or untreated (control) group. After one year the control group will undergo GH-therapy, too. Children randomized to the control group will get the possibility to continue treatment for a further year. The study will end after 2 and 3 years of observation, respectively.
224181800|NCT00174460|OTHER|Control Arm|Controlled, prospective, randomized, multicenter study with an untreated (control) group during the first year. The children will be randomized into treatment or untreated (control) group. After one year the control group will undergo GH-therapy, too. The study will end after 2 and 3 years of observation, respectively. Children randomized to the control group will get the possibility to continue treatment for a further year.
224181801|NCT02467504|DRUG|hrIL-2 active|hrIL-2 active (1 million U doses of hrIL-2s.c.injection)
224181802|NCT02467504|DRUG|hrIL-2 placebo|hrIL-2 placebo (1 million U doses of hrIL-2 placebo s.c.injection)
224181803|NCT02467504|DRUG|MTX|Methotrexate (oral administration)
224181804|NCT02467504|DRUG|Folic Acid|Folic Acid (oral administration)
224181805|NCT02467504|DRUG|Loxoprofen|Loxoprofen (oral administration)
224181806|NCT04675437|OTHER|Aerobic exercise|12-weeks aerobic exercise program
224181807|NCT00584428|PROCEDURE|High-Dose Chemo with Autologous BMT|Carboplatin/VP-16/Cytoxan for women 18-59 and Carboplatin/Thiotepa/Cytoxan for women 60-70
224181808|NCT05618561|DIAGNOSTIC_TEST|EuGeni SARS-CoV-2 Antigen Rapid Diagnostic Test|Subjects have two swabs taken for analysis, one (combined or nasopharyngeal) with the kit under investigation and the other (by standard of care) for analysis with PCRl.
224307771|NCT01103830|DRUG|Eurartesim™|3 or 4 tablets of Eurartesim™ (40mg Dihydroartemisinin and 320 mg Piperaquine phosphate), depending of body weight (3 tablets for subjects weighting less than 75 kg, 4 tablets for subjects weighting 75 kg or more), once daily from Day 1 to Day 3.
224307772|NCT01103830|DRUG|Eurartesim™|3 or 4 tablets of Eurartesim™ (40mg Dihydroartemisinin and 320 mg Piperaquine phosphate), depending of body weight (3 tablets for subjects weighting less than 75 kg, 4 tablets for subjects weighting 75 kg or more), once daily from Day 1 to Day 3.
224307773|NCT01103830|OTHER|Placebo and finally Moxifloxacin|"3 or 4 tablets of Eurartesim™ placebo, depending of body weight, (3 tablets for subjects weighting less than 75 kg, 4 tablets for subjects weighting 75 kg or more), once daily from Day1 to Day 3.~1 tablet of Izilox® (400 mg moxifloxacin)on Day 4 morning."
224307774|NCT05495672|PROCEDURE|Local treatment|"Radical surgical resection, local radiotherapy, radiofrequency ablation (RFA) or interventional therapy (absolute alcohol or cryotherapy).~The equipment used for RFA of lung lesions consisted of the radiofrequency generator (CelonLab POWER), cold circulation pump (Celon Aquaflow Ⅲ), radiofrequency needle electrode (Celon proSurge: T20, T30 and T40 is an electrode length of 20, 30 and 40 mm respectively, and maximum output power of 20, 30 and 40 W; Olympus Surgical Technologies Europe, Hamburg, Germany)."
224181809|NCT00224757|PROCEDURE|Transoesophageal echocardiography|TEE
224181810|NCT03937531|PROCEDURE|Bladder Scanner|PVR will be measured by using a bladder scanner.
224181811|NCT05799976|BEHAVIORAL|Text message nudge|The text message nudge will be sent to patients 3 days and 1 day prior to a visit with the primary care practices and notify them of up to 3 care gaps based on electronic health record data. Care gaps will be selected based on availability and ranked in this order: influenza vaccination, pneumococcal vaccination, breast cancer screening, colorectal cancer screening, hemoglobin A1 testing, or statin therapy.
224181812|NCT00579059|DEVICE|Maxim® Knee System with Removable Molded Polyethylene Tibia|Used for total knee replacements
224181813|NCT00579059|DEVICE|Regular Maxim® Knee System|Used for total knee replacements
224181814|NCT01678287|DRUG|ASP1941|oral
224181815|NCT01678287|DRUG|Placebo|oral
224181816|NCT01035216|DRUG|GNKG168|GNKG168 will be administered as a 60 minute IV infusion once daily for 5 days followed by a 9 day rest period.
224181817|NCT04101994|DEVICE|Virtual cycling training|Virtual cycling training is a convenient and easy approach for muscle strengthening.
224181818|NCT04101994|DEVICE|Repetitive transcranial magnetic stimulation|Intermittent theta burst stimulation produces short TBS trains intermittently to facilitate cortical excitability.
224181819|NCT04101994|DEVICE|Transcranial electric stimulation|TES is a constant current with low intensity delivered to the skull through surface electrodes.
224307775|NCT02804022|DEVICE|VPIA analgesia|Recruited subjects will be given a VPIA device containing 1mcg/ml of morphine. Morphine will be administered via an intravenous infusion line with an anti-reflux valve to ensure precise drug administration and no backflow.
224307776|NCT02804022|DRUG|Morphine|Recruited subjects will be given a VPIA device containing 1mcg/ml of morphine. Morphine will be administered via an intravenous infusion line.
224307777|NCT02973230|OTHER|Dosage of VEGF serum concentration|Blood samples were collected by peripheral venous puncture before treatment; a total 15 mL of blood was withdrawn (2 mL for β-hCG, 3mL for progesterone, 10 mL for VEGF determinations). Blood samples for VEGF were collected in siliconized tubes and were allowed to coagulate at room temperature for 2-6 hours.
224307778|NCT04562155|DRUG|BAY1817080|Study drug BAY1817080 will be administered orally as tablet.
224307779|NCT04562155|DRUG|Placebo|Matching Placebo for BAY1817080 will be administered orally as tablet.
224307780|NCT02398630|RADIATION|TC Virtual Hysterosalpingography|Virtual hysterosalpingography: a new multidetector CT technique for evaluating the female reproductive system
224307781|NCT02398630|OTHER|MRI Virtual Hysterosalpingography|Magnetic Resonance Imaging Virtual hysterosalpingography
224307782|NCT02398630|OTHER|Antimullerian Hormone dosing|Blood Draw for Antimullerian Hormone dosing
224307783|NCT02398630|OTHER|Transvaginal Echography|Transvaginal Echography for evaluating the female reproductive system
224307784|NCT00459901|DRUG|Erlotinib and capecitabine|
224307785|NCT00790335|DRUG|Recombinant tissue plasminogen activator (rt-PA)|Pharmacomechanical catheter-directed thrombolysis, consisting of intrathrombus administration of rt-PA using a catheter/device.
224307786|NCT05094492|COMBINATION_PRODUCT|Curodont Repair Fluoride Plus|P11-4 self assembling peptide combined with fluoride
224307787|NCT05094492|OTHER|Bifluorid 10 fluoride varnish|5% Sodium Fluoride varnish (equal to 22,600 ppm fluoride)
224181820|NCT03677661|OTHER|Conventional approach|The intervention will consist of light cognitive and physical activity with no symptoms exacerbation followed by graded exertion. Participant will be evaluated by a neuropsychologist. The neuropsychological intervention will consist of advice relative to cognitive rest in line with the clinical evaluation results followed by an individualized step-by-step graded exposition to cognitive stimulus according to symptoms evolution. A kinesiologist will also evaluate the symptoms response to cardio-vascular exertion. According to the result of this clinical evaluation, a graded physical exercise program will be given to the participants. 8 in-clinic cardio-vascular exercise sessions in a 6-week period supervised by the kinesiologist (30 to 45 minutes each session) will be provided.
224181821|NCT03677661|OTHER|Personalized rehabilitation program|The same advice and exercise program than the active comparator group will be provided. However, 2 physiotherapists will provide 8 treatment session ( 30 to 45 minutes). One physiotherapist will initially evaluate the physical dysfunctions associated to mTBI with a standardized evaluation to build the treatment plan. He will provide cervical manual therapy and therapeutic exercises based on the best current clinical approach and according to the impairment specifically found initially. A vestibular physiotherapist will provide treatment of canalith repositioning manoeuvre, vestibular adaptation, ocular motor exercises, balance and/or habituation exercises. This treatment will be adapted to the individual patient. No more than 8 sessions will be delivered.
224181822|NCT04509206|BEHAVIORAL|Nutritional education|The curriculum for the four classes include understanding MyPlate guidelines, learn basic knife skills, meal prep, and plan, home farming and no-cook cooking.
224181823|NCT05594966|DIAGNOSTIC_TEST|multimodal MRI|patients are diagnosed with cerebral small vessel disease preoperatively using multimodal MRI
224181824|NCT00804596|DEVICE|Apollo Blood Glucose Monitoring System|Subjects with diabetes were rated for success in performing tasks with a new blood glucose monitoring system (BGMS). Also, subjects and healthcare professionals (HCPs) used the new blood glucose monitoring system with subject capillary blood. All blood glucose results were compared to a laboratory glucose method - Yellow Springs Instrument(YSI) Analyzer.
224181825|NCT00977366|OTHER|Hydrochloric acid (0.15 molar)|Hydrochloric acid (0.15 molar) will be infused in to the lower oesophagus through a distal infusion port located at the tip of an oesophageal stimulation catheter.
224181826|NCT00977366|OTHER|Saline|Normal saline will be infused in to the lower oesophagus through a distal infusion port located at the tip of an oesophageal stimulation catheter.
224181827|NCT00551694|DRUG|GSK256073A tablets|
224181828|NCT00779506|DRUG|Quetiapine Fumarate XR|oral, once daily, flexible dose
224181829|NCT01428570|DEVICE|Pentax-AWS (AWS; Pentax Corporation, Tokyo, Japan)|Each group of patients will be intubated using the Macintosh laryngoscope or Pentax-AWS.
224181830|NCT04047472|DRUG|Brolucizumab 6mg|Intravitreal injection
224181831|NCT04047472|DRUG|Aflibercept 2 mg|Intravitreal injection
224181832|NCT01934842|DEVICE|TAP20-C|
224181833|NCT01934842|DEVICE|SAFE-T-FILL|
224181834|NCT04952792|DRUG|Apixaban 2.5 milligram Oral Tablet|Apixaban 2.5mg/12h, oral, 28 days
224181835|NCT01965691|DIETARY_SUPPLEMENT|Protein intake|"Oral consumption of eight hourly experimental meals-~* 4 tracer free experimental meals containing a mixture of free amino acids and calories from protein free flavored liquid, protein free cookies and corn oil~* 4 isotopically labeled experimental meals."
224181836|NCT04101162|DIAGNOSTIC_TEST|shear waves elastography; liver biopsy|Diagnostic accuracy in a new ultrasound software compared to histology for Non Alcoholic Fatty liver disease (NAFLD) and Non Alcoholic Steato Hepatitis (NASH)
224181837|NCT06421727|OTHER|Rehabilitation by optokinetic stimulation and virtual reality exercises .|Rehabilitation by optokinetic stimulation and virtual reality exercises(by deviceVirtual reality system(Meta Quest 2\_Advanced All-In-One Virtual Reality Headset\_ 128 GB)).
224181838|NCT01977664|OTHER|no intervention|
224307788|NCT02405884|OTHER|Kowa HA-2 Perkins applanation tonometer.|Patients were divided into groups according to the days on which they underwent hemodialysis. Intraocular pressure was measured with a Kowa HA-2 Perkins applanation tonometer. The tonometry included three measurements in the central region of the cornea before and after hemodialysis. In all patients, the measurements were performed three times on the days when hemodialysis sessions were performed, with 24 hours between each session, and the means of the measurements were obtained. All parameters were measured under prior corneal anesthesia with 0.1% proparacaine and 0.25% fluorescein eye drops.
224307789|NCT04986384|DRUG|Atoderm SOS spray Aerosol 200ml|A bottle of 200ml topical spray was used on the eczematous skin lesions for itch relief.
224307790|NCT04385121|OTHER|Questionnary|Family member's will answer the questionnaires by phone
224307791|NCT00001705|DRUG|GP100 peptide|
224307792|NCT00001705|DRUG|IL-2|
223587795|NCT03984656|DRUG|lidocaine treatment|The index marks the upper edge of the lower rib of the selected intercostal space to avoid the vasculonervous bundle sitting at the lower part of the overlying rib.Non-targeted subcutaneous infiltration is performed in the drainage area with 5 to 10 mL of Lidocaine 20 mg / mL non-adrenaline, plane by plane, with regular aspiration until air or fluid confirming effusion.
224181839|NCT02030067|DRUG|RX-3117|
224181840|NCT03438773|DRUG|Envarsus|Patients randomized into the Envarsus group will be prescribed Envarsus, mycophenolate and prednisone once daily.
224307793|NCT00422552|DRUG|Indacaterol (QAB149)|
224307794|NCT05110482|DRUG|Syntocinon|uterotonic drugs
224307795|NCT05110482|DRUG|Carbetocin|uterotonic drug
224307796|NCT01085201|DRUG|Lexiscan|Given as an infusion
224307797|NCT03143426|PROCEDURE|3D laparoscopic cholecystectomy|Laparoscopic cholecystectomy will be performed under 3D visualization as opposed to 2D visualization (conventional method). 3D supposedly provide sharper view with better depth perception and therefore might lead to reduce complication rates.
223745455|NCT03767920|DRUG|bupivacaine|TAP block with 20 ml of 0.25% bupivacaine bilaterally
224181841|NCT03438773|DRUG|Tacrolimus|Patients randomized to the Tacrolimus group will be prescribed Tacrolimus twice-daily with standard of care immunosuppression, anti-proliferative and prednisone once-daily.
224181842|NCT05431816|DIETARY_SUPPLEMENT|Dietary intervention|dietary fiber （Inulin 4g，Resistant Starch 4g，β-glucan 2g）
224181843|NCT01682694|DIETARY_SUPPLEMENT|Glucosamine and Chondroitin|Glucosamine (1500 mg) and Chondroitin (1200 mg)
223587796|NCT03984656|DRUG|serratus plane block treatment|"The Serratus plane block is located at the level of the 5th rib, on the midaxillary line, on the drainage side, ultrasound guided. The block is performed with a 70 mm needle in the ultrasound plane, and the needle is directed postero-inferior, after visualization of the structures from the surface to the depth: dorsal muscle~* anterior serratus large muscle (serratus anterior)~* intercostal muscle~* 4th and 5th ribs~* pleura A single injection of 30 mL of Ropivacaine 4.75 mg / mL is performed around the Serratus muscle.~An intravenous injection of 8 mg of Dexamethasone is added to prolong the duration of the block."
224181844|NCT01682694|DIETARY_SUPPLEMENT|placebo|
224307798|NCT05010616|DEVICE|Fixed orthodontic appliances|"Visual presentation of patient's predicted teeth alignment at the end of orthodontic treatment:~Presenting predicted teeth alignment after orthodontic treatment to patients before treatment starts, by using photos and videos of dental digital set-up.~Predicted teeth alignment can be described as: well-leveled and aligned patient's dental arches, well engaged posterior teeth and normal frontal teeth relationships."
224181845|NCT03098992|DEVICE|Fotona Dynamis Er:YAG Laser System|Treatment of urodynamic proven stress urinary incontinence using the Fotona Dynamis Er:YAG Laser System in the active arm
224181846|NCT03098992|DEVICE|Fotona Dynamis Er:YAG Laser System with sham handpience|Sham treatment with a sham handpiece and parameter presentations masked
224181847|NCT06235177|COMBINATION_PRODUCT|Decompartmentalization Framework|"I will also be using mental imagery, consciousness, cognition, and cognitive psychology during this study to show the effectiveness of the conscious mind, and how the mind can influence behavior.~Decompartmentalize means to remove excessive compartmentalization; to restore from a compartmentalized state; to merge back together."
224181848|NCT06235177|DIETARY_SUPPLEMENT|Liquid Herbal TInctures|I will make and administer liquid herbal tinctures that will be made from all natural leafs, roots and flowers. I will focus on and track the participants' diagnosis, side effects, and how they feel before, during and after taking the liquid tincture.
224181849|NCT06235177|OTHER|Mental Imagery|I will have the participants focus on a particular shape, sound or image that they can see, think, or hear. This will allow the participant to have a clear mind, and release any negative thoughts, negative energy and boost their moods and their 5 senses.
224181850|NCT06235177|DIAGNOSTIC_TEST|Clinical Yoga|I will show the participants many different yoga positions that will give them a peace of mind, stretch their muscles and release any tension throughout their body, and have an overall well-being, as well as promoting mindfulness.
224181851|NCT06235177|DIETARY_SUPPLEMENT|Dietary Supplements|I will have the participants take an herbal supplement and/or vitamin that relates to the symptoms and current issues/diagnosis they have. The Dietary Supplements/Vitamins will enhance their capacity to overcome their health conditions, protect their body from unwanted germs and bacteria, and relieve the participants' mind and body from the symptoms they are experiencing based on their current condition.
224181852|NCT06235177|BEHAVIORAL|Applied Relaxation|"Applied Relaxation is a specialized form of relaxation training that aims to teach the participant how to relax in common social situations.~Mindfulness training encourages participants to gain psychological distance from their worries and negative emotions, seeing them as an observer would see them. 2 types of mindfulness will be used, which is mindfulness-based stress reduction and mindfulness-based cognitive therapy. Treatment starts with general education about stress and social anxiety."
224181853|NCT06235177|BEHAVIORAL|Pain Relaxation Techniques|"Relaxation can reduce the feelings of stress, helping them to gain more control. Reduce pain by decreasing muscle tension, aches and pains. The body releases endorphins (the body's natural pain-killers) to relieve pain.~Yoga incorporates breath control, meditation, and gentle movements to stretch and strengthen muscles.~Mind-body techniques, which includes meditation, mindfulness, and breathing exercises help you restore a sense of control over your body and turn down the fight or flight response, which can worsen chronic muscle tension and pain."
224181854|NCT06235177|BEHAVIORAL|Comprehensive Theocentric Psychological Assessment|To enhance the lives of add to the lives of those who are well adjusted but know they have a greater potential within themselves to ring forth and live more fulfilling lives,
224181855|NCT05617274|PROCEDURE|Sectioning of the full arch mandibular fixed prosthesis|The one unit full arch fixed prosthesis is sectioned at the midline into two pieces
224181856|NCT05151952|RADIATION|Other: Registry|Registry of cancer patients who receive proton radiation therapy.
224181857|NCT06272773|DEVICE|Forced Oscillation Test|Participant will breathe normally through the device which sends different frequency sounds into the airways, monitoring the response coming back from central and peripheral airways to calculate airway impedence, reactance and resistance.
224307799|NCT03516110|OTHER|Data collection|Subjects will be treated in accordance with usual medical practice during their participation in this study. No additional assessments or tests will be required.
223490416|NCT03873831|BEHAVIORAL|Social skills group|"The group program is 10 weeks in duration, with 1-hour long sessions once per week. Children will be taught new social skills each week using an established teaching interaction procedure, in which the therapist first describes the target skill, provides a rational and context for the behavior, divides the skill into smaller steps, demonstrates the behavior, and has each learner role-play the skill while providing feedback in the form of praise and tokens and corrective instruction. The last week involves a probe free-play session, in which children are assessed in a more naturalistic environment without any corrective feedback from therapists."
223490417|NCT05406778|DEVICE|SPARK Test|Thirty (30) minutes of resting state EEG data collection.
224181858|NCT04983849|DRUG|metronidazole hydrogel|scaling and root planning in adjunct to the use of metronidazole in the periodontal pocket
224307800|NCT02699060|PROCEDURE|Upper gastrointestinal endoscopy with biopsy and collection of refluxate|we analyzed esophageal mucosa, expression of inflammatory changes, location, size, number of mucosal defects, as well as the appearance of the gastric and duodenal mucosa.
223490418|NCT06965478|BEHAVIORAL|Visual Training|Participants are asked to detect or discriminate visual stimuli.
224181859|NCT04983849|PROCEDURE|scaling and root planning|scaling and root planning
224181860|NCT04211506|BEHAVIORAL|Controlled sleep|Duration and timing of sleep will be assigned and monitored in a controlled laboratory environment with controlled lighting and meals.
224181861|NCT02833142|DRUG|BIIB033 (opicinumab)|
224181862|NCT03119428|DRUG|OMP-313M32|OMP-313M32 is a monoclonal antibody which binds to the human TIGIT receptor on T cells.
224181863|NCT03119428|DRUG|Nivolumab|Human IgG4 anti-PD-1 monoclonal antibody
224181864|NCT01632345|DRUG|Doravirine|Part I: Doravirine 25 mg, 50 mg (25 mg X 2), 100 mg, or 200 mg (100 mg X 2) depending upon randomization, taken orally every morning with or without food for at least 24 weeks. Part II: Selected dose of doravirine depending upon randomization (either 25 mg, 50 mg, 100 mg, or 200 mg) tablet orally every morning with or without food for 96 weeks.
224181865|NCT01632345|DRUG|Efavirenz|Efavirenz 600 mg tablet orally at bedtime taken without food on an empty stomach for 96 weeks
224181866|NCT01632345|DRUG|TRUVADA®|Open-label TRUVADA® (fixed combination 200 mg emtricitabine and 300 mg tenofovir disoproxil fumarate) tablet taken orally with food in the morning for 96 weeks
224181867|NCT01632345|DRUG|Placebo for Doravirine|Placebo tablets matching doravirine
224181868|NCT01632345|DRUG|Placebo for Efavirenz|Placebo tablets matching efavirenz
224181869|NCT02403089|OTHER|Tubes fund recovery blood count|Tubes fund recovery of blood counts among newborns
224181870|NCT02403089|OTHER|the rest of the blood test and stool sample|blood samples on the recovery kinetics after transplant. The rest of the blood test and stool sample done as part of a routine examination.
224181871|NCT05892094|OTHER|Resistance and Aerobic Training|For aerobic exercise, participants will do brisk walking 30 minutes in the first two weeks, 3-6. weeks will be 35 minutes, 7th and 8th weeks will be 40 minutes.The first and last 10 minutes of each walk will be said to be done at a slow pace, for the warm-up and cool-down periods. Participants will be called regularly to monitor their participation in the aerobic exercise program, and their compliance with the exercise will be checked, and they will be motivated to continue the exercises by providing the necessary information. Resistance exercises sessions will include five minutes of warm-up, forty minutes of resistance training and five minutes of cool-down. The training load will be provided by progressively increasing the repetitions. The Borg Scale will be used to adjust the exercise intensity. Rest time between sets will be 60 seconds.
224181872|NCT04371068|BIOLOGICAL|Culture of removed prosthesis using DTT|No specific or supplementary intervention is performed among patients. The included patients have scheduled surgery consisting of prosthesis removal or change. Instead of being discarded, the prosthesis which was removed during the surgery was sent to the laboratory using the MicroDTTect system and bacterial culture was performed with the fluid obtained. Results will be then compared to classical culture of periprosthetic tissues (PPT).
224181873|NCT04469309|OTHER|Group I Brandt-Daroff Exercises|"In group I Brandoff Exercises will be performed using standard method, in which the patient is in the sitting position on examination table, the patient moves into the lying position on the affected side on the shoulder, with the head angled upward with about 45. The patient stays in this for 30 s and then goes back to the sitting position, looks forward and remains in this position for 30 s as well. The patient repeats the same procedure for the other side, too.~The patient performs this maneuver 2 times, twice a day. For total 9 days for 3 weeks. Pre, mid and post assessment."
224181874|NCT04469309|OTHER|Group II Half-Somersault Maneuver|In group II Half-Somersault Maneuver will be done, the patient performs this maneuver 2 times, twice a day. For total 9 days for 3 weeks.
224181875|NCT02013999|OTHER|Virtual reality program for upper extremity rehabilitation|
224181876|NCT02013999|OTHER|standard occupational therapy|
224181877|NCT06374511|DIAGNOSTIC_TEST|Test for CMV reactivation|All enrolled patients are monitored for CMV reactivation and hepatic encephalopathy using regular clinical tests or library test
224307801|NCT02699060|PROCEDURE|Esophageal high-resolution manometry and 24-h esophageal pH-impedance monitoring|we analyzed following HRM parameters: the distal contractile integral (DCI), the lower esophageal sphincter resting pressure (LES RP) and standard measuring parameters were be collected: percentage of total time when pH was \<4, longest reflux event, number of reflux events longer than 5 minutes, and number of reflux episodes in 24 hours.
224307802|NCT03490760|DRUG|Durvalumab|Durvalumab 1500 mg (or 20 mg/m2 if \<30 kg) IV every 4 weeks
223490419|NCT05029999|DRUG|PLD Chemotherapy|PLD chemotherapy will be administered 40 mg/m2 as intravenous injection once per cycle.
223490420|NCT05029999|DRUG|CDX-1140|CDX-1140 will be administered 1.5mg/kg as intravenous injection once per cycle.
223490421|NCT05029999|DRUG|CDX-301|CDX-301 will be administered 75µg/kg as subcutaneous injection daily x 5 doses per cycle for 2 cycles.
224181878|NCT02174952|BEHAVIORAL|Self-help version of the New Forest Parenting Programme|
224181879|NCT05422027|DRUG|Selinexor|"Selinexor (ATG-010# is a first-in-class, oral selective exportin 1 (XPO1) inhibitor (1,2). Selinexor functions by binding with and inhibiting the nuclear export protein XPO1 (also called CRM1), leading to the accumulation of tumor suppressor proteins in the cell nucleus along with inhibition of translation of oncoprotein mRNAs.~Selinexor dose escalation: 40, 60mg respectively on day 1,8,15 for 21 days cycles"
224181880|NCT05422027|DRUG|Bortezomib|"The investigators gave patients subcutaneous bortezomib 1.3mg/sqm on days 1, 8,15 of a 21- day cycle.~standard bortezomib-lenalidomide-dexamethasone"
223490422|NCT06494761|DRUG|zongertinib|zongertinib, Hernexeos®
223490423|NCT06494761|DRUG|midazolam|midazolam
223490424|NCT06494761|DRUG|omeprazole|omeprazole
223490425|NCT06494761|DRUG|repaglinide|repaglinide
223490426|NCT06263478|DRUG|INCA034176|IV infusion
223745456|NCT03767920|DRUG|dexamethasone|TAP block with 4 mg dexamethasone bilaterally
223745457|NCT03767920|DRUG|placebo to dexamethasone|TAP block with 4 mg placebo to dexamethasone bilaterally
224181881|NCT05422027|DRUG|Lenalidomide|"The investigators gave patients oral lenalidomide 25mg on days 1 to 14 of a 21-day cycle.~standard bortezomib-lenalidomide-dexamethasone"
224181882|NCT05422027|DRUG|Dexamethasone|"The investigators gave patients oral dexamethasone 40mg on days 1, 8, 15 of a 21-day cycle.~standard bortezomib-lenalidomide-dexamethasone"
224307803|NCT03490760|RADIATION|Radiation Therapy|24 Gy in 3 daily fractions to one lesion during Week 3 and 24 Gy in 3 daily fractions to the second lesion during Week 5.
224307804|NCT00384644|DEVICE|NiRS measurment of tissue oxygenation|NiRS measurment of tissue oxygenation
224181883|NCT03524560|OTHER|Comprehensive geriatric assesment|Comprehensive Geriatric Assesment (CGA) consisting of detailed history and examination, drug consumption information, Body Mass Index (BMI), Waist Circumference (WC), Timed Up \& Go test (TUG), Clock Drawing Test (CD), Activities of Daily Living and Instrumental Activities of Daily Living scales (ADL \& IADL), Mini Mental State Examination (MMSE), Tinetti Gait and Tinetti Balance scores (TG \&TB), 30 items Geriatric Depression Scale (GDS) was performed for each subject
224181884|NCT04176016|DRUG|OTSA101-DTPA-111In|single IV injection, 185MBq/body
224181885|NCT04176016|DRUG|OTSA101-DTPA-90Y|IV injection (max. 3 injections per patient), 1110MBq/body
224181886|NCT03264027|DRUG|Carbon dioxide|Carbon dioxide will be used as an insufflating gas during argon fulguration of the dilatated anastomosis.
224181887|NCT03264027|DRUG|Ambient air|Ambient air will be used as an insufflating gas during argon fulguration of the dilatated anastomosis.
224181888|NCT03264027|DRUG|Argon fulguration|The dilatated anastomosis from the gastric bypass surgery will be reduced in diameter using fulguration with argon. Patient in both groups will be placed in the left lateral decubitus position, with anesthesia being performed exclusively using propofol; adequate cardiopulmonary monitoring will be carried out during the entire procedure. After sedation, endoscopy will be performed with an Olympus CV-180 endoscope (Olympus, Tokyo, Japan) and analysis and measurement of the anastomosis will be achieved using Raptor foreign body forceps (Endoscopy Group US, Inc., Mentor - Ohio, USA). The images will be transferred to an Olympus EvisExera II processor connected to a computer with the ZScan 5 program (Goiânia, GO, Brazil).
224181889|NCT03023436|PROCEDURE|Cytoreductive surgery|"Gastrectomy with D2 lymph node dissection and Metastasectomy for peritoneal metastatic sites only.~A total, distal, or proximal gastrectomy and the type of reconstruction will be selected according to the surgeon's experience.~Metastasectomy is limited to peritoneal metastatic sites only to render the patient no evidence of disease (NED) with at least 1cm negative margins when possible."
224181890|NCT03023436|PROCEDURE|Hyperthermic Intraperitoneal Chemotherapy|Docetaxel 120 mg diluted in 5.0 L of saline is forced into the abdomen through the inflow catheter by a pump and pulled out through the drains as a heated intraperitoneal perfusion.A heat exchanger keeps the intraperitoneal fluid at 43±0.5℃ and duration limited to 70 minutes.24 hours after cytoreductive surgery no less than 2 cycles postoperative chemotherapy will be recommended.
224181891|NCT03023436|DRUG|Fluoropyrimidine|CF regimens or other first line regimens based on Fluoropyrimidine and Platinum according to the NCCN Guidelines（Gastric Cancer，version 3.2016) are recommended.Regimens and dosing schedules are not limited in this trial.
224181892|NCT03023436|DRUG|Cisplatin|CF regimens or other first line regimens based on Fluoropyrimidine and Platinum according to the NCCN Guidelines（Gastric Cancer，version 3.2016) are recommended.Regimens and dosing schedules are not limited in this trial.
223490427|NCT05877846|DIETARY_SUPPLEMENT|Beta-hydroxymethyl butyrate supplement|Beta-hydroxymethyl butyrate (750 mg) - Vitamin D3 (200 IU) capsules. The formulation is 750 mg of Beta-hydroxymethyl butyrate with 200 IU of vitamin D3 per capsule. Frequency is 2 capsules twice daily (morning, evening)
224181893|NCT01756846|OTHER|usual care|During 14 months, patients presenting with chest pain to the ED of participating hospitals will be included in the study. First, all hospitals will apply 'usual care' to all patients, i.e. risk assessment and subsequent management without application of the HEART score. Then, during a 14 month period, each 1,5 month 1 randomly allocated hospital will sequentially start to apply the HEART score in all chest pain patients (intervention period); during this intervention period patients with a HEART score 0-3 will not be admitted to the hospital, and patients with a HEART score above 3 will be treated according to current guidelines.
224181894|NCT01756846|OTHER|use of HEART risk score|During 14 months, patients presenting with chest pain to the ED of participating hospitals will be included in the study. First, all hospitals will apply 'usual care' to all patients, i.e. risk assessment and subsequent management without application of the HEART score. Then, during a 14 month period, each 1,5 month 1 randomly allocated hospital will sequentially start to apply the HEART score in all chest pain patients (intervention period); during this intervention period patients with a HEART score 0-3 will not be admitted to the hospital, and patients with a HEART score above 3 will be treated according to current guidelines.
224181895|NCT01521260|PROCEDURE|placebo|Implants with peri-implantitis lesions will be surgically exposed, followed by a mechanical cleansing using curettes and gauzes and cotton pellets soaked in saline, 1 minute of rinsing with a placebo solution (saline with appearance of chlorhexidine + CPC) and 1 minute of saline rinsing.
224181896|NCT01521260|PROCEDURE|Chlorhexidine|Implants with peri-implantitis lesions will be surgically exposed, followed by a mechanical cleansing using curettes and gauzes and cotton pellets soaked in saline, 1 minute of chemical cleansing using 0,12% chlorhexidine + cetylpyridinium chloride (CPC) without alcohol (Perio-aid®) and 1 minute of saline rinsing.
224181897|NCT01780285|DEVICE|Nitinol-framed lightweight PTFE mesh for hiatal repair|"The heart-shaped nitinol-framed lightweight PTFE prosthesis Rebound HRD-Hiatus hernia (Minnesota Medical Development, Inc.) of small (4,0 x 4,5 cm) to large size (5,5 х 6,0 cm) is sutured to the crura posteriorly to oesophagus with 3 or 5 interrupted non-absorbable (Ethibond 3-0 by Ethicon, Inc.) sutures, thus performing complete tension-free hiatal repair."
224205718|NCT01351194|PROCEDURE|hepatic resection|SR was carried out under general anesthesia using a right subcostal incision with a midline extension.Intra-operative ultrasonography was performed routinely to evaluate the tumor burden, liver remnant, and the possibility of a negative resection margin. Anatomic resection, in the form of segmentectomy and/or subsegmentectomy as described by Makuuchi et al. (16) was the preferred surgical method of liver resection. Pringle's maneuver was routinely used with a clamp and unclamp time of 10 min and 5 min, respectively; this technique was used repeatedly throughout the entire procedure. Hemostasis of the raw liver surface was done with suturing and application of fibrin glue.
223490428|NCT05877846|DIETARY_SUPPLEMENT|Vitamin D supplement|Beta-hydroxymethyl butyrate (750 mg) - Vitamin D3 (200 IU) capsules. The formulation is 750 mg of Beta-hydroxymethyl butyrate with 200 IU of vitamin D3 per capsule. Frequency is 2 capsules twice daily (morning, evening)
223490429|NCT05877846|DIETARY_SUPPLEMENT|Matching Beta-hydroxymethyl butyrate supplement without Vitamin D|Beta-hydroxymethyl butyrate (750 mg) capsules. The formulation is 750 mg of Beta-hydroxymethyl butyrate per capsule. Frequency is 2 capsules twice daily (morning, evening)
223490430|NCT05516498|DRUG|Part A: Placebo (matching zibotentan capsule & matching dapagliflozin tablet)|"placebo capsule (matching zibotentan capsule)~placebo tablet (matching dapagliflozin tablet)"
223587797|NCT00004874|RADIATION|tositumomab and iodine I 131 tositumomab|Dosimetric Dose:Unlabeled anti-B1 (450mg) will be given as peripheral or central IV infusion over one hour or longer depending upon rate-dependent side effects. A trace-labeled dose of 131I-anti-B will be infused over 20 minutes, if rate-dependent side effects permit. An amount of unlabeled Anti-B1 Antibody is added to the 5 mCi of Iodine-131 Anti-B1 Antibody sufficient to result in a final amount of 35 mg of Anti-B1 antibody. On study Day 7 (may be delayed up to study Day 14), patients will receive the therapeutic dose, which consists of an infusion of 450mg of Anti-B1 Antibody followed by an infusion of Iodine-131 Anti-B1 Antibody.
223587798|NCT06303856|BEHAVIORAL|Active Breathing Exercises|Active breathing exercises aim to enhance the strength and flexibility of respiratory muscles through a series of exercises, improving breathing patterns and increasing respiratory efficiency. The following are common components of active breathing exercises: 1) Deep Breathing. 2) Chest Expansion. 3) Diaphragmatic Breathing. 4) Coughing Techniques. 5) Expiratory Resistance Training. 6) Gradual Increase in Activity.
223490431|NCT05516498|DRUG|Part A: zibotentan (dose B) + dapagliflozin|"zibotentan capsule~dapagliflozin tablet"
223587799|NCT02254395|DEVICE|Deep Brain Stimulation|
224181898|NCT01780285|DEVICE|Partially absorbable lightweight mesh for hiatal repair|"A fashioned according to the dimensions of hernia defect partially absorbable lightweight mesh Ultrapro (Ethicon, Inc.) will be sutured to both crura posteriorly to oesophagus with 3 to 5 interrupted non-absorbable (Ethibond 3-0 by Ethicon, Inc.) sutures (as tension-free repair). Subsequent 2 to 3 interrupted non-absorbable sutures will approximate crura to completely cover a mesh to preclude its contact with the esophagus (original sandwich sub-lay technique).~In both arms procedure will be done in a standard fashion: placement of 30 Fr esophageal bougie, reduction of hernia with excision of hernia sac and mobilization of distal esophagus, exposure of borders of hiatal opening, repair of hiatal hernia defect, a short (2,5 - 3,5 cm) 360° fundoplication wrap (floppy-Nissen procedure)."
224181899|NCT03990155|PROCEDURE|HFNCOT+ECCO2R|NIV will be discontinued, the ECCO2R setting will be unchanged (both sweep gas flow and blood flow through the artificial lung) and HFNCOT will be started, titrating the fraction of inspired Oxygen (FiO2) to obtain an oxygen saturation at periphery (SpO2) 88-92%; HFNCOT start temperature will be 31°C, the initial flow rate will be 60 L/min.
224181900|NCT00545740|DRUG|SPD476 (1.2g)|1.2g SPD476 once daily (QD) orally
224181901|NCT00545740|DRUG|SPD476 (2.4 g)|2.4g SPD476 QD orally
223587800|NCT04566146|OTHER|scapular muscle training, serratus anterior strength, scapular stabilization exercises|patients will be scheduled to attend physical therapy three sessions per week for one month. Three sets of 10 repetitions for each exercise were prescribed per session, with a 1-minute rest between sets.
224181902|NCT00545740|DRUG|SPD476 (4.8 g)|4.8g SPD476 QD orally
224181903|NCT00545740|DRUG|Placebo|QD orally
223490432|NCT05516498|DRUG|Part B: Placebo (matching zibotentan capsule & matching dapagliflozin tablet)|"placebo capsule (matching zibotentan capsule)~placebo tablet (matching dapagliflozin tablet)"
223490433|NCT05516498|DRUG|Part B: placebo (matching zibotentan capsule) + dapagliflozin|"placebo capsule (matching zibotentan capsule)~dapagliflozin tablet"
223490434|NCT05516498|DRUG|Part B: zibotentan (dose A) + dapagliflozin|"zibotentan capsule~dapagliflozin tablet"
223587801|NCT00119964|BEHAVIORAL|internet based weight management tools|
223587802|NCT00381030|DRUG|carvedilol plus nurse management|
223587803|NCT02160444|BEHAVIORAL|CBT plus Parent as CBT Coach Training|Standard CBT for treatment of anxiety disorders in youth is completed by the children while their primary caregiver receives training in the same cognitive behavioral skills, how to recognize when he or she is accommodating his or her child's anxiety, and how to create and implement exposure activities.
223587804|NCT01379300|DRUG|dabigatran etexilate|dabigatran etexilate, orally, as 2 x 75-mg capsules (150 mg), single administration
223587805|NCT01379300|DRUG|rivaroxaban|rivaroxaban, orally, as 2 x 10-mg tablets (20 mg), single administration
223587806|NCT06497296|DRUG|Lidocaine|Lidocaine spray in both group with same puff number, but the timing before EGD insertion is different
223587807|NCT01954563|BIOLOGICAL|MVA85A|Modified vaccinia virus Ankara (MVA) is a highly attenuated strain of vaccinia with an antigen 85A insert.
223587808|NCT01739543|DEVICE|Hem-Avert|Application of Hem-Avert
223587809|NCT03164330|BEHAVIORAL|Workplace Wellness Program|Treatment group members will then be offered the opportunity to participate in a biometric screening and health risk assessment (biometric screening + HRA), and -- conditional on completing an biometric screening + HRA -- up to two, semester-long wellness programs. Treatment group members will be offered varying levels of cash reward for completing the biometric screening + HRA (none, moderate, high), and an additional cash reward for completing each wellness activity (low, high), for a total of 6 treatment cells. Follow-up surveys and biometric screenings will be administered one year later, among a subset of control and treatment group members.
223745458|NCT01204476|BIOLOGICAL|Cixutumumab|Given IV
223745459|NCT01204476|DRUG|Everolimus|Given PO
223745460|NCT01204476|OTHER|Laboratory Biomarker Analysis|Correlative studies
223745461|NCT01204476|DRUG|Octreotide Acetate|Given IM
224181904|NCT01483378|OTHER|Choosing to receive the vaccine|
224181905|NCT01306240|PROCEDURE|Surfactant instillation|Intra-tracheal poractant alpha instillation after tracheal intubation
223490435|NCT05516498|DRUG|Part B: zibotentan (dose B) + dapagliflozin|"zibotentan capsule~dapagliflozin tablet"
223490436|NCT05516498|DRUG|Part B: zibotentan (dose C) + dapagliflozin|"zibotentan capsule~dapagliflozin tablet"
223490437|NCT05350202|DRUG|Empagliflozin|Empagliflozin was administered according to the approved product information.
223490438|NCT06576869|PROCEDURE|Upper extremity orthopedic surgeries.|Upper extremity orthopedic surgeries that require the use of a tourniquet.
223490439|NCT06269900|DRUG|Dexamethasone|Dexamethasone phosphate injection is given as a slow injection or infusion (intravenous drip) into the veins.
223490440|NCT06269900|DRUG|Placebo|Placebo injection is given as a slow injection or infusion (intravenous drip) into the veins.
223490441|NCT06967129|DEVICE|Investigational daily disposable, soft, toric lenses manufactured on 4th Generation Technology (4GT) lines with extended mini-stack hydration using propylene glycol (PG) as the hydration solvent.|Test Lens
223490442|NCT06967129|DEVICE|ACUVUE® Oasys 1-Day for Astigmatism (AO1DfA) soft contact lenses manufactured on 3rd Generation Technology (3GT) legacy lines using isopropyl alcohol (IPA) as the hydration solvent.|Control Lens
224181906|NCT01306240|PROCEDURE|nCPAP|Nasal Continous Positive Airways Pressure (nCPAP). Positive End Expiratory Pressure (PEEP) is set between 4 to 6 cm H2O. FiO2 is adjusted for a target post-ductus arteriosus SpO2 between 92% and 96%.
224181907|NCT04524013|OTHER|There is no intervention. It is an observational study.|There is not intervention
224181908|NCT03942991|DRUG|articaine|infiltration injection of 4%artpharmadent
224181909|NCT03942991|DRUG|Mepivacaine 2% Injection|infiltration injection of 2% Mepecaine-L
224181910|NCT06481046|BIOLOGICAL|Platelet Rich Plasma (PRP)|Platelet Rich Plasma (PRP) prepared from patient blood, spun twice to concentrate platelets. 45 cc of initial blood resulting in 4cc of injectable PRP.
224181911|NCT03869489|DEVICE|Anodal left dorsolateral prefrontal cortex tDCS stimulation|Anodal tDCS will be applied to the left dorsolateral prefrontal cortex of participants
224181912|NCT03869489|DEVICE|Anodal right dorsolateral prefrontal cortex tDCS stimulation|Anodal tDCS will be applied to the right dorsolateral prefrontal cortex of participants
224181913|NCT03869489|DEVICE|Sham tDCS stimulation|Sham tDCS stimulation will be applied
224181914|NCT00040066|PROCEDURE|Cocaine (IV)|
224181915|NCT05705960|OTHER|Chestnut|Daily consumption of roasted chestnut (150g) for 14 days
224181916|NCT05228236|DIETARY_SUPPLEMENT|Plant based protein|A single dose of \~30 g of a plant-based protein blend was ingested 30-60 min after physical practice in training days or 30-60 min before bedtime in resting days.
224181917|NCT05228236|DIETARY_SUPPLEMENT|Whey protein|A single dose of \~30 g of whey protein was ingested 30-60 min after physical practice in training days or 30-60 min before bedtime in resting days.
224181918|NCT03336307|OTHER|Rehabilitation program|"all patients received a rehabilitation program planned according to the European Physiotherapy guideline for Parkinson's disease and focus on:~* endurance, strength, flexibility and balance with functional practice for all H/Y stage~* endurance also for H/Y stage 1,~* motor learning principles and cue functional for H/Y stage 2-3~* external cues and self-instruction strategies and attention H/Y for stage 2-3 The rehabilitative program comprised 60-minute sessions a day (3d/wk)."
224181919|NCT04981080|DIAGNOSTIC_TEST|Urodynamic study|The urodynamic assessment, including noninstrumented uroflowmetry, filling cystometry with 35°C distilled water at a rate of 60 mL/sec, a pressure flow study, and urethral pressure profilometry, was performed with the patient in a sitting position according to the recommendations by the International Continence Society.
224181920|NCT04269629|DRUG|Insect Venom|Patients receive insect venom immunotherapy. The frequency of systemic side-effects is recorded and compared between patients under antihypertensive treatment and patients not taking antihypertensive drugs.
224181921|NCT02359942|DRUG|Citric acid|Giving the citric acid (4g) solving in 200 ml of water before UBT
224181922|NCT00933816|DRUG|sorafenib, cisplatin, fluorouracil|Sorafenib will be administered orally at a dose of 400 mg bid for 28 days in the all patients. Cisplatin at the dose of 10-20 mg/m2 will be administered at day 1 and day8, and fluorouracil at the dose of 170-330 mg/m2 will be administered continuously at day 1-day 5, and day8-day12 via the implanted catheter system. A cycle is defined as 28 days and 3 cycles of this combination therapy will be continued.
224181923|NCT04654819|DEVICE|Dental anesthesia simulator usage|Training on dental anesthesia simulator
223490443|NCT05378204|OTHER|Main study:|"For each included patient, tumor biopsy specimen and blood samples will be collected at baseline visit (before the first dose of PARPi treatment).~During the treatment period: blood samples will be scheduled every 8 weeks (i.e. 2 cycles).~At the time of progression: tumor biopsy and blood samples will be collected."
223490444|NCT05378204|OTHER|Sub-study:|For each included patient, tumor biopsy specimen and blood samples will be collected as soon as possible after progression (before initiation of the post PARPi anti-tumoral treatment).
223490445|NCT04635423|BIOLOGICAL|V503|9-valent vaccine, HPV 6/11/16/18/31/33/45/52/58, L1 virus-like particle (VLP) 30/40/60/40/20/20/20/20/20 mcg per dose.
223490446|NCT04635423|OTHER|Placebo|0.9% sodium chloride (NaCL)
223490447|NCT06282861|DRUG|Trelegy Ellipta 100/62.5/25Mcg Inh 30D|Product to be used according to specifications. 1 inhalation daily for 12 months
223490448|NCT06282861|DRUG|Brimica|As per product specifications
223490449|NCT06282861|DRUG|Duaklir|As per product specifications
224181924|NCT04862273|DIAGNOSTIC_TEST|Native T1 CMR|Observed method
224181925|NCT04862273|DIAGNOSTIC_TEST|Web-based ATTR probability estimator (Pfizer, New York)|Observed method
224181926|NCT04862273|DIAGNOSTIC_TEST|99mTc-DPD scintigraphy|Reference method
224181927|NCT04862273|DIAGNOSTIC_TEST|Laboratory screening for multiple myeloma / AL amyloidosis|Reference method
224181928|NCT04862273|PROCEDURE|Cardiac biopsy|If non-invasive tests for CA (99mTc-DPD scintigraphy, biochemistry) are inconclusive
224181929|NCT05538442|OTHER|Physiological recordings|Physiological, cognitive, biological measurments
224181930|NCT04061668|OTHER|single needle path PECS I and II block group|The probe is placed inferior to the clavicle . The US probe is placed below outer third of the clavicle showing pectoralis major and minor muscles and the thoraco- acromial artery then moved infero-laterally to locate fourth rib where pectoralis major and pectoralis minor muscles will be visualised . The probe is moved toward anterior axillary line till pectoralis minor and serratus anterior muscles ise identified at 4th rib at the level of thoraco-acromial artery , the needle is inserted in plane with the probe from caudal to cranial using an inclined manner, 15mL of bupivacaine is put into the potential space between pectoralis minor muscle and serratus muscle (PECS II) then it is withdrawn to inject another 15 ml of bupivacaine in the plane between pectoralis muscles . The block will be performed with needle introduced in-plane with the ultrasound probe, and the local anesthetic injection is visualised.
224205719|NCT04846907|OTHER|Web-based survey|Eligible participants received emails or text messages with links to a REDCap-created and managed web-based questionnaire
223490450|NCT06282861|DRUG|Ultibro|As per product specifications
223490451|NCT06282861|DRUG|Ulunar|As per product specifications
223490452|NCT06282861|DRUG|Xoterna|As per product specifications
223490453|NCT06282861|DRUG|Anoro|As per product specifications
223490454|NCT06282861|DRUG|Laventair|As per product specifications
223490455|NCT06282861|DRUG|Spiolto Respimat|As per product specifications
223490456|NCT06282861|DRUG|Yanimo|As per product specifications
223490457|NCT06282861|DRUG|Foradil|As per product specifications
223490458|NCT06282861|DRUG|Broncoral|As per product specifications
223490459|NCT06282861|DRUG|Formoterol stada|As per product specifications
223490460|NCT06282861|DRUG|Oxis|As per product specifications
223490461|NCT06282861|DRUG|Formatris|As per product specifications
223490462|NCT06282861|DRUG|Formoterol Aldo|As per product specifications
223490463|NCT06282861|DRUG|Onbrez|As per product specifications
223490464|NCT06282861|DRUG|Oslif|As per product specifications
223490465|NCT06282861|DRUG|Hirobriz|As per product specifications
223490466|NCT06282861|DRUG|Striverdi|As per product specifications
223587810|NCT03164330|BEHAVIORAL|Biometric Screening/HRA - No Compensation|The biometric test will measure: (1) anthropometrics such as height, weight, and waist circumference (to assess obesity and overweight status); (2) resting blood pressure (to assess hypertension); (3) blood glucose (to assess diabetes risk); and (4) total, LDL, and HDL cholesterol levels, total cholesterol ratio, and triglycerides (to assess risk of cardiovascular disease). The HRA is a survey designed to identify areas of health improvement, by asking a series of questions related to wellness, health status, nutrition, healthy activities, desire to improve health, preventative health measures. The HRA is also pre-populated with biometric information from the screening. Upon completion, participants are given customized feedback on areas of improvement. No compensation for completion.
223745462|NCT01204476|OTHER|Pharmacological Study|Correlative studies
223745463|NCT01341600|DRUG|Clopidogrel|Over a 6 week period participants will be given: 75 mg of clopidogrel for 8 days, at least 1 week washout, 150 mg of clopidogrel for eight days, at least 1 week washout, 300 mg of clopidogrel for eight days.
224181931|NCT04061668|OTHER|double needle path PECS I and II block group|The US probe will be initially placed below outer third of the clavicle after skin sterilization showing pectoralis major and minor muscles and the thoraco- acromial artery then moved inferolaterally to locate fourth rib where pectoralis major and pectoralis minor muscles will be visualised, then the needle will be inserted in plane with the probe and 15mL of bupivacaine 0.25% after negative aspiration will be put into the potential space between pectoralis muscles. In the second puncture , the US probe will be moved toward anterior axillary line till pectoralis minor and serratus anterior muscles will be identified at 4th rib at the level of thoraco-acromial artery then the needle will be inserted in plane with the probe from caudal to cranial in an inclined way, 15mL of bupivacaine 0.25% after negative aspiration will be put into the potential space between pectoralis minor muscle and serratus muscle (PECS II).
223490467|NCT06282861|DRUG|Beglan|As per product specifications
223490468|NCT06282861|DRUG|Betamican|As per product specifications
223745464|NCT01341600|DRUG|Omeprazole/Clopidogrel|After a washout of at least 1 week, participants will have the option to participate in a final intervention in which they will be given 75 mg of clopidogrel together with 20 mg of omeprazole daily for eight days.
224181932|NCT05130736|DEVICE|Robot rehabilitation|Effectiveness of using a rehabilitation robot in post-COVID-19 rehabilitation
224181933|NCT05585801|DEVICE|Dexcom G6 continuous glucose monitor|"Continuous glucose monitor will be used to measure interstitial glucose and aid in guiding the insulin therapy to achieve target blood glucose range of 6-10 mmol/l.~In the control group, blood glucose will be measured according to standards of care and a blinded continuous monitor will be used to compare the time i range between the arms."
224181934|NCT05585801|DIAGNOSTIC_TEST|Blood glucose measurements according to standards of care|Blood glucose will be measured using point of care glucose meter and standard biochemistry methods. Blinded CGM will be applied to obtain continuous glucose values for post-hoc comparison.
224181935|NCT01741610|BIOLOGICAL|Cristalloid and colloid coloading|Cristalloid coloading (Group L) Colloid coloading (Group C) No coloading (Group E)Placebo Comparator
224181936|NCT06145269|DRUG|New oral anticoagulant (rivaroxaban) and Marevan (warfarin)|comparison between 2 drug, (rivaroxaban) and Marevan (warfarin)
224181937|NCT00755521|DRUG|etoricoxib|"Treating Fibromyalgia with etoricoxib~etoricoxib - 90mg"
224181938|NCT03872739|PROCEDURE|enhanced computed tomography|undergoing enhanced computed tomography
223490469|NCT06282861|DRUG|Inaspir|As per product specifications
223490470|NCT06282861|DRUG|Serevent|As per product specifications
223490471|NCT06282861|DRUG|Soltel|As per product specifications
223490472|NCT06282861|DRUG|Eklira|As per product specifications
223490473|NCT06282861|DRUG|Bretaris|As per product specifications
223490474|NCT06282861|DRUG|Seebri|As per product specifications
223490475|NCT06282861|DRUG|Tovanor|As per product specifications
223490476|NCT06282861|DRUG|Enurev|As per product specifications
223490477|NCT06282861|DRUG|Spiriva|As per product specifications
223490478|NCT06282861|DRUG|Tavulus|As per product specifications
223490479|NCT06282861|DRUG|Sirkava|As per product specifications
223490480|NCT06282861|DRUG|Braltus|As per product specifications
223490481|NCT06282861|DRUG|Gregal|As per product specifications
223490482|NCT06282861|DRUG|Incruse|As per product specifications
223490483|NCT06282861|DRUG|Rolufta|As per product specifications
223490484|NCT06567678|DRUG|Colchicine 0.5 MG oral tablet twice daily|Blood samples will be collected from participants in 2 separate instances. Initially, a baseline VerifyNow P2Y12 PRU and Aspirin reaction unit test assay, followed by a subsequent repeat test 2-week after a 2-week, colchicine 0.5mg oral tablet twice-daily
223490485|NCT05822544|DRUG|TLC-6740 Oral Solution|Oral solution of TLC-6740
223490486|NCT05822544|OTHER|Placebo Oral Solution|Placebo-to-match oral solution TLC-6740
223490487|NCT05822544|DRUG|TLC-6740 Tablet|Tablet formulation of TLC-6740
223490488|NCT05822544|DRUG|Drug Metabolizing Enzyme|Oral dose of omeprazole, voriconazole, itraconazole, or rifampicin
223490489|NCT05822544|DRUG|Tirzepatide|Subcutaneous injection of tirzepatide
223490490|NCT05822544|OTHER|Placebo Tablet|Placebo-to-match tablet formulation of TLC-6740
223490491|NCT06026709|BEHAVIORAL|EmoEase|"The online interventionEmoEase integrates two distinct trainings for anxiety and depression. Each training includes approximately twenty 10-minute sessions, and each are centered around different themes. These two trainings will be delivered through a WeChat Mini Program."
224181939|NCT00066716|DRUG|carboplatin|Dosed to an AUC of 6 by the Calvert formula, intravenously over 1 hour after paclitaxel on days 1, 22, and 43.
224181940|NCT00066716|DRUG|celecoxib|400 mg orally BID begins 3-7 days before the first dose of chemotherapy to the morning of surgery. Celecoxib 400 mg orally BID will resume post-operatively 4-8 weeks if there is adequate wound healing and will be continued for 1 year total, that is, 1 year from the date of surgery + 2 weeks unless tumor recurrence is documented.
224181941|NCT00066716|DRUG|paclitaxel|200 mg/m2 as a 3-hour intravenous infusion on days 1, 22, and 43.
224181942|NCT00066716|PROCEDURE|adjuvant therapy|"1. Surgery will be performed 3-4 weeks after the third dose of paclitaxel and carboplatin.~2. Operation will be performed within 6-12 hours from the last dose of celecoxib.~3. Surgery will include an esophagectomy as well as a complete mediastinal and abdominal lymph node dissection.~4. Celecoxib 400 mg orally BID will resume post-operatively 4-8 weeks if there is adequate wound healing and will be continued for 1 year."
224181943|NCT00066716|PROCEDURE|conventional surgery|"1. Surgery will be performed 3-4 weeks after the third dose of paclitaxel and carboplatin.~2. Operation will be performed within 6-12 hours from the last dose of celecoxib.~3. Surgery will include an esophagectomy as well as a complete mediastinal and abdominal lymph node dissection."
224181944|NCT00066716|PROCEDURE|neoadjuvant therapy|"1. Surgery will be performed 3-4 weeks after the third dose of paclitaxel and carboplatin.~2. Operation will be performed within 6-12 hours from the last dose of celecoxib.~3. Surgery will include an esophagectomy as well as a complete mediastinal and abdominal lymph node dissection."
224181945|NCT01913275|PROCEDURE|Endoscopic stenting|Endoscopic stenting to decrease preopertaive jaundice
224181946|NCT01913275|PROCEDURE|cholecystojejunostomy|surgical procedure to decrease preoperative jaundice
224181947|NCT03500315|OTHER|HIV D+/R+|Kidney from an HIV-infected deceased donor
224181948|NCT04537364|DIAGNOSTIC_TEST|combined diagnosis of renal parenchymal damage|"This study is an observational study to evaluate the accuracy of renal parenchymal damage combined diagnosis with no intervention. All patients from the cohort accept MRI-DWI scan，the urinary biomarkers detection, disease gene detection and DMSA scan.~1. This combined diagnosis includes MRI-DWI scan and the urinary biomarkers detection.~   MRI-DWI： All the scans are performed using the MagnetomVerio 3.0T magnetic resonance imaging system from Siemens.~   Urinary polypeptide collection: Urine samples requirements: volume between 50-100ml, specific gravity \>1.010. Immunomagnetic beads isolation technique is used to collect polypeptide.~2. The reference standard is DMSA scan: Intravenous injection of 99mTC-DMSA5mCi is followed by anterior and posterior planar imaging of the renal area 1 hour later. The DMSA scan images are read by 2 trained radiologists and confirmed by the special doctor of the center for diagnosis and treatment of renal and urinary diseases at the same time."
224181949|NCT00104273|DRUG|Rasagiline|
224181950|NCT05954273|PROCEDURE|Osseodensification crestal sinsus graft|Osseodensification Mediated Maxillary Sinus Crestal Grafting
224181951|NCT03845504|DEVICE|Intermittent Theta Burst Stimulation|Stimulation will be administered using the MagVenture MagPro rTMS Research System at currently FDA approved parameters (www.magvitatms.com). The TBS parameters will be 3-pulse 50-Hz bursts given every 200 ms (at 5 Hz) and an intensity of 80% active motor threshold, as measured from the right first dorsal interosseous muscle by a hand-held 700-mm figure-of-eight coil. rTMS will be applied for 9 min delivering a total of 1800 pulses/session.
224181952|NCT02283801|DRUG|Eslicarbazepine acetate|
224181953|NCT02283801|DRUG|Lamotrigine|
224181954|NCT03681808|DEVICE|Control|Contact Lens
224181955|NCT03681808|DEVICE|Test|Soft Contact Lens
224181956|NCT05200468|OTHER|Ketogenic diet|Weekly menus will be delivered according to diet with the following macronutrient distribution: 25% protein, 10% carbohydrate, 65% fat. Participants will receive a 30-day food menu guide.
224181957|NCT05200468|OTHER|Caloric restriction diet|Weekly menus will be provided according to their usual diet with 500 kcal restriction with the following macronutrient distribution 25-35% protein, 45-55% carbohydrates, 20-30% fat. Participants will receive a 30-day food menu guide.
223490492|NCT05928247|BEHAVIORAL|Functional Communication Training (FCT)|During FCT, reinforcement will be discontinued for challenging behavior and only the alternative communication response will be reinforced. For participants with challenging behavior determined to be maintained by social-positive reinforcement (attention and/or tangible), the investigators also will typically recommend using a multiple schedule FCT (mult-FCT) to signal when reinforcement is available and to thin the schedule of reinforcement to render the treatment more practical for caregivers to implement. For participants with challenging behavior determined to be maintained by social-negative reinforcement (escape), the investigators will recommend using a chained schedule FCT (chained-FCT).
223587811|NCT03164330|BEHAVIORAL|Biometric Screening/HRA - Moderate Compensation|The biometric test will measure: (1) anthropometrics such as height, weight, \& waist circumference (to assess obesity and overweight status); (2) resting blood pressure (to assess hypertension); (3) blood glucose (to assess diabetes risk); \& (4) total, LDL, and HDL cholesterol levels, total cholesterol ratio, and triglycerides (to assess risk of cardiovascular disease). The HRA is a survey designed to identify areas of health improvement, by asking a series of questions related to wellness, health status, nutrition, healthy activities, desire to improve health, preventative health measures. The HRA is also pre-populated with biometric information from the screening. Upon completion, participants are given customized feedback on areas of improvement. Moderate compensation for completion.
224181958|NCT05200468|OTHER|Intermittent fasting 16/8|Calorie-restricted menus will be provided with a 16:8 time-restricted feeding. The feeding window will be 8 hours with a fasting time of 16 hours (04.00 pm- 08.00 am or 05.00 pm - 09.00 am), during the fasting window participants will only be allowed to drink water, unsweetened tea, mineral water and coffee without added sugar. Participants will receive a 30-day food menu guide.
224181959|NCT03123549|DEVICE|Simplify Disc|Simplify Disc at two levels of the cervical spine
224181960|NCT02915133|PROCEDURE|macular buckling surgery|Participants with high myopia foveoschisis are scheduled to macular buckling (MB) surgery.
224181961|NCT02297620|DRUG|Suglat®|oral
224181962|NCT03370133|DRUG|Bimekizumab|Bimekizumab will be provided at pre-specified time intervals.
224181963|NCT03370133|DRUG|Ustekinumab|Ustekinumab will be provided as dose 1 for subjects weighing \<=100 kg and as dose 2 for subjects weighing \>100 kg at pre-specified time intervals.
224181964|NCT03370133|OTHER|Placebo|Subjects will receive Placebo at pre-specified time points.
224181965|NCT00562081|BEHAVIORAL|Education|24/7 access to a Certified Asthma Educator
224181966|NCT00562081|BEHAVIORAL|Education|Patient does not have 24/7 access to a Certified Asthma Educator.
224181967|NCT02561104|PROCEDURE|Laser-assisted cataract surgery.|
224181968|NCT02561104|PROCEDURE|Traditional manual phacoemulsification|
224181969|NCT03826316|DRUG|Nalbuphine|Pharmacokinetic study under fasting conditions
224181970|NCT00636506|DEVICE|AMS 700 IPP with MS Pump|AMS 700 Series Inflatable Penile Prosthesis with MS Pump
224181971|NCT01849549|BEHAVIORAL|Neuropsychological testing|Experimental test about cognitive deficit of interest and standard neuropsychological tests.
224181972|NCT01849549|OTHER|MRI|Anatomical, diffusion, and/or functional MRI
224181973|NCT03742271|DEVICE|senofilcon A|TEST Lens
224181974|NCT04361721|DRUG|Erenumab|First injection of erenumab 70 mg subcutaneously was administered in hospital. The second injection of erenumab 70 mg was administered in hospital after 28 days, while the third and last dose of erenumab 70 mg was self-administered at home by the patients themselves after an additional 28-day interval.
224307805|NCT00711438|BEHAVIORAL|Breathlessness Intervention Service (BIS)|BIS consists of a clinical specialist physiotherapist \& palliative care consultant. It aims to manage the symptom of breathlessness in patients with any disease using a rehabilitative approach. Interventions include: evidence-based non-pharmacological interventions (psychological, social \& physical); palliative care input (e.g. end of life issues, psychosocial issues, family concerns); \& pharmacological review. This BIS seeks to enhance self-management of breathlessness. Uniquely, care is located in clinic or in patients' own homes, as appropriate. Referrals come from medical specialists, GPs \& allied health professionals (with medical consent).
224307806|NCT00711438|BEHAVIORAL|Best supportive care (Standard care)|Standard care: specialist outpatient appointments in secondary care (e.g. respiratory) which may include specialist nurse input, and primary care services.
224307807|NCT04516759|DRUG|AZD1656|50mg film-coated tablets (at daily dose of 100mg BID)
224307808|NCT04516759|OTHER|Placebo|Matched placebo tablets
224307809|NCT05462171|DIAGNOSTIC_TEST|Questionnaires|Participants will be asked to complete validated questionnaires (the five-item International Index of Erectile Function - IIEF-5, Premature Ejaculation Diagnostic Tool - PEDT, International Prostate Symptom Score - IPSS, Overactive Bladder - Validated 8-question Screener - OAB-V8, Hospital Anxiety and Depression Scale - HADS, Athens Insomnia Scale - AIS).
223745465|NCT04877275|DRUG|Selinexor (80mg/d)|"Selinexor (ATG-010） is a first-in-class, oral selective exportin 1 (XPO1) inhibitor (1,2). Selinexor functions by binding with and inhibiting the nuclear export protein XPO1 (also called CRM1), leading to the accumulation of tumor suppressor proteins in the cell nucleus along with inhibition of translation of oncoprotein mRNAs.~Arm I：80mg/d QW ;"
224181975|NCT01601990|DRUG|Placebo group(once daily)|eligible patients were randomized to LC15-0444 50mg or placebo groups and received the assigned treatment for 24 weeks.
224181976|NCT01601990|DRUG|LC15-0444 50mg qd|eligible patients were randomized to LC15-0444 50mg or placebo groups and received the assigned treatment for 24 weeks
224181977|NCT01529827|DRUG|fludarabine phosphate|Given IV
224181978|NCT01529827|DRUG|melphalan|Given IV
224181979|NCT01529827|RADIATION|total-body irradiation|Undergo TBI
224181980|NCT01529827|DRUG|tacrolimus|Given IV or PO
224181981|NCT01529827|DRUG|mycophenolate mofetil|Given IV or PO
224181982|NCT01529827|DRUG|methotrexate|Given IV
224181983|NCT01529827|OTHER|laboratory biomarker analysis|Correlative studies
224181984|NCT01529827|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Undergo allogeneic PBSCT
224181985|NCT01529827|PROCEDURE|peripheral blood stem cell transplantation|Undergo PBSCT
224181986|NCT02675582|OTHER|Herbal Beverage|Intervention involves consuming one beverage at the beginning of each visit during the incomplete block design sequence
224181987|NCT05431972|DEVICE|Cardea SOLO|Neurologist cardiac rhythm translation with 12 lead EKG versus Cardea SOLO
224181988|NCT05431972|DEVICE|12 Lead EKG|Neurologist cardiac rhythm translation with 12 lead EKG versus Cardea SOLO
224181989|NCT01758172|DRUG|6% hydroxyethyl starch 130/0.4|
224181990|NCT01758172|DRUG|Albumin|
224181991|NCT00315523|DRUG|Levocetirizine|
224181992|NCT04441658|BIOLOGICAL|Umbilical Cord Mesenchymal Stem Cells|human umbilical cord mesenchymal stem cells were peripheral intravenous infused to experimental group
224181993|NCT04441658|BIOLOGICAL|saline|saline containing human albumin will be infused to the control group
224181994|NCT01097434|DEVICE|Biodegradable polymer limus-eluting stents|due randomization biodegradable polymer limus-eluting stents will be implanted
224181995|NCT01097434|DEVICE|Permanent polymer limus-eluting stent|due randomization permanent polymer limus-eluting stent will be implanted
224181996|NCT05298410|OTHER|Limitless|Participants will be instructed to take Limitless for 30 days.
224181997|NCT00791011|DRUG|AMG 655|AMG 655 is an investigational, fully human monoclonal agonist antibidy that selectively binds to Death Receptor-5 (DR-5).
224181998|NCT00791011|OTHER|Vorinostat|Vorinostat, a second generation polarplanar compound, binds to the catalytic domain of the histone deacetylases (HDAC).
224181999|NCT00791011|OTHER|Bortezomib|A dipeptide boronic acid analogue with antineoplastic activity.
224182000|NCT03463109|OTHER|Electrocutaneous stimulation|Painful electrocutaneous stimuli will be randomly delivered to electrodes positioned in a random order on the participants' back. Participants will be instructed to draw with a stylus pen on a digital body chart displayed on a tablet where they will perceive each painful stimulation.
224182001|NCT03463109|OTHER|Assessment + Electrocutaneous stimulation|"Patients will be asked to provide information about their lifestyle, level of disability, actual pain and general pain, assessment of kinesiophobia and health status.~Subsequently, painful electrocutaneous stimuli will be randomly delivered to electrodes positioned in a random order on the patients' back. Patients will be instructed to draw with a stylus pen on a digital body chart displayed on a tablet where they will perceive each painful stimulation."
224182002|NCT02996240|DIETARY_SUPPLEMENT|Omega-3 FFA|Omega-3 Free Fatty Acid will be given as a fish oil in a capsule.
224182003|NCT03245099|OTHER|cross sectional|Electroencephalograph will be done to all patients who fulfill the inclusion criteria to detect presence of electrical discharge with in the brain.Complete blood count ,liver function test ,kidney function test ,blood glucose level and serum electrolytes will be done to selected cases according to the clinical presentation
224182004|NCT03170635|BEHAVIORAL|Refreshing Recess program|6-week program integrated into recess in order to build capacity of recess supervisors to foster active play and socialization so that all students enjoy recess and socialization with peers.
223490493|NCT05928247|BEHAVIORAL|Non-Contingent Reinforcement (NCR)|During NCR, the investigators will deliver the functional and competing reinforcers on time-based schedules and use multiple and chained schedules to signal when noncontingent reinforcement is available (similar to multiple- and chained-FCT).
223490494|NCT05928247|BEHAVIORAL|Competing Items and Response Blocking|The investigators will conduct a competing stimulus assessment (CSA) to identify items that produce at least an 80% reduction in challenging behavior when the participant is engaged with them. The investigators will evaluate conditions in which participants have free access to the item(s), when engagement with the item(s) is prompted, and when challenging behavior is physically blocked. Treatment will include one or more of the following components: non-contingent reinforcement informed by the CSA, reinforcing adaptive behavior, and blocking challenging behavior. The investigators will also use multiple and chained schedules to thin the reinforcement schedules and increase the practicality of the this treatment. The ending duration of the S-delta component will be based on input from caregivers and the participant's school personnel.
223490495|NCT05928247|BEHAVIORAL|Research Units in Behavioral Intervention (RUBI) protocol|Caregivers of participants with mild challenging behavior will receive training on a variety of topics, such as prevention strategies and functional communication training, throughout implementation of the RUBI protocol.
223490496|NCT05311527|DEVICE|Urolift|Urolift Implant
224182005|NCT04191694|OTHER|Chewing Gum|Patients will be given a packet of chewing gum on arrival in the post-operative recovery room. They will be asked to start chewing gum in the recovery room and then asked to chew gum according to their preference over course of the following 24 hours.
224182006|NCT04191694|DRUG|Ondansetron 4 MG|Ondansetron 4mg intravenously, intra-operatively as part of standard hospital caesarean section protocol
224182007|NCT02513355|BIOLOGICAL|Endostar|Endostar 15mg/m2, 21 days per cycle, 4 to 6 cycles
224182008|NCT02513355|DRUG|Changchun marina|25mg/m2,d1 and d8,q21d×4
224307810|NCT06443411|OTHER|Monitoring of cerebral hemodynamics|A specially designed pair of goggles will be put on the patient's head. The closed eyelids, along with the surrounding tissues, will be in contact with a thin, elastic, non-allergic film used to seal water filled inside the goggles. Pulse waves, including those originating from cerebrospinal fluid pulsation, will be transmitted from the eyelids to the water, where they will be detected by a pressure sensor and recorded with a laptop.
224307811|NCT00528411|DRUG|Ticagrelor Tablets|Oral, 90 mg; 180 mg loading dose followed by 90 mg twice daily (BD)
224307812|NCT00528411|DRUG|Clopidogrel (over encapsulated) capsule|Oral 75 mg; 600 mg loading dose followed by 75 mg once daily (ODD)
224307813|NCT00528411|DRUG|Aspirin Tablets|Oral, 75 mg to 100 mg once daily. Aspirin obtained locally by the investigator, according to local practice. The dose remained constant throughout the study.
224307814|NCT04916444|DEVICE|rTMS|repetitive transcranial magnetic stimulation is a painless, noninvasive form of neurostimulation. This study uses an accelerated protocol in which the neurostimulation pulses are delivered in 4 sessions per day over 4 consecutive days (16 total sessions). Active or sham rTMS will be provided at 9 weeks following botox injections.
224307815|NCT03247192|DIETARY_SUPPLEMENT|Whey protein-placebo|This investigation was carried out over a period of 26 weeks divided in two phases. The first phase of the study was an eight-week period (weeks 3-10), during which subjects were familiarized to RT. Phase 2, supplementation phase, the participants was randomized in three groups and started 12 weeks dedicated to supplementation plus RT (weeks 13-24). At the beginning and the end of each phase of the experiment, two weeks were allocated for evaluations (weeks 1-2, 11-12 and 25-26) consisting of anthropometric, body composition, blood samples, blood pressure, one repetition maximum tests (1RM) and dietary intake measurements
224307816|NCT03247192|DIETARY_SUPPLEMENT|Placebo-whey protein|This investigation was carried out over a period of 26 weeks divided in two phases. The first phase of the study was an eight-week period (weeks 3-10), during which subjects were familiarized to RT. Phase 2, supplementation phase, the participants was randomized in three groups and started 12 weeks dedicated to supplementation plus RT (weeks 13-24). At the beginning and the end of each phase of the experiment, two weeks were allocated for evaluations (weeks 1-2, 11-12 and 25-26) consisting of anthropometric, body composition, blood samples, blood pressure, one repetition maximum tests (1RM) and dietary intake measurements
223490497|NCT05311527|RADIATION|SABR|Stereotactic Body Radiation Therapy for prostate cancer
223745466|NCT04877275|DRUG|Selinexor (100mg/d)|"Selinexor (ATG-010） is a first-in-class, oral selective exportin 1 (XPO1) inhibitor (1,2). Selinexor functions by binding with and inhibiting the nuclear export protein XPO1 (also called CRM1), leading to the accumulation of tumor suppressor proteins in the cell nucleus along with inhibition of translation of oncoprotein mRNAs.~Arm II：100mg/d QW ;"
223745467|NCT04877275|DRUG|Pegylated liposomal doxorubicin|25 mg/m\^2 intravenously on day 1 , QW
223745468|NCT04877275|DRUG|Dexamethasone|Dexamethasone 40mg/d QW
223745469|NCT04877275|DRUG|Cyclophosphamide|Cyclophosphamide：300mg/m2, d1 QW，
224182009|NCT02513355|DRUG|cisplatin|80mg/m2,d1, q21d×4
224182010|NCT02513355|DRUG|Taxol|135-175mg/m2,d1,q21d×4
224182011|NCT02513355|DRUG|parapl|AUC=5-6,d1,q21d×4
224182012|NCT05202184|PROCEDURE|Percutaneous thermal ablation|All thermoablation procedures were performed percutaneously under ultrasound and/or CT guidance
224182013|NCT05183594|DIETARY_SUPPLEMENT|TSupport (a Traditional Chinese Medicine)|TSupport is made up of 11 Chinese medicinal herbs.
224182014|NCT03884803|BEHAVIORAL|E-health website|Access to the e-health intervention (website)
224182015|NCT03884803|OTHER|Standard Care|Control group to continue with standard care
224182016|NCT04080349|DRUG|Dinoprostone 3 mg|1 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia \& Upjohn, Puurs, Belgium) inserted by the study nurse 3 hours before IUD insertion.
224182017|NCT04080349|DRUG|Misoprostol 200Mcg Tab|1 vaginal tablet of misoprostol (200 mcg) (Misotac®; Sigma Pharma, SAE, Egypt) inserted by the study nurse 3 hours before IUD insertion.
224182018|NCT04080349|DRUG|placebo|one tablet of placebo inserted by the study nurse 3 hours before IUD insertion
224182019|NCT02158195|BIOLOGICAL|blood samples|
224182020|NCT03614702|BIOLOGICAL|1-dose cIPV + 2-doses bOPV (Candy)|Health subjects received 1-dose cIPV intramuscularly in the centre of anterolateral thigh followed by 2-doses bOPV(Candy) through mouth at 0, 28, 56 days schedule.
224182021|NCT03614702|BIOLOGICAL|1-dose sIPV + 2-doses bOPV (Candy)|Health subjects received 1-dose sIPV intramuscularly in the centre of anterolateral thigh followed by 2-doses bOPV(Candy) through mouth at 0, 28, 56 days schedule.
224182022|NCT03614702|BIOLOGICAL|2-doses cIPV + 1-dose bOPV (Candy)|Health subjects received 2-doses cIPV intramuscularly in the centre of anterolateral thigh followed by 1-dose bOPV(Candy) through mouth at 0, 28, 56 days schedule.
223490498|NCT03628209|DRUG|Nivolumab|Participants will be treated with Nivolumab intravenously (IV), 3 mg/kg on days 1 and 15 of each cycle.
223490499|NCT03628209|DRUG|Azacitidine|Phase I Dose Escalation - Dose level 1: NA. Dose level 2: 60 mg/m\^2. Dose level 3: 75 mg/m\^2. Phase II Expansion - Treated at recommended Phase II dose (RP2D).
223490500|NCT03628209|PROCEDURE|Post Treatment Surgery|Resection surgery at end of Cycle 1 treatment, day 28-35.
223490501|NCT04164979|DRUG|Cabozantinib|Given PO
223490502|NCT04164979|DRUG|Pembrolizumab|Given IV
223490503|NCT06070649|DRUG|0.3mg/kg/min Dimethyltryptamine + Normal Saline infusion|Infusion
223490504|NCT06070649|DRUG|0.2 mg/kg/min + Dimethyltryptamine 0.01mg/kg/min infusion|Infusion
224182023|NCT03614702|BIOLOGICAL|2-doses sIPV + 1-dose bOPV (Candy)|Health subjects received 2-doses sIPV intramuscularly in the centre of anterolateral thigh followed by 1-dose bOPV(Candy) through mouth at 0, 28, 56 days schedule.
224182024|NCT03614702|BIOLOGICAL|2-doses cIPV + 1-dose tOPV (Candy)|Health subjects received 2-doses cIPV intramuscularly in the centre of anterolateral thigh followed by 1-dose tOPV(Candy) through mouth at 0, 28, 56 days schedule.
224182025|NCT03614702|BIOLOGICAL|2-doses sIPV + 1-dose tOPV (Candy)|Health subjects received 2-doses sIPV intramuscularly in the centre of anterolateral thigh followed by 1-dose tOPV(Candy) through mouth at 0, 28, 56 days schedule.
224182026|NCT03614702|BIOLOGICAL|1-dose cIPV + 2-doses bOPV (Liquid)|Health subjects received 1-dose cIPV intramuscularly in the centre of anterolateral thigh followed by 2-doses bOPV(Liquid) through mouth at 0, 28, 56 days schedule.
224182027|NCT03614702|BIOLOGICAL|1-dose sIPV + 2-doses bOPV (Liquid)|Health subjects received 1-dose sIPV intramuscularly in the centre of anterolateral thigh followed by 2-doses bOPV(Liquid) through mouth at 0, 28, 56 days schedule.
224182028|NCT03614702|BIOLOGICAL|2-doses cIPV + 1-dose bOPV (Liquid)|Health subjects received 2-doses cIPV intramuscularly in the centre of anterolateral thigh followed by 1-dose bOPV(Liquid) through mouth at 0, 28, 56 days schedule.
224182029|NCT03614702|BIOLOGICAL|2-doses sIPV + 1-dose bOPV (Liquid)|Health subjects received 2-doses sIPV intramuscularly in the centre of anterolateral thigh followed by 1-dose bOPV(Liquid) through mouth at 0, 28, 56 days schedule.
224182030|NCT03614702|BIOLOGICAL|2-doses cIPV + 1-dose tOPV (Liquid)|Health subjects received 2-doses cIPV intramuscularly in the centre of anterolateral thigh followed by 1-dose tOPV(Liquid) through mouth at 0, 28, 56 days schedule.
224182031|NCT03614702|BIOLOGICAL|2-doses sIPV + 1-dose tOPV (Liquid)|Health subjects received 2-doses sIPV intramuscularly in the centre of anterolateral thigh followed by 1-dose tOPV(Liquid) through mouth at 0, 28, 56 days schedule.
224182032|NCT01551628|DRUG|Recombinant human arginase 1 Peg5000|Patients will receive weekly IV infusions of PEG-BCT-100, until evidence of disease progression, intolerable adverse events, or withdrawal of patient consent. For safety sake, each subject will receive an induction dose of PEG-BCT-100 500 U/kg and 1000 U/kg at week -2 and week -1, respectively. The study dose of PEG-BCT-100 1600 U/kg will be initiated at week 1 (Day1). Each escalation of dose level will be determined by the investigator according to each subject's tolerability and criteria for treatment discontinuation.
224182033|NCT02105168|PROCEDURE|Blood sample|Optional
224182034|NCT02105168|PROCEDURE|Tumorous biopsy|Optional
224182035|NCT02105168|PROCEDURE|Healthy material sample|Optional
224182036|NCT02477540|DRUG|Cellgram-CLI|"Appearance: White cell suspension is filled in a clear plastic syringe, and fixed with an occlude on the prefilled syringe tip~Main ingredient: Autologous bone marrow-derived mesenchymal stem cells~Dosage: 50,000,000 cells/10ml, 2-time injection~Storage: An airtight container, 20\~25℃~Injection Method: Intramuscular"
224182037|NCT03351140|OTHER|Qualitative Interviews|Subjects will participate in a qualitative interview lasting up to 90 minutes. The interviews will include a concept elicitation component to explore details of the subject's perceived disease condition, functional limitations and impacts on daily life and health-related quality-of-life (HRQoL). In addition, a card sorting exercise will be used to evaluate the relevance and comprehension of PROMIS Physical Function items.
224182038|NCT03351140|OTHER|PROMIS Physical Function Items|PROMIS Physical Function Items is a set of self-report measurement tools. The latest version of PROMIS Physical Function Items contains 165 items for self-assessment. PROMIS Physical Function Cancer Item Bank contains a subset of 45 items relevant to cancer subjects. Subjects will complete half of the PROMIS Physical Function Items during their enrollment visit and the other half of items prior to their interview.
224182039|NCT01251081|OTHER|extra high volume hemofiltration|extra high volume hemofiltration (85 mL/kg/h, EHVHF)
224182040|NCT01251081|OTHER|high volume hemofiltration|high volume hemofiltration (50 mL/kg/h, HVHF)
224182041|NCT04983004|BEHAVIORAL|tele-rehabilitation|According to the pre-arranged case service schedule, the researcher is asked to push the computer and cart to the case ward for installation, and use the communication software to interact with each other in real time. The intervention method directly plays the recorded video to demonstrate the action according to the action needs of the case. The therapist can observe the video demonstration and the actual action execution of the case at the same time from the screen.
223490505|NCT06070649|DRUG|25 mg Diphenhydramine (5 min) + Normal Saline|Infusion
224182042|NCT04983004|BEHAVIORAL|bedside rehabilitation|The bedside therapist and the case work together to set an activity schedule. The case is asked to establish and record daily routine activities, provide basic exercise and activity schedules to avoid degradation and reduce the lack of active participation in activities. The protection is to wear personal protective equipment, including protective clothing, gloves, masks, and face shields, and wash hands and disinfect before and after treatment.
224182043|NCT02309216|OTHER|Whol-Body MRI scan|
224182044|NCT05136209|PROCEDURE|PCCC procedure without A-vit|In this randomized clinical trial, patients receive cataract surgery on both eyes on the same day. For each patient, one eye is randomly assigned to undergo PCCC+A-Vit procedure, while the fellow eye is undergoing PCCC procedure without A-Vit.
224182045|NCT05136209|PROCEDURE|PCCC+A-Vit procedure|PCCC+A-Vit procedure
224182046|NCT02112149|BEHAVIORAL|LIVESTRONG|The LIVESTRONG at the YMCA is a twelve-week, small group (\< 16 participants) program designed for adult cancer survivors. YMCA fitness instructors work with each participant to fit the program to their individual needs. The instructors are trained in the elements of cancer, post rehabilitation exercise and supportive cancer care. There are two YMCA fitness instructors overseeing each exercise session. Each session is 90 min in duration, twice per week, for 12-wks (total of 24 sessions). Each session begins with a warm-up, then aerobic exercise (e.g., treadmill) and resistance training exercises, followed by a cool-down period, and follows the recommendations of the American College of Sports Medicine.
224182047|NCT03779828|DEVICE|HOME LINK|Telemonitoring system which include web platform and connected devices.
224182048|NCT02299544|DEVICE|BlueWind Medical system|The BlueWind Medical System is intended for the treatment of patients with overactive bladder (OAB) including urinary urgency frequency and urge incontinence.
224182049|NCT04599660|OTHER|Treatment of Low Risk GISTs according clinical practice (includes drugs, surgery or any other received treatments)|This observational study collects all the treatments received by the patients according clinical practices or experimental trials and therefore includes drug/biological/surgical and any other applicable treatments
224182050|NCT00201058|BEHAVIORAL|Tailored Web-based Asthma Management|Web-based asthma management
224182051|NCT00201058|BEHAVIORAL|Generic web-based asthma education|4 computer sessions over a period of 180 days
224182052|NCT01864629|BEHAVIORAL|Focused contraception counseling|This intervention will be provided to those randomized to the intervention group only. This counseling will follow a pre-written, structured script describing all contraceptive methods in rank order starting with most effective to least effective in preventing unplanned pregnancy.
224182053|NCT05306860|OTHER|No intervention was applied to the groups the samples will be collected in terms of the diagnosis (periodontitis, healthy)|No intervention was applied to the groups the samples will be collected in terms of the diagnosis (periodontitis, healthy)
224182054|NCT01899729|DRUG|IMO-8400 Regimen 1|IMO-8400 0.075 mg/kg q wk x 12 wk by subcutaneous injection
224182055|NCT01899729|DRUG|IMO-8400 Regimen 2|IMO-8400 0.15 mg/kg q wk x 12 wk by subcutaneous injection
224182056|NCT01899729|DRUG|IMO-8400 Regimen 3|IMO-8400 0.3 mg/kg q wk x 12 wk by subcutaneous injection
224182057|NCT01899729|DRUG|Saline Placebo|Saline q wk x 12 wk by subcutaneous injection
224182058|NCT01899729|DRUG|IMO-8400 Regimen 4|IMO-8400 0.6 mg/kg q wk x 12 wk by subcutaneous injection
224307817|NCT03247192|DIETARY_SUPPLEMENT|Placebo-placebo|This investigation was carried out over a period of 26 weeks divided in two phases. The first phase of the study was an eight-week period (weeks 3-10), during which subjects were familiarized to RT. Phase 2, supplementation phase, the participants was randomized in three groups and started 12 weeks dedicated to supplementation plus RT (weeks 13-24). At the beginning and the end of each phase of the experiment, two weeks were allocated for evaluations (weeks 1-2, 11-12 and 25-26) consisting of anthropometric, body composition, blood samples, blood pressure, one repetition maximum tests (1RM) and dietary intake measurements
223490506|NCT06974175|OTHER|Deprox_HP|Use of nutraceutic based on a compound of pollen extracts from pollen, mais and timothy
223490507|NCT06974175|OTHER|Peacist|Use of a nutraceutic based on palmitoilethanolamide + Bromelin + Horse Chestunt extract
224182059|NCT03866239|DRUG|Obinutuzumab|Obinutuzumab will be administered by intravenous (IV) infusion as either a split or single dose approximately 2 weeks before Cycle 1, Day 1 (cycle = 21 days).
224182060|NCT03866239|DRUG|Atezolizumab|Atezolizumab will be administered at a fixed dose of 1200 mg by IV infusion on Day 1 of each 21-day cycle until radiographic progression, unacceptable toxicity, or loss of clinical benefit.
224182061|NCT03866239|DRUG|Cibisatamab|Cibisatamab will be administered at a fixed dose of 100 mg by IV infusion on Day 1 of each 21-day cycle until radiographic progression, unacceptable toxicity, or loss of clinical benefit.
224182062|NCT03866239|DRUG|Tocilizumab|Tocilizumab will be administered by IV infusion as necessary to manage adverse events (AEs)
224182063|NCT02194192|DRUG|Placebo|Normal saline 10 ml
224182064|NCT02194192|DRUG|Ondansetron|Ondasetron 8 mg IV after spinal anesthesia
224182065|NCT02194192|DRUG|Ephedrine|Ephedrine 10 mg IV after spinal anesthesia
224182066|NCT03847272|DRUG|prednisone and ustekinumab treatment|Treatment with prednisone and ustekinumab (90 mg subcutaneously at inclusion (W0), W4 and W16)
224182067|NCT03847272|OTHER|Ophthalmologic examination|Best corrected visual acuity (BCVA) testing, Slit Lamp Exam, tonometry, dilated indirect ophthalmoscopy, optical coherence tomography (OCT), Fluorescein angiography and Indocyanin green angiography
223490508|NCT06965998|DRUG|Full dose rivaroxaban|The intervention group will receive full dose rivaroxaban for 90 days.
223490509|NCT06965998|DRUG|Low dose rivaroxaban|The comparator group will receive the standard treatment of low dose rivaroxaban.
223490510|NCT06965998|DRUG|Placebo|Since the treatment arm has an AM and PM dose of study drug from Day 1-21, the comparator group will take 1 placebo pill in the PM to keep the two arms blinded.
223490511|NCT06973785|DRUG|dispense of study drug|• Cohort Group 1 (Experimental): ketorolac 10mg with rescue medication oxycodone 5mg All patients will be given acetaminophen
224182068|NCT03847272|OTHER|Questionnaires|VFQ-25 and SF-36
224182069|NCT03847272|BIOLOGICAL|Blood samples|Additional blood samples for immunomonitoring
224182070|NCT04839211|DEVICE|Inspiratory muscle training|Inspiratory muscle training will be performed three sessions per week as one supervised and two unsupervised for 8 weeks using an inspiratory muscle training device (PowerBreath). The inspiratory muscle training session will consist of 7 cycles including a 2:1 ratio of work and rest interval. Resistance will be adjusted to the highest tolerable load and will be gradually increased.
224182071|NCT04839211|DEVICE|Sham inspiratory muscle training|Sham inspiratory muscle training will be performed three sessions per week as one supervised and two unsupervised for 8 weeks using an inspiratory muscle training device (PowerBreath). The inspiratory muscle training session will consist of 7 cycles including a 2:1 ratio of work and rest interval. Resistance will be adjusted to the unloaded.
224182072|NCT04744311|OTHER|ObsQoR-11T Questionnaire|The ObsQoR-11T questionnaire consists of 11 items assessing different aspects of postpartum recovery: physical comfort and pain, physical independence and emotional status. If the patient is not able to read the questionnaire herself, a third person can ask the questions orally to the patient. Each item is scored from 0 to 10 and the total score is the sum of the score for each item, which is a score from 0 to 110.
224182073|NCT04026633|BEHAVIORAL|CAA|Participants will write about the use of PBS and alcohol use.
224182074|NCT04026633|BEHAVIORAL|Control|Participants will write about eating and exercise.
224182075|NCT02220660|DRUG|BI 1744 CL|
224182076|NCT02220660|DRUG|BI 54903 XX|
224182077|NCT02220660|DRUG|BI 1744 CL + BI 54903 XX FDC|
224182078|NCT02220660|DRUG|Placebo|
224182079|NCT05835544|OTHER|Active Comparator: HIIT Control|Complete 3 sets of five repetitions of 30 seconds cycling at 100% of maximal aerobic power with 30 seconds of active unloaded recovery between repetitions; 3 minutes of passive rest between sets.
224182080|NCT05835544|OTHER|Experimental: HIIT + BFR between cycling sets|Complete 3 sets of five repetitions of 30 seconds cycling at 100% of maximal aerobic power with 30 seconds of active unloaded recovery between repetitions; 3 minutes of passive rest between sets. Blood flow restriction is applied for 2 minutes during the passive rest at 80% of limb occlusion pressure.
224182081|NCT05835544|OTHER|Experimental: HIIT + BFR moderate occlusion during cycling|Complete 3 sets of five repetitions of 30 seconds cycling at 70% of maximal aerobic power with 30 seconds of active unloaded recovery between repetitions; 3 minutes of passive rest between sets. Blood flow restriction is applied during and between exercise repetitions at 50% of limb occlusion pressure and deflated during passive rest periods.
224182082|NCT05835544|OTHER|Experimental: HIIT + BFR high occlusion during cycling|Complete 3 sets of five repetitions of 30 seconds cycling at 70% of maximal aerobic power with 30 seconds of active unloaded recovery between repetitions; 3 minutes of passive rest between sets. Blood flow restriction is applied during and between exercise repetitions at 80% of limb occlusion pressure and deflated during passive rest periods.
224182083|NCT03593720|PROCEDURE|Measurement in Office|Penile length and glans size in 3 dimensions
223490512|NCT06973785|DRUG|Ketorolac|Patients will be randomized to either Ketorolac or Oxycodone
223490513|NCT05325281|DRUG|CPI-613® (Dose level -1.0 250 mg/m^2)|CPI-613® is a mitochondrial metabolism inhibitor. CPI-613® is a lipoic acid antagonist that abrogates mitochondrial energy metabolism to induce apoptosis in various cancer cells.
223587812|NCT03164330|BEHAVIORAL|Biometric Screening/HRA - High Compensation|The biometric test will measure: (1) anthropometrics such as height, weight, and waist circumference (to assess obesity and overweight status); (2) resting blood pressure (to assess hypertension); (3) blood glucose (to assess diabetes risk); and (4) total, LDL, and HDL cholesterol levels, total cholesterol ratio, and triglycerides (to assess risk of cardiovascular disease). The HRA is a survey designed to identify areas of health improvement, by asking a series of questions related to wellness, health status, nutrition, healthy activities, desire to improve health, preventative health measures. The HRA is also pre-populated with biometric information from the screening. Upon completion, participants are given customized feedback on areas of improvement. High compensation for completion.
223745470|NCT03356496|DEVICE|AirLife 4000 cc incentive spirometry device|Incentive spirometry device provides improved lung expansion and respiratory muscle strength
224182084|NCT03593720|PROCEDURE|Measurement in OR|Penile length and glans size in 3 dimensions
224182085|NCT00315692|DEVICE|Biomarker Assay (CA125 and HE4)|
223490514|NCT05325281|DRUG|CPI-613® (Dose level 1.0 500 mg/m^2)|CPI-613® is a mitochondrial metabolism inhibitor. CPI-613® is a lipoic acid antagonist that abrogates mitochondrial energy metabolism to induce apoptosis in various cancer cells.
223490515|NCT05325281|DRUG|CPI-613® (Dose level 2.0 1,000 mg/m^2)|CPI-613® is a mitochondrial metabolism inhibitor. CPI-613® is a lipoic acid antagonist that abrogates mitochondrial energy metabolism to induce apoptosis in various cancer cells.
223490516|NCT05325281|DRUG|CPI-613® (Dose level 3.0 1,500 mg/m^2)|CPI-613® is a mitochondrial metabolism inhibitor. CPI-613® is a lipoic acid antagonist that abrogates mitochondrial energy metabolism to induce apoptosis in various cancer cells.
224182086|NCT02415582|OTHER|Aerobic exercise|Aerobic exercise on treadmill
224182087|NCT02415582|OTHER|Combined exercises|Combined resistance and aerobic exercise
224182088|NCT02415582|OTHER|Control|45 minutes resting sitting
224182089|NCT03586076|BIOLOGICAL|JHL1922|Single doses of JHL1922 2.5 mg and then 10 mg per eRapid nebulizer
224182090|NCT03586076|BIOLOGICAL|dornase alfa|Single doses of Pulmozyme® 2.5 mg and then 10 mg per eRapid nebulizer
224182091|NCT00003368|DRUG|irinotecan hydrochloride|
224182092|NCT05275140|OTHER|Physical activity|Combat sports and exercise
224182093|NCT04557696|OTHER|REFLECT Curriculum|Annual quarterly workshops will consist of guest lecturers, role playing, patient panels, coaching, knowledge assessments, Standardized Patient (SP) simulations and debriefing/feedback sessions.
224182094|NCT03194672|BEHAVIORAL|Healthy Adolescent Transitions (HAT) program|"The components of the intervention are described in the arm description.~The intervention is based upon the theoretical framework of behavioral economics, which suggests that low intensity nudges can help recipients accomplish their own goals. All components of the intervention are voluntary; some participants may wish to discuss all components, while other participants may wish to discuss selected components consistent with their priorities."
224182095|NCT04545086|BEHAVIORAL|Video Based Education, Music Therapy|Video Based Education and Music Therapy was given as a part of Interventions to relieve anxiety of patients undergoing Magnetic Resonance Imaging
224182096|NCT04589117|BEHAVIORAL|Expressive writing|"The 4-week study intervention will invite participants through a progression of expressive writing exercises designed to support emotional expression and enhance personal resilience. Weekly instruction writing sessions will be conducted via Zoom. The sessions will not be recorded, but participants who cannot attend the sessions live (or prefer not to, for any reason) will receive each week's instructions and prompts via email.~The progression of writing exercises flows as follows:~* Week 1: Writing to expressive difficult emotions~* Week 2: Writing to cultivate compassion \& forgiveness~* Week 3: Writing to nurture positive emotions~* Week 4: Writing to invite insight, perspective, \& growth"
224182097|NCT01574118|BEHAVIORAL|Revisiting the Trauma memories|Patient engages in repeated revisiting of their trauma memory under the guidance of the therapist for about 40 minutes. During each revisiting trial the patient closes their eyes and verbally describes the trauma and the feeling and thoughts experienced during the trauma.
224182098|NCT01574118|BEHAVIORAL|Processing the trauma memories|The patient and therapist discuss the patient's experience during the trauma revisiting with the goal of helping the patient gain alternative perspectives of the trauma.
224182099|NCT01574118|BEHAVIORAL|Psychoeducation|Through patient handouts and didactic instruction, the patient learns about the common reactions to trauma and the rationale for exposure therapy.
224182100|NCT01574118|BEHAVIORAL|Trauma Memory Retrieval Trial|Prior to the start of Imaginal Exposure, the patient is asked to recall a threatening element of their trauma memory for 1 minute. This is followed by a 30-minute rest-period prior to beginning imaginal exposure.
224182101|NCT01574118|BEHAVIORAL|Exposure to video clips related to the patient's trauma|Patient is seated in front of a computer monitor and instructed to view a 30-min looped video clip that thematically resembles the patient's trauma.
224182102|NCT01574118|BEHAVIORAL|Breathing retraining|Patient is seated comfortably in a chair and instructed to breathe slowly and deeply in a relaxed manner.
224182103|NCT01574118|BEHAVIORAL|Exposure Homework|Therapist assists the patient in identifying trauma-related situations/activities that the patient is avoiding and encourages the patient to begin to confront these situations between sessions.
224182104|NCT01574118|BEHAVIORAL|Compound extinction|The patient repeatedly confronts the truama-related media clip while simultaneously listening to their own trauma script through headphones.
224182105|NCT05247736|DIAGNOSTIC_TEST|Infrared Thermography|Non-contact body thermometry
224182106|NCT02589873|BEHAVIORAL|In-Person Diabetes Prevention Program|Lifestyle intervention program involving group-based educational sessions, diet and physical activity tracking, and weekly weigh ins. Participants complete the intervention over 12 months.
224182107|NCT02589873|BEHAVIORAL|Online Diabetes Prevention Program|Lifestyle intervention program involving web-based educational videos, diet and physical activity tracking, and recording weight. Participants complete the intervention over 12 months.
224182108|NCT03106857|OTHER|Group A|Group A Physical activity and low caloric diet for
224182109|NCT01402206|BEHAVIORAL|Structured patient-centered follow up of depression|"All patients who agree to participate in the study are diagnosed by their GP with a diagnostic assessment instrument called PRIME-MD. Participants in the intervention group visit their GPs at baseline and 4, 8, and 12 weeks. At each visit, participants complete MADRS-s for the assessment of depression severity and discuss the results with their GP in a patient-centered consultation. We have chosen to use the MADRS/MADRS-S depression rating scale in this study because it is a easy to use standard instrument especially suitable for measuring change in depressive symptoms.~The control group receives treatment as usual (no intervention)."
224182110|NCT03125902|DRUG|Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody|Atezolizumab will be administered at a dose of 840 mg via IV infusion on Days 1 and 15 (± 3 days) of every 28-day cycle.
224182111|NCT03125902|DRUG|Atezolizumab Placebo|Placebo matching to atezolizumab will be administered via IV infusion on Days 1 and 15 (± 3 days) of every 28-day cycle.
224182112|NCT03125902|DRUG|Paclitaxel|Paclitaxel will be administered at a dose of 90 mg/m\^2 via IV infusion on Days 1, 8, and 15 of every 28-day cycle.
224182113|NCT00015015|DRUG|Dichloroacetate|
224182114|NCT05353907|RADIATION|Whole Body MRI|Once recruited, the participant will undergo a WB-MRI scan as part of their usual standard-of-care. As part of the research study, the participant will be consented to undertake an additional WB-DECT research scan at a time of their choosing (on the same day as the MRI scan, or on another day, if preferred)
224182115|NCT01083615|DRUG|custirsen sodium|An antisense oligonucleotide that blocks production of clusterin
224182116|NCT01083615|DRUG|isotonic, 0.9% sodium chloride|Placebo for custirsen sodium
224182117|NCT01083615|DRUG|docetaxel|
224182118|NCT01083615|DRUG|cabazitaxel|
224182119|NCT01083615|DRUG|prednisone|
223587813|NCT03164330|BEHAVIORAL|Wellness Activities - Low Compensation|Courses are designed by the UI Wellness Center and include an Active Living class; self-paced online health challenges in physical activity, weight management, and healthy eating; a weight management class; a tobacco cessation hotline; a stress management class; a Tai Chi class; and a chronic disease management class. Low compensation for each class.
223587814|NCT03164330|BEHAVIORAL|Wellness Activities - High Compensation|Courses are designed by the UI Wellness Center and include an Active Living class; self-paced online health challenges in physical activity, weight management, and healthy eating; a weight management class; a tobacco cessation hotline; a stress management class; a Tai Chi class; and a chronic disease management class. High compensation for each class.
223587815|NCT03649009|OTHER|Normal Saline|Normal Saline 50 mls infused over 1 hour 3 times per day for total 3 days after recruitment and randomization.
224182120|NCT01681537|DRUG|Lenalidomide|
223587816|NCT03649009|DRUG|Thiamine|IV Thiamine 200 mg diluted in 50 mls normal saline infused over 1 hour 3 times per day for total 3 days after recruitment and randomization
224182121|NCT01681537|DRUG|Mitoxantrone|
224182122|NCT01681537|DRUG|Etoposide|
224182123|NCT01681537|DRUG|Cytarabine|
224182124|NCT00795938|DRUG|Sildenafil|Single Dose of 50 mg Sildenafil Oral Tablet With Water
224182125|NCT00795938|DRUG|Sildenafil|Single Dose of 50 mg Sildenafil Experimental Tablet With Water
224182126|NCT00795938|DRUG|Sildenafil|Single Dose of 50 mg Sildenafil Experimental Tablet Without Water
224182127|NCT02619461|OTHER|Exercise|Exercise at 70%VO2max on a recumbent bicycle for 30 minutes to investigate the effects of exercise at high intensities on appetite and biomarkers of appetite and inflammation.
224182128|NCT05237609|DIETARY_SUPPLEMENT|rehabilitation with muscle strengthening + Oral Nutritional Supplements|Combination of protein intake and muscle strengthening exercises for the improvement of walking capacities, patients in the experimental group
224182129|NCT05237609|OTHER|rehabilitation with muscle strengthening|Physical activity with only muscle strengthening
224182130|NCT04313894|BIOLOGICAL|Wharton Jelly Originated Mesencimal Stem Cell|In this study, the patient who has no systemic disease from Erciyes University, Obstetrics and Gynecology Department will be taken to the cord transport solution which will be medical waste after delivery. Samples for transport bacteriological tests from the transport solution to the laboratory shall be separated. They will be processed in a number of ways. The cells obtained will be administered intraarticularly at a dose of 1 x 100.000.000.
224182131|NCT05003687|DRUG|Lu AG06474|solution, orally (Parts A and B)
224182132|NCT05003687|DRUG|Placebo|solution, orally (Part A only)
224182133|NCT00072215|DRUG|cisplatin|given IV
224182134|NCT00072215|DRUG|ifosfamide|given IV
224182135|NCT00072215|DRUG|paclitaxel|given IV
224182136|NCT00072215|DRUG|vinblastine|given IV
224182137|NCT03117192|DRUG|Zinc Sulfate|Zinc supplementation in syrup form
224182138|NCT03117192|DRUG|Sucrose Syrup|Sucrose as placebo, with same taste and consistency as zinc
224182139|NCT00300989|DEVICE|Inion OTPS Biodegradable Fixation System|
224182140|NCT01078389|DRUG|Febuxostat|Febuxostat capsules
224182141|NCT01078389|DRUG|Placebo for Febuxostat|Febuxostat placebo-matching capsules
224182142|NCT00643331|BEHAVIORAL|Exercise|Exercise performed at gym and at home comprising strength, balance and impact exercise
224182143|NCT01002573|DRUG|ibuprofen|Ibuprofen, 10 mg/kg
224182144|NCT01002573|DRUG|acetaminophen|Acetaminophen, 10mg/kg
224182145|NCT00606463|DEVICE|Cardiac Ablation (Gen2 Cardiac Ablation System)|Ablation of isthmus-dependent atrial flutter
224182146|NCT00458055|DRUG|Atorvastatin; Fenofibrate; Niacin|Atorvastatin 20 mg; Fenofibrate 200 mg; Niacin 2g used sequentially for 8 weeks, after 4 weeks washout.
223587817|NCT03649009|DRUG|Hydrocortisone|If patient develop redness or rashes after normal saline infusion, IV hydrocortisone 200 mg stat will be given
223587818|NCT03649009|OTHER|Metoclopramide|If patient develop nausea after IV thiamine infusion, IV metoclopramide 10mg stat will be given. If patient develop redness or rashes after normal saline infusion, IV hydrocortisone 200 mg stat will be given.
223587819|NCT01702506|DRUG|dacomitinib fasted|Overnight fasted subjects will receive a single 45 mg dose of dacomitinib
223587820|NCT01702506|DRUG|dacomitinib fed|Subjects will receive a single 45 mg dose of dacomitinib with a high calorie high fat meal
223587821|NCT01702506|DRUG|dacomitinib+antacid|Subjects will receive a single 45 mg dose of dacomitinib when there are treated with rabeprazole
223587822|NCT04369625|BEHAVIORAL|CHIMPS-T|CHIMPS-T (Children of mentally ill parents) is a family-oriented lowfrequency brief therapy for diagnosis and treatment of mental disorders in children and adolescents.
223745471|NCT05546684|OTHER|footbath|footbath for patients before sleeping
224182147|NCT01454895|BEHAVIORAL|Sampler of hearing protection devices|In a pilot study, hearing protection devices were mailed to farmers, resulting in a significant increase in use. These results suggested that overall, HPDs were acceptable to farmers, and that access to HPDs may be an important contributor to frequency of use. The study will build on this earlier work by providing an assortment of hearing protection devices to a sub-sample of each group of farmers receiving the Interactive and Static Web Interventions. The assortment includes the most commonly used types of devices (i.e., muffs, foam plugs, pre-molded plugs, and semi-aurals). The sampler is delivered, together with manufacturers' standard written instructions for use, via mail at the designated time according study design.
224182148|NCT01454895|BEHAVIORAL|Static Web-based information|The standard information promoting HPD use delivered via Internet will be based on an informational brochure previously developed for use by farmers (i.e., Have You Heard? and They're Your Ears Protect Them). These brochures, including color graphics and text, are available on the Internet (as PDF files). Although they have been printed and distributed by NIOSH, most farmers will not have been exposed to copies. There are important differences between the SWI and IWI interventions, including interactivity, animation, explication of farmer-generated tips and techniques for addressing common barriers to hearing protector use, use of color, audio, and video, hotlinks, and farmer testimonials.
224182149|NCT01454895|BEHAVIORAL|Interactive Web-based information|This intervention includes a number of features/techniques designed to promote behavior change. Messages focus on farmer-friendly techniques for adopting use of HPDs. The factors found to be significant predictors of HPD use (Barriers to Use and Situational Factors Influencing HPD Use) are particularly relevant to farmers' learning needs, and are especially emphasized in this model-based intervention to increase hearing protector use among farmers. Participants will select the sequence of features they visit, as well as the time spent in each feature and number of visits to the site. Their patterns of use will be tracked by the enrollment and data collection systems and used in analysis.
224182150|NCT03377218|DIETARY_SUPPLEMENT|Iodine|Receiving 150 μg iodine (as potassium iodide) daily
224182151|NCT03377218|DIETARY_SUPPLEMENT|Iodine + Selenium|Receiving a combination of 150 μg iodine (as potassium iodide) and 100 μg selenium daily
224182152|NCT00211133|DRUG|epoetin alfa|
224182153|NCT03529552|PROCEDURE|Anterior Cruciate Ligament Reconstruction|Placement of an SMS bioresorbable interference screw (DEDIENNE Santé)
224182154|NCT05038007|DRUG|Liposomal bupivacaine|As prior described
224182155|NCT05038007|DRUG|Bupivacaine Hydrochloride|As prior described
224182156|NCT05631873|OTHER|Assistance with implementing Epic Smartlist|A research assistant helps GI providers add a new SmartList in to patient letters in Epic EHR that auto populates the colonoscopy recommendation time interval in patient records
224182157|NCT01822782|BIOLOGICAL|Bacteriological analysis of vaginal sample|Bacteriological analysis of vaginal sample
224182158|NCT06401902|PROCEDURE|carotid clamping|Occurrence of consciousness perturbations, language difficulties and/or contralateral motor deficit during the carotid-clamping test and requiring shunt placement.
223587823|NCT04369625|BEHAVIORAL|CHIMPS-P|CHIMPS-P is a family-oriented prevention for children and adolescents without signs of mental disorders in the initial screening. These families will receive the 3 family sessions from the modular CHIMPS intervention.
223587824|NCT04369625|BEHAVIORAL|CHIMPS-MFT-group|The CHIMPS-MFT-group is a prevention with a multi-family setting based on the CHIMPS approach. The multi-family intervention comprises 8 sessions for children and adolescents without psychiatric disorders and their families.
224182159|NCT02679560|DRUG|Liposomal Bupivacaine|A fascia iliaca compartment block using liposomal bupivacaine will require less total opioid administration compared to a fascia iliaca block using 0.2% ropivacaine
224182160|NCT02679560|DRUG|Ropivacaine HCL|Ropivacaine HCL is a member of the amino amide class of local anesthetics. Naropin injection is a sterile, isotonic solution that contains the enantiomerically pure drug substance, sodium chloride for isotonicity and water for injection. It is administered parenterally.
224182161|NCT05483062|OTHER|galla chinensis|toothpaste
224182162|NCT05483062|OTHER|Stannous fluoride|Toothpaste
224182163|NCT04325126|OTHER|Exposure factors|Exposure factors，such as diet，exercise，environment
224182164|NCT05962073|DEVICE|HFNC|High-flow oxygen therapy before intubation for preoxygenation
224182165|NCT03691831|DRUG|Active|A-101 45% (hydrogen peroxide 45% topical solution)
224182166|NCT03691831|OTHER|Vehicle|Vehicle solution containing isopropyl alcohol and water
224182167|NCT02028182|BIOLOGICAL|Lyral®|Alergen panel containing ascending doses of Lyral (0.10 mg/cm\^2, 0.20 mg/cm\^2 and 0.40 mg/cm\^2) and negative control
224182168|NCT03087682|DIAGNOSTIC_TEST|Optical Coherence Tomography (OCT)|OCT is used to measure thickness (numbers) of retinal nerve fibres in different areas of the retina
224182169|NCT03270280|DRUG|Nigella Sativa Oil|The individuals will apply 55 drops of Nigella sativa Oil on gingivae twice daily for two weeks
224182170|NCT03270280|DRUG|Normal saline|The individuals will apply 55 drops of Normal saline on gingivae twice daily for two weeks
224182171|NCT01684930|DRUG|Beetroot Juice (Beet-It Stamina Shot) & Supervised Exercise Training|The beverage is high in inorganic nitrate and bottled and supplied by James White Drinks. This supplement will be used in conjunction with supervised exercise training.
224182172|NCT01684930|OTHER|Placebo Comparator Beverage (Beet-It Stamina Shot) & Exercise Training|The beverage is identical in look and taste to Beet-It Stamina Shot but with active ingredient removed. It is also bottled and supplied by James White Drinks. This placebo supplement will be used in conjunction with supervised exercise training.
224307818|NCT06187558|PROCEDURE|Pelvic and abdominal organ suspension technique|The intervention involves a unique organ suspension technique tailored for minimally invasive gynecologic surgeries. A fragment of a Foley catheter (2 cm of a 1 Fr/Ch) is tied at the end of an absorbable 2-0 Polyglactin suture with a straight needle to create the suspension device. This suture is introduced into the pelvic cavity via an ancillary port. It's designed to penetrate organs such as the ovary, posterior peritoneum, vesico-uterine peritoneum, or bowel. Once the suture is retrieved by passing it through the abdominal wall and pulled so that the Foley segment faces the organ's surface, it's secured using a Kelly clamp. This setup eliminates the need for a knot and offers the surgeon the flexibility to adjust the suspension tension as required.
224307819|NCT00734396|PROCEDURE|Mesenchymal stem cell infusion|MSC infusion: two doses of 1-2x106 MSCs per kilogram body weight, intravenously, 7 days apart.
224307820|NCT02201212|DRUG|Everolimus|
224307821|NCT02182635|DRUG|Ba253BINEB|
224307822|NCT04881019|DEVICE|Continuous glucose monitoring|Continuous monitoring of blood sugar over a 10-day period.
224307823|NCT03292159|DEVICE|Active RAVANS concurrent with arm motor training|Patient receives non-painful, sensory-level stimulation to the skin of left outer ear, where nerve endings of the auricular branch of the vagus nerve reside, while participating in arm motor training
224307824|NCT03292159|DEVICE|Inactive RAVANS concurrent with arm motor training|Patient does not receive stimulation delivered to the skin of left outer ear while participating in arm motor training
224307825|NCT02951975|DRUG|dexamethasone intravitreal implant|Dexamethasone intravitreal implant (OZURDEX®) as prescribed in clinical practice.
224182173|NCT02198040|OTHER|Manual Therapy|"* 5 minutes. Termotherapy shalow to 50 cm away from the elbow, using a bulb of 250w.~* 15 minutes. Joint traction of elbow, in submaximal mobility amplitude with distal fixation of humerus and proximal fixation of radius and ulna in neutral position of forearm. Joint traction in I-II degree of flexion and extension submaximal of elbow.~* 15 minutes. Passive muscle stretching (within the limits of mobility).~* 15 minutes. Proprioceptive neuromuscular facilitation (PNF) of upper limb, from the abduction, flexion and external rotation of shoulder.~* 10 minutes. Local cryotherapy with ice bag and protection between it and the skin"
224182174|NCT02198040|OTHER|Educational group|"* Theory: Introduction to hemophilia: clinic and treatment; Anatomy and biomechanics of elbow; Anatomy of elbow musculature. Function of muscles and haematomas treatment; Haemarthrosis, synovitis and arthropathy: clinical manifestations and treatment; Proprioception: definition and importance in hemophilia; and Physical activity and sport: risks and benefits.~* Practice: exercises in favor of gravity; isometric and isotonic exercises of elbow; active exercises for mobility and pain management; elbow proprioception exercises; and swimming technique."
224182175|NCT00666640|DEVICE|DXA scan of hip|Dual-energy X-ray Absorptiometry scan
224182176|NCT00666640|DEVICE|CT scan of hip|Computed Tomography scan
224182177|NCT03495596|DEVICE|Videolaryngoscopy|Videolaryngoscopy device type
224307826|NCT02598856|DRUG|Intranasal (IN) naloxone 1x|Administered as 100 μl 14.0 mg/ml (1.4 mg naloxone) by Aptar Unitdose device as one puff in one nostril
224307827|NCT02598856|DRUG|Intranasal (IN) naloxone 2|Administered as 2x 100 μl 14 mg/ml (2.8 mg naloxone) by Aptar Unitdose device as two puffs within the same nostril with 3 minutes interval
224307828|NCT02598856|DRUG|Intravenous (IV) naloxone|Administered as 1 ml Naloxon B Braun 0.4 mg/ml (0.4 mg naloxone), in an intravenous cannula in the opposite arm of which the blood samples are drawn from. IV bolus will be given rapidly (in less than 5 seconds)
224182178|NCT01760317|PROCEDURE|Midline vs Parasagittal Lumbar Epidural Steroid Injection|
224182179|NCT04524663|DRUG|Camostat Mesilate|Camostat Mesilate administered as oral tablets
224182180|NCT04524663|DRUG|Placebo|Placebo to match camostat mesilate
224182181|NCT04524663|OTHER|Standard of Care Treatment|Standard of Care Treatment for COVID-19 Infection
224182182|NCT03961984|PROCEDURE|Biodesign® anal fistula plug|Patient in general anesthesia and lithotomy position. Mucosa excision of the internal fistula opening is performed. The plug was prepared in 0.9% sodium chloride, and secured to the endoluminal brush by a suture with a 2-0 vicryl tie. The narrow end of the of the plug was then pulled through the internal opening into the fistula tract. The plug was pulled until it covered the whole length of the fistula and blocked the internal opening, the excess plug material coming out through the external opening. The plug was fixed at the internal opening by reabsorbable 3-0 sutures. Special attention was paid to ensuring that the plug was covered by mucosa when closing the internal opening. The excess plug material was trimmed by the external opening that was left open for drainage.
224182183|NCT00175110|BEHAVIORAL|herbal therapy/botanical therapy (Hibiscus sabdariffa)|
224182184|NCT00435266|PROCEDURE|Remote ischemic preconditioning|Inflation of blood pressure cuff 4 x 5 minutes during transportation to primary PCI
224182185|NCT00337935|DRUG|Epoetin Alfa|Epoetin alfa administered at 20,000 IU subcutaneously every 2 weeks for a period of 26 weeks
224182186|NCT00337935|OTHER|Standard of care|
224182187|NCT00915421|PROCEDURE|Induction of therapeutic mild hypothermia|Rapid administration of 4°C cold normal saline to the peripheral vein, dose 5 - 30 ml/kg, to decrease body core temperature below 34°C
224182188|NCT02974764|OTHER|No intervention/exposures|
224182189|NCT01986179|OTHER|Telephone Interpretation|Professional interpretation provided over the phone by a national network of certified medical interpreters
224182190|NCT01986179|OTHER|Video Interpretation|Professional interpretation provided over video by a national network of certified medical interpreters
224182191|NCT01823575|DEVICE|Silicone-covered metallic stent|deployment of silicone-covered metallic stent for malignant ureteral obstruction as a new therapy as compared with placement of double-J stent as a conventional therapy
224182192|NCT01823575|DEVICE|Double-J stent|Placement of double-J stent as a conventional treatment to be compared with a new experimental treatment - deployment of silicone-covered metallic stent
224182193|NCT02873806|PROCEDURE|Implantation of two iStent inject micro-bypass stents|\- Implantation of two trabecular micro-bypass stents (iStent inject) in a standalone procedure (i.e., without cataract surgery).
224182194|NCT02873806|DRUG|Topical travoprost|\- Topical travoprost (0.004%, 1 drop each evening in study eye) started on postoperative Day 1.
224182195|NCT02873806|DEVICE|Two iStent inject micro-bypass stents|\- Two trabecular micro-bypass stents (iStent inject) implanted in a standalone procedure.
224182196|NCT02873806|DRUG|Tobramycin|"Topical antibiotic (tobramycin):~1 drop four (4) times per day in the study eye for one week (in cases of allergy or contraindication, Polytrim (polymyxin B sulfate + trimethoprim sulfate ophthalmic solution, USP, or equivalent) may be used as an alternative medication) ."
224182197|NCT02873806|DRUG|Dexamethasone|"Topical anti-inflammatory medication (dexamethasone ophthalmic suspension 0.1%):~* Week 1: 1 drop four (4) times per day in the study eye~* Week 2: 1 drop three (3) times per day in the study eye~* Week 3: 1 drop two (2) times per day in the study eye~* Week 4: 1 drop one (1) time per day in the study eye"
224182198|NCT03798652|DEVICE|Research CMR scan|CMR scanning at a 3Tesla scanner at King's College London
224182199|NCT03798652|DEVICE|Research 3D transthoracic echocardiogram|The scan is required to assess left ventricular systolic function
224182200|NCT03798652|OTHER|6-minute walk test|Sub maximal exercise that provides a measure for integrated global response of multiple cardiopulmonary and musculoskeletal systems involved in exercise.
224307829|NCT02598856|DRUG|Intramuscular (IM) naloxone|Naloxone administered as 2 ml Naloxon B Braun 0.4 mg/ml (0.8 mg naloxone) in a Braun Omnifix 2.5 ml syringe using a BD Microlance 3 21G (green) 0.8x40 mm needle in the deltoid muscle of the non-dominant arm
224307830|NCT00519688|DRUG|Thalidomide|100 mg, BID
223490517|NCT05325281|DRUG|CPI-613® Maximum Tolerated Dose (MTD)|MTD will be determined by testing increasing doses of CPI-613®, starting from 500 mg/m\^2 and up to 1,500 mg/m\^2, on dose escalation cohorts of three patients (maximum 24 patients) in combination with Gem-RT therapy. MTD reflects the highest drug dose that does not cause unacceptable adverse effects, with a target dose-limiting toxicity (DLT) rate of 30%. Final dose will be revised as appropriate.
223490518|NCT05325281|DRUG|Gemcitabine|Subjects will be administered 400 mg/m\^2 gemcitabine once per week by IV infusion over approximately 30 minutes for six weeks.
223490519|NCT05325281|RADIATION|Intensity-modulated Radiation Therapy|1.8 Gy per fraction, 5 fractions per week, 30 fractions total (54 Gy) across six weeks.
223490520|NCT03133156|OTHER|Exercise Intervention|10-Week Aerobic Exercise Training
223490521|NCT05633654|DRUG|Sacituzumab govitecan-hziy (SG)|Administered intravenously
223490522|NCT05633654|DRUG|Pembrolizumab|Administered intravenously
224182201|NCT00033683|DRUG|CMF regimen|
224182202|NCT00033683|DRUG|cyclophosphamide|
224182203|NCT00033683|DRUG|docetaxel|
224182204|NCT00033683|DRUG|epirubicin hydrochloride|
224182205|NCT00033683|DRUG|fluorouracil|
223490523|NCT05633654|DRUG|Capecitabine|Tablets administered orally
223490524|NCT06543576|BIOLOGICAL|Bevacizumab|Given IV
224182206|NCT00033683|DRUG|methotrexate|
224182207|NCT00033683|DRUG|tamoxifen citrate|
224182208|NCT00033683|PROCEDURE|adjuvant therapy|
224182209|NCT00033683|RADIATION|radiation therapy|
224182210|NCT00711009|DRUG|lopinavir/ritonavir (LPV/r)|LPV/r 400/100 mg BID
224182211|NCT00711009|DRUG|emtricitabine/tenofovir disoproxil fumarate (FTC/TDF)|FTC/TDF 200/300 mg QD
224182212|NCT00711009|DRUG|raltegravir (RAL)|RAL 400 mg BID
224182213|NCT03359811|DRUG|Local Anesthetic Solution|A bolus or infusion of local anesthetic solution with or without the addition opioids given before surgical incision according to anesthesia provider's clinical judgment.
224307831|NCT00519688|DRUG|Tegafur/Uracil|125 mg/m2, based on tegafur, BID
224182214|NCT03359811|DRUG|Bupivacaine HCl|30 mg of Bupivacaine HCl in 10 cc of preservative free normal saline (PFNS) injected before surgical incision in each of the four quadrants.
224182215|NCT03359811|DRUG|Liposomal Bupivacaine|65 mg of Liposomal Bupivacaine in 10 cc of PFNS injected before surgical incision in each of the four quadrants.
224182216|NCT06187454|DEVICE|Active Transcranial direct current stimulation|Transcranial direct current stimulation (tDCS) is a method for noninvasive brain stimulation, where a weak electrical current is delivered through two scalp electrodes by a portable battery-powered stimulator.
224182217|NCT06187454|DEVICE|Sham Transcranial direct current stimulation|For sham tDCS, the electrode positions and stimulation parameters will be the same as that used for anodal stimulation except that the current will be delivered only for the initial 30 seconds.
224182218|NCT05944731|DEVICE|Continuous glucose monitor|Continuous Glucose Monitoring (CGM) device is a small electronic tool that you put on your skin, and it tells you the amount of glucose in your body. It is different from a finger prick glucose machine in that you do not need to prick your finger to get some blood to put on the reader paper like you have to do for a finger prick glucose machine.
224182219|NCT04054531|BIOLOGICAL|KN046|IV infusion
224182220|NCT04054531|DRUG|Paclitaxel|IV infusion
224182221|NCT04054531|DRUG|Pemetrexed|IV infusion
224182222|NCT04054531|DRUG|Carboplatin|IV infusion
224182223|NCT01062230|DRUG|Bortezomib (Velcade)|"Bortezomib will be administered as a 3-5 second bolus IV injection at the dose of 0.7 mg/m2 on days 1, 4, 8, and 11 q. 21 days times three cycles.~Patients will undergo three 21-day cycles."
224182224|NCT05588622|BEHAVIORAL|Meru Health Program|The Meru Health Program is a 12-week, evidence-based, smartphone-delivered, therapist-supported digital mental health intervention with as-needed psychiatrist oversight. Enrolled participants work through the program with a cohort of peers similarly affected by depression, with whom they can engage in confidential, anonymous, voluntary group chats overseen by a licensed clinical therapist. The MHP incorporates a continuous care model including daily interaction with a dedicated clinician, several evidence-based treatment components such as cognitive behavioral therapy (CBT), behavioral activation therapy, and mindfulness meditation (MM), as well as promising newer types of depression treatments such as HRVB, nutritional psychiatry, and sleep training. Practices are introduced to weekly topics via video lessons that are reinforced via CBT practices, meditations, and biofeedback sessions and therapist messaging.
224182225|NCT03937882|DRUG|RGN-259|A preservative-free, sterile eye drop solution containing Thymosin beta 4 for direct instillation into each eye, four times a day (QID) for 14 days
224182226|NCT03937882|DRUG|Placebo|It is composed of the same excipients as RGN-259 but does not contain Thymosin beta 4
224182227|NCT02025127|OTHER|Enteral nutrition|Enteral nutrition introduced via a feeding tube
224182228|NCT01437982|DRUG|Loteprednol Etabonate|Ocular administration of study drug. at least once within any indication of the label.
224182229|NCT01437982|DRUG|Prednisolone Acetate 1% Oph Susp|Ocular administration of study drug. at least once within any indication of the label.
223490525|NCT06543576|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223490526|NCT06543576|RADIATION|Brachytherapy|Undergo brachytherapy
224182230|NCT05106101|DRUG|L-glutamine|L-glutamine oral powder in 5 gram packet
224182231|NCT00511966|OTHER|Non-Pharmacologic Treatment|Non-Pharmacologic Treatment
223490527|NCT06543576|DRUG|Cisplatin|Given IV
223490528|NCT06543576|RADIATION|External Beam Radiation Therapy|Undergo EBRT
224182232|NCT00511966|DRUG|Rabeprazole|As prescribed
224182233|NCT01682876|BIOLOGICAL|MenACWY-CRM|The investigational meningococcal (groups A, C, Y, and W-135 vaccine) oligosaccharide diphtheria CRM197 conjugate vaccine (MenACWY-CRM) was administered intramuscularly in the nondominant arm
224182234|NCT00578331|DRUG|Olopatadine 0.6% nasal spray|2 sprays each nostril twice daily
224182235|NCT00578331|DRUG|Placebo Nasal Spray|2 sprays each nostril twice daily
224182236|NCT06345573|BEHAVIORAL|Mental stress|Two consecutive validated mental stress tests, namely 1) the Montreal Imaging Stress Task consisting of two series of 15-minute mental calculation tests, without (Control Mode) and with (Stress Mode) negative feedback, respectively; and 2) the Trier Social Stress Test consisting of a 5-minute mock job interview (Speech Part) followed by a 5-minute mental calculation test (Mental Arithmetic Part).
224182237|NCT03852901|DRUG|empagliflozin (Jardiance) 25 mg|Oral empagliflozin 25 mg/day x 14 days
224182238|NCT03339440|BEHAVIORAL|Hearts & Parks|The Hearts \& Parks intervention will be looking to evaluate how different types of physical activity and nutrition education and support (in addition to normal clinical care) through attendance and participation in the Duke Healthy Lifestyles/Bull City Fit clinic/community program, affect children's health. The investigators will be looking at changes in BMI, physical activity, nutrition and overall health.
224182239|NCT03726840|OTHER|Fragrance|peppermint, rosemary, and zest/pulp will increase memory recall for navigation and improve reaction times for braking, compared to performance during unscented conditions
224182240|NCT01872663|PROCEDURE|Continuous positive airway pressure|The use of positive pressure airway seeking the prevention or treatment of hypoxic respiratory failure, improved arterial oxygenation, restoration or maintenance of lung volume reduction and atelectasis, decrease the work of breathing, decreased dyspnea index and increased residual volume.
224182241|NCT01872663|PROCEDURE|Incentive spirometry|The volume of incentive spirometry (Voldyne ®) is able to provide increased transpulmonary pressure gradient, which can prevent or reverse atelectasis.
224182242|NCT01872663|PROCEDURE|Breath Stacking|The method allowed to obtain a maximum lung expansion with minimal patient compliance.
223490529|NCT06543576|DRUG|Paclitaxel|Given IV
223490530|NCT06543576|BIOLOGICAL|Pembrolizumab|Given IV
223490531|NCT06543576|OTHER|Questionnaire Administration|Ancillary study
223490532|NCT05144503|DEVICE|SpherePVI™ Catheter|SpherePVI™ Catheter with the Affera Mapping and Ablation System
223490533|NCT05315700|DRUG|ORIC-114|ORIC-114 oral daily
223490534|NCT05315700|DRUG|Chemotherapy drug|21 days for up to 4 cycles
223587825|NCT04369625|BEHAVIORAL|iCHIMPS|iCHIMPS is an online intervention. In terms of content, iCHIMPS is based on the CHIMPS program as well as on other evidence-based interventions of the study group. iCHIMPS will also be comprised of one module for children and adolescents as well as one module for parents; moreover; modules for the family system will be included.
224182243|NCT01872663|PROCEDURE|Expiratory Positive Airway Pressure|The use of positive pressure airway seeking the prevention or treatment of hypoxic respiratory failure, improved arterial oxygenation, restoration or maintenance of lung volume reduction and atelectasis, decrease the work of breathing, decreased dyspnea index and increased residual volume.
224182244|NCT01872663|PROCEDURE|Intermittent positive pressure breathing|The use of positive pressure airway seeking the prevention or treatment of hypoxic respiratory failure, improved arterial oxygenation, restoration or maintenance of lung volume reduction and atelectasis, decrease the work of breathing, decreased dyspnea index and increased residual volume.
224182245|NCT01872663|PROCEDURE|Bi-level positive airway pressure|The use of positive pressure airway seeking the prevention or treatment of hypoxic respiratory failure, improved arterial oxygenation, restoration or maintenance of lung volume reduction and atelectasis, decrease the work of breathing, decreased dyspnea index and increased residual volume.
224182246|NCT02534324|DRUG|Antihypertensive meds|Antihypertensive medications will be given to newly-diagnosed or non-compliant cases. The additional oral antihypertensive drugs instruction to adjust their current regimens will be given to the patients with underlying hypertension for more BP control. The choices of drugs will be at discretion of treating physicians.
224182247|NCT01459016|OTHER|PET scan using florbetapir|A single intravenous microdose of 260 MBq (7 mCi) 18F-AV-45 (florbetapir F 18) will be administered.
224182248|NCT01459016|OTHER|MRI Scan|Three different measurements will be taken: volumetric MRI (vMRI), diffusion tensor imaging (DTI), and resting state functional MRI (rsfMRI). In addition, radiological MRI scans will be taken to monitor vasogenic edema and microhemorrhages.
224182249|NCT01738516|PROCEDURE|Electroencephalography|Epileptic patients, as in healthy volunteers will be offered a review of EEG recording equipment resting on EEG-HR 256-channel EGI © in operation since January 2012 in the Van Gogh Service Unit of Neurology Rennes University Hospital (hospital Pontchaillou). The EEG is a routine now included in the Phase I report some epileptic patients during presurgical investigation. Patients to be included in this research protocol pass all review on the new device EEG-HR 256 channels. In addition to the rest condition, shared by both groups of participants, the healthy control subjects participate in two additional experimental tasks to be performed during recording. A picture naming task and a task of spelling words represented by these images.
224182250|NCT01738516|PROCEDURE|Electroencephalography and additional experimental tasks|Epileptic patients, as in healthy volunteers will be offered a review of EEG recording equipment resting on EEG-HR 256-channel EGI © in operation since January 2012 in the Van Gogh Service Unit of Neurology Rennes University Hospital (hospital Pontchaillou). The EEG is a routine now included in the Phase I report some epileptic patients during presurgical investigation. Patients to be included in this research protocol pass all review on the new device EEG-HR 256 channels. In addition to the rest condition, shared by both groups of participants, the healthy control subjects participate in two additional experimental tasks to be performed during recording. A picture naming task and a task of spelling words represented by these images.
224182251|NCT02056808|DRUG|SMT C1100|Comparison of safety and pharmacokinetic of different dosages of drug
224182252|NCT03163823|OTHER|Proloquo2Go|Use of communication application Proloquo2Go modified for the ICU setting on an iPad device
224182253|NCT03163823|OTHER|Standard of Care|Standard of Care communication methods
224182254|NCT04011514|BEHAVIORAL|Dedicated stroke nurse care in ED|A specialized SU nursing team partner with ED nursing staff for timely fulfillment of stroke quality care indicators while awationg admission to a dedicated stroke unit
224182255|NCT02874755|OTHER|Tuberculosis Program|The intervention includes a variety of (1) non-financial incentives that are intended to reduce clinical and financial costs for presumptive TB patients and TB cases for diagnostic testing and treatment (free digital chest X-ray, free sputum microscopy, free or subsidized drug-susceptibility testing, free first-line anti-TB treatment) within the PPIA network, and (2) training or certified medical education (CME) sessions for the providers from the PPIA. Meanwhile, program marketing, CMEs, and other advocacy efforts are aimed to raise awareness in the communities.
224182256|NCT03616652|DRUG|Placebo|Placebo pill
224182257|NCT03616652|OTHER|Film sequence|The experimental group watches a film about the power of placebo effects.
223490535|NCT06615258|BEHAVIORAL|Dynamic Neuromuscular Stabilization based breathing training and pelvic floor muscle training|"DNS-based breathing exercises will be taught to the women in this group using tactile biofeedback. To create tactile stimulation, one of the hard sponges placed within a belt will be positioned anteriorly in the inguinal region, and the other posteriorly in the Grynfeltt-Lesshaft triangle region. Breathing training will be provided in 3 different positions: sitting, crawling, and happy baby pose.~Pelvic floor muscle training: PFME will consist of 2 parts: relaxation training for pelvic floor muscles and pelvic floor muscle exercises.~Pelvic floor muscles will be given relaxation training in 3 different relaxation positions (modified butterfly pose, child pose and deep squatting position) suggested by Çeliker Tosun et al. PFME will be taught by the physiotherapist in the side-lying with external coccyx palpation. PFME will be applied in the hook-lying position, sitting position and standing position."
224182258|NCT03616652|OTHER|Film sequence|The control group watches a film about sleep.
224182259|NCT00852800|DRUG|Albumin|1.5 g/kg IV on day 1 and 1 g/kg IV on day 3 with saline solution to complete total volume of 1000 ml on day 1 and 500 ml on day 3. Infusion in 4 hours.
224182260|NCT00852800|DRUG|Albumin|1 g/kg IV on day 1 and 0.5 g/kg IV on day 3 with saline solution to complete total volume of 1000 ml on day 1 and 500 ml on day 3. Infusion in 4 hours.
224182261|NCT03442270|OTHER|No Intervention|This is an observational study, so standard of care will be followed.
223490536|NCT06615258|BEHAVIORAL|Pelvic floor muscle training|Pelvic floor muscle training: PFME will consist of 2 parts: relaxation training for pelvic floor muscles and pelvic floor muscle exercises. Pelvic floor muscles will be given relaxation training in 3 different relaxation positions (modified butterfly pose, child pose and deep squatting position) suggested by Çeliker Tosun et al. PFME will be taught by the physiotherapist in the side-lying with external coccyx palpation. PFME will be applied in the hook-lying position, sitting position and standing position.
223490537|NCT04565054|DRUG|Abemaciclib 50 MG; 150mg 1-0-1 per os|Experimental: Abemaciclib plus ET Abemaciclib 150 mg, 2 x daily, resulting in 300 mg/day, oral, 24 months plus endocrine treatment of physician´s choice
223490538|NCT04997902|DRUG|Tipifarnib|Oral administration
223490539|NCT04997902|DRUG|Alpelisib|Oral administration
223490540|NCT05748626|DEVICE|Anti-snoring device|For group 1, the study team will aid the subject in molding and preparing the device in the pre-operative area. They will wear the device throughout the entirety of the case.
223490541|NCT05748626|PROCEDURE|No anti -snoring device during their procedure.|For group 2 there will be no anti snoring device used during the case.
224182262|NCT05423275|DEVICE|Negative ion therapy|Negative ion generator
224182263|NCT05423275|DEVICE|Light therapy|Fluorescent light box
224182264|NCT02497274|OTHER|taste assessment and epithelium gustatory smear and biopsy|assessment of taste perceptions and expression of taste receptors before and after bariatric surgery and epithelium gustatory smear and biopsy
224182265|NCT00919620|BEHAVIORAL|stage-specific case-management|Stage-specific case-management for psychosis by designated key-workers according to specified protocol
224182266|NCT00240331|DRUG|10mg Rosuvastatin|
224182267|NCT00240331|DRUG|Placebo|
224182268|NCT02415491|OTHER|Correlation Heart Magnetic Resonance Imaging at rest and stress with Cardiopulmonary stress test|"MRI of the heart, coronary arteries and pulmonary artery at rest and stress induced will be performed. Cine pictures are taken for evaluation of pulmonary perfusion.~Afterwards induced stress MRI will be performed according to standard protocol with elevation of dobutamine levels until the reach of peak HR. If applicable the procedure will be stopped) in case of e.g. arrhythmia.~Cardiopulmonary exercise stress test will be performed; patient will sit at rest on the ergometer, the subject's gas exchange will be recorded; with the pedal speed constant, the resistance will be increased from 0.5 watt/kg to 3 watt/kg over 10 minutes. Electrocardiography and heart rate will be taken continuously during and until 10 minutes afterwards. Blood pressure will be taken before, during and after the stress test. Respiratory gas exchange parameters will be taken continuously, peak oxygen uptake (VO2) determined as well as Ventilatory Efficiency."
224182269|NCT05647174|PROCEDURE|MGPOCUS-assisted bronchoscope-guided intubation|Application of ultrasound instruments that can detect magnetic signals to determine the position of the magnetised bronchoscopy to guide the direction of its advancement and thus optimise difficult endotracheal intubation.
224182270|NCT05647174|PROCEDURE|Bronchoscope-guided intubation|Routine bronchoscope- guided intubation.
224182271|NCT05821166|DEVICE|moderate Whole Body Hyperthermia (mWBH)|Patients receiving 3-4 times mWBH
224182272|NCT00620126|OTHER|UC Home Automated Telemanagement|Weekly assessment with UC Home Automated Telemanagement
224182273|NCT00620126|OTHER|Best Available Care|Routine follow up visits and as needed telephone calls and clinic visits, written action plans, educational fact sheets from the CCFA
224182274|NCT02850757|DEVICE|U shaped Guedl's airway|To use U shaped Guedl's airway for assisting fiberoptic bronchoscope during endotracheal intubation
223490542|NCT05307250|BEHAVIORAL|Multiple Family Groups for HIV stigma reduction (MFG-HIVSR) plus FEE|"In addition to the BSOC, ALHIV and their caregivers will participate in a family strengthening intervention plus a family economic empowerment intervention.~MFG is an evidence-based family-centered, group-delivered, evidence-informed, strength-based 10-session (weekly) intervention for children whose families struggle with poverty. Six additional sessions covering HIV stigma stigma-related issues will be added.~ALHIV will receive a YDA with a 1:1 matched savings program at a financial institution accredited by the Bank of Uganda. Each YDA will be opened in the name of the adolescent, with their primary caregiver as a co-signer, until the adolescent turns 18 years. The account will then be matched with money from the program on 1:1 rate."
223490543|NCT05307250|BEHAVIORAL|Multiple Family Groups for HIV stigma reduction (MFG-HIVSR) plus FEE plus Group-based stigma reduction for educators (GED-HIVSR).|In addition to BSOC and MFG-HIVSR+FEE, ALHIV in this arm will receive the school-level HIV stigma reduction intervention targeting teachers, school nurses, matrons, and administrators (headteachers, director of studies) in their schools. GED-HIVSR seeks to impart educators in the intervention schools with HIV related knowledge, provide a safe space for educators to explore their personal values and bias that may promote or hinder their role of supportive individuals and systems for ALHIV, and empower them with knowledge and skills to act as change agents within their schools.
223490544|NCT05307250|OTHER|Bolstered Standard of Care (BSOC)|All participants (in control and treatment arms) will receive medical and psychosocial support as part of the BSOC. 1) Medical SOC: All public clinics, including our study sites, follow procedures for pediatric ART initiation and monitoring, as outlined in the National Department of Health Guidelines for pediatric HIV care in Uganda. Specifically, immediately after initiation, or if clinically unstable, ALHIV are seen more frequently (weekly to monthly). Laboratory data (VL and CD4 counts) are collected every six months until the patient is stabilized and then annually, using the National Health Laboratory Service standardized protocol. A
223745472|NCT04014257|DRUG|NOV1601(CHC2014)|a highly selective pan-TRK(tropomyosin receptor kinase) inhibitor targeting tropomyosin receptor kinase A (TRKA), tropomyosin receptor kinase B(TRKB), and tropomyosin receptor kinase C(TRKC)
223745473|NCT03072966|DEVICE|Wearable device (Fitbit Charge HR® or Fitbit Alta ®)|Physical activities will be monitored by wearable device.
223745474|NCT05714111|OTHER|Radiology evaluations and interventions|Diagnostic and interventional radiology procedures
224182275|NCT02850757|DEVICE|Modified William's airway|Use Modified William's airway for assisting fiberoptic bronchoscope dduring endo tracheal intubation
224182276|NCT00784225|DRUG|selenium|200 mcg daily for 7-12 years
224182277|NCT00784225|DRUG|vitamin E|400 IU daily by mouth for 7-12 years
224182278|NCT00784225|DRUG|vitamin E placebo|daily for 7-12 years
224182279|NCT00784225|DRUG|selenium placebo|daily for 7-12 years
224182280|NCT00303004|DRUG|Bosentan and Sildenafil|
224182281|NCT02354040|BEHAVIORAL|Talking Rx|For patients in the intervention group, the physician written prescription for anti-platelet and statin will be transferred on an OMR sheet and will be scanned. The information on the prescription (dose, name of the medication, duration, route or any other special instruction) will be sent to the patients via a text and a voice SMS (in Urdu language). The patients also receive an individualized code that helps them request for repeated reminders for their medication timings. However, a weekly medication reminder SMS will be sent to the patients in the intervention arm.
224182282|NCT06372158|DIETARY_SUPPLEMENT|Stage 1|Number 1-10 :General vitamin C powder group (Contains 1500 mg Ca); Number 11-20: liposomal encapsulation Ca powder group (Contains 1500 mg of Ca and lecithin and is coated)
223745475|NCT03893552|DEVICE|Negative expiratory pressure|Using a cough assist, a negative expiratory pressure will be applied while recording the respiratory flow in patients suffering from sleeping disorders or snoring.
223745476|NCT02943733|DRUG|TAS-102|Anti-metabolite agent, taken orally.
223745477|NCT02943733|DRUG|Temozolomide|Oral chemotherapy drug.
223490550|NCT05748990|DRUG|Intranasal insulin|160 IU insulin (Humalog) is administered intranasally using a metered spray bottle 15 minutes prior to the PET scan.
223490551|NCT05748990|DRUG|Placebo|0.9% saline is administered intranasally using a metered spray bottle 15 minutes prior to the PET scan.
223490552|NCT06226051|DEVICE|PEAPOD Infant Body Composition measuring device|PEAPOD is a device to that collects body composition measurements.
223490553|NCT06375733|DRUG|GFH009|administered as an IV infusion at the dose levels 75mg, 60mg, and/or 100mg QW.
223490554|NCT06375733|DRUG|Zanubrutinib|administered at 160mg BID oral; 28-day a cycle until disease progresses.
224182283|NCT06372158|DIETARY_SUPPLEMENT|Stage 2|Number 11-20 :General vitamin C powder group (Contains 1500 mg Ca); Number 1-10: liposomal encapsulation Ca powder group (Contains 1500 mg of Ca and lecithin and is coated)
224182284|NCT02491463|BIOLOGICAL|GSK3389245A_LD GROUP|2 doses administered intramuscularly at Day 0 and Day 30 in the deltoid region of the non-dominant arm
224182285|NCT02491463|BIOLOGICAL|GSK3389245A_HD GROUP|2 doses administered intramuscularly at Day 0 and Day 30 in the deltoid region of the non-dominant arm
224182286|NCT02491463|BIOLOGICAL|Bexsero|2 doses administered intramuscularly at Day 0 and Day 30 in the deltoid region of the non-dominant arm
224182287|NCT02491463|DRUG|Placebo|2 doses administered intramuscularly at Day 0 and Day 30 in the deltoid region of the non-dominant arm
224182288|NCT01491802|DRUG|LAMA/LABA|GSK573719/GW642444 inhalation powder used in the Novel Dry Powder Inhaler (DPI): a long-acting beta2-agonist (GSK642444, 25mcg) with a long-acting muscarinic antagonist (GSK573719, 125mcg) combination therapy will be taken once daily for 4 weeks.
224182289|NCT01491802|DRUG|LAMA|GSK573719 (125mcg) inhalation powder is a long-acting muscarinic antagonist that will be taken once daily for 4 weeks
224182290|NCT04340102|BEHAVIORAL|BecomeAnEx|This research study is focused on a smoking cessation program called BecomeAnEx. We are studying how to adapt BecomeAnEx for people with a mental health disorder who want to reduce or quit their tobacco smoking. BecomeAnEx includes a website that provides education about smoking and quitting. It also has a text messaging program that delivers personalized information. Persons in the program have access to real-time digital coaching with a remote coach who has experience helping people quit smoking. In addition, the program has an on-line community of current and former smokers that can provide support and encouragement.
224182291|NCT03993314|DRUG|Chloroprocaine|Adding 5 cc 1% Chloroprocaine with 10 cc sterile saline in the epidural
224182292|NCT03993314|DRUG|Bupivacaine|1 cc of 0.5% bupivacaine with 15 mcg fentanyl 10 cc of sterile saline in the epidural
224182293|NCT00884195|BEHAVIORAL|Gratitude Journaling|Participants will be asked to write down 5 things every day for which they are grateful.
224182294|NCT00884195|BEHAVIORAL|Neutral Journaling|Participants will be asked to write down 5 things every day that they noticed about being involved in a weight loss program.
224182295|NCT02647021|BEHAVIORAL|Therapeutic Exercise|A specialized therapeutic exercise program to address neck and shoulder dysfunction due to spinal accessory nerve damage.
223490555|NCT06375733|DRUG|GFH009|the RP2D of GFH009 defined in the preliminary phase 1b trial with the same schedule as in the phase Ib.
223490556|NCT06375733|DRUG|Zanubrutinib|administered at 160mg BID oral; 28-day a cycle until disease progresses.
223490557|NCT05457985|BEHAVIORAL|Prolonged Exposure for Primary Care (PE-PC)|Treatment follows the standardized PE-PC manual and workbook.PE-PC consists of four weekly 30-minute sessions. In vivo and imaginal exposure are introduced at the first session and reviewed at Sessions 2-4. To conduct in vivo exposure, participants repeatedly and systematically approach objectively safe people, places, objects, and situations that they avoid because these stimuli remind them of their trauma. At the 4th session or 9-week assessment point (whichever comes first), early responders will step down to every-other-week sessions for the duration of the second stage.
223490558|NCT05457985|BEHAVIORAL|Full Prolonged Exposure|Treatment will follow the standardized PE manual. Participants will have 60 minute sessions once a week for eight weeks During these sessions, participants will practice in vivo, imaginal, and emotional exposure as well as continue these exposure exercises every day at home.
224182296|NCT02647021|BEHAVIORAL|Therapeutic + Lower Body Exercise|A combined therapeutic exercise program (as per the comparison arm) plus the addition of lower body resistance exercise
224182297|NCT05596695|OTHER|Minimizing blood pressure variability|Intraoperative blood pressure management will be performed to maintain a systolic blood pressure of 120 ±5mmHg using a continuous infusion of a vasopressor starting at induction of anaesthesia.
224182298|NCT03500302|DRUG|Evolocumab|Evolocumab sq once a month for a total of two doses
224182299|NCT03112759|BEHAVIORAL|Cognitive Behavioral Therapy|Cognitive behavioral therapy (CBT) uses pain coping skills as a method of managing symptoms associated with chronic pain.Cognitive behavioral therapy teaches patients to identify and modify negative thoughts and behaviors that increase pain intensity, distress, and pain-related disability
224182300|NCT04957706|DIAGNOSTIC_TEST|anterior drawer test at 90° of hip flexion|anterior drawer test at 90° of hip flexion
223745478|NCT02943733|DRUG|Filgrastim|Filgrastim provides growth factor support in multiple doses. It stimulates bone marrow to create neutrophils for patients undergoing chemotherapy.
224182301|NCT04957706|DIAGNOSTIC_TEST|Lachman test|Lachman test
224182302|NCT04957706|DIAGNOSTIC_TEST|anterior drawer test|anterior drawer test
224182303|NCT04957706|DIAGNOSTIC_TEST|pivot-shift test|pivot-shift test
224182304|NCT05681975|DIAGNOSTIC_TEST|Food-specific Immunoglobulin G4 and/or Immunoglobulin E antibody reactions|Immunoassay kits (NutriSMART® and Fastcheckpoc20® In-Vitro Diagnostic kits, DST GmbH, Schwerin, Germany) are performed in a population with suspicion of having a food allergy or a food intolerance with related symptoms.
224182305|NCT03108352|DRUG|Conbercept ophthalmic injection|Conbercept ophthalmic injection at a dose of 0.5 mg every month(day0-month 5); If sbujects meets the criteria for repeated administration, the subject receives 0.5 mg Conbercept injection into the study eye (Month 6 \~ 11)
224182306|NCT03108352|OTHER|sham/Conbercept ophthalmic injection|Sham injection every month (Day 0 - Month 5); 0.5 mg Conbercept ophthalmic injection in month 6; If sbujects meets the criteria for repeated administration, the subject receives 0.5 mg Conbercept injection into the study eye (Month 7 \~ 11)
224182307|NCT02010099|DRUG|PP110 Gel|
223490559|NCT05457985|BEHAVIORAL|Clinician Supported PTSD Coach App|This is a brief psychotherapy that uses the PTSD Coach mobile app developed by the study team. The PTSD Coach app incorporates evidence-based assessment, psychoeducation, and cognitive behavioral therapy and self-management strategies that are customizable to the user.
223490560|NCT06620510|BIOLOGICAL|Immuncell-LC|Activated T lymphocyte
223490561|NCT06620510|BIOLOGICAL|No Interventions|Patients who were in non-treatment group in phase 3 clinical trial IIC-I01(NCT00699816).
223490562|NCT06523634|RADIATION|Stereotactic body radiotherapy (SBRT)|5 fractions of SBRT to the prostate bed with or without whole pelvic radiotherapy Treatment every other day.
223490563|NCT06523634|RADIATION|SOC RT|"Standard salvage radiotherapy to the prostate bed with or without whole pelvic radiotherapy. Each participating centre can specify upfront which RT schedule will be used in the control arm, with the choice between the following schedules:~* Hypofractionated: 20 fractions (Daily treatment (OTT 4-5 weeks))~* Normofractionated: 32-35 fractions (Daily treatment (OTT 7-8 weeks))"
223745479|NCT02943733|DRUG|Pegfilgrastim|Pegfilgrastim provides growth factor support in a single dose. It stimulates bone marrow to create neutrophils for patients undergoing chemotherapy.
223490564|NCT02990793|DEVICE|Active MeRT Treatment|A personalized biometrics-guided protocol known as magnetic EEG/ECG resonance therapy (MeRT) treatment that is tailored specifically to each participant's EEG intrinsic alpha frequency (IAF). rTMS is applied at the participant's IAF.
223490565|NCT02990793|DEVICE|Sham MeRT Treatment|rTMS coil does not emit magnetic stimulation.
223490566|NCT05986188|OTHER|Pathways to Potential|Pathways to Potential stations MDHHS caseworkers, called success coaches, in local elementary, middle, and high schools. After identifying a social or material need that is a barrier to school attendance (e.g., transportation barriers, caregiver unemployment), success coaches connect students and families to community resources and public assistance.
223490567|NCT06063486|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
223490568|NCT06063486|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
223490569|NCT06063486|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
223490570|NCT06063486|DIETARY_SUPPLEMENT|Curcumin/ Demethoxycurcumin/Bisdemethoxycurcumin-containing Supplement|Given PO
223490571|NCT06063486|DIETARY_SUPPLEMENT|Piperine Extract (Standardized)|Given PO
223490572|NCT06063486|DRUG|Placebo Administration|Given PO
223490573|NCT06063486|OTHER|Questionnaire Administration|Ancillary studies
223490576|NCT06975098|OTHER|Life balance intervention group program|Life balance intervention group program is a four-week group intervention program for individuals with depression, with sessions lasting two hours each week. The program will address life balance issues such as daily scheduling, time management, stress coping, emotional regulation, and social participation, and will be tailored to individual patient needs. Through group discussions and practical exercises, participants will learn to apply these skills in their daily lives. Telephone support will be provided during the intervention period to offer emotional support and enhance participation rates.
223587826|NCT03853564|BEHAVIORAL|Video-Feedback Intervention|Mothers and infants of the VFG arm will participate to a 6-session video-feedback intervention structured as follows: 4 sessions of video-review discussions with a trained clinician + 2 sessions of integrative intervention aimed at translating into practical caregiving the insights developed during the video-review discussions.
223587827|NCT03853564|OTHER|Phone-Call Intervention|Mothers of the PCG arm will participate in 6-session of telephone call during which a trained collaborator will ask details on different domains of infants behavioral development.
223587828|NCT00794066|PROCEDURE|measuring the ankle brachial index|"Assessment of the ankle brachial index using the boso-ABI-system 100 (www.boso.de)."
223745480|NCT04698733|DEVICE|BEST™ HVPC microcurrent electrical stimulation Pro-Sport Ultra® device|"Participants will receive two (2) 20-minute treatments a week on nonconsecutive days for 6 weeks in the clinic. At the end of 6 weeks, participants will have a 6-week pause in treatment.~Active Avazzia PRO-Sport Ultra® medical device, BEST™ HVPC microcurrent electrical stimulation, FDA cleared for pain relief"
224182308|NCT02010099|DRUG|PP110 Medicated wipes|
224182309|NCT02010099|DRUG|Preparation-H Cream|
224205720|NCT00609115|DEVICE|AMES device (test)|Eighteen treatment sessions for each qualifying subject limb using the AMES device. Each treatment session being 30 minutes long. Sessions to be scheduled preferable 2 to 3 times per week, with the 18 sessions to be completed within the 6 month anniversary date of the subject's stroke.
224205721|NCT00609115|DEVICE|AMES device (sham)|Eighteen treatment sessions for each qualifying subject limb using the AMES device (sham) in which the limb is moved, but no active assistance is provided by the subject and the vibration is delivered at a very low frequency to the shortening (i.e., rather than lengthening) muscle. Each treatment session to provide thirty minutes of the placebo form of AMES therapy.
223745481|NCT02753062|DRUG|bendamustine, rituximab|subjects will receive rituximab 375mg/m2 on day 1 and bendamustine 120mg/m2 by intravenous infusion on day 2 and 3 in the first cycle. From the 2nd to 6th cycle, rituximab will be administered subcutaneously at a fixed dose of 1400mg and bendamustine 120mg/m2 by intravenous infusion on day 1 following administration of rituximab and day 2.
224182310|NCT04087733|DRUG|OZODROP|3 days before the cataract surgery (T0), two conjunctival swabs will be taken from the patients enrolled in the study, one in the eye to be operated and one in the control eye, who will be kept at a controlled temperature (+ 2 / + 7 ° C) and sent to the laboratory within 24 hours. Than, starting on the day of collection, the patients will instill the OZODROP® eye drops in the eye to be used (2 drops 4 times a day, 1 drop every 4 hours: 9:00 am, 1:00 pm, 5:00 pm: 00, h21: 00), while the contralateral eye will be treated with a saline solution and it will serve as a control. Immediately before the cataract surgery (T3), the patients enrolled in the study will again receive two conjunctival swabs, one in the eye to be operated and one in the control eye. The last OZODROP® instillation will be carried out 10 minutes before the withdrawal. For the microbiological evaluation, the conjunctival swabs taken at T0 and T3 will be sent to the Microbiology laboratory
224182311|NCT00001256|DRUG|prednisone and methotrexate|
224182312|NCT00142207|DRUG|Intermittent preventive treatment:sulphadoxine-pyrimethamine|Two doses given twice during pregnancy (once in the second trimester, and once in the third trimester). Oral medication in tablet form: single daily dose given on each occasion
223490577|NCT06976229|BIOLOGICAL|Allogeneic Human Induced Pluripotent Stem Cell (iPSC)-Derived Motor Neuron Progenitor Cells|"Description:~The Single Ascending Dose (SAD) and Muliple Ascending Dose (MAD) stages were built up in the study. XS228 in SAD and MAD following intrathecal injection through lumbar puncture in subacute spinal cord Injury participants.For SAD,the participants will single intrathecal injection with the dose level as 5×10\^7 cells 、1.5×10\^8 cells. For MAD, the participants will intrathecal injection of XS228 in Day 1, Day15, Day 29, Day 43 under the dose level of 5×10\^7 cells、1.5×10\^8 cells.Dose escalation followed a rule-based 3+3 design.~XS228 is an investigational, allogeneic cell therapy product composed of motor neuron progenitor cells (MNPCs) derived from human induced pluripotent stem cells (iPSCs). This advanced therapy medicinal product (ATMP) is being developed for the treatment of subacute spinal cord injury and represents a novel approach in regenerative medicine."
223490578|NCT06976710|BEHAVIORAL|Preoperative Exercise|Aerobic, Endurance, Respiratory, Muscle Strength, Education
223490579|NCT06976710|BEHAVIORAL|Postoperative Exercise|Aerobic, Endurance, Respiratory, Muscle Strength, Education
223490580|NCT06976710|DIETARY_SUPPLEMENT|Preoperative Nutrition|Malnutrition screening, Weight monitoring, Symptom management, Dietetic counselling, Nutrition support
223490581|NCT06976710|DIETARY_SUPPLEMENT|Postoperative Nutrition|Malnutrition screening, Weight monitoring, Symptom management, Dietetic counselling, Nutrition support
223490582|NCT06976710|BEHAVIORAL|Preoperative Psychology|CBT skills, Skills training, Emotional validation, Behavioural activation, Psycho-education
224182313|NCT00142207|DEVICE|Insecticide-treated mosquito bed net|Insecticide-treated mosquito bed net
224182314|NCT05332171|BEHAVIORAL|Pyhsiohterapy and rehabilitation|Before starting the exercise program, 10 repetitive warm-up exercises will be given including the lower and upper extremities and distal joints. The exercises will be started with 5 repetitions in the first week. Depending on the patient's tolerance, the intensity of the exercise will be increased as 10 repetitions, 15 repetitions and 20 repetitions, and optional rest will be allowed between exercises. It is aimed that the patients reach 20 repetitions in the 6th week at the latest.
223490583|NCT06976710|BEHAVIORAL|Postoperative Psychology|CBT skills, Skills training, Emotional validation, Behavioural activation, Psycho-education
223490584|NCT06976710|OTHER|Preoperative Nursing|Risk management, Managing pain, Wound care, Bowel function, Surgical education
223490585|NCT06976710|OTHER|Postoperative Nursing|Risk management, Managing pain, Wound care, Bowel function/Stoma management, Education
223490586|NCT06976710|BEHAVIORAL|Preoperative Peer Support Group|"Fortnightly sessions moderated by a social worker including patients and carers:~Safe space, Share experiences/ideas, Support, Education"
223490587|NCT06976710|BEHAVIORAL|Postoperative Peer Support Group|"Fortnightly sessions moderated by a social worker including patients and carers:~Safe space, Share experiences/ideas, Support, Education"
223490588|NCT06976710|OTHER|Usual Care|All participants will receive usual care according to their health care team, which may consist of advice on smoking cessation, reduction of alcohol intake, nutritional counselling, and medical optimisation in the preoperative anaesthetic clinic visits.
223490589|NCT06028464|DRUG|BI 1810631|BI 1810631
223490590|NCT06028464|DRUG|Carbamazepine|Carbamazepine
223490591|NCT05291234|DRUG|ABBV-916|Intravenous administration
223490592|NCT05291234|DRUG|Placebo|Intravenous administration
223490593|NCT06575348|DEVICE|YouControl-A-Fib mHealth Application|Participants will use the app for 3 months, includes 1 month phone call with Health Coach
223490594|NCT05993728|BEHAVIORAL|Body Project|The Body Project prevention program is a body acceptance program to promote a healthy body image and prevent eating disorder onset.
223490595|NCT05993728|BEHAVIORAL|Psychoeducational control|Participants randomized to the educational control condition will receive videos addressing body image and eating disorders
223490597|NCT05848908|OTHER|Telehealth Visit|telemedicine visit and follow-up surveys
223490598|NCT06619418|DEVICE|TENS device|will be using an FDA- cleared TENS device for electrical stimulation (TENS 7000, Compass Health Brands) in combination with commercially-available headphones for acoustic stimulation (AKG 845 BT).Will be shown how to use the device, trained on the multimodal stimulation procedure, and sent home with the device for 12 weeks.
223587829|NCT03346967|COMBINATION_PRODUCT|adipose-derived mesenchymal stem cells|Collect adipose-derived mesenchymal stem cells from the patients. Adipose-derived mesenchymal stem cells will be isolated, expanded and characterized in vitro under the GMP- grade procedure
223587830|NCT01067365|DRUG|Androxal|12.5 mg once daily
223587831|NCT01067365|DRUG|Androxal|25 mg once daily
224307832|NCT05729685|OTHER|Interval training|"The interval training group trained using the interval method. During the exercise sessions the participants ran each bout at an intensity corresponding to 90% of PTV. PTV was used to prescribe the exercise intensity at the INT group. The duration of the running-bouts was equal to ¼ of the individual time to exhaustion at 90% of PTV (determined during the CV testing) followed by passive rest equal to 2/3 of exercise duration. The duration of the exercise-bouts was individualized based on the time to exhaustion at 90% of PTV to reduce the between subject's variability. The participants terminated each exercise session when an RPE value of 17 was reached. Running bout duration and intensity were adjusted after 7 training sessions (during the 3rd week) following a reassessment of the time to exhaustion at 90% of the new PTV achieved during mid-testing as a result of training."
224307833|NCT05729685|OTHER|Continuous training|The continuous group trained using the continuous method. During the training sessions the participants ran with an intensity corresponding to -2,5% of CV until they reported a rating of 17 at the 6-20 Borg's scale. Running velocity was adjusted after 7 training sessions (during the 3rd week) after reassessment of CV. CV was used to determine the exercise intensity in the CONT group to ensure that all individuals would ran at the heavy intensity domain and be able to complete at least 15 min of continuous running, and to minimize the high inter-individual variations in endurance time at intensities near the upper limit of the heavy intensity domain. Using PTV to determine the intensity in the CONT group, would increase the possibility for trainees to exercise at different exercise intensity domains.
223490599|NCT06619418|BEHAVIORAL|Integrative health modalities|will be instructed on the integrative health modalities for this study. They will be given a tablet that includes the videos for the visually guided deep breathing. They will also receive the reflective journal and be set up for health coaching visits. At the end of the 12 weeks, this group of participants will return to the U of M campus and complete an interview about satisfaction and usability of the IH modalities.
223490600|NCT01352520|DRUG|SGN-35|1.8 mg/kg administered by outpatient IV infusion given over approximately 30 minutes on Day 1 of each 21-day cycle.
223490601|NCT04981093|DRUG|Dexamethasone Injection|"Intravenous injection after induction of anesthesia~Injection 0.15mg/kg dexamethasone (2ml)"
224182315|NCT02399345|DRUG|ombitasvir/paritaprevir/ritonavir, dasabuvir|tablet; ABT-450 coformulated with ritonavir and ABT-267, ABT-333 tablet
224182316|NCT02399345|DRUG|sofosbuvir (SOF)|tablet
224182317|NCT02399345|DRUG|ribavirin (RBV)|tablet
224182318|NCT01269528|OTHER|Methacholine Challenge Test (MCT)|MCT challenge with determination of methacholine concentration that causes a 20% decrease from baseline FEV1 (forced expiratory volume in the 1st second of expiration) - PC20-FEV1 - is a well-documented method of assessing bronchial hyper-reactivity (BHR) in both adults and children. Our group has shown that the determination of PC20 by spirometry is feasible in preschool children. MCT is considered safe in this age group and our group has extensive experience with no adverse events. In the current study MCT will be performed (for the first time) in premature babies born at 30-32 weeks of gestation during 2008-2009 when they reach the age of 3-4 years (2011 and 2012, respectively). The results of MCT of the two groups will be compared.
224307834|NCT01808820|BIOLOGICAL|Dendritic Cell Vaccine|Between 1.2 to 12 million DC per dose administered once a week via intradermal injection for 4 weeks.
223490602|NCT04981093|DRUG|Normal saline|2ml of normal saline was injected intravenously after induction of anesthesia
224182319|NCT01269528|OTHER|Monthly telephone contact|Monthly telephone contact with the parents/caregivers will be scheduled from enrollment until the final visit at age 3-4 years. Subject illnesses and other medical events occurring during the past month will be recorded at each monthly follow-up.
223587832|NCT00909740|DRUG|MEGF0444A|Intravenous escalating dose
223587833|NCT00774982|DRUG|Delayed Release 6 mercaptopurine|oral tablet, 1 x 40 mg Delayed Release 6MP tablet, single-dose
223587834|NCT00774982|DRUG|6 Mercaptopurine|Oral Tablet, 2 x 50 mg 6MP Reference, single-dose
223745482|NCT04529889|OTHER||
224182320|NCT01269528|OTHER|Visits to the study site|Visits to the study site will be conducted at 6-month intervals in which physicians will record intercurrent doctor visits, emergency visits, and hospitalizations for respiratory symptoms.
224182321|NCT01269528|OTHER|Blood Test|For assessing IgE levels, Eosinophils count and cytokines levels
224182322|NCT01269528|OTHER|Fractional exhaled nitric oxide|Participant blow tidal volume for determination of exhaled NO in Exhaled breath.
224182323|NCT03728647|BEHAVIORAL|multimedia health education|The program (flat touch computer) consisted of knowledge and technology levels. Knowledge: diabetic introduction, treatment, management of hyper- and hypoglycemia, complications, and experience sharing of insulin injection by a patient group. Technology: steps of insulin injection skills and complete technology demonstration . The program contents were organized using a unit-based piecemeal teaching approach. Participants could adjust their learning pace according to individual situations and could practice injection skills using an injection mold during hospitalization. A diabetes educator has assessed the learning outcome of each participant after intervention. At the day of discharge from hospital, each participant would acquire a copy of the multimedia health education compact disc.
224182324|NCT03728647|BEHAVIORAL|regular health education|The traditional education program (a diabetes educator) consisted of knowledge and technology levels. Knowledge: diabetic introduction, treatment, management of hyper- and hypoglycemia, and complications. Technology: steps of insulin injection skills and complete technology demonstration.
224182325|NCT04067310|OTHER|Spray skin protector|Patients will use spray skin protector treatment from the randomization day until the last day of radiotherapy.
223587835|NCT00800410|BEHAVIORAL|Community Health Worker (CHW) services|CHW services included access to an 11 week healthy lifestyle education curriculum, two home visits per month, two additional phone contacts per month, and accompanied participants to one clinic visit within the six month intervention period
223587836|NCT03299283|DIAGNOSTIC_TEST|BioFire test platform|Analysis of analyte stability under various conditions as measured by BioFire test platforms
223587837|NCT04936347|PROCEDURE|cold knife|Transcervical resection of adhesions is performed with scissors to restore the shape of uterine cavity, promote the regeneration and repair of endometrium, and ultimately improve the reproductive prognosis of patients.
224182326|NCT04067310|OTHER|moisturizer Dnativ Revita derm|Patients will use conventional preventive treatment from the randomization day until the last day of radiotherapy.
223490603|NCT06473207|OTHER|Remote ischemic post conditioning sessions|Three sessions of RIPOST (within the 4 hours following cardiac arrest and then 12 and 24 hours after cardiac arrest), as follows: four cycles of cuff inflation to 200 mmHg for 5 min and then deflation to 0 mmHg for another 5 min (40 min total duration of the intervention), using an inflatable thigh tourniquet
223490604|NCT06473207|OTHER|Sham sessions|Three sessions of a sham procedure (within the 4 hours following cardiac arrest and then 12 and 24 hours after cardiac arrest), as follows : application of a thigh tourniquet during 40 min without any inflation
223490605|NCT06838325|OTHER|Prostate Cancer Screening|"The focus group will take about 2 hours to complete and will be led by the study Investigator and a research coordinator. A member of the research team will also take notes during the focus group, and the discussion will also be audio recorded and transcribed (written down word for word).~Additionally, participant demographic information will be collected (such as your age)."
223490606|NCT05537116|BEHAVIORAL|Personalized feedback|Following the baseline assessment, participants will be sent a link via text message to a secure website containing substance-impaired driving specific personalized feedback. Feedback will include the following elements: a personalized substance use profile and substance-impaired driving profile, information on social norms related to substance use and substance-impaired driving, personalized information on BAC (or level of impairment due to drug use) prior to driving, costs associated with a DUI citation in Kentucky, and information on combined drug and alcohol impaired driving risk (if endorsed).
223490607|NCT05537116|BEHAVIORAL|Personalized feedback and text messages|Following the baseline assessment, participants will be sent a link via text message to a secure website containing substance-impaired driving specific personalized feedback (described above). Participants will be asked to send a text message back to the study administrator after viewing the feedback document. After confirming receipt and processing of the document, the study administrator will then send the participant three text messages containing open-ended questions.
223490608|NCT05537116|BEHAVIORAL|Information Only|Students randomized to the information condition will receive standard information about alcohol and other drugs and substance-impaired driving via a link to a website delivered through text message.
223490609|NCT06202638|DEVICE|HemoSphere monitor with Acumen Hypotension Prediction Index Software|Two concomitant courses of intraoperative data will be recorded: 1. the arterial waveform and pressure on the standard hemodynamic patient monitor and 2. the data from the HemoSphere monitor with Acumen Hypotension Prediction Index Software
223490610|NCT04046471|DIETARY_SUPPLEMENT|enhanced Stop Light Diet|Stop light diet enhanced with portion-controlled meals
223490611|NCT04046471|BEHAVIORAL|Group Remote|Participants will receive remotely delivered weight loss in a group setting.
223490612|NCT04046471|BEHAVIORAL|Individual In-Person|Participants will receive a weight loss intervention during individual, at-home visits.
223490613|NCT03824158|BEHAVIORAL|Facilitated advance care planning (in-person or telephonic)|The facilitator will contact the patient to schedule the ACP discussion. ACP discussions will be led by a nurse or social worker with supportive oncology experience who has been trained as a Respecting Choices facilitator, include the patient's caregiver when available, last 45-60 minutes, and be held in a private location at or near the patient's oncology clinic, or telephonically. Facilitators will use a structured interview tool as a discussion roadmap and provide guidance in choosing a medical decision maker, exploring serious illness understanding and experiences, identifying goals and values, and making future treatment decisions. Facilitators will provide a copy of a written advance directive, assist with completion when appropriate, and make recommendations for communicating goals and sharing written preferences.
223587838|NCT04936347|PROCEDURE|hot knife|Transcervical resection of adhesions is performed with bipolar electric cutting to restore the shape of uterine cavity, promote the regeneration and repair of endometrium, and ultimately improve the reproductive prognosis of patients.
223587839|NCT05088668|OTHER|Augmented reality|"The subjects will perform scapular repositioning exercise using glasses of augmented reality to see their scapular movement simultaneously. Furthermore, they will also see at the same time a video record of an ideal scapular movement, and will me encouraged to simulate that ideal scapular movement."
223587840|NCT05088668|OTHER|Scapular repositioning exercise|Subjects will perform scapular repositioning exercises for improving scapular movement.
223587841|NCT01667874|DRUG|Collatamp G sponge|Collatamp G is an antibiotic impregnated sponge
223587842|NCT05494372|OTHER|safety precautions|Nursing safety precautions on CPB
223587843|NCT05381285|OTHER|No intervention|Non-interventional study
223587844|NCT02540291|DRUG|E7046|E7046 will be administered as a single agent orally once daily (QD) continuously in 21-day cycles. In the dose escalation part, increasing doses of E7046 ranging from 125 mg to 750 mg will be administered to cohorts of 6 participants. In the cohort expansion part, participants will be treated at the RP2D.
223587845|NCT04293367|OTHER|High Intensity Interval Training (HIIT)|"HIIT involves exercising in blocks of time (typically 4-5 minutes) where a small percentage of the time (typically 1 minute) is spent above the anaerobic (lactate) threshold (the work interval) followed by the remainder of the time at a sub-anaerobic threshold (active recovery)."
224073328|NCT06984744|DEVICE|MIIP-E2 containing gum|Each subject will be instructed to refrain from using any oral dental hygiene procedures during the study treatment period (4 days). Subjects assigned to the experimental and negative treatment regimen will use only the provided gum product three times a day for 10 minutes after meals (breakfast, lunch, and dinner). Starting on one side of the mouth, chewing for 1 minute, and switching to the other side for another minute. Afterward, they continue chewing for the remaining time however they like. To assess compliance, each subject assigned to a chewing gum product will be provided a diary to record every time they use the product and record any events associated with their study participation. Finally, subjects will be scheduled to return for an end-of-regimen visit. MIIP-E2 is an ultrapure (\>99%) fully native and completely active form of bovine lactoferrin purified directly from raw milk.
224182327|NCT05632094|DIETARY_SUPPLEMENT|L-Carnitine|The clozapine-intoxicated patients will receive conventional supportive care in addition to IV L-carnitine with a loading dose of 100 mg/kg IV over 30-60 min (maximum 6 g) and the maintenance dose was 50 mg/kg IV every 8 h.
224182328|NCT05011669|DRUG|Lurasidone|Oral administration with a meal or within 30 min after eating in the evening. The dosage could be adjusted from Day 8.
224182329|NCT02287831|BIOLOGICAL|umbilical cord mesenchymal stem cells|
223490614|NCT03824158|BEHAVIORAL|Web-based advance care planning|Instructions for accessing and using the PREPARE website will be shared with participants upon randomization. Patients and their caregivers review the 5 steps of PREPARE (approximately 10 minutes per step) and create an action plan for each step. The PREPARE website includes a link to a written advance directive that participants are able to complete. The PREPARE website can be reviewed on a home computer or on a tablet in the oncology practice.
223490615|NCT03006068|DRUG|Upadacitinib (ABT-494)|Upadacitinib (ABT-494) will be administered orally.
223490616|NCT03006068|DRUG|Placebo|Placebo will be administered orally.
223490617|NCT06443541|BEHAVIORAL|High-intensity implementation strategies (HIS)-Students|Students in the HIS group will receive educational outreach in a pre-implementation in-person orientation to GlobalConsent, covering similar topics and three monthly one-hour learning sessions during implementation in which technical questions about program access or progression can be addressed; more intensive intervention to enhance adherence with more frequent email/Short Message Service (SMS), completion reminders; and demand generation encouraging program completion.
223490618|NCT06443541|BEHAVIORAL|Low-intensity implementation strategies (LIS) for Students|Students in the LIS group will receive basic implementation strategies of the GlobalConsent often used to deliver online programs at US universities with email/SMS completion reminders with a predetermined frequency for 12 weeks.
223490619|NCT06443541|OTHER|High-intensity implementation strategies (HIS) for Faculty|"* Passive access to web-based educational materials~* Town halls (3) with general faculty to define sexual violence; rates in young people; acute/chronic effects over the life course; primary-prevention evidence-based interventions (EBIs)"
223490620|NCT06443541|OTHER|Low-intensity implementation strategies (LIS) for Faculty|Passive access to web-based educational materials
223490621|NCT06443541|OTHER|High-intensity implementation strategies (HIS) for Leaders|"* Site-specific invitation to participate~* Passive access to web-based educational materials~* One pre-implementation webinar to define sexual violence; rates among young people in Vietnam; acute/chronic effects over life course; primary-prevention EBIs; recap of project description and collaboration; share GlobalConsent website for passive access to educational materials~* Monthly emails from trained internal facilitators to university leaders with updates on implementation progress~* One post-implementation webinar to share anonymized findings (by IS group); discuss plan for sustainment (including guidance on how to handle reporting of sexual violence in existing university counseling centers)"
223490622|NCT06443541|OTHER|Low-intensity implementation strategies (LIS) for Leaders|"* Site-specific invitation to participate~* Passive access to web-based educational materials~* One pre-implementation webinar to define sexual violence; rates among young people in Vietnam; acute/chronic effects over life course; primary-prevention EBIs; recap of project description and collaboration; share GlobalConsent website for passive access to educational materials"
224182330|NCT01347931|DEVICE|NIOV System|Each subject's standard oxygen therapy will be used as the control treatment and compared to the test ventilator (NIOV) system during selected activities of daily living.
224182331|NCT01347931|DEVICE|Standard Oxygen Cannula|Supplemental oxygen via a standard oxygen cannula connected to a portable oxygen cylinder
223490623|NCT06443541|OTHER|High-intensity implementation strategies (HIS) for Implementation Team Members|"* Passive access to web-based educational materials~* In-person technical training on campus-wide implementation of GlobalConsent; discussion and demonstration of GlobalConsent program; standardized implementation manual~* In-person leadership training to champion GlobalConsent with internal stakeholders (leaders, implementation teams, faculty, students); leadership styles; managing teams; influence without authority; managing conflict; emotional intelligence; negotiation; leading change~* Biweekly (six) 1-hr recorded quality-improvement team webinars to provide refresher training; assess implementation progress; assess modifications; build peer-network; provide anonymized data on implementation progress for discussion"
223490624|NCT06443541|OTHER|Low-intensity implementation strategies (LIS) Implementation Team Members|"* Passive access to web-based educational materials~* In-person technical training on campus-wide implementation of GlobalConsent; discussion and demonstration of GlobalConsent program; standardized implementation manual"
223490625|NCT06573229|DIETARY_SUPPLEMENT|Aminolife Plus by Piemme Pharmatech, Italy|A nutritional supplement containing whey protein, vitamin D, carnitine, HMB, perilla, arginine, coenzyme Q10, inositol)
223490626|NCT06617884|OTHER|Gait and balance training|The training includes individually adapted, targeted, video-based coordination and balance training, which should lead to an improvement in gait and balance. It includes strength, coordination and flexibility exercises.
223490627|NCT06395285|DRUG|DF-003|140 mg on Days 1, 2, and 3 followed by a maintenance dose of 45 mg QD starting on Day 4 through Day 28. DF-003 will be administered PO with approximately 240 mL of water in the morning once daily for 28 consecutive days.
223490628|NCT05528419|DRUG|Sacubitril-valsartan|sacubitril valsartan 100mg initiated, and titrated to 200mg according to mean clinic blood pressure at 1-month follow-up
223490629|NCT05528419|DRUG|Valsartan|valsartan 80mg initiated, and titrated to 160mg according to mean clinic blood pressure at 1-month follow-up
223587846|NCT01922843|DRUG|DP001 softgel capsules|
223587847|NCT01922843|DRUG|Placebo|
224182332|NCT02036892|BEHAVIORAL|Lifestyle counseling with smartphone|Lifestyle counseling with health promoting smartphone software
224182333|NCT02036892|BEHAVIORAL|Lifestyle counseling|Lifestyle counseling
223490630|NCT03562572|PROCEDURE|Ischemia driven revascularization|In the ischemia driven complete revascularisation strategy group all flow limiting (FFR ≤ 0.80) lesions will receive treatment by PCI and stenting during the index intervention
223587848|NCT00346229|BIOLOGICAL|filgrastim|
223587849|NCT00346229|BIOLOGICAL|pegfilgrastim|
223587850|NCT00346229|DRUG|lyso-thermosensitive liposomal doxorubicin(Thermodox)|
223587851|NCT00346229|PROCEDURE|hyperthermia treatment|
223587852|NCT02545244|DIETARY_SUPPLEMENT|Black Tea|0.5% Black Tea 5mL used as Mouthwash twice daily for two weeks after scaling of teeth.
223587853|NCT02545244|DIETARY_SUPPLEMENT|Green Tea|0.5% Green Tea 5mL used as Mouthwash twice daily for two weeks after scaling of teeth.
223587854|NCT02545244|DRUG|0.12% Chlorhexidine Mouthwash.|5mL of 0.12% Chlorhexidine used as mouthwash twice daily for two weeks after scaling of teeth.
223745483|NCT05049993|DEVICE|Aequalis Pyrocarbon Humeral Head|Hemi Shoulder Arthroplasty using the Aequalis Pyrocarbon Humeral Head
223587855|NCT01569230|PROCEDURE|Standardized Acupuncture|The treatment was applied twice a week for 20 minutes for 6 weeks(12sessions) 9 Acupuncture points(SP9,GB34, ST36, ST35, Xiyan(EX-LE5), BL60, GB39, SP6 and KI3)were used for all the patients assigned to this group. Sterile Stainless Steel(25mm x 40mm) disposable acupuncture needles manufactured by Dong-Bang Acupuncture Co.(Korea) were used.
224307835|NCT01808820|BIOLOGICAL|Tumor Lysate|Post-DC Vaccine therapy. Up to 1.5 mg of Lysate of tumor per dose administered via intradermal injection at intervals defined by study protocol.
224307836|NCT01808820|DRUG|Imiquimod|5% topical cream applied to vaccine site before and after administrations of DC vaccine or lysate
224307837|NCT01808820|PROCEDURE|Leukapheresis|Baseline, post-surgery blood draw via catheter to obtain peripheral blood mononuclear cells (PBMCs) from which Dendritic cells will be obtained.
224307838|NCT02481362|OTHER|CAKE|For the CAKE condition, participants will play a computer task to earn points for cake that they can consume.
224307839|NCT02481362|OTHER|APRICOTS|For the APRICOTS condition, participants will play a computer task to earn points for apricots that they can consume.
224307840|NCT01939574|OTHER|Chemoradiation Therapy|"* Radiation therapy:For both intensity-modulated radiation therapy (IMRT) and three-dimensional conformal radiation therapy (3D-CRT) plans, one treatment of 2 Gy will be given daily 5 days per week for a total of 60 Gy over 6 weeks.~* Temozolomide will be administered continuously from day 1 of radiotherapy to the last day of radiation at a daily oral dose of 75 mg/m2 for a maximum of 49 days.~* Bevacizumab will be administered intravenously on days 1 and 15 of each 28-day cycle,at the beginning of the 4th week of radiation. The dose will be 10 mg/kg of actual body weight."
224307841|NCT01939574|OTHER|Adjuvant Therapy|"* Temozolomide will be administered orally once per day for 5 consecutive days (days 1-5) of a 28-day cycle. The starting dose for the first cycle will be 150 mg/m2/day, with a single dose escalation to 200 mg/m2/day in subsequent cycles if no treatment-related adverse events\> grade 2 are noted.~* Bevacizumab will be administered intravenously on days 1 and 15 of each 28-day cycle. The dose will be 10 mg/kg of actual body weight."
224307842|NCT01221363|BEHAVIORAL|Life style intervention|Reduction of sedentary behavior through theory-based individually tailored lifestyle intervention.
224307843|NCT00002393|DRUG|Indinavir sulfate|
224307844|NCT00002393|DRUG|Efavirenz|
224307845|NCT04261907|DRUG|ASC09/ritonavir group|ASC09/ritonavir(300mg/100mg tablet), one tablet each time, twice daily, for 14 days, +conventional standardized treatment
224307846|NCT04261907|DRUG|lopinavir/ritonavir group|Lopinavir/ritonavir tablets(200mg / 50mg tablet), two tablets each time, twice daily, for 14 days, +conventional standardized treatment
224307847|NCT04618783|BIOLOGICAL|Three doses of low-dosage investigational sIPV, vaccinated within one-month interval between doses|Antigen content: 7.5, 22.5, and 22.5 D-antigen unite for type 1, 2, and 3 in 0.5 ml diluent per dose
224307848|NCT04618783|BIOLOGICAL|Three doses of medium-dosage investigational sIPV, vaccinated within one-month interval between doses|Antigen content: 15, 45, and 45 D-antigen unite for type 1, 2, and 3 in 0.5 ml diluent per dose
224307849|NCT04618783|BIOLOGICAL|Three doses of high-dosage investigational sIPV, vaccinated within one-month interval between doses|Antigen content: 22.5, 67.5, and 67.5 D-antigen unite for type 1, 2, and 3 in 0.5 ml diluent per dose
223490631|NCT03562572|OTHER|Usual care group|In the randomised to usual care group the procedure will stop after the PCI of the culprit artery and the patient will be referred to his treating cardiologist and/ or heart team who will decide whether a staged PCI of the non- IRA artery should take place. If the treating cardiologist (after advise of the heart team) decides to perform the non-IRA PCI revascularisation, than such treatment should take place within six weeks from the primary PCI in order to count as a scheduled staged PCI procedure.
223587856|NCT01569230|PROCEDURE|sham acupuncture|The treatment was applied twice a week for 6 weeks(12sessions). The sham acupuncture was applied on the 9 same acupuncture points as in the standardized acupuncture group. Each session was 20 minutes long
224073329|NCT06984744|DEVICE|placebo gum without MIIP-E2|Each subject will be instructed to refrain from using any oral dental hygiene procedures during the study treatment period (4 days). Subjects assigned to the experimental and negative treatment regimen will use only the provided gum product three times a day for 10 minutes after meals (breakfast, lunch, and dinner). Starting on one side of the mouth, chewing for 1 minute, and switching to the other side for another minute. Afterward, they continue chewing for the remaining time however they like. To assess compliance, each subject assigned to a chewing gum product will be provided a diary to record every time they use the product and record any events associated with their study participation. Finally, subjects will be scheduled to return for an end-of-regimen visit.
224307850|NCT04618783|BIOLOGICAL|Three doses of control wIPV, vaccinated within one-month interval between doses|Antigen content: 40, 8, and 32 D-antigen unite for type 1, 2, and 3 in 0.5 ml diluent per dose
224307851|NCT04618783|BIOLOGICAL|Three doses of control sIPV, vaccinated within one-month interval between doses|Antigen content: 30, 32, and 45 D-antigen unite for type 1, 2, and 3 in 0.5 ml diluent per dose
224307852|NCT00150761|DRUG|Levocetirizine (drug)|
224307853|NCT00525447|DRUG|SGN-40|2-12 mg/kg IV (in the vein) on Days 1, 4, 8, 15, and 22 of Cycle 1; 4-12 mg/kg IV (in the vein) on Days 1, 8, 15, and 22 of Cycles 2-4; 4-12 mg/kg IV (in the vein) on Days 1, 8, and 15 of Cycles 5-8.
224307854|NCT00525447|DRUG|lenalidomide|Up to 25 mg daily of a 21-day cycle.
224307855|NCT00525447|DRUG|dexamethasone|40 mg administered weekly.
224307856|NCT04204291|PROCEDURE|Bronchoscopy|Multiple level sampling of the respiratory mucosa (cytology brush and biopsies forceps)
224307857|NCT02430831|DIETARY_SUPPLEMENT|Nidina|
224307858|NCT02430831|DIETARY_SUPPLEMENT|Placebo|
224307859|NCT02186626|BIOLOGICAL|WN/DEN4Δ30 Vaccine|WN/DEN4Δ30 vaccine is a live attenuated, recombinant, chimeric virus. Dose: 10\^4 plaque-forming units (PFUs); delivered by subcutaneous injection in the deltoid region of the upper arm.
224307860|NCT02186626|BIOLOGICAL|Placebo|Delivered by subcutaneous injection in the deltoid region of the upper arm.
224307861|NCT03351465|BEHAVIORAL|Coordinated Anxiety Learning and Management|The intervention for this study, CALM Tools for Living-Il, is a computer-assisted cognitive behavioral therapy for anxiety and depression that guides both the patient and CALM specialist. It is a reformulation of CALM Tools for Living42 that directly incorporates our previously optional modules for depression into the main program. The computerized internet format is designed to retain the fidelity of CBT when delivered by novice clinicians. The program is intended to be delivered in 6 to 8 sessions, although flexibility is allowed.
224307862|NCT04201691|OTHER|classic rehabilitation|The intervention is conventional rehabilitation that included streching, balance and coordination training. The intervention is applied to participants, manually.
224307863|NCT04201691|OTHER|classic rehabilitation+mobilization|Another intervention is manuel therapy that included gliding technics, rotational technics at cervical region. (in addition to classic rehabilitation). The intervention is applied to participants, manually.
224307864|NCT04951986|DRUG|Rifampin|Rifampicin up to 35 mg/kg/day for 14 days
224307865|NCT04951986|DRUG|Levofloxacin|Levofloxacin 750mg daily (for weight \<50kg) or 1 g daily (for weight \>50 kg) daily for 14 days
224307866|NCT04951986|DRUG|Rifampicin, Pyrazinamide, Ethambutol and Isoniazid|Rifampicin 10 mg/kg; Isoniazid 5 mg/kg; Pyrazinamide 15 mg/kg; Ethambutol15 mg/kg in fixed dose combination administered per weight band. Standard of care control arm
224307867|NCT04951986|DRUG|Prednisone|Prednisone 1.5mg/kg/day for 14 days
224307868|NCT04951986|DRUG|Placebo|Placebo identical to Prednisone
224307869|NCT04187339|BIOLOGICAL|NGM395|NGM395 Dose 1
224307870|NCT04187339|BIOLOGICAL|NGM395|NGM395 Dose 2
224307871|NCT04187339|BIOLOGICAL|NGM395|NGM395 Dose 3
224307872|NCT04187339|BIOLOGICAL|NGM395|NGM395 Dose 4
224307873|NCT04187339|BIOLOGICAL|NGM395|NGM395 Dose 5
224307874|NCT04187339|BIOLOGICAL|NGM395|NGM395 Dose 6
223490632|NCT04123535|DEVICE|ExAblate 2000/2100 Magnetic Resonance-guided Focused Ultrasound (MRgFUS)|The ExAblate 2100 MRgFUS system (InSightec, Inc., Dallas, Texas, USA) is a noninvasive thermal ablation device fully integrated with an MR imaging system and used for the ablation of soft tissue and bone.14-16 The ExAblate combines a focused ultrasound surgery (FUS) delivery system and a conventional diagnostic 3T Magnetic Resonance (MR) scanner. The ExAblate systems provide a real-time therapy planning algorithm, thermal dosimetry, and closed-loop therapy control. The ExAblate transducer device is an integrated component of the MR table
223490633|NCT04111419|DRUG|Amlodipine/Atorvastatin 5 Mg-20 Mg ORAL TABLET|amlodipine/atorvastatin (5/20mg tablet) once a day
223490634|NCT04111419|DRUG|Amlodipine/Atorvastatin 5 Mg-10 Mg ORAL TABLET|amlodipine/atorvastatin (5/10mg tablet) once a day
223490635|NCT04111419|DRUG|Allisartan Isoproxil|allisartan (240mg/tablet) once a day
223490636|NCT06179667|BEHAVIORAL|Mobile Application|"It is aimed to develop the mobile application to address the problems and training needs of informal caregivers regarding the caregiving process. In this context, in order to determine the needs of caregivers, face-to-face in-depth interviews will be held with caregivers using the Semi-Structured Questionnaire for Qualitative Interviews at the University of Health Sciences GTRH Geriatrics Department. The content of the mobile application will be created according to the topics determined as a result of qualitative research. Technical development of the application will be carried out by the web application designer."
223490637|NCT05626816|DEVICE|Genital Nerve Stimulation|Electrical stimulation applied to the genital nerve with surface electrodes using an off the shelf TENS unit (Ultima Plus). First, an amplitude threshold for the pudendo-anal reflex responses will be determined. Then, sham (1-2 Hz) and effective stimulation (20 Hz) will be briefly applied to record responses. Then, stimulation will be applied in random presentation order to record any changes in anorectal manometry outcomes due to both sham and effective stimulation.
223587857|NCT01569230|PROCEDURE|Individualized Acupuncture|The treatment was applied twice a week for 20 minutes for 6 weeks(12sessions)
224307875|NCT04187339|OTHER|Placebo|Placebo
224307876|NCT02556463|DRUG|MEDI9197|Subjects will receive MEDI9197 (every 4 weeks) as monotherapy (or MEDI9197 every 8 weeks + durvalumab every 4 weeks)(PA6)
224307877|NCT02556463|BIOLOGICAL|durvalumab|Subjects will receive durvalumab every 4 weeks
224307878|NCT01336452|RADIATION|DCE MRI|DCE (dynamic contrast enhanced) MRI will be obtained just before CCRTx and immediately after finishing CCRTx with 0.1mmol/kg of MR contrast media; CEUS will be obtained just before CCRTx, immediately after finishing CCRTx, and 1 month after CCRTx with 2.4 mL of SonoVue. Blood sampling for biomarker analysis will be performed just before CCRTx, immediately after finishing CCRTx, and 1 month after CCRTx (20mL)
224307879|NCT04245241|OTHER|High-flow nasal cannula (HFNC)|24 patients who receiving HFNC within 24 hours after extubation were prospectively enrolled in this study. EIT was used to monitor regional lung ventilation distributions at baseline (conventional oxygen therapy) and three flow rate levels of HFNC therapy (20, 40 and 60 L/min).
224307880|NCT06549283|DEVICE|Nasal intermittent positive pressure ventilation (NIPPV) via binasal cannula during neonatal intubation|Researchers applied NIPPV treatment using binasal cannulas through a mechanical ventilator during intubation.
224307881|NCT04890912|RADIATION|Conventional Fractionation|Dose prescribed is 45 Gy in 25 fractions (1.8 Gy per fraction) delivered daily over 5 weeks.
224307882|NCT04890912|RADIATION|Hypofractionation|Dose prescribed is 30 Gy in 5 fractions (6 Gy per fraction) delivered every other day over 11 days. There will be a minimum of 36 hours and maximum of 96 hours between fractions. The entire course of treatment should be completed within no less than 10 days.
224307883|NCT05546008|DEVICE|Multislice CT|all patient will be subjected to echocardigraphy and multislice ct and compare thier results
224307884|NCT02904824|BIOLOGICAL|adipose derived regenerative cells|Stem cells from autologous adipose tissue in which autologous tissue is enriched or in suspension to fill the paralyzed vocal cord. The aim is to induce the overexpression and production of microvessels at local level. Route of administration: injection into the thickness of a paralyzed vocal cord.
224307885|NCT02904824|BIOLOGICAL|centrifuged autologous fat|centrifuged adipose tissue which is autologous tissue is used to fill the paralyzed vocal cord. The aim is to increase the volume of the vocal fold, to reduce the glottal gap.This effect is temporary. Route of administration: injection into the thickness of a paralyzed vocal cord.
223490638|NCT05626816|DIAGNOSTIC_TEST|Clinical exam|Examination by physician determines the presence of pelvic reflexes (pudendo-anal and bulbocavernosus) which are essential for GNS to have an effect.
223490639|NCT05626816|DIAGNOSTIC_TEST|Collection of SCI common data elements|Data regarding participant demographics, history of injury, and medical history will be collected.
223587858|NCT01569230|OTHER|Waiting|No interventions were applied to the patients in this group.
223745484|NCT01280552|BIOLOGICAL|ICT-107|Autologous dendritic cells pulsed with immunogenic antigens
223745485|NCT01280552|BIOLOGICAL|Placebo DC|Autologous dendritic cells (DC) that have not been pulsed with antigens
224182334|NCT02896686|RADIATION|Control CT|"At the end of the follow up (12 Months) a CT scan will be done. Radiologically the incisional hernia is defined as a solution of continuity of the abdominal wall seen on the abdominal CT scan with the patient at rest.~The radiologist is blinded to the patient's history and the technique used for fascial closure."
224182335|NCT02896686|OTHER|Clinical Follow Up|The presence of incisional hernia was evaluated by physical examination at scheduled clinical visits (3 and 6 months after surgery) Clinically, an incisional hernia is defined as the presence of a reducible bulge or protrusion at the laparotomy incision scar, palpable during the Valsalva maneuver.
224182336|NCT02896686|PROCEDURE|Reinforcement with Light Polypropylene Mesh|Reinforcement with Light Polypropylene Mesh
224182337|NCT06142032|BEHAVIORAL|Metaverse support group|"Delivery method: Online, virtual platforms. Number of sessions: 5. Duration of each session: 1.5 hours. Sessions will adhere to evidence-based protocols for conducting support groups with a trauma-informed approach. Each session will cover a specific topic of interest related to the challenges faced by Ukrainian refugees (e.g., stress management, cultural adjustment, self-care, etc.).~Support group session structure:~* Introduction, check-in, ground rules;~* Introducing the topic (topics will be chosen based on the feedback received from a previous session; the first session will cover a topic chosen by the facilitator);~* Encouragement of participants to share thoughts, ideas and experiences;~* Psychoeducation on the topics;~* Summary, takeaway, feedback."
224182338|NCT06142032|BEHAVIORAL|In-Person support group|"Delivery method: In-Person, traditional. Number of sessions: 5. Duration of each session: 1.5 hours. Sessions will adhere to evidence-based protocols for conducting support groups with a trauma-informed approach. Each session will cover a specific topic of interest related to the challenges faced by Ukrainian refugees (e.g., stress management, cultural adjustment, self-care, etc.).~Support group session structure:~* Introduction, check-in, ground rules;~* Introducing the topic (topics will be chosen based on the feedback received from a previous session; the first session will cover a topic chosen by the facilitator);~* Encouragement of participants to share thoughts, ideas and experiences;~* Psychoeducation on the topics;~* Summary, takeaway, feedback."
224182339|NCT01693042|BIOLOGICAL|intracoronary infusion of autologous bone marrow-derived cells|Intracoronary infusion into open vessel / bypass supplying previous (\> 3 months) infarct area
224307886|NCT05782881|BEHAVIORAL|phone calls and encouraging patients' lifestyle change and medication adherence|Use some methods to strictly intervene blood glucose , blood pressure and blood lipids for protocol treatment group people.
224307887|NCT05782881|DRUG|Statin|Treatment and management according to the guidelines
223490640|NCT05626816|DIAGNOSTIC_TEST|Bowel function survey completion|Two surveys will be conducted to assess the bowel function of the participant. The International SCI Bowel Function Basic Data Set (ISCI BF BDS v2.1) and the SCI Qulaity of Life Bowel Management Difficulties (SCI-QoL BMD) survey scales collect data on overall bowel function and how any difficulties impact the participants quality of life.
223490641|NCT05626816|DIAGNOSTIC_TEST|International Standard for Neurological Classification of SCI (ISNCSCI)|The physician will conduct the ISNCSCI to determine the level and severity of injury to the spinal cord. This is done by determining the ability to detect light touch and pinprick stimulation. Outcomes will be a Spinal Injury Association Impairment Scale (AIS) grade of A-D.
223490642|NCT05626816|DIAGNOSTIC_TEST|Response to genital nerve stimulation (GNS)|GNS will be applied to determine if there is a response in the participant. If the participant has no response to the stimulation they will be excluded from the second visit as it is dependent on the ability to respond to GNS.
223490643|NCT05626816|DIAGNOSTIC_TEST|Anorectal Manometry testing (ARM)|"The participant will be instrumented for ARM testing. This requires a special balloon catheter to be inserted into the anus and secured, surface electrode pads being applied to the anal sphincter, and electrode pads being applied to the genital nerve stimulation sites.~Once instrumented, the participant will be tested with the London Classification procedure. This procedure asks the participant to perform several actions (squeeze to withhold a bowel movement, push to have a bowel movement, and cough) as well as inflating the balloon on the catheter to determine reflex thresholds (RAIR, retroanal inhibitory reflex which relaxes the anal sphincter in response to rectal distension) and sensory thresholds (first senstation,"
223490644|NCT05928325|OTHER|Comprehensive Geriatric Assessment|Complete geriatric assessments
223490645|NCT05928325|BEHAVIORAL|Health Education|Receive survivorship care education
223490646|NCT05928325|OTHER|Medical Device Usage and Evaluation|Wear activity tracking device
223490647|NCT05928325|OTHER|Supportive Care|Receive geriatric assessment-guided interventions
223490648|NCT05372484|DEVICE|Multimodal optical imaging|Women referred for colposcopy due to abnormal cervical screening will be recruited into the experimental group of the study. Imaging of study participants will take place during the colposcopy examination.
223490649|NCT06302543|PROCEDURE|autologous bone marrow cells injection|under general anesthesia bone marrow aspiration done followed by cell concentration and transvaginal ovarian injection
223490650|NCT06389240|OTHER|6 weeks post-operatively early weight bearing|Early mobilization 6 weeks post-operatively. Gait analyses is carried out on when full mobilization is allowed. Gait analysis is performed while using force-measuring insoles (loadsol, Novel).
223490651|NCT06389240|OTHER|10 weeks post-operatively weight bearing (standard of care)|Standard of care mobilization at 10 weeks post-operatively. Gait analyses is carried out on when full mobilization is allowed. Gait analysis is performed while using force-measuring insoles (loadsol, Novel).
223490652|NCT02972840|DRUG|Acalabrutinib|Administered orally (PO)
223490653|NCT02972840|DRUG|Bendamustine|Administered intravenously (IV)
223490654|NCT02972840|DRUG|Rituximab|Administered intravenously (IV)
223490655|NCT02972840|DRUG|Placebo|Placebo comparator
223745486|NCT05423067|PROCEDURE|bilateral permanent occlusion of uterine arteries|bilateral permanent Occlusion of uterine arteries through abdominal route
223745487|NCT05754606|DIAGNOSTIC_TEST|Audio recordings|Automatica analysis of audio recordings
223745488|NCT02016625|DRUG|Faldaprevir|
223745489|NCT02016625|DRUG|Faldaprevir|
224307888|NCT03928210|DRUG|Digoxin|Patients will receive a daily maintenance dose of digoxin. The daily dose of digoxin will be calculated according to the renal function and the target serum digoxin concentration and applied in an adjusted regimen based on the availability of 0.125 mg and 0.25 mg pills in the morning (before 10 am). Blood samples for analyses of mean CTC cluster size will be drawn at screening, on day 0 (2 hrs after first oral intake), on day 3 and on day 7. Depending on the digoxin serum level maintenance therapy with digoxin will be continued up to 3 weeks if the digoxin serum level on day 7 or day 14 is below 0.70 ng/ml. For the third week of maintenance therapy individual dose adjustments will be carried out as needed.
224307889|NCT05324410|DRUG|VX-840|Solution for oral administration.
224307890|NCT05324410|DRUG|Placebo|Placebo matched to VX-840 for oral administration.
224307891|NCT03016819|DRUG|AL3818|Anlotinib (AL3818) 12 mg orally administered once daily in 21-day cycles (14 days on treatment, 7 days off treatment)
224307892|NCT03016819|DRUG|Dacarbazine|Dacarbazine 1000 mg/m2 as a 20-120 minute IV infusion on Day 1 of each 21-day treatment cycle
224307893|NCT03016819|DRUG|AL3818 or placebo|AL3818 or placebo 12 mg orally administered once daily in 21-day cycles (14 days on treatment, 7 days off treatment)
224307894|NCT03451552|BEHAVIORAL|Patient Navigator|Navigators will support patients to access community based resources for healthy living and self-management, rather than providing specific information about health issues. Navigators will teach patients how to identify available and relevant programs to meet their health-related goals, in their language of choice. The navigator will ensure that the individual understands the reason for referral and potential benefits. They will discuss social barriers potentially affecting patients' access to community health resources, and assist patients to prioritize their health goals and relevant resources to achieve these. The navigator will then assist patients to access the community-based services in the language of their choice to which they have been referred. The navigator may assist the patient in making appointments, coordinating transportation, and/or accompaniment to resources as required).
224307895|NCT00083603|BIOLOGICAL|rMVA-HIV (rMVA-HIV env/gag + rMVA-HIV tat/rev/nef-RT)|rMVA 10\^7 pfu /2mL administered in each deltoid
224307896|NCT00083603|BIOLOGICAL|rFPV-HIV (rFPV-HIV env/gag + rFPV-HIV tat/rev/nef-RT)|Vaccines administered as two separate 1-mL intramuscular injections, with rFPV-HIV env/gag into the left deltoid, rFPV-HIV tat/rev/nef-RT into the right deltoid
224307897|NCT00083603|BIOLOGICAL|Empty TBC-FPV|Empty FPV 10\^9 pfu/2mL administered as two separate 1 mL intramuscular injections, one into each deltoid.
224307898|NCT00083603|BIOLOGICAL|rMVA-HIV (rMVA-HIV env/gag + rMVA-HIV tat/rev/nef-RT)|rMVA 10\^8 pfu /2mL administered in each deltoid
224307899|NCT00083603|BIOLOGICAL|rMVA-HIV (rMVA-HIV env/gag + rMVA-HIV tat/rev/nef-RT)|rMVA 10\^9 pfu /2mL administered in each deltoid
224307900|NCT00083603|BIOLOGICAL|TBC-MVA and TBC-FPV|Empty MVA 10\^7 pfu/2mL administered into each deltoid
223490656|NCT05797155|BEHAVIORAL|CoQuit App - Cognitive Dissonance Based Smoking Cessation + Smoking Cessation Tips|CoQuit App (Cognitive Dissonance Based Smoking Cessation) Use of the CoQuit app, completion of cognitive dissonance activities, sharing of videos with online group, and providing support to other group members
223490657|NCT05797155|BEHAVIORAL|Tips for Smoking Cessation App|App containing daily tips for smoking cessation
223490658|NCT04886284|DRUG|Ertapenem|Adjunctive ertapenem
223490659|NCT04886284|DRUG|Placebo|Saline placebo
223490660|NCT04657289|DRUG|Ranibizumab|"Arm A: Participants will receive ranibizumab delivered through the PDS implant with 100 mg/mL in the study eye on Day 1 and receive refill-exchanges at fixed 36-week intervals~Arm B: Participants will receive ranibizumab delivered through the PDS implant with 100 mg/mL in the study eye on Day 1 and receive refill-exchanges at fixed 24-week intervals"
223490661|NCT04657289|DEVICE|Port Delivery System with Ranibizumab|"Arm A: Participants will receive ranibizumab delivered through the PDS implant with 100 mg/mL in the study eye on Day 1 and receive refill-exchanges at fixed 36-week intervals~Arm B: Participants will receive ranibizumab delivered through the PDS implant with 100 mg/mL in the study eye on Day 1 and receive refill-exchanges at fixed 24-week intervals"
223490662|NCT04865770|DRUG|Semaglutide|Semaglutide given subcutaneously (sc, under the skin) once weekly. Dose gradually increased over 8 weeks from 0.25 to 1.0 mg. The study will last for about 1 year.
223490663|NCT04865770|DRUG|Placebo (Semaglutide)|Placebo (Semaglutide) given subcutaneously (sc, under the skin) once weekly. Dose gradually increased over 8 weeks from 0.25 to 1.0 mg. The study will last for about 1 year.
223490664|NCT05453630|BEHAVIORAL|Patient Navigation|Patients will receive navigation from a trained lay navigator at a community-based nonprofit organization that supports access to high quality healthcare. The patient navigator will work with patients to schedule their colonoscopy and identify, explore, and overcome barriers. They will educate patients about the colonoscopy procedure and preparation, provide resources, and coach and motivate patients.
223490665|NCT05453630|BEHAVIORAL|Usual Care Control|Educational brochure about colonoscopy
223490666|NCT05030818|DRUG|Polypill of acetylsalicylic acid, ramipril and atorvastatin|Administration of acetylsalicylic acid, ramipril and atorvastatin in a polypill during 3 months more
223490667|NCT05030818|DRUG|Drugs taken separately: acetylsalicylic acid, ramipril and atorvastatin|Patients will be receiving during 3 months more the same components acetylsalicylic acid, ramipril and atorvastatin than with the polypill
223490668|NCT05589519|DEVICE|Partial rehabilitation using PEEK|A 3-unit implant-supported fixed prosthesis using PEEK polymer in its composition delivered as definitive prosthesis for partial rehabilitation of edentulous jaws.
223490669|NCT05046353|DRUG|D-serine|Auditory remediation +/-D-serine
223490670|NCT05046353|OTHER|Placebo|Auditory remediation +/-D-serine
223490671|NCT06303739|DRUG|psilocybin|25mg of psilocybin administered during treatment session, accompanied by preparation before, integration after, and assistive therapy during the session.
223490672|NCT06967415|OTHER|Pain, central sensitization,functional status and quality of life.|The patients' pain status, central sensitization functional status, and quality of life will be evaluated according to their stenosis grade.
223490673|NCT05813288|DRUG|Dexpramipexole Dihydrochloride|Oral administration of dexpramipexole tablet
223490674|NCT05813288|DRUG|Placebo|Oral administration of placebo tablet
223490675|NCT06505083|OTHER|modified stepping trainings|step-up on box texture difference
223745490|NCT02016625|DRUG|Cyclosporine|
223745491|NCT02016625|DRUG|Tacrolimus|
223587859|NCT04778800|DRUG|almonertinib|Patients was given a standard dose of 110mg/day of almonertinib, orally, and the first efficacy evaluation was carried out 4 weeks later. If the patient's lungs and/or other parts of the disease (PD) progress, then leave the group to receive other treatment; if the patient's lungs If the brain and other parts are stable or relieved and the brain has not progressed, continue the original dose treatment, and evaluate the effect every 8 weeks. Until the patient's lungs and/or other parts progress (PD), then leave the group to receive other treatment; if If the patient's lungs and other parts are stable or relieved and the brain is progressing, the dose of almonertinib can be increased to 165mg/day, orally ± radiotherapy (the investigator's decision), and then the efficacy will be evaluated every 8 weeks until the patient's lungs and/ Or there is progress (PD) in other parts, then the group will receive other treatment.
223745492|NCT02155738|DRUG|IV Acetaminophen|
223745493|NCT02155738|DRUG|IV normal saline|IV normal saline
223745494|NCT04147065|DRUG|Duration of eradication regimen|14 day eradication regimen
223745495|NCT04974658|PROCEDURE|Inter-semispinal plane block|Ultrasound Inter-semispinal plane block in block group
223745496|NCT02639104|RADIATION|Radiography|"Obtaining patients lateral spot cervical spine radiography and will measure;~1. The segmental angle will be measured from C2-C7 inferior endplates on the lateral radiography~2. If there is a segmental kyphosis (for example kyphotic angle in C4-5 level), the segmental cobb angle will be measured in the level of the main kyphosis~3. The segmental cobb angle will be measured between C2-C4 inferior endplates and C4-C7 inferior endplates"
223745497|NCT02639104|OTHER|Electromyography|"Serratus anterior needle electromyography:~The needle can be inserted into the muscle superficially to the fourth to sixth rib in the medial or posterior axillary line. The usual nerve latency time is between 2.6-4 ms."
223745498|NCT02699203|BEHAVIORAL|High-carbohydrate meal|Participants will consume a high-carbohydrate low fat meal. The macronutrients content will be 55% carbohydrate, 25% protein and 20% fat providing 400-500 kcal. Between interventions there will be at least a 48-hours washout, where participants are encouraged to return to their baseline dietary habits.
224307901|NCT00083603|BIOLOGICAL|TBC-MVA and TBC-FPV|Empty MVA 10\^8 pfu/2mL administered into each deltoid
224307902|NCT00083603|BIOLOGICAL|TBC-MVA and TBC-FPV|Empty MVA 10\^9 pfu/2mL administered into each deltoid
224307903|NCT01114100|DRUG|sertraline|starting dose 25 mg for 1 week, the increasing to 50 mg, after each visit evaluation whether dosage has to be increased to maximally 150 mg
224307904|NCT01114100|DRUG|placebo|patients received 1 pill, according to their complaints the number of pills was increased to maximally 3
224307905|NCT02695537|DRUG|Epidiolex|Epidiolex oral solution (100 mg/mL CBD concentration) with inactive ingredients including anhydrous ethanol, sesame seed oil, strawberry flavor, and sucralose).
224307906|NCT03335215|OTHER|cognitive remediation|The innovative nature of this program is that it integrates both neuropsychological psychoeducation, the principles of reeducation of altered cognitive functions and the setting in addictological context benefiting from the interactions of the group situation. Thus, during the three months of REMED management, six modules corresponding to six altered cognitive domains that may have an impact on the maintenance of the therapeutic contract will be offered to patients. The REMED group will benefit from cognitive remediation of episodic memory disorders, executive and attentional functions, and the theory of the mind integrating psychoeducation, training and systematic situations related to an alcoholic context. The different procedures of neuropsychological management (facilitation, use of preserved capacities and compensation) will help to integrate the concepts and addictological strategies necessary to maintain the therapeutic contract taking into account cognitive impairments.
224307907|NCT04538183|OTHER|WO 5000|WO 5000
224307908|NCT04538183|OTHER|WO 5001|WO 5001
224307909|NCT03680989|DEVICE|Bright Light Exposure|"For 10 consecutive days, participants will use an Ultralux(R) V HD-LED light therapy light for 30 minutes beginning 30 minutes after waking. The light will be preset to deliver \~10,000 lux at 22."
224307910|NCT03680989|DEVICE|Natural Light Exposure|"For 10 consecutive days, participants will use an Ultralux(R) V HD-LED light therapy light for 30 minutes beginning 30 minutes after waking. The light will be preset to deliver \~500 lux at 22."
224307911|NCT03597529|DRUG|Melatonin|melatonin
224307912|NCT06194760|PROCEDURE|Vitrectomy with ILM peeling|Vitrectomy with traditional internal limiting membrane (ILM) peeling technique is regarded as the gold standard treatment for MH; it works by completely relieving of the traction of the macula and increasing the flexibility of the retina
224307913|NCT03769714|DRUG|Saline Solution for Injection|Injection of 20mL of 0.9%Normal Saline
224307914|NCT03769714|DRUG|Exparel|Exparel (bupivacaine liposome injectable suspension) is a liposome injection of bupivacaine, an amide-type local anesthetic, indicated (bupivacaine liposome injectable suspension) for administration into the surgical site to produce postsurgical analgesia.
224307915|NCT04191850|PROCEDURE|Single Port Video-Assisted Thoracoscopic Surgery|Single Port Video-Assisted Thoracoscopic wedge resection was performed for primary spontaneous pneumothorax.
224307916|NCT04263324|BEHAVIORAL|Self-hypnosis/self-care|Learning phase of self-hypnosis/self-care.
224307917|NCT03819894|DIAGNOSTIC_TEST|Introduction of a lower female hs-cTn threshold|The new female hs-cTn threshold will be baed on current recommendations for each of the assays used (hs-cTn T and I). The hospitals are the unit of randomization. At 5-month intervals, randomly selected hospitals will be advised that they are to transition to the intervention phase. For all men, the standard of care, overall population threshold will be used throughout the entire study.
224307918|NCT05205343|OTHER|Standard of Care|complete a questionnaire within 30 days before your surgery and then at 1, 3, 6, and 12 months after surgery
224307919|NCT05205343|OTHER|Control Group|complete a questionnaire within 30 days before your surgery and then at 1, 3, 6, and 12 months after surgery
224307920|NCT00401609|DRUG|gemcitabine|
224307921|NCT00401609|DRUG|vinorelbine|
224307922|NCT00401609|DRUG|cisplatin|
224307923|NCT00401609|DRUG|etoposide|
224307924|NCT00401609|DRUG|carboplatin|
224307925|NCT00237653|DRUG|Valganciclovir|
224182340|NCT04004299|DIAGNOSTIC_TEST|HCV RNA self-test|Self-test set including instruction manual (video available as well), finger prick device, tube and envelope to safely transport biological material. Patient takes capillary blood sample, collects it in the tube and sends the sample to the lab by regular post mail.
224182341|NCT00002600|BIOLOGICAL|filgrastim|
224182342|NCT00002600|DRUG|carboplatin|
224182343|NCT00002600|DRUG|cyclophosphamide|
224182344|NCT00002600|PROCEDURE|autologous bone marrow transplantation|
224182345|NCT00002600|PROCEDURE|peripheral blood stem cell transplantation|
224182346|NCT04563845|DRUG|GSK3640254|GSK3640254 will be administered.
223490676|NCT06344325|DRUG|fospropofol|The initial dose of fospropofol disodium in the youth group is 15mg/kg,the middle-aged group is 10mg/kg, the elderly group is 7.5mg/kg, and the concentration of adjacent intervals is 0.5mg/kg.
223490677|NCT05067491|BEHAVIORAL|Augmented reality exposure therapy|Virtual objects will be placed in the patient's visual field, superimposed on their real environment for exposure therapy.
223490678|NCT06326216|OTHER|Non-Interventional Study|Non-interventional study
223490679|NCT05184842|DRUG|Venetoclax|Venetoclax 400 mg po on days 1, 8, 15 and 22 of each cycle (28-day cycle)
223490680|NCT05184842|DRUG|Decitabine|Decitabine 0.2 mg/kg SQ (subcutaneous) on days 2, 9, 16, 23 (for aggressive disease will add decitabine on days 3, 10, 17, 24)
223587860|NCT04778800|DRUG|LM-first line treatment|Patients were given a standard dose of almonertinib 110 mg/day, orally, and the first efficacy evaluation was performed 4 weeks later. If there was no disease progression in two consecutive evaluations, the dose of almonertinib was increased to 165 mg /Day, oral ± radiotherapy (decided by the investigator), continue to evaluate the efficacy every 4 weeks until the patient progresses; if there is no disease progression in two consecutive assessments, the dose of almonertinib is increased to 220 mg/day, orally ± Radiotherapy treatment (determined by the investigator), continue to evaluate the efficacy every 4 weeks until the patient progresses.
223587861|NCT04778800|DRUG|LM-second line treatment|Patients were given a standard dose of almonertinib 110 mg/day, orally, and the first efficacy evaluation was performed 4 weeks later. If there was no disease progression in two consecutive evaluations, the dose of almonertinib was increased to 165 mg /Day, oral ± radiotherapy (decided by the investigator), continue to evaluate the efficacy every 4 weeks until the patient progresses; if there is no disease progression in two consecutive assessments, the dose of almonertinib is increased to 220 mg/day, orally ± Radiotherapy treatment (determined by the investigator), continue to evaluate the efficacy every 4 weeks until the patient progresses.
223587862|NCT03256435|BEHAVIORAL|RAMP PrEP initiation, adherence, and retention intervention|The intervention arm will receive facilitated strengths-based case management (SBCM)-delivered by trained interventionists-to help navigate the PrEP medical care system and support the participant and health care staff in meeting the challenges faced with obtaining PrEP medication (e.g., overcoming insurance barriers or barriers with co-pays). This also includes facilitated integration into the PrEP clinic and obtaining monthly PrEP prescription refills.
223587863|NCT01132586|DRUG|Lenalidomide|Given PO
224182347|NCT04563845|DRUG|Placebo|Placebo will be administered.
224182348|NCT04563845|DRUG|Moxifloxacin|Moxifloxacin will be administered.
223490681|NCT02025543|DEVICE|MRI|R2 MRI scan
223490682|NCT05707949|DRUG|Atogepant|Oral Tablet
223490683|NCT05119569|DRUG|Fenebrutinib|Fenebrutinib will be administered orally.
223490684|NCT05119569|DRUG|Placebo|Placebo will be administered orally.
223490685|NCT05045612|OTHER|Stop antibiotic therapy|Stop antibiotic therapy instituted by the admitting physician
223490686|NCT03893955|DRUG|ABBV-927|Intravenous (IV) Infusion
223587864|NCT01132586|DRUG|Cytarabine|Given IV
223745499|NCT02699203|BEHAVIORAL|Low-carbohydrate meal|Participants will consume a low-carbohydrate high fat meal. The macronutrients content will be 10% carbohydrate, 25% protein and 65% fat and will provide 400-500 kcal (matched to the high carbohydrate meal). Between interventions there will be at least a 48-hours washout, where participants are encouraged to return to their baseline dietary habits.
224182349|NCT00800189|RADIATION|Anterior electronic portal images (EPI)|EPI's are taken for the first three consecutive days of treatment to detect set-up errors.
223490687|NCT03893955|DRUG|ABBV-368|Intravenous (IV) Infusion
223490688|NCT03893955|DRUG|ABBV-181|Intravenous (IV) Infusion
223490689|NCT03893955|DRUG|Carboplatin|Intravenous (IV) Infusion
223587865|NCT01132586|DRUG|Idarubicin|Given IV
223587866|NCT01132586|OTHER|Pharmacological Study|Correlative studies
223587867|NCT01132586|OTHER|Laboratory Biomarker Analysis|Correlative studies
223587868|NCT00371982|DRUG|Fish oil (Maxepa)|
223587869|NCT03661086|DEVICE|O2matic|O2matic controls oxygen with the aim of maintaining SpO2 within a predefined target interval, e.g. 88-92 % with the lowest possible supplementation of oxygen by nasal cannula
223587870|NCT02243891|PROCEDURE|Atrial fibrillation ablation|Percutaneous catheter ablation for Atrial fibrillation.
223587871|NCT02243891|PROCEDURE|ROX Coupler insertion|The ROX Coupler is a CE-marked device designed to maintain an iliac arteriovenous fistula
224182350|NCT04797676|PROCEDURE|different methods of specimen acquisition|After informed consent, the investigators use two methods to obtain specimens for patients with pancreatic ductal adenocarcinoma, who needs eus-fnb for auxiliary diagnosis and had the opportunity of surgery. One method is EUS-FNB with wet suction technique, the other is surgery (including radical operation and cytoreductive surgery). Both methods are used on the same patient to remove deviations in results caused by tumor heterogeneity.
224182351|NCT03107273|OTHER|Dynamic cultures of in vitro hematopoietic stem cells|Improvement of prognostic scores used in myelodysplastic syndromes by identifying by dynamic in vitro culture of hematopoietic stem cells dynamic factors, reflections of ineffective haematopoiesis
224182352|NCT01020812|PROCEDURE|TACE|Standard of Care
224182353|NCT01020812|PROCEDURE|SBRT|Standard of Care
224182354|NCT04468100|BIOLOGICAL|Tigerase®|2.5 mL (2.5 mg) dornase alfa nebulized once daily for 168 (+/-7) days
224182355|NCT04468100|BIOLOGICAL|Pulmozyme®|2.5 mL (2.5 mg) dornase alfa nebulized once daily for 168 (+/-7) days
224182356|NCT03465215|DEVICE|Digital holographic microscopy|Tissue obtained from CD patients will be analyzed using digital holographic microscopy. Results will be compared between non-stenotic and stenotic tissue of the intestinal wall of CD patients.
223490690|NCT03893955|DRUG|Nab-paclitaxel|Intravenous (IV) Infusion
223490691|NCT03683030|DEVICE|Multi-Electrode RF Balloon Catheter|Multi-Electrode RF Balloon Catheter will be inserted
223490692|NCT06101303|OTHER|Psychophysical assessment|"Thermal stimuli: The Thermal Sensory Analyzer will be used to deliver heat and cold stimuli. All targeted stimulus temperatures will be less than 50°C, and participants will be free to remove their arm or leg at any time from the thermode. Noxious cold stimuli will also be delivered with a plastic water bath or an electronic electronic temperature-controlled water bath. Participants will be free to pull out of the water bath at any time.~Pressure stimuli: Pressure stimuli will be applied by using a handheld algometer. These devices have a round probe that allows quantifying the amount of pressure that is being applied by real-time visual feedback to control and monitor applied pressure rates. Pressure will be applied to the lower leg, volar forearm, or trapezius.~Mechanical stimuli: A set of standardised von Frey filaments (0.25, 0.5, 1, 2, 4, 8, 16, 32, 64, 128 and 256mN). The contact area of the hairs with the skin is of uniform size (\<1 mm²) and texture."
223490693|NCT06101303|BEHAVIORAL|Psychophysical assessments of experimental pain|"Pain ratings- Pain intensity and pain unpleasantness ratings will be assessed~Pain thresholds to heat, cold and/or pressure will be tested and participants will be instructed to press a button the first moment they feel pain.~Temporal summation- participants will rate the pain evoked by a single pinprick stimulus and by a series of 10 identical pinprick stimuli.~Conditioned pain modulation (CPM) efficiency - CPM testing includes the application of a test stimulus without conditioning (heat or pressure stimuli) and a subsequent application of the same test stimulus together with a conditioning stimulus (cold stimulus).~Offset analgesia will be assessed using the three-temperature method (T1°C 5s, T1+1°C 5s, T1°C 20s). During the OA paradigm, real time pain intensity ratings will be obtained~Cold pain tolerance will be assessed by having participants immerse their hand or foot in a cold water bath. Tolerance will be defined by the time of hand/foot withdrawal."
223490694|NCT06101303|DIAGNOSTIC_TEST|Blood, urine and saliva samples|Blood (approximately 2 tablespoons), urine and saliva samples will be collected and sent to ZRT Laboratory, LabCorp, or internal Washington University lab for analyses of sex hormone levels (e.g., testosterone, estradiol, progesterone). Additional samples will be stored in a biobank for future processing.
223490695|NCT06101303|PROCEDURE|Biopsy and surgery-related data.|During the surgery, biopsies will be collected from the endometriosis lesions as well as from a healthy peritoneum. If there are no endometriosis lesions, biopsies will be taken of two common locations where endometriosis lesion grows (the infra-ovarian fossa). The lesions will be characterized based on their appearance and invasiveness of the lesions (i.e., powder-burn lesions, nonclassical red or white lesions, and superficially or deeply infiltrating (\>5mm) lesions). In addition, surgery-related data such as the incision size, type of anesthesia, pain ratings after the surgery, analgesic medication after the surgery, and side effects will be documented. Blood, saliva, urine, and samples will be collected for hormonal analyses or stored in a Biobank for future analyses.
223490696|NCT02633878|DRUG|"Chinese Herbal Medicine (New Shoutai Wan) plus Oral Progesterone"|"Chinese Herbal Medicine (New Shoutai Wan, one pack twice daily) + Oral Progesterone (100 mg thrice daily)"
223490697|NCT02633878|DRUG|"Chinese Herbal Medicine (New Shoutai Wan) plus Oral Progesterone Placebo"|"Chinese Herbal Medicine (New Shoutai Wan, one pack twice daily) + Oral Progesterone Placebo (100 mg thrice daily)"
223490698|NCT02633878|DRUG|"Chinese Herbal Medicine Placebo (New Shoutai Wan placebo) plus Oral Progesterone"|"Chinese Herbal Medicine Placebo (New Shoutai Wan placebo, one pack twice daily) + Oral Progesterone (100 mg thrice daily)"
223490699|NCT02633878|DRUG|"Chinese Herbal Medicine Placebo (New Shoutai Wan placebo) plus Oral Progesterone Placebo"|"Chinese Herbal Medicine Placebo (New Shoutai Wan placebo, one pack twice daily) + Oral Progesterone Placebo (100 mg thrice daily)"
223490700|NCT03488524|DRUG|AMX0035|Combination therapy of PB and TURSO
223490701|NCT05786664|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
223490702|NCT05786664|OTHER|Electronic Health Record Review|Review of records
223490703|NCT05786664|OTHER|Quality-of-Life Assessment|Complete quality-of-life questionnaires
223490704|NCT05786664|OTHER|Survey Administration|Complete surveys
223490705|NCT04787679|PROCEDURE|Hip replacement surgery|After hip replacement surgery the sponsor obtains femoral head samples for the study
223490706|NCT06469385|BIOLOGICAL|ENS-002|"Live biotherapeutic product (LBP) consisting of commensal, clonal, non-pathogenic bacteria.~Low Dose ENS-002 High Dose ENS-002"
223490707|NCT03229200|DRUG|Ibrutinib|Subjects will continue with the current ibrutinib dosing regimen established in the parent ibrutinib study.
223490708|NCT02390284|DRUG|Latanoprost|Lower intraocular pressure (IOP) by increasing outflow of fluid from the eye.
223490709|NCT02390284|DRUG|Bimatoprost|Lower intraocular pressure by increasing outflow of fluid from the eye.
223745500|NCT05427396|DRUG|JS004|Usage and dosage: Inject 200mg once every 3 weeks
223745501|NCT05427396|DRUG|Toripalimab Injection|Usage and dosage: Inject 240mg once every 3 weeks
224073330|NCT06607627|COMBINATION_PRODUCT|Gefurulimab|Combination product consisting of syringe prefilled with gefurulimab will be administered weekly via subcutaneous (SC) injection.
224073331|NCT06588894|BEHAVIORAL|Questionnaire and Physical Exam|Individuals motor imagery skills will be assessed using a mental chronometer and mental rotation, body awareness will be assessed using the Body Awareness Questionnaire, and cognitive functions will be assessed using the Montreal Cognitive Assessment questionnaire.
224073332|NCT06588894|BEHAVIORAL|Motor Imagery Ability|Individuals motor imagery skills will be assessed using a mental stopwatch and mental rotation, body awareness will be assessed using the Body Awareness Questionnaire, and cognitive functions will be assessed using theMontreal Cognitive Assessment questionnaire.
224073333|NCT06617143|OTHER|mindfulness-based cognitive therapy|In this study, it is planned to apply MBCT to asthmatic inpatients in the patient room in groups of 2 or 3. This application is planned to continue for one hour.
224073334|NCT06617143|OTHER|routine treatment and care|routine treatment and care
224073335|NCT06547021|DEVICE|Transcranial Direct Current Stimulation (tDCS)|"A light electrical current with zero frequency (tDCS) will be applied to the participants' scalp via 2 electrodes, while the participants perform cognitive exercises with the guidance of a trained research assistant. Cognitive exercises will be performed through the Mind Triggers app on an iPad where the participants perform memory and learning games/tasks."
224182357|NCT06519578|DRUG|hepatic artery infusion chemotherapy|"HAIC is a regional therapy that takes advantage of the fact that hepatic tumors, particularly hepatocellular carcinoma, predominantly receive their blood supply from the hepatic artery. The procedure typically involves the insertion of a catheter into the hepatic artery, often through a percutaneous approach or during a surgical procedure.~FOLFOX (5-fluorouracil, leucovorin combined with oxaliplatin) or RALOX (raltitrexed combined with oxaliplatin) Q3W."
224182358|NCT02528643|DRUG|Enzalutamide|Oral capsule
223490710|NCT02390284|DRUG|Travoprost|Lower intraocular pressure by increasing outflow of fluid from the eye.
223490711|NCT02390284|DRUG|Timolol|Lower intraocular pressure by decreasing production of fluid
223490712|NCT02390284|DRUG|Dorzolamide|Lowers intraocular pressure by decreasing intraocular fluid production
223490713|NCT02390284|DRUG|Brinzolamide|Lowers intraocular pressure by decreasing intraocular fluid production
223490714|NCT02390284|DRUG|Acetazolamide|Lowers intraocular pressure by decreasing intraocular fluid production
223490715|NCT02390284|DRUG|Methazolamide|Lowers intraocular pressure by decreasing intraocular fluid production
223490716|NCT01242436|PROCEDURE|intravenous contrast administration|"The additional burden is restricted to a WB-DWI scan before and during therapy.~MRI is a technique based on magnetic fields and do not require the use of ionizing radiation. Because of the strong magnetic field, a few precautions should be taken. This means that all metal and magnetized objects must be removed from the patient before entering the MRI room. Patients with a pacemaker, a cardiac defibrillator or other implanted conductor/prosthesis are for this reason not eligible for the study.~During the examination, an intravenous will be administered. In most cases, patients do not experience any discomfort and the use of this contrast agent is part of the clinical routine."
223490717|NCT03980223|DRUG|Doxycycline Hyclate Delayed-Release 200 mg|200 mg of doxycycline taken by mouth after condomless sexual contact as post exposure prophylaxis (PEP)
223490718|NCT05136599|BIOLOGICAL|Bordetella pertussis D420|Intranasal inoculation of Bordetella pertussis D420 in each naris on Day 0 of the study.
223490719|NCT06239610|DEVICE|electromagnetic placement device|Daily use of an EMPD to verify FT position
223490720|NCT06516575|BEHAVIORAL|sentence manipulations|Auditory stimuli (sentences) are manipulated to have key words masked by noise, or to have prosody (pitch contour) manipulated to be consistent or inconsistent with a specific inferred meaning. Participants repeat the sentences while a camera tracks changes in their eye movements and changes in pupil dilation.
223490721|NCT00434434|DRUG|omalizumab|Aged Liquid; subcutaneous repeating dose
223490722|NCT00434434|DRUG|omalizumab|Lyophilized; subcutaneous repeating dose
223490723|NCT00434434|DRUG|placebo|Subcutaneous repeating dose
223490724|NCT01922934|BEHAVIORAL|Commercial weight loss program|vouchers for Weight Watchers
223490725|NCT01922934|BEHAVIORAL|Colorado Weigh|Group behavioral weight loss program
223490726|NCT01922934|DIETARY_SUPPLEMENT|Meal replacements|Health Management Resources meal replacement products (shakes and entrees)
223490727|NCT01922934|DRUG|Obesity pharmacotherapy|Phentermine or phentermine-topiramate (Qsymia)
223490728|NCT01922934|BEHAVIORAL|Recreation center passes|1 year pass to a Denver recreation center
223490729|NCT04312100|OTHER|oxygen treatment|different kinds of oxygen treatments will be given to patients according to their state of illness
223490730|NCT03495518|OTHER|Symptom feedback to Health Care Provider|"These children will complete SPARK daily for 5 days in a row, daily symptom reports will be printed and provided in the patient chart. On days 1 and 3, a report describing symptoms that are a lot or extremely bothersome will be emailed to the physician providing direct medical"
223490731|NCT03495518|OTHER|Standard of care|A clinical research associate will visit the participant on days 1 and 5±1 and will obtain SSPedi scores on an iPad. Reports will not be printed or emailed to the physician.
224182359|NCT02528643|DRUG|Placebo|Oral capsule
224182360|NCT04864964|PROCEDURE|combined conventional and pulsed radiofrequency (CCPRF)|Patients with trigeminal neuralgia who underwent combined conventional and pulsed radiofrequency (CCPRF) for treatment of pain.
224205722|NCT00609115|DEVICE|AMES device (crossover)|Eighteen treatment sessions for each qualifying subject limb using the AMES device. Each treatment session being 30 minutes long. Sessions to be scheduled preferable 2 to 3 times per week, with the 18 sessions to be completed as soon as possible after the completion of Arm C-1 Sham Comparator.
224205723|NCT03166670|DIAGNOSTIC_TEST|stool examination|collection of stool specimen and microscopic examination for parasites
224205724|NCT03166670|DIAGNOSTIC_TEST|real time polymerase chain reaction|evaluation of genotype of cryptosporidium in stool specimen
224205725|NCT03273010|PROCEDURE|Free gingival graft|Free gingival graft was harvested from palatal donor site
224205726|NCT03273010|PROCEDURE|Cyanoacrylate application|Periacyrl was applied on palatal wounds
224205727|NCT06650943|BEHAVIORAL|Nursing Consultation in Weight Management and Metabolic syndrome|Based on the Carbohydrate-insulin Theory
224205728|NCT04935866|OTHER|Near-infrared spectroscopy (NIRS)|Non invasive brain oxygenation monitoring with Near-Infrared Spectroscopy (NIRS) technology. Patients enrolled in the NeurO2 study will have bilateral NIRS sensors applied to the forehead according to manufacturer recommendations. Data will be monitored continuously throughout the study intervention in the parent trials (HEMOTION and SAHaRA trials) in the neurocritical care unit. Data will be extracted from the device at the end of the study period.
224205729|NCT00245258|DRUG|Sildenafil Citrate|
224205730|NCT04381468|DRUG|Pepinemab|Pepinemab is a humanized IgG4 monoclonal antibody. The antibody is formulated at 20 mg/mL in 20 mM Sodium Acetate buffer, pH 5.4, containing 130 mM Sodium Chloride and 0.02% Polysorbate 80
224205731|NCT04381468|DRUG|Placebo|Placebo consists of formulation buffer only which is 20 mM Sodium Acetate buffer, pH 5.4, containing 130 mM Sodium Chloride and 0.02% Polysorbate 80
224205732|NCT02903095|DRUG|TD-1439|
224205733|NCT02903095|DRUG|Placebo|
224205734|NCT02125734|DRUG|QVA149|QVA149 capsules 110/50 µg for inhalation via Concep-1-inhaler device, taken once a day
224205735|NCT02125734|DRUG|Tiotropium|Tiotropium 18 µg capsules for inhalation via HandiHaler device taken once a day
224205736|NCT03230695|DEVICE|Robotic Therapy|Robotic therapy (MIT - Manus, Interactive Motion Technologies) will be administered for 40 minutes to the paretic upper limb.
223490732|NCT06032637|PROCEDURE|Pfannenstiel incision|Patients randomized to the supra-umbilical transverse incision arm will receive a transverse skin incision halfway between the umbilicus and xiphoid process, extending laterally to the semilunar lines. The subcutaneous tissue will be bluntly dissected until the anterior rectus sheath is exposed. A transverse incision will be made through the rectus sheath in line with the skin incision, avoiding injury to the superior epigastric vessels. The rectus muscles will be split manually using blunt dissection. The peritoneum will be incised transversely and the hysterotomy extended laterally to deliver the fetus. The visceral peritoneum will not be closed. The rectus muscles will not be re-approximated. The subcutaneous tissue will not be irrigated but closed if over 2cm depth. The skin will be closed with non-absorbable suture subcuticularly.
223490733|NCT06032637|PROCEDURE|Supra-umbilical transverse incision|Patients randomized to the supra-umbilical transverse incision arm will receive a transverse skin incision 3-4cm above the umbilicus, extending laterally to the semilunar lines, without panniculus retraction. The subcutaneous tissue will be bluntly dissected until the anterior rectus sheath is exposed. The rectus sheath will be incised transversely using electrocautery for hemostasis, avoiding injury to the superior epigastric vessels. The rectus muscles will be split manually along the midline using blunt dissection. The peritoneum will be transversely incised and the hysterotomy extended laterally to deliver the fetus. The visceral peritoneum will not be closed. The rectus muscles will not be re-approximated. The subcutaneous tissue will not be irrigated but closed if over 2cm depth. The skin will be closed with non-absorbable suture subcuticularly.
223490734|NCT00120978|DRUG|Advair|
223490735|NCT00120978|DRUG|Flovent|
223490736|NCT00608179|DRUG|Glimepiride|Glimepiride (Amaryl) 4 mg oral dose during protocol, given once during each protocol.
223490737|NCT00608179|DRUG|glyburide|Glyburide (Dia-Beta) 10 mg oral dose during protocol, given once during each protocol.
223490738|NCT00608179|OTHER|glucose clamp|Hyperinsulinemic euglycemic glucose clamp procedure-120 minutes
223490739|NCT00608179|OTHER|glucose clamp|hypoglycemic glucose clamp procedure -120 minutes
224073336|NCT06547021|DEVICE|Gamma Transcranial Alternating Current Stimulation (tACS)|"A light electrical current with personalized gamma frequency (tACS) will be applied to the participants' scalp via 2 electrodes, while the participants perform cognitive exercises with the guidance of a trained research assistant. Cognitive exercises will be performed through the Mind Triggers app on an iPad where the participants perform memory and learning games/tasks."
224073337|NCT06547021|DEVICE|Theta Transcranial Alternating Current Stimulation (tACS)|"A light electrical current with personalized theta frequency (tACS) will be applied to the participants' scalp via 2 electrodes, while the participants perform cognitive exercises with the guidance of a trained research assistant. Cognitive exercises will be performed through the Mind Triggers app on an iPad where the participants perform memory and learning games/tasks."
224073338|NCT06547021|DEVICE|Sham|"Sham stimulation (i.e. only slight stimulation at the beginning and at the end for a few seconds with majority of the time having no stimulation) will be applied to the participants' scalp via 2 electrodes, while the participants perform cognitive exercises with the guidance of a trained research assistant. Cognitive exercises will be performed through the Mind Triggers app on an iPad where the participants perform memory and learning games/tasks."
224073339|NCT06547021|DEVICE|Gamma Transcranial Alternating Current Stimulation (tACS)-Precuneus|"A light electrical current with personalized gamma frequency (tACS) will be applied to the participants' scalp via 2 electrodes, while the participants perform cognitive exercises with the guidance of a trained research assistant. Cognitive exercises will be performed through the Mind Triggers app on an iPad where the participants perform memory and learning games/tasks."
224073340|NCT05036083|PROCEDURE|Contrast-Enhanced Mammography|Undergo CEM
224073341|NCT05036083|PROCEDURE|Digital Tomosynthesis Mammography|Undergo DBT
224073342|NCT05036083|OTHER|Electronic Health Record Review|Medical records reviewed
224073343|NCT05036083|DRUG|Iodinated Contrast Agent|Given IV
224073344|NCT07133880|DRUG|umeclidinium 62.5 µg and vilanterol 25 µg|DPI Treatment
224073345|NCT07133880|DRUG|Revefenacin 175 µg, Formoterol 20 µg|Nebulizer Treatment
224073346|NCT07133880|DRUG|Placebo ( Revefenacin and Formoterol )|Placebo Nebulizer Treatment
224073347|NCT07133880|DRUG|Placebo DPI|Placebo DPI Treatment
224073348|NCT07128355|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|Starting on Day 1 participants will have 2-4 treatments per week for about 2 weeks, with no more than 2 days in a row. This is expected to last about 2 weeks but could last up to 3 weeks.
224073349|NCT07128355|DRUG|Botensilimab|Administered once every 6 weeks by intravenous infusion over about 30 minutes, on Day 1 of Cycles 1-4 (six-week cycles). Administered 30 minutes after balstilimab.
224073350|NCT07128355|DRUG|Balstilimab|Administered once every 2 weeks by intravenous infusion over about 30 minutes, starting on Day 1 of Cycle 1 and continuing for 4 six-week cycles (with botensilimab) followed by up to 14 six-week cycles of balstilimab alone. Participants will receive balstilimab for a total of 18 six-week cycles.
224073351|NCT06675799|BEHAVIORAL|Sleep Extension|Weekly educational material about sleep health and weekly brief phone coaching calls for a total of 6 weeks.
224073352|NCT06675799|BEHAVIORAL|Healthy Living Psychoeducation|Weekly educational materials about healthy habits and weekly brief phone calls to clarify terms or concepts.
224073353|NCT07006233|BEHAVIORAL|Whole Food Ketogenic Diet|Education around immediate changes to improve diet quality and barriers to dietary behaviour change. Participants will consume a whole-food diet focused on improving diet quality based on the NOVA classifications of unprocessed or minimally processed foods/ingredients (removal of NOVA category 4 foods from diet). This group will focus on the consumption of low-energy, nutrient dense whole foods with a targeted carbohydrate intake of 30-50g per day to achieve nutritional ketosis. The WFKD will adjust carbohydrate level for the individual participant to achieve average blood/urinary ketone levels of between 0.5 and 3.0 mmol/L (tested for objective feedback using a mix of urinary ketone sticks and finger prick blood measures).
224205737|NCT03230695|DEVICE|Active stimulation|Active transcranial direct current stimulation will be applied with the cathode positioned over the ipsilesional primary motor cortex and the anode over the contralateral supraorbital region for 20 minutes (1mA).
224205738|NCT03230695|DEVICE|Sham stimulation|In sham transcranial direct current stimulation, no current will be delivered through the transcranial direct current stimulation device after the first 30 seconds.
224205739|NCT06417749|BEHAVIORAL|Control arm|Participants will receive a copy of the Chinese Dietary Guidelines leaflet at baseline.
224182361|NCT04310904|OTHER|contrast assessment of cardiac output (CO)|Patients hospitalized in ICU will be included if they need a trans esophageal echocardiographic evaluation and a research of intra cardiac shunt (using a saline contrast test). Patients with Swan Ganz catheter will be included as well. Cardiac output will be measured using cardiac Doppler. Simultaneously, 4.5 ml of saline with 0.5 ml of air will be agitated to have a contrast solution. This solution will be injected as usual and echocardiographic imaging will be recorded. These imaging will be analyzed off-line and CO will be calculated with an algorithm previously developed and compared with the reference method. In case of swan ganz catheter, the cardiac output will be also measured using the thermodilution technique.
224182362|NCT04310904|OTHER|cardiac Doppler technique|Patients hospitalized in ICU will be included if they need a trans esophageal echocardiographic evaluation and a research of intra cardiac shunt (using a saline contrast test). Patients with Swan Ganz catheter will be included as well. Cardiac output will be measured using cardiac Doppler. Simultaneously, 4.5 ml of saline with 0.5 ml of air will be agitated to have a contrast solution. This solution will be injected as usual and echocardiographic imaging will be recorded. These imaging will be analyzed off-line and CO will be calculated with an algorithm previously developed and compared with the reference method. In case of swan ganz catheter, the cardiac output will be also measured using the thermodilution technique.
224182363|NCT04692974|DEVICE|Mobile phone application and smart watch|Mobile phone application prompts
224182364|NCT03572348|PROCEDURE|Transecting anastomotic repair (tAR)|Classic technique, which involves full thickness transection of the corpus spongiosum and the embedded urethral blood supply.
224182365|NCT03572348|PROCEDURE|Vessel-sparing anastomotic repair (vsAR)|Alternative technique, leaving the bulbar arteries intact, only transecting and excising the narrow segment of the urethra and the surrounding spongiofibrosis.
223490740|NCT04235946|OTHER|accompanied and adapted water polo program|"Validated questionnaires in French will measure fatigue, quality of life, post-traumatic growth and the coach-athlete relationship. All questionnaires will be administered face to face before the sessions by a member of the social psychology research team.~The collection of qualitative data (semi-structured interviews) will be carried out by one of the members of the research team in social psychology on three occasions (inclusion, Week 10 and Week 20) in order to assess the psychological variables of interest (quality interpersonal relationships, self-esteem, post-traumatic growth) and their dynamics.~Physiological variables (weight, fat / lean mass, capacity of the operated arm) will be evaluated monthly. The physical measurement data will be recorded in an electronic case report form"
223490741|NCT01053455|DEVICE|SiPAP|biphasic CPAP (SiPAP) to be alternated in 1 hour blocks with NCPAP
223490742|NCT04004182|DIETARY_SUPPLEMENT|Fruit bar with addition of polyphenols|Fruit bar with addition of 600mg bilberry anthocyanins and 1200mg apple polyphenols
223490743|NCT00003308|RADIATION|stereotactic radiosurgery|
223490744|NCT02314013|DRUG|Cephalosporin + Metronidazole|intravenous antibiotics injection (3rd generation cephalosporin + metronidazole)and then change to oral antibiotics (3rd generation cephalosporin+ metronidazole) (an expected average 10 days)
223490745|NCT03641157|OTHER|Easy Intubation|
223490746|NCT06280651|OTHER|dietary preferences and their implications for oral health in children with Autism Spectrum Disorder|This study design typically does not involve interventions. Instead, it observes and analyzes existing conditions or behaviors-in this case, dietary preferences and their implications for oral health in children with Autism Spectrum Disorder (ASD)-without the researchers applying any specific treatment or experimental condition to the participants. The aim is to identify correlations or patterns at a specific point in time, rather than to assess the effects of an intervention.
223490747|NCT02354118|OTHER|Heparinized saline catheter flush|The control group will have their port catheters flushed with 20mL saline + 5mL heparin 100 units/mL; q 3 months
223490748|NCT02354118|OTHER|Saline-only catheter flush|The intervention group will have their port catheters flushed with saline only.
223490749|NCT04103008|DIAGNOSTIC_TEST|Speckle tracking echocardiography|assess left ventricular function on admission and after 40 days
223490750|NCT04781062|DIAGNOSTIC_TEST|Blood and urine molecular analysis (Timing 0)|peripheral blood and urine sample collection
223490751|NCT04781062|DIAGNOSTIC_TEST|Blood and urine molecular analysis (Timing 1)|peripheral blood and urine sample collection
223490752|NCT01180062|DRUG|Latanoprost|"Group 1 will be given a single, low dose Latanoprost SR insert that contains a daily dose of 0.5µg Latanoprost.~Group 2 will be given two, low dose Latanoprost SR inserts that contain a combined daily dose of 1.0µg Latanoprost.~Duration of drug release is expected to be 3-6 months.~Group 3 will be given a single, low dose Latanoprost SR insert that contains a daily dose of 2.0µg Latanoprost."
223490753|NCT01180062|DRUG|Arm 2|Group 2 will be given two, low dose Latanoprost SR inserts that contain a combined daily dose of 1.0µg Latanoprost.
223490754|NCT01180062|DRUG|Latanoprost SR insert|Group 3 will be given a single, low dose Latanoprost SR insert that contains a daily dose of 2.0µg Latanoprost.
223490755|NCT01583088|DEVICE|phenique nerve stimulation NeurX™ (Synapse Biomedical)|phenique nerve stimulation NeurX™ (Synapse Biomedical)
223490756|NCT01583088|DEVICE|sham phrenic nerve stimulation|sham phenic nerve stimulation
223490757|NCT05166876|DRUG|Brequinar Sodium|50 mg, 100 mg, 150 mg, 200 mg x 5 days
223490758|NCT05166876|DRUG|Dipyridamole 75 MG|75 mg TID for 5 days
223490759|NCT05166876|DRUG|Placebo|50 mg, 100 mg, 150 mg, 200 mg x 5 days
223490760|NCT05790590|DIAGNOSTIC_TEST|Double low dose CT|Simultaneous reduction of both radiation dose and contrast media dose
223490761|NCT05790590|DIAGNOSTIC_TEST|Standard dose CT|CT with standard radiation dose and contrast media dose
223490762|NCT00658528|DRUG|Rabeprazole sodium|Rabeprazole ER 50 mg capsule, taken orally, once daily for 4-8 weeks.
223490763|NCT00658528|DRUG|Esomeprazole|Esomeprazole 40 mg capsule, taken orally, once daily for 4-8 weeks.
223490764|NCT05919134|DIETARY_SUPPLEMENT|Dentoblis|dissolve the tablets in the mouth once a day for 4 weeks
223490765|NCT05919134|DIETARY_SUPPLEMENT|Placebo|dissolve the tablets in the mouth once a day for 4 weeks
223490766|NCT01918228|BEHAVIORAL|Talks about what science says about LBP|Two talks, a folder with general stretching exercises and possibility to contact health professional by telephone
223490767|NCT03052621|PROCEDURE|Omental transposition|Harvesting the omentum to cover irradiated defects of breast cancer
223490768|NCT01937299|DRUG|Brinzolamide 1%/brimonidine 0.2% ophthalmic suspension|
223490769|NCT01937299|DRUG|Vehicle|Inactive ingredients used as a placebo comparator
223490770|NCT01937299|DRUG|Travoprost 0.004% ophthalmic solution|
223490771|NCT05507177|OTHER|communication training programme for healthcare providers|the communication training programme is specifically designed to help Dutch primary care healthcare providers facilitate adequately deprescribing cardiometabolic medication in older patients
223490772|NCT01550926|DRUG|120 mg orlistat|2 X60 mg capsule
223490773|NCT01550926|DRUG|60 mg orlistat|60 mg orlistat
223490774|NCT01550926|DRUG|orlistat experimental dose|experimental
224205740|NCT06417749|BEHAVIORAL|Intervention arm|Participants will be given three MIND diet education videos on different topics at baseline and during follow-up. In addition, each participant will receive a MIND diet education brochure at baseline and some food supply during follow-up.
223490775|NCT04923451|DEVICE|Active Trans-cranial direct current stimulation (tDCS)|5 active sessions (1/day for 5 consecutive days) of tDCS (NeuroConn DC), active anode 8cm2 on right dorso-lateral prefrontal cortex and neutral cathode, 2 mA, during 30 min will be performed
223490776|NCT04923451|DEVICE|Sham Trans-cranial direct current stimulation (tDCS)|5 placebo sessions (1/day for 5 consecutive days) of sham tDCS (NeuroConn DC), anode 8cm2 on right dorso-lateral prefrontal cortex and neutral cathode during 30min will be performed
223490777|NCT00385840|BIOLOGICAL|Influenza Vaccine GSK1247446A|Single dose, intramuscular injection
223490778|NCT00385840|BIOLOGICAL|FluarixTM|Single dose, intramuscular injection
223490779|NCT00555854|BEHAVIORAL|An individual motivational intervention program to promote and maintain self-care behaviour|5 individual interviews in an one year period
223490780|NCT03292302|DRUG|Placebo|Placebo comparator
223490781|NCT03292302|DRUG|ELX-02|Synthetic aminoglycoside
223490782|NCT04801212|OTHER|core stability exercises with teeth clenching|The intervention frequency will be 2 sessions per week for the duration of 6 weeks, comprising of 45 minutes session. Both groups will receive heat pack on lumbar spine for 12 minutes and both interventions will be held under the supervision of qualified Musculoskeletal Physiotherapists. During intervention and after 6 weeks of intervention.
223490783|NCT04801212|OTHER|core stability exercises|The intervention frequency will be 2 sessions per week for the duration of 6 weeks, comprising of 45 minutes session. Both groups will receive heat pack on lumbar spine for 12 minutes and both interventions will be held under the supervision of qualified Musculoskeletal Physiotherapists. During intervention and after 6 weeks of intervention.
223490784|NCT00692796|OTHER|Pulmonary rehabilitation|Pulmonary rehabilitation is a multi-disciplinary program that includes exercise training, disease education, psychosocial education (e.g., stress management, coping with chronic illness) and nutrition education.
223490785|NCT02970045|PROCEDURE|Biospecimen Collection|Undergo collection of blood, tissue, and other biological samples
223490786|NCT02970045|PROCEDURE|Evaluation of Cancer Risk Factors|Ancillary studies
224073354|NCT07006233|BEHAVIORAL|Whole Food Diet|Education around immediate changes to improve diet quality and barriers to dietary behaviour change. Participants will consume a whole-food diet focused on improving diet quality based on the NOVA classifications of unprocessed or minimally processed foods/ingredients (removal of NOVA category 4 foods from diet). This diet is high carbohydrate (45-65% of total energy coming from carbohydrate, 20-35% from fat and 15-25% from protein) based on the Australian dietary guidelines focusing on the consumption of low-energy, nutrient dense whole foods. The higher carbohydrate diet reflects current contemporary 'standard care' dietary recommendations as outlined by the National Health and Medical Research Council's Australian Dietary Guidelines, and therefore represents the most appropriate control diet to compare to the effects of the proposed intervention.
223490787|NCT02970045|OTHER|Medical Chart Review|Review of medical chart
224073355|NCT07019376|OTHER|Visual biofeedback supported lumbopelvic movement training|6 exercises that provide movement of the lumbopelvic region will be performed for 8 weeks and 2 times each week. The exercises will be followed visually with the help of a laser.
224073356|NCT07019376|OTHER|visual biofeedback unsupported lumbopelvic movement training|6 exercises that provide movement of the lumbopelvic region will be performed for 8 weeks and 2 times each week. The exercises will be the same exercises as the group with laser support, but no visual support will be provided.
224073357|NCT06245603|DEVICE|Hydeal Cyst®|"BCG or MMC will be started within 1-2 weeks from randomization (within 4-6 weeks after TURB).~BCG or MMC will be administered once a week by intravesical instillation: BCG will be abministered for 6 weeks and MMC for 8 weeks. (induction cycles) Before instillations a physical examination will be performed and symptoms evaluated: changes from baseline and abnormalities will be recorded in patient notes.~IPSS questionnaire and QoL questionaire will be administered to the patient at week 1, 4 and 6/8 (6 for BCG and 8 for MMC) of treatment.~48 hours after post BCG or MMC intravesical instillation, patients of Arm A will undergo Hydeal Cyst intravesical instillation.~BCG patiens will received 6 Hydeal Cyst intravesical instillation; MMC patiens will received 8 Hydeal Cyst intravesical instillation."
224073358|NCT07018661|DIAGNOSTIC_TEST|[18F]FAPI-74 PET/CT|Patients included in the study will undergo FAPI-PET/CT after initial staging with gastroscopy and a contrast-enhanced CT of thorax and abdomen, but before undergoing a staging laparoscopy. Based on the results of the FAPI-PET/CT, the MDT and/or treating physician will decide on the next step: confirming possible malignant lesions on PET/CT by biopsies (either percutaneous of by staging laparoscopy), or in case of negative PET/CT, diagnostic laparoscopy.
224073359|NCT07018661|DRUG|[18F]-FAPI-74|\[18F\]-FAPI-74 will be administered intravenously 60 minutes before PET/CT-scanning to be able to detect (metastases of) gastric cancer
224073360|NCT06627517|DEVICE|Episodic overnight patch pump|Subjects will wear the study device overnight for a period of 13 weeks in conjunction with use of Dexcom G6.
224073361|NCT06631872|BEHAVIORAL|Tele-prehabilitation education session: Surgery School|Online telehealth education program using videos and a live clinician facilitator
223490788|NCT02970045|OTHER|Quality-of-Life Assessment|Ancillary studies
223490789|NCT02970045|OTHER|Questionnaire Administration|Ancillary studies
223490790|NCT01785901|OTHER|without interventions|without interventions
223490791|NCT01034553|DRUG|Aurora A kinase inhibitor MLN8237|Given orally
223490792|NCT01034553|DRUG|bortezomib|Given IV
223490793|NCT05000762|DIETARY_SUPPLEMENT|Zinc|Zinc gluconate 30 mg/day orally
224182366|NCT02664974|DIETARY_SUPPLEMENT|Enteral nutrition|"Home Enteral Nutrition was planned to cover the basal energy requirement calculated with Harris Benedict Formula, it was administrated preferentially during nocturnal hours as an integration of oral diet.~Enteral Nutrition included any standard polymeric formula providing 1-1.5 Kcal/mL with carbohydrates 50%-60%, lipids 25%-35% and protein 12%-20%.~Home Enteral Nutrition can be withdrawn in the treated group, after 2 months from discharge, whenever a weight gain ≥ 5% is reported, and oral alimentation is regular and adequate."
224182367|NCT02664974|OTHER|Dietary counseling|"Specific nutritional advices including total energy and protein requirements were provided to patients and oral high-calorie supplements were prescribed whenever necessary.~Home Enteral Nutrition can be started in patients of the control group, not before two months from discharge, if a further weight loss ≥ than 5% is reported."
224182368|NCT02463812|DRUG|Intralipid|
224182369|NCT02463812|DRUG|Saline|
224182370|NCT00372658|DRUG|1% Lidocaine intracervical injection|
224182371|NCT00761891|OTHER|Chewable aspirin|chewable aspirin 81mg daily for 2 weeks
224182372|NCT02708576|BIOLOGICAL|NGM313|
224182373|NCT02708576|OTHER|Placebo|
224182374|NCT00777790|BIOLOGICAL|Meningococcal Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
223490794|NCT04552093|DRUG|Floxuridine|Administration of intra-arterial floxuridine via the HAIP (HAIP chemotherapy) to the liver with concomitant Dutch standard of care systemic FOLFOX (5-FU, leucovorin and oxaliplatin) or FOLFIRI (5-FU, leucovorin and irinotecan).
223490795|NCT04552093|DEVICE|Tricumed IP2000V infusion pump|Surgical implantation of hepatic artery infusion pump (HAIP) followed by administration of the combined chemotherapy (HAIP and systemic).
223490796|NCT04607031|DIAGNOSTIC_TEST|measurement of serum ST2 concentrations in serum of patients with acute, ischemic stroke|7 measurements of serum ST2 concentrations from day 0 to day 6, modified Rankin scale before, 6th and 90th day, NIHSS from day 0 to day 6 and 90, TOAST and OCSP classifications
223490797|NCT05548894|DEVICE|stabilization splint|upper acrylic splint rest on the maxillary teeth and had flat surface
223490798|NCT05548894|DEVICE|laser therapy|The laser apparatus had a hand piece on which either a specially designed optic prism was attached to transfer laser energy to the tip of the prism
224182375|NCT00777790|BIOLOGICAL|Meningococcal Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
224182376|NCT00777790|BIOLOGICAL|Meningococcal Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
224182377|NCT05728710|PROCEDURE|Endoscopic submucosal dissection|standard ESD performed and complicated with a perprocedural or delayed perforation
224182378|NCT04839900|OTHER|Proactive iCCM|CHWs in the proactive iCCM intervention arm will conduct weekly visits of all households in their communities to detect children \< 5 years with diarrhea or cough, and people of all ages complaining of fever or history of fever. People with fever or history of fever in the past 48 hours, or any person with symptoms suggestive of malaria (chills, headache, muscle ache, fatigue, etc), will receive an RDT; those with positive results will be defined as confirmed malaria cases, and will receive the first line antimalarial. Any child under 5 years with diarrhea will be treated with oral rehydration solution (ORS) and zinc, and any child meeting diagnostic criteria for pneumonia will receive the first line antibiotic recommended per national iCCM policy. If the CHW does not have the indicated therapy on hand, the patient will be referred for treatment.
223490799|NCT05548894|DEVICE|stabilization splint and laser therapy|the stabilization splint used in combination of treatment with laser therapy
223490800|NCT04685811|DRUG|68Ga-PSMA-generator vs. 68Ga-PSMA-cyclotron|68Ga-PSMA-generator vs. 68Ga-PSMA-cyclotron; single dose each, approximately 100-300 mBq.
223490801|NCT01706328|DRUG|FF/VI 100/25 Inhalation Powder NDPI|Subjects randomized to the FF/VI Inhalation Powder Novel Dry Powder Inhaler (NDPI) arm will receive a single inhalation of 100 mcg FF and 25 mcg VI via NDPI every morning for 12 weeks.
223490802|NCT01706328|DRUG|Fluticasone Propionate/Salmeterol 250/50 Inhalation Powder ACCUHALER/DISKUS|Subjects randomized to the Fluticasone Propionate/Salmeterol Inhalation Powder ACCUHALER/DISKUS arm will receive a single inhalation of 250 mcg Fluticasone Propionate and 50 mcg Salmeterol via ACCUHALER/DISKUS once in the morning and once in the evening for 12 weeks.
223490803|NCT01706328|DRUG|Placebo Inhalation Powder NDPI|Subjects randomized to the Fluticasone Propionate/Salmeterol Inhalation Powder ACCUHALER/DISKUS arm will receive a single inhalation of placebo inhalation powder via NDPI every morning for 12 weeks.
223490804|NCT01706328|DRUG|Placebo Inhalation Powder ACCUHALER/DISKUS|Subjects randomized to the FF/VI Inhalation Powder NDPI arm will receive a single inhalation of placebo inhalation powder via ACCUHALER/DISKUS once in the morning and once in the evening for 12 weeks.
223490805|NCT01706328|DRUG|Salbutamol as needed|Salbutamol inhalation powder
224182379|NCT01919749|OTHER|treated recommended|Treatment will be recommended after reviewing the profiling analysis
224182380|NCT02336191|PROCEDURE|living donor liver transplantation|living donor liver transplantation
224182381|NCT02074059|DRUG|Lucinactant for Inhalation|Lucinactant for Inhalation refers to the active investigational agent, lucinactant, in combination with the investigational delivery device (drug-device combination product)
224182382|NCT02074059|DEVICE|nCPAP alone|nCPAP therapy
224205741|NCT01308762|BIOLOGICAL|Heat killed whole cell M. obuense (IMM-101) 0.1 mg|"Each patient will receive an intradermal placebo injection of borate buffered saline solution (day -3) to provide an intra patient placebo control. Patients who were willing and able to proceed with the study will receive an intradermal injection of a single dose level of IMM 101 on three subsequent occasions. Doses of IMM 101 were administered over a 4 week period on days 0, 14 and 28.~Dose levels to be administered are 0.1 mg, 0.5 mg and 1.0 mg."
223490806|NCT02015156|BIOLOGICAL|PF-05280014|Concentrate for solution for infusion, sterile vial 150 mg, single-dose 6 mg/kg administered as 90-minute infusion on Day 1
223490807|NCT02015156|BIOLOGICAL|Herceptin®|Concentrate for solution for infusion, sterile vial 440 mg, single-dose 6 mg/kg administered as 90-minute infusion on Day 1
223490808|NCT01762189|PROCEDURE|Phototherapy|The decision to use phototherapy conformed to the hour-specific threshold value for phototherapy presented by the American Academy of Pediatrics guidelines and was not at the discretion of the investigators.
223490809|NCT04727008|BIOLOGICAL|CXCR4 modified anti-BCMA CAR T cells|intravenous infusion
223490810|NCT03160170|DEVICE|SISTER device|Use of the Suction-Integrated Surgical Tissue Elevator \& Retractor (SISTER) device during surgery
223490811|NCT03018938|DRUG|Insulin Analog Mid Mixture|Administered SC
223490812|NCT03018938|DRUG|Basal Insulin Analog|Administered SC
223490813|NCT01769586|DRUG|Diphenhydramine|
223490814|NCT01769586|DRUG|Midazolam|
223490815|NCT06646471|GENETIC|Bio-bank repository|Blood samples taken during the screening phase prior to the first administration of systemic treatment and stored in a repository for a maximum duration of 10 years
223490816|NCT06646471|OTHER|Quality of Life (QoL)|"Collection of EORTC QoL questionnaires QLQ-F17, QLQ-LC13 and QLQ-ELD14:~* stage 3 non-operable/non-radiable, stage 4: at inclusion, 12 weeks, 6 months of treatment, first-line progression.~* operable stage 1 to 3b: at inclusion, end of neoadjuvant period before surgery post-operative baseline, at 6 months, at 12 months.~* radiable stages 3a to 3c: at inclusion, at the end of thoracic radiotherapy, at 6 months, at 12 months."
223490817|NCT06646471|PROCEDURE|G-Code|G-CODE: Katz Autonomy Scale (ADL), Instrumental Activities of Daily Living questionnaire (IADL), Charlson score, mini GDS, mini COG, falls history, Timed Get Up and Go test, social environment.
223490818|NCT05184816|DRUG|Deferoxamine (DFO)|The accelerated single-patient dose escalation will apply to dosing cohorts 1 through 4 (10mg, 30mg, 60mg, 100mg) and will convert to a 3+3 dose escalation for cohorts 5 through 9 (150mg, 210mg, 280mg, 372mg, 495mg).
223490819|NCT06390904|DRUG|GnRH antagonist|Gonadotropin-releasing hormone analogue, intramuscular injection of 3.75mg will be given every 4 weeks, and the maximum treatment courses will be 6. If the patient get CR within 6 courses, another 2 courses will be used as consolidation therapy.
223490820|NCT06390904|DRUG|Letrozole 2.5mg|2.5mg po qd.
223490821|NCT05360706|GENETIC|AAV5-hFIX|AAV5 containing a codon-optimized human factor IX gene
223490822|NCT06064149|BEHAVIORAL|CARE-PC Web-Based Application|The CARE-PC app is a pragmatic, patient-oriented, web-based application that enables the education of patients regarding cardiovascular (CV) risks and collects CV and prostate cancer-related risk variables and CV care access data from prostate cancer patients receiving ADT.
223490823|NCT06532773|BEHAVIORAL|Nite2Day+|Mindfulness-based sleep strategies and cognitive-behavioral symptom coping skills.
223490824|NCT03619525|PROCEDURE|lung recruitment|During bypass, patients in this group will receive a lung protective design in the form of continuous positive airway pressure (CPAP) by closing APL valve at pressure of 5 Cm H2o combined with intermittent recruitment by sustained manual lung inflation at a pressure of 35 cmH2O for 30 seconds every (30-40) minute
223490825|NCT03672162|PROCEDURE|Total abdominal hysterectomy|Each drug group undergo elective total abdominal hysterectomy with the same general anesthesia
223490826|NCT05618301|DRUG|Motixafortide|Motixafortide is to be administered as a subcutaneous injection at a dose of 1.25 mg/kg
223490827|NCT05618301|DRUG|Natalizumab|Natalizumab will be administered as an IV infusion at a flat dose of 300 mg
223490828|NCT05618301|PROCEDURE|Leukapheresis|Leukapheresis consisting of a 1 Blood Volume procedure
223490829|NCT06010017|BEHAVIORAL|STEPP Intervention|Peer support intervention comprised of five learning modules on psychoeducation and supportive psychotherapy strategies, via virtual platform. If participants do not have a smart device, one will be provided by the study team.
223490830|NCT04323475|BIOLOGICAL|Bacteriophage cocktail spray|Study intervention consists of a dosage-metered airless spray containing a cocktail of 14 bacteriophages at a concentration of 1.4 x 10\^8 PFU/mL for an effective dosage of 2.5 x10\^5 PFU/cm\^2 of burned area. The study intervention will be applied in conjunction with standard of care.
223490831|NCT04323475|DRUG|Xeroform|Standard of care will consist of Xeroform primary dressing and Kenacomb topical antibiotic cream (for wounds with signs of localized infection)
223490832|NCT05054881|OTHER|sciatic nerve blockade under ultrasound control with a peripheral nerve stimulator|"Following the ultrasound visualization of the sciatic nerve, a insulated injection needle was connected to the nerve stimulator . Under ultrasound visualization guidance, the needle of the electronic nerve stimulator was positioned at the sciatic nerve (in plane) from its lateral side at a slightly superior position . A marker for LA introduction was the visualization of the needle end near the nerve, and a positive muscular response . Subsequently, the introduction of LA solution was initiated.If LA was spreading from the lateral side down to the nerve, then the needle was replaced to the upper point of the nerve and the rest of LA was introduced, and vice versa . The presence of a complete and incomplete spread of LA along the entire circumference of the nerve was assessed. Correspondingly, if the anesthetic was spreading upwardly, the needle would be downwardly replaced.~In addition, a femoral nerve block is performed."
223490833|NCT05054881|OTHER|sciatic nerve blockade under ultrasound control without a peripheral nerve stimulator|"Under ultrasound visualization guidance, the needle owas positioned at the sciatic nerve (in plane) from its lateral side at a slightly superior position . A marker for LA introduction was the visualization of the needle end near the nerve. Subsequently, the introduction of LA solution was initiated. The position of the needle was corrected 1-2 times according to the type of anesthetic spread. If LA was spreading from the lateral side down to the nerve, then the needle was replaced to the upper point of the nerve and the rest of LA was introduced, and vice versa . The presence of a complete and incomplete spread of LA along the entire circumference of the nerve was assessed. Correspondingly, if the anesthetic was spreading upwardly, the needle would be downwardly replaced.~In addition, a femoral nerve block is performed."
223490834|NCT06468462|DRUG|WHO-recommended periodic presumptive treatment|400 mg po cefixime plus 1 gram azithromycin po under direct observation
223490835|NCT06468462|DRUG|Doxycycline post-exposure prophylaxis|200 mg po doxycycline within 24-72 hours after condomless anal or vaginal sex as frequently as daily
223490836|NCT02053116|DRUG|PF-05175157|Tablet, 200 mg, twice daily, 6 weeks
223490837|NCT02053116|DRUG|Placebo|Tablet, 0 mg, twice daily, 2 weeks
224182387|NCT05038111|DRUG|Dexmedetomidine|perioperative dexmedetomidine infusion
224182388|NCT00266604|DRUG|Topiramate|
224182389|NCT01335659|DEVICE|Fractional flow reserve|Fractional flow reserve measured by pressure wire
224182390|NCT01335659|DEVICE|IVUS|"intravascular ultrasound~:IVUS was performed in a standard fashion using an automated motorized pullback system (0.5mm/s) with commercially available imaging catheter"
223490838|NCT05604950|DIAGNOSTIC_TEST|Since the data were collected retrospectively, there were no interventions|Since the data were collected retrospectively, there were no interventions
223490839|NCT00637897|DRUG|docetaxel|
223490840|NCT00637897|DRUG|ixabepilone|
223490841|NCT00637897|DRUG|paclitaxel|
223490842|NCT00637897|DRUG|paclitaxel albumin-stabilized nanoparticle formulation|
223490843|NCT00637897|DRUG|paricalcitol|
224073362|NCT06631872|BEHAVIORAL|Individualised Inspiratory Muscle Training and Walking Program|An individualised inspiratory muscle training and walking program delivered by a Physiotherapist using telehealth.
224073363|NCT06631872|OTHER|Usual Care|Usual care alone. Usual care will be reviewed every four months during the trial and site leads will be asked to provide information about any changes to usual hospital and medical care at their site.
224073364|NCT07023003|DRUG|Enalapril 10mg QD|Enalapril 10mg PO QD will be given to manage postpartum hypertension. Duration of treatment to be dictated by primary provider.
224073365|NCT07023003|DRUG|Nifedipine 30mg XL BID|Nifedipine 30mg XL BID will be given to manage postpartum hypertension. Duration of treatment to be dictated by primary provider.
224073366|NCT07025005|DRUG|Bortezomib + Lenalidomide + Dexamethasone + Fenofibrate 160 mg tablet|"Bortezomib (VELCADE® 3.5mg/ml) is diluted by 1.4 ml of normal saline (0.9%) solution to give a solution of a concentration of 2.5 mg/mL then the dose will be 1.3 mg/m2 administered subcutaneously at thigh or abdomen at days 1,8,15,22.~Lenalidomide is given as 25mg orally at days from 1 to 21. Dexamethasone is given as 40mg orally at days 1,8,15,22. Fenofibrate 160 mg tablets orally once daily during the period of the 6 cycles of the(VRd) regimen."
224073367|NCT07025005|DRUG|Bortezomib + Lenalidomide + Dexamethasone|"Bortezomib (VELCADE® 3.5mg/ml) is diluted by 1.4 ml of normal saline (0.9%) solution to give a solution of a concentration of 2.5 mg/mL then the dose will be 1.3 mg/m2 administered subcutaneously at thigh or abdomen at days 1,8,15,22.~Lenalidomide is given as 25mg orally at days from 1 to 21. Dexamethasone is given as 40mg orally at days 1,8,15,22."
224073368|NCT07028554|DEVICE|Cartridges of Disposable Endoscopic Linear Cutting Staplers, Disposable Powered|Investigational devices encompassing all models of the Cartridges for Disposable Endoscopic Linear Cutting Staplers, as well as Staplers utilized in conjunction with the Cartridges specified in the Study Plan (Plan number: WEKD-QS-PMCF).
224073369|NCT07029009|DRUG|Liraglutide|Liraglutide will be prescribed following FDA approved packet insert for type 2 diabetes in our test population.
224073370|NCT04312113|DRUG|Adipose derived, autologous mesenchymal stem cells|Fat tissue will be enzymatically treated and cells will be cultured until a sufficient number are obtained for the treatment protocol.
224073371|NCT06929143|DRUG|Aflibercept (Eylea, BAY86-5321)|8 mg (0.07 mL) intravitreal (IVT) injection (114.3mg/mL).
224073372|NCT07130266|PROCEDURE|Procedure/Surgery: Hyaluronic acid gel application|After root surface cleaning and infected cement removal, 0.8% HA gel was applied to the root surface, bone, and inner surface of the flap and left for 2 minutes.
224073373|NCT07130266|PROCEDURE|giving an impression of the application|In the control group, instead of HA gel, the area was irrigated with physiological saline solution.
224073374|NCT00376610|DEVICE|ASR/Re-cap|
224182391|NCT02159911|DRUG|Misoprostol administered orally one hour before surgery|"Closed and numbered envelopes, containing a capsule with either 200mcg or 400mcg of misoprostol were randomly distributed to the patients. Each envelope was coded randomly and only the pharmaceutical department of the hospital knew the content of these envelopes and kept a list of their codes.~The misoprostol was administered by the floor nurse, per-os to the patient one hour before hysteroscopy with a small amount of water. The number on the envelope was noted by the nurse on the document relative to the patient. Hence, the patient, the physician performing the biopsy, the nurse and the research associate did not know the exact dose of misoprostol that was ingested by the patient."
224182392|NCT02675933|BEHAVIORAL|Questionnaire|There will be a single page document, a patient-centered questionnaire, distributed to parents of study participants who have been randomized to the intervention arm.
224182393|NCT00958282|DRUG|lisdexamfetamine/Behavior Therapy|
224182394|NCT00958282|OTHER|placebo|
224182395|NCT04570124|DEVICE|Home Blood Pressure Telemonitoring|Women will complete a 9-question survey (pre-education) prior to discharge and will go over an education video a study team member. Once discharged, women will be asked to measure their blood pressure daily for the first postpartum week, and then weekly until postpartum week 6. Women who have a doctor's visit scheduled during the first 10 days, a member of the study team will meet them there to assess blood pressure and answer any questions. Women who do not have a visit scheduled they will have a telehealth visit during days 8-10 to complete the same assessments. At the final visit, participants will measure their blood pressure via HBPT, prior to returning the unit, complete a post-education questionnaire, a post-study questionnaire and have any questions or concerns addressed.
224182396|NCT03613766|OTHER|Physical activity program|
224182397|NCT02764229|DRUG|LYC-30937-EC|LYC-30937-EC 25 mg by mouth once daily
224182398|NCT02094131|OTHER|Voldyne group (VG)|"VG: slow deep breaths through the mouthpiece of the incentive Voldyne5000® were conducted from the tidal volume (TV) until the total lung capacity (TLC), holding the maximum inspiration. All individuals should maintain yellow cup (yellow flow cup) at a range of flow Best in as long as possible. The training lasted approximately 50 minutes, were held twice a week on alternate days, for five consecutive weeks, totaling 10 sessions. Performed three sets of 15 repetitions."
224182399|NCT02094131|OTHER|Cliniflo group (CG)|"CG: slow deep breaths through the mouthpiece of the incentive Cliniflo® from tidal volume (TV) were performed until the total lung capacity (TLC), holding the maximum inspiration. The volume flow of 100 ml / s for Cliniflo® was standardized, being envisaged to keep the yellow indicator behind the happy face for all individuals.The training lasted approximately 50 minutes, were held twice a week on alternate days, for five consecutive weeks, totaling 10 sessions. Performed three sets of 15 repetitions."
224182400|NCT00779142|DRUG|Methotrexate intravenous 25mg/ml|Methotrexate intravenous 25mg/ml delivered once or twice (based on the therapeutic response) over a period of 2 months maximum. Total dosage 400ug in each dose. Statistical analysis would not be applicable in this small sample.
224182401|NCT02736942|PROCEDURE|Laparoscopic TME|Laparoscopic Total Mesorectal Excision
224182402|NCT02736942|PROCEDURE|TaTME|Transanal Total Mesorectal Excision
224182403|NCT02688452|DIETARY_SUPPLEMENT|Control Unmodified Placebo Water|
224182404|NCT02688452|DIETARY_SUPPLEMENT|Electrokinetically modified water (EMW)|
224182405|NCT02688452|DIETARY_SUPPLEMENT|Electrokinetically modified water (EMW)|
224182406|NCT02688452|DIETARY_SUPPLEMENT|Control Unmodified Placebo Water|
224182407|NCT01909635|BEHAVIORAL|Food Feelings|
224182408|NCT01909635|BEHAVIORAL|Other Feelings|
224182409|NCT04051320|DRUG|Leuprolide Acetate 3.75 MG/ML|3.75 mg/month leuprolide acetate intramuscular injection
224182410|NCT04051320|DRUG|Estradiol 2 Mg tablet|2 mg estradiol tablet
224182411|NCT04051320|DRUG|Micronized progesterone|200 mg micronized progesterone tablets
224182412|NCT05906043|BEHAVIORAL|Exercise Intervention|Exercise intervention
224182413|NCT05906043|BEHAVIORAL|Acceptance and Commitment Therapy|ACT will be used for patients with psychological disability as well as for those with sleep disturbance
224182414|NCT05906043|DIETARY_SUPPLEMENT|Probiotic|Use of a probiotic
224182415|NCT01984840|DEVICE|Telemedicine|
223490844|NCT05841875|OTHER|C reactive protein algorithm|"Antibiotic therapy discontinuation will be encouraged under the following conditions:~If the peak CRP is below 100 mg/L: Consider stopping antibiotics when CRP falls below 35 mg/L, with a minimum treatment duration of 3 days.~If the peak CRP is above 100 mg/L or the patient meets criteria for sepsis or septic shock: Consider stopping antibiotics when CRP has decreased by 50%, after a minimum of 5 days.~If the patient does not meet the CRP criteria: Antibiotic discontinuation will be recommended after 5-7 days, provided there is clinical improvement.~Before discontinuing antibiotic therapy, physicians should confirm that the patient is clinically improving, with no signs of a persistent infectious focus. Additionally, they will be encouraged to verify that the Sequential Organ Failure Assessment (SOFA) score is stable or decreasing. These factors will assist in determining the appropriateness of stopping antibiotics."
223490845|NCT03087552|PROCEDURE|Transradial balloon aortic valvuloplasty|Mini-invasive balloon aortic valvuloplasty consisting in transradial access
224182416|NCT00265382|DRUG|Ziprasidone oral capsules|Study medications will include oral ziprasidone capsules of 20 mg, 40 mg, 60 mg, and 80 mg strength. Subjects will be dosed daily for 26 weeks using a flexible dose design with a minimal dose range of 20mg bid to a maximum dose range of 80 mg bid.
224182417|NCT00091039|BIOLOGICAL|recombinant fowlpox GM-CSF vaccine adjuvant|
224182418|NCT00091039|BIOLOGICAL|recombinant fowlpox-CEA(6D)/TRICOM vaccine|
224182419|NCT00091039|BIOLOGICAL|recombinant vaccinia-CEA(6D)-TRICOM vaccine|
224182420|NCT00091039|DRUG|carboplatin|
224182421|NCT00091039|DRUG|paclitaxel|
224182422|NCT00091039|RADIATION|radiation therapy|
224182423|NCT00812591|PROCEDURE|OGTT and CLAMP|"Oral Glucose Tolerance Test (OGTT):~Oral glucose tolerance test combined with subcutaneous insulin delivery and glucose sampling using a single microdialysis or microperfusion probe.~Hyperinsulinemic euglycemic clamp (CLAMP):~Hyperinsulinemic euglycemic clamp with simultaneous subcutaneous insulin delivery and glucose sampling using microdialysis and microperfusion probe."
224182424|NCT01729065|OTHER|Physical therapy intervention|Exercises addressing cervical range of motion, shoulder range of motion and strengthening and scapular stabilization.
223587872|NCT02733965|OTHER|Pharmaceutical Consultations|"The first part of the pharmaceutical consultation focuses on a complete clinical medication review, the effective use of drugs will be discussed with the patient.~Study of health behaviors Concerning self-medication and alternative medicine Addictions Drug adherence List and grade (NCI version 4) of clinical signs and laboratory abnormalities The biological data will be obtained Clinical signs will be obtained from patient questioning The second part of the consultation is to achieve firstly a pharmaco-therapeutic analysis of the treatment in order to detect problems with drugs as classified by the French Society of Clinical Pharmacy The third step consists on providing pharmaceutical interventions following the pharmaco-therapeutic analysis (18).~These pharmaceutical interventions might concern the prescribers, the other caregivers, or the patient himself. T"
223587873|NCT02733965|OTHER|No Pharmaceutical Consultations|
223490846|NCT03087552|PROCEDURE|Transradial balloon aortic valvuloplasty|Rapid pacing using the 0.035-in. retrograde left ventricular support wire
223490847|NCT03016637|DEVICE|SharkCore (TM) FNB Exchange System|
223490848|NCT01744821|DIETARY_SUPPLEMENT|Arm A: Vitamin D3 Group|
223490849|NCT01744821|DIETARY_SUPPLEMENT|Placebo|
223490850|NCT05593887|PROCEDURE|Hip reconstruction surgery.|This group will undergo Hip reconstruction surgery Anterior approach overlying the iliac crest: open reduction, pelvic osteotomy and pelvic osteotomy. Lateral approach: derotation-varization osteotomy and shortening of femur, internal fixation
223490851|NCT05593887|PROCEDURE|Proximal femoral resection|Resection of the proximal part of the femur below the level of the lesser trochanter by 2 to 3 cm and constructed a capsular flap across the acetabulum. The quadriceps muscle will be sutured around the resected end of the femur
223490852|NCT05593887|PROCEDURE|Proximal femoral valgus ostetomy|The patient is positioned in the lateral decubitus Position A straight incision is cantered over the greater trochanter and extends proximally. Head and neck are resected. A closing wedge, shortening, valgus-producing osteotomy of 40 to 50 degrees is marked just below the lesser trochanter and fixed by a plate
223490853|NCT03463239|BIOLOGICAL|Autologous tissue engineered corpora|penile tissue construct
223587874|NCT02048371|DRUG|Regorafenib|Adults: 160 mg daily; 21 days on and 7 days off Pediatrics: 82mg/m2 (rounding to the nearest 20mg) daily; 21 days on and 7 days off
223587875|NCT02048371|DRUG|Placebo|21 days on and 7 days off
224182425|NCT02573142|BEHAVIORAL|Bull City Healthy and Fit|Integrated model of child obesity treatment including clinical care plus community-based program for family-based experiential learning of healthy habits.
224182426|NCT02573142|BEHAVIORAL|Healthy Lifestyles Clinic|Clinic-only model of care including clinical care and educational materials
224182427|NCT04930133|DRUG|Gilotrif|This is non-interventional, multi-center, multi-cohort study based on existing data from EGFR sensitizing mutation-positive NSCLC patients treated with afatinib as the first-line treatment. Enrolled patients will be categorized into four cohorts (cohort A, B, C and D) according to the type of second line treatment with biopsy results before start of second line treatment.
224307926|NCT06453369|PROCEDURE|Y shaped Tunnel with Connective tissue graft|Sulcular incision followed by Micro-periosteal elevator will be used to elevate vertical full thickness tunnel starting coronally from the gingival sulcus and directed apically. CTG will be prepared and inserted into the coronal tunnel aperture using blunt instrument to facilitate intrusion of graft into tunnel. CTG insurted into the tunnel up to the apical level leaving a coronal part to completely cover the recession defect. Finally single interrupted suture will be used to secure the coronal exposed part of the CTG followed by sling suture fixation of the gingival flap with that of CTG. The donor CTG will be stabilized to the underlying connective tissue interproximally using 5.0 sutures.
224307927|NCT02211196|BEHAVIORAL|smoking cessation intervention|Receive evidence-based tobacco cessation strategies
223490854|NCT03590028|OTHER|Early Nephrology Consult (ENC)|The electronic risk prediction algorithm (ESTOP-AKI) will interface with electronic medical data to determine the likelihood for the patient to develop AKI. Early Nephrology Consult (ENC) will be implemented. A nephrologist will assess the subject and consult with their care team to advise a treatment plan during the hospitalization.
223490855|NCT03590028|OTHER|Standard of Care (SOC)|Subjects will receive nephrology consultation at the typical timepoint after symptoms of AKI appear.
223490856|NCT03307356|OTHER|Uterine Transplant|Transplant of a uterus from a donor, deceased or living
223490857|NCT03713125|BEHAVIORAL|Reading Tutoring|20 hours of 1:1 reading tutoring intervention over 6 weeks
223490858|NCT00778180|DRUG|furosemide 80 mg tablets|
223587876|NCT06136130|DEVICE|Tortoise Positioning Material Group|Preterm infants were placed in the nest with positioning material and placed in lateral and prone positions The positioning material and hand-face maneuver were applied together to the preterm infants in the Positioning Material Group 2, and they were given lateral and prone positions in this way
224073375|NCT06943573|DRUG|psilocybin (25 mg)|Single-dose psilocybin (25 mg)-assisted therapy (PAT)
224073376|NCT06943573|DRUG|psilocybin 1mg micro-dose|Single dose active placebo psilocybin-assisted therapy
223490859|NCT00116909|DRUG|OSI 7904L|
223490860|NCT04573530|BEHAVIORAL|We Walk Plus Intervention|The frequency and content of weekly personalized SMS are based on each participant's preference. Prior to implementation of intervention, the investigators will conduct focus groups to learn participants' social network activities and preferences, strategies that can be used to encourage engagement via a private Fitbit community network.
223490861|NCT02916771|DRUG|Ixazomib|Oral, proteasome inhibitor
224073377|NCT07143318|DRUG|KLA578-1 for injection|Intravenous injection, single dose
224073378|NCT07143318|DRUG|Etopcoxib Tablets|P.O., single dose
224073379|NCT07142785|PROCEDURE|Epiretinal membrane peeling|All patients will receive standard pars plana vitrectomy, followed by only epiretinal membrane peeling.
224073380|NCT07142785|PROCEDURE|Epiretinal membrane peeling combined with internal limiting membrane peeling|All patients will receive standard pars plana vitrectomy, followed by epiretinal membrane peeling and internal limiting membrane peeling.
224073381|NCT07144020|BIOLOGICAL|CD117 CAR T-cells|Each subject receive CD117 CAR T-cells by intravenous infusion
224307928|NCT02211196|OTHER|survey administration|Ancillary studies
224307929|NCT02211196|OTHER|questionnaire administration|Ancillary studies
224073382|NCT07143747|OTHER|Hyperpolarized 129Xe MRI|Inhalation of hyperpolarized 129Xe gas followed by breath-hold MRI for ventilation imaging.
224307930|NCT00115830|DRUG|Atorvastatin|
224182428|NCT02033642|BEHAVIORAL|Family Based Behavioral Intervention|Family Based Behavioral Intervention (FBBI) is a 24-session lifestyle intervention designed to: (1) educate adolescent/young adult participants and their parents in principles of good nutrition and physical activity, and (2) train parents to implement lifestyle changes at home to facilitate weight loss in their child by monitoring diet and physical activity behaviors, setting goals, providing support and reinforcement, and assessing and making changes to the home environment.
223490862|NCT02916771|DRUG|Lenalidomide|Oral, immunomodulatory agent
223490863|NCT02916771|DRUG|Dexamethasone|Oral, steroid
223490864|NCT05057637|DEVICE|Optical coherence tomography measurements|Optical coherence tomography measurements in femoropopliteal tract
224307931|NCT00115830|DRUG|Rosuvastatin|
223490865|NCT05675085|DIAGNOSTIC_TEST|Personalized screening protocol|"At the first screening round (recruitment) all participating women had the same tests;~* Two-view tomosynthesis of both breasts~* Calculation of volumetric breast density (VBD)~* Calculation of lifetime risk (LTR) using the Tyrer-Cuzick model~At subsequent rounds:~1. Women with non-dense breasts and low breast cancer risk are re-screened only with DBT every 2 years;~2. Women with dense breasts and low breast cancer risk are re-screened with DBT+US every 2 years;~3. Women with non-dense breasts and intermediate breast cancer risk are re-screened only with DBT every year;~4. Women with dense breasts and intermediate breast cancer risk are re-screened with DBT+US every year;~5. Women at high risk of breast cancer associated with a family history of breast cancer (w/wo hereditary factors) undergo DBT and MRI every year."
223490866|NCT05899634|BEHAVIORAL|Defaults|Participants will receive healthy recipes (3 main meal + 1 snack/breakfast/lunch recipe per week of the two-week intervention). In addition, in this group, participants' online grocery shopping carts will be pre-filled with ingredients corresponding to the provided recipes. They will be told that their cart has been filled with items that can be used to make recipes from the provided recipe cards, and that they can modify it as they like.
223490867|NCT05890404|BEHAVIORAL|LGBTQ-Affirmative CBT Training: Materials Only|"Participants will be provided a digital suite of online self-guided learning materials, including step-by-step treatment materials, client handouts, and how to instructions for delivering the treatment."
223490868|NCT05890404|BEHAVIORAL|LGBTQ-Affirmative CBT Training: Direct Training|"Participants will be provided a digital suite of online self-guided learning materials, including step-by-step treatment materials, client handouts, and how to instructions for delivering the treatment. In addition, participants will receive 12 weekly 1-hour live training webinars on delivering LGBTQ-affirmative CBT led by expert trainers."
223490869|NCT05890404|BEHAVIORAL|LGBTQ-Affirmative CBT Training: Local Supervision|"Participants will be provided a digital suite of online self-guided learning materials, including step-by-step treatment materials, client handouts, and how to instructions for delivering the treatment. In addition, participants will receive 12 weekly 1-hour live training webinars on delivering LGBTQ-affirmative CBT led by expert trainers. This arm will also receive one year of ongoing (at least monthly) supervision in LGBTQ-affirmative CBT from an expert supervisor at your center."
223490870|NCT06147271|DRUG|SGLT2i|A randomized clinical trial of superiority with active control (2 arms), with central randomization to evaluate the efficacy and safety of adding dapagliflozin or empagliflozin 10 mg once daily to post-TxC routine compared with no intervention for 6-8 months.
223490871|NCT04280952|DEVICE|CONVIVO|tumor tissue with the CONVIVO system
223490872|NCT03646617|RADIATION|Hypofractionated Radiation Therapy (HFRT)|The dose of HFRT will be 8 Gy x 3 fractions, given over a maximum of 7 days timespan.
223490873|NCT03646617|DRUG|Nivolumab|Nivolumab (1 mg/kg) will be administered as an IV infusion over 30 minutes, followed by ipilimumab (3 mg/kg) on the same day given as an IV infusion over 90 minutes. The two drugs will be given on day 1, then every 3 weeks for a total of four doses. After these 4 doses, the patient and investigator will decide to continue with nivolumab (240 mg) every 2 weeks or Nivolumab (480mg) every 4 weeks as monotherapy for up to one year as an IV infusion over 30 minutes.
223490874|NCT03646617|DRUG|Ipilimumab|Nivolumab (1 mg/kg) will be administered as an IV infusion over 30 minutes, followed by ipilimumab (3 mg/kg) on the same day given as an IV infusion over 90 minutes. The two drugs will be given on day 1, then every 3 weeks for a total of four doses.
223490875|NCT05556343|DRUG|MYK-224|Specified dose on specified days
223490876|NCT06166303|DIAGNOSTIC_TEST|sFlt-1/PGIF|Index of sFlt-1/PGIF
223490877|NCT06547957|DRUG|EOS301984|Multiple doses of EOS301984
223490878|NCT06547957|DRUG|Anti-PD-1 monoclonal antibody|Multiple doses of EOS301984 in combination with Anti-PD-1
223587877|NCT00076349|DRUG|bendamustine and rituximab|Patients will receive rituximab on the first day of a cycle at a dose of 375 mg/m2, followed on the second and third day of a cycle by SDX-105 (bendamustine) at a dose of 90 mg/m2/day of treatment. Four cycles are planned. Patients will receive a dose of rituximab alone 7 days prior to the first cycle of the combination and a dose of rituximab 28 days after the last cycle of the combination. If there is documented disease regression, a fifth and sixth cycle of SDX-105 plus rituximab may be administered.
223587878|NCT03416075|DEVICE|Mechanical ventilation|Noninvasive and/or invasive mechanical ventilation were performed when patients had respiratory failure.
223587879|NCT02108691|DIETARY_SUPPLEMENT|Glycin max(L.) Merr. peel extract|Glycin max(L.) Merr. peel extract (2.5g/day)
223587880|NCT02108691|DIETARY_SUPPLEMENT|Placebo|Placebo (2.5g/day)
223490879|NCT06048445|DEVICE|intraoperative plancement of Biliary Drainage Stent|plancement of Biliary Drainage Stent in liver transplantation of pediatric patients
223490880|NCT06054347|OTHER|VINELAND II|Standardised questionnaire filled by the investigator during an interview with the parents or with the patient himself if capable of it. Duration 1 hour to 1 hour and a half.
223490881|NCT05197426|DRUG|Oral Azacitidine|Specified dose on specified days
223490882|NCT05197426|OTHER|Placebo|Specified dose of specified days
223490883|NCT06409819|DRUG|phage therapy|phage therapy will consist of a combination of three lytic phages that are active against the participant's E. coli isolates and will be administered intravenously twice daily for 7 days.
223490884|NCT06409819|DRUG|control|Participants assigned to the control arm will start a 7-day course of intravenous sterile normal saline (placebo) administered twice daily.
223587881|NCT04147546|DIAGNOSTIC_TEST|Additional screening using ultra sensitive RDTs|At each ANC visit, study nurses will perform an HS-RDT for participants in the intervention arm
224307932|NCT03007238|BIOLOGICAL|Aldesleukin|Given SC
224307933|NCT03007238|PROCEDURE|Extracorporeal Photopheresis|Undergo ECP
224182429|NCT02033642|BEHAVIORAL|Maintenance|The Maintenance condition in this study is a 12-session intervention designed to extend FBBI and continue to teach adolescent/young adult participants and their parents to continue practicing lifestyle behaviors, generalize healthful behaviors to new environments, find additional social and community supports, and prevent and manage relapse.
224182430|NCT00734916|DIETARY_SUPPLEMENT|Parenteral lipid emulsion (Omegaven)|Omegaven 10%, 0.2g/kg/hr i.v.during 1 hour on 3 consecutive days
224182431|NCT00734916|DIETARY_SUPPLEMENT|Parenteral lipid emulsion (Intralipid)|Intralipid 10%, 0.2g/kg/hr i.v. during 1 hour on 3 consecutive days
224182432|NCT00734916|DIETARY_SUPPLEMENT|Parental lipid emulsion (Saline 0.9%)|Placebo (Saline 0.9%), same volume/hr as lipid emulsions
224182433|NCT05875272|PROCEDURE|interchangeability of arterial or venous hemostasis|Paired arterial and venous blood sampling respectively on the radial arterial catheter and on the central venous catheter before the extracorporeal circulation, and on the sampling ramp during the extracorporeal circulation. Point of care biology exams are performed on two HSE devices simultaneously. Controls carried out, routinely, every 20 minutes according to the service protocol, before the CPB (starting ACT without heparin), during the CPB (ACT objective ≥400 seconds), after protamine reversal of heparin. On average, 10 samples are taken during heart surgery.
223490885|NCT04274179|OTHER|Modified Atkins Diet|Low carb (20g/day), high fat, moderate protein diet. Started as an outpatient in clinic.
223490886|NCT04274179|DRUG|Absence epilepsy medications|At neurologist's discretion. \*OF NOTE\< THIS ARM IS COMPLETED
224182434|NCT04688385|BIOLOGICAL|Multipeptide Vaccine+ XS15|Peptide vaccination will take place in CLL patients that achieved at least a partial remission with detectable MRD after at least 6 and less than 9 months of an ibrutinib-based treatment regime. MRD will be determined by flow cytometry. MRD positivity is defined as \> 10-4 CLL cells in peripheral blood or bone marrow. Patients will receive either ibrutinib monotherapy or combinational therapy before study treatment. Vaccination will be done under ibrutinib monotherapy (i.e. after the end of e.g. anti-CD20 treatment, if applicable).
224182435|NCT01995396|PROCEDURE|APE with intersphincteric dissection|Abdominal operation where the rectum is resected down to the levator and then the anus is resected by an intersphincteric dissection and order to leave the outer sfincter and levator in place to avoid a large wound and a high rate of infectious complications.
224182436|NCT01995396|PROCEDURE|Hartmann´s procedure|Abdominal operation where the rectum is resected and stapled off distally and a stoma is created
224182437|NCT00769821|OTHER|questionnaire administration|
224182438|NCT00769821|PROCEDURE|assessment of therapy complications|
224182439|NCT00769821|PROCEDURE|bioimpedance spectroscopy|
224182440|NCT00769821|PROCEDURE|quality-of-life assessment|
224182441|NCT04506073|DRUG|Mesenchymal Stem Cells|1 dose is 10 X 10\^6 MSC/kg
224182442|NCT04506073|DRUG|Placebo|Placebo will be identical to the investigational product but will not contain mesenchymal stem cells (MSCs).
224182443|NCT03547960|DIETARY_SUPPLEMENT|Guar gum|Fibre supplement to be taken with each meal
224182444|NCT03547960|DIETARY_SUPPLEMENT|Cellulose|Placebo. Fibre supplement to be taken with each meal
224182445|NCT03811899|DIAGNOSTIC_TEST|18F-DCFPyL|The purpose of this study is to determine whether HG SOC are 18F-DCFPyL (=GCP-II)-avid and to compare the performance of this PET to CT and findings at time of surgery.
224182446|NCT02815007|DRUG|Chidamide with EGFR-TKI|Chidamide and EGFR-TKI, dosage described in arm description.
224182447|NCT05657301|DRUG|KH631|KH631: AAV vector containing a coding sequence for an anti-VEGF protein
224182448|NCT04555993|PROCEDURE|lower abdominal surgery|Patients will undergo lower abdominal surgery under general anesthesia.
224182449|NCT04555993|OTHER|Erector spinae plane block|patients will receive erector spinae plane block using 20 mL levobupivacaine (0.25%).
224182450|NCT04555993|OTHER|Transversus abdominis plane block|patients will receive transversus abdominis plane block using 20 mL levobupivacaine (0.25%).
224182451|NCT00323804|BIOLOGICAL|Peginterferon alfa-2b|PegIFN alfa 2b in addition to ribavirin or ribavirin-placebo, from day 0 to M36
224182452|NCT00323804|DRUG|Ribavirin|Ribavirin in addition to PegIFN alfa 2b, from day 0 to M36
224182453|NCT00323804|DRUG|Ribavirin-Placebo|Ribavirin-placebo in addition to PegIFN alfa 2b, from day 0 to M36
224182454|NCT02245295|PROCEDURE|Moderate Sedation for EBUS/TBNA|EBUS-TBNA was performed by one of the pulmonologists in moderate sedation (D.F., M.K.).
224182455|NCT02245295|PROCEDURE|General anesthesia for EBUS/TBNA|EBUS-TBNA was performedin general anaesthesia by one of the thoracic surgeons (D.S., P.K.)
223490887|NCT06804837|OTHER|Visual consent|Visual key information page
223490888|NCT06804837|OTHER|Standard consent|Summary text only
224182456|NCT00529152|DRUG|Deferiprone|Ferriprox (deferiprone) oral solution will be given orally at a total daily dose of 75 mg/kg body weight or 100 mg/kg body weight, divided into 3 doses, for 24 weeks.
224182457|NCT01907750|DEVICE|biliary drainage tube|
224182458|NCT03342807|DRUG|Insulin|Insulin infusion for subjects in Group Insulin.
224182459|NCT03342807|DEVICE|Aphesis|Aphesis for subjects in Group Aphesis.
224182460|NCT02499380|DEVICE|PneumRx Coil System|
224182461|NCT01927276|OTHER|Gluten Free Flour|
224182462|NCT01927276|OTHER|Wheat Flour|
224182463|NCT02590627|DRUG|Artemether-lumefantrine|Artemether-lumefantrine
224182464|NCT02590627|DRUG|Dihydroartemisinin-piperaquine|Dihydroartemisinin-piperaquine
224182465|NCT02172820|BEHAVIORAL|Financial incentives|Patients in the experimental group will receive financial incentives for completing exercise sessions.
224182466|NCT04915742|BEHAVIORAL|exercises|The exercise group ha in FTAs 2, each session will be 30 minutes of evil sown in stretching , which made combining relaxation and strengthening exercises therapeutic exercise program for 6 weeks from the online platform will be implemented in the form of group exercise form is planned.
224182467|NCT04915742|BEHAVIORAL|thetahealing and exercises|"The exercise group ha in FTAs 2, each session will be 30 minutes of evil sown in stretching , which made combining relaxation and strengthening exercises therapeutic exercise program for 6 weeks from the online platform will be implemented in the form of group exercise form is planned.~The exercise and Thetahealing treatment group, on the other hand, is planned for 6 weeks , 1 session per week, 30 minutes per session, in addition to the exercise sessions, the first and last sessions to be individual and personalized .~Applications will be carried out on the online platform."
224182468|NCT01040000|DRUG|NPC-1C/NEO-102|Subjects will receive NPC-1C at a dose of 3.0 mg/kg. NPC-1C will be given intravenously (by vein) over approximately 1-6 hours, once every 2 weeks for 4 doses per course. Courses will be repeated in the absence of disease progression or unacceptable toxicity.
224182469|NCT03720158|DIETARY_SUPPLEMENT|Omega 3 Group|Five mL of an Omega-3 highly concentrated substance (containing 2.25 g of EPA and 1.08 g of DHA) will be added daily to the standard enteral diet during the entire radiotherapy
224182470|NCT03720158|DIETARY_SUPPLEMENT|Placebo or Control Group|Five mL of pigmented and flavored corn oil will be added daily to the standard enteral diet during the entire radiotherapy treatment period (from 5-7 weeks)
224182471|NCT06173726|BIOLOGICAL|BST02 Injection|"The TIL used for tumor tissue surgical sampling of qualified subjects was used to prepare BST02 injection, and the subjects who successfully received the surgical sampling were considered to be enrolled.~In the study process, cell transfusions were recorded as day 0 of the study. On the 3rd day (D-3) before infusion of BST02 injection, it is necessary to receive eluvial pretreatment. Considering that this product is unmodified autologous T lymphocytes, previous studies have shown that low-intensity cyclophosphamide can stimulate their proliferation in vivo. Therefore, the cyclophosphamide (Cy) single-drug regimen is recommended: Cy 250mg\~1.5g/m2, a single intravenous infusion"
224307934|NCT03007238|OTHER|Laboratory Biomarker Analysis|Correlative studies
224307935|NCT03007238|OTHER|Quality-of-Life Assessment|Ancillary studies
224307936|NCT01273896|DRUG|STA-9090|All patients will receive 200 mg/m2 of STA-9090 once weekly by a 1-hour IV infusion for three consecutive weeks followed by a 1 week dose-free interval. Subjects tolerating therapy may continue on study until disease progression.
223490889|NCT06032221|DEVICE|Thermidas Vista Telehealth App|Thermal camera with telemedicine app
223490890|NCT05788029|PROCEDURE|laparoscopic pancreaticoduodenectomy|laparoscopic pancreaticoduodenectomy
223490891|NCT05788029|PROCEDURE|open pancreaticoduodenectomy|open pancreaticoduodenectomy
223490892|NCT05991713|BEHAVIORAL|Modifying Exploration|Participants in this group will use a mobile phone sensor data application that uses an accelerometer, Wireless Fidelity (WiFi) and/or GPS designed for smartphone devices. This technology allows the phones to capture information automatically and passively on the participant's activity. The application will be collecting participants' data 24 hours a day, 7 days a week. Participants will be asked to make alterations to their exploration levels approximately 20 days of their participation in the study.
223490894|NCT06652958|BIOLOGICAL|VH4527079|VH4527079 solution for injection or infusion will be administered either by SC injection or IV infusion respectively.
223490895|NCT06975319|BIOLOGICAL|V-212 (or Placebo) administered by i.m injection (3 vaccinations) - low dose|V-212 is a peptide antigen-based vaccine.
223490896|NCT06975319|BIOLOGICAL|V-212 (or Placebo) administered by i.m injection (3 vaccinations) - medium dose|V-212 is a peptide antigen-based vaccine.
223490897|NCT06975319|BIOLOGICAL|V-212 (or Placebo) administered by i.m injection (3 vaccinations) - high dose|V-212 is a peptide antigen-based vaccine.
223490898|NCT06978530|DEVICE|3D custom plate|Custom 3D plate will be designed using preoperative CT and virtual surgical planning.
223490899|NCT06978530|DEVICE|Standard titanium fixation plates|The fixation will be performed according to established surgical principles for managing displaced mandibular sub-condylar fractures without patient-specific planning or customization.
223490900|NCT06979388|DRUG|balcinrenone/ dapagliflozin|Participants will be receiving balcinrenone/ dapagliflozine in fasted or fed condition.
223490901|NCT06979388|DRUG|quinidine|Participants will be receiving quinidine orally in fasted condition.
223587882|NCT04147546|DRUG|Dihydroartemisinin-piperaquin|All pregnant women with a positive HS-RDT will be treated with a full course of dihydroartemisinin-piperaquine (DP) over 3 days. The first dose of DP will be administered under direct observation at the antenatal care clinic (ANC) and the subsequent doses of the intervention in days 2 and 3 will be taken unsupervised at home
223587883|NCT04147546|OTHER|Reminders|Before each scheduled ANC visit, reminders using SMS or phone call will be used. This is order to increase ANC attendance
224073383|NCT07143747|OTHER|Tc-99m Technegas Ventilation Imaging|Inhalation of Tc-99m-labeled carbon aerosol (Technegas) followed by SPECT imaging to assess lung ventilation.
224073384|NCT07144059|OTHER|ECG by the SMUR after medical interrogation by the SAMU|Patients who had the qualifying ECG by the SMUR after medical interrogation by the SAMU
224073385|NCT07144059|OTHER|ECG performed by a non-medical vector|Patients who have called the emergency services with either an ECG performed by a non-medical vector (SP or ambulance), or a decision to reinforce SMUR during the first aid assessment
224073386|NCT07143188|DIETARY_SUPPLEMENT|elemental diet (ED)|mBIOTA is a palatable elemental diet formulation
223490902|NCT07130370|BEHAVIORAL|Acceptance and commitment therapy|Acceptance and Commitment Therapy (ACT) is a mindfulness-informed behavioral intervention that helps individuals accept difficult thoughts and feelings, clarify personal values, and commit to meaningful actions. It aims to improve psychological flexibility, enabling healthier coping with life's challenges.
223490903|NCT02738606|DRUG|Chemotherapy|
224073387|NCT07142980|DRUG|HRS-7172 Tablets|HRS-7172 tablets.
224073388|NCT07143565|BEHAVIORAL|Online platform hub and mHealth Text Messaging|The treatment package includes both optional and mandatory treatments. The mandatory treatments consist of mHealth text messaging and an online platform hub. We have developed a game which educates teenagers about alcohol reduction and promotes awareness of alcohol-related harm. Designed to be both engaging and informative, the game uses real-life scenarios, interactive storytelling, and decision-based gameplay to help young people understand the risks of excessive drinking. Also, participants with Audit Score \> 7 will receive individualized chat-based instant text messages from WhatsApp for 8 weeks. They will have real-time and one-to-one interaction. The conversation intensity depends on the participants' need.
224073389|NCT07143565|BEHAVIORAL|Self-help material|Self-help material like leaflet is a common method used in preventing teenage Drinking.
224182472|NCT04606225|DRUG|Losartan|administration of losartan (50 mg) (oral) Cozaar Oral Tablet
224307937|NCT05690490|PROCEDURE|Endoscopic mucosal resection with circumferential incision|The endoscope will be passed into the intestine to the site of the tumor. Using an endoscopic needle, the solution will be injected into the submucosa to create a pillow. Then, using an endoscopic knife (insulated tip knife, Olympus or Water Jet, Erbe), a circular incision will be made around the lesion with an offset of 2-5 mm. Then there will be a one-stage electro excision of the neoplasm using an endoscopic loop.
224307938|NCT05690490|PROCEDURE|Endoscopic submucosal dissection|The endoscope will be passed into the intestine to the site of the tumor. Using an endoscopic needle, the solution will be injected into the submucosa to create a pillow. Then, using an endoscopic knife (insulated tip knife, Olympus or Water Jet, Erbe), a circular incision is made around the lesion. Then dissection will be performed in the submucosal layer.
224307939|NCT00670202|DRUG|Fasudil Hydrochloride|Fasudil 40 mg three times a day x 14 days
224307940|NCT00670202|DRUG|Placebo Oral Tablet|Placebo oral tablet manufactured to mimic fasudil three times a day x 14 days
224307941|NCT00400699|OTHER|counseling intervention|
224307942|NCT00400699|OTHER|study of socioeconomic and demographic variables|
224307943|NCT00400699|PROCEDURE|psychosocial assessment and care|
224307944|NCT05566184|DEVICE|Modified pacifier|In the experimental group, a modified pacifier will be given to the child during the procedure, and the data will be collected. In the application of vascular access to children, a) before the procedure (20 minutes before), b) just before the procedure (20. minutes), c) during the procedure (between 20.-40. minutes), and d) 20 minutes after the procedure (40. minutes). Physiological variables that will be evaluated four times, once for each application, will be observed on the monitor, the FLACC Pain Assessment Scale will be recorded by the researcher and salivary cortisol level will be measured.
224307945|NCT05543343|DRUG|High dose or normal dose staphylococcus albicans|8 staphylococcus albicans tablets(0.3 mg) 3 times daily or 4 staphylococcus albicans tablets(0.3 mg)+4 placebo tablets 3 times daily
224307946|NCT05543343|DRUG|Placebo|8 placebo tablets 3 times daily
224307947|NCT01667237|BEHAVIORAL|Home-based pulmonary rehabilitation program|The rehabilitation program will be a self-monitored and minimally supervised home-exercise program. Exercise training modalities and intensity will be adapted to patient's individual condition. It will include aerobic and strength exercises 5 times a week for 4 weeks. Aerobic training will be done on a portable ergocycle. The target intensity will correspond to 60% of the maximal work rate achieved during the maximal progressive cardio-pulmonary exercise test, aiming for a cumulative time of 40 minutes per day. The heart rate, corresponding to an exercise level of 60% of max exercise capacity during the maximum exercise test, will be noted and patients will be instructed to train at this heart rate ± 10 beats. Muscle exercises will be performed using elastic bands and use of gravity.
224307948|NCT01667328|PROCEDURE|Massage therapy|Presurgical 15 minute massage performed by a licensed massage therapist
224307949|NCT01667328|PROCEDURE|Standard of care|Control group will receive standard of care with no massage therapy
224307950|NCT04643561|OTHER|Travelan OTC|5 days of treatment with Travelan food supplement 3 times a day, blood will be drawn prior and after intervention
224307951|NCT02032056|DIETARY_SUPPLEMENT|Probiotic (10^9 CFU/day)|
224307952|NCT02032056|DIETARY_SUPPLEMENT|Probiotic (10^8 CFU/day)|
224182473|NCT04606225|DRUG|Placebo Oral Tablet|administration of placebo (oral)
224307953|NCT02032056|OTHER|Placebo|
224307954|NCT02865460|DRUG|Ubiquinol|Take oral tablets as directed (2x200 mg for 2 months; 1x200 mg for 4 months) with food each morning- upon waking
224307955|NCT02865460|DRUG|Placebo|Take oral tablets as directed (2x200 mg for 2 months; 1x200 mg for 4 months) with food each morning- upon waking
224307956|NCT06500793|DRUG|PF614 capsule|PF614 capsules (25-100 mg)
224307957|NCT06500793|DRUG|Nafamostat Mesylate|Nafamostat IR/ER solution/beads (total 1-10 mg)
224307958|NCT02816008|BEHAVIORAL|Cognitive rehabilitation training with RGS in the clinic|Daily cognitive training with the Rehabilitation Gaming System (RGS) in the clinic during 6 weeks (5 days per week a 30 minutes).
224307959|NCT02816008|BEHAVIORAL|Passive/conventional cognitive training at home.|Daily conventional cognitive rehabilitation at home as recommended by the neurologist during 6 weeks (5 days per week a 30 minutes).
224307960|NCT01497808|DRUG|Ipilimumab|
224307961|NCT01497808|RADIATION|Stereotactic Body Radiation Therapy|
224307962|NCT04553016|BIOLOGICAL|Vaccine|IM vaccination with ChAdOx1.tHIVconsv1, MVA.tHIVconsv3 and MVA.tHIVconsv4
224307963|NCT04553016|BIOLOGICAL|Placebo|IM administration of 0.9% sterile sodium chloride solution
224307964|NCT01015937|DRUG|Turmeric extract|turmeric 500 mg TID for 45 days
224307965|NCT01015937|DRUG|Angiotensin-converting enzyme (ACE) inhibitor + Angiotensin-II type 1 receptor (ATI) blocker|maximum dosage as patient tolerated for 45 days
224307966|NCT04558918|DRUG|LNP023|Taken Orally b.i.d. Dosage Supplied: 200 mg Dosage form: Hard gelatin capsule Route of Administration: Oral
224307967|NCT04558918|DRUG|Eculizumab|"Administered as intravenous infusion every 2 weeks as per the stable regimen, the maintenance dose is a fixed dose.~Dosage Supplied: 300 mg/30mL Dosage form: Concentrate solution for infusion"
224307968|NCT04558918|DRUG|Ravulizumab|"Administered as intravenous infusion every 8 weeks, the maintenance dose is based on body weight.~Dosage Supplied: 300 mg/30mL Dosage form: Concentrate solution for infusion"
224307969|NCT06633783|DRUG|Semaglutide|The dose escalation phase, starting with 0.25mg once weekly and increasing every 4 weeks (0.5mg, 1.0mg, 1.7mg), is expected to last 16 weeks; In the dose maintenance phase, the target dose of 2.4mg was maintained for 28 weeks.Treatment duration 44 weeks.
224182474|NCT04505007|OTHER|Specialized heart function clinic|This information has already been provided.
224182475|NCT06231186|RADIATION|iHD-SRT|received isotoxic individualized fSRT, with BED 10\>50Gy and \<100Gy, and strict OAR limits
224182476|NCT01843933|DEVICE|Capnography|Capnostream 20 Portable Capnography Monitor with Internal Printer by Oridion
224182477|NCT00174876|DRUG|Drug Abilify|
224182478|NCT01931189|BIOLOGICAL|NI-071|100mg/vial
224182479|NCT01931189|BIOLOGICAL|Infliximab|100mg/vial
224182480|NCT01535638|DRUG|BI 207127|Medium dose film-coated tablet
224182481|NCT01535638|DRUG|BI 207127|Medium dose film-coated tablet
224182482|NCT01535638|DRUG|BI 207127|Medium dose film-coated tablet
223490904|NCT02738606|OTHER|Laboratory Biomarker Analysis|Correlative studies
223587884|NCT06526156|DRUG|Bupivacaine injection|A 3 mL hypobaric (0.33%) solution of bupivacaine, prepared by mixing 2 mL of isobaric (0.5%) bupivacaine with 1 mL of sterile water. Dural puncture will be performed using a 25 or 27G (gauge) spinal needle at the L5-S1 intervertebral space, and the 3 mL of 0.33% bupivacaine will be injected into the intrathecal space.
223587885|NCT03337464|OTHER|cycling exercise|5 x 3 minute bouts of cycling exercise separated by 3 minute rest periods
223587886|NCT00334711|DRUG|Sulfonylurea|
223490905|NCT02738606|PROCEDURE|Metastasectomy|Undergo lung metastasectomy
223587887|NCT03417934|PROCEDURE|Hip Arthroscopy Procedure|The purpose of this pilot study is to evaluate the effects of hip distraction without a perineal post on the lower extremity during hip arthroscopic procedures by peri-operative monitoring of various prognostic markers for venous, nerve and tissue injury.
223587888|NCT00922714|DRUG|Glutamine|Intravenous glutamine supplementation (0.285 g/kg body weight/24 h)
223587889|NCT00922714|DRUG|saline (placebo)|NaCl 0.9 g/L
223587890|NCT03996317|OTHER|Room air|Avoidance of hyperoxygenation
223587891|NCT00552604|DRUG|standardized cannabis extract|Cannabis extract (delta-9-THC 2.5mg, CBD 1.25 mg per capsule), flexible dosing between 5 mg and 25 mg THC/d, administered twice daily
223587892|NCT00552604|DRUG|Placebo|Matching placebo capsules, twice daily
223490906|NCT02738606|OTHER|Quality-of-Life Assessment|Ancillary studies
223490907|NCT02738606|PROCEDURE|Therapeutic Conventional Surgery|Undergo hepatectomy
223490908|NCT05812131|BEHAVIORAL|COPEWeb online training|COPE training delivered via online COPEWEb to providers
223587893|NCT03693781|DRUG|Colchicine 1 MG Oral Tablet|Colchicine tablets depending on arm (0.01 mg/kg/day, 0.005 mg/kg/day, placebo) and on weight (\>70 kg or \<71 kg) for 30 weeks of duration.
223587894|NCT03693781|DRUG|Colchicine 1 MG Oral Tablet|Colchicine tablets depending on arm (0.01 mg/kg/day, 0.005 mg/kg/day, placebo) and on weight (\>70 kg or \<71 kg) for 30 weeks of duration.
223587895|NCT03693781|DRUG|Placebo Oral Tablet|Corresponding tablets for 30 weeks
223587896|NCT06431230|BEHAVIORAL|standard high-intensity interval training|The project will use an intensive intermittent exercise intervention according to the high-intensity interval training programme. The programme will be implemented during physical education lessons. It involves 4 minutes of exercise in a structure of 20 seconds of intense effort and 10 seconds of rest, for a total of 8 cycles. It will be repeated twice a week (in two PE lessons) for 8 weeks. It is based on the standard physical exercises: squats, push-ups, sit-ups, toe-touches, mountain climber, jumping jacks, standing abs twist and squat to side.
223587897|NCT06431230|BEHAVIORAL|plyometric high-intensity interval training|The project will use an intensive intermittent exercise intervention according to the high-intensity interval training programme. The programme will be implemented during physical education lessons. It involves 4 minutes of exercise in a structure of 20 seconds of intense effort and 10 seconds of rest, for a total of 8 cycles. It will be repeated twice a week (in two PE lessons) for 8 weeks. However, there is a difference, comparing to the St-HIIT, related to different exercises used in protocol. This kind of HIIT programme will be based on plyometric exercises: jumping jacks, skip A, skip C, jumps back into a push-up position and returns to the squat position, throwing the legs out of support and jumping out, jumping out of a squat.
223587898|NCT02085330|DEVICE|Hyperbaric oxygen therapy|100%, 2 ATA, 90 minutes
224073390|NCT07143864|BIOLOGICAL|Stapokibart|A humanized monoclonal antibody that targets the interleukin (IL)-4 receptor subunit alpha
224073391|NCT07143864|OTHER|Placebo drug|Placebo drugs without Stapokibart
224073392|NCT07144475|BIOLOGICAL|Lactobacillus casei Shirota|Consumption of Lactobacillus casei Shirota three times daily for three days before surgery at 6 AM, 2 PM and 10 PM.
224073393|NCT07144475|BIOLOGICAL|Lactobacillus acidophilus|Consumption of Lactobacillus acidophilus three times daily for three days before surgery at 6 AM, 2 PM and 10 PM.
223490909|NCT05812131|BEHAVIORAL|COPE In Person|COPE training provided in person to providers
223490910|NCT06569186|BEHAVIORAL|Cue-based feedings|Speech therapists will use cue-based protocols to guide feeds
223490911|NCT06040385|DEVICE|Implant supported hybrid prosthesis|For each patient, implant supported mandibular hybrid prosthesis will be fabricated digitally. Frameworks will be tried in patient's mouth, scanned intraorally by intraoral scanner (IOS).
223490912|NCT06827457|DRUG|GenSci120|Administered SC.
223490913|NCT06827457|DRUG|Placebo|Administered SC.
223490914|NCT05643209|PROCEDURE|ablation|epicardial substrate homogenization (ablating abnormal fragmented prolonged low-frequency ventricular electrograms) in consecutive patients undergoing catheter ablation
223490915|NCT05501691|OTHER|Placebo|Laser Simulation
223490916|NCT05501691|RADIATION|445 nm Diode Laser Wavelength|Irradiated Using a 445 nm Diode Laser Wavelength
223490917|NCT05501691|RADIATION|660 nm Diode Laser Wavelength|Irradiated Using a 660 nm Diode Laser Wavelength
223490918|NCT05501691|RADIATION|970 nm Diode Laser Wavelength|Irradiated Using a 970 nm Diode Laser Wavelength
223490919|NCT00945737|DIETARY_SUPPLEMENT|Soy protein; 25 grams/day|Soy protein
223490920|NCT00945737|DIETARY_SUPPLEMENT|Control protein|Milk protein
223490921|NCT01331564|BEHAVIORAL|electronic intervention during pregnancy and postpartum|Electronically-mediated behavioral interventions to encourage women to gain an appropriate amount of weight during pregnancy and to follow a healthy lifestyle postpartum to minimize postpartum weight retention
223490922|NCT01331564|BEHAVIORAL|electronic intervention during pregnancy|Electronically-mediated behavioral interventions to encourage women to gain an appropriate amount of weight during pregnancy.
223490923|NCT01331564|BEHAVIORAL|Control|Control women will receive non-weight related content during both time periods at the project website.
223490924|NCT00535470|DRUG|0.04% Mechlorethamine gel|Mechlorethamine 0.04% PG applied to affected skin areas (lesions) once daily for up to seven (7) months. The frequency of application may be adjusted for toxicity. After seven (7) months, they will be terminated from the study.
223490925|NCT04748978|PROCEDURE|hysteroscopy|OPPIum and Myolysis
223490926|NCT03832478|DEVICE|Virtual Reality Headset Given|Samsung Gear VR Headset with guided mindfulness meditation app
223490927|NCT01416779|BEHAVIORAL|Writing Intervention|Finding Balance Writing Intervention
224182483|NCT05488873|DRUG|WST-057 Active|WST-057 Topical Solution
224182484|NCT05488873|DRUG|Placebo|Matching Placebo Topical Solution
223490928|NCT02383615|PROCEDURE|Saphenous nerve block|Ultrasound guided saphenous nerve blocks with 0.5% Ropivacaine for patients undergoing elective foot and ankle surgery for post-operative pain relief.
223490929|NCT06512987|OTHER|technology-driven, interactive ICU diary|Through the diary platform, patients can share their feelings and needs, while family members can send supportive messages, pictures, and videos. Healthcare providers will use the platform to connect with families and monitor patient conditions.
223490930|NCT02056132|OTHER|Exhaled Breath Condensate|Lab results of Exhaled Breath Condensate
223490931|NCT02647177|OTHER|Pancreatic Cyst Aspiration|10 CC of pancreatic cyst aspiration
223490932|NCT05899114|OTHER|Transitional Multidisciplinary Pharmacotherapeutic Care|"A structured medication review with improved transitional care and multidisciplinary collaboration.~TMPC consists of the following four elements:~1. A structured pharmacotherapeutic analysis~2. A transitional multidisciplinary discussion.The treating physician in the hospital will be involved. The general practitioner and community pharmacist will be consulted.~3. An interview and discussion with the patient and/or legal representative by a member of the Pharmacotherapy-team, which will be performed before the patient is discharged from the hospital.~4. A discharge note with the pharmacotherapeutic care plan. This will be sent to the community pharmacist and the general practitioner."
223587899|NCT03417986|DRUG|TEP|"For safety reasons the clinical trial will first enroll 14 subjects (7 patients and 7 healthy volunteers) for Group 1a receiving 26 mg TEP daily for 4 days with subsequent safety evaluation, based on adverse events and the safety parameters discussed in the protocol. A second set of patients (Group 1b), which will receive a higher dosage of 52 mg per day for 4 days will be enrolled optionally after recommendation to continue and subsequently treatment Group 2 with a treatment paradigm of 26 mg TEP daily for 54 days will start.~Subjects eligible for participation are subjects with newly diagnosed (within last 12 month) early-to-mild dementia due to AD and healthy volunteers who fulfill all inclusion criteria and have none of the exclusion criteria present at screening."
223587900|NCT02138357|DRUG|buprenorphine transdermal delivery system (BTDS)|
223587901|NCT02138357|DRUG|Placebo for BTDS patch|A placebo patch will be manufactured to mimic the BTDS patch.
223587902|NCT04216355|DRUG|Azacitidine|Low-dose AZA
223587903|NCT04216355|DRUG|CAG Protocol|Short term CAG derived regimen
223587904|NCT00867906|BIOLOGICAL|Cat-PAD|Cat-PAD dose 1x8 administrations 2 weeks apart
223587905|NCT00867906|BIOLOGICAL|Placebo|Placebo comparator, 1x8 administrations 2 weeks apart
223587906|NCT05077332|DRUG|Famotidine|80 mg tablet, QID for 14 days
223587907|NCT05077332|DRUG|Celecoxib|400 mg (initial dose) then 200 mg capsule, BID for 5 days
223587908|NCT05077332|OTHER|Placebo|tablet, QID for 14 days; capsule, BID for 5 days
223587909|NCT05162313|DEVICE|confirmation of endotracheal tube positioning|After performing the tube insertion by direct laryngoscopy, videolaringoscopy or fiberoptic technique, the attending neonatologist will connect both the colorimetric capnometer and the proximal flow-sensor to the tracheal tube. If the flow sensor is not proximal but incorporated into the mechanical ventilator, the care provider will connect the capnometer only. During the procedure, the information given by the capnometer will be evaluated by the care provider performing the intubation, while the flow sensor information will be monitored only by a study investigator, who will not reveal any details to the care provider. In particular, the yellow color change by the capnometer and the presence of exhalation flow curves on the ventilator screen will be considered as confirmation of correct tracheal tube positioning, respectively.
223587910|NCT04707248|DRUG|DS-6000a|Intravenous administration at doses starting at 1.6 mg/kg on Day 1 of Cycle 1
223587911|NCT04707248|DRUG|DS-6000a|Intravenous administration at RDE on Day 1 of Cycle 1
223490933|NCT06443632|BEHAVIORAL|WASPE Sleep Adjustment Protocol|Parents are instructed to implement the WASPE protocol (Watching videos, Activities outdoors, Stimulation to stay awake, Playing with toys, and Eating snacks) to keep the child awake from morning until the scheduled RT slot (14:00-16:00), thereby inducing natural deep sleep during RT without pharmacologic sedation. Treatment setup is verified with CBCT and monitored in real time using OSMS with a 5-mm motion threshold.
223490934|NCT06443632|DRUG|Chloral Hydrate|Oral or rectal chloral hydrate (typically 30-50 mg/kg, maximum 1 g) administered approximately 30 minutes before each RT fraction per institutional pediatric sedation protocol. Vital signs are monitored continuously. CBCT and OSMS are used as in the experimental arm.
223587912|NCT00304655|DRUG|Aripiprazole|
223587913|NCT00707954|DRUG|TA-7284|Patients will receive single ascending dose of TA-7284 in each step (4 doses planned: 25, 100, 200 and 400 mg), once daily, 15 days (1 day followed by a 1 day washout period and then 14 consecutive days)
223587914|NCT00707954|DRUG|Placebo of TA-7284|Patients will receive placebo tablets in each step, once daily, 15 days (1 day followed by a 1 day washout period and then 14 consecutive days)
224182485|NCT01308151|OTHER|Other|No interventions other than the culturally adapted manualised cognitive behavioral therapy
224182486|NCT04651751|BEHAVIORAL|Facilitating an Exercise Habit and Identity via the Multi-Process Action Control Model- A Randomized-Controlled Trial|Participants attended a workshop which consisted of a presentation and an exercise planning exercise.
223490935|NCT06815692|BEHAVIORAL|Psychoeducation|Focus on understanding mechanisms of concussion
223490936|NCT06815692|BEHAVIORAL|Physiotherapy|Gradual training and physical exercises
223490937|NCT06815692|BEHAVIORAL|Treatment of tinnitus and increased sound sensitivity|Treatment given individually or in groups
223587915|NCT06534359|OTHER|Transpyloric tube feeding|Tube feeding into the small bowel
224182487|NCT00004333|DRUG|NTBC|
224182488|NCT01482598|DEVICE|Remote Care Follow up|Patient device is checked daily through remote transmitter (Merlin@Home) and every 6 month a complete transmission with all device data is performed
224182489|NCT05953129|DIAGNOSTIC_TEST|Right Jugular Vein Collapsibility Index|Ultrasonography will be used to evaluate the diameter of the jugular vein (minimum and maximum values) and carotid diameter. The jugular vein collapsibility index will be measured by the anesthesiologist using non-invasive ultrasonography. Jugular vein collapsibility index will be calculated using the measured diameters.
223490938|NCT06815692|BEHAVIORAL|Vision training and examination|Training and examination by a neuro-optometrist
224182490|NCT00724789|DRUG|ganirelix|Daily 0.25 mg ganirelix administered to prevent premature LH surges during COS in order to achieve a pregnancy
224182491|NCT00724789|DRUG|GnRH agonist|Long protocol of GnRH agonist administered to prevent premature LH surges during COS in order to achieve a pregnancy
224182492|NCT01373294|DRUG|Bacille Calmette-Guerrin (BCG)|Participants will receive BCG instillations once per week for the first 6 weeks. At 3 months and 6 months, participants will receive BCG instillations once per week for three weeks.
224182493|NCT01373294|DRUG|Lenalidomide|Participants may also receive capsules of lenalidomide 10 mg to swallow once per day for 7 months. The study doctor will tell participants if they will be taking lenalidomide.
224182494|NCT05892302|BEHAVIORAL|Access to Asma Guardian website/app|The Asma Guardian intervention application is a culturally-tailored web-platform that includes 3 tool kits. The contents of the tool kits include Asthma Specialty Care, Family Asthma Management, and Home Environmental Intervention.
224182495|NCT05892302|BEHAVIORAL|Delayed Access to Asma Guardian website/app|Delayed access to the website/app. The Asma Guardian intervention application is a culturally-tailored web-platform that includes 3 tool kits. The contents of the tool kits include Asthma Specialty Care, Family Asthma Management, and Home Environmental Intervention.
224182496|NCT03626389|OTHER|Physiotherapy|
224182497|NCT02694562|DEVICE|40um Embozene TANDEM Microspheres|40um Embozene TANDEM Microspheres loaded with Irinotecan (up to 150 mg).
224182498|NCT01751269|DRUG|RPX7009|Ten (10) cohorts of 8 subjects (6 active and 2 placebo) are planned for evaluation.
224182499|NCT01751269|DRUG|Placebo|Ten (10) cohorts of 8 subjects (6 active and 2 placebo) are planned for evaluation.
223490939|NCT06815692|BEHAVIORAL|Sleep guidance and education|Counselling to achieve better sleep and reduce fatigue.
223490940|NCT06815692|BEHAVIORAL|Mindfulness with a cognitive therapeutic approach|Training by certified mindfulness instructor
223490941|NCT06815692|BEHAVIORAL|Employment-oriented intervention|The Concussion Team therapists work with a patient's employer to facilitate a gradual return to normal working hours.
224182500|NCT04847167|PROCEDURE|Single balloon enteroscopy assisted ERCP using a mechanistic loop resolution strategy group|The SBE was introduced alternately with an overtube apparatus (ST-SB1S; Olympus Corp., Japan) following the mechanistic loop resolution strategy under endoscopic and fluoroscopic guidance. The overtube was advanced along the enteroscope, by gently pulling the enteroscope, like as ERCP accessory advancement over the guidewire.
224307970|NCT06633783|DRUG|Semaglutide|The dose escalation phase, starting with 0.25mg once weekly and increasing every 4 weeks (0.5mg, 1.0mg, 1.7mg), is expected to last 16 weeks; In the dose maintenance phase, the target dose of 2.4mg was maintained for 28 weeks.Treatment duration 44 weeks.
224307971|NCT01722201|DRUG|Risperidone Tablet 1 mg|1 mg tablet once a day
224307972|NCT01722201|DRUG|Risperidone|1 mg tablet once a day
224307973|NCT05076019|DRUG|Atorvastatin 80mg|Dosage: 80 mg Form: Tablets Frequency: 1 tabl. per day. Duration: From 7 to 14 days prior to surgery until 30 days postoperative
224307974|NCT05076019|DRUG|Placebo|Form: Tablets Frequency: 1 tabl. per day. Duration: From 7 to 14 days prior to surgery until 30 days postoperative
224307975|NCT05578183|DEVICE|theta burst stimulation|expect for the TBS, all patients get cognitive training alike on a training system in medical center.
224307976|NCT05578183|DEVICE|sham stimulation|expect for the TBS, all patients get cognitive training alike on a training system in medical center.
224307977|NCT05986227|DRUG|toripalimab FOLFOX|Toripalimab（3mg/kg, q2w, IV）oxaliplatin (85 mg/m2 IV), leucovorin (400 mg/m2 IV) and 5-FU (2400 mg/m2/day continuous IV infusion over 48 h)
224307978|NCT05816590|OTHER|Med@HOME Mobile App|Meds@HOME is a software application designed for use on a personal mobile device. The app allows primary caregiver to create routines where they can detail how to perform the routine, start date and time, and frequency (daily, weekly, monthly). Optional push notifications can be set so that users are alerted to an upcoming routine. Only primary caregivers can create, edit, and delete routines. All caregivers can check off on routines and receive notifications. Caregivers can also post notes related to routines or events. App enables an inventory of caregiver troubleshooting strategies and inventory reminders.
224307979|NCT04987489|DRUG|Etavopivat tablets|Etavopivat 400 mg once daily
224182501|NCT02974673|PROCEDURE|Ejaculatory test|Measures of sphincter pressures during ejaculation will be registered using a sensor introduced in the urethra on patient with spinal cord injury.
224182502|NCT01051414|DRUG|BMS-790052|Tablets, Oral, 60 mg, daily, 24 weeks
224307980|NCT04501133|DEVICE|Peripheral electrical stimulation|Electrical stimulation will be delivered to forearm muscles with an electrical stimulator (Digitimer Ltd., Hertfordshire, UK) so that they generate forces opposed to those arising from the tremorgenic input.
224307981|NCT04501133|DEVICE|Single pulse TMS|Single-pulse TMS (spTMS) will be delivered with a TMS stimulator (MagPro X100 w/ MagOption, MagVenture, Farum, Denmark) and a figure-of-eight TMS coil. An MRI-based TMS navigation system will be used to navigate the TMS coil (Localite, St Augustin, Germany).
224307982|NCT04977986|DRUG|ZYN002 - transdermal gel|Pharmaceutically manufactured cannabidiol formulated as a clear gel that can be applied to the skin (transdermal delivery)
224307983|NCT04977986|DRUG|Placebo|"Placebo formulated as a clear gel that can be applied to the skin (transdermal delivery)~Other Names:~Placebo Comparator Matching Placebo"
224307984|NCT02174432|DRUG|nalbuphine HCl ER|nalbuphine HCl ER BID for up to 50 weeks
224307985|NCT06578442|OTHER|Magnetic Field Treatment|Magnetic Field Treatment was applied to the participants for 30 minutes a day, twice a week for 8 weeks, using an electromagnetic field therapy device, in a supine position, by placing circular magnetotherapy electrodes in the abdominal area, at 25 Hz and 30 Gauss power.
224307986|NCT06578442|OTHER|Constipation Coping Training|"The control group was given constipation coping training and asked to perform the taught methods every day for 8 weeks. Whether the individuals applied the methods was checked every day via telerehabilitation."
223490942|NCT06815692|BEHAVIORAL|Energy management and graded exercise|Counselling to achieve more energy and vitality.
223490943|NCT06815692|OTHER|Neuropsychological counseling|Talks with a neuropsychologist about mTBI sequelae.
223490944|NCT06597058|DRUG|MAR|Once-daily tablet
224182503|NCT01051414|DRUG|BMS-650032|Tablets, Oral, 1200 mg, daily, 24 weeks
224307987|NCT03066739|DRUG|Remifentanil|0.1 micrograms/kg/mL
224307988|NCT03066739|DRUG|Remifentanil+ Placebo|high dose remifentanil (0.4 mg) combined with placebo (HI, 0.4 micrograms/kg/mL)
224182504|NCT01547208|PROCEDURE|Immediate radiofrequency ablation of ventricular tachycardia|Radiofrequency ablation of ventricular tachycardia is performed immediately after an appropriate ICD shock
224182505|NCT01547208|PROCEDURE|Radiofrequency ablation of ventricular tachycardia|Radiofrequency ablation of ventricular tachycardia will be performed after an arrhythmic storm occurs
223490945|NCT06086054|BEHAVIORAL|Navigation and EMR referral to childcare facility|See arm description
224182506|NCT05071391|PROCEDURE|Roux-en-Y gastric bypass|"Gastric bypass, also called Roux-en-Y gastric bypass, is a type of weight-loss surgery that involves creating a small pouch from the stomach and connecting the newly created pouch directly to the small intestine. After gastric bypass, swallowed food will go into this small pouch of stomach and then directly into the small intestine, thereby bypassing most of your stomach and the first section of your small intestine.~Gastric bypass is one of the most commonly performed types of bariatric surgery. Gastric bypass is done when diet and exercise haven't worked or when you have serious health problems because of your weight."
224182507|NCT01333865|DRUG|Memantine|"Memantine (Namenda®) was approved by the U.S. Food and Drug Administration in 2003 and by the European Agency for the Evaluation of Medical Products in 2002 for the treatment of moderate to severe Alzheimer's disease. Evidence from available treatment trials of memantine in ASD and non-ASD populations of youth and adults strongly suggest that memantine could be an effective agent for the treatment of adults with ASD.~During the 12 weeks of study duration, subjects will be evaluated at weekly intervals for the first 4 weeks and thereafter every 3 weeks. Memantine will be administered in divided dose twice a day in the morning and evening. Titration of study medication will be guided by a forced titration schedule with an option for slower titration or holding at lower dose per clinician judgment. Safety, effectiveness, response and side effects will be evaluated."
224182508|NCT02320591|OTHER|care management fee|for each Medicare beneficiary attributed to the practice, the practice received a monthly care management fee
224307989|NCT03066739|DRUG|Remifentanil +ultra-low dose naloxone|high dose remifentanil (0.4 mg) combined with ultra-low dose naloxone (HN, 0.004 micrograms/kg/mL naloxone
223490946|NCT05759338|DEVICE|Revian Red All LED cap|"The cap is a dual-band LED light therapy wireless smart cap. It has been shown to be effective in androgenetic alopecia (used once daily, 10-minute treatment regimen) for both men and women."
224182509|NCT02320591|OTHER|feedback reports|Each participating practice received quarterly reports showing the practice's trend in key outcomes during the pre-intervention and intervention periods. The risk adjusted average Medicare expenditures of their patients were also shown in relation to all of the other CPC practices in their region, and to those with a similar average risk profile. Unadjusted hospitalization rates and emergency room visits were also plotted over time and compared to those of other CPC practices in the region
224182510|NCT02320591|OTHER|technical assistance|CPC practices could ask for technical assistance on transformation activities from a regional learning faculty (RLF). The RLF also provided seminars and other learning activities, as well as provided a forum for participating practices to share lessons they had learned.
224182511|NCT05713344|OTHER|Clinical history|Detailed clinical history including demographic details, pain details (character, pattern, location, change in character, involvement of new areas), duration of disease, co-morbidities, family history, adverse life events, sleep details, details of stress/anxiety.
224182512|NCT05713344|OTHER|Clinical examination|Thorough clinical examination, anthropometric measurement, assessment of pain (Izbicki score, Visual analog scale, modified brief pain inventory, pain catastrophising score, painDetect)
224182513|NCT05713344|OTHER|Evaluation of quality of life|Use of the EORTC QLQ c30 with PAN 28 to evaluate quality of life
224307990|NCT06369831|DIAGNOSTIC_TEST|68Ga-NOTA-ABSCINT-HER2 PET/CT|68Ga-ABS011, is a single domain antibody (sdAb) with the capability to bind HER2 tumor antigens very fast, while the unbound fraction is rapidly cleared from the blood. ABS011 is labeled with gallium-68, a short-lived isotope (68Ga, t1/2: 68 min). Combining rapid targeting of HER2, fast clearance and low radiation burden make 68Ga-ABS011 is suited for specific tumor marker whole body PET/CT imaging.
224307991|NCT05728047|PROCEDURE|Evaluation of sublingual microcirculation with side-stream dark field imaging (cytocam)|The 'Cytocam' is a hand held computer-controlled device, a third generation video-microscope, which enables real time visualisation of the in vivo microcirculation, based upon the principle of incident dark field (IDF) illumination.
224307992|NCT06152406|PROCEDURE|Ablation and Pacemaker Implantation|All patients will be implanted with a pacemaker device with one lead positioned in right ventricle (control arm only) and an additional lead will be positioned on the distal (ventricular) HIS bundle if in intervention arm. All patients will undergo ablation.
224307993|NCT02737748|DRUG|TWB-103 Group|Each subject received TWB-103+Tegaderm for up to 10 days or to the day of 100% re-epithelialization, whichever comes first, followed by Tegaderm alone application from Day 10 to 14 if failing to achieve 100% re-epithelialization by Day 10.
223490947|NCT06597006|DRUG|Inclisiran|Inclisiran (inclisiran sodium 300 mg subcutaneous (s.c.) for participants with body weight ≥23 kg, inclisiran sodium 180 mg s.c. for participants with body weight \<23 kg to ≥16 kg, or inclisiran sodium 100 mg s.c. for participants with body weight \<16 kg. The dose level is based on the participant's body weight on Day 1 (for Part 1) and Day 360 (for Part 2), respectively.
223490948|NCT06597006|DRUG|Placebo|Sterile normal saline (0.9% sodium chloride in water for subcutaneous injection)
223490949|NCT04918173|DRUG|Atenativ|Antithrombin concentrate
223490950|NCT06983210|DRUG|Add-on effect of adding tamivarotene (AM80) to gemcitabine, cisplatin, and nivolumab combination therapy|To explore the efficacy and safety of the combination of tamivarotene (AM80), gemcitabine, cisplatin, and nivolumab in the treatment of patients with untreated unresectable or recurrent urothelial cancer
223490951|NCT06614127|DEVICE|Dexcom G7® sensor placed in upper arm and positioned over deltoid|"For the subjects with Dexcom G7® sensor placed in the upper arm and positioned over the deltoid cohort, study personnel will place the Dexcom G7® sensor on the subjects' deltoid and the electrodispursive pad on the thigh."
223587916|NCT06534359|OTHER|Gastric tube feeding|Tube feeding into the stomach
223587917|NCT05409066|DRUG|Epcoritamab|Subcutaneous Injection
223587918|NCT05409066|DRUG|Rituximab|Intravenous Infusion
223587919|NCT05409066|DRUG|Lenalidomide|Oral Capsules
223587920|NCT05858710|DRUG|DPPG2-TSL-DOX|DPPG2-TSL-DOX is a thermosensitive liposomal formulation of doxorubicin.
223490952|NCT06614127|DEVICE|Dexcom G7® sensor placed in anterior thigh|"For the subjects with Dexcom G7® sensor place in anterior thigh cohort, study personnel will place the Dexcom G7® sensor in the anterior thighs and the electrodispursive pad will be placed on the opposite thigh."
223490953|NCT06982820|DEVICE|Prism Training|Participants will complete 20 Prism training sessions. The Prism training sessions take place twice a week over a 10-week period, with a minimum of one night of sleep between sessions. Participants will also receive two single booster sessions, 4 weeks and 8 weeks after their last NF session completed.
223490954|NCT06311383|DRUG|First-line Ribociclib + endocrine therapy|Ribociclib + letrozole, or Ribociclib + anastrazole, or Ribociclib + exemestane, or Ribociclib + fulvestrant
223490955|NCT06311383|DRUG|First-line endocrine therapy|As of physicians choice
223490956|NCT06311383|DRUG|First-line chemtherapy|As of physicians choice
223490957|NCT06657183|DEVICE|Alio Smart Patch™|"Alio Smart Patch is a non-invasive wearable biosensor that combines a unique, multi-sensor, wearable device with a provided- based portal to track sequentially the participant's physiologic, hematologic and electrolyte data. It works in conjunction with a home hub data relay system and an end-to-end cloud software data path. The system has been developed to enable home monitoring for multiple key metrics by healthcare provider caring for participants.~Enhanced Care Management (ECM) is a comprehensive, system-centric approach crafted to bridge the latent gaps in traditional care paradigms. ECM provides an exhaustive review of a participant's medical history and their personalized social needs, addressing both in a cohesive, participant-focused strategy.~This intervention couples Quantify Remote Care's Enhanced Care Management with the Alio Smart Patch technology."
223490958|NCT06649773|DRUG|Noiiglutide Injection|Experimental group
223490959|NCT06649773|DRUG|Noiiglutide Placebo|Placebo Comparator group
223490960|NCT06985888|DEVICE|SpeediCath® Standard male new coating|Intermittent catheterization through the urethra draining the bladder, using SpeediCath® Standard male new coating CH12 by HCP
224182514|NCT05713344|OTHER|Evaluation of mental state|Use of Beck depression inventory and Hospital Anxiety Depression score to evaluate depression and anxiety
224182515|NCT05713344|DIAGNOSTIC_TEST|Pancreatic quantitative sensory testing|Pancreatic quantitative sensory testing will be performed to evaluate temporal summation, pain detection threshold, pain tolerance threshold, and conditioned pain modulation.
224182516|NCT00515021|DRUG|Eplerenone (Morning)|"Eplerenone - 50mg, by mouth, daily, in the morning x 2 weeks followed by 4 weeks at 100mg.~100mg, by mouth, daily, in the morning x 4 weeks then patients cross over to 100mg, by mouth, daily, in the evening x another 4 weeks."
224182517|NCT00515021|DRUG|Eplerenone (Night-time)|Eplerenone - 50mg, by mouth, daily in the evening x 2 weeks followed by 4 weeks at 100mg
224307994|NCT02737748|DRUG|Placebo Group|Each subject received Placebo+Tegaderm for up to 10 days or to the day of 100% re-epithelialization, whichever comes first, followed by Tegaderm alone application from Day 10 to 14 if failing to achieve 100% re-epithelialization by Day 10.
224307995|NCT01018589|OTHER|Cicatrix cream|"We will be carried out the topical application of the product (Cicatrix cream) in the epidermic burns or post surgical scars by administration fo the patients twice a day during two months to a dose of 0,1 ml of cream for each cm of surface, being controlled by the specialist in biweekly consultations.~To the patient will be explained the technique of the application."
223490961|NCT06985888|DEVICE|SpeediCath® Standard male|Intermittent catheterization through the urethra draining the bladder, using SpeediCath® Standard male CH 12 by HCP
223490962|NCT06821113|BEHAVIORAL|COVID-19 Group Problem Solving|"Participants will have three core components to be delivered at the corner by trained data collectors. Interactive dialogue component that incorporates popular education activities aimed at developing social cohesion among LDLs, building awareness about COVID-19 risks and protective behaviors and developing a personal commitment called Mi Promesa to implement COVID mitigation practices. Navigation Component will consist of providing information and linking LDLs with social service providers and the Multiplicador de salud/Health Multiplier component that builds from the theoretical and practice-based method of mobilizing social networks and social support."
223490963|NCT06821113|BEHAVIORAL|Standard of Care|Participants will receive a COVID-19 prevention flyer and social resources list only
223490964|NCT06821113|BEHAVIORAL|Booster session|"Participants in this group will also receive a booster phone call 10 to 15 days after the small group intervention to provide brief prompts to encourage participants to act on their personal commitments and encourage them to seek community resources."
223490965|NCT06986967|PROCEDURE|Antegrade Perfusion|Procedure in which the surgeon accesses one of two arteries that branch off from the aorta to provide blood to the brain.
223490966|NCT06986967|PROCEDURE|Retrograde Perfusion|Procedure in which the surgeon accesses the superior vena cava to supply blood to the brain.
223490967|NCT06305026|DIAGNOSTIC_TEST|Muscle- and skin biopsies|RA patients with and without concomitant fibromyalgia will be examined with muscle and skin biopsies.
223490968|NCT03024008|BIOLOGICAL|BonoFill-II|"Surgery will be performed under local or general anesthetics according to the Investigator's and anesthesiologist discretion.~A standard orthopedic approach will be made according to the fracture site.Then the transplantation of BonoFill-II into the fracture site and the fixation of the fracture by intramedullary nail or plate and screws or external fixator as required will be performed.~internal fixation (plate and screws and intramedullary nails) will not be routinely removed. External fixators will be removed upon achievement of satisfactory bone union."
223490969|NCT02924376|DRUG|Pemigatinib|Pemigatinibonce a day by mouth for 2 consecutive weeks and 1 week off therapy
223490970|NCT04740307|BIOLOGICAL|Pembrolizumab/Quavonlimab|Pembrolizumab/Quavonlimab (400 mg/25 mg) administered via IV infusion Q6W.
223490971|NCT04740307|DRUG|Lenvatinib|Lenvatinib 12 mg (body weight \[BW\] ≥60 kg) or 8 mg (BW \<60 kg) administered orally every day (QD).
224182518|NCT02095028|BEHAVIORAL|Dietary and lifestyle intervention|participants in the intervention group were provided with an individualized dietary intake protocol. Patients received a diet of not fewer than 1500 calories per day in the first trimester and not fewer than 1800 calories per day after 13wks of gestation.
224307996|NCT05811377|DRUG|Ferumoxytol|After fully emptying the bladder with a catheter,1.5mg of Ferumoxytol combined with Gadobutrol 302 mg will be instilled into the bladder through the catheter. The catheter will be plugged, and the patient will submit to an MRI scan of the bladder. After the MRI is completed, the Ferumoxytol will be drained through the catheter and the catheter will be removed.
223587921|NCT05858710|DRUG|Dexrazoxane|For cardioprotection of participants.
223587922|NCT02462161|DRUG|Insulin aspart|Participants will administer 20 IU insulin aspart two times per day with an intranasal delivery device.
224182519|NCT04528433|BEHAVIORAL|Medical-education-community Collaborated Intervention|The Medical-education-community Collaborated Intervention adds an additional part in comparison with the control group of classroom management guidance for teachers, review and practice organizational skills based on school daily activities in the school, teacher rewards and encouragement of students.
224307997|NCT05811377|DRUG|Gadobutrol|After fully emptying the bladder with a catheter, 302 mg of Gadobutrol (combined with Ferumoxytol) will be instilled into the bladder through the catheter. The catheter will be plugged, and the patient will submit to a MRI scan of the bladder. After the MRI is completed, the Gadobutrol will be drained through the catheter and the catheter will be removed.
224307998|NCT00662623|BEHAVIORAL|i-PAP|Internet Intervention based on wireless telemonitoring of CPAP data and patient-centered, collaborative care
223490972|NCT04740307|BIOLOGICAL|Pembrolizumab|Pembrolizumab (400 mg) administered via IV infusion Q6W, in the event of intolerable toxicity to pembrolizumab/quavonlimab.
223490973|NCT05912647|BEHAVIORAL|MTM|Participants will receive added medicine management support from a pharmacist. This will involve one 60-minute session with the pharmacist either in-person or over the phone and at least four 30-minute follow-up sessions with the pharmacist over the phone.
223490974|NCT05912647|BEHAVIORAL|CHW|Participants will receive support from a Community Health Worker (CHW) to address life challenges that might be affecting their health and diabetes and to discuss diabetes beliefs and concerns. This will involve one \~30-minute phone call with the CHW to discuss needs and a 2-hour session with the CHW in-person for a comprehensive assessment. Participants will also receive \~10, 15 to 30-minute calls from the CHW to discuss diabetes beliefs and concerns.
223490975|NCT01471639|DRUG|intranasal ketorolac|15 mg
223490976|NCT00327093|DRUG|cetuximab|indication : second intention treatment
223490977|NCT00327093|DRUG|bevacizumab|Indication: first intention treatment
223490978|NCT06587139|BEHAVIORAL|Teen Connection Project (TCP)|The Teen Connection Project (TCP) includes seven 90-minute sessions facilitated by transgender and/or gender minority (TGM) adults. Each transgender and/or gender minority youth (TGMY) will be paired with a TGM adult mentor based on TGMYs' rank-ordered preference for mentors. The research team seeks to match mentors \& mentees such that each TGMY is matched with one of their top 3 preferred mentors. Mentors and mentees participate together in each session along with other mentors \& mentees. Facilitators direct activities/discussion to promote TGMY social-emotional skills acquisition and facilitate mentor-mentee conversations. TCP sessions also include mentor-mentee breakout sessions where mentors share challenges they personally faced as TGMY and how they overcame them. Break-out discussions focus on self-acceptance, coming out, dating questions, hopes and goals for the future, \& how other marginalized social identities, such as race and ethnicity, intersect with identifying as TGMY.
223490979|NCT06588283|DRUG|Ixekizumab|Administered SC
223490980|NCT06588283|DRUG|Tirzepatide|Administered SC.
223490981|NCT06825897|OTHER|Conventional Triage for Mechanical Thrombectomy|Participants undergo the conventional standard-of-care triage process. Upon arrival at the thrombectomy-capable center, patients first undergo an initial evaluation in the emergency department (ED), which includes diagnostic imaging (CT or MRI) to confirm eligibility for mechanical thrombectomy (MT). If the patient is found to have a large vessel occlusion (LVO) suitable for thrombectomy, they are transferred to the neurointerventional suite for treatment.
223490982|NCT06825897|OTHER|Direct Transfer to Angiography Suite (DTAS|Patients who arrive at the thrombectomy-capable center (from home, mobile stroke units, or interfacility transfer) are immediately transferred to the neurointerventional suite, bypassing the emergency department (ED). Upon arrival in the neurointerventional suite, initial neuroimaging (typically using flat panel CT or other imaging modalities) is conducted to confirm the presence of a large vessel occlusion (LVO). If the patient is eligible for mechanical thrombectomy (MT), treatment is initiated directly in the angiography suite. This approach aims to reduce delays in care and improve clinical outcomes by providing faster access to thrombectomy treatment.
223587923|NCT02462161|DRUG|Placebo|Participants will administer placebo two times per day with an intranasal delivery device.
223587924|NCT04584255|DRUG|Niraparib|Predetermined dosage PO Daily
223587925|NCT04584255|DRUG|Dostarlimab|Predetermined Dosage, IV,q3 weeks
223587926|NCT04062305|BEHAVIORAL|Hand Function Test|Complete tasks that test grip strength, pinch strength, and ability to use and feel with hands
223587927|NCT04062305|PROCEDURE|Navigated Transcranial Magnetic Stimulation|Undergo nTMS
223587928|NCT04062305|OTHER|Quality-of-Life Assessment|Ancillary studies
223587929|NCT04062305|OTHER|Questionnaire Administration|Ancillary studies
223587930|NCT04037254|BIOLOGICAL|Gonadotrophin Releasing Hormone|Receive standard of care GnRH agonist androgen suppression therapy
223587931|NCT04037254|RADIATION|Intensity-Modulated Radiation Therapy|Undergo standard of care IMRT
223587932|NCT04037254|DRUG|Niraparib|tablet
224182520|NCT04528433|BEHAVIORAL|routine clinical care|Routine clinical care includes a structured family behavioral intervention for ADHD symptom management and organizational skill training, the medication will be used if necessary.
224182521|NCT00620815|BIOLOGICAL|MF59-eTIV-H5N1+ placebo /pandemic influenza vaccine|Tetravalent influenza vaccine (MF59-eTIV-H5N1)and placebo on day 1 followed 3-5 weeks later by pandemic influenza vaccine, including serology blood draw at V1+V3.
224182522|NCT00620815|BIOLOGICAL|Pandemic influenza vaccine + placebo /MF59-eTIV-H5N1|Pandemic influenza vaccine plus placebo on day 1 followed 3-5 weeks later by tetravalent influenza vaccine (MF59-eTIV-H5N1), including serology blood draw at V1+V3.
223587933|NCT01306656|DRUG|10,000 IU Vitamin D3|"Month 1: 20,000 IU vitamin D3 once a week~Months 2-6: 10,000 IU vitamin D3 once a week"
223587934|NCT01306656|OTHER|Placebo|"Month 1: Placebo once a week~Months 2-6: Placebo once a week"
223587935|NCT01306656|DIETARY_SUPPLEMENT|Vitamin D|Daily multivitamin with 400 IU vitamin D.
224182523|NCT00620815|BIOLOGICAL|Pandemic influenza vaccine + seasonal influenza vaccine /pandemic influenza vaccine|Pandemic influenza vaccine plus seasonal influenza vaccine, 3-5 weeks later pandemic influenza vaccine , including serology blood draw at V1+V3.
224307999|NCT00662623|BEHAVIORAL|Usual Care (Standard Care)|Pre-determined clinic visits and telephone support
224308000|NCT01292226|DRUG|mycophenolate mofetil|1 g PO BID for 24 weeks
223490983|NCT06660732|DRUG|Rilonacept|320 mg subcutaneous (SC) loading dose delivered as two 2-mL, subcutaneous injections of 160 mg on the same day at different anatomical sites followed by once weekly 160 mg SC doses.
223490984|NCT06859866|OTHER|Standard oral hygiene|Standard protocol includes oral hygiene instructions (OHI), professional supragingival and subgingival instrumentation, and air polishing. A combination of manual tools (scalers/curettes) and electric tools (sonic/ultrasonic instruments) will be used to remove plaque and tartar, with particular attention to avoid damaging the implant surface. Both supragingival and subgingival surfaces will be treated with the air polishing device using glycine powder. A local antiseptic (1% chlorhexidine gel) will be prescribed twice daily for 7 days after TNC. OHI will be reinforced at each follow-up visit.
223490985|NCT06859866|DEVICE|The addition of home-based dual-light photodynamic therapy (Lumorinse® + Lumoral®)|Lumorinse® is an effervescent tablet that provides a final concentration of indocyanine green (ICG) of 250 μg/mL when dissolved in 30 mL of water. After rinsing the mouth for 1 minute, the Lumoral® device is used to activate the ICG. The device consists of 48 LED lights in the shape of a mouthguard, which simultaneously provide antibacterial blue light (aBL) at 405 nm and near-infrared (NIR) LED light at 810 nm. In combination with the ICG photosensitizer, the device delivers simultaneous aBL and aPDT action on dental plaque. After 10 minutes of use (30 J/cm2 radiant exposure), the device automatically shuts off. After treatment, patients will follow regular home oral hygiene procedures according to the OHI provided.
223490986|NCT06988033|BEHAVIORAL|Whole Body Vibration Therapy|Participants receive whole-body vibration therapy in a static upright position on a vibration platform (Power Plate My5). The intervention is applied 3 times per week for 8 weeks, progressively increasing frequency from 8 Hz to 40 Hz and amplitude from 2 mm to 5 mm. Each session lasts up to 15 minutes. No exercise is performed during the vibration.
223587936|NCT05010447|DEVICE|Virtual Coach App|The avatar-guided app aims to deepen the user's understanding of Acceptance and Commitment Therapy (ACT) and promote application of ACT skills in every-day-life. Event-Sampling-Methodology (ESM) is used to capture the user's progress as it unfolds.
224182524|NCT00620815|BIOLOGICAL|Pandemic influenza vaccine + placebo / MF59-eTIV-H5N1|Pandemic influenza vaccine plus placebo followed 3-5 weeks later by tetravalent influenza vaccine (MF59-eTIV-H5N1), including serology blood draw at V1, V2 and V3.
224182525|NCT00620815|BIOLOGICAL|Pandemic influenza vaccine + seasonal influenza vaccine / pandemic influenza vaccine|Pandemic influenza vaccine plus seasonal influenza vaccine followed 3-5 weeks later by pandemic influenza vaccine, including serology blood draw at V1, V2 and V3.
224308001|NCT01292226|DRUG|antibody induction|According to manufacturer recommendation
224182526|NCT00620815|BIOLOGICAL|MF59-eTIV-H5N1 + Placebo/pandemic influenza vaccine|Tetravalent influenza vaccine (MF59-eTIV-H5N1)plus placebo followed 3-5 weeks later by pandemic influenza vaccine, including serology blood draw at V1, V2 and V3.
224182527|NCT01492660|DEVICE|echogenic needle and catheter|Visibility of needle shaft and tip with engraved markers. Ultrasonographic Visibility of catheter tip
224182528|NCT01492660|DEVICE|Neurostimulation to position needle and catheter|The non echogenic needle will be positioned using ultrasonography and neurostimulation and the catheter will be positioned using neurostimulation with plantar or dorsiflexion with 0.6-1.5mA current. 20mL of 2% mepivacaine will be injected via the catheter. Sensory motor block will be evaluated every 5 minutes for 30 mins
224182529|NCT05365984|DIAGNOSTIC_TEST|end tidal carbon monoxide corrected for ambient carbon monoxide （ETCOc）|The measurement of end tidal carbon monoxide corrected for ambient carbon monoxide （ETCOc）is conducted in the process of risk evaluation.
224308002|NCT01292226|DRUG|Cyclosporine|According to manufacturer recommendation
224308003|NCT01292226|DRUG|corticosteroid|According to manufacturer recommendation
224308004|NCT05990478|DIAGNOSTIC_TEST|Contrast-Enhanced Mammography|Participants will have pre- and post-treatment CEM of the affected breast
224308005|NCT05990478|DIAGNOSTIC_TEST|Breast MRI|Pre- and post-NAT breast MRI will be performed for all participants
223587937|NCT03057080|PROCEDURE|Percutaneous transluminal angioplasty (PTA)|The main goal of the angioplasty (which was also the definition of technical success) was to achieve straight-line flow (SLF) from the aorta down to either a patent dorsalis pedis or plantar arch.
223587938|NCT00017290|BIOLOGICAL|autologous immunoglobulin idiotype-KLH conjugate vaccine|
223587939|NCT00017290|BIOLOGICAL|keyhole limpet hemocyanin|
223587940|NCT00017290|BIOLOGICAL|sargramostim|
223587941|NCT00017290|DRUG|cyclophosphamide|
223587942|NCT00017290|DRUG|prednisone|
223587943|NCT00017290|DRUG|vincristine sulfate|
224308006|NCT06499805|DEVICE|Audiologist-based fitting|Description hearing aids will be fitted by audiologists using established procedures.
224308007|NCT06499805|DEVICE|Over-the-counter fitting|In this group, over-the-counter hearing aids will be used by subjects. Subjects will take the full initiative and responsibility for learning and using hearing aids.
224308008|NCT06125951|DRUG|Xanamem|Xanamem drug product is formulated as an immediate-release film-coated tablet formulation for oral administration. Each Xanamem tablet contains 10 mg Xanamem (UE2343) drug substance and excipients.
223587944|NCT05390658|OTHER|Not application|Not application
223587945|NCT00711789|DRUG|Angiotensin II|Angiotensin II will be given by continuous infusion for 24 hours starting at a dose of 5ng/kg/min and then titrated to a maximum dose of 15 ng/kg/min according to a blood pressure based protocol
224182530|NCT05365984|OTHER|Internet Plus technology|The Internet Plus technology is applied in the process of follow-up management.
224182531|NCT03026764|PROCEDURE|Outpatient|Patients in the outpatient group will be discharged from the hospital the same day of surgery following a total hip arthroplasty
224182532|NCT03026764|PROCEDURE|Inpatient|Patients in the inpatient group will be discharged from the hospital the following day after a total hip arthroplasty
224182533|NCT01835964|PROCEDURE|Glucose Variability Observation|On the morning of \~Day 17 for a metabolic challenge involving a standardized liquid mixed meal intended to raise the blood glucose approximately 150 mg/dl, followed four hours later by the induction of hypoglycemia with intravenous insulin administration with goal glucose of 55 mg/dl. After carbohydrate rescue, the subject will receive a meal and will be monitored until glucose is stable above 80 mg/dl.
224308009|NCT06125951|DRUG|Placebo|Matching placebo which is identical in appearance to the test product (10 mg Xanamem once daily) except that it contains no active ingredient.
223587946|NCT00711789|DRUG|Saline placebo|Saline placebo will be given by continuous infusion according to a blood-pressure base protocol. This protocol will also incorporate noradrenaline for blood pressure control (as is true in the active drug arm), such that blood pressure targets will be rapidly achieved in both arms of the study; the only difference being that in the active drug arm, at least part of the pressor effect will be provided by angiotensin II.
223745502|NCT03459664|BEHAVIORAL|RECOVER|"For each patient baseline assessment and individual support by a diagnostic and crisis resolution home treatment team is available. In addition, patients will be treated with specific interventions based on their severity grade:~Grade 1 (mild): social support, information about mental disorder, e-therapy, consultation, self help, peer-support, supported employment.~Grade 2 (medium): psychotherapy (stepped short-term and group therapy), if applicable medical treatment, e-therapy, peer-support, supported employment.~Grade 3 (medium to severe): case management, psychotherapy (stepped short-term and group therapy), if applicable medical treatment, e-therapy, peer-support, supported employment.~Grade 4 (severe): assertive community treatment, psychotherapy, medical treatment, e-therapy, peer-support, supported employment."
224182534|NCT02815475|DIETARY_SUPPLEMENT|Placebo comparator|
223490987|NCT06988033|BEHAVIORAL|Whole Body Vibration with Exercise|Participants perform lower extremity strengthening exercises on a vibration platform simultaneously with whole-body vibration. The protocol includes lunges, squats, heel raises, and ball squeezes. Vibration frequency ranges from 30 to 40 Hz and amplitude from 2 to 5 mm. Sessions are performed 3 times per week for 8 weeks, with duration progressing from 2 to 18 minutes depending on tolerance.
223490988|NCT06988033|BEHAVIORAL|Conventional Physiotherapy|Participants receive standard post-total knee arthroplasty physiotherapy 3 times per week for 12 weeks, lasting 40 to 70 minutes per session. In addition, a home-based exercise program is performed 3 times daily. The program includes range of motion, strengthening, and balance exercises. No vibration therapy is applied in this group.
223490989|NCT06991257|DRUG|Placebo|ARM 1
223490990|NCT06991257|DRUG|Low Dose PF-07328948|ARM 2
223587947|NCT01910467|DEVICE|NIRS visible and predefined interventions|NIRS measurements are visible and the patients will be treated according to predefined clinical interventions: If cTOI/pTOI ratio increases \>5% within a six-hours-period echocardiography will be performed and based on results of echocardiography and blood pressure a volume bolus or, if ventilated, modification of ventilation or treatment of patent ductus arteriosus will be considered.
223587948|NCT01910467|DEVICE|NIRS not visible and treatment as usual|NIRS not visible and the patients will be treated according to routine
223587949|NCT04654078|DRUG|IN-C004 with water|One time dose of IN-C004 taken with water
223587950|NCT04654078|DRUG|IN-C004 without water|One time dose of IN-C004 taken without water
223587951|NCT04654078|DRUG|K-CAB tab. with water|One time dose of K-CAB tab. taken with water
223587952|NCT00020878|DRUG|celecoxib|Dosing will occur for a total of 6 months. 400 mg by mouth twice daily.
223587953|NCT05348239|DRUG|Sodium Copper Chlorophyllin|Sodium-copper-chlorophyllin (CHL) is a phytopharmaceutical drug obtained from green plant pigment, chlorophyll. Chlorophyllin scavenges radiation-induced free radicals and reactive oxygen species. It is used as a food colorant and OTC in the USA, Japan, Australia and China for many years for a variety of health benefits including prevention of body odour in geriatric patients, enhanced wound healing, antibacterial action, prevention of cancer in the high-risk populations exposed to hepatocarcinogen aflatoxin B1, treatment of faecal incontinence etc. Studies have shown that CHL has immunostimulatory, anti-inflammatory and antiviral effects in addition to antioxidant and radioprotective properties. It increases the expression of a transcription factor (protein) Nrf2 which improves lymphocyte survival and enables efficient detoxification after exposure to radiation. The duration of therapy will be up to 6 months depending upon the response of participants.
223587954|NCT05014685|DRUG|Rabeprazole|20mg bid
224182535|NCT02815475|DIETARY_SUPPLEMENT|Curcumin|
224182536|NCT02815475|DIETARY_SUPPLEMENT|Turmeric powder|
224182537|NCT04013633|OTHER|Lifesaver virtual reality training|CPR training using the Lifesaver virtual reality application
224308010|NCT05818241|PROCEDURE|Treatment of fracture by forearm cast|Patient that are not surgically treated for DRF
223490991|NCT06991257|DRUG|Medium Dose PF-07328948|ARM 3
223490992|NCT06991257|DRUG|High Dose PF-07328948|ARM 4
224182538|NCT04013633|OTHER|Face-to-face training|Short face-to-face CPR training
224182539|NCT00099606|DRUG|Dasatinib|Tablets, Oral, Dose Finding Study - Range was 35 mg BID, 5 days on/2 days off - 120 mg BID Continuous Daily Dosing, Once daily, Patients remained on study until treatment discontinuation due to unacceptable toxicity, disease progression or death.
223587955|NCT05014685|DRUG|Bismuth potassium citrate|0.6g bid
223490995|NCT06174402|DRUG|Fenofibrate|Fenofibrate 200 mg/day
223490996|NCT06174402|DRUG|Placebo|1 tablet/ day
223490997|NCT06174402|DRUG|UDCA|UDCA 13-15mg/kg/day
223490998|NCT06991842|PROCEDURE|Permanent dental restoration|In both study arms, permanent dental restorations are made with resin-based composite in permanent anterior teeth. Both study arms will use identical materials for the resin-based composite restoration (Tetric Plus Flow and Tetric Plus Fill) and universal adhesive (Adhese Universal), with the only difference being the duration of the phosphoric acid etching step. All other aspects of the restorative procedure, such as isolation of the operative field, application techniques, and final polishing, will remain consistent across both arms.
223587956|NCT05014685|DRUG|Metronidazole|0.4g tid
223587957|NCT05014685|DRUG|Amoxicillin|1g tid
224182540|NCT04006431|OTHER|embolization|Retrospective, observational collection with division of patients into two groups according to unilateral or bilateral embolization of the porstatic arteries.
224182541|NCT02102776|PROCEDURE|MMC|Standardized cotton soaked in mitomycin C (0.02%) will be applied underneath conjunctiva for 5 minutes after pterygium excision.
224182542|NCT02102776|PROCEDURE|AMT|Amniotic membrane transplantation will be applied to cover the conjunctival defect after pterygium excision.
224182543|NCT02102776|PROCEDURE|CAG|A conjunctival autograft, harvested from the superior bulbar conjunctiva of the operating eye, will be applied to cover the conjunctival defect after pterygium excision.
224182544|NCT02102776|PROCEDURE|Pterygium excision|Pterygium head, minimal conjunctiva and anterior tenon's capsule underneath will be removed in the excision of pterygium tissue.
224182545|NCT00877929|DRUG|Telmisartan 80|Telmisartan 80 mg
223587958|NCT04241471|PROCEDURE|incision and loop drainage|incision and loop drainage utilizing the rolled ring of a sterile glove technique
224182546|NCT00877929|DRUG|Amlodipine 10|Amlodipine 5 for two weeks, then forced titration to Amlodipine 10
223490999|NCT06992778|DEVICE|Remote fine-tuning of hearing aids|"Remote Fine-Tuning of Hearing Aids allows patients to adjust their hearing aids remotely, without having to visit a clinic. Using a mobile app on the patient's device, real-time adjustments are made based on their feedback, with immediate changes during the session.~Unlike traditional face-to-face adjustments, this approach lets patients stay in their own familiar surroundings. This helps create a more accurate listening environment, as the adjustments are made based on the sounds they experience in their everyday life."
223491000|NCT06992778|DEVICE|Face-to-face fine-tuning of hearing aids|In the clinic, the standard procedure for fine-tuning hearing aids (HAs) involves a face-to-face consultation with an audiologist, typically lasting 30 minutes.
223491001|NCT05513560|DRUG|Ibudilast|10mg pills, 2 pills twice per day
223491002|NCT05513560|DRUG|Pentoxifylline|400mg pill 3 times per day
223491003|NCT05513560|OTHER|Placebo|Placebo matching ibudilast, 2 pills twice per day OR placebo matching pentoxifylline 1 pill 3 time per day.
223491004|NCT03698162|OTHER|Dynamic Contrast-Enhanced Magnetic Resonance Imaging|Undergo STAR DCE-MRI
223491005|NCT03698162|OTHER|Bevacizumab Injection|Bevacizumab will be give to participants who have recurrent high-grade glioma as part of standard of care.
223491006|NCT03351348|DRUG|Bupivacaine|The intervention in this study is the insertion of 20cc of 0.5% bupivacaine via a drain into the mastectomy wound for 2 hours ± 30 minutes postoperatively in patients undergoing unilateral mastectomy without breast reconstruction +/- SLNB, +/- axillary dissection.
223491007|NCT03351348|BEHAVIORAL|patient-reported pain scores|Will be recorded by the nurse in the PACU as per usual practice. Patients will be given a follow-up Brief Pain Inventory (short form) 6 months and 1 year after surgery to assess their level of chronic pain. Patients may be discharged when table either on the day of surgery or post-operative day 1 (on pill diary for same-day discharge patients).
223491008|NCT03351348|OTHER|saline|The intervention in this study is the insertion of 20cc of saline via a drain into the mastectomy wound for 2 ± 30 minutes hours postoperatively in patients undergoing unilateral mastectomy without breast reconstruction +/- SLNB, +/- axillary dissection.
223491009|NCT06992960|DEVICE|ChitoCare® medical Scar Healing Gel (Örsáragel)|ChitoCare® medical Scar Healing Gel is a topical gel indicated for the treatment of new and old scars. The Scar Healing Gel provides a soothing effect and support to the scar tissue to heal in an orderly manner. It protects against infections, stimulates cell proliferation in old and new scars, as well as correct tissue organization with proper collagen alignment for a better aesthetic appearance and skin flexibility. Ideal for treating scars after accidents, surgery, C-section and cosmetic surgery. For smoother and less visible scars. May be used by the whole population, also elderly and children.
223491010|NCT06992960|DEVICE|Amoena CuraScar Mammilla Circles Silicone Scar Patch and Amoena CuraScar Anchors Silicone Scar Patch|Amoena CuraScar Mammilla Circles Silicone Scar Patch and Amoena CuraScar Anchors Silicone Scar Patch are silicon-based, single-patient, multi-use scar patches intended for use as scar reduction therapy in surgical breast scars. The silicone creates a moist environment on the scar, which prevents the scar from drying out. It keeps the scar soft and has a positive effect on scar tissue. The devices are specifically designed for breast scarring and are shaped to fit the normal surgical scars experienced after breast surgery.
223491011|NCT07000227|BEHAVIORAL|Low FODMAP diet|High FODMAP foods are swapped for low FODMAP alternatives, for two weeks (Elimination phase)
223587959|NCT04241471|DEVICE|traditional incision and drainage (I&D)|traditional incision and drainage (I\&D)
223587960|NCT02787915|BIOLOGICAL|DC1-CTL|Autologous cytotoxic of T lymphocytes (CTL) were induced by type-1 polarized dendritic cells (DC1) loaded with MAGE-3/MAGE-4/survivin/ her2 /COX-2 CTL epitope peptides .
224182547|NCT00877929|DRUG|Amlodipine 10|Amlodipine 5 for two weeks, then forced titration to Amlodipine 10
223491012|NCT07000227|BEHAVIORAL|Gentle FODMAP diet|Key High FODMAP foods will be identified from patients' food diaries and swapped with low FODMAP alternatives. (Elimination phase)
223491013|NCT07000227|BEHAVIORAL|Traditional Dietary Advice|Subjects are required to follow a set of healthy eating guidelines set by NICE guidelines for IBS for two weeks a. Have regular meals and take time to eat b. Avoid missing meals or leaving long gaps between eating c. Drink at least eight cups of fluid a day, especially water or other non-d. caffeinated drinks, such as herbal teas d. Restrict tea and coffee to three cups a day e. Reduce intake of alcohol and fizzy drinks . Limit intake of high-fibre food g. Reduce intake of resistant starch h. Limit fresh fruit to three portions a day
223491014|NCT06670937|OTHER|Induced sputum|Patients will provide 1) an induced sputum sample after inhaling 15 ml of 0.9% NaCl solution
223491015|NCT06670937|OTHER|Blood sample|Patients will provide 2) a blood sample.
223491016|NCT07003425|DRUG|APG777|APG777 subcutaneous injection
223587961|NCT00005949|BIOLOGICAL|aldesleukin|Given SC
223587962|NCT00005949|BIOLOGICAL|gp100:209-217(210M) peptide vaccine|Given SC
223587963|NCT00005949|OTHER|laboratory biomarker analysis|Correlative studies
223587964|NCT02504580|DRUG|HTX-011|HTX-011 (bupivacaine/meloxicam) by injection.
223587965|NCT02504580|DRUG|Placebo|Saline placebo by injection.
224182548|NCT00548366|OTHER|Sodium restriction|4 gram sodium diet
224182549|NCT00548366|OTHER|Sodium restriction|2 gram sodium diet
224182550|NCT05878340|BEHAVIORAL|Miffy|A method to stimulate children to try different fruits and vegetables using reward and role modelling
224182551|NCT05878340|BEHAVIORAL|Reward|Reference method to stimulate children to try fruits and vegetables using reward alone
224182552|NCT05853172|DRUG|AK104|Subjects will receive AK104 until disease progression or for up to 6 cycles.
224182553|NCT05853172|DRUG|Apatinib|Subjects will receive apatinib until disease progression or for up to 6 cycles.
224182554|NCT05853172|DRUG|Paclitaxel|Subjects will receive paclitaxel until disease progression or for up to 6 cycles.
224182555|NCT05853172|DRUG|S-1|Subjects will receive S-1 until disease progression or for up to 6 cycles.
224308011|NCT05818241|PROCEDURE|Surgical treatment of fracture|Patients that are surgically treated for DRF
224182556|NCT01482338|DRUG|EE 20 microgram with desogestrel 150 mg|Comparison of 2 different low-dose oral contraceptive pill which one consists of 20 microgram ethinyl estradiol and 150 mg desogestrel and the other consists of 20 microgram ethinyl estradiol and 3 mg drospirenone. Both were taken orally by participants every day beginning Day1 to Day 3 of the first menstrual cycle until complete 24 days and continued with free-hormone pills for 4 days. The next cycle has to continue in the same way until complete 6 cycles.
224182557|NCT01482338|DRUG|EE 20 microgram with drospirenone 3 mg|Comparison of 2 different low-dose oral contraceptive pill which one consists of 20 microgram ethinyl estradiol and 150 mg desogestrel and the other consists of 20 microgram ethinyl estradiol and 3 mg drospirenone. Both were taken orally by participants every day beginning Day1 to Day 3 of the first menstrual cycle until complete 24 days and continued with free-hormone pills for 4 days. The next cycle has to continue in the same way until complete 6 cycles.
224182558|NCT00689728|BIOLOGICAL|LY2127399|LY2127399 will be administered as a single IV infusion over 30 minutes.
224182559|NCT00689728|DRUG|Placebo|Placebo will be administered as a single IV infusion over 30 minutes.
224182560|NCT01365897|DRUG|Modafinil|Modafinil 200mg
224182561|NCT01825811|BIOLOGICAL|TissueGene-C (Low dose)|TissueGene-C at 1.0 x 10\^6 cells mixed with fibrin-glue
223491017|NCT07003425|DRUG|APG777|APG777 subcutaneous injection every 12 weeks
223491018|NCT07003425|DRUG|APG777|APG777 subcutaneous injection every 24 weeks
223491019|NCT06455111|OTHER|Keenoa|Keenoa is an artificial intelligence-enhanced, image-assisted tool, is a newly designed mobile application that may facilitate collection of dietary data. Serving as a visual food diary, individuals can upload a picture of their meal, choose the food items eaten using a preselected food list available by the app, and confirm the portion size with the presented visual aids.
223491020|NCT06455111|OTHER|ASA24|The Automated Self-Administered 24-Hour (ASA24) dietary recall or record is a free, web-based tool that enables multiple, automatically coded, self-administered 24-hour diet recalls and/or single or multi-day food records, also known as food diaries.
223491021|NCT06871111|BIOLOGICAL|Commensal Bacteria Strains|7 doses containing 8 capsules will be administered over 7-10 days
223491022|NCT07009717|OTHER|No intervention (observational study)|No intervention; observational study
223491023|NCT05592197|DRUG|Lenvatinib|Lenvatinib will be initially provided to patients first (dose: 8 mg qd for patients \< 60 kg, and 12 mg qd for patients ≥ 60 kg)
223491024|NCT05592197|PROCEDURE|TACE|TACE will be performed one day after oral administration of lenvatinib. Either cTACE or DEB-TACE can be used, depending on the condition of each center.
223491025|NCT05592197|RADIATION|External beam radiation (RT)|RT will be given within 4 weeks after the first TACE with linear accelerator-based photon beams. Gross tumor volume is defined as intrahepatic tumor and vascular invasion including a 1-cm margin into the contiguous HCC. Prescription dose will be 4500-6000 cGy in 25 fractions.
223491026|NCT03421561|DEVICE|"Stellarex 0.035 OTW Drug-coated Angioplasty Balloon"|"The Stellarex 0.035 OTW Drug-coated Angioplasty Balloon is indicated for percutaneous transluminal angioplasty (PTA), after appropriate vessel preparation, of de novo or restenotic lesions up to 180 mm in length in native superficial femoral or popliteal arteries with reference vessel diameters of 4-6 mm."
223491027|NCT03421561|DEVICE|EverCross™ 0.035 PTA Balloon Catheter|The control device is a commercially available PTA balloon catheter (EverCross™ 0.035 PTA Balloon Catheter, Medtronic, Plymouth, MN 55441, USA).
223491028|NCT05112120|DRUG|Olumiant|Olumiant (4mg) will be administered in line with standard of care guidance.
223491029|NCT00524498|DRUG|OPC-18|OPC-18: 500IU \* 3 times a week, sc 5-FU : 500mg infusion for 5days into hepatic artery
224182562|NCT01825811|BIOLOGICAL|TissueGene-C (High dose)|TissueGene-C at 3.0 x 10\^6 cells mixed with fibrin-glue
224182563|NCT06477523|DRUG|AK104|IV infusion
223491030|NCT00524498|DRUG|cisplatin|infusion into hepatic artery with cisplatin 10mg and 5-FU 250mg a day
224182564|NCT06477523|DRUG|Etoposide|Etoposide intravenous infusion was administered at a dose of 100 mg/m\^2 on Days 1, 2, and 3 of each 21-day cycle during the induction phase (Cycles 1-4).
224182565|NCT06477523|DRUG|Carboplatin|Carboplatin intravenous infusion to achieve an initial target AUC of 5 mg/mL/min was administered on Day 1 of each 21-day cycle during the induction phase (Cycles 1-4).
224182566|NCT06477523|RADIATION|low-dose radiotherapy|"The subjects will receive LDRT, from C1D1-C1D5, once a day for 3Gy, until the target dose of 15Gy is achieved (Cycles 1).~LDRT treatment for primary/mediastinal positive lymph nodes/metastatic lesions during maintenance therapy (C1D1-C1D5, 15Gy)."
224182567|NCT05500742|DIETARY_SUPPLEMENT|Coenzyme Q10|Soft 100 mg capsules containing coenzyme Q10 in vegetable oil provided by Pharma Nord
223491031|NCT05285449|DIETARY_SUPPLEMENT|Cannabidiol (CBD) powder formulation|30 mg CBD in the form of 300 mg of 10% CBD isolate
223491032|NCT05285449|DIETARY_SUPPLEMENT|Matching Placebo Cannabidiol (CBD) powder formulation|Matching Placebo
223491033|NCT05259215|OTHER|physiotherapy|Standard usual care physiotherapy after stroke
223491034|NCT03118882|BEHAVIORAL|Diet group|A meeting where an expert illustrates the scientific basis of a proper diet. Moreover, clear and practical indications for dietary habits improvement and for suggested food purchase are provided. After having completed the basic module, participants are offered the opportunity of deepening the educational process through an advanced module:hree theoretical and practical cooking meetings (total of 10 hours) held by cooks with an expertise in natural cuisine and by trained dieticians.
223491035|NCT03118882|BEHAVIORAL|Physical activity group|A meeting where an expert illustrates the benefits of a constant PA. Moreover, indications are given on sport opportunities and walking groups in the city organised by public authorities. After having completed the basic module, participants are offered the opportunity of deepening the educational process through an advanced module: three theoretical and practical lessons (total of 10 hours) held by expert physical trainers.
223587966|NCT02504580|DRUG|HTX-002|HTX-002, by injection or instillation (pooled).
223587967|NCT02504580|DRUG|Bupivacaine HCI (Marcaine)|Bupivacaine HCI (Marcaine) by injection.
223587968|NCT02504580|DRUG|HTX-011A|HTX-011A (bupivacaine/meloxicam) by injection.
224182568|NCT05500742|DIETARY_SUPPLEMENT|Selenium|100 mcg tablets provided by Pharma Nord
224182569|NCT05500742|DIETARY_SUPPLEMENT|Resveratrol|350 mg capsules provided by NOW Foods
224182570|NCT05500742|DIETARY_SUPPLEMENT|TA-65 MD|100 unit capsules provided by TA Sciences
224182571|NCT05500742|OTHER|Placebo-1|Soft capsules containing vegetable oil, externally identical to coenzyme Q10 capsules, provided by Pharma Nord
224182572|NCT05500742|OTHER|Placebo-2|Tablets containing excipients, externally identical to selenium tablets, provided by Pharma Nord
224182573|NCT01244971|DRUG|Acarbose|100mg, 3 times daily
224182574|NCT01244971|BEHAVIORAL|Exercise|Moderate combined exercise, 50 minutes 3 times per week
224182575|NCT01244971|OTHER|Exercise + Acarbose|See respective monotherapy description
224182576|NCT03498911|PROCEDURE|Mucogingival surgery|The gingiva around the mucosal recession at implant site will be coronally positioned by releasing the underlying mucosa
224308012|NCT02922881|OTHER|Ulcerative Colitis Diet (UCD)|The primary study intervention is a novel dietary intervention, the UC Diet. The UC Diet is a structured 12-week diet with a step down phase designed to remove products that allow harmful bacteria to thrive and add products that can change the bacteria in the gut to induce remission
224308013|NCT01584843|DRUG|GSK1358820|IM injection of Botulinum Toxin Type A
224308014|NCT03666559|DRUG|Azacitidine|Chemotherapy
224308015|NCT01157806|RADIATION|short course of palliative radiotherapy|5x5 Gy + XELOX 7 days after radiotherapy
223491036|NCT03118882|BEHAVIORAL|Physical activity and diet group|A meeting where the indications given to the previous groups are presented simultaneously. Particular attention is paid to the interaction between the two activities. After having completed the basic module, participants are offered the opportunity of deepening the educational process through an advanced module: four theoretical and practical meetings (total of 12 hours), two lessons focus on diet and two on PA.
223491037|NCT05008770|OTHER|No intervention|No intervention
223491038|NCT05181722|OTHER|Patient navigator support|Support of a patient navigator for patients who have experienced an abnormal screening mammogram
224182577|NCT02720627|DRUG|cortexolone 17α-propionate|CB-03-01 cream is a topical steroidal antiandrogen that is being developed for the potential treatment of acne vulgaris, an androgen-dependent skin disorder.
224182578|NCT04759391|OTHER|Exercise|Pelvic floor muscle training program planned under the supervision of a physiotherapist was applied and followed to the exercise group, using the digital application.
224182579|NCT04759391|OTHER|Lifestyle recommendations|Information was given within the scope of lifestyle recommendations (fluid intake, diet, constipation, weight control, smoking related to lower urinary system symptoms
224182580|NCT02966912|DIETARY_SUPPLEMENT|400 mg of Magnesium Oxide twice daily for 24 weeks|
224182581|NCT02966912|OTHER|Open label (none)|
224182582|NCT01742013|DRUG|GCJBP Laennec Inj.|Test drug
224182583|NCT01742013|DRUG|Placebo|Comparator
224182584|NCT00861627|BIOLOGICAL|REOLYSIN®|3x10E10 TCID50, 1 hour intravenous infusion, administered on Days 1, 2, 3, 4 and 5 of a 21 day cycle
224182585|NCT00861627|DRUG|Carboplatin|5 AUC mg/mL min, 30 min intravenous infusion, given on Day 1 of a 21 day cycle
224182586|NCT00861627|DRUG|Paclitaxel|175 mg/m2, 3 hour intravenous infusion, given on Day 1 of 21 day cycle
223491039|NCT05319470|DIAGNOSTIC_TEST|Intraocular pressure (IOP)|Measurement of intraocular pressure in both eyes of the study population using the Goldman applanation tonometer.
223491040|NCT05319470|DIAGNOSTIC_TEST|Tear Break-up Time (TBUT)|TBUT will be calculated after instillation of a drop of fluorescein dye, by slit lamp biomicroscopy.
223491041|NCT05319470|DIAGNOSTIC_TEST|Conjuctival Hyperemia|Conjunctival hyperemia will be assessed by slit lamp biomicroscopy using a validated grading system.
224308016|NCT02196701|DRUG|Adalimumab|Administered by subcutaneous injection every other week.
223491042|NCT05319470|DIAGNOSTIC_TEST|Schirmer Test|Schirmer test will be performed on both eyes to asses tear production.
223491043|NCT05319470|DIAGNOSTIC_TEST|Visual Fields and OCT RNFL|Visual field examination using a Humphrey perimeter and measurement of peripapillary retinal nerve fiber layer thickness with optical coherence tomography.
223491044|NCT00077194|DRUG|romidepsin|
223491045|NCT02653820|OTHER|Reflexology|
223491046|NCT04959513|PROCEDURE|LPRF bone block|Guided bone regeneration using an L-PRF bone block (composite graft composed of a xenograft, a membrane from the patient's blood and a collagenous membrane) after a short healing period of 6 to 8 weeks after tooth extraction
223491047|NCT03956875|OTHER|yoga|yoga is a mind-body practice that guides the body through a series of poses and breathing exercises
223491048|NCT05954871|DRUG|GDC-1971|GDC-1971 capsules or tablets will be administered as specified in each treatment arm.
224182587|NCT04826315|BEHAVIORAL|COPE +|Six sixty minute sessions that teaches participants distress and communication coping skills.
224182588|NCT05422950|OTHER|Relationship between physical condition and functionality in post-covid patients|Correlation study between the physical condition and functionality of patients after intubation due to covid 19
224182589|NCT01772017|DEVICE|Tongue Advancement Retainer Device|Tongue Advancement Retainer Device
224182590|NCT01219686|DRUG|escitalopram, pindolol|escitalopram p.o., once daily, day 1-2: 10mg, days 3-42: 20mg pindolol p.o., twice daily 7.5 mg days 1-14, once daily 7.5 mg days 15-17
224182591|NCT01219686|DRUG|escitalopram|escitalopram p.o., once daily. days 1-2: 10 mg, days 3-4: 20 mg, days 5-42: 30 mg
224182592|NCT01219686|DRUG|escitalopram|escitalopram 20 mg, p.o., once daily. Days 1-2: 10mg, days 3-42: 20 mg
224182593|NCT02554916|BEHAVIORAL|Dual-Belt Exercise|The dual-belted exercise treadmill can control the speeds of the right and left legs individually. When asymmetric, the dual-belt treadmill imposes mechanical and sensory perturbations independently to each leg such that the central nervous system (CNS) must solve and adapt to the challenge to maintain walking.
224182594|NCT02554916|BEHAVIORAL|Treadmill Exercise|The treadmill exercise will maintain the speed of the right and left leg together while walking.
224182595|NCT02554916|OTHER|Usual Care|This group will not be assigned to a treadmill but is as a non-exercising control group.
224182596|NCT02554916|DEVICE|Dual-Belt Treadmill|
224308017|NCT02196701|DRUG|Methotrexate|Methotrexate was provided as 2.5 mg tablets for oral administration.
224308018|NCT01254266|BEHAVIORAL|inpatient hospitalization and follow up|An inpatient program and a 1-year weekly follow up that include multi-disciplinary interventions for weight reduction and maintenance.
224308019|NCT01254266|BEHAVIORAL|inpatient treatment and follow up|one month inpatient treatment followed by a year-long follow up on the inpatient unit.
224308020|NCT01254266|PROCEDURE|bariatric surgery|bariatric surgery.
224182597|NCT00106496|DRUG|Protopic|topical
224182598|NCT00106496|DRUG|Corticosteroid|topical
224308021|NCT01254266|BEHAVIORAL|inpatient treatment with follow up|1 month inpatient treatment followed by a year-long follow up on the inpatient unit.
224308022|NCT03401359|GENETIC|tissue biopsy, blood sample|At baseline, 100 tumor/blood samples will be banked. Only \~60 will be profiled if the paired samples are acquired post-progression or on-treatment. On-treatment blood samples will be serially collected and banked from all consenting patients.
224308023|NCT04532359|DEVICE|Implant placement|Implant placement
224308024|NCT01877226|DRUG|Tapentadol|Tapentadol tamper resistant prolonged-release formulation (TRF) will be administered as 250 milligram oral tablet once (in the morning, 30 minutes after breakfast) on Day 1 and 6, and twice daily (in the morning, 30 minutes after breakfast and in the evening) on Day 4 and 5.
224308025|NCT02092896|DRUG|Liraglutide|Subjects randomised to 1.2 mg liraglutide treatment or liraglutide placebo will receive 0.6 mg for 1 weeks followed by 1.2 mg for 11 weeks. At baseline and week 12 study 1 is performed.
224308026|NCT02092896|DRUG|Placebo|Subjects randomised to 1.2 mg liraglutide treatment or liraglutide placebo will receive 0.6 mg for 1 weeks followed by 1.2 mg for 11 weeks. At baseline and week 12 study 1 is performed.
224308027|NCT02092896|DRUG|Liraglutide|Subjects randomised to 1.2 mg liraglutide treatment or liraglutide placebo will receive 0.6 mg for 1 weeks followed by 1.2 mg for 11 weeks. At baseline and week 12 study 2 is performed.
224308028|NCT02092896|DRUG|Placebo|Subjects randomised to 1.2 mg liraglutide treatment or liraglutide placebo will receive 0.6 mg for 1 weeks followed by 1.2 mg for 11 weeks. At baseline and week 12 study 2 is performed.
224308029|NCT04244123|COMBINATION_PRODUCT|integrated information and nurse led telephone clinic|combining web-based information from easypod connect with nurse led telephone clinic
224308030|NCT05980195|PROCEDURE|Hyperbaric oxygen therapy|Hyperbaric oxygen therapy for 30 times within 50 days
224308031|NCT05980195|DRUG|Standard medical treatment|"Standard medical treatment consists of dual antiplatelet treatment (aspirin 100 mg per day for the entire follow-up, clopidogrel 75 per day mg, or ticagrelor 90 mg twice per day for 3 months after stenting).~Other Name: Dual antiplatelet therapy for 3 months"
224308032|NCT05980195|BEHAVIORAL|Risk factor management|Management of risk factors including hypertension, diabetes, lipoprotein metabolism disorder, smoking and exercise
224308033|NCT04810403|BEHAVIORAL|SOMEBODY Eating Disorder Prevention Program|Participants will receive daily activities to complete on their most frequently used social media platform for 14 consecutive days. Daily activities have been adapted from the Body Project - an intervention that has been demonstrated to reduce internalization of the thin ideal and reduce risk for eating disorders. Examples of activities to be piloted include unfollowing social media accounts the participant perceives as reinforcing the thin-ideal and posting a selfie without makeup or editing. Based on feedback from participants, the intervention may be altered to improve acceptability, feasibility, and preliminary evidence of potential efficacy.
224308034|NCT02724930|BEHAVIORAL|Enhanced facilitation of COPES|Enhanced facilitation of COPES implementation consists of promotional meetings, automated case finding and proactive outreach to recruit patients, marketing and educational materials, local champion, and academic detailing.
224308035|NCT00311402|DRUG|Aggrenox capsule|extended-release dipyridamole 200 mg plus ASA 50 mg in a capsule, 2 capsules twice daily
224308036|NCT00311402|OTHER|Acetylsalicylic Acid (ASA)|Acetylsalicylic Acid (ASA) 81 mg, 1 tablet once daily
224308037|NCT05713851|DRUG|Dapagliflozin|dapagliflozin is given for 21 days vs standard of care
224308038|NCT03082287|DEVICE|Fecal Calprotectin Level|Measurement of calprotectin in feces
224308039|NCT00073619|BEHAVIORAL|Cognitive-behavioral group therapy|School-based anxiety preventive intervention (cognitive-behavioral group therapy) originally designed for Australian children that was culturally and contextually modified for inner-city children exposed to community violence. Participants received the weekly intervention and rewards for participating in the assessments.
224308040|NCT02823418|PROCEDURE|No neuraxial labor analgesia|Neuraxial analgesia will not be performed. Analgesics will be prescribed by the obstetricians according to routine practice.
224308041|NCT02823418|PROCEDURE|Neuraxial labor analgesia|Epidural or combined spinal-epidural labor analgesia will be performed when the cervix is dilated to 1 cm or more and continued until the cervix is fully dilated to 10 cm.
224308042|NCT05919121|OTHER|Therapeutic exercise|"1. Stretching exercise of posterior shoulder capsule~2. Strengthening exercises: consists of 6 strengthening exercises all of which have been recommended as essential for any shoulder rehabilitation program.~3. The remaining 2 exercises are the seated press-up and the elbow push up. Both will be performed to fatigue or for a maximum of 25 repetitions. The quality of all repetitions of each exercise will continuously monitored by the investigator of the study"
224182599|NCT00106496|DRUG|placebo|topical
224182600|NCT02018276|DRUG|Lidocaine|The administered drugs for each group were prepared by an anesthetist who did not participate in the study according to directions given by the patient in charge of the study. (for Lidocaine Group, 1% lidocaine 40 mL was prepared in a 50 mL syringe
224182601|NCT02018276|DRUG|Magnesium|The administered drugs for each group were prepared by an anesthetist who did not participate in the study according to directions given by the patient in charge of the study. (for Magnesium Group, MgSO4 4g 40 mL was prepared in a 50 mL syringe)
224308043|NCT05919121|OTHER|hydrocortisone phonophoresis|In this study, the effective area of radiation (ERA) in the mode continuous (100 percent) is 5 cm2, in 1 MHz and 0.7 W/cm2, with four ERA treated areas. Therapy lasted five minutes (three minutes in the insertion of the supraspinatus and 37 two minutes in the infraspinatus insertion) three times weekly over 6 weeks in addition to therapeutic exercises
224182602|NCT03590613|DRUG|GSK2982772|GSK2982772 will be available as white to almost white, round, film coated tablets to be administered via oral route
223491049|NCT05954871|DRUG|Osimertinib|Osimertinib tablets will be administered as specified in each treatment arm.
224182603|NCT03590613|DRUG|Placebo|Placebo matching GSK2982772 will be available as white to almost white, round, film coated tablets to be administered via oral route.
223491050|NCT05954871|DRUG|Cetuximab|Cetuximab, solution for infusion will be administered as specified in each treatment arm.
223491051|NCT06571305|BEHAVIORAL|Brief Behavioral Treatment for Insomnia (BBTI)|"BBTI is brief patient-focused intervention for patient-sleep-partner caregiver dyads, aimed at altering participants' sleep behaviors to improve sleep. BBTI utilizes behavioral education in sleep restriction and stimulus control. For sleep restriction, participants will be instructed to limit the time spent in bed, which serves to increase sleep efficiency. For stimulus control, participants will be instructed to go to bed only when feeling sleepy and reserve the bed for sleep and intimacy.~BBTI will be delivered over four weeks, in weekly one-hour sessions, one session per week."
223491052|NCT06571305|BEHAVIORAL|My Sleep Our Sleep (MSOS)|"MSOS is a sleep intervention developed by the investigator aimed at improving sleep health for patient-sleep-partner caregiver dyads using behavioral education in sleep behaviors, sleep cognition and sleep in relationship.~MSOS will be delivered over four weeks, in weekly one-hour sessions, one session per week."
223491053|NCT06502483|BEHAVIORAL|Promoting Resilience in Stress Management Program|Promoting Resilience in Stress Management (PRISM; Rosenberg et al., 2018; Rosenberg et al., 2021) is is an evidence-based skills-based resilience intervention. In the current study, PRISM sessions with be facilitated by a trained mental health provider to equip participants with skills for coping with anxiety, low mood, and adjustment to cancer diagnosis and to target four resilience resources (i.e., stress management, goal setting, cognitive reframing, and meaning-making). Sessions will be conducted by phone or Zoom, a HIPAA-compliant telemedicine platform. The optional mPRISM phone application includes 6 modules to practice PRISM skills and is available for iOS/Android.
223491054|NCT00005047|DRUG|cisplatin|
223491055|NCT00005047|DRUG|doxorubicin hydrochloride|
223491056|NCT00005047|DRUG|methotrexate|
224182604|NCT00315640|DRUG|Anecortave Acetate Sterile Suspension, 6 mg/mL|One 0.5 mL anterior juxtascleral depot (AJD) injection in the study eye
224182605|NCT00315640|DRUG|Anecortave Acetate Suspension Depot, 30 mg/mL|One 0.5 mL anterior juxtascleral depot (AJD) injection in the study eye
224308044|NCT05919121|OTHER|hydrocortisone iontophoresis|A direct current electrical stimulation unit will be used to apply iontophoresis. The unit has two electrodes; one electrode is for the negative current, and one is for the positive current. The Active (Negative) electrode will be placed on the anterolateral aspect of the shoulder joint. The passive electrode: will be placed on the upper arm region. Intensity of the current: Between the range of 3-5 mA at the point of sensation of patient was set. Treatment duration: Calculated accordingly with intensity of current. Method of application: hydrocortisone gel 10% will be administered by applying on the active rubber electrode for each session three times weekly over 6 weeks in addition to therapeutic exercises.
224308045|NCT05241028|DRUG|Ensartinib|Ensartinib 225mg oral daily for 3 years or until recurrence of the disease or intolerable toxicity
224308046|NCT01794026|PROCEDURE|diffusion weighted magnetic resonance imaging|for diagnostic purposes, diffusion weighted magnetic resonance imaging in all patients
224308047|NCT01600430|DIETARY_SUPPLEMENT|Cholecalciferol|200 IU/day given orally once per day as one of 4 doses of 0.5ml each given every 6 hours. Other 3 doses will be placebo (sterile water). Duration of 28 postnatal days
224308048|NCT01600430|DIETARY_SUPPLEMENT|Cholecalciferol|800 IU/day given orally per day as 4 doses of 200 IU/0.5ml each every 6 hours. Duration of 28 postnatal days
224308049|NCT01600430|DIETARY_SUPPLEMENT|Placebo|Sterile water 0.5ml given orally every 6 hours. Duration of 28 postnatal days
224308050|NCT02640053|PROCEDURE|Cryotherapy|Applied topically
224308051|NCT02640053|DRUG|Paclitaxel|Given IV
224308052|NCT02640053|OTHER|Quality-of-Life Assessment|Ancillary studies
224308053|NCT02640053|OTHER|Questionnaire Administration|Ancillary studies
224308054|NCT03506906|DIAGNOSTIC_TEST|Sleep studies under noninvasive ventilation therapy|Polysomnography Transcutaneous capnography
223491057|NCT00005047|DRUG|vinblastine|
223491058|NCT00232882|DRUG|Candesartan Thiazide|Candesartan 16 mg for 4 weeks then added hydrochlorothiazide for 4 weeks
223491059|NCT00232882|DRUG|Atenolol Thiazide|Atenolol 100 mg for 4 weeks followed by atenolol 100 mg + hydrochlorothiazide 12.5 mg for 4 weeks
223491060|NCT00232882|DRUG|Thiazide Candesartan|Thiazide 25 mg for 4 weeks then added with Candesartan 16 mg
223491061|NCT05722301|DRUG|Testosterone Therapy|The testosterone pellet implantation will be performed 2 weeks before surgery. The dose is determined by baseline levels of sex hormone binding globulin (SHBG) in the following manner: If SHBG \> 60nmol/L implant 5 Testosterone Compounded 200mg (total 1000mgs testosterone). If SHBG 41-59 nmol/L implant 4 Testosterone Compounded 200mg (total 800mgs testosterone). If SHBG \<40 nmol/L implant 3 Testosterone Compounded 200mg (total 600mgs testosterone).
223491062|NCT05722301|OTHER|No Testosterone Therapy|For the sham procedure no pellets will be implanted.
223491063|NCT00104689|DRUG|capecitabine|
224182606|NCT00315640|DRUG|Anecortave Acetate Sterile Suspension, 60 mg/mL|One 0.5 mL anterior juxtascleral depot (AJD) injection in the study eye
224182607|NCT00315640|OTHER|Anecortave Acetate Vehicle|One 0.5 mL anterior juxtascleral depot (AJD) injection in the study eye
224308055|NCT03506906|DIAGNOSTIC_TEST|Routine tests|Spirometry, six minute walk test, blood gas analysis, questionnaires (Epworth sleepiness score, health related quality of life severe respiratory insufficiency questionnaire)
224308056|NCT04502823|PROCEDURE|Management based on sFlt-1/PlGF values|"In women allocated to the intervention group, the sFlt-1/PlGF result will be revealed to the investigators that will act according to the results of sFlt/PlGF:~* Fetuses with sFlt-1/PlGF ≥38, elective delivery will be recommended immediately (within 24h) at ≥37 weeks.~* Fetuses with sFlt-1/PlGF \<38 weekly follow up will be recommended and delivery at ≥40 weeks."
223491064|NCT00104689|DRUG|oxaliplatin|
223491065|NCT06437171|BIOLOGICAL|Omalizumab|Omalizumab dose and frequency based on baseline subject weight and total IgE
223491066|NCT01808742|DEVICE|Treatment with CryoTouch III Device|Bilateral forehead treatment with CryoTouch III device on the temporal branch of the facial nerve. Subject will be treated once and may be retreated up to 7 days after initial treatment.
223491067|NCT02249325|DIETARY_SUPPLEMENT|Probiotic dietary supplement|Florajen3 is a commercially available probiotic supplement containing three bacteria of human origin (\>7.5 x10\^9 L. acidophilus, \>6.0 x10\^9 .B. lactis, and \>1.5 x10\^9 B .longum). Once capsule was administered daily by mouth from 28 through 36 weeks gestation.
224182608|NCT05343403|OTHER|Family Integrated Care|The intervention will consist of FICare, including parental participation in medical rounds (FCR). Parents and healthcare professionals will be educated and supported by the four pillars of FICare: parent education, education of healthcare professionals, psychosocial support and a supportive environment of the neonatal ward.
224182609|NCT00519415|OTHER|Tongue plate|A functional appliance use for maxillary protraction.It has two adams clasp and two C clasp to retained the appliance and long palatal plate in the canine area which cages the tongue and transfer the force of the tongue during physiological activity to the upper arch. It has posterior bite plate and middle screw for maxillary expansion.It should be used all the time except meal time and brushing the teeth,the acrylic appliance makes specifically for the patient.
224308057|NCT05912361|BEHAVIORAL|receiving a one hour theoretical and hands on training session before using an AI-based platform|The students at the experimental group will receive a one-hour hands-on training session before logging in to the online platform. The session will be presented by a dentist with AI experience and this session will present basic aspects of AI in radiology, deep learning (DL) applications for cariology and endodontics, as well as basics of excavation therapy and pulp exposure. the theoretical part will be followed by a hands on session on which each participant will check 11 cases of teeth with deep caries and will find the closest line between caries and pulp. their performance will be supervised by the training session presenter and the correct line will be shown them in case of making wrong line.
224308058|NCT03283761|DRUG|Nab-paclitaxel 150 mg/m^2|Stage I (N=12), on day 1 and day 15 Stage II (N= 25), on day 1 and day 15
224308059|NCT03283761|DRUG|Oxaliplatin 85 mg/m^2|Stage I (N= 12), on day 1 and day 15 Stage II (N= 25), on day 1 and day 15
223491068|NCT06189950|DEVICE|Intracranial stent for wide-necked aneurysms|Intracranial stent for wide-necked aneurysms
223491069|NCT03863912|OTHER|Disney movie|Disney movie on portable DVD Player.
223491070|NCT03863912|OTHER|EORTC QLQ-C30 and EORTC QLQ-FA12 surveys|EORTC QLQ-C30 and EORTC QLQ-FA12 surveys
223491071|NCT05049694|DEVICE|zirconia crowns|esthetic crowns for capping permanent molars with caries
223491072|NCT05049694|DEVICE|stainless steel crowns|stainless steel crowns for capping permanent molars with caries
223491073|NCT06095388|DRUG|JR-441|IV infusion
223491074|NCT06095388|DRUG|JR-441|IV infusion
223491075|NCT06095388|DRUG|JR-441|IV infusion
224308060|NCT03283761|DRUG|5-FU 1200 mg/m^2 x 2 D|Stage I (N= 12), on day 1 and day 15-16 Stage II (N= 25),on day 1 and day 15-16
223491076|NCT04614155|OTHER|Educational Intervention|Take part in health education session
223491077|NCT04614155|PROCEDURE|HPV Self-Collection|Receive HPV self-collection kit
223491078|NCT04614155|OTHER|Questionnaire Administration|Complete questionnaires
223491079|NCT05135975|DRUG|Cabozantinib|Enrolled patients will be treated with cabozantinib maleate, tablet formulation, using the recommended Phase 2 dose of 40 mg/m2/day to a maximum of 420 mg/week. Treatment will be administered in 28- day cycles.
223491080|NCT06345079|DRUG|Cessation of somatostatin analogues|Patients randomised to cease SSA will receive their last SSA injection ≥28 days prior to their first cycle of PRRT and will remain off SSA for the duration of the study. If there is concern from the treating team that a patient may experience a carcinoid flare after PRRT, then short acting octreotide is allowed to be used to control any symptoms.
223491081|NCT06345079|DRUG|Continuation of somatostatin analogues|Patients randomised to continue SSA will receive a SSA injection ≥28 days prior to their first cycle of PRRT, during PRRT and will continue receiving SSA every 4 weeks after PRRT.
223491082|NCT05388643|DIAGNOSTIC_TEST|Enhanced First Trimester GDM Screening|Women who are randomly assigned to this condition will be required to have early glucose screening with a prediction model composed of additional clinical risk factors and serum biomarkers (triglycerides, PAPP-A, and lipocalin-2) with their initial prenatal laboratory assessment.
224308061|NCT03283761|DRUG|Leucovorin 400 mg/m^2|Stage I (N= 12),on day 1 and day 15 Stage II (N= 25), on day 1 and day 15
223491083|NCT05388643|DIAGNOSTIC_TEST|Routine Gestational Diabetes Screening|Women who will be randomized to the comparison condition of usual standard of care will undergo routine standard of care. The standard of care will consist of routine screening for diabetes in pregnancy between 24 to 28 weeks of gestation via the two-step screening method with possible early screening with either plasma fasting glucose, oral glucose tolerance test, or hemoglobin A1c at the providers discretion to represent true clinical practice.
223491084|NCT04262856|DRUG|Domvanalimab|Domvanalimab is a humanized monoclonal antibody targeting human TIGIT
223491085|NCT04262856|DRUG|Etrumadenant|Etrumadenant is an A2aR and A2bR antagonist
223491086|NCT04262856|DRUG|Zimberelimab|Zimberelimab is a fully human anti-PD-1 monoclonal antibody
223491087|NCT03954535|BEHAVIORAL|Free2b|The intervention will consist of a website and 9 sessions. The intervention sessions will facilitate youths' acquisition of personal and social cognitive-behavioral skills. The intervention will focus on goal setting, decision making, enhancing self-worth, coping with stress, combating distorted thinking, communication skills, using alcohol and other drugs and a review session. Each session will require approximately 20 minutes and must be finished in a single sitting. Sessions will be delivered on a weekly basis. The website will include entertainment features and resources.
223491088|NCT03954535|BEHAVIORAL|Attention-Placebo|Access to the website with entertainment features and resources - but no session content.
223491089|NCT04016389|DRUG|Cisplatin|Cisplatin is an antineoplastic agent that is commonly used for the treatment of cervical cancer.
223491090|NCT04016389|DRUG|Carboplatin|Carboplatin is an antineoplastic agent that is commonly used for the treatment of cervical cancer.
223587969|NCT02504580|DRUG|HTX-011B|HTX-011B (bupivacaine/meloxicam) by injection, instillation or combination.
224182610|NCT00519415|OTHER|Facemask|An extraoral appliance use for treatment of maxillary deficiency in growing patients.It takes anchorage from chin and forehead, it has removable intraoral appliance with hooks for elastics that exerted a force of 300 gr.It should be used 14 hours a day.
224182611|NCT03060109|OTHER|Blood draw within 12 hours of injury|
224182612|NCT05365256|BEHAVIORAL|Standard distraction during chemotherapy treatment period|habitual distraction of patients during chemotherapy sessions authorized as part of routine care
224182613|NCT05365256|BEHAVIORAL|Virtual distraction during chemotherapy treatment period|A virtual reality headset will be worn for 15 minutes per hour of treatment
224182614|NCT01701531|DRUG|RBCPF|
223491091|NCT04016389|DRUG|Paclitaxel|Paclitaxel is an antineoplastic agent that is commonly used in combination with cisplatin or carboplatin for the treatment of cervical cancer.
224182615|NCT00551681|DEVICE|biventricular pacemaker with epicardial left ventricular lead|epicardial left ventricular lead placement
224182616|NCT00551681|DEVICE|transvenous left ventricular lead placement|implantation of biventricular pacemaker with transvenous left ventricular lead placement
224182617|NCT05115812|PROCEDURE|Pre-Operative Information|Demographics (e.g., age, gender), patient characteristics (e.g., BMI, American Society of Anesthesiologists class), and pre-operative medical history (e.g., tobacco use; comorbidities: hypertension, cardiopulmonary disease, diabetes; indication for RAT; lesions; previous renal revascularization; serum creatinine level).
223491092|NCT04016389|PROCEDURE|Trachelectomy|Surgery to remove the cervix but keep the uterus intact.
223491093|NCT06285747|OTHER|Non-Interventional Study|Non-Interventional Study
223491094|NCT00373672|DRUG|armodafinil (Nuvigil)|armodafinil (Nuvigil)150 mg qd
223491095|NCT00373672|DRUG|placebo|identical in appearance to active comparator
223491096|NCT06685133|DEVICE|Robotic assisted bronchoscopy|Subjects will undergo a robotic navigated bronchoscopy to biopsy peripheral pulmonary nodules.
223491097|NCT06683378|PROCEDURE|Reparative Autologous peripheral nerve tissue|"At the time participants are receiving the standard of care deep brain stimulation (DBS) surgery, a standard incision on the lateral aspect near the ankle is made, the sural nerve is identified, an about 3 cm biopsy of the sural nerve is obtained and the incision is closed.~From the biopsied section, the epineurium is removed, fascicles are cut, and (\~5 pieces per side; \~ 5mm length x 1.5 mm diameter: approximately 10 cubic millimeters) implanted bilaterally into the nucleus basalis of Meynert (NBM) or substantia nigra (SN)."
223491098|NCT06348108|BIOLOGICAL|Talquetamab|Given subcutaneously (SQ)
223491099|NCT06348108|DRUG|Iberdomide|Given orally (PO)
223491100|NCT06348108|DRUG|Dexamethasone|Given PO
223491101|NCT06348108|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
223491102|NCT05612100|OTHER|Electronic Health Record Review|Ancillary studies
223491103|NCT05612100|OTHER|Questionnaire Administration|Complete alopecia questionnaires
223587970|NCT02504580|DRUG|HTX-009|HTX-009 by injection and instillation (combination).
223587971|NCT05310812|DIAGNOSTIC_TEST|Biochemical evaluation.|Blood will be taken for biochemical evaluation-ELISA.
223587972|NCT05014997|OTHER|no intervention|this study was designed as retrospective observational study
223491104|NCT05612100|OTHER|Survey Administration|Complete alopecia surveys
223491105|NCT06666075|OTHER|Digital and Interactive Reminiscence|The intervention for the experimental group aims to enhance the psychological well-being of institutionalized seniors with Alzheimer's through a digital and interactive reminiscence therapy program. It begins with selecting participants based on specific inclusion and exclusion criteria, followed by developing personalized digital profiles that include photographs, music, videos, and life anecdotes to evoke emotional memories. Care staff receive training in using the digital software and reminiscence techniques. The core intervention consists of digital reminiscence sessions held twice a week for eight weeks, lasting about 60 minutes each, featuring multimedia content to encourage discussion and memory sharing. Interactive activities foster active participation, with facilitators promoting emotional expression and connection among participants, creating a supportive environment that stimulates cognitive function and reduces isolation.
224073394|NCT07143201|DRUG|Standard Dose - Ibuprofen oral suspension|Standard dosing administers ibuprofen without adjustments, starting with an initial loading dose followed by two maintenance doses at 24-hour intervals: 10/5/5 mg/kg for infants aged ≤72 hours, and 20/10/10 mg/kg for those \>72 hours old.
223491106|NCT06322342|DRUG|RVP-001|MRI contrast agent
223491107|NCT06619249|DIETARY_SUPPLEMENT|CoQ10 supplementation|Long-distance runners will be supplemented with CoQ10 for 4 weeks in cross-over manner with 4 weeks of wash out period.
223491108|NCT06619249|DIETARY_SUPPLEMENT|Placebo supplementation|Long-distance runners will be supplemented with placebo for 4 weeks in cross-over manner with 4 weeks of wash out period.
224073395|NCT07143201|DRUG|Precision Dose - Ibuprofen oral suspension|Precision Dosing (Model-Informed Precision Dosing - MIPD): Begins with the same initial loading dose as the Standard Dosing arm, with subsequent doses adjusted based on a Bayesian forecasting model that integrates real-time PK and echocardiographic data.
224073396|NCT05901818|DRUG|Autologous induced neural stem cell-derived DA precursor cells|The autologous induced neural stem cell-derived DA precursor cells will be stereotactically implanted into the striatum of PD patients.
224073397|NCT06285097|DRUG|PF-07820435|immune agonist
224073398|NCT06285097|BIOLOGICAL|Sasanlimab|A monoclonal antibody that blocks the interaction between PD-1 and PD-L1/L2
224073399|NCT01841723|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
224073400|NCT01841723|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration and biopsy
224073401|NCT01841723|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow aspiration and biopsy
224073402|NCT01841723|PROCEDURE|Computed Tomography|Undergo CT
224073403|NCT01841723|DRUG|Ibrutinib|Given PO
224073404|NCT01841723|PROCEDURE|Ultrasound Imaging|Undergo ultrasound
224073405|NCT05752279|DRUG|Plasma-Lyte 148|Plasma-Lyte® 148 intravenous fluid for resuscitation in patients with keto-acidosis
224073406|NCT05752279|DRUG|0.9% sodium chloride|0.9% sodium chloride intravenous fluid for resuscitation in patients with keto-acidosis
224073407|NCT04532710|DRUG|Eye Drops, Solution in Single-Dose Container|Application of eye drops
224182618|NCT05115812|PROCEDURE|Intra-Operative Data|Operative time, total OR time, concomitant procedures, transfusions, conversions, intraoperative adverse events, autotransplantation technique
224182619|NCT05115812|OTHER|Post-Operative Data (up to discharge)|Postoperative adverse events, discharge status, hospital length of stay, information on enhanced recovery program
223587973|NCT02353195|OTHER|Radiofrequency|The equipment used, 35-mm diameter CAP and 30-mm diameter RES movable electrode was used on the affected site, and a planar electrode was used as a return electrode on the abdomen. The electricity was administered in the following manner: cream was applied to the site with the severest pain and its adjacent area, and the electrical output was increased by moving the movable electrode within the patient´s tolerance level, while monitoring the skin temperature tolerable to the patient.
223587974|NCT00448747|DRUG|AEZS-130 (formerly ARD-07)|A single oral administration of AEZS-130 as Growth Hormone Stimulation Test
223587975|NCT00448747|DRUG|L-ARG+GHRH|A single administration of L-ARG+GHRH (iv bolus) followed by a 30min infusion of L-ARG as Growth Hormone Stimulation Test
223587976|NCT03670368|BEHAVIORAL|Mentoring|The intervention will include one-on-one mentoring sessions held after school, focusing on coping, social relationships, and healthy lifestyles.
224182620|NCT05115812|OTHER|Short-Term Follow-Up Data|Adverse events, re- admissions, re-operations related to the index procedure
224182621|NCT01625364|BEHAVIORAL|SHARP program|Staying Healthy-Asthma Responsible and Prepared is an academic and counseling asthma health education program for older school-age students with asthma and members of their social networks including their family caregivers.
223587977|NCT03670368|BEHAVIORAL|Comparison group - written materials|Written materials from the mentoring sessions will be provided to those in the comparison group
223587978|NCT01575314|DEVICE|stapling device|Stapling device include GIA 80, TA 45, endo GIA 60, endo GIA 45
223587979|NCT01052506|DRUG|BIIB033|Single, escalating doses of BIIB033 (8 cohorts IV, 1 cohort SC)
223587980|NCT01052506|DRUG|Placebo|Single dose of placebo comparator (8 cohorts IV, 1 cohort SC)
223587981|NCT04423081|OTHER|EXIT scale|completion of EXIT scale translated in french
223587982|NCT04936009|BEHAVIORAL|Transcranial Magnetic Stimulation (TMS)|Subjects will receive both active and sham TMS in a randomized crossover assignment involving two study sessions
223587983|NCT00056446|DRUG|Vatalanib|
223587984|NCT00421135|DRUG|ZIO-201|ZIO-201 as a single dose given once every 21 days. This is a dose escalation arm.
223587985|NCT01365858|OTHER|Rehabilitation|"The experimental group patients receive rehabilitation by training Virtual Action Planning - Supermarket on a computer 45 minutes 5 times a week during a 2-week period. The control group will receive similar duration cognitive rehabilitation (no extra computer training) during this period (problem solving and occupational therapy)."
223587986|NCT01387464|DRUG|ISV-303|0.075% bromfenac in DuraSite dosed QD
223587987|NCT01387464|DRUG|Bromday™|0.09% bromfenac dosed QD
223587988|NCT05513794|DEVICE|MRI Imaging|Neuromelanin sequence imaging
224182622|NCT01625364|BEHAVIORAL|Open Airways for Schools|OAS is a non-academic asthma health education program for elementary students with asthma and their parents.
224182623|NCT05805332|OTHER|pulmonary rehabilitation|The participants would undergo pulmonary rehabilitation.
224308062|NCT04159935|DEVICE|iLux® system|Commercially available medical device intended for use by qualified eye care professionals to apply localized heat and pressure therapy to a patient's eyelids.
224308063|NCT04781192|DRUG|Durvalumab|Intra-Venous(IV) once every 28 days (approximately every 4 weeks \[q4w\])
224308064|NCT04781192|DRUG|Regorafenib|Oral once per day, Days 1 - 21 every 28 days
224308065|NCT00148642|DEVICE|silver salts coated endotracheal tube|intubation with silver coated tube
224308066|NCT00148642|DEVICE|uncoated endotracheal tube|intubation
223587989|NCT04091048|DEVICE|Evolut™ PRO and Evolut™ PRO+ System (Evolut™ FX System for the addendum)|Aortic valve replacement
223587990|NCT04494295|DEVICE|Aurora Surgiscope System|MIS evacuation of hematoma using the Aurora Surgiscope System
223587991|NCT05814640|DRUG|Fluoxetine|Commonly used oral antipsychotics intervention therapy.
224182624|NCT00280059|DRUG|Pregabalin|dose 150-600 mg/day given BID
224308067|NCT05375526|DEVICE|Magtrace|"In the proper ovarian ligament (or its remnants), close to the ovary and just below the peritoneum Magtrace® will be injected via a 12 Gauge (2mm) needle. This injection will be followed by an injection of 20 MBq 99mTc via the same 12 Gauge (2mm) needle.~If a hysterectomy has been conducted, this step can be omitted. In the infundibulopelvic ligament (suspensory ligament of the ovary), close to the ovary and just below the peritoneum Magtrace® will be injected via a 12 Gauge (2mm) needle. This injection will be followed by an injection of 20 MBq 99mTc via the same 12 Gauge (2mm) needle."
224308068|NCT05783544|DIAGNOSTIC_TEST|Interleukin-1B|Level of serum interleukin-1B will be detected
224182625|NCT00280059|DRUG|Lamotrigine|dose 100-500 mg/day given BID
224182626|NCT04369742|DRUG|Hydroxychloroquine (HCQ)|HCQ 400mg (2 tab) by mouth BID (day 1), 200mg (1 tab) by mouth BID (days 2-5)
224182627|NCT04369742|DRUG|Placebo: Calcium citrate|Calcium citrate 2 tablets (400mg) BID on day 1, 1 tablet (200mg) on days 2-5
224182628|NCT02533011|OTHER|HBP lab test|Plasma level of Heparin Binding Protein will be evaluated on extra blood specimens already collected as part of standard of care.
224182629|NCT04280185|PROCEDURE|Hyperthermic Intraperitoneal Chemotherapy|HIPEC is a way of intraperitoneal chemotherapy
224308069|NCT05783544|DIAGNOSTIC_TEST|Interleukin-4|Level of serum interleukin-4 will be detected
224308070|NCT05783544|DIAGNOSTIC_TEST|Interleukin-6|Level of serum interleukin-4 will be detected
224308071|NCT05783544|DIAGNOSTIC_TEST|tumor necrosis factor - a|Level of serum tumor necrosis factor - a will be detected
224308072|NCT05783544|DIAGNOSTIC_TEST|interferon- gamma|Level of serum interferon- gamma will be detected
224308073|NCT02036775|DRUG|Lasolvan tablet|One Lasolvan tablet 30 mg twice daily for 5 days.
224308074|NCT02036775|DRUG|Lasolvan tablet|One Lasolvan tablet 30 mg twice daily for 5 days.
224308075|NCT02036775|DRUG|Lasolvan tablet|One Lasolvan tablet 30 mg twice daily for 5 days.
224308076|NCT02036775|DRUG|Lasolvan tablet|One Lasolvan tablet 30 mg twice daily for 5 days.
224308077|NCT02036775|DRUG|Lasolvan effervescent tablet|One-half Lasolvan effervescent tablet 60mg twice daily for 5 days.
224308078|NCT02036775|DRUG|Lasolvan effervescent tablet|One-half Lasolvan effervescent tablet 60mg twice daily for 5 days.
224182630|NCT03964311|OTHER|Emergency Room Evaluation Tool (ER2)|Emergency Room Evaluation Tool represents a screening method that will be used at the Emergency by nurses. This tool evaluates the health conditions of all the patients who are 75 years and over.
224182631|NCT02984228|BIOLOGICAL|PRP|
224182632|NCT02984228|DRUG|Hyaluronic Acid|
224182633|NCT02984228|DEVICE|Ultrasound|
224182634|NCT06425185|OTHER|Single-leg stance under different instability conditions|"Participants will perform three attempts of 20 seconds of single-leg stance on the floor and on the 7 selected configurations of the BB. The order of measurement will be randomized. The description of the chosen configurations can be found in the Detailed Description section. In all cases, the participant's objective is to ensure that the edges of the BB are not in contact with the floor.~The position of the participant on the BB will be a single-leg stance on the randomly chosen foot, with the contralateral knee slightly flexed and hands placed on the hips. Participants will look at a fixed point placed 3 meters in front of them.~A rest period of 30 seconds will be allowed between trials. The physiotherapist responsible for supervising the measurements will be the one to adjust the BB configurations when needed."
224182635|NCT01688362|BIOLOGICAL|Platelet Rich Plasma (PRP)|Subjects in this group will receive 2 injections with PRP. Subjects will have will have 15cc of blood drawn with the Arthrex ACP syringe. The blood will be placed into the Arthrex PRP centrifuge and spun at 1500 rpms for 5 minutes. The platelets will be drawn off to create the PRP for injection. A posterior glenohumeral injection under ultrasound guidance will be performed to inject the PRP solution using a 22g needle. A dry sterile dressing will be placed on the injection site. This injection will Take place at time zero and then two weeks later it will be repeated.
223491109|NCT02108054|DEVICE|7T MRI|Modifying, refining, and verifying the feasibility and applicability of tasks for functional magnetic resonance imaging (fMRI) to measure intended concomitant brain activation
223491110|NCT05255991|DRUG|Placebo|Placebo administered QID
223491111|NCT05255991|DRUG|Inhaled Treprostinil|Inhaled treprostinil (6 mcg/breath) administered QID
223491112|NCT05255991|DEVICE|Treprostinil Ultrasonic Nebulizer|Treprostinil ultrasonic nebulizer which emits a dose of approximately 6 mcg per breath.
223491113|NCT03575832|OTHER|Counseling|Complete nutrition counseling sessions
223491114|NCT03575832|OTHER|Informational Intervention|Receive an exercise plan and printed materials
223491115|NCT03575832|OTHER|Quality-of-Life Assessment|Ancillary studies
223491116|NCT03575832|OTHER|Questionnaire Administration|Ancillary studies
223587992|NCT05814640|DRUG|Sertraline|Commonly used oral antipsychotics intervention therapy.
224308079|NCT02036775|DRUG|Lasolvan effervescent tablet|One-half Lasolvan effervescent tablet 60mg twice daily for 5 days.
223491117|NCT03575832|BEHAVIORAL|Telephone-Based Intervention|Receive telephone coaching calls
223491118|NCT03136146|DRUG|Bortezomib|Given SC
223491119|NCT03136146|DRUG|Clofarabine|Given IV
223491120|NCT03136146|DRUG|Cyclophosphamide|Given IV
223491121|NCT03136146|DRUG|Dexamethasone|Given IV or PO
223491122|NCT03136146|DRUG|Etoposide|Given IV
223491123|NCT03136146|BIOLOGICAL|Ofatumumab|Given IV
223491124|NCT03136146|BIOLOGICAL|Pegfilgrastim|Given SC
223491125|NCT03136146|BIOLOGICAL|Rituximab|Given IV
223491126|NCT03136146|DRUG|Vincristine Sulfate Liposome|Given IV
223491127|NCT05168540|OTHER|no intervention|Children will be included on the occasion of an admission to pediatric unit, the emergency room, the intensive care unit or a consultation in a specialized unit for children at risk of abuse. Their primary care pathway will be analyzed.
223587993|NCT05814640|DRUG|Vortioxetine|Commonly used oral antipsychotics intervention therapy.
224308080|NCT02036775|DRUG|Lasolvan prolonged-release hard capsule|One Lasolvan prolonged-release hard capsule 75 mg once daily for 5 days
224308081|NCT02036775|DRUG|Lasolvan prolonged-release hard capsule|One Lasolvan prolonged-release hard capsule 75 mg once daily for 5 days
223491128|NCT03927885|OTHER|Placebo Administration|Given open labeled placebo PO
223491129|NCT03927885|OTHER|Quality-of-Life Assessment|Ancillary studies
223491130|NCT03927885|OTHER|Questionnaire Administration|Ancillary studies
223491131|NCT03927885|OTHER|Waiting List|Assigned to a waiting list
223491132|NCT04929002|OTHER|No intervention|No intervention
223491133|NCT04871074|DRUG|UCB-J|PET imaging with UCB-J
223491134|NCT04871074|DEVICE|MRI Scan|MRI exams will be performed using a 3T MRI scanner, scan duration is typically 60 minutes
223491135|NCT04871074|DEVICE|PET Scan|PET imaging may be collected using either a PET scanner or a PET/Computed Tomography (CT) scanner, a PET scan will be initiated with the injection of radiotracer
223491136|NCT06011798|DRUG|Aflibercept|Anti-VEGF control
223491137|NCT06011798|DRUG|foselutoclax|Experimental drug
223491138|NCT06605404|DIAGNOSTIC_TEST|blood and tissue samples|routine standard of care
223491139|NCT06605404|OTHER|blood and tissue samples|Routine standard of care
223491140|NCT06745297|DRUG|BI 3776528|BI 3776528
223491141|NCT06745297|DRUG|Placebo matching BI 3776528|Placebo matching BI 3776528
223491142|NCT06745297|DRUG|short-acting benzodiazepine|short-acting benzodiazepine
223491143|NCT06228092|DRUG|neostigmine/glycopyrrolate|Anesthesia personnel will administer the drug as a bolus over 5 seconds in an intravenous catheter upon conclusion of anaesthesia with a TOF within the range from TOF count of 2 to a TOF ratio \< 0.60
223587994|NCT05814640|DRUG|Duloxetine|Commonly used oral antipsychotics intervention therapy.
223587995|NCT05814640|DRUG|Aripiprazole|Commonly used oral antipsychotics intervention therapy.
223587996|NCT05814640|DRUG|Lithium Carbonate|Commonly used oral antipsychotics intervention therapy.
223587997|NCT05814640|DRUG|Olanzapine|Commonly used oral antipsychotics intervention therapy.
223587998|NCT05814640|BEHAVIORAL|GCBT|Commonly used intervention therapy of psychotherapy.
223587999|NCT05529654|DEVICE|Impella 5.5 with SmartAssist|For subjects enrolled in the Trial, the Impella 5.5 will be placed intra-operatively during the index cardiac surgical procedure
224308082|NCT02036775|DRUG|Lasolvan prolonged-released capsules|One Lasolvan prolonged-release hard capsule 75 mg once daily for 5 days
224308083|NCT02036775|DRUG|Lasolvan tablet|One Lasolvan tablet 30 mg twice daily for 5 days.
224308084|NCT02036775|DRUG|Lasolvan tablet|One Lasolvan tablet 30 mg twice daily for 5 days.
224182636|NCT01688362|DRUG|Corticosteroid|"Subjects in this group will receive one injection with corticosteroids and then one injection with local anesthetic two weeks later. For the first injection patients will have 15ml of blood drawn. This blood will then be discarded in a biohazard container. A 6ml solution of 4ml 0.25% Bupivacaine, 1ml 40mg Kenalog, and 1ml 4mg Dexamethasone will be prepared. A posterior glenohumeral injection under ultrasound guidance will be performed to inject the steroid solution using a 22g needle. A dry sterile dressing will be placed at the injection site.~For the second injection two weeks later patients will have 15 ml of blood drawn. This blood will then be discarded in a biohazard container. Using the same technique as in Visit 2, the investigator will inject a 6 ml solution of 2 ml sterile normal saline with 4 ml 0.25% Bupivacaine to the shoulder using ultrasound. A dry sterile dressing will be placed at the injection site."
224182637|NCT03579862|OTHER|Blood Draw|
224182638|NCT01196065|DRUG|RO5313534|single oral dose
224182639|NCT01196065|DRUG|memantine|multiple doses to steady state
224182640|NCT00693524|DRUG|tacrolimus|oral
224182641|NCT00693524|DRUG|Anti-IL2R AB|i.v.
224182642|NCT00693524|DRUG|Mycophenolate mofetil|oral
224182643|NCT00693524|DRUG|prednisone|oral
224182644|NCT03596307|DIETARY_SUPPLEMENT|Ashwagandha extract|Shoden 180 mg capsule.
224182645|NCT03596307|DIETARY_SUPPLEMENT|Placebo|Placebo 180 mg (Sucrose) capsule.
224182646|NCT01639807|DRUG|Latanoprost|Latanoprost (0.005%) eye drops, once daily in the evening
224182647|NCT01639807|PROCEDURE|SLT|Selective Laser Trabeculoplasty
224308085|NCT02036775|DRUG|Lasolvan prolonged-release hard capsule|One Lasolvan prolonged-release hard capsule 75 mg once daily for 5 days
224308086|NCT02036775|DRUG|Lasolvan effervescent tablet|One-half Lasolvan effervescent tablet 60mg twice daily for 5 days.
224308087|NCT02036775|DRUG|Lasolvan prolonged-release hard capsule|One Lasolvan prolonged-release hard capsule 75 mg once daily for 5 days
223491144|NCT06228092|DRUG|Sugammadex|Anesthesia personnel will administer the drug as a bolus over 5 seconds in an intravenous catheter upon conclusion of anaesthesia with a TOF within the range from TOF count of 2 to a TOF ratio \< 0.60
223588000|NCT03976180|DEVICE|Stadard low-flow oxygen|In the control group, standard low-flow oxygen will be delivered via nasal prongs (LFNO), up to hospital discharge or secondary ACS onset, in order to achieve normoxia (target pulse oxymetry saturation of 95%). This strategy is in accordance with current recommendations and usual care
223588001|NCT03976180|DEVICE|HFNO with low FiO2 (21%-30%)|HFNO with low FiO2 (21%-30%) targeting normoxia: to test the effect of improved pulmonary function
223588002|NCT03976180|DEVICE|HFNO with intermediate FiO2 (50%)|In this group, FiO2 will be set at 50% during the first 24 hours of intervention to target moderate hyperoxia, then reduced to 21-3025% during the following 48 hours to target normoxia
224182648|NCT03725709|PROCEDURE|spinal anesthesia|Plan to enroll 120 Type 2 diabetes and 120 non-diabetes patients with received spinal anesthesia.Blood will be collected at time point of pre-anesthesia 10 minutes and CSF samples will be collected at time point during spinal anesthesia induction. Blood will be collected, drawn into EDTA-coated tube.
224182649|NCT02174406|PROCEDURE|breast ultrasound|
224182650|NCT02174406|PROCEDURE|DBT (Full field digital mammography + tomosynthesis)|
224182651|NCT04636333|BIOLOGICAL|Two doses of middle-dose recombinant SARS-CoV-2 vaccine (CHO Cell) at the schedule of day 0, 14|Two doses of middle-dose (20µg/0.5ml) recombinant SARS-CoV-2 vaccine (CHO Cell) at the schedule of day 0, 14.
224182652|NCT04636333|BIOLOGICAL|Three doses of middle-dose recombinant SARS-CoV-2 vaccine (CHO Cell) at the schedule of day 0, 14, 28|Three doses of middle-dose (20µg/0.5ml) recombinant SARS-CoV-2 vaccine (CHO Cell) at the schedule of day 0, 14, 28.
224182653|NCT04636333|BIOLOGICAL|Two doses of high-dose recombinant SARS-CoV-2 vaccine (CHO Cell) at the schedule of day 0, 14|Two doses of high-dose (40µg/0.5ml) recombinant SARS-CoV-2 vaccine (CHOCell) at the schedule of day 0, 14.
224182654|NCT04636333|BIOLOGICAL|Three doses of high-dose recombinant SARS-CoV-2 vaccine (CHO Cell) at the schedule of day 0, 14, 28|Three doses of middle-dose (40µg/0.5ml) recombinant SARS-CoV-2 vaccine (CHO Cell) at the schedule of day 0, 14, 28.
224182655|NCT04636333|BIOLOGICAL|Two doses of placebo at the schedule of day 0, 14 #middle-dose group#|Two doses of placebo (0.5ml) at the schedule of day 0, 14.
224308088|NCT02036775|DRUG|Lasolvan prolonged-release hard capsule|One Lasolvan prolonged-release hard capsule 75 mg once daily for 5 days
224182656|NCT04636333|BIOLOGICAL|Three doses of placebo at the schedule of day 0, 14, 28 #middle-dose group#|Three doses of placebo (0.5ml) at the schedule of day 0, 14, 28.
224182657|NCT04636333|BIOLOGICAL|Two doses of placebo at the schedule of day 0, 14 #High-dose group#|Two doses of placebo (0.5ml) at the schedule of day 0, 14.
224182658|NCT04636333|BIOLOGICAL|Three doses of placebo at the schedule of day 0, 14, 28 #High-dose group#|Three doses of placebo (0.5ml) at the schedule of day 0, 14, 28.
224182659|NCT01861587|DEVICE|tDCS|20 minutes of either real or sham stimulation
224182660|NCT01442961|PROCEDURE|laparoscopy, laparoscopic hysterectomy|laparoscopic hysterectomy
224182661|NCT01442961|PROCEDURE|vaginal : vaginal hysterectomy|Vaginal hysterectomy
224182662|NCT02119728|DRUG|HPPH|Undergo photodynamic therapy with HPPH
224182663|NCT02119728|DEVICE|Light Infusion Therapy™|Undergo photodynamic therapy with HPPH
224182664|NCT02119728|PROCEDURE|therapeutic conventional surgery|Undergo standard of care surgery
224308089|NCT02036775|DRUG|Lasolvan effervescent tablet|One-half Lasolvan effervescent tablet 60mg twice daily for 5 days.
224308090|NCT02036775|DRUG|Lasolvan effervescent tablet|One-half Lasolvan effervescent tablet 60mg twice daily for 5 days.
224308091|NCT05590832|BEHAVIORAL|Activity of Whatsapp messages|Informative messages will be sent to the initiative group on Mondays, Wednesdays and Fridays for the first 10 weeks / three times a week (up to the 28th week), and reminder messages will be sent once a week on Wednesdays between the 29th-36th weeks.
224308092|NCT00769990|DIETARY_SUPPLEMENT|genistein|Genistein will be taken orally once daily as 500 mg capsules throughout the study (60 days).
224308093|NCT00769990|RADIATION|radiation therapy|A course of palliative external beam radiation therapy -performed within 8 weeks prior to start of the study.
224308094|NCT02131961|DRUG|Collagenase ointment|250 collagenase units/g
224308095|NCT02131961|DEVICE|Modified Contact Cast System|1 Unit
224182665|NCT05389761|DIETARY_SUPPLEMENT|fibroDAO®|One DAO enzyme capsule is taken with water 20 minutes before each meal, 3 times a day. DAO enzyme capsules contains 0.3 mg DAO enzyme divided into 2 white/beige tablets (each gastro-resistant tablet contains 0.15 mg DAO enzyme) and 80 mg magnesium divided into 2 lilac tablets (each immediate-release tablet contains 40 mg of Mg).
224182666|NCT05389761|DIETARY_SUPPLEMENT|Placebo|One placebo capsule is taken with water 20 minutes before each meal, 3 times a day. Placebo capsules consist of microcrystalline cellulose and gelatin capsules with the same shape, size and colour as the DAO enzyme.
224182667|NCT05429528|BEHAVIORAL|Implicit Tax|This will be levied only on certain beverage categories: a 50% tax on the sales prices of carbonated drinks and sugar-sweetened beverages (SSBs) and 100% tax on the sales prices of energy drinks (milk, milk-based products, and natural fruit juice are excluded).
224182668|NCT05429528|BEHAVIORAL|Explicit Tiered Tax|This is an explicit tiered tax based on (underlying) Nutri-Score (NS) grades which will be levied on all food and beverages. In this arm, the investigators implement a 20% sales tax on the retail price for NS D beverages and 10% for NS D foods along with a 50% sales tax on NS E beverages and 20% on NS E foods. The NS labels will not be displayed.
224182669|NCT04065711|DEVICE|Soliton's Rapid Acoustic Pulse (RAP)|Treatment for the temporary improvement in the appearance of cellulite.
224182670|NCT03463720|OTHER|Infected|Extremity wound, infected
224182671|NCT03463720|OTHER|Not infected|Extremity wounds, non-infected
224182672|NCT00723060|DRUG|escitalopram|escitalopram high dose group (40mg) escitalopram conventional dose group (20mg)
224182673|NCT02052180|DRUG|Exparel|EXPAREL arm: one vial (266 mg/20 mL) of EXPAREL (Bupivicaine Extended-Release Liposome, 13.3mg/ml), undiluted, will be administered for each of the specified procedures.
224182674|NCT02052180|DRUG|Marcaine (Control)|15 cc of Marcaine 0.5% (Bupivacaine 0.5%, 5mg/ml) will be administered into the wrist per the Surgeon's Standard practice.
224308096|NCT06209567|DIAGNOSTIC_TEST|68Ga-PSMA-11 PET Scans|Participants will be injected intravenously with 68Ga-PSMA-11 via intravenous catheter. PET scans will first be interpreted without information on the results of other imaging modalities. Following the blinded read of the 68Ga-PSMA-11 PET scans, all recorded findings will be correlated with the results of CE CT and MR studies and 18F-FDG PET/CT or PET/MR performed as part of standard clinical care.
224308097|NCT06990750|PROCEDURE|15 mmHg|Insufflation pressure was set to 15 mm Hg at the time of single port robotic sacrocolpopexy.
224308098|NCT06990750|PROCEDURE|12 mmHg|Insufflation pressure was set to 12 mm Hg at the time of single port robotic sacrocolpopexy.
223491145|NCT05963516|OTHER|LIVEBORN: A Mobile Health Application (app) for Newborn Resuscitation|LIVEBORN is a mobile health application designed to help providers learn from their clinical practice during newborn resuscitation through real-time guidance and debriefing. Using LIVEBORN, an observer can document events during a resuscitation such as the actions of the provider and when the baby cries. A battery-operated heart rate meter, NeoBeat, measures and sends the newborn's heart rate to the LIVEBORN app via Bluetooth. LIVEBORN integrates data from the observer and NeoBeat to provide audio-visual real-time guidance to the provider during a resuscitation. Following the resuscitation, providers can also debrief using LIVEBORN. The app operates on the Android system and is functional off-line, except for the need for an internet connection to upload data to the cloud for research.
223491146|NCT05963516|DEVICE|NeoBeat: Heart Rate Meter for Newborn Resuscitation|NeoBeat is a low-cost device for the measurement of newborn heart rate (HR) that was developed by Laerdal Global Health for use in low-resource settings. It is applied by placing the device around the torso of the newborn. It detects HR accurately, quickly (\<5 sec), is reusable and can be easily disinfected. NeoBeat's dry electrodes detect HR which is digitally displayed and recorded. It uses an impedance system to sense skin contact and motion detection to validate signal quality. It does not require the use of buttons, adhesive, gel or cables and has no disposable parts. A single birth attendant can apply NeoBeat in 2-3 seconds.
223491147|NCT04388475|DRUG|OKN-007|Drug: OKN-007 (400 mg OKN-007/mL in a phosphate buffer) Administered via IV infusion, at a dose level of 60 mg/kg, given three times a week for 12 weeks, two times a week for a further 12 weeks and once per week until disease progression or up to two years.
223745503|NCT03459664|BEHAVIORAL|Treatment as usual|"For each patient all common care options within the German health care system are available, depending on the severity grade 1 to 4.~This includes the following options: hospital based in-patient, out-patient treatment and day care, community based health care services, general practitioners, private psychiatrists and psychotherapists, self help."
223745504|NCT01190254|DRUG|asenapine 2.5 mg|asenapine 2.5 mg tablets for sublingual administration
223745505|NCT01190254|DRUG|asenapine 5.0 mg|asenapine 5.0 mg tablets for sublingual administration
223745506|NCT01190254|DRUG|placebo|asenapine-matched placebo tablets for sublingual administration
223745507|NCT00422266|DRUG|Omega 3 fatty acids and plant sterol enriched drink|
224182675|NCT03464162|BEHAVIORAL|Social Network Meetings|Social Network Meetings are a type of family therapy that includes clients and members of their social network.The social network may include family members, friends or anyone else that clients believe can help them move toward recovery. The meetings will focus on improving communication within the social network.
224182676|NCT00006162|BEHAVIORAL|exercise and diet|
224182677|NCT00036660|DRUG|SarCNU|
224182678|NCT03776331|DIAGNOSTIC_TEST|Flow mediated dilation|Measurement of the change in the vasodilatative reserve of the brachial artery
224182679|NCT06326073|PROCEDURE|Non Surgical Periodontal Treatment|Phase 1 periodontal (full mouth debridement) treatment was applied to groups with periodontitis in one session.
224308099|NCT06989697|DRUG|Cilostazol / Ginko Leaf Dried Ext.|Patients will receive a light green, oval-shaped, sustained-release film-coated tablet containing a combination of cilostazol (200 mg) and ginkgo biloba extract (160 mg), administered orally once daily.
224308100|NCT06989697|DRUG|Placebo|Patients will receive a placebo identical in taste, aroma, and formulation to the active treatment, administered orally once daily.
224308101|NCT06989411|OTHER|Clinical pilates exercises +Interferential current therapy (real current)|All treatments were given three times a week for 8 weeks. The current intensity was determined as the mA CC level that the patient felt at the maximum but did not feel any discomfort.
224308102|NCT06989411|OTHER|Clinical pilates exercises+ Interferential current therapy (Placebo current)|All treatments were given three times a week for 8 weeks. The current intensity was set to 0.1 mA CC (necessary for the machine to work)
224182680|NCT03862729|PROCEDURE|Minimally invasive surgery|Intracranial hematoma will be removed by intraoperative stereotactic computer tomography-guided endoscopic surgery, or surgical aspiration followed by alteplase clot irrigation (1·0 mg every 8 h for up to nine doses). CTA will be performed before operation in all the patients for intraoperative navigation, and the minimally invasive surgery will be performed within 24 hours after intracerebral hemorrhage onset.
224182681|NCT03862729|PROCEDURE|conventional treatment|Conventional treatment includes medical treatment and conventional craniotomy.
224182682|NCT01130831|DRUG|Lanthanum carbonate|
224182683|NCT05789901|OTHER|MARVIN|Chatbot on Meta (Facebook) Messenger for HIV Patients
224182684|NCT05789901|OTHER|MARVIN-Pharma|Chatbot on Meta (Facebook) Messenger for community pharmacists
224182685|NCT05789901|OTHER|MARVINA|Chatbot on Meta (Facebook) Messenger for breast cancer patients
224308103|NCT06991036|OTHER|Gastric emptying test|"After the radiolabeled breakfast meal is ingested, the participant is positioned upright between the two detectors of the Brightview system (Phillips Medical Systems, Cleveland, OH). Detector height is adjusted to include esophageal uptake, the stomach, and the small bowel. Anterior and posterior static images are acquired at 2 minutes per image using a 256 x 256 word mode matrix. Anterior and posterior images are again acquired at 1 and 2 hours post-ingestion of the radiolabeled breakfast meal.~The participant is then given the designated 'push' meal after completion of the 2-hour images. At 4 hours post-ingestion, images are acquired in the same manner as at previous time points."
224308104|NCT06990061|RADIATION|Radiation therapy|Radiation therapy will be given in 20 fractions of 2.75 Gy (total dose of 55 Gy) covering the whole bladder over 4 weeks in combination.
224182686|NCT05789901|OTHER|MARVIN-CHAMP|CHatbot to Assist the Management of Pediatric patients with infectious conditions (CHAMP)
224308105|NCT06990217|DRUG|Oxytocin Grindeks 10 IU/ml- solution for injection|our study is aims to compare two oxytocin regimens - low VS high dose among obese women who need induction or augmentation of labor
224308106|NCT06989073|PROCEDURE|Muscle Energy Technique|METs are soft tissue or joint techniques that are employed in the treatment of musculoskeletal dysfunctions.
224308107|NCT06989073|PROCEDURE|Convenional treatment|Hot pack, Range of Motion Exercises, Stretching Exercises and Strengthening exercises.
224308108|NCT06989931|DEVICE|Intracranial Distal Access Catheter|Patients with mechanical thrombectomy for acute ischemic stroke, treatment of intracranial aneurysms and other ischemic and hemorrhagic diseases, requiring the use of Intracranial Distal Access Catheter(X-Track) to complete the procedure
224308109|NCT06991127|DEVICE|MAIA|MAIA is an automatic microperimeter with fundus imaging capabilities that measures retinal sensitivity, fixation stability and locus of fixation, and allows the acquisition of confocal images of the retina, thanks to its confocal scanning imaging system which uses infrared and visible light.
224308110|NCT06990048|DEVICE|AFX2 System|"The AFX2 System comprises of the following:~AFX2 Bifurcated Endograft System and delivery system AFX Vela Proxmal Endograft System and delivery system AFX Stand Alone Endograft System and delivery system"
224308111|NCT06989892|DEVICE|Super High-flux dialyzer (Elisio 19HDx)|Dialysis with Super High-flux dialyzer for intervention group
224308112|NCT06989892|DEVICE|High-flux dialyzer (Elisio 19H)|Dialysis with High-flux dialyzer for control group
224308113|NCT00942695|OTHER|1.5PD|average American diet plus 1.5 oz per day pistachios
224308114|NCT00942695|OTHER|3.0PD|average American diet plus 3.0 oz per day pistachios
224308115|NCT00942695|OTHER|control|average American diet without pistachios
224308116|NCT04222374|PROCEDURE|Intervention in the UroCCR sites|"1. Blood sampling of a 5ml tube per patient. (for eligible patients recruited in the study, after signing the consent)~2. DNA extraction:~   * For the patients of Bordeaux University Hospital, 2 aliquots will be constituted:~  * 1 aliquot for Expanded GWAS, containing at least 2 μg of DNA,~  * 1 aliquot for the UroCCR biobank.~  * For patients from other UroCCR centers, only 1 aliquot will be constituted:~  * 1 aliquot for Expanded GWAS, containing at least 2 μg of DNA.~3. Transmission of the extracted DNA samples to the Biological Resource Center (CRB) of Bordeaux."
224308117|NCT04222374|PROCEDURE|Intervention in the CRB of Bordeaux University Hospital|"1. Temporary storage of DNA samples for Expanded GWAS before shipping to the NCI. Storage of samples for the DNA biobank.~2. Overall packing of GWAS samples for shipment to the NCI.~3. Shipping to the NCI: Constitutive DNA samples must be sent to the NCI by May 1, 2020 for inclusion in the Expanded GWAS study."
224308118|NCT04222374|PROCEDURE|Intervention at the Methodology and Data Management Centre of Bordeaux University Hospital|Transfer of the data associated with the samples to the NCI.
224308119|NCT04222374|PROCEDURE|Subsequent intervention at the NCI (for information)|"1. Samples will be genotyped at the NCI Cancer Genomics Research Lab using the Illumina Global Screening Network.~2. GWAS combined meta-analysis, based, among others, on the results from the UroCCR samples."
224308120|NCT02953951|OTHER|blood transfusion|blood transfusion different sources
224308121|NCT02608151|OTHER|massage with oil|Application or not of an oil consisting of 4 vegetable oils (40% sunflower oil, 3% grape seed oil, 1.5% coriander oil, and 57% of rapeseed oil) during the massage. This oil was chosen due to its composition of essential fatty acids (60%) including: linoleic acid (omega 6,25g 100 g)), linolenic acid (omega 3 5.3g to 100 g) and tocopherol (vitamin E) .
224308122|NCT02608151|OTHER|massage without oil|
224182687|NCT06163144|OTHER|lab investigation|"Platlets count by : advia cell counter principles . This flow cytometry-based system uses light scatter, differential white blood cell (WBC) lysis, and myeloperoxidase and oxazine 750 staining to provide a complete blood cell count, a WBC differential, and a reticulocyte count. A cyanide-free method is used to measure hemoglobin colorimetrically.~\*Automated cell counters~* Advia 2120 8 difference~* PLT , parameters , MPV . Prothrombin time , prothrombin concentration , International normalized ratio , activated partial thromboplastin time . BUN, Serum Createnin Serum Albumin Serum Ca, Ph, PTH HBsAg, HCV - Abs Erythrocyte sedimintation rate ,C- reactive protein . 2.Specific lab: C3 - C4, Anti Neuclear Antibody, Anti douple stranded DNA , if suspect lupus . PCR for HCV or HBV serum lactate if sepsis is suspected. drugs level if Addiction is suspected."
224182688|NCT00380601|DRUG|MRA(Tocilizumab)|8mg/kg/4 weeks
224182689|NCT00745004|DRUG|Ondansetron|Over-encapsulated 4mg ondansetron tablets. Ondansetron 4mg OD, dose titrated up to a maximum of 8mg tds or down to a minimum of 4mg alternate days. For 5 weeks.
224182690|NCT00745004|DRUG|Placebo|Capsule matching over-encapsulated experimental drug. 1 capsule OD, dose titrated up to a maximum of 2 capsules tds or down to a minimum of 1 capsule alternate days. For 5 weeks.
224182691|NCT02204267|OTHER|prolonged ECG monitoring|Start of long-term ECG immediately after admission to the stroke unit by using a portable ECG recorder for a max. duration of 7 days (or hospital discharge)
224182692|NCT02204267|DEVICE|ECG|
224182693|NCT04808167|DEVICE|autoRIC®|The autoRIC device will be modified by the company from the standard cuff inflation of 200 mmHg to 180 mmHg for the purposes of this study. Three cuff sizes are available from the company: small, medium, and large, correlating to standard adult cuff sizes. The remote ischemic preconditioning cycles will be performed daily by trained research personnel during the preparative regimen through day 0 (see Figure 1), defined as transplantation of stem cells (last preconditioning cycle on day -1). A control group will undergo a similar procedure, however, the cuff will not be inflated.
224182694|NCT02534181|DRUG|Caloric Management Protocol|Strategy based on reduction of nutritional intake and electrolyte replacement.
224182695|NCT04900714|PROCEDURE|Decremental PEEP|High PEEP to low PEEP.
224182696|NCT04900714|DIAGNOSTIC_TEST|Lung ultrasound score|lung ultrasound to determine the extend of atelectasis. Uses validated lung ultrasound score.
224182697|NCT04900714|DIAGNOSTIC_TEST|Blood gas analysis|Blood gas analysis to determine arterial oxygen tension
224182698|NCT04900714|DIAGNOSTIC_TEST|Registration of respiratory mechanics|Pressures and volumes will be registered by the Fluxmed respiratory monitor (MBMED, Argentina)
224182699|NCT04900714|DIAGNOSTIC_TEST|Evaluation of dead space|Dead space will be measured non-invasively using volumetric capnography on the FluxMed respiratory monitor (MBMED, Argentina)
224182700|NCT00951912|DIETARY_SUPPLEMENT|Placebo|10g soy protein isolated per day
224182701|NCT00951912|DIETARY_SUPPLEMENT|Daidzein|50mg daidzein +10g soy protein isolated per day
224182702|NCT00951912|DIETARY_SUPPLEMENT|Genistein|50mg genistein +10g soy protein isolated per day
223491148|NCT04388475|DRUG|Temozolomide (TMZ)|Administered via oral, at a dose level of 150 mg/m2, once daily on Days 1-5 of each 28 day cycle in Cycle 1. If this dose level is tolerated, then in Cycle 2 (and subsequent cycles), at a dose level of 200 mg/m2, once daily on Days 1-5 of each 28 day cycle.
223491149|NCT03837964|DRUG|BI 1291583|Tablet
223491150|NCT00098475|DRUG|Dexamethasone|Given PO
224182703|NCT04606810|OTHER|multidisciplinary educational intervention|At randomization, participants in arm 1 received the educational DVD with the instruction to review its contents within the next two weeks. Between 2 and 4 weeks after randomization, reinforcement teleconferences were done in small groups of 10 participants maximum per session with every participant who mentioned having watched the DVD. Each participant attended only to one teleconference. Usual care consisted in regular follow-up with the treating rheumatologist and possibility of asking questions of the rheumatology nurse by phone.
224182704|NCT00250042|DRUG|Gleevec and Arsenic Trioxide|Pts. who fit the inclusion criteria, \& were on imatinib, 400 mg/day, will be treated with a month of imatinib at 800 mg/d in divided doses (400mg bid) \& then started on arsenic trioxide. Pts. already on imatinib 800 mg/day may be started on arsenic trioxide. Pts. unable to tolerate 800 mg/d should be treated at the max. dose tolerated above 400 mg/d. A total of 16 weeks of arsenic trioxide treatment will be administered (15 weeks of maintenance). Pts. are to continue on imatinib 800 mg/day,(or the max. tolerated dose) while receiving the arsenic trioxide. If a pt. has been taken off the arsenic trioxide, they should be continued on gleevec 800 mg per day (or the maximum tolerated dose) until there is evidence of progression of disease.
224182705|NCT03417999|DRUG|Dexmedetomidine|Dose-escalation of atomized intranasal dexmedetomidine
224182706|NCT00000799|DRUG|Cidofovir|
224182707|NCT00000799|DRUG|Probenecid|
224182708|NCT01845129|DEVICE|atDCS|atDCS will be delivered with a constant current of 1 mA during simultaneous resting-state (RS) and task-related (picture naming) functional magnetic resonance imaging (fMRI). The current will be turned on prior to the RS-fMRI scan and continues for 20 minutes.
224182709|NCT01845129|DEVICE|sham tDCS|During sham the current will be increeased and decreased in a ramp-like fashion (10 sec)
224182710|NCT04301492|DRUG|Vortioxetine|16 weeks for each participant. During the first visit a collection of medical and pharmacological history will be collected and ECG, laboratory tests and clinical assessment will be performed. After verifying the absence of significant abnormalities at the ECG and laboratory tests and after confirming all inclusion and exclusion criteria, subjects will perform the second visit to receive study drug (Brintellix drops 20 mg/ml). All subjects will be instructed to take Vortioxetine 1 drop every day after lunch, increasing of 1 drop per day arriving to 10 drops per day. After 5 days from the beginning of treatment, subject will be contacted by phone to check on tolerability and in absence of side effects, the dosage will be increased to 10 drops per day. At Week 4-8-12 patients will return to the site to perform all clinical evaluations required and to receive study drug.
224182711|NCT02127580|PROCEDURE|BAV|
224182712|NCT02127580|PROCEDURE|without BAV|
224182713|NCT02185729|DRUG|Intralipid|Infusion of Intralipid (soybean-derived fat)
224182714|NCT02185729|DRUG|ClinOleic|Infusion of ClinOleic (olive oil-based)
224182715|NCT02185729|DRUG|Dextrose|Infusion of dextrose (sugar) without fat
224182716|NCT02185729|OTHER|Saline (control)|Infusion of 0.9% normal saline
223491151|NCT00098475|OTHER|Laboratory Biomarker Analysis|Optional correlative studies
223491152|NCT00098475|DRUG|Lenalidomide|Given PO
223491153|NCT00098475|DRUG|Thalidomide|Given PO
223588003|NCT03976180|DEVICE|HFNO with high FiO2 (100%)|In this group, FiO2 will be set at 100% during the first 24 hours of intervention to target intense hyperoxia, then reduced to 21-3025% during the following 48 hours to target normoxia
223745508|NCT00422266|DIETARY_SUPPLEMENT|Omega 3 fatty acids and plant sterols|Capsules and Yoghurt based minidrink
224182717|NCT04196244|DIAGNOSTIC_TEST|Abdominal or body CT with intravenous contrast|Abdominal or body CT with intravenous contrast
224182718|NCT04196244|DIAGNOSTIC_TEST|Abdominal or body CT without intravenous contrast (native CT)|Abdominal or body CT without intravenous contrast (native CT)
224182719|NCT02089165|DIETARY_SUPPLEMENT|Krill oil|Krill oil from Antarctic krill, per oral, capsule, targeted daily n-3 PUFA dose of 1 700 mg, single administration
224182720|NCT02089165|DIETARY_SUPPLEMENT|Krill meal|Krill meal, granular meal from Antarctic krill, per oral, targeted daily n-3 PUFA dose of 1 700 mg, single administration
223588004|NCT06437470|OTHER|blood flow restriction technique|"All participants in the control group will receive the conventional physical therapy program with the use non-inflated cuff as a sham treatment during exercising.~All participants in the intervention group will receive the conventional physical therapy program combined to blood flow restriction to 80% of limb occlusive pressure by using blood flow restriction cuff."
224182721|NCT02089165|DIETARY_SUPPLEMENT|Fish oil|Fish oil, per oral, capsule, targeted daily n-3 PUFA dose of 1 700 mg, single administration
224182722|NCT01248429|BIOLOGICAL|CPK dosage|CPK dosage during a blood sample realized at least one week after the begining of the treatment
223491154|NCT05393232|BEHAVIORAL|Dietitian-Assisted DASH groceries|"The DASH (Dietary Approaches to Stop Hypertension), is a healthy dietary pattern that lowers blood pressure without reducing weight. The DASH diet emphasizes fruits, vegetables, and low-fat dairy products; includes whole grains, poultry, fish, and nuts; and is reduced in red meat, sweets, and sugar-containing beverages.~Intervention Phase:~This intervention is a weekly, 12-week DASH dietary intervention. A dietitian will assist participants in ordering groceries in a pattern consistent with the DASH diet to be delivered to their homes. The quantity of groceries will be based on participant Calorie needs and family size.~Observation Phase:~For months 4-12 of the study, participants will be asked to continue following a DASH grocery shopping pattern without the provision of weekly groceries."
223491155|NCT05393232|BEHAVIORAL|Self-directed shopping|"Intervention Phase:~Participants will receive some basic information on healthy eating and a monthly stipend at 4, 8, and 12-weeks of the intervention.~Observation Phase:~For months 4-12 of the study, participants will be asked to follow their typical shopping pattern without the provision of a monthly stipend."
223491156|NCT05007821|DRUG|Linezolid 600 mg|One 600mg tablet taken orally once daily (QD) in the morning during weeks 1-26
223491157|NCT05007821|DRUG|Linezolid 1200 mg (QD)|Two 600mg tablets taken orally once daily (QD) in the morning during weeks 1-4
223588005|NCT03033251|DEVICE|Non Invasive Ventilation|Patients will receive non invasive ventilation as a standard of care.
223588006|NCT03033251|DEVICE|High Flow Oxygen Cannula 50|Patients will receive High Flow Oxygen Cannula with a flow set at 50 L/min
223588007|NCT03033251|DEVICE|High Flow Oxygen Cannula 30|Patients will receive High Flow Oxygen Cannula with a flow set at 30 L/min
223588008|NCT04864847|DIAGNOSTIC_TEST|RENISCHEM L-FABP POC Test|Point-of-care test cassette with quantitative reader used for the measurement of L-type fatty acid binding protein (L-FABP) in human urine specimens.
223588009|NCT05851430|DEVICE|PEF ablation|Pulsed Electric Field (PEF) Ablation per institutional standard of care
223588010|NCT01854268|DRUG|Healthy adults who receive capsaicin|Participants will be seated in a comfortable chair and fitted with cotton elastic bands designed to measure changes in chest wall and abdominal movement during cough. The participant will hold a facemask attached to a pneumotachograph, nebulized, and dosimeter. The participant will receive 3 nebulized doses of 200 microMolar capsaicin through the facemask. The participants will have a minute in between each presentation and water will be available at all times.
223588011|NCT01646242|PROCEDURE|removal of eligible polyps using cold snare polypectomy technique|Snare polypectomy using a mini (10 mm open diameter) size electrosurgical snare without application of electrocautery
223588012|NCT01646242|PROCEDURE|removal of eligible polyps using double biopsy technique|Cold forceps polypectomy using a standard- capacity forceps with double biopsy technique (two bites per one forceps pass)
223588013|NCT02563938|DRUG|AK001|Given parenterally.
223588014|NCT02563938|DRUG|Placebo|
223588015|NCT00358969|DRUG|guanfacine (Tenex)|
223588016|NCT06298201|OTHER|E-Based Physical Exercise Intervention|The intervention comprises a 6-months home-based resistance training for the lower extremities, conducted twice weekly.
224182723|NCT01248429|OTHER|Clinical exam|Examination of the patient for myalgia, cramps, medical history and concomitant medication
224182724|NCT02897830|DRUG|Ixazomib|"induction therapy: comprising three 28-day cycles with Ixazomib (4 mg) on Days 1, 8 and 15 plus Lenalidomide (25 mg) on Days 1 through 21 and Dexamethasone (40 mg) on Days 1, 8, 15 and 22.~Early consolidation : (consolidation part 1) will start 2 months (-/+ 14 days) after transplantation and will comprise 2 cycles of MLN - Rd (MLN R identical to induction therapy but low dose of Dexamethasone 20mg/d once a week).~Late consolidation (consolidation part 2) will consist in 6 additional 28-day cycles of Ixazomib (4 mg on Days 1, 8 and 15) plus Lenalidomide (25 mg on Days 1 through 21)."
223588017|NCT04336852|PROCEDURE|Flow mediated dilation (brachial and femoral arteries)|Assessment of vascular function of the brachial and femoral arteries.
223588018|NCT04336852|PROCEDURE|Cerebral vascular reactivity to carbon dioxide (CO2)|Cerebral blood flow responses to increasing partial pressure of CO2
224182725|NCT02897830|DRUG|Lenalidomide|"induction therapy: comprising three 28-day cycles with Ixazomib (4 mg) on Days 1, 8 and 15 plus Lenalidomide (25 mg) on Days 1 through 21 and Dexamethasone (40 mg) on Days 1, 8, 15 and 22.~Early consolidation : (consolidation part 1) will start 2 months (-/+ 14 days) after transplantation and will comprise 2 cycles of MLN - Rd (MLN R identical to induction therapy but low dose of Dexamethasone 20mg/d once a week).~Late consolidation (consolidation part 2) will consist in 6 additional 28-day cycles of Ixazomib (4 mg on Days 1, 8 and 15) plus Lenalidomide (25 mg on Days 1 through 21).~Maintenance therapy will start within 28 days after the last dose of Lenalidomide in last cycle of Late Consolidation: Lenalidomide 10 mg/d taken on Days 1 through 21 for thirteen 28-day cycles"
224182726|NCT02897830|DRUG|Dexamethasone|"induction therapy: comprising three 28-day cycles with Ixazomib (4 mg) on Days 1, 8 and 15 plus Lenalidomide (25 mg) on Days 1 through 21 and Dexamethasone (40 mg) on Days 1, 8, 15 and 22.~Early consolidation : (consolidation part 1) will start 2 months (-/+ 14 days) after transplantation and will comprise 2 cycles of MLN - Rd (MLN R identical to induction therapy but low dose of Dexamethasone 20mg/d once a week)."
224182727|NCT02206230|RADIATION|Hypofractionated radiation therapy|
224182728|NCT02206230|RADIATION|Standard radiation therapy|
224182729|NCT05099458|BIOLOGICAL|Additional blood sampling (100 ml)|only an additional blood volume will be collected at the same time of the standard blood collection for these patients
224182730|NCT05043896|PROCEDURE|Li-ESWT|Li-ESWT twice weekly for 4 weeks
224182731|NCT05043896|DRUG|Tadalafil 2.5Mg Tab|tadalafil 2.5mg once daily
224182732|NCT00003824|DRUG|cephalexin|500 mg oral bid for 3 days starting the night before resection
224182733|NCT00003824|PROCEDURE|surgical procedure|
224182734|NCT00003824|DRUG|Ciprofloxacin|500 mg oral bid for 3 days starting the night before resection
224308123|NCT05761925|BEHAVIORAL|COMA-F|The intervention will teach resiliency skills (mindfulness, coping, interpersonal communication, etc.) to the comatose patient's caregiver. These sessions will take place in person or on Zoom, depending on the participant's preference.
224308124|NCT00004421|DEVICE|implanted pulse generator|
224308125|NCT06676306|OTHER|Non-Interventional Study|Non-Interventional Study
224308126|NCT03718052|PROCEDURE|Early valve surgery (EVS)|Early valve surgery (EVS) within 72 hours of randomization
224308127|NCT03718052|PROCEDURE|Conventional Care|Conventional care according to the 2015 European guidelines.
224308128|NCT06990100|DEVICE|ACL surgery|ligamentoplasty surgery - ACL reconstruction surgery
224308129|NCT06988852|COMBINATION_PRODUCT|FOLFOX (oxaliplatin, leucovorin, 5-fluorouracil [5FU])|The procedures of FOLFOX-HAIC were as follows: 1) a 5 French sheath was inserted into the femoral artery by Seldinger technique, then a 3.5 French catheter entered the coeliac trunk and superior mesenteric artery to assess the feeding arteries of tumors and identify any extra-collateral vessels which may cause drug leakage. These vessels would be embolized with gelatin sponge particles or metallic coils if necessary. A 2.7 French microcatheter was selectively inserted into the left/right/proper hepatic artery then patients were transferred to inpatient ward to start chemotherapy drug infusion. The FOLFOX regimen involving oxaliplatin (130mg/m2, day 1, 0-2h), leucovorin (400 mg/m2, day 1, 2-3h), 5-Fu (400mg/m2, day 1, bolus at 3h, then 2400 mg/m2, day 1-3, 3-49h), was administered via the microcatheter. The microcatheter and sheath were removed after HAIC finished. We didn't implanted port catheter system and repeated percutaneous femoral artery puncture and catheterization once every 3
224308130|NCT06988852|PROCEDURE|hepatic arterial infusion chemotherapy (HAIC)|The procedures of FOLFOX-HAIC were as follows: 1) a 5 French sheath was inserted into the femoral artery by Seldinger technique, then a 3.5 French catheter entered the coeliac trunk and superior mesenteric artery to assess the feeding arteries of tumors and identify any extra-collateral vessels which may cause drug leakage. These vessels would be embolized with gelatin sponge particles or metallic coils if necessary. A 2.7 French microcatheter was selectively inserted into the left/right/proper hepatic artery then patients were transferred to inpatient ward to start chemotherapy drug infusion.
224308131|NCT06988852|DRUG|Bevacizumab|We would inject bevacizumab at the dose of 7.5mg/kg once every 3 weeks if the primary tumors located from right-side to splenic flexure colon or the genotype of RAS or RAF was mutational.
224308132|NCT06988852|DRUG|Cetuximab (Erbitux)|We would inject cetuximab at an initial dose of 400mg/m2 and maintained a dose of 250mg/m2 once every week if we didn't choose bevacizumab.
223588019|NCT04336852|PROCEDURE|Cerebral vascular function test|Cerebral blood flow responses to a reactive hyperemia stimulus
224308133|NCT06988852|PROCEDURE|liver resection|If patients reached potential resectable state, we would perform liver resection.
224308134|NCT06395376|OTHER|Bikram Hot Yoga Intervention|"Active participants engage in a yoga intervention which entails participating in a minimum of 60-minutes of hot yoga (Bikram sequence), 3x per week in a heated room at 40 degrees C. The intervention will be 6-weeks of active intervention when they are participating in yoga, followed by an 6-week washout period where they will be asked to not practice yoga. Participants will be asked to give blood at 9 timepoints throughout the 12-week study, including baseline, week one, midpoint, end of Hot Yoga Intervention (Week 6) and after Washout (Week 12)"
224308135|NCT06395376|OTHER|Hot Yoga Washout|"The Washout period consists of 6-weeks occurring immediately after the Hot Yoga Intervention during which the participants do not perform any hot yoga."
224308136|NCT03923530|DRUG|Eplerenone|Eplerenone 50 mg daily
224308137|NCT00273234|PROCEDURE|Autologous Platelet Gel (APG)|
224308138|NCT04154150|DRUG|Intravenous ketamine|Single subanesthetic infusion of ketamine (0.5mg/kg)
224308139|NCT04154150|BEHAVIORAL|Cognitive training|8 sessions of computer-based cognitive training
224308140|NCT04154150|BEHAVIORAL|Sham Training|8 sessions of computer-based sham training
224308141|NCT02098421|DRUG|Oxytocin|Use of oxytocin while the Foley bulb is in place
224308142|NCT01923194|DRUG|Highly Purified Urofollitropin|for Injection
224308143|NCT01923194|DRUG|Recombinant Human Follitropin Alfa|for Injection
224308144|NCT00515931|RADIATION|Radiation therapy (external beam photons)|A cumulative radiation dose of 30 to 40 Gy is administered in 1.8 to 2.0 Gy fractions, 5 fractions per week, to the target lesion(s).
224308145|NCT05387538|PROCEDURE|One-layer Duct-to-mucosa Pancreaticojejunostomy|To create the anterior suturing layers, double needles with a 4/0 or 3/0 Prolene line will be used; one side of the needles will be inserted from the anterior inner side of the pancreatic duct and out through the ventral parenchyma of the pancreatic stump to the anterior surface of the pancreas about 3 cm from the cut edge. The other side of the needles will be started from the inner side of the jejunum lumen, then pushed through the subserosa and seromuscular region, and out from the posterior surface of the bowel but its done after completion of the posterior layer. The posterior suturing layer will be treated in the same manner. An internal pancreatic duct stent will be used
223588020|NCT01474070|DEVICE|Intraocular Pressure Measurement|Intraocular pressure is measured with GAT and with DCT
223745509|NCT02140437|DRUG|Fulvestrant|Adding fulvestrant to the standard endocrine therapy, anastrozole
224182735|NCT05852002|DRUG|35 kDa hyaluronan fragment|100 mg of 35kDa hyaluronan fragment was injected deeply into abdominal fat layer once a day for 28 consecutive days.
224182736|NCT03815006|DEVICE|Free Style Libre 2|FreeStyle Libre 2 (FSL2) is a novel glucose monitoring device (Flash glucose monitoring) in the form of a disc worn on the arm for 14 days and a hand-held reader which is designed to largely replace the recommended 4-10 painful finger-stick blood glucose tests required each day for the self-management of type 1 diabetes (T1D).
224182737|NCT06218290|DRUG|Oxylanthanum Carbonate|Phosphate Binder to Reduce Hyperphosphatemia
224182738|NCT00396266|DRUG|G-CSF Plus Plerixafor|Participants underwent mobilization with G-CSF 10 µg/kg/day for 4 days, administered by subcutaneous injection (SC) injection each morning. On the evening of Day 4, participants received a dose of plerixafor 240 µg/kg, administered by SC injection. On Day 5, participants returned to the clinic and received a morning dose of G-CSF 10 µg/kg and underwent apheresis approximately 10 to 11 hours after the dose of plerixafor (within 60 minutes after administration of G-CSF). Participants continued to receive an evening dose of plerixafor followed the next day by a morning dose of G-CSF and apheresis for up to a maximum of 5 aphereses or until ≥ 5\*10\^6 CD34+ cells/kg were collected.
224182739|NCT01812564|BIOLOGICAL|Platelet Poor Plasma (PPP)|
224182740|NCT01812564|BIOLOGICAL|Platelet Rich Plasma (PRP)|
224182741|NCT00422942|DRUG|rituximab [MabThera/Rituxan]|1000mg iv on days 1 and 15
223588021|NCT03071289|RADIATION|Radiation Method B|The gross tumor volume (GTV) is the residual lesion after radical resection and given a dose of 60Gy. The clinical target volume (CTV) is delineated according to the lymph drainage pathway and included all the lymphocyst. The CTV is given a dose of 45Gy.
223588022|NCT03071289|DRUG|Cisplatin|The regimen of chemotherapy is cisplatin 30mg/m2 every week.
223588023|NCT03071289|RADIATION|Radiation Method A|The gross tumor volume (GTV) is the residual lesion after radical resection and given a dose of 60Gy. The clinical target volume (CTV) is delineated according to the lymph drainage pathway and given a dose of 45Gy.
223588024|NCT05443724|DRUG|CVL-231 30 mg|Oral tablets
223588025|NCT06972095|PROCEDURE|EVAR|endovascular repair of the AAA with the endurant stent graft
223588026|NCT06447701|DRUG|Tocilizumab|Single dose intravenous application
223588027|NCT06447701|DRUG|NaCl 0.9% 100ml|Single dose intravenous application
224182742|NCT00422942|DRUG|Methotrexate|10-25mg po weekly
224182743|NCT02406599|DEVICE|Margin Probe|The surgeon will use the MarginProbe System to identify cancerous tissue at the margins (≤ 1mm) of the main ex-vivo lumpectomy specimen following primary excision
224182744|NCT02406599|OTHER|Control: Additional inspection|The surgeon will perform additional inspection and assessment of the margins of the main ex-vivo lumpectomy specimen following primary excision
224308146|NCT05387538|PROCEDURE|Two-layer Duct-to-mucosa Pancreaticojejunostomy|The same double needle and 4/0 or 3/0Prolene line will be used. First, the region approximately 1.0 cm from the cutting edge of the pancreatic remnant will be freed; then, the posterior surface of the pancreatic remnant will be sutured to the seromuscular layer of the jejunum using the interrupted suturing method. The jejunum will be brought closer to the stump of the pancreas, and a hole of similar diameter to the main pancreatic duct will be made on the jejunum near the entrance of the main pancreatic duct. The posterior wall of the jejunum near the hole will be sutured to the posterior wall of the pancreatic duct using the interrupted suturing method with Prolene line, and a suitable internal pancreatic duct stent will used . The interior side of the jejunum and pancreas will be sutured using the same method. Then, the anterior surface of the pancreatic remnant and the seromuscular layer of the jejunum will be tightly sutured using the interrupted method.
224308147|NCT05189938|DIAGNOSTIC_TEST|HBA1c data and glucose levels|All subjects will wear the professional FreeStyle Libre Pro for glucose data and HbA1c data will be collected at different time points over the participation period.
224308148|NCT04455178|DRUG|Spironolactone|spironolactone 20mg once daily, up-titrated to 40mg once daily at 4-week or 8-week visit
224308149|NCT04455178|DRUG|Indapamide|indapamide 1.5mg once daily, up-titrated to 3mg once daily at 4-week or 8-week visit
224308150|NCT01222390|DEVICE|Contour Profile Tissue Expander|The Contour Profile Tissue Expander is a tissue expander with a greater height to width ratio than traditional tissue expanders. This increased ratio allows for greater lower pole expansion, thus creating a more natural looking, ptotic breast. Additionally, the suture tabs on the back of the expander hold the expander in place and prevent malposition and displacement.
224308151|NCT03757975|PROCEDURE|urethral length measure|measure of urethral length, distribution of questionnaires before and after operation
223588028|NCT06585150|DRUG|Obeldesivir|Tablet administered orally
223588029|NCT06585150|DRUG|Obeldesivir Placebo|Tablet administered orally
223588030|NCT06112938|DRUG|Antibiotic|We aim to examine differences in clinical outcomes and failure rates between standard and alternative treatment strategies such as minocycline (or moxifloxacin, ciprofloxacin, ceftazidime) alone or in combination with TMP-SMX, alternative TMP-SMX dosing regimens, or variations in durations of therapy for the treatment of S. maltophilia infections within Methodist Health System (MHS).
223588031|NCT05848297|DEVICE|Transcranial Doppler ultrasonography (TCD)|Portable, bedside, non-invasive diagnostic tool used for real-time assessment of cerebral hemodynamics
223588032|NCT06573242|OTHER|Home-based cardiac rehabilitation for people living with Heart Failure and their caregivers|Intervention DK:REACH-HF is a home-based 12-week CR program for people living with HF and their caregivers.
223588033|NCT04051827|DRUG|Midazolam|Midazolam Oral Solution and Midazolam Intravenous Infusion.
223588034|NCT04051827|DRUG|TAK-788|TAK-788 Oral Capsules.
223588035|NCT01921686|OTHER|Sample collection and Questionnaire|This is an observational biospecimen collection and questionnaire study. The subjects will be asked to complete a symptom questionnaire at screening visit. In addition, 3 esophageal biopsy samples will be taken to conduct laboratory analyses.
224182745|NCT03757936|DRUG|HLX04|Recombinant Anti-VEGF Humanized Monoclonal Antibody Injection
224182746|NCT03757936|DRUG|HLX10|Recombinant Anti-PD-1 Humanized Monoclonal Antibody Injection
224182747|NCT04418752|OTHER|Psychological therapy|"The National Institute for Health and Care Excellence (2018) specifies NET as a psychological intervention for the treatment of PTSD or prominent symptoms of PTSD in adults. NET is a short-term treatment which incorporates elements of CBT exposure therapy and testimonial therapy. In exposure therapy, clients are encouraged to repeatedly discuss traumatic experiences in detail, including emotions and sensory experiences (Schauer, Elbert, \& Neuner, 2011).Testimonial therapy involves the construction of a detailed and coherent report of the survivor's biography including an explicit description of the traumatic events (Neuner, Schauer, Roth \& Elbert, 2002, pp.5-6). Therefore, NET aims to embed the traumatic experience within the context of the person's life and the mechanisms of change are theorised to be exposure and habituation to the traumatic experience and the reconstruction of autobiographical memory."
224182748|NCT04855474|DIETARY_SUPPLEMENT|Amino Acid Intake|Participants will consume hourly (8 hours) isoenergetic, isonitrogenous beverages containing one of the three protein intakes (0.2g/kg/d, 1.2 g/kg/d, 2.0g/kg/d) assigned in a randomized order between the three metabolic trials. Drinks will be enriched with stable isotope \[13C\]phenylalanine. The use of stable isotope \[13C\]phenylalanine will allow for the determination of the fate of AA in the body (incorporation into body protein or oxidation) which can be used to determine protein (AA) requirements.
224308152|NCT05190653|OTHER|Early palliative and supportive care|The intervention itself will be predominantly the provision of education and information. It is possible that patients in the intervention arm may receive treatment recommendations to help manage symptoms.
224308153|NCT05034276|OTHER|MORE-VR|Mindfulness-Oriented Recovery Enhancement therapy delivered over virtual reality.
224308154|NCT02468492|BIOLOGICAL|Platelet Rich Plasma|Platelet rich plasma injection into knee versus placebo (saline) injection.
224308155|NCT02468492|OTHER|Normal Saline|Platelet rich plasma injection into knee versus placebo (saline) injection.
224308156|NCT05011630|OTHER|Pancreaticoduodenectomy|The incidece of IAA after pancreaticoduodectomy; to validate the risk factors of IAA
224308157|NCT00703573|DRUG|S-777469 400 mg|S-777469 400 mg BID
224308158|NCT00703573|DRUG|S-777469 800 mg|S-777469 800 mg BID
224308159|NCT00703573|DRUG|Placebo|Placebo BID
223491158|NCT05007821|DRUG|Linezolid 1200 mg (TIW)|Two 600mg tablets taken orally three times per week (TIW; Mon-Wed-Fri) in the morning during weeks 5-26
223491159|NCT05007821|DRUG|Bedaquiline 200 mg|Two 100mg tablets taken orally once daily in the morning during weeks 1-8
223588036|NCT01424566|DRUG|Nabiximols|
224182749|NCT04456114|DEVICE|Acid etched brackets|The brackets will be bonded to the teeth with composite on the same patient in a split mouth design and observed for bracket debonding for 18 months
223491160|NCT05007821|DRUG|Bedaquiline 100 mg|One 100mg tablet taken orally once daily in the morning during weeks 9-26
223491161|NCT05007821|DRUG|Delamanid 300 mg|Six 50mg tablets taken orally once daily in the morning during weeks 1-26
223491162|NCT05007821|DRUG|Clofazimine 300 mg|Three 100mg capsules taken orally once daily in the morning during weeks 1-2
223491163|NCT05007821|DRUG|Clofazimine 100 mg|One 100mg capsule taken orally once daily in the morning during weeks 3-26
224182750|NCT04456114|DEVICE|Sandblasted brackets|The brackets will be bonded to the teeth with composite on the same patient in a split mouth design and observed for bracket debonding for 18 months
224182751|NCT02612194|DRUG|Crizotinib|Crizotinib was administered orally at 250mg twice daily
224182752|NCT03715127|DRUG|Psilocybine oral capsule|single dose of psilocybin (0.215mg / kg body weight)
224182753|NCT03715127|DRUG|Placebo oral capsule|single dose of placebo (100% mannitol)
224182754|NCT03164291|DRUG|Rifabutin|Rifabutin dosage dependent on clinical factors such as age, weight, and patient-specific health status
224182755|NCT00377273|DRUG|fluorouracil cream 0.5%|
224182756|NCT00300794|DRUG|Ketamine|
224182757|NCT02592980|GENETIC|Pharmacogenetic anticoagulation|The investigators use a algorithm pharmacogenetic for adjust only the first dose in the study.
224182758|NCT02592980|DRUG|Traditional anticoagulation|The physician will adjust the dose according to current INR value based on guidelines.
224182759|NCT04647682|OTHER|physical activity program|"* 30 second chair test,~* balance with joint-feet and semi-tandem stance~* 4 meters comfortable walking test were evaluated"
224182760|NCT02837874|PROCEDURE|Isoperistaltic|Same direction of peristalsis between stomach and jejunum, efferent loop of jejunum is located on the distal part of remnant stomach
224182761|NCT02837874|PROCEDURE|Antiperistaltic|Reverse direction of peristalsis between stomach and jejunum, efferent loop of jejunum is located on the proximal part of remnant stomach
224182762|NCT00149227|DRUG|Valsartan|Valsartan add-on arm: valsartan 40-160 mg per day, and an additional antihypertensive drugs other than ARB and ACEI are administered if necessary.
224182763|NCT00149227|DRUG|Non-ARB|'Non-ARB' was defined conventional anti-hypertensive treatment except for ACEIs and ARBs
224182764|NCT04954560|DRUG|losartan and eprosartan|. Each study drug was given in a random order as a single morning dose (50 mg of losartan or 600 mg of eprosartan) for two periods each lasting 3 months separated by 2-week wash-out time.
224182765|NCT02539160|DRUG|ticagrelor|Diabetic patients with or without chronic kidney disease will be randomized 1:1 to either (A) standard dose (90mg twice daily of ticagrelor) for 7-10 days and then cross-over to low dose (60mg twice daily of ticagrelor) for 7-10 days; (B) low dose (60mg twice daily of ticagrelor) for 7-10 days (phase 1) and then cross-over to standard dose (90mg twice daily of ticagrelor) for 7-10 days (phase 2).
224182766|NCT04000074|BEHAVIORAL|Telephonic Services|Provides linkage services to local programs that address the social determinants of health remotely via phone, email and/or fax
224182767|NCT04000074|BEHAVIORAL|In-Person Services|Provides linkage services to local programs that address the social determinants of health directly to the client during face-to-face visits as well as remotely via phone, email, etc.
224182768|NCT02078674|BIOLOGICAL|Monovalent Avian Influenza VLP (H7N9)|
224182769|NCT02078674|BIOLOGICAL|Matrix-M1™ adjuvant|
224182770|NCT02078674|BIOLOGICAL|Placebo|
224182771|NCT01681004|DEVICE|iFuse Implant System|Placement of iFuse implant system via surgery
224182772|NCT01681004|OTHER|Non-surgical management|Medications for pain, physical therapy, SI joint injection and RF ablation
224182773|NCT05205681|DIAGNOSTIC_TEST|Pre-operative imaging|Use of pre-operative imaging or the diagnosis of acute appendicitis
224182774|NCT04420390|RADIATION|Radiotherapy|Low-dose radiotherapy
224182775|NCT00021346|DRUG|carboplatin|
224182776|NCT00021346|DRUG|gemcitabine hydrochloride|
224182777|NCT03431246|BIOLOGICAL|Gardasil and Gardasil-9|All subjects will receive one dose of Gardasil-9. Blodd samples for serological testing will be collected just before and one month post Gardasil-9 administration.
224182778|NCT00367146|DRUG|MMF|
224182779|NCT03229512|DRUG|Sildenafil|Topical 1% Sildenafil Cream
224182780|NCT01085149|DRUG|Simvastatin|10 mg simvastatin, slow release in socket of extracted tooth (single application only)
224182781|NCT05997511|BEHAVIORAL|Card-Sorting Activity (Pre-intervention design)|Study team members within each country will free list misinformation or misconceptions that they commonly encounter in clinical practice or daily life. Each item will be used to create paired cards - one containing the misinformation and a second containing the corresponding correct information. During qualitative interviews, we will ask CHWs to participate in a series of card sorting activities, which is a participatory research method that can inform the design of health interventions.
224182782|NCT05997511|BEHAVIORAL|SMS Crafting (Pre-intervention design)|A two-person team consisting of one local communication expert and one clinician will draft clinically correct, easy-to-understand SMS messages designed to counter identified misinformation. We will draft messages that use various styles and use cognitive interviewing with CHWs to assess their understanding of and responses to each style. The final messages used in our intervention will be determined by CHW preference.
224182783|NCT05997511|BEHAVIORAL|SMS Messaging|Final messages will be sent via SMS to all CHWs working in our study area. CHWs will also be provided with contact information for a helpline staffed by a local team member who can answer follow-up questions in the local language.
224182784|NCT00759551|DRUG|Azilsartan|Azilsartan 2.5 mg, tablets, orally, once daily and olmesartan placebo-matching capsules and tablets, orally, once daily for up to 8 weeks.
224182785|NCT00759551|DRUG|Azilsartan|Azilsartan 5.0 mg, tablets, orally, once daily and olmesartan placebo-matching capsules and tablets, orally, once daily for up to 8 weeks.
223588037|NCT01424566|DRUG|Placebo (GA-0034)|
224182786|NCT00759551|DRUG|Azilsartan|Azilsartan 10 mg, tablets, orally, once daily and olmesartan placebo-matching capsules and tablets, orally, once daily for up to 8 weeks.
224182787|NCT00759551|DRUG|Azilsartan|Azilsartan 20 mg, tablets, orally, once daily and olmesartan placebo-matching capsules and tablets, orally, once daily for up to 8 weeks.
224182788|NCT00759551|DRUG|Azilsartan|Azilsartan 40 mg, tablets, orally, once daily and olmesartan placebo-matching capsules and tablets, orally, once daily for up to 8 weeks.
224308160|NCT04321798|BEHAVIORAL|Physical Activity|Four group sessions and one individual session delivered over a period of 12 weeks in a primary care setting. Each session includes patient education and support for behaviour change as well as a supervised practical exercise component. The intervention is based upon a combination of self-determination theory and COM-B framework (capability, opportunity, motivation and behaviour) and employs motivational interviewing techniques.
224308161|NCT02119117|DIETARY_SUPPLEMENT|CoQ10|This is a dietary supplement which will be administered daily to the patient for 3 months prior to IVF
224308162|NCT02119117|DIETARY_SUPPLEMENT|Placebo|This is a placebo which will be administered daily to the patient for 3 months prior to IVF.
224308163|NCT03465917|COMBINATION_PRODUCT|Renal Denervation|Bilateral denervation of the renal arteries using extravascular administration of neurolytic alcohol
224308164|NCT00228241|DEVICE|AAI vs. DDD vs. BIV pacing in different patients groups|
224308165|NCT03814941|OTHER|paper-based anesthesia record|to evaluate the incidence of artifacts in the AIMS database by paper-based anesthesia record
224308166|NCT03814941|OTHER|electronic documents|to evaluate the incidence of artifacts in the AIMS database by electronic documents anesthesia record
224308167|NCT01458106|DRUG|BIIB031 (rFVIIIFc)|Vials of rFVIIIFc were combined as needed, based on the actual labeled potency to achieve the participant's calculated dose. Partial vial use was allowed, in order to achieve the calculated dose.
224308168|NCT01458106|DRUG|FVIII (PK subgroup only)|Baseline prestudy FVIII dosing in participants who enter the PK subgroup. Vials of prestudy FVIII were combined as needed, based on the nominal labeled potency (e.g., 250 IU, 500 IU, and 1000 IU), to achieve the participant's calculated dose.
224308169|NCT04650113|COMBINATION_PRODUCT|MTA material|Partial pulpotomy is a procedure in which the inflamed tissue beneath an exposure is removed to a depth of 1 to 3 mm or deeper to reach healthy pulp tissue.
224308170|NCT06989918|DRUG|MHB018A|MHB018A 450mg for subcutaneous injection once every 4 weeks (Q4W)
223491164|NCT06273852|DRUG|PBA-0405|Intratumoral microdose injection by the CIVO device.
223491165|NCT04132050|DRUG|R788|Oral administration
223491166|NCT04132050|DRUG|Placebo|Oral administration
223588038|NCT06493240|RADIATION|radiation|45 Gy radiation dose in 25 fractions to the pelvis
223588039|NCT06493240|DRUG|PD-1 Monoclonal Antibody|200mg Sintilimab after radiation (3 times, 2-week interval)
223588040|NCT06493240|PROCEDURE|TME surgery|TME surgery for 6\~8 weeks after radiation
223588041|NCT06035458|DIAGNOSTIC_TEST|Diagnostic radiology|Clinical procedures include bone mineral measurement (bone densitometry, dxa) performed according to clinical practice; venipunctures for laboratory assessments (haematology and blood chemistry; bone turnover biomarkers P1NP and CTX).
223588042|NCT04160390|OTHER|Biospecimen Collection-Blood|Undergo collection of blood
223588043|NCT04160390|OTHER|Biospecimen Collection-Stool|Undergo collection of stool
223745510|NCT02140437|DRUG|Anastrozole|standard endocrine therapy
224182789|NCT00759551|DRUG|Placebo|Azilsartan placebo-matching tablets, orally, once daily and olmesartan placebo-matching capsules, orally, once daily for up to 8 weeks.
224182790|NCT00759551|DRUG|Olmesartan|Azilsartan placebo-matching tablets, orally, once daily and olmesartan 20 mg, capsules, orally, once daily for up to 8 weeks.
224308171|NCT06989918|DRUG|MHB018A placebo|6 subcutaneous injections of MHB018A placebo once every 4 weeks (q4w)
224308172|NCT00362921|DRUG|Gliadel wafers in combination with O6-benzylguanine|
224308173|NCT00855803|RADIATION|radiation|Given in 1 or 5 fractions
224308174|NCT02839421|DRUG|Scaling and Root Planing combined with moxifloxacin|Scaling and Root Planing combined with systemically administered moxifloxacin (MOX) 400 mg, once daily for 7 days
224308175|NCT03316378|DRUG|Ropivacaine injection|single dose, subcutaneous injection
224308176|NCT05100979|OTHER|The Art of Medicine Series|The Art of Medicine Series is a smartphone-based educational tool focused on teaching communication strategies to clinicians and patients.
224308177|NCT06131827|OTHER|Neural mobilization|Neural mobilization will be performed with twenty oscillations per minute being repeated three sets of one minute respecting one minute interval of rest between each set for 4 days weekly for six week
224308178|NCT06131827|OTHER|Task based activities|Task based activities consisted of different types task which will be performed with the dosage of 45 minute session 5 days weekly for six week.
224182791|NCT02828982|DEVICE|Powered ankle prosthesis|This device is a commercially available powered ankle prosthesis, (BioM, Bionx, Bedford, MA) which was given FDA device exempt status.
224182792|NCT02828982|DEVICE|Dynamic Response Foot|This condition is a sham condition as the participant will wear the prosthesis they were clinically prescribed and usually wear.
224182793|NCT05277597|DIAGNOSTIC_TEST|The exercise 60 minutes, 3 times per week, on a bicycle ergometer followed by a 30-minute dry Finish sauna treatment.|Participants in the group ET+S (n=8) exercised 60 minutes, 3 times per week, on a bicycle ergometer followed by a 30-minute dry Finish sauna treatment.Blood and stool samples were collected before and after the 4-week training program.
224182794|NCT05277597|DIAGNOSTIC_TEST|The same exercise training program without the sauna treatments|The control group (ET, n=7) engaged in the same exercise training program without the sauna treatments. Blood and stool samples were collected before and after the 4-week training program.
224182795|NCT01833351|DRUG|IV Vitamin C|"We will begin by enrolling 3 people at each dose level and if there are any problems seen, we will enroll 3 more people to that dose to see if that problem happens again and this may total a maximum of 6 people. Therefore a maximum of 6 people may be enrolled at each of these Vitamin C dose levels, 1 gram, 5 grams, 10 grams, 25 grams, 50 grams, 75 grams, and 100 grams.~If you are eligible for the study and decide to participate, the total time involved could be approximately 4 weeks."
224308179|NCT01693627|DEVICE|Pinnacle/Corail with collar|Uncemented THA using Pinnacle-100/Marathon XLPE(Depuy, Warsaw, IN) acetabular component and Corail(Depuy,Warsaw,IN)collared femoral stem with 32mm Alumina Biolox Forte(Depuy,Warsaw,IN). Tantalum beads will be inserted into periprosthetic bone.
223491167|NCT06850701|BEHAVIORAL|mbsr|In order to evaluate the effect of MBSR programme on stress, anxiety, self-compassion and prenatal attachment of pregnant women with perinatal pregnancy loss, MBSR will be applied for four weeks (two sessions per week) for a total of eight sessions in the experimental group. The intervention protocol of this study includes the entire MBSR programme consisting of two sessions per week for 1 month and homework assignments given throughout the programme. In all sessions, mindfulness exercises such as 3-minute breathing, body and breathing exercises, body scanning meditation, sitting meditation, mountain meditation, compassion meditation will be applied to the participants under the guidance of the researcher (H.G.Ö) who is trained and certified in the field of MBSR. It will be done in sessions and individual practices in an environment where pregnant women will not be disturbed at any time of the day. The live online MBSR programme will be provided through mobile communication tools. Sess
223588044|NCT06679361|BEHAVIORAL|Motor Exercise Program|This program consists of wrist motor exercises focused on active range of motion (including flexion, extension, ulnar and radial deviation, and finger flexion) along with nerve mobilization exercises for the medial, radial, and ulnar nerves. The aim is to enhance motor function in the wrist and hand.
223588045|NCT06679361|BEHAVIORAL|Sensory Exercise Group|Arm Description: This group will engage in sensory exercises designed to enhance sensory awareness in the hand and wrist. Exercises will include interaction with varied textures (such as sand and sensory balls), different fabrics (fur, satin, linen), and multisensory foam gels. The goal is to improve sensory function and tactile discrimination.
223588046|NCT06679361|BEHAVIORAL|Combined Motor and Sensory Exercise Group|Participants in this group will perform both motor and sensory exercises as described for the first two groups. By combining motor and sensory interventions, this group aims to improve both motor skills and sensory awareness in the wrist and hand, potentially enhancing overall hand function more effectively.
224205742|NCT01308762|BIOLOGICAL|Heat-killed whole cell M.obuense (IMM-101) 0.5 mg|Each patient will receive an intradermal placebo injection of borate buffered saline solution (day -3) to provide an intra patient placebo control. Patients who were willing and able to proceed with the study will receive an intradermal injection of a single dose level of IMM 101 on three subsequent occasions. Doses of IMM 101 were administered over a 4 week period on days 0, 14 and 28.
224205743|NCT01308762|BIOLOGICAL|Heat killed whole cell M.obuense (IMM-101) 1.0 mg|Each patient will receive an intradermal placebo injection of borate buffered saline solution (day -3) to provide an intra patient placebo control. Patients who were willing and able to proceed with the study will receive an intradermal injection of a single dose level of IMM 101 on three subsequent occasions. Doses of IMM 101 were administered over a 4 week period on days 0, 14 and 28.
224205744|NCT05564494|PROCEDURE|Bankart Repair|Patients Randomized to Bankart Repair Group
224205745|NCT05564494|PROCEDURE|Anatomic Glenoid Reconstruction|Patients Randomized to Anatomic Glenoid Reconstruction Group
223588047|NCT06500442|DRUG|NEU-111|Oral Doses
223588048|NCT06500442|DRUG|Placebo|Oral Doses
223588049|NCT02573753|BEHAVIORAL|Sleep restriction|
223588050|NCT02573753|DIETARY_SUPPLEMENT|Weight gain|
223588051|NCT06054178|DRUG|Fluorescein Sodium|Intravenous administration of 1 mg/kg. If initial dosing is insufficient, additional doses may be administered up to a total of 3 mg/kg
223588052|NCT05987787|PROCEDURE|laparoscopic sleeve gastrectomy without suture reinforcement|The procedure begins by dissecting the small branches of the gastroepiploic arch 6 cm from the pylorus. The dissection continues along the great curvature of the stomach, remaining very close to the gastric wall, up to the short gastric vessels which are also dissected. The stomach is then raised to expose its posterior wall and the adhesions are lysed. His angle is fully mobilized and the left diaphragmatic pillar exposed. The gastric tubule is created on the guide of a 40 F Bugie using mechanical suturing machines with charges of different thickness depending on the thickness of the gastric wall. At this point the bougie is removed and the resected stomach is extracted from the abdomen through the mesogastric access.
223588053|NCT05987787|PROCEDURE|laparoscopic sleeve gastrectomy with suture reinforcement|The procedure begins by dissecting the small branches of the gastroepiploic arch 6 cm from the pylorus. The dissection continues along the great curvature of the stomach, remaining very close to the gastric wall, up to the short gastric vessels which are also dissected. The stomach is then raised to expose its posterior wall and the adhesions are lysed. His angle is fully mobilized and the left diaphragmatic pillar exposed. The gastric tubule is created on the guide of a 40 F Bugie using mechanical suturing machines with charges of different thickness depending on the thickness of the gastric wall. At this point the bougie is removed and the resected stomach is extracted from the abdomen through the mesogastric access. At this point, it is applied running seromuscular stitches at the proximal third of the stapled line using unidirectional 2/0 barbed sutures to invaginate the staple line completely.
223491168|NCT06413927|BEHAVIORAL|Online Vehicle and Driver Safety Education|This online video education program provides education in vehicle and driver safety (e.g. vehicle maintenance, adjusting car seats and seatbelts). This online training will take up to 2 hours to complete and will have a short quiz at the end to determine compliance with this online training.
224182796|NCT01833351|DRUG|IV Vitamin C|"There will be 4 dose levels of intravenous vitamin C selected for this part of the study. The first dose level will be 25% of the top dose level found to be safe in Part 1, followed by 50% of the top dose level, followed by 75% of the top dose level, and finally 100% of the top dose. For example, if 100 grams of vitamin C given by vein is found to be safe in Part 1, then the first dose level we will choose will be 25 grams, followed by 50 grams, then 75 grams, and finally 100 grams.~Three to 6 people will be invited to participate in each of the dose levels and you will be asked to get a total of 4 doses at that level spread out over 4 weeks. In addition, you will have an initial visit and a follow-up visit both lasting 30 minutes. This will total 6 visits."
223491169|NCT06413927|BEHAVIORAL|Online Driver Skills Training|The online driver training is the Accelerated Curriculum to Create Effective Learning (ACCEL) is designed to enhance the ability to anticipate, recognize and respond to hazards and to maintain attention to the road. The training is delivered online via a computer and can be done from home or at a school or other site that has a computer with internet access. It requires up to two hours to complete, and will be hosted on a platform that will track progress and completion through the training (such as accuracy, duration in modules, time to complete) and a short quiz will be provided at the end to assess learning.
223491170|NCT06413927|BEHAVIORAL|Behind-the-Wheel Driver Training|The professional behind-the-wheel training course will be conducted in-person, delivered by local driving school partner Coastline Academy. The curriculum consists of 6 hours of training with assigned practice between lessons, and meets Pennsylvania and national standards. Post-lesson forms completed by the instructors will record adherence and consistency (intervention fidelity).
223491171|NCT05974332|DIAGNOSTIC_TEST|Oncostatin M|Test to diagnosis of Ulcerative colitis
223491172|NCT01940848|DRUG|STW5 (Iberogast, BAY98-7411)|Applied orally over 28 days, 20 drops STW 5 three times daily
223491173|NCT01940848|DRUG|Placebo|Applied orally over 28 days, 20 drops placebo three times daily
223588054|NCT06922097|DRUG|Giving atropine at heart rates below 60 beats per minute|In patients assigned to the atropine therapy at heart rates below 60 beats per minute, atropine will be given at a dose of 0.5 mg when heart rate is below 60 beats per minute for one continuous minute. A second and third atropine dose of 0.5 mg will be given if heart rate remains or again drops below 60 beats per minute for one continuous minute. Patients will not be given more than 1.5 mg atropine.
223588055|NCT06922097|DRUG|Giving atropine at heart rates below 30 beats per minute|In patients assigned to atropine therapy at heart rates below 30 beats per minute, atropine will be given at a dose of 0.5 mg when heart rate is below 30 beats per minute for one continuous minute. A second and third atropine dose of 0.5 mg will be given if heart rate remains or again drops below 30 beats per minute for one continuous minute. Patients will not be given more than 1.5 mg atropine.
223588056|NCT05138549|DRUG|Astaxanthin|12 mg oral astaxanthin supplement
223588057|NCT05138549|OTHER|Placebo|Oral placebo identical to astaxanthin supplement
223588058|NCT07011043|DRUG|Budoprutug|Single IV dose of study product on Day 1 of study
224182797|NCT00372905|DRUG|rituximab|Induction therapy will last 28 days. Bortezomib will be given on days 1, 8, 15, and 22. Rituximab will be given on days 8 and 15 along with 111-indium-ibritumomab tiuxetan. During consolidation therapy, Bortezomib will be given intravenously on days 1, 8, and 15 of each cycle for a maximum of 3 cycles. Rituximab or Y-90-ibritumomab tiuxetan will not be given during consolidation therapy.
224182798|NCT00372905|DRUG|bortezomib|Induction therapy will last 28 days. Bortezomib will be given on days 1, 8, 15, and 22. Rituximab will be given on days 8 and 15 along with 111-indium-ibritumomab tiuxetan. During consolidation therapy, Bortezomib will be given intravenously on days 1, 8, and 15 of each cycle for a maximum of 3 cycles. Rituximab or Y-90-ibritumomab tiuxetan will not be given during consolidation therapy.
223491174|NCT05833815|DRUG|Everolimus 10 mg|Oral Everolimus 10 mg daily in addition to standard of care i.e. GemOx or CapOx
223491175|NCT05833815|DRUG|Standard of care|GemOx or CapOx
223491176|NCT05873738|DRUG|Nicotine replacement|Nicotine patches
223491177|NCT01997580|DRUG|escitalopram|SSRI antidepressant
223491178|NCT01334099|BIOLOGICAL|CP-675,206|Intravenous infusion for one cycle (further cycles permitted as per medical assessment). Patient assigned dose of 3mg/kg, 6mg/kg, 10mg/kg, or 15mg/kg.
223588059|NCT06680440|DRUG|ASC30|Tablet, QD
223588060|NCT06680440|OTHER|Placebo|Tablets, QD
223588061|NCT04394715|OTHER|Electronic Alert|"Providers will see an automated electronic alert for each eligible hyperlipidemia patient at high risk for future atherosclerotic CVD events. This alert will appear when the provider enters the order entry screen in the patient's medical record during the patient's first eligible outpatient visit. The alert consists of a pop up that notifies the physician that the patient is at very high risk for ASCVD events, displays the most recent cholesterol values and the patient's current lipid lowering therapy. It also includes a link to full treatment guidelines for hyperlipidemia, which includes a continuing medical education (CME) option to obtain CME credits."
223491179|NCT01334099|RADIATION|External local radiation therapy|One cycle of 2000cGy administered locally to one site over 5 days.
223491180|NCT02295449|DEVICE|biopsy sample performed after the SonoVue® injection|
223491181|NCT00433537|DRUG|bortezomib|Given IV
223491182|NCT00433537|BIOLOGICAL|rituximab|Given IV
223491183|NCT00433537|DRUG|cyclophosphamide|Given IV
223491184|NCT00433537|DRUG|doxorubicin hydrochloride|Given IV
223491185|NCT00433537|DRUG|vincristine|Given IV
223491186|NCT00433537|DRUG|dexamethasone|Given IV
223491187|NCT00433537|BIOLOGICAL|filgrastim|Given SC
223491188|NCT00433537|BIOLOGICAL|pegfilgrastim|Given SC
223491189|NCT00433537|PROCEDURE|Autologous stem cell transplantation (ASCT)|
223491190|NCT04328194|DIAGNOSTIC_TEST|Serum Autotaxin|Marker
223491191|NCT04328194|RADIATION|chest x-ray|chest x- ray will be done for the study group
223491192|NCT04328194|DIAGNOSTIC_TEST|Breast ultrasound or mammography|Breast ultrasound or mammography will be done for the study group to diagnosis of breast cancer
224308180|NCT01693627|DEVICE|Marathon/Corail with collar|Reversed hybrid THA using cemented Marathon XLPE(Depuy,Warsaw,IN) acetabular component and an uncemented Corail(Depuy,Warsaw,IN)collared femoral component with 32 mm Alumina Biolox Forte(Depuy,Warsaw,IN)head. Tantalum beads will be inserted into periprosthetic bone.
223491193|NCT04328194|DIAGNOSTIC_TEST|Histopathological examination of breast mass specimens|by True cut or fine needle aspiration cytology
224182799|NCT00372905|DRUG|Ibritumomab tiuxetan|Induction therapy will last 28 days. Bortezomib will be given on days 1, 8, 15, and 22. Rituximab will be given on days 8 and 15 along with 111-indium-ibritumomab tiuxetan. During consolidation therapy, Bortezomib will be given intravenously on days 1, 8, and 15 of each cycle for a maximum of 3 cycles. Rituximab or Y-90-ibritumomab tiuxetan will not be given during consolidation therapy.
224182800|NCT02297867|DRUG|ADSCs|autologous ADSCs
224182801|NCT04301557|DRUG|PD-1 Antibody|PD-1 antibody 240mg,I.V,D1,repeat every 3 weeks, Four cycles in the neoadjuvant treatment, and four cycles in the adjuvant treatment,
224182802|NCT04301557|DRUG|Oxaliplatin|Oxiliplatin 130mg/m\^2 (100mg/m\^2 during radiotherapy),I.V,D1,repeat every 3 weeks, Four cycles in the neoadjuvant treatment in Capeox regimen, and two cycles in the adjuvant treatment in Capeox regimen
224182803|NCT04301557|DRUG|Capecitabine|Capecitabine 1000mg/m\^2,Bid,P.O,D1-D14,repeat every 3 weeks, Four cycles in the neoadjuvant treatment in Capeox regimen, and two cycles in the adjuvant treatment in Capeox regimen, and two cycles in adjuvant treatment in Capecitabine regimen
224182804|NCT04301557|RADIATION|External beam radiotherapy|Neoadjuvant radiotherapy, 50Gy/25Fractions to the GTV, 45Gy/25Fractions to the CTV
224182805|NCT04301557|PROCEDURE|Total mesorectal excision|Total mesorectal excision
224182806|NCT06217926|BEHAVIORAL|Experimental Group (Educational content; ChatGPT and Google Bard training)|"Educational content; ChatGPT and Google Bard training for senior students of the Faculty of Health Sciences who volunteered to participate in the study was provided by Dr. Lecturer It will be given by member Yasemin Özyer Güvener. After the training is completed, students will be asked to use generative artificial intelligence for educational purposes.~During the posttest implementation of the study (one week before the final exams), the Personal Information Form, Attitude Scale Towards Artificial Intelligence and Westside Exam Anxiety Scale will be re-administered to the 3rd and 4th year students of the Faculty of Health Sciences."
224182807|NCT04915209|OTHER|Narrative interviews|During the workshop, the participants will collectively create a common representation of the patient journey and co-design the envisioning care delivery model that support both social care and medical care.
224182808|NCT04048434|DEVICE|Cytosorb|extracorporeal cytokine adsorption
224182809|NCT02312934|DRUG|Transdermal nicotine|Nicotine patches are currently FDA approved for smoking cessation. Nicotine has effects that have been well studied for many years. Studies have shown that nicotine by itself does not appear by itself to be cancer causing. The use of the nicotine patch is not expected to increase risk of breast cancer recurrence.
224182810|NCT02312934|OTHER|Placebo Transdermal Patch|Matching transdermal placebo patches will be used. Participants will follow the same titration schedule as the transdermal nicotine arm.
224182811|NCT02978339|DRUG|Curcumin|Subjects will receive one 750 mg softgel by mouth twice a day for 12 weeks. Each each 750 mg CuraMed® softgel supplies 500 mg of highly bioavailable BCM-95 curcumin.
224182812|NCT04927585|BIOLOGICAL|env (A,B,C,A/E)/gag (C) DNA Vaccine|Administered by intramuscular injection in the deltoid
224182813|NCT04927585|BIOLOGICAL|gp120 (A,B,C,A/E) Protein Vaccine|Administered by intramuscular injection in the deltoid
224182814|NCT04927585|BIOLOGICAL|GLA-SE adjuvant|Administered by intramuscular injection in the deltoid.
224182815|NCT04927585|BIOLOGICAL|Placebo|Sodium Chloride for Injection, USP 0.9%; Administered by intramuscular injection in the deltoid.
224182816|NCT00701064|OTHER|Bright Light Exposure|Administered via bright light box
224182817|NCT00701064|OTHER|Negative Ion Generator|Administered via Negative Ion Generatore
224182818|NCT00689299|BIOLOGICAL|Standardized Allergenic Extract, Cat Hair|Standardized Cat Hair Allergenic Extract sublingual drops
224182819|NCT00689299|BIOLOGICAL|Placebo|Placebo Sublingual Drops
223491194|NCT04328194|RADIATION|Magnetic Resonance Imaging ( MRI) and Bone scan|will be done for the study group
223491195|NCT04328194|DIAGNOSTIC_TEST|Peripheral haemogram|blood sample will be taken from the patients
223491196|NCT04328194|DIAGNOSTIC_TEST|Renal and liver functions|to exclude any other morbidity
223491197|NCT04328194|DIAGNOSTIC_TEST|Prothrombin time and concentration|blood sample will be taken from the patients
223491198|NCT04328194|DIAGNOSTIC_TEST|Cancer Antigen 15-3 (CA15-3).|will be done for the 2 groups
223491199|NCT04328194|OTHER|Full medical history|full medical history will be taken from all patients
224182820|NCT04536142|DIAGNOSTIC_TEST|MRI|A research MRI scan will be performed within 1 week prior to surgery and again 2 weeks after surgery. The surgical removal of the brain tumor(s) is not a component of this research. The MRI scan will perform both programs (diffusion MRI, resting state MRI) during the same single session. The healthy controls will obtain identical research scans with the second session between two and three weeks following the first session, since they will not undergo a surgery.
224182821|NCT04536142|DIAGNOSTIC_TEST|neuropsychological tests and qualitative assessment|"Neuropsych Tests: COWA, Trails, RCFT, RAVLT, WMS-III subtests, NAB Digits, Grooved Pegboard, Stroop Color Word Test, verbal and spatial working memory, WRAT-IV, Word Reading subtest.~Standardized quality of life measures: MDASI-BT, FACT-Br, FrSBe"
224182822|NCT01738906|OTHER|Orange juice|
224182823|NCT01738906|OTHER|maltodextrin|
224182824|NCT01738906|OTHER|Vodka|
224182825|NCT01738906|OTHER|butter cake MSF|chewing on 40 gram cake for 6 minutes and before swallowing expectorating the bolus in cup.
224182826|NCT01738906|OTHER|butter cake consumption|chewing for 6 min on 40 gram cake and then swallow it.
224308181|NCT01693627|DEVICE|Pinnacle/Corail without collar|Uncemented THA using Pinnacle-100/Marathon XLPE(Depuy, Warsaw, IN) acetabular component and Corail(Depuy,Warsaw,IN)collarless femoral stem with 32mm Alumina Biolox Forte(Depuy,Warsaw,IN). Tantalum beads will be inserted into periprosthetic bone.
224308182|NCT01693627|DEVICE|Marathon/Corail without collar|Reversed hybrid total hip arthroplasty using cemented Marathon XLPE(Depuy,Warsaw,IN) acetabular component and an uncemented Corail(Depuy,Warsaw,IN)collarless femoral component with 32 mm Alumina Biolox Forte(Depuy,Warsaw,IN)head. Tantalum beads will be inserted into periprosthetic bone.
224182827|NCT03641599|DIAGNOSTIC_TEST|echocardiography|echocardiographic assessment of the RV and LV systolic function
224182828|NCT03162380|OTHER|Date collection|Date collection
224182829|NCT02218424|DRUG|Magnesium|
224182830|NCT02218424|DRUG|Normal saline|
224182831|NCT03012035|OTHER|positive treatment expectations|Before participants undergo the exposure training their expectation of treatment efficacy is manipulated with different information regarding the following treatment. The experimental group will get positive treatment expectations induced with the accurate information, that exposure training refers to the gold standard in psychotherapy to reduce spider fear (= open administration of treatment).
224182832|NCT03012035|OTHER|neutral treatment expectations|The comparator group will get neutral expectations regarding treatment outcome. To induce neutral treatment expectations about the following exposure training, it is necessary to tell them they are in the comparator group and that they will receive a comparator condition exposure training for diagnostic purposes only (= hidden administration of treatment).
224182833|NCT06313567|DRUG|Metronomic capecitabine group|500 mg/m2 body surface area twice daily for 1 year; metronomic capecitabine group
224182834|NCT06313567|OTHER|Observation|observation
224182835|NCT02613910|DRUG|Ofatumumab|Ofatumumab (human monoclonal antibody) will be provided as a liquid concentrate in a prefilled glass syringe with staked needle, stopper, and plunger containing 0.4 millilitre (mL) (20 mg) drug product of 50 mg/mL concentration
224182836|NCT02613910|DRUG|Acetaminophen/paracetamol|Acetaminophen/paracetamol will be supplied by study centre as 1 gram tablet, caplet, capsule or liquid for oral administration
224182837|NCT02613910|DRUG|Antihistamine (cetirizine or equivalent)|Antihistamine (cetirizine or equivalent) will be supplied by study center as 10 mg tablet, caplet, capsule or liquid for oral administration
224182838|NCT02613910|DRUG|Prednisone/Prednisolone|Prednisone/Prednisolone will be supplied from the dose range 2.5, 5, 7.5, 10, 12.5, 15, 17.5, 20, 25, 30, 40, 50, 60, 80, 100, 120, 140, 160, 180, 200, 220 and 240 mg for oral administration
224308183|NCT05200962|DEVICE|transcranial direct current stimulation|In tDCS, direct electrical currents are generated by an electrical stimulator and are noninvasively delivered to the scalp through a pair of saline-soaked sponge electrodes (7×5 cm).
223491200|NCT04328194|OTHER|Full clinical examination|full clinical examination will be done for the patients
224182839|NCT04036214|DEVICE|Selective Laser Trabeculoplasty|Selective Laser Trabeculoplasty Laser
224182840|NCT03956459|OTHER|Patients with a cancer for which a FDG-PET scanner must be performed|"For each patient, 2 consecutive PET-CT scanners will be performed using 2 different systems of PET-CT scanners:~* Discovery MI~* Discovery IQ~Only one contrast agent injection (FDG) will be given for both scanners."
224182841|NCT01013805|RADIATION|External Beam Radiotherapy|"Weeks 3 to 5: radiotherapy 25.2 Gy in 14 fractions over 3 weeks with 85 mg/m2 oxaliplatin on the first day and continuous infusion 5-FU 200 mg/m2/day on the days of radiotherapy.~Weeks 8-10: as per Weeks 3-5"
224182842|NCT01013805|DRUG|Oxaliplatin|"Week 1: Oxaliplatin 100 mg/m2 Day 1 (over 2 hours), leucovorin 200mg/m2 Day 1 concurrent with oxaliplatin over 2 hrs (then 5-FU).~Weeks 3 to 5: radiotherapy 25.2 Gy in 14 fractions over 3 weeks with 85 mg/m2 oxaliplatin on the first day Week 6: as per Week 1, Weeks 8-10: as per Weeks 3-5 Weeks 11: as per Week 1."
224182843|NCT01013805|DRUG|Fluorouracil|"Week 1: (after Oxaliplatin and leucovorin)5-FU 400mg/m2 bolus Day 1, then 5-FU continuous infusion 2.4 g/m2 over 46 hours from Day 1.~Weeks 3 to 5: radiotherapy 25.2 Gy in 14 fractions over 3 weeks with 85 mg/m2 oxaliplatin on the first day and continuous infusion 5-FU 200 mg/m2/day on the days of radiotherapy Week 6: as per Week 1, Weeks 8-10: as per Weeks 3-5 Weeks 11: as per Week 1.~Leucovorin 200 mg/m2 Day 1 concurrent with Oxaliplatin over 2 hrs, then 2nd: 5-FU 400 mg/m2 bolus Day 1, then 3rd: 5-FU continuous infusion 2.4 g/m2 over 46 hours from Day 1"
224182844|NCT01013805|DRUG|Leucovorin|Week 1: Oxaliplatin 100 mg/m2 Day 1 (over 2 hours), leucovorin 200mg/m2 Day 1 concurrent with oxaliplatin over 2 hrs (then 5-FU) Week 6: as per Week 1, Weeks 11: as per Week 1.
224182845|NCT01013805|PROCEDURE|Surgical Resection|Surgery is to be performed according to the standard procedure for locally advanced rectal cancer 4 to 6 weeks after completion of the integrated preoperative radiotherapy with FOLFOX chemotherapy regimen.
224182846|NCT06393205|DEVICE|Naso-Esophageal Tube Feeding|During nasogastric tube feeding, a thin, flexible tube is carefully inserted through one nostril and passed down the throat into the stomach. Once in place, liquid nutrition, medication, or fluids can be administered through the tube, providing essential nutrients and hydration directly to the patient's digestive system. Nasogastric tube feeding may be used temporarily to support patients during acute illness or surgery, or it may be a long-term solution for individuals with chronic conditions that affect their ability to eat normally.
224182847|NCT06393205|DEVICE|Nasogastric Tube Feeding|The control group was given enteral nutritional support with Nasogastric Tube Feeding according to the relevant guidelines. Within 4 hours after admission, the placement of the feeding tube was conducted by professional medical staffs and after intubation, the tube was secured to the patient cheek with medical tape. The feeding was conducted once every 3-4 hours, with 200-300ml each time. The total feeding volume was determined based on daily requirements. The feeding content was formulated by the nutritionists based on the patients condition and relevant guidelines to reach the energy demand as 20-25 kcal/kg/day and protein supplementation of 1.2-2.0 g/kg/day for both two groups. For patients with limited tube feeding compliance, we made appropriate adjustments to ensure that they were not at risk of severe malnutrition as much as possible.
224182848|NCT06393205|BEHAVIORAL|Routine treatment|"Including： Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training.~Pulmonary function training, including standing training, cough training, and diaphragm muscle training."
224308184|NCT05541991|DIETARY_SUPPLEMENT|single dose coated tablet Fruits & Fibres Rhubarbe with standardised rhubarb extract|coated tablet with a single dose of standardised rhubarb extract
224308185|NCT05541991|DIETARY_SUPPLEMENT|placebo coated tablet|coated tablet without active principle
224308186|NCT05541991|DIETARY_SUPPLEMENT|double dose coated tablet Fruits & Fibres Rhubarbe with standardised rhubarb extract|coated tablet with a double dose of standardised rhubarb extract
224308187|NCT02310282|DEVICE|Telemedicine|In-hospital telemedicine
224308188|NCT06709807|DRUG|CKD-378 25/1000mg|QD, PO
224182849|NCT00695318|DRUG|Fluocinolone Acetonide|0.2 µg/Day in study eye + Sham in fellow eye
223491201|NCT05146765|DEVICE|Mobile application|Device: Use of mobile application Participants will be instructed to use the speech therapy app for 30 minutes to one hour per day over a 4-week period.
223491202|NCT05146765|OTHER|Treatment as usual|The patients will follow the treatment as usual, including conventional stroke therapy if needed based on the medical guidelines.
223491203|NCT04175756|DEVICE|Caiman 5 articulating Maryland|Laparoscopic colorectal surgery
223491204|NCT06166823|OTHER|EMR alert|EMR alert for medication optimization
223491205|NCT05239572|COMBINATION_PRODUCT|screening, prevention and counselling|Screening in Intergenerational solidarity clubs in Myanmar and Vietnam and in Posbindu programme in Indonesia
223491206|NCT05867121|DRUG|RO7496353|RO7496353 will be administered as per the schedules specified in the respective arms.
223491207|NCT05867121|DRUG|Atezolizumab|Atezolizumab will be administered as per the schedules specified in the respective arms.
223491208|NCT05867121|DRUG|Capecitabine|Capecitabine will be administered as per the schedule specified in the respective arm.
223491209|NCT05867121|DRUG|S-1|S-1 will be administered as per the schedule specified in the respective arm.
223491210|NCT05867121|DRUG|Nivolumab|Nivolumab will be administered as per the schedule specified in the respective arm.
223491211|NCT05867121|DRUG|Oxaliplatin|Oxaliplatin will be administered as per the schedule specified in the respective arm.
223491212|NCT05867121|DRUG|Nab-paclitaxel|Nab-paclitaxel will be administered as per the schedule specified in the respective arm.
223491213|NCT05867121|DRUG|Gemcitabine|Gemcitabine will be administered as per the schedule specified in the respective arm.
223491214|NCT00297401|DRUG|ruboxistaurin|32 mg, QD, PO, up to 8 weeks
223491215|NCT00297401|DRUG|placebo|QD, PO, up to 8 weeks
223491216|NCT02588287|OTHER|Blood draws for tenofovir PK, renal function|
223491217|NCT06202183|BEHAVIORAL|Exercise Program|A 12 week, home-based, virtually supervised, aerobic and resistance exercise training program comprised of 36 sessions. Participants will be provided with a home stationary bike, resistance bands, and Fitbit. Virtually supervised sessions will be accessible via Zoom platform. For participants who do not have a device, a Wi-Fi-enabled tablet will also be provided.
223491218|NCT05948605|DEVICE|Empower Neuromodulation System|The Empower Neuromodulation System is designed to provide transcutaneous stimulation to the branches of a spinal nerve. The system comprised of three key components: (A) The Stimulator, (B) the Empower smartphone app, and (C) the Gel Patch. The smartphone application is used to coordinate treatment and record participant responses.
223491219|NCT00843882|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
223491220|NCT00843882|BIOLOGICAL|Epoetin Alfa|Given SC
223491221|NCT00843882|OTHER|Laboratory Biomarker Analysis|Correlative studies
223588062|NCT02075892|DIETARY_SUPPLEMENT|Mushroom Blend|Scivation
223588063|NCT02075892|DIETARY_SUPPLEMENT|Placebo|
224182850|NCT00695318|DRUG|Fluocinolone Acetonide|0.5 µg/Day in study eye +Sham in fellow eye
224205746|NCT04383769|OTHER|questionnaires survey|data will be collected from the medical records already existed in the hospital and community-based organization (CBO) systems and entered into case report form (CRF). The expected number of participants is 5000. For each participant, the data will be collected prospectively for 24 months and retrospectively up to 5 years from the screening date. This study has no intervention and will not alter ART services whether be standard or DSD-ART at hospitals.
224205747|NCT00403923|DIETARY_SUPPLEMENT|Lactose in water|
224205748|NCT02299661|DRUG|DS-1093a|DS-1093a, single oral doses up to 50 mg
223491222|NCT00843882|DRUG|Lenalidomide|Given PO
223491223|NCT06833736|DEVICE|"The See Yourself Differently app"|As the app has not been evaluated before in terms of its impact on dietary change, the first intervention group will have the app as it stands. The overall aim of the syd is to improve general wellbeing across several health-related domains, which is achieved through engaging with its main features (the daily plan, journal, user profile, and chat function).
223491224|NCT06833736|DEVICE|"The See Yourself Differently app + messages"|The plant-forward recipes and information pages available on the app will be made more salient for app users in this group through sending them via targeted messages in the chat function at specific times. Each day, the information pages will be sent at 09:30 and the recipes will be sent at 13:00.
223491225|NCT06833736|BEHAVIORAL|General information|The (no app) control group will be sent general health and sustainability information via email immediately after randomisation is done. To incentivise participation in both baseline and follow-up assessments, the control group will be offered lifetime access to the app and a summary of their self-reported food intake at week 10. The control group will be sent one email reminder halfway through (week 5) to remind them that they are involved in the study, provide them with instructions on the follow-up assessment, and that they will receive the intervention and dietary feedback at week 10.
223491226|NCT04652141|DIAGNOSTIC_TEST|AsthmaTuner|AsthmaTuner consists of a treatment-adjusting algorithm that gives patient immediate feedback on the status of symptom control (i.e. controlled, partly controlled or uncontrolled) and a treatment recommendation with an image of the correct inhaler or other type of medication and the dose based on lung function (FEV1) and symptom scores (0-4 points).
223491227|NCT04208919|BIOLOGICAL|Donor-derived DCreg|Regulatory dendritic cells that were prepared from a donor leukapheresis will be infused into liver transplant recipients 7 days prior to the start of immunosuppression weaning.
223491228|NCT02904343|DEVICE|domestic hemodialysis machine|WEGO, DBB-27C
223491229|NCT02904343|DEVICE|imported hemodialysis machine|Fresenius, 4008s
224205749|NCT00529165|PROCEDURE|injection-meal-interval|"The patient injects human insulin (as Actrapid from NovoNordisc) as usual in their insulin routine. The injection is subcutaneous and the dosage is dependent on the blood glucose monitoring. Patients will inject insulin previous every meal, with the following differences:~1. Group A: with injection-meal-interval: 50 patients educated to inject the insulin with an injection-meal-interval of 15 minutes~2. Group B: without injection-meal-interval: 50 patients educated to inject the insulin without injection-meal-interval~Cross-over will occur to the other group after 12 weeks. The follow up is 28 weeks."
224205750|NCT02032446|BIOLOGICAL|UMBILICAL CORD DERIVED MESENCHYMAL STROMAL CELLS (UC-MSC)|"pentostatin, dose 1 mg/m2~§ MSC doses:~1. 3 patients → 3 infusions of 1x106 cells /kg~2. 3 patients → 3 infusions of 2x106 cells /kg~3. 3 patients → 3 infusions of 3x106 cells /kg"
224182851|NCT04050891|DEVICE|combined supraclavicular and interscalene block|"Supraclavicular block An in plane approach, a 22G needle 75mm was advanced from lateral to medial to the corner pocket where the lower trunk commonly lies at this area between the subclavian artery medially, first rib inferiorly and the plexus superiorly then 10ml of the mixture local anesthetic was injected, the remaining volume was injected just above and lateral to the subclavian artery.~Interscalene block After local anesthetic infiltration of the skin, a 22G needle 75mm was inserted in plane approach from lateral to medial toward the inter-scalene groove between the anterior and middle scalene muscles. The anesthetic mixture 15 ml was injected toward C5, C6 cervical nerve roots aiming to block nerves escaped from supraclavicular nerve block."
224182852|NCT02098733|DRUG|Pioglitazone/glimepiride|Pioglitazone/glimepiride combination tablets
224182853|NCT00934752|DEVICE|Lutonix Paclitaxel-Coated Balloon|Percutaneous transluminal coronary angioplasty (PCTA)
224182854|NCT01711944|BEHAVIORAL|Problem-Solving Skills Training|8-session manualized intervention to provide problem-solving skills training in the context of childhood cancer.
224182855|NCT03395704|DRUG|LJPC-401|LJPC-401 subcutaneous injection, up to 20 mg weekly for 16 weeks. The minimum weekly dose will be 5 mg and the maximum weekly dose of LJPC-401 will be 20 mg.
224182856|NCT03395704|DRUG|Placebo|0.9% Sodium Chloride Injection, USP, or equivalent
224182857|NCT04789564|DIAGNOSTIC_TEST|cardiovascular magnetic resonance (CMR)|Testing CMR on patients of 7 days and 6 months after myocardial infarction
224182858|NCT00115622|DRUG|fluticasone furoate|
224182859|NCT02020213|DRUG|Posaconazole|400 mg po bid for 8 weeks
224182860|NCT01926366|DRUG|AZD6423|Drug: AZD6423 Single or Multiple doses via infusion.
224182861|NCT01926366|DRUG|Placebo|Placebo to match AZD6423 Single or Multiple doses of matching placebo delivered via infusion
224182862|NCT00000662|DRUG|Zidovudine|
224182863|NCT05044715|BEHAVIORAL|Treatment as Usual|"Treatment as usual-TAU groups include:~1. Mood Groups - General Process Groups~2. Anxiety Groups - Cognitive Behavioral Therapy~3. Body Image and Eating Concerns Groups~4. Reconciling Faith and Sexuality Groups"
224182864|NCT05044715|BEHAVIORAL|Compassion-Focused Therapy (CFT)|The CFT protocol assumes that participants have no prior experience with meditation, mindfulness, and self-compassion and teaches principles of each as well as skills such as guided meditations.
223491230|NCT05317546|DRUG|Cannabidiol|In counterbalanced order, 50 youth (ages 16-22) will receive 600mg of cannabidiol or placebo three hours before a neuroimaging and behavioral assessment paradigm, separated by an approximate 18-day washout period.
223491231|NCT03331250|DRUG|Eribulin|It may work by preventing the cancer cells from dividing and eventually cause the tumor cells to die
223491232|NCT05215587|DEVICE|TEVAR|A TEVAR stent graft will be placed in the descending aorta in order to cover the primary entry of the dissection.
223588064|NCT06695533|BEHAVIORAL|Diabetes self management workbook|The diabetes self-management workbook section used in this pilot study will focus on diet management, specifically carbohydrates, following ADA guidelines. It will include exercises based on the ADA diabetes plate method, aimed at helping subjects understand meal planning, food categories, portion sizes, goal setting, and the impact of foods on blood glucose levels. Activities will include word searches, crosswords, and goal-setting exercises. Subjects will begin the first section during a clinic visit. They can complete the workbook at home over three months, with input from subjects and Certified Diabetes Care and Education Specialists to refine the content.
224182865|NCT02628366|OTHER|Personalized Dialysate Temperature|Dialysis centres randomized to the intervention will provide temperature-reduced personalized hemodialysis. A nurse will set the temperature of the dialysate to 0.5°C below each patient's body temperature measured just before starting the dialysis treatment. We are aware that some dialysis machines (e.g. Fresenius 5008) are only able to modify dialysate temperature by 0.5°C increments. For centres with those machines, the nurse will set the dialysate temperature 0.5 to 0.9 °C below each patient's body temperature (measured before starting the hemodialysis treatment) to a minimum of 35.5°C.
224182866|NCT05057975|DEVICE|Sunrise|Use of the Sunrise device for three nights to register mandibular movements that will be automatically analysed using artificial intelligence.
224182867|NCT05057975|DEVICE|polysomnography|Reference protocol to diagnose OSA (in-lab or outpatient PSG)
224182868|NCT06724185|DIETARY_SUPPLEMENT|LP28 capsule|LP28 capsule : 5.0×10\^9 CFU/capsule
224182869|NCT06724185|DIETARY_SUPPLEMENT|Placebo Capsule|Maltodextrin
224182870|NCT01213511|PROCEDURE|Coronary artery bypass grafting with the use of minimal extracorporeal circulation|The MECC system (Maquet Cardiopulmonary, Hirlingen, Germany) consists of a pre-connected closed CPB circuit containing a RotaFlow centrifugal pump and a Quadrox D diffusion membrane oxygenator. A flow meter and a bubble sensor are integrated in the drive unit of the centrifugal pump. The system features a tip-to-tip heparin coating (Bioline Coating, Maquet Cardiopulmonary, Hirlingen, Germany). No arterial or venous line filters are included. Initial priming volume of the system is 500 mL, while using retrograde autologous priming (RAP) the circuit could be filled in with autologous blood, thus reducing hemodilution. Since no cardiotomy suction is used, shed blood is collected with a cell-saving device (Haemonetics Corp, Braintree, MA).
223491233|NCT04590963|DRUG|Monalizumab|Participants will receive IV infusion of monalizumab as stated in arm description.
223491234|NCT04590963|DRUG|Cetuximab|Participants will receive IV infusion of cetuximab as stated in arm description.
223491235|NCT04590963|OTHER|Placebo|Participants will receive IV infusion of placebo as stated in arm description.
224205751|NCT05031286|OTHER|Cutaneous thermal stimuli|Application of thermal stimuli of different intensities to the skin
224205752|NCT05597514|OTHER|3D printed educational model|Slide-based presention plus 3D printed airway suction model
224205753|NCT05597514|OTHER|Tranditional model education|Slide-based presention plus tranditional model
223491236|NCT05886894|DEVICE|Lotrafilcon B multifocal soft contact lenses|Commercially available soft (hydrophilic) contact lenses indicated for the correction of presbyopia, with or without myopia or hyperopia
223491237|NCT05886894|DEVICE|Comfilcon A multifocal soft contact lenses|Commercially available soft (hydrophilic) contact lenses indicated for the correction of refractive ametropia (myopia and hyperopia) and emmetropia with presbyopia
223491238|NCT05481151|DRUG|P1101 (Ropeginterferon alfa-2b-njft)|Ropeginterferon alfa-2b-njft
223491239|NCT05481151|DRUG|Ropeginterferon alfa-2b-njft (P1101)|Ropeginterferon alfa-2b-njft
224182871|NCT01213511|PROCEDURE|Coronary artery bypass grafting under conventional extracorporeal circulation|A standard open CPB circuit is used, consisting of uncoated PVC tubing, a hard-shell venous reservoir, a microporous membrane oxygenator (Dideco, Mirandola, Italy) and a roller pump (Stöckert S3, Munich, Germany). The circuit contains a 40 μm arterial line blood filter (Dideco, Mirandola, Italy) and it is primed with 1500 mL of a balanced crystalloid/colloid solution (1000 mL of Ringer's solution, 200 mL of mannitol 20%, and 300 mL of hydroxyethyl starch 6%). Cardiotomy as well as sump sucker are integrated to the circuit.
224182872|NCT00490477|DEVICE|Polymyxin -B fiber hemoperfusion system|two hours treatment for two days
224182873|NCT05637749|OTHER|Medical serious game intervention (educational)|Medical serious game designed to facilitate the rehearsal of diabetes management knowledge. Players are presented with a colony of individuals, all of whom have some form of diabetes, and are tasked to manage food, insulin, and medication intake throughout the day. The intervention may be played with a facilitator.
224182874|NCT05637749|OTHER|Medical serious game intervention (educational)|Medical serious game designed to facilitate the rehearsal of diabetes management knowledge. Players are presented with a colony of individuals, all of whom have some form of diabetes, and are tasked to manage food, insulin, and medication intake throughout the day. The intervention may be played alone.
224182875|NCT03347461|DRUG|Otiprio|Otiprio is a single-dose, physician-administered, sustained-exposure otic fluoroquinolone antibacterial for the treatment of pediatric patients with bilateral otitis media with effusion undergoing tympanostomy tube placement surgery. Otoprio (6% ciprofloxacin, 60 mg/mL) will be administered through the tube lumen by the otolaryngologist immediately after tympanostomy surgery.
224182876|NCT03347461|DRUG|Ciprodex|Ciprodex is a combined antibiotic and steroid ear drop used to treat otitis media with tympanostomy tubes. Four drops of Ciprodex (0.14mL) instilled by the otolaryngologist into the affected ear immediately after tympanostomy surgery. Each mL of Ciprodex contains ciprofloxacin hydrochloride 0.3 % (equivalent to 3 mg ciprofloxacin base) and dexamethasone 0.1 % equivalent to 1 mg dexamethasone
224182877|NCT06319677|DEVICE|ECMO treatment|Critically ill patients were treated with ECMO while receiving antimicrobial therapy
224182878|NCT02582008|DRUG|Bupropion Hydrochloride|Given PO
223491240|NCT06556121|PROCEDURE|Saddle block|The injected solution will be comprised of 5mg of heavy Bupivacaine 0.75% plus 100mcg of Morphine will be injected into the intrathecal space.
223491241|NCT06556121|PROCEDURE|pudendal nerve block|As part of the analgesic plan, all patients will receive a multimodal analgesic regimen with acetaminophen, NSAIDs and opioids plus a surgeon-administered pudendal nerve block by anatomical landmarks with a mixture of Local Anesthetic as follows: 50mL of Normal Saline, 30mL of 0.25% Bupivacaine with epinephrine 1:200.000 and 20mL Lidocaine 1%. A volume of 20 mL of this mixture is used for the pudendal nerve block, and infiltration of the surgical incision and bilateral spermatic cord block is performed with an additional 20 mL of the same mixture of local anesthetic. 30ml of the solution is used to soak the vaginal plug made of gauze that is put inside the vaginal canal by the end of the procedure.
223491242|NCT06371924|DEVICE|Machine Perfusion|The quality of DCD organs can be improved by replacing the icebox (static cold storage or SCS), which remains the main approach to preserve the livers after having been retrieved, by strategies that perfuse the livers in a machine (machine perfusion or MP). There are currently 3 MP strategies employed in the clinic: normothermic regional perfusion (NRP) is used in the donors by perfusing the liver with the donor's blood at 37 degrees Celsius, and normothermic (NMP) or hypothermic (HOPE) perfusion are used in the procured livers out of the body (using warm or cold perfusion fluids, respectively). To date, no controlled objective comparisons of these different MP strategies have been undertaken and the doctors do not have a good understanding of their mechanisms of action.
223491243|NCT05920759|DIAGNOSTIC_TEST|Cerebral blood flow|Transcranial Doppler (TCD) is a non-invasive diagnostic tool used to estimate cerebral blood flow velocity (CBFV), cerebral autoregulation, cerebrovascular reactivity (CVR), intracranial pressure, cerebral perfusion pressure as well as other indicators of cerebral hemodynamics and autoregulation.
223491244|NCT06557772|DRUG|Amlitelimab|Pharmaceutical form: Injection solution Route of administration: SC injection
223491245|NCT06557772|DRUG|Placebo|Pharmaceutical form: Injection solution Route of administration: SC injection
223491246|NCT06557772|DIETARY_SUPPLEMENT|SIGE|Pharmaceutical form: Capsule Route of administration: Oral
223491247|NCT06557772|DIETARY_SUPPLEMENT|Gluten-free product (GFP)|Pharmaceutical form: Capsule Route of administration: Oral
223491248|NCT04057365|DRUG|Nivolumab|Nivolumab is believed to work by attaching to and inhibiting a specific protein in the cancer that controls parts of the immune system (the system in the body that fights off infections and diseases) by shutting down certain immune responses. The investigators believe that nivolumab will inhibit the protein, thus allowing the immune cells to recognize and destroy cancer cells.
223491249|NCT04057365|DRUG|DKN-01|DKN-01 is believed to work by attaching to and inhibiting (stopping) a specific pathway in the cells that is responsible for processes such as cell growth
223491250|NCT02129543|PROCEDURE|Blood Draw|Whole blood samples will be collected from study subjects for immune cell and plasma analysis per protocol.
223491251|NCT06499519|DIAGNOSTIC_TEST|SpinChip hs-cTnI|SpinChip Platform, consisting of the SpinChip hs-cTnI test (self-contained cartridge) and SpinChip Analyzer (instrument)
223491252|NCT04607421|DRUG|Encorafenib|75 mg capsules
224182879|NCT02582008|OTHER|Laboratory Biomarker Analysis|Correlative studies
224182880|NCT02582008|DRUG|Nicotine Replacement|Given NRT
224182881|NCT02582008|OTHER|Quality-of-Life Assessment|Ancillary studies
224182882|NCT02582008|OTHER|Questionnaire Administration|Ancillary studies
224182883|NCT02582008|DRUG|Varenicline|Given PO
224182884|NCT01491711|DRUG|Methylaminolevulinate PDT in 2 sessions|The methylaminolevulinate creme is applied to the tumour with a margin of 1 cm, ± 1-2 mm thick. Tegaderm®, a gauze and tinfoil is placed over the area to prevent contact with UV light. After 4 hours the area is illuminated with Aktilite (632 nm, 570-670 nm, 75 J/cm2). The light intensity at the lesion surface should not exceed 200 mW/cm2. During illumination a fan is used to cool the treatment site. After the first treatment the skin area is covered to prevent exposure to daylight during 48 hours. After one week (on day 8), the same procedure is repeated. After the treatment the skin area is covered to prevent exposure to daylight during 48 hours. A side-effect of the treatment is a burning pain during illumination and slight erythema afterwards lasting a few days. Sometimes blistering occurs.
224182885|NCT01491711|DRUG|Fractionated 5-aminolevulinic acid hydrochloride 20% gel PDT|The 5-ALA HCl 20% gel is applied to the tumour with a margin of 1 cm, ± 1-2 mm thick. Tegaderm®, a gauze and tinfoil is placed over the area to prevent contact with UV light. After 4 hours the area is illuminated with Aktilite (632 nm). During illumination a fan is used to cool the treatment site. The treatment site is covered again with Tegaderm for 2 hours after first treatment, whereupon a second illumination with the same light takes place. A side-effect of the treatment is a burning pain during illumination and slight erythema afterwards lasting a few days. Sometimes blistering occurs. Patients are advised to avoid direct sunlight two days after treatment.
224182886|NCT02409251|BEHAVIORAL|Education and feedback|
224182887|NCT01288742|DRUG|Rosuvastatin|One 10-mg tablet for 1 day (Trt C).
224182888|NCT01288742|DRUG|Rosuvastatin|One 10-mg tablet together with 1 capsule of TMC435 (150 mg) on Day 7 of Trt D.
224182889|NCT01288742|DRUG|TMC435|One 150-mg capsule once daily for 7 days (Trts B and D).
224182890|NCT01288742|DRUG|Digoxin|One 0.25-mg tablet together with 1 capsule of TMC435 (150 mg) on Day 7 of Trt B.
224182891|NCT01288742|DRUG|Digoxin|One 0.25-mg tablet for 1 day (Trt A)
224182892|NCT04591704|OTHER|hospitalisation, necessity of ICU, mortality rate, lung involvement|hospitalisation, necessity of ICU, mortality rate, lung involvement
224182893|NCT02300844|DRUG|NNC0174-0833|"Subjects will receive a single s.c. (subcutaneous/under the skin) dose of NNC0174-0833.~Up to nine dose levels of single s.c. doses of NNC0174-0833 are planned to be investigated."
224182894|NCT02300844|DRUG|placebo|Subjects will receive a single s.c. (subcutaneousl/under the skin) dose.
224182895|NCT00386529|DRUG|Aspirin enteric coated pellests 100mg|
224182896|NCT03961724|DEVICE|magnetic resonance image (MRI)|serum metabolomics
223491253|NCT04607421|DRUG|Cetuximab|Injection for intravenous use 100 mg/vial, 200 mg/vial, or 500 mg/vial
223491254|NCT04607421|DRUG|Oxaliplatin|Powder for solution for intravenous use 50 mg/vial, 100 mg/vial, or 200 mg/vial
223491255|NCT04607421|DRUG|Irinotecan|Solution for intravenous infusion 40 mg/vial, 100 mg/vial, or 300 mg/vial
223491256|NCT04607421|DRUG|Leucovorin|Injection 50 mg/vial, 100 mg/vial, 200 mg/vial, or 350 mg/vial
223491257|NCT04607421|DRUG|5-FU|Injection for intravenous use 250 mg/vial, 500 mg/vial, or 1000 mg/vial
223491258|NCT04607421|DRUG|Capecitabine|150 mg or 500 mg Tablet
223491259|NCT04607421|DRUG|Bevacizumab|Optional Injection for intravenous use 100 mg/vial or 400 mg/vial
223491260|NCT06433037|DIETARY_SUPPLEMENT|Chicory inulin|Chicory inulin (12g/day) divided over two dosages (6g per dose)
223491261|NCT06433037|DIETARY_SUPPLEMENT|Resistant dextrin|Resistant dextrin (14g/day) divided over two dosages (7g per dose)
223588065|NCT01441700|PROCEDURE|Prone and Supine emergence from anaesthesia|Aims: The aim of this study was to compare haemodynamic changes and to evaluate the incidence of coughing, laryngospasm, loss of monitoring in patients undergoing lumbar disc surgery extubated in prone position and supine position. Settings and design: This open-level prospective randomized study was carried out in 50 patients who were admitted for elective lumbar surgery. Methods: The patients were randomly allocated to one of the two groups of 25 each at conclusion of surgery. First group was extubated in prone position and second in supine position at conclusion of surgery. Supine group patients were rolled back and prone group patients were left undisturbed. Extubation was done after complete reversal of neuromuscular block. Heart rates, Mean Arterial Pressure were noted at various points of time. Coughing, laryngospasm, vomiting, monitor disconnection if any were also noted. Statistical methods: Data was analyzed using
224182897|NCT01475227|DRUG|1 Solvazinc tablet, day 2 to day 15|Zinc sulphate 125mg, day 2 to day 15
224182898|NCT01475227|DRUG|1 Solvazinc tablet, day 15 to day 28|Zinc sulphate 125mg, day 15 to day 28
224182899|NCT00918905|DEVICE|Telemonitor|"Within 24 hours after the patient was discharged due to exacerbation in COPD the telemedicine equipment was installed at the patient's home. The patients were included for four weeks followed by a visit to the outpatient clinic with. The patient had the equipment for approximately one week and had at least one follow-up phone call. Televideo consultations could be made from 8 AM to 3 PM every day. The patient could call the telemedicine department in the same period.~During the televideo consultations the nurse made clinical observations (i.e. dyspnoea, anxiety), measured saturation and lung function and informed the patients how to prevent exacerbations. The telemedicine consultation was agreed on with the patient and the telemedicine nurse from day to day."
224182900|NCT01075568|DIETARY_SUPPLEMENT|Nutrigal Okara - 100|
224182901|NCT00434876|DRUG|Quetiapine XR|Quetiapine is a second generation antipsychotic medication, which has also recently shown to be associated with properties of mood stabilization in bipolar disorder.
224182902|NCT00434876|DRUG|Placebo.|Inactive or inert pill which will be used as a comparator.
224182903|NCT00457093|DRUG|glargine|
224182904|NCT00457093|DRUG|detemir|
224182905|NCT07058740|PROCEDURE|early cholangiography|We perform cholangiography on the early group in advance
224182906|NCT02510976|DRUG|prucalopride|
224182907|NCT02510976|DRUG|placebo|
224182908|NCT04216628|OTHER|Amniotomy|Artificial rupturing of membranes and IV infusion of Oxytocin
223491262|NCT06433037|DIETARY_SUPPLEMENT|Seaweed polysaccharide|Seaweed polysaccharide (1g/day) divided over two dosages (0.5g per dose). Additionally contains 7g/day of placebo as a volumetric and isocaloric filler.
223491263|NCT06433037|DIETARY_SUPPLEMENT|Placebo|Maltodextrin (7g/day) will be provided in two divided doses (3.5g per dose)
224182909|NCT05273203|BEHAVIORAL|FIM-1|A football group (12 participants/session) will participate in 60 minutes football training that will contain warm-up, football technical drills and exercises, fitness exercises and football game.
223491264|NCT06565962|OTHER|Educaiton group|The experimental group will be made to watch training videos prepared by AFAD on disaster preparedness, disaster moment and post-disaster by using virtual reality goggles.
223491265|NCT06565962|OTHER|control group|The control group will receive standard care. The standard care programme will include brochures and guidance.
223491266|NCT05775289|DRUG|Tobemstomig|Participants will receive intravenous (IV) tobemstomig for four 21-day cycles
223491267|NCT05775289|DRUG|Pembrolizumab|Participants will receive IV pembrolizumab four 21-day cycles
224182910|NCT05273203|BEHAVIORAL|FIM-2|A football group (12 participants/session) will participate in 60 minutes football training that will contain warm-up, football technical drills and exercises, fitness exercises and football game.
224182911|NCT05273203|BEHAVIORAL|FIM-3|A football group (12 participants/session) will participate in 60 minutes football training that will contain warm-up, football technical drills and exercises, fitness exercises and football game.
224182912|NCT05273203|BEHAVIORAL|Control|No football training will be performed during 6 months period. Participation only in measurements at baseline and at 6 months.
224182913|NCT02406131|OTHER|Remote Ischemic Preconditioning|standard blood pressure cuffs applied to upper limb . The cuff will be inflated to 200 mmHg applied for 5 minutes alternating with 5 minutes rest to the total of 4 cycles
223491268|NCT05775289|DRUG|Paclitaxel|Participants will receive IV paclitaxel Q3W for four 21-day cycles
223491269|NCT05775289|DRUG|Pemetrexed|Participants will receive IV pemetrexed Q3W until disease progression or unacceptable toxicity
223491270|NCT05775289|DRUG|Carboplatin|Participants will receive IV carboplatin Q3W for four 21-day cycles
223491271|NCT03976375|BIOLOGICAL|Pembrolizumab|IV infusion of pembrolizumab at 200 mg
223491272|NCT03976375|DRUG|Lenvatinib|Oral capsules (unit strength: 4 and 10 mg) at 20 mg or 24 mg total daily dose.
223491273|NCT03976375|DRUG|Docetaxel|IV infusion of docetaxel at 75 mg/m\^2.
223491274|NCT05757856|DRUG|NDX-3315 and NDX-3324|Oral solution
223491275|NCT06965530|DIETARY_SUPPLEMENT|Clinic-Based Medically Tailored Groceries (CB-MTG)|Patients have the opportunity to pick up medically tailored groceries every other week at the Food Is Medicine Clinic or Market associated with their provider.
223491276|NCT06965530|DIETARY_SUPPLEMENT|Home Delivered Medically Tailored Groceries (HD-MTG)|Patient receive home delivered medically tailored groceries every two weeks during pregnancy and up to 6 months post-delivery.
223588066|NCT06872515|BEHAVIORAL|Exercise and Nutrition|"The exercise and nutrition intervention will last up to 8 weeks and will include:~* 3-5 times per week of resistance training and 3-5 times per week of aerobic training. The prescribed exercise will be personalized based on the participant's baseline functionality.~* IMPACT Advanced Recovery nutrition supplement drinks: 2 per day for 5 consecutive days leading up to surgery."
223588067|NCT06872515|BEHAVIORAL|Usual Care Group|The CONT group will not receive any intervention during study participation and undergo usual medical treatment and surveillance during the duration of the study.
223588068|NCT05968755|DEVICE|A chatbot designed to promote PrEP awareness and uptake for Black MSM|Participants in the intervention group will have access to a theory-informed (Self-Determination Theory) chatbot and receive an automated personalized question message (root-node message) from the chatbot. The root-node messages are questions written into the chatbot algorithms to initiate interactive communication with participants. In each round of the interactive communication, the chatbot will provide automated personalized PrEP-related information, autonomous motivation, and psychological needs based on Self-Determination Theory constructs.
223588069|NCT05968755|OTHER|General educational messages|Participants in the control group will received general education messages from a research assistant including healthy diet, exercise, and COVID-19 prevention. The frequency of contact will be pre-specified by participants in interviews prior to the RCT.
224182914|NCT00758394|DRUG|Fluoride|Brush two times a day for 4 days.
224182915|NCT00758394|DRUG|Triclosan/Fluoride|Brush two times daily for 4 days
223491277|NCT06965530|DIETARY_SUPPLEMENT|Home Delivered Medically Tailored Groceries plus Education (HD-MTG_PLUS)|Patients receive home delivered medically tailored groceries every two weeks during pregnancy and up to 6 months post-delivery, plus also receives additional nutrition and culinary education and support throughout the trial.
223491278|NCT06965010|BEHAVIORAL|Measurement-based care|Patients will complete MBC measures with their treatment provider and follow-up surveys conducted at baseline and monthly intervals. Both providers and patients will use the Greenspace Mental Health tools to regularly assess patient-reported symptoms, review results together, and collaboratively design individualized treatment plans. Providers will implement MBC to guide treatment adjustments based on these assessments.
223491279|NCT06965010|BEHAVIORAL|Measurement As Usual|Patients will participate in Measurement As Usual (MAU) via the existing processes available within treatment sites. Currently, patients are assessed and participate in semi-structured interviews at 6-month increments to assess progress and appropriateness of level of care.
224182916|NCT00758394|DRUG|Triclosan/Fluoride|Brush twice daily for 4 days
224182917|NCT00758394|DRUG|Triclosan/Fluoride|Brush twice daily for 4 days
223491280|NCT06205030|DRUG|anti-diabetic herbal drug|All the volunteers directed to the laboratory so that biochemical tests can be performed on them before taking the drug. Volunteers are asked to take the received NOSHIN SHAHD drug 20 ml three times per day after food. at the end of the six week. then, the sample collection will be done to review all the tests of the end stage of receiving the drug.
224182918|NCT03377985|PROCEDURE|brachial plexus block|
224182919|NCT06457529|DIAGNOSTIC_TEST|conventional treatment with Prolotherapy|"Group A got prolotherapy along with conven¬tional treatment, which includes ultrasonic therapy for 10 minutes. The intensity will be 3MHz at 1.0 watts/cm2.~Prolotherapy is an injection treatment used to relieve pain. Your healthcare provider will inject a small amount of an irritant into your body. Dextrose (sugar) solution is the most commonly injected irritant. Proponents of prolotherapy claim it relieves pain by jumpstarting your body's natural healing abilities."
223491281|NCT05065996|DIAGNOSTIC_TEST|Aortic MRI + 4D flow MRI|Together with routine aortic MRI specific 4D flow MRI sequence will be done.
223491282|NCT06255392|DRUG|Fluzoparib|Fluzoparib capsules appropriate dose oral, each treatment cycle defined as 3 weeks (21 days).
223491283|NCT06255392|DRUG|Apatinib Mesylate|Apatinib Mesylate oral; each treatment cycle defined as 3 weeks (21 days).
223491284|NCT06255392|DRUG|Capecitabine tablets|Capecitabine tablets, reasonable dosage with reference to guidelines, each treatment cycle defined as 3 weeks (21 days).
224182920|NCT06457529|OTHER|Dry Needling and conventional treatment|"Group B Subjects in Group B will get Dry Needling along with conventional treatment, which includes ultrasonic therapy for 10 minutes. The intensity will be 3MHz at 1.0 watts/cm2.~Trigger-point dry needling is an invasive procedure where a fine needle or acupuncture needle is inserted into the skin and muscle"
224182921|NCT02045615|PROCEDURE|Proposed technique for removal of the Wichita Fusion Nail|
224182922|NCT03968588|DRUG|Tacrolimus(reduced), Mycophenolate mofetil(standard)|tacrolimus target trough blood level: 3\~8ng/mL MMF dose: 1.5\~2g/d
224182923|NCT03968588|DRUG|Tacrolimus(standard), Mycophenolate mofetil(reduced)|tacrolimus target trough blood level: 5\~15ng/mL MMF dose: 0.5\~1g/d
224182924|NCT04695444|DEVICE|nasotracheal tube (Ring-Adair-Elwin)|different materials for nasotracheal intubation conventional PVC tube
224182925|NCT04695444|DEVICE|nasotracheal tube (Ring-Adair-Elwin)|different materials for nasotracheal intubation conventional PVC tube with rubber suction catheter
224182926|NCT04695444|DEVICE|nasotracheal tube (portex)|different materials for nasotracheal intubation velvet soft PVC tube.
224182927|NCT04840914|DRUG|LY3461767|Administered SC.
224182928|NCT04840914|DRUG|Placebo|Administered SC.
224182929|NCT00148980|DEVICE|DBM for creation of bone marrow microenvironment|
224182930|NCT01197495|DEVICE|hyaluronic acid gel|Dosage per Investigator's discretion to obtain lip treatment gel; 1 touch-up treatment is allowed 14 to 30 days after initial treatment. Repeat treatment occurs at month 12. Subjects in the control group start with treatment at month 3. Maximum total volume per subject is 4.8 mL for initial and touch-up treatment combined.
224182931|NCT00078455|DRUG|ILX651|
224182932|NCT05008302|PROCEDURE|hand motor coordination in a sitting positin|Before each test, the patient was instructed on how the exercise should be done. The test consisted of two motor tasks, carried out in two different starting positions: sitting and lying down (supine). During the first examination, the subject sat on the therapeutic table (without back support), feet resting on the floor. The upper limb was to be examined in adduction, with the elbow bent in the intermediate position between pronation and supination of the forearm. In the supine position, the upper limb was stabilized at the subject's body (adduction in the humeral joint, elbow flexion in the intermediate position).
224182933|NCT04449614|PROCEDURE|Thoracoscopic CPAM resection|Surgical removal of lung lesion
224182934|NCT00982800|DRUG|Gabapentin|200mg 3x/day for 3 days (9 doses total)
224182935|NCT00982800|DRUG|Placebo Sugar Pill|
224182936|NCT00195702|BIOLOGICAL|Adalimumab|Self-administered, subcutaneous injection of 20 mg adalimumab (1.6 mL/injection) once weekly (ew) for up to 52 weeks.
224182937|NCT00195702|BIOLOGICAL|Adalimumab|Self-administered, subcutaneous injection of 40 mg adalimumab (1.6 mL/injection) every other week (eow) for up to 52 weeks.
224182938|NCT00195702|DRUG|Placebo|Self-administered, subcutaneous injection of placebo (1.6 mL/injection) once weekly (ew) for up to 52 weeks.
224182939|NCT00195702|BIOLOGICAL|Adalimumab|Self-administration, subcutaneous (SC) injection of adalimumab 20 mg (1.6 mL/injection) once weekly (ew) for 52 weeks, followed by self-administration, SC injection of adalimumab 40 mg (0.8 mL/injection) every other week (eow) for up to Week 520.
224182940|NCT00195702|BIOLOGICAL|Adalimumab|Self-administration, subcutaneous (SC) injection of adalimumab 40 mg (1.6 mL/injection) every other week (eow) (with a placebo 1.6 mL/injection on alternate weeks) for 52 weeks, followed by self-administration, SC injection of adalimumab 40 mg (0.8 mL injection) eow for up to Week 520.
224182941|NCT00195702|BIOLOGICAL|Adalimumab|Self-administration, subcutaneous (SC) injection of placebo solution (1.6 mL/injection) once weekly (ew) for 52 weeks, followed by self-administration, SC injection of adalimumab 40 mg (0.8 mL/injection) every other week (eow) for up to Week 520.
224182942|NCT03721549|BIOLOGICAL|Norwalk GI.1 Virus|Norwalk virus causes viral gastroenteritis, which is also known as acute nonbacterial gastroenteritis, food poisoning, food infection, or stomach flu.
224182943|NCT03066661|DRUG|Entrectinib|Open-label expanded access, capsules
224182944|NCT05640141|PROCEDURE|MRI evaluation|"Multimodal MRI evaluation :~* T1 structural,~* Resting echo planar imaging~* Diffusion-weighted imaging~* Arterial sping labeling~* Fluid-attenuated inversion recovery"
224182945|NCT05640141|BEHAVIORAL|Actimetry & IMU|"Evaluation of daily activities and life rythms (physical activity, inactivity, sleep) using actimeters (Motion 8), inertial sensors (GaitUP) and questionaires during 14 days :~* Actimetry : evaluation of daily activity and inactivity, sleep rythms~* Inertial sensors : gait evaluation during daily activities~* Questionaires : sleep (Spiegel \& St Mary's Hospitral) and fatigue (MFI-20)"
224182946|NCT05640141|BEHAVIORAL|Gait evaluation|"Evaluation of gait characteristics (spatio-temporal parameters \& non-linear characteristics) in virtual environment :~* Locomotor simple task : gait only in congruent environment~* Locomotor dual task : gait in similar environment combined with a visually displayed Stroop task~* Sensorimotor gait adaptaition : evaluation of the adaptation capability throughout a split-belt treadmill sequence (realized in simple or dual -combined with the visual Stroop task-)"
223491285|NCT06255392|DRUG|Vinorelbine Tartrate Oral|For the first three courses: reasonable dosage with reference to guidelines. After 3 courses of medication, it is recommended to increase the dose of vinorelbine tartrate once a week. Each treatment cycle defined as 3 weeks (21 days).
223491286|NCT06255392|DRUG|Eribulin mesylate injection|Eribulin, reasonable dosage with reference to guidelines, each treatment cycle defined as 3 weeks (21 days).
223491287|NCT06255392|DRUG|Gemcitabine Hydrochloride|Gemcitabine, reasonable dosage with reference to guidelines, each treatment cycle defined as 3 weeks (21 days).
223491288|NCT06255392|DRUG|Paclitaxel-albumin|Paclitaxel-albumin, reasonable dosage with reference to guidelines, each treatment cycle defined as 3 weeks (21 days).
223491289|NCT06292741|DEVICE|Sudoscan|recording of sudomotor function and pupillary reactivity
223491290|NCT03890432|DEVICE|GLUCOSAFE 2|Use of GLUCOSAFE 2 software for nutrition management and insulin-therapy
223491291|NCT03890432|DEVICE|Local protocol control group with routine care|Use of the local protocols (electronic or paper version) for nutrition management and blood glucose control.
223491292|NCT03890432|DEVICE|Historical control group with routine care|Use of the local protocols (electronic or paper version) for nutrition management and blood glucose control.
223491293|NCT03502967|DRUG|Hyperpolarized [1-13C] Pyruvate|Bolus injection of study drug
223491294|NCT03502967|DRUG|Hyperpolarized [2-13C] Pyruvate|Bolus injection of study drug
224182947|NCT05640141|BEHAVIORAL|Neuropsychological evaluation|"Complete neuropsychological examination including attentional and executive functions, learning and retrieval abilities in episodic memory and general cognitive skills :~* Divided attention (TAP; test of attentional performance)~* California Verbal Learning Test~* The Rey-Osterrieth Complex Figure~* Symbol search and coding (WAIS-IV)~* Go/No-go (TAP)~* Flexibility (TAP)~* Original task of multimodal integration~* Verbal fluencies (GREFEX)"
224182948|NCT03044730|DRUG|Capecitabine|Given PO
224182949|NCT03044730|OTHER|Laboratory Biomarker Analysis|Correlative studies
223491295|NCT06542198|DIAGNOSTIC_TEST|Mannitol Infusion (blinded)|1 g of mannitol per kg body weight is infused in 30 minutes (≙ 5 ml/kg body weight), with an upper limit of 80 g, equivalent to a body weight of 80 kg or a volume of 400 ml. The solution used for infusion is 20% mannitol in water for injection and is administered at a rate of 0.17 ml/kg/min.
223491296|NCT06542198|DIAGNOSTIC_TEST|Placebo Infusion (blinded)|0.9% saline will be administered in the same amount as the mannitol dose infusion (= 5 ml/kg body weight), with a rate of 0.17 ml/kg/min in 30 minutes, with an upper limit of 400 ml (equivalent to a body weight of 80 kg).
223491297|NCT06542198|DIAGNOSTIC_TEST|Mannitol Infusion (open label)|1 g of mannitol per kg body weight is infused in 30 minutes (≙ 5 ml/kg body weight), with an upper limit of 80 g, equivalent to a body weight of 80 kg or a volume of 400 ml. The solution used for infusion is 20% mannitol in water for injection and is administered at a rate of 0.17 ml/kg/min.
223491298|NCT06543316|PROCEDURE|Low Thermal Plasma (LTP) Treatment|For patients randomized to the LTP group, the first LTP treatment will be administered during the initial esophagogastroduodenoscopy (EGD) using a single-use 2.3 mm filtered argon plasma coagulation (FiAPC probe). The argon plasma will be applied at low power settings (\~1 W) to the ulcerated areas using pulsed APC effect 0.1.
223491299|NCT06543316|OTHER|Standard of Care Ulcer Treatment (typically PPI Administration)|Standard of care for treatment of ulcers is administration of a proton pump inhibitor (PPI). For patients in the SOC group whose ulcers have not healed completely by the second follow-up at 8 weeks, crossover to LTP treatment will be offered. This treatment will follow the same procedure as the initial LTP treatment.
223491300|NCT05411666|PROCEDURE|Saline solution maintenance of the CVC|"Saline solution maintenance of the Central venous catheter (CVC) - Celsite IMPLANTOFIX from B\|Braun, according to local standard procedures."
223491301|NCT05411666|PROCEDURE|No maintenance of the CVC|"No maintenance of the Central venous catheter (CVC) - Celsite IMPLANTOFIX from B\|Braun. Just visual inspection to local site of CVC insertion."
223491302|NCT01063114|RADIATION|proton beam radiation|Given once a day, 5 days a week (Monday-Friday)
223491303|NCT06348225|BEHAVIORAL|Exercise|Participants will walk on a treadmill for 30 minutes at 55-60% of heart rate reserve. The treadmill will be set at 2mph and 2% grade, then be adjusted in the first 5 minutes to achieve target heart rate.
223491304|NCT06348225|OTHER|Heat Therapy|Participants will place their legs in a deep leg bath (mid-calf) set to 42C for 45 minutes.
223491305|NCT06348225|OTHER|Sham leg bath|Participants will place their legs in a deep leg bath (mid-calf) set to 36C for 45 minutes.
223491306|NCT04115098|DRUG|Celecoxib|Celecoxib 200 mg capsules twice daily (BID) All 3 medications will be over-encapsulated in identical opaque capsules
223491307|NCT04115098|DRUG|Naproxen|Naproxen 500 mg tablets twice daily (BID) All 3 medications will be over-encapsulated in identical opaque capsules
223491308|NCT04115098|DRUG|Meloxicam|Meloxicam 7.5 mg tablets twice daily (BID) All 3 medications will be over-encapsulated in identical opaque capsules
223491309|NCT03346135|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo standard of care ASCT with a conditioning regimen of melphalan
223491310|NCT03346135|BIOLOGICAL|Daratumumab|Given IV
224182950|NCT03044730|BIOLOGICAL|Pembrolizumab|Given IV
224308189|NCT02098096|OTHER|Negative Work|"Exercise will be performed twice per week for 12 weeks and exercise intensity will be progressed in three phases. These phases are:~1. Familiarization~2. Acclimatization~3. Progression~Exercise volume will be 3 sets of 10 repetitions (progressing to 4 sets at Week 6) for the knee flexors and extensors.~All exercise will be supervised by a physical therapist and performed on a Biodex isokinetic dynamometer."
223491311|NCT03346135|OTHER|Laboratory Biomarker Analysis|Correlative studies
223491312|NCT03346135|DRUG|Melphalan|Undergo standard of care ASCT with a conditioning regimen of melphalan
223491313|NCT05785078|BEHAVIORAL|Educational session about vaccinations|An educational session about maternal and childhood vaccinations was held in the context of the Childbirth Preparation Course held monthly at the FPG. In this occasion, on-site flu vaccination was offered to pregnant women attending the course and their partners, if present.
223491314|NCT06084234|DIAGNOSTIC_TEST|GALAD|GALAD is a 3 biomarker panel incorporating AFP, AFP-L3% and DCP (all FDA approved), with patient age and sex.
223491315|NCT06084234|DIAGNOSTIC_TEST|Liver Ultrasound with or without AFP|This intervention consists of current standard of care ultrasound based surveillance with or without alpha-fetoprotein measurement.
223491316|NCT05473598|BEHAVIORAL|Stand Down app|Patients in this condition will receive Usual Care (UC) and be provided a unique code and password to access Stand Down. The app is based on principles of motivational enhancement and cognitive-behavioral therapies and comprises 7 modules organized around 4 goals: 7 modules organized around 4 goals: (i) Enhance awareness of drinking patterns (assessment and personalized feedback), (ii) Establish and monitor progress towards drinking goal - i.e., moderation or abstinence, (iii) Manage cravings and other problems using in-the-moment tools, and (iv) Connect users with other types of support. App usage will be tracked by the research team for the duration of the study (32 weeks).
223491317|NCT05473598|BEHAVIORAL|Peer-Supported Stand Down|Patients assigned to this condition will receive UC and access to Stand Down, plus four phone sessions from a Peer over 8 weeks. Sessions will be bi-weekly, approx. 15-30 minutes in length, and focus on enhancing patients' engagement with the app.
223491318|NCT05473598|OTHER|Usual Care|All patients, regardless of condition, will have access to usual care for hazardous drinking in primary care. In this setting, usual care entails a spectrum of alcohol-related services including annual screening for hazardous drinking, brief intervention following a positive screen (advice from a provider to reduce their drinking), and referral (as needed) to specialty AUD treatment.
223491319|NCT05852054|BEHAVIORAL|OB Provider Clinical Decision Support (CDS)|When an eligible patients' chart is opened by a provider, the provider will be alerted to counsel patients about future risk for T2D and hypertension and the need to establish a primary care medical home. The alert will include a 'referral' to primary care and a brief guide with 'key points for counseling'. For patients with prior GDM, this will also include an option to order guideline-recommended oral glucose tolerance test (OGTT) with a single click.
223588070|NCT06701578|OTHER|Safe and Sound Protocol|Listening to specially designed filtered and modulated music that is tailored to enhance the individual's auditory system's ability to process and respond to auditory stimuli for up to five hours.
224182951|NCT01388114|DEVICE|Electrosensing Antibody Probe System (e- Ab sensing)|Electrosensing antibody probing system (e- Ab sensing), which was developed for the rapid and sensitive detection of hapten, proteins or viral antigen in medical samples, will be used for analyzing the interaction kinetics between anti-procalcitonin antibody and procalcitonin in the serum of the patients. The system incorporates the use of engineered semiconductive antibodies or virus in vertical and lateral chip (eAbchip) or lateral flow through (eAbsignal) formats. In electrosensing antibody probing, semiconductive antibodies are bound as a suitable electrosensing probe which specifically and selectively binds procalcitonin polypeptide target molecules in the test specimen
224182952|NCT01650610|BEHAVIORAL|Gait training executive functions tasks|The training will consist of 10 sessions, two times per week for five weeks, and consists of 30 minutes of global exercises that involves stretching, muscle strengthen and axial mobility exercises, and another 30 minutes of gait training in a dual-task condition associated with distracting tasks that require handling of the main executive functions: volition, self-awareness, planning, response inhibition, response monitoring and attention.
224182953|NCT01327586|BEHAVIORAL|ATM|Weekly counseling focused on improving money management, abstaining from cocaine,and minimizing unprotected sex
224182954|NCT01327586|BEHAVIORAL|Individual Drug Counseling|Standard individualized drug counseling, modified from that described by Woody and colleagues
224182955|NCT01115114|BEHAVIORAL|TAU|A medical assistant will provide feedback on and educational materials describing the meaning of lab values to individuals identified as needing follow-up for metabolic syndrome, and will provide educational materials regarding healthy eating and exercise. The psychiatrist will recommend that the individual contact a primary care physician to follow-up on out of range values, and alter behaviors (over eating, being sedentary) to help improve health.
224182956|NCT01115114|BEHAVIORAL|IMBED|After identifying individuals through routine screening that need medical follow-up for metabolic syndrome, these individuals will be scheduled to see the on site primary care provider. Rapid scheduling (within 2 weeks) will be attempted. Patients will be seen by the primary care provider monthly or as needed as determined per patient. The primary care provider will prescribe medications for metabolic syndrome, discuss the patient with psychiatry staff and recommend follow-up appointments for physical problems based upon recommended guidelines and clinical judgment of necessity and urgency. Referral to a specialist will be made according to standard primary care practice guidelines. During the Metabolic Syndrome Clinic, if individuals bring up other medical conditions, they will be referred for treatment of these conditions to an outside primary care provider.
224308190|NCT02098096|OTHER|Stretching|Home exercise program will be performed by the Placebo Comparator group and feature stretching over the 12 week intervention period.
224308191|NCT03039179|DEVICE|polyurethane foam dress|Application of the polyurethane foam dress at the heel in the immediate postoperative period before applied the Walker
223491320|NCT05852054|BEHAVIORAL|Patient Education (OB Visit)|A 1-page document will be printed or delivered electronically for eligible patients after every postpartum OB visit during the STEP-UP condition. The document will encourage patients to know the risk and will describe the importance of routine primary care and chronic disease evaluation and management. It will also provide tips for lowering risk through lifestyle changes. Patient materials will be delivered in English or Spanish based on the structured EHR variable for preferred language.
223491321|NCT05852054|BEHAVIORAL|Text messaging|At 3 months postpartum, all eligible patients who have not scheduled a primary care visit will receive a motivational text to prompt scheduling; a second text will be sent for those who still have not made an appointment. Among those who schedule a visit, a reminder text will be sent before the visit. Texts will be in English or Spanish based on patients' preferred language field in the EHR and written at a \<5th grade reading level.
223491322|NCT05852054|BEHAVIORAL|Patient Outreach|Patients who have not scheduled a primary care visit by 4 months postpartum will receive outreach from a trained coordinator who will assist with scheduling and help patients troubleshoot common barriers, such as concerns about transportation or cost.
223588071|NCT06701578|OTHER|Control|Listening to music that is not filtered and modulated for up to five hours.
223588072|NCT02394717|BEHAVIORAL|Healthy Eating and Physical Activity|Create partnerships with ASPs to help facilitate changes in programming to meet the National Afterschool Alliance's HEPA Standards.
223588073|NCT06713616|DRUG|Racemic ketamine|Ketamine will be given intravenously. Per FDA guidance, the max dose of ketamine will be 60mg per day, with a total lifetime limit of 8 doses. Ketamine will be infused over 40 minutes.
223588074|NCT06713616|DRUG|Spravato (Esketamine)|Spravato® (Esketamine) will be given intranasally. For esketamine, the dose will be between 56 and 84mg, according to the FDA label for the drug. Allowances will be made for patients who have difficulty tolerating these doses to be dosed at 28mg in subsequent treatment sessions.
223588075|NCT06200051|DIAGNOSTIC_TEST|Prediction of high risk of cancer|This initiative is aimed at comprehending the incidence rates of these four types of cancers, including lung cancer (LCA), liver cancer (LC), upper gastrointestinal cancer (UGIC), and CRC, to provide a theoretical foundation for the implementation of more practical and effective cancer screening strategies.
223588076|NCT06710262|DIAGNOSTIC_TEST|T-TAS PL Assay|The T-TAS PL assay is a flow chamber assay for measuring primary hemostatic function
223588077|NCT07038278|DRUG|5-ALA|5-ALA), also known by its brand name Gleolan, is an intermediate in the heme synthesis pathway that has been studied in tumor resections, especially in intracranial tumor resections. One advantage of intraoperative visualization with 5-ALA is the ability to directly visualize fluorescent tumor in the surgical field using a headset-mounted devices with fluorescence in the visual wavelength in real-time.
223588078|NCT06725810|DRUG|Enarodustat|Patients are administered with enarodustat with dosage adjusted according to hemoglobin levels to achieve and maintain hemoglobin target over 96 weeks.
224308192|NCT03776838|DRUG|Intravenous Fentanyl guided by SoC+NOL|Predeterminated bolus of IV Fentanyl will be given at the induction of anesthesia (2 mcg/kg), at the time of incision (1 mcg/kg). During surgery, administration of 0.5 mcg/kg of IV Fentanyl will be administred following a pre determinated algorithm based on NOL index + heart rate + mean arterial blood pressure variations.
224308193|NCT03776838|DRUG|Intravenous Fentanyl guided by SoC|Bolus of IV Fentanyl at the discretion of a physician will be given at the induction of anesthesia, and at the time of incision. During surgery, administration of IV Fentanyl at the discretion of a physician will be administred following a pre determinated algorithm based on heart rate + mean arterial blood pressure variations.
224182957|NCT01115114|BEHAVIORAL|Liaison|Patients will be seen by the MCM bi-weekly or as needed as determined per patient. The MCM will discuss findings of the labs with the patient, work to get the individual an appointment with a primary care doctor, get releases of information to discuss treatment coordination between the primary care and psychiatric teams, obtain necessary records from primary care, and communicate findings to the treating psychiatrist. The MCM will also assist the patient in getting to primary care appointments by providing bus passes or other transportation, and with obtaining medications prescribed by the primary care provider. This may necessitate enrolling the patient in specific care plans as needed.
224182958|NCT01078181|PROCEDURE|gastric bypass|laparoscopic gastric bypass with circular stapled 21mm gastrojejunostomy
224182959|NCT01922336|BIOLOGICAL|SB2|IV infusion
224182960|NCT01922336|BIOLOGICAL|EU Remicade|IV infusion
224182961|NCT01922336|BIOLOGICAL|US Remicade|IV infusion
224182962|NCT03647059|DIAGNOSTIC_TEST|LSCM examination|Cut a piece of donor liver and conduct the LSCM examination after staining fluorescein
224182963|NCT00726167|DEVICE|Procalcitonin Level|Procalcitonin concentrations will be determined every day and will be compared with the clinical diagnosis based upon standard clinical practice. All subjects enrolled will be followed until the patient is either extubated or discharged from the SICU.
224182964|NCT03539900|DRUG|Bupropion Hydrochloride, Naltrexone Hydrochoride Drug Combination|NB medication will combine BUPROPION HYDROCHLORIDE (360 mg/day) and NALTREXONE HYDROCHLORIDE (32 mg/day). Taken daily in pill form.
224182965|NCT03539900|OTHER|Placebo|Placebo will be inactive and taken daily in pill form.
224182966|NCT04605133|DEVICE|Electrical impedance tomography|Every patient is monitored with electrical impedance tomograpy before, during and after prone position.
224182967|NCT00996385|DRUG|Velcade (bortezomib) plus Eloxatin (oxaliplatin)|One cycle is defined as an interval of 28 days. A cycle is comprised of four treatments of Velcade (Bortezomib) 1.3 mg/m2 given on days 1, 14, 15, and 18 and two treatments of Eloxatin (Oxaliplatin) 85 mg/m2 on days 4 and 18.
224182968|NCT01096615|DIETARY_SUPPLEMENT|Placebo|"Description:~\- capsule size 3~Composition of the product:~* 45 mg of microcristalline cellulose,~* 132 mg of maltodextrin,~* 3 mg of magnesium stearate.~Composition of the capsule:~* 46 mg of hypromellose,~* 1 mg of titanium dioxide.~Packaging:~Products are packaged in aluminium tubes of 30 capsules.~Storage:~The product should be stored in a fridge. Direction for use: subject should consume 1 capsule daily together with a meal, with a glass of water.~The study products will be consumed daily for 7 weeks."
224182969|NCT01096615|DIETARY_SUPPLEMENT|Lactobacillus paracasei LP-33|"Description:~* minimum 2.0x109 CFU of Lactobacillus paracasei LP-33~* capsule size 3 1 capsule daily together with a meal, with a glass of water."
224182970|NCT04021342|DIETARY_SUPPLEMENT|Montmorency tart cherry concentrate|Based on previous analysis done by our laboratory each 60 ml of Montmorency tart cherry concentrate contains approximately 73.5 mg of anthocyanins (cyanidin-3-glucoside equivalents) and 178.8 mg of total phenolics (mean gallic acid equivalents)
224182971|NCT04021342|DIETARY_SUPPLEMENT|Placebo|Placebo beverage matched for calorie content and visual properties of the cherry concentrate
224182972|NCT00916994|DEVICE|SpaceGuard Balloon|Positioning of the balloon into the subacromial space between the humerus head and the acromion
223491323|NCT05852054|BEHAVIORAL|Primary Care Provider Clinical Decision Support (CDS)|The CDS will notify the provider that the patient had a recent high-risk pregnancy and signal the need to counsel the individual about their future risk for T2D and/or hypertension and the need for ongoing care. A brief guide with 'key points for counseling' described in plain language will be provided. For patients with prior GDM, the CDS will also include an easy to access 'smartset' to order appropriate testing (A1c, FG, or OGTT) based on time since delivery and provider discussions with the patient.
223491324|NCT05852054|BEHAVIORAL|Patient Education (Primary Care Visit)|A 1-page material will again be automatically printed or delivered electronically for eligible patients after their first primary care visit; it will replicate content from prior material provided after the OB visit.
223491325|NCT06370533|BEHAVIORAL|behavioral interventions|The investigators set diet, physical activity, and weight goals for each participant. During the lifestyle intervention period, the participants need to complete weekly self-monitoring of weight, weekly recording of diet behavioral goals, timely exercise logging, online health education course learning by using the WeChat public account. They will receive corresponding timely reminder and tailored feedback in the form of graphical illustration and text according to diet, physical activity, and weight data collected by WeChat public account and Huawei Wristband. They will receive individual face to face or telephone sessions every 2 weeks to complete health education, goal review, motivational interview as well as collecting adverse events.
223491326|NCT05556057|OTHER|mindfulness meditation(MM)|Participants will be provided with a unique invitation code that will allow them to download and use the free research version of the Mindfulness Coach app that is designed to deliver mindfulness training developed by the Veteran Affairs' National Center for PTSD.The app is tailored to users who may be skeptical about meditation practices by providing simple instructions and brief meditation exercises. The app offers written information about mindfulness as well as 12 audio-guided meditations each lasting 8-13 minutes, with an average length of 10 minutes
224182973|NCT02532829|OTHER|blood sample analysis|Measurement of GLP-1, Peptide YY, Glucose and Insulin before and 30-60-120 minutes after Oral Mixed Meal Tolerance Test.
224182974|NCT00175552|BEHAVIORAL|Psychotherapy Training|
224182975|NCT01197976|DEVICE|TEPSO cloth|TEPSO stocks should be worn continuously for 4 weeks of the study and will be changed every 3 days without wearing again those already used (even after washing).
224182976|NCT01197976|DEVICE|Standard cloth|Standard cotton stocks should be worn continuously for 4 weeks of the study and will be changed every 3 days without wearing again those already used (even after washing).
224182977|NCT04049344|DRUG|Decitabine; Oxaliplatin|Patients receive Decitabine 10 mg/day for 5 consecutive days (d1-5) plus Oxaliplatin 75mg/m2 2-week-cycle (d6, d20) within 4 weeks. One cycle is defined as 4 weeks of treatment and total of 6 cycles are designed for patients.
224182978|NCT02144142|BIOLOGICAL|Moisturizer with each subject's own antimicrobial bacteria|
224308194|NCT05124197|OTHER|prone position|extension of prone position duration
223588079|NCT07043959|PROCEDURE|Isometrics Exercise|"Shoulder Squeeze:~The therapist instructed the patient to lift their arms to shoulder height while keeping the elbows bent, then move the arms backward until the shoulder blades come together.~Arm Lift to Front and Side:~The therapist instructed the patient to raise their arm forward and upward while applying gentle resistance for 2-3 seconds to facilitate front arm elevation. Then, the patient was guided to lift the arm sideways, with slight resistance applied for 2-3 seconds to assist in side-arm elevation."
223588080|NCT07043959|PROCEDURE|Range of Motion Exercises|"Wall Climb for Flexion: The therapist instructed the patient to move their fingers upward along the wall until they reach their limit, then repeat the movement.~Arm across Chest for Adduction and Internal Rotation: The therapist instructed the patient to move the affected arm toward the unaffected arm and shoulder.~Wand Exercise for Flexion and Abduction: The patient was instructed to hold a wand with both hands and move it forward and sideways toward the affected side"
223588081|NCT06720714|DRUG|Rozanolixizumab|Dose formulation: Solution for injection Route of administration: Subcutaneous infusion
224182979|NCT05664412|DEVICE|at-home tACS using Starstim-Home tES|We will use transcranial alternating current stimulation (tACS) of the dorsolateral prefrontal cortex and temporal cortex by adopting a high-density (HD) montage with 3 electrodes to target the dorsolateral prefrontal cortex and 3 electrodes to target the temporal cortex. To select individualized parameters for stimulation, we will first acquire and analyse structural MRI (comprising T1 and T2-weighted sequences) and EEG data during a working memory task. We planned one session of HD-tACS per day for 5 consecutive days every week over four weeks; each session will last 21 minutes. All sessions will occur during cognitive training (i.e., execution of a working memory task).
224182980|NCT02615665|PROCEDURE|Hepatic resection|Removal of a part of the liver during surgery
224182981|NCT01579240|OTHER|Internet exercise program|12 voluntary weekly visits to website
224182982|NCT02651740|DRUG|Rifaximin|400mg tid\* 3d
224182983|NCT02651740|PROCEDURE|Fecal microbiota transplantation|Using filtered fresh donor stool, 100-200ml per time throuth enteral nutrition tube for at least one time
224182984|NCT04077112|BEHAVIORAL|Parent Child Interaction Therapy|Behavioral parent training program targeting parent-child relationship
224182985|NCT02968095|BEHAVIORAL|Text Message Craving Program|Text messages targeting cravings delivered 2-3 times per day.
224182986|NCT02968095|BEHAVIORAL|Self-Help Manual Plus Control Texts|Self-help manual plus motivational text messages delivered 2-3 times per day.
224182987|NCT01417949|OTHER|Time of starting antiretroviral therapy|"Within 24 hours after sending the screening form, the site investigator will receive a randomization sheet with the decision when to start ART (immediate or deferred). The day of receiving the randomization sheet will be defined as baseline visit."
224182988|NCT04772118|OTHER|Carevive PROmpt™|Patient Reported Outcomes Mobile Patient (Carevive PROmpt™), a digital cancer symptom monitoring platform.
224182989|NCT02973399|DRUG|SNX-5422 plus ibrutinib|SNX-5422 capsule(s) dosed every other day for 21 days out of a 28-day treatment cycle to a total dose of 56 mg/m2 SNX-5422. Subjects will self-administer daily oral ibrutinib in the afternoon at least 8 hours apart from SNX-5422 for 28 days of each cycle.
224182990|NCT01798433|DEVICE|One stent technique alone|One stent technique alone with drug-eluting stent
224182991|NCT01798433|DEVICE|One stent technique + Elective FKB|One stent technique + Elective FKB with drug-eluting stents + balloon
223588082|NCT06727578|DEVICE|of intrapleural saline irrigation with CLR irrigator|patients will have a CLRTM port and CLRTM irrigator (CLR Medical, Calverton, MD, USA) added to their chest tube and atrium circuit to facilitate pleural irrigation.
224182992|NCT01798433|PROCEDURE|Provisional approach|Provisional approach with drung-eluting stents
224182993|NCT01798433|DEVICE|Elective 2-stent|Elective 2-stent with drug-eluting stents
224182994|NCT00273715|PROCEDURE|Surgical wound closure techniques|Subjects will be randomized to either receive sutures or staples during the surical procedure to close the incision
224182995|NCT00273715|PROCEDURE|Surgical wound closure techniques (Comparator)|Subjects will be randomized to either receive sutures or staples during the surical procedure to close the incision
224182996|NCT01921842|BEHAVIORAL|NAP-SACC Child Care Wellness Program|Nutrition And Physical activity Self-Assessment for Child Care
224182997|NCT04741880|DRUG|Lidocaine IV|"Will be sent to Group L a 10 ml syringe of 2% lidocaine and 200 ml of lidocaine solution at 8mg.ml-1 (80ml of 2% lidocaine associated with 120ml 0.9% sodium chloride)~A syringe with 10 ml of solution and a bag with 200 ml of solution indistinguishable between the groups, with the identification of the patient by label prepared specifically for the study will be prepared by the Pharmacy personal. The bag and the solution will be sealed in a waterproof and opaque envelope and sent to the Operating Theatre (OT). The envelope will be stored in the refrigerator of the sector between 3º C and 8º C until the patient is sent to the operating room, when the drugs will be sent to the operating room. At the time designated for the start of the intervention, a bolus of 0.075 ml.kg-1 of the syringe solution, followed by 0.25 ml.kg-1.h-1 in the infusion pump of the solution in the bag will be administered."
224182998|NCT04741880|DRUG|Saline|"Group S will be sent a 10 ml syringe of 1% lidocaine and 200 ml of saline solution (0.9% sodium chloride)~A syringe with 10 ml of solution and a bag with 200 ml of solution indistinguishable between the groups, with the identification of the patient by label prepared specifically for the study will be prepared by the Pharmacy personal. The bag and the solution will be sealed in a waterproof and opaque envelope and sent to the Operating Theatre (OT). The envelope will be stored in the refrigerator of the sector between 3º C and 8º C until the patient is sent to the operating room, when the drugs will be sent to the operating room. At the time designated for the start of the intervention, a bolus of 0.075 ml.kg-1 of the syringe solution, followed by 0.25 ml.kg-1.h-1 in the infusion pump of the solution in the bag will be administered."
223588083|NCT07040839|DRUG|Clarithromycin 500 mg|Clarithromycin 500 mg orally twice daily for 14 days
223588084|NCT07040839|DRUG|Amoxicillin 1 g|Omeprazole 40 mg orally twice daily for 14 days, then 40 mg once daily for 4 weeks
223588085|NCT07040839|DRUG|Omeprazole 40 mg|Omeprazole 40 mg orally twice daily for 14 days, then 40 mg once daily for 4 weeks
223588086|NCT07040839|DRUG|Clarithromycin 500 mg|Clarithromycin 500 mg orally twice daily for 14 days
223588087|NCT07040839|DRUG|Amoxicillin 1 g|Amoxicillin 1 g orally twice daily for 14 days
223588088|NCT07040839|DRUG|Vonoprazan 20 mg|Vonoprazan 20 mg orally twice daily for 14 days, then 20 mg once daily for 4 weeks
224182999|NCT04823494|DEVICE|Hearing aids|Earbud style hearing aids fit to both ears
224183000|NCT03726320|BEHAVIORAL|Education Counseling Session for PSA Screening|counseling from extensively trained CHW
224183001|NCT03726320|BEHAVIORAL|General Health Counseling Coaching|coaching using an educational tool focused on dietary and lifestyle modification
223491327|NCT05556057|OTHER|Health Education (active control)|Participants will be asked to download and use the free TED Talk app.Each participant's account will include a list of over 80 TED Talks related to the six broad categories of sleep, nutrition, mood, relationships, chronic pain, and health behaviors. These talks range from 4 to 18 minutes and were reviewed/selected by the investigator team. The research coordinator(RC) will instruct them to watch or listen to these videos for ≥ 10 minutes daily for 6 days per week. The RC will ask participants to complete weekly logs of their TED Talk app use
223491328|NCT05661331|DEVICE|Transjugular intrahepatic portosystemic shunt|The GORE® VIATORR® TIPS Endoprosthesis with Controlled Expansion is indicated for use in the treatment of portal hypertension and its complications such as variceal bleeding and refractory ascites. The GORE® VIATORR® TIPS Endoprosthesis with Controlled Expansion is a current generation of the GORE® VIATORR® TIPS Endoprosthesis. The GORE® VIATORR® TIPS Endoprosthesis with Controlled Expansion was designed to build on the success of the GORE® VIATORR® TIPS Endoprosthesis. The GORE® VIATORR® TIPS Endoprosthesis with Controlled Expansion allows for intraoperative diameter control to reach a targeted portal pressure gradient.
223491329|NCT05502107|BEHAVIORAL|PRESS Intervention|The study intervention is PRESS protocol training and educational delivered to EMS providers, followed by protocol implementation. EMS providers will be trained to screen all EMS patients for protocol eligibility and will start using the protocol at the beginning of the intervention phase. The PRESS EMS protocol includes 2 major components: 1) an evidence-based sepsis screening tool, and 2) a prehospital sepsis alert call to the receiving hospital for participants who screen positive. Upon arrival to the ED, ED providers will provide immediate medical assessment to the patient to determine whether there is concern for sepsis. If the treating provider determines there is concern for sepsis, the provider will deliver usual sepsis care per local hospital protocols, workflows, or care pathways. Sepsis treatment interventions will not be specified by this study protocol.
223491330|NCT06113328|BIOLOGICAL|MK-6194|MK-6194 administered subcutaneously (SC)
223491331|NCT06113328|DRUG|Placebo|Placebo comparator to MK-6194 administered SC
223491332|NCT02842619|BIOLOGICAL|BonoFill-II|"Sinus augmentation - Surgery will be performed by either open or close sinus augmentation as per investigator discretion and as per common medical practice. After the elevation, BonoFill-II will be transplanted on the residual sub-antral bone.~Bone grafting after removal of cysts from jaws - Treatment will be performed according to the size of the cyst: in relatively small cyst total enucleation will be performed. In large cysts, a process of marsupialization will be performed. The entire cyst will be removed, including the epithelium layer, and the BonoFill-II product will be used for filling."
223491333|NCT06124196|DEVICE|wearable technology|Three wearable devices
223491334|NCT04720898|DEVICE|LUNA-EMG|The LUNA-EMG (Samcom) system is a robot that allows the evaluation of muscular strength through the recording of muscle activity (electromyography - EMG) in order to provide precise objective data on the patient's muscle function. In addition to the diagnostic aspect (evaluation of muscle strength, range of motion and proprioception), the LUNA-EMG robot provides optimized range of motion's movements and a visual feedback on the patient's performance. In addition, it may enhance neuroplasticity due to the increased number of movements repetitions which could influence motor learning.
223491335|NCT03620669|DRUG|Durvalumab|Durvalumab 1500mg q4W until progression or unacceptable toxicity
223512483|NCT05299957|DIAGNOSTIC_TEST|PETMRI|PET/MRI data will be acquired on the integrated PET/MRI scanner. After fast-view T1-weighted MR localizer sequence for scout imaging and Dixon VIBE sequence for attenuation correction, a whole-body PET scan will be performed to cover from the head to the proximal thigh, with an acquisition time of 4 min per bed position. Simultaneously, whole body MR image acquisition will be performed with the axial HASTE sequence and coronal STIR sequence as well as the sagittal T1-weighted Turbo spine echo and STIR sequence. Afterwards, regional PET and MRI images will be simultaneously performed. DWI will be performed using a single shot spin-echo echo-planar technique. A total of 10 b values will be used for the reconstruction of IVIM and kurtosis imaging. DCE-PWI will be acquired by using a 3D T1-weighted spoiled gradient-echo sequence. Thereafter, dedicated regional MRI will be obtained. Finally, whole body axial VIBE with fat saturation will be performed.
223588089|NCT07040839|DRUG|Levofloxacin 500 mg|Levofloxacin 500 mg orally once daily for 14 days
223588090|NCT07040839|DRUG|Amoxicillin 1 g|Amoxicillin 1 g orally twice daily for 14 days
223588091|NCT07040839|DRUG|Omeprazole 40 mg|Omeprazole 40 mg orally twice daily for 14 days, then 40 mg once daily for 4 weeks
224183002|NCT06386276|PROCEDURE|Colorectal bowel resection|The TrEnd is a single-institutional retrospective/prospective study, conducted in a high-volume referral centre for the endometriosis diagnosis and management, with the aim of systematically collecting data from consecutive patients undergoing segmental sigmoid colon/rectal resection for deep endometriosis.
224183003|NCT02616120|DRUG|SQJZ herbal mixtures|The SQJZ herbal mixtures is Chinese herb extracts. It contains Rehmannia glutinosa Libosch，Astragalus membranaceus (Fisch.) Bunge etc.( 29.375g, 2 times per day)
224183004|NCT02616120|DRUG|Placebo|placebo contains 5%SQJZ herbal mixtures and 95% dextrin,identified to SQJZ herbal formula (29.375g, 2 times per day)
224183005|NCT01974310|PROCEDURE|Vitrectomy & Intraocular gas fill|
224183006|NCT01974310|PROCEDURE|Postoperative face-down positioning|
224183007|NCT03922945|DRUG|VI-0521 oral capsule|Phentermine/Topiramate
224183008|NCT03922945|DRUG|Placebo oral capsule|Inactive drug
224183009|NCT03922945|BEHAVIORAL|Lifestyle Modification|The lifestyle modification includes physical activity, behavior change, reduced calorie diet advice, and family support. This intervention is applied to all treatment groups.
223588092|NCT07040839|DRUG|Levofloxacin 500 mg|Levofloxacin 500 mg orally once daily for 14 days
224183010|NCT00039377|DRUG|imatinib mesylate|Given PO
224183011|NCT00039377|DRUG|methotrexate|Given IT and IV
224183012|NCT00039377|DRUG|vincristine sulfate|Given IV
224183013|NCT00039377|DRUG|leucovorin calcium|Given IV and PO
224183014|NCT00039377|PROCEDURE|peripheral blood stem cell transplantation|Undergo PBSCT
224183015|NCT00039377|PROCEDURE|autologous hematopoietic stem cell transplantation|Undergo autologous PBSCT
224183016|NCT00039377|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Undergo allogeneic PBSCT
224183017|NCT00039377|RADIATION|total-body irradiation|Undergo TBI
224183018|NCT00039377|DRUG|tacrolimus|Given IV or PO
224183019|NCT00039377|BIOLOGICAL|filgrastim|Given SC
224183020|NCT00039377|DRUG|etoposide|Given IV
224183021|NCT00039377|DRUG|cyclophosphamide|Given IV
224183022|NCT00039377|DRUG|cytarabine|Given IV
224183023|NCT00039377|OTHER|laboratory biomarker analysis|Correlative studies
224183024|NCT02873598|DRUG|FOLFIRINOX or gemcitabine/abraxane|Patients will have received induction chemotherapy for 3+ months with either FOLFIRINOX or gemcitabine/abraxane with at least stable disease.
224183025|NCT02873598|RADIATION|SBRT|After completion of induction chemotherapy, stereotactic body radiation therapy (SBRT) will be administered in 3 fractions, every other day, on an outpatient basis. Dose escalation will start with dose level 1 (9 Gy x 3 fractions) and increase by 1 Gy per fraction at each dose level, dose level 2 will be 10 Gy x 3 fractions and dose level 3 will be 11 Gy x 3 fractions.
224183026|NCT04620005|OTHER|Observational|Survey
224183027|NCT02380417|PROCEDURE|paravertebral catheter placement|a thoracic paravertebral catheter was placed and connected to an elastomeric pump with a continuous infusion of 0.2% ropivacaine
224183028|NCT02380417|DRUG|0.2% ropivacaine|0.2% ropivacaine was infused through the elastomeric device
224183029|NCT02380417|DEVICE|Elastomeric pump|An elastomeric pump was connected to the paravertebral catheter
223491336|NCT06965686|BEHAVIORAL|PERI-MIND|PERI-MIND will be informed by the focus group findings from phase one. However, the investigators anticipate including core components related to psychoeducation, psychological grounding, \& behavioral activation, which will be specifically adapted to the perimenopausal and menopausal population. Psychoeducation in this context will focus on menopausal symptoms like brain fog (e.g., how common they are, how long they typically last), information about dementia and its risk factors (e.g., most actionable risk factors in mid-life), and links between menopause and dementia (e.g., hormonal replacement therapy). Psychological grounding content will focus on practical training exercises in mindful monitoring of concerns about brain fog and other menopausal symptoms (e.g., meditation, deep breathing). Behavioral activation will focus on exercises to recognize and disrupt avoidant coping behaviors, and increase engagement in valued activities (e.g., social engagement, exercise, healthy eating).
223491337|NCT03848260|DEVICE|Magnetic device prototype|The device prototype comprises a near-infrared light-emitting diode (SMT910, Epitex Inc, Kyoto, Japan) and receiver (PD15-22C TR8, Everlight Electronics Corporation, New Taipei City, Taiwan), a permanent electromagnetic actuator (JNP-12/12, Joint Magnetic Technology Corporation, Shenzhen, China), an iron sheet affixed to the paralytic upper eyelid, and a bio-signal acquisition module. The efficacy and safety of the device prototype was assessed using the device prototype.
223491338|NCT06967324|OTHER|Stepped care|Graduated palliative cross-sectoral care
223491339|NCT06967324|OTHER|Usual Care|Usual care at the outpatient respiratory clinic
223491340|NCT06972056|DRUG|Atogepant 60 mg|Atogepant at a dose up to 60 mg daily.
223491341|NCT06972056|DRUG|Propranolol 160 mg|Daily propranolol up to 80 mg twice daily.
223491342|NCT06972056|DRUG|Topiramate 100 mg|Daily topiramate, up to 50 mg twice daily
223491343|NCT04199026|DRUG|Doxorubicin|Given via microdevice
224183030|NCT05649020|DRUG|Dose of prilocaine|With the patient in the sitting position, spinal anesthesia was performed using the midline approach at the L3-L4; L4-L5 interspace with a spinal needle. The dose of HP that a patient received was determined by the previous patient's response. If successful anesthesia was obtained, the next patient's dose was decreased. The first patient will receive a dose of 20 mg. The dose decrement/increment for each subsequent patient will be set at 2 mg. A nurse blinded to the dose, will assess the sensitive level achieved with each block. Furthermore, all patients will be unaware of the injected dose of HP. For purposes of the study, anesthesia was considered successful when there was complete loss of pinprick and cold sensation at the L1 dermatome. Values of ED 50 will be determined by calculating the midpoint concentration after at least 8 crossover points sufficient/insufficient anesthesia will be obtained. A single measurement will be obtained from each patient.
223491344|NCT04199026|DRUG|Doxorubicin Hydrochloride|Given via microdevice
223491345|NCT04199026|DEVICE|Drug Delivery Microdevice|Undergo percutaneous implantation of drug delivery microdevice
223491346|NCT04199026|DRUG|Everolimus|Given via microdevice
223491347|NCT04199026|BIOLOGICAL|Ganitumab|Given via microdevice
223491348|NCT04199026|DRUG|Ifosfamide|Given via microdevice
223491349|NCT04199026|DRUG|Irinotecan|Given via microdevice
223491350|NCT04199026|DRUG|Pazopanib|Given via microdevice
223491351|NCT04199026|DRUG|Polyethylene Glycol|Given via microdevice
224183031|NCT06143176|BEHAVIORAL|VR-based occupational therapy|All patients will undergo 20 sessions of virtual reality based occupational therapy for 30 minutes a day, 5 days a week for 4weeks
224183032|NCT03189680|OTHER|Exercise therapy|3-week-long intervention, administered daily, targeted postural instability and mobility using at-limit intensity sensorimotor and visuomotor agility training
224183033|NCT04701931|DEVICE|Maestro2 OCTA|The Maestro2 OCTA with SS-OCT Angio software is an OCT with a fundus camera used for diagnostic purposes
224183034|NCT04701931|DEVICE|Cirrus HD-OCT 5000|The Zeiss Cirrus HD-OCT 5000 is an OCT used for diagnostic purposes
224183035|NCT04701931|DEVICE|TRC-50DX|The TRC-50DX retinal camera images the fundus used for diagnostic purposes
224183036|NCT03326882|DEVICE|Endotracheal intubation|
224183037|NCT00245492|PROCEDURE|Chromocolonoscopy|Indigocarmine dye applied to entire colon to highlight mucosal detail and enhance detection of flat lesions.
224183038|NCT02810210|OTHER|fundus examination|"In cohort 3, a fundus examination will be carried in addition to the current medical practice.~This exam is part of current medical practice for other groups."
223491352|NCT04199026|DRUG|Temozolomide|Given via microdevice
223491353|NCT04199026|DRUG|Temsirolimus|Given via microdevice
223491354|NCT04199026|PROCEDURE|Therapeutic Conventional Surgery|Undergo standard of care surgery
223491355|NCT04199026|DRUG|Vincristine|Given via microdevice
223512484|NCT04250363|BIOLOGICAL|PfSPZ Challenge|Participants received 3200 units of Plasmodium falciparum sporozoites by DVI on Day 1.
224183039|NCT02810210|OTHER|Head ultrasound|"In cohort 3, a head ultrasound will be carried in addition to the current medical practice.~This exam is part of current medical practice for other groups."
224308195|NCT01303705|DRUG|Anti-OX40|Anti-OX40 will be administered intravenously at 0.4 mg/kg on days 4, 6 and 8 of the study. The total anti-OX40 dose will be reconstituted in 100 ml 0.9% saline and infused over no more than 60 minutes intravenously. A single-use non-pyrogenic durapore membrane low protein binding filter (e.g.: Braun 1.2 micron air eliminating filter or equivalent) shall be used to filter the study product in the line between infusion bag and patient.
224308196|NCT01303705|RADIATION|Radiation|8.0 Gy in 1 fraction to a maximum of three bone metastatic deposits will be administered on Day 4 of treatment. Imaging such as bone scan, MRI, CT scan, or radiograph must identify the target lesion as consistent with metastatic disease. Any bone lesion that is inducing pain or where there may be a clinical concern for potential pathological fracture will be selected over asymptomatic lesions.
224308197|NCT01303705|DRUG|Cyclophosphamide|CTX will be administered on day 1 (Friday only) at a dose determined by cohort assignment. The drug should be diluted per institutional standards. An added dose of IV fluids may help prevent bladder toxicity. In this protocol, CTX will be administered intravenously over 30 - 60 minutes.
224308198|NCT02178280|OTHER|liver transplantation combined with neoadjuvant therapy|liver transplantation combined with neoadjuvant radiochemotherapy
224308199|NCT01965392|OTHER|Health education intervention|'Health education intervention'
223491356|NCT04431960|DRUG|blackcurrant (BC) extract|A calcium citrate caplet (Bayer AG, Germany) will be taken by all 3 groups to avoid bone deterioration related to calcium and vitamin D deficiency
223491357|NCT05153239|DRUG|Irinotecan|Irinotecan 75 mg/m² intravenously Days 1 \& 8 q3wk
223491358|NCT05153239|DRUG|Lurbinectedin|Lurbinectedin 3.2 mg/m² will be administered intravenously on Day 1 q3wk
223491359|NCT05153239|DRUG|Irinotecan|For patients aged \<70 years: irinotecan 350 mg/m² intravenously Day 1 q3wk For patients aged ≥70 years: irinotecan 300 mg/m² intravenously Day 1 q3wk
223491360|NCT05153239|DRUG|Topotecan|Topotecan 2.3 mg/m² oral or 1.5 mg/m² intravenously Days 1-5 q3wk
223491361|NCT05153239|DRUG|Lurbinectedin|Lurbinectedin 2.0 mg/m² will be administered intravenously on Day 1 q3wk
223491362|NCT06646575|OTHER|Qualitative data, no intervention|This is a qualitative study
223491363|NCT05116722|DEVICE|Shoulder Pacemaker|Shoulder pacemaker treatment for 15 - 30 minutes at 3-months, 6-months and 12-months during physical therapy.
223491364|NCT02466971|RADIATION|Brachytherapy|Undergo brachytherapy
223491365|NCT02466971|DRUG|Cisplatin|Given IV
223491366|NCT02466971|RADIATION|External Beam Radiation Therapy|Undergo EBRT
223491367|NCT02466971|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
223491368|NCT02466971|OTHER|Laboratory Biomarker Analysis|Correlative studies
223491369|NCT02466971|RADIATION|Radiation Therapy|Undergo conventional RT
223491370|NCT02466971|DRUG|Triapine|Given IV
223491371|NCT03169673|DIAGNOSTIC_TEST|Hyperpolarized Helium 3 Magnetic Resonance Imaging|Hyperpolarized noble gas imaging using Helium-3 has been used to explore structural and functional relationships in the lung in patients with lung disease and healthy controls. In contrast to proton-based MRI imaging, 3He gas is used as a contrast agent to directly visualize the airways, and thus ventilation. Whereas the normal density of gas is too low to produce an easily detectable signal, this is overcome by artificially increasing the amount of polarization per unit volume using optical pumping.
223491372|NCT05007106|BIOLOGICAL|Pembrolizumab/Vibostolimab Co-Formulation|Pembrolizumab 200 mg plus vibostolimab 200 mg administered via IV infusion Q3W
223491373|NCT05007106|BIOLOGICAL|Pembrolizumab|Pembrolizumab 200 mg administered via IV infusion Q3W.
223491374|NCT05007106|DRUG|Lenvatinib|Lenvatinib 20 mg, 12 mg, or 8 mg (dependent on cancer type and body weight) administered via oral capsule QD
223491375|NCT05007106|DRUG|5-Fluorouracil|5-FU 800 mg/m\^2/day administered via continuous IV infusion on each of days 1 to 5 Q3W for up to 35 cycles
223491376|NCT05007106|DRUG|Cisplatin|Cisplatin administered via IV infusion
223491377|NCT05007106|DRUG|Paclitaxel|Paclitaxel administered via IV infusion at investigator's choice of dose
223491378|NCT05007106|DRUG|Gemcitabine|Gemcitabine administered via IV infusion on Day 1 and Day 8 of each 3-week cycle, until PD or unacceptable toxicity
223491379|NCT05007106|DRUG|Carboplatin|Carboplatin administered via IV infusion at investigator's choice of dose and frequency
223491380|NCT05007106|DRUG|Docetaxel|For participants who cannot receive paclitaxel due to hypersensitivity or adverse event (AE), docetaxel administered via IV infusion Q3W, Day 1 of each cycle for up to 5 cycles
223491381|NCT05007106|DRUG|Bevacizumab|Bevacizumab (or biosimilars such as MVASI®, Zirabev®, Aybintio®, ALYMSYS®, Abevmy®, Onbevezy®, Vegzelma®) administered via IV infusion Q3W; Day 1 of each 3-week cycle for up to 15 cycles
223491382|NCT05007106|DRUG|Capecitabine|Capecitabine administered via oral tablet twice daily on Days 1 to 14 of each cycle (Q3W) for up to 35 cycles
223491383|NCT05007106|DRUG|Oxaliplatin|Oxaliplatin administered via IV infusion Q3W up to 35 cycles
223491384|NCT03409367|OTHER|Participant choice of over-the-counter emollients: Vaseline, Vanicream, CeraVe Healing Ointment, CeraVe cream, Cetaphil cream|Lipid-rich emollient serving as skin barrier
223512485|NCT04250363|DRUG|Palcebo|Participants received single oral dose of placebo matched to M5717 capsule on Day 1.
224183040|NCT02493712|DRUG|High dose|6 capsules of IBD98-M, twice a day
224183041|NCT02493712|DRUG|Low dose|4 capsules of IBD98-M
224183042|NCT02493712|DRUG|Placebo|Placebo
224183043|NCT02452138|OTHER|Severe sepsis management|
224183044|NCT04824599|PROCEDURE|PECS II|Pectoral nerves block (PECS II) is performed with the help of ultrasound. Two injection are performed in two fascial planes. One between pectoralis major muscle and serratus anterior muscle. Second one between pectoralis major and minor muscles.
224308200|NCT02171676|DRUG|Docetaxel|
224308201|NCT02171676|DRUG|BIBW 2992|
224308202|NCT03050060|DRUG|Atezolizumab|Given IV
224308203|NCT03050060|RADIATION|Hypofractionated Radiation Therapy|Undergo hypofractionated radiation therapy
224308204|NCT03050060|OTHER|Laboratory Biomarker Analysis|Correlative studies
224308205|NCT03050060|DRUG|Nelfinavir Mesylate|Given PO
224308206|NCT03050060|BIOLOGICAL|Nivolumab|Given IV
224308207|NCT03050060|BIOLOGICAL|Pembrolizumab|Given IV
224183045|NCT04824599|PROCEDURE|Local anesthetic infiltration|Ropivacaine is administered by surgeon prior to scrubbing and following the removal of the tumor.
224183046|NCT04824599|PROCEDURE|Subcutaneus local anesthetic infiltration|Ropivacaine is administered by the surgeon at the end of surgery
224183047|NCT04824599|DRUG|Ropivacaine|Local anesthetic ropivacaine is administered in both study arms according to the study protocol
224183048|NCT04824599|DEVICE|bk medical Flex Focus 500 Ultrasound Machine|Ultrasound with linear probe is performed. Using in-plane technique a correct placement of the injection needle is secured.
224183049|NCT03243552|DRUG|L-DOPA versus Placebo|Participants will be randomized in a blocked schedule to yield 1:1 L-DOPA: placebo assignment.
224183050|NCT03243552|BEHAVIORAL|Social Skills Training|ASD participants will be enrolled concurrently in a 16-week manualized, structured, group-based, social skills training program (PEERS).
224183051|NCT04176237|OTHER|UV Dosimetry Laboratory|The UV Dosimetry Laboratory is a one hour lesson that incorporates science and health education - kids hypothesize what UV levels will be around the school yard, go and measure UV, review their results, and then come up with a SunSmart plan for playing in the school yard.
224183052|NCT02449733|BEHAVIORAL|Condom choices|Men will receive the condom package that includes an assortment of styles, sizes, features and colors at their baseline visit, and will be able to get more condoms for free at any time after that visit by coming to a study clinic during clinic hours, or during a scheduled study visit.
224183053|NCT02449733|BEHAVIORAL|Condom-compatible lubricant choices|Men will receive condom-compatible lubricant that will include different types of lubricant (e.g., silicone-based) and different packaging (individual sachets or flat, discreet packages) at their baseline study visit, and participants will be able to access enhanced condom-compatible lubricant at any time after that visit by coming to a study clinic during clinic hours, or during a scheduled study visit.
224183054|NCT02449733|BEHAVIORAL|Couples HIV counseling and testing (CVCT)|Participants will be invited to schedule couples voluntary HIV counseling and testing (CVCT) appointments with a clinic counselor at any point after they complete their baseline study visit.
224183055|NCT02449733|DRUG|Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF)|"FTC/TDF is a once daily oral tablet taken with or without food. The tablet includes 200 mg of emtricitabine (FTC) and 300 mg of tenofovir disoproxil fumarate (TDF).~For men who meet eligibility criteria, Pre-exposure prophylaxis (PrEP) with Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) will be made available beginning one month into the study. Men who express interest and meet eligibility criteria at their baseline visit can initiate PrEP at 1 month if they test negative for HIV. For men with extenuating circumstances, whose risk profile changes, of those who become more comfortable with the PrEP intervention through enrollment in the study, PrEP will be available to initiate at the 4 month visit."
224183056|NCT02449733|OTHER|HIV Testing|Rapid HIV testing at multiple time points
224183057|NCT02449733|OTHER|Linkage to care|Men will be linked to needed services including HIV care and treatment for positives identified at baseline or during the study, including antiretroviral medications, and mental health services. At the end of their baseline visit, participants will receive service referral handouts for HIV care and treatment, mental health services, and other resources, as appropriate. Men who test positive for sexually transmitted infections (STIs )will be treated at the clinic site.
223491385|NCT06335797|DIETARY_SUPPLEMENT|Senna Tab|Senna 8.6mg two tablets per day post operative day 1 and and if needed, then continue on the same dose regiment until post operative day 5.
223491386|NCT06335797|DIETARY_SUPPLEMENT|Dulcolax Suppositories|Dulcolax 1 suppository to be placed rectally on the evening of post operative day 1 and if needed, then continue using the same dose regiment until the post operative day 5.
224183058|NCT02449733|PROCEDURE|Post-exposure prophylaxis (PEP)|Two to three antiretroviral medicines as soon as possible (recommended is emtricitabine/tenofovir disoproxil fumarate plus either raltegravir or dolutegravir), but no more than 72 hours (3 days) after one may have been exposed to HIV, to try to reduce the chance of becoming HIV-positive. They must be taken for 28 days.
224183059|NCT02449733|BEHAVIORAL|Risk-reduction counseling|Risk-reduction counseling will be provided to all men at baseline and additionally at 3, 6, and 12 month visits, with an additional counseling session for men on PrEP at their initiation visit (either month 1 or 4), their 1-month follow-up visit (either month 2 or 5) and at their 9 month visit. Risk reduction counseling will be client-centered counseling, according to CDC's Fundamentals of HIV Prevention Counseling protocol.
224183060|NCT02583854|DEVICE|RY-STOP hemostasis device|
224183061|NCT02583854|DEVICE|TR-Band, Terumo|
224183062|NCT05014945|PROCEDURE|(atelocollagen group)|Epidural nerve block and atelocollagen injection into the multifidus muscle were performed sequentially. The target level is determined by the clinician by combining the pre-MRI and the patient's symptoms. All procedures are performed under the guidance of fluroscopy. For epidural nerve block, use 10cc of 0.9% normal saline mixed with 3000IU of hyaluronidase to be injected. After the epidural nerve block, a solution of 1 mL of atelocollagen mixed with 1 mL of 1% lidocaine is injected into the multifidus muscle to complete the entire procedure.
224183063|NCT00466284|DRUG|Tarceva (erlotinib)|
224183064|NCT02797600|BEHAVIORAL|Questionnaires|Questionnaires will be used to obtain self-reported demographic, behavioral, social, family and medical history, and quality of life data. The questions are standardized and taken from either nationally recognized surveys, CARE I surveys, or represent validated survey items.
224183065|NCT02797600|OTHER|Biological Samples|All biological samples will be collected at the time of the clinical Pap smear for the controls, and will be collected for the Arm 2 (newly diagnosed) during a scheduled clinic visit. For those individuals in Arm 1, biological samples will be collected during a scheduled visit with the research staff.
224183066|NCT00238680|BEHAVIORAL|Bladder rehabilitation|
224183067|NCT00238680|BEHAVIORAL|Bladder rehabilitation with programmable timer|
223588093|NCT07040839|DRUG|Amoxicillin 1 g|Amoxicillin 1 g orally twice daily for 14 days
224308208|NCT04431882|PROCEDURE|optic nerve sheath fenestration|A standard medial transconjunctival orbitotomy was performed in all cases under general anesthesia. The medial rectus muscle was disinserted and reflected nasally with 6-0 synthetic polyester suture in typical fashion for eye muscle surgery. A traction suture was then placed through the insertion stump of the medial rectus in a baseball stitch fashion to facilitate abduction of the globe. The pupil was monitored at all times. A custom- made cupped orbital retractor was inserted along the medial scleral wall and used to retract the orbital fat and allow visualization of the optic nerve sheath. Retraction and globe abduction were relaxed if any changes in pupil size were noted. When adequate visualization was achieved, multiple dural sheath fenestrations approximately 3 mm in length. Expulsion of cerebrospinal fluid was invariably observed with the initial incision into the dural sheath.
224183068|NCT04566016|PROCEDURE|Regional anesthesia|Patients scheduled for lower limb arterial bypass surgery will be randomly allocated for treatment with spinal anesthesia associated with spontaneous ventilation (nasal cannula with supplemental oxygen - Group 1) or treatment with general anesthesia under controlled mechanical ventilation (tidal volume 6 to 8 ml / kg of the predicted body weight and PEEP of 5 cmH2O - Group 2).
224183069|NCT04580875|PROCEDURE|Minimally invasive surgery (laparoscopy and laparoscopic-assisted procedures) in both diagnosis and treatment of penetrating abdominal trauma in Children|
224183070|NCT05870423|DRUG|olaparib|18 days olaparib during each cycle of PRRT
224183071|NCT02382419|DRUG|carrageenan-containing gel|Applied vaginally
224183072|NCT02382419|OTHER|Placebo|Applied vaginally
224308209|NCT00003592|DRUG|methotrexate|
224308210|NCT00003592|DRUG|paclitaxel|
223491387|NCT04649788|DEVICE|Ultrasound-guided axillary vein access|Venous access is performed through ultrasound-guided axillary vein puncture and Seldinger technique. After venous access is obtained, a guide-wire is advanced through the access needle, and the tip of the guide-wire is positioned in the right cardiac atrium.
223491388|NCT04649788|DEVICE|Cephalic vein access|Venous access is performed through a cephalic vein cutdown approach. After venous access is obtained, a guide-wire is advanced and the tip of the guide-wire is positioned in the right cardiac atrium.
223491389|NCT06298916|COMBINATION_PRODUCT|64Cu-LNTH-1363S|64Cu-LNTH-1363S, is a highly selective, high affinity FAP inhibitor (FAPi) that is radiolabeled with Copper-64 (64Cu) for PET/CT Imaging,
223491390|NCT06480032|DEVICE|Blood Flow Restriction band|Blood Flow Restriction (BFR) band operate by partially occluding arterial blood flow to distal structures, but more significantly impeding venous outflow from under the cuff, thereby also hindering venous return. The compression of vasculature proximal to the skeletal muscle leads to inadequate oxygen supply (hypoxia) within the muscle tissue, resulting in a localized hypoxic environment. Additionally, the reduction in venous blood flow causes blood to accumulate in the capillaries of the occluded limb, often manifesting as visible erythema. This temporary restriction will be maintained for a duration of 8 weeks.
223491391|NCT04518748|DRUG|Yttrium-90|Radioactive isotope Y-90 at day 0, administered by selective internal radiation therapy (SIRT)
223491392|NCT04518748|DEVICE|Selective Internal Radiation Therapy|SIRT at day 0, to administer Yttrium-90 (Y-90) Theraspheres
223491393|NCT04518748|RADIATION|Stereotactic Body Radiation Therapy|3-5 fractions over 1-2 weeks, after Y-90 SIRT
223491394|NCT04518748|DIAGNOSTIC_TEST|PET/CT|Within 3 hours of completing Y-90 SIRT
224308211|NCT03245957|OTHER|Ischemic stroke|Patients with acute stage of stroke clinical picture, with ischemic, haemorrhagic or mimick stroke diagnosed using MRI or CT scan
224308212|NCT03245957|OTHER|Haemorrhagic stroke|Patients with acute stage of stroke clinical picture, with ischemic, haemorrhagic or mimick stroke diagnosed using MRI or CT scan
223491395|NCT04518748|DEVICE|Therasphere|Glass microspheres containing Y-90, administered at day 0 by SIRT
223491396|NCT04903353|DRUG|Comparison of Risperidone and Aripiprazole|Comparing two FDA approved medications for treatment of irritability in autism
223512486|NCT04250363|DRUG|M5717 30 mg|Participants received 30 mg single oral dose of M5717 capsule on Day 1.
224183073|NCT02382419|OTHER|Laboratory Biomarker Analysis|Correlative studies
224308213|NCT05499780|DEVICE|Sentinox|The treatment will be administered in a dose of 0.5 ml into each nostril (5 sprays) per 3 times/day (8 am, 2 pm and 8 pm), for 21 days from Visit 1.
224308214|NCT01826786|DRUG|JNJ-42165279 (100 mg)|JNJ-42165279 (100 mg/day) will be orally administered once daily for 4 consecutive days.
224308215|NCT01826786|DRUG|Placebo|Matching placebo to JNJ-42165279 will be orally administered once daily for 4 consecutive days.
223512487|NCT04250363|DRUG|M5717 60 mg|Participants received 60 mg single oral dose of M5717 capsule on Day 1.
224183074|NCT02382419|OTHER|Questionnaire Administration|Ancillary studies
224183075|NCT02112396|BEHAVIORAL|Community Reinforcement and Family Training|The Intervention is based on the CRAFT literature and includes Building and sustaining motivation of CSOs, functional analysis of problem behaviors, domestic violence precautions (if mandatory), improving communication skills of CSOs, use of negative consequences of drinking behavior, positive reinforcement of clean and sober behavior, strategies to enrich CSOs lives, and strategies for inviting the addicted individual to enter treatment.
224183076|NCT01625559|BIOLOGICAL|MA09-hRPE|MA09-hRPE cells
224183077|NCT02443727|DRUG|Syntocinon (synthetic oxytocin)|Dosage and details described in arm.
224183078|NCT02443727|OTHER|Placebo|Dosage and details described in arm.
224183079|NCT05492552|BEHAVIORAL|Active-at-home-HF|Increase daily step count by 2,000 and weekly telephone calls.
224183080|NCT05710848|DRUG|STM-416|STM-416 monotherapy
224308216|NCT02681146|OTHER|Multimodal intervention|Educational advice + physiotherapist treatment
224308217|NCT03792087|DRUG|SmofKabiven Peripheral|Total Parenteral Nutrition
224308218|NCT03792087|DRUG|Hospital compounded emulsion|Total Parenteral Nutrition
224308219|NCT06444932|PROCEDURE|Joint Mobilization|Patellofemoral and tibiofemoral joint mobilization
224308220|NCT06444932|PROCEDURE|Resistance Exercise Training|Lower limb resistance exercise training
224308221|NCT06444932|DEVICE|Transcutaneous Electric Nerve Stimulation (TENS)|Transcutaneous Electric Nerve Stimulation (TENS)
224308222|NCT06444932|DEVICE|Heating Pad|Heating pad for heat therapy
224308223|NCT01058720|DIETARY_SUPPLEMENT|Vitamin D3|2000 IU orally once daily for 12 weeks
224308224|NCT02288182|DEVICE|Straumann VivOss|Patients will receive Straumann VivOss for sinus augmentation.
223491397|NCT04818112|BEHAVIORAL|ATVV|A 15-minute behavioral intervention that mothers administer once daily to their infant for 3 months providing Auditory, Tactile, Visual, and Vestibular (ATVV) stimulation. Multisensory stimuli are presented in gradual progression. Mother-infant engagement is attempted throughout ATVV so that mothers learn to identify, interpret and adapt to their infants cues. ATVV can be given without eye to eye gaze making it appropriate for newborns. ATVV is offered contingent on infant cues to promote self-regulation and withdrawn if any persistent disengagement cues. Mothers are taught how to adapt ATVV as their infant grows. Fidelity to the intervention is checked with weekly phone calls and monthly study visits. Mothers also receive a daily text from REDCap to document an intervention frequency log.
224183081|NCT00682539|DRUG|Bevacizumab (Avastin)|The intravitreal injection of Bevacizumab (Avastin®) is performed in the operating room under sterile conditions. The patient receives an initial drop of lidocaine 4% into the study eye followed by betaisodona solution. Then the lid margins, the lids and the periocular skin are washed carefully with betaisodona. The eye is draped in a sterile fashion. A sterile lid speculum is inserted by the surgeon. Another drop of betaisodona is applied into the eye. A circle is used to mark the injection site 3.5mm from the limbus in the inferior temporal quadrant. The injection is given at the marked site, slowly, at a 90 degree angle. After injecting the total volume of 0.1ml the needle is slowly withdrawn. Another drop of betaisodona is given as well as an antibiotic/steroid ointment.
224183082|NCT00682539|DRUG|Triamcinolone|The intravitreal injection of triamcinolone (Volon A®) is performed in the operating room under sterile conditions at baseline. The patient receives an initial drop of lidocaine 4% into the study eye followed by betaisodona solution. Then the lid margins, the lids and the periocular skin are washed carefully with betaisodona. The eye is draped in a sterile fashion. A sterile lid speculum is inserted by the surgeon. Another drop of betaisodona is applied into the eye. A circle is used to mark the injection site 3.5mm from the limbus in the inferior temporal quadrant. The injection is given at the marked site, slowly, at a 90 degree angle. After injecting the total volume of 0.1ml the needle is slowly withdrawn. Another drop of betaisodona is given as well as an antibiotic/steroid ointment.
224183083|NCT00682539|DRUG|Sham|Patients receiving sham intravitreal injections do not receive an actual injection of study drug. The injecting physician performing the sham injection will be unmasked to the treatment to the treatment assignment regarding active versus sham. The injecting physician will perform the same pre-injection procedures for the patients receiving bevacizumab or triamcinolone, An empty syringe without a needle will be used in the sham injection. The injecting physician will mimic an intraocular injection by making contact with the conjunctiva and applying pressure without the needle. Immediately following the sham injection, the injecting physician will perform the same post-injection procedures as those performed on patients receiving bevacizumab or triamcinolone.
224183084|NCT00682539|PROCEDURE|Lucentis|The intravitreal injection of Ranibizumab (Lucentis®) is performed in the operating room under sterile conditions. The patient receives an initial drop of lidocaine 4% into the study eye followed by betaisodona solution. Then the lid margins, the lids and the periocular skin are washed carefully with betaisodona. The eye is draped in a sterile fashion. A sterile lid speculum is inserted by the surgeon. Another drop of betaisodona is applied into the eye. A circle is used to mark the injection site 3.5mm from the limbus in the inferior temporal quadrant. The injection is given at the marked site, slowly, at a 90 degree angle. After injecting the total volume of 0.05ml the needle is slowly withdrawn. Another drop of betaisodona is given as well as an antibiotic/steroid ointment.
224183085|NCT03243318|DIAGNOSTIC_TEST|MEPs induced by TMS|Using TMS induced MEPs over motor cortex of the affected side to predict motor recovery potentials
224183086|NCT00002021|DRUG|Foscarnet sodium|
224183087|NCT00995202|PROCEDURE|Standard Monitoring CEA|No specific follow-up of CEA
224183088|NCT00995202|PROCEDURE|Intensive Monitoring CEA|CEA levels are measured every 3 months for 3 years, then every 6 months for 2 years.
224183089|NCT00995202|PROCEDURE|Standard Monitoring Imagery|Abdominal ultrasound examination every 3 months during 3 years then every 6 months during 2 years then annually. Chest X-ray examination eveyr 6 months during 3 years then annually during 2 years
224183090|NCT00995202|PROCEDURE|Intensive Monitoring Imagery|Alternation every 3 months of TDM thoraco-abdomino-pelvis and abdominal ultrasound examination during 3 years and twice a year after during 2 years. Coloscopy at 3 years and then evry 5 years if normal
224183091|NCT03063515|DRUG|Pyridostigmine|single oral dose of 60 mg pyridostigmine tablet
224183092|NCT04214145|DRUG|Phenylephrine|"Continuous infusion of Phenylenphrine 250 μg/mL (=Phenylephrine 10mg \* 5@ + D5W 200 mL) if mean BP \< 60mmHg.~1. Initial rate: 0.42 μg/kg/min (=0.1 mL/kg/hr)~2. Increment by 0.21 μg/kg/min (=0.05 mL/kg/hr) if mean BP \< 60mmHg after 5 minutes~3. Maximum rate: 3.33 μg/kg/min (=0.8 mL/kg/hr)"
224308225|NCT02288182|DEVICE|Geistlich Bio-Oss|Patients will receive Geistlich Bio-Oss for sinus augmentation.
224308226|NCT03106649|DEVICE|Echocardiography|Before administration of spinal anesthesia, Echocardiography will be performed to determine the LVEDA. If the LVEDA is more than 10 square cms, the patient will be considered as volume replete and spinal anesthesia will be administered. If the LVEDA is less than 10 square cms, a fluid bolus of 250 ml of a balanced salt solution will be given and LVEDA reassessed. This will be repeated till the LVEDA is more than 10 square cms or fluid bolus has been given twice and still the LVEDA is less than 10 square centimeters, in which case phenylephrine 1-2µg/kg will be given before administering spinal anesthesia.
223491398|NCT04818112|BEHAVIORAL|Attention control|Mothers in the Attention Control group receive a similar amount of daily texts, weekly phone call and in-person study visit attention as mothers in the ATVV group, but with distinctly different content. Over the first 3 postnatal months, mothers learn safe infant-care that includes content on diapers, infant clothing, blankets, infant care including bathing, sleep positions, sleep habits, holding the baby, safety of infant equipment, breastfeeding, formula, and age appropriate toys.
223491399|NCT05926765|GENETIC|AAV2-hAQP1 Concentration 1|Administration of concentration 1 of AAV2-hAQP1 via Stensen's duct to each parotid gland
223491400|NCT05926765|GENETIC|AAV2-hAQP1 Concentration 2|Administration of concentration 2 of AAV2-hAQP1 via Stensen's duct to each parotid gland
223491401|NCT05926765|OTHER|Placebo|Administration of diluent via Stensen's duct to each parotid gland
223491402|NCT05926765|GENETIC|AAV2-hAQP1 Concentration 3|Administration of concentration 3 of AAV2-hAQP1 via Stensen's duct to each parotid gland
224183093|NCT04214145|DRUG|Norepinephrine|"Continuous infusion of Norepienphrine 20 μg/mL (=NE 4mg \* 1@ + D5W 200 mL) if mean BP \< 60mmHg.~1. Initial rate: 0.03 μg/kg/min (=0.1 mL/kg/hr)~2. Increment by 0.015 μg/kg/min (=0.05 mL/kg/hr) if mean BP \< 60mmHg after 5 minutes~3. Maximum rate: 0.24 μg/kg/min (=0.8 mL/kg/hr)"
224183094|NCT04214145|DRUG|Vasopressin|"Continuous infusion of Vasopressin 0.1 u/mL (=Vasopressin 20u \* 1@ + D5W 200 mL) if mean BP \< 60mmHg.~1. Initial rate: 0.01 u/kg/hr (=0.1 mL/kg/hr)~2. Increment by 0.005 u/kg/hr (=0.05 mL/kg/hr) if mean BP \< 60mmHg after 5 minutes~3. Maximum rate: 0.08 u/kg/hr (=0.8 mL/kg/hr)"
224183095|NCT04008173|OTHER|Non-interventional patient registry|Non-interventional patient registry
224183096|NCT03705858|DRUG|Ac-Lintuzumab|225Ac-lintuzumab will administered at 4 dose levels: 0.25, 0.5, 0.75 or 1 µCi/kg intravenously (IV) over 30 ± 10 minutes. The starting dose will be 0.5 µCi/kg. A dose of 0.25 µCi/kg will be studied only if 0.5 µCi/kg is determined to exceed the MTD. The lintuzumab dose will be adjusted to maintain a specific activity of 0.16 µCi/µg
224183097|NCT04143815|DRUG|MBA-P01 (Botulinum toxin A)|Intramuscular injection, dose varies by groups
224308227|NCT03106649|DEVICE|Treatment of spinal hypotension|For treatment of spinal hypotension, in the event of hypotension(defined as a mean arterial pressure less than 60 mm Hg or decrease in mean arterial pressure of more than 20% from the baseline value) after spinal anesthesia, the LVEDA will be assessed. If more than 10 square centimeters, the patient will be considered volume replete and a vasopressor in the form of phenylephrine 1-2µg/kg will be given. If the LVEDA is less than 10 square centimeters, a volume bolus of 250ml will be given. On reassessment if the LVEDA is still less than 10 square centimeters the volume bolus can be repeated. In the event of hypotension persisting in spite of volume resuscitation, phenylephrine 1-2µg/kg will be given.
224308228|NCT02582866|DRUG|Lacosamide|"* Pharmaceutical Form: Oral tablets~* Concentration: 50 mg~* Route of Administration: Oral administration"
223491403|NCT05926765|GENETIC|AAV2-hAQP1 Concentration 4|Administration of concentration 4 of AAV2-hAQP1 via Stensen's duct to each parotid gland
223491404|NCT04892953|DRUG|Carboplatin|Given IV
223491405|NCT04892953|BIOLOGICAL|Durvalumab|Given IV
223491406|NCT04892953|DRUG|Gemcitabine|Given IV
223491407|NCT04892953|PROCEDURE|Local Consolidation Therapy|Undergo LCT
223491408|NCT04892953|DRUG|Nab-paclitaxel|Given IV
224183098|NCT04143815|DRUG|Placebo|Intramuscular injection
223491409|NCT04892953|DRUG|Paclitaxel|Given IV
223491410|NCT04892953|DRUG|Pemetrexed|Given IV
223491411|NCT04892953|OTHER|Quality-of-Life Assessment|Complete questionnaire
223491412|NCT04892953|OTHER|Questionnaire Administration|Complete questionnaire
223491413|NCT06174038|DEVICE|Hearing Intervention|"The hearing intervention includes an auditory needs assessment, hearing aid fitting, establishing Bluetooth connectivity from hearing aids to devices such as smartphones and computers, systematic orientation and instruction in device use, and provision and discussion of hearing toolkit materials for self-management and communication strategies. The hearing intervention is person-centered, focusing on identification of individual needs, setting of specific goals, engagement in shared-informed decision-making, and development of self-management abilities. Intervention-centric outcomes (e.g., hearing aid data logging, real ear measures) to verify the best-practices intervention will be gathered at all 5 intervention sessions as well as weeks 16 and 52. Additional visits to troubleshoot hearing aids or address concerns will be scheduled as needed."
223491414|NCT06174038|BEHAVIORAL|Health Education Intervention|"The evidence-based interactive health education program is designed for older adults and addresses chronic disease and disability prevention. Session content will be individualized for each participant based on a key, depending on his/her goals/interests. The curriculum includes didactics, activities, and goal setting led by staff trained/certified to deliver the intervention."
223491415|NCT06973525|DRUG|Patients will initially receive trastuzumab, pyrotinib, and albumin-bound paclitaxel. Those who do not achieve a radiological response after Cycle 2 will switch to SHR-A1811 (a HER2-targeted antibody|Drug: SHR-A1811 Drug: Pertuzumab
223491416|NCT06973525|DRUG|Patients will initially receive trastuzumab, pyrotinib, and nab-paclitaxel. Those who achieve a partial response (PR) or complete response (CR) after cycle 2 will continue on the same regimen.|Patients will initially receive trastuzumab, pyrotinib, and nab-paclitaxel. Those who achieve a partial response (PR) or complete response (CR) after cycle 2 will continue on the same regimen.
224183099|NCT04754009|BEHAVIORAL|Trauma-Sensitive Yoga + TAU|Trauma-Sensitive Yoga is a movement-based approach that are used to integrate both mind and body, and promote body awareness and acceptance for those who have been exposed to traumatic events and currently experience trauma symptoms.
224183100|NCT04754009|BEHAVIORAL|Chen Style Tai Chi + TAU|Chen Style Practical Method tai chi is a martial art that is used as a form of self-defense and to maintain physical health and well-being.
224183101|NCT04754009|BEHAVIORAL|Treatment as Usual|Consists of traditional talk therapy for mental health.
224183102|NCT02087020|PROCEDURE|Debridement, antibiotics and implant retention|DAIR treatment protocol embodies an extensive surgical debridement and a radical excision of infected tissue. This is followed by exchange of modular components (articulating surfaces of the implant such as the femoral head, acetabular liner in total hip arthroplasty and the tibial insert, the polyethylene meniscus, in total knee arthroplasty). The wound is then copiously irrigated (\> 9 litre) with 0.9 % sodium chloride and then closed.
223512488|NCT04250363|DRUG|M5717 80 mg|Participants received 80 mg single oral dose of M5717 capsule on Day 1.
223512489|NCT04250363|DRUG|M5717 100 mg|Participants received 100 mg single oral dose of M5717 capsule on Day 1.
223512490|NCT04250363|DRUG|M5717 200 mg|Participants received 200 mg single oral dose of M5717 capsule on Day 1.
223512491|NCT04250363|DRUG|Placebo|Participants received single oral dose of placebo matched to M5717 capsule on Day 5.
223512492|NCT04250363|DRUG|M5717 60 mg|Participants received 60 mg single oral dose of M5717 capsule on Day 5.
223512493|NCT04250363|DRUG|M5717 100 mg|Participants received 100 mg single oral dose of M5717 capsule on Day 5.
223512494|NCT04250363|DRUG|M5717 200 mg|Participants received 200 mg single oral dose of M5717 capsule on Day 5.
223512495|NCT02242903|DRUG|LY3079514|Administered SC
223512496|NCT02242903|DRUG|LY3079514|Administered IV
223512497|NCT02242903|DRUG|Placebo|Administered SC
223512498|NCT02242903|DRUG|Placebo|Administered IV
223588094|NCT07040839|DRUG|Vonoprazan 20 mg|Vonoprazan 20 mg orally twice daily for 14 days, then 20 mg once daily for 4 weeks
224183103|NCT03593109|DRUG|Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy|Patients will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of CAR-T cells. After a pre-treatment lymphodepletion therapy, patients will receive the Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy by intravenous injection.
223491417|NCT06740370|PROCEDURE|TACE|TACE procedure was a 2.8-F microcatheter was super-selectively inserted into the tumor feeding artery using the coaxial technique. Then a combination of lipiodol (5-15 ml), lobaplatin (30-50 mg), and Pirarubicin (30-50 mg) was infused into each tumor. We defined technical success as complete embolization of the tumor-feeding artery resulting in no tumor staining observed by angiogram at the end of procedure.
224183104|NCT04463719|BEHAVIORAL|Counseling using the electronic conversation aid|Patients receive counseling about thyroid biopsy with the use of the conversation aid.
224183105|NCT04463719|BEHAVIORAL|counseling by routine care|Patients receive counseling by routine care without the use of the conversation aid
224183106|NCT04159558|DEVICE|Mobile application|Experimental group will use a mobile application to help them in their self-care
224308229|NCT03261765|OTHER|Assessment of adhesions|Modified Nair scoring system
224183107|NCT03028324|DEVICE|Transcranial Magnetic Stimulation (TMS)|Non-invasive brain stimulation, high frequency repetitive TMS delivered in 10 sessions over a 2-week period.
224183108|NCT00612963|DRUG|Frio Oral Rinse|Prescription Mouth Rinse
224183109|NCT05360017|DEVICE|litestepper single lower limb rehabilitation training robot|The experimental group adopts litestepper single lower limb rehabilitation training robot walking training on the basis of routine rehabilitation management of stroke patients with hemiplegia, walking training once a day, 40 ± 5 minutes each time; The control group was treated with routine rehabilitation management of stroke patients with hemiplegia. The trial was an open design. Both researchers and subjects knew the treatment allocation and conducted three evaluations within 21 days to evaluate the effectiveness and safety of litestepper single lower limb rehabilitation training robot in the training of lower limb motor function of stroke patients with hemiplegia.
224308230|NCT02175576|DEVICE|Vanguard XP Bicruciate Knee System|The Vanguard XP is a bicruciate retaining total knee design and is constrained by natural soft tissue.
224308231|NCT02175576|DEVICE|Vanguard CR Knee System|The Vanguard CR system requires the ACL to be sacrificed and is constrained by soft tissue and device design.
224308232|NCT04060316|DRUG|GLS-1200|GLS-1200 is given as a nasal spray using an atomizer
224308233|NCT04060316|DRUG|Placebo|Placebo is given as a nasal spray using an atomizer
224308234|NCT05919316|DEVICE|Rhinophototherapy|Intranasal rhinophotometer to be used at home for 4.5 minutes three times daily for 14 days
224308235|NCT05919316|DRUG|Nasonex Nasal Spray|50mcg/dose, 2 sprays each nostril (morning or evening) once daily for 14 days
224308236|NCT02972918|DRUG|Levosimendan|24h preoperative infusion of levosimendan (0,1 mcg/Kg/min)
223491418|NCT06740370|DRUG|Lenvatinib|(12 mg (body weight ≥60 kg) , 8 mg (body weight \<60 kg) orally once a day
223491419|NCT06740370|DRUG|PD-1 Inhibitors|Tislelizumab (200mg intravenously every 3 weeks), Sintilimab (200mg intravenously every 3 weeks), Camrelizumab (200mg intravenously every 3 weeks)
223512499|NCT05698992|OTHER|evidence-based individualized rehabilitation|The experimental group will receive structured individualized assessment based on physical, psychological or social needs and will be offered evidence-based interventions to promote rehabilitation and recovery.
223512500|NCT04504669|DRUG|AZD8701|FOXP3 antisense oligonucleotide
223512501|NCT04504669|BIOLOGICAL|Durvalumab|anti PDL-1 monoclonal antibody
223588095|NCT06727136|DRUG|TBP-PI-HBr|TBP-PI-HBr film-coated immediate-release tablets
223588096|NCT07044635|RADIATION|Radiation Therapy|Reduced dose and Hypofractionated radiation therapy
223588097|NCT06729918|OTHER|Virtual reality|Thoracic lung physical examination will be studied using a virtual reality-based thoracic and lung physical examination learning tool.
223588098|NCT06729918|OTHER|simulated patient|Thoracic lung physical examination will be studied using a simulated patient.
223588099|NCT07041775|OTHER|myoelectric interface for neurorehabilitation (MINT) conditioning|Myoelectric interface for neurorehabilitation (MINT) conditioning involves training to reduce abnormal co-activation of limb muscles to improve movement.
223588100|NCT07041775|OTHER|One muscle myoelectric feedback|Training to control muscle activity in one muscle only.
223588101|NCT06885229|DEVICE|FloMask - reuseable face mask|Reuseable, elastomeric face mask with replaceable filters
224308237|NCT05217719|DRUG|recombinant human thrombopoietin|The dose of rhTPO is 15,000 U per day. The subcutaneous injection will be terminated when PCs are increased to normal. The duration of rhTPO will be 7 days.
224308238|NCT05217719|DRUG|normal saline|Patients in the control group will receive the same amount of saline as a placebo, which is injected subcutaneously. The duration of saline will be 7 days.
224308239|NCT06248541|DEVICE|treatment with low-level laser therapy|low-level laser therapy (wavelength of 620 - 640nm)
224308240|NCT06248541|DEVICE|treatment with conventional light diodes|conventional light diodes
224308241|NCT05975138|PROCEDURE|implant insertion|a minimally invasive full-thickness flap will be raised in order to visualize the anatomy of the ridge. The vertical thickness of the supracrestal soft tissue will be measured and recorded. The preparation of the implant site will be performed with rotary burs and the bone quality will be recorded. An implant will be placed according to the manufacturer's recommendations. The length of the implant will be chosen in order to obtain a bicortical anchorage on the floor of the maxillary sinus
224308242|NCT01974336|DRUG|ursodeoxycholic acid|
224308243|NCT02784353|BEHAVIORAL|Perioperative rehabilitation program|"Perioperative rehabilitation program~* preoperative rehabilitation : 2 weeks prior to operation~* postoperative rehabilitation : 3 months after operation"
224308244|NCT02784353|BEHAVIORAL|Conventional|conventional perioperative management without rehabilitation program
224308245|NCT06297954|DRUG|Metoclopramide|Patients will receive metoclopramide 20 mg IV in a single dose prior to randomization.
224308246|NCT06297954|DRUG|Placebo|Patients will receive placebo 10 ml IV in a single dose prior to randomization.
224308247|NCT00658645|DRUG|Bifeprunox|20 mg daily, encapsulated tablets, orally, 12 months
224308248|NCT00658645|DRUG|Placebo|Encapsulated tablets, orally, 12 weeks
224183110|NCT02177227|DEVICE|Attune TruMatch (TM) Patient-Specific Instrumentation|Patients to receive total knee replacement with TruMatch Patient-Specific Instrumentation
223491420|NCT06187909|PROCEDURE|PECS II BLOCK|The patient laid supine with the ipsilateral arm abducted and externally rotated. The high-frequency linear probe was placed transversely between the clavicle medially and above and the shoulder joint laterally. After identifying the pectoralis major and minor muscles and the plane between them, the probe was angled caudally to look for the pulsating pectoral branch of the thoraco-acromial artery. After that, the block needle was inserted in an in-plane approach to the artery's location and 10 mL of 0.25% bupivacaine were administered. Then probe was moved laterally and caudally towards the anterior axillary fold until the serratus muscle appears beneath the pectoralis minor muscle attaching to the underlying ribs. The third and fourth ribs were detected. The needle targeted the plane between pectoralis minor and serratus muscles at the level of the third rib, followed by negative aspiration into the fascial plane then injection of 10 mL of 0.25% bupivacaine was done.
223491421|NCT06187909|PROCEDURE|MTP BLOCK|The block was performed with the patient in a sitting position. A high-frequency linear probe was placed in a vertical orientation 3 cm lateral to the midline at the T2 level in the parasagittal plane. The distance between the parietal pleura and the transverse process was measured using ultrasound guidance. The block needle was inserted out of plane to the probe and advanced to a depth equivalent to half of the measured distance beyond the transverse process. Then, 10 mL of 0.25% bupivacaine was injected. A similar injection was performed at the T6 level, with sonographic identification and level determination achieved by counting from the second rib.
223491422|NCT06424275|DIAGNOSTIC_TEST|Risk-based screening algorithm|Risk-based screening algorithm
223491423|NCT05735327|DRUG|No intervention|As this is an observational study, no intervention will be administered.
223491424|NCT06067399|DIAGNOSTIC_TEST|Glycated hemoglobin (HbA1C)|Blood test will be done at time of recruitment (for 2 groups) , after 3 months and after 6 months (for group 1 )
223491425|NCT06067399|DIAGNOSTIC_TEST|RDW|Blood test will be done at time of recruitment (for 2 groups) , after 3 months and after 6 months (for group 1 )
223491426|NCT06067399|DIAGNOSTIC_TEST|Lipid profile|Blood test will be done at time of recruitment (for 2 groups) , after 3 months and after 6 months (for group 1 )
223491427|NCT05997342|DRUG|TQB3912 tablets|TQB3912 is a small molecule Phosphorylated protein kinase inhibitor. Activation of the pathway plays an important role in cell survival, proliferation, migration, and differentiation.
223491428|NCT06321068|DRUG|carboplatin|the usage and dosage should be determined by the investigator
223491429|NCT06321068|DRUG|Paclitaxel|the usage and dosage should be determined by the investigator
223491430|NCT06321068|DRUG|Recombinant humanized anti-PD-1 monoclonal antibody injection|Strength 100 mg/4 mL, intravenous drip, recommended dose 300 mg, administered every 3 weeks (21 days) (Q3W).
223491431|NCT06798324|DEVICE|Active Transcranial Direct Current Stimulation (tDCS)|Transcranial direct current stimulation (tDCS) is a form of non-invasive brain stimulation. Active tDCS involves brief (e.g., 20-min) application of weak electric current (e.g., 2 mA) to the scalp. The tDCS device that will be used for this study is the Soterix 1x1 mini-CT.
223491432|NCT06798324|DRUG|Varenicline 1mg BID|"Varenicline is the most effective approved treatment for quitting smoking. Varenicline as per standard prescribing for dose escalation (i.e. Days 1 to 3: 0.5 mg once daily; Days 4 to 7: 0.5 mg twice daily; Days 8 to end of treatment: 1 mg twice daily) will be given concurrently over the same 2 weeks as the tDCS protocol and continue for an additional 10 weeks as per standard treatment duration recommended on the product monograph for a total of 12 weeks of varenicline treatment. Dose adjustments due to adverse events will be allowed (i.e. decrease to 0.5 mg twice daily).~The target quit date for smoking cessation will be on the last day of the two weeks of daily tDCS which corresponds to the recommended quit date after starting varenicline treatment."
223491433|NCT06798324|DEVICE|Sham Transcranial Direct Current Stimulation (tDCS)|Sham tDCS consists of 30s of 2 mA at the beginning and at the end of the 6 session (ramp up and down), then receiving 0 mA stimulation for the middle 19 min. The tDCS device that will be used for this study is the Soterix 1x1 mini-CT.
223491434|NCT06142383|BIOLOGICAL|Placebo|S.C. Injection
223491435|NCT06142383|BIOLOGICAL|XXB750 Low dose|S.C. Injection
223491436|NCT06142383|BIOLOGICAL|XXB750 Medium Dose|S.C. Injection
223491437|NCT06142383|BIOLOGICAL|XXB750 High Dose|S.C. Injection
223491438|NCT06142383|DRUG|Sacubitril/valsartan|Tablet
223491439|NCT06648512|OTHER|No Interventions|No Intervention
223491440|NCT05077605|OTHER|Functional residual capacity measure by electrical impedance tomography|Patient functional residual capacity will be measured by electrical impedance tomography before extubation and then at 0, 10, 15 and 20 min after extubation.
224183111|NCT00131027|DRUG|Cyclophosphamide|
224183112|NCT00131027|DRUG|Daunorubicin|
223491441|NCT05323149|OTHER|Saline|Giving saline (loading dose of 1gm of saline 0.9%, followed by a 1gm of maintenance saline dose over 8 hours for 48 h).
223491442|NCT05323149|DRUG|Tranexamic acid|Giving TXA (loading dose of 1gm of TXA, followed by a 1gm of maintenance dose over 8 hours for 48 h).
223491443|NCT06128525|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223491444|NCT06128525|DEVICE|Microwave Ablation|Undergo transperineal MRI/US fusion guided transperineal targeted microwave ablation
223491445|NCT06128525|DEVICE|Multiparametric Magnetic Resonance Imaging|Undergo planning mpMRI of prostate
223491446|NCT06128525|OTHER|Questionnaire Administration|Ancillary studies
223491447|NCT06128525|PROCEDURE|Radical Prostatectomy|Undergo RP
223491448|NCT05200442|DRUG|VS-6766/avutometinib|An oral anti-cancer medication.
223491449|NCT05200442|DRUG|Cetuximab|A chemotherapy drug used to treat head, neck and colorectal cancer.
223491450|NCT05200442|OTHER|Pill Diary|A diary where participants in phase 2 of study will log their medications and times they are taken on study.
223491451|NCT03135327|DIETARY_SUPPLEMENT|Ocufolin|Ocufolin medical food capsules will be taken once a day by mouth each morning with a meal for the first week, two capsules orally each morning with a meal for the second week and three capsules orally each morning with a meal for the rest of the 6 months study duration.
223491452|NCT06075264|DRUG|Artesunate ointment|topical ointment, as a non-surgical treatment
224183113|NCT00131027|DRUG|Vincristine|
224183114|NCT00131027|DRUG|Prednisolone|
224183115|NCT00131027|DRUG|L-asparaginase|
223491453|NCT06075264|DRUG|Placebo ointment|topical placebo ointment
223491454|NCT06624124|BEHAVIORAL|Gamified Training in Diversity Considerations in the Management of Pain and Opioid Use|Use of a video game-based training platform
223491455|NCT06624124|BEHAVIORAL|Traditional Training in Diversity Considerations in the Management of Pain and Opioid Use|Use of a traditional text-based training platform
223491456|NCT06208241|DRUG|Allocetra-OTS|Allocetra-OTS is a cell-based therapy consisting of non-HLA-matched allogeneic peripheral blood mononuclear cells, derived from a healthy human donor following a leukapheresis procedure, induced to an apoptotic stable state and suspended in a solution containing DMSO.
223491457|NCT06976892|DRUG|Dose Level 2 (starting dose)|Idetrexed: 9 mg/m2 I.V. (days 1 \& 8) Olaparib: 300 mg P.O. (days1-7, 15-21)
223491458|NCT06976892|DRUG|Dose Level 1|Idetrexed: 9 mg/m2 I.V. (days 1 \& 8) Olaparib: 200 mg P.O. (days1-7, 15-21)
223491459|NCT06976892|DRUG|Dose Level -1|Idetrexed: 9 mg/m2 I.V. (days 1 \& 8) Olaparib: 150 mg P.O. (days1-7, 15-21)
223491460|NCT06976892|DRUG|Dose Level 3|Idetrexed: 12 mg/m2 I.V. (days 1 \& 8) Olaparib: 200 mg P.O. (days1-7, 15-21)
224183116|NCT00131027|DRUG|Cytarabine|
224183117|NCT00131027|DRUG|Etoposide|
224183118|NCT00131027|DRUG|Dexamethasone|
224183119|NCT00131027|DRUG|Methotrexate|3 g/sqm (high dose)
224183120|NCT00131027|DRUG|Mercaptopurine|
224183121|NCT00131027|DRUG|Doxorubicin|
224183122|NCT00131027|DRUG|Methotrexate|0.5 g/sqm (intermediate dose)
224183123|NCT02213627|DRUG|Corifollitropin alfa|
224183124|NCT02213627|DRUG|Recombinant FSH|
224183125|NCT02213627|DRUG|HP-hMG|
224183126|NCT00137982|PROCEDURE|Treatment of ectopic pregnancy|
224183127|NCT05747157|DRUG|Metabolically Armed CD19 CAR-T cells|Each subject receive metabolically armed CD19 CAR-T cells by intravenous infusion.
223491461|NCT06976892|DRUG|Maximum Tolerated Dose|MTD of Olaparib in combination with idetrexed established from Dose Escalation
223491462|NCT06974604|DRUG|Dexamethasone oral|Dexamethasone 10 mL daily for days 1-5 for each of the ﬁrst 3 cycles of therapy Datopotamab Deruxtecan 6.0 mg/kg IV on day 1 every 21 days
223491463|NCT04907799|BEHAVIORAL|Daily caloric restriction|Weight loss based on daily caloric restriction and increased physical activity
223491464|NCT04907799|OTHER|Standard advice control|Initial nutrition consultation without subsequent counseling
223491465|NCT04275648|DIAGNOSTIC_TEST|AsthmaTuner exercise field test|AsthmaTuner consist of a a bluetooth spirometer and smartphone app with protocol for measuring lung function (FEV1) and perform 8 min exercise challenge test and a healthcare web interface.
223491466|NCT05007873|DRUG|Dasatinib|Given PO
223491467|NCT05007873|DRUG|Decitabine and Cedazuridine|Given PO
223491468|NCT04046133|DRUG|Pembrolizumab|Pembrolizumab, an immune checkpoint inhibitor, concomitantly with standard CRT in patients with locally advanced T3/4 anal cancer.
223491469|NCT05092542|BEHAVIORAL|Refugee and Immigrant Well-being Project (RIWP)|6-month mental health intervention that pairs university students with newcomers to engage in mutual learning, resource mobilization, and social change efforts
223491470|NCT00929006|DRUG|Micronized progesterone suspension|Micronized progesterone 0.8 mg/kg at 0700, 1500, 2300 and 0700 h. Progesterone is a natural hormone.
223491471|NCT00929006|DRUG|Placebo|Placebo contains only inert ingredients and is not expected to exert any direct physiological effects
223491472|NCT06084741|OTHER|Omitting of usage of intraabdominal drains after repair of peptic ulcer perforations|omitting the intraabdominal drains
223491473|NCT06084741|OTHER|Using intraabdominal drains|The investigators will put intraabdominal drains
223491474|NCT04452526|OTHER|Best Practice|Receive usual care
223491475|NCT04452526|OTHER|Educational Intervention|Receive educational materials
223491476|NCT04452526|OTHER|Questionnaire Administration|Ancillary studies
223491477|NCT04452526|OTHER|Reminder|Receive reminder letter
223491478|NCT06975696|PROCEDURE|Standard endovascular thrombectomy with Fusion|Standard endovacular procedure with the addition of Fusion imaging according to the intended use of the ARTIS Icono Biplane.
223491479|NCT06975696|PROCEDURE|Standard EVT without Fusion|Standard endovacular procedure without the use of Fusion imaging on the ARTIS Icono Biplane.
223491480|NCT06119607|DEVICE|TRIFLO Heart Valve|Surgical Aortic Valve Replacement - Mechanical Valve
223491481|NCT06424509|OTHER|High degree of long (>5 days) and/or compulsory psychiatric inpatient care|High degree of long (\>5 days) and/or compulsory psychiatric inpatient care
223491482|NCT06340581|DRUG|Treatment A: BGF MDI HFA|Participants will receive 4 oral inhalations of BGF MDI HFA as a single dose with AeroChamber Plus Flow-Vu spacer with charcoal.
224183128|NCT03186950|PROCEDURE|Restoration with Stainless Steel Crowns|After finishing the endodontic treatment with Guedes-Pinto Paste, the restoration of the teeth will be made using Stainless Steel Crowns.
224183129|NCT03186950|PROCEDURE|Restoration using BulkFill CR|After finishing the endodontic treatment with Guedes-Pinto Paste, the restoration of the teeth will be made using BulkFill composite resin
224183130|NCT02515890|DRUG|Dexmedetomidine|Selected subjects received this drug during a portion of the study
224183131|NCT02515890|DRUG|Midazolam|Selected subjects received this drug during a portion of the study
224183132|NCT02515890|DEVICE|Peripheral nerve stimulation|Experimental acute pain stimulus was delivered using a nerve stimulator. These painful shocks were paired randomly with some of the auditory experimental cues.
224183133|NCT02515890|DRUG|Ketamine|Selected subjects received this drug during a portion of the study
224183134|NCT00927277|DEVICE|Erchonia(R) LipoLASER PL; Erchonia(R) EML Laser|The Erchonia(R) EML Laser is a low level laser light therapy medical device that was applied during the liposuction procedure, by emitting 1 mw of red (635nm wavelength) light via a Class II electric laser diode energy source (CDRH classification). The fluence is considered to be at 10.8 joules per area treated.
224183135|NCT00927277|DEVICE|Erchonia(R) LipoLASER PL|
224183136|NCT05103462|BEHAVIORAL|Telehealth Physical Therapy|Weekly sessions of physical therapy provided using two-way, interactive, video technology consisting of education, advice and exercise instruction.
224183137|NCT02662140|BEHAVIORAL|Mobile Health Applictaion|"Component 1: Delivering homework via a highly engaging, multiplayer, interactive, cooperative, and skill-building game platform aimed at improving the Design and Do process of HW.~Component 2: Focuses on targeting factors putative related to poor HW implementation within the Do process"
224183138|NCT04282551|OTHER|dietary intervention with oligosaccharides|intervention with oligosaccharide 1 or 2, or placebo, given once a day
224183139|NCT00981331|PROCEDURE|Subtalar joint manipulation|The intervention is defined as a toggle-recoil, high-velocity, low-amplitude subtalar joint manipulation.
224183140|NCT00981331|PROCEDURE|Sham subtalar joint manipulation|The sham manipulation is conducted by placing the ankle in a non-manipulative position, and the operator simply engages the toggle board to simulate the audible noise of the toggle board dropping. No force or thrust is applied to the ankle.
224183141|NCT03135873|DIETARY_SUPPLEMENT|Mastiha|Mastiha is a natural product of Greece and has a license of manufactures Foods for Particular Nutritional Uses and of National Organization of Medicines (EOF).
224183142|NCT03135873|DIETARY_SUPPLEMENT|Placebo|Placebo is designed to have identical characteristics with verum.
224183143|NCT01878968|OTHER|Script and CPR/Mechanical ventilation video.|Patients will be randomized to receive the script (see addendum) plus video. Video was produced by and is the property of the study investigators.
224183144|NCT05896072|PROCEDURE|Erector Spinae Plane Block|"Application of ultrasound-guided erector spinae plane block for perioperative analgesia for elective inguinal hernia repair. Erector spinae plane block will be administered under general anesthesia before the surgery~Drug: Bupivacaine (Block Drug)~For block performances, 0,25% Bupivacaine will be used at 0,5 ml/kg (max. 20cc)."
224183145|NCT05896072|PROCEDURE|Caudal Block|"Application of caudal block for perioperative analgesia for elective inguinal hernia repair. The caudal block will be administered under general anesthesia before the surgery.~Drug: Bupivacaine (Block Drug)~0,25% Bupivacaine will be used at 0,5 ml/kg (max. 20cc) for block performances"
224183146|NCT01729559|DRUG|5000 Units unfractionated Heparin Q 8 hr|Venous thromboembolic prophylaxis medication
224183147|NCT01729559|DRUG|30mg enoxaparin Q12 hr|Venous thromboembolic prophylaxis
224183148|NCT04796259|DIETARY_SUPPLEMENT|Malt ingredient|Solution with malt-derived ingredient
224183149|NCT04796259|DIETARY_SUPPLEMENT|Non-alcoholic beer solids|Solution with non-alcoholic beer solids
224183150|NCT02461342|OTHER|not intervention|This is a cross-sectional study, no intervention was performed.
224183151|NCT04112108|PROCEDURE|PTMC|percutaneous mitral ballooning with Inoue balloon
224183152|NCT05342727|DEVICE|transcranial direct current stimulation (tDCS)|In tDCS, direct electrical currents at the intensity of interest (2 mA for example) are generated by an electrical stimulator and are noninvasively delivered to the scalp through a pair of saline-soaked sponge electrodes (7×5 cm).
224183153|NCT05342727|DEVICE|transcranial alternating current stimulation (tACS)|In tACS, alternating electrical currents at the frequency of interest (8 Hz for example) are generated by an electrical stimulator and are noninvasively delivered to the scalp through a pair of saline-soaked sponge electrodes (7×5 cm).
224183154|NCT01967927|DRUG|18F-MISO|A radiolabeled imaging agent that has been used for investigating tumor hypoxia with positron emission tomography (PET).
224183155|NCT01559142|DRUG|Infliximab with azathioprine (IIFX + AZA)|Infliximab with azathioprine during whole one year study
223491483|NCT06340581|DRUG|Treatment B: BGF MDI HFO|Participants will receive 4 oral inhalations of BGF MDI HFO as a single dose with AeroChamber Plus Flow-Vu spacer with charcoal.
223491484|NCT06340581|DRUG|Treatment C: BGF MDI HFO|Participants will receive 4 oral inhalations of BGF MDI HFO as a single dose without spacer with charcoal.
223491485|NCT06340581|DEVICE|AeroChamber Plus Flow-Vu Spacer|Participants will receive 4 inhalations of BGF MDI HFA (treatment A) and BGF MDI HFO (Treatment B) as a single dose with AeroChamber Plus Flow-Vu spacer.
223491486|NCT05020743|OTHER|No intervention|Not applicable for a Natural History Study
223491487|NCT06460298|DRUG|ProAgio Dose Levels (DL) 1,2,3,4|ProAgio combined with Gemcitabine in patients with metastatic TNBC who have been previously treated with at least two prior lines of therapy.
223491488|NCT06460298|DRUG|ProAgio Dose Expansion|ProAgio combined with Gemcitabine in patients with metastatic TNBC who have been previously treated with at least two prior lines of therapy.
223491489|NCT04730921|DEVICE|Left bundle branch area pacing|Left bundle branch area pacing(LBBAP) is a novel physiological pacing form for ventricular pacing. In patients received LBBAP, the pacing lead will be placed at left bundle branch area to achieve narrow paced QRS duration.
223491490|NCT04730921|DEVICE|Right ventricular pacing|Right ventricular pacing is the traditional pacing modality for ventricular pacing. The pacing lead was placed in the apex or septum of right ventricle.
223491491|NCT06177301|DRUG|Tislelizumab combined with GX|"Tislelizumab：200mg vgtt，q3w；treatment until disease progression, patients withdrawal of informed, or intolerable toxicity.~Gemcitabine：1000mg/m2, vgtt, d1,8, q3w, repeat 4-6 cycles. Capecitabine: 1000mg/m2, bid，po, d1-14, q3; treatment until disease progression, patients withdrawal of informed, or intolerable toxicity."
224183156|NCT01559142|DRUG|Infliximab (IFX alone)|Infliximab continuously; azathioprine stopped in 26 week
224183157|NCT04282499|PROCEDURE|combined exercise|Patients will be undergone to aerobic exercises in addition to the resistance training.
224183158|NCT04282499|PROCEDURE|aerobic exercise|Patients will be trained through the aerobic exercises only.
224183159|NCT02492321|DRUG|EBI-005|
224183160|NCT02492321|DRUG|Placebo Comparator|
224183161|NCT01356615|DRUG|low molecular weight heparin (enoxaparin sodium)|Enoxaparin sodium (Clexane; 40 mg) was administered 3-4 min before dialysis as a bolus dose, into the arterial line pre-dialyzer.
224183162|NCT01356615|DRUG|standard unfractionated heparin|Heparin (sodium heparin 5000 IU/ml) was administered as a bolus dose (50 IU/kg body weight) intravenously into the pre-dialyzer arterial line of the extracorporeal blood circuit, followed by a maintenance dose of 1000 IU sodium heparin per hour.
224183163|NCT04099940|BEHAVIORAL|Virtual Reality Avatar Therapy (VRAT)|The Virtual Reality Avatar Therapy (VRAT) is a Cognitive Behavioral Intervention, delivered through Virtual Reality.
224183164|NCT04099940|BEHAVIORAL|Assertiveness Training Program (ATP)|The Assertiveness Training Program (ATP) is a Cognitive Behavioral Intervention, delivered as group therapy.
224183165|NCT06262009|OTHER|human faecal collection|collecting stools 6 times over a 90 days period and complete a questionnaire at the same times: D1, D7, D15, D30, D60 and D90
224183166|NCT06262009|OTHER|ancillary study|interviews and/or ethnographic observations for 50 volunteers
224183167|NCT01613209|DRUG|Candesartan cilexetil|candesartan 16 mg tablets p. o. for 14 days (morning), then candesartan 32 mg tablets for 28 day (morning)s,
224183168|NCT01613209|DRUG|Olmesartan/Amlodipin|olmesartan/amlodipine 40/5 mg tablets for 14 days (morning), then olmesartan/amlodipine 40/10 mg tablets for 28 days (morning), then olmesartan/amlodipine 40/10 mg tablets for 42 days (evening)
224183169|NCT04067687|OTHER|Palliative home visit|a 3-month home visit, providing two-way communication between a trained health worker and patients with or without their parents were conducted as the intervention (report by proxy or self-report). Interventions were given in 6 sessions (1 session every 2 weeks) focusing on problems solving education, symptoms management, self-care, communication, decision making, and long-term care plan assistance.
224183170|NCT06283654|DEVICE|1-lead ECG|patient were handed out a 1 lead ECG device, they were free to use it anyway they wanted, even not at all
224183171|NCT01122719|DEVICE|Drug Eluting Stent|
224183172|NCT06338527|OTHER|Aromatherapy|Lavender oil was used for aromatherapy intervention.
224183173|NCT06338527|OTHER|No intervention|No aromatherapy intervention was performed during the period of the study.
224183174|NCT01707667|DRUG|prucalopride|One 2 mg tablet orally administered on Day 1
224183175|NCT01707667|DRUG|PEG 3350|13.8g polyethylene glycol (PEG) 3350 with sodium bicarbonate, sodium chloride, and potassium chloride as a solution in water. Administered twice orally on Day 1(once in the morning and once prior to lunch).
224183176|NCT05980637|DRUG|Shaoyao Gancao Decoction with Addition|11g twice daily for 4 weeks
224183177|NCT05980637|OTHER|Placebo|11g twice daily for 4 weeks
224308249|NCT00658645|DRUG|Quetiapine|600 mg daily, encapsulated tablets, orally, 12 months
224308250|NCT00698880|PROCEDURE|Right hepatic vein embolization|Embolization of the right hepatic vein
224308251|NCT06390644|DIAGNOSTIC_TEST|Periorbital Massage Therapy|Participants in this arm will receive periorbital massage therapy administered by a trained practitioner. The massage technique will involve gentle circular motions around the eye sockets and brow bone area, aiming to improve eyelid and tear gland function.
224308252|NCT06390644|OTHER|Control Group (Standard Care)|"Participants in this arm will receive standard care for dry eye disease, which include artificial tears. They will not receive periorbital massage therapy."
224308253|NCT00578669|DRUG|Fluoxetine|20mg once daily for 16 weeks
224308254|NCT00578669|DRUG|Dextrose|Once daily for 16 weeks
224308255|NCT03033082|OTHER|Questionnaire sheets|"A- Marital satisfaction Index (MSI). Interview (Modified Arabic translation)~B- Sexual Satisfaction Scale:(SSS). The Arabic version of the sexual satisfaction scale was used.~C- International Index of Erectile Function Questionnaire (IIEF-5): For male subjects.~D- The Eysenck Personality Questionnaire (EPQ):~The Arabic version of the EPQ was used."
224308256|NCT02777112|OTHER|e-mental health program|This program is delivered over the Internet, which includes modules of Information (about depression, workplace factors and alcohol use), Practical Tips (Cognitive Behavioral Therapy, Mindfulness relaxation, workplace strategies), Tools (for monitoring and predicting depression and occupational functioning), and Goal Setting and Tracking.
223491492|NCT06177301|DRUG|Tislelizumab combined with GP|"Tislelizumab: 200mg vgtt，q3w；treatment until disease progression, patients withdrawal of informed, or intolerable toxicity.~Gemcitabine: 1000mg/m2, vgtt, d1,8, q3w, repeat 4-6 cycles； Cisplatin: 80mg/m2, ivgtt, d1 (high-dose cisplatin antiemetic and hydration regimen), q3w，repeat 4 \~ 6 cycles."
223491493|NCT06379113|DRUG|GnRH antagonist|Gonadotropin-releasing hormone analogue, intramuscular injection of 3.75mg will be given every 4 weeks, and the maximum treatment courses will be 6. If the patient get CR within 6 courses, another 2 courses will be used as consolidation therapy.
224183178|NCT04805892|DIAGNOSTIC_TEST|BIOZEK COVID-19 Antigen Rapid Test|The BIOZEK COVID-19 Antigen Rapid Test is used for the detection of SARS-CoV-2 antigens in nasopharyngeal swab specimens from individuals who are suspected of having COVID-19.
224183179|NCT00440362|BIOLOGICAL|AVX502|1 dose at 2e8 IU given at t=0 via IM route
224183180|NCT00440362|BIOLOGICAL|AVX502|1 dose at 2e7 IU given at T=0 via the IM route
224183181|NCT00440362|BIOLOGICAL|AVX502|1 dose at 2e7 IU given at t=0 via the SC route
224183182|NCT00440362|BIOLOGICAL|AVX502|1 dose at 2e8 IU given at T=0 via the SC route
224183183|NCT00440362|BIOLOGICAL|AVX502|2 doses at 2e7 IU given at T=0 and 8 weeks via the IM route
223491494|NCT06379113|DRUG|Letrozole 2.5mg|2.5mg po qd.
223491495|NCT05224726|OTHER|Platelet Rich Plasma|Injection of 5cc of PRP preparation at the myometrium around the uterine incision after it has been sutured.
224183184|NCT00440362|BIOLOGICAL|AVX502|2 doses at 2e8 IU given at T=0 and 8 weeks via the IM route
224183185|NCT00440362|BIOLOGICAL|AVX502|2 doses of 2e7 IU given at t=0 and 8 weeks via the SC route
224183186|NCT00440362|BIOLOGICAL|AVX502|2 doses at 2e8 IU given at T=0 and 8 weeks via the SC route
224183187|NCT00440362|BIOLOGICAL|Placebo|1 dose of placebo given at T=0 via the IM route
224183188|NCT00440362|BIOLOGICAL|Placebo|1 dose of placebo given at T=0 via the SC route
224183189|NCT00440362|BIOLOGICAL|Placebo|2 doses of placebo given at T=0 and 8 weeks via the IM route
224183190|NCT00440362|BIOLOGICAL|Placebo|2 doses of placebo given at T=0 and 8 weeks via the SC route
224183191|NCT00518167|BEHAVIORAL|Intensive lifestyle counselling|"Individualized dietary and physical activity counselling aiming at~1. weight reduction~2. dietary fibre 15 g /1000 kcal or more~3. energy proportion of dietary fat less than 30%~4. energy proportion of saturated fat less than 10%~5. moderate physical activity \>30 minutes per day or 4 hours per week"
224308257|NCT02777112|OTHER|e-mental health program and job coaching|This combines the e-mental health program and interactive job coaching delivered through telephone. The e-mental health program is delivered over the Internet, which includes modules of Information (about depression, workplace factors and alcohol use), Practical Tips (Cognitive Behavioral Therapy, Mindfulness relaxation, workplace strategies), Tools (for monitoring and predicting depression and occupational functioning), and Goal Setting and Tracking. The job coaching can be accessed by appointment.
224308258|NCT02777112|OTHER|No intervention|Receiving generic information about men's depression from the Movember Foundation website: https://ca.movember.com/programs/mental-health
224308259|NCT02314091|PROCEDURE|onlay mesh hernioplasty|
224308260|NCT00004089|BIOLOGICAL|filgrastim|
224308261|NCT00004089|DRUG|fluorouracil|
224308262|NCT00004089|DRUG|hydroxyurea|
224308263|NCT00004089|DRUG|paclitaxel|
224308264|NCT00004089|PROCEDURE|conventional surgery|
224308265|NCT00004089|RADIATION|radiation therapy|
224183192|NCT04059328|PROCEDURE|Surgical training|This was a gyn laparoscopy training and simulation course
224183193|NCT01054794|DEVICE|Gastric mucosal stimulation|The lead is a sterile, 2mm diameter insulated wire (Temporary Transvenous Pacing Lead 6416-200cm, Medtronic, Minneapolis, MN) with 2 electrodes on the distal end. The mucosal stimulation parameters(Current:10 mA; Frequency: 14Hz; Pulse width: 330 ms; Cycle ON: 0.1 s; Cycle OFF: 5 s) are within the range used for standard permanent implanted GES (Enterra therapy) within the serosa and muscle layers of the stomach, and which has been shown to be safe, without any tissue damage.
224183194|NCT05270564|PROCEDURE|Drain|Surgical drains are placed as a standard of care (control arm) or not (experimental arm)
224183195|NCT05270564|PROCEDURE|No drain|Surgical drains are placed as a standard of care (control arm) or not (experimental arm)
224183196|NCT04786782|DIAGNOSTIC_TEST|PPG-detecting software|Virtual PPG (vPPG) of patients in experimental group is calculated based on anatomical and hemodynamic information of portal system collected by ultrasound and CT tests.
224183197|NCT04786782|DIAGNOSTIC_TEST|LSM and PLT count|Patients whose LSM \>15kPa, or PLT count \< 150\*10\^9 should be screened with upper GI endoscopy
224183198|NCT03611907|DEVICE|"Oocyte retrieval with only aspiration system SL1(Cook® Single Lumen)"|In this intervention a 17-Gauge needle is used to aspirate the follicles
224183199|NCT03611907|DEVICE|"Oocyte retrieval with aspiration and flushing system DL1 (Cook® EchoTip® Double Lumen)"|In this intervention a 17-Gauge needle is used to aspirate follicle, and consequently a 1 mL flush is injected and aspirated twice for each punctured follicle
223491496|NCT05224726|OTHER|Placebo|Injection of 5cc of 0.9% Normal Saline at the myometrium around the uterine incision after it has been sutured.
223491497|NCT06620406|DIETARY_SUPPLEMENT|Synbiotic IVS-1|A mixture of the prebiotic potato resistant starch (RS, Bobs Red Mill) and the probiotic IVS-1 (Bifidobacterium adolescentis).
223491498|NCT06620406|DIETARY_SUPPLEMENT|Maltodextrin|Maltodextrin, a carbohydrate packaged similarly to the study intervention
223491499|NCT05614115|DRUG|Empagliflozin|is a sodium-glucose co-transporter 2 (SGLT2) inhibitor.
224183200|NCT02212249|BIOLOGICAL|soluble Ve cadherin|dosage of soluble VE cadherine in each arms
224183201|NCT00836199|BIOLOGICAL|NicVAX vaccine|NicVAX vaccine given 6 times over 6 months
223491500|NCT05614115|OTHER|Placebo|Placebo comparator
223491501|NCT02351141|OTHER|Hyperpolarized Noble Gas MRI|"Hyperpolarized Helium-3 and/or Xenon-129. Noble gas magnetic resonance imaging (MRI) has recently emerged as another research approach for the non-invasive measurement of lung structure and function, including conduction of gas through airways and into airspaces.~Noble gas MRI provides a complimentary and alternative method for evaluating lung disease and may be superior to CT because it allows simultaneous visualization of both airway and airspace structure and function."
223491502|NCT03636438|OTHER|No Intervention|No Intervention
223491503|NCT04186832|DEVICE|FitBit|Wear FitBit
223491504|NCT04186832|DEVICE|Pedometer|Wear pedometer
224183202|NCT00836199|BIOLOGICAL|Placebo vaccine|Placebo vaccine given 6 times over 6 months
224308266|NCT00813527|DRUG|Lapaquistat acetate and fenofibrate|Lapaquistat acetate 100 mg, tablets, orally, once daily and fenofibrate 145 mg, tablets, orally, once daily for up to 12 weeks.
224308267|NCT00813527|DRUG|Fenofibrate|Lapaquistat acetate placebo-matching tablets, orally, once daily and fenofibrate 145 mg, tablets, orally, once daily for up to 12 weeks.
223491505|NCT04186832|OTHER|Quality-of-Life Assessment|Ancillary studies
223491506|NCT04186832|OTHER|Questionnaire Administration|Ancillary studies
223491507|NCT05171647|DRUG|Mosunetuzumab|Participants will receive SC mosunetuzumab on Days 1, 8, and 15 of Cycle 1, and on Day 1 of Cycles 2-8 (cycle length = 21 days).
223491508|NCT05171647|DRUG|Polatuzumab vedotin|Participants will receive IV polatuzumab vedotin every three weeks (Q3W) for 6 cycles (cycle length = 21 days).
223491509|NCT05171647|DRUG|Tocilizumab|Participants will receive IV tocilizumab as needed to manage cytokine release syndrome (CRS) events.
223491510|NCT05171647|DRUG|Rituximab|Participants will receive IV rituximab on Day 1 of each cycle for 8 cycles (cycle length = 14 days).
223491511|NCT05171647|DRUG|Gemcitabine|Participants will receive IV gemcitabine on Day 1 of each cycle for 8 cycles (cycle length = 14 days).
223491512|NCT05171647|DRUG|Oxaliplatin|Participants will receive IV oxaliplatin on Day 1 of each cycle for 8 cycles (cycle length = 14 days).
223491513|NCT01683526|PROCEDURE|Direct laryngoscopy|
223491514|NCT01683526|DEVICE|Video laryngoscopy (Glidescope)|
223491515|NCT01494558|OTHER|Chemoradiotherapy Regimen between PC and PE|etoposide 50mg/m2 d1-5, 29-33 and cisplatin 50mg/m2 d1,8,29 and 36 29-33 during radiotherapy paclitaxel 45mg/m2 weekly and carbplatin AUC =2mg/mL/min weekly during radiotherapy
223512502|NCT05315583|OTHER|Collection of biological samples|All participants will have at each of the visits: a venipuncture sample of 2 dry tubes of 7 mL to make up 3 aliquots and a nasopharyngeal swab (optional). The aliquots of serum / plasma and the nasopharyngeal swab will be stored at -80°C until sent to the Pasteur Institute.
224183203|NCT04416074|BEHAVIORAL|An online 5-week professional identity group psychotherapy|This is an online 5-week group psychological intervention for the nursing students during clinical rotation practice. It aims at promoting the professional identity and career sefl-efficacy for them. There are five sessions in the intervention, and each session lasts from 60min to 90min at each week. The intervention will be delivered via an online meeting software, like Zoom. There will be 15-20 students in one meeting group.
224183204|NCT04416074|OTHER|Message push|Controlled group will receive online messages of self-care knowledge forward by researchers once per week. The knowledge contain stress regulation, strategies for relaxation, self-protection during clinical practice.
224183205|NCT01673204|DRUG|Calcitriol|dosage of 0.5mcg administered orally once daily for 12 month
224183206|NCT01673204|DRUG|Placebo|
224183207|NCT02090140|PROCEDURE|ADSC Application|Patients will undergo arthroscopic resection of approximately 5cc of the infrapatellar fat pad, which will be collected for processing for a population of ADSCs. Patients will undergo arthroscopy and preparation of the chondral defect and removal of the calcified cartilage layer. Tisseel Fibrin glue will be placed at the base of the defect side, followed by the application of the acellular collagen dermal matrix, ADSCs, and an additional layer of fibrin glue.
224183208|NCT02090140|PROCEDURE|Microfracture|Microfracture surgery is the standard of care for articular cartilage lesions. Patients will undergo arthroscopy with standard technique of microfracture preparation, including the creation of vertical, stable defect edges and removal of the calcified cartilage layer. A microfracture awl will then be used to perform the microfracture technique (6mm below the subchondral plate).
224183209|NCT01593800|DIETARY_SUPPLEMENT|Bio-25|Bio-25 is an innovative formula containing 11 different strains of unique probiotic bacteria and over 25 billion active bacteria in each capsule. All participants will receive either Probiotics (Bio-25,will be provided by SupHerb) or placebo pills blindly for six months. One day prior to each visit, subjects will be asked to consume lactose, fructose and sorbitol free foods, in order to avoid high base line of hydrogen from the presence of unabsorbed carbohydrates. Subjects will also be asked not to smoke 24 hours prior to each visit.
224183210|NCT04455958|DRUG|Lopinavir/Ritonavir|Given PO
223491516|NCT04673734|DIAGNOSTIC_TEST|myelin sensitive MRI scan|"Acquisition of 3 myelin sensitive MRI scans as follows: 1. Two MRI during 1 day; the second after 30 min interval and a repositioning.~2\. One MRI within one week after the first one.~The total scan time will be \~ 1 hour. T1 maps will be calculated after magnetization-prepared 2 rapid acquisition gradient echoes (MP2RAGE6) acquisition based on a product sequence. Magnetization Transfer (MT) sat maps will be calculated. Quantitative susceptibility mapping (QSM) maps will be reconstructed using an in-house implementation of the structural feature based collaborative reconstruction algorithm (SFCR). For the reconstruction of multi-shell diffusion data, AMICO10 Accelerated Microstructure Imaging via Convex Optimization (AMICO) from diffusion MRI data will be used. Myelin Water Fraction maps will be fitted voxel-wise using a Non-Negative Least Squares fitting."
223491517|NCT04477863|OTHER|Follow-up Interview|Non Applicable
223491518|NCT00933153|DIETARY_SUPPLEMENT|Ensure Plus|Ensure plus supplement with meals
223491519|NCT00933153|DIETARY_SUPPLEMENT|Meals on Wheels|Two Meals on Wheels twice daily
223491520|NCT03820232|DEVICE|temperature monitoring|In every patient observed in this prospective observational study, body core temperature will be contemporaneously monitored through the oesophageal probe and the heated controlled servo sensor. Both are routinely used for this purpose in clinical practice
223491521|NCT05806970|OTHER|Email Nudge|An email to UCLA Health Cardiology clinic managers with a list of MRA-eligible HFrEF patients and a request to schedule or change cardiology appointments.
223491522|NCT04260113|DRUG|Apatinib Mesylate|Apatinib orally 500mg once daily half an hour after meal
223588102|NCT06454877|DEVICE|active heating|"Preheating will be performed for 15 minutes 30 minutes before surgery with a hot air blowing device in accordance with the normothermia care package so that the body temperature is 36-37 C°.~Active heating during surgery will be done with a heating bed placed on the operating table.~Patients taken to the postoperative care unit will continue to be heated with a hot air blower and the device will be turned off when the body temperature reaches 37 C°."
223588103|NCT06454877|BEHAVIORAL|pasive heating|"In accordance with the normothermia care package, the reflective blanket will be covered to cover the whole body 30 minutes before surgery.~During the operation, the body will be covered with a reflective blanket in accordance with the surgical intervention.~Patients taken to the postoperative care unit will continue to be warmed with reflective blankets."
223588104|NCT06045910|DRUG|ALETA-001|ALETA-001 will be administered intravenously (IV) every two weeks.
223745511|NCT06365021|BEHAVIORAL|Acceptance and Commitment Therapy|The ACT protocol for this study was developed by ACT psychologist Tatiana Cohab Khafif specifically for this study and for Bipolar Patients. It is a 12-session protocol that combines psychoeducation elements, mindfulness exercises, experiential exercises, discussions and group processes, homework assignments, and flexible repertoire modeling and training. The protocol is designed to fit into a single trimester. It covers all the basic aspects of Bipolar Disorder and the six processes of ACT.
224183211|NCT04455958|DRUG|Placebo Administration|Given PO
224183212|NCT04455958|OTHER|Questionnaire Administration|Ancillary studies
224183213|NCT06309524|DEVICE|Tricuspid transcatheter edge-to-edge repair|Transcatheter tricuspid leaflets approximation
224183214|NCT02365246|DEVICE|immunoadsorptions with an IgE-specific adsorption column|immunoadsorptions
224183215|NCT03432819|BEHAVIORAL|Siempre Seguiré|A culturally congruent CBT group intervention for HIV-positive LMSM, to include strategies for ART adherence and retention in HIV care.
224183216|NCT04196010|DRUG|Cladribine|Given IV
223491523|NCT04243668|PROCEDURE|ANTI REFLUX MUCOSAL ABLATION THERAPHY (ARMA)|"In patients fulfilling inclusion criteria and willing for ARMA, the procedure involves ablation of the mucosa of the EGJ using TT knife (ARMA). Subsequently, saline solution mixed with indigo-carmine is injected at the submucosa level to raise a submucosal bleb, followed by ablation of the mucosa along the lesser curvature using TT knife.The approximate duration of the procedure is 40min.~Follow up will include objective evaluation of reflux disease with: upper endoscopy, esophageal manometry, pHmetry,reflux questionnaire."
223491524|NCT06335199|PROCEDURE|Unilateral Left tVNS stimulation|Electrical stimulation to the cymba concha or tragus (depending on the ear dimension) of the outer ear on the left side after successful trials.
223491525|NCT06335199|PROCEDURE|Bilateral tVNS stimulation|Electrical stimulation to the cymba concha or tragus (depending on the ear dimension) of the outer ear on both sides after successful trials.
223491526|NCT06335199|PROCEDURE|Unilateral Left Sham stimulation|Electrical stimulation to the earlobe of the outer ear on the left side after successful trials.
223491527|NCT06335199|PROCEDURE|Bilateral Sham stimulation|Electrical stimulation to the earlobe of the outer ear on both sides after successful trials.
223491528|NCT06335199|PROCEDURE|Unilateral Right tVNS stimulation|Electrical stimulation to the cymba concha or tragus (depending on the ear dimension) of the outer ear on the right side after successful trials.
223491529|NCT06335199|PROCEDURE|Unilateral Right Sham stimulation|Electrical stimulation to the earlobe of the outer ear on the right side after successful trials.
223588105|NCT04528056|DRUG|Sulfasalazine|Sulfasalazine is an anti-inflammatory and immunosuppressive drug
224183217|NCT04196010|DRUG|Cytarabine|Given IV
224183218|NCT04196010|BIOLOGICAL|Recombinant Granulocyte Colony-Stimulating Factor|Given subcutaneously
224183219|NCT04196010|DRUG|Mitoxantrone|Given IV
224183220|NCT01905241|DEVICE|Anatomic TSA using RTI|Anatomic Total Shoulder Arthroplasty (TSA) will be performed using the SmartBone and Real Time Instrumentation (RTI) to transfer the preoperative plan for glenoid implant positioning to the patient's anatomy.
223491530|NCT01577914|DRUG|Carvedilol Tablets USP 12.5 mg|12.5mg tablet once a day
223491531|NCT01577914|DRUG|Carvedilol|12.5mg tablet once a day
223491532|NCT05265572|BEHAVIORAL|Domestic Hygiene and household hygiene Intervention|A demonstration on the domestic hygiene intervention will be conducted where participants will be guided on optimal cleaning of windowsills, floors and other surfaces with water and detergent, and advised on appropriate method of cleaning. Participants will be provided with a package of cleaning materials (mop, bucket, detergent, hand wash liquid soap and cloth for wet dusting) which will be used during the demonstration, and retained by participants to facilitate sustainability of the intervention during and after the study. Participants will be further engaged in an educational discussion, with the aid of a specially designed educational pamphlet containing information about health effects potentially associated with dust lead exposure from mine dumps and the personal hygiene and domestic hygiene steps that may be followed to reduce dust lead exposure.
223491533|NCT05645991|DIETARY_SUPPLEMENT|Coconut Sap Powder (CSP)|CSP was given once daily (1.5 g/day) for 8 weeks.
223491534|NCT05645991|DIETARY_SUPPLEMENT|Placebo|Capsules containing aspartame (1.5 g/day) were taken orally once daily for 8 weeks.
223491535|NCT01913353|BIOLOGICAL|MVA BN®|0.5 ml MVA BN® with a nominal titer of 1x10E8 TCID50, administered as a subcutaneous injection
223491536|NCT01913353|BIOLOGICAL|ACAM2000®|0.0025 ml ACAM2000®, consisting of 2.5-12.5x10E5 plaque forming units of live vaccinia virus (VACV). Picked up with a bifurcated needle and administered by the percutaneous route (scarification) using 15 jabs of that bifurcated needle.
223491537|NCT00051597|DRUG|SGN-30 (monoclonal antibody)|
223491538|NCT02835066|OTHER|Integrated Fitness Assessment|Undergo function/fitness assessment
223491539|NCT02835066|PROCEDURE|Psychosocial Assessment and Care|Undergo psychosocial health assessments
223491540|NCT02835066|PROCEDURE|Quality-of-Life Assessment|Complete EORTC QLQ-C30 and QLQ-LC13 questionnaires
223491541|NCT05808959|BEHAVIORAL|Education group|After the discharge training given at the clinic in the postoperative period, the participants will be given structured training on sexual health.
223491542|NCT01276834|DRUG|everolimus|comparison of everolimus-based and CNI-based immunosuppression
223491543|NCT00163059|DRUG|NMDA Antagonist, CP-101,606 (traxoprodil)|
223491544|NCT00056147|DRUG|denufosol tetrasodium (INS37217)|
223491545|NCT03183817|BEHAVIORAL|Person-centred care at distance|Person-centred care at distance through an eHealth platform
223491546|NCT04017962|DRUG|Letermovir Pill|Patients enrolled on the study will receive oral LTV 480 mg daily (240 mg daily for patients receiving cyclosporine A). The maximum duration of LTV administration will be 14 weeks. Patients receiving oral medication will be administered a pill diary for drug compliance purposes. This will be administered and reconciled in clinic.
223491547|NCT04017962|OTHER|blood draw|Collection of blood samples for CMV-CMI analysis via CMV immunity T cell panel assay on day 100. Patients with negative CMI on day 100 undergo collection of blood samples for retesting on day 180.
223491548|NCT06381245|DIAGNOSTIC_TEST|PPG-based remote heart rhythm/rate monitoring|PPG-based remote heart rhythm/rate monitoring
223491549|NCT06381245|DIAGNOSTIC_TEST|ECG-based remote heart rhythm/rate monitoring|ECG-based remote heart rhythm/rate monitoring
223491550|NCT06381245|DIAGNOSTIC_TEST|Transthoracic and transesophageal echocardiography examination|Transthoracic and transesophageal echocardiography examination
223491551|NCT06381245|DIAGNOSTIC_TEST|Liver ultrasound examination|Liver ultrasound examination
223491552|NCT06381245|DIAGNOSTIC_TEST|Rotational angiography with three-dimensional reconstruction|Rotational angiography with three-dimensional reconstruction
223491553|NCT06381245|DIAGNOSTIC_TEST|Blood-derived biomarker analysis|Blood-derived biomarker analysis
223491554|NCT06381245|DIAGNOSTIC_TEST|Mobile health-based spirometry|Mobile health-based spirometry
223491555|NCT01207960|BEHAVIORAL|Eye Movement Desensitization and Reprocessing (EMDR)|The intervention consists of three 90-minute sessions of individual psychotherapy. Sessions take place weekly according to a treatment manual.
223491556|NCT05590468|DIETARY_SUPPLEMENT|Nicotinamide Riboside|Vitamin B3 derivative; a total of 1000 mg/day in a regimen of 500mg every 12 hours by mouth (either fasting or fed)
223491557|NCT05590468|DRUG|Placebo|Looks exactly like the study drug, but it contains no active ingredient
223491558|NCT02071498|DEVICE|Pillbox app named ALICE|Participants in the experimental group were given a BQ tablet or an iPad with the ALICE app installed and personalised according to the medications they had been prescribed as listed in their medical record
223491559|NCT02071498|OTHER|oral and written information|oral and written information about the most common errors of patients
223491560|NCT03793153|PROCEDURE|Uterine Cooling Technique|Standard LSCS will be done except immediatelyfollowing delivery of the fetus the uterus will beexternalized in the usual fashion and the body of theuterus cephalad to the hysterotomy incision will bewrapped in sterile surgical towels saturated in sterile,iced normal saline. These towels will come from asterile cooling pot set to 30 degrees Fahrenheit. Theskin of the abdomen will be draped to prevent contactwith the cold towels. Iced saline-soaked towels will bekept in place for a minimum of 5 minutes and replacedat the discretion of the attending obstetrician until thehysterotomy is closed and the uterus is replaced intothe patient's abdomen.
223491561|NCT04165057|OTHER|Optimal muscle tension management|including TOF monitor and reversal of neuromuscular blockade agent : sugammadex
223491562|NCT02695407|OTHER|3 days cannulation|assessment of artery stenosis after 3 days of artery cannulation
223491563|NCT02695407|OTHER|5 days cannulation|assessment of artery stenosis after 5 days of artery cannulation
223491564|NCT03517982|DRUG|Mycophenolate Mofetil|Film Coated Tablet, each tablet contains 500mg Mycophenolate Mofetil
224183221|NCT01905241|PROCEDURE|Anatomic Total Shoulder Arthroplasty|Anatomic Total Shoulder Arthroplasty will be performed by the two surgeons of the study as their Standard of Care. All procedures associated with the surgery will be the same with the exception of the instrumentation used to place the guide pin for placement of the glenoid implant.
223491565|NCT04311957|DRUG|Continuation of boosted PI|"Continuation of the same second-line regimen taken prior to entry:~LPVr 400 mg/100 mg BID or ATVr 300 mg/100 mg QD + 2 NRTIs"
223491566|NCT04311957|DRUG|B/F/TAF|Single-tablet, fixed dose combination of bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg (B/F/TAF) administered orally, once daily.
223491567|NCT00101959|DRUG|Rebif|
223491568|NCT02061800|DEVICE|CliniMACS CD34+ Reagent System|The CliniMACS® Reagent System (Miltenyi Biotec, Germany), is a semi-automated immunomagnetic cell selection medical device that is used in vitro to select and enrich specific cell populations in a closed, sterile environment. The system is comprised of a computer controlled medical device containing a permanent magnet, a closed-system sterile tubing set containing columns coated with a ferromagnetic matrix, and a magnetic cell specific labeling reagent.
223491569|NCT02061800|DRUG|Thiotepa|Standard of care: Thiotepa should be diluted in normal saline (NS) (1-5 mg/ml) and infused over 2 hrs on Days -5, -4. IV fluids should be at maintenance rate (1500 ml/m2). It is recommended that total parental nutrition not being used during Thiotepa administration as amino acid infusions may interfere with Thiotepa metabolism.
223491570|NCT02061800|DRUG|Cyclophosphamide|Standard of care: Cyclophosphamide (Cytoxan) should be infused over one hour. The drug can be diluted in dextrose water solvent (D5W), NS, or other solutions (250cc) to a maximum concentration of 20 mg/mL.
223491571|NCT02061800|DRUG|Alemtuzumab|Standard of care: Each dose of alemtuzumab is to be diluted in D5W or NS (maximum concentration: 0.3 mg/mL) for IV infusion over two hours.
223491572|NCT02061800|DRUG|Tacrolimus|Standard of care: Tacrolimus dosing will be 0.03mg/kg/24 hours as continuous IV infusion or 0.12 mg/kg/day po divided Q8-12 hr
223491573|NCT02061800|DRUG|Melphalan|Standard of care: Melphalan 45mg/m2 (1.5 mg/kg IV for children \<1 year of age or \<10 kg) diluted in 0.9% NS to a concentration of 0.1- 0.45mg/ml, given IV over 30 minutes.
223491574|NCT02061800|DRUG|Busulfan|Standard of care: Busulfan will be given IV in 0.9% sodium chloride or D5W to a final solution for infusion equal to 10 times the volume of diluent to Busulfex (to a concentration \>0.5 mg/mL), through a central venous access device over 2 hours.
223491575|NCT02061800|DRUG|Fludarabine|Standard of care: Fludarabine will be given IV in 50-100 ml of D5W or 0.9% sodium chloride, over 30 minutes.
223491576|NCT02061800|DRUG|Methylprednisolone|Standard of care: Methylprednisolone will be give IV slow infusion over 15-30 minutes.
223491577|NCT03725553|DRUG|Intramyometrial Vasopressin|a bolus injection of vasopressin (4 IU) diluted to 2 mL with saline into the myometrium of the placental bed during slow (30-seconds) immediately after delivery, as soon as the umbilical cord was clamped.
223491578|NCT03725553|DRUG|Placebo|the group received a 10-mL bolus injection of saline into the myometrium during slow (30-seconds)as soon as the umbilical cord was clamped.
223491579|NCT02013362|DRUG|Pralatrexate injection|
223491580|NCT02013362|DIETARY_SUPPLEMENT|Vitamin B12|
223491581|NCT02013362|DIETARY_SUPPLEMENT|Folic Acid|
223491582|NCT01428245|DRUG|Progesterone|oral progesterone suspension (20 mg/ml, 25-100 mg) three times a day at 0700, 1500, and 2300 hr for seven days
223491583|NCT01428245|DRUG|Estrace (estrogen)|oral estrace, 0.5-1 mg once a day for seven days
223491584|NCT06418867|BEHAVIORAL|Mindfulness|Mindfulness Practice including 6 sessions with 1 hour for each
223491585|NCT06157476|OTHER|Stretch-shortening exercise|The SSC-Ex program was conducted for 35 minutes/session twice weekly over 12 weeks. The program was directed by a pediatric physical therapist in accordance with the safety performance guidelines defined by the American Academy of Pediatrics and the US National Strength and Conditioning Association. The program consisted of ten unilateral and bilateral upper extremity exercises in the form of push-ups and ball slams/throws/passes activities and was preceded by a warm-up for 5 minutes and ended with a cool-down for 5 minutes.
223491586|NCT06157476|OTHER|Standard exercise program|The standard exercise program lasted for 35 minutes/session and repeated two times a week for 12 consecutive weeks. The program was conducted by a pediatric physical therapist and consisted of flexibility exercises, strength training, weight-bearing exercises, proprioceptive neuromuscular facilitation, manual guidance, and functional training.
223491587|NCT00489580|DEVICE|SaeboFlex Dynamic Hand Orthosis|
223491588|NCT00489580|PROCEDURE|Saebo F.T.M. Arm Training Program|
223491589|NCT01260948|DRUG|Donepezil Hydrochloride|10 mg Orally Disintegrating Tablet
223491590|NCT01260948|DRUG|Aricept®|10 mg Orally Disintegrating Tablet
223491591|NCT05085145|BIOLOGICAL|Coronavirus vaccine|Coronavirus vaccine was inoculated on day 0 and day 25±3, respectively
223491592|NCT01067300|PROCEDURE|Transplantation of unrelated cord blood unit(s)|Myeloablative conditioning regimen includes, according to the patient age, either total body irradiation, fludarabine and cyclophosphamide with a GvHD prophylaxis based on cyclosporine A and mycophenolate, or the association busulfan, cyclophosphamide and anti-thymocyte globulin with GvHD prophylaxis being cyclosporine A and steroids.
223491593|NCT04151459|DRUG|Metformin|Use Metformin for 3 months to treat PCOS
223491594|NCT03534219|DEVICE|EarPopper|The EP device is 510(K) regulated (510(K) Number K073401) as a non-surgical, non-drug related treatment for middle ear pressure problems. The device is based on the Politzer Maneuver, and works by opening the Eustachian tube by delivering a safe, constant stream of air into the nasal cavity. In clinical studies funded by the National Institutes of Health (Grant#: 5R44DC003613-03), the EarPopper has proven to be effective in reducing chronic middle ear effusions. By regularly aerating the middle ear, we hypothesize that the EarPopper device will be an effective prophylactic measure to reduce incidence of AOM in children with recurrent OM. The device delivers a jet of air pressure from the nozzle at 5.2PSI, at a volume velocity of 1,524mL/min.
223491595|NCT00462462|DRUG|Ethanol 96% Gel|
223491596|NCT00462462|DRUG|Ethanol 98% Solution|
223491597|NCT03365245|DEVICE|Microperimetry|Microperimetry is performed at three different days
223491598|NCT03365245|DEVICE|automated visual field|Automated visual field ist performed at three different days
223491599|NCT05193487|OTHER|inferior alveolar nerve block|inferior alveolar nerve block using Articaine 4% with 1/200000 Adrenaline and a traditional needle injection
223491600|NCT05193487|OTHER|intra-osseous mandibular anaesthesia|intra-osseous mandibular anaesthesia using Articaine 4% with 1/200000 Adrenaline and a special intra-osseous injection device
223491601|NCT00017160|DRUG|doxorubicin|
223491602|NCT00017160|DRUG|filgrastim|
223491603|NCT00017160|DRUG|ifosfamide|
223491604|NCT00017160|PROCEDURE|biological response modifier therapy|
223491605|NCT00017160|PROCEDURE|brachytherapy|
223491606|NCT00017160|PROCEDURE|chemotherapy|
223491607|NCT00017160|PROCEDURE|colony-stimulating factor therapy|
223491608|NCT00017160|PROCEDURE|conventional surgery|
223491609|NCT00017160|PROCEDURE|cytokine therapy|
223491610|NCT00017160|PROCEDURE|intraoperative radiotherapy|
223491611|NCT00017160|PROCEDURE|radiation therapy|
223491612|NCT00017160|PROCEDURE|surgery|
223491613|NCT03979404|DEVICE|Intermittent Theta Burst Stimulation|The Magstim Rapid2 Magnetic Stimulator (Magstim ®, UK) will be used to administer active TBS.
223491614|NCT03024372|DEVICE|AV Fistula creation with sutures|End-to-side anastomosis (of AV fistula) is to be constructed using sutures. The incision is to be irrigated and closed using Vicryl, Biosyn and skin glue.
223491615|NCT03024372|DEVICE|AV Fistula creation with clips|End-to-side anastomosis (of AV fistula) is to be constructed using clips. The incision is to be irrigated and closed using Vicryl, Biosyn and skin glue.
223588106|NCT04528056|DRUG|Ambrisentan|Ambrisentan is one of the specific drug therapy for pulmonary arterial hypertension
223491616|NCT06417047|OTHER|Hand Holding|During the intramuscular injection, the aim is to draw the patients' attention elsewhere by holding their hand.
223588107|NCT04528056|DRUG|Sulfasalazine's placebo|Sulfasalazine's placebo is similar to Sulfasalazine in form and dosage
223491617|NCT01163617|DEVICE|Adalimumab delivered in current syringe|Pre-filled currently approved glass syringe containing 40 mg/0.8 mL adalimumab to be injected subcutaneously
223491618|NCT01163617|DEVICE|Adalimumab delivered in Physiolis syringe|Pre-filled Physiolis glass syringe containing 40 mg/0.8 mL adalimumab to be injected subcutaneously
223491619|NCT01163617|DEVICE|Adalimumab delivered in current autoinjector|Pre-filled currently approved autoinjector containing 40 mg/0.8mL adalimumab to be injected subcutaneously
223491620|NCT01163617|DEVICE|Adalimumab delivered in Physiolis autoinjector|Pre-filled Physiolis autoinjector containing 40 mg/0.8 mL adalimumab to be injected subcutaneously
223491621|NCT01250938|BEHAVIORAL|ESI - Community Outreach|This is an individualized caregiver-implemented intervention (ESI-CO) offered in 2 weekly sessions to teach caregivers how to embed strategies to support social communication skills within everyday routines, activities, and places for 3 months. Additionally, families receive 6 months (3 months during weekly home sessions and three months upon the completion of weekly home sessions) of resource support to identify local and community autism programs available for continued intervention and services.
223491622|NCT02394756|DEVICE|Marketed Soft Contact lens|Replacement schedule every 2 weeks
223491623|NCT02394756|DEVICE|AIR OPTIX® AQUA|Replacement schedule every 4 weeks
223491624|NCT02394756|DEVICE|Biofinity®|Replacement schedule every 4 weeks
223491625|NCT03972540|BEHAVIORAL|Mindful eating intervention|A Mindful Eating Workshop™ workbook was used for standardization and reproducibility of these sessions. The group sessions were focused on teaching applied strategies to consume food with intention and attention and aimed at improving emotional relationships with food. Intervention sessions were held once a week in the evening for 2 hours per session over 8 weeks. The intervention was delivered in a large conference room on the University of Georgia campus. Participants were required to attend seven out of eight sessions. If participants missed a session, they met with the instructor 30 minutes before the beginning of the following week's session to receive individual instruction on content of the missed session.
223491626|NCT03120793|DEVICE|Esophageal balloon catheter|Measurements obtained from mechanically ventilated patients with ARDS in the supine, upright and prone positions
223491627|NCT02907372|OTHER|neuropsychologic evaluation|
223491628|NCT02907372|OTHER|oncogeriatric evaluation|
223491629|NCT02763618|OTHER|Neurofeedback|Neurofeedback theta/beta ratio training. See 'Neurofeedback theta/beta ratio training' in detailed study description.
223491630|NCT02763618|OTHER|Placebo Neurofeedback training|The placebo training will be a previously recorded Neurofeedback session of a participant in group A
223491631|NCT05188482|DEVICE|vibroacoustic therapy|Vibroacoustic respiratory therapy
223491632|NCT02552940|DRUG|Tocilizumab|Participants with RA receive TCZ SC, as per routine clinical practice and are followed for approximately 6 months.
223491633|NCT00398229|DRUG|s.c. human chorionic gonadotropin (Ovitrelle)|S.C. Ovitrelle 250 mcg once
223491634|NCT02335944|DRUG|Capmatinib|"In the Phase 1, capmatinib was administered orally, twice per day, at a dose of 200 mg or 400 mg, in fasted state.~In the Phase II, participants received capmatinib at the RP2D (400 mg twice per day) in fasted state (Groups 1, 2 and 3) or fed state (Group 4).~Participants in Phase II Group 5 were to start with capmatinib monotherapy (fasted or fed state) and then would have had the opportunity to continue with the combination of nazartinib and capmatinib (fasted or fed state)."
223588108|NCT04528056|DRUG|Ambrisentan's placebo|Ambrisentan's placebo is similar to Ambrisentan in form and dosage
223588109|NCT06809517|DRUG|AK112|Intrathecal injection of PD-1/VEGF bispecific antibody was administered every two weeks for six weeks during the induction phase, followed by monthly injections during the maintenance phase, until recurrence or death.
223491635|NCT02335944|DRUG|Nazartinib|"In the Phase 1, nazartinib was administered orally, once a day, at a dose of 50 mg, 75 mg, 100 mg or 150 mg in fasted state.~In the Phase II, participants received nazartinib at the RP2D (100 mg once daily) in fasted state (Groups 1, 2 and 3) or fed state (Group 4). Participants in Phase II Group 5 were to start with capmatinib monotherapy (fasted or fed state) and then would have had the opportunity to continue with the combination of nazartinib and capmatinib (fasted or fed state)."
223491636|NCT05013801|OTHER|Cosmetic facial serum Q69|Cosmetic facial serum
223491637|NCT05013801|DRUG|2% Hydroquinone|2% Hydroquinone cream
223588110|NCT06809517|DRUG|Pemetrexed (Alimta)|Pemetrexed was administrated by intrathecal injection, first as induction therapy, twice per week for 2 weeks, followed by consolidation therapy, once per week for 4 weeks, then maintenance therapy, once per month until the patient's death, leptomeningeal metastasis progresses, or intolerable severe adverse events occurred.
223588111|NCT04971252|DIAGNOSTIC_TEST|Hematologic tests for patients with diabetes mellitus and chronic kidney disease|Study basic coagulation profile and platelet indices among diabetic patients with chronic kidney disease
223491638|NCT04728256|BEHAVIORAL|Laughter therapy+Music listening+Keeping diary|"Laughter therapy was carried out by the researcher as a total of three sessions every 15 days, and each session lasted 30 minutes.~Participants listened to the types of music that they like (pop, Turkish folk music). In the meeting room in FHC, Two professional artists performed music recitals with a guitar and saz (qopuz) to pregnant women, and pregnant women actively participated in this process. The performance was carried out as three sessions, once every 15 days, and each session took 40 minutes.~In addition to music listening and laughter therapy, the pregnant women were asked to keep a diary to write down their emotions about their health status, pregnancy and baby. Then, each participant had an opportunity to explain her emotions or replies to the questions during the group therapy sessions every 15 days so that pregnant women were able to express their feelings."
223491639|NCT04374136|DRUG|AL001|Administered via intravenous (IV) infusion
223491640|NCT04374136|DRUG|Placebo|Administered via intravenous (IV) infusion
223491641|NCT04374136|DRUG|Open label - AL001|Administered via intravenous (IV) infusion
224183222|NCT04981236|PROCEDURE|Pericapsular nerve group block|A curvilinear 2-5MHz ultrasound probe will be initially placed in a transverse plane over the anterior superior iliac spine and then aligned with the pubic ramus by rotating the probe counterclockwise approximately 45 degrees. In this view, the iliopubic eminence, the iliopsoas muscle and tendon, the femoral artery, and pectineus muscle will be observed. A 22-gauge, 80-mm needle will be inserted from lateral to medial in an in-plane approach to place the tip in the musculofascial plane between the psoas tendon anteriorly and the pubic ramus posteriorly. A total volume of 20 ml of ropivacaine 0.3% will be injected.
224183223|NCT04981236|PROCEDURE|Periarticular block|The periarticular injection solution contained 20mL of 7.5 mg/mL ropivacaine, 30mg of ketorolac, and 0.3mL of 1.0 mg/mL epinephrine. These agents were mixed with normal saline to a combined volume of 50mL. The surgeon injected this mixture into the tensor fascia lata, subcutaneous tissues, abductors, short external rotators muscles, and structures in the capsule.
224183224|NCT05261321|DRUG|Cannabis oil with a high ratio of THC to CBD|In the first active condition, cannabis oil with a high THC to CBD ratio will be administered to participants.
224183225|NCT05261321|DRUG|Cannabis oil with a high ratio of CBD to THC|In the second active condition, cannabis oil with a high CBD to THC ratio will be administered to participants.
224183226|NCT05261321|DRUG|Placebo|In the control condition, the placebo will be administered to participants.
224183227|NCT00669253|PROCEDURE|Er: YAG Laser|Scaling and root planing at baseline and surgery for remaining deep pockets after 6 months both using Er:YAG laser
224183228|NCT00669253|PROCEDURE|Conventional treatment 1(ultrasonic and manual means)|Scaling and root planing at baseline and surgery for remaining deep pockets after 6 months both using conventional methods : ultrasonic and manual means
224183229|NCT00669253|PROCEDURE|Conventional treatment 2 (ultrasonic and manual means)|Surgery at baseline for all deep pockets using conventional methods: ultrasonic and manual means
224183230|NCT02478736|OTHER|No actual intervention|Contact with enrolled subjects requires application of ceberal oximetry electrodes and the preoperative ultrasound (transcranial doppler) of the both MCA. No actual intervention done to subject.
224183231|NCT04142697|BEHAVIORAL|Heading direction adaptation|Will adapt subject's perceived heading direction using exposure to visual environments that include rotation and situations where visual and inertial heading direction are systematically offset.
224183232|NCT05615948|DRUG|VTS-K|Proprietary oral formulation of 486mg aspirin and 80mg ketamine
224183233|NCT00261599|DRUG|AQUAVAN® (fospropofol disodium) Injection|
224183234|NCT00261599|DRUG|Midazolam HCI|
224183235|NCT05015959|OTHER|observation|quality
224183236|NCT00003089|DRUG|amifostine trihydrate|
224183237|NCT00003089|DRUG|carboplatin|
223491642|NCT00576537|BIOLOGICAL|Dendritic Cell Immunotherapy|Patients will receive four vaccines.
223491643|NCT03535415|DRUG|Recombinant Human Growth Hormone Injection (rhGH)|rhGH 0.05mg/kg/d by subcutaneous injection
223491644|NCT03424642|BEHAVIORAL|Interactive 4D-ultrasound examination|Randomized controlled trial
224183238|NCT00003089|DRUG|paclitaxel|
223491645|NCT02873663|PROCEDURE|Plasma and head hair collection|Plasma and head hair collection
223491646|NCT03236389|DEVICE|Q Collar|measuring changes in brain during MRI while wearing the Q collar
223491647|NCT01197066|DRUG|Certolizumab Pegol|Certolizumab Pegol 200mg
223491648|NCT02530866|OTHER|Lower glycemic targets|Women will be randomized to either standard or lower glycemic targets.
224183239|NCT00003089|RADIATION|radiation therapy|
223491649|NCT04651712|DIAGNOSTIC_TEST|POC-PCR|The result of the POC-PCR will be presented by the study assistant to the treating physician within four hours upon admission. The treating physician will along with the result receive a recommended action list, developed by microbiologists.
223491650|NCT00576082|OTHER|Cutaneous biopsy|Cutaneous biopsy in order to search Borrelia by means of culture and PCR in this tissue sample
223491651|NCT05953467|OTHER|No intervention, observational.|None, observational study
223491652|NCT04230070|DRUG|Levonorgestrel 15.0 mg and Ethinyl estradiol 0.03 mg Test Drug|Bioequivalence
223491653|NCT04230070|DRUG|Levonorgestrel 15.0 mg and Ethinyl estradiol 0.03 mg Reference Product|Bioequivalence
223491654|NCT02811159|DRUG|Telapristone acetate|Telapristone acetate, orally, once daily for three 18-weeks courses separated by an ODI.
224183240|NCT01609049|DRUG|Peginterferon alfa-2a|Administration of treatment will be according to local recommendation under local labeling.
224183241|NCT01609049|DRUG|Ribavirin|Ribavirin tablets twice daily orally will be administered depending on body weight, according summary product characteristics and prescribing of ribavirin in real clinical practice.
224183242|NCT01310491|BEHAVIORAL|Health coaching|Telephone based health coaching supported by tele-monitoring.
224183243|NCT03016520|DRUG|DWJ1392|
224183244|NCT03016520|DRUG|DWC20164|
224183245|NCT00006382|PROCEDURE|bronchoscopic and lung imaging studies|
224183246|NCT00006382|PROCEDURE|comparison of screening methods|
224183247|NCT00006382|PROCEDURE|computed tomography|
224183248|NCT00006382|PROCEDURE|radiography|
224183249|NCT00006382|PROCEDURE|study of high risk factors|
223588112|NCT06584448|OTHER|Deuterium Metabolic Imaging with deuterated acetate tracer|Deuterium Metabolic Imaging (DMI) is a method by which Magnetic Resonance Spectroscopy (MRS) is used to map the appearance of deuterium from a tracer source (e.g., deuterated acetate) in products of metabolism. In this case we will map the combination of glutamate and glutamine, called Glx, to serve as a tag to measure the brain's rate of acetate consumption. That is, the more deuterium appears in Glx, the more acetate that part of the brain consumes.
223588113|NCT06892639|BIOLOGICAL|D-Fi|D-Fi is composed of fibroblasts isolated from the subject's skin biopsies which are genetically corrected with the full length COL7A1 gene encoding for type VII collagen.
223588114|NCT07081425|DEVICE|VRG Group|Care was taken to ensure that patients did not receive analgesia for at least 4 hours before the procedure. Before drain removal, the patient's NRPS level was assessed, and the STAI-I questionnaire was filled out. The experimental group was given a video to watch before the procedure began, and the use of glasses was explained. VRG was put on the patient, and the drain was removed in the 3rd minute while the video was being watched. After the procedure, the patients' pain perception during the procedure was assessed with the NRPS form. The STAI-I questionnaire was filled out again.
223588115|NCT07080944|PROCEDURE|SLN identification using technetium-99m|SLN Biopsy after pre-surgery positive SLN visualization.
223588116|NCT07080944|PROCEDURE|SLN intra-operatory identification with radioguided surgery|SLN biopsy after no pre-surgery SLN visualization using technetium-99m and intra-surgery SLN identification.
223491655|NCT00580086|OTHER|MR spectroscopy|(1H MRS) on 1.5 Tesla (1.5T), using a software package from General Electric Medical Systems, Milwaukee, WI
223491656|NCT04428749|DIAGNOSTIC_TEST|Yale Swallow Protocol|The YSP is a three-step method consisting of an assessment of the patient's awareness, the patient's ability to follow simple instructions and finally the patient's ability to drink 90 ml water from a cup or by straw without stopping, choking or coughing.
223491657|NCT04428749|DIAGNOSTIC_TEST|FEES (fiberoptic endoscopic evaluation of swallowing)|"The FEES will be performed bedside by an experienced occupational therapists. The patient will be sitting upright in a chair and be given 1) 2 spoons of applesauce, 2) 2 spoons of water, 3) several sips of water, 4) 90 ml of water. All items colored blue.~The FEES will use a single-use AMBU rhino-laryngo scope slim and the AMBU monitor. the examination will be terminated in case of aspiration below the vocal cords."
223491658|NCT06385353|OTHER|Quantification of deep vein thrombosis burden and assessment of post-thrombotic syndrome|"Post-thrombotic syndrome will be assessed by the Villalta score until 6 months of follow-up.~Data collected from colour doppler ultrasound will be used to calculate the Venous Volumetric Index to quantify deep vein thrombosis burden until 6 months of follow-up."
223491659|NCT05174624|OTHER|No intervention|No intervention
223588117|NCT07080944|PROCEDURE|Axillary Limph Node Dissection (ALND)|Axillary Limph Node Dissection (ALND) after no pre-surgery SLN visualization using technetium-99m and no intra-surgery SLN identification.
223588118|NCT07081347|DEVICE|MINT Minimally Invasive Nasal Trabeculostomy|The MINT® system is a powered surgical device for ab-interno nasal trabeculostomy. It creates \~100-micron trabeculostomy openings from the anterior chamber into Schlemm's canal by removing trabecular meshwork (TM) segments. The system includes a sterile stainless-steel Surgical Device with a micro trephine, driven by a motorized Activation Device that controls rotation and movement. The procedure facilitates aqueous outflow to lower IOP, with minimal collateral tissue damage.
223588119|NCT07083024|BEHAVIORAL|infection control education|This intervention includes a lecture, hands on practice and identifying IPAC practices in videos
223588120|NCT07079982|OTHER|Freeze-dried whole grape powder|Studying the effects of freeze-dried whole grape powder on immune profiles in healthy aging adults
223588121|NCT07079982|OTHER|Control grape-free powder|Studying effects of a control grape-free powder on immune profiles in healthy aging
223588122|NCT05929612|RADIATION|Ultra Low Dose 4 Gy Radiation|4 Gy in 2 fractions
223588123|NCT06900920|DRUG|TQB3473 Tablets|TQB3473 tablet is a selective Spleen tyrosine kinase (Syk) inhibitor.
223588124|NCT06900920|DRUG|TQB3473 Placebo|Placebo contains no active substance.
223745512|NCT06365021|OTHER|Bipolar Disorder Psychoeducation Therapy|The psychoeducation protocol for this study was developed by clinical psychologist Tatiana Cohab Khafif specifically for this study and for Bipolar Patients. It is a 3-session protocol that combines psychoeducation elements, mindfulness exercises, and discussions regarding the main aspects and symptoms of BD. The protocol is designed to fit into a single month, and has a specifically brief format in order for it not to crossover with psychotherapy. It covers all the basic aspects of Bipolar Disorder.
223745513|NCT03055247|DRUG|Ibuprofen|Ibuprofen: 3 mg/kg tid (total daily dose: 9 mg/kg); administered orally from day 1 to day 5 and then from day 14 to the day before the last LP.
224183250|NCT03494764|OTHER|Hyperbaric Oxygen Therapy|Hyperbaric oxygen (HBO) provides 100% oxygen at a pressure above atmospheric pressure (typically twice to three times standard sea level pressure (2.0-3.0 ATA)). This dramatically increases the amount of oxygen dissolved in blood plasma, which in turn increases oxygen delivery to tissues. This effect of hyperbaric oxygen is used clinically to treat acute hypoxia in crush injuries, severed limbs, and failing skin grafts
224183251|NCT03315416|OTHER|Speech Sound Assessment|Formal standardised speech sound assessment typically used as part of standard NHS care by Speech and language Therapists
223745514|NCT03055247|DRUG|Myelostim|Myelostim (G-CSF): 5 µg/kg bid (total daily dose 10 µg/kg); administered subcutaneously from day 19 to the day of the last LP.
223745515|NCT03055247|DRUG|Mozobil|Mozobil (Plerixafor): 0,24 mg/kg daily. When CD34+ are ≥ 10 /μL Plerixafor will be administered subcutaneously from the next day (or from day 24 if CD34+ are \< 10 /μL) to the day of the last LP.
223745516|NCT02603809|DRUG|Aprocitentan 5 mg|One capsule of 5 mg aprocitentan, orally, once daily in the morning for 8 weeks, along with placebo capsule matching lisinopril.
223745517|NCT02603809|DRUG|Aprocitentan 10 mg|Two capsules of 5 mg aprocitentan, orally, once daily in the morning for 8 weeks.
223745518|NCT02603809|DRUG|Aprocitentan 25 mg|One capsule of 25 mg aprocitentan, orally, once daily in the morning for 8 weeks, along with placebo capsule matching lisinopril.
223491660|NCT05548374|DEVICE|Acupuncture|The acupoints of Shangyintang, Danzhong(RNl7), Jvque(RN14), Liangmen(ST21), Zhongwan(RNl2), Hegu(LI4), Waiguan(SJ5), Zusanli(ST36), Sanyinjiao(SP6), Taichong(LR3) are selected as main acupoints and used per treatment. The other three acupoints will be chosen one each session according to the syndrome differentiation: Taixi (KI3) for liver and kidney deficiency, Fenglong (ST40) for spleen deficiency and phlegm coagulation, and Xuehai (SP10) for qi-stagnation and blood-stasis. Sterile adhesive pads will be placed on the acupoints after skin disinfection. Hwato-brand disposable acupuncture needles (size 0.30×40mm) will be inserted into the acupoints through the adhesive pads. Afterwards, the acupuncture will be lifted, thrusted and twirled gently for 3 times to achieve deqi sensation and manipulated every ten minutes during 30-minute maintenance.
223491661|NCT05548374|DEVICE|Sham acupuncture|The acupoints of Shangyintang, Danzhong(RNl7), Jvque(RN14), Liangmen(ST21), Zhongwan(RNl2), Hegu(LI4), Waiguan(SJ5), Zusanli(ST36), Sanyinjiao(SP6), Taichong(LR3) are selected as main acupoints and used per treatment. The other three acupoints will be chosen one each session according to the syndrome differentiation: Taixi (KI3) for liver and kidney deficiency, Fenglong (ST40) for spleen deficiency and phlegm coagulation, and Xuehai (SP10) for qi-stagnation and blood-stasis. Sterile adhesive pads will be placed on the acupoints after skin disinfection. The needles (with the handle identical to the needles in the acupuncture group and the body at a size 0.30 × 25 mm) will be inserted into adhesive pads without skin penetration. Needles will be lifted, thrusted and twirled gently for 3 times to mimic real acupuncture. No manipulation will be conducted during 30-minute maintenance.
223491662|NCT00817791|DEVICE|Hyperbaric oxygen pretreatment (GR2200)|2 hours/day,5 days before surgery
223491663|NCT02717650|OTHER|A-STEP|"Study A) Study A) Development of new exercise test protocol and Observational Feasibility/Safety Study (no comparator).~Feasibility/safety of a newly designed, incremental, maximal, standardised step test in adults with Cystic Fibrosis."
223491664|NCT02717650|OTHER|A-STEP (New Protocol)|Study B) Validation Study (random allocation of test order). Validity of an incremental, maximal, standardised incremental step test with breath-by-breath gas analysis using portable metabolic measurement equipment against CPET.
223491665|NCT02717650|OTHER|Comparator: CPET cycle ergometer (Gold Standard)|"Study B) Validation study (random allocation of test order) Gold standard CPET. An incremental, maximal standardised cycle ergometer exercise test (performed as per published protocol) using portable metabolic measurement equipment."
223491666|NCT05306353|DRUG|Placebo for VIB4920|26 participants will receive VIB4920 placebo administered intravenously at weeks 0, 2, 4, 8, and 12 while continuing background rheumatoid arthritis (RA) therapy including tumor necrosis factor alpha inhibitor (TNFi) (double-blinded)
223491667|NCT05306353|DRUG|VIB4920 with TNFi|52 participants will receive 1500 mg administered intravenously at weeks 0, 2, 4, 8, and 12 while continuing background rheumatoid arthritis (RA) therapy including Tumor necrosis factor alpha inhibitor (TNFi) (double blinded)
223491668|NCT05306353|DRUG|VIB4920 without TNFi|Participants will receive 1500 mg administered intravenously at weeks 0, 2, 4, 8, and 12 but discontinue necrosis factor alpha inhibitor (TNFi) while continuing all other background rheumatoid arthritis (RA) therapy (evaluator-blinded)
223491669|NCT04603066|DRUG|Ondansetron 16 mg with Tariquidar|In randomized order, each participant will receive two IV infusions of ondansetron, 3 weeks apart; one with placebo (D5W), and one with tariquidar (4mg/kg dose in D5W) administered IV over 60 minutes. Ondansetron will be diluted in 100mL 0.9% normal saline, and tariquidar will be diluted in 500mL D5W.
223491670|NCT04603066|DRUG|Ondansetron 16 mg with Placebo|In randomized order, each participant will receive two IV infusions of ondansetron, 3 weeks apart; one with placebo (D5W), and one with tariquidar (4mg/kg dose in D5W) administered IV over 60 minutes. Ondansetron will be diluted in 100mL 0.9% normal saline, and tariquidar will be diluted in 500mL D5W.
223491671|NCT02983656|BIOLOGICAL|live attenuated varicella vaccine|
223491672|NCT04020172|DRUG|Dobutamine|intraoperative fluid administration will be guided by cardiac output monitoring
223491673|NCT02406612|DEVICE|X-Seal 6F Vascular Closure Device|
223491674|NCT02363660|BIOLOGICAL|GINI|
223491675|NCT05186155|PROCEDURE|Severe ROP|The treatment for ROP was either primary intravitreal injection (IVI) of anti-vascular endothelial growth factor (anti-VEGF) or laser photocoagulation or vitrectomy, and the indication for treatment was type 1 ROP, as defined by the ETROP Study.
223491676|NCT06059859|PROCEDURE|Augmented reality robot-assited radical prostatectomy|Robot assisted radical prostatectomy using the Da Vinci surgical robot system (XI model; Intuitive Surgical, Sunnyvale, Calif) and a port device (Alexis; Applied Medical, Rancho Santa Margarita, Calif) system for prostate extraction. Virtual image of the prostate will be overlapped onto the endoscopic view of the Da Vinci surgical robot system using the TilePro system.
223491677|NCT06059859|DEVICE|Mixed reality intraoperative frozen section analysis|Microsoft Hololens head-mounted display system will be used for inking prostate margins during intraoperative frozen section analysis
223491678|NCT06059859|PROCEDURE|Robot-assited radical prostatectomy|Robot assisted radical prostatectomy using the Da Vinci surgical robot system (XI model; Intuitive Surgical, Sunnyvale, Calif) and a port device (Alexis; Applied Medical, Rancho Santa Margarita, Calif) system for prostate extraction.
223491679|NCT06078540|OTHER|USeeBP|"USeeBP is a low risk mobile medical app that proposes to do no more than:~* Help patients (i.e., users) self-manage their disease or conditions without providing specific treatment or treatment suggestions;~* Provide patients with simple tools to organize and track their health information;~* Provide easy access to information related to patients' health conditions or treatments;~* Help patients document, show, or communicate potential medical conditions to health care providers;"
223491680|NCT05660785|DRUG|Herombopag|"Hetrombopag is a TPO receptor agonist approved in China in 2021 for idiopathic thrombocytopenic purpura (ITP) and second-line severe aplastic anemia (SAA). Indications of chemotherapy-induced thrombocytopenia (CIT), pediatric/juvenile ITP and naive severe aplastic anemia are under development. Hetrombopag was granted Orphan Drug Designation by FDA for the treatment of CIT.~Cyclosporine A is a calcineurin inhibitor, which has an effect on reducing T-cell proliferation and activation, can reverse pancytopenia and alleviate transfusion requirements in NSAA."
223588125|NCT03259815|PROCEDURE|P.I.O.S.|Physiologically-Guided Incremental Optimisation Strategy
223588126|NCT03259815|DIAGNOSTIC_TEST|Pre and post-PCI coronary physiology measurements|Pre and post-PCI coronary physiology measurements will be performed but not disclosed to the operator
223491681|NCT04249024|DEVICE|Laser treatment|The participants in the laser group are treated with a 970 nm diode laser and if calculus is present scaling and root planning (SRP). The peri-implant pocket will be radiated with the 970 nm laser, removing bacteria, diseased epithelium and granulation tissue. The laser will be used at a maximum of 20s intervals before water irrigation. Laser settings continuous wave mode and power between 1.0-1.3W. Total treatment time will vary with the depth of the pocket and size of the surrounding bone crater.
223491682|NCT04249024|PROCEDURE|Mucosal flap surgery|The participants will receive a conventional peri-implant mucosal flap surgery of affected implants, and return after 7-10 days for suture removal. The surgery is a well-established treatment of peri-implantitis.
223491683|NCT04249024|BEHAVIORAL|Oral hygiene instructions|Oral hygiene instructions of how to clean around dental implants as per individual needs in terms of access to clean and fine motor skills.
223491684|NCT06005220|OTHER|SBD121|Medical Food
223491685|NCT06005220|OTHER|Placebo|Placebo
223491686|NCT06666452|BEHAVIORAL|COMFI - a COMbined Fatigue Intervention|The COMFI intervention is a 24-week group-based outpatient fatigue intervention consisting of 1) Six group sessions based on CBA covering topics such as fatigue and related factors, PA, trying out PA, energy management, and enhancing peer support 2) a seventh group session intended as a booster session in week 24, 3) one optional individual session in week 6-9 of the intervention, and 4) a support line in week 13-23 of COMFI.
223745519|NCT02603809|DRUG|Aprocitentan 50 mg|One capsule of 50 mg aprocitentan, orally, once daily in the morning for 8 weeks, along with placebo capsule matching lisinopril.
223745520|NCT02603809|DRUG|Lisinopril 20 mg|One capsule of 20 mg lisinopril, orally, once daily in the morning for 8 weeks, along with placebo capsule matching aprocitentan
223745521|NCT02603809|DRUG|Placebo|One capsule each of placebo matching aprocitentan and placebo matching lisinopril orally, once daily in the morning for 8 weeks.
224183252|NCT04414150|DRUG|SHR-1802|This study will evaluate the preliminary safety, tolerability, pharmacokinetic characteristics and initial efficacy of SHR-1802 The goal is to establish the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of sequential escalating doses of SHR-1802 when administered to patients with locally advanced/ unresectable or metastatic malignant tumours that are refractory to available therapy or for which no standard therapy is available.
224183253|NCT01059955|DRUG|Dexamethasone Phosphate Ophthalmic Solution (EGP-437)|Transcleral iontophoretic delivery of dexamethasone phosphate ophthalmic solution. Dexamethasone phosphate ophthalmic solution as a ready to use 40 mg/mL solution (preservative free and intended for single-use only).
223491693|NCT05761249|OTHER|HeartInsight activation|HeartInsight is activated at enrollment. The attending physicians are free on how to integrate HeartInsight in the patient care. Any treatment is based on routine care according to guidleines. Only documentation occurs on how the physicians use HeartInsight and actions taken in response to HeartInsight alerts
223491694|NCT05609864|OTHER|Quantification of injectable drugs wastage|Drugs are prescribed at discretion of physicians. For each patient who have anesthesia in the operating room, all labelled syringes having contained drugs (name + dilution) are collected and analyzed.
223491695|NCT06386029|BEHAVIORAL|Power Down bedtime manipulation|The Power Down is a bedtime manipulation protocol targeting elevated arousal level at bedtime due to a hypothesized effect of sensory over-responsivity (a common experience for autistic children). The Power Down incorporates sensory-based tools (gentle tactile pressure and auditory cues) to support nervous system regulation prior to attempting sleep onset. Participants (caregivers and their child) will be educated in the Power Down protocol and data collection methods for the 2 week intervention trial. Caregivers will lead a nightly gentle massage with guided relaxation script just prior to the child trying to fall asleep. The child will also wear a watch-like activity monitor (ActiGraph GT9x) for the 2 week period throughout the day and night to measure changes in sleep and activity patterns. Caregivers will complete daily diary questions in the morning and evening reporting their child's emotions and sleep timing.
223491696|NCT06254274|DRUG|RAY1225|Administered SC
223491697|NCT06254274|DRUG|Placebo|Administered SC
223491698|NCT06665633|DRUG|Oxygen 100 % Gas for Inhalation|Oxygen 100% Gas for Inhalation in Hyperbaric Oxygen Therapy Chamber at 1.5 ATA
223491699|NCT06665633|DEVICE|Hyperbaric Oxygen Therapy Chamber|Hyperbaric Oxygen Therapy, 40 treatments, at 1.5 ATA and 100% Oxygen
223491700|NCT06668090|BEHAVIORAL|Moderate intensity bike exercise|Participants will do moderate intensity bike exercise for up to one hour thrice weekly for 12 weeks.
223491701|NCT06809582|PROCEDURE|The T-Tilt position|"The T-Tilt position is a modified lithotomy position used during retrograde intrarenal surgery (RIRS). In this position:~The patient is placed in a 30-degree Trendelenburg position, meaning the head is slightly lower than the feet.~The surgical side is elevated at a 30-degree angle to improve access to the kidney.~This modified positioning is designed to enhance stone clearance, particularly by facilitating the movement of stone fragments away from the lower kidney calyces, where residual stones often remain. Researchers will compare this position to the standard lithotomy position to determine its impact on stone-free rates and surgical outcomes."
223491702|NCT05220345|DEVICE|colonoscopy assisted by both balloon-Behind The Folds visualizing and Computer assisted detection (CADe)|All participants will be subjected to a colonoscopy procedure, assisted by both G-eye balloon and the Discovery CADe system. Standard of care regarding the colonoscopy procedure will be applied to all study subjects. Any lesions detected during the procedure will be removed directly
223491703|NCT05973045|PROCEDURE|Operative Hysteroscopy 24 Centigrade Degree|Operative hysteroscopy will be performed at room temperature distention medium.
223491704|NCT05973045|PROCEDURE|Operative Hysteroscopy 37 Centigrade Degree|Operative hysteroscopy will be performed using a heated distention medium.
223491705|NCT05521958|PROCEDURE|Acute injury without compartment syndrome|"Acute tibial shaft or tibial plateau fractures who do not have clinical compartment syndrome.~Muscle punch biopsy of the anterior compartment will be taken."
223491706|NCT05521958|PROCEDURE|Acute injury with compartment syndrome|"Acute tibial shaft or tibial plateau fractures who have clinical compartment syndrome.~Muscle punch biopsy of the anterior compartment will be taken."
223491707|NCT05521958|PROCEDURE|Exertional compartment syndrome|For patients with exertional compartment syndrome, a muscle biopsy will be obtained from affected extremity.
223491708|NCT06810583|DRUG|Dalbavancin|3 doses of q28 days dalbavancin (12 weeks).
223588127|NCT04320888|PROCEDURE|Computed Tomography|Undergo CT, PET/CT, and/or CT/MRI
224183254|NCT01059955|DRUG|Dexamethasone phosphate ophthalmic solution|Transcleral iontophoretic delivery of dexamethasone phosphate ophthalmic solution. Dexamethasone phosphate ophthalmic solution as a ready to use 40 mg/mL solution (preservative free and intended for single-use only)
224183255|NCT04415931|PROCEDURE|Local infiltration analgesia|"Local infiltration injection intraoperatively prior to closing during the procedure. A standardized dose of 100 mL of infiltration will be utilized according to the following formula. The mixture will be injected into the deltoid and pectoralis major muscles and fasciae, and subcutaneous tissues using an 18-guage needle.~Total dose 100mL~Ropivacaine 0.5% 40mL Epinephrine 1mg/mL 0.1mL Ketorolac 30mg/mL 1mL Morphine 10mg/mL 0.5mL Normal saline 0.9% 58.4mL"
224183256|NCT04415931|PROCEDURE|Interscalene block|Standard interscalene brachial plexus regional block
223491709|NCT06810583|DRUG|Fluoroquinolone (either ciprofloxacin or levofloxacin at the discretion of the treating clinician)|28 days dalbavancin plus fluoroquinolone (either ciprofloxacin or levofloxacin at the discretion of the treating clinician) for up to 3 doses (12 weeks).
223491710|NCT07113587|DRUG|Application of intraperitoneal and intravenous meropenem in in automated peritoneal dialysis patients without peritonitis|
223491711|NCT07113587|DRUG|Application of intraperitoneal and intravenous ampicillin in automated peritoneal dialysis patients without peritonitis|
223491712|NCT07113587|DRUG|Application of intraperitoneal and intravenous aztreonam in automated peritoneal dialysis patients without peritonitis|
223491713|NCT07113587|DRUG|Application of intraperitoneal and intravenous ciprofloxacin in automated peritoneal dialysis patients without peritonitis|
223491714|NCT04628507|OTHER|Spent media collection|Embryo spent culture media, otherwise discarded as per standard of care, is collected once embryos have completed in vitro culture.
223491715|NCT07131384|DIETARY_SUPPLEMENT|Dietary Supplement: Inorganic Nitrate (Beetroot juice)|Participants will be supplemented with inorganic nitrate in the form of beetroot juice for 4 days (12.9 mmol of NO3/day), and their vascular health, insulin sensitivity, and exercise capacity will be measured post-supplementation. This is a randomized crossover design with 2 parallel groups (Group 1: Currently taking metformin, Group 2: Naive to metformin).
223491716|NCT07131384|DIETARY_SUPPLEMENT|Dietary supplement: Placebo (Nitrate-depleted beetroot juice)|Participants will be supplemented with nitrate-depleted beetroot juice for 4 days (\<0.01 mmol NO3/day), and their vascular health, insulin sensitivity, and exercise capacity will be measured post-supplementation. This is a randomized crossover design with 2 parallel groups (Group 1: Currently taking metformin, Group 2: Naive to metformin).
223588128|NCT04320888|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI, PET/MRI, and/or CT/MRI
223588129|NCT04320888|PROCEDURE|Positron Emission Tomography|Undergo PET, PET/CT, and/or PET/MRI
223588130|NCT04320888|PROCEDURE|Radionuclide Imaging|Undergo scintigraphy
223588131|NCT04320888|DRUG|Selpercatinib|Given PO
223588132|NCT04320888|PROCEDURE|X-Ray Imaging|Undergo x-ray imaging
224183257|NCT05425082|OTHER|Motor relearning program|Treatment session of one hour per day for five days a week, for four weeks for each participant until 20 sessions
223491717|NCT03617718|DRUG|Glycine Buffer|Subjects will be asked to perform an Inhaled Glycine Buffer followed by a series of Pulmonary Function Tests (PFTs) and then a research bronchoscopy will happen at visit 3.
223491718|NCT05879146|DRUG|Nirogacestat|Given by PO
223491719|NCT06587113|OTHER|Visual tasks|In the experiments, participants sit in front of a computer screen with their head in a chinrest to control for distance from the monitor and eye-tracking equipment. For the visual search task, participants will search for a visual target among distractors and make a response regarding its orientation. For the stop-signal task, participants will make an eye movement to a target that appears on the screen, except on trials where a visual signal appears indicating they should cancel this behavior. In the useful field of view task, participants will report the location of a briefly-presented and masked target, while also responding to the identify of a central target in some blocks.
223491720|NCT01371981|DRUG|Asparaginase|Given IM
223491721|NCT01371981|DRUG|Bortezomib|Given IV
223588133|NCT07081256|DRUG|QLM2010 for injection；dexamethasone|QLM2010 for injection；Drug for preventing nausea and vomiting caused by chemotherapy dexamethasone: Drug for preventing nausea and vomiting caused by chemotherapy
223588134|NCT07081256|DRUG|fosaprepitant dimeglumine for injection；palonosetron hydrochloride injection；dexamethasone|fosaprepitant dimeglumine for injection: Drug for preventing nausea and vomiting caused by chemotherapy palonosetron hydrochloride injection: Drug for preventing nausea and vomiting caused by chemotherapy dexamethasone: Drug for preventing nausea and vomiting caused by chemotherapy
223588135|NCT07089329|DRUG|Striatin|Daily administration of Striatin extract will be carried out for 14 days. The dose is 1 sachet/day (5 g of Striatin) which dissolved in 10 mll of syrup.
223588136|NCT07089329|DRUG|Placebo|Daily administration of 1 sachet of placebo will be carried out for 14 days.
223588137|NCT07089095|OTHER|questionnaire|This is a Relation Research. Use the patient decision aids for acute stroke rehabilitation, then data are collected with patients' characteristics, National Institutes of Health Stroke Scale (NIHSS), Barthel Index (BI), Modified Rankin Scale (mRS), and factors and preferences in the patient selection of rehabilitation care questionnaire.
223588138|NCT07089264|OTHER|Physical rehabilitation|Physical Rehabilitation in 36 sessions
223745522|NCT03127449|DRUG|Alflutinib|patients take Alflutinib orally once per day at different dose
223745523|NCT00006374|BIOLOGICAL|filgrastim|
223745524|NCT00006374|DRUG|cisplatin|
223745525|NCT00006374|DRUG|etoposide|
223745526|NCT00006374|DRUG|paclitaxel|
223745527|NCT00006374|DRUG|topotecan hydrochloride|
224183258|NCT05425082|OTHER|Neurodevelopmental therapy|Treatment session of one hour per day for five days a week, for four weeks for each participant until 20 sessions.
224183259|NCT00374920|DRUG|MEM 1003|
224183260|NCT05611281|DRUG|GS3-007 oral liquid or Placebo GS3-007 oral liquid oral medication|The dosage was calculated according to body weight and dose group once a day according to the assigned group.
224183261|NCT03751462|DEVICE|Purkinjemeter|The Purkinjemeter will be used for assessment of IOL wobbling, tilt and decentration in patients with pseudoexfoliation syndrome or traumatic cataract
224183262|NCT04879576|OTHER|Treatment|Telerehabilitation including pulmonary rehabilitation and posture exercises at 8 weeks in total with 2 sessions per week
223491722|NCT01371981|DRUG|Cytarabine|Given IT or IV
223491723|NCT01371981|DRUG|Daunorubicin Hydrochloride|Given IV
223491724|NCT01371981|DRUG|Etoposide|Given IV
223491725|NCT01371981|OTHER|Laboratory Biomarker Analysis|Correlative studies
223491726|NCT01371981|DRUG|Mitoxantrone Hydrochloride|Given IV
223491727|NCT01371981|OTHER|Pharmacological Study|Correlative studies
223491728|NCT01371981|OTHER|Quality-of-Life Assessment|Ancillary studies
223491729|NCT01371981|OTHER|Questionnaire Administration|Ancillary studies
223491730|NCT01371981|DRUG|Sorafenib Tosylate|Given PO
223491731|NCT06593886|DEVICE|BabyG|This involves wearing a harness connected to the overhead device while in a 10 X 10 play area filled with toys and equipment commonly used for infants to promote mobility skills (e.g. crawling and walking). Families can choose to come for 3 30-minute or 2 45-minute sessions per week. Half of the children will participate in the training immediately after enrollment in the study, the others will wait for 12 weeks before starting training. All will receive a comprehensive assessment at 0, 12 and 24 weeks, with additional developmental assessments at 6 and 18 weeks
223491732|NCT06590727|OTHER|Distress Thermometer|Enrolled patients will be given a clinical psychological interview. Then they will be given an anamnestic interview and the aforementioned questionnaires will be administered.
223491733|NCT06502860|OTHER|skin to skin with sling|In the intervention group, skin-to-skin contact will be facilitated using a specially designed sling. This approach aims to enhance the quality and duration of skin-to-skin contact between the mother and the newborn.
223491734|NCT06596954|RADIATION|lymphocyte-sparing radiotherapy|the radiotherapy regimen is 41.4Gy/23Fx. Ensure 95% coverage of the PTV (Planning Target Volume) and limit the doses to the heart, bilateral lungs, and spinal cord to meet the required dose constraints. While maintaining target coverage and traditional OAR (Organs At Risk) dose constraints, also address dose for lymphocyte-relate organs including the TVB1-12 thoracic vertebral bodies, ribs, spleen, and major thoracic blood vessels.
223491735|NCT06596954|RADIATION|conventional radiotherapy|the radiotherapy regimen is 41.4Gy/23Fx. Ensure 95% coverage of the PTV (Planning Target Volume) and limit the doses to the heart, bilateral lungs, and spinal cord to meet the required dose constraints. do not limit dose for lymphocyte-relate organs including the TVB1-12 thoracic vertebral bodies, ribs, spleen, and major thoracic blood vessels.
223491736|NCT06785129|DEVICE|Thermal stimuli|The Thermal Sensory Analyzer (TSA-II or PATHWAY platform - Medoc, Ramat Yishai, Israel) will be used to safely deliver heat and cold stimuli. These devices can deliver relatively complex stimuli via computer control. All targeted stimulus temperatures will be less than 50°C, and participants will be free to remove their arm or leg at any time from the thermode. Noxious cold stimuli will also be delivered with a plastic water container or a water bath (FISHER, USA). Participants will be free to pull out of the water bath at any time
223588139|NCT07089537|OTHER|progressive muscle relaxaiton|Participants will undergo approximately 30 minutes of Progressive Muscle Relaxation (PMR). Prior to the session, a brief introduction to the basic concepts of PMR will be provided. Participants will be instructed to close their eyes and focus on the sensations in their muscles. Following verbal instructions, they will sequentially contract and relax 14 major muscle groups from top to bottom. For each muscle group, participants will be asked to contract the muscles as strongly as possible for 7 seconds, followed by a 45-second relaxation period. This process will be repeated twice for each muscle group.
223491737|NCT06785129|DEVICE|Pressure stimuli|Pressure stimuli will be applied by using a handheld algometer (Wagner Instruments) or the Pressure Algometer (Medoc, Ramat Yishai, Israel). These devices have a round probe that allows quantifying the amount of pressure that is being applied. The Pressure Algometer allows a real-time visual feedback to control and monitor applied pressure rates. Pressure will be applied to the lower leg, volar forearm, or trapezius.
223491738|NCT06785129|BEHAVIORAL|Pain ratings|Pain intensity and pain unpleasantness ratings will be assessed.
223491739|NCT06785129|BEHAVIORAL|Conditioned pain modulation (CPM) response|"The CPM paradigm assesses endogenous inhibitory pain modulation efficiency. CPM testing includes the application of a test stimulus without conditioning (control run, pressure pain thresholds) and a subsequent application of the same test stimulus together with a conditioning stimulus (conditioning run, a 60 second of foot immersion in cold water). The CPM response is the difference in the pressure pain thresholds between the control and the conditioning runs."
223491740|NCT06785129|BIOLOGICAL|Hormonal assessment|Blood samples (approximately 2 tablespoons) and/or saliva and/or urine will be collected for analyses of sex hormone levels (e.g., prolactin, testosterone, estradiol).
223491741|NCT06979362|DRUG|CDR132L|CDR132L will be administered intravenously once every 4 weeks.
223491742|NCT06979362|DRUG|Placebo|Placebo will be administered intravenously once every 4 weeks.
223491743|NCT06982352|DRUG|LPX-TI641|Oral solution administered QD for 28 consecutive days
223491744|NCT06982352|DRUG|Placebo|Drug is LPX-TI641 oral solution. Placebo an identical oral solution without the LPX-TI641.
223491745|NCT05481931|DRUG|prabotulinumtoxinA|Botulinum toxin Type A powder for solution for injection
223491746|NCT06812325|DRUG|VRDN-003|VRDN-003 is an investigational, subcutaneously administered, humanized monoclonal antibody directed against the Insulin-like Growth Factor-1 receptor (IGF-1R).
223491747|NCT06812325|DRUG|Placebo|Placebo injections that appear identical to VRDN-003 injections but have no active drug.
223491748|NCT04880044|DIAGNOSTIC_TEST|EsoCheck/EsoGuard (EC/EG)|EC is a swallowed capsule on a tethered catheter that obtains a touch sample of the distal esophagus. The obtained sample is placed in a buffer and sent to a diagnostics lab for testing of methylated markers from extracted DNA. EG is a methylated DNA test . A positive EG is associated with Barrett's esophagus at all its stages.
223491749|NCT04880044|DIAGNOSTIC_TEST|Esophago-gastro-duodenoscopy (EGD)|SOC diagnostic endoscopic procedure that visualizes the upper part of the gastrointestinal tract down to the duodenum. Tissue samples collected.
223491750|NCT02745470|DRUG|Lixisenatide|Colorless, transparent liquid contained in a glass prefilled syringe pen-like injection (GLP-1 receptor agonist)
223491751|NCT02745470|OTHER|Placebo|Normal saline injection before performing fMRI
223491752|NCT05317351|DEVICE|Standard Colonoscopy|Subjects randomized into arm 1 will undergo standard colonoscopy using a standard colonoscope
223491753|NCT05317351|DEVICE|Artificial Intelligence Aided Colonoscopy (GI Genius™)|Subjects randomized into arm 2 will undergo colonoscopy using a standard colonoscope aided by Artificial Intelligence (GI Genius™)
224183263|NCT04553796|DEVICE|fibroscan|Fibroscan is a non-invasive test that helps assess the health of your liver. Specifically, it uses ultrasound technology to determine the degree of fibrosis or scarring that may be present in your liver from various liver diseases or conditions
223491754|NCT05317351|DEVICE|Combined Artificial Intelligence Aided Colonoscopy (GI Genius™) and G-EYE® Balloon Aided Colonoscopy|"Subjects enrolled to arm 3 (AG) will undergo colonoscopy using the G-EYE® Colonoscope and Artificial Intelligence Aided Colonoscopy (GI Genius™)."
223491755|NCT00590473|DEVICE|Interstim|Unilateral vs. Bilateral Placement of Interstim IPG
223491756|NCT03043781|OTHER|Continuous epidural infusion|Continuous infusion, 5 ml/h
223491757|NCT03043781|OTHER|Intermittent epidural bolus|Intermittent bolus 5 ml every hour
223491758|NCT06815471|DRUG|COR-1167|28-day treatment
223491759|NCT06815471|DRUG|Placebo|28-day treatment
223491760|NCT05287503|DRUG|Ambroxol Hydrochloride|Drug Ambroxol hydrochloride 200 mg plus excipients. The manufacturing process of the 200 mg Ambroxol hydrochloride tablets will be performed by wet granulation, drying, mixing and compression to the target final weight.
223491761|NCT05287503|DRUG|Placebo|Excipients
223491762|NCT00715611|PROCEDURE|Pleurectomy/Decortication|Pleurectomy/decortication will be performed as per standard technique
223491763|NCT00715611|DRUG|pemetrexed and cisplatin or carboplatin|The combination of pemetrexed and cisplatin or carboplatin will be given every 3 weeks for up to 4 cycles. Pemetrexed will be administered at 500mg/m2 as a 10-minute infusion. Cisplatin will be administered at 75mg/m2 as a 60-minute infusion. Carboplatin will be administered at an AUC of 5 over 30 minutes. Chemotherapy may be administered in the neoadjuvant or adjuvant setting.
223491764|NCT00715611|RADIATION|Intensity Modulated Radiation Therapy|IMRT will be administered over approximately 6 weeks at 50.4 Gy in 28 fractions with an optional SIB to gross residual disease (pending meeting normal tissue constraints).
223491765|NCT05447806|DEVICE|Active Electronic Medical Record Inpatient Diabetes Clinical Decision Support|This prospective intervention will be carried out over 36 months and encompass 12 alternating GlucAlert-CDS phases lasting 3 months each. Six active phases (ON period) and six inactive phases (OFF period) will represent 18 months of intervention and control respectively. GlucAlert-CDS recognizes gaps in care denoting the automatic process of subjects' identification and inclusion. During the ON period, gap in care events detected in patients' EMR will evoke alert messages and care recommendations for clinicians in real time for their consideration. These notifications are programmed to be delivered to primary inpatient providers in direct care of these hospitalized patients. During the OFF period, the program will record the gaps in care events detected, but alerts will be inactive for providers' viewing.
223491766|NCT05520359|DEVICE|Mobility Device|Use of mobility device during session.
223491767|NCT05520359|DEVICE|Spinal Stimulation|A stimulator will be used non-invasively stimulate the spine at the neck and/or lower back (cervical and/or lum
223491768|NCT04246879|OTHER|MRI|Subjects undergo one additional delayed MRI sequence
223491769|NCT06985121|OTHER|Placebo control|Placebo control (base formula without caffeine and panthenol). Applied 1mL evenly to the scalp once daily after hair wash for 56 consecutive days.
223491770|NCT06985121|OTHER|Base formula only|Base formula consisting of active ingredients caffeine and panthenol. Applied 1mL evenly to the scalp once daily after hair wash for 56 consecutive days.
223491771|NCT06985121|OTHER|Base formula plus IGF-1 and FGF-7|Base formula plus insulin growth factor 1 (IGF-1) and fibroblast growth factor-7 (FGF-7). Applied 1mL evenly to the scalp once daily after hair wash for 56 consecutive days.
223491772|NCT06985121|OTHER|Base formula plus Centella asiatica extracellular vesicles|Base formula plus Centella asiatica extracellular vesicles. Applied 1mL evenly to the scalp once daily after hair wash for 56 consecutive days.
223491773|NCT06985121|OTHER|Base formula plus Centella asiatica extracellular vesicles, IGF-1 & FGF-7|Base formula plus Centella asiatica extracellular vesicles, insulin growth factor-1 (IGF-1) and fibroblast growth factor-7 (FGF-7). Applied 1mL evenly to the scalp once daily after hair wash for 56 consecutive days.
223588140|NCT07089537|OTHER|Rest|Rest in a semi-recumbent position with eyes closed for 30 minutes, without any additional intervention.
223588141|NCT07088133|DRUG|NA(s)+HT-102+FD-001|Nucleos(t)ide analogues will be administrated throughout the entire treatment course; Patients will be injected with HT-102 once in Day1 (Week1), Day8 (Week2), Day15 (Week3), Day22 (Week4); Patients will be injected with FD-001 once in Day29 (Week5), Day57 (Week9), Day85 (Week13), Day113 (Week17), Day141 (Week21), Day169 (Week25) after confirmed reduction of serum HBsAg to below 10 IU/mL.
223491774|NCT06986083|PROCEDURE|Prostate Biopsy|Transperineal prostate biopsy
223491775|NCT06986083|DRUG|Local anesthesia|Local anesthesia in addition to IV sedation
223491776|NCT06982066|BEHAVIORAL|ReSPECT|ReSPECT is an interactive, web-based digital platform that integrates (1) an AYA-centered pre-visit questionnaire (PVQ) that will discretely alert clinicians to relevant SRH questions/concerns, (2) targeted patient education on PVQ selections, and (3) clinician-centered guidance for addressing SRH issues. At enrollment, all participants will complete a baseline survey (T1). AYAs will have access to the ReSPECT digital platform and will receive the first prompt to complete the PVQ 3-5 days before their next clinic appointment. Once completed, AYAs will receive an email/text with a link to tailored information based on their PVQ selections for review. Clinicians will receive an email with a link to the patient's PVQ results on the ReSPECT platform along with clinical management recommendations. All participants will complete a brief virtual survey (T2) and interview within 48 hours of the first postintervention clinic visit and a follow-up survey 2 months after study enrollment (T3).
223588142|NCT07088354|DIAGNOSTIC_TEST|The high-throughput extraction of large amounts of quantitative image features from medical images|The high-throughput extraction of large amounts of quantitative image features from medical images
223588143|NCT07088159|DRUG|SPG302|300 mg SPG302 will taken by mouth once daily.
223588144|NCT07088263|DRUG|Gemcitabine, Vinorelbine, Eribulin, or Utidelone|Gemcitabine, Vinorelbine, Eribulin, or Utidelone is recieved every 28 days. The chemotherapy interval is one cycle every 28 days.
223588145|NCT07087522|BEHAVIORAL|Stress Ball Use|Participants will perform hand exercises using a rubber stress ball for 5 minutes, 3 times daily, for 3 days prior to radial angiography.
224183264|NCT00906516|DRUG|Neuradiab in combination with Bevacizumab (Avastin)|"Patients will be treated following surgical removal of recurrent glioblastoma with a single intracavitary dose of Neuradiab® delivering 44 Gy±10% to the ridge of the surgically created resection cavity followed by therapy with Bevacizumab (Avastin) at a minimum of 30 days after Neuradiab administration.~Treatment with Bevacizumab will consist of 10mg/kg iv on days 1 and 15 every 28 days. Other chemotherapies (in addition to Avastin) will be permitted based on most current clinical practice and clinical evaluation of the patient."
223491777|NCT06605508|PROCEDURE|Autologous Adipose Tissue-Derived Stem Cell Injection for Erectile Dysfunction|This intervention involves the use of autologous adipose tissue-derived stem cells (ADSC) to treat erectile dysfunction. The process begins with a minimally invasive liposuction procedure to harvest fat tissue from the participant\&#39;s own body. The harvested fat is then processed to isolate stem cells, which are subsequently injected directly into the erectile tissue of the penis. This approach aims to enhance erectile function by promoting tissue regeneration and improving blood flow. Unlike other treatments for erectile dysfunction, this intervention uses stem cells derived from the participant\&#39;s own fat, which may reduce the risk of immune rejection and offer a novel regenerative therapy option. The treatment is designed to address ED in patients who have not responded adequately to conventional therapies like PDE-5 inhibitors.
223491778|NCT06605508|PROCEDURE|Stem cell-derived Exosomes Injection for Erectile Dysfunction|This intervention involves the use of stem cell-derived exosomes to treat erectile dysfunction. Exosomes are nano-sized extracellular vesicles secreted by stem cells, containing bioactive molecules such as growth factors and signaling proteins that promote tissue repair and regeneration. Unlike therapies requiring the transplantation of live cells, this cell-free approach eliminates the need for invasive harvesting procedures. The exosomes are carefully purified from cultured stem cells and prepared for direct injection into the erectile tissue of the penis. This approach aims to enhance erectile function by stimulating tissue regeneration, reducing inflammation, and improving blood flow. Unlike other treatments for erectile dysfunction, exosome therapy offers a novel regenerative option, potentially benefiting patients who have not responded adequately to conventional therapies such as PDE-5 inhibitors.
223491779|NCT06985043|DEVICE|Auricular vagus nerve stimulation (AVNS)|Auricular vagus nerve stimulation (AVNS) will be applied to both ears simultaneously, using a biphasic, asymmetric waveform with pulses of 300 microsecond duration and a frequency of 25 Hz, continuously for 20 minutes. The application will be performed in a single session and the follow-up time will be determined as 30 minutes.
223491780|NCT06605560|OTHER|Platelet Rich Plasma|PRP contains a high concentration of platelets obtained by centrifugation of autologous blood. After degranulation of platelets, various growth factors and cytokines are released and accelerate cartilage matrix synthesis, restrain synovial membrane inflammation and promote cartilage healing.
223491781|NCT06984484|DEVICE|Afluxin®|Afluxin® stick pack is an oral suspension to be taken without any liquid 3 times a day after breakfast, lunch and before going to bed, for 7 days.
223491782|NCT06984484|DRUG|Placebo|Inactive control stick pack is an oral suspension to be taken without any liquid 3 times a day after breakfast, lunch and before going to bed, for 7 days.
223491783|NCT06593314|BEHAVIORAL|Message with EchoGo|This alert will inform the provider that the patient has subclinical HFpEF
223491784|NCT06593314|BEHAVIORAL|Standard Message|This alert will inform the provider of guideline directed treatment options for patients with diabetes to prevent heart failure.
223491785|NCT06590961|DRUG|UBX-303061|UBX-303061 oral dosage
223491786|NCT06811324|DRUG|Tirzepatide|Once weekly tirzepatide starting at 2.5 mg/weekly, with dose escalation monthly by 2.5 mg to a target dose of 10 mg/weekly or maximum tolerated
223491787|NCT06811896|BEHAVIORAL|Stress Management and Resiliency Training Program|The Stress Management and Resiliency Training Intervention is an evidence-based intervention to reduce physiologic responses to stress that may contribute to cardiovascular disease risk. The intervention is typically delivered over an 8-week period and works to decrease stress responses by improving psychological resiliency to structural and social stressors and decreasing sympathetic nervous system activation. Eliciting the relaxation response through meditation, mindfulness, and autogenic training are core components.
223491788|NCT06811896|OTHER|Usual Care|Usual social and clinical services provided to patients at the recruiting clinic
224183265|NCT02808299|OTHER|HBV infection history|HBV infection history or HBV carriers
224183266|NCT02109731|OTHER|Negative airway pressure delivery|Negative airway pressure delivery (breathing against a vaccuum) in order to improve the tone of the upper airway muscles and make them less susceptible to collapse during sleep.
223491789|NCT06295406|OTHER|Neuropsychological assessment|Neuropsychological tests assessing reading abilities, skills of motor coordination, postural stability, manual dexterity, including graphomotor skills, and estimation of time will be performed
223491790|NCT05637294|DEVICE|splinting|neutral-positioned wrist orthosis
223491792|NCT04362293|DRUG|hydroxyurea, azathioprine, alemtuzumab, thioptepa, low dose total body irradiation and sirolimus|"The conditioning regimen will consist of hydroxyurea (30mg/Kg) and azathioprine (3mg/Kg) by mouth daily from day -60 to day -8, alemtuzumab subcutaneously daily for 5 days (0.03mg/kg on Day -7, 0.1mg/kg on Day -6, 0.3mg/kg on days -5 to -3), thiotepa intravenously (10mg/Kg) on day -3 and low dose total body irradiation (TBI) 200 cGY on day -2 with gonadal shielding (if possible). The HSCT graft will be G-CSF mobilized PBSCs with minimum CD34+ of 5 x10\^6/kg recipient weight.~GVHD prophylaxis will be sirolimus with a loading dose 3 mg/m2 on day -1. Sirolimus dose will be adjusted to maintain a target trough level 5-15 ng/mL. Low dose donor lymphocyte infusions will begin on day +28 and continue till donor lymphocyte chimerism reaches at least 90% donor."
223588146|NCT07088289|BEHAVIORAL|TRIPP|In this study, participants will use TRIPP with a VR headset at home, engaging in short mindfulness sessions 3+ times per week for 4-12 weeks.
223745528|NCT00238277|DRUG|temozolomide|
223745529|NCT00238277|PROCEDURE|adjuvant therapy|
223745530|NCT00238277|PROCEDURE|chemotherapy|
223745531|NCT00238277|PROCEDURE|radiation therapy|
224183267|NCT05311631|BEHAVIORAL|Breastfeeding support|"The core of the intervention is a trustful relation between the health visitor and the families based on principles of needs based communication. Health visitors will enhance parents' action competence based on breastfeeding self-efficacy, focusing on parents' wishes and needs.~The breastfeeding support includes four main messages: joint parenting task, skin-to-skin contact, frequent breastfeeding, and good positioning.~Training of health visitors includes e-learning and a two-day course with physical attendance. Supportive materials are developed including communicative support tools and a web-page providing support and knowledge when the health visitor is off hours.~All families in intervention sites accepting the health visitor program will receive the improved breastfeeding support. Families in the high-risk group are offered an intensified intervention with close follow-up by telephone in planned time-intervals, thus a higher dose of the intervention."
223491793|NCT04362293|DRUG|hydroxyurea, azathioprine, alemtuzumab, thiotepa, plerixafor, low dose total body irradiation, cyclophosphamide and sirolimus|"The conditioning regimen will consist of hydroxyurea (30mg/Kg) and azathioprine (3mg/Kg) by mouth daily from day -60 to day -8, alemtuzumab subcutaneously daily for 5 days (0.03mg/kg on Day -7, 0.1mg/kg on Day -6, 0.3mg/kg on days -5 to -3), thiotepa intravenously (10mg/Kg) on day -3, plerixafor (0.24mg/Kg) subcutaneously every 12 hours on days -3 and -2 and low dose total body irradiation (TBI) 200 cGY on days -2 and -1 with gonadal shielding (if possible). The HSCT graft will be G-CSF mobilized PBSCs with minimum CD34+ of 5 x10\^6/kg recipient weight.~GVHD prophylaxis will be cyclophosphamide (50mg/Kg) intravenously on days +3 and +4 and sirolimus with a loading dose 3 mg/m2 starting on day +5. Sirolimus dose will be adjusted to maintain a target trough level 5-15 ng/mL. Low dose donor lymphocyte infusions will begin on day +28 and continue till donor lymphocyte chimerism reaches at least 90% donor."
223491794|NCT06821269|PROCEDURE|Robotic assisted total knee arthroplasty|Total knee arthroplasty with robotic assisatance
223491795|NCT06821269|PROCEDURE|Manual total knee arthroplasty|Total knee arthroplasty without robotic assistance
223491796|NCT06821269|PROCEDURE|Robotic assisted revision total knee arthroplasty|Revision total knee arthroplasty with robotic assistance
223491797|NCT06821269|PROCEDURE|Manual revision total knee arthroplasty|Revision total knee arthroplasty without robotic assistance
223491798|NCT06819111|DRUG|Potassium Citrate Extended Release Oral Tablet|In this crossover study, patients will serve as their own controls. Patients will receive slow-release potassium citrate (UroCit-K), potassium magnesium citrate (powder), or potassium magnesium citrate (tablets). The study period will last approximately 6 weeks for each participant. Patients will be instructed to take one form of potassium citrate for one week at a time followed by a washout period for one week. This process will be completed a total of three times as we seek to study the effects of three forms of potassium citrate.
223491799|NCT06127732|DIETARY_SUPPLEMENT|Phytosterol supplements|Participants were randomized into two groups to receive diet plus phytosterols (DP) for 12 weeks, followed by a 7-day washout period with a second period of intervention, where treatments were switched, and participants received diet alone (D) and were followed for another 12 weeks.
223491800|NCT06401434|DIAGNOSTIC_TEST|On-site radiologist|All participants in this arm will be screened by CXR. All CXR images will be interpreted by only an on-site radiologist. Participants with an abnormal CXR result from the radiologist will be indicated for follow-on diagnostic testing with the Xpert MTB/RIF Ultra assay.
223491801|NCT06401434|DIAGNOSTIC_TEST|CAD-based triage (with INSIGHT CXR software)|All participants in this arm will be screened by CXR. All CXR images will first be processed with the INSIGHT CXR CAD software (Lunit, South Korea) to identify the totally normal/clear CXR images; only those with the possibility of containing an abnormality (abnormality score ≥ 20) will be sent to the on-site radiologist for reading/interpretation. Participants with an abnormal CXR result from the radiologist will be indicated for follow-on diagnostic testing with the Xpert MTB/RIF Ultra assay.
223491802|NCT06651593|DRUG|SAR444881|Given by IV
223491803|NCT06651593|DRUG|Cemiplimab|Given by Iv
223491804|NCT06983392|BEHAVIORAL|Abstain from smoking/vaping|They may be asked to stop smoking cigarettes or vaping during the study for 21 days. If they are asked to abstain from their product use they will be given nicotine patches and/or lozenges to help with abstinence during the study.
223491805|NCT04665206|DRUG|VT3989|25, 50, 100,150 or 200 mg capsules for oral administration.
223491806|NCT04665206|DRUG|Nivolumab & Ipilimumab|"Nivolumab infusion - 360 mg every 3 weeks, 30-minute intravenous infusion~Ipilimumab infusion - 1 mg/kg every 6 weeks, 30-minute intravenous infusion"
223491807|NCT04665206|DRUG|Osimertinib|40 or 80 mg tablets for oral administration
223491808|NCT03472092|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|This intervention will consist of 8 weekly sessions. The duration of each session is about 45 minutes and will be led by a psychologist/therapist using a manualized protocol. About half of the sessions will be conducted in person and the remaining sessions will be offered via telehealth (Skype or phone).
223491809|NCT03472092|DRUG|Placebo|The placebo pill will be administered once a day at home for 8 weeks, to be taken by mouth with or without food under the supervision of the participant's parent or guardian. To maintain blinding, all participants will receive 1 matching capsule as a daily dose to be taken each evening during the study.
223491810|NCT03472092|DRUG|Amitriptyline|Amitriptyline will be administered once a day at home for 8 weeks, to be taken by mouth with or without food under the supervision of the participant's parent or guardian. To maintain blinding, all participants will receive 1 matching capsule as a daily dose to be taken each evening during the study. For this study, a dose of 0.25 mg/kg/day will be provided for the 1st 2 weeks, followed by a dose of 0.5 mg/kg/day for 2 weeks, 0.75 mg/kg/day for 2 weeks and a maximum dose of 1.0 mg/kg/day for 2 weeks based on tolerability. Participants experiencing tolerability issues, may be held a current dose rather than titrated to the next dosage if deemed appropriate by the study doctor.
224183268|NCT01992146|DRUG|Target-controlled naloxone-infusion|
224183269|NCT01992146|DRUG|Placebo|
224183270|NCT03860870|DRUG|Clenbuterol Oral Product|Subjects ingest 4x20 microgram clenbuterol tablets
224183271|NCT03860870|DRUG|Placebo|Subjects ingest placebo tablets
224183272|NCT06606171|BEHAVIORAL|Chair Sitting (30 minutes)|This intervention involves a single session of chair sitting for 30 minutes, where participants will sit in a standardized non-swivel chair and perform desk-based activities like computer use.
224183273|NCT06606171|BEHAVIORAL|Floor Sitting (30 minutes)|This intervention entails a single session of floor sitting for 30 minutes, with participants seated on a cushioned mat performing similar desk activities as in the chair sitting session.
224183274|NCT06606171|BEHAVIORAL|Daily Floor Sitting Practice (1 month)|Participants will be instructed to incorporate at least one hour of floor sitting into their daily routine for a duration of one month.
224183275|NCT03440398|PROCEDURE|Robotic NSM|Surgical technique conducted using robot to perform nipple sparing mastectomy and breast reconstruction
224183276|NCT03440398|PROCEDURE|Open NSM|Open nipple-sparing mastectomy and immediate breast reconstruction with implant
224183277|NCT04462731|PROCEDURE|Non-surgical root canal treatment filled with WVT|All eligible teeth were isolated with a rubber dam during root canal treatment. The procedures were performed under a microscope (OPMI Pico; Carl Zeiss, Gottingen, Germany). After access, location of canals, and determination of working length (WL) with Root ZX II apex locator (J Morita, Kyoto, Japan), the canals were instrumented using various .04 taper rotary NiTi instruments to a minimum apical size of 35. 4% Sodium hypochlorite was used as the main irrigant with a 31-gauge needle. 17% EDTA was used as the final irrigant. Passive ultrasonic irrigation with size 20 Acteon tip inserted 2mm short of WL was performed with both 4% sodium hypochlorite and 17% EDTA for 10 seconds in each canal. After final irrigation, the canals were dried with paper points. The master gutta-percha cone fit was verified with periapical radiographs before filling the tooth. WVT was used to fill the tooth when the months were January, March, May, July, September, and November.
223491811|NCT03472092|BEHAVIORAL|Biofeedback-Assisted Relaxation Training (BART)|This intervention will consist of 8 weekly sessions. The duration of each session is about 45 minutes and will be led by a psychologist/therapist using a manualized protocol. About half of the sessions will be conducted in person and the remaining sessions will be offered via telehealth (Skype or phone).
223491812|NCT03472092|BEHAVIORAL|Cognitive Reappraisal Training (CR)|This intervention will consist of 8 weekly sessions. The duration of each session is about 45 minutes and will be led by a psychologist/therapist using a manualized protocol. About half of the sessions will be conducted in person and the remaining sessions will be offered via telehealth (Skype or phone).
223491813|NCT06483737|DRUG|Human albumin infusion at a modified dosage|Participants receive intravenous infusion of human albumin at different dosages according to the serum albumin level.
223491814|NCT06483737|DRUG|Human albumin infusion at a routine dosage|Participants receive intravenous infusion of human albumin according to the current clinical practice.
223491815|NCT06483737|DRUG|Lactulose|All participants will receive standard treatment of overt HE according to the current practice guideline.
223491816|NCT06483737|DRUG|Rifaximin|All participants will receive standard treatment of overt HE according to the current practice guideline.
223491817|NCT06483737|DRUG|Ornithine Aspartate|All participants will receive standard treatment of overt HE according to the current practice guideline.
223491818|NCT06483737|DRUG|Branched-Chain Amino Acids|All participants will receive standard treatment of overt HE according to the current practice guideline.
223491819|NCT06483737|DRUG|Arginine|All participants will receive standard treatment of overt HE according to the current practice guideline.
223491820|NCT06661655|DEVICE|Liver ultrasound|Hepatoscope is a point of care ultraportable ultrasound device that is capable of conventional grayscale ultrasound imaging, of 2D transient elastography (imaging + liver stiffness measurement), and of quantitative ultrasound properties measurement (ultrasound attenuation, backscattering coefficient, sound speed) related to liver steatosis.
223491821|NCT05996835|BIOLOGICAL|TIN816 70 mg lyophilisate powder|Immunotherapy Recombinant human CD39 enzyme
223491822|NCT05996835|OTHER|Placebo|0.9% sterile saline solution
223491823|NCT06389513|BIOLOGICAL|MCV4|4 doses of vaccine on Day 0, Day30, Day 60 and Month 12
223491824|NCT02899052|DRUG|Carfilzomib|"Carfilzomib lyophilized administered intravenously as a 10 to 30 minute infusion in Cycles 1 and beyond within 30 minutes to 4 hours after dexamethasone dosing.~Dose level 1 (K1) Cycle 1: 20 mg/m2 on Days 1 and 2, 27 mg/m2 on Days 8, 9, 15, and 16; Cycles 2 - 12: 27 mg/m2 on Days 1, 2, 8, 9, 15, and 16; Cycles 13 - 18: 27 mg/m2 on Days 1, 2, 15, and 16; Cycles 19 and beyond, for participants that have not previously transitioned to monotherapy: 27 mg/m2 on Days 1, 2, 15, and 16.~Dose Level K2: Cycle 1: 20 mg/m2 on Day 1; 70 mg/m2 on Days 8 and 15 Cycles 2 - onward: 70 mg/m2 on Days 1, 8, and 15. Dose Level K3: Cycle 1: 20 mg/m2 on Days 1 and 2; 56 mg/m2 on Days 8, 9, 15, and 16.~Cycles 2 - onward: 56 mg/m2 on Days 1, 2, 8, 9, 15, and 16."
223491825|NCT02899052|DRUG|Venetoclax|Venetoclax tablet administered orally once daily during Cycles 1 - onward. Venetoclax dose level 1 (Ven1) 400 mg once daily, Ven2 800 mg once daily.
223491826|NCT02899052|DRUG|Dexamethasone|Dexamethasone tablet administered orally during Cycles 1 - onward. Dexamethasone dose level 1 (Dex1) 40 mg once weekly, Dex2 40 mg once weekly, Dex3 20 mg twice weekly.
223491827|NCT06530576|DRUG|Thalidomide and methotrexate|Thalidomide at a dose of 50-100 mg/QN, Methotrexate 10 mg/m2 orally once a week.
223491828|NCT06361420|PROCEDURE|Driving pressure-guided positive end expiratory pressure|The positive end expiratory pressure setting rules are as follows: a 10-cycle experimental ventilation will be carried out at each level of positive end expiratory pressure after intubation, and the driving pressure of the last cycle will be recorded. The positive end expiratory pressure value corresponding to the lowest driving pressure is recognised as the optimal ventilation parameter. Partial pressure of carbon dioxide monitoring is employed to determine the tidal volume and respiratory rate. Inspiration/expiration pattern is adjusted based on the preoperative small airway condition. This parameter is subject to modification upon cessation of ventilation, ICU admission, and every morning throughout the ventilation period. During cardiopulmonary bypass, mechanical ventilation is maintained using the low-level parameters.
223588147|NCT07087457|BEHAVIORAL|The digital stimulus command|"The digital stimulus command: Providing information on the harms of inactivity and sedentary lifestyle on online, digital platforms. The individual will take the HRV measurement in a sitting position for 5 minutes every morning (before consuming tobacco products for smokers) as taught and will send the screenshot of the data to the researcher via WhatsApp. Ensuring that the digital stimulus commands that will remind the activity in line with TTM are followed by reminders sent to the computer screen or mobile phones. Taking a break from sitting when the command It's time for activity comes (taking a total of 6 breaks in the working hours of 08:30 - 17:30, 1 every 60 minutes recording the activity as completed in the digital diary and survey form) \*Activities of office workers other than the time they spend sitting; Recording the number of steps and activities in the office, its surroundings and in daily life in a digital diary."
224183278|NCT04462731|PROCEDURE|Non-surgical root canal treatment filled with SBT|All eligible teeth were isolated with a rubber dam during root canal treatment. The procedures were performed under a microscope (OPMI Pico; Carl Zeiss, Gottingen, Germany). After access, location of canals, and determination of working length (WL) with Root ZX II apex locator (J Morita, Kyoto, Japan), the canals were instrumented using various .04 taper rotary NiTi instruments to a minimum apical size of 35. 4% Sodium hypochlorite was used as the main irrigant with a 31-gauge needle. 17% EDTA was used as the final irrigant. Passive ultrasonic irrigation with size 20 Acteon tip inserted 2mm short of WL was performed with both 4% sodium hypochlorite and 17% EDTA for 10 seconds in each canal. After final irrigation, the canals were dried with paper points. The master gutta-percha cone fit was verified with periapical radiographs before filling the tooth. SBT was used to fill the tooth when the months were February, April, June, August, October, and December.
223491829|NCT06361420|PROCEDURE|Optimal oxygenation-guided positive end expiratory pressure|Positive end expiratory pressure will be maintained at the level facilitating optimal oxygenation during the off-pump period. Partial pressure of carbon dioxide monitoring is employed to determine the tidal volume and respiratory rate. Inspiration/expiration pattern is adjusted based on the preoperative small airway condition. This parameter is subject to modification upon cessation of ventilation, ICU admission, and every morning throughout the ventilation period. During cardiopulmonary bypass, mechanical ventilation is maintained using the low-level parameters.
224183279|NCT02324426|DRUG|Reduced Glutathione|200 mg GSH delivered in 1 cc sterile saline using a syringe with a Mucosal Atomization Device (MAD) tip.
224183280|NCT04204967|DRUG|Fentanyl Transdermal System|in the experimental arm transdermal fentanyl will be administered with a starting dose of 50 mcg/hr simultaneously with the preexistent remifentanil continue infusion. Remifentanil infusion rate will be increased or decreased based on PaCO2 value resulting from the Arterial Blood Gases sample (ABG) collected at each visit. After randomization, the transdermal fentanyl dose can be modified every 24 hours according to the study protocol to achieve the desired effect in terms of PaCO2 value resulting from the Arterial Blood Gases sample (ABG) collected
224183281|NCT04204967|DRUG|Remifentanil|"In the active comparator arm remifentanil infusion is administered alone, the infusion rate will be increased or decreased according to the study protocol based on PaCO2 value resulting from the Arterial Blood Gases sample (ABG) collected at each visit.~In the experimental arm remifentanil is use together with transdermal fentanyl"
224183282|NCT02247167|PROCEDURE|adenotonsillectomy|adenotonsillectomy in children with OSAS and adenotonsillar hypertrophy.
224183283|NCT01784094|DEVICE|StromaGlide|
224183284|NCT05325502|DIETARY_SUPPLEMENT|caffeine|two doses per day: 200 mg caffeine in the morning; 100 mg caffeine in the afternoon
224183285|NCT05325502|DIETARY_SUPPLEMENT|mannitol|two doses per day: 200 mg in the morning \& 100 mg in the afternoon
224183286|NCT05371340|DIETARY_SUPPLEMENT|Quercetin (500 mg)|Once-daily 500 mg Quercetin
224183287|NCT05371340|OTHER|Placebo (500 mg)|Once-daily 500 mg methylcellulose 9E4M)
223491830|NCT06361420|PROCEDURE|Ventilation strategy|A Pressure regulated volume control mode is used in the patients before extubation. The ventilation target are: (1) a pulse oximetry ≥ 90% or a partial pressure of arterial oxygen ≥ 60mm Hg; (2) a partial pressure of arterial carbon dioxide: 35 \~ 50 mm Hg and (3) a pondus hydrogenii (pH) value \> 7.20. The ventilation parameters are: (1) tidal volume: 6 \~ 8 mL/Kg predictive body weight; (2) respiratory rate 10 \~ 15 cycles per minute; (3) inspiratory/expiratory ratio: 1:1.5 (1:2.5 - 1:3 in the patients with chronic obstructive pulmonary disease); positive end expiratory pressure: 0 \~ 8 cm centimeter water column. On-pump ventilation parameters are: (1) tidal volume: 4 mL/Kg predictive body weight; (2) respiratory rate: 4 circles per minute; (3) positive end-expiratory pressure: 4 cm centimeter water column; (4) inspiratory oxygen fraction: 21%.
223491831|NCT06361420|PROCEDURE|Management of hypoxemia|Management of hypoxemia will be initiated immediately through the following steps: (1) carefully checking anaesthesia apparatus malfunction, airway normality, and monitoring accuracy; (2) improving cardiac function, correcting fluid overload, and alleviating systemic inflammation; (3) performing alveolar recruitment manoeuvres as described above; (4) increasing the tidal volume and positive end expiratory pressure within the upper limits; (5) increasing the respiratory rate while addressing concurrent hypercapnia; (6) titrating the fraction of inspiratory oxygen until the pulse oximetry reaches or exceeds 90%; and (7) considering the use of extracorporeal membrane oxygenation if any following situations occurred 14: (a) a partial pressure of arterial oxygen \< 50 mm Hg for more than 3 hours; (b) a partial pressure of arterial oxygen to inspiratory oxygen fraction ratio \< 80 mm Hg for more than 6 hours; or (c) a critical respiratory acidosis for more than 6 hours.
223512503|NCT01704560|OTHER|Coversheet to Informed Consent|The intervention is a one page cover sheet to be affixed to the front of the standard permission form for the trial for which permission is being sought (attached to application). The form will identify the study as research and contain sections that include investigator contact information, the purpose of the study, a brief description of the study procedures, the alternatives, the voluntary nature, the risks, the potential benefits, a discussion of privacy and confidentiality, the costs and the payments. Each topic will also contain a reference to the page in the consent containing the full description of the topic. The form is designed to have a reading level no higher than 6th to 8th grade. Parents will also receive the full permission form, and all required signatures will still be collected on the permission form.
223512504|NCT05823077|OTHER|Bergamot|The affected knee will be massaged with Bergamot oil for 4 weeks, 2 sessions per week.
224183288|NCT01794221|PROCEDURE|stitches and skin adhesive|In addition to stitches, 2-octyl cyanoacrylate skin adhesive will be applied to the circumcision wound.
224183289|NCT01794221|PROCEDURE|stitches only|standard of care
224183290|NCT02567721|OTHER|Vaccine safety surveillance|Extraction of routinely collected primary care data from nine GP practices and an active surveillance approach in 3 of the 9 GP practices, by using an existing card-based ADR reporting system (MHRA Yellow Card), to estimate proportions of AEIs among seasonal influenza-vaccinated individuals.
224183291|NCT00766870|DRUG|Lu AA34893|Per oral doses, divided in twice daily administrations as capsules during 8 weeks, followed by a two-week tapering period
224183292|NCT00766870|DRUG|Venlafaxine extended release|Per oral, once daily, during 8 weeks, followed by a two-week tapering period
224183293|NCT00766870|DRUG|Placebo|Per oral doses, twice daily as capsules during 10 weeks
224183294|NCT02211287|OTHER|'Comfort Care at the End of Life for Persons with Dementia'|A guide for caregivers to provide information on the trajectory of the disease, clinical issues, decision-making processes, and symptom management. The guide is written in a Q\&A form and can help answer frequent family questions.
223491832|NCT06449989|DIAGNOSTIC_TEST|Tumor samples will be tested for mutation status of KRAS, NRAS, BRAF, HER2 and MSI|"For molecular genetic research, archival formalin-fixed and paraffin-embedded tumor blocks will be used. Research method - HRM-PCR sequencing to determine mutation status of KRAS, NRAS and BRAF (RotorGene 6000, ABI Prism 3500) and fragmentation analysis to determine MSI (ABI Prism 3500) Subject to study: mutations in the KRAS, NRAS, BRAF genes, as well as MSI status and HER2neu expression (± amplification) Somatic mutations in the RAS family genes are planned to be studied in exons 2 (codons 12 and 13), exon 3 (codon 61) and exon 4 (codon 146). In the case of the BRAF gene - exon 15 (codons 597-601). Determination of microsatellite instability is planned using five markers: BAT25, BAT26, NR21, NR24, NR27, associated with structural and functional disorders of the DNA unpaired base repair system.~Assessment of HER2 gene status is planned by immunohistochemical (IHC) screening of HER2neu expression. IHC-screening of HER2-status will be performed using an antibody clone 4B5 (Ventana)."
223491833|NCT06459869|DRUG|NG-350A IV administration|a tumour-selective anti-CD40-expressing adenoviral vector
223491834|NCT06459869|DRUG|Capecitabine oral administration|chemotherapy
223491835|NCT06459869|RADIATION|Radiotherapy|long-course intensity-modulated radiotherapy
223491836|NCT06816004|DEVICE|Remotely Supervised Transcranial Direct Current Stimulation (RS - tDCS)|tDCS is a noninvasive brain stimulation device that modulates brain activity delivering a low-intensity electrical current.
223491837|NCT06816004|DEVICE|Remotely Supervised Transcutaneous Auricular Vagus Nerve Stimulation (RS - taVNS)|taVNS is a noninvasive peripheral nerve stimulation device that modulates vagus nerve activity delivering a low-intensity electrical current (\< 5mA) through hydrogel electrodes to the left auricular branch of the vagus nerve.
223491838|NCT06816004|DEVICE|Remotely Supervised Transcutaneous Cervical Vagus Nerve Stimulation (RS - tcVNS)|tcVNS is a noninvasive peripheral nerve stimulation device that modulates vagus nerve activity delivering a low-intensity electrical current (\< 5mA) through cervical hydrogel electrodes to the left cervical branch of the vagus nerve.
223491839|NCT06980051|BEHAVIORAL|Virtual window|The virtual window, which displays 24h time-linked outdoor scene on a high-definition video monitor, will be on during working hours for three days each week.
223491840|NCT06610968|DIETARY_SUPPLEMENT|Vitamin D (Cholecalciferol )|5000 IU Vitamin D (as cholecalciferol) capsules (Vitamin D3 125 mcg \[5,000 IU\], Pure Encapsulation, LLC) daily
223491841|NCT06610968|DIETARY_SUPPLEMENT|Placebo Group|One placebo capsule (Zeebo Imagine, Zeebo) daily.
223491842|NCT06859008|PROCEDURE|Biopsy|Undergo biopsy
223491843|NCT06859008|PROCEDURE|Biospecimen Collection|Undergo urine and blood sample collection
223491844|NCT06859008|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration and biopsy
223491845|NCT06859008|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow aspiration and biopsy
223491846|NCT06859008|PROCEDURE|Computed Tomography|Undergo CT
223491847|NCT06859008|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223491848|NCT06859008|OTHER|Questionnaire Administration|Ancillary studies
224183295|NCT02211287|OTHER|Project Nurse - ACP Facilitator|A nurse will receive training in the 'Respecting Choices Facilitator Curriculum' - an online program consisting of a series of six critical thinking modules designed for healthcare professionals who want to enhance their ACP facilitation skills. Local training resources in Northern Ireland will supplement.
224183296|NCT02020811|DEVICE|Sentinel|
223491849|NCT06859008|DRUG|Sonrotoclax|Given PO
223491850|NCT06859008|DRUG|Zanubrutinib|Given PO
223491851|NCT05589532|DEVICE|Prosthetic single-tooth prosthesis using PEEK|A single tooth implant-supported fixed prosthesis using PEEK polymer in its composition delivered as definitive prosthesis.
223491852|NCT05064631|DRUG|Bacterial Lysate|Bacterial lysate medicines are made from bacterial cells that are broken down and are intended to stimulate the immune system.
223491853|NCT05253807|DRUG|Pemigatinib|13.5 mg tablet
223491854|NCT06859515|OTHER|No intervention, only for observational studies|No intervention, only for observational studies
223491855|NCT06061341|DIAGNOSTIC_TEST|TruGraf®|TruGraf® is a non-invasive blood-based test to assist the clinician in lowering immunosuppression in liver transplant patients. It is the first and only blood-based test that offers biomarker guidance to aid physicians in minimizing immunosuppression in transplant recipients.
223491856|NCT06613451|OTHER|Mobile Application|Mobile Application Use on the Intravenous, Intramuscular and Subcutaneous Drug Administration
223512505|NCT05823077|OTHER|Placebo|The affected knee will be massaged with sweet almond oil for 4 weeks, 2 sessions per week.
223512506|NCT05102838|OTHER|Anti-virus treatment|Anti-virus treatment
223512507|NCT05365464|DRUG|Progesterone Pill|Orally active progesterone
223512508|NCT05365464|DRUG|hCG|Given by subcutaneous injection
223512509|NCT03250195|DIAGNOSTIC_TEST|PET/MRI|PET/MRI scan
223512510|NCT03932383|DEVICE|Custom CPAP mask|Modified CPAP mask based on 3D image capture
223512511|NCT02417480|BEHAVIORAL|Vegan diet|Participants in the omnivorous arm will be asked to follow their normal diet for one week and then follow a vegan diet for one week.
223512512|NCT02417480|BEHAVIORAL|Follow habitual, usual diet|Participants will be asked to consume their habitual, usual diet.
223512513|NCT01433081|DRUG|Placebo infusion of .9 normal saline|administration of .9 normal saline
223512514|NCT01433081|DRUG|administration of magnesium sulfate|administration of magnesium sulfate
223512515|NCT06276075|PROCEDURE|Conventional rehabilitation, the Erigo®Pro table, motor imagery|66 stroke patients were randomly assigned to three groups (22 people each) with different therapy (conventional, with the addition of Erigo®Pro and enriched with motor imagery). The therapy duration was two weeks. Patients underwent assessment before and after completion of therapy. The study used the Trunk Stability Test, Berg Balance Scale to assess balance, as well as the Riablo device to measure static balance. Additionally, an evaluation of the superficial tension of the transverse abdominis and multifidus muscles was conducted.
223491857|NCT05360186|DEVICE|MateRegen® gel (BioRegen)|Modification of Hyaluronic acid structure to 3-dimensional self-cross-linked network structure enables all-dimensional coverage of tissue surface to enhance better healing process. Self-cross-linked HA hydrogels can maintain the biocompatibility and biodegradability that characterize the unmodified material. Moreover, high dynamic viscosity enables continuous indwelling in the uterine cavity. The gel could provide precise regulation, and degradation and absorption time prolonged to 7-14 days post operatively, which completely cover key postoperative healing period (5-7 days), at the highest time of intrauterine adhesion formation.
224183297|NCT02409576|BIOLOGICAL|Expanded , Activated NK cells|"1. Chemotherapy - Each patient will receive immunosuppressive chemotherapy before infusion of NK cells.~   Day -7 Cyclophosphamide at 60mg/kg Day -6 Fludarabine at 25mg/m2 daily for 5 days~2. Radiation - Each patient will receive radiation within 48 hr of NK cell infusion to make the tumor cells more sensitive to NK cell killing Radiation 2Gy~3. Cytokine support - Each pateint will receive IL-2 to support NK cell activation and expansion in vivo Day -1 alternate day for a total of 6 doses~4. NK cells - Expanded activated haploidentical NK cells will be infused on day 0."
224183298|NCT04777422|DRUG|Defibrotide|Defibrotide 6.25 mg/kg IV q6h up to 7 days
224183299|NCT00967473|DEVICE|ACRYSOF® Single-Piece NATURAL Toric IOL Model SN60T9 and Model SN60T8.|ACRYSOF® Single-Piece Toric NATURAL Intraocular Lens (IOL) Model SN60T9 in the first eye and either the ACRYSOF® Single-Piece Toric NATURAL IOL Model SN60T9 or Model SN60T8 in the second eye.
223491858|NCT06445725|BEHAVIORAL|Acceptance Based Coping (ABaCo)|The educational ABaCo protocol consists of core Acceptance \& Commitment Therapy (ACT) interventions, culturally and contextually-tailored for this population, and in accordance with clinician-led versions of ACT for diabetes to include (a) identification of patient values, (b) teaching acceptance and brief mindfulness skills, and (c) techniques for engaging in valued activities while coping with difficult experiences (e.g., sugar cravings, distress). It is delivered by a community health worker (promotor/a) over 6 consecutive weeks over the phone, followed by a booster call at week 10.
223491859|NCT04611126|DRUG|Ipilimumab|Ipilimumab 3 mg/kg is administered 2-6 weeks before surgical removement of the tumor. The medicine is administered i.v. over 30 minutes.
223491860|NCT04611126|DRUG|Cyclophosphamid|Cyclophosphamide 60 mg/kg is administered i.v. on day -7 and day -6.
223491861|NCT04611126|DRUG|Fludarabine Phosphate|Fludarabine 25 mg/m2 is administered on day -5 to day -1.
223491862|NCT04611126|BIOLOGICAL|Tumor Infiltrating Lymphocytes infusion|Tumor-infiltrating lymphocytes grown ex-vivo from resected from cancer tissue and reapplied to the patient via an intravenous infusion. The maximum number of expanded TILs are infused over 30-45 minutes on day 0.
223491863|NCT04611126|DRUG|Nivolumab|Nivolumab 240 mg i.v. is administered on day -2 and every 2 weeks for a total of 4 doses. The medicine is administered over 30 minutes.
223588148|NCT07087457|BEHAVIORAL|5 day 30-minute walking program|5 day 30-minute walking program. This group was also defined as the human stimulus group because, in addition to the digital stimulus command, they will be invited by the researcher and will participate in the walking program with the researcher. This group will first receive the activity program and simultaneously will also receive the digital stimulus command interventions.
223588149|NCT07089030|PROCEDURE|Standard endoscopic evaluation|Examinations of the gastrointestinal (GI) tract (including the stomach, small intestine, and colon) will be performed to identify the source of bleeding. These examinations may be repeated based on the treating physician's assessment. Iron supplementation (ferrous sulfate) will be administered either orally (per os) or intravenously (IV), and blood transfusions will be provided if necessary.
223588150|NCT07089030|PROCEDURE|Conservative Medical Management|The investigational intervention involves a conservative treatment approach guided by a decision-making algorithm based on iron deficiency anemia values. This algorithm, developed from guidelines by the British Society of Gastroenterology and the American Gastroenterological Association, determines whether patients receive oral or IV ferrous sulfate or a blood transfusion. Laboratory parameters (hemoglobin, ferritin) will be monitored at weeks 4, 12, 38, and 64. After iron therapy, hemoglobin response will be assessed at 4 weeks, and treatment will continue for \~3 months post-normalization to ensure iron store repletion. Blood tests will be repeated every 6 months to detect recurrence.
224183300|NCT02205580|DRUG|continuous intravenous sufentanil 0.02μg•kg-1•h-1 infusion|
224183301|NCT02205580|DRUG|continuous intravenous sufentanil 0.03μg•kg-1•h-1 infusion|
223491864|NCT04611126|DRUG|Relatlimab|Relatlimab 80 mg i.v. is administered on day -2 and every 2 weeks for a total of 4 doses. The medicine is administered over 60 minutes.
223491865|NCT06863233|DRUG|Zirconium Zr 89 crefmirlimab berdoxam|Zirconium Zr 89 crefmirlimab berdoxam, the investigational agent proposed in this imaging study, is an anti-CD8 minibody (crefmirlimab), conjugated with deferoxamine (Df, berdoxam) and radiolabeled with Zirconium-89.
223491866|NCT06863233|DIAGNOSTIC_TEST|PET/CT Scan|Each patient will undergo up to four infusions of Zirconium Zr 89 crefmirlimab berdoxam followed by PET/CT 24 hours later (+/- 3 hours).
224183302|NCT02205580|DRUG|continuous intravenous sufentanil 0.04μg•kg-1•h-1 infusion|
224183303|NCT01348074|DRUG|Double dose|For each individual the dose on Day 1 and Day 2 will be twice the one normally taken
224183304|NCT00876291|DIETARY_SUPPLEMENT|Lactobacillus GG (probiotic )|LGG capsules: each cp containing 3 × 109 colony forming units, CFU
224183305|NCT00876291|DIETARY_SUPPLEMENT|Placebo|placebo which consisted of capsules identical in taste and appearance to the active study product except for the absence of freeze-dried LGG (and cryoprotectants)
224183306|NCT02618681|OTHER||
224183307|NCT01407965|PROCEDURE|microdialysis catheter|Placing of microdialysis catheter in fatty tissue and in the peritoneal cavity
223491867|NCT06857955|OTHER|Saline|0.9% sodium chloride saline solution
223491868|NCT06857955|DRUG|QCZ484|Solution of Injection
223491869|NCT03884374|BEHAVIORAL|Focused Breathing and Attention Training (BAT)|Participants will receive mindfulness-based mental training regimen to independently practice mindfulness meditation.
223491870|NCT03884374|BEHAVIORAL|Standard Breathing and Attention Training (BAT)|Standard BAT intervention will incorporate most of the general aspects of the Focused BAT intervention but without the specific instructions related to mindfully attending to the breath in a non-evaluative manner.
223491871|NCT03884374|DEVICE|Transcranial Direct Current Stimulation (tDCS)|A Soterix 1x1 Clinical Trials Direct Current Stimulator will apply 20 minutes of 2.0mA direct current through two bicarbon rubber electrodes encased in saline-soaked sponges
224183308|NCT01407965|PROCEDURE|microdialysis catheter|Placing of microdialysis catheter in fatty tissue and in the peritoneal cavity
224183309|NCT01071902|DRUG|Moxidex otic solution|4 drops into the infected ear(s) twice daily (morning and evening) for 7 days
224183310|NCT01071902|DRUG|Moxifloxacin otic solution|4 drops into the infected ear(s) twice daily (morning and evening) for 7 days
224183311|NCT01071902|OTHER|Vehicle|4 drops into the infected ear(s) twice daily (morning and evening) for 7 days
224183312|NCT01071902|DEVICE|Tympanostomy tubes|Tubes surgically inserted through the ear drum for the treatment of recurrent otitis media in children
224183313|NCT03720639|DEVICE|Abbott, Inc Confirm Rx™ versus Medtronic, Inc Reveal LINQTM|Comparing reliability and timeliness in data transmission between two implantable cardiac monitors.
224183314|NCT04738123|DRUG|Xanomeline and Trospium Chloride Capsules|Oral xanomeline 50 mg/trospium 20 mg BID on days 1-2 followed by xanomeline 100 mg/trospium 20 mg BID on days 3-7. The dose is increased to xanomeline 125 mg/trospium 30 mg BID on days 8-35 unless the subject is experiencing adverse events from the xanomeline 100 mg/ trospium 20 mg dose. Subjects who were increased to xanomeline 125 mg/trospium 30 mg will have the option to return to xanomeline 100 mg/ trospium 20 mg depending on clinical response and tolerability.
223491872|NCT03884374|DEVICE|Sham Transcranial Direct Current Stimulation (tDCS)|Sham stimulation procedures will be identical except for the duration of stimulation. Participants will receive 30 seconds of 2 mA (30s ramp up/down) of stimulation at the beginning of the session.
224183315|NCT04738123|DRUG|Placebo|Placebo Capsules
224183316|NCT03153085|BIOLOGICAL|TBI-1401(HF10)|"1x10\^7 TCID50/mL TBI-1401(HF10) (for a total of 6 injections; the first 4 injections at 1-week intervals; the remaining 2 injections at 3-week intervals).~Following combination therapy, patients may continue to receive the 1x10\^7 TCID50/mL TBI-1401(HF10) alone for up to an additional 13 injections (total of 19 injections = 1 year) if eligible for administration."
224183317|NCT03153085|DRUG|Ipilimumab|3 mg/kg ipilimumab (for a total of 4 intravenous infusions, each administered at 3-week intervals).
224183318|NCT04662957|DIETARY_SUPPLEMENT|Multi-strain probiotic mixture of four Bifidobacterium, five Lactobacillus and one Streptococcus species or placebo|Oral supplementation with multi-strain probiotic preparation
224183319|NCT04662957|DIETARY_SUPPLEMENT|Maltodextrin|Maltodextrin as placebo
223491873|NCT03240211|DRUG|Pembrolizumab|Pembrolizumab 200 mg IV
223491874|NCT03240211|DRUG|Pralatrexate|Pralatrexate 20 or 30 mg/m2 IV push
223491875|NCT03240211|DRUG|Decitabine|Decitabine 10 mg/m2
223491876|NCT03561376|DRUG|Topical zinc oxide vs. petrolatum post-surgical scars|"Following linear closure on non-scalp skin with scar length \> 4.5 cm, incision site will be split and petrolatum applied to one half and zinc oxide ointment to the other half daily for one month following surgery."
223491877|NCT04172779|DRUG|Erlotinib Hydrochloride|Oral administration of erlotinib 25mg tablet
223491878|NCT05482971|DRUG|Ropeginterferon alfa-2b-njft (P1101)|Ropeginterferon alfa-2b-njft (P1101)
223491879|NCT06948695|OTHER|Warm-up|5-minute warm-up run on treadmill at a freely chosen speed
223491880|NCT06948695|OTHER|Random blade test|4-minute run on a treadmill with a flat incline.
223491881|NCT06948695|OTHER|Random blade test|4-minute run on treadmill with a 10% gradient
223491882|NCT06948695|OTHER|Comfort speed test|1 min running test on an instrumented treadmill (Gaitway, H/P/Cosmos, Nußdorf, Germany) at comfort speed.
223491883|NCT06948695|OTHER|Outdoor random blade test|100-metre outdoor run at a comfort speed
223491884|NCT06860035|OTHER|Dementia Caregivers' Link to Assistance and Resources (DECLARE)|The intervention for treatment branches includes two parallel processes: (1) calling eligible caregivers to field a self-assessment instrument and upload caregiver responses to the patient record, and (2) identifying and flagging cases for expedited social work access with dementia-trained social workers.
223491885|NCT06865222|PROCEDURE|Electromagnetic Brain Pulsing Variable Pulse Protocol (EMBP) - 2 weeks|"The Electromagnetic Brain Pulsing Variable Pulse Protocol (EMBP) will be administered through an FDA-approved Transcranial Magnetic Stimulation (TMS) medical device. Results of the baseline EEG will be uploaded to NoetherTech's EMBP software on the Mayo Clinic campus, and transferred to Noethertech servers for TMS parameter determination~TMS treatment will be one 30 min session per day, 5 days per week (Monday-Friday), for 2 weeks."
223491886|NCT06865222|PROCEDURE|Electromagnetic Brain Pulsing Variable Pulse Protocol (EMBP) - 4 weeks|"The Electromagnetic Brain Pulsing Variable Pulse Protocol (EMBP) will be administered through an FDA-approved Transcranial Magnetic Stimulation (TMS) medical device. Results of the baseline EEG will be uploaded to NoetherTech's EMBP software on the Mayo Clinic campus, and transferred to Noethertech servers for TMS parameter determination~TMS treatment will be one 30 min session per day, 5 days per week (Monday-Friday), for 4 weeks."
223491887|NCT07002528|BEHAVIORAL|sucrose solution|apply sucrose solution to evaluate pain among local anesthesia
223491888|NCT07002528|BEHAVIORAL|Cryotherapy|apply cryotheraby to evaluate pain among local anesthesia
223491889|NCT07002528|BEHAVIORAL|topical anesthesia|apply topical anesthesia to evaluate pain among local anesthesia
223588151|NCT07089251|DRUG|low-dose epinephrine and tranexamic acid|low-dose epinephrine and tranexamic acid
223491890|NCT05984381|DRUG|Prednisolone|prednisolone 0.75mg/kg/day (a maximum dose of 40mg at baseline) orally
223491891|NCT05984381|DRUG|Dapsone|Dapsone 100 mg/day
223491892|NCT05984381|DRUG|Methotrexate|Methotrexate 15 mg weekly
223491893|NCT03414008|DRUG|BI 1291583|Single dose
223491894|NCT03414008|DRUG|Matching placebo: Tartaric acid|Single dose
223491895|NCT06652841|DEVICE|transShield Embolic Protection System|Patient undergoing TAVR procedure will receive the transShield EPS with the intent to capture and remove debris dislodged during the interventional procedure.
223588152|NCT07089251|DRUG|Tranexamic Acid (TXA) treatment|Tranexamic Acid
224183320|NCT00757354|PROCEDURE|Metal on Metal cementless hip|Metal on Metal hip arthroplasty
224183321|NCT02053649|BEHAVIORAL|Triple Chronotherapy|triple chronotherapy (TC will consist of bright light therapy, sleep phase advance, and sleep deprivation/restriction
224183322|NCT02053649|OTHER|Usual Care|UC will consist of medication administered by a perinatal psychiatrist and/or psychotherapy
224183323|NCT05190406|PROCEDURE|Pulpotomy|After achieving hemostasis, in pulpotomy group bioceramic material will be placed and then permanent restoration will be done.
223491896|NCT07003932|OTHER|Remote monitoring|The remote monitoring group will be more closely followed than the control group in order to detect any deterioration over time. This group will not be scheduled for a face-to-face consultation unless it is deemed necessary by a physiotherapist or if the patient contacts the hospital themselves.
223491897|NCT07003932|OTHER|Usual Care|The control group will follow usual care with face-to-face consultation with a physiotherapist at 2 and 12 months. They will also anwer questionnaires at 2, 6 and 12 months, but these will not be monitored.
224183324|NCT05190406|PROCEDURE|root canal treatment|Single visit root canal treatment will be done according to standard protocol.
224183325|NCT01279421|BEHAVIORAL|Social Network HIV Testing|Crack users will be recruited for HIV testing and receive 3 coupons to recruit other crack users for HIV testing.
224183326|NCT01279421|BEHAVIORAL|Peer Network Intervention|Peer leaders will recruit small networks of crack users and facilitate a three-day prevention intervention.
224183327|NCT04090294|DRUG|Roflumilast|"Roflumilast is a phosphodiesterase (PDE) type 4 inhibitor will be prescribed for three month for the study group. the patients will then be assessed for improvement regarding exacerbation frequency , performance and pulmonary function test.~patients will receive Roflumilast 500 Mcg. Tablet once daily for three months"
224183328|NCT00026559|DEVICE|Shock Device|Shock Device
224183329|NCT00026559|DEVICE|Auditory Startle Device|Auditory Startle Device
224183330|NCT02911311|DRUG|intravitreal injection of conbercept|conbercept is an anti-VEGF agent and is approved by the Food and Drug Administration for wet age-related macular degeneration
224183331|NCT02911311|DEVICE|PRP|panretinal photocoagulation (PPR) is the standard treatment for proliferative diabetic retinopathy (PDR) and is applied to the peripheral retinal tissue to ablate areas of the peripheral retina and thereby reduce retinal oxygen consumption
224183332|NCT04123340|DIAGNOSTIC_TEST|Additional intraprocedural pre-ablation CT-scan|In 20 patients, besides de regular post-RFA scan, a pre-RFA contrast enhanced dual phase CT-scan will be acquired to investigate the feasibility of quantitative ablation assessment.
224183333|NCT03137433|DIETARY_SUPPLEMENT|Meal-replacement Therapy|We seek to examine the effect of meal-replacement therapy on weight loss outcomes in teens with severe obesity.
224183334|NCT00083616|BIOLOGICAL|Panitumumab|Panitumumab 6 mg/kg every once 2 weeks weeks administered by intravenous (IV) infusion.
224183335|NCT06137027|DRUG|Cannabidiol Oil|Cannabidiol oil will be administered sublingually 2-3 hours preoperatively
224183336|NCT06137027|DRUG|Placebo|Placebo will be administered sublingually 2-3 hours preoperatively
224183337|NCT00627991|DRUG|Valsartan|
224183338|NCT05895591|OTHER|Anti-aging cosmetic care product|"* frequency of application: Once a day (in the morning)~* modalities of application: Apply the cream on face (according to normal conditions of use) and on treated forearm, massage until complete penetration~* area: The whole face, neck, neckline and one randomized forearm (external photo-exposed area) the other forearm is untreated~* duration of investigational product application: 56 days (a window of + 72 hours is allowed)~* quantity: 2 pressures of product for the whole face, neck and neckline and 1 pressure of product for the treated forearm"
224183339|NCT00597129|BIOLOGICAL|90Y-hPAM4|Single dose of 90Y-hPAM4 will be given and all patients will be followed for 12 weeks.
223491898|NCT07003542|DRUG|Sitagliptin|"Sitagliptin will be self-administered orally by participants.~Dose level - sitagliptin~* 1 100 mg daily~* -1 50 mg daily~* -2 25 mg daily"
223491899|NCT03194893|DRUG|Alectinib|Alectinib capsules 600 mg twice a day (BID) orally until no further clinical benefit is to be expected, unacceptable toxicity, availability of commercial supply, withdrawal of consent, or death, whichever occurs first.
223491900|NCT03194893|DRUG|Crizotinib|Crizotinib capsules 250 mg BID orally until no further clinical benefit is to be expected, unacceptable toxicity, availability of commercial supply, withdrawal of consent, or death, whichever occurs first.
223491901|NCT03459846|DRUG|Durvalumab|Durvalumab 1500 mg IV q4w
223491902|NCT03459846|DRUG|Olaparib|Olaparib PO 300 mg BID adjusted based on patient's creatinine clearance.
223491903|NCT03459846|DRUG|Placebo|Matching placebo for oral tablet BID
223491904|NCT06602258|DRUG|E2814|E2814 IV infusion.
223491905|NCT06602258|DRUG|Lecanemab|Lecanemab SC injection.
223491906|NCT06602258|DRUG|Placebo|Placebo IV infusion.
223491907|NCT05423756|OTHER|Arm 1: Routine Care|Routine Antibiotic Stewardship Arm - Continuation of antibiotic stewardship activities in accordance with national standards.
223491908|NCT05423756|OTHER|Arm 2: INSPIRE Stewardship Bundle for Skin and Soft Tissue Infection|Quality improvement intervention that includes (1) computerized physician order entry (CPOE) decision support alert that provides physicians with patient-specific risk estimates for having a skin/soft tissue infection due to a multidrug-resistant organism (MDRO) and recommends standard spectrum antibiotics for low risk patients in the first 3 days of hospitalization; (2) clinician feedback reports, and (3) activities to support CPOE adoption (including education and alignment of CPOE workflows). Other antibiotic stewardship activities to continue in accordance with national standards.
223491909|NCT07126938|DRUG|Alcoholic beverage|Participants in the experimental group consumed self-selected amounts of alcohol, monitored by study staff to ensure safety and compliance with protocol guidelines. Participants then filled out the remainder of the general health questionnaire, including how many drinks they consumed, and whether or not they feel too impaired to drive a vehicle or go to work.
223512516|NCT02589912|DEVICE|Nucleus Profile ABI541 Auditory Brainstem Implant|
223512517|NCT01205737|BIOLOGICAL|TL011|375 mg/m2 iv every 3 weeks for 8 cycles
223512518|NCT01205737|BIOLOGICAL|Rituximab|375 mg/m2 iv every 3 weeks for 8 cycles
223588153|NCT07087873|DEVICE|Neuroelectrical modulation group|Participants received transcranial electrical stimulation using the Spanish Neuroelectrics StarStim 32 device.
224183340|NCT02440191|RADIATION|3DCRT|conventional radiotherapy
224183341|NCT01549327|OTHER|Oncology Interactive Navigator|
224183342|NCT01549327|OTHER|Routine Care|
224183343|NCT05450380|DEVICE|LIFT001|"The dermal filler of hyaluronic acid LIFT001 is applied to the facial area to provide firmness and counteract sagging for the correction of deep wrinkles and imperfections of face.~The dermal filler of hyaluronic acid LIFT001 is applied to the facial area to provide firmness and counteract sagging for the correction of deep wrinkles and imperfections of face."
224183344|NCT00135265|BEHAVIORAL|smoking cessation, practice change|Providers will be trained in a brief smoking cessation intervention for teens.
224308268|NCT00681512|DIETARY_SUPPLEMENT|berry powder|"All subjects (lung cancer survivors and volunteers) will consume 20 grams of berry powder (blueberries, black raspberries, or a mixture of both) per day by mouth for the first 3 days, then 40 grams of berry powder by mouth every day for 4 to 5 weeks.~The berry powder is to be mixed in subject's routine intake of milk, yogurt, juice, or water.~All subjects will have the option to continue the berry regimen for an extended period. Subjects who choose to do so will not consume any berry powder for one week. After one week, subjects will begin consuming 40 grams of the berry powder every day for an additional 4 to 5 weeks."
224308269|NCT00398255|BEHAVIORAL|self-management program|
224308270|NCT03584984|PROCEDURE|Mixture of Autogenous bone & Anorganic Bovine Bone (ABB)|Filling the socket with Mixing of autogenous bone graft and anorganic bovine bone in a 50:50 ratio
224308271|NCT03584984|PROCEDURE|Anorganic Bovine Bone (ABB)|Filling the socket with Anorganic bovine bone graft material only
224308272|NCT03584984|PROCEDURE|Absorbable gelatin sponge|Filling the socket with an absorbable gelatin sponge foam pack
223491910|NCT04488224|DEVICE|Nano-X Patient Rotation System|"The Nano-X prototype is a horizontal patient rotation system that immobilises participants while being rotated on the horizontal axis.~This device will be used to rotate patients horizontally while cone-beam Computed Tomography (CBCT) projections are acquired."
224183345|NCT02535858|DEVICE|Heart and respiratory rate and VE|To evaluate the effectiveness of the virtual environment (VE) as a biofeedback of chemically dependent's vulnerability front situations of risk, a total of 50 volunteers who were drug users, monitored by 10 therapists, were enrolled.
224183346|NCT02535858|DEVICE|Heart and respiratory rate and video|Anxiety is characterized by the average variability from both heart and respiratory rate of 30 volunteers undergoing stress environment situations.
224183347|NCT03303352|PROCEDURE|EUS FNA|Patients with solid pancreatic masses fulfilling the inclusion and exclusion criteria will be randomly allocated to receive EUS FNA (endoscopic ultrasound fine needle aspiration).
224183348|NCT02264132|DRUG|Pramipexole ER tablet|
224183349|NCT02264132|DRUG|Pramipexole IR tablet|
224183350|NCT02460185|BEHAVIORAL|Study group: Maternal Physical Exercise|Exercise: 30 minutes of walking, 3 times a week at 4 Km/h.
224308273|NCT06399809|DRUG|Fisetin|Fisetin is a flavanol, present in strawberries, apples, and persimmons, that destroys senescent cells (i.e. a senolytic therapy). Of three senolytic therapies being tested in clinical trials, fisetin has the best safety profile.
224308274|NCT06399809|DRUG|Placebo|The placebo will be matched to the Fisetin intervention
224308275|NCT02935205|DRUG|Enzalutamide|Given PO
223491911|NCT04488224|RADIATION|Conventional CBCT scan|A conventional cone-beam Computed Tomography (CBCT) scan is acquired on standard radiotherapy machinery.
223491912|NCT04488224|OTHER|Psychometrically validated questionnaires|The Claustrophobia Questionnaire (CLQ), Short Form State/Trait Anxiety inventory (STAI) and Fast Motion Sickness (FMS) questionnaires administered. CLQ only once before the first session, STAI and FMS both before and after each Nano-X CBCT session.
223491913|NCT06680778|DEVICE|Proactive Monitoring|Proactive monitoring of vital signs for the duration of the first two cycles of chemotherapy by using a Fitbit
223491914|NCT07005206|BEHAVIORAL|Six Hats Thinking|A total of 6 sessions of thinking training were given once a week for 6 weeks.
223491915|NCT07005206|DEVICE|No Intervention (Control)|No intervention was made to this group.
224308276|NCT02935205|DRUG|Indomethacin|Given PO
223491916|NCT06797687|DIAGNOSTIC_TEST|Cardiac computed tomography|Mitral valve annulus measurements in the enrolled patients obtained will be obtained from: coronary CT scan, intraoperative transesophageal echocardiography and the ring surgically implanted during surgery.
223491917|NCT06869148|OTHER|Prioritized assessment for older patients living with frailty|In the beginning of 2025, the Emergency department of University hospital of Linköping launched a clinical guideline which stated that patients aged 65 years or older should be assessed with CFS as early as possible, preferably in connection to triage. If the patients were assessed as living with frailty, the frailty score should be stated in the electronical overview of ED patients. The patient's needs of care should be met according to frailty level and the responsible clinical team should aim to decrease the ED length of stay for older patients living with frailty.
224183351|NCT03485976|DRUG|Ixekizumab|Treatment at the FDA-approved psoriasis dosing
224183352|NCT01870765|DEVICE|non-invasive ventilation|non-invasive ventilation via face mask
224183353|NCT01870765|DEVICE|high-flow oxygen|high-flow oxygen via nasal cannula
224183354|NCT01870765|PROCEDURE|fiberoptic bronchoscopy|fiberoptic bronchoscopy including broncho-alveolar lavage
224183355|NCT03639493|DRUG|Exforge® tab 10/160mg, Crestor® tab 20mg|Co-administration of Amlodipine 10mg/ Valsartan 160mg(combination drug) and Rosuvastatin 20mg
224308277|NCT02056392|DRUG|Selumetinib|Volunteers will receive 75 mg selumetinib oral dose (Treatment A)
224308278|NCT02056392|DRUG|Moxifloxacin|Volunteers will receive 400 mg Moxifloxacin oral dose (Treatment B)
224308279|NCT02056392|DRUG|selumetinib placebo|Volunteers will receive selumetinib placebo oral dose (Treatment C)
224308280|NCT05551819|DIETARY_SUPPLEMENT|MDF then RUTF/RUSF|Children randomized to feeding order 1: children will be provided MDF for the first two weeks then crossover to consume RUTF/RUSF for a second two weeks.
224308281|NCT05551819|DIETARY_SUPPLEMENT|RUTF/RUSF then MDF|Children randomized to feeding order 2: children will be provided RUTF/RUSF for the first two weeks then crossover to consume MDF for a second two weeks.
224308282|NCT04004156|DEVICE|PerQdisc® Nucleus Replacement Device.|All patients that meet the inclusion/exclusion criteria will receive the PerQdisc® Nucleus Replacement Device.
224308283|NCT05675306|BEHAVIORAL|Dynamic Temporal and Tactile Cueing Treatment|"DTTC is a dynamic, motor-based treatment approach designed for children with severe CAS. This approach is based on Integral Stimulation (Edeal \& Gildersleeve-Neumann, 2011; Maas \& Farinella, 2012; Maas et al., 2019; Strand \& Debertine, 2000; Strand \& Skinder, 1999), in which the clinician instructs the child to listen to me, watch me, and do what I do and systematically taxes and supports the speech motor system to facilitate system-wide change in speech output (Strand, 2020)."
224308284|NCT05102721|DRUG|Avelumab and Pepinemab|IV Infusions every two weeks.
224308285|NCT05999396|DRUG|Administration of CC-3|Accelerated titration phase, Standard 3+3 titration phase, expansion phase
223491918|NCT07011264|BEHAVIORAL|The BAJJAJJA intervention|"The BAJJAJJA intervention is composed of:~The IGA COMPONENT which is intended to promote economic empowerment by improving household income based on available resources. The component will consist of a series of 1-hour sessions with 3 separate GMC participant groups (8 GMCs per group). Two IGA experts will lead these sessions, weekly for the first two months and later monthly for the remaining 10 months of the 12-month intervention period.~The HEALTH COACHING COMPONENT will be informed by theChronic Disease Self-Management Education (CDSME) framework.54 This community-based, person-centered care model will be used to empower GMCs to manage their health through goal-setting, problem-solving, and chronic disease self-monitoring. I (PI) will leverage the community networks that I developed during my preliminary work to (1) recruit interventionists (two nurses) and (2) ensure their adequate training and adherence to the intervention manuals and procedures."
224183356|NCT03639493|DRUG|CJ-30060 10/160/20mg|Fixed-dose combination drug containing Amlodipine 10mg and Valsartan 160mg and Rosuvastatin 20mg
223491919|NCT06588088|OTHER|Dietary|The diet of these healthy volunteers was such that no calories were consumed after 19.30 in the evening in the first week, and in the second week, 25% of the daily calorie need calculated according to the Harris - Benedict formula was taken, taking into account the nighttime eating syndrome (NES) criteria, after 20.30 in the evening.
223491920|NCT07013643|DRUG|AZD6234|AZD6234 will be administered as a subcutaneous injection in the abdomen.
223491921|NCT07013643|DRUG|Ethinyl estradiol/Levonorgestrel (EE/LEVO)|EE/LEVO will be administered as combined oral tablets.
223491922|NCT07013643|DRUG|Acetaminophen (APAP)|APAP will be administered orally as a solution.
223491923|NCT07013643|DRUG|AZD9550|AZD9550 will be administered as a subcutaneous injection in the abdomen.
223491924|NCT07010835|DRUG|YK012|YK012 is a bispecific antibody targeting CD19 and CD3.
223491925|NCT02141113|DRUG|Guanfacine Hydrochloride|"1. mg Guanfacine Hydrochloride (orally)~2. mg Guanfacine Hydrochloride (orally)~3. mg Guanfacine Hydrochloride (orally)~4. mg Guanfacine Hydrochloride (orally)~5. mg Guanfacine Hydrochloride (orally)~6. mg Guanfacine Hydrochloride (orally)"
223491926|NCT02141113|OTHER|Placebo|Placebo of matching mg
223491927|NCT07013968|BEHAVIORAL|culturally tailored, trauma-informed mindfulness smoking cessation intervention|"Eight weekly in-person group sessions, each 90 minutes long. From the second half of PY01 to PY04, sessions will be performed in closed in groups of 7-10 participants (with a total of 6 groups). The curriculum is grounded in Lakota values and trauma-informed care. Each of the eight sessions will begin and end with a Lakota serenity prayer and wazílya (smudging of sage), and the meaning and relevance of one of the Lakota values will be discussed. Through a storytelling approach, which is central to Lakota culture, the participants will learn about their value as a Lakota woman, the role of caŋṡaṡa, the association between unresolved trauma and smoking, and the importance of Lakota mind-based and mindfulness strategies in their lives."
223491928|NCT07013110|DRUG|dnaJP1|The study drug is dnaJP1 peptide. It is a manmade short protein that can be taken easily as a pill. dnaJP1 works to restore the body's immune tolerance by improving its ability to self-adjust - helps to restore the immune system and improve controls on inflammation that has been lost.
223491929|NCT07013110|DRUG|Placebo|This is the control.
223491930|NCT07013578|BEHAVIORAL|Healing Circuits™ sessions|Treatment of the Study group will involve 12-weekly 50-minute sessions with a social worker who has been trained in the Healing Circuits™ Methodology - a structured mental health support delivered by a therapist in a one-on-one model.
223491931|NCT07013578|BEHAVIORAL|self-directed Healing Circuits™ curriculum|Treatment of the Control group will involve 12 weekly online modules of a self-directed Healing Circuits™ curriculum - structured mental health support being delivered in an web-based video instruction model.
224183357|NCT06399458|DIAGNOSTIC_TEST|For hypermobility; Beighton score and Brighton revised 1998 Criteria|Beighton score and Brighton revised 1998 Criteria
224183358|NCT03372304|DRUG|Ropivacaine 0.2%|Perineural infusion of Ropivacaine 0.2% using a peripheral nerve block catheter and a portable infusion pump.
224183359|NCT00667537|DRUG|Radium-223 chloride (Xofigo®, BAY88-8223) injection|Sterile, clear and colourless aqueous solution of radium-223 chloride free of endotoxins, for intravenous administration
223491935|NCT07014618|OTHER|Pre & Post Surveys|As part of this intervention, patients will complete a pre-treatment questionnaire at the time of consent, which can be administered in person, over the phone, or through the mHealth mobile app, based on their preference. One month after treatment, patients will complete a post-treatment questionnaire using their chosen method. At the six-month mark, patients will complete an additional post-treatment questionnaire along with the COST-Functional Assessment of Chronic Illness Therapy (COST-FACT) survey.
223491936|NCT07014618|OTHER|Opt Out of Questionnaire|As part of this intervention, patients declined to participate in the optional questionnaire. However, their data will still be collected through chart review and will be compared to the data of patients who accepted both the questionnaire and navigation services.
224183360|NCT05453552|DRUG|Granulocyte Colony-Stimulating Factor(G-CSF)|G-CSF was administered at 5 ug/kg/day on days-17 to -10. When white blood cell is more than 20G/L, stop using G-CSF.
224183361|NCT05453552|DRUG|Decitabine (DAC)|Decitabine was administered at 20mg/m2/day on days -14 to -10.
224183362|NCT05453552|DRUG|Busulfan|Busulfan was administered at 3.2 mg/kg/day on days -7 to -4 in G-CSF+DAC+BUCY group.
224183363|NCT05453552|DRUG|Fludarabine (FLU)|Fludarabine was administered at 30 mg/m2/day on days -7 to -3.
224183364|NCT05453552|DRUG|Cyclophosphamide (CY)|Cyclophosphamide was administered at 60 mg/kg/day on days -3,-2.
224183365|NCT05453552|DRUG|Busulfan (BU)|Busulfan was administered at 3.2 mg/kg/day on days -6 to -3 in G-CSF+DAC +BF group.
224183366|NCT03230539|DRUG|Ulipristal Acetate IUS delivering Cu and 5μg|This is a proof-of-concept study utilizing a randomized dose-finding, parallel design to assess the effects of an IUS delivering Cu and 5, 20, or 40 μg of UPA over 12 weeks.
224183367|NCT03230539|DRUG|Ulipristal Acetate IUS delivering Cu and 20μg|This is a proof-of-concept study utilizing a randomized dose-finding, parallel design to assess the effects of an IUS delivering Cu and 5, 20, or 40 μg of UPA over 12 weeks.
223588154|NCT07087873|DEVICE|Pseudo-neuromodulation group|Pseudo-stimulation is performed using the same equipment and procedures as in the neuromodulation group.
223588155|NCT03779503|DEVICE|midafilcon A|midafilcon A 1 day daily disposable contact lens
223491937|NCT07016178|BEHAVIORAL|Acceptability and Feasibility of Twistle messaging for PDM+ patients|PC patients identified by the PDM as high risk for developing or having undetected MCI or ADRD will receive the patient-informed message developed in Aim 2. The patient-informed message will include instructions for completing validated questions about subjective memory concerns. In addition, interested patients will have the option to schedule a visit with the BHN, or enroll in research opportunities.
223588156|NCT03779503|DEVICE|somofilcon A|somofilcon A 1 day daily disposable contact lens
223745532|NCT06838793|PROCEDURE|Single Level Intertransverse Process Block|"Patients will then be positioned in the lateral decubitus position with the side to be blocked facing upwards, the neck slightly flexed and the upper arm resting on the pillow for the USG ITPB.~The thoracic intervertebral levels (T3, T5, T7) will be identified and marked on the patient. Ultrasound gel will be applied to the skin foracoustic coupling and the transducer is placed 2-3 cm lateral to the spinous process, at the target vertebral level, in the t After obtaining the target transverse ultrasound window at the articular process level, under strict aseptic precautions and local infiltration (Lignocaine 1%), a SonoTap nerve block needle (Pajunk, 22G, 80 mm, Pajunk, Geisingen, Germany) will be inserted in-plane and slowly advanced from a lateral to medial direction until its tip is located at the medial aspect of the retro-SCTL space. After negative heme aspiration, 25 ml of LA mixture containing 0.5% ropivacaine with 1: 200,000 adrenaline will be injected slowly in small aliquots."
223491938|NCT04878263|OTHER|Conventional hospitalization|Conventional care pathway : patients will be hospitalized as long as necessary and then followed according to High Health Authorities recommendations and usual practices.
223491939|NCT04878263|OTHER|FIL-EAS ic care pathway|Organized care pathway with a maximum 4 working day long conventional hospitalization followed by hospitalization at home with a follow up combining hospital and private practice competences.
223491940|NCT06627296|OTHER|Exercise Training|"Individuals in the NMES group will have a total of 24 sessions of NMES application with 15 repetitions 3 days a week for 8 weeks and then exercise programs will be performed face-to-face. They will also be given home exercises to continue at home.~In the NMES group, NMES training will be performed for extensor carpi radialis longus (ECRL), extensor carpi radialis brevis (ECRB), abductor pollicis longus (APL), flexor carpi radialis (FCR) muscles. The pencil electrode will be used to stimulate the ECRL, ECRB, FCR and APL muscles in such a way that 30+30+30=90 contractions will be obtained from each muscle. According to the morphologic characteristics of each muscle, different current and will be applied.~P11th program to ECRL and APL : 65 Hz. 200 μs, P13th program to ECRB and FCR 50 Hz, 200 μs will be applied. Exercises includes intrinsic and extrinsic muscle strengthening, stabilization exercises and dart exercises, wrist neuromuscular exercises and perturbation exercises."
223491941|NCT06627296|OTHER|Exercise Training (Control Group)|"Patients in the control group will have face-to-face exercise programs with a physiotherapist for a total of 24 sessions of 15 repetitions 3 days a week for 8 weeks. Exercises will be performed 3 days a week with a physiotherapist. On the other days, patients will be asked to perform 3 sets of 15 repetitions every day as home exercises.~Exercise training includes intrinsic and extrinsic muscle strengthening, wrist stabilization exercises, dart exercises, wrist neuromuscular exercises using different materials, reactive muscle control, perturbation exercises.~Exercises will be at the limit of pain. Until the 6th month, overloading, strong gripping, weight transfer, rotations and lifting heavy objects should be avoided. Rehabilitation with functional range of motion is important. Exercises will be performed with a physiotherapist 3 days a week. On the other days, patients will be asked to perform 3 sets of 15 repetitions every day as home exercises."
223491942|NCT06627296|DEVICE|Neuromuscular Electrical Stimulation|Neuromuscular Electrical Stimulation
223491943|NCT00357565|BIOLOGICAL|filgrastim|All patients will receive G-CSF 5 mcg/kg/day intravenous (IV) (dose rounded to vial size) based on the actual body weight IV beginning on day +1 after umbilical cord blood (UCB) infusion. G-CSF will be administered daily until the absolute neutrophil count (ANC) exceeds 2.5 x 10\^9/L for three consecutive days and then discontinued. If the ANC decreases to \<1.0 x 10\^9/L, G-CSF will be reinstituted.
223491944|NCT00357565|DRUG|busulfan|Administered 1.1 mg/kg if \<12 kg intravenous (IV) every 6 hours (0.8 mg/kg if \>12 kg IV every 6 hours on Days -8 through -5.
223491945|NCT00357565|DRUG|cyclosporine|Patients will receive cyclosporine (CSA) therapy beginning on day -3 maintaining a level of \>200 ng/mL. For children \< 40 kg the initial dose will be 2.5 mg/kg intravenous (IV) over 2 hours every 8 hours.
223491946|NCT00357565|DRUG|fludarabine phosphate|Administered 25 mg/m\^2 intravenous (IV) over 60 minutes on Days -4 through -2.
223491947|NCT00357565|DRUG|melphalan|Administered 60 mg/m\^2 intravenous (IV) over 30 minutes on Days -4 through -2.
223491948|NCT00357565|DRUG|mycophenolate mofetil|All patients will begin mycophenolate mofetil (MMF) on day -3. Patients \<45 kilograms will receive MMF at the dose of 15 mg/kg/dose every 8 hours (max dose 1gm/dose) orally or intravenously (PO or IV).
223491949|NCT00357565|PROCEDURE|umbilical cord blood transplantation|The product is infused via IV drip directly into the central line without a needle, pump or filter on Day 0.
223588157|NCT00248716|DRUG|Ferrous gluconate and iron polysaccharide complex|Children with anemia will receive 5mg per kg per day of one of study medications. Treatment period for 3 months
223588158|NCT06256471|OTHER|Follow up of multiple sclerotic and nephrotic syndrome patients after 3 months|Follow up of multiple sclerotic and nephrotic syndrome patients after 3 months for detection of impact of parasitic infection on these diseases courses
223588159|NCT04122131|DIAGNOSTIC_TEST|Immunohistochemistry|Immunohistochemical analysis of biomarker in post-surgical sample
223588160|NCT01862367|DRUG|catridecacog|No treatment given. All patients enrolled in this observational study will receive their medication through usual commercial channels.
223588161|NCT00324441|DEVICE|Iratherm® 1000|
224183368|NCT03230539|DRUG|Ulipristal Acetate IUS delivering Cu and 40μg|This is a proof-of-concept study utilizing a randomized dose-finding, parallel design to assess the effects of an IUS delivering Cu and 5, 20, or 40 μg of UPA over 12 weeks.
224183369|NCT02552537|DRUG|Omeprazole|patients with walnut allergy will be exposed during 5 days before food challenge with Omeprazole
224183370|NCT02552537|DRUG|Placebo|patients with walnut allergy will be exposed during 5 days before food challenge with Placebo
224183371|NCT01416259|DRUG|Withdraw treatment|
224183372|NCT06308289|OTHER|Global Posture Re-education|Focusing on postural correction and movement patterns
224183373|NCT06308289|OTHER|Active Cycle of Breathing Technique|Emphasizing breathing control, thoracic expansion, and mucus clearance techniques
224183374|NCT02139891|DEVICE|Cardiac Resynchronization Therapy with MultiPoint Pacing|
224183375|NCT01310426|OTHER|3D transperineal Ultrasound|3D transperineal Ultrasound after vaginal delivery
224183376|NCT00748176|PROCEDURE|spinal anesthesia|spinal anesthesia with bupivacaine
224183377|NCT01475812|OTHER|Hyperinflation and ADL|Assessment of dynamic pulmonary hyperinflation during activities of daily living in COPD patients.
224183378|NCT00086060|BEHAVIORAL|Exercise regimen|Aerobic Exercise is a self-management technique that increases personal control over pain by enhancing physical fitness. Patients will be encouraged to choose activities best suited to their tastes and current lifestyle, incorporating lifestyle physical activities (climbing stairs, household chores, etc) and more traditional exercise activities (walking, cycling, etc.). Subjects will use ratings of perceived exertion (RPE) to guide their effort. The intervention will consist of two-hours of face-to-face contact followed by weekly telephone contact for 8 weeks. Face-to-face contract will include receiving a standardized instruction manual for exercise, a demonstration on how to perform relaxation, and tailoring homework assignments to be monitored on the weekly phone call.
224183379|NCT00086060|BEHAVIORAL|Relaxation training|Relaxation is a self-management technique that increases personal control over pain by relaxing tense muscles, allowing the body to rest, and improving mental clarity through concentration and attention and has a great deal of empirical research supporting its effectiveness as a means of pain management. A variety of relaxation skills will be taught with some being based on muscle relaxation, and others focused more on cognitive relaxation and imagery. The intervention will consist of two-hours of face-to-face contact followed by weekly telephone contact for 8 weeks. Face-to-face contract will include receiving a standardized instruction manual for relaxation, a demonstration on how to perform relaxation, and tailoring homework assignments to be monitored on the weekly phone call.
224183380|NCT00086060|BEHAVIORAL|Standard Care|Participants in the standard care control group will not receive any additional intervention beyond that which they are receiving from their routine health care professional.
224183381|NCT06424756|DIETARY_SUPPLEMENT|MitoQ|MitoQ supplement is composed of mitoquinol mesylate, which is a synthetic analog of coenzyme Q10
224183382|NCT06424756|DIETARY_SUPPLEMENT|Placebo|MitoQ matched Placebo
223491950|NCT07018960|PROCEDURE|Chest wall reconstruction with 3D printed titan custom prothesis|"Dynamic Chest Wall Reconstruction with Patient-Specific 3D-Printed Titanium Prostheses~1\. Intervention Overview~A custom-designed, 3D-printed titanium prosthesis is surgically implanted to reconstruct chest wall defects following oncologic resection or traumatic injury. The prosthesis is engineered to:~Restore structural integrity of the thoracic cavity Preserve physiological chest wall dynamics during respiration Provide long-term biomechanical stability"
223491951|NCT07020559|DRUG|allogeneic platelet plasma|Al-PRP derived from healthy blood donors
223491952|NCT07020559|DRUG|autologous platelet plasma|Autologous platelet-rich plasma from the patient themselves
223491953|NCT05341284|OTHER|Questionnaire Survey and Cervical Cancer Screening|"A brief questionnaire will be administered to all participants at enrollment and at the pre-scheduled follow-up visit at Month 36.~For the subject who are eligible for the screening (i.e. (1)≥ 18 years old; (2) had sexual debut prior to enrollment, (3) no contradiction to the screening, (4) voluntary to the screening) will be referred to the study site hospitals by offering the subjects a cervical cancer screening voucher, and the type-specific HPV test will be performed as primary screening approach at Month 0 and 36."
223491954|NCT07017010|BEHAVIORAL|phonemic awareness intervention (PA)|All 12 weeks of lessons will exclusively focus on instruction at the phoneme level (i.e., the individual sounds in words), with activities addressing the blending of sounds to form short words. Other activities may include counting the number of sounds heard in a word, matching letter tiles to the sounds heard in the word, and separating short words into their component sounds.
223512519|NCT00970177|BIOLOGICAL|Monovalent A/H1N1 influenza vaccine|This trial will be performed at multiple study sites in a population of healthy adults and elderly. Subjects will be randomized to receive two IM injections of low dose of antigen \& adjuvant, or high dose of antigen \& adjuvant, or high dose of antigen, according to the study groups.
223512520|NCT02220400|DRUG|Ketamine|
223512521|NCT03374956|DRUG|Phentermine-Topiramate|Extended Release at dose of 7.5/46 mg oral daily
223512522|NCT03374956|DRUG|Liraglutide|dose of 3 mg subcutaneous daily
223512523|NCT03374956|DRUG|Naltrexone/bupropion|Oral naltrexone extended-release/bupropion extended-release at dose of 32/360 mg oral daily (divided in 2 tables in morning and 2 tablets in evening)
223512524|NCT03374956|DRUG|Phentermine|15-37.5 mg oral daily
223512529|NCT03401580|DRUG|Viena II 160/10|once daily
223512530|NCT03401580|DRUG|Viena II 190/10|once daily
223512531|NCT03401580|DRUG|Viena II 160/12|once daily
223512532|NCT03401580|DRUG|Viena II 190/12|once daily
223512533|NCT01019057|PROCEDURE|ILIF|Interlaminar lumbar instrumented fusion (ILIF™) is a compound surgical solution to spinal stenosis, combining direct neural decompression with an allograft interspinous spacer (ExtenSure® H2) to maintain the segmental distraction, and a spinous process fixation plate (Affix™) to maintain stability for eventual segmental fusion.
223512534|NCT02197065|DRUG|Atorvastatin|Atorvastatin or placebo will be started at least 4 hours prior to surgery, and continued nightly until postoperative day 45
223512535|NCT02197065|DRUG|Placebo|
223512536|NCT03059888|DRUG|Abatacept Injection|Subcutaneous administration of abatacept
223512537|NCT00000472|DRUG|tissue plasminogen activator|
223512538|NCT00000472|DRUG|heparin|
223491955|NCT07017010|BEHAVIORAL|phonological sensitivity + phonemic awareness intervention (PSPA)|The first six weeks of intervention will include a focus on being able to manipulate (separate and blend) parts of words larger than the individual sounds. This will include manipulating compound word components, syllables, and initial sounds and rhyming components of words. Activities may include matching pictures of words, assembling/disassembling puzzle pieces that represent words, and sorting pictures (words) by their first or ending sounds. The second six weeks of intervention will focus on phonemic awareness, as described for the PA intervention condition, and be the same as what the children in the DPA intervention condition experience.
223491956|NCT07017010|BEHAVIORAL|delayed onset phonemic awareness intervention (DPA)|The six weeks of intervention will focus on phonemic awareness, as described for the PA intervention condition, and be the same as the second six weeks of lessons that the children in the PSPA intervention condition experience.
223491957|NCT07011797|DRUG|CX11|CX11 tablets administered orally once daily (QD) with meals
223491958|NCT07011797|OTHER|Placebo|Matching placebo tablets administered orally once daily (QD) with meals
223491959|NCT04430699|DRUG|Cisplatin|Participants will be given Cisplatin by intravenous infusion at a predetermined dose 1x weekly up to 8 weeks.
223491960|NCT04430699|DRUG|Pembrolizumab|Participants will be given Pembrolizumab by intravenous infusion at a predetermined dose 1x every 3 weeks up to 36 weeks.
223491961|NCT04430699|RADIATION|Radiation Therapy|Standard of care radiation therapy 1x daily up to 8 weeks.
223491962|NCT06704932|DRUG|SAR446959|Pharmaceutical form:solution for injection-Route of administration:Intra-articular injection
223491963|NCT06704932|DRUG|Placebo|Pharmaceutical form:solution for injection-Route of administration:Intra-articular injection
223491964|NCT06714279|DRUG|Tap Block - Bupivacaine|The medicinal product for both groups is the same - Bupivacaine. The mode of administration is what this study is reviewing: Control group (Intraperitoneal infiltration to liver) and Study Group - Laparoscopic Transversus Abdominis Plane Block (LTap Block)
223491965|NCT06714279|DRUG|Intraperitoneal infiltration to liver|The medicinal product for both groups is the same - Bupivacaine. The mode of administration is what this study is reviewing: Control group (Intraperitoneal infiltration to liver) and Study Group - Laparoscopic Transversus Abdominis Plane Block (LTap Block)
223491966|NCT07044908|DRUG|TQB2922 injection ± TAS-102 tablets|TQB2922 is an anti-EGFR/c-Met bispecific antibody, subtype Immunoglobulin G1 (IgG1). TQB2922 blocks the activation of EGFR and c-Met signalling pathway by binding to EGFR and c-Met on the surface of tumour cells, thus preventing tumour growth and progression. At the same time, TQB2922 can target EGFR and c-Met on the surface of tumour cells through antibody-dependent cytotoxicity (ADCC) and antibody-dependent cell phagocytosis by natural killer cells and macrophages, thus killing tumour cells.
223491967|NCT07044908|DRUG|TQB2922 injection+TAS-102 tablets ± Bevacizumab|TQB2922 is an anti-EGFR/c-Met bispecific antibody, subtype IgG1. TQB2922 blocks the activation of EGFR and c-Met signalling pathway by binding to EGFR and c-Met on the surface of tumour cells, thus preventing tumour growth and progression. At the same time, TQB2922 can target EGFR and c-Met on the surface of tumour cells through antibody-dependent cytotoxicity (ADCC) and antibody-dependent cell phagocytosis by natural killer cells and macrophages, thus killing tumour cells.
223491968|NCT06886165|BEHAVIORAL|My Avenue to HelP|"The MAP intervention is based on AMBIT principles. A MAP team, consisting of designated employees from CAMHS and two municipalities, will be trained in AMBIT. A Key-Worker and a Mentalizing Case Manager will be assigned to each participant and step into the existing network, taking responsibility for integrating AMBIT principles into all aspects of the work with and around the young person. The Key-worker from the MAP team is responsible for reaching out to the young person at least once a week during the intervention. The Mentalizing Case Manager ensures that mentalization is upheld in the professional network. CAMHS will offer treatment as usual in accordance with the existing evidence-based clinical guidelines and best practice for any specific mental health disorder.~The MAP team members will meet once a week to work as a team and collaborate closely with family members and other potential informal caregivers. The network of helpers will meet and coordinate monthly."
223491969|NCT06886165|BEHAVIORAL|Management as Usual|"Participants in the control group will receive non-manualized, standard treatment in CAMHS in collaboration with their municipality of residence, following local practice and guidelines. The MAU will be slightly enhanced compared to standard treatment: a) the young people will have an open case file during one year of participation in the MAP project (and longer if indicated), and b) the standard care services will receive feedback from the research assessment at baseline (after approval of the specific content from parents and the young person) in order to help the young person's caseworker to coordinate the support. These enhancements are made to improve the cohesion of care for the young person, yet without applying the mentalization-based AMBIT principles and MAP teams of the MAP treatment condition.~principles applied in the MAP treatment condition."
223491970|NCT07051993|DRUG|ZN-A-1041|Participants will be administered either a ZN-A-1041 capsule or a tablet orally.
223491971|NCT07051993|DRUG|Rabeprazole|Participants will be administered rabeprazole BID.
223745533|NCT06838793|PROCEDURE|Three Level Intertransverse Process Block|Patients will then be positioned in the lateral decubitus position with the side to be blocked facing upwards, the neck slightly flexed and the upper arm resting on the pillow for the USG ITPB. After obtaining the target transverse ultrasound window at the inferior articular process level (described above) at the T7 level, under strict aseptic precautions and local infiltration (Lignocaine 1%), a SonoTap nerve block needle (Pajunk, 22G, 80 mm, Pajunk, Geisingen, Germany) will be inserted in-plane and slowly advanced from a lateral to medial direction until its tip is located at the medial aspect of the retro-SCTL space. After negative heme aspiration, 8 ml of LA mixture containing 0.5% ropivacaine with 1:200,000 adrenaline will be injected slowly in small aliquots. Subsequently, similar injections will be performed at T5 and T3 level with 8 ml and 9 ml LA mixture, respectively (Total LA mixture volume: 25 ml).
224308286|NCT06848010|DEVICE|Automated endotracheal cuff controller|The automated endotracheal tube cuff pressure controller will continously assess and maintain the endotracheal tube cuff pressure at pre-specifed pressure level of 25 cmH20.
224308287|NCT06844305|OTHER|Prosthetic foot|The most- and least-preferred prosthetic foot
224308288|NCT06844305|OTHER|Physical therapy|Personalized physical therapy
223491972|NCT07053618|DEVICE|Implantation of the VADLINK Percutaneous Left Ventricular Assist Device|To implant VADLINK percutaneous left ventricular assist device during percutaneous coronary intervention (PCI).
223491973|NCT07053618|DEVICE|VA-ECMO|Received venous arterial extracorporeal membrane oxygenation (VA-ECMO) during PCI.
224308289|NCT04682964|DRUG|Nebulizer inhalation irrigation of the mucous membranes of the tonsils with a bacteriophage.|Bacteriophage therapy using a liquid complex of pyobacteriophages (pyobacteriophage complex liquid - PСL). PСL was administered via nebulizer inhalation to irrigate the mucous membranes of the tonsils. In total, 5 ml of PCL was inhaled for up to 10 minutes once every 5 days.
223491974|NCT07055555|BEHAVIORAL|Acute Stress|Participants randomized to the acute stress condition will complete the Trier Social Stress Test (TSST), a validated experimental method for inducing acute psychosocial stress. The TSST consists of a brief anticipation period followed by a 5-minute mock job interview and a 5-minute surprise mental arithmetic task, performed in front of a neutral panel of judges in professional attire.
223491975|NCT07055555|BEHAVIORAL|Non-Stress Control Task|Participants randomized to the control condition will complete a non-stressful task designed to parallel the structure of the Trier Social Stress Test without eliciting acute stress. They will have a brief anticipation period followed by a 5-minute description of their typical day or favorite hobby. This task is conducted without an evaluative panel, minimizing the potential for stress or anxiety.
223491976|NCT05285904|OTHER|Ofatumumab|Prospective observational cohort study. There is no treatment allocation. Patients administered Ofatumumab, that have started before inclusion of the patient into the study will be enrolled.
223491977|NCT06742346|BEHAVIORAL|Non Tailored Messages|Generic messages promoting a plant-based diet were developed, with each message addressing one of the three most commonly mentioned motives for plant-based eating (Miki et al., 2019; Miki et al., 2020): health motives, environmental motives, and animal welfare motives. All messages were designed to be factual (including science-based statistics), concise (4-5 sentences), relevant to teens (e.g., addressing health concerns like acne), and autonomy-supportive (offering suggestions and tips rather than directives) (Hingle et al., 2013). The messages were intentionally crafted in a neutral linguistic style, avoiding highly emotive language, non-standard syntax, or emojis. These messages are delivered from Monday to Friday for two weeks.
223491978|NCT06742346|BEHAVIORAL|Linguistically tailored health messages|Linguistically tailored messages are generated using a Large Language Model. Generic messages promoting a plant-based diet were customized to align with participants' linguistic style, including their preferred choice of words, expressed valence, syntax, and emoji use. These messages are delivered from Monday to Friday for two weeks.
223491979|NCT06749912|DEVICE|Low back pain wrap|The low back pain wrap device includes heat, vibration, and red light to assist with reducing pain sensation, improving function.
223491980|NCT06004882|OTHER|PNS therapy|PNS therapy-NS is a 60-day therapy targeting chronic pain. The procedure involves implanting a small piece of wire next to the nerve causing pain, and the wire is connected to an external device that is then used to apply electric pulses to the nerve, blocking pain signals, for 60 days
223491981|NCT06004882|DRUG|Triamcinolone|Given by Injection
223491982|NCT06004882|DRUG|Bupivacaine|Given by Injection
223491983|NCT06004882|OTHER|Placebo|Given by Injection
223491984|NCT07059767|DRUG|ETH47|single intranasal dose of ETH47
223588162|NCT06380894|DEVICE|Virtual Reality Cognitive Training|"Participants who were assigned to the VRCT intervention group underwent 60 minutes of weekly VRCT sessions over a 10-week intervention period. The program consisted of two components: (1) psychoeducation on cognitive functioning and ways to maintain cognitive health, (2) VR multi-domain cognitive training tasks that target cognitive domains of attention, memory, and executive functioning.~The VR experiences were administered through a head-mounted Oculus Go Screen V7. The VR system runs on a software developed by Dancing Mind Pte Ltd. The software specifications and service provided by Dancing Mind Pte Ltd include: MindGym System Functions: System Setup (Processor Setup, Password Changing etc) and Data Centre (Memory Care Therapy Data Analytics Report Querying and Printing Functions). The MindGym cognitive training content was developed based on the Singaporean culture, with visual stimuli reflecting familiar local environments."
224183383|NCT06424756|DRUG|MitoTempo|During each experimental visit, intradermal microdialysis will be used to locally infuse MitoTempo (a mitochondria-specific superoxide dismutase mimetic) into the cutaneous microvasculature in the ventral aspect of the left forearm.
223491985|NCT07059767|DRUG|Placebo|single intranasal dose of placebo
223491986|NCT05888857|DRUG|MEDI5752|A treatment cycle consists of 3 weeks. MEDI5752 will be administered by intravenous infusion at a fixed dose on Day 1 of each cycle
223491987|NCT07060768|OTHER|Mandala Coloring|Mandala coloring at least 20 minutes each day. Totally 10 days intervention
224183384|NCT06424756|DRUG|Tempol|During each experimental visit, intradermal microdialysis will be used to locally infuse Tempol (a superoxide dismutase mimetic) into the cutaneous microvasculature in the ventral aspect of the left forearm.
224183385|NCT06424756|DRUG|L-NAME|During each experimental visit, L-NAME (nitric oxide synthase inhibitor) will be perfused through microdialysis fibers for quantification of nitric oxide-mediated vasodilation.
224183386|NCT06424756|DRUG|SNP - Sodium Nitroprusside|At the end of each experimental visit, SNP will be perfused through microdialysis fibers to elicit a maximal vasodilation response.
224183387|NCT01903096|BEHAVIORAL|Cognitive Behavioral Treatment|Seven ninety-minute sessions of evidence-based psychological techniques designed to treat anxiety, depression and somatization disorders during a period of 24 weeks.
224183388|NCT01903096|DRUG|Primary Care Treatment As Usual|Usual treatment offered in Primary Care Services: depending on the diagnoses, patients will be prescribed different medications until symptoms disappear.
224183389|NCT02727452|OTHER|Skin-to-skin contact|
224183390|NCT00202267|DEVICE|Four-layer Bandage (Elastomeric)|Precise components of the four-layer system depend on the circumference of the ankle. All the bandages are discarded after a single use, usually one week.
224308290|NCT03673007|BEHAVIORAL|Gift card to be used for contraceptives that is valued at 50% of cost of name-brand IUD (August 26, 2018-March 3, 2019)|M-CARES will randomize allocation of vouchers (gift cards) for contraception valued up to 50% of inserting a name-brand IUD (e.g., Skyla, Paraguard, Mirena) for women with out of pocket costs at Planned Parenthood. This intervention occurred between August 18, 2018, and March 3, 2019.
224308291|NCT03673007|BEHAVIORAL|Gift card to be used for contraceptives that is valued at 100% of cost of name-brand IUD (March 4, 2019-March 31, 2023)|M-CARES will randomize allocation of vouchers (gift cards) for contraception valued up to 100% of inserting a name-brand IUD (e.g., Skyla, Paraguard, Mirena) for women with out of pocket costs at Planned Parenthood. This intervention occurred after March 3, 2019.
224308292|NCT04740476|DRUG|STK-001|STK-001 drug product is an antisense oligonucleotide administered as an intrathecal injection.
223491988|NCT07056842|DRUG|Rifampin + VCT220|Participants will receive a single oral dose of VCT220 160 mg on Day 1. Rifampin 600 mg will be administered once daily from Day 4 to Day 10 and from Day 12 to Day 14. On Day 11, rifampin 600 mg will be administered followed 30 minutes later by VCT220 160 mg. All doses are administered under fed or fasting conditions with standardized restrictions on fluid and food intake.
223491989|NCT07056842|DRUG|Itraconazole + VCT220|Participants will receive a single oral dose of VCT220 40 mg on Day 1. Itraconazole 200 mg will be administered once daily from Day 4 to Day 11 and from Day 13 to Day 14. On Day 12, VCT220 40 mg will be co-administered with itraconazole 200 mg after breakfast. All doses are administered under fed conditions with standardized fluid and fasting controls.
223491990|NCT05164978|DRUG|DEP combine with PD-1 antibody|Doxorubicin hydrochloride liposome injection 25 mg/m2 day 1 Etoposide 100 mg/m2 day1 Methylprednisolone 1.5 mg/kg days 1 to day 3, 0.25mg/kg days 4 to 14 Sintilimab Injection 200mg d4
223491991|NCT05113381|DEVICE|CerebroFlo™ EVD Catheter|The CerebroFlo™ EVD Catheter is indicated for temporary insertion into a ventricular cavity of the brain for external drainage of cerebrospinal fluid (CSF) in those patients with elevated intracranial pressure (ICP), intraventricular hemorrhage, or hydrocephalic shunt infections.
223491992|NCT01466868|DRUG|MK2206|"Treatment will be administered orally once weekly, 2 hours before or after a meal, at day 1, 8, 15, 22 over a 28 day cycle period.~The starting dose level is 200 mg. 2 dose reduction are allowed (135 mg and 90 mg)in case of documented toxicity according to the specific algorithms."
223491993|NCT06789510|OTHER|Autologous Platelet Rich Plasma|10 mL PRP intralesional injections will be administered. After the injections, participants will be instructed to perform penile stretching exercises daily until the next injection and to continue these exercises after the final injection until the 3-month follow-up.
223491994|NCT06789510|OTHER|Saline solution|10 mL saline solution intralesional injections will be administered. After the injections, participants will be instructed to perform penile stretching exercises daily until the next injection and to continue these exercises after the final injection until the 3-month follow-up.
223491995|NCT06795165|DRUG|Moxidectin 2 MG Oral Tablet|active medication
223491996|NCT06795165|DRUG|Placebo|placebo pills
223491997|NCT00578526|DRUG|SU011248|50 mg capsule OD PO for 28 days followed by 14 days of rest until tumor progression
223491998|NCT00578526|DRUG|Placebo|50 mg capsule OD PO for 28 days then 14 days rest until disease progression
223491999|NCT05569681|DRUG|Bemiparin 3500|"Bemiparin sodium 3,500 IU anti Xa/0.2 ml solution for injection in the pre-filled syringe will be provided for each patient in one group; subcutaneously 6 hours after the surgery(orthopedic and non-orthopedic) and then daily for up to 10 days for moderate and high - risk group and for 30 days in very high risk-group patients according to Caprinin risk classification for venous thromboembolism.~Other Name: Hibor; Laboratories Rovi Pharmaceuticals"
223492000|NCT05569681|DRUG|Bemiparin 5000 IU|"Bemiparin sodium 5000 IU anti Xa/0.2 ml solution for injection in the pre-filled syringe will be provided for each patient in one group; subcutaneously 6 hours after the surgery(orthopedic and non-orthopedic) and then daily for up to 10 days for moderate and high - risk group and for 30 days in very high risk-group patients according to Caprinin risk classification for venous thromboembolism.~Other Name: Hibor; Laboratories Rovi Pharmaceuticals"
223492001|NCT04761588|DIETARY_SUPPLEMENT|Tyr sphere|"Tyr sphere is a powdered, low phenylalanine and tyrosine protein substitute, containing a balanced mix of casein glycomacropeptide (cGMP) isolate, essential and non-essential amino acids, carbohydrate, fat, vitamins, minerals and the long chain polyunsaturated fatty acid (LCP) and docosahexaenoic acid (DHA). It contains sugars and sweetener.~The product is designed to be prescribed based on its protein content, not its energy content."
223492002|NCT07071766|BEHAVIORAL|Proud of Baby and Me|The original Baby \& Me curricula was adapted to be delivered in outpatient substance use treatment settings to newly postpartum women receiving medications for opioid use disorder (MOUD) for this study.
223492003|NCT06614192|DRUG|Telisotuzumab Adizutecan|Intravenous (IV) Infusion
223492004|NCT06614192|DRUG|Trifluridine/Tipiracil|Oral Tablet
223492005|NCT06614192|DRUG|Bevacizumab|IV Infusion
223492006|NCT06898125|OTHER|Extracorporeal Shockwave Therapy|Shock wave therapy is a new modality for the improvement of cellulite and lipedema; it is an easy, noninvasive, local therapy, without side effects, with short periods of application. Its original idea was the stimulation of lipid mobilization and improved lipolysis in areas with edema.
223492007|NCT06898125|OTHER|Complex Decongestive Therapy|Complex decongestive therapy (CDT) is one of the most important treatment modalities of choice for patients with this clinical condition. CDT has two phases: treatment and maintenance. The first stage consists of skin care, manual lymph drainage, kinesiotherapy and bandaging of the limb. Drainage can facilitate the return of lymphatic flow by stimulating the cisterna chyli. Next, kinesiotherapy is applied, which aims to activate the lymph. Finally, the limb is moistened and then a compressive bandage is applied aimed at creating a pressure gradient towards the areas where lymph absorption is greater. The second phase continues skin care, physical exercises and external compression applications using bandages with varying degrees of elasticity.
223492008|NCT06781307|OTHER|skin to skin|Intervention measures include 1 hour of skin-to-skin contact between mother and baby every day from day 1 to day 30 postpartum.
224308293|NCT05192876|RADIATION|Radiotherapy|Outcomes and adverse events using radiation therapy
224308294|NCT04946396|DRUG|dexmedetomidine intravenous infusion|Dexmedetomidine intravenous infusion during laparoscopic cholecystecthomy
224308295|NCT04946396|DRUG|0.9%sodium chloride|0.9%sodium chloride intravenous infusion during laparoscopic cholecystecthomy
224308296|NCT04616430|DRUG|Topical endoxifen|topical solution
224308297|NCT04616430|DRUG|Placebo|topical
223492009|NCT06822517|DRUG|VENT-02|Orally administered capsules
223492010|NCT06822517|DRUG|Placebo|Orally administered capsules
223492011|NCT06733363|BEHAVIORAL|Behavioral Dietary Intervention|Participate in POW-R Health Only/Core program
223492012|NCT06733363|BEHAVIORAL|Telephone- Based Intervention|Receive live phone calls
223492013|NCT04643002|DRUG|Isatuximab|Pharmaceutical form: Concentrated solution for intravenous infusion; Route of administration: Intravenous infusion
223492014|NCT04643002|DRUG|Dexamethasone|Pharmaceutical form: Tablet; Route of administration: Oral
223492015|NCT04643002|DRUG|Pomalidomide|Pharmaceutical form: Capsule; Route of administration: Oral
223492016|NCT04643002|DRUG|Belantamab mafodotin|Pharmaceutical form: Solution for infusion; Route of administration: Intravenous
223492017|NCT04643002|DRUG|Pegenzileukin|Pharmaceutical form: Solution for infusion; Route of administration: Intravenous
223745534|NCT03112044|DRUG|Sofosbuvir-velpatasvir (400 mg/100 mg)|Patients will have standard monitoring with HCV RNA and liver panel assessment at 2 week intervals until HCV is undetectable and then at the end of treatment and 3 and 6 months following its completion. Post-operative transplant care and immunosuppression will be carried on as usual transplant practice at Toronto General Hospital.
223745535|NCT03112044|DEVICE|Ex Vivo Lung Perfusion (EVLP)|Normothermic EVLP is a method of donor lung preservation, assessment, treatment, and repair of injured organs. This method allows donor lungs to be treated for at least 12h under protective physiological conditions.
223745536|NCT05986162|DRUG|Itolizumab|Patients to be treated with Itolizumab.
223745537|NCT03409172|OTHER|CTR|no counseling or nutritional therapy and no exercise
223745538|NCT03409172|OTHER|MICT|no counseling or nutritional therapy. 8 weeks of individualized and supervised ergometer-based moderate continuous intensity training (MICT).
223745539|NCT03409172|OTHER|HIIT|no counseling or nutritional therapy. 8 weeks of individualized and supervised ergometer-based high intensity interval training (HIIT)
223745540|NCT02637700|DRUG|Intravenous Immunoglobulin|Comparison between intravenous immunoglobulin and placebo (saline 0.9%).
224183391|NCT00202267|DEVICE|Short-stretch Bandage (Non-elastomeric)|These bandages are applied in a figure-eight technique; two bandages are applied at full extension in opposite directions up the leg (i.e., clockwise and counter clockwise). The participant will wash the short-stretch wherever possible and reused. The number of bandages supplied to each patient will be recorded on the visit record.
223492018|NCT04643002|DRUG|SAR439459|Pharmaceutical form: Solution for injection; Route of administration: Intravenous
223492019|NCT04643002|DRUG|Belumosudil|Pharmaceutical form: tablet; route of administration: oral
223492020|NCT04643002|DRUG|Evorpacept|Pharmaceutical form: Solution for infusion; Route of administration: Intravenous
223492021|NCT06511297|DIAGNOSTIC_TEST|comprehensive metabolic phenotyping|The investigators will employ state of the art techniques to metabolically phenotype the study groups using brain, cardiac and whole body magnetic resonance imaging (MRI), magnetic resonance spectroscopy (MRS), wearables, optical coherence tomography longitudinally. In addition, a battery of patient reported outcome measures will be used to explore psychosocial aspects of aging.
223492022|NCT07085403|OTHER|Cognitive Orientation to daily Occupational Performance (CO-OP) is a cognitive problem-solving approach|Cognitive Orientation to daily Occupational Performance (CO-OP; CO-OP approach) is a performance-based treatment approach for children and adults who experience difficulties performing the skills they want to, need, to or are expected to perform. CO-OP is a specifically tailored, active client-centered approach that engages the individual at the meta-cognitive level to solve performance problems. Focused on enabling success, the CO-OP approach employs collaborative goal setting, dynamic performance analysis, cognitive strategy use, guided discovery, and enabling principles. These elements, all considered essential to the CO-OP Approach, are situated within a structured intervention format, and may involve the parent/significant other as appropriate.
223492023|NCT07141420|BEHAVIORAL|Routine Care|Participants receive standard post-ICU follow-up care according to hospital protocols . This includes routine health assessments and general rehabilitation guidance at designated intervals (discharge, 1/3/6 months post-discharge). No structured PICS management program or AI technology is provided.
223512539|NCT02748174|BEHAVIORAL|Audio Files|Patients will be given a link to download audio files. They consist of breathing techniques, imaging, progressive relaxation, and more. Patients will be asked to perform 20 minutes of relaxation therapy at least 3 times per week. Patients will record their headache frequency and intensivy, in addition to other symptoms, and the frequency of practiving the behavioral therapy using Curelator Headache.
223512540|NCT05398666|DEVICE|White LED light|Participants will be exposed to white LED lights (4 lux) in a dark room for 1-2 hours per day for 10 weeks.
223512541|NCT05398666|DEVICE|Green LED light|Participants will be exposed to green LED lights (4 lux) in a dark room for 1-2 hours per day for 10 weeks.
223512542|NCT03207087|DEVICE|WEB Aneurysm Embolization|Subjects will be screened for study eligibility after giving informed consent. The WEB embolization procedure will be performed in the catheterization room using standard angiographic techniques.
223512543|NCT06564402|BEHAVIORAL|Positive Mental Rehearsal|After exposure trial, participants are asked about the positive aspects of their exposure experience (e.g., thoughts, feelings), based on which an imagination script is formulated and recounted
223512544|NCT06564402|BEHAVIORAL|Mental Rehearsal|After exposure, participants are asked about what happened during the exposure experience and whether their central concerns/expected outcome actually occurred during exposure
223512545|NCT06564402|BEHAVIORAL|Exposure|All participants complete exposure exercises (i.e., talking on the phone and talking with a stranger) before positive mental rehearsal is executed
223512546|NCT02520362|DRUG|denosumab|subcutaneous injection
223512547|NCT02520362|DRUG|bisphosphonate|The assessment of bisphosphonates includes branded oral bisphosphonates (eg, alendronate \[Fosamax®\], risedronate \[Actonel®\], ibandronate \[Boniva®/Bonviva®\] oral); generic bisphosphonates, including alendronate, neridodronate, and olpadronate; intravenous bisphosphonates including ibandronate IV, and zoledronate \[Reclast®/Aclasta®\].
223745541|NCT02637700|DRUG|Placebo|Comparison between placebo (saline 0.9%) and intravenous immunoglobulin.
223745542|NCT04798547|PROCEDURE|Short Myotomy|Evaluation of short length myotomy
224183392|NCT02929875|BEHAVIORAL|Education based on TPB|Three Training sessions were given to the case group; each lasted for one hour, during a period of twenty days. During each one-hour training session a period of 45 minutes was dedicated to listening to lectures, having discussions, and discussing methods of using teaching aids such as pamphlets and manuals. The last 15 minutes was used to summarize issues and answer questions.
224183393|NCT02600195|BEHAVIORAL|Evidence-based Practice for Improving Quality (EPIQ) method|The intervention NICUs (n = 12) will receive training in the Evidence-based Practice for Improving Quality (EPIQ) method and then develop, implement, and document evidence-based practice changes to reduce hospital-acquired infection. Compliance with practice changes and neonatal outcomes will be monitored. NICUs will receive quarterly feedback on their progress, as well as access to implementation support.
224183394|NCT03258710|DRUG|Tenofovir Disoproxil Fumarate|Tenofovir Disoproxil Fumarate is a nucleos(t)ide analogue that inhibits HBV growth. All subjects will receive one tablet of TDF 300 mg once daily orally for 96 weeks.
224183395|NCT04513249|DIAGNOSTIC_TEST|dynamics of coagulation parameters|the effects of fresh frozen plasma administered during a plasma exchange therapy on viscoelastic tests
224308298|NCT03574350|BEHAVIORAL|KS in Kangaroo Position|KSKP was applied daily at regular interval corresponding to the presence of parents. Our protocol is based on the Tiffany Field's protocol with some adjustments corresponding to the constraints of the hospital : the KS was applied 3 times a day and during 15 consecutive days in the hospital or at home and parents were responsible of delivering the intervention. Sunflower oil was used. During the first 5 days, parents performed KSKP with the support of the psychologist. After day 5, parents were expected to perform KSKP by themselves but could ask for help at any moment while in hospital or in the ambulatory follow-up. The KS always began approximately 60 minutes after the feed.
224308299|NCT03574350|BEHAVIORAL|KS in incubator|The infant is in the incubator, unclothed with diaper. Parents delivered KSI with the infant in supine position, stroking with the flats of the fingers with moderate pressure. Five 1-minute intervals, consisting of six 10-s periods of stroking, were applied to the following body regions: head, back, both legs and arms. The same process was repeated in prone position. The last part of the intervention was composed of 6 flexions of each extremity.
224308300|NCT02647801|BEHAVIORAL|Mindfulness intervention|"Mindfulness is practiced with a weekly computer based guided breathing meditation in which one's own breath has to be counted repetitively from 1 to 9. Participants have to press a specific button for breaths 1 to 8 and then press another button for breath 9 on a keyboard. During this practice they put on headphones and listen to a voice that guides them through breathing meditation. A click sound will occur if breath is miscounted (Levinson et al., 2014). After each computer based breathing meditation the experimenter and participants exchange meditation experiences and views. After the first mindfulness training participants in the experimental group are also able to practice mindfulness at home by listening to audio files on the mobile phone (bodyscan or breathing meditation)."
224308301|NCT01447277|PROCEDURE|Sciatic Block|Performing a sciatic block in addition to a femoral block preoperatively
224308302|NCT01447277|PROCEDURE|Femoral Block only|Performing a preoperative sciatic nerve block only
224308303|NCT00633243|PROCEDURE|Modified Directly Observed Therapy (mDOT)|
224308304|NCT00633243|PROCEDURE|Self-Administered Therapy (SAT)|
224308305|NCT02022748|DRUG|ticagrelor|Group A is hemodialysis subjects. Crossover design will be implemented for Group A subjects. Group A will be randomized into 2 sequences, Sequence 1 and Sequence 2. In Sequence 1, subjects will receive treatment A in Period 1 and treatment B in Period 2. Washout period of at least 7 days between Period 1 and Period 2 in Sequence 1. Treatment A and Treatment B are defined as follows: Treatment A subjects will be dosed with oral 90 mg ticagrelor tablet 1 day following the dialysis session but 2 days before the next dialysis session. Treatment B will be dosed with oral 90 mg ticagrelor tablet just prior to dialysis session.
223745543|NCT04798547|PROCEDURE|Standard Length Myotomy|Standard Length Myotomy
223745544|NCT04729127|BEHAVIORAL|Project ImPACT|Project ImPACT (Improving Parents As Communication Teachers) is an evidence-based parent-mediated intervention program based on best practices in early intervention. The program is designed for young children up to age six with social communication delays, including autism spectrum disorder. Project ImPACT focuses on social engagement, language, social imitation, and play. Project ImPACT is a naturalistic developmental behavioral intervention (NDBI).
223492024|NCT07141420|BEHAVIORAL|Health Promotion Model-Based Optimized Program|"An evidence-based, multidisciplinary rehabilitation protocol for Post-Intensive Care Syndrome (PICS) management, developed using the Health Promotion Model (HPM). It includes:~Personalized rehabilitation plans addressing physical, cognitive, and psychological recovery.~Structured follow-up at discharge, 1/3/6 months post-discharge. Components: Physical function training, cognitive exercises, anxiety/depression coping strategies, and sleep hygiene education.~Delivery: Clinician-guided (no AI/technology involved). Developed via literature review and validated by ICU physicians and nursing experts ."
223512548|NCT06639815|OTHER|clinical and radiographic examination|clinical and radiographic examination
223745545|NCT00887354|DRUG|Teriparatide|Administered subcutaneously
223745546|NCT00887354|DRUG|Risedronate|Administered orally
223745547|NCT00887354|DRUG|Placebo|"Weekly: Administered orally~Daily: Administered subcutaneously"
223745548|NCT00887354|DIETARY_SUPPLEMENT|Calcium|Approximately 500 to 1000 mg/day administered orally throughout study.
223745549|NCT00887354|DIETARY_SUPPLEMENT|Vitamin D|Approximately 800 International Units per day (IU/day) administered orally throughout study.
223745550|NCT03775980|DEVICE|Emprint Microwave Ablation System|Microwave Ablation of colorectal liver metastases
223745551|NCT00824044|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|The CBT group will receive weekly 50-minute individual sessions over the course of 12 weeks conducted by experienced therapists who are trained in manual based CBT.
223492025|NCT07141420|BEHAVIORAL|LLM-Enhanced Optimized Program|"Combines the HPM-Based Optimized Program with Large Language Model (LLM) technology for dynamic personalization:~AI-generated rehabilitation plans: ChatGPT-4 synthesizes patient data (baseline + follow-ups) to create/update monthly plans, reviewed by a multidisciplinary expert team.~Patient-facing LLM tool: Kimi Smart Assistant installed for daily health queries under strict safety protocols (all outputs validated by nurses via WeChat).~Phased implementation:~Pre-discharge: LLM training + baseline plan generation. 1/3/6 months: Plan updates + outcome tracking. 3/6 months: Semi-structured interviews on LLM experience. Includes LLM usage guidelines and expert validation safeguards ."
224183396|NCT05870358|DRUG|Melatonin 3 MG|In this clinical trial, all patients that have both diabetes mellitus and periodontitis were performed full mouth scaling and root planning in order to start their periodontal treatments. Different from the control group, in fmSRP-mel group's patients systemic melatonin tablets (6 mg daily, for 30 days) were given immediately after the fmSRP procedure in order to support the scaling and root planning.
223492026|NCT07141810|DRUG|Antifibrotic drugs (nidanib or pirfenidone)|One group received primary therapy, and another group received an antifibrotic drug (nidanib or pirfenidone) in addition to primary therapy.
223492027|NCT05578872|DRUG|ANV419|ANV419 administered by intravenous (IV) infusion
224183397|NCT04467216|DEVICE|Computerised cognitive training using virtual reality|Immersive VR training system tailor-made for the daily living experiences in the Hong Kong context to provide interactive experiences for older people in Hong Kong.The VR systems available in the market for older people are only for non-interactive activities (e.g., watching movies) to provide unusual experiences for disabled older people who cannot travel too far from home.
224183398|NCT03549546|BIOLOGICAL|Blood samples|"Blood samples will be collected in patients undergoing lung cancer surgery:~* before lung cancer surgery,~* the next day lung cancer surgery,~* 3 days after lung cancer surgery. They will be treated in flow cytometry."
224183399|NCT00918502|DEVICE|AVIVO system|Non invasive external monitoring device
224183400|NCT02242305|DRUG|Hyoscine Butylbromide - Tablet|
224183401|NCT02242305|DRUG|Hyoscine Butylbromide - Capsule|
224183402|NCT02242305|DRUG|Placebo|
224183403|NCT06013579|BEHAVIORAL|Phase 1 Gym Exercise HIIT|Following a 5-minute warm-up at 50% VO2peak, high and moderate-intensity exercise bouts alternate, progressing to five bouts of 4-minute high-intensity exercise (90% VO2peak), alternating with four 3-minute bouts of moderate-intensity exercise (50% VO2peak) by week 8, followed by a 5 minute cool-down. The total exercise time is 42 minutes.
224183404|NCT06013579|BEHAVIORAL|Phase 1 Gym Exercise CME|Following a 4 minute warm-up at 50% VO2peak, the participant walks for up to 42 continuous minutes at 60% VO2peak172, followed by a 4 minute cool-down. The total exercise time is 50 minutes.
224183405|NCT06013579|BEHAVIORAL|Phase 2 Home Exercise Coaching Text Messages|The coaching intervention will consist of daily text messages tailored to the individual participant's self-reported symptom experiences and barriers to exercise on that specific day. One daily message with a survey will be sent, and responses to survey items will determine the subsequent once daily motivational message.Tailored messages address a range of possible barriers to adherence based on past research, and will provide advice and guidance. Text messages will be varied each week so that even if participants continue to report the same barriers they receive different text messages.
224183406|NCT06013579|BEHAVIORAL|Phase 2 Home Exercise Control Text Messages|"The control group will receive general daily texts from the study team (i.e., Hope you are doing well!), and reminding them of their next study appointments. These text messages are primarily social/generic in content and serve to maintain involvement and enhance retention of the control group."
224183407|NCT06268288|DEVICE|GammaCore intervention|Use of the vagal nerve stimulator, GammaCore, on the right side of the neck for two 2 minute stimulations performed 3 times a day
224183408|NCT06268288|OTHER|STEPS management protocol|STEPS is the acronym for the standard management program for our patients with POTS. It includes liberal use of salt, taking in 90-100 ounces of fluid, gradually increasing the duration of aerobic exercise, possible use of one of two prescription medications (metoprolol, and midodrine), and encouragement to set priority and goals
224183409|NCT00276354|DRUG|PEG 4000 (Forlax ®)|
224183410|NCT03901742|OTHER|Protein-enriched nutrition|Protein-enriched enteral nutrition with a polymeric infant formula
224183411|NCT03901742|DIETARY_SUPPLEMENT|High Protein-enriched Nutrition|High protein-enriched enteral nutrition with a polymeric infant formula plus a protein supplement
224183412|NCT03901742|OTHER|Standard Enteral Nutrition|Cow's milk based infant formula.
224183413|NCT02832986|OTHER|Medical Questionary|"The medical questionary will contain :~* Date of initial infection by Herpes zoster~* Localisation~* Severity~* Presence of postherpetic pain~* Postherpetic pain Intensity~* Postherpetic pain duration~* Antiviral treatment~* History of chronic pathologies~* Concomitant treatment"
224183414|NCT04052711|DRUG|FMX-101|
224183415|NCT06112249|BEHAVIORAL|SAFE Employment Training|The SAFE program includes lessons in the following areas: 1) Overview of What COVID-19 is and how it spreads 2) What is PPE and How to properly use 3) Social Distancing 4) Community Participation 5) Employment 6) Self Efficacy. We would also like to know if you learn more when the SAFE program is taught by a peer (person who also has an intellectual developmental disability).
224183416|NCT06520046|OTHER|Experimental Group|Propioceptive exercises
224183417|NCT06520046|OTHER|Control Group|Usual exercises
224183418|NCT03451630|BEHAVIORAL|High-Touch|Intensive, in-person and/or telephonic support.
224183419|NCT03451630|BEHAVIORAL|High-Tech|Remote care management and self-directed digital tools.
224183420|NCT03451630|BEHAVIORAL|Optimal Discharge Planning|Transition to other Health Plan disease management programs and/or community resources.
224183421|NCT04994860|DRUG|BIA 5-1058|Oral BIA 5-1058 (Zamicastat) 100 mg tablets
224183422|NCT04994860|DRUG|Sildenafil|Oral Sildenafil ( Revatio) 20 mg film coated tablets
224183423|NCT05608707|BEHAVIORAL|Physical activity intervention|The 12 week intervention will involve 2 weekly group exercise sessions incorporating strength and balance exercises, along with home-based exercise focused on increasing time spent walking.
224183424|NCT05608707|DIETARY_SUPPLEMENT|Personalised nutrition intervention|Two Plant-based Protein and Fibre (PPF) product products have been selected from six initially developed, with best amino acid blend, taste, and bioavailability. Participants will be provided with the PPFs to consume daily as part of a personalised diet over 12 weeks.
224183425|NCT01738568|BEHAVIORAL|High intensity aerobic training|High intensity aerobic interval training will be performed 12-weeks. Exercise training will last 1 hour per day, 5 days per week and include high intensity interval cycling at \~70-95% maximum workload for 4 minutes followed by 3 minutes of rest.
224183426|NCT01738568|BEHAVIORAL|Sedentary Control|Sedentary control participants will not perform any regular exercise for 12-weeks.
224308306|NCT02022748|DRUG|ticagrelor|Group A is hemodialysis subjects. Crossover design will be implemented for Group A subjects. Group A will be randomized into 2 sequences, Sequence 1 and Sequence 2. In Sequence 2, subjects will receive treatment B in Period 1 and treatment A in Period 2. Washout period of at least 7 days between Period 1 and Period 2 in Sequence 2. Treatment A and Treatment B are defined as follows: Treatment A subjects will be dosed with oral 90 mg ticagrelor tablet 1 day following the dialysis session but 2 days before the next dialysis session. Treatment B will be dosed with oral 90 mg ticagrelor tablet just prior to dialysis session.
224308307|NCT02022748|DRUG|ticagrelor|Group B is healthy subjects. Group B healthy subjects will receive oral 90 mg ticagrelor referred to as Treatment H.
224308308|NCT01638598|DRUG|matching placebo|matching placebo in each dose level
224308309|NCT01638598|DRUG|Test drug|BI 1021958
223492028|NCT06056609|OTHER|Yoga|An 8 week online mother and baby yoga programme to include daily diary completion and questionnaires at designated study timepoints
223492029|NCT06310239|OTHER|Collection of biologic samples and data|"* collection of skin flora samples via swabs~* data collection regarding subject's medications See Detailed Description in Study Description section above for more details"
223492030|NCT01806792|DRUG|risedronate combine|
223492031|NCT01806792|DRUG|Risedronate|
223492032|NCT01806792|DRUG|Placebo(for Risedronate)|
223492033|NCT01806792|DRUG|Placebo(for risedronate combine)|
223492034|NCT00189384|DRUG|ceftriaxone, procaine penicillin and gentamicin, oral cotrimoxazole and gentamicin|
223492035|NCT02995889|DEVICE|FLT-PET|
223492036|NCT04939584|DEVICE|MultiPulse Therapy|Electrical Stimulation
223492037|NCT00370708|PROCEDURE|Oral Intake following admittance to the postpartum ward|
223492038|NCT03358953|DEVICE|Electron Cigarette|Blended Tobacco flavour, 18mg/ml
223492039|NCT03358953|DEVICE|Nicotine Replacement Patch|NiQuitin 21mg
223492040|NCT02802475|BIOLOGICAL|vena punction|
223492041|NCT03506477|DRUG|Enstilar® foam|for 4 weeks
223492042|NCT03506477|DRUG|Vehicle foam|for 4 weeks
223492043|NCT00473499|DEVICE|DEBlue vs Cypher vs BMS|BMS vs DES vs DEB+BMS
223492044|NCT04474821|OTHER|Educational Intervention|Receive educational materials on HPV
223492045|NCT04474821|OTHER|Survey Administration|Ancillary studies
223492046|NCT05057013|DRUG|HMBD-001|Participants with advanced solid tumours will receive their assigned dose level of HMBD-001 diluted in 0.9% sodium chloride, administered once a week as a 120-minute intravenous (IV) infusion. Cycles are 28 days with no break in between; administration may continue for up to 6 cycles but may continue for longer if the participant is deemed to be benefitting.
223492047|NCT05057013|DRUG|HMBD-001 and enzalutamide|Participants with metastatic castration resistant prostate cancer (mCRPC) confirmed as HER3 positive with no PTEN loss or with a NRG1 fusion rearrangement will receive the HMBD-001 recommended Phase 2 dose (RP2D) as determined in Part A, diluted in 0.9% sodium chloride and administered once a week as a 120-minute IV infusion, in combination with enzalutamide administered at a fixed dose of 160 mg once daily, in 28-day cycles with no break between cycles. Immediately before commencing combination therapy, participants may receive one 28-day cycle of enzalutamide monotherapy to confirm that their disease does not respond to enzalutamide alone. HMBD-001 may be administered for up to 6 cycles; enzalutamide may be continued until disease progression or unacceptable toxicity.
223492048|NCT05085873|DRUG|Sodium Oxybate injection|"* Induction dosage : 60 mg/kg by direct intravenous injection.~* Continuous dosage : 45 mg/kg/h by continuous intravenous injection.~* Additional dosage if the Richmond Agitation Sedation Scale (RASS) score exceeds -4 : 1000 mg sodium oxybate by direct intravenous injection bolus every hour at most until RASS score reaches -4.~Sedation maintained until patient death."
223492049|NCT05085873|DRUG|Midazolam injection|"* Induction dosage : 1 mg every 3 min by direct intravenous injection until RASS score reaches -4 (with a maximum of 30 min).~* Continuous dosage : Half of titration dosage every hour by continuous intravenous injection.~* Additional dosage if the RASS score exceeds -4 : 1 mg every 3 min by direct intravenous injection (without exceeding 10 mg/h).~Sedation maintained until patient death."
223492050|NCT03678129|DRUG|AZD7325_10|Single oral dose (10mg)
223492051|NCT03678129|DRUG|AZD7325_20|Single oral dose (20mg)
223492052|NCT03678129|DRUG|Placebo|Single oral dose placebo (capsule)
223492053|NCT03678129|DRUG|Clobazam|Single dose (5mg)
223492054|NCT06547255|DRUG|Bupivacaine liposome injectable suspension|At the end of the third molar extraction surgical procedure performed under general anesthesia and at least fifteen minutes following the most recent administration of 2% lidocaine with 1:100,000 epinephrine nerve block (routine for this procedure), all patients will receive bilateral infiltrations with 3mL of 1.3% liposomal bupivacaine (Exparel) OR with 3mL of 0.5% bupivacaine with 1:200,000 epinephrine while they are still under general anesthesia.
224183427|NCT06334237|OTHER|personalized treatment|According to the condition of each individuals, the study continues their routine clinical care. The study does not offer anything more than a routine clinical care. It is named personalized treatment because the condition of each individual varies, so the doctor may prescribe or offer clinical advice accordingly. .
224308310|NCT01638598|DRUG|matching placebo|matching placebo in each dose level
224308311|NCT01638598|DRUG|Test drug|BI 1021958
224308312|NCT01638598|DRUG|Test drug|BI 1021958
224308313|NCT01638598|DRUG|Test drug|BI 1021958
224308314|NCT01638598|DRUG|Test drug|BI 1021958
224308315|NCT01638598|DRUG|matching placebo|matching placebo in each dose level
223512549|NCT03381651|RADIATION|Higher dose (50.4Gy/28F) of neoadjuvant chemoradiation|50.4Gy/28F radiation and concurrent chemotherapy with paclitaxel plus CBP used weekly
224183428|NCT01724021|DRUG|Cyclophosphamide, Hydroxydaunorubicin, Oncovin, Prednisone/Prednisolone (CHOP)|Standard chemotherapy
224183429|NCT01724021|DRUG|Cyclophosphamide, Vincristine, Prednisone/Prednisolone (CVP)|Standard chemotherapy
224183430|NCT01724021|DRUG|Bendamustine|Standard chemotherapy
224183431|NCT01724021|DRUG|Rituximab|1400 mg subcutaneously (SC), Day 1 Cycles 2-4
224183432|NCT01724021|DRUG|Rituximab|375 mg/m2 IV, Day 1 Cycles 1-4
224183433|NCT01724021|DRUG|Rituximab|375 mg/m2 intravenously (IV), Day 1 Cycles 1 and 4-8
223492055|NCT06236932|DIETARY_SUPPLEMENT|Mediterranean diet|Hypocaloric Mediterranean Diet consist of a nutritional regimen with customized daily energy intake, calculated considering the Basal Metabolism and Physical Activity Level (LAF) of each patient. The distribution of macronutrients will be worked out as follows: ≃ 55-60% Carbohydrates (of which 80% are complex carbohydrates, pasta, bread, rice, whole grains and 20% simple sugars), ≃ 10-15% Proteins (of which the 60% of animal origin (meat, especially white) and 40% of vegetable origin (beans, chickpeas, lentils and legumes in general), ≃ 25-30% of lipids (predominantly olive oil).
223492056|NCT06236932|DIETARY_SUPPLEMENT|Melatonin supplementation|Melatonin (supplement formulation in capsules, 1mg/die one hour before sleep) will be associated with mediterranean diet for 12 w.
223492057|NCT05273190|DEVICE|Vibrotactile Stimulation|Small electric motors, similar to a vibrating cell phone or gaming joystick, deliver vibration to the throat. Participants will assess cough symptoms throughout the study period.
223492058|NCT05725421|PROCEDURE|Donor Radical and Partial Nephrectomy|Donor participants will undergo laparoscopic radical nephrectomy (RN) . Donor kidney then will undergo cold perfusion and ex-vivo partial nephrectomy (PN) with cold ischemia. During PN, careful inspection of tumor will be performed to ensure it is well-encapsulated. If any infiltrative features (versus well encapsulated tumor) are noted intraoperatively then transplant will not be performed. Multiple surgical margins will be sent (either frozen section or standard with priority). If final margins are positive or concerning, then transplant will not be performed. Biopsies of the tumor will be performed and sent to pathology (either frozen section or standard with priority).
223492059|NCT05725421|PROCEDURE|Kidney Transplantation|The donor kidney will remain on ice while pathologic analysis is performed, and transplant recipient surgery is initiated (if pathologic analysis satisfactory). Cold ischemia with delay for pathology will have minimal functional impact in this setting based on extensive prior experience with renal transplantation where kidneys are routinely kept hypothermic for several hours prior to transplantation.
223492060|NCT05725421|PROCEDURE|Laparoscopic Radical Nephrectomy|Radical nephrectomy consists of the removal of the kidney together with the perirenal fat and regional lymph nodes. The transperitoneal approach allows early control of the renal vessels.
223492061|NCT06408857|DRUG|MAM01 300 mg SC|MAM01 300 mg will be administered SC
223492062|NCT06408857|DRUG|MAM01 300 mg IM|MAM01 300 mg will be administered IM route
223492063|NCT06408857|DRUG|MAM01 2000 mg IV|MAM01 2000 mg will be administered IV
223492064|NCT06408857|DRUG|MAM01 190 mg SC|MAM01 190 mg will be administered SC
223492065|NCT06408857|DRUG|MAM01 225 mg SC|MAM01 225 mg will be administered SC
223588163|NCT06380894|BEHAVIORAL|Active Control|Participants who were assigned to the active control group were provided treatment-as-usual, which included: (1) psychoeducation on MCI, cognitive functioning, and compensatory strategies, and (2) brain training cognitive stimulation booklet which consisted of weekly homework activities focusing on attention, memory, and executive functioning. Control participants were reviewed for 3 sessions monthly to follow up on their progress on the cognitive stimulation activity booklet.
223588164|NCT05664802|BEHAVIORAL|e-HERO: Ending the HIV Epidemic in Rural Oklahoma|A behavioral intervention utilizing online platforms to assess the impact of cultural tailoring of health education material.
223745552|NCT00824044|DRUG|Escitalopram|The medication group will receive open label treatment of escitalopram, 10-20 mg/day, flexible dose, for 12 weeks, and will be seen every two weeks by a study physician.
224183434|NCT01724021|DRUG|Rituximab|1400 mg SC, Day 1 Cycles 5-8
224183435|NCT02146911|DRUG|Bupropion|
223492066|NCT06408857|DRUG|MAM01 150 mg SC|MAM01 150 mg will be administered SC
223492067|NCT06408857|DRUG|MAM01 150 mg IM|MAM01 150 mg will be administered IM
223492068|NCT06408857|DRUG|MAM01 150 mg IV|MAM01 150 mg will be administered IV
224183436|NCT02146911|DRUG|Varenicline|
224183437|NCT02146911|BEHAVIORAL|Weekly Motivational Emails|The e-mails will include tips on several things other than the medications that participants can do to help them quit smoking. The contents of the emails will vary from week to week. The e-mails will provide tips on ways to create an atmosphere that promotes quitting and staying abstinence. They will also include recommendations on how to address issues with withdrawal symptoms and cravings. In addition, they will provide positive motivational messages by stating facts on benefits of quitting smoking.
224183438|NCT04915365|DRUG|Acetazolamide|Acetazolamide (oral capsules @125 mg), starting dose 3 capsules (375 mg), subsequent doses 1 capsule (125 mg) in the morning, 2 capsules (250 mg) in the evening, administered in qualifying participants, during the stay at 3100 m.
224183439|NCT04915365|DRUG|Placebo|"Placebo (oral capsules, identically looking as active drug), starting dose 3 capsules, subsequent doses~1 capsule in the morning, 2 capsules in the evening, administered in qualifying participants, during the stay at 3100 m."
223492069|NCT06408857|DRUG|Placebo SC|Placebo will be administered SC
223588165|NCT02667782|BEHAVIORAL|Mindfulness-Based Stress Reduction (MBSR)|Recruited subjects that are randomly allocated into the MBSR group will have an intensive face-to-face (F-T-F) teaching-learning program that is focused on stress reduction. After that, there will be some regular telephone follow-ups for a closed group of 10-15 participants. Subjects would receive four consecutive weekly F-T-F sessions, then a weekly telephone follow-up for three months in combination with an F-T-F session once a month. The Interventionist will be an experienced mindfulness therapist who is qualified to deliver both MBSR and MBCT.
223745553|NCT04923503|BEHAVIORAL|diurnal fasting|subject conduct fasting in Ramadan for 30 days
224183440|NCT03503617|DEVICE|RehabTouch|Exercise using the motion sensing devices and a computer
224183441|NCT03503617|OTHER|Conventional tabletop exercise program|Exercise following printed sheets of exercises
224183442|NCT00638950|DIETARY_SUPPLEMENT|n-3 LC-PUFA|Patients received about 40 g fat daily (200 g yoghurt with 3.8% fat, 30 g cheese with about 50% fat in the dry matter, and 20-30 g butter). The milk fat was partially exchanged by special oils. The daily dose of n-3 FA amounted to 2.4 g, consisting of 1.1 g ALA, 0.7 g EPA, 0.1 g DPA, and 0.4 g DHA.
224183443|NCT00638950|DIETARY_SUPPLEMENT|Placebo|The placebo products were commercial dairy products with comparable fat contents.
224183444|NCT00389766|DRUG|iodine I 131 metaiodobenzylguanidine|
224183445|NCT00389766|DRUG|topotecan hydrochloride|
224183446|NCT00389766|PROCEDURE|chemotherapy|
224183447|NCT00389766|PROCEDURE|peripheral blood stem cell transplantation|
224183448|NCT00389766|PROCEDURE|radioisotope therapy|
224183449|NCT00389766|PROCEDURE|radionuclide imaging|
224183450|NCT00389766|PROCEDURE|radiosensitization|
224308316|NCT01638598|DRUG|matching placebo|matching placebo in each dose level
224308317|NCT01638598|DRUG|matching placebo|matching placebo in each dose level
223492070|NCT06408857|DRUG|Placebo IV|Placebo will be administered IV.
223492071|NCT06408857|DRUG|Placebo IM|Placebo will be administered IM
223588166|NCT02667782|BEHAVIORAL|Mindfulness-Based Cognitive Therapy (MBCT)|Recruited subjects that are randomly allocated into the MBCT group will have an intensive face-to-face (F-T-F) teaching-learning program that is focused on cognitive therapy. After that, there will be some regular telephone follow-ups for a closed group of 10-15 participants. Subjects would receive four consecutive weekly F-T-F sessions, then a weekly telephone follow-up for three months in combination with an F-T-F session once a month. The Interventionist will be an experienced mindfulness therapist who is qualified to deliver both MBSR and MBCT.
223588167|NCT05095857|DRUG|S-ketamine|S-ketamines is an NMDA-receptor antagonist with sedative and analgesic properties. It will in the present trial be given in sedative doses (2-3 mg/kg/hour) in case of clustered SDs following a dosing algorithm according to SD occurrence.
224183451|NCT00389766|PROCEDURE|total-body irradiation|
224183452|NCT03083262|OTHER|no intervention|None, there is no intervention
224183453|NCT01640704|BEHAVIORAL|Computerized reminders about treatment guidelines to providers who care for hypertensive patients|
224183454|NCT03933254|DIAGNOSTIC_TEST|Intraocular pressure measurement via ocular tonometry|Intraocular pressure and optic nerve sheath diameter changes of the patients undergoing laparoscopic cholecystectomy will be measured throughout the surgery at different times using ocular tonometry and ultrasound, respectively.
224183455|NCT04518826|DEVICE|fractional flow reserve|FFR is a physiological functional parameter indicating the severity of ischemic myocardium perfused by a diseased coronary artery. It is measured by a pressure wire placed in the coronary artery and calculated by the ratio of pressures distal and proximal to the stenosis.
224183456|NCT00817752|DIETARY_SUPPLEMENT|Ashwagandha|Participants consume 3mL of Ashwagandha for 5 days. Blood work/immune cells (CD4 T-cells, CD8 T-cells, B-cells, NK cells, macrophages, IL-1, IL-6 and TNF-alpha) and psychological assessments (POMS and STAI Self-Evaluation) given at specified time intervals.
224183457|NCT00000131|PROCEDURE|Photocoagulation Therapy|
224183458|NCT02109965|DRUG|Dexmedetomidine|Continue infusion (CIF) 0.1 - 0.7 mcg/kg/h Goal of sedation: Richmonad agitation-sedation scale 0 to -2
224183459|NCT02109965|DRUG|Midazolam|CIF Goal of sedation: Richmonad agitation-sedation scale 0 to -2
224183460|NCT02109965|DRUG|Propofol|CIF Goal of sedation: Richmonad agitation-sedation scale 0 to -2
224183461|NCT01767844|DIETARY_SUPPLEMENT|Creatine|Creatine, often found in meat and fish, make up an essential part of the systems that provide energy to the muscles for movement and exercise.
224183462|NCT01767844|DIETARY_SUPPLEMENT|Placebo|
224183463|NCT02699047|DIETARY_SUPPLEMENT|Encapsuled fish oil|Fish oil extracted from sardine, mackerel and anchovy. Nutritional information per capsule: Kcal: 13; protein: 0.35g; Total Fats: 1.25g; Saturated fat: 0g; polyunsaturated fat: 0.75g; EPA: 0.5g; DHA: 0.25g; Cholesterol: 0g. The supplement was provided in gelatinous capsule with antioxidant (tocopherols).
224183464|NCT02699047|DIETARY_SUPPLEMENT|Encapsulated Olive oil|Extra virgin olive oil. Nutritional information per capsule: Kcal: 10; protein: 0.35g; Total Fats: 1g; Saturated fat: 0.1 g; monounsaturated fat: 0.75g; polyunsaturated fat: 0.1g; EPA: 0g; DHA: 0g; oleic acid: 0.65g; Cholesterol: 0g. The supplement was provided in gelatinous capsule without antioxidants.
223492072|NCT04310826|DIETARY_SUPPLEMENT|Dietary Intervention|Receive dietary magnesium intervention
223492073|NCT04310826|OTHER|Media Intervention|Undergo video interviews
223492074|NCT04310826|BEHAVIORAL|Telephone-Based Intervention|Receive phone calls
223492075|NCT02379416|DRUG|Nilotinib + Paclitaxel|The BCR-Abl kinase inhibitor nilotinib demonstrated greater than additive activity in combination with the anti-tubulin agent paclitaxel in preclinical xenograft models, justifying the clinical evaluation of this combination for its antitumor activity
223492076|NCT05777681|PROCEDURE|Aortic Surgery|open surgical repair with resection of infected aortic segment, debridement of surrounding tissue and in situ graft replacement.
223492077|NCT03439735|DRUG|Endocrine Therapy and a CDK 4/6 inhibitor|Participants with untreated metastatic disease receiving ET and a CDK 4/6 i as first line therapy.
223492078|NCT03439735|DRUG|Endocrine Therapy and a CDK 4/6 inhibitor|Participants initiating a CDK 4/6 i after progression on ET.
223512550|NCT03381651|RADIATION|Lower dose (41.4Gy/23F) of neoadjuvant chemoradiation|41.4Gy/23F radiation and concurrent chemotherapy with paclitaxel plus CBP used weekly
223512551|NCT02663570|DRUG|Melatonin|
223512552|NCT03024671|OTHER|Patch test application|test patch with cosmetic product will be applied to the back
223512553|NCT03473301|BIOLOGICAL|Infusion of allogeneic umbilical cord blood|Subjects will receive a single infusion of allogeneic umbilical cord blood at the baseline visit.
223512554|NCT03473301|BIOLOGICAL|Infusion of MSCs|Subjects will receive 3 infusions of MSCs (baseline, 3 months and 6 months).
223512555|NCT06043765|DEVICE|real repetitive transcranial magnetic stimulation (rTMS)|real rTMS -- 3 sessions a week/7 weeks (21 sessions)
223512556|NCT06043765|DEVICE|sham repetitive transcranial magnetic stimulation (rTMS)|sham rTMS - 3 sessions a week/7 weeks (21 sessions)
223512557|NCT06043765|BEHAVIORAL|cognitive strategy training|7 weekly sessions with a trained neuropsychologist.
224183465|NCT04946331|DEVICE|Electrical impedance tomography system|Which can use the applied current and measurement voltage through the body surface electrode group, and use the reconstruction algorithm to construct an image imaging system that exceeds the cross-sectional, which can provide images of the internal physiological changes of the chest contour, in order to quantify the changes in lung function caused by rib fractures.
223492079|NCT03896737|DRUG|Daratumumab plus Velcade Cyclophosphamide Dexamethasone|To compare Dara-VCd versus VTd as pre transplant induction and post transplant consolidation, both followed by a maintenance phase with Ixazomib alone or in combination with Daratumumab, in newly diagnosed Multiple Myeloma (MM) young patients eligible for autologous stem cell transplantation.
223492080|NCT03896737|DRUG|Velcade Thalidomide Dexamethasone|To compare Dara-VCd versus VTd as pre transplant induction and post transplant consolidation, both followed by a maintenance phase with Ixazomib alone or in combination with Daratumumab, in newly diagnosed Multiple Myeloma (MM) young patients eligible for autologous stem cell transplantation.
223492081|NCT05544929|DRUG|KFA115|Immunomodulatory agent
223492082|NCT05544929|DRUG|pembrolizumab|Anti-PD-1 antibody
223492083|NCT05600907|BIOLOGICAL|JSP191|A monoclonal antibody that targets human CD117
223492084|NCT04941300|OTHER|Mailed FIT Outreach|We will mail an introductory letter to eligible individuals describing the importance of CRC screening and noting that follow-up mail will include a FIT Kit. Two weeks later they will receive a packet via mail containing the FIT kit, a one-page invitation inviting FIT completion and FIT instructions, COVID-19 messaging, and a postage-paid envelope for return.
223492085|NCT04941300|OTHER|Standardized navigation|"The standardized navigation includes, but is not limited to, the following key components:~1. Identification of individuals with abnormal FIT~2. Results review and colonoscopy order by provider~3. Results reporting to patient~4. Insurance approval for colonoscopy~5. Colonoscopy scheduling~6. Bowel preparation \& colonoscopy completion~7. Colonoscopy results provided to patient and CHC~8. Referral-to-Care for patients with CRC (if necessary)"
223492086|NCT05619614|DEVICE|eye-tracking glasses|endoscopists wear eye-tracking glasses during real-time colonoscopy
223492087|NCT06136403|DRUG|deucravacitinib|treatment by deucravacitinib in two phases of challenge
223588168|NCT05095857|OTHER|Isotonic saline (placebo)|Isotonic saline has the same appearance as S-ketamine with both being clear liquids with no bubbles or other distinguishing features.
223588169|NCT06143033|OTHER|DIME Beauty Luminosity Eye Serum|Test product contains: Water/Aqua, Organic Aloe Vera Juice, Lycium Barbarum (Goji Berry) Fruit Extract, Vitis Vinifera (Grape Seed) Extract, Cucumis Sativus (Cucumber) Extract, Glycerin, Niacinamide, Squalane, Camellia Seed Oil, DL-Panthenol (Vitamin B5), Carbomer, Sodium Hyaluronate, Ammonium Acryloyldimethyltaurate/VP Copolymer, Phenoxyethenol, Caprylyl Glycol, Acacia Senegal Gum, Caffeine, Helianthus Annuus (Sunflower) Seed Oil, Malus Domestica (Apple) Fruit Stem Cell Extract, Argania Spinosa (Argan) Sprout Stem Cell Extract, Tetrahexyldecyl Ascorbate (Vitamin C), Acetyl Tetrapeptide, Acetyl Hexapeptide-8, Vitamin E Mixed Tocopherols, Sodium Hydroxide.
224183466|NCT03316898|DRUG|AGN-242071|AGN-242071 capsules administered once daily to patients receiving donepezil 10 mg with or without memantine as prescribed per standard of care.
224183467|NCT03316898|DRUG|Placebo|Placebo capsules once daily to patients receiving donepezil 10 mg with or without memantine as prescribed per standard of care.
224183468|NCT03316898|DRUG|Donepezil|Donepezil 10 mg as prescribed by the physician as per standard of care.
224183469|NCT03316898|DRUG|Memantine|Memantine as prescribed by the physician as per standard of care.
224183470|NCT03570476|DRUG|Olaparib|Given orally
224183471|NCT03570476|PROCEDURE|Radical Prostatectomy|Undergo surgery
224183472|NCT02041533|BIOLOGICAL|Nivolumab|
224183473|NCT02041533|DRUG|Gemcitabine|
224183474|NCT02041533|DRUG|Cisplatin|
224183475|NCT02041533|DRUG|Carboplatin|
224183476|NCT02041533|DRUG|Paclitaxel|
224183477|NCT02041533|DRUG|Pemetrexed|
224183478|NCT02321163|DEVICE|NMES new paradigm|stimulation frequency: 2 Hz; intensity: low amplitude; duration: 3 hours, 2 times per day for 8 weeks
223492088|NCT06300138|DRUG|Itraconazole|oral itraconazole (children less than 15 years old 6 mg/kg/d; adult patients: 200 mg/d) for a total course of 3-6 months
223492089|NCT06300138|DEVICE|Infrared thermotherapy apparatus|infrared hyperthermia device for 3 consecutive days (times / day), each treatment for 30 minutes After two weeks (14 days), the lesions of the same target were treated continuously for 2 days (times per day), and then once a week for 2 consecutive times, the method was the same as before. After 7 times of treatment, the study physician decided whether to continue treatment n times after 1-2 weeks (n ≥ 0) according to the recovery of the subjects.
223492090|NCT06300138|OTHER|Itraconazole and Infrared thermotherapy apparatus|oral itraconazole (children less than 15 years old 6 mg/kg/d; adult patients: 200 mg/d) for a total course of 3-6 months, while infrared hyperthermia device for 3 consecutive days (times / day), each treatment for 30 minutes After two weeks (14 days), the lesions of the same target were treated continuously for 2 days (times per day), and then once a week for 2 consecutive times, the method was the same as before. After 7 times of treatment, the study physician decided whether to continue treatment n times after 1-2 weeks (n ≥ 0) according to the recovery of the subjects.
223492091|NCT05546814|PROCEDURE|Sodium algorithm|Infants will receive sodium and follow a sodium supplementation schedule or algorithm. This means that based on the sodium levels collected from the samples (stool and urine) they will receive an increase or maintain the same amount to help
223492092|NCT03279458|DEVICE|Linshom Respiratory Monitoring Device|Volunteers will breathe through a continuous positive airway pressure (CPAP) face mask fitted wth the Linshom device. The volunteers will be instructed to breathe normal through the CPAP mask on room air. The excursions of the thermistor tracings (from valley to peak) will be recorded by the Linshom device and displayed continuously on a laptop monitor in a waveform. The tidal volume will also be measured by the ventilator and the data downloaded in a Compact Flash card.
224183479|NCT02321163|DEVICE|NMES conventional|stimulation frequency: 50 Hz; intensity: maximally tolerated; duration: 30 min per day for 8 weeks
224308318|NCT02297399|DRUG|PEG-ascorbate 2L|"Subjects will be asked to proceed to colonic cleansing with the interventional agents as per summary of product characteristics and specific instructions from members of the research team.~Participants will be required to be on a low residue diet for 4 days before the procedure. The preparation will begin at 9:00 pm on the evening before the colonoscopy is scheduled. Participants will take 2 sachets (labelled A and B) of the investigational product and take their contents diluted in 1 liter of water. Two other sachets, also labelled A and B, will be taken diluted in 1 liter of water 4 to 5 hours before the procedure. Fasting will be required from 2 hours after the investigational product has been taken."
223492093|NCT05718596|OTHER|sweeps laser to use irrigation activation|The SWEEPS fiber tip (25 µs ultra-short dual pulse mode-Auto SWEEPS mode) was inserted into the Er:YAG laser source (2,940 nm, 20 mJ per pulse, 15 Hz, 0.3 W power, and 50 µs pulse frequency). 3% NaOCl solution was activated in three periods of 20 s. Then, the same procedure was repeated with 2 ml of 17% EDTA solution.
223492094|NCT05718596|OTHER|PUI to use irrigation activation|The irrigation solution was used by adapting an ultrasonic tip (IRRI S 21/25; VDW, Munich, Germany) to an ultrasonic device (VDW Ultra; VDW, Munich, Germany). The tip was activated a total of three times, with each cycle lasting 20 s and involving the use of 1 ml of 3% NaOCl. Then, 2 ml of 17% EDTA solution was activated for 1 min as describe above. The ultrasonic tip was placed 2 mm behind the working length without touching the canal walls.
223492095|NCT01060176|DRUG|Tranexamic Acid|
223492096|NCT01060176|DRUG|Saline Solution|
223492097|NCT04608630|DRUG|Denosumab 60 MG/ML|Patients allocated to the Denosumab arm will receive Denosumab 60mg in 1ml, administered via subcutaneous injection on Study Days 1 and 180.
223492098|NCT04608630|DRUG|Zoledronic Acid 5Mg/Bag 100Ml Inj|Patients allocated to the Zoledronic acid arm will receive Zoledronic acid 5mg in 100ml 0.9% Sodium Chloride or 5% Dextrose, administered via intravenous infusion over at least 15 minutes on Study Day 1.
223492099|NCT04608630|DRUG|Sodium Chloride 0.9% or 5% Dextrose Intravenous|Patients allocated to the placebo arm and Denosumab arm will receive 0.9% Sodium Chloride or 5% Dextrose 100ml administered via intravenous infusion over at least 15 minutes on Day 1.
223492100|NCT04608630|DRUG|Sodium Chloride 0.9% Injection|Patients allocated to the placebo arm and Zoledronic acid arm will receive 0.9% Sodium Chloride 1ml administered via subcutaneous injection on Days 1 and Day 180
223492101|NCT06386042|OTHER|no intervention, observational study|no intervention, observational registry of the prescription of medical therapy according to the European Society of Cardiology Heart Failure guidelines (quality of care).
223492102|NCT02751905|DRUG|BIIB074|Administered orally as specified in treatment arm
223492103|NCT01143012|OTHER|Group eczema education session|Subjects in the intervention group will participate in a group education visit to discuss topics such as subjects' general understanding and knowledge of eczema and its treatment.
223492104|NCT01143012|OTHER|Control group|The control group will not attend the group eczema education session.
223492105|NCT07114887|BEHAVIORAL|Virtual reality for vocational recovery|Intervention is an immersive virtual reality (VR) intervention, delivered through a VR headset, supported by a trained vocational specialist. Intervention content was co-designed with young people with mental health and vocational challenges, and vocational specialists with experiencing supporting this population. Content was guided by goals of vocational programs, including Individual Placement and Support.
223492106|NCT06827054|PROCEDURE|Biospecimen Collection|Undergo collection of blood and urine samples
223492107|NCT06827054|PROCEDURE|Functional Magnetic Resonance Imaging|Undergo fMRI
223588170|NCT06380010|OTHER|Mediterranean diet group|Females who met the inclusion and exclusion criteria were allocated in groups of one to either the Control group or the Intervention (MD) group using a random assignment method applied by an independent statistician. During the trial, every participant in both groups had two individual sessions with the assigned researchers. These sessions took place at the beginning of the trial and three months later, and involved anthropometry measurements, evaluation of dietary habits, assessment of psychological well-being, and collection of blood samples. Treatment allocation was not revealed to the appointed statistician until the end of the study and release of the final outcomes.
223588171|NCT04860622|DIAGNOSTIC_TEST|Serum thyroid function tests|At the first hospital visit, the blood tests will be made for TSH, FT4, FT3, and beta HCG concentration measurement
223588172|NCT02739516|DRUG|Human chorionic gonadotropin|In letrozole stimulated cycle; Human chorionic gonadotropin ( hCG) 10000 IU was given intramuscular when the mean ovarian follicle diameter was ≥18 mm.
223588173|NCT02739516|DRUG|FSH co-trigger|In letrozole stimulated cycle; FSH (urofollitropin; Fostimon, IBSA, Bazel, Swiz; 75 IU amp) 150 IU injected once intramuscular when the mean ovarian follicle diameter was ≥18 mm.
223492108|NCT06827054|OTHER|Interview|Ancillary studies
223492109|NCT06827054|DRUG|Psilocybine|Given PO
223492110|NCT06827054|BEHAVIORAL|Psychotherapy|Attend psychotherapy sessions
223492111|NCT06827054|OTHER|Questionnaire Administration|Ancillary studies
223588174|NCT02739516|DRUG|Letrozole|Letrozole oral tablets (Femara 2.5 mg tablet; Novartis Pharma Services, Switzerland) 2.5 mg tab twice daily for 5 days from cycle day 3.
223492112|NCT07121530|PROCEDURE|HPV infection in infertile males|To investigate the status of HPV infection in infertile males in Qena government, and to Analyse the effects of HPV infection on semen parameters.
223492113|NCT07115108|DIETARY_SUPPLEMENT|High energy density enteral nutrition|High-energy-density enteral nutrition (100 cal/100 ml) will be administered to infants following surgery for congenital heart disease. The target feeding volume will be determined based on the infant's body weight (80-100 ml/kg), with the volume per feeding and frequency appropriately adjusted.
223492114|NCT07115108|DIETARY_SUPPLEMENT|General energy density enteral nutrition|General energy density enteral nutrition (60-88 cal/100 ml) will be administered to infants following surgery for congenital heart disease. The target feeding volume will be determined based on the infant's body weight (80-100 ml/kg), with the volume per feeding and frequency appropriately adjusted.
223492115|NCT07121244|DRUG|68Ga-R11228|68Ga-R11228 is a gallium-labeled small molecule radioligand that is designed to localize tumor lesions
223588175|NCT05018741|PROCEDURE|liver transplantation|liver transplantation for chronic liver disease or acute liver failure
224183480|NCT02321163|DEVICE|NMES no stimulation|Placebo, electrode pad on, no stimulation
224183481|NCT06601478|BEHAVIORAL|The MedLIFE app|The intervention arm will receive the lifestyle counselling by the MEDLIFE app, and the control arm will go on with standard lifestyle recommendations in the form of a two-page written handout.
224183482|NCT05608265|DEVICE|OSNAT 800 IO|Real-time, combined scanning laser ophthalmoscope (SLO) and optical coherence tomography (OCT) for retinal imaging
223492116|NCT07121244|DRUG|177Lu-R11228|177Lu-R11228 is a lutetium-labeled small molecule radioligand designed to treat tumor lesions
223492117|NCT07119567|OTHER|Multimodal Sleep and Biomarker Assessment|Participants will undergo non-invasive sleep assessments including polysomnography recordings (using the Somfit® device), actigraphy, self-reported questionnaires (on sleep, substance use), and urinary biomarker collection (for cortisol and melatonin levels) at three distinct stages of their substance use/withdrawal timeline.
223492118|NCT07120906|DEVICE|MRI guided procedure software evaluation|For the use of the MRI-needle guidance system (LUMENA) developed by CLEAR GUIDE MEDICAL during clinical MRI-guided needle placement procedures for patients undergoing a liver biopsy/procedure.
223492119|NCT07120841|BEHAVIORAL|Telephone Education|Participants in this group will receive telephone follow-up education by a nurse during the two weeks after discharge
223492120|NCT07120841|BEHAVIORAL|Standard Care (in control arm)|Participants in this group will receive standard post-discharge care without any follow-up telephone education
223492121|NCT06651359|BEHAVIORAL|Surveys for Quality of Life|This group will take scheduled electronic surveys (at the beginning of the study, months 3, 6, 9, and 12) to assess the overall impact of prostate cancer on quality of life (QoL).
223492122|NCT06651359|BEHAVIORAL|Surveys and mHealth App access|"This group will take scheduled electronic surveys (at the beginning of the study, months 3, 6, 9, and 12) to assess the overall impact of prostate cancer on quality of life (QoL). Additionally, they will have a brief initial study visit, in-person or virtually, to review the app use. This arm of participants will use the mobile application at home for 12 months. During the first 12 weeks, the application will send daily surveys about symptoms, dietary and physical activities, weekly surveys about their mood, and an assessment of their overall QoL every 3 months. The app will provide tailored educational content, including short readings, videos, and audio recordings, to help users learn more about managing symptoms and improving their functioning. After 12 months of app use, an interview will be conducted to gather feedback about their experiences with the app. The information collected from these interviews will be analyzed to further enhance and improve the app's functionality."
223492123|NCT04597008|DRUG|Treatment group|Standard of Care + Local Vancomycin + Local Tobramycin: Participants in the treatment group will receive a dose of 1000mg of Vancomycin powder AND a dose of 1200mg of Tobramycin powder in their wound bed, which is placed right before wound closure at the final stafe of definitive fracture fixation.
223492124|NCT04597008|DRUG|Control group|Standard of Care + Local Vancomycin: Participants in the control group will receive a dose of 1000mg of Vancomycin powder in their wound bed, which is placed right before wound closure at the final stage of definitive fracture fixation.
223492125|NCT07125820|OTHER|Experimental Group|There are two groups: a study group and a control group. Both groups will continue taking their doctor-prescribed medications for migraine attacks. After the initial assessment, both groups will receive a 30-minute education and brochure containing lifestyle recommendations to address migraine triggers. The brochure will include recommendations for nutrition, environment, sleep, physical activity, and stress. Additionally, a Chattanooga Cefar® TENS device will be used. The frequency will be set at 100 Hz and the transition time will be set at 100 µs. The session will last 20 minutes. Individuals in the study group will be assigned an exercise program. Patients in this group will exercise in-person three days a week for eight weeks under the supervision of a physical therapist. The program will include cervical stabilization exercises, stretching, and balance exercises. The program is planned with a progression from easy to more difficult every two weeks.
223588176|NCT00687609|DRUG|Atomoxetine|0.5 milligrams per kilogram (mg/kg) daily for 1 week followed by 1.2 mg/kg daily for 11 weeks, orally, capsules.
223588177|NCT03255564|OTHER|feacal calprotectin concentration|"Intervention - To monitor the impact of cardiac surgery and enteral feeding on gut inflammation, biomarkers (faecal Calprotectin) will be measured 24-48hrs after surgery and 24-48hrs after enteral feed commences. Additionally, infants that are diagnosed with NEC will have calprotectin levels measured.~Faecal calprotectin - 50-100mg of faeces will be collected in plastic containers from infant's nappies. Samples will then be homogenised by shaking, and supernatants and then sent to laboratories for immediate analysis."
223588178|NCT00908037|DRUG|eltrombopag|thrombopoietin receptor agonist
223588179|NCT00908037|DRUG|Placebo|placebo for comparison
223588180|NCT03300778|BEHAVIORAL|aerobic exercise|Running at the intensity of 50%-70% of maximum heart rate (220-age) for 30 mins per day, 4 days per week, last for 3 months
223588181|NCT03300778|BEHAVIORAL|Placebo controlled group|6 sections of group activities: 3 sections of general psychological education; one section of group game, one section of group poetry reading activity, group singing entertainment.
223588182|NCT01727791|DRUG|pregabalin (Lyrica)|Subjects will receive a single 150 mg dose of pregabalin in the evening of Day 1, a 150 mg dose of pregabalin in the morning and evening of Day 2 and a 150 mg dose in the morning of Day 3.
224183483|NCT01359865|PROCEDURE|Lumbar Plexus Block|lumbar plexus block followed by a general anesthetic. The lumbar plexus block will be performed by an attending anesthesiologist using ultrasound guidance (for measuring the depth of the psoas compartment) and nerve stimulation. A standardized block solution of 30 mL 0.5% ropivacaine will be injected in fractionated doses when a quadriceps muscle twitch is present to nerve stimulation at \<0.50 mA. Fifteen minutes after block completion, the block's effectiveness will be evaluated with an ice test.
224183484|NCT04177186|OTHER|Strength training|Strength training for hamstring and gastrocnemius only, pre and post 12 weeks of intervention
223588183|NCT02981966|DRUG|Dapagliflozin|dapagliflozin, 10mg tablet
224183485|NCT04177186|COMBINATION_PRODUCT|Strength training with botulinum toxin|Strength training for hamstring and gastrocnemius with Ultra Sound Imaging method, pre and post 12 weeks of intervention
224183486|NCT00641979|DRUG|budesonide|Current product
224308319|NCT02297399|DRUG|PEG 4L|"Subjects will be asked to proceed to colonic cleansing with the interventional agents as per summary of product characteristics and specific instructions from members of the research team.~Participants will be required to be on a low residue diet for 4 days before the procedure. The preparation will begin at 9:00 pm on the evening before the colonoscopy is scheduled. Participants will take 8 sachets of the investigational product and take their contents diluted in 2 liters of water. Eight other sachets, also diluted in 2 liters of water will be taken 4 to 5 hours before the procedure. Fasting will be required from 2 hours after the investigational product has been taken."
224308320|NCT03851029|OTHER|Tai chi|"Session:~• 3 times a week for 30-45 min.~Duration:~• For 6 weeks~Warm-up:~• 10-15 mints~Cool-down:~• 10-15 mints or stretching's~Exercises time:~• 20-30 mints"
223492126|NCT07125820|OTHER|control group|Individuals in the control group will receive a single session of placebo Chattanooga Cefar® TENS application and home exercise program in addition to drug treatment and patient education.Patients in this group will receive a single session of placebo TENS. Electrodes will be placed as in the study group. The physiotherapist will turn on the device but will not increase the current. Thus, the stimulation light of the device will be on but no current will be delivered. Patients will be told that they will not feel anything during the treatment and that this is a feature of the application. The application will be performed for 20 minutes.Home Exercise Program After the initial evaluation and patient education, patients will be offered an exercise program to be performed at home. This program will only consist of stretching exercises for the trapezius and levator scapula muscles. The exercises will be recommended to be performed once a day, 3 days a week, for 8 weeks with 10 repetitions.
223588184|NCT02981966|DRUG|Placebo|Placebo for dapagliflozin
223588185|NCT00299247|DRUG|sulfadoxine/pyrimethamine|
223588186|NCT05287048|DIAGNOSTIC_TEST|MCM5 ELISA|ADXGYNAE is a non-invasive ELISA utilising a combination of two monoclonal antibodies for the detection of MCM5 in urine sediment. It is intended to aid in the detection of endometrial cancer in women with postmenopausal bleeding who are suspected of having endometrial cancer. Participants will be asked to provide a urine specimen, which will be centrifuged before the sediment is lysed. The lysed sample will then be tested with the MCM5 ELISA.
223588187|NCT04170387|OTHER|Relaxometer|Day 1: signing of informed consent, medical history, physical examination, Mini-Mental State Examination (MMSE), Fibromyalgia Impairment Questionnaire revised (FIQ-R), repetition of 6 minutes relaxometer pre-set programme for 3 times Day 2: repetition of 6 minutes relaxometer pre-set programme for 3 times Day 3: repetition of 6 minutes relaxometer pre-set programme for 3 times Day 8: 6 minutes relaxometer pre-set programme once Day 10: 6 minutes relaxometer pre-set programme once, Mini-Mental State Examination Day 30: Mini-Mental State Examination (MMSE), Fibromyalgia Impairment Questionnaire revised (FIQ-R)
223588188|NCT00368121|DRUG|Cetuximab +/- Dexamethasone|"Cetuximab dosing schedule:~• Loading dose of 400 mg/m2, followed by weekly doses of 250 mg/m2. Cetuximab will be administered once weekly over 16 weeks. Mode of administration: intravenous infusion~Dexamethasone dosing schedule:~• 20 mg administered on day 1-3, q1w, starting week 5 if evidence of tumor progression or week 9 if no PR or CR to Cetuximab alone.~Mode of administration: orally"
223588189|NCT01476631|BEHAVIORAL|Walking|"* 7 days prior to baseline participants must wear a blinded pedometer~* At baseline information on the blinded pedometer will downloaded to the computer for analysis as well as number of days worn and hours of wear. Sociodemographic, cancer risk factors, height/weight, fast blood draw to check levels on insulin, C-peptide, IL-6 and PEG-2 and questionnaires PPAQ, Exercise Confident Survey and Sallis Social Support Scale, Day/night; Home/Work, neighborhood safety, HINTS, IPAPS, CES-D, Brief COPE, Urban and Life Stress Scale."
223588190|NCT03724656|DEVICE|acupuncture treatment|"TAES treatment 30 minutes before induction of anesthesia. Bilateral Neiguan（PC6）, bilateral Zusanli（ST36）and bilateral Hegu （LI4）point were selected by electroacupuncture stimulation apparatus (HANS G6805-2, Huayi Co, Shanghai, China).After Deqi, electroacupuncture stimulation apparatus is connected and maintained until the end of operation."
223588191|NCT03724656|DEVICE|sham acupuncture treatment|"Participants in the sham acupuncture group received shallow needling (0.30mm×25mm) at bilateral sham points(nonacupoints located 5cm beside acupoints, about 20mm). The control group was treated with non-acupoint shallow acupuncture method and the needling depth was less than 2 mm. At the same time, the manual stimulation and Deqi was avoided."
223588192|NCT01756859|PROCEDURE|MRI Scan|
223588193|NCT03888118|DEVICE|Luna EMG|The duration of the overall therapeutic intervention in both groups will be the same.
223588194|NCT02185989|OTHER|Early electrical stimulation and early leg bicycling added to early standard rehabilitation|
223588195|NCT01691976|DRUG|Oestrogen Patches|
223588196|NCT01691976|DRUG|LHRHa|Luteinising hormone releasing-hormone agonists (LHRHa)
223588197|NCT02705274|DRUG|Bevacizumab|"Drug: 1.25-mg Bevacizumab Intravitreal injection of 1.25 mg Bevacizumab at baseline and up to every 4 weeks using defined retreatment criteria.~Other: Deferred panretinal photocoagulation PRP is deferred until failure/futility criteria for intravitreal injection are met."
223588198|NCT02705274|PROCEDURE|Panretinal photocoagulation|Panretinal photocoagulation (full session completed within 42 days).
223745554|NCT05721833|DEVICE|Non-invasive high-frequency oscillatory|Non-invasive high-frequency oscillatory ventilation generates high-frequency pressure fluctuations in the airway caused by the opening and closing of a solenoid valve.
223745555|NCT05721833|DEVICE|Noninvasive Bilevel Positive Pressure Ventilation|Noninvasive Bilevel Positive Pressure Ventilation.
223745556|NCT01682317|BEHAVIORAL|Eating Frequency|Thirty adults will be provided an 8-week standard lifestyle intervention, that includes a 1200-1500 kcal/day, \< 30% energy from fat dietary prescription, and a physical activity goal of 200 minutes/week. Participants will be randomized to one of two conditions differing in EF using a prescription we have tested previously. One condition will limit the number of eating bouts/day to three (Three Meal), while the second condition will consume at least 100 kcal every 2 to 3 hours which should lead to approximately 6 eating bouts/day (Grazing).
223492127|NCT06653218|OTHER|No interventions|It is a observational study
223492128|NCT06653218|OTHER|Not have interventions|It is a observational study
223745557|NCT00002233|DRUG|Indinavir sulfate|
223745558|NCT00002233|DRUG|Abacavir sulfate|
223745559|NCT00002233|DRUG|Amprenavir|
224308321|NCT03851029|OTHER|Aerobic Training|"Session:~• 3 times a week for 30-45 min.~Duration:~• For 6 weeks~Warm-up:~• 10-15 mints~Cool-down:~• 10-15 mints or stretching's~Exercises time:~• 20-30 mints"
224308322|NCT00461253|DEVICE|Levonorgestrel-releasing IUD|"This is a case-control-study; strictly speaking the category intervention type does not apply to this study."
223492129|NCT06977555|BEHAVIORAL|Communication Course and skills training|"A multi module intervention where the nurses will learn about communication with mechanically ventilated patients will be developed. The investigators hypothesize that this intervention will:~1. make it easier for mechanically ventilated ICU patients to communicate their needs and symptoms during mechanical ventilation and to improve their symptom burden.~2. improve ICU nurses' skills in communicating with ICU patients who are unable to speak. This will potentially contribute to better communication with critically ill patients, including those being delirious.~3. improve ICU nurses´ satisfaction with their communication."
223588199|NCT01402648|DIETARY_SUPPLEMENT|Eviendep (CM&D Pharma Limited, UK)|175 mg milk thistle (fruit dry extract, 70% in silymarin)+ 20 mg flaxseed (dry extract, 40% in secoisolariciresinoldiglucoside)+750 mg non-starch, insoluble and indigestible fiber (6% in lignin). Provided in 5 g sachets, to be dissolved in half glass water, administered twice a day for 60 days on top of the common diet.
223588200|NCT01402648|DIETARY_SUPPLEMENT|Maltodextrins|900 mg maltodextrin+excipient as per the active comparator eviendep, up to 5 g/sachet
223588201|NCT02024126|OTHER|Exercise therapy|Exercise therapy
223588202|NCT00366327|DRUG|Bifeprunox|Flex dose (20 or 30 mg)tablet, QD for 1 year
223745560|NCT00002233|DRUG|Lamivudine|
224183487|NCT00641979|DEVICE|Budesonide|New type device
223588203|NCT02399514|OTHER|Polysomnographic diagnostic|Polysomnographic diagnostic performed one prior to Coil Treatment, one six months after and one twelve month after Coil Treatment
224183488|NCT00641979|DRUG|Placebo|
224183489|NCT00565721|DRUG|Fluciclatide Injection - (AH111585 (F18))|18F labelled Cyclic RGD peptide PET agent for injection.
224183490|NCT01506310|BEHAVIORAL|Behavioral therapy|General written dietary recommendations (about cooking, lowering sugar intake, reducing salt intake, reducing beverages and food with added sugars) and written options for dining out. A brief written guide on behavior change.
223492130|NCT05791357|DIAGNOSTIC_TEST|PCR (Polymerase Chain Reaction) targeting the 16 ribosomal DNA|Molecular diagnostic using a broad range PCR on obtained histological material (native valve/valve prosthesis/fragments of them)
223492131|NCT00809627|DRUG|Caffeine|Caffeine 500 mg IV
223492132|NCT00809627|DRUG|saline|Normal saline
223492133|NCT06651788|OTHER|Ethyl Chloride|Topical anesthetic that rapidly cools the skin and underlying tissues
223588204|NCT02280447|BIOLOGICAL|1/3 IPV-Al SSI, manufactured by SSI, Denmark|Intramuscular injection of 0.5 mL vaccine into deltoid muscle
223588205|NCT02280447|BIOLOGICAL|1/5 IPV-Al SSI, manufactured by SSI, Denmark|Intramuscular injection of 0.5 mL vaccine into deltoid muscle
223588206|NCT02280447|BIOLOGICAL|1/10 IPV-Al SSI, manufactured by SSI, Denmark|Intramuscular injection of 0.5 mL vaccine into deltoid muscle
223588207|NCT02280447|BIOLOGICAL|IPV SSI, manufactured by SSI, Denmark|Intramuscular injection of 0.5 mL vaccine into deltoid muscle
223588208|NCT00581360|DRUG|doxorubicin and bortezomib|Patients will be treated with bortezomib 1.3 mg/m2, intravenously on days 1, 4, 8 and 11, and doxorubicin 20 mg/m2, intravenously on days 1 and 8, every 21 days. Zinecard will be added at the 8th cycle and all subsequent cycles with doxorubicin. After the completion of 14 cycles, if there is no progression, bortezomib once a week at a dose of 1.6 mg/m2 on days 1,8,15, every 28 days, will be administered alone. Treatment will continue unless disease progression or intolerable toxicity emerges.
223745561|NCT03302013|PROCEDURE|Vanguard XP Bi-cruciate Retaining Knee Replacement System|Newer design of knee replacement retaining the Anterior Cruciate Ligament as well as the Posterior Cruciate Ligament.
224183491|NCT01506310|OTHER|Exercise|The exercise groups will be advised to walk at least 20-minute a day.
224183492|NCT01506310|OTHER|Behavioral therapy and exercise|"General written dietary recommendations (about cooking, lowering fat intake, reducing salt intake, reducing beverages and food with added sugars) and written options for dining out.~Written recommendations for physical activity A brief written guide on behavior change"
224183493|NCT05057000|OTHER|aerobic exercises + Diet|Frequency 5-6 days per week Intensity To perform moderate intensity for weight-bearing aerobic exercise Time Goal of 20-30 min per session of moderate-intensity aerobic activity per week
224183494|NCT05057000|OTHER|diet proram|diet program for anorexic adolescent girls
224183495|NCT06082011|DEVICE|da Vinci SP Surgical System|Model and specification: SP1098 Manufacturer: Intuitive Surgical, Inc.
224308323|NCT00461253|DEVICE|Copper IUD|"This is a case-control-study; strictly speaking the category intervention type does not apply to this study."
223492134|NCT06651788|OTHER|Cold Saline Spray|placebo application of cold saline spray
224183496|NCT02500706|DRUG|Faster-acting insulin aspart|Injected subcutaneously (under the skin) three times daily for 26 weeks. Dose individually adjusted. Mealtime dosing is defined as injecting 0-2 minutes before the meal. Postmeal dosing is defined as injecting 20 minutes after the start of the meal.
223492135|NCT06976476|DRUG|IgPro20|Will be administered in addition to Standard of Care treatment. IgPro20 is intended for subcutaneous administration using an infusion pump
224183497|NCT02500706|DRUG|insulin aspart|Injected subcutaneously (under the skin) three times daily for 26 weeks. Dose individually adjusted. Mealtime dosing is defined as injecting 0-2 minutes before the meal.
224183498|NCT02500706|DRUG|insulin degludec|Injected subcutaneously (under the skin) once daily for 26 weeks. Dose individually adjusted
224183499|NCT01012700|DRUG|Hiltonol (poly ICLC)|2 mg administered subcutaneously or intranasally to healthy volunteers
224183500|NCT05473442|DRUG|EQU-001|20 mg pills of EQU-001
224183501|NCT05473442|OTHER|Matching Placebo|20 mg matching placebo pills
224183502|NCT01558206|OTHER|Pulmonary artery CT Angiography|Performing Pulmonary artery CT Angiography for patients with signs and symptoms in favor of PTE.
224183503|NCT01558206|OTHER|Emergency Bedside Ultrasonography of chest|Performing Emergency Bedside Ultrasonography of chest at the time of presentation for patients with signs and symptoms in favor of PTE.
224183504|NCT00070837|DRUG|MLN2704 (DM1 conjugated monoclonal antibody MLN591)|
224183505|NCT00527046|DRUG|CP-424,391|
224308324|NCT02051712|BEHAVIORAL|exercise training|individualized exercise training
224308325|NCT02051712|BEHAVIORAL|Adherence measures|Measures to increase adherence to exercise training
224183506|NCT05075434|OTHER|Conventional Treatment|This protocol will be the one prescribed by the health centre. It consists of calf stretching exercises, plantar fascia, proprioceptive exercises, ultrasound, magnetic therapy and gait re-education and proprioceptive exercises for 40-45 minutes. Participants will receive 8 treatment sessions spread over 4 weeks (2 sessions per week).
224183507|NCT05075434|OTHER|Diacutaneous fibrolysis|"15 minutes of the treatment technique. The FD intervention will be carried out with the same duration and protocol for all participants.~The intervention protocol will be: Start with the point of maximum tension between the two muscle bellies of the calf and hamstring (reverse hook). Then work on the peroneus longus lateralis and soleus. Then the external calf muscle belly and soleus and the internal calf muscle belly and soleus. Then work on the tendon of the flexor hallucis proprio of the big toe and the inner edge of the Achilles tendon and peroneus longus. Then treatment of the peroneus longus with the peroneus brevis. Scraping of the insertion of the Achilles tendon, hooking of the internal and external part of the plantar fascia. Finally, longitudinal friction of the plantar fascia."
224308326|NCT06511648|DRUG|Erdafitinib monotherapy|Patients will receive treatment with erdafitinib alone (cohort 1)
223492136|NCT03124355|DRUG|placebo sugar pill|placebo single oral dose
223492137|NCT03124355|DRUG|Pyridostigmine Pill|pyridostigmine bromide 30 mg single oral dose
223492138|NCT03124355|DRUG|Galantamine Pill|Galantamine hydrobromide 8mg single oral dose
223492139|NCT03124355|DEVICE|Vagal stimulation|Vagal stimulation will be given at 50 Hz during the tilt table tests
223492140|NCT03124355|DEVICE|Sham vagal stimulation|Sham vagal stimulation will be given at 0.01 mA during the tilt table tests
223492141|NCT06979128|PROCEDURE|PICC placement|Patient scheduled for PICC placement
223492142|NCT06084247|DEVICE|Curved KARL STORZ fetoscope|The KARLZ STORZ curved scope is used to see the inside of a pregnant person's uterus during minimally invasive surgery, similar to conventional scopes. The curved scope is rounded and thought to help visualize the anterior placenta because of its position on the uterus.
223492143|NCT06084247|DEVICE|Conventional Scopes|The conventional scopes are regularly used during laser photocoagulation of placental anastomoses.
223492144|NCT05583877|BEHAVIORAL|Diabetes BOOST|Participants will receive supportive care using technology for DSMT in addition to usual care.
223492145|NCT05583877|BEHAVIORAL|Usual Care|Participants will receive usual care for DSMT.
223492146|NCT06980480|BIOLOGICAL|IGI, 10%|IGI, 10% IV infusion.
223492147|NCT06980012|PROCEDURE|Pharmaceutical consultation|The pharmaceutical interview is a structured way of carrying out an optimized medication review with the patient. This interview takes place at the time of the first prescription of oral anti-cancer treatment.
223492148|NCT06980012|PROCEDURE|Pharmaceutical consultation and follow-up|After the first prescription and at the treatment renewal date (+/- 2 days), the hospital pharmacist will contact the dispensing pharmacist to inform him/her of the patient's treatment, and then as part of the follow-up to detect any problems with treatment compliance (non-renewal of treatment by the patient, lack of follow-up, complaints of adverse effects by the patient). These events will be recorded in the observation book.
223492149|NCT05744479|DRUG|Metformin|Metformin oral, 2000mg/day, for 24 weeks.
223492150|NCT05744479|DRUG|Placebo|Oral placebo for 24 weeks
223492151|NCT05744479|BEHAVIORAL|Lifestyle Intervention|Participants from both groups will meet a dietician and a diabetes educator at the study start to obtain advice regarding healthy diet, portion size, and meal planning to improve physical health. All participants will be invited to monthly group meetings to learn skills which will help them in a variety of wellness areas such as physical exercises and diet. Attendance in these sessions will be encouraged but not mandatory, and attendance will be recorded. Fidelity with these interventions will be captured using diet and physical activity questionnaires at RCT start, midpoint and end, and end of open label phase.
223492152|NCT06815627|DRUG|NH002 (Perflutren Lipid Microspheres) Injectable Suspension|NH002 is formulated as a microbubble injectable suspension for intravenous administration. NH002 requires an activation process prior to use.
223492153|NCT06815367|DEVICE|Pneumatic Compression|Following downhill running protocol, participants will complete 20 minutes of pneumatic compression at 100 mmHg.
223492154|NCT06815367|DEVICE|Blood Flow Restriction|Following the downhill running protocol, participants will complete 4 rounds of treatment: 3 minutes at 100% resting limb occlusion pressure, 2 minutes of 0% resting limb occlusion pressure.
223492155|NCT06841562|BEHAVIORAL|TRAINERa intensive exercise training|Remotely-delivered exercise training intervention
223492156|NCT06587282|DEVICE|Bloom Micro Occluder System|Percutaneous transcatheter closure of PDA using Bloom Micro Occluder System
223492157|NCT06857370|BIOLOGICAL|Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed (DTcP Lot 1)|Three doses of basic immunization were completed at 2, 4 and 6 months of age
223492158|NCT06857370|BIOLOGICAL|Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed (DTcP Lot 2)|Three doses of basic immunization were completed at 2, 4 and 6 months of age
223492159|NCT06857370|BIOLOGICAL|Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed (DTcP Lot 3)|Three doses of basic immunization were completed at 2, 4 and 6 months of age
223492160|NCT05796089|RADIATION|Thoracic Radiotherapy|"Participants will receive thoracic radiotherapy to a dose of 30 Gray (Gy) in 10 fractions (3 Gy per day) concurrently with cycle 3 or 4 of chemo-immunotherapy (Group 1).~Participants who are unsuitable for concurrent radiotherapy may receive consolidation radiotherapy. Consolidation thoracic radiotherapy will be administered to a dose of 30 Gy in 10 fractions, following 4 cycles of chemo-immunotherapy (Group 2).~Treatment fractions will be delivered daily, where treatment should be completed within 15 days (9-10 fractions a fortnight)."
223492161|NCT05796089|DRUG|Etoposide with Carboplatin or Cisplatin|"The chemotherapy in this study is a standard treatment for extensive-stage small-cell lung cancer (EC-SCLC). The combination of chemotherapy (etoposide + carboplatin or etoposide + cisplatin) which the participant will receive is dependent on what is standard at the treatment centre.~Chemotherapy will be administered via an intravenous infusion every 3 weeks (21 days) for 4 cycles."
223492162|NCT05796089|DRUG|Durvalumab|"The immunotherapy in this study is a standard treatment for ES-SCLC.~Participants will receive a dose of 1500 mg of Durvalumab via an intravenous infusion every 3 weeks (21 days) for 4 cycles, concurrently with chemotherapy.~A 1500 mg maintenance dose of Durvalumab will administered every 4 weeks after completion of chemotherapy (monotherapy)."
224183508|NCT06058338|BEHAVIORAL|Produce Prescription|Produce prescriptions mitigate health and food access inequities by partnering with healthcare providers to prescribe fruits and vegetables via financial incentives to patients experiencing food insecurity, low income, and/or chronic disease(s) risk.
224183509|NCT02489656|DEVICE|Double Loop Ureteral stent endoscopic placement.|A JJ stent placement may be indicated at the end of the endourological removal of kidney stones to ensure urine drainage and cicatrisation
224308327|NCT06511648|DRUG|Cetrelimab and Erdafitinib combination|Patients will receive treatment neoadjuvant with erdafitinib plus cetrelimab intravenously (IV).(cohort 2)
223745562|NCT03302013|PROCEDURE|Vanguard CR Single Cruciate Retaining Knee System|Current 'gold standard' for total knee replacement which retains Posterior Cruciate Ligament but sacrifices the Anterior Cruciate Ligament, instead providing artificial support.
223745563|NCT03503786|DRUG|Carboplatin|Carboplatin AUC 5 i.v. every 3 weeks for 6 - 8 cycles
224183510|NCT05798299|BEHAVIORAL|Arm 1: Transdiagnostic intervention|The UP-C/C consists of 15 weekly sessions for children, each lasting 90 minutes. It is also composed by three sessions for parents and a meeting with the family prior to the exposure sessions. Parents have access to weekly psychoeducational material (in written and in video format) and help the children with homework completion.
224183511|NCT05798299|BEHAVIORAL|Arm 2: Anxiety-focused intervention|The Coping Cat in group format is a cognitive-behavioral evidence-based intervention for anxiety problems. It is composed by 16 90-minute sessions for children and two parenting sessions.
224308328|NCT05024916|DIETARY_SUPPLEMENT|Intervention|26 g packets of freeze-dried blueberries (equivalent to 1 cup of fresh blueberries) will be given to participants to be consumed daily. Participants will be asked to consume 1 packet per day for 3 months.
224308329|NCT05024916|DIETARY_SUPPLEMENT|Control|26 g packets of isocaloric carbohydrate-matched powder will be given to participants to be consumed daily. Participants will be asked to consume 1 packet/day for 3 months.
224308330|NCT03077399|DEVICE|SCALA|All items of SCALA are applied
223492163|NCT06081244|DRUG|Sacituzumab govitecan|10 mg/kg twice on Days 1 and 8 of a continuous 21-day treatment cycle
223492164|NCT06081244|DRUG|Pembrolizumab|200 mg every 3 weeks (q3w)
223492165|NCT04871321|DRUG|nab-paclitaxel plus gemcitabine-cisplatin|\- gemcitabine 800mg/m2 + cisplatin 25 mg/m2 + nab-paclitaxel 100mg/m2 on day 1 and day 8, every 21 days
223492166|NCT06997094|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223492167|NCT06997094|DRUG|Chemotherapy|Given concurrent chemotherapy
223492168|NCT06997094|DRUG|Decitabine|Given IV
223492169|NCT06997094|RADIATION|External Beam Radiation Therapy|Undergo EBRT
223492170|NCT06997094|OTHER|Questionnaire Administration|Ancillary studies
223492171|NCT06997094|PROCEDURE|Surgical Procedure|Undergo standard of care surgery
223492172|NCT06002282|BEHAVIORAL|Tailored messages|Messages will be individually tailored to parents' responses to a baseline survey (child gender, vaccination status) and real-time responses to interactive prompts about vaccine hesitancy determinants with links to additional information (e.g., CDC, NJ Department of Health) and community resources to overcome barriers.
223492173|NCT06002282|BEHAVIORAL|Standard messages|Generic reminder/recall HPV vaccination messages.
223492174|NCT06857435|PROCEDURE|Full Thickness Skin Graft (FTSG)|Full thickness skin in FTSGs are harvested by different means by surgeon preference and standard of care. Typically an area of skin with matching color and texture to the site which needs reconstruction is identified from a hidden and/or non-cosmetic area and collected via excision. After excision the donor site is closed and the graft is thinned by using a scalpel or scissors to remove excess fat or other soft tissues from the deep surface before being placed in the donor site.
223492175|NCT06857435|PROCEDURE|Base of wound fat graft with Split Thickness Skin Graft (STSG) Reconstruction (Autologous Layered Composite Grafting).|Autologous Layered Composite Grafting consists of the layered strategy of simultaneous fat and skin grafting. Fat is harvested by minimally invasive liposuction and applied directly to the wound base without any chemical or biologic processing. Skin is harvested as a split thickness skin graft by dermatome and applied over the layer of adipose tissue.
223492176|NCT07000006|BEHAVIORAL|Home-based Core Stability Exercise|The online exercise program aims to improve trunk stability and reduce low back pain. A clinical exercise physiologist will deliver real-time exercise sessions, with each session lasting 40-45 minutes, three days a week for 12 weeks. Participants will join private group sessions using a free video platform.
223492177|NCT06994325|BEHAVIORAL|Conversations Helpful for Awareness of Illness Trajectory (CHAT) Intervention|The Conversations Helpful for Awareness of illness Trajectory (CHAT) intervention will incorporate 4 health-coach sessions, supplemented by 7 educational videos. Each session will be up to 60 minutes long and will be conducted remotely. During the health coach sessions, a trained health coach will work with subjects, reviewing the content of each video and emphasizing key learning content.
223492178|NCT06994325|BEHAVIORAL|Standard of Care (SOC)|The Standard of Care Group will not have access to the Health Coach or video-based educational content. This group will have no study activities during Weeks 1-7 but will participate in follow-up assessments.
223492179|NCT07000110|DRUG|Anifrolumab|Anifrolumab prescribed per local practice
223492180|NCT05865886|DRUG|BI 1291583|BI 1291583
223492181|NCT05865886|DRUG|Placebo to BI 1291583|Placebo matching BI 1291583
223492182|NCT05509218|BEHAVIORAL|Mobile-delivered personalized feedback|Following each daily survey on which a participant indicates prior day drinking, personalized feedback will be provided on how their most recent behavior (e.g., drinks last night, drinking days so far this week) compare/contrast with personal goals. Participants will then choose whether to receive additional feedback in any of 7 areas: blood alcohol concentrate on, high risk behaviors, consequences of drinking, caloric intake, spending, how drinking compares to peers, and safe drinking strategies. All participants will receive feedback on drinks consumed, and then be asked to choose at least one additional topic for feedback (following each drinking day). In addition to day-level feedback, an aggregate feedback report on drinking patterns and related behaviors will be delivered twice, once at the end of each 2-week period. Once again, they will have the option to view feedback across the range of topics noted above.
223492183|NCT06867640|OTHER|Forgiveness-Based Group Psychoeducation|The effect of forgiveness-based group psychoeducation applied to cancer survivors on fear of cancer recurrence, forgiveness and psychiatric conditions.
224183512|NCT03080389|PROCEDURE|Extended Urine Culture|"Extended Urine Culture Standard cultures will include 0.001 ml of specimen plated on sheep blood agar and MacConkey agar. Plates were inoculated and incubated at 35 degrees Celsius for 24 hours. Samples were considered positive if there were 10\^3 cfu or greater. The extended urine culture will be spun down by centrifuge (3000 rpm for 5 min) and 0.1 ml of the sediment will be cultured for 48 hours.~The participants will fill out the Bother, UDI-6, and PUF questionnaires before the cultures. If a patient has a positive urine culture, the patient will be asked to repeat the questionnaires 7-30 days post treatment with antibiotics. A comparison will be made between the standard and extended urine cultures to assess for a difference in identification and treatment of uropathogens."
224183513|NCT06370065|DRUG|HAIC+Serplulimab（HLX10）+ Bevacizumab Biosimilar（HLX04）|PD-1 inhibitor
224183514|NCT01712763|DRUG|degarelix|180 women will be treated with degarlix 120 mg, in only one administration covering three months
224183515|NCT01712763|DRUG|Leuprolide Acetate 11.25 MG/ML (Enantone 11,25)|180 women will be treated with leuprolide acetate11.25 only once covering three months
224183516|NCT04287673|OTHER|Rehabilitation involving strongly the trunk|The Rehabilitation involving strongly the trunk (RIST) leaded by a physiotherapist was based on exercises in different postures performed by the child each day that strongly involve the trunk to cope with balance.
224183517|NCT00956046|BIOLOGICAL|Swine A/H1N1 influenza vaccine (split virion, inactivated)|0.5 mL, Intramuscular on Day 0 and Day 21 (all participants); and 0.5 mL of a trivalent influenza vaccine (TIV) at Month 13 (antibody persistence subset).
224183518|NCT00956046|BIOLOGICAL|Swine A/H1N1 influenza vaccine (split virion, inactivated + Adjuvant)|0.5 mL, Intramuscular on Day 0 and Day 21 (all participants); and 0.5 mL of a trivalent influenza vaccine (TIV) at Month 13 (antibody persistence subset)
223492184|NCT06277258|OTHER|Patient Empowerment model|"Session I~* Knowledge about the disease, calories \& diet distribution, physical activities, symptoms of hypoglycemia, Blood Glucose target etc.~* Training on use of glucometer and record keeping Session II~* Evaluation and interpretation of sugar level based on the sugar chart.~* Tuning of diet and exercise if needed.~* Discussion about the challenges faced by the patient during maintenance of sugar level.~Session III \& ongoing~* Tuning of the diet based on calories, evaluation of the understanding~* Assessment of patient satisfaction~* Assessment of patients' knowledge and skill to designate her as Empowered~Assurance and counseling of patient and family will be rendered in each session."
223492185|NCT05154513|OTHER|Cohort 1|No intervention provided in this study
223492186|NCT03579771|DRUG|Cisplatin|Given IV
223492187|NCT03579771|DRUG|Gemcitabine|Given IV
223492188|NCT03579771|DRUG|Nab-paclitaxel|Given IV
223492189|NCT04822766|PROCEDURE|Hematopoietic stem cell transplantation|patients will undergo allo-HSCT after consolidation therapy (or completion of other appropriate non-palliative strategy) according to standard procedures of the transplant center (choice of donor, conditioning regimen, GVHD and infection prophylaxis). The use of novel therapies (such as sorafenib, midaustorine, venetoclax, etc.) will be allowed as post-transplantation maintenance strategy.
223492190|NCT04822766|DRUG|Best chemotherapy treatment|patients will be treated according to the standard procedures of the treating center for this type of population. Patients will receive the best available treatments (including additional conventional chemotherapy or other non-palliative therapies such as 5-azacytidine, decitabine, venetoclax, midaustorine, enasidenib, etc.).
223492191|NCT05984537|DRUG|Bivalirudin|Participants in the bivalirudin group received a one-time intravenous injection of 0.75 mg/kg during PCI, and then received a continuous intravenous infusion of 1.75 mg/kg/h for 4 hours according to the participants' condition after PCI.
223492192|NCT05984537|DRUG|standard heparin|Participants in the standard heparin group received a one-time intravenous injection of 50 U/kg of standard heparin during PCI.
223492193|NCT06819371|OTHER|Single Task Exercise|Patients will follow the exercises in a way to focus on only one task during the exercise sessions. In the creation of the exercise programme, the principles of the exercise prescription recommended by the American Sports Medicine Association for individuals with adult Type 2 diabetes will be taken into consideration. In this context, planning will be made by considering the progression of stretching, balance and walking exercises from simple to difficult.
223492194|NCT06819371|OTHER|Dual Task Exercise|Patients enrolled in the dual-task exercise group will perform a second task during the exercise sessions along with the exercises in the single-task exercise group. This second task will be determined individually according to the level and progress of the patient.
223492195|NCT01462448|PROCEDURE|Blood Draw|Single blood draw of 30 ml
223492196|NCT05708924|DRUG|FT538|FT538 IP at assigned dose level on Day 1, Day 8, and Day 15.
223492197|NCT05708924|BIOLOGICAL|Enoblituzumab|Enoblituzumab 15 mg/kg IV begin on Day -6 and continuing once every 3 weeks beginning on Day 22 until disease progression or unacceptable toxicity - refer to Section 7.2.1 for timing of the enoblituzumab dose on Day 22 if steroid pre-meds are needed due to an infusion reaction with the 1st enoblituzumab dose as there is a 14 day ban on corticosteroid use after the last dose of FT538
223492198|NCT05743140|DIAGNOSTIC_TEST|CaIMR|Investigators diagnose CMD with CaIMR. Investigators use OCT and OCTA to analyze the fundus microcirculation quantitatively.
223492199|NCT05374590|BIOLOGICAL|Efgartigimod IV or Efgartigimod PH20 SC|Intravenous infusion of Efgartigimod or Subcutaneous injection of Efgartigimod PH20 SC
223492200|NCT06364956|DRUG|Tislelizumab combined with two predefined dose groups of palbociclib|Tislelizumab, 200mg q3W, combined with two predefined dose groups of palbociclib: 100mg QD and 125mg QD, separately.
223492201|NCT06364956|DRUG|RP2D dose Of Tislelizumab combined with palbociclib was selected for phase II clinical trial.|After the exploration of Tislelizumab, 200mg q3W combined with palbociclib, and the maximal tolerated dose (MTD) was determined, then RP2D dose of Tislelizumab combined with palbociclib was selected for phase II clinical trial.
223492202|NCT02487134|DEVICE|TIGR Matrix|Reinforcement of the suture line with resorbable mesh
224183519|NCT00956046|BIOLOGICAL|Swine A/H1N1 influenza vaccine (split virion, inactivated + adjuvant)|0.5 mL, Intramuscular on Day 0 and Day 21
224308331|NCT06582602|BIOLOGICAL|MK-2060|Single doses of MK-2060 will be administered via IV infusion or syringe on Day 1 according to randomization.
224308332|NCT06582602|BIOLOGICAL|Placebo|Single doses of placebo will be administered via IV infusion or syringe on Day 1 according to randomization.
224183520|NCT04466592|BEHAVIORAL|Promotion of competences of participant involved in the management of the post operative period|The research psychologist will be in touch with the participants for 9 months after the surgery (weekly, biweekly or monthly) in order to help them recovering social and work activities, and dealing with the consequences of the surgery. Specifically, four competences will be promoted (future forethought; context evaluation; consequences of own actions forethought; use of available resources), each relevant to four areas (clinical; familiar; working; daily-activities).
224183521|NCT01497899|DRUG|E/C/F/TDF|150/150/200/300 mg FDC tablet administered orally once daily
224308333|NCT06554873|DRUG|Nicoderm|Depending on responder status and group assignment the maximum amount of time nicotine patches will be used is 24 weeks. The final four weeks of nicotine patch treatment will comprise 2 weeks of 14 mg patches and two weeks of 7 mg patches.
224308334|NCT06554873|DRUG|Nicorette 4Mg Chewing Gum|4mg Nicorette gum (flavors - cinnamon surge, fruit chill, and mint); as needed maximum usage 24 weeks.
223492203|NCT02487134|DEVICE|Control|Closure of the abdomen with conventional technique
223492204|NCT06865534|OTHER|Local language model|Group will be given access to local language model first after using ChatGPT and then will get access to pdf file
223492205|NCT06865534|OTHER|Guideline pdf|Group will be given access to pdf file after ChatGPT and then to a local language model
223492206|NCT06868355|OTHER|No intervention (observational study)|This is an observational study
223492207|NCT05628324|BEHAVIORAL|practice muscle activation patterns|practice upper limb muscle activation patterns using EMG-controlled games
223492208|NCT05628324|BEHAVIORAL|task practice|practice functional upper limb tasks
223492209|NCT06608277|PROCEDURE|Group A active comparator|Group A placebo comparator. Stellate Ganglion Block plus placebo (.9 normal saline) infusion
223492210|NCT06608277|DRUG|Group B active comparator|Active Comparator: Group B = Sham Stellate Ganglion Block plus ketamine infusion
223492211|NCT06608277|COMBINATION_PRODUCT|Group C Experimental|Group C experimental Stellate Ganglion Block plus ketamine infusion
223492212|NCT06608277|OTHER|Group D Placebo Comparator|Group D Placebo Comparator: Sham Stellate Ganglion Block plus placebo normal saline
223588209|NCT05674110|BEHAVIORAL|DSMES Intervention|This study will provide participants with on-line education, plus weekly text messaging that will contain messages of support or encouragement sent to participants in the individual's preferred language (English or Spanish). Participants will be encouraged to attend monthly group support meetings to review the content and address any questions. Group meetings will occur at 3-time intervals (end of months: 1, 2, and 3). Group support meetings will be held in-person at a food pantry and moderated by peer mentors, nursing students, registered dietitian nutritionist (RDN), and/or a diabetes care and education specialist (DCES). Group support meetings will be held in Spanish and/or English, with no more than 10 participants in a group at one time, and will last approximately 50 minutes. For the duration of the study, participants will continue to receive monthly food items from the food pantry.
224308335|NCT06554873|DRUG|Nicorette Lozenge Product|4mg Nicorette mint lozenge; as needed maximum usage 24 weeks.
223492213|NCT07010497|DRUG|irpagratinib|Patients will receive oral administration of ABSK-011 capsules in a repetitive dosing regimen for a period of 21 consecutive days as a cycle, either once daily or twice daily, until the investigators make a comprehensive assessment of imaging examinations, laboratory data, and the clinical condition of the patients, and determine that there is intolerable toxicity or disease progression.
223492214|NCT05186272|BEHAVIORAL|Stress reduction program 'A'|Participants will use stress reduction program 'A' app 10-20 min per day for 6 weeks.
223492215|NCT05186272|BEHAVIORAL|Stress reduction program 'B'|Participants will use stress reduction program 'B' app 10-20 min per day for 6 weeks.
223492216|NCT07018570|DRUG|Pembrolizumab|Pembrolizumab 200mg will be administered via intravenous infusion over 30 minutes, twice at 21-day intervals.
223492217|NCT07018570|DRUG|Docetaxel|Docetaxel 50 mg/m2 will be administered over 60 minutes.
223492218|NCT07018570|DRUG|Oxaliplatin|Oxaliplatin 85 mg/m2 will be administered over 2 hours.
223492219|NCT07018570|DRUG|Levofolinate|Leucovorin 200 mg/m2 will be administered over 2 hours.
223492220|NCT07018570|DRUG|Fluorouracil (5-FU)|5-FU 2600 mg/m2 will be administered over 24 hours.
223492221|NCT07018570|RADIATION|Radiation Therapy|25Gy (5Gy×5fr)
223492222|NCT06863012|DIAGNOSTIC_TEST|Endoscopic Ultrasound-Guided Portal Pressure Gradient (EUS-PPG) Measurement|Endoscopic Ultrasound-Guided Portal Pressure Gradient (EUS-PPG) measurement is a minimally invasive, ultrasound-based diagnostic procedure designed to assess portal hypertension in patients with chronic liver disease. Using an endoscopic ultrasound (EUS) probe, and a fine-needle aspiration (FNA) needle (EchoTip® Insight™) is used to directly measure intravascular pressures. Unlike the standard hepatic venous pressure gradient (HVPG) measurement, EUS-PPG provides direct pressure readings, does not require catheterization of the hepatic vein, and eliminates the need for radiation, iodinated contrast, and interventional radiology. This study aims to evaluate the accuracy, feasibility, and safety of EUS-PPG compared to HVPG.
223588210|NCT03171818|DRUG|Darbepoetin Alfa|Darbepoetin alfa (Aranesp, Amgen) 2 doses of 10 microgram/kg i.v.
223588211|NCT03171818|DRUG|Saline|The placebo will consist of saline, containing 9.0 g of salt per liter (0.90%) i.v.
223588212|NCT02816463|DEVICE|Ambu AuraGain|
223588213|NCT02816463|DEVICE|LMA Supreme|
223588214|NCT01443663|BIOLOGICAL|H5N1 Vaccine|Vaccine will be administered intramuscularly (IM) in the deltoid muscle at baseline for participants in Groups 1-4 and at baseline and Day 28 for participants in Group 5.
223745564|NCT03503786|DRUG|Paclitaxel|Paclitaxel 175 mg/m2 i.v. every 3 weeks for 6-8 cycles
224183522|NCT01497899|DRUG|E/C/F/TAF Placebo|Tablet administered orally once daily
224183523|NCT01497899|DRUG|E/C/F/TAF|150/150/200/10 mg FDC tablet administered orally once daily
224183524|NCT01497899|DRUG|E/C/F/TDF Placebo|Tablet administered orally once daily
224183525|NCT02288416|OTHER|educational intervention|Undergo video-based intervention
224183526|NCT02288416|OTHER|questionnaire administration|Ancillary studies
224183527|NCT02288416|OTHER|quality-of-life assessment|Ancillary studies
224183528|NCT02288416|OTHER|Best Practice|
224183529|NCT02935010|DRUG|Esomeprazole|proton pump inhibitor
224308336|NCT06554873|OTHER|NJOY e-cigarette|Each NJOY Classic Tobacco and Menthol pod is pre-filled with 1.9 mL of e-liquid with 5% nicotine (by weight); as needed maximum usage 24 weeks.
223492223|NCT06863012|DIAGNOSTIC_TEST|Hepatic Venous Pressure Gradient (HVPG) Measurement|Hepatic Venous Pressure Gradient (HVPG) measurement is the current gold standard for assessing portal hypertension in patients with chronic liver disease. The procedure involves catheterization of the hepatic vein via the jugular or femoral vein, where free hepatic venous pressure (FHVP) and wedged hepatic venous pressure (WHVP) are measured using a pressure transducer. HVPG is an indirect measure of portal pressure and requires fluoroscopy, radiation exposure, and specialized interventional radiology equipment. While widely used in clinical practice, HVPG has limitations, including the need for a hospital setting, potential patient discomfort, and limited feasibility in certain cases. This study will compare HVPG to EUS-PPG to determine whether EUS-PPG can serve as a less invasive and more accessible alternative.
223492224|NCT05880836|DEVICE|nebulizer via in-line drug delivery maintaining high-flow nasal cannula oxygen|nebulized delivery of bronchodilator via in-line drug delivery maintaining high-flow nasal cannula oxygen
224183530|NCT02935010|DRUG|Bismuth Potassium Citrate|Gastric mucosal protective drug with anti-H. pylori effect
224183531|NCT02935010|DRUG|Amoxicillin|antibiotic for H. pylori eradication
224183532|NCT02935010|DRUG|Clarithromycin|antibiotic for H. pylori eradication
224183533|NCT02935010|DRUG|Metronidazole|antibiotic for H. pylori eradication
223492225|NCT05880836|DEVICE|standard jet nebulization (SJN) with face mask|standard jet nebulization delivery of bronchodilator
223492226|NCT07019909|BIOLOGICAL|20vPnC|20 valent pneumococcal conjugate vaccine
223588215|NCT01066962|DRUG|darunavir/ritonavir QD + raltegravir BID|"darunavir 800 mg, i.e. 2 tablets of 400 mg once daily (QD)~ritonavir 100 mg, 1 tablet once daily (QD)~raltegravir 400 mg, 1 tablet twice daily (BID)"
223745565|NCT03503786|DRUG|Avelumab|Avelumab 10 mg/kg every 3 weeks for 6-8 cycles + Avelumab 10 mg/kg every 14 days until disease progression or unacceptable toxicity
224183534|NCT02935010|DRUG|Levofloxacin|antibiotic for H. pylori eradication
224183535|NCT02275949|DEVICE|acupuncture|Acupuncture needles are inserted at the acupoints Zusanli(ST 36), Neiguan(PC 6), Gongsun(SP 4), and Xiangu(ST 43) bilaterally.
223492227|NCT07019909|BIOLOGICAL|13vPnC|13 valent pneumococcal conjugate vaccine
223492228|NCT06626256|BIOLOGICAL|Aldesleukin|Given SC
223492229|NCT06626256|PROCEDURE|Biopsy|Undergo biopsy
223492230|NCT06626256|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223745566|NCT00192504|BIOLOGICAL|Motavizumab|Single dose of Motavizumab at a dose of 3 mg/kg administered intravenously (in the vein) on Day 0
223745567|NCT00192504|BIOLOGICAL|Motavizumab|Single dose of Motavizumab at a dose of 15 mg/kg administered intravenously (in the vein) on Day 0
223745568|NCT00192504|BIOLOGICAL|Motavizumab|Single dose of Motavizumab at a dose of 30 mg/kg administered intravenously (in the vein) on Day 0
223745569|NCT00192504|OTHER|Placebo|Single dose of placebo administered intravenously (in the vein) on Day 0
223745570|NCT00212732|DRUG|ONO-8025 (KRP-197)|
223745571|NCT02297828|DEVICE|Boussignac CPAP|Boussignac CPAP with a 50% FiO2 (adjusted in a piece adapted to the system) and a pressure of 5cmH2O (measured with a manometer) is applied immediately after extubation and mantained for two hours after extubation in the post anesthesia care unit (PACU).
224183536|NCT02275949|DEVICE|Electroacupuncture|The electric stimulator will be connected to the handles of each needles on the ST 36 and PC 6 bilaterally with 5Hz.
224183537|NCT02275949|DEVICE|Intradermal acupuncture|Intradermal acupuncture needles with tape are inserted on the ST36, PC6, SP4, ST43 bilaterally and maintained until the next session.
224183538|NCT02275949|DEVICE|Mock transcutaneous electrical nerve stimulation|Electrical insulator are attached on the ST36 and PC6 bilaterally, the same electric stimulator will be connected on the points with the same parameters as the study group, but without current intensity.
224183539|NCT02275949|DEVICE|sham intradermal acupuncture|Intradermal acupuncture needles are put over the tape not penetrating the skin.
224183540|NCT03283813|DIETARY_SUPPLEMENT|Zinc|In this active Group there will be a supplementation with Zinc (5 mg), Myo-inositol (2000 mg) and GOS (Galacto-oligosaccharides) of Pisum sativum (1000 mg)
223492231|NCT06626256|PROCEDURE|Computed Tomography|Undergo CT
223492232|NCT06626256|DRUG|Cyclophosphamide|Given IV
223492233|NCT06626256|PROCEDURE|Excisional Biopsy|Undergo excisional biopsy
223492234|NCT06626256|DRUG|Fludarabine|Given IV
223588216|NCT01066962|DRUG|darunavir/r QD + tenofovir/emtricitabine QD (fixed dose combination)|"darunavir 800 mg, i.e. 2 tablets of 400 mg once daily (QD)~ritonavir 100 mg, 1 tablet once daily (QD)~tenofovir/emtricitabine 245/200 mg, fixed dose combination, 1 tablet once daily (QD)"
223745572|NCT02297828|DEVICE|Venturi face mask|Venturi mask with a 50% FiO2 is used immediately after extubation and mantained for two hours in the post anesthesia care unit (PACU).
223745573|NCT02723968|OTHER|glucose solution at a dose of 1.75 g/kg (up to a maximum of 75 g) for the OGTT and glucose solution at a dose of 0.5 g/kg (up to a maximum of 35 g) was injected in 2.5-3 min for the IGTT|At the first visit at day 1an OGTT will be performed then the CGMS is implanted. Capillary glycaemia will be taken four times a day to set up the CGMS. A second visit is scheduled at day 4, where the intravenous glucose tolerance test is performed as well as the HbA1C level.
223745574|NCT02723968|PROCEDURE|HGPIV diagnosis test|
224183541|NCT03283813|DRUG|Placebos|In this placebo Group there will be a supplementation with a product placebo equal to the active product with GOS (Galacto-oligosaccharides) of Pisum sativum(1000 mg) but without Zinc and Myo-inositol.
224183542|NCT03283813|DRUG|Myoinositol|In this active Group there will be a supplementation with Zinc (5 mg), Myo-inositol (2000 mg) and GOS (Galacto-oligosaccharides) of Pisum sativum (1000 mg)
224183543|NCT02026193|PROCEDURE|oocyte vitrification|
224183544|NCT02026193|PROCEDURE|embryo freezing|
224183545|NCT01680835|DEVICE|EverFlex™ Self-Expanding Peripheral Stent System|Using the EverFlex™ Self-Expanding Peripheral Stent System to treat atherosclerotic superficial femoral artery (SFA) and proximal popliteal lesions 4-18 cm long in subjects with Rutherford Clinical Categories 2-4.
224183546|NCT00270816|DRUG|Interferon-ß-1b|250 micrograms (8 MIU) administered subcutaneously (sc) every other day with a discontinuance month every 2 months
224183547|NCT00270816|DRUG|Interferon ß-1b|250 micrograms (8 MIU) administered subcutaneously (sc) every other day
224183548|NCT00286234|DRUG|omega-3 acid ethyl esters|4 q qd
224183549|NCT00286234|DRUG|extended release niacin|2 g qpm
223492235|NCT06626256|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
224183550|NCT00286234|DRUG|placebo|omacor placebo plus niaspan placebo
224183551|NCT00286234|DRUG|omega-3 acid ethyl esters|4 g qd
224183552|NCT00286234|DRUG|combined treatment|omega-3 acid ethyl esters 4 g qd and extended release niacin, titrate up to 2 g Qpm
224183553|NCT06092411|BEHAVIORAL|Cognitive Behavioural Therapy for Depression|Consists of 8 weekly sessions (group-based, 90-min, 4-6 adolescents in each group). The intervention focuses on addressing depression, with the components such as psycho-education on depression, self-monitoring, behavioural activation, and cognitive restructuring (addressing negative and irrational thoughts often associated with depression in adolescents), relaxation techniques, and relapse prevention.
224183554|NCT06092411|DEVICE|Bright Light Therapy|Participants will undergo daily morning light therapy by wearing a validated portable light emitting device (i.e., Re-Timers: https://www.re-timer.com/) at home for 30 minutes. Participants will receive bright blue-green light (500 nm, 506 lux).
224183555|NCT05560412|DIETARY_SUPPLEMENT|Zein nanocapsules|1 g of Zein nanoencapsulated daily
224183556|NCT05560412|DIETARY_SUPPLEMENT|control|1 g of Zein non-encapsulated daily
224183557|NCT05049915|DEVICE|bioglass (S53P4)|surgical procedure: Masquelet defect augmentation with bioglass
224183558|NCT05049915|DEVICE|RIA and TCP|surgical procedure: Masquelet defect augmentation with RIA and TCP
224183559|NCT00309361|DRUG|Phentolamine Mesylate (NV-101)|
223492236|NCT06626256|PROCEDURE|Standard Treatment|Receive standard of care therapy
223492237|NCT06626256|BIOLOGICAL|Therapeutic Tumor Infiltrating Lymphocytes|Given STIL101 for injection IV
223492238|NCT06866132|DEVICE|Investigational Noninvasive Neuromodulation Device|The investigational noninvasive neuromodulation device will be setup by the patient at bedtime and will be used every night. The IRB has established that the investigational device is non-significant risk.
223492239|NCT06859320|PROCEDURE|laparoscopic sleeve gastrectomy|laparoscopic sleeve gastrectomy is one of the popular bariatric surgeries known for weight reduction
223492240|NCT06693661|OTHER|Kidney Health Coaching|"The intervention entails support from a KHC that includes:~* An initial rapport-building call~* Ongoing telephone support at least twice a month for six months~* Meeting the patient at all in-person clinic appointments~* Documenting interactions in the EMR using a customized platform~Telephone support begins with a social determinants of health (SDoH) screening tool to identify barriers and facilitators to CKD self-management and appointment adherence. This tool provides access to local resources based on the patient's ZIP code. Subsequent calls will follow up on resource usage, review CKD educational materials and treatment options, complete the Decision Aid for Renal Therapy tool, and facilitate communication through the patient portal. Each call will start with specific goals (e.g., review National Kidney Foundation CKD materials) and conclude with goals for the next session."
223588217|NCT02832336|DRUG|Vivarin|Adenosine is an endogenous sleep-promoting substance with neuronal inhibitory effects. Adenosine has been proposed to be a sleep-inducing substance accumulating in the brain during prolonged wakefulness. Caffeine is an adenosine receptor antagonist. It inhibits a part of the sleep cycle and, in turn, promotes the wakeup state. Caffeine results in the release of norepinephrine, dopamine and serotonin in the brain and the increase of circulating catecholamines, consistent with reversal of the inhibitory effect of adenosine.Vivarin Drug class :Central nervous system (CNS) stimulants.
224183560|NCT00531466|DRUG|tolperisone HCl (AV650)|One tablet orally three times a day for 28 days
224183561|NCT00531466|DRUG|Placebo|One tablet orally three times a day for 28 days
224183562|NCT01844414|BEHAVIORAL|Parolee Comprehensive Care + Phone Coach|A nurse case managed and specialized hepatitis education program with the hepatitis A/B (HAV/HBV) vaccination series (to all eligible) and coach-facilitated mentoring (mostly by cell-phone).
224183563|NCT01844414|BEHAVIORAL|Parolee Brief HBV Program + Phone Coach|A brief hepatitis/HIV education program with the Hepatitis A/B vaccine series and coach-facilitated mentoring.
224183564|NCT01844414|BEHAVIORAL|Usual Care Group|Control Group: A brief general health information program with one-on-one coaching and the Hepatitis A/B vaccine
224183565|NCT00090324|DRUG|quetiapine fumarate tablets|
224183566|NCT02347124|BEHAVIORAL|Usual Care Control|Standard quitline counseling and other treatment materials provided through each participating state quitline program + a series of text messages with general health promotion tips.
223588218|NCT02832336|DRUG|Fiber|Fiber will be used as placebo.
223588219|NCT01092793|DIETARY_SUPPLEMENT|Krill|Encapsulated oil from the antarctic crustacean Krill
223588220|NCT01092793|DIETARY_SUPPLEMENT|Fish oil|Encapsulated, raffined cod-oil
224183567|NCT02347124|BEHAVIORAL|Enhanced Intervention|Standard quitline counseling and other materials provided through each participating state quitline program + oral health-focused counseling + oral health focused text messages + access to additional oral health educational content (website and written materials) + oral health tools (toothbrush, dental floss)
224308337|NCT06554873|OTHER|on!|4mg on! Nicotine Pouch (flavors - Berry, Mint, and Original); as needed for maximum usage 24 weeks.
224308338|NCT03103789|DIAGNOSTIC_TEST|single catheter mucosal impedance testing|
224308339|NCT03103789|DIAGNOSTIC_TEST|balloon assembly mucosal impedance testing|
224308340|NCT02616432|DEVICE|Tomosynthesis|Three-dimensional imaging of both breasts in standard CC and MLO views
223588221|NCT02391493|DEVICE|functional magnetic resonance imaging|"Stimuli will be presented in 3 language conditions, French, English and switch in which the participant alternates between English and French every trial. A block design will be used, with 7 line drawings per language condition. Four 9-minute runs will be performed, there being 2 action runs and 2 object runs. In each run, there are 6 blocks of each language condition, presented in a fixed random order. No drawings are repeated. Each stimulus is preceded either by an English or a French prompt word (to or faire for actions and, say or dire for objects) for 450 msec; stimuli are presented for 1.5 seconds and followed by a blank screen for 1 second. Language blocks are separated by a variable duration (from 8 to 10 seconds)."
223588222|NCT00473525|DRUG|Placebo|Placebo QD
223588223|NCT00473525|DRUG|PF-00734200 10 mg QD|10 mg QD
223588224|NCT00473525|DRUG|PF-00734200 20 mg QD|20 mg QD
223588225|NCT00473525|DRUG|PF-00734200 5 mg QD|5 mg QD
224308341|NCT06633653|BEHAVIORAL|exercise intervention|Patients will participate in an 8-week supervised aerobic exercise program, the intensity was set at the moderate to vigorous intensity (≥150mins/week exercise on the treadmill).
224183568|NCT02846337|PROCEDURE|ULTRAFILTRATION|"Peritoneal dialysis: at least one daily contact, 5 days a week minimum, with a hypertonic solution. Le number of contact et the stasis duration will be decided by the practitioner.~Hemodialysis: at least one hemodialysis per week, one hemofiltration and/or hemodiafiltration per week, and at least 2 liter of ultrafiltrate extraction per week. In case of serious interdialytic weight gain, and/or hemodynamic unsteadiness, sessions can be up to 6 per weeks. Sessions duration will be adjusted to the needful ultrafiltrate and hemodynamic tolerance.~Isolated ultrafiltration: at least once a week, and includes an extraction of minimum 2 liter ultrafiltrate in less than 4 hours. It could be done, according to routines and department capacity, on a hemodialysis generator, plasmatic exchange generator, or mobile ultrafiltration device."
223588226|NCT00473525|DRUG|PF-00734200 2 mg QD|2 mg QD
223588227|NCT00552760|DRUG|Ramelteon|one 8 mg tablet at bedtime for up to 6 months
223588228|NCT00552760|DRUG|Placebo|one tablet at bedtime for up to 6 months
223588229|NCT01688908|PROCEDURE|Endoscopic Screening|"1. Upper G.I. endoscopic examination with Lugols Iodine in esophagus~2. Biopsy at the visually abnormal sites~3. Pathologic examination of all biopsy tissue specimens~4. Subsequent re-examination and further medical services among individuals who already have high-grade lesions found at screening.~5. Advises of endoscopic or surgical treatment will be given to participants who are diagnosed of high grade upper G.I. lesions."
223588230|NCT04079881|DRUG|Insulin|to give pre-prandial and post-prandial insulin (will use patient insulin dose patient use at home) to patients with T1D and evaluate the response of post-prandial glucagon and post-prandial hyperglycemia.
224183569|NCT02846337|PROCEDURE|ENHANCED MEDICAL TREATMENT|"* Close cardiologic and nephrologic follow-up, minimum 4 times a year, This incidence matches the heart failure, and chronic kidney failure care guidance for our sample~* Medical care adjustment in order to apply European and American guidance for chronic heart failure care~* Hydric, caloric, peptic and sodium input evaluation by a dietician, and adjustment if needed~* Physical rehabilitation suggestions by a physiologist~* Evaluation of an interventional approach requirement, and implementation if needed (pacemaker, defibrillator, cardiac resynchronization, diagnosis and therapeutic coronary angiography, ventricular stimulator) according to European and American guidance."
223492241|NCT06693661|OTHER|Usual Care|"ER Discharge (d/c): Patients may receive consultations and support from Care Management in the ER such as transportation or medication assistance. Follow-up by a social worker varies post-discharge.~Hospital d/c: All hospitalized patients are assessed by the care management team to identify psychosocial needs and begin discharge planning, which may include follow-up appointments and resources. High-risk patients receive additional follow-up from a care transitions coordinator for 30 days post-discharge.~Primary Care: Patients in primary care clinics have access to various support services. Those recently hospitalized or identified as high-risk receive care coordination from social workers. Internal referrals are managed by referral coordinators, while external referrals come from clinic staff. Discharge information is provided after visits.~Nephrology: There are no coordinated support services for chronic kidney disease (CKD) patients receiving nephrology care."
223492242|NCT04278898|DRUG|N-Acetylcysteine|N-acetylcysteine Single Dose 2700 mg taken orally
223492243|NCT07022054|DEVICE|iCare IC1000 measurement|Measurement of intraocular pressure with iCare IC1000
223492244|NCT06696053|OTHER|Transversal therapeutic education|Additional patient consultation for therapeutic education with nurses.
223492245|NCT06627504|BEHAVIORAL|Sleep Health and Circadian Timing Intervention|Participants will be prescribed a sleep schedule that allows them to obtain at least 1h more time in bed compared to their typical school week schedule. In addition, participants will be provided with pharmaceutical-grade exogenous melatonin and instructed to take 500mcg 2 hours before their scheduled bedtime. They will also be asked reduce evening light exposure starting 2 hours before bedtime by limiting household lights and dimming electronics. In the mornings, participants will be exposed to bright light for 30 minutes after waking by wearing provided ReTimer light therapy glasses.
223745575|NCT02723968|PROCEDURE|HOMAR-IR diagnosis test|
224183570|NCT05342376|DRUG|Dexmedetomidine Hydrochloride|The parturients will receive 10 micro-gram Dexmedetomidine diluted in 02 ml normal saline to be administered intravenously over 10 minutes after umbilical cord is clamped..
224183571|NCT05342376|DRUG|Normal Saline|The parturients will receive 02 ml normal saline as placebo, to be administered intravenously over 10 minutes after umbilical cord is clamped.
224308342|NCT04240392|BEHAVIORAL|Collaborative Care (CC)|"The sites randomized to CC will have 4-6 on-site support visits at the outset of the study. These visits will occur during the first 3 months of the project. During these visits, study staff will again review buprenorphine induction procedures (heretofore referred to as initiation rather than induction) and dosing of buprenorphine as well as therapeutic behavioral treatments. The investigators will provide the center with forms and educational materials as well as an app that can be run to help dosing during initiation procedures. At the same time, the investigators will teach obstetricians, nurses and support staff the principles of motivational interviewing. The investigators will set up visits for the CM to meet with a recovery coach trainer provided by the investigators' community partner."
223745576|NCT01210365|DRUG|Diurisa®|Furosemide 40 mg + amiloride chloride 10 mg.The patient will swallow onde tablet per day in whole form on an empty stomach with some liquid during 4 weeks.
223588231|NCT00868036|PROCEDURE|Patch Testing|"Patch testing will be performed with a modified North American Contact Dermatitis Group (NACDG) standard series, cosmetics/preservative, fragrance, and textile series in all patients. Based on patient history, other appropriate allergen series will be added. After two days, patches will be removed and the areas will be inspected for type IV hypersensitivity reactions including papules, edema or vesicles.~Results will be graded and interpreted at a delayed read, 3-4 days after allergens are placed with patch testing."
223588232|NCT06505538|DEVICE|NL-Mapp|Mobile applicaiton
223588233|NCT00924404|DRUG|Xylitol|5% solution for sinus rinse
223588234|NCT00924404|DRUG|Saline|saline for sinus rinse
223588235|NCT02725190|BEHAVIORAL|Sleepless night|Each subject will undergo 28 hours of sleep deprivation.
223588236|NCT02725190|BEHAVIORAL|Normal sleep night|Normal sleep at home before trial.
224183572|NCT04324983|OTHER|Blood sample|"Additional blood sample of about 30 ml that will be drawn for biomarker analyses (2 EDTA = ethylenediaminetetraacetic acid and 1 Cell-search-tubes).The drawn blood for CTC-Analysis and biomarker identification will be promptly processed ac-cording to the established standards at the Institute for Tumor Biology (see below).~The histological analysis of the resected tissue during salvage surgery is carried out according to clinical routine (conventional haematoxylin and eosin stained and PSMA-Immunohistochemistry). Additionally, tissue samples will undergo molecularpathological analysis if this does not affect routine pathological examination."
224183573|NCT02071342|PROCEDURE|angioplasty|patients with acute coronary syndrome and coronary angioplasty with bioresorbable vascular scaffold.
224183574|NCT04030351|OTHER|food - dried fruit|raisins, apricots, figs, and pineapple
224183575|NCT01098435|DRUG|RDC-0313 (ALKS 33)|Capsules for daily oral administration
224183576|NCT01098435|DRUG|Placebo|Capsules containing lactose and no active drug for daily oral administration
224183577|NCT04915937|OTHER|Study Infant Formula|RTF milk-based infant formula with oligosaccharides
224183578|NCT03931629|PROCEDURE|CONVENTIONAL PHACO|Cataract surgery by means of Femtosecond Laser-Assisted Cataract Surgery,
224183579|NCT02655315|DRUG|Deferiprone|15 mg / kg twice daily morning and evening (30mg / kg per day).The treatment lasts nine months.
224183580|NCT02655315|DRUG|Placebo|the placebo twice daily morning and evening. The treatment lasts nine months
224183581|NCT01643109|OTHER|Casting & CIMT|"A standardized CIMT protocol will be administered over a three week period. The first week will consist of wearing a below elbow cast on the non-hemiplegic limb followed by a two week CIMT camp (5 hours per day, 5 days per week) where the child/youth wears a constraint splint on the non-hemiplegic hand. The two week camp will follow a standardized CIMT camp protocol (Hand2Hand developed at HBKRH) that includes activities that focus on unilateral hemiplegic hand activity in the first week and increasing incorporation of bilateral hand activities in the second week. The camp protocol for CIMT is based on camp protocols utilized successfully in other paediatric research studies."
224183582|NCT02539680|PROCEDURE|endoscopy|duodenal biopsies
224183583|NCT00990522|PROCEDURE|debridement|There will be two (2) subject groups in the study. Subjects will be randomized into either the monthly debridement group or the weekly debridement group.
224183584|NCT02957500|DEVICE|Mediclore® (adhesion barrier)|
224183585|NCT04851041|OTHER|Potato|Controlled human intervention trial to evaluate the impact of boiled potato intake as part of a healthy dietary patterns on cardiometabolic health
224183586|NCT04851041|OTHER|Pasta/rice|Since potatoes, white rice and white pasta are all products with a high glycemic index and concomitant relatively steep glucose excursions after intake, this intervention group helps to compare the effect of potato vs another high glucemic index food.
224183587|NCT00079157|BIOLOGICAL|incomplete Freund's adjuvant|
224183588|NCT00079157|BIOLOGICAL|sargramostim|
224183589|NCT00079157|BIOLOGICAL|telomerase: 540-548 peptide vaccine|
224183590|NCT03336164|BEHAVIORAL|Front-of-pack labelling Nutri-Score|Introduction of the Nutri-Score front-of-pack nutrition label on shelf display tags for every food and beverage sold in the university restaurant
224183591|NCT05597592|PROCEDURE|Feasability of a personalised physical rehabilitation program at home|Monitoring of the realization of a personalised physical rehabilitation program at home by patients with neuromuscular and neurodegenrative disease
224183592|NCT05626959|DRUG|NTI164|Oil based. Full-spectrum medicinal cannabis plant extract with less than 0.08% THC.
224183593|NCT00572858|PROCEDURE|Blood test|for cholesterol, glucose and insulin levels and levels of various hormones, including but not limited to estrogen
224183594|NCT00572858|GENETIC|Blood test|Blood test for genetic testing
224183595|NCT00572858|PROCEDURE|Ultrasound of neck arteries|Non-invasive test using ultrasound waves to measure the thickness of the arteries
224183596|NCT00572858|PROCEDURE|Saliva test|Saliva test for cotisol levels
224183597|NCT04517825|DIAGNOSTIC_TEST|Cepheid Xpert HIV-1 Viral Load Assay|Rapid, on-site molecular HIV-1 viral load testing used in accordance with cleared/approved labeling
224183598|NCT05165186|OTHER|Video Intervention Arm|For participants randomized to the video intervention arm, participants will be shown two videos about Advanced Care Planning, and then they will be asked questions regarding the usefulness of the video and their comfort with the video.
224183599|NCT03391427|DRUG|Lidocaine|This group will receive lidocaine infusion
224183600|NCT03391427|DRUG|Ketamine|This group will receive Ketamine infusion
224183601|NCT03391427|DRUG|Lidocaine+ketamine|This group will receive mixture of ketamine and lidocaine infusion
224183602|NCT03391427|DRUG|Saline|This group will receive saline infusion
224183603|NCT00464854|DRUG|Glargine and insulin aspart or lispro|
223492249|NCT06827509|DIAGNOSTIC_TEST|Ultrasound-based flow imaging|Ultrasound-based flow imaging (based on blood speckle tracking) of the carotid artery will be acquired at 6-8 weeks after surgery.
223492250|NCT07024563|DRUG|Ravulizumab|Participants will receive Ravulizumab via intravenous (IV) infusion.
223492251|NCT06692114|DEVICE|Deep Transcranial Magnetic Stimulation, DTMS active|The treatment plan is to perform 2 treatments per day for 20 minutes each time, for a total of 28 treatments. Each treatment stimulates at a frequency of 20 Hz for 2 seconds, with a sequence interval of 20 seconds. Each treatment consists of 50 sequences, for a total of 2000 pulses.
223745577|NCT01210365|DRUG|Lasix ®|One group of patients will receive furosemide 40mg .The patient will swallow the tablet in whole form on an empty stomach with some liquid.
224183604|NCT06343259|PROCEDURE|General Anesthesia|After preoxygenation, intravenous fentanyl (1 μg/kg), propofol (2 mg/kg), and rocuronium (0.6 mg/kg) will be used for anesthesia induction. Intubation will be performed with a 7.0-8.0 sized tube, followed by the initiation of mechanical ventilation (tidal volume: 6-8 ml/kg, respiratory rate: 12 breaths/min). Sevoflurane will be used to maintain anesthesia (0.7-1 MAC), and remifentanil infusion will be administered for analgesia. Postoperatively, tramadol (1 mg/kg) and paracetamol (10 mg/kg) will be administered intravenously. Neuromuscular blockade will be reversed using sugammadex. Patients with an Aldrete Recovery Score ≥9 will be transferred to the post-anesthesia care unit after extubation.
224183605|NCT06343259|PROCEDURE|Spinal Anesthesia|Patients will be positioned laterally with the hip to be operated on the lower side, and skin asepsis will be ensured, followed by sterile draping. A dural puncture will be performed at the L3-4 spinal level using a 22-25 gauge Quincke-tip spinal needle. After the detection of cerebrospinal fluid, 7.5 mg of 0.5% hyperbaric bupivacaine will be slowly injected. Following a 10-minute interval, the sensory block level will be assessed using the pinprick test and modified Bromage scale, aiming for a T10 sensory block. Surgery will commence upon achieving adequate sensory block. Postoperatively, patients will be transferred to the recovery room. Patients failing to attain sufficient sensory block and experiencing pain will undergo transition to general anesthesia, terminating their cases.
224183606|NCT03049839|BEHAVIORAL|Intervention_ S|One year Structured intervention program for members of high-risk group (Subjects with FINDRISC score ≥12 points and impaired glucose tolerance (IGT))
223588237|NCT03831945|BIOLOGICAL|VRC-HIVMAB060-00-AB (VRC01)|VRC01 is a broadly neutralizing human mAb targeted against the HIV-1CD4 binding site. As single intravenous infusion of VRC01(40 mg/kg) plus10-1074 (30mg/kg) or placebo will be administered after the first analytical treatment interruption phase once the subject's plasma viremia is \> or = 200 copies/mL.
223588238|NCT03831945|BIOLOGICAL|10-1074|10-1074 is a recombinant, fully human mAb of the IgG1 lambda isotype that specifically binds to the base of the V3 loop within HIV-1 envelope gp-120. A single intravenous infusion of VRC01 (40 mg/kg) plus 10-1074 (30 mg/kg) or placebo will be administered after the first analytical treatment interruption phase once the subject's plasma viremia is \> or = 200 copies/mL.
223588239|NCT03831945|BIOLOGICAL|Normal Saline Placebo|2 sequential infusions of normal saline placebo in matching volumes to antibody infusions will be administered after the first analytical treatment interruption phase once the subject's plasma viremia is \> or = 200 copies/mL.
223588240|NCT01932775|DEVICE|GlucoTab System|
223588241|NCT06506539|DRUG|Placental Extract|add placental extract gel as a local delivery drug in periodontal pocket
223588242|NCT00111904|DRUG|paclitaxel-loaded polymeric micelle|
223588243|NCT06508879|COMBINATION_PRODUCT|Aquacel Ag Surgical®|Presurgical preparation was identical in both groups and no further intervention in patient treatment was made. See descpription of arms.
223588244|NCT06508879|OTHER|Standard Care (sterile gauze and adhesive tape)|Presurgical preparation was identical in both groups and no further intervention in patient treatment was made. See descpription of arms.
223588245|NCT00369694|DRUG|Terlipressin|2 mg Terlipressin stat, then 1 mg q6h for total of 72 hours
223588246|NCT00369694|DRUG|Terlipressin & then Dummy|2 mg Terlipressin stat then 1 mg q6 hours for 24 hours, then a Dummy of Terlipressin q6 hours for the next 48 hours.
223588247|NCT01462877|DRUG|fenofibrate|Fenofibrate Capsule 200mg qd orally
223588248|NCT06179420|OTHER|total cumulative gonadotrophin usage|total dosage in IU
223588249|NCT02973776|DRUG|LEO 90100 aerosol foam|
223588250|NCT02973776|DRUG|Dermoval®/Dermovate®|
223588251|NCT02973776|DRUG|Diprosone|
223588252|NCT02973776|DRUG|Elocon|
223588253|NCT02973776|DRUG|Locoid|
223588254|NCT02973776|OTHER|LEO 90100 foam vehicle|
224183607|NCT03049839|BEHAVIORAL|Intervention_ I|One year Informative intervention program for members of moderate risk group (People with normotolerant or impaired fasting glucose in the OGTT and a FINDRISC score ≥12 points)
224183608|NCT03049839|BEHAVIORAL|Intervention_ C|One year, Intervention program at Community level. People with a FINDRISC less than 12 points
223588255|NCT00945932|DRUG|GW870086X|Investigational product
223588256|NCT00945932|DRUG|Placebo|Placebo control
223588257|NCT01073007|DRUG|Simvastatin|Simvastatin 40 mgrs daily for three months.
223588258|NCT06276790|PROCEDURE|ultrasound-guided/hysteroscopic curettage|ultrasound-guided/hysteroscopic curettage
223588259|NCT06276790|PROCEDURE|Procedure/Surgery: laparoscopic removal of the pregnancy lesion|laparoscopic removal of the pregnancy lesion
223745578|NCT06537349|DRUG|3% Diquafosol tetrasodium|3% Diquafosol tetrasodium eye drops will be used to assess its usefulness in OK lens related dry eye
224183609|NCT02714621|DEVICE|Magnetic Resonance Image-guided High Intensity Focused Ultrasound (MR-HIFU)|
224183610|NCT04914650|OTHER|Telerehabilitation|Providing multidisciplinary rehabilitation to individuals with spinal cord injury or brain injury using virtual conference methods
223588260|NCT00710385|DRUG|Heroin|Heroin (25 mg)
223588261|NCT00710385|DRUG|Naloxone|.4 mg
223588262|NCT00710385|DRUG|Low Bup Dose|4 and 8 mg
223588263|NCT00710385|DRUG|High Bup Dose|8mg and 16 mg
223588264|NCT00710385|DRUG|Low Bup/Nal Dose|Buprenorphine/Naloxone 4/1 mg, 8/2 mg
223588265|NCT00710385|DRUG|High Bup/Nal Dose|Buprenorphine/Naloxone 8/2 mg, 16/4 mg
223588266|NCT00710385|DRUG|Placebo (PCB)|Placebo control administration
223588267|NCT02976103|DEVICE|Jacki Recovery jacket|An outer jacket that holds surgical drains and allows access for blood draws
223588268|NCT02976103|OTHER|Standard Care Pain medicine/management|Standard care pain medicine and management in hospitals where the study enrolls
223588269|NCT01985360|PROCEDURE|Cardiac Catheterization|Narrowed blood vessels can be opened without surgery using stents or can be bypassed with surgery. To determine which is the best approach for you the doctor needs to look at your blood vessels to see where the narrowings are and how much narrowing there is. This is done by a procedure known as a cardiac catheterization.
223588270|NCT01985360|PROCEDURE|Coronary Artery Bypass Graft Surgery|"Artery narrowing is bypassed during surgery with a healthy artery or vein from another part of the body. This is known as coronary artery bypass grafting, or CABG (said cabbage). The surgery creates new routes around narrowed and blocked heart arteries. This allows more blood flow to the heart."
223745579|NCT06065579|OTHER|Well-Being Promotion Program|the well-being promotion program (Suldo,2016) , an intervention designed to improve subjective well-being. It was postulated that this intervention will eventually assist in managing emotional and behavioural problems among adolescents enrolled in the program.
224183611|NCT03550508|BIOLOGICAL|Anti-RANKL Monoclonal Antibody|JMT103 is recombinant fully human anti-RANKL monoclonal antibody. JMT103 is provided as the injection,120 mg/vial. JMT103 was administered subcutaneously in the upper arm, upper thigh, or abdomen.
224183612|NCT02101866|DRUG|Vapendavir 300 mg tablet|tablet - single dose
224183613|NCT02101866|DRUG|Vapendavir 132 mg capsules|2 capsules - single dose
224183614|NCT05764694|OTHER|bullied children|A questionnaire will be answered by parent to measure the primary outcome of the study, which is Presence, duration, and frequency of Oral habits (Bruxism, Nail biting) in addition to a questionnaire answered by child to measure the secondary outcome which is Prevalence of Bullying and victimization.
224183615|NCT02075580|BEHAVIORAL|psychological support (interactive/cognitive strategies)|"* cognitive/behavioural intervention (6 times starting from hospital admission, in 90 days; for arm of intervention)~* metacognitive techniques (6 times starting from hospital admission, in 90 days; for arm of intervention)~* psychoeducational intervention (6 times starting from hospital admission; for arm of intervention)~* questionnaires: EORTC questionnaires and a written structured interview (3 times: hospital admission,15 days after surgical intervention, 90 days after intervention; in both arms)"
224183616|NCT01461187|OTHER|exercise during pregnancy|supervised aerobic physical exercises twice a week.
224183617|NCT00295152|BEHAVIORAL|community occupational therapy in dementia|
224183618|NCT06510192|BEHAVIORAL|Yuva Sath|The Yuva Sath Intervention comprises 6 one-on-one sessions with peer counselors who will use an intervention manual. The intervention also includes weekly phone text check-ins by peer counselors
224183619|NCT01853319|DRUG|Regorafenib (Stivarga, BAY73- 4506)|160 mg regorafenib per oral every day for 3 weeks of every 4 week cycle (i.e., 3 weeks on, 1 week off)
224183620|NCT05707819|DRUG|Sintilimab (PD-1 Antibody)|Patients will receive 3 cycles of induction chemotherapy with gemcitabine and cisplatin and concurrent cisplatin-radiation plus Sintilimab, and then receive 11 cycles of Sintilimab after intensity-modulated radiotherapy (IMRT). All patients will receive IMRT. Sintilimab will begin on day 1 of induction chemotherapy and continue every 3 weeks for 17 cycles.
224183621|NCT01874288|DRUG|DI-Leu16-IL2|DI-Leu16-IL2 will be administered per dose and schedule specified in the arm.
224183622|NCT01756482|DRUG|GS-5806|GS-5806, powder for oral solution
224183623|NCT01756482|DRUG|Placebo|
224183624|NCT02293200|DEVICE|Standard BLS|basic life support without any feedback device
224183625|NCT02293200|DEVICE|TrueCPR|CPR with feedback device
224183626|NCT00215904|DRUG|D-serine (~2g/day)|Two 6 weeks treatment arms. One arm: adjuvant treatment with D-serine (\~2g/day). Second arm : adjuvant treatment with placebo (\~2g/day).
224183627|NCT05563441|PROCEDURE|laparoscopic surgery|Patients over 70 years old underwent laparoscopic or laparotomic colorectal resection were enrolled.
224183628|NCT03524664|BEHAVIORAL|Tuning In to kids intervention|"The Tuning Into Kids Program involves:~* Meeting in a small group with other caregivers raising children with FASD.~* 8-week program that meets weekly for 2 hours at Mt. Hope Family Center or other community location.~* Learn and practice an approach of responding to children's emotions and behavior."
224183629|NCT04027842|DEVICE|Prewarming|In the operating theater, participants allocated in Prewarming group received 10 min-prewarming, which is cutaneous warming before induction of anesthesia. For prewarming, forced air warming system (WarmTouch WT 6000 Warming Unit, Medtronic, Minneapolis, MN, USA) was used and the warming temperature of the device was set to 45°C.
224183630|NCT04622878|PROCEDURE|thrombectomy and PTA|open femoral access with fogarty catheter then PTA with balloon and possible stenting if needed
223492252|NCT06692114|DEVICE|Deep Transcranial Magnetic Stimulation, DTMS sham|The treatment plan is to perform 2 treatments per day for 20 minutes each time, for a total of 28 treatments. Compared with active treatment, the sham stimulation coil only produced sound and scalp vibration.
223492253|NCT06698796|DRUG|Dazukibart|anti-interferon beta therapy
223588271|NCT01985360|PROCEDURE|Percutaneous Coronary Intervention|Percutaneous coronary intervention may be done as part of the cardiac catheterization procedure. With this procedure a small, hollow, mesh tube (stent) is inserted into the narrowed part of the artery. The stent pushes the plaque against the artery wall, and opens the vessel to allow better blood flow.
224183631|NCT00496145|BEHAVIORAL|Spanish Diabetes Self-Management Program|small-group self management education program
224183632|NCT01602627|DRUG|Hsp90 inhibitor AUY922|Given IV
224183633|NCT01602627|OTHER|pharmacological study|Correlative studies
224183634|NCT01602627|OTHER|laboratory biomarker analysis|Correlative studies
224183635|NCT01675401|OTHER|Weight-loss treatment|A very-low energy diet (Modifast Intensive) for 4-5 weeks providing 2.1 MJ/day in order to reduce body weight. After 4-5 weeks a mixed solid energy-restricted diet up to 4.2 MJ/day with a recommended composition for the following 1-2 weeks. Then, a diet matching their energy requirements to maintain newly achieved body weights (weight-stable conditions) for at least 2 weeks.
224183636|NCT01675401|OTHER|No-weight loss treatment|Maintenance of habitual diet and physical activity for 8 weeks to maintain body weights.
224183637|NCT02830295|OTHER|Basic Body Awareness Therapy|Basic body awareness therapy is a health oriented and person-centred approach with focus on the patient's resources. This is a method in physiotherapy, where we search to promote movement quality in daily life through self-exploration and self-experience.BBAT conceives the person from the biomechanical, physiological, bio-psycho-social and existential aspects, using the movement quality as a witness of the link in between all these perspectives.It can be done individually or in groups, through different daily life movements: lying, sitting, standing, walking, pair movements, use of voice and massages. BBAT has validated and reliable assesment tools, as BARS and BAS-I
224183638|NCT02142673|DEVICE|Filling pressure 80|The hysteroscope filling pressure will be 80mm Hg
224183639|NCT02142673|DEVICE|Filling pressure 60|The hysteroscope filling pressure will be reduced to 50mm Hg
223492254|NCT06160531|DRUG|CC-42344|Anti-influenza A agent
223492255|NCT06160531|DRUG|Placebo|Matching placebo
223588272|NCT01985360|BEHAVIORAL|Lifestyle|Diet, physical activity, smoking cessation
224183640|NCT02142673|DEVICE|Filling pressure 40|The hysteroscope filling pressure will be 40mm Hg
224183641|NCT01915355|DEVICE|Pulsed Dye Laser for the treatment of nail fungus|The purpose of this research is to investigate the use of the Candela V-beam Pulsed Dye Laser for the treatment of onychomycosis, a common nail fungus.
224183642|NCT02683330|BEHAVIORAL|Mindfulness-based intervention (MBI)|MBI consists of 8 sessions and will cover becoming aware of emotions, thoughts and physical sensations, decentering and acceptance. Recordings of the body scan, a sitting meditation and a mindful movement meditation will be provided for daily home practice. Special care will be taken to address safety in the context of PD, and to adapt meditations to the physical limitations of PD.
224183643|NCT00436085|BEHAVIORAL|Cognitive behavioral stress management training|
224183644|NCT04718883|BIOLOGICAL|CD19-targeted Chimeric Antigen Receptor (CAR) T Cells|JWCAR029 will be administered at dose level: 1 x 10\^8 CAR+T cells
224183645|NCT03088345|DRUG|Vasopressin, Arginine|Subjects will be started on a blinded continuous infusion of study drug/placebo in the OR, immediately following the completion of the MUF at 0.3 mU/kg/min. All caregivers will be blinded to the arm assignment. The infusion will run for 20 hours, at which time it will be weaned off at 0.1 mU/hr, over 3 hours.During the active study period, the care team will treat subjects per SOC, using any preferred medication to correct low cardiac output; there is no restriction on using open-label vasopressin during the active study treatment period.
223745580|NCT02448238|OTHER|VSL#3® probiotic|"Other: VSL#3® probiotic VSL#3® DS (Sigma-Tau Pharmaceuticals) is a well characterized water soluble, live (9 × 1011 bacteria/sachet), lyophilized preparation of 8 probiotic bacterium that have been detailed previously. Subjects will take 1 sachet of powder orally daily for 12 weeks. As many Malian homes lack refrigeration, subjects will be issued a special canari, a commonly used earthenware water container also containing sand that works on the principal of trans-evaporation to keep contents at room temperature (\~24°C) even in warmer climates. We have verified this in country. Probiotics will be placed in a sealed plastic bag within a sealed jar in the sand of the canari. At the research site, probiotics will be kept refrigerated (4-8°C) in a study provided refrigerator"
224183646|NCT03088345|DRUG|Placebo|Subjects will be started on a blinded continuous infusion of study drug/placebo in the OR, immediately following the completion of the MUF at 0.3 mU/kg/min. All caregivers will be blinded to the arm assignment. The infusion will run for 20 hours, at which time it will be weaned off at 0.1 mU/hr, over 3 hours.During the active study period, the care team will treat subjects per SOC, using any preferred medication to correct low cardiac output; there is no restriction on using open-label vasopressin during the active study treatment period.
224183647|NCT00382382|OTHER|diffusion tensor imaging (DTI)|Both groups will have a diffusion tensor imaging (DTI) perform.
224183648|NCT00072098|BIOLOGICAL|adenovirus vector|
224183649|NCT00072098|BIOLOGICAL|interleukin-12 gene|
224183650|NCT00132405|DRUG|ALGRX 3268|
224183651|NCT05156697|DIETARY_SUPPLEMENT|Capsinoids + Exercise|60 minutes of aerobic exercise (cycle-ergometer) at FATmax intensity + supplementation with 12 mg of dihydrocapsiate (7 min before starting the aerobic exercise)
224183652|NCT05156697|OTHER|Placebo + Exercise|60 minutes of aerobic exercise (cycle-ergometer) at FATmax intensity + placebo pills (7 min before starting the aerobic exercise)
224183653|NCT01522391|DRUG|DPK-060 1% ointment|DPK-060 1% ointment applied to the skin, two applications per day using approximately 3 mg ointment per cm2
224183654|NCT01522391|DRUG|Placebo for DPK-060 ointment|Placebo for DPK-060 ointment applied to the skin, two applications per day using approximately 3 mg ointment per cm2
224183655|NCT00408031|DRUG|D-cycloserine|D-cycloserine (DCS , Seromycin) is a broad spectrum antibiotic, in use for over thirty years against tuberculosis, that acts as a partial agonist at the NMDAR-associated GLY site.
224183656|NCT04846634|DRUG|Penpulimab+Cisplatin/Carboplatin+Pemetrexed/Paclitaxel/Gemcitabine/Docetaxel|A cycle of treatment is defined as 21 days of once daily treatment.
224183657|NCT04846634|DRUG|Penpulimab+Anlotinib+Cisplatin/Carboplatin+Pemetrexed/Paclitaxel/Gemcitabine/Docetaxel|A cycle of treatment is defined as 21 days of once daily treatment.
224183658|NCT04846634|DRUG|Penpulimab+Anlotinib|A cycle of treatment is defined as 21 days of once daily treatment.
224183659|NCT02250586|BEHAVIORAL|CBT-CSO|Internet-delivered cognitive-behavioral therapy for CSO's of treatment refusing problem gamblers
224183660|NCT00464841|PROCEDURE|Combined spinal epidural|0.7 mL of 0.25% isobaric bupivacaine and 15mcg of fentanyl
224183661|NCT00464841|PROCEDURE|Tsui Test for intrathecal catheter|0.7 mL of 0.25% isobaric bupivacaine and 15mcg of fentanyl
224183662|NCT05178563|PROCEDURE|IPT+PDT|The experimental arm consist of performing IPT in randomly assigning patients to receive local use of photodynamic therapy (PDT).
224183663|NCT05178563|PROCEDURE|IPT+Placebo|IPT+Placebo
224183664|NCT00591786|DRUG|Sugammadex|After induction of anesthesia an intubation dose of a neuromuscular blocking agent (NMBA) was administered IV: either 0.9 mg/kg rocuronium (arms 1-5) or 0.1 mg/kg vecuronium (arms 6-10). Maintenance doses of 0.1-0.2 mg/kg rocuronium IV or 0.02-0.04 mg/kg vecuronium IV could be administered if necessary. At reappearance of T2 the randomized single dose of sugammadex (0.5 to 8.0 mg/kg) IV was administered.
223492256|NCT06141005|DIAGNOSTIC_TEST|Ultrathin bronchoscopy with intratumoral washing|Each subject suspected or diagnosed of lung cancer will undergo bronchoscopic procedure. First, ultrathin bronchoscope is inserted and placed within tumor under radial EBUS, virtual bronchoscopic navigation, and fluoroscopy guidance. Then, intratumoral washing is performed. Subsequently, transbronchial lung biopsy is performed under radial EBUS, virtual bronchoscopic navigation, and fluoroscopy guidance.
223492257|NCT05856331|DRUG|SAR447537|A1PI, Recombinant, Bivalent Fc Fusion Protein
223492258|NCT05856331|DRUG|Zemaira|Alpha1-Proteinase Inhibitor (Human)
223492259|NCT05935410|BEHAVIORAL|DM Social Needs|6-monthly sessions of telephone delivered, manualized education and skills training on diabetes management, and problem solving and resolution of social needs.
223492260|NCT05935410|BEHAVIORAL|Usual Care|Diabetes education materials in accordance with recommendations from the American Diabetes Association (ADA) will be mailed monthly.
223492261|NCT07030452|DEVICE|Laser Acupuncture|Laser acupuncture irradiation was performed using an RJ Laser laserpen with a wavelength of 785 nm and an output power of 50 mW. The laser probe was positioned perpendicularly to the skin surface, using a continuous wave mode with a dose of 4 Joules. The acupuncture points targeted were EXB1 and CV17, as well as BL13 and ST36 on both sides of the body. Each point received irradiation for 1 minute and 20 seconds. During the therapy session, subjects wore a headset playing music and protective glasses. The treatment was administered twice a week for a total of 8 sessions.
223492262|NCT07030452|DEVICE|Sham Laser Acupuncture|Sham laser acupuncture irradiation was conducted using an RJ Laser laserpen with a wavelength of 785 nm and an output power of 50 mW at the acupuncture points EXB1 and CV17, as well as BL13 and ST36 on both sides of the body. However, the laser device was not activated, and no radiation was delivered to the patient. The laser probe was positioned perpendicularly to the skin surface at the same acupuncture points, but without activating the laser. During the session, subjects wore a headset with music and protective glasses, similar to the active treatment group. The sham treatment was administered twice a week for a total of 8 sessions.
224183665|NCT05139550|DEVICE|Smartphone Rehabilitation Application|"Upper Limb Exercise Protocol:~Passive Exercises~ROMs for shoulder, ROMs for elbow, ROMs for wrist,fingers and thumb~Active/Assisted Exercises~bilateral shoulder flexion with both hands interlocked, Elbow pronation and supination, Wrist flexion and extension with the help of unaffected hand, Forearm to box, Extend elbow (side), Hand to box (front)~Functional Activities~Lift can, Lift pencil, Lift paper clip, Stack checkers,Flip cards, Fold towel, drinking water from a glass, lifting a glass of water to a level of 90° shoulder flexion with an extended elbow, moving 5 crystals from the table to a box, wiping the table with a towel with the elbow extended, grasping and releasing a 6 cm in diameter tennis ball, combing their hair, Eating with affected hand, opening and closing jars"
223492263|NCT06703983|OTHER|Low Glycemic index therapy|In intervention arm, patients will receive a low glycemic index diet(LGIT). The LGIT is a modified form of the ketogenic diet that restricts carbohydrate intake to sources with a glycemic index of less than 50. This diet provides approximately 60% of total calories from fat, 30% from protein, and 10% from carbohydrates.In the LGIT arm, there will be 20 participants who will follow a LGIT diet under the care of a Registered Dietitian and a Pediatric Neurologist. After three months, seizure outcomes will be categorized into the following groups: At the end of the study period, seizure outcomes will be analyzed and categorized into four groups: Seizure-free participants. Participants with \>90% seizure reduction. Participants with \>50% seizure reduction. Participants with \<50% seizure reduction (non-responders). Results will be analyzed and compared with Classic Ketogenic diet which serves as the standard dietary therapy for epilepsy.
223588273|NCT01985360|DRUG|Medication|antiplatelet, statin, other lipid lowering, antihypertensive, and anti-ischemic medical therapies
223588274|NCT06334614|DEVICE|iReach|The iReach Device group will take part in playful multisensory motor and spatial activities for one month both at the clinic and at home with the medical device iReach.
223588275|NCT05302622|OTHER|There is no intervention planning|There is no intervention planning
223588276|NCT01492413|BEHAVIORAL|online lifestyle counseling and a fortified diet beverage|The fortified diet beverage contains green tea extract (total catechin 167 mg), soluble dextrin fiber (10 g), and caffeine (100 mg).
223588277|NCT05611814|OTHER|Osteopathic Manipulative Treatment|Targeted anatomical structures are Scalene Muscles (Anterior/Middle/Posterior), Sternocleidomastoid Muscles (SCM), Suboccipital region, Cervical Paraspinal Muscles, Levator Scapulae Muscles, Upper Thoracic Paraspinal Muscles, Upper Trapezius Muscles, Atlanto-occipital (OA), Atlanto-axial (AA), C2-C7 vertebrae, T1-T4 vertebrae, Rib 1 bilaterally. Techniques include Suboccipital Myofascial Release, Soft tissue inhibition, kneading stretching, Facilitated Positional Release, and muscle energy technique.
223588278|NCT05611814|OTHER|Sham treatment|"Targeted anatomical structures are Thoracic Paraspinal Muscles, Lumbar Paraspinal Muscles, Lower Trapezius Muscles, Sacrum, Supraspinatus, T5-T12, and Rib 2-12. Techniques include Soft tissue inhibition, Stretching, Kneading, counterstrain, Facilitated Positional Release, and muscle energy technique.~L1-L5"
223588279|NCT02237482|DEVICE|Trilogy cup|
223588280|NCT02237482|DEVICE|Trabecular metal cup (TM)|
223588281|NCT02237482|DEVICE|ZCA cup|
223588282|NCT05705661|DEVICE|HIGH FREQUENCY CHEST WALL OSCILLATION|The HFCWO device used a triangular wave form which increases the airflow velocity more than other devices. Therefore, clearing sticky airway mucus and alveolar exudates and maintaining airway patency has become currently the most urgent issue in the ventilatory management of patients with severe COVID-19.
223588283|NCT02975752|GENETIC|LC-RT-PCR and NGS|highly sensitive PCR vs. multiplex targeted-resequencing
223588284|NCT02198690|OTHER|Mammography decision aid|
223588285|NCT02198690|OTHER|Home safety pamphlet|
223588286|NCT03294629|DEVICE|SensAwake™ modification|SensAwake™ is a new design based on the research of Doctor Ayappa 5 years ago. The SensAwake™ modification to the Fisher and Paykel automatically titrating positive airway pressure (APAP) device aims to sense whether the patient is awake via respiratory patterns that differentiate between sleep and wake. Upon sensing that the patient is awake the device is able to reduce positive airway pressure PAP aiming to improve patient comfort which should result in more consolidated sleep.
223588287|NCT06107660|DRUG|Liposomal bupivacaine|Patients will receive either liposomal bupivacaine as part of the ESPB .
223588288|NCT06107660|DRUG|Bupivacaine|This is the control group comparator as this is standard of care at the investigator's institution.
223588289|NCT05857904|DEVICE|CT-FFR|CT -FFR(coronary computed tomography angiography drived fractional flow reserve derived) uses routine coronary computed tomography angiography (CTA) images and applies a specific algorithm to extract both anatomical and physiological information of the coronary arteries. By combining these two pieces of information, a fluid dynamics model of the coronary arteries can be established, allowing the calculation of FFR at any location of the coronary arteries.
223588290|NCT05857904|DEVICE|QFR|Quantitative flow ratio (QFR) is a new method for evaluating the functional significance of coronary artery stenosis based on angiography. It can be used for real-time detection of hemodynamic abnormalities in the coronary arteries in the catheterization lab. Unlike traditional methods that require the use of pressure wires and vasodilators such as adenosine, the QFR examination process only requires routine coronary angiography. By reconstructing the three-dimensional structure of the blood vessels and analyzing the hemodynamics, the QFR can evaluate the fractional flow reserve (FFR) without the need for pressure wires and vasodilators.
223588291|NCT05769166|OTHER|thired domain of nordic orofcial test-screen|its a questionnaire which the parent will answer
223588292|NCT06507033|DEVICE|Mobile application and an arm volume measurement device|The intervention consists mainly of two steps; (a) development of a mobile application with an arm volume measurement device (b) evaluation of the effectiveness of the products. Five components will be involved in the development of the mobile application. These components are; (I) exercise, (II) education, (III) coping mechanisms, (IV) arm volume measurement/recording and (V) appointment, exercise and measurement reminder panel. Exercise videos will include stretching exercises for the shoulder and arm as recommended in the guidelines
223588293|NCT06038994|OTHER|No intervention|This is an obvertional study, and there is no intervention.
224183666|NCT05511636|OTHER|Oxygen therapy|This study will be conducted on 180 patients who will be undergoing lung resection (wedge resection, segmentectomy, metastasectomy, lobectomy, or pneumonectomy) surgery at the Cardiothoracic department, Ain Shams University Hospitals; patients are to be extubated intraoperative, and at the ICU we will be comparing HFNC to standard oxygen therapy. The endpoints of the study are to investigate whether high-flow nasal cannula oxygen therapy is superior to conventional oxygen therapy for reducing hypoxemia and postoperative pulmonary complications in extubated patients after lung resection.
224183667|NCT06268366|OTHER|Exercise|Three exercises consisting of stretching and strengthening specific to the movement pattern dysfunction scored by Symmio will be prescribed to the participants. The exercises are standardized and assigned within the Symmio application with video instruction and guidance.
224183668|NCT04793243|DIETARY_SUPPLEMENT|Vitamin D3|Patients received oral supplementation of 10,000 IU daily for fourteen days of vitamin D3
224183669|NCT00182364|DRUG|Fragmin (Dalteparin) LMWH verus Unfractionated Heparin (UFH)|
224183670|NCT00171964|DRUG|Zoledronic acid in combination with therapy|
224183671|NCT03611179|DRUG|Bevacizumab|"The chemotherapy regimen will be Paclitaxel (175 mg/m2 of body surface area) administered intravenously over 3 h, followed by carboplatin (area under the curve 5) over 1 h, with standard antiemetic and hypersensitivity medications.~In patients who develop dose-limiting peripheral neuropathy or hypersensitivity, paclitaxel will be replaced with docetaxel (75 mg/m2), which is administered intravenously over 1 h.~Bevacizumab (15 mg/kg bodyweight) administered intravenously initially over 90 min (if tolerated, this time can be reduced to 60 min, and could be further reduced to a minimum of 30 min)"
224183672|NCT05931575|DRUG|Fasudil hydrochloride|Duration of intervention per patient: 22 days; Application scheme: one dose on day 1, two doses on days 2 - 21, one dose on day 22.
224183673|NCT05931575|DRUG|Placebo|0.05 ml Quinine dihydrochloride solution (from Quinina Labesfal) in screw flask supplemented with 30 ml Glucose 40% solution from miniplasco directly before use
224183674|NCT06289543|DIETARY_SUPPLEMENT|Preoperative carbohydrate solution|water and solution will be given to patients to drink 2 hours before the operation
224183675|NCT00566475|OTHER|telemedicine|School telemedicine intervention involving school personnel, the child with type 1 diabetes and at least 1 parent
224183676|NCT00000952|DRUG|Ritonavir|
224183677|NCT00000952|DRUG|Lamivudine|
224183678|NCT00000952|DRUG|Zidovudine|
224183679|NCT00229242|DRUG|Diuretic-Based or Non-Diuretic Based Hypertension Therapy|
223492264|NCT06703983|OTHER|Classic Ketogenic Diet|"This study includes two interventions: Low Glycemic Index Therapy(LGIT) and Classic Ketogenic diet(CKD) with the CKD used as a comparison.~There will have a total of 40 participants, randomly divided into two groups and each group would have 20 participants.~The randomization process will use the block randomization technique and will be conducted via a website.~Participants will first have a session with a pediatric neurologist and then meet with a Dietitian who will explain the ketogenic diet in detail for them.~The participants in the CKD group will follow a Classic Ketogenic diet where 90% of calories come from fats, 6% from proteins, and 4% from carbohydrates.~Patients receive the diet, and investigators will remain in online contact throughout the 3-month study, with monthly in-person visits for assessment and to ensure proper adherence to the diet.~The primary outcome will be the reduction in seizures, as reported by the participants' parents."
223492265|NCT07033689|DEVICE|Suizenji (an ultrasound-guided HIFU therapy system)|Suizenji (an ultrasound-guided HIFU therapy system)
223492266|NCT07033689|DRUG|Nal-IRI/FL|Standard of care
223492267|NCT07033689|DRUG|mFOLFIRINOX adjuvant chemotherapy|standard of care
223492268|NCT07033689|DRUG|Gem/nab-PTX|standard of care
223492269|NCT07114237|PROCEDURE|Opioid Free Anesthesia|patients will receive opioid free anesthesia and bilateral ultrasound guided transversus abdominus plane block.
223492270|NCT07114237|PROCEDURE|Control group (general anesthesia)|patients will receive conventional general anesthesia
223492271|NCT07043946|DRUG|Budoprutug|Single IV dose of study product on Day 1 and Day 15
223588294|NCT04152213|BEHAVIORAL|Low GI diet|This educational session will cover information on obesity, complications of obesity, the benefit of weight loss, the glycemic index and its associated low GI diet, a food-exchange table including high- to low-GI foods, and self-decision in food choices. The dietary advice will be based on the standard food pyramid for the conventional Chinese diet as promoted by the Hong Kong Department of Health, with an emphasis on the selection of low-GI products. Practical tips will be given such as the selection of low-GI rice and rice products, the impact of cooking methods (including cooking time, cooking conditions, and cooking liquid volume) on rice GI, intervention to reduce the GI of rice, and listing low-GI food options and meal plans.
224183680|NCT02296528|DEVICE|Swallowing Expansion Device|"SED looks like the letter T and has a plate and a post. The plate is like the top part of the T or smooth part of the tack. The plate is attached to the cartilage or flexible connective tissue of the throat. The SED post is like the bottom part of the T with a small ring. The post permanently sticks out from the throat, like a skin piercing. The SED is made out of titanium because this metal is extremely strong and commonly used in medical devices put into the body, such as hip joints or bone plates."
224183681|NCT02288793|OTHER|Survey|Survey about Knowledge and Attitude About Focused Assessment With Sonography in Trauma
224183682|NCT01193361|DRUG|BMS-791325|Tablets, Oral, 75 mg, twice daily, 4-48 weeks depending on response
224183683|NCT01193361|DRUG|BMS-791325|Tablets, Oral, 150 mg, twice daily, 4-48 weeks depending on response
224183684|NCT01193361|DRUG|Placebo|Tablets, Oral, 0 mg, twice daily, 4-48 weeks depending on response
224183685|NCT01193361|DRUG|Peg-interferon alfa-2a|Syringe, Subcutaneous Injection, 180 µg, once weekly, 4-48 weeks depending on response
224183686|NCT01193361|DRUG|Ribavirin|Tablets, Oral, 1000 or 1200 mg based on weight, twice daily, 4-48 weeks depending on response
224183687|NCT00952471|OTHER|Evidence Based Intervention to order set|The order set was altered to include evidence based care items
223492272|NCT06727253|DIETARY_SUPPLEMENT|Glycan|The post-operative CD patients will receive an orally administered glycan.
223492273|NCT06883695|DRUG|SHR-3045 Injection|SHR-3045 injection.
223492274|NCT06883695|DRUG|SHR-3045 Placebo Injection|SHR-3045 placebo injection.
224183688|NCT01663298|PROCEDURE|Dental implant surgery|Surgery involving placement of one dental implant, of either Astra Tech or Straumann system, is performed in all subjects within 2 weeks of screening examination. Implant placement is 1-stage, but can be either on edentulous ridges or in extraction sockets.This is not a randomized treatment arm/group design. The study is observational with regards to the analysis of tissue samples that are collected prior to the routine placement of implants. The implant choice is based upon patient needs and is not related to any outcome.
224183689|NCT03232151|DIAGNOSTIC_TEST|C-Arm Cone Beam Computed Tomography|C-ARM CBCT angiogram and CBCT perfusion imaging using prototype software (SMART-RECON) can rapidly and accurately assess the cerebral blood flow maps in the setting of decreased blood flow to the brain (ischemic cerebrovascular events). This rapid assessment would eliminate the need for the patient to be imaged in another scanner and be subsequently transported again to another room; all anatomic and physiologic imaging would occur in the angiography suite.
224183690|NCT01920061|DRUG|PF-05212384 (gedatolisib)|PF-05212384 weekly intravenous infusions starting at 90 mg/wk as a 3 week cycle
224183691|NCT01920061|DRUG|Docetaxel|Docetaxel intravenous infusions once every 3 weeks starting at 75 mg/m\^2
224183692|NCT01920061|DRUG|Cisplatin|Cisplatin intravenous infusions once every 3 weeks starting at 75 mg/m\^2
224183693|NCT01920061|DRUG|Dacomitinib|Dacomitinib to be taken orally as a continuous once daily regimen at a starting dose of 30 mg
224183694|NCT00554229|DRUG|ZD4054|ZD4054 10 mg oral tablet once daily
224183695|NCT00554229|DRUG|Placebo|Matching placebo oral tablet once daily
224183696|NCT01636674|OTHER|18F-fluordeoxyglucose positron emission tomography/ computed tomography|18F-fluordeoxyglucose positron emission tomography/ computed tomography for preoperative staging and post-operative follow-up
224183697|NCT00788801|DRUG|ABT-614|Baseline PET scan with radiotracer only, PET scan with radiotracer and ABT-614 Low Dose or ABT-614 High Dose
223492275|NCT06883097|BEHAVIORAL|Learn to Quit-HIV (LTQ-H) App|LTQ-H consists of 319 screens divided into: (a) HIV-tailored smoking cessation ACT skills, (b) education about tobacco dependence and treatment (USCPG), and (c) NRT psychoeducation and adherence. Content is gradually presented across 28 modules (14 education and 14 skills) that can be completed in 14 days.
223492276|NCT06883097|BEHAVIORAL|QuitStart|This DTx, QuitGuide was adapted from the National Cancer Institute Smokefree.gov Initiative's QuitGuide's 5 modules have the following intervention components: (a) psychoeducation about the impact of smoking on health, (b) setting up a quit date and a quit plan, (c) selecting reasons for quitting, (d) tracking triggers and smoking habits, and (e) tips for quitting.
223492277|NCT06892314|BIOLOGICAL|Exposure to hyperglycemia (type 2 diabetes)|Exposure to hyperglycemia, in the context of type 2 diabetes, as measured by continuous glucose monitoring
223492278|NCT06743074|OTHER|foot exercise|foot exercise
224183698|NCT05091840|OTHER|oximetry monitoring|monitoring oximetry in both groups using the INVOS™ system 5100C Oximeter
223588295|NCT00894478|PROCEDURE|Diffusion Tensor Imaging (DTI)|"MR and DTI: MRI and DTI will be done using 3.0T Philips MR scanner (Philips Medical Systems, Best, The Netherlands) using an eight channel head coil. DTI and axial 3D T1 will be performed on patients and controls.~1. DTI will be performed using single shot diffusion-weighted echo planar imaging, b=1000s/mm2 and 15 noncollinear directions (TR/TE=10,000/60 ms, slice thickness=2mm, field of view=22cm, matrix=112x112, NEX=2)~2. Axial 3D T1 (TR/TE=4.9/2.3 ms, slice thickness=1 mm, field of view = 24 cm, matrix=220x220, NEX=1) Patients will have additional sequences (axial and coronal T2, proton density and FLAIR) as part of their clinical scan"
224183699|NCT04075240|DRUG|Rivaroxaban 10 MG and acetylsalicylic acid 81 mg|Starting post op, rivaroxaban (5 days) followed by aspirin (9 days for TKA; 30 days for THA)
223492279|NCT06743074|OTHER|hip exercise|hip exercise
223492280|NCT06743074|OTHER|control|control
223492281|NCT07054281|DEVICE|UNITY Vitreoretinal Cataract System (VCS)|UNITY VCS is a commercially approved surgical system that facilitates the management of fluid and gases, as well as removal, grasping, cutting, illumination, and coagulation of ocular materials during eye surgery. In this study, the UNITY VCS posterior segment functionalities will be used to perform posterior segment (i.e., vitreoretinal) ophthalmic surgery.
223492282|NCT07054281|DEVICE|CONSTELLATION Vision System|CONSTELLATION is a commercially approved, multifunctional surgical instrument used during ophthalmic surgery to cut vitreous and tissues, emulsify the lens, illuminate the posterior segment of the eye, and apply diathermy to stop bleeding.
223492283|NCT07054281|PROCEDURE|Vitreoretinal ophthalmic surgery|Ophthalmic surgery performed in the posterior segment of the eye
223745581|NCT05316012|DEVICE|Smart diapers|"Residents receive standard continence care while using the smart diaper (without the alerting system) - fase 1~Diapers are changed as usual, e.g., after morning care, visual soiling, unpleasant odor, saturation, leakage.~Residents receive continence care while using the smart diaper with the alerting system - fase 2"
224183700|NCT04075240|DRUG|acetylsalicylic acid 81 mg|Starting post op, aspirin for 9 days for TKA and 30 days for THA
224183701|NCT01140646|DRUG|S-adenosyl-L-methionine disulfate p-toluene-sulfonate|Given orally
224183702|NCT01140646|OTHER|questionnaire administration|Ancillary studies
224183703|NCT01140646|PROCEDURE|quality-of-life assessment|Ancillary studies
223745582|NCT04779255|DRUG|Procedure (Tumesent anesthesia)|Photodynamic therapy of vertex with a solution of 180 ml of tumescent anesthesia diffused over 1 hour in three different sub-deceasing points.
224183704|NCT03011606|PROCEDURE|Robotic Surgery|Robotic Surgery after Focal Ablation Therapy
224183705|NCT04842942|PROCEDURE|TOETVA|Transoral Endoscopic Thyroidectomy Vestibular Approach
224183706|NCT04022109|DEVICE|Breath sampling for VOC detection|Breath sampling will be performed by using a special sensor device and or GC-MS analysis (by collecting breath samples in adsorbent tubes). Pepsinogen testing will be used in a subgroup to identify serological increased risk for atrophy
224183707|NCT04022109|PROCEDURE|Surgery material collection for VOC headspace analysis|Only for gastric cancer patients undergoing surgery (Group 1)
224183708|NCT04022109|DIAGNOSTIC_TEST|Upper endoscopy|Routine endoscopic evaluation with a standard biopsy work-up according to updated Sydney system. Additional gastric contents for GC-MS and microbiota analysis in a subgroup. Endoscopy will be used only according to the clinical indications (in Group 4 - according to the results of pepsinogen tests)
224183709|NCT04022109|DIAGNOSTIC_TEST|Microbiota testing|Faecal and gastric contents and biopsy samples for microbiota testing
224183710|NCT01314885|DRUG|PF-03715455|20mg, Inhaled, single dose
224183711|NCT01314885|DRUG|PH-797804|30mg, Oral, single dose
224183712|NCT01314885|DRUG|Placebo for PF-03715455|Single dose, inhaled, Placebo for PF-03715455
224183713|NCT01314885|DRUG|Placebo for PH-797804|Single Dose, Oral, Placebo for PH-797804
224183714|NCT04588909|PROCEDURE|Colorectal resections|All patients admitted with colorectal cancer were subjected to various types of colorectal resections
224183715|NCT04974931|DEVICE|PREVENA Incision Management System|Eligible participants, i.e. participants meeting inclusive criteria, will be randomised in equal proportions and divided into two arms. The PREVENA dressings will be applied to the
224183716|NCT00495274|DRUG|Formulation A|Formulation A represents the original formulation. SB-649868 10 mg film coated tablet (3 tablets to reach 30 mg), containing micronized drug substance. Formulation A will be administered in Part A.
224183717|NCT00495274|DRUG|Formulation B|Formulation B will represent SB-649868 10 mg film coated tablet containing micronized drug substance (3 tablets to reach 30 mg), but contains additional surfactant. Formulation B will be administered in Part A.
224183718|NCT00495274|DRUG|Formulation C|Formulation C will represent SB-649868 10 mg lipophilic capsule (3 capsules to reach 30 mg). Formulation C will be administered in Part A.
224183719|NCT00495274|DRUG|Formulation D|Formulation D will represent SB-649868 10 mg film coated tablet (3 tablets to reach 30 mg), containing nanomilled and spray dried powder. Formulation D will be administered in Part A.
223492284|NCT07055113|BEHAVIORAL|Individual-based Virtual Physical Therapy Program|"Twelve-week virtual physical therapy that includes one-on-one visits with a physiotherapist.~Multi-modal Self-management program comprises:~* Education to understand OA and its management: 'Understanding \& Managing OA'; 'Activity \& Exercise'; 'Managing Pain'; 'Healthy Eating'; 'Mental \& Emotional Well-being'; 'General Wellness'.~* Personalized Goal Setting in partnership with therapist to promote patient activation.~* Progressive neuro-muscular exercises of the core and lower extremity, customized to patient capacity with participants encouraged to perform exercises at least 2 times/week between PT sessions to improve strength and function; 2 levels of resistance bands will be provided to progress resistance.~* Physical activity goals using FitBit step count, to increase daily activity as tolerated."
223492285|NCT07055113|BEHAVIORAL|Group-based Virtual Physical Therapy Program|"Twelve-week virtual physical therapy that includes group classes (4-5 participants) with two physiotherapists. In each session, each participant will also have a 10-12 min one-on-one interaction with one of the physiotherapists.~Multi-modal Self-management program comprises:~Education to understand OA and its management: 'Understanding \& Managing OA'; 'Activity \& Exercise'; 'Managing Pain'; 'Healthy Eating'; 'Mental \& Emotional Well-being'; 'General Wellness'.~Personalized Goal Setting in partnership with therapist to promote patient activation.~Progressive neuro-muscular exercises of the core and lower extremity, customized to patient capacity with participants encouraged to perform exercises at least 2 times/week between PT sessions to improve strength and function; 2 levels of resistance bands will be provided to progress resistance.~Physical activity goals using FitBit step count, to increase daily activity as tolerated."
223492286|NCT04251416|DRUG|Sacituzumab Govitecan|Sacituzumab govitecan will be administered at 10 mg/kg weekly as an infusion for 2 consecutive weeks (2 weekly doses plus 1 week without treatment represents a single 3 week cycle). Treatment can be continued without a rest period in the absence of progression of disease or unacceptable toxicity.
223492287|NCT06740721|DEVICE|False Lumen Embolization System, IMPEDE-FX RapidFill|Embolization of the false lumen of an aortic dissection
223492288|NCT06840548|DRUG|[68Ga]Ga-OncoCAIX|Single intravenous bolus administration.
223492289|NCT03157635|DRUG|Crovalimab|Crovalimab will be administered as per schedule described in individual arm.
223492290|NCT03157635|DRUG|Placebo|Placebo will be administered as per schedule described in Part 1 placebo arm.
223492291|NCT07057115|PROCEDURE|vNOTES Salpingectomy Group.|Participants will undergo salpingectomy using the vaginal natural orifice transluminal endoscopic surgery (vNOTES) technique. This minimally invasive procedure is performed transvaginally without abdominal incisions, offering potential benefits such as less postoperative pain, faster recovery, and better cosmetic outcomes.
223492292|NCT07057115|PROCEDURE|Laparoscopic Salpingectomy|Participants will undergo conventional laparoscopic salpingectomy, a minimally invasive surgical technique performed through small abdominal incisions using a laparoscope. This method is the current standard approach for managing ectopic pregnancies.
223492293|NCT07056400|PROCEDURE|First Ejaculate for ICSI|Intervention 1: First Ejaculate for ICSI In this intervention, sperm collected from the first ejaculate will be used in Intracytoplasmic Sperm Injection (ICSI). The sperm will be analyzed for motility, morphology, and concentration before being used in fertilization and embryo culture. This arm will evaluate the quality of sperm obtained from the first ejaculate
223492294|NCT07056400|PROCEDURE|Second Ejaculate for ICSI|In this intervention, sperm collected from the second ejaculate (obtained within 1-2 hours after the first ejaculate) will be used in Intracytoplasmic Sperm Injection (ICSI). The sperm will be analyzed for motility, morphology, and concentration before being used for fertilization and embryo culture. This arm will evaluate the quality of sperm obtained from the second ejaculate and its impact on fertilization rates and embryo development
223492295|NCT03634241|BIOLOGICAL|Pembrolizumab|Given IV
223745583|NCT04779255|DRUG|Control Arm (Paracetamol)|Photodynamic therapy of vertex with 1g of paracetamol intake 1 hour before cold water is applied during the session.
223745584|NCT01139450|DRUG|0417|Topical 0417 test product applied twice daily for 4 weeks
223745585|NCT01139450|DRUG|Vehicle of 0417 test product|Vehicle of 0417 test product applied twice daily for 4 weeks
224183720|NCT00495274|DRUG|Formulation E|Formulation E will represent SB-649868 10 mg capsule (3 capsules to reach 30 mg), containing nanomilled and spray dried powder. Formulation E will be administered in Part A.
224183721|NCT00495274|DRUG|Formulation F|Formulation F will represent SB-649868 15 mg liquid filled capsule (2 capsules to reach 30 mg). Formulation F will be administered in Part A.
224183722|NCT00495274|DRUG|Formulation G|Formulation G will be the selected formulation of SB-649868 30 mg to be assessed in Part B. The formulation will be administered after a standard FDA High-Fat breakfast
224183723|NCT03006276|DRUG|DFN-15 Active|
224183724|NCT03006276|OTHER|DFN-15 Placebo|
224308343|NCT04240392|BEHAVIORAL|Extension for Community Healthcare Outcomes (ECHO)|The Weitzman Institute (WI), a community partner and provider for the ECHO condition, is a research and innovation center focused on improving care for medically underserved and special populations. Since 2013, CHCI/WI has provided education and technical assistance through an established video conference and online learning platforms to over 800 primary care providers and over 200 care team members who treat patients with chronic pain and opioid addiction. WI partners with national experts in pain care, substance abuse disorder, and MAT to create and deliver a robust training program for clinicians across the country through Project ECHO ®. The WI will work with the study team to develop and staff the sessions.
224308344|NCT05093777|OTHER|Program Intensified Habilitation|The program is based on a holistic and family-centered concept, which acknowledges parents as experts on their child's abilities and needs. The program involves both parents and local professionals, and includes goal setting and goal-directed treatment targeted to the needs of the individual child. The program lasts for about one year and contains three in-patient group sessions over 2 weeks. In between the children are receiving individualized home training programs at home and in pre-school/kindergarten. The children train on a daily basis, both during the inpatient sessions and in the home setting.
224308345|NCT05093777|OTHER|Habilitation as usual|"When the participants are not joining the study year containing the intervention program, they will be offered habilitation services as usual administered by the primary health care services in the local community."
224308346|NCT04186923|OTHER|F-SPOKE|This project includes communicative, emotional, and also organizational support with outreach across different sectors and phases (F-SPOKE - family-centered, cross-sector and cross-phase organizational, communicative, and emotional support).
223492296|NCT03634241|OTHER|Quality-of-Life Assessment|Ancillary studies
224183725|NCT04130360|BEHAVIORAL|Problem-solving|The steps of problem-solving are explained to the participants. Then, they are presented two conflictive situations and they are asked to apply the problem-solving steps to find a solution. Once they finish, they are asked to apply the steps in a conflictive situation they have experience in the last month. In the end, they are reminded of the steps and encouraged to practice them in their daily conflicts.
224183726|NCT03264976|DIAGNOSTIC_TEST|hematological examination, ophthalmic examination|Hematological examination includes biochemical examination, routine coagulation test, HbA1c, C reactive protein (CRP)；Ophthalmic examination includes the basic situation and clinical diagnosis of eyes, ETDRS visual acuity chart score, intraocular pressure, OCT examination, OCTA examination, fundus photos, Optos wide angle fundus imaging.
224183727|NCT00384969|DRUG|RAD001 and Sorafenib|RAD001 2.5mg to 10.0mg PO QD Sorafenib 400mg PO BID
224183728|NCT03049891|OTHER|Data abstraction|The investigators will abstract clinical data from down-referral sites and from NHLS to determine whether children made it to their down-referral sites or whether children are in care at a different facility.
224183729|NCT03049891|OTHER|Tracing questionnaire|The investigators will attempt to contact and visit caregivers of children who are determined to be LTF from DNH or from down-referral sites. If located and after providing consent, caregivers will be administered a tracing questionnaire, or a verbal autopsy if their child has died.
224183730|NCT03049891|OTHER|Tier.net|For all children who started ART at DNH between 2004 and 2013, the investigators will abstract data on these children from the electronic medical system in South Africa called Tier.net.
224183731|NCT03348644|DIETARY_SUPPLEMENT|Phosphate tablets.|
224183732|NCT03348644|DIETARY_SUPPLEMENT|High cheese intake.|
223492297|NCT03634241|PROCEDURE|Computed Tomography|Undergo CT
223492298|NCT03634241|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
223588296|NCT00894478|PROCEDURE|Magnetoencephalography|MEG will be performed using a whole-head Omega 151-channel gradiometer system (VSM MedTech, Port Coquitalam, BC, Canada). At least 15 2-minute periods of spontaneous data will be recorded with a sampling rate for data acquisition of 625Hz, a bandpass filter of 10 to 70 Hz and a notch filter of 60 Hz.
223588297|NCT05556213|PROCEDURE|laparoscopic examination|laparoscopic examination for staging of endometriosis
223588298|NCT05556213|DIAGNOSTIC_TEST|Blood sampling|Blood sample to detect endometriosis
224183733|NCT03348644|DIETARY_SUPPLEMENT|High milk intake.|
224183734|NCT00636116|BIOLOGICAL|Crotalinae (pit viper) equine immune F(ab)2|Anavip with Anavip Maintenance Therapy
224183735|NCT00636116|BIOLOGICAL|Crotalinae (pit viper) equine immune F(ab)2|Anavip with Placebo Maintenance Therapy
223492299|NCT07056244|DRUG|Dexmedetomidine|as adjuvant to bupivacaine in caudal epidural block for postoperative analgesia
223492300|NCT07056244|DRUG|Dexamethasone|as adjuvant to bupivacaine in caudal epidural block for postoperative analgesia
223492301|NCT06786533|DRUG|Anti-FLT3 CAR-T cells|Anti-FLT3 CAR-T cells is administered by intravenous infusion following standard lymphodepleting chemotherapy consisting of fludarabine and cyclophosphamide.
223492302|NCT01786265|DRUG|Abiraterone Acetate|Given PO
223492303|NCT01786265|DRUG|Bicalutamide|Given PO
223492304|NCT01786265|DRUG|Degarelix|Given via injection
223492305|NCT01786265|DRUG|Flutamide|Given PO
223492306|NCT01786265|DRUG|Goserelin Acetate|Given via injection
223492307|NCT01786265|DRUG|Leuprolide Acetate|Given via injection
223492308|NCT01786265|DRUG|Nilutamide|Given PO
223588299|NCT02795312|BEHAVIORAL|Smoking Cessation Program|Participants will take part in a 9-week Smoking Cessation Program
223745586|NCT01139450|DRUG|Tacrolimus Ointment 0.03%|Reference product for 0417 test product. Apply twice daily for 4 weeks
224183736|NCT00636116|BIOLOGICAL|Crotalidae Polyvalent Immune Fab, ovine|CroFab with CroFab Maintenance Therapy
224183737|NCT03884868|OTHER|Iconographies to communicate risks|Use of iconographies to communicate the risks of the different possible diagnosis after a positive FIT during the screening program nurse visit.
224183738|NCT02424136|OTHER|Questionnaire|5 minute questionnaire focused on symptoms of allergic disease
224183739|NCT02424136|OTHER|Peanut Skin prick test|Skin prick testing with peanut antigen, according to ASCIA Skin Prick testing manual
224308347|NCT04713475|BIOLOGICAL|PBGM01|AAVhu68 viral vector
224183740|NCT02424136|OTHER|Fraction of exhaled nitric oxide|Measurement of exhaled nitric oxide, according to American Thoracic Society/ European Thoracic Society (ATS/ERS) standardised procedures (Not required for those age less than 6 years).
224183741|NCT02424136|OTHER|Spirometry|Measurement of lung flows/volumes, according to ATS/ERS standardised procedures (Not required for those age less than 6 years).
224183742|NCT02424136|OTHER|Serum Peanut and Ara h2 specific immunoglobulin E|Peanut and Ara h2 specific IgE antibodies
224183743|NCT02424136|OTHER|Collection of blood biomarker|Correlation of blood biomarker levels in patients with successful or unsuccessful peanut food challenge
224183744|NCT02424136|OTHER|Peanut food challenge|Open label peanut challenge conducted according to ASCIA's peanut challenge protocol and PRACTALL consensus report
224183745|NCT04126187|DEVICE|Panoptix|Panoptix trifocal intraocular lens (IOL)
224183746|NCT05359575|BEHAVIORAL|Audio kit|MP3 audio files for each of 6 steps of c-collar application (totaling 1 minute, 19 seconds) and instructional flashcard with seven pictures corresponding to each of the 6 steps of c-collar application
224183747|NCT05359575|BEHAVIORAL|Instructional flashcard (version 1)|Single page with 7 pictures corresponding to each of the 6 steps of cervical collar (c-collar) application.
224183748|NCT05359575|BEHAVIORAL|In-person training|10 minute of an LFR spinal immobilization course (extracted from the current LFR Level 1 trauma course).
224183749|NCT05359575|BEHAVIORAL|Instructional flashcard (version 2)|Single page with 7 pictures corresponding to each of the 6 steps of cervical collar (c-collar) application edited for clarity based on initial pilot feedback.
224183750|NCT00532987|BEHAVIORAL|Questionnaire|Questionnaire form to be completed by patient
224183751|NCT05113849|BIOLOGICAL|IN-B009 (Low-dose)|Two doses, intramuscular injection
224183752|NCT05113849|BIOLOGICAL|IN-B009 (High-dose)|Two doses, intramuscular injection
224183753|NCT05504928|OTHER|School nurse program|School nurse program providing health care through assessment, intervention and follow-up of group A β-hemolytic streptococcal pharyngitis and facilitation of secondary antibiotic prophylaxis for children with latent rheumatic heart disease.
224183754|NCT06025656|DIAGNOSTIC_TEST|Leg Lateral Reach Test|"To conduct the leg reach test, participants began by positioning themselves with their arms hanging at their sides. They were then guided to raise the leg under assessment and extend it across the opposite leg to make contact with a wooden bar, employing trunk rotation in the process. During each trial, participants were consistently motivated to ensure that both shoulders remained in contact with the floor and to stretch their tested leg as far as they could along the length of the wooden bar. If a participant was unable to sustain contact between their foot and the wooden bar for a duration of 5 seconds at the point of maximal reach, or if both shoulders lifted off the floor, that specific trial was considered invalid and not included in the analysis.~Each participant completed three repetitions of this test for both the right and left sides, and the average of their reach distances was subsequently calculated for assessment."
224308348|NCT01523457|DRUG|Folfirinox|"* Oxaliplatin 85 mg/m2 IV infused over two hours, followed by~* Leucovorin 400 mg/m2 IV over two hours~* Irinotecan 135 mg/m2 IV over 90 minutes (concurrent with leucovorin during the last 90 min of the leucovorin infusion)~* 5-FU 300mg/m2 IV bolus, then 2400 mg/m2 continuous IV infusion over 46 hours~FOLFIRINOX is a chemotherapy regimen. It is made up of the following four drugs:~FOL - folinic acid (leucovorin), a vitamin B derivative that modulates/potentiates/reduces the side effects of fluorouracil; F - fluorouracil (5-FU), a pyrimidine analog and antimetabolite which incorporates into the DNA molecule and stops DNA synthesis; IRIN - irinotecan (Camptosar), a topoisomerase inhibitor, which prevents DNA from uncoiling and duplicating; and OX - oxaliplatin (Eloxatin), a platinum-based antineoplastic agent, which inhibits DNA repair and/or DNA synthesis."
224183755|NCT05224856|BIOLOGICAL|CT-P63 and CT-P66 / Placebo|Inhalation
224183756|NCT02795871|BEHAVIORAL|Neuropsychological and cognitive assessment|
224183757|NCT00673140|RADIATION|Far Infrared Radiation (5μm to 20μm wavelength)|Radiation: Far Infrared Radiation (5μm to 20μm wavelength). Far Infrared radiation for 30 to 40 minutes per treatment session.
224308349|NCT04428216|OTHER|Group RIB|In group RIB, RIB block will be performed. Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit.
224308350|NCT03537716|DEVICE|Treatment with High Intensity Focused ElectroMagnetic system|The treatment administration phase will consist of four (4) treatments, delivered twice a week. The applicator will be applied over the abdomen area. Visible contractions will be induced by the device.
224308351|NCT04061031|BEHAVIORAL|Parent-Child Interaction Therapy (PCIT)|A trained clinician teaches the caregiver to deliver a number of behavior modification techniques for use with the child and coaches the caregiver in the delivery of those techniques.
223492309|NCT01786265|DRUG|Prednisone|
223492310|NCT05387642|DRUG|10 mg PRAX-114, 20 mg PRAX-114, and Placebo|Single dose with a washout period between doses
223492311|NCT05387642|DRUG|10 mg PRAX-114 or 20 mg PRAX-114|Once daily oral treatment for 28 days
223745587|NCT00935870|DEVICE|Bioactive glass and/or autogenous bone|No intervention in the current study (10-year follow-up study)
224183758|NCT00673140|RADIATION|Far infrared radiation|Far infrared radiation at a frequency of 5 microns to 20 microns for 30 to 40 minutes per session.
224183759|NCT03349840|DRUG|Insulin Degludec U100|Patients on any basal insulin including insulin glargine will be randomised and converted to basal degludec insulin
224183760|NCT03349840|DRUG|Insulin Glargine|Patients on any basal insulin including insulin glargine will be randomised and either glargine will be continued or will beconverted to basal glargine insulin
224183761|NCT04852484|DRUG|local anesthetic-morphine|Before the operation, 19 mL of 0.5% Ropivacaine + 2 mg of morphine (20 mL in total) will be injected in the paravertebral space. Afterwards, there will be a pump of 500 ml of 0.2 % ropivacaine + 6 mg of morphine connected to the catheter after the end of the surgery, administered continuously at a rate of 10 mL/hr
224183762|NCT04852484|DRUG|local anesthetic-ketamine|Before the operation, 19 mL of 0.5% Ropivacaine + 50 mg of ketamine (20 mL in total) will be injected in the paravertebral space. Afterwards, there will be a pump of 500 ml of 0.2 % ropivacaine + 200 mg of ketamine connected to the catheter after the end of the surgery, administered continuously at a rate of 10 mL/hr
224308352|NCT04061031|BEHAVIORAL|Child-Centered Therapy with Parent Education|A trained clinician delivers non-directive, child-centered treatment techniques with the child while providing education to the parent based on current recommendations from the Department of Health and Human Services' Child Welfare Information Gateway.
224183763|NCT04852484|DRUG|local anesthetic|Before the operation, 19 mL of 0.5% Ropivacaine + 1 mL of normal saline (20 mL in total) will be injected in the paravertebral space. Afterwards, there will be a pump of 500 ml of 0.2 % ropivacaine connected to the catheter after the end of the surgery, administered continuously at a rate of 10 mL/hr
224183764|NCT03245372|PROCEDURE|Standard care|Heart rate 60-100 beats per minute, mean arterial pressure 65 mm Hg, serum lactate 2 mmol/L, oxygen saturation 95 % (90 % during one lung ventilation).
224183765|NCT03245372|PROCEDURE|Goal directed therapy|The hemodynamic algorithm will be based on systolic volume index and fluid challenges. FloTrac sensor (this sensor connects to any existing arterial catheter and provides advanced hemodynamic parameters through pulse contour analysis) and EV1000 clinical platform (clinical platform from Edwards Lifesciences that provides advanced hemodynamic monitoring) will be used to calculate cardiac index and systolic volume index.
223492312|NCT06603779|DEVICE|Ultasound Therapy|a device that transmit ultrasound waves to the participant through direct contact
223492313|NCT06603779|OTHER|Integrated Neuromuscular technique|Integrated Neuromuscular technique is a kind of Manual therapy which include Ischemic Compression, Strain counter-strain and muscle energy technique
223492314|NCT06603779|OTHER|Cervical and Scapular Stabilization exercises|Cervical and Scapular Stabilization exercises are a group of therapeutic exercises.
223492315|NCT06602479|DRUG|MEDI0618|MEDI0618 per protocol
223492316|NCT06602479|DRUG|Placebo|Volume-matched placebo for all arms
223588300|NCT06055660|GENETIC|Immunohistochemical detection of Moesin in Clear cell Renal Cell Carcinoma|Formalin-fixed paraffin-embedded renal cell carcinoma tissue blocks will be sectioned and immunohistochemically stained by anti moesin antibody.
223588301|NCT04881747|DRUG|Lasmiditan|Administered orally.
224183766|NCT06151743|DRUG|three cycles (toripalimab + cetuximab + platinum)|Cetuximab 250 mg/m2 i.v. qw (first loading dose 400 mg/m2) for nine doses; Toripalimab 240 mg/m2 i.v. d1, q21d, three cycles; Cisplatin 25 mg/m2 i.v. d1-3, q21d, three cycles or Carboplatin AUC 5 i.v. d1, q21d, three cycles (patients with cisplatin contraindications or renal impairment after cisplatin use).
224183767|NCT06151743|PROCEDURE|Radical surgery|The attending physician should select the appropriate surgical treatment and try to perform radical laryngeal preservation surgery for patients with tumor retraction after induction therapy. Patients who cannot preserve laryngeal function due to tumor load need to undergo total laryngeal resection. According to the scope of pharyngectomy, the surgical treatments include partial laryngopharyngectomy, total laryngectomy and partial pharyngectomy, total laryngopharyngectomy, and total pharyngo-laryngo-esophagectomy. Cervical lymph node dissection was performed when necessary.
224308353|NCT05210478|DEVICE|Optical coherence tomography (OCT)|Optical coherence tomography (OCT) is a non-invasive imaging test which uses light waves to take cross-section pictures of the retina.
223492317|NCT06842017|DEVICE|Passive Exoskeleton.|The passive exoskeleton is used to assist patients with shoulder musculoskeletal disorders during the performance of activities of daily living (ADLs), such as overhead reaching and lifting. The device helps reduce biomechanical load and muscle strain, providing support for the shoulder joint.
223492318|NCT06842017|PROCEDURE|Shoulder Rehabilitation with Passive Exoskeleton.|The rehabilitation protocol involves the use of a passive exoskeleton during physical tasks to improve shoulder function and reduce pain. Patients perform specific exercises while wearing the exoskeleton, which is tailored to their individual needs.
223492319|NCT06842017|OTHER|Usability Assessment and Patient Satisfaction.|The usability of the passive exoskeleton is evaluated using validated scales, such as the System Usability Scale (SUS), to assess its comfort, effectiveness, and overall satisfaction. The assessment also includes patient feedback on the ease of use and perceived benefits of the device during rehabilitation sessions.
223492320|NCT06346899|OTHER|No intervention|This is a non-interventional study.
223492321|NCT05016596|DIETARY_SUPPLEMENT|turmeric|Turmeric supplement
223492322|NCT05016596|DIETARY_SUPPLEMENT|placebo|Placebo
223492323|NCT05295407|GENETIC|Genetic Assessment|The trial is to observe whether inherited risk, including rare pathogenic mutations (RPMs) in several major genes and SNPs-based genetic risk scores (GRS), is correlated with prostate cancer detection rate from diagnostic prostate biopsy.
223588302|NCT00046553|DRUG|RU-486 (Mifepristone)|
223588303|NCT04829253|BEHAVIORAL|Dialectical Behavior Therapy -3-months|Modification of affect regulation, behavioral regulation, interpersonal functioning and identity functioning through the use of skills training, phone check-ins, crisis management and individual initial assessment.
224308354|NCT06370130|DRUG|Esketamine 0.2mg/kg|"Patients received 0.2 mg/kg of esketamine intravenously for 30 s，after 120 s of propofol and disappearance of the eyelash reflex, a laryngeal mask was inserted.~The test was performed using the sequential method. The initial dose of propofol was 2 mg/kg, which can be easily inserted into the LMA, and the propofol dose ratio of the adjacent patient was 0.9. If there was a positive reaction to the LMA insertion, the gradient was increased for the next patient; otherwise, the gradient was decreased, and the study was terminated after seven crossover inflection points."
223492324|NCT06768320|DRUG|Lomaira 8Mg Tablet|8 mg tablet up to three times a day
223492325|NCT06752213|DEVICE|Vagus nerve Stimulation|Vagus nerve Stimulation
223492326|NCT06752213|OTHER|Manual therapy|Manual therapy
223492327|NCT00632359|DRUG|Lenalidomide|10 mg daily given for 12 months
223492328|NCT07066891|DRUG|CSII in the prediction model group|"1. Everyday insulin dosage decided by AI prediction model.~2. CSII treatment continues for 1 to 2 weeks based on whehter or not the patient is newly diagnosed or with different disease duration."
223492329|NCT07066891|DRUG|CSII in the empirical group|"1. Everyday insulin dosage decided by clinicans' experience.~2. CSII treatment continues for 1 to 2 weeks based on whether or not the patient is newly diagnosed or with different disease duration."
223588304|NCT04829253|BEHAVIORAL|Dialectical Behavior Therapy -6-months|Modification of affect regulation, behavioral regulation, interpersonal functioning and identity functioning through the use of skills training, individual psychotherapy, coaching calls and treatment-team consultation.
223588305|NCT05701891|COMBINATION_PRODUCT|Physiotherapy with integrated Virtual Reality|A 12-week personalised, VR-integrated physiotherapy intervention.
223588306|NCT05701891|OTHER|Physiotherapy (usual care)|A 12-week usual physiotherapy care intervention.
223588307|NCT01629472|BEHAVIORAL|VSLA + Gender dialogue groups|Dialogue groups discussing household discussion making and gender norms facilitated by IRC.
223745588|NCT05324540|OTHER|Cool therapy|Application of cool therapy. A chilled (between 5C and 10C) instrument will be applied to the oblique sinus while the patient is in atrial fibrillation.
224183768|NCT06151743|RADIATION|Radiotherapy or chemoradiotherapy|"1. Using intensity-modulated radiotherapy (IMRT) technology, the dose of radiotherapy is determined according to whether there are adverse prognostic factors in the postoperative pathology, including positive margins, extracapsular invasion of lymph nodes, primary pT3 or T4, N2 lymph node lesions, peripheral nerve invasion, vascular/lymphatic infiltration.~   Primary site: residual GTV or tumor bed dose 60-70Gy: 1.8-2.12 Gy / fraction. Cervical lymph nodes or lymphatic drainage area: 56-70 Gy: 1.7-2.12 Gy / fraction.~2. Postoperative adjuvant concurrent chemotherapy regimen:~Cisplatin 25mg/m2 i.v. d1-3, d22-24 or Carboplatin AUC 5 i.v. d1, d22 (if cisplatin contraindications)."
224183769|NCT03164213|DEVICE|experimental: tDCS|The anode will be placed over the left M1 representation of the hand (C3 of the 10-20 EEG system). Twenty minutes of anodal-tDCS (1mA) will be administered at the beginning of the daily treatment session. Following the stimulation will be 45 minutes of naming therapy.
224183770|NCT03164213|DEVICE|sham tDCS|"The anode will be placed over the left M1 representation of the hand (C3 of the 10-20 EEG system). Twenty minutes of sham-tDCS will be administered at the beginning of the daily treatment session.~During sham-tDCS, the current will be ramped up and remained at 1mA only for 30 s before ramping down, which does not affect neural functions, but assures effective blinding of participants due to the initial tingling sensation on the scalp. Following the sham stimulation will be 45 minutes of naming therapy."
224183771|NCT05231291|OTHER|hand grip strength|Observational study
224183772|NCT04806191|OTHER|Evidence based treatment strategy|Evidence-based clinical examination and treatment plan
224183773|NCT04806191|OTHER|Targeted patient information package|GPs will in cooperation with the patients tailor a information package targeted to the patients needs regarding their clinical shoulder diagnosis and individual implications and needs (Pain, sleep, exercises etc.).
224183774|NCT04806191|OTHER|Treatment as usual (TAU)|Usual care as provided by the GP
223492330|NCT06461754|OTHER|Sonographic evaluation of diaphragm and lung|While the patient in a semi-sitting position (20-40 degree), by ultrasound, the diaphragm thickness was measured in the zone of apposition, on the mid-axillary line among the 8th and 10th intercostal spaces, using a 7-10 MHz linear probe in (M) mode. at the end of expiration and at the end of inspiration by capturing nearly three images during spontaneous patient breathing. The average of three DTI measurements was calculated In lung ultrasound, 2-4 MHz convex ultrasound probe in (B) mode was employed. We implemented a modified LUSm in our investigation, which assessed four lung regions on each side.
223492331|NCT06845553|DRUG|Vutiglabridin|Once-daily oral administration
223492332|NCT06845553|DRUG|Placebo|Once-daily oral administration
223492333|NCT06892847|PROCEDURE|Transcranial Magnetic Stimulation|Participants will receive TMS for treatment measures as determined by referral and presentation.
223492334|NCT06774625|DRUG|LTG-001 High Dose|LTG-001 High Dose
223492335|NCT06774625|DRUG|LTG-001 Mid Dose|LTG-001 Mid Dose
223492336|NCT06774625|DRUG|LTG-001 Low Dose|LTG-001 Low Dose
223492337|NCT06774625|OTHER|Placebo|Placebo
223492338|NCT06774625|DRUG|Suzetrigine|Active comparator - Nav1.8 inhibitor
223492339|NCT07041151|OTHER|At-home Foley Catheter Self-Removal with Passive Void Trial|Participants will remove their foley catheter at home and perform a passive void trial. They will be instructed to drink fluids and attempt to void within a designated time frame. Instructions and support will be provided to ensure safety and follow-up, including clinic contact if voiding is unsuccessful.
223492340|NCT07041151|OTHER|In-Office Foley Catheter Removal and Backfill Void Trial|Participants will return to clinic for removal of their foley catheter and undergo a backfill void trial. Standard protocols for instillation and assessment of urinary retention will be followed.
223588308|NCT00556413|BIOLOGICAL|cetuximab|
224183775|NCT00842829|DRUG|Fentanyl Buccal Tablet (FBT)|FBTs were self-administered by participants via the oral mucosa. During the open-label dose titration period, participants used 1 to 4 tablets of the 100 mcg or 200 mcg strength to individually titrate upwards to an effective dose through the range of available strengths (i.e. 100, 200, 400, 600, or 800 mcg). For the open-label treatment and continuation periods, single dose tablets at the effective dose identified during the titration period were used. The maximum dose allowed per breakthrough pain (BTP) episode was 800 mcg. On any single day, participants were not to use FBT for more than 4 BTP episodes.
224183776|NCT00287976|DRUG|irinotecan hydrochloride|
224183777|NCT04348825|DEVICE|Electroconvulsive therapy|
224183778|NCT01829542|DIETARY_SUPPLEMENT|Freeze-dried blueberry powder dissolved in water|Wild blueberry freeze-dried powder dissolved in water
224183779|NCT01829542|DIETARY_SUPPLEMENT|Control|Macro- and micro-nutrient matched control in water
224183780|NCT04047342|BEHAVIORAL|Welcome email|Email
224183781|NCT04047342|BEHAVIORAL|Loss frame|Email
224183782|NCT06016166|DEVICE|Eye mask|The 3D eye mask with the ability to adjust for different faces and eliminate light
224183783|NCT00784836|DRUG|BG9418 (interferon beta 1-a)|
224183784|NCT02365311|PROCEDURE|transesophageal echocardiography(TEE)|Transesophageal echocardiography examination will be performed TLV in supine and lateral position, 10, 20 and 30 min during OLV in left lateral decubitus position. By using the transesophageal echocardiography, we will evaluate the changes of pulmonary blood flow and cardiac function.
223588309|NCT00556413|DRUG|fluorouracil|
223588310|NCT00556413|DRUG|irinotecan hydrochloride|
223588311|NCT00556413|DRUG|leucovorin calcium|
223588312|NCT00556413|DRUG|oxaliplatin|
223588313|NCT00475215|DRUG|Sugammadex|Sugammadex solution for injection.
223588314|NCT00475215|DRUG|Rocuronium|Rocuronium bromide solution for injection.
223588315|NCT05104541|OTHER|Weight loss|"In addition to standard pharmacological treatment this group would receive diet comprising of 20-25 kcal and 1.2gm protein per kg ideal body weight per day.~The total distribution of the calories would be as 55-60% from carbohydrates, 25% from protein and 20% from fat. The diet would be explained to the patient with the help of individual diet charts."
223588316|NCT04986280|DIAGNOSTIC_TEST|[18F]PSMA-1007|PSMA PET/CT using the intervention.
223588317|NCT04337008|OTHER|blood draw|20 mL blood draw will be performed at J1 et J7
223588318|NCT05471180|OTHER|protective spray film|Skincare will be maintained with 3M Cavilon ® Cleansing Solution and the use of 3M Cavilon ® Protective Spray Film.
223588319|NCT05471180|DEVICE|photobiomodulation therapy|application in 8 points of the affected perineum region, these applications will occur 1 x a day every 24 hours for three days.
223588320|NCT01878669|DRUG|N-acetyl cysteine|
223588321|NCT01878669|DRUG|Saline|
223588322|NCT06941571|OTHER|Irrigation Solution|In this group, the effects of washing burn wounds with different irrigation solutions will be investigated.
223588323|NCT04598269|DRUG|ATI-1777|ATI-1777 topical solution 2.0% w/w
224183785|NCT04426227|OTHER|Gaze training|A training module in gaze training for peripheral nerve blockade
223492341|NCT06772077|DEVICE|Rehabilitation treatment with ATLAS2030|10 sessions of Rehabilitation Treatment with ATLAS2030 with With an evaluation session before the first session and another one after 10 sessions.
223492342|NCT05046080|OTHER|Electronic Health Record Review|Medical records reviewed
223492343|NCT05046080|OTHER|Laboratory Biomarker Analysis|Correlative studies
223492344|NCT07073170|DRUG|LY3549492|Administered orally
223492345|NCT07073170|DRUG|Placebo|Administered orally
224183786|NCT04426227|OTHER|Discovery learning|A phase of discovery learning guided by novice operators themselves
224183787|NCT05188560|OTHER|Action observation therapy|Subject is asked to observe videos with motor contents
224183788|NCT05188560|OTHER|motor imagery|mental simulation of a motor task
224183789|NCT02833727|OTHER|Smoking|Smoking equal or greater than 10 pack/years; never smokers: lifelong history without smoking.
224183790|NCT00660829|DRUG|Placebo|Placebo
224183791|NCT00660829|DRUG|0.15% Azelastine Hydrochloride|0.15% Azelastine Hydrochloride 822 mcg
224183792|NCT03108989|DRUG|Sugammadex|After the end of surgery, sugammadex of 2 mg/kg will be administered to reverse neuromuscular blockade.
224183793|NCT03108989|DRUG|Neostigmine|After the end of surgery, neostigmine will be administered to reverse neuromuscular blockade.
224183794|NCT03576456|DRUG|Alprazolam 0.5 mg|receive alprazolam prior to angio
223492346|NCT06874361|DEVICE|Mi-Helper|The Mi-Helper device is a non-invasive, drug-free, novel therapy that uses a patented process of dry air flow across the nasal turbinates to induce a phase change (evaporation) that extracts energy (thermodynamics) causing local cooling which modulates nerves associated with pain and other symptoms of migraine. The device delivers a controlled pressure and flow of dry room temperature air along with a nebulized saline mist for added comfort and evaporative efficiency.
223492347|NCT06419608|DRUG|BHV-7000|BHV-7000 75 mg taken once daily for 6 weeks
223492348|NCT06419608|DRUG|Placebo|Matching placebo taken once daily for 6 weeks
223492349|NCT04890834|OTHER|Best Practice|Receive standard care
223492350|NCT04890834|OTHER|Exercise Intervention|Participate in yoga sessions
223492351|NCT04890834|OTHER|Questionnaire Administration|Ancillary studies
223492352|NCT06891547|DIETARY_SUPPLEMENT|Spark Placebo Control 5.1|Participants will use their Radicle Spark Placebo Product 5.1 as directed for a period of 6 weeks.
223588324|NCT04598269|DRUG|Vehicle|Vehicle topical solution containing no ATI-1777
223588325|NCT05473286|DRUG|Oral Semaglutide|Patients will be treated with commercially available oral semaglutide according to local label and to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available oral semaglutide has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician based on local label before and independently from the decision to include the patient in this study.
223588326|NCT03436823|OTHER|nurse semi-structured interview|The first session of rTMS is D1. From the first meeting to D14 semi -structured interviews are set up
223588327|NCT03436823|OTHER|Music & Relaxation with eyes closed|The first session of rTMS is D1. From the first meeting to D14 music \& relaxation with eyes closed sessions are set up
223588328|NCT00318331|DRUG|Glutamine|Group A patients will receive 0.5g/kg/day of enteral glutamine daily while they are receiving tube feeds or at the end of 28 days (whichever comes first)
223588329|NCT05910333|OTHER|observation|To compare the effect of the mandibular implant retained OVD using quadrilateral distribution (QD) versus linear distribution (LD) on posterior mandibular ridge resorption (PMandRR), anterior maxillary ridge resorption (AMaxRR), and changes to the crestal bone level around implants after 10 years of function.
223588330|NCT02387489|BEHAVIORAL|Brief in-person motivational intervention|Brief in-person motivational intervention tailored to participants' risk behaviors, delivered by a nurse.
223588331|NCT02387489|BEHAVIORAL|Computerized Brief Intervention|Computer-delivered motivational intervention tailored to participants' risk behaviors.
223588332|NCT00721539|DEVICE|da Vinci Surgical Robot Platform|daVinci Surgical Robot Platform is a surgical device that enhances transoral access to the upper aerodigestive tract through miniaturization of endoscopes and micromanipulators that can be introduced through the mouth.
224183795|NCT03576456|DRUG|Placebo Oral Tablet|receive placebo prior to angio
224183796|NCT05294627|DIAGNOSTIC_TEST|Stockholm3|Stockholm3 test prior to prostate biopsy. Prostate biopsy is preformed irrespective of the Stockholm3 score.
224183797|NCT04041401|OTHER|PICU storybook|Narrative and developmentally appropriate intervention
224183798|NCT00427687|DRUG|AGG-523|
224183799|NCT02127931|DEVICE|Groundskeeper for ADHD group|Groundskeeper, a Video Game Diagnostic Tool for ADHD is administered to probands with ADHD and age, gender matched controls without ADHD.
224183800|NCT02127931|DEVICE|Groundskeeper for control group|Groundskeeper, a Video Game Diagnostic Tool for ADHD is administered to probands with ADHD and age, gender matched controls without ADHD.
224308355|NCT06370130|DRUG|Esketamine 0.3mg/kg|"Patients received 0.3 mg/kg of esketamine intravenously for 30 s，after 120 s of propofol and disappearance of the eyelash reflex, a laryngeal mask was inserted.~The test was performed using the sequential method. The initial dose of propofol was 2 mg/kg, which can be easily inserted into the LMA, and the propofol dose ratio of the adjacent patient was 0.9. If there was a positive reaction to the LMA insertion, the gradient was increased for the next patient; otherwise, the gradient was decreased, and the study was terminated after seven crossover inflection points."
224308356|NCT01025544|BIOLOGICAL|Vaxem Hib (Haemophilus influenzae type b (Hib) vaccine)|Comparator study of two commercially available Haemophilus influenzae type b (Hib) vaccines.
224308357|NCT01025544|BIOLOGICAL|Hiberix (Haemophilus influenzae type b (Hib) vaccine)|Comparator study of two commercially available Haemophilus influenzae type b (Hib) vaccines.
224308358|NCT00721630|DRUG|capecitabine, lapatinib|Capecitabine 2,000mg twice daily for 7 days followed by a 7-day rest in combination with lapatinib 1,250mg orally daily. Cycle length is 28 days (+/- 2 days).Toxicity assessment will occur q2 weeks for the first 4 weeks, then q4 weeks(+/- 2 days). Radiographic response assessment will take place q12 weeks (+/- 1 week). LVEF assessment will be repeated q12 weeks (+/- 1 week).
223492353|NCT06891547|DIETARY_SUPPLEMENT|Spark Active Study Product 5.1 Usage|Participants will use their Radicle Spark Active Study Product 5.1 as directed for a period of 6 weeks.
223492354|NCT06764927|BIOLOGICAL|Cryoprecipitate Intercept Fibrinogen Complex (IFC)|INTERCEPT Fibrinogen Complex is a pathogen-reduced cryoprecipitated fibrinogen complex derived from human plasma. It contains fibrinogen, Factor XIII, and von Willebrand factor to achieve stable clot formation and restore hemostasis1. Recently approved by the US Food and Drug Administration, it is used for the treatment of bleeding associated with fibrinogen deficiency.
223492355|NCT06764927|BIOLOGICAL|Cryoprecipitate Antihemophilic Factor (AHF)|Cryoprecipitate Antihemophilic Factor (AHF), also known as cryo, is a frozen blood product prepared from blood plasma. It is used for fibrinogen supplementation, particularly for hypofibrinogenemia fibrinogen, anemia associated with bleeding or congenital deficiency.
223492356|NCT02905591|DRUG|Radiation Therapy|Conformal radiation administered daily, Monday through Friday Total dose is 60 Gray (Gy) and is delivered in 2 Gy fractions. One fraction is delivered daily for a total of 30 fractions in 30 days
223492357|NCT02905591|DRUG|Paclitaxel|"Administered intravenously (IV) Given the same day as carboplatin, but given before the carboplatin is administered~* the dose is 45 mg/m2 (standard dose)~* Administered weekly~* 6 to 7 weeks of therapy, depending on when radiation starts~* Standardized dose reductions are used"
223492358|NCT02905591|DRUG|Carboplatin|"Administered intravenously (IV) GIven the same day as paclitaxel, immediately after the paclitaxel infusion is done.~* Prescribed at area-under-the-curve (AUC) = 2 using the Cockroft-Gault formula (standard)~* Administered weekly~* 6 to 7 weeks of therapy, depending on when radiation starts~* Standard dose reductions are used"
223492359|NCT02905591|DRUG|Ascorbic Acid|"Administered intravenously~* 75 grams per infusion; each infusion is about 2 hours~* 3 infusion per calendar week~* The infusion is actively running for at least 20 minutes when radiation begins~* May be given while chemotherapy is delayed due to low counts~* Dose reductions are not used~* Given for 6 to 7 weeks, depending on when radiation starts"
223492360|NCT07075835|PROCEDURE|Enhanced external counterpulsation|20 (5 days a week for 4 weeks) one-hour procedures (compression pressure 220-280 mmHg) of enhanced external counterpulsation (device: LUMENAIR EECP, Vasomedical Inc., USA, registration certificate №2018/6915 dated 15.03.2018). The systolic deflation/diastolic inflation sequence of enhanced external counterpulsation leads to systolic unloading and diastolic augmentation, resulting in increased blood flow in a pulsatile manner in coronary artery and in others organ arteries.
223492361|NCT07071428|PROCEDURE|Regular acupuncture|Primary acupoints: Baihui (GV20), Hegu (LI4, bilateral), Fengchi (GB20, bilateral), Taichong (LV3, bilateral), Jinsuo (GV8), and Ganshu (BL18, bilateral). Operational procedures: Preoperative preparation identical to the treatment group; for Baihui (GV20), perform subcutaneous insertion backward (0.5 cun); for Fengchi (GB20), apply oblique insertion toward the nasal tip (0.8 cun); for Hegu (LI4) and Taichong (LV3), use perpendicular insertion (0.5 cun); for back-shu points (Ganshu BL18), rapid needling is applied due to low safety and inconvenience of retaining needles. Needle manipulation for qi activation, cycle, and frequency align with the treatment group. Treatment protocol: 3 sessions per week, 10 sessions constituting one course, totaling 20 sessions.
223492362|NCT07071428|PROCEDURE|the Nourishing the vital energyand Regulating the spirit needle technique|Primary points: Zhongwan (RN12), Xiawan (RN10), Qihai (RN6), Guanyuan (RN4), Taixi (KI3/bilat.), Baihui (GV20), Sishencong (EX-HN1), Shenting (GV24), Benshen (GB13/bilat.). Supplemental points: Blinking: Zanzhu (BL2) + Taiyang (EX-HN5/affected); Mouth twitch: Dicang (ST4) + Jiache (ST6/affected); Neck twitch: Fengchi (GB20) + Shangqu (KI17/affected); Limb twitch: UL-Waiguan (SJ5) + Quchi (LI11/affected), LL-Futu (ST32) + Yanglingquan (GB34/affected); Vocal tics: Tongue Three Needles (HN23). Post-disinfection: Calm child pre-needling. Sequence: Scalp → abdomen → limbs. Techniques: Scalp points-subcutaneous backward 0.5in; Taixi (KI3)-perpendicular 0.5in, mild lift-thrust/twirl to deqi; Abdomen-abdominal acupuncture (linea alba ref.), adipose/fascial layer insertion (no muscle/deqi), 30min retention no manipulation; Rapid withdrawal with pressure. Protocol: 3 sessions/week, 10-session course, 20 sessions total.
223588333|NCT00721539|PROCEDURE|Transoral Robotic Surgery|Eligible patients will undergo transoral treatment of neoplastic disease of the upper aerodigestive tract using the daVinci Surgical Robot Platform as opposed to traditional (TOL - transoral laser; TEC - transoral electrocautery) methods.
223588334|NCT04054999|DRUG|Hydroxocobalamin|Hydroxocobalamin (Cyanokit): 5g IV infusion over 15 minutes
223588335|NCT04054999|DRUG|Methylene Blue|Methylene blue (PROVAYBLUETM), 2 mg/kg IV bolus administered over 15 minutes
223588336|NCT00225784|DRUG|Cetuximab/Gemcitabine|Once weekly Cetuximab, twice weekly Gemcitabine for six weeks
223588337|NCT00225784|PROCEDURE|Radiotherapy|Daily radiotherapy for 28 days
224308359|NCT05475886|DRUG|Hydroxyethyl starch 130/0.4|An initial infusion dose of 500 ml 6% Hydroxyethyl starch (130/0.4) coload simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 100 ml according to the responses of previous patients according to the up-down sequential allocation.
224183801|NCT03272672|OTHER|Össür Unloading Knee Brace|"During the braced walking condition, a valgus unloader brace (Össür Unloader One®, Össur Americas, Orange County, CA) will be fitted by a certified athletic trainer per manufacturer instructions to the dominant limb while the participant is seated with knee flexed to approximately 80°.~The brace will be maximally adjusted to unload the medial compartment."
224183802|NCT04470362|DEVICE|Isokinetic dynamometer|an isokinetic strengthening program for the quadriceps muscles. Twenty-four strengthening session will be performed using an isokinetic device. The exercise program begins with 60% of the mean peak torque, and the patient reaches this intensity by auditory biofeedback. An increasing dose program will be used in the first 5 sessions (1 set to 5 sets), and a dose of 6 sets will be applied from the sixth to twenty-fourth sessions, with the density rising from 60% to 80% of the mean peak torque according to the patient tolerance. Each set consisted of 5 repetitions of concentric (Con/Ecc) contraction in angular velocities of 30°/second and 120°/second for extensors. This program accomplished significant results in increasing the quadriceps power and strength.
224308360|NCT04878848|OTHER|Proprioceptive Neuromuscular Facilitation Exercises|Within the scope of proprioceptive neuromuscular facilitation exercises, rhythmic initiation, repeated stretch and hold-relax techniques in the upper extremity flexion-abduction-external rotation pattern and scapular patterns of anterior elevation, posterior depression, anterior depression and posterior elevation will be applied to the participants. In addition to these exercises, functional activities in the flexion-abduction-external rotation pattern such as hair combing, turning over from side lying, wearing a jacket, reaching on the shelf will be performed.
224308361|NCT04878848|OTHER|Conventional Rehabilitation Group|Active assisted / active range of motion exercises and Wand exercises will be applied to the participants in the conventional rehabilitation group for flexion, abduction and external rotation movements. Exercises will be applied as 5 repetitions in the first 2 weeks and 10 repetitions in the last 2 weeks. Strengthening exercises will be performed with an elastic band and free weights. Strengthening exercises will be started as 2 sets of 5 repetitions and at the end of the second week, it will be applied as 2 sets of 10 repetitions. In addition to these exercises, glenohumeral distraction, glenohumeral posterior and caudal glide will be applied for joint mobilization and it will show progression at the end of the second week.
224308362|NCT04782674|DIAGNOSTIC_TEST|Saliva Testing|Saliva EBV-DNA Detection comparing with PBMC and plasma EBV-DNA
224308363|NCT00000130|DRUG|Intravitreal Antibiotics|
224308364|NCT00000130|PROCEDURE|Initial Pars Plana Vitrectomy|
224308365|NCT03358186|PROCEDURE|surgically treated periprosthetic femur fracture|patients with surgically treated periprosthetic femur fracture
224308366|NCT04322110|OTHER|PronoKal Method|Multidisciplinary program of weight loss based on diet (initially ketogenic diet), physical activity and emotional support
224308367|NCT04322110|OTHER|Low calorie diet|Balanced hypocaloric diet (caloric intake 10% below basal metabolic rate) accompanied by physical exercise.
224308369|NCT05478512|DRUG|VenObi+Ven or VenObi+VenZan|"Patients will receive obinutuzumab 1000mg IV (cycle 1: day 1,8,15; Cycle2-6: day1) + venetoclax 400mg/d (preceded by a ramp-up phase) until cycle 9, day 28.~At cycle9:~* if uMRD = Venetoclax 400 mg/d orally until cycle 13.~* if residual disease in the BM or PB = Venetoclax 400 mg/d + Zanubrutinib 160 mg orally twice daily until cycle 21.~then, at cycle 21:~* if uMRD = stop treatment~* if residual disease in the BM or PB = zanubrutinib 160 mg orally twice daily until disease progression"
224308370|NCT01917981|DEVICE|Personal Heart Rhythm Monitor|
224308371|NCT04776538|BIOLOGICAL|Stem cells|Each participant will be double-blindly randomized to receive either adipose-derived allogeneic stem cells or placebo consisting of CryoStor10 (BiolifeSolutions), the freeze media for ASCs containing 10% Dimethyl sulfoxide (DMSO).
224308372|NCT04776538|BIOLOGICAL|Placebo|Each participant will be double-blindly randomized to receive either adipose-derived allogeneic stem cells or placebo consisting of CryoStor10 (BiolifeSolutions), the freeze media for ASCs containing 10% Dimethyl sulfoxide (DMSO).
224308373|NCT06324110|OTHER|Electronic Health Record Review|Ancillary studies
224308374|NCT06324110|OTHER|Interview|Ancillary studies
224308375|NCT06324110|BEHAVIORAL|Patient Navigation|Receive lung cancer screening care coordination services
224308376|NCT03957070|DEVICE|Liver Incyte|Ultrasound elasticity imaging
224308377|NCT04202003|DRUG|TJ011133|This is an open-label Phase 1/2a clinical study. The study will be conducted in two parts: Part I: Phase 1 dose escalation, TJ011133 is tentatively scheduled to be administered once weekly in 28-day treatment cycles;Part II: Phase 2a study TJ011133 will be administered at a dose of 30 mg/kg once weekly, and AZA will be administered at a dose of 75 mg/m2 by subcutaneous injection for 7 consecutive days from D1 to D7 in 28-day treatment cycles.
224308378|NCT05373004|DRUG|Empagliflozin 25 MG|It is the experimental drug in this trial. this drug has an approved efficacy in delaying kidney deterioration based on the results of (the EMPA-REG OUTCOME) trial. it is also recommended based on the ADA/EASD 2019 consensus, as the SGLT2 inhibitors are recommended in patients with type 2 diabetes in patients with CKD to prevent the progression of CKD. However, the previous trials where always add it to a patient already on an ACE inhibitor (in most cases). In this trial, it will be compared head to head with the gold standard treatment of CKD which is Enalapril 20 mg (ACE inhibitor).
224308379|NCT05373004|DRUG|Enalapril Maleate 20 mg|It is an ACE inhibitor, the active comparator in this trial, and is considered the gold standard for the treatment of diabetic kidney disease.
224308380|NCT02358135|OTHER|Collaborative Connected health, (CCH)|CCH is an asynchronous, secure online platform where patients can upload images of psoriasis lesions and submit assessments. Likewise, practitioners can request and/or initiate dermatology consultations, assume longitudinal care or communicate with patients directly.
223492363|NCT07073950|DRUG|Budesonide/Glycopyrronium/Formoterol Fumarate|BGF will be administered as 2 inhalations via oral route of administration
223492364|NCT07073950|DRUG|Placebo|Matching placebo will be administered as 2 inhalations via oral route of administration
223492365|NCT07073950|DEVICE|Metered dose inhaler|Participants will receive BGF and matching placebo via metered dose inhaler in treatment periods of the study.
223745589|NCT00895258|BEHAVIORAL|Individual placement and support plus cognitive training (IPS-CT)|One IPS plus one CT session each week for 12 weeks
224183803|NCT04656717|OTHER|Measure of the total cost of performing next-generation sequencing (NGS)|Resources consumed were collected for each laboratory using a standardized questionnaire. The production costs were calculated for the overall process and resources consumed for each step were identified.
224183804|NCT00887601|DRUG|MK3134|Single dose 25 mg (5 x 5 mg) MK3134 capsules in one of the four treatment periods.
224183805|NCT00887601|DRUG|Comparator: Placebo|Placebo capsules only in one of the four treatment periods.
224183806|NCT00887601|DRUG|Donepezil|Single dose 5 mg donepezil capsules in two of the four treatment periods.
224183807|NCT00887601|DRUG|MK3134|Single doses of 1 mg, 5 mg, or 25 mg MK3134 capsules in the assigned treatment periods
224183808|NCT01148836|DIETARY_SUPPLEMENT|Coenzyme Q-10 in Pulmonary Hypertension subjects|Take 100mg Co-Q for three times daily
224183809|NCT01148836|DIETARY_SUPPLEMENT|Coenzyme Q-10 in Normal Control subjects|Take 100mg Co-Q for three times daily
224183810|NCT02972294|DRUG|Iron Isomaltoside 1000|Iron Isomaltoside 1000 will be use. Blinding procedure will be put in place for the administration of the treatment
224183811|NCT02972294|DRUG|Tranexamic Acid|Tranexamic acid will be use.
224183812|NCT02972294|DRUG|Placebos iron isomaltoside 1000|placebo of Iron Isomaltoside 1000 correspond to a saline solution. Blinding procedure will be put in place for the administration of this treatment
223492366|NCT06077201|OTHER|HBCR hands-off|Home-based cardiac rehabilitation intervention facilitated by a custom app to deliver education, counseling on healthy living and modification of risk factors, mindfulness, and physical activity guidance.
223492367|NCT06077201|OTHER|HBCR interactive|Home-based cardiac rehabilitation intervention facilitated by a custom app to deliver education, counseling on healthy living and modification of risk factors, mindfulness, and physical activity guidance. Additionally, there are periodic video calls with an exercise physiologist.
223588338|NCT05977166|DEVICE|hyperbaric oxygen therapy|All patients participated in the current study will receive breathing excesses in form of Diaphragmatic breathing exercise and Pursed lip breathing with traditional medical treatment in form of (vitamin D, vitamin C and Anticoagulation drugs ,group A will receive 60 minutes of HBOT(100%oxygen at 2 ATA with five minutes air breaks every twenty minutes daily in morning for three weeks then take period time of rest about 30 minutes before starting breathing exercise.
223588339|NCT05977166|DEVICE|breathing exercise|All patients participated in the current study will receive breathing excesses in form of Diaphragmatic breathing exercise and Pursed lip breathing with traditional medical treatment in form of (vitamin D, vitamin C and Anticoagulation drugs ,group A will receive 60 minutes of HBOT(100%oxygen at 2 ATA with five minutes air breaks every twenty minutes daily in morning for three weeks then take period time of rest about 30 minutes before starting breathing exercise.
223588340|NCT05977166|DRUG|medical treatment|All patients participated in the current study will receive breathing excesses in form of Diaphragmatic breathing exercise and Pursed lip breathing with traditional medical treatment in form of (vitamin D, vitamin C and Anticoagulation drugs ,group A will receive 60 minutes of HBOT(100%oxygen at 2 ATA with five minutes air breaks every twenty minutes daily in morning for three weeks then take period time of rest about 30 minutes before starting breathing exercise.
224183813|NCT02972294|DRUG|Placebos tranexamic acid|placebo of tranexamic acid correspond to a saline solution.
224183814|NCT02374944|PROCEDURE|Hardware removal|Comparison of implant retention vs. scheduled implant removal in skeletally mature patients with previously operatively treated Lisfranc injuries requiring screw and/or plate fixation.
224183815|NCT00333242|DRUG|dextromethorphan|dextromethorphan PO titrated to 480 mg/day x 5 weeks
224183816|NCT04588376|BEHAVIORAL|Peer comparison feedback monthly|Monthly emailed data on performance for guideline-concordant use of antibiotics for three acute upper respiratory tract infections either at the clinician and clinic levels or at the clinic level only
224183817|NCT00460499|DRUG|A IV Insulin drip|These patients will receive 100units of insulin in 100ml of saline intravenously to keep blood glucose between 120-180mg/dl.
224183818|NCT00460499|DRUG|B Low Dose GIK|These patients will receive D5W+80unitsInsulin+40mEqKCL IV to keep blood glucose between 120-180mg/dl
224183819|NCT00460499|DRUG|C High Dose GIK|This group will receive D20W+160units IV insulin to keep blood sugar between 120-180mg/dl
224183820|NCT05524376|OTHER|no intervention|no intervention
224183821|NCT05486715|DRUG|Vit D|Vit D
224183822|NCT04543526|DEVICE|easyEndoTM Universal Linear Cutting Stapler and reloads (Ezisurg Medical)|Investigational device: easyEndoTM Universal Linear Cutting Stapler and reloads (Ezisurg Medical). Device for creating anastomoses during standard and robot-assisted laparoscopic RYGB, manufactured by Ezisurg Medical.
224183823|NCT04663386|DRUG|Budesonide-Formoterol|Dry powder inhaler
224183824|NCT03391063|OTHER|polyamide|metal reinforced polyamide denture base material
224183825|NCT03391063|OTHER|heat cured acrylic resin|conventional heat cured acrylic resin denture base material
224183826|NCT04201652|PROCEDURE|Superficial local anesthetic infiltration|Superficial infiltration of local anesthetic for carpal tunnel release.
224183827|NCT04201652|PROCEDURE|Deep local anesthetic infiltration|Deep and superficial infiltration of local anesthetic for carpal tunnel release.
224183828|NCT02637869|OTHER|Alternative Payment Model|Oregon developed an Alternative Payment Methodology (APM). Under this APM pilot participating CHCs will receive a prospective payment system (PPS) payment as a capitated equivalent in a per-member-per-month rate for all of their Medicaid patients
224183829|NCT00690612|DRUG|candesartan cilexetil|0.05, 0.2, 0.4 mg/kg, oral solution, single daily dose
223492368|NCT06162377|DRUG|Methylnaltrexone|Given by SC (injection)
223492369|NCT07075679|DIAGNOSTIC_TEST|Group with AI iCAD version 3|Reading mammograms by one radiologist with AI support
223492370|NCT07075679|DIAGNOSTIC_TEST|Group without AI|Standard double reading by two radiologists without AI.
223492371|NCT07078786|DRUG|Betamethason Sodium Phosphate|Intramuscular injection of Betamethasone 12mg will be administered on 2 consecutive days
223492372|NCT07078786|DRUG|Dexamethasone|two doses of 12mg of IM Dexamethasone given 24 hours apart
224308381|NCT02358135|OTHER|Control|In-person care is the control group because it is currently considered the standard of care in delivering dermatologic services. The intervention includes regular visits to a physician, and may include such treatments as ointments, steroids or UV therapy at the discretion of a physician. In-person care is the major healthcare-delivery model for managing chronic skin diseases and a realistic, primary option that patients face. The patients in the in-person arm can seek psoriasis care from PCPs or dermatologists, just as they would in the real world.
224308382|NCT04077190|DEVICE|Adipose-derived stem cells|5cc adipose derived stem cells.
224308383|NCT04077190|DEVICE|cortisone injection|cortisone injection
224308384|NCT06172244|OTHER|Applying with whole body vibration device|A total of 5 sets of vibration will be given at 30 Hz, 2 mm amplitude, 1 minute of application and 1 minute of rest.
223588341|NCT05703594|DIAGNOSTIC_TEST|performance based balance test|Performance based balance test; 360° Turn Test, Alternative Step Test, Pen Pickup Test,5 Repetitive Stand Up and Sit Test, 10 Meter Walk Test Lower extremity strengthening exercises; Quadriceps femoris strengthening exercise Hamstring strengthening exercise Gluteus medius muscle strengthening exercise Strengthening exercise for hip adductor muscles Balance exercises; Standing tandem walk Standing side walks Standing cross walks Standing back walking
223588342|NCT05086055|BEHAVIORAL|Kinematic movement analysis|moving arm/leg while registration with electromyography, electroencephalogram, accelerometers, functional near infrared spectroscopy and 3 dimensional video registration of hand, arm, foot and leg movements.
223588343|NCT03829956|DEVICE|Intraoral tongue stimulator (Snoozeal)|Electrical stimulation of the tongue muscle to improve muscle tone to treat primary snoring and mild obstructive sleep apnea.
224183830|NCT03684902|PROCEDURE|emergency midline exploratory laparotomy|Once an adequate level of anesthesia has been reached, the initial incision into the skin may be made. A scalpel is first used to cut into the superficial layers of the skin.with the diathermy The incision is then continued through the subcutaneous fat, the abdominal muscles, and finally, the peritoneum. (Morris J ;2017) For all the patients, closure of midline laparotomy wound was en-mass closure done with non-absorbable No. 1 (Polypropylene) or slowly absorbable (PDS) (double loop). sutures in continuous single layer fashion with 1 cm interval. (Morris J ;2017) The operative details were recorded with special consideration to the operative diagnosis, presence and types of adhesions, duration of surgery, the need for diversion and stoma formation, the use of intraperitoneal drain and the suture material to close the rectus sheath.
224183831|NCT03176979|OTHER|Contrast Agent|Given IV
224308385|NCT03443830|DRUG|Tyzivumab|Tyzivumab Injection, (100 mg/5 mL/Vial), Zika Virus (ZIKV) Monoclonal Antibody (mAb) Infused over 30 minutes
224308386|NCT04608123|OTHER|none (observational study)|DBS
224308387|NCT05726903|DRUG|Depo-subQ Provera Injectable Product|SC Injection at Home
224308388|NCT03700385|DEVICE|IOWA Approach Endocardial Ablation System|Endocardial ablation using the IOWA Approach Endocardial Ablation System
224308389|NCT00658515|DRUG|Dalcetrapib (RO4607381)|600mg po daily
224308390|NCT00658515|DRUG|Evidence-based medical care for Acute Coronary Syndrome|As prescribed
224308391|NCT00658515|DRUG|Placebo|po daily
223492373|NCT03986034|DRUG|During Venetoclax|Patients with CLL/SLL will enroll on the study. Subjects will be treated at the NIH Clinical Center for the duration of the ramp-up phase of venetoclax. After the ramp-up phase is complete, subjects will be transitioned to the care of their local hematologist/oncologist and receive venetoclax monotherapy or in combination with other agent(s) at the discretion of the treating oncologist. Subjects will have the option to follow-up at the NIH every 6 months (from initiation of venetoclax) and at (suspected) progression.
223588344|NCT02126072|DIETARY_SUPPLEMENT|Alcohol|They consume 1gram of alcohol per kilogram of bodyweight in wine (12%)
223588345|NCT02126072|DIETARY_SUPPLEMENT|Water|Volunteers consume the same volume of water as the would in wine according toe the protocol.
223588346|NCT04577079|DEVICE|Evaluation of the need of emergency medical services|The main aim of this study is to validate the use of IPFM in a hospital setting by evaluating the association of IPFM output with 1) clinical urgency and severity of the conditions (using Emergency Severity Index \[ESI\], an international triaging protocol for emergency units, and an assessment by triage nurse); and 2) actual diagnoses made by the hospital doctors. The objective is also to assess the correlation of IPFM output with redirection or referral to various specialties
224183832|NCT03176979|PROCEDURE|Digital Tomosynthesis Mammography|Undergo CESM with DBT
224183833|NCT03176979|PROCEDURE|Dual-Energy Contrast-Enhanced Digital Spectral Mammography|Undergo CESM with DBT
224308392|NCT04086407|DEVICE|Dual-axis inclinometer attached to the subject's forehead with tape|This is the first clinical trial in the industry to address OSA symptom severity and snoring as a direct function of head pitch and roll angle. The head pitch and roll angle can be used with high consistency to predict OSA symptom severity. The apnea equation is based on the gravitational crush forces of the mass of the tongue and nearby tissue on the upper air way and is valid for most OSA sufferers.
224308393|NCT05360485|BEHAVIORAL|MOV'D (Move Often eVery Day)|The MOV'D intervention is a remotely-delivered, peer-supported intervention that delivers exercise snack (2-5 minutes of moderate to vigorous activity) and behavior change technique (BCT) videos to a private social media support group with the goal of interrupting prolonged sitting at work with MVPA minutes.
224308394|NCT05360485|BEHAVIORAL|Fitbit Self-Monitoring|All participants receive a Fitbit and are told to monitor their physical activity for the duration of the study period.
224308395|NCT01555671|DRUG|Meperidine|0.5 ml meperidine injection intravenously injected in randomly selected patients
224308396|NCT01555671|DRUG|Saline|0.5 ml saline solution injection intravenously injected in randomly selected patients
223492374|NCT06192602|BEHAVIORAL|AIM_AT|The program consists of 10 weekly/biweekly, 2-hour sessions (4-months), based on the modified Kemp's model/manual of Adherence therapy and mindfulness-based psychoeducation program developed by the research team.
223588347|NCT00024375|DRUG|DHA-paclitaxel|
223588348|NCT02054793|DRUG|Itraconazole|100 mg 200 mg 300 mg
223588349|NCT02054793|DRUG|Orteronel|300 mg
223588350|NCT01781351|OTHER|Taping the ankle|
223588351|NCT02598128|DEVICE|RELiZORB|Peptamen 1.5 received Period A and Period B (washout only). Impact Peptide 1.5 received Period B (Days 1 and 9 only) and Period C.
223588352|NCT02598128|DEVICE|Placebo|Sham device
224183834|NCT04083287|OTHER|Erector spinae plane block (Group E)|"Patients will be administered A 400 mg dose of ibuprofen every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit.~Postoperative pain assessment will be performed using the VAS score (0 = no pain, 10 = the most severe pain felt). The VAS scores at rest and during cough will be recorded at postoperative 1, 2, 4, 8, 16, 24 and 48 hours. If the VAS score will be ≥ 4, 0.5 mg/ kg meperidine IV will be administered. Sedation level will be assessed with a 4-point sedation scale (0 = awake, eyes open, 1 = sleepy but responding to verbal stimulus, 2 = sleepy and hard to evoke, 3 = sleepy, not aroused by shaking). The first time of the use of rescue analgesic, intraoperative and postoperative opioid consumption, side effects such as nausea, vomiting, itching and block related complications will be recorded."
224183835|NCT04083287|OTHER|Interscalen brachial plexus block (Group I)|"Patients will be administered A 400 mg dose of ibuprofen every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit.~Postoperative pain assessment will be performed using the VAS score (0 = no pain, 10 = the most severe pain felt). The VAS scores at rest and during cough will be recorded at postoperative 1, 2, 4, 8, 16, 24 and 48 hours. If the VAS score will be ≥ 4, 0.5 mg/ kg meperidine IV will be administered. Sedation level will be assessed with a 4-point sedation scale (0 = awake, eyes open, 1 = sleepy but responding to verbal stimulus, 2 = sleepy and hard to evoke, 3 = sleepy, not aroused by shaking). The first time of the use of rescue analgesic, intraoperative and postoperative opioid consumption, side effects such as nausea, vomiting, itching and block related complications will be recorded."
224183836|NCT04668482|DEVICE|SCS is switched off|Spinal cord stimulator is switched off for 12 hours
224183837|NCT04668482|DEVICE|SCS is switched on|Spinal cord stimulator is functioning
224183838|NCT00184730|DRUG|somatropin|
224183839|NCT00402311|PROCEDURE|DOC-PG: integrated multidisciplinary assessment|
224183840|NCT00402311|PROCEDURE|Usual care: assessment by GP or one of the regional services|
224183841|NCT00318032|DRUG|multi-factorial intervention|
224183842|NCT02496715|DRUG|Fluticasone propionate 100 mcg / salmeterol 50 mcg|Brand inhaler containing pMDI containing fluticasone and salmeterol
224183843|NCT02496715|DRUG|Generic fluticasone propionate 100 mcg / salmeterol 50 mcg|Generic inhaler containing pMDI containing fluticasone and salmeterol
224183844|NCT02496715|DRUG|Placebo|Placebo inhaler
224183845|NCT01233076|DEVICE|Nelfilcon A contact lens|Commercially marketed, spherical contact lens for daily wear, daily disposable use
224183846|NCT01233076|DEVICE|Narafilcon B contact lens|Commercially marketed (US), spherical contact lens for daily wear, daily disposable use
224183847|NCT01154530|OTHER|Chlorhexidine|Mouthwash with a 0,2 % chlorhexidine solution for 30 seconds
223492375|NCT06192602|BEHAVIORAL|CPG|Psychoeducation group program (12-18 members/group) consists of 10 two-hour sessions, weekly/biweekly (similarly, 4-month duration) and is guided by a validated group-intervention protocol based on the research team's and McFarlane et al.'s psychoeducation programs for psychosis.
223492376|NCT06192602|BEHAVIORAL|TAU|Routine/Usual care only (control) group participants (and the two treatment groups) will receive usual community mental healthcare services.
223492377|NCT07080567|DRUG|Maraviroc|Maraviroc (300mg) twice daily for 90 days
223492378|NCT07080567|DRUG|Mannitol|Placebo intervention
223492379|NCT06717399|OTHER|Mindfulness meditation|Each mindfulness meditation session will be 30 minutes long, consisting of a 5-minute introduction, 15 minutes of guided mindfulness meditation, and 10 minutes of educational discussion.
224183848|NCT05647746|DEVICE|Compumedics Somfit HSAT device, WatchPAT HSAT device, Compumedics Grael /E-series PSG system|Each intervention is a separate diagnostic device. They will all be operating at the same time
224183849|NCT03648021|DRUG|Paracetamol|"\>50kg: Paracetamol 1 gramme in a solution of 10mg/mL administred intravenously. 1 dose~\>50kg: Paracetamol 15mg/kg/dose in a solution 10mg/mL administred intravenously. 1 dose"
224308397|NCT04932161|PROCEDURE|Titanium Granules|After degranulation of the intrabony defect, titanium particles will be placed in the defect and will be sutured.
223492380|NCT06406010|DRUG|Ropivacaine 5mg/ml 20ml|administered in a pericapsular nerve group (PENG) block
223492381|NCT06406010|DRUG|Saline 0.9%|administered in a pericapsular nerve group (PENG) block
223492382|NCT04506151|BEHAVIORAL|Sleep-Opt|12-week behavioral intervention
224308398|NCT04932161|PROCEDURE|Hydroxyapatite|After degranulation of the intrabony defect, hydroxyapatite will be placed in the defect and will be sutured.
223492383|NCT04506151|BEHAVIORAL|Healthy Living|Healthy Living
223492384|NCT06795451|DEVICE|transcutaneous spinal direct current stimulation|transcutaneous spinal direct current stimulation
223492385|NCT06705478|DRUG|Pramipexole ER|Tablets self-administered orally
223492386|NCT06705478|DRUG|Escitalopram|Tablets self-administered orally
223492387|NCT06751784|DRUG|Fampridine SR|Active study medication consists of 15 tablets of fampridine SR 10 mg formulated for oral administration taken in the morning and evening 12 h apart without food. Tablets must be administered whole.
223492388|NCT06751784|OTHER|Placebo|no active substance
223492389|NCT03408353|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
223492390|NCT03408353|PROCEDURE|Mammography|Undergo standard of care mammography
223492391|NCT03408353|OTHER|Questionnaire Administration|Complete questionnaires
223492392|NCT06682364|BEHAVIORAL|Trauma-informed case management for women who use drugs|This intervention assesses the adequacy in which components of the gender-specific and trauma-informed intervention function together using a sample of 50 community-recruited CJI women who use opioids illicitly.
223492393|NCT06682364|BEHAVIORAL|CRS Only Intervention|This intervention assesses the adequacy in which components of the gender-specific case management by certified peer recovery specialists function together using a sample of 50 community-recruited CJI women who use opioids illicitly.
223492394|NCT01125228|DRUG|Ziodovudine and Alpha Interferon|
223588353|NCT00111540|DRUG|exenatide|subcutaneous injection, 5 mcg, twice a day for 4 weeks (transition period), then 10 mcg twice a day till study termination
223588354|NCT01459913|DRUG|Telaprevir|Tablet
223588355|NCT01459913|DRUG|Pegylated Interferon Alfa-2a|Subcutaneous Injection
224183850|NCT03648021|DRUG|Placebo|100mL of chlorure de sodium 0.9% administred intravenously. 1 dose
224183851|NCT00057642|DRUG|Sertraline|
224183852|NCT00057642|DRUG|Venlafaxine Extended Release|
223492395|NCT07084350|DRUG|lactulose|"1. Two days before the colonoscopy: The patients should respectively take 30mL of lactulose orally on an empty stomach in the morning and at 8:00 PM of the same day, respectively.~2. One Day Before the Colonoscopy: The patients should take 30mL of lactulose orally at 7:00 PM.~3. On the Day of the Colonoscopy:~For Morning Appointments:The patients should take 30mL of lactulose orally at 2:00 AM.~For Afternoon Appointments:The patients should take 30mL of lactulose orally at 7:00 AM."
223492396|NCT07084350|DRUG|PEG (solution given 4 L)|"1. One Day Before the Colonoscopy: The patients should take 2000mL of PEG solution at 8:00 PM, and drink the entire solution within 2 hours.~2. On the Day of the Colonoscopy:~For Morning Appointments: The patients should take 2000mL of PEG solution at 3:00 AM and drink the entire solution within 2 hours.~For Afternoon Appointments: The patients should take 2000mL of PEG solution at 7:00 AM and drink the entire solution within 2 hours."
223492397|NCT07083232|DIETARY_SUPPLEMENT|standard normal diet|Group I: formed of normal animals. They were allowed standard normal diet and water. They received no drugs
223492398|NCT07083232|DRUG|low dose Streptozotocin|Non-treated diabetic rats; diabetes was induced by administration of 20% fructose solution in drinking water for 2 weeks, then intra peritoneal injection of a low dose STZ (40 mg/kg b.w.), was done
223492399|NCT07083232|DRUG|Sitagliptin (Novartis, USA)|Sitagliptin treated diabetic group sitagliptin was administered by gastric gavage in a dose 10mg/ kg /day for 4 weeks
223492400|NCT07083232|DRUG|Pioglitazone hydrochloride (Unipharma., Egypt)|Pioglitazone treated diabetic group (G4); Pioglitazone was administered by gastric gavage in a dose 10 mg/ kg /day for 4 weeks
223492401|NCT07083232|DRUG|Dapagliflozine hemihydrate (Janssen, USA)|Dapagliflozine treated diabetic group (G5); Dapagliflozine was administered by gastric gavage in a dose 1mg/ kg /day for 4 weeks
223492402|NCT06646406|BEHAVIORAL|Patient letter and clinician communication|Single mailing to patients from practice with a reminder that the influenza and COVID-19 vaccines are due, and monthly emailing to the patients' clinicians with information about how to make a strong recommendation for those vaccines
223492403|NCT07084142|OTHER|Online, patient-facing decision-making aid (app) with personalized risk information.|"The online, patient-facing decision-making aid will have the following features:~1. Clinical Data Input,~2. Introduction via Animated Video,~3. Common Questions,~4. Check-In Quiz,~5. Risk and Values Exploration based on patient specific information,~6. Wrap-Up,~7. Patient-Physician Worksheet,~These steps will be completed by the patient in advance of a provider visit where a shared-decision making process will decide whether an ICD is an appropriate sudden cardiac death-prevention strategy to pursue."
223588356|NCT01459913|DRUG|Ribavirin|Tablet
224183853|NCT05005715|DRUG|Dexmedetomidine|Patients were randomly assigned to the dexmedetomidine or control group. Dexmedetomidine group received intravenous dexmedetomidine and control group received intravenous normal saline during surgery.
224183854|NCT05005715|DRUG|normal saline|Patients were randomly assigned to the dexmedetomidine or control group. Dexmedetomidine group received intravenous dexmedetomidine and control group received intravenous normal saline during surgery.
224183855|NCT02620228|DEVICE|BIP Biopsy System|BIP Biopsy system is essentially similar as traditional biopsy systems but it enables real-time bioimpedance measurement from the tip of the biopsy needle.
224183856|NCT03948061|OTHER|Cherry juice|FruitSmart® Cherry Concentrate: Dark Sweet Cherry Juice Concentrate produced from dark sweet cherries to retain the characteristic color and flavor of the whole fruit.
224183857|NCT03948061|OTHER|Placebo beverage|Cherry flavored placebo beverage prepared from commercially available cherry syrup with food coloring and thickener to match the color and viscosity of the cherry concentrate.
224183858|NCT02723461|DRUG|Pulsatile Oxytocin|Using a programmable syringe pump, oxytocin will be administered for 10 seconds every 6 minutes and the dose (2 mU/pulse) doubled every 30 minutes until uterine contractions will be established (3-4 in 10 minutes).
223492404|NCT07084142|DEVICE|Implantable Cardioverter Defibrillator (ICD)|Some participants, in their course of medical care unrelated to the study intervention, will undergo implantation of an ICD.
223588357|NCT00499408|DIETARY_SUPPLEMENT|Vitamin D|Patients will receive oral supplementation of 2,000 IU per day of vitamin D (cholecalciferol)
223588358|NCT00499408|DIETARY_SUPPLEMENT|soy|Patients will receive oral supplementation of soy (160 mg per day soy isoflavones).
223588359|NCT05749952|DEVICE|Symphonie Aqua Digital System|We will digitally capture (via computer) the shape of your limb, which will create a digital file (computer file) of what the internal shape of your socket should be. This file will then be used with a computer software program to optimize the fit of your prosthesis. This image will be used to create a check socket (temporary socket) to confirm a correct anatomical and comfortable socket. Then the check socket (temporary socket) will be used to create a laminated final socket for home use and research outcomes. The check socket is temporarily used; whereas, the final socket is for long-term use.
224183859|NCT02723461|DRUG|Continuous Oxytocin|Oxytocin will be administered at starting dose (2 mU/min) in a continuous manner doubled every 30 minutes until uterine contractions will be established (3-4 in 10 minutes).
224183860|NCT04085354|DRUG|Multi-Vitamin Tablets|The distribution of the patients among the four groups was based on randomized coded cards, so the patients were unaware of the type of the drugs used. Group 1 was given placebo in form oral multivitamin tablet 1 h before intercourse.
224183861|NCT04085354|DRUG|Dapoxetine|The distribution of the patients among the four groups was based on randomized coded cards, so the patients were unaware of the type of the drugs used. Group 2 was given on-demand 30 mg dapoxetine 1-2 h before intercourse.
224183862|NCT04085354|DRUG|Dapoxetine and folic acid.|The distribution of the patients among the four groups was based on randomized coded cards, so the patients were unaware of the type of the drugs used. Group 3 was given on-demand 30 mg dapoxetine 1-2 h before intercourse and daily oral supplementation of 0.5 mg folic acid.
224183863|NCT04085354|DRUG|Dapoxetine and vitamin B12|The distribution of the patients among the four groups was based on randomized coded cards, so the patients were unaware of the type of the drugs used. Group 1 was given placebo in form oral multivitamin tablet 1 h before intercourse. Group 4 was given on-demand 30 mg dapoxetine 1-2 h before intercourse and daily oral supplementation of 0.5 mg vitamin B12
224183864|NCT00001426|DRUG|Cyclophosphamide|
224183865|NCT00001426|DRUG|Paclitaxel|
224308399|NCT00372411|DEVICE|Robot-Assisted Therapy - MIT-MANUS System|The MIT-MANUS robot consists of four modules to train the entire upper limb: module A: shoulder-elbow; module B: anti-gravity; module C: wrist, and module D: hand-unit. Training will be given for 12 weeks and is divided into 4 consecutive blocks, with 9 training sessions per block.
223492405|NCT07084142|OTHER|Online, patient-facing decision-making app without personalized risk information.|The online, patient-facing decision-making aid will have the following features: 1) Clinical Data Input, 2) Introduction via Animated Video, 3) Common Questions, 4) Check-In Quiz, 5) Generic Risk and Values Exploration without patient specific information, 6) Wrap-Up, 7) Patient-Physician Worksheet, These steps will be completed by the patient in advance of a provider visit where a shared-decision making process will decide whether an ICD is an appropriate sudden cardiac death-prevention strategy to pursue.
223492406|NCT07084285|DRUG|Dexamethasone|A single 4mg (1mL) dexamethasone injection via the posterior intra-articular route, under CT guidance
223492407|NCT07084285|OTHER|Isotonic saline solution|1 mL isotonic saline solution, injectable, for a single posterior intra-articular injection, under CT guidance.
223492408|NCT07116733|DRUG|Desﬂurane group|"After routine induction, maintain anesthesia with inhaled desflurane , adjusting concentration as needed to sustain 0.5-2 MAC . To maximize the cardioprotective effects of inhaled anesthetics, adhere to this intraoperative strategy:~Maintain ≥1 MAC continuous desflurane for ≥30 minutes ; For on-pump CABG , discontinue desflurane 15 minutes before initiating cardiopulmonary bypass (CPB) ;~If intraoperative desflurane cessation is required, implement a wash-in/wash-out strategy (recommended but non-mandatory):~Perform 3 alternating cycles of:~Wash-in : ≥10 minutes of desflurane at ≥0.5 MAC, Wash-out : ≥10 minutes of complete cessation of inhaled anesthetics. Propofol is strictly prohibited for anesthesia maintenance throughout the procedure , except during CPB."
223492409|NCT07116733|DRUG|Propofol group|Administer total intravenous anesthesia (TIVA) using propofol infusion at 3-8 mg/kg/h . No inhaled anesthetics are permitted for maintenance. This may be delivered via:target-controlled infusion (TCI) systems, or manual adjustment of intravenous infusion rates.
223492410|NCT07120464|OTHER|Observation Only|All participants will receive post-exposure rabies vaccination using either the Zagreb or Essen regimen, in accordance with national immunization guidelines.
223492411|NCT07120022|OTHER|Self-efficacy training|The primary goal of this study is to determine whether self-efficacy training can increase the probability of taking cold showers regularly over a three-month period.
223492412|NCT07119996|DRUG|Tislelizumab, Cisplatin, Gemcitabine and Vitamin B3|"1. Tislelizumab: 200mg, 1x time at d1 each cycle~2. Gemcitabine: 1000mg/ m2, in d1, d8 each cycle~3. Cisplatin: 70 mg/m2, in d2 each cycle Tislelizumab maintenance therapy: after chemoimmunotherapy, 200mg, q3W.~4. Vitamin B3 tablet(also known as nicotinic acid tablet) supplementation daily(300mg QD or 500mg QD) after antibiotic treatment."
223588360|NCT05749952|DEVICE|Symphonie Aqua System (Non-Digital)|A non-digital weight-bearing socket will be used to create the check socket (temporary socket), which will be used to create a laminated final socket for home use and research outcomes. The check socket is temporarily used; whereas, the final socket is for long-term use.
223588361|NCT02177513|DRUG|Placebo + Placebo|Participants will consume a brownie containing the equivalent of one placebo (0.001% THC) cigarette followed by smoking or inhaling (after vaporization) the equivalent of one placebo (0.001% THC) cigarette.
223588362|NCT02177513|DRUG|Oral Cannabis + Placebo|Participants will consume a brownie containing the equivalent of one active (6.9% THC) cannabis cigarette followed by either smoking or inhaling (after vaporization) the equivalent of one placebo (0.001% THC) cigarette.
223588363|NCT02177513|DRUG|Placebo + Inhaled Cannabis|Participants will consume a brownie containing the equivalent of one placebo (0.001% THC) cigarette
223588364|NCT02177513|DRUG|Placebo + Smoked Cannabis|Participants will consume a brownie containing the equivalent of one placebo (0.001% THC) cigarette followed by smoking the equivalent of one active (6.9% THC) cigarette.
223588365|NCT02177513|DRUG|6.9% cannabis oral|Participants will consume a brownie containing the equivalent of one active (6.91% THC) cannabis cigarette.
224183866|NCT00001426|DRUG|Cisplatin|
224183867|NCT00001426|DRUG|G-CSF|
224183868|NCT02127866|DRUG|CHF 5259 plus Foster 100/6 µg|Comparison of different doses of CHF 5259 (on top of Foster 100 /6 µg) versus Foster 100/6 µg over a treatment period of 6 weeks. Each subject will be allocated to 3 ouf of the 4 possible treatments performed in sequence during a cross over design (incomplete block)
224183869|NCT02127866|DRUG|Foster 100/6 µg|"Active comparator~Comparison of different doses of CHF 5259 (on top of Foster 100 /6 µg) versus Foster 100/6 µg over a treatment period of 6 weeks. Each subject will be allocated to 3 ouf of the 4 possible treatments performed in sequence during a cross over design (incomplete block)"
224183870|NCT06335225|BEHAVIORAL|Precise nutritional intervention|Diabetic precision nutrition prescription based on the results of nutrigenomics.
224183871|NCT06335225|BEHAVIORAL|Conventional nutritional intervention|Conventional diabetes nutrition prescription.
223588366|NCT01804569|OTHER|moxibustion|modernly developed moxibustion treatment device with safe cover on top of it.
224183872|NCT06048601|DIAGNOSTIC_TEST|18F-florbetaben PET/CT|18F-florbetaben positron emission tomography/computed tomography
224183873|NCT05119738|BIOLOGICAL|Three doses of BNT162b2 (observational)|BNT162b2 (COVID 19 mRNA vaccine)
224183874|NCT05119738|BIOLOGICAL|Two doses of Coronavac and one dose BNT162b2 (observational)|BNT162b2 (COVID 19 mRNA vaccine) Coronavac (COVID 19 inactive vaccine)
224183875|NCT00158002|DRUG|Topiramate|
224183876|NCT06231849|DIAGNOSTIC_TEST|stool analysis|stool analysis to determine number of gut microbiota in subjects with opioid use and its effect on its intoxication.
224308400|NCT00372411|OTHER|Intensive Comparison Therapy|The intensive comparison therapy protocol being used in CSP#558 was developed and field-tested at the Burke Rehabilitation Hospital. It exposes the patient to the identical number of treatments, time, and intensity that robot treated patients will receive (12 weeks, 3 times per week). Therapy sessions can be conducted on back-to-back days if needed and on more than 3 days a week (with approval from the Study Chairman) over a treatment period of up to 14 weeks in order to complete the 36 treatment sessions. During each 1-hour session, subjects participate in therapy in four successive stages: 1) warm-up and assisted stretching; 2) active arm treatments; 3) goal-directed planar reaching, and 4) functionally based Neurodevelopment Techniques (NDT)/Bobath arm training (Bobath, 1979).
224308401|NCT00372411|OTHER|Usual Care|The usual chronic stroke care as delivered at each participating medical center
223492413|NCT07121335|RADIATION|Stereotactic body radiotherapy (SBRT)|Stereotactic body radiotherapy (SABR) using photon or proton beams will be delivered per standard practice (1-5 fractions).
223492414|NCT07119658|BEHAVIORAL|Composite intervention to address MetS|"The composite intervention includes six components: 1. All patients will be provided a Fitbit Charge device at ED discharge with instructions to wear on their wrist for study duration. 2. Participants in the intervention group will first watch a brief (\~5 minute) educational video outlining the adverse effects of MetS and the benefit of walking, via iPad tablet. 3. Participants in the intervention group will also be given accompanying written exercise prescription encouraging them to walk 150 minutes per week. 4. Reminder texts encouraging continued walking behavior (i.e. Remember to get in your steps!) will be sent to the intervention group, at approximate 2-3x/week intervals for the 3-month follow-up period. 5. The intervention group will also be provided written resources for healthy eating practices upon ED discharge. 6. All intervention group participants will receive referrals into primary care clinic and the Eskenazi Health Healthy Me Program for follow-up."
223492415|NCT07121439|DRUG|a combination serum containing Melasyl™, 10% Niacinamide, Hyaluronic Acid, and HEPES|Subjects were randomized to receive a combination serum The combination serum contained Melasyl™, 10% Niacinamide, Hyaluronic Acid, and HEPES. applied twice daily, following QS-Nd:YAG 1064 nm low-fluence laser treatment. Clinical evaluations were conducted at baseline and at Weeks 1, 2, and 4 post-laser to assess pigmentation improvement, erythema, and overall skin condition.
223492416|NCT07121439|DRUG|2% hydroquinone cream|Subjects were randomized to received 2% hydroquinone cream, applied once daily at night, following QS-Nd:YAG 1064 nm low-fluence laser treatment. Clinical evaluations were conducted at baseline and at Weeks 1, 2, and 4 post-laser to assess pigmentation improvement, erythema, and overall skin condition.
223492417|NCT07115134|DEVICE|Bearables Gastrostomy Tube Dressing|"The gastrostomy tube dressing in its current design is composed of two parts, both of which are external to the patient: one part is rigid and holds the gastrostomy at a fixed position, this is a 3D printed design that is produced here. The second part is a 3 x 3 flexible, cushioned, biocompatible adhesive bandage designed to fit around the skin opening (Silicone Foam Dressing, NH NeuHeils, USA). The design is subject to minor changes including the number of parts and location with the structure of the padding and securement but will continue to be designed with comfort as a priority. After assembly, the device is packaged (sterilization pouches, Plastcareusa, USA), sealed, and sanitized using UV light prior to patient use."
223492418|NCT07116863|DRUG|KDF1901-R0|Fixed-dose combination tablet containing valsartan 80 mg and amlodipine 5 mg. Orally administered once daily for 4 weeks during the run-in period, and for 2 weeks during Treatment Period 1(Dual Therapy group).
223492419|NCT07116863|DRUG|KDF1901-L|"Fixed-dose combination tablet containing valsartan 80 mg, amlodipine 5 mg, and chlorthalidone 12.5 mg.~Orally administered once daily for 2 weeks during Treatment Period 1."
223492420|NCT07116863|DRUG|KDF1901|"Fixed-dose combination tablet containing valsartan 160 mg, amlodipine 10 mg, and chlorthalidone 25 mg.~Orally administered once daily for 6 weeks during Treatment Period 2."
223492421|NCT07116863|DRUG|KDF1901-R1|Fixed-dose combination tablet containing valsartan 160 mg and amlodipine 10 mg. Orally administered once daily for 6 weeks during Treatment Period 2.
223492422|NCT06183476|BEHAVIORAL|Amplify-RHYTHM|Amplify-RHYTHM will have two main components: 1) timed light exposure (increase light in the morning, blue light reduction in the evening and eye masks at night), 2) weekly remote coaching session by psychologist to optimize circadian and sleep behaviors
223492423|NCT07122037|DEVICE|DosMedical Smell Training Set|Olfactory training with four different odorants (e.g., rose, eucalyptus, lemon, and cloves) for approximately 10 seconds each, twice a day, in the morning and in the evening
223492424|NCT07122037|BEHAVIORAL|Nasal Airflow Inducing Maneuver|"Repeated generation of an underpressure in the oral cavity by simultaneously lowering the jaw, the floor of the mouth the tongue, the base of the tongue and soft palate with securely closed lips. This negative pressure created in the oral cavity generates an airflow through the nose."
223492425|NCT07124741|DIAGNOSTIC_TEST|Serial VEXUS Ultrasound Evaluation|Ultrasound assessments will be performed by an experienced anesthesiologist at three time points (0-4 hours, 12-24 hours, and 72 hours)to determine the degree of venous congestion using the VEXUS Score. No treatment changes will be made based on the VEXUS findings. The scores will solely be used for prognostic correlation with mortality outcomes.
223492426|NCT07124728|BEHAVIORAL|Technology-enabled Telehealth Care Plan|Participants receive a 6 month personalized telehealth intervention via a multidisciplinary care team, delivering care via a secure digital platform, including education, risk assessment, lifestyle coaching, medical history review, and stroke risk reduction planning. The Healthie EHR is used for communication, documentation, and data integration. Syntrillo Navigators and neurology providers conduct onboarding, telemedicine visits, and coordination with patient's primary care providers and care team.
223492427|NCT07124728|DEVICE|Blood Pressure Monitoring Device|Participants will receive a cellular-enabled, FDA-cleared blood pressure monitor supplied by Tenovi. Blood pressure is measured twice daily during baseline and at least once daily throughout the 6-month intervention. Data is transmitted via a secure gateway to the Healthie EHR for real-time monitoring and analysis.
223492428|NCT07124728|DEVICE|Tenovi Smart Pillbox|Participants receive a connected 7-day smart pillbox that detects compartment openings and refills. Medication adherence data is uploaded in real time to a secure dashboard and integrated into the EHR.
223492429|NCT07124728|DEVICE|Wearable Activity Trackers (Fitbit or Apple Watch)|Participants will utilize a commercially available wearable activity tracker to monitor step counts, resting heart rate, and heart rate variability. This data is integrated into the EHR. Devices will be provided if participants do not already own one.
223492430|NCT07124728|OTHER|Healthie EHR|HIPAA-compliant electronic medical record system used for participant management, secure communication, clinical documentation, and device data integration, consisting of custom workflows used for risk tracking and care planning.
223492431|NCT07124728|OTHER|Secure Messaging Platforms (TigerConnect, Weave, AirCall)|Participants and providers may communicate using secure messaging platforms for appointment reminders, assessments, and care support, to enhance participation engagement and care coordination.
223492432|NCT07124728|DRUG|Antihypertensive Medication Management|Participants may be prescribed or have existing antihypertensive regimens adjusted (ACE inhibitors, beta blockers, calcium channel blockers, diuretics, etc) by neurologists or nurse practitioners based on individual risk assessments and clinical findings during the study. Changed will be recorded in EHR.
224183877|NCT02936466|BEHAVIORAL|Bipolife® group|"The participant is proposed to play to the serious game Bipolife® with following instructions :~* At least one connection per week during 4 weeks~* Connection time is free On add on of usual treatment After the 4 weeks and the first visit (V1), the participant can continue to participate to the serious game as much as he wishes, without any specific instructions.~After connecting to the site www.bipolar.ubi.com, the participant is proposed to create his avatar and conduct him on his house. He realizes different kind of daily actions (like sleeping, sport activity, cooking) ; every action lead to win or to loose energy and mood points. The final aim is to stabilize the avatar's mood. Thanks to this experience, the participant can learn to distinguish positive and negative actions impacting on his condition."
224183878|NCT04835142|DRUG|Double blind control period A140|experiment arm： Drug A140:400 mg/m2（D1，iv）,250 mg/m2（qw，iv） Drug Oxaliplatin 85 mg/m2（D1,iv), Drug Calcium Folinate 400 mg/m2（D1,iv） Drug 5-FU 400 mg/m2（D1,iv），2400 mg/m2 (48±4h) control arm: Drug Erbitux:400 mg/m2（D1，iv）,250 mg/m2（qw，iv） Drug Oxaliplatin 85 mg/m2（D1,iv) Drug Calcium Folinate 400 mg/m2（D1,iv） Drug 5-FU 400 mg/m2（D1,iv），2400 mg/m2 (48±4h)
223492433|NCT07124728|DRUG|Statin Medication Management|Lipid-lowering medications, including statins, may be initiated or adjusted as part of participants' care plans. Medication use is guided by cardiovascular risk and AHA guidelines. Changed will be recorded in EHR.
223492434|NCT07124728|DRUG|Antiplatelet or Anticoagulant Therapy|Participants with atrial fibrillation or elevated cardiovascular risk may be started on or have changes to antiplatelet or anticoagulant therapy. Medication decisions are made by neurologist or nurse practitioners during telemedicine visits. Changed will be recorded in EHR.
223492435|NCT07124728|PROCEDURE|Laboratory Blood Test Collection|Blood samples may be collected at baseline and at 6 months to assess inflammation through high-sensitivity C-reactive protein.
223492436|NCT07119541|BEHAVIORAL|Alliance-Focused Dialectical Behavior Therapy plus Deliberate Practice|The alliance-focused DBT training plus deliberate practice is a 4-session weekly intervention delivered to therapists working with individuals with borderline personality disorder or emotion dysregulation. This training intervention involves a didactic component, video analysis, and case-based learning. Deliberate practice methods (e.g., setting individualized training goals, skills coaching, feedback, and opportunities for repeated practice) will be integrated both within and between training sessions.
223492437|NCT07119541|BEHAVIORAL|Alliance-Focused Dialectical Behavior Therapy plus Reflective Practice|The alliance-focused DBT training plus reflective practice is a 4-session weekly intervention delivered to therapists working with individuals with borderline personality disorder or emotion dysregulation. Trainings will involve a didactic component, video analysis, and case-based learning. Reflective practice methods (i.e., thinking about past experiences to gain insight for future actions) will be integrated both within and between training sessions.
223492438|NCT07122583|DEVICE|CoolSculpting Elite System|CoolSculpting Elite Applicator
223492439|NCT07123675|DEVICE|Device: AI Clinical Decision Support System|An AI-based software system that provides real-time, on-screen recommendations to the anesthesiologist regarding drug administration and adjustments to maintain optimal patient physiological parameter
223492440|NCT07123675|PROCEDURE|Procedure: Standard of Care Anesthesia|Standard anesthesia management according to institutional guidelines. The attending anesthesiologist makes all clinical decisions based on their expertise and judgment without input from the investigational AI system.
223492441|NCT07081516|PROCEDURE|temperature|Adjusting the temperature of the local anesthetic drugs injected intrathecally
223492442|NCT06930040|OTHER|Action observation therapy protocol|The examined group got 30 minutes of a standard, selected physical therapy program in addition to 30 minutes of AOT on the upper limb (total session time: 1 hour), 3 sessions per week for three consecutive months (total therapy time: 3 hours/week). Action observation was executed with therapist guidance and repeated practice (3 repetitions for each task). The child has been requested to perform the watched task with the same tool after observing a 3-minute video for each task on an adjustable monitor screen positioned one meter in front of him or her from forward, sideways, and backward directions. The therapist sat beside the child to provide verbal comments during the excursion and to guide the child's movement. The AOT for the examined group included six unimanual tasks and six bimanual tasks. The unimanual tasks included pressing a rubber stamp, stacking cups, drinking water from a cup, grabbing a pen, flipping cards, and putting things on a stick.
223588367|NCT03792152|DRUG|Rivaroxaban|After diagnosis of left atrial appendage thrombus by transesophageal echocardiography, then start with rivaroxaba 20mg qd (15mg If creatinine clearance is between 30-49 ml/min).
224183879|NCT04835142|DRUG|Open single period A140|Drug A140:400 mg/m2（D1，iv）,250 mg/m2（qw，iv） Drug Oxaliplatin 85 mg/m2（D1,iv), Drug Calcium Folinate 400 mg/m2（D1,iv） Drug 5-FU 400 mg/m2（D1,iv），2400 mg/m2 (48±4h)
224183880|NCT04008459|OTHER|Therapeutic exercise class|Physiotherapy exercise class includes education, stretching, strengthening, posture and balance interventions.
223588368|NCT03792152|DRUG|Warfarin|After the diagnosis of left atrial appendage thrombus by transesophageal echocardiography, subcutaneous injection of low molecular weight heparin (4000iu q12h) and oral warfarin treatment were started, and low molecular weight heparin was stopped after INR reached 2.
223588369|NCT00457223|PROCEDURE|Amniotic membrane transplantation using fibrin glue|After pterygium excision, amniotic membrane was shaped and attached to bare scleral area using fibrin glue (Quixil®) in 16 eyes of 16 patients of FG group and continuous suture with nylon 10-0 in 16 eyes of 16 patients of SU group.
223588370|NCT00739466|DRUG|Liposomal Alendronate|IV in a single low dose during the index procedure (coronary stent implantation) over 2 hours
224183881|NCT00042575|DRUG|Duloxetine|
224183882|NCT04950452|BEHAVIORAL|Exercise Training|Supervised exercise training
224183883|NCT04100759|DRUG|Sildenafil 50 mg Oral Tablet|Sildenafil 50 mg Oral Tablet
224183884|NCT01786707|BIOLOGICAL|Autologous stem cells|Pancreatic artery infusion of Autologous Stem cells.
224183885|NCT01786707|OTHER|Hyperbaric oxygen therapy|
223492443|NCT06930040|OTHER|Kenisiotaping|"Shoulder taping will done using two Kinesiotex tapes(2.5 · 7 cm), in the form of I shape. The tapes follow the line of pull of the anterior and posterior deltoid muscle fibers applied in order to assist the deltoid muscle action .~The tape was applied with the child in a sitting position by assistance from his care giver, while the therapist supported the child's arm. The first tape was initiated from the upper border of the lateral 1/3 of the clavicle to the deltoid prominence on the middle of the lateral side of the body of the humerus moving backward and lateralward while the arm was externally rotated and horizontally abducted. The second tape was initiated from the lower lip of the posterior border of the spine of the scapula towards also the humeral deltoid prominence moving forward and lateralward while the arm was horizontally adducted and internally rotated as if reaching to the outside of the contralateral hip."
223492444|NCT04253626|DRUG|Ferumoxytol Injection [Feraheme]|510mg intravenous ferumoxytol
223492445|NCT04253626|DRUG|Ferrous Sulfate|325mg oral ferrous sulfate
223588371|NCT00739466|DRUG|Liposomal Alendronate|IV in a single high dose during the index procedure (coronary stent implantation) over 2 hours
223588372|NCT00739466|DRUG|Saline infusion (placebo)|IV saline infusion during the index procedure (coronary stent implantation) over 2 hours
223588373|NCT00861016|DRUG|metoprolol succinate prolonged-release tablet and felodipine|a regimen that starts with metoprolol succinate prolonged-release tablet 47.5mg once daily, orally and allows for dose escalation to 95mg once daily, orally at 4 weeks if not controlled; at week 8 allows for the addition of felodipine sustained release tablet 5mg once daily, orally
224183886|NCT01786707|DRUG|Insulin|Insulin dose as per clinical management
223492446|NCT06930872|DRUG|Part 1|ZYN002 (transdermal), midazolam (oral), omeprazole (oral), losartan (oral), dextromethorphan (oral), caffeine (oral), repaglinide (oral), bupropion (oral)
223492447|NCT06930872|DRUG|Part 2|ZYN002 (transdermal), VPA (oral)
223492448|NCT07087015|PROCEDURE|Cervical sympathetic nerve block|Patients will receive a CSB.
223492449|NCT07087015|PROCEDURE|Subcutaneous sham injection|Patients will receive a subcutaneous sham injection of saline.
223492450|NCT07087015|DRUG|Ropivacaine|The CSB group will receive ropivacaine 0.5% 10ml.
223492451|NCT07087015|DRUG|Normal Saline|The control group will receive 3 ml of normal saline in the sham injection.
223492452|NCT07078773|PROCEDURE|peng block|A convex ultrasound probe (frequency 2-5 MHz) was positioned at the patient's inguinal ligament, with one end directed toward the anterior inferior iliac spine (AIIS), clearly visualizing the bony prominences of the iliopubic eminence and the AIIS. The needle tip was directed medially toward the pectineus muscle. Upon reaching the space between the pectineus muscle and the pubic bone, and after confirming the absence of blood on aspiration, 30 ml of 0.375% ropivacaine was injected.
223588374|NCT06232551|OTHER|EHR (electronic health record) alert|Pop-up alert that informs the discharging clinician that the patient meets criteria to be considered for extended duration thromboprophylaxis
223588375|NCT06232551|OTHER|No EHR (electronic health record) alert|During the baseline phase while risk is assessed and stored, no alerting occurs
223588376|NCT01930552|DRUG|Aflibercept AVE0005|Pharmaceutical form:Solution for infusion Route of administration: Intravenous
224183887|NCT01786707|DRUG|Metformin|Metformin dose as tolerated
224183888|NCT01300715|PROCEDURE|lumbar medial branch radiofrequency neurotomy|the classic tunnel vision technique versus the alternative technique
224183889|NCT05059561|RADIATION|X-ray radiograghy|Cobb angles of the patient and control groups were determined by using X-Ray radiography used in the radiological examination routinely applied to the individuals who applied for the health board examination.
224183890|NCT01560676|BEHAVIORAL|HEALTH[e]TEEN|8 lessons over 6-8 weeks
224183891|NCT01560676|BEHAVIORAL|HEALTH[e]TEEN + CST|12 lessons over 6-8 weeks
224183892|NCT01953380|BEHAVIORAL|extended information|
223492453|NCT07078773|PROCEDURE|obturator nerve block|An ultrasound probe was positioned at the inguinal ligament, with the needle inserted parallel to the long axis of the probe. After confirming no blood upon aspiration, 15 ml of 0.375% ropivacaine was injected into the fascial plane between the adductor brevis and adductor magnus, as well as into the midportion of the adductor longus and adductor brevis muscles.
223588377|NCT01930552|DRUG|Leucovorin|Pharmaceutical form:Solution for infusion Route of administration: Intravenous
223492454|NCT06904404|PROCEDURE|Cataract surgery at high IOP|Cataract surgery at high IOP (conventional)
223492455|NCT06904404|PROCEDURE|Cataract surgery at low IOP|Cataract surgery at low IOP
223588378|NCT01930552|DRUG|Irinotecan|Pharmaceutical form:Solution for infusion Route of administration: Intravenous
223588379|NCT01930552|DRUG|5-Fluorouracil|Pharmaceutical form:Solution for infusion Route of administration: Intravenous
223588380|NCT04826016|DRUG|POL6326|POL6326 (balixafortide): starting dose at 5.5 mg/Kg. Intravenous administration on day 1 and 8 of each 21-day cycle (+/- 1 day) (Phase Ib ARM A and Phase II ARM A ) or on day 1, 8 and 15 of each 28-day cycle (Phase Ib ARM B and Phase 2 ARM B) (+/- 1 day).
223745590|NCT00895258|BEHAVIORAL|Individual placement and support plus enhanced support (IPS-ES)|One IPS plus one ES session each week for 12 weeks
223745591|NCT02583776|DEVICE|Unblinded - CGM|Data from device will be readable and alarms on
224183893|NCT04489862|BIOLOGICAL|αPD1-MSLN-CAR T cells|Subjects will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of αPD1-MSLN-CAR T cells. During αPD1-MSLN-CAR T cells production, subjects will receive cyclophosphamide for the purpose of lymphocytes depletion，Cyclophosphamide 300 mg/m2/day IV infusion on days -5, -4 and -3. After lymphodepletion, subjects will receive one dose treatment with αPD1-MSLN-CAR T cells by intravenous (IV) injection. The initial dose of 1×10\^5 CAR+ T cells/kg will be infused on day 0.
224183894|NCT03740126|DIAGNOSTIC_TEST|Whole body 18F-FDG PET/CT|In the experimental arm (A), an FDG-PET/CT scan will replace the CT-scan at 6, 12, 18 and 24 months post-treatment. A standard CT-scan will be performed at 3, 9, 15 and 21 months post-treatment. All patients will be asked for a blood sample for liquid biopsy and to fill in a quality of life questionnaire, concurrently every 3 months.
224183895|NCT02058940|DRUG|Exenatide|50 ng/min IV for 30 minutes, then start 25 ng/min IV for a maximum duration of 48 hours
224183896|NCT00383344|PROCEDURE|FDG PET/CT|
224183897|NCT01132040|DRUG|Primidone|Primidone Tablets, USP 50 mg of Dr. Reddy's Laboratories Limited
224183898|NCT02011646|BEHAVIORAL|Healthy Weight|The PI will train 4 group leaders to deliver the intervention. Groups will be offered four times per week and consist of approximately 10 participants. Each group will be led by 2 group leaders and each group leader will lead two sessions per week during the 2.5 mo intervention period. Group leaders will digitally video-record all sessions of the first two groups they deliver so the PI can provide supervision and rate fidelity and competence for a random selection of 6 of these 12 sessions. Group leaders will transmit the video recordings via an encrypted, secure internet connection to Dr. Ochner (who was trained by Dr. Eric Stice, the creator of the intervention) within 3 d for supervision, and competence and fidelity assessments.
223492456|NCT05448365|DIETARY_SUPPLEMENT|Epigallocatechin gallate, Vitamin D, Vitamin B6, D-chiro-inositol|The patients will take for three months two tablets per day each containing 150mg epigallocatechin gallate, 25 mg D-chiro-inositol, 5mg Vitamin B6 and 25μg Vitamin D
223492457|NCT05448365|DIETARY_SUPPLEMENT|Placebo|Maltodextrines
223492458|NCT06905288|DRUG|Secukinumab|This is a prospective observational study. There is no treatment allocation. The decision to initiate treatment will be based solely on clinical judgement.
224183899|NCT02011646|BEHAVIORAL|Controlled Intervention|"The Weight of the World is a 51 min documentary focusing on the topics of obesity and healthy living. Via information presented by medical professionals and lifestyle experts, this film delves into issues related to preventing and combating obesity. Major topics include the importance of healthy eating and exercise behaviors and the changes that can be made by communities to reshape our lifestyles. Participants will be given a copy of the DVD. They will also be given the choice to stream it free on the web."
224183900|NCT03088566|PROCEDURE|The D-Foot method|The D-Foot method is a standardised routine of foot screening. The D-Foot i web program aimed to be used on a surf plate.
224183901|NCT03088566|PROCEDURE|Conventional foot screening|The foot screening is performed with clinical conventional methods.
224183902|NCT04675502|OTHER|supervised Exercise training|warm-up, loading (respiratory control training, breathing exercises, posture exercises with respiratory control , walking on the treadmill for 20 minutes without inclination , pedaling in the bicycle ergometer for 10 minutes), cooling, and relaxation exercises
224183903|NCT04675502|OTHER|home exercise trainig|Warm-up, loading (respiratory control training, shrunken lip breathing exhaustion, diaphragmatic, thoracic expansion exercises, posture exercises with respiratory control (pectoral stretching, four-way trunk exercises, head and neck exercises, bilateral shoulder flexion and abduction exercises), cooling and relaxation exercises
224183904|NCT01519700|DRUG|EP2006|Eligible patients will be teated with EP2006
224183905|NCT01519700|DRUG|Filgrastim|Eligible patients will be teated with Filgrastim
224183906|NCT04826042|OTHER|thoracic epidural catheterization|thoracic epidural catheterization
224183907|NCT00003576|DRUG|cisplatin|
224183908|NCT00003576|DRUG|fluorouracil|
224183909|NCT00003576|PROCEDURE|surgical procedure|
224183910|NCT00003576|RADIATION|radiation therapy|
224183911|NCT04988620|OTHER|Whole Blood transfusion|In this study the effect of storage time of whole blood will be investigated. Intervention is storage of whole blood.
224183912|NCT04430140|DEVICE|CT Scan|"CT Scan~Number of research exams: 1 Effective Dose (mSv) for 1 exam: 0.6 Total Effective Dose (mSv)\*: 0.6"
224183913|NCT01958944|DRUG|Nitric oxide|
223492459|NCT06879574|OTHER|Measuring dietary intake|During 5-week study, participants will monitor their usual dietary intake during two 3-day periods (on weeks 1 and 5). During week 3 (calibration week) participants will consume a test diet. Wearable camera technology, self-collected blood and urine samples, and online FFQ (eNutri) will be used to monitor food intake during study weeks. Study tools as well as foods/drinks for the test diet will be delivered to each participant and they will be asked to comply with the study procedures in their home or working environment. Participants will post study samples and the study equipment/logs at designated times using pre-paid envelopes or a courier collection, respectively.
223492460|NCT06812533|DEVICE|Alleviant ALV1 System|Creation of interatrial shunt
223492461|NCT06812533|OTHER|Sham-Control|Cardiac imaging
223492462|NCT00453505|DEVICE|TMS|\<=1 Hz TMS for up to 30mins and up to 115% of resting motor threshold intensity (MT).
223588381|NCT04826016|DRUG|Eribulin|Eribulin: 1.23 mg/m2 (equivalent to 1.4 mg/m2 eribulin mesylate). Intravenous administration on day 1 and 8 of each 21-day cycle (+/- 1 day) (Phase Ib ARM A and Phase II ARM A ) or on day 1, 8 and 15 of each 28-day cycle (Phase Ib ARM B and Phase 2 ARM B) (+/- 1 day).
223492463|NCT00453505|DEVICE|tDCS|tDCS up to 2 mA for up to 60mins.
223492464|NCT00453505|DEVICE|tACS|tACS up to 1 mA for up to 10 minutes.
223492465|NCT00453505|DEVICE|CPNS|CPNS alone with intensities below 130% of the peripherally-elicited-motor-threshold for up to 2 hours.
223492466|NCT06818968|DRUG|MK-6916|Oral administration
223492467|NCT06818968|DRUG|Diltiazem|Oral administration
223745592|NCT02583776|DEVICE|Blinded - CGM|Data from device will be blinded and alarms off
224183914|NCT02136446|DEVICE|EchoGlo Nerve Block Catheter|Catheter used for a paravertebral anesthesia block
224183915|NCT02136446|DEVICE|Pajunk® Nerve Block Catheter|Nerve Block Catheter
224183916|NCT06557967|OTHER|No drug|This is a non-interventional study and no study drug will be provided.
224183917|NCT05794204|DRUG|RMP-A03 - Dose 1|Patients will randomized to low dose of RMP-A03
224183918|NCT05794204|DRUG|RMP-A03 - Dose 2|Patients will be randomized to high dose of RMP-A03
224183919|NCT05794204|DRUG|RMP-A03 Placebo|Patients will be randomized to RMP-A03 Placebo
224308402|NCT03070587|BEHAVIORAL|Positive Affect Training for SAD|The PAT-S protocol will teach the participants the basics of mindfulness and how to be aware of their physical sensation, thoughts, and emotion at present moment by a nonjudgmental way in breathing, standing, or eating. After two mindfulness sessions, lovingkindness meditation (LKM) will be introduced. The participants will be taught to identify and focus the positive feelings such as gratitude, love, kindness, peacefulness, or friendliness when they wish their benefactor and beloved ones who they feel grateful or respectful, and transfer these feelings first to themselves, then to a neutral individual, to people whom they dislike, and finally to all living beings.
224308403|NCT05159167|OTHER|Baduanjin, a type of Qigong|Baduanjin is very popular in China. There is increasing evidence to support its positive effects on health outcomes in various groups of people with physical and mental disorders.
224183920|NCT03148834|PROCEDURE|Controlled Reperfusion|"Patients will be treated in the occluded coronary with a solution of venous blood and Dextran, prior to the Stenting procedure.~Controlled Reperfusion PCI consists of crossing the culprit lesion with guidewire and then advancing a balloon (over the wire) to the distal segment of the culprit vessel. Proximal to the main distal branch, inflate the balloon to low atmospheres, remove the guide wire and inject the solution through the light of the balloon. Then reposition the guidewire, perform angioplasty as usual on the lesion. If there is a large residual thrombus load and at the operator's discretion, change the balloon by a manual thromboaspiration catheter and use it.~Then perform stenting of the lesion. The solution will be given with a 1 cc syringe as a slow bolus, controlling symptoms and ST segment response.~The compounds in solution are venous blood drawn from the patient after administration of heparin and mixed with dextran in a 3/1 ratio."
224183921|NCT00974896|DRUG|AMG 479|AMG 479 is a fully human IgG1 monoclonal antibody that inhibits IGF-1R signalling. AMG 479 (6mg/kg or 12mg/kg) will be given IV every 2 weeks in combination with sorafenib (400 mg po BID) or erlotinib (150 mg po QD).
224308404|NCT01291394|DEVICE|Easypod™|Saizen (Somatotropin) as per Summary of Product Characteristics administered by Easypod™
223492468|NCT06771206|DEVICE|Owlet pulse oximeter neonatal accuracy validation|This study specifically evaluates the Owlet pulse oximetry sensor, which is specifically designed and FDA cleared for for infants, and whose accuracy is specifically being validated in the neonate population.
223492469|NCT06868082|BIOLOGICAL|Solrikitug|Solrikitug Formulation 1
223492470|NCT06868082|BIOLOGICAL|Solrikitug|Solrikitug Formulation 2
223492471|NCT05504291|PROCEDURE|Biospecimen Collection|Undergo aqueous humor, tissue, and blood sample collection
223492472|NCT05504291|DRUG|Carboplatin|Given IV
223492473|NCT05504291|DRUG|Etoposide|Given IV
223492474|NCT05504291|PROCEDURE|Examination Under Anesthesia|Undergo imaging of the eye during EUA
223588382|NCT04826016|DRUG|Nab paclitaxel|Nab-paclitaxel: 100 mg/m2. Intravenous administration on day 1 and 8 of each 21-day cycle (+/- 1 day) (Phase Ib ARM A and Phase II ARM A) or on day 1, 8 and 15 of each 28-day cycle (Phase Ib ARM B and Phase 2 ARM B) (+/- 1 day).
223492475|NCT05504291|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223492476|NCT05504291|DRUG|Melphalan|Given I-VITRE
223492477|NCT05504291|PROCEDURE|Ultrasound Biomicroscopy|Undergo UBM during EUA
223492478|NCT05504291|DRUG|Vincristine|Given IV
223492479|NCT06821048|BIOLOGICAL|Intraperitoneal infusion of FAST CEA-targeted CAR-T|Intraperitoneal infusion of FAST CEA-targeted CAR-T (PTC13); Subjects will be treated with Fludarabine and Cyclophosphamide based lymphodepleting chemotherapy before CAR-T cell infusion.
223492480|NCT05763875|DRUG|Inclisiran|284 mg (equivalent to 300 mg inclisiran sodium) subcutaneous injection given on Day 1 and Day 90
223588383|NCT00710242|DRUG|DF01|Once daily s.c. injections from approximately 3-7 days before expected delivery (maximum 2 weeks before) until delivery (maximum 2 weeks after expected delivery)
223588384|NCT00710242|DRUG|Placebo|Once daily s.c. injections from approximately 3-7 days before expected delivery (maximum 2 weeks before) until delivery (maximum 2 weeks after expected delivery)
223588385|NCT00346645|DRUG|Bortezomid (VELCADE®)|
223492481|NCT05763875|DRUG|Ezetimibe|10 mg over-encapsulated tablet taken once a day from Day 1 through Day 149
223492482|NCT05763875|DRUG|Matching Placebo for Inclisiran|0mg placebo injection solution for subcutaneous injection on Day 1 and Day 90
223492483|NCT05763875|DRUG|Matching Placebo for Ezetimibe|0mg over-encapsulated placebo tablet taken once a day from Day 1 through Day 149
223492484|NCT07079332|OTHER|New Scale to evaluate ataxia motor symptoms|The Ataxia Trunk, Lower And upper extremity Scale (ATLAS) is a new scale. It differs from other Ataxia Scale by focusing on the assessment of coordination abilities of specific body segments: the trunk, lower limbs, and upper limbs.
223492485|NCT07082777|BEHAVIORAL|Narrative therapy|The intervention is structured around 4 central tasks focusing on different aspects of narrative repair. Task 1: Introduction to life story exploration and building alliance. Task 2: Explore and process the impact of mental illness on identity, externalizing negative narratives, and making sense of emotional responses such as guilt, grief, or shame. Task 3: Identify positive identity conclusions (e.g., strengths, values, skills) from past or current life experiences, and support their integration into the personal narrative. Task 4: Support the imagining of a realistic and hopeful future narrative, grounded in insights of previous sessions. Tasks 1-4 are addressed in a total of 8-12 sessions, depending on the specific user needs. Sessions will have an app. duration of 45-60 mins and will be delivered by the PI who is a trained therapist and psychologist (MSc. Psych.), receiving ongoing supervision. The intervention manual will be made freely available in relation to study publication.
223492486|NCT07085819|DIETARY_SUPPLEMENT|Botanical Extract, 125mg|Two capsules per day (125 mg/day) before sleep, with or without food, for 8 weeks.
223588386|NCT01064687|DRUG|LY2189265|
223588387|NCT01064687|DRUG|Exenatide|
223588388|NCT01064687|DRUG|Placebo|
223588389|NCT01064687|DRUG|Metformin|
223588390|NCT01064687|DRUG|Pioglitazone|
223588391|NCT00619489|DRUG|vedolizumab|Vedolizumab for intravenous (IV) infusion
223588392|NCT02966015|DEVICE|Coloplast test catheter|This is a newly developed catheter
223588393|NCT01632644|OTHER|Survey/Interview|Each group will be surveyed and interviewed.
223588394|NCT01699711|DIETARY_SUPPLEMENT|Epigallocatechin-3-gallate (EGCG)|EGCG administration in Down syndrome patients will result in an improvement of their cognitive performance. A daily oral dose containing 9 mg/kg (range 6.9-12.7) of EGCG is given during twelve months.
223588395|NCT06316440|DEVICE|Wear noise-cancelling earphones|Intervention of wearing noise-canceling earphones after general anesthesia
223588396|NCT01187459|DIETARY_SUPPLEMENT|Vitamin D|10 ug/day Vitamin D, taken for 6 months.
223588397|NCT01187459|DIETARY_SUPPLEMENT|Vitamin D|50 ug/day Vitamin D, taken for 6 months.
223745593|NCT00696514|DIETARY_SUPPLEMENT|Vitamin B12, folic acid, Vitamin D3|500 µg vitamin B12; 0.4 mg folic acid; 600 IU vitamin D3 in one capsule, once per day
224183922|NCT02977741|DRUG|Olanzapine|
224308405|NCT05001217|DRUG|Conventional medication|Levodopa, dopamine agonist, Monoamine oxidase-B inhibitors, Catechol-O-methyltransferase inhibitors, etc.
224308406|NCT05001217|DRUG|Chinese herbal medicine treatment|"1. Huanglian Wendan Decoction~2. Jin Gui Shen Qi Pill~3. Liu Wei Di Huang Pill plus Tian Ma Gou Teng Decoction~4. Bu Yang Huan Wu Decoction"
223492487|NCT07085819|DIETARY_SUPPLEMENT|Botanical Extract, 250mg|Two capsules per day (250 mg/day) before sleep, with or without food, for 8 weeks.
223492488|NCT07085819|DIETARY_SUPPLEMENT|Botanical Extract, 500mg|Two capsules per day (500 mg/day) before sleep, with or without food, for 8 weeks
223492489|NCT07085819|DIETARY_SUPPLEMENT|Pacebo|Two capsules per day before sleep, with or without food, for 8 weeks.
223492490|NCT07089901|DRUG|transdermal nicotine replacement therapy|All participants will receive transdermal nicotine replacement therapy (21 mg. patches)
223492491|NCT07087795|DRUG|NNC0194-0499|Participants will receive subcutaneous NNC0194-0499 once weekly.
223492492|NCT07087795|DRUG|Placebo|Participants will receive placebo matched to NNC0194-0499 subcutaneously.
223492493|NCT07087795|DRUG|Semaglutide|Participants will receive subcutaneous semaglutide once weekly.
223492494|NCT06043427|DRUG|Paclitaxel|80 mg/m²
223492495|NCT06043427|DRUG|Ramucirumab|8 mg/kg
223492496|NCT06043427|DRUG|Zanidatamab|Dose and schedule to be assigned at enrollment
223492497|NCT07092254|DRUG|No drug|No study drug will be administered in this non-interventional study.
223492498|NCT04426214|DEVICE|tDCS|We will apply tDCS in combination with cognitive training. All participants receive cognitive training, and will be randomized to receive either active or sham tDCS
223492499|NCT04426214|BEHAVIORAL|Cognitive Training|cognitive training on computer
223588398|NCT05571956|OTHER|Pancreatic ductal adenocarcinoma organoids and cancer-associated fibroblasts establishment group|Pancreatic masses were sampled using a 22-gauge FNB needle. If a sufficient visible core was obtained on macroscopic inspection, the tissue materials from the following one needle pass were placed into the transfer medium for organoid generation. Using a tiny portion (about 20%) of the FNB sample, we isolated CAFs
224183923|NCT03690102|OTHER|T-CPR|Participants receive telephone instructions in cardiopulmonary resuscitation (T-CPR) from the Emergency Medical Services in Copenhagen during the cardiac arrest scenario test.
224183924|NCT03690102|OTHER|ERC standardized BLS course|Participants will receive and complete the standardized course in basic life support (BLS) from European Resuscitation Council (ERC).
224183925|NCT06724484|PROCEDURE|Surgical management of fracture|Surgical management of fracture
224183926|NCT06724484|OTHER|No intervention|No intervention
224183927|NCT02064491|DRUG|Erlotinib|
224183928|NCT02064491|DRUG|Chemotherapy|
224183929|NCT06514365|DRUG|IPACK block with Bupivacaine 0.25% with adrenaline|The iPACK in performed in the popliteal fossa about 1 finger breath above the patella, ecoguided. That aims to anesthetize the articular branches to the posterior aspect of the knee in the popliteal region.
224183930|NCT04165174|DRUG|Terepril monoclonal antibody; Apatinib|Terepril monoclonal antibody,240mg,ivdrip,Q3W Apatinib,250mg,po,QD
223492500|NCT03907046|DRUG|Apixaban|Apixaban is an oral anticoagulant of the Factor Xa inhibitor class.
223492501|NCT03907046|DRUG|Aspirin|Aspirin is an oral antiplatelet drug.
223492502|NCT06821321|BEHAVIORAL|Plyometric Training|Participants will receive a total of twenty-four 45-minutes in-person resistance-training sessions, twice per week, using three sets of eight repetitions per set on five upper body exercises. During resistance-training participants will be allowed 1-minute rests between sets. Participants will also perform two jump training exercises on a horizontal Pilates reformer, the leg plyometric and ankle plantar plyometric jumps.
223492503|NCT06821321|BEHAVIORAL|Power Training|Participants will receive a total of twenty-four 45-minutes in-person training sessions, twice per week using three sets of eight repetitions per set. During training participants will be allowed 1-minute rests between sets. Exercises will include five upper-body exercises and two lower-body exercises.
223492504|NCT03997123|DRUG|Capivasertib|400 mg (2 oral tablets) given on an intermittent weekly dosing schedule. Dosed on Days 2 to 5 of Weeks 1, 2, and 3 followed by 1 week off-treatment within each 28-day treatment cycle. Study treatment will be continued until disease progression unless there is evidence of unacceptable toxicity, or if the patient requests to stop the study treatment.
223492505|NCT03997123|DRUG|Paclitaxel|80 mg/m2 concentrate for solution for infusion, 3 consecutive weekly infusions of 80 mg/m2 (given on Day 1 of Weeks 1, 2, and 3), followed by 1 week off-treatment within each 28-day treatment cycle. Paclitaxel treatment will be continued for at least 6 cycles unless the patient experiences unacceptable toxicity that is attributed directly to treatment with paclitaxel.
223588399|NCT00552409|DIETARY_SUPPLEMENT|Cholecalciferol|2000 IU by mouth daily for one year
224183931|NCT04165174|RADIATION|SBRT|6-10Gy/F,5-8F
224183932|NCT01979640|PROCEDURE|39 Fr double lumen tube group|additional bronchial cuff volume is decided according to up-and-down biased coin design sequential method, by incremental volume of 0.1 ml
224183933|NCT01979640|PROCEDURE|37 Fr double lumen tube group|additional bronchial cuff volume is decided according to up-and-down biased coin design sequential method, by incremental volume of 0.1 ml
223492506|NCT03997123|DRUG|Placebo|Placebo: Oral tablets. 400 mg of Placebo (2 tablets) BD given on an intermittent weekly dosing schedule. Dosed on Days 2 to 5 of Weeks 1, 2, and 3 followed by 1 week offtreatment within each 28-day treatment cycle
223492507|NCT06461143|DRUG|%4 articaine with 1:200 000 adrenaline|For intraosseous anesthesia SleeperOne5 device is going to be used.
223492508|NCT07094724|BIOLOGICAL|Plasma|administration of IV high-titer WNV-neutralizing plasma
223588400|NCT00552409|DIETARY_SUPPLEMENT|Placebo|One softgel daily for one year
223588401|NCT04187742|BEHAVIORAL|Social Comparison Email vs. Standard Email|Evaluate whether emails with social comparison incentives will encourage greater report opening by physicians leading to greater reductions in antibiotic use, than a standard email without social comparison incentives
223745594|NCT00696514|DIETARY_SUPPLEMENT|Placebo (Vitamin D3) - 600 IU per day|600 IU vitamin D3 in one capsule, once per day
224183934|NCT01979640|PROCEDURE|35 Fr double lumen tube group|additional bronchial cuff volume is decided according to up-and-down biased coin design sequential method, by incremental volume of 0.1 ml
224183935|NCT02095834|DRUG|Bendamustine Hydrochloride|Given IV
224183936|NCT02095834|DRUG|Carfilzomib|Given IV
224183937|NCT02095834|DRUG|Dexamethasone|Given PO or IV
224183938|NCT02095834|OTHER|Laboratory Biomarker Analysis|Correlative studies
224183939|NCT00207116|DRUG|Cetuximab|IV solution, IV, 400 mg/m2 initial dose followed by weekly doses of 250 mg/m2, Weekly, until disease progression.
224308407|NCT01028924|DRUG|Teduglutide|subcutaneous (SC), single dose
224183940|NCT03829995|OTHER|Drug counseling|Participants can contact a hospital pharmacy department by phone or mail and ask questions regarding drug-related issues.
224183941|NCT05527249|DIETARY_SUPPLEMENT|Dietary Supplement|20g of protein powder + 650mg of pomegranate extracts
224183942|NCT05527249|OTHER|Placebo of the dietary supplement|20g of protein powder + 650mg of maltodextrin
223492509|NCT07094789|DEVICE|Next Generation Dome Helmet (NGDH)|Participants will receive two sessions of Magnetic Resonance-guided focused ultrasound neuromodulation, spaced four weeks apart, using the Next Generation Dome Helmet device. Treatments will target regions within the CSTC circuit identified by advanced MRI scans. Each session will include pre-treatment assessments, precise sonications of deep brain structures, real-time safety monitoring, and post-treatment imaging.
223492510|NCT06880276|DRUG|1.5% QLM3003 ointment|QLM3003 topical cream; 1.5% cream applied twice daily (BID)
223492511|NCT06880276|DRUG|2% QLM3003 ointment|QLM3003 topical cream; 2% cream applied twice daily (BID)
223492512|NCT06880276|DRUG|QLM3003 Placebo|vehicle; vehicle applied twice daily (BID)
223492513|NCT07092995|BEHAVIORAL|VR Freezing Task|Walking overground in immersive virtual reality (VR) environments that provoke freezing episodes
223492514|NCT07092995|BEHAVIORAL|Dual Task|Walking overground with and without concomitant performance of secondary cognitive or motor task
223492515|NCT07092995|BEHAVIORAL|External Cueing|Walking overground in immersive virtual reality (VR) environments that provoke freezing episodes with and without addition of visual and auditory cues.
223492516|NCT07094256|DEVICE|Peritorq|Novel torque device specifically designed for electrophysiology and ablation catheters
223492517|NCT03506451|OTHER|Demographics questionnaires and the FACT HN questionnaire|Patients will complete a baseline survey assessing socioeconomic household information, baseline symptoms, QOL, and financial toxicity, as well as attitudes toward cost conversations and educational handouts.
223492518|NCT06908967|DEVICE|EyeMirage device|This is a novel, smartphone-based device powered by artificial intelligence that will be used for virtual and remote routine eye examinations.
223588402|NCT04187742|BEHAVIORAL|Maintenance Certification Email vs. Standard Email|Evaluate whether emails with maintenance certification incentives will encourage greater report opening by physicians leading to greater reductions in antibiotic use, than a standard email without social comparison incentives
223588403|NCT04187742|BEHAVIORAL|Report Opening Status Email vs. Standard Email (among previous report openers and non-openers)|Evaluate whether emails informing physicians of their report opening status (among those who have previously opened at least one report and those who have never opened a report) will encourage greater report opening by physicians leading to greater reductions in antibiotic use, than a standard email without report opening status information
223588404|NCT02272179|BEHAVIORAL|As Safe As Possible|The ASAP (As Safe As Possible) treatment is a brief, intensive intervention initiated during inpatient care and transitioning to outpatient care. The intervention focuses on 1) using motivational interviewing (MI) strategies throughout care; 2) developing a safety plan, including adapting the plan to an interactive safety plan phone app, Brite); and 3) using treatment modules to target specific risk factors that are selected based on individual need.
224183943|NCT00190294|DRUG|MIFEPRISTONE 200 mg and misoprostol 400 µg|MIFEPRISTONE 200 mg and misoprostol 400 µg
224183944|NCT04120116|DRUG|FX-322 (One Dose)|Patients will receive one dose of FX-322.
224183945|NCT04120116|DRUG|FX-322 (Two Doses)|Patients will receive two doses of FX-322.
224183946|NCT04120116|DRUG|FX-322 (Four Doses)|Patients will receive four doses of FX-322.
224183947|NCT04120116|DRUG|Placebo|Patients will receive Placebo.
224183948|NCT01758991|DEVICE|transcranial direct current stimulation (tDCS)|tDCS is a safe and painless transcranial stimulation that modulates brain activity and could improve stroke recovery. Electrodes in soaked sponges are placed over specific brain regions and held with an elastic band. Direct current is then applied through the electrodes. The patients may feel nothing or a slight tingling under the electrodes.
224183949|NCT03523676|DIAGNOSTIC_TEST|Red Cell Distribution Width|
224183950|NCT06111976|PROCEDURE|Repetitive Transcranial Magnetic Stimulation (rTMS)|"rTMS with simultaneous reactivation of traumatic memory will be performed 3 to 4 times a week for 3 to 4 weeks through 12 sessions.~A traumatic script will be prepared by the patient at the inclusion visit, which will be used to reactivate the traumatic memory after every rTMS or sham rTMS sessions."
224183951|NCT06111976|PROCEDURE|Placebo|"sham rTMS with simultaneous reactivation of traumatic memory will be performed 3 to 4 times a week for 3 to 4 weeks through 12 sessions.~A traumatic script will be prepared by the patient at the inclusion visit, which will be used to reactivate the traumatic memory after every rTMS or sham rTMS sessions."
224183952|NCT01400191|DRUG|Metformin|The study was designed as a randomized, cross-over trial with a washout period of at least 4 weeks between the phases. In both phases, the volunteers fasted for 42 h. This was done in order to include an evaluation of the pharmacodynamic effect of metformin on the glucose production in fasting healthy volunteers.
224183953|NCT01730222|DRUG|cisplatin|cisplatin at 30 mg/m2 on days 1 and 15
224183954|NCT01730222|DRUG|capecitabine|capecitabine at 1250 mg/ m2 days 1-28
224183955|NCT01730222|DRUG|gemcitabine|gemcitabine at 800 mg/ m2 on days 1 and 15 in arm A; at 1000 mg/m2 on days 1, 8 and 15 in arm B
223492519|NCT06908590|BEHAVIORAL|Education, Providing and Engaging Social Support and Assistance with Health System Navigation|"1. Introduction to Program and Cardiac Rehab Needs Assessment Education about Cardiac Rehab~2. Education about CVD and how Cardiac Rehab can help in the participants recovery~3. Social Support Module~4. Health System Navigation Module"
223492520|NCT07095101|BEHAVIORAL|Mobistudy Application|Treatment with mobile application
223492521|NCT07095101|DEVICE|Occlusal splint|Treatment with an occlusal splint
223492522|NCT07097506|DRUG|bis-octanoyl (R)-1,3-butanediol (C8 ketone di-ester)|25 g C8 ketone di-ester taken daily for approximately 6-weeks
223492523|NCT07097506|OTHER|Placebo|25 g Placebo taken daily for approximately 6-weeks
223492524|NCT07095842|DRUG|Ketamine|Intramuscular ketamine 2 mg/kg (max 90 mg)
223492525|NCT07095842|DRUG|Midazolam|Intramuscular midazolam 0.2 mg/kg (max 10 mg)
223492526|NCT07095764|OTHER|Manual Lymphatic Drainage|Specific manual lymph drainage techniques including stationary circles, rotary circles, pumping, and scooping will be applied to both lower extremities using gentle, rhythmic skin movements in accordance with the direction of the lymphatic flow.
224183956|NCT01730222|DRUG|nab-paclitaxel|nab-paclitaxel at the recommended phase II dose day 1 and 15 in arm A; at 125 mg/m2 on days 1, 8 and 15 in arm B
224183957|NCT05637515|BIOLOGICAL|Humira 40 MG in Prefilled Syringe|Humira (40 mg every other week)
224183958|NCT05637515|BIOLOGICAL|Hulio 40 MG in Prefilled Syringe / Humira 40 MG in Prefilled Syringe|"• Subjects will receive Humira (initial dose of 80 mg \[2 × 40 mg\]; Day 1 administered subcutaneously (SC), followed by 40 mg SC given every other week starting 1 week after the initial dose (last dose at Week 10).~Hulio (40 mg every other week) at Week 12 and Week 14~* Humira (40 mg every other week) at Week 16 and Week 18, and~* Hulio (40 mg every other week) at Week 20, Week 22, Week 24 and Week 26."
224183959|NCT00996073|BIOLOGICAL|Lumbar Interbody Fusion with Autograft|Single Dose Autograft Surgical Implantation
224183960|NCT00996073|BIOLOGICAL|Lumbar Interbody Fusion with NeoFuse|Single Dose NeoFuse Surgical Implantation
224183961|NCT00996073|BIOLOGICAL|Lumbar Interbody Fusion with NeoFuse|Single Dose NeoFuse Surgical Implantation
224183962|NCT04758715|OTHER|Food provided from a commercial meal service provider for a week|Meals from a commercial meal service provider provide for a week to participant
224183963|NCT06564961|DRUG|Clomiphene Citrate|50 mg tab once daily
223492527|NCT07095764|OTHER|Cardiac Rehabilitation|An individualized program consists of progressive, low-intensity exercises including respiratory exercises, range of motion exercises for major joints, postural exercises, flexibility exercises, and gradual mobilization exercises such as sitting and walking will be applied.
223492528|NCT07096388|PROCEDURE|endovascular repair|at first the iliac pathology main endovascular treatment was the graft stenting extended along the common and the external iliac artery with the embolisation of the internal iliac artery, with an high risk of pelvic ischemic complications, bowel ischemia, spinal cord ischemia, buttock claudication, erectile dysfunction. Nowadays, off-the-shelf endografts with a special design, the Iliac Branch Endoprosthesis, are available. These grafts, which preserve the hypogastric artery, avoiding complications due to its occlusion; they ensure better distal sealing by reducing the rate of type Ib endoleaks. The patient can be treated under local anesthesia and sedation or general anesthesia. Ultrasound-guided percutaneous access to one or both femoral arteries and, if needed, to the axillary or brachial artery is gained.
223492529|NCT07096388|PROCEDURE|open surgical repair|in case of surgical repair of aorto-iliac aneurysms, general anesthesia is required. Access to the aorta can be achieved through a transperitoneal or retroperitoneal approach. A bifurcated graft is usually used for reconstruction as it is more similar to the native anatomical conformation, but it is not the only option. Although not mandatory, it may be necessary to revascularize one or both internal iliac arteries. This is a very complex surgical technique, challenging even for the most experienced operators due to the location of the iliac arteries. It is a procedure with a high risk of bleeding and mortality, and a high risk of damaging nearby structures such as the ureters and great veins. At the end of the procedure the patient is awake and is usually monitored in the recovery room and then translated to the ward, with fewer than 20% of patients needing Intensive Care Unit (ICU) admission.
223492530|NCT07096076|OTHER|Thoracolumbar fascia inhibition|Soft tissue mobilization: Participants will be asked to lie on their backs without a pillow in a hook-lying position, placing a foam roller under the inferior part of the scapula and clasping their hands behind the cervical region. Then, they will be instructed to lift their hips off the ground and roll the foam roller in a cranial and caudal direction from the inferior scapular region to the sacral area for 30 seconds, performing flexion and extension movements with their knees. This application will be performed in a total of 4 sets.
223492531|NCT07096076|OTHER|Suboccipital inhibition group|Soft tissue mobilization: Participants will be asked to lie in a supine position on an appropriate surface and keep their knees in extension. Then, they will be instructed to hold both ends of a sheet and place the middle part of the sheet on the plantar surface of one foot. Using the sheet and by dorsiflexing the ankle, they will pull the extended leg toward themselves. This position should be maintained for 30 seconds (8). It is important that the opposite knee does not flex during the exercise. The application will be performed bilaterally.
223492532|NCT07096076|OTHER|hamstring stretching|Participants performed passive hamstring stretching using a sheet for self-assistance. Participants will be asked to lie supine on an appropriate surface and keep their knees in extension. Then, they will be instructed to hold both ends of a sheet and place the middle part of the sheet on the plantar surface of one foot. Using the sheet and performing ankle dorsiflexion, they will pull the leg-kept in knee extension-toward themselves. This position should be held for 30 seconds (8). It is important that the opposite knee does not move into flexion during the exercise. The application will be performed bilaterally.
223492533|NCT07087951|DEVICE|Gamma auditory stimulation device (active setting)|Participants will receive auditory stimulation using the gamma auditory stimulation device (active setting) for 1 hour per day, 5 days a week, over 12 weeks, for a total of 60 hours.
223492534|NCT07087951|DEVICE|Gamma auditory stimulation device (sham setting)|Participants will receive auditory stimulation using the gamma auditory stimulation device (sham setting) for 1 hour per day, 5 days a week, over 12 weeks, for a total of 60 hours.
223492535|NCT07093034|DEVICE|Extended nocturnal use of auricular vagus nerve stimulator device|Patients will wear the ParasymTM device with an ear clip on the tragus that provides stimulation at sub-detection threshold.
223492536|NCT07096427|BEHAVIORAL|Virtual Reality-Based Prenatal Education|This intervention involves prenatal education based on Pender's Health Promotion Model delivered using immersive 360-degree virtual reality (VR) videos. The content focuses on healthy lifestyle behaviors during pregnancy, including nutrition, physical activity, stress management, and health responsibility. Participants view the videos via VR headsets in three weekly sessions, each lasting approximately 20 minutes. Motivational follow-up calls are conducted after the sessions.
223588405|NCT02272179|BEHAVIORAL|Brite|Brite is a HIPAA-compliant mobile application designed to provide the participants with emotion regulation and distress tolerance skills, social support, and convenient access to safety plan resources via the patients' phone.
224183964|NCT06564961|DRUG|Placebo|1 tab once daily
224183965|NCT06171165|DIAGNOSTIC_TEST|Yale Swallow Protocol|"All the participants will receive the two swallow screenings, i.e., Yale Swallow Protocol and Speech-language therapist, to classify the participants into either try swallow or NPO status."
224308408|NCT01886196|DRUG|Non-steroidal anti-inflammatory drug (Ibuprofen)|400mg of ibuprofen administered after exercise training session 3 days per week
224308409|NCT01886196|OTHER|placebo|placebo designed to mimic experimental drug (ibuprofen)
224183966|NCT04250558|PROCEDURE|Lower Extremity Amputation|patients 18 years of age or older who will have a planned lower leg (either below knee, through knee, or above knee) amputation surgery are scheduled to undergo a lower extremity amputation (either below knee, through knee or above knee), performed by a participating surgeon or delegate. Provision of informed consent.
224183967|NCT05549804|DRUG|KL340399 Intratumoral|KL340399 is a STING-activating. The strength of KL340399 is 0.2 mg/vial or 0.2 mg/vial.
224183968|NCT01503528|PROCEDURE|Motor Sparing Nerve Block|Continuous Motor sparing knee block (60mL of 0.5% ropivacaine with 10 mg Morphine, 30 mg Ketorolac and 150 mcg of epinephrine as the initial bolus) initiated in the preoperative period in the block room as per the standard practice and continued until discharge. Patients will be connected to an Ambit infusion pump in the postoperative period set to deliver ropivacaine 0.2% at a basal infusion rate of 7 mL/Hr with patient controlled boluses of 5mL every hour for breakthrough pain.
224183969|NCT01503528|PROCEDURE|Peri-articular Catheters|3 peri-articular catheters inserted at the end of surgery followed by periarticular infiltration with ropivacaine 0.2% and wound infusions will be continued until discharge using elastomeric devices.
224183970|NCT05461404|OTHER|Topical Emollient Therapy|Application of high-linoleate (\>60% linoleic acid) SSO to the epidermis.
224183971|NCT02567331|DRUG|Capecitabine|Participants will receive 1250 mg/m\^2 capecitabine administered twice daily as oral tablets for 14 days followed by a 7 day rest period for up to 6 treatment cycles.
224183972|NCT04010357|DRUG|Abemaciclib,|Abemaciclib (CDK4/6 inhibitors) is an investigational drug that works by interrupting the rapid and uncontrolled growth of cancer cells. Some cancer cells develop because their cells overrun the molecular brakes that normally permit cell to divide only when they are needed to replace old ones. These brakes are regulated by a group of enzymes known as cyclin-dependent kinases (CDKs). Alterations causing over-activity of two of these enzymes, CDK4 andCDK6, are found in a variety of cancers, including small cell lung cancer with retinoblastoma (Rb) protein.The drugs work by selectively turning off the overactive CDK4 and CDK6. As a result, the cancer cells' division cycle is halted, preventing them from proliferating.
224183973|NCT06101381|BIOLOGICAL|CART-19|The academic CART-19 consists of autologous T lymphocytes transduced with a lentiviral vector to express a second-generation chimeric antigen receptor with a single chain variable fragment (scFv) targeting the CD19 antigen conjugated with 4-1BB co-stimulatory and CD3z signaling domains.
224183974|NCT05648695|DEVICE|Non-invasive Neuromodulation|The electrodes will be placed with the help of gloves and adapted socks for 1 hour, each session, until 13 intervention sessions are completed. In addition, depending on the session, an adhesive electrode will be placed at the level of C7. Characteristics of microcurrents: pulsed monophasic rectangular wave with a pulse of 1.3 s and pause of 300 ms, voltage 3 millivolt and intensity 0.5 μA.
224183975|NCT05648695|DEVICE|Placebo Non-invasive Neuromodulation|The same protocol described for the experimental group will be applied, but microcurrents device which will be previously manipulated and tested with an oscilloscope so that they do not emit electrical currents.
224183976|NCT06507709|PROCEDURE|Low volume CBCT|3-D imaging used during dental practice
224183977|NCT06796712|DIETARY_SUPPLEMENT|Prebiotic fibre fortified bread roll|Subjects will consume a prebiotic fibre-fortified bread roll (10g of added prebiotic fibre/day).
224183978|NCT06796712|DIETARY_SUPPLEMENT|Regular bread roll|Subjects will consume a regular bread roll (0g of added prebiotic fibre blend/day).
223492537|NCT07096427|BEHAVIORAL|Booklet-Based Prenatal Education|This intervention includes prenatal education based on Pender's Health Promotion Model delivered through printed booklets. The educational content is identical to that of the VR group and covers healthy behaviors in pregnancy. The booklets are discussed in three face-to-face sessions, held once per week for three weeks. Each session lasts about 20 minutes. Participants receive motivational follow-up phone calls after the sessions.
223492538|NCT05828212|DRUG|CAR-T cells injection|CAR-T cells in the treatment of R/R neuromyelitis optica
223492539|NCT05629091|DEVICE|FibDex|Nanofibrillar cellulose wound dressing
224183979|NCT06829602|DIAGNOSTIC_TEST|Rapid Syphilis/HIV point-of-care test|The INSTI Multiplex HIV/Syphilis Duo Antibody Test is a rapid immunoassay that can detect HIV and syphilis antibodies in the blood using finger-prick blood samples. The test is Health Canada-approved.
224183980|NCT01355380|DRUG|Inhaled iloprost (Ventavis, BAYQ6256)|Patients treated with inhaled iloprost (Ventavis) 2.5 or 5 micrograms 6-9 times daily
223588406|NCT02272179|BEHAVIORAL|Treatment as Usual|Participants received usual treatment for suicidal adolescents as they transition from inpatient hospitalization to outpatient therapy, which included a paper safety plan.
223588407|NCT03323671|DRUG|preemptive mefenamic acid|preemptive analgesia before menstrual pain
224183981|NCT01162031|DRUG|Velcade|IV
224183982|NCT02079077|DRUG|Acetylsalicylic Acid (ASA)|Acetylsalicylic Acid (ASA) 81 mg. oral daily for two months
224183983|NCT02079077|DRUG|Hydroxychloroquine (HCQ)|Hydroxychloroquine (HCQ) 200 mg. oral, daily for two months.
224183984|NCT04259398|DRUG|Propofol|propofol 1-2 mg/kg bolus injection for induction of anesthesia propofol continuous infusion for maintenance of anesthesia
224183985|NCT04259398|DRUG|Sevoflurane|sevoflurane is administered for induction and maintenance of anesthesia
224308410|NCT01886196|BEHAVIORAL|Resistance exercise|3 sets of 8-12 repetitions of resistance exercise (full body with a focus on the distal radius) completed 3 days/week under supervision in the research gym
224308411|NCT01886196|BEHAVIORAL|Flexibility training|3 days of full body stretching program (approximately 1 hour) to be performed at participants home unsupervised
223492540|NCT05629091|DEVICE|Epicite hydro|Wound dressing
223492541|NCT05629091|DEVICE|Epiprotect|Wound dressing
223492542|NCT06911060|DIETARY_SUPPLEMENT|Flaxseed|30 g/day for 12 weeks
223492543|NCT06911060|BEHAVIORAL|Diet|Diet will be planned to patients with T2DM as a part of their medical nutrition therapy.
223588408|NCT03323671|DRUG|mefenamic acid|mefenamic acid given only during menstruation
223588409|NCT00509171|DEVICE|Reamer Irrigator Aspirator|Use of standard reamer vs reamer irrigator-aspirator during IM nailing of tibial shaft fractures
223588410|NCT02351284|OTHER|Measurement|Measurement of vitamin D, PTH, and BMD changes in HIV-infected patients
223588411|NCT03040986|OTHER|Laboratory Biomarker Analysis|Correlative studies
223588412|NCT03040986|DRUG|Selumetinib Sulfate|Given by mouth (PO)
223588413|NCT02887547|PROCEDURE|micro-osteoperforation|
224183986|NCT03465696|BEHAVIORAL|Group #2 (Intervention)|"Group #2 (Intervention)~Survey 2 will be administered, and patients will be asked the following primer:~Stelara® inhibits interleukin 23, one of the immune signaling molecules involved in psoriasis. People who are born with a genetic deficiency in the immune signal interleukin-23 are generally healthy, but also have a LOWER risk of getting immune diseases like psoriasis.~How willing would you be to take Stelara® to treat your psoriasis, on a scale of (1 = definitely willing, 2 = probably willing, 3 = probably not willing, 4 = definitely not willing)"
224183987|NCT03465696|BEHAVIORAL|Group #3 (Intervention)|"Group #3 (Intervention)~Survey 3 will be administered, and patients will be asked the following primer:~Stelara® inhibits interleukin 23, one of the immune signaling molecules involved in psoriasis. People who are born with a genetic deficiency in the immune signal interleukin-23 are generally healthy, but also have a LOWER risk of getting immune diseases like psoriasis.~What do you think would be the best way to describe this to a patient?~1. Stelara® acts in an almost all-natural way to help control psoriasis.~2. Stelara® blocks one of the genetic causes of psoriasis.~3. Stelara® makes psoriasis better by blocking the overactive signal that gets the immune system out of balance~4. Stelara® blocks interleukin-23, an important immune system signaling molecule involved in psoriasis~How willing would you be to take Stelara® to treat your psoriasis, on a scale of (1 = definitely willing, 2 = probably willing, 3 = probably not willing, 4 = definitely not willing)"
224183988|NCT03252808|BIOLOGICAL|TBI-1401(HF10)|1x10\^6 or 1x10\^7 TCID50/mL TBI-1401(HF10) administered by intratumoral injection at 2-week intervals. Patients may continue to receive the injections for up to 1 year if eligible for injection.
224183989|NCT03252808|DRUG|Gemcitabine|1000 mg/m\^2 Gemcitabine administered by intravenous infusion at weekly for 3 weeks followed by a week of rest.
224183990|NCT03252808|DRUG|Nab-paclitaxel|125 mg/m\^2 Nab-paclitaxel administered by intravenous infusion at weekly for 3 weeks followed by a week of rest.
224183991|NCT03252808|DRUG|TS-1|TS-1 (40-60 mg per body surface area) administered by oral at twice daily for 4 weeks followed by 2 weeks of rest.
224183992|NCT00772031|DRUG|propranolol LA|Propranolol LA up to 240 mg/day
224183993|NCT00772031|DRUG|topiramate|Topiramate is an effective, safe and generally well-tolerated drug used for treating chronic migraine. It is becoming the standard treatment among headache specialists.
224183994|NCT00772031|DRUG|placebo|an inactive substance
224183995|NCT06573034|BEHAVIORAL|Daoist Zhanzhuang|Each session of practice will last 30 minutes, and participants are expected to participate every day for 3 months. During the initial 3 weeks, participants will engage in in-person sessions 3 times a week. On non-session days, they can choose to either attend a Zoom practice session with the coach or submit a recording of their individual practice for fidelity check. In Week 4, participants will attend an in-person session for both practice and assessment. Over the subsequent 8 weeks, participants will either attend in-person or Zoom sessions, with a total of 3 check-in sessions.
224183996|NCT06573034|BEHAVIORAL|Sham Wall Squat|Same as the Zhanzhuang group.
224183997|NCT00668876|DIETARY_SUPPLEMENT|Oral IMPACT|oral supplementation for 5 days(1 L/d )before surgery of a formula enriched with arginine, omega-3 fatty acids, and RNA
224183998|NCT00668876|DIETARY_SUPPLEMENT|Oral IMPACT|postoperative enteral infusion of the formula with arginine, omega-3 fatty acids, and RNA
224183999|NCT00668876|DIETARY_SUPPLEMENT|Parenteral nutrition|Parenteral nutrition
224184000|NCT00656136|DRUG|placebo|Patients receive placebo once daily
223492544|NCT06906497|DRUG|lebrikizumab|"Patients will receive lebrikizumab with a 500 mg loading dose administered subcutaneously at baseline and Week 2 followed by 250 mg every 2 weeks until Week 24.~At week 24, patients with ≥ Eczema Area and Severity Index (EASI) 50 will continue in the study and begin receiving lebrikizumab 250mg every 4 weeks (Q4W), while patients with \<EASI 50 will be discontinued from the study.~At week 36, patients with EASI ≥50 to \<90 will remain on Q4W through W60 (do not enter withdrawal arm), while patients with sustained low disease activity (IGA 0/1 or EASI≥90 response for at least 3 months assessed at W24 and W36) will withdraw from lebrikizumab treatment"
223492545|NCT07098858|DEVICE|The Wise System|The WiSE CRT System is an implantable cardiac system to provide left ventricular (LV) pacing stimulation in conjunction with a co-implanted system that provides right ventricular (RV) stimulation. In combination, the devices deliver biventricular (BiV) pacing.
223492546|NCT07098572|DEVICE|Cyclic single channel neuromuscular stimulation|Cyclic single channel neuromuscular stimulation is used to trigger repetitive muscular contractions
223492547|NCT07098572|DEVICE|Electromyogram-triggered 4 channel neuromuscular stimulation|EMG-MES provides biofeedback by using electromyographic signals to trigger muscular contractions
223492548|NCT06910540|OTHER|Acu-TENS|This protocol makes use of the acu-TENS treatment on the acupoints Hegu (LI4), Zusanli (ST36), Sanyinjiao (SP6), and Taichong (LR3). After cleaning the acupoints with alcohol, electrode pads (HC-ROUND-32 2.0) will be placed on the acupoints according to the locations described in the Standard International Acupuncture Nomenclature. The electrode pads will be connected to a TENS machine (MTR+ Myolito Multifunctional Stimulator MTRP-00003), in which ipsilateral LI4 and SP36, SP6 and LR3 serve a pair. A pulse rate of 120 Hz, current of 3-5 mA, and pulse width of 300µS will be delivered continually during TUGOR.
223492549|NCT06910540|OTHER|Sham acu-TENS|In the sham acu-TENS, within the same time interval, TENS pads will be placed on the same acupoints, connected to the machine, but without electric current.
223492550|NCT06911346|DIETARY_SUPPLEMENT|Diet supplementation|Healthy plant-based diet (plus supplemental foods) as part of a hypocaloric diet.
223492551|NCT06911346|DIETARY_SUPPLEMENT|Polyphenol-rich supplement|Hypocaloric diet with polyphenol-rich supplement. Polyphenol-rich sachets containing ≈30g/day of a combination of plant extracts rich in polyphenol. Frequency: 2 sachets a day. Duration: 12 weeks
224308412|NCT01915758|DRUG|clindamycin1%/tretinoin 0.025% gel|clindamycin1%/tretinoin 0.025% gel
224308413|NCT01915758|DRUG|vehicle gel|vehicle gel
224308414|NCT00052299|DRUG|cytarabine|
224308415|NCT00052299|DRUG|etoposide|
224308416|NCT00052299|DRUG|gemtuzumab ozogamicin|
224308417|NCT00052299|DRUG|idarubicin|
224308418|NCT00052299|DRUG|mitoxantrone hydrochloride|
224308419|NCT04590040|OTHER|Placebo|0% nano-HAP toothpaste
224308420|NCT04590040|DEVICE|15% nano-HAP toothpaste|Toothpaste with identical base formulation as the placebo containing 15% nano-HAP
224308421|NCT04590040|DEVICE|5% KNO3 toothpaste|Toothpaste with identical base formulation as the placebo containing 5% KNO3
224184001|NCT00656136|DRUG|BIBW 2992|Patients receive afatinib tablets once daily, and can reduce dose for adverse event management. Afatinib is given once daily, continuously until disease progression or unacceptable toxicity.
224184002|NCT05284604|DRUG|Mesenchymal Stem Cells (MSCs)|The MSCs are recovered from bone marrows of healthy donors. Each donor is carefully screened for pathogens to assure the product is safe. The MSCs are strictly compliant with FDA standards under Current Good Manufacturing Practice (cGMP) regulations.
224184003|NCT01490385|DEVICE|LED Phototherapy|
224184004|NCT02087085|DRUG|400 µg Brimonidine Implant|400 µg brimonidine implant in the study eye using Brimo DDS® applicator on Day 1, and every 3 months through Month 21.
224184005|NCT02087085|OTHER|Sham|Sham treatment with needleless applicator (no implant) to the study eye on Day 1, and every 3 months through Month 21.
224184006|NCT03809702|DRUG|Pregabalin|Pain score in group 1 (intervention group) will be compared with pain score in group 2 (placebo group)
224184007|NCT03809702|DRUG|Placebo|Pain score in group 1 (intervention group) will be compared with pain score in group 2 (placebo group)
224184008|NCT00433979|DRUG|antiretroviral treatment|These antiretroviral drugs are a part of the participant's current drug regimen.
224184009|NCT01176422|GENETIC|Blood sample|Blood samples will be collected before and after treatment completion.
224184010|NCT01721213|DRUG|Trobalt™|Trobalt™ is a potassium channel opener used as an adjunctive treatment for partial onset seizures (a form of epilepsy where a seizure begins in a specific area in one side of the brain), with or without secondary generalization in adults aged 18 years and above with epilepsy.
224184011|NCT00963742|DEVICE|Lenstec Softec HD IOL implantation|surgical removal of cataract and implantation of Softec HD PCIOL
224184012|NCT04652609|OTHER|PRESIONA|Aerobic and strength exercise combined with restricction blood flow cuffs during chemotherapy treatment
224184013|NCT02792387|OTHER|CVP measurement|CVP measurements had been performed with an electronic pressure transducer in spontaneously breathing non-ventilated patients. Central vein access was established trough the subclavian or internal jugular veins. Mean CVP was recorded for each patient, measured in mmHg.
224184014|NCT00635804|DRUG|MK-3281|MK-3281 capsule administered orally BID for 7 or 10 consecutive days depending on randomized dose. The PM dose of MK-3281 was not administered on Day 7 (for HCV-infected males) or Day 10 (for healthy males)
224184015|NCT00635804|DRUG|Placebo to MK-3281|Dose-matched placebo to MK-3281 capsule administered orally BID for 7 or 10 consecutive days depending on randomized dose of MK-3281 in serial panel. The PM dose of matched placebo was not administered on Day 7 or 10 (depending upon allocation).
224184016|NCT02680158|DEVICE|Oculeve Intranasal|Oculeve device, intranasal (test) application for approximately 3 minutes.
224184017|NCT02680158|DEVICE|Sham|Sham device (control), intranasal application for approximately 3 minutes.
224184018|NCT02680158|DEVICE|Oculeve Extranasal|Oculeve device, extranasal (control) application for approximately 3 minutes.
224184019|NCT03593031|BEHAVIORAL|Office Based Vergence and Accommodative Therapy|Exercises that will stimulate disparity vergence or accommodation independently and then combined will be used.
224184020|NCT02718131|DEVICE|INFUSE Bone Graft (BMP-2)|The INFUSE bone graft, containing BMP-2 on a collagen sponge, will be wrapped around the tibia during the surgical process.
223492552|NCT06911346|OTHER|Placebo|Hypocaloric diet plus Placebo. The placebo is a sachet (≈30g/day) with similar appearance, taste, and texture but without active polyphenols. Frequency: 2 sachets a day. Duration: 12 weeks
224184021|NCT02718131|PROCEDURE|Control Group|The control group will receive the standard surgical protocol, without addition of the INFUSE device.
224184022|NCT03734601|RADIATION|Total body irradiation (TBI)|Administer Total body irradiation (TBI) 80 cGy on Day 1 of standard TLI ATG conditioning
224184023|NCT03734601|DRUG|Anti-thymocyte globulin (ATG)|Given intravenous (IV), Dose 1.5 mg/kg x 5 days
224184024|NCT03734601|DRUG|Tacrolimus|Oral, Dose 0.05 mg/kg twice daily, can be given intravenous (IV)
224184025|NCT03734601|DRUG|Mycophenolate mofetil (MMF)|Given Oral, 15 mg/k every 2 hours for peripheral blood stem cells (PBSC) from matched related donors; 15 mg/kg every 8 hours for PBSC from unrelated donors (URDs) or mismatched related donors.
224184026|NCT03734601|RADIATION|Total lymphoid irradiation (TLI)|9 x 120 cGy over 11 days
224184027|NCT02114905|BEHAVIORAL|OTs Trained and Deliver CBIT|"CBIT is a highly structured therapy that typically takes place on a weekly basis. The patient is taught to perform a specific behavior that makes the tic more difficult to do, as soon as the tic or urge appears. This competing response helps to reduce, and in some cases, even eliminate the tic. The functional intervention (FI), is based on the fact that certain situations or reactions to tics can make them worse than they might otherwise be. The goal of FI is to identify these situations and have the patient and family attempt to change them so the tics aren't made worse unnecessarily."
224184028|NCT04318015|DRUG|Hydroxychloroquine|All treatment will be administered orally.
224184029|NCT04318015|DRUG|Placebo oral tablet|All placebo will be administered orally
223492553|NCT07095023|DRUG|Paclitaxel oral solution plus Subcutaneous Pertuzumab/Trastuzumab|"Patients who meet the inclusion criteria will be enrolled and given paclitaxel oral solution and subcutaneous pertuzumab/trastuzumab for neoadjuvant treatment.~Paclitaxel oral solution: 200mg/m2 po bid, D1,D8,D15, q3w. Subcutaneous pertuzumab/trastuzumab: 1200 mg pertuzumab plus 600 mg trastuzumab loading dose in 15 mL, followed by 600 mg pertuzumab plus 600 mg trastuzumab maintenance doses in 10 mL, q3w."
224184030|NCT02862743|OTHER|patients with metastatic melanoma|Blood sample to realize molecular characterization of melanoma
224184031|NCT04656262|DRUG|Cyclophosphamide|Cyclophosphamide is formulated as coated tablets of 50mg for oral administration
224184032|NCT04656262|DRUG|Doxorubicin|Doxorubicin is formulated as 60 mg/mq for infusional use (i.v use)
223492554|NCT07099690|PROCEDURE|Perineal massage|"Perineal massage will be performed during labor, either between or during contractions, regardless of the position chosen by the laboring woman.~The researcher, wearing gloves, will insert one or two fingers (index and middle) into the participant's vaginal canal and move them from side to side in a U-shaped motion, for approximately one second in each direction. Light downward pressure will be applied toward the rectum, according to the woman's tolerance, until relaxation of the massaged perineal muscles is observed.~A water-based lubricant will be used to facilitate the procedure. The massage will last no longer than 5 minutes."
224184033|NCT01073384|DRUG|SGX201 (delayed release beclomethasone 17,21-dipropionate)|Delayed release beclomethasone 17,21-dipropionate before the first administration of radiation therapy continuing for 7 days after the end of radiation therapy.
224184034|NCT04522635|DRUG|(100 ml of Albumin 25%)|single dose of 25g albumin (100 ml of Grifols 25%) given intravenously at the start of IHD
224184035|NCT01247376|DEVICE|Cooling and compression|Cooling and compression of the knee postoperatively with an Aircast device.
224184036|NCT03382639|DRUG|Luvadaxistat|TAK-831 tablets.
224184037|NCT03382639|DRUG|Placebo|Luvadaxistat placebo-matching tablets.
224184038|NCT02406586|DRUG|Salsalate|Salsalate 750 mg
224184039|NCT02406586|DRUG|Carvedilol|Carvedilol 3.125 mg
224184040|NCT02406586|DRUG|Placebo|One tablet
224184041|NCT02406586|DRUG|Intralipid 20%|24-hour infusion of Intralipid 20% solution at 20 mL/h (96 g/24 h)
223492555|NCT07098390|BEHAVIORAL|Progressive Muscle Relaxation Exercise|"When patients are admitted to the Orthopedics and Traumatology Clinic for arthroplasty and agree to participate in the study, they will be informed about the research process and written informed consent will be obtained. The Descriptive Information Form, Numeric Rating Scale (NRS), The Fear of Falling Scale, and the State-Trait Anxiety Inventory (STAI) will be administered through face-to-face interviews by the researcher. After the pre-tests are completed, patients will be randomly assigned to the intervention and control groups.~In the preoperative period, upon admission to the clinic, patients in the intervention group will receive progressive muscle relaxation exercises (PMRE). To enhance concentration and minimize the impact of ambient noise, patients will listen to the exercises using headphones.~On the first postoperative day, the patient will be revisited by the researcher. After the physician explains that the patient will be mobilized, the State-Trait Anxiety Inventory will"
223492556|NCT07099443|OTHER|Non-Interventional Sample Collection and Analysis|This study is observational. Biological samples are collected as part of standard care or for research purposes and analyzed to characterize resistance mechanisms. No treatment or intervention is administered as part of the study protocol.
223492557|NCT07131969|OTHER|blood draw|Venous blood sampling into Tempus tube for RNA-sequencing
223492558|NCT06859307|PROCEDURE|intra-abdominal instillation of corticosteroids|after adhesiolysis, peritoneal lavage with diluted corticosteroids will be instillated intra-abdominally
223492559|NCT06859307|PROCEDURE|intra-abdominal instillation of fresh frozen plasma|after adhesiolysis, peritoneal lavage with diluted FFP will be instillated intra-abdominally
223492560|NCT06755450|DRUG|AUR112|Once daily
223492561|NCT07097025|DEVICE|vagus nerve stimulation|VNS is a neuromodulatory treatment involving implantation of a subcutaneous device that delivers intermittent electrical stimulation to the vagus nerve, modulating central pathways associated with mood regulation.
223492562|NCT07097532|PROCEDURE|Radiofrequency|Under sterile conditions and fluoroscopic guidance, pulsed radiofrequency treatment was applied unilaterally to the dorsal root ganglia at the L4-L5 and L5-S1 spinal levels. Sensory and motor stimulation were performed to confirm appropriate electrode placement. Pulsed radiofrequency was delivered at 45 volts for 300 seconds at 42°C using standard radiofrequency equipment. Patients were monitored for three hours following the procedure, and cutaneous silent period (CSP) recordings were obtained on the same day and during follow-up assessments.
224184042|NCT00189917|BIOLOGICAL|IMVAMUNE (MVA-BN)|1x10E08 TCID50, subcutaneous vaccination
224184043|NCT00962624|DRUG|meningococcal B vaccine & meningococcal ACYW conjugate vaccine|Meningococcal B vaccine will be administered at 0, 2 and 6 months and a single dose of meningococcal ACYW vaccine will be administered at 0 months, concomitantly with the first dose of the meningococcal B vaccine.
223588414|NCT02228447|BEHAVIORAL|Healthy Habits, Healthy Girls Group|The intervention group will receive a 6-month multicomponent intervention (i.e., enhanced physical education classes; interactive seminars; nutrition workshops; text messages; and parents newsletters) and materials (i.e., nutrition and PA handbooks; cooking books; Choreographies CDs and PA leadership handbook).
223588415|NCT00119496|DRUG|rosiglitazone|oral tablet, 4mg bd for 4 weeks
223588416|NCT00119496|DRUG|theophylline|Oral theophylline, 200mg bd
223588417|NCT00119496|DRUG|beclomethasone|inhaled beclomethasone, 200mcg bd
223588418|NCT00119496|DRUG|inhaled beclomethasone and oral theophylline|inhaled beclomethasone (400mcg/day), oral theophylline (400mg/day)
224184044|NCT00137527|DEVICE|Optimizing hemodynamic and anesthetic parameters to improve cerebral perfusion|
224184045|NCT02244827|DRUG|WCK 2349|levonadifloxacin (active drug) and the sulfate metabolite
224184046|NCT03378882|BIOLOGICAL|Parasitic serologies|"Suspected angiostrongylosis - Angiostrongylus cantonensis:~* An aliquot of CSF and an aliquot of serum will be sent to the laboratory of tropical medicine in Switzerland for research of specific antibodies.~* A CSF aliquot will be sent to the CDC for PCR.~Suspected angiostrongylosis- Angiostrongylus costaricensis:~\- An aliquot of serum will be sent to the laboratory of tropical medicine in Switzerland for research of specific antibodies."
224184047|NCT03378882|PROCEDURE|Biopsy|"Suspected angiostrongylosis - Angiostrongylus costaricensis:~\- A piece of biopsy or intestinal resection will be sent to the pathology laboratory for parasitic elements suggestive of Angiostrongylus costaricensis infection"
223588419|NCT02504931|DRUG|Sertraline|A Randomized Controlled Trial Design will randomize subjects to one of two arms. Sertraline is the active medication treatment arm.
223588420|NCT02504931|DRUG|Placebo|A Randomized Controlled Trial Design will randomize subjects to one of two arms. Placebo is the control medication treatment arm.
223588421|NCT00054028|DRUG|suramin|Given IV
224308422|NCT03916029|BEHAVIORAL|facilitator|Training and employment of community members to assist the diagnosis and management of otitis media
223588422|NCT00054028|DRUG|paclitaxel|Given IV
223588423|NCT00054028|OTHER|pharmacological study|Correlative studies
224184048|NCT06337773|BEHAVIORAL|8-weeks's on-line precision nursing education program|The intervention involved 8-weeks's on-line precision nursing education program, including Qigong exercise, and mindfulness training.
224184049|NCT02649673|DRUG|LCL161|
224308423|NCT04647565|OTHER|interviews|interviews (human and social sciences)
224308424|NCT03268707|DEVICE|Telemetric smartphone application|Structured follow up with a telemetric smartphone application
224308425|NCT03268707|OTHER|Conventional follow up|Conventional follow up at physician practice
223588424|NCT02925169|DEVICE|CT Scan|CT imaging
223492563|NCT07097532|PROCEDURE|Transforaminal Epidural Steroid Injection|Using a fluoroscopic C-arm device, transforaminal epidural steroid injection (TFESI) was performed at the L4-L5 and L5-S1 foraminal levels. At each level, a total of 4 mL of solution containing 16 mg of dexamethasone and sterile saline was administered following confirmation of appropriate contrast spread. Negative aspiration was verified prior to injection. Cutaneous silent period (CSP) measurements were conducted on the same day and at designated follow-up intervals.
223588425|NCT04054466|BEHAVIORAL|Nursing Counseling in the change of Alcohol Consumption Behavior in patients receiving HAART|"It is a health intervention, performed by the nurse with the purpose of providing support or support to the patient's health care. The main objective of counseling is to improve adherence to treatment in patients who receive HAART but also consume alcoholic beverages.~The components of the differentiated counseling according to the levels of consumption are consolidated according to the recommendations given by the World Health Organization (WHO) after the application of the AUDIT:~Social consumption (sometime in life, in the last year or in the last month) = mainly education about consumer risks, its application will be bi-monthly."
223588426|NCT04054466|BEHAVIORAL|Habitual Counseling|Regular counseling provided to patients receiving HAART, based on education and guidance to comply with antiretroviral treatment
223588427|NCT00235950|DRUG|Rosuvastatin or atorvastatin or simvastatin and clopidogrel|
223588428|NCT03274804|BIOLOGICAL|Pembrolizumab|Eligible subjects will receive pembrolizumab beginning on Day 1 of each 3-week dosing cycle (d1, qd22)
223588429|NCT03274804|DRUG|Maraviroc|Maraviroc will be administered perorally on day 1 to 21 of each cycle (d1-21; qd22)
223588430|NCT03323866|DRUG|Budesonide 0.5 MG/ML|2 cc nebule of budesonide in 240 cc of saline water (Sinus Rinse) once daily
223492564|NCT07093359|PROCEDURE|Laparoscopic or robotic LINX procedure|Participants randomised to laparoscopic or robotic magnetic sphincter augmentation (LINX procedure) will receive surgical treatment under general anaesthesia, with placement of the LINX device around the distal oesophagus. The LINX device comprises titanium beads with magnets in the centre.
223492565|NCT07093359|PROCEDURE|Laparoscopic or robotic fundoplication|Participants randomised to laparoscopic or robotic fundoplication will receive surgical treatment for managing GORD including a total or partial fundic wrap behind or in front of the distal oesophagus and gastro-oesophageal junction.
223492566|NCT07100912|OTHER|Mitopure Topical Formula 5|Topical skin cream containing Mitopure
223492567|NCT07100912|OTHER|Mitopure Topical Formula 6|Topical skin cream containing Mitopure
223492568|NCT07100912|OTHER|Mitopure Topical Formula 7|Topical skin cream containing Mitopure
223492569|NCT07100912|OTHER|Mitopure Topical Formula 8|Topical skin serum containing Mitopure
223492570|NCT07100912|OTHER|Mitopure Topical Formula 9|Topical skin exfoliator containing Mitopure
223588431|NCT03323866|DRUG|Mometasone nasal spray|Mometasone 50 mcg/spray 2 sprays twice daily
223588432|NCT00578630|OTHER|buccal swabs and obtaining peripheral blood|will be the collection of normal cells and assessments of toxicity following chemotherapy at routine clinic visits.
223588433|NCT02547051|OTHER|Food Allergy Testing and Elimination Diet|Food allergy testing and elimination diet
223492571|NCT07100912|OTHER|Mitopure Topical Formula 10|Topical skin cleanser containing Mitopure
223492572|NCT07103265|DEVICE|Transcranial focused ultrasound stimulation|Parameters Range of values Fundamental frequency 250 kHz Transducer diameter 15 cm Focal distance 13.5 cm (steerable +/- 5-10 mm from the center) Pulse repetition frequency 100 Hz Duty cycle 10% Duration 2 min for each of the 7 foci Peak spatial intensity (Isppa) 10.0 W/cm2 Peak temporal average intensity (Ispta) 1.2 W/cm2 Mechanical index (MI) 0.48 \* Thermal index (TI) 0.8oC \*\*
223492573|NCT07103265|DEVICE|Sham stimulation|Same set-up as for real stimulation but with without delivering any ultrasound stimulation
223492574|NCT07103564|OTHER|Immediately placed implant in maxillary premolars with local melatonin application|Patients will receive immediately placed implants with local melatonin powder (3mg) application.
223492575|NCT07103564|OTHER|Immediately placed implant in maxillary premolars without local melatonin application|Patients will receive immediately placed implants without local melatonin application.
223588434|NCT02583321|DEVICE|Endotracheal tubes not allowing SSD|In the participating center, a bundle of Ventilator-Associated Pneumonia (VAP) prevention will be applied: elevate the head of the bed to 30°-45°, regular oral care, manage patients with sedation algorithm, assess readiness to extubate daily, intermittent control of endotracheal tube cuff pressure
223588435|NCT02583321|DEVICE|Endotracheal tubes allowing SSD|"In the participating center, a bundle of VAP prevention will be applied: elevate the head of the bed to 30°-45°, regular oral care, manage patients with sedation algorithm, assess readiness to extubate daily, intermittent control of endotracheal tube cuff pressure.~In addition, SSD will be realized using a 10 ml syringe at in attending frequency of 2 hours."
224184050|NCT02649673|DRUG|Topotecan|Topotecan will also be administered orally. Patients in DL 1 will receive topotecan at 1.8 mg/m2 per day for the first 5 days of each 21-day cycle. Patients in DL 2 will receive topotecan at 2.3 mg/m2 per day for the first 5 days of each 21-day cycle. The maximum dose for topotecan will not exceed 2.3 mg/m2 per day in this study.
224184051|NCT02649673|DRUG|Pegylated GCSF (PEG-GCSF)|Pegylated GCSF (PEG-GCSF) (e.g. pegfilgrastim) on-body injector (OBI) or daily GCSF (e.g. filgrastim) will be given according to institutional policy after Day 5 of topotecan. Because patients treated with topotecan are at high risk of developing febrile neutropenia, GCSF will be given in the prophylactic setting.
224184052|NCT02812602|DRUG|Lidocaine patch|Lidocain patch will be applied around the surgical wound about 20 minutes before removal of staples.
224184053|NCT02812602|DRUG|placebo|Placebo patch will be applied around the surgical wound about 20 minutes before removal of staples.
224184054|NCT04058860|DEVICE|NIRS monitoring|Cerebral and somatic near-infrared spectroscopy (rScO2) measurements
224184055|NCT04058860|DEVICE|Cox monitoring|Cerebral autoregulation monitoring
224184056|NCT04058860|DEVICE|Sublingual microscopy|Sublingual mucosal microcirculation measurements during surgery using side dark field (SDF) imaging
224184057|NCT06152991|DRUG|GODEX|"The amount of active ingredient per dose (1 capsule)~* Carnitine Orotate 150mg~* liver extract antitoxic fraction 12.5㎎~* Adenine Hydrochloride 2.5mg~* Pyridoxine Hydrochloride 25mg~* Riboflavin 0.5mg~* Cyanocobalamin 0.125mg~* Biphenyl Dimethyl Dicarboxylate 25mg"
223588436|NCT01362387|OTHER|Alternative follow-up protocol|Women (n=1000) will be allocated by chance to one of two groups: alternative follow-up using a standard text message, online or telephone questionnaire and a low sensitivity urine pregnancy test, or standard follow-up which consists of an in person visit with an ultrasound or a telephone call and high sensitivity pregnancy test.
223588437|NCT00214084|DRUG|Allopurinol|
224184058|NCT06152991|DRUG|Placebo|"* Anhydrous lactose 50mg.~* Colloidal silicon dioxide 12mg.~* Amorphous cellulose 50mg.~* Lactose monohydrate 215.625mg.~* Magnesium stearate 7mg.~* Upper and lower brown opaque capsules 77mg."
224184059|NCT00218439|DRUG|Paroxetine|10 mg for 1 week followed by 20 mg for 3 weeks
224184060|NCT00218439|DRUG|Placebo|
224184061|NCT04676581|OTHER|Leech Therapy|Patient who received leeches (for more than 2 days) at the Amiens University Hospital over a period of 9 years (2010-2018)
224184062|NCT02594150|OTHER|Financial Incentive|Financial incentives provide small immediate and tangible rewards that are aligned with the abstract long-term rewards of cancer prevention.
224184063|NCT02477215|DRUG|MLN9708|4 mg of MLN9708 delivered on days 1, 8 and 15 of a 28 day cycle.
224184064|NCT02477215|DRUG|Dexamethasone|40 mg oral on Days 1, 8, 15 of each 28 day cycle.
224184065|NCT02477215|DRUG|Bendamustine (multiple dose levels)|70 mg/m\^2, 80 mg/m\^2, or 90 mg/m\^2 on days 1 and 2
224184066|NCT02477215|DRUG|Bendamustine (MTD)|80 mg/m\^2 on days 1 and 2
224184067|NCT05299060|PROCEDURE|cyanoacrylate adhesive (SecurePortIV®)|Application of cyanoacrylate tissue adhesive (SecurePortIV®) to the puncture site plus standard wound care.
224184068|NCT05299060|PROCEDURE|standard cure|"The standard cure consists of:~* Application of hemostasis at the point of insertion for 2 minutes post puncture or until bleeding stops.~* Fix with clear polyurethane dressing (3M®-1655 Tegaderm™ IV) and sutureless fixation device (BD-19940 StatLock™ PICC Plus)."
224184069|NCT03923062|DEVICE|chemicalpeeling|"Cleansing and degreasing the face with alcohol .~* The patients must be sitting at an angle of 45.~* A 2 × 2 cm cotton gauze will be used to apply TCA 20%.~* We will apply the acid from the midline to the right side of the forehead and under the right eye, covering the right cheek and perioral area.~* We then will wait for a few minutes and will observe the frost developing.~* The patient will be then allowed to wash her face."
224184070|NCT03923062|DEVICE|cryopeeling|Cryopeeling will be performed by spraying the freezing substance(Liquid Nitrogen) on the face at 1-2cm distance and moving along the affected area until freezing appear.
224184071|NCT03923062|COMBINATION_PRODUCT|microneedling|"Tranexamic acid will be used in aconcentration of 4mg/ml ,1ml will be used fo half of the face.~* After gentle cleansing, topical analgesic cream will be applied over the area to be treated.~* The microneedles will be used, the skin will be stretched and microneedling will be carried out in vertical, horizontal, and both diagonal directions for about four to five times. Tranexamic acid, 0.5 to 1 ml (4 mg/mL), will be applied over this area, and the procedure will be repeated four to five times in the above-said directions"
224184072|NCT02221804|BEHAVIORAL|14 days of voluntary step count reduction to no more than 1500 steps/day.|
224184073|NCT03223025|DRUG|CinnaTropin®|0.03 mg/kg daily subcutaneous injections
224184074|NCT03223025|DRUG|Nordilet®|0.03 mg/kg daily subcutaneous injections
224184075|NCT05535803|BIOLOGICAL|Olfactory mucosa-derived mesenchymal stem cells|Autologous olfactory mucosa-derived mesenchymal stem cells
224184076|NCT05535803|OTHER|Patients treated according to current clinical protocols|Patients treated according to current clinical protocols
224184077|NCT00004409|DRUG|collagenase|
224184078|NCT04284176|OTHER|Mirror therapy and action-observation therapy|The mirror therapy and action-observation therapy group will receive for 20 days a daily therapy of 15 minutes at home of MT and 45 of AOT, whereas the action-observation therapy group will receive 60 minutes of AOT.
223492576|NCT07102992|DEVICE|High intensity laser therapy|"High intensity Laser Therapy :A standard handpiece endowed with fixed spacers will used to provide the same distance to the skin and perpendicularly to the zone to be treated with a laser beam diameter of 5 mm. Three phases of treatment will be performed for every session. The total energy that will be delivered to the patient during one session will be 1275 J through three phases of treatment.~Frequency of treatment: Treatment will be given 5 times / week for 20 sessions."
223492577|NCT07102992|DEVICE|Shock Wave therapy|"radial extracorporeal shock wave therapy (2,000 shots, 4 Bar, 5 Hz) (once a week) will be administered to the ulnar nerve at the proximal cubital tunnel region.~Frequency of treatment: Treatment will be given 1 time / week for 4 sessions"
223492578|NCT07102992|OTHER|Ulnar nerve gliding exercises.|"While keeping patients head in a neutral position, will teach the patient to:~1. Begin with your arm out, palm side of the hand facing up.~2. Bend the elbow toward you, palm side facing you.~3. Rotate the palm of your hand outward and bend your wrist so that the fingers are pointing towards you.~4. Twist your wrist so that the palm of your hand is now facing upward.~5. While your wrist remains bent, stretch out your arm into a straight position, with your fingers bent towards the floor.~Hold each position for 5 seconds, repeat series 3-5 times. Frequency of treatment: Treatment will be given 5 times / week for 20 sessions."
223492579|NCT07104877|DRUG|SYS6010|Administered via intravenous infusion at the dose of 3.2-4.8 mg/kg
223492580|NCT07104877|DRUG|SYH2051|Administered via oral at the dose of 40-80 mg
223492581|NCT07100600|DRUG|Trastuzumab Rezetecan|Trastuzumab Rezetecan：4.8mg/kg Q3W
223492582|NCT07100600|RADIATION|FSRT or WBRT|FSRT （8Gy/3-5 fx）or WBRT（30Gy/10fx）
223492583|NCT07103590|PROCEDURE|single Sagittal Split plate|patients will be treated using a single Sagittal Split plate at the neutral zone of mandible
223588438|NCT01183468|BIOLOGICAL|Aralast NP 45 mg dose|\- 45 mg/kg/week
223588439|NCT01183468|BIOLOGICAL|Aralast NP 90 mg dose|\- 90 mg/kg/week
224184079|NCT02136927|DRUG|SPARC1210|
224184080|NCT02136927|DRUG|Reference1210|
224184081|NCT05449431|OTHER|TLC1_TM6|Following this inclusion, patients are performing 1-minute chair lift test (TLC1) before 6-minute Walk Test (TM6). Each exercise will be separated by 30 minutes during which the patient will be sitting in a waiting room.
223588440|NCT01183468|BIOLOGICAL|Aralast NP 180 mg dose|\- 180 mg/kg/week
223588441|NCT00845065|DRUG|Boceprevir|800 mg, using SCH 503034 200-mg capsules, three times a day (TID) orally (PO) for 48 weeks
223588442|NCT00845065|OTHER|Placebo|800 mg, using placebo matching SCH 503034 200-mg capsules, three times a day (TID) orally (PO) for 48 weeks
223492584|NCT07103590|PROCEDURE|two conventional miniplates|patients will be treated using two conventional miniplates according to Champy's osteosynthesis lines.
224184082|NCT05449431|OTHER|TM6_TLC1|Following this inclusion, patients are performing 6-minute Walk Test (TM6) before 1-minute chair lift test (TLC1). Each exercise will be separated by 30 minutes during which the patient will be sitting in a waiting room.
224184083|NCT03558230|BEHAVIORAL|Standardized Constraint-Induced Movement Therapy|The standardized Constraint-Induced Movement Therapy aims to improve the child's weak upper extremity through intensive frequent and repetitive movements. The therapy duration is 6 hours/day for 5 consecutive days.
224184084|NCT03558230|BEHAVIORAL|Vibration|Vibration applied to the wrist.
223492585|NCT07103174|BIOLOGICAL|MG-K10 placebo|Administer the drug once every 4 weeks for a total of 6 times
223492586|NCT07103031|BEHAVIORAL|Behavioral therapy|Patients in PedMIDAS stage 1-2 (score ≤ 30) received behavioral therapy including lifestyle counseling, stress management techniques, sleep hygiene education, and individualized headache triggers review. Additionally, each patient was provided with a headache report card to self-monitor symptoms, triggers, and medication use over a 3-month period.
223492587|NCT07103031|DRUG|Propranolol|Patients in PedMIDAS stage 3-4 (score \> 30) received oral propranolol treatment at a dose of 1-3 mg/kg/day, adjusted by weight and tolerance, for a total of 3 months. The medication was prescribed and monitored by a pediatric neurologist. Patients were followed with routine check-ups and adverse effects were recorded.
223492588|NCT05467527|BEHAVIORAL|Prosocial-orientated Acceptance and Commitment Training plus positive parenting advice|The PACT group will receive a combination of 6 online modules and 4 group-based video conferencing sessions of Prosocial-orientated Acceptance and Commitment Training plus positive parenting advice via a mobile app across 12 weeks. The modules will cover real-life scenarios of daily parenting challenges in caring for a child with SHCN, followed by age-appropriate positive parenting advice based on the Centers for Disease Control and Prevention guidelines. After going through the scenarios, parents will be audio/visually guided to participate in ACT activities, including mindfulness exercises, ACT metaphors and experiential exercises, which will be used to increase psychological flexibility.
223492589|NCT05467527|BEHAVIORAL|Positive parenting advice|The Control Group will receive a total of 6 online modules and 4 group-based video conferencing sessions in a closed group of 6-8, 60 minutes per session guided by a trained facilitator via the mobile app across 12 weeks. The online modules will provide identical contents to those in the PACT group, but no guided ACT metaphors or experiential exercises. The interaction sessions serve to review and discuss the contents of online modules, but without the contents related to ACT/prosociality.
223492590|NCT06913595|DRUG|Direct Oral Anticoagulant.|Direct Oral Anticoagulant AFTER BARIATRIC SURGERY
223492591|NCT06913595|DRUG|Low Molecular Weight Heparine|Low molecular weight heparin after bariatric surgery
223588443|NCT00845065|BIOLOGICAL|Peginterferon alfa-2a|Peginterferon alfa-2a, pre-filled syringes, given 180 μg/week subcutaneously (SC) for 48 weeks
223588444|NCT00845065|DRUG|Ribavirin|"Ribavirin 200-mg capsules, weight-based dosing~* \<75 kg, 1000 mg/day orally (PO), divided twice daily (BID)~* \>=75 kg, 1200 mg/day PO, divided BID~for 48 weeks"
224184085|NCT03558230|BEHAVIORAL|Placebo (for vibration)|No vibration applied to the wrist.
224184086|NCT02358720|RADIATION|Arm A|1x24Gy high dose IMRT on spinal bone metastasis
224184087|NCT02358720|RADIATION|Arm B|fractionated conformal RT 10 x 3 Gy on spinal bone metastasis
224184088|NCT01780948|DRUG|Atorvastatin 20 mg|Add atorvastatin 20 mg and compare 12-hour AUC of everolimus between Arm everolimus and everolimus with atorvastatin 20 mg
224184089|NCT01780948|DRUG|Everolimus|Administration only everolimus, no atorvastatin. Everolimus administration with adjusted dose to target C trough (C0)level between 3-12 ng/mL.
224184090|NCT01911546|DRUG|everolimus + low-dose tacrolimus|Patients are supplied everolimus (Zortress) + prograf
223492592|NCT07105657|OTHER|Rehabilitation|Three weeks intensive rehabilitation where patients undergo group-based and individualised rehabilitation focusing at improving pain, function and quality of life for the patient
223492593|NCT07103226|RADIATION|Hyperthermia|Hyperthermia will be applied for a period of 15 to 20 minutes in the area to be treated, maintaining a thermal sensation of gentle heat for the patient and accompanied by active-assisted or passive mobilization of the structures adjacent to the plantar fascia.
223492594|NCT07103226|OTHER|Physical Exercise|The therapeutic physical exercise focused on the flexor muscles of the foot will consist of 3 periods of isometric contraction of 15 seconds, with a rest period of 30 seconds, varying the number of repetitions from 3 to 5 depending on the patient's symptoms.
223588445|NCT02231268|DRUG|Gladem|
223588446|NCT05283590|DIAGNOSTIC_TEST|Automated echocardiographic inferior vena cava measurement|Patients will be place in supine position. view: subcostal view, importantly supine is standard position for IVC measurement, the IVC is larger in the right lateral decubitus position and vice versa, alternatively directly through a transhepatic approach. Measures will be performed in the two dimensional mode close to the hepatic vein (1 - 3cm from the IVC connection to the right atrium). The IVC will be measured by MM-Mode manually and with the automated mode (both measures will be recorded. In the manual mode this measure requires concurrent utilization of M-Mode and two dimensional mode
224184091|NCT01418066|DRUG|Ayurvedic Herbs|A tea made of Murraya koenigii leaves, Punica granatum and Curcuma as powder. Decoction of 12ml powder in 100ml hot water is taken twice daily at least 30 minutes before a meal.
224184092|NCT01418066|DRUG|Placebo tea|Graminis Flores and Maidis stigmata as a powder. Decoction made of 12ml in 100ml hot water. To drink twice daily at least 30 Minutes before a meal.
223588447|NCT00437255|DRUG|Clobetasol Propionate, 0.05%|Topical, twice daily for 4 weeks
223588448|NCT00437255|DRUG|Calcipotriene and betamethasone dipropionate ointment|Topical, once daily
224184093|NCT04057586|PROCEDURE|Nonintubated|During surgery, patient is deeply sedated and respiration is maintained by spontaneous breath under the nasal high flow oxygen support.
224184094|NCT04057586|PROCEDURE|Intubated|During surgery, patient received standard general anesthesia and respiration is maintained by using mechanical ventilation.
224184095|NCT00504816|DRUG|GSK189075|Given with Brevicon to determine any effects of GSK189075 on Brevicon PK.
224184096|NCT00504816|DRUG|Brevicon|Given with GSK189075 to determine if GSK189075 exerts an effect on GSK189075 PK.
224184097|NCT02631434|PROCEDURE|sit-to-stand test|
224184098|NCT02631434|PROCEDURE|six-minutes walking test|
223492595|NCT07103226|OTHER|Stretching|The plantar fascia stretch will be performed with the patient in the supine position. Maximum dorsiflexion will be achieved, and the lower limb will be elevated with the knee extended as tolerated. This procedure will be performed three times in a row for 30 seconds, with a 1-minute rest between each stretch.
224184099|NCT05628012|BEHAVIORAL|Circadian Based Time Restricted Eating|Personalized schedule to restrict eating based on DLMO, approximately \~4h prior to DLMO or sleep onset.
224184100|NCT04669275|BEHAVIORAL|Telephone Counselıng|Telephone counseling
224184101|NCT02979275|PROCEDURE|Open heart surgery on cardiopulmonary bypass.|Brain oximetry and tissue saturation will be measured during operation. NGAL, cystatin-C, and Acute Kidney Injury Network (AKIN) criteria of AKI will be assessed durin first post-op day.
224184102|NCT04302311|DIAGNOSTIC_TEST|Holter monitoring|Use of smart device application and technologies to assess for arrhythmias
224184103|NCT04302311|DIAGNOSTIC_TEST|Kardia/AliveCor monitoring|Kardia/AliveCor monitoring
224184104|NCT02590211|BEHAVIORAL|cognitive, emotional and clinical assessment|Cognitive and emotional assessment: Posner paradigm applied to emotional information (attention and emotional perception abilities), the modified Wisconsin Card Sorting Test (mental flexibility), the Hayling Sentence Completion Task (verbal inhibition), the Go - No Go test (motor inhibition) and the expressive suppression method (facial expression inhibition) Clinical assessment: gambling course and habits, level of cognitive distortions, control attribution (locus of control), social phobia, motivation for gambling, impulsivity, co-addictions, coping and gambling related-damage
223492596|NCT07103226|OTHER|Orthopedic insole|Imposition of an orthopedic insole
223492597|NCT07104708|PROCEDURE|The Child-Parent- Trainer exercise program|The Child-Parent-Trainer exercise program is a 12-week exercise training program, which is based on the sensory and cognitive needs of children with ASD, multiple game forms are integrated to form a multi-sensory intervention model. The exercise program is developed according to the types of exercise recommended in the Exercise Guidelines for Preschool Children of China, including the development of basic motor skills, such as physical movement, posture control, object control; development of important physical qualities, such as agility, balance, coordination. The training program for different age group consists of physical movement items, object control items and limb coordination items. The exercise intensity is moderate.
223492598|NCT07104708|PROCEDURE|The regular physical training|The regular physical training courses will last for 12 weeks. It is training in motor skills and fine motor skills. The items include passing the ball, lifting small dumbbells, running, handicrafts, etc. There is no requirement for the intensity of the exercise.
223492599|NCT07104526|DRUG|Propranolol + Bleomycin|Oral propranolol at 1 mg/kg/day for 6 months plus intralesional bleomycin (1 mg/mL solution) injected once monthly. The bleomycin dose was 0.2-0.5 mg per injection site, not exceeding a total of 1 mg/kg per session or a cumulative dose of 10 mg.
223492600|NCT07104526|DRUG|Propranolol|Oral propranolol hydrochloride solution administered at a dose of 1 mg/kg/day for 6 months.
223492601|NCT07103421|DIAGNOSTIC_TEST|Non-Surgical Periodontal Therapy|Non-surgical periodontal therapy involves the removal of bacterial plaque and calculus from tooth surfaces and root surfaces beneath the gum line using manual or ultrasonic instruments. This treatment is performed for patients with periodontitis to improve gum health and reduce inflammation. Serum cystatin C levels will be compared before and after treatment between healthy patients and those with renal impairment.
224184105|NCT01342809|BEHAVIORAL|Follow up|Follow up, consultations with general practitioner, written guidelines, supervision.
224184106|NCT01474291|BIOLOGICAL|Tocilizumab|Tocilizumab administered according to prescribing information and normal clinical practice.
224184107|NCT03339999|DRUG|AGN-242428|AGN-242428 administered as an oral capsule(s) once daily.
223492602|NCT07105150|BEHAVIORAL|video-based education program|"The video-based education program will include 4 workshops of 20 minutes each, at a rate of 1 video per week:~Video 1: Anatomy and physiology of the pelvic floor; Video 2: Physiology of the urinary tract; Video 3: Physiology of the digestive tract; Video 4: Pathophysiology of urinary incontinence and other pelvic floor disorders (genital prolapse and anal incontinence) and preventive measures in daily activities."
223492603|NCT07105150|OTHER|written information|The control group will receive a paper information document (containing the same information as the intervention group) during the 4-week period
223492604|NCT07104890|BEHAVIORAL|Enhanced Recovery After Surgery (ERAS) Protocol, which includes early oral intake, early mobilization, opioid-sparing multimodal analgesia, prophylactic antiemetics, early urinary catheter removal, an|The Enhanced Recovery After Surgery (ERAS) Protocol for elective cesarean section includes a multimodal perioperative care approach aimed at accelerating postoperative recovery. Key components are early oral intake, early mobilization, opioid-sparing multimodal analgesia, prophylactic antiemetics, early removal of the urinary catheter, and gum chewing to stimulate bowel function. This protocol is compared with Standard Perioperative Cesarean Care, which involves overnight fasting, delayed oral intake until bowel function returns, conventional analgesia, later mobilization, and routine catheter removal.
223492605|NCT07103434|BEHAVIORAL|VR Mindfulness intervention|Parallel randomized controlled trial
223492606|NCT07103434|BEHAVIORAL|Audio-based MBI|Parallel randomized controlled trial
223492607|NCT07103434|BEHAVIORAL|Waitlist control|Parallel randomized controlled trial
224184108|NCT03339999|DRUG|Placebo|Placebo administered as an oral capsule(s) once daily.
224184109|NCT03939429|DRUG|QPX2015|antibiotic
224184110|NCT03939429|DRUG|Placebo oral capsule|Placebo comparator
224184111|NCT01718860|PROCEDURE|Quantitative measurement of neuromuscular transmission|Quantitative measurement of neuromuscular transmission with train-of-four watches.
223492608|NCT07103694|DRUG|anti-CGRP monoclonal antibodies|erenumab, fremanezumab, galcanezumab, eptinezumab
223492609|NCT07103694|DRUG|gepants|atogepant, rimegepant
223492610|NCT07103694|DRUG|combination of sumatriptan and naproxen|combination of sumatriptan and naproxen
223492611|NCT07103694|DRUG|ditan|lasmiditan
223588449|NCT03645109|DIETARY_SUPPLEMENT|Vitamin D3|Capsules with 5,000 IU of vitamin D3 once a day (one capsule)
223588450|NCT03645109|OTHER|Capsules with placebo (talcum food grade)|Capsules with placebo (talcum food grade)
223588451|NCT02182765|DRUG|Nevirapine|
223588452|NCT02182765|DRUG|Amprenavir|
223588453|NCT02182765|DRUG|Abacavir|
223588454|NCT06455748|DRUG|Daratumumab/daratumumab and hyaluronidase-fihj|Daratumumab/daratumumab and hyaluronidase-fihj: Dara SC 1800mg subcutaneous (IH) or Dara 16mg/kg intravenously (IV) administered weekly (qwk) x 4 every 2 weeks X 3 doses per month starting C7.
224184112|NCT02039869|DEVICE|Confocal endomicroscopy|The probe allows microscopic evaluation of tissue in real time during endoscopy.
224184113|NCT02039869|DRUG|Proton pump inhibitor|Acid suppressing medication (over the counter)
224184114|NCT02039869|DRUG|Sucralfate|Coating agent for damaged intestinal lining.
224184115|NCT02002429|PROCEDURE|Intra-articular injection|Intra-articular injection into the affected facet joint(s) with 0.5 ml of a 50:50 solution containing 10 mg of depo-methylprednisolone and 0.5% bupivacaine. If the subject has a positive block a radiofrequency denervation will be performed at the affected joint.
224184116|NCT02002429|PROCEDURE|Medial branch block|Medial branch blocks at the nerves that supply the affected facet joint(s) with 0.5 ml of a 50:50 solution containing 10 mg of depo-methylprednisolone and 0.5% bupivacaine. If the subject has a positive block a radiofrequency denervation will be performed at the affected joint.
224184117|NCT02002429|PROCEDURE|Saline injection|Injection into the affected facet joint(s) with 0.5 ml of normal saline. All subjects in the group will receive radiofrequency denervation.
224184118|NCT01624818|BEHAVIORAL|Cardiac habilitation program|physical activity three weeks
224184119|NCT03153436|BIOLOGICAL|Myoinositol|
224184120|NCT03568136|DRUG|Secukinumab 300 mg|Solution for injection in pre-filled syringe
224184121|NCT03568136|DRUG|Placebo|Solution for injection in pre-filled syringe
224184122|NCT06027658|BEHAVIORAL|RECREATION therapy|Dance as therapy program with speech and movement co-therapy via body activity.
224184123|NCT03219996|OTHER|prognosis|The participants were divided into two groups based on survival at their hospital discharge.
224184124|NCT00752427|DRUG|Paliperidone ER OROS®|
224184125|NCT04784676|OTHER|restoration|indirect restoration
224184126|NCT02790476|OTHER|Letters|"The letters will be factual and nonjudgmental, signed by the County Medical Examiner, and would state that a patient they had treated with controlled substances died of an opioid poisoning. The letter will encourage judicious prescribing, and will provide information developed by an advisory group: how to identify and taper unsafe regimens (high dose, polypharmacy, or use of multiple prescribers); how to identify addiction and compassionately refer patients for medication-assisted treatment; and recommendations to avoid bad outcomes (e.g. do not fire your patient for signs of addiction.) The letter would also encourage use of the CURES system before prescribing, as well as co-prescribing of naloxone."
224184127|NCT01194076|BEHAVIORAL|5-day intensive treatment|Exposure Based Cognitive Behavioral Therapy administered in 10 appointments over 5 days with an added focus on training parents to be exposure coaches
224184128|NCT00731094|BEHAVIORAL|Expert system-based physical activity counseling|The intervention included 14 mailings to participants that involved completion of physical activity questionnaires printed on forms that were scanned into a computerized expert system program to generate individually-tailored feedback messages and related manuals based on the Stages of Motivational Readiness for Change Model. Newsletters providing additional support and suggestions for increasing physical activity were also part of the mailing program.
224184129|NCT03380091|DRUG|Metformin|Oral medication daily
224184130|NCT03380091|DRUG|Vitamin D|Oral medication daily
224184131|NCT01530776|BEHAVIORAL|Healthy Lifestyle Group|Electronically-mediated, behavioral intervention during and after pregnancy encouraging mothers to eat healthy, exercise, and return to their early pregnancy weights by 1 year postpartum
224184132|NCT02456272|DEVICE|External hearing aid|The external hearing aid (monaural) with an auditory prosthesis contour type, brand PHONAK type Bolero Q70 will be provided to the patients during a minimum of 2 months.For reasons of standardization and comparability of results, only one type of prosthesis (medium-high range) will be provided. The settings will be performed by audiologists of ENT service during the inclusion visit.
224184133|NCT02456272|PROCEDURE|Otosclerosis surgery|Surgical restoration of the columellar effect consists of the intraoperative verification of the stapedo-vestibular ankylosis which provides diagnostic. Then a stapedotomy (laser or Ototool°) is performed and partial ossicular prosthesis s inserted between stapedotomy and the long process of the incus.
224184134|NCT00021125|PROCEDURE|adjuvant therapy|
224184135|NCT00021125|RADIATION|radiation therapy|
224184136|NCT04188639|DRUG|Emicizumab Injection|All eligible patients with AHA will receive the same study medication consisting of once weekly subcutaneous emicizumab. For each subject, the maximal duration of the study will be 24 weeks including 12 weeks treatment with emicizumab and 12 weeks follow-up with Immunosuppressive therapy (IST) at the investigators discretion.
224184137|NCT00501748|DRUG|Rituximab|Rituximab is a highly purified, 1328-amino acid antibody with an approximate molecular mass of 145 kD. Rituximab is a sterile, clear, colorless, preservative-free liquid concentrate for intravenous (IV) administration. Rituximab is supplied at a concentration of 10 mg/mL in either 100 mg (10 mL) or 500 mg (50 mL) single-use vials. In this single arm study all subjects are treated with two cycles of rituximab. Each cycle consists of two 1000 mg infusions administered two weeks apart. The cycles of rituximab treatment are administered at baseline and at 9 months.
223492612|NCT07104396|OTHER|Cogito digital therapeutics development platform|Cogito will provide a turnkey solution for rapidly developing, evaluating, deploying, and scaling digital therapeutics for the prevention, treatment and/or management of any disease or disorder. This platform will allow researchers who are seeking to embed an evidence-based behavioral therapy into a digital delivery platform to do so via a drag and drop interface with no programming skills necessary. It will provide all the components for building a digital therapeutic for any health condition and population. Overall, Cogito offers great promise to markedly accelerate the pace and impact of science based digital therapeutics.
223492613|NCT07102758|PROCEDURE|L-PRF with dental implant and customized healing abutment|L-PRF with dental implant and customized healing abutment
223492614|NCT07102758|PROCEDURE|Connective tissue with dental implant and customized healing abutment|Connective tissue with dental implant and customized healing abutment
223492615|NCT07104045|OTHER|Reduced light color temperature|reduced light color temperature on postpartum mothers' well-being, breastfeeding motivation, and psychological well-being after a cesarean section
223588455|NCT06455748|DRUG|Pomalidomide|Pomalidomide: pom 2-4mg PO day (D) 1-21/28 (adjust dose for renal function).
224184138|NCT03054116|DIAGNOSTIC_TEST|Airflow pertubation device|Participants have airway resistance measured at the mouth by tidal breathing into a mouth-piece connected to the airflow perturbation device.
223492616|NCT07103577|PROCEDURE|Island osteoperiosteal flap|Crestal incision using no. 15 blade on a bard parker no. 3. Two blind lateral vertical ostotomies at about 1.5 to 2 mm from the adjacent tooth roots to preserve subpapillary and root bone coverage. These cuts are to ensure the complete fracture of buccal plate while being attached to the overlying periosteum.
223492617|NCT07103577|PROCEDURE|Conventional ridge splitting|Crestal incision and 2 vertical releasing incisions will be made using a no.15 blade mounted on a Bard Parker no.3. Then, a full mucoperiosteal flap reflection to expose bone.
223492618|NCT07103915|DRUG|Lidocaine 10% Spray|This study evaluates whether intranasal 10% lidocaine spray reduces pain and improves first-pass success during nasogastric tube (NGT) insertion compared to placebo.
223492619|NCT07103915|OTHER|Placebo|Drug: Placebo Spray (Ethanol-matched solution without lidocaine)
223492620|NCT07103291|OTHER|Respiratory muscle endurance training|Respiratory muscle endurance training program over 5 weeks.
223492621|NCT07103291|OTHER|Sham respiratory muscle endurance training|Respiratory muscle endurance training program over 5 weeks following a sham training procedure that is meant to elicit no physiologic changes.
223492622|NCT07103447|DRUG|AK112, Carboplatin, Paxlitaxel|The combination of AK112, a platinum-based chemotherapy agent, and Paxlitaxel is administered every three weeks as a neoadjuvant treatment for triple-negative breast cancer. After completing six cycles of this regimen, the participant undergoes surgical treatment.
223588456|NCT06455748|DRUG|Dexamethasone|Dexamethasone: dex C1: 20mg IV D1/8, 20mg PO D2/9 and 40mg PO C1D15 weekly up to C6, then 20mg IV monthly starting C7D1 and 20mg PO D8, 15, 22.
223588457|NCT01172574|OTHER|Motor control exercise|Participants of the exercise group were trained to consciously co-activate the transversus abdominis, pelvic floor and thoracic erector spinae muscle, relax the lumbar multifidus and use the diaphragmatic breathing pattern. They were encouraged to activate the specific muscles of the trunk regularly during daily activities, particularly in situations where they anticipated or experienced pain such as walking, twisting, lifting low-lying objects and working with the hands in sitting or standing positions
224184139|NCT05602818|DRUG|Soticlestat 300 mg|Administered orally.
223588458|NCT01198509|DRUG|doxycycline|doxycycline - 100 mg twice per day, for 2 months
223588459|NCT01198509|DRUG|vancomycin|vancomycin, 250 mg four times a day, for 2 weeks
223588460|NCT00499746|DRUG|tramadol|oral dose, once per day
223588461|NCT00499746|DRUG|placebo|oral dose, once per day
223588462|NCT00499746|DRUG|Hydromorphone|oral dose, once per day
223588463|NCT00499746|DRUG|Methylphenidate|oral dose, once per day
223588464|NCT03079856|BEHAVIORAL|Brief Intervention|"Intervention for emerging adults (EAs) seeking care in the ED. The intervention will be rooted in motivational interviewing (MI) and will be guided by social cognitive, self-determination, and the trans-theoretical theories. The ED visit presents a teachable moment for intervening to promote health behavior, therefore eligible EAs will receive a \~30 minute MI-based session in the ED. In order to capitalize on and potentially extend this moment, participants will receive daily booster notifications delivered through a secure mobile app that they will download to their phone at enrollment."
223588465|NCT04569812|PROCEDURE|Cardiopulmonary Resuscitation|flowchart-assisted standard resuscitation or chest compressions-only resuscitation for 5min
224184140|NCT05602818|DRUG|Soticlestat 600 mg|Administered orally.
224184141|NCT05602818|DRUG|Soticlestat 900 mg|Administered orally.
224184142|NCT05602818|DRUG|Alprazolam|Administered orally.
223492623|NCT07102667|BEHAVIORAL|Protein intake 1.2 g/kg/day and resistance exercise|Protein intake of 1.2 g/kg/day in combination with resistance exercise using resistance bands
223492624|NCT07102667|BEHAVIORAL|Protein intake 1.0 g/kg/day and resistance exercise|Protein intake 1.0 g/kg/day in combination with resistance exercise using resistance bands
224184143|NCT05602818|DRUG|Placebo|Administered orally.
224184144|NCT05174208|OTHER|CTE examination|each patients should have undergone CTE examination
223492625|NCT07104994|DEVICE|Dental implant|insertion of dental implants after surgical tranlocation of the inferior alveolar nerve.
223492626|NCT07102680|OTHER|L Max|L Max proprietary formulation
223492627|NCT07102680|OTHER|Placebo|Lactohale 300
223492628|NCT07105267|DRUG|FMT Protocol|FMT protocol Samples (urine, blood, stool) collection Psychological examination Pediatric quality of life Scale Bristol Stool form Scale
223492629|NCT07103837|OTHER|Reactive Skill Test|The Reactive Skill Test will be conducted using a setup consisting of four pods, white cones, and balls that match the colors of the light signals During the test, a ReactionX device configured with four distinct light colors (red, green, blue, and yellow) will be used. The test protocol is programmed via the ReactionX mobile application to control the sequence and display of lights. Each LED light is illuminated in a randomized order with zero delay time. Upon illumination, the participant is required to select the ball corresponding to the color of the light, place it on the matching cone, and then deactivate the LED light of the same color as the last placed ball. The test concludes once this sequence is completed for all four lights. Performance is evaluated based on parameters such as reaction time, accuracy, and total completion time. This protocol is specifically designed to assess cognitive skills such as color recognition, reaction time, motor coordination, and attention.
223492630|NCT07104734|OTHER|Placebo (Placebo trial)|The Placebo capsule supplement was taken for 2 weeks (2 capsules per day)
223492631|NCT07104734|OTHER|Hesperetin (Hesperetin trial)|The Hesperetin capsule supplement was taken for 2 weeks, with a daily dosage of 500 mg of Hesperetin (equivalent to 2 capsules per day, each containing 250 mg of Hesperetin and 50 mg Pycnogenol®).
223492632|NCT07103213|BEHAVIORAL|IMPACTREEL programme|The IMPACTREEL programme is a school-based intervention designed to promote positive body image in adolescents. It combines social media literacy education with third-wave strategies, including mindfulness, self-compassion, and psychological flexibility. The intervention consists of 7 weekly group sessions lasting 55 minutes each, delivered by trained psychologists facilitators during school hours. The content targets appearance ideal internalisation, critical thinking about social media, and healthier body image attitudes.
223492633|NCT07102888|DRUG|RSS0393 Ointment|RSS0393 ointment.
224184145|NCT04064190|DRUG|Vactosertib(TEW-7197)/ Durvalumab|Vactosertib (PO) in combination with Durvalumab (IV) every 4 weeks
223492634|NCT07104305|BEHAVIORAL|High-contact communication strategy|Patients will have contact with their clinician more frequently. The communication strategy may utilize text, email, portal, phone, video or other options as agreed on. The frequency will be at least once a week. All patients will complete a set of questionnaires at the end of the visit.
223492635|NCT07104656|PROCEDURE|Inferior Osteotomy made by border saw|Inferior border saw used to make the inferior border osteotomy
223492636|NCT07104656|PROCEDURE|Inferior Osteotomy made with reciprocating saw|reciprocating saw used to make the inferior osteotomy
223492637|NCT07103798|OTHER|College Park ICON|Subjects will be fitted and trained on the College Park ICON MPK. An accommodation period of 2 months will be provided prior to evaluation with the knee joint.
223492638|NCT07103798|OTHER|Conventional NMPK|Subjects will be tested walking with their conventional, mechanical prosthetic knee prior to being fitted with the MPK.
223492639|NCT04132440|OTHER|Interview|Complete interview
223492640|NCT04132440|OTHER|Questionnaire Administration|Complete questionnaire
223492641|NCT07104006|BEHAVIORAL|Multi-Theory Model (MTM)-Based Smoking Cessation Program|"Multi-Theory Model (MTM)-Based Smoking Cessation Program: A four-week online smoking cessation program based on the Multi-Theory Model (MTM). It uses behavior change strategies including participatory dialogue, building confidence, emotional transformation, practice for change, and changes in physical and social environment. Activities include storytelling, role-playing high-risk situations, emotional regulation, social support, stress management, reflection, and commitment exercises. The goal is to help young adults initiate and maintain quitting smoking.~Knowledge-Based Smoking Risk Education and Quit Strategies Program: A four-week, online educational program providing information on smoking risks, benefits of quitting, barriers, and practical quit strategies. This control arm focuses on increasing knowledge and awareness but does not include MTM-based behavior change techniques."
223492642|NCT07104019|PROCEDURE|Biofiller Injection|Biofiller will be prepared by heating the platelet-poor plasma (PPP) component obtained from peripheral blood, which is then mixed with concentrated PRF (c-PRF). After creating a surgical tunnel in the mandibular anterior region (canine to canine), 0.5 mL of the prepared biofiller will be injected into each tooth region under the gingiva. The procedure is performed under local anesthesia and aims to increase gingival thickness in patients with a thin periodontal phenotype.
223492643|NCT07104019|PROCEDURE|connective tissue graft|A connective tissue graft will be harvested from the palatal donor site and placed under the gingiva using a minimally invasive tunneling technique in the mandibular anterior region (canine to canine). The procedure will be performed under local anesthesia and aims to increase gingival thickness. No biomaterials or adjunctive agents will be used.
223492644|NCT05164172|DRUG|Eptinezumab|Concentrate for solution for infusion
223492645|NCT05019885|DRUG|Ketamine Hydrochloride|Three times a week (M, W, F) for 2 consecutive weeks.
223492646|NCT00217737|BIOLOGICAL|Bevacizumab|Given IV
223492647|NCT00217737|DRUG|Fluorouracil|Given IV
223588466|NCT02273960|DRUG|BMS-986004 75 mg IV|BMS-986004 (75 mg) infusion (50 ml) administered in 120 minutes
223588467|NCT02273960|DRUG|BMS-986004 225 mg IV|BMS-986004 (225 mg) infusion (100 ml) administered in 120 minutes
223588468|NCT02273960|DRUG|BMS-986004 675 mg IV|BMS-986004 (675 mg) infusion (100 ml) administered in 120 minutes
223588469|NCT02273960|DRUG|BMS-986004 1500 mg IV|BMS-986004 (1500 mg) infusion (100 ml) administered in 120 minutes
223588470|NCT04086992|OTHER|Remote monitoring|Caregivers will be able to monitor blood pressure from home and upload in a cloud-based application on a hand-held tablet. In addition, this technology will administer surveys to the caregiver to assess for therapy side effects and adherence. Nurse-led telemedicine visits will also be utilized. The healthcare team will be able to monitor these parameters remotely.
223588471|NCT03161574|DRUG|FOLFOXIRI|irinotecan\* 165 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5FU 2800 mg/m² cont. inf. 46h all on day 1 of each 2 weeks cycle
223588472|NCT05538546|DIAGNOSTIC_TEST|Complete blood count|Complete blood count will be conducted at 12th month and 24th month from baseline.
223588473|NCT05538546|DIAGNOSTIC_TEST|Transient elastrography|Transient elastrography, and endoscopy will be conducted at 12th month and 24th month from baseline.
223588474|NCT05538546|DIAGNOSTIC_TEST|Endoscopy|Endoscopy will be conducted at 12th month and 24th month from baseline.
223588475|NCT01070108|DRUG|Ketamine|group receiving one injection (25 mg) of ketamine (K1) intramuscularly (IM) at 3-4 hours before surgery or placebo (saline 0.9%, NS)
223588476|NCT01070108|DRUG|ketamine|ketamine at 11-12 hours (10 mg) and 3-4 hours (25 mg) before surgery (K2), with a corresponding NS group
223588477|NCT01070108|DRUG|ketamine|ketamine injected IM 17-18, 11-12, and 3-4 hours before surgery (5, 10 and 25 mg, respectively) (K3), and the second group received NS
223588478|NCT02999152|OTHER|blood and urines samples|"For all patients the blood samples must be organized: Before, 4 hours (+/-30 min), 1 day, 2 days, and 3 days after the start of the radiation therapy.~Collections of urine must be organized: Before, 1 day, and 2 days after the radiation therapy."
223588479|NCT04515329|DRUG|Cyclosporine|Eye drops taken twice daily.
223588480|NCT04515329|DRUG|Artificial tear|Preservative-free artificial tear drops 4 times a day.
223588481|NCT00300352|DRUG|Folic Acid|
224184146|NCT02507609|OTHER|Moderate neuromuscular blockade|TOF count is maintained to 1 to 2 by intermittent intravenous injection of rocuronium bromide 5 mg during operation
223492648|NCT00217737|DRUG|Leucovorin|Given IV
223492649|NCT00217737|DRUG|Oxaliplatin|Given IV
223492650|NCT01237093|OTHER|1. Meat, no fish or soda|weight maintaining diet with meat but no fish or soda
223492651|NCT01237093|OTHER|2. Meat and soda, no fish|weight maintaining diet with meat and soda but no fish
223492652|NCT01237093|OTHER|3. Meat and fish, no soda|weight maintaining diet with meat and fish but no soda
223492653|NCT01237093|OTHER|4. Meat and fish and soda|weight maintaining diet with meat, fish and soda
223492654|NCT01237093|OTHER|5. Fish, no meat or soda|weight maintaining diet with fish but no meat or soda
223492655|NCT01237093|OTHER|6. Fish and soda, no meat|weight maintaining diet with fish and soda but no meat
223492656|NCT01237093|OTHER|7. No meat, fish or soda|weight maintaining diet with no meat, no fish, and no soda (vegetarian)
223492657|NCT01237093|OTHER|8. Soda, no meat or fish|weight maintaining diet with soda but no meat or fish (vegetarian + soda)
224184147|NCT02507609|OTHER|Deep neuromuscular blockade|PTC is maintained to 1 to 2 degree by continuous infusion of rocuronium bromide intravenous route
224184148|NCT00325351|DRUG|Sagopilone (ZK 219477) + carboplatin|Chemotherapy for recurrent ovarian cancer
224308426|NCT04539327|DRUG|Rucaparib|Participating local sites (GEICO-associated hospitals with expertise in gynecological cancer management) will enter clinical data of those patients who have previously participated in the rucaparib access program (RAP) in Spain and have given their consent.
223492658|NCT07108660|BEHAVIORAL|Infection Preventionist Led Best Practices Reminders|Infection preventionists at each study hospital review a dashboard on a daily basis that contains predictions for the infection preventionist's hospital. If a patient is predicted to have a possible CLABSI by the ML model, the infection preventionist reviews the case and recommends next steps to the care team based on Providence's CLABSI prevention best-practices bundle, which include reviewing the line for necessity and recommending alternate IV access when appropriate. If line-removal isn't possible, the infection preventionist collaborates with the direct care team to ensure that the line maintenance best practices are observed, including maintaining a clean, dry and intact dressing and using daily chlorhexidine baths.
223492659|NCT07108894|BIOLOGICAL|ABCL575|Participants will receive SC injection of ABCL575
223492660|NCT07108894|BIOLOGICAL|Placebo (Normal Saline 0.9%)|Participants will receive SC injection of placebo (Normal Saline 0.9%)
223492661|NCT06828328|BIOLOGICAL|GC203 TIL|the candidates will be assigned to GC203 TIL(gene-edited TIL) group
223492662|NCT06448754|DRUG|Volrustomig|Participants will receive volrustomig via intravenous (IV) infusion.
223492663|NCT06448754|DRUG|Carboplatin|Participants will receive carboplatin via IV infusion.
223492664|NCT06448754|DRUG|Pemetrexed|Participants will receive pemetrexed via IV infusion.
223492665|NCT06448754|DRUG|Ramucirumab|Participants will receive ramucirumab via IV infusion.
223492666|NCT06448754|DRUG|Paclitaxel|Participants will receive paclitaxel via IV infusion.
223492667|NCT06240754|DRUG|Enasidenib|Provided by BMS.
223492668|NCT07110142|OTHER|Tongueometer|The Tongueometer device features an air-filled bulb that is placed against the roof of the mouth by the tongue for resistance training. This setup allows for an initial measurement of the patient's maximum tongue strength and endurance, which helps establish goals that are specific to each patient. The device connects to a mobile application that provides visual biofeedback, ensuring consistent monitoring as the patient completes exercises using the tongue bulb for resistance. Once the patient's goals are set based on their initial measurements, the app offers two exercise modules designed to improve both tongue strength and endurance.
223492669|NCT07101302|BEHAVIORAL|App-Based Cognitive Behavioural Therapy for Insomnia|The iCANSleep app is based on an established CBT-I protocol. The core features of the iCANSleep app include 1) a modified CBT-I protocol for cancer survivors and 2) daily sleep diaries. Core components of CBT-I treatment to be implemented include sleep restriction, stimulus control, cognitive restructuring, and psychoeducation. These components will be modified into 7-weekly modules.
223492670|NCT07104201|DRUG|Fenofibrate|Fenofibrate 200mg
224184149|NCT06021873|PROCEDURE|SADI-S|Single-anastomosis duodeno-ileal bypass with sleeve gastrectomy
224184150|NCT00118872|DRUG|LGG yogurt|Lactobacillus GG containing yogurt
224184151|NCT00118872|OTHER|Placebo yogurt|Yogurt NOT containing the active LGG bacteria
224184152|NCT03175068|BEHAVIORAL|CBT|CBT works by changing people's attitudes and their behavior by focusing on the thoughts, images, beliefs and attitudes that are held (a person's cognitive processes) and how these processes relate to the way a person behaves, as a way of dealing with emotional problems.
224184153|NCT03175068|BEHAVIORAL|ST|Treatment designed to improve, reinforce, or sustain a patient's physiological well-being or psychological self-esteem and self-reliance
224184154|NCT06285019|PROCEDURE|TOMOX-HAIC|Oxaliplatin 85mg/m\^2 plus Raltitrexed 3mg/m\^2, 21 days for a cycle
224308427|NCT02056912|GENETIC|Amplification by PCR and direct sequencing on the entire coding sequence and intron-exons boundaries of the candidate gene|
224308428|NCT02056912|BIOLOGICAL|Perform blood cells and fibroblasts biochemical and immuno-labeled investigations|Performed only in the two index patients enrolled in the sub-study
223492671|NCT07099326|OTHER|Educational Method Using Interactive Video|"Phase 1 - Interactive Video-Based Training (10 sessions of 30 minutes each):~Patients will access the platform via the website https://spotplayer.ir/ and watch a comprehensive interactive video related to end-stage renal disease (ESRD) and its replacement therapies. This video consists of ten 30-minute sessions, uploaded at the rate of one session per day. During the viewing, pop-up questions will appear, which patients are required to answer. Different response options will lead to the presentation of different educational scenarios. In addition, multiple-choice questions related to the content will be included throughout the video, and patients must record their answers in the system. The instructor will be able to review these responses through a management dashboard. It is worth noting that all patients will have previously received the necessary training to use the interactive videos, including Q\&A sessions designed to ensure sufficient skill acquisition in utilizing the interact"
224184155|NCT06285019|DRUG|Sintilimab|200mg, ivgtt, d1, 21 days for a cycle
224184156|NCT06285019|DRUG|Bevacizumab|7.5mg/kg, ivgtt, d1, 21 days for a cycle
224184157|NCT06433271|BEHAVIORAL|Transdiagnostic Behavior Therapy (TBT)|TBT manualized treatment incorporates daily exposure exercises from up to four categories of avoidance that are most characteristic of the emotional disorders (i.e., situational, interoceptive, imaginal, and positive emotional).
224308429|NCT06028880|BEHAVIORAL|Free2Be|Free2Be is a manualized 13-week face-to-face group intervention for SM individuals with one pre-session and plus 12 intervention sessions. The themes of each session are: Human nature \& Relation with suffering (S1), Emotional regulation \& Multiple selves (S2), Creative hopelessness \& Values (S3), Compassionate attention (S4), Compassionate acceptance (S5), Self-criticism; Compassion \& Flows of compassion (S6), Compassionate imagination; Compassionate self (S7), Early experiences; Stigma and shame; \& Compassionate cognitive desfusion (S8), Compassionate thinking (S9), Difficult emotions: Shame \& Anger (S10), Coming out \& Compassionate behaviour (assertiveness) (S11), Positive emotions \& Preparing for the future (S2).
224308430|NCT05016609|DEVICE|OraQuick HCV Antibody test (OraSure Technologies, Inc)|The OraQuick HCV test is a point of care antibody test for detecting HCV antibodies in fingerstick blood. The test takes 20 minutes to provide a result. Appropriate pre- and post-test counselling will be provided to participants.
223588482|NCT00569088|DRUG|Chinese herbs formula|"The chinese herbs formula includes eight herbs,and they are Radix et Rhizoma Rhei Palmati(Rhubarb,10 grams),Cornu Bubali(Buffalo Horn,30 grams),Radix Paeoniae Bubra(Red Peony Root,15 grams),Cortex Moutan Radicis(Tree Peony Root-bark,10 grams),Radix Rehmanniae(Adhesive Rehmannia Root Tuber,20 grams),Pheretima Aspergillum(Earth-worm,10 grams),Radix Notoginseng(Sanchi,5 grams)and Rhizoma Acori Tarainowii(Tararinow Sweetflag Rhizome,10 grams).~Boiled together. 150ml of the juice,p.o.,twice a day,for 28 days"
223588483|NCT00569088|DRUG|Mannitol|250 ml Mannitol Injection or Glycerin and Fructose Injection ,once a day, for 3-5 days
223588484|NCT04166760|DIETARY_SUPPLEMENT|speWHE|25 gram of a specific whey fraction (confidential)
223588485|NCT04166760|DIETARY_SUPPLEMENT|WHE|25 gram protein of a regular whey compound
224184158|NCT06433271|BEHAVIORAL|Treatment as Usual-Problem Solving Therapy (TAU-PST)|PST is an evidence- based psychotherapy implemented in VA Primary Care - Mental Health Integration (PC-MHI), with hundreds of VA providers trained in the intervention nationally. The primary aim of PST is to improve a patient's ability to cope with stressful events by adopting an adaptive perspective to stressors and using goal-focused, problem-solving behaviors to manage the problems associated with the stressors.
223492672|NCT07099326|OTHER|Educational Method Using Conventional Video|"This educational intervention will be carried out in two phases with a total duration of six hours. A total of 55 patients will participate in this study, organized into groups of five and guided by an experienced instructor familiar with the interactive video-based educational system.~Phase 1 - Conventional Video-Based Training (10 sessions of 30 minutes each):~Patients will access the platform through the website https://spotplayer.ir/ and watch in-depth educational videos related to end-stage renal disease (ESRD) and its replacement therapies. The video content consists of ten 30-minute sessions, which will be uploaded for the patients at the rate of one session per day.~Phase 2 - Consolidation and Reinforcement Session (1 hour):~After completing the ten video sessions, patients will participate in group discussions to analyze the scenarios, topics, and questions presented in the videos. The instructor will facilitate the discussions, summarize the outcomes, and assess the over"
223492673|NCT07103148|BIOLOGICAL|Yellow fever vaccine (live)|Powder and diluent for suspension for injection Subcutaneous
223492674|NCT07103148|BIOLOGICAL|Yellow fever vaccine (live)|Powder and diluent for suspension for injection Subcutaneous
223492675|NCT07103148|BIOLOGICAL|Yellow fever vaccine (live)|Powder and diluent for suspension for injection Subcutaneous
223492676|NCT07103148|BIOLOGICAL|Measles, combinations with mumps and rubella, live attenuated|Powder, lyophilized, for suspension for reconstitution Subcutaneous or intermuscular
223588486|NCT02989129|BEHAVIORAL|Questionnaires|Questionnaires regarding quality of life, pain level, and related symptoms completed at Baseline and at End of Study Visit.. It should take less than 1 hour to complete these questionnaires.
223588487|NCT02989129|DRUG|Quercetin|500 mg by mouth twice daily (after breakfast and dinner) for 12 weeks during study.
223588488|NCT00558272|DRUG|AZD0530|Daily oral dose
223588489|NCT00558272|DRUG|Zoledronic Acid|
223588490|NCT02880995|DEVICE|PET scan|The patient group and the healthy control group will undergo PET scan at the baseline. the investigators are going to measure striatal dopamine synthesis capacity using \[18 fluorine(F)\]DOPA positron emission tomography in drug-naïve first episode psychosis and determine treatment response after 6 weeks of treatment with amisulpride. Response will be defined as a \>30% reduction in symptom ratings on the Positive and Negative Syndrome Scale.
223588491|NCT02880995|BEHAVIORAL|clinical scale|Patient group should complete clinical scales at baseline and 6 week.
223588492|NCT02880995|DRUG|6 weeks of treatment with amisulpride|The investigators are going to measure striatal dopamine synthesis capacity using \[18 fluorine(F)\]DOPA positron emission tomography in drug-naïve first episode psychosis and determine treatment response after 6 weeks of treatment with amisulpride. Response will be defined as a \>30% reduction in symptom ratings on the Positive and Negative Syndrome Scale.
223588493|NCT06947642|DRUG|Pectoral nerve block (PECS)|Patients will receive pectoral nerve block (PECS).
224184159|NCT02553993|DEVICE|Wii Fit(30 Mins)|Receive Wi Fit games training for 30 minutes. There are 2 sections for 1 week; the intervention period will be 12 weeks.
224184160|NCT02553993|DEVICE|Tetrax biofeedback(30 Mins)|Receive Tetrax biofeedback games training for 30 minutes. There are 2 sections for 1 week; the intervention period will be 12 weeks.
223492677|NCT07102914|BEHAVIORAL|Screening, Brief Intervention and Referral for Treatment (SBIRT)|A single-arm, open pilot design maximizes the ability of the investigators to work collaboratively with NHAEC staff and administration to tailor the implementation strategy, establish the feasibility and acceptability of study methods and interventions (e.g., recruiting students, training SRSs to deliver SBIRT with integrity, response rates to assessment measures, student receipt of SBIRT, retention of SRSs and students), address the structural barriers within the AEC setting, identify the needs of the populations of interest, and gather data that points to best approaches to ensuring the study's success.
223492678|NCT07104448|BEHAVIORAL|Standardized Perioperative Care Protocol|A multi-component protocol involving preoperative patient education, nutritional screening, standardized anesthesia, goal-directed fluid therapy, multimodal opioid-sparing analgesia, and a structured physiotherapy-led mobilization schedule starting on postoperative day 1.
223492679|NCT07104448|OTHER|Conventional care|Standard, non-protocolized institutional perioperative care, with management decisions based on the discretion of the attending surgeon and care team.
223588494|NCT06947642|DRUG|Erector spinae plane block (ESP)|Patients will receive erector spinae plane block (ESP).
223588495|NCT06947642|DRUG|Serratus anterior plane block (SAP)|Patients will receive serratus anterior plane block (SAP).
223588496|NCT01102894|DEVICE|SmartPill|SmartPill
223588497|NCT00846716|DRUG|Pioglitazone add on to SU or biguanide|As an initial dosing, 15mg/day of pioglitazone is administered to the patients for 2 years, who are taking SU or biguanide.
223588498|NCT00846716|DRUG|SU or Biguanide|As an initial dose,a common dose of SU or biguanide is administered to the patients for 2 years.
223588499|NCT01780753|DRUG|Primaquine|Primaquine GPO® (Government Pharmaceutical Organization, Thailand) 0.5 mg/kg will be given once daily for 14 days.
223588500|NCT00031564|BIOLOGICAL|Interleukin-2|
223588501|NCT00031564|BIOLOGICAL|B7-1|
224184161|NCT02553993|OTHER|Conventional weight-shifting(30 Mins)|Receive weight-shifting exercise training for 30 minutes. There are 2 sections for 1 week; the intervention period will be 12 weeks.
223492680|NCT07105904|DIAGNOSTIC_TEST|Viscoelastometric hemostatic assay|As part of usual care, when weaning the patient from CPB during cardiac surgery, blood samples are withdrawn from the patient to assess hemostasis: we test both Quantra viscoelastometric assay and biological hemostasis including QT, ACT, fibrinogen and platelet count
223492681|NCT07108465|DRUG|Bupivacaine 0,5%|Injection of bupivacaine 0,5% in group A
223492682|NCT07108465|DRUG|Ropivacaine 0,75%|Injection of ropivacaine 0,75% in group B
223492683|NCT07104851|BEHAVIORAL|Resilience-Satir Hybrid Intervention|A structured, 12-week, group-based psychological intervention integrating principles from Resilience Theory and the Satir Model to enhance coping skills, self-esteem, communication, and family dynamics.
223492684|NCT07104851|OTHER|Treatment as Usual (TAU)|Standard care for adolescent depression, including pharmacotherapy and routine nursing support, without structured psychotherapy.
223492685|NCT07108335|OTHER|PROvider ReMote ObsTetric-Related Employment Education (PROMOTE)|An on-demand 30-minute web-based training for clinical team members that provides a high-level summary of federal employment laws, work note templates embedded into the electronic health record (EHR) that prompt the clinician team member to include relevant information, and a patient-facing infographic designed to facilitate clinician counseling.
223492686|NCT07112482|BEHAVIORAL|Standard Oncological Care + Tailored Dietary Counseling + Nutritional Monitoring|"Participants in this group will receive:~Standard oncological care (e.g., chemotherapy and routine cancer treatments)~Individualized dietary counseling: Nutrition plans tailored by a clinical dietitian to meet energy needs (25-30 kcal/kg/day) and protein needs (1.2-1.5 g/kg/day), adapted to clinical status, dietary tolerance, and treatment side effects.~Regular nutritional monitoring: Counseling sessions every 15-21 days over a period of six months.~Dietary adherence tracking: Through structured food records and goal adherence checklists.~Light physical activity guidance: Encouragement to engage in low-intensity activity suited to patient capacity.~Psychosocial support: Sessions with a certified clinical psychologist addressing emotional distress, fatigue, and anorexia.~Adherence criteria: Defined as attending ≥75% of sessions and meeting ≥80% of dietary goals."
223492687|NCT06910397|DRUG|Probiotic Arm|one tablet daily for 28 days
223492688|NCT06910397|OTHER|Placebo|placebo tablet once daily for 28 days
223492689|NCT07112118|OTHER|data collection|Collect the facial expressions, audio, text and postural behavior data of the respondents using electronic devices.
223492690|NCT07107529|DRUG|Teclistamab|Teclistamab will be administered via a subcutaneous injection (SC), fixed duration and will be retreated until disease progression or intolerable toxicity.
223492691|NCT07107529|DRUG|Talquetamab|Talquetamab will be administered via a subcutaneous injection (SC), fixed duration and will be retreated until disease progression or intolerable toxicity.
223492692|NCT07107529|DRUG|Daratumumab|Dartumumab will be administered via a subcutaneous injection (SC), fixed duration and will be retreated until disease progression or intolerable toxicity.
223492693|NCT07102706|DRUG|GR1803 injection|weekly dose up to week 24 , biweekly dose from week 24 to week 36, and triweekly dose from week 36 to week 52
223492694|NCT02145390|PROCEDURE|Transurethral Resection of the Bladder Tumor & Cystoscopy|"TURBT and Cystoscopy will be performed by the participating urologist prior to start of neoadjuvant chemotherapy, per the study protocol:~* Cystoscopic evaluation~* Bimanual examination under anesthesia,~* Transurethral resection of the bladder tumor,~* Biopsy of the prostatic urethra including both mucosa and stroma using a resection loop."
223492695|NCT02145390|RADIATION|Intensity Modulated Radiation Therapy|"For subjects with complete response to neoadjuvant chemotherapy. Subjects will receive 25 daily fractions (5 weeks) of radiation therapy for 5 days a week (Monday to Friday) except on weekends or holidays, when remaining fractions will be added to the end of treatment. The overall schema is for IMRT based radiation to the entire bladder, prostate (in men) and the pelvic lymph nodes:~* Pelvic lymph nodes: 45 Gy in 25 fractions at 1.8 Gy per fraction.~* Whole bladder and prostate: 50 Gy in 25 fractions at 2.0 Gy per fraction.~* Tumor boost area: 60-65 Gy in 25 fractions at 2.4-2.6 Gy per day~* Final boost dose will be determined at the discretion of the treating physician based on normal tissue exposure and volume."
223492696|NCT02145390|BEHAVIORAL|Expanded Prostate Cancer Index Composite Short Form 12|Quality of life questionnaire to be administered to subjects at intervals defined by the study protocol.
223492697|NCT02145390|BEHAVIORAL|International Prostate Symptom Score|Quality of life questionnaire to be administered to subjects at intervals defined by the study protocol.
223492698|NCT07105241|OTHER|VR therapy|Patients in the VR intervention group receive a VR 'relax and distract' intervention in addition to standard care. This type of VR utilizes video's, relaxation exercises and cognitive games to immerse patients in a novel, calming and distracting environment, enhancing the patient's ability to manage anxiety, stress and pain. The VR set is introduced to the patient in the cardiology day care unit prior to the procedure allowing for familiarization with the device. After moving the patient to the catheterization laboratory, the VR set is re-offered to the patient and the VR intervention is started. The intervention ends with the conclusion of the procedure, or when the patient indicates that they would like to discontinue the therapy earlier.
223492699|NCT07105241|OTHER|360 degree education videos|Prior to the procedure, patients in the VR intervention group are additionally offered an educational video consisting of a virtual tour of the EP laboratory with a visual explanation of the upcoming procedure. These videos will be recorded as 360ͦ videos to support an optimal immersive experience when viewed on the VR set. In this way, the videos will serve simultaneously as additional educational measures for the procedure, as well as a way to familiarize patients with the VR set. Use of the educational videos is not obligatory, but is offered optionally according to patients' preference.
223492700|NCT07104149|DRUG|Cadonilimab combined with cisplatin|Neoadjuvant chemotherapy plus cadonilimab for locally advanced cervical cancer
223588502|NCT01029444|PROCEDURE|Pulsatile Intravenous Insulin Therapy (Humulin, Humulog, Novolog )|Patients receive weekly treatments of Pulsatile Intravenous insulin therapy. The patient's Endocrinologist determines the insulin dosage each week based upon the patient's response to treatment RQ levels and their insulin resistance.
223588503|NCT05327764|OTHER|Work to rest cycles of 40:20 minutes|Walking in a hot environment for 2 hours with repeated 40 minutes of work and 20 minutes of rest
223588504|NCT05327764|OTHER|Work to rest cycles of 20:10 minutes|Walking in a hot environment for 2 hours with repeated 20 minutes of work and 10 minutes of rest
223588505|NCT05948046|BEHAVIORAL|Visual training in hospital|Completion of 1 session of standardized visual training
223492701|NCT07101458|BEHAVIORAL|Promoting Resilience in Stress Management intervention|PRISM is a manualized, skills-based training program comprised of three 60-minute, one-on-one sessions designed to build resilience resources (stress management, goal-setting, cognitive-reframing, and meaning-making) in adolescents and young adults (AYAs). The sessions are scheduled every 1-2 weeks based on participant preference. In this study, the PRISM sessions will be facilitated by trained nurses who hold bachelor's degrees in Nursing Science with a specialisation in mental health.
224184162|NCT04620356|DEVICE|DryNites Pyjama Pants|DryNites Pyjama Pants are disposable, absorbent youth pants designed to help children manage bed wetting by absorbing involuntary urine loss and protecting the child's garments and bedding. DryNites Pyjama Pants are underwear-like alternatives that can be discreetly worn beneath pyjamas or nightwear during the bedwetting phase.
224184163|NCT06342661|DIAGNOSTIC_TEST|Neuropsychological testing|The primary outcomes were Mini-Mental State Examination and Montreal Cognitive Assessment scores for screening of cognitive decline, which are recommended by NINDS-AIREN. The secondary outcomes included the performance in five cognition domains: (1) verbal memory, Hopkins Verbal Learning Test ; (2) visual-spatial ability, Clock Drawing test; (3) executive function, Trail Making test (TMT) (B time); (4) attention, TMT (A time); and (5) language tests, Boston Naming test2 (BNT-2)
224184164|NCT03004898|BEHAVIORAL|multidisciplinary renal education|multidisciplinary CKD care involving case management nurse, dietitian, social worker, pharmacists.
224184165|NCT00058097|DRUG|tipifarnib|Given orally
224184166|NCT00058097|RADIATION|radiation therapy|Undergo radiation therapy
224184167|NCT02291705|PROCEDURE|rectus sheath block|ultrasound-guided rectus sheath block with 0.25% 0.2 ml/kg levobupivacaine
223492702|NCT07103252|OTHER|Blood Flow Restriction Therapy|Personalized Blood Flow Restriction Therapy uses an an inflatable cuff (Delfi PTS system) around the upper thigh which partially restricts arterial inflow during exercise. BFR allows for similar improvements of muscular strength and muscle mass as traditional heavy load strength training while using significantly lower loads. The reduced stress on supporting tissues ( tendons, joints, bones and ligaments) allows people who normally couldn't tolerate high loads to enhance their strength and muscle mass.
223492703|NCT07104591|BIOLOGICAL|HLA-matched VSTs (Multivirus-specific Cytotoxic T Lymphocytes)|Banked, partially HLA-matched virus-specific T cells (VSTs) directed against EBV, CMV, adenovirus, and BK virus.
223492704|NCT07103759|BEHAVIORAL|Refrain from caffeine techniques|Participants will be asked to refrain from drinking caffeinated beverages in the late afternoon and evening.
223492705|NCT07103759|BEHAVIORAL|Project REST Platform|Participants will use the Project REST platform
223492706|NCT07110051|DRUG|Nalbuphine|this group will a single dose of nalbuphine (0.2 mg/kg) immediately after surgery to be repeated every 8 hours for the duration of the study (72 hours)
223492707|NCT07110051|DRUG|Tramadol|this group will receive a single dose of tramadol (2 mg/kg) immediately after surgery to be repeated every 8 hours for the duration of the study (72 hours).
223492708|NCT07104253|DEVICE|Ex vivo cryo-ablation|With informed consent obtained prior to transplantation, explanted lungs from patients undergoing lung transplantation will be obtained. The organs will be placed in an acrylic box and will be perfused at a temperature of 37 Celsius degrees. The lungs will be mechanically ventilated connected by an endotracheal tube size 7 inserted in the bronchus with the balloon inflated and a silk suture providing a hermetic closure proximal to the balloon. The cryocatheter will be inserted in the lungs and cryoablation will be performed with varying freeze-thaw cycles to confirm design and operating specifications of the device.
223492709|NCT07111637|DEVICE|AI software|icobrain ms is an Artificial Intelligence (AI)-assistive software which quantifies brain Magnetic Resonance Imaging (MRIs) and summarises clinically relevant findings for patients with Multiple Sclerosis in structured electronic radiological reports and annotated images.
223492710|NCT06979466|DEVICE|Q Therapeutic System (BQ 3.0) - Active|The BQ 3.0 is a medical device that produces and delivers non-invasive, extremely low intensity and frequency (1-100 Hz.; 0.1-1.0 G), frequency tuned electromagnetic fields in order to stimulate neuronal networks with the aim of reducing disability and promoting neurorecovery
223492711|NCT07103707|PROCEDURE|open cholecystectomy|standard open cholecystectomy performed under general anesthesia
223492712|NCT07103707|PROCEDURE|Laparoscopic cholecystectomy|Standard laparoscopic cholecystectomy using minimally invasive technique
223492713|NCT07106593|BEHAVIORAL|Cognitive Processing Therapy|CPT (Resick, Monson, \& Chard, 2024) consists of 12 50-minute sessions conducted over a 6- to 12-week period (Resick, Monson, \& Chard, 2008). The three phases of CPT include psychoeducation, processing, and challenging beliefs and assumptions related to the trauma, oneself, and the world.
223588506|NCT04346121|OTHER|GPs reports of potential patient safety incidents, non-COVID-19 related|GPs reports of potential patient safety incidents, non-COVID-19 related
224184168|NCT02291705|DRUG|Tramadol|tramadol 1 mg/kg iv
224184169|NCT03950531|OTHER|No intervention|
224184170|NCT00457951|DRUG|Open-Label|ODSH administered open-label
224184171|NCT00457951|DRUG|Placebo Comparator: Placebo-Control Arm 0.9% Sodium Chloride|Placebo-Control Arm: Bolus infusion followed by a 96 hour continuous infusion of 0.9%Sodium Chloride
224184172|NCT00457951|DRUG|ODSH|Randomized, Blinded, ODSH Arm
224184173|NCT03228615|OTHER|SDM Intervention|Intervention Component A: letter to activate families; Intervention Component B: in-clinic decision support; Intervention Component C: follow-up phone call
224184174|NCT00363376|DRUG|zonisamide|Zonisamide will be administered at an initial dose of 100 mg/d for 7 days. Subsequently, zonisamide may be increased, based on clinical response and tolerability, by 100mg/d every 7 days to a maximum of 600 mg/d by the end of the sixth week of treatment. The maximum amount of zonisamide allowed during the study will be 600 mg/day. The minimum amount of zonisamide allowed during the study will be 100 mg/d. Zonisamide will initially be given as a single pm dose, but alterations in dosing will be permitted to reduce side effects (e.g., as BID dosing to reduce nausea).
223588507|NCT02342262|DIETARY_SUPPLEMENT|EcologicBarrier|multispecies probiotic product, 2x10-9 cfu/gram
223588508|NCT02342262|OTHER|Placebo|similar appearance as the probiotic product, but without bacteria
223588509|NCT02745535|DRUG|Sofosbuvir/Velpatasvir/Voxilaprevir|
223588510|NCT00003709|DRUG|carbendazim|Patients receive oral carbendazim weekly for 3 weeks followed by 1 week of rest. Treatment is repeated every 28 days in the absence of disease progression or unacceptable toxic effects. Cohorts of 3-6 patients receive escalating doses of carbendazim. If dose limiting toxicity (DLT) is seen in 1 of 3 patients treated at a given dose level, 3 additional patients will be entered at the same dose level. Dose escalation continues until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience DLT. Patients are followed for up to 30 days posttreatment.
223588511|NCT04714021|OTHER|CO2|to insufflate CO2 into the stomach instead of air during the PEG
224184175|NCT00363376|DRUG|olanzapine|olanzapine will be administered open-label at 5-20 mg/d titrated to optimize response and minimize side effects
224184176|NCT00363376|DRUG|Zonisamide|zonisamide ranging from 100mg to 600mg daily
223492714|NCT07106593|BEHAVIORAL|CBT-t|The standard CBT-t protocol is gathered from the Progressive Tinnitus Management (PTM) program, and includes psychoeducation about how tinnitus can develop. CBT-t includes using behavioral principles to help manage tinnitus reactions, including the use of sounds: soothing sounds, background sound, and interesting sound. CBT-t teaches relaxation exercises, scheduling pleasant activities, and learn how to modify thoughts related to tinnitus. Therapists will also provide basic education on how to protect hearing health among participants in order to prevent worsening of tinnitus and to prevent exacerbation of any hearing loss.
223492715|NCT07105293|OTHER|PEEP 5 cmH2o applied group|A standardized anesthesia protocol involved volume-controlled ventilation with a tidal volume of 6-8 mL/kg and a frequency of 10-12 breaths/min, PEEP:5 cmH2o
223492716|NCT07105293|OTHER|PEEP 10 cmH2o applied group|A standardized anesthesia protocol involved volume-controlled ventilation with a tidal volume of 6-8 mL/kg and a frequency of 10-12 breaths/min, PEEP:10 cmH2o
223492717|NCT07103499|BEHAVIORAL|Pilates-Based Core and Breathing Exercise Program|An 8-week supervised Pilates-based exercise program for overweight and obese women, focusing on abdominal endurance and core stabilization. Sessions (3/week) include diaphragmatic breathing, use of reformer and cadillac equipment, and structured warm-up, main, and cool-down phases.
223492718|NCT07103655|DRUG|mavacamten|Add Mavacamten to guideline-directed standard medical therapy for patients with hypertrophic cardiomyopathy (HCM) and mid-to-apical left ventricular obstruction.
223492719|NCT07103655|DRUG|Beta Blocker (BB) - metoprolol, bisoprolol, carvedilol|Administer an appropriate dose of beta-blockers according to the patient's tolerance.
223492720|NCT07103655|DRUG|diltiazem|Administer an appropriate dose of diltiazem according to the patient's tolerance.
223492721|NCT07103746|DRUG|Ublituximab|Initial dose includes 150 mg dose followed by 450 mg two weeks later; maintenance dose is 450 mg
223492722|NCT07103746|DRUG|Placebo for Ublituximab|0.9% sodium chloride injection
223492723|NCT07104955|OTHER|MDT referral and review software|Use of the multi-disciplinary team (MDT) meeting software to submit, review and discuss referrals
223588512|NCT04714021|OTHER|air|to insufflate air into the stomach instead of CO2 during the PEG
223588513|NCT02584920|DRUG|HLX01|
223588514|NCT02584920|DRUG|Rituximab|
223588515|NCT03492931|DRUG|Ticagrelor|Patients will receive a single dose of ticagrelor
223588516|NCT03208439|DEVICE|lower-limb cycling system|patients will receive 30-minute cycling exercise
224184177|NCT00363376|DRUG|Sugar Pill (placebo)|sugar pill (placebo) for zonisamide
224184178|NCT02381366|BIOLOGICAL|Human Umbilical Cord Blood Derived-Mesenchymal Stem Cells|"Human Umbilical Cord Blood Derived-Mesenchymal Stem Cells:~Dose A: 10 million cells per kg / Dose B: 20 million cells per kg"
223492724|NCT07105072|PROCEDURE|Vitrectomy|vtrectomy is a surgical procedure to remove vitreous humor and can be used in case of viritis and as a debulking procedure for ciliary body granuloma.
223588517|NCT00849108|DRUG|BMS747158|"dosages at rest and at stress were not to exceed a total of 14 mCi.~Cohort 1: Patients received either 2 or 3 IV bolus injections of BMS747158: 1 at rest and 1 or 2 during stress, over a 1-day or 2-day period.~Cohort 2: Patients to recieve IV bolus injections of BMS747158:~For the Pharmacologic (Adenosine) Stress:~* Doses at rest were to range between 2.9 and 3.4 mCi.~* Doses under stress were to be a factor of 2.0 to 2.4 greater than the rest dose, resulting in a range of stress doses between 5.8 and 8.2 mCi.~For the Exercise Stress:~* Doses at rest were to range between 1.7 and 2.0 mCi.~* Doses under stress were to be a factor of 3.0 to 3.6 greater than the rest dose, resulting in a range between 5.1 and 7.2 mCi."
223588518|NCT05928416|DIAGNOSTIC_TEST|Saliva sample|"During the inclusion visit :~* a neurological examination is taken~* a saliva sample is taken"
223588519|NCT05928416|DIAGNOSTIC_TEST|Saliva sample|"During the inclusion visit :~* a saliva sample is taken"
223588520|NCT05403229|DRUG|Topiramate|The topiramate arm receives additional oral topiramate for 6 weeks. The dose of topiramate is started from 25mg orally daily with the weekly escalation of 25mg to a maximum of 100mg.
224184179|NCT05467995|BIOLOGICAL|AK111|AK111 administered subcutaneously at Week 0, 1, and 4, then every 4 weeks
224184180|NCT05467995|BIOLOGICAL|Placebo|Placebo administered subcutaneously at Week 0, 1, and 4, then every 4 weeks
224184181|NCT01136317|DRUG|Omeprazole|
224184182|NCT01136317|DRUG|Rabeprazole|
224184183|NCT01136317|DRUG|Lactose|
224308431|NCT05016609|DEVICE|Xpert HCV Viral Load Finger-stick Point-of-Care test (Cepheid)|Xpert® HCV VL Fingerstick is an in vitro reverse transcription polymerase chain reaction (RT-PCR) assay for the detection and quantification of Hepatitis C Virus (HCV) RNA in human venous and capillary fingerstick EDTA whole blood. Only participants who return a reactive OraQuick HCV Antibody test will be offered the Xpert® HCV VL Fingerstick test. Appropriate pre- and post-test counselling will be provided to participants.
223588521|NCT05403229|DRUG|Systemic Steroids|Both groups receive a systemic steroid with/without intratympanic steroids as the standard treatment of SSNHL.
223588522|NCT03051594|DEVICE|fluorescent camera|used too detect residual caries depending on the bacterial byproducts.
223588523|NCT03051594|OTHER|caries detector dye|dye used to detect the residual caries.
223588524|NCT03051594|DIAGNOSTIC_TEST|visual tactile assessment|method usually used to detect the residual caries.
224308432|NCT05016609|DRUG|Sofosbuvir/Velpatasvir (Gilead)|Participants with a detectable HCV antibody will be offered treatment with sofosbuvir/velpatasvir.
224308433|NCT00760734|DRUG|Low pressure hyperbaric oxygen therapy|HBOT at 1.5 ATA/60 minutes twice/day, five days/week for 40 or 80 treatments
223588525|NCT03499327|DIETARY_SUPPLEMENT|Wheat germ oil (UV treated)|"Wheat germ oil is naturally rich in vitamin D precursors (ergosterol and 7-dehydrocholesterol), which are converted into vitamin D2 and vitamin D3 by a defined UV light irradiation for the present study (wheat germ oil (UV treated).~The wheat germ oil (UV treated) is dispensed in dark glass bottles without label. The distinction between the groups is based on the expiration date (08.05.2018 vs. 09.05.2018). The distinction between the groups is not possible for the participants.~The daily dosage of wheat germ oil is 10 ml and the study products will be consumed over an entire period of 6 weeks (no follow-up).~Recommendation for intake: pure before a main meal."
223588526|NCT03499327|DIETARY_SUPPLEMENT|Wheat germ oil (untreated)|"commercial available wheat germ oil The wheat germ oil (untreated) is dispensed in dark glass bottles without label. The distinction between the groups is based on the expiration date (08.05.2018 vs. 09.05.2018). The distinction between the groups is not possible for the participants.~The daily dosage of wheat germ oil is 10 ml and the study products will be consumed over an entire period of 6 weeks (no follow-up).~Recommendation for intake: pure before a main meal."
224184184|NCT05954117|PROCEDURE|Adipose tissue biopsies|"During the 2 surgical time, when patient is under general anesthesia, two adipose tissue biopsies of 20cc each (one from abdominal subcutaneous adipose tissue and one from omental adipose tissue) are taken and characterize by oxygraphy (respirometry).~Before the 2 surgical times (before and after chemotherapy) patients will have evaluation of the muscle strength, cachexia (by scan analysis), energy expenditure, anthropometric criteria and biochemical inflammatory."
224184185|NCT01260064|PROCEDURE|Open appendectomy|The subjects will have traditional open appendectomy procedure.
224184186|NCT01260064|PROCEDURE|Laparoscopic appendectomy with metal endoclips|The subjects will have laparoscopic appendectomy in which the appendiceal stump is secured by metal endoclips.
224184187|NCT01260064|PROCEDURE|Laparoscopic appendectomy with suture ligation|The subjects will have laparoscopic appendectomy in which the appendiceal stump is secured by intracorporeal suture ligation.
224184188|NCT02115802|DEVICE|Activa PC+S|Subjects will undergo placement of bilateral standard Deep Brain Stimulation (DBS) electrodes (Medtronic model 3387/3389) and implantation of the Activa PC+S, a modified impulse generator (IPG) for DBS with the added technology of neural signal recording.
224184189|NCT03740152|DEVICE|Transcranial Light Therapy|Device: LiteCure® The PhotoBioModulation-1000 (TPBM-1000)
224184190|NCT04858516|DRUG|palbociclib and exemestane plus trastuzumab and pyrotinib|Neoadjuvant treatment with palbociclib and exemestane plus trastuzumab and pyrotinib in ER-positive, HER2-positive breast cancer
224184191|NCT00425594|DRUG|HalfLytely and Bisacodyl Tablets - Formulation 1|
223492725|NCT06914726|OTHER|Patient Centered Clinical Decision Support (PC-CDS)|The intervention provides patient specific recommendations on managing cancer risk due to hereditary cancer gene variants that is integrated into an existing point of care clinical decision support system that algorithmically identifies study-eligible patients and deploys patient-specific CDS output at an index visit and all subsequent primary care encounters using the most up to date available clinical information.
223492726|NCT07108283|DRUG|Zasocitinib|Zasocitinib capsules.
223492727|NCT07108283|OTHER|Placebo|Zasocitinib matching placebo capsules.
223492728|NCT07111390|DEVICE|60Hz Intermittent Light Therapy|Intermittent 60 Hz flickering white light delivered via a wearable headset.
223588527|NCT01563172|DRUG|Sodium fluoride / silica and carbopol, 0.5g|Dentifrice containing 1150 parts per million (ppm) fluoride as sodium fluoride / silica and 0.4% carbopol
223588528|NCT01563172|DRUG|Sodium fluoride / silica and carbopol, 1.5g|Dentifrice containing 1150 ppm fluoride as sodium fluoride / silica and 0.4% carbopol
223588529|NCT01563172|DRUG|Sodium fluoride / silica and carbopol, 1.5g|Dentifrice containing 250 ppm fluoride as sodium fluoride / silica and 0.4% carbopol
223588530|NCT01563172|OTHER|Fluoride free dentifrice|A non fluoride dentifrice was given to participants of each arm at washout period
223588531|NCT05019768|OTHER|accelerated custom-fast CXL|The accelerated custom fast CXL (aCFXL) has been developed on a published mathematical model that takes into consideration objective variables such as the equation governing the UVA-induced riboflavin consumption rate and the corneal thickness at its thinnest point. By knowing both values, the mathematical model allows to objectively calculate both the exact UVA irradiation value (intensity), expressed in mW/cm2, and the irradiation time
223588532|NCT05019768|OTHER|Standard CXL|The standard CXL procedure has been carried on following the Dresden protocol
223588533|NCT02934737|OTHER|Progression of diabetes|
223588534|NCT04107441|DRUG|AX-8 Part 1|5, 10, 20, and 40 mg AX-8 orally disintegrating tablets (ODTs), up to 80 mg/day split over 2 time points, 8 hours apart (i.e. Dose 1: 0 hour and Dose 2: + 8 hours). AX-8 ODTs will be administered orally and will be dissolved on the back of the tongue while the subject is in a sitting position. The subjects will be instructed not to suck, chew or swallow the tablet, i.e. to allow it to dissolve on the back of the tongue without any further intervention.
224184192|NCT00425594|DRUG|HalfLytely and Bisacodyl Tablets - Formulation 2|
224184193|NCT00425594|DRUG|NuLYTELY|
224308434|NCT00760734|DRUG|Low pressure hyperbaric oxygen therapy|HBOT: 1.5 ATA/60 minutes twice/day, 5 days/week for 40 or 80 treatments
224184194|NCT02382887|PROCEDURE|tracheal intubation|tracheal intubation with the Airtraq
224184195|NCT02382887|DEVICE|Airtraq|
224184196|NCT02382887|DEVICE|fiberscope|
224184197|NCT00679354|DRUG|cilengitide|Given IV
224184198|NCT00679354|OTHER|laboratory biomarker analysis|Correlative studies
224184199|NCT00679354|OTHER|pharmacological study|Correlative studies
224184200|NCT01700218|OTHER|telemonitoring|
224184201|NCT01700218|OTHER|control|
224184202|NCT02667262|OTHER|Algorithm to identify patients experiencing opioid abuse/addiction|
224184203|NCT03869931|DRUG|Fenofibrate|Fenofibrate 100 mg or 300 mg (according to CrCl)
223492729|NCT07111390|DEVICE|Sham Light Therapy|Constant white light delivered via a wearable headset.
223492730|NCT07105969|OTHER|Strontium Incorporated Hydroxyapatite [Sr-HA] coated mini-screws purchased from Dentarum company|Maxillary canine retraction by mini-screw loaded with 150g Niti coil spring
224184204|NCT02160184|DEVICE|Artificial pancreas system consisting of a predictive rule-based algorithm integrated on the Medtronic Portable Glucose Control System (PGCS)|
224184205|NCT03592251|DIETARY_SUPPLEMENT|Olive Oil Placebo|6 months placebo supplementation
224184206|NCT03592251|DIETARY_SUPPLEMENT|EPA-rich|6 months placebo supplementation
224184207|NCT03592251|DIETARY_SUPPLEMENT|DHA-rich|6 months placebo supplementation
224184208|NCT03682926|OTHER|Electro-stimulation|Intracavitary electrostimulation with Quark medical vaginal electrode for perineal muscle strengthening protocol.
224184209|NCT06373640|PROCEDURE|Insertion of drains|Insertion of lumbar drain and basal cistern drain
224184210|NCT06373640|DRUG|Vancomycin|Administration of vancomycin
224184211|NCT03612635|DEVICE|Implantation of a cardiac implantable electronic device|All patients enrolled in the registry underwent cardiac implantable electronic device implantation
224184212|NCT04541394|DEVICE|MolecuLight|MolecuLight is a device that utilizes a special light which, when used on wounds, helps identify the regions which pathogenic bacterial counts are the highest. The device applies 405nm violet light which is harmless to the human tissue. When specific components in bacteria catches up the light, a photoluminescent reaction is triggered and the fluorescence light is caught by the camera on this device in real time.
224184213|NCT06421194|OTHER|Investigational meal 1 - Commercial animal-based protein foods [Siew mai (6 pieces) and Ngoh hiang (2 pieces)]|Participants consume a meal consisting of commercial animal-based protein foods (steamed Siew mai and oven-baked Ngoh hiang) in a fasted state.
224184214|NCT06421194|OTHER|Investigational meal 2- Commercial animal-based protein foods [Gyoza (11 pieces) and Luncheon meat (5 pieces)]|Participants consume a meal consisting of commercial animal-based protein foods (steamed Gyoza and oven-baked Luncheon meat) in a fasted state.
224184215|NCT06421194|OTHER|Investigational meal 3- Formulated plant-based protein foods [Siew mai (6 pieces) and Ngoh hiang (1 piece cut into 2)]|Participants consume a meal consisting of formulated plant-based protein foods (steamed Siew mai and oven-baked Ngoh hiang) in a fasted state.
224184216|NCT06421194|OTHER|Investigational meal 4- Formulated plant-based protein foods [Gyoza (11 pieces) and Luncheon meat (5 pieces)]|Participants consume a meal consisting of formulated plant-based protein foods (Gyoza and Luncheon meat) in a fasted state.
224184217|NCT02701933|DRUG|Ketamine|Racemic ketamine, intravenous, at a concentration of 10mg ketamine per 50ml infusion
224184218|NCT02701933|DRUG|Saline|Saline, intravenous infusion
224184219|NCT03027180|DEVICE|Noninvasive positive airway pressure with different levels|
224308435|NCT05458882|BEHAVIORAL|"living with food allergy educational booklet"|An educational booklet giving information on social and eating out habits as well as reaction rates in food allergy Irish children.
223492731|NCT07115433|BEHAVIORAL|School-Based Oral Health Promotion Program|Arm Description: The oral health promotion intervention will be implemented through weekly interactive sessions lasting 30-40 minutes over a period of six months. These sessions, conducted by trained dental educators and teachers, will use animations, storytelling, demonstrations, and role-plays to teach proper toothbrushing, the importance of fluoride toothpaste, healthy eating habits, and the need for regular dental visits. Children will participate in supervised toothbrushing once a week, supported by peer ambassadors who reinforce daily practices. Educational leaflets and videos will engage parents, while posters in classrooms serve as reminders. Follow-up assessments, including questionnaires and clinical indices, will be conducted at six months.
223492732|NCT07116161|OTHER|Exercise Therapy Arm (ET)|Consists of a self-supervised individualized exercise prescription by the rehabilitation professional consisting of aerobic (e.g. brisk walking / cycling) and resistance training exercises, customized by patient preference.
223588535|NCT04107441|DRUG|AX-8 Part 2|5 and 40 mg AX-8 orally disintegrating tablets (ODTs), 45 mg/day split over 2 time points, 8 hours apart (i.e. Dose 1: 0 hour and Dose 2: + 8 hours). AX-8 ODTs will be administered orally and will be dissolved in the mouth while the subject is in a sitting position. The subjects will be instructed to actively move the tablet around in their mouth (i.e. active oral manipulation of the tablet) until it is fully dissolved.
223588536|NCT00474461|BIOLOGICAL|Treatment group|Intracoronary injection of cardiac stem cells
223588537|NCT00491374|DRUG|Mometasone Furoate Nasal Spray|Nasonex Nasal Spray 50 mcg/spray, 200 mcg (4 sprays) once daily every morning for 28 days.
223588538|NCT00491374|DRUG|Placebo|Placebo Nasal Spray 4 sprays once daily every morning for 28 days.
223745595|NCT03371901|OTHER|Physical therapy with BFR-LLST|"The criteria-based rehabilitation protocol for the patients with cartilage or meniscus repair may vary according to the surgical procedures.~Patients will attend 5 individual treatments, and a 6-week supervised group-based rehabilitation program with BFR-LLST (Blood Flow Restriction - Low Load Strength Training) twice a week at the rehabilitation centre. Patient will be instructed to perform BFR-LLST 5 times a week in total (twice supervised, 3 times at home).~During each BFR-LLST session, patients are encouraged to perform 4 sets of 30 repetitions, 15 repetitions, 15 repetitions, and 15 repetitions (or to fatigue in the final set), respectively.~The exercise intervention will adhere to TIDieR (template for intervention description and replication)."
223745596|NCT01010906|DRUG|Vaniprevir 300 mg|single dose administration of 300 mg oral tablet
223745597|NCT01010906|DRUG|Vaniprevir 200 mg|single dose administration of 200 mg oral tablet
224184220|NCT02059681|OTHER|Autologous bone marrow derived-CD133+ cells|Cell therapy
224184221|NCT02206776|DRUG|Intranasal Ketamine|A single dose of intranasal ketamine up to 50 mg
224184222|NCT02206776|DRUG|Intranasal Midazolam|A single dose of intranasal Midazolam up to 4 mg
224184223|NCT01002846|PROCEDURE|acupuncture|acupuncture group : subject will undergo 20minute sessions twice a week for 8weeks. Disposable acupuncture needle(4cm sterilized stainless steel) will be inserted up to 1 cm depth sham acupuncture group : subject will undergo 20 minute. Disposable acupuncture needle(4cm sterilized stainless steel) will be inserted under 1 cm slightly.
223745598|NCT06302192|DIAGNOSTIC_TEST|ARDS+AKI|according to the clinical practice Reanl doppler and VeXUS score will be performed
224184224|NCT01636102|BIOLOGICAL|Trivalent influenza virus vaccine (TIV)|A single 0.5 mL dose of the study vaccine supplied in prefilled syringes and administered intramuscularly in the deltoid muscle of (preferably) the non dominant arm
224184225|NCT02921594|DEVICE|Total knee arthroplasty with Vanguard XP|
224184226|NCT02921594|DEVICE|Total knee arthroplasty with Vanguard CR|
224184227|NCT04942951|DIAGNOSTIC_TEST|Gynecological examination|Gynecological examination was performed to the whole pregnant cohort included in the study to diagnose either the pelvic organ prolapse according to the POP-Q system or to be sure that they have no findings of pelvic organ prolapse.
224184228|NCT04942951|OTHER|Pelvic Organ Prolapse Quantification (POP-Q)|Gynecological examination was performed to the whole pregnant cohort included in the study to diagnose either the pelvic organ prolapse according to the POP-Q system or to be sure that they have no findings of pelvic organ prolapse.
224184229|NCT04942951|OTHER|Incontinence Consultation Questionnaire-Short Form (ICIQ-SF) questionnaire|ICIQ-SF questionnaire was applied to the Study group to determine the severity of urinary incontinence.
224184230|NCT04942951|OTHER|Pregnancy-Related Anxiety Questionnaire-Revised 2 (PRAQ-R2) questionnaire|PRAQ-R2 questionnaire was applied to the whole pregnant cohort included in the study to determine their anxiety status.
224184231|NCT00967356|DRUG|AZD5985|Single dose-The starting dose will be 40 mg, oral suspension, with up to 8 dose escalations not exceeding AstraZeneca predefined upper exposure limits
224184232|NCT00967356|DRUG|Placebo|Oral suspension
224184233|NCT04281095|DRUG|Botulinum toxin type A|Total of 20U/0.5mL is intramuscularly administered to five points of the glabellar region, 4U/0.1mL each
224184234|NCT06435052|BEHAVIORAL|Eye Movement Desensitization & Reprocessing Therapy|Eye Movement Desensitization and Reprocessing (EMDR) therapy will be administered face-to-face by a psychotherapist in a total of 12 sessions, with one session per week. The efficacy of EMDR therapy will be compared with Cognitive Behavioral Therapy in the treatment of Post-Traumatic Stress Disorder in Pakistan.
224184235|NCT06435052|BEHAVIORAL|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy will be comparatively checked with Eye Movement Desensitization \& Reprocessing Therapy for its efficacy. It will be administered by psychotherapist in 14 sessions (each session per week)
224184236|NCT04795570|PROCEDURE|Transurethral resection of the prostate or bladder|All patients undergoing TUR P/B will undergo a blood draw within 6 months after surgery to determine hormonal status and coagulation disorders.
223492733|NCT07116161|OTHER|Experimental: Exercise Therapy (ET) plus Cognitive Behavioural Therapy (CBT)|Consists of four major components adapted from previous studies,13,15,16 and delivered by qualified and trained study psychologists. First, the ABC model of cognitive behavioural therapy (A: activating events, B: beliefs, C: consequences) will be taught and applied to identify negative, unhelpful beliefs and the emotional, behavioural and physical consequences of those beliefs. Second, patients were taught behavioural strategies to manage fatigue (e.g. sleep hygiene, activity scheduling). Lastly, participants will be guided to reformulate dysfunctional cognitions regarding fatigue, improve coping strategies in relation to significant others (e.g. family, friends) and set goals.
223492734|NCT07115693|BEHAVIORAL|Telerehabilitation-Based Resistance Exercise Program|Participants received synchronous telerehabilitation sessions three times per week for six weeks. Each session lasted 45 minutes and included supervised resistance exercises for upper extremity muscle groups. Exercise bands were chosen based on baseline strength. Pulse oximeters were used to monitor heart rate and oxygen saturation.
223745600|NCT01170182|DRUG|Omeprazole|Omeprazole Delayed Release Capsules 40 mg
224184237|NCT04856072|DEVICE|Deep Brain Stimulation|Personalized Deep Brain Stimulation of Fornix
224184238|NCT00535262|DRUG|EmSam|Selegiline Transdermal System (STS); monoamine oxidase inhibitor patch
224184239|NCT01873274|DIETARY_SUPPLEMENT|MK-7 containing capsule|
224184240|NCT01873274|DIETARY_SUPPLEMENT|basic yogurt enriched with MK-7|
224184241|NCT01873274|DIETARY_SUPPLEMENT|nutrient-enriched yogurt with MK-7|
224184242|NCT05341011|BEHAVIORAL|PEERS® Social Skills Training|"The PEERS® consisted of 14 weekly 90-min didactic sessions. Adolescents and their parents attended separate concurrent sessions.~Each session began with a review of the homework assignment from the previous week and allowed time for troubleshooting problems encountered in completing the behavioral assignment. This was followed by a didactic lesson on the weekly topic. Didactic lessons included content related to various social skills and peer interactions. Parents attendance was a mandatory component of PEERS® intervention. Parents were expected to enhance generalization of social skills through in vivo social coaching in natural social settings and increase homework compliance as well as practice of newly learned social skills. A 10-min reunification between adolescents and caregivers was arranged at the end of each session to review the skills taught in the session and assign corresponding homework for the next session."
224184243|NCT00323934|DRUG|MGCD0103|Oral dosage 2 times weekly.
224184244|NCT05611944|DEVICE|Irrigation and suction through subcutaneus drains|Irrigation of wound will done by attaching 500cc saline to the drain on one side and let it flow freely from the other drain followed by suction of wound by attaching 60cc suction syringes on both sides creating suction pressure for 100 cc fluid.
224184245|NCT03879824|PROCEDURE|Secondary Radial Artery Access|Patients undergoing transcatheter aortic valve implantation (TAVI) will receive secondary arterial access via percutaneous access of the right radial artery for the purpose of insertion of a standard pigtail catheter for aortic route angiography during TAVI.
224184246|NCT03879824|PROCEDURE|Secondary Femoral Artery Access|Patients undergoing transcatheter aortic valve implantation (TAVI) will receive secondary arterial access via percutaneous access of the contralateral femoral artery for the purpose of insertion of a standard pigtail catheter for aortic route angiography during TAVI.
224184247|NCT04780126|OTHER|Sarcopenia diagnosis|History, physical, laboratory and ultrasound parameters to diagnose sarcopenia
224184248|NCT05361200|BEHAVIORAL|Dynamic high-cadence cycling|Resistance settings will be changed based on entropy of cadence every 3 sessions. Cadence will be set at 80RPM for both groups
224184249|NCT01934101|DRUG|CHR-5154|CHR-5154
223492735|NCT07115693|BEHAVIORAL|Home Exercise Program|Participants were given a home-based, unsupervised exercise program to follow three times per week for six weeks. The exercises were taught at the beginning, and adherence was monitored using a physical activity diary. No tele-supervision was provided.
223492736|NCT07115082|DRUG|Climen 21 Tablets|Climen is commonly used clinically as a hormone replacement therapy and was administered to all patients in both the control and experimental groups in this project.
223745601|NCT01170182|DEVICE|Prilosec® 40 mg|Prilosec® 40 mg
223745602|NCT04171973|DEVICE|Driving an electric wheelchair in real condition|For the control group, 3 test circuits of pipes in real condition of increasing difficulty are tested. Patients perform 2 passes in this condition.
223745603|NCT04171973|DEVICE|Driving an electric wheelchair in virtual condition|For the virtual reality group, the circuits have been digitized. Patients perform 2 passes in this condition.
224184250|NCT01934101|DRUG|Placebo|Placebo
224184251|NCT02118493|DEVICE|Benign Biliary Stenosis, Laser|Single use of laser to attempt excision of biliary ductal tissue causing stenosis.
224184252|NCT03260543|DIETARY_SUPPLEMENT|fermented ginseng powder|tablets (2 tablets/day, 125 mg \& 500 mg/day) for 12 weeks.
223588539|NCT04041245|DEVICE|Near infrared spectroscopy|"Near infrared spectroscopy will be adopted to assess the microcirculatory characteristics of meridian phenomenon for participants in the two groups.~1. Experimental device: a four-channel INVOS 5100C Oximeter (Somanetics Corp., Troy, USA)~2. Experimental process: The participants will be allowed to stabilize for 15 minutes in a supine position in the experimental room before formal examination.~   They are asked to keep silent, breathe normally and avoid movement of limbs during the whole measuring period. After ripping the transparent adhesive tape on the probe, the probes will be left at 4 measuring sites. Regional oxygen saturation (rSO2) will be recorded for 5 minutes.~3. Measurement sites: Shenmen (HT7) and Shaohai (HT3) of the Heart meridian, Taiyuan(LU9) and Chize (LU5) of the Lung meridian."
224184253|NCT03260543|DIETARY_SUPPLEMENT|Placebo|Placebo for 12 weeks.
224184254|NCT04102761|PROCEDURE|Intradiscal PRP & BMC Injections|The intervention to be studied is the intradiscal delivery of autologous Platelet Rich Plasma (PRP) or bone marrow concentrate (BMC) into the nucleus pulposus of the disrupted disc(s).
224184255|NCT06018766|DRUG|LAM-001|LAM-001 administered via dry powder inhaler
224184256|NCT06018766|DRUG|Placebo|Placebo administered via dry powder inhaler
224184257|NCT02898662|DRUG|AZD1419|Inhaled AZD1419 administered at the clinic as once weekly inhalations with the I-neb® device. Start dose is 4 mg and dose adaptation is applied (downtitration to 1mg or uptitration to 8 mg or remain on 4 mg) based on appearance of flu like adverse events
224184258|NCT02898662|DRUG|Placebo|Inhaled Placebo administered at the clinic as once weekly inhalations with the I-neb® device. Start dose is Placebo 4 mg and dose adaptation is applied (downtitration to 1mg or uptitration to 8 mg or remain on 4 mg) based on appearance of flu like adverse events
224184259|NCT04295629|PROCEDURE|Research on the effects of Ilioinguinal Nerve Block on Chronic Pain in Patients who undergo Inguinal Hernia with Spinal Anesthesia|The patients underwent inguinal hernia operation randomly classified into two groups in the operating room as; Group I (n:30); spinal block (SA): All patients were given SA in sitting position and 3ml 0.5% hyperbaric bupivacaine was injected in sterile conditions with 25 G injection in L3-4, L4-5 subarachnoid space. Times when the block reached T10 level were recorded.
224184260|NCT04295629|PROCEDURE|Ilioinguinal nerve block|Group 2 (n:30); SA in sitting position and 3ml 0.5% hyperbaric bupivacaine was injected in sterile conditions with 25 G injection in L3-4, L4-5 subarachnoid space and as a ilioinguinal block (IHNB) 10 ml 5% bupivacaine was injected to patients with peripheric nerve block injection in the reanimation unit after the surgery.
224184261|NCT02778594|DRUG|BIA 3-202|nebicapone 50 mg tablets; oral use
224184262|NCT02778594|DRUG|Placebo|Nebicapone matching placebo tablets
223492737|NCT07115082|BIOLOGICAL|hA-MSCs|The patients who were part of the experimental group were administered oral Clomid medication in conjunction with a combined intravenous injection of human amniotic MSCs.
223492738|NCT07115901|OTHER|Guaranteed Income|Participants will receive guaranteed income (GI) to the amount of $6,750 over the study period. While all participants will receive the GI intervention, there will be variation in the method of disbursement. Some participants will receive the GI as a one-time lump sum payment whereas other participants will receive the same GI amount split into 9-monthly installments.
223588540|NCT02014584|DRUG|Dutasteride|Dutasteride will be supplied as soft gelatin capsules, containing 0.5 mg of dutasteride to be administered orally.
223588541|NCT02014584|DRUG|Placebo|Dutasteride matching placebo will be supplied as capsules to be administered orally.
223745604|NCT05871359|DEVICE|Transcranial Direct Current Stimulation|The stimulator will be connected to two electrodes .The active electrode will be placed on the areas of the dorsal lateral pre-frontal cortex (DLPFC) contralateral to the more affected side.The other one on the supra orbital area.
224184263|NCT02778594|DRUG|levodopa 100 mg / benserazide 25 mg|Madopar® HBS 125 (levodopa 100 mg / benserazide 25 mg) capsules; oral use
224184264|NCT03802331|DRUG|BI 1323495,|single oral doses
224184265|NCT05140109|OTHER|Arm 1: Cognitive-dissonance based program|The first four sessions focus on body image and the last four sessions on eating behavior.
224184266|NCT05140109|OTHER|Arm 2: Mindfulness-based program|The sessions focus on different contents as body image, eating behavior and emotion regulation.
224184267|NCT05140109|OTHER|Arm 3: Person-centered program|The sessions are not structured. Participants can bring any subject they need to talk.
224184268|NCT03480529|DRUG|drug inducing arthritis, lupus, hepatitis, or capillary leak syndrom|Drugs susceptible to induce arthritis, lupus, hepatitis, or capillary leak syndrom
224184269|NCT02023476|RADIATION|MRI|MRI- imaging on the upper arm
224184270|NCT02699918|PROCEDURE|nocturnal oximetry|nocturnal oximetry for screening of sleep apnea syndrome. Patients with abnormal nocturnal oximetry will be further explored by polysomnography.
224184271|NCT02958449|DEVICE|Test - Standard Closure with TissuGlu Surgical Adhesive|Patients randomized into the Test group, TissuGlu® will be applied to the chest wall after removal of the breast tissue using the custom applicator during a standard mastectomy procedure followed by normal wound closure (suturing technique) without drain placement.
224184272|NCT05215106|DRUG|Durvalumab|Following preparation of durvalumab, the entire contents of the IV bag should be administered as an IV infusion over approximately 60 minutes (±5 minutes), using a 0.2μm in-line filter (or add-on filter).
224184273|NCT03499496|DIAGNOSTIC_TEST|ultrasound guided detection of atherosclerotic plaques|screening by ultrasound of atherosclerotic plaques
224184274|NCT00917553|DRUG|doxycycline monohydrate|50 mg
224184275|NCT00917553|DRUG|Placebo|Cellulose Placebo Capsule
224184276|NCT01932528|DRUG|500 mg [14C]-LX1606|500 mg dose of LX1606 containing a target dose of 3.32 Megabecquerel (MBq) of radiation as \[14C\]-LX1606.
224184277|NCT01616173|DRUG|Dexamethasone|IV dexamethsone 8mg in 50mL (diluted in NS)
224184278|NCT01616173|DRUG|Dexamethasone|8mg/2mL
224184279|NCT01616173|DRUG|Saline|2mL
224184280|NCT03861832|DIETARY_SUPPLEMENT|KB220Z|Acts to enhance dopamine
223492739|NCT07115797|OTHER|arthrocentesis - PRP injection -ARS|oarthrocentesis then PRP injection and then ARS
223492740|NCT07115797|OTHER|ARS|Insertion Of ARS Only
224184281|NCT03861832|DIETARY_SUPPLEMENT|Placebo|A placebo that looks the same, but does not contain amino acid precursors or any active ingredients in the nutraceutical
224184282|NCT01593566|DRUG|0.25% Bupivacaine|Femoral nerve block using 0.25% versus 0.5% bupivacaine
224184283|NCT01593566|DRUG|0.5% Bupivacaine|Femoral nerve block using 0.25% versus 0.5% bupivacaine for analgesia after ACL reconstruction
223492741|NCT07113691|DRUG|Iadademstat|Iadademstat is administered orally (PO) on an empty stomach (two hours after eating or one hour prior to food ingestion). After drinking the entire solution, the participant will be asked to refill the bottle with water and drink it again. Then they will drink another glass of water to wash their mouth and esophagus. Time of administration of the drug should be the same every day, preferentially in the mornings, and the time should be registered using the Dosing Instructions and Participant Drug Diary. If a dose is missed, the dose should be administered as soon as possible within 24 hours of the missed dose time. If more than 24 hours have passed, or a dose is vomited, the participant should call their medical team for instructions.
223492742|NCT07113691|DRUG|Atezolizumab|"Atezolizumab will be administered by IV infusion at a fixed dose of 1680mg on Day 1 (+/-3 days) of each 28-day cycle until unacceptable toxicity or loss of clinical benefit as determined by the treating investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status.~Administration of atezolizumab will be performed in a monitored setting where there is immediate access to trained personnel and adequate equipment and medicine to manage potentially serious reactions."
223492743|NCT07113691|RADIATION|SBRT|The first fraction of SBRT should be delivered after the initiation of iadademstat and atezolizumab, ideally between Cycle 1, Day 8, and Cycle 1, Day 15. Initiation of SBRT may be delayed up to 14 days beyond Cycle 1, Day 15 if iadademstat dose adjustment is required for toxicity
223492744|NCT07113886|PROCEDURE|Mixture of Autogenous and Xenograft Particulates|This group will receive guided bone regeneration using a 1:1 mixture of autogenous bone harvested from the mandibular ramus and xenograft bone substitute (e.g., Bio-Oss). The graft material will be covered with a titanium meshes. Standard flap design, fixation, and suturing techniques will be used
223492745|NCT07113886|PROCEDURE|Patient-Specific Sticky Bone|This group will receive guided bone regeneration using patient-specific sticky bone, created by mixing autogenous bone and xenograft with autologous fibrin glue (PRF). The sticky bone graft will be molded and applied directly to the defect site, covered with a titanium meshes, and stabilized using standard surgical protocol.
223492746|NCT07114939|DRUG|[18F]FluorThanatrace|Intravenous injection of ≤ 12 mCi of \[18F\]FTT for whole-body PET CT dynamic imaging and subsequent static scan.
223492747|NCT06920745|DEVICE|The TriClip System|The TriClip System
223492748|NCT07113704|PROCEDURE|Conventional Laparoscopic Cholecystectomy|Standard laparoscopic cholecystectomy technique starting at Calot's triangle. Used as the comparator group in this study.
223492749|NCT07113704|PROCEDURE|Fundus-First Laparoscopic Cholecystectomy|Laparoscopic cholecystectomy technique initiated at the gallbladder fundus and carried out retrogradely toward Calot's triangle. This method was applied to difficult gallbladders (Nassar Grade 3-4) to improve operative safety and avoid conversion to open surgery.
223492750|NCT06919757|DIAGNOSTIC_TEST|fetal ultrasound to assess lungs, heart and diaphragm|The potential association between fetal ultrasound parameters (estimation of lung volumes, diaphragmatic thickness and contractility, cardiac thickness and kinetics), perinatal complications and respiratory function in the first years of life will be studied. Variables include: neonatal complications, non-invasive markers of respiratory status during neonatal admission (e.g. peripheral oxygen saturation/rfaction of inspired oxygen ratio among others), lung function tests in the first two years of life.
223492751|NCT07115004|DRUG|VGA039|VGA039 SC administered for 49-weeks during the interventional phase following a 24-week observational period.
223492752|NCT07116447|BEHAVIORAL|Health messages - existing Swedish legislation|Textual health warning messages currently mandated for use in printed alcohol advertisements under the Swedish Alcohol Ordinance, focusing on communicated various alcohol harms
223492753|NCT07116447|BEHAVIORAL|Health messages - pictograms|Pictograms indicating no alcohol use during pregnancy and while driving
223588542|NCT02622646|DRUG|Recombinant VIII factor|"Identify and analyze cause(s) of poor bleeding control in patients on prophylaxis treatment and study the clinical impact of a personalized pilot program with a 1 year follow up to act on the specific causes.~1. Describe PK parameters in patients on prophylaxis treatment with Advate®~2. Analyze differences in PK parameters in non-controlled vs well controlled patients~3. Identify causes of poor clinical outcome in non-controlled patients. Patients' individual variables that influence bleeding risk will be studied (individual PK, bleeding pattern, joint status, physical activity, life style and patient's adherence).~4. Study the improvement in clinical outcomes (ABR and Joint status) of a 1 year Personalized Prophylaxis Program that acts specifically on the previously identified causes of bleeding in non-controlled patients (named: short half-life, high bleeding pattern, joint damage, high risk physical activity, active life style and poor patient's adherence)."
224184284|NCT00014560|BIOLOGICAL|bispecific antibody 4G7xH22|
224184285|NCT00014560|BIOLOGICAL|sargramostim|
224184286|NCT03753867|DRUG|Acitretin|Acitretin will be provided to participants in the formulation Soriatane. Soriatane doses are oral tablets taken daily by the participant. Participants will then receive 35mg of oral acitretin (Soriatane) daily for 8 weeks during the intervention phase. Participants will be asked to return two months after completion of the acitretin course for clinical follow-up and additional phlebotomy for laboratory testing.
224184287|NCT04193982|DRUG|Saroglitazar|Patient receives Saraglitazar 4mg once daily
224184288|NCT04193982|DRUG|Vitamin E|Patient receive Vitamin E 400mg twice daily after food for 6 months
224184289|NCT04193982|DRUG|Combination drug|Patient receives Vitamine E 400mg twice daily and Saraglitazar 4 mg once daily for 6 months
224184290|NCT04193982|BEHAVIORAL|Lifestyle Changes|Patients receives dietary advise and does exercise in form of aerobic and targets 7 to 10 percent weight loss in 6 months
224308436|NCT03762044|OTHER|Activity-oriented Proprioceptive Antiedema Therapy (TAPA)|"* Health education / patient empowerment.~* Neurodynamic activities oriented to ADL.~* Proprioceptive neuromuscular facilitation exercises oriented to ADL.~* Self-adherent self-adhesive antiedema of low compression."
224184291|NCT02349841|DRUG|Meropenem|To administer 2g daily 8 hourly for 14 days
224184292|NCT02349841|DRUG|Faropenem|To adminster 600mg 8 hourly daily for 14 days
223492754|NCT02266576|BEHAVIORAL|Standard DPP|The Standard Diabetes Prevention Program (DPP) delivered by the San Jose State Timpany Center is the Group Lifestyle Balance™ DPP, which has previously been tailored for urban American Indians and Alaska Natives by the Indian Health Service. Standard DPP components consist of 16 group classes, 4 visits with a lifestyle coach and access to a therapeutic swimming pool and gym.
223492755|NCT02266576|BEHAVIORAL|Enhanced DPP|Enhanced DPP components consist of access to a mental health counselor, active referrals to mental health services, and traditional healing workshops such as the use of talking circles, a modified photo voice and digital storytelling to address specific psychosocial issues that are a result of historical trauma, stress, and grief.
223492756|NCT06245239|DEVICE|perfusion index|measurement of perfusion index
223492757|NCT07115992|PROCEDURE|RARP±SRT|Participants will undergo robot-assisted radical prostatectomy (RARP). Upon biochemical recurrence, they will receive salvage radiotherapy: 52.5-62.5 Gy in 20-25 fractions/2.5-3.0 Gy per fraction, per 2025 AUA/ASTRO/SUO guidelines.
223492758|NCT07115992|PROCEDURE|RARP+ePLND|Participants will undergo robot-assisted radical prostatectomy (RARP) with extended pelvic lymph node dissection (ePLND), encompassing bilateral removal of obturator, external iliac, internal iliac, and common iliac lymph nodes. The dissection field extends laterally to the genitofemoral nerve, medially to the bladder wall, proximally to the ureter crossing the common iliac vessels, and distally to the deep circumflex iliac vein and femoral canal.
223492759|NCT07116187|OTHER|Train-Your-Brain (TYB) Stroke Recovery Programme|The intervention involves a structured brain health programme delivered by clinical neuropsychologists in three phases: an initial needs assessment, a multi-session intervention, and follow-up support. Participants will receive assessments, attend group sessions covering topics such as lifestyle, mood, cognition, and return-to-work strategies, and be supported with workbooks and referrals to community services. The programme combines in-person and online formats.
223492760|NCT07122258|DEVICE|CAROL NSCLC treatment Device|"Participants in this single-arm study will undergo treatment with the CAROL device for localized lung tumors (NSCLC ≤ 2 cm, cT1b). All participants will receive a single CAROL procedure using a conformable electrode, followed by surgical resection of the tumor.~The first 3 sentinel participants will receive a maximum dose of 0.3 mL of the conformable electrode. The next 4 participants will receive up to 2.0 mL. Safety and preliminary efficacy will be assessed through scheduled follow-up visits, including imaging, pulmonary function testing, laboratory assessments and pain monitoring.~Adverse events will be monitored throughout the study, with grading based on CTCAE v5.0, specifically focusing on Respiratory, thoracic, and mediastinal disorders. The study includes visits at screening, pre-procedure, post-procedure (24-36 hours), pre- and post-resection, and follow-up at approximately one and three months."
223492761|NCT07122765|OTHER|Mixed Meal Feeding Challenge|Liquid flavored Ensure Plus Shake of varying caloric content based on individual daily estimated caloric need
223492762|NCT07123441|DRUG|Bevacizumab,Irinotecan liposome (II),5-FU/LV|Bevacizumab: 5 mg/kg, intravenous infusion, Day 1; Irinotecan liposome (II): 60 mg/m² (based on free base), intravenous infusion for at least 90 minutes, Day 1; 5-FU: 400 mg/m², intravenous bolus injection, Day 1; followed by 1200 mg/(m²·day) × 2 days of continuous intravenous infusion (total dose 2400 mg/m², infused over 46-48 hours); LV: 400 mg/m², intravenous infusion over 2 hours, Day 1; Q2w, continued until an event meeting the treatment discontinuation criteria occurs or the subject withdraws from the study.
223492763|NCT07124260|DIAGNOSTIC_TEST|gut microbiota|Fresh fecal samples were collected from patients during the non-menstrual period and subjected to 16S rDNA sequencing.
223492764|NCT07124260|DIAGNOSTIC_TEST|tongue coating microbiota|Tongue coating samples were collected under fasting conditions between 6:00-9:00 AM on the same day as fecal specimen collection and subjected to 16S rDNA sequencing.
223492765|NCT07124260|DIAGNOSTIC_TEST|tongue picture|Tongue images were captured under fasting conditions between 6:00-9:00 AM on the same morning as fecal specimen collection.
223492766|NCT07125469|OTHER|The measurements taken from the CT scan will be used to determine the appropriate size for two types of theoretical Transcatheter Aortic Valve Replacement (TAVR) prostheses|"All patients with severe aortic stenosis (AS) who are scheduled for Surgical Aortic Valve Replacement (SAVR) with a bioprosthetic valve will undergo a pre-operative Computed Tomography (CT) scan. This CT scan will follow the pre-Transcatheter Aortic Valve Replacement (pre-TAVR) protocol and will focus only on imaging the aortic root, using a method called retrospective electrocardiogram (ECG) gating to capture detailed heart motion.~The measurements taken from the CT scan will be used to determine the appropriate size for two types of theoretical Transcatheter Aortic Valve Replacement (TAVR) prostheses:"
223492767|NCT07130591|OTHER|Cogniplat game platform|The Cogniplat gaming platform is designed to improve cognitive function in geriatric individuals, with or without mild cognitive impairment. Participants played the Cogniplat games face-to-face with a physiotherapist twice a week on non-consecutive days for 10 weeks, sessions lasting about 30-45 minutes. Scores from the platform were recorded to evaluate progress.
223492768|NCT07130591|OTHER|Control group|Individuals in this group did not participate in any regular play program. Demographic data were recorded. For evaluation purposes, a single session of Cogniplat game platform was applied in the first interview and in the second interview 10 weeks later. Initial and final evaluations were recorded.
223588543|NCT04943120|PROCEDURE|"Snow-plow technique"|In class II cavities, application of X-tra Base bulk fill flowable composite (VOCO) in 1 mm thickness without curing followed by X-tra Fill bulk fill packable composite (VOCO) to restore the proximal wall. Polymerization as one unit for 20 seconds.
223588544|NCT04943120|PROCEDURE|Bulk fill technique|In class II cavities, application of 4 mm increment of X-tra Fill bulk fill packable composite (VOCO) to restore the proximal wall. then the restoration id fully polymerized.
224184293|NCT02349841|DRUG|Amoxycillin/clavulanic acid|To administer 625mg 8 hourly daily for 14 days together with the faropenem and meropenem
224184294|NCT02349841|DRUG|Rifafour e275|To be taken as per the National TB treatment programme for 14 days
224184295|NCT00332982|BEHAVIORAL|Focused knowledge translation strategies|
224184296|NCT02195895|DRUG|Alendronate|Weekly oral alendronate 70 mg for 12 months
224184297|NCT02195895|DIETARY_SUPPLEMENT|Calcium|Daily oral 1000 mg Calcium
224184298|NCT02195895|DIETARY_SUPPLEMENT|Vitamin D|Daily oral 1000 IU
224184299|NCT02398643|OTHER|Pulmonary Education (PE)|Patients enrolled in PE will undergo focused education sessions following discharge from hospital.
224184300|NCT02398643|OTHER|Usual Care|Patients enrolled in usual care will receive general education sessions following discharge from hospital.
224184301|NCT00386035|DRUG|Delayed ART|Participants follow a drug conservation (DC) regimen in which ART is stopped or deferred until CD4 cell count dropped below 250 cells/mm3, initiated until CD4 cell count is at least 350 cells/mm3, and then are followed by episodic ART based on CD4 cell count.
224184302|NCT00386035|DRUG|Continuous ART|Group 2 participants follow a viral suppression (VS) regimen in which ART was continued to keep viral loads as low as possible, regardless of CD4 cell count.
224184303|NCT01636050|OTHER|squat exercise training|Intervention may include squat exercise for 8 weeks
224184304|NCT03770663|DRUG|Cyclophosphamide and azathioprine|European strategy 6 IV pulses of Cyclophosphamide (1000mg) followed from M5 to M12 by oral Azathioprine (2mg/kg/day), with a maximum of 150mg/day
223492769|NCT07138768|DEVICE|Magnetic Resonance Imaging|Magnetic Resonance Imaging will be performed to all patients
223492770|NCT07141030|DRUG|GZR18 injection|GZR18 injection:3mg
223492771|NCT07142200|DRUG|Disitamab Vedotin|Each patient will receive Disitamab Vedotin injection \[2.0 mg/kg, Q2W, iv\], with an expected total of 12 courses of treatment. The specific number of treatment cycles is determined by researchers based on the patient's response to the treatment, tolerance to the treatment plan, and comprehensive assessment of the condition. Patients with safety intolerance caused by any drug treatment should reduce or discontinue the medication according to the dosage adjustment plan specified in the plan. The medication is diluted with physiological saline and administered intravenously for one hour.
223492772|NCT07142200|DRUG|PD-1 inhibitor|Each patient will receive Triprolizumab injection \[3mg/kg, Q2W, iv\], with an expected total of 12 courses of treatment. The specific number of treatment cycles is determined by researchers based on the patient's response to the treatment, tolerance to the treatment plan, and comprehensive assessment of the condition. Patients with safety intolerance caused by any drug treatment should reduce or discontinue the medication according to the dosage adjustment plan specified in the plan. The medication is diluted with physiological saline and administered intravenously for one hour.
223492773|NCT07142200|RADIATION|radiotherapy|"1. Whole bladder treatment, recommended scope of application: T2 Suggestion: The total bladder radiotherapy dose is 2Gy/day, five times a week, up to a dose of 50Gy/25 times, to cover at least 95% of the planned target volume (PTV full bladder).~   The radiation dose for shrinking the field to bladder tumors is 2Gy/day, five times a week, with a total dose of 14Gy/7 times, to cover at least 95% of the planned target dose (PTV bladder tumors).~2. Whole pelvic radiotherapy (whole bladder+selective pelvic lymph node radiotherapy), applicable range: T3-T4a Suggestion: Whole pelvic radiotherapy at 2Gy/day, five times a week, up to a dose of 46Gy/23 times, to cover at least 95% of the planned target dose.~Reduce the dosage to 2Gy/day for the entire bladder and up to 4Gy/twice. Bladder tumor (PTV bladder tumor) 2Gy/day, five times a week, with a total dose of 14Gy/7 times, to cover at least 95% of the planned target volume.~The above radiotherapy plan is a suggestion, and the specific plan will"
223492774|NCT07141212|DEVICE|Virtual reality glass|"Virtual reality (VR), with its immersion and interactivity, offers the possibility to amplify the effectiveness of breathing techniques in promoting mental health by creation of relaxing scenarios and has been successfully employed in promoting relaxation and stress reduction. Virtual reality can turn breathing exercises into an interactive experience that feels more like a fun activity than a tedious task. It consists of VR headset, two touch controllers, glasses spacer with adjustable straps for good vision as follows:~1. Colour Breathing VR program (Box Breathing) :~   Patient sit in comfortable position with relaxed both shoulders. Breath in for 4 second, Hold breath for 4 sec, Breath out for 4 sec, Hold for 4 sec, Inhalations and exhalations move a 3D cloud shaped object closer and farther away from the user.~2. LAMINAL VR (Calm): Inhalations and exhalations grow and shrink a 2D circle with bubbles in between, changing in color."
223492775|NCT07141212|PROCEDURE|Buteyko Breathing|"1. The ''Control pause (CP)'' breathing test: Hold his nose on the out breath, with empty lungs but not too empty and count how many seconds that he can comfortably last before the need to breathe in again.~2. Shallow breathing Sit up straight: breathe air slightly into the tip of the nostrils. Concentrate on calming his breath to reduce the amount of warm air he feel on his finger, try to maintain the need for air for about 4 min.~3. Putting it together Take Control pause:~Reduced breathing for 4 min. Wait 2 min and take Control pause. Reduced breathing for 4 min. Wait 2 min and take Control pause."
223492776|NCT07142408|DRUG|Chlorhexidine gluconate (4%)|Chlorhexidine 4% solution will be applied from the neck down (avoiding the face, penis, and vagina), allowed to sit on the skin for one minute, then rinsed off in the shower every day for 5 days prior to surgery.
223492777|NCT07142408|DRUG|Mupirocin 2% Ointment|Mupirocin 2% ointment will be applied to the inside of the nostrils twice daily, in the morning and evening, for 5 days prior to surgery. A small amount of the ointment will be placed on the tip of a cotton swab to facilitate application to each nostril.
223492778|NCT07141823|DIETARY_SUPPLEMENT|Vitamin C (Ascorbic Acid) regularly has been taken|
223588545|NCT03963102|DRUG|Ameluz|Leaving on the gel for 4 hours rather than the standard 3 hours.
223588546|NCT01295970|PROCEDURE|Surgery|Prior to surgery, patients will have placement of scalp fiducials and undergo a contrast enhanced MRI scan. Once the patient is anesthetized or sedated, the head will be secured with a head frame and scalp fiducials will be registered to the stereotactic neuronavigation system. The tumor will then be resected and the patient will be taken to the recovery unit.
224184305|NCT03770663|DRUG|Tacrolimus|American strategy Tacrolimus given orally from M0 to M12 (started at the initial dose of 2x2mg/day). Tacrolimus doses are regularly adapted to its serum concentration to reach 5-15ng/mL.
224184306|NCT04382066|DRUG|Plitidepsin 1.5 mg/day|"Plitidepsin 1.5 mg/day will be IV infused through a pump device over 1 hour and 30 minutes, 3 consecutive days.~All patients must receive the following prophylactic medications 20-30 minutes before the infusion of plitidepsin:~* Diphenhydramine hydrochloride 25 mg iv or equivalent.~* Ranitidine 50 mg iv or equivalent.~* Dexamethasone 8 mg iv.~* Ondansetron 8 mg i.v. 15 minutes infusion or equivalent.~* Ondansetron 4 mg p.o. administered every 12 hours until 48 hours after the last administration of plitidepsin."
224308437|NCT03762044|OTHER|Complete Decongestive Therapy (CDT)|"* Skin care.~* Kinesitherapy~* Manual lymphatic drainage (MLD)~* Multilayer bandage.~The maintenance phase is based on self-care and the use of compression garments."
224184307|NCT04382066|DRUG|Plitidepsin 2.0 mg/day|"Plitidepsin 2.0 mg/day will be IV infused through a pump device over 1 hour and 30 minutes, 3 consecutive days.~All patients must receive the following prophylactic medications 20-30 minutes before the infusion of plitidepsin:~* Diphenhydramine hydrochloride 25 mg iv or equivalent.~* Ranitidine 50 mg iv or equivalent.~* Dexamethasone 8 mg iv.~* Ondansetron 8 mg i.v. 15 minutes infusion or equivalent.~* Ondansetron 4 mg p.o. administered every 12 hours until 48 hours after the last administration of plitidepsin."
224184308|NCT04382066|DRUG|Plitidepsin 2.5 mg/day|"Plitidepsin 2.5 mg/day will be IV infused through a pump device over 1 hour and 30 minutes, 3 consecutive days.~All patients must receive the following prophylactic medications 20-30 minutes before the infusion of plitidepsin:~* Diphenhydramine hydrochloride 25 mg iv or equivalent.~* Ranitidine 50 mg iv or equivalent.~* Dexamethasone 8 mg iv.~* Ondansetron 8 mg i.v. 15 minutes infusion or equivalent.~* Ondansetron 4 mg p.o. administered every 12 hours until 48 hours after the last administration of plitidepsin."
224184309|NCT04830293|PROCEDURE|Carotis Doppler Ultrasound|Neck was rotated about 30-45 ° to the opposite side of the image. The common carotid artery and internal jugular vein were viewed transversely on the B Mode USG image. Then, the probe was rotated approximately 90 ° and the carotid artery was visualized in the longitudinal plane. The probe and guide line were adjusted so that the Doppler angle was 60 °. The image was created with the guiding line parallel to the blood flow. After imaging of the carotid artery bifurcation, measurements were made 1 cm distal to this level.
224184310|NCT05648305|PROCEDURE|Root Canal Treatment/ Re-treatment|The provision of Root Canal Treatment for teeth with Endodontic infection or to prevent Endodontic infection.
224184311|NCT01957904|DEVICE|ArterX Surgical Sealant|
224184312|NCT00504595|DRUG|ACZ885 (investigational)|The ACZ885 was supplied in 6 mL colorless glass vials each containing nominally 150 mg ACZ885 (with 20% overfill). The vials were kept at 2-8°C. At the investigator's site, solutions for infusion were prepared depending on the volume and dose administered.
224184313|NCT00504595|DRUG|Placebo|Matching placebo of ACZ885 was supplied in the form of a lyophilized cake (Powder for Solution for Infusion). At the investigator's site, solutions for infusion were prepared depending on the volume and dose administered.
224184314|NCT03754881|BEHAVIORAL|Pulmonary rehabilitation|"In this study, we'll educate pulmonary rehabilitation to patients and make reservation for re-visiting outpatients clinics with PR diary after 8 weeks.~we want to confirm whether patients, who perform home based PR during more than 30 minutes in 3 days per week, present improved dyspnea score or quality of life compared with non-compliance group."
223492779|NCT07141069|OTHER|Art therapy combined with Exercise|one hour of expressive art intervention followed by one hour of exercise training. The art therapy will be conducted in small groups of eight participants, facilitated by a part-time registered expressive art therapist. Each session begins with a 5-minute introduction and check-in, welcoming participants and inviting them to share their current status. This is followed by a 10-minute brief mindfulness exercise to help center participants and promote relaxation, setting the stage for the creative activities that follow. The core of each session consists of a 20-minute art-making process centered around specific themes that guide participants in exploring their pain and personal narratives.
223492780|NCT07141069|OTHER|Exercise|each one-hour session in the exercise control group will involve progressive back and general reconditioning exercises, along with back care education to support self-management of LBP.
223492781|NCT07140835|DEVICE|SurgiStep Platform|The Surgistep (pedal-controlled, adjustable platform) allows real-time height adjustment during surgery. The surgeons can adjust the height of the platform.
223492782|NCT07140835|DEVICE|Standard Foot stool|Foot stool is considered as the standard of care during surgery.
223492783|NCT07142174|DEVICE|cervical facet implant will be introduced into the cervical levels that were mobile on flexion-extension x-ray and exhibited foramen stenosis or spondylolisthesis|"The patients will be managed according to the current practice for posterior cervical spine surgical approaches regarding patient positioning, surgical exposure, and neural decompression. The patients will be positioned prone with the head in a Mayfield headrest, All patients will be monitored using intraoperative motor evoked potentials (MEP) and somatosensory evoked potentials (SSEP). Intra-operative X-rays (antero-posterior and lateral) will be used to identify the index cervical level and to guide facet preparation and CeLFI insertion. Exposure of the posterior surface of the lateral mass at the index level of the cervical spine will be done either through a midline open technique or para-midline; inter-muscular approach (MIS). The facet joint-space (FJS) will be opened using a monopolar cautery with careful attention to preserve the joint's capsule on the lateral and medial boundaries.~The FJS will be prepared using sequential dilators; designed for this purpose. Each dilator me"
223745605|NCT05871359|PROCEDURE|Dual task|The Dual Task consists of walking for 20 minutes along a hallway, simultaneously patient has to answer to a different ecological cognitive (attention, fluences, calculation) and motor tasks (hold a tray, turn head, ecc..)
223745606|NCT03161431|DRUG|SX-682|SX-682 is an oral small molecule selective inhibitor of C-X-C Motif Chemokine Receptor 1 (CXCR1) and C-X-C Motif Chemokine Receptor 2 (CXCR2)
223745607|NCT03161431|BIOLOGICAL|Pembrolizumab|Pembrolizumab is a humanized antibody that targets the programmed cell death 1 receptor (PD-1).
223745608|NCT00525174|DEVICE|Bangerter filters|Bangerter filter worn on sound eye spectacle lens full time
223745609|NCT00525174|DEVICE|Patching|2 hours daily patching of the sound eye
223745610|NCT00525174|PROCEDURE|Near activities|one hour near visual activities
224184315|NCT04281966|BEHAVIORAL|Ability School Engagement Program Conference|"The ASEP conference focuses on understanding the reasons behind why the young person is not attending school regularly, understand how the young person's non-attendance affects other conference participants, highlight the legal consequences of parents and/or guardians to ensure that their child attends school, and the development of a young person-centered Action Plan, which will specifically detail the actions that all parties are to take over the next three months to ensure that the young person re-engages with school and/or transitions into paid work."
224184316|NCT03326323|PROCEDURE|Acute Normovolemic Hemodilution|Collection and reinfusion of a patients own blood during coronary artery bypass graft surgery.
224184317|NCT02271763|OTHER|ultrasound|subjects' neck will be scanned using ultrasound
224184318|NCT01509651|DRUG|Sugammadex|After the induction of anaesthesia, monitoring neuromuscular function is initiated and performed continuously using the TOF-Watch SX (Organon Ireland Ltd, Ireland) at the thumb. Repetitive train-of four (TOF) stimulation is applied every 15 s at the ulnar nerve until the end of anaesthesia, at least until recovery of the TOF ratio to 0.9 after administration of sugammadex. Each patient receives a single IV bolus dose of rocuronium 0.6 mg kg-1, after which tracheal intubation is performed. Maintenance doses of rocuronium 0.1 mg kg-1, are permitted as required and administered at the reappearance of the second twitch in the TOF. On reappearance of the second twitch at the end of surgery, patients receive a single IV bolus dose of sugammadex, 2.0 mg kg-1, for reversal.
224184319|NCT05635110|DRUG|VX-548|Tablets for oral administration.
224184320|NCT05635110|DRUG|Omeprazole|Tablets for oral administration.
224184321|NCT05635110|DRUG|Rifampin|Capsules for oral administration.
224184322|NCT04225026|DRUG|GC4419 (avasopasem manganese)|90 mg, by 60-minute IV infusion, prior to each fraction of RT
224184323|NCT03048175|PROCEDURE|Wisdom tooth removal|After inferior dental and buccal nerve anesthesia a triangular full thickness flap with releasing incision on the mesio-buccal aspect of the second molar is designed. Ostectomy is then performed and tooth is sectioned and gently elevated. Once all the tooth components are extracted, the socket is carefully inspected and flap is sutured with interrupted sutures.
224184324|NCT05941494|DRUG|Propofol|Patient will receive propofol as their maintenance agent during surgery. The typical dose is 150-200 mg/kg/min.
224184325|NCT05941494|DRUG|Sevoflurane|Patient's anesthesia will be maintained with 1 MAC of sevoflurane during surgery.
224184326|NCT05941494|DRUG|Ephedrine|The patient will receive ephedrine infusion as the primary vasopressor of choice. The typical dose of ephedrine infusion is 10-50 mg/hr (dilution 2 mg/ml).
224184327|NCT05941494|DRUG|Phenylephrine|Patient will receive phenylephrine infusion as the primary vasopressor of choice. The typical dose of phenylephrine infusion is 10-40 mcg/min (dilution 100 mcg/ml).
224184328|NCT05886374|DRUG|HMPL-415S1|HMPL-415S1 will be supplied as 0.5 mg, 5 mg and 25 mg capsules
224184329|NCT05744466|DRUG|Deucravacitinib|As prescribed by treating clinician
224184330|NCT05744466|DRUG|Apremilast|As prescribed by treating clinician
224184331|NCT02982122|OTHER|For both groups, CPP targets will be achieved first by ICP control if this is raised and then by ABP support by titration (up or down) of vasopressors and fluids according to local protocols.|For both groups, CPP targets will be achieved first by ICP control if this is raised and then by ABP support by titration (up or down) of vasopressors and fluids according to local protocols.
223492785|NCT07142629|PROCEDURE|Selective caries removal|Selective carious removal to firm dentine. Subsequently, 2 mm of Biodentine will be placed as a liner over the pulpal wall leaving the peripheries of the cavity available for bonding of the subsequent restoration.
223492786|NCT07142629|PROCEDURE|Non-Selective caries removal|Complete caries excavation will be done to hard scratchy dentine, with the aid of caries detector dye.If no pulp exposure is evident 2 mm of Biodentine will be placed and the cavity will be restored. If pulp exposure occurred, and it is bleeding normally and uniformly red with no zones of degeneration or necrosis then direct pulp capping will be attempted with Biodentine as a capping material. If no hemostasis is achieved, then the procedure will be modified to either partial pulpotomy, full pulpotomy or RCT depending on the clinical assessment.
224184332|NCT00756379|OTHER|Comprehensive therapy program for risk factor modification|Patients enrolled in the comprehensive therapy arm will have a baseline myocardial perfusion PET and the support of a team of professionals aiming to modify and minimize all the known CAD risk factors. During the 5 year follow-up they will be educated and guided toward a healthy lifestyle by a dietician, an exercise physiologist/cardiovascular physician specialist.
224184333|NCT03826849|BEHAVIORAL|Insomnia Coach|Insomnia Coach is a mobile application that provides psychoeducation and self-management tools for insomnia symptoms based on cognitive behavioral therapy for insomnia (CBT-I)
224184334|NCT03006042|DRUG|Bupivacaine|
224184335|NCT06092866|BEHAVIORAL|Digital triage|A registered nurse assesses the symptoms reported by the patient on the online platform and gives appropriate advice for further care using chat.
224184336|NCT04284579|DEVICE|IV cannula|We measure the time duration needed for IV cannulation
224184337|NCT00851721|BIOLOGICAL|Factor VIII Inhibitor Bypassing Activity (nanofiltered, vapor heat-treated)|85 ± 15 U/kg of FEIBA NF every other day during the 12-month prophylactic period
224184338|NCT00851721|BIOLOGICAL|Factor VIII Inhibitor Bypassing Activity (nanofiltered, vapor heat-treated)|FEIBA NF dose and dosing interval as prescribed by the treating physician
224184339|NCT02240901|DEVICE|Laryngeal mask airway（LMA）|Laryngeal mask airway（LMA） is used to maintain mechanical ventilation during intra-operative
224184340|NCT02240901|DEVICE|Endotracheal intubation（ETI）|Endotracheal intubation group（ETI）is used to maintain mechanical ventilation during intra-operative
224184341|NCT03223649|OTHER|Walking Bouts|Six daily 3 hour sessions with prompted 3-minute moderate-intensity walking bouts performed on a treadmill every 30 minutes throughout the 3 hour duration. There will be a total of 6 walking bouts (18 minutes total) each day. Moderate-intensity walking speed and grade will be selected to achieve 80% of the heart rate achieved at the ventilatory threshold as determined during a V02max test.
224184342|NCT03223649|OTHER|Sedentary|(Control 'intervention') Six daily 3 hour sessions with no physical activity (i.e. subject remains sedentary in seated or recumbent position) throughout the 3 hour duration.
224184343|NCT01988844|OTHER|Assessment|The children with cerebral palsy were assessed. Different measures evaluating the upper limbs functionality are used.
224184344|NCT03328572|OTHER|E-max Endocrown|Endocrown preparation
224184345|NCT03328572|OTHER|Cerasmart Endocrown|Endocrown preparation
224184346|NCT01599091|OTHER|Specimens collection|Tooth extraction will be preformed in the regular way regardless of the study. Patients will be asked permission to obtain the extracted tooth and excess of gingival remnants for further in vitro investigation in the main investigator's laboratory.
224184347|NCT01478490|DRUG|mirabegron|oral
224184348|NCT01478490|DRUG|metoprolol|oral
224184349|NCT03247140|DRUG|JLP-1401|Administration of JLP-1401(Telmisartan/Amlodipine/Rosuvastatin)
224184350|NCT03247140|DRUG|Telmisartan/Amlodipine, Rosuvastatin|Administration of Temlisartan/Amlosipine(Twinsta®) and Rosuvastatin(Crestor®)
224184351|NCT03487562|DRUG|DWP14012 Amg|DWP14012 Amg
224184352|NCT03487562|DRUG|DWP14012 Bmg|DWP14012 Bmg
223588547|NCT01295970|PROCEDURE|Stereotactic Radiosurgery|This will be delivered using Gamma Knife technology. Patients randomized to this arm will be fitted with a stereotactic head-frame for stereotactic localization of brain metastases.
223588548|NCT06004570|DIETARY_SUPPLEMENT|Complex product|Extracts from the fruits of Vaccinium myrtillus L. + Aronia Melanocarpa (Michx.) Elliot + Lonicera caerulea var. Kamtschatica, rutin, vitamin B6, vitamin B12, folic acid Single oral dose - 2 capsules
223588549|NCT06004570|DIETARY_SUPPLEMENT|Polyphenol-rich extracts|Extracts from the fruits of Vaccinium myrtillus L. + Aronia Melanocarpa (Michx.) Elliot + Lonicera caerulea var. Kamtschatica Single oral dose - 2 capsules
224184353|NCT03487562|DRUG|Clarithromycin|Clarithromycin 500 mg
224184354|NCT03487562|DRUG|Amoxicillin|Amoxicillin 1 g
224184355|NCT03487562|DRUG|Lansoprazole|Lansoprazole 30 mg
224184356|NCT05421689|BIOLOGICAL|Autologous Muscle Derived Cells for Gastro-Intestinal Repair (AMDC-GIR)|The study will treat 66 patients at 2 clinical sites: UC Davis Center for Voice and Swallowing and UCSF Voice and Swallowing Center. Patients will be randomized 1:1 to receive either 2 AMDC-GIR doses of 150 x 10⁶ cells or 2 doses of identical placebo composed of the same cryopreservation medium used for AMDC-GIR. Enrollment is expected to be completed within 2 years of initiating the study. Patients will be followed for 24 months post-treatment.
224184357|NCT05421689|OTHER|Placebo|two doses of placebo will be administered and spaced 4-6 weeks apart.
223492787|NCT07142122|PROCEDURE|Total laparoscopic proximal gastrectomy with preservation of both the hepatic and celiac branches of the vagus nerve, followed by double-tract reconstruction.|Total laparoscopic proximal gastrectomy with meticulous preservation of the hepatic branch of the vagus nerve (via fenestration of the lesser omentum) and the celiac branch (via skeletonization of the left gastric artery). The esophagus was transected ≥3 cm proximal to the tumor, preserving \>50% of the residual stomach. Double-tract reconstruction was then performed: an end-to-side esophagojejunostomy was created first, followed by a side-to-side gastrojejunostomy between the residual stomach and jejunum, and finally a side-to-side jejunojejunostomy approximately 40 cm distal to the gastrojejunal anastomosis. This approach achieves oncological resection while maximizing preservation of digestive physiology (gallbladder contraction, reduced dumping syndrome, and partial gastric reservoir function).
223492788|NCT07142122|PROCEDURE|Total laparoscopic proximal gastrectomy with preservation of the hepatic branch of the vagus nerve but deliberate resection of the celiac branch, followed by double-tract reconstruction.|Total laparoscopic proximal gastrectomy with meticulous preservation of the hepatic branch of the vagus nerve (via lesser omentum fenestration adjacent to the liver edge), while deliberately not preserving the celiac branch (by direct transection at the root of the left gastric artery). The esophagus was transected ≥3 cm proximal to the tumor with preservation of \>50% gastric remnant. Double-tract reconstruction was then executed: end-to-side esophagojejunostomy (circular stapler) → side-to-side gastrojejunostomy (linear cutter) → side-to-side jejunojejunostomy approximately 40 cm distal to the gastrojejunal anastomosis. This technique achieves oncological resection while utilizing the residual stomach and dual-pathway design to minimize postoperative dumping syndrome and preserve partial gastric function.
223492789|NCT07140822|DEVICE|Coronary Cutting Balloon Catheter|This product uses a pressure device to pressurize the balloon to expand it. The blades designed on the surface of the balloon produce a cutting effect on the vascular lesions, allowing it to better embed into the plaque.
223492790|NCT07140822|DEVICE|VesscideTM Cutting Balloon System|This product utilizes a pressure mechanism to inflate the balloon, causing it to expand. The blades on the balloon's surface create a cutting action on the vascular lesions, enabling the device to penetrate the plaque more effectively.
223492791|NCT07141095|DRUG|maribavir|Maribavir tablets are administered orally at a dose of 0.4 g per administration (2 tablets of 0.2 g each), twice daily. The recommended duration of treatment is 8 weeks; however, the specific treatment duration should be individualized based on the clinical characteristics of each patient.
223492792|NCT07141407|OTHER|Supportive Care|Attend TAC telephone-based coaching sessions
223588550|NCT06004570|OTHER|Placebo|Single oral dose - 2 capsules
223588551|NCT06304779|DRUG|Lidocaine|"Lidocaine group receive a loading dose of 1.5 mg/kg 2% lidocaine at anesthesia induction, followed by continuous intravenous infusion at 1.5 mg/kg/h until 24 hours postoperatively and Control group receive an equivalent volume of normal saline at anesthesia induction and throughout the perioperative period until 24 hours postoperatively.~Both groups will receive the same anesthesia and postoperative analgesia protocols, lung-protective ventilation strategy, and fluid, transfusion, and warming strategies. The only difference is the intervention during surgery, with the lidocaine group receiving continuous intravenous lidocaine."
224184358|NCT06408103|OTHER|Multi-component, transdisciplinary and multifocal intervention for the cognition|"Multi-component intervention (12 weeks, twice/week, with professional support at home)~Physical activity for the patient: dual training, strength, balance, with intensity increase monthly, plus moderate walking of 30 minutes/day, 5 days per week.~Nutritional advice for the patient: Month 1- reduction of added sugars and processed carbohydrates. Month 2- increase consumption of healthy fats and reduction of saturated fats; Month 3- increase in consumption of fruits and vegetables, and a monthly group practical workshop.~Cognitive training for the patient: activities focused on orientation, attention and concentration, working memory, mathematical reasoning, language, visual construction, executive functions, and reminiscence therapy.~Accompaniment for the family member: Activities aimed at care and self-care, understanding cognitive deterioration and its progression, support for patient adherence to the intervention, and activities in groups once a week."
224184359|NCT06495645|DEVICE|AI-assisted upper gastrointestinal endoscopy|AI-assisted upper gastrointestinal endoscopy
224184360|NCT03970603|OTHER|Early Weight-Bearing|Being directed to bear weight on the affected ankle two weeks from suture button fixation for syndesmotic disruption
224184361|NCT03970603|OTHER|Delayed/Late Weight-Bearing|Being directed to bear weight on the affected ankle six weeks from suture button fixation for syndesmotic disruption
223588552|NCT06304779|DRUG|Placebo|atients receive an equivalent volume of normal saline at anesthesia induction and throughout the perioperative period until 24 hours postoperatively.
223745611|NCT00914810|DIETARY_SUPPLEMENT|Vitamin D (cholecalciferol)|2000 I.U. daily for 6 weeks
223745612|NCT00914810|DIETARY_SUPPLEMENT|Placebo|Placebo (sugar pill) daily for 6 weeks
224184362|NCT04550143|OTHER|Diaphragm ultrasound (DUS)|"DUS assessments of diaphragmatic thickness (TDI), thickness fraction (TFDI) and shear modulus (SMDI), this last measured by shear-wave elastography (SWE), will be performed for both right and left hemi-diaphragms.~A landmark between the 8th and 10th intercostal space in the mid-axillary or antero-axillary line, 0.5-2 cm below the costophrenic sinus, will be used. Here, the diaphragm can be seen as the less echogenic structure between two echogenic lines; TDI (cm) will be the calculated as the distance between the two lines at the end of expiration and TFDI as the rate of change between end-expiration and end-inspiration thicknesses (TFDI = thickness at end inspiration - thickness at end-expiration / thickness at end-expiration, %).~SMDI will assess muscle's stiffness. For each image, a region of interest covering the widest possible surface of diaphragm and allowing an acquisition frequency of 2Hz will be set; results will be retrieved in kilopascals (kPa)."
224184363|NCT04550143|OTHER|Peripheral Muscle Ultrasound (PMUS)|"PMUS assessments of quadriceps rectus femoris (RF) muscle cross-sectional area (CSARF), echogenicity (ECHORF) and shear modulus (SMRF), this last measured by shear-wave elastography (SWE), will be performed.~Probe will be placed perpendicularly to the anterior plane of the thigh, in 2 anatomical points, as follows:~(i) in the midpoint between the anterior superior iliac spine and the upper pole of the patella and (ii) the border of the lower 1/3 and upper 2/3 between the anterior superior iliac spine and the upper pole of the patella.~CSARF (cm2) will be calculated by outlining the area under the muscle hyperechoic line (aponeurosis). For ECHORF (differences in grey-scale images), the analysis of a region of interest (ROI) of 2cm x 2cm will be performed.~For SMRF (kPa), a ROI covering the widest possible area of the RF and allowing an acquisition frequency of 2Hz will be set for analysis.~All assessments will be performed with minimal compression and a copious amount of water-gel."
224184364|NCT04550143|OTHER|Airway occlusion pressure (P0.1)|"P0.1 is the pressure developed in the occluded airway 100 milliseconds after the onset of inspiration. Its use doesn't require any additional equipment since it can be easy measured by using patient's ventilator.~For the measurement itself, patients will be in semi-recumbent position (head elevation between 30° and 45°) with knee extended in neutral position and will be asked to stay as relaxed as possible. After 5 minutes breathing without any interruption or disturbance, 4 measurements will be observed and recorded as displayed on the ventilator screen."
224184365|NCT04550143|OTHER|Medical Research Council (MRC) sum score|"This is a manual muscle strength testing tool, used very often in the ICU setting. It's based on the assessment of the following muscle groups: shoulder abduction, elbow flexion, wrist extension, hip flexion, knee extension, and dorsiflexion of the ankle, all scored bilaterally. Muscle strength is graded as follows: 0, no visible/palpable contraction; 1, visible/palpable contraction without movement of the limb; 2, movement of the limb, but not against gravity; 3, movement against gravity; 4, movement against gravity and some resistance; 5, normal.~The sum score ranges between 0 and 60 (between 0 and 5, in 12 muscle groups), with a score \<48 indicating the presence of weakness."
224184366|NCT03111810|DRUG|AZD4017 and prednisolone|The drug AZD4017 will be given together with prednisolone 20mg daily for 7 days to compare its effects on metabolic tissues against the placebo arm where the participants will take placebo and prednisolone 20mg daily for 7 days.
224184367|NCT03111810|DRUG|Placebo Oral Tablet and prednisolone|Placebo Oral tablet will be given together with prednisolone 20mg daily for 7 days to compare the effects on metabolic tissues of AZD4017 and prednisolone 20mg daily against the placebo arm.
224184368|NCT03982069|BIOLOGICAL|FluMist live attenuated influenza vaccine|Participants randomized to this study influenza vaccine arm will receive FluMist live attenuated influenza vaccine at baseline after the baseline blood draw is complete.
224184369|NCT03982069|BIOLOGICAL|Flucelvax inactivated influenza vaccine|Participants randomized to this study influenza vaccine arm will receive Flucelvax cell-culture inactivated influenza vaccine at baseline after the baseline blood draw is complete.
224184370|NCT06533176|DEVICE|Personalized brain state-dependent single-pulse TMS|Single-pulse TMS will be applied to the lesioned hemisphere during brain activity patterns associated with strong residual corticospinal tract activation and random brain activity patterns.
224184371|NCT03062644|DRUG|MR308|two times daily; Mode of Administration:oral
224184372|NCT03062644|DRUG|MR308|four times daily; Mode of Administration:oral
224184373|NCT03062644|DRUG|MR308|two times daily; Mode of Administration:oral
224184374|NCT03062644|DRUG|MR308|given four times daily to maintain the blind; Mode of Administration:oral
224184375|NCT03110757|BIOLOGICAL|GLA-AF|Previously referred to as Gluco-pyranosylphospho-lipid A aqueous formulation (GLA-AF). It is a toll-like receptor-4 agonist
223492793|NCT07141407|BEHAVIORAL|Telephone-Based Intervention|Attend TAC telephone-based coaching sessions
223492794|NCT07141407|OTHER|Survey Administration|Ancillary studies
224184376|NCT03110757|BIOLOGICAL|Hepatitis B Virus Vaccine (Recombinant)|A non-infectious subunit viral vaccine derived from hepatitis B surface antigen (HBsAg) produced in yeast cells.
224184377|NCT03110757|BIOLOGICAL|Sm-TSP-2/Alhydrogel|Sm-TSP-2/Alhydrogel
224184378|NCT00175734|PROCEDURE|High Hemoglobin Concentration|The purpose of this study is to document relevant and related clinical changes associated with different hemoglobin concentrations in diabetic hemodialysis patients.
224184379|NCT00175734|PROCEDURE|Low Hemoglobin Concentration|The purpose of this study is to document relevant and related clinical changes associated with different hemoglobin concentrations in diabetic hemodialysis patients.
224184380|NCT05393778|PROCEDURE|Measured Technique|Manual intra-operative checks and tools are used to aid in component placement during surgery.
224184381|NCT05393778|PROCEDURE|Navigated Technique|IntelliJoint® navigation is an imageless-based navigation system that utilizes a miniature infrared camera and microelectronics to measure hip center of rotation, acetabular inclination and version, leg length, and offset. The device provides accurate real-time data on implant positioning to aid in placement of the components during surgery.
224184382|NCT03115164|OTHER|To study the characteristics of patients with DIA / DIG|Describe the characteristics of patients with DIA / DIG treated in French SFCE pediatric oncology centers according to whether these tumors behave in a benign or malignant manner.
224184383|NCT04390620|DEVICE|Mucosal Closure|mucosal closure in oral surgery (mucosal sutures)
223492795|NCT07141407|OTHER|Educational Intervention|Receive an ACP brochure/handout
223492796|NCT07140744|DIAGNOSTIC_TEST|P-tau217|Blood biomarker testing
223492797|NCT07140744|OTHER|Standard of Care|Standard of care
223588553|NCT06544759|BEHAVIORAL|Aa educational Documentry|"The Gift of Life: Become an Organ Donor, Transform the Future! is an informative and captivating documentary that delves into the world of organ transplantation and the powerful implications of organ donation. This documentary aims to dispel common misconceptions about organ donation and shares a heartwarming real-life story that highlights the life-saving potential of organ transplants. Through its comprehensive exploration of the subject and engaging storytelling, the documentary not only educates but also inspires profoundly. The documentary challenges preconceptions and aims to cultivate a culture of empathy, generosity, and life-saving commitment through its meticulous examination of the topic. The documentary serves as a powerful tool to raise awareness about the importance of organ donation and its potential to make a positive change in the world."
223588554|NCT02383771|DRUG|Ticagrelor|(Ticagrelor 90mg Bid) x 7days
224184384|NCT01218477|DRUG|Dasatinib|Oral tablets, 100-140 mg once daily, depending on cohort (100 mg for those with chronic myeloid leukemia \[CML\]-chronic phase; 140 mg for those with CML-advanced phase)
224184385|NCT01218477|DRUG|BMS-833923|Oral capsules, 50-200 mg, depending on cohort (100 mg for those with CML-chronic phase; 140 mg for those with CML-advanced phase)
224184386|NCT02120274|DRUG|Vitamin D|Oral vitamin D 2,000 IU qd throughout, irrespective of baseline vitamin D level.
224184387|NCT02120274|DRUG|Vitamin B 12|Intramuscular vitamin B12 5000 UI will be given weekly in the first 12 weeks followed by a monthly injection until the end of therapy.
224184388|NCT04406155|PROCEDURE|3D-RWC-TVS with bowel preparation|"Rectal water contrast transvaginal ultrasonography is based on the distention of rectosigmoid with saline solution. Three-dimensional reconstructions convert standard 2D grayscale ultrasound acquisitions into a volumetric dataset.~Bowel preparation is based on a low-residue diet given in the two days before the examination and a rectal enema administered a few hours before the procedure."
224184389|NCT04406155|PROCEDURE|3D-RWC-TVS without bowel preparation|Rectal water contrast transvaginal ultrasonography is based on the distention of rectosigmoid with saline solution. Three-dimensional reconstructions convert standard 2D grayscale ultrasound acquisitions into a volumetric dataset.
224184390|NCT00787527|DRUG|Zolinza (vorinostat)|Up to two 100 mg capsules of Vorinostat (dosage will vary from 100 mg orally (PO) twice daily (BID), 300 mg PO every evening and 200 mg PO BID with the starting dose at 300 mg PO every evening for the phase I trial) are to be administered orally twice daily (once in the morning and once in the evening, or if in the daily dosing cohort once in the evening) in repeated 21-day cycles consisting of 10 days dosing starting on days 5 through 14 followed by a 7-day rest period, during which no vorinostat will be administered.
224184391|NCT00787527|DRUG|Cyclophosphamide|750 mg/m\^2 by vein over 1 hour on Day 1 of 21 day cycle
224184392|NCT00787527|DRUG|Doxorubicin|50 mg/m\^2 by vein over 15 minutes on Day 1 of 21 day cycle
224184393|NCT00787527|DRUG|Vincristine|1.4 mg/m\^2 by vein over 15 minutes on Day 1 of 21 day cycle
223492798|NCT07141264|DRUG|Adebrelimab combined with Etoposide Capsules|Each treatment cycle spans 3 weeks. Sequential medication administration begins on the first day of each cycle: Adebrelimab is administered at a dosage of 1200mg on day 1, every 3 weeks, while Etoposide Capsules is given orally at a dosage of 50mg or 25mg daily, every 3 weeks. Administration timing allows for a window of ±5 days. Subjects are required to undergo comprehensive assessments, including vital signs monitoring, anthropometric measurements, physical examinations, laboratory analyses, and performance status evaluations, to assess treatment tolerability for continuation.
223492799|NCT07142616|OTHER|03 - Summaries of and clinical notes from several providers|Access to all clinical notes across three providers: General practitioner, Social services and Specialist care, like in arm 02. In addition, access to information management features, such as summaries of patient's priorities, and clinical summaries of key health problems, including links to source documents.
223492800|NCT07142616|OTHER|01 - Clinical notes from one provider|Access to all clinical notes available to the provider in the patient's case. The provider is General practice in two patient cases, and hospital in one patient case.
223492801|NCT07142616|OTHER|02 - Access to notes from primary and secondary care|Access to all clinical notes across three providers: General practitioner, Social services and Specialist care.
223492802|NCT07141797|OTHER|Executive functions assessment|"Inhibition: Emotional (hot) and logical (cold) inhibition using Emotional and Classic Stroop tests. Participants identify the color of words or emotion in photos while inhibiting automatic responses. Inhibition scores are based on the difference in response times between congruent and interference conditions.~Working Memory: Participants recall a sequence of points on a grid, first in the original order, then in reverse. The working memory score is the difference between the two tasks.~Cognitive Flexibility: A task requiring alternation between identifying numbers as greater/less than 5 or even/odd based on color cues. Flexibility is scored by comparing response times for alternating and non-alternating tasks.~Visuospatial abilities are assessed with a global-local task. Raven's Progressive Matrices will assess general intelligence, and socio-economic data will be collected."
223492803|NCT07141979|DEVICE|Active tDCS|20 min, 2 milliampere (mA), Anodal tDCS in left DLPFC
223492804|NCT07141979|DEVICE|Sham tDCS|20 min, left DLPFC Sham tDCS
223492805|NCT07140978|DIETARY_SUPPLEMENT|Green Chef Meal Delivery Program|Participants will receive Green Chef meals for lunch and dinner, delivered weekly for 16 weeks. Meals include organic produce, responsibly sourced protein, and nutritionist-approved recipes. Participants will also receive guidelines for preparing healthy breakfasts and will use smart devices to record biomarker data.
224184394|NCT00787527|DRUG|Prednisone|100 mg tablets by mouth once a day on Days 1-5 of 21 day cycle
224184395|NCT03970330|DRUG|Naltrexone|4.5mg daily dose, taken orally
224184396|NCT03970330|DRUG|Norethindrone Acetate|5 - 15mg daily dose, taken orally
224184397|NCT03970330|DRUG|Placebo|daily placebo pill, taken orally
224184398|NCT05278663|DRUG|E6742|E6742 tablet.
224184399|NCT05278663|OTHER|Placebo|E6742-matching placebo tablet.
224184400|NCT01252992|GENETIC|Genetic analysis|"1. identification of candidates genes by a differential analysis of the whole transcriptome of the peripheral leucocytes of 20 PR+ patients and 20 RP- controls, at D0, D15, M2,;~2. Genetic association analysis: comparison of allelic distributions of SNPs (diallelic markers) within the candidate genes, between PR+ and PR- patients, in the whole cohort.~One supplementary ACD tube of 5 ml à D0, D15, M2, PR+, for RNA extraction."
224184401|NCT01252992|RADIATION|Body scan (CERVICO THORACO ABDOMINAL) + Cranian IRM|at day 0, Month 2, paradoxical reaction, end of treatment, read by an independent radiologist
224184402|NCT01252992|OTHER|Immunologic analysis|For patients included until 20 PR+ : blood puncture of 4 ACD tubes of 10 ml, 1 EDTA tube of 7,5 ml et 1 heparinate lithium tube of 7,5ml at D0, D15, M2, and M6 and at the time of an potential RP+
224184403|NCT01252992|OTHER|QuantiferonTB Gold test|at M0, M2, M6 and in case of PR+.
224184404|NCT04795752|DEVICE|TearCare System|TearCare procedures in this study will include an in-office eyelid debridement, 15 minute bilateral thermal session with the TearCare System, immediately followed by manual expression of the meibomian glands using the Clearance Assistant Plus device. Subjects randomized to TearCare will receive one in-office TearCare procedure within 7 days of the Baseline visit and at 5 Months. Beginning at 9 Months, subjects will receive an additional TearCare procedure when TBUT drops lower than Baseline or within 2 seconds of baseline AND/OR if OSDI worsens by at least 1 category.
224184405|NCT04795752|DRUG|Restasis|Restasis group will be required to self-administer 1 drop twice a day from baseline through the Month 6 visit. At Month 6, subjects will be crossed over to the TearCare group and will receive one (1) TearCare procedure.
224184406|NCT03723746|BIOLOGICAL|JNJ-67670187|Participants in Cohorts 1, 3 and 4 will receive Dose 1 and participants in Cohorts 2, 5, 6, 7, 8 and 9 will receive Dose 2.
224184407|NCT03723746|BIOLOGICAL|Placebo|Participants will receive matching placebo in all cohorts.
224184408|NCT03334682|DRUG|spironolactone|Dispensation of spironolactone at each visit according to the arm description described above.
224184409|NCT03334682|DRUG|Doxycycline|Dispensation of doxycycline then placebo, at each visit according to the arm description described above.
224184410|NCT03822390|DEVICE|CAD-CNN system|The CAD-CNN system will be trained in predicting the histology of diminutive polyps. Before training, the dataset will be split up into a training set and a test set. To ensure a completely independent test and training set there will be no overlap between patients (i.e. if polyps from a patient A is present in the training set it cannot be in the test set as well).
224184411|NCT04020042|OTHER|Ultrasound image guidance|Epidural landmarks will be determined with using ultrasound image
224184412|NCT04020042|OTHER|Landmark palpation|Epidural landmarks will be determined with palpation
223492806|NCT07141927|OTHER|Measurements|First, the demographic characteristics of all participants were recorded. For those who met the inclusion criteria, primary and secondary outcome measurements were performed by the same physical therapist in a single session
223492807|NCT07141017|OTHER|Initial standardized global review|"The intervention under study will be the initial standardized global review, which will be performed as soon as axial spondyloarthritis is diagnosed (less than 12 months from diagnosis is mandatory) and only at the baseline visit.~This review includes both the assessment of different domains of the disease, but also the education and information on such different domains of the disease and its management~The domains assessed during the intervention will be: diagnosis of spondyloarthritis, spondyloarthritis phenotype, disease activity, disease severity and function, treatment adherence and comorbidities.~At the end of the intervention, a detailed medical report on this initial standardized global review will be produced and sent to the patient, their rheumatologist, their general practitioner, and their dispensing pharmacist."
223492808|NCT07142187|OTHER|electro-thumbtack needle|The treatment acupoints include bilateral ovarian acupoints, Guan Yuan (CV4), bilateral Shen Shu (BL23), bilateral waist and eye acupoints (EX-B7), bilateral San Yin Jiao (SP6), and bilateral Zu San Li (ST36), totaling 11 acupoints. Among them, the bilateral ovarian acupoints and bilateral waist eye acupoints (EX-B7) were treated with electro-thumbtack needle. Other acupoints were treated with thumbtack needle.Choose a sparse and dense waveform, adjust the intensity to the maximum patient can tolerate, and stimulate for 30 minutes each time. After the stimulation is completed, remove the electrode patch and electroacupuncture device, and keep the electric needle at the acupoint for another 3 days.During the needle retention period, the electric needles at the bilateral ovarian acupoints and bilateral waist and eye acupoints were alternately stimulated once every other day using an electroacupuncture device for 30 minutes each time.
223492809|NCT07142187|OTHER|placebo electro-thumbtack needle|The control group selected acupoints that were the same as the treatment group. Bilateral ovarian acupoints and bilateral waist and eye acupoints are treated with placebo electro-thumbtack needle, while other acupoints are treated with placebo electro-thumbtack needle. The treatment methods for placebo electro-thumbtack needle and placebo thumbtack needle are the same as those for the treatment group.
223588555|NCT02383771|DRUG|Aspirin + Ticagrelor|(Aspirin 100mg daily + Ticagrelor 90mg Bid) x 7days
224184413|NCT03243201|DRUG|Colloidal silver nanoparticles|Contains 10ppm colloidal silver nanoparticles
224184414|NCT03243201|OTHER|Purified Water|Purified water will be given as placebo
224184415|NCT00656942|DEVICE|Quantitative Sensory Testing (QST)|QST consists of a series of heat and cold stimulation tests.
224184416|NCT01728675|OTHER|Exercise|Participants will perform two isokinetic eccentric exercise bouts
224184417|NCT01199952|BEHAVIORAL|Treatment group: receives counseling phone call intervention|Subjects in the treatment arm will receive a phone call from a health educator to assist with contraception, 3 to 4 weeks after enrollment.
224184418|NCT06221852|OTHER|Ketogenic diet|The ketogenic diet (KD) is a normo-caloric diet composed of high-fat, low carbohydrate, and adequate protein intake. The KD will consist of 3 meals a day plus snacks, targeting 75-80% fat, 13-18% protein, 7% carbohydrates.
224184419|NCT06221852|OTHER|Dietary Guidelines for Americans|Dietary Guidelines for Americans diet is a normo-caloric diet consisting of 3 meals a day plus snacks, emphasizing nutrient dense foods to meet food group needs (85% of calories), and limits foods and beverages higher in added sugars and saturated fat (15% of calories).
224184420|NCT03603626|DRUG|Pregabalin 150mg|Preemptive pregabalin 150 mg administered 1 hour before surgery
224184421|NCT03603626|DRUG|Placebo oral capsule|Placebo administered 1 hour before surgery
224184422|NCT01474993|DRUG|Sulforaphane-rich Broccoli Sprout Extract|"30 subjects will be randomly selected to receive sulforaphane-rich Broccoli Sprout Extract. The medication will be supplied and dispensed as No.1 size gelcaps (each gelcap containing \~ 250 mg sulforaphane rich Broccoli Sprout Extract, equivalent to \~ 50 µmol of sulforaphane). The dosage of sulforaphane will depend on subject's body weight:~1. Subjects with body weight less than 101 lbs will receive \~ 50 micromol sulforaphane per day (1 gelcap to be taken once a day)~2. Subjects with body weight 101 lbs to 199 lbs will receive \~ 100 micromol sulforaphane per day (2 gelcaps to be taken once a day)~3. Subjects with bidy weight \> 199 lbs will receive \~ 150 micromol sulforaphane per day (3 gelcaps to be taken once a day)"
223588556|NCT02383771|DRUG|Control|No Anti-platelet Therapy
224184423|NCT01474993|DRUG|Placebo|15 subjects will be randomly selected to receive inactive placebo (Gelcaps identical in appearance to that of active medication and containing microcrystalline cellulose)
224184424|NCT00760994|BEHAVIORAL|Experiential acceptance|The experiential acceptance coping condition will focus on changing one's relationship to one's internal events by learning to remain in contact with negative and positive thoughts and feelings and cravings as they are, without defense or judgment or attempting to cling to them (Eifert \& Forsyth, 2005; Hayes, Strosahl, \& Wilson, 1999; Kadden et al., 1992; Levitt, Brown, Orsillo, \& Barlow, 2004).
224184425|NCT00760994|BEHAVIORAL|Cognitive restructuring|The cognitive restructuring coping condition will focus on how to change the content and frequency of internal events by changing one's thinking patterns (Kadden et al., 1992).
223492810|NCT07140926|DEVICE|Recovery Connect|"Recovery Connect is a white-labeled version of the Recovery Path platform, rebranded to maintain partner organizations' brand identity while leveraging its established digital infrastructure. Recovery Path is a HIPAA-compliant remote patient monitoring system that supports a blended model of care for medication for opioid use disorder (MOUD), integrating in-person treatment with continuous digital engagement.~The app provides patients with daily check-ins, access to evidence-based resources and coping strategies, and secure messaging with their care teams. Clinicians receive real-time data on patient progress, risks, and setbacks. Between visits, clinicians can recommend tailored coping tools and psychoeducational content, reinforcing accountability and enhancing continuity of care.~RC is also integrated into the clinic's electronic medical record system to streamline workflows, reduce administrative burden, and improve documentation accuracy through auto-generated case notes."
223492811|NCT04527419|PROCEDURE|No mediastinal lymph node dissection|No mediastinal lymph node dissection will be performed.
223492812|NCT06943443|DEVICE|Miniscrew-Assisted Rapid Palatal Expansion (MARPE) Treatment|"Vitamin D Supplementation: Vitamin D plays a crucial role in calcium absorption, bone health, immune system function, and cellular growth. It is primarily obtained through sunlight exposure, certain foods, and supplements. In the context of your study, Vitamin D supplementation will be used to improve the Vitamin D levels in patients undergoing Miniscrew-Assisted Rapid Palatal Expansion (MARPE) treatment.~Key Points:~Purpose: To correct Vitamin D deficiency, which may affect bone metabolism and orthodontic treatment outcomes.~Administration: Vitamin D supplementation is typically provided in the form of oral tablets or soft gels, with a usual dosage of 800-2000 IU per day, depending on the individual's baseline levels.~Measurement: Vitamin D levels will be measured at the beginning and end of treatment using 25-hydroxyvitamin D (25(OH)D tests to assess the effectiveness of supplementation.~Effect on MARPE: Adequate Vitamin D levels may support better bone remodeling and healing, pote"
223492813|NCT06938685|OTHER|Standard of Care|Wound cleansing, Sharps debridement, Dressing for moisture balance, Offloading
223492814|NCT06938685|OTHER|NeoThelium FT|NeoThelium FT is a dehydrated wound covering derived from donated human placental tissue. NeoThelium FT is a dual-layer membrane with amnion and chorion combination layers.
223492815|NCT07141693|PROCEDURE|NIRS-guided management|NIRS-guided management where a predefined 6-step intervention protocol (volume optimization, vasoactive drugs, inotropes, heart rate management, transfusion, and FiO₂ increase)
223492816|NCT07141693|PROCEDURE|Standard anesthesia management|Standard anesthesia management
223492817|NCT07141316|DEVICE|Blood flow restriction combined with electrostimulation.|Participants will perform 30 minutes of blood flow restriction once a day during electrostimulation of the quadriceps of the operated limb.
223492818|NCT07141771|DRUG|Serplulimab|Serplulimab: 4.5mg/kg, ivgtt, 21 days/cycle
223492819|NCT07141771|DRUG|Fluzoparib|100mg BID oral
223492820|NCT07141771|DRUG|Topotecan/Irinotecan/Paclitaxel/Temozolomide|second-line chemotherapy options: Topotecan/Irinotecan/Paclitaxel/Temozolomide etc.
223492821|NCT07141771|DRUG|Etoposide/Carboplatin/Cisplatin|First-line chemotherapy: the original first-line chemotherapy regimen, recommended Etoposide 100mg / m2 d1-3, Carboplatin AUC = 5 d1 / Cisplatin 75mg / m2 d1 q21d
224184426|NCT00760994|OTHER|No-intervention control: Nutrition information|The no-intervention condition will be taught the plate method, a nutritional servings guideline, which will have no content related to AUD or PTSD, in order to control for time and contact with a research assistant.
223492822|NCT07141771|DRUG|Lurbinectedin|2.6mg/m2 (3 patients, if safe, in the 3.2mg / m2 dose group) or 3.2 mg / m2, ivgttd,21d / cycle .
224184427|NCT01265628|PROCEDURE|perimetry|automated static perimetry with adapted GATE strategy
224184428|NCT01853397|DEVICE|Liposonix System (Model 2)|
223492823|NCT07141771|DRUG|Temozolomide|150mg/m2, oral, on days 1-5,28d / cycle
223492824|NCT07142057|BIOLOGICAL|23-valent pneumococcal vaccine|Receive the 23-valent pneumococcal vaccine; Do not receive the 23-valent pneumococcal vaccine
223588557|NCT02383771|DRUG|Aspirin + Ticagrelor|Dual anti-platelet therapy (Aspirin 100mg daily + Ticagrelor 90mg Bid) after percutaneous coronary intervention (PCI)
223588558|NCT01601210|DRUG|Creatine monohydrate or placebo|Placebo, 2g, 4g, and 10g of creatine monohydrate
223588559|NCT00975663|DRUG|Tacrolimus and MMF|Tacrolimus: daily oral dose divided into 2 doses (morning and evening). MMF: daily dose divided into 2 doses at 12 hour intervals or 3 doses at 8 hour intervals.
224184429|NCT05785559|PROCEDURE|uterine biopsies|uterine biopsies performed on the areas of cesarean section scars
224184430|NCT03161015|DRUG|GBT440|Oral
224184431|NCT06186674|DIAGNOSTIC_TEST|sorensen test for back endurance|• Biering-Sorensen test will be utilized to gauge the trunk extensor muscles' isometric endurance. The patient will be lying on a treatment couch, prone. The top half of the body will be permitted to rest on a chair prior to the test starting. The patient will be told to elevate their upper trunks off of the chair at the start of the test. the examiner determined how long the individual could hold this position.
223588560|NCT00975663|DRUG|Tacrolimus and MMF|Tacrolimus: daily oral dose divided into 2 doses (morning and evening). MMF: daily dose divided into 2 doses at 12 hour intervals or 3 doses at 8 hour intervals.
223588561|NCT00772109|BIOLOGICAL|Influenza Virus Vaccine USP Trivalent Types A and B|0.1 mL, Intradermal
223588562|NCT00772109|BIOLOGICAL|Influenza Virus Vaccine USP Trivalent Types A and B|0.1 mL, Intradermal
224184432|NCT06186674|DIAGNOSTIC_TEST|6 minute walk test|"It gauges how far a person can go while walking for a total of six minutes on a level, hard surface. Cones will be used to mark turns at the start and end of the 30-meter border and every three meters throughout the corridor or walkway that was utilized for the test. The patient's objective is to cover the most distance in six minutes at a reasonable pace.~It gauges how far a person can go while walking for a total of six minutes on a level, hard surface. Cones will be used to mark turns at the start and end of the 30-meter border and every three meters throughout the corridor or walkway that was utilized for the test. The patient's objective is to cover the most distance in six minutes at a reasonable pace."
223588563|NCT00772109|BIOLOGICAL|Influenza Virus Vaccine USP Trivalent Types A and B|0.1 mL, Intradermal
223588564|NCT00772109|BIOLOGICAL|Influenza Virus Vaccine USP Trivalent Types A and B|0.5 mL, Intramuscular
224184433|NCT06186674|DIAGNOSTIC_TEST|c7-s1 SVA|Subjects will obtain standardized lateral views radiographs in a neutral standing position for the whole spine. The C7- S1 SVA will be measured as the distance from the plumb line dropped from the center of the C7 vertebral body to the most posterior edge of the upper sacral endplate surface.
224184434|NCT06337656|DEVICE|Galileo WBV|Side-Alternating Whole-Body Vibration Training
224184435|NCT02132312|DRUG|OMS302|
224184436|NCT02132312|DRUG|Phenylephrine HCl|
224184437|NCT04467138|DRUG|Omegaven|Pure fish oil emulsion (Omegaven®, Fresenius Kabi) was used as the additional product along with the standard lipid emulsion to reach a fish oil dose of approx. 0.5 g fish oil/kg/d.
224184438|NCT03166774|OTHER|Program of support of the sexual health|Patients included in the study have to answer to a questionnaire
224184439|NCT00486720|DRUG|vorinostat|vorinostat 400 mg by mouth (P.O.) capsules once daily (q.d.). Treatment in 21 day cycles for up to 8 cycles.
224184440|NCT00486720|DRUG|vorinostat|vorinostat 200 mg by mouth (P.O.) capsules three times daily (t.i.d.). Treatment in 21 day cycles for up to 8 cycles.
224184441|NCT02452892|DEVICE|LFMS|Low field magnetic stimulation (1 kilohertz oscillating magnetic field) will be administered using a portable tabletop device capable of generating time-varying electromagnetic fields of LFMS. For sham therapy, the device will be on; however, no magnetic field stimulation will be delivered.
224184442|NCT05794672|DRUG|Elarekibep|Subjects will receive single or multiple inhaled doses A, B or C, or single IV dose D of elarekibep.
223492825|NCT07141667|PROCEDURE|Erector spinae plane block with liposomal bupivacaine|In the anesthesia induction suite, the anesthesiologist administers an ultrasound-guided erector spinae plane (ESP) block under local anesthesia prior to the induction of general anesthesia. The procedure involves the sequential injection of 10 mL of normal saline, followed by the administration of 20 mL of 1.33% liposomal bupivacaine.
223492826|NCT07141667|PROCEDURE|Erector spinae plane block with bupivacaine HCL|In the anesthesia induction suite, the anesthesiologist administers an ultrasound-guided erector spinae plane (ESP) block under local anesthesia prior to the induction of general anesthesia. The procedure involves the sequential injection of 10 mL of normal saline, followed by the administration of 20 mL of 0.5% bupivacaine HCL.
223492827|NCT07141173|BEHAVIORAL|Individual lifestyle management|Manage the diet, exercise, weight and healthy lifestyle of pregnant women
224184443|NCT05794672|DRUG|Placebo|Subjects will receive single or multiple inhaled doses A, B or C.
224184444|NCT02117024|DRUG|Viagenpumatucel-L|Vaccine derived from irradiated human lung cancer cells genetically engineered to continually secrete gp96-Ig
224184445|NCT02117024|DRUG|Metronomic Cyclophosphamide|One 50mg tablet administered orally daily for 7 days on alternating weeks for a total of 6 weeks of therapy over 12 weeks
224184446|NCT02117024|DRUG|Physician's Choice Regimen (Vinorelbine, Erlotinib, Gemcitabine, Paclitaxel, Docetaxel, Pemetrexed)|"Physician will select one of the following to be given in nominal 21 day cycles with dose and route according to investigator's standard practice:~* Vinorelbine~* Erlotinib~* Gemcitabine~* Paclitaxel~* Docetaxel~* Pemetrexed"
224184447|NCT03138798|DEVICE|Laboraide TM dental support device|Patients will give consent in the first stage of labor. Subsequently a randomization will be performed using sealed envelopes opened at the time of pushing in the second stage of labor. Women assigned to Group A will received a sealed Laboraide TM package. Duration of the second stage and time spent pushing will be recorded. Obstetric management will not be altered by group assignment. Following delivery, patients assigned to Group A will complete a patient satisfaction survey.
224184448|NCT02813681|PROCEDURE|US-epidural SVD|participants who received US examination prior to epidural placement. The purpose of this group is to determine if US derived landmarks reduce pressure sensitivity.
224184449|NCT02813681|PROCEDURE|US sham- epidural SVD|participants who received US examination process but with the monitor turned off. The purpose of this group is to determine if the standard of care epidural placement technique will increase pressure sensitivity at the insertion site. The purpose of this group will also be to reduce the placebo effect from the US exam and to maintain blinding of the patient to their group status (US epidural or US sham epidural).
223492828|NCT07140965|PROCEDURE|Pegulicianine Fluorescence-Guided Surgery|Given by Surgery
223492829|NCT07140965|PROCEDURE|Digital Breast Tomosynthesis|Given by Procedure
223492830|NCT07140965|PROCEDURE|Breast Conserving Therapy|Given by Procedure
223588565|NCT01624090|DRUG|Mithramycin|30 mcg/kg intravenous (IV) over 6 hours once daily for 7 days, to be repeated every 21 days (one cycle) until disease progression or unacceptable toxicity
223588566|NCT04706000|GENETIC|Beclin 1 gene|The determination of Beclin 1, LC3-II and p62 genes, which are evaluated by immunohistochemistry, at the protein level will be done by ELISA method in MSKU Medical Faculty Medical Biology Laboratory.
223588567|NCT05727800|DRUG|VX-668|Suspension for oral administration.
223588568|NCT05727800|DRUG|Placebo|Suspension for oral administration.
223588569|NCT01893736|OTHER|In-hospital professional support|In-hospital professional lactation support will consist of two 30-minute one-to-one hands-on breastfeeding counseling sessions in first 24 hours post-partum and one further 30-minute one-to-one hands-on breastfeeding counseling session on the second day of post-partum hospitalization for a total of three 30-minute sessions. The one-to-one sessions will focus on: (1) education and advice on correct breastfeeding positions and techniques, (2) education and advice on milk supply and how to avoid common breastfeeding problems, and (3) hands-on instruction and assistance with proper breastfeeding positioning and technique, latching on and newborn attachment to the breast, and manual expression of breast milk.
223588570|NCT01893736|OTHER|Postpartum telephone follow-up support|Postpartum telephone follow-up support will consist of telephone support 72 hours after hospital discharge and weekly for the first 4 weeks, or until weaned. Earlier telephone contacts will focus more on breastfeeding topics. Information will be solicited from the participants about problems or difficulties they are experiencing. Supportive advice will be provided regarding management of breastfeeding problems, and support and encouragement for the continuation of breastfeeding. Later contacts will focus more on advice and encouragement on breastfeeding while resuming daily activities or returning to work, nursing in public places, and expressing and storing breast milk.
223588571|NCT00651365|DRUG|JNJ-38877605|
223588572|NCT03888209|DEVICE|tDCS|20 minutes of anodal tDCS (C3/FP2 or C4/FP1 depending on side of lesion) 2mA or sham
224184450|NCT02813681|PROCEDURE|Spontaneous vaginal delivery without an Epidural|Spontaneous vaginal delivery without an Epidural The purpose of the control group is to serve as a baseline (or a measure of normal). The control participant's measurement will be compared to those that did receive treatments (either epidural alone or ultrasound and epidural). This information will tell the investigator how many women have back pain after spontaneous vaginal delivery. Participant must meet the inclusion requirements and not meet any of the exclusion requirements
224184451|NCT03523390|DRUG|Avelumab 3 mg/kg Q2W|Participants received intravenous infusion of Avelumab over 1 hour duration at a dose of 3 milligrams per kilogram (mg/kg) once every 2 weeks (Q2W) until disease progression, significant clinical deterioration, unacceptable toxicity, or any criterion for withdrawal from the study or from Avelumab occurs.
224184452|NCT03523390|DRUG|Avelumab 10 mg/kg Q2W|Participants received intravenous infusion of Avelumab over 1 hour duration at a dose of 10 mg/kg Q2W until disease progression, significant clinical deterioration, unacceptable toxicity, or any criterion for withdrawal from the study or from Avelumab occurs.
224184453|NCT03523390|DRUG|Avelumab 20 mg/kg Q2W|Participants received intravenous infusion of Avelumab over 1 hour duration at a dose of 20 mg/kg Q2W until disease progression, significant clinical deterioration, unacceptable toxicity, or any criterion for withdrawal from the study or from Avelumab occurs.
224184454|NCT03523390|DRUG|Avelumab 10 mg/kg QW|Participants received intravenous infusion of Avelumab over 1 hour duration at a dose of 10 mg/kg every week (QW) for the first 12 weeks followed by once every 2 weeks, started at Week 13 until disease progression, significant clinical deterioration, unacceptable toxicity, or any criterion for withdrawal from the study or from Avelumab occurs.
224184455|NCT02384629|DEVICE|OCT-guided PCI with AXXESS stent|The AXXESS stent (Biosensors Europe SA, Morges, Switzerland) is a dedicated self-expanding bifurcation stent eluting the sirolimus analog Biolimus A9 emulsed in a biodegradable polymer. It has the advantage to preserve the ostium of both distal branches and allows additional stent implantation in the distal branches for complete lesion coverage, while reducing large stent overlap and eliminating deformation. Optical coherence tomography (OCT), has enabled the evaluation of strut coverage and arterial healing after DES implantation with a superior resolution and delineation over other imaging modalities. With using these superiorities of OCT, there have been many studies assessing the neointimal coverage following various types of DES implantation in various periods.
224184456|NCT02384629|DEVICE|OCT-guided PCI with conventional DES (Biomatrix flex stent)|BioMatrix Flex is abluminal biodegradable polymer DES. Its abluminal coating is absorbed after 6 to 9months and turns the DES into a BMS. It combines the proven safety of a DES with an abluminal biodegradable polymer, the prove efficacy of BA9 and an advanced stent design. Optical coherence tomography (OCT), has enabled the evaluation of strut coverage and arterial healing after DES implantation with a superior resolution and delineation over other imaging modalities. With using these superiorities of OCT, there have been many studies assessing the neointimal coverage following various types of DES implantation in various periods.
224184457|NCT02384629|DEVICE|Angio-guided PCI with AXXESS stent|The AXXESS stent (Biosensors Europe SA, Morges, Switzerland) is a dedicated self-expanding bifurcation stent eluting the sirolimus analog Biolimus A9 emulsed in a biodegradable polymer. It has the advantage to preserve the ostium of both distal branches and allows additional stent implantation in the distal branches for complete lesion coverage, while reducing large stent overlap and eliminating deformation. We use the conventional coronary angiography.
223492831|NCT07142460|BEHAVIORAL|Intervention|The students in the experimental group were shared the digital stories prepared for drug applications from the WhatsApp group and were asked to watch them for two weeks. Students were able to watch the stories on their mobile phones at the time and frequency they wanted. During 2 weeks, the researchers met with the students twice in the classroom environment and received feedback on the digital stories. Feedbacks about the real meaning of the stories and their contribution to education were obtained by using discussion and question-answer methods. Each student explained their opinions about the stories and had the opportunity to think deeply about them by receiving feedback from their classmates.
223492832|NCT03855800|DIAGNOSTIC_TEST|Blood, stool, pancreatic juice and cyst fluid collection|Blood and stool will be collected at baseline from all study participants. Those in the Immediate Surgery group may undergo endoscopic pancreatic juice collection before surgery, either at the time of a clinically indicated endoscopic ultrasound (EUS) exam or during an optional pre-operative research endoscopy. Pancreatic cyst fluid will also be obtained from all participants in the Immediate Surgery group, either at the time of surgery, or during a clinically indicated preoperative EUS FNA procedure, or both. Pancreatic juice and cyst fluid will be collected opportunistically from participants in the Clinical Follow-up group who undergo a clinically indicated EUS, EUS FNA, or endoscopy exam.
223588573|NCT00752726|DRUG|Orlistat|Weight loss treatment
223745613|NCT05129488|DEVICE|All participants received Biotrue ONEday lenses with and without an alternate packaging solution (EPG03)|Participants were given both Commercially available Biotrue ONEday lenses and Biotrue ONEday Contact Lenses with EPG03 Packaging Solution. Lens material is made from a hydrophilic copolymer of 2- hydroxyethyl methacrylate and N-vinylpyrrolidone and is 78% water by weight when immersed in saline solution.EPG03 Packaging Solution contains a phosphate buffered saline solution containing potassium chloride, poloxamine, poloxamer 181, glycerol (glycerin), erythritol, and polyquaternium-1.
223588574|NCT00752726|DRUG|Placebo|Inactive
223745614|NCT02670044|DRUG|Cobimetinib|Cobimetinib will be administered orally as per schedule in Arm description.
224184458|NCT02384629|DEVICE|Angio-guided PCI with PCI with conventional DES (Biomatrix flex stent)|BioMatrix Flex is abluminal biodegradable polymer DES. Its abluminal coating is absorbed after 6 to 9months and turns the DES into a BMS. It combines the proven safety of a DES with an abluminal biodegradable polymer, the prove efficacy of BA9 and an advanced stent design. We use the conventional coronary angiography.
224184459|NCT05047601|DRUG|PF-07321332|PF-07321332
224184460|NCT05047601|DRUG|Placebo for PF-07321332|Placebo
224184461|NCT05047601|DRUG|Placebo for Ritonavir|Placebo
224184462|NCT05047601|DRUG|Ritonavir|Ritonavir
224184463|NCT00208572|DRUG|Citalopram|
224184464|NCT06479577|OTHER|ultrasound|ultrasound 1 MHZ continuous for 20 minute with routine physical therapy 3 days /week 150 minutes/ week resistance training 5-10 exercises involving major muscles of leg and foot 3-4 sets per exercise and 10- 15 repetition per set
224184465|NCT06479577|OTHER|high intensity laser therapy|905 nm super pulsed laser 40 minute session 3 days /week 150 minutes/ week resistance training 5-10 exercises involving major muscles of leg and foot 3-4 sets per exercise and 10- 15 repetition per set
224184466|NCT01455064|DEVICE|FreeStyle Navigator II Continuous Glucose Monitoring System|This is not an interventional study. Subjects must maintain their own diabetes treatment regimen throughout the study duration
224184467|NCT03136809|DRUG|Cu(II)ATSM|copper-containing synthetic small molecule
224184468|NCT04241627|BEHAVIORAL|Cell Phone Support|Cell Phone Support includes short phone calls (\<5 minutes) made each weekday by a human AF to provide social support, medication reminders, problem-solving coaching, incentives for answering calls, and referrals to other services. Cell Phone Support calls focus on assisting AYAs in identifying and accessing resources and support from their natural environments, such as finding ways they can receive needed help from their families, peers, medical teams, and communities. Live Text Support will deliver the same intervention, by text message.
224184469|NCT05579938|DIETARY_SUPPLEMENT|Enzyme-containing lozenge|A lozenge containing 3 active enzymes
224184470|NCT05579938|DIETARY_SUPPLEMENT|Placebo lozenge|Identical placebo lozenge
224184471|NCT01619631|BEHAVIORAL|12-week Tai Chi intervention|Tai Chi classes will be conducted weekly for one hour each for 12 weeks. Classes will begin with warm-up exercises designed to loosen the body, increase awareness of alignment and structural integration, improve efficiency of breathing, incorporate mindfulness and imagery into movement.
224184472|NCT01619631|BEHAVIORAL|Education control group|The education control group will meet twice weekly for 12 weeks for one hour, and research staff will present didactic information modified from psychoeducation curriculums created by the Benson Henry Institute and a stress reduction study for depressed minority patients.
224184473|NCT05020470|DEVICE|Virtual Auricular Point Acupressure (APA)|Participants will learn how to self-administer APA by themselves.
223492833|NCT03855800|PROCEDURE|Pancreatic Surgery|Surgical resection of pancreatic cyst
223492834|NCT03855800|PROCEDURE|Endoscopy Exam|Clinically indicated endoscopic ultrasound
223492835|NCT07138781|DRUG|Ketamine|Patients will receive 29 ml bupivacaine 0.25% + 1 ml ketamine (50 mg).
223492836|NCT07138781|DRUG|29 ml bupivacaine 0.25% + 1 ml saline|Patients will receive 29 ml of bupivacaine 0.25% + 1 ml of saline.
223492837|NCT07142538|OTHER|exercises|Exercise training was provided to both groups.
223492838|NCT07141680|PROCEDURE|Replantation|Root canal treatment Tooth extraction and replacement Splinting
223492839|NCT07141680|PROCEDURE|Splint|Root canal treatment Splinting
223588575|NCT00042666|DRUG|LY317615|500 mg, oral, QD, up to six 28 day cycles
223588576|NCT00805064|DRUG|triamcinolone and bevacizumab|
224184474|NCT05020470|OTHER|In-Person Training|Participants will receive in-person training to self-administer APA.
224184475|NCT05020470|OTHER|Usual Care|Participants will continue to do whatever they are instructed by theirs physicians.
224184476|NCT04220294|PROCEDURE|Subcutaneous tissue closure|Subcutaneous tissue closure with 2-0 vicryl suture.
224184477|NCT00283062|DRUG|Docetaxel (TAXOTERE®) Chemotherapy|"75 mg/m\^2 docetaxel administered intravenously over 1 hour on Day 1 every three weeks (q3w) for 6 cycles. The first cycle was to be administered within 8 days after randomization.~Corticosteroid pre-medication was mandatory. The following schedule was recommended - 8 mg Dexamethasone orally for 6 doses given - the night before chemotherapy, the morning of chemotherapy, 1 hour before docetaxel infusion, the night of chemotherapy, the morning of the day after chemotherapy and the night of the day after chemotherapy."
223492840|NCT07141953|BEHAVIORAL|Yoga|Participants in the intervention group will take part in an 8-week yoga program designed for women who have entered surgical menopause after gynecological cancer surgery. The program will consist of two 60-minute sessions per week, one delivered online and one delivered face-to-face, conducted in small groups (5-6 participants) or individually, depending on participant availability. The sessions will include physical postures, breathing exercises, and relaxation/meditation techniques. The program will be delivered by a certified yoga instructor.
223492841|NCT07141615|COMBINATION_PRODUCT|Qingwei Huazhuo Decoction: Mulberry leaf powder, lotus leaf powder, malt powder, hawthorn powder, Poria cocos powder, gardenia powder, dried tangerine peel powder, licorice powder, momordica grosvenor|"On the basis of receiving dietary and exercise education, the pediatric patients were given the Qingwei Huazhuo Decoction orally.~Composition:Mulberry Leaf Powder, Lotus Leaf Powder, Germinated Barley Powder, Hawthorn Powder, Poria Mushroom Powder, Cape Jasmine Fruit Powder, Tangerine Peel Powder, Licorice Root Powder, Monk Fruit Powder.~Administration Method:Take one sachet each time, add 150ml of warm boiled water, stir well, and drink.~Treatment Course:The first-stage course lasts for 12 weeks.For participants in the experimental group who have completed the first 12-week stage, they may continue to take the Qingwei Huazhuo Decoction orally for another 12 weeks"
223588577|NCT03504748|DEVICE|deep rTMS|
224184478|NCT00283062|DRUG|Leuprolide acetate ( ELIGARD®) Hormonal Therapy|22.5 mg leuprolide acetate injection administered subcutaneously (SC) every 3 months for 18 months. The first injection was to be administered within 8 days after randomization.
223588578|NCT03504748|DEVICE|placebo deep rTMS|
223588579|NCT02189681|PROCEDURE|Conventional landmark guided midline spinal anaesthesia|Spinal anaesthesia was administered based on conventional landmark based midline approach.
223745615|NCT02670044|DRUG|Idasanutlin|Idasanutlin will be administered orally as per schedule in Arm description.
224184479|NCT00283062|DRUG|Docetaxel (TAXOTERE®) Chemotherapy|"75 mg/m\^2 docetaxel administered IV over 1 hour on Day 1 q3w for 6 cycles. The first cycle was to be administered within 30 days after progression was confirmed.~Corticosteroid pre-medication was mandatory. The following schedule was recommended - 8 mg Dexamethasone orally for 6 doses given - the night before chemotherapy, the morning of chemotherapy, 1 hour before docetaxel infusion, the night of chemotherapy, the morning of the day after chemotherapy and the night of the day after chemotherapy."
224184480|NCT00283062|DRUG|Leuprolide acetate ( ELIGARD®) Hormonal Therapy|22.5 mg leuprolide acetate injection administered subcutaneously (SC) every 3 months for 18 months. The first injection was to be administered within 30 days after progression is confirmed (on Day 1 of docetaxel administration).
224184481|NCT00283062|DRUG|Leuprolide acetate ( ELIGARD®) Hormonal Therapy|22.5 mg leuprolide acetate injection administered subcutaneously (SC) every 3 months for 18 months. The first injection was to be administered within 30 days after progression is confirmed.
224184482|NCT04174430|BIOLOGICAL|severe bronchiolitis|Prematurity (gestational age ≤36 weeks), Low birth weight, Age less than 12 weeks,Chronic pulmonary disease, particularly bronchopulmonary dysplasia (also known as chronic lung disease), Anatomic defects of the airways, Hemodynamically significant congenital heart disease, Immunodeficiency, Neurologic disease
224184483|NCT01234662|PROCEDURE|SPA|Spinal anesthesia and opioids
224184484|NCT01234662|PROCEDURE|CSE|CSE and epidural opioids
224184485|NCT01234662|PROCEDURE|CSEPCEA|CSE and continuous epidural patient controlled analgesia using an epidural catheter for 24 hrs
224184486|NCT00781027|PROCEDURE|Phacoemulsification|Comparison of longitudinal phacoemulsification and torsional phacoemulsification
224184487|NCT04084275|BEHAVIORAL|breastfeeding education|
224184488|NCT04084275|BEHAVIORAL|personal hygiene education|In this training, the puerpera was informed about personal hygiene to prevent infection.
224184489|NCT04084275|BEHAVIORAL|nutrition education|In this training, the amount of nutrients that breastfeeding women should take daily was explained.
224184490|NCT04084275|BEHAVIORAL|fatigue education|In this training, suggestions were made to prevent the negative effects of fatigue
224184491|NCT04084275|BEHAVIORAL|sleep education|In this training, suggestions were offered the puerperants for better sleep. Strategies to improve sleep quality were explained.
224184492|NCT04084275|BEHAVIORAL|pilates exercises education|In this study, pilates exercises exclusively for postpartum women were selected from two reference books, Fitness Professional's Handbook and Guide Women's and Fitness Health, which include 13 movements: Bridging, Hundred, Roll Up, One Leg Circle (both ways), Rocker with close legs,Single Straight Leg Stretch, Double Leg Stretch, Spine Stretch Forward, Single Leg Kick, Side Kick up and down, Side Kick circles, Rest position (stretch and relaxation) and Curling. The trainings were provided by the investigator during home visits to the puerpera in the intervention group and the pilates exercises by the investigator who was also a pilates trainer. An appropriate setting was prepared at the homes of puerpera so that they could do the pilates exercises easily.
224184493|NCT02138864|RADIATION|18F-FP-(+)-DTBZ|no available
224184494|NCT04718038|DRUG|Cetuximab combind mFOLFOX6/FOLFIRI|Cetuximab 500mg/m2 ivgtt 2h d1 ,q14d;mFOLFOX6: Oxaliplatin 85mg/m2 ivgtt 2h d1, 5-Fu 400mg/m2 iv d1,Lefucovorin 400mg/m2 ivgtt 2h d1, 5-Fu 2.4/m2 CIV 46h, q14d; FOLFIRI: CPT-11 180mg/m2 ivgtt 60-90mins d1, 5-Fu 400mg/m2 iv d1,Lefucovorin 400mg/m2 ivgtt 2h d1,5-Fu 2.4/m2 CIV 46-48h, q14d
224184495|NCT05584072|DIAGNOSTIC_TEST|Active pedal plantarflexion (APP) test|Active pedal plantarflexion (APP) test
224184496|NCT02471625|DEVICE|ClearView Scanning|
224184497|NCT03388450|DRUG|Omega 3|Enteral 1000 mg omega 3 fatty acid.
224184498|NCT03388450|DRUG|Placebo|Enteral nutrition without omega 3 fatty acid.
224184499|NCT01449604|RADIATION|stereotactic radiotherapy|Stereotactic radiotherapy, hypofraction using 18 Gray in 3 fractions
224184500|NCT01449604|RADIATION|stereotactic radiosurgery|Radio surgery 12 Gy
224184501|NCT04343937|PROCEDURE|retrolaminar block|local anesthetic injection on the between the lamina of the vertebra and the paraspinous muscle
223745616|NCT02670044|DRUG|Venetoclax|Venetoclax will be administered orally as per schedule in Arm description.
223745617|NCT01214707|OTHER|Exercise|Exercise during EMU stay
224184502|NCT00997906|DRUG|carboplatin,|Given IV
224184503|NCT00997906|DRUG|cisplatin|Given IV
224184504|NCT00997906|DRUG|gemcitabine hydrochloride|Given IV
224184505|NCT00997906|DRUG|paclitaxel|Given IV
223745618|NCT04782856|DRUG|Levothyroxine|levothyroxine sodium tablet for oral use
223745619|NCT04782856|DRUG|Liothyronine|Liothyronine sodium tablets for oral use treatment of hypothyroidism
223745620|NCT04782856|DRUG|Placebo|inert sugar tablets for oral use blinding for treatment of hypothyroidism
224184506|NCT00997906|RADIATION|intensity-modulated radiation therapy|Given once daily 5 days a week for 6½ weeks.
224184507|NCT00992485|DRUG|ADIPOPLUS|autologous adipose-derived stem cell
224184508|NCT00144456|DRUG|ED-71|0.75μg/day(p.o.)for 144 weeks
224184509|NCT00144456|DRUG|Alfacalcidol|1.0μg/day(p.o.)for 144 weeks
224184510|NCT00144456|DRUG|ED-71 placebo|0 μg/day(p.o.)for 144 weeks
224184511|NCT00144456|DRUG|Alfacalcidol placebo|0 μg/day(p.o.)for 144 weeks
224184512|NCT02909920|OTHER|Telerehabilitation|Initial Videoconference following telerehabilitation programs self-workout exercise with video support.
224184513|NCT02909920|OTHER|Traditional Physiotherapy|Traditional Physiotherapy receives assistance in a physiotherapy center with personalized therapy consisting of 1 to 1 with a physical therapist (Manual Therapy, home exercise programs and other physiotherapy techniques).
224184514|NCT04327115|PROCEDURE|"Control strategy"|"Patients included in the control group will received the usual cares of the unit during their stay : support in the gestures of daily life and walking according to their ability and at the discretion of the care teams."
224308438|NCT01404286|BEHAVIORAL|Physical exercise|After the adaptation sessions, volunteers underwent a session of resistance training at 60% of 1 RM organized as follows: 3 sets of 10 to 12 repetitions on each exercise machine with a 1 minute and 30 second interval between each set and an interval of 2 minutes between each exercise machine, giving a total duration of training between 50 and 60 minutes. The sequence of exercise machines used was alternated by body segment. The sessions were performed at the same time of day (morning) under controlled temperature conditions (24 ± 21C).
223492842|NCT07141615|BEHAVIORAL|diet and exercise education|"① Dietary Education With reference to the Balanced Diet Pagoda for School-Age Children Aged 6-10 Years in the Chinese Dietary Guidelines for School-Age Children (2022), the children were required to record their daily diet and complete a dietary diary.~② Exercise Education~Children were advised to accumulate at least 60 minutes of moderate-to-vigorous physical activity (MVPA) daily, mainly consisting of aerobic exercise. The specific requirements were as follows:~1.3-5 sessions of aerobic exercise per week; 2.2-3 sessions of resistance exercise per week; 3.Daily screen time limited to less than 2 hours. The parents were asked to record their children's daily completion of the above requirements."
224205754|NCT03916055|BEHAVIORAL|Exposure and response prevention (ERP)|"The intervention consists of 10 modules/chapters for children/adolescents, delivered over 10. Each of the 10 modules includes age-appropriate texts, animations and exercises. The intervention is primarily based on ERP techniques. During the treatment, participants are instructed to practice suppressing their tics, this is known as 'response prevention'. Then, with the help of their caregiver/parent, the participant is instructed to provoke premonitory urges (a sensation usually felt before a tic is expressed), while still suppressing tics, which is known as 'exposure'.~The parent is provided with her/his own separate login to the internet platform, which consists of 10 separate modules/chapters. The parent intervention consists mainly of information regarding parent coping strategies, social support and functional analysis relating to tics. Both the child/adolescent and the parent have individual access to the same therapist."
224308439|NCT04660240|DEVICE|Abluminus Sirolimus Eluting Stent System (ASES)|"The procedure will be conducted in accordance with the CE mark instructions for use for the ASES.~The need or not for postdilation in any segment of the stent will be at the discretion of the operator, seeking its adequate expansion and apposition. To consider PCI to be successful, residual stenosis must be less than or equal to 30% by angiography at the end of the procedure, including the absence of coronary dissection that compromises distal flow or a hemodynamically significant pressure gradient across the lesion."
223492843|NCT07141368|OTHER|Curcumin Dispersome formulation|75% BLG (600 mg (2 capsules of 300 mg each, containing 90 mg curcumin per capsule
223492844|NCT07141368|OTHER|Non-formulated Curcumin|dose: 90 mg, 1 capsule
223492845|NCT07141368|OTHER|Benchmark Formulation 1 - Turmipure Gold™|recommended daily dose: 300 mg, 1 capsule
223588580|NCT02189681|PROCEDURE|pre-procedure ultrasound guided L5S1 paramedian spinal|In group P, a portable ultrasound unit was used for initial pre-procedural marking. The L5 S1 interspinous space with best image of the anterior complex (ligamentum flavum dura complex- LFD) and posterior complex (posterior longitudinal ligament- PLL) was obtained. At this selected interspace, and with the probe positioned to obtain the clearest ultrasound image, a skin marker was used to mark the midpoint of the long border of the probe and the midpoints of the short borders of the probe . At the same horizontal level as the midpoint of the long border of the probe, the midpoint of the line drawn between the two short border midpoints of the probe was used as paramedian insertion point for the spinal needle.Spinal anaesthesia is then administered based on these landmarks.
223588581|NCT02189681|DEVICE|spinal anaesthesia|Spinal anaesthesia is administered with appropriate spinal needle
223588582|NCT04246957|BEHAVIORAL|general quality of life questionary|Every patient will have to fill out a general quality of life questionary : DLQI (Dermatology Life Quality Index)
223588583|NCT04246957|BEHAVIORAL|specific quality of life questionary|Every patient will have to fill out a specific quality of life questionary : Hair Specific Skindex 29.
223588584|NCT05658380|DRUG|atropine|patients will receive 0.01 mg/kg intravenous atropine in 5 ml normal saline 0.9 % before induction of spinal anaesthesia
223588585|NCT05658380|DRUG|Isotonic saline|patients will receive the same volume of isotonic saline 0.9% 5ml (control group) before induction of spinal anaesthesia
223588586|NCT04232215|DEVICE|HeraBEAT™|A wireless Smart Fetal Ultrasound Doppler measuring device designed to be self-administered by the expectant mother throughout the different stages of pregnancy
223588587|NCT04232215|DEVICE|Doppler fetal heart rate monitor|A hand-held ultrasound transducer that uses the Doppler Effect to provide an audible simulation of the heart beat and displays the number of beats per minute.
223588588|NCT03674879|OTHER|Text Message|Patient contact attempted with text message.
223588589|NCT02797496|OTHER|Asymmetric Motor Strengthening|"In the Asymmetric Motor Strengthening program, the principle is to concomitantly reinforce the body openers and stretch the body closers. One alternates two types of practice during a session. Active exercises consist of fatiguing series of rapid alternating movements against light weights working on movements of extension/abduction/external rotation/supination. Stretch postures consists of short 1-2 minutes bouts of flexor/internal rotator/adductor/pronator stretch. The duration of rehabilitation program is 8 weeks."
223588590|NCT02797496|OTHER|Conventional therapy|Conventional therapy will include general stretch, strengthening and balance exercises, respiratory exercises and relaxation methods.
223588591|NCT00435084|DRUG|APO866|
223588592|NCT03946085|DIETARY_SUPPLEMENT|Lumega-Z|A specially-formulated carotenoid supplement formula that utilizes a micronized, lipid-based liquid form of delivery.
223492846|NCT07141368|OTHER|Benchmark Formulation 2 - Qunol, Turmeric, Curcumin Complex, Extra Strength|recommended daily dose: 1000 mg, 2 capsules of 500 mg each
223492847|NCT07142434|DEVICE|neonatal Umbilical Catheter Pathway Simulator|evaluate the quality of simulator
223492848|NCT07142213|PROCEDURE|ALPPS|In recent years, Associating Liver Partition and Portal Vein Ligation for Staged Hepatectomy (ALPPS) provides new hope for the solution of large/unresectable hepatobiliary malignancies. This technique promotes the rapid proliferation and regeneration of the remaining liver by separating the liver and ligation of the portal vein, so that the patients whose original liver function is not enough to tolerate large-scale liver resection can complete liver regeneration in a short time, so as to perform secondary resection. Compared with traditional two-stage hepatectomy, ALPPS significantly speeds up the rate of liver regeneration, shortens the waiting time for a second surgery, and provides a safer radical treatment for tumors in high-risk patients.
223588593|NCT03946085|DIETARY_SUPPLEMENT|AREDS2|A commercially-available multivitamin soft gel formula.
223588594|NCT02454153|DEVICE|REMStar Positive Airway Pressure|Positive airway pressure therapy is the standard of care for managing obstructive sleep apnea
223588595|NCT02454153|BEHAVIORAL|LifeStyle Counseling|Lifestyle guidelines developed by the American Diabetes Association for weight loss will be provided to all subjects.
224184515|NCT04327115|PROCEDURE|"Intervention strategy"|"Patients included in the intervention group will received the usual cares of the unit during their stay : support in the gestures of daily life and walking according to their ability and at the discretion of the care teams.~They will also get a physical activity program realized with a nurse or a nursing assistant, twice a day (morning and evening) for 5 days. The intervention consists of physical support with mimed instructions, the nature of which depends on the falling risk of the participant :~* High falling risk : out of bed exercise (on a chair for at least 30 min)~* Mild falling risk : out of bed exercise + in front of chair (The participant stands standing in static equilibrium to a chair holding the back of it for 2 minutes, on both feet or one foot)~* Low falling risk : out of bed exercise + in front of chair + FTSS exercise (The participant performs a transfer activity of sitting to standing repeated 5 times, with physical assistance or not)"
223492849|NCT07141186|DRUG|QL1706 (bispecific antibody targeting PD-1 and CLTA-4)|Enrolled patients will receive intravenous infusion of QL1706 once every 3 weeks at a dose of 5.0 mg/kg until disease progression, death, intolerable treatment toxicity, or withdrawal from the clinical trial for any reason.
223492850|NCT07141524|OTHER|Physiology measurements|Measurement of lung perfusion (via EIT) and transpulmonary pressure (via esophageal manometry) during decremental PEEP trial
223492851|NCT07141290|DEVICE|Silent fish and bunny game|Participants play two levels of a computer game. In one level they need to squat at different levels to make a bunny jump and catch some carrots. In the other level they need to catch fiches by adjusting the extension of their leg.
223492852|NCT07141290|DEVICE|Sound supported fish and bunny game|In the auditory feedback group sound is used to transfer the Knowledge of Results. The sound is linked to the joint position.
223492853|NCT07142096|DIETARY_SUPPLEMENT|MitoQ (mitoquinol mesylate)|Dietary supplement course before surgery or chemo/radio-therapy
223492854|NCT07142226|GENETIC|Circulating Tumor DNA (ctDNA) Testing (ctDNA-based Next-Generation Sequencing (NGS))|Peripheral blood will be collected from patients with advanced biliary tract cancer for circulating tumor DNA (ctDNA) testing. Next-generation sequencing (NGS) will be performed to detect clinically relevant genomic alterations, including IDH1 mutations, FGFR2 fusions, ERBB2 amplifications, and MSI-H/dMMR. The ctDNA results will be compared with tissue-based genomic profiling to evaluate concordance and clinical utility.
223492855|NCT07142421|DRUG|Combination therapy (COMB)|Trifluridine/tipiracil combined with Anlotinib in treatment
223492856|NCT07142070|OTHER|Saliva, serum sampling|Saliva were collected to analyze the selected markers as unstimulated samples during the early hours of the day. The saliva was centrifuged and then transferred into Eppendorf tubes. Venous puncture was performed after saliva collection and 10 mL of blood samples were collected by qualified staff from each participant (Periopaper, Oraflow Inc., Plainview, NY, USA). Saliva, serum were then stored at -80 °C until analysis.
223588596|NCT05277428|DIETARY_SUPPLEMENT|GTB1|2 capsule/day
223588597|NCT05277428|DIETARY_SUPPLEMENT|Placebo|2 capsule/day
224184516|NCT02981238|DIETARY_SUPPLEMENT|Phytostandard® Eschscholtzia / Valerian|
224184517|NCT02331927|BIOLOGICAL|Aflibercept|"Early marker-driven switch of antiangiogenic treatment (bevacizumab to aflibercept) maintaining the chemotherapy backbone until definite radiological progression.~compared to a conventional treatment approach of changing chemotherapy and antiangiogenic agent at time of radiologic progression."
224184518|NCT05168189|DRUG|Ivabradine|follow up chronic coronary syndrome patients receiving Ivabradine for ( 6 months ) if the participants develop atrial fibrillation using 24 hours holter .
224308440|NCT04660240|DEVICE|Orsiro Sirolimus Eluting Coronary Stent System (OSES)|"The procedure will be conducted in accordance with the CE mark instructions for use for the OSES.~The need or not for postdilation in any segment of the stent will be at the discretion of the operator, seeking its adequate expansion and apposition. To consider PCI to be successful, residual stenosis must be less than or equal to 30% by angiography at the end of the procedure, including the absence of coronary dissection that compromises distal flow or a hemodynamically significant pressure gradient across the lesion."
224308441|NCT04545320|BEHAVIORAL|Usual care control group|Health education
224308442|NCT04545320|BEHAVIORAL|HIIT group|Once-a-week HIIT
223588598|NCT05161689|BEHAVIORAL|HUG-M+|A multicomponent, multi-level, community mobilization, combination intervention (HUG-M+) to address the entire HIV Continuum of Prevention and Care.
223588599|NCT00006455|DRUG|cyclophosphamide|
223588600|NCT00006455|DRUG|cytarabine|
223588601|NCT00006455|DRUG|dexamethasone|
223588602|NCT00006455|DRUG|doxorubicin hydrochloride|
223588603|NCT00006455|DRUG|etoposide|
223588604|NCT00006455|DRUG|ifosfamide|
223588605|NCT00006455|DRUG|leucovorin calcium|
223588606|NCT00006455|DRUG|methotrexate|
223588607|NCT00006455|DRUG|therapeutic hydrocortisone|
223588608|NCT00006455|DRUG|vinblastine sulfate|
223588609|NCT05124171|BIOLOGICAL|BNT162b2|"ARM 1 receiving Pfizer-BioNTech vaccine~* Group 1.A: 18-64 years old~* Group 1.B: 65 years and older"
223588610|NCT05124171|BIOLOGICAL|CoV2 preS dTM adjuvanted vaccine (D614), Sanofi/GSK|"ARM 2 receiving SP/GSK subunit D614 vaccine~* Group 2.A: 18-64 years old~* Group 2.B: 65 years and older"
223588611|NCT05124171|BIOLOGICAL|CoV2 preS dTM adjuvanted vaccine (B.1.351), Sanofi/GSK|"ARM 3 receiving SP/GSK subunit B.1.351 vaccine~* Group 3.A: 18-64 years old~* Group 3.B: 65 years and older"
223588612|NCT03514901|OTHER|Experimental combination beyond Focal Progression|"Vemurafenib is taken on a 28-day cycle. Each dose consists of four 240 mg (960 mg) tablets twice daily for 28 consecutive days. The first dose should be taken in the morning and the second dose in the evening approximately 12 hours later. Each dose can be taken with or without a meal. Vemurafenib tablets should be swallowed whole with a glass of water and should not be chewed or crushed.~Cobimetinib is taken on a 28-day cycle. Each dose consists of three 20 mg tablets (60 mg) and should be taken orally, once daily for 21 consecutive days, followed by a 7-day break. Each subsequent treatment cycle should start after the 7-day treatment break has elapsed. The dose should be taken in the morning.~Local treatment (i.e. surgery, radiotherapy)."
223588613|NCT03514901|DRUG|Pembrolizumab or Nivolumab|Pembrolizumab 2 mg/kg is administered as an intravenous infusion over 30 minutes every 3 weeks OR Nivolumab 3 mg/kg is administered intravenously over 60 minutes every 2 weeks.
223588614|NCT01555125|DRUG|secukinumab 150 mg|After the data base lock of week 52 data has been performed, subjects will receive secukinumab 150 mg treatment as open label for the remainder of the extension treatment period
224184519|NCT05168189|DIAGNOSTIC_TEST|transthoracic echo|performing baseline transthoracic echo for all patients to exclude any chamber dilatation
224184520|NCT05168189|DEVICE|24 hours holter|perform 24 hours Holter monitoring for all patients at the start of the study and follow up after 6 months
224184521|NCT03996525|DEVICE|Electrical Stimulation|"Two-Stage Facial Reanimation (Standard Practice) with electrical stimulation for one hour at 20Hz (Experimental Procedure).~1. Cross-Facial Nerve Graft (CFNG) immediately followed by electrical nerve stimulation proximal to the coaptation site on the donor facial nerve.~2. Nine-to-Twelve Months later, Free Muscle Transfer (FMT) followed by electrical nerve stimulation proximal to the coaptation site in the intraoral incision."
224184522|NCT03996525|DEVICE|Sham Treatment|"Two-Stage Facial Reanimation (Standard Practice) with sham electrical stimulation for one hour (Placebo).~1. Cross-Facial Nerve Graft (CFNG) followed by placement of unelectrified electrodes proximal to the coaptation site on the donor facial nerve.~2. Free Muscle Transfer (FMT) followed by placement of unelectrified electrodes proximal to the coaptation site in the intraoral incision."
224184523|NCT02827331|OTHER|Exposition to hypnotics or anxiolytics benzodiazepines|"Exposition to at least one drug belonging to the following classes during the last 12 months before index date :~* Benzodiazepine derivatives (N05BA)~* Benzodiazepine derivatives (N05CD)~* Benzodiazepine related drugs (N05CF)"
224184524|NCT02827331|OTHER|Exposition to non benzodiazepines antidepressants, hypnotics or anxiolytics|"Exposition to at least one drug belonging to the following classes during the last 12 months before index date :~* Antipsychotics (N05A)~* Antiepileptics with the exception of clonazepam (N03)~* Drugs used for alcohol dependance (N07BB)~* Drugs used for opioids dependance (N07BC)"
224184525|NCT02827331|OTHER|Medical consultation without prescription|Medical consultation without prescription of any drugs of interest
224184526|NCT02827331|OTHER|Administrative and medical data|"* Gender~* Birthdate~* Department of residence~* City of residence~* Vital status (month and date of death)~* Affiliation to Universal Health Coverage~* Number of chronic long-term illness, medical diagnostic or pathology (CIM 10 code), onset and end dates~* Drugs reimbursements (Date of care onset, drugs identification code, number of box delivered)~* Data collected from medicalisation program of information system and private and public home care structures~* Medical consultations, medical acts ( Common Classification of Medical Acts nomenclature)"
224184527|NCT03137173|DRUG|ceftobiprole medocaril|ceftobiprole 500 mg was to be administered every 8 hours as a 2-hour IV infusion (with dose adjustment for renal impairment). The treatment duration was for a minimum of 5 days and a maximum of 10 days. Treatment could be extended up to 14 days if in the investigator's opinion this was required, and the extension was approved by the sponsor's medical monitor.
224308443|NCT04545320|BEHAVIORAL|MICT group|Once-a-week MICT
224308444|NCT05659212|DRUG|Dexmedetomidine|Patients will receive IV dexmedetomidine 0.5 μg /kg diluted up to 10 ml with normal saline infused over 10 min before induction of anesthesia, and 10 ml of normal saline immediately before induction of anesthesia.
223492857|NCT07142070|DRUG|oral isotretinoin|oral isotretinoin
224308445|NCT05659212|DRUG|Magnesium sulphate|Patients will receive IV magnesium sulphate 50 mg/kg diluted up to 10 ml with normal saline infused slowly over 10 min before induction of anesthesia, and 10 ml of normal saline immediately before induction of anesthesia.
223492858|NCT07140887|OTHER|Bone Ring|"Patients in this group will be treated with the bone ring technique. An implant drill will be used next to prepare central osteotomies corresponding to the final implant diameter to be placed in the center of the disc converting it to a bone ring."
223492859|NCT07140887|OTHER|Split Bone block|Patients of this group will be treated with split bone block with simultaneous implant technique. The bone shell will be split into two bone shells each 1 \~ 2 mm in thickness using a disc.
223492860|NCT07142330|PROCEDURE|Atherectomy|Two different techniques : rotational atherectomy or thromboendarterectomy
223492861|NCT04903795|DRUG|hEGFRvIII-CD3 (BRiTE)|Bispecific T cell engager possessing one effector binding arm specific for the epsilon subunit of CD3 (a signaling molecule complex associated with the T cell receptor on T cells) while the opposing target-binding arm is directed against the hEGFRvIII epitope that is differentially expressed on the surface of tumor cells
223492862|NCT06299761|DRUG|BBI-825|Oral RNR inhibitor
223492863|NCT04523961|DRUG|2.5 g of lidocaine 23% / tetracaine 7% ointment without occlusion|Topical anesthetic used to numb the skin prior to laser procedures
223492864|NCT04523961|DRUG|7.5 g lidocaine 2.5%/ prilocaine 2.5% cream with occlusion|Topical anesthetic used to numb the skin prior to laser procedures
223492865|NCT06187077|BEHAVIORAL|DHA-Enhanced FAITH! App|This group of participants will follow an 11-week guided intervention with the FAITH! App. Weekly educational modules provide information on components of cardiovascular health (CVH). Participants are given a Fitbit to track physical activity, which will automatically synch to the app and will be asked to track their daily fruit and vegetable intake on the app. DHAs will promote CVH and digital health readiness as peer mentors by guiding participants through the educational modules and encouraging use of the additional interactive app features. During the guided intervention phase, they will facilitate weekly visits with participants in their church, which will follow the FAITH! App modules and integrate a digital health topic. Following the 11-week guided intervention, participants will have a 12-month maintenance phase with access to use the app as they wish.
223588615|NCT01555125|DRUG|secukinumab 300 mg|After the data base lock of week 52 data has been performed, subjects will receive secukinumab 300 mg treatment as open label for the remainder of the extension treatment period
223588616|NCT01555125|DRUG|placebo|Subjects who were on placebo at Week 52 cannot continue in the extension treatment period
224308446|NCT05659212|DRUG|Lidocaine|Patients will receive IV lidocaine 1.5 mg/ kg diluted up to 10 ml with normal saline immediately before induction of anesthesia and 10 ml of normal saline infused over 10 min before induction of anesthesia.
223588617|NCT02651220|DRUG|Epiduo® Forte Gel|Adapalene and Benzoyl Peroxide Gel, 0.3%/2.5% w/w
223588618|NCT02651220|DRUG|Adapalene and Benzoyl Peroxide Gel|Adapalene and Benzoyl Peroxide Gel, 0.3%/2.5% w/w
223588619|NCT02651220|DRUG|placebo gel|vehicle used as placebo
223588620|NCT06228859|PROCEDURE|overdentures with different attachments|different types of overdenture attachments in relation to retention, bite force, and periimplant tissue health.
223588621|NCT02795091|OTHER|manual cleaning|manual clean the rag and floor towel
223588622|NCT02795091|DEVICE|machine clean|machine clean the rag and floor towel
223588623|NCT03880344|DEVICE|Vibration Therapy|Vibration therapy as a pre-operative rehabilitation programme 3 times a week for 3 months + Normal Regular out-patient department physiotherapy
223588624|NCT03880344|COMBINATION_PRODUCT|Physiotherapy|Physiotherapy as post-operative rehabilitation programme for 6 months.
223588625|NCT01530607|DRUG|Standard cyclophosphamide|AC (3 mos/4 cycles), CAF (6 mos/cycles), TAC (6 mos/cycles), CEF (6 mos/cycles) AC followed by taxane (6 mos/8 cycles), CMF (6 mos)
224184528|NCT03137173|DRUG|vancomycin+aztreonam|"Vancomycin 1000 mg (or 15 mg/kg) was to be administered every 12 hours (with dose adjustment for renal impairment) as 2-hour IV infusion. Vancomycin dose adjustment for morbidly obese and hypermetabolic patients was to be done according to local standard of care. When locally available, vancomycin trough testing (VTT) might have been used by the unblinded pharmacist or delegate to adjust the vancomycin dose. The treatment duration was for a minimum of 5 days and a maximum of 10 days. Treatment could be extended up to 14 days if in the investigator's opinion this was required, and the extension was approved by the sponsor's medical monitor.~Aztreonam 1000 mg was to be administered as a 0.5-hour IV infusion every 12 hours. If CLCR was \< 30 mL/min (i.e., severe renal impairment), the aztreonam dosage regimen was to be adjusted. The requirement to continue aztreonam therapy beyond Day 3 was to be reassessed at the 72-hour study visit."
224184529|NCT02822274|DRUG|Coppertone (BAY987517)|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation: SR15-70\_R84-064)
224184530|NCT00001126|DRUG|Cidofovir|
224184531|NCT00395720|BIOLOGICAL|MVA85A (TB vaccine)|Intradermal vaccine
224308447|NCT00381914|DRUG|Vitamin D|400 IU vitamin D / day
224308448|NCT00381914|DRUG|Vitamin D|800 IU vitamin D / day
224308449|NCT00381914|DRUG|Vitamin D|1200 IU vitamin D / day
224308450|NCT03376061|DRUG|Tranexamic Acid|Tranexamic Acid is a medication used to treat or prevent excessive blood loss from major trauma, post partum, surgery, tooth removal, nose bleeds, and heavy menstruation.
224308451|NCT06123455|DIETARY_SUPPLEMENT|Taurine|Taurine supplementation in capsules of 1.0 gram of taurine powder. Dosage: 2.0 gram/day. Frequency: 2 time/day.
224308452|NCT06123455|BIOLOGICAL|Sintilimab|Sintilimab
223492866|NCT06187077|BEHAVIORAL|FAITH! App|This group of participants will follow an 11-week guided intervention with the FAITH! App. Each week, an educational module is completed in the app, which provides information on a component of cardiovascular health. Participants will be given a Fitbit to track their physical activity, which will automatically synch to the app, and will be asked to track their daily fruit and vegetable intake on the app as well. Following the 11-week guided intervention, participants will have a 12-month maintenance phase in which they will have access to use the app as they wish.
223492867|NCT02799524|OTHER|comparison of screening scales|Concordance degrees Assessment of each of 2 scales ( HADS and GDS ) from the DSM- V , for diagnostic confirmation of major depressive episodes in elderly patients with cancer or haematological malignancies
223492868|NCT04949451|DIETARY_SUPPLEMENT|Whey protein supplement|Participants consume whey protein at the beginning of the eating period.
223588626|NCT01530607|DRUG|Goserelin (Zoladex)|Chemotherapy in Arm 1 plus Goserelin given one week before first chemotherapy dose. Goserelin is given once every 4 weeks during chemo
223588627|NCT03755908|DEVICE|Forced oscillation technique (FOT)|FOT will be measured using the TremoFlo C-100 Airwave Oscillometry System (Thorasys , Montreal, Quebec, Canada). R5, R20, R5-20 (resistances in the reported frequency), X5 (reactance in 5hz) and Ax5 (reactance area in 5hz) will be reported.
223588628|NCT02420548|BEHAVIORAL|Parent Ed. and Youth Skills Coaching|The experimental intervention will have two components: (1) a caregiver parenting group, including all caregiver types (biological, foster, kinship), that meets weekly for 90-minutes for four months, focused on increasing parenting skills, and (2) a Life Coach component where trained and supported skills coaches meet individually with youth weekly for 60 minutes over the same four-month period to build the girls' social skills and peer/partner relationships skills.
223588629|NCT02420548|BEHAVIORAL|Services as Usual|Services as usual as provided by community service organizations from which the sample was drawn.
223588630|NCT02575703|DRUG|[¹⁴C]-LY3023414|LY3023414 in solution containing approximately 100 microCi \[¹⁴C\]-LY3023414
223492869|NCT04949451|DIETARY_SUPPLEMENT|Ketogenic aid|Participants consume ketogenic aid upon waking.
223492870|NCT04949451|OTHER|Control group - time restricted feeding only|Time restricted feeding.
223492871|NCT00001073|DRUG|Isotretinoin|
223588631|NCT01704703|DRUG|panitumumab|Panitumumab 6,0 mg/kg day 1 i.v. 60 min
223588632|NCT01704703|DRUG|FOLFIRI|Irinotecan 180 mg/m2 day 1 i.v. 30-90 min Folinic acid 400 mg/ m2 day 1 i.v. 120 min 5-FU 400 mg/ m2 day 1 Bolus 5-FU 2.400 mg/ m2 day 1 i.v. 46 hours
223588633|NCT00158951|DEVICE|CONTAK RENEWAL 2/4/4HE CRT-D|
223588634|NCT00158951|DEVICE|EASYTRAK 2 Lead|
223588635|NCT04374058|OTHER|less-frequency hemodialysis|Patients of treatment group would be evaluated quarterly
223745621|NCT02696642|DRUG|Anetumab ravtansine (BAY94-9343)|All subjects received anetumab ravtansine 6.5 mg/kg BW (body weight) once every three weeks
223745622|NCT03961607|PROCEDURE|Aminolevulinic acid photodynamic therapy|Aminolevulinic acid photodynamic therapy
223745623|NCT02469428|OTHER|Clean air|Each subject will be exposed to clean air for 2 hours. Subjects will exercise on a bike. Each exercise session will consist of a 15 minute exercise interval at a level of up to 20 L/min/m2 BSA followed by a 15 minute rest period, repeated 4 times.
224184532|NCT00395720|BIOLOGICAL|MVA 85A|Intradermal vaccine
224184533|NCT06125626|DIETARY_SUPPLEMENT|Probiotical|A daily sachet of Lacticaseibacillus rhamnosus LR04 + Streptococcus thermophilus FP4 + Bifidobacterium breve BR03 will be given to this group
224184534|NCT06125626|OTHER|Placebo|A daily sachet of placebo will be given to this groups
224184535|NCT01365468|DRUG|Everolimus (RAD001)|oral daily dosing of tablet starting with 2.5 mg
224184536|NCT03636009|OTHER|concurrent traction and neuromobilization technique|participant will be on a mechanical traction machine with an on:off cycle. During the on cycle, the primary researcher will be performing a neuromobilization technique on the symptomatic arm. Patients will also receive exercise and manual therapy
224308453|NCT06123455|DRUG|XELOX regimen|Oxaliplatin + capecitabine
224308454|NCT06123455|DRUG|SOX regimen|Oxaliplatin + S-1 (tegafur/gimeracil/oteracil potassium)
224308455|NCT06123455|DRUG|FOLFOX regimen|Oxaliplatin + leucovorin + fluorouracil
223492872|NCT03606824|DRUG|Pitavastatin and placebo|The initial dosage of pitavastatin is 2mg, and it will be regulated according to the level of LDL-C and the upper limit is 4mg.Since the investigators are blind to the arms,the fake regulation of placebo dosage will be same as the Pitavastatin and levothyroxine group.
223492873|NCT03606824|DRUG|Pitavastatin and levothyroxine|The initial dosage of pitavastatin is 2mg and the initial dosage of levothyroxine is 12.5ug. The dosage of levothyroxine will be regulated according to thyroid function test every 2-3 weeks. The regulation of pitavastatin dosage is same as the monotherapy group.
223492874|NCT06231121|DRUG|Faricimab|The Injections were performed according to local standard protocol, that included the use of 2-3 drops of topical tetracaine anesthesia, use of eye speculum, topical 5% povidone-iodine disinfection, a 30G-needle, injection site 3.5 mm posterior from the limbus marked by calipers in supertemporal or inferotemporal quadrants, a sterile cotton tip tamponade at the site of injection after removal of the needle, and no post-procedure antibiotics.
223492875|NCT00475046|BEHAVIORAL|Motivational Interviewing|
223492876|NCT05389696|DRUG|Single subcutaneous administration and Blood collection|Single subcutaneous administration and Blood collection
223492877|NCT05389696|DRUG|Single subcutaneous administration and then IV injection.|Single subcutaneous administration and then single intravenous administration after 2 weeks. In addition Blood collection is conducted as scheduled.
223492878|NCT05389696|DRUG|MIT-001 20mg and 40mg_Multiple administration|Multiple subcutaneous administration for 7 days and then blood collection
223492879|NCT03947034|DRUG|Drugs inducing hyperammonemia|Drugs susceptible to induce metabolic toxicities such as hyperammonemia
223492880|NCT06398288|OTHER|Dermal matrix (Oracell, LifeNet, USA)|Mechanical detoxification using curettes + NiTi brushes + EA (GalvoSurge) for 2 minutes + a mixture of anorganic bovine bone (Straumann Xenograft, Straumann) and cortical mineralized/demineralized allograft (Oragraft, Lifenet Health) + dermal matrix on the buccal aspect (Oracell, Lifenet Health)
223492881|NCT06398288|OTHER|No dermal matrix|Mechanical detoxification using curettes + NiTi brushes + EA (GalvoSurge) for 2 minutes + a mixture of anorganic bovine bone (Straumann Xenograft, Straumann) and cortical mineralized/demineralized allograft (Oragraft, Lifenet Health)
223492882|NCT00119704|DRUG|Botulinum toxin A injection or normal saline|
223492883|NCT00417222|DRUG|olmesartan medoxomil|5 to 40mg P.O. daily until the end of the study
223492884|NCT03260400|DEVICE|a bipolar percutaneous intramuscular electromyography electrode|The device, a bipolar percutaneous intramuscular electromyography electrode, is intended for use in upper-limb amputation patients who have received the regenerative peripheral nerve interface surgical procedure, in order to enable the use of advanced prosthetic arms and hands.
223745624|NCT02469428|OTHER|Ozone|Each subject will be exposed to 0.3 ppb ozone for 2 hours. Subjects will exercise on a bike. Each exercise session will consist of a 15 minute exercise interval at a level of up to 20 L/min/m2 BSA followed by a 15 minute rest period, repeated 4 times.
223745625|NCT02564614|DRUG|RO7070179|RO7070179 (13 mg/kg/week) will be administered as 2-hour IV infusion.
223745626|NCT06504199|DRUG|Obinutuzumab|No dose adjustment of Obinutuzumab is allowed.
223745627|NCT06504199|DRUG|Zanubrutinib|Zanubrutinib was allowed to be titrated to 80 mg bid or 80 mg qd
223745628|NCT06504199|DRUG|Lenalidomide|Lenalidomide was allowed to be titrated to 15 mg/day (induction phase) or 5 mg/day (maintenance phase).
224184537|NCT03636009|OTHER|sequential traction and neuromobilization technique|Participants will receive neuromobilzation techniques followed by supine cervical traction
223492885|NCT05690516|BEHAVIORAL|Wearing face masks|Participants are asked to wear face masks in public spaces.
223492886|NCT00620607|DRUG|huC242-DM4|dose of 126 mg/m2 or 168 mg/m2 given as IV once every 3 weeks
223492887|NCT01732783|OTHER|Panitumumab + Chemotherapy|Participants receiving panitumumab in combination with chemotherapy as prescribed by the treating physician prior to enrollment in this study and according to routine clinical practice for patients with wild-type RAS metastatic colorectal cancer.
223492888|NCT02333032|OTHER|Inclined treadmill training|
223745629|NCT06504199|DRUG|Cytarabine|The specific dose is determined by the investigator according to the actual situation of the patient.
224184538|NCT03636009|OTHER|active exercise program|Participants will have 4-5 exercises to perform at each session
224184539|NCT03636009|OTHER|manual therapy to cervical and thoracic spine|Lateral glides to cervical spine and thoracic manipulations
224184540|NCT04286737|OTHER|Therapeutic Touch|Therapeutic Touch will be applied to infants for 3 consecutive days, once a day, 10 minutes at any time during the day. There will be a four-day break. The Therapeutic Touch will be done a total of 6 times in 2 weeks.
224184541|NCT02557633|BIOLOGICAL|Grass MATA MPL 10200|
224184542|NCT02557633|BIOLOGICAL|Grass MATA MPL 18200|
224184543|NCT02557633|BIOLOGICAL|Placebo|
224308456|NCT02466841|PROCEDURE|Cubital tunnel release|Patients undergoing cubital tunnel release for ulnar nerve compression at elbow
223492889|NCT01540734|DRUG|Marketed paracetamol|Marketed formulation
223492890|NCT01540734|DRUG|Experimental paracetamol formulation|Experimental formulation
223492891|NCT06135259|DRUG|erythropoietin|erythropoietin solutions of 150, 300, and 500 IU/mL were mixed with trimethyl chitosan (M) solutions. glycerophosphate solution was then added to the mixture to obtain erythropoietin-loaded hydrogel comprising final concentrations of trimethyl chitosan(5%) and glycerophosphate (20%).
223492892|NCT06135259|DRUG|Triamcinolone acetonide|Each 0.1 mg triamcinolone acetonide in a dental paste containing gelatin, pectin, cream flavor, vanilla flavor and carboxymethylcellulose sodium in Plasticized Hydrocarbon Gel, a polyethylene and mineral oil gel base.
223745630|NCT06504199|BIOLOGICAL|CAR-T|zanubrutinib in combination with lenalidomide was allowed for maintenance treatment in high-risk patients for 1 year and zanubrutinib for 2 years after recovery of hemogram 2 months after CAR-T. High-risk Patients with any of the following conditions: Mantle cell lymphoma International Prognostic Index (MIPI-c) high-risk, blastic/pleomorphic type, TP53 mutation/deletion, CDKN2A deletion, MYC amplification/translocation, or incomplete response at induction stage; Non-high-risk group: no high-risk features.
224184544|NCT04815915|OTHER|Graston technique|Graston tool was used to treat patients 3 times in a week according protocol for 6 weeks' treatment plan with extensions bised exercises protocol following pattern of APTA.
224308457|NCT01386255|DRUG|Baclofen|The final baclofen dose will be 0.7 mg/kg (to a maximum of 40 mg/day) divided in three doses.
224308458|NCT01386255|DRUG|placebo|placebo. No other names
223492893|NCT04545177|DEVICE|NICO Myriad and Tissue Preservation System (TPS)|Tumor tissue will be obtained by the NICO Myriad and Tissue Preservation System (TPS) via an automated, standardized methodology
223492894|NCT04056026|BIOLOGICAL|Fecal Microbiota Transplant|Fecal material from a healthy family donor will be transplanted into the patient via colonoscopy
224184545|NCT02205177|DEVICE|Mayo Clinic Anxiety Coach|Mayo Clinic Anxiety Coach is a smartphone application based on cognitive-behavioral treatment for anxiety disorders (i.e., exposure-based therapy) that can be used as 1) a stand-alone treatment requiring minimal provider contact, and 2) an augmentation of face-to-face treatment that increases clinician fidelity and patient adherence to evidence-based treatment. The design of Anxiety Coach is based on evidence and theory suggesting that information and communication technologies (ICTs) are well-suited for encouraging behavior change through 1) scheduled reminders to engage in therapeutic exercises, 2) point of performance support, 3) individually tailored information, 4) real-time symptom assessment, and 5) readily accessible asynchronous communication.
224184546|NCT01380847|GENETIC|mRNAs encoding genes|investigate whether the levels of 21 mRNAs encoding genes involved in EMT/fibrogenesis and the alloimmune response are a sensitive and specific non-invasive diagnostic test for CAN in renal allografts
224184547|NCT04885205|BEHAVIORAL|cognitive behavioral therapy for insomnia (CBT-I)|The CBT-I program is a 6-week, 1x/week, one-on-one program. The delivery of CBT-I will be done remotely over a secure teleconference service (Zoom) or phone. Participants will maintain a sleep diary during the course of the program to aid in tailoring the intervention. Each session lasts about 45-60min:
224184548|NCT01545089|OTHER|Mattress protector for days 1 and 2|A mattress protector is placed in the bed for the first two days and then removed for days 3 and 4.
224184549|NCT01545089|OTHER|Mattress protector for days 3 and 4|A mattress protector is not placed in the bed for the first two days and then added to the bed for days 3 and 4.
224308459|NCT00438061|BEHAVIORAL|Weight loss by dietary restriction|
223492895|NCT02717611|DRUG|ACP-196 (acalabrutinib)|ACP-196 100 mg to be administered orally (PO) twice a day BID.
223492896|NCT06172907|BEHAVIORAL|Young Adults Coping with Cancer Together Intervention|This intervention is based on cognitive-behavioral therapy and couples' therapy. It aims to improve cancer and caregiving-related self-efficacy and coping, as well as promote relationship maintenance in context of cancer. The intervention will be delivered by a trained mental health practitioner and include didactics, experiential exercises, and home practice.
223492897|NCT06974058|DIETARY_SUPPLEMENT|Nasafytol® (Quercetin/Curcumin Supplement)|Participants in this group will receive Nasafytol®, a combined dietary supplement containing quercetin (65 mg) and curcumin (42 mg). Participants will take two capsules (single administration) twice a day for a duration of 8 weeks. The supplement is intended to alleviate mild to moderate symptoms of Long COVID-19, including but not limited to fatigue, cognitive function, generalized body pain, low mood, sleep disturbance, and overall quality of life.
223492898|NCT06097507|BEHAVIORAL|Educational intervention|The consented patients will be given an information packet containing an infographic about the climate impact of inhalers, a letter explaining the option of changing inhalers (which clearly outlines that the Bricanyl Turbuhaler will not cost them more money than the Ventolin) and a pre-filled prescription for Bricanyl Turbuhaler.
223745631|NCT05375552|DEVICE|Transcranial direct current stimulation|Participants will experience two repeated 20 minute sessions of tDCS (1.2 mA), with a 10-minute break.
224308460|NCT00792961|DEVICE|Endomicroscopy|Rigid drop-in endomicroscope imaging probe
223492899|NCT05960773|DRUG|Decitabine/cedazuridine|Decitabine/cedazuridine (INQOVI) oral tablet (35 mg decitabine and 100 mg cedazuridine) taken 3 consecutive days during the first week of every cycle (1 cycle=28-days) for 6 cycles (i.e., 1 course). Additional 6 cycles (i.e., Course 2) for subjects with stable disease or disease regression. Max (total) of 2 treatment courses.
223492900|NCT02364713|BIOLOGICAL|Bevacizumab|Given IV
223492901|NCT02364713|DRUG|Gemcitabine Hydrochloride|Given IV
223492902|NCT02364713|OTHER|Laboratory Biomarker Analysis|Correlative studies
223492903|NCT02364713|BIOLOGICAL|Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter|Given IP
223492904|NCT02364713|DRUG|Paclitaxel|Given IV
223492905|NCT02364713|DRUG|Pegylated Liposomal Doxorubicin Hydrochloride|Given IV
223492906|NCT02364713|OTHER|Quality-of-Life Assessment|Ancillary studies
223745632|NCT03503721|PROCEDURE|BipolEP|the prostate will be transurethrally enucleated using a bipolar current
224184550|NCT00423267|DRUG|Posaconazole|Posaconazole 400 mg orally (PO) (oral suspension 40 mg/mL) administered twice daily with meals or oral nutritional supplements for 12 months
223492907|NCT02364713|DRUG|Topotecan Hydrochloride|Given IV
223492908|NCT05438199|DEVICE|Toilet seat that measures waste output|Participants will use a toilet that includes a apparatus designed to measure waste output.
223492909|NCT06122077|DIAGNOSTIC_TEST|blood draw|Subjects who provide informed consent and meet the eligibility criteria will have 50 ml of blood collected and sent to Freenome or Freenome's designee for processing, testing, and storage, and will then complete a standard-of-care screening LDCT.
223745633|NCT03503721|PROCEDURE|bipolarTURP|the prostate will transurethrally resected using a bipolar current
223745634|NCT04139954|OTHER|There is no intervention in the study|There is no intervention in the study
224184551|NCT00423267|DRUG|Fluconazole|Fluconazole 400 mg PO (given as two 200-mg oral encapsulated tablets) administered once daily for 12 months
224308461|NCT01284361|DEVICE|30 cm Intermittent Catheter|Randomized cross-over
224308462|NCT01284361|DEVICE|40 cm Intermittent Catheter|randomized cross-over
224308463|NCT03636685|DRUG|Anlotinib combined with pemetrexed and carboplatin, phase I|"Non-squamous cell lung cancer, Anlotinib Plus PC~This study will include a sequential evaluation of 3 subjects per dose group. low-dose groups: Anlotinib 8mg per day plus pemetrexed and carboplatin. middle-dose groups: Anlotinib 10mg per day plus pemetrexed and carboplatin. high-dose groups: Anlotinib 12mg per day plus pemetrexed and carboplatin to determine the appropriate dose of anlotinib in combination with paclitaxel and carboplatin"
223745635|NCT00652236|OTHER|Physiotherapy|The two groups passed an in-patient rehabilitation and a physiotherapy: FCT function-centred vs. PCT pain-centred
223745636|NCT01465022|DRUG|Combined estrogen-progestin pill|1 mg norethindrone and .035 mg ethinyl estradiol orally for 21 days followed by 7 days of placebo
224184552|NCT03970967|DEVICE|Device: Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)|An intratumoral insertion of radioactive sources \[Ra-224 containing stainless-steel 316LVM tubes- (Alpha DaRT seeds)\]. The seeds release by recoil into the tumor short-lived alpha-emitting atoms.
224184553|NCT05542472|OTHER|Family Support Program Based on a Nurse-Led Case Management Model|A Family Support Program Based on the Nurse-Led Case Management Model create for the care givers in the intervention group. Case management is the process of planning an individual's care, coordinating it, managing it, implementing it and reviewing it. The aim in case management is to improve a person's quality of life by coordinating health care services and providing these services at a reasonable cost and in a productive way. The use of case management requires the cooperation of professionals from many different disciplines. Therefore, in areas where case management is applied, the case manager coordinates an individual's or patient's care by enabling this cooperation. In this way, in areas where health services are provided, the case manager may be a doctor, a nurse, a physiotherapist, a social services expert, or a speech therapist.
224184554|NCT00827112|DRUG|maraviroc|maraviroc (Selzentry, Celsentri) 150mg QD + atazanavir (Reyataz) /ritonavir (Norvir) (300/100mg) QD OR maraviroc (Selzentry, Celsentri) 150mg QD+ darunavir (Prezista)/ritonavir (Norvir) (800/100 mg) QD (if atazanavir (Reyataz) /ritonavir (Norvir) is replaced by darunavir (Prezista)/ritonavir (Norvir)) OR maraviroc (Selzentry, Celsentri) 150mg QD+ lopinavir/ritonavir (Kaletra, Aluvia) (400/100 mg) BID (if atazanavir (Reyataz) /ritonavir (Norvir) is replaced by lopinavir/ritonavir (Kaletra, Aluvia))
224184555|NCT00827112|DRUG|maraviroc|emtricitabine/tenofovir (Truvada) 200/300mg QD + atazanavir (Reyataz) /ritonavir (Norvir) 300/100 mg QD OR emtricitabine/tenofovir (Truvada) 200/300 mg QD + darunavir (Prezista)/ritonavir (Norvir) (800/100 mg) QD (if atazanavir (Reyataz) /ritonavir (Norvir) is replaced by darunavir (Prezista)/ritonavir (Norvir)) OR emtricitabine/tenofovir (Truvada) 200/300 mg QD + lopinavir/ritonavir(Kaletra, Aluvia) (400/100 mg) BID (if atazanavir (Reyataz) /ritonavir (Norvir) is replaced by lopinavir/ritonavir (Kaletra, Aluvia))
224184556|NCT00606710|DEVICE|Cognis 100-D, Teligen DR, VR 100 HE|ICD or CRT - Therapy
224184557|NCT03459976|DIAGNOSTIC_TEST|evaluate serum level HE4 in endometrial cancer|"1. HE4 in beignin endometrial diseases~2. HE4 in endometrial cancer"
224184558|NCT05273294|DEVICE|Portable color Doppler ultrasound system|In the ultrasound group, the catheter type was selected according to the results of ultrasonic measurement of transverse diameter of cricoid cartilage after induction of general anesthesia, and tracheal intubation was performed with ordinary laryngoscope after measurement
224184559|NCT01402622|DRUG|Propofol anesthesia|In the TIVA and TIVA-P group, propofol and remifentanil were used for induction and maintenance of anaesthesia. In the control group, propofol and remifentanil were used for induction and anaesthesia was maintained with desflurane and remifentanil. In the control and TIVA-P group, ramosetron 0.3mg was administered at the end of surgery. In all patients, postoperative pain was controlled with fentanyl-based intravenous patient-controlled analgesia. he depth of anaesthesia was monitored with a bispectral index score monitor and maintained at 40-60.
224184560|NCT02612558|DRUG|Fostamatinib 150 mg bid|Fostamatinib 150 mg bid. The dose of Fostamatinib may be reduced at any time to as low as 100 mg PO once daily (qd) if dose limiting adverse events are observed.
224184561|NCT02465541|PROCEDURE|Gentle yoga therapy|Mindfulness in Motion is a mindfulness based intervention that is an 8-10 week program for adults interested in learning a practical strategy for stress reduction, intended to be delivered on the worksite or home.
224184562|NCT02465541|OTHER|counseling intervention|Undergo dietary counseling that will include 10 (20-min) nutritional counseling sessions with a registered dietitian.
224184563|NCT02465541|OTHER|educational intervention|Undergo enhanced usual care
223492910|NCT05013138|BEHAVIORAL|Training for ACEs and study procedures|"The providers will lead a resilience-based conversation discussion regarding the impact of caregiver ACEs, after receiving training for ACEs and study procedures.~The first training component will provide an overview of ACEs using the ACE Interface Training. The second training component will address the implementation of the caregiver ACEs screening in the clinic."
224184564|NCT02465541|OTHER|quality-of-life assessment|Ancillary studies
224184565|NCT02465541|OTHER|questionnaire administration|Ancillary studies
224184566|NCT06374316|DEVICE|Ceiling-Mounted Air Purifiers|The devices will be turned on every working day except Tuesdays. Air purifiers will be set at levels perceived as acceptable by both teachers and students during operational hours.
224184567|NCT06374316|DEVICE|Portable Air Purifiers|The devices will be turned on every working day except Tuesdays. Air purifiers will be set at levels perceived as acceptable by both teachers and students during operational hours.
224184568|NCT06374316|DEVICE|Portable or Ceiling Mounted Air Purifiers|The Ceiling-Mounted and Portable devices will alternate weekly between being activated and deactivated in the three classrooms. Each classroom will also have three weeks with no purifier activated.This alternating pattern aims to assess the impact of the various air purifiers on air quality. Air purifiers will be set at levels perceived as acceptable by both teachers and students during operational hours.
224184569|NCT05840627|OTHER|Fruit juice|Daily consumption of 200 mL of fruit juice at lunch for 14 consecutive days, provided by the research team.
224184570|NCT01475214|DIETARY_SUPPLEMENT|potassium bicarbonate|potassium bicarbonate in dose of 1.0 mmol/kg per day, given in three even daily doses after meals with a full glass of water
224184571|NCT01475214|DIETARY_SUPPLEMENT|potassium bicarbonate|potassium bicarbonate in dose of 1.5 mmol/kg per day, given in three even daily doses after meals with a full glass of water
224184572|NCT01475214|OTHER|Inactive placebo capsule|microcrystalline cellulose
224184573|NCT03363126|PROCEDURE|Endonasal transsphenoidal pituitary tumor removal|Removal of pituitary tumor by transsphenoidal endonasal surgery
224184574|NCT05879848|OTHER|VR|virtual reality scenario synchronized with the uterine contractions
223745637|NCT01465022|DRUG|Progestin-only pill|.35 mg norethindrone once a day orally
223745638|NCT05366439|DRUG|AT-752|Parallel Assignment
223745639|NCT05366439|DRUG|Placebo Comparator|Parallel Assignment
224184575|NCT04152109|OTHER|Without laying on of hands subgroup|The patients will remain in bed supine with blindfolds. A volunteer will move close to the patient with hands behind and mentally repeat the alphabet or count during 5 minutes, around 8 weeks.
223492911|NCT05013138|BEHAVIORAL|Training on study procedures|Instead of ACEs training, standard of care providers will undergo training on study procedures including obtaining survey instruments from caregivers and proper storage of survey instruments. This training will stress the importance of not reviewing caregiver ACE scores and minimizing possible treatment contamination.
223492912|NCT05611970|DEVICE|Vaginal pessary|A reusable vaginal pessary for stress urinary incontinence
223492913|NCT06462976|OTHER|mechanical power calculation|Mechanical Power= 0.098×Minute ventilation× (peak pressure - 0.5 (plato pressure-PEEP)). These parameters are monitored on the monitor while the patient is mechanically ventilated and placed into the equation
223492914|NCT05185440|BEHAVIORAL|GIFTSS Training|training for college health center staff and clinicians on GIFTSS intervention (Giving Information for Trauma Support and Safety -- universal education and brief counseling to address sexual violence prevention and intervention)
223492915|NCT05185440|BEHAVIORAL|Learning Collaborative|learning collaborative (anticipated meeting monthly) with college health center staff and clinicians to address common barriers to implementation of GIFTSS intervention, reinforce GIFTSS training
223492916|NCT05185440|BEHAVIORAL|Provider Scripts|scripts and prompts for college health center staff and clinicians to encourage implementation of GIFTSS intervention
223492917|NCT05847790|DEVICE|Invu monitoring belt|INVU monitoring belt used for remote NSTs
223492918|NCT05847790|OTHER|Standard of care|In-clinic NSTs - standard of care
223492919|NCT00325416|DRUG|melphalan|(Days -4,-3,-2) 50 mg/m\^2/day IV over 30 minutes (total dose 150 mg/m\^2)
223492920|NCT00325416|DRUG|topotecan (TPT)|"Phase I Dose Escalation: Level 1 - 20 mg/m\^2; Level 2 - 30 mg/m\^2; Level 4 - 54 mg/m\^2; Level 5 - 72 mg/m\^2; Level 6 - 96 mg/m\^2; Level 7 - 127.8 mg/m\^2; Level 8 - 170.1 mg/m\^2~Phase II: Treatment at maximum tolerated dose (MTD)"
223492921|NCT00325416|PROCEDURE|Autologous Stem Cell Rescue|Day 0
223492922|NCT04608552|BEHAVIORAL|OMT Exercises|Oral and oropharyngeal exercises
223492923|NCT04608552|BEHAVIORAL|Nasal Breathing Exercises|Nasal breathing exercises each week
223492924|NCT04608552|OTHER|Use of Nasal Lavage|Use of nasal lavage with application of 10ml of saline in each nostril two times per day
223492925|NCT06429241|BIOLOGICAL|Mesenchymal Stem Cells (MSCs)|single dose injection (120 million cells)
223492926|NCT05368649|OTHER|Short-wave diathermy|The SWD will be applied using a CEC M-8 shortwave thermotherapy unit (CEC Electrónica S.R.L., Argentina) that emits RF at a frequency of 27.12 MHz. The device has two rectangular capacitive applicators (18 × 12 cm), which will be placed below and above the dominant shoulder. The coplanar application will be done using the continuous wave mode. The intensity of SWD will be gradually increased until the volunteer perceives a sensation of heat, and once familiar with this perception, the intensity will be increased until a sensation of constant but tolerable pain is evoked. This sensation will be maintained throughout the SWD application, and three repetitions will be performed. Healthy volunteers will be in a lateral supine position, and a cotton towel will be used to absorb perspiration and avoid unwanted heat effects.
223492927|NCT04589650|DRUG|Alpelisib|Adult participants (group 1) will receive 125 mg of alpelisib oral tablets once daily. Pediatric participants (Group 2: 6 to 17 years old) will receive 50 mg of alpelisib oral tablets once daily. Pediatric participants (Group 4: 2 to 5 years old) will receive 50 mg of alpelisib oral tablets once daily, Pediatric participants (Group 3: 0 to 5 years old) will receive alpelisib granules formulation with an age-dependent starting dose and maximum dose levels ranging from 20 mg every other day to 50 mg once daily. Pediatric participants (Group 5: 6 to 17 years old) will receive 125 mg of alpelisib oral tablets once daily.
223492928|NCT04589650|DRUG|Placebo|Participants will receive matching placebo once daily up to week 16.
223492929|NCT02404571|DRUG|GDP chemotherapy|gemcitabine (1000mg/m2 intravenously over 30 minutes on days 1 and 8), cisplatin (25mg/m2 intravenously over 60 minutes on days 1-3), and dexamethasone (20mg/d orally on days 1-4 and days 11-14), which was administered every 21 days.
223492930|NCT04993261|PROCEDURE|Dual-Energy Computed Tomography|Undergo dual energy CT scan
223492931|NCT04156698|DRUG|Docetaxel|Docetaxel is a chemotherapy drug.
224184576|NCT04152109|OTHER|Laying on of hands without Spiritual connection|Participants included in this subgroup will be exposed to the laying on of hands with healing intent by volunteers. The patients will be blindfold in the supine bed during 5 minutes, around 8 weeks.
224184577|NCT04152109|OTHER|"Laying on of hands by Spiritual Passe"|"The participants will be subjected application of the laying on of hands by the volunteer who will give the Spiritist passe. Patients remain in the supine bed blindfolded for 5 minutes, around 8 weeks."
223492932|NCT04156698|DRUG|Cisplatin|Cisplatin is a chemotherapy drug.
223492933|NCT04156698|DRUG|Capecitabine|Capecitabine is a chemotherapy drug.
223492934|NCT04156698|DRUG|Camrelizumab|Camrelizumab is a humanized anti-PD1 IgG4 monoclonal antibody.
223492935|NCT00639184|OTHER|Early intervention counseling|Bi-monthly home visits by counselor
223492936|NCT00639184|OTHER|Health education counseling|World Health Education health education counseling program at home visits,twice per month
223492937|NCT02324153|DRUG|Ramelteon|1 pre-operative and 2 nightly postoperative doses of Ramelteon/placebo will be administered
223492938|NCT02324153|DRUG|Microcrystalline Cellulose|Placebo Comparator
223492939|NCT02324153|DRUG|Riboflavin 100 mg|Riboflavin will be added to both placebo and active intervention capsules in order to track adherence to dose while taken as an outpatient (i.e. only the first preoperative dose)
223492940|NCT01267578|BIOLOGICAL|vaccination|Biological/Vaccine: URLC10, CDCA1, and KOC1 peptides
223512558|NCT05287685|BEHAVIORAL|Screen media adapted School Readiness Parenting Program|For the screen time adapted parenting intervention, screen time intervention components will be infused into the SRPP (described below) to address three primary areas shown in research to play an important role in healthy screen media use: (1) reducing and managing screen time use; (2) maximizing benefits of screen time content; and (3) promoting positive parent-child interactions during co-use of screen media. Psychoeducation and practice of these strategies will be incorporated into sessions of the SRPP in which relevant behavioral concepts are addressed.The screen time adapted parenting intervention will utilize the same format (large group, 8 weekly 1.5 hour sessions) as the SRPP.
224184578|NCT03021733|PROCEDURE|Operative management|Rotator cuff surgery
224184579|NCT03824756|OTHER|NGO supported GMP program|An International NGO has signed a contract with Government to support in implementing the growth Monitoring and Promotion (GMP) program. This program will be implemented at Community clinics. It will ensure the sustainability of community clinics in the selected areas through capacity building and follow up with community groups, community support groups, and Government Health and Family Planning service providers.
224184580|NCT03824756|OTHER|Non-supported GMP program|This is control arm of the study. In this arm, there will be Government's usual GMP program implemented at community clinics without any NGO support.
224184581|NCT05345431|DEVICE|endovascular denervation|Treating with EDN at the site of the iliac artery distal to the superficial femoral artery proximal before balloon dilation or stent implantation
224184582|NCT05345431|DEVICE|PTA|Treating with balloon dilation or stent implantation
224184583|NCT02992054|OTHER|stimulating activities|
224184584|NCT01834040|OTHER|Intralesional/ Intravenous of Autologous Stem cells.|Intralesional/ Intravenous of Autologous MNCs per dose
224184585|NCT02980211|DRUG|Alveolar Ridge Reconstruction|Reconstruction of dehiscence defects in extraction sockets with a minimally invasive technique using a particulate bone allograft and a non-absorbable dense polytetrafluoroethylene (dPTFE) membrane
224184586|NCT06360510|PROCEDURE|%5 dextrose injection|hydrodissection with %5 dextrose
224184587|NCT06360510|PROCEDURE|betamethasone injection|perineural betamethasone injection
224184588|NCT06413030|DIAGNOSTIC_TEST|10 Meter Walk Test|Gait Speed Test
223492941|NCT01814540|DIETARY_SUPPLEMENT|Bovine Milk Oligosaccharide|The BMO powder will be isolated from whey streams by Hilmar Ingredients (Hilmar, California 95324). Hilmar Ingredients employs the same membrane filtration, and centrifugation processes used to purify whey protein in their commercial practice to extract and purify BMO from whey permeate. Furthermore, the same sterilization processes used on the equipment to purify whey products will be used to purify BMO. This method uses a novel high-throughput food-grade isolation protocol that leads to purification of specific BMOs with bifidogenic activity as prebiotic oligosaccharides that mimic the activities observed for Human Milk Oligosaccharides (HMO). This strategy of developing methods for their large scale fractionation allows us to obtain a final product that mimics the naturally beneficial oligosaccharides present in human milk.
223492942|NCT01814540|DIETARY_SUPPLEMENT|Placebo Glucose Polymer|
223492943|NCT01563081|DRUG|Levocetirizine|Clear solution, 0.50 mg levocetirizine dihydrochloride contains in one milliliter of the solution. Levocetirizine oral solution are administered once daily at a dose of 2.5 mL (1.25 mg of levocetirizine) in the morning to infants aged between 6 months and 1 year old
223492944|NCT01563081|DRUG|Levocetirizine|Clear solution, 0.50 mg levocetirizine dihydrochloride contains in one milliliter of the solution. Levocetirizine oral solution are administered twice daily at a dose of 2.5 mL (1.25 mg of levocetirizine) in the morning and evening before sleep to infants aged between 1 year and 2 years old
224184589|NCT03732040|OTHER|miswak stick|miswak stick use as preventive hygiene measures
224184590|NCT03732040|OTHER|Miswak plus tooth brushing and tooth paste|use of miswak stick with tooth brushing and fluoride toothpaste for oral hygiene measures
224184591|NCT03732040|OTHER|Standard preventive measures (tooth brushing , interdental cleaning and mouth rinse use containing CHX and Fluoride)|use toothbrush with fluoride toothpaste and interdental cleaning by dental flossing and use mouth wash containing chlorohexadine
224184592|NCT00617994|DRUG|Ruxolitinib|Ruxolitinib 1.5% cream BID for 28 days
223492945|NCT03122106|BIOLOGICAL|Personalized neoantigen DNA vaccine|-Personalized polyepitope inserts integrating the prioritized neoantigens and mesothelin epitopes will be designed and then synthesized and cloned into the pING parent vector
224184593|NCT00638248|DRUG|Desmoteplase|Desmoteplase 90µg/kg BW i.v. bolus
224184594|NCT00638248|DRUG|Desmoteplase|Desmoteplase 125 µg/kg BW i.v. bolus
224184595|NCT00638248|DRUG|Placebo|Placebo i.v. bolus
223492946|NCT03122106|DEVICE|TDS-IM Electrode Array System|-Ichor Medical Systems
223492947|NCT03122106|PROCEDURE|Peripheral blood draws|-Enrollment, mid adjuvant chemotherapy, end of chemotherapy, week 1, week 5, week 9, week 13, week 17, week 21, week 25, and week 77
223492948|NCT06310863|DEVICE|LASBEAU Strong or Restylane Lyft injection as hyaluronic acid fillers|"Subjects will be randomized to receive LASBEAU Strong or Restylane Lyft injections into each of the nasolabial folds on both sides.~LASBEAU Strong or Restylane Lyft Injection Box"
223492949|NCT05237375|OTHER|The MIDWIZE model|"So-called MIDWIZE ambassadors are planned to be appointed to lead the clinical implementation of the quality improvement components.~Initial training workshops will be held with the ambassadors on practical aspects of the chosen components and how to explain their benefits to the units' staff. Training will also be provided on how to enhance interdisciplinary teamwork and coordinate quality improvements. The workshops will be held onsite at Naguru hospital and online via the project's MIDWIZE virtual platform. The ambassadors will themselves hold training workshops to support midwives and other healthcare providers at the clinics during the implementation of the quality improvements components. The virtual MIDWIZE platform will contain videos, posters, presentations, and other training material that the ambassadors can utilise to enhance the units' capacity and engage their colleagues."
223745640|NCT04009421|DIAGNOSTIC_TEST|Coronary artery plaque assessment by CT coronary angiography QAngio CT RE|Assessment of segmental plaque volume and composition
224184596|NCT01778673|PROCEDURE|Cast immobilization|
224184597|NCT01205464|DRUG|Doxycycline|Doxycycline, 100 mg, 2 capsules once daily, 24 hour time interval, 21 days.
224184598|NCT01205464|DRUG|Placebo|Placebo, 100 mg, 2 capsules once daily, 24 hour dosage interval, 21 days.
224184599|NCT04322552|DRUG|Apatinib Mesylate|Apatinib at a dosage of will be administered daily from on D5 through D16
224184600|NCT04322552|DRUG|Digoxin tablet|Digoxin at a dosage of 0.25mg will be administered at day 1 and day 12
224184601|NCT03898882|DRUG|oxytocin|PK measurements of oxytocin
224308464|NCT03636685|DRUG|Anlotinib combined with paclitaxel and carboplatin, phase I|"Squamous cell lung cancer, Anlotinib plus TC~This study will include a sequential evaluation of 3 subjects per dose group. low-dose groups: Anlotinib 8mg per day plus paclitaxel and carboplatin. middle-dose groups: Anlotinib 10mg per day plus paclitaxel and carboplatin. high-dose groups: Anlotinib 12mg per day plus paclitaxel and carboplatin to determine the appropriate dose of anlotinib in combination with paclitaxel and carboplatin"
224308465|NCT03636685|DRUG|Anlotinib combined with pemetrexed and carboplatin, phase II|Anlotinib: established dose QD PO d1-14, pemetrexed,carboplatin, 21 days per cycle after 4-6 cycles, Anlotinib p.o, qd and it should be continued until disease progress or toxicity cannot be tolerated or patients withdraw consent
224184602|NCT03898882|DEVICE|Shore durometer|The investigators will take serial readings from a digital durometer at the uterine fundus at 3, 6, 9 and 12 minutes following OXT administration to provide data that will inform an estimate of the timing of peak effect. Shore durometers measure the hardness of materials on a scale of 0-100 Shore Units (SU). Preliminary (unpublished) data provided a range of 10-56 SU after oxytocin administration at cesarean delivery. Durometer readings were also shown to correlate positively with the obstetrician's manual assessment of uterine contractility, which is traditionally used to determine the success or failure of uterotonic therapy.
224184603|NCT01080794|DEVICE|Repetitive transcranial magnetic stimulation (rTMS)|"DLPFC Active rTMS: Each treatment will consist of 2000 stimuli (50 X 4-second trains of 40 stimuli at 10 Hz, administered every 30 seconds for 25 minutes). Stimulus intensity for the first and second trains will be 80 and 90 percent of motor evoked potential (MEP), respectively. If no adverse effects are observed following each of the first two trains, then the subsequent trains will be given at MEP threshold.~M1 Active rTMS: Stimulation will be applied one side at a time, to the motor cortex site at 90 percent of each subject's motor threshold intensity, and at a frequency of 10 Hz with 1000 stimuli per side (25 X 8-second trains of 40 stimuli).~Sham rTMS: Patients from all four centers randomized to receive sham treatment will undergo the same procedures used in patients receiving active rTMS."
224184604|NCT01304576|BEHAVIORAL|Neuropsychological testing|Experimental test about orientation agnosia and standard neuropsychological tests.
224184605|NCT01304576|OTHER|MRI|Cerebral MRI
224184606|NCT00911508|DEVICE|Left atrial ablation|"St. Jude: Livewire TC™ , Therapy™ Dual / Thermocouple, Safire,Therapy Cool Path~Biosense Webster: NAVI-STAR, NAVI-STAR/NAVI-STAR DS, Celsius Braided/Long Tip, NAVI-STAR™ and Celsius™ ThermoCool, NAVI-STAR® RMT, Celsius® RMT, ThermoCool® SF~Medtronic CryoCath LP: Freezor®/Freezor MAX®, Artic Front®, Cardiac Ablation System~Bard: Stinger~Boston Scientific: Blazer II RF/XP, Blazer RPM, Chilli II Cooled, SteeroCath"
223492950|NCT01214278|DRUG|rTG|EPA+DHA as re-esterified triglycerides (rTGs) from fish-oil; uncoated capsules (4 per day); 2016 mg n3 fatty acids daily (1008 mg EPA and 672 mg DHA)
223492951|NCT01214278|DRUG|GArTG|EPA+DHA as rTGs from fish-oil in gastric acid resistant (coated) capsules (GArTG); 4 capsules per day; 2016 mg n-3 fatty acids (1008 mg EPA and 672 mg DHA)
223492952|NCT01214278|DRUG|EE|EPA+DHA as ethylesters (EE) from fish-oil uncoated capsules (4 per day); 2016 mg n-3 fatty acids (1008 mg EPA and 672 mg DHA)
223492953|NCT01214278|DRUG|KPL|DHA+EPA as phospholipids from krill-oil, uncoated capsules (KPL); 7 capsules per day; 2100 mg n-3 fatty acids (1050 mg EPA and 630 mg DHA)
223492954|NCT04961359|BIOLOGICAL|Recombinant new coronavirus vaccine (CHO cell) group|Intramuscular injection of deltoid muscle of upper armof 25μg/0.5ml/person doseRecombinant new coronavirus vaccine (CHO cells).
223492955|NCT04961359|BIOLOGICAL|Recombinant new coronavirus vaccine (CHO cells) placebo group|Intramuscular injection of deltoid muscle of upper armof 0.5ml/person doseRecombinant new coronavirus vaccine (CHO cells) placebo.
223492956|NCT05413421|DRUG|ORIC-944|Oral, once daily, continuous
223492957|NCT05413421|DRUG|Abiraterone acetate (Zytiga®) 250 mg or 500 mg tablets|Oral, 1000 mg once daily, continuous
223492958|NCT05413421|DRUG|Apalutamide (Erleada™) 60 mg or 240 mg tablets|Oral, 240 mg once daily, continuous
224308466|NCT03636685|DRUG|Anlotinib combined with paclitaxel and carboplatin, phase II|"Anlotinib :established dose QD PO d1-14, paclitaxel,carboplatin, 21 days per cycle~after 4-6 cycles, Anlotinib p.o, qd and it should be continued until disease progress or toxicity cannot be tolerated or patients withdraw consent"
223492959|NCT05413421|DRUG|Darolutamide (Nubeqa®) 300 mg tablets|Oral, 600 mg twice daily, continuous
223492960|NCT05413421|DRUG|Enzalutamide (Xtandi®) 40 mg capsules or 40 mg and 80 mg tablets|Oral, 160 mg once daily, continuous
223492961|NCT02352194|OTHER|Rehabilitation|Physiotherapy and physical activity
223492962|NCT06387017|DIAGNOSTIC_TEST|blood sampling|blood collection
223492963|NCT06387017|DIAGNOSTIC_TEST|stool collection|stool collection
223492964|NCT06387017|RADIATION|low dose CT scan|low dose CT scan evaluation
223492965|NCT02871102|PROCEDURE|Recruitment Maneuver with PEEP and Tidal Volume Optimization|A staircase recruitment maneuver will be performed on pressure control ventilation followed by a decremental PEEP trial. During the decremental PEEP trial inspiratory tidal volumes will be varied at each step between 3 ml/kg and 10 ml/kg predicted body weight while recording the continuous pressure and flow tracings from the mechanical ventilator. With each PEEP and tidal volume combination, end expiratory and end-inspiratory plateau pressure and stress index will be assessed. At the completion of the decremental PEEP trial, the patient will be returned to ARDSnet-recommended ventilator settings.
223492966|NCT03834090|DEVICE|rESWT|rESWT was administered once per week for 3 weeks using a ShockMaster 500 device with 1.8 bar pneumatic pressure, 10 Hz frequency, with 2000 pulses.
223492967|NCT03834090|OTHER|Supervised exercises|A program including post-isometric relaxation, and progressive resistance exercise (eccentric wrist extension) on the wrist extensors
223492968|NCT03167918|DRUG|Calcium Dobesilate|gave each patient 0.5 g bid，
223492969|NCT03167918|DRUG|Xuefuzhuyu Decoction|gave each patient100 ml bid，po
223492970|NCT03167918|DRUG|Xuefuzhuyu Decoction & Calcium dobesilate|gave each patient Calcium dobesilate 0.5 g bid，po and Xuefuzhuyu Decoction 100 ml bid，po
223492971|NCT03167918|DRUG|metformin|gave each patient 1000 mg, bid, PO
223492972|NCT03167918|DRUG|Mecobalamin Tablets|gave each patient 0.5 mg bid, PO
223492973|NCT04343144|DRUG|Nivolumab Injection|Treatment consists of an infusion of OPDIVO® 3mg/kg on day 1 (D1).
223745641|NCT00006240|BIOLOGICAL|sargramostim|
223745642|NCT00006240|DRUG|dexamethasone|
224184607|NCT00911508|DRUG|Rate or Rhythm Control Therapy|"Rate control: Metoprolol 50-100mg, Atenolol 50-100mg, Propranolol 40-80mg, Acebutolol 200-300mg, Carvedilol 6.25-25mg, Diltiazem 180-240mg, Verapamil 180-240mg, Digoxin 0.125-0.25mg~Rhythm control: Propafenone 450-625mg, Flecainide 200-300mg, Sotalol 240-320mg, Dofetilide 500-1000mcg, Amiodarone 200-400mg, Quinidine 600-900mg, Dronedarone 800mg"
224184608|NCT01409382|BEHAVIORAL|Daily brisk walking plus a carbohydrate-restricted diet|Daily brisk walking at moderate speed (4 km/h) for at least 40 minutes per day, 7 days a week. Patients will be recommended to avoid high-glycemic index meals (such as snacks, candies, fiber-free juices and sugar-sweetened beverages), and to eat at least two daily servings of meat, poultry, fish (e.g. 2 g/kg) or other protein-rich food, starting when they decided to get pregnant and continuing until delivery. Recommendations will be emphasised at every appointment. Antidepressants will not be discontinued in both groups, but patients on paroxetine and sertraline, will be switched to fluoxetine.
224184609|NCT04587362|DIAGNOSTIC_TEST|Musculoskeletal Ultrasound|High quality ultrasound scanners and high-resolution transducers, will be used to scan 16 joints sites for each subject. Ultrasound had excellent spatial resolution, making it an highly efficient, non-invasive tool for the assessment on enthesitis, which is an early feature of psoriatic arthritis. It is an affordable and accessible tool that is widely used in rheumatology practice.
224184610|NCT03301246|DEVICE|Artimes Pro Low Profile Dilatation Catheter|Pre-dilation catheter for the purpose of preparing the vessel to deliver the final therapy.
224184611|NCT01074320|OTHER|Other|Observational study
224184612|NCT04945291|BEHAVIORAL|New way of counting calories using the hands|The participants will learn how to estimate the portions and calories content of food using their hands as a measurement tool;
224184613|NCT04945291|BEHAVIORAL|Mobile applications|the participant will use a mobile application to log their calories
224184614|NCT05099744|BEHAVIORAL|Electrostimulation Therapy|During 20 minutes participants are connected to the handles and receive electrostimulation therapy.
224184615|NCT05099744|BEHAVIORAL|Relaxation|During 20 minutes participants receive a session of relaxation with guided imagination. These sessions will be implemented by a trained therapist who will follow a script. The relaxation sessions are based on Schultz's autogenic relaxation training, a relaxation technique based on autosuggestion.
224184616|NCT05099744|BEHAVIORAL|Placebo|During 20 minutes participants will be connected to the handles but will not receive any frequency.
223492974|NCT03290768|DEVICE|Continuous Glucose Monitor (CGM)|Subjects will use a CGM to develop an understanding of how their behaviors influence their glucose levels.
223492975|NCT03290768|DEVICE|Activity Tracker|Subjects will use the activity tracker, in combination with a continuous glucose monitor (CGM), to develop an understanding of how their activity levels affect their glucose levels.
223492976|NCT03290768|BEHAVIORAL|Coaching|Coaches will help subjects understand the readings from the CGMs and how they are affected by diet choices, use of diabetes medications, etc. Coaches and subjects will have weekly conversations about CGM data and behaviors that affect CGM readings. Coaching will occur via telephone, text messaging, and automated text messaging.
223492977|NCT00065871|BEHAVIORAL|Contraceptive Screening by Pharmacist|
223492978|NCT00065871|BEHAVIORAL|Contraceptive Prescribing by Pharmacist|
223492979|NCT03907345|BEHAVIORAL|Exposure|The exposure session comprises a hierarchy of 7 steps, reaching from (1) holding a glass with the spider 30cm in from the body / face, to (7) letting the spider walk on the arm. The exposure session has a duration of 120 minutes. Prior to the exposure, participants receive psychoeducation on anxiety and phobias. A house spider (Tegenaria domestica) is used for the exposure.
223492980|NCT01147458|DRUG|PF-04191834|100 mg tablets of PF-04191834 to provide a 600 mg BID dose administered for two weeks
223492981|NCT01147458|DRUG|PF-04191834 placebo|Matching PF-04191834 placebo tablets to be administered BID for two weeks
223492982|NCT01147458|DRUG|Naproxen placebo|Matching naproxen placebo tablets to be administered BID for 4 weeks
223492983|NCT01147458|DRUG|PF-04191834 placebo|Matching PF-04191834 placebo tablets to be administered BID for two weeks
223492984|NCT01147458|DRUG|PF-04191834|100 mg tablets of PF-04191834 to provide a 600 mg BID dose administered for two weeks
223492985|NCT01147458|DRUG|Naproxen placebo|Matching naproxen placebo tablets to be administered BID for 4 weeks
224184617|NCT00491595|DRUG|High Dose Soy isoflavones|
224184618|NCT04115202|PROCEDURE|lumbar arthrodesis|two approaches anterior versus posterior, optimally by leaving physicians free to use them as they do daily without modifying their procedures
224184619|NCT02833779|OTHER|Individual exercises|
223492986|NCT01147458|DRUG|PF-04191834|100 mg tablets of PF-04191834 to provide a 600 mg BID dose administered for two weeks
223492987|NCT01147458|DRUG|Naproxen|Naproxen 500 mg tablet administered BID for a total of four weeks
223492988|NCT01147458|DRUG|PF-04191834 placebo|Matching PF-04191834 placebo tablets to be administered BID for two weeks
223492989|NCT01147458|DRUG|Naproxen|Naproxen 500 mg tablet administered BID for a total of four weeks
224184620|NCT02833779|OTHER|Group exercises|
223492990|NCT01147458|DRUG|PF-04191834 placebo|Matching PF-04191834 placebo tablets to be administered BID for two weeks
223492991|NCT01147458|DRUG|PF-04191834|100 mg tablets of PF-04191834 to provide a 600 mg BID dose administered for two weeks
223492992|NCT04055870|PROCEDURE|EUS-guided liver biopsy at MDMC|Endoscopic ultrasound (EUS) guided liver biopsy sampling is emerging as an alternative to the aforementioned approaches that offers several advantages, including decreased sampling variability and procedure-related complications.
223492993|NCT02603900|DRUG|ropivacaine|15 ml 0.5% Ropivicaine for primary adductor canal block under ultrasound guidance and 0.2% Ropivicaine infusion 10 ml/hr.
224184621|NCT05126966|DRUG|Ranibizumab|Ranibizumab will be administered at a dose of 100 mg/mL delivered via the PDS.
223492994|NCT02603900|DRUG|bupivacaine|20 ml bupivacaine ( Marcaine 0.25% with epinephrine 1:200000, Hospira Inc. Lake Forest, IL) diluted with 40 ml of normal saline injected intraoperatively into the knee joint before closure.
223492995|NCT02603900|DEVICE|Sham Adductor Canal Catheter|Sham catheter placement via ultrasound-guided adductor canal block and 10ml/hr saline via OnQ Pump via continuous catheter in adductor canal.
223745643|NCT00006240|DRUG|oral sodium phenylbutyrate|
224184622|NCT05126966|DRUG|Aflibercept|Aflibercept will be administered at a dose of 2 mg in the study eye per treat-and-extend. The decision to extend, maintain, or reduce the interval until next treatment will be per investigator judgment
224184623|NCT05126966|DEVICE|Port Delivery System with ranibizumab (PDS)|PDS is an investigation intraocular drug delivery device designed to continuously deliver anti-VEGF therapy.
224184624|NCT06477731|BEHAVIORAL|total anesthetic consumption|total anesthetic consumption required to reach the optimal depth of anesthesia (BIS 50) depending on the anxiety of the waiting period in the preoperative waiting room and the degree of anxiety.
224184625|NCT01004822|DRUG|CVX-241|0.3 mg/kg infusions of CVX-241 on Days 1, 8, 15, and 22 of each 28 day cycle. Weekly infusions administered until progression or unacceptable toxicity develops.
224184626|NCT01004822|DRUG|CVX-241|1 mg/kg infusions of CVX-241 on Days 1, 8, 15, and 22 of each 28 day cycle. Weekly infusions administered until progression or unacceptable toxicity develops.
224184627|NCT01004822|DRUG|CVX-241|3 mg/kg infusions of CVX-241 on Days 1, 8, 15, and 22 of each 28 day cycle. Weekly infusions administered until progression or unacceptable toxicity develops.
224184628|NCT01004822|DRUG|CVX-241|6 mg/kg infusions of CVX-241 on Days 1, 8, 15, and 22 of each 28 day cycle. Weekly infusions administered until progression or unacceptable toxicity develops.
224308467|NCT06151769|OTHER|topical pomegranate seed oil|Intervention groups: In addition to the routine care of the patients, Pomegranate seed oil will be applied to the sacrum and heels twice a day between 09.00-21.00 without pressing. 1.5 cc will be applied to the back of the sacrum and 1 cc to each heel, using circular movements without pressure for approximately 5 seconds. It will be waited for 2-3 minutes for the body to absorb the oil, then it will be touched and removed with a napkin without any rubbing movements. The application will be applied for 6 days. The patient follow-up form will be completed by the researcher every day at 12:00 noon. Again, on the 6th day of the application, evaluation surveys with the Braden risk assessment scale will be conducted by the researcher.
224184629|NCT01004822|DRUG|CVX-241|12 mg/kg infusions of CVX-241 on Days 1, 8, 15, and 22 of each 28 day cycle. Weekly infusions administered until progression or unacceptable toxicity develops.
224184630|NCT01004822|DRUG|CVX-241|15 mg/kg infusions of CVX-241 on Days 1, 8, 15, and 22 of each 28 day cycle. Weekly infusions administered until progression or unacceptable toxicity develops.
224184631|NCT01004822|DRUG|CVX-241|18 mg/kg infusions of CVX-241 on Days 1, 8, 15, and 22 of each 28 day cycle. Weekly infusions administered until progression or unacceptable toxicity develops.
224184632|NCT01004822|DRUG|CVX-241|25 mg/kg infusions of CVX-241 on Days 1, 8, 15, and 22 of each 28 day cycle. Weekly infusions administered until progression or unacceptable toxicity develops.
223492996|NCT02603900|DEVICE|Adductor Canal Catheter|Catheter placed in adductor canal via ultrasound guidance and continuous infusion via OnQ pump.
223492997|NCT03829384|BIOLOGICAL|mRNA-1944|mRNA encoding Chikungunya antibody
223492998|NCT03829384|OTHER|Placebo|Saline
224184633|NCT03421873|OTHER|0h/1h hs-cTnT protocol|Implementation of a 0h/1h hs-cTnT protocol in routine care
224184634|NCT00003701|DRUG|carboplatin|
224184635|NCT00003701|DRUG|cisplatin|
224184636|NCT00003701|DRUG|doxorubicin hydrochloride|
224184637|NCT00003701|DRUG|methotrexate|
224184638|NCT00003701|DRUG|paclitaxel|
223492999|NCT03550209|DRUG|LCPUFA Oil Supplement|25 mg/kg, 50 mg/kg, or 75 mg/kg of GLA+EPA+DHA as Omega 3-6 oil to be administered twice per day by mouth for 90 days
223493000|NCT03550209|DIETARY_SUPPLEMENT|Canola Oil Placebo|Equal volume (25 mg/kg, 50 mg/kg, or 75 mg/kg) of placebo (canola) oil to be administered twice per day by mouth for 90 days
223493001|NCT00143572|DRUG|Magnesium Pidolate, Hydroxyurea|Intervention Description: Mg pidolate in combination with HU in patients with sickle cell disease who have been on a therapeutic dose (15-30 mg/kg/day) of HU for at least 6 months. Mg pidolate will be given at an initial dose of 0.6 mEq/kg/day divided into 2 daily doses for the first cohort of patients. This dose will be escalated for the subsequent patient cohorts as defined by a classic Phase I design (according to toxicity).
223493002|NCT06319118|DRUG|Placebo|placebo + usual care, placebo 5 mg daily; 2.5mg 2 times daily, after breakfast and dinner.
223493003|NCT06319118|DRUG|dihydroergotine mesylate sustained-release tablets|Dihydroergotine mesylate extended-release tablets + conventional treatment, dihydroergotine mesylate sustained-release tablets 5mg daily; 2.5mg 2 times daily, after breakfast and dinner.
223493004|NCT02555878|DRUG|Rivaroxaban|Rivaroxaban 10 milligram (mg) tablet will be administered orally once daily for 180 days.
223493005|NCT02555878|DRUG|Placebo|Placebo tablet will be administered orally once daily for 180 days.
224184639|NCT00003701|DRUG|vinblastine sulfate|
224184640|NCT01858701|DEVICE|Lotrafilcon B toric contact lens|Commercially available, silicone hydrogel contact lens for correction of astigmatism
224184641|NCT01858701|DEVICE|Comfilcon A toric contact lens|Commercially available, silicone hydrogel contact lens for correction of astigmatism
224184642|NCT00005068|DRUG|fluorouracil|
224308468|NCT06151769|OTHER|Sesame oil|Sesame oil
224184643|NCT00005068|DRUG|irinotecan hydrochloride|
224184644|NCT00005068|DRUG|leucovorin calcium|
224184645|NCT00005068|DRUG|oxaliplatin|
224184646|NCT05451758|OTHER|Mindfulness-based stress reduction (MBSR)|The participants were asked to attend a brief version of the MBSR programme lasting six weeks. The intervention was a structured 6-week programme with groups of between 6 and 10 participants. Each weekly session lasted one hour and included mindfulness meditation/exercises and group discussion led by a qualified mindfulness instructor.
224184647|NCT02295124|DRUG|Oxycodone|Patients will receive oxycodone 10mg (5mg if \> 65) every 2 hours based on an equianalgesic dose calculation. As per routine practice, the dose will be titrated according to the patient's pain at the discretion of the Acute Pain Service physician who will not be blinded to group allocation.
223493006|NCT04254757|PROCEDURE|Two different treatment|One group treated by percutaneous endoscopic surgery. The another group treated by open decompression and fusion surgery
223493007|NCT00765076|BIOLOGICAL|GSK Biologicals' influenza vaccine GSK2186877A|One intramuscular injection at Day 0
224184648|NCT02295124|DRUG|Hydromorphone|Patients will receive an initial dose of hydromorphone 2mg (1mg if \> 65) every 2 hours as needed based on an equianalgesic dose calculation. As per routine practice, the dose will be titrated according to the patient's pain at the discretion of the Acute Pain Service physician who will not be blinded to group allocation.
224184649|NCT05234281|OTHER|Interdisciplincary concentrated group rehabilitation|"All arms receive a concentrated interdisciplinary rehabilitation with similar focus and structure:~Three phases:~1. Pre-intervention preparation (1-2 months): mobilize the patients' resources for change~2. Concentrated group intervention (2-5 days): (further described below)~3. Post-intervention follow-up (1 year): digital follow-up~The core intervention is based on the concentrated rehabilitation format:~1. Initiate treatment when the patient is ready for change~2. Focus on the behavioral patterns which maintain the disorder, identify situations where they can break the patterns (micro-choices).~3. Assist the patient when breaking the patterns.~4. Use long sessions to ensure that they face a broad range of potential micro-choices~5. Work side-by side with others going through an analogous pattern of change~6. Prepare them for taking responsibility for integrating the change into every-day living"
223493008|NCT00765076|BIOLOGICAL|GSK Biologicals' Fluarix|One intramuscular injection at Day 0
224184650|NCT05587621|DRUG|statins, ezetimibe, bempedoic acid, evolocumab, alirocumab, inclisiran|dietary advice for low cholesterol food
224184651|NCT02654184|PROCEDURE|supine position|Anesthesia induction with sevoflurane for the patient while he is in supine position.
224184652|NCT02654184|PROCEDURE|Right lateral position|Anesthesia induction with sevoflurane for the patient while he is in right lateral position.
224184653|NCT06469333|BEHAVIORAL|Eye movements (EM)|The participant focuses on the intrusive thought and visually follows the horizontal movement of a white dot (Ø 1 cm) on the black computer screen 8 times for 24 seconds.
224184654|NCT06469333|BEHAVIORAL|Auditory stimulations|"The participant focuses on the intrusive thoughts and hears the auditory beeps through the headphones provided 8 times for 24 seconds."
224184655|NCT06469333|BEHAVIORAL|Tactile stimulations|The participant focuses on the intrusive thought and applies tactile self-stimulation 8 times for 24 seconds.
224184656|NCT00977600|DRUG|HPN-100|HPN-100 is a triglyceride that has a similar mechanism of action as Buphenyl. It is a liquid with minimal taste and odor. HPN-100 is broken down to phenylbutyric acid (PBA). PBA is converted to phenyl acetic acid (PAA) that is the active metabolite. Three teaspoons of HPN-100 (\~17.4mL) delivers equivalent amount of PBA that 40 tablets of NaPBA do.
224184657|NCT00977600|DRUG|Ammonul|
224184658|NCT00977600|DRUG|Buphenyl|
224184659|NCT03730259|OTHER|Web-based Tailored Intervention Preparation for Surgery|A Tailored Internet-based Preparation Program for Perioperative Anxiety and Pain (WebTIPS) is developed using the conceptual framework of the Triple Aim that evaluates the intervention within the context of clinical efficacy, improved child and parent experience, and reduced resource utilization during the surgical episode. WebTIPS aims at reducing perioperative anxiety and pain in children via an internet-based platform with short message service (SMS) two-way communication between a healthcare provider and patient.
224184660|NCT05128552|DEVICE|Lung volume recruitment technique|A self inflating Ambu bag with one way valve , augmentation volume of air within 3 to 4 successive breaths and holding few seconds then coughing
224184661|NCT05128552|OTHER|Traditional chest physiotherapy|Positioning of the patient according the drainage position for each lobe of each lung and applying airway hygiene techniques such as percussion and vibration
224184662|NCT03540628|DIETARY_SUPPLEMENT|Thiamine and Vitamin C|Supplementary vitamins for the patient in septic shock
224184663|NCT04271111|BEHAVIORAL|Online Treatment for Interpersonal Stress|Intervention designed to build social support and reduce loneliness by giving participants skills to strengthen their relationships
224184664|NCT04271111|BEHAVIORAL|Physical Health Education Tool|Intervention designed to improve physical health through exercise, eating habits, and sleep
223493009|NCT05234671|OTHER|Exercise programme|12-week exercise programme. The estimated session's duration of 55 minutes. For the prescription of high intensity interval training (HIIT) and the collection of individualised peak power output (PPO) a baseline peak oxygen uptake on an arm crank ergometer will be performed. Each session will consist of 5 minutes warm up performing light to moderate intensity arm cranking (55-65% PPO), 30-minutes' high intensity interval training (HIIT; 30s 100% PPO/ 30s passive recovery) on an arm crank ergometer. The HIIT protocol will be combined with resistance training (RT) lasting for a total of 15 min.The intensity will be at 75-80% of one repetition maximum. Following each exercise session, patients will undertake a 5 min cool-down period.
223493010|NCT05948488|OTHER|Questionnaires|The questionnaires focus on anxiety, fear and quality of life.
223493011|NCT00632294|PROCEDURE|Tissue Sample|A leftover sample of the removed allograft bone will be collected.
223493012|NCT00594139|BIOLOGICAL|Autologous neobladder construct|provision of an autologous neo-bladder construct
223493013|NCT06251947|DRUG|Efbemalenograstim Alfa|Efbemalenograstim Alfa is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in adult patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.
223493014|NCT02701491|DIETARY_SUPPLEMENT|Ginger|ginger
224184665|NCT05999227|DRUG|68Ga-FAPI-04|A fibroblast activation protein (FAP) -targeted PET imaging agent
224184666|NCT05999227|DRUG|18F-FDG|A general glucose metabolism imaging agent
224184667|NCT04098991|DRUG|Levothyroxine|All participants will be treated for their hypothyroidism according to the standard of care as reflected in recent guidelines from the American Thyroid Association.
224184668|NCT03072576|DEVICE|Xpert MTB/RIF Ultra|Next generation Xpert MTB/RIF assay, this cartridge is intended for the detection of M. tuberculosis in sputum as well as the detection of M. tuberculosis mutations associated with resistance to rifampin
224184669|NCT04519827|OTHER|New Rice-based hydrolysate|A rice-based hydrolysed infant formula with new ingredient
224184670|NCT04519827|OTHER|Amino Acid-based infant formula|An amino acid-based infant formula
223588636|NCT00896441|DRUG|Citalopram|"Refer to Detailed Description Section for full description of intervention. Week 1 (baseline): Subject will complete several tests to assess the subject's memory and concentration. Following visit, they will begin treatment with the antidepressant citalopram.~Week 1 MRI: Subject will have their first MRI. Week 2 visit: Physician will meet with they to assess the subject's overall condition.~Week 2 MRI: Subject will have the subject's second MRI. Week 4 visit: The study physician will meet with the subject to assess their overall condition.~Week 6 (Telephone check-in): The study physician will check in with the subject by telephone to assess the subject's overall condition.~Week 8: (End-of-study visit) Subject will take repeated tests of memory and concentration. The study physician will also discuss recommendations for further treatment of the subject's depression.~Week 8 MRI: Around the time of the subject's week 8 visit they will have the subject's third and final MRI."
223588637|NCT04806360|PROCEDURE|ACRF surgery|A new surgical procedure that previously proposed by our team.
223493015|NCT02701491|OTHER|Placebo|Placebo
223493016|NCT02875080|DRUG|OPC-34712|
223493017|NCT06439680|OTHER|"HASCV-R Health Programme"|"HASCV-R program Healthy nutrition, Active life, Ways to cope with Stress, Cancer and cancer screening, Vaccination - Reproductive health Training programme"
223493018|NCT06069089|RADIATION|Dexa scan|No intervention
223493019|NCT05042297|PROCEDURE|Combined posterior and anterior ring fixation: Active comparator. Isolated posterior ring fixation: Experimental intervention|Reduction of the posterior ring was either closed reduction in SI joint dislocations \& fracture-dislocations and sacral fractures or open reduction in iliac wing fractures through the lateral window of the ilioinguinal approach. Anterior pelvic ring reduction and fixation in the combined APR fixation group was done via the classic Pfannenstiel approach or extension more lateral \& completing the anterior intrapelvic approach. Fixation was via pubic rami plating.
223493020|NCT01812915|DEVICE|Cylindrical-shape cuff ETT (Group C)|Randomized allocation of the endotracheal cuffs for general anesthesia, mechanical ventilation will be maintained with Mallinckrodt Hi-Lo(TM) endotracheal tube.
223493021|NCT01812915|DEVICE|Tapered-shape cuff ETT (Group T)|Randomized allocation of the endotracheal cuffs for general anesthesia, mechanical ventilation will be maintained with Mallinckrodt TaperGuard(TM) endotracheal tube.
223493022|NCT02066116|PROCEDURE|Kinect-based rehabilitation plus occupational therapy|The developed kinect-based rehabilitation system will be used for 30min/session. Conventional 30min occupational therapy also will be applied for the patient enrolled.
224184671|NCT02652676|PROCEDURE|Reversible Pulmonary Artery Banding|A sternotomy incision is used for application of the rPAB. Tightening is under echocardiographic control until the inter-ventricular septum becomes a midline structure. Myocardial function is augmented with inotropic and vasodilator agents that are weaned after 2-4 weeks. The infant is separated from mechanical ventilation within the first week, and enteric feeding is resumed. The infant is discharged on oral medications, with follow-ups. Band enlargement is in stages as a balloon catheter-based procedure if a finding of increasing right ventricular dilation, onset or worsening tricuspid valve regurgitation, or a gradual late increase in plasma B-type natriuretic peptide (BNP) levels, opting for a mild residual right ventricle-main pulmonary artery pressure gradient of 15-30 mmHg.
224184672|NCT02652676|PROCEDURE|GORE-TEX DualMesh EMERGE PLUS Biomaterial|The study is being conducted to evaluate the procedure, not the materials being used. The study uses the patch as materials to create the band around the pulmonary artery which is currently done routinely off label. The patch is approved as a cardiovascular patch. FDA 501(k) K032168.
224184673|NCT02022566|BEHAVIORAL|A supported self management of osteoarthritis program|Three theoretical sessions, each of about 90 minutes, held as group sessions with about 10 participants in each group. After the intervention patients are offered an individual exercise program, and the opportunity to practice this program together with others under supervision of a physical therapist for 6 weeks.
223493023|NCT02066116|OTHER|sham virtual rehabilitation education plus occupational therapy|For the sham virtual rehabilitation, computer-based cognitive rehabilitation program will be used. Patients will be encouraged to use their affected arm to push the button but the motion will be minimal and not related to the concept of upper extremity rehabilitation.
223493024|NCT02756897|DRUG|Ibrutinib|Given PO
223493025|NCT02756897|OTHER|Laboratory Biomarker Analysis|Correlative studies
223493026|NCT02756897|DRUG|Venetoclax|Given PO
223493027|NCT00768053|DRUG|Etanercept|Etanercept 50 mg once a week
223493028|NCT00304577|PROCEDURE|Bilateral recession|
223493029|NCT00304577|PROCEDURE|Unilateral recession and resection|
223493030|NCT01164475|DRUG|Granulocyte-colony stimulating factor (G-CSF)|
223493031|NCT01164475|DRUG|Fixed Dose Plerixafor|
223493032|NCT01164475|DRUG|Weight-Based Plerixafor|
223493033|NCT05991817|PROCEDURE|Surgery/general anesthesia|Adult patients between the ages of 30 and 50 who are to undergo elective surgery under general anesthesia will have their spatial memory tested and interleukin 1beta and alpha tumor necrosis measured before and after surgery.
223493034|NCT02349880|BEHAVIORAL|shared decision making training|
223588638|NCT04806360|PROCEDURE|conventional anterior surgery|Anterior cervical discectomy and fusion surgery or anterior cervical corpectomy and fusion surgery.
223588639|NCT04806360|PROCEDURE|conventional posterior surgery|Laminectomy and fusion surgery or laminoplasty surgery.
223588640|NCT01304589|DRUG|Milnacipran|6-week titration period starting at 12.5mg daily and moving up to 200mg daily (or maximum tolerated dose) for 12 weeks - total treatment period is 18 weeks
223588641|NCT01633177|DIETARY_SUPPLEMENT|Vitamin D3|Vitamin D3 (cholecalciferol), 2000 IU per day.
223493035|NCT02959268|DEVICE|Al-Sense|Liner for diagnosis of amniotic fluid leakage verified by standard clinical diagnostic tests
223493036|NCT05267457|OTHER|Plasma vanadium concentration|Plasma vanadium concentrations were measured using inductively coupled plasma mass spectrometry (ICP-MS) (Agilent 7700 Series, United States)
223493037|NCT01634594|DRUG|Group R|
223493038|NCT01634594|DRUG|Group N|
223493039|NCT01634594|DRUG|Group D|
223493040|NCT02574091|DRUG|1% icotinib hydrochloride cream|Topical administration for twice daily
223493041|NCT02574091|DRUG|2% icotinib hydrochloride cream|Topical administration for twice daily.
223493042|NCT02574091|DRUG|Placebo|Topical administration for twice daily.
223493043|NCT00437762|DRUG|Botulinum Toxin A Injection|Botulinum Toxin A Injection
223493044|NCT00437762|DRUG|Placebo injection|Placebo Injection
223493045|NCT04733885|DEVICE|Experimental|Current application will be made in the frequency range of 20-50 Hz. The Chattanooga (Intelect Neo) device with interfering current will be used for treatment, vacuum electrodes will be made in the form of 4 pole application. Two electrodes to the outside of the inguinal ligament, the other two electrodes will be placed on the upper inner part of the thigh.ES applications will be performed in the supine position with head and knee pillow supported.
223493046|NCT04733885|DEVICE|Control|The Chattanooga (Intelect Neo) device with interfering current will be used for treatment, vacuum electrodes will be made in the form of 4 pole application. Two electrodes to the outside of the inguinal ligament, the other two electrodes will be placed on the upper inner part of the thigh. The same device used in ES application to the sham group will be attached to the patients, however, active ES will not be issued from the device and only vacuum will turn on. ES applications will be performed in the supine position with head and knee pillow supported.
223493047|NCT04235855|DEVICE|Endoscopic USG guided Liver biopsy|Diagnostic yield with EUS guided liver biopsy - Left lobe Bx vs combined right and left lobe or vs right lobe would be assessed.
223493048|NCT04235855|DEVICE|Percutaneous Liver Biopsy|All liver biopsies done in the Institute as routine procedure by percutaneous route would be compared with the EUS guided biopsy in respect to safety , tissue quality and diagnostic yield .
223493049|NCT01719328|BEHAVIORAL|Vinyasa yoga|
223493050|NCT02205021|OTHER|No intervention|
223493051|NCT01859091|DEVICE|The Zeltiq System|Non-invasive cooling is applied to the treatment area with a defined cooling rate and duration.
223493052|NCT04455932|DIAGNOSTIC_TEST|Abbreviated non-contrast MRI of the liver|every 6 months
223493053|NCT04455932|DIAGNOSTIC_TEST|Ultrasound surveillance|every 6 months
223493054|NCT04455932|DIAGNOSTIC_TEST|Multiphase contrast-enhanced liver MRI|screening
223493055|NCT02247544|DRUG|Trabectedin|Trabectedin administered at a dose of 1.5 mg/m2 - 1.3 mg/m2 (at investigator's discretion, with a top-dose of 2.6 total mg per cycle) as a 24-hour continuous infusion via a central venous access until progressive disease, major toxicity, patient's intolerance, unwillingness to continue treatment, or medical decision by the responsible physician
223493056|NCT06645847|OTHER|Ketone ester|"Ketone ester (KE) (Chemical name: Bis-octanoyl-(R)-1,3-butanediol, Common name: C8 ketone di-ester) formulated as a dietary supplement.~KE 12.5 g per day for 1 week; followed by KE 25 g per day for 1 week; followed by KE 37.5 g per day split into two doses for 1 week; followed by KE 50 g per day split into two doses for 17 weeks"
223493057|NCT06645847|OTHER|Placebo Comparator: Non-ketone placebo|Placebo oil (non-ketogenic canola oil) formulated as a dietary supplement. Placebo oil 12.5 g per day for 1 week; followed by Placebo oil 25 g per day for 1 week; followed by Placebo oil 37.5 g per day split into two doses for 1 week; followed by Placebo oil 50 g per day split into two doses for 17 weeks
223493058|NCT00649948|DRUG|Metformin Hydrochloride ER Tablets 500 mg|500mg, single dose fed
223493059|NCT00649948|DRUG|Glucophage XR 500 mg|500mg, single dose fed
223493060|NCT06978088|DRUG|LP-168|Patients will receive LP-168 200 mg daily beginning day 1 of therapy for 12 cycles.
223493061|NCT06978088|DRUG|Obinutuzumab|Patients will with LP-168 and then receive obinutuzumab for a total of 6 cycles, beginning cycle 7, days 1, 2, 8 and 15, and then day 1 of cycles 8-12. A minimum of 12 cycles of therapy will be administered.
223493062|NCT07124702|BEHAVIORAL|Simultaneous cessation intervention|This simultaneous cessation intervention group will target CCs and ECs at the same time. Participants in this group will receive a multi-component cessation intervention, including behavior counseling, biomarker feedback via monitoring changes in levels of exposure to nicotine (urine cotinine) and CC smoke (breath carbon monoxide), and contingent financial incentives for biochemically verified abstinence.
223493063|NCT07124702|BEHAVIORAL|Stepwise cessation intervention|This stepwise cessation intervention group will first target CCs and then target ECs after quitting CCs. Participants in this group will receive a multi-component cessation intervention, including behavior counseling, biomarker feedback via monitoring changes in levels of exposure to nicotine (urine cotinine) and CC smoke (breath carbon monoxide), and contingent financial incentives for biochemically verified abstinence.
223493064|NCT07124702|BEHAVIORAL|Behavior counseling only|Participants assigned to the control group will receive behavior counseling only. They will complete the same number of study visits as their counterparts in the intervention groups.
223493065|NCT04667585|RADIATION|De-escalated radiation dose|Reduced dose of radiation applied to remaining radiation therapy when favorable interim PET-CT signature is produced
223493066|NCT04667585|RADIATION|Standard radiation dose|Standard dose of radiation applied to remaining radiation therapy when favorable PET-CT signature is not produced
223493067|NCT04667585|OTHER|18 fluorodeoxyglucose (FDG)-positron emission tomography (PET)-Computed Tomography (CT)|The CT scan - also called computerized tomography or just CT - combines a series of X-ray views taken from many different angles to produce cross-sectional images of the bones and soft tissues inside the body. CT scans in planning radiation therapy are standard of care. A PET is a highly specialized imaging technique that uses short-lived radioactive substances (such as FDG a simple sugar labeled with a radioactive atom) to produce three-dimensional colored images of those substances functioning within the body. These images are called PET scans and the technique is termed PET scanning. PET scanning provides information about the body's chemistry not available through other procedures. Unlike CT or MRI (magnetic resonance imaging), techniques that look at anatomy or body form, PET studies metabolic activity or body function.
223493068|NCT07125248|PROCEDURE|Bilateral chest tube placement|Bilateral chest tubes will be passed in this intervention group through intercostal spaces
223493069|NCT07125248|PROCEDURE|Single drain placement|A single transhiatal drain will be placed in mediastinum in this group
223493070|NCT06237712|DIETARY_SUPPLEMENT|Dietary supplement consisting of 40 mmol/daily of potassium chloride|The supplements are delivered in plain vegetable 00 caps, stabelizing additives are potatostarch, sunflower lecithine and sunflower oil. The capsuels are free of titanium oxide and suited for human consumption.
223493071|NCT06237712|DIETARY_SUPPLEMENT|Dietary supplement consisting of 40 mmol/daily of potassium gluconate|The supplements are delivered in plain vegetable 00 caps, stabelizing additives are potatostarch, sunflower lecithine and sunflower oil. The capsuels are free of titanium oxide and suited for human consumption.
224184674|NCT02849873|DRUG|IDP-123 Lotion|Lotion
224184675|NCT02849873|DRUG|Tazorac Cream|Cream
224184676|NCT03580031|DRUG|hCG|A booster dose (10,000 IU of hCG) was given IM 48 hours after first triggering dose
224184677|NCT03580031|DRUG|Saline Solution|2 ml of normal saline will be injected 48 hours after first triggering dose
224184678|NCT01621139|PROCEDURE|Acupuncture|Patients on mechanical ventilation greater than two days will be randomly assigned to real acupuncture group or sham acupuncture group
224184679|NCT03057769|DRUG|Papillary epinephrine spraying|All patients in this group receive 20 ml of 0.02% epinephrine sprayed on the duodenal papilla, over a period of 10-15 seconds using sphincterotome, at the end of procedure, just before the withdrawal of endoscope.
224184680|NCT03057769|DRUG|Papillary saline spraying|All patients in this group receive 20 ml of saline sprayed on the duodenal papilla, over a period of 10-15 seconds using sphincterotome, at the end of procedure, just before the withdrawal of endoscope.
224184681|NCT03057769|DRUG|Indomethacin|All patients without contraindications should be administrated with rectal indomethacin within 30 min before ERCP.
224184682|NCT00456586|DRUG|KW-6002 (istradefylline)|
224184683|NCT04705259|BEHAVIORAL|Antimicrobial Stewardship ENGAGEMENT bundle|"Given that a single intervention is unlikely to be effective in stewardship programs, nor in care improvement processes at RACFs \[7\], this trial will deliver a set of multimodal, multidisciplinary interventions to optimise antibiotic use in RACFs. This RACF AMS ENGAGEMENT bundle will comprise the following key interventions:~* Education and engagement of prescribers, nurses, pharmacists and residents and family members~* Nursing initiatives to improve UTI diagnosis and reduce inappropriate urine testing~* Guideline development specific to antibiotic use in RACF residents~* Antimicrobial stewardship team creation in RACF with GP involvement~* EMergency department liaison and use of clinical pathways to ensure consistency of practice across the care continuum~* ElectroNic decision support to guide RACF urine testing and GP antibiotic prescribing~* Telehealth support for key intervention components"
224184684|NCT02426359|DRUG|Q301 Cream|
224184685|NCT02426359|DRUG|Placebo|
224184686|NCT02106715|OTHER|Training|Two exercises for training of core stability and mobility.
224184687|NCT04264806|DRUG|Azacitidine|Participants will receive subcutaneous (SC) or intravenous (IV) injection of Azacitidine 75 mg/m\^2.
224184688|NCT04264806|DRUG|Cusatuzumab|Participants will receive SC or IV injection of Cusatuzumab 20 mg/kg.
224184689|NCT04472273|PROCEDURE|high-flow nasal cannula / classic nasal cannula|The oxygen given with nasal cannula cannot be humidified, causing drying in mucous membranes at high flow rates of more than 4L/min and problems in patient compliance.This situation prevents us to increase the oxygen FiO2 rate applied to the patient above 40%.According to the nasal cannula high-flow nasal cannula where heated and humidified oxygen can be delivered, oxygen therapy can be applied at a flow rate of 25L/min.It provides high flows easily, prevents the airway epithelium from drying out and improves mucus cleansing, causing a decrease in anatomical dead space.It provides discharge of expired air in the upper airways.It increases alveolar ventilation.It offers a stream adjusted to all children.Flow and titration can be adjusted according to the child's weight and effect.
224184690|NCT05417373|OTHER|calculated radscore|The development cohort is case\_control research. The validation cohort is prospective study to test the accuracy of calculated radscore based on diagonisis model.
224184691|NCT01978067|PROCEDURE|transvaginal resection of Uterine Scar|Expose, grasp and traction the cervix. An incision was made at the anterior cervicovaginal junction, and the bladder was dissected away until the anterior peritoneal reflection was identified. The anterior drawing hook was inserted.into the vaginal incision to retract the bladder upwards. The PCSD was identified as a'fornix' located in the anterior part of the lower uterine segment. A transverse incision was made to remove the scar deficiency, and the edges of the incision were trimmed with scissors, and the myometrial and vaginal defects were closed.
224308469|NCT03168230|PROCEDURE|Portal vein embolization (PVE)|"Portal vein embolization (PVE) is a procedure that induces regrowth on one side of the liver in advance of a planned hepatic resection on the other side. The procedure is frequently used in primary liver cancer (hepatocellular carcinoma) and colorectal liver metastases.~An interventional radiologist will place a needle percutaneously (through the skin) into the liver and identify the blood vessel on the side where the largest part of the tumor is being supplied. Tiny microspheres are then infused into the portal vein which supplies blood to the area, embolizing it by cutting off its blood supply.~This blockade of the blood supply induces the other side of the liver to regrow. After several weeks, the non-embolized side has grown enough so that surgery is now a viable option.~Source of this information : http://general.surgery.ucsf.edu/conditions--procedures/portal-vein-embolization-(pve).aspx"
224184692|NCT01881867|BIOLOGICAL|Glycosylated Recombinant Human Interleukin-7|Given SC
224184693|NCT01881867|OTHER|Laboratory Biomarker Analysis|Correlative studies
224184694|NCT01795846|OTHER|Allergen specific immunotherapy and placebo injections|
224184695|NCT06323655|DRUG|Tasimelteon|oral capsule
224184696|NCT06323655|DRUG|Active Control Placebo|oral capsule
224184697|NCT06323655|DRUG|Tasimelteon Placebo|oral capsule
224184698|NCT06323655|DRUG|Active Control|oral capsule
224184699|NCT01875900|OTHER|Video-assisted learning and self-directed training|The Neonatal Resuscitation Program (NRP) DVD will be provided for video study and a low-fidelity newborn manikin for self-directed resuscitation training (90 minutes training time, six students per group).
224308470|NCT05830344|DEVICE|Placebo Multi Radiance Medical® Super Pulsed Laser|Placebo, without therapeutic dose.
224308471|NCT05830344|DEVICE|Active Multi Radiance Medical® Super Pulsed Laser|Active with a dose of 8.02 J per site.
224308472|NCT04905940|DRUG|Turmeric mouthwash|Turmeric mouthwash evaluation in controlling halitosis
224308473|NCT06202729|OTHER|Questionnaire|GAD-7, VAS-A, NRS
223493072|NCT06237712|DIETARY_SUPPLEMENT|Dietary supplement consisting of 40 mmol/daily of potassium bicarbonate|The supplements are delivered in plain vegetable 00 caps, stabelizing additives are potatostarch, sunflower lecithine and sunflower oil. The capsuels are free of titanium oxide and suited for human consumption.
223493073|NCT06237712|DIETARY_SUPPLEMENT|Dietary supplement consisting of 40 mmol/daily of sodium chloride|The supplements are delivered in plain vegetable 00 caps, stabelizing additives are potatostarch, sunflower lecithine and sunflower oil. The capsuels are free of titanium oxide and suited for human consumption.
223588642|NCT01633177|DRUG|Omega-3 fatty acid (fish oil)|Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid \[EPA\] and 375 mg of docosahexaenoic acid \[DHA\]).
224184700|NCT01875900|OTHER|Simulation-based neonatal resuscitation training|Students will learn initial assessment of newborns and basic resuscitation skills and actively apply these skills during simulated clinical scenarios both with a low- and high-fidelity manikin (90 minutes training time, six students per group).
224184701|NCT01400659|PROCEDURE|CFP counting|Patients receive a standardized test meal at lunch time. The required insulin dose is calculated by CFP counting. Insulin is given as bolus and basal rate using an insulin pump. Continuous glucose monitoring is performed by sensor-augmented pump system for 6 hours after the meal. The intervention is taking part under in-patient clinical conditions.
224184702|NCT01400659|PROCEDURE|CARB counting|Patients receive a standardized test meal at lunch time. The required insulin dose is calculated by CARB counting. Insulin is given as bolus and basal rate using an insulin pump. Continuous glucose monitoring is performed by sensor-augmented pump system for 6 hours after the meal. The intervention is taking part under in-patient clinical conditions.
224184703|NCT01678391|PROCEDURE|Common bile duct stone removal without fluoroscopy.|ERCP stone extraction technique without fluoroscopy involves: (1) catheter or catheter with wire access into the bile duct, (2) confirmation of biliary access with catheter aspiration of bile, (3) performance of endoscopic biliary sphincterotomy or balloon dilation to widen the bile duct opening to permit stone removal, (4) stone removal - number of stones seen on EUS should match the number removed.
224184704|NCT03044691|BEHAVIORAL|ResearchACTS software|screen patients for tobacco and nicotine product use (using the anticipate and ask components of the 6As) by having youth complete a tobacco and nicotine use screening tool using the ResearchACTS software.
224184705|NCT02377674|DEVICE|Vascular Graft, Model COR-VG-001|The intended use of the Xeltis Vascular Graft, Model COR-VG-001 is to create an extracardiac total cavopulmonary connection (EC-TCPC) connection to divert the venous blood from the inferior vena cava to the pulmonary arteries without passing through the morphologic right ventricle reducing the volume load on the functional single ventricle and thereby improving hemodynamics by minimizing the deleterious effects of ventricular hypertrophy.
224184706|NCT03628573|DEVICE|repetitive transcranial magnetic stimulation (MagPro X100).|accelerated rTMS.
224184707|NCT03628573|DEVICE|Intermittent Theta burst stimulation ( iTBS)|
224184708|NCT05681221|OTHER|Nano silver particles and calcium hydroxide|Combination of two materials that can possibly eradicate the mixed odontogenic infection in the periapical area and dentinal tubules in necrotic primary second molars.
224184709|NCT05681221|OTHER|TAP|Triple antibiotic paste (TAP) is considered the gold standard in LSTR. It is a combination of ciprofloxacin, metronidazole and minocycline. Many anaerobic bacteria are resistant to ciprofloxacin. Hence, it is often used with metronidazole in treating mixed infections to compensate for its limited scope. Therefore, TAP can affect gram-negative, gram-positive, and anaerobic bacteria, and this combination can be effective against odontogenic microorganisms.
224184710|NCT02442739|DRUG|Ketamine|Ketamine 0.5 mg/kg mixed with syrup will be given by mouth once a week for 12 weeks.
224184711|NCT02442739|OTHER|Placebo|Placebo syrup will be given by mouth once a week for 12 weeks.
224184712|NCT03679234|OTHER|Routine infant formula|Routine infant formula with probiotic
224184713|NCT00204542|DRUG|Diclofenac|Solaraze® (Diclofenac sodium) 2x/day topical for 3 months
224184714|NCT00204542|DRUG|Diclofenac|Solaraze® (Diclofenac sodium) 2x/day topical for 6 months
224184715|NCT01789476|DRUG|CR845|CR845 dosage = 0.005 mg/kg per dose, IV bolus. The initial dose was administered upon reaching a qualifying pain intensity score and followed by a supplemental dose, if requested by patient for pain. Additional doses could be administered every 8 hours up to 48 hours.
224184716|NCT01789476|DRUG|Placebo|Matching placebo administered using same dosing algorithm as the active arm
224184717|NCT00501969|DRUG|Rotigotine|"Rotigotine trans-dermal patches once daily:~20 cm2 (4 mg/24 hours); 30 cm2 (6 mg/24 hours); 40 cm2 (8 mg/24 hours) 50 cm2 (10 mg/24 hours) 60 cm2 (12 mg/24 hours) 70 cm2 (14 mg/24 hours) 80 cm2 (16 mg/24 hours)"
224184718|NCT00716365|DEVICE|HemCon bandage|5 cm X 5 cm
224184719|NCT01813786|DEVICE|755nm Alexandrite Laser with handpiece 2|Focusing energy on skin
224184720|NCT01813786|DEVICE|755nm Alexandrite Laser with handpiece 1|focusing energy at skin surface
224184721|NCT01813786|DEVICE|755nm Alexandrite Laser with handpiece 3|Focusing energy on skin
224184722|NCT05921539|DRUG|steroid hydrodilatation|ultrasound-guided steroid hydrodilatation
223493074|NCT06237712|DIETARY_SUPPLEMENT|Dietary supplement consisting of 40 mmol/daily of sodium bicarbonate|The supplements are delivered in plain vegetable 00 caps, stabelizing additives are potatostarch, sunflower lecithine and sunflower oil. The capsuels are free of titanium oxide and suited for human consumption.
223493075|NCT06237712|DIETARY_SUPPLEMENT|Placebo caps|The supplements are delivered in plain vegetable 00 caps, stabelizing additives are potatostarch, sunflower lecithine and sunflower oil. The capsuels are free of titanium oxide and suited for human consumption.
223493076|NCT04616313|DIAGNOSTIC_TEST|Hyperpolarized Xenon-129 MRI of the lungs|Participants will be imaged using MRI using hyperpolarized xenon-129 gas as a contrast gas
224184723|NCT05921539|DRUG|axillary nerve injection|ultrasound-guided axillary nerve injection
224184724|NCT01229865|DRUG|VB-111|
224184725|NCT05499104|DEVICE|NovaDress|NovaDress is constructed of pure cellulose derived from tree pulp. The tree pulp is reconstructed into hydrated sheets wrapped in nonwoven viscose and irradiated.
224184726|NCT05499104|DEVICE|Mepilex Ag|Mepilex Ag is an antimicrobial foam dressing that absorbs low to moderate exudate and maintains a moist wound environment.
224184727|NCT05499104|DEVICE|Xeroform|Xeroform® Occlusive Dressing (XF) is a fine-mesh gauze impregnated with a petrolatum blend, 3% bismuth tribromophenate.
224184728|NCT00965458|BIOLOGICAL|Alefacept|Weekly intramuscular injections of alefacept (15 mg) for 2 cycles of 12 weeks each, separated by a 12 week pause in treatment.
224184729|NCT00965458|DRUG|Placebo|Weekly intramuscular injections of a placebo saline solution of equal volume to the alefacept group for 2 cycles of 12 weeks each, separated by a 12 week pause in treatment.
224184730|NCT06690086|PROCEDURE|Lesion biopsy|Lesions enrolled in the study are biopsied to confirm histopathology
224184731|NCT06690086|DEVICE|DermaSensor Device Use|Users are blinded to the DermaSensor Device result
224184732|NCT04284241|BEHAVIORAL|Parents'Health-Education Handbook|We created a Parents' Health-Education Handbook to teach the newborns' parents to enhance their knowledge of pediatric stone, with a view to changing parents' cognition, attitude and behavior for preventing pediatric stone formation by this cluster randomized control trail.
224184733|NCT06542679|BEHAVIORAL|Mobile Application|A mobile health application based on Social Cognitive Theory (SCT) and the Information-Motivation-Behavioral Skills (IMB) model has been developed. The design of the mobile health application is grounded in SCT, the IMB model, and behavioral change interventions and techniques. The content of the mobile application is based on the 'Healthy Weight Gain Guide for Pregnancy.' The application offers a comprehensive program that provides evidence-based recommendations using self-monitoring, feedback, shaping information, goal setting, planning, and reward techniques for healthy nutrition, physical activity, and optimal gestational weight gain for pregnant women.
224184734|NCT00942110|DEVICE|CPAP treatment|maintains upper airway patency and minimizes the obstructive events
224184735|NCT00994123|DRUG|MM-121|MM-121 (SAR256212) = intravenous solution
224184736|NCT00994123|DRUG|Erlotinib|erlotinib = daily oral tablet
224184737|NCT02223637|BIOLOGICAL|Meningococcal quadrivalent CRM-197 conjugate vaccine|This pregnancy registry is strictly observational. Decisions of vaccination are made by health care providers.
224184738|NCT02928198|DEVICE|ABSORB BVS|
224184739|NCT00692198|DRUG|Supplemental oxygen therapy|Oxygen dose at rest and during sleep will be 2 L/min via nasal cannula. The oxygen dose used while walking will be individually prescribed and will be sufficient to maintain oxygen saturation at 90% or above for at least 2 minutes while walking. Participants who have low blood oxygen levels at rest will be instructed to use oxygen 24 hours per day. Participants who have normal resting blood oxygen levels, but low or very low blood oxygen levels during exercise, will be instructed to use oxygen during physical activity and sleep.
224184740|NCT04129645|DEVICE|URS|"URS is a permanent ureteral stent made of nitinol and covered by a polymer, that is indicated to open strictures in the ureter.~Study patients who has strictures in the ureter, will be implanted with the URS for long term opening of the stricture."
224184741|NCT03830073|GENETIC|Measurement of VDR genetic polymorphism|VDR genetic polymorphism will be measured by RFLP and correlated with viral, autoimmune markers.
224184742|NCT05620966|DEVICE|CGX Systems Quick-20m|The Quick-20m is an FDA-approved wireless, battery-operated 10-20 montage EEG headset, which utilizes dry sensor technology. This device provides an integrated approach to the wireless acquisition of electrical potentials arising from activity in the cortex. The Quick-20m includes advanced amplification and shielding to reject ambient electrical noise. The Quick-20m is placed on the participant's scalp and requires minimal scalp preparation. No conductive gel is used. Patients may or may not have hair. The sensor pads must have direct contact with the scalp and hair will be maneuvered to obtain direct contact. All three arms of participants will receive this intervention.
224184743|NCT05111548|DEVICE|tDCS (Active)|tDCS is a non-invasive procedure in which electrodes are attached to the scalp and send a small direct current to stimulate brain function. Participants in the experimental arm will receive a steady current delivery through the device.
224184744|NCT05111548|BEHAVIORAL|BrainHQ|BrainHQ is a web-based, commercially available cognitive training program that includes exercises to enhance working memory
223493077|NCT04616313|DIAGNOSTIC_TEST|Computed Tomography (CT)|Participants will undergo a CT scan of the thoracic cavity
223745644|NCT05717010|DEVICE|Near infrared spectroscopy|The Near Infrared Spectroscopy (NIRS) is the method used for monitorize the risk of the development of cerebral ischaemia while providing information about brain tissue oxygenation.
224184745|NCT05111548|DEVICE|tDCS (Inactive)|tDCS is a non-invasive procedure in which electrodes are attached to the scalp and send a small direct current to stimulate brain function. Participants in the sham arm will wear the device but will not receive a steady current delivery.
224184746|NCT03079648|DIETARY_SUPPLEMENT|Angelica gigas N. extract|capsules (2cap/d, 1,000mg/d) for 12 weeks.
224184747|NCT03079648|DIETARY_SUPPLEMENT|Placebo|Placebo for 12 weeks
224184748|NCT06542822|DRUG|Ferric derisomaltose|See group descriptions
224184749|NCT00379639|DRUG|Romidepsin|7, 10 or 12 mg/m\^2 via intravenous infusion over 4 hours on either Days 1, 8 and 15 or Days 1 and 15 of each 28-day cycle.
224184750|NCT00379639|DRUG|Gemcitabine|800 or 1000 mg/m\^2 via intravenous infusion over 30 minutes on either Days 1,8 and 15 or Days 1 and 15 of each 28 day cycle.
224184751|NCT00594958|BIOLOGICAL|IC51|6 mcg, intramuscularly \[i.m.\], 0.5 mL
224184752|NCT00406939|GENETIC|IL-12 gene|
224184753|NCT04928924|PROCEDURE|Total Hip Arthroplasty|We will be observing patients who have undergone surgical replacement of arthritic hip with an implant.
223493078|NCT04616313|DIAGNOSTIC_TEST|Pulmonary Function Tests (PFT)|Participants will have their lung function evaluated using PFT
223745645|NCT01327300|DRUG|Mesalamine|Apriso is a 5-ASA drug with Intellicor ™ extended-release delivery technology. A 1.5 gram dosage of Apriso (equaling four 375 mg capsules) once a day will be administered orally for a period of 12 weeks followed by a 3 week wash out prior to crossing over to the placebo arm.
224184754|NCT04121091|DRUG|Pramipexole Pill|Add-on pramipexole
223493079|NCT04616313|DIAGNOSTIC_TEST|Cardiopulmonary exercise testing (CPET)|Participants will perform cardiopulmonary exercise testing as a measure of exercise capacity
223493080|NCT04616313|DIAGNOSTIC_TEST|Sputum analysis|Participants will provide a sputum sample that will be analysed for eosinophils
223493081|NCT04616313|DIAGNOSTIC_TEST|Blood analysis|Participants will have their blood drawn and analysed for eosinophil count.
223493082|NCT04616313|OTHER|Questionnaires|Participants will complete questionnaires to assess activity related dyspnea, respiratory symptoms and health status impairment and respiratory related quality of life.
223493083|NCT06258447|DEVICE|Autologous bone marrow mononuclear cells processed / delivered using the CardiAMP cell therapy system|the ABM MNC is obtained from the study patient via bone marrow aspiration in the hip and processed and delivered using the CardiAMP cell therapy system during the cardiac catheterization.
224184755|NCT06042465|OTHER|acupuncture and Tui-na manipulations|"i. Patients in supine position with knee elevated 20-30 degrees bending using a pillow below.~ii. Acupuncture needle using 0.25 mm diameter and 1.5-inch length. iii. Choose 'A shi point' to inject the acupuncture needles. iv. Inject 4 acupuncture needles respectively at the upper, lower, lateral and medial edge of the patella, along the medial and lateral edge at the posterior surface of patella.~v. Connect the needles with electro-therapy, selecting high frequency and strength that the patients have sensation and acceptable. Time duration is 30 minutes each time. Infra-radiation is provided and warm above the treatment region.~vi. Tui-na manipulations using the method of 'Tui-na'. Time duration is 2-5 minutes. Patella is pushed up and elevated during treatment.~vii. No external herbal medicine for TCM group , other medication such as painkiller is required to record"
224184756|NCT06042465|OTHER|Physiotherapy|"i. Total 12 sessions of physiotherapy for 8 weeks training; ii. Treatment: Closed kinetic chain exercises program will be used when appropriate, which include:~1. Mini walk squat exercise~2. Forward step up~3. Lateral step up~4. Terminal knee extension~5. Knee taping~6. Unstable base training~7. Pain control~8. Manual Therapy Each session will approximately cost each patient 1 hours' time. There is no Chinese medicine is allowed for PT group , other medication such as painkiller is required to record."
224184757|NCT00151775|DRUG|olmesartan medoxomil|"Cohorts A and B: 2.5mg to 40mg olmesartan, as a suspension (depending on weight), once daily. Tablets were used to prepare a suspension.~Cohort C: 0.3mg/kg olmesartan ,as a suspension, once daily"
224184758|NCT00151775|DRUG|placebo|Cohorts A, B, C: placebo, once daily
224184759|NCT00151775|DRUG|olmesartan medoxomil|"Cohorts A and B: Open label olmesartan medoxomil suspension or tablets 10mg - 40 mg. Tablets were used to prepare the suspension or were given directly.~Cohort C: Open label olmesartan medoxomil suspension 0.3 mg/kg - 0.6 mg/kg"
224184760|NCT05235633|DIAGNOSTIC_TEST|Assessment of the accomplishment regarding Activities of Daily Living at the end of acute treatment|Participants perform a test battery to assess the capability to accomplish Activities of Daily Living that includes a standardized and validated questionnaire, a parcour with tasks based on Activities of Daily Living and a motor performance test.
224184761|NCT03184467|DRUG|Normal Saline 0.9%|Normal saline 0.9% is subcutaneously administered once weekly schedule for 4 weeks (4 times) followed by every two weeks until week 24 (10 times). A total number of administration is 14 times.
224184762|NCT03184467|DRUG|GV1001 0.56 mg|GV1001 0.56 mg is subcutaneously administered once weekly schedule for 4 weeks (4 times) followed by every two weeks until week 24 (10 times). A total number of administration is 14 times.
224184763|NCT03184467|DRUG|GV1001 1.12 mg|GV1001 1.12 mg is subcutaneously administered once weekly schedule for 4 weeks (4 times) followed by every two weeks until week 24 (10 times). A total number of administration is 14 times.
224184764|NCT00128336|BEHAVIORAL|Lifestyle: diet and exercise intervention|
224184765|NCT00000459|BEHAVIORAL|diet, fat-restricted|
224184766|NCT05673954|DIAGNOSTIC_TEST|C-Read test|C-Read is a reliable and valid clinical tool for quantitatively testing the reading ability of readers of simplified Chinese characters.
224184767|NCT05590182|DEVICE|Angiography|"Randomization either in the study arm (CO2) or in the control arm (iodine-CM) occurs right before angiography. Stenosis graduation and length are measured after diagnostic angiography and before intervention. The calculated values through the software-quantification-tool, including also a final sequence of the distal outflow with the same contrast media used during intervention, are be compared and statistically analyzed.~A pain protocol to the current pain-situation is led by the present medical-laboratory assistant after administration of CO2 and iodine-CM during intervention."
224184768|NCT04516291|DRUG|Vupanorsen|Vupanorsen and placebo will be provided as prefilled syringes packaged and dispensed in cartons with tamper-evident seals. Only single-use syringes will be used.
224184769|NCT04516291|DRUG|Placebo|Vupanorsen and placebo will be provided as prefilled syringes packaged and dispensed in cartons with tamper-evident seals. Only single-use syringes will be used.
224184770|NCT06652022|RADIATION|Systematic therapy combined with radiotherapy|Systematic medical therapy is same as the systematic treatment group. SBRT radiotherapy or conventional fractionated radiotherapy can be used according to the extent and size of the metastatic foci. SBRT radiotherapy is preferred, and a higher dose should be given as far as possible when the normal tissues permit, with a preferred single dose of ≥5Gy.
223493084|NCT05584059|BEHAVIORAL|Focused Acceptance and Commitment Therapy|This is an individual-based FACT counselling programme which composes of 4-6 sessions on a weekly basis (45-60mins/session). All the sessions are delivered by a trained FACT interventionist via either video-conferencing (e.g., Zoom or Windows Teams) or face-to-face format. The programme aims to increase the psychological flexibility of the parent, so that he/she is able to (i) experience the present moment and take perspective on self (i.e., Awareness); (ii) detach the distressing private experiences and associated rules and to take a non-judgemental, accepting stance toward the painful experiences (i.e., Openness) and (iii) exhibits strong connection with values and commit to values-consistent actions. The trained interventionist will use different ACT strategies in these sessions, including ACT metaphors, experiential exercises, guided mindfulness exercises, guided imagery exercises and values clarification exercises to reinforce the above principles.
223493085|NCT06979583|DEVICE|4.8 Fr Ureteral stents|After surgery, patients will have the Boston Scientific 4.8 Fr ureteral stent placed.
223493086|NCT06979583|DEVICE|7 Fr Ureteral stents|After surgery, patients will have the Bard 7 Fr ureteral stent placed.
223493087|NCT06659757|DRUG|KIT2014|KIT2014 will be administered by inhalation with a nebuliser
223493088|NCT06659757|OTHER|Placebo|Placebo will be administered by inhalation with a nebuliser
223493089|NCT06210919|BIOLOGICAL|TRTP-101|Intradermal injection of the each of four sites
223493090|NCT06557356|DRUG|LY3532226|Administered SC
223493091|NCT06557356|DRUG|Placebo|Administered SC
223493092|NCT04396808|DEVICE|Decipher|The Decipher test (GenomeDx Biosciences) is a genomic test that will be performed on prostate biopsy tissue. Results will be provided to the patient and physician prior to making a treatment decision.
223588643|NCT01633177|DIETARY_SUPPLEMENT|Vitamin D3 placebo|Vitamin D3 placebo
224184771|NCT06652022|DRUG|Systematic drug treatment|The choice of first-line treatment is based on the guidelines, and may include chemotherapy or immune checkpoint inhibitors, or a combination of therapies. For patients who can tolerate cisplatin, chemotherapy is given with the gemcitabine-cisplatin regimen, as follows: gemcitabine 1000mg/m2 d1,8; cisplatin 70 mg/m2, avoiding light, intravenous drip d2; 3 weeks for 1 cycle. For intolerant patients, the gemcitabine-carboplatin regimen is given as follows: gemcitabine 1000 mg/m2 d1,8, IV, carboplatin (4.5×\[GFR+25\]) mg, IV, d1; 3 weeks as 1 cycle. Immune checkpoint inhibitors and targeted agents may be administered if the patient does not tolerate chemotherapy; either in combination with chemotherapy or directly as first line.
223588644|NCT01633177|DRUG|Fish oil placebo|Fish oil placebo
224184772|NCT03039686|DRUG|RO7239361|Take RO7239361 subcutaneously on specified days over a 48 week blinded period
224184773|NCT03039686|DRUG|Placebo for RO7239361|Take placebo subcutaneously on specified days over a 48 week blinded period
224184774|NCT00718146|BIOLOGICAL|Split virion, inactivated Influenza vaccine|0.5 mL, Intramuscular (IM)
224184775|NCT00718146|BIOLOGICAL|Split virion, inactivated Influenza vaccine|0.5 mL, Intramuscular (IM)
224184776|NCT06454955|DRUG|[68Ga] B7H3 Affibody-BCH|An affibody structure specifically targeting B7H3 was developed based on the B7H3 binding domain, and it was structurally optimized to yield a small molecular agent, B7H3 Affibody-BCH, suitable for nuclear medical diagnostic and therapeutic uses targeting B7H3. By labeling with the radioactive isotope \^68Ga, this agent can be used for PET/CT diagnosis of solid tumors.
224184777|NCT02158949|BEHAVIORAL|mROAD|
224184778|NCT03512106|OTHER|Acupuncture|Chinese traditional acupuncture
224184779|NCT05054088|DEVICE|T-Detect COVID test|• The T-DetectTM COVID test is an EUA granted investigational device that is indicated to assess a T-cell immune response to SARS-CoV-2 via the testing of blood samples from patients with signs and symptoms of suspected COVID-19.
224184780|NCT05341427|DEVICE|electromagnetic device|electromagnetic waves for burn wound
224184781|NCT02181634|DRUG|Nab-Paclitaxel and Gemcitabine|Nab-Paclitaxel will be administered first, at a dose of 125 mg/m² IV over a period of 30 minutes; gemcitabine will be administered second, at a dose of 1000 mg/m² over a period of 30 minutes.
224184782|NCT03338907|DRUG|Oxycarbon (5% CO2+ 95% O2)|Oxycarbon will be administered by mechanical ventilation
224184783|NCT00103376|DRUG|Velcade|"Part A: 1.3 mg/m2 administered on days 1, 4, 8 and 11 followed by 10 days rest. A second cycle will be given at the same schedule. Cycle 3 will include 3 weekly injections.~Part B: 1.3mg/m2 administered weekly for 3 weeks followed by 1 week break"
224184784|NCT00103376|DRUG|LH-RH Agonist|given as a 3 month depo-injection
224184785|NCT00103376|DRUG|Androgen Receptor Antagonists|given orally daily for 3 months
224184786|NCT01503502|DRUG|flumatinib|Flumatinib was supplied as 100 and 200 mg film-coated tablets for oral administration. Storage condition: 25°C, light proof, sealed.
224184787|NCT01503502|DRUG|imatinib|Imatinib was supplied as 100 mg film-coated tablets. Storage condition: 25°C (77°F). Protected from moisture.
224184788|NCT03231423|OTHER|Drainage|Using drain after operation
224184789|NCT06091527|BEHAVIORAL|Yoga practice|90-minute group yoga classes twice weekly for 12 weeks.
224184790|NCT06091527|BEHAVIORAL|Education|90-minute group education classes twice weekly for 12 weeks to learn holistic healthcare modules.
224184791|NCT04209166|DRUG|SSRIs/SNRIs (Selective Serotonin Reuptake Inhibitors/ Serotonin and Norepinephrine Reuptake Inhibitors)|Patients will be treated with Selective Serotonin Reuptake Inhibitors/ Serotonin and Norepinephrine Reuptake Inhibitors.
224184792|NCT04209166|DRUG|SSRIs/SNRIs+Mood Stabilizer|Patients will be treated with Mood Stabilizer combined with Selective Serotonin Reuptake Inhibitors/ Serotonin and Norepinephrine Reuptake Inhibitors.
224308474|NCT05279911|RADIATION|low-level laser therapy (LLLT)|low-level laser therapy (LLLT) with dental implants has been suggested to improve bone quality during osseointegration. Low-level laser (Gallium Aluminum Arsenide Diode \[Ga-Al-As\]) (wavelength: 808 nm, average power density: 50 mW, circular spot diameter:0.71 cm, spot area: 0.4cm2) in continuous mode was applied in six points in contact with peri-implant soft tissue (1.23 minutes in each point of application; dose per point 11 J) before and immediately after suturing. The application points were divided into two points in the labial region where the implant would be placed (apical and cervical); two points in the lingual region (apical and cervical); and two points in the occlusal direction. After suturing the laser protocol was repeated in the same points following the same protocol, resulting in a total dose of 66 J for each application moment (before and after implant placement).
224308475|NCT00757211|GENETIC|polymorphism analysis|
224308476|NCT00757211|OTHER|laboratory biomarker analysis|
223493093|NCT04396808|DEVICE|Prolaris|The Prolaris test (Myriad Genetics, Inc.) is a genomic test that will be performed on prostate biopsy tissue. Results will be provided to the patient and physician prior to making a treatment decision.
223493094|NCT04396808|DEVICE|Oncotype Dx Genomic Prostate Score (GPS)|The Oncotype Dx GPS test (Exact Sciences corp.) is a genomic test that will be performed on prostate biopsy tissue. Results will be provided to the patient and physician prior to making a treatment decision.
223493095|NCT04396808|OTHER|Standard of care (askMUSIC score)|AskMUSIC is a risk calculator based on standard clinical and pathologic variables (https://ask.musicurology.com/) and is generally included as part of routine clinical care.
223493096|NCT06649032|OTHER|No intervention|no difference: both cohorts are followed in the same way
223493097|NCT06606743|BEHAVIORAL|High-Intensity Interval Training|Participants will receive a total of 20 in-person sessions of 45 minutes duration. Subjects perform high-speed movements with minimal recovery between movements. Hand weight will be used to increase intensity as training progresses.
223493098|NCT06606743|BEHAVIORAL|High-Velocity Circuit Resistance Training|Participants in this group will perform a total of 20 in-person training sessions using 12 resistance exercises performed in 3 circuits with minimal recovery between exercises.
223493099|NCT06606730|DRUG|Pembrolizumab|Administration of pembrolizumab for 6 months
223493100|NCT06606730|OTHER|Deescalation|Patients will be followed up according to standard practice for 4 years
223493101|NCT06595290|OTHER|High intensity care|This arm follows a structured algorithm for initiating and uptitrating all four pillars of HFrEF oral medications post-randomization (pre-discharge) and during at least 4 visits over 6 weeks post-discharge.
223493102|NCT06595290|OTHER|Usual care|Patients will be managed by their cardiologist according to their usual practice. Follow-up appointments will be scheduled as per the cardiologist\&#39;s instructions. Participants will return to the recruiting study site for clinical outcome assessment by study investigators at 90 and 180 days post-discharge.
223493103|NCT06590857|DRUG|RYZ101|Ac-225
223493104|NCT06587061|DRUG|HRS-4642+AG|HRS-4642 in Combination With Gemcitabine and Albumin-bound Paclitaxel will be administrated per dose level in which the patients are assigned.
223493105|NCT00558545|DRUG|AEG35156|AEG35156 will be given as a 2-hour intravenous infusion once weekly only on weeks when paclitaxel is administered, with a 2-hour loading dose given daily in the 2 days immediately prior to Day 1 (on Days -2 and -1) only in Cycle 1.
223493106|NCT06597721|DRUG|ADCE-T02|Administered intravenously
223493107|NCT03244189|BEHAVIORAL|Fluid prescription|The additional amount of fluid that the participant will need to consume each day, using the smart water bottle, in order to meet the study-specified urine output. This fluid is in addition to any other sources of fluid (ex. cups of coffee, bottled sports drink) that the participant consumes each day.
223493108|NCT03244189|BEHAVIORAL|Financial incentive|Participants in the Intervention Arm who meet their fluid intake goal on randomly selected days will receive a small payment for that day.
224184793|NCT04209166|DRUG|SSRIs/SNRIs+Quetiapine|Patients will be treated with Quetiapine combined with Selective Serotonin Reuptake Inhibitors/ Serotonin and Norepinephrine Reuptake Inhibitors.
224184794|NCT04209166|DRUG|Usual Treatment|Patients' treatment will be decided by the clinical doctor.
224184795|NCT00326339|DRUG|R788|R788 50 mg, 100 mg, or 150 mg PO bid
224184796|NCT00326339|DRUG|Placebo|Placebo PO bid
224184797|NCT04857879|OTHER|GLA:D program (Good Life with osteoArthritis in Denmark)|GLA:D includes disease-specific education combined with neuromuscular exercises. Control interventions include disease-specific education combined with exercises to optimize movement and strength of the affected knee.
224184798|NCT04672434|DRUG|Sym021|Sym021 is a humanized anti-PD-1 antibody.
224184799|NCT04672434|DRUG|Sym024|Sym024 is an anti-CD73 antibody.
224184800|NCT04726787|RADIATION|Bridging Radiotherapy|Bridging Radiotherapy will start immediately after leukapheresis and before Tisagenlecleucel treatment
224184801|NCT05349214|BIOLOGICAL|VAY736|ianalumab s.c.
223493109|NCT03244189|BEHAVIORAL|Structured Problem Solving|Structure Problem Solving involves interactions with health coaches to help participants develop feasible solutions to overcoming personal barriers to maintaining the prescribed fluid intake.
223493110|NCT06988176|DIAGNOSTIC_TEST|Frailty assessment, nutrition assessment, cognition assessment, muscle strength testing|"Participants will undergo a structured frailty and muscle-strength assessment battery performed during their routine preoperative evaluation. These assessments serve as the primary exposure measures of interest and include:~Clinical Frailty Scale (CFS) evaluation (functional frailty assessment) Respiratory muscle strength assessment (Maximal Inspiratory Pressure (MIP) and Maximal Expiratory Pressure (MEP) using a MicroRPM handheld respiratory pressure meter) Hand-grip strength measurement (using Jamar dynamometer) Physical performance evaluation (Timed Up-and-Go (TUG) test) Skeletal muscle mass estimation (Bioelectrical impedance analysis, InBody 120) Muscle thickness measurement (Rectus femoris muscle thickness using portable ultrasound) Cognitive function screening (Mini-Cog test) Nutritional risk screening (Perioperative Nutrition Screen \[PONS\]) No additional interventions beyond these observational assessments will be conducted."
224184802|NCT05349214|BIOLOGICAL|VAY736|ianalumab s.c.
224184803|NCT05349214|OTHER|Placebo|placebo s.c.
223493111|NCT05415774|DEVICE|1 : S-C1-C2|"Deep brain stimulation of the substantia nigra pars reticulata and of the subthalamic nucleus according to the order of randomisation (see intervention name) :~* Standard stimulation~* 125Hz at both STN and SNr for C1,~* 125Hz for STN and 60 for SNr for C2"
223493112|NCT05415774|DEVICE|2 : S-C2-C1|"Deep brain stimulation of the substantia nigra pars reticulata and of the subthalamic nucleus according to the order of randomisation (see intervention name) :~* Standard stimulation~* 125Hz at both STN and SNr for C1,~* 125Hz for STN and 60 for SNr for C2"
223493113|NCT05415774|DEVICE|3 : C1 - S - C2|"Deep brain stimulation of the substantia nigra pars reticulata and of the subthalamic nucleus according to the order of randomisation (see intervention name) :~* Standard stimulation~* 125Hz at both STN and SNr for C1,~* 125Hz for STN and 60 for SNr for C2"
223588645|NCT00244634|DRUG|candsartan cilexetil|
223588646|NCT01769820|DRUG|Dexamethasone|studies 1\&2:0.75mg twice daily for 5 days, starting on day LH (Luteinising Hormone)+8 of menstrual cycle; Study 3 (adaptive) 0.2,0.4,0.5,0.75,0.8,0.9mg twice daily as above
223588647|NCT01769820|DRUG|placebo|
224184804|NCT05122364|BEHAVIORAL|Telerehabilitation and telecoaching|Language Sessions online and coaching parents online to improve language and social outcomes of their children
224184805|NCT05122364|BEHAVIORAL|Face to Face Language sessions|Language sessions Face to Face at sohag phoniatrics unit
224184806|NCT06765642|DIAGNOSTIC_TEST|Transcranial Magnetic Stimulation|The use of this approach aims to potentially maximize motor recovery in chronic stroke by harnessing corticospinal plasticity and modulating motor learning behavior.
224184807|NCT05480852|OTHER|Bis-GMA Free dental resin composite|Restorative Material
224184808|NCT02843282|BEHAVIORAL|Advanced Reasoning Training|This is a strategy-based intervention to enhance frontal lobe function. Strategies equip participants to improve their strategic attention, integrated reasoning, and innovation abilities.
224184809|NCT01393652|DRUG|PF-05105679|Subjects will receive single ascending doses of PF-05105679 or placebo to investigate safety/tolerability and pharmacokinetics of PF-05105679
224184810|NCT01393652|DRUG|PF-05105679|Subjects will receive single ascending doses of PF-05105679 or placebo to investigate safety/tolerability and pharmacokinetics of PF-05105679
224184811|NCT01393652|DRUG|PF-05105679|Subject will be randomized to a treatment sequence, and assigned to placebo, 2 separate single doses of PF-05105679 in the fasted state and to controlled-release Oxycodone 20 mg (positive control) , with at least one week wash-out between doses.
224308477|NCT00757211|OTHER|questionnaire administration|
223588648|NCT03189836|BIOLOGICAL|ACTR707|autologous T cell product
223588649|NCT03189836|BIOLOGICAL|rituximab|CD20-directed cytolytic antibody
223588650|NCT04858282|OTHER|mobile application (BC-SDM)|"The mobile application (BC-SDM)includes four functions to support SDM activity: Understanding breast cancer, Surgical approach, Choose the right breast cancer knowledge, and Let's make a decision for myself. Patients first read the information in Understanding breast cancer and Surgical approach to receive a tailored education in breast cancer"
223493114|NCT05415774|DEVICE|4 : C1 -C2 - S|"Deep brain stimulation of the substantia nigra pars reticulata and of the subthalamic nucleus according to the order of randomisation (see intervention name) :~* Standard stimulation~* 125Hz at both STN and SNr for C1,~* 125Hz for STN and 60 for SNr for C2"
223588651|NCT01447121|DEVICE|Tatsu/Tradewind Investigational BG Monitoring System|Tradewind is a Bayer investigational meter that used an investigational sensor.
223493115|NCT05415774|DEVICE|5 : C2 - S - C1|"Deep brain stimulation of the substantia nigra pars reticulata and of the subthalamic nucleus according to the order of randomisation (see intervention name) :~* Standard stimulation~* 125Hz at both STN and SNr for C1,~* 125Hz for STN and 60 for SNr for C2"
223493116|NCT05415774|DEVICE|6 : C2 - C1 - S|"Deep brain stimulation of the substantia nigra pars reticulata and of the subthalamic nucleus according to the order of randomisation (see intervention name) :~* Standard stimulation~* 125Hz at both STN and SNr for C1,~* 125Hz for STN and 60 for SNr for C2"
223493117|NCT06988202|PROCEDURE|Pulmonary Vein Isolation (PVI) without Left Atrial Posterior Wall Isolation (PWI)|"A doctor inserts a thin, flexible tube (called a catheter) through a blood vessel, usually in the groin, and guides it to the heart.~Once the catheter is in place, the doctor uses pulsed field electroporation, heat (radiofrequency) or cold (cryoablation) to create small scars in the area where the pulmonary veins connect to the left atrium of the heart.~These scars block the faulty electrical signals that cause AF, helping the heart maintain a normal rhythm."
223588652|NCT03000036|DRUG|Doxorubicin|Patients had prescribed endovenous doxorubicin as part of their chemotherapy regimen (mean cumulative dose 102,66 mg/m2, administered in 4 doses with 21 days interval).
223588653|NCT03000036|DEVICE|Achieva, Philips Medical Systems (3T magnet)|Patients were imaged in supine position in a 3T magnet (Achieva, Philips Medical Systems, Best, The Netherlands). The protocol consisted of electrocardiographically gated cine imaging with steady state free-precession to assess left ventricular (LV) ejection fraction and LV mass. For imaging of late gadolinium-DTPA enhancement (LGE) we used an inversion-recovery-prepared, gradient-echo sequence with segmented acquisition, which was triggered every other heartbeat. LGE images were acquired during end-expiratory breath-holding, after administration of Dotarem. T1 was performed with a Look-Locker sequence with a non-slice-selective adiabatic inversion pulse, followed by segmented gradient-echo acquisition for 17 times after inversion, covering approximately two cardiac cycles. T1 imaging was repeated in the same LV short-axis slice, once before and five to seven times after the injection of gadolinium to cover an approximately 30-min period of slow contrast clearance.
223588654|NCT03000036|DRUG|Gadoterate Meglumine|LGE images were acquired starting within 10 min after bolus administration of a cumulative dose of 0.2 mmol/Kg of gadoterate meglumine (Dotarem, Guerbet, Aulnay-sous-Bois, France).
223588655|NCT01976143|DRUG|NKTR-102|
223588656|NCT01257022|BEHAVIORAL|Familias Unidas|There will be 8 group sessions and 4 family visits. During the group sessions, the facilitator offers support for parents and gently corrects maladaptive interactions between parents and adolescents. During family visits, facilitators assist families in practicing skills and restructuring family interactions. The parent group sessions focus on parental investment in the adolescent's worlds (e.g., peer and school worlds), family communication, family support, behavior management/positive parenting, parental monitoring, adolescent substance use, and adolescent unsafe sex and HIV.
223588657|NCT04256252|DRUG|Rituximab|A scheduled therapeutic regimen with low-dose rituximab was performed.
223588658|NCT04294914|OTHER|Cold Pressor Test|The participant submerges one limb into a tank of cold (1-2 ° C), circulating water.
223588659|NCT04294914|OTHER|Cold Pressor Test + Virtual Reality|The participant submerges one limb into a tank of cold (1-2 ° C), circulating water while interacting with a virtual reality environment
224184812|NCT06018389|BEHAVIORAL|Structural only|"A shared list of school policies for or related to, school-based social events at school premises. The policy initiatives include (but are not limited to): increasing the number of social events without alcohol; promoting non-alcoholic beverages at parties; working with student associations regarding their roles and responsibilities; encouraging parental involvement at school events and disseminating the schools' alcohol policy among students and parents. The school principal and management will be responsible for the implementation and enforcement of the policies.~The Information-based interactive parent meetings will be 45 minutes and will take place at the schools. Parents will be offered concrete, research-informed advice about how they can reduce risk of hazardous substance use and promote well-being among their adolescents. Following a 15-minute presentation, the group leader facilitates a discussion and exchange of experience between parents."
223493118|NCT06988202|PROCEDURE|Pulmonary Vein Isolation (PVI) with Left Atrial Posterior Wall Isolation (PWI)|PVI with an additional step where the doctor also isolates the back wall (posterior wall) of the left atrium.
223588660|NCT02001337|OTHER|medical chart review|baseline, quarterly follow-up for 24 months
223588661|NCT02001337|OTHER|survey administration|baseline
223588662|NCT02001337|OTHER|Specimen collection|baseline
223588663|NCT03582696|BEHAVIORAL|CHANGE Study|The CHANGE strategy is designed to improve the dissemination and implementation of CVD EBIs by strengthening clinical-community linkages
223588664|NCT06147583|OTHER|Simulation of an insulin pump failure|The intervention will consist in simulating an insulin pump failure by suspending insulin infusion and monitoring the consequent hyperglycemia.
223588665|NCT01870648|DRUG|Ondansetron|Eligible children will receive one weight based (0.13 - 0.26 mg/kg) dose of an oral ondansetron disintegrating tablet. Subsequent therapy will be in accordance with World Health Organization guidelines as dictated by the child's hydration status.
223493119|NCT06991114|DRUG|Allogeneic NK Cells|AlloNK, dosed after a conditioning regimen, combined with Rituximab.
223493120|NCT06170827|DRUG|AIO-001|AIO-001 Solution for SC injection.
223493121|NCT06990724|OTHER|Videogame Intervention|No Baby No video game
224184813|NCT06018389|BEHAVIORAL|Structural+Group MI|"Within school classes, students are divided into groups of 5-8 students and each group will be assigned a group leader from the research team. The group-based Motivational Interviewing (group MI) is manualized and consists of two one-hour group sessions administered over two consecutive weeks. The first session is focused on Tell your story, Gains from not drinking, and Social norms. In the second session, the focus is on Personal values, Linking values with behavior and Planning/choices regarding alcohol. Both group MI sessions will take place at the schools during the school day."
224184814|NCT06412289|DIAGNOSTIC_TEST|US-GUIDED PERCUTANEOUS LUNG NEEDLE BIOPSY|The ultrasound investigation will be conducted using the ultrasound machine supplied to the Center involved in the trial and usually used in eTTNA procedures. Before the procedure, the vital signs of the patient will be noted and each operator will choose the most appropriate position for the sampling, based on the location of the lesion. The thoracic area to biopsy will then be defined and then there will be the setting of the sterile field. At this point, local anesthesia with a maximum of 20ml of 2% lidocaine will be administrated, marking down this time as the time of the beginning of the procedure. 18 Gauge needles will be used to collect the sample. For each patient, there will be collected a minimum number of one and a maximum number of three bioptic sampling .
224184815|NCT06412289|DIAGNOSTIC_TEST|CT-GUIDED PERCUTANEOUS LUNG NEEDLE BIOPSY|The CT scan will be performed using the CT machinery equipped by the Center involved in the trial and usually used for the tTTNA procedures. Before the procedure, the vital signs of the patient will be noted and each operator will choose the most appropriate position for the sampling, based on the location of the lesion. The thoracic area to biopsy will then be defined and then there will be the setting of the sterile field. At this point, local anesthesia with a maximum of 20ml of 2% lidocaine will be administrated, marking down this time as the time of the beginning of the procedure. 18 Gauge needles will be used to collect the sample. For each patient, there will be collected a minimum number of one and a maximum number of three bioptic sampling .
224184816|NCT03263052|DRUG|Tacrolimus XR (Envarsus)|Elderly patients (age 60 or older) on tacrolimus experiencing neurological AEs (tremor, insomnia, vertigo, photophobia, mood disturbances, or headache) presumably from tacrolimus immediate-release or tacrolimus XL will be converted to Envarsus. This conversion will be based on the Envarsus package insert which is a 20% reduction in total daily dose and is taken once a day. The conversion from Astagraf to Envarsus will be a 36% reduction.
223493122|NCT06990724|OTHER|Commercial game control|Commercial video game
224184817|NCT03674645|DEVICE|MRI acquisitions|Procedure of the study is an MRI exam without any injection or invasive procedure, that will be performed on the Siemens Magnetom Aera imager of Liryc institute (L'Institut de RYthmologie et modélisation Cardiaque) (Xavier Arnozan site - Bordeaux)
224184818|NCT05734586|OTHER|EAT-10 (Eating assessment Tool) screening questionnaire|After inclusion, issuance of the EAT-10 screening questionnaire for swallowing disorders by the healthcare team
224184819|NCT05734586|PROCEDURE|Protective measures for the upper airways|"In the event of an EAT ≥2 score, immediate implementation or within three days by the healthcare team of protective measures for the upper airways in 3 sectors:~1: Postural maneuvers; 2: Hygienodietetic rules; 3: Food textures"
224184820|NCT00752518|DRUG|bortezomib|
224184821|NCT05986409|OTHER|light cover|10 wards were randomly selected as the intervention group (opaque black tape covering part of the light source), and another 10 wards were selected as the control group (no intervention).
224184822|NCT02505945|DRUG|Omeprazole|
223493123|NCT06989970|COMBINATION_PRODUCT|Active tDCS on the DLPFC + Cognitive Intervention(s)|"Combination Product: Active tDCS and cognitive training intervention. Participants will receive cognitive training paired with active tDCS for 3 weeks, followed by follow-up sessions immediately after and 2 months later, during which the patient's performance on the cognitive training exercises and executive functions will be assessed. Cognitive training exercises have been drawn from a computer-aided cognitive training program (BrainHQ).~For the active tDCS, stimulation will be delivered by a battery-driven constant current stimulator. The electrical current will be administered to the left DLPFC at an intensity of 2 milliamperes (mA) (estimated current density 0.04 mA/cm2; estimated total charge 0.048 Coulombs/cm2) in a ramp-like fashion for a maximum of 20 minutes."
223493124|NCT06989970|COMBINATION_PRODUCT|Sham tDCS on the DLPFC + Cognitive Intervention(s)|"Combination Product: Sham tDCS and cognitive training intervention~Participants will receive cognitive training paired with sham tDCS for 3 weeks, followed follow-up sessions immediately after and 2 months later, during which the patient's performance on the cognitive training exercises and executive functions will be assessed. Cognitive training exercises have been drawn from a computer-aided cognitive training program (BrainHQ).~For the sham tDCS, electrodes will be placed in the same area as in the active tDCS condition, but current will be administered in a ramp-like fashion but after the ramping the intensity will drop to 0 mA. Current under the Sham condition will last for a maximum of 30 seconds."
223493125|NCT06585462|DRUG|AMG 513|AMG 513 will be administered by SC or IV injection.
223588666|NCT01870648|DRUG|Placebo|Eligible children will receive one dose of an oral disintegrating Placebo (sugar pill) tablet. Subsequent therapy will be in accordance with World Health Organization guidelines as dictated by the child's hydration status.
224184823|NCT02505945|DEVICE|LINX Reflux Management System|
224184824|NCT04079699|DIAGNOSTIC_TEST|Liquid Biopsy|Measuring biomarkers in blood and urine samples
224184825|NCT04079699|DIAGNOSTIC_TEST|Standard biopsy|Histological examination of tissue biopsies
224184826|NCT01097057|DRUG|Carboplatin|Given IV
224184827|NCT01097057|DRUG|Etoposide|Given IV
224184828|NCT01097057|BIOLOGICAL|Filgrastim|Given SC
224184829|NCT01097057|DRUG|Ifosfamide|Given IV
224184830|NCT01097057|PROCEDURE|Leukapheresis|Given through catheter
224184831|NCT01097057|DRUG|Plerixafor|Given SC
224184832|NCT01097057|BIOLOGICAL|Rituximab|Given IV
224184833|NCT03586063|OTHER|Data collection|"This is a non-interventional (observational) national multicentre prospective study.~Treatment was administered according to the Summary of Product Characteristics (SmPC): maximum 6 injections administered every 28 days.~The decision to prescribe GnRH-a (Diphereline 3,75 mg) was made prior to and independently from the decision to enroll the patient into the study."
223493126|NCT06585462|DRUG|Placebo|Placebo will be administered by SC or IV injection.
223493127|NCT06585462|DRUG|AMG 513|AMG 513 will be administered by SC injection.
223493128|NCT06585462|DRUG|Placebo|Placebo will be administered by SC injection.
223745646|NCT01327300|OTHER|Placebo|4 capsules (.375 gm sugar pill capsules) administered orally once a day. This group will receive the placebo for 12 weeks then a wash out for 3 weeks prior to crossing over to the drug arm.
223745647|NCT00115973|DEVICE|pump|
223745648|NCT00115973|DRUG|insulin aspart|
223493133|NCT04375631|DRUG|Cladribine|Given IV
223493134|NCT04375631|DRUG|Cyclophosphamide|Given IV
223493135|NCT04375631|DRUG|Cyclosporine|Given IV then PO
223493136|NCT04375631|DRUG|Cytarabine|Given IV
223493137|NCT04375631|BIOLOGICAL|Filgrastim|Given SC
223493138|NCT04375631|PROCEDURE|Hematopoietic Cell Transplantation|Undergo HCT
223493139|NCT04375631|DRUG|Mitoxantrone|Given IV
223493140|NCT04375631|DRUG|Mycophenolate Mofetil|Given IV or PO
223493141|NCT04375631|DRUG|Mycophenolate Sodium|Given PO
223493142|NCT04375631|RADIATION|Total-Body Irradiation|Undergo TBI
223493143|NCT04375631|DRUG|Idarubicin|Given IV
223493144|NCT04375631|DRUG|Fludarabine|Given IV
223493145|NCT04375631|DRUG|Cytarabine|Given IV
223493146|NCT04375631|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
223493147|NCT04375631|PROCEDURE|Echocardiography Test|Undergo ECHO
223493148|NCT04375631|PROCEDURE|X-Ray Imaging|Undergo x-ray
223493149|NCT04375631|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy and aspirate
223493150|NCT04375631|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow biopsy and aspirate
223493151|NCT04375631|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223493152|NCT06860906|PROCEDURE|V-Y advancement flap|anal stenosis treated by removal of scarring tissue and cover the defect using V-Y advancement flap
223493153|NCT06994065|DRUG|Ferric Carboxymaltose (FCM)|This study will dose each patient according to their calculated iron deficit through Ganozi formula Iron deficit(mg) = bodyweight(kg) x (target Hb - actual Hb) (g/dl) x 2.4 + Iron storage depot(mg)
223493154|NCT06994065|DRUG|Iron Sucrose injection|This study will dose each patient according to their calculated iron deficit through Ganozi formula Iron deficit(mg) = bodyweight(kg) x (target Hb - actual Hb) (g/dl) x 2.4 + Iron storage depot(mg)
223588667|NCT05350189|DRUG|Gadobutrol (Gadavist/Gadovist, BAY86-4875)|At discretion of attending physician
223493155|NCT05330442|BEHAVIORAL|Written Exposure Therapy (WET)|The WET protocol for primary care settings consists of six, 30-minute sessions. The first session consists of psychoeducation of PTSD and treatment rationale. Written narratives are conducted in sessions 2-6, following specific writing instructions and 20 minutes of writing in each session.
223493156|NCT06865417|DRUG|Filgotinib|IP will be provided as commercially developed film-coated tablets (100 and 200 mg strength) or reduced-strength (65 mg) age-appropriate film-coated tablets for use in pediatric subjects aged at least 8 years and needs to be taken orally q.d. at approximately the same time every morning (with or without food).
223493157|NCT04972760|DRUG|Baricitinib|Baricitinib, 4 mg/d, oral route for 24 weeks
223493158|NCT04972760|DRUG|Placebo|Placebo, 4 mg/d, oral route for 24 weeks
223493159|NCT06863740|DRUG|Cannabis oil|5:1 CBD:THC oral formulation with a concentration of 25 mg/g CBD and 5 mg/g THC in a pharmaceutical grade medium chain triglyceride (MCT) oil.
223493160|NCT06863740|DRUG|Cannabis placebo|Placebo oil
223493161|NCT06864689|BEHAVIORAL|Video-log (vlog) series with videos tailored to cisgender Black women or to healthcare providers|This intervention is a video-log (vlog) series based health communication intervention that will be disseminated through community health centers (CHCs) and social media to increase willingness for and use of PrEP among cisgender Black women and to increase willingness to prescribe and refer PrEP among healthcare providers.
223493162|NCT06503614|DRUG|Durvalumab|Durvalumab 1500mg IV
223493163|NCT06503614|DRUG|Monalizumab|Monalizumab 1500mg IV
223493164|NCT06611813|DRUG|Neoadjuvant Chemotherapy in Combination with Toripalimab|Epirubicin (or Liposomal Doxorubicin)+Cyclophosphamide, intravenous infusion of 100 mg/m2. Epirubicin (or 35 mg/m2 liposomal doxorubicin)+600 mg/m2 cyclophosphamide, starting from the first day of the week, for a total of 12 weeks. Paclitaxel, administered intravenously at a dose of 260 mg/m2 every 3 weeks for a total of 12 weeks. During neoadjuvant chemotherapy and postoperative adjuvant therapy, use of Toripalimab: intravenous infusion of 240 mg, once every 3 weeks, combined with preoperative neoadjuvant and postoperative adjuvant therapy for a total of 1 year.
223493165|NCT06611813|DRUG|HR+ HER2 breast cancer|During neoadjuvant chemotherapy and postoperative adjuvant therapy, use of Toripalimab: intravenous infusion of 240 mg, once every 3 weeks, combined with preoperative neoadjuvant therapy and postoperative adjuvant therapy for a total of 1 year.
223493166|NCT06675864|BIOLOGICAL|rapcabtagene autoleucel (YTB323)|CAR-T cell suspension for intravenous infusion
223493167|NCT06861543|BIOLOGICAL|TMT101 Injection|Three dose levels are planned to be explored: 0.1 mg, 0.2 mg, and 0.4 mg. The initial dose is 0.1 mg with a dose reduction for safety reasons, the level of dose reduction will be discussed jointly between the investigator and the sponsor. TMT101 will be injected intramuscularly, Once a week,a total of 9 times
223493168|NCT06860321|DEVICE|Adjunct antibacterial home-use dual-light medical device|Crossover active intervention.
223493169|NCT06860321|OTHER|Regular oral self care|Crossover regular intervention.
223493170|NCT06042283|BEHAVIORAL|Metacognitive Training-Silver|"The Metacognitive Training-Silver program includes the following topics: Thinking and Reasoning 1 (module 1), Memory (module 2), Thinking and Reasoning 2 (module 3), Self-Esteem (module 4), Thinking and Reasoning 3 (module 5), Behaviors and Strategies (module 6), Thinking and Reasoning 4 (module 7) and Perception of Feelings (module 8).~Each session is planned to last 45-60 minutes. Materials will be used in the Metacognitive Training-Silver program are PPT (Power Point Presentations) slides, videos, homework exercises, and yellow-red cards.~Metacognitive Training-Silver is planned to be applied face-to-face in 3 groups (12, 10, and 10 people) at scheduled times in a quiet room suitable for the group. In order to increase compliance with the Metacognitive Training-Silver program, the sessions will be applied during the routine treatment period."
223493171|NCT06999629|DIETARY_SUPPLEMENT|Relaxation Placebo Control|Participants will use their Relaxation Placebo Control as directed for a period of 6 weeks.
224184834|NCT01101321|DRUG|Reformulated OXY (Totowa) (oxycodone HCl)|Reformulated OXY 80-mg tablet (Totowa) x 1 dose taken without food.
224184835|NCT01101321|DRUG|Reformulated OXY (Wilson) (oxycodone HCl)|Reformulated OXY 80-mg tablet (Wilson) x 1 dose taken without food.
224184836|NCT02063802|DRUG|metformin|total dose: 1 gr per day (250mg tablets). The patient takes 2 tablets with breakfast and 2 tablets with dinner and 2 placebo tablets with food by mouth for four months.
224184837|NCT02063802|DIETARY_SUPPLEMENT|Conjugated Linoleic Acid|total dose: 3gr/día(500mg capsules). The patient takes 2 capsules with breakfast, 2 capsules with lunch and 2 capsules with dinner for four months.
224184838|NCT02063802|DRUG|Placebo|Total dose 6 tablets per day. The patient takes 2 tablets with breakfast, two tablets with lunch and two tablets with dinner by mouth for four months
224184839|NCT02063802|BEHAVIORAL|Healthy habits program|
224184840|NCT00005990|DRUG|tipifarnib|
224184841|NCT00005990|DRUG|topotecan hydrochloride|
223493172|NCT06999629|DIETARY_SUPPLEMENT|Relaxation Active Product 1|Participants will use their Relaxation Active Product 1 as directed for a period of 6 weeks.
223493173|NCT06999629|DIETARY_SUPPLEMENT|Relaxation Active Product 2|Participants will use their Relaxation Active Product 2 as directed for a period of 6 weeks.
223588668|NCT05464264|DRUG|Ketamine|Participants suffering from TRD will receive their ketamine treatment intravenously twice weekly for two weeks (4 treatments in total). A dose of 0.5 mg/kg is infused over 40 minutes, with dose adjustments made at the psychiatrist's discretion.
223588669|NCT02517320|DRUG|MT-3995 Low|
223588670|NCT02517320|DRUG|MT-3995 Middle|
223588671|NCT02517320|DRUG|MT-3995 High|
224184842|NCT01110603|DRUG|MK-4827|Capsules, orally, once daily, on Days 1 and 3 of each 21- or 28-day Cycle, at the assigned dose level, starting at 40 mg per dose.
223588672|NCT02517320|DRUG|Placebo|
223588673|NCT01729494|DRUG|Alemtuzumab|Alemtuzumab will be dosed on day of transplant (Study Day 1) at dose of 30 mg given intravenously (IV) over a period of 2 hours after induction of anesthesia. Methylprednisolone IV will be administered 30-60 minutes prior to the administration of alemtuzumab.
223588674|NCT01729494|DRUG|rabbit antithymocyte globulin|Rabbit antithymocyte globulin will be dosed post-operatively at a total cumulative dose of 4.0-6.0mg/kg given by days 5-10 post-transplant. It will be administered by local standards of care with the following recommendations. The initial intravenous intra-operative dose will be administered approximately one hour after the methylprednisolone dose. The first dose will be administered so that approximately 25% of the dose is infused prior to revascularization of the graft. Subsequent doses will be administered over a minimum of 4 hours. Premedication with acetaminophen 650mg p.o. and diphenhydramine 25mg p.o. prior to rabbit antithymocyte globulin dose will be given to reduce the incidence of infusion reactions.
223588675|NCT01729494|DRUG|Belatacept|Belatacept will be administered via intravenous (IV) infusion according to the FDA approved dosage recommendations. Subjects randomized to belatacept arms will receive the first dose of IV belatacept (10 mg/kg) within 12-24 hours post reperfusion. The second dose will be given between post-transplant days 4 -6 (Study Days 5-7), and then study days 14, 28, 56, and 84 (12 weeks) and then subjects will receive belatacept at the maintenance dose of 5 mg/kg every 4 weeks until completion of the trial at 24 months (104 weeks). Study Day 1 is defined as the day of transplant.
223745649|NCT02807350|DEVICE|Overminus treatment|spectacles with full cycloplegic refraction plus 2.50 D overminus added to the sphere
223745650|NCT02807350|DEVICE|Non-overminus treatment|spectacles with full cycloplegic refraction without overminus
224184843|NCT01110603|DRUG|carboplatin|Intravenous infusion, at AUC 5, once, on Day 3 of each 21- or 28-day cycle
224184844|NCT01110603|DRUG|paclitaxel|Intravenous infusion, 175 mg/m2, once, on Day 3 of each 21-day cycle
224184845|NCT01110603|DRUG|liposomal doxorubicin|Intravenous infusion, 30 mg/m2, once, on Day 3 of each 28-day cycle
224184846|NCT02716402|RADIATION|Cerebral MRI and V/Q SPECT/CT|Cerebral MRI and V/Q SPECT/CT
224184847|NCT06661603|BEHAVIORAL|GSY Yoga Intervention|In the GSY yoga intervention, where participants received 90 minutes/week yoga intervention for duration of 10 weeks.
224184848|NCT05585099|OTHER|Exercise|Participants will stand on lower body positive pressure treadmill and participate in walking exercise.
224184849|NCT05597852|DEVICE|SpaceOAR|SpaceOAR hydrogel spacer between the prostate and rectum, in an effort to decrease toxicity and improve patient's bowel quality of life.
224184850|NCT02738073|DRUG|Control: Saline|
224184851|NCT02738073|DRUG|Tranexamic Acid|
224184852|NCT02488265|OTHER|Balance Training|Balance training with rhythmical (BRT), is a motor program to improve balance associated with rhythmical auditory cues (RACs).
224184853|NCT02488265|OTHER|Screening to prevent falls|Questionary to Scheduled screening falls and progression in training will be used to indicate the capacity to continue to progress.
224184854|NCT05799482|OTHER|Qualitative Interview|Qualitative, semi-structured interview
224184855|NCT04501991|OTHER|antidiabetic treatment|Every kind of antidiabetic treatment, oral or injective, were considered including patients treated only with diet
224184856|NCT01102439|DRUG|Clopidogrel|300 mg loading dose, then 75 mg daily
224184857|NCT01102439|DRUG|Clopidogrel|600 mg loading dose, 150 mg daily day 2-7, then 75 mg daily
223493174|NCT07002125|OTHER|Whole Body Vibration|Each exercise session will be performed with a frequency of 30 Hz and an amplitude of 2 mm. Participants are in a 110° squat position on the platform (the degree will be adjusted using a goniometer). Participants will exercise for 16 minutes from week one to week three, 20 minutes from week four to week six and 24 minutes from week seven to week eight, respectively (8 iterations and 1 minute of vibration with 1 minute interval between each iteration)
224184858|NCT01102439|DRUG|Aspirin|81 mg daily
224184859|NCT01102439|DRUG|Aspirin|325 mg daily
224184860|NCT05961124|DRUG|Niraparib|Niraparib (Zejula) will be administered as an oral treatment once daily (continuously in a 28-day cycle). Niraparib will be administered in a dose escalation design where patients will start at a dose of 100 mg PO daily for the first two cycles (28-days each cycle), if tolerated, the dose will be increased to 200 mg PO daily for the third and fourth cycle.
224184861|NCT03437980|DRUG|propofol|A bolus of 0.7 mg/kg will be given initially, additional incremental doses of 20 mg propofol will be given if the patient complained of pain or moved arms towards the back. Patients will be sitting on the middle of the operating table facing towards the table's foot. The table's foot will be dropped 45 degrees for a comfortable chair position, Monitoring through pulse oximeter (SaO2), non-invasive blood pressure (NIBP) adjusted every 2 minutes automatic measuring and capnography tube in contact with nostrils.
224184862|NCT01708473|DRUG|Advil|One (1) tablet 800 mg Advil one hour prior to treatment.
224184863|NCT01708473|DRUG|Lortab|One (1) tablet 10/500 mg of Lortab one hour prior to treatment.
224184864|NCT01708473|DEVICE|Ulthera System Treatment|Focused ultrasound energy delivered below the surface of the skin
224184865|NCT03547674|OTHER|barefoot|Gait analysis under 4 conditions (barefoot, shoes only, untuned AFO with shoes, tuned AFO with shoes) will be performed in a random order.
224184866|NCT03547674|OTHER|shoes only|Gait analysis under 4 conditions (barefoot, shoes only, untuned AFO with shoes, tuned AFO with shoes) will be performed in a random order.
224184867|NCT03547674|OTHER|untuned AFO with shoes|Gait analysis under 4 conditions (barefoot, shoes only, untuned AFO with shoes, tuned AFO with shoes) will be performed in a random order. AFO are walking aids to improve gait pathologies. They are custom-built using plaster casts. AFO for equinus and/or drop foot pathologies are specifically indicated to control excessive ankle plantar flexion. Push-up elements that return the energy from the stance-phase to support lifting the foot during the swing-phase (similar to a spring) are used.
224184868|NCT03547674|OTHER|tuned AFO with shoes|Gait analysis under 4 conditions (barefoot, shoes only, untuned AFO with shoes, tuned AFO with shoes) will be performed in a random order. Modular AFO tuning means that patients try different pushup elements with varying stiffness and design before the final design is determined.
224184869|NCT02701374|DRUG|TRK-700|
224184870|NCT02701374|DRUG|Placebo|
224184871|NCT00124865|BIOLOGICAL|rFla-MBP|
224184872|NCT02681094|DRUG|Dapagliflozin|5mg, orally, Green, plain, diamond-shaped, film-coated tablet
224184873|NCT02681094|DRUG|Placebo for Dapagliflozin|Does not contain active ingredient, orally, Green, plain, diamond-shaped, film-coated tablet
224184874|NCT02681094|DRUG|Saxagliptin|5mg, orally, Plain, yellow, biconvex, round, film-coated tablet
224184875|NCT02681094|DRUG|Placebo for Saxagliptin|Does not contain active ingredient, orally, Plain, yellow, biconvex, round, film-coated tablet
223493175|NCT07002125|OTHER|Aerobic Exercise|From week one to week three, from week four to week six and from week seven to week eight, the participants will exercise for 30 minutes (5 minutes of running at 60-70% of heart rate and 5 minutes of active rest at 30-45% of maximum heart rate), 42 minutes (7 minutes of running at 60-70% of heart rate and 7 minutes of active rest at 30-45% of maximum heart rate) and 60 minutes (10 minutes of running at 60-70% of heart rate and 10 minutes of active rest at 30-45% of maximum heart rate). The exercise sessions consist of warm-up, main program and cool-down phases.
223493176|NCT07002112|BIOLOGICAL|LVIVO-TaVec100 product|Prior to infusion of the LVIVO-TaVec100 product, subjects will receive bridging therapy if needed.
223493177|NCT07001241|BEHAVIORAL|Telehealth Exercise Program|BfitBwell-TP is a 12-week telehealth exercise intervention. Exercise prescriptions are created, personalized, and delivered by Cancer Exercise Specialists. Exercise content is delivered using a combination of videoconference sessions and a commercial personal training application (accessible via smartphone or internet browser). Patient-reported symptoms (specifically cancer-related fatigue) are assessed every two weeks via emailed surveys. Survey scores are compared to a reference chart of predicted improvements during the program, developed from an established clinical exercise oncology program. Additional videoconference sessions are initiated for participants demonstrating lower than expected symptom improvement, with the goal of adapting the current exercise prescription to improve symptom response.
223745651|NCT03890770|DRUG|BMS-986165|Oral administration
223745652|NCT01437007|DRUG|TKM-080301|
223745653|NCT02877277|DIETARY_SUPPLEMENT|Vitamin C|Oral intake of vitamin C tablet (500 mg) daily for 56 days
224184876|NCT03595072|OTHER|observation of VNS stimulation effects|ECOGs will be recorded during VNS stimulation and inter stimulation periods
224184877|NCT02133612|DRUG|paclitaxel; cisplatin|The adjuvant chemotherapy regimen consisted of paclitaxel 150mg/m2 intravenously (IV) over 3 hours on day 1, followed by cisplatin 50mg/m2 IV on day 2 every 14 days for 4 to 6 cycles.
224184878|NCT04277286|BEHAVIORAL|survey|"Behavioral study of patients who are in the Transend Program (compliance in follow-up visits after transfert from pediatric to adult care in the 24 months)"
224184879|NCT05217017|DIAGNOSTIC_TEST|FACS|Diagnostic Test: Assessment of disability and behavior (by questionnaires)
224184880|NCT01270139|PROCEDURE|Transplantation of nanoparticles|60 patients into nanogroup with the use of 60/15-70/40 nm silica-gold nanoparticles (NPs) transplanted by endoscopic cardiac surgery in the composition of bioengineered on-artery patch grown on the basis of biopolymeric scaffold and host circulating CD45-CD34-CD73+CD105+ progenitor cells
224184881|NCT01270139|PROCEDURE|Transplantation of iron-bearing nanoparticles|60 - into ferro-magnetic group with 60/15-70/40 nm silica-gold iron-bearing NPs with delivery in hand of magnetic navigation system
224184882|NCT01270139|DEVICE|Stenting|60 - in sirolimus-eluting stenting control
224184883|NCT01512758|DRUG|Alisertib|Alisertib enteric-coated tablets
224184884|NCT00134563|DRUG|Teriflunomide|"Film-coated tablet~Oral administration"
224184885|NCT00134563|DRUG|Placebo (for teriflunomide)|"Film-coated tablet~Oral administration"
224184886|NCT05517031|OTHER|ASDAS score , VAS score, BASFI score , Katz ADL index|Scores that done on patient to fullfill criteria of diagnosis , and measure affection of disease on patients and their daily living activity
224184887|NCT01973920|DRUG|Oshadi Icp|
224184888|NCT04081246|DEVICE|Bipolar transurethral modified en bloc resection of bladder tumour|Olympus TURis Bipolar HF-resection electrode (Model: WA22306D)
224184889|NCT03280446|DEVICE|Intragen fractional radiofrequency with NeuViVa|The Transcutaneous Fractional Radiofrequency Device (TFRF) is a minimal risk device that is currently cleared by the FDA K142833.The device uses a non-invasive, transepithelial treatment probe to elevate epithelial tissue temperatures to 40-45 oC for the purpose of promoting tissue contracture. Real-time tissue impedance monitoring will be carried out using the treatment probe.
224184890|NCT02360358|DRUG|Tiscover|two step procedure, week 0 and week1. Dosage depends on wound size.
224184891|NCT02360358|OTHER|AS210|two step procedure, week 0 and week1. Dosage depends on wound size.
224184892|NCT00987558|DRUG|Eslicarbazepine acetate|
223493178|NCT04193891|OTHER|Modified Atkins Diet|The ketogenic diet, where individuals restrict their carbohydrate intake and significantly increase their intake of fats, was initially primarily used in children with severe epilepsy, often due to genetic syndromes. Recently, with the advent of slightly less restrictive forms of ketogenic dietary therapy (e.g. the modified Atkins diet), it has begun to be used in adults with intractable seizures who are not surgical candidates.
223493179|NCT05779930|BIOLOGICAL|CD19 specific Chimeric Antigen Receptor T Cell|Infusion of CD19 CAR-T Cells manufactured on-site using the CliniMACS Prodigy
223493180|NCT07003685|DEVICE|GDD in posterior chamber|GDD in posterior chamber
223493181|NCT07003685|DEVICE|GDD in aterior chamber|GDD in anterior chamber
223493182|NCT07011849|DRUG|Pembrolizumab|Given by IV
223493183|NCT07011849|DRUG|Lenvatinib|Given by mouth
223493184|NCT05694364|DRUG|Fludarabine|Fludarabine is an antimetabolite given prior to lymphodepletion.
223493185|NCT05694364|DRUG|Cyclophosphamide|Cyclophosphamide is a nitrogen mustard-derivative, polyfunctional alkylating agent given prior to lymphodepletion.
223493186|NCT05694364|BIOLOGICAL|PRGN-3007|PRGN-3007 T cells are autologous T cells that are genetically modified ex vivo with the Sleeping Beauty (SB) system to express a ROR1-specific chimeric antigen receptor (ROR1 CAR), membrane bound interleukin-15 (mbIL15), a kill switch derived from truncated form of human epidermal growth factor receptor (HER1t) and include a built-in mechanism for intrinsic downregulation of programmed cell death receptor 1 (PD-1) expression on UltraCAR-T cells.The transgenes are delivered from a SB transposon which ensures co-expression all transgenes in all transfected cells. T cells are selected from the apheresis product and can be modified with the SB system to manufacture the T cells with the potential of infusing within 2 days from genetic modification.
223493187|NCT07016971|DRUG|CBG/CBD Oil|Participants will receive a commercially available high CBG/CBD hemp extract oil that also contains small amounts of cannabichromene (CBC). The product is formulated as a sublingual oil and administered twice daily. Participants will take 0.5 mL of the oil sublingually twice daily during the first week, followed by 1 mL sublingually twice daily for the remaining 11 weeks. The oil has a defined and independently verified cannabinoid and terpene profile and is marketed as a dietary supplement.
223493188|NCT07018362|OTHER|restricted fetal growth|The fetus is of abnormal size and has not reached its genetic growth potential in utero. Fetal birth weight is less than two standard deviations from the average weight for the same gestational age, or less than the 10th percentile of normal weight for the same age.
223493189|NCT06875180|OTHER|Tele-rehabilitation exercise|For this group, McKenzie extension exercises were applied to 50 patients online via the zoom platform.
223493190|NCT06875180|OTHER|Face-to-face exercise|For this group, 50 patients face-to-face in the clinical environment under the supervision of a physiotherapist in charge.
224184893|NCT00987558|DRUG|Simvastatin|
223493191|NCT06612294|BEHAVIORAL|PEF Interventional Session|3 sessions over 6 weeks for asthma management
223493192|NCT06612294|BEHAVIORAL|Control Sessions|3 sessions over 6 weeks for asthma management
223493193|NCT06612294|BEHAVIORAL|Control Booster|A single booster session after the 6-months assessments are completed.
223493194|NCT06612294|BEHAVIORAL|Active booster|A single booster session after the 6-months assessments are completed.
223493195|NCT06683352|BIOLOGICAL|Investigational Influenza Vaccine|Investigational Influenza Vaccine
224184894|NCT02318641|DEVICE|oximetry|Retinal oximetry will be performed with Oxymap.
223493196|NCT06683352|BIOLOGICAL|COVID-19 Vaccine|Pfizer-BioNTech COVID-19 Vaccine
223493197|NCT06683352|COMBINATION_PRODUCT|Influenza and COVID Combination Vaccine|Combined investigational influenza and Pfizer-BioNTech COVID-19 Vaccine
223493198|NCT06683352|BIOLOGICAL|Licensed Influenza Vaccine 1|Licensed Influenza Vaccine 1
223493199|NCT06683352|BIOLOGICAL|Licensed Influenza Vaccine 2|Licensed Influenza Vaccine 2
223493200|NCT06683352|OTHER|Placebo|Saline
223493201|NCT07023302|DRUG|Upadacitinib|Oral Tablets
224184895|NCT04325490|DRUG|Liquid powder|apply the study drug 1 fingertip unit to cover intertrigo lesion twice a day for two weeks.
224184896|NCT04325490|DRUG|Hydrocortisone cream 1%|apply the study drug 1 fingertip unit to cover intertrigo lesion twice a day for two weeks.
224184897|NCT05411705|DRUG|rhTPO|rhTPO 300U/kg/d QD, subcutaneous injection applied for 5 days per cycle, total 3 cycles. If the patient's platelet count showed a trend of continuous decline and/or was accompanied by the risk of bleeding during the treatment or after the completion of 5 doses of rhTPO, the investigator judged that rhTPO should be continued for treatment, and rhTPO could be administered subcutaneously at 300U/kg/ day for a maximum of 14 doses per cycle. Discontinue when the absolute platelet count increases by ≥50×10\^9/L or when the platelet count rises to ≥250×10\^9/L.
223493202|NCT07023302|DRUG|Upadacitinib Placebo|Oral Tablets
223493203|NCT04950686|BEHAVIORAL|Media Aware for Young Adults|Media Aware for Young Adults is a web-based sexual and relationship health promotion program designed for young adults that uses a media literacy education (MLE) approach.
223493204|NCT04950686|BEHAVIORAL|Health Aware for Young Adults|Media Aware for Young Adults is a web-based sexual and relationship health promotion program designed for young adults.
223493205|NCT05849740|DRUG|Daratumumab and corticosteroid treatment|Daratumumab and corticosteroid treatment
223493206|NCT07021443|OTHER|non-interventional|non-interventional
223493207|NCT02184013|PROCEDURE|Catheter ablation|Catheter ablation (in addition ot PVI) guided by ECGI mapping, and atrial fibrosis mapping (DE-MRI).
223493208|NCT05931380|DRUG|Orforglipron|Administered orally
223493209|NCT05931380|DRUG|Placebo|Administered orally
224184898|NCT05411705|DRUG|Control|Non-rhTPO treatment
224184899|NCT04201223|BEHAVIORAL|FLARE Intervention|\[See arm/group descriptions\]
224184900|NCT00145080|BEHAVIORAL|Disease Management Assessment|
224184901|NCT03253380|OTHER|Early Rehabilitation Program In Critically Ill Chronic Obstructed Airway Disease patients|Early rehabilitation of MV patients in the respiratory ICU
224184902|NCT01594164|RADIATION|Cone Beam Computed Tomography|CBCT scan of upper airway, in upright position.
224184903|NCT01594164|RADIATION|High Resolution Computed Tomography|HRCT scan of upper airway, in supine position.
224184904|NCT04545645|BEHAVIORAL|median nerve mobilization|The patient is placed in a supine position and his cervical spine with 25º of lateral flexion on the opposite side of the member in which we perform the test. First a passive scapular depression is performed, 90º of shoulder abduction combining external shoulder rotation. Next, a supination of the forearm is performed with wrist extension and finger extension. Finally, the elbow is extended to the limit of resistance or when the investigator observes the elevation of the shoulder girdle.
224184905|NCT04545645|BEHAVIORAL|Neural stress provocation with cognitive auditory distraction|Neural provocation of the median nerve is performed but an auditory distraction is added with a metronome with a constant time of 50 beats per minute.
224184906|NCT04545645|BEHAVIORAL|Providing neural stress with a motor distraction|The neural provocation of the median nerve is performed and we add a motor distraction that consists of the patient intermittently squeezing a ball with the opposite hand.
224184907|NCT04545645|BEHAVIORAL|Neural stress provocation with auditory and motor cognitive distraction.|The neural provocation of the median nerve is performed, we add auditory distraction with the metronome with a constant time of 50 BPM and a motor distraction consisting of squeezing a ball to the rhythm that sounds the metronome.
224184908|NCT00079079|DRUG|carboplatin|
224184909|NCT00079079|DRUG|cisplatin|
224184910|NCT00079079|DRUG|gemcitabine hydrochloride|
224184911|NCT00490828|DRUG|Hydrocortisone|Hydrocortisone
223493210|NCT07024082|OTHER|Land-based Liuzijue exercise|This group includes 40 patients.Will be Performed twice a week from 9:00 to 10:00 a.m. in the rehabilitation department of Shanghai Yue-Yang Hospital under the guidance of an experienced instructor. The LG exercise program consisted of three parts: (1) Warm ups: 5-10 min of stretching and joint activity covering the limbs, neck, and trunk; (2) Land-based Liuzijue exercise: Liuzijue exercise consist of six distinct sounds (xu, he, hu, si, chui, and xi) and corresponding movements was performed with the knees in a semi-flexed position for 45 min; and the time to complete an intact Liuzijue exercise lasts 12-15 min; (3) Cool down: regulate breathing and relax muscles including flap and stretch muscles for 5-10 min.
223493211|NCT07024082|OTHER|Water-based Liuzijue exercise|"This group includes 40 patients. Water-based Liuzijue exercise will be performed twice a week, from 1:00-2:00 p.m., between June and September 2016, in the thermostatic swimming pool located at Shanghai University of Sport (Shanghai, China). The temperature of swimming pool was between 26°C and 30°C, while the temperature of air was between 30°C and 34°C, and the relative humidity was between 60% and 80%. Circulating water purification and disinfection equipment coordinated with chlorine disinfectant was used to sterilize the pool water. The participants were immersed in water to a level between their xiphisternum (lowest part of the sternum) and clavicles. Water-based Liuzijue exercise requires that participants remain awake and have eaten no sooner than 1 h prior to entering the pool to exercise. The WG exercise program consisted of three parts similar with LG:~(1) Warm ups; (2) Water-based Liuzijue exercise; and (3) Cool down."
223493212|NCT05504811|DEVICE|FitMi AD|Exercise using the motion sensing devices and a tablet computer
224184912|NCT06050811|DIETARY_SUPPLEMENT|2'-Fucosyllactose|2'-Fucosyllactose given orally with water or food for four weeks, followed by a three week washout period.
224184913|NCT06050811|DIETARY_SUPPLEMENT|Placebo|Maltodextrin given orally with water or food for four weeks, followed by a three week washout period.
224184914|NCT02723682|OTHER|Collect 24-hour urine specimen|A random half sample of NHANES participants 20-69 examined in the mobile examination center were asked to collect a 24-hour urine specimen.
224308478|NCT05907239|DEVICE|Focused Extracorporeal Shockwave Therapy|We will apply 2000 focal shock wave impulses starting in each region of the affected masticatory muscles and looking for compromised muscles in the masticatory muscles such as: masseter, temporal, pterygoid (medial and lateral and digastric through a piezoelectric generator F7, G3 with a focus of 1.5cm in depth, frequency of 8Hz and intensity of 0.048mJ/mm² as long as it is tolerable to the patient (it can be reduced to a tolerable intensity of at least 0.018mJ/mm²) starting with a density of energy flow between 0.12 to 0.15 mJ/mm2, starting from an adaptation dose of 0.10 mJ/mm2 in the first 500 impulses. The non-stationary technique will be used, slowly moving the applicator. Shockwave therapy will be weekly, totaling five consecutive weeks.
224184915|NCT00770731|DRUG|Torisel (Temsirolimus)|Starting Dose 5 mg Intravenously over 30-60 minutes, Days 1, 8, and 15 of 21 Day Cycle
224184916|NCT00770731|DRUG|Hycamtin (Topotecan)|Starting Dose 0.8 mg/m\^2 Intravenously over 30-60 minutes on Days 1 and 8 of 21 Day Cycle
224184917|NCT00770731|DRUG|Velcade (Bortezomib)|Starting Dose 0.3 mg/m\^2 Intravenously over 1 minute on Days 1, 4, 8, and 11 of 21 Day Cycle
224184918|NCT01391026|BEHAVIORAL|Enhanced patient-centered care|The experimental arm will be referred to a multi-disciplinary clinic
224184919|NCT04780230|DEVICE|tDCS active|An anodal high-definition tDCS of 2 mA lasting for 20 minutes will be delivered to the orofacial area of the primary motor cortex (SM1) during speech therapy.
224184920|NCT04780230|DEVICE|tDCS sham|An anodal high-definition tDCS of 2 mA lasting for 30 seconds will be delivered to the orofacial area of the primary motor cortex (SM1) during speech therapy.
224184921|NCT05822973|DEVICE|3.0 monocryl suture|incision will be closed with absorbable suture
224184922|NCT05822973|DEVICE|3.0 nylon suture|incision will be closed with non-absorbable suture
223493213|NCT05504811|OTHER|Conventional exercise program|Exercise following printed sheets or booklet
224184923|NCT05461846|OTHER|integrated neuromuscular inhibition technique|is a manual deactivation trigger points technique and includes the application of ischemic pressure and stretch, the muscle energy technique and the Strain-counterstrain technique.
224184924|NCT01741558|DRUG|Methotrexate|The treatment group will receive a bolus dose of 0.05 mg/kg of methotrexate before primary angioplasty followed by 0.05 mg/kg per hour for 6 hours
224184925|NCT01741558|DRUG|Riboflavin|We use riboflavin in placebo group to remain the double-blind fashion: methotrexate has a yellow color and riboflavin in that concentration has the same color.
224184926|NCT04490421|DRUG|Camrelizumab combined with Apatinib, Etoposide and Cisplatin|Camrelizumab combined with Apatinib, Etoposide and Cisplatin
224184927|NCT02210559|DRUG|FG-3019|FG-3019 will be administered per dose and schedule specified in the arm group description.
224184928|NCT02210559|DRUG|Gemcitabine|Gemcitabine will be administered per dose and schedule specified in the arm group description.
224184929|NCT02210559|DRUG|Nab-paclitaxel|Nab-paclitaxel will be administered per dose and schedule specified in the arm group description.
224184930|NCT03651375|DRUG|Sequential chemotherapy - 3 courses of AI|Three courses of doxorubicin and ifosfamide (AI, doxorubicin 75 mg/sqm and ifosfamide 10 g/sqm with prophylactic mesna), one before radiotherapy and two within the gap between radiotherapy and surgery.
224184931|NCT03651375|RADIATION|Hypofractionated radiotherapy|Preoperative hypofractionated 5x5 Gy radiotherapy (5 consecutive days) prescribed on planned target volume (tumor volume + elective margins + setup/error margin) with a daily image guidance with cone beam-CT-based position verification.
224184932|NCT06377670|PROCEDURE|Wassel IV Thumb Duplication Surgery|This intervention involves the surgical correction of Wassel IV thumb duplication, which is a congenital hand anomaly. The study retrospectively evaluates the outcomes of various surgical techniques that have been employed to correct this condition, with a focus on functionality and aesthetics of the thumb post-surgery. Data collected post-intervention include preoperative metacarpophalangeal angle, type of skin flap, surgical reconstruction technique, immobilization method, and postoperative complications. Additionally, patient satisfaction and daily pain levels are assessed using standardized questionnaires. Each patient serves as their own control, with outcomes compared to their contralateral healthy thumb.
224184933|NCT00190385|PROCEDURE|Ultrasonographic screening|Ultrasonographic screening
224184934|NCT02546193|DEVICE|Foley catheter|The Foley catheter is a device used to achieve cervical ripening at the start of labor induction. It is a single balloon catheter placed transcervically by a provider, either digitally or using a speculum for visualization. The balloon is placed above the internal os but below the fetal head, amniotic membranes, and placenta and is inflated. In this study, it will be inflated with 60 cc of normal saline and taped to the patient's thigh for traction. Over several hours, the balloon gradually dilates the cervix. The catheter is typically expulsed when the cervix is 3-4 centimeters.
224184935|NCT02546193|DRUG|Misoprostol|Misoprostol is a prostaglandin E1 analogue that is used for cervical ripening during labor induction. A 25 microgram tablet is placed in the vagina by a provider. A new 25 mcg tablet can be used vaginally every 4 hours for up to 6 total doses.
224184936|NCT01773460|DRUG|Everolimus|Everolimus is given beyond progress (comparison with placebo)
224184937|NCT01773460|DRUG|Everolimus-placebo|Everolimus-placebo
224184938|NCT03878576|OTHER|REFERENCE: white bread - BGL0 [RP]|Determination of glycemic response after consumption of BGL0.
223493214|NCT06004830|DRUG|Spironolactone|All participants will receive a prescription for spironolactone and will meet with a clinical pharmacist and addiction psychiatrist for further support
223493215|NCT07030959|DRUG|AUBE00|AUBE00 as an oral administration
223493216|NCT06877624|DRUG|QRL-101|This cross-over design study will evaluate three formulations (Formulations 1, 2, and 3) of QRL-101, beginning in a fasted condition before moving to a fed cross-over design.
223493217|NCT06693843|DRUG|Aleniglipron or Placebo|Drug: Aleniglipron Administered orally Drug: Placebo Administered orally
223493218|NCT06693843|DRUG|Aleniglipron or Placebo|Drug: Aleniglipron Administered orally Drug: Placebo Administered orally
223493219|NCT06693843|DRUG|Aleniglipron or Placebo|Drug: Aleniglipron Administered orally Drug: Placebo Administered orally
223493220|NCT06693843|DRUG|Aleniglipron|Drug: Aleniglipron Administered orally
223493221|NCT06693843|DRUG|Aleniglipron|Drug: Aleniglipron Administered orally
224184939|NCT03878576|OTHER|TEST: b-glucan enriched bread - BGL2 [IP1]|Determination of glycemic response after consumption of BGL0.
224184940|NCT03878576|OTHER|TEST: b-glucan enriched bread - BGL3 [IP2]|Determination of glycemic response after consumption of BGL0.
223493222|NCT06693843|DRUG|Aleniglipron|Drug: Aleniglipron Administered orally
223493223|NCT06693843|DRUG|Aleniglipron|Drug: Aleniglipron Administered orally
223493224|NCT07032077|DRUG|HRS-7058|HRS-7058 combimed with antitumor drugs
223493225|NCT06701006|OTHER|Integrated skills and safety planning app|This is a digital app that includes supported safety planning resources in clinic as well as coping skills and lived experience videos for adolescents, young adults and parents/caregivers that can be accessed in clinic or at home.
224184941|NCT03878576|OTHER|TEST: b-glucan enriched bread - BGL4 [IP3]|Determination of glycemic response after consumption of BGL0.
224184942|NCT00310440|DEVICE|P-15 Synthetic osteoconductive bone substitute|Safety and efficacy of synthetic bone substitute used for fusion in spinal surgery
224184943|NCT00310440|OTHER|Autologous bone|Local autologous bone will be harvested, milled and placed into the cavity of the structural allograft ring
224184944|NCT00990366|DEVICE|Cook´s biliary stent with an antireflux stent, normal biliary stent|arms are assigned randomly by closed envelope method
224184945|NCT04897126|RADIATION|Shexiang Baoxin pill（MUSKARDIA）|On the basis of routine treatment, MUSK Pills were added to 4 capsules / day, 3 times per day until the end of follow-up.
224184946|NCT04897126|RADIATION|Placebo|On the basis of routine treatment, Placebo were added to 4 capsules / day, 3 times per day until the end of follow-up.
224184947|NCT00107666|DRUG|CTI-01 (ethyl pyruvate)|
224184948|NCT01977066|BEHAVIORAL|Six months supervised resistance training|progressive resistance training (2x/week), starting at the earliest 8 weeks after surgery until maximum 12 months after the surgery with only low-to-moderate-intensity training during the first 4 weeks.
224184949|NCT01977066|BEHAVIORAL|Six months home-based exercise training|Home-based exercise training (2x/week) with initial counseling and weekly telephone contact starting at the earliest 8 weeks after surgery until maximum 12 months after the surgery.
224184950|NCT02096601|DRUG|LD/CD SC solution|Levodopa/carbidopa SC solution
224184951|NCT02096601|DRUG|Entacapone|Entacapone 200 mg oral tablet
224184952|NCT01781130|PROCEDURE|Steroid injection|
224184953|NCT04105465|DEVICE|PlasmaJet|The PlasmaJet device is used following groin node dissection on the side randomised to receive it as per protocol specifications
224184954|NCT06169410|DRUG|nab-paclitaxel, lobaplatin, and S-1 combined with ramucirumab|Patients in Experimental group will be given ramucirumab (8mg/kg) by intravenous drip on the first day of each cycle, 3 weeks a cycle.
223493226|NCT06877533|DRUG|EOS006215|Multiple doses of EOS006215
223493227|NCT06877533|DRUG|Anticancer agent|Multiple doses of EOS006215 in combination with other anticancer agents
223745654|NCT02877277|DIETARY_SUPPLEMENT|Placebo|Oral intake of placebo tablet daily for 56 days
223493228|NCT06703398|BIOLOGICAL|GC101 TIL|Patients with advanced melanoma (excluding uveal melanoma) who have failed to PD-1 antibodies (if BRAF mutation is present, BRAF and MEK inhibitors have failed; if NRAS mutation is present, tunlametinib have failed) and are ineligible for resection
223493229|NCT06703398|DRUG|dacarbazine, temozolomide, paclitaxel ,platinum or cisplatin|monotherapy or combination of dacarbazine, temozolomide, paclitaxel, platinum or cisplatun, and the chemotherapy's dosage could refer to the drug label or the relevant treatment guideline, the final decision is up to investigator
223493230|NCT06878430|OTHER|Functional and Cognitive scores|We will collect information about prior neurological symptoms, including prior symptoms suggestive of TIA or stroke, cognitive or motor symptoms, blood pressure and other known vascular risk factors, medicines, frailty, functional status, education, and employment status We will collect a baseline validated function and cognitive score, and take a sample of speech. Speech will be measured at assessment, in collaboration with the NeuroCARE Clinical and Digital Measures Module (22/SS/0010 IRAS No. 310885).
223493231|NCT07026344|PROCEDURE|Stent placement|For patients who fail thrombectomy, perform stent placement.
223493232|NCT07026344|PROCEDURE|Continued Thrombectomy|For patients with failed thrombectomy, perform at least one additional thrombectomy attempt
223493233|NCT07026344|PROCEDURE|balloon angioplasty|For patients who fail thrombectomy, perform balloon angioplasty.
223493234|NCT07032649|DRUG|Benzoyl Peroxide 10% Bar|Active ingredient for drug included. Blind identification by package number
223493235|NCT07032649|OTHER|Placebo|Placebo that looks like active treatment, blinded but available to ID via package number
223493236|NCT07034677|DRUG|Indapamide 1.5 MG SR|14 days treatment with indapamide 1.5 mg/day compared to placebo
223493237|NCT07034677|DRUG|Placebo|14 days treatment with placebo
223493238|NCT07033897|BEHAVIORAL|Adapted HARP|The adapted HARP intervention includes two to three in-home visits conducted by an OT practitioner over approximately 5 weeks in the homes of PwD. At the end of the first home visit, solutions to remove the identified fall hazards will be determined collaboratively with the participant, using motivational interviewing to establish hazards and shared-decision making and tailoring to help the participant brainstorm solutions to remove the hazards. Participants will then receive one to two additional visits from the OT, and a contractor if needed, to implement solutions using a self-management approach, identifying any additional hazards and subsequent modifications if necessary. All adaptive equipment and modifications will be provided at no cost to the participant. Booster visit(s) will be completed 3-6 months after the initial treatment sessions to ensure the home modifications are still appropriate, troubleshoot any equipment issues and review the self-management process.
223493239|NCT06712641|DRUG|Gentamicin + narrow spectrum betalactam|Empirical therapy for suspected community-acquired sepsis with gentamicin + narrow spectrum betalactam (either one of penicillin, ampicillin, or cloxacillin)
223493240|NCT06712641|DRUG|Cefotaxime|Empirical therapy for suspected community-acquired sepsis with cefotaxime
224184955|NCT06169410|DRUG|nab-paclitaxel, lobaplatin, and S-1|Patients will be given lobaplatin (30 mg/m2) and nab-paclitaxel (100mg/m2) by intravenous drip on the first day of each cycle, 3 weeks a cycle, together with oral S-1 (patients with a body surface area less than 1.25 m2, will give 40 mg each time. Patients with a body surface area between 1.25 and 1.5 m2; will give 50 mg each time; patients with a body surface area greater than 1.5 m2, will give 60 mg each time), 2 weeks on and 1 week off.
223493241|NCT06712641|DRUG|Piperacillin-tazobactam|Empirical therapy for suspected community-acquired sepsis with piperacillin-tazobactam
223493242|NCT06710509|BEHAVIORAL|Three Messaging Nudges|Patients in the Experimental Condition will receive a set of up to three email and text messages over the course of five days, while also receiving usual care which could include messaging from their practice or the electronic health record.
223493243|NCT06709053|DIAGNOSTIC_TEST|standing hight-based|The model equation for predicting double-lumen tube insertion depth using standing hight -based: Depth = 1.083 + 0.166×standing hight (cm)
223493244|NCT06709053|DIAGNOSTIC_TEST|sitting height-based|The model equation for predicting double-lumen tube insertion depth using sitting height ( depth = 0.32 × sitting height)
223493245|NCT06709053|DIAGNOSTIC_TEST|CT-based|The model equation for predicting double-lumen tube insertion depth using CT depth = 1.543 + 0.155\*standing hight,cm + 0.202\*Ds-c,cm
223493246|NCT06710886|BEHAVIORAL|Augmented Theme|The music is augmented by embedding the natural rhythms of bodily functions (e.g. breathing, heart rate variability, vascular tone, etc) that signal the body to calm.
223493247|NCT06710886|BEHAVIORAL|Mozart Theme|The selected Mozart composition consists of: Composition Eine kleine Nachtmusik, K. 525 (5 minutes 30 seconds), Andante from Piano Concerto No. 21, K. 467 (6 minutes 30 seconds), and Ave verum corpus, K. 618 (3 minutes).
223493248|NCT07028398|BEHAVIORAL|Nurse Nudge|Nurses will be nudged to call the patients, which may increase the likelihood that the patient receives a post- appointment follow-up call.
223493249|NCT07102797|BEHAVIORAL|ActiveGirls Physical Activity Program (Full)|Participants in the ActiveGirls Full Intensity intervention group will receive a series of 6 health coaching visits delivered via telemedicine. These visits will address physical activity goal setting within the family. Participants will also receive the ActiveGirls education messaging which will include 3-4 text messages per week (Months 1-6 of their study participation).
223493250|NCT07102797|BEHAVIORAL|ActiveGirls Physical Activity Program (Delayed Lower Intensity)|Participants in this group will only receive the ActiveGirls education messaging which will include 3-4 text messages per week (Months 7-12 of their study participation)
223493251|NCT07114770|DEVICE|Theta Burst Stimulation (TBS, an advanced variant of repetitive transcranial magnetic stimulation)|Participants will receive a single session of either iTBS or cTBS (600 pulses) targeting the right cerebellar Crus I/II. One week after the initial TBS, they will receive another single session of iTBS or cTBS (600 pulses) at the same site.
224184956|NCT02679924|DEVICE|Hyaluronic Acid filler|The objective of this study is to determine the efficacy and safety of Restylane® Silk Hyaluronic Acid filler microinjections when used in a grid-like injection pattern for the correction of fine lines to the cheeks.
224184957|NCT02679924|OTHER|Sham Comparator|Micro-injections of normal saline for correction of mid to low cheek fine lines and wrinkles.
224184958|NCT00987857|PROCEDURE|2 yearly endoscopy|2 yearly endoscopy versus endoscopy at need
224184959|NCT00987857|PROCEDURE|comparison of screening methods|2 yearly endoscopy versus endoscopy at need
223588676|NCT01729494|DRUG|Tacrolimus|Tacrolimus will be administered orally twice daily (BID). The recommended total initial dose of tacrolimus is 0.1 mg/kg/day in two divided doses orally. Tacrolimus should be started post-transplant within 48 hours or when serum creatinine drops lower than 4mg/dL, whichever comes first. The initial targeted trough level of tacrolimus will be 8 - 12 ng/mL for Days 1 through 30, with dose reduction to achieve a 12-hour trough target of 5 - 10 ng/mL thereafter.
223588677|NCT01729494|DRUG|Mycophenolate mofetil|The first dose of mycophenolate mofetil/EC mycophenolate sodium will be administered pre-operatively. Patients receiving mycophenolate mofetil will be dosed 1000 mg twice daily (2000mg/day). Patients receiving EC mycophenolate sodium will be dosed 720 mg twice daily (1440 mg/day). Dose may be increased for African American transplant recipients to mycophenolate mofetil 1500 mg twice daily (3000mg/day) or EC mycophenolate sodium 1080 mg twice daily (2160 mg/day).
223588678|NCT01729494|DRUG|early cessation of steroids|"Glucocorticoid therapy will be administered as described. Methylprednisolone will be administered on Days 1 through 3. Additional tapering doses of glucocorticoids will continue to be given until Day 5 as below:~Day 1 (day of transplant): 500mg IV prior to alemtuzumab (Group A) or rabbit antithymocyte globulin (Groups B and C) Day 2: 250mg IV Day 3: 125mg IV Day 4: 80mg p.o. Day 5: 60mg p.o. No further steroids"
223588679|NCT04313491|OTHER|Yoga|Relaxation yoga exercises, yoga breathing, yoga sound and imagery practices
223588680|NCT05296993|DIETARY_SUPPLEMENT|Extracts found in the Extended Longevity supplements|Ingredients found in these serums are all naturally occurring, and extracted from a variety of plant species.
223588681|NCT05749393|DRUG|Heparin sodium|Intravenous heparin was administered during intracranial aneurysm embolization with a guide catheter and discontinued at the end of the procedure.
223588682|NCT05327361|DRUG|Liftactiv B3|Participants will apply a dime size amount of the serum to 1 side of the face.
223588683|NCT05327361|OTHER|Sunscreen|Participants will apply a dime size amount of sunscreen to cover the other half of the face.
223588684|NCT04672850|DIETARY_SUPPLEMENT|Probiotic|The participants will consume 2 capsules daily for three months
223588685|NCT04672850|DIETARY_SUPPLEMENT|Placebo|The participants will consume 2 capsules daily for three months
223588686|NCT05477914|OTHER|questionnaire|questionnare about nutritional knowledge of pregnant women
223588687|NCT01439373|DRUG|GSK2336805|Active Investigational Drug
223588688|NCT01439373|DRUG|Pegylated interferon alfa-2a|Standard of Care drug
223588689|NCT01439373|DRUG|Ribavirin|Standard of Care drug
224184960|NCT00987857|PROCEDURE|diagnostic endoscopic procedure|2 yearly endoscopy versus endoscopy at need
224184961|NCT00987857|PROCEDURE|endoscopic biopsy|2 yearly endoscopy versus endoscopy at need
224184962|NCT00987857|PROCEDURE|endoscopic procedure|2 yearly endoscopy versus endoscopy at need
224184963|NCT00987857|PROCEDURE|quality-of-life assessment|QOL aims to elicit any differences in QOL between 2 yearly endoscopy versus endoscopy at need
224184964|NCT00987857|PROCEDURE|screening method|All Barretts patients to be screened
223588690|NCT01439373|DRUG|GSK2336805 Matching Placebo|Placebo of Investigational Drug
223588691|NCT00366912|DEVICE|non-invasive ventilation|
223588692|NCT03135977|DRUG|Apatinib, Etoposide|Patients receive etoposide 50mg from day 1 to day 14 and apatinib 250mg/d from day 1 to day 21, repeated every 21 days until progressive Disease(PD) .
223588693|NCT02628548|BEHAVIORAL|Cognitive training program|8 week cognitive training program
223588694|NCT06171646|BEHAVIORAL|breathing exercise|The patients in the intervention group will first be informed by the researcher about pursed lips and diaphragmatic breathing exercises through a face-to-face interview technique, and then the breathing exercises will be taught practically to each patient for approximately 30 minutes, and the first session will be held. Each session takes place once a day in the morning, lasts 10-15 minutes and is applied every day; Sessions other than the first session will consist of 10 pursed lip breathing exercises, relaxation (2 minutes) and 10 diaphragmatic breathing exercises; Three days a week, the researcher will be reminded via online video call once a day in the morning, and on the other days, the patients will be reminded by phone call that they will be asked to do themselves, and breathing exercises will be performed for a total of four weeks.
223588695|NCT03196531|DRUG|Loratadine (Xisimin [Test Treatment])|Participants will receive 10 mg loratadine as Xisimin (test treatment) as per the treatment sequence.
223588696|NCT03196531|DRUG|Loratadine (Clarityne [Reference Treatment])|Participants will receive 10 mg loratadine as Clarityne (reference treatment) as per the treatment sequence.
223588697|NCT00709878|PROCEDURE|Skin Biopsy of Skin Rash Secondary to EGFRI Use|Patients who were treated with lapatinib, cetuximab, panitumumab or erlotinib who subsequently developed a skin rash have been biopsied as standard of care. The biopsies will be used for this study.
223588698|NCT00371904|DRUG|Rituximab|Single dose (375 mg/m2) of rituximab to be given intravenously (IV) 14 days prior to transplantation
224184965|NCT00173758|PROCEDURE|co-culture of embryos and endometrial cells|
224184966|NCT04424758|OTHER|Video information about mammography screening|A video informing about mammography screening
224184967|NCT04424758|OTHER|Video information about smart energy systems|A video informing about smart energy systems
224184968|NCT06423118|DEVICE|ANNE Vital Sign System|The ANNE Vital Sign System is a pair of non-invasive, flexible sensors originally designed for vital signs monitoring in the paediatric intensive care unit.
224184969|NCT01287403|OTHER|Refined wheat flour|A treated cereal flour mixed with milk.
224184970|NCT01287403|OTHER|Esterase wholegrain wheat flour|A treated cereal flour mixed with milk.
224184971|NCT01287403|OTHER|Wholegrain wheat flour|A treated cereal flour mixed with milk.
224184972|NCT01287403|OTHER|Liquid whole grain wheat flour|A treated cereal flour mixed with milk.
224184973|NCT01287403|OTHER|Wholegrain barley flour|A treated cereal flour mixed with milk.
224184974|NCT01287403|OTHER|Liquid wholegrain barley flour|A treated cereal flour mixed with milk.
224184975|NCT03088306|DRUG|Standard analgesia use [Oxygen]|A protocol directed and clinically appropriate post-operative analgesia. In this study, standard post-operative analgesia is defined as: oxygen, volatile anesthesia, fentanyl, hydromorphone.
224184976|NCT03088306|DRUG|Standard analgesia use [Hydromorphone]|A protocol directed and clinically appropriate post-operative analgesia. In this study, standard post-operative analgesia is defined as: oxygen, volatile anesthesia, fentanyl, hydromorphone.
223588699|NCT00371904|DRUG|Standard Care|Standard care
223588700|NCT01961648|DEVICE|Rebreathing bag|
223588701|NCT01961648|DEVICE|Sham rebreathing|
223588702|NCT01961648|DEVICE|Mask|
223588703|NCT03389178|DIAGNOSTIC_TEST|Cohen Perceived Stress Scale-10 (PSS-10)|Participants with a PSS-10 score ≥19 will be categorized as stressed and entered into Phase II. For every consented subject categorized as stressed, the next screened participant matching for maternal and gestational age with a PSS-10 score \< 19 will be entered into Phase II as control
223588704|NCT01896245|DRUG|sevoflurane 1,0|anesthesia induction with propofol, remifentanil, and sevoflurane 1,0 MAC; afterwards tracheal intubation
223588705|NCT01896245|DRUG|sevoflurane 1,2|anesthesia induction with propofol, remifentanil, and sevoflurane 1,2 MAC; afterwards tracheal intubation
223588706|NCT01896245|DRUG|sevoflurane 1,4|anesthesia induction with propofol, remifentanil, and sevoflurane 1,4 MAC; afterwards tracheal intubation
223588707|NCT01078168|DRUG|Acitretin|30mg per day from Day 1 to Day 28
223588708|NCT01078168|DRUG|Placebo|Placebo
224308479|NCT05907239|DEVICE|Placebo Focused Extracorporeal Shockwave Therapy|We will apply 2000 focal shock wave impulses starting in each region of the affected masticatory muscles and looking for compromised muscles in the masticatory muscles such as: masseter, temporal, pterygoid (medial and lateral and digastric through a piezoelectric generator F7, G3 with a focus of 0cm depth, frequency of 8Hz and intensity of 0.048mJ/mm² with a fake gel pad applicator.
224308480|NCT04003896|DRUG|Abemaciclib|"Participant will take 200 mg capsules or tablets orally twice daily. The participant will be instructed to swallow abemaciclib as a whole tablet and not to chew, crush or split capsules or tablets before swallowing. Participants should not ingest abemaciclib tablets if broken, cracked, or otherwise not intact. Doses should be taken at a approximately the same time every day, twice daily. Capsules or tablets can be taken orally with or without food. If the participant vomits or misses a dose of abemaciclib, the participant will be instructed to take the next dose at its scheduled time.~Participants will also be provided with a diary and instructed to keep a twice daily record of the times they have taken their medications and any other events such as vomiting, diarrhea, etc."
224308481|NCT00336076|OTHER|Collection of blood and bone marrow|5-8 cc blood or bone marrow was additionally collected for analysis during diagnostic procedures. No assigned interventions.
224308482|NCT02289443|OTHER|complete denture|Comparison of different procedures
224308483|NCT01843738|RADIATION|Radiation therapy|Per standard of care
224308484|NCT01843738|DRUG|Vemurafenib|The starting dose of vemurafenib will be the patient's baseline tolerating dose, between 720 - and 960 mg PO bid.
224308485|NCT02274506|DRUG|Cyclophosphamide|60 mg/kg by vein on Days -8 and -7.
224308486|NCT02274506|DRUG|Fludarabine|25 mg/m2 by vein on Days -6 to -2.
224308487|NCT02274506|PROCEDURE|T-Cell Infusion|T-cells infused no sooner than 48 hours and no later than 1 week post completion of chemotherapy on Day 0.
224308488|NCT03104478|PROCEDURE|Biological samples collection|In addition to collection and characterization of tumor biopsy samples done for diagnosis (standard care), collection of blood samples at study entry for further biological analyses.
224308489|NCT05861297|DRUG|Dexamethasone|Patients were initiated with High Dose-Dexamethasone with a dose of 40 mg/m2 daily for four days per week immediately after the diagnosis of ITP for 6 months
224308490|NCT05861297|DRUG|Prednisolone and Azathioprine|the second group received 20 mg of Prednisolone three times daily and 1 mg/kg of oral Azathioprine once daily for two weeks, then tapering the Prednisolone dose through the subsequent weeks (6 weeks). While continuing treatment with Azathioprine for a total of six months.
224308491|NCT05861297|DRUG|Rituximab|The third group received 500 mg/m2 intravenously of Rituximab once weekly for one month
224308492|NCT05861297|DRUG|Eltrombopag|The fourth group received 50 mg of Eltrombopag four hours before or after meals as oral daily doses for 6 months
224308493|NCT05861297|DRUG|Romiplostim|The fifth group received 3μg/kg subcutaneous injection of Romiplostim once a week for 6 months
224308494|NCT02026687|DRUG|Epidural|
224308495|NCT02026687|DRUG|Intrathecal|
224308496|NCT01957397|DEVICE|Coloplast Test 1|Coloplast Test 1 is a newly developed 2-piece convex ostomy appliance
224308497|NCT01957397|DEVICE|Coloplast Test 2|Coloplast Test 2 is a newly developed 2-piece convex ostomy appliance
223588709|NCT00302757|DRUG|Radioimmunotherapy|
223588710|NCT00302757|PROCEDURE|allogeneic hematopoietic cell transplantation|
223588711|NCT02147769|DEVICE|NIRS monitoring|All enrolled infants will undergo NIRS monitoring of cerebral oxygenation in addition to monitoring of continuous arterial blood pressure.
223588712|NCT01681524|DRUG|Flurpiridaz F18|Injection of Flurpiridaz F18 for the purposes of PET MPI analysis
224308498|NCT01957397|DEVICE|Coloplast Test 3|Coloplast Test 3 is a newly developed 2-piece convex ostomy appliance
224308499|NCT01857141|DRUG|preemptive dexmedetomidine epidural bolus injection(1.5 mcg/kg)|Patients in the pre-emptive groups recived a dose of 1.5㎍/kg dexmedetomidine dissolved into normal saline 10cc before the induction of
224308500|NCT01857141|DRUG|normal saline|patients in the control groups received the equivalent volume of normal saline.
224308501|NCT03043404|DEVICE|Transcatheter aortic valve replacement|TAVR with Lotus Valve Flex System
224308502|NCT03335826|PROCEDURE|Combined epidural-general anesthesia|Combined epidural-general anesthesia and postoperative epidural analgesia.
224308503|NCT03335826|PROCEDURE|General anesthesia|General anesthesia and postoperative intravenous analgesia.
224308504|NCT03407469|BEHAVIORAL|Questionnaires|Questionnaires completed at the time participant joins this study and then about 30 days, 3 months, 6 months, and 12 months after that. Questionnaires will be about quality of life and experiences with treatment for venous thromboembolism (VTE). It should take less than 10 minutes to complete the questionnaires each time.
224308505|NCT00324649|DRUG|Truvada|Truvada once daily with continuation of the current NNRTI or PI at randomization.
224308506|NCT00324649|DRUG|Zidovudine/lamivudine|Continuation of the zidovudine + lamivudine containing regimen plus the current NNRTI or PI at randomization.
224308507|NCT00540293|DRUG|Atorvastatin|Prescription of 10/20/40mg dose atorvastatin based on the personal risk factor that is defined in the NCEP ATP III guideline in a single patient group
224184977|NCT03088306|DRUG|Standard analgesia use [Volatile Anesthesia]|A protocol directed and clinically appropriate post-operative analgesia. In this study, standard post-operative analgesia is defined as: oxygen, volatile anesthesia, fentanyl, hydromorphone.
224184978|NCT03088306|DRUG|Standard analgesia use [Fentanyl]|A protocol directed and clinically appropriate post-operative analgesia. In this study, standard post-operative analgesia is defined as: oxygen, volatile anesthesia, fentanyl, hydromorphone.
224184979|NCT03088306|DRUG|Multi-modal pain management [Acetaminophen + Gabapentin]|Administration of acetaminophen (1 gm po) plus gabapentin (600-1200 mg po) in the preparation area prior to surgery; pre-induction opioid titration with fentanyl until pain is relieved and/or respiratory depression ensues; intravenous ketamine (1 mg/kg load prior to incision then 10 mcg/kg/min) during surgery; acetaminophen, valium plus gabapentin during hospitalization; and prescription for acetaminophen, valium plus gabapentin at discharge.
224184980|NCT03088306|DRUG|Multi-modal pain management [Fentanyl]|Administration of acetaminophen (1 gm po) plus gabapentin (600-1200 mg po) in the preparation area prior to surgery; pre-induction opioid titration with fentanyl until pain is relieved and/or respiratory depression ensues; intravenous ketamine (1 mg/kg load prior to incision then 10 mcg/kg/min) during surgery; acetaminophen, valium plus gabapentin during hospitalization; and prescription for acetaminophen, valium plus gabapentin at discharge.
224184981|NCT03088306|DRUG|Multi-modal pain management [Intravenous Ketamine]|Administration of acetaminophen (1 gm po) plus gabapentin (600-1200 mg po) in the preparation area prior to surgery; pre-induction opioid titration with fentanyl until pain is relieved and/or respiratory depression ensues; intravenous ketamine (1 mg/kg load prior to incision then 10 mcg/kg/min) during surgery; acetaminophen, valium plus gabapentin during hospitalization; and prescription for acetaminophen, valium plus gabapentin at discharge.
224184982|NCT03088306|DRUG|Multi-modal pain management [Valium + Gabapentin]|Administration of acetaminophen (1 gm po) plus gabapentin (600-1200 mg po) in the preparation area prior to surgery; pre-induction opioid titration with fentanyl until pain is relieved and/or respiratory depression ensues; intravenous ketamine (1 mg/kg load prior to incision then 10 mcg/kg/min) during surgery; acetaminophen, valium plus gabapentin during hospitalization; and prescription for acetaminophen, valium plus gabapentin at discharge.
224184983|NCT02425670|OTHER|BMSCs|30-500 million Autologous BMSCs will be given intravenously to patients with acute ischemic stroke (onset from 7 to less than 30 days).
224184984|NCT02358707|OTHER|Ibuprofen phonophoresis|
224184985|NCT01583699|PROCEDURE|Confocal laser endomicroscopy|Endomicroscopy of the upper gastrointestinal tract to capture endomicroscopic pictures from the small bowel, stomach and esophagus.
224184986|NCT01583699|DEVICE|Confocal Laser Endomicroscope|Pentax EC-3870 CIFK with the ISC-1000 confocal endomicroscopy processor - Pentax, Tokyo, Japan and Optiscan Pty Ltd, Notting Hill, Victoria, Australia
224184987|NCT02450656|DRUG|Afatinib|Tablet
224184988|NCT02450656|DRUG|Selumetinib|Capsule
224184989|NCT02450656|DRUG|Docetaxel|
224184990|NCT00118885|BEHAVIORAL|Tai Chi Chih|
224184991|NCT00148109|DRUG|Cetuximab|The initial dose of cetuximab is 400 mg/m2 intravenously administered over 120 minutes, followed by weekly infusions at 250 mg/m2 IV over 60 minutes.
224184992|NCT00148109|DRUG|Cetuximab|Cetuximab 400 mg/m2 over 120 min IV initial does followed by weekly Cetuximab 250 mg/m2 over 60 min
224184993|NCT02053415|DIETARY_SUPPLEMENT|Krill oil low dose|3 capsules krill oil per day
223493252|NCT07116070|OTHER|Clinical Assessments|"Participants will undergo the following assessments:~* Muscle strength: Handgrip strength test (using a digital dynamometer),~* Muscle mass: Bioelectrical impedance analysis (BIA) or DXA,~* Physical performance: 6-minute walk test, 5-repetition sit-to-stand test,~* Fatigue: Modified Fatigue Impact Scale (MFIS),~* Disability: EDSS,~* Nutritional status: Mini Nutritional Assessment (MNA),~* Physical activity: Godin Leisure-Time Exercise Questionnaire,~* Quality of life: MSQoL-54."
223493253|NCT07116252|PROCEDURE|EDTA|17% EDTA as a final rinse after instrumentaion (sequential chelation)
223493254|NCT07116252|PROCEDURE|Etidronate|9% HEBP as a final rinse after instrumentation (sequential chelation)
223493255|NCT07116252|PROCEDURE|clodronate|0.26 M (7.6%) clodronate as a final rinse after instrumentation (sequential chelation)
223493256|NCT07116252|PROCEDURE|Etidronic acid /sodium hypochlorite|(2.5% NaOCl + 9% HEBP) during instrumentation and as a final rinse after instrumentation (continous chelation)
224184994|NCT02053415|DIETARY_SUPPLEMENT|Krill oil high dose|9 capsules krill oil per day
224184995|NCT03058861|BEHAVIORAL|Play Nicely Program|Play Nicely multimedia program and handbook that provides education about healthy discipline strategies.
224184996|NCT05463315|DEVICE|Moziak Device|Applying Moziak Device Compared to Standard Manual Compression
224184997|NCT03043287|BIOLOGICAL|onabotulinumtoxinA|onabotulinumtoxinA (BOTOX®)100 to 200 U
224184998|NCT04591782|OTHER|PomJuice|Drink 8 oz pomegranate juice
224184999|NCT04591782|OTHER|Water|Drink 8 oz water
224185000|NCT04591782|OTHER|Sugar Water|Drink 8 oz of water with 18.6 g of glucose + 18.3 g of fructose dissolved in
224185001|NCT03769792|DIAGNOSTIC_TEST|Blood and faeces tests|During V0 - Laboratory tests, particularly for calprotectin concentration assessment
224185002|NCT03769792|DEVICE|Impedance spectroscopy test|During V1 - the electrical impedance of pelvic floor muscles will be measured
224185003|NCT03769792|DIAGNOSTIC_TEST|Full gynecological and proctological examination|During V1 - Examination with a gynecological speculum, Two-handed examination, Rectal examination and Anoscopy
224185004|NCT03769792|DIAGNOSTIC_TEST|Transanal ultrasonography|During V2 - reference diagnostic methods with documented effectiveness and safety; for comparison with impedance spectroscopy results.
224185005|NCT03769792|DIAGNOSTIC_TEST|Anorectal manometry|During V2 - reference diagnostic methods with documented effectiveness and safety; for comparison with impedance spectroscopy results.
224185006|NCT05478473|DRUG|Chidamide combined with Toripalimab|chidamide：oral, 30 mg/time, twice weekly; Toripalimab：intravenous drip, 240mg, once every 3 weeks
224308508|NCT01574690|DEVICE|Mespere Venus System|For this non-invasive system, an adhesive patch (connected to the Mespere Venus system) is placed on the neck of the subject, to determine if the CVP values displayed by the device correlates with the CVP values obtained by RHC and physical exam
223493257|NCT07116252|PROCEDURE|clodronate + sodium hypochlorite|2.5% NaOCl + 0.26 M (7.6%) clodronate during instrumentation and as a final rinse after instrumentation (continuous chelation)
224185007|NCT03854669|DEVICE|pain reporting accuracy|pain reporting accuracy will be assessed by the Focused Analgesia Selection Task (FAST) procedure. The FAST is based on recording a subject's pain reports in response to repeated administration of thermal noxious stimuli of various intensities, applied on the non-dominant arm with the Medoc® Thermal Sensory Analyzer II. The subjects will receive 1 of 7 designated temperatures (44°C, 45°C, 46°C, 47°C, 48°C, 49°C, and 50°C), each presented 7 times in a random block-ordered design (49 stimuli in total).
224185008|NCT05605366|DRUG|Minocycline|Minocycline is a second-generation tetracycline antibiotic with good central nervous system penetration and anti-neuroinflammatory effect.
224308509|NCT01574690|PROCEDURE|Right heart catheterization (RHC)|Invasive procedure to assess CVP. Standard of care.
224308510|NCT01574690|PROCEDURE|Physical examination of jugular vein|Physicians assess CVP using the subject's jugular vein.
223493258|NCT07113795|PROCEDURE|TCM dummy therapy combined with mesenchymal stem cell injection therapy|Combines TCM dummy therapy with mesenchymal stem cell injection, integrating traditional local stimulation and modern stem cell regenerative mechanisms.
223493259|NCT07113795|PROCEDURE|Dummy Line Therapy Group|Utilizes traditional thread-embedding techniques, placing specialized threads at specific sites to effectively drain inflammatory exudates and necrotic materials.
223493260|NCT07113795|PROCEDURE|MSC Group|Administers mesenchymal stem cell injections directly to target areas, leveraging their differentiation and anti-inflammatory properties to enhance tissue repair.
223745655|NCT03202862|DRUG|Fulvestrant|Fulvestrant 500 mg given as two 5 ml intramuscular inections, one in each buttoc, on days 1, 15, 2 and every 2 ( ) days thereafter.
223493262|NCT07119203|PROCEDURE|Robotic cholecystectomy|Robotic multiport cholecystectomy
223493263|NCT07119203|PROCEDURE|Laparoscopic cholecystectomy|Conventional multiport laparoscopic cholecystectomy
223493264|NCT07120880|PROCEDURE|AD + SHR + active LT and extended-release melatonin 2mg|Patients will receive an SSRI antidepressant (e.g., Fluoxetine, Sertraline, Paroxetine, Escitalopram) or SNRI (e.g., Venlafaxine, Duloxetine) antidepressant (as clinically appropriate), combined with sleep hygiene education, daily morning LT (10,000 lux for 30 minutes between 7-8 a.m. using the Dayvia Slim Style 3 lamp), and 2 mg of extended-release melatonin taken one hour before bedtime, all for a duration of 8 weeks.
223493265|NCT07120880|PROCEDURE|AD + SHR + active LT and placebo melatonin|Patients will receive an SSRI or SNRI, sleep hygiene instructions, daily morning bright LT (10,000 lux, 30 cm, 30 min, 7-8 a.m., using Dayvia Slim Style 3 lamps), and placebo melatonin taken one hour before bedtime, all for a duration of 8 weeks.
223588713|NCT01264419|DEVICE|Silk Road Embolic Protection System|System that delivers a carotid artery stent, via transcervical access using reverse flow cerebral protection, as treatment for high-grade extracranial carotid artery disease
223588714|NCT02012049|DRUG|Risperdal OD Tab. 2mg|1 tablet Risperdal OD 2 mg administered orally.
223588715|NCT02012049|DRUG|Risperdal Quicklet Tab. 2mg|1 tablet Risperdal Quicklet Tab. 2mg administered orally.
223588716|NCT01735942|DRUG|Ingenol mebutate|
223588717|NCT01735942|PROCEDURE|cryotherapy|
223588718|NCT03869307|OTHER|Exercise|The exercise programme includes exercises identified in literature to target scapular and rotator cuff muscles.
223588719|NCT03048604|DEVICE|Genio(TM) bilateral hypoglossal nerve stimulation system|Subjects will be consented, enrolled and eligibility criteria checked. If the subject is eligible, subject will proceed with the Genio(TM) implant implantation. Four (4) weeks after implantation, the implant will be activated and the subject will be assessed at 1 month plus 1 week, 2, 3, 4 and 6 month(s) after implantation.
223588720|NCT05023278|DRUG|Venlafaxine 37.5 MG|venlafaxine 37.5mg daily for 7 consecutive days.
223588721|NCT05023278|DRUG|Placebo|placebo filled pill daily for 7 consecutive days.
224185009|NCT05605366|DRUG|Placebo|This is capsule that is identical in size and appearance as the drug, but without active drug ingredient.
224185010|NCT04487626|DEVICE|AI|After taking standard bowel preparation regimen, patients receive colonoscopy under the AI system device. During the withdrawal phase, bowel preparation quality is assessed by AI-associated scoring system. The withdrawal time is targeted at least 6min. Every detected polyp will be removed and obtained for pathological assessment.
224185011|NCT01098266|DRUG|NGR-hTNF plus Best Investigator's Choice (BIC)|"* NGR-hTNF: 0.8 mcg/m² as 60-minute intravenous infusion every week until confirmed evidence of disease progression or unacceptable toxicity occurs.~* Best Supportive Care: antibiotics, analgesics, antiemetics, thoracentesis, pleurodesis, blood transfusions, nutritional support, and focal external-beam radiation for control of pain, cough, dyspnea, or hemoptysis~* Investigator's Choice: one of the following single-agent chemotherapy might be administered in combination:~  1. Doxorubicin: 60-75 mg/m2 every 3 weeks, for a maximum of 6 cycles~ 2. Gemcitabine: 1,000-1,250 mg/m2 on days 1 and 8, every 3 weeks, for a maximum of 6 cycles~ 3. Vinorelbine: 25 mg/m2 iv (or 60 mg/m2 per os) on days 1 and 8, every 3 weeks, for a maximum of 6 cycles (or weekly for 12 weeks)"
224308511|NCT01185197|DRUG|Myfortic plus low-dose steroid|Prednisolone: 0.25 mg/kg/day for 8 weeks then 0.15 mg/kg/day for 8 weeks then 0.1 mg/kg/day for 8 weeks then off Myfortic: 720 mg b.i.d. (540 mg b.i.d. if body weight less than 60 kg) for 24 weeks then off
224308512|NCT01185197|DRUG|Prednisolone|1 mg/kg/day to be tapered over a period of 24 weeks at the discretion of the attending physician
223588722|NCT02789592|DRUG|Melatonin PR|For experimental treatment of RBD
223588723|NCT02789592|DRUG|Clonazepam|For experimental treatment of RBD
223588724|NCT02789592|DRUG|Melatonin PR placebo|Placebo pill manufactured to mask melatonin PR 2mg tablet
223588725|NCT02789592|DRUG|Clonazepam placebo|Placebo pill manufactured to mask clonazepam 0.5mg tablet
223745656|NCT04709328|DRUG|SCTA01|Diluted by 0.9% normal saline，IV
223745657|NCT04709328|OTHER|Placebo|IV
223745658|NCT03050619|DRUG|Empagliflozin|
224308513|NCT05721287|DRUG|SBS-1000|SBS-1000 administered as a single continuous IV infusion over 60 minutes
224308514|NCT05721287|DRUG|Placebo|Normal saline (0.9% sodium chloride \[NaCl\]) administered as a single dose IV infusion over 60 minutes
224308515|NCT01006798|OTHER|Placebo|enteric coated capsule containing no vaccine virus
224308516|NCT01006798|BIOLOGICAL|Ad4-H5-Vtn|a live, replication-competent, recombinant Ad4 virus expressing the HA of H5N1 influenza (A/Vietnam/1194/2004) in an enteric capsule for oral administration
223745659|NCT03050619|DRUG|Other SGLT2 inhibitors|
224185012|NCT01098266|DRUG|Placebo plus Best Investigator's Choice (BIC)|"* Placebo: 0.8 mcg/m² as 60-minute intravenous infusion every week until confirmed evidence of disease progression or unacceptable toxicity occurs.~* Best Supportive Care: antibiotics, analgesics, antiemetics, thoracentesis, pleurodesis, blood transfusions, nutritional support, and focal external-beam radiation for control of pain, cough, dyspnea, or hemoptysis~* Investigator's Choice: one of the following single-agent chemotherapy might be administered in combination:~  1. Doxorubicin: 60-75 mg/m2 every 3 weeks, for a maximum of 6 cycles~ 2. Gemcitabine: 1,000-1,250 mg/m2 on days 1 and 8, every 3 weeks, for a maximum of 6 cycles~ 3. Vinorelbine: 25 mg/m2 iv (or 60 mg/m2 per os) on days 1 and 8, every 3 weeks, for a maximum of 6 cycles (or weekly for 12 weeks)"
224185013|NCT00136266|DRUG|Ferrous sulphate drops with vitamins A, D, and C|
223745660|NCT03050619|DRUG|Other non-insulin GLDs|metformin, sulfonylureas, DPP-4 inhibitors, GLP-1 agonists
224185014|NCT00136266|DRUG|Ferrous fumarate sprinkles with vitamins and minerals|
224185015|NCT03804723|DRUG|oral Prednisone 5mg|patients randomized to this arm will stop prednisone 5 mg
224185016|NCT00589823|DRUG|Fentanyl citrate|nasal spray, 100, 200, 400 or 800 mcg dosage according to need, to treat up to four episodes of BTCP per day
224185017|NCT00589823|DRUG|Immediate release morphine sulphate|drug dose as required by patient taken to treat up to four epsiodes of BTCP per day
224185018|NCT01296581|DRUG|X-82|Dose escalation starting at 20 mg, oral once or twice a day, 28 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
224185019|NCT03665558|DEVICE|Temporary DDD pacing|Measurements will be performed in patients otherwise undergoing invasive catheterization procedure. Baseline ventricular and aortic hemodynamic parameters (continuous pressure recordings) will be recorded. Thereafter, DDD pacing with stepwise changing of the AV delay will be performed. During each pacing steps left ventricular and aortic pressures at different aortic levels will be continuously recorded. From these hemodynamic data, left ventricular and aortic dP/dt values will be calculated off line.
223745661|NCT04728269|OTHER|Lactibiane Topic AD|Application of Lactibiane topic AD twice a day (morning and evening) on one lesional area
224308517|NCT01006798|BIOLOGICAL|Sanofi Pasteur Influenza Virus Vaccine, H5N1|Single administration of a heterologous boost given to volunteers 3 to 15 months following their last vaccination with Ad4-H5-Vtn or placebo.
224308518|NCT01988129|OTHER|Sleep disorders education and screening|Firefighters were instructed to attend an education presentation as operations allowed which provided information on firefighter mortality, fatigue-related health hazards and discussed the importance of sleep, and also included strategies to improve sleep hygiene and how to use caffeine and naps effectively to promote alertness. Firefighters were then invited to complete a voluntary sleep disorders screening survey. This survey used validated, self-report screening tools for obstructive sleep apnea, moderate to severe insomnia, restless legs syndrome and shift work disorder. All of those who screened positive for a high risk of any sleep disorder were notified by letter as to their risk and provided with contact information for a partnering sleep clinic if they chose to follow-up.
224308519|NCT04848922|OTHER|Hot shower intervention|Intervention group took a shower in a standing position at a water temperature of 37-41°C for 10-20 minutes between 6 and 12 hours after vaginally birth.
223745662|NCT04728269|OTHER|Placebo|Application of placebo twice a day (morning and evening) on the symmetrical lesional area
224185020|NCT03501134|DEVICE|NovoTTF|We are studying the effect of Tumor Treating Fields (NovoTTF), for example Optune™, on the quality of life, including exercise, sleep quality, and mood, of patients with malignant glioma who plan to use the NovoTTF device.
224185021|NCT01196754|OTHER|sevoflurane|
224185022|NCT04871451|DRUG|ABP-450|ABP-450 (prabotulinumtoxinA) contains a 900kDA botulinum toxin type-A complex produced by the bacterium Clostridium botulinum.
224185023|NCT00714831|BEHAVIORAL|Physical activity intervention|3-months physical activity intervention
224185024|NCT00714831|BEHAVIORAL|Health educational program|Health education sessions and stretching sessions
224185025|NCT01395420|DRUG|CAZ104|IV Infusion
224185026|NCT01395420|DRUG|CAZ104|IV Infusion
224185027|NCT05136989|BEHAVIORAL|Individual and collective semi-structured interviews|Individual and collective semi-structured interviews will be performed with professionals to identify levers (practices, knowledge, tools, regulations) which, at the level of services and establishments, enable the development of a policy of less recourse to coercion
224185028|NCT05136989|BEHAVIORAL|Individual semi-structured interviews with ex-patients|Individual semi-structured interviews will be performed with ex-patients in order to gather their experiences in the seven institutions concerned and to better understand the impact of their hospitalization in these institutions on their lives
224185029|NCT05136989|BEHAVIORAL|Observations out in the services|Observations will be carried out in the services in order to measure the gap between rhetoric and practice, and to observe the effective implementation of lesser use practices
224185030|NCT00649220|DRUG|Memantine|memantine tablets, twice a day (bid), for 20 weeks
224185031|NCT00405925|DRUG|Trizivir|
224185032|NCT00405925|DRUG|zidovudine,lamivudine,abacavir|zidovudine 300 mg bid, lamivudine 150mg bid, abacavir 300mg bid
224185033|NCT03861442|DEVICE|Audio processor SONNET|AI - N/A, WNR - Mild, Beam-former - NAT, AGC Compression - 3:1, AGC Sensitivity - 75%, ANR - N/A, TNR - N/A
224185034|NCT03861442|DEVICE|SONNET 2: Configuration 1|AI - Off, WNR - Mild, Beam-former - NAT, AGC Compression - 3:1, AGC Sensitivity - 75%, ANR - Mild, TNR - Mild
224185035|NCT03861442|DEVICE|SONNET 2: Configuration 2|AI - Off, WNR - Mild, Beam-former - NAT, AGC Compression - 3:1, AGC Sensitivity - 75%, ANR - Strong, TNR - Strong
224185036|NCT03861442|DEVICE|SONNET 2: Configuration 3|AI - Mild, WNR - Mild, Beam-former - Auto (NAT), AGC Compression - 3:1, AGC Sensitivity - 75%, ANR - Auto (Off-Mild), TNR - Auto (Off-Mild)
224185037|NCT03861442|DEVICE|SONNET 2: Configuration 4|AI - Strong, WNR - Strong, Beam-former - Auto (OMNI-ABF), AGC Compression - 3:1, AGC Sensitivity - 75%, ANR - Auto (Off-Strong), TNR - Auto (Off-Strong)
224185038|NCT03861442|DEVICE|SONNET 2: OPUS 2 configuration|AI - Off, WNR - Off, Beam-former - OMNI, AGC Compression - 3:1, AGC Sensitivity - 75%, ANR - N/A, TNR - N/A
223588726|NCT03753139|DEVICE|Heart rhythm monitoring with portable device|"The study compares the ability of lightweight measurement methods to detect different heart rhythms compared to the Holter registration.~1. Faros 360 ECG sensor with wet electrodes. Faros 360 Holter is CE and FDA 510 cleared class 2a medical device, which is attached to the patient's chest with five single-use wet electrodes.~2. Suunto Movesense one-time ECG device (Suunto Oy, http://www.suunto.com Vantaa Finland). Movesense is CE cleared consumer device, which is used with two dry electrodes to the ECG measurement.~3. Empatica E4 activity bracelet (Empatica Ltd http://www.empatica.com Milan, Italy), which is CE cleared consumer device. Empatica E4 is a photopletysmogram which measures optically the amount of blood circulating in the blood vessel.~4. Samsung Gear S3 wearable (Samsung Electronics, Co., Soul, South Korea) which is CE cleared consumer device. Gear S3 is a photopletysmogram, which measures optically the amount of blood circulating in the blood vessel."
223588727|NCT03465787|DRUG|Lurasidone HCL 160 mg|Lurasidone HCL 2 80mg tablets, QD
223588728|NCT03465787|DRUG|Quetiapine XR 600 mg|Quetiapine XR 2 300 mg tablets, QD
223588729|NCT04675996|DRUG|INT-1B3|60-min i.v. infusions twice per week in 21-day cycles
223588730|NCT04889482|OTHER|No intervention|No intervention
224185039|NCT03861442|DEVICE|SONNET 2: SONNET configuration|AI - Off, WNR - Mild, Beam-former - NAT, AGC Compression - 3:1, AGC Sensitivity - 75%, ANR - N/A, TNR - N/A
224185040|NCT05726617|BEHAVIORAL|Avatar Intervention|8 weekly sessions of 60 minutes.
224185041|NCT00525499|DRUG|ASC-J9 cream|Topical application to the face twice daily for 12 weeks.
224185042|NCT00525499|DRUG|placebo|vehicle control applied topically twice daily for 12 weeks
224185043|NCT00438815|BIOLOGICAL|C1 esterase inhibitor [human] (C1INH-nf)|
224185044|NCT05557266|BEHAVIORAL|Mindfulness-based intervention|An mindfulness instructor will conduct meditations lasting 15 to 30 minutes. The first day of each week the intervention will be given in streaming and the rest of the days the participants will have audio files designed ad hoc with the practice of the week so they can do it individually at home.
224185045|NCT05557266|BEHAVIORAL|Physical exercise|An aerobic and fitness trainer will conduct aerobic exercise lasting 15 to 30 minutes. The first day of each week the intervention will be given in streaming and the rest of the days the participants will have video files designed ad hoc with the practice of the week so they can do it individually at home.The intensity of the chosen exercise will be moderate, maintaining between 120-140 beats per minute.
224308520|NCT05552079|OTHER|No intervention|Patients will be asked to show their consultation slip to confirm they attend to clinic on the day. The will also be asked to show their HKID card to comfirm they are aged 40 or above. The purpose of the study will be explained. If patient agrees to proceed, he/she will be given a self-administered questionniare. An interviewer-administered questionnaire will be provided for subjects who have poor sightedness or are illiterate. Since only anonymous data and no identifiable information will be collected, participants cannot be identified from the questionnaire. Therefore, inform consent will not be obtained.
224308521|NCT05968599|DRUG|Enzalutamide|As provided in real-world setting
224308522|NCT05968599|DRUG|Abiraterone acetate|As provided in real-world setting
224308523|NCT00027248|DRUG|MBI 226|
224308524|NCT02029573|DRUG|Atorvastatin|80 mg po daily until disease progression or unacceptable toxicity. (starting dose of 40 mg po daily for the first 21 days)
224185046|NCT03343665|DRUG|Nivolumab 40 mg in 4 ml Injection|40 mg by intravenous (IV) infusion on day 1 Duration of cycle 14 days
224308525|NCT02029573|DRUG|Temozolomide|75mg/m2 po daily during radiotherapy, followed by 150-200mg/m2/day po on days 1-5 of each 6x4 week cycle of adjuvant therapy
224308526|NCT02029573|RADIATION|Radiotherapy|60 Gy in 30 fractions
224308527|NCT00329472|DRUG|gemcitabine, cisplatin|
224308528|NCT01751763|DRUG|Sorafenib (Nexavar, BAY43-9006)|treatment (including dose, duration, modification) decided by the investigator.
224308529|NCT04901169|DRUG|Angiotensin II|Infusion of Angiotensin II initiated if participants require norepinephrine at a rate of \> 0.05 mcg/kg/min. The infusion will be titrated no more frequently than every 10 minutes during liver transplantation as a second line vasopressor and discontinued prior to leaving the operating room when the surgery is complete.
224308530|NCT04901169|DRUG|Saline|Infusion of 0.9% saline initiated if participants require norepinephrine at a rate of \> 0.05 mcg/kg/min. The infusion will be titrated no more frequently than every 10 minutes during liver transplantation as a second line vasopressor and discontinued prior to leaving the operating room when the surgery is complete.
224308531|NCT03407235|DEVICE|Computerized Laparoscopic Trainer|Gold standard laparoscopic trainer using simulated computerized equipment.
224308532|NCT03407235|DEVICE|Box trainer with eye patch|Simple, cost effective box trainer, with loss of dept perception achieved with use of eye patch
224308533|NCT05000879|BEHAVIORAL|MMB for Moms|12-week program that emphasizes mindfulness and cognitive behavioral skills
224308534|NCT06116084|OTHER|Ericksonian Hypnosis|An Ericksonian hypnosis session given to patients during a scintigraphic or PET examination, in a conventional manner, i.e. the hypnotherapist (MERM) is close to the patient in the examination room at the time of the session and communicates with him/her without any special device dedicated to this purpose.
224308535|NCT06116084|OTHER|Hypnosis|A hypnosis session given to patients during a scintigraphic or PET examination, in a remote manner, i.e. the hypnotherapist (MERM) is in the control room at the time of the session and communicates with the patient via a microphone and the patient has headphones.
224308536|NCT06223243|OTHER|Stingless bee honey mouthrinse|Three bottles of 90ml of stingless bee honey of 20% concentration was given to each subject. This mouthrinse preparation was instructed for subjects to be taken 30ml each, thrice daily for three days.
224308537|NCT06223243|OTHER|normal saline mouthrinse|Subjects were instructed to rinse with 30ml of normal saline (0.9% concentration) thrice daily for three days.
224308538|NCT06223243|OTHER|chlorhexidine mouthrinse|Subjects were instructed to rinse with 30ml of chlorhexidine mouthrinse thrice daily for three days.
224185047|NCT03420846|OTHER|OCT Mapped|Presurgical mapping of Basal Cell Carcinoma margins
224185048|NCT03251716|DRUG|berberine|berberine 300mg TID add-on for berberine adjunctive group
224185049|NCT00843817|DRUG|Pulmozyme|Pulmozyme® 2.5mg by inhalation
224185050|NCT01917396|DRUG|Fleet enema|
224185051|NCT01111058|DRUG|Everolimus (RAD 001)|10mg of Everolimus or Placebo taken by mouth once daily for 1 year or until progression (whichever comes first).
224185052|NCT01111058|OTHER|Placebo|
224185053|NCT05962658|OTHER|qEEG|qEEG data was collected with patients and healthy individuals in resting eyes-closed: the relative spectral power of the frequency bands delta, theta, alpha and beta was evaluated.
223493266|NCT07120880|PROCEDURE|AD + SHR + placebo LT and extended-release melatonin 2mg|Patients will receive an SSRI or SNRI, sleep hygiene instructions, daily placebo light exposure (\<10 lux, 30 cm, 30 min, 7-8 a.m., using Dayvia Slim Style 3 lamps in non-therapeutic mode), and 2 mg of extended-release melatonin taken one hour before bedtime, all for a duration of 8 weeks.
223493267|NCT07120880|PROCEDURE|AD + SHR + placebo LT and placebo melatonin|Patients will receive an SSRI or SNRI, sleep hygiene instructions, daily placebo light exposure (\<10 lux, 30 cm, 30 min, 7-8 a.m., using Dayvia Slim Style 3 lamps), and oral placebo melatonin taken one hour before bedtime, all for a duration of 8 weeks.
223493268|NCT07123818|DEVICE|AI software|AI software that will verify brain NECT scans on the presence of unruptured intracranial aneurysms (UIA). Brain NECT scans will be send to the AI software which will detect possible unruptured intracranial aneurysms (UIA). NECT scans on which a possibe UIA has been detected will be send to a platform on which involved radiologist can verify the AI result(s).
223493269|NCT07035197|DRUG|Eptinezumab|"Eptinezumab 100 mg IV q 3 months~* Baseline visit: Within 24 hours of receiving eptinezumab (duration of IDI \~30 - 45 minutes)~  * Semi-structured In-depth interview~ * MMD (days)~ * Thai version MIDAS (total score, grading)~ * Thai version EQ-5D-5L (5 domains \& 5 levels of severity; index score)~* 3-month follow-up visits (duration of interview: \~10 minutes):~  * Semi-structured brief interview~ * MMD (days)~ * Thai version MIDAS (total score, grading)~ * Thai version EQ-5D-5L (5 domains \& 5 levels of severity; index score)~* 6-month follow-up visit:~  * no interview~ * MMD (days)~ * Thai version MIDAS (total score, grading)~ * Thai version EQ-5D-5L (5 domains \& 5 levels of severity; index score)"
223493270|NCT07035197|OTHER|Sham (No Treatment)|"\*\* No intervention, neither eptinezumab nor placebo, was given~* Baseline visits: Within 24 hours of giving eptinezumab administration (duration of IDI \~30 - 45 minutes) - Semi-structured in-depth interview"
223493271|NCT07035886|OTHER|No intervention|As this is an observational study, no intervention will be administered.
223493272|NCT04539041|DRUG|antisense oligonucleotide|solution of antisense oligonucleotide injected intrathecally (spine tap) at multiple dose levels
223493273|NCT04539041|DRUG|placebo|placebo for each dose level
223493274|NCT07038785|DIAGNOSTIC_TEST|Breath test|Breath sample collection using a sample collection kit
223493275|NCT06720636|DEVICE|EndoSign|"The EndoSign cell collection device is a non-endoscopic capsule sponge device used to collect pan-esophageal samples.~The Endosign procedure consists of an expandable, spherical mesh, which is attached to a string and contained within a soluble capsule. Seven minutes after swallowing (once the capsule has dissolved), the spherical mesh, which measures around 3cm in diameter is retrieved by pulling on the string. Upon retrieval the capsule-sponge scrapes against the surface of the top of the stomach and esophagus and collects epithelial cells. The capsule-sponge sample is then placed into a preservative fluid and the specimen is processed for molecular tests."
223493276|NCT06721793|DIETARY_SUPPLEMENT|carbohydrate electrolyte drink|2% carbohydrate solution with 1,020 mg/L of Sodium
223588731|NCT03764930|OTHER|Unsuspected Retinoblastoma|To study the clinical characteristics and treatment outcomes of patients who experienced inadvertent trauma before diagnosis of retinoblastoma.
223588732|NCT05889078|BEHAVIORAL|A 4-week walking intervention|Participants will walk along a predetermined route 3 times per week for a period of 4 weeks, answering a pre- and post-intervention questionnaire as well as weekly questionnaires measuring their affect and other variables related to wellbeing. Participants will be randomly assigned to one of two conditions (nature vs urban setting), determining whether the predetermined route they will walk is in a nature or urban setting.
223588733|NCT02654665|BEHAVIORAL|Lifestyle modification|Diet and exercise designed for 5-7% weight loss over 6 months
224185054|NCT01733758|DRUG|Albiglutide 30 mg weekly|Albiglutide will be available as a pen injector that delivers 30mg of albiglutide
224185055|NCT01733758|DRUG|Albiglutide 50 mg weekly|Albiglutide will be available as a pen injector that delivers 50mg of albiglutide
223588734|NCT02654665|DRUG|Liraglutide|GLP-1 agonist
224185056|NCT01733758|DRUG|Placebo|Albiglutide matching placebo will be available as a pen injector
224185057|NCT01733758|DRUG|Liraglutide 0.9 mg daily|Liraglutide will be available as prefilled multidose pens that can deliver 0.9 mg dose
223493277|NCT06721793|DIETARY_SUPPLEMENT|no-sugar electrolyte drink|1% carbohydrate solution with 1,060 mg/L of Sodium
223493278|NCT06721793|DIETARY_SUPPLEMENT|Caffeinated Carbohydrate and electrolyte drink|2% carbohydrate solution with 1,000 mg/L of Sodium, and 200mg/L caffeine
223588735|NCT01280695|DRUG|Placebo|Placebo Capsules
223588736|NCT01280695|DRUG|MSDC-0602 100 mg|MSDC-0602 100 mg Capsules
223588737|NCT01280695|DRUG|MSDC-0602 250 mg|MSDC-0602 250 mg Capsules
223588738|NCT01280695|DRUG|MSDC-0602 250 mg|MSDC-0602 500 mg Capsules
223588739|NCT01280695|DRUG|Pioglitazone|Pioglitazone 45 mg Capsules
223588740|NCT05456971|DEVICE|Art Filler Volume|Midface correction with injectable hyaluronic acid based-filler
223588741|NCT05456971|DEVICE|Art Filler Lips|Lipscorrection with injectable hyaluronic acid based-filler
223588742|NCT05231239|DEVICE|tDCS : Transcranial direct current stimulation|Transcranial direct current stimulation
223588743|NCT00246701|DRUG|Simvastatin|Simvastatin
224185058|NCT06515834|DRUG|FE 999301|To assess the safety and tolerability of FE 999301 after single intravenous (IV) dose infusion in healthy Japanese men
224185059|NCT06515834|DRUG|Placebo|Placebo to assess the safety and tolerability of FE 999301 after single intravenous (IV) dose infusion in healthy Japanese men
224185060|NCT05024721|DRUG|HIP2101|Test drug
224185061|NCT05024721|DRUG|RLD2101|Reference drug
224185062|NCT05024721|DRUG|HPP2101|Placebo drug
224185063|NCT05024721|DRUG|HPP2102|Placebo drug
224185064|NCT05405621|DRUG|BAT8009 for Injection|BAT8009 will be administered as a 90-minute (± 5min) IV infusion on Day 1 of Cycle 1. If there is no infusion related reaction after initial dose, the next dose of BAT8009 will be infused intravenously into each patient for approximately 30\~120 minutes.
224185065|NCT01751490|OTHER|physiotherapy|physiotherapy
223493279|NCT06721793|DIETARY_SUPPLEMENT|Water (Placebo)|flavored water with non-caloric, non-sodium-containing sweetner
223493280|NCT07040592|DRUG|semaglutide|All participants will receive a prescription for semaglutide and will meet with a clinical pharmacist and addiction psychiatrist for further support
223493281|NCT03421808|DEVICE|Transcranial Magnetic Stimulation (TMS)|TMS
223493282|NCT07037134|OTHER|Natural soundscape exposure|Participants receive a standardized 20-minute auditory exposure to curated natural soundscapes via high-fidelity open-back reference headphones powered by a DAC/amplifier and corrected for frequency response using calibration software. Participants are randomly assigned one of 22 recordings. Each includes 10-second fade-in/out effects and are calibrated to 45-55 dB. The stereo recordings (320-kbps MP3, 48 kHz/24-bit) feature biophony (e.g., bird vocalizations) and geophony (e.g., rainfall), free of urban sounds and selected for ecological validity based on predefined criteria: (i) recognizable/context-specific sounds; (ii) culturally neutral; (iii) foreground presence and depth; (iv) no prolonged silence; (v) no technical artifacts. During exposure, they lie supine in a 60° Fowler's position on a therapy table, with sensory input minimized through auditory isolation and controlled ambient conditions. The session involves active, causal listening under continuous researcher supervision.
223493283|NCT07037134|OTHER|Urban soundscape exposure|Participants receive a standardized 20-minute auditory exposure to curated urban soundscapes, using the same equipment and technical specifications as all other intervention conditions. Each participant is randomly assigned one of 22 recordings, calibrated to 45-55 dB (Leq,20min). The recordings feature anthropophony (e.g., unintelligible background speech) and technophony (e.g., transportation-related sounds), free of natural sounds and selected for ecological validity based on the same predefined criteria as the natural soundscapes. To prevent semantic processing, participants are pre-screened and post-session reconfirmed to ensure they do not understand the languages used. During exposure, participants lie supine in a 60° Fowler's position on a therapy table, with sensory input minimized through auditory isolation and controlled ambient conditions. The session involves active listening in a causal mode and is conducted under continuous researcher supervision.
224185066|NCT01751490|PROCEDURE|shoulder stabilisation surgery|arthroscopic stabilisation surgery
224185067|NCT01250691|OTHER|ward-type ICU|frequency of hospital acquired pneumonia in the ICU
224185068|NCT06080529|OTHER|Sandbag exercise|Both arms include an exercise intervention consisted of 8 different exercises with sandbag: (1) lateral bag drag, (2) dead bag, (3) shoulder to shoulder thruster, (4) sumo DL with pull, (5) front lunge, (6) single leg RDL, (7) reverse lunge with rotation and (8) clean
224185069|NCT00877526|OTHER|No treatment given|Subject will only fill out a questionaire when entering the observational study.
224185070|NCT04963517|BEHAVIORAL|Exercise therapy|8 weeks personalized, multi-modal exercise with focus on lower extremity
224185071|NCT04963517|OTHER|Information|"* Initial consultation with recommendations for general physical activity~* Brochure with exercise recommendations."
224185072|NCT04387396|OTHER|Exercise|Exercise specific to knee osteoarthritis.
224185073|NCT06234566|PROCEDURE|Conventional dental implant surgery|It is performed to reconstruct lost teeth. These are surgical procedures performed to place dental implants in the jaw bones. To prepare the implant socket, drilling is performed with serum irrigation at a speed of 800 rpm.
224185074|NCT06234566|PROCEDURE|Low Speed Drilling Without Irrigation|It is performed to reconstruct lost teeth. These are surgical procedures performed to place dental implants in the jaw bones. To prepare the implant socket, drilling is performed at a speed of 50 rpm without serum irrigation.
224185075|NCT06235060|OTHER|Computer-assisted simulation technique training group|After the training given with the demonstration method, the training videos on https://www.montgomerycollege.edu/academics/departments/nursing-tpss/nursing-simulation-scenario-library.html were shown to the participants using interactive training methods in parallel with this training.
224185076|NCT06235060|OTHER|Imagery GROUP|After the training given with the demonstration method, scenarios suitable for the imagery technique were prepared by the second trainer (Ö.S.A.) in parallel with this training and CAST training.
223493284|NCT07037134|OTHER|Broadband sound exposure|Participants receive a standardized 20-minute auditory exposure to broadband sounds (i.e., white or pink noise), using the same equipment and technical specifications as all other intervention conditions. Each participant is randomly assigned to one of the two noise types, with equal distribution across conditions. The stimuli are generated using professional audio software and calibrated to 50 dB (Leq,20min). During exposure, participants lie supine in a 60° Fowler's position on a therapy table, with sensory input minimized through auditory isolation and controlled ambient conditions. The session involves active listening in a causal mode and is conducted under continuous researcher supervision.
223588744|NCT00246701|DRUG|Simvastatin + Lovaza|Simvastatin + Lovaza (omega-3-acid ethyl esters)
223588745|NCT01662323|BEHAVIORAL|GP's treating HF according the dutch guidelines|
224185077|NCT05861882|OTHER|functional movement screen|FMS consists of seven test component which are used to evaluate various main movement models.Individuals completed one by one deep squat, high stepping, single line lunge, shoulder mobility, straight leg raises, trunk stability push-ups, rotation stability which are component tests. Subcomponent tests assess asymmetry by measuring the individual bilaterally. Each component test was scored on an ordinal scale (0 to 3 points), with a maximum score of 3, based on the quality of the movement. Less than 3 points indicated that the individual performed some form of compensation or was unable to complete the entire movement.While individuals were doing these tests, they were recorded in the video , the final scoring was done by evaluating the images. The scores of the component tests were summed, resulting in a composite score between 0 and 21 points, with a maximum score of 21
224185078|NCT05861882|OTHER|survey application|Participants are evaluated with kasari physical activity survey. According to the FIT score, physical activity level is commented as sedentary between 0-20, poor between 21-40, normal between 41-60, good between 61-80 and perfect between 81-100
224185079|NCT05861882|OTHER|Y balance test|YBT, which is performed in the standing position on one leg , is dynamic a test. Participants stood on the footplate in the centre of the Y Balance Test area and then, it was given instruction them that they should maintain a single leg stance while reaching as far as possible with the opposite leg and return to the starting position on the centre platform without losing balance.In the test, individuals were asked to reach the maximum distance in 3 directions (anterior, posteromedial and posterolateral), allowing 3 trials for each leg. The maximum reach distance was recorded for each consecutive trial
224185080|NCT05861882|OTHER|Core stabilization assessment|The flexor muscle endurance test is initiated with the subject in a sitting position, with the back leaning against an apparatus angled 60 degrees from the floor. Both knees and hips are flexed to 90 degrees and the support apparatus is withdrawn and the time the person maintains the position is recorded The extensor muscle endurance test is performed with the upper trunk extended towards the end of the bed on which the test is performed and the pelvis, knees and hips fixed. The time the upper trunk maintains its level is recorded The lateral bridge test was performed with the individual lying in the full side bridge position (left and right side separately). Individuals supported themselves on one elbow and their feet while lifting their hips off the floor to form a straight line from head to toe. The test was terminated when the individual lost the straight back posture and/or their hips touched the floor.
223493285|NCT07037134|OTHER|Blank tape attention placebo control|Participants receive a standardized 20-minute exposure to blank audio (silence), using the same equipment and technical specifications as all other intervention conditions. At study onset, participants are informed they will hear a range of environmental sounds, including some that may be inaudible (i.e., present but beyond the range of human hearing). During the placebo condition, a blank recording is played, producing silence, while participants remain unaware of whether they are receiving an active or placebo stimulus. This attention-control condition ensures procedural consistency while delivering no auditory stimulation. During exposure, participants lie supine in a 60° Fowler's position on a therapy table, with sensory input minimized through auditory isolation and controlled ambient conditions. The session involves active listening in a causal mode and is conducted under continuous researcher supervision.
223493286|NCT06723743|OTHER|Transcutaneous vagus nerve stimulation for attention in veterans with TBI|taVNS does not require surgery or medication, offering a safe and accessible treatment option. Each participant undergoes both an active taVNS session and a sham (placebo) session. Sham stimulation mimics the sensory experience of taVNS but does not deliver electrical currents to the vagus nerve, ensuring blinding and providing robust comparisons. The study is completed in a single visit lasting 2.5 to 3 hours, minimizing participant burden.
223493287|NCT06723743|DEVICE|Soterix Medical Vagus Nerve Stimulation mini-CT|Soterix Medical min-CT VNS device is used for non-invasive stimulation procedures and trials. It has blinding features such as single-blind for this study in which patients will either receive active or shame taVNS.
223493288|NCT06184152|DIAGNOSTIC_TEST|CEUS imaging|Contrast-enhanced ultrasound (CEUS)
223493289|NCT06184152|DIAGNOSTIC_TEST|aMRI imaging|contrast enhanced abbreviated MRI (AMRI)
223493290|NCT07042945|DRUG|MK-4646|MK-4646 in capsular form administered orally
223493291|NCT07038668|PROCEDURE|Using of viscoelastic during the operation|Using of viscoelastic during the operation
223493292|NCT07038668|PROCEDURE|No using of viscoelastic during the operation|No using of viscoelastic during the operation
223493293|NCT07039305|BEHAVIORAL|Physical capacity training for chronic stroke - building aerobic capacity and muscle strength|The general format of each exercise session includes assessment of resting heart rate (HR), blood pressure (BP), and rating of perceived exertion (RPE) followed by a 5-minute warm-up, a minimum of 30 minutes of aerobic exercise followed by 25 minutes of resistance exercise. Aerobic exercise will always include a minimum of 10 minutes of walking (overground or treadmill) at the prescribed intensity followed by cycle, arm or rowing ergometry. Sessions will begin at a target intensity of \~60% heart rate reserve (HRR) determined from the exercise tolerance test performed at baseline and calculated using Karvonen's formula. The goal will be to increase training intensity by \~5% HRR every \~3 weeks and progressed as tolerated. Resistance exercise will target all major muscle groups and include multiple sets dosed at the 10-repetition to fatigue level (\~75% of the 1-repetition maximum). Resistance exercises will be progressed with improvements in strength or as tolerated.
223493294|NCT07043322|PROCEDURE|Coasting|In their ICSI cycle patients will continue their agonist treatment while stopping the human menopausal gonadotropin (hMG) injections for 1 to 3 days until drop of estradiol to a safe level to prevent OHSS. Early OHSS is assessed at day of embryo transfer and 7 days after this date. Late OHSS is assessed 14 days after embryo transfer.
223493295|NCT07043322|DRUG|Cabergoline|Cabergoline is used to treat different types of medical problems that occur when too much of the hormone prolactin is produced. It can be used to treat certain menstrual problems, fertility problems in men and women, and pituitary prolactinomas
223493296|NCT06382480|OTHER|Diet with specific macronutrient composition.|The intervention is about an isocaloric diet that differs in terms of distribution of carbohydrates and protein throughout the day. The interventions include a HP-breakfast and a HC-dinner vs. a HC-breakfast and a HP-dinner. A HP low-carb meal (breakfast or dinner) will contain 35%E protein, 35%E carbs, and 30%E fat, and a HC meal (breakfast or dinner) will contain 10%E protein, 60%E carbs, and 30%E fat.
223493297|NCT07038915|DRUG|Tiragolumab|Given by IV
223493298|NCT07038915|DRUG|Ivonescimab|Given by IV
223493299|NCT06728358|DIAGNOSTIC_TEST|Molecular analyses|Search for molecular alterations that correlate with patient prognosis
223493300|NCT07050433|DIAGNOSTIC_TEST|CXCR2 as a biomarker|CXCR2 biomarker expression will be measured in tumor and immune cell samples
223493301|NCT06736405|OTHER|Pericapsular nerve group block|Pericapsular nerve group block will be applied to patients in addition to standard treatment to prevent postoperative pain
223493302|NCT06736405|OTHER|No Pericapsular nerve group block|Patients will be given standard treatment to prevent postoperative pain
223493303|NCT06734364|DEVICE|buddy tape|Buddy-taping a finger dynamically splints one finger to an adjacent, uninjured finger.
223493304|NCT06734364|DEVICE|splint|Short arm splint immobilize and maintain stability of the injured finger, the hand is immobilized in the intrinsic plus position with syndactyly of the injured finger and adjacent finger
223493305|NCT01688492|DRUG|Ipilimumab|Abiraterone acetate (JanssenBiotech, Inc/Johnson \& Johnson) 1000 mg orally daily plus prednisone 5 mg orally twice daily will be administered continuously during the duration of the trial. Starting at cycle 3 (Combination Therapy), Ipilimumab (Bristol-Myers Squibb) will be infused intravenously (IV) once every 3 weeks for a total of 4 infusions.
223493306|NCT02769273|DEVICE|Percutaneous Transluminal Angioplasty|
223493307|NCT06726096|BIOLOGICAL|Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection|"The drug was administered once every 4 weeks.~Other Names:~Tocilizumab Injection placebo control"
224185081|NCT05468866|GENETIC|Genotyping of rs1980422-related single-nucleotide polymorphisms by real time PCR|detection of rs1980422-related single-nucleotide polymorphisms and percentage of (CD3,CD4,CD28) by immunophenotyping
224185082|NCT00542074|OTHER|hygienic information plus 62% ethyl alcohol in emollient gel|The male partner in each couple was asked to apply Purell® to his penis at least daily, and immediately prior to and following intercourse. Couples received a brochure with information on control of STI and good hygienic practices. Brochures for intervention and control arms were similar except the intervention arm brochure provided information on how to use the study product (Purell®).
224185083|NCT00542074|OTHER|hygienic information|Couples received a brochure with information on control of STI and good hygienic practices.
224185084|NCT04130204|DRUG|DYV700|Proprietary transdermal delivery platform
224185085|NCT04130204|DRUG|Placebo|Vehicle transdermal delivery platform
224185086|NCT04130204|DRUG|Colchicine 0.6 mg|Standard of care, 2 tablets (1.2 mg) loading dose followed by 1 tablet (0.6 mg) 1 hour later at onset of gout flare.
224185087|NCT00316966|BEHAVIORAL|Multidisciplinary dietary intervention|
224185088|NCT01631123|OTHER|Isocaloric high carbohydrate diet intervention|Time of 6 week, the last 6 days are standardized
224185089|NCT01631123|OTHER|Isocaloric high fat diet intervention|Time of 6 weeks; the first and the last 6 days are standardized
224185090|NCT04096924|DEVICE|Guidewire for echo-guided interventions|Under echocardiography guided treatment of ASD with a novel interventional guidewire
224185091|NCT04096924|DEVICE|Cook lunderquist guidewire|Subjects with ASD treated with amplatzer using the Cook lunderquist guidewire.
223493308|NCT05934838|DRUG|Tazemetostat Pill|Participants will take 800 mg of tazemetostat twice a day starting 7 days before apheresis and continue to take tazemetostat until lymphodepletion, which is chemotherapy given prior to receiving the CAR T cells. Participants will stop taking tazemetostat after lymphodepletion until after CAR T cell infusion. Once lymphocyte counts increase, tazemetostat will be resumed and tazemetostat will be taken for 6 - 12 months, depending on participant response.
223493309|NCT06732154|DRUG|HRS-5632|HRS-5632 Injection
223493310|NCT06732154|DRUG|Placebo|Sodium chloride injection
223493311|NCT06886464|DRUG|Cilastatin Sodium|Intravenous cilastatin reconstituted in normal saline solution
223493312|NCT06886464|DRUG|Placebo-Saline|Identical looking normal saline solution
223493313|NCT07048496|OTHER|BCG delivery at home|The BCG at home project will be a single-arm prospective pilot, to evaluate the feasibility, scalability and effectiveness of home treatment, and utilize the BB-Bot (chatbot) for PRO and adverse event measurement.
224185092|NCT03933358|OTHER|Thyroid hormone levels|This is an observational study. Exposure: Different thyroid hormone levels.
224185093|NCT03007680|OTHER|Core muscle activation|
224185094|NCT05903976|DRUG|P2Y12 inhibitor de-escalation|Comparing, in patients at High Bleeding Risk (HBR) after a recent Acute Coronary Syndrome (ACS), continuation of full-dose potent P2Y12 inhibitor with a P2Y12i de-escalation strategy transitioning to clopidogrel 75mg, prasugrel 5mg or ticagrelor 60mg/bid.
224185095|NCT01288820|DRUG|Dihydroartemisinin/piperaquine + primaquine|Dihydroartemisinin 2.25mg/kg and piperaquine 16-18mg/kg on day 0, 1, and 2 and primaquine 15 mg/kg form day 0-13.
224185096|NCT01288820|DRUG|Artesunate-amodiaquine + primaquine|Standard treatment with artesunate-amodiaquine plus primaquine, with artesunate 4mg/kg and amodiaquine 10mg/kg on day 0, 1, and 2 and primaquine 15 mg/kg form day 0-13.
224185097|NCT05836389|PROCEDURE|Pulmonary veins isoltation in bilateral thoracoscopy|Ablation of the atrial fibrillation performin isolation of the pulmonary vein. The procedure is video-assisted, access is minimally invasive: access to the heart is provided to instruments and camera via small bilateral chest incisions
224185098|NCT01065662|DRUG|temsirolimus|Given on days 1, 8, 15 and 22 of each cycle
224185099|NCT01065662|DRUG|cediranib|Taken orally daily
224185100|NCT00968565|DRUG|sodium citrate|Continuous infusion of 4% sodium citrate at 300 ml/hour into ECMO circuit
224185101|NCT04795674|BEHAVIORAL|EWM Training|Training tasks will target Executive Working Memory areas of the brain. Task difficulty will be adaptively increased across the 5 weeks of training based on session-to-session performance.
224185102|NCT04795674|BEHAVIORAL|Placebo Training|Computerized tasks with comparable engagement that do not tap executive working memory processes
224185103|NCT03256591|OTHER|HBB facilitators with simulation training|HBB training from facilitators with simulation skills. Standard HBB facilitators do not have simulation skills
224185104|NCT05257876|OTHER|Breathing exercise|Participants will receive breathing exercise training, and a 4-week self exercise
223493314|NCT06891066|DRUG|ISL|ISL 1mg oral capsule will be administered as 2mg orally (each capsule 1mg) as part of ISL and ULO combination to group 1 participants for 96 weeks and for group 2 participants in part 2 of the study from 49 to 96 weeks.
223493315|NCT06891066|DRUG|ULO|ULO 100mg oral tablet will be administered as 200mg (2 tablets) orally as part of ISL and ULO combination to group 1 participants for 96 weeks and for group 2 participants in part 2 of the study from 49 to 96 weeks.
223493316|NCT06891066|DRUG|BIC/FTC/TAF|BIC 50mg oral tablet/FTC 200mg oral tablet/TAF 25 mg oral tablet administered orally to group 2 participants for 48 weeks in part 1 of the study.
224185105|NCT05003765|DRUG|Bupivacaine 0.25% Injectable Solution|Injection of Bupivacaine 0.25% Injectable Solution for SPIP Nerve Block.
224185106|NCT05003765|DRUG|Bupivacaine 0.25% Injectable Solution, Magnesium Sulfate 200 mg|Injection of Bupivacaine 0.25% Injectable Solution for SPIP Nerve Block. Addition of 200mg of magnesium sulfate as adjuvant.
224185107|NCT05003765|DRUG|Bupivacaine 0.25% Injectable Solution, Magnesium Sulfate 200 mg, Buprenorphine 300 mcg|Injection of Bupivacaine 0.25% Injectable Solution for SPIP Nerve Block. Addition of 200mg of magnesium sulfate and 300 mcg buprenorphine as adjuvants.
224308539|NCT05164887|PROCEDURE|Laparoscopic colorectal resection|the patients candidate to laparoscopic colorectal resection for cancer are perioperatively treated with mechanical bowel preparation, oral antibiotics and administration of probiotics
223493317|NCT06892340|DEVICE|Transcutaneous Auricular Neurostimulation device|The Sparrow Ascent device will be programmed to the preset stimulation parameters. Two individual stimulation frequencies will be set: 15 Hz at cymba concha (Region 1/Channel 1; vagal innervation) and 100 Hz adjacently anterior to the tragus (Region 2/Channel 2; trigeminal innervation). The pulse duration will be set to 250 #s for all participants. The stimulation intensities (mA) will be set to 1.0 and 1.4 (for Region 1 and 2, respectively) based on the median values observed in the previous data set. If the participant states that the stimulation intensity is discomforting, the research coordinator will gradually decrease/increase until a comfortable stimulation intensity is achieved
223588746|NCT02476786|BEHAVIORAL|FACT-B|The FACT-B (Version 4) is a 37-item measure that contains the four general subscales along with the Breast Cancer-Specific subscale that assesses symptoms/concerns of particular relevance to breast cancer (e.g., body image, arm swelling and tenderness).
224185108|NCT04721431|DIAGNOSTIC_TEST|Myotonometric assessment|MyotonPro device is vertically placed on the muscle, a probe (3 mm diameter) creates constant pre-excitations (0.18 N) and generates short-term (15 ms), low-force (0.4 N) mechanical stimulations.These stimulations induce damped natural oscillations in the tissue and the device records these oscillations using an accelerometer. Muscle tone, elasticity, and stiffness are calculated separately by the device
224185109|NCT01768169|DIETARY_SUPPLEMENT|fish oil capsule|500 mg of natural fish oil, made up of 30% omega-3 PUFA (EPA:DHA = 3:2)
224185110|NCT01708369|DRUG|Placebo|Orange juice administered 15 minutes before subjects take oseltamivir or aspirin
224185111|NCT01708369|DRUG|Ethanol|Ethanol will be mixed with orange juice and subjects will drink the mixture 15 minutes before receiving oseltamivir or aspirin
224185112|NCT01708369|DRUG|Oseltamivir|Oseltamivir 150 mg orally
224185113|NCT01708369|DRUG|Aspirin|Aspirin 650 mg orally will be given
224185114|NCT01574924|OTHER|No intervention.|There are no interventions in this observational study.
224185115|NCT02164058|DEVICE|TandemHeart System|
224185116|NCT02164058|PROCEDURE|Percutaneous coronary intervention|
223493318|NCT06892184|BEHAVIORAL|hypnotic communication|During local anaesthesia, the operator will not remain silent, nor will he describe to his patient the anaesthesia he is performing, nor warn his patient of possible future pain. When performing anesthesia, the operator will use a dissociative, hypnotic language, standardized across all patients.
223493319|NCT06892184|BEHAVIORAL|conventional communication|suggestions typically uttered by the practitioner, who describes what he is doing and warns of possible pain.
223493320|NCT06670534|DRUG|JMKX003142 tablets|JMKX003142 tablets for experimental groups.Take the JMKX003142 tablets（on empty stomach） once daily for seven days.
223493321|NCT06670534|DRUG|Torasemide tablets|Torasemide tablets for active comparator group.Take the torasemide tablets once daily for seven days.
223493322|NCT06740760|BEHAVIORAL|Genetic counselling|Behavioral: genetic counselling
223493323|NCT06740760|BEHAVIORAL|Leaflet|Genetic information as a form of a leaflet
223588747|NCT02476786|DRUG|Goserelin|
223588748|NCT02476786|DRUG|Anastrozole|
223745663|NCT03001258|OTHER|Presbyopia screening training|The training module and the protocol were designed in a way that a layman with limited education could be trained for screening and could sell reading glasses without any hassle, accurately and responsibly. Training module included the general anatomy of eye, common vision problems, aetiologies, determination of proper acuity of vision, sales techniques of the reading glass, marketing of products and services, and management of inventory and referrals. All the providers who participated in the current study, had no prior experience/training of screening presbyopia before the intervention. Each of the intervention arm used letter acuity chart i.e. Snellen chart as it commonly used for as a test of visual acuity
223588749|NCT02476786|DRUG|Exemestane|
223745664|NCT03078621|BIOLOGICAL|Stem Cell Therapy|Intravenous and Intrathecal transplantation of purified autologous bone marrow-derived stem cells and mesenchymal stem cells.
223493324|NCT06611436|DRUG|BE-101|IV Infusion of BE-101 dose from Dose Level 1
223493325|NCT06611436|DRUG|BE-101|IV Infusion of BE-101 dose from Dose Level 2
223493326|NCT06611436|DRUG|BE-101|IV Infusion of BE-101 dose from Dose Level 3
223493327|NCT06611436|DRUG|BE-101|IV Infusion of BE-101 with optimal dose selected from Part 1 Dose Escalation
223493328|NCT06750276|DRUG|AZD2389|Doses of AZD2389 or placebo will be administered orally.
223745665|NCT01530295|DRUG|DOCETAXEL|75 mg/m2, IV (in the vein) on day 1 of each 21 day cycle. Number of Cycles: 3 times pre-op and 3 times after surgery
223745666|NCT00078026|DRUG|Apomine|
223745667|NCT04067128|BEHAVIORAL|Health coaching|Brief telephonic intervention consisting of up to three phone calls
223588750|NCT02476786|DRUG|Fulvestrant|
224185117|NCT04594213|DRUG|NT 201|Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% NaCl.
224185118|NCT04594213|DRUG|Placebo|Solution for injection prepared by reconstitution of powder with percent (%) Sodium Chloride (NaCl).
224185119|NCT00538434|BIOLOGICAL|Reslizumab|
224185120|NCT00538434|OTHER|Saline|
224185121|NCT05409742|DIAGNOSTIC_TEST|Modified Hall technique|The standard Hall technique was later modified with several modifications including occasional/rare use of anesthetic and about 1 mm proximal slice that the preformed metal crown fits without separation, and minimal occlusal reduction of the cusps
224185122|NCT03054493|BEHAVIORAL|no intervention|no intervention
223588751|NCT02476786|DRUG|Tamoxifen|
223588752|NCT02476786|OTHER|Archived tissue collection|
223588753|NCT01390922|DRUG|Botulinum Toxin Type A|Botulinum Toxin Type A
223588754|NCT03545074|BEHAVIORAL|Mindful Awareness Practices- English|The 6-week intervention aimed at teaching mindfulness-based strategies to participants (in English)
224185123|NCT03024294|OTHER|Post-operative care pathway for patients undergoing VATS lobectomy or segmentectomy|To place participants on this specific post-operative care pathway upon the completion of their VATS surgery to determine the discharge rate by midnight on post-operative day (POD) three.
224185124|NCT02709980|BEHAVIORAL|Sleep Education|The sleep education intervention will parallel the CBT-I intervention in number, format (in-person) and length of sessions. It is intended to disseminate information about sleep including sleep hygiene information that is widely available. Subjects will be instructed to read and review 6 publications from the American Academy of Sleep Medicine; sessions will review the material to ensure complete access to the information.
224308540|NCT02828306|OTHER|Patient Specific Implant|Implantation of Patient Specific Implant
224308541|NCT00993837|PROCEDURE|thyroidectomy|total thyroidectomy via endoscopic approach and that convert to open procedure
224308542|NCT02740699|DRUG|Rosuvastatin|Participants will receive 20-40 mg once daily
224308543|NCT02740699|DRUG|Atorvastatin|Participants will receive 40-80 mg once daily.
223588755|NCT03545074|BEHAVIORAL|Mindful Awareness Practices- Spanish|The 6-week intervention aimed at teaching mindfulness-based strategies to participants (in Spanish)
224308544|NCT02740699|RADIATION|Cardiac Computed Tomography (CT)|Cardiac CT angiography (CCTA) provides a non-invasive method of evaluating both calcified and noncalcified plaque volume. Performed at baseline, 12 months 24 months, and 36 months.
224308545|NCT02740699|RADIATION|Cardiac Magnetic Resonance Image (MRI)|Provides a non-invasive method of evaluating both calcified and noncalcified plaque volume. Cardiac MRI may be performed at baseline, and 24 months (optional).
223493335|NCT06882057|DRUG|Blinatumomab|All LR-B-ALL patients will be treated with 14 days of blinatumomab (Blina-14) as early intensification to replace CAT+ (historically given in LR-B-AL with MRD19\>0.1% in the 2020 protocol). Additionally, second 14 days of blinatumomab will be given after completion of HDMTX consolidation treatment.
223493336|NCT06882057|DRUG|Reinduction-2 omission|Reinduction-2 will be omitted for patients with NGS-MRD46\<10\^-6 who have receive the two courses of Blina-14.
223493337|NCT06882057|DRUG|Chemo-light Maintenance 2|Patients with FCM-MRD19\<0.01% and IgH rearrangement NGS MRD 46\<10\^-6 will receive chemo-light maintenance-2 with 4 cyles of 8-week course of MTX + 6MP (totally 32 weeks).
223493338|NCT07080528|DRUG|Sevofluorane|Investigation of the effect of Sevoflurane on muscle relaxation
223493339|NCT07080528|DRUG|Propofol|Investigation of the effect of Propofol on muscle relaxation
223493340|NCT06878846|OTHER|Correlation Study|Assessment of correlation
223493341|NCT05061888|OTHER|Smart Intervention for Food Waste Management and Replacing current diet with Fruits and Vegetables|Will receive a Smart Intervention on Food Waste Management and replacing less healthy foods with fruits and vegetables.
223493342|NCT05061888|OTHER|Smart Intervention for Stress Management|Will receive a Smart Intervention on stress management practices and strategies.
223493343|NCT06828432|DEVICE|CRUISE CTICU CareTaker Vitalstream Device|The CareTaker Vitalstream device is a patented PDA technology and artificial intelligence algorithms derive continuous hemodynamic parameters by analyzing reflective pulse wave analyzes the pulse pressure waveform at 500 times per second, isolates the individual central aortic pulses that give rise to the observed pulse shape, reads central aortic measurements therefore eliminating the effects of hydrostatic pressure, and tracks vascular tone.
223493344|NCT06828432|DEVICE|CRUISE CTICU CNAP Device|The CNAP Monitor provides advanced hemodynamic information from the non-invasive reusable CNAP finger sensor. It supports your Goal Directed Therapy whenever an arterial line is not indicated. Patient-friendly, easy-to-use, cost-efficient. CNAP Monitor offers a unique set of parameters to support your daily routine - all non-invasive \& continuous allowing for perioperative fluid management even in low and moderate-risk surgeries and patients.
223493345|NCT06828432|DEVICE|CRUISE CTICU Edwards Clearsight Device|The Edwards ClearSight system provides continuous blood pressure and advanced hemodynamic parameters from a noninvasive finger cuff. Continuous data offered by the ClearSight system enables you to proactively optimize perfusion through hemodynamic management.
223493346|NCT06813053|OTHER|Decision Aid (DA)|Tools designed to foster shared decision-making by contextualizing the risks and benefits of treatment options around the patient's personal values, thereby allowing them to weigh personal preferences when making treatment decisions. The study team has developed a prototype DA incorporating longitudinal institutional QoL data among patients who have undergone breast cancer surgery .
223493347|NCT06813053|OTHER|Standard of Care (SOC)|Electronic copy of an alternative educational pamphlet discussing surgical options for breast cancer.
223493348|NCT03842007|DIAGNOSTIC_TEST|Rectal Barostat Study|Contractions will be recorded with a balloon inserted into the rectum and inflated
223493349|NCT03842007|DIAGNOSTIC_TEST|Fecoflowmetry|Rectum will be filled with a small amount of paste.Two thin catheters will be inserted into the anus to measure pressures and electrical activity (electromyography or EMG). Subjects will be asked to sit on a commode, contract (squeeze) your anal muscles, blow into a balloon, and expel the paste into the commode.
223493350|NCT06773975|DIETARY_SUPPLEMENT|Oral nutritional supplementation|The oral nutritional supplement is a locally made plant based formulation targeted to improve the nutritional status of the elderly
223493351|NCT07121374|DRUG|Neoadjuvant chemo-immunotherapy|Neoadjuvant chemotherapy (2 cycles of cisplatin OR carboplatin accord healthcare- investigator's choice - PLUS pemetrexed fresenius AND immunotherapy (2 cycles of Opdivo PLUS 1 cycle of Yervoy for inoperable T2-T3 TNM 9 patients with PM
223493352|NCT07121374|PROCEDURE|Extended pleurectomy/decortication in case of reaching operability|After the systemic treatment the surgery will follow if patient is operable.
223493353|NCT07121114|OTHER|No treatment given|No treatment given
223588756|NCT03545074|BEHAVIORAL|Health Education - English|The health education condition is a weekly 2-hour, 6 session course aimed at knowledge acquisition in subjects related to health care in general (in English)
223588757|NCT03545074|BEHAVIORAL|Health Education - Spanish|The health education condition is a weekly 2-hour, 6 session course aimed at knowledge acquisition in subjects related to health care in general (in Spanish)
223588758|NCT05549791|DRUG|Remimazolam Tosilate for Injection|Remimazolam Tosilate for Injection
224308546|NCT04302558|BEHAVIORAL|Exercise Blood Flow Restriction training|While exercising, an Inflatable cuff, similar to a blood pressure cuff, is applied to the proximal aspect of the femur of the affected lower extremity inflated to occlude blood flow
224308547|NCT04302558|BEHAVIORAL|SHAM Exercise Blood Flow Restriction training|While exercising Inflatable cuff, similar to a blood pressure cuff, applied to the proximal aspect of the femur of the affected lower extremity with limited inflation pressure to not occlude blood flow
224308548|NCT01050608|DEVICE|Body worn alcohol gel dispenser|Records hand hygiene events of provider and tabulates on the group level.
223588759|NCT02146794|DEVICE|Renal denervation|Renal denervation
223745668|NCT04346472|OTHER|Repeated Measurements of the relative regional cerebral blood volume|Repeated Measurements of the relative regional cerebral blood volume variation through an every 6 monts Magnetic Resonance Imaging use.
223745669|NCT05075226|DEVICE|Vivity Extended Depth of Focus|Cataract surgery
224308549|NCT01050608|DRUG|62% ethanol based hand cleanser|"CDC based guidelines with regard to utilization in the health care environment the nest"
224308550|NCT01050608|BEHAVIORAL|Educational component with regard to teaching CDC guidelines|12 minute education prior to deploying device for all providers.
224308551|NCT01050608|BEHAVIORAL|Provider and group feedback|Provide feedback with regard to expected hand hygiene goals to providers and reported anonymous group results based on recorded information.
224185125|NCT02709980|BEHAVIORAL|Cognitive Behavior Therapy for Insomnia|Treatment will involve a standardized 6-session intervention, with demonstrated efficacy, that combines education and behavioral techniques to reduce insomnia. The core components include (1) education about sleep and insomnia, stimulus control, and sleep restriction (session 1); (2) sleep hygiene education (session 2); and 3) relaxation training, cognitive therapy, adherence monitoring, adjusting the recommended sleep-wake schedule, and addressing any problems in implementation (session 3-5). The final session will include a review of treatment content and relapse prevention.
223493354|NCT07113808|DEVICE|contrast-enhanced ultrasound examination|to evaluate the the application of contrast-enhanced ultrasound examination in children with intra-abdominal diseases that require clear diagnoses aged from 29 days to 18 years old
223493355|NCT07113808|DRUG|SonoVue®|perform contrast enhanced ultrasound (CEUS) using Sonovue as the contrast agent
223493356|NCT07124897|BEHAVIORAL|VR-Supported Psychosocial Nursing Care Based on Swanson's Theory of Caring|This intervention involves psychosocial nursing care based on Swanson's Theory of Caring, supported by VR technology. It is applied to women experiencing perinatal loss, aiming to reduce grief, anxiety, depression, and stress, postpartum depression, and to enhance psychosocial well-being. The care is delivered face-to-face during hospitalization and includes emotional support, active listening, presence, and empathy, aligned with the core concepts of Swanson's theory. The VR component consists of immersive, calming 360-degree visual environments that are integrated into the care sessions to promote emotional regulation. The intervention continues with structured psychosocial support via telephone on day 7 and day 30 after discharge.
223493357|NCT07124897|BEHAVIORAL|Psychosocial Nursing Care Based on Swanson's Theory of Caring|This intervention involves psychosocial nursing care based on Swanson's Theory of Caring, without the use of VR. It is delivered to women who have experienced perinatal loss, aiming to support emotional healing and reduce psychological symptoms such as grief, anxiety, depression, stress, and postpartum depression. The intervention is provided face-to-face during hospitalization and focuses on presence, listening, empathy, and emotional support in alignment with Swanson's caring processes. Follow-up support is also provided via telephone calls on day 7 and day 30 after discharge, continuing the psychosocial care process without any technological enhancement.
223588760|NCT02416596|PROCEDURE|Hysteroscopy|"Office hysteroscopy will be performed during the Luteal phase of the proceeding menstrual cycle.~All OH (office hysteroscopy) procedures will be performed with a vaginoscopic approach without utilizing a speculum and applying traction to the cervix with a tenaculum.~Antibiotic prophylaxis: None OH will be cancelled until after treatment of vaginal infection."
223588761|NCT02416596|DEVICE|Hysteroscope|"The device used is a rigid hysteroscope (continuous flow, 30 degree forward oblique view) assembled in a 4-mm diameter diagnostic sheath with an atraumatic tip (Karl Storz Endoscopy).~Illumination: High intensity cold light source and fiberoptic cable Distention medium: solution of 0.9% normal saline with pressure at 100-120 mmHg"
223588762|NCT06170918|DRUG|Remimazolam|remimazolam is given intravenously
223588763|NCT00079092|DRUG|procarbazine hydrochloride|
224185126|NCT00078689|DRUG|Daclizumab|
224185127|NCT01182480|BEHAVIORAL|Patient Relationship Management (PRM) Program|"Patients will be contacted through SMS text messaging under the following circumstances:~* 7 days, 2 days, and 1 day before scheduled appointments. Messages will contain the date, time, and location where the appointment is scheduled. Patients will be prompted to respond with 'YES' if they are able to keep their appointment, and 'NO' if they need to reschedule. An acknowledgement of receipt will be sent in response to all patient-initiated messages.~* 3 days per week to request that patients respond with fasting blood sugar measurements. An acknowledgement of receipt will be sent in response to all patient-initiated messages."
224185128|NCT00136344|DRUG|Cefuroxime|
223588764|NCT00079092|DRUG|thalidomide|
224185129|NCT00136344|DRUG|Levofloxacin|
224185130|NCT00816244|DRUG|Atorvastatin|Atorvastatin 80 mg daily for two weeks, ending at the day of operation for breast cancer.
224185131|NCT00512226|OTHER|Cardiac and Liver T2* MRI|Laboratory examinations that are routinely used in follow up of those patients and T2\* MRI analysis.
224185132|NCT03378024|DEVICE|oscillometric (Omron Colin co)|fast measurements of the brachial-ankle pulse wave velocity (baPWV) and the resting ankle-brachial index(ABI) with the oscillometric method (Omron Colin co, Japan)
224185133|NCT05129358|DRUG|Dehydration|The subject is brought to mild dehydration (loss of approximately 1.5% of body weight) through intravenous injection of up to 40 ug Furosemide. The subject shall not ingest any fluid for the next 120 minutes.
224185134|NCT05129358|DIETARY_SUPPLEMENT|Rehydration|The subject is rehydrated by oral intake of 1.5 liters Resorb Sport (Nestlé). The subject is monitored for 60 minutes following intake.
224185135|NCT02353234|OTHER|Bread|In each arm subjects consume bread
224185136|NCT00001422|DRUG|fludarabine|
224185137|NCT02486458|DRUG|5% sodium fluoride varnish|Fluoride varnish containing 22,600 ppm F, as NaF, in a neutral base
224185138|NCT02486458|DRUG|1.23% sodium fluoride acidic gel|Fluoride gel containing 12,300 ppm F (as NaF) in an acidic pH (by addition of phosphoric acid)
224185139|NCT00509275|DRUG|W0027|capsule
224185140|NCT00509275|DRUG|Placebo|Placebo
224185141|NCT01589185|DRUG|KBSA301|KBSA301 administered as a single intravenous infusion at dose 1, 2, 3 and 4.
224185142|NCT01589185|DRUG|Placebo|Placebo administered as a single intravenous infusion
224185143|NCT02046993|BEHAVIORAL|Smart phone telemonitoring HBP + enhanced usual care|Smart phone telemonitoring home Blood pressure (HBP) Patients input their HBP readings to their smart phone which is sent to the data center regulary
224185144|NCT02046993|BEHAVIORAL|Enhanced usual care|Encouraged to do HBP measurement and record BP readings in paper diary
224185145|NCT03605277|DRUG|Asciminib|40 mg single dose
224185146|NCT03472391|BEHAVIORAL|Physical Therapy|A 4-week (2 exercise session af week, of 40 minutes )tailored physiotherapeutic exercise program. The sessions are individually and supervised by physical therapist and tailored to patients with severe anorexia nervosa. The exercise program mainly consist of strength training exercises without any equipment other than a floor mat.
224185147|NCT00118560|BEHAVIORAL|Physical exercise|treadmill walking
224185148|NCT00118560|BEHAVIORAL|Physical walking|calf muscle exercise
224308552|NCT04713553|BIOLOGICAL|BNT162b2|Intramuscular injection
224308553|NCT04713553|BIOLOGICAL|BNT162b2.B.1.351|Intramuscular injection
224185149|NCT03971968|PROCEDURE|Skin replacement with artificial skin|Integra® Dermal Regeneration Template is a bilayer membrane system for skin replacement. The dermal replacement layer is made of a porous matrix of fibers of cross-linked bovine tendon collagen and glycosaminoglycan (chondroitin-6-sulfate). The epidermal substitute layer is made of thin polysiloxane (silicone) layer to control moisture loss from the wound. The silicone outer layer temporarily closes the wound to ward off infection and control fluid and heat loss. As skin cells migrate into the matrix the collagen is slowly absorbed into the body and replaced with protein that is naturally produced by the skin. In approximately 14 to 21 days, new dermal skin is produced and the silicone layer can be removed. A thin skin graft of the person's epidermis is applied to the wound area to complete the procedure. In total, the two surgical procedures are typically completed within 30 days. A person is left with flexible growing skin and minimal damage at the skin graft donor sites.
223493358|NCT07124871|BIOLOGICAL|PRP-derived exosomes injection|"All subjects will receive three sessions of PRP-derived exosomes injection with 21± 3 days treatment interval.The patient will be positioned supine.~A ¼-inch Penrose drain will be used as a tourniquet by placing it at the base of the penis and maintaining it in place under tension by a sterile clamp. We will obtain 10 mL of PRP per patient, but one of them will be used for platelet cell count analysis. A total 9 mL of the PRP-derived exosomes will be infused steadily over a 2 minutes period - 4.5 mL each into the right and left corpus cavernosum. The infusion will be performed at this slow speed - each side over 2 minutes of infusion - to minimize injury to the exosomes and cells. Following administration, compression of the penis will be achieved with a clenched fist for 20 minutes. At 20 minutes, the tourniquet will be removed, and a compressive dressing will be placed around the penile shaft. The patient will be instructed to remove the compression bandage in 4 hours"
223493359|NCT07122609|DRUG|Pirtobrutinib|Dose:200mg，d1-21
223493360|NCT07122609|DRUG|R-GemOx|Dose: Rituximab: 375mg/m2, d1; Gemcitabine: 1000mg/m2, d2; Oxaliplatin:100mg/m2, d2
223493361|NCT07122609|DRUG|Polatuzumab Vedotin|Dose: 1.8mg/kg，iv，d1 (For patient who is CD79b positive and has not previously received polatuzumab Vedotin)
223493362|NCT07123571|BEHAVIORAL|Contagious Laughter|Contagious laughter videos
223493363|NCT07121998|PROCEDURE|Core needle biopsy|Core needle biopsy of metastatic lesions
223493364|NCT07121998|PROCEDURE|Phlebotomy|Phlebotomy of peripheral vein
223493365|NCT06901544|DIAGNOSTIC_TEST|Serum C Reactive Protein|values for serum albumin is 35 to 55 g/l and for CRP is less than 6 mg/dl CLI will be calculated as CRP divided by serum albumin and multiplied by 100
223493366|NCT06420219|OTHER|Non-Interventional Study|Non-interventional study
223493367|NCT04455698|BEHAVIORAL|Remote Telegenetic Counseling by Phone|Participants will receive standard of care pre-test and disclosure genetic counseling with a genetic counselor by Telephone.
223493368|NCT04455698|BEHAVIORAL|Remote Telegenetic Counseling by Videoconferencing|Participants will receive standard of care pre-test and disclosure genetic counseling with a genetic counselor using Videoconferencing Technology.
223493369|NCT04455698|BEHAVIORAL|Usual Care Arm|Participants in the usual care arm will receive usual care services depending on which referral method they choose and if they initiate services. After a 6 month status survey, if they have not had genetic services through usual care they will be offered services and re-randomized to ARM A/ARM B.
223493373|NCT07093476|DRUG|Metformin|tablets, QD, oral administration
223493374|NCT07093476|DRUG|Alogliptin|tablets, QD, oral administration
224185150|NCT04176068|COMBINATION_PRODUCT|calcium hydroxylapatite (Radiesse) and IFUS (Ulthera)|Patients will receive IFUS to a randomly chosen side. Immediately after IFUS treatment, patients will receive the first CaHA injection. Injections will be given in the lower, anterior third of the thigh, above the knee. Only dermatology faculty will perform the filler injections. The patients will be instructed to return to the office in 6 weeks, 12 weeks, and 24 weeks (+/- 5 business days) for their next appointment for follow-up and injection of CaHA if deemed necessary by the investigator. At all visits (Visits 1-4) patients will have photographs and unblinded physician/patient questionnaires will be completed. At Visit 4 (24 weeks +/- 5 business days), patients will be given the option to receive treatment for skin laxity to the previously untreated side. If the patient chooses to receive treatment, patients will receive their second IFUS and CaHA combination treatment at this time. They will not receive further treatment after this visit.
223493375|NCT07093476|DRUG|empagliflozin|tablets, QD, oral administration
223493376|NCT07099222|DRUG|Low, non-weight based dose of Dexamethasone and Dexmedetomidine in peripheral nerve blocks|Low, non-weight based dose of Dexamethasone and Dexmedetomidine adjunct with Ropivacaine (local anesthetic) for use in peripheral nerve blocks to look for synergistic effects of the combination in extending the duration of the block while limiting any potential side effects of each additive.
223493377|NCT07099222|DRUG|Ropivacaine with low, non weight based Dexamethasone additive|Very accepted, standard peripheral nerve block with steroid adjunct solution used to increase the duration of local anesthetic by 4-6hrs.
223493378|NCT07094035|DIETARY_SUPPLEMENT|food supplement based on a mixture of green tea extract and a pool of probiotics.|two capsules of food supplement (verum) or placebo, daily for 56 consecutive days. The daily consumption of the food supplement provides: green tea extract (Camellia sinensis (L.) Kuntze - folium) 300 mg, as a green capsule, and a pool of probiotics (Lactobacillus rhamnosus LRH020 2x10\^9 UFC, Bifidobacterium lactis BL050 2x10\^9 UFC, Lactobacillus plantarum PBS067 2x10\^9 UFC), as a white capsule.
223493379|NCT07094035|DIETARY_SUPPLEMENT|Placebo|1 capsule/day of maltodextrin (500 mg) with a green shell, and 1 capsule/day of maltodextrin (500 mg) with a white shell for 56 days. The two colours are applied to maintain the binding.
223493380|NCT07097961|BEHAVIORAL|Pulmonary Rehabilitation|The intervention includes twice-weekly walking and wall sit exercises, guided by a physiotherapy assessment. Participants use a pedometer, receive written instructions, and are monitored weekly by phone or home visit. Caregivers supervise the exercises and sessions are logged in a participant workbook.
223493381|NCT05279300|DRUG|CS5001|The dose and dosing schedule is decided by the Safety Monitoring Committee.
223493382|NCT05279300|BIOLOGICAL|Rituximab|IV infusion
223493383|NCT05279300|DRUG|Gemcitabine|IV infusion
223493384|NCT05279300|DRUG|Oxaliplatin|IV infusion
223493385|NCT05279300|DRUG|Lenalidomide|PO
223588765|NCT01233063|BEHAVIORAL|Physical Activity and Diet Intervention via Alive2|Weekly email/web goal-setting intervention to improve physical activity and diet, with and without additional phone and mail support.
223493386|NCT05279300|DRUG|Cyclophosphamide|IV infusion
224185151|NCT06523322|BEHAVIORAL|Let's Cook Together|The 8-week Let's Cook Together program is intended to increase: caregiver knowledge of the benefits of a whole foods approach to eating; preparedness for caregiving; and caregiver self-efficacy for managing patients' nutrition-related side effects. The entire program will be delivered remotely. Caregivers will be recruited to participate in an 8-week remote culinary medicine intervention, including four remote synchronous culinary workshops (one 90-minute introductory event and three, 90-minute culinary/cooking sessions), and four bi-weekly caregiver coaching telephone calls (lasting 15-20 minutes).
224185152|NCT00886626|DRUG|Exenatide|Exenatide, subcutaneous injection, 10 mcg, twice per day
224185153|NCT05406466|DRUG|Tislelizumab|a PD-1 immune check inhibitor
224185154|NCT05406466|DRUG|Lenvatinib|multitargeted receptor tyrosine kinase inhibitor
224185155|NCT05406466|DRUG|Cryoablation|Cryoablation will be performed with a two-cycle freeze-thaw phase protocol; US or non-contrast CT images will be obtained to visualize the evolving ablation zone
224185156|NCT03542825|DRUG|Lactoferrin|parallel use of the three drugs to compare the efficacy of each arm in prevention of anemia
224185157|NCT03542825|DRUG|Iron Supplement|Iron Sulphate 150 mg once daily
224185158|NCT03542825|DRUG|Chelates, Iron|Amino acid chelated iron capsules contain 15 mg
224185159|NCT01488695|DEVICE|GlideScope Groove|GlideScope Groove
224308554|NCT04060030|DRUG|Levoleucovorin Calcium|Liquid leucovorin calcium dosed by weight
224185160|NCT01488695|DEVICE|Control: Macintosh blade|Control: Patients will be intubated using the Macintosh blade
224185161|NCT04493255|DRUG|[14C]E7090|\[14C\]E7090, oral capsule.
224185162|NCT04309149|DIETARY_SUPPLEMENT|MCT fats|Subjects will be asked to take 3 new MCT products for 7 days each over a 25 day period (21 days taking the new products with 2 days between each new product trialled).
224185163|NCT06355518|DIETARY_SUPPLEMENT|Immunonutrition|This formula is enriched in arginine, nucleotides (RNA) and omega-3 fatty acids and provides, with the proposed therapeutic volume (2 units per day), 36 grams of protein and 682 kcal/day.
224308555|NCT04060030|OTHER|Placebo|Placebo
224308556|NCT00810316|DRUG|Alprazolam|Administration of a single oral dose tablet of 1 mg of alprazolam immediate release on Day 1 morning, between 8-9 am with 250 ml of water in at least 10 hours of fasting conditions
224308557|NCT00810316|DRUG|Alprazolam XR|Administration of a single oral dose tablet of 1 mg of alprazolam modified release on Day 1 morning, between 8-9 am with 250 ml of water in at least 10 hours of fasting conditions
224308558|NCT00810316|DRUG|Clonazepam|Administration of a single oral dose of two tablets of 0.5 mg of clonazepam on Day 1 morning, between 8-9 am with 250 ml of water in at least 10 hours of fasting conditions
223493387|NCT05279300|DRUG|Doxorubicin|IV infusion
223493388|NCT05279300|DRUG|Vincristine|IV infusion
223493389|NCT05279300|DRUG|Prednisone|PO
223493390|NCT06862115|DRUG|ACE-I and/or ARB antihypertensive treatment|When the ACE-I and/or ARB duration of action is ≥24 hours, the drug will be stopped 48 hours prior to surgery. All other ACE-I and/or ARB will be stopped 24 hours before surgery.
223493391|NCT06795126|OTHER|Little NIRVANA|Augmented reality (AR) digital solution where children interact with the game using a magic wand
223493392|NCT07095725|DIAGNOSTIC_TEST|Record EMG maximum amplitude from rectus abdominis, erector spinae L3 level|"EMG Electrode Placement and Muscle Assessment:~Electrodes for the rectus abdominis were placed longitudinally at the umbilical level. For the erector spinae, L3 was located using a line between the posterior superior iliac crests, and electrodes were placed \~3 cm lateral to the L3 spinous process.~Assessment:~Rectus Abdominis: In the crook-lying position, participants performed a slow curl-up (\~35-40°), holding for 10 seconds.~Erector Spinae: In the prone position with a 10-cm pad under the abdomen, participants lifted the upper body with neutral cervical alignment for 10 seconds.~Each test was repeated three times with 2-minute rest intervals."
223493393|NCT07096674|DRUG|ORX750|Oral ORX750
223493394|NCT07096674|DRUG|ORX750|Oral ORX750
223493395|NCT07096674|DRUG|ORX750|Oral ORX750
223493396|NCT07095868|BIOLOGICAL|EVM14|Cancer Vaccine
223493397|NCT07095868|COMBINATION_PRODUCT|Pembrolizumab|Anti-PD1 antibody
223493398|NCT05997576|DRUG|TG103 22.5 mg|Subcutaneous injections with calorie restrict diet and increased physical activity for 52 weeks. Doses gradually increased from 7.5 mg to 22.5 mg.
223493399|NCT05997576|DRUG|Placebo|Subcutaneous injections with calorie restrict diet and increased physical activity for 52 weeks.
223493400|NCT06908629|OTHER|Implementation of social determinants of health screening and referral|Participants will be referred to community-based resources in response to their answers on the screening tool.
223493401|NCT06910774|OTHER|Dosage of serotonin and tryptophan metabolites levels in serum|These measurements will be performed on residual blood samples in the laboratory, after blood collection carried out as part of routine care. Patients will not need to undergo an additional blood draw.
223493402|NCT03105102|DRUG|Placebo for Risankizumab SC|Placebo for Risankizumab SC Subcutaneous (SC) Injection
223493403|NCT03105102|DRUG|Risankizumab IV|Risankizumab IV Intravenous (IV) infusion
223493404|NCT03105102|DRUG|Placebo for Risankizumab IV|Placebo for Risankizumab IV Intravenous (IV) infusion
223493405|NCT03105102|DRUG|Risankizumab SC|Risankizumab SC Subcutaneous (SC) injection
223493406|NCT03105102|DRUG|Risankizumab On-Body Injector (OBI)|Subcutaneous (SC) injection; on-body injector (OBI)
223493407|NCT07102524|DRUG|TSHA-105|AAV9/SLC13A5
223493408|NCT07101575|DIAGNOSTIC_TEST|Transthoracic echocardiography|Transthoracic echocardiography with bubble test, by intravenous infusion of agitate saline solution
223493409|NCT06744322|PROCEDURE|Fast discharge strategy|Patients undergoing invasive management after myocardial infarction will be discharged after 24 (+/- 12) hours.
224308559|NCT01235832|OTHER|Avocado Diet|The avocado diet will be designed to ensure that all subjects incorporate 1 avocado (\~136g) per day into a moderate fat diet. Both the Lower-Fat diet and avocado diet will be matched for SFA and dietary cholesterol, but will differ in total fat, primarily MUFA as provided by the avocado. The moderate fat plus avocado diet will provide 34% of calories from total fat, 18% calories from MUFA, and 9% calories from PUFA.
223493410|NCT07099534|DRUG|IV Ketamine (0.5 mg/kg) Infusion - Two Doses Administered 24 Hours Apart for Severe Borderline Personality Disorder|Participants receive two intravenous (IV) infusions of ketamine at a dose of 0.5 mg/kg over 40 minutes. The first infusion is administered at Hour 0 (H0) and the second at Hour 24 (H24). Vital signs and potential adverse effects are closely monitored before, during, and after each infusion. This intervention aims to assess the short-term efficacy and safety of ketamine in reducing symptoms of severe borderline personality disorder.
223493411|NCT02180867|DRUG|Doxorubicin|Given IV
223493412|NCT02180867|DRUG|Doxorubicin Hydrochloride|Given IV
224185164|NCT06355518|DIETARY_SUPPLEMENT|Standard Oral Nutritional Supplement|This formula provides 38 grams of protein and 500 kcal/day with the proposed therapeutic volume.
224185165|NCT00598442|DRUG|peginesatide|Participants received peginesatide by subcutaneous injection once every 4 weeks. The starting dose was 0.025 milligram per kilogram (mg/kg) and was adjusted throughout the study to maintain a hemoglobin target range of 11.0-12.0 grams per deciliter (g/dL).
224185166|NCT00598442|DRUG|peginesatide|Participants received peginesatide by subcutaneous injection once every 4 weeks. The starting dose was 0.04 mg/kg and was adjusted throughout the study to maintain a hemoglobin target range of 11.0-12.0 g/dL.
224185167|NCT00598442|DRUG|Darbepoetin alfa|Participants received darbepoetin alfa by subcutaneous injection once every 2 weeks, as prescribed. The starting dose was 0.75 microgram per kilogram (mcg/kg) and was adjusted throughout the study to maintain a hemoglobin target range of 11.0-12.0 g/dL.
223493413|NCT02180867|DRUG|Ifosfamide|Given IV
223493414|NCT02180867|DRUG|Pazopanib|Given PO
223493415|NCT02180867|DRUG|Pazopanib Hydrochloride|Given PO
223493416|NCT02180867|RADIATION|Radiation Therapy|Undergo radiation therapy
223493417|NCT02180867|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
223493418|NCT07104266|DRUG|Celecoxib (Celebrex)|The participants will take one capsule celecoxib (100 mg) or placebo after breakfast and one after supper, starting 7 days before radiotherapy and ending 14 days after radiotherapy.
223493419|NCT07104266|DRUG|Placebo|Participants will take one capsule of placebo after breakfast and one after supper, starting 7 days before radiotherapy and ending 14 days after radiotherapy.
223493420|NCT07105202|DRUG|levosimendan|Participants randomized to to the intervention will receive levosimendan. The infusion is administered over 24 hours, starting at a dose of 0.1 µg/kg/min. After 4 hours, the dose may be increased to 0.2 µg/kg/min if tolerated, based on clinical judgment. A maximum of four treatment cycles may be given if the patient is not successfully weaned from mechanical ventilation within 7 days.
223493421|NCT07105202|DRUG|Soluvit|Participants randomized to this arm will receive a placebo consisting of Soluvit diluted in glucose 5%, administered as an intravenous infusion over 24 hours. The infusion will mimic the Levosimendan administration protocol, starting at 0.1 µg/kg/min and potentially increasing to 0.2 µg/kg/min after 4 hours, to maintain blinding. A maximum of four placebo treatment cycles may be administered if the patient is not successfully weaned from mechanical ventilation within 7 days.
223493422|NCT07105202|OTHER|Standard care|All patients in this arm will receive standard ICU care, including daily assessments for readiness to wean from invasive ventilation.
223493423|NCT07103902|BEHAVIORAL|Moderate-Intensity Exercise|Participants will engage in 20 minutes of cycling at approximately 70% max heart rate with a 2.5 minute warm up and a 2.5 minute cool down.
223493424|NCT07103902|BEHAVIORAL|Low-Intensity Exercise|Participants will engage in 20 minutes of cycling at approximately 40-50% max heart rate with a 2.5 minute warm up and a 2.5 minute cool down.
223493425|NCT07104864|DIAGNOSTIC_TEST|histopathological confirmation|histopathological confirmation
223493426|NCT07103681|PROCEDURE|Ventriculoperitoneal Shunt (VP)|VP Shunt surgery involves surgical insertion of a catheter (tube) to divert brain fluid from the cerebral ventricles to the abdominal peritoneum. This will be performed in Group 1 patients as clinically indicated.
223493427|NCT07103681|PROCEDURE|Brain and Skin Biopsy|Brain and skin biopsy's may be taken during the VP shunt to assist in histological analysis for neurodegenerative changes.
223493428|NCT07103681|DIAGNOSTIC_TEST|MRI Brain|MRI brain with diffusion imagining will be performed before and after shunt surgery.
224185168|NCT00431106|DRUG|Gemcitabine|Gemcitabine at the dose of 1000 mg/m2 intravenously (IV) every 2 weeks for 12 consecutive cycles
224185169|NCT00431106|DRUG|Capecitabine|Capecitabine at the dose of 1250 mg/m2 twice daily orally (os), from day 1 to day 14, every 3 weeks for 6 consecutive cycles
224185170|NCT00431106|DRUG|Vinorelbine|Vinorelbine at the dose of 25 mg/m2 IV on day 1 every 2 weeks for 12 consecutive cycles
224185171|NCT03924570|BEHAVIORAL|IPASS|IPASS is behavioral package to improve transitions of care by providing a framework to hands off.
224185172|NCT03701971|OTHER|evaluation of the intensity of pruritus|evaluation of the intensity of pruritus with various questionnaires
223511695|NCT06569446|OTHER|There is no intervention. This a qualitative study to explore barriers to rectal irrigation|"This will involve semi-structured, open-ended questions about hypothesized barriers to rectal irrigation where the interviewer will ask a pre-determined number of questions and the participants will answer which will further initiate discussion allowing new themes to emerge. After the entire list of barriers is discussed, participants will be asked if they have any new barriers to add which have not been discussed. All new barriers identified will be added to the hypothesized barriers list for the next focused group sessions. Focused group sessions will continue until no new barriers are found in two consecutive sessions (thematic saturation).~9.2 Phase - 2 includes Cognitive Interviews This will involve semi-structured, open-ended questions about barriers to rectal irrigation identified during focused group sessions where the interviewer will ask pre-determined number of questions for individual participants to answer."
223493429|NCT07105410|OTHER|Aim #1: The effect of post-exercise circulatory occlusion on H-reflex and V-wave|Aim #1 follows a randomized and crossover design in which 16 young and healthy males are evaluated during thigh circulatory occlusion performed after a submaximal isometric plantar flexion contraction (PECO day). In the other session, participants are evaluated during free-flow conditions and without previous fatiguing contraction (no-PECO day). In PECO day, participants complete a 3-min contraction at 40% of maximal force. Then, for testing, blood flow from lower-leg is blocked during 4 min, by an inflatable cuff around the ipsilateral thigh before task termination, during which H- reflex is tested. At the end of recordings, the cuff is deflated. Participants ware allowed to rest for 5-10 min. Then, they are requested to perform a new 3 min contraction with the cuff being inflated before task termination. The cuff remains inflated for \~ 2 min during which V-wave recordings are obtained. In both days, leg pain intensity is reported by participants and brachial AP is measured.
223493430|NCT07105410|OTHER|Aim #2: The hypoalgesic effects of acute exercise of different modalities|Aim #2 follows a randomized and crossover-controlled design, consisting on two experimental sessions. 24 healthy male (all diferent from Experiment 1) are randomly allocated to one of the following exercising regimens: aerobic, anaerobic or dynamic resistance (8 participants for each exercise group). In one of the experimental days, participants are evaluated for pain sensitivity and neuromuscular responses both before and after a lower-limb acute exercise protocol (exercise day) and in the other day before and after 15 min of quiet rest (non-exercise day). In both sessions, participants are evaluated for rectus femoris, upper trapezius and biceps brachiis muscles pressure pain threshold, followed by the application of a cold pain tolerance test on the foot. The intensity of pain is reported by a 0-100mm VAS and AP and HRV continously measured. Then, participants are tested for H-reflex and V-wave excitability during PECO, with leg pain intensity (0-10) and brachial AP recorded.
223745670|NCT06496841|DRUG|Transnasal Sphenopalatine ganglion block|The transnasal approach to the sphenopalatine ganglion block allows for non-invasive access to the sphenopalatine ganglion, which is located deep in the nasopharynx in a recess posterior to the middle turbinate. A long cotton swab is inserted posterior to the nasopharynx until it is properly seated, and 2 mL of 2% lidocaine is injected through the outer end of the swab and left for 30 minutes. Patients are monitored for any potential complications or adverse effects throughout the procedure and for a period of time afterwards.
223493431|NCT07105410|OTHER|Aim #3: The hypoalgesic effects of chronic training of different modalities|Aim #3 follows a randomized-controlled design. 32 healthy male (all the 24 participants from Experimental 2 plus 8 new subjects) are randomly allocated to one of the following groups: aerobic, anaerobic, dynamic resistance training and no-training (control) (8 participants for each group). Each intervention group perform 6 weeks of exercise training (3x week). Participants allocated to each training group are evaluated before and after training (2 assessment days in each time-point). On one day participants are tested for pressure pain threshold and cold pain tolerance with concomitant measures of pain ratings (0-100mm VAS), AP and HRV. The influence of metaboreflex activation on H-reflex and V-wave is also measured (during PECO). In addition, during PECO ischemic pain rating and AP are obtained. On another day, participants are evaluated for motor performance (maximal oxygen uptake, maximal voluntary contraction and peak power) and neuromuscular adaptations (i.e. H-reflex and V-wave)
223493432|NCT07104136|BEHAVIORAL|COPD-care seminar|"A two day seminar which will include:~Lecture: Understanding COPD and Current Guidelines Overview of COPD pathophysiology. Review of the latest GOLD guidelines and treatment strategies Hands-on Session: Inhaler Technique and Device Selection Practical demonstration of different inhaler devices. Evaluating patient inspiratory effort and selecting suitable devices. Understanding advantages of each device and molecule. Motivational interview seminar- On line pre-course lectures about the theory behind motivational interview. Two workshops for simulation and practice of the technic through clinical cases with relevance to COPD patients including smoking cessation counseling techniques.~Panel Discussion: Multidisciplinary Approach to COPD Management Involving respiratory specialists, physiotherapists, and primary care physicians.~Discussion on referral practices and collaborative care."
223493433|NCT07105059|DRUG|Teclistamab|After the priming, patients will start Teclistamab step up dosing. Mezigdomide will not be given during the Teclistamab step up. After the priming and step-up, patients will start combination treatment with Teclistamab and Mezigdomide.
223493434|NCT07105059|DRUG|Mezigdomide|Start with 14 days of Mezigdomide. After the priming and step-up, patients will start combination treatment with Teclistamab and Mezigdomide.
223493435|NCT07103824|OTHER|Upper Extremity Neurocognitive Tests|The validity and test-retest reliability of the Reactive Neurocognitive Upper Extremity Tests (Reactive CKCUEST and Reactive 90/90 Wall Throws Test) will be analyzed through this protocol. Participants will undergo three assessment sessions spaced one week apart: measurements will be conducted using the Catchpad device during the first and third weeks, and the BlazePod™ device during the second week. To ensure blinding, the personnel responsible for conducting the assessments, recording the data, and performing the statistical analyses will be distinct individuals. Participants will be familiarized with the devices one week prior to testing, and a standardized 5-minute free walking warm-up will be administered at each session. All assessments will be performed under similar environmental conditions and at consistent times of day.
223493436|NCT07104435|OTHER|Artmaking and exergaming|Weekly visual artmaking and exergaming
223493437|NCT07103616|DRUG|Randomization of Propofol or Dexmedetomidine|This intervention is a randomization of Propofol or Dexmedetomidine. Each group will receive three minutes of research images, followed by induction of anesthesia and immediately followed by three minutes of imaging. The subject will receive standard care clinical magnetic resonance imaging for 45 minutes and three minutes of research images at the end of the scan.
223493438|NCT07105124|DRUG|Sibeprenlimab|Sibeprenlimab is being developed for the treatment of immunoglobulin A nephropathy (IgAN), an autoimmune glomerulonephritis characterized by the deposition of immunoglobulin (Ig) A-containing immune complexes in the kidney.
223493439|NCT07104071|OTHER|reduced light brightness|reduced light brightness
223511696|NCT03912415|BIOLOGICAL|BCD-100|Anti-PD-1 monoclonal antibody, IV infusion
223511697|NCT03912415|BIOLOGICAL|Bevacizumab|IV infusion
223511698|NCT03912415|DRUG|Paclitaxel|IV infusion
223511699|NCT03912415|DRUG|Cisplatin (or Carboplatin)|IV infusion
223511700|NCT03912415|OTHER|Placebo|Placebo
224185173|NCT03077581|DRUG|Transevrsus abdominus plane block|a blunt needle was advanced in the midaxillary line to reach the fascial layer between the internal oblique and transverse abdominis muscles detected by facial click sensation. The LA was slowly injected so as to detect any sign of toxicity or incorrect needle tip position (as resistance) requiring needle repositioning then TAPB was repeated on the opposite side.
224185174|NCT03077581|DRUG|Rectus sheath block|In RSB group, 2-3 cm from midline, about 3-5 cm above the umbilicus, the needle was advanced at right angle to the skin. The needle reaches the space between the posterior layer of the rectus sheath and rectus abdominis muscle detected by firm resistance of the posterior wall, The LA was slowly injected then the same steps were repeated on the other side.
224185175|NCT03077581|DRUG|local anesthesia infiltartion|40 mls of 0.255 bupivacaine will be infiltrated at skin incision
224308560|NCT01235832|OTHER|Lower-Fat Diet|The Lower-Fat diet will provide \~24% of calories from fat and meet the SFA and cholesterol recommendations of a Step-II diet recommended by the National Heart, Lung, and Blood Association's National Cholesterol Education Program. SFA will provide 7% of calories, and cholesterol will be less than 200mg/day. Vegetables and fruits in the Lower-Fat diet will be selected from foods that are low in antioxidants.
224308561|NCT01235832|OTHER|Moderate Fat Diet|This diet is designed to be the control diet for the avocado diet and will have an identical fatty acid profile. MUFA-enriched food (fats) will be substituted for avocado. The substitution foods will not contain antioxidant or cholesterol-lowering components similar to those in avocado.
224308562|NCT05117983|DEVICE|Repetitive transcranial magnetic stimulation (rTMS)|Real-time MRI-guided neuronavigation with a Visor neuronavigation system (ANT Neuro, Enschede, Netherlands) will be used for coil positioning. Left dorsolateral prefrontal cortex target is located in each participant.
224308563|NCT03967171|OTHER|before uterine incision oxytocin|blood loss during elective cesarean section
224308564|NCT03967171|OTHER|after clamping the umbilical cord oxytocin|blood loss during elective cesarean section
224308565|NCT02174419|DRUG|nalbuphine HCl ER tablets 90 mg BID|nalbuphine HCl ER tablets 90 mg BID administered for 8 weeks
224308566|NCT02174419|DRUG|nalbuphine HCl ER tablets 180 mg BID|nalbuphine HCl ER tablets 180 mg BID administered for 8 weeks
224073408|NCT06267027|BEHAVIORAL|Exercise|The aim of exercise therapy is to stretch and strengthen the wrist extensor and flexor muscles. All study groups were given a home exercise program including stretching and eccentric strengthening exercises. The patient was instructed to start with stretching, and the patient was informed to stretch for 30s by flexing the wrist with the other hand while the shoulder was flexed 90 degrees, the elbow was in extension and the forearm was pronated. When stretching exercises could be performed painlessly, the patient was instructed to move on to strengthening exercises. Eccentric strengthening exercises for wrist extensors and flexors were explained with a support under the forearm and each patient was given a written program supported with visuals. It was emphasized that the exercises should be performed within the pain limit and patients were told to stop if they had severe pain. The exercise program was told to be performed 2 times a day, in 3 sets, 10 repetitions.
224308567|NCT02174419|DRUG|Placebo tablets BID|Placebo tablets BID administered for 10 weeks
224308568|NCT05939635|PROCEDURE|Bilateral ultrasound guided external oblique intercostal block (EOIB)|"Bilateral ultrasound-guided EOIB (total of 60 ml, %0.25 bupivacaine) will be performed + IV morphine PCA Multimodal analgesia : Patients are administered iv tenoxicam 20mg and tramadol 100 mg after induction of general anesthesia, and iv paracetamol 1 gr and 0.05 mg/kg, ideal body weight (IBW), iv morphine will be administered. End of the surgery, hyoscine-N-butyl bromide will be administered. Postoperative analgesia: iv paracetamol 1gr every 8 hours and IV PCA of 0,5 mg/ml morphine (the bolus dose is 20 μg/kg, the lock-in time of 6-10 minutes, the 4-hour limit is adjusted to be 80% of the calculated total amount). In cases where rescue analgesia is required (NRS score ≥4), 50 mg of meperidine is administered to patients.~Patients are routinely administered ondansetron 8 mg IV 20 minutes before extubation for postoperative nausea and vomiting prophylaxis."
224308569|NCT05939635|PROCEDURE|Bilateral ultrasound guided Modified thoracoabdominal nerves block through perichondrial approach(M-TAPA) block|"Bilateral ultrasound guided Modified thoracoabdominal nerves block through perichondrial approach(M-TAPA) block (total of 60 ml, %0.25 bupivacaine) will be performed + IV morphine PCA Multimodal analgesia : Patients are administered iv tenoxicam 20mg and tramadol 100 mg after induction of general anesthesia, and iv paracetamol 1 gr and 0.05 mg/kg, ideal body weight (IBW), iv morphine will be administered. End of the surgery, hyoscine-N-butyl bromide will be administered. Postoperative analgesia: iv paracetamol 1gr every 8 hours and IV PCA of 0,5 mg/ml morphine (the bolus dose is 20 μg/kg, the lock-in time of 6-10 minutes, the 4-hour limit is adjusted to be 80% of the calculated total amount). In cases where rescue analgesia is required (NRS score ≥4), 50 mg of meperidine is administered to patients.~Patients are routinely administered ondansetron 8 mg IV 20 minutes before extubation for postoperative nausea and vomiting prophylaxis."
224308570|NCT05939635|DRUG|IV morphine patient-controlled analgesia (PCA)|Morphine will be administered via PCA device for the first 24 hours after surgery
224308571|NCT01853930|BEHAVIORAL|Platform for Administering Eye-movement Control Training|The Platform for Administering Eye-movement Control Training (PAECT) meta program will incorporate all of the exercises that the investigators have developed and validated over the course of our previous Merit Review grants (Seiple, Szlyk et al., 2005, 2011). The PAECT platform will be designed to allow patients to easily run the training exercises in their homes and to practice at their convenience. The PAECT will employ an executive component that will keep track of the exercises that are practiced and record performance. Each time a subject opens the platform, it will choose the exercise for that subject based upon previous training and performance.
224308572|NCT05876663|OTHER|Kinesio Taping|Kinesio Taping will be applied for 6 weeks and it will be changed with new one after every two days
224185176|NCT05092217|DRUG|Tirelizumab|Tirelizumab: 200 mg, intravenous injection over 60 minutes (Q3W); Tirelizumab should be applied since 2-6 weeks after surgery until confirmed disease progression, death, unacceptable toxicity, withdrawal of consent, investigator decision, or 1 year.
224185177|NCT05092217|PROCEDURE|salvage surgery|Endoscopic nasopharyngectomy for recurrent nasopharyngeal tumor
224185178|NCT02735720|OTHER|TEVAR|Thoracic endovascular aortic repair, which includes the implantation of stent-graft in the thoracic aorta to repair the lesion. This may be done with a variety of stent-graft brands and types. The type and brand of stent-graft is left to the discretion of the care taking physician.
223745671|NCT06496841|DRUG|Ultrasound-guided suprazygomatic sphenopalatine ganglion block|The ultrasound transducer is placed in the infrazygomatic area, above the maxilla, at approximately a 45 cephalad angle. With this transducer position, the ptrigopalatine fossa, bounded anteriorly by the maxilla and posteriorly by the pterygoid process, is visualized. A 25 gauge spinal needle is inserted 1 to 1.5 cm above the zygomatic arch and posterior to the posterior orbital rim and advanced through an out-of-plane approach to reach the pterigolapalatine fossa. After the aspiration test, 3 mL of 2% lidocaine is injected and the spread of the drug is monitored by ultrasound. Patients are monitored for possible side effects and complications.
223745672|NCT00146874|DEVICE|cardiac resynchronization therapy|
223745673|NCT05231590|BIOLOGICAL|Low-dose SARS-CoV-2 recombinant spike protein + Advax-SM adjuvant|SARS-CoV-2 recombinant spike protein (12.5 µg) with Advax-SM adjuvant (7.5 mg) in two doses with a 21-day interval administered with intramuscular injections in the non-dominant arm
224073409|NCT06267027|DEVICE|Kinesiotaping|Area where the tape would be applied was clean and dry. If there is excessive hair in the application area, patients were asked to shave this area. It was explained that cream and similar substances should not be used. Muscle inhibition technique and fascia correction technique were used as the application technique. An X strip of approximately 25 cm and a Y strip of 10 cm in length are prepared as long as the distance between the lateral epicondyle and the wrist. The short arms of the X strip are adhered to the dorsal side of the hand without stretching and the crossed part of the strip is placed on the wrist with maximal stretching. The long arms of the X strip are adhered along the extensor carpi ulnaris and extensor carpi radialis to the lateral epicondyle without stretching. The Y strip was applied using the fascia correction method. The tails of the Y band were applied using an oscillating motion. The taping procedure was applied 2 times a week for 3 weeks for a total of 6 times.
224073410|NCT06267027|DEVICE|High intensity laser therapy|The elbow area was marked and then the epicondylitis protocol was selected. The epicondylitis protocol consists of 3 phases. Phase 1 and 2 consist of analgesic treatment and phase 3 consists of anti-inflammatory treatment. In phase 1 and phase 2 treatment protocol, 8 W was applied to a circular area with a radius of 1.0 cm for 3 min. In Phase 3 protocol, a dose of 80 J/cm2 at 8 W power was applied and the patient's treatment was completed.
224073411|NCT00004575|DRUG|Miconazole, L-NMMA, Bradykinin|
224073412|NCT06181162|OTHER|Social and/or physical environmental interventions|To be determined in the co-creation groups at the four sites (Denmark, the Netherlands, Nigeria, South Africa)
224073413|NCT04784221|RADIATION|Radiation by protontherapy associated to nanoparticles injection|"Treatment for the study will be based on proton therapy and the administration of AGuIX® nanoparticles.~Protontherapy will be carried out for 4 consecutive weeks with 5 sessions per week (20 sessions) from D1 to D26.~The administration of the AGuIX® nanoparticle will be done on Days 1, 8 and 15 during protontherapy"
224073414|NCT02968810|PROCEDURE|Biospecimen Collection|Undergo collection of blood
224073415|NCT02968810|PROCEDURE|Computed Tomography|Undergo CT
224073416|NCT02968810|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
224073417|NCT02968810|OTHER|Placebo Administration|Given PO
224073418|NCT02968810|OTHER|Questionnaire Administration|Ancillary studies
224073419|NCT02968810|DRUG|Simvastatin|Given PO
224073420|NCT06211231|BEHAVIORAL|Digitally delivered mindfulness- and acceptance-based psychological intervention|MY-ENDO is developed specifically for endometriosis and includes ten themes; one for each session: 1) endometriosis, 2) chronic pain and pain mechanisms, 3) stress, 4) thoughts and feelings, 5) grief, 6) identity and meaning, 7) everyday life and relations, 8) health, diet and exercise, 9) value-based action and 10) a good life with endometriosis.
224073421|NCT01790503|DRUG|PLX3397|
224073422|NCT01790503|RADIATION|Radiation Therapy|
224073423|NCT01790503|DRUG|Temozolomide|
224073424|NCT04201483|OTHER|DCE without RUSI feedback|Participants assigned to this group will perform an exercise known to selectively activate the semispinalis cervicis muscle
224073425|NCT04201483|OTHER|DCE + RUSI feedback about performance|Participants in this group will perform the same exercise as the DCE group to selectively activate the semispinalis cervicis muscle but receiving RUSI feedback about correct performance
224073426|NCT03879564|DRUG|Ketamine|ketamine in NSS (1 mg/ml) IV bolus 0.3 ml/kg then drip 0.09 ml/kg/hr
224073427|NCT03879564|DRUG|Normal saline|NSS IV bolus 0.3 ml/kg then drip 0.09 ml/kg/hr
224073428|NCT01951469|DRUG|Gefitinib and Pemetrexed/platinum|Gefitinib 250mg is Taken Orally on day 1-28,combined Pemetrexed (D1)+cisplatin (D1-3) or Pemetrexed (D1) + nedaplatin (D1) chemotherapy, every 28 days
224073429|NCT01951469|DRUG|Gefitinib mono-therapy|Gefitinib 250mg is Taken Orally everyday
224073430|NCT02605642|DRUG|CT-P13|biosimilar infliximab
224073431|NCT00734669|DRUG|Glibenclamide|Taking a single dose of 3.5 mg glibenclamide
224073432|NCT02762513|DRUG|Axitinib|
224073433|NCT02165384|DEVICE|Ear tube placement with the Hummingbird TTS|Using the Hummingbird TTS to make a myringotomy and deliver a tympanostomy tube across the tympanic membrane with one pass.
224073434|NCT01390909|DRUG|Anti-epileptic drug (AED)|Prescription claim for at least one AED including lamotrigine, tiagabine, pregabalin, ethosuximide, lacosamide, phenytoin, carbamazepine, valproic acid, felbamate, levetiracetam, zonisamide, primidone, oxcarbazepine, vigabatrin, phenobarbital, gabapentin, topiramate.
224185179|NCT02735720|OTHER|Non-TEVAR medical treatment|Any clinical management by physicians caring for these patients. This includes whatever blood pressure and heart rate medication is prescribed by the treating physician, without any surgery. The type and dosage of medication is left to the discretion of the care taking physician.
224185180|NCT02612766|DIETARY_SUPPLEMENT|Pure, uncontaminated oats|
224185181|NCT04167449|DIETARY_SUPPLEMENT|HRG80 Hydroponic Red Ginseng|Powdered root preparation of Panax ginseng standardized to 31.7 mg total ginsenosides
224185182|NCT04167449|DIETARY_SUPPLEMENT|Conventional White Ginseng|Powdered root preparation of Panax ginseng standardized to 9.8 mg total ginsenosides
224073435|NCT04724161|DIAGNOSTIC_TEST|ANC surveillance|Clinic-based testing of all pregnant women during antenatal care visits using national standards and commercially available malaria rapid diagnostic tests
224073436|NCT00984204|DEVICE|Therapy Cool Path Duo|All patients will be treated with Therapy Cool Path Duo Ablation System for the treatment of typical atrial flutter.
224185183|NCT04167449|DIETARY_SUPPLEMENT|Placebo|Visually identical placebo capsule containing rice flour
224308573|NCT05876663|OTHER|Conventional physiotherapy protocol|"Stretching exercise for pectoralis minor and major:10 sets and 2 sessions per day for 6 weeks.~Strengthening of Rhomboids and Trapezius muscle: 10 sets and 2 sessions per day for 6 weeks.~Deep Breathing: 10 rep and 2 sessions per day for 6 weeks."
224308574|NCT03126617|BIOLOGICAL|Elotuzumab|Elotuzumab (Emplicitii) is a Signaling Lymphocytic Activation Molecule Family member 7 (SLAMF7) directed immunostimulatory antibody approved by the US Food and Drug Administration (FDA) and indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received one to three prior therapies. Please contact your physician for more details.
224308575|NCT00459121|DRUG|carboplatin|Carboplatin AUC6 IV, every 3 weeks starting on day 1 of cycle 1
224308576|NCT00459121|DRUG|paclitaxel|Paclitaxel- 200mg/m2 IV, every 3 weeks starting on day 1 of cycle 1.
223493440|NCT07103109|OTHER|Proximal stabilization exercises|Patients will receive Scapular mobilization in five manners, superior glide, inferior glide, up-ward rotation, down-ward rotation, and distraction. Each mobilization will be done ten times. A thirty second break will be given between each set. Also scapular strengthening exercises composed of diagonal two (D2) flexion pattern to augment the upper, middle, lower, and serratus anterior muscles' activity level. To activate upper trapezius muscle, shoulder shrug exercise will be used. To activate serratus anterior muscle, Wall slide exercise will be used. Scapular retraction exercise for rhomboids and middle trapezius activation will be done. Strengthening exercises will be performed using weights were initiated with two sets of ten repetitions, beginning with a weight of 0.5 kg and progressed to 0.75, and1kg, it will be applied 5 days per week for 6 weeks
223588766|NCT02391181|DRUG|Iron Sucrose Azad|Test product Iron Sucrose Azad will be administered intravenously via a 18 gauge (18G) needle. For intravenous injection, a 5 mL single dose of test product (each mL containing 20 mg/mL elemental iron as iron sucrose in water for injection) will be diluted in 0.9% isotonic sterile sodium chloride (NaCl) up to 15 mL. The injection solution will be intravenously administered to the forearm vein, resulting in a total injection volume of 15 mL administered over a period of 5 minutes.
224185184|NCT02216539|BEHAVIORAL|Self-hypnosis|Patients will be trained to self-hypnosis prior to surgery, in order to be able to use self-hypnosis as a pain-management tool after surgery
224185185|NCT02216539|PROCEDURE|Lung transplantation|
224185186|NCT02216539|OTHER|Standard post-operative pain management|Post-operative pain management treatments as per usual protocols in the hospital
224185187|NCT00081276|DRUG|triapine|Given IV
224185188|NCT00081276|DRUG|cisplatin|Given IV
224185189|NCT00081276|OTHER|laboratory biomarker analysis|Correlative studies
224185190|NCT05346731|DRUG|Ondansetron|Ondnsetron will be administered at a dose of 0.15 mg/kg IV/PO every 8 hours on the day(s) of chemotherapy and 3 days after completion of chemotherapy
224185191|NCT05346731|DRUG|Dexamethasone|Dexamethasone will be administered at a dose of 5 mg/m2 intravenously/orally once on the day(s) of chemotherapy and 3 days after completion of chemotherapy;
224185192|NCT05346731|DRUG|Aprepitant|"Aprepitant will be administered based on body weight:~body weight 30-40 kg: days 1-3 - 80 mg orally; body weight \> 40 kg: day 1 - 125 mg orally, days 2, 3 - 80 mg orally"
224308577|NCT00459121|DRUG|Zactima|Zactima- 100 mg orally daily, starting on day 1 of cycle 1.
224308578|NCT00459121|PROCEDURE|neoadjuvant therapy|Neoadjuvant surgery: Surgical resection of the tumor will be performed after the resolution of all the adverse effects from the last cycle of treatment but no earlier than 3 weeks after the last cycle of treatment.
224308579|NCT05275803|DIETARY_SUPPLEMENT|Probiotics|The participant would receive non-surgical periodontal treatment, after which the participant uses probiotics (BioGaia Prodentis, L. reuteri DSM 17938+L. reuteri ATCC 5289, 0.8g, qn) for another 30 days.
224308580|NCT05275803|DIETARY_SUPPLEMENT|Control|The participant does not use probiotics after non-surgical periodontal treatment.
224308581|NCT02315196|DRUG|pegylated liposomal doxorubicin hydrochloride|Given IV
224308582|NCT02315196|DRUG|epirubicin hydrochloride|Given IV
224308583|NCT02315196|DRUG|carboplatin|Given IV
224308584|NCT02315196|PROCEDURE|therapeutic conventional surgery|Undergo definitive surgery
224308585|NCT02315196|DRUG|paclitaxel|Given IV
224308586|NCT02315196|OTHER|laboratory biomarker analysis|Correlative studies
224308587|NCT02315196|OTHER|quality-of-life assessment|Ancillary studies
224185193|NCT05346731|DRUG|Olanzapine|Olanzapine will be administered at a dose of 0.07 mg/kg orally on the day(s) of chemotherapy and 3 days after completion of chemotherapy (rounded up to the maximum multiple of 2.5 mg, maximum daily dose of 5 mg).
224185194|NCT01654666|PROCEDURE|Remote ischemic preconditioning|Remote ischemic preconditioning consisted of five 5-min cycles of bilateral arm ischemia/reperfusion, which is induced by an automated cuff-inflator placed on bilateral arm and inflated to 200 mmHg for 5-min followed by deflating the cuff for 5-min.
224185195|NCT01654666|PROCEDURE|Sham remote ischemic preconditioning|Sham remote ischemic preconditioning consisted of five 5-min cycles of bilateral arm ischemia/reperfusion, which is induced by an automated cuff-inflator placed on bilateral arm and inflated to 60 mmHg for 5-min followed by deflating the cuff for 5-min.
224185196|NCT01654666|PROCEDURE|Carotid Artery Stenting|Carotid Artery Stenting is an invasive therapy of carotid artery stenosis.
224185197|NCT02647931|BEHAVIORAL|Voice therapy for Muscle Tension Dysphagia|Voice therapy for Muscle Tension Dysphagia
224185198|NCT03210909|DRUG|BMS-986231|BMS-986231
224185199|NCT02433704|DEVICE|New Intraosseous|Intraosseous administration of prophylactic antibiotics
224185200|NCT02433704|DRUG|Cefazolin|Cefazolin 1 gram will be given through an intraosseous cannula, placed into the medial aspect of the proximal tibia, after draping and before skin incision. The cefazolin will be administered as a bolus in 200 mL of normal saline.
224185201|NCT06452680|PROCEDURE|Preserving IPL during surgery|IPL was preserved during surgery
224185202|NCT03947333|OTHER|My Diabetes Care|The My Diabetes Care is embedded within an existing patient web portal (My Health at Vanderbilt) and includes graphics to visualize and summarize patients' health data, incorporates motivational strategies (e.g., social comparisons and gamification), provides literacy-level sensitive educational resources, and contains secure-messaging capability.
224185203|NCT01275118|DEVICE|Tecnis Multifocal IOL|Presbyopia correcting IOL
224185204|NCT01275118|DEVICE|crystalens Accommodating IOL|Presbyopia correcting IOL
224185205|NCT05327868|OTHER|Low Fat Diet (LFD)|Subjects will be asked to adhere to a low fat diet (assigned in random order) and be counseled by a dietitian using 5 days of sample menus, monitored online using a shared nutrient analysis program, and supplied with low fat foods to increase compliance
224185206|NCT05327868|OTHER|High Fat Diet (HFD)|Subjects will be asked to adhere to a high fat diet that is rich in SFAs (assigned in random order) and be counseled by a dietitian using sample 5 days of menus, monitored online using a shared nutrient analysis program, and supplied with high fat foods to increase compliance
224185207|NCT03716206|DEVICE|Exergame|This intervention included upper limb task-orientation training, upper limb coordination training, shoulder range of motion and upper limb activity training.
224185208|NCT03716206|OTHER|Physical therapy|This intervention included upper limb task-orientation training, upper limb coordination training, shoulder range of motion and upper limb activity training.
224185209|NCT00368069|DRUG|Keppra® extended release formulation - XR|500mg extended release oral tablet, 2 tablets once daily
224185210|NCT00368069|DRUG|Placebo|oral tablets, 2 tablets once daily
223493441|NCT07103109|OTHER|Conventional physical therapy|Patients will receive shoulder joint mobilization, posterior capsular stretching, and ROM exercises in form of Codman/pendulum exercise. To mobilize the shoulder joint, distraction of the glenohumeral joint, posterior glide and caudal glide will be performed to the patients in a supine lying position at a frequency of two to three oscillations/second for one to two minutes. Every direction was repeated three to four times. At the resting position rhythmic oscillations grade I and II will be applied. In posterior capsule stretching each stretch will be repeated ten times for 20 seconds, between each stretching a 30-second break will be given. Pendulum exercise will be demonstrated to the patient at first, then they will performed it in the forward-backward direction, side-to-side direction, and circular pattern, for two to three minutes in each direction, it will be applied 5 days per week for 6 weeks
223493442|NCT07104331|DRUG|nab-Sirolimus|nab-Sirolimus 100 mg/m2 will be administered as an intravenous infusion over 30 minutes on Days 1 and 8 of each 21-day cycle.
223493443|NCT07103005|PROCEDURE|Intensive behavioral change with physical activity and diet. A single-group pre-post design|"The group of 43 participants recieved a lifestyle intervention, and was measurred before and after the intervention.~The intervention was intensive physical activity with focus om muscle strength and dietary advice from dietition, with focus on more fruits, vegetables, proteins and fiber.~Body composition was measurred using Bioelectrical impedance, DEXA and WRIC. Health related quality of life was measured using the questionnaire RAND-36, and diet was registered with the questionnaire DIGIKOST."
223493444|NCT07105007|BEHAVIORAL|Exercise Intervention|After completing the education sessions, the participants will start 8 weeks of a hybrid exercise intervention, three days/week, being one supervised session in the exercise center and two unsupervised sessions at home. Sessions at the exercise center will be supervised by experienced exercise trainers in a 1:1 ratio. The intervention is designed to meet the recommendation of at least 150 minutes of MVPA per week and the recommendations on exercise intensity and volume from the ACSM. Each exercise session will be composed of aerobic and resistance exercises at moderate intensity (i.e., combined exercise training), which is the best exercise model for the needs of PLWH. Additionally, poor muscle strength has been associated with lower VO2peak among PLWH, suggesting that appropriate muscle-strengthening exercises can improve the aerobic performance of these patients. The aerobic exercise will be performed in a continuous manner and prescribed using the heart rate reserve.
223493445|NCT07105007|BEHAVIORAL|Education sessions|At the beginning of the program, the participants will receive two face-to-face group education sessions, consisting of 90 minutes of exercise and cardiovascular health education. The material for the education sessions will be developed by the study team (a diverse team including exercise scientists, nurse, cardiologist, and infectious disease specialist). The focus of the sessions will be to increase the participants' knowledge and self-efficacy. The education sessions will occur prior to the start of the exercise intervention, to teach the participants how to safely perform the home-based exercises. An interventionist, who will possess a degree in a health profession, will present the content following the completion of standard training using material and guidance developed for this purpose. The content of the sessions will include a self-assessment on exercise and physical activity, and incorporate the ACSM recommendations for quantity and quality of exercise
223493446|NCT07105007|BEHAVIORAL|Behavioral coaching|At the end of their weekly in-person exercise sessions, the participants will receive a 20 minute coaching session to address their attitudes, self-efficacy, and behavioral self-management skills towards exercise. During the sessions, the trainers will be taught to use motivational interviewing, an evidence-based communication strategy that identifies and enhances patients' own motivations and reasons for health behavior change. Motivational interviewing is an approach to assessment and intervention based on the Stages of Motivational Readiness for Change model, which has been shown to increase physical activity in people with chronic health conditions. According to the Stages of Motivational Readiness for Change Model, individuals move through a series of stages (i.e., Precontemplation, Contemplation, Preparation, Action, and Maintenance) as they adopt and maintain a new habit. The coaching session will also address barriers from the home-based sessions, discuss HIV-specific barriers
223745674|NCT05231590|BIOLOGICAL|SARS-CoV-2 recombinant spike protein + Advax-SM adjuvant|SARS-CoV-2 recombinant spike protein (25 µg) with Advax-SM adjuvant (15 mg) in two doses with a 21-day interval administered with intramuscular injections in the non-dominant arm
223745675|NCT02253212|DEVICE|SonoCloud|SonoCloud : dose escalation
224073437|NCT03844906|DRUG|SAGE-718|SAGE-718 in combination with Ketamine
224073438|NCT03844906|DRUG|Placebo|Placebo in combination with Ketamine
224073439|NCT03716089|PROCEDURE|Laparoscopic resection|Laparoscopic surgery under general anesthesia
224073440|NCT00388050|BEHAVIORAL|Diabetes Medication Choice decision aid|The decision aid covers five commonly prescribed anti-hyperglycemic medications and their attributes.
224073441|NCT00388050|BEHAVIORAL|Usual Care|Patients and clinicians in this arm will discuss anti-hyperglycemic agents in their usual manner.
224073442|NCT02212132|OTHER|behavioral assessments|Neuropsychological evaluation, psychopathological assessment and fatigue
224073443|NCT00002800|BIOLOGICAL|filgrastim|
224073444|NCT00002800|BIOLOGICAL|lintuzumab|
224073445|NCT00002800|DRUG|cytarabine|
224073446|NCT00002800|DRUG|etoposide|
224073447|NCT00002800|DRUG|idarubicin|
224185211|NCT01440231|DRUG|Placebo|Matching placebo administered by subcutaneous injection, once weekly
224185212|NCT01440231|DRUG|Atacicept|Atacicept 5 mg administered by subcutaneous injection, once weekly
224308588|NCT05484037|OTHER|CANATEXTS|Canadian Asthma Text Messaging (CANATEXTS) is a TH intervention facilitating access to an electronic AAP (eAAP) via a mobile device.
224308589|NCT03058094|DRUG|Pemetrexed|Pemetrexed will be administered as an intravenous infusion over 10 minutes on Day 1 of each 21-day cycle. Folic acid will be administered 1-2 weeks prior to the 1st dose, then daily during the treatment period until 21days post the last dose. Vitamin B12 will be administered on the same day of pemetrexed infusion during the treatment period. Corticosteroid will be adminstered on the day prior to, on the day, and on the day after infusion.
223493447|NCT07105007|BEHAVIORAL|Mobile health support|At the beginning of the program the participants will receive a fitness activity tracker (e.g., Fitbit or similar) to help in achieving their PA goals. Contemporary activity trackers provide reliable information on heart rate, steps count, and amount of PA performed, that will help the participants to monitor the intensity and amount during the home-base sessions. Heart rate monitoring will also be used to assess compliance with the home-based exercise prescription. Trackers also include gamification, awarding badges and trophies when goals are attained, that is demonstrated to be motivating.
223493448|NCT07105345|BEHAVIORAL|Cognitive Processing Therapy (CPT)|Participants will receive 12 weekly 90-minute individual sessions of Cognitive Processing Therapy (CPT) following the Resick manual. The intervention includes cognitive restructuring, trauma-related belief processing, and structured behavioral assignments. Sessions are delivered by trained therapists.
223493449|NCT07105345|OTHER|Treatment as Usual (TAU)|Participants will receive routine outpatient psychiatric care as determined by clinicians. This may include medication, general supportive therapy, or psychoeducation, but will not include structured CPT sessions.
223493450|NCT07105306|OTHER|Buteyko Breathing Technique Training|Buteyko Breathing Technique (BBT), developed in the 1950s, which focuses on reducing dysfunctional hyperventilation patterns through breath control and extended breath-holding phases called control pauses
223493451|NCT07103161|DEVICE|Uresta bladder support device|The Uresta bladder support device is an intravaginal device indicated for adult women over 18 years of age who experience stress urinary incontinence, including urine leakage during exercise and non-exercise activities such as coughing and laughing. The device is FDA-cleared and licensed by Health Canada. Participants receive the entire kit that includes the three most common sizes which fit 90% of women. Two additional sizes are available in the lab if needed. Participants will be instructed to self-insert the Uresta prior to running, following the manufacturer instructions with researcher guidance as needed. The device aims to provide mechanical support to the urethra and bladder neck to prevent urine leakage during activities that provoke leakage.
223493452|NCT07103161|DEVICE|Sportex regular tampon|Participants will use a regular absorbency Sportex tampon as a conservative intravaginal support to potentially reduce stress urinary incontinence (SUI) symptoms during running. Participants will be instructed to insert the tampon prior to running into the mid-to-upper vaginal canal while standing or sitting.
223493453|NCT07105033|BEHAVIORAL|FACT Session|Participants will participate in 4 weekly, 35-45 minute sessions
223493454|NCT07105033|BEHAVIORAL|Enhanced Usual Care and Assessments|Participants will complete a symptoms questionnaire
223493455|NCT07104747|PROCEDURE|Static Exercise Intervention|Static exercises generally involve maintaining a fixed position without movement-such as standing on one leg or holding a specific posture-emphasizing isometric muscle control and stability.
223493456|NCT07104747|PROCEDURE|(Dynamic Exercises Group|Dynamic exercises were structured across three progressive stages-basic, moderate, and advanced-each increasing in complexity and difficulty. These exercises were performed in various positions, including sitting, standing, and walking.
223493457|NCT05765500|DRUG|Relugolix|Gonadotropin-releasing hormone (GnRH) antagonist, oral tablet taken 1x daily.
223493458|NCT05765500|DRUG|Leuprolide|Gonadotropin-releasing hormone (GnRH) antagonist, intramuscular injection 1x every 3 months.
223493459|NCT07105826|OTHER|Prebiotic Soda 1|A single dose of 12 ounces of Olipop will be provided to the 10 participants while fasted. Blood samples will be collected at baseline (before the drink) and at 15, 30, 60, 90, and 120 minutes after the drink.
223493460|NCT07105826|OTHER|Prebiotic Soda 2|A single dose of 12 ounces of Poppi will be provided to the 10 participants while fasted. Blood samples will be collected at baseline (before the drink) and at 15, 30, 60, 90, and 120 minutes after the drink.
223493461|NCT07105826|OTHER|Diet Soda|A single dose of 12 ounces of Diet Coke will be provided to the 10 participants while fasted. Blood samples will be collected at baseline (before the drink) and at 15, 30, 60, 90, and 120 minutes after the drink.
223493462|NCT07105826|OTHER|Regular Coke|A single dose of 12 ounces of Regular Coke will be provided to the 10 participants while fasted. Blood samples will be collected at baseline (before the drink) and at 15, 30, 60, 90, and 120 minutes after the drink.
223493463|NCT06911541|DEVICE|Wireless respiratory rate monitor|This sensor is being fasten on the chest of the patients and measures respiratory rate with the help of an accelerometer. Data is being sent wireless to a backend monitor.
223493464|NCT07106138|DEVICE|Conventional syringe injection|Manual injection using a conventional dental syringe and needle to deliver local anesthetic.
223493465|NCT07106138|DEVICE|Star Pen|A computer-controlled local anesthetic delivery system designed to provide slow, controlled injection with improved comfort.
224185213|NCT01440231|DRUG|Atacicept|Atacicept 25 mg administered by subcutaneous injection, once weekly
224185214|NCT01440231|DRUG|Atacicept|Atacicept 75 mg administered by subcutaneous injection, once weekly
224185215|NCT01440231|DRUG|Atacicept|Atacicept 115 mg administered by subcutaneous injection, once weekly
224185216|NCT04920305|DIETARY_SUPPLEMENT|Phosphatidylserine|subjects in the treatment group oral the PS (600mg/d, q.d.) for 6 months.
224185217|NCT04920305|DIETARY_SUPPLEMENT|Bean powder|Subjects in the control group were given a placebo, which was the same shape of bean powder(600mg/d, q.d.).
224308590|NCT03058094|DRUG|Cisplatin 75mg/m2|Cisplatin will be administered as an intravenous infusion.
224308591|NCT03058094|DRUG|AC0010|300mg, orally, BID
224308592|NCT04770467|DRUG|BRII-196 and BRII-198|BRII-196 and BRII-198 given by intravenous administration
224308593|NCT04770467|DRUG|Placebo|Placebo given by intravenous administration
223745676|NCT02253212|DRUG|Carboplatin|Carboplatin : min 6 cycles - individual dose determination according to renal function and AUC
224185218|NCT05610228|OTHER|NO intervention|No intervention
224185219|NCT01617265|PROCEDURE|Clinical Procedure to Prevent Oversedation|Sedation and analgesia will be administered according to a bundle of measures aimed at limiting oversedation, including repeated assessment of patients needs and graduate therapeutic response to control pain, discomfort, poor synchrony with the ventilator and agitation. The therapeutic options include non hypnotic anxiolytics, repeated IV hypnotics boluses, short-duration (6 hours) IV hypnotics infusion and round the clock IV hypnotics infusion.
224185220|NCT01617265|PROCEDURE|Usual sedation practice|Sedation and analgesia will be administered according to the usual practices in each participating center.
224185221|NCT00000322|BEHAVIORAL|Tyrosine|
224185222|NCT04993144|DEVICE|continuous theta burst stimulation|stimulatory protocol
224185223|NCT05977777|DIAGNOSTIC_TEST|Contrast- enhanced ultrasound|Contrast- enahnched ultrasound is performed on target pancreatic lesion
224185224|NCT05630742|OTHER|chronic non-neoplastic pain|comparison of questionnaires scores
224185225|NCT02391649|BEHAVIORAL|Self-learning program|The PSBBP in this study consists of 5 modules (Module 1: Caregiver's well-being; Module 2:Getting the best out of support services; Module 3:Well-being of the person with schizophrenia; Module 4:Dealing with the \[psychosocial\] effects of the illness; and Module 5:Dealing with \[physical and mental health\] effects of the illness), helping each caregiver from developing a positive attitude to caregiving, identifying caring related problems and obstacles, predicting positive and negative implications of each alternative, to trying out the solution and monitor if it worked.
224185226|NCT02391649|BEHAVIORAL|Psycho-education program (in Phase 2)|The program consists of 12 two-hour sessions held weekly/biweekly completed in 5 months, with 4 main components, including 'introduction and goal setting'; 'an education workshop on mental illness, treatment and community services'; 'group exercises/rehearsals and discussion on symptom management, coping and self-care'; and 'review and future plan'.
224308594|NCT05974436|OTHER|Blood and dialysate sampling|"Blood is sampled from the inlet and outlet dialyzer bloodline at 5min after dialysis start.~Spent dialysate is sampled from the outlet dialysate line at 5, 30, 90 and 240min after dialysis start.~Blood and dialysate samples are analysed for different uremic toxins. Dialysis efficiency is calculated from the analysed toxin concentrations."
224308595|NCT00042536|DRUG|Naltrexone HCL/ Yohimbine HCL|
223493466|NCT07106138|DEVICE|Comfort-In|A needle-free injection system that delivers anesthetic through high-pressure jet injection, reducing injection-related discomfort.
223493467|NCT07106138|DEVICE|Vibraject|A vibrating attachment for dental syringes that provides vibrotactile stimulation during injection to distract from pain perception
223493468|NCT07106775|BEHAVIORAL|Family Intervention Program (PIF)|Home psychoeducational intervention in an individual format driven by a practitioner where caregivers learn parenting competences and children learn autonomy and emotional regulation skills
223493469|NCT07106385|DEVICE|rtms|Participants will undergo a treatment protocol involving six sessions of rTMS using the EXOMIND™ device, administered once or twice a week. Each session will deliver 6,300 pulses at alternating frequencies of 12, 15, and 18 Hz, with a total duration of 24 minutes and 30 seconds. The target site would be left dorsolateral prefrontal cortex (DLPFC), determined by the most common used 5-cm rule. The procedure would be conducted in our research centre with medical staff supported.
223493470|NCT06630091|DRUG|Golidocitinib|150 mg once per day by PO
223493471|NCT06630091|DRUG|Cyclophosphamide|750 mg/m2 by IV
223493472|NCT06630091|DRUG|Doxorubicin|50 mg/m2 by IV
223493473|NCT06630091|DRUG|Vincristine|1.4 mg/m2 (max: 2 mg) by IV
223493474|NCT06630091|DRUG|Prednisone|100 mg by PO
223493475|NCT07104903|OTHER|Data collection from medical records|Data are collected from the information system and medical records, including demographic characteristics, presence of surgical site infection, comorbidities, data regarding neoadjuvant oncological therapy, preoperative laboratory findings, type and duration of surgical intervention, perioperative complications, and SENIC and NNIS scores are calculated.
223493476|NCT05145595|DEVICE|Thermal Sensory Analyzer|Thermal stimuli: The Thermal Sensory Analyzer (TSA-II or PATHWAY platform - Medoc, Ramat Yishai, Israel) will be used to deliver heat and cold stimuli. These devices can deliver relatively complex stimuli via computer control. All targeted stimulus temperatures will be less than 50°C, and participants will be free to remove their arm or leg at any time from the thermode. Noxious cold stimuli will also be delivered with a plastic water container or a water bath (FISHER, USA). Participants will be free to pull out of the water bath at any time.
223493477|NCT05145595|DEVICE|Pressure Stimuli|Pressure stimuli: Pressure stimuli will be applied by using a handheld algometer (Wagner Instruments) or the Pressure Algometer (Medoc, Ramat Yishai, Israel). These devices have a round probe that allows quantifying the amount of pressure that is being applied. The Pressure Algometer allows a real-time visual feedback to control and monitor applied pressure rates. Pressure will be applied to the lower leg, volar forearm, or trapezius.
223493478|NCT05145595|DEVICE|Mechanical Stimuli|Mechanical stimuli: A set of standardised von Frey filaments (0.25, 0.5, 1, 2, 4, 8, 16, 32, 64, 128 and 256mN). The contact area of the hairs with the skin is of uniform size (\<1 mm²) and texture.
223493479|NCT05145595|BEHAVIORAL|Pain Ratings|Pain intensity and pain unpleasantness ratings will be assessed by numerical rating scale (ranging from 0- no pain/unpleasantness to- 100 the most intense/unpleasantness pain imaginable) and by mechanical and computerized visual analog scales (VAS which ranges between ''no pain sensation'' and ''most intense pain imaginable'').
223745677|NCT02430337|BEHAVIORAL|Technology-Assisted SafeCare|A technology-enhanced version of SafeCare
223745678|NCT02430337|BEHAVIORAL|SafeCare|SafeCare, an evidence-based home visiting program
223745679|NCT04019743|DRUG|CKD-330 16/10mg Tab. 1T and D086 Tab. 1T|single oral administration under fasting condition
223745680|NCT04019743|DRUG|CKD-333 16/10/40mg formulation 1 Tab. 1T|single oral administration under fasting condition
223745681|NCT04019743|DRUG|CKD-333 16/10/40mg formulation 2 Tab. 1T|single oral administration under fasting condition
223745682|NCT05222061|DEVICE|Drug coated balloon for the side brunch|Intervention is explained in group description
223745683|NCT05222061|DEVICE|Conventional balloon for the side brunch|Intervention is explained in group description
224185227|NCT00670098|PROCEDURE|Bariatric surgery|patients receive either gastric bypass or lap-band
223493480|NCT05145595|BEHAVIORAL|Thermal pain thresholds|Cold and heat pain thresholds (CPT and HPT, respectively) will be determined \[22; 55\]. Thresholds are determined by continuous ramping of temperature from 32°C baseline temperature until the participant press a button at the first moment he/she feels pain from the stimulus. Cut-off temperatures are 0°C and 50°C, to minimize potential damage to the skin. The baseline temperature to which the thermode returns before each test is 32°C. The first threshold measurement will be used as a familiarization. The average threshold is calculated from three measurements.
223493481|NCT05145595|BEHAVIORAL|Pressure pain thresholds (PPT)|Pressure will be increased continually and participants will be instructed to press a button the first moment they feel pain from the pressure stimulus. The first threshold measurement will be used as a familiarization. The average threshold is calculated from three measurements.
223493482|NCT05145595|BEHAVIORAL|Mechanical temporal summation|A pinprick stimulus with standardised intensity (#6.10 or #6.45 von Frey filament) and a flat contact area of 0.25mm diameter will be used. In this test, participants will rate the pain evoked by a single pinprick stimulus and by a series of 10 identical pinprick stimuli. The 10 identical pinprick stimuli are applied with a frequency of 1 s-1 within an area of 1 cm2. Immediately following the single stimulus and series of stimuli, an evaluation of the pain will be collected. The difference in pain ratings evoked with the one stimuli vs. the 10 stimuli is the temporal summation value.
223588767|NCT02391181|DRUG|Venofer®|Reference product Venofer® will be administered intravenously via a 18 gauge (18G) needle. For intravenous injection, a 5 mL single dose of reference product (each mL containing 20 mg/mL elemental iron as iron sucrose in water for injection) will be diluted in 0.9% isotonic sterile sodium chloride (NaCl) up to 15 mL. The injection solution will be intravenously administered to the forearm vein, resulting in a total injection volume of 15 mL administered over a period of 5 minutes.
223588768|NCT04457063|PROCEDURE|PKP|"1. The horizontal axis was marked with a pointed marker at the slit lamp immediately before surgery.~2. TICL loading into the STAAR injector cartridge~3. Temporal clear corneal 3 mm incision \& 2-side ports then viscoelastic injection into the AC~4. Implantation of the TICL using the injector, then rotation according to the implantation diagram guided with Mendez protractor, and lastly placement of the haptics under the iris.~5. Pupil constriction with A.Ch.~6. Washing the viscoelastic \&Wound hydration.~7. Topical antibiotic steroids (Vigamox and Tobradex) 4 times /day for 3weeks"
223588769|NCT03846609|DEVICE|double balloon interventional platform (DiLumen)|double balloon interventional platform (DiLumen) is used for removal of colonic polyp
223588770|NCT03846609|DEVICE|no double balloon interventional platform (DiLumen)|double balloon interventional platform (DiLumen) is not used for removal of colonic polyp
223588771|NCT00477152|DRUG|hyaluronidase (human recombinant)/rehydration fluid|Single 150 U subcutaneous (SC) HYLENEX dose administered immediately prior to start of SC infusion of rehydration fluid. Additional 150 U HYLENEX dose to be administered prior to any additional fluid infusion beyond 24 hours.
223588772|NCT01321957|DRUG|Oxaliplatin, 5FU/LV, Bevacizumab|bevacizumab at a dose of 5 mg/kg iv over 30 to 90 min (day 1) oxaliplatin at a dose of 85 mg/m2 iv over two hours (day 1) I-LV at a dose of 200 mg/m2 iv over two hours (day 1) 5-FU at a dose of 3200 mg/ m2 iv over 48 hours (day 1-3)
223588773|NCT01321957|DRUG|5FU/LV, Oxaliplatin, Bevacizumab, Irinotecan|bevacizumab at a dose of 5 mg/kg iv over 30 to 90 min (day 1) irinotecan at a dose of 165 mg/m2 iv over two hours (day 1) oxaliplatin at a dose of 85 mg/m2 iv over two hours (day 1) I-LV at a dose of 200 mg/m2 iv over two hours (day 1) 5-FU at a dose of 3200 mg/ m2 iv over 48 hours (day 1-3)
223588774|NCT00742729|BEHAVIORAL|Arm 1|Educational small group session with free FOBT kit
223588775|NCT00742729|BEHAVIORAL|Arm 2|Educational small group session with no FOBT kit
223588776|NCT00742729|BEHAVIORAL|Arm 3|Educational small group session, exercise
223588777|NCT05541445|DRUG|Pembrolizumab|The subjects first receive induction therapy with pembrolizumab combined with chemotherapy for 6 weeks, and then receive sequential therapy with pembrolizumab combined with concurrent chemoradiotherapy for 6 weeks, and receive surgical treatment within 4-8 weeks after neoadjuvant therapy. For patients whose postoperative pathology is confirmed as PCR (pathological complete response), the patients will be observed with long-time follow-up; If the postoperative pathology is confirmed as non-PCR, pembrolizumab will be administrated until 1 year or disease progression or intolerable toxicity.
223588778|NCT03944408|PROCEDURE|stent implantation|stent implantation
223588779|NCT06271395|DRUG|Injectable Type A Botulinum Toxin|Injectable Type A Botulinum Toxin (National Medical Products Administration Approval Number S10970037) 100 unit, diluted with 1ml of 0.9% sodium chloride solution for injection and kept ready for use. Only once. Using an ultrasound probe to scan the neck, the position of the lowest point, highest point, and lower middle point of the esophageal high-pressure zone are determined, and marks are made on the body surface and catheter wall. The high-pressure point and the lower middle point are selected as injection sites on the left side. The above area is locally disinfected, and the probe is covered with a sterile cover and coated with sterile coupling agent. Using a plane approach, 0.3ml or 30 unit of botulinum toxin is injected separately after reaching the esophageal circular layer at each of the two left injection points. A total of 60 unit of botulinum toxin is injected at the two left points.
223588780|NCT00172341|DRUG|Staloral TM|
223588781|NCT06514313|DRUG|Mitoxantrone Hydrochloride Liposome+Irinotecan+Vincristine|Mitoxantrone hydrochloride liposome will be administered by an intravenous infusion , 4 cycles.
223588782|NCT06514313|DRUG|Temozolomide+Irinotecan+Vincristine|Q3W, 4 cycles
223588783|NCT01737853|DRUG|Ganforti|Enrolled patients will be visiting their clinical site at month 2 and month 3, after starting the study medication; at the end of the third month of treatment, a cross-over maneuver will be indicated; all patients will undergo a follow-up scheme similar to the first period of the study (at month 5 and month 6)
224185228|NCT00670098|BEHAVIORAL|lifestyle intervention (behavioral weight loss)|participants attend biweekly weight loss counseling group sessions
224185229|NCT06098001|DIETARY_SUPPLEMENT|Low dose dietary fiber|Subjects will receive a low dose or high dose of the dietary fiber product in a dose esacalation design
224185230|NCT06098001|DIETARY_SUPPLEMENT|High dose dietary fiber|Subjects will receive a low dose or high dose of the dietary fiber product in a dose escalation design
224185231|NCT03222869|DIAGNOSTIC_TEST|Measure Airway Resistance Across Stenosis|Measure pressure and air flow Across Stenosis
224185232|NCT01203566|PROCEDURE|LESS appendectomy|See under arms description
224185233|NCT01203566|PROCEDURE|Conventional 3-port laparoscopic appendectomy|See under arms description
224185234|NCT04680273|DRUG|[14C]-GDC-9545|Participants will receive a single oral dose of \[14C\]-GDC-9545 capsule, 30 milligrams (mg) (not more than \[NMT\] 4.6 megabecquerel \[MBq\]; 124 microcurie \[μCi\]) with approximately 240 millilitres (mL) water in the fasted state.
224185235|NCT04680273|DRUG|GDC-9545 Solution for Infusion|Treatment B: 30 mg GDC-9545 as a solution for infusion, 3 mg/mL administered intravenously (IV) in 10 mL as an infusion over 30 minutes.
224185236|NCT04680273|DRUG|GDC-9545/F12 Capsule|Treatment C: GDC-9545/F12 capsule, 30 mg, administered orally with approximately 240 mL water.
223493483|NCT05145595|BEHAVIORAL|Conditioned pain modulation (CPM) efficiency|"The CPM paradigm assesses endogenous inhibitory pain modulation efficiency related to spatial filtering of nociceptive information. CPM testing includes the application of a test stimulus without conditioning (control run) and a subsequent application of the same test stimulus together with a conditioning stimulus (conditioning run). Heat-CPM and pressure-CPM. Heat and pressure CPM will be tested in random order.~The difference between the pain ratings/thresholds of the test stimulus with vs. without the concomitant conditioning stimulus is the CPM magnitude. CPM\<0 (reduction in pain) implies efficient inhibitory pain modulation of spatial filtering."
223493484|NCT05145595|BEHAVIORAL|Offset analgesia efficiency|"Offset analgesia (OA) paradigm assesses endogenous inhibitory pain modulation efficiency of temporal filtering of nociceptive information. The mechanisms underlying OA are distinct from the CPM mechanisms \[41\]. OA is characterized by a disproportionately large reduction in pain perception after a small decrease in temperature during noxious thermal stimulation.~Offset analgesia will be assessed using the three-temperature method (T1°C 5s, T1+1°C 5s, T1°C 20s). The T1 will be noxious heat (44-48°C) delivered to the hand or leg. During the OA paradigm, real time pain intensity ratings will be obtained using the computerized VAS.~The difference between the pain ratings of the 10-20 seconds noxious stimulus in the OA paradigm compared to a control paradigm (30 seconds of T1) is the OA magnitude. OA\<0 (reduction in pain) implies efficient inhibitory pain modulation of temporal filtering."
223493485|NCT05145595|BEHAVIORAL|Cold pain tolerance|Cold pain tolerance will be assessed by having participants immerse their hand or foot in a cold (4-12°C) water bath. Tolerance will be defined by the time of hand withdrawal. VAS ratings of cold pain intensity might be obtained periodically, and both pain intensity and pain unpleasantness will be recorded upon hand withdrawal. Limb immersion in the cold water bath will be terminated after 120 s if participants do not withdraw their hand before then.
223493486|NCT07103980|DRUG|Mesenchymal stem cell derived exosome nebulization combined with compound methoxyphenamine capsule|"Mesenchymal stem cell derived exosome nebulization (FITCELL 5ml nebulization QD) was combined with compound methoxyphenamine capsule ( Asmei 2 capsules oral TID) for cough treatment."
223493487|NCT07103980|DRUG|Normal saline nebulization combined with the compound methoxyphenamine capsule|"Normal saline nebulization (0.9% sodium chloride 5ml nebulization QD) was combined with the compound methoxyphenamine capsule (Asmei 2 capsules oral TID) for cough treatment."
223493488|NCT07103460|COMBINATION_PRODUCT|Essential Oil Diffusion Combined with Respiratory Training|three commonly used essential oils (wintergreen, peppermint, and eucalyptus) will be integrated into IS respiratory training
223493489|NCT07103473|DEVICE|Interactive Binocular Treatment|Patients in the intervention group will be asked to play the games which will be designed based on the Interactive Binocular Treatment System and the patients in the placebo group will be asked to play games without the Interactive Binocular Treatment System.
223493490|NCT07104552|DRUG|Course of amoxicillin|Oral amoxicillin per os at 50 mg/kg/day
223493491|NCT07105332|DEVICE|OMI and Photometer|A glucose sensitive ocular mini insert (OMI) is placed sub-conjunctivaly. When exited by photometer the glucose concentration is measured.
223493492|NCT07102745|BEHAVIORAL|HomeLink|HomeLink is a structured post-discharge home-based care program for people living with HIV, designed to improve health outcomes after hospital discharge. Starting one week after discharge, trained nurse-clinician and counselor teams conduct regular home visits every two weeks for up to six visits. During these visits, the team will provide clinical assessments, medication adherence support, psychosocial counseling, specimen collection, and home safety evaluations. The intervention aims to offer personalized, continuous care that addresses medical, psychological, and social needs in the participant's home environment, enhancing recovery and reducing post-hospital mortality.
223493493|NCT07102745|BEHAVIORAL|HomeLink Plus Nutritional Support|This intervention combines the HomeLink home-based care program with the provision of nutritional support through food parcels. Participants receive food parcels designed to address nutritional needs and support overall health and recovery. The combined approach aims to improve post-discharge outcomes by addressing both medical and nutritional factors contributing to patient well-being.
223493494|NCT07103785|OTHER|Mobile game app|The mobile game designed to modify attentional bias toward alcohol-related cues was developed by integrating game elements into a modified version of the dot-probe task. This gamified intervention was installed on the smartphones of participants assigned to the experimental group, and each participant was provided with a unique username and password for access. Participants were instructed to engage with the mobile game every other day over one month.
223588784|NCT01737853|DRUG|Krytantek|Enrolled patients will be visiting their clinical site at month 2 and month 3, after starting the study medication; at the end of the third month of treatment, a cross-over maneuver will be indicated; all patients will undergo a follow-up scheme similar to the first period of the study (at month 5 and month 6)
223588785|NCT03592485|PROCEDURE|Erector Spinae Plane blockade|Before the beginning of the procedure, ESP blockade will be performed under ultrasound control. A single-shot technique will be used with 0.375 % solution of ropivacaine: 0.1 mL per patients' KG. The maximum dose is 20 mL.
223588786|NCT03592485|PROCEDURE|Pectoral Fascia block|Before the beginning of the procedure, PECS type I and II blocks will be performed under ultrasound control. A single-shot technique will be used with 0.375 % solution of ropivacaine: 0.1 mL per patients' KG. The maximum dose is 20 mL.
224185237|NCT04680273|DRUG|GDC-9545/F18 Capsule|Treatment D: GDC-9545/F18 capsule, 30 mg, administered orally with approximately 240 mL water.
224185238|NCT03907072|DRUG|WVE-210201 (suvodirsen)|WVE-210201 is a stereopure antisense oligonucleotide (ASO)
224185239|NCT03907072|DRUG|Placebo|Buffered saline solution
224073448|NCT00865384|DRUG|Mirtazapine 15 mg tablets, single dose|A: Experimental Subjects received Purepac formulated products under non-fasting conditions
223493495|NCT07103785|DRUG|Akamprosat or Naltrekson or combined medical treatment (Akamprosat and Naltrekson)|Medicines prescribed by a doctor for the treatment of Alcohol Use Disorder (Akamprosat or Naltrekson or combined medical treatment (Akamprosat and Naltrekson))
223493496|NCT07103928|BEHAVIORAL|Impart Assisted Partner Notification|Participants randomized to the Impart arm may choose per partner either a) sell-tell notification or b) having an Impart-trained APN notifier team locate, notify, and offer HIV testing to their partners without revealing the identity of who had named them. Impart notifiers initially contact named partners by telephone and identify themselves as health service providers with important information about the partner's health that needs to be shared in person. Partners who agree to meet are asked to choose a location. Notification by telephone is only delivered as a last resort when circumstances prevent in-person notification or a partner insists on learning the reason for the telephone call. Once contact is made at a private location, partners will be advised of their possible shared exposure to HIV. APN notifiers never reveal participant names or identifying information during this meeting. All notified partners are offered immediate HIV testing and treatment referral, if HIV-positive.
223493497|NCT07103928|BEHAVIORAL|Self-Tell Notification|"Participants who wish to self-notify one or more partners are coached to do so either in person or by telephone. APN counselors confirm the names of partners for whom participants provide contact information before giving the phone to the participant to explain the reason for the call: I want to speak with you because I was diagnosed with HIV and I believe we shared an exposure. Alternately, participants who wish to notify partners in person are coached to inform partners that they have a serious health matter that they wish to discuss, and ask the partner to visit them in jail/prison. Either way, the APN counselor is present to record the names of partners whom participants self-notify, and offers to speak with the partner immediately afterwards to answer their questions about HIV and to provide information about HIV testing and contact information should the partner wish to contact an HIV provider on their own to learn more about HIV testing or to schedule an HIV test."
223493498|NCT05199948|OTHER|Soybean Oil Foods|Three food product containing 10g of soybean oil each will be consumed each day for a today of 30g of soybean oil consumed each day
223493499|NCT05199948|OTHER|Palm Oil Foods|Three food product containing 10g of palm oil each will be consumed each day for a today of 30g of palm oil consumed each day
223493500|NCT02337686|OTHER|Laboratory Biomarker Analysis|Correlative studies
223493501|NCT02337686|BIOLOGICAL|Pembrolizumab|Given IV
223493502|NCT02337686|OTHER|Pharmacological Study|Correlative studies
223493503|NCT02337686|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
223493504|NCT06762808|DRUG|Atezolizumab|Given by IV infusion
223493505|NCT06762808|DRUG|Talazoparib|Given by IV infusion
223493506|NCT06082037|DRUG|Belumosudil|Tablet, Oral
223493507|NCT06082037|DRUG|Azithromycin|Depends on pharmaceutical presentation, Oral
223493508|NCT06082037|DRUG|Placebo|Tablet, Oral
223493509|NCT06448637|DEVICE|Drug Coated Balloon (DCB)|Drug Coated Balloon (DCB) in patients with indication of Percutaneous Coronary Intervention (PCI)
223493510|NCT06448637|DEVICE|Drug Eluting Stent (DES)|Drug Eluting Stent (DES) in patients with indication of Percutaneous Coronary Intervention (PCI)
223588787|NCT03592485|DRUG|Oxycodone|Each patient, before the end of surgery, will be administered i.v. 0.1 mg of oxycodone. PCA with oxycodone (1mg/mL) will be utilized during the postoperative period: 5-minute interval.
224073449|NCT00865384|DRUG|REMERON® 15 mg tablets, single dose|B: Active comparator Subjects received Organon Inc. formulated products under non-fasting conditions
224073450|NCT02828072|OTHER|SKY therapy|slow breathing
224073451|NCT02828072|DRUG|usual drug therapy|
224073452|NCT01076465|OTHER|Disease management program|1\. Educational intervention on management of heart failure and comorbidity to improve patient's knowledge of his/her disease and self-care 2) Monitoring of clinical status 3) Monitoring and improvement of therapeutic adherence.
224073453|NCT01076465|BEHAVIORAL|Usual care|Usual care
224073454|NCT03394560|DEVICE|High frequency repetitive transcranial magnetic stimulation|Gait training with body weight support will be performed through Biodex Rehabilitation treadmill. It will performed for 20 minutes and researchers will assist the patient in placing the foot on the ground, in the extension of the knee and in the alignment of pelvis and trunk. The percentage of body weight support and speed of treadmill will be modified based on the performance of each patient. Repetitive transcranial magnetic stimulation will be applied by an eight-shaped coil positioned on the patient's scalp and performed according to the 10-20 international system (primary motor cortex). In sham rTMS two coils will be used: (i) a coil connected to the stimulator will be positioned behind the patient (away from the scalp) to generate characteristic stimulus sound, and (ii) another coil will be disconnected from the stimulator and positioned on the scalp individual. The active and sham stimulation will last 20 minutes.
224185240|NCT00591305|DIETARY_SUPPLEMENT|diindolylmethane (DIM)|3-month DIM
224185241|NCT00591305|DEVICE|585 nm pulsed dye laser|once-time PDL
224185242|NCT00389909|DRUG|Doxapram|"Dosing comparison between fixed scheduled and sex related dosage.~Dosing related to weight only versus chart taking into account weight, age and gender."
224185243|NCT01488175|PROCEDURE|tourniquet|a tourniquet around the thigh is used during insertion of the TKA to achieve a bloodless environment
224185244|NCT01488175|PROCEDURE|no tourniquet|a tourniquet around the thigh is not used during insertion of the TKA
224185245|NCT04168775|DEVICE|Home PIFR monitoring with InCheck Dial|The In-Check G16 DIAL® (Alliance Tech Medical, Granbury TX) is a simple hand-held device that measures PIFR via a brief inspiratory maneuver.
224185246|NCT01430559|DRUG|Meloxicam|7.5mg x2 once a day for 12 weeks
224185247|NCT01430559|DRUG|Placebo|Study subjects will be randomized to two treatment groups: one with Meloxicam 7.5 mgx2 once a day and another one with placebo. The duration of the interventional treatment is 12 weeks.
224185248|NCT03028506|OTHER|Carbohydrate intake|By calculating carbohydrate amounts at meals and snacks, as well as classifying meals and snacks as high fat, the investigators will examine the correlation to higher preprandial blood glucose values and large for gestational age infants.
224185249|NCT05619185|BEHAVIORAL|CRAFT Web-Based Intervention|Session 1 addresses CPs' mental health issues and drinking. CPs select reasons why they are seeking help and steps they will take towards those goals. Session 2 is focused on improving their relationship through communication exercises. Session 3 is focused on functional analysis of their partner's drinking, and how to positively reinforce their partner's sobriety and negatively reinforce their drinking. Finally, Session 4 focuses on continuing self-care and talking with their partner about their concerns while interacting with them in healthy ways. The WBI contains audio, video, text, and exercises that utilize digital storytelling and vignettes to convey teaching points - a method utilized by the military to address stigma and increase treatment utilization. Actresses portrayed different experiences that the CP may be going through and modeled skills. CPs clicked on the vignette that they most connected with and followed that character across all the sessions.
223493511|NCT07108296|OTHER|cardiopulmonary exercise testing (CPET)|In this study, the cardiopulmonary exercise testing (CPET) system used breath-by-breath continuous analysis for gas exchange and ventilation variables. The protocol included spirometry with an 8-breath data collection method. The cycle ergometer workload ranged from 10 to 40 W/min using a RAMP protocol. The standard CPET protocol comprised a 3-min rest, 3-min warm-up, 8 - 12 min incremental exercise phase, and 3-min each of active and passive recovery.
223493512|NCT07108387|DRUG|Tocilizumab|"Participants will continue Tocilizumab (TCZ) at a lower dose of either 4 mg/kg IV monthly or 162 mg SC every 2 weeks~Participants randomized to the stepped-down treatment arm will receive TCZ on their current route of administration. The route of administration may change if needed during study participation at the discretion of the investigator"
223493513|NCT07108387|DRUG|Discontinue Tocilizumab|"Participants will discontinue Tocilizumab and will have visits at Week 2, Month 1 and 2, and then every 2 months during the TCZ Withdrawal Phase until the Month 18 Visit.~Participants who remain in remission will enter the Follow-Up Phase for an additional 12 months at Month 18 and will continue withdrawal at that time."
223493514|NCT07110285|OTHER|Artificial intelligence-based algorithm|Trigger day timing decision by an artificial intelligence-based algorithm
223588788|NCT03592485|PROCEDURE|general anesthesia|Each patient will generally anesthetized and endotracheal tube will be inserted
224185250|NCT05619185|BEHAVIORAL|Phone-Based CRAFT|The phone-based CRAFT intervention consists of six individual sessions with a CRAFT clinician that will explore what they learned from the WBI and additional skills they need. Session content includes positive reinforcement of non-drinking SM behaviors, refraining from interfering in SM's consequences of alcohol use, communication skills, and self-care.
224185251|NCT05619185|BEHAVIORAL|CRAFT Workbook|The self-directed CRAFT workbook Table 1.Partners Connect WBI has a parent and partner version that uses CRAFT to help the CP help with understanding, self-care, communication, and actions (e.g., how to react when a partner has been using substances and when they have not been using substances, how to talk to partner so that they are more likely to be heard) and includes more information about communicating than the WBI and several interactive worksheets.
224185252|NCT05619185|BEHAVIORAL|Gottman Self-Guided Resources|"To match time spent reviewing the website, CPs will receive an orientation guide that includes the website URL and a 4-week guide for how they can navigate this website for 20-30 minutes per week (e.g., read article 'It's Not My Fault!': Why Defensiveness is Damaging and write down one tool to dissolve defensiveness you're willing to try). We will send reminder emails each week to visit the website and include questions in the emails and our first online follow-up survey asking CPs approximately how many times they visited the website and how long they spent viewing content on the website. Reminder emails will be programmed such that CPs get directed automatically to the website if the CP notes no time spent on it."
224185253|NCT04241705|OTHER|Treatment of positive individuals per national treatment guidelines|"Treatment for everyone except children \<6 months of age, pregnant women, women breastfeeding children \<6 months of age, and women 12-49 years of age with an unknown pregnancy status:~* P. falciparum cases: artemether-lumefantrine (AL) plus single dose primaquine (PQ) (0.25mg/kg daily)~* P. vivax cases: chloroquine (CQ) plus 14 days of PQ (0.25mg/kg daily)~* Mixed infections: AL plus 14 days of PQ (0.25mg/kg daily)~Treatment for pregnant women and women breastfeeding children \<6 months of age:~* P. falciparum cases or mixed infections: Quinine (1st trimester); AL (2nd \& 3rd trimesters or breastfeeding)~* P. vivax cases: Chloroquine (CQ)"
224185254|NCT04241705|OTHER|Presumptive treatment with artemether-lumefantrine (AL) plus 14 days of primaquine (PQ)|"Everyone who is eligible for the study except pregnant women and women breastfeeding children \<6 months of age AND who are confirmed to have normal G6PD status will be treated presumptively with artemether-lumefantrine (AL) plus 14 days of primaquine (PQ). Treatment will be given without RDT for malaria.~* Women in the first trimester of pregnancy will be treated presumptively with quinine.~* Women in the second and third trimesters or women who are breastfeeding will receive artemether-lumefantrine (AL).~Again, treatment will be given without RDT for malaria."
224308596|NCT04859543|DEVICE|FoundationOneHeme|Tumor tissue obtained during standard surgery will be subsequently examined histopathologically and the content of cancer cells will be determined. Broad molecular profiling of the tumor; with potential results finding such molecular changes, for which the specific targeted anti-tumor treatment will be performed.
223588789|NCT03592485|DRUG|paracetamol|Paracetamol will be given i.v. every 6 hours.
223588790|NCT03155438|DIAGNOSTIC_TEST|Oxidative stress-related gene expression (RNA expression)|Oxidative stress-related gene expression (RNA expression),Superoxide dismutase 1 (SOD1) , SOD2 , Glutathione peroxidase (GPX) and Inducible nitric oxide synthase (iNOS) , measured by Real time PCR technique.
223588791|NCT03155438|DIAGNOSTIC_TEST|oocyte competence biomarkers|Oocyte competence biomarkers ,GDF9, BMP15, Amphiregulin and CoQ10 measured by ELISA
223588792|NCT05476523|OTHER|NeuraLight|NeuraLight is an investigational software-based platform used for measuring eye movements in response to visual stimuli and captured using a simple webcam
223588793|NCT01563016|DIETARY_SUPPLEMENT|glucose drink|participants will receive a drink rich in glucose
223493515|NCT07104643|DRUG|TYK-00540|Take the specified dose (20mg or 30mg) orally twice a day. Take it on an empty stomach in the morning with about 200 mL of warm water.
223493516|NCT07104643|DRUG|Enzalutamide|Take orally, 160mg each time, once a day. Take orally with or without meals.
223588794|NCT02905006|DRUG|Bimekizumab|Subjects will be randomized to receive a combination of injections of Bimekizumab.
224073455|NCT03394560|DEVICE|Sham High frequency repetitive transcranial magnetic stimulation|Gait training with body weight support will be performed through Biodex Rehabilitation treadmill. It will performed for 20 minutes and researchers will assist the patient in placing the foot on the ground, in the extension of the knee and in the alignment of pelvis and trunk. The percentage of body weight support and speed of treadmill will be modified based on the performance of each patient. Repetitive transcranial magnetic stimulation will be applied by an eight-shaped coil positioned on the patient's scalp and performed according to the 10-20 international system (primary motor cortex). In sham rTMS two coils will be used: (i) a coil connected to the stimulator will be positioned behind the patient (away from the scalp) to generate characteristic stimulus sound, and (ii) another coil will be disconnected from the stimulator and positioned on the scalp individual. The active and sham stimulation will last 20 minutes.
223493517|NCT07109557|OTHER|Baduanjin|Baduanjin exercise
223493518|NCT07109895|OTHER|Standard Care Only|Standard care includes routine wound debridement, moist wound dressings infection control, glycemic management, vascular assessment, and patient education in line with international DFU management guidelines.
223493519|NCT07109895|OTHER|TENS plus Standard Care|This experimental group will receive the same intervention plus Transcutaneous Electrical Nerve Stimulation (TENS) in burst mode (1-4 Hz at 100 Hz) applied around the wound site for 30 minutes, along with standard care.
223493520|NCT07109895|OTHER|Custom Insole + Standard Care|The experimental group will receive customised polyethene foam insoles with a Poron top layer along with standard care.
223493521|NCT07109895|OTHER|TENS + Custom Insole + Standard Care|Participants in this group will receive a combination of transcutaneous electrical nerve stimulation (TENS), custom-made insole therapy, and standard care for diabetic foot ulcers (DFUs).
223493522|NCT05948761|OTHER|Hypoxia through modified hypoxic generator|Commercially available hypoxic generator, modified to allow for convenient remote interventions by non-expert participants.
223493523|NCT05948761|OTHER|Normoxia through hypoxic generator without active elements|Commercially available hypoxic generator, modified to allow for convenient remote interventions by non-expert participants, without active elements.
223493524|NCT07111494|DRUG|GLP-1 agonists|GLP-1, any assigned drug
223493525|NCT07111494|OTHER|Nutrition Counseling|Nutrition Counseling in PsA
223493526|NCT07102836|DRUG|Zinc sulfate|Oral zinc sulfate syrup in a dose providing 5mg elemental zinc daily as adjuvant to phototherapy.
223493527|NCT07102836|DRUG|Probiotic lactobacillus rhamnosus GG|Oral Probiotic Lactobacillus rhamnosus GG drops daily as adjuvant to phototherapy.
223493528|NCT00080626|BIOLOGICAL|pegfilgrastim|6 mg injection on day 1 of each cycle
223493529|NCT00080626|DRUG|docetaxel|100 mg per meter-squared, every 14 days for 4 cycles
223493530|NCT00080626|PROCEDURE|conventional surgery|lumpectomy or mastectomy at end of treatment
223493531|NCT00080626|PROCEDURE|neoadjuvant therapy|treatment prior to definitive breast surgery
223493532|NCT07106879|OTHER|Blood Work|Collection of blood samples for metabolic and other necessary biomarker analysis, including Hemoglobin A1c (HbA1c), Lipid Panel, Liver and Kidney function tests and other protocol-defined assays.
223493533|NCT07103954|OTHER|McKenzie Exercises plus Conventional Physical Therapy|"First of all conventional physical therapy is applied. For this we will use transcutaneous electrical nerve stimulation (TENS) and hot pack, positioned over the neck region, for 15-20 minutes. This will help in improving blood flow and increasing muscle activation.~For McKenzie exercises, the participant will be in a comfortable sitting posture with proper back support. He will be asked to perform the following exercises:~1. Retraction in supine and sitting positions~2. Retraction with patient and therapist overpressure~3. Retraction with extension and rotation~4. Rotation with patient and therapist overpressure~5. Lateral flexion~6. Lateral flexion with patient and therapist overpressure • All these exercises will be done with a hold of one or two seconds and the movement is then repeated for five to six times."
224073456|NCT01976923|DRUG|Intravitreal bevacizumab|A sterile lid speculum is used to separate the lids. A subconjunctival injection of 1% lidocaine is applied to the inferotemporal quadrant. A 5% povidone iodine solution is used to disinfect the entire conjunctival surface. 1.25 mg / 0.05 mL of bevacizumab is injected using a 30-gauge needle inserted through the inferotemporal pars plana 3.5 mm from the limbus.
224073457|NCT01976923|PROCEDURE|Small-gauge pars plana vitrectomy|
223493534|NCT07103954|OTHER|Mulligan Mobilization with Conventional Physical Therapy|"First of all conventional physical therapy is applied. For this we will use transcutaneous electrical nerve stimulation (TENS) and hot pack, positioned over the neck region, for 15-20 minutes. This will help in improving blood flow and increasing muscle activation.~The Mulligan mobilization, the patient will be seated in a comfortable position on a chair and the therapist stood behind to perform the mulligan mobilization. A gliding force will be applied by the therapist on the patient's spinous process or on the facet joint of the superior vertebra of the target segment for treatment. This gliding force will be maintained by the therapist. Then the patient will move his head towards the painful side (flexion, extension, rotation, and lateral flexion), and more pressure will be applied by the patient at the end of active movement. The Mulligan mobilization will be repeated 10 times for 3 sets."
223493535|NCT07112781|RADIATION|Single Dose Radiotherapy|Procedure: external-beam radiotherapy (EBRT) on a linear accelerator with a dose 24 Gy in one session using technique of image-guided volumetric intensity modulation arc therapy (VMAT-IGRT) and a set of dedicated devices that ensure target immobilization and reproducibility of prostate anatomical localization during treatment. A special air-filled endorectal balloon will be used for immobilization of the prostate and anatomical reproducibility of organs at risk during treatment. A Foley catheter will be used to ensure reproducibility of the urethral position and online tracking of the prostate gland position during treatment. A special external immobilization system, including patient positioning on a patient transfer trolley, which allows for patient transfer without removing the endorectal balloon and urinary catheter from the table at all stages of pre-radiation preparation (MR, CT, Positron emission tomography (PET) / CT simulation) and during the treatment.
224073458|NCT00004493|DRUG|sodium dichloroacetate|
224073459|NCT00699348|DRUG|Methoxy polyethylene glycol-epoetin beta (C.E.R.A.)|Intravenous methoxy polyethylene glycol-epoetin beta (C.E.R.A.) at starting dose of 120, 200, or 360 micrograms every 4 weeks for 24 weeks.
224073460|NCT05233657|DRUG|JX11502MA|Oral capsule
224073461|NCT05233657|DRUG|Placebo|Oral capsule
224073462|NCT00135304|DRUG|Sensipar®|Cinacalcet hydrochloride
223745684|NCT03946735|BEHAVIORAL|Cognitive Behavioural Therapy as an Effective Treatment for Social Anxiety, Perfectionism, and Rumination|Week one involved introducing CBT and assessing the negative effects of perfectionism, rumination, and social anxiety. Week two allowed participants to specify stressful social activities, stressful social situations, and enjoyable activities. Week three to week six allowed participants to identify automatic thoughts and thinking errors (for example, all or nothing thinking, self-criticism, dysfunctional schemas for self-evaluation, and unrealistic standards). Assignments were provided to participants with the content of exposure to anxiety evoking situations in the treatment sessions and at home. Achievable behavioural goals were set for participants in the treatment sessions and at home.
223493536|NCT07111533|PROCEDURE|Open Flap Debridement (OFD)|Under Local Anesthesia , intrasulcular incisions using surgical blade #15c Then, a full thickness mucoperiosteal flap will be raised . Then, the granulation tissue in the intrabony defect will be debrided and the root will be planned using manual and ultrasonic instruments followed by saline and chlorohexidine irrigation till obtaining a healthy sound bone surface.
223493537|NCT07111533|PROCEDURE|Bone Graft|Bovine Xenograft material packed into the debrided defect.
223493538|NCT07111533|PROCEDURE|Autogenous Periosteal Pedicle Graft (PPG)|"* Vertical releasing incisions will be used if necessary for better access.~* The periosteal membrane will be separated from this flap and released with one vertical incision mesially and one horizontal incision apically . Posteriorly, the periosteum remained attached to the mucoperiosteal flap for adequate blood supply.~* periosteal membrane will be turned over to cover this defect completely and sutured with the lingual flap with a synthetic 6-0 bioabsorbable Vicryl suture. \*The soft tissue flap will be sutured with 5-0 nonabsorbable prolene suture material and a periodontal dressing was given."
223493539|NCT07111533|PROCEDURE|Pericardium Membrane|A pericardium membrane was adapted for defect coverage and sutured with the lingual flap with a synthetic 6-0 bioabsorbable Vicryl suture.
223493540|NCT04391556|DRUG|Firmagon|120 mg subcutaneous Injection of Firmagon after a TEP-PSMA
223493541|NCT06736821|DIETARY_SUPPLEMENT|Open sinus augmentation with melatonin gel mixed with xenograft|"All Patients in this group underwent open sinus procedures to lift the sinus membrane followed by application of the melatonin gel which was mixed with xenograft as an augmentation material.~Preclinical studies proved the direct action of melatonin in enhancing the differentiation and proliferation of bone-forming osteoblasts. In addition to increasing bone mass, melatonin also facilitates new bone growth and osteointegration, making melatonin a particularly attractive molecule for use in bone implants when used alone or in combination with other growth factors"
223493542|NCT06736821|PROCEDURE|Open sinus augmentation with xenograft|All Patients in this group underwent open sinus procedures to lift the sinus membrane followed by application of the xenograft as an augmentation material xenograft is used instead of autogenous bone graft to avoid the morbidity of the donor side
223493543|NCT07104188|DIETARY_SUPPLEMENT|A non-active placebo supplement.|Placebo powder mixed into 100 ml grape juice and 200 ml water, consumed 30 minutes before testing.
223493544|NCT07104188|DIETARY_SUPPLEMENT|Caffeine|220 mg caffeine powder mixed into 100 ml grape juice and 200 ml water, consumed 30 minutes before testing.
223493545|NCT07104188|DIETARY_SUPPLEMENT|Energy Drink|A supplement containing 220 mg caffeine, 1800 mg anserine extract, and 400 mg elderberry extract, mixed into 100 ml grape juice and 200 ml water, consumed 30 minutes before testing.
223588795|NCT02905006|OTHER|Placebo|Subjects randomized to the placebo group, will receive a combination of several injections of Placebo to maintain the blinding.
223588796|NCT03090672|DRUG|Normal Saline|Normal Saline IV delivery
223588797|NCT03090672|PROCEDURE|Tissue Stromal Vascular Fraction|tSVF
224073463|NCT00135304|DRUG|Vitamin D|Vitamin D administered IV
224308597|NCT03924206|DEVICE|Smoke evacuation system|The smoke evacuation system removes the surgical smoke directly near the electrocautery tip, where it is generated
224308598|NCT00246142|BIOLOGICAL|Botulinum toxin type A|
224308599|NCT00005983|RADIATION|radiation therapy|
224308600|NCT00005983|PROCEDURE|surgery|surgery
223588798|NCT03090672|BIOLOGICAL|Platelet Rich Plasma|PRP
223588799|NCT03090672|PROCEDURE|Cellular Stromal Vascular Fraction|cSVF
223588800|NCT03088943|OTHER|TTE Apical 4 Chamber View|We will measure a number of echocardiography parameters by TTE (apical 4 Chamber View) prior to and after induction
223745685|NCT02477995|BIOLOGICAL|DTaP Vaccine A|Adsorption tetanus-diphtheria-acellular pertussis (DTaP) Vaccine A(Bejing minhai Biological Co., LTD) of 0.5ml, three doses, 28 days interval
224073464|NCT03269344|DRUG|Gabapentin|Gabapentin is an anticonvulsant and has been used to manage neuropathic pain and is FDA-approved for the treatment of post-herpetic neuralgia and partial onset seizures
224073465|NCT03269344|DRUG|Placebo Oral Capsule|Placebo
224073466|NCT01099202|DRUG|Procrit (epoetin alfa)|Starting dose 40,000 Units subcutaneously once a week during your regularly scheduled chemotherapy for up to 6 courses of chemotherapy (around 5 months).
224073467|NCT02597855|DRUG|Aflibercept|Total 4 times of intravitreal aflibercept injection was performed
224073468|NCT02597855|DRUG|Indocyanine green angiography (intraveonus indocyanine green dye)|At initial visit, indocyanine green angiography was performed. After 1 month of third Aflibercept injection, indocyanine green angiography was performed to evaluate polyp closure.
224073469|NCT04788082|DIAGNOSTIC_TEST|3D Printed Heart Model|Prior to surgical intervention, the surgeon will be exposed to clinically-indicated images and a patient-specific 3D printed model of the subject's heart anatomy.
224073470|NCT04390867|DEVICE|TOPS1 DBS|TOPS1 is an investigational novel pattern of stimulation that is programmed non-invasively into an already implanted DBS system
224073471|NCT04390867|DEVICE|TOPS2 DBS|TOPS2 is an investigational novel pattern of stimulation that is programmed non-invasively into an already implanted DBS system
224073472|NCT04390867|DEVICE|TOPS3 DBS|TOPS3 is an investigational novel pattern of stimulation that is programmed non-invasively into an already implanted DBS system
224073473|NCT04390867|DEVICE|Standard DBS|Standard is the pattern of stimulation that is usually delivered clinically by a DBS system
224073474|NCT04769791|DEVICE|intracuff pressure measurement|intracuff pressure is measured by a pressure manometer
224073475|NCT04769791|DEVICE|intracuff pressure measurement|intracuff pressure is measured by a pressure manometer
224073476|NCT04769791|DEVICE|intracuff pressure measurement|intracuff pressure is measured by a pressure manometer
223493546|NCT07105761|BEHAVIORAL|Body-Mind-Spirit|The experimental group participated in a 10-week BMS group intervention, with weekly 130-minute sessions. The intervention combined Eastern philosophy and Western psychotherapy to enhance emotional balance and psychological resilience. Core components included observing merits (recognizing strengths), cultivating gratitude, and practicing forgiveness. Physical activities such as finger dexterity training, diaphragmatic breathing, and stretching supported autonomic regulation and flexibility. Psychological strategies involved positive thinking, emotional expression, and life story sharing. All materials were adapted with audio descriptions for accessibility. Participants with visual impairment received orientation training and volunteer support for transportation and on-site assistance.
223493547|NCT07105046|OTHER|Interviews|A 30 to 45-minute in-depth semi-structured interview by phone will be administer, following a semi-structured interview guide.
223493548|NCT07105046|OTHER|Focus Groups|45 to 60 minutes video conference
223493549|NCT07103330|DEVICE|Metallic fixation hardware|Control
223493550|NCT07103330|DEVICE|Cranial flap placement and fixation using only Montage Flowable Settable Bone Paste|Experimental
223493551|NCT07104344|BIOLOGICAL|CM355|CM355 injection
223493552|NCT07103525|BEHAVIORAL|INSPIRE Initiative|Culturally relevant, multi-level intervention designed to increase HIV testing through reducing intersectional stigma. Intervention includes series of four one-on-one conversations (45 minutes each over a six-week period) via mobile phone between the Hunter peer advocates and FSWs, which are reinforced through weekly text messages from the peer advocates and through role-model stories shared online.
223493553|NCT07103525|BEHAVIORAL|Standard of Care|Standard HIV prevention information with no tailored components via one mobile phone verbal conversation with peer advocates.
223493554|NCT07107243|DIAGNOSTIC_TEST|Speaking valve combined with airway pressure|All patients wore speaking valves for 30 minutes, during which the transtracheal end-expiratory pressure was measured to assess the patency of the upper airway.
223493555|NCT07107243|DIAGNOSTIC_TEST|Bronchoscopy|The same examiner performed bronchoscopy on all patients to assess upper airway patency.
223493556|NCT07113496|BIOLOGICAL|Allogeneic CAR-T|Patients will receive lymphodepletion chemotherapy followed by a single intravenous infusion of Allogeneic CAR-T cells. In select cases, CAR-T infusion may be administered post-autologous hematopoietic stem cell transplantation (auto-HSCT)
223493557|NCT07105397|OTHER|Conversational AI system|The conversational AI intervention utilizes interactive dialogue to collect patient medical histories. Powered by advanced Large Language Models (LLMs), the system engages participants in open-ended, natural language conversations. A Dialogue Manager coordinates the dialogue, ensuring conversations remain medically relevant, personalized, and safe. Clinicians monitor the interactions in real-time, validating and ensuring accuracy of antidepressant recommendations informed by an evidence-based Antidepressant Knowledgebase.
223493558|NCT07105397|OTHER|Structured Survey Questionnaire|"The structured questionnaire intake utilizes a predefined, multiple-choice survey that systematically collects patient medical history without conversational interaction. Questions are algorithmically selected based on the patient's earlier responses to maximize information efficiency, typically requiring fewer than 13 items. Patients select from standardized responses (including options like I do not know or I do not want to say). Contextual help messages are provided as needed. Upon completion, the system generates antidepressant recommendations using the same Antidepressant Knowledgebase as the Conversational AI system, clearly explaining its rationale. A prototype version is available at http://MeAgainMeds.com, with ongoing development to enhance features and usability."
223493559|NCT07104409|OTHER|virtual reality hypnosis device|VRH group, in which patients will receive conventional sedation (remifentanil 0.1 mcg/kg/min and propofol 0.5 mg/kg if necessary) and a Virtual Reality headset with an environment chosen by the patient and hypnosis support with suggestions to reduce their anxiety.
223493560|NCT07116564|DRUG|Enhanced Recovery After Surgery|Preoperatively ERAS protocol includes, No solid food for 6 hours before procedure; 800 ml (fantomalt powder) Carbohydrate drink 8 hours before surgery; 400 ml (fantomalt powder) 2 hours before surgery; Celecoxib 200g 1 hour before surgery . Intraoperatively, on induction lidocaine 1.5 mg/kg and Fentanyl 1 to 2 mcg/kg followed by IV lidocaine infusion at 1.5 mg/kg/h.
223493561|NCT07116564|DRUG|Control|Preoperatively, NPO 6 hours before the procedure Intraoperatively, on induction Nabuphine 0.1mg/kg
223493562|NCT07114523|PROCEDURE|collagen membrane|collagen membrane apply to distal surface of second molar after third molar surgery
223493563|NCT07114523|PROCEDURE|third molar surgery|standard third molar surgery without any additional application
223493564|NCT07113938|DEVICE|Ambient AI Scribe|Software that records audio of a clinical interaction and generates a clinical note.
223493565|NCT07115511|PROCEDURE|Surgery|Recombined recanalization surgery
224308601|NCT04729309|DRUG|[12C] RO7049389|Participants will receive oral \[12C\] RO7049389.
223493566|NCT07115771|OTHER|Postoperative analgesia management|After determining the L5-S1 level with ultrasound guidance, an 80 mm block needle (Stimuplex Ultra®, Braun, Melsungen, Germany) will be advanced in a cranio-caudal direction. Following hydrodissection, 30 ml of 0.25% bupivacaine local anesthetic solution containing 7.5 mcg of epinephrine (1:200,000) will be administered.
223588801|NCT03088943|OTHER|TEE dTG View|We will measure a number of echocardiography parameters by TEE (dTG View) prior to cardiopulmonary bypass and after cardiopulmonary bypass (atrially paced at 80, 100, and 120 bpm)
223588802|NCT03088943|OTHER|TEE ME 4C View|We will measure a number of echocardiography parameters by TEE (ME 4C View) prior to cardiopulmonary bypass and after cardiopulmonary bypass (atrially paced at 80, 100, and 120 bpm)
224308602|NCT04729309|DRUG|[13C] RO7049389|Participants will receive IV \[13C\] RO7049389.
224308603|NCT04729309|DRUG|[14C] RO7049389|Participants will receive an oral suspension of \[14C\] RO7049389.
223588803|NCT00763841|DEVICE|Transcranial magnetic stimulation|Stimulation will be given daily at a particular site for three days a week
223588804|NCT00763841|DEVICE|Sham|
223588805|NCT05586776|DRUG|4% Chlorhexidine Gluconate|Used for daily showering/bathing for 30 days after hospital discharge.
223588806|NCT05586776|DRUG|2% Mupirocin|Applied to each nostril twice daily for five days for the first two weeks after hospital discharge.
223493567|NCT07115771|OTHER|Postoperative analgesia management|After identifying the adductor canal with a high-frequency linear US probe (GE ML6-15-D Matrix Linear), 30 ml of 0.25% bupivacaine local anesthetic solution containing 7.5 mcg of epinephrine (1:200,000) will be administered into the adductor canal using an 80 mm block needle (Stimuplex Ultra®, Braun, Melsungen, Germany).
223493568|NCT07114861|DRUG|Study drug: KN510 120mg/day + KN713 90mg/day, Combination Chemotherapy: mFOLFIRINOX|KN510 120mg/day + KN713 90mg/day: once daily in 14-day (2-week) cycles. mFOLFIRINOX: Treatment is repeated every 2 weeks
223493569|NCT07114861|DRUG|Study drug: KN510 120mg/day + KN713 120mg/day, Combination Chemotherapy: mFOLFIRINOX|KN510 120mg/day + KN713 120mg/day: once daily in 14-day (2-week) cycles. mFOLFIRINOX: Treatment is repeated every 2 weeks
223493570|NCT07114809|DEVICE|Experimental group (EG) performing Anodal-tDCS (A-tDCS) and VR|"Patients in the EG group will undergo a simultaneous A-tDCS over the left DLFPC. The tDCS will be delivered by a battery-driven, constant current simulator, two holding bags of plant cellulose (7x5 cm) and two electrodes of conductive silicone. The active (anodal) electrode will be placed by means of a cap on the scalp overlying the left DLPFC (46 Brodmann Area). The reference electrode will be located over the right shoulder. The choice of the left DLPFC as the site of stimulation relies upon the evidence that this region has a critical role in the top-down control of the task-relevant stimuli processing (Miller 2001).The DLPFC contributes to increase cognitive control through its connections with the anterior cingulate cortex and has been shown to enhance working memory and executive function. During the cognitive training (on-line procedure), A-tDCS (current of 1,5 mA) will be delivered for 20 minutes, while maintaining the current density (0.06 mA/cm2) below the safety limits."
223493571|NCT07114809|DEVICE|Sham Comparator: Control group (CG) performing sham-tDCS (S-tCDS) and VR|CG will receive a S-tDCS over the DLPFC. In the S-tDCS session, the current will be turned off 30 sec after the beginning of the stimulation and turned on for the last 30 sec. By doing this, the patient feels an itching sensation below the electrodes at the beginning and at the end of stimulation, making this condition indistinguishable from the real A-tDCS stimulation. Doing this, all the subjects will be blinded on the type of stimulation. As well as in the EG, CG performs cognitive training including motor and cognitive exergames that incorporate enjoyment, technology, and health care.
223493572|NCT07114211|DIAGNOSTIC_TEST|99mTc-HYNIC-FAPI-04 SPECT-CT|Perform quantitative SPECT/CT with 99mTc-HYNIC-FAPI-04 on selected patients. Acquire whole-body images in a planar format and SPECT/CT images of two or more sites in a tomographic format.
223493573|NCT07114432|DRUG|BCMA/CD19-targeted allogeneic CAR-T|Lymphodepletion chemotherapy followed by allogeneic CAR-T cell (RN1201) infusion
223493574|NCT07114328|OTHER|hand massage|The hand massage was applied to both hands for 5-6 minutes, for a total of 10-12 minutes
223493575|NCT07114627|DRUG|Blood sampling for pharmacokinetics|Extra blood samples are collected for assement of the pharmacokinetics of capecitabine.
223493576|NCT07115498|BEHAVIORAL|iTAG|Participants in this intervention start by receiving a brief (15 minute) in-person standard-of-care counseling session focused on increasing their knowledge of HIV treatment adherence and strategies to improve adherence. Following this session, they will then receive daily or less frequent text messages (SMS) over the course of three months. Messages are primary two-way, automated, and have preprogrammed response options. Message content includes HIV medication reminders, motivational messages, information on topics relevant to HIV treatment (e.g., HIV disclosure) in the form of quizzes, opportunities to reach out for support from clinic staff or peer mentors, and game-based messages including story messages, a weekly scoreboard, point system progress, and peer interactions.
223493577|NCT07116551|DEVICE|Abbott BE TAVI System|Abbott BE TAVI System
223493578|NCT07114315|DRUG|AK112|Following a predefined dose and date.
223493579|NCT07114315|DRUG|AK130|Following a predefined dose and date.
223493580|NCT07115485|DRUG|HLX43 DOSE 1|HLX43 is an anti-PD-L1 monoclonal antibody conjugated with a novel high potency DNA topoisomerase I (topo I) inhibitor, with a drug-antibody-ratio (DAR) of 8. DOSE 1 is 2.0mg/kg
223493581|NCT07115485|DRUG|HLX43 DOSE 2|HLX43 is an anti-PD-L1 monoclonal antibody conjugated with a novel high potency DNA topoisomerase I (topo I) inhibitor, with a drug-antibody-ratio (DAR) of 8. DOSE 1 is 2.5mg/kg
223493582|NCT07115485|DRUG|HLX43 DOSE 3|HLX43 is an anti-PD-L1 monoclonal antibody conjugated with a novel high potency DNA topoisomerase I (topo I) inhibitor, with a drug-antibody-ratio (DAR) of 8. DOSE 1 is 3.0mg/kg
223493583|NCT07114588|DIETARY_SUPPLEMENT|ETHANWELL BALANCED|A nutritional powder providing 250 kcal, 13.5 g protein (including 6.75 g whey protein and 2740 mg BCAAs), and 166.953 mg POLYCAN® (β-glucan) per serving. Administered 3 times daily for 8 weeks.
223493584|NCT07114588|BEHAVIORAL|Elastic Band Training|Participants perform 5 specific resistance exercises (push up \& press down, straight arm lift, seated rowing, squat, seated leg raise). Each exercise is done in 3 sets of 10 reps, 3 times per week, for 8 weeks.
223493585|NCT07113548|BEHAVIORAL|Personalized iCBT for depression|"Participants receive 12 sessions of personalized treatment in an online iCBT program. The treatment includes the option for weekly written feedback from a psychologist, or video-based interventions depending on the participant's current status. The content of the 12-week program is tailored to the participant's individual symptom profile.~The treatment incorporates elements from standard Cognitive Behavioral Therapy (CBT), Acceptance and Commitment Therapy (ACT), Compassion-Focused Therapy (CFT), and Positive Activity Interventions (PAT).~The program consists of nine modules, each targeting a specific area:~Rumination,~Anhedonia,~Tearfulness and emotional regulation,~Sleep problems,~Difficulty concentrating,~Eating issues,~Low energy,~Social withdrawal,~Self-critical thinking,~The treatment concludes with support aimed at preventing relapse."
223588807|NCT05586776|DRUG|Soap Without Antiseptic Properties (Placebo)|Used for daily showering/bathing for 30 days after hospital discharge.
223588808|NCT05586776|DRUG|Placebo Nasal Ointment|Applied to each nostril twice daily for five days for the first two weeks after hospital discharge.
223745686|NCT02477995|BIOLOGICAL|DTaP Vaccine B|Adsorption tetanus-diphtheria-acellular pertussis (DTaP) Vaccine B(Changchun changsheng Biological Co., LTD ) of 0.5ml in 600 infants aged 3-5months on day 0, 28, 56.
223493586|NCT07113548|BEHAVIORAL|Standard iCBT|"Standard iCBT consisting of a one size fits all progression of cognitive behavioral therapy over 12 weeks. This includes:~Introduction to Online Cognitive Behavioral Therapy~Start of Treatment~Rumination~Activity Monitoring~Activity Planning~Cognitive Restructuring~Behavioral Experiment I~Behavioral Experiment II~Core Beliefs I~Core Beliefs II~Relapse Prevention"
223493587|NCT07111546|DRUG|LBL-024 for Injection|Intravenous infusion.
223493588|NCT07111546|DRUG|Durvalumab Injection|Intravenous infusion.
223493589|NCT07111546|DRUG|Cisplatin Injection|Intravenous infusion.
223493590|NCT07111546|DRUG|Gemcitabine Hydrochloride for Injection|Intravenous infusion.
223493591|NCT07111546|DRUG|Bevacizumab Injection|Intravenous infusion.
223493592|NCT06914713|DRUG|Jin-shui Huan-xian granule|"Jin-shui Huan-xian Granules: on the basis of treatment guided by Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline , the experimental group was given Jin-shui Huan-xian Granules for treatment. The granules were taken orally, 1 dose per day, twice a day, and the continuous administration lasted for 52 weeks."
223493593|NCT06914713|DRUG|Jin-shui Huan-xian granule placebo|"Jin-shui Huan-xian granule placebo: on the basis of treatment guided by Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline , the experimental group was given Jin-shui Huan-xian Granules placebo for treatment. The granules were taken orally, 1 dose per day, twice a day, and the continuous administration lasted for 52 weeks.The Jin-shui Huan-xian granules and their placebo are identical in appearance, weight, color and smell."
223493594|NCT06921603|OTHER|Furosemide (Standard Diuretic) Treatment|Participants in this group will receive intravenous furosemide as part of their routine care, based on clinical assessments including symptoms, physical examination. Daily POCUS imaging will be performed for research purposes; however, the findings will not be shared with the treating clinical team. Fluid management decisions and discharge planning will follow usual care protocols, without additional imaging-based guidance.
223493595|NCT06921603|OTHER|POCUS-Assessed Diuretic Management|POCUS will be used to provide objective, non-invasive assessments of fluid status by measuring right internal jugular vein (RIJV) cross-sectional area (CSA) and calculating the Distensibility Index (DI). This information will be shared with the treating clinical team as an additional tool for fluid management. However, all final decisions regarding diuretic therapy will be made at the discretion of the treating physicians.
223493596|NCT07115810|OTHER|No additional drugs(control Group)|No intervention
223493597|NCT07115186|BEHAVIORAL|Psychoeducation|Psychoeducation sessions for adolescents focus on essential topics like stress, emotional distress, and mental disorders, offering foundational knowledge to enhance their understanding and ability to manage these challenges effectively.
223493598|NCT07115186|BEHAVIORAL|guided written therapy|In the guided writing intervention, students are asked to write about a recent event that triggered strong emotions on paper and, based on the requirements of each session, attempt to regulate their emotions. This approach aims to enhance students' abilities in emotional identification and emotion regulation.
223493599|NCT07115186|BEHAVIORAL|wait-list condition|Participants will engage in their regular school activities, and after the intervention group completes the program, they will receive the same intervention content as the intervention group.
223493600|NCT07114263|DRUG|Group F (fentanyl group)|Group F (fentanyl group):will receive intrathecal 1.5 ml hyperbaric bupivacaine 0.5% and 0.5 ml (25 mcg) Fentanyl and 1 ml glucose 5% with total volume of 3ml.
223493601|NCT07114263|DRUG|Group D :Dexmedetomidine group|Group D :Dexmedetomidine group: will receive intrathecal 1.5 ml hyperbaric bupivacaine 0.5% and 1 ml (4 mcg) Dexmedetomidine and 0.5 ml glucose 5% with total volume of 3ml.
223493602|NCT07114263|DRUG|Group DF :Fentanyl and Dexmedetomidine group|Fentanyl and Dexmedetomidine group:will receive intrathecal 1.5 ml hyperbaric bupivacaine 0.5%, 0.5 ml (25 mcg) Fentanyl and 1 ml (4 mcg) Dexmedetomidine with total volume of 3ml.
223493603|NCT07114354|OTHER|PDCogniCare platform|Digital platform designed to support early and accurate detection of dementia in people living with Parkinson's disease
223493604|NCT07116603|DIAGNOSTIC_TEST|Questionnaire and Physical Exam|Participants completed the International Continence Questionnaire-Short Form (ICIQ-SF) and the Incontinence Impact Questionnaire (IIQ-7) form were completed
224073477|NCT05220592|BEHAVIORAL|Internet-based recovery training program|The iRTP was based on recovery experiences (psychological detachment, relaxation, mastery, and control), converted into a recovery training intervention, and inspired by Hahn et al. (2011). The iRTP comprised five modules distributed over five weeks, with modules lasting 60-120 minutes per week. Each module contained psycho education, worksheets, images, cases, audio and video files, and homework assignments.
223493605|NCT07113899|OTHER|Approach to spirituality through hope and acceptance|"This study is a prospective longitudinal research study. The sample consisted of two groups: the Intervention Group, which included patients from the community palliative care support team (ECSCP-BM), and the Control Group, with primary health care selected patients from the family health units Nautilus and Coimbra Centro (CSP), with serious illness, comorbidities, and a poor prognosis. The patients chosen from ECSCP-BM were made up only of new patients referred to the team without any prior home consultations. The first questionnaire application took place during the first visit, and the second one was administered fourteen days later. The Primary Health Care patients were selected by invitation, and the questionnaire was administered. It included sociodemographic data, clinical data, the Herth Hope Index and open questions.~During the palliative care team's home visit, spirituality was addressed in in the clinical history through the assessment of hope and acceptance."
224073478|NCT02977923|DEVICE|VR distraction via Oculus Rift|In addition to standard pharmacological treatment, Virtual reality distraction through the use of Oculus Rift® will be used as the experimental intervention. The Oculus Rift (Consumer version) is made of two Oled panels with a resolution of 1200p running at 90Hz. It has very effective 360 degree positional tracking and integrated 3D audio. These combine to produce a high level of immersion, with high photorealism while maintaining the low latency necessary to induce presence and prevent cybersickness. The child, depending on the site of the injury, will have the opportunity to interact with the game. Video games, approved by healthcare professionals with extensive experience in pediatrics, were adapted for children and tailored to minimize cyber sickness.
223493606|NCT07115225|OTHER|Analytical test - Shoulder Range of Motion (ROM)|Passive external rotation in supine position with arm in 90° abduction - passive internal rotation in supine position with arm in 90° abduction.
223493607|NCT07115225|OTHER|Analytical test - Shoulder Strength|Shoulder external rotation and internal rotation measured with a hand held dynanometer in supine lying
223493608|NCT07115225|OTHER|Modified-Athletic Shoulder Test (M-AST)|Shoulder strength in the antero-posterior plane measured with a hand held dynanometer in prone lying
224185255|NCT04241705|OTHER|Optimized malaria control interventions|Optimized malaria control interventions that includes strengthened surveillance systems and commodities management, scale-up of vector control and case management services including follow-up, and social and behavior change communication to seek prompt treatment and use long lasting insecticidal nets (LLINs). Case management includes passive detection of malaria cases and treatment with artemether-lumefantrine (AL) plus single low dose primaquine (PQ) (0.25mg/kg once) for Plasmodium falciparum (Pf) cases and chloroquine (CQ) plus 14 days of PQ (0.25mg/kg daily) for Plasmodium vivax (Pv) cases, and AL plus 14 days of PQ (0.25mg/kg daily) for mixed infections as well as follow-up at the health post or health center on days 3, 7, and 13 for those receiving 14 days of PQ to assess for adverse events and adherence as per the national treatment guidelines.
224185256|NCT00664729|BEHAVIORAL|Caloric Restriction|Reduced calorie diet (400 kcal/day deficit)
224185257|NCT00664729|BEHAVIORAL|Caloric Restriction + Low-Intensity aerobic exercise|400 kcal/day deficit plus 3 days/week aerobic exercise at 45-50% maximal aerobic fitness
224185258|NCT00664729|BEHAVIORAL|Caloric Restriction plus High-intensity aerobic exercise|400 kcal/day deficit and 3 d/week of aerobic exercise at 65-75% maximal fitness
224185259|NCT01177943|DRUG|Atomoxetine|Administered orally, once.
224185260|NCT00727662|OTHER|Iyengar Yoga|The poses and breathing techniques to be used in this study are based on sequences developed by B.K.S. Iyengar for breast cancer survivors who suffer from fatigue. Women will start with simple versions of the poses and progress to more advanced versions over the course of the intervention.
224185261|NCT00727662|OTHER|Wellness Seminar Series|The Wellness Seminar Series consists of lectures on key topics, followed by group discussion. This series will focus entirely on cancer survivorship, including sessions on quality of life, side effects of cancer treatment, stress, nutrition and psychosocial issues.
223493609|NCT07115225|OTHER|Physical performance test - Unilateral Seated Shot-Put Test (USSPT)|Set up requires that the subject is placed in a seated position (knees bent at 90° degrees) with their back against the wall, and a 3 kg medicine ball held at height of the shoulder. When ready, the subject will perform a shot put motion to push the medicine ball as far as possible in a horizontal direction. The average of three trials is recorded for each arm.
223588809|NCT01932502|DRUG|clobazam (Onfi)|"Subject's clonazepam will be converted to the following Onfi doses per day:~Clonazepam 0.5mg converted to Onfi 10mg first week, then titrated up to 40mg per day.~Clonazepam 1.0-2.0mg converted to Onfi 20mg first week, then titrated up to 40mg per day.~Clonazepam 2-4mg converted to Onfi 20mg first week, then titrated up to 60mg per day.~Initial conversion will occur over two weeks followed by upward titration of up to 10mg increment per week toward the target dose. Down titration of up to 10mg will be allowed during the study.~The following will be the initial conversion schedule from clonazepam to Onfi:~Week 1: 50% reduction of clonazepam and starting dose of Onfi, replacing the reduced clonazepam dose with the conversion rate of clonazepam 0.5mg = Onfi 10mg.~Week 2: Discontinuing clonazepam and increasing the dosage of Onfi by two-fold. Week 3+: Titrate the dose of Onfi up to 40mg per day as tolerated"
223588810|NCT01932502|DRUG|Initial conversion and titration|Initial conversion will occur over two weeks followed by upward titration of up to 10mg increment per week toward the target dose. Down titration of up to 10mg will be allowed during the study.
223588811|NCT01932502|DRUG|Conversion schedule - Week 1|"The following will be the initial conversion schedule from clonazepam to Onfi:~Week 1: 50% reduction of clonazepam and starting dose of Onfi, replacing the reduced clonazepam dose with the conversion rate of clonazepam 0.5mg=Onfi 10mg."
223588812|NCT01932502|DRUG|Conversion schedule - Week 2|Week 2: Discontinuing clonazepam and increasing the dosage of Onfi by two-fold.
224185262|NCT00951587|DEVICE|PillCam™ (Capsule Endoscopy)|Medical Device
224185263|NCT01697631|DRUG|biphasic insulin aspart 30|Administrated subcutaneously (s.c., under the skin) at breakfast and evening main meals
224185264|NCT01697631|DRUG|insulin aspart|Administrated subcutaneously (s.c., under the skin) before lunch
224185265|NCT01500291|OTHER|2 courseware databases.|All participant voluntarily response all items in the SST and SAST courseware database.
223493610|NCT07115225|OTHER|Physical performance test - modified-Closed Kinetic Chain Upper Extremity Stability Test (m-CKCUEST)|The test is performed in a push-up position with the hands one half-arm span apart on strips of athletic tape. The person reaches with alternating hands across the body to touch the piece of tape under the opposing hand. The number of cross-body touches performed in 15 seconds is recorded. In total, three 15-s test trials were performed, with 45 s rest between each trial.
223493611|NCT07115225|OTHER|Supine moving apprehension test (SMAT)|The beginning position of the participant is lying in a supine position while holding the weight just over their chest. Participants move their shoulder to 135° of abduction with the elbow extended, then returning to the starting position, and immediately move their shoulder to 180° of abduction with the elbow fully extended and finally return to the starting position. This cycle is repeated as much as possible for 1 minute.
223493612|NCT07115225|OTHER|Physical performance test - Posterior shoulder endurance test (PSET)|The participant is positioned prone, with the test shoulder off the table and the arm in 90° of horizontal abduction, the point at which the participant is to hold the arm as long as possible until fatigue. The participant holds a weight equal to 2% of his body weight (rounded to the nearest 0.5 kg).
223588813|NCT01932502|DRUG|Conversion schedule - Week 3|Week 3+: Titrate the dose of Onfi up to 40mg per day as tolerated.
223588814|NCT02429791|DRUG|DTG 50 mg|Participants received one oral tablet of 50 mg DTG daily administered concomitantly with RPV. Each DTG tablet contained 52.62 mg dolutegravir sodium salt, which was equivalent to 50 mg dolutegravir free acid.
224185266|NCT03946072|PROCEDURE|Transseptal Aortic Approach Catheter Ablation Procedure|The transseptal approach entails obtaining femoral venous access, and, guided by fluoroscopy and intra-cardiac ultrasound, starting with a transseptal needle or radio frequency (RF) device inside the dilator of a long sheath; pulling down until the fossa ovalis in the interatrial septum is engaged on both fluoroscopy and intracardiac echo imaging; once on the left side, the long sheath is advanced over the transseptal needle, the needle and dilator are removed, and the ablation catheter can then be advanced across the mitral valve into the left ventricle.
224185267|NCT03946072|PROCEDURE|Retrograde Aortic Approach Catheter Ablation Procedure|The retrograde aortic approach entails obtaining femoral arterial access and leaving a sheath in the femoral artery. Under fluoroscopy, an ablation catheter is then advanced up the ascending aorta where the catheter tip is curved using an internal mechanism controlled on the handle of the catheter to form a large loop (to prevent the tip from traveling down a coronary artery and causing trauma such as a dissection); the curved loop is advanced around the aortic arch and down the ascending aorta. To cross the aortic valve with this loop, the catheter is typically torqued in various directions until it falls through the aortic valve and into the left ventricle.
224185268|NCT02713633|OTHER|internal Double-J stents|internal stent, we use to approaches to insert it: 1- Retrograde by cystoscopy and this will take 10 minutes before starting the surgical procedure itself and we put the stent under fluoroscopy guidance and this is the commonest way we use now to put the internal stents. 2- ante grade, and this is basically inserting the stent during the surgical procedure itself from the kidney down to the ureter and this is done without fluoroscopy
223493613|NCT07115225|OTHER|Patient-reported outcome measure - The Shoulder Instability-Return to Sport after Injury (SIRSI)|Psycho-social questionnaire assessing the psychological readiness of athletes to return to sport following traumatic shoulder instability and conservative or surgical management. The SIRSI includes 12 questions with an 11-point Likert scale in the form of blocks to be ticked from 0 to 10. The total score is equal to the sum of the values of the 12 responses then determined in relation to 100 to obtain a percentage. High scores correspond to a positive psychological response.
223493614|NCT07115225|OTHER|Patient-reported outcome measure - Numeric Pain Rating Scale (NPRS)|"Patient's shoulder pain will be measured using an 11-point NRS, with a minimum value of zero (no pain) and a maximum score of 10 (the worst pain possible)"
223493615|NCT07115225|OTHER|Modified Tampa-Scale of Kinesiophobia for Anterior Shoulder Instability (TSK-SI)|"modified Tampa Scale of Kinesiophobia (TSK) to make it suitable for application in patients with anterior shoulder instability. The TSK-SI contains 18 items and the total score can range from 18 to 72, with 18 being the best score (no fear of movement/kinesiophobia) and 72 being the worst score (severe fear of movement/kinesiophobia)"
223493616|NCT07113574|DRUG|Meropenem 1000 mg|Administration of meropenem after intraperitoneal administration via cycler-therapy in APD patients without peritonitis
223493617|NCT07113574|DRUG|Aztreonam 2000 mg|Administration of aztreonam after intraperitoneal administration via cycler-therapy in APD patients without peritonitis
223493618|NCT07113574|OTHER|automated peritoneal dialysis with following long time dwell|The cycler therapy, followed by a prolonged dwell, will be performed as outlined in the study protocol.
223493619|NCT07113574|DIAGNOSTIC_TEST|Sampling|The sampling of blood, dialysate, and urine will be performed as outlined in the study protocol.
223588815|NCT02429791|DRUG|RPV 25 mg|Participants received one oral tablet of 25 mg RPV daily administered concomitantly with DTG along with a meal. Each RPV tablet contained 27.5 mg of rilpivirine hydrochloride, which was equivalent to 25 mg of RPV.
224185269|NCT02713633|OTHER|External Stent|we use one method, we choose were we will leave the stent and then we create a small hole in the kidney and then pull the stent through the hole and then create small hole in the abdominal fascia and then the skin, all this done under direct vision and control. So now the sent is outside the patient and connected directly to the kidney and the renal pelvis, then the distal part of the stent will be inserted across the anastomosis and before closing the renal pelvis (also under vision) toward the ureter. The external stent will be connected at the end of the procedure to a urine bag.
224185270|NCT06303791|BEHAVIORAL|Digital Psychosocial intervention|The psychosocial program with digital support has been developed by combining different theoretical perspectives on intervention in children with ASD without intellectual disabilities and children with ADHD. The contents of the program are based on three main approaches, each of which has separately demonstrated evidence in the treatment of these neurodevelopmental disorders: psychoeducation and stress management, cognitive behavioral techniques, and techniques in social and communication skills (Dahl et al., 2020; DuPaul et al., 2020; Tan-MacNeill et al., 2021).
224185271|NCT02711085|OTHER|No intervention|No intervention - observational study
224185272|NCT03420456|DEVICE|Transcranial Light Therapy|Transcranial light therapy penetrates the skin and brain using light energy; this makes transcranial light therapy noninvasive. Transcranial light therapy may activate under-stimulated brain regions.
223493620|NCT07114367|DRUG|NB02 (Poseltinib)|Dose Level 1, Dose Level 2, Dose Level 3
223493621|NCT07116304|DRUG|Lidocaine, a local anaesthetic.|it will be given as a pretreatment prior to injection of propofol, with a tourniquet applied.
223493622|NCT07116304|DRUG|Parecoxib 40mg|atients in this group will receive IV parecoxib 40 mg (the standard full dose for an adult) diluted to a total volume of 5 mL with normal saline.
223588816|NCT02429791|DRUG|CAR|CAR included the following combinations: 2 NRTIs + 1 INI, 2 NRTIs + 1 NNRTI, or 2 NRTIs + 1 PI
223493623|NCT07114172|DIAGNOSTIC_TEST|68Ga-ACC-DE/68Ga-FASN-DE/68Ga-ACLY-DE PET/CT|Recruit 15 healthy adult volunteers, divided into three groups, to undergo dynamic PET/CT (1 hour) and static PET/CT (2 hours and 3 hours) imaging with 68Ga-ACC-DE, 68Ga-FASN-DE, or 68Ga-ACLY-DE, respectively, to assess safety, biodistribution, and radiation dosimetry, laying the foundation for subsequent studies.
223493624|NCT07115095|DRUG|TP Chemotherapy + Trastuzumab + Pertuzumab|Chemotherapy regimen: Paclitaxel (150 mg/m²) intravenously on Day 1 and Carboplatin (400 mg/m²) intravenously on Day 2. Targeted therapy: Trastuzumab (8 mg/kg) intravenously and Pertuzumab (initial dose 840 mg, subsequent doses 420 mg) intravenously. This regimen was repeated every 21 days for 6 cycles.
223588817|NCT04201093|DRUG|Tavapadon|Participants will be randomized to receive tavapadon 5mg tablet once daily orally for 27 weeks.
223588818|NCT04201093|DRUG|Placebo|Participants will receive placebo matching to tavapadon QD orally for 27 weeks.
224185273|NCT00672490|DRUG|Quetiapine Fumarate|"Oral treatment, twice daily. 100 mg/day at Day 1, 200 mg/day at Day 2, 300 mg/day at Day 3, 400 mg/day at Day 4, from 400 mg/day to 600 mg/day before Day 8, from 600 mg/day to 800 thereafter, judged by the investigator.~Tablets"
224185274|NCT00672490|DRUG|Lithium|Oral treatment, twice daily. 250 mg/day to 2000mg/day from Day1 to Day 7, 500mg/day to 2000mg/day thereafter, judged by the investigator.
224185275|NCT03698370|DRUG|Gallium Ga 68 DOTA-NeoBOMB1|Administered intravenously (IV)
224185276|NCT03698370|DEVICE|Gallium Ga 68 PSMA-R2|Administered intravenously (IV)
224185277|NCT03485404|DRUG|methylcobalamin|methylcobalamin tablets, 0.5mg/tablet, 3 tablets/day.
224185278|NCT03485404|DRUG|Folic Acid|folic acid tablets, 5mg/tablet, 1 tablet/day
224185279|NCT03485404|OTHER|Placebo for methylcobalamin|orange tablets that looks exactly like methylcobalamin
224185280|NCT03485404|OTHER|Placebo for folic acid|yellow tablets that looks exactly like folic acid
224185281|NCT03485404|PROCEDURE|non-cardiac surgery|patients elective for non-cardiac surgery will undergo scheduled surgery after 7 days of intervention
224185282|NCT03485404|BEHAVIORAL|NPB test|participants will accept Mini-Mental State Examination (MMSE), Patient Health Questionnaire (PHQ-9), ADL, and NPB test before intervention, and NPB by discharge or similar time intermittent after the first assessment for non-surgical controls. Also ADL will be tested again through telephone interview at 3 months after discharge.
224185283|NCT03491982|DEVICE|Remote Cardiac Rehab|Remote Cardiac Rehab
224185284|NCT02997852|BEHAVIORAL|Therapy dog visitation|The TDV will consist of a 10-minute visit from the same Faithful Paws animal handler and her dog. Each therapy dog meets obedience, temperament, and health standards appropriate to therapy dog visitation in hospital settings. The dog will be leashed and under control of the animal handler and the TDV will be casual and not restrict the handler with conversing, which is standard practice in TDV. Visual and tactile contact with the dog will be promoted by the animal handler. Per hospital protocol, the patient will be assisted in washing his/her hands before and after the TDV and the dog will be placed on the bed or remain at the bedside in close proximity allowing petting. A clean sheet will be placed over the patient when the dog is placed on the bed. The research staff will collect data before and after each arm of the study.
223493625|NCT07115095|DRUG|TP Chemotherapy + Trastuzumab|Chemotherapy regimen: Paclitaxel (150 mg/m²) intravenously on Day 1 and Carboplatin (400 mg/m²) intravenously on Day 2. Targeted therapy: Trastuzumab (8 mg/kg) intravenously. This regimen was repeated every 21 days for 6 cycles.
223493626|NCT07114159|DEVICE|Sacral nerve stimulation|Device: G132 system, Beijing PINS Medical Co., China Neuromodulation was performed according to the usual protocol
223493627|NCT07116005|BEHAVIORAL|Mandala Coloring|"Participants in this group receive the Mandala Art Therapy intervention, a creative, mindfulness-based activity rooted in complementary and alternative medicine. The intervention is designed to reduce exam-related anxiety by fostering visual focus, emotional calm, and self-expression. The Mandala protocol includes the following components:~* Distribution of printed Mandala outlines on A4 paper~* Provision of six colored pencils (red, orange, yellow, green, blue, and purple)~* A 20-minute individual coloring session in a quiet and relaxed setting~* No prescribed patterns-participants color freely to encourage self-directed engagement The Mandala coloring session is conducted exactly one hour before the Objective Structured Clinical Examination (OSCE). The activity is supervised by the researcher to ensure a supportive and distraction-free environment. Participants are encouraged to concentrate on the process of coloring to promote psychological grounding and reduce pre-exam stress."
223493628|NCT07113652|DEVICE|TI stimulation device (nerviox-1000）|"The TI stimulation device (nerviox-1000) delivers temporally interfering electrical fields with a 130 Hz envelope frequency, generated by high-frequency carrier waves. The stimulation is applied for 20 minutes per session, with a peak current of 3-4 mA per channel, adjusted based on individual tolerance. The stimulation targets include the nucleus accumbens, bed nucleus of the stria terminalis, amygdala, caudate nucleus, and putamen. Stimulation is administered twice daily, with each treatment phase lasting 7 consecutive days.~Sham stimulation uses identical electrode placement and setup as active stimulation. A brief 30-second ramp-up is applied to mimic real stimulation, followed by rapid reduction to 0 mA or minimal current. A 1 mA tail current is delivered in the final 30 seconds to simulate the tapering effect of active stimulation."
223493629|NCT07113834|DRUG|Adalimumab|A tumor necrosis factor-alpha (TNF-α) inhibitor used as a biologic agent for the treatment of ankylosing spondylitis. Administered subcutaneously as part of systemic immunomodulatory therapy.
223588819|NCT04201093|DRUG|Tavapadon|Participants will be randomized to receive tavapadon 15mg tablet once daily orally for 27 weeks.
223588820|NCT01956370|DEVICE|PrePex™ device for adult male circumcision|The PrePex™ device is designed to enable bloodless male circumcision procedure with no anesthesia and no sutures.
224185285|NCT02860676|DRUG|cirmtuzumab|cirmtuzumab, dose based on ongoing phase 1 trial, q14days x 4 doses, then q28 days x 4 doses, until disease progression.
224185286|NCT01115205|BEHAVIORAL|Supervised walking|Walk training, 3 sessions per week for 4 months, under the supervision of a qualified personal trainer.
224185287|NCT01115205|BEHAVIORAL|Standard counselling procedure|Verbal and written information about the benefits of exercise and instructions aimed to encourage physical activity. In addition, one group session of counselling on these issues.
224185288|NCT01024894|DRUG|Interleukin-7|3 dose levels: 3, 10 \& 20 µg/kg. 4 administrations, 1 per week
224185289|NCT04549766|OTHER|calculate PRECISE DAPT score using clinical data|calculate PRECISE DAPT score using clinical data in STEMI patients after PPCI
224185290|NCT03929237|OTHER|observe when return to school after surgery|Short written questionnaire asking when they returned to school and what accommodations, if any, the school made available for them
224185291|NCT01074086|DRUG|RAD 001|RAD 001 in steps of 3 patients from 10mg in day 1 and day 7 to 50 mg
224185292|NCT00366665|DEVICE|Legacy 20000|
224185293|NCT00366665|DEVICE|Infinit system|
223493630|NCT07113834|DRUG|Systemic corticosteroids|Oral or intravenous corticosteroids (e.g., prednisolone) used to suppress systemic inflammation in cases of active AS or severe uveitis.
223588821|NCT01956370|PROCEDURE|Surgical circumcision|The penis will be surgically circumcised according to one of the WHO recommended circumcision methods as described in the Manual for Male Circumcision under Local Anaesthesia Version 2.5C January 2008
223588822|NCT02135978|OTHER|Shoulder home exercise program|Patients receive instruction and practice on the shoulder home exercise program, receive a notebook with handouts including pictures and written instructions on how to perform the program, and receive a kit containing the exercise equipment. Patients are asked to perform the exercises at home 3 days a week over the next 3 years.
224073479|NCT02977923|OTHER|Standard pharmacological treatment|according to the unit's protocol and adjusted to each participant's age, weight and condition by the anesthetist and pain clinic nurse.
223493631|NCT07116577|RADIATION|Palliative radiotherapy|Conventional fractionation, low-dose hypofractionated radiotherapy, or high-dose hypofractionated radiotherapy may be employed.
223493632|NCT07116577|DRUG|Iparomlimab and tuvonralimab|5 mg/kg, intravenously infused on Day 1 of each cycle, administered every 3 weeks (with each cycle defined as 21 days).
223493633|NCT07116577|DRUG|TAS-102|35 mg/m², orally twice daily on Days 1 to 5 and Days 8 to 12 of each cycle, with each cycle spanning 28 days (4 weeks).
223588823|NCT04046172|PROCEDURE|supra/sub gingival root surface debridement|The test group will undergo Intensive periodontal treatment (IPT)
224073480|NCT04505683|DRUG|Benapenem|Benapenem for IV injection administered as a 1-gram IV infusion
224073481|NCT04505683|DRUG|Ertapenem|Ertapenem for IV injection administered as a 1-gram IV infusion
224073482|NCT06164405|DEVICE|arterial dp/dtmax|to assess the variations of the arterial dp/dt max after drugs or fluids administration
224073483|NCT03660878|DRUG|Reproxalap Ophthalmic Solution (0.25%)|Reproxalap Ophthalmic Solution (0.25%) administered four times a day and an additional four times a day on an as needed basis.
224073484|NCT03660878|DRUG|Reproxalap Ophthalmic Solution (0.5%)|Reproxalap Ophthalmic Solution (0.5%) administered four times a day and an additional four times a day on an as needed basis.
224073485|NCT03660878|DRUG|Vehicle Ophthalmic Solution|Vehicle Ophthalmic Solution administered four times a day and an additional four times a day on an as needed basis.
224073486|NCT01282073|DRUG|Mycophenolate mofetil, low dose steroid|"Mycophenolate Mofetil: Myconol capsule 250mg, Myconol 500 mg bid per day (less than 50kg), 750 \~ 1000 mg bid per day (more than 50kg)~Steroid: Methylprednisone 4mg tablet or Prednisolone 5mg tablet or Deflazacort 6mg tablet. Prednisolone dose: 0.15mg/kg up to a maximum dose of 15mg/day~Duration: 48 weeks"
224073487|NCT01282073|DRUG|Cyclosporin, low dose steroid|"Cyclosporin: Implanta soft cap (cyclosporin microemulsion) 25mg/100mg, starting dose of 4mg/kg per day and titrate according to investigator's decision based on cyclosporin trough level (100±50 ng/ml)~Steroid: same dosage with active comparator goup~Duration: 48 weeks"
224073488|NCT05753722|BIOLOGICAL|PRTH-101|PRTH-101 is a humanized immunoglobulin gamma-1 (IgG1) monoclonal antibody
224073489|NCT05753722|BIOLOGICAL|Pembrolizumab|PRTH-101 in combination with Pembrolizumab
224073490|NCT03704194|BEHAVIORAL|Adapted LiFE|The standardized components include presenting the Adapted LiFE user manual to participants, and teach participants to embed the exercise activities in their daily routine with the LiFE activity calendar.
224073491|NCT03704194|BEHAVIORAL|Attention control|Attention will be provided to the control group to ensure they experience the same effects of time and attention but no effect on the outcome of interest.
224073492|NCT06492954|PROCEDURE|Surgical Resection|Removal of all lung nodules, including the radiated nodule, per the standard of care for osteosarcoma patients with lung metastasis.
224073493|NCT06492954|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|Dose level 1: 8 Gy\* 3 (Total 24 Gy) Dose level 2: 18 Gy\* 3 (Total 54 Gy)
224073494|NCT06492954|DRUG|Atezolizumab|For subjects \<18 years of age at the time of enrollment, Atezolizumab will be administered IV on Day 1 of each 21-day cycle at a dose of 15 mg/kg (maximum dose of 1200 mg). Subjects ≥ 18 years old will receive a flat dose of 1200 mg IV on Day 1 of each 21-day cycle
224073495|NCT06175234|DEVICE|Ablation Treatment|For subjects with paroxysmal AF, Pulmonary Vein Isolation will be performed with the FARAWAVE NAV catheter. For subjects with persistent AF, left atrial posterior wall isolation (PWI) may also be performed at the discretion of the investigator, with the FARAWAVE NAV PFA catheter.
224073496|NCT05565950|BIOLOGICAL|AI-09|Botulinum toxin, Type A, intramuscular injection, administered once at baseline
224073497|NCT05565950|BIOLOGICAL|Vehicle|Vehicle Formulation
224073498|NCT04274985|OTHER|Questionnaire application|Patients will complete the mentioned questionnaires.
224073499|NCT02375230|PROCEDURE|Control group|Health care provider randomized to the control group will receive a copy of the NRP text pages discussing MR SOPA at every shift for self-study. They will be encouraged by the educator to study these pages for five minutes at every shift. The educator will be there to answer questions if they arise.
224073500|NCT02375230|PROCEDURE|MR SOPA|"Health care provider randomized to the MR SOPA group will receive MR SOPA training provided by a qualified educator on every shift. This training will be five minutes long and will consist of each MR SOPA step. These corrective steps will be demonstrated and practiced on a low-fidelity neonatal mannequin. The alternative airway practice will be performed on an intubation mannequin in the DR also placed on the DR resuscitation unit. Each participant will receive five minutes of training at the start of each shift."
224073501|NCT05743452|DEVICE|GBR with CS@Mg|The patient was treated by GBR with magnesium calcium silicate scaffold for alveolar bone defect.
224073502|NCT04880577|DRUG|TENOFOVIR ALAFENAMIDE FUMARATE 25 Mg ORAL TABLET [VEMLIDY]|The study is designed to add on TAF to anti-CD20 therapies
224073503|NCT04880577|DRUG|Placebo|Placebo arm
224073504|NCT05022641|DEVICE|PTeye|The surgeon will first take 5 baseline NIRAF measurements on the thyroid gland (or neck muscle, if thyroid is absent) using the disposable sterile fiber probe that is connected to the PTeye console (see Figure 1), as per device functionality requirements.
223493634|NCT07116577|DRUG|Bevacizumab|7.5 mg/kg via intravenous infusion on Day 1 of each 21-day cycle.
224073505|NCT05022641|OTHER|Standard of Care|The surgeon will rely solely on her/his surgical experience in identifying the parathyroid glands during the operations.
224073506|NCT01931800|BIOLOGICAL|Sampling of blood|
224185294|NCT04151420|OTHER|Remote monitoring tool (infections questionnaire) validation|"There will be no treatment intervention in the current study (no drugs will be used). Instead, patients are enrolled in a routine care eHealth care-pathway with myIBDcoach. MyIBDcoach (MijnIBDcoach, Dutch, Sananet Care B.V., Sittard, The Netherlands, https://www.mijnibdcoach.nl) is a web-based platform for home-monitoring and patient- provider communication in patients with IBD.~Patients already using the myIBDcoach will be informed on this study. Patients will be asked to continue routine care including monitoring of PROs through the myIBDcoach. When a patient completes the infections disease questionnaire for the first time, this will be regarded as the starting point (T=0) for this patient. Patients will complete the questionnaire every three months after the starting point as part of their routine follow-up. Results from these questionnaires will be stored electronically and will be analyzed alongside medical records of GP's and drug delivery data from pharmacies."
224185295|NCT06256861|BEHAVIORAL|Rehabilitation treatment|This group is given rehabilitation treatment. The main intervention measures included: 1) non-invasive ventilator treatment, generally at least once every night and typically not exceeding continuous daily usage.; 2) attention to feeding and sleeping positions, with a recommended sleeping position of lateral recumbent and the head of the bed raised by 20-30°; 3) swallowing function training, such as tongue muscle stretching training, assisted anterior jaw protrusion training, lemon ice stimulation to the soft palate, pharyngeal wall, etc., generally 5 days per week, twice per day, 5-20 minutes each time; 4) pulmonary ultrashort wave therapy, generally at least 2-3 times a week, and not more than once a day; 5) physical therapy, such as intensive training for gross motor functions including lifting the head, turning over, sitting, crawling, standing, etc., generally 3-5 days per week, 1-2 times per day, 5-20 min each time.
224185296|NCT06256861|BEHAVIORAL|Myofascial Release Therapy|Myofascial release, also known as fascial release or fascial manipulation, is a physical therapy used to treat muscle and fascial tissue tension or pain. It involves applying appropriate pressure and stretching to release tight fascia and soft tissues, improving blood circulation, alleviating pain, and promoting rehabilitation. Myofascial release therapy is commonly used to treat muscle spasms, chronic pain, skeletal and joint issues, among others.
224185297|NCT03707249|DRUG|Ferric Carboxymaltose Injectable Product|iv iron infusion: 15 mg / kg up to a maximum 1g dose of Ferinject diluted in normal saline (0.9%) up to a total volume of 250 ml
224185298|NCT03707249|DRUG|Normal Saline 0.9% Infusion Solution Bag|250 ml of normal (0.9%) saline given by intravenous infusion over 20 minutes. This constitutes the control for the iron infusion.
224185299|NCT01483495|DEVICE|Diffuse optical spectroscopy|Diffuse Optical Spectroscopy Imaging Cerebrovascular Reactivity
224185300|NCT05881538|OTHER|Exercise group|Participants will perform a 16-week High Intensity Interval Training exercise program, twice a week. The intervention will be conducted telematically with real time supervision.
224185301|NCT04468555|OTHER|Global postural reeducation|It consisted of Global Postural Re-Education sessions divided into 3 sessions and performed with a frequency of 1 per week for 3 weeks. The sessions were performed individually, with an approximate duration of 40 minutes and all of them were assessed by the same physiotherapist.
223493635|NCT07115628|DEVICE|Transcranial Magnetic Stimulation|TMS is a non-invasive brain stimulation technique
223493636|NCT07118267|DIETARY_SUPPLEMENT|Lactiplantibacillus plantarum|containing 60 billion CFU (administered as two capsules per day)
223493637|NCT07117760|DRUG|225Ac-LNC1011|administered intravenously once every 8-10 weeks (1 cycle) for 4 cycles
223493638|NCT07117760|DRUG|68Ga-PSMA-11|Intravenous dose of approx. 150 MBq at screening and at time of centrally confirmed radiographic progressive disease
223493639|NCT07118319|DRUG|Human Allogeneic Induced Pluripotent Stem Cells (iPSCs) -Derived Motor Neuron Progenitor Cells (XS228CN)|Injection, once, 6 months
223493640|NCT07118319|DRUG|Human Allogeneic Induced Pluripotent Stem Cells (iPSCs) -Derived Motor Neuron Progenitor Cells (XS228CN)|Injection, every two weeks for four doses, 6 months
223493641|NCT07116954|PROCEDURE|Twenty-Two adult Patients who indicated for bilateral maxillary first premolar extraction will be randomly assigned into two equal group.|Group1: Elastomeric chains will be used on the right side, and NiTi closed-coil springs will be used on the left side. Group2: NiTi closed-coil springs will be used on the right side, Elastomeric chains will be used on the left side.
223493642|NCT07116954|PROCEDURE|Canin retraction with NiTi Closed-Coil Springs and elastomeric chains|Comparison between canine retraction using NiTi closed-coil springs versus elastomeric chains
223493643|NCT07118397|OTHER|dry needling|Dry needling involved the insertion of fine needles into identified myofascial trigger points within the plantar fascia and associated muscles. The technique aimed to release muscle tightness and alleviated pain by stimulating the trigger points. Needles were inserted perpendicularly to the skin at the identified trigger points, with the depth of insertion typically ranged from 35 to 70 mm, with 0.30mm diameter.
223493644|NCT07118397|OTHER|kinesiology taping|Kinesiology Taping was applied using an I-shape technique. The taping began from the metatarsal head, extending through the plantar fascia and along the Achilles' tendon to the calf muscle. The application involved specific tension levels to support the plantar fascia and improve functional movement. The taping was applied with the foot in a slightly dorsiflexed position to ensure proper adherence and function.
223493645|NCT07117370|BEHAVIORAL|Coach Mpilo|Peer support for treatment navigation. Peer supporters (coaches) with TB and HIV treatment experiences are trained in listening, support, and action planning to assist men in navigating and staying on treatment.
223493646|NCT07117045|DIAGNOSTIC_TEST|Diagnostic Evaluation for Positive AI Findings|MDT will review positive AI findings (including PDAC, pancreatic precursor lesions and benign lesion) cases to determine next steps: (1) Suspected PDAC and pancreatic precursor lesions are referred for hospital examination with diagnostic results collected; (2) Benign lesion cases receive personalized monitoring until endpoint events or study end; (3) Cases with positive AI findings but MDT-confirmed normal pancreatic issues receive at least one year of follow-up. If any abnormal results arise, management will transition to either plan (1) or (2).
223493647|NCT07114419|DRUG|Efsubaglutide Alfa 20 mg QW|Efsubaglutide Alfa 20 mg QW
224185302|NCT05654948|OTHER|computerised cognitive performance test : MindPulse|In practice, this tool measures the speed at which an individual reacts to the appearance of a simple image on a screen with instructions to react only to certain images. It thus makes it possible to measure the speed of information processing, attention, executive functions and reaction to difficulty
223493648|NCT07114419|DRUG|Efsubaglutide Alfa 40 mg QW|Efsubaglutide Alfa 40 mg QW
223493649|NCT07114419|DRUG|Efsubaglutide Alfa 40 mg Q2W|Efsubaglutide Alfa 40 mg Q2W
223493650|NCT07114419|DRUG|Efsubaglutide Alfa 80 mg QW|Efsubaglutide Alfa 80 mg QW
223493651|NCT07114419|DRUG|Efsubaglutide Alfa 80 mg Q4W|Efsubaglutide Alfa 80 mg Q4W
223493652|NCT07114419|OTHER|Placebo|Placebo
223493653|NCT07114393|BEHAVIORAL|Liberal use of intracoronary imaging during complex PCI|A new protocol regarding use of intracoronary imaging will be implemented in multiple PCI centers in the Netherlands. Main goal of this protocol will be to increase the use of imaging in complex PCI in the Netherlands. Moreover operators will be trained according to the new protocol and on site training will be organized to improve the skills in using imaging during complex PCI.Operators are requested to use of intracoronary imaging preferentially in all complex coronary lesions, but at least increase their use with at least 50% and minimum of 25% of the cases. Throughout the second phase, individual participating operators will receive personalized feedback on their use of intracoronary imaging at multiple intervals. Based on this result, the implementation process will be refined as necessary. These intermediate measurements will also be shared with all participating centres anonymous.
223493654|NCT06923605|DRUG|Epoetin 4000|Erythropoietin hormone
223493655|NCT06923605|OTHER|Placebo|isotonic (normal saline) with concentration 0.90% of sodium chloride (NaCl) 4 times daily
223493656|NCT07116460|DEVICE|Austin Air Cleaner|The Austin Air Purifier consists of 4 stages, a large particle pre-filter, medium pre-filter, a medical grade HEPA filter and a high efficiency gas arrestance carbon cloth to reduce air pollution in homes.
223493657|NCT07114718|DEVICE|Ductus Arteriosus Stent|The eligible subjects will proceed to implantation of the Lifeline Ductus Arteriosus Stent to maintain patency of the PDA.
223493658|NCT07121257|DEVICE|VENTIJET system|The Ventijet system is an investigational ventilation device delivering continuous high-velocity gas flow through a proximal nozzle. The system is designed to maintain alveolar recruitment with low driving pressures, acting as an expiratory brake. Patients received continuous flow ventilation using Ventijet for 1 to 24 hours after baseline assessment with conventional mechanical ventilation.
223493659|NCT07121738|BEHAVIORAL|Healthy Eating Active Lifestyle (HEAL): Gyn Cancer Program|Evidence-based lifestyle medicine program for cancer survivors
223493660|NCT07121049|BEHAVIORAL|Strength training|Through systematic muscle training and promotion of outdoor activities, the program integrates early childhood education college students with kindergartens to promote the all-round development of children and establish habits to prevent myopia.
223493661|NCT07120009|PROCEDURE|selective caries removal|The caries is not completely removed but covered with a remineralizing material. Its purpose is to maintain pulp vitality.
223493662|NCT07120009|PROCEDURE|partial pulpotpmy|Complete cleaning of the caries resulting in pulp expose. pulp tissue is surgically removed by 1-3 mm.The aim is to remove the inflamed superficial pulp tissue to allow healing from the underlying healthy tissue.
224185303|NCT04526639|BEHAVIORAL|Virtual Reality-based Interactive Cognitive Training Program|Three virtual reality-based games designed to train inhibitory control, working memory, and cognitive flexibility among children with TBI
224185304|NCT04526639|BEHAVIORAL|Placebo Virtual Reality Game|A virtual playground for control group to interact without training executive functions
224185305|NCT03319160|DEVICE|Wearable Cardioverter Defibrillator|A non-invasive wearable cardioverter defibrillator detects and treats VT/VF without the need for bystander intervention
224185306|NCT03473691|DRUG|Glembatumumab Vedotin|Standard neo-adjuvant dose-dense doxorubicin 60 mg/m2 and Cytoxan 600 mg/m2 IV every 14 days for 4 cycles followed by GV 1.9 mg/kg IV every 21 days for 4 cycles.
224308604|NCT01515930|BEHAVIORAL|Parent Computer-Delivered Motivational Intervention|Motivational Interviewing (MI) is a client-centered, directive method for enhancing intrinsic motivation to change by exploring \& resolving ambivalence, with a strong evidence for improving adolescent \& adult health behaviors. Three motivational sessions will be provided by an animated character who delivers the intervention with high fidelity to MI principles. Small amounts of psychoeducation about potential improvements illness management that can result from parental monitoring of diabetes care will be integrated with more purely motivational elements. Mailings will be sent to participants to remind them of the reasons they gave as motivation \& goals they set regarding monitoring diabetes care.
223493663|NCT07117656|BEHAVIORAL|Project Vuselela|A four session intervention with people who inject drugs and family members. Delivered three group sessions and one dyad session. Session content designed to improve coping and communication skills that will in turn improve treatment outcomes.
223493664|NCT07118800|DRUG|FOLFOX4s|"6 cycles of FOLFOX4s intravenously: Oxaliplatin 85mg/m² over 2h, folinic acid 400mg/m2 (or L-folinic acid 200 mg/m2) over 2h, Fluorouracil bolus 400mg/m², Fluorouracil: 2400mg/m² over 46h, every 14 days for 12 weeks (max: 6 cycles). FOLFOX4 regimen will be started 2-4 weeks after completion of radiotherapy"
223493665|NCT07118800|RADIATION|Short Course Radiotherapy|25Gy in 5 fractions of 5Gy delivered in one week (short-course radiotherapy)
223493666|NCT07119372|BIOLOGICAL|BCD-131 (pegdarbepoetin beta)|BCD-131 (pegdarbepoetin beta), subcutaneous injection; regimen: once every 4 weeks; therapy duration: 52 weeks
223493667|NCT07119372|BIOLOGICAL|Mircera (methoxypolyethylene glycol-epoetin beta)|Mircera (methoxypolyethylene glycol-epoetin beta), subcutaneous injection; regimen: once every 4 weeks; therapy duration: 52 weeks
223493668|NCT07121504|DEVICE|Hybrid closed-loop insulin delivery system|Perioperative patients with T2D receiving parenteral nutrition will receive hybrid closed-loop insulin delivery system for glycemic management.
223493669|NCT07121504|DEVICE|conventional insulin pumps combined with CGM|Perioperative patients with T2D receiving parenteral nutrition will receive conventional insulin pumps combined with CGM for glycemic management.
223493670|NCT07121140|PROCEDURE|Home Blood Transfusion|Participants will be provided with transfusion of blood products, specifically red blood cells and platelets, in the home setting.
223588824|NCT04046172|PROCEDURE|supra-gingival scaling and polishing|Control group will receive the Control periodontal treatment (CPT).
223588825|NCT00007020|DRUG|Cholic Acids|10-15 mg/kg body weight/day taken orally.
224185307|NCT06416462|PROCEDURE|antimicrobial photodynamic therapy|When starting the research, all wounds, regardless of the study group, will be cleaned with 0.9% saline solution (SF0.9%), using a 40x12 needle and a 500ml bottle of SF0.9%, in order to maintain pressure. for equal cleaning of all wounds and a hydrofiber plate with silver was used as standard coverage. Experimental group (n=45): When starting the intervention, all services in both groups will follow the cleaning standard described previously. In the aPDT group, 1% methylene blue will be used as a photosensitizer applied with the aid of a syringe (with a pre-irradiation time of 5 minutes), 6 J of laser will be applied.
224185308|NCT03846310|DRUG|Etrumadenant|Etrumadenant is an A2aR and A2bR antagonist
224185309|NCT03846310|DRUG|Zimberelimab|Zimberelimab is a fully human anti-PD-1 monoclonal antibody
224185310|NCT03846310|DRUG|Carboplatin|Carboplatin administered as part of standard chemotherapy regimen
224185311|NCT03846310|DRUG|Pemetrexed|Pemetrexed administered as part of standard chemotherapy regimen
224185312|NCT03846310|DRUG|Pembrolizumab|Pembrolizumab is a humanized anti-PD-1 monoclonal antibody
224185313|NCT04533672|DIAGNOSTIC_TEST|MRI Sequences|New multiparametric MRI techniques
224185314|NCT04470349|DEVICE|LITOS|Patients who received a LITOS dynamic distraction system after 31.12.2017
224185315|NCT04470349|DEVICE|Ligamentotaxor|Patients who received a Ligamentotaxor dynamic distraction system after 31.12.2017
224185316|NCT00730249|DRUG|methylphenidate hydrochloride|sustained release, twice daily, dosage according to an individual titration schedule
224185317|NCT00730249|DRUG|Placebo|twice daily according to an individual titration schedule
224185318|NCT00006025|DRUG|irinotecan hydrochloride|
224185319|NCT00006025|DRUG|temozolomide|
224308605|NCT01515930|BEHAVIORAL|Parent & Child Computer-Delivered Motivational Intervention|Motivational Interviewing (MI) is a client-centered, directive method for enhancing intrinsic motivation to change by exploring \& resolving ambivalence, with a strong evidence for improving adolescent \& adult health behaviors. Three motivational sessions will be provided by an animated character who delivers the intervention with high fidelity to MI principles. Small amounts of psychoeducation about potential improvements illness management that can result from monitoring/completing diabetes care will be integrated with more purely motivational elements. Mailings will be sent to participants to remind them of the reasons they gave as motivation \& goals they set regarding diabetes care.
224308606|NCT01515930|BEHAVIORAL|Computer-Delivered Information|Computer-Delivered Information about issues related to living with diabetes that do not directly impact completing diabetes care.
223493671|NCT07120204|DRUG|Corticosteroid Injection|The symptomatic foot will be prepared with povidone-iodine and draped in a sterile manner. A sterile-covered ultrasound probe will be placed over the heel to visualize the calcaneus, plantar fascia, and any calcaneal spur. Subsequently, 1 mL of triamcinolone acetonide 40 mg (KENACORT-A IM/Intra-articular Retard 40 mg ampoule) and 1 mL of 2% lidocaine (Aritmal 2% ampoule) will be injected over the plantar fascia.
223511701|NCT05781503|BEHAVIORAL|Identity Capital Intervention (Coach + Co-designed Leadership Guide)|Young people randomized to the intervention group will engage in a co-designed leadership guide with their assigned coach. The co-designed leadership guide contains 12 chapters with the overarching aim of enhancing identity capital along with providing strategies to achieve participant-identified goals. Each chapter contains four activities (e.g., self-reflection exercise or listening to a podcast). Ideally, youth will complete one chapter every month. Each young person in this group will meet individually with their coach every two weeks and with a larger group of 10 youth participants and their coach every month.
223511702|NCT05781503|OTHER|Monthly Rent Subsidies|All study participants will receive a monthly rent subsidy ($800 for those living in Toronto; $700 for those living in St. Catharine's or Hamilton due to differences in cost of living) for 12 months.
223511703|NCT06258512|OTHER|Intervention with a narrative approach.|"Health social workers will carry out a intervention with a narrative approach, through its training profile based on transversal skills, which will consist of 10 sessions carried out over five months. The interval between sessions will be of two weeks with a specific duration of fifty minutes per session. This type of intervention, with the objective of reorienting and redefining the demand or the initial problems that motivated the consultation, gives space to the patient\&#39;s subjective complaint, as well as to locate the understanding of the discomfort and the symbolic meaning of the symptoms.~That is, recognizing the physical symptoms while listening to stories of chaos to legitimize both the user and his symptoms, an encounter that allows return the user to its context without feeling rejected or judged by the health system."
223511704|NCT00597792|DEVICE|NDO Full-thickness Plicator|A low-profile (≤6mm) gastroscope was advanced and an EGD followed by Savary wire placement was performed. The gastroscope was then removed and the Plicator was advanced directly over the wire and into the stomach. The gastroscope was re-introduced through the Plicator, and the Plicator was retroflexed under direct endoscopic visualization to the anterior gastric cardia, approximately 1cm below the gastroesophageal (GE) junction. The Plicator arms were opened and the endoscopic tissue retractor was advanced deeply into the gastric cardia. The gastric wall was then retracted into the open arms of the Plicator. The arms were closed and a single, transmural pledgeted suture was deployed. The Plicator and gastroscope were then removed and the gastroscope re-inserted to evaluate the post-plication GE junction.
223511705|NCT03090035|DRUG|Pegylated Interferon α2|Peg-INF was given in a dose of 180 μg/week
223511706|NCT03090035|DRUG|Ribavirin|ribavirin 1200 mg/day to every patient for the period of 24 weeks for HCV genotype 2 \& 3
223511707|NCT01990352|DRUG|Pegylated liposomal doxorubicin|Doxil will be administered intravenously at 30mg/m2 on days 1 of a 21 day cycle.
223511708|NCT01856660|BEHAVIORAL|Low-Carbohydrate Diet|Participants are provided with a 6-month standard lifestyle intervention where carbohydrate intake is limited to 50 g/day. There is no calorie restriction for participants following the Low-Carbohydrate diet. Gradual increase in physical activity across the trial to \> 40 min per day, 5 times/week.
223511709|NCT01856660|BEHAVIORAL|Low-fat Diet|Participants are provided with a 6-month standard lifestyle intervention. They will follow an energy restricted, low-fat diet where the daily energy consumption target is 1,200- 1,500 kilocalories/d. The fat intake target is 28% or less of daily kilocalories. Gradual increase in physical activity until participants are active at least 40 min per day, 5 times/week.
223511710|NCT01257893|DRUG|Aspirin (acetylsalicylic acid)|Aspirin one 81 mg capsule per day for 10-14 consecutive days
223493672|NCT07120204|PROCEDURE|Radiofrequency thermocoagulation|The patient will be in the lateral decubitus position with the symptomatic foot below. The foot was prepared with povidone-iodine and draped under sterile conditions. A sterilized ultrasound probe was placed over the heel to visualize the calcaneus, plantar fascia, and calcaneal spur. A 10 cm long radiofrequency (RF) needle with a 5 mm active tip was advanced in-plane under ultrasound guidance toward the tip of the calcaneal spur. Sensory stimulation at 50 Hz elicited paresthesia in the medial calcaneus, while motor stimulation at 2 Hz did not produce any muscle contractions. The RF generator (Beijing Neo Science Co., RFE 4b) was set to 80 °C for 90 seconds, and the RFA procedure was initiated.
223493673|NCT06921980|OTHER|Brain function and psychological assessment|Patients will be assessed before cell therapy and on Days 1, 4, 7, 10, 14, 21, and 28 after treatment.
223493674|NCT02259621|DRUG|Nivolumab|Anti-PD-1 Therapy
223493675|NCT02259621|DRUG|Carboplatin|Anti-PD-1 Therapy
223493676|NCT02259621|DRUG|Paclitaxel|Anti-PD-1 Therapy
223493677|NCT02259621|DRUG|Ipilimumab|Anti-PD-1 Therapy
223493678|NCT06915844|BEHAVIORAL|SHARP Tanzania|Building on existing adolescent health services, including HPV+, this intervention adds desired services for adolescent health education, screening, counseling, and referrals. In addition, this intervention has strategic community engagement to identify out of school girls with limited access to existing integrated health services available in schools, community sensitization activities, and training for healthcare workers.
223493679|NCT06919198|DRUG|Ketamine|ketamine 2.5 mg/kg
223588826|NCT00881504|DRUG|"Bevacizumab in combination with modified FOLFOX6."|Oxaliplatin 85 mg/m2 IV on Day 1 5-FU: 400 mg/m2 IV bolus on Day 1, followed by 2400 mg/M2 over 46 hours Leucovorin: 400 mg IV Day 1 Bevacizumab: 10 mg/kg IV on Day 1 Repeat cycles every 2 weeks until death, disease progression, unacceptable toxicity, patient refusal, or treatment delay \> 4 weeks
223588827|NCT06133296|OTHER|Conventional fixed treatment|Roth brackets (.018; Gemini Roth System, 3M Unitek, USA) were used for the fixed orthodontic attachment
223588828|NCT06133296|OTHER|Clear aligner treatment|After the clear aligners came from the manufacturer (Align Technology, Santa Clara, CA), the compatibility of the guide aligner with each patient's mouth was checked for attachments
223588829|NCT06506929|OTHER|Task specific physical therapy|Physical Therapy based specifically on tasks that the participant os having difficulty with
223588830|NCT01276223|DRUG|Difluprednate 0.05% ophthalmic emulsion|Topical ocular steroid
223588831|NCT01276223|OTHER|Difluprednate vehicle|Inactive ingredients used as Run-In and placebo comparator
223588832|NCT00999960|PROCEDURE|Laparoscopic Radical Prostatectomy (without a simulator)|without simulator
223493680|NCT07122323|PROCEDURE|robotic arm-assisted total hip replacement|using robotic total hip replacement in patients with Legg-Calvé-Perthes disease
223493681|NCT07122323|PROCEDURE|conventional total hip replacement|applying conventional total hip replacement in patients with Legg-Calvé-Perthes disease
223588833|NCT00999960|PROCEDURE|Laparoscopic Radical Prostatectomy (with a simulator)|Learning with a simulator
223493682|NCT07119294|DIAGNOSTIC_TEST|FAPI PET/MR|FAPI PET/MR prior surgery or during recurrence suspiscion
223493683|NCT06923293|DEVICE|Utilization of motorized orthosis|While part of this study, participants will be fitted for the motorized orthosis and will complete walking tests with and without the AFO.
223493684|NCT07123168|BEHAVIORAL|Triangle Hierarchical Management|A nurse-led, risk-stratified management model where patients are categorized into high-, medium-, or low-risk tiers. High-risk patients receive intensive professional care (90%) and minimal self-management education (10%); medium-risk patients receive a balanced approach (50% each); and low-risk patients focus on self-management education (90%) with minimal professional care (10%). The intervention is delivered by trained nurses over 24 weeks.
223588834|NCT02618551|PROCEDURE|Bronchial thermoplasty for treatment of severe asthma|"Three sessions of bronchial thermoplasty are needed to treat patients. There will be 3 to 4 weeks between each procedure.~Bronchial thermoplasty procedure is performed under general anesthesia. The medical device used in this research to achieve the thermoplasty is the Alair system (class IIb medical device ; Boston scientific)~A confocal endomicroscopy will be conducted at the first and final session of thermoplasty. This examination involves analyzing and recording the structure of bronchi microscopy through a small catheter placed on the bronchus. Photographs of the bronchi will be realized."
223588835|NCT03966131|DEVICE|Tongue pressure recordings with the PRESLA prothesis for the Arm1 (patients wearing the complete denture for the first time)|Tongue pressure recordings during speech production, wet and dry swallowing tasks planned in 3 sessions, when the complete denture is worn for the first time, after 3 weeks, then after 3 months in order to characterise the adaptation to this new prosthesis.
224073507|NCT05982262|OTHER|Naturopathic-pharmacological consultation|The naturopathic-pharmacological consultation includes a naturopath and a clinical pharmacist and will consist of at least two meetings.
224073508|NCT01894204|OTHER|HTPPE|No drug and no placebo were used in this study. Some exams must be performed (DLCO - evaluation of the dyspnoea and pulmonary scintigraphy), and in function of the result of the pulmonary scintigraphy, the medical care of the patient will be different : negative pulmonary scintigraphy, stop of the explorations and taken care usual of the patients; positive pulmonary scintigraphy,realisation of a cardiac echography to estimate the presence or not of a not very probable, possible or likely HTP. The indication of the right cardiac catheterization is then put on the combination of the results of the cardiac echography and the evaluation of the dyspnoea.
224073509|NCT01548001|DRUG|Iguratimod|25 mg/tablet, taken orally, 2 tablets/day (bid)
224073510|NCT01548001|DRUG|Methotrexate|2.5 mg/tablet, taken orally once a week, 4 tablets/week (week 1-week 4) , 6 tablets/week (week 5- week 52)
224073511|NCT02889796|DRUG|Filgotinib|200 mg or 100 mg tablet(s) administered orally once daily
224073512|NCT02889796|DRUG|Placebo to match filgotinib|Tablet(s) administered orally once daily
224073513|NCT02889796|DRUG|Adalimumab|40 mg administered via subcutaneous injection once every two weeks
224073514|NCT02889796|DRUG|Placebo to match adalimumab|Administered via subcutaneous injection once every two weeks
224073515|NCT02889796|DRUG|MTX|Commercially sourced tablet(s) administered orally
224073516|NCT00360659|DEVICE|Continuous Positive Airway Pressure|
224073517|NCT01629797|BEHAVIORAL|Educational script on Acne|An educational script on Acne will be presented by investigator
223493685|NCT07123168|BEHAVIORAL|routine care|Standard nursing management for hemodialysis patients, including monthly monitoring, routine assessments, and general health education sessions. This care does not involve risk stratification or tailored interventions.
223493686|NCT07121803|OTHER|specialized food based on ice cream, order 1|Order of intervention: 1. ice cream with 0.014% brazzein, 6% maltitol and 8% oligofructose; 2: ice cream with 0.014% brazzein, 7.5% erythritol, 2.5% maltitol and 4% inulin; 3: standard ice cream (12% fat)
223493687|NCT07121803|OTHER|specialized food based on ice cream, order 2|"1. ice cream with 0.014% brazzein, 7.5% erythritol, 2.5% maltitol and 4% inulin;~2. ice cream with 0.014% brazzein, 6% maltitol and 8% oligofructose;~3. standard ice cream (12% fat)"
224185320|NCT01486979|DRUG|estradiol, 10 mcg|One vaginal tablet once daily in the morning during the first two weeks of treatment followed by one vaginal tablet twice weekly in the morning for 10 weeks
224185321|NCT01486979|DRUG|estradiol, 25 mcg|One vaginal tablet once daily in the morning during the first two weeks of treatment followed by one vaginal tablet twice weekly in the morning for 10 weeks
224185322|NCT02853903|BIOLOGICAL|NK immunotherapy|Each treatment: 8-10 billion cells in all, transfusion in 3 times, i.v.
224185323|NCT03604159|DRUG|Buprenorphine Extended Release|XRB is available in dosage strengths of 100 mg/0.5 mL and 300 mg/1.5 mL buprenorphine. Each dose is provided in a prefilled syringe with a 19 gauge 5/8-inch needle.
224308607|NCT04260971|DEVICE|Abbott St Jude Medical Infinity 7 neurostimulator|The stimulator has the capability to deliver both continuous and cyclical modes of stimulation which is being investigated in this study
224308608|NCT03914911|DEVICE|Smart Biopsy Device|The radiologist will perform a routine ultrasonic guided biopsy procedure using the smart biopsy system, with the device readings not visible (i.e. the radiologist will be blinded to device readings)
224308609|NCT04764136|DEVICE|Scoliometer (scolioscope)|Individuals with scoliosis will participate in this study. The device will be used to determine spinal rotation on the transverse plane. Repeated measures will be taken.
224308610|NCT04558268|DRUG|Prednisone|"Prednisone is a corticosteroid. It prevents the release of substances in the body that cause inflammation. It also suppresses the immune system.~Prednisone is used as an anti-inflammatory or an immunosuppressant medication. Prednisone treats many different conditions such as allergic disorders, skin conditions, ulcerative colitis, arthritis, lupus, psoriasis, or breathing disorders."
224308611|NCT04558268|DRUG|Progesterone|"Progesterone is a female hormone important for the regulation of ovulation and menstruation.~Progesterone is used to cause menstrual periods in women who have not yet reached menopause but are not having periods due to a lack of progesterone in the body. It is also used to prevent overgrowth in the lining of the uterus in postmenopausal women who are receiving estrogen hormone replacement therapy."
224308612|NCT04558268|DIETARY_SUPPLEMENT|vit D|Vitamin D acts on our bones, intestines, kidneys and parathyroid glands to keep calcium in balance throughout our body. Vitamin D receptors are also located within our cardiovascular system, lungs, pancreas, skeletal muscle, skin, and reproductive organs. In summary, vitamin D is a prohormone that is essential for good health.
224308613|NCT04558268|DIETARY_SUPPLEMENT|Iron Supplement|Iron is one of the minerals in the human body. It is one of the components of hemoglobin, the substance in red blood cells that helps blood carry oxygen throughout the body.
224308614|NCT04558268|DIETARY_SUPPLEMENT|Folic Acid|"Folic acid is a type of B vitamin that is normally found in foods such as dried beans, peas, lentils, oranges, whole-wheat products, liver, asparagus, beets, broccoli, brussels sprouts, and spinach.~Folic acid helps your body produce and maintain new cells, and also helps prevent changes to DNA that may lead to cancer."
224308615|NCT04098289|PROCEDURE|Hysteroscopic septum resection|Hysteroscopic septum resection, using a 26 French continuous-flow resectoscope with monopolar energy and electrolyte-free distension medium.
223493688|NCT07121803|OTHER|specialized food based on ice cream, order 3|"1. standard ice cream (12% fat)~2. ice cream with 0.014% brazzein, 6% maltitol and 8% oligofructose~3. ice cream with 0.014% brazzein, 7.5% erythritol, 2.5% maltitol and 4% inulin"
223493689|NCT07123155|DRUG|S-606001|S-606001 administered orally
223493690|NCT07123155|DRUG|Placebo|S-606001 matching placebo administered orally
223511711|NCT01257893|DRUG|Placebo|1 placebo capsule identical in appearance and excipient to aspirin capsule per day for 10-14 consecutive days
223511712|NCT01429935|DRUG|Ginger powder|capsules contain 500mg Ginger powder,every 6hours,for 5 days
223511713|NCT01429935|DRUG|Ibuprofen|capsules of Ibuprofen 400 mg, every 6 hours for 5 days
223511714|NCT01429935|OTHER|placebo|capsules contain starch
223511715|NCT04432298|DRUG|Pamrevlumab|Sterile liquid for injection
223511716|NCT04432298|DRUG|Placebo|Sterile liquid for injection
223511717|NCT04187690|DRUG|Jin-shui Huan-xian granule|Jin-shui Huan-xian granule will be administered 5days on and 2 days off for 52 weeks.
223511718|NCT04187690|DRUG|Jin-shui Huan-xian granule placebo|Jin-shui Huan-xian granule placebo will also be administered 5days on and 2 days off for 52 weeks. The placebo consists 5% of the same components as Jin-shui Huan-xian granule besides dextrin and bitter. The There is no obvious difference in appearance, weight and odor between Jin-shui Huan-xian granule and placebo.
224308616|NCT04098289|PROCEDURE|In vitro fertilization|Fertilization of oocytes with the spermatozoa of the partner, after induction of ovulation and capacitation of the sperm, using fertilization in vitro and embryo transfer (FIVET) or intracytoplasmic sperm injection (ICSI).
224308617|NCT03924089|DIETARY_SUPPLEMENT|Oral nutritional supplement with probiotics|Oral nutritional supplement specifically developed for undernourished hemodialysis patients enriched with functional nutrients (extra virgin olive oil, omega 3 fatty acids, whey protein, antioxidants and carnitine), with probiotics.
224308618|NCT03924089|DIETARY_SUPPLEMENT|Oral nutritional supplement without probiotics|Oral nutritional supplement specifically developed for undernourished hemodialysis patients enriched with functional nutrients (extra virgin olive oil, omega 3 fatty acids, whey protein, antioxidants and carnitine), without probiotics.
223511719|NCT00678574|DRUG|fluoxetine|Fluoxetine 20 mg daily by mouth for 2-3 months.
223511720|NCT01282138|DRUG|Olopatadine hydrochloride, 0.1% ophthalmic solution (Patanol)|One drop twice daily in each eye for 5 days, followed by an additional drop in each eye prior to allergen test.
223511721|NCT01282138|OTHER|Dextran 70 0.1%, hydroxypropyl methylcellulose 0.3% (Tears Naturale II)|One drop twice daily in each eye for 5 days, followed by an additional drop in each eye prior to allergen test.
224308619|NCT03924089|OTHER|Dietary recommendations|Dietary recommendations
223511722|NCT02451007|DRUG|lurbinectedin (PM01183)|
223511723|NCT03997591|OTHER|Ready2E.A.T. PROGRAM|"Training tasks based on:~reaching activities during attention tasks, memory tasks, sequential tasks This group was assessed at T0 and then after 6 weeks of conventional therapy."
223511724|NCT01118637|BEHAVIORAL|StopPulling.com|subsidized access to an interactive self-help website for TTM
223511725|NCT00618566|BEHAVIORAL|WPD and Depression Treatment Group|Intervention selected will depend on Phase I data analysis.
223511726|NCT06243250|DIAGNOSTIC_TEST|Hyperpolarized 13C-MRI|Metabolic MRI using IV injection of hyperpolarized \[1-13C\]pyruvate.
223511727|NCT00348374|DRUG|Insulin Lispro|Weight based initiation dose, and individually adjusted doses, per subject's blood glucose, over the six months study, in addition to insulin glargine and oral agents.
223511728|NCT00348374|DRUG|Exubera|Weight based initiation dose, and individually adjusted doses, per subject's blood glucose, over the six months study, in addition to insulin glargine and oral agents.
224073518|NCT03346460|OTHER|Tongue Scraping|Tongue scraping will be performed by the same operator in all patients. Posterior-anterior movements will be performed with the scraper over the lingual dorsum, followed by cleaning the scraper with a gauze. This procedure will be performed ten times in each patient, in order to standardize the mechanical removal of the tongue coating.
224073519|NCT03346460|RADIATION|aPDT|One session of aPDT will be performed with the photosensitizer (PS) urucum manipulated at a concentration of 20% (Fórmula e Ação®) in spray, to be applied in sufficient quantity to cover the middle third and back of the tongue (5 sprinkles) for 5 minutes for incubation. The excess will be removed with a sucker in order to keep the surface wet with the PS itself, without using water. Six points with a distance of 1 cm between them will be irradiated, considering the halo of light scattering and effectiveness of aPDT. The apparatus shall be precalibrated at wavelength 440-480nm for 60 seconds per point, irradiance of 450mW/cm and the light shall be irradiated so that a halo of 2cm diameter is formed per point.
224073520|NCT03346460|RADIATION|Tongue scraper and aPDT|Tongue scraping will be performed by the same operator in all patients. Posterior-anterior movements will be performed with the scraper over the lingual dorsum, followed by cleaning the scraper with a gauze. This procedure will be performed ten times in each patient, in order to standardize the mechanical removal of the tongue coating. After, one session of aPDT will be performed with the photosensitizer (PS) urucum manipulated at a concentration of 20% (Fórmula e Ação®) in spray, to be applied in sufficient quantity to cover the middle third and back of the tongue (5 sprinkles) for 5 minutes for incubation. Six points with a distance of 1 cm between them will be irradiated, considering the halo of light scattering and effectiveness of aPDT. The apparatus shall be precalibrated at wavelength 440-480nm for 60 seconds per point, irradiance of 450mW/cm and the light shall be irradiated so that a halo of 2cm diameter is formed per point.
224073521|NCT05000346|DRUG|Drug, inhalation|Solution administered by inhalation
224073522|NCT05006885|DRUG|ALT-801|Injected subcutaneously (SC)
224073523|NCT05006885|OTHER|Placebo|Injected subcutaneously (SC)
224073524|NCT05564065|PROCEDURE|Radiofrequency thermocoagulation of sensory branches of hip joint|There are two main nerves that carry the pain sensation of the hip joint. These nerves are the femoral and obturator nerves. The sensory branches of these nerves going to the hip joint will be detected with a radiofrequency device under fluoroscopy and percutaneous ablation will be performed.
224073525|NCT05564065|PROCEDURE|Intraarticular steroid injection of hip joint|Fluoroscopy guided percutaneous intra articular steroid injection of hip joint will be performed
224073526|NCT04957134|DEVICE|Electro-acupuncture|The acupoints of electro-acupuncture will be selected as Zusanli ,Sanyinjiao ,Zhongwan , Tianshu , Shuifen , Daheng ,Daimai , Shuidao ,Huaroumen and Fujie . We will deliver electrical stimulation with dense-disperse waves at 50 Hz and 10 V through the electrical acupuncture stimulation instrument to the abdominal points. The bodily needles will be retained for 30 minutes . Electro-acupuncture treatment will be applied 3 times a week, once every other day, for 8 consecutive weeks.
223511729|NCT02241031|BIOLOGICAL|MPs|MPs are generated from cord blood using a combination of cytokines.
223511730|NCT02241031|DRUG|thrombopoietin (TPO) and interleukin-11|Platelet stimulating factors include thrombopoietin (TPO) and interleukin-11 and so on.
223511731|NCT05298969|PROCEDURE|Temporalis Myofascial flap|Improvement of speech and feeding quality in patients with palatal defects by temporalis myofascial flap
223511732|NCT04952688|OTHER|OCT- Angiographie|Ophthalmological examinations
224073527|NCT04957134|DEVICE|Sham electro-acupuncture|The acupoints of sham electro-acupuncture will be selected as nonacupoints . The internal output power cord of the electrical acupuncture stimulation instrument will be interrupted. The bodily needles will be retained for 30 minutes . Sham acupuncture treatment will be applied 3 times a week, once every other day, for 8 consecutive weeks.
224073528|NCT02516748|BEHAVIORAL|Feedback|Less experienced endoscopists in optical diagnosis will receive feedbacks about their own accuracy of optical diagnosis.
224073529|NCT00360581|BEHAVIORAL|Yoga|
224073530|NCT00360581|BEHAVIORAL|Yoga and Cognitive Behavioral Therapy|
224073531|NCT02479802|BIOLOGICAL|Albumin|"27 plasma exchange procedures using Albumin 5% (estimated 3000 mL per plasma exchange) as replacement solution:~* three weeks of intensive treatment with two plasma exchanges per week~* twenty-one weeks of maintenance treatment with one weekly plasma exchange"
224073532|NCT01882907|DRUG|vildagliptin|vildagliptin 50mg bid for 16 weeks
224073533|NCT01882907|DRUG|Pioglitazone|Pioglitazone 15mg bid for 16 weeks
224073534|NCT06320483|DEVICE|Vibroacoustic device BARK VibroLUNG|"The BARK VibroLUNG vibroacoustic device is intended for the treatment and prevention of respiratory pathologies.~The BARK VibroLUNG vibroacoustic device with accessories is a medical device and is intended for the treatment of pathological conditions associated with obstructive and restrictive lung diseases in patients in medical institutions.~Field of application: physiotherapy of the chest organs, treatment and prevention of respiratory failure.~The therapeutic mechanism of action is due to three main effects: improved bronchial drainage, improved ventilation-perfusion ratios, and the lung opening maneuver."
224073535|NCT01978093|BIOLOGICAL|Hib-MenCY-TT (MenHibrix®)|4 doses administered intramuscularly (IM) in the right upper anterolateral thigh at Day 0, Month 2, Month 4 and Month 10-13 in the HibCY Group.
224308620|NCT04917289|DRUG|Chemotherapy|Started chemotherapy or change the current adjuvant therapy
224185324|NCT03604159|DRUG|Sublingual Buprenorphine (SUBOXONE, Zubsolv, or generic tablets)|SLB is administered sublingually or buccally as a single daily dose. Medication should be prescribed in consideration of the frequency of visits. Provision of multiple refills is not advised in early treatment or without appropriate follow-up visits. After treatment induction and stabilization, the maintenance dose of SLB is generally in the range of 4mg/1mg buprenorphine/naloxone to 24mg/6mg buprenorphine/naloxone per day depending on the individual patient and clinical response.
224185325|NCT01226134|DRUG|Itopride,|Itopride,50 mg capsules,thrice a day,for Four weeks
224185326|NCT01226134|DRUG|Placebo|placebo capsules,thrice a day for four weeks
224185327|NCT00758316|OTHER|Thoracoscopy and Pleurx|Talc poudrage and tunneled pleural catheter
224185328|NCT00758316|PROCEDURE|Thoracoscopy|Talc poudrage
224185329|NCT02816255|DEVICE|Full Face Mask with same CPAP Pressure|Full Face Mask with same CPAP Pressure
224185330|NCT02816255|DEVICE|Full Face Mask with new Pressure|New cpap pressure derived from our formula for the final two weeks.
224185331|NCT01072227|PROCEDURE|Sample Collection|Tissue
224185332|NCT05899127|DRUG|Lidocaine|1.5mg/kg induction，1.5 mg/kg/h maintenance
224185333|NCT05899127|DRUG|0.9%NaCl|2mg/kg induction，1.5 mg/kg/h maintenance
224185334|NCT06017349|DEVICE|Non-invasive glucose meter|Blood glucose levels were measured while fasting, after breakfast, and after lunch，Place your index finger into the non-invasive blood glucose meter and wait for the instrument to display the reading.
224185335|NCT06017349|DEVICE|EKF analyzer|Blood glucose levels were measured while fasting, after breakfast, and after lunch，After collecting venous blood and separating plasma, blood glucose detection is performed using the EKF analyzer with the hexokinase method.
223493691|NCT07122466|DIAGNOSTIC_TEST|Tumor DNA circulating in the bloodstream (circulating tumor DNA; ctDNA)|ctDNA will be measured at the same times as CT scans (just before the start of treatment, as well as 2 months after), and the response measured by the ctDNA change will be compared to the response seen on the changes between the CT scans. The goal is to make sure that ctDNA response correlates well with CT scan response measurement.
223493692|NCT07123922|DIETARY_SUPPLEMENT|Silymarin|Participants received Silymarin 140 mg capsule orally thrice daily for 12 weeks
223493693|NCT07123922|DIETARY_SUPPLEMENT|Placebo|Participants received Silymarin placebo capsule thrice daily for 12 weeks
224185336|NCT06017349|DEVICE|Accu-Chek Guide|Blood glucose levels were measured while fasting, after breakfast, and after lunch，Use Accu-Chek Guide blood glucose meter to prick the finger and obtain blood for glucose measurement
224185337|NCT05613244|OTHER|Phone call|Patients will be asked to complete a questionnaire via a phone call
224185338|NCT05381740|DEVICE|Novel rTMS Approach|Participants in this arm will receive rTMS-based facilitation of the contralesional higher motor cortices located in the non-stroke hemisphere before the start of each rehabilitation session. High-frequency rTMS (5Hz) will be delivered using 42 10 second trains of 50 pulses each (total 2100 pulses) for a period of 22 minutes. Immediately after the completion of rTMS, participants will undergo therapist-guided upper limb therapy for a total of one hour. Participants will receive these interventions 2 days a week for 6 weeks for a total of 12 sessions.
224185339|NCT05381740|DEVICE|Sham rTMS Approach|Participants in this arm will receive sham rTMS given over the contralesional higher motor cortices located in the non-stroke hemisphere before the start of each rehabilitation session. Immediately after the completion of sham rTMS, participants will undergo therapist-guided upper limb therapy for a total of one hour. Participants will receive these interventions 2 days a week for 6 weeks for a total of 12 sessions.
224185340|NCT05608811|BEHAVIORAL|Social Skills Training|"Intervention:~The training is planned as 8 sessions. During this 4-week period, 2 sessions were held each week. The training, which will be held via Zoom, was carried out as a group or individual application. The first session was planned as four basic skills, the second session communication skills, the third session assertiveness skills, the fourth session conflict management skills, the fifth session social life skills, the sixth session friendship flirting skills, the seventh session health maintenance skills, and the eighth session professional/work skills."
224185341|NCT04533204|BEHAVIORAL|mnemonic strategy training|training using mnemonic strategies
224185342|NCT04533204|BEHAVIORAL|spaced retrieval training|training using spaced retrieval
224185343|NCT03023124|DRUG|Trabectedin|Treatment with trabectedin repeated every 21 days for 6 cycles
224185344|NCT03023124|DRUG|Adriamycin|Treatment with Adriamycin at day 1 every 21 days for 6 cycles
224308621|NCT01584557|DRUG|Tolvaptan or Samsca|uncoated tablet, 30mg, once per day, for up to 7 days.
224308622|NCT01584557|DRUG|placebo or sugar pill|sugar pill
223745687|NCT03257631|DRUG|Pomalidomide|: Subjects will be administered pomalidomide on Days 1 to 21, followed by a 7-day rest period, of each 28-day treatment cycle and will continue treatment for up to 24 cycles or until disease progression, withdrawal of consent/assent or unresolved toxicities as described in the protocol.
224185345|NCT03023124|DRUG|Dacarbazine|Treatment with Dacarbazine at days 1 and 2 every 21 days for 6 cycles
224185346|NCT02934919|DRUG|Nalmefene|30 patients with ICDs, will be treated with 18 mg per day of nalmefene during 3 months
224185347|NCT06365957|OTHER|Ketone monoester supplementation|Exogenous ketones are a class of ketone bodies that are ingested using nutritional supplements or foods. This class of ketone bodies refers to the three water-soluble ketones (acetoacetate, β-hydroxybutyrate, and acetone).
224185348|NCT06365957|OTHER|High-intensity interval exercise|High-intensity interval exercise is a type of interval training exercise. It incorporates several rounds that alternate between several minutes of high-intensity movements to significantly increase the heart rate to at least 80% of one's maximum heart rate, followed by short periods of lower-intensity movements. The exercise will be conducted on a computer-monitored cycle ergometer.
224185349|NCT06365957|OTHER|Moderate-intensity continuous exercise|Moderate-intensity continuous exercise generally consists of 30-60 min of aerobic exercise at 64-76% peak heart rate, while interval training involves more intense bouts interspersed by recovery periods. The exercise will be conducted on a computer-monitored cycle ergometer.
224185350|NCT06365957|OTHER|Placebo|The placebo will be the taste-matched water.
224308623|NCT05539430|BIOLOGICAL|LB1908|Claudin 18.2-Targeted autologous Chimeric Antigen Receptor T-cells
224308624|NCT00326560|PROCEDURE|Pterygium excision and conjunctival autograft|
223493694|NCT07123961|OTHER|High Driving Pressure Mechanical Ventilation|"A participant who is already invasively mechanically ventilated will be placed on Pressure Control Ventilation mode on an Evita V500 (Manufacturer: Dräger, Lübeck, Germany) ventilator if they are not already. The driving pressure will be set to 25 cmH2O (rate of pressure delivery). The Children's Hospital of Philadelphia (CHOP) PICU's standard of care regarding sedation, fluid management, ventilator weaning, and extubation readiness for invasively mechanically ventilated children will be adhered to for the duration of the study. An Enlight 2100 Electrical Impedance Tomography (EIT) Device (Manufacturer: Timpel) strap will be placed across the participant's chest up to four times throughout the study for a few hours to image the aeration in the lungs."
223493695|NCT07123961|OTHER|Low Driving Pressure Mechanical Ventilation|"A participant who is already invasively mechanically ventilated will be placed on Pressure Control Ventilation mode on an Evita V500 (Manufacturer: Lübeck, Germany) ventilator if they are not already. The driving pressure will be set to 15 cmH2O (rate of pressure delivery). CHOP PICU's standard of care regarding sedation, fluid management, ventilator weaning, and extubation readiness for invasively mechanically ventilated children will be adhered to for the duration of the study. An Enlight 2100 (EIT) Device (Manufacturer: Timpel) strap will be placed across the participant's chest up to four times throughout the study for a few hours to image the aeration in the lungs."
223493696|NCT07122999|DEVICE|Eustachi|A handheld device that delivers pulsed air through the nasal passage to facilitate opening of the eustachian tube. Participants in this group use the device twice daily for 5 weeks after tympanostomy tube extrusion.
223493697|NCT07125768|OTHER|Thermal Radiofrequency Neurolysis|Patients received C-arm guided neurolysis of superior medial \[SM\], superior lateral \[SL\], and inferior medial \[IM\] genicular nerves by thermal radiofrequency.
223493698|NCT07125768|OTHER|Alcoholic Neurolysis|Patients received C-arm guided injection of each of the three genicular nerves with 1 ml of a solution containing 70% alcohol in 0.25% lidocaine.
223493699|NCT07120776|DRUG|Camzyos (Mavacamten)|Camzyos (Mavacamten), a selective cardiac myosin inhibitor prescribed as part of routine care in patients with symptomatic HOCM. The study evaluates its effect on myocardial perfusion over a 12-month period using PET-CT imaging.
223493700|NCT07124195|DRUG|Medroxyprogesterone acetate oral suspension|Medroxyprogesterone acetate oral suspension (Meishiya®) (administered from Day 1 to 21, 5 ml, once daily)
224185351|NCT03001726|PROCEDURE|Gastrectomy|In patients assigned to surgery followed by chemo- therapy, a total, distal, or proximal gastrectomy with metastasis dissection was done depending on tumour location.
224185352|NCT03001726|DRUG|oxaliplatin|oxaliplatin 100 mg/m2
224185353|NCT03001726|DRUG|S1|S1 40mg/m2
224185354|NCT03001726|DRUG|Docetaxel|docetaxel 40 mg/m2
224185355|NCT00697255|DRUG|corifollitropin alfa|SC corifollitropin alfa on the 1st, 2nd or 3rd day after onset of a progestagen-induced withdrawal bleeding (Stage 1a: 15mcg, Stage Ib/II: 30 mcg).
224185356|NCT00697255|BIOLOGICAL|recombinant Follicle Stimulating Hormone (recFSH)|Daily injections of SC recFSH (50 IU/75 IU) administered as soon as the largest follicle reaches a size ≥12 mm 4 days after a corifollitropin alfa injection on stimulation day 5, 9 or 13.
224185357|NCT00697255|BIOLOGICAL|human Chorion Gonadotropin (hCG)|Daily injections of SC hCG (200 IU) administered as soon as the largest follicle reaches a size ≥12 mm 4 days after a corifollitropin alfa injection on stimulation day 5, 9 or 13.
224185358|NCT00697255|BIOLOGICAL|hCG Bolus injection|Bolus injection of SC hCG was administered to induce final oocyte maturation if at least one follicle is ≥18 mm and no more than two follicles ≥15 mm are observed.
224185359|NCT05374070|DIETARY_SUPPLEMENT|Streptococcus salivarius K12 Powder 1 Billion colony forming units /g)|Probiotic Streptococcus salivarius K12 products are commercially available in traditional formats such as lozenges for local delivery in the oral cavity to provide oral health benefits. In this study, a powder formulation will be evaluated for its potential of delivering probiotic Streptococcus salivarius K12 to the oral cavity.
224185360|NCT05374070|DIETARY_SUPPLEMENT|Streptococcus salivarius K12 Powder (1 Billion colony forming units /g) with a prebiotic included|In this study, a powder formulation containing Streptococcus salivarius K12 and a prebiotic will be evaluated for its potential of delivering probiotic Streptococcus salivarius K12 to the oral cavity.
224185361|NCT05374070|DIETARY_SUPPLEMENT|Streptococcus salivarius M18 Powder (1 Billion colony forming units /g)|In this study, a powder formulation will be evaluated for its potential of delivering probiotic Streptococcus salivarius M18 to the oral cavity.
224185362|NCT05374070|DIETARY_SUPPLEMENT|Streptococcus salivarius M18 Powder (1 Billion colony forming units /g) with a prebiotic included|In this study, a powder formulation containing S. salivarius M18 and a prebiotic will be evaluated for its potential of delivering probiotic Streptococcus salivarius M18 to the oral cavity.
224185363|NCT01005355|BIOLOGICAL|IMC-1121B|Cycle 1: Upon completion of enrollment criteria confirmed at screening, the first dose of study medication should be administered within 7 days. The infusion will be planned every 2 weeks or every 3 weeks on the same day of the week of the first infusion. Dose escalation to Cohort 2 may occur in the absence of a dose-limiting toxicity (DLT) in the first three participants treated in Cohort 1 during the initial 6-week dosing period (Cycle 1). The same procedure will be followed for dose escalation from Cohort 2 to Cohort 3. If 1 of 3 participants in any cohort experiences a DLT in the first 6 weeks (Cycle 1), 3 additional participants will be enrolled in that cohort. Dose escalation to the next cohort may occur if less that 2 of 6 participants experience a DLT during Cycle 1.
224185364|NCT01473108|DRUG|Finerenone (BAY 94-8862) PEG solution|2.5, 5, 10, 20 mg polyethylene glycol (PEG) solution of BAY 94-8862
224185365|NCT01473108|DRUG|Finerenone (BAY 94-8862) immediate release tablet|20 mg BAY 94-8862 administered as 2 x 10 mg IR tablets
224185366|NCT01473108|DRUG|Eplerenone (Inspra®)|Single oral dose of 50 mg eplerenone
224185367|NCT01473108|DRUG|Placebo|Matching placebo (solution/tablet) corresponding to BAY 94-8862 dose in respective dose step
224185368|NCT00656331|DRUG|Amlodipine and Hydrocholorothiazide|Arm 1 gets Amlodipine and Arm 2 gets Hydrocholorothiazide
224185369|NCT04073680|DRUG|Serabelisib|Subjects will be dosed with Serabelisib on 3 consecutive days a week in a 28 day cycle until tumor progression. in combination with Canagliflozin 300mg, both are oral medications
224185370|NCT04073680|DRUG|Canagliflozin 300mg|All subjects will be dosed with 300 mg canagliflozin in combination with serabelisib
223493701|NCT07124195|COMBINATION_PRODUCT|high antiemetic regimen|Ondansetron Injection (administered on Day 1, 8 mg, once daily), Dexamethasone Tablets (administered on Day 1, 12 mg, once daily; administered from Day 2 to 4, 3.75 mg, twice daily), Fosaprepitant (administered on Day 1, 150 mg, once daily)
223493702|NCT07124195|COMBINATION_PRODUCT|moderate antiemetic regimen|Ondansetron Injection (administered on Day 1, 8 mg, once daily), Dexamethasone Tablets (administered on Day 1, 12 mg, once daily; administered from Day 2 to 4, 3.75 mg, twice daily)
223493703|NCT07124390|DEVICE|Name: Electroacupuncture (EA) Type: Device-based acupuncture therapy|Description: Insertion of acupuncture needles at specific points with electrical stimulation (2 Hz) for 30 minutes per session.
223493704|NCT07124390|DEVICE|Neuromodulation therapy|"Type: Neuromodulation therapy~Description: Insertion of a needle electrode near the medial malleolus with low-voltage electrical stimulation (20 Hz) applied for 30 minutes per session."
223493705|NCT07124390|DEVICE|Sham Acupuncture|"Type: Placebo~Description: Non-invasive, non-penetrating placebo needles placed at the same points as in the EA group, without electrical stimulation, for 30 minutes per session."
223493706|NCT07125508|DRUG|Tranexamic Acid (TXA) treatment|Patients randomized to the interventional arm will take oral tranexamic acid 650 mg three times per day for 3 months. They will have blood work drawn every month for the 3 month trial period.
223493707|NCT07125508|DRUG|Placebo|Placebo intervention
223493708|NCT07125118|BEHAVIORAL|The OurRelationship Program|A guided self-help program for couples delivered online over 10 weeks. Participants complete structured learning modules and engage in planned couple conversations focused on improving communication, problem-solving, and emotional connection. Each couple receives support from a trained coach through five scheduled telephone or video calls. The program is designed to be flexible and completed at the couple's own pace within the 10-week period.
223493709|NCT07125118|BEHAVIORAL|Bibliotherapy|"An unguided self-help program for couples using the Danish book Take Care of Your Relationship \[Pas på Parforholdet\] and an accompanying reading guide. Couples are encouraged to read assigned sections, engage in planned couple conversations, and apply strategies for improving relationship functioning. The intervention is self-paced and completed over 10 weeks without guidance from a coach or therapist."
223493710|NCT07125937|DRUG|38% Silver Diamine Fluoride|A topical ammonia solution containing silver and fluoride ions applied directly to enamel caries lesions. Application will follow the UCSF protocol: lesions will be cleaned, isolated, and treated with SDF for 2 minutes using a microbrush applicator.
223493711|NCT07124715|DEVICE|Rough Surface Zygomatic Implant|Surgical placement of a zygomatic implant with a fully roughened surface from apex to collar. Used for the control arm.
223493712|NCT07124715|DEVICE|Partially Machined Surface Zygomatic Implant|Surgical placement of a modified zygomatic implant with a smooth machined coronal portion, a non-threaded machined middle section, and a rough apical portion. Used for the test arm.
223493713|NCT07124806|COMBINATION_PRODUCT|Botulinum toxin guided by ultrasonography and anatomical references|The botulinum neurotoxin (BoNT) will be calculated according to the weight of each patient. It will be injected in four places: two of them into the medial gastrocnemius and the other two into the lateral gastrocnemius. For medial gastrocnemius muscle, ¼ of the dose will be injected into the muscle belly at the 25% of the distance between the popliteal fossa and the intermalleolar line. Another ¼ will be injected into the muscle belly at the 35% of the previously mentioned distance. For lateral gastrocnemius, ¼ of the dose will be injected into the muscle belly at the 20% of the distance between the popliteal fossa and the intermalleolar line. The remaining ¼ of the dose will be injected into the muscle belly at the 30% of the previously described distance. All patients will conduct the same physical therapy program and under the direction of the same team of physical therapists. This program will begin two weeks after receiving the BoNT injection.
223493714|NCT07124806|COMBINATION_PRODUCT|Botulinum neurotoxin guided by ultrasonography and in vivo location of innervation zones guided by high-density electromyography|The botulinum neurotoxin (BoNT) will be calculated according to the weight of each patient. It will be injected in eight places: four will be located in vivo for gastrocnemius medialis and four for gastrocnemius lateralis. These places will correspond to innervation zones located by high-density electromyography in different zones of each muscle. Thus, each of the eight located innervation zones will receive 1/8 of the calculated dose for the gastrocnemius muscle. All patients will conduct the same physical therapy program and under the direction of the same team of physical therapists. This program will begin two weeks after receiving the BoNT injection.
223493715|NCT07124637|BEHAVIORAL|Multicomponent Social Cognitive Theory-Based Educational Program to Increase Fruit and Vegetable consumption in Students|"This multilevel blended educational intervention applies Social Cognitive Theory (SCT) to increase fruit/vegetable (F/V) intake among female middle school students. The 8-week program includes:~A) Student Components:~* Seven 60-minute sessions (4 in-person, 3 WhatsApp-delivered)~* Interactive activities: cooking demonstrations, goal-setting workshops, and educational games~* SCT-focused content: self-efficacy building, outcome expectation modification~B) Parental Engagement:~* Weekly SMS nutrition tips~* Two virtual workshops on creating F/V-supportive home environments~* School Environment Modifications:~* Cafeteria redesign to promote F/V accessibility~* Peer-led 'Healthy Eating Ambassador' program~Unique aspects distinguishing this intervention:~* First SCT-based program specifically adapted for Iranian adolescent females~* Dual delivery (in-person + digital) optimized for school settings~* Simultaneously targets individual, social, and environmental determinants."
224073536|NCT01978093|BIOLOGICAL|Pediarix®|3 doses administered IM in the left upper anterolateral thigh at Day 0, Month 2 and Month 4. 2 doses administered IM in the left upper anterolateral thigh at Day 0 and Month 2 and 1 dose administered IM in the right upper anterolateral thigh at Month 4 in the PedHIB Group.
224073537|NCT01978093|BIOLOGICAL|Rotarix®|2 doses administered orally at Day 0 and Month 2 each in the HibCY Group and PedHIB Group.
224073538|NCT01978093|BIOLOGICAL|Prevnar 13®|4 doses administered IM in the left lower anterolateral thigh at Day 0, Month 2, Month 4 and Month 10-13 each in the HibCY Group and PedHIB Group.
224073539|NCT01978093|BIOLOGICAL|PedvaxHIB®|3 doses administered IM in the right upper anterolateral thigh at Day 0, Month 2 and Month 10-13 in the PedHIB Group.
224073540|NCT01978093|BIOLOGICAL|Havrix®|2 doses administered IM in the left upper anterolateral thigh at Month 10-13 and Month 16-19 each in the HibCY Group and PedHIB Group.
224073541|NCT05882786|PROCEDURE|Corticosteroid injection|Subacromial injection of 40mg triamcinolone acetonide.
223493716|NCT07125547|DRUG|PD-1 inhibitior|Tislelizumab 200mg iv will be administered on Day 1 every 3 weeks for 2-3 cycles.
223493717|NCT07125547|DRUG|Nab-paclitaxel|Nab-Paclitaxel 125mg/m2 IV will be administered on Day 1 every 3 weeks for 2-3 cycles
223493718|NCT07125547|PROCEDURE|distal ureterectomy|Distal ureterectomy (Distal ureterectomy + Partial cystectomy +Psoas hitch procedure + Ureteral reimplantation into the bladder + Ipsilateral pelvic lymph node dissection) will be conducted after neoadjuvant treatment.
223493719|NCT07125833|DEVICE|Cryoneurolysis|Cryoneurolysis of the suprascapular nerve
223493720|NCT07125833|OTHER|No cryoneurolysis|Control Group
223493721|NCT07124988|PROCEDURE|regional flap|regional flap reconstruction for palatomaxillary defects
223493722|NCT07124988|PROCEDURE|distant flap|Distant flap reconstruction for palatomaxillary defects
224073542|NCT05882786|PROCEDURE|Dry Needling|Dry needling treatment to the supraspinatus, infraspinatus, and subscapularis muscles tendons.
224073543|NCT06298071|DRUG|SIBP-R002|Injection; strength: 4mg. Each group consists of 12 participants. Firstly, 4 sentinel participants were enrolled in the single dose phase of peruricase for injection and methotrexate. After the sentinel participants completed a 5-day safety observation of the single dose, the remaining 8 participants in this group can be enrolled simultaneously. If there are no special circumstances, the participants in this group will enter the multi-dose stage of peruricase for injection combined with methotrexate within 2-4 weeks after completing a single dose.
224073544|NCT06298071|DRUG|SIBP-R002|Injection; strength: 8mg. Each group consists of 12 participants. Firstly, 4 sentinel participants were enrolled in the single dose phase of peruricase for injection and methotrexate. After the sentinel participants completed a 5-day safety observation of the single dose, the remaining 8 participants in this group can be enrolled simultaneously. If there are no special circumstances, the participants in this group will enter the multi-dose stage of peruricase for injection combined with methotrexate within 2-4 weeks after completing a single dose.
224073545|NCT06298071|DRUG|SIBP-R002|Injection; strength: 12mg. Each group consists of 12 participants. Firstly, 4 sentinel participants were enrolled in the single dose phase of peruricase for injection and methotrexate. After the sentinel participants completed a 5-day safety observation of the single dose, the remaining 8 participants in this group can be enrolled simultaneously. If there are no special circumstances, the participants in this group will enter the multi-dose stage of peruricase for injection combined with methotrexate within 2-4 weeks after completing a single dose.
223493723|NCT07124663|OTHER|Breastfeeding education|Women will receive education on breast milk and breastfeeding during pregnancy.The education program consists of two sessions, with a total duration of 60 minutes.
223493724|NCT07123311|BEHAVIORAL|Online Stress Management Program|"This is an online pilot stress management program tailored for health students, combining cognitive-behavioral therapy and guided mindfulness meditation. Over eight sessions, participants engage with interactive psychoeducation modules, videos, and practical exercises to understand stress and develop coping strategies.~The sessions cover stress awareness, mindfulness meditation (basic and advanced), breathing techniques, time management using the Eisenhower matrix, and cognitive-behavioral methods to foster positive thinking and problem-solving.~The final session helps participants create a personalized action plan to integrate learned skills into daily life. Throughout the program, a support group encourages interaction and provides ongoing guidance to enhance well-being and stress management."
223493725|NCT07138794|OTHER|Subtransverse process interligamentary|Patients will receive subtransverse process interligamentary (STIL) block using 20ml of bupivacaine 0.25%.
223493726|NCT07138794|OTHER|Thoracic paravertebral block|Patients will receive a thoracic paravertebral block (TPVB) using 20ml of bupivacaine 0.25%.
223493727|NCT07105085|PROCEDURE|living donor liver transplantation|other intervention cannot be applied.
223493728|NCT07141628|DIAGNOSTIC_TEST|lipoprotein A level dosing|Plasma levels measured in mmol/l
224073546|NCT06298071|DRUG|Methotrexate|Combination drugs: Methotrexate, dose15 mg, oral.
224073547|NCT05702515|OTHER|Digital ECG Data Collection|synchronized digital data collected from the G4 and ECG machines during the PICC insertion procedure
224073548|NCT06845813|DRUG|AZD6234|Dose 1
224073549|NCT01954693|DRUG|Placebo|5mg daily administered for 6 months as two oral 2.5 mg tablets once daily.
224073550|NCT01954693|DRUG|Everolimus (RAD001)|5mg daily administered for 6 months as two oral 2.5 mg tablets once daily
224073551|NCT05202522|BEHAVIORAL|Virtual GERAS DANCE|Dance is a form of aerobic exercise that involves multicomponent training with physical, cognitive, and social dimensions and may have synergetic benefits when delivered in combination. GERAS DANcing for Cognition and Exercise (DANCE), a community-based rehabilitation program for older adults with cognitive decline and/or mobility impairments, has been adapted for virtual delivery through videoconferencing systems. Participants will receive twice-weekly (one hour per session) virtual dance sessions for a total of 6 weeks.
224073552|NCT04204174|DIETARY_SUPPLEMENT|Tyrosine, brand name: myprotein|tyrosine at a dose of 100 mg/kg is then administered orally to the participants once
224073553|NCT03464500|DIETARY_SUPPLEMENT|Mitopure 500mg|Mitopure containing softgels
224073554|NCT03464500|DIETARY_SUPPLEMENT|Mitopure 1000mg|Mitopure containing softgels
224073555|NCT03464500|DIETARY_SUPPLEMENT|Placebo|Placebo containing softgels
224073556|NCT04970251|DRUG|Aflibercept Ophthalmic|Panretinal photocoagulation and intravitreal aflibercept (2 mg/0.05 ml) injection were given, and trabeculectomy with mitomycin C was performed within 2 weeks after intravitreal aflibercept injection.
224073557|NCT00142701|BEHAVIORAL|diet|
224073558|NCT00142701|BEHAVIORAL|physical activity|
224073559|NCT00142701|BEHAVIORAL|stress management|
224073560|NCT00142701|BEHAVIORAL|smoking cessation|
224073561|NCT02499432|BEHAVIORAL|Motivational Enhancement|Motivational Enhancement/Interviewing is a form of discussion that seeks to increase change behavior.
224073562|NCT02698735|DRUG|Gentamicin|Gentamicin was either formulated into a 0.1% ointment or solutions for injection were purchased directly from suppliers.
224073563|NCT02698735|DRUG|Placebo|There are two placebos used in this study. The ointment vehicle (same as used to formulate gentamicin) and vehicle solution for injection.
224185371|NCT05129618|DIETARY_SUPPLEMENT|MHS 1031|prebiotic syrup in individual sachets containing 1g (1.4 ml) of panosyl-isomaltooligosaccharides
224308625|NCT05980663|DIETARY_SUPPLEMENT|Meal replacement product- STANDARD PRODUCT|standard product line contains common ingredients and this type of product already exists on world markets
224308626|NCT05980663|DIETARY_SUPPLEMENT|Meal replacement product- INNOVATIVE PRODUCT|innovative product line contains raw materials that are considered better sources of potentially bioactive components
223493729|NCT07142304|DEVICE|The Lilac Device|The Lilac Glove and Boot devices are wearable, non-sterile device for patients undergoing cancer treatment who wish to reduce the risk of peripheral neuropathy. Treatment with the Lilac Glove and Boot devices is administered by the healthcare professional in the healthcare environment. The Lilac Glove and Boot devices are designed for continual use; the devices must be fitted and turned on before infusion begins; the devices must be used without interruption during infusion, and for up to two (2) hours after infusion is complete.
223493730|NCT07142304|DEVICE|Sham device|The sham device will look, appear to function and worn for the same duration as the Lilac Device. The only difference between the devices is the level of compression applied.
223493731|NCT07142499|BEHAVIORAL|Memory Support System|Participants and study partners in the MSS treatment group will work with a study trainer to learn the MSS and eventually adapt the skills to support functioning in their daily life. The MSS trainer will follow a 10-session MSS Training Workbook as the standardized protocol for training. Additional sessions beyond the standard 10 sessions can be added if needed to support mastery of the MSS (up to a maximum of 15 total sessions). Participants and study partners will also receive a copy of the brain health education workbook that contains the same educational information for the control group at the 8-week follow up.
223493732|NCT07142499|BEHAVIORAL|Brain Health Education|Participants and study partners in the control group will be provided with the MSS guidebook and day planner for self-study of the MSS system. They will also meet with a study trainer to complete 10 sessions of a brain health education course that is tailored for individuals with MCI. The trainer will use a HABIT-based brain health education workbook to provide the content. Additional sessions beyond the standard 10 sessions can be added up to a maximum of 15 total sessions. Participants and study partners will receive a copy of the brain health education workbook at the 8-week follow up.
223493733|NCT07141056|OTHER|Psychological Stress Status|Psychological stress status will be assessed using both self-reported and clinician-rated measures. Participants will be categorized into stressed and non-stressed groups based on the following criteria: Self-reported measures (either): PHQ-9 score ≥ 5 (depression symptoms) and/or; GAD-7 score ≥ 5 (anxiety symptoms) Clinician-rated measures (either): HAMD score ≥ 7 (mild depression) and/or HAMA score ≥ 7 (mild anxiety) Additional assessments: Clinical Global Impression Scale (CGI) EORTC QLQ-C30 (quality of life) Assessment timing: Baseline (before starting immunotherapy) After 2-3 cycles of treatment Every 3 months during follow-up.
223493734|NCT07141056|OTHER|Psychological Stress Status|Psychological stress status will be assessed using both self-reported and clinician-rated measures. Participants will be categorized into stressed and non-stressed groups based on the following criteria: Self-reported measures (either): PHQ-9 score ≥ 5 (depression symptoms) and/or; GAD-7 score ≥ 5 (anxiety symptoms) Clinician-rated measures (either): HAMD score ≥ 7 (mild depression) and/or HAMA score ≥ 7 (mild anxiety) Additional assessments: Clinical Global Impression Scale (CGI) EORTC QLQ-C30 (quality of life) Assessment timing: Baseline (before starting immunotherapy) After 2-3 cycles of treatment Every 3 months during follow-up.
223493735|NCT07141056|OTHER|Psychological stress status|Psychological stress status will be assessed using both self-reported and clinician-rated measures. Participants will be categorized into stressed and non-stressed groups based on the following criteria: Self-reported measures (either): PHQ-9 score ≥ 5 (depression symptoms) and/or; GAD-7 score ≥ 5 (anxiety symptoms) Clinician-rated measures (either): HAMD score ≥ 7 (mild depression) and/or HAMA score ≥ 7 (mild anxiety) Additional assessments: Clinical Global Impression Scale (CGI) EORTC QLQ-C30 (quality of life) Assessment timing: Baseline (before starting immunotherapy) After 2-3 cycles of treatment Every 3 months during follow-up.
223493736|NCT07141875|OTHER|No intervention|This is an observational study without any interventions.
223493737|NCT06932315|DRUG|HRS-9190 for Injection|Subject will receive the HRS-9190 injection at different dose levels.
223493738|NCT06142682|DEVICE|Cochlear Implant|cochlear implantation with dexamethasone eluting electrode
223745688|NCT03257631|DRUG|Pomalidomide|Pomalidomide will be provided as gelatin capsules and as an oral suspension. The starting dose will be 2.6 mg/m²/day, administered on Days 1 to 21, followed by a 7-day rest period, of each 28-day treatment cycle.
224073564|NCT04036409|DRUG|Intensive Control of Systolic Blood Pressure (SBP)|Participants in the Intensive arm have a goal of SBP \<120 mm Hg. The use of angiotensin converting enzyme (ACE)-inhibitors/Angiotension receptor blockers (ARBs), Thiazide-type diuretics, calcium channel blockers (CCB), Sustained-release calcium channel blockers (CCBs) will be encouraged, preferably fixed-dose combinations of indapamide + perindopril arginine, perindopril arginine + amlodipine or indapamide + perindopril arginine +amlodipine
224073565|NCT04036409|DRUG|Standard control of Systolic Blood Pressure (SBP)|The same medications used in the Intensive BP arm will be used for the Standard BP arm.
224073566|NCT01888458|DRUG|Micafungin|All patients meeting selection criteria will receive micafungin IV. Prophylaxis will start within 48 hours of the beginning of the transplant-related conditioning regimen until 5 days after recovery from neutropenia (ANC ≥ 500/µl), or occurrence of an IFI, or up to 42 days, or withdrawal for any reason (e.g. patient's or investigator's decision, development of intolerance, death), whichever come first
224073567|NCT04079270|OTHER|Nutrition intervention|The diet recommendations will be provided by a certified dietitian. Participants will be asked to document their food intake and daily activities including exercise and sleep using a dedicated smartphone app throughout the intervention period.
224073568|NCT04313829|BEHAVIORAL|Pharmacist Counseling Intervention|We used the counseling module (in the form of a guide book) for pharmacist-based counseling that had been validated regarding constructive content by an endocrinologist and a pharmacist expert in diabetes drug counseling. The module explained the T2DM causes and symptoms, the reasons for the importance of therapy, the non-pharmacological and pharmacological therapies available (drug names, strengths, indications, rules of use, side effects, interactions, and storage), the purpose of controlling blood sugar levels, medications that need to be avoided, and guidelines for missed doses. The pharmacists should explain all the content within the module in 15 minutes to each patient of the intervention group each month for 6 months. As an ethical consideration, the control group patients were given the same explanation module through pharmacist counseling after the study finished.
224308627|NCT00442039|DRUG|Lithium Carbonate|The starting dose of lithium was 300 mg for patients weighing \< 20 kg
224073569|NCT01726348|DRUG|No intervention|This is an observational study. Darunavir will be administered as per the recommended doses and will be given orally every 4 weeks for a period of 24 weeks. For treatment-naive and treatment-experienced adult patients with no darunavir resistance associated substitutions: Darunavir 800 mg will be administered with ritonavir 100 mg once daily with food. For treatment-experienced adult patients with at least one darunavir resistance associated substitution: Darunavir 600 mg will be administered with ritonavir 200 mg twice daily with food.
224185372|NCT05129618|OTHER|placebo|liquid combination formulation of Neotame 7.92 mcg/g, phosphoric acid, and sterile water, designed to have the same degree of sweetness as the test material, provided in individual sachets containing 1.4 ml.
224185373|NCT03744208|DRUG|Anti-EGFR monoclonal antibody|DDP(75mg/m2),d1; 5-FU(750mg/m2),d1-5, every 21d; PF chemothrapy up to 6 cycles. 6.0mg/kg of SCT200 will be administered once a week for a maximum of 6 cycles. After 6 cycles, 8.0mg/kg of SCT200 will be administered every two weeks until disease progression
224185374|NCT02184312|DRUG|Nevirapine XR low dose|
224185375|NCT02184312|DRUG|Nevirapine XR medium dose|
224185376|NCT02184312|DRUG|Nevirapine XR high dose|
224185377|NCT02184312|DRUG|Nevirapine (VIRAMUNE®)|
224185378|NCT01303159|DEVICE|Endoscopic bipolar radiofrequency probe (ENDOHPB)|EndoHPB (EMcision Ltd, UK) is a single use sterile device for use at ERCP or PTC. It is a 8F (2.6mm) catheter with a 1.8m working length, that is designed to be inserted into the target duct of the hepatic, biliary or pancreatic system over a guide wire. The device is compatible with endoscopes that have a working channel of 3.2mm or greater. It comprises of a coaxial over the wire (OTW) catheter with 2 ring electrodes spaced 8mm apart at its distal end. The distal electrode is 5mm from the leading edge of the catheter. The two electrodes at the distal end of EndoHPB are designed to produce a heating zone length of approximately 25 mm.
224185379|NCT05849649|BEHAVIORAL|BumptUp|The app contains a number of evidence-based, expertly designed features to help women with healthier lifestyle habits during and after pregnancy.
224185380|NCT05849649|BEHAVIORAL|Educational Brochure|An evidence-based brochure on physical activity
224185381|NCT03996655|DRUG|Sugammadex Injection [Bridion]|Reversal of neuromuscular blockers
224308628|NCT00442039|DRUG|Lithium Carbonate|"The dose of lithium was increased weekly by 300 mg to maximum tolerated dose depending upon the patients response and tolerability. The starting dose of lithium was 900 mg and the dose of lithium was increased weekly by 300 mg to maximum tolerated dose depending upon the patients response and tolerability"
224308629|NCT00442039|DRUG|Lithium Carbonate|"The starting dose of lithium was 900 mg and the lithium dose was increased by 300 mg every 3 days, (no more than twice weekly) to maximum tolerated dose based upon the patients response and tolerability."
224308630|NCT00442039|DRUG|Placebo|During the third phase, which is the Discontinuation Phase, patients will be randomized to either placebo or lithium treatment for up to 28 weeks.
224308631|NCT01366430|PROCEDURE|Gufoni|For Gufoni maneuver, the patient was quickly brought down on the healthy side from the sitting position, and the head was then turned about 45 degree down, so that the nose was on the bed. After 2 minutes in this position, the patient was returned to the upright position.
224308632|NCT01366430|PROCEDURE|Sham|The sham maneuver the opposite of the first step for barbecue rotation; lying down from sitting position for 30 seconds, and head turn 90degree to the affected side for 1 minute, and then sit up.
224308633|NCT01366430|PROCEDURE|Barbecue|For barbecue rotation, the head was rotated rapidly 90degree while supine in the direction of the healthy ear, which was immediately followed by a truncal rotation of 90degree in the same direction to lie on the intact side. After 30-60 seconds when the induced nystagmus was dissipated, the patients were subjected to a further 90degree rotation of the head and trunk en block in the same direction to attain the nose-down position. After a further 30-60 seconds, the head was again turned in the same direction so that the affected ear was downward. Finally, after another 30-60s, the patient was brought to sitting position. Only one maneuver was performed per session.
224308634|NCT03122925|DEVICE|MR|MR
224073570|NCT02343471|DIETARY_SUPPLEMENT|20 g whey protein|
224073571|NCT02792842|DRUG|ART-123 (3-day ART)|ART-123 380 U/kg infusion once daily on days 1-3 in each cycle
224185382|NCT03996655|DRUG|Neostigmine|Reversal of neuromuscular blockers
224185383|NCT02967406|BEHAVIORAL|4 x 4 lifestyle modification|Participants in the intervention group will be given 4x4 lifestyle modification intervention, which will address four health behaviors (diet, physical activity, alcohol drinking and smoking) at four different levels: individual, household, knowledge management and community levels. A new computer program called 'iActive' adapted from the GPAQ with add-on functions to allow real-time assessment and presentation of the energy expenditure along with recommendations specific to each individual will be used. Dietary counseling will be given individually following assessment using a new dietary assessment program called Dietary Assessment Scanning Calculator. Home visit will be done every 3 months by responsible nurses and village health volunteers. Knowledge management will be done through meetings between participants and villages with support from trained nurses. Situation analysis and community action will be encouraged to address four health behaviors.
224308635|NCT00537303|DRUG|insulin detemir|Treat-to-target dose titration scheme (individually adjusted dose) for a once daily injection s.c. (under the skin)
224308636|NCT00537303|DRUG|insulin aspart|Administered 1 - 3 times daily, at largest prandial increment, injection s.c. (under the skin)
224308637|NCT00537303|DRUG|insulin aspart|Administered 1 - 3 times daily, at largest meals, injection s.c. (under the skin)
224308638|NCT01397643|OTHER|Non-operative|Patients in the non-operative arm will be managed conservatively using a sling, or an above elbow lightweight cast if problems with pain, for 10-14 days post injury. Patients will then be allowed to mobilise as able.
224308639|NCT01397643|OTHER|Operative|For those patients in the operative group, tension band wire of plate fixation will be employed depending on the choice of their supervising consultant. Following surgery, the post-operative assessment and course will be as per normal protocol for patients who are not in this study. Patients in the operative group will be immobilised depending on fracture fixation during surgery and the decision will be made by the treating surgeon. Physiotherapy will be arranged when required.
224308640|NCT01045538|DRUG|Vorinostat, capecitabine, and cisplatin|Vorinostat 200\~400mg per day on day1-day14 combined with capecitabine 800-1,000mg/m2/dose, BID on day1-day14, and cisplatin 60-80mg/m2 on day 1
223493739|NCT07141433|OTHER|LLM-Assisted Public Health Emergency Training Program|"A hybrid training program integrating the hospital's standard public health emergency (PHE) curriculum with Large Language Model (LLM) technology as an auxiliary learning tool. Participants receive:~* Standardized PHE training (online lectures + offline simulations) covering professional knowledge, skills, and emergency drills (e.g., infectious disease response, trauma management).~* LLM-enabled interactive support: Structured guidance to use LLMs for:~Reviewing session content Resolving knowledge uncertainties via Exploring unfamiliar PHE concepts~• Duration: 1 month, with 20-minute sessions. Distinguishing feature: Uses LLMs to dynamically adapt to individual learning needs, enabling on-demand knowledge reinforcement and overcoming spatiotemporal limitations of traditional training."
223493740|NCT07141433|OTHER|Standard Public Health Emergency Training Program|"The hospital's existing public health emergency (PHE) training program without AI augmentation. Participants receive:~* Identical core content as the experimental group: Professional knowledge, skills training, and emergency drills for PHE response (e.g., disaster protocols, infection control).~* Explicit restriction: Prohibited from using LLMs or any AI tools for learning support.~* Delivery: Hybrid format (online + offline), 1-month duration, 20-minute sessions.~Distinguishing feature: Represents traditional training methods reliant on instructor-led content without personalized, on-demand AI-driven reinforcement."
223588836|NCT03966131|DEVICE|Tongue pressure recordings with the PRESLA prothesis for the Arm2 (patients used to wear the complete denture)|These measures provide to establish a spatial and temporal mapping of contacts applied by the tongue and lips to the prosthesis during speech production in patients used to their prosthesis. They also provide to establish a spatial and temporal mapping of contacts applied by the tongue and lips to the prosthesis during swallowing) in these patients. The measurement is made at once when the new denture which replaces the old one is placed in the mouth.
223588837|NCT02516319|DRUG|ICG Dye|
224073572|NCT02792842|DRUG|ART-123 (1-day ART)|ART-123 380 U/kg infusion once on day 1 and placebo infusion once daily on days 2-3 in each cycle
224073573|NCT02792842|DRUG|Placebo|Placebo infusion once daily on days 1-3 in each cycle
224073574|NCT05904301|OTHER|Usual medical management of patients, additional blood and stool samples for biobanking|"For all systemic diseases the following data will be collected:~Clinical examination, Laboratory data, Current medications, Constitution of biobanking.~For each disease:~Pathology specific Activity score, Global subjective disease activity by patient and by physician."
224073575|NCT01345331|BEHAVIORAL|Real stimulation VS Sham|Ear stimulation at specific points should work by stimulating a nerve called the vagus nerve. Previous research has shown that stimulating this nerve can help patients feel less pain. During any testing session, participants may receive either the real ear stimulation or a sham (placebo) treatment. The sham treatment will use the same equipment as the real treatment, but will not deliver any real stimulation to the ear. We use placebo/sham procedures in research to make sure that the study results are related to the study procedure, and not to other reasons.
224073576|NCT03264430|DRUG|Ketamine|an antagonist of the NMDA receptor
224073577|NCT03264430|DRUG|bupivacaine|local anaesthetic
224073578|NCT02697383|DRUG|Ixazomib (MLN9708)|
224073579|NCT02697383|DRUG|Dexamethasone|
224073580|NCT06271265|DRUG|EXPAREL|A single dose of EXPAREL Injectable Product via LIA
224073581|NCT06271265|DRUG|bupivacaine|A single dose of 0.25% bupivacaine via LIA
224073582|NCT02258880|DRUG|SUN13837|
224073583|NCT02258880|DRUG|placebo|
224073584|NCT02401737|DRUG|NVR 3-778|
224073585|NCT02401737|DRUG|Placebo for NVR 3-778|Sugar pill manufactured to mimic the NVR 3-778 capsule
224073586|NCT02401737|DRUG|Pegasys|
224073587|NCT04710329|DRUG|Ascorbic acid|The daily administration of 6 grams of vitamin C intravenously in 4 equal doses every 6 hours occurred and the treatment lasted 96 hours. Vials containing 1.5 gr vitamin C were placed in 100 cc 5% dextrose and infused intravenously in 30-60 minutes. Prepared serum bottles and sets are wrapped with aluminum foil in order to protect them from sunlight.
224073588|NCT04703894|DIETARY_SUPPLEMENT|AYMES 'CARDIFF'|AYMES CARDIFF is a Food for Special Medical Purposes (FSMP) and must, therefore, be used under medical supervision. It is not designed as a sole source of nutrition.
224073589|NCT01349166|BEHAVIORAL|Behavior: Supervised physical training|protocol designed to evaluate effects of physical activity on cardiometabolic and inflammatory biomarkers according to glucose tolerance
224073590|NCT06540950|DRUG|vinorelbine|Vinorelbine is administered orally at 60mg per square meter per week by body surface area before radiotherapy and continued to be administered at 30mg per square meter per week during radiotherapy until the end of radiotherapy. Within 6 weeks after the end of radiotherapy, there are no serious side effects, and immune checkpoint inhibitors monotherapy can be performed.
224073591|NCT06237517|BEHAVIORAL|Assessment of Vasomotion of People With Idiopathic Chilblains|Investigation of vasomotion of people with and without idiopathic chilblains
224073592|NCT02571010|OTHER|Standard Medical treatment|Standard treatment with drugs and usual rehabilitation
224073593|NCT02571010|DEVICE|Vibrotactile stimulation|Rehabilitation by vibrotactile stimulation at medical center
224073594|NCT02571010|DEVICE|Sham Stimulation with Vibradol device switched off|Sham Rehabilitation at medical center but with Vibradol device switched off
224073595|NCT01390259|DEVICE|Open-Loop|This admission was to assess the subjects' level of glucose control and created a base to compare the performance of the closed-loop system. Subjects monitored their own blood glucose values and administer their basal/bolus as they would at home. Otherwise, the admission remained the same as in the closed-loop admission (i.e. meals, exercise, etc...).
224073596|NCT01390259|DEVICE|Closed-Loop|In this study, the researchers compared the management of diabetes during physical activity and meals with the closed-loop system developed at the University of Virginia. This system uses two DexComTM Seven Continuous Glucose Monitor, a computer containing an investigational control algorithm (well-defined instructions that are expressed in mathematical equations), and an OmniPod Insulin Management System, a portable subcutaneous (under the skin) insulin pump. During the closed-loop admission, the computer based algorithm used CGM values to make recommendations of insulin treatment. The study included a challenge to the insulin management system with meals and mild exercise, so as to demonstrate its capacity to avoid large glucose excursion with changing metabolic state.
224073597|NCT04929171|OTHER|Physical Therapy|Physical therapy for chronic upper quarter myofascial pain syndrome, as prescribed by the patients' physicians
223588838|NCT02744989|DEVICE|Neuroconn or Neuroelectric tDCS stimulator|Stimulation parameters were chosen in conformity with those for the treatment of schizophrenic symptoms (Brunelin et al, 2012), adapted according to the latest data from the literature and the tDCS operating stimulator. The experimental tDCS group will receive the ACTIVE stimulation with the following parameters: oscillatory Direct Current with high frequency random noise stimulation (hf-tRNS - 100 to 500 Hz), Intensity = 2 mA, offset = + 1 mA, seance duration = 20 minutes ramp up/ramp down 30 seconds. Total number of sessions = 10 (sessions twice daily for 5 days separated by at least 2 hours for 5 consecutive weekdays).
223588839|NCT02744989|DEVICE|Sham tDCS|The control group will receive the SHAM stimulation (placebo) following the same regimen (i.e., twice daily sessions separated by at least 2 hours for 5 consecutive weekdays). Sham stimulation consists of a 20 minutes session including 40 seconds of active stimulation (same parameters as in the ACTIVE arm) at the beginning of the sessions, whatever the stimulator
224185384|NCT00955682|BIOLOGICAL|Meningococcal vaccine GSK134612|One intramuscular dose (Booster)
224185385|NCT00955682|BIOLOGICAL|Meningitec™|One intramuscular dose (Booster)
224185386|NCT03085160|BEHAVIORAL|Learning to Breathe|Six-session group program that involves meditation and interactive activities to learn mindfulness skills for coping with stress
224185387|NCT03085160|BEHAVIORAL|Health Education|Six-session group program that covers topics important for healthy living such as avoiding drug use, conflict resolution, bullying, sun safety and others
224185388|NCT01251666|OTHER|Colonoscopy|Colonoscopy if at least one of the faecal occult blood tests is positive (blinded to each test result)
223588840|NCT03094065|OTHER|News items with spin|Interpretation of news items with spin
223588841|NCT03094065|OTHER|News items without spin|Interpretation of news items without spin
223588842|NCT02488460|BEHAVIORAL|Physically active math lessons|The intervention consists of a nine month period with physical activity as part of, and integrated, in math lessons
224185389|NCT02926833|BIOLOGICAL|KTE-C19|A single infusion of KTE-C19 CAR-T cells administered intravenously
224185390|NCT02926833|BIOLOGICAL|Atezolizumab|Administered intravenously
224185391|NCT02926833|DRUG|Cyclophosphamide|Administered intravenously
224185392|NCT02926833|DRUG|Fludarabine|Administered intravenously
224185393|NCT00329433|DRUG|Desirudin (Iprivask™)|Patients who are randomized to the desirudin (study) group will receive 15 mg of subcutaneous desirudin twice a day (at 0900 and 2100). These patients will also receive an injection of normal saline placebo at 1300 so that patients in both groups will receive three injections at the same time points.
224185394|NCT00329433|DRUG|Heparin|The patients who are randomized to the Heparin (standard of care) group will receive subcutaneous injections of heparin three times a day (0900, 1300 and 2100).
224185395|NCT04085120|PROCEDURE|0.75 % Ropivacaine/ 4mg/mL dexamethasone injection|Distal glossopharyngeal nerve in the neck will be blocked by using 0.75 % Ropivacaine/ 4mg/mL dexamethasone injection
224185396|NCT04085120|PROCEDURE|10% lignocaine injection|Distal glossopharyngeal nerve in the neck will be blocked by using 10% lignocaine injection
224185397|NCT05741762|OTHER|Retrospective chart review|The retrospective chart review will be done for patient admitted into ICU between 01/06/2017 to 01/06/2022
224185398|NCT01189201|DRUG|BI 10773/linagliptin|medium single dose of BI 10773/linagliptin FDC (Formulation A1)
224185399|NCT01189201|DRUG|BI 10773/linagliptin|medium single dose of BI 10773/linagliptin FDC (Formulation A3)
223588843|NCT06210555|PROCEDURE|Renal transplantation|Operative procedure - receipt of a kidney
223588844|NCT06210555|PROCEDURE|Living kidney donation|Operative procedure - donation of a kidney
223588845|NCT02136147|DRUG|methylphenidate medication|
223588846|NCT02136147|DRUG|atomoxetine medication|
223588847|NCT02136147|DRUG|lisdexamphetamine medication|
223588848|NCT02136147|DRUG|guanfacine medication|
223588849|NCT04772508|PROCEDURE|Scaling and root planing|15 sites with periodontal pockets ≥ 5mm received only SRP
223588850|NCT04772508|BIOLOGICAL|Amnion membrane|15 sites with periodontal pockets ≥ 5mm received SRP along with placement of amnion membrane.
223588851|NCT04772508|DRUG|Taurine|15 sites with periodontal pockets ≥ 5mm received SRP along with placement of amnion membrane hydrated with taurine.
223588852|NCT02881619|DRUG|Etodolac|The patient will receive a single-dose of Etodolac (400 mg) one hour before the bleaching procedure.
223588853|NCT02881619|DRUG|Placebo|The patient will receive a single-dose of placebo one hour before the bleaching procedure.
223588854|NCT04480255|OTHER|Group 1: Standard of Care|"Those who are in Group 1 will receive the usual care which includes:~1. a welcome packet from the nursing staff~2. access to their infant's medical team including doctors and nurse~3. opportunities to ask any questions and understand the care their baby is receiving through participation in daily work rounds or through setting up family meetings with the medical team."
224073598|NCT02710357|PROCEDURE|Mandibular Overdenture|Placement of an implant in the mandibular midline.
224073599|NCT02710357|PROCEDURE|Mandibular complete denture|No intervention. Maintenance of the dentures will be done when needed.
224073600|NCT01226238|OTHER|Online self-help|Provision of online self-help
224073601|NCT00000645|DRUG|Hypericin|
224073602|NCT02981836|BIOLOGICAL|Investigational live attenuated varicella vaccine|The investigational vaccine was manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd.
224073603|NCT02981836|BIOLOGICAL|diluent of lyophilized vaccine|The diluent of lyophilized vaccine was manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd.
224073604|NCT02361645|DRUG|Ketorolac 0.5% eyedrops|
224073605|NCT02361645|DRUG|Indomethacin 0.5% eyedrops|
224073606|NCT02361645|DRUG|Bromfenac 0.09% eyedrops|
224073607|NCT02361645|DRUG|Nepafenac 0.1% eyedrops|
224185400|NCT01189201|DRUG|BI 10773/linagliptin SID|medium single dose of mono components BI 10773/linagliptin
224185401|NCT01189201|DRUG|BI 10773/linagliptin FDC|medium single dose of BI 10773/linagliptin FDC (Formulation A1) after high fat, high caloric meal
224185402|NCT05324774|DRUG|9MW0813|"The active ingredient of 9MW0813 injection is recombinant human vascular endothelial growth factor receptor-antibody fusion protein.~9 doses(2mg) of the drug will be injected intravitreously."
223493741|NCT07141355|DIAGNOSTIC_TEST|microcirculation using the video microscopy tool.|"The study intervention is the assessment of microcirculation using the video microscopy tool.~This study's primary purpose is to perform this specific diagnostic procedure-measuring microcirculatory parameters with the CytoCam-IDF device-at two distinct time points: at inclusion (H0) and again 48 hours later (H48).~The administration of empagliflozin (or not), which is pa and 48 hours after initiating empagliflozin treatment, microcirculatory data will be collected using a videomicroscope. A camera, roughly the size of a large pen, is placed under the patient's tongue for a few seconds to acquire images of the sublingual microcirculation. The entire image acquisition process takes less than 5 minutes and is unaffected by whether the patient is intubated.~Images are then analyzed in real-time by the MicroTools software, which calculates key microcirculatory parameters.~All anonymized images are stored on a dedicated, password-protected computer accessible only to the investigators."
223588855|NCT04480255|OTHER|Group 2: NICU2HOME+ app|In addition to the usual care made available to Group 1 as described above, Group 2 parents will receive the smartphone app. Group 2 parents will be asked to download the NICU2HOME app.
223588856|NCT05325476|OTHER|JomPrEP App|The JomPreP app will be ideally designed to optimize HIV prevention cascade by providing a virtual platform to access to HIV prevention (e.g., HIV testing and PrEP) and other support services (e.g., mental health). The JomPrEP app will be available on the Apple Store and the Google Play Store for the users to download. However, access to the app will be restricted to the research participant using a unique registration code.
223588857|NCT05325476|OTHER|Inactivated JomPrEP app|Participants will have access to the JomPrEP app with major intervention features inactivated. Information and resources for HIV testing, PrEP, and available mental health and addiction services will be available along with access to risk assessment tools. The RA will assist in downloading the app and provide a tutorial in using the assessment tool of the app.
223588858|NCT05856227|DRUG|Ceftobiprole medocaril|Ceftobiprole medocaril: 7.5 mg/kg every 12 hours to 15 mg/kg every 8 hours, administered IV as a 2-hour infusion.
224073608|NCT03725618|BIOLOGICAL|Yellow Fever 17DD Vaccine|live attenuated vaccine based on the 17DD strain
224185403|NCT05324774|DRUG|Aflibercept|"Aflibercept (trade name: Eylea®/EYLEA®) is an anti-VEGF drug developed by Regeneron/Bayer. It is a fusion protein of human VEGFR1 and VEGFR2 extracellular domains and human immunoglobulin Fc segment genes.~9 doses(2mg) of the drug will be injected intravitreously."
224185404|NCT03011931|DRUG|Simvastatin|20 mg Simvastatin given, Blood draw, Urine collection, Celiac serology testing, DNA sampling, Dietary review
224185405|NCT02776631|DEVICE|Pinloc|Internal fixation device
224185406|NCT02776631|DEVICE|Hansson Pins (LIH)|Internal fixation device
224185407|NCT01277757|DRUG|Akt Inhibitor MK2206|Given orally (PO) weekly, starting (dose 0) at 200 mg
224185408|NCT01277757|OTHER|Laboratory Biomarker Analysis|Correlative studies
224185409|NCT01277757|OTHER|Pharmacological Study|Correlative studies
224185410|NCT02503969|OTHER|Exposure to having a long-term condition.|"Long-term conditions are self-reported: twelve named conditions are recorded, along with an other condition - these shall all be considered with the exception of the named condition cancer."
223493742|NCT07141160|OTHER|Combined: Mobile app + 6WELLS|Mobile based digital toolkit for cognitive health, remote assessment and multi-component intervention, comprising the 4 key pillars of assessment; cognitive training and stimulation; cognitive wellness; and dual-task training. Together with onsite 6 WELLS Group-Based Activity is a structured, group-based, cognitive health promotion programme that aims to build communities of practice, stimulate goal attainment, and drive behavioural change towards cognitive health and wellbeing. The curriculum is delivered via a 10-week onsite programme comprising weekly facilitated small-group activities centred on six key components.
224185411|NCT01491152|DEVICE|Galileo® tilt table for children|Two weeks of introduction and 12 weeks of training with side-alternating whole body vibration (WBV) (Galileo® tilt table)
224185412|NCT04667611|BEHAVIORAL|Psychosocial interventions|Cognitive behavioural therapy (CBT) based individual and group intervention
224185413|NCT06189482|DEVICE|Intermittent Oral-esophageal Tube Feeding|During the 15-day treatment, both groups of patients are hospitalized, while conventional care and enteral nutrition support are provided to the two groups. Specifically, conventional care includes health education, dietary adjustments, nasopharyngeal hygiene, management of risk factors (blood pressure and lipid control, etc.), exercise rehabilitation, and psychological support. The frequency and content of these interventions are arranged based on the patients\&#39; health condition.The observation group receives IOE for enteral nutrition support (developed by the Dysphagia Institute of Zhengzhou University, CN201821314797.2, as shown in the Appendix), which is made of silicone material, 40 cm long, with an inner diameter of 0.54 cm.
224185414|NCT06189482|DEVICE|nasogastric tube feeding|During the 15-day treatment, both groups of patients are hospitalized, while conventional care and enteral nutrition support are provided to the two groups. Specifically, conventional care includes health education, dietary adjustments, nasopharyngeal hygiene, management of risk factors (blood pressure and lipid control, etc.), exercise rehabilitation, and psychological support. The frequency and content of these interventions are arranged based on the patients\&#39; health condition.The control group is provided with nutritional support as NGT, performed 6-10 times per day according to relevant guidelines, with an interval of more than 2 hours between every two feedings, and a feeding volume not exceeding 200 ml per time.
224185415|NCT02914873|PROCEDURE|Active surveillance|Active monitoring of prostate cancer and curative treatment if there are signs of tumor progression.
224185416|NCT03425240|DEVICE|Nerve Stimulation|Acute placement of electrodes on the pelvic plexus to apply electrostimulation during open radical prostatectomy.
223493743|NCT07141160|OTHER|Remote mobile based app|Mobile based digital toolkit for cognitive health, remote assessment and multi-component intervention, comprising the 4 key pillars of assessment; cognitive training and stimulation; cognitive wellness; and dual-task training.
223493744|NCT07140757|OTHER|Questionnaire|This questionnaire includes twenty-four questions covering patients complaints ranging from 0 to 4. Patients will be asked about the presence and severity of each item currently on the medical appointment.
224185417|NCT04308668|DRUG|Hydroxychloroquine|200mg tablet; 800 mg orally once, followed in 6 to 8 hours by 600 mg, then 600mg once a day for 4 consecutive days
224073609|NCT01716481|OTHER|Mesenchymal stem cell|intravenous transplantation of autologous mesenchymal stem cells expanded with autologous serum
224073610|NCT03390179|DRUG|Steroid Drug|mesure of the glucose concentration
223493745|NCT07142564|OTHER|Carrier Care (CC)|Carrier care uses an infant carrier to secure the infant to the caregiver, while SSC does not have a securing device. The caregiver holds the infant with their arms.
223493746|NCT07141940|OTHER|Indonesian-language application-based auditory guided imagery therapy|This study used a mobile application developed by researchers using Indonesian language to deliver an auditory guided imagery therapy
223588859|NCT02984540|OTHER|Low-Carbohydrate Diet|Participants assigned to the Modified Ketogenic-Mediterranean Diet will keep their carbohydrate consumption below 20 grams per day throughout the 6-week intervention.
224185418|NCT04308668|OTHER|Placebo|4 placebo tablets once, followed in 6 to 8 hours by 3 tablets, then 3 tablets once-a-day for 4 consecutive days
224185419|NCT05033821|BEHAVIORAL|Adapted FOY+ImPACT|The Adapted FOY+IMPACT is a selective, group-level intervention designed to prevent sexual risk-taking and substance use among adolescents affected by parental drug use. There are eight sessions for youth (FOY) and one session with youth and adults (ImPACT).
224185420|NCT03584399|OTHER|PICS in critically ill pediatric population|Collection of additional blood sample from those subjects meeting criteria for the study.
224185421|NCT01308385|OTHER|Conditioned pain modulation|When evaluating conditioned pain modulation, pressure pain threshold in the musculus quadriceps femoris act as test stimulus and 2 minutes cold pressor test (stirred ice and water) acts as the conditioning stimulus. The difference between pain thresholds before and after the cold pressor test is defined as the effect of CPM.
224185422|NCT02919709|BIOLOGICAL|blood taking|
224185423|NCT01336647|DRUG|Group A - Low-Dose Ha44 0.37% w/w|Low Dose Ha44 Gel applied to scalp and hair for 10 minutes
224185424|NCT01336647|DRUG|Group B - High Dose Ha44 Gel 0.74% w/w|High Dose Ha44 Gel applied to scalp and hair for 10 minutes
224185425|NCT01336647|DRUG|Group C - Placebo|Placebo- vehicle Ha44 Gel without active ingredient applied to scalp and hair for 10 minutes
224185426|NCT03808298|DRUG|Balovaptan therapeutic dose Treatment A|Days 1-14: A single once daily dose at dose level A of balovaptan for 14 days
224185427|NCT03808298|DRUG|Balovaptan supra-therapeutic dose Treatment B|Days 1-14: A single once daily oral dose at dose level B of balovaptan for 14 days.
224185428|NCT03808298|DRUG|Active control [moxifloxacin] on Day 2 Treatment C|Day 2: A single oral dose of 400 mg moxifloxacin capsule.
224185429|NCT03808298|DRUG|Active control [Moxifloxacin] on Day 15 Treatment D|Day 15: A single oral dose of 400 mg moxifloxacin capsule.
224185430|NCT03808298|DRUG|Placebo for Balovaptan Treatment C|Days 1-14: Matching placebo for balovaptan for 14 days.
224185431|NCT03808298|DRUG|Placebo for Balovaptan Treatment D|Days 1-14: Matching placebo for balovaptan for 14 days.
223493747|NCT07141940|OTHER|Psychoeducation|Psychoeducation consists of sleep hygiene and relaxation therapy (breathing exercise, progressive muscle relaxation, and guided imagery)
223493748|NCT07141758|DIAGNOSTIC_TEST|ELISA|Unstimulated saliva samples will be non-invasively collected from participants in this study to measure the concentrations of E-cadherin, Calprotectin, and MMP-9. These protein concentrations will be quantified using commercially available Enzyme-Linked Immunosorbent Assay (ELISA) kits.
224185432|NCT03808298|DRUG|Placebo for Moxifloxacin Treatment A|Day 2 and 15: A single oral dose of a matching placebo capsule for moxifloxacin.
224185433|NCT03808298|DRUG|Placebo for Moxifloxacin Treatment B|Days 2 and 15: Single oral dose of a matching placebo capsule of moxifloxacin.
224185434|NCT03808298|DRUG|Moxifloxacin Treatment C|Day 2: A single oral dose of 400 mg moxifloxacin capsule.
224185435|NCT03808298|DRUG|Placebo for Moxifloxacin Treatment C|Day 15: A single oral dose of a matching placebo capsule for moxifloxacin.
224185436|NCT03808298|DRUG|Placebo for Moxifloxacin Treatment D|Day 2: A single oral dose of a matching placebo capsule for moxifloxacin.
223588860|NCT02984540|OTHER|Low-Fat Diet|Participants assigned to the Low-Fat Diet will be encouraged to limit their amount of fat intake to \<40 grams/day, while eating plentiful fruits, vegetables, and carbohydrates containing adequate fiber.
224185437|NCT03808298|DRUG|Moxifloxacin Treatment D|Day 15: A single oral dose of 400 mg moxifloxacin capsule.
224185438|NCT03160092|OTHER|Intervention|"The intervention aims to:~* Support the participant to explore their unusual experiences~* Reduce the distress or anxiety participants feel in response to their unusual experiences, through:~  * Helping them to recognise how common these unusual experience~ * Supporting them to make sense of their unusual experiences~ * Supporting them to understand why they may be experiencing these symptoms~ * Challenging any unhelpful beliefs they hold about their symptoms~* Help the participant to recognise the triggers to their unusual experiences~* Support the participant to increase their activities and socialisation~The intervention is not aiming to 'get rid' of the participant's symptoms, but to reduce their distress in response to them, which may result in improved wellbeing and reduced symptoms."
224185439|NCT06045468|OTHER|Amputation-specialized rehabilitation|Study center; amputation-specialized unit within rehabilitation facility; fully practicing national guidelines
224185440|NCT06045468|OTHER|Non-amputation-specialized rehabilitation|Control clinics; treating some amputated patients each year but do not practice national guidelines or partially practicing national guidelines
224185441|NCT05033769|DRUG|Eribulin Injection [Halaven]|on days 1 and 8 q21d
224185442|NCT05033769|DRUG|Paclitaxel injection|on days 1, 8, and 15 q21d
224185443|NCT00077896|PROCEDURE|Direct Current Polarization|
223493749|NCT07141511|DRUG|BG-71332|Administered orally
223493750|NCT07141511|DRUG|Zanubrutinib|Administered orally
223493751|NCT07141511|DRUG|Sonrotoclax|Administered orally
223493752|NCT07142343|DRUG|Pozelimab|Administered per the protocol
223493753|NCT07142161|DRUG|RD13-02 cell infusion|CAR T-cell therapy administered intravenously after a lymphodepleting therapy regimen consisting of fludarabine and cyclophosphami
223493754|NCT07141602|DIAGNOSTIC_TEST|lateral cephalometric x- ray and dental panoramic tomogram|lateral cephalometric x- ray and dental panoramic tomogram
224185444|NCT02117466|DRUG|Dose escalation cetuximab|dose escalation of cetuximab (described in the second arm)
224185445|NCT02117466|DRUG|Standard dose cetuximab|500mg/m2 bsa cetuximab (described in the first arm)
223493755|NCT07140848|BEHAVIORAL|CGM-DPP|Participants in the DPP who receive personalized CGM coaching.
224185446|NCT05237843|DRUG|Hydroxychloroquine|Besides anti-thrombotic effects, hydroxychloroquine have immunoregulatory properties and can block the production of pro-inflammatory cytokines ( Mekinian A et al ,2015 ) , Few in vitro studies showed a potential benefit of hydroxychloroquine in early trophoblastic migration and implantation. Hydroxychloroquine restored trophoblastic fusion and differentiation and restored the annexin A5 expression.( Guller S et al ,2011 )
224185447|NCT01801475|DRUG|Ondansetron|Pregnant \& non-pregnant women will receive either 4mg or 8mg of Ondansetron (IV) once prior to surgical procedure (open-label). Women are in the study for 8 hours. Babies of pregnant women are not given Ondansetron but are in the study for 24-48 hours.
224185448|NCT00421928|DRUG|oxycodone|10, 20, 30, 40, 50mg twice a day (BID) during 15 weeks
224185449|NCT00421928|DRUG|placebo|matching placebo twice a day (BID) during 15 weeks
224185450|NCT00421928|DRUG|tapentadol (CG5503)|50, 100, 150, 200, 250mg twice a day (BID) during 15 weeks
224185451|NCT04854928|DRUG|LTX-109 gel, 3%|A Single dose of LTX-109 gel will be applied topically to both nostrils by a qualified health professional. A large drop of IMP will be applied into each nostril and distributed to cover the whole area of the nostril.
224185452|NCT04854928|DRUG|Placebo gel|A Single dose of placebo gel will be applied topically to both nostrils by a qualified health professional. A large drop of IMP will be applied into each nostril and distributed to cover the whole area of the nostril.
224185453|NCT00444028|DRUG|inhaled Loxapine 0.625 mg|Single 0.625 mg (lowest) dose of inhaled loxapine
224185454|NCT00444028|DRUG|inhaled Loxapine 1.25 mg|Single 1.25 mg (2nd) dose of inhaled loxapine
224185455|NCT00444028|DRUG|inhaled Loxapine 2.5 mg|Single 2.5 mg (3rd) dose of inhaled loxapine
224185456|NCT00444028|DRUG|inhaled Loxapine 5 mg|Single 5 mg (4th) dose of inhaled loxapine
224185457|NCT00444028|DRUG|inhaled Loxapine 10 mg|Single 10 mg (5th) dose of inhaled loxapine
224185458|NCT00444028|DRUG|inhaled Placebo (0 mg)|Single placebo dose of inhaled loxapine
224185459|NCT00201266|PROCEDURE|Screening|Characterization tests including blood group typing, measures of lung function, measures of allergy, and collection of DNA.
224185460|NCT06363227|PROCEDURE|Standardized pain management|multimodal postoperative pain protocol
224185461|NCT04034329|PROCEDURE|ASVAL|Ambulatory Selective Varices Ablation under Local Anesthesia
224185462|NCT04034329|PROCEDURE|EVLA|Endovenous Laser Ablation
224185463|NCT00000565|PROCEDURE|intermittent positive-pressure breathing|
224185464|NCT06248866|OTHER|Extracorporeal Shock Wave Therapy|The affected hand or fingers will be positioned comfortably to ensure optimal access to the fibromatosis lesion. Gel or oil will be applied to the skin to enhance the transmission of shock waves. Shock wave therapy will be administered using the selected energy level and frequency settings. Energy level and frequency will be customized based on individual patient requirements. (1000-1500 shock/session, frequency between 5-12HZ, compression power of 1.5- 2.5 bars).and will receive traditional treatment
224185465|NCT06248866|OTHER|traditional treatment|the patients will receive traditional treatment in the form of laser (A low-level laser device with a wavelength of 830 nm and power output of 50 mW will be used as one Of the pain relief methods), ultrasound (An ultrasound device with a frequency of 1 MHz and an intensity of 1.5 W/cm² will be used), stretching and strengthening exercise and splinting.
224185466|NCT01469416|DRUG|Rosuvastatin|Rosuvastatin 20 mg PO x 1
224185467|NCT01469416|DRUG|Clopidogrel|Clopidogrel 300 mg PO x 1 (30 minutes prior to rosuvastatin dose); Clopidogrel 75 mg PO x 1 (24 hours post-rosuvastatin dose)
224185468|NCT02695316|OTHER|Focus Group Discussion in native Language|Group Interview with semi-structured key question, moderated in the native language of the participants. Interpreters translate the discussion for the Researcher analogically and adapt it culturally. The discussions are audio-recorded, summarized, translated and transcribed into German.
224185469|NCT02695316|OTHER|Focus Group Discussion|Group Interview with semi-structured key question, audio-recorded and ad verbatim transcription
224185470|NCT02695316|OTHER|One-to-one Interview|One-to-one Interview with semi-structured key question, audio-recorded and ad verbatim transcription.
224185471|NCT02695316|OTHER|Retrospective Quantitative Analysis|Retrospective Quantitative Analysis of questionnaires (Telephone Interpreting Protocols)
223493756|NCT07140848|BEHAVIORAL|Control|Participants in control group will be referred to DPP.
223493757|NCT07142239|DIAGNOSTIC_TEST|• Complete blood count , MPV|CBC report
224185472|NCT00002110|DRUG|Cysteamine|
224185473|NCT00002110|DRUG|Zidovudine|
223493758|NCT07142239|DIAGNOSTIC_TEST|Calculation of PLR: Platelet count / Lymphocyte count and Calculation of NLR:|CBC report
223493759|NCT07142239|DIAGNOSTIC_TEST|Antiphospholipid antibody profile|Patient record
223493760|NCT05922085|OTHER|Ultrasound|performed within 3 hours prior to extubation
223493761|NCT05922085|OTHER|nasofibroscopie|performed within 24 to 36 hours after extubation
224185474|NCT05915455|OTHER|HCP-facing Portfolio Diet Infographic + Informative Video|Resources to evaluate include the healthcare professional-facing Portfolio Diet infographic (1-page) and 4-minute accompanying video
224185475|NCT05915455|OTHER|Portfolio Diet Application|Resource to evaluate includes the Portfolio Diet mobile application
224185476|NCT04784806|OTHER|Ground beef|Subjects will consume a 106g patty of cooked ground beef.
224185477|NCT04784806|OTHER|Ground pork|Subjects will consume a 118g patty of cooked ground pork
223493762|NCT00676884|DRUG|Aeroderm (also known as pitrakinra, AER 001, BAY 16-9996)|30 mgs s.c. b.i.d.
223493763|NCT00676884|DRUG|placebo|1.5 mL s.c. b.i.d.
223493764|NCT06219005|BEHAVIORAL|ultrasound education and simulation workshop|workshop testing emergency physician knowledge and technical skills in performing ultrasound-guided nerve blocks in a simulation model
223493765|NCT05892198|PROCEDURE|surgery|surgery with primary closure, Rhomboid flap , or Rotational flap
224185478|NCT04784806|OTHER|Tofu|Subjects will consume a 113g patty of cooked tofu
224185479|NCT04784806|OTHER|Beyond Meat|Subjects will consume a 113g BeyondMeat patty.
224185480|NCT06463132|COMBINATION_PRODUCT|PEP/Euflexxa|Euflexxa (PMA: P010029)
224185481|NCT06463132|DRUG|PEP|PEP (Purified Exosome Product)
224185482|NCT03175809|OTHER|PFM training|The PFM training will be delivered with an electromyographic biofeedback (bEMG). In order to perform the muscular training, the Biotrainer software was used, the training protocol will follow a rationale of evolutionary complexity throughout each session. The training protocols will focus on both muscle relaxation and contraction training and coordination.The parameters for the biofeedback will be tailored to the participant's presentation and will be determined and adjusted between each session as needed by the treating therapist. The treatment parameters will be determined by the treating therapist based on the participant's assessment that will be conducted at each treatment session. The Maximum voluntary contraction will be assessed at the beginning of each training day.
224185483|NCT03175809|OTHER|Dry needling|The dry needling technique will be applied to the abdominal muscles (external oblique, rectus abdominis), lumbar spine (lumbar multifidus and erector spinae) and hip muscles (piriformis, gluteus medius, psoas major and adductors). Both active of latent myofascial trigger points will be treated with sterile stainless steel needles (0.25x0.4 mm or 0.2x0,7mm, DongBang, Korea). After diagnosis of the area of muscle pain, the tight band of the muscle will be palpated and the needle will be introduced subcutaneously. The second insertion will be toward the muscle point until a local twitch response (LTR) is elicited. Then the needle will be removed and the area will be compressed for 30 seconds.
224185484|NCT00039429|DRUG|atrasentan hydrochloride|
224185485|NCT02138227|BEHAVIORAL|Assisted CEaD Condition|In the assisted condition, participants use the CEaD training materials supplemented with simulators to practice the communication skills. OPO requesters will be assisted by having the CEaD DVD supplemented through working the scenarios with live simulated patients who will be trained to act out the scenarios with the OPO requesters and provide feedback.
224185486|NCT02138227|BEHAVIORAL|Autonomous CEaD Condition|In the autonomous condition, participants view the CEaD training materials on a DVD along with a self-training guide.
223493766|NCT00639093|BEHAVIORAL|psychoeducational / motivational combined with crushing|"All participants will receive an eight-session psychoeducational and motivational program. During the first four weeks, all participants will be immersed in virtual reality (VR).~During the immersions in VR, 45 of the participants will use a virtual reality arm to catch and crush virtual cigarettes (on a computer)."
223493767|NCT00639093|BEHAVIORAL|psychoeducational / motivational combined with control|"All participants will receive an eight-session psychoeducational and motivational program. During the first four weeks, all participants will be immersed in virtual reality (VR).~During the immersions in VR, the 45 participants in the control condition will use a virtual reality arm to catch and crush virtual fruits (on a computer)."
223493768|NCT04926415|DEVICE|taVNS|A bipolar clip electrode is attached to the auricle at the location of the cymba conchae. Electrical stimulation (30 Hz stimulation frequency, 300 μs pulse width) is applied for 30 min. The stimulation current is determined individually for each participant by slowly increasing the stimulation current until the participants feel a mild tingling sensation at the site of the electrode. Then the current is gradually reduced until the tingling sensation disappears. This current will then be used for taVNS. A TENS 7000 or EMS 7500 device (510(k): K080661) is used.
223493769|NCT04926415|DEVICE|Sham taVNS|A bipolar clip electrode is attached to the auricle at the location of the cymba conchae but no electrical current is applied to the electrode.
223588861|NCT05849376|BEHAVIORAL|Emergent Multi-Class Imitation Training|Sessions will be conducted in a room with minimal distractions containing a table, two chairs, a timer, and 3-4 highly preferred (HP) items identified by preference assessments. A maximum of 10 sessions per week will be distributed across at least 3 days per week. Each session will take 15-20 min to conduct. Novel probe trials will be embedded throughout all sessions to continuously assess for the emergence of generalized imitation. When participants can consistently imitate novel probe responses, the intervention will conclude.
223588862|NCT05881252|PROCEDURE|Clinical blood pressure threshold of SBP >= 160 mmHg for acute treatment of hypertension|Patients are treated for hypertension if SBP \>= 160 mmHg.
223588863|NCT05881252|PROCEDURE|Clinical blood pressure threshold of SBP >= 180 mmHg for acute treatment of hypertension|Patients are treated for hypertension if SBP \>= 180 mmHg.
223588864|NCT06634134|BEHAVIORAL|Adjusting training advice|Based on discomfort related to the menstrual cycle the female cyclist can choose to adjust the suggested training.
223588865|NCT03950492|DEVICE|Deep Brain Simulator|This is an open-label, safety, tolerability, and feasibility study for participants who have treatment refractory OUD that are eligible to have DBS targeting the NAc/VC.
224185487|NCT02608073|DRUG|Capecitabine|Participants will receive oral capecitabine, 1000 mg/m\^2 BID on Days 1 to 14 of each 21-day cycle, for up to 8 treatment cycles (24 weeks).
224185488|NCT02608073|DRUG|Cisplatin|Participants will receive cisplatin, 100 mg/m\^2 via IV infusion on Day 1 of each 21-day cycle, for up to 8 treatment cycles (24 weeks).
224185489|NCT03194724|OTHER|Vitamin A supplementation|Bi annual vitamin A supplementation programme
224185490|NCT02228148|DEVICE|NFS|Cochlear Nucleus Fitting Software
224185491|NCT02228148|DEVICE|CSS|Cochlear Nucleus Custom SoundTM Suite
223493770|NCT00128388|OTHER|PFPP|Psychoanalytic Psychotherapy for panic disorder
223493771|NCT00128388|OTHER|ART|Applied Relaxation Training
223493772|NCT01089595|DRUG|Nilotinib|Nilotinib 400 mg po bid
223493773|NCT01089595|DRUG|Nilotinib with Imatinib|Nilotinib 400 mg po BID Imatinib 400 mg po daily
223493774|NCT01816607|PROCEDURE|new functional magnetic resonance imaging (MRI) protocols|diffusion-weighted MRI, dynamic-contrast enhanced MRI, MR spectroscopy, blood-level oxygen dependent (BOLD) MRI
223493775|NCT00376844|RADIATION|External Beam Radiation Therapy|
223493776|NCT00376844|RADIATION|Vaginal Brachytherapy|
223493777|NCT02210754|OTHER|blu™ Classic Tobacco rechargeable (2.4% nicotine, glycerin vehicle)|electronic cigarettes
223493778|NCT02210754|OTHER|blu™ Classic Tobacco rechargeable (2.4% nicotine, glycerin/PG vehicle)|electronic cigarettes
223493779|NCT02210754|OTHER|blu™ Magnificent Menthol rechargeable (2.4% nicotine, glycerin vehicle)|electronic cigarettes
223493780|NCT02210754|OTHER|blu™ Classic Tobacco rechargeable (1.6% nicotine, glycerin vehicle)|electronic cigarettes
224185492|NCT03152721|DEVICE|Parkinson KinetiGraph|The Parkinson Kinetigraph (PKG) is a wrist-worn accelerometer shaped as a watch. It records spontaneous movements and for every two minutes provides a bradykinesia score and a dyskinesia score. Furthermore it analysis movement for tremor-like episodes and registers the time with tremulous movements as well as time with extreme immobility suggesting sleep. The device can be programmed with drug intake times and provide a reminder signal. Intake of drug can be indicated on the device.
224185493|NCT03152721|OTHER|Self assessment|Administration of self assessment questionnaires are made within 2 weeks from starting a PKG recording. The assessments are Parkinson Disease Quality of life 8 question short version and the Non Motor Symptom in Parkinson Disease Questionnaire.
224185494|NCT04156802|DEVICE|Real TBS to the mPFC|This will be delivered with the Magventure Magpro system; 600 pulses with the active sham coil (double blinded)
223493781|NCT02210754|OTHER|blu™ Classic Tobacco rechargeable (1.6% nicotine, glycerin/PG vehicle)|electronic cigarettes
223493782|NCT02210754|OTHER|Marlboro Cigarette|cigarettes
223493783|NCT04709887|PROCEDURE|Wound treatment|According to the guidelines and recommendations of the International Diabetic Foot Working Group, ulcer surface debridement, negative pressure suction drainage, and routine dressing were performed until the wound healed or the end of the trial.
223493784|NCT04709887|PROCEDURE|Vascular intervention surgery|Segmented distal angiography under the guidance of digital subtraction angiography (DSA) were perform after local anesthesia. The superficial artery is expanded by a 3-4 mm balloon.
223493785|NCT04709887|PROCEDURE|Tibial transverse transport surgery|In the anteromedial area of the proximal tibia of the affected limb, the external fixation frame was compared with the area along the midline of the medial longitudinal axis of the proximal tibia. Subsequently, two 3.0 Steinmann pins were inserted through the single layer of cortical bone. The skin was cut along the long axis with the 3.0 Steinmann pin as the centre, and the subcutaneous tissue was separate bluntly to expose the periosteum. The Steinmann pins were used as the centre point for the drilling on four sides with a 2.0 drill bit and use of a rapid osteotomy device; the length of each side was 2.5 cm. Subperiosteal osteotomy was performed with a 5-mm narrow bone knife at an angle of 15°-30° to the bone surface. The surgeons should pay attention to protect the blood supply of the periosteum during this procedure. The external fixators were fixed with 4.0 Steinmann pins at the distal and proximal ends. The subcutaneous tissue and skin were sutured.
223493786|NCT01692015|OTHER|Questionnaire on dietary history|
223493787|NCT01692015|OTHER|Questionnaire on nosebleed severity|
223493788|NCT01692015|OTHER|One week food diary generated by weighing foods|
223493789|NCT01692015|PROCEDURE|Blood tests for full blood count, albumin, and indices of nutritional status|
223493790|NCT04681872|PROCEDURE|Destruction of Marshall bundles|Destruction of Marshall bundles by ethanol 96% infusion (2 separate injections of 5ml on 1 minute each) followed by ablation of the distal coronary sinus bundles, the ridge and the saddle.
223588866|NCT04281979|DRUG|Study Agent|The study agent will be administered via beverages and/or a capsule. The substances used in the study are legal, non-prescription, and are proven safe for human consumption at the doses used. The study agent may be a depressant (such as alcohol), a stimulant (such as caffeine), or an analgesic (such as aspirin).
223588867|NCT04281979|DRUG|Placebo|In the placebo conditions participants will consume beverages and capsules that contain no or very small quantities of the study agent.
223588868|NCT01571232|DRUG|dexamethasone intravitreal implant|Ozurdex, 0.7 mg intravitreal dexamethasone implant, given at initial visit and at month 4 (visit 5)
223493791|NCT04681872|PROCEDURE|Pulmonary veins isolation|Achievement of a wide disconnection of the right and left pulmonary veins.
223493792|NCT04681872|PROCEDURE|Linear ablation in the left and right atria|Ablation of the mitral, the roof, and the cavo-tricuspid isthmus
223493793|NCT00084253|DRUG|Atazanavir/ Stavidine / Lamivudine|Capsules, Oral, ATV (2 x 200 mg) QD + 3TC (2 x 150 mg) QD + Zerit XR (1 x 100 mg) QD, Once daily, 96 weeks.
223493794|NCT00084253|DRUG|Atazanavir-Ritonavir/ Stavidine / Lamivudine|Capsules, Oral, ATV (2 x 150 mg) QD + RTV (1 x 100 mg) QD + 3TC (2 x 150 mg) QD + Zerit XR (1 x 100 mg) QD\*, Once daily, 96 weeks.
223588869|NCT01571232|DRUG|intravitreal bevacizumab|Avastin, 1.25 mg intravitreal bevacizumab, given at initial visit and Q1month for a total of 5 treatments.
223588870|NCT00771615|BIOLOGICAL|GSK A/turkey H5N1 Influenza vaccine|One dose administered intramuscularly (IM) in the deltoid region. Different formulations are tested.
223588871|NCT02870088|BEHAVIORAL|Prolonged Sitting|After consuming 1st meal, participants sat on a chair for 180 min. After 180 min, the 2nd meal was provided. After finishing the 2nd meal, participants sat on a chair for another 120 min.
224185495|NCT04156802|DEVICE|Sham TBS to the mPFC|This will be delivered with the Magventure Magpro system; 600 pulses with the active sham coil (double blinded). The MagVenture MagPro system has an integrated active sham that passes current through two surface electrodes placed on the skin beneath the coil.
223493795|NCT01614418|DEVICE|Endoscopic radiofrequency ablation catheter|Endoscopic radiofrequency ablation
223493796|NCT02408822|DEVICE|PTA Balloon dilatation catheter Advance® (Cook® Medical)|2-minutes inflation of the plain balloon on pre-dilated stenosis segment, at nominal pressure
223493797|NCT02408822|DEVICE|Drug-eluting PTA Balloon dilatation catheter Advance® 18 PTX®|2-minutes inflation of the drug-eluting balloon on pre-dilated stenosis segment, at nominal pressure
223493798|NCT03772873|PROCEDURE|minimally invasive pilonidal excision|MIPE procedure with trephine excision of pits and sinuses
223493799|NCT02807090|OTHER|Lumbar Stabilization Exercise|There will be 16 sessions, twice a week, with 40-60 minutes each session. In this arm the participants will learn basic notions about anatomy and biomechanics and the lumbar stabilization technique. They will be evaluated by a pressure biofeedback in the first day that will be used in the training. The lumbar stabilization technique consists of three stages: cognitive, associated and automatic. The biofeedback is used in the first stage and it helps patients to do the best contraction of stabilization muscles in different levels of pressure. Then, in stage two the patients do the contraction without the use of biofeedback and in the last phase different exercises are associated with the contraction of stabilization muscles.
224185496|NCT04156802|DEVICE|Real TBS to the MC|This will be delivered with the Magventure Magpro system (double blinded).
223493800|NCT02807090|OTHER|Circular dance|There will be 16 sessions, twice a week, with 60 minutes each session. In this arm the participants will do the exercises in a group of 20 subjects. In every meeting there will be the follow stages: reception, reflection, warming/stretching, explanation about circular dance, choreography orientation, practice and finishing.
223588872|NCT02870088|BEHAVIORAL|Breaking Sitting|After consuming 1st meal, participants walked 2 min on a treadmill every 20 minutes for the following 180 min. For the remainder of the time participants sat on the chair. After 180 min, the 2nd meal was provided. After finishing the 2nd meal, participants continued 2 min of walking every 20 min for the following 120 min.
224185497|NCT04156802|DEVICE|Sham TBS to the MC|This will be delivered with the Magventure Magpro system (double blinded). The MagVenture MagPro system has an integrated active sham that passes current through two surface electrodes placed on the skin beneath the coil.
224185498|NCT05550103|PROCEDURE|Remote ischemic conditioning|Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflations of a blood pressure cuff to 200 mm Hg.
224185499|NCT05550103|PROCEDURE|Sham remote ischemic conditioning|Sham remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflations of a blood pressure cuff to 60 mm Hg.
224185500|NCT05550103|OTHER|Standard medical treatment|Standard medical treatment
224185501|NCT03401827|DRUG|Chemotherapy (Gemcitabine + nab-paclitaxel)|"Nanoparticle albumin-bound paclitaxel (125 mg/m2) miv over 30 min, Day 1,8,15~Gemcitabine (1,000mg/m2) and N/S 150mL miv over 30 min, Day 1,8,15"
224185502|NCT04621604|OTHER|blood samples|Extra blood samples will be collected during chemotherapy administration to analyze pharmacokinetics of the iPD1
224185503|NCT00296777|DRUG|Escitalopram|8 weeks: up to 40 mg/day
224185504|NCT00296777|DRUG|Bupropion|8 weeks: up to 450 mg/day (for patients without history of seizures or risk for developing seizures.
223493801|NCT00687518|DRUG|Erythropoietin|Intravenous injection of 50 U/kg of erythropoietin
223493802|NCT00687518|DRUG|Placebo|Intravenous injection of equivalent volume of saline serum
223493803|NCT00358514|DEVICE|Continuous Compartment Pressure Monitoring|See Detailed Description.
223588873|NCT02455076|DRUG|Exenatide|Exenatide is dispensed via a 1.2 mL prefilled pen with 250 mcg/mL solution for subcutaneous (s.c.) injection and will be administered twice daily starting at 5 mcg per dose, either in the abdomen, thigh or upper arm. Exenatide injections will be given within 60 minutes prior to morning and evening meals (or before the two main meals of the day, approximately 6 hours or more apart between doses). The exenatide dose will be increased to 10 mcg twice daily after 1 month based on clinical response.
223745689|NCT04965194|PROCEDURE|erector spinae plane block|Superficial probe will be placed 2-3 cm lateral to the spine using a sagittal approach at the level of T8. After identification of erector spinae muscle and transverse processes, the needle will be inserted deeply into the erector spinae muscle. Correct position of the needle tip is confirmed with administration of 0.5-1 ml of local anesthetic (LA), and 20 ml of 0.25% bupivacaine will be administered to perform ESP block. LA spread to both cranial and caudal directions will be seen.
224185505|NCT00296777|DRUG|Imipramine|"8 weeks: up to 300mg/day~\*if patient does not have contraindication."
224185506|NCT06470126|PROCEDURE|2.5% NaOCl group: The interventions performed in the study are root- canal therapies and disinfection procedure of these therapies.|10 mL 2.5% NaOCl application followed the mechanical preparation. After 2 mL 0.9% saline application, the second samples were taken by placing a sterile cone in the largest canal of the tooth (distal canal for 60 seconds). The mesiobuccal and distobuccal canals were closed with a sterile cotton pellet while the samples were taken. After the application, the root canal filling was completed with a calcium hydroxide-containing paste (TgPex™, London, England), glass ionomer cement (Ionofil U, Voco, Cuxhaven, Germany) was placed, and the teeth were restored with a Stainless-Steel Crown (3M ESPE, Seefeld, Germany)
224185507|NCT06470126|PROCEDURE|0.9% sterile saline solution combined with 80 seconds: The OzonyTronX® interventions performed in the study are root- canal therapies and disinfection procedure of these therapies.|The canals were irrigated with 10 mL 0.9% sterile saline. Ozone treatment (OzonyTronX with CA probe) was applied for 80 seconds, and 2 mL 0.9% saline application was performed. Finally, the second samples were taken by the method described in group with 2.5% NaOCl, and the canal treatment was completed.
224185508|NCT06470126|PROCEDURE|2.5% NaOCl with 80 seconds OzonyTronX®:The interventions performed in the study are root- canal therapies and disinfection procedure of these therapies.|The disinfection of root canals was done using 10 mL, 2.5% NaOCl, and ozone treatment for 80 seconds, and 2 mL 0.9% saline application was performed. Finally, the second samples were taken by the method described in group with %2.5 NaOCl, and the canal treatment was completed.
224185509|NCT05310604|PROCEDURE|Blood withdrawal|Single blood withdrawal for determination of immunoglobulin levels
224185510|NCT02616107|OTHER|Managing Cancer Care: A Caregiver's Guide|"MCC-CG is a set of 7 printed modules including information about caregiver-nominated SM topics, conversation starters to facilitate communication with patients and providers, and links to caregiver resources. The modules are as follows:~1. Becoming a Cancer Caregiver \[role, changes, challenges, adjusting, self-care\]~2. Basics of Cancer Caregiving \[physical, functional, emotional, social, \& spiritual support; treatment timeline worksheet\]~3. Caregiver's Role in Managing Patient Care \[who/what is involved; health care professionals worksheet\]~4. Managing Cancer Symptoms and Side Effects \[common symptoms/side effects; maintaining health; nutrition \& exercise; medication management worksheet\]~5. Care Options: \[information on curative, palliative and hospice care\]~6. Talking About Goals of Care \[information on goals of care conversations\]~7. Managing Transitions \[defining transitions, transition examples, helping yourself and patient to manage transitions; transitions worksheet\]"
223493804|NCT05372770|DEVICE|Flourish Vaginal Care system|Flourish includes Restore® vaginal moisturizing gel, a Class II medical device cleared by the FDA, in addition to two other kit components
223493805|NCT04519775|BEHAVIORAL|Home Based Self-management and Cognitive Training Changes lives (HOBSCOTCH)|HOBSCOTCH is a home-based self-management program to treat cognitive symptoms and improve quality of life, while minimizing the barriers of access to care. The program is based on Problem Solving Therapy (PST) and teaches problem solving strategies and compensatory mechanisms to help manage cognitive dysfunction and enhance quality of life.
224185511|NCT02616107|OTHER|Symptom Management Toolkit|Along with an overview of symptom management, the Toolkit provides concise information on commonly experienced symptoms, including fatigue, alopecia, cognitive dysfunction, nausea and vomiting, and sleep problems, among others. Each chapter uses a question-and-answer format to cover the topics of who is most likely to experience the symptom, when and why the symptom may occur, how the symptom can be managed, and when to call a provider. Drs. Schulman-Green and McCorkle have previously tested the Symptom Toolkit in an attention-control group.
224185512|NCT04145739|OTHER|Rehabilitation protocol|The rehabilitation treatment was performer in single session, lasted 60 minutes for session, 2 times a week, carried-out a 6-week exercises program for a total of 12 sessions, by a physiotherapist trained in oncologic rehabilitation, who started with a first phase of at least 15-20 min of low-impact aerobics warm-up. The second phase consisted in diaphragmatic breathing and postural exercises for the midline alignment in a supine position. Finally the patient continued in front of the mirror with exercises for the recovery of shoulder joint, isometric reinforcement exercises for the recovery of strength of shoulder stabilizer muscles. In the presence of lymphedema an additional weekly lymph drainage session was performed for a total of 10 sessions.
224185513|NCT03814824|DIAGNOSTIC_TEST|IRIS (Intelligent real-time image segmentation)|IRIS has the ability to identify and display three specific images features that may correlate with dysplasia that are represented in different color schemes.
224185514|NCT03814824|DIAGNOSTIC_TEST|VLE (Volumetric laser endomicroscopy)|VLE uses infrared light to produce real time high-resolution cross sectional imaging of the esophagus.
224185515|NCT06479317|DRUG|Hydroxychloroquine Oral Tablet|Hydroxychloroquine is taken at the dose of 0.1g / dose, twice a day for 1 year, regardless of food intake.
224185516|NCT06479317|DRUG|Dexamethasone oral|Dexamethasone is given at 40mg every morning after meals for 4 consecutive days( if platelet count does not recover higher than 30×10\^9/L after 2 weeks, dexamethasone is given 40mg every day for another consecutive 4 days).
224185517|NCT03330275|DEVICE|Investigational Contact Lens|JJVC senofilcon A-based contact lens with new UV-blocker
223493806|NCT02826473|OTHER|BRAINCHECK|Subjects of the Intervention-Group will undergo a brief cognitive assessment, using the BRAINCHECK, during hospital admission assessments. Subjects with positive results will then be referred to a Memory Clinic undergoing subsequent interdisciplinary comprehensive diagnostic examinations. Patients with established diagnosis will be invited to counselling services of the Alzheimer Association (providing social counselling).
223493807|NCT01177176|OTHER|Extended Care Management|Telephone-based care management of tobacco cessation for 3 months after hospital discharge that features 2 innovations: (1) to increase medication use, smokers receive a free refillable 30-day sample of their choice of FDA-approved smoking cessation medication (nicotine replacement, bupropion, or varenicline) at hospital discharge; (2) to increase counseling cost-effectiveness, interactive voice recognition (IVR) technology is used to make automated telephone calls to identify the smokers seeking or most likely to benefit from continued counseling after hospital discharge.
224185518|NCT03330275|DEVICE|Commercial ACUVUE OASYS|senofilcon A
224185519|NCT03330275|DEVICE|Commercial ACUVUE OASYS and Spectacles|Senofilcon A and Spectacles
224185520|NCT04856488|DRUG|Iodine-Potassium Iodide 5%-10% Oral and Topical Solution|Iodine Potassium Iodide 5% oral solution, administered 3 times per day for 10 days
224185521|NCT01161212|OTHER|Physical education sessions|3(60 minutes each) or 4 (45 minutes each) short sessions of physical education (PE) sessions
224185522|NCT01161212|OTHER|Physical education sessions|1 (3 hours) or 2 long PE sessions (1 hour and 30 minutes each)
224185523|NCT04979325|OTHER||
224185524|NCT00744068|BEHAVIORAL|Continuing Care Telephone Support|Counselor-provided telephone support as strategies to promote patient aftercare attendance and sustained abstinence from stimulant use. To this end, we will develop and compare the efficacy of four low-cost telephone support protocols for patients who have completed the intensive phase of a structured, outpatient stimulant abuse treatment program.
224185525|NCT05632055|OTHER|blood draw|Blood test for miRNA and FGF21. However, the laboratory result is not reported and not involved in management
224185526|NCT05247606|DEVICE|Mobile application|Lifestyle intervention through web-based mobile application
224185527|NCT01891227|DRUG|Capecitabine|Capecitabine will be dosed at 1000mg/m2 twice daily for 14 days, followed by a 7-day rest period for a total cycle time of 21 days (until disease progression or unacceptable toxic effects).
224185528|NCT01891227|DRUG|Bendamustine|Bendamustine 80mg/m2 will be administered on day 1 and 8 of a three week cycle (for a maximum of eight cycles).
224185529|NCT00030849|BIOLOGICAL|recombinant interferon alfa|
224185530|NCT00030849|DRUG|bexarotene|
224185531|NCT03910309|DEVICE|TLIF with Titan TT/TO interbody cage|fusion surgery
224185532|NCT02145949|DRUG|Essential Amino Acids (EAA)|Twice daily ingestion of 20 or 23 grams of EAA for 7 days leading up to surgery and continuing for 6 weeks after surgery \[surgery = primary total knee arthroplasty\]
224185533|NCT02145949|DRUG|Placebo (Alanine)|Twice daily ingestion of 20 or 23 grams Placebo (alanine) for 7 days leading up to surgery and continuing for 6 weeks after surgery \[surgery = primary total knee arthroplasty\]
224185534|NCT05656430|BEHAVIORAL|Internet-based Cognitive Behavioral Therapy|Intervention based on cognitive behavioural therapy principles and adapted to the coronavirus pandemic situation. The 20 modules that the intervention consists of include psycho-educational texts as well as examples and exercises.
224185535|NCT06216600|BEHAVIORAL|Acceptance and Commitment Therapy (ACT)|Participants will undergo ACT in combination with exercise and social support.
224185536|NCT06216600|BEHAVIORAL|Body weight circuit training|Participants will learn and undergo body weight circuit training in combination with ACT and social support.
224185537|NCT06216600|BEHAVIORAL|Empathetic social support|Study participants will participate in empathetic social support
224185538|NCT06216600|OTHER|Control - list of resources|A local list of resources to access exercise, therapy and social support will be provided.
224185539|NCT03842202|DRUG|Semaglutide|Participants will receive gradually increasing doses of semaglutide (subcutaneous \[s.c.\], in the thigh, abdomen or upper arm) injection once weekly, until they reach a dose of level of 2.4 mg, which they will continue for 5 weeks.
224185540|NCT03842202|DRUG|Placebo|Participants will receive once weekly injections of semaglutide matched placebo.
223493808|NCT01177176|OTHER|Standard Care|Usual care provided to hospitalized smokers during their inpatient stay, with no post-discharge care management plan
223493809|NCT05992727|DIAGNOSTIC_TEST|Galectin 3 measurement in serum and saliva by ELIZA|Galectin 3 measurement in serum and saliva by ELISA in the two groups
223493810|NCT02886663|OTHER|stimulation of the blind visual field|
223493811|NCT00742677|PROCEDURE|nutritional support|Given orally
223493812|NCT00177671|DRUG|Escitalopram|Escitalopram, 10mg to 20mg daily.
223588874|NCT02455076|DRUG|Glargine|"Glargine will be given once daily, at the same time of day. If the BG is between 140-200 mg/dL, the dose will be 0.2 units/kg/day; for BG levels 201-400 mg/dL, the dose will be 0.25 units/kg/day. The patients will be discharged on glargine once daily at 50% of the hospital dose.The total daily dose (TDD) of glargine is based on the patient's fasting BG levels for the last 2 days.~1. FBG \>180 mg/dL, no hypoglycemia; glargine increased by 4 IU.~2. FBG \>140 mg/dL, no hypoglycemia; glargine increased by 2 IU.~3. FBG 100-140 mg/dL, no hypoglycemia; no change in dosage.~4. FBG 70 - 99 mg/dl, decrease glargine by 4 IU or 10% of TDD.~5. FBG or RBG \< 70 mg/dl, decrease glargine by 8 IU or 20% of TDD.~6. FBG or RBG \< 40 mg/dl, decrease dose of glargine by 30%."
224185541|NCT06175000|PROCEDURE|Cognitive Assessment|Ancillary studies to evaluate neurocognitive function at study entry and at 2 years after study entry.
224185542|NCT06175000|BIOLOGICAL|Obinutuzumab|Given IV
224185543|NCT06175000|OTHER|Quality of Life Assessment|Ancillary studies to evaluate quality of life at study entry and at 2 years after study entry.
224185544|NCT06005792|BIOLOGICAL|XmAb27564|Subjects to receive four doses of XmAb27564 at one of six escalating dose-levels administered subcutaneously every 2 weeks (Q2W).
224185545|NCT06005792|BIOLOGICAL|Placebo|Subjects to receive four doses of placebo administered subcutaneously every 2 weeks (Q2W).
224185546|NCT04831957|DIAGNOSTIC_TEST|Assesment of thyroïd function|Blood sample for TSH, fT4, fT3, anti TPO, anti TG thyroid ultra sound Iodine urine sample
224185547|NCT06793410|BIOLOGICAL|Early start post-transplant vaccination with Gardasil 9®|Subjects will receive Gardasil 9® as part of the early post-transplant vaccination, starting at 9 months after transplantation.
224185548|NCT06793410|BIOLOGICAL|Late post-transplant vaccination with Gardasil 9®|Subjects will receive Gardasil 9® as part of the late post-transplant vaccination, starting at 15 months after stem cell transplantation.
224185549|NCT05846412|OTHER|Catheter Ablation and M-TEER|Already included in arm descriptions.
224185550|NCT06311045|DIETARY_SUPPLEMENT|N-acetylcysteine (NAC)|Participants will take two NAC 600mg capsules daily for four weeks.
224185551|NCT06311045|DIETARY_SUPPLEMENT|Placebo|Participants will take two placebo 600mg capsules daily for four weeks.
224185552|NCT06311045|PROCEDURE|Positive Airway Pressure (PAP) Therapy|All participants will receive PAP therapy per standard of care for OSA.
224185553|NCT04791449|OTHER|Structured exercise program|Medically-supervised participation in 2-3 exercise sessions per week over 12-wk study period. Exercise conducted in the cardiac rehabilitation program.
224185554|NCT06384599|DEVICE|VT Cryoablation System|All subjects will receive a cryoablation procedure using the VT Cryoablation System (catheter, stylets, and console)
224185555|NCT05119114|DIAGNOSTIC_TEST|Magnetic Resonance Imaging (MRI)|A standardized multi-parametric MRI protocol will be implemented for all patients. All sequences will be acquired on a 1.5 Tesla scanner. After completion of the MRI study, the digital imaging and communication data will be sent to a diagnostic workstation for post-processing and analysis. Patients of the study will be subjected to detailed structural MRI for detection of signs of neurodegenerative changes. Volumetric high-resolution 3D scans will be used for quantitative study.
224185556|NCT05934422|OTHER|Intervention (Study Nutritional Drink)|Study nutritional drink containing a mix of enriched micronutrients, probiotics and myo-inositol.
224185557|NCT05934422|OTHER|Control (Standard Nutritional Drink)|Control nutritional drink containing a standard mix of micronutrients
223493813|NCT00177671|DRUG|Donepezil|Donepezil, 5mg to 10mg daily.
223493814|NCT00177671|DRUG|Venlafaxine|Venlafaxine, 150mg to 300mg daily.
223493815|NCT00177671|DRUG|Placebo|
223493816|NCT00177671|DRUG|Duloxetine|
223493817|NCT04410822|OTHER|Clinical tests|Semi-qualitative interviews and questionnaire FITAS
223493818|NCT04462679|OTHER|COMMIT mHealth application|We will develop Community-based mHealth Motivational Interviewing Tool (COMMIT) using iterative design and testing with frequent, structured input from the key stakeholders: community health workers (CHWs), their supervisors and youth living with HIV (YLWH).The tool will be used by community CHWs in Achham, Nepal to: 1) obtain decision-support to deliver motivational interviewing (MI) for patients in their communities, and 2) capture consented audio recordings of client interactions for review and feedback by their supervisors, allowing CHWs to maintain MI skills beyond the initial training period.
223493819|NCT01644929|PROCEDURE|transcranial direct current stimulation (tDCS)|Anodal tDCS of the ipsilesional motor cortex and cathodal tDCS of contralesional motor cortex (1.5 mA, 30 minutes) for 15 days during three weeks, then sham stimulation for 30 seconds on 15 days during 3 weeks
224185558|NCT06113458|BEHAVIORAL|Standard and One-time Training|"Patient-level intervention: Patients in the standard group will receive automated reminder SMS text messages and remote BP monitoring.~Clinic-level intervention: Clinics in the one-time training group will receive one-time training on standard work and algorithms, audit and feedback, and panel-based outreach."
223493820|NCT01644929|PROCEDURE|Sham stimulation, then tDCS|Sham stimulation for 30 seconds on 15 days during 3 weeks, then anodal tDCS of the ipsilesional motor cortex and cathodal tDCS of contralesional motor cortex (1.5 mA, 30 minutes) for 15 days during three weeks
224185559|NCT06113458|BEHAVIORAL|Standard and Practice Facilitation|"Patient-level intervention: Patients in the standard group will receive automated reminder SMS text messages and remote BP monitoring.~Clinic-level intervention: Clinics in the practice facilitation group will receive regular/ongoing training on standard work and algorithms, audit and feedback, and panel-based outreach."
223493821|NCT01644929|PROCEDURE|Sham stimulation|Sham stimulation for 30 seconds on 15 days during 6 weeks
224185560|NCT06113458|BEHAVIORAL|High-intensity and One-time Training|"Patient-level intervention: Patients in the high-intensity group will receive personalized feedback SMS text messages and remote BP monitoring.~Clinic-level intervention: Clinics in the one-time training group will receive one-time training on standard work and algorithms, audit and feedback, and panel-based outreach."
224185561|NCT06113458|BEHAVIORAL|High-intensity and Practice Facilitation|"Patient-level intervention: Patients in the high-intensity group will receive personalized feedback SMS text messages and remote BP monitoring.~Clinic-level intervention: Clinics in the practice facilitation group will receive regular/ongoing training on standard work and algorithms, audit and feedback, and panel-based outreach."
224185562|NCT05584007|DRUG|Flucloxacillin Only Product in Oral Dose Form|Patients will be prescribed flucloxacillin 500mg QDS for 5 days followed by blinded flucloxacillin 500mg for 2 days, reaching a total of 7 days of antibiotic treatment
224185563|NCT05584007|DRUG|Placebo Only Product in Oral Dose Form|Patients will be prescribed flucloxacillin 500mg QDS for 5 days followed by a blinded placebo for 2 days, reaching a total of 5 days of antibiotic treatment
224185564|NCT03991520|DRUG|Anakinra 100Mg/0.67Ml Inj Syringe|The study drug is100mg/day Anakinra, which is the standard, FDA approved dose for the treatment of rheumatoid arthritis. The randomized treatment will be self-administered by the subject each evening by subcutaneous injection.
224185565|NCT03991520|DRUG|Placebo|The placebo is comparable to the anakinra formulation without the active medication - a solution (pH 6.5) containing anhydrous citric acid (1.29 mg), disodium EDTA (0.12 mg), polysorbate 80 (0.70 mg), and sodium chloride (5.48 mg) in water for injection
224185566|NCT03476681|DRUG|NEO-201 in combination with pembrolizumab|NEO-201 will be given intravenously every 2 weeks in combination with pembrolizumab. In each cycle subjects will receive 3 doses of NEO 201 and one dose of pembrolizumab.
224185567|NCT04470960|BEHAVIORAL|Training course for the community center health coordinators|"These community centers who have volunteered to join the project will receive a 12 week training session which includes the values and principles of health promotion and the principles of building a health promotion project.~The participants will be requested to build a health promotion project within their community. Building and implementing the project will be assisted by a health promotion specialist. Each health promotion project will be evaluated according to the principles of health promotion."
224185568|NCT03266211|OTHER|Questionnaire Patients|Patient will have to answer a quiz which is about their vaccination against tetanus.
224185569|NCT03266211|OTHER|Questionnaire General practitioner|General practitioner will have to answer a quiz which is about their medical practice concerning vaccination against tetanus.
224185570|NCT00224952|OTHER|No intervention; Urine Collection|Urine collected from children receiving carbamazepine or valproic acid as part of their clinical management
224185571|NCT04087967|DRUG|Decitabine plus HAAG regimen|"Decitabine:20mg/m2/d,d1\~5, intravenous infusion; Homoharringtonine:1mg/d,d3\~16,intravenous infusion; Aclarubicin:10mg/d, d3\~d10, intravenous infusion; Cytarabine:10mg/m2,q12h,d3-16, subcutaneous injection;~Granulocyte colony-stimulating factor (G-CSF):~50-300μg/d (when WBC counts are less than 20×10\^9/L ),subcutaneous injection;"
224185572|NCT04087967|DRUG|Idarubicine plus Cytarabine regimen|Idarubicine :12mg/m2, d1-3, intravenous infusion; Cytarabine :100mg/m2, d1-7, 24-hours continuous intravenous infusion
224185573|NCT03039959|DIAGNOSTIC_TEST|No intervention|No intervention
223493822|NCT01723059|DRUG|Standard Triple Therapy|for 10 days
223493823|NCT01723059|DRUG|Sequential Therapy|total 10 days
223493824|NCT02852083|DRUG|Pioglitazone|Pioglitazone 25 mg once daily, p.o.
223493825|NCT02852083|DRUG|nivolumab|3 mg per kilogram of body weight every 2 weeks, p.o. (standard treatment)
223493826|NCT02852083|DRUG|Treosulfan|Treosulfan 250 mg twice daily, p.o.
223493827|NCT02852083|DRUG|Clarithromycin|Clarithromycin 250 mg twice daily p.o.
223493828|NCT01323218|DRUG|25 OH vitamin D|After written informed consent, patients will be randomized to receive a single dose of oral vitamin D (400 000 UI) or placebo. Subjects will undergo medical screening before randomisation into placebo or active group. Follow-up measurements will be performed at the beginning (day 0) and after 32 days of vitamin D supplementation: clinical examination, biological check up and sleep parameter evaluation. Patients will be instructed to stop using continuous positive airway pressure device for two nights before nocturnal sleep studies
223493829|NCT05861271|DRUG|Capecitabine，Pyrotinib|Pyrotinib and Capecitabine for half a year
223493830|NCT02293499|BEHAVIORAL|PLASMA|"A structured asthma self-management manual (Let's Talk about Asthma \[LTAA\],developed by the study team will be utilized in a camp like setting and administered by either peers or adults medical professionals. The manual adheres to the 2007 NAEPP Guidelines Training strategies will involve didactic sessions, discussion, demonstrations, and role-play. Group learning activities will closely align with the program manual (LTAA) that consists of three sessions. Participants will also learn and practice skills in using the peak flow meter, spacer and inhaler, daily symptom diary and asthma action plan. Besides instructional activities, participants will engage in recreational activities that each camp site."
223493831|NCT00690898|DRUG|Lanreotide autogel 120 mg|12 months
223493832|NCT05732545|BEHAVIORAL|enteral nutrition program for patients with abdominal hypertension guided by abdominal pressure|There are 4 aspects of intra-abdominal pressure monitoring, source control and treatment for the etiology of increased abdominal pressure, enteral nutrition program, enteral nutrition tolerance evaluation and treatment
223493833|NCT05783973|DIAGNOSTIC_TEST|Next generation sequencing|Extract DNA from bile，tissue and tissue sample, minimum DNA amount should be over 50ng.
223493834|NCT03483753|DRUG|Vasopressin|"Blinded Vasopressin will be started if there is persistent hypotension, characterized by mean arterial pressure \<65 mmHg after fluid replacement.~Continuous infusion of the drug at doses ranging from 0.01 U / min to 0.06 U / min"
224185574|NCT05821998|OTHER|Thoracic block technique|Manual compression of the healthy lung during expiration associated with the use of invasive or non invasive mechanical ventilation
224185575|NCT05821998|OTHER|Designed chest physical therapy program|Percussion, vibration and modified postural drainage
224185576|NCT02825745|DIETARY_SUPPLEMENT|Betashot|Betashot is a Food for Special Medical Purposes (FSMP). Suitable for use from 3 years of age.
224185577|NCT05406882|DRUG|Live Combined Bifidobacterium and Lactobacillus Tablets、Compound Glutamine Entersoluble capsules|Live Combined Bifidobacterium and Lactobacillus Tablets：probiotics. Compound Glutamine Entersoluble capsules：combined traditional Chinese medicine and glutamine
223588875|NCT02455076|DRUG|Rapid-acting insulin analogs|"If the BG levels are \>140 mg/dL, rapid acting insulin analogs will be administered following the supplemental/sliding scale protocol. If a patient is able and expected to eat all or most of his/her meals, supplemental insulin will be administered before each meal and at bedtime following the usual dose of the sliding scale protocol. If a patient is not able to eat, supplemental insulin will be administered every 6 hours following the sensitive dose of the sliding scale. If the BG is 141-180 mg/dL, then 2,3 or 4 units of insulin will be given; for BG 181 - 220 mg/dL; the units of insulin will be 3, 4 or 6; for BG 221 - 260 mg/dL, the units of insulin will be 4,5 or 8; for BG 261 - 300 mg/dL, the units of insulin will be 5, 6 or 10; for BG 301 - 350, the insulin will be 6, 8 or 12 units; for BG 351 - 400 mg/dL, the units of insulin will be 7,10 or 14; for BG\> 400 mg/dL, the insulin will be 8,12 or 16 units."
223588876|NCT06543680|OTHER|Dental restoration|Each patient will randomly receive one cervical restoration with one of the tested restorative systems
223588877|NCT03147443|DRUG|Individualized Decoction|Applied in the Tested Drug Observation Period. It is the highly individualized treatment of traditional Chinese medicine,the modification of Bronchiectasis Stabilization Decoction(Radix Lithospermi 15 g, Rhizoma Fagopyri Cymosi 30 g, Radix Ophiopogonis 15 g, Poria cocos 15 g, Radix Astragali 20 g, Rhizoma Bletillae 10 g, Platycodon grandiflorum 10 g, and Semen Coicis 30 g) based on syndrome differentiation. For example,for patients with qi and yin deficiency syndrome, we added Radix Adenophorae, and Radix Rehmanniae Recens. Besides, the herbs in a prescription could be changed according to different symptoms of individual patients.
223588878|NCT03147443|DRUG|placebo|Applied in the placebo Observation Period. Placebo is made by dextrin, bitter agent, edible pigment etc and added 5% test drug. The test drug and control drug have no differences in dosage form, appearance, color, specification, label, and so forth.
223588879|NCT03147443|DRUG|Tested drug minus heat-clearing herbs|It is the decoction of the Syndrome Differentiation Decoction(tested drug) minus heat-clearing herbs. For example, heat-clearing herbs such as Scutellaria baicalensis or Herba Violae will be removed from the Syndrome Differentiation Decoction.
223588880|NCT06581172|DIAGNOSTIC_TEST|D_dimer|DIC score including FDPs,D\_dimer
223745690|NCT04965194|PROCEDURE|Quadratus lumborum plane block|"A curved array transducer for the transmuscular QL (TQL) nerve block is placed in the axial plane on the patient's flank just cranial to the iliac crest. The shamrock sign is visualized: The transverse process of vertebra L4 is the stem, whereas the erector spinae posteriorly, QL laterally, and psoas major anteriorly represents the three leaves of the trefoil. The target for injection is the fascial plane between the QL and psoas major muscles. The needle is inserted using an in-plane technique from the posterior end of the transducer through the QL muscle. The injectate (20ml of bupivacaine 0.25%) should ideally spread from the injection site inside the fascial plane between the QL and psoas major muscles to the thoracic paravertebral space with a goal to accomplish segmental somatic and visceral analgesia from T4 to L1."
223745691|NCT04965194|OTHER|placebo|patients received no regional block
223745692|NCT05978154|OTHER|Thigh muscle mass and muscle wasting (exposure)|Thigh muscle mass and muscle wasting (exposure variable)
223745693|NCT04667039|BIOLOGICAL|GNR-067|GNR-067 will be used intravitreally once every 4 weeks in 0.5 mg doses (the injection volume is 0.05 mL)
223493835|NCT03483753|DRUG|Norepinephrine|Blinded Norepinephrine will be started if there is persistent hypotension, characterized by mean arterial pressure \<65 mmHg after fluid replacement. Continuous infusion of the drug at doses ranging from 0.1 mcg / kg / min to 1.0 mcg / kg / min.
223493836|NCT03527602|PROCEDURE|Foraminal enlargement|After determining the working length, a rotary file will be inserted 1 mm beyond the WL and the apical foramen will be enlarged.
223493837|NCT01360476|DIETARY_SUPPLEMENT|cholecalciferol (Vitamin D)|50,000 UI, chewable wafer every 2 weeks for 52 weeks (27 total doses)
223493838|NCT01360476|DIETARY_SUPPLEMENT|Placebo|chewable wafer every 2 weeks for 52 weeks (27 total doses)
223493839|NCT00782093|DRUG|volociximab|volociximab intravitreal injection
223493840|NCT05139147|DEVICE|DAISe Thrombectomy System|DAISe Thrombectomy System for mechanical thrombectomy
223493841|NCT05370326|OTHER|Enhanced Opioid Stewardship Program|The goal of the enhanced opioid stewardship intervention is to manage chronic pain while reducing risk of inappropriate/risky opioid use and preventing harms of opioid use.
223493842|NCT06461884|OTHER|Percussions|Group A: Percussions and diaphragmatic breathing exercise will be performed with 1 session a day for total 3 days in a week for 4 weeks
223493843|NCT06461884|OTHER|, Diaphragmatic breathing exercise|Group B: Diaphragmatic breathing exercise will be performed with 1 session a day for total 3 days in a week for 4 weeks
223745694|NCT04667039|BIOLOGICAL|Lucentis®|Lucentis® will be used intravitreally once every 4 weeks in 0.5 mg doses (the injection volume is 0.05 mL)
223745695|NCT00233623|DRUG|Iressa (Gefitinib)|
223493844|NCT01369303|DRUG|Tenofovir 1% vaginal gel|Tenofovir 1% gel is supplied as a clear, transparent, viscous gel packaged in pre-filled single use applicators. Each applicator contains 4.0 mL of tenofovir gel (equal to 4.4 gm) at a concentration of 1% (weight for weight) formulated in purified water with edetate disodium, citric acid, glycerin, methylparaben, propylparaben and hydroxyethylcellulose, and is pH adjusted to 4-5.
223493845|NCT03138681|DRUG|Placebo|placebo is given intravenously twice a day for 14 days
223493846|NCT03138681|DRUG|ATP|ATP (100mg) is given intravenously twice a day for 14 days
223493847|NCT03138681|DRUG|Phosphocreatine|Phosphocreatine (1g) is given intravenously twice a day for 14 days
223493848|NCT06005376|OTHER|Breakfast rolls consisting of wheat flour with and without a E304i/zinc additive|The participants were provided with two Breakfast rolls (a 40 g) a day during the intervention week. In addition, they were provided with gluten-free foods during the whole trial.
223493849|NCT03877809|DRUG|Sirolimus 0.5 mg|Daily administration of 1 or more tablets
223493850|NCT05447832|DEVICE|Lung function monitoring equipment at home - 2 weeks|The parent/carer setup the lung function monitoring equipment (Ventica®), and placed the WheezeScan® device on the child's chest at home before the child goes to sleep. This is performed once daily for 2 weeks.
223493851|NCT05447832|DEVICE|Lung function monitoring equipment at home - 4 months|The parent/carer setup the lung function monitoring equipment (Ventica®), and placed the WheezeScan® device on the child's chest at home before the child goes to sleep. This is performed once weekly for 4 months.
223745696|NCT00233623|DRUG|Irinotecan|
223745697|NCT00233623|DRUG|5Fluorouracil|
223745698|NCT00233623|DRUG|Leucovorin|
224185578|NCT01296321|BEHAVIORAL|Tailored Internet-administrated CBT-Treatment|"This intervention contains 6-8 text-based self-help modules in which 4 modules are fixed (the first three and the last) and the rest are prescribed following the diagnostic telephone interview. These modules contain material on panic disorder, social phobia, stress management, assertiveness training, concentration, relaxation among other things."
224185579|NCT01296321|BEHAVIORAL|Waitlist|Passive waitlist during 8-10 weeks.
224185580|NCT01234142|DRUG|varenicline free base patch|varenicline transdermal delivery system (12.0 mg payload \[drug amount loaded in each patch\]) will be applied to the skin once daily for 14 days
224185581|NCT01234142|DRUG|varenicline free base patch|varenicline transdermal delivery system (18.0 mg payload \[drug amount loaded in each patch\]) will be applied to the skin once daily for 14 days
224185582|NCT01234142|DRUG|placebo patch|Matched placebo transdermal delivery system will be applied to the skin once daily for 14 days
224185583|NCT01234142|DRUG|varenicline free base patch|varenicline transdermal delivery system (24.0 mg payload \[drug amount loaded in each patch\]) will be applied to the skin once daily for 14 days
224185584|NCT01234142|DRUG|placebo patch|Matched placebo transdermal delivery system will be applied to the skin once daily for 14 days
224185585|NCT01234142|DRUG|varenicline free base patch|2 varenicline transdermal delivery systems (combined to achieve a maximum drug payload of 36 mg) will be applied to the skin, side by side once daily, for 14 days
224185586|NCT01234142|DRUG|placebo patch|Matched placebo transdermal delivery systems will be applied to the skin, side by side, once daily for 14 days
223493852|NCT05447832|DIAGNOSTIC_TEST|Inflammation and remodelling from clinical indicted bronchoscopy|For patients who are undergoing clinically indicated bronchoscopy, consent will be obtained to use any surplus clinical samples for this study. The samples to be collected are broncho-alveolar lavage and endobronchial biopsies. Both of these are taken from the airways during clinical bronchoscopy.
223493853|NCT03307850|OTHER|Observation During Exercise and Stress|"Patients with type 1 diabetes (T1D) on an insulin pump will be studied for 5 weeks in the outpatient setting performing their normal activities, to include their normal diet and exercise, while assessing the amount of type of exercise performed, and emotional stress levels, using stress sensor, questionnaires and salivary cortisol levels.~Subjects at the William Sansum Diabetes Center will perform graded exercise on a treadmill for up to 45 minutes with all activity and stress monitors running, achieving 30 and 60% calculated heart rate reserve, once during the study. Subjects at Mayo Clinic will perform a graded exercise test on a treadmill to determine V02max and ensure stable cardiac status, once during the study."
224185587|NCT04654299|PROCEDURE|External biliary stent|The biliary stent consisted of a multi-perforated, natural rubber tube, measuring 3.5 mm in diameter, that we placed transanastomotically, with exteriorization sited at 20 cm utilizing the Witzel jejunostomy approach
224185588|NCT03578211|BEHAVIORAL|Shared decision making with decision aids|For obese patients, we use shared decision making with decision aids to help them choose the suitable types of bariatric surgery.
223493854|NCT05853068|DEVICE|Mechanical ventilation|Need for endotracheal intubation and invasive mechanical ventilation
223493855|NCT01847209|PROCEDURE|Video-Assisted Thoracic Surgery (VATS) wedge resection|
223493856|NCT04706338|DEVICE|TMS treatment|Using TMS to stimulate (5 Hz, 90%\~110% resting motor threshold) patients' primary motor area and SMA.
223493857|NCT02880176|OTHER|Financial Incentive to Increase Ambulation|Financial Incentive and possibility for financial lottery entry in addition to education on the benefits of post-surgery ambulation
223493858|NCT03956706|RADIATION|Stereotactic Radiosurgery|Stereotactic radiosurgery dose escalation by either 18, 20, or 22 Gy to the subventricular zone in addition to standard of care
223493859|NCT05403918|OTHER|conventional physiotherapy|Hot pack, TENS, and therapeutic ultrasound will be applied for 10 minutes. Then glides will be given 30 x 3 times in grades III and IV. The rest of the exercises will be prescribed as 3 sets for 10 repetitions with 2 minutes of rest between sets for 6 weeks with respect to 3 sessions per week.
223493860|NCT05403918|OTHER|scapular stabilization exercises along with conventional physiotherapy|Each stretch will be repeated 3 times. Each active exercise will be progressed from 3 sets of 10 reps to 3 sets of 15 reps. If the subject easily completed 3 sets of 15 reps of active exercise, they will go on to resisted exercises. These will be performed once a day, for 6 weeks, 3 sessions per week.
223493861|NCT00000142|DRUG|Cidofovir|"Three groups:~1. the deferral group, treatment deferred until retinitis progressed~2. Low-dose cidofovir group, 5 mg/kg of body weight once weekly for two weeks, then maintenance therapy with cidofovir, 3mg/kg once every 2 weeks.~3. High-dose cidofovir group, 5mg/kg once weekly for 2 weeks, then maintenance therapy with cidofovir, 5mg/kg once every two weeks."
223493862|NCT02606305|DRUG|Mirvetuximab soravtansine|
223493863|NCT02606305|DRUG|Bevacizumab|
223493864|NCT02606305|DRUG|Carboplatin|
223493865|NCT02606305|DRUG|Pegylated Liposomal Doxorubicin|
223493866|NCT02606305|DRUG|Pembrolizumab|
223493867|NCT00984945|BIOLOGICAL|H5 VLP pandemic influenza vaccine 5 µg|0.5 mL, IM, 2 injections 21 days apart
223493868|NCT00984945|BIOLOGICAL|H5 VLP pandemic influenza vaccine 10 µg|0.5 mL, IM, 2 injections 21 days apart
223493869|NCT00984945|BIOLOGICAL|H5 VLP pandemic influenza vaccine 20 µg|0.5 mL, IM, two injections 21 days apart
224185589|NCT02119559|OTHER|Blood analysis by EPISPOT and CellSearch®|
224185590|NCT01928758|DRUG|Reduced Nicotine Content Cigarettes|Research cigarettes will have gradually reduced nicotine content
224185591|NCT01928758|DRUG|Usual Nicotine Content Cigarettes|Usual Nicotine Content Cigarettes
223493870|NCT00984945|BIOLOGICAL|Placebo|0.5 mL, IM, two injections 21 days apart
223493871|NCT00865605|DRUG|Halobetasol Propionate 0.05% Ointment, single exposure|A: Other Subjects received Alpharma/Purepac USHP formulated products
223493872|NCT00865605|DRUG|Ultravate® 0.05% ointment, single exposure|Subjects received Bristol-Myers Squibb Company formulated products
223493873|NCT02199587|BEHAVIORAL|Presence of medical clown during endocrine test|
223745699|NCT00940212|DRUG|AZD2423|oral, single administration
224185592|NCT03607968|PROCEDURE|The novel anterior TVM surgeries|A novel transvaginal mesh (TVM) surgery fro women with pelvic organ prolapse (POP) had been reported. Chang TC, Hsiao SM, Chen CH, Wu WY, Lin HH. Clinical outcomes and urodynamic effects of tailored transvaginal mesh surgery for pelvic organ prolapse. Biomed Res Int http;//dx.doi.org/10.1155/2015/191258.
224185593|NCT01393925|DRUG|parecoxib|parecoxib 40mg at 30min before the end of surgery, at 8h and 20h after the surgery, intravenously
224185594|NCT03606018|DRUG|Insulin Lispro Mix 25|insulin lispro biphasic in doses 0.4 ME/kg
224185595|NCT03606018|DRUG|Humalog® Mix 25|insulin lispro biphasic in doses 0.4 ME/kg
224185596|NCT04600518|DEVICE|nProfiler I Stomach Cancer Assay Kit|nProfiler I Stomach Cancer Assay Kit (Novomics Co., Korea)
224185597|NCT02164890|OTHER|micafungin|This is a pharmacokinetic study where a total number of 14 blood samples will be drawn per patient. Clinical and biological data will be concomitantly collected.
224185598|NCT00719706|DRUG|acetyl-l-carnitine PLUS alpha-lipoic acide|1000-3000 mg/day of acetyl-l-carnitine in addition to 600-1800 mg/day of alpha-lipoic acid.
224185599|NCT00719706|DRUG|Placebo|Placebo
224185600|NCT01540721|DRUG|Marketed paracetamol|marketed formulation
224185601|NCT01540721|DRUG|Experimental paracetamol formulation|Experimental formulation
224185602|NCT04763460|DEVICE|Programming of CRT device settings|Reprogramming of CRT device to maximize the benefit derived from the electrocardiographic assessment.
224185603|NCT01071772|DRUG|insulin|There will be used individual intravenous insulin (actrapid) infusion to prevent non-intended hyperglycemia.
224185604|NCT06088017|DRUG|CKD-391(2)|QD, PO
224185605|NCT06088017|DRUG|CKD-331, D337|QD, PO
224185606|NCT00402376|DRUG|Pravastatin, Carvedilol, Perindopril|
224185607|NCT00402376|DEVICE|Biventricular assist device (Thoratec paracorporeal assist device)|
224185608|NCT05426694|OTHER|Scapular clock exercises|In scapular clock exercises, the hand is placed on the wall in front of your body. Move the hand in direction of 12 and 6 o'clock to elevate and depress the scapula. Then move hands towards 9 o' clock and 3 o'clock direction to protract and retract the scapula. Hold each position for 10 seconds. From 3rd week and onward the patient will use thera-band and then perform clock exercises.
224185609|NCT05426694|OTHER|Stretching and strengthening exercises|Stretching and strengthening exercises of shoulder and scapular muscles was performed including wall washes, corner stretch, pectoral muscles stretch and wall push ups.
224185610|NCT02859025|BIOLOGICAL|anterior iliac crest graft|Anterior iliac crest spongy bone filled the defects followed by coverage with collagen membrane.
224185611|NCT02859025|BIOLOGICAL|lateral ramus cortical bone+BFPSC+NBBM|ramus cortical bone cage created a protected healing space and BFPSCs cultured over NBBM were put over the graft.
224185612|NCT02859025|BIOLOGICAL|anterior iliac crest graft+BFPSC+NBBM|Anterior iliac crest spongy bone filled the defects and BFPSCs cultured over NBBM were put over the spongy bone.
223493874|NCT01610193|PROCEDURE|Appendicectomy|Also known as appendectomy, surgical removal of the appendix. Laparoscopic (single or 4 port), McBurney's incision, mid-line laparotomy, laparoscopic converted to open.
223745700|NCT00940212|DRUG|Placebo|oral administration and single dose
224185613|NCT03103724|DRUG|Xtandi|Enzalutamide 160 mg (4 x 40 mg capsules), orally once daily
224185614|NCT00146458|PROCEDURE|18F-fluorodeoxyglucose positron emission tomography|
224185615|NCT03858621|DRUG|fentanyl NOL guided|Intervention is NOL monitoring in this group that will help to guide intravenous administration of fentanyl during surgery.
224185616|NCT03143465|DRUG|Calcitonin Gene-Related Peptide|
224185617|NCT03143465|DRUG|Sildenafil|
224185618|NCT03143465|DRUG|Placebo|
224185619|NCT03741257|DRUG|Hypertonic saline|resuscitation fluid
224185620|NCT02263976|DRUG|BEA 2180 BR|
224185621|NCT02263976|DRUG|Placebo|
224185622|NCT02263976|DEVICE|Respimat® A 4|
223745701|NCT02338869|BEHAVIORAL|Dialogue-based psychosocial rehabilitation|
224185623|NCT02263976|DRUG|Methacholine Chloride|methacholine challenge test
224185624|NCT02263976|DRUG|Spiriva|
224185625|NCT02264327|BEHAVIORAL|Motivational Interviewing Simulator (SIM)|The interactive, case-based, multiplayer web-based game allows service providers to deepen their skills in Motivational Interviewing (MI), a widely recognized evidence-based practice that supports people to make positive behavior changes related to health, wellness, mental illness, and addiction.The SIM will have three arenas for play, so that users can practice more advanced MI skills and include: Single Player, Two Player, and Advanced Free play. The SIM is equipped with multiple story-lines and characters to keep learners engaged over time and to provide practice on diverse case scenarios, making the Sim relevant to a wide audience. Lastly the SIM will provide an opportunity for feedback from peers and MI experts.
224185626|NCT02264327|BEHAVIORAL|Motivational Interviewing eBook (eBook)|"The Phase I research team developed a 69-page eBook as a credible online comparator that presents information comparable to that included in the Sim, but without the interactive, role-playing, peer learning functionalities embodied in the Sim. Developed in Hyperlink Markup Language, the eBook presented MI skills, followed by transcripts of effective and not-effective samples of MI from the Sim itself. The e-Book includes the story-lines along with sample dialogue and expert feedback on MI skills."
224185627|NCT02264327|BEHAVIORAL|Motivational Interviewing Training (MI Training)|The training intervention consists of a free two-day standardized Motivational Interviewing (MI) training provided by experienced MI trainers.
224185628|NCT01827462|BIOLOGICAL|Trivalent, inactivated influenza vaccine (TIV)|Licensed Seasonal Influenza Vaccine TIV
224185629|NCT01827462|BIOLOGICAL|Quadrivalent, inactivated influenza vaccine (IIV4)|Licensed Seasonal Influenza Vaccine IIV4
224185630|NCT01827462|BIOLOGICAL|High-Dose Trivalent, inactivated influenza vaccine (TIV High-Dose)|Licensed Seasonal High-Dose Influenza Vaccine TIV
224185631|NCT02452320|DRUG|intravenous acetaminophen|administration of 1000mg of intravenous acetaminophen or placebo every 6 hours for a total of 4 doses; first dose to be administered after induction of general anesthesia
224185632|NCT02452320|DRUG|Placebo|Subjects randomized to placebo will receive every 6 hours for a total of 4 doses; first dose to be administered after induction of general anesthesia
224185633|NCT01211860|DRUG|Diazoxide Choline Controlled-Release Tablet|DCCR 290 mg once a day for 10 days
224185634|NCT01384513|DRUG|Fludarabine|Given IV
224185635|NCT01384513|DRUG|Busulfan|Given IV
224185636|NCT01384513|RADIATION|Total Body Irradiation (TBI)|2 Gy administered as part of the conditioning regimen
224185637|NCT01384513|BIOLOGICAL|Donor Lymphocyte Infusion (DLI)|Undergo DLI
224185638|NCT01384513|DRUG|Cyclophosphamide (CY)|Given IV
224185639|NCT01384513|DRUG|Tacrolimus|Given IV or PO
224185640|NCT01384513|DRUG|Mycophenolate mofetil|Given IV
224185641|NCT01384513|DEVICE|Allogeneic hematopoietic stem cell transplantation|Undergo CD34+ allogeneic PBSCT
224185642|NCT01384513|PROCEDURE|Peripheral blood stem cell transplantation (PBSCT)|Undergo CD34+ allogeneic PBSCT
223493875|NCT01330927|DRUG|VA106483|"Once daily oral dose of placebo for 2 nights~Once daily oral dose of 0.5 mg VA106483 for 2 nights~Once daily oral dose of 1 mg VA106483 for 2 nights~Once daily oral dose of 2 mg VA106483 for 2 nights~Once daily oral dose of 4 mg VA106483 for 2 nights~Placebo: as above"
223493876|NCT03233750|BEHAVIORAL|Stress Inoculation Training|see description in arm/group descriptions
223493877|NCT03233750|BEHAVIORAL|Crisis Resource Management|During each scenario, facilitators identify performance gaps in either situation awareness, leadership, communication or resource allocations. During debriefing session, these are raised with the learner and their cognitive frames are identified and corrected as necessary.
223493878|NCT03735576|BEHAVIORAL|Psychotherapy|15-session individually-delivered CBT specific for LLD in comparison with a supportive unspecific intervention (SUI) of the same quantity
223493879|NCT03735576|DIAGNOSTIC_TEST|Questionnaires|There will be a total of four assessments (see primary \& secondary endpoints). The first visit of the study will be a screening and baseline (T0) visit. After the baseline assessment, the subjects will be randomized to either of the two treatment arms. Within one week, the first of the successive bi-weekly 50-minute individual face-to-face treatment sessions will be performed by a study therapist. After 7 therapy sessions, the primary and secondary outcomes will be obtained in week 5 (T1) by the blinded rater. This will be followed by the treatment sessions 8 to 15 which will be carried out by the therapist. End-of-treatment primary and secondary outcomes will be obtained in week 10 (T2). The final follow-up assessment (T3) will be performed 6 months after randomization by the blinded rater.
223493880|NCT03735576|OTHER|Magnetic Resonance Imaging|Underlying mechanisms are examined using neuroimaging. MRI data are acquired at four scanning sites and will be performed at baseline, end-of-treatment and follow-up to obtain a high-resolution structural T1-weighted image, a T2-weighted FLAIR image, a resting state fMRI, and diffusion tensor imaging (DTI) of the subjects' brain.
223493881|NCT03735576|OTHER|Blood analysis|Blood sampling will be acquired in order to investigate the underlying mechanisms in LLD and the specific effects of psychotherapy. Blood samples are acquired at five sites at baseline (T0), T1, T2 and T3 for genetic and epigenetic analyses, measurement of Amyloid-β, Neurofilament light chain (NFL), Peripheral Blood Mononuclear Cells (PBMCs), Metabolomics, Proteomics and miRNA analyses.
223493882|NCT04462146|BEHAVIORAL|Internet-based Self Applied Treatment Program|"It is a self-applied treatment for PGD through the web psicologíaytecnología.labpsitec.es. There are 8 treatment modules. Each module lasts approximately 60 minutes. It contains written information, videos, audios, photos and interactive questionnaires. The total duration of treatment is up to 8-10 weeks. A weekly support call will be made (maximum 10 minutes) to answer questions and reinforce and motivate the patient. No additional clinical content or counselling will be provided. Main components of the treatment: Motivation for change, Psychoeducation, Behavioral activation, Exposure, Mindfulness and compassion strategies, integration of loss, restoration and reconstruction of meaning, Cognitive reappraisal and Relapse prevention"
223493883|NCT04462146|BEHAVIORAL|Videoconference treatment with a therapist|"It is a treatment for PGD applied by a therapist composed of 8-10 treatment sessions. Each session lasts approximately 60 minutes. No weekly support call will be provided.~The sessions will take place by videoconference. Main components of the treatment: Motivation for change, Psychoeducation, Behavioral activation, Exposure, Mindfulness and compassion strategies, integration of loss, restoration and reconstruction of meaning, Cognitive reappraisal and Relapse prevention."
223493884|NCT04355273|DRUG|Heparin|heparin with a concentration of 2 U/ml is used for pressurized continuous flushing of the invasive arterial pressure monitoring tube
223493885|NCT04355273|DRUG|Heparin|heparin with a concentration of 4 U/ml is used for pressurized continuous flushing of the invasive arterial pressure monitoring tube
223493886|NCT04355273|DRUG|normal saline|normal saline is used for pressurized continuous flushing of the invasive arterial pressure monitoring tube
223588881|NCT01373320|BEHAVIORAL|Lay health advisor interactions|"For smoking cessation: Cooper-Clayton group sessions plus motivational interviewing, both delivered by local lay health advisor.~For all cancer screenings: lay health advisor home visits incorporating motivational interviewing and focused on decreasing participant-identified barriers to screening."
223588882|NCT03517969|DRUG|Berzosertib|Given IV
223588883|NCT03517969|DRUG|Carboplatin|Given IV
223588884|NCT03517969|DRUG|Docetaxel|Given IV
223588885|NCT03517969|OTHER|Laboratory Biomarker Analysis|Correlative studies
223588886|NCT03060954|DEVICE|MINI WELL READY ®|BILATERAL IMPLANTATION OF MINI WELL READY®, A PROGRESSIVE EXTENDED DEPTH OF FOCUS INTRAOCULAR LENS IN PATIENTS WITH CATARACT SURGERY
223588887|NCT03060954|DEVICE|FINE VISION®|FINE VISION®, A TRIFOCAL INTRAOCULAR LENS IMPLANTATION IN PATIENTS WITH CATARACT SURGERY
223588888|NCT00596141|DEVICE|OroScience Topical Oral Wound Emulsion|TOWE will be applied 3 times daily for a period of 7 days by the patient dispensing TOWE into a disposable dental tray and placing the dental tray over the dental arch and covering the surgical site.
223588889|NCT05788133|OTHER|treatment and screening by neuropsychological tests on humanoid robot|treatment and screening by neuropsychological tests on humanoid robot
224185643|NCT04916808|DIAGNOSTIC_TEST|DCISionRT Test|The Prelude DCISionRT Test was developed by Prelude Corporation and is performed at its CLIA laboratory facility. The biomarkers used to evaluate the biologic signature of DCIS tissue are based on over a decade of research including the University of California, San Francisco, Yale University as well as Prelude Corporation. The test is prognostic for 10-year recurrence risk and predicts RT treatment benefit for invasive breast cancer. The laboratory is regulated under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high-complexity clinical testing and is accredited by the College of American Pathologists (CAP).
223588890|NCT01091818|DRUG|dexmedetomidine|Dexemedethomidine is given as major sedative drug
223493887|NCT06339840|DIETARY_SUPPLEMENT|Low-carbohydrate diet group|During the initial 8-week weight loss phase, participants will adopt a low-carbohydrate dietary pattern (with carbohydrate energy ratio of 20-30%, protein energy ratio of 30-40%, and fat energy ratio of 40-45%), with a caloric intake approximately 75% of their usual daily intake, but not less than 1200 kcal. Throughout the intervention period, participants will receive a daily nutritionally balanced meal replacement for 8 weeks to substitute for staple foods and control carbohydrate intake. Nutritionists will reinforce interventions by setting health goals, providing health education, implementing dietary and exercise interventions, and monitoring through a combined approach using a mobile platform. During the subsequent 4-week transition phase, participants' diets will gradually transition to a balanced dietary pattern (with carbohydrate energy ratio of 45-60%, protein energy ratio of 20-30%, and fat energy ratio of 20-25%) under the guidance of nutritionists.
223493888|NCT06339840|BEHAVIORAL|Health Education Group|Upon enrollment, nutritionists will provide lifestyle guidance to patients, including personalized adjustments such as limiting total energy intake to \<1600 kcal/day, adjusting macronutrient distribution to 45-55% for carbohydrates, 20-30% for fats, and 20-30% for protein. Participants are advised to accumulate at least 150 minutes of moderate-intensity aerobic exercise per week (achieving 50%-70% of maximum heart rate). At enrollment, nutritionists will educate participants on healthy lifestyle principles, train them on nutritional intervention tools, and assist in food selection for weight management planning. Throughout the intervention, nutritionists will conduct follow-ups with patients via phone or mobile platforms to monitor weekly dietary and exercise habits, weight changes, and address any participant concerns promptly.
223493889|NCT02008370|DRUG|Exparel infiltration|Exparel infiltrated into wound and chest tube sites
223493890|NCT00601627|BIOLOGICAL|panitumumab|
223493891|NCT00601627|DRUG|capecitabine|
223493892|NCT00601627|DRUG|fluorouracil|
223493893|NCT00601627|DRUG|gemcitabine hydrochloride|
223493894|NCT00601627|RADIATION|radiation therapy|
223493895|NCT04999787|DRUG|HSK21542|HSK21542-0.3 μg/kg，HSK21542-0.6 μg/kg
223493896|NCT04999787|DRUG|Placebo|Placebo
223588891|NCT01091818|DRUG|Midazolam|Midazolam is given as major sedative drug
223588892|NCT04318327|BIOLOGICAL|PHE885|Infusion
223588893|NCT00687102|DRUG|tamoxifen|oral tamoxifen plus placebo daily for 5 years
223588894|NCT00687102|DRUG|raloxifene|oral raloxifene plus placebo daily for 5 years
223588895|NCT02227394|DRUG|Z7200|"Total dose budesonide/formoterol is 160 mcg/4.5 mcg) to be administered only with the inhaler device (RS-01).~At visit 2 or 3 (cross-over design)"
224185644|NCT03198559|DRUG|Disulfiram, (National Drug Code) NDC 0378-4141-01|This study will provide open label disulfiram. Participants will take 2 grams (4x500mg tablets) of disulfiram per day for a total of 28 days
224185645|NCT03198559|DRUG|Vorinostat, NDC 00006-0568-40|This study will provide open label vorinostat. Participants will take 400mg (4x100mg capsules) of vorinostat per day on days 8, 9, 10 and days 22, 23, 24.
224185646|NCT01072175|DRUG|GSK2118436|GSK2118436 is a potent and selective inhibitor of BRAF kinase activity with a mode of action consistent with adenosine triphosphate-competitive inhibition.
224185647|NCT01072175|DRUG|GSK1120212|GSK1120212 is a potent and highly selective inhibitor of MEK1/2 activation and kinase activity.
224185648|NCT00755976|DRUG|epirubicin hydrochloride|
223493897|NCT02479490|DRUG|Prednisone + Everolimus|"Prednisone + Everolimus: Everolimus is formulated as tablets of 5-10 mg strength, blister-packed under aluminium foil in units of 10 tablets. Prednisone will be dispensed to patients at the dose of 5 mg twice daily (BID). Everolimus at dose of 10 mg (one 10 mg tablet or two 5 mg tablets). Both drugs will be self-administered orally, continuously from Day 1 (Visit 2) until progression of disease, unacceptable toxicity, death or discontinuation for any other reason.~A treatment cycle consists of 28 days."
223493898|NCT02749734|PROCEDURE|Subretinal transplantation|Transplant hESC-RPE into subretinal space of patients with macular degeneration
223493899|NCT04884568|DEVICE|Exufiber|Wound dressed with Exufiber for up to 21 days.
223493900|NCT01858948|DRUG|Omega|Omega-3 supplements
223493901|NCT01858948|DRUG|Placebo|Similar in shape and color to Omega supplements
223493902|NCT01858948|DRUG|Quetiapine fumarate|Prior to randomization to Omega/placebo, patients were started on 100 mg BID of quetiapine, and the dose adjusted based on tolerability and response. The quetiapine target dose is 400-600 mg.
223493903|NCT03317496|DRUG|Avelumab 800 mg in combination with pemetrexed / carboplatin|Avelumab Pemetrexed Carboplatin
223588896|NCT02227394|DRUG|Symbicort® Turbohaler®|Total dose budesonide/formoterol is 320 mcg/9 mcg. At visit 2 or 3 (cross-over design)
223588897|NCT04390724|DEVICE|Y90 radioembolization|Patients with HCC who are eligible to receive standard-of-care Y90 radioembolization and are hepatic resection candidates with inadequate future liver remnant
223588898|NCT06038227|PROCEDURE|Robotic Assisted Thoracic Surgery|Surgeons will pre-determine to perform a segmentectomy or lobectomy using RATS.
223588899|NCT06038227|PROCEDURE|Video Assisted Thoracic Surgery|Surgeons will pre-determine to perform a segmentectomy or lobectomy using VATS.
223588900|NCT05373693|DEVICE|Single vision lens|Wear single vision lens
223588901|NCT05373693|DEVICE|+2D PDL|Wear Peripheral defocus lense with +2D
223588902|NCT05373693|DEVICE|+3D PDL|Wear Peripheral defocus lense with +3D
223588903|NCT05373693|DEVICE|+4D PDL|Wear Peripheral defocus lense with +4D
223588904|NCT04396158|RADIATION|radioactive iodine|80-200 mCi of radioactive iodine will be given to thyroid cancer patients
223588905|NCT03680300|OTHER|Post Facilitation Stretch|"The Post Facilitating Stretch technique is performed as follows:~The hamstring muscle will be placed between a fully stretched and a fully relaxed state. The patient will be asked to contract the agonist using a maximum degree of effort for 5-10 seconds while the therapist resists the patients force. The patient will then be asked to relax and release the effort, whereas the therapist will apply the rapid stretch to a new barrier and will be held for 10 seconds. Then the patient will relaxes for approximately 20 seconds and the procedure will be repeated between three to five times and five times more. Instead of starting from a new barrier, the muscle will be placed between a fully stretched and a fully relaxed state before every repetition."
224185649|NCT00755976|DRUG|sulindac|
224185650|NCT00755976|OTHER|immunologic technique|
223745702|NCT01613521|OTHER|DCE-MRI and 18F-FMISO PET|DCE-MRIs: (i) Baseline DCE-MRI within two weeks before chemoradiation; (ii) Second DCE-MRI after the second week of chemoradiation (within a week); (iii) Third DCE-MRI three months after chemoradiation. iii. 18F-FMISO PET: Baseline 18F-FMISO PET within two weeks before chemoradiation (only 10 patients as a pilot study). iv. Clinical Follow-up: (i) Physical examination (every 3 months); (ii) Pap smear or cervical biopsy (every 3 months); (iii) follow-up imaging studies (CT and/or MRI) as per routine clinical follow-up of patients.
224185651|NCT05804539|BEHAVIORAL|Manual therapy|The therapist checks the range of motion of the cervical joints and gives manual treatment to the restricted joints. Throughout the examination, the subject lied in a supine position on a professional rehabilitation bed with the seventh cervical vertebra (C7) on the edge of the bed and the other the body above the C7 were placed off the bed. The therapist held the subject's occipital bone with one hand and the radial aspect of the second metacarpophalangeal joint of the other hand to grip the spinous process of the sixth cervical vertebra and slowly pushed the occiput downward to check the joint mobility of the fifth cervical vertebra and the sixth cervical vertebra. After the examination, the restricted joint was accurately located and treated with targeted manual therapy. For example, stretching was performed with the right side of C4-C5 flexed, closing only the right side of the subject's C4-C5 as much as possible to increase joint mobility on the right side of C4-C5.
224185652|NCT05804539|BEHAVIORAL|Tai Chi|Based on the characteristics of young people and the need to correct their FHP, the classic Yang's 24 Forms of Tai Chi has been improved. The movements are mostly upper limb movements and the lower limb movements have been simplified to make the movements easy to learn. The modified Tai Chi exercise retains the traditional Tai Chi movements but is simple and easy to learn; at the same time, it increases the movement of the shoulder and neck joints. The subjects performed each exercise session in a group setting at the school gymnasium, with a professional Tai Chi instructor guiding them through a warm-up session, followed by a Tai Chi exercise session.
224185653|NCT05804539|BEHAVIORAL|Tai Chi and Manual therapy|Intervention content of MSG included 15-min Tai Chi exercise and 15-min manual therapy, with the order of intervention being Tai Chi exercise first and then manual therapy.
224185654|NCT04725864|DRUG|Progesterone vaginal tablet|The study drug is progesterone 100 mg administrated as a vaginal tablet three times daily.
224185655|NCT01379339|DRUG|Cabazitaxel 10mg/m2|"* Cabazitaxel on D1 Dose: 10mg/m2 IV x 1 Route: Intravenous infusion over 60 minutes, mixed as described in protocol over 1 hour Schedule: Day 1, every 21 days (+ 2 days)~* Cisplatin on D1 Dose: 100 mg/m2 Route: Intravenous infusion over 60 minutes to 3 hours, mixed in 1000 ml of normal saline Schedule: Day 1, every 21 days (+ 2 days)~* 5 Fluorouracil on D1-D4 Dose: 800 mg/m2/day Route: 24-hour continuous infusion over 4 days Schedule: Days 1, 2, 3 and 4 of Cycles 1, 2 and 3 (every 21 days) + 2 days)"
224185656|NCT01379339|DRUG|Cabazitaxel 12.5mg/m2|"* Cabazitaxel on D1 Dose: 12.5mg/m2 IV x 1 Route: Intravenous infusion over 60 minutes, mixed as described in protocol over 1 hour Schedule: Day 1, every 21 days (+ 2 days)~* Cisplatin on D1 Dose: 100 mg/m2 Route: Intravenous infusion over 60 minutes to 3 hours, mixed in 1000 ml of normal saline Schedule: Day 1, every 21 days (+ 2 days)~* 5 Fluorouracil on D1-D4 Dose: 800 mg/m2/day Route: 24-hour continuous infusion over 4 days Schedule: Days 1, 2, 3 and 4 of Cycles 1, 2 and 3 (every 21 days) + 2 days)"
223493904|NCT03317496|DRUG|Avelumab 800 mg in combination with gemcitabine / cisplatin.|Avelumab Gemcitabine Cisplatin
223493905|NCT03317496|DRUG|Avelumab 1200 mg in combination with pemetrexed/carboplatin|Avelumab Pemetrexed Carboplatin
223493906|NCT03317496|DRUG|Avelumab 1200 mg in combination with gemcitabine/cisplatin|Avelumab Gemcitabine Cisplatin
223493907|NCT02737618|DEVICE|"Trojan Chameleon Personal Lubricant"|silicone base with sensate
223493908|NCT00977418|BEHAVIORAL|SMART- Strategic Memory and Reasoning Training|Teach people to filter out un necessary or unimportant details to enhance mental efficiency. This training will be done over 12 weeks for 3 hours each week.
223493909|NCT00977418|OTHER|Physical Exercise|The group with undergo 1 hour of aerobic exercise (at 50-70 % of the participants max oxygen intake) 3 times a week for 12 weeks.
223493910|NCT01684605|DRUG|NESP 60μg|Administrated NESP 60μg once intravenously
223493911|NCT01684605|DRUG|CKD-11101 60μg|Administrated CKD-11101 60μg once intravenously
223493912|NCT03014362|DEVICE|Neuronetics NeuroStar XPLOR magnetic stimulator - Active|"Localization: Left prefrontal dorsolateral neocortex. Dose Delivery: Figure-8 solid core coil at 120% motor threshold, 10 Hz, 4 second train duration, 10 second interval for 30 minutes.~Treatment Dose: \~4k/session, 12-15k/day, 36-45k total pulses. Sessions: 9 in total; 3/day for 3 consecutive days over and above SOC."
223493913|NCT03014362|DEVICE|Neuronetics NeuroStar XPLOR magnetic stimulator - Sham|Localization: Left prefrontal dorsolateral neocortex. Sham Delivery: Figure-8 solid core coil rendered inert via blocking insert. Dose: Zero pulses. Sessions: 9 in total; 3/day for 3 consecutive days over and above SOC.
223493914|NCT01503801|DRUG|Nitric Oxide|The infants in experimental group will receive inhale nitric oxide initiated at 5 ppm for 24 h followed by 2 ppm for 6 days or until weaning off
223493915|NCT01503801|DEVICE|respiratory support|Routine respiratory support.
223493916|NCT02716285|DRUG|Ileocolonic release peppermint oil|Peppermint oil, menthae piperitae aetheroleum
223493917|NCT02716285|DRUG|Placebo|Placebo capsule, containing microcrystalline cellulose
223493918|NCT02716285|DRUG|Small intestinal release peppermint oil|Peppermint oil, menthae piperitae aetheroleum
223493919|NCT00038415|BIOLOGICAL|CLL vaccine using DNA plasmid vector|
223493920|NCT00989027|DRUG|Oxytocin|Oxytocin, 10-9mol/L to 10-3mol/L, in Krebs-Henseleit solution.
223493921|NCT00989027|DRUG|Ergonovine|Ergonovine, 10-9mol/L to 10-3mol/L, in Krebs-Henseleit solution.
223493922|NCT00989027|DRUG|Carboprost|Carboprost, 10-9mol/L to 10-3mol/L, in Krebs-Henseleit solution.
223493923|NCT00989027|DRUG|Oxytocin and Ergonovine|Oxytocin and Ergonovine, 10-9mol/L to 10-3mol/L, in Krebs-Henseleit solution.
223493924|NCT00989027|DRUG|Oxytocin and Carboprost|Oxytocin and Carboprost, 10-9mol/L to 10-3mol/L, in Krebs-Henseleit solution.
223493925|NCT03907423|DRUG|Rosuvastatin10 mg tablet|Diabetic patients treated with Rosuvastatin 10mg/day plus Glimepiride 1-8mg/day and Metformin 500-2550 mg/day oral
223493926|NCT03907423|DRUG|Placebo Oral Tablet|Diabetic patients treated with Glimepiride 1-8mg/day and Metformin 500-2550 mg/day oral
223493927|NCT04650620|DEVICE|Plenhyage® thin|0.75%
223493928|NCT04650620|DEVICE|Plenhyage® medium|2%
223588906|NCT03680300|OTHER|Post Isometric Relaxation|"The Post Isometric Relaxation technique is performed as follows :~The hamstring muscle will be taken to a length just short of pain, or to the point where resistance to movement is first noted. A submaximal (10-20%) contraction of the hypertonic muscle will be performed away from the barrier for between 5 and 10 seconds and the therapist applies resistance in the opposite direction. The patient should inhale during this effort. After the isometric contraction the patient will be asked to relax and exhale while doing so. Following this a gentle stretch will be applied to take up the slack till the new barrier. Starting from this new barrier, the procedure is repeated two or three times."
223588907|NCT03680300|OTHER|Friction Massage|Each patient in group C will receive hot pack along with Tens for 20 mins then the patients will receive frictional massage alone for about one months on daily basis. Friction massage on hamstrings will be given for 20 mins by thrive massager by a therapist.
223588908|NCT06321965|OTHER|evaluation of muscle function|Myogrip (≥ 6 years): precise dynamometric measurement of gripping force, measuring force in Newton up to 90kg with 0.01kg resolution. It's evaluated at D0, M6, M12, M18, and M24 Myopinch (≥ 6 years) : measure thumb-index force up to 15 kg with a resolution of 0.001 kg using a precision sensor equipped with two steel distance blades. It's evaluated at D0, M6, M12, M18, and M24
223588909|NCT06321965|OTHER|First-line cognitive assessment|"Vineland-II (All patients) : is a scale for assessing adaptive behaviors. will be carried out during the telephone call at M1/V2.~All tests are evaluated at D0, and M18 :~Bayley-4 language part (\< 42 months) PVSE (≥ 4 years) CELF-5 (≥ 5 years) Conners-3 (≥ 6 years) AQ (≥ 4 years), EQ (≥ 11 years)~M-CHAT-R (\< 4 years) :~SRS-2 (≥ 2 years)"
223588910|NCT06321965|OTHER|second-line cognitive assessment|"In the event of positive cognitive screening at D0 or M18, a second-line cognitive assessment will be carried out at a subsequent visit. A list of tests is proposed below, but will be adapted according to the tests available at each center.~* EVALO BB (0-2 years) or EVALO (2-6 years) or full CELF-5 (5-18 years) following positive screening in the communication domain of first-line tests (Vineland II communication domain, Bayley 4, CELF-5 pragmatic profile)~* FEE and DSM-5 diagnostic criteria for ADHD (from age 6 only) following positive screening in the attention and executive functions domain of first-line tests (Conners 3, BRIEF)~* M-CHAT-R/F (\< 4 years) or SCQ (≥ 4 years) and ADOS-2 (≥ 12 years) following a positive screening in the area of social cognition and autistic traits on first-line tests (Vineland II, M-CHAT-R, SRS-2, EQ, AQ)."
223588911|NCT06321965|OTHER|Cardiac evaluation|"All tests are evaluated at D0, M12, and M24 :~Electrocardiogram (ECG) : This examination will be carried out in accordance with the 12 leads recording the following parameters: verification of sinus rhythm, P wave, PR interval, QRS complex (interval), ST segment, T wave, QT complex, heart rate.~Cardiac ultrasound: Non-invasive ultrasound will focus on the following parameters measured from 2-dimensional images, to look for cardiomyopathy and/or structural abnormality:~* end-diastolic/end-systolic diameter/left ventricular ejection fraction~* Septal wall thickness / left ventricular posterior wall~* Fractional shortening 24-hour Holter-ECG : This examination consists of a continuous test recording the heart rhythm for 24 hours."
223588912|NCT06321965|RADIATION|MRI|"Cerebral MRI : Performed at D0, only for patients with ASI type 1 ≥ 6 years, or younger patients for whom the investigator considers that the examination can be performed without sedation or general anesthesia. It will include sequences:~* 3D T1, gradient echo, 1.1 mm voxel, sagittal acquisition~* axial T2, spin-echo, slice thickness 4 mm~* 3D FLAIR, spin-echo, 1 mm voxel, sagittal acquisition Muscular MRI: performed at V1/J0, and V6/M24. The examination will include water-fat imaging (Dixon) in full-body, 3D mode, with proton density weighting and millimeter resolution."
223617726|NCT01573546|BEHAVIORAL|DASH diet|Participants in the DASH condition only receive instruction in modifying the content of their diet to meet DASH guidelines. Participants will be explicitly asked not to exercise and to focus their attention on what they eat. Participants will have been told (in the initial consent form) that the study is designed to study effects of two interventions (altering diet content and exercise) both of which have been shown to improve health. Participants will also be told that it may be easier or more effective for them if they focus first on learning to alter diet content, and they are free to exercise at the end of the 6-month period. Following an initial 1-day feeding period, participants, along with their study partners, will receive instruction on the DASH diet and feedback on their adherence to the diet in a series of half-hour, weekly small group sessions (3 to 4 participants).
224185657|NCT01379339|DRUG|Cabazitaxel 15mg/m2|"* Cabazitaxel on D1 Dose: 15mg/m2 IV x 1 Route: Intravenous infusion over 60 minutes, mixed as described in protocol over 1 hour Schedule: Day 1, every 21 days (+ 2 days)~* Cisplatin on D1 Dose: 100 mg/m2 Route: Intravenous infusion over 60 minutes to 3 hours, mixed in 1000 ml of normal saline Schedule: Day 1, every 21 days (+ 2 days)~* 5 Fluorouracil on D1-D4 Dose: 800 mg/m2/day Route: 24-hour continuous infusion over 4 days Schedule: Days 1, 2, 3 and 4 of Cycles 1, 2 and 3 (every 21 days) + 2 days)"
223493929|NCT04650620|DEVICE|Plenhyage® strong|2.5%
223493930|NCT04324320|DIAGNOSTIC_TEST|medical assessment|"medical assessment includes the collection of~* sociodemographic data~* anthropometric data (weight, height, body mass index)~* medical data~* psycho-oncologic basis assessment (PO-BADO questionnaire)~* pain assessment (VAS: visual analogue scale)~* 3 functional tests:~  * handgrip strength~ * 6 Minute Walking Test~ * Timed Get up and Go Test"
224185658|NCT01379339|DRUG|Cabazitaxel 17.5mg/m2|"* Cabazitaxel on D1 Dose: 17.5mg/m2 IV x 1 Route: Intravenous infusion over 60 minutes, mixed as described in protocol over 1 hour Schedule: Day 1, every 21 days (+ 2 days)~* Cisplatin on D1 Dose: 100 mg/m2 Route: Intravenous infusion over 60 minutes to 3 hours, mixed in 1000 ml of normal saline Schedule: Day 1, every 21 days (+ 2 days)~* 5 Fluorouracil on D1-D4 Dose: 800 mg/m2/day Route: 24-hour continuous infusion over 4 days Schedule: Days 1, 2, 3 and 4 of Cycles 1, 2 and 3 (every 21 days) + 2 days)"
223493931|NCT04324320|DIAGNOSTIC_TEST|psychological assessment|"psychological assessment includes several standardized screening and assessment questionnaires and tools:~* quality of life: SF-36~* anxiety, depression, stress: Hospital Anxiety and Depression Scale (HADS-D)~* subjective stress perception: Perceived Stress Scale (PSS-10)~* resilience: resilience scale (RS-13)~* fatigue: Brief Fatigue Inventory (BFI)~* disability related to pain: Pain Disability Index (PDI)~* workability: Work Ability Index - short version (WAI-K)~* psychological assessment based on the checklist of the International Diagnoses (IDCL) for ICD-10 and the ICD-10 checklist of symptoms for psychological disorders (SCL))"
223493932|NCT01879852|BEHAVIORAL|Quadriceps intensive strengthening|Quadriceps intensive strengthening includes high-intensity neuromuscular electrical stimulation to the quadriceps muscle for 10 minutes and overload to the the eccentric phase of quadriceps strengthening exercises.
224185659|NCT01379339|DRUG|Cabazitaxel 20mg/m2|"* Cabazitaxel on D1 Dose: 20mg/m2 IV x 1 Route: Intravenous infusion over 60 minutes, mixed as described in protocol over 1 hour Schedule: Day 1, every 21 days (+ 2 days)~* Cisplatin on D1 Dose: 100 mg/m2 Route: Intravenous infusion over 60 minutes to 3 hours, mixed in 1000 ml of normal saline Schedule: Day 1, every 21 days (+ 2 days)~* 5 Fluorouracil on D1-D4 Dose: 800 mg/m2/day Route: 24-hour continuous infusion over 4 days Schedule: Days 1, 2, 3 and 4 of Cycles 1, 2 and 3 (every 21 days) + 2 days)"
224185660|NCT02204722|DRUG|600mg/day of Imatinib|
224185661|NCT02204722|DRUG|400mg/day of Imatinib|
223493933|NCT01879852|BEHAVIORAL|Standard rehabilitation|Standard rehabilitation will include interventions for typical knee impairments (effusion, knee motion deficits, lower extremity muscle weakness, and gait deviations) as well as advanced rehabilitation interventions as indicated (jump and agility exercises)
223493934|NCT05124678|DRUG|Isoniazid Tablets|High dose of isoniazid
223493935|NCT05217264|OTHER|Assesment|This is a single-center, prospective, observational study. The assessment and reporting will be followed the Consensus-Based Standards for the Selection of Health Status Measurement Instruments (COSMIN) checklist.
223493936|NCT02696616|DRUG|BI 655088|
223493937|NCT02696616|DRUG|Placebo|
223493938|NCT00884065|OTHER|Diacutaneous Fibrolysis|The implementation of the technique consists of three consecutive stages: The first stage involves manual palpation, which is carried out by the hand that is not holding the hook, with the objective to find the area to be treated; the second, or instrumental palpation stage, is carried out by introducing the spatula of the hook together with the index finger of the palpatory hand to locate with precision the adherent connective fibers or fibrous corpuscles; the third, or fibrolysis stage, is the actual treatment. Here, a brief supplementary traction is carried out with the hook.
223493939|NCT00884065|OTHER|Diacutaneous Fibrolysis (placebo)|The placebo was designed for this study and the stages of manual and instrumental palpation occur strictly at a superficial level. In the third stage, instead of fibrolysis a pinch of skin is hold with the thumb of the palpatory hand and the tip of the spatula, so that the patient feels the hook distinctly but without any action taking place on the deep tissular planes.
223493940|NCT06208332|BEHAVIORAL|Photo-Narrative|Photo-Narratives include 1-3 photos of the pediatric patient and their family to tell a story about palliative care topics that are shared with the child's clinicians.
223493941|NCT04553315|PROCEDURE|chest expansion exercises|Chest mobility exercises with Incentive spirometer and segmental breathing exercise ) and breath stacking technique e.
223493942|NCT01500083|DRUG|Bendamustine at a dose of 100 mg/m2|Bendamustine will be administered intravenously over 30 minutes.
223493943|NCT01500083|DRUG|Bendamustine at a dose of 120 mg/m2|Bendamustine will be administered intravenous (i.v.) over 60 minutes.
223588913|NCT06321965|OTHER|Assessment of activity and muscle fatigue|"Syde® : evaluated at D0, M6, M12, M24. Patients aged 2 and over will receive the Syde® wearable device to collect their daily activities.~Muscular endurance tests (≥ 6 years) : evaluated at D0, M12, M24 ( only one of 3 tests based on motor function level) oESNHPT : In this test, patients are asked to walk a 10-meter path. oESBBT : In this test, patients have to move 10 blocks over a partition. oESWT: In this test, patients must repeatedly place and remove 9 sticks in 9 holes.~PedsQL Fatigue (≥ 2 years): evaluated at D0, M12, M24. Scale designed to measure fatigue in patients with acute and chronic conditions, as well as in healthy school and community populations.~Fatigue rating scale (≥ 6 years): evaluated at D0, M12, M24. The fatigue assessment scale has 11 numerical points ranging from 0 to 10. The patient is asked to give a rating that best reflects his or her perception of fatigue at that particular moment."
223588914|NCT06321965|OTHER|Assessment of bulbar function|"DDD-pNMD (≥ 2 years) : evaluated at D0, M6, M12, M18, and M24, is a list of 9 questions used by doctors to screen for dysphagia and dysarthria.~NdSSS (All Patients) : evaluated at D0, M6, M12, M18, and M24, is an 8-level scale for assessing swallowing.~TOMASS-c : (≥ 4 years of age, in patients able to eat solids safely, after assessment of the risk of a false route by the speech therapist): this is a score designed to assess mastication when eating a cracker. Age-dependent standards exist for different types of cracker.~\- Fluid intake test (\> 110 cm, in patients able to drink a liquid safely, after assessment of the risk of a false route by the speech therapist): swallowing limit."
223493944|NCT03035539|OTHER|Cardiac rehabilitation|AF specific cardiac rehabilitation Group education 1 hour each week for 3 months Physical training 1 hour each week for 3 months with physiotherapist
223493945|NCT03035539|OTHER|Standard treatment|Standard treatment
223493946|NCT00176332|DRUG|rosuvastatin|
223493947|NCT00429247|DRUG|Trastuzumab|Trastuzumab,first administration at the dose of 8mg/Kg IV, subsequent administrations at the dose of 6mg/Kg IV,every 3 weeks for 6 cycles
223493948|NCT02744768|DRUG|Dasatinib|Adult Ph+ ALL (≥18 years old, with no upper age limit) patients will begin treatment with Dasatinib, 140 mg/day, from day 1 to day +84.
223493949|NCT02744768|DRUG|Blinatumomab|"Upon induction:~patients in CHR will receive Blinatumomab at a dose of 15 µg/m²/day as continuous intravenous infusion (CIVI) at a constant flow rate for four weeks, followed by a two-week infusion-free interval, defined as one treatment cycle. At least 2 cycles should be administered, up to a maximum of 5 cycles, if deemed necessary."
223493950|NCT01555931|DRUG|Levonorgestrel-releasing intrauterine system|Placement within 48 hours of delivery
223493951|NCT02499315|DRUG|AMG 357|Oral tablets in 20 count bottles. Dose strengths include 5, 25, and 50 mg tablets.
223493952|NCT02499315|DRUG|Placebo|Oral tablets in 20 count bottles. Dose strengths include 5, 25, and 50 mg tablets.
223493953|NCT01063907|DRUG|KW-2478|Administered Days 1, 4, 8 and 11 of a 21 day cycle
223493954|NCT01063907|DRUG|Bortezomib|Administered on Days 1, 4, 8 and 11 of a 21 day cycle
223493955|NCT04831658|DRUG|the dose-escalation phase|"The study adopts the 3+3 design,The dose planned to be explored is the daily oral dose of the BTK inhibitor abutinib, which is 100 mg, 150 mg and 200 mg, respectively.Orelabrutinib continues to be taken orally until the tumor is relieved for 3 months; PD-1 monoclonal antibody is used by intravenous drip, 21 days as a treatment cycle, and a total of 1 year of observation; formustine is used by intravenous drip for 21 days It is a treatment cycle, a total of 6 cycles of observation; after 2 cycles, the efficacy is evaluated, and adverse reactions are recorded. At the same time, MTX 12mg+Ara-C 50mg+Dex 5mg was injected into the CSF cytology-positive sheath, and intrathecal injection once per treatment cycle, a total of 6 times."
223588915|NCT06321965|OTHER|Evaluation of body composition and metabolism|"Food survey : The dietary survey questionnaire will be sent to parents at D0 and M18. Parents will be asked to complete it for 3 days before the M6 and M24.~Bioelectrical impedancemetry: Evaluated at M6 and M24. Renal ultrasound: Evaluated at M6, is a non-invasive examination that analyzes the appearance of the kidney and urinary tract.~Dual-energy X-ray absorptiometry (DXA) : Evaluated at M6, it measures body composition using spectral imaging, including fat mass, lean mass and bone mineral density.~Fibroscan : Evaluated at M6 and M24. This examination uses pulse elastography to measure liver elasticity, which provides information on the presence of hepatic fibrosis, and sound attenuation, which provides information on the presence of liver fat overload.~Indirect calorimetry : Evaluated at M6. This device enables precise measurement of Resting Energy Expenditure , Respiratory Quotient and metabolic substrate oxidation."
223588916|NCT06321965|OTHER|Questionnaires|"SMAIS : The questionnaire has been developed specifically for ASI. At D0, M6, M12, M18 and M24.~HUI2 : specializes in preference-based measures of health-related quality of life. At D0, M6, M12, M18 and M24.~Peds QL : is a modular instrument designed to measure health-related quality of life and disease-specific symptoms. At D0, M6, M12, M18 and M24.~Neuromuscular module : 17 disease-related items. It is evaluated at D0, M6, M12, M18 and M24.~Family impact module : It measures parents' reported physical, emotional, social and cognitive functioning, communication and concerns. At D0, M12, and M24.~ASI cost questionnaire: At visit 1 (D0): This questionnaire, completed by the parents, includes information on occupation, parents' working hours and any reduction in them due to the child's pathology, the number of working days missed by the parents or school days missed by the child, and disability-related costs."
223588917|NCT06321965|BIOLOGICAL|Biocollection|"A blood bio collection (optional) will be offered to patients at D0, M6 , M12, M18, M24.~Patients receiving intrathecal injections will also be offered the opportunity to participate in a CSF (cerebrospinal fluid) biocollection (optional)."
223588918|NCT06321965|OTHER|Skinfold measurement|The tricipital point should be marked on the posterior aspect of the arm, on the midline of the tricipital muscle, midway between the acromion and the radius. At D0, M6, M12, M18 and M24
223588919|NCT05562778|OTHER|Chatbot|A chatbot is a software program designed to simulate human conversation, typically via text. Chatbots utilize natural language processing to gather patient data, anticipate questions, and predict responses. In this study, the Chatbot will simulate a text-like conversation with patients via a smartphone and use this platform to deal with the time-consuming nature of family history collection. The chatbots can then triage the collected family history against medical guidelines to determine which patients warrant genetic testing. For those patients meeting criteria for genetic testing, the chatbot can offer pre-test education and assist physicians with ordering genetic testing for interested patients meeting high-risk criteria.
223588920|NCT06259136|PROCEDURE|A transitional palliative care intervention|The Pal-Cycles intervention starts just before the care transition from curative oncology care to palliative care with a goals of care conversation between a hospital care provider and the patient. The conversation will be recorded in a summary of treatment and care form which will be completed by a hospital based clinician based on the key elements of the conversation with the patient and the treatment and care plan. Afterwards a (digital) copy of the form is given to the patient and another copy is sent to the general practitioner in combination with the discharge letter.
223588921|NCT05863650|DEVICE|Digital based simulation|Algorithms will be created for various musculoskeletal diseases and these algorithms will be controlled by taking the opinions of physiotherapists and physicians who are experts in their fields. After the algorithms are created, a website with patient scenarios containing these algorithms will be established with the support of a software company. In addition to the website, a database will be created and the applications made on the site will be recorded. In this way, the data of users using the website will be collected.
223588922|NCT05863650|OTHER|Face to face education|In the face-to-face education group, one case analyzes will be applied by the students together with the educators themselves in the classroom environment, with the educational content prepared in parallel with the patient scenarios in the simulation-based education group.
223745703|NCT00891358|BEHAVIORAL|Prevention Empowerment Intervention for Young Women|"Using three intervention sites, focus groups will guide the development of the intervention's framework and content areas. An initial list of content areas and potential activities for presentation to the focus groups will be developed by the protocol team by reviewing existing HIV prevention interventions that have been implemented with adolescents and young adults, as well as interventions that have targeted HIV+ populations.~The three focus groups will be convened (1 per selected ATN site) with young women living with HIV to solicit information on their intervention needs."
223745704|NCT01254435|PROCEDURE|Colonoscopy|Recording of colonoscopic extubation
223745705|NCT05678062|DIAGNOSTIC_TEST|Point-of-care ultrasound|An ultrasound examination (approximately 35-40 minutes in duration) will be performed. The ultrasound examination will consist of evaluation of lung- and cardiac ultrasound, as well as optic nerve sheath diameter.
223745706|NCT06368232|OTHER|püPatients undergoing bariatric surgery|Patients will not be intervened. Only nutritional status after bariatric surgery will be evaluated.The data of 76 patients aged 19-64 years who had undergone bariatric surgery and were followed by a dietitian dietitian for at least 6 months were included.
223745707|NCT05324163|DRUG|X0002 Spray|X0002 spray 17.5mg, twice a day; Celecoxib placebo 200mg, once a day
223745708|NCT05324163|DRUG|Celecoxib capsules|X0002 spray placebo 17.5 mg, twice a day; Celecoxib capsule 200mg, once a day
223745709|NCT05324163|DRUG|placebo|X0002 spray placebo 17.5 mg, twice a day; Celecoxibplacebo 200mg, once a day
224185662|NCT01724723|DRUG|entecavir (BARACLUDE®)|entecavir 0.5 mg per day during and within 6 months after anti-tuberculous treatment
224185663|NCT05282901|DRUG|Pembrolizumab 25 MG/1 ML Intravenous Solution|Taken together, we hypothesize that combining pembrolizumab with lenvatinib in metastatic UM may target essential cellular oncogenic pathways while normalizing tumor vascularization, thus allowing an increased infiltration of the tumor by immune cells and an improved immune response.
224185664|NCT05929872|OTHER|Non-invasive brain stimulation|ACTIVE transcranial direct current stimulation( tDCS)
224185665|NCT05929872|OTHER|Sham non-invasive brain stimulation|SHAM tDCS
224185666|NCT01151865|DRUG|Dexmedetomidine|"Dexmedetomidine will be administered intravenously as a maintenance infusion of 0.2 to 1.5 mcg/kg/hour, commencing at 0.5 mcg/kg/hour and titrated according to effect, for as long as deemed necessary by the treating physician. Specifically, the study medication may be (as recommended by the manufacturer) continued after extubation, and if discontinued may be restarted at any time up until ICU discharge. The clinician will have the option of using a loading dose of 1.0 mcg/kg IV over 20 minutes, as recommended by the manufacturer.~Bedside nursing staff will adjust drug infusion rates as necessary, in consultation with the treating physician, aiming to achieve a Riker Sedation-Agitation Scale 20 score of 4."
224185667|NCT01151865|DRUG|Saline placebo|An identical syringe containing only saline with no dexmedetomidine added will be supplied. Initial rate of infusion and subsequent adjustments will be the same as in the active comparator group.
224185668|NCT05743712|OTHER|SMART-Wrap|This intervention, SMS (short message system)-based augmentation, seeks to improve the impact and approach of the Wraparound service model by utilizing SMS, which has been shown to increase treatment adherence and sustained engagement. This intervention will facilitate regular, repeated evaluation of intermediate outcomes through self-report assessments.
224185669|NCT02883608|PROCEDURE|cap assisted forward-viewing endoscope|a cap fitted to the to top of the forward-viewing endoscope
224185670|NCT03759795|BEHAVIORAL|ACTr (Acceptance and Commitment Training)|The programme is based on Acceptance and Commitment Training (ACT), a contemporary, empirically supported approach to psychological well-being.
224185671|NCT05973422|DEVICE|SIGI Insulin Management System|Continuous subcutaneous insulin infusion with Sigi, and wearing the Dexcom G7 sensor using the Dexcom App.
224185672|NCT05296239|OTHER|SimpleC Wellness Platform with Social Robot Interaction|"Once respondents enroll, they will receive the SimpleC Wellness Platform, including introduction training on the SAR system. During the study period, participants and others will receive instructions for the SAR system and use it as part of scheduled interactions, which includes interactions as part of the general schedule. In the third week, the social robot will be installed, and staff trained in group sessions as available. Participants may use the full SAR system as they are willing.~Interactions specific to the virtual and physical robot include notifications to join activities as per community schedule as well as trivia."
224185673|NCT04465903|OTHER|Turkish Version of Sydney Swallow Questionnaire|The Turkish Version of Sydney Swallow Questionnaire consists of 17 questions related with dysphagia.
224185674|NCT04151654|OTHER|Footwear Assessment Score|It was assessed using the Sharpened Romberg test and Single Leg Stance test for static balance. It was assessed Berg Balance Scale for dynamic balance, and Timed Up and Go test for functional performance. Balance and performance tests were done with and without footwear in all individuals.
224185675|NCT01711073|DRUG|Mobilization with G-CSF and Mozobil|Treatment with drugs for mobilization of MSCs
224185676|NCT06217627|BIOLOGICAL|secretome|The secretome is the secretions of MSCs or explants from umbilical cord tissues. It contains diverse trophic molecules including cytokines, chemokines, angiogenic factors, and growth factors.
223493956|NCT02299167|DRUG|Dixon's up-and-down method|using a modified Dixon's up-and-down method (using 0.5 mg as a step size) (16). The first patient was tested at a dose 1.5 mg bupivacaine, if patient responded with failed block then the next patient received an increment of 0.5mg bupivacaine, if patient responded with successful block, then the next patient received a decrement of 0.5mg bupivacaine. The research continued until we obtained seven crossover midpoints.
223493957|NCT02957825|DEVICE|Continuous wireless monitoring|Continuous wireless monitoring of vital signs
223493958|NCT03960827|OTHER|EE Training|Participants randomized to EE engage in four center-based EE sessions each week for 12 weeks; each session lasting roughly 1-hour with a 40-45 minute stimulus phase and the remaining time being used to warm up and cool down. Each week, two of the sessions occur on a cycle ergometer and two involve treadmill exercise (4 total sessions per week). During all sessions, the participant's heart rate is monitored to ensure they maintain exercise intensity at 70% of heart rate reserve (± 5%). Periodically during training sessions perceptual data from participants are recorded, which is used to track the subjective experience of participants and in interpreting adherence data.
223493959|NCT03960827|OTHER|RE Training|Participants randomized to RE engage in four center-based RE sessions each week for 12 weeks; each session lasting roughly 1-hour with a 40-45 minute stimulus phase and the remaining time being used to warm up and cool down. The prescription is a 2-day split, meaning approximately half of the major muscle groups are exercised each session and each muscle group is exercised twice per week. Two sessions per week include seven exercises that focus on the hips/thighs, back and biceps, and the other two sessions per week include seven exercises that focus on the chest, shoulders, triceps, calves and abdominal muscles. The first set per muscle group is a warm-up performed at 50-70% of prescribed loads that are based on 10-repetition maximum (10RM). Three sets per exercise are then performed at 10RM intensity. Load increases when a participant can perform 12 repetitions for 2 of 3 sets of an exercise. During all sessions, heart rate is monitored and perceived exertion is recorded.
223493960|NCT03807635|DEVICE|ergoLance safety lancet|The ergoLance contact activated safety lancets type 450 are sterile, single-use safety lancets designed for the sampling of capillary blood from the fingertip of patients.
223588923|NCT05779007|DRUG|Pirfenidone|Pirfenidone
223588924|NCT05779007|DRUG|Nintedanib|Nintedanib
223588925|NCT04597437|DRUG|Zanamivir|Intravenous zanamivir
223745710|NCT01172951|OTHER|Oral glucose tolerance test|75g anhydrous glucose powder mixed with 100mls water
224185677|NCT02190994|DRUG|Hydrocortisone|used intravenously
223588926|NCT04597437|OTHER|Placebo|In the placebo group, participants will receive placebo normal saline solution intravenously every twelve hours for 5 days.
223588927|NCT05500807|DRUG|Emicizumab|Subcutaneous injection of emicizumab for prophylaxis
223588928|NCT06979518|DRUG|GSK3862995B|GSK3862995B will be administered.
223588929|NCT06979518|DRUG|Placebo|Matching placebo will be administered.
223588930|NCT06115291|OTHER|Smell Test|Oils are used for each of the different scents. Each scent is administered via an aromatherapy inhaling stick.
223588931|NCT05076682|DRUG|Choline|Choline 300mg tid or 500mg bid, p.o
223745711|NCT01172951|OTHER|Oral lipid tolerance test|150ml drink composed of 2 commercially available high fat products
223745712|NCT01972269|DRUG|Bupivacaine-fentanyl|0.125% bupivacaine-fentanyl 5mcg/mL
223745713|NCT01972269|DRUG|Lidocaine|2% lidocaine
224185678|NCT02190994|DRUG|Prednisone|used as tablet form
224185679|NCT05604482|DIAGNOSTIC_TEST|CXCR4-PET|New imaging modality using CXCR4 for imaging in GCA
224185680|NCT06046989|BEHAVIORAL|Building Emotion Awareness and Mental Health (BEAM)|BEAM is based on best-practices in telehealth and science-based program design principles aimed at promoting parental mental health and supportive parenting. The BEAM Program mobile application is designed and managed by MindSea. The weekly one-on-one check-ins with peer coaches (parents who previously participated in another research group-based mental health intervention) will use the secure videoconferencing platform Zoom (Healthcare license) and direct messaging through the BEAM app. Peer coaches will also engage with participants on the community peer support forum. Monthly drop-in group peer support sessions will be facilitated by peer coaches and/or mental health professionals on the BEAM research team. The BEAM program's content emphasizes self-compassion, effective communication practices, and building social support networks.
224185681|NCT04019080|OTHER|Anti-fibrostic drugs|The real-Life use of anti-fibrotic drugs in patients with idiopathic pulmonary fibrosis in Sweden
224185682|NCT01493791|DRUG|CDB-2914|
224185683|NCT03589066|DRUG|LY03003|28 mg intramuscular suspension
224185684|NCT00002715|BIOLOGICAL|Bleomycin sulfate|A component of the Stanford V regimen.
223745714|NCT04415099|OTHER|Muscle fatigue protocol|"Tibialis posterior was fatigued using 2 exercises:~1. Unilateral heel raise exercise~2. Close chain resisted foot adduction exercise"
224185685|NCT00002715|DRUG|Stanford V regimen|
223493961|NCT03807635|DEVICE|Acti-Lance safety lancet|The Acti-Lance safety lancet type 610 is a sterile, single use device used to carry out skin punctures for the purpose of collecting capillary blood samples.
223493962|NCT00259636|DRUG|zonisamide|zonisamide 100 mg -300 mg daily vs placebo
223493963|NCT03170310|DRUG|Apatinib|Apatinib500 mg,po,qd,continuous dosing until PD, death or not tolerated toxicity.
223588932|NCT05076682|DRUG|anti-PD-1 antibody and chemotherapy|PD-1 antibody SHR1210 200mg q2w chemotherapy (whether and which should be given depends on the treatment regimen before enrollment)
223588933|NCT05076682|DRUG|Sodium Cromoglicate|Sodium Cromoglicate will be administered intranasally (nasal spray) (5 spray each nostril 4 times a day, 1 mg/spray)
223588934|NCT05076682|DRUG|Efavirenz|Efavirenz 600mg qd, p.o
223588935|NCT05076682|DRUG|SHR-A1811|4.8mg/kg q3w
223588936|NCT05076682|DRUG|SHR-A2102|6mg/kg q3w
223745715|NCT02312726|PROCEDURE|Postplacental IUD insertion|Postplacental IUD insertion using the standardized ring forceps technique (Speroff and Mishell 2008) under ultrasound guidance, within 10-30 minutes of vaginal delivery.
223745716|NCT01223144|BEHAVIORAL|Iowa Gambling Task and Ekman facial recognition test|"Iowa Gambling Task: mean number of cards chosen from decks with low (A+B) and high gain (C+D).~Ekman facial recognition test: mean number of faces correctly recognized (60 images with 6 different expressions: happiness, sadness, fear, surprise, disgust and anger)."
224185686|NCT00002715|DRUG|Doxorubicin hydrochloride|A component of the Stanford V regimen.
224185687|NCT00002715|DRUG|Etoposide|A component of the Stanford V regimen.
224185688|NCT00002715|DRUG|Mechlorethamine hydrochloride|A component of the Stanford V regimen.
224185689|NCT00002715|DRUG|Prednisone|A component of the Stanford V regimen.
224185690|NCT00002715|DRUG|Vinblastine|A component of the Stanford V regimen.
224185691|NCT00002715|DRUG|Vincristine sulfate|A component of the Stanford V regimen.
223493964|NCT04229901|DRUG|HepaStem|HepaStem will be administered as an intravenous (IV) infusion
223493965|NCT04229901|DRUG|Placebo|Placebo will be administered as an intravenous (IV) infusion
223493966|NCT01706627|DRUG|10 mg Melatonin|Active Comparator: Drug: Melatonin 10 mg
223493967|NCT01706627|DRUG|20 mg Melatonin|Active Comparator: Drug: Melatonin 20 mg
223588937|NCT05076682|DRUG|SHR-1316|1200mg q3w
223588938|NCT05076682|DRUG|Mecapegfilgrastim|Mecapegfilgrastim, 6mg, d3, q3w, s.c.
223588939|NCT05076682|DRUG|AK131|AK131, 40mg/kg i.v., q2w
223588940|NCT06818097|DRUG|TKI|Lenvatinib
223588941|NCT06818097|DRUG|anti PD-1|Sintilimab or Camrelizumab or Tislelizumab
223745717|NCT02057471|DRUG|Intravenous ferric carboxymaltose|1 gram intravenous ferric carboxymaltose (FERINJECT) will be administered to all patients within the study
223745718|NCT03042234|OTHER|Group Insulin-Resistant|High intensity interval training: 3 to 6 sets of 60-second sprints at 100% of the peak velocity interspersed by a 3-min active recovery period.
223745719|NCT03042234|OTHER|Group Insulin-Sensitive|High intensity interval training: 3 to 6 sets of 60-second sprints at 100% of the peak velocity interspersed by a 3-min active recovery period.
224185692|NCT04553328|DEVICE|Us guided nerve blocks|The ILIH nerves were identified and located in the fascia compartment between the internal oblique and the transverse abdominis or external oblique muscles, a 20 G needle was advanced between the aponeurosis of the internal oblique and transverses abdominis muscles then 30 ml bupivacaine 0.25% was injected with intermittent aspiration,then 10 ml bupivacaine 0.25% was injected around the nerves.
224185693|NCT04019028|DEVICE|low frequency rTMS + Navigation System|1Hz low-frequency rTMS stimulation over primary motor area using navigation system
224185694|NCT04019028|DEVICE|only low frequency rTMS|1Hz low-frequency rTMS stimulation over primary motor area
223493968|NCT01706627|DRUG|Matched placebo|Matched placebo (identical formulation and delivery, without active ingredient)
223493969|NCT02747160|BEHAVIORAL|Managing Anxiety from Cancer (MAC)|The intervention consists of six telephone-administered sessions. Session topics include psychoeducation on anxiety, behavioral strategies for managing anxiety, cognitive restructuring, communication skills training, acceptance techniques (patient only), problem-solving strategies (caregiver only), and planning for future anxiety. Session content is tailored for older adults and caregivers of older adults with cancer.
223588942|NCT06818097|DRUG|XELOX chemotherapy|Capecitabine and Oxaliplatin
223588943|NCT06987890|OTHER|Practical Geriatric Assessment|The Practical Geriatric Assessment (PGA) is an abridged version of the Comprehensive Geriatric Assessment (CGA). This tool can be completed by any provider within 10-25 minutes while still capturing the key domains of the CGA. This screening tool, which is now recommended by American Society of Clinical Oncology (ASCO), the International Society for Geriatric Oncology (SIOG), and the Cancer \& Aging Research Group (CARG), has the potential capacity to delineate relevant baseline features in geriatric populations without creating undue provider burden.
224185695|NCT04019028|DEVICE|Sham low frequency rTMS + Navigation System|1Hz low-frequency sham rTMS stimulation over primary motor area using navigation system
224185696|NCT00197691|PROCEDURE|blood draws, etc.|
224185697|NCT06181903|BEHAVIORAL|Emotional freedom technique group|Control group
223493970|NCT01523197|DEVICE|BiPAP ventilation, auto-trilevel ventilation|Noninvasive ventilation including fixed BiPAP ventilation and auto-trilevel ventilation. Using the same IPAP, treatment include one night with BiPAP ventilation mode 1, one night with BiPAP ventilation mode 2 and one night with auto-trilevel ventilation mode. Each treatment last 8 hours for each night.
223493971|NCT01600859|DRUG|E2609|"E2609 capsules: 5 mg, 25 mg, 50 mg, and 200 mg~E2609 doses: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg, 200 mg, and 400 mg~According to the randomized study design, participants who are assigned to receive E2609 will each receive a single assigned dose consisting of two capsules of E2609 or in some cases one capsule of E2609 and one of placebo"
223588944|NCT06981351|BEHAVIORAL|Attention to Context (ATC) training|ATC training focuses on learning to attend to and integrate contextual cues present in the environment. Three tasks, Reversal Learning, Divided Visual Field, and Affective Gaze, require ATC functioning and provide individuals with practice noticing changes in contextual information, such as rule changes and using emotion information to modulate behavior.
223588945|NCT06981351|BEHAVIORAL|Affective Cognitive Control (ACC) training|ACC training focuses on providing individuals with practice inhibiting behavior, particularly within motivational or affective contexts. Three tasks, Shapes, Numbers, and Lottery, tap ACC functioning and place demands on the basic employment of cognitive control, such as task switching, as well as on the concurrent engagement of cognitive control and affective processing.
223588946|NCT05943119|RADIATION|Radiotherapy in painting dose on histoscannographic mapping|"The target volumes to be delineated are as follows:~* High-risk CTV (Clinical Target Volume), corresponding to all initially invaded areas, as identified by comparison between the operative report and the anatomo-pathological report (ideally with histo-surgical mapping).~* Low-risk CTV, corresponding to naso-sinusal structures not initially invaded but at risk of recurrence, and located close to the high-risk target volume, including at least 5 mm around the high-risk volume and excluding non-risk areas (muscle, bone)."
223588947|NCT05943119|RADIATION|Standard pan-sinusal Radiotherapy|"The target volumes to be delineated are as follows:~* High-risk CTV, including the entire post-operative cavity,~* Low-risk CTV, adapted from the recommendations described by Lapeyre (Cancer/Radiotherapy 2005), and including at least 5 mm around the high-risk volume, excluding non-risk areas (muscle, bone)."
223588948|NCT04494113|PROCEDURE|Biopsy Procedure|Undergo biopsy
223588949|NCT04494113|PROCEDURE|Biospecimen Collection|Undergo collection of tissue and blood samples
223588950|NCT04494113|PROCEDURE|Resection|Undergo surgical resection
224185698|NCT02626962|DRUG|ipilimumab|Ipilimumab every 3 weeks for a total of four doses (Cycles 1 and 2)
224185699|NCT02626962|DRUG|Nivolumab|Nivolumab every 3 weeks for a total of four doses (Cycles 1 and 2) followed by Nivolumab every 2 weeks
224185700|NCT00496691|BEHAVIORAL|Family-based HIV prevention program|comparison between parent-child intervention targeting parent-teen sexual communication, condom use skills, and assertiveness training to an adolescent-only intervention that targets similar constructs minus parent-teen sexual communication and a general health promotion intervention
224185701|NCT02357394|DEVICE|Arabin Pessary|Arabin pessary is a ring manufactured from medical grade silicone. It comes in 13 different sizes. Participants will be fitted to the appropriate size by the study team.
224185702|NCT04678089|DRUG|Bortezomib|Objective To observe the safety and efficacy of bortezomib related biomarkers. Including genes, metabolites, etc
224185703|NCT03344029|BIOLOGICAL|SP Shz TIV|0.5 mL, intramuscular into the deltoid muscle, single injection on Day 0
224185704|NCT03344029|BIOLOGICAL|Hualan TIV|0.5 mL, intramuscular into the deltoid muscle, single injection on Day 0
224185705|NCT03015662|OTHER|Dry Needling Therapy|Dry needling procedures will be performed in the following pairs of muscles in the same intervention: occipital, splenius capitis, sternocleidomastoid (Clavicular branch TrPs 1, 2 and 3; sternal branch TrPs 1, 2, 3 and 4), scalene (anterior TrPs 1, and 2; medial TrP (Trigger Point) 1; posterior TrP 1), trapezius (upper TrPs 1, and 2; middle TrPs 5, 6 and 7; lower TrPs 3, and 4), supraspinatus (central point; myotendinous union; tendon insertion), infraspinatus (medial/superior; lateral/superior; lateral scapular side; medial scapular side), and multifidus (level C6).
223493972|NCT01600859|DRUG|Placebo for E2609|"Placebo capsules~According to the randomized study design, participants who are assigned to receive placebo will each receive a single dose consisting of two capsules of placebo"
223493973|NCT00832806|BEHAVIORAL|Extended IVR (integrated voice response technology)|See detailed description
223493974|NCT00832806|DRUG|Varenicline (Champix)|See detailed description
223493975|NCT00832806|BEHAVIORAL|IVR treatment|See detailed description
223493976|NCT00908778|DRUG|Vitreosolve|intravitreal injection
223493977|NCT00908778|DRUG|Vitreosolve|intravitreal injection
223493978|NCT04700605|BEHAVIORAL|Dual task balance test|Participants will be conducting two dual task tests; an 8m gait test and a Wii Balance Board test with simultaneous various cognitive tests.
223493979|NCT04529460|DIAGNOSTIC_TEST|COVID-19 antibody point of care test kit|A disponible point of care test that identifies the presence of antibodies to COVID-19
223493980|NCT02632214|OTHER|fMRI measure|
223588951|NCT04494113|DRUG|Triapine|Given IV
223745720|NCT03642821|DEVICE|intracranial aneurysm coiling|endovascular treatment of intracranial aneurysm by coiling procedure using OPTIMA coils system
223745721|NCT06022250|DRUG|JS207|Patients will receive specific dose of JS207 via intravenous infusion.
223745722|NCT06410209|OTHER|Goal Setting|Set physical activity goals
223745723|NCT06410209|OTHER|Interview|Participate in a one-on-one interview
223745724|NCT06410209|OTHER|Interview|Ancillary studies
224185706|NCT03015662|OTHER|Myofascial Release Therapy|Patients will develope a myofascial therapy protocol, administered in the following order in the same intervention: deep fascia release in temporal region, suboccipital release, compression-decompression of temporomandibular joint, global release of cervicodorsal fascia, release of pectoral region, diaphragm release (transverse slide), and transverse diaphragmatic plane.
224185707|NCT02425774|PROCEDURE|Vagus stimulation|
224185708|NCT02425774|PROCEDURE|Sham stimulation|
223493981|NCT06831565|DIAGNOSTIC_TEST|ROTEM|ROTEM Tests
224185709|NCT02425774|DRUG|Prucalopride|
224185710|NCT02425774|DRUG|Placebo|
224185711|NCT05723120|OTHER|Assessment Respiratory and Neuromuscular|Comparative Score
224185712|NCT06383715|BEHAVIORAL|Cognitive-Behavioral Therapy Workshop for Content Moderators|"This 4-session group workshop is based on the principles of Cognitive Behavioral Therapy. It consists of four sessions:~1. Presentation. Scientific evidence of psychological consequences on content moderatos. Psicoeducation on the effects of vicarious trauma exposure.~2. Presentation of the cognitive model. Identification/operationalization of thoughts. Discussion of possible irrational thoughts.~3. Psychoeducation of emotions and their adaptive function. Behavioral strategies of emotions: exposure therapies and behavioral activation.~4. The role of social support. Strategies for appropriate work and sleep hygiene. Strategies for maintaining gains. Farewell."
224185713|NCT01377142|DEVICE|Laparoscopic sacral hysteropexy|Laparoscopic sacral hysteropexy is performed laparoscopically with or without robotic assistance
224185714|NCT01377142|DEVICE|Vaginal mesh hysteropexy|Uphold device used which includes sacrospinous ligament fixation
224185715|NCT01980056|DRUG|Vosaroxin|Dose level 1: Vosaroxin 50 mg\^m2 IV on Days 1 and 4 of 28 day cycle Dose level 2: Vosaroxin 72 mg\^m2 IV on Days 1 and 4 of 28 day cycle Dose level 3: Vosaroxin 50 mg\^m2 IV on Days 1, 4, 8 and 11 of 28 day cycle
223493982|NCT02145858|DEVICE|Blood drainage post cardiac surgery using PleuraFlow System|
223493983|NCT05569941|DRUG|ABI-4334 Tablet|ABI-4334 Tablet
223493984|NCT05569941|DRUG|ABI-4334 Placebo|Placebo to ABI-4334 Tablet
223493985|NCT03175939|RADIATION|Radiotherapy|External beam radiotherapy with curative intent, at least 66 Gy
223493986|NCT03175939|DRUG|Cisplatin|cisplatin IV injection over 3 hours
223493987|NCT03175939|DRUG|5-FU|5-FU IV 24 hours continuous infusion
223493988|NCT04615507|DEVICE|JJVC Investigational Multifocal Contact Lens|TEST Lens
223493989|NCT04615507|DEVICE|Dailies Total 1® Multifocal Contact Lens|CONTROL Lens
223588952|NCT03441698|DEVICE|Genuine acupuncture (A)|A) Acupuncture is administered bilaterally to the acupuncture point PC6 located two body-inches proximal of the wrist crease, between the tendons of palmaris longus and flexor carpii radialis. Sharp acupuncture needles were inserted into a depth of a half body-inch. The needles are manipulated three times (at the start, middle and end of the treatment session) by twirling and lifting until deqi occurs. Within the groups A, B and C, the participants are randomized to two communication types: 1) neutral communication or 2) strengthened positive communication regarding expected relaxing effects of their treatment, using a standardized communication model.
223588953|NCT03441698|DEVICE|Sham acupuncture (B)|B) Sham acupuncture is administered bilaterally to a non-acupuncture point two body-inches proximal and one body-inch radial from PC6. The telescopic Park Sham Device was used. The needle looks identical to a real needle, but is blunt and glides upward into its handle instead of penetrating. The marking tubes holds the needle in place. The therapist give an illusion of manipulating the needle by turning it three times until it touched the skin, but no deqi occurs. Within the groups A, B and C, the participants are randomized to two communication types: 1) neutral communication or 2) strengthened positive communication regarding expected relaxing effects of their treatment, using a standardized communication model.
224185716|NCT00351611|DRUG|Lyrica (pregabalin)|150 mg twice a day, oral administration
224185717|NCT00351611|DRUG|placebo|Twice a day, oral administration
224185718|NCT03960788|DRUG|Gadoxetate Sodium|Gadoxetate Sodium is an FDA approved contrast agent to be used during magnetic resonance imaging.
224185719|NCT00242645|BEHAVIORAL|Health Information|
224185720|NCT00242645|BEHAVIORAL|Preventive Services|
223493990|NCT01144806|BEHAVIORAL|Nutrition education|Parent/care givers of children with severe malnutrition in enrolled in this group will be given nutrition education using the principles of infant and young child feeding (IYCF) and dietary diversification
223493991|NCT01144806|DIETARY_SUPPLEMENT|RUTF|Ready to use therapeutic food (RUTF / PlumpyNut) will be provided to the parent/care givers of children with severe malnutrition in enrolled in this group
223493992|NCT05044988|DRUG|HS-10342|HS-10342 tablet once daily from Day 1 to 21 of a 28-day cycle
223493993|NCT06224257|DRUG|Linperlisib|"Elevated PI3K activity in T-LGL likely plays an important role in the ability of the pathologic cells to avoid homeostatic apoptosis, since inhibition of this pathway leads to apoptosis in the population of cells harboring the pathologic clone. More importantly, the activity of this pathway may represent a kind of Achilles heel for T-LGL in that PI3K inhibitors alone are quite effective at inducing spontaneous apoptosis in the clonal CTLs after a short incubation."
223493994|NCT06968403|BEHAVIORAL|Community emotional intelligence network|This intervention focuses on developing emotional intelligence (EI) to tackle climate change-induced mental health challenges like eco-anxiety, solastalgia, and stress from displacement and natural disasters. It is community-centered, utilizing local resources and volunteers for EI training and mental health support, unlike traditional clinical interventions that depend on centralized healthcare systems. A mobile app is integrated to facilitate communication, learning resources, and participant connections, offering remote support and continuous engagement, even during climate events like floods or cyclones. Targeting coastal communities in Bangladesh, this program addresses the mental health impacts of frequent natural disasters, saltwater intrusion, and displacement. Unlike other mental health programs, it not only treats symptoms but also builds resilience against environmental stressors, empowering communities to cope with climate-induced mental health challenges.
223493995|NCT05799352|DEVICE|Endoscopic lung volume reduction|a prospective monocentric study on hyperinflated COPD patients without collateral ventilation. Patients were evaluated before and 3 months after unilateral ELVR by transdiaphragmatic pressure (Pdi) measured at the functional residual capacity (FRC) after magnetic phrenic stimulation and by high-resolution computed tomography at the FRC allowing 3D modelling of the diaphragm for measurements of fibers length, length of the zone of apposition and radius of curvature of the diaphragmatic domes.
223493996|NCT06299644|DEVICE|Endoscopic Sleeve Gastroplasty - Belt and Suspenders|Endoscopic sleeve gastroplasty using belt and suspender plications.
223745725|NCT06410209|OTHER|Media Intervention|View private social media peer support group content
224185721|NCT00242645|BEHAVIORAL|Computer tailored information|
224185722|NCT04166188|PROCEDURE|Lumbar erector spinae plane block|Injection of blue solution in the erector spinae plane in L4 ultrasound-guided and posterior dissection of the lumbar region.
223493997|NCT06299644|DEVICE|Endoscopic Sleeve Gastroplasty - Belt|Endoscopic sleeve gastroplasty using belt only plications.
223493998|NCT04083183|BIOLOGICAL|Astatine At 211 Anti-CD45 Monoclonal Antibody BC8-B10|Given IV
224185723|NCT02007798|DRUG|dexmedetomidine|2 ml of dexmedetomidine at a concentration of 100 ug/ml is diluted by 98 ml normal saline to a concentration of 2 ug/ml. The required amount of experimental drugs is confirmed according to the weight and grouping, and diluted using normal saline to 20 ml.
224185724|NCT02007798|DRUG|normal saline|100 ml per bag
224185725|NCT00517166|DEVICE|CAT (Combat Arms Tourniquet)|device
224185726|NCT04499118|DRUG|AT regimen|Doxorubin 60mg/㎡ d1 or Epirubicin 75mg/㎡ d1 Docetaxel 75mg/㎡ d1 1/21d
224185727|NCT04499118|DRUG|TP regimen|Albumin paclitaxel 125mg/㎡ d1, 8 Cisplatin 75mg/㎡ d1-3 1/21d✖6 or carboplatin AUC6 d1 1/21d✖6
224185728|NCT04480905|DEVICE|Dynamic tape|The dynamic tape will stick from anterior inferior iliac spine to the middle of the tibia in supine and full knee extension position
224185729|NCT04480905|DEVICE|Sham tape|The 3M™ Soft Cloth Tape will stick from anterior inferior iliac spine to the middle of the tibia in supine and full knee extension position
224185730|NCT04559048|DRUG|FK506|FK506 (tacrolimus), a calcineurin inhibitor, is widely used as an immunosuppressant to lower the risk of organ rejection after organ transplantation
224185731|NCT05070182|DIAGNOSTIC_TEST|REE - Resting Energy Expenditure|"REEs represent 60-70% of the needs for a sedentary person and 50% of physically active people.~For the measurement of REE will be used the metabolic computer (Medical Graphics, Ultima CCM, Minneapolis, USA), which with continuous recording of breath-to-breath volume (Vt), respiratory rate (RR) of ventilation per minute volume (MV) ), of inhaled and exhaled gases (O2 and CO2) has the ability to calculate the values of VO2, VCO2 and with the help of equations the values of REE and RQ.~All patients in the study will be monitored with the metabolic computer. Their measurements will be recorded every day during their stay in the ICU."
223493999|NCT04083183|DRUG|Fludarabine|Given IV
223494000|NCT04083183|DRUG|Cyclophosphamide|Given IV
223494001|NCT04083183|BIOLOGICAL|Lapine T-Lymphocyte Immune Globulin|Given IV
223494002|NCT04083183|RADIATION|Total-Body Irradiation|Undergo TBI
223494003|NCT04083183|PROCEDURE|Hematopoietic Cell Transplantation|Undergo hematopoietic cell transplantation
223494004|NCT04083183|DRUG|Mycophenolate Mofetil|Given PO or IV
223494005|NCT04083183|DRUG|Sirolimus|Given PO
223494006|NCT04083183|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
223494007|NCT04083183|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223494008|NCT06971887|OTHER|Clear Communication of Lab Test Result letter|The Clear Communication of Lab Test Result letter (CCLR) was designed using clear communication and health literacy best practices to explain test done, meaning of results, and any future action recommended.
224185732|NCT05070182|DIAGNOSTIC_TEST|Transcranial Doppler|"The measurement of flow velocities in the middle cerebral artery will be done with the transcranial Doppler using a low frequency (2 MHz) ultrasound head.~All patients entering the study will be examined with the TCD every day during their stay in the ICU."
223494009|NCT05115214|DEVICE|SpherePVI™ Catheter|Affera SpherePVI™ Multi-Ablation System
223494010|NCT06127563|OTHER|creation of a clinical pathway to increase vaccination coverage in frail patients|creation of a clinical pathway to increase vaccination coverage for frail patients, integrating hospital and local health units through an automated algorithm
223494011|NCT05836870|OTHER|Enhanced Usual Care|Participants will receive general recommendations to maintain physical activity.
223494012|NCT05836870|BEHAVIORAL|Tele-supervised resistance exercises|Participants will take part in a monitored exercise program.
223588954|NCT03441698|OTHER|Rest|C) Rest means resting for 30 minutes, either sitting or lying down. Within the groups A, B and C, the participants are randomized to two communication types: 1) neutral communication or 2) strengthened positive communication regarding expected relaxing effects of their treatment, using a standardized communication model.
223588955|NCT05251038|DRUG|Sotorasib|Intervention instruction outlined in protocol
223588956|NCT05251038|DRUG|Liposomal Irinotecan (nal-IRI)|Intervention instruction outlined in protocol
223588957|NCT05251038|DRUG|5 Fluorouracil (5FU)|Per standard of care
223588958|NCT05251038|DRUG|Leucovorin (LV)|Per standard of care
223494013|NCT06286982|OTHER|Oral Symptom Assessment Scale|The Oral Symptom Assessment Scale is a patient-rated oral (or mouth) symptom assessment tool
223494014|NCT04598828|DEVICE|Non-invasive brainstem stimulation|Study participants will self-administer \~19-minute treatments twice daily in the home setting using a non-invasive brainstem modulation device. The device has been deemed as a nonsignificant risk for studies in Parkinson's disease by the United States Food and Drug Administration.
223494015|NCT06097559|DIAGNOSTIC_TEST|Endometrial fluid and biopsy collection|"The ERA and EMMA test require an endometrial biopsy to be taken at P+5 (after 120±6 hours of exogenous progesterone administration) in a HRT cycle, according to the common clinical practice. On the same day, a sample of endometrial fluid will be aspirated immediately prior to the biopsy.~Regardless of the endometrial receptivity profile, a subsequent regular FET will be performed within the standard WOI (after 120±6 hours of progesterone exposure) in an HRT cycle following the clinical standard practice.~Those patients willing to participate in the rescue phase will follow the recommendation of the ERA test for the subsequent pET."
223494016|NCT06097559|DIAGNOSTIC_TEST|Endometrial fluid and biopsy collection|"The ERA and EMMA test require an endometrial biopsy to be taken at P+5 (after 120±6 hours of exogenous progesterone administration), according to the common clinical practice. On the same day, a sample of endometrial fluid will be aspirated immediately prior to the biopsy.~Regardless of the endometrial receptivity profile, a subsequent regular FET will be performed within the standard WOI (after 120±6 hours of progesterone exposure) in an HRT cycle following the clinical standard practice.~Those patients willing to participate in the rescue phase will follow the recommendation of the ERA test for the subsequent pET. In case of a non-receptive endometrium result, a second EB sample must be collected when indicated by the ERA report. Fluid sample collection will not be repeated in these cases."
223494017|NCT06069479|PROCEDURE|craniofacial surgery|Surgical treatment, either stripcraniectomy or fronto-orbital advancement
223588959|NCT05251038|DRUG|Gemcitabine (GEM)|Per standard of care
224185733|NCT00808665|DRUG|Dexmedetomidine|Patients will be given 0.7 mcg/kg/hr of dexmedetomidine over the first hour of surgery, followed by continuous infusion of 0.5 mcg/kg/hr of dexmedetomidine for the next 2 hours of surgery. Dexmedetomidine dose will be reduced to 0.2 mcg/kg/hr for the duration of the procedure and continued at that rate for four hours postoperatively. Patients in the placebo arm will receive an equal per-kg IV volume of 0.9% Sodium Chloride over the same periods. Drug administration will be controlled for both arms of the study using a continuous infusion pump.
224185734|NCT00808665|DRUG|0.9% Saline|Patients in the placebo arm will receive an equal per-kg IV volume of 0.9% Sodium Chloride over the same periods. Drug administration will be controlled for both arms of the study using a continuous infusion pump.
224185735|NCT05216302|BEHAVIORAL|Group-based Nordic Walking Exercise Program|An exercise intervention based on nordic walking and health education of one hour and 15 minutes per session. Each session includes 10 min of health education followed by 15 minutes of warm-up exercises, 30 minutes of nordic walking and finally 15 min to cool-down. The intervention is meant to last during two months (last round of chemotherapy and one month pre-surgery), twice weekly for approximately a total of 16 sessions.
224185736|NCT00332059|DRUG|bimatoprost/timolol fixed combination|
224185737|NCT05772039|DRUG|Topical application of 38% Silver Diammine Fluoride Solution|"* Application of petroleum jelly on lips and around the mouth for prevention of temporary silver tattoo.~* Before SDF application, the affected area will be thoroughly dried and isolated using the cotton rolls or dri-angle.~* Isolation throughout the procedure and following three minutes is considered most desirable.~* The varnish should be allowed to be in place for 60 seconds. This is the most critical step in the process. Applied varnish will be dried with gentle flow of compressed air.~* SDF will be applied with a microbrush to all carious lesions and to all pits and fissures on posterior (molar) teeth for 60 seconds.~* To avoid gingival or mucosal irritation, contact of varnish with any oral tissue other than affected area will be avoided.~* If the application time is shorter due to unforeseen reasons reapplication will be considered."
224185738|NCT05772039|DRUG|Topical application of 5% Sodium Fluoride with functional Tricalcium phosphate Varnish|"* According to manufacturer, Clinpro® White Varnish can be applied to tooth surfaces where plaque is present. A prophylaxis is not required.~* The applicator brush provided along is used to thoroughly mix the varnish inside the single-unit dose pack, since components of all sodium fluoride varnishes are separate during storage.~* Excessive contact with soft tissue should be avoided.~* Only enough varnish to form a thin coating on the desired treatment area should be used.~* After application, patient should be instructed to close their mouth to set the varnish.~* Rinsing or suctioning immediately after application is not recommended.~* The operator might appreciate the formation of a thin coating on the teeth and the patient should be informed that they may feel a thin coating when rubbing the treated area with their tongue."
224185739|NCT06409182|DEVICE|Hemopill|HemoPill® acute capsule (Ovesco Endoscopy, Tuebingen, Germany) is a swallowable, wireless, sensor capsule designed for in vivo detection of liquid blood or hematin. The capsule has integrated optical microsensor for blood detection, by transmitting red and violet light via LEDs. It allows the detection of blood by photometric measuring method, in small volumes or in unprepared digestive tract. The dimensions of the capsules are 7.0mm x 26.3mm. The maximal examination time is 9 hours. The HemoPill® receiver is a portable receiver for displaying and storing measured values from the HemoPill® acute capsule. It allows a real-time, wireless, telemetric data transmission. Once activated, the HemoPill® acute capsule can be swallowed by patients with real-time measurement of HemoPill® Indicator (HI). An HI value in the red range suggests a positive finding - liquid blood or hematin has been detected.
224185740|NCT02330406|DRUG|Anagliptin|Suiny 100 mg
224185741|NCT02330406|DRUG|Sitagliptin|Januvia 50 mg Glactiv 50 mg
224185742|NCT03235674|OTHER|High-intensity stair climbing exercise|High intensity stair climbing exercise at a vigorous pace as measured by rating of perceived exertion.
224185743|NCT05568251|DEVICE|transcranial Direct Current Stimulation|Participants will receive a single session of active/sham tDCS. During each session, 2 milliAmpers of active or sham tDCS will be applied for 20 minutes over the dorsolateral prefrontal cortex (right anodal/left cathodal).
224185744|NCT05568251|PROCEDURE|Cognitive training|Participants will be administered Game of Dice Task concurrent with the tDCS session
224185745|NCT06547502|DRUG|GZR4|single dose
223494018|NCT06598462|DRUG|Solrikitug Low Dose|Solrikitug low dose subcutaneous injection
223494019|NCT06598462|DRUG|Solrikitug Mid Dose|Solrikitug mid dose subcutaneous injection
223494020|NCT06598462|DRUG|Solrikitug High Dose|Solrikitug high dose subcutaneous injection
223494021|NCT06598462|OTHER|Placebo|Placebo subcutaneous injection
223494022|NCT02676973|PROCEDURE|Open, Robotic, or Laparoscopic|Sacral Colpopexy is a surgery performed either through an incision in the abdomen or through several small incisions with the help of a laparoscope (a slender tube) or robot. The surgery is done with a permanent synthetic (man-made) mesh. The mesh is sutured (stitched) to the vagina and sacrum (tail bone) and is used as reinforcement. It provides additional support to weakened tissues and/or muscles.
223494023|NCT02676973|PROCEDURE|Transvaginal Native Tissue Repair|Transvaginal Native Tissue Repair is a surgery performed with an incision through the vagina (transvaginal). The surgery is done using both permanent and absorbable sutures (stitches), to support weakened tissue and/or muscles, and attach the top of the vagina to ligaments in the pelvis (either to the sacrospinous ligament or uterosacral ligament).
223494024|NCT02676973|PROCEDURE|Uphold™ LITE|Transvaginal Mesh Repair is a surgery performed with an incision through the vagina (transvaginal). The surgery is done with a permanent synthetic (man-made) mesh. The mesh is attached to ligaments in the pelvis and is used to reinforce natural tissue and/or muscles, which are no longer able to provide support to the vagina.
223494025|NCT06144606|DRUG|Tecartus|Tecartus is a CD19 directed CAR T-cell therapy that utilizes CD28 costimulatory and CD3 zeta stimulatory domains. Tecartus is manufactured from purified autologous T-cells via retroviral transduction with a median time to product release of 13 days.
223494026|NCT06524349|DEVICE|3D printed knee extender device|Participants will receive a 3D printed knee extender device with sealed water bottles and an at-home rehabilitation program designed to be used with the 3D printed knee extender device.
223588960|NCT05251038|DRUG|Nab paclitaxel|Per standard of care
224185746|NCT05818774|PROCEDURE|Radiofrequency neurotomy (RFN) of Cervical Medial Branch Nerves (CMBNn) with parallel lesioning|"Intervention type: RF nerve lesioning at 80-85 degree Celsius for 90 seconds Intervention name: Straight sharp conventional (SIS's technique)~Intervention description:~Technique as described in the SIS Practice Guidelines for parallel lesioning cannulae placement"
224185747|NCT05818774|PROCEDURE|Radiofrequency neurotomy (RFN) of Cervical Medial Branch Nerves (CMBNn) with end-on lesioning with multitined trident cannulae|"Intervention type: RF nerve lesioning lesioning at 80-850 Celsius for 90 seconds Intervention name: End-on placement of the multitined trident cannulae~Intervention description:~Patient in lateral position, targeting joint position between the inferior C2 and superior C3 facets, the middle of the facet pillars for the third to fifth cervical levels, and the superior part of the sixth and seventh cervical facets."
224185748|NCT02935023|RADIATION|CIRT with systemic therapy arm|carbon ion radiotherapy to the prostate(59.2GyE/16Fx to prostate and seminal vesicle) Systemic therapy:Hormonal therapy (LHRH agonist and/or antiandrogens) or chemotherapy
224185749|NCT00665002|BIOLOGICAL|WT-1|Immune responses were to be evaluated at weeks 6 and 12 via delayed-type hypersensitivity, CD4 T cell proliferation, CD4 and CD8 T cell interferon release, as well as by bone marrow cytogenetics including polymerase chain reaction (PCR) to look for molecular evidence of disease. Patients who had an immunologic response and had not had disease progression could continue with up to 6 more vaccinations administered approximately every month. In that case, patients were to be reevaluated with bone marrows/immunologic studies after the 9th and 12th vaccination. In addition, patients would undergo evaluations for residual disease including immunohistochemistry and/or quantitative polymerase chain reaction (RQ-PCR) for WT-1 expression (on selected patients), and multiparameter flow cytometry (AML/ MDS).
224185750|NCT00665002|DRUG|Montanide|The WT-1 vaccine is given with another substance, called Montanide, which clumps the WT-1 vaccine and thereby improves the immune response.
224185751|NCT00665002|DRUG|Sargramostim (GM-CSF)|GM-CSF was administered at a dose 70 mcg (140ul) as a subcutaneous injection at the site of vaccination on day -2 and day 0.
224185752|NCT01489332|DRUG|intensified preoperative chemotherapy|"capecitabine 1250 mg/m² p.o. twice daily for 14 consecutive days, 7 days rest for one cycle; radiotherapy: 50.4 Gy to the pelvis (25x 1.8 Gy on days 1-33, excluding weekends) plus 5.4 Gy on days 36-38 as a boost to the primary tumour (3 fractions of 1.8 Gy).Three- dimensional CT planing and a four field box technique with high energy photons (15 MV) will be used. capecitabine 825 mg/m² p.o. twice daily on days 1-38 (including weekends), One week after completion of radiochemotherapy patients receive 2 cycles of capecitabine based chemotherapy (1250 mg/m² p.o. twice daily for 14 consecutive days every three weeks).~Radical surgery (TME): to be undertaken 8 weeks following completion of chemoradiation Postoperative treatment:capecitabine 1250 mg/m² p.o. twice daily for 14 consecutive days every three weeks; 3 cycles (R0 beginning 6-8 weeks after surgery"
224185753|NCT03570658|DRUG|RO7049389|RO7049389 will be administered orally either as a single dose (SAD) or as multiple doses defined by the SAD portion of the study (MAD).
224185754|NCT03570658|DRUG|Placebo|Placebo will be administered orally at a dose and frequency matched to RO7049389.
224185755|NCT03809260|DRUG|Metformin (part 1)|1\~4d: Metformin 1000 mg bid (Except for 500 mg after 1d lunch), 16d\~19d: Metformin 1000 mg bid (Except for 500 mg after 16d lunch).
224185756|NCT03809260|DRUG|Vancomycin|11d: Vancomycin 250 mg bid, 12\~17d: Vancomycin 500 mg bid
223494027|NCT05472441|BEHAVIORAL|Mid-Ohio Food Farmacy|The Food Farmacy arm receives weekly produce through a consortium of local food banks at the direction of the Mid-Ohio Food Collective.
223494028|NCT05472441|BEHAVIORAL|Mid-Ohio Food Farmacy + Cooking for Diabetes|The Food Farmacy + Cooking for Diabetes Arm receives weekly produce through a consortium of local food banks at the direction of the Mid-Ohio Food Collective and Cooking for Diabetes, a 6-week diabetes self-management education and support and culinary education intervention.
223494029|NCT05472441|BEHAVIORAL|Mid-Ohio Food Farmacy + Health Impact Ohio Pathways Hub|The Food Farmacy + Health Impact Ohio Pathways Hub Arm receives weekly produce through a consortium of local food banks at the direction of the Mid-Ohio Food Collective and has social needs address through a community health worker model at the direction of Health Impact Ohio. The community health worker meets with participants, evaluates and addresses non-medical, health-related social needs.
223494030|NCT05472441|BEHAVIORAL|Mid-Ohio Food Farmacy + Cooking for Diabetes + Health Impact Ohio Pathways Hub|The Food Farmacy + Cooking for Diabetes + Health Impact Ohio Pathways Hub Arm receives all 3 interventions. Participants receive weekly produce through a consortium of local food banks at the direction of the Mid-Ohio Food Collective, Cooking for Diabetes, a 6-week diabetes self-management education and support and culinary education intervention and has social needs addressed through a community health worker model at the direction of Health Impact Ohio. The community health worker meets with participants, evaluates and addresses non-medical, health-related social needs.
223494031|NCT05958381|DEVICE|Transcranial Direct Current Stimulation|Transcranial direct current stimulation will be delivered via a Neuroelectrics Starstim tES. Stimulation will consist of 1 milliamp stimulation, with anodal stimulation delivered at electrode Fz (International 10/10 System for electroencephalography electrode placement) and electrodes F7, FP1, FP2, and F8 as returns. All electrodes are 1 cm diameter Ag/AgCl electrodes and make contact with the scalp via connective gel. Stimulation will linearly ramp up from 0 milliamps to 1 milliamp over 60 seconds, then remain at 1 milliamp of stimulation over 20 minutes, and finally ramping down at to 0 milliamps over 60 seconds.
223745726|NCT06410209|OTHER|Medical Device Usage and Evaluation|Wear a Fitbit physical activity tracker
223745727|NCT06410209|OTHER|Medical Device Usage and Evaluation|Wear a research grade activity measuring device
224185757|NCT03809260|DRUG|Metformin (part 2)|1\~4d: Metformin 1000 mg bid (Except for 500 mg after 1d lunch)
224185758|NCT05162599|DEVICE|Diagnostic study, experimental evaluative cross-sectional study|This is a cross-sectional diagnostic study with collection of information from the gold standard (or reference test) and the new device
224185759|NCT00372073|DRUG|seliciclib|1200 mg bid x 3 days every 2 weeks
224185760|NCT00372073|DRUG|placebo|1200 mg bid x 3 days every 2 weeks
224185761|NCT01061762|BEHAVIORAL|Stick To It|3-counseling session adherence intervention tailored for people with poor literacy skills
224185762|NCT01061762|BEHAVIORAL|Standard medication adherence counseling|3 counseling sessions for adherence improvement derived from standard behavioral approaches.
224185763|NCT01061762|BEHAVIORAL|Health Counseling|3-session of health improvement counseling to serve as an attention control.
223588961|NCT03445559|BEHAVIORAL|Clinical Order Check|A Clinical Order Check is an evidence-based, systems-level method to affect significant behavior change. It addresses the intervention functions of education, enablement and incentivization which are effective methods to change behaviors driven by beliefs about capabilities, knowledge, social influences, beliefs about consequences, and environmental context and resources. All VA facilities currently use locally adapted clinical reminders. This strategy is technologically simple, straightforward, and is considered to be a best practice within the VA IT community. The reminder will be self-explanatory and non-intrusive to workflow.
223588962|NCT03445559|BEHAVIORAL|Academic Detailing|Academic detailing is an individual and facility-level intervention consistently shown to improve provider behavior. This strategy addresses the intervention functions of persuasion, coercion, modeling, and education which are effective methods for affecting behaviors driven by beliefs about capabilities, knowledge, social influences, beliefs about consequences, and environmental context and resources. During the meeting, the detailer will follow a script explaining that the visit is part of an experimental program to provide physicians with up-to-date, unbiased information about imaging to stage prostate cancer.
223588963|NCT03445559|BEHAVIORAL|Audit and Feedback|Audit and feedback is an effective, individual-level intervention for changing healthcare provider behavior, resulting in small but potentially clinically important benefits. Audit and feedback addresses the intervention functions of education, persuasion and incentivization, all of which are important for addressing beliefs about capabilities and consequences, knowledge, and social influence.
223588964|NCT06587165|OTHER|N15-thymidine|50mg/kg (oral administration)
224185764|NCT02347345|DRUG|Harvoni (Fixed dose combination ledipasvir/sofosbuvir)|Harvoni (Fixed dose combination ledipasvir/sofosbuvir), one pill daily x 12 weeks
224185765|NCT01307527|DRUG|Riboflavin|0.1%, applied every 5 minutes for 60 minutes
224185766|NCT01307527|DEVICE|Kera-X|3 mW/cm2, to the central 7.5 mm of the cornea, for 30 minutes
224185767|NCT06221085|DIAGNOSTIC_TEST|Pain Pressure Threshold (PPT)|"Researchers measure pain pressure thresholds (PPTs) by applying a Pressure gauge algometer (PGA) over the myofascial trigger points (TrPs) on the body. PPT is defined as the lowest stimulus intensity at which a subject perceives pain.~The clinician applies it perpendicular to the long axis of the structure on which it is placed. The examiner increases the pressure at a rate of 1 kg/s until the subject feels pain or discomfort, and then the PPT values are measured three times for each muscle. Participants verbally report the first sensation of pain or discomfort, at which point the examiner stops the pressure."
224185768|NCT00142714|PROCEDURE|Sympathetic manipulation on sexual arousal in women|
224185769|NCT01621659|BEHAVIORAL|Multidisciplinary team intervention|Intervention arm receives regular assessments and treatments from cardiology team, clinical nutrition, pharmacist, exercise physiologist and physiotherapist
224185770|NCT01165268|DRUG|Dapagliflozin|Tablets, Oral, 10 mg, Once daily, 7 days
223494032|NCT05958381|DEVICE|Sham transcranial direct current stimulation|Sham transcranial direct current stimulation will be delivered via a Neuroelectrics Starstim tES. The sham setup will consist of anodal electrode Fz (International 10/10 System for electroencephalography electrode placement) and electrodes F7, FP1, FP2, and F8 as returns. All electrodes are 1 cm diameter Ag/AgCl electrodes and make contact with the scalp via connective gel. Stimulation will linearly ramp up from 0 milliamps to 1 milliamp over 60 seconds, ramp down to 0 milliamps over 60 seconds and then be left off for 20 minutes.
223494033|NCT04558619|BEHAVIORAL|Kōmmour Prenatal|Centering Pregnancy, a group prenatal care model, is a promising intervention that challenges the standard model of one-on-one counseling of prenatal care. The model, is currently implemented at the UAMS, but as of yet to be adapted for Pacific Islanders. Centering Pregnancy replaces the individual prenatal care visit with a group model for obstetrically low-risk women. This model provides substantially more health promotion content than the traditional one-on-one prenatal care model. The intervention occurs from week 14 of pregnancy through birth, following the same same schedule as individual care. Group visits are 90-120 minutes each and follow a unique structured curriculum that incorporates standards of care. In the group setting, credentialed prenatal providers conduct a one-on-one assessment with each patient (30 min) and then facilitate group discussions on the topics of pregnancy, using adult learning principles (60-90 min).
223494034|NCT05357612|DRUG|Pimavanserin|PD related Psychosis
223494035|NCT02580604|DRUG|Calcium Chloride/Calcium Gluconate|Calcium (as either calcium chloride or calcium gluconate in half normal saline) will be delivered via IV during exercise to keep serum ionized calcium levels above baseline. The clamp is modeled after the hyperglycemic glucose clamp.
223494036|NCT02580604|DRUG|Half-Normal Saline|This is the placebo comparative infusion. Half-normal saline will be infused at the second collection visit following the identical infusion schedule determined during the calcium infusion visit.
223588965|NCT05432024|DEVICE|Catheter ablation|An ablation catheter is introduced in the heart. Ablation is performed by applying ablation energy to the target tissue. The aim of ablation is to create an ablation lesion that does not conduct the electrical signals that induce or sustain the cardiac arrhythmia.
223588966|NCT06085664|DRUG|REGN5678|Given by IV (vein)
223588967|NCT06085664|DRUG|Piflufolastat F18|Given by IV (vein)
223745728|NCT06410209|OTHER|Questionnaire Administration|Ancillary studies
223745729|NCT06410209|OTHER|Reward|Receive badges
224185771|NCT03077074|OTHER|low carbohydrate consumption|consumption of up to 60 grams of carbohydrate a day for 10 days FMRI will be performed prior and after the intervention during the luteal cycle phase
224185772|NCT00733096|DRUG|etanercept|Two transforaminal epidural injections of 4 mg, two weeks apart
224185773|NCT00733096|DRUG|methylprednisolone|Two transforaminal epidural steroid injections with 60 mg, two weeks apart
224185774|NCT00733096|DRUG|normal saline|Two transforaminal epidural saline injections, two weeks apart
224308641|NCT04197050|DRUG|Sacubitril / Valsartan Oral Tablet|After recruiting participants and collecting the baseline information, sacubitril/valsartan group will receive sacubitril/valsartan and optimal pharmaceutical treatment (OPT). The control group will receive valsartan and OPT. A CMR scan and a post-processed imaging procedure will later be carried on in order to detect the cardiac impairment.
224185775|NCT00496782|DRUG|maraviroc|Treatment-experienced subjects on failed therapy, with HIV RNA ≥ 1000 copies/mL, are eligible who will receive a tropism assay at screening (Day -14 to 0). Subjects who are eligible will receive maraviroc added to a failing regimen from Day 1 to 14. On day 15, subjects will discontinue the current treatment regimen and begin a new OBT. Subjects with only R5 HIV will continue receiving maraviroc plus OBT. Subjects with non-R5 virus will discontinue receiving maraviroc but continue to receive the new OBT. Investigator selects OBT based on results of phenotype/genotype testing at baseline. The nominal dose for maraviroc is 300 mg BID. The maraviroc dose should be adjusted based on OBT patient is taking. If OBT includes CYP3A4 inhibitor (with or without inducers) maraviroc dose should be 150 mg BID and if OBT includes CYP3A4 inducer (without inhibitors) maraviroc dose should be 600mg BID. If OBT does not include any CYP3A4 inducers or inhibitors maraviroc dose should be 300 mg BID.
224185776|NCT00496782|PROCEDURE|Trofile Assay and HIV RNA quantification assay|Trofile Assay and HIV RNA quantification assay
224185777|NCT00349960|DRUG|NeoRecormon SC once-weekly versus once-every-other-week|
224185778|NCT02735382|BEHAVIORAL|Tobacco quitline EHR referral|Using an EHR-based referral to the tobacco quitline from primary care outpatient clinics.
224185779|NCT02735382|BEHAVIORAL|Tobacco quitline Fax referral|Using an Fax--based referral to the tobacco quitline from primary care outpatient clinics.
224185780|NCT05791123|PROCEDURE|a bone graft mixed with PRF & covered by PRF membrane in fresh extraction socket|Extraction sockets were filled with minced PRF clots mixed with the bovine xenograft and covered by PRF membranes to seal the extraction sockets.
224185781|NCT03920046|BEHAVIORAL|Control Group|The prevalence of laryngospasm in sedation applied to endoscopic intervention whose parents no smoking.
224185782|NCT01446744|RADIATION|Stereotactic ablative radiotherapy|Total dose and number of fractions will depend on the site of disease. Treatment will be given daily, or every other day, over 1 -3 weeks.
224185783|NCT01446744|RADIATION|palliative radiotherapy|"Investigators should follow the principles of palliative radiotherapy as per the individual institution. Treatment recommendations are as follows:~Brain: Whole brain radiotherapy i.e. 20 Gy in 5 fractions, 30 Gy in 10 fractions~Lung: Palliative radiotherapy as per 2011 consensus guidelines.15 i.e. 8 Gy in 1 fraction, 20 Gy in 5 fractions, 30 Gy in 10 fractions~Bone: Palliative radiotherapy as per 2011 consensus guidelines.16 i.e. 8 Gy in 1 fraction (most common), 20 Gy in 5 fractions, 30 Gy in 10 fractions~Liver: 20 Gy in 5 fractions if standard institutional practice"
224185784|NCT02863406|OTHER|Bronchoalveolar lavage|Bronchoalveolar lavage in order to determine rate of dust
224185785|NCT03369925|DIETARY_SUPPLEMENT|Placebo supplement|Cellulose
224185786|NCT03369925|DIETARY_SUPPLEMENT|Citicoline supplement|Cognizin
224185787|NCT01979692|PROCEDURE|confocal laser microscopy CLM at trans thoracic needle biopsy TTNB|
224185788|NCT01979692|DEVICE|CT guided trans thoracic needle biopsy|
224185789|NCT03721406|DRUG|Ropivacaine|ropivacaine administerd via thoracic paraveretebral catheter
224185790|NCT01288911|DRUG|enzalutamide|capsules
224185791|NCT01288911|DRUG|bicalutamide|tablets
224185792|NCT05963555|DEVICE|NovoThor|Following the baseline block (first four weeks), participants will use the NovoThor device 2-3 times per week for 20 minute sessions at the WVU Rockefeller Neuroscience Institute.
224185793|NCT05963555|DEVICE|VieLight|Following the baseline block (first four weeks), participants will use the VieLight device 2-3 times per week for 20 minute sessions and may be completed at home.
224185794|NCT05963555|DEVICE|ZeroBody|Following the baseline block (first four weeks), participants will use the Zerobody device 2-3 times per week for 20 minute sessions at the WVU Rockefeller Neuroscience Institute.
223494037|NCT05840484|OTHER|Active Surveillance|Participants will be asked to complete questionnaires, have physical and rectal examinations, have prostate biopsies, and have imaging scans (such as MRIs). These visits will be done between every 6 months and every 2-3 years, depending on the test/procedure.
223588968|NCT06609590|PROCEDURE|Glenoid nerve block combined with Sub-omohyoid Anterior Suprascapular nerve Block|Ultrasound guided anterior glenoid nerve block combined with Sub-omohyoid Anterior Suprascapular nerve Block
223588969|NCT06609590|PROCEDURE|Interscalene brachial plexus block|Ultrasound guided interscalene brachial plexus block
223745730|NCT06410209|OTHER|Text Message-Based Navigation Intervention|Receive text messages
223745731|NCT06410209|OTHER|Text Message-Based Navigation Intervention|Receive reminders
224185795|NCT02871024|DEVICE|Toraymyxin|Toraymyxin is an extracorporeal hemoperfusion device designed to reduce blood endotoxin levels in sepsis
224185796|NCT04768439|DRUG|Low Dose Vitamin D|Patients will receive a 200 IU/d vitamin D since they tolerate full enteral nutrition.
224185797|NCT04768439|DRUG|High Dose Vitamin D|Patients will receive 1600 IU/d vitamin D since they tolerate full enteral nutrition.
224185798|NCT02189239|DRUG|Zeller Entspannung film coated tablet|
224185799|NCT02189239|DRUG|Placebo|
224185800|NCT02189239|OTHER|No Treatment|
224185801|NCT00694239|BEHAVIORAL|Knowledge of Cardiovascular Risk Assessment|Knowledge of Cardiovascular Risk Assessment and risk reduction at target BP, reviewed every 3-6 months.
224185802|NCT00336986|DRUG|recombinant interleukin-21|
224185803|NCT02745093|DRUG|Mifepristone|Women at 64-84 days' gestation will use the following dosing regimen: 200 µg mifepristone administered orally in the clinic on Day 1.
224185804|NCT02745093|DRUG|Misoprostol|The client will then be given a total of 2400 µg misoprostol tablets to take home, and will be instructed to take 800 μg misoprostol administered sublingually 24-48 hours later at home and to administer a subsequent dose of 400 μg misoprostol sublingually every 3 hours up to a total of four further doses or until expulsion of the products of conception, whichever comes first.
224185805|NCT02930928|OTHER|Accuracy of weight estimation|Computer based comparison
223494038|NCT00870506|BEHAVIORAL|video|5-minute video compared (intervention) to no video and no other intervention (control)
223494039|NCT05936437|DEVICE|Subjects treated with Newest medical device|"Newest is a sterile, non-pyrogenic, viscoelastic gel for single use for intradermal infiltrations. Newest is a medical device containing 2ml of the original association of polynucleotides (10mg/ml) and hyaluronic acid (10mg/ml).~Total number of treatments will consist in 4 Newest administrations: at T0 - basal, at T1- 2 weeks, at T2 - 4 weeks, at T3- 6 weeks."
223494040|NCT06023953|DEVICE|Nerivio device|REN treatment with Nerivio device
224185806|NCT02620566|PROCEDURE|Bupivacain- Caudal|Bupivacain for caudal blocks, Group C received 1 ml kg of 0.25% (maximum volume 20 ml).
224308642|NCT05362838|PROCEDURE|robotic-assisted laparoscopy|Superficial and deep endometriosis resection will be performed in the usual standard fashion. All superficial lesions suspicious for endometriosis (pigmented and nonpigmented) will be completely resected until non-diseased peritoneal margins are visualized around the defect; all deep lesions suspicious for endometriosis will be completely resected until non-diseased margins are visualized in the tissue surrounding the defect. Cystectomy will be performed for endometriomas. Additional procedures are performed as needed to completely resect all endometriosis lesions. The fascia of any port ≥10 mm will be reapproximated. If bowel resection and re-anastomosis is necessary this will be performed together with a General Surgeon.
224308643|NCT05362838|PROCEDURE|Conventional laparoscopy|Superficial and deep endometriosis resection will be performed in the usual standard fashion. All superficial lesions suspicious for endometriosis (pigmented and nonpigmented) will be completely resected until non-diseased peritoneal margins are visualized around the defect; all deep lesions suspicious for endometriosis will be completely resected until non-diseased margins are visualized in the tissue surrounding the defect. Cystectomy will be performed for endometriomas. Additional procedures are performed as needed to completely resect all endometriosis lesions. The fascia of any port ≥10 mm will be reapproximated. If bowel resection and re-anastomosis is necessary this will be performed together with a General Surgeon.
223494041|NCT04549636|OTHER|V/Q SPECT-CT|At visits 1 and 2, ventilation will be assessed by 99mTc Technegas SPECT ventilation scan and perfusion will be assessed by 99mTc Macroaggregated Albumin SPECT perfusion scan.
223494042|NCT04549636|OTHER|St. George's Respiratory Questionnaire (SGRQ)|At visits 1 and 2, quality of life will be evaluated using the St. George's Respiratory Questionnaire (SGRQ).
223494043|NCT04549636|OTHER|mMRC (Modified Medical Research Council) Dyspnea Scale|At visits 1 and 2, dyspnea will be evaluated using the mMRC (Modified Medical Research Council) Dyspnea Scale.
224185807|NCT02620566|PROCEDURE|Bupivacaine- Local|Bupivacain for Local Wound Infiltration Group L received 0,2 ml kg 0,25% (maximum volume 4 ml).
223494044|NCT04549636|OTHER|Six-minute walk test (6MWT)|At visits 1 and 2, exercise capacity will be evaluated using the six-minute walk test (6MWT).
223494045|NCT04549636|OTHER|Spirometry|At visits 1 and 2, spirometry will be performed to quantify the forced expiratory volume in one second (FEV1), the forced vital capacity (FVC) and FEV1/FVC.
223494046|NCT04549636|OTHER|Plethysmography & DLCO|At visits 1 and 2, plethysmography and the diffusing capacity of the lung for carbon monoxide (DLCO) will be performed.
223494047|NCT04549636|OTHER|Airwave Oscillometry|At visits 1 and 2, airwave oscillometry will be performed to obtain resistance (R) and reactance (X) at 5 Hz (R5) and 19 Hz (R19). The resonance frequency (fres), area above the reactance curve (AX) and the heterogeneity of obstruction (R5-19) will be derived from R and X.
223588970|NCT06610825|DRUG|Enhertu|This is an open label, multi-center, single arm, phase II study designed to investigate the anti-tumor activity, efficacy and safety of Enhertu in HER2-positive metastatic castrate-resistant prostate cancer patients who progressed on androgen deprivation therapy and novel hormonal agents (such as Abiraterone and Enzalutamide), who also progressed, refused, or were not candidates to receive taxane-based chemotherapy.
223588971|NCT01761773|DRUG|cabozantinib|3 20-mg strength capsules (60 mg dose) administered as a single oral dose on Day 1 of study participation.
223588972|NCT05081219|DRUG|Insulin (Humulin® R U-100)|Participants will administer 40 IU of Humulin® U-100 insulin four times per day with an intranasal delivery device.
223588973|NCT05081219|DRUG|Empagliflozin 10 MG|Participants will be assigned to receive Empagliflozin 10 mg capsules to be taken by mouth once daily.
224185808|NCT05300256|DEVICE|Peripheral Heating|Peripheral heating of the feet
224185809|NCT05300256|DEVICE|Sham|Sham
224185810|NCT06067373|OTHER|questionnaire|"After agreeing to participate, the patients receive a questionnaire in paper form.~This consists of a total of 12 higher-level self-compiled questions as well validated survey instruments. The free questions relate, among other things, to to the surgery postponement, the associated burden, complications occurred, Effects on the employment situation, as well as the current state. The following validated survey instruments are used in the questionnaire: the NCCN Distress Thermometer to record the mental stress, a Severity Symptom Scale to record the symptom burden and the PROMIS-10 for recording the health-related life quality."
223494048|NCT01078662|DRUG|olaparib|Tablets Oral BID
223494049|NCT02920658|DRUG|NAVS Naphthalan|
223494050|NCT02920658|DRUG|0.05% Betamethasone dipropionate|
223494051|NCT05695313|DRUG|OnLife®|"It is administered for the duration of PACLITAXEL chemotherapy with the first administration performed 5 days before the first PACLITAXEL administration. The OnLife supplement will be continued for another 4 weeks after the last PACLITAXEL administration.~One tablet in the morning and one in the evening daily"
223494052|NCT05695313|OTHER|Placebo|"It is administered for the duration of PACLITAXEL chemotherapy with the first administration performed 5 days before the first PACLITAXEL administration. Placebo will be continued for another 4 weeks after the last PACLITAXEL administration.~One tablet in the morning and one in the evening daily"
223494053|NCT02198638|BIOLOGICAL|A nasal swab|A nasal swab was performed by a research assistant and influenza virus infection was confirmed by enzyme-linked immunosorbent assay and reverse transcription-polymerase chain reaction on viral cultures
223494054|NCT01502891|OTHER|Decision Aid|The decision aid, Depression Medication Choice, uses plain language and is designed to enhance patient understanding and satisfy the International Patient Decision Aid Standards (IPDAS) requirements for a safe and unbiased decision aid.
223494055|NCT04412421|PROCEDURE|Gastric Bypass, Sleeve Gastrectomy|Lifelong vitamin and Mineral supplementation
224185811|NCT06443138|OTHER|Personalized pre-habilitation program|"Each patient will undergo 4 weeks of individualized pre-habilitation before surgery.~Each session (1 session per day) will be carried out autonomously by the patient at home, via a dedicated application (Activiti Pro) installed on their tablet or smartphone."
223588974|NCT05081219|DEVICE|Aptar Pharma CPS Intranasal Delivery Device|Participants will be assigned to receive Humulin® insulin or placebo administered through the Aptar Pharma CPS intranasal delivery device.
224185812|NCT01960036|BEHAVIORAL|Mindful Awareness in Body-oriented Therapy|
224185813|NCT01960036|BEHAVIORAL|Womens Health Education|
224308644|NCT05408234|OTHER|Smart Foot Exercise|"The patient lies supine (supine) with the legs raised 450 while supported for 1-3 minutes until blanching occurs (the skin becomes pale).~The patient sits on the edge of the bed with the legs hanging down and then performs dorsiflexion, plantarflexion, inversion, and eversion for 3 minutes until the skin appears red.~The patient lies supine with the legs covered with a blanket for 3-5 minutes. This whole cycle is repeated 3-6 times per session, and each session is repeated 2-4 times a day.~Movement using newspaper media, namely by:~Place a sheet of newspaper on the floor, then shape the sheet into a ball with both feet.~The ball shape is then opened into a sheet as before with both feet. Tear the newspaper into two parts, and separate the two parts of the newspaper. Tear the first newspaper into small pieces with both feet. Remove the bunch of stubs and place them in a second, whole newspaper. Wrap everything into a ball shape with both feet. This step is enough to do once."
224308645|NCT00196924|BIOLOGICAL|HPV-16/18 L1/AS04|
224308646|NCT01110135|DRUG|bendamustine hydrochloride|Given IV
223494056|NCT01294813|DEVICE|Electrical Impedance Tomography (EIT)|EIT measurements of 1-2 minutes are performed in patients who routinely undergo bronchoscopy (during 1.5 hours) before, directly after and 10, 30, 60 minutes after bronchoscopy. Therefore the rubber belt including 16 integrated electrographic electrodes is placed around the patient´s chest and connected with an EIT device. EIT data are generated by application of a small alternating current of 5mA and 50kHz and are stored and analyzed offline on a personal computer. Pseudonomyzed EIT data are evaluated descriptively.
224185814|NCT01381601|DRUG|Targeted agents indicated in management of advanced/metastatic RCC (sunitinib, sorafenib, bevacizumab, and pazopanib)|Metastatic RCC patients on either sunitinib or sorafenib or bevacizumab or pazopanib (identified based on claims) will be evaluated for presence or absence of common severe adverse events. These common severe adverse events will be identified from agent's product labels.
224185815|NCT02254616|BEHAVIORAL|Mirror Therapy with tDCS|The MTtDCS group will receive a 20-minute tDCS at 1.5 mA current intensity per session followed by a 40-minute mirror therapy and 30-minute functional training during the first two weeks. Sixty-minute pure mirror therapy during the last 2 weeks, and followed by a 30-minute functional training.
224185816|NCT02254616|BEHAVIORAL|Mirror Therapy with sham-tDCS|The MTtDCS(m) group will receive a 20-minute sham-tDCS per session followed by a 40-minute mirror therapy and 30-minute functional training during the first two weeks. Sixty-minute pure mirror therapy during the last 2 weeks, and followed by a 30-minute functional training.
224185817|NCT02254616|BEHAVIORAL|Mirror Therapy|The MT group will receive a 60-minute MT per session followed by a 30-minute functional training.
224308647|NCT01110135|DRUG|dexamethasone|Given PO
223494057|NCT00058591|BIOLOGICAL|Intravenous injection of EBV specific CTLS|"The dose levels for this study are as follows:~Level Dose~1. 2 x 107 CTLs/m2~2. 5 x 107 CTLs/m2~3. 1 x 108 CTLs/m2~If patients have a clinical response to the first infusion defined by an improvement in the fatigue score or resolution of clinical abnormalities such as lymphadenopathy or an improvement in laboratory parameters such as a decrease in VCA titer or reduction in free EBV DNA they will be eligible to receive up to 3 additional injections of CTLs at the original dose at 3 monthly intervals."
223494058|NCT01021189|DRUG|AZD1446|Oral solution Dose single and followed by 7-day multiple dosing.Specific doses depend on panel.
223588975|NCT05081219|DRUG|Placebo (Insulin Diluent)|Participants will administer placebo (insulin diluent) four times per day with an intranasal delivery device.
223745732|NCT03599050|BEHAVIORAL|Audiotaped Counseling Session|Patients and nurses will complete audio taped counseling session at least 3 months following the baseline visit. Patients will rate quality of nurse communication skills
224185818|NCT02254616|BEHAVIORAL|Control Intervention|The CI group will receive a 60-minute conventional stroke rehabilitation training followed by a 30-minute functional training.
224308648|NCT01110135|BIOLOGICAL|filgrastim|Given SC
224308649|NCT01110135|PROCEDURE|leukapheresis|Given IV
223588976|NCT05081219|DRUG|Placebo (Capsules)|Participants will be assigned to receive placebo capsules (Empagliflozin 10 mg) to be taken by mouth once daily.
223588977|NCT00424697|DRUG|placebo|
223588978|NCT00424697|DRUG|lorazepam|
224185819|NCT00520273|DEVICE|cobas s 201 TaqScreen MPX Test|Donors testing reactive for one or more of the viral markers will be advised to seek further advice/treatment from their physician.
224185820|NCT02431559|DRUG|Durvalumab|Durvalumab is administered as an IV infusion over 60 ± 5 minutes.
223588979|NCT00424697|DRUG|GW876008|
223588984|NCT06993350|OTHER|experimental group|eight weeks of targeted weight bearing program
223588985|NCT06409052|BEHAVIORAL|Qualitative interviews|Interviews will be conducted for approximately 45-60 minutes
223745733|NCT03009929|OTHER|Observational study|No intervention, observational only
224185821|NCT02431559|DRUG|Pegylated Liposomal Doxorubicin|PLD was administered as an IV infusion in accordance with local prescribing information.
224308650|NCT01110135|OTHER|laboratory biomarker analysis|Correlative studies
224308651|NCT01110135|OTHER|flow cytometry|Correlative studies
224308652|NCT01110135|DRUG|etoposide|Given IV
223588986|NCT06597799|DRUG|MRT-6160|Orally administered tablets or capsules of MRT-6160
223588987|NCT06597799|DRUG|Placebo|Orally administered tablets or capsules of placebo
223745734|NCT05016557|DIETARY_SUPPLEMENT|Protein ingestion|Bolus ingestion of 25g protein
223588988|NCT07000734|BEHAVIORAL|Risk managment|Behavioral lifestyle changes including an exercise program, healthy eating recommendations, reviewing medical management for cardiometabolic risk conditions, deprescribing review for brain toxic meds, online cognitive training, as well as recommendations to improve sleep quality, or smoking cessation as needed
223588989|NCT07000734|DRUG|Dasatinib|dasatinib 100mg The intervention will involve the participant taking dasatinib 100mg and quercetin 1250ng combined, intermittenly throughout the trial
223588990|NCT07000734|DIETARY_SUPPLEMENT|Quercetin (dietary supplement)|e intervention will involve the participant taking dasatinib 100mg and quercetin 1250ng combined, intermittenly throughout the trial
223588991|NCT07000734|DRUG|Vortioxetine|Participants will be prescribed vortioxetine to take daily, in combination with online cognitive training
223588992|NCT07087886|BEHAVIORAL|Combined Resilience Intervention|"A two-phase behavioral intervention aimed at improving psychological resilience among socioeconomically disadvantaged adolescents. The intervention includes:~1. a 5-day structured summer camp led by trained university student volunteers, featuring psychoeducational group sessions, emotional expression activities, and life skills training, based on SEL, CBT, and positive psychology frameworks; and~2. a 10-month pen-pal letter-writing component, where each child is matched with a trained university volunteer to receive monthly supportive letters. This stage reinforces the gains from the summer camp through sustained emotional support, skill reminders, and positive guidance.~The intervention is designed to be low-cost, scalable, and ethically safe, and has been standardized through manuals and training protocols."
223588993|NCT05453513|BEHAVIORAL|MRI Study|fMRI Tasks
223588994|NCT00050674|DRUG|Filgrastim-SD/01|6 mg SC on Day 9 (24 hours after the end of the chemotherapy infusion)
223588995|NCT05719714|DRUG|Dapagliflozin 10 MG [Farxiga]|10mg (milligram) tablet to be taken orally once daily for 6 months. Manufacturer: Astrazeneca. Study drug will be stored and dispensed by the Interventional Drug Service Pharmacy at Northwestern University.
223588996|NCT06624540|BEHAVIORAL|This is a pre- and post- quasi-experimental study.|We will use new equipment and implement EBP (VAP management) for patients by trained nurses (Phase 2) and check the outcome of the patients. We will compare our phase 1 findings for this study as historical data.
223588997|NCT06624540|BEHAVIORAL|Education with EBP|"Phase 2: Nurse's EBP training ( VAP management), 2 hours lecture and 3 hours skill training for total 4 times in 1 month.~Phase 3: Introduce new equipment necessary for EBP implementation for VAP management, and EBP-trained nurses implementation for VAP management."
223588998|NCT06624904|DRUG|Losartan potassium 50mg|Single dose losartan (50 mg), encapsulated identically to placebo.
223588999|NCT06624904|OTHER|Placebo|Single tablet encapsulated identically to placebo.
223589000|NCT07012122|OTHER|visual spatial memory task|The child will be asked to put numbers in an imagined matrices and memorize the position very well then will be asked to remember the position of these numbers.
223589001|NCT07012122|OTHER|nonspatial verbal memory task|The child is presented with a series of sentences that are similar in structure and content, with only slight variations in elements such as the verb, subject, or object. The child's task is to remember and accurately recall these sentences. For example: The dog is running in the park, The cat is running in the park, The dog is playing in the park, The dog is running in the yard.
223589002|NCT07012122|OTHER|visuomotor tracking task|Then the rest will be introduced in the form of computer screen in front of the child with a dot moving under the control of a computer mouse and asking the child to track the dot while maintaining his balance as much as he can.
223589003|NCT05952960|OTHER|Placebo|Open Label Placebo + Rationale
223589004|NCT04969536|DIETARY_SUPPLEMENT|Branched Chain Amino Acids|Supplementation with 8 g Nutrex Research Amino Acid Drive BCAA in 8 ounces of water once each immediately pre-exercise and after 30 minutes of exercise
223589005|NCT04969536|OTHER|Placebo|Supplementation with 2.0 milliliters of a sucralose-based drink mix with 8 ounces of water once each immediately pre-exercise and after 30 minutes of exercise
223589006|NCT00740623|DRUG|Carisbamate|800 mg/day for 14 weeks
223589007|NCT00740623|DRUG|placebo|placebo for 14 weeks
223589008|NCT00740623|DRUG|Carisbamate|1,200 mg/day for 14 weeks
223589009|NCT00459472|BEHAVIORAL|laparoscopic training curriculum|All general surgery interns and PGY-2-5's already participate in a surgery training curriculum that includes lectures, surgery, laparoscopic training, attending surgeons evaluating performance of residents at the end of surgical procedures, written tests, and skills tests.
224185822|NCT02431559|DRUG|Motolimod|Motolimod was administered as an SC injection. Within 30 minutes prior to each dose of motolimod, subjects were administered 650-1000 mg acetaminophen by mouth to help mitigate potential adverse events (AEs) commonly associated with the administration of motolimod (e.g., fever, myalgia). On days with concurrent motolimod and durvalumab dosing, motolimod administration occurred 30-60 minutes after the end of the durvalumab infusion. After completion of Phase 1, a protocol amendment was implemented to remove motolimod dosing from the study.
224185823|NCT02543918|DRUG|Ixekizumab|Administered by SQ injection
224185824|NCT02543918|DRUG|Boostrix®|Administered by IM injection
224185825|NCT02543918|DRUG|Pneumovax®23|Administered by IM injection
224185826|NCT04672694|PROCEDURE|Vagus nerve block|Ropivacine 0.75% 2mL will be injected two times around the vagus nerve (just below the bifurcation of recurrent laryngeal nerve); one before starting the surgical resection of lung including complete mediasitnal lymph node dissection and one at the end of operation.
224185827|NCT04672694|PROCEDURE|No vagus nerve block|No vagus nerve block will be conducted during the surgery.
224185828|NCT02826005|DEVICE|MRI|
224185829|NCT06643936|BEHAVIORAL|E3 Multidisciplinary Team|The E3 Multidisciplinary team is composed of a remote pharmacist, social worker, community health worker, and dietician working together to overcome barriers to diabetes control via behavioral change, medication adherence and titration, diet and lifestyle education and resource referrals for social needs.
223589010|NCT02484950|BIOLOGICAL|Mesenchymal stem cell augmentation in rotator cuff repair|Patients undergoing mesenchymal stem cell augmentation will receive a total injection of 6 milliliters (mL). Of this, 3 mL will be injected in the tendon at the junction between bone and tendon, while 3 mL will be injected in the bone at the site of the surgical footprint.
223494059|NCT01021189|DRUG|Placebo|Oral solution Dose single and followed by 7-day multiple dosing.
223494060|NCT05731765|DIAGNOSTIC_TEST|Machine Learning Model|Automated machine learning system for the detection of spontaneous venous pulsations and quantification of intracranial pressure
223494061|NCT00990886|DRUG|Placebo|Once daily for 12 weeks
223494062|NCT00990886|DRUG|Oxybutynin chloride|15 mg once daily for 12 weeks
223494063|NCT01813175|OTHER|Regular non-hydrolysed cow's milk I|Regular non-hydrolysed cow's milk based infant formula with synbiotics mixture I
223494064|NCT01813175|OTHER|Regular non-hydrolysed cow's milk II|Regular non-hydrolysed cow's milk based infant formula with synbiotics mixture II
223494065|NCT01813175|OTHER|Regular non-hydrolysed cow's milk - control|Regular non-hydrolysed cow's milk based infant formula without synbiotics mixture
223494066|NCT06036095|DRUG|Sevoflurane|Inhalational maintenance of anesthesia group using sevoflurane
223494067|NCT06036095|DRUG|Propofol|Intravenous maintenance of anesthesia group using propofol
223494068|NCT05130437|BIOLOGICAL|mRNA-3927|mRNA-3927 dispersion for IV infusion
223494069|NCT02239289|OTHER|Biofeedback|Idem as described in the arm section (above)
223494070|NCT00700635|BIOLOGICAL|Menactra®: Meningococcal Polysaccharide Diphtheria Conjugate|0.5 mL, 2 doses Intramuscular
223494071|NCT00700635|BIOLOGICAL|Menactra®: Meningococcal Polysaccharide Diphtheria Conjugate|0.5 mL, 2 doses Intramuscular
223494072|NCT00700635|BIOLOGICAL|Menactra®: Meningococcal Polysaccharide Diphtheria Conjugate|0.5 mL, 1 dose Intramuscular
223494073|NCT05869474|PROCEDURE|Iodine125-Seeds implantation|Endoscopic ultrasound-guided intratumoral iodine125-Seeds implantation
223494074|NCT05869474|DRUG|Gem/nab-P Chemotherapy|nab-paclitaxel (125 mg per square meter of body-surface area) followed by gemcitabine (1000 mg per square meter) on days 1, 8 every 3 weeks
223589011|NCT02484950|PROCEDURE|Standard arthroscopic rotator cuff repair|All patients will undergo full thickness rotator cuff repair using a double row, transosseous-equivalent (TOE) repair with anchor/suture technique. Acromioplasty will be performed in all patients. Alternate procedures such as biceps tenotomy/tenodesis and distal clavicle excision will be performed at the discretion of the surgeon and recorded.
224185830|NCT06643936|BEHAVIORAL|E3 Self-Guided Type 2 Diabetes Education|Patients will receive timed, mailed educational materials on diabetes monitoring, diet and lifestyle modifications to supplement usual clinic based type 2 diabetes care with their primary care doctor. A registered nurse will ensure patients have glucometers and supplies, and remind patients to obtain A1C readings at 3 months and 6 months via phone call.
223589012|NCT05147662|BIOLOGICAL|Damoctocog alfa pegol (Jivi, BAY94-9027)|"Part A: 40 IU/kg (up to 60 IU/kg at the investigator's discretion), two times per week (2x/week) with the first 4 infusions under medical supervision. Thereafter, participants will continue their treatment as home treatment. Dose may be increased up to 60 IU/kg if needed at any time during the study at the investigator's discretion.~Part B: Each participant may continue on prophylaxis dose regimen as prescribed in part A (40 - 60 IU/kg, 2x per week) or adjustments to prophylaxis dose / dose frequency can be made at the investigator's discretion (based on the bleeding events and individual needs): Dose frequency may be decreased to every 5 days with a prophylaxis dose of 60 IU/kg."
223589013|NCT07020780|RADIATION|Adjuvant 5 fractions whole breast irradiation with simultaneous integrated boost to the tumor bed|Experimental arm (arm 1-five fractions WBI) patients will be treated to a total dose (TD) of 26 Gy in 5 fractions to whole breast, and a simultaneous integrated boost (SIB) to a TD of 30 Gy to the tumor bed, while arm 2-fifteen-fractions WBI patients with 40 Gy/15 fractions to PTV, and 48 Gy SIB to the tumor bed.
223589014|NCT03626285|PROCEDURE|Bone Marrow Transplantation|Undergo BMT
223589015|NCT03626285|DEVICE|CliniMACS CD34 Reagent System|CD34 selection ex vivo
224185831|NCT03856242|DRUG|Tamsulosin Oral Capsule|Tamsulosin Oral Capsule - alpha-1-adrenoblocker for treatment LUTS/BPH 0.4 mg
224185832|NCT03856242|PROCEDURE|TURP|Routine transurethral prostatic resection
224185833|NCT02519127|OTHER|Low glycaemic load diet|Subjects will first be subjected to a 2-week run-in diet consisting of products that fit into a typical 'Western' diet. Thereafter subjects will be allocated to a low glycemic load diet for 6 weeks.
224185834|NCT02519127|OTHER|Western diet|Subjects will first be subjected to a 2-week run-in diet consisting of products that fit into a typical 'Western' diet. Thereafter subjects will be allocated to a 'Western' diet for 6 weeks.
223494075|NCT01453231|PROCEDURE|thighplasty|Plastic surgery of thigh
223494076|NCT05172570|DRUG|Gabapentin|Gabapentin is a common medication used preoperatively and postoperatively as part of multimodal analgesia to help with acute pain.
223494077|NCT05632991|OTHER|ultrasound guided external oblique intercostal plane block|ultrasound guided external oblique intercostal plane block 20 ml local anesthetic each side
223494078|NCT05632991|OTHER|Subcostal Transversus Abdominis Plan Block Group|ultrasound guided Subcostal Transversus Abdominis Plan Block Group 20 ml local anesthetic each side
223494079|NCT00942851|DRUG|Acetyl-Hexapeptide Topical Treatment|AH-8 containing topical treatment
223494080|NCT00942851|DRUG|placebo|topical treatment NOT containing AH-8
223494081|NCT02157090|OTHER|Herpes Patch SOS (Hansaplast®)|
223494082|NCT02157090|OTHER|Herpes vesicle patch of Compeed®|
223589016|NCT03626285|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Receive CD34-selected peripheral blood stem cells from related or unrelated donors
224185835|NCT05489146|DEVICE|transcranial random noise stimulation and functional electrical stimulation facilitated task practice|Participants were randomized to one of the two intervention groups \[transcranial current stimulation (tRNS) and functional electrical stimulation (FES) or FES with sham tRNS\] before pre-intervention testing. After randomization, participants underwent pre-intervention testing, followed by intervention 3 times per week for 6 weeks. Each intervention session lasted for 1 hour, where tRNS or sham-tRNS were delivered concurrently with the FES-facilitated task practice. tRNS or sham-tRNS was delivered for the first 30 minutes. Both tRNS and sham tRNS were delivered by the Starstim system. FES was delivered using the Neuromove system. All participants were treated by a licensed occupational therapist, who was trained on a manualized protocol.
224185836|NCT02094339|PROCEDURE|Local analgesic|Patient will be performed under combined lumbar plexus and sciatic nerve block with 0.33% ropivacaine.At the end of surgery,two catheters are left in the wound.One is intraarticular and the other is on the surface of articular cavity.And then a pump elastomeric infusion pump will be connected with the catheters, which runs 5mL every hours.
224185837|NCT02094339|PROCEDURE|Nerve Block|Combined lumbar plexus and sciatic nerve block with 0.33% ropivacaine will be performed before the surgery.After the a bolus of 30mL ropivacaine around lumbar plexus,a catheter will be left in Psoas gap with 6cm.A pump elastomeric infusion pump running 5mL every hours will also be connected with the catheters at the end of the operation.
224185838|NCT02094339|PROCEDURE|Intravenous analgesic|People in this group will also receive an anesthesia of combined lumbar plexus and sciatic nerve block with 0.33% ropivacaine.An intravenous electronic analgesia pump infusion of flurbiprofen axetil 250mg,palonosetron 0.5mg,pentazocine 240mg.dezocine 30mg will will provide postoperative pain management.The patients will received a 2 mL/h continuous basal infusion and 1 mL boluses with a lockout time of 30 min after a 5 mL Loading dose at the end of the surgery.
224185839|NCT02094339|DRUG|ropivacaine|0.2% ropivacaine
224185840|NCT02094339|DRUG|ropivacaine|0.2% ropivacaine
224185841|NCT02094339|DRUG|opioid|flurbiprofen axetil 250mg,palonosetron 0.5mg,pentazocine 240mg.dezocine 30mg
224185842|NCT03917394|DRUG|rHuEPO|rHuEPO was administrated daily with 10000 IU or 20000 IU
224185843|NCT03917394|DRUG|Iron sucrose|Iron sucrose was administrated daily with 100mg or 200mg
224185844|NCT05852964|GENETIC|Molecular Immunology , gene expressions|Expression levels of inflammatory and anti-inflammatory genes
224185845|NCT03718728|BEHAVIORAL|Mind&Life|Acceptance and mindfulness-based group intervention program.
223589017|NCT05096949|OTHER|Home visit delivery strategy|A nurse will deliver and administer Cabenuva injection at patient's home
223589018|NCT05839730|DEVICE|Pacemaker PLR + TRT ON|RAMware modified implantable pulse generator (IPG) with personalized lower rate (PLR) and tachycardia remodeling therapy (TRT) ON
223589019|NCT05839730|DEVICE|Pacemaker non-pacing mode or an exertional rate-adaptive pacing mode with no planned pacing at rest.|RAMware modified implantable pulse generator (IPG)
223589020|NCT07082257|OTHER|Functional Assessment|Undergo chair-to-table assessment
223589021|NCT07082257|BEHAVIORAL|Timed Get Up and Go Test|"Undergo Get Up and Go assessment"
224185846|NCT03718728|BEHAVIORAL|Standard|Personalized diet and physical exercise recommendations.
224185847|NCT02485340|DRUG|5-ISMN (isosorbide-5-mononitrate)|5-ISMN is given both study days to induce headache. One day the headache is treated with placebo and the other day with sumatriptan
224185848|NCT02485340|DRUG|Sumatriptan|5-ISMN is given both study days to induce headache. One day the headache is treated with placebo and the other day with sumatriptan
224185849|NCT02485340|DRUG|Placebo|5-ISMN is given both study days to induce headache. One day the headache is treated with placebo and the other day with sumatriptan
224185850|NCT00469391|DEVICE|GI Sleeve Implantable weight loss device (EndoBarrier)|device for weight loss
224185851|NCT00469391|PROCEDURE|Sham Procedure|Weight loss
224185852|NCT04477018|DIETARY_SUPPLEMENT|Iron bis-glycinate chelate and vitamin C|28 mg iron; 240 mg vitamin C
224185853|NCT04477018|DIETARY_SUPPLEMENT|Iron bis-glycinate chelate|28 mg iron only
224185854|NCT04477018|DIETARY_SUPPLEMENT|Placebo|Matched placebo
224185855|NCT00842504|DRUG|Micafungin|3 mg/kg IV once over 1 hour
224185856|NCT04330586|DRUG|Ciclesonide Metered Dose Inhaler [Alvesco]|Ciclesonide 320ug oral inhalation q12h for 14 days
224185857|NCT03824444|DEVICE|PODS|Percutaneous Osseointegrated device for transhumeral patients
224185858|NCT02581852|OTHER|Cross sectional assessment|Assessment of workability, functional disability, frailty, muscle strength, quality of sleep and sexual functioning
224185859|NCT01005875|DRUG|Sorafenib|Nexavar in bottles of 120 tables
223589022|NCT07088887|OTHER|control group|The control group included patients aged 18-65 who were systemically healthy, had no clinical or self-reported signs of bruxism, and were eligible for implant treatment. Data collected included demographic characteristics (age, gender), systemic and periodontal health status, and clinical examination findings confirming the absence of bruxism. These patients also completed the Fonseca Anamnestic Index (FAI) to assess temporomandibular disorder (TMD) symptoms and the Perceived Stress Scale-14 (PSS-14) to evaluate emotional stress levels. A bruxism awareness questionnaire was also applied to determine baseline knowledge in individuals without bruxism. All assessments were conducted before implant surgery using standardized diagnostic tools.
223589023|NCT07088575|PROCEDURE|major gastrointestinal or hepatobiliary surgery under general anesthesia|major gastrointestinal or hepatobiliary surgery under general anesthesia
223589024|NCT07088107|DEVICE|fNIRS-triggered TMS|The firing of TMS will be triggered according to fNIRS signal intensity.
223589025|NCT07089407|DEVICE|Dental implant placement|Implant site prepared through a consecutive drilling procedure in the maxilla or the mandible, implant placed.
224073611|NCT03880500|OTHER|Spinal Manipulative Therapy|The patient lies in sidelying position, with the hip of the upper leg flexed to 90° and the foot of the flexed leg hooked behind the popliteal space of the downside leg. The chiropractor faces the subject at a 45°-angle, fixates the flexed knee with his own knee/thigh. The fingers of the cephalic hand reach under the patient's upper arm to contact the upside lateral surface of the superior spinous process. The fingers of the caudal hand hook down-side aspect of the spinous process, the forearm contacts the patient's buttock and thigh. The cephalic hand thrusts lateromedially and caudocranially, from upside toward downside (push). The caudal hand thrusts lateromedially in the opposing direction, from downside toward upside (pull). SMT is repeated after the patient turns to left side lying.
224185860|NCT01005875|RADIATION|Stereotactic Body Radiotherapy (SBRT)|SBRT
224185861|NCT04201444|DIAGNOSTIC_TEST|Patient group|Patients with Cushing Disease (CD) receiving a medical treatment: n = 30 Plasmatic cortisol UFC Urine biocollection Salive biocollection
224185862|NCT04201444|DIAGNOSTIC_TEST|Remission control group|Patients in remission of CD and having recovered a normal pituitary function for at least 12 months following pituitary surgery (normal UFC associated to: cortisol suppression following dexamethasone suppression test, or normal LNSC, or midnight serum cortisol \< 200 nmol/L) n = 15 Plasmatic cortisol UFC Urine biocollection Salive biocollection Haircortisol
224185863|NCT04201444|DIAGNOSTIC_TEST|Bilateral surrenalectomy control group|Patients with previous CD, treated with bilateral adrenalectomy and receiving weight adjusted doses of hydrocortisone for at least 6 months. Last daily dose of Hydrocortisone should be administered no later than 5 pm. n = 15 Plasmatic cortisol UFC Urine biocollection Salive biocollection Haircortisol
224185864|NCT00078715|DRUG|Yohimbine hydrochloride|Participants receive yohimbine 0.125 mg/kg administered over 3 minutes during REM sleep.
223589026|NCT07089758|DEVICE|Cerebral open flow microperfusion|"Patients will undergo intra-operative microperfusion using Joanneum Research's cerebral open flow microperfusion (OFM) catheters, push and pull tubing, and MPP102-II pump. This process utilizes a probe (catheter) inserted into the parenchyma to collect analytes of any size and polarity from the microenvironment. The microperfusion pump peristaltically pushes and pulls perfusate with no net fluid-exchange when the pump heads are set at equal flow rates. As perfusate enters the tip of the microperfusion catheter, analytes are exchanged based on a gradient between the interstitial fluid and the perfusate. The sample is then recovered via the pull portion of the peristaltatic microperfusion pump, enabling constant sampling volumes and preventing loss of the perfusate into the tissue.~The duration is 60-80 minutes (dependent on the speed of progress resecting portions of the tumor without catheters)"
223589027|NCT07088549|DEVICE|Continuous glucose monitoring|Intravenous insulin therapy will be guided by interstitial glucose measurements using DexcomG7 continuous glucose monitor. Confirmatory blood glucose tests will be performed daily. In extreme clinical conditions (post-resuscitation, pH \< 7.20, severe hypoxia, severe haemodynamic compromise), confirmatory blood tests will be performed in 2 hour intervals until clinical improvement.
224185865|NCT00078715|DRUG|Placebo|Participants receive an inactive equivalent of yohimbine 0.125 mg/kg administered over 3 minutes during REM sleep.
224185866|NCT02178215|OTHER|Placebo shower gel|Wash forearm with placebo shower gel for 10 seconds, twice a day, 2 weeks
224308653|NCT03156335|DEVICE|Focused Ultrasound|MR-guided Focused Ultrasound (MRgFUS) offers the possibility of lesioning deep brain targets, while obviating the need for open surgical approaches. There is no radiation, incision, or burr hole, and lesions are generated in real-time under MR image guidance. Intracranial FUS for other applications, essential tremor most notably, has been shown to be safe and effective, recently receiving Health Canada approval for this indication. The technology, methods and procedures used in this study are identical to those in essential tremor.
224185867|NCT02178215|OTHER|Holly Mangrove Shower Gel|Wash forearm with Holly Mangrove shower gel containing Acanthus ebracteatus Vahl for 10 seconds, twice a day, 2 weeks
224185868|NCT01496781|PROCEDURE|Hemoclip|Hemoclip application is a standard treatment option after endoscopic mucosal resection of colonic lesion to stop and prevent post-procedure bleeding.
224185869|NCT01496781|PROCEDURE|EndoClot|EndoClot hemostat is applied immediately after EMR to achieve hemostasis.
224308654|NCT02879734|OTHER|Prophylactic laparoscopic omentopexy|Fixation of omentum with sutures to anterior abdominal wall during laparoscopic surgery
223494083|NCT03796663|BEHAVIORAL|Mindful Parenting Program|"The Mindful Parenting Program consists of 7, 2.5 hour weekly group sessions. In the program, parents learn to apply the skills of mindfulness to themselves and to their experience of parenting their children. Parents are introduced to formal meditation practices, including the bodyscan; choiceless awareness; mindful walking; and yoga. They are also introduced to mindfulness of everyday activities from the beginning of the sessions, with an added focus on day-to-day parenting and family activities. Additionally, short self-compassion practices occur throughout the weekly sessions, culminating in the teaching of formal loving-kindness meditation.~Additionally, the program encourages parents to engage in home practice, where parents can experience and practice many of the new skills they are learning. This includes both formal, longer meditation practices, as well as shorter practices, which can occur throughout the day, such as mindfulness of daily routines."
223494084|NCT03796663|BEHAVIORAL|MATCH BPT Program|The MATCH BPT Program consists of 8-12 weekly (depending on how long it takes for individual parents and their assigned trainer to get through the material), 60 minute individually-implemented sessions.The sessions will consist of the coach obtaining and reviewing weekly assignments completed by the parent, followed by activities and discussions that focus on a particular parenting skill (i.e. praise, active ignoring, giving effective instructions). The discussions will emphasize benefits and possible problems that the parent may encounter throughout the week while implementing the new skill. The coach will assign to the parent a practice assignment to further encourage use of the concept.
223494085|NCT02627716|PROCEDURE|SOS Plan|"It is a customised procedure that involves a meeting (crisis planning meeting) with the patient, their various medical and social referrers and any other person who they may have desired to invite.~The booklet outlines four avenues to consider:~* Contact details / contact person~* Treatment and current follow-ups~* Medical care in the event of a crisis~* Practical aid in the event of a crisis~Updating the SOS Plan every 6 months in the absence of hospitalisation or after each relapse that leads to an unscheduled psychiatric hospitalisation lasting more than two weeks."
223494086|NCT00229801|RADIATION|MRI|
223494087|NCT05319704|OTHER|Test of effort on cycle on concentric or excentric mode|participants may receive 4 interventions sequentially during the protocol
223494088|NCT05319704|OTHER|Kinetics on concentric or excentric mode during test of effort|participants may receive 4 interventions sequentially during the protocol
223494089|NCT02100787|OTHER|TheraTears lubricating drops|A over-the-counter lubricating eye drop to be used 1 drop in both eyes 4 times a day (QID) for 8 weeks
224185870|NCT01597076|DIETARY_SUPPLEMENT|iridoid enriched mixed fruit beverage|Mixed fruit beverage consisting of noni (Morinda citrifolia) juice, Cornelian cherry (Cornus mas \& Cornus officinalis) puree and juice, olive (Olea europea) leaf extract, and other fruit juices and natural flavors
224185871|NCT02907866|DEVICE|Ultrasound with EBUS scope and with linear ultrasound probe|All subjects will have an ultrasound of the chest performed with the tip of the EBUS scope as well as the linear ultrasound probe, which will be used as a reference for comparison. At the end of the procedure, while the patient in the supine position, the transducer of the EBUS bronchoscope will be placed on the anterior thorax, superficial to the skin and in a sagittal direction that is perpendicular to 2 ribs. The depth of the ultrasound beam will be increased to identify the pleural sliding sign and B lines (vertical lines) when present.This will be followed by use of linear ultrasound probe to scan the chest wall for normal lung sliding, B-lines and potential pneumothorax. The patient will remain in supine position. The linear probe will be placed on anterior thorax at the level of second intercostal space. The depth of the ultrasound beam will be adjusted to identify lung sliding and B-lines.
224308655|NCT02085135|DRUG|ALKS 5461|Sublingual tablet taken once daily
223494092|NCT04937387|DRUG|FF/VI|FF/VI will be administered.
223494093|NCT04937387|DRUG|FF/UMEC/VI|FF/UMEC/VI will be administered.
223494094|NCT04937387|DEVICE|ELLIPTA|FF/UMEC/VI and FF/VI will be administered via ELLIPTA inhaler.
224185872|NCT04882579|DIAGNOSTIC_TEST|Point-of-care-ultrasound examination|"The intervention consists of three ultrasound modalities:~1. Cardiac ultrasound assessing signs of right ventricular strain or other obvious pathology.~2. Deep venous ultrasound assessing presence of a deep venous thrombus~3. Lung ultrasound assessing presence of pulmonary infarctions, pleural effusion, pneumothorax or interstitial syndrome."
224185873|NCT01226186|BEHAVIORAL|Nurse dispensed oral morphine.|Nurse will dispense oral morphine on request from the patient.
224185874|NCT01226186|BEHAVIORAL|Patient self medication of oral morphine.|Patients will self medicate their oral morphine pain control solution following surgery.
224185875|NCT02160639|OTHER|diabetes self management support|diabetes self management support is telephonic and provided by health investigators
224185876|NCT02367196|DRUG|CC-90002|
224185877|NCT02367196|DRUG|Rituximab|
224185878|NCT01348828|DEVICE|Endovascular Aortic Aneurysm Repair (Endologix Fenestrated Stent Graft System)|Endovascular repair of juxtarenal or pararenal aortic aneurysm using the Endologix Fenestrated Stent Graft System
223494095|NCT02708836|PROCEDURE|Induction of anesthesia|At the discretion of the primary anesthesiologist. Typically involves the administration of an analgesic agent, hypnotic agent, and neuromuscular blocking agent
224185879|NCT03035175|OTHER|Video Laryngoscopy|Residents intubate using video laryngoscopy.
224185880|NCT03035175|OTHER|Traditional Laryngoscopy|Residents intubate without using video laryngoscopy.
224185881|NCT00902122|DRUG|rAd-p53 gene|pre-surgery p53 gene treatment: 10exp12 virus particles per 3 days for 5 times
224185882|NCT00902122|PROCEDURE|surgery|removal of thyroid tumor
223494096|NCT02708836|DEVICE|Placement of LMA [Ambu (R) AuraGain (TM) disposable laryngeal mask]|By standard method. Sizing at the discretion of the primary anesthesiologist.
223494097|NCT02708836|DEVICE|Laryngoscopy and placement of ETT|Via direct or indirect laryngoscopy. Sizing at the discretion of the primary anesthesiologist. Mallinckrodt (TM) Intermediate Hi-Lo cuffed endotracheal tube (Covidien)
223494098|NCT02708836|PROCEDURE|Ventilation via the ETT|Ventilator mode, tidal volume/ ventilation pressure, respiratory rate, positive end expiratory pressure, inspired to expired ratio at the discretion of the primary anesthesiologist.
223494099|NCT02708836|PROCEDURE|Removal of the ETT|Either upon emergence of anesthesia after suctioning of the oropharynx and after a positive pressure breath or while deeply anesthetized after release of the pneumoperitoneum in the combined LMA/ETT group.
223494100|NCT02708836|PROCEDURE|Intubation of the trachea through the LMA|With ETT using fiberoptic bronchoscope guidance.
223494101|NCT02708836|PROCEDURE|Ventilation via the LMA|After removal of the ETT. Ventilator mode, tidal volume/ ventilation pressure, respiratory rate, positive end expiratory pressure, inspired to expired ratio at the discretion of the primary anesthesiologist.
223494102|NCT02708836|PROCEDURE|Emergence from anesthesia|"At the discretion of primary team. Airway device (either ETT or LMA) will be removed when patient is adequately ventilating and able to respond to commands (such as open your eyes or squeeze my hand)."
223494103|NCT07119333|DEVICE|Air purifiers|Air purifiers
223494104|NCT07119333|DEVICE|Sham air purifiers|Sham air purifiers
223494105|NCT07115420|DEVICE|Fully covered self expanding metal stent (FCSEMS) within LAMS|In those randomised to FCSEMS, size will depend on the size of the LAMS with a 6mm LAMS to be stented with 8mm diameter FCSEMS and an 8mm LAMS to be stented with a 10mm FCSEMS, 4cm or 6cm length. The aim is to have at least 3cm of FCSEMS in the duodenal lumen If unable to place FCSEM through LAMS, crossover to DPS is allowed with plan for both intention to treat and per protocol analysis to be undertaken after completion of the study
223589028|NCT07088549|DIAGNOSTIC_TEST|Control Arm - standard of care|Intravenous insulin dosing will be guided according to blood glucose measurements using RadiometerABL800 (standard of care). DexcomG7 continuous glucose monitor will be applied in blinded mode for interstitial glucose monitoring for later CGM metrics and comparison analysis.
224185883|NCT00902122|DRUG|p53 gene therapy|p53 gene treatment: 10exp12 virus particles per 3 days for 10 times
224185884|NCT00902122|RADIATION|p53 gene therapy with radioactive iodine|p53 gene therapy with concurrent radioactive iodine pre-surgery p53 gene treatment: 10exp12 virus particles per 3 days for 10 times
224185885|NCT03183661|BIOLOGICAL|ALLO-ASC-CD|ALLO-ASC-CD is intravenous infusion containing allogenic adipose-derived mesenchymal stem cells. Adipose-derived stem cells are directed to injured tissue, and reduce inflammation. Furthermore their immunomodulatory effects are significant for treating immune-related disease. Finally, ALLO-ASC-CD may provide a new option in treating a crohn's disease. This study is a follow-up study without intervention.
223494106|NCT07115420|DEVICE|Double pigtail stent (DPS) within LAMS|In those randomised to DPS, a double pigtail will be placed through the LAMS. The size of the stents will be left to the discretion of the proceduralist though 7Fr calibre with 7cm length is the recommended size
224185886|NCT00545974|DRUG|memantine|memantine 10mg BID
224185887|NCT00545974|DRUG|Placebo pill|Placebo pill BID
224185888|NCT03710395|PROCEDURE|Blood and breast milk sampling|At least 15 days after starting treatment with 20 mg slow-release nifedipine every 12 hours. Blood and breast milk will be sampled before first dosing in the morning.
223589029|NCT07089849|OTHER|Rapid HIV testing|At the designated sites for RHT, providers will offer RHT to patients as part of their dental routine care.
224185889|NCT03710395|DRUG|Nifedipine|Chronic hypertensive breastfeeding women will be treated with slow-release 20 mg nifedipine, twice a day.
224185890|NCT01130220|OTHER|Focus Group|"A single focus group will be held until a saturation of themes has been identified."
224185891|NCT05029102|DRUG|TAS 102|35 mg/m2，per oral，twice daily, days 1-5 and 8-12 of each 28-day cycle
224185892|NCT05029102|DRUG|Anlotinib|10mg，per oral，once daily，days 1-14 of each 21-day cycle
224185893|NCT04561700|DIAGNOSTIC_TEST|Reporting of sucking patterns captured by Instrumented Bottle|In the intervention group, data on nutritive sucking and feeding cues captured by the Instrumented Bottle will be made available to speech therapists to document the feeding session and provide written recommendations in their weekly report.
224185894|NCT04561700|DIAGNOSTIC_TEST|Control|In the control group, the information captured by the Instrumented Bottle will not be made available to speech therapists and therefore, will not be used to document a feeding session or provide weekly recommendations.
224308656|NCT05251519|OTHER|Kinesio Taping|Derotation taping with Kinesio Tex is applied to the patients through a pediatric physiotherapist.
223589030|NCT07089849|OTHER|Referral for HIV testing|At the designated sites for HIV testing referral, providers will offer an HIV test referral to the affiliated CHC laboratory to patients as part of their dental routine care.
223494107|NCT07120230|PROCEDURE|Tubeless Lung Transplantation Surgery|Patients undergoing this surgery receive lung transplantation surgery without standard tracheal intubation. Instead, they will breathe on their own using a special airway device called a laryngeal mask airway (LMA), combined with a bronchial blocker to separate lung ventilation during surgery. Sedation is maintained with intravenous medications (propofol, remifentanil, and dexmedetomidine), and participants will remain spontaneously breathing or receive minimal breathing assistance as needed. The surgical incision will be numbed using local anesthesia with lidocaine and ropivacaine injections. After surgery, the LMA will be removed in the operating room, and participants will transition directly to non-invasive breathing support before being monitored in the ICU.
223589031|NCT07089069|DEVICE|3 mA transcranial direct current stimulation|The intervention will be conducted using a battery-powered stimulator (TCS-E2000, Shenzhen Yingchi Technology Co., Ltd) through a pair of saline-soaked sponge electrodes (5 cm × 7 cm).The stimulation intensity will be set at 3 mA. The stimulation will last for 20 minutes each time, with a 10 s fade-in period at the start and a 10-s fade-out period at the end of stimulation. The participants will receive intervention lasting for four weeks(10 sessions).The anodal electrode will be placed over the primary motor cortex (M1), and the reference electrode will be positioned at the center of the forehead.
223589032|NCT07089069|DEVICE|2 mA transcranial direct current stimulation|The intervention will be conducted using a battery-powered stimulator (TCS-E2000, Shenzhen Yingchi Technology Co., Ltd) through a pair of saline-soaked sponge electrodes (5 cm × 7 cm).The stimulation intensity will be set at 2 mA. The stimulation will last for 20 minutes each time, with a 10 s fade-in period at the start and a 10-s fade-out period at the end of stimulation. The participants will receive intervention lasting for four weeks(10 sessions).The anodal electrode will be placed over the primary motor cortex (M1), and the reference electrode will be positioned at the center of the forehead.
223589033|NCT07089069|DEVICE|1 mA transcranial direct current stimulation|The intervention will be conducted using a battery-powered stimulator (TCS-E2000, Shenzhen Yingchi Technology Co., Ltd) through a pair of saline-soaked sponge electrodes (5 cm × 7 cm).The stimulation intensity will be set at 1 mA. The stimulation will last for 20 minutes each time, with a 10 s fade-in period at the start and a 10-s fade-out period at the end of stimulation. The participants will receive intervention lasting for four weeks(10 sessions).The anodal electrode will be placed over the primary motor cortex (M1), and the reference electrode will be positioned at the center of the forehead.
223589034|NCT07089069|DEVICE|sham transcranial direct current stimulation|The intervention will be conducted using a battery-powered stimulator (TCS-E2000, Shenzhen Yingchi Technology Co., Ltd) through a pair of saline-soaked sponge electrodes (5 cm × 7 cm).The intervention will last for 20 minutes each time, with a 10 s fade-in period at the start and a 10-s fade-out period at the end of stimulation，but there is not current in between. The participants will receive intervention lasting for four weeks(10 sessions).The anodal electrode will be placed over the primary motor cortex (M1), and the reference electrode will be positioned at the center of the forehead.
223589035|NCT07088367|BEHAVIORAL|Virtual reality meditation|"This intervention involves immersive virtual reality (VR)-based guided meditation sessions using MediboothVR, the first Turkish-language supported virtual reality meditation application developed in Türkiye. It is distinct from other VR interventions in the following ways:~Cultural and language adaptation: MediboothVR is fully available in Turkish, providing culturally relevant audio-guided content. This makes it more accessible and emotionally resonant for Turkish-speaking participants, unlike many VR applications designed in other languages.~Duration and consistency: The intervention is delivered over three consecutive days, with a different video used each day, each lasting approximately 10 minutes.~Technical delivery: The application is used exclusively via VR headsets, creating a fully immersive experience that eliminates visual and auditory distractions from the hospital environment."
223617727|NCT01573546|OTHER|Health education control|The Health Education control group will receive weekly 30-min lectures on relevant, health-related topics but will not receive instruction in the DASH diet nor will exercise be promoted. These participants will be asked to maintain their usual dietary and exercise habits for 6 months until they are re-evaluated. These sessions are designed to provide useful information about medical aspects of CVD, but will not provide instruction in the DASH diet or exercise.
224185895|NCT01689831|BIOLOGICAL|To confirm the potency of Aplisol formulated with newly produced Tuberculin PPD compared to PPD-S2 standard.|Comparison of different dosages of Aplisol PPD relative to reference standard PPD-S2.
224185896|NCT01689831|BIOLOGICAL|Reactivity of Aplisol compared to reference standard PPD-S2.|Reference standard PPD-S2 formulated to contain different dose concentrations.
224185897|NCT03581708|OTHER|lung cancer|If the patient is diagnosed with lung cancer in advanced stage, he/she will be followed up for VTE incidence
224185898|NCT01579383|BIOLOGICAL|ALD403|Single Dose IV infusion on Day 1
224185899|NCT01579383|BIOLOGICAL|ALD403|Single Dose subcutaneous injection on Day 1
224185900|NCT01579383|BIOLOGICAL|Sumatriptan|Single Dose subcutaneous injection on Day 1
224185901|NCT00004219|DRUG|granisetron hydrochloride|
224185902|NCT00004219|DRUG|lerisetron|
224185903|NCT00004219|RADIATION|radiation therapy|
224185904|NCT00845598|DRUG|Azelastine , fluticasone|"Azelastine Hydrochloride BP 0.10% w/v AND Fluticasone propionate BP 0.0357% w/v as combination~1 squirt in each nostril twice daily"
224185905|NCT00845598|DRUG|Fluticasone propionate|Fluticasone propionate 0.05% w/w 2 squirts in each nostril (50 μg per squirt)
224185906|NCT00100711|DRUG|Motexafin Gadolinium|
224185907|NCT05308420|PROCEDURE|Pericapsular nerve group (PENG) block|A 22 gauge 120mm nerve block needle will be introduced under ultrasound guidance in plane from superolateral to posteromedial to position the needle tip posterolateral to the ileopsoas tendon in-between the anterior inferior iliac spine and the ileopubic (ileopectineal) eminence and 20ml 0.5% levobupivacaine with 2mg (0.5ml) dexamethasone injected (total volume of injectate 20.5ml) between the tendon and the inferior pubic ramus just proximal to the attachment of the anterior hip capsule
224185908|NCT05308420|PROCEDURE|Spinal anesthesia|Spinal anesthesia will be performed at the level of the presumed interspace in-between the third and fourth lumbar vertebrae by introducing a 27 gauge pencil-point spinal needle and 15mg of levobupivacaine (3ml) injected intrathecally
224185909|NCT05308420|DRUG|Intrathecal morphine|100 micrograms of preservative free morphine diluted to a volume of 0.5ml is added to the local anesthetic solution injected for spinal anesthesia (total injectate volume 3.5ml)
224185910|NCT05308420|PROCEDURE|Sham PENG block|A 22 gauge 120mm nerve block needle will be introduced under ultrasound guidance in plane from superolateral to posteromedial to position the needle tip posterolateral to the ileopsoas tendon in-between the anterior inferior iliac spine and the ileopubic (ileopectineal) eminence and a placebo solution consisting of 20.5ml 0.9%NaCl injected between the tendon and the inferior pubic ramus just proximal to the attachment of the anterior hip capsule
224185911|NCT05308420|DRUG|Intrathecal placebo|0.5ml of placebo solution (0.9%NaCl) is added to the local anesthetic solution injected for spinal anesthesia (total injectate volume 3.5ml)
223494108|NCT07121322|DRUG|dornase alfa i.v. and cisplatin|Cisplatin 100mg/m2 day 1, every 3 weeks, Dornase alfa 125 microgram/kg day 1-5 i.v. push over 30 seconds±5 seconds
224185912|NCT00388128|DRUG|Caffeine 6mg/kg|Capsules of caffeine 6 mg/kg, taken orally at each test. Before and after treadmill testing
224185913|NCT01713907|DEVICE|Ulthera® Treatment|Focused ultrasound energy delivered below the surface of the skin.
224185914|NCT01571973|PROCEDURE|pharmacotherapeutic follow-up|health education adjustment of dose improve compliance replacement of medication
224185915|NCT00242658|BEHAVIORAL|Tailored Physical Activity Intervention|Tailored physical activity computer reports will be provided to patients and physicians.
224185916|NCT02653989|BIOLOGICAL|MDV9300|MDV9300 will be administered at a dose of 200 mg by intravenous (IV) infusion every 2 weeks until treatment discontinuation criteria are met.
223494109|NCT07121686|DEVICE|Red light exposure|Patients in the red light group received red light therapy concurrently with standard care.
223494110|NCT07121686|DEVICE|Red-blue light exposure|Patients in the red and blue light group received combined red and blue light therapy concurrently with standard care.
223494111|NCT07121634|DRUG|Misoprostol 25 µg Vaginal|The Misoprostol group (n=40) were Misoprostol cases, a synthetic PGE1 in the form of vaginal tablets of 25 µg (Vagiprost; ADWIA Co/Egypt) applied locally to the posterior fornix every 4 hours for cervical ripening before induction of labor is started (up to 3-doses).
223494112|NCT07121634|DRUG|Isosorbide Mononitrate|"The Isosorbide Mononitrate group (n=40) were nitric acid donor cases applied to the posterior fornix prior to induction of labor. Isosorbide mononitrate (IMN) (Monomack; Mack Pharmaceutics; Jordan) in a vaginal dose of 40 mg was used every 4 hours (up to 3 doses).~Women who scored a BS of \> 6 from the assigned time were labelled as (1), after the passage of 40 hours, while those women whose BS was less than 6 were labelled (0) for construction of the Kaplan Meier curve for both groups."
223494113|NCT07120334|BEHAVIORAL|PortionSize Ed + MedDiet Support|Full PortionSize Ed app access with personalized dietary feedback, educational videos, 3 virtual sessions with a registered dietitian (RDN), standard of care (for post-stroke with pre-diabetes or T2D) over 12 weeks.
223589036|NCT07088367|BEHAVIORAL|Virtual Reality Videos|"This intervention involves the use of a virtual reality headset to present immersive 360-degree calming nature videos to participants. It is distinct from other video- or relaxation-based interventions in several key ways:~Delivery via VR headset: Unlike standard video-based relaxation interventions presented on screens or tablets, this method delivers video content in a fully immersive virtual reality environment, which blocks out external visual and auditory stimuli from the unit.~Non-guided and passive exposure: The video group receives no audio-guided instruction or meditation scripting, making it a purely visual and passive exposure intervention.~Cultural relevance and visual neutrality: The nature videos are non-verbal, visually neutral, and free of religious, symbolic, or emotionally provocative imagery, allowing them to be suitable for a diverse patient population."
223589037|NCT07089420|DEVICE|ALPCO Calprotectin CLIA|Measurement of calprotectin in feces
224185917|NCT01815099|DEVICE|rTMS Treatment|Either 10 or 15 rTMS sessions (2 or 3 times/week for 5 weeks, respectively)
224185918|NCT04494087|OTHER|Explanatory video|Links to explanatory videos handed out to patients to be watched at home after standard informed consent giving
224185919|NCT04494087|OTHER|Informed consent form|Links to a digital version of the informed consent form already discussed during the process of informed consent giving.
224185920|NCT04932915|DRUG|Niclosamide|Niclosamide is a broad spectrum, host targeting antiviral that inhibits viral replication (by neutralizing endosomal pH) and increases viral clearance (by increasing the autophagic flux). The niclosamide solution is administered directly to the nasal cavity via a nasal spray.
224185921|NCT04932915|DRUG|Placebo|The placebo formulation contains purified water, sodium chloride as common isotonizing agent and the FAO/WHO approved colorant FD\&C Red 40 to match the red-orange colour of the active solution. The solution is administered directly to the nasal cavity via a nasal spray.
223494114|NCT07120334|BEHAVIORAL|Standard of care for Stroke and Prediabetes or T2D|Uses a basic version of the PortionSize Ed app without feedback or RDN support and receives usual care for stroke recovery and prediabetes or T2D for 12 weeks.
223494115|NCT07119216|BEHAVIORAL|Peer Mentorship|The iPeer2Peer intervention is a peer support mentorship program that will provide modelling and reinforcement by pre-screened and trained peer mentors to the mentees. The mentorship program will encourage mentees to develop and engage in self-management and transition skills and support the participants; practice of these skills. The mentors will provide information and support to mentee participants via 5-10 calls (using WhatsApp) of 20-30 minute durations and text messaging (using WhatsApp) for 12 weeks to encourage participation in self-management skill building tailored to their needs.
224185922|NCT03725904|DIAGNOSTIC_TEST|Progesterone analysis in saliva|Analysis of salava progesterone
223494116|NCT07122960|OTHER|Visual ICF|This visual ICF fully represents all the content of the standard, text-only ICF using cartoon characters, graphics and easy text.
223494117|NCT07122960|OTHER|Text-only ICF|Text-only ICF
223494118|NCT07121673|BEHAVIORAL|Dental appointment message|Patients receive a WhatsApp message offering a preventive dental check-up for $19,990.
224185923|NCT00643851|DRUG|Dapagliflozin|Tablets, Oral, Once daily, 24 weeks
224185924|NCT00643851|DRUG|Metformin XR|Tablets, Oral, Once daily, 24 weeks
224185925|NCT00422955|DRUG|rosiglitazone|
224185926|NCT01353976|DRUG|Econazole Nitrate Foam 1%|Econazole Nitrate Foam 1% applied once a day for 4 weeks
224185927|NCT01353976|OTHER|Vehicle Foam|Vehicle foam applied once a day for 4 weeks
224185928|NCT00397527|DRUG|lactoserum|
223494119|NCT07121673|BEHAVIORAL|Dental appointment message with price discount|Patients receive a WhatsApp message offering a preventive dental check-up for $990.
223494120|NCT07121673|BEHAVIORAL|Bundling frame|The message includes language indicating they can schedule the dental appointment on the same day as their upcoming medical appointment to save time.
223494121|NCT07120711|PROCEDURE|EGR2/NLRP3 pathway activity|"Peripheral blood collection \& PBMC isolation:~Children: 3 mL venous blood drawn from the right antecubital vein preoperatively; Adults: 3 mL fasting venous blood drawn the morning after PSG.~Collected in EDTA tubes; PBMCs separated via Ficoll-Paque density gradient. Flow cytometry: 1×10⁶ PBMCs stained for CD14/CD16, HLA-DR, CD11b, CD80/CD86, CD163/CD206.~RNA extraction: Remaining PBMCs lysed in TRIzol and stored at -80 °C for RT-qPCR of EGR2, NLRP3, and downstream genes Serum/plasma: Within 1 h of collection, centrifuge at 400 × g for 10 min at 4 °C; 1 mL used for ELISA quantification of TNF-α, IL-6, IL-1β, CCL2, IL-17, CRP; remainder stored at -80 °C for future proteomic or metabolomic assays~Saliva sampling \& processing:~2-3 mL unstimulated saliva expectorated into sterile tubes, kept at 4 °C, processed (centrifuged, aliquoted) within 2 h, then stored at -80 °C."
223494122|NCT07120711|PROCEDURE|fatty tissue|"Subcutaneous fat biopsy (adults undergoing surgery):~100-200 mg obtained intraoperatively, placed in RNAlater at 4 °C for 24 h, then frozen at -80 °C for downstream RNA-seq, RT-qPCR, and Western blot analyses of EGR2, NLRP3, and related inflammatory markers"
223589038|NCT07088744|DIAGNOSTIC_TEST|Probe-based Confocal Laser Endomicroscopy|Confocal Laser Endomicroscopy (CLE) is an advanced in vivo imaging technique that combines confocal microscopy with endoscopy, enabling real-time, microscopic visualization of tissues at a cellular level during endoscopic procedures. Probe-based CLE (pCLE) can enter the stomach cavity through the biopsy channel of the endoscope and observe the gastric mucosa. All patients scheduled for endoscopic submucosal dissection (ESD) of gastric lesions must undergo probe-based confocal laser endomicroscopy (pCLE) prior to the ESD procedure.
223589039|NCT07088744|DIAGNOSTIC_TEST|Pathological biopsy|A pathological biopsy is a medical procedure that involves the removal of a small sample of tissue or cells from the body for microscopic examination. It is a crucial diagnostic tool used to identify diseases, particularly cancer, infections, inflammatory conditions, and other abnormalities.
223589040|NCT07089433|PROCEDURE|Palatal stent as wound dressing|The palatal wound after graft harvesting will be protected with a flowable composite resin adhesively secured to adjacent teeth
223589041|NCT07089433|PROCEDURE|Conventional suturing|The wound will be covered with a collagen sponge that will be hold in place with sutures
223589042|NCT07088783|BEHAVIORAL|Mobile App Education|A 24-week self-care education delivered via a mobile application based on Orem's Self-Care Model
223589043|NCT07089381|DIETARY_SUPPLEMENT|Resveratrol 1 gm.|59 patients will receive the standard treatment for management of RA in addition to Resveratrol 1 gm daily, (Organix, Egypt) (given as one 1000 mg tablets once daily) for 3 months.
223589044|NCT07089381|DRUG|Methotrexate|59 patients will receive the standard treatment for management of RA for 3 months
223589045|NCT07089290|BEHAVIORAL|Nurse-led Telehealth Intervention|"Control group: Patients will receive standard care as per Nepal government guidelines. This includes lifestyle counseling (salt reduction, physical activity, avoiding tobacco/alcohol), antihypertensive medications based on BP and risk profile, and follow-up every 1-3 months. BP will be recorded at 3 and 6 months by research nurses.~Intervention group: Nurse-led telehealth care will be delivered over six months using the Intervention Mapping approach. Participants will receive initial orientation, a BP diary, and instructions to check BP at least twice weekly at nearby centers. Nurses will train local staff, and conduct teleconsultations via Viber/WhatsApp every 15 days (months 1-2) and monthly (months 3-6) covering BP review, adherence, and lifestyle advice. If \<75% of BP readings meet target, nurses will consult physicians for medication adjustments. Emergency protocols will be in place. Data will be collected at baseline, 3, and 6 months."
223589046|NCT07087808|BEHAVIORAL|Digital Wellness Nurse - FIT Families|Participants in this arm will receive a digital adaptation of FIT families, an evidenced based treatment for adolescent obesity. The social support condition will add one additional participant to the treatment group (i.e., caregiver, youth, community health worker, and social support person). The social support person's role is to review the daily engagement reports and completion of weekly goals and provide encouragement via peer-to-peer messaging in the DWN app. The social support person does not communicate with the CHW or participate in any treatment sessions. This person is selected by the family at the beginning of the study and provides reinforcement to the family through encouraging messages.
223617728|NCT03088891|OTHER|Antioxidant-rich snacks|Bama Smoothies (Bama, Oslo, Norway), Freia Premium Dark Chocolate (Freia, Oslo, Norway), Walnuts (Eldorado, Norway), Dried fruits and berries (Cranberries, Gojiberries, apricots)(Bama, Oslo, Norway and Rema 1000, Norway)
223617729|NCT03088891|OTHER|Control snacks|Milkshake (Tine, Oslo, Norway), YT restitusjonsdrikk (Tine, Oslo, Norway), Bixit (Sætre, Oslo, Norway), Ritz (Mondelez, Oslo, Norway), White chololate (Freia, Oslo, Norway)
224185929|NCT03715036|DIAGNOSTIC_TEST|Point-of-care US|The intervention includes reassuring the AC and DVP
224185930|NCT06204133|OTHER|Artificial intelligence model building|Using non-image medical data of cervical lesions and clinical pathology results in different medical institutions, machine learning is adopted to establish multiple multi-modal cervical cancer intelligent screening prediction models. This method was used to analyze the prediction performance of the multi-modal cervical cancer intelligent screening prediction and risk triage model, and to evaluate and optimize the self-learning ability of the established multi-modal cervical cancer intelligent screening prediction model.
224185931|NCT00004911|PROCEDURE|bowel obstruction management|
223617730|NCT01050634|DRUG|Aromasin (exemestane)|25mg oral tablet, daily, for \>1yr
223617731|NCT00900510|PROCEDURE|Incision and drainage|
223617732|NCT00900510|DRUG|Trimethoprim/Sulfamethoxazole (Bactrim)|Trimethoprim/Sulfamethoxazole, oral
223617733|NCT00900510|DRUG|Placebo|
224185932|NCT00004911|PROCEDURE|quality-of-life assessment|
224185933|NCT01450566|DRUG|Lidocaine|Use of lidocaine
224185934|NCT01450566|DRUG|Saline|Saline
224308657|NCT05251519|OTHER|Conventional Rehabilitation|Conventional rehabilitation program is applied to the patients through a pediatric physiotherapist
224308658|NCT03219619|DEVICE|Cap-EGD|Undergoing cap-assisted endoscopy
224308659|NCT03219619|DEVICE|Duo|Undergoing side-viewing duodenoscope
224185935|NCT04273620|BEHAVIORAL|Optokinetic stimulation and cueing-based reading therapy (OKS-READ)|"Each intervention session starts with an optokinetic stimulation (OKS) of at least 15 minutes duration. A pattern of squares, dots, triangles and stars will coherently and continuously move to the left on a computer screen in front of the patients. Patients are instructed to choose one stimulus and follow it with the eyes until it has reached the left side of the screen, then jump to the right edge of the screen and start again.~The second part of each intervention session is the cueing-based reading therapy (READ), which will also last at least 15 minutes. The task of the patient is to read out loud words or a text presented on a paper in front of them. We will use exogenous (e.g., the therapist highlights words when they were omitted) and endogenous cues (verbal instructions which require intrinsic action by the patient) to facilitate attentional shifts to the left. The intensity of cueing will be matched to the actual severity of neglect (adaptive therapy)."
224185936|NCT04273620|BEHAVIORAL|General neuropsychological treatment|As a control treatment the patients will receive neuropsychological treatment without targeting visuospatial attention. Examples for components implemented are supporting conversations, diagnostic assessments (e.g. memory diagnostics) and training of memory and executive functions.
224185937|NCT06371560|OTHER|Questionnaire|online based questionnaire
224185938|NCT04806334|DIAGNOSTIC_TEST|MRI imaging of the pelvis/bladder|The pelvic MRI will be multiparametric (mp)-4D MRI incorporating high resolution diffusion weighted imaging (HR-DWI).
224185939|NCT04806334|DIAGNOSTIC_TEST|genomic analysis of tumor|Single cell RNA sequencing of transurethral resection of bladder tumor (TURBT)
224185940|NCT05502120|DEVICE|Laryngoscopy with Vie-Scope laryngoscope|Evaluation of laryngeal view using Vie-Scope laryngoscope, intubation efficacy, complications
223494123|NCT07119528|OTHER|AF application enhancing AF education|This group will use AF-application. The app will include content related to anticoagulation therapy, such as: medication reminders or intake confirmation for anticoagulants, the importance of anticoagulation therapy in stroke prevention, the role of antiarrhythmic and rate-control medications in symptom management, the necessity of controlling risk factors such as hypertension, diabetes, and hyperlipidemia, and quality of life and cognitive function assessments through questionnaires.
223494124|NCT07119528|OTHER|AF application without enhancing AF education and drug adhrence|This group will use AF-application. However, this application will not contain materials enhancing AF education and adherence.
223494125|NCT07122089|DEVICE|Selective Internal Radiotherapy|SIRT will use Yttrium-90 glass-microspheres (TheraSphereTM). SIRT needs two steps: the treatment simulation (diagnostic angiography and scintigraphy of hepatic perfusion with 99mTc-MAA) and the administration (during a therapeutic angiography).
223494126|NCT07122089|DRUG|Tremelimumab|Tremelimumab should be done 1 to 3 weeks after SIRT and is administrated according to the Summary of Product Characteristic (SPC).
223494127|NCT07122089|DRUG|Durvalumab|After the end of the tremelimumab infusion, patient receive durvalumab then one injection every 4 weeks until further progression upon investigator decision. Also administrated according to the Summary of Product Characteristic (SPC).
223494128|NCT07113600|OTHER|Nerve Block|"Ilioinguinal/ Iliohypogastric nerve block:~In the supine position, the ultrasound probe probe is positioned in a transverse manner, superior to the anterior superior iliac spine. The three anterior abdominal muscle layers are identified, and the two nerves are identified in the abdominal neurovascular plane.~A echogenicneedle is inserted in a medial-to-lateral direction. After negative aspiration, 5 ml saline is injected to ensure correct needle tip position then 20 ml of bupivacaine 0.25% is injected gradually close to the nerves.~Erector spinae plane block:~In a lateral position, the erector spinae is visualized about 3 cm lateral to T7-T9 spinous processes on the target side. A echogenic needle (50 mm/22 gauge) is advanced in a cephalad to caudad direction until the tip reaches the plane deep to the erector spinae muscle immediately lateral to the transverse process. A 20 ml bupivacaine 0.25% is injected gradually into this plane."
223494129|NCT06653842|DRUG|QTORIN 3.9% rapamycin anhydrous gel|QTORIN 3.9% Rapamycin Anhydrous Gel
223494130|NCT06653647|BEHAVIORAL|Guided Imagery Therapy|Participants will be asked to listen to a pre-recorded, 10 to 15 minute guided imagery therapy (GIT) session via mobile application 5 out of 7 days per week for 8 weeks in addition to their usual care for their abdominal pain.
223494131|NCT06977711|DRUG|Loncastuximab|Intravenous (IV) administration 0.15 mg/kg day 1 cycles 1-2, and 0.075mg/kg day 1, cycles 3-5
223494132|NCT06977711|DRUG|Roflumilast|Oral administration of 500mcg days 1-21, cycles 1-8
223494133|NCT06977711|DRUG|Rituximab|IV administration of 375mg/m2 day 1, cycles 1-8
223494134|NCT06977711|DRUG|Cyclophosphamide|IV administration of 750mg/m2 day 1, cycles 3-8
223494135|NCT06977711|DRUG|Vincristine|IV administration 1.4mg/m2 (max 2mg) day 1, cycles 3-8
223494136|NCT06977711|DRUG|Doxorubicin|IV administration 50mg/m2 day 1, cycles 3-8
223494137|NCT06977711|DRUG|Prednisone|Oral administration 100mg/days 1-5, cycles 3-8
223494138|NCT07124364|BEHAVIORAL|Benson Relaxation Technique|The Benson Relaxation Technique is a structured relaxation method involving the repetition of a word, sound, or phrase while sitting quietly in a comfortable position with eyes closed, combined with passive muscle relaxation. In this study, it will be delivered in weekly 30-minute group sessions for 8 weeks by a trained instructor. Participants will be instructed to practice the technique daily at home for 10-15 minutes.
223494139|NCT07124364|BEHAVIORAL|Mindfulness-Based Stress Reduction Meditation|Mindfulness-Based Stress Reduction meditation is a practice focusing on cultivating awareness of the present moment through seated meditation and mindful breathing. In this study, participants will attend weekly 30-minute group sessions for 8 weeks, guided by an experienced instructor. They will also be encouraged to perform daily mindfulness meditation at home for 10-15 minutes.
223494140|NCT07124364|BEHAVIORAL|Breathing Therapy|Breathing therapy consists of guided breathing exercises designed to promote relaxation, reduce stress, and improve psychological well-being by regulating breathing patterns. In this study, participants will attend weekly 30-minute group sessions for 8 weeks, led by a trained facilitator. Daily home practice of slow deep breathing techniques for 10-15 minutes will be encouraged.
223494141|NCT07125963|PROCEDURE|Custom-made positioning appliance-assisted mandibular segment repositioning|A patient-specific surgical guide designed using STL-based digital planning in Blender and produced via 3D printing with biocompatible surgical resin (Formlabs SLA printer). Used to guide and stabilize the proximal mandibular segment during sagittal split ramus osteotomy.
224185941|NCT05502120|DEVICE|Laryngoscopy with Macintosh blade laryngoscope|Evaluation of laryngeal view using stnadard Macintosh blade laryngoscope
223494142|NCT07125963|PROCEDURE|Conventional Manual Positioning|The proximal mandibular segment is positioned manually by the surgeon based on visual and tactile feedback without the use of a positioning guide. This technique represents the standard method in sagittal split ramus osteotomy.
223494143|NCT07124208|DEVICE|Biophoton Generators|Biophoton Generators will be placed around the subject's bed and used during the night sleep during the entire study period.
223494144|NCT07125456|OTHER|Postmortem Care Teaching Simulation|"The participants in the experimental group will be administered the Informed Consent Form, Demographic Characteristics Form, Postmortem Care Knowledge Test for Nursing Students (PCKTNS), and End-of-Life and Postmortem Care Self-Efficacy Scale for Nursing Students (ELPMCSESN) prior to the theoretical education. Following the pre-tests, it is planned to provide theoretical education for approximately 4 class hours (with each class hour lasting 45 minutes). The first 2 hours of the theoretical education will cover topics related to Death and General Aspects of Death, while the remaining 2 class hours will be delivered as a PowerPoint presentation focusing on postmortem care application content.~Following the theoretical education, the experimental and control groups will be shown the Postmortem Care Skills Video. Additionally, prior to the teaching simulation for postmortem care, the experimental group will be shown the Scenario Case Video, after which the scenario prepared fo"
223494145|NCT07124936|DRUG|HDM2005|HDM2005 will be administered as an intravenous injection.
223494146|NCT07124936|DRUG|Rituximab or Rituximab biosimilar|Rituximab or Rituximab biosimilar will be administered as an intravenous injection.
223494147|NCT07124936|DRUG|Gemcitabine|Gemcitabine will be administered as an intravenous injection.
223494148|NCT07124936|DRUG|Oxaliplatin|Oxaliplatin will be administered as an intravenous injection.
223494149|NCT07124936|DRUG|Cyclophosphamide|Cyclophosphamide will be administered as an intravenous injection.
223494150|NCT07124936|DRUG|Doxorubicin|Doxorubicin will be administered as an intravenous injection.
223494151|NCT07124936|DRUG|Prednisone|Prednisone will be administered orally.
223494152|NCT06106477|BEHAVIORAL|Intermittent Fasting|"Participants will be asked to adhere to a six-month intermittent fasting intervention, a daily-recurring dietary plan consisting of:~* An approximately fourteen-hour nightly fasting period that is followed by~* An approximately ten-hour eating period with their last meal of the day occurring between 17:00 (5:00 PM) and 21:00 (9:00 PM)."
223494153|NCT06590974|DRUG|Freeze-dried Human Protein C Concentrate|Freeze-dried Human Protein C Concentrate (TAK-662) intravenous injection
223494154|NCT06986512|PROCEDURE|bronchoscopy|We will perform bronchoscopy and collect bronchoalveolar lavage fluid (BALF)
224185942|NCT02948244|DIETARY_SUPPLEMENT|Creatine Monohydrate|Synthetically produced dietary supplement Creatine Monohydrate will be used in powder form reconstituted to a drink. The dosage will be 100mg/kg/day up to a maximum of 10 grams daily.
224185943|NCT02948244|DIETARY_SUPPLEMENT|Placebo|Placebo
224185944|NCT00307073|DEVICE|Implantable Pulse Generator|
224185945|NCT02918136|BIOLOGICAL|Adipose derived regenerative cells|
224185946|NCT02918136|DRUG|Cortisone Injectable|
224185947|NCT06376201|DRUG|Amphotericin B cholesterol-sulfate complex for injection|"Patients were eligible for enrollment on antifungal therapy with injectable amphotericin B cholesterol-sulfate complex (ABCD) at the same time as a treatment for underlying disease.~Dosage: According to the patient's condition and the investigator's judgment, the initial dose of ABCD can be 0.5-1.0mg/kg/d, and the dose can be increased daily according to the situation, and the therapeutic dose can be increased to 3.0-4.0mg/kg/d on the third day.~Course of treatment: ≥ 14 days (whether to continue to receive trial drug treatment after 14 days is decided by the investigator according to the patient's condition)."
223494155|NCT06857344|PROCEDURE|AI Controlled General Anesthesia|During gastrointestinal endoscopy, anesthesia will be induced using ciprofol, and controlled by an AI model.
223494156|NCT06857344|PROCEDURE|General Anesthesia (GA)|Anesthesia will be induced using ciprofol, and controlled by experienced anesthesiologists.
223494157|NCT06855810|DRUG|Venetoclax|All T-ALL patients will receive 8 mg/m2/day dexamethasone in induction therapy. For all ETP/near-ETP T-ALL patients, venetoclax will replace daunorubicin in induction therapy. CAT will replace CAT+ during early intensification. Venetoclax will replace daunorubicin in interim therapy 2 and 4. In maintenance therapy 2, the CTX+Ara-C treatment cycles are reduced to 5, in order to minimize the impact of alkylating agents on fertility.
223494158|NCT06855810|DRUG|Dasatinib|All T-ALL patients will receive 8 mg/m2/day dexamethasone in induction therapy. All non-ETP T-ALL patients will receive dasatinib after initial window phase in induction therapy. For non-ETP T-ALL patients with MRD \<0.01% on day 46, CAT will replace CAT+ during early intensification, and patients will be continuously subjected to dasatinib combined with chemotherapy during early intensification, interim tharapy, reinduction therapy and maintenance therapy. In maintenance therapy 2, the CTX+Ara-C treatment cycles are reduced to 5, in order to minimize the impact of alkylating agents on fertility.
223617734|NCT01840007|DRUG|Metformin Group|"The chosen posology is 2540 mg/day of metformin-base so 3 tablets/day of Glucophage ® 1000.~Patients should take 3 tablets/day at the rate of 1tablet in morning, noon and evening to favor the absorbtion and reduce the risk of gastrointestinal intolerance. In case of missed dose, patients will be allowed to take 2 tablets on the next grip. The drug will be presented in its officinale form of Glucophage ® 1000 with specifications indicated in the Vidal dictionary. It will be provided each month, to patient, 3 boxes of 30 tablets of Glucophage ® 1000. The patient will be asked to rate each day, on a calendar, the number of tablets of Glucophage ® 1000 effectively taken. It will also ask to the patient to bring back used boxes of Glucophage ® 1000 to count any tablets not taken."
224185948|NCT03365401|PROCEDURE|decompression surgery|undertake decompression surgery
224185949|NCT03365401|PROCEDURE|nonsurgical treatment|complete on bed with prevention of complication
224185950|NCT04306575|OTHER|Trans-venous lead extraction|Patients with a dysfunction or infection of a cardiac pacemaker or a defibrillator are indicated for extraction of these devices, so lead extraction is done transvenously to remove these leads
224185951|NCT03726099|DRUG|esomeprazole, amoxicillin, furazolidone，tetracycline|Patients will go through a gastroscopy and antimicrobial susceptibility test. Liver and kidney function will be monitored by blood test before and after the treatment. Then, patients will receive a 14-day concomitant therapy containing esomeprazole 40mg bid, amoxicillin 1000mg bid , furazolidone 100mg bid and tetracycline 500mg qid.
224185952|NCT01626599|DEVICE|ProGuardian|"The investigational system is composed of a sensor, patch, hub, and caregiver application. The sensor is applied externally during periods of nocturnal sleep for up to 7 nights.~The investigational system:~* is not implantable and no surgical procedure is required for a human subject to use the devices;~* is not for use in supporting or sustaining a human life; and~* is not of substantial importance in diagnosing, curing, mitigating, or treating disease, or otherwise preventing impairment of human health.~* Contains skin-contacting materials made of medical grade materials (e.g. sold for use as surgical or wound care) with well-established biocompatibility testing profiles."
223494159|NCT06855810|DRUG|homoharringtonine|All T-ALL patients will receive 8 mg/m2/day dexamethasone in induction therapy. All non-ETP T-ALL patients will receive dasatinib after initial window phase in induction therapy. For non-ETP T-ALL patients with MRD ≥0.01% on day 46，CAT+ will be replaced with randomized doses of homoharringtonine (HHT) during early intensification, and HHT will be administrated during reinduction therapy. In maintenance therapy 2, the CTX+Ara-C treatment cycles are reduced to 5, in order to minimize the impact of alkylating agents on fertility.
223494160|NCT06979921|DEVICE|Blood test|Blood test
223494161|NCT06618040|BEHAVIORAL|Bedtime Stories Sleep Health Education Program for Caregivers (BTS-C)|The BTS-C includes 6 educational modules on different topics related to sleep health: principles of healthy sleep practices include sleep routines, the sleep environment, considerations for screen time, timing of sleep and activities surrounding sleep, expectations for healthy sleep and sleep duration. Caregivers will also receive a combination of tailored messages or prompts to explore progress, identify strategies for change, and goal setting.
223494162|NCT06123338|DRUG|Pembrolizumab|Pembrolizumab will be administered on an every 3-week dosing schedule
223494163|NCT06123338|DRUG|Trastuzumab|Trastuzumab will be administered on an every 3-week dosing schedule
223494164|NCT06123338|DRUG|Oxaliplatin|Oxaliplatin every 3 weeks, +/-7 days
223494165|NCT06123338|DRUG|Capecitabine|Capecitabine twice daily on days 1 to 14 every 3 weeks or 5-FU on days 1 to 5 every 3 weeks
223494166|NCT06123338|DRUG|5-Fluorouracil|5-Fluorouracil administered as a 24 hour IV continuous infusion once every 2 weeks
223494167|NCT06123338|DRUG|Docetaxel|Docetaxel administered intravenously once every 2 weeks.
223494168|NCT06661668|DEVICE|Gastric pacemaker (Enterra system) implantation|Laparascopic implantation of a gastric pacemaker (Enterra system) for patients with therapy refractive gastroparesis
223589047|NCT07089810|DEVICE|Digital intervention has a high blood pressure in the high-risk population of stroke Study on the effect of stress on self-management behavior of patients|"Intervention group (n = 60) : Interventions were developed for five behavioral problems, as follows:~1. Lack of knowledge about hypertension~   \- Measures: APP push knowledge (risk factors, medication, lifestyle, etc.), blood pressure monitoring teaching, monthly online lectures, regular feedback and encouragement of blood pressure data.~2. Poor medication compliance~   \- Measures: Medication reminders were set by the APP, and repeated and recorded when no medication was taken.~3. Obesity/overweight Targets: BMI 18.5-23.9, waist circumference \<90cm in men and \<85cm in women Interventions: promoting knowledge about the dangers of obesity, daily exercise reminders, setting weight loss goals and encouraging weight loss.~4. A high-sodium diet Target: \<6g salt per day~   \- Measures: Release of low-salt dietary guidelines (graphic and text) and distribution of salt-limiting spoons (1-2 grams).~5. Drinking too much Target: ≤25g alcohol per day for men and ≤15g for women; Weekly male ≤140g, female ≤80"
223589048|NCT07089212|BEHAVIORAL|Phased Rehabilitation Training|"Rehabilitation is divided into three postoperative phases:~Early Phase (Weeks 1-2): Focus on edema control, quadriceps activation, and passive/active-assisted range of motion (ROM) exercises.~Intermediate Phase (Weeks 3-6): Progress to strength training, endurance exercises, and early proprioception drills.~Late Phase (Weeks 7-12): Advance to functional training , dynamic proprioception, and full ROM restoration."
224185953|NCT05190328|OTHER|Muscle Energy Technique|"Experimental: Muscle Energy Technique Post isometric relaxation: Patient will perform isometrics on upper trapezius and levator scapulae one by one. Each isometric contraction will be held for 10 seconds and then participants will be asked to relax the contraction with exhalation. This will be repeated five times in one session.~Routine Physical Therapy including TENS, Hot Pack, Strengthening, and stretching exercises will also be delivered along with Muscle energy technique."
224185954|NCT05190328|OTHER|Active Release Technique|"Experimental: Active Release Technique: Therapist will apply deep pressure on both sides of levator scapulae and upper trapezius muscles (over the area of tenderness) and the patient is instructed to actively move the muscle from the shortened to a lengthened position and thereby breaking adhesions. 1 set of 5 repetitions in one session.~Routine Physical Therapy including TENS, Hot Pack, Strengthening, and stretching exercises will also be delivered along with Active Release Technique."
223494169|NCT05732818|DEVICE|PerQdisc Nucleus Replacement System|Lumbar spine disc nucleus replacement system. All patients meeting all inclusion criteria and no exclusion criteria will be considered for nucleus replacement surgery following a review by the Medical Advisory Board.
223494170|NCT06603285|DRUG|Treprostinil|sc/iv continuously
223494171|NCT06669351|DRUG|ZX-7101A|On day1: Take two tablets of ZX-7101A orally once (specification: 10mg/ tablet) with appropriate amount of warm water
223494172|NCT06669351|OTHER|Placebo for ZX-7101A tablet|"Placebo for ZX-7101A tablet:~The appearance and properties of placebo tablets were identical to those of the trial drug ZX-7101A tablets. On Day 1, two placebo for ZX-7101A tablets were taken orally with appropriate warm water."
223494173|NCT06669351|DRUG|Oseltamivir phosphate dry suspension|"Drug: Oseltamivir phosphate dry suspension:~From Day1 to Day 5 : Oseltamivir phosphate suspension was orally administered twice a day, dose according to the label."
223494174|NCT06669351|OTHER|Placebo for Oseltamivir phosphate dry suspension:|"Drug: Placebo for Oseltamivir phosphate dry suspension:~From Day1 to Day 5 : Placebo for Oseltamivir phosphate suspension was orally administered twice a day, dose according to the label."
223494175|NCT06162403|OTHER|Peripheral Nerve Stimulation|The leads are inserted through a needle. If needed, the study team may give participants anesthetic (for example, as a cream/gel on your skin and/or as an injection) to numb the area where the leads will be injected.
223494176|NCT04620915|BEHAVIORAL|High-level construal|"In the high-level construal condition, participants will be sent messages asking them to consider why they are quitting (What are your main reasons for quitting?) and to imagine what their lives will look like in the future if they succeed (What would quitting mean to you and your family's future?; Yeager et al., 2014). The corpus for this condition is 100 messages composed by a large independent sample of mTurk workers who are smokers and validated by a team of RAs trained to 0.8 reliability on ratings of high-level construal. To meet criteria for inclusion, a message must be rated as significantly closer to high-level (vs. low-level) on a rating scale of construal level.~In addition to the texting, participants will complete biweekly online booster sessions using Qualtrics with a custom, personalized link sent to the participant via email and text."
223494177|NCT04620915|BEHAVIORAL|Down-regulation of craving for cigarettes|"In the down-regulation of craving condition, participants will be sent messages that encourage inhibitory control of cravings for cigarettes (e.g., using cognitive reappraisal or attentional control) and that provide strategies to do so (e.g., When you feel an urge to smoke, think about the health consequences). The corpus for this condition is 100 messages composed by a large, independent sample of mTurk smokers and validated by a team of RAs trained to 0.8 reliability on ratings of plausibility AND effortful cognitive inhibition or control.~In addition to the texting, participants will complete biweekly online booster sessions using Qualtrics with a custom, personalized link sent to the participant via email and text."
223494178|NCT04620915|BEHAVIORAL|Up-regulation of goal energization|"In the up-regulation of goal energization condition, participants will be sent messages that encourage them to consider the core values that drive their desire to quit smoking. These messages will name a specific core value that the participant rated in the top three (of 19) during the baseline session, and will draw a connection between quitting and the core value. For example, a message for a person who nominated family as one of her top three core values might read, Quitting will help you model a healthy lifestyle for your family. This intervention is grounded in robust theory and evidence supporting Self-Affirmation Theory. The corpus for this condition is 100 messages composed by a large, independent sample of mTurk smokers and validated by a team of RAs trained to 0.8 reliability in correctly identifying to which core value the message is tied.~In addition to the texting, participants will complete biweekly online booster sessions using Qualtrics."
223494179|NCT06364865|DEVICE|laparoscopic procedure|Not applicable, subject requiring procedure will have a laparoscopic procedure performed according to the institutions standard of care procedures. There are no clinical procedures performed on the subject as part of this registry study. Surgeon will answer questionnaires regarding use of the device upon completion of the laparoscopic procedure.
223494180|NCT04882709|DEVICE|Recording with hearing aid|Each participant will listen to sound samples via headphones. Sound samples have been recorded with a hearing aid that was set to each participant's individual hearing loss and different amplification strategies, and an unaided reference. Participants will be asked to rate different aspects of sound quality while listening to the different sound samples.
223494181|NCT07008482|OTHER|Music intervention|patient enrolment, administration of the APAIS and NRS scales (T0), administration of the standard music therapy/assistance intervention (20 minutes duration), re-evaluation with re-administration of the APAIS and NRS scales (T1) and completion of the CRF. The administration will take place at the patient's bedside, respecting the privacy and confidentiality of the subjects involved, guaranteeing absolute tranquillity, also with the help of dividers to avoid distractions and interruptions.
223494182|NCT06869967|PROCEDURE|Auricularis Magnus Nerve Block|Auricularis Magnus Nerve block will be performed using 5 mL of %0.5 bupivacaine
223494183|NCT06869967|PROCEDURE|Control Group|Intravenous analgesics 1 gram paracetamol, 20 mg tenoxicam, 8 mg ondansetron will be administered.
223494184|NCT06672016|DRUG|Transdermal system containing progestin|MR-130A-01 transdermal system, patch to be used for female contraception
223494185|NCT06987318|BIOLOGICAL|VRC07-523LS|Administered by Intravenous (IV) infusion at Week 0 and 12 weeks later
223494186|NCT06987318|BIOLOGICAL|PGT121.414.LS|Administered by IV infusion at Week 0
223589049|NCT07089212|DEVICE|Cyclic Compression Cryotherapy|"Initiation: Begin within 24 hours postoperatively. Each session lasts 20-30 minutes, administered 2-3 times daily.~Procedure: Apply a cryotherapy wrap circumferentially around the knee using a pneumatic compression device, with precise control of pressure and temperature.~Pressure Settings: Start at Level I-II (low-to-moderate) and adjust incrementally based on patient tolerance.~Temperature Control: Maintain at 10-12°C."
224185955|NCT01294761|DRUG|Raltegravir, Darunavir/r|"An arm to change the regimen to: raltegravir and darunavir/ritonavir~Prezista naive 2 tabs PC QD, Norvir soft-capsule 1 cap PC QD and Isentress 1 tab BID or Prezista 2 tabs PC BID and Norvir soft-capsule 1 cap PC BID, and Isentress 1 tab BID~from: Kaletra 4 tabs QD and Truvada 1 tab QD or Kaletra 4 tabs QD, Viread 1 tab QD, Epivir300mg 1 tab (or Epivir 150mg 2 tabs) QD"
224185956|NCT03602209|PROCEDURE|Removal of infected implant|
224185957|NCT03602209|DRUG|Antibiotic durations|
224185958|NCT03491501|OTHER|Ergonomic evaluation using questionnaires|Employees will be provided with questionnaires such as the 'Rapid Entire Body Assessment' and NIOSH to obtain information regarding ergonomic working situations
224185959|NCT04657406|DRUG|Zofin|Subjects will receive standard of care plus 1 mL of Zofin on day 0, day 4 and day 8, containing 1-5 x 10\^11 particles/mL.
224185960|NCT04640792|PROCEDURE|Screening or Surveillance Conventionall colonoscopy|Patients in Group A (CC) will undergo Screening or Surveillance Conventual Colonoscopy, Patients in Group B (MEAC) will undergo Screening or Surveillance Colonoscopy with ME-ADPS Device
224185961|NCT01049789|BEHAVIORAL|COMB - Combination Cognitive Behavioral Therapy and Medication Management|"Phase I: 24-week intervention consisting of Cognitive Behavioral Therapy (CBT) and Medication Management (MM) manuals. Study coordinators and site clinicians will document depression symptoms and treatment regimens for all participants for 24 weeks. Site staff and participants at COMB sites will participate in an exit interview and findings will be used to revise CBT and MM intervention manuals at the end of Phase I.~Phase II: similar procedures as Phase I; COMB sites will implement the revised CBT and MM manuals. Depression symptoms and treatment regimens for all participants will be documented for 24 weeks. All Phase II participants will have 2 follow-up visits at weeks 36 and 48."
224185962|NCT01049789|BEHAVIORAL|TAU - Treatment as Usual|"Phase I: Participants enrolled at TAU sites will receive treatment for depression that is typical at that site, which may include medication management, psychosocial therapy, or a combination of the two.~Phase II: Participants at TAU sites will receive treatment for depression that is typical at that site. As in Phase I, psychopharmacological and psychosocial interventions will not be standardized and participants may receive any depression treatment recommended by the site clinicians while on study. Depression symptoms and treatment regimens for all participants will be documented for 24 weeks. Additionally, all Phase II participants will have 2 follow-up visits at weeks 36 and 48."
224185963|NCT05512273|PROCEDURE|Piezosurgery assisted osteotomy|Sequential osteotomy drilling was done using mectron piezosurgery implant drilling protocol
224185964|NCT05512273|PROCEDURE|Conventional drilling osteotomy|bone osteotomy for implant placement was done following the BEGO Semados RS/RSX TrayPlus conventional drilling
224185965|NCT04557189|DRUG|TAK-951|TAK-951 SC injection
224185966|NCT04557189|DRUG|Ondansetron|Ondansetron IV injection
224308660|NCT05394649|DEVICE|Intravascular Lithotripsy|"A new device has been designed by Shockwave Medical Inc. for the treatment of calcified vascular lesions to support stent delivery: the C2 Shockwave Medical® (IVL), Inc. coronary lithotripsy system. The system is based on lithotripsy to induce microfractures in the calcified plaque before low-pressure balloon dilation. The C2 Shockwave Medical® coronary lithotripsy (IVL) system consists of an IVL Catheter with two lithotripsy emitters enclosed within an integrated balloon, an IVL Generator, and an IVL Connector Cable."
224185967|NCT04557189|DRUG|Ondansetron Placebo|Ondansetron placebo-matching IV injection
224308661|NCT05394649|DEVICE|Rotational Atherectomy|Rotational Atherectomy is a technique of calcic coronary plaque preparation based on the debulking of superficial calcium by a high-speed burr in order to improve vessel compliance and immediate vessel lumen gain before stenting.
224308662|NCT05763108|DIAGNOSTIC_TEST|genetic test|COL1A1 or COL5A1 genetic test
224308663|NCT05763108|OTHER|Beighton joint laxity test|Based on Beighton scale.
224308664|NCT03555006|OTHER|"Dual ultrasound reading local vs remote"|The examination will be interpreted by a department's radiologist and by a remote radiologist in blind of the first interpretation and a posteriori by a third radiologist.
224308665|NCT03555006|OTHER|"Dual ultrasound reading local vs local"|The examination will be interpreted by two department's radiologists and a posteriori by a third radiologist.
224308666|NCT04851652|OTHER|No intervention nor exposure|As an observational study, no intervention nor exposure is interested.
224308667|NCT02730117|DEVICE|Dialysis with continuous renal replacement therapy|Continuous renal replacement therapy is a form of 24-hour dialysis in the ICU
224308668|NCT02730117|DEVICE|Mechanical ventilator|Invasive or noninvasive form of respiratory support
224308669|NCT02730117|DRUG|Anti-Bacterial Agents|Antibacterial agents deemed appropriate by physicians in the ICU
223494187|NCT06880445|PROCEDURE|Povidone-Iodine (PVP-I)|The experimental group will use povidone-iodine for disinfection.
223494188|NCT06880445|PROCEDURE|Water|The control group will undergo perineal preparation using clean water
223494189|NCT06674824|DEVICE|massimo|measure plethysmography variability index in patients on spontaneous trial planning for extubation and evaluate its sensitivity in relation to transthoracic echocardiographic velocity time integral in early detecting weaning induced pulmonary edema
223494190|NCT06867094|DRUG|SAR441566|Pharmaceutical form: Tablet Route of administration: Oral
224185968|NCT04557189|DRUG|TAK-951 Placebo|TAK-951 placebo-matching SC injection
224185969|NCT03658213|DRUG|ZOLADEX 10.8 mg|10.8 mg depot for injection (equivalent to 10.8 mg goserelin)
224185970|NCT03658213|DRUG|ZOLADEX 3.6mg|3.6 mg depot for injection (equivalent to 3.6 mg goserelin)
224185971|NCT00954356|DRUG|XPF-001|Single oral administration of 500 mg XPF-001 capsules (5 x 100 mg capsules)
224308670|NCT02730117|DRUG|Vasopressors|Vasopressors such as Norepinephrine, dopamine, milrinone, dobutamine
224308671|NCT04720118|OTHER|No Intervention|There is no intervention for this study.
224308672|NCT01915706|PROCEDURE|Ripcord removal|Patients randomized to intervention will have their ripcords removed in clinic at post-operative week 3. Ripcord removal will be performed by study PI at the slit lamp with standard of care sterile technique and topical/local anesthesia. Patients will be monitored 30 minutes following ripcord removal for intraocular pressure as well as complications.
224308673|NCT05305482|DEVICE|Drug-coated stent|The polymer-free drug-coated stent (BioFreedom Ultra stent) will be implanted for the DCS group.
224308674|NCT05305482|DEVICE|Drug-eluting stent|The Biodegradable polymer drug-eluting stent (Ultimaster stent) will be implanted for the DES group.
224308675|NCT01310270|DIETARY_SUPPLEMENT|Pro-Omega|Pro-Omega, 4.4gm/day x 1 month
224308676|NCT01310270|DIETARY_SUPPLEMENT|Omega 3 Fatty Acid|4.4 gm/day for 1 month
224308677|NCT02535871|DRUG|IDP-121 Lotion|Investigational Product: IDP-121 Lotion
223494191|NCT06867094|DRUG|SAR441566 matching Placebo|Pharmaceutical form: Tablet Route of administration: Oral
223494192|NCT05300139|OTHER|Color Doppler Ultrasound|Comparison between D90±5 and baseline CDUS
223494193|NCT07009847|OTHER|Case control study of clinical malaria|Case control study of clinical malaria
223494194|NCT07009847|OTHER|Case control study of severe malaria|Case control study of severe malaria
223494195|NCT07009847|OTHER|Case control study of death (all cause)|Case control study of death (all cause)
223494196|NCT05635370|DRUG|Pentoxifylline|Pentoxifylline claim is used as the exposure group.
223494197|NCT05635370|DRUG|Cilostazol|Cilostazol claim is used as the reference group.
223494198|NCT06678022|DEVICE|No Drone delivery|Usual ART delivery to landing sites
223494199|NCT06678022|DEVICE|Fixed Wing drones|Last Mile fixed wing drone delivery
223494200|NCT06426498|DEVICE|Brainsonix Bx Pulsar machine tFUS|This is a tFUS device, delivering ultrasound at a dose within the FDA safety guidelines.
223494201|NCT06685640|OTHER|prefabricated stainless steel crowns|Full coverage restoration after pulpal treatment in multi-surface deep caries of primary mandibular second molars requiring pulpotomy
223494202|NCT06685640|OTHER|prefabricated zirconia crowns|Full coverage restoration after pulpal treatment in multi-surface deep caries of primary mandibular second molars requiring pulpotomy
224185972|NCT00954356|DRUG|placebo|Single oral administration of 5 x 100 mg Placebo capsules.
224185973|NCT04681469|DRUG|Niraparib|"For all patient's population:~* Niraparib 200 mg/day: day -49 to day -21;~* Dostarlimab 500 mg iv: day -49 and day -28; At day -21, clinical evaluation will be performed and the patient will be directed to surgery with exclusion from the study in case of progressive disease. Radiological assessment will be performed according to the physician's judgement.~If no clinical evidence of disease progression:~* Niraparib 200 mg/day: day -21 to day -7~* Dostarlimab 500 mg iv: day -7~* Radiological assessment (day -1, ± 3 days),~* Surgery (original margin) at day 0 (±3 days)~* Standard postoperative (chemo)radiotherapy according to pathologic report;~* Maintenance Niraparib, 200 mg/day for 6 months~* Maintenance Dostarlimab, 500 mg iv q3W for the first four cycles and 1000 mg iv Q6W thereafter for 3 months."
224185974|NCT04374526|BIOLOGICAL|COVID-19 Convalescent Plasma|ABO matched pathogen-inactivated CCP is transfused at a dose of 200 ml/day for 3 days (days 1, 2, and 3).
224185975|NCT06212518|OTHER|GENPOP ad libitum fluid intake|Unrestricted fluid intake.
224185976|NCT06212518|OTHER|GENPOP fluid restriction|In the 24 hours between the first and last face scan, reduce fluid intake by approximately 75% (equating to approximately 700 ml (women) and 800 ml (men)).
224185977|NCT06212518|OTHER|ATHLETE ad libitum fluid intake|No restriction on fluid intake
224185978|NCT06212518|OTHER|ATHLETE restricted fluid intake|Not permitted to drink during training session.
224185979|NCT03769857|DIETARY_SUPPLEMENT|NEM® + BIOCURC®|Dietary supplement combination for the support of joint health.
224185980|NCT03769857|DIETARY_SUPPLEMENT|Placebo|Placebo
224185981|NCT01731600|DRUG|turoctocog alfa pegol|Fixed dose of turoctocog alfa pegol for intravenous injections (i.v.) twice weekly for prophylaxis. In addition, turoctocog alfa pegol will be administered to treat bleeding episodes during the trial period. Bleeding episodes will be treated with doses of 20-75 U/kg body weight.
224185982|NCT04925466|DEVICE|CPAP at pressure of 10 cmH2O|Patients used CPAP with the pressure of 10 cmH2O during overnight polysomnography
224185983|NCT04925466|DEVICE|CPAP at minimal effective pressure|Patients with OSA will be treated with CPAP at minimal effective pressure derived from manual titration during sleep.
224185984|NCT03440606|BEHAVIORAL|Mindful-Compassion Art Therapy Supervision|"Each Mindful-Compassion Art Therapy Supervision group will focus on 3 major areas that cultivate self-care, resilience and communal support. The specific structure include: (1) Self-care and Stress Management in Week 1 and 2 (i.e., concept of mindfulness and art, the symbol of the mandala and its use in self-care, mindfulness practice and art); (2) Sharing of Clinical Expertise and Experiences in Week 3 and 4 (i.e., Create mindful art about one meaningful and one challenging patient/client interaction with small group discussion); and (3) Understanding Grief and Meaning-Making in Week 5 and 6 (i.e., Create mindful art representing a clinical encounter of mortality, and meaning-making from reflection on grief)."
224185985|NCT03458468|DRUG|Tranexamic Acid|1g Tranexamic acid prior to skin incision
224185986|NCT03458468|DRUG|Saline|Equivalent volume of saline prior to skin incision
224185987|NCT00465894|DRUG|Extended Release Tolterodine LA|Tolterodine LA 4 mg once daily for 52 weeks. At 12 Weeks, the subjects were offered the addition of the alternative therapy with follow-up at 24 and 52 weeks
224185988|NCT00465894|DRUG|Intra Vaginal Estradiol Cream|17-B estradiol cream 0.5 grams nightly for 6 weeks then two times weekly for 46 weeks. At 12 Weeks, the subjects were offered the addition of the alternative therapy with follow-up at 24 and 52 weeks.
224185989|NCT05066516|DRUG|FCDP, dapagliflozin 10mg/linagliptin 5 mg or co-administration of a single dose of dapagliflozin and linagliptin|FCDP, dapagliflozin 10mg/linagliptin 5 mg or ICs, co-administration of a single dose of dapagliflozin and linagliptin
224185990|NCT02793115|BEHAVIORAL|Disclosure Letter-RISKS|This disclosure letter will provide information on the physicians' financial relationships with industry, and will also provide a standardized statement regarding the potential RISKS of physicians' conflicts of interest with for-profit industry. This letter also includes a standard statement reminding the patient about the appointment and the location of the appointment.
224185991|NCT02793115|BEHAVIORAL|Disclosure Letter-BENEFITS|This disclosure letter will provide information on the physicians' financial relationships with industry, and will also provide a standardized statement regarding the potential BENEFITS of physicians' conflicts of interest with for-profit industry. This letter also includes a standard statement reminding the patient about the appointment and the location of the appointment.
224185992|NCT02793115|BEHAVIORAL|Disclosure Letter-RISKS AND BENEFITS|This disclosure letter will provide information on the physicians' financial relationships with industry, and will also provide a standardized statement regarding the potential RISKS AND BENEFITS of physicians' conflicts of interest with for-profit industry. This letter also includes a standard statement reminding the patient about the appointment and the location of the appointment.
224185993|NCT02793115|BEHAVIORAL|Disclosure Letter-NO RISKS OR BENEFITS|This letter includes a standard statement reminding the patient about the appointment and the location of the appointment.and DOES NOT provide any information on the physicians' financial relationships with industry nor information regarding the potential risks and benefits of physicians' conflicts of interest with for-profit industry.
224185994|NCT02793115|BEHAVIORAL|Letter-APPOINTMENT REMINDER|This letter only includes a standard statement reminding the patient about the appointment and the location of the appointment.
224185995|NCT04747028|DIAGNOSTIC_TEST|Dmf score|A chart to calculate the caries index
223494203|NCT07014345|PROCEDURE|DLT placement performed in lateral position|In the lateral position group, patients were positioned laterally (as required for surgery) before anesthesia induction. After anesthesia induction, Double lumen tube placement was performed while the patient remained in the lateral position.
224185996|NCT04982276|BIOLOGICAL|AK109|Subjects will receive AK109 by intravenous administration.
223494204|NCT07015515|OTHER|Sham blood flow restriction exercise|"a BFR cuff will be placed on the upper extremity in the same location as in the real BFR group. During the application, the participant will be led to believe that the cuff is being inflated, although no actual pressure will be applied. The participant will see the cuff being wrapped and apparently inflated, but there will be no physical pressure restricting circulation during the exercise. This aims to control the psychological effects (e.g., the belief that something is being applied) on performance"
223494205|NCT07015515|OTHER|Control group|Participants perform push-up exercises without any cuff application. The same repetition and rest protocol is followed
224185997|NCT04982276|DRUG|paclitaxel|Subjects will receive AK109 in combination with paclitaxel.
224185998|NCT04982276|DRUG|paclitaxel|Subjects will receive AK104 and AK109 in combination with paclitaxel.
224185999|NCT04982276|BIOLOGICAL|AK104|Subjects will receive AK104 by intravenous administration.
224186000|NCT01636076|DRUG|QMF149|delivered via Concept1 device
224186001|NCT01636076|DRUG|Salmeterol|delivered via Accuhaler®
224186002|NCT00002276|DRUG|Ibuprofen|
224308678|NCT02535871|DRUG|IDP-121 Vehicle Lotion|Comparator Product: IDP-121 Vehicle Lotion
224308679|NCT00883909|DRUG|dutasteride|A follow-up study in adult male subjects who have received investigational product
224308680|NCT00446537|PROCEDURE|Methylphenidate|
224073612|NCT05651035|OTHER|oral feeding|"In experimental group infants: Preterms in this group will be breastfed by their own mother.~In control group infants: Preterms in this group will be fed by the researcher by putting the baby's own mother's milk in the bottle. During feeding, the preterm will be placed on the lap by the researcher in a standing position on the same mother's breast, and will be given a raised side-lying position. In this position, the preterm's head and body will be elevated 45-60 degrees with the help of a small pillow. While the researcher will support the preterm's head, neck and shoulder with one hand, he will control the bottle with the other hand. By touching the preterm's nipple to the preterm's lips, the preterm will be prepared for feeding, and the bottle will be placed in the baby's mouth with the mouth opening and the tongue lowering. During feeding, stimulating movements such as pushing the bottle back and forth in the mouth, which will lead the newborn to suck faster, will not be made."
224308681|NCT03177174|DRUG|Cisplatin|radiotherapy combined with Chemotherapy Drugs, Cancer
224308682|NCT03177174|DRUG|Docetaxel|Docetaxel
224308683|NCT06627491|BEHAVIORAL|Imagined muscle contractions|The intervention involved imagining, with no physical movement, of muscle contractions.
224308684|NCT01830894|DEVICE|MRI|3 MRI on different times during the study for each arm.
224308685|NCT04689867|BEHAVIORAL|Cognitive Behavioral Suicide Prevention for psychosis CBSPp)|Cognitive and behavioral approach to suicide prevention among individuals with psychosis
224308686|NCT01136967|DRUG|Lenvatinib|Participants received lenvatinib 24 mg orally, once daily continuously in 28-day cycles until disease progression, development of unacceptable toxicity or withdrawal of consent.
224308687|NCT00570895|DIETARY_SUPPLEMENT|Vitamin C|"Visit 1: Subjects will receive 1mg iron-58 sulfate as an aqueous solution with 50mg ascorbic acid.~Visit 2: Subjects will consume a meal of a bread muffin labelled with 4mg of iron-57 as ferrous fumarate, and a glass of apple juice containing 0 or 25mg ascorbic acid.~Visit 3: During this admission the apple juice will contain either 0 or 25mg ascorbic acid, the opposite of what was given to the subject in visit 2."
223494206|NCT07015515|OTHER|Blood flow restriction exercise group|Participants will perform push-up exercises with 50% arterial occlusion pressure applied to their dominant arm. The cuff is inflated before the exercise and maintained throughout 3 sets of 5 repetitions. There is a 2-minute rest between sets.
223494207|NCT03890887|DRUG|BI 1291583|Tablet
223494208|NCT03890887|DRUG|Itraconazole|Oral solution
223494209|NCT04836546|DEVICE|Blood glucose meter|First phase: SMBG for 6 months
223494210|NCT04836546|DEVICE|Eversense CGM System|Second phase: CGM for 6 months
223494211|NCT06436209|BEHAVIORAL|Multitask Practice Intervention (MPI)|Multitask practice intervention (MPI) includes multiple behavioral testing sessions during which participants receive practice with multitasking two tasks using the psychological refractory period procedure.
224186003|NCT00002276|DRUG|Zidovudine|
224308688|NCT03839823|COMBINATION_PRODUCT|Docetaxel / Capecitabine|"Docetaxel (IV Infusion) / Capecitabine (Tablets for oral use):~Docetaxel once, on day 1 of the 3-weeks cycle. Capecitabine twice daily, on Days 1 to 14, followed by a 1-week rest period, in 3 weeks cycle.~Docetaxel (60 - 75 mg/m²)/capecitabine (1600 - 2500 mg/m²/day)"
223494212|NCT06436209|BEHAVIORAL|Single-task Practice Intervention (SPI)|Single task practice intervention (SPI) includes multiple behavioral testing sessions during which participants receive separate practice on two tasks.
223494213|NCT05308654|DRUG|ABBV-453|Oral; Tablet
223494214|NCT05308654|DRUG|Dexamethasone|Oral Tablet
223494215|NCT05308654|DRUG|Daratumumab|Subcutaneous Injection
223494216|NCT05308654|DRUG|Lenalidomide|Oral Capsule
223494217|NCT07011992|DRUG|Rosuvastatin|Oral tablet
223494218|NCT07011992|DRUG|BPN14770|Oral capsule
223494219|NCT03485794|PROCEDURE|Biospecimen Collection|Undergo collection of blood
223494220|NCT03485794|OTHER|Laboratory Biomarker Analysis|Correlative studies
223494221|NCT07021027|DRUG|Whole Egg - 4|Participants will be asked to consume 4 medium Eggland's Best eggs per day for 5 months.
223494222|NCT07021027|DRUG|Whole Egg - 2|Participants will be asked to consume 2 medium Eggland's Best eggs per day for 5 months.
223494223|NCT07014826|DRUG|HRS-5965|HRS-5965
223494224|NCT07014826|DRUG|Placebo|Placebo
223494225|NCT06682559|OTHER|Prefabricated healing abutment with scan peg|12 participants will receive single posterior implants by fully guided implant protocol followed by placement of prefabricated healing abutment with scan peg having convex emergence profile
224073613|NCT03889041|OTHER|Quality of life assessment|The Turkish Feeding/Swallowing Impact Survey will be completed by the caregivers
224186004|NCT04135599|DEVICE|transcranial direct current stimulation|Transcranial direct current stimulation (tDCS) is a non-invasive, safe and easy-to-operate neuro-electrophysiological technique, which becoming an emerging therapeutic option for many mental disorders.It can modulate cortical excitability of target brain region, neuron plasticity and brain connections. Previous studies suggest that tDCS could reduce cue-induced craving and improve cognition in drug addiction.
224186005|NCT02949544|OTHER|water immersion|warm water immersion
224186006|NCT02662374|DRUG|.02% Chlorohexidine Gluconate|5ml of the drug in mouthwash form to be swished four times a day
224186007|NCT02662374|DRUG|3% Sodium Bicarbonate|5ml of the drug in the form of a prepared solution to be swished four times a day
224186008|NCT02662374|DRUG|Nystatin 10000U/ml|5ml of the drug in mouthwash form to be swished and swallowed four times a day
224308689|NCT03839823|COMBINATION_PRODUCT|Capecitabine / Vinorelbine|"Capecitabine (Tablets for oral use) / Vinorelbine (Capsule for Oral use/IV infusion ).~Capecitabine twice daily on day 1 to 14, followed by a 1-week rest period, in 3 weeks cycle.~Vinorelbine, once, on Day 1 and Day 8 in 3 weeks cycles.~Capecitabine (1600 - 2500 mg/m2/day)/vinorelbine (60 to 80 mg/m2/day \[oral\] or (25 to 30 mg/m2 \[IV infusion\]"
224308690|NCT03839823|COMBINATION_PRODUCT|Paclitaxel / Gemcitabine|"Paclitaxel (IV Infusion) / Gemcitabine (IV Infusion):~Paclitaxel via 3-hour intravenous (IV) infusion on Day 1 in 3-weeks cycles, OR Paclitaxel via 1 hour intravenous (IV) infusion on Day 1 and day 8- in 3-weeks cycles.~Gemcitabine at via 30 minute IV infusion on Day 1 and Day 8 in 3 weeks cycles.~Paclitaxel (175 mg/m2) (on Day 1 in 3-weeks cycles)/ gemcitabine (1000 - 1250 mg/m2)~OR~Paclitaxel (80 - 90 mg/m2) (on Day 1 and Day 8 in 3-weeks cycles) / gemcitabine (800 - 1250 mg/m2)"
224308691|NCT03839823|DRUG|Ribociclib|Dose: 600 mg (200 mg \* 3) Days 1 to 21 of each 28 day cycle Tablets for oral use
224308692|NCT03839823|DRUG|Letrozole OR Anastrozole|"Letrozole:~Dose: 2.5 mg All days of every cycle without interruption). Tablets for oral use~Anastrozole:~dose: 1 mg All days of every cycle without interruption. Tablets for oral use~The NSAI (letrozole or anastrozole) will be decided by the treating physician."
223494226|NCT06682559|OTHER|Customized healing abutment|12 participants will receive single posterior implants by fully guided implant protocol followed by placement of custom healing abutment having concave emergence profile
223494227|NCT07021794|DRUG|Placebo|A single dose of placebo (saline) indistinguishable from the active drug in appearance
223494228|NCT07021794|BIOLOGICAL|Sipavibart|A single intramuscular dose of Sipavibart, 300 mg
223494229|NCT07023081|BIOLOGICAL|20vPnC|20vPnC vaccine
223494230|NCT06686121|BEHAVIORAL|Home Based Exercise|This is a six month intervention where participants will walk at home for exercise with guidance from a study coach. They will attend two to four weekly meetings with the coach at the clinical site in the first 4 weeks following randomization, followed by once weekly telephone coaching calls for the remainder of the six-month intervention
223494231|NCT06686121|DRUG|Nitrate Rich Beetroot Juice|Participants will drink one shot of nitrate rich beet-root juice twice daily for six months.
223494232|NCT06686121|BEHAVIORAL|Attention Control|"Participants will be asked to participate in weekly meetings with the coach in the attention control group for weeks 1-26. A staff member will present a topic from the National Institute on Aging age pages relevant to health, such as cancer screening or blood pressure treatment. Calls will last approximately 5-15 minutes and will focus on educational topics such as diabetes, healthy eating, and Medicare Part D."
223494233|NCT06686121|DRUG|Placebo Beetroot Juice Without Nitrate|Participants will drink one shot of placebo beetroot without nitrate juice twice daily for six months.
223589050|NCT07089212|BEHAVIORAL|Conventional rehabilitation treatment.|The control group underwent a 12-week conventional rehabilitation program, which primarily included muscle strength training, endurance training, proprioception training, and joint range of motion (ROM) exercises. Assessments were conducted at baseline (before treatment), as well as at 2 weeks, 6 weeks, and 12 weeks post-treatment. The evaluated outcomes included knee joint ROM, muscle strength, knee function, pain levels, and activities of daily living (ADL).
223589051|NCT07087327|DRUG|EB-1020 (Centanafadine) low dose|low dose, capsule, oral, once daily, for 52 weeks
223589052|NCT07087327|DRUG|EB-1020 (Centanafadine) high dose|high dose, capsule, oral, once daily, for 52 weeks
223589053|NCT07087782|OTHER|Fortini formula|Fortini, a commercially available formula providing 30 kcal/oz, is commonly used in older children with failure to thrive or feeding intolerance. It offers the theoretical benefit of providing higher caloric density in a lower volume, which may be advantageous in infants with single ventricle physiology, who often have limited volume tolerance and high metabolic demands.
223589054|NCT07087782|OTHER|Standard Nutritional Care|Standard infant formulas (including hydrolyzed formulas) fortification to 24-30 kcal/oz
224073614|NCT06221982|OTHER|No intervention, observational study|Observational study, no intervention
224308693|NCT03839823|DRUG|Goserelin|"Dose: 3.6 mg Day 1 of each 28 day cycle (regardless of ribociclib treatment cycle) with an administration window of + 3 days.~Subcutaneous implant"
223494234|NCT06631144|BEHAVIORAL|Spanish-language Caregiver-Enabled Care Program (CECP)|CECP is a nonmedical digital population health intervention to support and engage family caregivers of persons with dementia. CECP consists of digital content, including health education videos and tutorials, that is delivered to caregivers on a dedicated tablet based on their specific needs. Caregivers are supported by a proactive human coach who provides support, access to resources, and performs risk mitigation measures as necessary. Alerts are shared with providers and/or care management teams via a data hub that makes it easy to track, manage and resolve alerts. CECP is delivered over a 6-month period via a dedicated tablet that is shipped to the caregiver's home at no cost to the caregiver or person with dementia. This study's CECP is in Spanish.
223494235|NCT06690346|OTHER|Systematic oral health education|Provide systematic oral health education to patients in experimental group, including oral hygiene instruction and dietary instruction
223589055|NCT07087548|OTHER|Peloid Therapy|Peloid therapy will be applied using medical mud packs at 45°C for 30 minutes per session, 5 sessions per week for 3 consecutive weeks. The therapy will be administered to the lower back region in patients diagnosed with chronic lumbar disc herniation. This intervention aims to reduce pain and improve function through thermomechanical and biochemical effects of natural peloid.
224073615|NCT01491178|DRUG|Prazaxa|Dabigatran etexilate
224073616|NCT04520178|DRUG|5-Hydroxytryptophan 100 MG|100mg combined with 50mg carbidopa
224073617|NCT04520178|DRUG|5-Hydroxytryptophan|50mg combined with 50mg carbidopa
224073618|NCT04520178|DRUG|Carbidopa|50mg
224073619|NCT04520178|DRUG|Placebo|Placebo
224075933|NCT06670859|OTHER|Control-Intervention|Patients will complete the STAI before the first mobilization after surgery and then the patients' pain status and the level of anxiety they feel about their physical privacy with the traditional hospital gown they will wear during mobilization will be assessed with the VAS.Than,will be asked to perform 4 activities (putting on the gown-mobilization-sitting in the wheelchair and moving-taking off the gown) with the gown.Than,will be asked to evaluate the indicator level that they think the gown they wear protects physical privacy, and the levels of comfort and satisfaction they feel about the gown with the VAS.During the next mobilization, patients will be asked to perform the same application protocol with the mobilization coverall.Participants who have tried both clothing designs will be interviewed about their experiences using 'interview form' their satisfaction.At the end of the interview, participants will have completed the study by filling out the QUEST 2.0.
224308694|NCT05727371|COMBINATION_PRODUCT|Regen Matrix-PRP-XLHA|Single intra-articular injection at Day 0
224308695|NCT05727371|DEVICE|Hylan G-F 20|Single intra-articular injection at Day 0
223589056|NCT07087548|OTHER|Hotpack Therapy|The hot pack group applied 20 minutes, 5 days a week, once a day, for 15 sessions on the lumbar region. The boiler temperature of the hot packs used was 90 °C. Two towels were used, with the thickest side of the towels placed on the lumbar area of the individuals. Then, conventional TENS (80 Hz frequency) was applied to the painful area in the lumbar region for 20 minutes
223745735|NCT05595681|DRUG|Adipose tissue derived mesenchymal stromal/stem cells (Cell2Cure®)|"The investigational product is a C2C\_ASC cell product (Cell2Cure®, Cell2Cure ApS, Denmark).~C2C\_ASC is an advanced therapy investigational medicinal product (ATIMP) manufactured from abdominal adipose tissue derived mesenchymal stromal cells (ASC) from healthy donors. C2C\_ASC is aseptically procured and manufactured according to tissue law and GMP by Cell2Cure ApS or Cardiology Stem Cell Center, Rigshospitalet, Copenhagen, Denmark, using manual isolation of cells from abdominal fat tissue, xeno-free cell expansion in automated closed bioreactor systems and cryopreservation of the final product.~The active substance is the in vitro expanded ASCs. The final product, C2C\_ASC, is provided as a cryopreserved suspension of 50 million ASCs per ml with a total volume of 1,3 ml per vial. The exipient is CryoStor10 (Biolife Solutions), holding 10% DMSO."
224186009|NCT02662374|DEVICE|Extra Soft Toothbrush|To be moistened with 0.9% normal Saline and used twice daily to remove dental plaque
223494236|NCT06690346|OTHER|Routine oral health education|Provide routine oral health education to patients in control group, including routine oral self-care instruction
223494237|NCT06690970|DIAGNOSTIC_TEST|68Ga/18F-PSMA/PSFA|Each subject receive a single intravenous injection of 68Ga/18F-PSMA/PSFA, and undergo PET/CT imaging within the specificed time.
223494238|NCT01290835|RADIATION|Stereotactic radiotherapy delivered by CyberKnife|Adjuvant radiotherapy will be delivered using CyberKnife radiotherapy using twice daily sessions for five days for a total of ten sessions.
223494239|NCT01290835|RADIATION|stereotactic radiotherapy|
223494240|NCT07023731|DRUG|ARV-806|Intravenous infusion at assigned dose and dosing schedule
223494241|NCT07023640|DIAGNOSTIC_TEST|68Ga-DOTA-mPNE|PET/CT examination was performed after intravenous injection of 68GA-DOTA-mPNE tracer
223589057|NCT07088848|DEVICE|Gamified Digital Balance Assessment|"The GDBA further enhances the digitalized Brief-BESTest experience by incorporating gamification elements tailored to older adults, including points, avatars, real-time performance graphs, and leaderboards. The system provides automated feedback and maintains engagement through periodic avatar demonstrations when user inactivity is detected. Upon meeting task initiation criteria, a countdown triggers data capture.~The interface is designed for accessibility, featuring a high-contrast color scheme (black background with orange/green highlights), voice prompts, and intuitive controls. Upon completion, users receive a comprehensive report including total score, task-level feedback and training recommendations. A leaderboard feature promotes continued engagement, with gamified training modules under development.~At the end of the assessment, the system displays a summary including total balance score, task-specific feedback, a fall risk rating, and personalized training suggestions. Users"
223745736|NCT01290666|DEVICE|Fistula Plug|Bioabsorbable fistula plug
223745737|NCT03285971|OTHER|Electronic CPP pager alert|Anesthesia providers will receive a pager alert when CPP decreases beow 60 mmHG (median value over 5-minute epochs)
224073620|NCT01604512|DIAGNOSTIC_TEST|MRI perfusion and PET/CT scans|The MRI perfusion and PET/CT scans will be obtained within 12 weeks of each other. These scans are part of the standard of care for patients with brain tumors and uncertain tumor response or progression after treatment. Although every effort will be made to perform both MRI perfusion and PET/CT on the same day or during the same week, some patients may experience longer intervals between scans due to scheduling conflicts. The disease in question (radiation injury vs. tumor progression) may change slightly during this interval (e.g., the lesion may grow or shrink slightly), but no large changes are expected between the two scans. The patients may continue existing treatments in the interval between scans (e.g., steroids, chemotherapy), but the two scans must be performed before any change or new treatment occurs. Fusion images of MRI and PET/CT will not be reviewed by the neuroradiologist interpreting the MRI perfusion nor the nuclear medicine radiologist interpreting the PET/CT.
224073621|NCT00612443|BEHAVIORAL|Sham treatment|The sham/placebo treatment will consist of the RN graduate assistant standing near the table, slowly walking around from each side and to the foot of the table stopping periodically. The RN graduate assistant will be instructed to not focus on the patient in thought. While providing the placebo treatment the RN graduate assistant will mentally do multiplication equations. This serves as a distracter to keep the RN graduate assistant from setting intention or thoughts on the participant. At no time will the RN performing the placebo treatment move hands or arms over or around the participant or come in physical contact with the participant. The placebo treatment will be a minimum of 20 minutes but no greater than 30 minutes in length. A timer will be set in the treatment room to notify the practitioner of the time limit.
224073622|NCT00612443|BEHAVIORAL|Healing Touch|Behavioral: Healing Touch The Healing Touch intervention will consist of a brief meditative state in which the practitioners sets the intention of healing for the session. A hand scan to assess the biofield; consists of a technique of where the practitioner slowly moves her hands three to six inches above the body going from head to toe, to assess for any disturbances in the biofield; a non-contact Healing Touch treatment which will follow, to include a connection of the chakras. The chakras are connected by placing the hands above the body over each chakra, starting at the feet and progressing to the head. This will be followed by smoothing the biofield, achieved by the Practitioner slowly moving her hands above the body from the head and moving towards the feet (Hover-Kramer et al., 1996). At no time will the Practitioner make physical contact with the participant during the treatment. The treatment will be 20 minutes to 30 minutes in length.
224073623|NCT06487624|DRUG|HCB301|HCB301 administered via. intravenous (IV) infusion.
224073624|NCT03132636|DRUG|cemiplimab|Regimen as per protocol
224073625|NCT02129751|DRUG|bupropion hydrobromide|study drug
224073626|NCT02129751|DRUG|Placebo|placebo arm
224073627|NCT03461445|DRUG|Envarsus|Patients will be randomized to receiving Envarsus instead of IR Tacrolimus
224186010|NCT02662374|DRUG|Supersaturated Calcium Phosphate|5ml of the solution to be swished four times a day
224186011|NCT05191927|OTHER|male|Nine preoperative predictors were identified for the nomogram: gender, age, platelet counts, TPOAb level and US signatures including maximum diameter, boundary, component, calcification and cervical lymph node enlargement.
224308696|NCT05727371|DRUG|Placebo|Single intra-articular injection at Day 0
223494242|NCT07024134|OTHER|Shoulder flossing application|Select a floss band, typically made of latex, which is about 1-2 inches wide. Ensure the area to be wrapped is clean and dry to prevent slipping. Begin wrapping the floss band around the upper arm, just below the shoulder joint. Start at the deltoid's base. Leave about 2 inches of the band free at the start to tuck in the end when you finish wrapping. Wrap the band tightly but not to the point of causing discomfort or cutting off circulation, the band should be snug but not so tight that it causes numbness or tingling. Aim for about a 50% stretch of the band as you wrap. Continue wrapping down the arm, covering the entire upper arm and ending just above the elbow Overlap each layer by about 50% to ensure even coverage and compression. Once you reach the desired coverage area, tuck the end of the band under the last loop to secure it. Check the tightness to ensure it is snug but not overly constrictive.
223494243|NCT07024134|OTHER|Nerve glide application|With the band in place, perform slow and controlled arm movements. Start with shoulder abduction (lifting the arm sideways) and progress to external rotation (turning the arm outward) this is for axillary nerve glide, (extending your arm and fingers while tilting your head away from the affected side) this for median nerve glide and (Extend your arm out to the side at shoulder height-Rotate the arm so the palm faces upwards-Flex the wrist and fingers back gently-Tilt your head away from the extended arm to increase the stretch) this for radial nerve glide. Ensure movements are within a pain-free range. Stop if any discomfort occurs. Keep the floss band in place for 1-2 minutes while performing nerve glides. Remove the band after the exercise, allowing the skin to recover from compression.
223494244|NCT07024134|OTHER|Shoulder flossing with Nerve Glide|Procedures of Shoulder flossing application adding to Procedures of Nerve glide application.
223589058|NCT07088848|DEVICE|Digitalized Brief-BESTest design|"The digitalized Brief-BESTest was designed to digitize and automate the Brief-BESTest. While the traditional clinician-administered Brief-BESTest relies on subjective scoring, the digitalized Brief-BESTest enables self-guided assessments with automated, objective scoring-improving accessibility in community and home settings.~The system employs OpenPose to capture skeletal data via a standard 2D camera, tracking 17 anatomical landmarks (e.g., nose, neck, shoulders, hips, knees). Ten joint angles relevant to static and dynamic postural tasks (e.g., standing, sitting, single-leg stance, and simulated falls) are computed. The torso is defined as a vector from the neck to the midpoint between the hips, serving as a reference for postural alignment.~To convert pixel-based coordinates into metric units, the system uses the user's self-reported height with adjustments based on ISO anthropometric standards (correction factors: 10.77 cm for males, 10.06 cm for females) to approximate true body"
223589059|NCT07087470|BEHAVIORAL|Simulation-based education and classical education|Simulation-based psychosocial care skills training and classical psychosocial care skills training will be prepared for oncology nurses.
223589060|NCT07087470|BEHAVIORAL|classical education|classical psychosocial care skills training will be prepared for oncology nurses.
223589061|NCT07087730|BEHAVIORAL|Virtual Training Program|Therapists randomized to this condition will receive the professional development via an asynchronous virtual training course. The Virtual Training will include written material, videos, interactive learning activities, and a text-based discussion forum where therapists and faculty will be able to interact in relation to the given activities. Clinical scenario and simulation-based interactive learning will allow therapists to explore clinical situations, make decisions, and evaluate consequences of their actions in a safe environment. Therapists will complete 6 study-related therapy sessions with 3 new patients. After therapists receive the Virtual Training and after they enroll their first patient, therapists will attend bi-weekly 1-hour online consultation meetings that include up to 6 therapists at a time and led by two of the training faculty. Each therapist will attend 10 of these posttraining consultation sessions.
223589062|NCT07087730|BEHAVIORAL|Training as Usual|Therapists randomized to this condition will receive the professional development training via a 3-day synchronous workshop delivered via video conference covering the same didactic content as the virtual training course. The workshop will include lectures, written material, videos, and live role play activities. Therapists will complete 6 study-related sessions with 3 new patients. After therapists receive the professional development through Training as Usual and after they enroll their first patient, therapists will attend bi-weekly 1-hour online consultation meetings that include up to 6 therapists at a time and led by two of the training faculty. Each therapist will attend 10 of these posttraining consultation sessions.
223589063|NCT07087730|BEHAVIORAL|No Training|Therapists randomized to this control condition will provide psychotherapy via the study video conference platform to 3 new enrolled patients in their typical manner except that they and their patients will also complete the assessments necessary for the study. After study completion, the investigators will provide therapists in the control condition with access to virtual training.
223589064|NCT07088926|BIOLOGICAL|AZD0292|AZD0292 high-dose or low-dose administered starting on Day 1 via IV infusion, subsequent administrations per schedule of assessments.
223589065|NCT07088926|OTHER|Placebo|Placebo administered starting on Day 1 via IV infusion, subsequent administrations per schedule of assessments.
223589066|NCT07087977|DEVICE|HoYAG laser|Patients will be randomly assigned (1:1) to HoYAG laser or TFL laser group for miniPCNL surgery according to standard of care.
223589067|NCT07087977|DEVICE|TFL laser platform|Patients will be randomly assigned (1:1) to HoYAG or TFL laser group for MiniPCNL surgery according to standard of care.
223589068|NCT07088198|PROCEDURE|Joshi's step|Patients will undergo dorsal onlay buccal mucosal graft urethroplasty with Joshi's step
223589069|NCT07088445|DRUG|Faricimab|Intravitreal injection of 6mg famotizumab into the vitreous cavity of patients with non primary wet age-related macular degeneration
223589070|NCT07088965|OTHER|16 / 5.000 survey application|Participants will be administered a self-administered questionnaire containing basic demographic information, questions on job profile and lifestyle practices, as well as the Standardized Nordic Questionnaire (SNA).
224186012|NCT02354027|DRUG|SHR3824 metformin|"Two 500-mg tablets of metformin on Day 1 followed by 25 mg of SHR3824 once daily on Days 4 through 8 followed by two 500-mg tablets of metformin and 25 mg of SHR3824 on Day 8.~Drug: SHR3824 + Metformin"
224308697|NCT00527553|DIETARY_SUPPLEMENT|not enriched egg|daily consumption of a regular egg, not enriched with either lutien nor zeaxanthin
224308698|NCT00527553|DIETARY_SUPPLEMENT|lutein|daily lutein enriched egg
223589071|NCT04676867|DRUG|Dalcetrapib|Dalcetrapib 300 mg Film-Coated Tablets
224186013|NCT02895074|PROCEDURE|Femtosecond laser-assisted cataract surgery|A femtosecond laser (Alcon-Lensx, Alcon-Lensx, Inc.) was used in this study. After pupil dilation and topical anesthesia, the laser was docked to the eye using a curved contact lens to applanate the cornea. With the integrated OCT imaging system, the locations of the cornea and the anterior and posterior surfaces of the crystalline lens were determined. A 5.0-mm-diameter capsulotomy was created by scanning a cylindrical pattern and followed by lens fragmentation. The laser was disconnected, and the remainder of the surgery was performed as phacoemulsification (Infiniti® Vision System; Alcon, USA). Folded intraocular lenses (IOLs) were implanted in the capsular bags.
223494246|NCT07026266|OTHER|Water|"Calcium-bicarbonate mineral water Lete"
223589072|NCT04676867|OTHER|Placebo|Placebo Tablets
223589073|NCT07087756|PROCEDURE|laparoscopic ovarian suspension|Suspension of the ovary during laparoscopy for endometriosis
223589074|NCT07088952|PROCEDURE|Trigger at smaller folicular size|Trigger indicated at folicular diameter smaller than standard clinical practice, from 13mm to 16.9mm
223589075|NCT07089472|BEHAVIORAL|Dry Needling Therapy|Dry needling will be applied along the lateral femoral cutaneous nerve (LFCN) pathway, targeting muscles such as piriformis, iliacus, tensor fascia latae, vastus lateralis, and sartorius. Sterile solid filiform needles (0.25x30mm and 0.30x50mm) will be inserted for 90 seconds to 2 minutes using a cone technique and retained in situ for 15 minutes. Sessions will occur twice weekly for 8 weeks, with standard physiotherapy (hot pack, EMS, and guided stretches) administered alongside.
223589076|NCT07089472|BEHAVIORAL|Cyriax Technique|"The Cyriax technique involves deep friction massage and mobilization of the lateral femoral cutaneous nerve (LFCN) near the anterior superior iliac spine (ASIS). Using the pinch and roll and deep pressure technique, therapists will apply sustained pressure along the nerve path in 3-5 repetitions per session, holding each for 10-15 seconds. Sessions will occur twice weekly for 8 weeks, alongside standard physiotherapy modalities and exercises."
223589077|NCT07089199|DRUG|neoadjuvant therapy|tislelizumab （200mg，iv, q3w） + Anlotinib （10mg, orally, D1-14, q3w）+nab-paclitaxel（260mg/m2，q3w）3-4cycle
223589078|NCT07089199|PROCEDURE|Surgery|Surgery should be performed 4 to 6 weeks after the last neoadjuvant therapy (at least 4 weeks after the end of anlotinib treatment).
223589079|NCT07089199|DRUG|Adjuvant therapy|Tislelizumab: 200mg, iv, Q3W, 1year at most(including preoperative treatment medication, a total of 17 cycles).
223589080|NCT07088328|DRUG|Pentoxifylline|Intravenous administration for 3 days
223589081|NCT07088328|OTHER|placebo distilled water|Intravenous administration for 3 days
223589082|NCT06087263|DRUG|Regorafenib|Given by PO
223589083|NCT07088094|PROCEDURE|bone-patellar tendon-bone or meniscus allograft transplantation techniques|This clinical study follows an interventional design, focusing on the evaluation of bone-patellar tendon-bone and quasi-anatomical meniscus allograft transplantation techniques。
223589084|NCT07088094|PROCEDURE|Quasi-anatomical meniscus allograft transplantation|Quasi-anatomical meniscus allograft transplantation
223589085|NCT05930145|DEVICE|Double stentriever|Double stentriever technique
223589086|NCT05930145|DEVICE|Single stentriever|Single stentriever technique
223589087|NCT04450628|PROCEDURE|Surgeon unblinded|"The surgeon will be able to augment the surgical intent based on EndoFLIP measurements, such as adding or removing hiatal sutures or repeating the fundoplication. The data will be evaluated to assess if intraoperative calibration influences postoperative symptoms by comparing the two groups.~Surgery will be scheduled and patients will undergo intraoperative impedance planimetry with EndoFLIP obtaining measurements of the cross-sectional area, balloon pressure, minimum diameter, compliance, length of high pressure segment, and distensibility index of the EGJ using an 8cm EndoFLIP balloon. Sequential assessments will be performed to 30ml and 40ml for up to a minute for each volume of distension. An initial baseline measurement will be obtained after establishment of pneumoperitoneum. A second measurement will occur following hiatal dissection and mobilization but prior to crural closure. Two additional measurements will be obtained after hiatal closure and after fundoplication."
223617735|NCT01089686|PROCEDURE|Venoplasty|Venous access is obtained from the groin through the femoral vein. The catheter will be advanced into the veins in the neck and chest. Angiographic images will be taken of the extracranial venous system as well as the azygous vein. These images will be used to confirm CCSVI. Venoplasty is performed by inserting an additional catheter with a balloon at the tip. The balloon will be inflated to open the vessel. Once dilation of the vessel is confirmed, the venous sheath will be removed and manual compression applied to the groin access.
223617736|NCT01089686|PROCEDURE|Sham procedure (non-treatment)|Venous access is obtained from the groin through the femoral vein. The catheter will be advanced into the veins in the neck and chest. Angiographic images will be taken of the extracranial venous system as well as the azygous vein. These images will be used to confirm CCSVI. Since the patient has been randomized to the non-treatment arm of the trial, the procedure will end without venoplasty. After completion of the diagnostic venogram, the venous sheath will be removed and manual compression applied to the groin access.
223617737|NCT02356445|OTHER|Cytotoxic drug|Observe patients versus treatment type
224186014|NCT02895074|PROCEDURE|Conventional phacoemulsification cataract surgery|Phacoemulsification was performed through a temporal 3.2-mm clear corneal incision with the same machine and followed by IOLs implantation.
224186015|NCT02895074|DRUG|Tropicamide|After pupil dilation, 1 drop of tropicamide (0.5%) was applied every 15 minutes for 3 applications
223494247|NCT07026266|OTHER|Water|"Oligomineral water Sorgesana"
223494248|NCT06696781|PROCEDURE|Pacemaker stimulation|We deactivate the pacemaker to establish baseline measurements of NOL, bispectral index (BIS), mean arterial pressure (MAP), and heart rate (HR), recorded every minute for 5 minutes. We then adjust the pacemaker to 90 bpm and 110 bpm in subsequent 5-minute phases to assess the physiological responses. After deactivating the pacemaker to analyze washout effects, we reactivate it at 110 bpm to observe any changes. A temporary disconnection of the NOL monitor for 1 minute tests system reliability, followed by continued monitoring at the same rate for an additional 5 minutes. Each measurement phase averages data from the last 10 seconds each minute to ensure accuracy and reduce artifacts.
223494249|NCT07027488|DRUG|AB821|AB821 will be administered via IV infusion using weight-based dosing. Patients will receive the drug at a dose escalation every two weeks for up to 52 cycles.
223589088|NCT04450628|DEVICE|EndoFLIP 1.0 System EF-100|"The surgeon will be able to augment the surgical intent based on EndoFLIP measurements, such as adding or removing hiatal sutures or repeating the fundoplication. The data will be evaluated to assess if intraoperative calibration influences postoperative symptoms by comparing the two groups.~Surgery will be scheduled and patients will undergo intraoperative impedance planimetry with EndoFLIP obtaining measurements of the cross-sectional area, balloon pressure, minimum diameter, compliance, length of high pressure segment, and distensibility index of the EGJ using an 8cm EndoFLIP balloon. Sequential assessments will be performed to 30ml and 40ml for up to a minute for each volume of distension. An initial baseline measurement will be obtained after establishment of pneumoperitoneum. A second measurement will occur following hiatal dissection and mobilization but prior to crural closure. Two additional measurements will be obtained after hiatal closure and after fundoplication."
223589089|NCT03472664|OTHER|low carbohydrate/high fat diet|Modified Mediterranean-Ketogenic Diet is a low carbohydrate/high fat diet.
223589090|NCT03472664|OTHER|low fat/high carbohydrate diet|American Heart Association Diet is a low fat/high carbohydrate diet.
223589091|NCT06912360|OTHER|CPAP|Continuous Positive Airway Pressure (CPAP) with Boussignac valve
223589092|NCT07089563|BEHAVIORAL|Calisthenics Exercise Program|The exercises were administered twice a week for eight weeks alongside their regular swimming training, with each session lasting approximately 30 minutes. Calisthenics exercise included crunch, reverse crunch, plank, super plank, superman, sumo squat, and squat jump movements.
223589093|NCT07089563|BEHAVIORAL|Life Kinetik Exercise Program|The exercise program was conducted twice a week for eight weeks alongside regular swimming training, with each session lasting approximately 30 minutes. It included various exercises designed to improve hand-eye coordination, balance, reaction time, and motor control, such as throwing, catching, and dribbling balls with both the right and left hands. Exercises involved catching the ball mid-air or after a bounce, tossing tennis balls simultaneously with both hands, and throwing balls against a wall with different catching techniques and hand usages to provide varied challenges.
223494250|NCT06700070|DRUG|PBA-0111|Intratumoral microdose injection by the CIVO device.
223494251|NCT07026331|PROCEDURE|balloon angioplasty|Balloon angioplasty treatment followed by standard medical therapy post-procedure.
223494252|NCT07026331|PROCEDURE|Stent|Patients will receive either balloon-assisted stenting or direct stenting, followed by standard medical therapy after the endovascular treatment.
223494253|NCT07032597|DEVICE|HArmonyCa Lidocaine Injectable Gel|Subdermal or Deep Dermal or Supraperiosteal Injection
223494254|NCT07032597|DEVICE|Restylane® Perlane® Lidocaine|Subcutaneous to Supraperiosteal Implantation Injection
223494255|NCT07033663|DRUG|Monoclonal antibody|non-intervention. Drug used in clinical practice as per practitioner decision
223494256|NCT06711991|DRUG|TQC3927 powder for inhalation|TQC3927 is a targeted inhibitor
223745738|NCT05811546|DIAGNOSTIC_TEST|Immunohistochemical staining for DNMT1 and EZH2|Immunohistochemical staining for DNMT1 and EZH2 using rabbit monoclonal/polycolonal antibodies with immunoperoxidase staining will be used as a visualization method. Antibodies dilutions, antigen retrieval methods, and incubation time will all be conducted according to the manufacturer's instructions.
224186016|NCT02895074|DRUG|Proparacaine hydrochloride|topical anesthesia with proparacaine hydrochloride (0.5%) was applied.
224186017|NCT01229592|DRUG|Ethanol|Every three day lock using Ethanol(70%)in all the lumen(1ml/per lumen) of the Catheter
224308699|NCT00527553|DIETARY_SUPPLEMENT|zeaxanthin|daily zeaxanthin enriched egg
223494257|NCT06711991|DRUG|TQC3927 powder for inhalation placebo|A placebo without drug substance.
223494258|NCT07119164|OTHER|Laughter yoga|Laughter yoga is a mind-body practice that combines unconditional laughter with yogic breathing techniques (known as pranayama). Developed by Dr. Madan Kataria in 1995, the practice is based on the principle that voluntary laughter can provide similar physiological and psychological benefits as spontaneous laughter. It is typically conducted in group sessions involving eye contact, playful behavior, and laughter exercises, which aim to reduce stress, enhance mood, and promote overall well-being.
223494259|NCT07120529|OTHER|CT scan|CT chest, abdominal, pelvis during follow-up
223589094|NCT07088172|PROCEDURE|free gingival grafts during the second stage of implant surgery|Free gingival graft surgery performed simultaneously with implant stage II, followed by upper restoration 6-8 weeks later.
223589095|NCT07088172|PROCEDURE|free gingival grafts prior to the implantaion|Free gingival graft surgery performed 6-8 weeks before implant placement
223589096|NCT07089615|DEVICE|Capsule swallow|Participant will swallow the investigational device
223589097|NCT07087418|DIAGNOSTIC_TEST|Kaplan-Meier analysis with log-rank testing|The non-inferiority of the virtual endoscopy group will be verified by comparing the predictive performance for prognostic indicators (e.g., clinical remission rate, recurrence risk) between the two groups during follow-up.
223589098|NCT07089589|DRUG|Preoperative Statin Use|Administration of any statin medication prior to liver transplantation. Statin therapy was previously prescribed by the treating physician before the transplant procedure, not assigned by the study protocol.
223589099|NCT07088003|BEHAVIORAL|Yoga as Mindful Movement|YMM is an 8-week hybrid (in-person and virtual) school-based mindful yoga program (modified from its original 10-week, in-person design due to complications of COVID-19) informed by the teachings of Radiant Child Yoga. It was designed to teach students about self regulation through the integration of movement, breath, and present-moment awareness. It was delivered in the form of three, 30-minute YMM sessions each week by the same instructor-an individual with training and experience as an occupational therapist and yoga teacher through the Yoga Alliance and Radiant Child Yoga.
223589100|NCT07088003|BEHAVIORAL|Adapted Physical Education|Adapted PE took place daily (Monday-Friday) for one hour and consisted of lessons on movement skills such as catching, throwing, aiming, running, jumping, skating, and dancing through various activities and games.
224186018|NCT01229592|DRUG|Heparine|Every three day lock using Heparin(Fibrilin TM) 3ml in all the lumen of the Catheter
224186019|NCT00219531|BEHAVIORAL|perception of rectal balloon distention|functional Magnetic Resonance Imaging (fMRI) study with measurement of brain MRI response to rectal balloon distention.
224186020|NCT05712343|DRUG|Valacyclovir group|The valacyclovir group will be received, valacyclovir (500 mg, 3 times a day for 3 days)
224308700|NCT00527553|DIETARY_SUPPLEMENT|egg product from enriched eggs|daily egg product from lutein enriched eggs
224308701|NCT03849287|DRUG|CKD-333, formula I|Test drug
223589101|NCT05546671|DIAGNOSTIC_TEST|Hand grip strength measurement|"Preoperative hand grip strength will be measured in kilograms using a digital hand dynamometer (Baseline Smedley Digital Hand Dynamometer, Model 12-0286, Baseline Evaluation Instruments, China). Participants will be instructed to grip the hand dynamometer for 5 seconds with their dominant hand 3 times. They will be allowed to rest for 20 second between each grip. The highest measurement of 3 attempts will be recorded. Participants will be categorized as strong grippers or weak grippers according to Fried criteria as previously defined by Linda P. Fried and colleagues. A weak grip will be defined as follows:~For men:~BMI ≤24: hand grip strength ≤29 kg; BMI =24.1 to 28: hand grip strength ≤30 kg; BMI \>28: hand grip strength ≤32 kg~For women:~BMI ≤23: hand grip strength ≤17 kg; BMI =23.1 to 26: hand grip strength ≤17.3 kg; BMI =26.1 to 29: hand grip strength ≤18 kg; BMI \>29: hand grip strength ≤21 kg"
223745739|NCT05368740|DEVICE|integrated pulmonary index monitor|Integrated Pulmonary Index (IPI) is a new monitoring method calculated using respiratory rate (RR), end-tidal carbon dioxide (EtCO2), peripheral oxygen saturation (SpO2), and heart rate (HR). It is designed to obtain information about the patients' oxygenation and ventilation in the form of a single value or waveform from 1 to 10 with a mathematical algorithm using fuzzy logic. According to this scoring system; 10= normal, 8-9= within normal range, 7= close to normal range, requires attention, 5-6= requires attention and may require intervention, 3-4= requires intervention, 1-2= requires immediate intervention \[2\].
223745740|NCT06214572|DRUG|Systemic therapy (Gemcitabine plus Cisplatin)|"Participants will receive one of the following Gemcitabine-based systemic therapy alone:~Gemcitabine 1000mg/m2 and Cisplatin 25 mg/m2, each administered on Days 1 and 8 every 3 weeks (q3w)~Duration: 3 months (in addition to 3 months previously received)"
223745741|NCT06214572|RADIATION|RT|"Participants will receive radiation therapy in addition to systemic therapy Hypofractionated external image guided radiation to a dose of 40-55Gy in 10 sessions (up to 60Gy in 15 sessions) over 2-3 weeks.~This is followed by systemic therapy as in the Systemic therapy alone arm."
223745742|NCT06214572|DRUG|Systemic therapy (Gemcitabine plus oxaliplatin)|"Gemcitabine 1000 mg/m2 and oxaliplatin 100 mg/m2 IV infusion on days 1 and 8 q2w.~Duration: 3 months"
224073628|NCT03461445|DRUG|IR Tacrolimus|Patients will be randomized to receiving IR Tacrolimus instead of Envarsus
223494260|NCT07120529|PROCEDURE|Ultrasound scan (Transvaginal or Transabdominal)|Transvaginal and transabdominal ultrasound scan during follow-up
223494261|NCT07120529|PROCEDURE|Gynecological examination|Gynecological standard examination during follow-up
223494262|NCT07121010|DIETARY_SUPPLEMENT|Animal-Based Protein Smoothie|This smoothie is formulated to deliver 50% of its total caloric content from high-quality animal-based protein, such as whey protein isolate or pasteurized egg whites. It is designed to evaluate the postprandial metabolic and immune response to animal-derived protein sources. The smoothie does not contain any added free amino acids and is prepared in a food-safe certified kitchen under standardized conditions. All participants consume the smoothie after an overnight fast to ensure consistency in metabolic assessment.
223494263|NCT07121010|DIETARY_SUPPLEMENT|Plant-Based Protein Smoothie|This smoothie is formulated to deliver 50% of its total caloric content from plant-based protein, such as pea or rice protein isolate. It is designed to evaluate the postprandial metabolic and immune response to plant-derived protein sources. The smoothie does not contain any added free amino acids and is prepared in a food-safe certified kitchen under standardized conditions. All participants consume the smoothie after an overnight fast to ensure consistency in metabolic assessment.
223494264|NCT07121010|DIETARY_SUPPLEMENT|Plant-Based Protein Smoothie with Leucine|This smoothie is formulated to deliver 50% of its total caloric content from plant-based protein, using sources such as pea or rice protein isolate. In addition, it is supplemented with pharmaceutical-grade leucine to match the leucine content typically found in animal-based protein sources. The smoothie is designed to assess whether leucine supplementation can modulate the postprandial metabolic and immune response to plant-derived protein. It is prepared in a food-safe certified kitchen and consumed after an overnight fast to maintain consistency across study conditions.
223494265|NCT07120750|DRUG|Intervention for Group 1|Participants will receive standard NAs therapy, which may include entecavir (ETV), tenofovir disoproxil fumarate (TDF), tenofovir alafenamide fumarate (TAF), or tenofovir amibufenamide (TMF). NAs are antiviral medications used to suppress HBV replication and manage chronic hepatitis B infection.
223494266|NCT07120750|DRUG|Intervention for Group 2|Participants will receive Peg-IFNα-2b in addition to NAs therapy. Peg-IFNα-2b is an antiviral medication that works by boosting the immune system and has additional antiviral, antifibrotic, and anti-tumor effects. It is used to treat chronic hepatitis B and may help reduce the recurrence of liver cancer.
223494267|NCT07121062|OTHER|Online parent administered questionnaire|Unsettled Infant Questionaire (UnIQue)
223617738|NCT05884086|OTHER||no intervention is necessary. Clinical observation and clinical examination only.
223617739|NCT03880292|PROCEDURE|Document intraoperative Maneuvers|Monitoring procedure during surgery
223617740|NCT00496015|BIOLOGICAL|Pneumococcal conjugate vaccine GSK1024850A.|1 intramuscular injection.
223617741|NCT00496015|BIOLOGICAL|Infanrix hexa.|1 intramuscular injection.
223617742|NCT00496015|BIOLOGICAL|Meningococcal vaccine GSK134612.|1 intramuscular injection.
224073629|NCT03207672|DRUG|E7389-LF|intravenous infusion
224073630|NCT04761055|OTHER|Clinical Breast exam (CBE)|The standard CBE will be performed by a nurse practitioner (NP) who will record any positive CBE finding.
224073631|NCT04761055|DEVICE|iBreastExam device|The iBE is an FDA 510(k) cleared portable device which utilizes an array of dynamic capacitive pressure sensors to perform electronic palpation for breast abnormalities. The iBE exam will be administered by a mammogram technologist, blinded to CBE results.
223494268|NCT07119346|PROCEDURE|EOI block|EOI block with 0.25% ropivacaine 1 mL/kg (max 40 mL) bilaterally under ultrasound guidance
223494269|NCT07119346|PROCEDURE|sham block|Sham block with equal volume of normal saline bilaterally under ultrasound guidance
224073632|NCT04761055|DIAGNOSTIC_TEST|mammogram|All patients will have routine standard mammographic views performed. Patients with positive iBE and/or CBE findings will have additional mammographic and/or ultrasound imaging to determine if a correlating breast lesion is present using the same standard of care algorithm as is used currently for positive CBE findings.
224075934|NCT06993844|DRUG|ETX-636 dose escalation|ETX-636 is a pan-mutant-selective PI3Kα Inhibitor and degrader in the form of an oral tablet that will be taken once per day in 28-day cycles, to evaluate escalating dose levels.
224186021|NCT05712343|OTHER|Control group|The control group will receive placebo medication, three times a day for 3 days.
224186022|NCT00507312|DEVICE|HD medical device (ViScope)|Device
224186023|NCT00507312|DEVICE|CSIRO device|device
223494270|NCT07120867|DIAGNOSTIC_TEST|Pleural manometry|Pleural manometry will be performed during the first thoracentesis using a water column connected to the pleural drainage system. Pleural pressure will be measured at baseline and at intervals during fluid removal to evaluate lung expandability. The water column manometer allows estimation of pressure changes in real time. Based on the pressure curve and indicators of non-expandable lung (such as early pressure drop, plateauing, or sustained negative pressures), the treatment plan will be adapted. If adequate lung re-expansion is observed, pleurodesis will be considered. If the pressure pattern suggests a non-expandable lung, pleurodesis will be avoided due to the high risk of failure, and a tunneled pleural catheter will be recommended instead.
224186024|NCT01305616|PROCEDURE|Phacoemulsification with yellow-tinted intraocular lens|Phacoemulsification is a kind of cataract surgery using ultrasound machine. Yellow-tinted intraocular lens are a sort of lens with the ability to filter blue and ultraviolet spectrum of light (380-500 nanometer)
224186025|NCT01305616|PROCEDURE|Phacoemulsification with yellow-tinted intraocular lens|Phacoemulsification is a kind of cataract surgery using ultrasound machine. Yellow-tinted intraocular lens are a sort of lens with the ability to filter blue and ultraviolet spectrum of light.
224308702|NCT03849287|DRUG|CKD-333, formula II|Test drug
223494271|NCT07125404|RADIATION|Low-level laser auriculotherapy (LLLT-AT)|Low-Level Laser Auriculotherapy (LLLT-AT) is a non-invasive, painless treatment that applies infrared laser (class IIIb, 905 nm) to specific auricular acupuncture points. It aims to reduce musculoskeletal pain and anxiety by stimulating mitochondrial cytochrome c oxidase, increasing ATP production, promoting tissue repair, and modulating inflammation. LLLT also reduces nerve excitability and triggers β-endorphin release, aiding in pain control. Auricular stimulation may influence autonomic nervous system activity, impacting both physical and emotional symptoms. The intervention consists of two sessions per week over three weeks, following standard laser safety procedures.
223494272|NCT07125404|OTHER|Sham Low-level laser auriculotherapy (sham LLLT-AT)|Sham LLLT-AT replicates the active procedure using the same laser device and parameters, but without light emission. The probe will be deactivated and applied to the same auricular points twice weekly for three weeks. As LLLT is painless and athermal, participants are unlikely to distinguish the sham condition. Standard safety protocols will be maintained.
223494273|NCT07125404|OTHER|Myofascial release|Myofascial release is a manual therapy applied bilaterally to the masseter and temporalis muscles as a baseline intervention. Each session includes 1 minute of ischemic pressure, 1 minute of myofascial release, 30 seconds of positional release, and 30 seconds of general mobilization per muscle. The protocol consists of two sessions per week for three weeks (six sessions total), aiming to reduce muscle tension and improve mandibular function.
223494274|NCT07124039|DRUG|Finerenone (Kerendia, BAY948862)|Retrospective cohort analysis using the EHR data from the Tianjin Healthcare and Medical Big Data Platform (China) database.
223589102|NCT07088809|PROCEDURE|Nanocrystalline hydroxyapatite loaded in PRF+ coronally advanced flap|"Two horizontal incisions were made at right angles to the adjacent interdental papillae at the CEJ level without interfering with the gingival margin of the neighbouring teeth. To mobilize the flap, two oblique vertical releasing incisions were extended beyond the mucogingival junction. A full thick¬ness trapezoidal flap was then elevated up to the mucogingival junction, and follow¬ing penetration of the periosteum, a par¬tial thickness flap was dissected further apically. The papillae mesial and distal to the recession defects were deepithelialized.~Following conditioning, the root surface was rinsed with sterile saline for 1 minute. Following conditioning, the root surface the PRF membrane loaded by nanocrystale hydroxyapatite was positioned to cover the recession up to CEJ. The flap was then coronally advanced to cover the membrane, and flap was closed using simple interrupted sutures. A periodontal dressing was placed over the recipient site for 10 days to protect the wounds."
223617743|NCT00496015|DRUG|Paracetamol.|Body weight of \< 7 kg: none; Body weight of ≥ 7 kg to \< 9 kg : 3 suppositories of 125 mg to be administered at 8h intervals after vaccination. Body weight of ≥ 9 kg: 4 suppositories of 125 mg to be administered at 6h intervals after vaccination.
224186026|NCT05848128|DRUG|5% Tavilermide ophthalmic solution|Twice a day topicial dosing
224308703|NCT03849287|DRUG|CKD-330, D090|Reference Drug
223494275|NCT07125729|PROCEDURE|Biospecimen Collection|Undergo archival tissue and/or blood sample collection
223494276|NCT07125729|OTHER|cfDNA or ctDNA Measurement|Undergo Haystack MRD and Signatera ctDNA/cfDNA testing
223494277|NCT07125729|OTHER|Electronic Health Record Review|Ancillary studies
224186027|NCT05848128|OTHER|Vehicle ophthalmic solution|Twice a day topical dosing
224186028|NCT03737305|DEVICE|TMJ Condilar Distraction Device|The patients will perform condylar distraction with the condylar distraction device in an ambulatory basis.
224186029|NCT03737305|DEVICE|Conventional Physical Therapy|Conventional Physical Therapy, performed in office by a experienced physical therapist for the TMJ condition.
224186030|NCT01212627|DRUG|Ridaforolimus|Ridaforolimus 20 Daily, 5 days each week, (Mon-Fri) on a 28 day cycle
224186031|NCT00277862|DRUG|Pegylated IFN- alpha 2b|
224186032|NCT00277862|DRUG|Ribavirin|
224186033|NCT02291068|BEHAVIORAL|psychotherapy treatment|3 months long (12 sessions) dynamic psychotherapy. The dynamic psychotherapeutic technique which will be applied in the current research is derived from Malan's focused, brief psychodynamic psychotherapy (Malan 1976) and from the literature specifying psychodynamic psychotherapies distinctive techniques (Shedler 2010). The principle of this treatment is a time limited intervention in which the primary objective is to enhance the patient's insights regarding repetitive conflicts. As psychodynamic psychotherapy is suitable for all kinds of adjustment disorders, no special adjustment in the course of therapy was made for the different subtypes (Cabaniss et al. 2011).
224186034|NCT05551182|DRUG|Nicergoline|The participants in both arms will receive nicergoline for treatment dysphagia 12 weeks.
224186035|NCT02896972|PROCEDURE|Vitrectomy|Vitrectomy with inverted ILM technique or ILM peeling
224186036|NCT05376163|OTHER|Survey Study|Headache Disabilty Index (HDI) will be applied.
223494278|NCT06712914|DEVICE|MagPro X100 by MagVenture|Participants will receive 5 session per day of TBS for 6 days (30 sessions total). Six treatment days have to occur within a 2 week period. Each session will be comprised of 1800 pulses, using a MagVenture MagPro X100.
223494279|NCT07036406|BEHAVIORAL|Semantic Feature Analysis (traditional)|This treatment involves naming pictures of objects, describing the objects' features (e.g., category membership, physical attributes, etc.), and creating sentences using the objects' names. It does not include direct metacognitive strategy training.
223494280|NCT07036406|BEHAVIORAL|Semantic Feature Analysis + Metacognitive Strategy Training|This treatment involves metacognitive teaching and practice, naming pictures of objects, describing the objects' features (e.g., category membership, physical attributes, etc), creating sentences using the objects' names, debriefing on overall performance, and discussing recent and future opportunities for strategy implementation in real life.
223617744|NCT00675402|OTHER|supervised treadmill exercise program|Supervised treadmill therapy consists of a walking exercise on a treadmill under supervision of a physiotherapist, 2-3 times a week. This program is combined with individual walking every other day and the total duration of the program is 6 months. Guided by the painfree walking distance, every month the angle and/or speed of the treadmill will increase. A standardized protocol for this type of therapy is already in use by many physiotherapists in Limburg (Willigendael, 2005).
223617745|NCT03004729|OTHER|CoMiSS questionnaire|
223617746|NCT00190437|DRUG|Amoxicillin-clavulanic|Amoxicillin-clavulanic
223617747|NCT04792736|DIAGNOSTIC_TEST|Blood lactate level|Blood lactate level measured at admission H0, every 6 hours during the first 24 h and at H48
224186037|NCT02173158|DRUG|lomitapide|
224186038|NCT00332930|BIOLOGICAL|recombinant fowlpoxvirus (rFPV) expressing HIV gag-pol antigens|
224186039|NCT00332930|BIOLOGICAL|HIV gag-pol antigens and interferon-gamma (IFN-y)|
224186040|NCT01817218|DRUG|Platelet Rich Plasma|
224186041|NCT01817218|DEVICE|Osakidetza protocol|"Patients in the control group will be treated following the recommendations of the Ezkerraldea-Enkarterri Health Region, that is, using a moist healing environment (as described in Uso racional de los productos de cura en ambiente húmedo. Plan de formación continuada de Osakidetza, 2011).~The type of material used to treat and dress the wound will be chosen after the assessment of the wound and surrounding skin, type and quantity of exudate and whether there are signs of infection. Wound care will be carried out every 48-72 hours, as is the current usual practice."
224186042|NCT00989417|OTHER|ACTIVATION of HOME MONITORING|Both patient groups will be followed for 27 months and will have Home Monitoring switched on. The data from the CONTROL group will not be presented online to the attending physician, but a retrospective analysis on differences between the two groups will be performed.
224186043|NCT04035408|OTHER|Skin health assessment|Assess and measure the natural history of facial skin changes in pre and perimenopausal women undergoing chemotherapy and/or endocrine therapy for breast cancer
224186044|NCT02195349|BIOLOGICAL|GSK2831781|GSK2831781 (100 milligram (mg)/mL) and its dilutions (Diluent - 0.9 percent saline solution containing 0.015 percent Polysorbate 80) as clear or opalescent, colourless, yellow to brown liquid solution administered by IV over approximately 2 hours.
224186045|NCT02195349|BIOLOGICAL|Placebo|Commercial saline solution administered by IV over approximately 2 hours
224186046|NCT01953419|DRUG|Pemetrexed disodium|Patients received Pemetrexed disodium 500mg/m2 every 21 days until the presence of progressive disease or unacceptable toxicity.Patients were instructed to take oral folic acid 400 mg daily beginning 5 days before the first therapy and until the final therapy. Patients received vitamin B12 before the first cycle of Pemetrexed and every three cycles of chemotherapy.
224186047|NCT03302260|BEHAVIORAL|CardioPrevent® Program|This is a 1-year, evidence-based behaviour change lifestyle program that consists of 25 contacts (in person, by phone and in groups) with a trained lifestyle counsellor to facilitate desired lifestyle behaviours within the participants' own social context.
224186048|NCT00402662|DRUG|everolimus|
224186049|NCT00402662|DRUG|Imatinib|
224186050|NCT01000233|DIETARY_SUPPLEMENT|Phytine (phytate)|300 mg tid \* 24 months
224186051|NCT01000233|DIETARY_SUPPLEMENT|Placebo|Phytine (Phytate)
224186052|NCT01679756|PROCEDURE|Laparoscopic right hemicolectomy for cancer|After induction of anesthesia, a foley catheter and an NG tube will be inserted. All patients will have their NG tubes removed after the procedure. During the procedure patients will be placed in Trendelenburg position with 15 degrees of tilt and with a right side up (tilt to the left of 25 degrees). A Veres needle will be inserted and pneumoperitoneum induced and maintained at 12 mmHg for the entire duration of the procedure. Under direct vision, three 10-12mm trocars will be inserted in the left abdominal wall. The ileocolic vessels, the right colic vessels (when present), the right branch of the middle colic vessels and the right gastroepiploic vessels will be ligated intracorporeally at their origin using clips. Anastomosis are described in each arm description.
223494281|NCT07123454|DRUG|AZD4512|AZD4512 is an antibody-drug conjugate targeting cluster of differentiation 22 (CD22) that will be administered via IV infusion
223494282|NCT07122375|DIAGNOSTIC_TEST|Angle Specific Torque Profile Analysis|All assessment data will be obtained from the archival records of young healthy adults, and no new assessments will be conducted. Raw data from wrist flexion and extension evaluations performed using an isokinetic dynamometer will be utilized.
223494283|NCT07122440|OTHER|acute mastoiditis|retrospective data collection from clinical charts
223494284|NCT07123636|DIETARY_SUPPLEMENT|Hair Care Products|"Daily oral intake of 2 tablets (Not Today, Grey). Twice-daily application of 3-4 pumps of To The Root serum. Wash and Smooth used according to hair type (daily or every other day)."
223494285|NCT07114575|OTHER|Gait Analysis|All participants will undergo gait analysis at three different walking speeds.
223494286|NCT07122336|PROCEDURE|PVI|PVI
223494287|NCT07122336|PROCEDURE|PWI|PWI
223494288|NCT07122336|PROCEDURE|EGM|EGM
223494289|NCT07124689|OTHER|Treatment outcome|Patients will be evaluated for their central sensitization scores before the injection, the pain they experienced during the injection 1 hour after the injection, their daytime and nighttime pain intensity before and 1 month after the injection, their pain thresholds for tactile sensation around the shoulder, and their pain and disability levels.
224186053|NCT04659356|OTHER|Patients admitted in Intensive Care Units|Data will be collected computerized patient records by the clinicians in charge of the patient.
223494290|NCT07123090|DRUG|Sasanlimab|Recombinant humanized monoclonal antibody, prefilled syringe, subcutaneous (under the skin) injection per protocol
223494291|NCT07123090|DRUG|Palbociclib|Cyclin-dependent kinase (CDK) 4/6 inhibitor, tablet taken orally per protocol
223589103|NCT07088809|PROCEDURE|Nanocrystalline tricalcium phosphate (NcTCP) loaded in PRF+ coronally advanced flap|"Two horizontal incisions were made at right angles to the adjacent interdental papillae at the CEJ level without interfering with the gingival margin of the neighbouring teeth. To mobilize the flap, two oblique vertical releasing incisions were extended beyond the mucogingival junction. A full thick¬ness trapezoidal flap was then elevated up to the mucogingival junction, and follow¬ing penetration of the periosteum, a par¬tial thickness flap was dissected further apically. The papillae mesial and distal to the recession defects were deepithelialized.~Following conditioning, the root surface was rinsed with sterile saline for 1 minute. Following conditioning, the root surface the PRF membrane loaded by Nanocrystalline tricalcium was positioned to cover the recession up to CEJ. The flap was then coronally advanced to cover the membrane, and flap was closed using simple interrupted sutures. A periodontal dressing was placed over the recipient site for 10 days to protect the wounds."
223589104|NCT07089355|DEVICE|Toro 88 Super Bore Aspiration Catheter|The Toro 88 Super Bore Aspiration Catheter is a neurovascular device designed for clot aspiration during mechanical thrombectomy procedures.
223589105|NCT05696574|DRUG|Vaginal Misoprostol|Women in this group will include 40 pregnant women who will be offered misoprostol (placed in the post-fornix of the vagina) in a dose of 25µg to be repeated every 6 hours if no response is achieved with a maximum of 4 doses.
223589106|NCT05696574|DRUG|Oral Misoprostol|Women in this group will include 40 pregnant women who will be offered oral misoprostol in a dose of 25µg to be repeated every 6 hours if no response is achieved with a maximum of 4 doses.
223589107|NCT02907749|DRUG|Spironolactone and carvedilol|Patients are treated with carvedilol in combination with spironolactone.
223589108|NCT02907749|DRUG|Carvedilol|Patients are treated with carvedilol only.
223589109|NCT00336635|BIOLOGICAL|cell-culture derived smallpox vaccine|
223589110|NCT05027984|DEVICE|Optical coherence tomography|OCT images will be acquired by means of the FD C7 XR system or the OPTIS system (both St. Jude Medical, St. Paul, MN, USA) with a non-occlusive technique.(33) The acquired OCT coronary images will be analyzed on-line using a proprietary OCT console (St Jude Medical, Inc., USA). Definitions and cut-offs for OCT vulnerability parameters derived from available consensus documents and from main IVUS/OCT studies.
223589111|NCT05027984|DEVICE|iFR/FFR/RFR|The iFR and FFR measurements will be obtained using a coronary-pressure guidewire (Pressure Wire / Certus or Aeris for FFR assessment and PressureWire™ X Guidewire/QUANTIEM™ for the RFR assessment by Abbott Vascular, Abbott Park, Illinois, U.S.A; Comet by Boston Scientific, Marlborough, MA, USA), OptoWire by Opsens, Quebec, Canada, or Verrata by Philips, San Diego, CA, USA.).
223589112|NCT02643732|DRUG|Methylphenidate (overencapsulated)|10mg (1 capsule) methylphenidate (standard release) twice daily, increased to 20mg (2 capsules) twice daily after 2 weeks. The drug can be down-titrated in the event of side effects, although re-uptitration is not allowed even if the side effects resolve on the lower dose.
223589113|NCT02643732|DRUG|Placebo (Over-encapsulated tablet)|Identical capsules (over-encapsulated placebo tablets), administered initially one capsule twice daily, increased to 2 capsules after 2 weeks. As with the methylphenidate arm, the dose can be down-titrated in the event of side effects, although re-uptitration is not allowed even if the side effects resolve on the lower dose.
223589114|NCT07088055|DEVICE|Chewing device only|This group will be administered the Myo Munchee and be given a protocol to follow over the 26-week study period. They will also have the clinical and questionnaire measurements taken at the beginning, week 10 and week 26 of the study.
223617748|NCT00043719|DRUG|Nitroglycerin ointment|
224186054|NCT01728454|DRUG|Placebo|Placebo matching capsules, orally, once daily for 18 weeks.
224186055|NCT01728454|DRUG|Telapristone acetate|Telapristone acetate capsules, orally once daily for 18 weeks.
224186056|NCT04619043|DEVICE|Ankle Orthotic|
224186057|NCT01190839|BIOLOGICAL|Infliximab|Type=equal, unit=mg, number=5, form=intravenous infusion, route=intravenous use, once every 8 weeks
224186058|NCT01190839|DRUG|Placebo|Type=equal, unit=mg, number=5, form=intravenous infusion, route=intravenous use, once every 8 weeks
223494292|NCT07123090|DRUG|Axitinib|Vascular endothelial growth factor (VEGF) inhibitor, tablet taken orally per standard of care
223494293|NCT07122063|DRUG|SYS6045|SYS6045, IV Q3W
223494294|NCT07123038|OTHER|Long Term Safety Monitoring Procedures|In accordance with the schedule of assessments, participants will complete the long term safety and health questionnaire and will undergo routine physical examinations. A review will be conducted on selected adverse events, medical history, and concomitant medication use. Collection of biospecimens (blood and tissue) will be taken as appropriate at scheduled visits to monitor for delayed adverse events related to prior cell therapy.
223494295|NCT07122050|DEVICE|Prizvalve® system Transcatheter valve-in-valve replacement|Transcatheter valve-in-valve replacement procedure was performed according to standard clinical practice. Successful vascular access, delivery and deployment of the device and successful retrieval of the delivery system will be attempted.
223617749|NCT00043719|DRUG|Calcium supplement with vitamin D|
223617750|NCT00527735|DRUG|Ipilimumab|Ipilimumab, 10 mg/kg, administered as a single-dose, intravenously (IV), over 90 minutes depending on randomization every 3 weeks (up to 6 doses). Participants could receive additional maintenance ipilimumab at a dose of 10 mg/kg every 12 weeks starting 24 weeks after the first ipilimumab dose.
223617751|NCT00527735|DRUG|Placebo|Matched placebo for ipilimumab administered as a single dose IV over 90 minutes every 3 weeks (up to 6 doses) as part of induction. Participants could also receive additional maintenance placebo administered IV over 90 minutes every 12 weeks starting 24 weeks after the first placebo dose.
223617752|NCT00527735|DRUG|Paclitaxel|175 mg/m\^2, administered as a single IV dose over 3 hours every 3 weeks (up to 6 doses). Dose modifications (reductions as well as delays) done as per product label.
223617753|NCT00527735|DRUG|Carboplatin|Area under the concentration curve (AUC)=6, administered as a single IV dose over 30 minutes every 3 weeks (up to 6 doses) as per randomization. Dose modifications (reductions as well as delays) done as per product label.
223494296|NCT07122115|BEHAVIORAL|Mindfulness-Based Childbirth and Parenting Education|"The intervention was an 8-week mindfulness-based childbirth and parenting education program specifically adapted for pregnant women experiencing prenatal distress. The program included weekly 120-minute online sessions combining formal mindfulness practices (such as mindful breathing, body scan, and sitting meditation), informal exercises (e.g., mindful eating, mindful walking), psychoeducation, group sharing, and guided reflections.~Participants were also asked to complete daily home practice assignments using audio recordings. The content was adapted from the Mindfulness-Based Childbirth and Parenting (MBCP) curriculum and integrated with prenatal education. The intervention was delivered by a trained instructor and tailored to meet the emotional and cognitive needs of expectant mothers."
223494297|NCT07124481|BEHAVIORAL|Mindfulness based stress reduction|8 weekly sessions of 2.5 hour per session, face-to-face in a group consisting of maximum 15 participants, supervised by a certified mindfulness trainer
223494298|NCT07125716|DEVICE|1 inch|1 inch suture length
223494299|NCT07125716|DEVICE|0.5 inch|0.5 inch suture length
223494300|NCT06876909|DIETARY_SUPPLEMENT|barley green|Oral administration: 30 minutes before meals Dosage: 4 g powder, 5 g tablet Frequency: 2 times a day
223494301|NCT06704022|DIETARY_SUPPLEMENT|Oral nutritional supplement|Consumption of the oral nutritional supplement
223494302|NCT06877962|BEHAVIORAL|Home-based Tele Exercise|The participants in the study group will be given an online personalized exercise program at home in hemodialysis (HD) days. Synchronous tele-exercise will be delivered using the free teleconference application (app) (Google Meets software). The groups of tele-exercises will be private, and the professional will send the link for each training session and will control the access of the participants.
223589115|NCT07088055|DEVICE|Myo Munchee and Oral Motor Therapy Treatment|This group will be administered an Oral Motoro Therapy program as well as a Myo Munchee protocol to follow over the 26-week study period. They will also have the clinical and questionnaire measurements taken at the beginning, week 10 and week 26 of the study.
223589116|NCT07088055|OTHER|Oral Motor Therapy Treatment Arm|This group will be administered an Oral Motor Therapy program to follow over the 26-week study period. They will also have the clinical and questionnaire measurements taken at the beginning, week 10 and week 26 of the study.
223494303|NCT07031687|DEVICE|Active TIBS|Participants receive active TIBS targeted at the bilateral hippocampus. Stimulation parameters include a 5 Hz (Theta band) low-frequency modulation envelope, generated by two high-frequency current pairs (e.g., f1=2000 Hz, f2=2005 Hz). Peak-to-peak current intensity for each pair will be 2 mA (or 1 mA per electrode). Stimulation is delivered daily for 40 minutes, 6 days/week, for a total of 2 weeks. Individualized targeting and initial intensity optimization are guided by baseline sMRI and DTI. Real-time high-density EEG monitoring during each daily session (D2-D11) provides feedback on brain activity
223494304|NCT07031687|DEVICE|Sham TIBS|Participants receive sham stimulation designed to mimic the sensation of active TIBS without therapeutic output. This involves using a sham coil or a device mode with extremely low current intensity (e.g., 0.1-0.2 mA) or brief ramp-up/ramp-down sensations at the beginning and end of sessions, with no effective current delivery during the main stimulation period. The stimulation position and apparent parameters are identical to the active TIBS group to maintain blinding.
223494305|NCT06712355|DRUG|BNT327|Solution for intravenous infusion
223494306|NCT06712355|DRUG|Atezolizumab|Concentrate for solution for intravenous infusion
223494307|NCT06712355|DRUG|Etoposide|Solution for infusion
223494308|NCT06712355|DRUG|Carboplatin|Solution for infusion
223494309|NCT07042022|DEVICE|Development of digital defocus vision training (DDVT)|During a six-month follow-up period, participants received 10 minutes of DDVT twice a day (once in the morning, and the other in the afternoon) using a head-mounted VR display. In daily life during non-training sessions, participants were required to wear frame glasses with complete correction.
223494310|NCT06702462|DRUG|HFA-152A propellant|HFA-152A propellant is administered via oral inhalation
223494311|NCT06702462|DRUG|HFA-134A propellant|HFA-134A propellant is administered via oral inhalation
223494312|NCT06883175|DIAGNOSTIC_TEST|FLIP|Functional Lumen Impedance Planimetry
223494313|NCT06883175|DIAGNOSTIC_TEST|HRM|HIgh Resolution Manometry
223494314|NCT06883175|OTHER|Prucalopride|Medication
223494315|NCT06714526|GENETIC|Point-of-Care CYP2C19 Testing|Genetic testing with the Genomadix cube to determine P2Y12 inhibitor
223494316|NCT06714526|DRUG|ticagrelor + aspirin|If patients are poor or intermediate metabolizers of clopidogrel, they will receive ticagrelor (90 mg PO BID) + aspirin (81 mg PO daily)
223494317|NCT06714526|DRUG|clopidogrel + aspirin|Normal, rapid, and ultra-rapid metabolizers of clopidogrel will receive 75 mg PO daily of clopidogrel and 81 mg PO daily of aspirin.
223494318|NCT06550882|DRUG|OBIZUR|OBIZUR injection.
223589117|NCT02182271|DRUG|BI 201335 ZW - single rising dose|
223589118|NCT02182271|DRUG|Placebo|
223589119|NCT06187168|PROCEDURE|exposure to hypotension during the Endoscopic Retrograde Cholangiopancreatography (ERCP) for obstructive jundice.|This is not an intended intervention in the study. This cohort study will study the exposure to intraoperative hypotension and the occurrence of sepsis after the ERCP procedures.
223589120|NCT04262713|OTHER|Radiographs|Radiographs of the implanted hip with Meije duo size1 or 2 are performed in eligible patients ( Weigh\>60, Long neck stem, Varus; DEVANE score ≥ 4)
223589121|NCT04334213|DRUG|CKD-501|QD, PO
223589122|NCT04334213|DRUG|D745, D150|QD, PO
223589123|NCT04334213|DRUG|CKD-501, D745, D150|QD, PO
223589124|NCT00964847|BEHAVIORAL|Yoga exercise program|Subjects in the yoga exercise program participate in structured bi-weekly 1.5 hour yoga classes held at a yoga studio as well as develop a weekly hour-long home practice over the 6 months of the study.
223589125|NCT00964847|BEHAVIORAL|Blood pressure education/walking program|The program will consist of small group health education classes and a walking program. Subjects will be expected to attend a dietician-led nutrition class twice a month. On alternate weeks the subjects will be given either motivational talks about a variety of topics including weight loss, walking programs, and healthy lifestyle choices or they will be given educational DVDs or literature to read on the weeks that they are not attending a BPEP class. These subjects will all receive 12 nutrition classes and 12 motivational experiences. The subjects will also be expected to walk 6 days a week gradually increasing to 180 minutes of walking per week or 10,000 steps per day.
223589126|NCT02326766|DIETARY_SUPPLEMENT|KRG|5g Korea red ginseng (KRG)
223494319|NCT06886204|BEHAVIORAL|YEAH: Youth Empowered Advocating for Health|"The Youth Empowered Advocating for Health (YEAH) program is a Youth Participatory Action Research (YPAR) intervention aimed at addressing community violence by fostering youth and community healing. It combines photovoice and theater arts performances.~In photovoice sessions, Black youth explore structural determinants of community violence through a participatory research process. Guided by trained facilitators, youth learn the method after obtaining parental consent and youth assent. Using the structured SHOWED framework, they analyze and discuss images, generating ideas for social action. During the photovoice sessions, photo assignments will be completed, with discussions recorded, analyzed for themes, and shared for validation.~The final four sessions will integrate these themes into theater arts performances, allowing youth to creatively express insights and experiences, fostering empowerment and social change."
223494320|NCT05420207|OTHER|No intervention|No intervention included
223494321|NCT07044674|DEVICE|UNITY Vitreoretinal Cataract System|UNITY VCS is a commercially approved surgical system that facilitates the management of fluid and gases, as well as removal, grasping, cutting, illumination, and coagulation of ocular materials during eye surgery. It consists of a console, remote control, foot controller, video overlay, and compatible anterior segment devices. In this study, it will be used for the removal of cataracts.
223494322|NCT07044674|DEVICE|CENTURION Vision System with Active Sentry|CAS is a commercially approved surgical system for use during anterior segment ophthalmic surgery. It consists of a console, foot controller, remote control, video overlay, and compatible anterior segment devices. The Active Sentry handpiece will be used.
223494323|NCT07044674|PROCEDURE|Anterior segment ophthalmic surgery|Cataract surgery during which the crystalline lens (often cloudy) is broken into small pieces and gently removed from the eye with suction (phacoemulsification)
223494324|NCT07045493|DRUG|A single dose of Albendazole 400mg + Ivermectin (200 µg/ kg) combination therapy|Children will receive the medication after being randomly assigned to either treatment arm. Albendazole will be administered as a syrup and ivermectin tablets as powdered tablets because ivermectin suspension is not available in Bangladesh. The commercially available 6 mg unscored Ivermectin tablets will be crushed, the tablet fragments ground into a powder, and stored in an airtight plastic container in a dry, cool environment after all aseptic procedures. According to the weight of the children, the investigators will provide the needed amount (weighted by microgram scale) of the drug mixed with 5 ml of water. The study field staff will help the parents to give the medicine to the child by the direct observation therapy (DOT) method. The parents will be advised to bring the children on an empty stomach in the morning. Ivermectin will be given first, and a light snack will be provided 30 minutes after taking ivermectin. Then albendazole will be given to the children.
223494325|NCT07045493|DRUG|A single dose of 400 mg Oral Albendazole monotherapy|Albendazole will be given in syrup form. The study field staff will help the parents to give the medicine to the child by the direct observation therapy (DOT) method. The parents will be advised to bring the children on an empty stomach in the morning. Ivermectin will be given first, and a light snack will be provided 30 minutes after taking ivermectin. Then albendazole will be given to the children. Both drugs will be given using direct observation at the field clinic. Parents will be advised to report any adverse effects, including vomiting, after taking the medication. If vomiting occurs within one hour of medication, a redosing will be provided.
223494326|NCT06723457|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
223494327|NCT06723457|PROCEDURE|Computed Tomography|Undergo PET/CT
223494328|NCT06723457|BIOLOGICAL|Epcoritamab|Given SC
223494329|NCT06723457|DRUG|Lenalidomide|Given PO
223494330|NCT06723457|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223494331|NCT06723457|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
223494332|NCT07043478|OTHER|Bragg ACV Liquid|Apple Cider Vinegar
223494333|NCT07043478|OTHER|Placebo|Water
223494334|NCT06717477|PROCEDURE|Changes to the care pathway for carpal tunnel syndrome (The Carpal Tunnel Plus Pathway)|Changes to the care pathway for carpal tunnel syndrome. Features of the CTS+ pathway include new referral form, care map for mild, moderate and severe CTS established, point or care ultrasound with steroid injection introduced, and expedited referral to surgeons.
223494335|NCT03496129|BEHAVIORAL|Personalized feedback|Following the baseline assessment, participants will be sent a link via text message to a secure website containing substance-impaired driving specific personalized feedback. Feedback will include the following elements: a personalized substance use profile and substance-impaired driving profile, information on social norms related to substance use and substance-impaired driving, personalized information on BAC (or level of impairment due to drug use) prior to driving, costs associated with a DUI citation in Kentucky, and information on combined drug and alcohol impaired driving risk (if endorsed).
223494336|NCT03496129|BEHAVIORAL|Personalized feedback and text messages|"Experimental: Personalized feedback and text messages~Following the baseline assessment, participants will be sent a link via text message to a secure website containing substance-impaired driving specific personalized feedback (described above). Participants will be asked to send a text message back to the study administrator after viewing the feedback document. After confirming receipt and processing of the document, the study administrator will then send the participant three text messages containing open-ended questions."
223494337|NCT03496129|BEHAVIORAL|Information Only|"Active Comparator: Information Only~Students randomized to the information condition will receive standard information about alcohol and other drugs and substance-impaired driving via a link to a website delivered through text message."
223589127|NCT02326766|DIETARY_SUPPLEMENT|Placebo|5g placebo
223589128|NCT00004751|PROCEDURE|Surgery|
223589129|NCT00004751|PROCEDURE|Physical therapy|
223589130|NCT02073851|DEVICE|TriGuard™HDH|TriGuard™HDH Embolic Deflection Device in patients undergoing Transcatheter Aortic Valve Replacement (TAVR)
223589131|NCT01498016|DRUG|Busulfan|Iv busulfan 1.6mg/kg q12h D1- D4
223589132|NCT02603848|DRUG|Ibuprofen|(10mg/kg; maximum 600 mg) every six hours as needed
223589133|NCT02603848|DRUG|Morphine|0.2 mg/ kg morphine suspension (maximum 10mg) every four hours as needed
223589134|NCT05504551|PROCEDURE|ultrasound guided superficial cervical plexus block|SCP block is given using high frequency linear ultrasound probe connected to an ultrasound machine to visualize SCP posterior to the midpoint of SCM muscle. Once SCP is identified, a combination of 5 ml bupivacaine (0.5%) and 5 ml lidocaine (2%) are injected after negative aspiration followed by injection of 1 ml to confirm the area, using a 22 gauge B-bevel needle Echogenic Needle.
224186059|NCT03338608|PROCEDURE|Anterior Cervical Decompression and Fusion|Patients will receive the anterior cervical decompression and fusion as part of their standard of care. They will be randomized to either receive the vertical or transverse platysma incision.
224186060|NCT03338608|PROCEDURE|Vertical Platysma Incision|A vertical platysma Incision will be used for the anterior cervical decompression and fusion surgical procedure
224186061|NCT03338608|PROCEDURE|Transverse Platysma Incision|A transverse platysma incision will be used for the anterior cervical decompression and fusion surgical procedure
224186062|NCT03266159|DRUG|GSK525762 Besylate tablets|GSK525762 Besylate film coated tablets will be available as a 20 mg tablet strength, yellowish pink in color, round and biconvex with no markings. It will be administered with 240mL of liquid.
224186063|NCT03266159|DRUG|Trametinib tablets|"Trametinib film coated tablets will be available as 0.5 mg and 2 mg dose strengths. Trametinib 0.5 mg will be yellow colored, modified oval, biconvex, tablets with 'GS' debossed on one face and 'TFC' on the opposing face.~Trametinib 2 mg will be pink colored, round, biconvex tablets with 'GS' debossed on one face and 'HMJ' on the opposing face. Doses will be taken at least 1 hour before or at least 2 hours after a meal."
223494338|NCT03084757|DIAGNOSTIC_TEST|research of druggable molecular alterations on tumor biopsy|The study will run in 2 steps. Before starting a new treatment, patients with advanced cancer will undergo a tumor biopsy of a metastatic site in order to perform molecular analyses seeking for druggable molecular alterations
223494339|NCT06729463|DRUG|Humira|Assess the pharmacogenetic association between IKBKB gene polymorphism (SNPs) in psoriatic patients taking systemic biologic therapy
223494340|NCT07044440|OTHER|digital outpatient follow-up|In addition to routine outpatient follow-up visits on day 14 and 28 post-operative, digital follow-up by questionnaire on their health status and general well-being are provided. Possibility to request an interaction with a doctor from our department at any time during the 28 days following discharge
223494341|NCT07044440|OTHER|standard follow-up|routine outpatient follow-up visits on day 14 and 28 post-operative
223494342|NCT07049341|DEVICE|MemorEM|The MemorEM device delivers 915MHz electromagnetic waves to the head via 8 emitters in a cap worn on the head and powered by a control box and battery worn on the arm.
223494343|NCT02790515|DRUG|Anti-thymocyte globulin (rabbit)|Given intravenous (IV) prior to transplant on Days -14, -13, -12.
223494344|NCT02790515|DRUG|Blinatumomab|Given by continuous IV infusion at least 2 weeks post-engraftment. Blinatumomab will be given only to patients with CD19+ malignancies.
223494345|NCT02790515|DRUG|Cyclophosphamide|Given by IV infusion prior to transplant on Day -9.
223494346|NCT02790515|DRUG|Fludarabine|Given IV prior to transplant on Days -8, -7, -6, -5, and -4.
223494347|NCT02790515|DRUG|G-CSF|Given IV or subcutaneous (SQ) following transplant on Days 6 and 7.
223589135|NCT03696901|DRUG|Xydalba|Information will be recorded about Xydalba administration (e.g. dose(s), number of infusions, length of infusions, dates or schedule of administration, sites of administration \[e.g. hospital, ICU\]), and reason for discontinuation, including response to treatment to assess whether the patient was clinically improving when Xydalba was discontinued
224186064|NCT02427412|DRUG|Tranexamic Acid|An anti-fibrinolytic drug injected into the knee joint at the end of surgery, 3 g diluted in 30 ml saline water.
224186065|NCT02427412|DRUG|Saline water|30 ml of Saline water injected into the knee capsula at the end of surgery.
224186066|NCT02427412|DRUG|Tranexamic Acid|An anti-fibrinolytic drug injected intravenous at the beginning of surgery for BOTH groups.
223494348|NCT02790515|DRUG|Melphalan|Given IV prior to transplant on Days -2 and -1.
223494349|NCT02790515|DRUG|Mesna|Given IV prior to cyclophosphamide administration and at approximately 3, 6, and 9 hours after cyclophosphamide infusion.
223589136|NCT05676216|DRUG|Diphenhydramine|Diphenhydramine 30 mg in 100 mL normal saline intravenous dripping when vertigo patients visit Emergency Department
223589137|NCT05676216|DRUG|Sodium Bicarbonate|Sodium bicarbonate 66.4 mEq in 100 mL normal saline intravenous dripping when vertigo patients visit Emergency Department
223589138|NCT05676216|DRUG|Diphenhydramine + Sodium Bicarbonate|Diphenhydramine 30 mg in 100 mL normal saline intravenous dripping with Sodium bicarbonate 66.4 mEq intravenous push when vertigo patients visit Emergency Department
223589139|NCT02387294|BIOLOGICAL|Vaccination with Fluval AB Novo suspension for injection, half dose of a single intramuscular dose (0.25 ml)|vaccination
223589140|NCT02387294|BIOLOGICAL|Vaccination with Fluval AB Novo suspension for injection, single intramuscular dose (0.5 ml)|vaccination
223589141|NCT01447303|OTHER|Subject outcomes following viscosupplementation of the knee|The study subject outcomes (WOMAC, VAS, SF-36, Chair rise, Stair climb, Six minute walk and Gait analysis) measured at 1, 3, 6 and 12 months following viscosupplementation of the knee
224186067|NCT05707104|OTHER|Pilates Exercises|"NO. Exercises Targeted muscles Repetitions~1. Pelvic curl Abdominals, Hamstrings \& Quadriceps Femoris, Gluteus Maximums. 05~2. Chest lift Rectus Abdominus, Internal \& External Oblique Muscles 10~3. Leg lift supine Quadriceps Femoris, Internal \& External Oblique Muscles 10~4. Leg lift side Quadriceps Femoris, Posterior Spinal Group, Internal \& External Oblique Muscle 10~5. Leg full side Adductor Longus Brevis, Magnus , gracilis, Pectineus, muscles 10~6. Spine twist supine Abdominals,Quadriceps \& Hamstring group of Muscles 10~7. Chest lift with rotation Internal \& External Oblique, Rectus \& Transverses Abdominus Muscles 5 on each side~8. Back extension BACK EXTENSION Abdominal group, Gluteus Maximus \& Hamstrings Muscle 5 each side Rest between exercises 20 seconds Rest between set of exercises 45 to 60 seconds"
223494350|NCT02790515|DRUG|Rituximab|Given IV prior to transplant on Day -1.
223494351|NCT02790515|DRUG|Tacrolimus|Given oral (PO) or IV beginning prior to transplant on Day -2. The dose will begin to taper at approximately day +60 after transplant in the absence of GVHD. Tacrolimus was used for the first 5 participants enrolled on study. Subsequent participants receive sirolimus.
223494352|NCT02790515|DRUG|Thiotepa|Given IV prior to transplant on Day -3.
223589142|NCT00071448|DRUG|insulin human|
223589143|NCT00071448|DRUG|insulin lispro|
223589144|NCT00071448|DRUG|insulin aspart|
223617754|NCT02916966|OTHER|Patient Registry|Patient Registry
223589145|NCT02551419|DIETARY_SUPPLEMENT|ketogenic drink|6 months' supplementation with the ketogenic drink . Product will be taken daily - 125 ml will be consumed at the morning meal, and 125 ml at the evening meal.
224186068|NCT05707104|OTHER|plyometrics exercises|"1. SIDE TO SIDE ANKLE HOPS STANDING JUMP AND REACH FRONT CONE HOPS 2×15 2×15 5×6~2. SIDE TO SIDE ANKLE HOPS STANDING JUMP LATERAL JUMP BARRIER 2×15 5×6 2×15~3. DOUBLE LEG HOPS LATERAL CONE HOPS 5×8 2×12~4. DIAGONAL CONE HOPS LATERAL SPRINT 4×8 4×8~5. LATERAL CONE HOPS SINGLE LEG BOUNDING LATERAL JUMP SINGLE LEG 4×12 4×7 4×7~6. DIAGONAL CONE HOPS HEXAGONAL DRILL CONE HOPS WITH CHANGE OF DIRECTION SPRINT DOUBLE LEG HOPS LATERAL JUMP SINGLE LEG 2×12 2×12 4×6 3×8 4×6"
224186069|NCT03759002|DIAGNOSTIC_TEST|Imaging|Imaging including Echocardiography for determining cardiac indices (ejection fraction, left ventricular mass index, strain rate, global longitudinal strain) and Doppler ultrasound for measuring carotid intima media thickness
223494353|NCT02790515|BIOLOGICAL|HPC,A Infusion|Hematopoietic Progenitor Cell, Apheresis (HPC,A) infusion of TCRɑβ+ depleted cells on day of transplant (Day 0) and HPC,A infusion of CD45RA+ depleted cells on Day +1 following transplant.
223494354|NCT02790515|DEVICE|CliniMACS|The mechanism of action of the CliniMACS Cell Selection System is based on magnetic-activated cell sorting (MACS). The CliniMACS device is a powerful tool for the isolation of many cell types from heterogeneous cell mixtures, (e.g. apheresis products). These can then be separated in a magnetic field using an immunomagnetic label specific for the cell type of interest, such as CD3+ human T cells.
223494355|NCT02790515|DRUG|Sirolimus|Given orally (PO) starting Day 0. The dose will be tapered off over two weeks starting on Day +42 in the absence of GVHD.
223494356|NCT07044414|DEVICE|Manual Acupuncture|Manual acupuncture is administered at bilateral ST36 Zusanli, SP6 Sanyinjiao, and midline points CV4 Guanyuan and CV6 Qihai using sterile, single-use 0.25 × 25 mm acupuncture needles. The insertion depth follows standard clinical practice and safety guidelines, with twirling stimulation performed at minutes 0 and 10. Each session lasts approximately 20 minutes and is conducted three times per week for a total of 21 sessions. Participants continue to receive their standard chemoradiotherapy for head and neck cancer.
223494357|NCT07044414|DEVICE|Sham Manual Acupuncture|Sham Manual acupuncture uses Park sham needles with telescopic tips that do not penetrate the skin, applied at the same acupoints (ST36, SP6, CV4, CV6) with identical procedure and appearance to mimic real acupuncture. Adhesive bases are used to fix the sham needles. Stimulation is mimicked at minutes 0 and 10. Sessions last the same duration and frequency as the intervention group. Participants also continue their standard chemoradiotherapy.
223494358|NCT07047638|DEVICE|Restylane Skinboosters Vital Lidocaine|Restylane Skinboosters Vital Lidocaine is an injectable, sterile, transparent, biodegradable gel of non-animal crosslinked sodium hyaluronate. Restylane Skinboosters Vital Lidocaine has the addition of lidocaine hydrochloride. They are supplied in a glass syringe.
223494359|NCT06740487|BEHAVIORAL|Traditional Exposure Therapy (ET) Treatment|Traditional exposure therapy (ET) includes the following components: (a) psychological education about trauma (sessions 1 and 2), (b) repeated in vivo exposure to trauma-related stimuli (in vivo exercises are assigned as homework during sessions 3 through 9), (c) repeated, prolonged, imaginal exposure to traumatic memories (imaginal exposure is implemented during sessions 3 - 9; patients listen to session audiotapes for homework between sessions), and (d) relapse prevention strategies and further treatment planning (session 10).
223494360|NCT06740487|BEHAVIORAL|Traditional Exposure Therapy (ET) Treatment with addition of Augmented Reality (AR) Component|Traditional exposure therapy (ET) with addition of Augmented Reality component includes the following: (a) psychological education about trauma (sessions 1 and 2), (b) repeated in vivo exposure to trauma-related stimuli (in vivo exercises are assigned as homework during sessions 3 through 9), (c) repeated, prolonged, imaginal exposure to traumatic memories (imaginal exposure is implemented during sessions 3 - 9; patients listen to session audiotapes for homework between sessions), (d) relapse prevention strategies and further treatment planning (session 10), and (e) 30 minutes of each 90 minute session dedicated to augmented reality exposure therapy (ARET). During ARET, the clinician guides participant, who is wearing augmented reality (AR) goggles, through preset scenarios during which characters mingle with each other (e.g., grocery store, social gathering), as well as custom scenarios where participant can interact with the character.
223494361|NCT06739447|OTHER|Consumer Wearable Device Vital Sign Measurement|Consumer Wearable Devices such as the Fitbit, are durable devices that can provide vital sign data.
223511733|NCT04157582|OTHER|Pilates training|"1. Pilates warm-up training (5 minutes) consisted of Breathing, the Chest stretch, the Toy soldier, Upper extremity PNF patterns, and Roll down.~2. Pilates mat training performed in 5 different positions (30 minutes).~   1. One leg stretch, Hundreds, the Double leg stretch, Scissors, the Shoulder bridge, Oblique preparation, and the Hip twist were performed in the supine position(Fig.7).~  2. Clare, the Side kick, Arm openings, the Lower lift, Leg lifts, and the Side bend were performed in the side-lying position.~  3. Swan dive, the One leg kick, Swimming, the Breast stroke preparations, the Breast stroke performed in the prone position(Fig.8).~  4. Half roll back, Oblique roll up were performed in the sitting position.~  5. Swimming was performed in the kneeling position.~3. The Pilates cool down training (5 minutes) were the Spine stretch, Saw, Chest stretch, Toy soldier. (Cruz et al .,2011)"
223589146|NCT02551419|DIETARY_SUPPLEMENT|placebo|6 months' supplementation with the placebo drink . Product will be taken daily - 125 ml will be consumed at the morning meal, and 125 ml at the
223589147|NCT05204433|OTHER|no intervention|no intervention
223589148|NCT00313859|DRUG|simvastatin|
223589149|NCT01970059|DRUG|Extended-Release Carvedilol Sulfate|
223589150|NCT01970059|DRUG|Sustained-release Metoprolol Succinate|
223617755|NCT04759235|DIAGNOSTIC_TEST|Magnetic resonance imaging (MRI)|Anatomical (T2W) and functional MRI (DWI) at a 3.0T Siemens or Philips scanner Three MRI scan series (before, during, after nCRT) Measurements: change in apparent diffusion coefficient (ADC)
223617756|NCT04759235|DIAGNOSTIC_TEST|18F-Fluorodeoxyglucose (FDG)-positron emission tomography/computed tomography (PET/CT)|PET-CT scan at diagnosis and 4-6 weeks after nCRT before operation Measurements: change in TLG (Total Lesion Glycolysis), SUVmax (Standardized Uptake Value)，MTV（Metabolic tumor volume）
223617757|NCT04759235|DIAGNOSTIC_TEST|Blood and urine metabolic biomarker|Blood and urine specimens are collected before radiotherapy, the third week of radiotherapy, and at the end of radiotherapy.
224186070|NCT03759002|OTHER|Blood sampling|Blood sampling will performed on all participants for measuring hematological parameters including MPV.
224186071|NCT00702637|DRUG|Modafinil|
224186072|NCT03853915|DIAGNOSTIC_TEST|[18-F]- FDG - PET|\[F-18\]-FDG Injection is an intravenous diagnostic radiopharmaceutical used for Positron Emission Tomography. While this is not the subject of investigation in this study, \[F-18\]-FDG will be used in the PET imaging assessment of study participants during their 3 month follow-up post-treatment.
223494362|NCT05666245|BEHAVIORAL|Personal Protective Equipment (PPE) - Under High Air Hygiene|"Intervention Recipients (IRs) will be required to wear a lightweight plastic face shield, comply with hand hygiene (i.e., using a hand sanitization product every 15 minutes, plus periodic hand washing with soap and water), and avoid face touching during each planned exposure event. The face shield may only be removed after leaving the exposure room to go to the bathroom, for other short comfort breaks, and at mealtimes. In these instances, hand hygiene will be used after removing or replacing the face shield; and Donors will not be present. Hand washing with soap and water will be required before meals. IR will be separated from Donors by more than 6 feet during meals. The exposure room will be supervised by a trained member of the study staff who will monitor to ensure that Intervention Recipients wear the face shield continuously, are separated from Donors at meals, and do not touch their faces.~High air hygiene is achieved by filtration and/or use of germicidal UV-C."
224308704|NCT02419144|BEHAVIORAL|AMI and campaigns|The intervention we are proposing is a tailored bi-level intervention with two components, an individual level component (component A) with tailored messages based on performance on clinical assessment results, ADLs and cognitive domains in the survey delivered through adapted motivational interviewing with practice to mastery (AMI-PM); , and a building level campaign (component B) for those enrolled in the study (but open to all building residents that includes building tailored messages based on cognitive domains and skills reinforcement through Practice to Mastery.
223494363|NCT05666245|BEHAVIORAL|No Intervention - Under High Air Hygiene|"No intervention~High air hygiene is achieved by filtration and/or use of germicidal UV-C."
223494364|NCT05666245|BEHAVIORAL|Personal Protective Equipment (PPE) - Under Low Air Hygiene|"Intervention Recipients (IRs) will be required to wear a lightweight plastic face shield, comply with hand hygiene (i.e., using a hand sanitization product every 15 minutes, plus periodic hand washing with soap and water), and avoid face touching during each planned exposure event. The face shield may only be removed after leaving the exposure room to go to the bathroom, for other short comfort breaks, and at mealtimes. In these instances, hand hygiene will be used after removing or replacing the face shield; and Donors will not be present. Hand washing with soap and water will be required before meals. IR will be separated from Donors by more than 6 feet during meals. The exposure room will be supervised by a trained member of the study staff who will monitor to ensure that Intervention Recipients wear the face shield continuously, are separated from Donors at meals, and do not touch their faces.~Low air hygiene is achieved with minimal ventilation."
223494365|NCT05666245|BEHAVIORAL|No Intervention - Under Low Air Hygiene|"No intervention~Low air hygiene is achieved with minimal ventilation."
223494366|NCT07051668|OTHER|Pediatric Sepsis Diagnostic Toolkit|The toolkit consists of the following items: 1) a recommendation to request and report vital signs in all pediatric hospital/ED transfers, 2) dissemination of evidence based pediatric sepsis diagnostic criteria to accepting and referring providers and transfer nurses, and 3) accepting physician education in conversational strategies to promote improved diagnostic accuracy during pediatric transfer conversations.
223494367|NCT02996773|DRUG|Bendamustine|After transplant, given intravenously on day +4 as part of Phase Ib.
223494368|NCT02996773|DRUG|Cyclophosphamide|After transplant, given intravenously on day +3 as part of Phase 1b.
223494369|NCT04042844|BIOLOGICAL|BRTX-100|Hypoxic cultured mesenchymal stem cells (MSCs) from autologous bone marrow with autologous platelet lysate.
223494370|NCT04042844|DRUG|Saline|Sodium Chloride (0.9%) intravenous infusion preparation is a sterile and non-pyrogenic solution
223494371|NCT06896201|DIAGNOSTIC_TEST|Neuropsychological Assessments and Other Questionnaires|A brief assessment of the cognitive status will be performed by the means of Mini-Mental State Examination (MMSE), Clinical Dementia Rating Scale (CDR-SB), Activities of the Daily Living (ADL) and Instrumental Activities of the Daily Living (IADL) scales. Moreover, extended neuropsychological assessments assessing memory, language, executive functions, attention and visuospatial perception will be conducted by trained neuropsychologists, as per clinical practice. Concerning depression and behavioural / neuropsychiatric symptoms, which are known to be relevant in cognitive decline and ageing, data will be collected by the means of Neuropsychiatric Inventory (NPI). Additional questionnaires about subjective cognitive decline, quality of sleep (Pittsburgh scale) and cognitive reserve (CRIq) will be conducted on some subgroups of subjects.
223494372|NCT06896201|BIOLOGICAL|Blood Exams, Fluid Biomarkers, Genetics|All patients will undergo a blood samples collection at T0 and T4, as per clinical practice. Additional blood samples will be collected stored and processed according to literature recommendation-based standardized operating procedures.. Blood will be collected into EDTA tubes and will be immediately refrigerated and centrifugated at 2000x g for 10 minutes. Plasma will then be aliquoted in 0.5 ml polypropylene vials and frozen at -80°C. Levels of blood biomarkers of amyloidopathy, tauopathy, neurodegeneration and neuroinflammation will be measured using the Lumipulse G assays (Fujirebio) and the Multiplex assays for Ella (Biotechne). Whole blood samples will be used for genetic analysis, which will include the determination of APOE genotype
223589151|NCT04758520|DEVICE|FLOAT upper limb exoskeleton|The FLOAT device is composed by a wearable exoskeleton assembled on a poly-articulated arm that, in turn, is mounted on a support base with unlockable wheels. The exoskeleton includes 5 motors arranged in a way that, when generating movement, ensures the optimal involvement of all the articulations of the shoulder complex, particularly the glenohumeral and the scapulothoracic joints. According to the chosen modality of use of the exoskeleton, the device allows patient's passive or active-assisted mobilization. The poly-articulated arm supporting the exoskeleton is capable to compensate exoskeleton weight in every configuration and, if configured appropriately, permits exoskeleton use both in seated and standing positions. The support base of the device has unlockable wheels that, if unlocked, permit the free movement of the patient in the workspace, enabling the performance of more complex functional activities while assisted by the exoskeleton.
224308705|NCT02107365|DRUG|Asunaprevir|Asunaprevir 100 mg, 1 capsule twice a day from Day 0 to Week 24
224308706|NCT02107365|DRUG|Daclatasvir|Daclatasvir 60 mg, 1 tablet once a day from Day 0 to Week 24
224308707|NCT02107365|DRUG|Ribavirin|Ribavirin tablets or capsules 200 mg, weight-based daily dose ( \<75 kg : 1000 mg ; ≥ 75 kg : 1200 mg), from Day 0 to Week 24
224186073|NCT03342209|DEVICE|Fisher&Paykel AIRVO™ 2 High Flow Nasal Cannula Therapy|"A high flow nasal cannula will be implemented to the CO-poisoned patients. In the meantime, intravenous access and cardiac monitorization will have been establishing. When the high flow nasal cannula becomes ready, the first venous blood sample will be taken and the treatment will be started without any delay. The gas flow rate will be started at the rate of 30 liters per minute and will be increased to the max flow rate which patient can tolerate and FiO2 of 1.0. If the first COHb level is lesser than 10%, the patient will be excluded and will receive standard emergency care.~The blood sample will be drawn from existing IV access every 10 minutes until the COHb levels become %50 or lesser of the initial level.~Once the COHb level becomes 50% of initial measurement, following blood samples will be taken in every 30 minutes."
224186074|NCT03773354|BEHAVIORAL|Cognitive-behavioural therapy group for individuals with somatic symptom disorders|The intervention is a cognitive-behavioural therapy group for designed for individuals with a formal diagnosis of a somatic symptom disorder (i.e., Somatic Symptom and Related Disorders from the DSM-5) who are interested in learning self-management skills to cope with somatic symptoms and reduce emotional dysregulation, increasing their understanding of factors that contribute to somatic symptoms, and learning relaxation skills to help reduce stress.
224308708|NCT02107365|DRUG|Pegylated Interferon alpha-2a|Pegylated Interferon alpha-2a, by subcutaneous injection 180µg / week, from Day 0 to Week 24
223494373|NCT06896201|OTHER|Connectivity Analysis|"Functional Magnetic Resonance Imaging (fMRI) and/or high-density electroencephalography (EEG) will be used to assess connectivity in selected group of subjects. EEG data will be collected during four 5-minute runs of alternating eyes-open and eyes-closed conditions using a 128-electrode high-density EEG system.~The EEG spectral coherence analysis will evaluate the functional coupling between the brain areas under study. Brain connectivity measures will be computed for each frequency band and for each subject, to be used as measure of weight of the graph in a graph analyses.~A subsample of subjects will be also investigated with connectivity measures of MRI by applying FA e DTI technique. All the data will be collected both at baseline and after a 2-years-period during which the prevention and intervention strategies will be performed."
223494374|NCT06896201|DEVICE|Physical Activity|Participants will be proposed an unsupervised, monitored exercise program consisting of three 60-minute sessions of moderate-intensity aerobic exercise (40%-85% of their maximum heart rate) each week. To track exercise intensity. The activity will be personalized according to specific attitude of each subjects including walking session, bike sessions or swim sessions. The type, frequency and intensity of the activity will be recorded by means of a commercially available wearables (Garmin Vivosmart 4, Garmin Vivosmart 5) and the Healthentia application. Those non using the wearables will keep a diary of the activity. Study investigators will ensure both protocol adherence and participant safety through regular follow-up telephone contacts.
223494375|NCT06896201|DEVICE|Healthentia|Healthentia, developed by Innovation Sprint, is a Software as a Medical Device (SaMD) designed for remote patient monitoring, virtual coaching, and automatic alerts using real-world data. It has been successfully used in over 20 studies and integrates features like teleconsultations, activity tracking, medication management, and support for wearable devices. It provides a patient companion app, offering remote patient monitoring and self-reporting, personalized advice or content in the form of dialogues. It is designed to optimize and improve patient engagement and ensure data integrity. The software facilitates daily self-reporting, providing information to patients and collecting other current data through self-reported questionnaires (health status, physical activity, quality of life, etc.), which will be crucial in order to control the adherence of patients to the program
223494376|NCT06896201|DEVICE|Eligence|Based Platform exercising the brain and the cognitive skills through 35+ games and activities designed by specialized health experts. It offers over 30 games focusing on cognitive skills such as memory, reasoning, attention, orientation, executive functions, construction skills, and language. It allows healthcare professionals to create personalized training sessions, monitor performance in real-time, and generate detailed evaluation reports. Accessible from any device, it is aimed at individuals in early stages of dementia or rehabilitation phases. In our clinical study, subjects will be trained on seven cognitive programs, which can be executed at home with or without assistance and supervision of a Health Professional (who can easily create personalized sessions to follow-up at distance) and/or an informal carer
223494377|NCT06896201|OTHER|Nutrition|Participants will follow a personalized nutrition plan, as per clinical practice, receiving dietary advice derived by the same scheme already used in the FINGER project on prevention. The plan focuses on balanced, nutrient-rich meals, based on the reduction of carbohydrate assumption and stable inclusion of seeds, vegetables, fish and omega 3 aliments in the diet that may protect the brain through anti-inflammatory and antioxidant properties. A diary of the meals will be recorded in a diary included in the Healthentia application. No integrated meals or nutraceutical product will be used.
223494378|NCT06739655|RADIATION|Preoperative radiotherapy|"In this study the patients assigned to the experimental treatment arm will receive preoperative radiotherapy instead of postoperative radiotherapy.~This preoperative radiotherapy will follow the standard of care (SoC) principles as they are defined for postoperative radiotherapy in breast cancer, as defined by international guidelines."
223494379|NCT06739655|RADIATION|Postoperative radiotherapy|Standard of care (SoC) postoperative radiotherapy, as defined by international guidelines.
223494380|NCT06739655|PROCEDURE|Immediate breast reconstruction|In the experimental arm of the PRADAIIBE, the participants will undergo immediate breast reconstruction surgery. This is defined as breast reconstruction taking place at the same time as oncological surgery. Using one of the following primary techniques: 1) Autologous tissue reconstruction (1 phase); 2) Tissue expander and autologous tissue reconstruction (2 phases); 3) Breast implant based reconstruction (1 phase); 4) Tissue expander and breast implant based reconstruction (2 phases); 5) Combined autologous tissue and breast implant reconstruction (1 phase); 6) Tissue expander and combined autologous tissue and breast implant reconstruction (2 phases). Adjuvant techniques are allowed to be added.
223511734|NCT04157582|OTHER|Conventional physical therapy|"1. Gentle manual stretching exercises for (elbow flexors, wrist flexors , hamstring and calf muscle).~2. Strengthening Exercises for ( elbow extensors, wrist extensors and dorsiflexors)~3. Balance training (Wobble board training) :~   * Patient will stand on squared then circled wobble board while it moves within parallel bars in front of mirror with hand support(with repetition 10times)~  * Patient will stand on squared then circled wobble board while it moves within parallel bars in front of mirror without hand support(with repetition 10times)."
224186075|NCT03788109|PROCEDURE|device: combined solid state HRiM|The HRiM catheter (Medical Measurement Systems, Enschede, The Netherlands) incorporating 36 pressure sensors, spaced at 2 cm in the stomach and esophagus and at 1 cm in the LES and upper esophageal sphincter (UES), and 16 impedance channels throughout the esophagus, will be placed transnasally, after topical anesthesia. Manometry will be used to record pressures in the stomach, the esophagus, the LES and the UES. In this way, it is possible to detect and characterize TLESRs, and to measure GA. The impedance channels will be used to measure bolus movement, and thus to detect and characterize gastro-esophageal reflux.
224186076|NCT00978705|DRUG|Autologous cultured keratinocyte cell|3x10\^7 cell/ vial
224186077|NCT01832753|DRUG|Levothyroxine|
224186078|NCT06717217|PROCEDURE|NURSING EDUCATION GIVEN BEFORE TYMPANOPLASTY SURGERY|EAR CARE TRAINING
224186079|NCT06715761|OTHER|Myofascial release|The sequence of myofascial release is as follows: 30 seconds of contact between the therapist's hands and the entire region of the participant's spine, sliding with medium pressure in a caudocranial direction; palpation of the erector spinae, quadratus lumborum, gluteus and piriformis muscles bilaterally, to identify trigger points, marking each point of tension with a dermographic pencil for subsequent manipulation; 3 cycles of bilateral paravertebral release, by sustained pressure with crossed hands, until the restrictive tissue barrier is found, for 60 seconds; 90 seconds of the vertical rolling technique (superficial elevation of the skin and mobilisation of the tissue with the tips of all the fingers) on the bilateral paravertebrals and, at the end, sliding along the entire length of the bilateral multifidus, with the fingers flexed, using the bony prominence between the proximal and middle phalanges as contact with the skin, in a caudocranial direction and returning craniocaudal.
224308709|NCT03453801|BIOLOGICAL|Fluzone®|Fluzone® Quadrivalent (IIV4; inactivated influenza virus vaccine): The pediatric dose (6-35 months) will be supplied in a prefilled, single dose syringe, 0.25 mL (no preservative). Each 0.5 mL dose of Fluzone® Quadrivalent (36 months-adult) will be supplied in a prefilled, single dose syringe, 0.5 mL (no preservative). Both formulations given IM.
223494381|NCT06739655|PROCEDURE|Immediate or delayed breast reconstruction|In the standard arm of the PRADAIIBE, the participants will undergo immediate or delayed breast reconstruction surgery. This is defined as breast reconstruction taking place at the same time as oncological surgery (immediate), or at a later time (delayed). Using one of the following primary techniques: 1) Autologous tissue reconstruction (1 phase); 2) Tissue expander and autologous tissue reconstruction (2 phases); 3) Breast implant based reconstruction (1 phase); 4) Tissue expander and breast implant based reconstruction (2 phases); 5) Combined autologous tissue and breast implant reconstruction (1 phase); 6) Tissue expander and combined autologous tissue and breast implant reconstruction (2 phases). Adjuvant techniques are allowed to be added.
223494382|NCT04404283|DRUG|Brentuximab vedotin|1.2 mg/kg administered into the vein (IV; intravenously) infusion every 3 weeks
223494383|NCT04404283|DRUG|Rituximab|375 mg/m\^2 administered via intravenous infusion on Cycle 1 Day 1. 1400 mg injected under the skin (subcutaneous) permitted every 3 weeks from Cycle 2 Day 1 through end of treatment.
223494384|NCT04404283|DRUG|Lenalidomide|20 mg given by mouth (orally) daily
223494385|NCT04404283|OTHER|Placebo|Administered via intravenous infusion every 3 weeks
223494386|NCT05979935|DIAGNOSTIC_TEST|tongue diagnosis|The tongue image of participants will be collected via camera, and tongue images will be used for AI deep model learning analysis.
223494387|NCT06213831|DRUG|Ruxolitinib Cream 1.5%|Ruxolitinib Cream 1.5%
223494388|NCT03324646|DRUG|[11C]PS13|A novel PET ligand to selectively image COX-1
223494389|NCT07061340|BEHAVIORAL|Therapeutic Touch|no Therapeutic Touch
223494390|NCT07057089|DRUG|Capecitabine|Capecitabine: 825mg/m2, bid;
223494391|NCT07057089|DRUG|Camrelizumab|Camrelizumab: 200mg
223494392|NCT07057089|DRUG|CAPOX|CAPOX
223494393|NCT07057089|RADIATION|Involve-field irradiation|Involve-field irradiation: Primary rectal tumor + metastatic or suspicious pelvic lymph nodes, mesorectal region, and presacral region
223494394|NCT07057089|RADIATION|Elective nodal irradiation|Elective nodal irradiation: Large pelvic field
223494395|NCT07057089|PROCEDURE|TME surgery|TME surgery
223494396|NCT00230516|DRUG|Nexium|
223494397|NCT00230516|DRUG|Prevacid|
223494398|NCT01838538|DRUG|Bevacizumab|
223494399|NCT01838538|DRUG|TC:paclitaxel + carboplatin|
223494400|NCT06757205|DIAGNOSTIC_TEST|Using a structured questionnaire to collect quantitative and qualitative data on adolescents' experiences and perceptions. The Italian version of the Mentalization Questionnaire (MZQ) was develop|"Using a structured questionnaire to collect quantitative and qualitative data on adolescents' experiences and perceptions.~* The Italian version of the Mentalization Questionnaire (MZQ) was developed as a self-rated instrument to assess mentalization. It consists of 15 items with responses ranging from 1 = 'no agreement at all' to 5 = 'total agreement' on a 5-point Likert scale. Calculated sum scores for the total scale range from 15 to 75 with higher scores indicating lower mentalization capacities.~* The Toronto Alexithymia Scale (TAS) is a measure of deficiency in understanding, processing, or describing emotions (alexithymia). It has twenty statements rated on a five-point Likert scale. The total score ranges from 40 to 200 and the higher score indicates a greater level of alexithymia."
224308710|NCT03453801|BIOLOGICAL|FluMist®|FluMist® Quadrivalent: live, attenuated influenza virus vaccine quadrivalent, given by intranasal spray
224308711|NCT01348412|DRUG|oxaliplatin|130 mg/m²Every 21 days
224308712|NCT01348412|DRUG|raltitrexed|3 mg/m² with a maximum of 6 mg every 21 days
223494401|NCT07053787|BEHAVIORAL|Standard Yoga|Weekly hatha yoga for 12 weeks augmented by home practice guided by yoga instructional videos.
223494402|NCT07053787|BEHAVIORAL|Enhanced Yoga|"Weekly hatha yoga for 12 weeks augmented by home practice guided by yoga instructional videos ...~plus six weekly 50-minute 1-on-1 coaching sessions starting week 10 of the standard yoga intervention and ending week 15 (3 wks after end of standard yoga). During this transition, participants are supported with development and execution of their plan for continuing their yoga practice. Participants will be offered 1 additional ad-hoc coaching session to help them re-start yoga if they get off track and/or experience major life events such as moving, job change, medical issues, etc."
223494403|NCT06864832|OTHER|Mirror image postural exercises|Patients will recieve mirror image postural exercise on the 3D postural analysis
223494404|NCT06864832|OTHER|Back exercises|Exercises in the form of back muscles stretching exercises and abdominal muscles strengthening exercises.
224186080|NCT06715761|OTHER|Cupping therapy|The acrylic cups (DongBang®) will be placed on the meridional points, as Traditional Chinese Medicine calls them, 1 cup in the central region of each popliteal fossa, the so-called B40 or Wei Zhong point, 6 cups in the region of the quadratus lumborum muscles, more specifically on the BL23 or Shenshu points (approximately 5 centimetres lateral to the edge of the L2 spinous process), BL24 or Qihaishu (approximately 5 centimetres lateral to the edge of the spinous process of L3) and BL25 or Dachangshu (approximately 5 centimetres lateral to the edge of the spinous process of L4) bilaterally, as well as a cup on a single point of the participant's choice, where they report the most lower back pain (ashi point). The cups will be attached to the skin using a gun, applying two suction pressures, and the participant will be asked to signal whether the pressure is strong or weak. The cups will remain attached for 12 minutes on the B40 meridian and 15 minutes on the other meridians. If a cup lo
224186081|NCT03098667|DEVICE|LMA Protector|After induction of general anesthesia, the LMA Protector will be applied for airway management. The size of the laryngeal mask will be chosen according to the manufacturer's instructions. Lubricant gel will be applied to the dorsal side of the mask to ease the insertion to the oropharynx. The cuff of the mask will be filled with air by syringe until the indication of the integrated cuff pressure indicator is appropriate according to the manufacturer (green indication). If the indication changes during surgery, air will be added or removed accordingly. If the ventilation of the patient is inadequate at the beginning or anytime during the operation, the mask will be removed and the patient will be intubated.
224186082|NCT03098667|DEVICE|Endotracheal tube|After induction of general anesthesia, the endotracheal tube be applied for airway management. The size of the tube will be 7.5 for female and 8.5 for male patients. The cuff of of the tube will be filled with 10ml air.
224186083|NCT02230644|OTHER|Enhanced clinical environment|Surgical booths containing artwork and calming background music.
224186084|NCT02230644|OTHER|Other distraction|Such as newspaper, magazine or the news on television
224308713|NCT01348412|DRUG|other intravenous chemotherapy drugs|
224308714|NCT02976324|DEVICE|external diaphragmatic pacemaker group|9 counts per minute, with stimulate frequency 40 Hz
223494405|NCT06551402|DRUG|Dabigatran Etexilate 150mg|100 CVT patients will receive dabigatran 150mg Bid for 6 months. We will assess the Proportion of subjects who have partial or complete venous recanalization by Day 180 the rate of drug hemorrhagic complications using the PLATO bleeding definition, and the rates of patients who achieved a favorable outcome with (mRS = 0-2) after one week and after 180 days in a face-to-face interview in the outpatient clinic, Proportion of subjects with recurrent venous thromboembolism (any thrombosis at a new site, including cerebral venous thrombosis in a separate location from the index event) at Day 180 or the end of anticoagulation, whichever is sooner, rates of a composite of pulmonary embolism, DVT, myocardial infarction, and death due to vascular events after 180 days of follow-up, the MoCA, HIT-6 by 180 days, the rate of treatment-related adverse effects assessed by a follow-up questionnaire.
223511735|NCT03608007|DRUG|X-396 Capsule|225 mg once daily
223511736|NCT03241160|OTHER|Chewing evaluation|Chewing evaluation will be performed. An experienced physical therapist who will take a scale training session will do the chewing evaluation according to the chewing performance scale.This scale classifies chewing function on an ordinal scale with five levels between 0 and 4 based on the sequence of functional movements during chewing.
223511737|NCT05684198|DEVICE|subcutaneous NPWT|Following fascia closure, NPWT system will be inserted into subcutaneous tissue, continuous negative pressure of 120 mmHg will be applied.
223511738|NCT02801227|DRUG|Oxytocin|Intravenous oxytocin: 2.5 mIU per minute with increments of 2.5 mIU every 20 minutes until achieving 4-5 contractions during 10 minutes or 20 mIU. Then after continuous infusion without increasing oxytocin dose will be continued. In case of lack of painful contraction/active labor after 24 hours with oxytocin a trial with PGE2 will be initiated (as described for PGE2)
223511739|NCT02801227|DRUG|Prostaglandin E2|PGE2 2 mg wil be inserted to the posterior fornix, this will be repeated every 6 hours until achieving painful contractions or up to 4 doses (24 hours). In case of lack of painful contraction/active labor after the fourth dose of PGE2 a trial with oxytocin will be initiated (as described for Oxytocin).
223511740|NCT01644331|DRUG|Tolvaptan|IV furosemide plusTolvaptan (given at 0, 24 and 48 hours)
223511741|NCT01644331|DRUG|Placebo|IV furosemide plus oral placebo (given at 0, 24 and 48 hours)
223511742|NCT01631929|OTHER|One bag|Infusion of dextrose and electrolytes using one bag
223511743|NCT01631929|OTHER|Two bags|Using 2 bags with different solutions with the same electrolyte content but different dextrose concentration (0% and 10%), administered simultaneously through the same intravenous line.
223511744|NCT02062008|DEVICE|PET-MRI|PET-MRI with intravenous Gadolinium and FDG. The entire study will take approximately one hour.
223511745|NCT05398848|BIOLOGICAL|Recombinant two-component COVID-19 vaccine (CHO cell)|Before reconstitution: Lyophilized powder for reconstitution in single-use vials After reconstitution with BFA03 adjuvant: Milk-white solution with no visible foreign matter
223511746|NCT05398848|BIOLOGICAL|Placebo|"Before reconstitution:~Lyophilized powder for reconstitution in single-use vials~After reconstitution with BFA03 adjuvant:~Milk-white solution with no visible foreign matter"
223511747|NCT00000437|DRUG|Naltrexone Tablet and Nicotine Patch|
223511748|NCT00000437|DRUG|Naltrexone Tablet and Placebo Patch|
223511749|NCT00000437|DRUG|Placebo Tablet and Nicotine Patch|
223511750|NCT00000437|DRUG|Placebo Tablet and Placebo Patch|
223511751|NCT04482920|DIAGNOSTIC_TEST|p-aminohippurate clearance study|To measure kidney blood flow, small doses of a substance called p-aminohippurate (PAH) are used.
223511752|NCT04482920|DIAGNOSTIC_TEST|Iohexol infusion|To measure glomerular filtration rate (GFR)
223511753|NCT04760457|PROCEDURE|Implant placement with flapped surgery|Four mini implants will be placed reflecting a flap.
223511754|NCT04760457|PROCEDURE|Implant placement with flapless surgery|Four mini implants will be placed without reflecting a flap.
223511755|NCT04760457|PROCEDURE|Implant immediate loading|Four mini implants will be immediately loaded.
223511756|NCT04760457|PROCEDURE|Implant delayed loading|Four mini implants will be loaded after a 6-week healing period.
223511757|NCT02327143|DRUG|LY2835219|Administered orally
223511758|NCT02327143|DRUG|¹³C₈-LY2835219|Administered IV
223511759|NCT03570385|DEVICE|MRI|MRI in diffusion tensor (DTI : Diffusion Tensor Imaging)
224186085|NCT03077646|BEHAVIORAL|Be SMART|An educational campaign that is non-political reviewing gun safety measures for preventing firearm injuries in children. There is both a video and written materials reviewing the information. The acronym SMART stands for: Secure all guns in your home, Model responsible behavior, Ask about unsecured guns in other homes, Recognize the risks of teen suicide, Tell your peers to be SMART
224186086|NCT03077646|BEHAVIORAL|Control: TSE|"A video called Kids and Smoke Don't Mix and handouts on tobacco smoke exposure (TSE) developed by the New York state quit-line."
223494406|NCT06551402|DRUG|Rivaroxaban 20 MG Oral Tablet|100 CVT patients will receive Rivaroxaban 20mg daily for 6 months. We will assess the Proportion of subjects who have partial or complete venous recanalization by Day 180 the rate of drug hemorrhagic complications using the PLATO bleeding definition, and the rates of patients who achieved a favorable outcome with (mRS = 0-2) after one week and after 180 days in a face-to-face interview in the outpatient clinic, Proportion of subjects with recurrent venous thromboembolism (any thrombosis at a new site, including cerebral venous thrombosis in a separate location from the index event) at Day 180 or the end of anticoagulation, whichever is sooner, rates of a composite of pulmonary embolism, DVT, myocardial infarction, and death due to vascular events after 180 days of follow-up, the MoCA, HIT-6 by 180 days, the rate of treatment-related adverse effects assessed by a follow-up questionnaire.
223494407|NCT06767059|OTHER|Walking Group|Patients will be asked to walk for 30 minutes at least 3 times for 8 weeks. In order to ensure regular follow-up, patients will be asked to write on the walking tracking form when they walk and the number of steps before they start walking and the number of steps after walking using the application.
223494408|NCT06767059|OTHER|Grounding Group|Patients will be asked to walk with a grounding stick for 30 minutes at least 3 times for 8 weeks. Patients will be asked to fill in the walking follow-up form and grounding follow-up form for regular follow-up.
223494409|NCT06631417|DRUG|BI 1291583|formulation 1
223494410|NCT06631417|DRUG|BI 1291583|formulation 2
223494411|NCT06631417|DRUG|BI 1291583|formulation 3
223494412|NCT04628624|DIETARY_SUPPLEMENT|Placebo control|8 week supplementation period, with participants consuming 2 capsules per day containing potato starch
223494413|NCT04628624|DIETARY_SUPPLEMENT|GTE 1|8 week supplementation period, with participants consuming 2 capsules per day containing green tea extract (571mg/d)
223494414|NCT04628624|DIETARY_SUPPLEMENT|GTE 2|8 week supplementation period, with participants consuming 2 capsules per day containing green tea extract with additional antioxidants (150mg of quercitin and 150mg of alpha lipoic acid)
223494415|NCT06796738|DIAGNOSTIC_TEST|HPV testing|This study will use the Roche Cobas® 8800 system for HPV testing. The Roche Cobas HPV test is a PCR test that detects 14 hrHPV types and specifically identifies types 16 and 18.
223494416|NCT06840600|BEHAVIORAL|Public safety rationale|Rationale provided for policy is to increase community safety.
223494417|NCT06840600|BEHAVIORAL|Right-to-health rationale|Rationale provided for policy is to support humans' right to healthy food.
223494418|NCT06840600|BEHAVIORAL|Cost-saving rationale|Rationale provided for policy is to save the government money.
223589152|NCT00399100|PROCEDURE|HBO - hyperbaric oxygen treatment|
223589153|NCT02414620|DEVICE|Generation II Dental Vibe Unit|. The Dental Vibe emits strong pulsed vibration which is transmitted via a silicone mouth piece to mucosal tissue.
223589154|NCT02903394|DEVICE|mLCI Device|imaging of cervical epithelium using mLCI device
223589155|NCT01628003|DEVICE|Brain MRI|Brain MRI
223589156|NCT01628003|DEVICE|MRI|Physical examination Neuropsychological testing Questionnaires
224186087|NCT03077646|BEHAVIORAL|Be SMART + MD review|"An educational campaign that is non-political reviewing gun safety measures for preventing firearm injuries in children. There is both a video and written materials reviewing the information. The acronym SMART stands for: Secure all guns in your home, Model responsible behavior, Ask about unsecured guns in other homes, Recognize the risks of teen suicide, Tell your peers to be SMART.~After being presented to parents/guardians via video and handouts, this information will be reviewed in person with a Physician."
224186088|NCT00006358|DRUG|temozolomide|
224186089|NCT00006358|DRUG|thalidomide|
224186090|NCT03028649|DIETARY_SUPPLEMENT|β-hydroxy-β-methylbutyrate and a placebo supplementation|
223494419|NCT06840600|BEHAVIORAL|No rationale (Control)|In this arm, no rationale is provided for the policy.
223494420|NCT04994132|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223589157|NCT04378231|DRUG|Amoxicillin-Clavulanate 200 Mg-28.5 Mg Oral dry suspension|dry suspension of amoxicillin clavulanate potassium
223589158|NCT02882100|BIOLOGICAL|adjuvanted trivalent influenza vaccine|Nursing home residents over 65 years are allocated to receive adjuvanted trivalent vaccine. Residents under 65 years are provided standard trivalent vaccine (TIV-Fluvirin).
224186091|NCT04584619|DEVICE|Spine fusion surgery with Clariance Idys TLIF 3DTi|Posterior fusion of the lumbar spine with Clariance Idys TLIF 3DTi interbody fusion device used in conjunction with a posterior fixation system (pedicle screws and rod).
223494421|NCT04994132|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
223494422|NCT04994132|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
223494423|NCT04994132|PROCEDURE|Bone Scan|Undergo bone scan
223494424|NCT04994132|PROCEDURE|Computed Tomography|Undergo CT
223589159|NCT02882100|BIOLOGICAL|trivalent influenza vaccine|Nursing home residents are allocated to receive standard trivalent vaccine (TIV).
224186092|NCT00765726|BIOLOGICAL|Moroctocog alfa(AF-CC)|Dosing is at the discretion of the investigator during the study
224186093|NCT00765726|PROCEDURE|Blood draw for laboratory testing|Hematology and Chemistry panels, Factor VIII inhibitor and recovery studies
223494425|NCT04994132|DRUG|Cyclophosphamide|Given IV or PO
223494426|NCT04994132|BIOLOGICAL|Dactinomycin|Given IV
223589160|NCT04874090|OTHER|Acupuncture|Investigator will apply the acupuncture treatment to the first group to the neck area. BL-15, BL-18, BL-23, BL-25, KB-4, Du-20, GB-20, CV-14, KB-10, Ex-26, Yin Tang, Ah-shi points will be used. 0.25x25 mm, sterile, steel, disposable, acupuncture needle will be used for acupuncture points and painful trigger points. The treatment will be applied twice a week, on average 10 sessions. Dry needling treatment will be applied to the patients by a certified physician. All patient will be performed the neck exercises program
223589161|NCT04874090|OTHER|Exercises|Patient will perform neck exercises
223589162|NCT00549770|DRUG|LCZ696|
224186094|NCT05718011|DRUG|Dexmedetomidine|0.5 micrograms/kg diluted in 10mL of normal saline 0.9% given as IV infusion over 10 minutes
224186095|NCT05718011|DRUG|Ketamine|0.5 milligrams/kg diluted in 10mL of normal saline 0.9% given as IV infusion over 10 minutes
223589163|NCT00549770|DRUG|Valsartan|
223589164|NCT00549770|DRUG|AHU377|
223589165|NCT00549770|DRUG|Placebo|
223589166|NCT04761484|PROCEDURE|Vascular access on admission|PIVC insertion
223589167|NCT02742311|PROCEDURE|Endoscopic disectomy|Endoscopic discectomy is an established method for treatment of lumbar disc herniation. Edoscopic discectomy provides a safe and minimal access corridor for lumbar discectomy. The technique also allows early postoperative mobilization and faster return to work.
223589168|NCT01283685|OTHER|breathing helium-hyperoxia|40% O2, 60% He
223589169|NCT01283685|OTHER|breathing supplemental oxygen|oxygen (4 L/min) provided by nasal cannula
223589170|NCT02803996|DRUG|Aramchol|Part A: Aramchol oral tablets at 400 mg or 600 mg single dose Part B: Aramchol oral tablets at 400 mg or 600 mg multiple dose for 10 consecutive days.
223589171|NCT02803996|DRUG|Placebo|Part A: Placebo oral tablets single dose Part B: Placebo oral tablets multiple dose for 10 consecutive days.
223589172|NCT04578925|BEHAVIORAL|Happy, Healthy, Loved|A text message based, mobile-device delivered intervention that provides educational information to primiparous mothers and their partners about breast-feeding and coping with stress.
223589173|NCT01705678|DIETARY_SUPPLEMENT|Krill oil|Krill oil 300 mg DHA/EPA daily for 6 weeks
223589174|NCT01705678|DIETARY_SUPPLEMENT|Fish oil|Fish oil 500 mg DHA/EPA daily for 6 weeks
223589175|NCT03610776|DEVICE|Portion control plate|Portion control plate including demarcations and pictures for recommended amounts of main food groups (starch, protein and vegetables), 25 cm in diameter, enamel, white background.
223589176|NCT03610776|DEVICE|Conventional plate|Conventional plate without demarcations or images, 25 cm in diameter, enamel, white.
223589177|NCT00028886|BIOLOGICAL|filgrastim|
224186096|NCT02058966|DRUG|Entacapone|Entacapone 200 mg oral dose
224186097|NCT02058966|DRUG|Methamphetamine|Methamphetamine 20 mg oral dose
224186098|NCT02058966|DRUG|Placebo|capsules compounded to be of similar appearance to the active drugs
224308715|NCT02459535|OTHER|oral stimulation glucose|oral stimulation with glucose, AS or glucose+AS in fasted state, blood samples from fasted state up to 120 min post-ingestion
224186099|NCT05391113|DIAGNOSTIC_TEST|MRI|an fMRI measurement of the BOLD physiological signal for sensory responses
224308716|NCT02459535|OTHER|oral stimulation saccharin|
224186100|NCT05391113|DIAGNOSTIC_TEST|EEG|These tests, through videos with a social or non-social content (human presence or absence on the stereoscopic projection), will allow us to study two types of sensorialities (visual and interoceptive). Thus, it will be possible to obtain inter- and exteroceptive profiles of the participants, a direct reflection of the processing of the internal bodily sensations of the body.
224186101|NCT01191359|BIOLOGICAL|oral immunotherapy|orally applied specific immunotherapy
224186102|NCT05132751|DEVICE|Machine Learning Ventilator Decision System|Artificial intelligence ventilator system for personalized mechanical ventilation
224308717|NCT02459535|OTHER|oral stimulation aspartame|
224308718|NCT02459535|OTHER|oral stimulation sucralose|
224308719|NCT03908879|PROCEDURE|Standard intraosseous (IO) catheter confirmation procedure|The physician will evaluate the ability or inability of the intraosseous (IO) catheter to stand upright unassisted, the ability or inability to aspirate blood or bone marrow from the IO catheter, and whether or not there is visible or palpable extravasation of infusate from the IO catheter insertion site or surrounding subcutaneous tissue during IO catheter use.
223589178|NCT00028886|BIOLOGICAL|recombinant interferon alfa|
223589179|NCT00028886|DRUG|cyclophosphamide|
223589180|NCT00028886|DRUG|dexamethasone|
223589181|NCT00028886|DRUG|doxorubicin hydrochloride|
223589182|NCT00028886|DRUG|melphalan|
223589183|NCT00028886|DRUG|thalidomide|
223589184|NCT00028886|DRUG|vincristine sulfate|
223589185|NCT00028886|PROCEDURE|bone marrow ablation with stem cell support|
223589186|NCT00028886|PROCEDURE|peripheral blood stem cell transplantation|
223589187|NCT05241145|DRUG|IVMED-80|Good Manufacturing Practices-grade copper (ІІ) sulfate pentahydrate (CuSO4 #5H2O MW 249.69) was dissolved in a vehicle solution comprised of a balanced salt solution (BSS) with osmolality of approximately 500 mOsm/L. Copper sulfate was concentrated to 0.15 mg/mL. The drops were manufactured on prior to the study at a compounding pharmacy in Salt Lake City, Utah.
223589188|NCT05241145|OTHER|Placebo|This was identical to the IVMED-80 product, but without the active ingredient, copper sulfate.
223589189|NCT00348647|BEHAVIORAL|physical training program to prevent injuries|
223589190|NCT01209221|DRUG|Placebo - MAD|Once or twice daily doses of matching placebo to RO5271983 for 14 days
223589191|NCT01209221|DRUG|Placebo - SAD|Single dose of matching placebo to RO5271983 for up to 3 periods
223589192|NCT01209221|DRUG|RO5271983 - MAD|Once or twice daily doses of RO5271983 for 14 days
223589193|NCT01209221|DRUG|RO5271983 - SAD|Single dose of RO5271983 at each period (for up to 3 periods)
223589194|NCT01105156|BEHAVIORAL|VEW Questionnaire|Patient Self reported questionnaire filled in.
223589195|NCT00665236|OTHER|Craniosacral therapy|Eight weekly 45-minute sessions with therapist
223589196|NCT00665236|PROCEDURE|Low strength static magnets|Placement of magnets on/around subject body by therapist; frequency: weekly for 45-minutes x 8 weeks
223589197|NCT05215158|DRUG|Dexmedetomidine|to compare perineural (peribulbar) dexmedetomidine versus intravenous (I.V.) dexmedetomidine when used as an adjuvant with local anesthesia in adult strabismus surgery.
223589198|NCT01079936|DRUG|Lenalidomide|Beginning dose level 25 mg by mouth (PO) on Days -8 to -2
223589199|NCT01079936|DRUG|Melphalan|Dose level 100 mg/m2 by vein (IV) Days -3 and -2 over 30 minutes infusion
223589200|NCT01079936|PROCEDURE|Stem Cell Infusion|Stem cell infusion on Day 0.
223589201|NCT06047496|BEHAVIORAL|Time restricted eating|Caloric intake restricted to a self-defined 8-10 hour window in each 24-hour period.
223589202|NCT00898391|OTHER|laboratory biomarker analysis|Correlative studies
223589203|NCT00898391|GENETIC|polymerase chain reaction|Correlative studies
223589204|NCT00898391|GENETIC|polyacrylamide gel electrophoresis|Correlative studies
224186103|NCT05043493|PROCEDURE|Injection in the intraarticular space of glenohumeral joint|U/S guided injection of platelet rich plasma (PRP) or normal saline (NS)
224186104|NCT02993731|DRUG|Napabucasin|Napabucasin will be administered orally, twice daily, with doses separated by approximately 12 hours.
224186105|NCT02993731|DRUG|Nab-paclitaxel|Nab-paclitaxel 125 mg/m\^2 immediately followed by gemcitabine 1000 mg/m\^2 will be administered on Days 1, 8 and 15 of every 28-day cycle via intravenous infusion.
224186106|NCT02993731|DRUG|Gemcitabine|Nab-paclitaxel 125 mg/m\^2 immediately followed by gemcitabine 1000 mg/m\^2 will be administered on Days 1, 8 and 15 of every 28-day cycle via intravenous infusion.
224186107|NCT01265511|DRUG|Placebo|Oral tablets given bid for 28 days
224186108|NCT01265511|DRUG|SCY-635|SCY-635 tablets, 300 mg bid for 28 days
224186109|NCT01265511|DRUG|Pegasys|180 ug prefilled syringe given once per week for up to 48 weeks
224186110|NCT01265511|DRUG|Copegus|tablets given bid for up to 48 weeks
224186111|NCT04157907|BEHAVIORAL|Mentalization based therapy|Mentalization based therapy is a specialized treatment for patients with borderline personality disorder. The treatment program combines individual and group therapy, as well as psychoeducation
224186112|NCT04658511|DEVICE|Ultrasound|On the spot, during the pre-op clinic visit, an ultrasound exam will be done by the PI trying to visualize the arcade of Struthers
224186113|NCT00935961|DRUG|RAD001 + docetaxel + cisplatin|Patients will receive daily RAD001 (everolimus, per dose escalation scheme) plus concurrent docetaxel (75 mg/m2 intravenously every 3 weeks) + cisplatin (75 mg/m2 intravenously every 3 weeks). Pegfilgrastim (6 mg/subcutaneously) will be administered on day 2 of each cycle. Patients will be followed for toxicity for 30 days after the last dose of RAD001. Patients should undergo re-staging imaging studies within 2 - 6 weeks after the final treatment with cisplatin/docetaxel. After the completion of induction chemotherapy and the 30-day observation period after treatment, patients are removed from the study.
224186114|NCT03755037|DRUG|Clomid, Respatio and Ethinyl estradiol|Drugs were received during the menstrual cycle.
224186115|NCT00323479|DRUG|Anastrozole|1mg/Day oral
224308720|NCT03908879|PROCEDURE|Color flow Doppler intraosseous (IO) catheter confirmation procedure|The high frequency probe of a portable ultrasound with color flow Doppler is placed adjacent to the intraosseous (IO) catheter, visualizing the IO space in long or short axis. Color flow Doppler signal will be turned on during IO use and the physician will determine if the Doppler signal is in the intraosseous space or the extraosseous space. Saved data of the ultrasound image will be reviewed independently by at least two blinded reviewers. If the conclusions from the blinded reviewers are discordant then a third blinded reviewer will evaluate the saved data.
224308721|NCT03908879|PROCEDURE|Pressure transduction intraosseous (IO) catheter confirmation procedure|The intraosseous (IO) catheter will be attached to a pressure transducer to demonstrate a waveform on the telemetry monitor. Physicians will evaluate for the presence of a pulsatile waveform with objective measurements of a systolic pressure, diastolic pressure and mean pressure. Saved data of the waveform image will be reviewed independently by at least two blinded reviewers. If the conclusions from the blinded reviewers are discordant then a third blinded reviewer will evaluate the saved data.
224308722|NCT00054808|DRUG|gallium nitrate|
224308723|NCT00010621|PROCEDURE|Acupuncture|
224308724|NCT00010621|PROCEDURE|chiropractic therapy|
224308725|NCT00010621|PROCEDURE|bodywork therapy|
224308726|NCT00304837|GENETIC|pVGI.1 (VEGF-2)|
224308727|NCT00735306|DRUG|Avastin|Avastin 10 mg/kg IV on days 1, 15 and 29 Begins the first day of radiation therapy
224308728|NCT00735306|DRUG|Tarceva|Daily by mouth per assigned dose, for 5.5 weeks Begins the first day of radiation therapy
224308729|NCT00735306|RADIATION|Radiation Therapy|Radiation to the pancreas Monday through Friday for 28 treatments
223589205|NCT00898391|GENETIC|DNA analysis|Correlative studies
223589206|NCT00358839|DRUG|CGRP|
223589207|NCT05954429|DRUG|serplulimab|"Serplulimab is an innovative monoclonal antibody targeting PD-1, developed by Shanghai Henlius Biotech, Inc.~300 mg, q3w Other name: HLX10"
223589208|NCT05954429|DRUG|Fruquintinib|5mg (QD) orally for 2 weeks, 1 week off, repeated every 3 weeks until disease progression or intolerable toxicity.
224308730|NCT03002571|DRUG|IDP-124 Lotion|IDP-124 Lotion, twice-daily application
224308731|NCT03002571|DRUG|IDP-124 Vehicle Lotion|IDP-124 Vehicle Lotion, twice-daily application
224308732|NCT03151811|DRUG|Melflufen|Intravenous infusion
224308733|NCT03151811|DRUG|Pomalidomide|Oral capsules
224308734|NCT03151811|DRUG|Dexamethasone|Oral tablets
224308735|NCT05228028|PROCEDURE|fascia iliaca compartement block|Ultrasound-guided suprainguinal FICB (30 ml of 0.375% ropivacaine with 75 µg of epinephrine) is done on the ipsilateral surgical side at the end of surgery.
224308736|NCT05228028|PROCEDURE|quadratus lumborum block|Ultrasound-guided anterior QLB (30 ml of 0.375% ropivacaine with 75 µg of epinephrine) is done on the ipsilateral surgical side at the end of surgery.
224308737|NCT02676583|PROCEDURE|Tonsillectomy|Closure or not closure of tonsil fossa
224308738|NCT00054665|DRUG|PS-341|1.3 mg/m\^2 intravenous injection days 1, 4, 8, 11 every 3 weeks
224308739|NCT00054665|DRUG|Etoposide|50 mg/m\^2 day continuous intravenous infusion (CIV) days 1-4, 96 hour infusion. Repeat cycle every 21 days.
224308740|NCT00054665|DRUG|Doxorubicin|10 mg/m\^2 day CIV days 1-4, 96 hour infusion. Repeat cycle every 21 days.
224308741|NCT00054665|DRUG|Vincristine|0.4 mg/m\^2 day CIV days 1-4, 96 hour infusion. Repeat cycle every 21 days.
224308742|NCT00054665|DRUG|Cyclophosphamide|750 mg/m\^2 day IV day 5 bolus. Repeat cycle every 21 days.
223589209|NCT05061628|DRUG|JS006 as Monotherapy|"1. JS006 as Monotherapy dose-escalation: JS006, 18/ 60/ 180/ 600/ 1800mg, IV infusion, every 3 weeks (q3w).~2. JS006 as Monotherapy dose-extension: JS006, 1 or 2 specific dose, IV infusion, every 3 weeks (q3w)."
224186116|NCT03651011|DRUG|Aflibercept Injection [Eylea]|Intravitreal injection 2 mg Eylea every 4 weeks M0-M2 (loading phase). M3-M12: continue in a pro re nata treatment regimen.
224186117|NCT03651011|PROCEDURE|Navigated laser photocoagulation|Navigated laser photocoagulation planned from flourscein angiography.
224186118|NCT06143449|OTHER|Observational study - registry|Observational study - registry
224186119|NCT05356637|DEVICE|Werewolf Fastseal 6.0|bi-polar hemostatic wand
224186120|NCT03014700|BIOLOGICAL|Fibrinogen Concentrate|Subject will be administered Fibrinogen Concentrate to control bleeding after open heart surgery when randomized to Fibrinogen Concentrate group
224186121|NCT03014700|BIOLOGICAL|Cryoprecipitate|Subject will be administered Cryoprecipitate to control bleeding after open heart surgery when randomized to Cryoprecipitate group
224186122|NCT05078268|BEHAVIORAL|HRV biofeedback training and self-help CBT-I|Participants will receive a booklet with content related to both self-help CBT-I and HRV biofeedback per week for 6 consecutive weeks. Participants are required to use around 1 hour to read through the content and perform the HRV biofeedback practice for around 20 minutes a day, 5-7 days a week and record their practice.
224186123|NCT05078268|BEHAVIORAL|Self-help CBT-I only|Participants will receive a booklet with content related to self-help CBT-I only per week for 6 consecutive weeks. Participants are required to use 30 to 40 minutes to read through the content.
224308743|NCT00054665|DRUG|Prednisone|60 mg/m\^2 by mouth twice a day days 1-5. Repeat cycle every 21 days.
224308744|NCT00054665|DRUG|Filgrastim|300 micrograms subcutaneously days 6 to absolute neutrophil count recovery greater than or equal to 5000/mm\^3. Repeat cycle every 21 days.
223494427|NCT04994132|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223494428|NCT04994132|PROCEDURE|Positron Emission Tomography|Undergo PET
223494429|NCT04994132|RADIATION|Radiation Therapy|Undergo radiation therapy
223494430|NCT04994132|DRUG|Vincristine Sulfate|Given IV
223494431|NCT04994132|DRUG|Vinorelbine Tartrate|Given IV
223494432|NCT04994132|PROCEDURE|X-Ray Imaging|Undergo x-ray imaging
223494433|NCT06586957|DRUG|NKT3964|Oral CDK2 Degrader
223494434|NCT06884033|BEHAVIORAL|Cinematherapy|Cinematherapy, also known as cinema therapy and movie therapy, involves therapist-directed viewing of movies for specific therapeutic purposes.
223494435|NCT04611087|BEHAVIORAL|Discussion|Attend focus groups
223494436|NCT04611087|OTHER|Interview|Attend interviews
223494437|NCT04611087|OTHER|Survey Administration|Ancillary studies
223494438|NCT02206347|BEHAVIORAL|attention focus|
224186124|NCT04012866|BEHAVIORAL|Aerobic exercise training|The aerobic exercise program using progressive resistive stationary bicycle training which will contain warm-up, resistive physical exercise, and cool-down. The training resistance will increase with improvement of participants' performance.
224186125|NCT04012866|BEHAVIORAL|Computerized cognitive training|The computerized cognitive training program will be implemented with the brainHQ to target abilities of visuospatial processing, attention, memory, and executive function. The level of the training program will become more difficult with progress in participants' targeted cognitive abilities.
224186126|NCT04012866|BEHAVIORAL|Control training|The Control training will receive an intervention including combinations of non-aerobic physical activities and unstructured mental activities.
224186127|NCT01725724|PROCEDURE|Autologous blood transfusion|Per- and postoperative transfusion of autologous salvaged blood collected with the Sangvia Blood Collection System.
224186128|NCT01725724|PROCEDURE|Allogeneic blood transfusion|Transfusion of allogeneic blood according to the transfusion guidelines at each of the participating hospitals.
224186129|NCT05689229|DRUG|Colistin|COVID-19 patients with secondary gram-negative bacterial infections receive colistin IV or aerosolized
224186130|NCT01362062|DRUG|Tocilizumab|
224186131|NCT02760420|DRUG|Amoxicillin|Oral amoxicillin dispersible tablets (DT), 250 mg tablets, given according to age band, two times daily
224308745|NCT04181073|DEVICE|Jet Nebuliser|Jet Nebuliser
224308746|NCT04181073|DEVICE|Vibrating Mesh Nebuliser|Aerogen Device
224308747|NCT06574360|DRUG|S1RA plus NMDAE|Use of an S1R agonist plus an NMDA enhancer for the treatment of treatment-resistant schizophrenia.
224308748|NCT06574360|DRUG|S1RA plus Placebo Cap|Use of an S1R agonist plus placebo as a comparator
223494439|NCT02643277|BEHAVIORAL|Mobile phone text messaging|The intervention will be text messages delivered by an automated text messaging manager. The message content will be designed to induce lifestyle modification (diet and physical activity) and will be motivational, based on the content which has been proven to be effective in reducing progression to diabetes in people with pre-diabetes. Other text messages will aim to improve drug compliance and disease monitoring, based on our pilot studies in India. The control arm will receive conventional management, according to local guidelines in the Indian centers, which in all cases are compatible with those of the International Diabetes Federation.
223494440|NCT02643277|OTHER|Conventional care|Conventional care is comprised of a one-to-one interview by a trained research personnel on diet and exercise advice at baseline and during every visit. The goals were to reduce portion size (total calories) and, to avoid simple sugars and refined carbohydrates, reduce total fat intake, restrict use of saturated fat, include more fibre rich food-(e.g., whole grains, legumes, vegetables, and fruits).
223494441|NCT06763952|OTHER|AI-BRIDGE|AI-based eye screening program
223494442|NCT07059819|DEVICE|Local hyperthermia device|Local hyperthermia at 44℃ for 30 mins on cervical region, at days of 1,2,3 and 17, 18.
223494443|NCT07058558|BEHAVIORAL|Nutrition Education and Community Gardening|Participants will be presented with 16 nutrition education modules based on the Portfolio Diet, through group-based virtual sessions delivered by the investigators for one year. In addition, participants will take part in two community gardening sessions during growing season, and will grow Portfolio Diet foods such as eggplant, okra, and temperate climate fruit.
223494444|NCT06758388|OTHER|home exercise program|The prepared home exercise program is a program that includes gradual strengthening exercises that participants will do once a day, 5 days a week, for 8 weeks. The exercises will be performed as 1 set for the first 2 weeks, 2 sets in the 3rd and 4th weeks, and 3 sets in the last 4 weeks.
223511760|NCT05450120|OTHER|Functional Rehabilitation|Functional rehabilitation protocol
223511761|NCT05450120|OTHER|Neuromuscular Electrical Stimulation|Neuromuscular electrical stimulation protocol
223511762|NCT02447406|DRUG|AZD6094|
223511763|NCT02447406|DRUG|docetaxel|
223511764|NCT00714363|PROCEDURE|LASIK|Refractive surgery
223589210|NCT05061628|DRUG|JS006 in combination with Toripalimab|"1. JS006 in combination with Toripalimab dose-escalation: JS006, 2 or 3 specific dose, IV infusion, every 3 weeks (q3w), combined with Toripalimab, 240mg, IV infusion, every 3 weeks (q3w).~2. JS006 in combination with Toripalimab dose-extension: JS006, 1 or 2 specific dose, IV infusion, every 3 weeks (q3w), combined with Toripalimab, 240mg, IV infusion, every 3 weeks (q3w).~3. JS006 in combination with Toripalimab indications expansion: JS006, RP2D, IV infusion, every 3 weeks(q3w), combined with Toripalimab, 240mg, IV infusion, every 3 weeks (q3w)."
223589211|NCT04556422|OTHER|Aerobic exercise|15 minutes of aerobic exercise using stationary bicycle
224186132|NCT02760420|DRUG|Placebo|Oral placebo dispersible tablets (DT), 250 mg tablets, given according to age band, two times daily
224186133|NCT01272245|DRUG|Omacetaxine|1.25 mg/m2 subcutaneously (SQ) every 12 hours (+/- 3 hours) for 3 days (Days 1-3). Each cycle will be 4-7 weeks.
224186134|NCT01272245|DRUG|Cytarabine|20 mg subcutaneously every 12 hours (+/- 3 hours) for 7 days (Days 1-7). Each cycle will be 4-7 weeks.
224186135|NCT00483067|DRUG|2-CdA|12 mg/m\^2/day by vein (IV) Continuous Infusion x 5 Days
224186136|NCT00483067|DRUG|Ara-C|1 gm/m\^2/day IV Over 2 Hours x 5 Days
224186137|NCT00483067|DRUG|G-CSF (Granulocyte colony-stimulating factor)|5 mcg/kg/day given under the skin (subcutaneously) starting Day 9
224186138|NCT06323863|PROCEDURE|stapedectomy|stapes removal and replacement by a prosthesis
224186139|NCT06323863|RADIATION|ultra high resolution CT|imaging study
224186140|NCT02557815|DEVICE|Repetitive Transcranial Magnetic Stimulation|Repetitive 10Hz right DLPFC stimulation using Magstim TMS apparatus
224308749|NCT06621004|DRUG|Patients will receive propranolol 1-2 mg.|Patients will receive propranolol 1-2 mg. prepared in a 10 ml syringe (100 ug/ml).
224308750|NCT06621004|DRUG|Patient receives magnesium sulphate|Magnesium sulphate 10%: 1g ampoule (10ml), will be prepared in a syringe pump to be given at a rate of 40 ml/hr . Another syringe of 10 ml 0.9% sodium chloride will be prepared to be given in group (P).
223494445|NCT06758388|BEHAVIORAL|home exercise program + brisk walking exercise|In addition to the home exercise program applied by the control group, a brisk walk will be performed. The brisk walking exercise will be done for 30 minutes, 5 days a week for 8 weeks. The intensity of the exercise will be adjusted according to the Borg CR-10 scale and the Speech test. Moderate intensity exercise is recommended for participants. The participant will walk rhythmically for 30 minutes at a speed where he/she will give 4-6 points on the Borg CR-10 Scale, and can speak a few sentences without getting out of breath according to the Speech test, but cannot sing. Before and after the brisk walk, he/she will be asked to walk at a slow speed for 5 minutes (warm-up-cool down).
223494446|NCT06769022|BEHAVIORAL|Goal Setting and Exercise Intensity Intervention|Participants' goal-setting and exercise intensity are manipulated based on group assignment.
223494447|NCT03630991|DRUG|Edetate Calcium Disodium|Given IV
223494448|NCT03630991|DIETARY_SUPPLEMENT|Multivitamin|Given PO
223494449|NCT03630991|DRUG|Succimer|Given PO
223745743|NCT06214572|DRUG|Systemic therapy (Gemcitabine plus Cisplatin plus Durvalumab)|"Durvalumab 1500 mg via intravenous (IV) infusion q4w, starting on Cycle 1 in combination with cisplatin 25 mg/m2 and gemcitabine 1000 mg/m2 each administered on Days 1 and 8, q3w.~Duration 3 months Durvalumab (12 months)"
223745744|NCT06214572|DRUG|Systemic therapy (Gemcitabine plus cisplatin plus nab-paclitaxel)|Gemcitabine 800 mg/m2, cisplatin, 25 mg/m2, and nab-paclitaxel 100 mg/m2, on days 1 and 8, q3w Duration: 3 months
223745745|NCT03036098|BIOLOGICAL|Nivolumab|Specified Dose on Specified Days
223745746|NCT03036098|BIOLOGICAL|Ipilimumab|Specified Dose on Specified Days
223494454|NCT07064616|DEVICE|Catheter ablation using pulsed field ablation|"PulseSelect™ Pulsed Field Ablation System:~This intervention uses the PulseSelect™ system to perform pulsed field ablation (PFA) for pulmonary vein isolation in patients with persistent atrial fibrillation. PFA delivers short, high-voltage electrical pulses that selectively affect myocardial cells while minimizing damage to surrounding tissues such as the esophagus or phrenic nerve. This technique is designed to reduce procedural complications and improve safety compared to traditional thermal ablation methods."
223589212|NCT04556422|OTHER|Sauna bathing|Passive heat exposure
223589213|NCT05308771|DEVICE|VPC syringe|Use of the visual pressure control syringe for epidural space detection
223494455|NCT07064616|DEVICE|Catheter ablation using cryoballoon ablation|"Cryoballoon Ablation:~This intervention uses a cryoballoon catheter to perform pulmonary vein isolation by freezing tissue around the pulmonary veins. The balloon delivers extreme cold temperatures to create transmural lesions that block abnormal electrical signals responsible for atrial fibrillation. Cryoballoon ablation is widely used and considered effective for atrial fibrillation treatment but may carry risks related to collateral tissue injury."
223589214|NCT00548717|DRUG|Sirolimus|
223589215|NCT00548717|DRUG|Mycophenolate mofetil|
223589216|NCT00548717|DRUG|Bortezomib|
223589217|NCT04989647|RADIATION|No adjuvant therapy|Patients will not receive any type of adjuvant therapy.
223589218|NCT04989647|RADIATION|Adjuvant radiotherapy|Patients will receive adjuvant treatment composed of either pelvic radiotherapy external beam radiotherapy ± brachytherapy or concomitant chemoradiotherapy (pelvic radiotherapy + chemotherapy).
223589219|NCT03587753|OTHER|Dietary fatty acid partitioning|There is no intervention as such, just a physiological assessment of the partitioning and oxidation of two different types of dietary fatty acids
223589220|NCT02759224|DRUG|BRI-1501|
224186141|NCT05217004|OTHER|Dementia Talk mobile application|The app includes features for caregivers such as medication management, behavior symptom management and monitoring, stress management tips and strategies, and task management with other care providers.
224186142|NCT05217004|OTHER|CLEAR Dementia Care mobile application|The app provides information about dementia (e.g., types and symptoms of dementia) and allows caregivers to record, monitor, and chart behaviors in the care recipient.
224186143|NCT02216227|DRUG|Mupirocin|Patients with known positive MRSA or MSSA and patients who have unknown status will decolonize BID x 5 days
224186144|NCT02216227|DRUG|Chlorhexidine gluconate|"Patients that are MRSA or MSSA positive or have unknown status will bathe in CHG daily x 5 days.~Patients that are MRSA or MSSA negative will bathe with CHG the night before and morning of surgery."
224186145|NCT02216227|DRUG|Cefazolin|All patients will receive Cefazolin during surgery
224308751|NCT05485701|DIAGNOSTIC_TEST|Screening tools for common mental disorders|A number of screening tools will be administered which will establish the likelihood of depression, anxiety, PTSD, somatisation and suicidality.
223494456|NCT07065058|DRUG|Drug: VCT220, Repaglinide, Rosuvastatin, and Digoxin|Single dose of Repaglinide at Day 2, Rosuvastatin and Digoxin at Day 3 Orally VCT220 once daily from Day 9 to Day 78, titrated from 20mg to 160mg. Co-administrated Repaglinide at Day 72, co-administrated Rosuvastatin and Digoxin at Day 73
223494457|NCT07064005|DRUG|Gamma- glutamylcysteine|400 mg (two times) per day
223494458|NCT07066202|OTHER|No intervention is planned in this study. Only the assessment of a specific condition.|No intervention is planned in this study. Only the assessment of a specific condition.
223494459|NCT06776341|OTHER|GEMIN5-Related Neurodevelopmental Disorder|This is an observational study. The investigators will collect data from participants' medical records regarding neurodevelopmental outcomes (eg. cognitive, speech and language, motor skills, developmental skills, vision, hearing), Time to event (Acquistion and loss of developmental milestones), and, if available, data regarding MRIs (presence of cerebellar atrophy), survival, visiion, hearing, and biomarkers of disease.
223494460|NCT06769490|DRUG|Ziftomenib|Participants will receive treatment in tablet form
223494461|NCT06769490|DRUG|Quizartinib|Participants will receive treatment in tablet form
223494462|NCT01579552|BEHAVIORAL|survey, questionaire|The intervention components (mailed tailored print materials followed by telephone-delivered Brief MI). Following enrollment into the study and completion of the informed consent form and baseline survey, participants will be randomized to the active intervention group or the attention control group. The data that will be used in the analysis will come from the baseline survey, medical records of breast imaging studies, and a 12-month follow-up questionnaire.
223494463|NCT01579552|BEHAVIORAL|survey, questionaire|The intervention components (mailed tailored print materials followed by telephone-delivered Brief MI). Following enrollment into the study and completion of the informed consent form and baseline survey, participants will be randomized to the active intervention group or the attention control group. The data that will be used in the analysis will come from the baseline survey, medical records of breast imaging studies, and a 12-month follow-up questionnaire.
223494464|NCT02872714|DRUG|pemigatinib|Pemigatinib once a day by mouth for 2 consecutive weeks and 1 week off therapy.
223494465|NCT02872714|DRUG|pemigatinib|Pemigatinib once a day by mouth continuously.
223494466|NCT07068932|DRUG|SHR-4506 Injection|SHR-4506 injection.
223589221|NCT02759224|DRUG|Lafutidine|
224308752|NCT01243112|DRUG|1% Lidocaine with Epinephrine (1:100,000)|0.2ml Intradermal injection once.
224308753|NCT01243112|DRUG|0.25% Bupivacaine with Epinephrine (1:200,000)|0.2ml Intradermal injection once.
224308754|NCT01243112|DRUG|0.5% Lidocaine, 0.125 Bupivacaine, and epi (1:150,000)|0.2ml Intradermal injection once.
224308755|NCT01243112|DRUG|1% Lidocaine, 0.5% Bupivacaine, and epinephrine (1:150,000)|0.2ml Intradermal injection once.
224308756|NCT04892225|BEHAVIORAL|Technology-supported behavioral intervention (text message)|A simple text message regarding the salt and fluid restriction in order to reduce the inter-dialytic weight gain will be send on daily basis to all the individuals in the intervention group.
224308757|NCT03824496|DIAGNOSTIC_TEST|Cranial Accelerometry Measurement|Measuring the HeadPulse using cranial accelerometry
224308758|NCT02444117|OTHER|functional rehabilitation of social communication|
223511765|NCT00714363|PROCEDURE|SBK|Refractive surgery
223511766|NCT00721890|DIETARY_SUPPLEMENT|Double-Brewed Green Tea|liquid, 4 celsius; 500 mL ID, 3 hours after meals and 1 hour before next meal; duration: to the first of the following events: 18 months or relapse
223511767|NCT01585207|DRUG|vigabatrin|3 tablets, bid for 8 weeks
223511768|NCT03489083|OTHER|Strength training|Strength training was performed three times per week for twelve weeks. Supervised (by qualified sport and exercise scientists) exercise was performed in a gym on three non-consecutive days of the week. Each session lasted \~60 min and consisted of a warm up, the resistance exercise training and a cool down. The training programme consisted of a combination of upper and lower body exercises using gym equipments, free weights and body weight as the primary resistance. The twelve weeks of strength training were divided into three mesocycles of four weeks each. The resistance training was performed using two to three sets per exercise at intensities between 12-15 repetition maximum-RM.
223511769|NCT03489083|OTHER|No Training|"Control group performed a placebo stretching/relaxing session once a week (for adherence purposes) for twelve weeks. To avoid any significant adaptation, all stretching exercises (for large muscle groups only) were performed at very low intensity without any significant discomfort."
223511770|NCT00742690|DRUG|terlipressin given by intravenous boluses and albumin|Patients who will be randomly assigned to arm 1 will received terlipressin given by intravenous boluses at the initial dose of terlipressin was 0.5 mg/4 hr. In case of non response, the dose of terlipressin was progressively increased up to a maximum of 2 mg/4 hr. Human albumin will be given intravenously at the dose of 1 g/kg of body weight on the first day followed by 20-40 g/day.
223511771|NCT00742690|DRUG|terlipressin given by continuous intravenous infusion and albumin|Patients who will be randomly assigned to arm 1 will received terlipressin given as intravenous boluses at the initial dose of 0.5 mg/4 hr. In case of non response, the dose of terlipressin will be progressively increased up to a maximum of 2 mg/4 hr. Human albumin will be given at the dose of 1 g/kg of body weight at the first day followed by 20-40 g/day.
223511772|NCT03426852|OTHER|No intervention|No intervention
223511773|NCT01254539|PROCEDURE|Laminectomy and bone marrow stem cells transplantation|"Autologous bone marrow cells collection under sedation. Sixty ml are obtained and processed through a ficoll gradient.~T3-T4 laminectomy and bone marrow ficoll separated mononuclear autologous cells intraspinal transplantation"
223511774|NCT01254539|PROCEDURE|Intrathecal infusion of autologous bone marrow stem cells|"Autologous bone marrow cells collection under sedation. Sixty ml are obtained and processed through a ficoll gradient.~Patients were drawn 2 ml of cerebrospinal fluid and infused 2 ml (two 1 ml syringes) of Autologous Stem Cells."
223511775|NCT01254539|PROCEDURE|Intrathecal infusion of placebo (saline solution).|Patients were infused 2 ml of saline solution
223511776|NCT02956564|PROCEDURE|intrauterine intervention|choose different surgeries according to different causes
223589222|NCT02759224|DRUG|Irsogladine maleate|
223589223|NCT02049619|DEVICE|pharyngeal pack|Following endotracheal intubation, one saline soaked, gauze pharyngeal pack was inserted into the hypopharynx under direct vision using McGill's forceps. The packs were tied to the endotracheal tube and their placements were documented on the scrub nurse's count board.
223589224|NCT01968577|DRUG|Rosuvastatin|Rosuvastatin 40 mg before percutaneous coronary intervention
223589225|NCT03459053|BEHAVIORAL|CBART|Cognitive Behavioral protocol that uses art-making for stress reduction and cognitive interventions
223589226|NCT00275977|PROCEDURE|Coronary catherization and stem cell infusion|
224186146|NCT02216227|DRUG|Vancomycin|Patients who are positive for MRSA, or have unknown MRSA status, will receive vancomycin along with cefazolin during surgery.
224186147|NCT02216227|DRUG|Nasal Povidone Iodine|The purpose of this research is to evaluate a SSI checklist. This checklist includes decolonizing a patient's nose and skin and optimizing antibiotics prior to surgery. At the time that we wrote it, the predominate product to decolonize patient's noses was mupirocin. However, in 2017, an FDA final monograph stated that nasal povidone-iodine may be used for pre-surgical decolonization. Nasal povidone-iodine should be able to overcome barriers to checklist implementation that we identified in Aim 3. We now plan to replace the nasal agent mupirocin with the nasal agent povidone-iodine at 3 participating medical centers (Iowa City VA, Minneapolis VA and Portland VA) to assess whether this overcomes the barriers to our SSI checklist.
224186148|NCT04927858|DRUG|Empagliflozin|Empagliflozin
224186149|NCT01026558|DRUG|Ceftobiprole|Ceftobiprole, 500 mg as single iv infusion over 2 hours
224186150|NCT01017211|OTHER|auricular acupuncture|"Experimental group to receive ear needles in the Battlefield Acupuncture points.~Sham group to receive ear needles at points thought to be ineffective but standardized."
224186151|NCT00298792|BEHAVIORAL|Cognitive Behavioral Treatment|Psychosocial treatment emphasizing teaching of coping skills to maintain sobriety.
224186152|NCT00298792|BEHAVIORAL|Cognitive-behavioral treatment|Psychosocial treatment emphasizing teaching of coping skills to maintain sobriety
224186153|NCT03355001|DEVICE|Monosyn® Quick|"* Mucosal sutures in the facial and oral~* Dermal sutures, particularly in pediatrics~* Episiotomy~* Circumcision"
224186154|NCT02545504|DRUG|Andecaliximab|800 mg administered intravenously on Days 1 and 15 of each 28-day treatment cycle
224186155|NCT02545504|DRUG|Placebo|Administered intravenously on Days 1 and 15 of each treatment cycle
224186156|NCT02545504|DRUG|Leucovorin|Administered intravenously per standard of care on Days 1 and 15 of each treatment cycle
224186157|NCT02545504|DRUG|5-fluorouracil|Administered intravenously per standard of care on Days 1 and 15 of each treatment cycle
224186158|NCT02545504|DRUG|Oxaliplatin|Administered intravenously per standard of care on Days 1 and 15 of each treatment cycle
224186159|NCT01568983|DIETARY_SUPPLEMENT|Placebo|500 ml/day Per 100g 6.25 g sucrose 6.25 g maltodextrin 1.3 g citric acid E330 (pH 3.0) 2.5 g Carmine solution E120 (4% carmine colouring agent) 0.025 g blueberry aroma Potassium sorbate E202 water
224308759|NCT01001624|OTHER|Melanil facial cream|Dosage commensurate with surface to be treated, Melanil facial cream (Topical use), twice a day, for 8 weeks. The affected surface will be washed and dried before application with a thin layer of Melanil facial cream.
223511777|NCT03355261|PROCEDURE|complete remission (CR) group|According to the RECIST 1.1, 32 patients were allocated into the complete remission (CR) group based on their responses to neoadjuvant chemotherapy (NAC).
223511778|NCT03355261|PROCEDURE|partial remission (PR) group|According to the RECIST 1.1, 61 patients were allocated into the partial remission (PR) group based on their responses to neoadjuvant chemotherapy (NAC).
223511779|NCT03355261|PROCEDURE|stable disease (SD) group|According to the RECIST 1.1, 12 patients were allocated into the stable disease (SD) group based on their responses to neoadjuvant chemotherapy (NAC).
223511780|NCT03355261|PROCEDURE|progressive disease (PD) group|According to the RECIST 1.1, 5 patients were allocated into the progressive disease (PD) group based on their responses to neoadjuvant chemotherapy (NAC).
223511781|NCT04858347|DEVICE|Total knee replacement|Implantation of the GEMINI SL Fixed Bearing PS knee prosthesis. The operation technique of the GEMINI SL Fixed Bearing PS knee prosthesis will be followed.
223511782|NCT02070380|DRUG|MultiHance 0.1 mmol/kg|MultiHance administered at 0.1 mmol/kg
223511783|NCT02070380|DRUG|Dotarem|Dotarem administered at 0.1 mmol/kg
223511784|NCT02070380|DRUG|MultiHance 0.05 mmol/kg|MultiHance administered at 0.05 mmol/kg
223511785|NCT05479227|PROCEDURE|Management of bile duct injury|There are different options for BDI management, we analyzed their utilization and results
223511786|NCT03850431|BEHAVIORAL|Social Norms + Behavioral Instructions|A letter with two types of nudges. One points out the common behavior of attending appointments. And one provides clear, specific instructions for making appointment changes. The appointment reminder also includes usual care (basic appointment information on date, location, and phone number(s) for scheduling changes).
223511787|NCT03850431|BEHAVIORAL|Caring + Consequences for Others + Behavioral Instructions|A letter with three types of nudges. One suggests that the institution cares about the patient. One highlights a potential negative consequence for others if the patient no-shows. And one provides clear, specific instructions for making appointment changes. The appointment reminder also includes usual care (basic appointment information on date, location, and phone number(s) for scheduling changes).
223511788|NCT03850431|BEHAVIORAL|Caring + Consequences for Self + Behavioral Instructions|A letter with three types of nudges. One suggests that the institution cares about the patients. One highlights potential negative consequences for the patient if s/he no-shows. And one provides clear, specific instructions for making appointment changes. The appointment reminder also includes usual care (basic appointment information on date, location, and phone number(s) for scheduling changes).
223511789|NCT03850431|BEHAVIORAL|Caring + Consequences for Others + Consequences for Self + Social Norms + Behavioral Instructions|A letter with all types of nudges combined. One suggests that the institution cares about the patients. One highlights a potential negative consequence for others if the patient no-shows. One highlights potential negative consequences for the patient if s/he no-shows. One points out the common behavior of attending appointments. And one provides clear, specific instructions for making appointment changes. The appointment reminder also includes usual care (basic appointment information on date, location, and phone number(s) for scheduling changes).
224186160|NCT01568983|DIETARY_SUPPLEMENT|Mana-juice|500 ml/day of a grape,cherry, bilberry,aronia juice 13g carbohydrates/100g 150mg K/100g
224186161|NCT01568983|DIETARY_SUPPLEMENT|Optijuice|500 ml/day of a Grape,cherry, bilberry,aronia, black current juice 13g carbohydrates/100g 150mg K/100g
223494467|NCT06475547|OTHER|Descriptive|This study is observational and does not involve any clinical intervention. The primary procedure involves the collection of epicardial fat tissue samples. The collected samples are then processed and analyzed to compare inflammatory gene expression between the two groups. The analysis includes RNA sequencing to identify differentially expressed genes associated with atrial fibrillation and inflammation.
223494468|NCT07062965|DRUG|PF-07248144|KAT6 inhibitor
223494469|NCT07062965|DRUG|Fulvestrant|Endocrine therapy
224186162|NCT05899946|OTHER|A community-based network training program|A 3-phase program including establishing a community-based network, video competition, and Video promotions will be conducted.
224186163|NCT06227689|OTHER|Vaccine chatbot that offering HPV vaccine-related information|The intervention group will be invited to use the HPV vaccine chatbot online through WeChat or any web browsers, where they can ask any questions related to the HPV vaccine and get previously validated answers from the chatbot immediately. All the answers will be drawn from a database, whose content were obtained from official websites of Chinese government, HPV vaccine enterprises, and International organizations like WHO, and had been validated by experts. The intervention lasts two weeks, with invitations sent every four days to reinforce the intervention.
224186164|NCT00967343|BIOLOGICAL|Donor lymphocyte preparation depleted of host functional alloreactive T-cells|Single intravenous infusion with 2x10E6 T-cells/kg
224186165|NCT00609089|BEHAVIORAL|CRAFT-T|The Community Reinforcement and Family Training for Treatment Retention and HIV Risk Reduction treatment (CRAFT-T) was be developed in phase 1 and 2 of the current study and consists of twelve manual-guided weekly one-hour individual sessions for the concerned significant other and 2 one hour sessions for the identified patient. The intervention also allows for up to two additional sessions (total of 14 visits) to help arrange re-entry into substance abuse treatment when needed. The identified patient receives this intervention in addition to the usual services at the drug treatment program (Maryhaven).
223494470|NCT07062965|DRUG|Everolimus|mTOR inhibitor
223494471|NCT07062965|DRUG|Exemestane|Endocrine therapy
223494472|NCT07068607|DRUG|Vonoprazan|Vonoprazan - amoxicillin dual therapy: Vonorazon 20 mg daily for 14 days # amoxicillin 1000 mg by mouth three time daily for 14 days; Vonoprazan-tetracycline dual therapy:Vonorazon 20 mg daily for 14 days # tetracycline 500 mg by mouth three time daily for 14 days; Vonoprazan-minocycline dual therapy:Vonorazon 20 mg daily for 14 days # minocycline 100 mg by mouth two time daily for 14 days; Bismuth-containing quadruple therapy:Amoxicillin 1000 mg, clarithromycin 500 mg, vonoprazan 20 mg, and colloidal bismuth tartrate 220 mg, all twice a day for 14 days
223494473|NCT07068607|DRUG|Tetracycline 500mg tid|Vonoprazan-tetracycline dual therapy:Vonorazon 20 mg daily for 14 days # tetracycline 500 mg by mouth three time daily for 14 days
223494474|NCT07068607|DRUG|Minocycline|Vonoprazan-minocycline dual therapy Vonorazon 20 mg daily for 14 days # minocycline 100 mg by mouth two time daily for 14 days
223494475|NCT07068607|DRUG|Bismuth|Bismuth-containing quadruple therapy:Amoxicillin 1000 mg, clarithromycin 500 mg, vonoprazan 20 mg, and colloidal bismuth tartrate 220 mg, all twice a day for 14 days
223494476|NCT07068607|DRUG|Clarithromycin 500 mg|Bismuth-containing quadruple therapy:Amoxicillin 1000 mg, clarithromycin 500 mg, vonoprazan 20 mg, and colloidal bismuth tartrate 220 mg, all twice a day for 14 days
223494477|NCT07068607|DRUG|Amoxicillin|Vonoprazan - amoxicillin dual therapy:Vonorazon 20 mg daily for 14 days # amoxicillin 1000 mg by mouth three time daily for 14 days; Bismuth-containing quadruple therapy:Amoxicillin 1000 mg, clarithromycin 500 mg, vonoprazan 20 mg, and colloidal bismuth tartrate 220 mg, all twice a day for 14 days
223494478|NCT01434316|DRUG|Dinaciclib|Given IV
223494479|NCT01434316|DRUG|Veliparib|Given PO
223494480|NCT06392126|DRUG|nL-CHCHD-001|Personalized antisense oligonucleotide
223494481|NCT04905901|DRUG|Tranexamic acid|Tranexamic acid nebulization 15 minutes before sinus surgery
223494482|NCT04905901|OTHER|Saline placebo|Normal saline placebo nebulization 15 minutes before sinus surgery
223494483|NCT07071779|OTHER|Alcohol-specific inhibition training|Twelve sessions of alcohol-specific inhibition training
223494484|NCT07071779|OTHER|Control training|Twelve sessions of unspecific inhibition training
223494485|NCT07071402|PROCEDURE|Ultrasound-guided vacuum-assisted excision combined with surgical treatment|Patients undergoing VAE surgery （EnCor® vacuum-assisted minimally invasive rotary system）are placed in an appropriate position, undergo routine disinfection and blanching, and the tumor location is located by ultrasound. After local anesthesia, a vacuum-assisted rotary cutting needle is percutaneous punctured beneath the tumor. Under ultrasound guidance, the tumor tissue is gradually resected until the ultrasound shows complete tumor resection. The resected tissue is sent for pathological examination. After the patient is confirmed to have breast cancer through VAE resection biopsy, depending on the patient's specific condition, they are hospitalized for radical mastectomy. The surgical methods can be breast-conserving surgery or mastectomy. At the same time, sentinel lymph node biopsy is performed, and the resected tissue is sent for pathological examination. The surgical process follows the surgical treatment norms for breast cancer.
223494486|NCT07070700|DRUG|QL1706 (bispecific antibody targeting PD-1 and CLTA-4)|QL1706 will be administered by IV, 5 mg/kg on day 1 of each 21 day cycle until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
223494487|NCT07070700|DRUG|Lenvatinib|Lenvatinib will be administered (bodyweight ≥ 60 kg, 12 mg; \< 60 kg, 8 mg) orally daily until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
223494488|NCT07070700|PROCEDURE|cryoablation|Cryoablation will be performed with a two-cycle freeze-thaw phase protocol; US or non-contrast CT images will be obtained to visualize the evolving ablation zone. Lenvatinib plus QL1706 will be administered 1-3 days after cryoablation.
223494489|NCT07071337|DRUG|SKB264|5mg/kg, IV on Day 1 and Day 15 of each 28 day cycle
223494490|NCT07071337|DRUG|Nab-paclitaxel|100 mg/m\^2, IV, on Days 1, 8, and 15 every 4 weeks
223494491|NCT07071337|DRUG|Paclitaxel|90 mg/m\^2, IV, on Days 1, 8, and 15 every 4 weeks; or 80 mg/m\^2, IV, weekly, every 3 weeks
224186166|NCT00609089|BEHAVIORAL|Treatment as usual|Treatment as usual will be the normal course of treatment for concerned significant others (CSOs) in the outpatient department.
224186167|NCT01733394|DRUG|"Lamotrigine Generic A Lamotrigine Generic B Lamotrigine Brand"|
224186168|NCT01733394|DRUG|lamotrigine|
224186169|NCT04476641|OTHER|CELL|inject the DC-CIK(dendritic cell activated and cytokine induced killer cell)
224186170|NCT02217046|PROCEDURE|device replacement(pocket capsule removal)|remove previously inserted cardiac device and posterior pocket capsule. the pocket that will receive the heart mechanism is sterilized with a hydroperoxide soaked gauze
224186171|NCT05891457|COMBINATION_PRODUCT|Nutritional Intervention|"* Severe acute malnourished children were provided with appropriate nutritional therapy/treatment that include supplementation of a high-calorie diet; i.e., F-100 milk and khichuri-halwa for nutritional rehabilitation.~* Egg milk and micronutrient supplementation for recovery from severe stunting following standard guidelines for facility based management and recently conducted community based nutrition intervention studies.~* Wasted children were treated with suitable local nutritional management (NM), such as infant and young child feeding practices (IYCF), providing MNP and nutrition education."
224186172|NCT02225626|DRUG|BI 1060469|tablet, oral administration with 240 mL of water after an overnight fast of at least 10 h
224186173|NCT02225626|DRUG|BI 1060469|tablet, oral administration with 240 mL water 30 minutes after subject is served a standardised high-caloric high-fat administration
224186174|NCT02225626|DRUG|Other: standard breakfast|tablet, oral administration with 240 mL water 30 minutes after subject is served a standardised high-caloric high-fat administration
224186175|NCT03461705|DEVICE|Volcano Verrata Pressure Wire|"Steerable guidewire with a pressure transducer mounted 3cm proximal to the tip. The guidewire has a diameter of 0.014.~and is packaged preconnected to the connector with a torque device to facilitate navigation through the vasculature."
224186176|NCT03461705|DEVICE|St. Jude Medical (SJM) Aeris Pressure Wire System|The pressure wire is a 0.014'' guidewire with a pressure and temperature sensor integrated into the tip to enable measurements of physiological parameters.
224186177|NCT01508182|DRUG|Canagliflozin tablets|Type = exact number, unit = mg, number = 300, form = tablet, route = oral use. One canagliflozin tablet taken orally (by mouth) on Day 1 of Treatment Period 1.
224186178|NCT01508182|DRUG|Metformin IR tablets|Type = exact number, unit = mg, number = 500, form = tablet, route = oral use. Two metformin IR tablets taken orally (by mouth) on Day 1 of Treatment Period 1.
224186179|NCT01508182|DRUG|Canagliflozin/metformin IR FDC tablets|Type = exact number, unit = mg, number = 50/500, form = tablet, route = oral use. Two Canagliflozin/metformin IR FDC tablets taken orally on Day 1 of Treatment Period 2.
224186180|NCT01508182|DRUG|Canagliflozin tablets|Type = exact number, unit = mg, number = 300, form = tablet, route = oral use. One canagliflozin tablet taken orally (by mouth) on Day 1 of Treatment Period 2.
224186181|NCT01508182|DRUG|Metformin IR tablets|Type = exact number, unit = mg, number = 500, form = tablet, route = oral use. Two metformin IR tablets taken orally (by mouth) on Day 1 of Treatment Period 2.
224308760|NCT01001624|OTHER|Hydroquinone 2% cream|Dosage commensurate with surface to be treated, Hydroquinone 2% cream (Topical use), twice a day, for 8 weeks. The affected surface will be washed and dried before application with a thin layer of Hydroquinone 2% cream.
223494492|NCT07071337|DRUG|Capecitabine|1000-1250 mg/m\^2, orally, Days 1-14, twice daily, every 3 weeks
223494493|NCT07071259|OTHER|TMS Stimulation|For the TMS session, participants will be positioned on a chair, in a seated position. They will be equipped with an EEG cap 64 active electrodes, using gel to ensure good measurements of brain activation, and a sensor on the forehead to measure the location of the head in space for the neuronavigation system. They will also wear headphones generating white noise to mask the TMS coil noise. Preparation time for the EEG acquisitions is estimated at 30 min. The TMS coil will be shaped in 8 for good spatial resolution. It will be positioned on the participant's head using a robot (approved medical CE) allowing good targeting accuracy and stability during the experiment. The stimulation target will be defined beforehand on the participant's MRI, and the robot will read this information to position itself.
223494494|NCT06383611|COMBINATION_PRODUCT|VT-X7 Treatment System|Local antibiotic irrigation via the VT-X7 Treatment System adjuvant to two-stage exchange arthroplasty per standard of care.
223494495|NCT06854328|DEVICE|Prism|Prism is using an amygdala-fMRI-guided model for processing EEG signals. The model, termed EEG fMRI pattern (EFP), uses several electrodes EEG-signal to produce a real time amygdala-EFP biomarker signal. GrayMatters' product, Prism, is used to train patients in downregulating the amygdala-derived-EFP biomarker during therapy sessions.
223494496|NCT07073404|DRUG|Omalizumab Injection|Treatment with omalizumab in monotherapy for 16 weeks in patients allergic to vegetables due to sensitization to lipid transfer proteins (LTPs) and profilin.
223494497|NCT07073274|DIAGNOSTIC_TEST|EEG analysis|All patients will have a continous recording of their EEG during anesthesia
224186182|NCT01508182|DRUG|Canagliflozin/metformin IR FDC tablets|Type = 2, unit = mg, number = 50/500, form = tablet, route = oral use. Two Canagliflozin/metformin IR FDC tablets taken orally on Day 1 of Treatment Period 1.
224186183|NCT06924619|RADIATION|neoadjuvant radiotherapy|Target the primary tumor region with 40-50 Gy in 20-25 fractions.
224186184|NCT06924619|DRUG|cisplatin|The cisplatin will be given concurrently with radiotherapy (25 mg/m² , D1, QW) for 4-5 cycles.
224186185|NCT04390334|DRUG|Daridorexant|Daridorexant will be administered orally as 1 film-coated tablet of 50 mg strength to be taken in the morning under fasted conditions.
224186186|NCT04390334|DRUG|Famotidine|Famotidine will be administered orally as 1 film-coated tablet of 40 mg strength to be taken in the morning under fasted conditions.
224186187|NCT04390334|DRUG|Efavirenz|Efavirenz will be administered orally as 1 film-coated tablet of 600 mg strength o.d. in the evening.
224308761|NCT01081834|DRUG|Canagliflozin|One 100 mg or 300 mg over-encapsulated tablet orally (by mouth) once daily for 52 weeks (Main Study) or 26 weeks (High Glycemic Substudy)
224308762|NCT01081834|DRUG|Placebo|One matching placebo capsule orally once daily for 26 weeks (Main Study)
224308763|NCT01081834|DRUG|Sitagliptin|One 100 mg over-encapsulated tablet orally once daily beginning at Week 26 until Week 52 (Main Study)
224308764|NCT02988024|DRUG|LY03005|LY03005
224308765|NCT02988024|DRUG|Pristiq|
224186188|NCT04087824|DEVICE|AI assisted recognition of colonic segments|After receiving standard bowel preparation regimen, patients go through colonoscopy under the AI monitoring device. The whole withdrawal process is monitored by AI associated recognition system. Key colonic segments include ileocecal valve, ascending colon, transverse colon, descending colon, sigmoid colon and rectum. When typical anatomic sites are detected, the AI device will automatically captured relevant images and report the name of each segment on the screen. The operating endoscopy expert will give the final answer and judge the performance of AI, which is set as a golden standard. Then all the AI captured images will be reviewed by human group, which consists of three to five experienced endoscopic physicians.
224186189|NCT01047631|BEHAVIORAL|Functional circuit training and lifestyle counseling|"Tests are performed at the beginning, and repeated after 12 and 24 weeks:~* Measure general fitness levels such as walking, strength and balance.~* Walk on a treadmill to measure your maximum fitness while wearing a mask to analyze your oxygen use.~* Blood and urine tests and a heart ultrasound.~* Questionnaires \& activity measures.~Group assignment for 12 weeks:~-Exercise classes \& activity guidance: Twice-weekly class that focuses on exercises that are similar to daily activities, such as walking and carrying objects. Obtain customized information and education to help you exercise and follow a low salt diet.~Follow-up:~-Monthly phone calls during the 12 week follow up period."
224186190|NCT01047631|BEHAVIORAL|Health education and independent walking|"Tests are performed at the beginning, and repeated after 12 and 24 weeks.~* Measure general fitness levels such as walking, strength and balance.~* Walk on a treadmill to measure your maximum fitness while wearing a mask to analyze your oxygen use.~* Blood and urine tests and a heart ultrasound.~* Questionnaires \& activity measures.~Group assignment for 12 weeks:~-Health education and walking: Weekly health education classes covering general topics related to heart failure, like medications, diet and exercise. Receive a pedometer for an at-home walking program.~Follow-up:~-No follow up support"
224186191|NCT00790595|DRUG|SU011248|5 Subjects will receive 50.0 mg/d of the study drug for 2 weeks.
224186192|NCT00790595|DRUG|SU011248|5 Subjects will receive 50.0 mg/d of the study drug for 4 weeks.
224186193|NCT00790595|DRUG|SU011248|5 Subjects will receive 50.0 mg/d of the study drug for 1 week.
224186194|NCT00790595|DRUG|SU011248|5 Subjects will receive 37.5 mg/d of the study drug for 1 week.
223494498|NCT07070349|DRUG|HRS-6213|HRS-6213 IV administered as imaging agent for PET scan.
223494499|NCT03973229|DRUG|Estradiol patch|Estradiol (E2) patches at a dose of 100ug will be applied 24-48 hours before the MRI scan is performed.
223494500|NCT03973229|OTHER|Placebo patch|Placebo patch identical to the estradiol patch will be applied 24-48 hours before the MRI scan is performed.
223494501|NCT07068581|PROCEDURE|Maternal voice|"Mothers of the infants in the intervention group will be asked to read aloud the lyrics of a designated in a calm tone of voice in a quiet environment, and their voices will be recorded. The recorded maternal voice will then be played to the infants in the NICU using the same Bluetooth-enabled device with built-in speakers. The audio device will be placed inside the incubator or open warmer, approximately 20-30 cm from the infant.~Each infant will be assigned an individual audio device, which will be used exclusively for that infant. Maternal voice playback will begin 20 minutes before morning and evening oral feedings and will continue throughout the feeding session, twice daily, for a maximum of 5 days. If the infant is discharged earlier, the intervention will be discontinued.. During the playback of the maternal voice, monitor sounds in the NICU will be minimized, and the staff will be instructed to speak quietly to maintain a calm environment."
223494502|NCT07068581|OTHER|Control Group (standard feeding )|The control group will not be exposed to maternal voice, and standard feeding procedures will be applied.
223494503|NCT06898151|PROCEDURE|CEA/CAS plus best medical treatment|Timing of CEA/CAS plus best medical treatment
223494504|NCT05813873|OTHER|Triflow|Triflow
223494505|NCT05813873|OTHER|Control|Exercise
223494506|NCT06632951|DRUG|Livmoniplimab|Intravenous (IV) Infusion
223494507|NCT06632951|DRUG|Budigalimab|IV Infusion
223494508|NCT06632951|DRUG|Docetaxel|IV Infusion
223494509|NCT06632951|DRUG|Paclitaxel|IV Injection
223494510|NCT06632951|DRUG|Docetaxel|IV Injection
223494511|NCT06632951|DRUG|Paclitaxel|IV Infusion
224186195|NCT00790595|DRUG|SU011248|5 Subjects will receive 37.5 mg/d of the study drug for 2 weeks.
224186196|NCT04785781|OTHER|without masks|apply a bicycle ergometer test protocol to individuals without a mask
224186197|NCT04785781|OTHER|Surgical face mask (Vheal Med Co., Ltd., Istanbul, Turkey)|apply a bicycle ergometer test protocol to individuals with a surgical mask
224186198|NCT04785781|OTHER|FFP2\N95 protective face mask (Musk protective technology, Gaziantep, Turkey)|apply a bicycle ergometer test protocol to individuals with a FFP2\\N95 mask
224186199|NCT05476965|COMBINATION_PRODUCT|induction therapy; surgery; radiotherapy|Radiotherapy: de-escalation radiotherapy or standard radiotherapy
224186200|NCT00103831|DRUG|Oral Taxane|
224186201|NCT04984629|DEVICE|HYDRAFIL|The HYDRAFIL System contains the following items: the Delivery System and the Pressure Gauge. The HYDRAFIL implant is contained within a pre-filled syringe that is inserted into the delivery system housing during the manufacturing process. The implant is heated within the delivery system prior to use to ensure a flowable implant that can be injected through a standard coaxial needle.
223494512|NCT06632951|DRUG|Gemcitabine|IV Infusion
223494513|NCT05063162|DRUG|Rozanolixizumab|"* Pharmaceutical form: Solution for infusion~* Route of administration: subcutaneous infusion~Participants will receive pre-specified doses of rozanolixizumab."
223494514|NCT05063162|OTHER|Placebo|"* Pharmaceutical form: Solution for infusion~* Route of administration: subcutaneous infusion~Participants will receive placebo."
223494515|NCT07069244|DIAGNOSTIC_TEST|Complete Blood Count Test|Complete blood count test provides data on total white blood cell count, neutrophil count, neutrophil percentage, lymphocyte count, lymphocyte percentage, monocyte count, monocyte percentage, eosinophil count, eosinophil percentage, basophil count, basophil percentage, platelet count, platelet distribution width (PDW), mean platelet volume (MPV), plateletcrit (PCT), erythrocyte count, hemoglobin, hematocrit (HCT), mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC) and red blood cell distribution width (RDW). In addition, neutrophil-lymphocyte ratio (NLR), monocyte-lymphocyte ratio (MLR), platelet-leukocyte ratio (PLR), Pan-Immune-Inflammation Value (PIV), Systemic Immune-Inflammation Index (SII), Hemoglobin-to-Red Cell Distribution Width Ratio (HRR) values are also formulated from these parameters.
224186202|NCT00950755|BIOLOGICAL|tositumomab and Iodine I 131 tositumomab (anti-B1 antibody)|For the treatment of 1st or 2nd relapsed indolent B cell lymphomas or B cell lymphomas that have transformed to a more aggressive histology
224186203|NCT02549040|DRUG|Treatment A: Doravirine 100 mg film coated tablet|Single doravirine 100 mg film coated tablet administered orally at the start of Period 2
223589227|NCT05375214|DEVICE|Magnus Transcranial Magnetic Neuromodulation System (MNS) with SAINT®(Stanford Accelerated Intelligent Neuromodulation Therapy)|Novel intermittent theta burst stimulation protocol with individualized targets in the brain for stimulation using structural and functional MRI inputs
224186204|NCT02549040|DRUG|Treatment B: Doravirine 150 mg tablet (40% drug loaded granule)|Single doravirine NF Type 1 dose (150 mg tablet \[40% drug loaded granule\]) administered orally at the start of Period 1
224186205|NCT02549040|DRUG|Treatment C: Doravirine 150 mg tablet (30% drug loaded granule)|Single doravirine NF Type 2 dose (150 mg tablet \[30% drug loaded granule\])administered orally at the start of Period 3
224186206|NCT02549040|DRUG|Treatment D: Doravirine 150 mg tablet (50% drug loaded granule)|Single doravirine NF Type 3 dose (150 mg tablet \[50% drug loaded granule\])administered orally at the start of Period 4
223589228|NCT03550768|OTHER|MDP|evaluate the anatomy of each major duodenal papilla before selective cannulation during ERCP
223589229|NCT04357977|DIAGNOSTIC_TEST|RBA-2|Collection of non-invasive in vivo saliva from confirmed cases of both infected and non-infected COVID-19 patients or site staff at the testing site and compare the test results using the RBA-2 against the standard test results used for diagnosis.
224186207|NCT02549040|DRUG|Treatment E: Doravirine 100 mg tablet (30% drug loaded granule)|Single doravirine NF Type 4 dose (100 mg tablet \[30% drug loaded granule\]) administered orally at the start of Period 5
224186208|NCT00508820|BIOLOGICAL|Romiplostim|Romiplostim will be administered subcutaneously QW. Romiplostim will be manufactured and packaged and distributed using Amgen's clinical study investigational product distribution procedures. Romiplostim is presented as a lyophilized, white powder in 5.0 mL glass vials.
224186209|NCT06106399|PROCEDURE|WALLANT|Comparison between (WALLANT) and (CPB) as a sole anesthesia in clavicle surgery
224186210|NCT03740516|DRUG|CC-10004|CC-10004 will be administered orally
224186211|NCT04609436|DEVICE|"Cardiac monitoring with the wireless device SmartCardia"|Monitoring of arrhythmia with a wireless device (SmartCardia)
224186212|NCT03092076|DRUG|Ticagrelor|180 mg loading dose
223494516|NCT07069244|DIAGNOSTIC_TEST|Periodontal examinations|With periodontal evaluation, plaque percentage, probing pocket depth, percentage of bleeding on probing, clinical attachment level, number of teeth, periodontal inflammatory surface area (PISA) parameters are recorded.
223494517|NCT07069244|DIAGNOSTIC_TEST|Clinical Dementia Rating scale|Stage I: mild Alzheimer's disease, Stage II: moderate Alzheimer's disease, Stage III: severe Alzheimer's disease
224186213|NCT05090111|DRUG|ALG-055009|Single or multiple doses of ALG-055009
224186214|NCT05090111|DRUG|Placebo|Single or multiple doses of Placebo
224186215|NCT01390727|DEVICE|Device-guided breathing (Resperate - InterCure, Israel)|After randomization, the patients allocated in this arm will be instructed to use a device-guided breathing, for 15 minutes per day during 8 weeks, with the aim to reduce the respiratory frequency to less than 10 breaths/min
224186216|NCT01390727|OTHER|Listen music|After randomization, the patients allocated in this arm will be instructed to listen to calm music for 15 minutes per day during 8 weeks
224186217|NCT04029246|BEHAVIORAL|Follow up phone call|Telephone call to ask if patient has received letter and whether they would like an appointment
223589230|NCT02463864|OTHER|Intervention exercise|Twice daily, individual, targeted, strengthening, balance and endurance exercises for the duration of the hospital stay, prescribed and delivered by a senior physiotherapist.
224186218|NCT04029246|BEHAVIORAL|Incentive|Offer of a shopping voucher if patient attends for appointment
223589231|NCT02463864|OTHER|Sham Exercise|Twice daily stretching and relaxation exercises for the duration of the hospital stay, by a senior physiotherapist.
223589232|NCT02809053|BIOLOGICAL|SAIT101|Dose of 375mg/m2 body surface area (BSA) i.v. on Days 1, 8, 15, and 22
223589233|NCT02809053|BIOLOGICAL|MabThera®|Dose of 375mg/m2 body surface area (BSA) i.v. on Days 1, 8, 15, and 22
223745747|NCT03036098|DRUG|Gemcitabine|Specified Dose on Specified Days
224186219|NCT00280540|DRUG|Valsartan/Hydrochlorothiazide|
224186220|NCT00451776|DRUG|etomidate|patients who received etomidate
224186221|NCT00451776|DRUG|propofol|patients who received propofol
224308766|NCT05151666|OTHER|Sunny Health & Fitness Magnetic Mini Exercise Pedal Cycle - SF-B020026 Gray|The intervention will be that the patient cycles in a sitting position within the first 2 hours of hemodialysis treatment for 15-60 minutes/as tolerated, either intermittent/continuous duration. - Graded duration will increase every 2 weeks. This will be supervised by a dialysis nurse as per the schedule of study assessments.
223494518|NCT07069244|DIAGNOSTIC_TEST|Standardized Mini-Mental Test|Cognitive status is assessed with the Standardized Mini-Mental Test.
223494519|NCT07066189|BEHAVIORAL|Exercise and Medical Nutrition|10, 30-minute sessions spread out over the course of their neoadjuvant therapy and in the weeks leading up to surgery. On weeks counseling is not scheduled an exercise session will be observed.
223745748|NCT03036098|DRUG|Cisplatin|Specified Dose on Specified Days
223745749|NCT03036098|DRUG|Carboplatin|Specified Dose on Specified Days
224186222|NCT03297463|DRUG|Interleukin-2 & Ipilimumab (P-Ib)|"Phase Ib:~\- Ipilimumab will be administered in a 3 + 3 dose escalation design.~* The starting dose will be 0.3 mg/kg administered within 7 days of day 1 cycle 2 ALdesleukin (IL-2).~* If dose limiting autoimmune toxicities (DLTs) are not observed, the next cohort will receive 1.5 mg/kg.~* The final cohort will receive 3 mg/kg, in the event that cohort 2 does not exhibit DLTs.~* In the event of excessive toxicity in cohort 1, then a -1 dose level of 0.1 mg/kg may be evaluated in subsequent cohorts. Cohort sizes will increase to 6 patients if 1 of 3 patients in a cohort experience a DLT.~* Once the maximum tolerated dose/recommended phase 2 dose (MTD/RP2D) is declared, no staggering of enrollment is required for accrual."
224186223|NCT03297463|DRUG|Interleukin-2 & Ipilimumab (P-II)|"Phase II:~\- Interleukin-2 \& Ipilimumab will be administered at the maximum tolerated dose/recommended phase 2 dose (MTD/RP2D)."
224186224|NCT06001164|PROCEDURE|ACL reconstruction: Double bundle|DB: Two tunnels were created on the femoral side through an anteromedial portal. These tunnels were created manually. On the tibial side, the tunnels were created using a guide to ensure they matched the anatomic insertion site of the ACL at the tibia. The hamstring grafts for the procedure were then harvested from the same leg and doubled. The femoral side was fixed from the inside out, whereas the tibial side was fixed from the outside in. bioresorbable screws were used.
224186225|NCT06001164|PROCEDURE|ACL reconstruction: Single bundle|SB: The femoral tunnel was created using an anteromedial portal. A freehand technique was used. For the tibial tunnel, a tibial guide was used to ensure it was positioned at the midpoint of the tibial ACL attachment site. The tendons of the semitendinosus and gracilis muscles were then harvested, doubled over, and inserted through the tibial tunnel, extending into the femur, and fixed with metallic or bioabsorbable interference screws.
224186226|NCT05365204|PROCEDURE|Near infrared fluorescence navigated sentinel lymph node mapping|Patient will undergo sentinel lymph node biopsy with near infrared fluorescence navigation. The dosage of ICG will not exceed 2.5 mg in total, and the volume of the assigned solvent will not exceed 5 mL in total.
224186227|NCT04260360|DRUG|NanoDoce (sterile nanoparticulate docetaxel) Powder for Suspension|NanoDoce is manufactured using a Precipitation with Compressed Antisolvent (PCA) technique that employs supercritical carbon dioxide and acetone to generate docetaxel nanoparticles within a well-characterized particle-size distribution. Prior to administration, the NanoDoce powder in vial is suspended with a sterile solution of Polysorbate 80 (0.0075% - 0.0375% (w/w))/Ethanol (0.06% - 0.3% (w/w)) in 0.9% Sodium Chloride for injection.
224186228|NCT00755560|DRUG|Albendazole|Albendazole 10 - 15 mg/kg/day BID for 15 days
224186229|NCT00755560|DRUG|Placebo|Placebo BID for 15 days
224186230|NCT04478591|OTHER|Questionnaires|All participants will fill in two questionnaires before or during their next treatment with ocrelizumab: the MSIS-29 questionnaire and a wearing-off questionnaire. After two weeks, participants fill in two digital questionnaires (MSIS-29, additional wearing-off questionnaire).
224186231|NCT04077060|DIAGNOSTIC_TEST|NIPT|"Women randomized in the intervention group will be offered cfDNA screening, along with an early detailed anatomy scan, including nuchal measurement, at 11-13 weeks of gestation. cfDNA analysis will include a simultaneous microarray-based assay of non-polymorphic (chromosomes 13, 18, 21, X and Y) and polymorphic loci to estimate chromosome proportion and fetal fraction. NIPT will be performed at the time of randomization or after if gestational age at randomization \< 9 6/7 weeks of gestation.~Women in both groups will be given oral counseling by obstetricians and will be counseled about test procedures, reporting time, test sensitivity and specificity, and the necessity to confirm abnormal screening results with invasive testing."
223494520|NCT07073235|DEVICE|Intermittent Theta Burst Stimulation|iTBS protocol: 600 pulses at 80% of AMT for 190 sec on the contralesional cerebellum, targeted with the support of a neuronavigational system, 15 sessions over a period of 5 weeks
223494521|NCT07073235|DEVICE|Sham Intermittent Theta Burst Stimulation|It is identical to its active version, replicates operational sounds, and delivers a very shallow magnetic field to mimic the sensation of magnetic stimulation.
223494522|NCT06241287|BEHAVIORAL|Better Living with Non-memory led Dementia programme|an 8-week duration 6-module educational programme covering the following topics: 1) Welcome to the programme and what to expect from it; 2) Understanding the disease; 3) How to provide better support for the person with dementia; 4) How to look after the caregiver's own mental health; 5) Where to find additional sources of support, and 6) An introduction to the value of support groups. At the end of modules 2, 3, and 4, participants will be asked to complete a real-life task to put in practice skills learned in the specific module (e.g., approaching a friend and explaining the disease in lay terms). The first session (onboarding) will be facilitated via Zoom by one of the members of the research team. Up to 3 total interactions between facilitators and participants will be offered to support participants' engagement with the programme. All course modules will be printable using the pdf download button on the programme's page.
223494523|NCT06241287|OTHER|Waiting list|Signposting individuals to the publicly available Rare Dementia Support website. The control group will further receive access to the Better Living with Non-memory led Dementia programme after completing the collection of measures at 6 months.
223494524|NCT07073248|DEVICE|Intermittent Theta Burst Stimulation|iTBS protocol: 600 pulses at 80% of AMT for 190 sec on the ipsilesional motor cortex, targeted with the support of a neuronavigational system, 15 sessions over a period of 5 weeks
223494525|NCT07073248|DEVICE|Sham Intermittent Theta Burst Stimulation|It is identical to its active version, replicates operational sounds, and delivers a very shallow magnetic field to mimic the sensation of magnetic stimulation
223589234|NCT03323606|BEHAVIORAL|Gambling Internet Intervention|The gambling Internet intervention consists of a new online version of self-change tools that have previously been translated successfully into an online form and shown to have a significant impact on gambling in three trials. A major focus of this intervention is to provide individuals with clear and concise behavioral and cognitive strategies for meeting the goal of reducing or quitting gambling.
223589235|NCT03323606|BEHAVIORAL|Check Your Drinking|A brief online intervention designed to provide personalized normative feedback aimed at motivating reductions in drinking
223589236|NCT00084149|DRUG|Abacavir sulfate, Lamivudine, and Zidovudine|antiretroviral therapy
223494526|NCT07071883|BEHAVIORAL|Holotropic breathwork|HB is the practice of self-directed hyperventilation while lying down with the support of a selected music set and trained facilitators. Participants may experience an expanded state of consciousness with altered cognition, perception, and emotions.
223494527|NCT07071883|BEHAVIORAL|Multiple modality|Multiple Modality (MM) intervention (yoga, meditation, and a film/discussion)
223589237|NCT00084149|DRUG|Lopinavir/Ritonavir|antiretroviral therapy
223589238|NCT03639142|OTHER|Prunus domestica|Patients will receive prunes at dose 3,5 g/kg/d (max.100mg/day) in three portions a day, for 4 weeks (amount of prescribed prunes will be calibrated with the weight that child ought to have on WHO growth charts at 50th percentile). Prunes should be introduced every day in three meals. Prunes can be chopped or grinded before eating them. They can be eaten alone or child may eat them as a part of bigger meal (which is preferred version). Prunes can be introduced with yogurt, cereals, nuts and seeds as a morning meal.
223589239|NCT03639142|DRUG|Polyethylene Glycol 4000|Patients will receive PEG at dose 0,5 g/kg/d once daily orally, for 4 weeks.
224186232|NCT04077060|DIAGNOSTIC_TEST|combined screening|Control group includes the standard of care. In our department, first-trimester risk assessment is performed routinely at 11-13 weeks of gestation by FTCS as per standard of care. FTCS includes crown-rump length, NT measurements, and a detailed ultrasound examination based on ISUOG guidelines. All operators who perform this examination are certified by the UK Fetal Medicine Foundation (FMF). A specific risk for aneuploidy is not calculated if NT measurement is \>3.5 mm or if fetal anomaly is identified. These cases are deemed to be at a very high risk for chromosomal abnormalities and are offered invasive testing.
224186233|NCT02574429|BEHAVIORAL|Cognitive Processing Therapy|Cognitive Processing Therapy is an evidenced-based treatment for PTSD. The investigators are offering CPT group over 13 weeks (12 group sessions \& 1 individual session). CPT focuses on challenging beliefs that developed or were reinforced following the trauma(s).
224308767|NCT01740726|BEHAVIORAL|Behavioral Activation|18 weeks of 1-hour individual therapy focused on increasing rewarding behaviors. Therapy follows Behavioral Activation manual supported through previous research of this therapy for adolescents. BA intervention includes monthly booster sessions offered throughout 6-month follow up.
224186234|NCT03846466|DRUG|KHK4323 IV/S|IV / Single administration
224186235|NCT03846466|DRUG|KHK4323 SC/S|SC / Single administration
224186236|NCT03846466|DRUG|KHK4323 IV/M|IV / Multiple administration
224186237|NCT03846466|DRUG|Placebo IV/S|IV / Single administration
224186238|NCT03846466|DRUG|Placebo IV/M|IV / Multiple administration
224186239|NCT03846466|DRUG|Placebo SC/S|SC / Single administration
224186240|NCT03195166|DIAGNOSTIC_TEST|FloTrac sensor/Vigileo|blood pressure (systolic, diastolic and mean), stroke volume cardiac output ephedrine consumption after bupivacaine continuous spinal anesthesia
224186241|NCT02137031|DEVICE|Mini Link REAL-Time Transmitter|Children used the Mini Link REAL-Time Transmitter to measure glucose continuously for a minimum of three days per week for three months.
224308768|NCT01740726|DRUG|Fluoxetine|Initial 10mg dose titrated as necessary to 40mg daily; weekly visits for 4 weeks, biweekly visits for next 6 weeks, monthly visits for remaining 8 weeks of active treatment and through 6-month follow up. Therapists will be available between sessions and throughout the follow-up interval to manage clinical concerns or emergencies.
223494528|NCT06797713|PROCEDURE|Esophageal doppler|Fluid/inotrope decisions will be made with parameters such as stroke volume (SV), stroke volume variation (SVV), pulse pressure variation (PVV), systemic vascular resistance (SVR), and cardiac output (CO) on the Doppler monitor screen.
223494529|NCT06797713|PROCEDURE|Conventional method|Fluid therapy is performed by monitoring parameters such as blood pressure, urine output, lactate...
223494530|NCT06794866|DRUG|OnabotulinumtoxinA|Intramuscular Injections
223494531|NCT06794866|DRUG|Placebo|Intramuscular Injections
223494532|NCT04610866|DRUG|Mitapivat|Investigational drug mitapivat (also known as AG-348, AGI-1480 and AGX-0841) is an orally bioavailable, broad-spectrum allosteric activator of alleles of the RBC-specific form of pyruvate kinase (PKR), as well as liver-type pyruvate kinase (PKL) and muscle pyruvate kinase (PKM1 and PKM2).
223494533|NCT06680128|BIOLOGICAL|GBP560-A|"injection volume of 0.5mililiter (mL) with each dose on V2(1day) and V5 (29day) in stage1 and stage2.~Low dose: 3μg Mid dose: 15μg High dose: 50μg"
223494534|NCT06680128|BIOLOGICAL|GBP560-B|"injection volume of 0.5mL with each dose on V2(1day) and V5 (29day) in stage1 and stage2.~Low dose: 3μg Mid dose: 15μg High dose: 50μg"
223494535|NCT06680128|BIOLOGICAL|IXIARO|injection volume of 0.5mL on V2(1day) and V5 (29day) in stage1 and stage2
224308769|NCT04557020|DRUG|PD-1 antibody|neoadjuvant: PD-1 inhibitor Toripalimab 240mg combined with neoadjuvant chemotherapy by cis Platinum and gemcitabine every 3 weeks for 3 cycles ; adjuvant: Toripalimab 240mg every 3 weeks for 9 cycles after concurrent chemoradiotherapy
224308770|NCT04557020|DRUG|Gemcitabine|neoadjuvant chemotherapy: 1000mg/m2 in day 1 and day 8 and repeats every 3 weeks for 3 cycles
223494536|NCT06680128|BIOLOGICAL|IMOJEV|injection volume of 0.5mL on V5 (29day) in stage1 and stage2
223494537|NCT06680128|BIOLOGICAL|Normal Saline (Placebo)|injection volume of 0.5mL on V2 (1day) in stage1 and stage2 (This is for IMOJEV placebo)
223494538|NCT06771323|DRUG|Valbenazine|To assess if valbenazine 80mg daily improves motor symptoms in idiopathic CD patients with persistent symptoms despite current treated with botulinum toxin injections.
223494539|NCT06771323|DRUG|Placebo|Placebo
224186242|NCT01164631|DEVICE|Bioajusta X Orthodontic treatment|Oral Appliance that promotes semi-rapid maxillary expansion, while corrects tongue positioning and jaws relationship
224186243|NCT05470530|DRUG|Dexamethasone|Dexamethasone was given either intrathecal or intravenous in spinal anesthesia during ceaseran section while normal saline was given in control group
224308771|NCT04557020|DRUG|Cisplatin|neoadjuvant chemotherapy: 80mg/m2 in day 1, and repeats every 3 weeks for 3 cycles. Concurrent chemoradiotherapy: Cisplatin 100mg/m2 in day 1, 22, and 43 during IMRT
224308772|NCT04557020|RADIATION|IMRT|70Gy to GTV, 60Gy to CTV1 and 54Gy to CTV2 in 32 to 33 fractions
223494540|NCT06035120|DEVICE|AeriSeal System|The AeriSeal System comprises AeriSeal Foam and the AeriSeal Balloon Catheter Preparation Kit that is used for bronchoscopic delivery of AeriSeal Foam to the targeted regions of the lung.
223494541|NCT05222620|OTHER|Questionnaire Administration|Ancillary studies
223494542|NCT05222620|RADIATION|Stereotactic Radiosurgery|Undergo single fraction SRS
223494543|NCT05222620|RADIATION|Stereotactic Radiosurgery|Undergo fractionated SRS
223494544|NCT05222620|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223494545|NCT06494657|OTHER|Corticosteroid injection|Corticosteroid injection for frozen shoulder
223494546|NCT05521373|DEVICE|ultrasound cervical selective nerve root block|"A (7-12) MHz linear transducer will be applied to the symptomatic side of the neck in the transverse plane. The targeted nerve root of each patient will be identified by moving the transducer cranially from the C7 transverse process as a reference point.~After the targeted nerve root identified, a needle will be gently introduced toward the dorsal aspect of the nerve root under real-time US guidance with an in-plane approach. The needle tip will be placed between the nerve root and posterior tubercle outside of the intervertebral foramen and the vessels will be around the nerve root with color Doppler. On confirmation of the absence of abnormal findings and careful aspiration, 3 cc of the treatment drug composed of dexamethasone (10 mg) and 0.2% lidocaine, will be injected under real-time US guidance"
223511790|NCT00130559|PROCEDURE|BNP guided diagnostics and initial therapy|BNP guided diagnostics and initial therapy
223494547|NCT05521373|DEVICE|ultrasound and fluoroscopy-guided cervical selective nerve root block|The targeted transverse process was identified by slowly moving the probe in all directions with the 7th cervical spine transverse process as the reference point. a spinal needle 22 G was inserted. First, 1 ml of the contrast media was injected. The antero-posterior images were obtained to confirm the distribution or spread pattern of the injected contrast media with C-arm fluoroscopy. The following steps were initiated after confirming for proper shadowed contrast of the nerve root and absence of intravascular injection of the contrast media. Three cc of the treatment drug, composed of dexamethasone (10 mg) and 0.5 % lidocaine will be injected after confirming the absence of abnormal findings.
223494548|NCT06401538|DRUG|BMB-101|BMB-101 liquid administered orally twice a day for 3 months
223494549|NCT05495464|DRUG|Acalabrutinib|Given by PO
223494550|NCT05495464|DRUG|Rituximab|Given by IV (vein)
223494551|NCT05495464|OTHER|Brexucabtagene Autoleucel|Given by IV (vein)
223494552|NCT05495464|DRUG|Cyclophosphamide|Given by IV (vein)
223494553|NCT05495464|DRUG|Fludarabine Phosphate|Given by IV (vein)
223494554|NCT06760182|DRUG|TQH2722 injection|TQH2722 injection is a humanized monoclonal antibody targeting interleukin-4 receptor alpha (IL-4Rα).
223494555|NCT06760182|DRUG|TQH2722 Placebo|Placebo without drug substance.
223494556|NCT06901310|DEVICE|Hyberbaric Oxygen Therapy|Treating participants with 100% Oxygen at 2.4 Atmospheres for 90 minutes at 10 treatments.
223494557|NCT03858322|DRUG|Paclitaxel|The drug work by damaging the RNA or DNA that tells the cell how to copy itself in division. If the cells are unable to divide, they die.
223494558|NCT03858322|DRUG|Cyclophosphamide|The drug work by damaging the RNA or DNA that tells the cell how to copy itself in division. If the cells are unable to divide, they die.
223494559|NCT03858322|DRUG|Carboplatin|The drug work by damaging the RNA or DNA that tells the cell how to copy itself in division. If the cells are unable to divide, they die.
223494560|NCT06692322|DRUG|Zongertinib (BI 1810631)|Film-coated tablet
223589240|NCT02093910|DRUG|Monosialotetrahexosylganglioside|
223589241|NCT05807984|RADIATION|Carbon ion radiation therapy DT: 74Gy/20 fractions|patients with unresectable local recurrent rectal cancer will be treated with carbon ion radiation therapy as re-irradiation
223589242|NCT00389675|DRUG|Darusentan|Darusentan capsules at a dose of 50, 100, or 300 mg administered orally once daily
223589243|NCT00389675|DRUG|Guanfacine|Guanfacine 1 mg capsules administered orally once daily
223589244|NCT04787185|RADIATION|Valutation of toxicity|"Observation of toxicity~All patient with Brain metastases from NSCLC who are candidates for RS or HFSRT in course of immunotherapy"
223589245|NCT00117689|BIOLOGICAL|Thymoglobulin|Antibody inductions with tacrolimus and corticosteroid sparing maintenance therapy
223494561|NCT07074327|DRUG|VX-407|Suspension for oral administration.
223494562|NCT07074327|DRUG|LNG/EE|Combination Tablets for Oral Administration.
223494563|NCT07074327|DRUG|NGM/EE|Combination Tablets for Oral Administration.
223494564|NCT07074327|DRUG|NET/EE|Combination Tablets for Oral Administration.
223494565|NCT07074327|DRUG|DRSP/EE|Combination Tablets for Oral Administration.
223494566|NCT07073469|DRUG|Tenecteplase (TNK) (0.25 mg/kg, to maximum of 25mg)|Tenecteplase (TNK) (0.25 mg/kg, to maximum of 25mg)
223494567|NCT07073469|OTHER|Standard medical treatment|Standard medical treatment according to local guidelines
223589246|NCT00117689|DRUG|Corticosteroid|For a minimum of 3 months
223589247|NCT00117689|DRUG|Tacrolimus|Between Day 3 the last dose of Thymoglobulin
223494568|NCT07073001|OTHER|Telephone interview|A structured telephone interview at three months will assess the degree of implementation, explore associated barriers (administrative, cognitive, organizational, ...), and investigate any potential link with hospital readmissions or changes in patients' living situations.
223494569|NCT05797740|DRUG|Mavenclad|This is an observational study, participants who received cladribine tablets in routine clinical practice following the SmPC will be included.
223494570|NCT06345339|DRUG|Armour Thyroid|Oral Capsule or Tablet
223494571|NCT06345339|DRUG|Levothyroxine|Oral Capsule
223494572|NCT07129187|DRUG|SHR-A1811|Drug: SHR-A1811 4.8mg/kg
223494573|NCT06927245|DEVICE|PTeye Device|Near infrared stimulation of parathyroid tissue using light at a wavelength of approximately 690 - 770 nm results in autofluorescence of parathyroid tissue. Near infrared autofluorescence detection devices, such as PTEye have been developed with probe-based methods, displaying quantitative real-time information to aid surgeons in detection of parathyroid tissue relative to surrounding tissue.
223494574|NCT05486182|DRUG|18F Fluoroestradiol Radiopharmaceutical with PET/CT|Administration of one dose of 18F FES for PET/CT imaging
223494575|NCT06382272|DEVICE|Bionic Breast implant|A small medical device will be temporarily implanted in one of the breasts at the time of the mastectomy. This device is capable of sending very small electrical currents to the nerves that can deliver sensory stimulation in response to touch and pressure applied to the breast
223494576|NCT06013722|DIAGNOSTIC_TEST|18F-Na PET Scan|For the intermediate risk population who would demonstrate within 6 to 18 months after first calcium score either an increase of percentile of more than 20% or an increase above 20 points of the calcium score and for high risk population, 18F-Na PET scan will be recommended and repeated 6 months later. Secondary prevention treatment will then be administered in the event of an abnormal examination.
223494577|NCT07072091|OTHER|Total body physiotherapy|This intervention consists in 5 weeks of 2 x week 60 min sessions of physiotherapy consisting in active exercise performed in upper limb, trunk, and lower limb muscles, in a whole-body approach.
223494578|NCT07072091|OTHER|Focus shoulder physiotherapy|This intervention consists in 5 weeks of 2 x week 60 min sessions of physiotherapy consisting in active exercise performed only in the shoulder district, focusing on the trunk-arm muscles.
223494579|NCT07072091|OTHER|Education|Single education session providing information about posture hygiene and proper warm-up
223589248|NCT00117689|DRUG|Mycophenolate Mofetil|for at least 1 month posttransplant
223617758|NCT01535807|DEVICE|CorMatrix extra cellular matrix (ECM)|"* Cormatrix ECM group will receive the CorMatrix ECM during surgery for the closure of the pericardium according to the specific recommended surgical technique.~* No Intervention group will not receive the CorMatrix ECM during surgery, leaving the pericardium open according to current standard of care."
224186244|NCT05731830|OTHER|Data extraction|"The exposure of patients to air pollution compounds in the two years prior to the occurrence of TTS will be analysed. We will investigate: PM10, PM2.5, O3, NO2, C6H6, SO2 e CO. Residential addresses will be obtained from medical records. Annual average 24-h of pollutants levels will be measured matching each individual's home address, and the ArpaLazio website (http://www.arpalazio.net/main/aria/sci/basedati/chimici/chimici.php), which provides the concentration of NO, NO2, NOx, PM10, PM2.5, O3, CO, C6H6, SO2 expressed in micrograms per cubic meter (µg/m3). Hourly data are available for all gaseous pollutants, while the levels of PM10 and PM2.5 are expressed daily. Data will be obtained from the air quality monitor closest to each participant's residence that was active for the entire year, and short-term (daily and weekly) and long-term (annual) air pollution exposure will be quantified as daily, weekly, and annual average 24-h pollutants level of measurements before TTS."
224186245|NCT05731830|OTHER|Clinical follow-up|All patients will undergo a clinical follow-up by telephonic interview and/or clinical visit at 6, 12, 24, 36, 48 and 60 months from hospital discharge, during which the incidence of MACE, defined as the composite of all-cause mortality, non-fatal MI, transient ischemic attack (TIA)/stroke, and hospitalization for heart failure, and the recurrence of TTA in the past months will be investigated and collected.
224186246|NCT06177925|DRUG|Adebrelimab|Adebrelimab intravenous infusion will be administered during the induction phase (Cycles 1-2 ) and maintenance phase.
224186247|NCT06177925|DRUG|Carboplatin/Cisplatin|Carboplatin/Cisplatin intravenous infusion will be administered during the induction phase, concurrent chemoradiotherapy phase and maintenance phase(Cycles 1-4 or 6).
223494580|NCT07076069|DRUG|Multimodal Pain Regimen|"Preoperatively: One dose of Pregabalin 100mg and Celecoxib 400mg along with interscalene block~Intraoperatively: Intravenous Dexamethasone 0.1mg/kg (maximum dose of 8mg), Magnesium 2g, Acetaminophen 1000mg, and local infiltration of 0.5% Ropivacaine 20ml~Postoperatively (Discharge): Acetaminophen 975mg every 4 hours, Meloxicam 7.5mg once per day, Pregabalin 50mg twice per day, Magnesium 400mg once per day, along with rescue Oxycodone 5mg every 4 hours, as needed"
223494581|NCT07076069|DRUG|Standard of Care Pain Regimen|No preoperative medications. Interscalene block in the preoperative holding area. Alternating Acetaminophen 975mg and Ibuprofen 600mg every 4 hours, with rescue Oxycodone 5mg every 4 hours, as needed
223494582|NCT07073924|BEHAVIORAL|Implementation strategy bundle|The anticipated strategy bundle will include integrated patient-, provider-, and system-level interventions to support sustainable implementation. At the patient level, this may involve education, peer support, and navigation services; at the provider level, training, decision-support tools, and workflow enhancements; and at the system level, policy changes, electronic health record integration, and organizational alignment to promote and maintain prescribing of PrEP and injection equipment.
223589249|NCT03624088|BEHAVIORAL|RealRisks|RealRisks is a web-based patient decision aid with modules on risk assessment, family history and breast cancer, genetic testing, and prevention options. Participants enter family history data into RealRisks, and RealRisks calculates 5-year breast cancer risk, lifetime breast cancer risk, and the probability of carrying a BRCA mutation. This information is then interactively presented to the participant. RealRisks facilitates the participant in identifying their intention to undergo BRCA genetic testing and the factors that are important to the participant in making this decision. RealRisks produces a summary of all of this information that the participant can print and take with her to a health care appointment.
223589250|NCT03976284|BEHAVIORAL|Garden-fresh produce and exercise|The Garden-fresh produce and exercise (GFPE) health promotion intervention features 10 weekly sessions that take place after Sunday services in the Lincoln Memorial Church kitchen/meeting space. Each session includes a cooking demonstration focused on how to prepare and cook a meal composed of fiber-rich plant foods minimally processed. Each session also includes brief, didactic nutrition instruction and a 10-minute bout of physical activity.
223589251|NCT01856621|DRUG|Seretide Diskus and charcoal|2 inhalations as a single dose
223589252|NCT01856621|DRUG|Seretide Diskus|2 inhalations as a single dose
223589253|NCT01856621|DRUG|SF Easyhaler and charcoal|2 inhalations as a single dose
223589254|NCT01856621|DRUG|SF Easyhaler|2 inhalations as a single dose
223589255|NCT02099201|DRUG|ACT-389949 40 mg|
223589256|NCT02099201|DRUG|ACT-389949 200 mg|Predicted dose
223589257|NCT02099201|DRUG|ACT-389949 800 mg|Predicted dose
223589258|NCT02099201|DRUG|ACT-389949 (Group C1 dose to be selected)|
223589259|NCT02099201|DRUG|ACT-389949 (Group C2 dose to be selected)|
223589260|NCT02099201|DRUG|Placebo|
223589261|NCT05389189|BEHAVIORAL|Intervention Arm|"The MITIG.RA program incorporates the following key topics during the 8 weeks of intervention (1st phase):~(i) Psychoeducation on RA, sleep hygiene, exercise, and general nutritional recommendations (promote behavioural change and self-care, boost the sense of self-worth and self-efficacy) (ii) Activity engagement and pacing (iii) The functioning of the mind and its problematic patterns (iv) Focusing on the 'here and now' (mindfulness) (v) Learning new ways of self-relating - self-compassion (vi) Making room for suffering (acceptance); and (vii) Moving towards what matters (identification of valued life directions and promotion of consistent values and goals-directed behaviour)."
223589262|NCT05241925|OTHER|Rehabilitation, exercise|"Combined training (continuous aerobic + resistance) The protocol will consist of supervised exercise lasting 1h10min each session (5 min of warm-up, 30 min of aerobic exercise, 30 min of resistance exercise and 5 min of cool-down/relaxation).~Combined training (high-intensity interval (IAI) + resistance) - Supervised exercise lasting 30 min each session (5 min warm-up, 20 min IAI and 5 min cool-down/relaxation).~And Resistance Training~\- Resistance exercise will be performed at 70-80% of one repetition maximum (1-RM); 2 to 3 sets of 8 to 12 repetitions. The main muscle groups will be trained using training equipment with free weights and body mass of the participants. Exercises included leg extension, seated bicep curl, squat, seated triceps extension, sit-up, seated shoulder press, and standing pulldown"
223589263|NCT00869401|DRUG|dasatinib|Given orally
223589264|NCT00869401|DRUG|temozolomide|Given orally
223589265|NCT00869401|OTHER|placebo|Given orally
223589266|NCT00869401|RADIATION|radiation therapy|Radiation therapy is performed as 30 fractions of 200 cGy for a total of 6000 cGy.
223589267|NCT00508612|BEHAVIORAL|Williams LifeSkills Stress and Anger Management Workshop|Williams LifeSkills Stress and Anger Management Workshop
223589268|NCT00508612|BEHAVIORAL|High school classes|The control group will attend regular high school classes.
223494583|NCT04725539|PROCEDURE|hypoxic exposure|"Administration of different hypoxic doses.~Intermittent hypoxia:~days 1-5 duration of breathing periods 5\*3min (FiO2 14-21%) days 8-12 duration of breathing periods 4\*4min (FiO2 = 12%) and 3\*3 min (FiO2 = 21%) days 15-19 duration of breathing periods 5\*5min (FiO2 = 10%) and 4\*3 min (FiO2 = 21%)~one night at 1900m"
223494584|NCT02157324|DRUG|acalabrutinib|
223494585|NCT02157324|DRUG|ACP-319|
223494586|NCT06843070|PROCEDURE|PENILE BLOCK ARM|P arm: Patients who underwent Dorsal Penile Block after circumcision surgery
223494587|NCT06843070|PROCEDURE|SACRAL ESP BLOCK ARM|S arm: Patients who underwent Sacral Erector Spinae Plane Block after circumcision surgery
223494588|NCT07080957|PROCEDURE|Mesh-free laparoscopic uterus-preserving pectopexy|Laparoscopic pectopexy without synthetic mesh was performed by utilizing native tissue fixation techniques. The uterus was suspended to the iliopectineal ligaments using permanent sutures without mesh implantation. The procedure aimed to provide apical support and avoid mesh-related complications. Postoperative follow-up included assessments of anatomical correction, functional recovery, and patient satisfaction.
223494589|NCT07080957|PROCEDURE|Mesh-based laparoscopic uterus-preserving pectopexy|Laparoscopic pectopexy was performed using a synthetic mesh to provide apical support while preserving the uterus. The mesh was bilaterally fixed to the iliopectineal (Cooper's) ligaments, and the uterus was suspended in a tension-free manner. This technique is designed to restore pelvic anatomy and improve symptoms of prolapse. Patients were followed postoperatively to assess anatomical success, complications, and functional outcomes.
223494590|NCT06372145|DRUG|Tolebrutinib|Pharmaceutical form:Tablet-Route of administration:oral
223494591|NCT06372145|DRUG|Placebo|Pharmaceutical form:Tablet-Route of administration:oral
223494592|NCT06372145|DRUG|Teriflunomide|Pharmaceutical form:Tablet-Route of administration:oral
223494593|NCT07120243|PROCEDURE|Toothpaste Product|Administration ofa toothpaste
223494594|NCT07120243|PROCEDURE|Varnishes, Fluoride|The tooth will be dried, and cotton roll isolated. According to manufacturer instructions, thin coat of the varnish will be applied on the teeth for 10 - 20 s using a microbrush in a horizontal sweeping motion , then drying with air will be done.
223494595|NCT07123493|BIOLOGICAL|Anti ALPP CAR-T cells treatment|Biological: anti ALPP CAR-T cells Treatment follows a lymphodepletion Drug: Fludarabine and Cyclophosphamide
223494596|NCT07123506|DRUG|Beta-blocker treatment group|After PFO closure, the beta-blocker treatment group will receive an extended-release beta-blocker, either bisoprolol or nebivolol, at a dose of 1.25 mg QD for 30 days.
223494597|NCT07123506|DRUG|Non-treatment group|After PFO closure, the non-treatment group will not receive a beta-blocker.
223494598|NCT07125300|DIAGNOSTIC_TEST|Artificial Intelligence-Assisted Colonoscopy|"The intervention involves the use of an artificial intelligence tool during screening colonoscopy. This system includes two integrated functions:~* CADe (Computer-Aided Detection): Highlights suspected lesions in real time on the endoscopic video to assist in identifying polyps.~* CADx (Computer-Aided Diagnosis): Provides real-time optical histology predictions to help distinguish between hyperplastic and adenomatous polyps.~The AI system operates autonomously during the procedure and displays visual cues on the monitor to support the endoscopist in detecting and characterizing colorectal lesions."
223494599|NCT06905171|OTHER|Auditory Stimulation|A tone at a 1000 Hz frequency, delivered through speakers at a comfortable volume
223494600|NCT06905171|OTHER|Visual Stimulation|A checkerboard pattern displayed on a monitor, with colors alternating every 25 ms
224186248|NCT06177925|DRUG|Etoposide|Etoposide intravenous infusion will be administered during the induction phase, concurrent chemoradiotherapy phase and maintenance phase(Cycles 1-4 or 6).
223494601|NCT06905171|OTHER|Somatosensory Stimulation|A train of three electrical stimuli, each lasting 1 ms, separated by 8 ms, at an intensity that clearly elicits a pricking sensation
223494602|NCT06905171|OTHER|Auditory-Visual Stimulation|Stimulation using auditory and visual stimuli concomitantly
223745750|NCT06410118|BEHAVIORAL|DreamChanger+IRT|Families will receive the DreamChanger remote along with 3 instructional videos for parents, explaining how to present the remote to children, and how to rehearse alternative dream imagery using the DreamChanger remote.
223494603|NCT06905171|OTHER|Visual-Somatosensory Stimulation|Stimulation using visual and somatosensory stimuli concomitantly
223494604|NCT06905171|OTHER|Auditory-Somatonsensory Stimulation|Stimulation using auditory and somatosensory stimuli concomitantly
223494605|NCT06905171|OTHER|Auditory-Visual-Somatosensory Stimulation|Stimulation using auditory, visual and somatosensory stimuli concomitantly
223494606|NCT07092826|OTHER|Psychopathological assessment and non-invasive multisensory stimulation|This intervention consists of a non-invasive, cross-sectional assessment involving standardized psychopathological interviews and multisensory stimulation tasks (auditory, tactile, and combined). It is designed to explore formal and content-related features of obsessive-compulsive symptoms, insight levels, and trauma-related correlates in patients with OCD and schizophrenia spectrum disorders. No pharmacological treatment or experimental therapy is administered as part of this study.
223494607|NCT07099885|DIAGNOSTIC_TEST|Standard of Care (SOC)|Diuretic treatment per attending physician.
223494608|NCT07099885|DIAGNOSTIC_TEST|Algorithhm-based decongestion|Patient will receive standarized furosemide dosing based on the result of the algorithm-estimated 6h urine output (profiles of diuretic response).
223494609|NCT07104097|PROCEDURE|spinal anesthesia|spinal anesthesia at L3-L4 plain bupivacaine 0.5% 2.2 ml
223494610|NCT07104097|PROCEDURE|superficial erector spinal plane block (ESPB)|Lidocaine 1% + ropivacaine 0.25% 30 ml with adrenaline 1:200.000 on top of L3 transverse process, between bone and erector spinae muscle
223494611|NCT07104097|PROCEDURE|deep (inter laminar) erector spinal plane block (ESPB)|Lidocaine 1% + ropivacaine 0.25% 30 ml with adrenaline 1:200.000 between L3 and L4 transverse process, between erector spinae muscle and deep muscles
223494612|NCT07104097|DRUG|Dexamethasone|8 mg iv preoperatively
223494613|NCT07104097|DRUG|Ibuprofen 400 mg|preoperatively and postoperatively (every 8 hours)
223745751|NCT05069766|OTHER|BioXmark™|During a scheduled outpatient gastroscopy, the tumor margins will be endoscopically marked by BioXmark™. BioXmark™ will be implanted at the most proximal margin of the tumor and 5 cm proximally of the tumor border.
224186249|NCT06177925|RADIATION|Radiation therapy|IMRT for thoracic of 45--55Gy in 15-22 fractions，SBRT for metastases during the concurrent chemoradiotherapy phase
224186250|NCT04500925|PROCEDURE|UNILATERAL THYROIDECTOMY|
223494614|NCT07104097|DRUG|Paracetamol|1000 mg preoperatively and postoperatively (every 8 hours)
223494615|NCT07104097|DRUG|Morphine|Patient Controlled Analgesia
223494616|NCT07113964|DRUG|QL1706 + olaparib|"QL1706 is a novel dual immune checkpoint blockade containing a mixture of anti-PD1 IgG4 and anti-CTLA4 IgG1 antibodies.~Other Names: Iparomlimab and Tuvonralimab Injection Olaparib is a poly (ADP-ribose) polymerase (PARP) inhibitor with biologic activity in ovarian cancer as well as other solid tumors..~Other Names: NA"
224186251|NCT01266967|DRUG|GSK2118436|Subjects in this study receive 150 mg of GSK2118436 twice daily and continue on treatment until disease progression, death, or unacceptable adverse event.
224186252|NCT02360904|OTHER|Yoga|The intervention will consist of 12 weekly 60-minute yoga classes taught by a certified yoga instructor with cancer-specific yoga training. Classes will be conducted at the Beth Israel Comprehensive Cancer Center in a closed-group format, and will be offered twice a week. Yoga mats will be provided for each patient. The maximum number of patients attending each class will be 12. The classes will combine physical postures (asanas), breathing (pranayama), and deep relaxation (savasana). We would also encourage patient to practice yoga at home and keep a diary.
224186253|NCT05090592|DEVICE|orthokeratology|orthokeratology wearing for myopia control
224186254|NCT05090592|DRUG|0.01 atropine|0.01% atropine eye drop prevent myopic progression
224186255|NCT01945866|DRUG|intravitreal ranibizumab 0.3 mg|Intravitreal injection of 0.3mg ranibizumab performed on the day of randomization and up to every 4 weeks using defined treatment criteria
224186256|NCT01945866|DRUG|dexamethasone intravitreal implant|The dexamethasone intravitreal injection will be given within 0-8 days of the ranibizumab injection. If defined criteria are met, a second dexamethasone injection in combination with intravitreal ranibizumab (within 0-8 days) will be given at the 12 week visit. If the injections are given consecutively on the same day, the ranibizumab injection must be given first.
224186257|NCT01945866|PROCEDURE|Sham injection|No injection is given. It is a sham injection to keep the participant masked. The sham injection will be given within 0-8 days of the ranibizumab injection. If the injections are given consecutively on the same day, the sham injection must be given first.
223494617|NCT07114822|BEHAVIORAL|Harnessing Online Peer Education|This group will have peer leaders that will engage participants in the groups. These peer leaders are those with type II diabetes that have over the recommended amount of exercise each week.
223494618|NCT07116239|DRUG|Edoxaban 60 mg|film-coated tablet, manufactured by Daiichi Sankyo Europe GmbH
223494619|NCT07116239|DRUG|Enoxaparin 40 mg|enoxaparin sodium, prefilled syringe of 0.4mL injectable solution, manufactured by SANOFI WINTHROP INDUSTRIE
223494620|NCT07116226|OTHER|Medical Keto Education Program|4 hour asynchronous educational class
223589269|NCT03997643|RADIATION|Radiotherapy to all dissected areas|Post operative radiation therapy +/- chemotherapy based on historic treatment volumes (including the primary site, dissected areas +/- elective areas
223589270|NCT03997643|RADIATION|Omit radiation to pN0 neck|post operation radiation therapy +/- chemotherapy that avoids targeting the dissected pN0 neck
223589271|NCT03046524|OTHER|Chart Review|Data between the years of 1/1/2002 and 12/31/2013 analyzed.
223589272|NCT03511469|OTHER|Control Group|Control Group: Standart rehabilitation
223589273|NCT03511469|OTHER|Isokinetic Group|Concentric group: Standart rehabilitation + isokinetic training
223589274|NCT03530670|OTHER|oral midazolam|0.5 mg/kg oral midazolam administered 20 minutes before anesthesia induction
223494621|NCT07116135|DEVICE|hearing instruments|Participants will be fit with three different models of hearing instruments.
223494622|NCT07117461|BEHAVIORAL|NCCN Distress Thermometer|A tool used to determine on a number scale the amount of distress for the past week
223494623|NCT07118761|BEHAVIORAL|Home-based walking training|Patients enrolled in the experimental group will undergo an exercise-based intervention at home guided by a smartphone application. Each exercise session will encompass 8 walking minutes at home at a fixed slow speed to be repeated twice per day. Every week the speed will be slightly increased to maintain an adequate training stimulus.
223494624|NCT07118163|OTHER|Other|No intervention was applied in this study.
223494625|NCT07118163|OTHER|No intervention; Observational study|No intervention
223494626|NCT07115147|DEVICE|Blue diode laser|All procedures would be performed under spinal or general anaesthesia. Blue diode laser vaporization would be performed according to the standard approach for the obstructing prostate
223494627|NCT07117721|PROCEDURE|Endoscopic Band Ligation (ENDOBAND-DM)|Endoscopic band ligation of the second through fourth parts of the duodenum, from just distal to the ampulla of Vater to the ligament of Treitz. The aim is to induce localized mucosal remodeling that may enhance enteroendocrine signaling (GLP-1, GIP) and improve glycemic control in patients with type 2 diabetes mellitus.
223494628|NCT07121127|COMBINATION_PRODUCT|FSN+Vitamin supplement|Fu's subcutaneous needling with oral Vitamin C and vitamin E supplements
223494629|NCT07121127|DRUG|Vitamin Supplements|oral Vitamin C and vitamin E supplements
223494630|NCT07119671|OTHER|HOPAIR Intervention: Meeting between Peer Helper and Concerned Individual in Psychiatric Crisis Unit|This intervention begins with an initial discussion focused on the individual's lived experience, followed by an explanation of the Hope Box's principle, utility, and use. After each intervention, the peer supporter will complete a satisfaction self-questionnaire to provide feedback.
223494631|NCT07117929|DEVICE|Active PEMF|PEMF: 1.5mT, 10Hz, 10 minutes
223494632|NCT07117929|DEVICE|Sham PEMF|PEMF 0mT, 0Hz, 10 minutes
223589275|NCT03530670|OTHER|Film http://www.animaturk.com/animasyon/suko-ameliyat-oluyor.|"Patients will be watched a short movie (at URL:~http://www.animaturk.com/animasyon/suko-ameliyat-oluyor.html#.Wd-YhFu0PIU) 20 minutes before induction."
223589276|NCT03530670|OTHER|Playing smartphone game|Patients will be played with smartphone (angry birds, subway surfers or snail Bob) 20 minutes before induction
223589277|NCT01147900|BIOLOGICAL|Boostrix™|Intramuscular, single dose
224186258|NCT01173666|PROCEDURE|stenting angioplasty plus medical therapy|Patients will be treated by stenting angioplasty of renal artery plus medical therapy. Medical therapy is based on antihypertensive, statin or antiplatelet drugs according to clinical indications.
224186259|NCT01173666|DRUG|Medical therapy|Patients will be treated by standard medical therapy. Medical therapy is based on antihypertensive, statin or antiplatelet drugs according with clinical indications.
223494633|NCT07117929|OTHER|Exercise|Standardised home exercise protocol
224186260|NCT04816942|BIOLOGICAL|Convalescent Plasma|Two units of ABO compatible COVID-19 convalescent plasma will be administered.
223494634|NCT07118865|OTHER|Online Pilates exercise|Participants will be asked to do their Pilates practice while watching the videos (not from memory) to ensure that they are performing techniques optimally. Each module lasts 25 minutes, but includes some resting activities so modules are not vigorous or fatiguing for most people. Nonetheless, subjects will be instructed to omit activities that they feel they cannot do safely. Participants can pause a session to add more rest breaks, if needed, or stop and complete a session later. Participants will attempt to do 3 Pilates modules per week, for a total of 75-90 minutes/week (depending on the exact length of the modules they do).
223494635|NCT07121881|DEVICE|Bar Attachment|A bar attachment supported by three mandibular implants (placed in the midline and canine regions) is used to retain a mandibular overdenture. The bar provides rigid splinting across the implants and allows retention using friction or clips, without additional attachment components. This serves as the control group.
223494636|NCT07121881|DEVICE|Bar with OT Equator Attachment|A bar attachment supported by three mandibular implants is combined with two OT Equator attachments to enhance denture retention and allow slight vertical and rotational resilience. The OT Equator system includes metal housings and retentive nylon caps, intended to reduce cap wear and improve patient comfort. This is the experimental arm.
223494637|NCT07125755|DRUG|Cisplatin|Concurrent Cisplatin chemotherapy (100 mg/m2 intravenous injection,once every 3 weeks, twice in total, on days 1 and 22) will be given plus intensity modulated radiotherapy
223494638|NCT07102953|BEHAVIORAL|Focused-attention meditation|This is a type of mindfulenss meditation, which instructes participants to keep focusing on own breathing with a sitting and rest posture.
223494639|NCT07102953|BEHAVIORAL|Open-monitoring meditation|This is a type of mindfulenss meditation, which instructs participants to stay aware of their vision with a sitting and rest posture.
223494640|NCT07102953|BEHAVIORAL|Audio-listening control|Participants listen to stories about creativity with a sitting and rest posture.
223494641|NCT07120178|OTHER|slit lamp examination|data collected: tumor size, pigmentation, vascularization, cells
223494642|NCT07120178|OTHER|dermatoscopy examination x20 and x400|data collected: tumor size, pigmentation, vascularization, cells
223494643|NCT07120178|OTHER|confocal microscopy examination|data collected: tumor size, pigmentation, vascularization, cells
223494644|NCT07120698|DRUG|Sintilimab|"Patients who met the inclusion criteria were treated with adaptive adjuvant sintilimab therapy guided by MRD.~Patients should test twice at postoperative days 3 to 7 and again at postoperative day 28 (±3 days). The results of these two tests will be used to determine the subsequent treatment pathway. Participants with two consecutive positive MRD tests or a single positive MRD test will be enrolled in the MRD+ treatment cycle：they will receive adjuvant treatment with sintilimab (200 mg, intravenous infusion, every 3 weeks). Follow-up visits will be conducted every 3 months, during which chest CT scans and MRD testing will be performed. If MRD becomes negative, treatment will be discontinued and the participant will be monitored. If MRD remains positive, treatment with sintilimab will continue.~Participants with two consecutive negative MRD tests will be enrolled in the MRD- treatment cycle：they will undergo follow-up observation only. Follow-up visits will be conducted every 3 months"
223494645|NCT07141784|DEVICE|C-Mill® Treadmill Training Combined with Conventional Physiotherapy|Participants received a 4-week integrated rehabilitation program consisting of 10 C-Mill® treadmill training sessions in addition to individualized conventional physiotherapy. C-Mill® sessions incorporated virtual reality and gamified tasks to improve static and dynamic balance, gait speed, stride regulation, and safe obstacle negotiation. Conventional physiotherapy targeted mobility, muscle strength, and functional skills to enhance walking performance and independence.
223494646|NCT07141550|OTHER|Clinical Pilates Group|Participants will be introduced to the principles of Pilates, the workout program, and its five key elements: neutral spine, lumbopelvic and scapular stabilization, focus, and breathing. Clinical Pilates sessions will be held twice weekly for 8 weeks, 60 minutes each, via synchronous telerehabilitation (Zoom/WhatsApp). Each session includes a 10-minute warm-up, 40 minutes of Pilates exercises, and a 10-minute cool-down. The physiotherapist will provide visual and verbal guidance to ensure correct posture and breathing. Exercises start with 6-8 repetitions in the first week, increasing progressively according to participant ability and advancing to higher-level positions.
223589278|NCT01147900|BIOLOGICAL|Boostrix™-US formulation|Intramuscular, single dose
223589279|NCT05768815|BEHAVIORAL|Breaking the Cycle Program|BTC is a prevention and early intervention program in Toronto, Canada, serving substance-using pregnant and/or parenting women with children under six years of age. Established by the Canadian Mothercraft Society in 1995, BTC is funded by the Community Action Program for Children and the Canadian Prenatal Nutrition Program through the Public Health Agency of Canada. BTC provides three program components that act synergistically: a) individualized services for mothers, b) individualized services for children, and c) relational interventions that enhance the mother-child relationship and promote infant mental health. Coordinated supports are offered through formal partnerships across service sectors. In 2004, BTC was recognized by the United Nations as an exemplary program serving pregnant and parenting women with substance use problems, and their young children.
223745752|NCT05760807|DRUG|Oxytocin nasal spray|Intranasal oxytocin, administered dose 24 international units (IU) twice daily, delivered over 7 days of a residential inpatient withdrawal admission.
223745753|NCT05855031|DIAGNOSTIC_TEST|Transient Elastography|One transient elastography 1-2 weeks after randomization
223745754|NCT03453684|DRUG|Administration of Vancomycin|Intravenous Vancomycin Administration
224186261|NCT05661006|DIETARY_SUPPLEMENT|Use of food supplement|"On day 1 subjects start with intervention on prearranged day. First dosage of test product is consumed during day 1 between regular meals (not as meal substitute).~In the following days: continuation of consumption of test product once per day until end of the intervention. Subjects are recording daily consumption of the product. Intervention diet recording during last week of intervention (days 49-56): 3x24h dietary records (two days during weekday, one weekend day).~Intervention end on day 56 ±3 (fasted condition):~Measuring S-25-OH-VitD, S-VitB12, S-protein, S-albumin, S-CRP Measuring body weight \& height Collecting data regarding the palatability of the product"
223745755|NCT03303846|PROCEDURE|Magnetic Resonance Imaging|Undergo high risk breast cancer screening MRI
223745756|NCT03303846|PROCEDURE|Biospecimen Collection|Undergo blood and tissue sample collection
223745757|NCT03303846|OTHER|Laboratory Biomarker Analysis|Correlative studies
223494647|NCT07141550|OTHER|Kinesthetic Brain Exercises Group|16 sessions, approximately 40 minutes each, will be administered twice a week for eight weeks by a physical therapist via video chat programs such as Zoom or WhatsApp. Kinesthetic brain exercises consist of three phases: a warm-up phase, an exercise phase, and a cool-down phase. The warm-up and cool-down phases consist of hand-eye coordination and relaxation exercises. The exercise phase consists of independent and dependent movements, as well as a combination of both.
223494648|NCT07140952|BEHAVIORAL|Strong SC|The Strong SC intervention combines the StrongPeople StrongHearts program with a supplemental medically tailored grocery program. The StrongPeople StrongHearts program is a 12-week group program, with two meetings per week, that incorporates education on nutrition and physical activity for weight management and cardiovascular health, as well as strength training and aerobic exercises. The supplemental MTG program will utilize a grocery delivery platform(s) to deliver a weekly medically tailored grocery box of produce worth approximately $30 (costs covered by grant funds). Box contents will be tailored by the PI, who is a registered dietitian licensed in South Carolina, to participants' nutrition needs and functional abilities (e.g., pre-cut vegetables for participants with limited hand functionality). Participants will receive an allotment of produce each week, as well as a recipe(s) and virtual cooking demonstration providing practical strategies on incorporating each week's produce.
223494649|NCT07140952|BEHAVIORAL|StrongPeople StrongHearts|The StrongPeople StrongHearts program is a 12-week group program, with two meetings per week, that incorporates education on nutrition and physical activity for weight management and cardiovascular health, as well as strength training and aerobic exercises. Participants of this intervention will receive a systematically adapted version of this program tailored to the physical capacities of the target population (chronic stroke survivors). The systematically adapted version of StrongPeople StrongHearts will be used across both experimental arms in this study.
223494650|NCT07141108|DEVICE|Paindrainer Care system|Self management digital tool for chronic pain
224186262|NCT05661006|DIETARY_SUPPLEMENT|Use of placebo food supplement|On day 1 subjects start with intervention on prearranged day. First dosage of test product is consumed during day 1 between regular meals (not as meal substitute). In the following days: continuation of consumption of test product once per day until end
224186263|NCT01670552|DRUG|Nimesulide + Pantoprazole|1 tablet each 12 hours for 14 days plus 1 tablet each 12 hours for 14 days of the Naproxen + Esomeprazole placebo.
223494651|NCT07142447|BEHAVIORAL|Multi-Component Behavioral intervention|"A multicomponent behavioral intervention during pregnancy and up to the first 18 months after delivery, composed by:~1. Digital tool called App Hypiend Digital Tool aimed at promoting lifestyle habits to reduce EDC exposure by providing personalized recommendations~2. Telephone monitoring~3. Workshop about environmental health education"
223494652|NCT07142447|BEHAVIORAL|Control group|Minimal behavioral intervention. Usual care
223494653|NCT03850106|DIETARY_SUPPLEMENT|Placebo|Placebo
223494654|NCT03850106|DIETARY_SUPPLEMENT|Indus810|Active product
223494655|NCT03869437|DRUG|Cefiderocol|2 grams intravenously administered over 3 hours every 8 hours for a period of 5 to 14 days (dosage adjustment is necessary based on renal function).
223494656|NCT03869437|OTHER|Best Available Therapy|Standard of care was determined by the investigator
224186264|NCT01670552|DRUG|Naproxen + Esomeprazole|1 tablet each 12 hours for 14 days plus 1 tablet each 12 hours for 14 days of the Nimesulide + Pantoprazole placebo.
224186265|NCT01246193|DRUG|CKD-828(FDC)|Drug: Telmisartan 80mg + S-Amlodipine 2.5mg(FDC) Tablet, Oral, Once Daily
224186266|NCT01246193|DRUG|Combination Therapy|"Drug: Telmisatan 80mg Tablet, Oral, Once Daily~Drug: S-Amlodipine 2.5mg Tablet, Oral, Once Daily"
224186267|NCT04393961|DEVICE|Premier Biotech COVID-19 IgG/IgM Rapid test Cassette|"Current emergency situation, there are large numbers of COVID-19 Antibody tests being made available at a record pace.~The protocol is designed to be test agnostic. However, for this first volley, we have chosen the The COVID-19 IgG and IgM Rapid Test provided by Premier Biotech.~We chose the Precision Bio test for 4 reasons~1. It is available as a single use test kit in one sealed unit.~2. It's a rapid test, with results available in 10 minutes.~3. It has clear and easy to read instructions already included~4. It has one of the lowest false positive rates of known tests at the moment"
224186268|NCT06665009|DEVICE|Manually Opened and Device-Opened Ampoules|this study is to evaluate the ampoule peeling device in terms of safety, ease of use, time efficiency, difficulty of operation, and user satisfaction among nurses when opening ampoule bottles of different capacities
223494657|NCT05983406|DEVICE|Doppler investigation|Doppler investigation
223494658|NCT05845593|OTHER|Decision Support Test|LuGENE®, a transcriptomic-based LDT, with standard evaluation of patients diagnosed with SLE
223494659|NCT06213974|OTHER|No Intervention|This is non-interventional study.
223494660|NCT02749955|BEHAVIORAL|PS-PrEP Intervention Group|This group will involve working with a PS-PrEP social worker to learn about PrEP. The PS-PrEP social worker will help subjects develop a care plan based on the subject's decision about whether or not to use PrEP. This may include referrals for PrEP, other services, and/or HIV testing. Personal contact will continue by way of phone calls, and messages in between visits.
223494661|NCT02749955|BEHAVIORAL|PrEPLine Control Group|This group follows routine department of public health care as a Linkage to Care Specialist from the PrEPLine provides subjects with PrEP education and the ability to schedule an initial PrEP appointment. In addition to this care, subjects will be referred for additional testing for STIs/HIV and subjects will be given information about programs available to prevent HIV infection, which include PrEP.
223494662|NCT05020912|DRUG|ALA|At first visit, ALA applied to one BCC lesion
223494663|NCT05020912|PROCEDURE|PDT|PDT with blue light (for 30 min (\~20 mJ/cm2))
223494664|NCT05944549|BEHAVIORAL|Financial coaching using TrustPlus|Participants will be assigned a financial coach, who will, prepare a budget, conduct a soft pull of their credit report and score to analyze the credit score. Based on the participant's goals and financial limitations as highlighted by the, the participant and financial coach will create a personalized financial action plan comprising of strategies, follow-up actions, and resources, which includes unlimited access to one-on-one sessions with the financial coach. After the intensive financial coaching, participants will maintain access to the TrustPlus Portal and can continue to connect with their financial coach as needed throughout the 6-month intervention period. Participants will also have ongoing access to educational webinars and Trust+Ed, an interactive resource that provides self-guided content on many financial topics of interest, such as credit building and debt management.
224186269|NCT00243477|DRUG|Escitalopram|Escitalopram 10mg or placebo once a day
224186270|NCT06381947|DRUG|Lipid-lowering therapy combination with PCSK9 inhibitors, bempedoic acid and ezetimibe|Evaluation of therapy of bempedoic acid with PCSK9 inhibitors and ezetimibe in reducing LDL-C in statin-intolerant patients.
224186271|NCT06381947|DRUG|Lipid-lowering therapy combination with PCSK9 inhibitors and ezetimibe|Evaluation of therapy of PCSK9 inhibitors with ezetimibe in reducing LDL-C in statin-intolerant patients.
223494665|NCT05944549|BEHAVIORAL|Brighter Bites|Families receive a weekly distribution of fresh fruits and vegetables for 24 weeks, there will be Nutrition education in school throughout the school year using the evidence-based CATCH (Coordinated Approach to Child Health) program and weekly healthy recipe tastings and cooking skill demos for families during produce pick-up time.Fruit and vegetable access is complemented by CATCH, an evidence based, Texas Education Agency-approved, coordinated school health program designed to promote healthy nutrition, physical activity, and prevent obesity in schoolchildren. In addition, the Brighter Bites website and mobile app are freely available in English and Spanish.
223494666|NCT05944549|BEHAVIORAL|Noom|Participants will get access to Noom which is a mobile app for weight loss that shifts the paradigm from dieting to a digitally supported and artificial intelligence (AI)-driven cognitive behavioral therapy approach to support personalized behavior changes towards eating, physical activity and stress management. The Noom Healthy Weight curriculum covers foundations in weight loss, nutrition, physical activity, sleep and stress management.Daily tasks (e.g., weight and food logs, readings) are organized vertically in simple cards on the phone screen, allowing users to easily scroll through what needs to be done. It will pull physical activity data (e.g., steps) directly from the health app on smartphones or apps associated with external devices such as Fitbit. Furthermore, Noom stands out from other app-based programs by assigning a personal coach to each user, helping users navigate the emotional and physiological experiences of the Noom weight loss experience.
223494667|NCT04445415|DIAGNOSTIC_TEST|COVID-19 antibodies testing|antibodies aganist COVID-19 detected in the serum of patients
223494668|NCT01435941|DRUG|Non-steroidal anti-inflammatory drug (NSAID)|Participants who self-report that they have treated headaches with any drug in the non-steroidal anti-inflammatory drug (NSAID) class
223494669|NCT01435941|DRUG|Triptan|Participants who self-report that they have treated headaches with any drug in the NSAID class and any drug in the triptan class including naratriptan, sumatriptan, rizatriptan, frovatriptan, almotriptan, eletriptan, and zolmitriptan
223494670|NCT01092923|DRUG|sevoflurane on air/O2|sevoflurane on air/O2
223494671|NCT01092923|DRUG|sevoflurane in N2O/O2|sevoflurane in N2O/O2
223494672|NCT04392804|PROCEDURE|scaling and root planing|one appointment for scaling and root planing of selected periodontal pockets, with periodontal curette (HuFriedy, Chicago, IL, USA), rinsing with saline solution
223494673|NCT02124174|DRUG|Vidaza and Valproic Acid|"Days 1-5: 5-Azacytidine 40 mg/m\^2 daily Days 1-5: +Valproic acid 15 mg/kg daily Days 6-28: Valproic acid 15 mg/kg daily~\*treatments will be repeated on the same days of each cycle for up to 4 total cycles. Each cycle will consist of 28 days."
223494674|NCT01292902|OTHER|inspiratory muscle exercise|To conduct the exercise to the inspiratory muscles was used for IMT Threshold ® device (Threshold Inspiratory Muscle Trainer, HealthScan Products Inc., Cedar Grove, New Jersey) is one of the most used for training of inspiratory muscles in patients with several pathologies such as ICC.Threshold ® has been engaged in the patient's mouth by a mouthpiece, with the nose occluded by a nose clip. The exercise time was 3 minutes. During this period, participants were encouraged to only breathe through the mouth and maintain a respiratory rate between 12 and 16ipm. The exercise would be stopped if HR increased more than 20% and / or SpO2 \< 88%.
223494675|NCT01292902|OTHER|inspiratory muscle exercise|Equal to the group with chronic heart failure.
223494676|NCT02742688|DIETARY_SUPPLEMENT|Pyrus pyrifolia var. culta(Makino) NaKai peel extract|Pyrus pyrifolia var. culta(Makino) NaKai peel extract(4g/day)
223494677|NCT02742688|DIETARY_SUPPLEMENT|Placebo|Placebo(4g/day)
223494678|NCT02159638|DEVICE|Guardian Enlite sensor|Sensor insertion
223494679|NCT02159638|DEVICE|Dexcom G4 platinum sensor|Sensor insertion
223494680|NCT06515730|DRUG|Apixaban|5 mg tablet twice a daily with dose reduction according to label
223494681|NCT06515730|DRUG|Warfarin|2.5 mg tablet once daily, with individual dosing according to coagulation tests
223494682|NCT05002751|OTHER|UCSD Vaginal Dilator Questionnaire|14 question survey
224186272|NCT03131531|OTHER|Patient registry|Clinical data, specific procedures and treatments will follow the Institutional standard operative procedures
224186273|NCT00777504|DRUG|usage oral angiogenesis inhibitor|see under 'study arms'
224186274|NCT00777504|DRUG|stop oral angiogenesis inhibitor|see under 'study arms'
223494683|NCT05002751|OTHER|EORTC Sexual Health Questionnaire|22 question survey
223494684|NCT01415076|PROCEDURE|Insufflation with CO2|Patients were randomly allocated to receive whole procedure or extubation-only CO2 insufflation, using a randomized computer-generated list.
223494685|NCT01680172|DRUG|Ketamine|Single dose (0.5 mg/kg) of liquid ketamine 10mg/mL solution taken by mouth
223494686|NCT01680172|DRUG|Placebo|Single dose of liquid placebo solution taken by mouth
223494687|NCT01626716|OTHER|care management|patients who assigned to the intervention group will take 7 times phone calls from case manager
223494688|NCT02981589|DEVICE|Invasive mechanical ventilation|Invasive ventilation was performed to all eligible patients. When patients met predefined criteria, spontaneous breathing trial was performed. Given spontaneous breathing trial passed, patients were extubated; on the contrary, patients would continue to receive invasive ventilation. If patients had respiratory failure after extubation, reintubation and invasive ventilation were necessary.
223494689|NCT06403059|DIAGNOSTIC_TEST|Cervical Length|trans vaginal ultrasound
223494690|NCT06403059|DIAGNOSTIC_TEST|Uterocervical Angle|by trans vaginal ultrasound
224186275|NCT06316076|BIOLOGICAL|CD19-CAR-DNT cells|Lentiviral vector-transduced DNT cells to express anti-CD19 CAR. Prior to cellular infusion, each patient received cyclophosphamide and fludarabine lymphodepleting chemotherapy.
224186276|NCT02059473|PROCEDURE|Rotator cuff repair|Physiotherapy \& Surgery
224186277|NCT02059473|PROCEDURE|Physiotherapy|
224308773|NCT01434082|BEHAVIORAL|comparison of types of sleep disordered breathing|comparison of types of sleep disordered breathing (primary snoring, upper airway resistance syndrome, obstructive sleep apnea) in children with and without arthritis.
224186278|NCT01921582|DRUG|Methylphenidate|"* Weekly appointments with study psychiatrists for the first four weeks, and then biweekly appointments for the last eight weeks.~* Intervention will consist of medication as well as components of Med-Plus treatment (e.g., medication management, general support, and compliance enhancement strategies)."
224308774|NCT00482651|RADIATION|Multidetector computed tomography scanning|contrast Multidetector CT-scanning
223494691|NCT00992888|DEVICE|Prometheus Liver Dialysis system (Fresenius Medical Care)|6 hour dialysis for 3 consecutive days
223494692|NCT02109224|DRUG|Ibrutinib|Given PO
223494693|NCT02109224|OTHER|Laboratory Biomarker Analysis|Correlative studies
223494694|NCT02109224|OTHER|Pharmacological Study|Correlative studies
223494695|NCT04168489|DEVICE|active rTMS|(rTMS) is received preliminary approval because of its noninvasive and safe analgesic effect.
223494696|NCT04168489|DEVICE|sham rTMS|The sham rTMS is inactive and similar to placebo effect.
223494697|NCT00083278|DRUG|MDX-010|
223494698|NCT02329288|DRUG|Triamcinolone Acetonide|
223494699|NCT02329288|DRUG|placebo|
223494700|NCT02314884|DRUG|Cafusertib Hydrochloride|
223494701|NCT04320537|OTHER|abstinence from use of marijuana and other abused drugs|abstinence from use of marijuana use and other abused drugs
223494702|NCT00025142|DRUG|FOLFOX regimen|
223494703|NCT00025142|DRUG|fluorouracil|
223494704|NCT00025142|DRUG|gefitinib|
223494705|NCT00025142|DRUG|leucovorin calcium|
223494706|NCT00025142|DRUG|oxaliplatin|
223494707|NCT03318419|DRUG|Cladribine|5mg/㎡ d1-5
223589280|NCT05768815|BEHAVIORAL|Maxxine Wright Program|Founded in 2005 and located in Surrey, British Columbia, the Maxxine Wright Community Health Centre (MWCHC) supports women who are pregnant and/or have young children and are impacted by substance use and/or violence. Women do not need to have children in their care to receive services. The program is funded and operated by the Fraser Health Authority, with additional in-kind support from the BC Ministry for Children and Family Development and the BC Ministry of Social Development and Poverty Reduction. MW addresses maternal substance use and exposure to violence through women-centered, trauma-informed, culturally grounded, and interdisciplinary approaches. Primary services offered include addiction counselling, primary health care, and group therapy to address interpersonal violence. Within MW, child-focused services are limited to primary health (e.g., well baby checks, childcare).
224308775|NCT00482651|PROCEDURE|Coronary angiography (CAG)|CAG and if necessary PCI. Included patients are already assigned for CAG
223494708|NCT03318419|DRUG|G-CSF|300ug d0-14
223494709|NCT03318419|DRUG|Cytarabine|10mg/㎡ q12h SC d1-14
223494710|NCT03318419|DRUG|Pegaspargase|2500U/m2 im d1
223494711|NCT05301699|OTHER|data analysis; validating the nomogram|Not Applicable. Our study did not involve intervention
223494712|NCT05686941|OTHER|Trans-cutaneous Laryngeal ultrasound (TLUS)|Assessment of the larynx (specifically the vocal cords) with hand held portable ultrasound device to assess the movements of the vocal cords
223494713|NCT05686941|OTHER|TLUS and simultaneous laryngoscopy|Assessment of the larynx (specifically the vocal cords) with hand held portable ultrasound device to assess the movements of the vocal cords with simultaneous video laryngoscopy (usual care)
223494714|NCT03568903|OTHER|Comprehensive physical therapy|Each session included exercises for posture, strength, range of motion, balance. In addition, different transfers and gait training was performed. Each session began with exercises in laying position (15 minutes), thereafter exercises in sitting were performed for 10 minutes. Then different exercises in standing position were performed for 15 minutes, followed by 10 minutes of gait training. 10 minutes of exercises for manual dexterity and upper limb function ended the session.
223494715|NCT00049829|DRUG|Zoledronic Acid|
223494716|NCT01035788|BEHAVIORAL|Mindfulness Based Cognitive Behavioral Conjoint Therapy|This intervention combines Cognitive Behavioral Conjoint Therapy for PTSD and mindfulness skills. Cognitive Behavioral Conjoint Therapy for PTSD includes PTSD psychoeducation, communication skills training and cognitive restructuring. Mindfulness involves teaching individuals skills that improve their ability to attend to their experience in the present moment while suspending judgment and to purposefully shift their attention. Thus mindfulness enhances the ability to monitor and manage emotions and thought processes so that individuals can reflect on, choose, and implement more effective responses.
223494717|NCT01035788|BEHAVIORAL|CBCT for PTSD - Communication Skills|This control intervention will provide psychoeducation including the communication skills content from sessions 1-7 of Cognitive Behavioral Conjoint Therapy for PTSD.
223494718|NCT04691934|PROCEDURE|Anesthesia management|Patients who underwent cesarean section and had positive PCR nasopharyngeal swabs for COVID-19 were included in the study. Patients who tested negative and were clinically suspicious were excluded from the study. PCR test was not performed on all elective and emergency pregnant women to be taken for cesarean section in our hospital. It was only applied to patients with symptoms or patients who were suspected. All patient demographics and information about anesthesia were analyzed retrospectively from the patient files.
223494719|NCT02590315|OTHER|Invitation for breast screening and random allocation|Invitation for breast screening; Women who consent to take part in the trial will be randomised to DBT or DM.
223494720|NCT02590315|DEVICE|DBT|Combo-mode DBT. DBT participants will have an additional radiation exposure for breast tomosynthesis.
223494721|NCT02590315|DEVICE|Conventional digital mammography.|Conventional digital mammography.
223494722|NCT05304325|PROCEDURE|Bariatric surgery|Sleeve gastrectomy
223494723|NCT05304325|OTHER|Blood sampling|Blood samples will be collected to measure glucose, insulin, albumin, uric acid, HbA1c, lipids, hepatic enzymes, TSH, hs-CRP, complete blood cell counts and persistant organic pollutants
223494724|NCT05304325|OTHER|Blood pressure|Systolic and diastolic blood pressure will be measured.
223494725|NCT05304325|OTHER|Anthropometric measurements|Body weight, height and waist circumference will be measured.
223494726|NCT05304325|OTHER|Body composition|Body composition will be evaluated by dual-energy X-ray absorptiometry.
223494727|NCT05304325|OTHER|Resting metabolic rate|Resting metabolic rate will be measured by indirect calorimetry.
223494728|NCT05304325|OTHER|Food intake|Food intake, energy intake and food quality will be evaluated using the food frequence questionnaire.
223494729|NCT05304325|PROCEDURE|Adipose tissue biopsy|A sample of 3-5g of adipose tissue will be collected under local anesthesia by needle aspiration in the periumbilical region.
224186279|NCT01921582|BEHAVIORAL|Cognitive Behavioral Therapy|"Cognitive Behavior Therapy will include three phases:~* Phase 1 undertakes to eliminate binge episodes and introduce a 'regular' pattern of eating;~* Phase 2 aims to reduce food intake and restructure eating-related cognitions;~* Phase 3 focuses upon relapse prevention"
223494730|NCT06049342|BIOLOGICAL|NCR100 injection|Subjects will receive a one-dose intra-articular NCR100 injection.
223494731|NCT02748031|PROCEDURE|slit-lamp-adapted anterior segmental photography|The eligible patients underwent pupil dilation and slit-lamp-adapted anterior segmental photography to electronically record and monitor the morphology of their cataractous lens.
223494732|NCT00704353|DRUG|Ferric Carboxymaltose|15 mg/kg up to a maximum of 750 mg at 100 mg/minute intravenously on Day 0.
223494733|NCT00704353|DRUG|Standard Medical Care (SMC)|Per product label
223494734|NCT06552195|OTHER|learning with augmented reality|"Study presentation: participants will be given a 10-minute general introduction on the study followed by a 20 minutes tutorial to introduce the HoloLens 2 and the TEACHANATOMY learning platform.~* Study session: The study session consists of three learning blocks of approximately 20 minutes each, plus a repetition block to assess the acquired knowledge. During the study session participants will be given no time constraints and free breaks.~* Assessment test: Participants will be assessed with a 30 minutes knowledge assessment test at the end of the study and after three months.~* Final questionnaire: At the end of the study session participants will be given a questionnaire to assess adverse health symptoms and user experience."
223494735|NCT06552195|OTHER|learning with traditional methods|"* Study presentation: participants will be given a 10-minute general introduction on the study followed by a presentation to introduce the study session.~* Study session: The study session consists of the learning resources most used by students: specific sections from four different neuroanatomy books, access to two websites, two 3D videos, and two online learning programs. During the study session participants will be given no time constraints and free breaks.~* Assessment test: Participants will be assessed with a 30 minutes knowledge assessment test at the end of the study and after three months.~* Final questionnaire: At the end of the study session participants will be given a questionnaire to assess adverse health symptoms and user experience"
223494736|NCT03819127|DRUG|Vildagliptin 50 MG Oral Tablet|
223494737|NCT03819127|DRUG|Metformin Pill|
223494738|NCT03380741|DIAGNOSTIC_TEST|Tumour markers detection|Lab on a chip detection of tumour markers measured from vaginal/cervical cytology swab
223494739|NCT01001104|DRUG|LY2189265|Administered by subcutaneous (SC) injection, once weekly (QW) for 12 weeks.
223494740|NCT01001104|DRUG|Placebo|Administered by SC injection, QW for 12 weeks.
223494741|NCT01007877|OTHER|Red Bull Energy drink|During a 15 minute break, subjects consume 250 ml of Red Bull® Energy Drink or placebo. Before and after the break, a 2 hour driving test is scheduled.
223494742|NCT00087412|DRUG|erlotinib hydrochloride|Given orally
223494743|NCT00087412|OTHER|laboratory biomarker analysis|Correlative studies
223494744|NCT02092428|OTHER|Image Quality|"The following procedures may be conducted as part of this study:~* Coronary MRI scan with no contrast~* Coronary MRI scan enhanced with a gadolinium-based contrast agent (Optimark, MultiHance, Ablavar) administered intravenously at a total dose of up to 0.2 mmol/kg~* MRI scan with an oral beta blocker (metoprolol)~* Cardiac Stress Test MRI scan with a pharmacologic stress drug; either adenosine (dosage depends on the subject's weight and is set at 140mcg/kg/min) or regadenoson (0.4mg/5ml bolus)~Determination of study drugs will be made depending upon study focus, subjects' health conditions, blood pressure, heart rate and concomitant medications. Both groups are eligible for all combinations of interventions."
223494745|NCT02092428|OTHER|Diagnostic Accuracy|Both groups are eligible for all combinations of interventions. This arm will also include collection of conventional x-ray angiography.
223494746|NCT02560766|DRUG|HORIZANT 300 mg|HORIZANT 300 mg once daily
223494747|NCT02560766|DRUG|HORIZANT 600 mg|HORIZANT 600 mg once daily
223494748|NCT02560766|DRUG|Placebo|Placebo once daily
223494749|NCT02397837|DRUG|Pramipexole|Up to 4.5mg, PO, (by mouth) per day of the 12-week study.
223494750|NCT02397837|DRUG|Placebo|placebo match study drug
223494751|NCT03235414|DEVICE|MRI|Will receive a one time research MRI (MR elastography)
223494752|NCT03235414|DIAGNOSTIC_TEST|Blood draw|Will receive a one time blood draw to confirm healthy liver status
223494753|NCT05592691|PROCEDURE|Fascial block|The end of the drug infusion will be considered the time zero (T0); subsequently blood samples (4ml) will be taken at pre-established time intervals (after 5, 15, 30, 60, 120 and 180 minutes). Blood samples will be collected in test tubes and centrifuged within 1 hour of collection; subsequently they will be stored at a low temperature and transported to the reference analysis laboratory.
223494754|NCT05016336|OTHER|Social interaction combined with cognitive training based on mnemonic strategies.|In the first six sessions, participants in the experimental group learned and practiced six different mnemonic strategies: Story-Formation strategy, Face-Name strategy, Peg-Word strategy, Chunking strategy, Key-Word strategy and the Method of Loci. In the following six sessions, in order to assimilate the strategies they learned, participants practiced the same tasks.
223494755|NCT05016336|OTHER|Social interaction group|In the control group, each session also began with a conversation between the participants. The sessions then dealt with the content of interpersonal communication and the acquisition of tools for creating interpersonal relationships. Participants were asked to share the way they used the tools they acquired between sessions and received feedback from the other participants
223494756|NCT00599313|DRUG|Sunitinib|50 mg/day orally each of Days 1-28 of each 6 week cycle
223494757|NCT00078494|DRUG|EBV-LMP-2|
223494758|NCT00258661|PROCEDURE|Osteopathic Manipulative Treatment|In addition to conventional treatment for pneumonia, a 10-minute standardized OMT protocol + 5-minute nonstandardized component was performed twice daily for the duration of hospitalization.
224186280|NCT02479594|BEHAVIORAL|competence-feedback|competence-feedback
224186281|NCT02479594|OTHER|control|control group without competence-feedback
224308776|NCT00482651|PROCEDURE|Intravascular ultrasound|During CAG Intravascular Ultrasound will be performed in the three coronary arteries
224308777|NCT00482651|PROCEDURE|Blood sample|a blood sample at baseline after 3 months and at the end of the follow up (after 12 months)
224308778|NCT03929341|DIAGNOSTIC_TEST|Coronary Computed Tomography Angiography (CCTA)|Cardiac imaging test that is able to detect changes is cardiac vessels and the heart.
224308779|NCT03929341|OTHER|Cardiac Link|Clinical patient flow pathway that will enable radiologist to activate expedited cardiology referral for patients who exhibit clinically significant changes during CCTA.
223494759|NCT00258661|PROCEDURE|Light-touch Treatment|In addition to conventional treatment for pneumonia, a 10-minute standardized light-touch protocol (designed to mimic OMT standardized protocol) + 5-minute auscultation of carotid bruits, heart, and lungs was performed twice daily for the duration of hospitalization.
223494760|NCT03745781|DRUG|Placebos|placebo pills
223494761|NCT02536794|BIOLOGICAL|Anti-B7H1 Monoclonal Antibody MEDI4736|Given IV
223494762|NCT02536794|OTHER|Laboratory Biomarker Analysis|Correlative studies
223494763|NCT02536794|OTHER|Pharmacological Study|Correlative studies
223494764|NCT02536794|BIOLOGICAL|Tremelimumab|Given IV
223494765|NCT04033913|OTHER|Self questionnaire|Patients who have successfully perform self-catheterization complete a self questionnaire on the importance of each criterion in choosing the catheter they have made.
223494766|NCT01011296|DRUG|PF-04427429|Single 0.2mg dose of intravenous infusion
223494767|NCT01011296|DRUG|PF-04427429|Single 1mg dose of intravenous infusion
223494768|NCT01011296|DRUG|PF-04427429|Single 3 mg dose of intravenous infusion
223494769|NCT00926120|DIETARY_SUPPLEMENT|Mogroside sweetener (PureLo)|Mogroside sweetener administered at a dosage level of 5g every 6 hours for 14 days
223494770|NCT01926639|BIOLOGICAL|Radiotherapy, rituximab and DC|Lymphoma lymph nodes are irradiated with 8 Gy single treatment and injected with rituximab (5 mg) and autologous DC intratumorally. The treatment is performed 3 times targeting different lymph nodes
223494771|NCT01191385|DRUG|Any treatment for unresectable HCC as chosen by the physician|Only those patient are allowed to be enrolled that receive any HCC treatment for unresectable HCC as chosen by the physician except sorafenib. During the course of the study, each treatment is allowed.
223494772|NCT01406912|OTHER|Recreational Activity|Recreational activities (playing cards, arts and crafts, dominoes, jenga or a ball game) and conventional rehabilitation.
223494773|NCT01406912|OTHER|Wii Gaming System Arm|Virtual reality Wii games (tennis and bowling from Wii® Sports, and bean bag, bocce ball, ping cup, darts or shuffleboard from Wii® Game Party 3) and conventional rehabilitation.
223494774|NCT00169260|BEHAVIORAL|motivational counseling|behavioral motivational counselling
223494775|NCT00169260|BEHAVIORAL|placebo|
223494776|NCT00458835|DRUG|Ciclesonide|
223494777|NCT02887599|PROCEDURE|Blood collection|1ml of blood specimen collection
223494778|NCT04424602|DRUG|cyclo phosphamide|500mg vial
223494779|NCT04424602|DRUG|mycophenolate|500mg film-coated tablets.
223494780|NCT05397418|BEHAVIORAL|Supervised resistance exercise program|12 week supervised low impact resistance training program
223494781|NCT05397418|BEHAVIORAL|Unsupervised resistance exercise program|12 week unsupervised low impact resistance training program
223494782|NCT00005795|DRUG|arsenic trioxide|
223494783|NCT05470998|DRUG|L-Arginine|L-Arginine 1000 mg free form, rapid release capsules
223494784|NCT06096948|DEVICE|NEXPOWDER-ENDOHS|Standard of care ESD or EMR procedure and application of Nexpowder on the resection site to prevent delayed bleeding.
223494785|NCT02979288|DRUG|Lactobacillus casei rhamnosus (Lcr 35 regenerans)|Probiotic vaginal tablets vith active probiotic strains
223494786|NCT02979288|OTHER|NO Intervention|NO Intervention
223494787|NCT05678114|DIETARY_SUPPLEMENT|Myo-inositol|Myo-inositol (4g/die)
223494788|NCT01149785|DRUG|crizotinib|Treatment A: a single 150-mg dose of crizotinib will be administered in the fasted state on Day 1 as 1 × 50-mg and 1 × 100-mg Immediate Release Tablets.
223494789|NCT01149785|DRUG|ketoconazole|Treatment B: 200 mg twice a day (approximately 12 hrs apart) doses of ketoconazole will be administered orally on an empty stomach from Day 1 to Day 16.
223589281|NCT03850002|OTHER|Early detection of CLAD by Lung Clearance Index (LCI)|Lung transplant candidates without prior CLAD (evaluated in study part I) will be followed over a period of 3 years to evaluate the potential of LCI to detect early CLAD
224308780|NCT05158036|OTHER|Classic massage group|Classic massage application will be given to the Classic massage group
224308781|NCT05158036|OTHER|Connective tissue masage|Connective tissue masage application will be given to the Connective tissue masage group
223494790|NCT01149785|DRUG|crizotinib|Treatment B: A single 150-mg dose of crizotinib will be administered in the fasted state on Day 4 as 1 × 50-mg and 1 × 100-mg Immediate Release Tablets.
223494791|NCT01201863|DRUG|Androgel (Testosterone Gel)|2.5 gram stickpacks administered with starting dosage of 5g increasing to a max of 10g.
223494792|NCT01201863|OTHER|Placebo gel|2.5 gram stickpacks with starting dose of 5g increasing to max of 10g.
223494793|NCT00448357|BIOLOGICAL|rabbit anti-thymocyte globulin (ATG)|.5 mg/kg on day -3 and 2.5 mg/kg on day -2
223494794|NCT00448357|BIOLOGICAL|therapeutic allogeneic lymphocytes|minimum total cluster of differentiation (CD34+) cells of 3 x 10\^6 cells/kg and a maximum of 8 x 10\^6 cells/kg will be infused on day 0
223494795|NCT00448357|DRUG|busulfan|PK-targeted continuous IV infusion over 90 hours on Days -7 to -4.
223494796|NCT00448357|DRUG|fludarabine phosphate|30 mg/m\^2/day x 5 days intravenous piggyback (IVPB) over 30 minutes on Days -7 through -3
223494797|NCT00448357|DRUG|tacrolimus|The suggested starting dose is 0.03 mg/kg po bid starting on day -1
223494798|NCT00448357|PROCEDURE|allogeneic hematopoietic stem cell transplantation|A minimum total CD34+ cell dose of 3 x 10\^6 cells/kg and maximum of 8 x 10\^6 cells/kg will be infused on day 0
223494799|NCT00448357|PROCEDURE|peripheral blood stem cell transplantation|minimum total CD34+ cell dose of 3 x 10\^6 cells/kg and a maximum of 8 x 10\^6 cells/kg will be infused on day 0
223494800|NCT00448357|DRUG|methotrexate|5 mg/m\^2 on days +1, +3 and +6
223494801|NCT02714738|PROCEDURE|Ultrasound guided peripheral nerve block|Ultrasound guided peripheral nerve block
223494802|NCT04221971|DRUG|chemotherapy combined with NK cells infusion|chemotherapy combined with NK cells infusion
223494803|NCT02413762|OTHER|No intervention|No intervention
224308782|NCT02789618|OTHER|A01|Subjects will brush their teeth twice a day using their assigned toothpaste for 56 days. The gel will be applied in the evening of three consecutive days during the study time period
224186282|NCT01715480|DIETARY_SUPPLEMENT|Broccosprouts® (Brassica Protection Products LLC) homogenate|"In the in-vitro part of the study, sulphoraphane will be added into the culture media used to grow and differentiate the erythroid cells from blood samples obtained from three Hb AA volunteers and three Hb SS subjects. The subjects will have a single clinic visit for the blood donation.~In the second part of the study, enrolled subjects will be asked to consume homogenates of broccoli sprouts by mouth daily for three weeks. They will have a maximum of five clinic visits for medical assessments and lab draws during this time. They will then have a final clinic visit after a washout period of six weeks."
223494804|NCT02500355|PROCEDURE|Carpal Tunnel Release via limited approaches|Carpal tunnel release with partial excision of the flexor retinaculum via two small incisions.
223494805|NCT02500355|PROCEDURE|Carpal Tunnel Release via standard approach|Carpal tunnel release with partial excision of the flexor retinaculum via the standard incision.
223494806|NCT02500355|PROCEDURE|Endoscopic Carpal Tunnel Release|Carpal tunnel release under endoscope.
223494807|NCT02500355|DEVICE|endoscope or an arthroscopic device|
223589282|NCT04527627|BEHAVIORAL|Nursing Empowerment Intervention|"Nursing empowerment intervention The intervention will be carried out during the ICU discharge planning. A Patient Information Guide for Intensive Care Unit patients will be developed.~The guide will be based on the findings obtained in a previous qualitative study and on previous studies on patient empowerment and education. Its structure will take into account the dimensions of empowerment: bio-physiological, functional, social, experience, ethics and the financial aspect. The guide will be reviewed by experts in the development of information guides for patients and family members and will be evaluated by the participating ICUs before use.~EG patients will receive the intervention verbally and in booklet format from the study nurses at each ICU."
223589283|NCT02602665|PROCEDURE|Shallow catheter tip placement|for shallow placement tip of catheter placed 1 vertebral body above to even with the carina
223589284|NCT02602665|PROCEDURE|Deep catheter tip placement|deep placement catheter tip is placed 1.5 to 2.5 vertebral bodies below the carina
223589285|NCT05329207|BEHAVIORAL|Experimental group|Web Based Adolescent Health Promotion Education Program
223589286|NCT01950091|BEHAVIORAL|FitBack on-line intervention|On-line Fitback intervention: Self care for on-going pain; behaviors to lessen the chance of reoccurrence
223589287|NCT01950091|OTHER|Alternative Website Control|Intervention is a Menu of links to 4 popular Websites offering back pain education
223589288|NCT00715858|DRUG|doxycycline|capsule, 100 mg, b.i.d., 12 months
223589289|NCT00715858|DRUG|rifampin|capsule, 300 mg, od, 12 months
223589290|NCT00715858|DRUG|placebo|placebo matched to rifampin; placebo matched to doxycycline
223589291|NCT01435837|DRUG|C2 (200mg of caffeine; 1/2 L of water)|200mg of caffeine (tablet); 1/2 of water
223589292|NCT01435837|DRUG|C3(200mg of caffeine; 1 L of water)|Ingestion of 200 mg of caffeine and 1 Liter of water after between pretest and posttest.
223589293|NCT01435837|DRUG|C1 (200mg of caffeine, no water)|Ingestion of 200mg of caffeine (tablet); no water ingestion.
223589294|NCT01435837|DRUG|Placebo (no caffeine, no water).|No ingestion of caffeine; no ingestion of water between pretest and posttest.
224308783|NCT02789618|OTHER|B99|Subjects will brush their teeth twice a day using their assigned toothpaste for 56 days. The bonding agent will be professional applied immediately prior to the clinical assessments.
223494808|NCT00898807|DRUG|citalopram|target dose 30mg daily for 9 weeks
223494809|NCT00898807|DRUG|placebo|daily for 9 weeks
223589295|NCT01953913|DRUG|Afatinib|Patient will receive afatinib once daily
223494810|NCT02885675|OTHER|blood sampling|sample no more than 3ml
223494811|NCT04804488|PROCEDURE|nasal polyp surgery|A retrospective study for patients with recurrent nasal polypi operated at Otorhinolaryngology Department, Sohag University Hospital will be carried out.
223494812|NCT00817063|DRUG|alitretinoin|Patients receive alitretinoin 30mg one capsule daily for up to 24 weeks
223494813|NCT00817063|DRUG|Placebo|Patients receive matching placebo for up to 24 weeks
223589296|NCT01862653|DEVICE|Auricular Acupuncture|Subjects receiving the auricular acupuncture intervention will be treated in a quiet private room sitting in a comfortable chair. The external ear cartilage of both ears will be cleaned with isopropyl alcohol swabs. A clean insertion technique will be used with stainless steel SEIRIN D type acupuncture needles (0.20mm diameter, 15mm length) on each of the identified acupuncture points (Shen men, Point zero, brain, thalamus, Pineal, Master cerebral, Insomnia 1, Kidney, Heart, Insomnia 2, Occiput, Forehead) to bilateral ears for a total of 30 minutes. Acupuncture will be administered by a board certified Psychiatrist with supplemental privileges to perform acupuncture.
223589297|NCT05407961|DRUG|LY3532226|Administered SC.
223494814|NCT02103842|DRUG|Omega-3 fatty acids|
223589298|NCT05407961|DRUG|Placebo|Administered SC.
223589299|NCT05407961|DRUG|Dulaglutide|Administered SC.
223589300|NCT03437707|DRUG|Morphine Sulfate|Patients will be received morphine with intravenous patient controlled analgesia (IV PCA) device during postoperative 24 hours. The PCA solution will be prepared with 100 mg morphine in 200 mL of saline (0.5 mg/ml). The PCA device was adjusted as infusion: 0 ml/h, bolus: 1 ml, lockout period: 7 min.
223617759|NCT00472225|DRUG|Rituximab|"Rituximab Induction: Rituximab 375 mg/m2 weekly IV for 4 consecutive weeks~Rituximab Maintenance: Rituximab 375 mg/m2 monthly IV for 4 consecutive months"
223617760|NCT04851626|OTHER|Hypnotic intervention for persistent pelvic pain.|Education about persistent pelvic pain followed by 7 recordings of hypnosis intervention across 7 weeks accessed online through recordings.
224308784|NCT02789618|OTHER|M89|Subjects will brush their teeth twice a day using their assigned toothpaste for 56 days.
223494815|NCT01773369|BEHAVIORAL|Early leg training|Children will engage in \~1 hour/day, 4 days/week treatment for 3 months. The treadmill will consist of supported walking on a treadmill, over ground, stair climbing, standing, kicking, splashing ... etc. leg activity. Activities will be directed by a physical therapist in the clinical setting.
223494816|NCT01773369|BEHAVIORAL|Delayed leg training|The training activity will be exactly the same as the Early leg training group, except that it will occur \~3 months after recruitment.
223494817|NCT01773369|BEHAVIORAL|Parent leg training|Children will engage in \~1 hour/day, 4 days/week treatment for 3 months. The treadmill will consist of supported walking on a treadmill, over ground, stair climbing, standing, kicking, splashing ... etc. leg activity. Activities will be directed by parents in their home or community environment.
224186283|NCT06474780|DEVICE|Weight: 414g Size: 19.5cm x 14cm x 11cm Compatibility: Android and iOS VR Box 3.0 3D Virtual Reality Glasses Has the Feature of Fixation with Headband It has a lens mechanism tha|Patients in the experimental group were fitted with virtual reality glasses for 3 cycles and were allowed to watch videos of city tours, walks in the forest, and nature walks for 15 minutes, depending on their choice.
224186284|NCT02620826|PROCEDURE|Indirect pulp therapy|Decayed dentin is lined with a resin-modified glass ionomer (Vitrebond Plus)
223494818|NCT01496456|DEVICE|Resin infiltration|Split-mouth design (at least two lesions per patient): Treatment of one caries lesion with resin infiltration therapy
223494819|NCT01496456|BEHAVIORAL|Caries management|Split-mouth design (at least two lesions per patient). Baseline preventative caries management: dietary and behavioral modification, and over-the-counter fluoride supplements
223494820|NCT00942643|DEVICE|CPAP machine|a machine delivers positive airway pressure into the upper airway via a nasal mask
223589301|NCT03437707|DRUG|Intravenous paracetamol|1 g paracetamol will be administered 30 minutes before the end of surgery. All administrations will be applied through IV infusion over 30 minutes. Patients will be received morphine with intravenous patient controlled analgesia (IV PCA) device during postoperative 24 hours. The PCA solution will be prepared with 100 mg morphine in 200 mL of saline (0.5 mg/ml). The PCA device was adjusted as infusion: 0 ml/h, bolus: 1 ml, lockout period: 7 min.
223589302|NCT03437707|DRUG|Intravenous ibuprofen|800 mg ibuprofen (diluted with 250 ml saline) will be administered 30 minutes before the end of surgery. All administrations will be applied through IV infusion over 30 minutes. Patients will be received morphine with intravenous patient controlled analgesia (IV PCA) device during postoperative 24 hours. The PCA solution will be prepared with 100 mg morphine in 200 mL of saline (0.5 mg/ml). The PCA device was adjusted as infusion: 0 ml/h, bolus: 1 ml, lockout period: 7 min.
223589303|NCT00645463|DRUG|CP-945,598|20 mg CP-945,598 + 240 mg MR Diltiazem
223589304|NCT00645463|DRUG|CP-945,598|20 mg CP-945,598 alone
223589305|NCT05512013|DRUG|Ibuprofen 800 mg|Ibuprofen taken orally 2 hours prior to exercise
223589306|NCT05512013|DRUG|Celecoxib 200mg|Celebrex taken orally 2 hours prior to exercise
223589307|NCT05512013|DRUG|Flurbiprofen 100 mg|Flurbiprofen taken orally 2 hours prior to exercise
223589308|NCT05512013|DRUG|Placebo|Inert placebo taken orally 2 hours prior to exercise
223589309|NCT01732913|DRUG|Placebo|Tablets administered orally twice daily
223589310|NCT01732913|DRUG|Rituximab|375 mg/m\^2 administered intravenously weekly for 4 weeks, then every 8 weeks (up to a total of 8 infusions)
224186285|NCT02620826|PROCEDURE|Pulpotomy|A cervical pulpotomy is done and the radicular pulp is lined with Mineral Trioxide Aggregate
224186286|NCT00014066|DRUG|hematoporphyrin derivative|
224186287|NCT00014066|RADIATION|brachytherapy|
224186288|NCT05353920|OTHER|Cognitive training|cognitive related training bu virtual reality system
224186289|NCT03780673|DRUG|Simvastatin|Simvastatin 20 mg/day for 12 months
223494821|NCT01374737|DRUG|Dexmedetomidine|dexmedetomidine, 0.1ug/kg up or down
223494822|NCT01800760|DIETARY_SUPPLEMENT|Probiotics|Probiotics once a day for three weeks.
223494823|NCT00795574|DRUG|infliximab|Dosing is 5mgs/kg at weeks 0,2 and 6 to complete loading dose of drug and then every 8 weeks thereafter until end of treatment phase.
223494824|NCT00795574|DRUG|Placebo Comparator|5mgs /kg given IV over a minimum of 2 hours at weeks 0,2 and 6 to complete loading dose and then every 8 weeks during maintenance treatment period.
223494825|NCT04444869|DRUG|Cisplatin injection|Standard dose cisplatin given concurrently with radiation therapy
223589311|NCT01732913|DRUG|Idelalisib|150 mg tablets administered orally twice daily
223589312|NCT02350504|BEHAVIORAL|Full interactive instruction|This is a prospective randomized controlled trial in which the level of the child's exposure to instruction is controlled according to the group he is attributed to. The children are divided randomly, each Sunday (the day there is an available anesthesia staff) we change the extent of the instruction. In the intervention group, we use Full interactive instruction- which include an instructional booklet, a movie and a simulator's practice.
223589313|NCT02175914|DRUG|Erythromycin|Oral Treatment with Erythromycin 500mg, twice daily, for 12 weeks
223589314|NCT00697281|DRUG|OC000459|"Tablets twice daily for 8 days~Dose level 1"
223589315|NCT00697281|DRUG|OC000459|"Tablets twice daily for 8 days~Dose level 2"
223589316|NCT00697281|DRUG|OC000459|"Tablets twice daily for 8 days~Dose level 3"
223589317|NCT00697281|DRUG|OC000459|"Tablets twice daily for 8 days~Dose level 4"
223589318|NCT00697281|DRUG|Placebo|"Tablets twice daily for 8 days~Dose level 5"
223589319|NCT00436592|DEVICE|NeuroFlo™ Catheter|45 minute Treatment
223589320|NCT03525132|PROCEDURE|Laser Doppler Velocimetry + Optic Adaptative Camera|Fluxometry measure while subject is sitting in front of the optic adaptative camera
223589321|NCT00064402|DRUG|arformoterol tartrate inhalation solution|arformoterol 50 mcg QD
223589322|NCT00064402|DRUG|arformoterol tartrate inhalation solution|arformoterol 25 mcg BID
223589323|NCT00064402|DRUG|arformoterol tartrate inhalation solution|arformoterol 15 mcg BID
224186290|NCT03780673|DRUG|Rifaximin|Rifaximin 400/8 hours for 12 months
224186291|NCT03780673|DRUG|Placebo of Simvastatin|Placebo of Simvastatin once a day for 12 months
224186292|NCT03780673|DRUG|Placebo of Rifaximin|Placebo of Rifaximin/8 hours for 12 months
224186293|NCT05214131|DEVICE|gogoband|use of biometric alarm to wake patient prior to wetting
224186294|NCT05214131|DEVICE|SNEA group|standard bedwetting alarm is used to treat patients, alarm sounds after wetting accident has occurred
224186295|NCT04782882|BEHAVIORAL|Progressive muscle relaxation+laughter therapy|"Laughter therapy:Laughter therapy is a technique that changes the mood by breathing correctly and by combining childish exercises with laughter exercises to turn into real laughter for no reason.~Progressive muscle relaxation procedure:~the participants were asked to tighten and relax large muscle groups in the body with deep breathing exercises. Progressive muscle relaxation was applied to the muscles of the head and face, neck, chest, back, arms, hands, abdomen, hips, legs and feet. The procedure was applied in a dark environment and accompanied by candlelight and relaxing music."
224186296|NCT04504682|BEHAVIORAL|Ambulation|Patients will be encouraged to ambulate for 20 minutes of every hour.
224308785|NCT02701270|DIETARY_SUPPLEMENT|Experimental Dietary Fibre 1|22.17 g of product diluted in 250 ml of water taken once orally.
223494826|NCT00513448|OTHER|Group wellness intervention|
223494827|NCT00513448|OTHER|Individualized physical rehabilitation|
223494828|NCT06091514|DEVICE|CS Medical Watch|The Use of the CS Medical Watch during the participation period of the clinical investigation (between 3 and 12 months according to the period at risk of AF).
223494829|NCT06091514|OTHER|Specific questionnaire|Specific questionnaire during the last study visit (takes place at M3 to M12 according to the period at risk of AF)
223494830|NCT04919161|DEVICE|Body weight support system control group|The BWSS control group interventions consisted of various balance activities, including: marching, side-stepping, retro-ambulation, step-taps, and step-ups. The BWSS control group also practiced various gait tasks, including: ambulation over the ground, going up and down stairs, and performing sit-to-stand transitions.
223494831|NCT04919161|DEVICE|Body weight support system with balance perturbations|"The BWSS with balance perturbations group conducted the same balance and gait activities as the control group, including: marching, side-stepping, retro-ambulation, step-taps, step-ups, ambulation over the ground, going up and down stairs, and performing sit-to-stand transitions.In addition, this arm will receive eight balance perturbations, two in each direction (lateral, anterior, and posterior) each session. BWSS-P participants will start at perturbation level one and progress up to level ten as appropriate. Each session, the perturbation level will be set based on the participant's progress."
223494832|NCT00712920|DRUG|0.15% azelastine hydrochloride|0.15% azelastine hydrochloride 1644 mcg
223494833|NCT00712920|DRUG|0.1% azelastine hydrochloride|0.1% azelastine hydrochloride 1096 mcg
223494834|NCT00712920|DRUG|Placebo|Placebo
223494835|NCT03808857|BIOLOGICAL|GB226|GB226 is administrated at the dose of 3mg/kg, once per 2 weeks (±3 days), and distributed in 100ml of 0.9% sodium chloride solution. The concentration of GB226 shall be strictly controlled at 1mg/ml\~10mg/ml, the duration is 60 min (±10 min) for the first infusion of the drug, and can be reduced to 30 min (±10 min) for the subsequent infusion of the drug if there is infusion related adverse reaction.
223494836|NCT03686111|DIAGNOSTIC_TEST|oocytes collect|After stimulation, an echo-guided oocyte puncture is performed under anesthesia
223494837|NCT06348043|DEVICE|Jarvik 2015 LVAD|Medical device used to treat children awaiting heart transplant who fail optimal medical therapy.
223494838|NCT02199496|BIOLOGICAL|Stelara (ustekinumab)|"* In the single-phase part of the study, subjects receive a single dose of Stelara (ustekinumab) 270 mg subcutaneously on Day 0 study visit.~* In the multi-phase part of the study, subjects receive single dose of Stelara (ustekinumab) 270 mg subcutaneously on Day 0 study visit with follow up dose of Stelara (ustekinumab) 90 mg subcutaneously at Week 8, Week 16, Week 24, Week 32 and Week 40"
223494839|NCT02826096|BEHAVIORAL|Biofeedback therapy|The brief version of biofeedback therapy is conducted by psychologists following the structure way. Biofeedback therapy is six session treatment once a week.
223494840|NCT06413407|BEHAVIORAL|Tai Chi Exercise|Tai Chi Exercise will be applied to this group.
223589324|NCT00064402|DRUG|Salmeterol|Salmeterol MDI 42 mcg BID
223589325|NCT00064402|DRUG|Placebo|Placebo BID
223589326|NCT02831322|PROCEDURE|Percutaneous coronary intervention|Percutaneous coronary intervention was a nonsurgical technique for treating obstructive coronary artery disease
223589327|NCT00479479|DRUG|Hydroxycobalamin (Vitamin B12 Depot, Nycomed Pharma)|an intramuscular injection of 400 µg hydroxycobalamin (Vitamin B12 Depot, Nycomed Pharma, Norway)
223589328|NCT05674253|DRUG|Dexmedetomidine + Hydrocortisone|Patients will receive dexmedetomidine 0.7 ɥg/kg/hr IV infusion before aortic cross-clamping, and will be continued intra-operatively and in ICU till weaning from mechanical ventilation Patients also will also receive Hydrocortisone 100 mg intravenous (IV) before aortic cross-clamping then 100 mg every 8 hours after surgery which will be continued for 48 hours
224308786|NCT02701270|DIETARY_SUPPLEMENT|Experimental Dietary Fibre 2|21.84 g of product diluted in 250 ml of water taken once orally.
223494841|NCT06413407|BEHAVIORAL|Receptive Music Therapy|Receptive Music Therapy will be applied to this group.
223494842|NCT06413407|BEHAVIORAL|Experimental|Tai Chi Exercise and Receptive Music Therapy techniques will be applied together to this group.
223494843|NCT04863534|DEVICE|Ultrasound|Muscular grayscale ultrasound
223494844|NCT02004171|OTHER|electronic cigarette|V2 Cigs with 24 mg nicotine cartridges
223494845|NCT02004171|DRUG|nicotine inhaler|nicotine inhaler with 10 mg nicotine cartridges
223494846|NCT02971904|OTHER|human milk collection|
223494847|NCT02362451|BIOLOGICAL|Autologus elutriated monocyte placebo vaccine|20x10\^6 viable cells/dose at weeks 3, 6, 9, 12, 15 and 24
223494848|NCT02362451|BIOLOGICAL|Multi-epitope (ME) T-cell receptor g alternate reading frame protein (TARP) vaccine|20x10\^6 viable cells/dose at weeks 3, 6, 9, 12, 15 and 24
223494849|NCT05920265|PROCEDURE|Quadratus Lumborum plain Block|ultrasound guided Quadratus Lumborum plain Block using 0.5 ml/kg bupivacaine 0.25% .
223494850|NCT05920265|PROCEDURE|fascia iliaca block|ultrasound guided fascia iliaca block using 0.5 ml/kg bupivacaine 0.25%
223494851|NCT05920265|DIAGNOSTIC_TEST|control group|no intervention
223494852|NCT03425370|PROCEDURE|Closure of surgical wounds using buried sutures or tissue adhesive on aesthetic outcome.|Effect of replacing buried sutures with tissue adhesive on aesthetic outcome of surgical wounds will be measured using the POSAS.
223494853|NCT04926493|BIOLOGICAL|microbiological characterization|microbiological characterization of endotracheal tube biofilm
223494854|NCT05259293|OTHER|No intervention - retrospective study|This is a retrospective study. No intervention.
223617761|NCT04851626|OTHER|Control group persistent pelvic pain no intervention.|Control group no hypnotic intervention. Waitlist control.
223617762|NCT01590979|DRUG|Ranolazine|1000mg, two times a day, 12 hour intervals
223617763|NCT01590979|DRUG|Placebo|two times a day, 12 hour intervals
223617764|NCT00138749|DRUG|SS-RBX|
223617765|NCT02533414|DEVICE|RIRS with UAS|Ureteral access sheath (UAS) will be used during RIRS.
223617766|NCT02533414|DEVICE|RIRS without UAS|Ureteral access sheath will not be used during RIRS.
223617767|NCT01178463|OTHER|Biospecimen staining|The sections will be incubated with rabbit anti GPR125 followed by Cy3-conjugated anti rabbit secondary antibodies.
223617768|NCT01178463|OTHER|Biospecimen staining|The sections will be incubated with rabbit anti GPR125 followed by Cy3-conjugated anti rabbit secondary antibodies.
224186297|NCT05874882|OTHER|resveratrol mouthwash as adjunct to scaling and root planing in periodontitis patients|patients with periodontitis will receive scaling and rootplaning and a resveratrol mouthwash twice daily for 4 weeks. saliva will be collected at the 1st visit and after one month then biochemical analysis for inflammatory biomarker will be done. periodontal parameters also will be evaluated at the 1st visit and after 1 month
224186298|NCT05874882|OTHER|chlorhexidine mouthwash as adjunct to scaling and root planing in periodontitis patients|patients with periodontitis will receive scaling and rootplaning and a chlorhexidine mouthwash twice daily for 4 weeks. saliva will be collected at the 1st visit and after one month then biochemical analysis for inflammatory biomarker will be done. periodontal parameters also will be evaluated at the 1st visit and after 1 month
224186299|NCT05874882|OTHER|placebo mouthwash as adjunct to scaling and root planing in periodontitis patients|patients with periodontitis will receive scaling and rootplaning and a placebo mouthwash twice daily for 4 weeks. saliva will be collected at the 1st visit and after one month then biochemical analysis for inflammatory biomarker will be done. periodontal parameters also will be evaluated at the 1st visit and after 1 month
224186300|NCT01992926|BEHAVIORAL|interactive educational intervention|Use of a concise, literacy-sensitive, physician-led, educational interaction with the patient.
224186301|NCT04398030|DEVICE|coil-reinforced soft polymer indwelling cannula|Insulin infusion set will be used for up to 7 days of continuous use or until failure
223494855|NCT06018168|OTHER|Skincare Routine|"Morning:~1\. GENTLECLEAN - Wash with a quarter-sized amount of lukewarm water. Pat skin dry after.~2 CELLRENEW - Shake well, apply 2-3 pumps over the entire face, and massage into the skin 3. YOUARESUNSHINE - Apply generously and evenly as the last step in the skincare routine (before makeup).~Night:~1. VITAMINSCRUB - Wet your face with lukewarm water \& apply a quarter-sized amount to wet palms. Lather until foamy. Gently massage the scrub using circular motions for 5-10 seconds. Rinse with lukewarm water and pat dry.~2. CLEARITY - Apply 2-3 pumps and massage into the skin avoiding the eye area. Let sit for 10-15 minutes. Do not wash off.~3. CELLRENEW - Shake well, apply 2-3 pumps over the entire face, and massage into the skin~4. HYDRAGLOW - Apply a dime-size amount of lotion and massage into the face"
223494856|NCT06018168|DIETARY_SUPPLEMENT|MINDBODYSKIN Supplement|Participants will take 3 capsules daily with a meal. The MINDBODYSKIN acne supplement contains Vitamin A (6,100mcg per serving of 3 capsules), Vitamin B12, Vitamin B-5, 5-Hydroxytryptophan (5-HTP), 3,3'-Diindolymethane (DIM), a proprietary liver blend of milk thistle, dandelion extract and L-glutathione, turmeric root extract, a proprietary digestive blend of protease and betaine hydrochloride, and silicon dioxide.
223494857|NCT04501575|OTHER|Osteopathic Consultation|A consultation including case history taking, physical assessment, osteopathic manual treatment, exercise prescription, and postural advice.
223494858|NCT04501575|OTHER|Sham Osteopathic Consultation|A sham treatment using light touch on bony structures, no diagnosis, advise or prescriptions
223589329|NCT04181177|OTHER|Cosmetic product|"Cosmetic balm: application twice daily on the whole body in sufficient quantity to cover all the xerosis areas. It contains an I-modulia(r) complex which decreases the sensation of itching, CER-OMEGA which are lipids similar to those of the skin, help repair and nourish the skin, finally Avène Thermal Spring Water which have soothing and softening properties.~Targeted education action consist in advices and preventive measures (including hygiene) regarding xerosis and associated dermatological signs / symptoms. Emollient and application tips and other supportive care tips will be provided. The targeted educational action will be monitored by the medical and paramedical teams (specialized nurses)."
223589330|NCT05016843|BEHAVIORAL|Treatment condition: Internet-administered Unified protocol|"Treatment condition:~The cognitive, behavioral treatment Unified protocol is a transdiagnostic treatment for anxiety and depression. Participants are taught five techniques in order to find new and more helpful ways to react to hindering thoughts and feelings: mindfulness, cognitive flexibility, identify and reduce behavioral avoidance, increase willingness to experience physiological sensations and exposure. The intervention is delivered online through a secure platform. Modules consist of text and the participants can work with the material whenever they wish to. Participants gain access to a new treatment modul every week."
223617769|NCT03614117|DIETARY_SUPPLEMENT|Lactobacillus salivarius PS7 during 6 months|7 months intervention study: A 6 months intervention period and 1 month follow-up after intervention finishing time. During the 6 months of intervention the participants will intake one daily dose of the product that contains 1\*10E9 CFU of L. salivarius PS7. Then, a 1 month follow-up period will be completed.
223617770|NCT03614117|DIETARY_SUPPLEMENT|Lactobacillus salivarius PS7 during 3 months|7 months intervention study: A 6 months intervention period and 1 month follow-up after intervention finishing time. During the 3 months of intervention the participants will intake one daily dose of the product that contains 1\*10E9 CFU of L. salivarius PS7. After that, the participants will intake one daily dose of the placebo. Then, a 1 month follow-up period will be completed.
223617771|NCT03614117|DIETARY_SUPPLEMENT|placebo|7 months intervention study: A 6 months intervention period and 1 month follow-up after intervention finishing time. During the 6 months of intervention the participants will intake one daily dose of placebo supplement.Then, a 1 month follow-up period will be completed.
223617772|NCT01153165|DRUG|Citalopram|Participants will be commenced on Citalopram 20mgs daily. At week 4 participants will be assessed for response to treatment . If no response, dose of Citalopram will be increased to 40mgs for the remaining 8 weeks of the study. Patients who respond will remain on 20mgs for remaining 8 weeks.
224186302|NCT04398030|DEVICE|soft Teflon indwelling catheter|Insulin infusion set will be used for up to 7 days of continuous use or until failure
224186303|NCT04178330|RADIATION|tomotherapy|Whole brain radiation (WBRT) with 38-40Gy in 20 fractions and concurrent boost of 60-70Gy of the lesions. TMZ is used if necessary: concomitant TMZ: 75mg/m2 adjuvant TMZ: 150mg/ m2\*5d, q28d, up to 6cycles.
224186304|NCT02123186|OTHER|newborn screening test for SMA|Routine newborn screening dried blood spots sample is used to test if missing 2 copies of SMN1 gene.
224186305|NCT01014104|DRUG|Methylprednisolone|Administration of Methylprednisolone
224186306|NCT01014104|DRUG|Control|Normal salin injection
224186307|NCT05631158|DIAGNOSTIC_TEST|MRI|"The clinical examination includes a short physical exam, a brief history of allergies, previous diseases and medications, and disease-related questionnaires.~All the participants will undergo 4 serial MRI scans: one MRI scan at the baseline visit, 6, 12, 18 months follow-up visit, respectively to record the changes in the brain, which include the neuromelanin scan.~For future proving the value of our study, we will also collect and store blood samples at the initial visit."
224186308|NCT05727696|PROCEDURE|Henry approach; volar approach|Radial Shortening : Supine position, general anesthesia, volar approach, Henry approach, osteotomy 1 inch from radio-carpal joint surface, shortening 2.5 mm of distal shaft radius, fixation by small DCP or small T plate.
224186309|NCT05727696|PROCEDURE|dorsal approach|Capitate Shortening : Supine position, general anesthesia, dorsal approach, separation between 2nd and 3rd compartments of extensor tendons, osteotomy \& shortening 2.5 mm of capitate, compression by Herpert screw.
224186310|NCT00223158|DRUG|Liothyronine|
224186311|NCT06519396|DEVICE|ultrasonography evaluation|Ultrasonographic measurements of the Achilles tendon were taken using Samsung Sonoace X7 ultrasound system equipped with an 8-13MHz linear transducer. After assuming a prone position on the examination table, the patients placed their feet against the wall and flexed their ankles to ensure optimal contact between the probe and the tendon. Measurements were taken separately on the right and left sides for each patient. Initially, the probe was positioned perpendicular to the long axis of the tendon for an axial plane assessment, followed by measurements of thickness (anterior-posterior), width (medial-lateral), and area at the level of the medial malleolus. The thickness and width measurements utilized the tendon's major axes, while the area measurements were automatically calculated by the device through continuous tracing of the tendon circumference in the same section
224186312|NCT06519396|DEVICE|tetrax device evaluation|A Tetrax device was used to assess static balance. The patient was positioned on the platform and subjected to tests in eight different positions. For each position, a test measurement was made for a duration of 32 seconds, for a total of approximately 5 minutes. The normal eyes-open position was taken as the reference. The effects of vision on balance were observed in the eyes-closed position. Balance is dependent on the back of the heels and the lower vertebrae in this position. Conversely, in the eyes-closed position with the head tilted 30 degrees forward, there is a load on the upper vertebrae and neck. Following the measurements, the Tetrax software program was used to calculate the Fall Index and Stability Index
224186313|NCT05466916|BEHAVIORAL|Exercise and diet education and instruction|1:1 or small group sessions consisting of educational materials and exercise instruction.
224186314|NCT03805763|PROCEDURE|Large extent of ILM Peeling|The extent of ILM peeling is 4DD
223494859|NCT02078037|DEVICE|Arctic Sun cooling device|The Arctic Sun® 5000 Temperature management systems (Bard Medical), a non- invasive, surface cooling technology that allows rapid and precise manipulation of core body temperature will be employed to maintain normothermia (normal temperature) in patients with ICH randomized to the treatment group.
223494860|NCT02078037|OTHER|Standard of Care|Patient will be given standard fever management (acetaminophen + cooling blanket at the discretion of the treating physician)
223494861|NCT00817102|PROCEDURE|FFR, IVUS, VH, or combination of the three|Fractional Flow Reserve (FFR), Intravascular Ultrasound (IVUS), Virtual Histology (VH) or some combination of these three procedures will be completed during the cardiac catheterization procedure.
223494862|NCT05017636|DEVICE|shock wave therapy|The participants received the treatment protocol established by the manufacturer of the Thork Shock Wave® device, IBRAMED- Industria Brasileira de Equipamentos Electromédicos, Amparo, São Paulo approved by Anvisa No. 10360310036. (Figure 1). The parameters were, 4,000 thousand shots with energy of 180mJ and frequency of 15Hz with 15mm stainless steel tip and 2,000 shots with energy of 100mJ and frequency of 15Hz with 15mm plastic tip, and for the tip slip, Neutral Thork® Lotion, RMC was used. Seven ESWT sessions were held, the average time of each was seven minutes, twice a week and the seventh session was held minutes before the surgical procedure of bariatric surgery, therapy was performed in an area of 150cm² on the left side of the abdominal region following the midline. The right side of the participants' abdomen did not receive ESWT and was termed as control.
223494863|NCT00308776|PROCEDURE|Cholecystokinin (CCK) infusion|Participants will begin infusion with a normal saline solution. After 10 minutes of saline infusion, participants will eat a small bowl of tomato soup, followed 20 minutes later by a 15-minute infusion of saline plus CCK.
223494864|NCT00308776|PROCEDURE|Saline infusion|Participants will begin infusion with a normal saline solution. After 10 minutes of saline infusion, participants will eat a small bowl of tomato soup, followed 20 minutes later by a 15-minute infusion of saline only.
223494865|NCT03139201|DEVICE|OxyAqua|OxyAqua (olifilcon D) silicone hydrogel soft contact lens
223494866|NCT03139201|DEVICE|Si-Hy|Si-Hy (oliflcon B) silicone hydrogel soft contact lens
223589331|NCT05016843|BEHAVIORAL|Treatment condition: Internet-administered Affect phobia treatment|The aim of psychodynamic Affect phobia treatment is for the patient to reach an intellectual and emotional understanding of his/hers problems. The goal of the treatment is for participants to decrease emotional avoidance and start to approach emotions and increase emotional awareness. Participants are taught this through linking their symptoms to their emotional avoidance, observe frequent and maladaptive patterns in relationships and see how these are linked to emotional avoidance. The intervention is delivered online through a secure platform. Modules consist of text and the participants can work with the material whenever they wish to. Participants gain access to a new treatment modul every week.
223589332|NCT05016843|OTHER|Treatment condition: Waitlist control|The waitlist condition is a control condition without any intervention.
223589333|NCT05016843|OTHER|Treatment length: 8 weeks|Participants will partake in their treatment condition for 8 weeks.
223589334|NCT05016843|OTHER|Treatment length: 16 weeks|Participants will partake in their treatment condition for 16 weeks.
223745758|NCT05982054|PROCEDURE|core decompression with local bone marrow mononuclear cells injection|under local anesthesia ,anterior approach, with ultrasound and fluoroscopy guide
224186315|NCT03805763|PROCEDURE|Small extent of ILM Peeling|The extent of ILM peeling is 2DD
224186316|NCT02274363|OTHER|No Intervention|Participants will not receive any intervention in this study. Participants with chronic plaque type psoriasis will be assessed at a single time point, primarily for severity of plaque-type psoriasis Participants will not be followed over time. Data will be collected from the medical consultation notes, medical records and during interviews.
224186317|NCT04717986|DRUG|Dapagliflozin 10Mg Tab|patients who meet the inclusion criteria will be randomized to receive dapagliflozin 10 mg every 24 hours for 12 months
224186318|NCT04717986|DRUG|Placebo|patients meeting the inclusion criteria will be randomized to receive a placebo solution every 24 hours for 12 months
224186319|NCT04564534|OTHER|MoCA cognitive assessment|cognitive assessment using the validated MoCA test administered via an application on an iPad
223589335|NCT05016843|OTHER|Access to a moderated forum|During their treatment, participants will have access to a discussion forum moderated by a clinician. Participants are encouraged to discuss questions and experiences related to their treatment condition.
223589336|NCT05016843|OTHER|No access to a moderated forum|Participants will not have access to a moderated forum, hence their treatment is self-guided.
223589337|NCT03726931|DIAGNOSTIC_TEST|18F-Fluorestradiol PET/CT scan|\[18F\]FES PET/CT scan will be performed after administration of radioactive labelled estrogen.
224186320|NCT02007824|DEVICE|ULSD-12D|wound cleansing and debridement using ULSD-12D
223494867|NCT01010620|BEHAVIORAL|Various Screening psychiatric and medical assessments|Possibly blood draws, urine samples, toxicology screens, computer-based and written psychological, psychiatric, and behavioral questionnaires and assessments.
223494868|NCT00215956|DRUG|topotecan|Preoperative treatment: oral topotecan 5 days per week for up to 5 weeks
223494869|NCT00215956|PROCEDURE|radiation|Preoperative radiation
223589338|NCT05245214|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|Muscle analysis by Magnetic Resonance Imaging
223589339|NCT02472613|DEVICE|acupuncture|"Patients will be treated at Renzhong（Du26）, Yintang（EX-HN3）、accupuncture Shangxing（DU23）penetrate to Baihui（DU20）,Sishencong（EX-HN1）; Neiguan（PC6）,Sibai（ST2）,Fengchi（GB20）and Sanyinjiao（SP6）in bilateral;Jianyu（LI15）,Quchi（LI11）,Shousanli（LI10）,Hegu（LI 4）, Fengshi (GB31),Xuehai（SP10） ,Zusanli（ST36）、Taichong（LR 3） of the hemiplegia side. There are another six groups of acupoints in bilateral. The acupuncturist will choose one group acupoints according to patients syndrome:Zhigou (SJ6),Qimen (LR14);Xingjian (LR2),Xiaxi(GB43);Fenglong (ST40),Lianquan(RN23);Tongli (HT5),Xinshu (BL15);Xinshu (BL15),Pishu(BL20);Shenshu (BL23),Taixi (KI3).~The acupoints are inserted at the depth of 20-30mm except Renzhong（Du26）, Sibai（ST2）, Sishencong（EX-HN1）are inserted at the depth of 5-10mm. The needles will be left for 30 minutes and then removed. Acupuncture treatment will consist of three sessions per week for 12 consecutive weeks."
223589340|NCT02472613|DRUG|placebo|Placebo was given for 12 consecutive weeks.
223589341|NCT02472613|DEVICE|sham-acupoint acupuncture|"Jianliao（SJ14）,Tianquan（PC2）,Xiabai (LU4),Xiaoluo (SJ12),Shouwuli (LI13),Sidu (SJ9),Huizong (SJ7),Wenliu (LI7),Zhouliao (LI12),Quze（PC3）,Kongzui（LI6）,Zhigou（SJ6）,Zhongzhu（SJ3）,Futu（ST32）,Jimen (SP11),Yinshi (ST33),Liangqiu（ST34）,Shangjuxu（ST37）,Xiajuxu（ST39）,Xiyangguan（GB33）,Ligou（LR5）,Pucan (BL61),Jinggu (BL64),Rangu (KI2),Ligou (LR5),Neiting （ST44） of the hemiplegia side.~• The acupoints are inserted at the depth of 20-30mm,except Pucan (BL61),Jinggu (BL64),Rangu (KI2) ,Neiting （ST44）are inserted at the depth of 5-10mm. The needles will be left for 30 minutes and then removed. Acupuncture treatment will consist of three sessions per week for 12 consecutive weeks."
223589342|NCT02472613|DRUG|Fluoxetine|Fluoxetine was given at a dose of 20 mg/day for12 consecutive weeks.
223745759|NCT02979847|PROCEDURE|hybrid approach|Before transseptal puncture, epicardial puncture is performed through subxyphoid approach. Atrial epicardial potentials are recorded using multi-electrode catheter, leading an activation map for atrial tachycardia and map for continuous fractionated atrial electrograms during atrial fibrillation. Endocardial potentials are also recorded in the same fashion. Procedural endpoint is a tachycardia termination or a noninducibility of tachycardia.
223745760|NCT02979847|PROCEDURE|conventional endocardial approach|Atrial endocardial potentials are recorded using multi-electrode catheter, leading an activation map for atrial tachycardia and map for continuous fractionated atrial electrograms during atrial fibrillation. Procedural endpoint is a tachycardia termination or a noninducibility of tachycardia.
224186321|NCT02007824|DEVICE|SONOCA-180|wound cleansing and debridement using SONOCA-180
223745761|NCT00708539|DRUG|progesterone|90 mg, vaginal, once daily
223745762|NCT00708539|DRUG|Progesterone|200 mg, vaginal, three times daily used in Denmark, 400 mg, vaginal, three times daily used in Sweden
224186322|NCT03559595|BEHAVIORAL|Project Prevent|The Project Prevent intervention entails 1) a media campaign to raise PrEP awareness, 2) geographically targeted education initiatives with medical personnel to increase access to consumers, and 3) programming with AIDS service organizations to improve service delivery around PrEP.
224186323|NCT01334502|BIOLOGICAL|rituximab|PO
224186324|NCT01334502|DRUG|cyclophosphamide|IV
224186325|NCT01334502|DRUG|doxorubicin hydrochloride|IV
224186326|NCT01334502|DRUG|everolimus|PO
224186327|NCT01334502|DRUG|prednisone|PO
224186328|NCT01334502|DRUG|vincristine sulfate|IV
223494870|NCT00215956|PROCEDURE|surgery|surgery to remove tumor 4 to 8 weeks following completion of preoperative treatment
223494871|NCT00169312|BEHAVIORAL|behavioral dietary intervention|
223494872|NCT00169312|DIETARY_SUPPLEMENT|dietary intervention|
224186329|NCT04639895|PROCEDURE|Virtual Reality|The Virtual Reality group will be involved in the Standard treatment protocol and will perform personalized activities of daily living in a virtual city environment (Reh@City).
224186330|NCT04639895|PROCEDURE|Paper and Pencil|The paper and Pencil group will be involved in the Standard treatment protocol and will perform personalized cognitive paper-and-pencil tasks, using the Task Generator tool.
224186331|NCT04639895|PROCEDURE|Control Group|The standard treatment protocol.
223494873|NCT00169312|OTHER|educational intervention|
223494874|NCT00169312|OTHER|internet-based intervention|
223494875|NCT00169312|OTHER|preventative dietary intervention|
223494876|NCT00169312|PROCEDURE|evaluation of cancer risk factors|
223494877|NCT02648906|DRUG|Choline alfoscerate|
223494878|NCT02648906|DRUG|Placebo|
223494879|NCT05523739|DRUG|STI-1558|An oral small molecule prodrug that effectively inhibits the SARS-CoV-2 main protease (Mpro).
223494880|NCT02115386|DRUG|Nilotinib|supplied in 150 mg capsules to be taken orally
223494881|NCT05496010|OTHER|Dry Needling and Ischemic Compression Technique|"For Group A, Dry needling will be applied into trigger points which are active and present in the muscles, efficiently and within the safe limits taking all the safety precautions.~For group B, Ischemic Compression Technique will be applied on trigger points.~The complete treatment session will be comprised of 3 sessions per week for two weeks followed by follow up after 1 month until the symptoms have been improved for both the groups."
224186332|NCT01674010|DRUG|ELND005|
224186333|NCT01674010|DRUG|Lamotrigine|
224186334|NCT01674010|DRUG|Valproic acid|
224186335|NCT01674010|DRUG|Placebo|
223589343|NCT05946005|DRUG|honey|Tresno Joyo honey applied routinely to the wound two times a day for 14 days. BPOM (National Agency of Drug and Food Control) number: MD252109001219
224186336|NCT03781310|DRUG|Tocilizumab|IV Tocilizumab once every 4 weeks at reduced dose according to algorithm.
224186337|NCT02874469|OTHER|Diary|"The diary was specifically created for the purpose of the present study by personal working at ICU at CHRU of Lille (France).~All relatives, doctors and paramedics close to the patient during his hospital stay are allowed to write some comments inside the diary when he is comatose.~The diary will be implemented during the second period of the study within the first 8 hours after admission.~It will be given to the patients themselves at discharge or to their relatives in case of in-hospital death. An anonymous copy will be kept by investigators."
224186338|NCT01206296|DRUG|Intraperitoneal Gemcitabine|"Standard pancreatic resection followed by heated intraoperative intraperitoneal gemcitabine 1000 mg/m2~Adjuvant intraperitoneal gemcitabine treatments (days 1, 8 and 15 of each 4-week cycle) for 6 cycles"
224186339|NCT03839316|DEVICE|tDCS|A constant current stimulator (ZMI Electronics LTD.,Taiwan,2012) will be used through 2 saline-soaked surface gel-sponge electrodes (22 cm2 active area). Real stimulation consisting of thirty minutes of 2 mA direct current with the anode placed over the ipsilesional and the cathode over the contralesional motor cortex (C3 and C4 of the international 10-20 EEG electrode system).
224186340|NCT03839316|DEVICE|sham tDCS|For sham tDCS, the same electrode positions were used. The current was ramped up to 2 mA and slowly decreased over 30 seconds to ensure the typical initial tingling sensation
224186341|NCT00054821|PROCEDURE|Ankle distraction permitting motion|External fixator is applied to ankle joint for 85 - 95 days; ankle motion is permitted
223494882|NCT02493855|DRUG|Ombitasvir/ABT-450/Ritonavir|Ombitasvir/ABT-450/ritonavir combination tablets
223494883|NCT02493855|DRUG|Dasabuvir|Dasabuvir tablets
223494884|NCT02493855|DRUG|Ribavirin (RBV)|Ribavirin tablets
223494885|NCT02453048|BIOLOGICAL|BPZE1|Intranasal live, attenuated vaccine
223494886|NCT02453048|OTHER|Placebo|Diluent
223494887|NCT00656526|DRUG|Lidocaine, perineural injection, intraoperatively|0.5 cc lidocaine, one single injection over the dorsal root.
223494888|NCT00656526|DRUG|Lidocaine|0.5 cc %2 lidocaine,single injection
223494889|NCT06193629|DRUG|Lang Qingata|Lang Qingata: (Artificial bezoar: 0.1g, Safflower: 15g, five spirit fat: 15g, Tangerine: 30g, Swertia: 15g, nutmeg: 10g, Astragalus: 25g, wood fragrance: 10g, Parasol tiger grass: 15g, Coriander fruit: 10g, Agarwood: 3g, pomegranate seed: 20g, Rhododendron: 8g, Dongquai fruit: 15g, licorice: 10g). Water decoction (hospital decoction), Decoction in water for oral use，2 times/day, 4 weeks for a course of treatment.
223589344|NCT05946005|DRUG|lidocaine|Dolones cream applied routinely to the wound two times a day for 14 days. BPOM (National Agency of Drug and Food Control) number: DKL0922246629AI
223589345|NCT05946005|DRUG|povidone-iodine|Betadine cream applied routinely to the wound two times a day for 14 days. BPOM (National Agency of Drug and Food Control) number: PKD20501710037
223589346|NCT05946005|OTHER|control groups|no intervention is given
223589347|NCT01409369|DRUG|RO4995819|single oral dose
223745763|NCT02803151|RADIATION|Stereotactic ablative radiotherapy|SABR with 36 to 45 Gy in six fractions to the defined target volume with met organ-at-risk constraint criteria using intensity modulated radiotherapy or volumetric modulated arc therapy (VMAT or RapidArc). Treatment should be given once per day, 2-3 fractions per week with no more than 2 consecutive daily fractions, over 2 to 2.5 weeks.
224186342|NCT00054821|PROCEDURE|Ankle distraction without motion|External fixator is applied to ankel joint for 85 - 95 days; ankle motion is not permitted
224186343|NCT04869202|DIAGNOSTIC_TEST|COVID-19 test|Naso-pharyngeal swab test
224186344|NCT00938002|DIAGNOSTIC_TEST|Acceler8 Pheno|
223494890|NCT06193629|DRUG|placebo|Placebo is a Chinese medicine granule with 5% active ingredient and has the same taste as Lang Qingata，Decoction in water for oral use
223494891|NCT02111980|DEVICE|RF Assure Scanning|CIED and temporary pacemaker patients will be scanned with RF surgical sponge detection wand and mat as well as with and without the RF sponge. The scanning will only be conducted on the device scheduled for removal. Patients will have device interrogated before and after scanning (for CIEDs) to determine if there have been any clinically significant changes in programming or settings due to scanning with RF technology. Vitals will be monitored and recorded before, during, and after scanning.
223494892|NCT01574404|PROCEDURE|Polar body biopsy with PGS|PB biopsy and analysis by comparing the PB results to the FISH/microarray results
223494893|NCT00589368|BEHAVIORAL|Transfer of grasp control across hands|transfer of planning and execution of grasp across hands in terms of its effect on fingertip forces, and the timing and magnitude of muscle contraction in patients with hemiparesis and healthy controls
223494894|NCT03646578|OTHER|State of anxiety|"Patient anxiety assessment by STAI-Y-A self-assessment questionnaire provided before and after pediatric interview.~The assessment is given to patients upon arrival in the hospitalization service of pregnancies and again after the pediatric interview. This pediatric interview should take place between 1 and 7 days after admission to the hospital ward.The second part includes a 6-week inclusion period with assessment of patients' state of anxiety by a STAI-Y-A self-assessment questionnaire given before and after pediatric interview associated with the delivery of a written document. on prematurity."
223589348|NCT01409369|DRUG|activated charcoal|orally 3 times daily, Days 1-7
223589349|NCT01828411|DEVICE|Transpharyngeal ultrasonography|Transpharyngeal Dopplerultrasonography (Device: iE33 xMatrix Philips). Assessment of cerebral blood flow by detection of blood flow velocities in the extracranial carotid arteries.
223589350|NCT01828411|DEVICE|Duplex sonography|Assessment of cerebral blood flow by detection of blood flow velocities in the extracranial carotid and middle cerebral arteries during coronary artery bypass grafting.
223589351|NCT04627935|BEHAVIORAL|The COPD Assessment Test|Used to assess symptoms in COPD patients.
223589352|NCT04627935|DIAGNOSTIC_TEST|Navicular Drop Test|It is the test used to measure the amount of pronation in the foot.
223589353|NCT04627935|BEHAVIORAL|International Physical Activity Questionnaires (IPAQ)|The International Physical Activity Questionnaires (IPAQ) comprises a set of 4 questionnaires. The purpose of the questionnaires is to provide common instruments that can be used to obtain internationally comparable data on health-related physical activity.
224308787|NCT02701270|DIETARY_SUPPLEMENT|Polydextrose|21.48 g of product diluted in 250 ml of water taken once orally.
224186345|NCT05180123|PROCEDURE|Anterior cruciate ligament reconstruction|Adolescent patients with confirmed full thickness ACL injury were operated arthroscopically with semitendinosus and gracilis autograft anatomical reconstruction.
223494895|NCT04399005|OTHER|after-each-case room disinfection|After-each-case room disinfection was defined as after completing each case.
223494896|NCT04399005|OTHER|daily room disinfection|Daily room disinfection was defined as disinfection after completing 8 non-general anesthesia gastroscopy or 4 general anesthesia gastroscopy.
223494897|NCT03415256|OTHER|passive vibration|The passive vibration is delivered using a Physio Plate (Domino S.R.L, San Vendemiano, Italy). The frequency delivered is 50 Hz for a total number of ten cycles for a period of ten minutes approximately (one cycle= 60seconds working time with 2 seconds rest time).
223494898|NCT03415256|OTHER|no passive vibration|The control group will not receive any treatment and continue their usual lifestyle.
223494899|NCT00536835|DRUG|GSK461364|GSK461364 will be given intravenously as a 4 hour infusion in either a final volume of 500 or 1000 mLs. The starting dose for Stage A - Schedule 1 was 50 mg and doses were to be escalated as described in protocol until maximum tolerated dose established.
223494900|NCT04791826|BEHAVIORAL|On-screen electronic alert|On-screen computer-based alert notifying the provider that the patient is at an increased risk of developing HF based on the WATCH-DM risk score and associated guideline recommendation for preventive management of these patients.
223494901|NCT05256264|DRUG|Ketamine|Ketamine infusion at different dose to observe EEG DSA changes
223494902|NCT00918307|DRUG|Varenicline|Day 1 to day 3 : 0.5 mg daily ; Day 4 to day 7 : 0.5 mg twice daily ; Day 8 to week 12 : 2 x 0.5 mg twice daily
223494903|NCT00918307|DRUG|Placebo|Day 1 to day 3 : 1 pill daily ; Day 4 to day 7 : 2 pills daily ; Day 8 to week 12 : 2 pills twice daily
223494904|NCT04693728|BEHAVIORAL|Resilient Intrinsic Self-Regulation Strategies in Extremes|The manualized intervention covered resilience strategies organized into four modules: (1) engagement, (2) social relatedness, (3) transformation of pain and (4) building a good life. The modules were delivered in 8 weekly sessions of 90 minutes each.
223494905|NCT03459651|BEHAVIORAL|ANS training|In-home computer-based ANS training
223494906|NCT03600428|BIOLOGICAL|Live Attenuated Influenza Vaccine (LAIV)|1 dose, 0.2 mL, intranasal administration
223494907|NCT03600428|BIOLOGICAL|Inactivated Influenza Vaccine (IIV)|1 dose, 0.5 mL, intramuscular administration
223494908|NCT04171076|PROCEDURE|Transcutaneous spinal cord stimulation|Theta burst stimulation at thoracic level (T5) over 2 minutes
223494909|NCT01287247|BIOLOGICAL|Xeomin®|Xeomin® (incobotulinumtoxinA) at a dose determined by the physician based upon his/her clinical experience with botulinum toxin.
223494910|NCT05404659|OTHER|Oscillatory Mobilization|conventional physical therapy treatment, postural correction and maitland's oscillatory mobilizitions.
223589354|NCT04627935|BEHAVIORAL|COPD and Asthma Fatigue Scale (CAFS)|CAFS is a comprehensive, brief, patient-centered questionnaire developed to capture fatigue experienced by patients with asthma or COPD.
223589355|NCT04627935|BEHAVIORAL|Saint George Respiratory Questionnaire|Disease-specific instrument designed to measure impact on overall health, daily life, and perceived well-being in patients with obstructive airways disease.
224186346|NCT00004808|DRUG|fluconazole|
224186347|NCT03247608|BEHAVIORAL|Ambio Health Remote Monitoring|Participants in the Connected Heart Health study will complete a 24 week CarePlan including education, biometric monitoring, and communication with the health care team members. Each day the participant will receive an email from Ambio Health with a daily task list that includes a variety of activities. These tasks include uploading biometrics (weight and blood pressure), completing assessment on self-management skills (nutrition, physical activity, and medication management), accessing educational content (videos, web links, interactive quizzes), participation in challenges, and communicating with the care team and care givers.
224186348|NCT01520038|RADIATION|Proton therapy|
224186349|NCT01520038|RADIATION|IMRT|
223494911|NCT05404659|OTHER|Mckenzie Retraction Exercises|conventional physical therapy treatment, postural correction and Mckenzie retraction exercises.
223494912|NCT01056575|DRUG|OC000459|OC000459 100mg tablet, twice daily
223494913|NCT03611127|OTHER|pulmonary rehabilitation|pulmonary rehabilitation standardized program
223494914|NCT06268119|OTHER|training nurses and caring for patients to prevent, diagnose, and intervene in postoperative delirium.|The intervention group received care in line with the postoperative delirium prevention, diagnosis and intervention protocol after the delirium training given by the researcher to intensive care unit nurses.
223494915|NCT01442636|DEVICE|stent|Implantation of one or more Everolimus-eluting XIENCE PRIME™ Everolimus Eluting Coronary Stent Systems.
223494916|NCT04548128|DEVICE|HeartMate 3 Left Ventricular Assist System (HM3 LVAS)|This clinical trial investigates implant of the HM3 LVAS by techniques other than full median sternotomy.
223494917|NCT03637829|OTHER|Control|Water
223494918|NCT03637829|OTHER|White chocolate|Experimental snack treatment
223494919|NCT03637829|OTHER|Dark chocolate 1|Experimental snack treatment
223494920|NCT03637829|OTHER|Dark chocolate 2|Experimental snack treatment
223494921|NCT01029821|DRUG|Low-Molecular-Weight Heparin|Isolated Ankle Fracture Single planned operation
223511791|NCT01210599|DRUG|Pamidronate|The study was a randomized, double blind, dose-escalation trial of IV pamidronate. Study participants were divided among four study phases. Each group received IV placebo or escalating doses of IV pamidronate of 30mg, 60mg, 90mg and 180mg.
223511792|NCT04348058|BEHAVIORAL|Telephone recruitment to screening colonoscopy|Utilisation of dedicated call center for recruitment to screening program instead of traditional, paper invitation
223511793|NCT04348058|BEHAVIORAL|Combined methods recruitment to screening colonoscopy|Utilisation of dedicated call center for recruitment to screening program in participants, who did not respond to traditional, paper invitation
223511794|NCT03673982|BEHAVIORAL|iCASK|Materials and support to aid transitions
223511795|NCT04891861|DRUG|Apixaban|Direct Oral Anticoagulation all at label dose and frequency
223511796|NCT05795660|BIOLOGICAL|platelet rich plasma|platelet rich plasma injection
223511797|NCT03939494|BEHAVIORAL|Telehealth Encounter|Contact will be made with participants via Face Time or Skype.
223511798|NCT01857115|DRUG|Carfilzomib|
223511799|NCT01857115|DRUG|Cyclophosphamide|
223511800|NCT01857115|DRUG|Dexamethasone|
223494922|NCT03517215|BEHAVIORAL|Enhanced CB-ASP|The education session will be a 1-hour on site presentation that will cover antimicrobial resistance, antimicrobial stewardship, an introduction to effective primary care interventions for reducing antibiotic prescribing, and a review of the clinic's baseline audit of antimicrobial prescribing for the prior year. E-Modules will be completed online and audit and feedback sessions will be held in person to give an overview of each clinic's prescribing numbers.
223494923|NCT03517215|BEHAVIORAL|Standard CB-ASP|A one hour introductory educational seminar will be offered to prescribers via a web-link. They will be provided with access to e-modules each month by email and sent their audit and feedback reports by email.
223494924|NCT05667129|DRUG|XEN-101|Capsule formulation
223494925|NCT05667129|DRUG|Placebo|capsule formulation
223494926|NCT04797728|DRUG|Elacestrant|Elacestrant continuously at 400 mg given orally (PO), once a day, in a continuous schedule (QD) for 4 weeks (+/- 2 days)
223494927|NCT00538538|DRUG|vitrectomy with subretinal lucentis|A gas bubble will be placed in the eye after the gel has been removed.
223494928|NCT00538538|DRUG|vitrectomy with subretinal lucentis|These patients will have a vitrectomy where the gel is removed but will not receive the gas bubble.
223494929|NCT02112591|PROCEDURE|transobturator subtrigonal tape S-TOT|Minimally invasive surgery for placement of suburethral polypropylene tape (TOT), which is widely used around the world and considered the standard of treatment at present, has very limited efficacy when considering the correction of SUI without affecting normal micturition. There is evidence that the placement of autologous fascia tape in subtrigonal position has higher efficacy. Thus, the subtrigonal placement of polypropylene mesh tape through minimally invasive procedures could have higher efficacy.
223494930|NCT02112591|PROCEDURE|Transobturator suburethral tape (TOT)|Minimally invasive procedures in which needles are inserted via transobturator approach for the placement in mid-urethral position of polypropylene tape that is 1.5cm wide for the treatment of SUI
223494931|NCT00063622|DRUG|Pioglitazone|30 mg daily
223494932|NCT00063622|DIETARY_SUPPLEMENT|Vitamin E|800 IU daily
223494933|NCT00063622|DRUG|Matching placebo|Daily
223494934|NCT01878266|RADIATION|Hypofractionated Arm (1)|A total dose of 39 Gy in daily fractions of 3 Gy, 5 Fractions per week
223494935|NCT01878266|RADIATION|Hypofractionated Arm (2)|The total dose to 4500 cGy in 15 fractions in 3 weeks
223494936|NCT01878266|RADIATION|Conventional Arm (3)|A total dose of 54 Gy in 30 fractions giving 1.8 Gy per fraction.Conventional arm
223589356|NCT03046979|DRUG|Apatinib|500mg, once a day, oral of each 28 day cycle. Number of cycle: until progression or unacceptable toxicity develops.
223494937|NCT00248053|DRUG|curcumin|curcumin 500 mg by mouth, three times a day for 9 months
223494938|NCT02551146|DEVICE|A Locator with retention elements|Insertion of GC Pilier locator abutments with retention elements
223494939|NCT02551146|DEVICE|B Locator without retention elements|Insertion of GC Pilier locator abutments without retention elements
223494940|NCT00006180|DRUG|Alendronate|
223494941|NCT00738088|DRUG|gliclazide|Gliclazide 80mg bd for 6 weeks
223494942|NCT02800252|DRUG|Placebo|One-stage full-mouth periodontal ultrasonic debridement plus placebo intervention
223494943|NCT02800252|DRUG|3g omega-3 plus 100mg aspirin daily for 60 days|Full-mouth periodontal debridement, 3g omega-3 plus 100mg aspirin daily for 60 days after periodontal therapy
223494944|NCT02800252|DRUG|omega-3 plus aspirin before periodontal therapy|Full-mouth periodontal debridement, 3g omega-3 plus 100mg aspirin daily for 60 days before periodontal therapy
223589357|NCT06407102|OTHER|Collection of nasal cells during programme surgery|During programmed surgery (meatotomy, septoplasty or turbinoplasty for example, or other programmed surgeries), the surgeon will take an atraumatic sample from the nasal cavity using a dedicated device (brush) from the healthy nasal mucosa.
223589358|NCT03392870|OTHER|Integrative interventional programme|The active condition includes specialized, multidisciplinary and intensive individual (weekly to monthly) or group interventions (weekly). Only high-functioning subjects will be considered for group interventions.
223589359|NCT03392870|OTHER|As usual|The control group will follow treatment as usual, consisting in conventional general psychiatrist/psychologist clinical follow-up. The frequency varies between 3-6 months or 15-21 days if worsening of symptoms or comorbid conditions.
223494945|NCT02153281|OTHER|phenelzine treatment|Subjects will have a PET and MRI scan before and after treatment with phenelzine.
223494946|NCT04373070|COMBINATION_PRODUCT|CAir|The CAir desk is a custom-built home disease monitoring device. The device consists of a smartphone (A320 \[2017\], Samsung Group, Seoul, Korea), home spirometer (Air Next Spirometer, NuvoAir, Stockholm, Sweden), physical activity tracker (Charge 3, Fitbit Inc., San Francisco CA, USA), and an air-quality monitor (Foobot, Airboxlab, Esch sur Alzette, Luxembourg). The components of the CAir desk are CE-certified.
223494947|NCT00634387|DIETARY_SUPPLEMENT|Anthocyans|Anthocyans
223494948|NCT00634387|OTHER|placebo|
223494949|NCT00634387|DIETARY_SUPPLEMENT|Anthocyans|
223494950|NCT01792466|PROCEDURE|Transpancreatic sphincterotomy|A sphinctertome will be placed into the pancreatic duct over a guidewire and the sphincter will be cut in the direction of the bile duct
224073633|NCT05044065|OTHER|Physical exercise|The intervention group will receive an exercise program consisting of a combination of supervised and home-based exercise with a focus to induce metabolic stress (blood flow restriction exercise) during both a pre- and postoperative period consisting of a total of 6-10 weeks. Protein supplementation will be given to exclude insufficient intake.
223494952|NCT05316987|RADIATION|Narrow band ultraviolet B|48 sessions of narrow band ultraviolet
223494953|NCT03184272|PROCEDURE|baseline alert 1|measurement in supine position
223494954|NCT03184272|PROCEDURE|Anti-Trendelenburg-position (ATB)|measurement under ATB
223494955|NCT03184272|PROCEDURE|ATB in narcosis|measurement under ATB in narcosis
223494956|NCT03184272|PROCEDURE|baseline in narcosis 1|measurement in supine position in narcosis
224073634|NCT05337423|DEVICE|Photobiomodulation|Group 1 will receive 630 nm LED and group 2 will receive sham treatment twice a week in the palmo-plantar areas of the hands and feet (4 J/cm2) for 4 weeks.
224073635|NCT05337423|OTHER|Moisturizer|Both groups will receive moisturizer.
224073636|NCT05553704|DRUG|Metformin|metformin group will take mesalamine 1 gm three times daily plus metformin 500 mg two times daily
224073637|NCT00152542|DRUG|Inhaled nitric oxide|1 day of iNO at 10 ppm, then 5 ppm of iNO for days 2-7
224186350|NCT03159455|DRUG|BI 1467335|Duration - 28 days
224186351|NCT03159455|DRUG|Placebo|Duration - 28 days
224186352|NCT00187655|DRUG|Cefotaxime|Cefotaxime will be administered as a single IV push of 2 grams over 5 minutes.
224186353|NCT05040295|DRUG|ritlecitinib|30 mg intact adult capsule
224186354|NCT05040295|DRUG|ritlecitinib|10 mg pediatric capsule
224186355|NCT05040295|DRUG|ritlecitinib|30 mg spray congealed beads
224186356|NCT03058549|BEHAVIORAL|Family Expectations|Relationship education and referral services for expectant couples.
224186357|NCT00953849|DRUG|Celecoxib|Celecoxib (400 mg twice daily)
224186358|NCT00953849|DRUG|Calcitriol|3 week pre-surgical enteral treatment of Calcitriol (1,25-dihydroxyvitamin D3) (3 cycles of 4 microg Calcitriol 3 for each of 3 sequential days followed by 4 days of no treatment)
223494957|NCT03184272|PROCEDURE|passive leg raising|measurement under passive leg raising
223494958|NCT03184272|PROCEDURE|volume bolus substitution|measurement in supine position after volume bolus (15 ml/kgKG Sterofundin balanced solution intravenous)
223494959|NCT03184272|PROCEDURE|baseline in narcosis 2|measurement in supine position
223494960|NCT03184272|PROCEDURE|start capnoperitoneum|measurement in supine position
223494961|NCT03184272|PROCEDURE|ATB plus capnoperitoneum|measurement under ATB plus capnoperitoneum
223494962|NCT03184272|PROCEDURE|ATB plus capnoperitoneum plus volume bolus substitution|measurement in ATB plus capnoperitoneum after volume bolus (15 ml/kgKG Sterofundin balanced solution intravenous)
223589360|NCT00082381|DRUG|Exenatide (AC2993)|subcutaneous injection, twice daily; 5 mcg for 4 weeks followed by 10 mcg for 22 weeks
223589361|NCT00082381|DRUG|Insulin glargine|subcutaneous injection, once daily; forced titration to target blood glucose level
223494963|NCT03184272|PROCEDURE|ATB loss of capnoperitoneum|measurement under ATB
223494964|NCT03184272|PROCEDURE|baseline|measurement in supine position
223494965|NCT03184272|PROCEDURE|baseline alert 2|measurement in supine position
223494966|NCT03184272|PROCEDURE|torso position rising 30° at the beginning|measurement in the recovery unit
223494967|NCT03184272|PROCEDURE|torso position rising 30° at the end|measurement in the recovery unit
223494968|NCT01695746|DRUG|C.E.R.A.|Participants receiving 0.6 mcg/kg of C.E.R.A. once every two weeks for correction of anemia and conversion to C.E.R.A. dose 120, 200, or 360 mcg either once monthly; or 60, 100, or 180 mcg once every 2 weeks for maintenance of Hb according to local clinical practice or prescribing information will be observed.
223494969|NCT06520059|COMBINATION_PRODUCT|Platelet rich-plasma - PRP - intraosseous and intra-articular admnistration|"Group 1 will receive two intraosseous injections of PRP and a subsequent/synchronous intra-articular injection of PRP on the same day.~Group 2 will only receive two intra-articular injections of PRP, separated by one week."
223494970|NCT00837460|OTHER|rehabilitation|4 weeks of bilateral followed or preceded by 4 weeks of unilateral similar prehension oriented repeated rehabilitation tasks. About 45 minutes 3 times a week, the subject is coached by a physiotherapist to enhance his prehension habilities.
223494971|NCT02487576|OTHER|Carbohydrate-rich (HC)|65% Carbohydrate; 20% Fat; 15% Protein
223494972|NCT02487576|OTHER|Fat-rich (HF)|35% Carbohydrate; 50% Fat; 15% Protein
223494973|NCT03212937|DRUG|Selinexor|Oral KPT-330 is administered on Day 3, 5, and 7 of each 21-day cycle. Starting dose is 40mg will be adjusted according to toxicity
223494974|NCT03212937|DRUG|ICE Chemotherapy|"IV Ifosfamide 5g/m\^2 on Day 2 (inpatient) or D1 (outpatient) of each 21-day cycle~IV Carboplatin AUC 5 on Day 2 (inpatient) or D1-3 (outpatient) of each 21-day cycle~IV Etoposide 100 mg/m\^2 on Days 1-3 of each 21-day cycle"
223494975|NCT06530810|DRUG|HS-10382+Flumatinib|Drug:HS-10382+Flumatinib HS-10382 is administered orally BID Drug:Flumatinib Flumatinib 400mg once daily
223589362|NCT01869413|DRUG|Tranexamic Acid|Tranexamic acid will be administered as an intravenous infusion of 10 mg/kg over 10 minutes (loading dose) prior to surgical incision, followed by 5 mg/kg/hour continuous maintenance infusion for the length of surgery (typically 4 to 8 hours).
223589363|NCT01869413|DRUG|Placebo|As there is no standard of care concerning administration of anti-fibrinolytic agents in cystectomy procedures, controls will follow the same dosing and schedule as above (loading dose followed by maintenance infusion), but with 0.9% sodium chloride.
223589364|NCT04485260|DRUG|KRT-232|administered by mouth
223589365|NCT04485260|DRUG|Ruxolitinib|administered by mouth
223589366|NCT00025155|DRUG|ixabepilone|Given IV
224073638|NCT00152542|DRUG|Placebo|No iNO given for days 1-7
224073639|NCT02261727|DRUG|Theophylline|Theophylline is an oral methylxanthine which relaxes smooth muscle through its action as a phosphodiesterase inhibitor
224073640|NCT02261727|DRUG|Prednisone|Prednisone is an oral glucocorticosteroid which has anti-inflammatory properties
224073641|NCT02261727|DRUG|Placebo (for prednisone)|"* Arm 1 : Theophylline Placebo 1 tab twice daily and Prednisone placebo 1 tab once daily~* Arm 2 : Theophylline 100mg 1 tab twice daily and Prednisone placebo 1 tab once daily"
224073642|NCT02261727|DRUG|Placebo (for Theophylline)|One tablet twice daily in arm 1 (theophylline placebo 1 BD + prednisone placebo 1 once daily)
224075935|NCT06993844|DRUG|ETX-636 dose escalation in combination with fulvestrant|ETX-636 is a pan-mutant-selective PI3Kα Inhibitor and degrader in the form of an oral tablet. ETX-636 will be taken in combination with fulvestrant in 28-day cycles, to evaluate escalating dose levels. EXT-636 is an oral tablet that will be taken once per day. Fulvestrant will be administered as an injection 2 weeks apart in the first 28 days, followed by monthly injections.
224186359|NCT00953849|DRUG|Celecoxib plus Calcitriol|3 week pre-surgical enteral treatment of Calcitriol (1,25-dihydroxyvitamin D3) (3 cycles of 4 microg Calcitriol for each of 3 sequential days followed by 4 days of no treatment) plus Celecoxib (400 mg twice daily)
224186360|NCT04242121|DIAGNOSTIC_TEST|fluorescence flow cytometry|Countification of plasma cells by fluorescence flow cytometry (hematology analyzer XN-1000/20)
224186361|NCT05239065|BEHAVIORAL|The basic intervention|The participants will receive a paper-printed booklet introducing stress and stress management strategies, regular exercise, deep breathing and mediation, etc, as well as a HUAWEI portable device at the recruitment. During the following 3-month intervention phase, there is not informational materials, portable device data feedback, online group discussion or interpersonal communications with the participants. The participants will only need to fill in a simplified questionnaire biweekly.
223494976|NCT06480630|DRUG|Basiliximab|Addition of CD25 monoclonal antibody（Basiliximab） at +3 days post unrelated umbilical cord blood transplantation (UCBT)
223494977|NCT00886457|DRUG|Decitabine and Pegylated Interferon-Alfa 2B|Patients will receive decitabine 3.7 mg/m2/day i.v. over 1 hour daily in 10 doses over 2 weeks elapsed time (Monday-Friday) every 28 days plus fixed dose of PEG-Intron (0, 0.5, 1.5, 3 or 6 mcg/kg PEG-Intron) weekly by subcutaneous injection in 28-day cycles .
223494978|NCT03785821|DIETARY_SUPPLEMENT|BMSO|BMSO was extracted from Hualien No. 4 cultivate of bitter melon seed. BMSO were incorporated into capsules containing 0.5 g of oil. All persons took 3 capsules after each meal, i.e. 9 capsules (4.5 g of oil) daily, resulting in daily consumption of 2.3 g alpha-ESA in the BMSO group.
223494979|NCT03785821|DIETARY_SUPPLEMENT|OO|Olive oil (extra virgin grade) was purchased from La Espanola (Acesur, Spain). OO were incorporated into capsules containing 0.5 g of oil, identical appearance to BMSO. All persons took 3 capsules after each meal, i.e. 9 capsules (4.5 g of oil) daily.
223494980|NCT05699681|DIAGNOSTIC_TEST|Transthoracic and transesophageal echocardiography|"After induction of anaesthesia and stabilization of hemodynamics, transthoracic echocardiography will be done on a GE Vivid e9 workstation (GE Vingmed, Horton, Norway) with MS5 transthoracic probe with synchronized ECG.~From TTE the following views and measurements will be acquired :~* Apical four chamber (A4C) view~* Apical two chamber view (A2C) view~* Right ventricle (RV) focused A4C view~* Right ventricular systolic pressure (RVSP)~* Pulmonary arterial acceleration time (PAAT),~* Tricuspid annular plane systolic excursion (TAPSE),~* Tricuspid annular plane systolic velocity (s'),~* Right ventricular fractional area change (RV FAC)~* RV free wall strain,~* RV myocardial performance index (MPI),~* RV isovolumic relaxation time (IVRT),~* RV isovolumic acceleration time (IVA)~Invasive PA pressure measurement will be done after surgical exposure with a fine needle and a zeroed transducer by the Surgeon."
223494981|NCT01202591|DRUG|AZD4547|Tablet oral twice daily
223494982|NCT01202591|DRUG|Exemestane|Tablet oral once daily
223494983|NCT01202591|DRUG|Placebo|Tablet oral twice daily
223494984|NCT01202591|DRUG|Fulvestrant|A monthly intramuscular injection of a depot formulation with a loading dose 14 days after initial administration
223494985|NCT04298853|DRUG|Morphine PRN|Dose given every 3 hours as-needed for severe NAS, defined by a threshold Finnegan score.
223494986|NCT04298853|DRUG|Morphine scheduled|Dose given every 3 hours on a scheduled basis and slowly weaned once stabilized.
223494987|NCT02830087|PROCEDURE|Tourniquet Cuff Pressure|Tourniquet cuff pressure is how hard the tourniquet cuff, which is placed around the patient's thigh, presses on the thigh in order to cut off blood supply to the lower leg during total knee surgery.
223494988|NCT07104617|DRUG|TY-302|Take the specified dose (75mg or 100mg) orally once a day. Take it on an empty stomach in the morning with about 200 mL of warm water.
223494989|NCT07104617|DRUG|Abiraptor|Take orally, 1000mg each time, once a day. Take it on an empty stomach in the morning with warm water, or take it orally at least two hours after fasting.
223494990|NCT07104058|DIAGNOSTIC_TEST|68Ga-FAPI PET / CT|IgG4-RD patients with clinical complete remission after hormone and immunosuppressive therapy and 18F-FDG PET / CT negative were included. After enrollment, 68Ga-FAPI PET / CT screening was performed.
223494991|NCT07115303|PROCEDURE|Laparoscopic Appendectomy with application of clips for stump closure|in patients who will undergo Laparoscopic Appendectomy, appendicular stump will be closed by application of clips
223494992|NCT07115303|PROCEDURE|Laparoscopic Appendectomy with ligature for stump closure|in patients who will undergo Laparoscopic Appendectomy, appendicular stump will be closed by ligation
223494993|NCT07114146|OTHER|WALK THROUGH ENVIRONMENT A|A 3 km solo hike at a leisurely walking pace on a path that is easy to walk and has very little elevation gain. Located in Pontevedra Province.
223494994|NCT07114146|OTHER|WALK THROUGH ENVIRONMENT B|A 3 km solo hike at a leisurely pace on an easy walking trail with very little elevation gain. Located in the province of Pontevedra.
223494995|NCT07114146|OTHER|WALK THROUGH ENVIRONMENT C|3 km solo hike at a leisurely pace on an easy trail with little elevation gain. Located in the province of Pontevedra.
223494996|NCT07114146|OTHER|WALK THROUGH ENVIRONMENT D|Individual 3 km treadmill walk in a closed room facing a wall without pictures or windows at a leisurely walking pace with no gradient. This room will be located on the Pontevedra University Campus.
223494997|NCT07113717|OTHER|virtual Hospital at Home|telemedicine set-up, virtual Hospital at Home
223494998|NCT07117123|DEVICE|Transcutaneous electrical acupoint stimulation|The doctor will stick special electrodes on your wrist (Lieque point) and the inside of your ankle (Zhaohai point), and connect the electrical stimulation device (Han's Pain Treatment Device, Nanjing Jisheng Medical Technology Co., Ltd., which has been clinically used and provided by this project team). The current intensity will gradually increase from a small amount to the maximum level you can tolerate (starting from 1mA, not exceeding the maximum safety range of 10mA). The entire transcutaneous acupoint electrical stimulation lasts for 30 minutes. This electrical stimulation is non-traumatic and painless. Most people only feel slight numbness, swelling, and heat.
223494999|NCT07117123|OTHER|No electrical stimulation|The doctor will attach special electrodes to your wrist (Lieque point) and the inside of your ankle (Zhaohai point), and connect them to an electrical stimulation device (Han's pain treatment device, Nanjing Jisheng Medical Technology Co., Ltd., which has been clinically used and is provided by this project team). No electricity (i.e. no stimulation)
223495000|NCT07116720|OTHER|Unloading maneuvers|Participants will perform unloading maneuvers four times with 15 min of spinal flexion protocol in between. The intervention will include self traction on a box (5 s) and sustained standing trunk extension (8 s). Both maneuvers will be repeated twice at each timepoint.
223495001|NCT07118644|DRUG|MEOPA|Induced sputum with be performed by trained physiotherapist using hypertonic saline aerosol and salbutamol. MEOPA will be used for nebulization. MEOPA is a gas with analgesic, amnesic and anxiolytic properties.
223495002|NCT07118644|OTHER|Standard induced sputum|Induced sputum with be performed by trained physiotherapist using hypertonic saline aerosol and salbutamol. Oxygen will be used for nebulization.
223495003|NCT07118618|DRUG|Probenecid Oral Tablet|2gr daily
223495004|NCT07118618|DRUG|Placebo Oral Tablet|Inactive compound
223589367|NCT03022981|DRUG|SOF/VEL|SOF/VEL fixed-dose combination (FDC) 400/100 mg tablets or SOF/VEL FDC 200/50 mg tablets (based on swallowability assessment)
223589368|NCT03022981|DRUG|SOF/VEL|SOF/VEL FDC 200/50 mg oral granules
223495005|NCT07120802|BEHAVIORAL|BETTER4U Mobile App and Wearable Use (End-User Group)|"Participants from the general population (end-users) will use a smartwatch and the BETTER4U mobile app for 21 days. The app passively collects data (physical activity, sleep, eating behaviors, environment), while participants may self-report certain behaviors. The goal is to assess the usability, feasibility, and acceptability of the tools and to collect real-world behavioral data for refining AI models."
224186362|NCT05239065|BEHAVIORAL|The personalized interventions|The participants will receive a paper-printed booklet introducing stress and stress management strategies and a HUAWEI portable device at the recruitment. A neurologist will be the health educator to host an online group for free communications. The typical stress-relieving methods and the strategies of using portable device will be explained by providing small videos, online article links and nursing coaching in person. The health educator will give regular knowledge educations about the stress hazards, stress management necessities and skills on weekly basis. The weekly data of HUAWEI portable devices will be sent to the participants along with personalized suggestions by trained nurses. At certain occasions, gifts and rewards will be sent out for encouragement and keeping attachment to the program. The participants will be required to fill in the weekly questionnaires online for feedback.
224186363|NCT02319018|DRUG|Alisertib|Given PO
224186364|NCT02319018|DRUG|Fluorouracil|Given IV
224186365|NCT02319018|OTHER|Laboratory Biomarker Analysis|Correlative studies
224186366|NCT02319018|DRUG|Leucovorin Calcium|Given IV
223495006|NCT07120802|BEHAVIORAL|BETTER4U Intervention Platform Testing (Implementer Group)|Healthcare professionals and other potential implementers will test the BETTER4U Intervention Platform and mobile app for 7 days. They will assess system usability, complete synthetic case simulations, and provide daily feedback via Google Forms. They also wear the smartwatch and use the app for data validation purposes. The goal is to evaluate platform usability and collect ground-truth data for validating AI algorithm outputs.
223495007|NCT07121348|PROCEDURE|Platelet rich fibrin|platelet rich fibrin is obtained by removing the middle layer from a centrifuged blood sample and is rich with platelets that plays an important role in tissue regeneration mesoporous silica nanoparticles are high surface area and excellent biocompatibility and enhance the outcome hyalurnic acid nanoparticles are high water capacity and involved in cell proliferation and adhesion and help in tissue regeneration pomegranate nanoparticles has anti-inflammatory and antibacterial effect and also help in tissue proliferation and regeneration
224186367|NCT02319018|DRUG|Oxaliplatin|Given IV
224186368|NCT02617602|PROCEDURE|Goal directed therapy|"Based on transpulmonary thermodilution data, the following interventions will be implemented:~Global end diastolic volume (GEDV) ≤ 430 ml/m2 and extravascular water index (EVWI) ≤ 10 ml/kg: fluid load; GEDV ≥ 550 ml/m2 and EVWI ≥ 10 ml/kg: furosemide;~cardiac index (CI) ≤ 2 l/min/m2 - inotropic support:~* decreased heart rate (HR): dobutamine, dopamine;~* normal or increased HR: epinephrine, norepinephrine; CI ≥ 2 l/min/m2 and normovolemia: phenylephrine."
224186369|NCT02617602|OTHER|Control|
223495008|NCT07120113|OTHER|cupping massage|This group will receive cupping massage three sessions per week for four weeks
223495009|NCT07120113|OTHER|Myofascial release technique|This group will receive the myofascial release technique three sessions per week for four weeks
223495010|NCT07120113|OTHER|Traditional exercises|This group will receive traditional exercises three sessions per week for four weeks
223495011|NCT07123844|DIETARY_SUPPLEMENT|low cholesterol diet|low cholesterol diet
223495012|NCT07122362|DEVICE|Elastic Lower Extremity Orthosis|Participants in the intervention group receive conventional neurodevelopmental therapy combined with an elastic lower extremity orthosis designed to correct internal rotation deformities and improve gait and balance in children with spastic cerebral palsy. The orthosis applies elastic tension around the femoral region and tibia to target rotational problems.
223495013|NCT07122362|BEHAVIORAL|Neurodevelopmental Therapy|Participants receive conventional neurodevelopmental therapy only.
223495014|NCT07124065|DIAGNOSTIC_TEST|Diffuse reflectance spectroscopy|Spectral data collection with diffuse reflectance spectroscopy
223511801|NCT02258919|PROCEDURE|Decompressive craniectomy (DC) and best medical treatment|"Decompressive craniectomy:~All patients in the treatment group will receive DC of at least 12 cm according to institutional guidelines and a published surgical protocol.~Best medical treatment:~Best medical treatment is based on American Heart Association/American Stroke Association (AHA/ASA) and European Stroke Organisation (ESO) as published in the current protocol from 2010 and 2014 respectively."
224186370|NCT04037579|OTHER|Survey|Non-randomised survey
224186371|NCT05392543|OTHER|Brunnstrom movement therapy.|"Group A: Will be treated with Brunnstrom movement therapy for three days in a week for four weeks (1 h) approximately 12 sessions to every subject.~Subjects received Brunnstrom hand manipulation (BHM) and conventional occupational therapy for the upper extremity and lower extremities. The detailed BHM is applied on hand. The major goal of the BHM was the acquisition of mass grasp and mass release of objects. Once the goal was achieved, more prehensile activities were focused. Reflexive, passive, synergistic and active movements were used sequentially to enhance the hand recovery."
224186372|NCT05392543|OTHER|Mirror Therapy|"Group B: Will be treated with Mirror therapy 45 minutes, for three days in a week for four weeks approximately 12 sessions to every subjects.~First 30 minutes therapy consists of conventional therapy as given conventional tasks only with the affected upper extremity. 15 minutes were continued with mirror. Mirror is placed in front of the midline of the patient so that the affected limb is fully covered by the mirror and the reflection of the unaffected limb is fully visible. The affected limb positioned in a safe and comfortable position behind the mirror. The non-affected limb should be positioned in a similar position as the affected limb, as this facilitates the intensity of the mirror illusion. Patients in the experimental group received 45 minutes of consecutive session."
224186373|NCT02426164|DRUG|Liposomal bupivacaine|Periarticular infiltration of the liposomal bupivacaine with 20cc of normal saline
224186374|NCT02426164|DRUG|bupivacaine HCl, morphine, epinephrine, methylprednisolone|Periarticular infiltration of 24c of bupivacaine HCl, 0.8cc morphine, 0.3cc epinephrine, and 1cc of methylprednisolone
224308788|NCT02701270|DIETARY_SUPPLEMENT|Dextrose|23.89 g of dextrose diluted in 250 ml of water taken once orally.
224308789|NCT00727870|DEVICE|Shapes by PolyMem dressing|Shapes by PolyMem dressing on one site compared to antibiotic ointment covered with band-aid type dressing on second site
223589369|NCT03537196|DRUG|Sofosbuvir 400 mg and Daclatasvir 60 mg|All patients will receive sofosbuvir 400-mg and daclatasvir 60-mg (1 tablet each per day) during 12 weeks.
224186375|NCT01297738|OTHER|Meal size increase with HFHS|On top of a healthy, eucaloric diet, study subjects consume a 40% calory surplus by consuming a high-fat, high-sugar liquid medical food supplement (Nutridrink®). Subjects consume the Nutridrink® with their meals, which results in an increase in meal size.
224186376|NCT01297738|OTHER|Meal size increase with HS|On top of a healthy, eucaloric diet, study subjects consume a 40% calory surplus by consuming commercially available sugar-sweetened beverages. Subjects consume these sugar-sweetened beverages with their meals, which results in an increase in meal size.
224186377|NCT01297738|OTHER|Meal frequency increase with HFHS|On top of a healthy, eucaloric diet, study subjects consume a 40% calory surplus by consuming a high-fat, high-sugar liquid medical food supplement (Nutridrink®). Subjects consume the Nutridrink® 3 times a day in between meals, which results in an increase in meal frequency.
224186378|NCT01297738|OTHER|Meal frequency increase with HS|On top of a healthy, eucaloric diet, study subjects consume a 40% calory surplus by consuming commercially available sugar-sweetened beverages. Subjects consume these sugar-sweetened beverages 3 times a day in between meals, which results in an increase in meal frequency.
224186379|NCT03907059|DIETARY_SUPPLEMENT|whey protein|supplementation individually adjusted to 1.6g/kg/day
224186380|NCT03907059|DIETARY_SUPPLEMENT|soy protein|supplementation individually adjusted to 1.6g/kg/day
224186381|NCT01660152|OTHER|Sexual Health Inventory for Men (SHIM) questionnaire administration|Questionnaire will be completed prior to surgery and at 3, 6, 12 months and the compliance questionnaire at 3, 6, 12 months.
224186382|NCT01660152|PROCEDURE|management of therapy complications|Receive VED
224186383|NCT01660152|PROCEDURE|Daily vacuum therapy|Patients randomized to Group A or Group B following removal of catheter at first post op visit following surger. Daily vacuum therapy for approximately 10 minutes. Depending on which group randomized to erection held for 2 minutes or 5 mintues.
223495015|NCT07126002|BEHAVIORAL|Yoga|: Participants in this arm received a structured yoga course intervention for a period of 4 months. Sessions were held twice weekly, with each lasting 60 minutes. The curriculum was specifically designed to be gentle, slow-paced, and low-impact, making it suitable for older adults while emphasizing body awareness, mind-body integration, and psychological regulation. The course content included: breathing exercises (e.g., basic abdominal breathing combined with simple movements), asana (posture) practice (e.g., seated chair exercises, standing poses, prone poses, supine poses, and side-lying poses, emphasizing muscle activation, joint flexibility, bodybalance training, and coordination of breath with movement), and meditation and relaxation (e.g.supine rest, moon breath training, and OM chanting). All classes were instructed by experienced yoga teachers certified by the Yoga Alliance.
223495016|NCT07125690|OTHER|local heat application|The newborns included in this group received local dry heat application 5 minutes before the heel prick procedure, with the newborn in the supine position. Local dry heat was applied using a thermometer heated with water between 40 and 45˚C. The temperature of the water inside the thermometer was measured before application. The thermometer was applied to the sole of the newborn's right foot. Contact with bare skin was prevented, and the thermometer was used in a protective cover.
223495017|NCT07125690|OTHER|oral sucrose|In accordance with the Neonatal Pain and Treatment Guidelines, a total of 1 ml of sucrose at a 24% concentration recommended for full-term infants was prepared in a syringe. It was administered to the anterior tongue 2 minutes before the heel prick
223495018|NCT07125690|OTHER|mixed group|Newborns included in the combined intervention group received local dry heat with a thermometer heated with water at 40-45˚C 5 minutes before blood collection, with the infant in the supine position. At the third minute of the local heating, 1 ml of 24% sucrose was applied to the anterior tongue over 1 minute. A stopwatch was used to monitor the procedure times.
223495019|NCT07124143|OTHER|PRP|venous blood will be drawn postoperatively and sent to Erciyes University Medical Faculty laboratories for PRP preparation. PRP will be centrifuged according to the manufacturer's specifications, transferred to sterile eye drop bottles, and given to the patients for application. Since PRP maintains its efficacy for seven days, a second blood draw and PRP preparation will be conducted during the first-week follow-up.
223495020|NCT07124143|OTHER|Placebo|Patients will be provided with sterile eye drop bottles containing physiological saline and instructed to apply 3-4 drops to the wound site four times a day for 14 days.
223511802|NCT02258919|PROCEDURE|Best medical treatment|Best medical treatment is based on American Heart Association/American Stroke Association (AHA/ASA) and European Stroke Organisation (ESO) as published in the current protocol from 2010 and 2014 respectively.
224186384|NCT05942742|DEVICE|MRI Linac|External radiotherapy will be performed at Linac MRI, 25 fractions of radiation will be delivered for each patient.The MR-linac offers the ability to individualise and adapt daily treatment plans based on the position or anatomy of the day, following either a simple 'virtual couch shift' adapt-to-position (ATP) approach, or a more complex full reoptimisation adapt-to-shape (ATS) method based on the recontouring of relevant structures. During each radiation therapy, T2-weighted images and diffusion images will be purchased.Treatment plans can be produced and checked by appropriately trained Radiation Oncologists. Each radiation oncologist will decide based on the anatomy of the day the type of workflow to be used (ADP or ATS) for treatment.Patients will undergo accurate image acquisition, registration and interpretation to make sound clinical judgements and proceed to safe and accurate treatment delivery.
223511803|NCT05957094|DRUG|Pharmacological agent: Citalopram|Participants will be given 40 mg in capsule form, which is a normal clinical dose.
223511804|NCT05957094|OTHER|Placebo|Participants will ingest a placebo (sugar pill) that is identical in appearance to the drug condition.
223511805|NCT04029662|BEHAVIORAL|Valsalva Maneuver|Performing Valsalva maneuver will reduce the pain intensity during spinal needle insertion.
223511806|NCT02105012|DRUG|BD MDI 320 µg|Budesonide Inhalation Aerosol administered as 2 inhalations BID
224186385|NCT03096899|OTHER|Observational|Best Supportive Care
224186386|NCT01431599|RADIATION|short-course radiation|33Gy/10 fractions
224308790|NCT00727870|DEVICE|Shapes by PolyMem Silver Dressing|Shapes by PolyMem Silver dressing on one site compared to antibiotic ointment covered with band-aid type dressing on second site
224308791|NCT00727870|DEVICE|Shapes by PolyMem on one site and Shapes by PolyMem Silver dressing on second site|Shapes by PolyMem dressing on one site. Shapes by PolyMem Silver dressing on other site.
224308792|NCT01475097|DRUG|Iodixanol|Iodixanol 320 mg I/mL given by intra-arterial administration. Comparator agent Isovue (iopamidol) 370 mg I/mL given as intra-arterial administration.
223589370|NCT03537196|DRUG|Sofosbuvir 400 mg and Daclatasvir 90 mg|For HIV/HCV co-infected patients receiving efavirenz or nevirapine, daclatasvir dose will be increased to 90-mg per day.
223617773|NCT01153165|DRUG|Placebo|Participants in the control group will receive a matched placebo. At week 4 participants will be assessed for response to treatment. If no response, dose of placebo will be increased to 40mgs for the remaining 8 weeks of the study. Patients who respond will remain on 20mgs for remaining 8 weeks.
224186387|NCT01559649|BEHAVIORAL|Establishing Validity and Reliability|Consecutive individuals admitted with suspected stroke will be recruited to participate. Individuals will undergo screening of swallowing and a videofluoroscopic swallow study within two hours. Eight screening items will be tested for validity and inter-rater reliability: 6 nonswallowing features and 2 swallowing features. Reliability in nursing observations of each screening item will be completed in all participants. Speech pathologists trained in the screening items will serve as the reference standard from which to compare reliability with registered nurses who routinely work on the hospital ward with stroke patients
223495021|NCT07125287|BEHAVIORAL|Exposure based CBT|This intervention is an exposure-based CBT program developed for children with blood-injection-injury (BII) phobia and a co-occurring somatic illness. The treatment includes a structured home training kit with medical materials (e.g., syringes, swabs) related to the child's fear, enabling frequent and realistic exposure exercises at home between sessions, guided by parents. This allows for higher treatment intensity and continuity. The intervention is tailored to children who require regular medical procedures and whose phobia interferes with essential care. Unlike previous studies, this model integrates both clinical sessions and structured home practice to increase adherence and reduce fear in medical settings.
223495022|NCT07125170|DEVICE|Kinesix XR on Meta Quest 3|Participants receive cognitive rehabilitation using immersive virtual reality through the Meta Quest 3 headset and the Kinesix XR application. Each session lasts one hour, with the first 30 minutes involving VR-based tasks guided by an occupational therapist. The intervention consists of a total of ten sessions, delivered two to three times per week. The VR component is integrated into the standard outpatient cognitive rehabilitation program. The study aims to evaluate the feasibility, safety, and acceptability of using this device during therapy.
223495023|NCT07124000|DRUG|Trastuzumab deruxtecan|Trastuzumab deruxtecan monotherapy
223495024|NCT07125352|OTHER|neutrophil lymphocyte ratio in COPD patients|Neutrophil lymphocyte ratio in determining severity and prognosis in exacerbation of COPD patients
223511807|NCT02105012|DRUG|BD MDI 160 µg|Budesonide Inhalation Aerosol administered as 2 inhalations BID
223511808|NCT02105012|DRUG|BD MDI 80 µg|Budesonide Inhalation Aerosol administered as 2 inhalations BID
223511809|NCT02105012|DRUG|BD MDI 40 µg|Budesonide Inhalation Aerosol administered as 2 inhalations BID
223511810|NCT02105012|DRUG|Placebo MDI|Placebo MDI administered as 2 inhalations BID
223511811|NCT00936039|BEHAVIORAL|unloading|2 weeks of unloading of a single leg
223511812|NCT03670433|OTHER|Cost analysis of medication reconciliation|"1. The MR at entry is performed by the pharmaceutical team as soon as possible after admission. The sequences of the medical conciliation are attributed to the health professionals according to the recommendations of the French National Authority for Health (HAS).~2. The MR at the discharge is carried out in collaboration between the pharmaceutical and medical teams. It associates the patient through pharmaceutical interview and relies on the sharing of informations related to the patient's medical treatments. These informations are synthesized in an output conciliation sheet transmitted in real time by secure messaging to the attending physician and the dispensing pharmacist. In parallel, the liaison letter and the patient discharge order are generated in order to guarantee a perfect homogeneity between all the documents transmitted at the patient's exit. MR sequences are attributed to health professionals according to the recommendations of the HAS."
223511813|NCT06496971|DRUG|Bevacizumab|An anti-angiogenic agent to block tumor growth
223511814|NCT06496971|DRUG|Microbubble|Open the Blood-Brain Barrier (BBB) using focused ultrasound and microbubble
223511815|NCT06496971|DEVICE|Low-Intensity Focused Ultrasound|Open the Blood-Brain Barrier (BBB) using focused ultrasound and microbubble
223511816|NCT03436420|DRUG|Gemcabene|Participants will take 300 milligrams (mg) of gemcabene, once per day for 12 weeks.
223511817|NCT02988388|PROCEDURE|Lung biopsy/lobectomy|Lung biopsies and lobectomies are not experimental. Participants will undergo a lung biopsy or a lobectomy as part of standard of care.
223511818|NCT02512159|PROCEDURE|drenovac handcrafted|under local anesthesia, sepsis and antisepsis, place sterile field, prepared area go out all devitalized or necrotic tissue using liquid soap surgical and irrigation back saline 0.9%. We introduce a device to distribute the negative pressure or vacuum on ulcer; conducted margins make recommendations 5-12 mm over the edge of the wound, applying negative pressure or vacuum retracted sponges, likewise for the spare fewer gauze was placed Sterile adhesive film covering the defect to seal the system cover adequately the probe output nelaton not to submit drain the system. Connect the probe to the sterile nelaton this hose and a suction system with pressure gauge, pressure -80-125 mmHg. Change it every 72 hours.
223511819|NCT02512159|PROCEDURE|Healing|"Were handled as follows:~1. Under local anesthesia, prior asepsis and antisepsis of the skin ulcer with iodinepovidone sterile fields are placed, we proceeded to debridement of all necrotic tissue or devitalized then a cure with liquid soap surgery was performed and was irrigated with 1000 cc of solution physiological 0.9%, and finally the ulcer was covered with sterile gauze.~2. healing of skin ulcers were performed every 24 hours.~3. the evolution of skin ulcers was evaluated every 3 days, requesting a differential valuing of clinical and biochemical form the aforementioned variables."
223511820|NCT03276481|DIAGNOSTIC_TEST|Oral microbiota assessment|Whole mouth microbiota will be assessed by having participants swish in their mouth 10 ml of sterile water for 30 sec and then expectorate in a sterile container. Specimens will be immediately placed on wet ice and transferred to the laboratory for processing or for storage at -80° C until they are ready to be prepared for sequencing.
223511821|NCT03276481|DIAGNOSTIC_TEST|Comprehensive chemical gustometry|Chemical gustometry assessments will be performed by a trained clinician on the study team, including a Registered Dietitian, Physician's Assistant, or Research Nurse. The test solutions and gradients will be formulated in house using sterile water and the following constituents: Sweet taste; 0.05, 0.1, and 0.2 g/ml sucrose, sour taste; 0.05, 0.09, and 0.165 g/ml citric acid, salty taste; 0.016, 0.04, and 0.1 g/ml NaCl and bitter taste; 0.0004, 0.0009, and 0.0024g/ml quinine-HCl. Umami will be tested with MSG at 25, 50, and 75 mM.
223589371|NCT03537196|DRUG|Ribavirin|"In case of cirrhosis:~* Ribavirin will be added to sofosbuvir/daclatasvir during the 12 weeks of treatment. The dose will be adapted to the patient weight although the vast majority of patients (weight \< 75 kg) will receive 500 mg x 2/day.~* In case of ribavirin contra-indication or side effects leading to ribavirin discontinuation, sofosbuvir/daclatasvir will be used 24 weeks."
223589372|NCT03537196|DRUG|Sofosbuvir and Daclatasvir for 24 weeks|In case of cirrhose and of ribavirin contra-indication or side effects leading to ribavirin discontinuation, sofosbuvir/daclatasvir will be used 24 weeks.
223589373|NCT03704610|DRUG|Infliximab|An initial period with 2 injections with infliximab allowing the determination of the primary criteria Then an extension with infliximab with 3 supplementary perfusions
223589374|NCT03704610|DRUG|Placebo|An initial period with 2 injections with placebo allowing the determination of the primary criteria Then an extension with infliximab with 5 supplementary perfusions
223589375|NCT01577472|DRUG|High Dose Clomiphencitrat|100mg of clomiphencitrate(Serophene®) are added to a high dose of HMG (450 IU of Merional®) in the early follicular phase of the stimulation (day 3 to 7).
224073643|NCT05272800|DEVICE|Spectroscopy Bioimpedance Analysis|Initial evaluation using Body Composition Monitor (BCM) (Fresenius Medical Care, Bad Homburg, Germany), with information on extracellular (ECW), intracellular (ICW) and total body water. Based on these measurements, the equipment calculates parameters such as overhydration (OH), derived from the difference between the extracellular water measured and that expected for an individual of the same weight and stature in euvolemia. BCM also calculates extra- to intracellular water ratio (E/I). The measurement was performed by previously trained personal before a mid-week HD session, after five minutes of rest in the supine position, using electrodes placed on ipsilateral high and lower limbs. The patient was advised to avoid coffee or any meal 30 minutes before the evaluation. The data obtained was stored in a memory card to be discharged and analyzed with use of an accompanying software (Fluid Management Tool, Fresenius Medical Care).
224075936|NCT06993844|DRUG|ETX-636 dose expansion in combination with fulvestrant|ETX-636 is a pan-mutant-selective PI3Kα Inhibitor and degrader in the form of an oral tablet. ETX-636 will be taken in combination with fulvestrant in 28-day cycles, to expand selected dose levels. EXT-636 is an oral tablet that will be taken once per day. Fulvestrant will be administered as an injection 2 weeks apart in the first 28 days, followed by monthly injections.
223495025|NCT07124156|BIOLOGICAL|SUM-101|Once randomised to either the SUM-101 or the rabies control vaccine, the participant will always receive the same dose of the same compound (150 µg MSP1 protein dissolved in 0.9% NaCl with 250 µl (5µg) of adjuvant GLA-SE and there are no dose adjustments foreseen. The three vaccine doses will be applied in 4-week intervals on day 0, day 28 and day 56.
223495026|NCT07124156|OTHER|CHMI|"Experimental intervention: The participants will receive a target dose of 2,800 viable intraerythrocytic P. falciparum 3D7 parasites, in a volume of 2 mL injectable saline. The erythrocytes will be thawed, resuspended and viability will be calculated. The total erythrocyte number will be between \~3.9×106 and \~5.2×108 (average: \~4.55×108) per dose with ≥80% (\~3.64×108) P. falciparum ring-stage parasites and around 34% (\~1.24×108) viability. This number of viable P. falciparum ring-stage parasites will be diluted to establish 2800 per syringe that will be administered. Challenge dose will be administered to all volunteers as an intravenous injection at the clinical site following instructions in an established SOP. The parasites injected in each volunteer will be quantified retrospectively using qPCR analysis.~The parasites injected in each volunteer will be quantified retrospectively using qPCR analysis. No dose adjustments are foreseen. As described in the protocol"
223495027|NCT07124156|BIOLOGICAL|Verorab®|Once randomised the participant will receive the or Verorab® and there are no dose adjustments foreseen. The three vaccine doses will be applied in 4-week intervals on day 0, day 28 and day 56.
223495028|NCT01253486|BEHAVIORAL|Disease-related Expressive writing|Participants in the disease-related expressive writing condition write about their feelings about cardiac disease four times, for at least 20 minutes each time, during a two week period.
223495029|NCT01253486|BEHAVIORAL|Active Comparator: Traditional expressive writing|Participants in the traditional expressive writing condition write about their feelings about one or more stressful experiences they lived in the past, for at least 20 minutes each time, during a two week period
223495030|NCT01253486|BEHAVIORAL|Sham Comparator: Neutral writing|Participants in the neutral writing condition write about the facts about cardiac disease, for at least 20 minutes each time, during a two week period
223495031|NCT01267032|BEHAVIORAL|Integrated Care|A PTSD-aware smoking cessation intervention developed by Miles McFall, PhD.
223495032|NCT01267032|BEHAVIORAL|Cognitive-Behavioral Treatment for Insomnia|A behavioral treatment aimed at improving sleep continuity and subjective sleep through stimulus control, sleep restriction, and attenuation of maladaptive sleep-related cognitions.
223495033|NCT01267032|BEHAVIORAL|Desensitization Treatment for Insomnia|A credible sham treatment for insomnia matching CBTI in treatment time, patient expectations, therapist expectations, etc.
223495034|NCT02583269|DIAGNOSTIC_TEST|Laboratory Biomarker Analysis|Correlative studies
223495035|NCT02583269|DRUG|Muscadine Grape Skin Extract|Given PO
223495036|NCT02583269|PROCEDURE|Quality-of-Life Assessment|Ancillary studies
223495037|NCT04503005|OTHER|Time Restricted Eating|Effect of 16, 14 or 12 hours of daily fasting
223495038|NCT02812043|DEVICE|1,064nm Long-pulsed Nd:YAG|Long-pulsed 1,064nm will be used for the treatment of onychomycosis which wll use 35-45 J/cm2 spot size 4, frequency 1 Hz for 2 passes on the infected nails
223495039|NCT02812043|DRUG|Amorolfine|Amorolfine nail lacquer will be applied by the patient once a week on the infected nails
223495040|NCT02402751|PROCEDURE|acquisition of normative database with ultra high field MRI|characterize non-invasively with an unprecedented resolution and sensitivity (high field MRI), anatomy as well as certain physiological, hemodynamic and metabolic function of brain, spinal cord, musculoskeletal system, and heart
223589376|NCT01577472|DRUG|Low Dose Clomiphencitrat|100mg of clomiphencitrate(Serophene®) are added to a low dose of HMG (150 IU of Merional®) in the early follicular phase of the stimulation (day 3 to 7).
223589377|NCT01577472|DRUG|High Dose Placebo|Placebo is added to a high dose of HMG (450 IU of Merional®) in the early follicular phase of the stimulation (day 3 to 7).
223589378|NCT01577472|DRUG|Low dose Placebo|Placebo is added to a low dose of HMG (150 IU of Merional®) in the early follicular phase of the stimulation (day 3 to 7).
223617774|NCT01548274|DRUG|Sarpogrelate|Sarpogrelate 300mg/day
224186388|NCT04064099|DEVICE|Custom-fitted sports mouthguard|Pressure dual laminated technique will be used to fabricate the mouthguards. Ethylene-vinyl acetate (EVA) thermoplastic sheets of 3 mm in thickness with 125 mm diameter (Dentsply International Raintree Essix, Court East Sarasota, USA) will be used. Two 3 mm sheets pressure-laminated together should form an even thickness of 4 mm mouthguard. The design of the mouthguards takes into consideration of the following limits: (i) the labial borders of the mouthguard were extended to within 2 mm of the vestibular reflection, (ii) the palatal margins were trimmed to the cervical area of the palatal surface of the upper teeth, (iii) enclosing the maxillary teeth to the distal surface of the first molars.
223589379|NCT01119677|DRUG|Avonex|Group 1 subjects will receive weekly Avonex 30 mcg (full dose) IM injections from Week 1 to Week 8. Group 2 subjects will titrate in quarter dose increments every week up to a full dose of Avonex over a 3 week period from Week 1 to Week 3 and then continue on full dose from Week 4 to Week 8. Group 3 subjects will titrate in quarter dose increments every 2 weeks up to a full dose of Avonex over a 6 week period from Week 1 to Week 6 and continue on full dose from Week 7 to Week 8
224186389|NCT02335359|DRUG|tranexamic acid diluted in 100 ml of saline solution (loading dose)|
224186390|NCT02335359|DRUG|tranexamic acid undiluted (continous infusion)|
223589380|NCT06507124|OTHER|This is observational with no intervention|This is observational with no intervention
224186391|NCT02335359|DRUG|Placebo|Saline
224186392|NCT03914456|OTHER|rehabilitation treatment|
224186393|NCT03389633|OTHER|rehabilitation|
224308793|NCT01475097|DRUG|Iopamidol|Iodixanol 320 mg I/mL given by intra-arterial administration. Comparator agent Isovue (iopamidol) 370 mg I/mL given as intra-arterial administration.
224308794|NCT03149445|DRUG|Tesofensine/Metoprolol|Study medication will be administered for 91 days.
224308795|NCT03149445|DRUG|Placebos|Study medication will be administered for 91 days.
223495041|NCT02402751|DEVICE|MRI|
223495042|NCT05662618|PROCEDURE|Percutaneous selective arteriography of peripheral arteries|Treatment of stenosis or occlusion of superficial femoral artery and/or popliteal artery with rapamycin coated balloon catheter.
223495043|NCT05662618|PROCEDURE|Percutaneous selective arteriography of peripheral arteries|Paclitaxel coated balloon catheter for the treatment of stenosis or occlusion of superficial femoral artery and/or popliteal artery.
223495044|NCT02172547|DRUG|Spiriva|
223495045|NCT02677389|OTHER|Educational Intervention|Receive educational material regarding physical activity and standardized emails with wellness tips and information on stress management
223495046|NCT02677389|OTHER|Internet-Based Intervention|Receive email and technical or how-to support from study coordinator
223589381|NCT02599623|PROCEDURE|Local Anesthesia|Patients in LA group received the local infiltration technique. A mixture of 2% lidocaine 20ml and 0.9%NS 30ml was used as the local anesthetic. Patients required extra analgesia during the surgery were given 20-40mg parecoxib sodium intravenously. Conversion to GA was performed if LA was intolerant for patient, which was evaluated by both anesthetists and surgeons.
223589382|NCT02599623|PROCEDURE|General Anesthesia|In group GA, anesthesia was induced with propofol 2mg/kg and fentanyl 0.1-0.2mg intravenously. Inhalation anesthesia was given at the same time with a mixture of oxygen and isoflurane 1-2% through an intubation.
224075937|NCT06672224|PROCEDURE|Fluid Therapy|Given IV
224075938|NCT06672224|DRUG|Indocyanine Green|Given subcutaneously
223495047|NCT02677389|DEVICE|Monitoring Device|Wear a Fitbit web-integrated physical activity tracker
223495048|NCT02677389|OTHER|Quality-of-Life Assessment|Ancillary studies
223495049|NCT02677389|OTHER|Questionnaire Administration|Ancillary studies
223495050|NCT04910464|DRUG|Tranexamic acid|administer 1 gram of TXA in 100 ml of 0.9% normal saline, intravenous over 10 minutes as soon as possible but no later than three hours after diagnosis, infuse a second gram of TXA IV over 8 hours in 0.9% normal saline for first 3 days.
223495051|NCT04910464|OTHER|0.9% saline|administer the same volume (100ml normal saline) and same duration (first three days).
223495052|NCT06982508|DRUG|Obicetrapib 10mg|Active Drug
223495053|NCT06982508|DRUG|Placebo|Placebo Control
223495054|NCT06396416|DRUG|Semaglutide|Maximum tolerated dose of semaglutide subcutaneously once weekly. Maximum dose of 2.0 mg.
223495055|NCT06396416|BEHAVIORAL|Virtual Weight Management Coaching|Virtual meeting with intervention coach once every 4 weeks for 6 months, where the coach will discuss the goals and progress with participant, nutritional advice, exercise advice, and motivational support.
223495056|NCT06989814|DIAGNOSTIC_TEST|Blood Product|An (extra) blood test will be done on participants. This will be analyzed for circulating tumor DNA (ctDNA) via a multi-omics approach.
223495057|NCT00514254|OTHER|questionnaire administration|
224075939|NCT06672224|OTHER|Questionnaire Administration|Ancillary studies
224075940|NCT06672224|OTHER|Research or Clinical Assessment Tool|Undergo lymphedema assessment
224075941|NCT06672224|PROCEDURE|SPY Elite Fluorescence Imaging|Undergo SPY imaging
224075942|NCT06672224|OTHER|Survey Administration|Ancillary studies
224075943|NCT04971954|OTHER|Nicotine gum|Nicotine (6 mg) will be administered in the form of polacrilex gum that is available as an over-the-counter medication
224075944|NCT04971954|OTHER|Placebo gum|The placebo will also be a commercially available gum that resembles the nicotine gum in flavor, size, shape, color, and texture.
224075945|NCT06229470|DEVICE|Evoke Spinal Cord Stimulation (SCS) System|A spinal cord stimulation (SCS) system that measures and records evoked compound action potentials (ECAPs) and automatically adjusts the stimulation current to maintain a consistent ECAP amplitude.
224075946|NCT05527210|DIETARY_SUPPLEMENT|Prebiotic|Prebiotin® is a fine, white to slightly yellow powder, which is mixed into water and has a slightly sweet taste.
224075947|NCT05527210|DIETARY_SUPPLEMENT|Placebo Prebiotic|Placebo prebiotic mixed into water
224075948|NCT06615479|DRUG|BMS-986393|Specified dose on specified days
224075949|NCT06615479|DRUG|Cyclophosphamide|Specified dose on specified days
224075950|NCT06615479|DRUG|Fludarabine|Specified dose on specified days
224075951|NCT06615479|DRUG|Daratumumab|Specified dose on specified days
224075952|NCT06615479|DRUG|Pomalidomide|Specified dose on specified days
224075953|NCT06615479|DRUG|Dexamethasone|Specified dose on specified days
223495058|NCT00514254|OTHER|study of socioeconomic and demographic variables|
223495059|NCT00514254|PROCEDURE|evaluation of cancer risk factors|
223495060|NCT06993363|OTHER|Quadriceps Strengthening|"Static Quad Pull the toes up towards your shin, push your knee into the bed to tighten the quad muscles. This should cause your heel to slightly lift off the bed. Hold for 7 seconds. Repeat on affected leg.~Straight leg raising~* Lie on back with hips square and legs laid out comfortably on the floor~* Bend the knee of non-injured leg at a 90-degree angle, planting the foot flatly on the floor.~* Stabilize the muscles on your straight leg by contracting your quadriceps (the group of muscles on the front of your thigh).~* Inhaling slowly, lift the straight leg six inches off the ground.~* Hold for three seconds.~* Exhaling slowly, lower the leg to the floor with control~* Relax and repeat 10 times more."
223495061|NCT06993363|OTHER|Hamstring and calf stretching exercise|"Hamstring stretching exercise will be done in the long sitting position. The patient will be instructed to keep his affected knee always extended while folding the other leg to the side then he will bend his trunk forward as much as he could in order to touch his toes by his fingers.~Calf muscle stretching: The patient will be positioned in the long-sitting with the knees extended. The patient will be instructed to pull his foot into dorsiflexion as much as he could with the assistance of a rolled towel holding this position for 30 seconds (Fig14). The patient will then be instructed to go back to starting position and relax for 30 seconds. This exercise will be done 5 times per session."
223495062|NCT06993363|OTHER|Kinesotaping application|"1 full 25cm strip of KT Tape cut in half. Apply one hour before beginning activity. Clean dirt, oils and lotions from area. After application rub tape vigorously to activate adhesive. Bend the knee at a 90 degree angle Anchor the middle of a half strip of tape diagonally over the point of pain with 80% stretch. Apply ends of tape without stretch.~Anchor the middle of a second half strip across the first strip to form an X pattern over the point of pain with 80% stretch."
223589383|NCT06485466|COMBINATION_PRODUCT|TACE plus camrelizumab and apatinib|"TACE plus camrelizumab and apatinib group:~Patients who were randomized to this group, TACE is performed via an injection into the hepatic artery of agents by puncturing the common femoral artery.Adriamycin(30 to 60 mg) and oxaliplatin (50-150mg) are considered as basic chemotherapy drugs in the process of transcatheter endovascular perfusion. The dose of lipiodol (5-20ml) and other embolic agent( blank microspheres/ PVA/gelatin sponge particles) were determined by diameter and blood supply type of HCC. Within 1 week after first TACE treatment, camrelizumab 200mg intravenously every 3 weeks and apatinib 250 mg orally once daily."
223589384|NCT06485466|COMBINATION_PRODUCT|Camrelizumab and apatinib|"Camrelizumab and apatinib group:~Patients who were randomized to this group, camrelizumab 200mg intravenously every 3 weeks and apatinib 250 mg orally once daily."
223589385|NCT00444067|DEVICE|Spinal Sealant|Spinal Sealant System
223589386|NCT00444067|OTHER|Standard of Care|Standard of Care
223589387|NCT06050798|DIAGNOSTIC_TEST|Von willebrand antigen|Von willebrand antigen change and hematological disorder in patients with angiodysplasia
223589388|NCT00269854|DRUG|Infliximab 5 mg/kg|Infliximab (anti-TNF chimeric monoclonal antibody \[cA2\]) 10 milligram per kilogram (mg/kg) will be administered as infusion at Week 0, 2 and 6.
224073644|NCT05272800|OTHER|Clinical Examination alone|The clinical evaluation was performed by a nephrologist with hemodialysis expertise and includes blood pressure measurements before and after a dialysis session, lung examination searching for crackles and lower limbs (or sacral region for bedridden patients) for oedema. The aim of the examination is the estimation and/or revaluation of estimated dry weight. The blood pressure was measured using a sphygmomanometer (Tycos, Welch Allyn, EUA) by the auscultatory technique, with the patient seated in the dialysis chair and upper limb extended. The cuff was placed two to three centimeters from cubital fossa, and a stethoscope (Litmann, 3M, EUA) placed over the brachial artery to detect Korotkoff sounds during inflation and disinflation of the sphygmomanometer cuff.
224073645|NCT05744739|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
224073646|NCT05744739|DRUG|Tomivosertib|Given PO
224073647|NCT02419287|DRUG|crizotinib|
224073648|NCT04293861|DEVICE|HYMOVIS|HYMOVIS is a clear hydrogel obtained by hydration of the HA-based derivative named HYADD4p5. The conjugate compound is constituted by a partial hexadecylamide of hyaluronic acid, which is produced by a fermentation process.
224073649|NCT01018875|DRUG|ABT-288|Subjects will take 4 capsules once daily for 12 weeks.
224073650|NCT01018875|DRUG|donepezil|Subjects will take 4 capsules once daily for 12 weeks.
224073651|NCT01018875|DRUG|placebo|Subjects will take 4 capsules once daily for 12 weeks.
224073652|NCT02961556|DRUG|AJG555|Participants will receive 1 to 6 sachets daily per participants' age and conditions.
224075954|NCT06615479|DRUG|Carfilzomib|Specified dose on specified days
224075955|NCT06204848|DEVICE|SVO-ID|Combined scanning laser ophthalmoscope (SLO) and optical coherence tomography (OCT) for imaging of the eye
224075956|NCT06865781|OTHER|Forgone overnight vital signs|No vital signs (temp, heart rate, respiratory rate, blood pressure, oxygen saturation) taken at 0000 or 0400
224075957|NCT06258200|BEHAVIORAL|Gender and immunization activities|Household visits from community mobilizers, participation in couples communication groups, and messaging from community leaders.
224075958|NCT06258200|OTHER|No intervention|Participants in the comparison group will not receive any intervention
224308796|NCT02784873|OTHER|High intensity interval training|High intensity interval training within a standard cardiac rehabilitation programme
224075959|NCT07010692|DRUG|Tirbanibulin ointment 1%|Tirbanibulin ointment is applied for 5 nights following the in-office fractional laser procedure for patients with more advanced carcinomas.
224075960|NCT07010692|DEVICE|non-ablative fractional laser|Every skin cancer will be treated with two wavelengths (1550nm and 1927nm) of a non-ablative fractional laser.
224075961|NCT07012863|BIOLOGICAL|Dry plasma|Patient that fulfil the inclusion criteria for this study and are randomized for active treatment will get dry plasma as intervention.
224075962|NCT05016245|COMBINATION_PRODUCT|TheraSphere™ Yttrium-90 Glass Microspheres|"TheraSphere™ Yttrium-90 Glass Microspheres TheraSphere™ is steam sterilized and supplied in 6 standard dose sizes: 3 GBq, 5 GBq, 7 GBq, 10 GBq, 15 GBq, 20 GBq. Custom dose sizes are also available in 0.5 GBq increments between 3 and 20 GBq.~TheraSphereTM is supplied with the following accessories:~Administration Set Administration Accessory Kit"
223495063|NCT04960566|OTHER|Cognitive Behavioral Therapy|The CBT intervention is based on the theoretical framework that under stress (reflux symptoms) a person makes a rapid cognitive appraisal of the potential threat (automatic thoughts), leading to both emotional and physical responses in the body, thereby reacting behaviorally (avoidance, increased HCU) in an attempt to mitigate unpleasantness. CBT is a collaborative, present-focused treatment that utilizes a skills-based approach with home practice exercises. CBT targets automatic thoughts and appraisals of threat via education, self-monitoring of stressors and symptoms, and strategies to reframe problematic thinking patterns to more adaptive ones. Resonance frequency breathing (RFB) is achieved when a person breathes at a pace, typically 4 to 6 breaths per minute, that engages the body's baroreflex to modulate arousal. Prior research demonstrates 4 to 6 weeks of RFB training is sufficient to significantly increase baseline HRV with enduring effects for up to 6 months.
223495064|NCT04960566|OTHER|Sham-SOC Lifestyle Coaching|Sham-SOC Lifestyle Coaching
223495065|NCT06672185|DRUG|ARC101|ARC101 will be administered according to an assigned dose schedule.
223495066|NCT06280677|OTHER|AURORA-Donor|Explorative study of cumulus cells gene expression in relation to the oocyte competence for good quality blastocyst formation and predictive for clinical pregnancy.
223495067|NCT06673979|DIAGNOSTIC_TEST|Numeric Rating Scale|The patients are asked to rate their pain according to the Numeric Rating Scale (0=no pain; 10=worse possible pain).
223495068|NCT06998875|DRUG|Tofacitinib and Acitretin Capsules.|The same with Arms.
223495069|NCT06998875|DRUG|Acitretin Capsules.|The same with Arms.
223495070|NCT07001384|DRUG|Alectinib|All patients will receive a lead-in cycle (28 days) of alectinib.
223495071|NCT07001384|DRUG|Duvelisib|After the lead-in cycle of alectinib, in the absence of progressive disease as assessed by PET/CT scan, all patients will then receive two 28-day cycles of alectinib plus duvelisib.
223495072|NCT07009288|OTHER|Children's Oncology Group Heart Health Link|Educational materials on healthy lifestyle behaviors.
223495073|NCT07009288|OTHER|Monthly weights|Weight (kg): measured remotely via Withings Body + scale, Height, weight, waist circumference, BP, and % body fat
223495074|NCT07009288|OTHER|Fasting|(14-hour fast x 2 weeks; 15-hour fast x- 1 week; 16-hour fast for the remainder of the active intervention)
223495075|NCT07009288|OTHER|Calls|Month 1-3: Bi-weekly call using motivational interviewing Months 4-6: Monthly call using motivational interviewing Support via SMS text
223495076|NCT07009288|OTHER|Participant Questionnaires|Questions on worry, perceived self-efficacy, health beliefs and knowledge of late effects (adapted from EQUAL study), Behavioral Risk Factor Surveillance System, Physical Activity Questionnaire, Link to Automated Self-Administered 24-Hour (ASA24) Dietary Assessment Tool with accompanying sleep module
223495077|NCT07009288|OTHER|Dried blood spot|Glucose, insulin, hemoglobin A1c, lipids. Measured remotely in the fasting state via dried blood spots in the participant's home.
223495078|NCT06615570|DRUG|VX-973|Suspension for oral administration.
223495079|NCT06615570|DRUG|Placebo|Suspension for oral administration.
223495080|NCT06072183|DRUG|Ritlecitinib|100mg Capsule
223495081|NCT06072183|DRUG|Ritlecitinib|50mg Capsule
223495082|NCT06072183|DRUG|Placebo|Matching capsule
223745764|NCT05023187|BEHAVIORAL|SCOT|"A 8-week social and cognitive online training to improve both cognitive and social functioning, which includes 2 sessions (\~45 minutes each) of individual cognitive training through the BrainHQ© program 2020 (BrainHQ© Posit Science) and a psycho-educational group session for each week (24 sessions in total).~In the experimental intervention, all activities are focused on enhancing executive functions (working memory, processing speed, inhibitory control etc.) and social cognition abilities (identifying/recognizing facial expressions, styles attribution, drawing conclusions etc.)."
223495083|NCT06622109|BIOLOGICAL|20-valent Pneumococcal Conjugate Vaccine|Injection in the muscle or subcutaneous , 1 dose 0.5mL
223495084|NCT07016295|BEHAVIORAL|Biomechanical analysis of arm movement|Marker based kinematic analysis
223495085|NCT07016295|BEHAVIORAL|Pose estimation of arm movement|Marker free kinematic analysis
223495086|NCT06688734|PROCEDURE|Inital water seal|After chest tube placement, the chest tube will be placed to 20cm H2O of suction for 1 minute to evacuate all pneumothorax. After this, the chest tube will be placed to water seal, defined as the water seal chamber on the chest tube drainage system being filled up to the 2cm line and not on suction. All other management decisions related to the chest tube will be left to the providers.
223495087|NCT06688734|PROCEDURE|Initial suction|After chest tube placement, the suction group will have their chest tube placed to 20cm H2O of suction delivered by the chest tube drainage suction. All other management decisions related to the chest tube will be left to the providers.
223495088|NCT05823727|DIETARY_SUPPLEMENT|SOLUGEL|Bovine collagen peptide supplement
223495089|NCT05823727|DIETARY_SUPPLEMENT|Placebo|Maltodextrin
223495090|NCT05419024|OTHER|Acute Treatment Interruption|Participants randomized to ATI will halt their ART medications starting 2 weeks (more or less 3 days) after the first imaging visit. This plan will be discussed with participants during the baseline visit. Patients will be contacted 1-3 days prior to ATI initiation. ATI may be delayed or cancelled if there are new safety concerns. HIV plasma viral levels and CD4 counts will be monitored every week during the ATI phase. If a participant meets any of the ART restart criteria during the ATI phase, then they will discontinue ATI and restart ART. Participants who do not meet restart criteria will remain off ART and continue to be monitored weekly until they have been on ATI for 90 days, and then will restart ART.
223495091|NCT06874933|DRUG|Neoadjuvant Chemotherapy in Combination with Anlotinib and Benmelstobart|"Group A: Epirubicin + cyclophosphamide + Benmelstobart are administered by intravenous drip once every 3 weeks for a total of 2 cycles, followed by nab-paclitaxel + Benmelstobart administered by intravenous drip once every 3 weeks for a total of 2 cycles. During the treatment period, Anlotinib is simultaneously combined. It is taken orally once a day, before breakfast. Take the medicine continuously for two weeks, then stop taking it for one week. One cycle is 21 days, and there are a total of 3 cycles.~Group B: Nab-paclitaxel + Benmelstobart are administered by intravenous drip once every 3 weeks for a total of 2 cycles, followed by Epirubicin + cyclophosphamide + Benmelstobart, which are administered by intravenous drip once every 3 weeks for a total of 2 cycles. During the treatment period, Anlotinib is also used in combination. It should be taken orally once a day before breakfast, continuously for two weeks, then stop taking it for one week."
224186394|NCT03159715|BEHAVIORAL|Internet-based Global Protocol|Internet-based Global Protocol is an Internet-based treatment which includes therapeutic components of evidence-based treatments for depression: Motivation, Psychoeducation, Cognitive Therapy, and Relapse Prevention. Furthermore, it incorporates a Behavioural Activation component (BA). The whole protocol stresses the importance and benefits of being active and remaining involved in life, values and goals. The program also includes a component of Positive Psychology (PP). It allows the individual to learn and practice adaptive ways to cope with depressive and anxiety symptoms and confront daily problems. It is a multimedia (video, image, etc.) interactive program designed for optimal use on the computer, but it can also be used on a tablet.
224186395|NCT03159715|BEHAVIORAL|Internet-based Behavioral Activation Protocol|Internet-based Behavioral Activation Protocol is an Internet-based treatment based on Behavioral Activation. It stresses the importance and benefits of being active and remaining involved in life, values and goals . It is a multimedia (video, image, etc.) interactive program designed for optimal use on the computer, but it can also be used on a tablet.
224186396|NCT03159715|BEHAVIORAL|Internet-based Positive Psychology Protocol|Internet-based Positive Psychology Protocol is an Internet-based treatment based on Positive Psychology, offering strategies to promote and enhance positive mood. It is an Internet-based treatment based on Positive Psychology. It is a multimedia (video, image, etc.) interactive program designed for optimal use on the computer, but it can also be used on a tablet.
224186397|NCT01584193|PROCEDURE|Ultrasound-guided subclavian vein puncture|Central venous access port implementation through ultrasound-guided subclavian vein puncture and Seldinger technique
224186398|NCT01584193|PROCEDURE|Cephalic vein dissection|Central venous access port implementation through cephalic vein dissection and cutdown
223495092|NCT06626399|DIAGNOSTIC_TEST|Diagnosis of SSI|Diagnosis of SSI by manual system in colorectal surgery procedures enrolled in the SSI surveillance programme.
223495093|NCT06686784|BEHAVIORAL|After School Plus|"The afterschool program as usual runs M-H and consists of a variety of clubs from which middle school students chose to enroll for a semester (\~4 months). Clubs are offered on either a M/W or T/H schedule. Students receive a snack in the cafeteria each day before attending their class.~Afterschool plus is the same as Afterschool as Usual with the addition of young adult mentors. Following snack, mentors will lead students in a short emotion regulation exercise including physical activity and breathing exercises. Mentors will prompt students to identify how they are feeling and make connections between the activities they are doing and their mood and then do activities with students in each class. On T/H, \~4 mentors will lead a new DiscoverU  club which is based on behavioral activation principles and spends more time helping students identify and do more activities that improve their mood. The class promotes physical activity as an important strategy for mental health."
223495094|NCT07023354|DRUG|BI 1291583|BI 1291583
223495095|NCT03611946|BIOLOGICAL|Single dose of rZIKV/D4Δ30-713 (10^3 PFU) via subcutaneous injection (0.5ml)|Administered at a dose of 10\^3 plaque-forming units (PFUs) by subcutaneous injection
223495096|NCT03611946|BIOLOGICAL|Single dose of placebo via subcutaneous injection (0.5ml).|Administered by subcutaneous injection.
223495097|NCT03611946|BIOLOGICAL|Single dose of rZIKV/D4Δ30-713 (10^4 PFU) via subcutaneous injection (0.5ml)|Administered at a dose of using 10\^4 plaque-forming units (PFUs) by subcutaneous injection.
223495098|NCT02244073|DRUG|Human insulin - Insulin administration to control blood glucose level.|On ICU admission, the glycated hemoglobin level (A1c) is measured and insulin IV is possibly administered using a web based nurse driven insulin infusion protocol (https://extranet.chu-lyon.fr/cpg) to maintain blood glucose level below 10 mmol/l. Glycated hemoglobin result triggers patient randomization. Thereafter, during ICU stay, blood glucose level is maintained either below 1.59 × A1c - 1.59 (mmol/l) (Individualized blood glucose target group), or bellow 10 mmol/l (Conventional blood glucose target group).
223495099|NCT07114133|OTHER|Environmental Probiotic Spray Intervention|The probiotic strains include Bacillus subtilis YHX001J, Bacillus amyloliquefaciens YHX002J, and Bacillus velezensis YHX003J
223495100|NCT07114133|OTHER|Purified water spray (containing no active ingredients) as the placebo control|Purified water spray
223495101|NCT07114952|BEHAVIORAL|alternative nasal breathing|The alternate nasal breathing exercise involves breathing in and out through both nostrils in a certain pattern and for a certain period of time. For example, an individual who breathes in through the right nostril for 5 seconds with the left nostril closed, then closes the right nostril and exhales through the left nostril for 5 seconds. Then he/she inhales through the left nostril for 5 seconds and exhales through the right nostril. A total of 6 breaths are taken per minute. The application is applied for 5 minutes, the patient rests in a calm environment for two minutes and the application is performed for another 5 minutes. In order to increase the compliance of individuals with the application, a sample video was watched and application instructions were given by the researcher. The application was performed while the patients were in an upright sitting position.
223495102|NCT07121101|DRUG|TRD205 tablets|Administered orally every 12 hours for a total of four times；Take TRD205 2 tablets and Placebo 4 tablets for the first time ，TRD205 1 tablets and Placebo 2 tablets each for the other three times
223495103|NCT07121101|DRUG|TRD205 tablets|Administered orally every 12 hours for a total of four times；Take TRD205 4 tablets and Placebo 2 tablets for the first time ，TRD205 2 tablets and Placebo 1 tablets each for the other three times.
223495104|NCT07121101|DRUG|TRD205 tablets|Administered orally every 12 hours for a total of four times；Take TRD205 6 tablets and Placebo 0 tablets for the first time ，TRD205 3 tablets and Placebo 0 tablets each for the other three times.
223495105|NCT07121101|DRUG|placebo|Administered orally every 12 hours for a total of four times；Take Placebo 6 tablets for the first time ，Placebo 3 tablets each for the other three times.
223495106|NCT07036666|DIETARY_SUPPLEMENT|Active Product|Women's (vaginal) Health Active Product
224186399|NCT05502809|DRUG|Deep-frozen platelets|Cryopreserved platelets
224186400|NCT06382428|OTHER|Pelvic floor muscle training|The PFMT program was carried out for 45-50 minutes, 2 days a week for 8 weeks, by two physiotherapists specialized experienced in the pelvic floor. The program consisted of education, diaphragm breathing exercises, pelvic mobility exercises, exercises to strengthen and stretch the pelvic floor muscles and other muscles related to the pelvis. In addition, the participants were expected to do the same exercises at home 2 days a week.
224186401|NCT05056311|OTHER|Decision Aid Website|The (private) decision aid website contains information in text, graphic, and video form about hypospadias and considerations for choosing surgery and no surgery.
224186402|NCT02111473|DRUG|Testosterone|Testosterone 250 mg injection per 3-4 weeks for 6 months
223495107|NCT07125417|DRUG|Single Antiplatelet Therapy or No Therapy (Control)|Monotherapy with oral anticoagulants (OAC) including direct oral anticoagulants (DOAC) and vitamin K antagonist oral anticoagulants (VKA) for 45 days after left atrial appendage closure (LAAC), followed by aspirin-directed antiplatelet monotherapy (Single Antiplatelet Therapy: SAPT) through the end of the observational period.
223495108|NCT07125417|OTHER|Non-Antithrombotic Therapy|Monotherapy with OAC for 45 days after LAAC, followed by no antithrombotic therapy (Non-Antithrombotic Therapy: NAPT) from enrollment through the end of the observational period.
223495109|NCT07037121|BEHAVIORAL|Whole Food Plant Based Diet Jumpstart|"Participants receive personally-tailored support by a research nutritionist during five total visits: (1)baseline visit to collect surveys on health status, current home kitchen-based habits, kitchen inventory, food preferences, and clinical measures, followed by assessing health goals, obstacles, and opportunities. At least two breakfast, three lunch, and five dinner WFPB recipes will be selected. (2) A kitchen-centered visit will target the fridge, pantries, and cabinets to assist participants in cleaning out ultra-processed junk foods. These foods will be stored in a large tote during the study. (3) The day before the intervention starts will be a grocery shopping trip to purchase the WFPB heart-healthy groceries together. (4) Intervention day 1 will focus on jumpstarting meal prep. After day 1, weekly 30-min telehealth nutrition consultations will provide additional support. (5) Clinical measures and postintervention surveys will be collected on day 29."
223495110|NCT06718218|BEHAVIORAL|Mindfulness Pain Management|Participants will listen to a 5-minute audio recording of a mindfulness exercise consisting of a 1-minute introduction to mindful pain management and a 4-minute mindfulness practice.
223495111|NCT06718218|BEHAVIORAL|Mindfulness Recording With Sustained Tone|Participants will listen to a 5-minute audio recording of a mindfulness exercise consisting of a 1-minute introduction to mindful pain management and a 4-minute mindfulness practice, that is accompanied by a sustained low C tone at 65.41 Hertz.
223495112|NCT06718218|BEHAVIORAL|Mindfulness Recording with Binaural Beats|Participants will listen to a 5-minute audio recording of a mindfulness exercise consisting of a 1-minute introduction to mindful pain management and a 4-minute mindfulness practice that is accompanied by binaural beats resulting from the delivery of a sustained 65.41 Hertz tone in the left ear and a sustained 69.41 Hertz tone in the right ear.
223495113|NCT06718218|BEHAVIORAL|Mindfulness Recording with Binaural Beats and Theta Music|Participants will listen to a 5-minute audio recording of a mindfulness exercise consisting of a 1-minute introduction to mindful pain management and a 4-minute mindfulness practice that is accompanied by binaural beats resulting from the delivery of a sustained 65.41 Hertz tone in the left ear and a sustained 69.41 Hertz tone in the right ear as well as instrumental theta wave music.
223495114|NCT06705933|OTHER|Core stability exercise|Lumbo-pelvic stabilizing exercises (posterior pelvic tilt, bilateral hip abduction, bilateral knee raise, bridging, hip shrugging) will be performed three times per week for eight weeks.
223495115|NCT06705933|OTHER|Myofascial release|The participants will receive myofascial release technique for 20 min for 3 times per week for 8 weeks.
223495116|NCT06705933|OTHER|Kinesiotaping|The participants will receive Kinesio-Taping over the sacroiliac joint and the hip region. Following a test trial of a small patch for 24 hours, they will be instructed to keep the tape on for 48 hours (it will be replaced after 48 hours) . It will be applied for 8 weeks.
223495117|NCT06704867|OTHER|High flow nasal cannula|Subjects undergoing endoscopic ultrasound will receive high flow nasal cannula during the procedure
223495118|NCT07041177|OTHER|NeoThelium FT|NeoThelium FT is a dehydrated wound covering derived from donated human placental tissue. NeoThelium FT is a dual-layer membrane with amnion and chorion combination layers.
223495119|NCT06882889|DEVICE|Domestic hearing aids|The domestic hearing aids used in this study are from the Bigsound brand. Using domestic hearing aids for intervention, one first evaluates the patient's hearing condition through pure-tone audiometry. Subsequently, by thoroughly understanding the patient's hearing needs, lifestyle, and other relevant factors, the most suitable type and functions of hearing aids are selected to best meet the individual's specific situation.
223495120|NCT06882889|DEVICE|Imported hearing aids|The imported hearing aids used in this study are from the Phonak brand. Using imported hearing aids for intervention, one first evaluates the patient's hearing condition through pure-tone audiometry. Then, by thoroughly understanding the patient's hearing needs, lifestyle, and other relevant factors, the most suitable type and functions of hearing aids are selected to best meet the individual's specific situation.
223495121|NCT06703606|DRUG|MARSTACIMAB|Marstacimab 150 mg administered subcutaneous (SC) once weekly (QW)
223495122|NCT06878703|DRUG|Midazolam|Continuous intravenous administration with a loading dose of 10 µg/kg over 30 min, followed by a maintenance dose (from 10 to 40 µg/kg/h)
223495123|NCT06878703|DRUG|Dexmedetomidine|Continuous intravenous administration with a loading dose of 0.05 μg/kg over 30 minutes followed by a maintenance dose (from 0.05 to 0.2 μg/kg/h)
223495124|NCT06717451|DEVICE|Control-IQ Technology v1.5|"Tandem t:slim X2 insulin pump or Tandem Mobi insulin pump with Control-IQ technology v1.5.~Every month participants will receive a survey to complete assessments including any severe hypoglycemia or diabetic ketoacidosis events experienced since the prior assessment. Participants will also complete surveys related to patient reported outcomes at baseline, 6 months, and 12 months."
223495125|NCT05793060|DRUG|Dexmedetomidine Hydrochloride|Dexmedetomidine 50 Mcg
223495126|NCT05793060|DRUG|Dexamethasone Phosphate|Dexamethasone 4 mg
223589389|NCT00269854|DRUG|Infliximab 10 mg/kg|Infliximab (anti-TNF chimeric monoclonal antibody \[cA2\]) 5 mg/kg will be administered as infusion at Week 0, 2 and 6.
224186403|NCT01046175|PROCEDURE|Air-stacking with a manual resuscitator|Stacking air into the lungs up to maximal insufflation capacity (MIC)with a manual resuscitator
224186404|NCT01046175|PROCEDURE|Air-stacking with ventilator|Stacking air into the lungs to maximal insufflation capacity (MIC) with ventilator
224186405|NCT03044327|PROCEDURE|LPS challenge|LPS inhalation and bronchial instillation
224186406|NCT03169127|DRUG|Ibuprofen 600 mg|After lower third molars surgeries, pharmacogenetic and clinical efficacy of Ibuprofen 600mg was study.
224186407|NCT02369380|DEVICE|Hyaluronic acid|Injections of Hyaluronic acid under the metatarsal heads
224186408|NCT01890876|OTHER|Walking uphill|ascending about 500 m
224186409|NCT01890876|OTHER|Walking downhill|descending about 500 m
224186410|NCT04510662|DRUG|Telmisartan|Patients in this group will receive telmisartan 40 mg daily plus standard care.
223495127|NCT06704126|OTHER|Passive movement|This study will use a passive movement protocol delivered on a Biodex isokinetic dynamometer at 1Hz for 60 seconds on, 60 seconds off, for a total of 30 minutes.
224186411|NCT02641691|RADIATION|Radiation|
223495128|NCT06704126|OTHER|Passive movement with blood flow restriction|This study will use a passive movement protocol delivered on a Biodex isokinetic dynamometer at 1Hz for 60 seconds on, 60 seconds off, for a total of 30 minutes. During the 60 seconds on of passive movement training, blood flow restriction cuffs which will be applied to the legs, will be inflated to cause 80% arterial blood flow occlusion.
224186412|NCT02641691|DRUG|Oxaliplatin|
224186413|NCT02641691|DRUG|Leucovorin|
224186414|NCT02641691|DRUG|Fluorouracil|
224186415|NCT04711031|OTHER|FLUS|The participating GPs use ultrasonography on a weekly basis and will use the ultrasonography device already available to them; however, the ultrasound machine system and type of transducer will be reported. The GPs will use a 14-zone FLUS scanning protocol that has previously been validated in a general practice setting. Each of the scanning zones on the patient's left side can be denoted from 1L to 7L and from 1R to 7R on the right side. Each scanning zone should be assessed using FLUS. The transducer is placed in the middle of a scanning zone making a cross sectional image of an intercostal space and the underlying pleura blades. The patients will be examined in an upright position. The GPs will be trained in the 14-zone scanning protocol during a FLUS training program prior to recruitment of patients. FLUS pathological findings are predefined, and the variables will be dichotomized into present or not present for each scanning zone.
224186416|NCT06191757|BEHAVIORAL|supported with the developmental support program|Babies were developmentally supported with the developmental support program
224186417|NCT04595825|BIOLOGICAL|Anti-human CCL24 monoclonal antibody (CM-101)|Anti-human CCL24 monoclonal antibody (CM-101) 100 mg Intravenous Infusion over 60 minutes (±5 minutes)
224186418|NCT04595825|OTHER|Placebo|Placebo - intravenous infusion
224186419|NCT05431673|DRUG|Doxycycline|Doxycycline 100mg/day for 6 weeks used as single or combination treatment for Rhinoscleroma
224186420|NCT05431673|DRUG|Ciprofloxacin|Ciprofloxacin 500mg/day for 4 weeks used as single or combination treatment for Rhinoscleroma
224186421|NCT05431673|DRUG|Rifampin|Rifampin 600mg/day for 6 weeks used as single or combination treatment for Rhinoscleroma
223495129|NCT06719713|BEHAVIORAL|Store Safely|"The Store Safely intervention occurs online and is self-administered. Once directed to the Store Safely website, participants are welcomed and instructed to complete each step of the online program. Upon clicking Start, participants are taken to Step 1 of the intervention and instructed to review a brief video. Step 2 involves a review of a data infographics. Participants are then directed to the Decision Aid in Step 3. In Step 4, participants are instructed to complete the Family Firearm Storage Action Plan. In Step 5, participants will review another brief video. There will also be an optional step, consisting of a resource page that details local options for obtaining safe storage devices. At the end of each step, participants mark a checkbox to indicate they have completed the intervention activity which facilitates website analytics of participant engagement. Lastly, participants are thanked and provided with details about the final steps of the trial."
223495130|NCT07047209|DRUG|Digoxin|Digoxin tablets will be administered orally in a once daily dosage. Each tablet is scored and is of 125 mcg strength. Participants will take 1 tablet, two tablets or half a tablet depending on the dosing tier they are in during study participation.
223495131|NCT06734858|DEVICE|SAT014|SAT-014 in Combination with Baseline Conventional Treatment Participants in this arm will use the SAT-014 application for 6 weeks in combination with their baseline conventional treatment, which may include pharmacological therapy or simple counseling (excluding cognitive behavioral therapy and psychoanalytic counseling therapy). The aim of this study is to assess the efficacy and safety of SAT-014 for alleviating symptoms of trauma and stressor-related disorders, such as PTSD and adjustment disorder.
223495132|NCT06734858|OTHER|Control|Baseline Conventional Treatment Participants in this arm will receive only conventional treatment, which includes the medication they were taking at baseline for the indication or the basic counseling therapy they were receiving at baseline.
223495133|NCT05371613|DRUG|tividenofusp alfa|Intravenous repeating dose
223495134|NCT05371613|DRUG|idursulfase|Intravenous repeating dose
223495135|NCT06892002|DRUG|Teplizumab|This study will not administer any treatment, only observe the treatment as prescribed in real-world clinical practice.
223495136|NCT06889831|BEHAVIORAL|WORTH Paths Digital Intervention|Participants in this arm will receive the WORTH Paths digital intervention, a culturally tailored program designed for women involved in the criminal legal system with substance use disorders and unmet contraceptive needs. The intervention consists of three facilitated group sessions over videoconference with digital interactive activities to support behavior change.
223495137|NCT06889831|BEHAVIORAL|WORTH Paths Wellness Group|A wellness-focused intervention consisting of three facilitated group sessions over videoconference with digital interactive activities. Sessions cover general health, stress reduction, and navigating health services, including education about substance use and sexual/reproductive health risks, guided meditation, stress management techniques, and an overview of available health services. Participants also receive digital wellness resources, including recorded mindfulness exercises and links to online health service platforms.
223495138|NCT04968496|OTHER|Food Secure Group|Weekly meals (five breakfast and five lunch meals) will be provided to all children randomized to this group to prevent the onset of summertime food insecurity
223495139|NCT02207608|DRUG|Hyaluronic Acid|Add hyaluronic acid to BCG Treatment
223495140|NCT02207608|DRUG|BCG (Immucist®)|Usual BCG treatment
223495141|NCT05628350|OTHER|No UPF controlled diet|Following a two-week eucaloric lead-in diet, participants will be provided and consume a diet without UPF (0% total energy) for 6 weeks. Diets will be eucaloric (50% carbohydrate, 35% fat, 15% protein) and matched for dietary soluble and insoluble fiber, added sugar, mono- and polyunsaturated fat, saturated fat, antioxidant nutrients, sodium, pre- and probiotics, and overall diet quality.
223589390|NCT00269854|DRUG|Infliximab 20 mg/kg|Infliximab (anti-TNF chimeric monoclonal antibody \[cA2\]) 20 mg/kg will be administered as infusion at Week 0, 2 and 6.
224186422|NCT01447069|DRUG|Salbutamol|The initial dose will be 0.5mg bid, with acceleration of the dose every two weeks by 1mg, up to a maximal dose of 2mg bid or an increase in heart rate by 50% above the baseline heart rate, as long as it remains \<100 bpm
224186423|NCT00043134|DRUG|decitabine|
224186424|NCT01749241|DRUG|Loteprednol etabonate ophthalmic ointment|Thin ribbon ointment to assigned eye twice daily for 14 days
224186425|NCT01749241|DRUG|Vehicle Ophthalmic Ointment|Thin ribbon ointment to assigned eye twice daily for 14 days
224186426|NCT02713490|DRUG|EXPAREL|EXPAREL and bupivacaine HCl
224186427|NCT02713490|DRUG|Bupivacaine|Single dose of bupivacaine HCl 0.5%
223495142|NCT05628350|OTHER|High UPF controlled diet|Following a two-week eucaloric lead-in diet, participants will be provided and consume a diet with high UPF intake (81% total energy) for 6 weeks. Diets will be eucaloric (50% carbohydrate, 35% fat, 15% protein) and matched for dietary soluble and insoluble fiber, added sugar, mono- and polyunsaturated fat, saturated fat, antioxidant nutrients, sodium, pre- and probiotics, and overall diet quality.
223495143|NCT05465408|BEHAVIORAL|Culturally Aware Adjuvant Endocrine Therapy (AET) Non-Initiation Intervention|One-to-One virtual (videoconference) behavioral intervention.
223495144|NCT02279953|DRUG|Vortioxetine 10-20 mg|
223495145|NCT02279953|DRUG|Placebo|
223495146|NCT02279953|DRUG|SSRI|escitalopram, citalopram or sertraline
224186428|NCT03540602|DIETARY_SUPPLEMENT|Tart Cherry|NordicCherry Tart Cherry Extract Powder 500 mg from Specnova, inc
224186429|NCT03540602|OTHER|Placebo Oral Capsule [CEBOCAP]|Rice flour
224186430|NCT04353323|OTHER|Blood sampling|3 blood samples (D0, D15 and D30) will be taken from each participant
224186431|NCT03572621|OTHER|Therapeutic education|"Patients will benefit from the first session of preoperative therapeutic education, then the next 5 sessions will be done postoperatively over a period of 4 month and a half.~Session 1: The first session will be devoted appropriately to patient education. It will take place on the day of the preoperative anesthesia consultation.~Session 2: day of discharge from hospital. Make the patient adhere to the concept of post PR erectile rehabilitation in the same way as sphincter reeducation.~Session 3: Presentation of available treatments, start intracavernous injections.~Session 4: Acquisition of know-how on treatment management. Reduce anxiety. Session 5: Encourage the resumption of intercourse very gradually. The presence of the partner will be advised.~Session 6: measure of the evolution of the representations and knowledge of the patient. The skills of the patient will be evaluated from problem situations, motivation scale. The know-how will be evaluated using observation grid."
223495147|NCT04753515|DRUG|dexmedetomidine combined with midazolam and remifentanil.|Patients in this group will receive a bolus of midazolam 0.03 mg/kg intravenously, and then a loading dose of 0.5 mcg/kg remifentanil and 0.5 mcg/kg dexmedetomidine over 5 min via separate syringe pumps.
223495148|NCT04753515|DRUG|propofol combined with midazolam and remifentanil.|Patients in this group will receive a bolus of midazolam 0.03 mg/kg intravenously, and then a loading dose of 0.5 mcg/kg remifentanil and 0.33 mg/kg propoful over 5 min via separate syringe pumps.
223495149|NCT07070973|DEVICE|Assisted Fluid Management|Intraoperative fluid infusion will be regulated according to the Assisted Fluid Management (AFM) software and on Hypotension Prediction Index (HPI) will be used to titrate vasopressors and inotropes.
223589391|NCT00269854|DRUG|Placebo|Matching placebo will be adminstered at Week 0, 2 and 6.
224186432|NCT03572621|OTHER|Collection of data concerning their sexuality|Patients in the control group are offered to participate in the study, which consists of collecting data on their sexuality. This in addition to the current care by the teams of care about erectile rehabilitation (information and medication prescriptions).
224186433|NCT03572621|OTHER|Participation|Participation in a therapeutic education day.
224186434|NCT01053143|BIOLOGICAL|A/H1N1 pandemic influenza vaccine (non- adjuvanted)|0.5 mL, Intramuscular
224186435|NCT06447870|DRUG|biologic therapy(eg:IFX,ADA,UST,VDZ)|The patients received biologic therapy during the baseline period, and the specific type of medication was determined based on the professional doctor's diagnosis and treatment opinions. Patients were then divided into two groups based on whether primary non-response occurred or not.
224186436|NCT00346775|DRUG|Beclomethasone dipropionate|Beclomethasone dipropionate
224186437|NCT00346775|DRUG|Flunisolide|Flunisolide
224186438|NCT02380599|OTHER|Spinal Manipulation|Mid-thoracic spinal manipulation to T3-5 region
223495150|NCT07070973|OTHER|Goal Directed Fluid Therapy (GDT)|Institutional goal directed therapy protocol used to optimize SVI and reduce intraoperative hypotension
223495151|NCT05993884|DRUG|iEPCs|Patients receive iEPCs IV with the single dose
223495152|NCT05993884|DRUG|Placebo|Patients receive placebo IV with a single dose
223495153|NCT04743466|OTHER|Electronic Health Record Review|Biobank records are reviewed
223495154|NCT06594991|DRUG|Fianlimab|Fianlimab IV given every three weeks
223495155|NCT06594991|DRUG|Cemiplimab|Cemiplimab IV given every three weeks
223495156|NCT06594991|DRUG|Ipilimumab|Ipilimumab will be give every 6 weeks continuously
223589392|NCT00000802|DRUG|Atovaquone|
223589393|NCT00000802|DRUG|Dapsone|
223589394|NCT03178669|DRUG|cobitolimod|Rectal administration
223589395|NCT03178669|DRUG|Placebo|Solution manufactured to mimic cobitolimod
223589396|NCT01014468|DRUG|Ranibizumab (Intravitreal injection)|Intravitreal injection of Ranibizumab 0.5 mg or Bevacizumab 1.25 mg (3 monthly injection followed by monthly
224186439|NCT02380599|OTHER|Spinal Mobilization|Mid-thoracic spinal mobilization to T3-5 region
224186440|NCT02380599|OTHER|Sham Ultrasound|Sham ultrasound to T3-5 region
224186441|NCT00811499|DRUG|ARRY-371797, p38 inhibitor; oral|multiple dose, single schedule
224186442|NCT00811499|DRUG|Placebo; oral|matching placebo
224186443|NCT00811499|DRUG|Placebo; oral|multiple dose, single schedule
224308797|NCT05594264|BEHAVIORAL|HBPStories|The objective of this arm was to pilot test the web-based storytelling program to determine the preliminary impact on blood pressure and medication adherence, and if the web-based approach was an engaging approach for individuals managing hypertension.
224186444|NCT02946515|BEHAVIORAL|Educational Intervention|The educational intervention will be the online simulation training program. Participants will be taught how to use the simulation during a 30 minute orientation session with a research staff person. We will use a mastery based approach rather than prescribing an absolute number of hours participants need to play. The criteria are as follows: 1) achieving a score of 90% or more on 2 out of the last 3 simulations played or 2) maximum of 8 hours of play, whichever comes first. After the orientation sessions, training sessions will be completed by participants on their own. The research team will confirm remote usage, and contact participants by email and phone to prompt usage as needed. The research team anticipates that the proposed method will accommodate for participant schedules while still ensuring intervention compliance.
224186445|NCT02946515|BEHAVIORAL|Wait List Control|Access to the online simulation training after the follow-up measurement visit is complete
223495157|NCT07076355|DRUG|Botulinum Toxin type a (Botox)|A single dose of 25 units of botulinum toxin type A (BTX-A) was injected into the lateral pterygoid muscle using ultrasonography-guided technique. The injection was performed under local anesthesia with patient monitoring.
223495158|NCT07079189|BEHAVIORAL|Lifestyle tool|Regular use of the digital Lifestyle tool
223495159|NCT06455189|OTHER|Control Group - Standard of care neurosurgical resection|The control group will include only standard of care tools. - Standard of care neurosurgical resection will include the use of all standard neurosurgical instruments and techniques (eg, microscope, intraoperative ultrasound, 5-ALA fluorescence guided surgery and neuronavigation system).
223495160|NCT06455189|PROCEDURE|MRF/MRI infiltration guidance for extended resection|Magnetic resonance imaging, MRI, is a procedure that uses radio waves, a powerful magnet, and a computer to make a series of detailed pictures of areas inside the body
223495161|NCT07066098|DRUG|IBI343|Subjects in the experimental arm will receive IBI343 6mg/kg intravenous infusion (IV) D1, Q3W in 3-week cycle
223495162|NCT07066098|DRUG|Placebo|Subjects in the control arm will receive placebo 6mg/kg intravenous infusion (IV) D1, Q3W in 3-week cycle
223495163|NCT05805501|DRUG|Tobemstomig|Participants will receive IV tobemstomig Q3W.
223495164|NCT05805501|DRUG|Tiragolumab|Participants will receive IV tiragolumab Q3W.
223495165|NCT05805501|DRUG|Pembrolizumab|Participants will receive IV pembrolizumab Q3W.
223495166|NCT05805501|DRUG|Axitinib|Participants will receive axitinib PO BID.
223495167|NCT06846008|BEHAVIORAL|Ahead of the Game|"Evidence-based injury prevention training programs and exercises will be send weekly to participants in the intervention arm.~Additionally, participants in the intervention arm will be encouraged to access a study specific online platform containing information, inspiration, pep-talks and posters on injury prevention training."
223495168|NCT06846008|OTHER|Usual Practice|Usual training
223495169|NCT01294332|OTHER|Aerobic Exercise Training|supervised exercise on the treadmill at target heart rate range for 12 weeks, 3 times a week for 30 minutes.
223495170|NCT07117214|DRUG|[68Ga]Ga-DWJ155|Radioligand imaging agent
223495171|NCT07118995|OTHER|Analysis of preoperative CTA|A review of preoperative contrast-enhanced CTA from patients with thoracoabdominal aneurysms, included in Braile's database, who were indicated for endovascular treatment with Braile's custom-made multi-branched endograft between 2022 and 2024
223495172|NCT07114874|DRUG|NBI-1117568|NBI-1117568 will be administered per schedule specified in the arm description.
223589397|NCT01014468|DRUG|Bevacizumab (Intravitreal injection)|Intravitreal injection of Ranibizumab 0.5 mg or Bevacizumab 1.25 mg (3 monthly injection followed by monthly
224186446|NCT02538432|DRUG|RQ-00000007|RQ-07 250 mg will taken orally, with or without food, each morning and evening, approximately 12 hours apart. Drug administration will be continuous. Every 21 day period will be considered one cycle of treatment.
223495173|NCT07118137|DEVICE|7T MRI|Resting and activity-based MRI. Dring activity based MRI, the participant will complete tasks testing semantic memory.
223495174|NCT07118137|DEVICE|EEG|Resting-state EEG
223495175|NCT07118137|BIOLOGICAL|Blood samples|Blood samples taken for analysis of central blood biomarkers.
223495176|NCT07118137|BIOLOGICAL|Stool samples|Stool samples collected to identify distinct gut-microbiota compositions between the groups.
223495177|NCT07118137|DIAGNOSTIC_TEST|Neuropsychologic test (MoCA)|Map cognition with clinically well-established neuropsychology test
223495178|NCT07124793|DRUG|IBI363+IBI305|Each treatment cycle lasts for 21 days (the first treatment cycle is 28 days). Subjects will receive IBI363 Q3W in combination with bevacizumab Q3W until 2 years of treatment, PD, intolerable toxicity, start of new anti-tumor treatment, withdrawal of informed consent, death, or study termination (whichever occurs first).
223495179|NCT07125924|DEVICE|Blad-Care (sodium hyaluronate 1.6%, 800 mg/50 mL, BioPlus Co., Ltd.)|Bladder instillation of Blad-Care (sodium hyaluronate 1.6%, 800 mg/50 mL, BioPlus Co., Ltd.) will be administered aseptically once weekly for a total of five times following each session of radiotherapy.
223495180|NCT07125924|OTHER|Normal Saline (NS)|Normal saline will be instilled into the bladder following the same schedule as the intervention group, i.e., five times after each radiotherapy session.
223495181|NCT07124286|OTHER|Abdominal Bracing Training|The group underwent an abdominal bracing maneuver training. Following the training, they performed the Closed Kinetic Chain Upper Extremity Stability Test and the Seated Medicine Ball Throw Test in 2 conditions: with abdominal bracing and without abdominal bracing.
223495182|NCT07124546|BEHAVIORAL|Acceptance and Commitment Therapy|Attend ACT-HBC telehealth group sessions
223495183|NCT07124546|OTHER|Questionnaire Administration|Ancillary studies
223495184|NCT07124546|OTHER|Telemedicine|Attend ACT-HBC telehealth group sessions
223589398|NCT02626390|OTHER|Frequent instructions/feedback and an Internal Focus of Attention|
223589399|NCT02626390|OTHER|Minimal instructions/feedback and an External Focus of Attention|
223589400|NCT00738218|OTHER|Multidetector Computed Tomography - 64 detectors|Multidetector computed tomography angiography
223589401|NCT01309685|DRUG|Varenicline|
223589402|NCT05751148|DRUG|Hyperbaric bupivacaïne|Spinal anesthesia with 10mg of hyperbaric bupivacaïne. A syringe filled with 2 mL of hyperbaric bupivacaïne + 0,5 ml of saline solution
223495185|NCT07125586|DIAGNOSTIC_TEST|High-Sensitivity Spectroscopy with Autofluorescence for eCRSwNP Diagnosis|This intervention employs a non-invasive diagnostic procedure using a high-sensitivity spectroscopy system with autofluorescence to identify eosinophilic chronic rhinosinusitis with nasal polyps (eCRSwNP). A specialized thin probe, guided by an endoscopic light source, contacts nasal polyp tissue to emit a proprietary wavelength laser light, exciting fluorescent substances (primarily flavin adenine dinucleotide, FAD). The probe captures autofluorescence signals at a specific emission wavelength, and signal intensity analysis distinguishes eosinophilic from non-eosinophilic polyps in real-time. Unlike invasive histopathological diagnosis via biopsy or surgery, this method enables rapid preoperative typing. Conducted once at the initial visit, results are validated against post-biopsy/surgical histopathology (gold standard) to assess diagnostic accuracy (sensitivity ≥90%, specificity ≥85%). Safety is monitored for adverse events like mucosal irritation or bleeding within 24 hours.
223589403|NCT05751148|DRUG|Hyperbaric prilocaïne|Spinal anesthesia with 50mg of hyperbaric prilocaïne. A syringe filled with 2,5 mL of hyperbaric prilocaïne
223589404|NCT04842305|DIAGNOSTIC_TEST|Blood- and saliva tests|Measurement of SARS-CoV-2 spike glycoprotein RBD antibodies in plasma and saliva
224186447|NCT02538432|DRUG|Gemcitabine|For patients with breast or lung cancer who have not previously received gemcitabine as part of their therapy or who may benefit from re-challenge with gemcitabine, gemcitabine will be administered at 1000 mg/m2 IV over 30 minutes for 3 out of 4 weeks after appropriate pre-medications. Every 4 week period (28 days) will be considered one cycle.
224186448|NCT03242811|DIAGNOSTIC_TEST|MRI scan of knee, ankle and wrist|"At the day of the intervention, the subject is informed about the study by a nurse and provides written informed consent.~Girls must leave urine tests to rule out pregnancy. The questionnaire for the study is answered by the subject and weight and length are measured. The subject is asked to self-assess his/her puberty.~After detailed information on how a magnetic camera examination is carried out, an examination of five selected growth zones (knee joint, ankle joint including heel leg and wrist) is performed using 1.5 Tesla magnetic camera with dedicated cartilage sequence."
223589405|NCT01600092|BIOLOGICAL|RotaTeq™ experimental formulation|
223589406|NCT01600092|BIOLOGICAL|RotaTeq™ existing formulation|
223589407|NCT03266913|DRUG|Probiotic|Probiotics drop
223589408|NCT05492357|OTHER|Liquid platelet-rich fibrin|Liquid platelet-rich fibrin is prepared from the patient's blood and injected into the extraction socket every two weeks (up to 3 months = Just 4 times of application)
223589409|NCT05492357|OTHER|Advanced Platelet-rich fibrin plus|A-PRF+ is placed into the extraction socket immediately after tooth extraction
224186449|NCT04358809|DRUG|Suspension of heat killed (autoclaved) Mycobacterium w|Suspension of heat killed (autoclaved) Mw along with Standard of care (SOC) treatment for COVID-19
224186450|NCT04358809|OTHER|Placebo|Placebo along with Standard of care (SOC) treatment for COVID-19
223495186|NCT07122635|DRUG|Diquafosol Sodium 3%|Diquafosol Sodium 3% ophthalmic solution, 1 drop each time, 6 times daily, from baseline (1 week after the surgery) to 12 weeks
223495187|NCT07123545|BIOLOGICAL|iNeo-Vac-P01 Personalized Neoantigen Peptide Vaccine|Administered subcutaneously at 0.3 mg/peptide on Days 1, 4, 8, 15, 22, 52, and 82, followed by booster immunizations every 2-3 months.
223495188|NCT07123545|BIOLOGICAL|iNeo-Vac-T01 Personalized T Cell Injection|Administered via intravenous infusion: Dose Level 1: 5×10⁹ to 10×10⁹ cells; Dose Level 2: 1×10¹⁰ to 5×10¹⁰ cells.
223589410|NCT06782997|DEVICE|Electroretinogram|Electroretinogram (RETevalTM devices, LKC Technologies) performed and interpreted by an advanced practice nurse compared to the gold standard (retinography) interpreted by an ophthalmologist
223589411|NCT04420260|DIETARY_SUPPLEMENT|Group A: oropharygeal spray and immunostimulant emulsion|"Intervention 1: Preparation in a liquid solution to be used for oropharyngeal spray, composed of 3 natural bioactive substances of routine use in humans, that feature homologous molecular structures to the native viral receptor.~Intervention 2. Preparation in an emulsion functional food presentation for oral administration, that contains the 8 bioactive compounds that have demonstrated antiviral activity and modulation of the inflammatory response recognized at the moment in the immune activation against the virus."
223589412|NCT04420260|DIETARY_SUPPLEMENT|Group D:Placebo oropharyngeal spray + Placebo taken PO|"Intervention 1: Preparation in a liquid solution to be used for oropharyngeal spray, composed of Placebo substances of routine use in humans.~Intervention 2. Preparation in an emulsion presentation for oral administration that contains the Placebo compounds"
223589413|NCT01152177|DEVICE|Electronic reminder letters|Electronic reminder letters if adherence is not obtained (up to four)
223745765|NCT05023187|BEHAVIORAL|CON|"A 8-week active control intervention consisting of 2 sessions (\~45 minutes each) of cognitive stimulation exercises and a group session for each week (24 sessions in total) during which the various cognitive domains are deepened and the exercises carried out during the week are reviewed all together.~The online control intervention has been specifically designed to increase the cognitive involvement of the subjects and to replicate the condition of exposure to social dynamics."
223495189|NCT07122206|PROCEDURE|Blood Draws|Research-related blood draws will be used to ascertain FGF19 levels.
223495190|NCT06902961|OTHER|Game-based exercise group|Game-based exercise group
223495191|NCT06902961|OTHER|control group|control group
223495192|NCT04919824|PROCEDURE|Endoscopic Submucosal Dissection|Endoscopic submucosal dissection (ESD) is a novel technique for the removal of advanced colonic polyps with high-risk features. ESD is minimally invasive and allows the removal of colonic adenomatous polyp without resorting to surgery. The process of ESD includes marking the lesions selected for removal, followed by submucosal injection of a lifting agent, then circumferential incisions using a specialized knife followed by submucosal dissection of the entire lesion.
223495193|NCT04919824|PROCEDURE|Endoscopic Mucosal Resection|Endoscopic mucosal resection (EMR) is a conventional endoscopic technique commonly used for the resection of superficial neoplastic lesions in the GI tract. EMR carries lower morbidity and mortality compared to surgery.
223495194|NCT04851119|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223495195|NCT04851119|PROCEDURE|Dual X-ray Absorptiometry|Undergo DEXA scan
223495196|NCT04851119|DRUG|Tegavivint|Given IV
223495197|NCT04851119|PROCEDURE|X-Ray Imaging|Undergo x-ray imaging
223495198|NCT06903702|DRUG|Azacitidine (AZA)|given daily for 7 days starting on Day 1 of each Cycle
223495199|NCT06903702|DRUG|Venetoclax|orally daily for 28 days
223495200|NCT06903702|PROCEDURE|Allogeneic hematopoietic stem cell transplantation|After the conditioning treatment, the HSCT procedure is part of standard care on Day 0.
223495201|NCT07096921|DRUG|Mosapride citrate 5 mg + DA-9701 30 mg|Experimental: Mosapride citrate 5 mg + DA-9701 30 mg, Oral, 3 times/day, 30 min before meals for 4 weeks
223495202|NCT07096921|DRUG|Mosapride citrate 5 mg + DA-9701 30 mg placebo|Placebo Comparator: Mosapride citrate 5 mg + DA-9701 placebo, Oral, 3 times/day, 30 min before meals for 4 weeks
223495203|NCT07092384|DRUG|Remifentanil|Observe the incidence of pruritus and paresthesia after different doses of remifentanil and fospropofol disodium
223495204|NCT07092384|DRUG|Sufentanil|Observe the incidence of pruritus and paresthesia after sufentanil and fospropofol disodium
223495205|NCT06911931|OTHER|EEG measure of visual processing|Non-invasive scalp EEG measure of early cortical visual processing.
223495206|NCT00980460|DRUG|Cisplatin|Given IV
223495207|NCT00980460|DRUG|Dexrazoxane|Given IV
223495208|NCT00980460|DRUG|Doxorubicin Hydrochloride|Given IV
223495209|NCT00980460|DRUG|Fluorouracil|Given IV
223495210|NCT00980460|DRUG|Irinotecan Hydrochloride|Given IV
223495211|NCT00980460|OTHER|Laboratory Biomarker Analysis|Correlative studies
223495212|NCT00980460|PROCEDURE|Liver Transplantation|Undergo liver transplant
223495213|NCT00980460|DRUG|Temsirolimus|Given IV
223495214|NCT00980460|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
224073653|NCT00857727|DRUG|Dexmedetomidine|Dexmedetomidine will be dissolved in saline. An initial loading dose of 1.0 mg/kg given over 10 minutes followed by a continuous infusion at 0.4-0.7 mg/kg/hour. Beginning approximately one hour prior to end of surgery and continuing for one hour of recovery in the PACU and the PICU. This, the maximum dose for any one patient will be 2.4 mg/kg
223745766|NCT01834287|BEHAVIORAL|Physical Activity Intervention|Participants in the Physical Activity intervention arm of the study receive a Spanish language, motivationally-tailored, Internet-based Physical Activity intervention that specifically addresses the Physical Activity barriers and intervention needs/preferences of Latinas.
223495215|NCT00980460|DRUG|Vincristine Sulfate|Given IV
223495216|NCT06908538|DEVICE|cryoablation|Cryoanalgesia, also known as Cryoablation, Cryoneurolysis, or Cryonerve Block, has been used for decades to treat chronic pain and has recently been employed for the management of Phantom Limb Pain. Cryoanalgesia involves the use of a probe to apply extreme cold (approximately -70◦C) to induce reversible axonal injury and Wallerian degeneration to produce a temporary conduction block that is sustained until regeneration of the axon and sensation is restored, typically weeks to months later.
223495217|NCT06911294|BEHAVIORAL|Polygenic Risk Score|genetic test for the evaluation of cardiovascular risk
223745767|NCT01834287|BEHAVIORAL|Wellness Control|Participants will receive a Spanish language, Internet-based Wellness Contact control intervention addressing relevant health topics other than physical activity.
223495218|NCT06911294|BEHAVIORAL|Digital app and wearable device|a wearable device connected with its app
223495219|NCT07098377|DIAGNOSTIC_TEST|nasopharyngeal swab for biological sample analysis|nasopharyngeal swab for biological sample analysis
223495220|NCT07111052|BEHAVIORAL|Lock and Protect is a self-administered, web-based decision aid for caregivers of adolescents at risk for suicide.|Lock and Protect is a user-friendly web-based decision aid that identifies preferences and explores options for removing or storing lethal means safety through: (a) education on home means of suicide, such as firearms, medications, and other potentially dangerous home and external items/situations (e.g., poisons, methods/ligatures used in suffocation/hanging), and community hazards (e.g., subways, heights); (b) safe storage options; and (c) protective monitoring and supervision as a means of increasing adolescent safety during a time of elevated risk.
223495221|NCT07111403|PROCEDURE|SAP fluoride plus|The agent was applied by removing the safety clip, activating the applicator and squeezing out the sponge above the lesion and the solution was left to diffuse for 5 min.the patients were instructed to eat only soft foods and avoid hot liquids for two hours. Also, they were educated and motivated about the importance of oral hygiene.
223495222|NCT07111403|PROCEDURE|10% n-HAp.|the pastes were applied using micro brushes. The excess was removed after four minutes with a cotton swab. The subjects were advised not to drink or eat for 30 minutes after the treatment. The treatment was applied once every week for a period of four weeks.they instructed to adhere to oral hygiene measures.
223495223|NCT07111403|PROCEDURE|10% n-BAG.|the pastes were applied using micro brushes. The excess was removed after four minutes with a cotton swab. The subjects were advised not to drink or eat for 30 minutes after the treatment. The treatment was applied once every week for a period of four weeks. patients instructed to adhere to oral hygiene measures.
223495224|NCT07111403|PROCEDURE|Flour Protector S|After application of varnish, the patient was instructed to avoid abrasive diet for the rest of the day and not brush or floss until the next morning. The treatment was done at baseline and after 6 months.
223495225|NCT07111702|DRUG|Cefazolin|A single 2g intravenous dose administered once before surgery.
223495226|NCT07109492|OTHER|Mandala|Mandala Painting
223495227|NCT06480539|DRUG|Placebo|The comparator is a placebo, namely pure saline (NaCl 0.9%), which will be administered following the same regimen as the intervention.
223495228|NCT06480539|DRUG|Dexmedetomidine|Nocturnal administration of dexmedetomidine (0.2-1.0 mcg/kg/h) during the first night after surgery. Dexmedetomidine infusion, not preceded by a bolus administration, will be started at 0.4 mcg/kg/h in the intervention group at 8 p.m. the day of surgery. Dexmedetomidine infusion will be titrated every 30 minutes with 0.1 mcg/kg/h steps until a RASS of -1 to -3 (drowsy, light to moderate sedation) is reached. The infusion will be discontinued at 6 a.m. the next morning.
223495229|NCT06395519|DRUG|ETX-19477|Oral medication taken daily
224073654|NCT00857727|DRUG|Saline|Given by a continuous infusion
224073655|NCT01202656|DRUG|G-CSF|One infusion of G-CSF 300 units administered by intrauterine infusion
224073656|NCT01202656|DRUG|Saline|intrauterine saline infusion 1 cc
224073657|NCT01131000|DRUG|Ibuprofen|Intravenous ibuprofen, 100 mg, Single-dose
224073658|NCT01131000|DRUG|Ibuprofen|Intravenous ibuprofen, 200mg, single dose
224073659|NCT01131000|DRUG|Ibuprofen|Intravenous ibuprofen, 400 mg, Single-dose
224073660|NCT01131000|OTHER|Normal Saline|Normal Saline, 100 ml, Single-dose
224073661|NCT03779113|DRUG|HMPL-523|Oral HMPL-523
224186451|NCT06175845|PROCEDURE|Intraductal biliary radiofrequency ablation|Radiofrequency ablation via catheter and transpapillary access of malignant bile duct obstruction
224186452|NCT00886977|DRUG|YAM80|Oral administration, 2 to 6 mg, once a day.
224186453|NCT03799198|OTHER|Weight Management Program (WMP)|As part of usual care, participants will: 1) Discuss and choose one of three diet options: protein-sparing modified fast, Mediterranean, or meal replacement. 2) Be referred to a nutritionist appointment. 3) Initiate a series of twelve monthly study visits in the context of shared medical appointments (SMAs) covering nutrition, physical activity, appetite control, sleep issues, and anxiety/depression/stress. 4) Be referred to an exercise physiologist for a personalized physical activity program. 5) If assessed relevant by the study clinician, be referred to a mental health specialist and/or sleep clinic.
224186454|NCT03799198|DRUG|Medication for chronic weight management (Rx)|"Following listed 5 drugs will be administered as prescribed by the study doctor:~1\) Orlistat (Xenical® pills, per os \[p.o.; by mouth\]). 2) Lorcaserin or lorcaserin extended-release (Belviq®/Belviq XR® pills, p.o.). 3) Phentermine/topiramate extended-release (Qsymia® pills, p.o.). 4) Naltrexone/bupropion extended-release (Contrave® pills, p.o.). 5) Liraglutide 3.0 mg (Saxenda® injections, subcutaneously \[under the skin\])."
223495230|NCT07115290|DEVICE|Glass ionomer-based fissure sealant|A high-viscosity, self-curing glass ionomer sealant used for the occlusal surfaces of newly erupted permanent molars. This material releases fluoride and is moisture-tolerant during application. The product used in this study was Fuji Triage™ Capsule (GC Corporation, Japan).
223495231|NCT07115290|DEVICE|Resin-based fissure sealant|A moisture-tolerant, light-cured resin-based fissure sealant designed for application to occlusal surfaces in partially erupted permanent molars. The material exhibits strong adhesion in moist conditions and forms a durable barrier against caries. The product used in this study was UltraSeal XT® Hydro (Ultradent Products Inc., USA).
223495232|NCT07116512|DRUG|Finerenone (BAY94-8862): intervention A|Study intervention A: one tablet of dose strength 1 one tablet of dose strength 1 = two tablets of dose strength 2
223495233|NCT07116512|DRUG|Finerenone (BAY94-8862): intervention B|Study intervention B: two tablets of dose strength 2 two tablets of dose strength 2 = one tablet of dose strength 1
223589414|NCT05710276|OTHER|abdominal infrared radiation|In a specific room (controlled temperature and humidity) with a patient lying on his back, we will determine the abdominal infrared radiation with a FLIR® thermal camera (without contact) and quantify the thermal signal by spectral analysis (in degrees Celsius).
223589415|NCT05135962|DEVICE|orthodontic - rapid maxillary expansion|Rapid expansion: when RME was in situ, patients started the screw activation of one-quarter turn a day until overcorrection was achieved and RME was kept on teeth as a passive retainer and removed after one year from its application.
223589416|NCT05135962|DEVICE|orthodontic - slow maxillary expansion with leaf expander|Leaf expander: The screw delivers a maximum expansion of 6 or 9 mm by activating (compressing) the spring, which generates a light (450g or 900g) and constant force. The leaves are preactivated in the laboratory to deliver 3mm of expansion. Reactivation is performed in the office by 10 quarter-turns (leaf 450g) or 15 quarter-turns (leaf 900g) of the screw per month until expansion has been completed. After active expansion the Leaf Expander is maintained passively in place for retention period. Leaf expander was kept on teeth as a passive retainer and removed after one year from its application.
223589417|NCT05135962|DEVICE|orthodontic - slow maxillary expansion with self leaf expander|Leaf self expander: similar to Leaf expander with no need for reactivation or patient compliance.
223589418|NCT03590249|PROCEDURE|Osteopathic Manipulative Treatment|Osteopathic manipulation involves a number of different manual (hands-on) techniques. These include muscle inhibition (applying pressure to a muscle to induce relaxation); myofascial release (applying pressure to the fascia and moving it toward/away from a strain); muscle energy stretch (contraction of a stretching muscle); counterstrain (shortening a strained muscle); facilitated positional release (moving a vertebra into a restriction and applying a gentle compression); osteopathy in the cranial field (balancing the cranial tissue); balanced ligamentous tension/ligamentous articular strain (moving a joint into ease to release tension in the ligament); one or all of these techniques may be used. Participants will be positioned on an exam table supine, seated, lateral decubitus, prone, or in their position of greatest comfort for the procedure. Treatment will last approximately 45 minutes.
223589419|NCT06149377|PROCEDURE|Test cohort|
224186455|NCT04386798|OTHER|survey work|Bebeği Yenidoğan Yoğun Bakım Ünitesinde Yatan Annelerin Stres ve Anksiyete Düzeyleri anket yöntemi ile ölçülecektir.
224186456|NCT00148174|BEHAVIORAL|Intensive telephone followup|Telephone calling
223495234|NCT07114250|PROCEDURE|spinal anesthesia|Spinal Anesthesia group: Patients included in this group will undergo supine Percutaneous nephrolithotomy under spinal anesthesia
223495235|NCT07114250|PROCEDURE|General Anesthesia|General Anesthesia : Patients included in this group will undergo supine Percutaneous nephrolithotomy under general anesthesia
223495236|NCT07116343|DRUG|Ropivacaine|The patient will receive 0.2% ropivacaine (20.0 ml) into the pleural cavity intraoperatively before sternal closure. A continuous infusion of 0.2% ropivacaine will be administered through a microcatheter into the drained pleural cavity, with titration of the infusion rate. The initial infusion rate is set at 10 ml/hour.
223495237|NCT07116343|DRUG|0.9 % NaCl|The patient will receive 20.0 ml of a 0.9% sodium chloride solution into the pleural cavity intraoperatively, prior to sternal closure. A continuous infusion of 0.9% sodium chloride solution will then be administered through a microcatheter into the drained pleural cavity. The initial infusion rate is set at 10 ml/hour.
223495238|NCT07115446|DRUG|HS-20093|Intravenous (IV) administration of HS-20093 Q3W; Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and confirmed disease progression.
223495239|NCT07115446|DRUG|HRS-5041|HRS-5041 was given oral administration, QD, at a 21-day cycle.
223495240|NCT07115550|DRUG|Iparomlimab and Tuvonralimab Injection (QL1706) in combination with Regorafenib|Iparomlimab and Tuvonralimab Injection (QL1706) in combination with Regorafenib
224186457|NCT03530267|DRUG|Aflibercept + mLV5FU2|Patients receive aflibercept 4mg/kg as 1-h infusion followed by folinic acid 350 mg/m² by 2-h intravenous infusion, 5-fluorouracil 1920 mg/m² 46-h intravenous infusion (mLV5FU2) every 2 weeks (qd15).
224186458|NCT03530267|DRUG|mFOLFOX7|Patients in this arm receive modified (m) FOLFOX 7: Folinic acid 350 mg/m² and oxaliplatin 68 mg/m² by concurrent 2-h intravenous infusion, 5-FU 1920 mg/m² 46-h intravenous infusion every 2 weeks (qd15).
224186459|NCT03859908|DRUG|Iodine Povacrylex 7 MG/ML / Isopropyl Alcohol 0.74 ML/ML|As preoperative antiseptic, applied once as suggested by Centers for Disease Control recommendations in surgical asepsis
224186460|NCT03859908|DRUG|Chlorhexidine Gluconate 20 MG/ML / Isopropyl Alcohol 0.7 ML/ML|As preoperative antiseptic, applied once as suggested by Centers for Disease Control recommendations in surgical asepsis
224186461|NCT05033691|RADIATION|Stereotactic surgery|At two month (8 weeks) post Osimertinib start, patients will be randomized into one of the two study arms. Arm A patients will be treated with stereotactic surgery (SRS). In both arms Osimertinib treatment will continue.
224186462|NCT00960869|DRUG|PA32540|PA32540 tablets contain 325 mg enteric coated (EC) aspirin and 40 mg immediate-release omeprazole
224186463|NCT00960869|DRUG|EC-Aspirin 325 mg|The comparator aspirin 325 mg enteric coated tablet (PA32540 minus omeprazole)
223495241|NCT07116538|OTHER|Nishauri mHealth Intervention|The Nishauri mHealth intervention, developed by Palladium with Kenya's Ministry of Health and funded by PEPFAR/CDC, is a client-centered digital platform designed to enhance HIV care in Kenya. It supports appointment scheduling, ART referrals, and patient engagement through features such as automated medication and appointment reminders, tailored health education, two-way communication, and behavior-change strategies. Interoperable with national health systems like KenyaEMR and Ushauri, it enables real-time data exchange and continuity of care. Despite national scale-up, uptake remains low and varies across facilities, providers, and patients, particularly among men, who face unique sociocultural barriers. Addressing gender norms and contextual factors is key to improving implementation and achieving sustained engagement and better outcomes.
223495242|NCT07116655|BEHAVIORAL|Single-session solution focused consultation|"In the SSC, the interventionist first sets expectations, explaining that the session is a means of providing short-term support. The interventionist will then praise the participant for agreeing to receive support and introduce the Action Plan, which will guide the session's structure. The interventionist will then work with the participant to (1) identify a specific, modifiable issue they are facing; (2) use the miracle question to envision their ideal outcome where the problem is resolved, and rates their current proximity to that; (3) determine the smallest possible step they can take towards this outcome through a scaling exercise; and (4) develop a personalized action plan that leverage on their current resources to begin addressing the problem. Upon ending the SSC, the interventionist writes a personalized note to the participant, highlighting their strengths and expressing confidence in their ability to follow through."
223495243|NCT07116655|BEHAVIORAL|Single-session supportive intervention|In the supportive consultation session, the interventionist will allow the participant to decide what they wish to discuss during the session and listen empathetically, validate their feelings and offer reassurance to the patient. The exact wording or questions will vary depending on the client's needs and sharing.
223495244|NCT07114107|DEVICE|VPAT (Vibratory Positive Pressure Therapeutic Apparatus）|"VPAT (Vibratory Positive Pressure Therapeutic Apparatus）is a physical solution which can relieve nasal congestion and discomforts by applying acoustic vibration and oscillatory positive expiratory pressure. Clinical research has shown that low-frequency vibration at approximately 130 Hz promotes the production of the highest concentration of Nitric Oxide (NO) in the paranal sinuses, which helps to regulate the nasal mucosal blood, restoring the mucous membrance-cilia mechanism, clean up the bacteria, viruses and allergenic particles in the respiratory tract.~Combined with Oscillatory Positive Expiratory Pressure and Transnasal Breathing, it can help to cultivate the habit of nasal breathing and slow breathing, as well as to restore the function of lungs."
223495245|NCT07114107|DRUG|basic medications (antihistamines, mometasone furoate nasal spray, ICS-LABA|"All participants need basic control drugs contains antihistamines(Ebastine 10 mg once daily for 2 weeks), mometasone furoate nasal spray(Spray 2 puffs into each nostril, each puff contains 50 μg of mometasone furoate, i.e., 100 μg per administration, once daily for 2 weeks).~Asthma participants should added Inhaled corticosteroids-long-acting beta-agonists (ICS-LABA) therapy. For mild to moderate asthma: budesonide/formoterol (160μg/4.5μg) , with 1 inhalation each time, twice daily, or salmeterol/fluticasone propionate (50μg/100μg) with 1 inhalation each time, twice daily. For moderate to severe asthma: Budesonide/Formoterol (320μg/4.5μg), with 1 inhalation each time, twice daily; or salmeterol/fluticasone propionate (50μg/250μg or 50μg/500μg) with 1 inhalation each time, twice daily. Dosage adjustments should be evaluated and determined by the physician based on the patient's disease control status."
223495246|NCT07114107|DEVICE|OPEP（Oscillating Positive Expiratory Pressure device）|Oscillating Positive Expiratory Pressure (OPEP) device contain a inner ball that creates a resistance and oscillates when the patient blows through the device. This resistance helps splint the airways open during exhalation whilst the oscillation loosens the mucous within the airways. This makes it easier for some patients to clear their sputum.
223495247|NCT07115160|OTHER|Training following a predefined protocol.|Training following a predefined protocol.
223589420|NCT00079677|DRUG|Armodafinil 150 mg/day|Armodafinil 150 mg once daily in the morning
224186464|NCT04348760|BEHAVIORAL|Rotation Diet|Based on the food-specific IgG measurement and relative distribution, a personalized food profile was created for each subject identifying 1 to 3 relevant food groups/nutritional clusters. Subjects were then instructed to avoid the foods highlighted in their personal food profile in certain days of the week, and to assume them in 7 of the 21 meals of the week. No calorie restriction was imposed in the diet.
224186465|NCT01518894|DRUG|PF-04958242|PF-04958242 0.10 mg oral solution Q24 hours for 14 days
224186466|NCT01518894|DRUG|PF-04958242|PF-04958242 0.20 mg oral solution Q24 hours for 14 days
224186467|NCT01518894|DRUG|PF-04958242|PF-04958242 oral solution Q24 hours for 14 days (dose to be determined)
224186468|NCT01518894|DRUG|Placebo|Placebo oral solution Q24 hours for 14 days
224186469|NCT04932980|DRUG|Aflibercept|administration of anti-VEGF Aflibercept (Eylea)
224186470|NCT04932980|DRUG|Brolucizumab|administration of anti-VEGF Brolucizumab (Beovu)
224186471|NCT04932980|PROCEDURE|early treat and extend (T&E)|extension of treatment intervals (T\&E) from the beginning of treatment
224186472|NCT03202329|OTHER|standard care|cardiologists assist in treatment and provide heart failure guidance post-operatively if required by the treating surgeon
224186473|NCT03202329|OTHER|Nurse-based care|board-certified heart failure nurses provide heart failure guidance post-operatively on every working day
224186474|NCT02593331|DRUG|BFKB8488A|Participants will receive either a single escalated dose of BFKB8488A administered SC or a single dose of BFKB8488A administered IV on Day 1.
223495248|NCT07115654|DRUG|CM336 (BCMA/CD3 bispecific antibody)|CM336 is a bispecific antibody targeting BCMA and CD3, designed to redirect T cells to eliminate abnormal plasma cells.
223589421|NCT00079677|DRUG|Placebo|Matching placebo tablets once daily
223589422|NCT00196053|DEVICE|Archimedes Constant Flow Implantable Pump|
223589423|NCT00025623|DRUG|carboplatin|
223589424|NCT00025623|DRUG|cyclophosphamide|
223589425|NCT00025623|DRUG|doxorubicin hydrochloride|
223589426|NCT00025623|DRUG|etoposide|
223589427|NCT00025623|DRUG|vincristine sulfate|
223589428|NCT00025623|PROCEDURE|conventional surgery|
223589429|NCT05428813|BEHAVIORAL|art therapy techniques|Art therapy is a method that allows individuals to increase their self-awareness and realize their emotions better through artistic techniques.
223495249|NCT07115251|BEHAVIORAL|Plans4Care|Caregivers assigned to treatment condition will receive: 1) access to the web-app; 2) an orientation to the web-app involving initial set up; and 3) a brief video explaining use of the web-app. Caregivers will be guided through accessing the platform, creating an account and completing a brief set of background questions.
223495250|NCT07114731|OTHER|Synchronous Action Observation Therapy|Real-time observation and execution of motor tasks through structured video modules designed based on participants' GMFCS level and extremity involvement.
223495251|NCT07114731|OTHER|Asynchronous Action Observation Therapy|Observation of structured motor task videos followed by delayed execution, adapted to individual GMFCS levels and extremity involvement patterns.
223495252|NCT07114289|PROCEDURE|Spontaneous breathing trial using pressure support ventilation|Patients will receive low level pressure support ventilation for 1 hour before extubation
223495253|NCT07114289|PROCEDURE|Spontaneous breathing trial using T-Piece|Patients will receive a T-piece with oxygen for 1 hour before extubation
223495254|NCT07114029|PROCEDURE|Mesh-free Sacrocolpopexy via VNOTES|Mesh-free sacrocolpopexy is performed via the VNOTES technique to treat pelvic organ prolapse. Outcomes will be evaluated before and 6 months after surgery.
223495255|NCT07114562|DEVICE|Epicare|All participants will receive treatment with the Epicare fractional nano-thulium (Tm:YAP, 1938 nm) laser device for the reduction of periorbital wrinkles.
223495256|NCT07114497|DIAGNOSTIC_TEST|surgery (any volume) and / or pharmaceuticals treatment initiated or planned or only dynamic observation, in accordance with current clinical guidelines|During surgery, degenerated intervertebral disc tissues will be collected under sterile conditions and stored at -80°C in cryotubes. miRNA expression profiles will be analyzed using rt-PCR. Candidate miRNAs are selected based on databases such as miRBase, miRTar, and miRDB.
223495257|NCT07114497|DIAGNOSTIC_TEST|excised|Intervertebral disc tissues that are not degenerated will be collected during surgery and stored in the same manner as in the IVDD group. These samples will be used for comparative analysis of miRNA expression via rt-PCR to serve as the control baseline.
223589430|NCT02373514|DRUG|Paracetamol|1 gr paracetamol in 100 ml saline with rapid infusion
223589431|NCT02373514|DRUG|Dexketoprofen|50 mg dexketoprofen in 100 ml saline with rapid infusion
223589432|NCT01300455|DRUG|Suvorexant|40 mg tablets, orally once daily for 4 consecutive days in the evening
223589433|NCT01300455|DRUG|Matching Placebo|Placebo tablets, orally once daily for 4 consecutive days in the evening
223589434|NCT06092775|DEVICE|DEXA scan,X_ray|"DEXA scan detect osteoporosis~,X\_ray show subclinical vertebral fractures"
223589435|NCT05052593|OTHER|compressive myofascial release|Patients in this group will receive treatment through CMR that includes shaking the muscle belly of vastus lateralis for 30 seconds. Then the hip is fully extended on treatment table and CMR is applied on Vastus lateralis muscle for 1 minute. Treatment consists of broad strokes applied with clinicians knuckles to release superficial restrictions, followed by more specific strokes applied with clinicians' thumb on tight muscle. Strokes are applied at a contact point of 45 degree. With pressure directed from distal to proximal.
223495258|NCT07114497|DIAGNOSTIC_TEST|Diagnostic work up|During surgery, degenerated intervertebral disc tissues will be collected under sterile conditions and stored at -80°C in cryotubes. miRNA expression profiles will be analyzed using rt-PCR. Candidate miRNAs are selected based on databases such as miRBase, miRTar, and miRDB.
223589436|NCT05052593|OTHER|conventional treatment group|Patients in this group will receive treatment of Hot pack and Tens for 20 minutes, Range of motion exercises (knee flexion and extension ROM's), Stretching exercises (3sets, 10 reps for 5 second hold)
223495259|NCT07114705|DIAGNOSTIC_TEST|Transvaginal ultrasound|This is the only method
223495260|NCT07114783|DEVICE|Dual-function semi-rigid thoracoscopy|Patients received pleural biopsy via dual-function semi-rigid thoracoscopy.
223495261|NCT07114783|DEVICE|Rigid thoracoscopy|Patients received pleural biopsy via rigid thoracoscopy.
223589437|NCT00084487|DRUG|becatecarin|Given IV
223589438|NCT00520260|DRUG|bromfenac|0.09%, BID, 6 weeks
223589439|NCT00520260|DRUG|ketorolac|0.4%, BID, 6 weeks
223589440|NCT06259682|BEHAVIORAL|Paradoxical Intention|Paradoxical intention (PI). PI is described as instructing patients with sleep onset insomnia to try to remain awake for as long as possible rather than to focus on trying to fall asleep
223589441|NCT02982083|DRUG|Raloxifene hydrochloride|20 patients consume raloxifene hydrochloride oral tablet daily for one year.
223589442|NCT02982083|DRUG|Placebo Oral Tablet|20 patients consume placebo oral tablets daily for one year.
223589443|NCT00565136|DEVICE|TOPAS|A mesh sling permanently implanted to increase pelvic floor support
223589444|NCT04893499|BEHAVIORAL|Chios mastic water|Participants randomized to this intervention arm will be provided with a sparkling water enriched with the natural mastic aqueous extract (0.06%), a by-product of Chios mastic processing, and will be asked to consume it daily (3 bottles of 200 mL each) for 3 months. Participants will also be instructed to keep the use of medication and dietary supplements stable and preserve their typical lifestyle habits throughout the study.
223589445|NCT04893499|BEHAVIORAL|Placebo water|Participants randomized to this intervention arm will be provided with a standard sparkling water and will be asked to consume it daily (3 bottles of 200 mL each) for 3 months. Participants will also be instructed to keep the use of medication and dietary supplements stable and preserve their typical lifestyle habits throughout the study.
223745768|NCT05839522|DIAGNOSTIC_TEST|Point-of-care hepatitis C antibody test|Qualitative point-of-care test for hepatitis C antibodies (saliva sample)
223495262|NCT07115056|DRUG|Tranexamic Acid (TXA)|Oral tranexamic acid (TXA) is administered at a dose of 1.95 grams per day, divided into three 650 mg capsules taken once daily, starting on postoperative day (POD) 1 through POD 10 (10 total doses; 30 capsules) to the treatment group.
223495263|NCT07115056|DRUG|Placebo|Participants in this arm will receive oral placebo capsules (microcrystalline cellulose), 3 capsules daily from postoperative day (POD) 1 to POD 10, for a total of 10 doses (30 capsules).
223495264|NCT07113756|DRUG|topical metformin 30% cream|"each patient will use topical metformin 30% cream twice daily for 12 weeks.~o Preparation of metformin 30% cream: Weighing 30 gm standard metformin ( E. Merck ) supplied by chemtech. Using digital balance then Grinding the powder by pestle \& Morter then Adding 30 ml propylene glycol and alcohol to reach a total 100 gm weight then adding parabens mix as preservative with 0.5 gm then mix thoroughly followed by Levegating \& mixing then divide to smaller well tighten closure with labels"
223495265|NCT07113756|DRUG|betamethasone valerate.1% cream|"each patient (age, sex and BMI matched) will use topical betamethasone valerate 0.1% cream twice daily for 12 weeks.~o Manufactured by Egyptian international pharmaceutical industries co. E.I.P.I.C.O. and will be purchased from local pharmacy, Sohag, Egypt."
223495266|NCT07116356|DIAGNOSTIC_TEST|Antibiotic administration|different samples were collected from patients admitted at oncology center at sohag
223495267|NCT07116356|DIAGNOSTIC_TEST|Molecular detection of antibiotic resistance|"Molecular detection of carbapenem resistant genes:~* Extraction of nucleic acid from isolated organisms by boiling.~* Primers will be used for detection of carbaenem resistant genes"
223495268|NCT07114978|DEVICE|Echocardiography|simple, bedsided, non-invasive
223495269|NCT07115316|OTHER|Exercises|"1. Nordic hamstring curls~2. Seated leg curls~3. Prone leg curls~4. Knee Straightening (Extension)~5. Knee Bend (Flexion)~6. Inner Range Quads~7. Straight Leg Raise~8. Lunge to Split Lunge~9. Single Leg Sit to Stand~10. Standing Hamstring Curls~11. Double/Single Leg Bridge~12. Side Lie Hip Abductions~13. Crab Walks~14. Forward Step Ups~15. Calf Raises~16. Single Leg Balance~17. Clock Face Mini Squat~18. Arabesque Clock~19. Two-Legged Jump / Single-Legged Hop"
223495270|NCT07111507|DRUG|Tarlatamab|Patients receive lower dose of tarlatamab on Cycle 1 Day 1 (D1) followed by the full dose on Cycle 1 days 8, 15 and days 1 and 15 for all subsequent cycles.
223495271|NCT07116473|DRUG|Acoramidis (AG10)|TTR stabilizer administered orally twice daily (BID)
223495272|NCT07114926|DIETARY_SUPPLEMENT|Taiwanese green propolis|"Intervention Details:~Experimental Group: Take two capsules of Taiwan Green Propolis (each containing 500 mg/mL of propolis) before breakfast and dinner daily, totaling four capsules/day for 12 consecutive weeks.~During the intervention period, both groups will maintain their usual diet and activity levels and receive the same health education on nutrition and exercise."
223495273|NCT07114926|DIETARY_SUPPLEMENT|placebo|Take placebo capsules identical in appearance, smell, and content, with the same dosage and frequency.
223495274|NCT07114666|BIOLOGICAL|XH001|mRNA neoantigen cancer vaccine
223495275|NCT07114666|DRUG|Chemotherapy|Gemcitabine+Capecitabine or Oxaliplatin+lrinotecan+Calcium folinate+5-FU
223495276|NCT07115836|PROCEDURE|Standard duodenal switch|Standard duodenal switch as second stage surgery after a sleeve gastrectomy (100cm common channel and 150cm alimentary limb)
223495277|NCT07115836|PROCEDURE|Single-anastomosis duodenal switch|Single-anastomosis duodeno-ileal anastomosis as second stage surgery after a sleeve gastrectomy (250cm common channel)
223495278|NCT06918704|BEHAVIORAL|Coherence|Coherence is a music-based rhythm training app.
223495279|NCT06918704|BEHAVIORAL|Worder|Worder is a word search app.
223495280|NCT07115719|OTHER|No Intervention: Observational Cohort|NO INTERVENTION
223589446|NCT04893499|BEHAVIORAL|Chios mastic fruit juice|Participants randomized to this intervention arm will be provided with a sparkling fruit juice enriched with the natural mastic aqueous extract (0.55%), a by-product of Chios mastic processing, and will be asked to consume it daily (3 bottles of 200 mL each) for 3 months. Participants will also be instructed to keep the use of medication and dietary supplements stable and preserve their typical lifestyle habits throughout the study.
223745769|NCT05839522|DIAGNOSTIC_TEST|Point-of-care hepatitis C RNA test|Hepatitis C Viral Load point-of-care test (fingerstick wholeblood sample)
223495281|NCT07115641|DRUG|Huoluo Pills|Huoluo Pills: Orally take 1 pill once, twice a day (swallow with warm water)
223745770|NCT05839522|DIAGNOSTIC_TEST|Point-of-care hepatitis B surface antibody test|Qualitative hepatitis B surface antibody point-of-care test (fingerstick wholeblood sample)
223745771|NCT05839522|DIAGNOSTIC_TEST|Point-of-care hepatitis B surface antigen test|Qualitative hepatitis B surface antigen point-of-care test (fingerstick wholeblood sample)
223745772|NCT05839522|DIAGNOSTIC_TEST|Point-of-care HIV antibody test|Qualitative HIV antibody point-of-care test (saliva sample)
224186475|NCT02593331|OTHER|Placebo|Participants will receive a single dose of placebo on Day 1.
223495282|NCT07115641|DRUG|Iguratimod Tablets|Iguratimod Tablets: Orally take 1 tablet once, twice a day (one tablet in the morning and one in the evening, after meals)
223495283|NCT07114991|BEHAVIORAL|E-Bike Commuting|Participants in the intervention group will receive a pedal-assist electric bicycle (e-bike), a helmet, safety training, and a cycling computer. They will be asked to use the e-bike for commuting or personal travel at least four times per week for 12 weeks. E-bike usage will be monitored using a Garmin Edge device. Participants will also complete baseline, 12-week, and 24-week assessments including fitness testing, blood tests, body composition, surveys, and wearable activity monitoring.
223495284|NCT07113873|OTHER|ultra-translucent monolithic multi layered zirconia|laminate veneer
223495285|NCT07113873|OTHER|lithium disilcate ceramics|laminate veneer
223495286|NCT07114094|OTHER|Deprescribing Tool|"Deprescribing Tool will be used for medication review during patient consultation. The prescriber will be encouraged to refer to the tool for medication review of elderly patients aged ≥ 60 years and take deprescribing decision if indicated.~Deprescribing may take place in any of the following ways-~1. Immediate discontinuation of a drug, e.g., a duplicate drug~2. Initiation of gradual tapering of a drug e.g., an anxiolytic, which is no longer indicated~3. Reduction in dose of a drug, e.g., lower dose of an NSAID for relief of symptoms of rheumatoid arthritis Only 1-3 medicines will be deprescribed at a time. Medicines with overlapping indications will not be deprescribed at the same time so it is clear which medicine is responsible if withdrawal effects occur."
223495287|NCT07114848|DRUG|Tamsulosin|Tamsulosin 0.4 mg once daily for 14 days
223495288|NCT07114848|DRUG|solifenacin|Solifenacin 5 mg once daily for 14 day
223495289|NCT07115381|BEHAVIORAL|Therapeutic Horticulture|Therapeutic Horticulture uses plant cultivation and related gardening activities as the medium of action, allowing patients to participate in gardening activities such as planting, maintenance, and harvesting of plants.
223495290|NCT07115381|OTHER|Routine treatment and nursing|The conventional treatment mainly involves the use of antidepressant drugs, supplemented by physical therapy, psychological therapy, and rehabilitation training, etc. The routine care includes admission introduction, health education (manifestations, hazards, treatment methods of depression and non-suicidal self-harm, as well as the importance of following medical advice for treatment), medication guidance, discharge guidance, and psychological care, etc.
223495291|NCT07117825|OTHER|AORTIC DISSECTION CT SCAN ANALYSIS|Patients with type A or type B acute aortic dissection, treated either with medical therapy or with endovascular/open surgery in the study period and who underwent subsequent radiological follow-up.
223495292|NCT07118709|DRUG|KC1086|"Part 1: Dose-escalation phase , five dose groups are included: 1 mg, 2 mg, 4 mg, 6 mg, and 8 mg.~Part 2: Dose-expansion phase, 2 to 3 dose levels will be selected for expansion based on the results of the dose escalation phase."
223495293|NCT07117175|DRUG|Anti-human CD7 CAR-NK cell injection|Administer anti-human CD7 CAR-NK cell injection on D0
223589447|NCT04893499|BEHAVIORAL|Placebo fruit juice|Participants randomized to this intervention arm will be provided with a standard sparkling fruit juice and will be asked to consume it daily (3 bottles of 200 mL each) for 3 months. Participants will also be instructed to keep the use of medication and dietary supplements stable and preserve their typical lifestyle habits throughout the study.
223589448|NCT04300803|BIOLOGICAL|Tafasitamab, 12 mg/kg. 4 week cycles: weekly (Cycle 1-3) to bi-weekly (Cycle 4 onwards), loading dose Cycle 1, day 4. Cycle 4 onwards day 1, day 15 until disease progression|Expanded Access Program, Non-Interventional Study
223589449|NCT06334874|DRUG|Astaxanthin Oral Capsule|12 mg of astaxanthin oral capsule
223589450|NCT06334874|DRUG|Placebo|starch placebo capsule
223589451|NCT01420666|DRUG|Acetaminophen|Acetaminophen 325 mg, three tablets four times a day, orally, with food
223589452|NCT01420666|DRUG|Maxigesic 325|Maxigesic 325 (Acetaminophen 325 mg+ ibuprofen 97.5mg), three tablets four times a day, orally, with food
223589453|NCT01420666|DRUG|Ibuprofen|Ibuprofen 97.5mg, three tablets four times a day, orally, with food
223589454|NCT01420666|DRUG|Placebo|placebo, three tablets four times a day, orally, with food
223589455|NCT05771961|DIAGNOSTIC_TEST|coronary pressure/temperature sensor-tipped guidewire|"In brief, a 6-F angioplasty guiding catheter without side-holes will be used first used to engage the left main coronary artery. A pressure-temperature sensor guidewire ( PressureWire™ X Guidewire) will be used for physiology measurements including IMR measurements.~Pressure measurement from the wire will be first equalized with that of the guiding catheter. Then the pressure sensor will be positioned two-thirds of the way down the LAD artery. Intracoronary nitroglycerin will be administered (100 to 200 μg). Hyperemia will be induced with adenosine intracoronary injections."
223589456|NCT05771961|DIAGNOSTIC_TEST|Angiography-derived index of microcirculatory resistance (IMRangio)|Angiography-derived index of microcirculatory resistance (IMRangio) will be calculated by an anticipated software
223589457|NCT00262990|DRUG|EPO906 (Patupilone)|
223589458|NCT00262990|DRUG|doxorubicin|
223589459|NCT03973294|DEVICE|EIT-measurement|"The use of electrical impedance tomography (EIT) (SentecTom BB2, Landquart, Switzerland) allows the investigators to obtain a visual and quantitative representation of the areas of ventilation and aeration of the lung. The fundamental principle of lung EIT relies on the application of small alternating electrical currents into the thorax and voltage measurements using electrodes on the skin surface generating cross-sectional images representing impedance change in a slice of the thorax. It is a radiation-free imaging method which has the advantage to reveal real-time information.~An array of electrodes (textile belt with 32 integrated electrocardiographic electrodes) has to be placed around the thorax to inject currents and to measure the resulting voltages on the thoracic surface."
223589460|NCT05986903|DRUG|Tumor necrosis factor (TNF)-alpha inhibitors|"Proactive drug monitoring was defined as the assessment of trough concentrations to optimize dosing during induction therapy and intermittently thereafter regardless of symptoms or inflammatory markers.~During induction, the following target concentrations are employed: 25-30 mcg/ml (week 2) and 20 mcg/ml (week 6) for Infliximab and \> 10 mcg/ml (week 2 and 4) for Adalimumab. Checks are performed systematically at week 2 and 6 (infliximab) and at week 4 (adalimumab).~During the maintenance, the targets are 5-10 mcg/ml for Infliximab and 8-12 mcg/ml for Adalimumab. In case of perianal disease, the targets are 7-20 mcg/ml."
223589461|NCT01362452|GENETIC|T-Cell Infusion|Infusion of CD19-specific T cells derived from cord blood (CB) 42 days following stem cell transplantation.
223589462|NCT01362452|PROCEDURE|Cord Blood Infusion|Cord blood infusion on Day 0.
224186476|NCT01714726|DRUG|MEDI2070|1 iv infusion on Week 0 and Week 4
224186477|NCT01714726|DRUG|placebo|1 iv infusion on Week 0 and Week 4
224186478|NCT04037826|DIETARY_SUPPLEMENT|L. reuteri DSM 17938 and L. reuteri ATCC PTA 6475|L. reuteri Gastrus (L. reuteri DSM 17938 and L. reuteri ATCC PTA 6475) at dose of 2x108 Colony Forming Units (CFU) per tablet. One chewable tablet is to be taken twice per day (one in the morning and one in the afternoon) giving a total daily dose of at least 4x108 CFU/day.
223495294|NCT07104110|DRUG|QLH12016|oral AR PROTAC
223495295|NCT07104110|DRUG|abiraterone acetate|oral CYP17 inhibitor
223495296|NCT07104110|DRUG|enzalutamide|oral androgen receptor inhibitor
223495297|NCT06231511|DEVICE|Hip flexion soft exosuit|Participants will utilize a Wyss designed hip flexion soft exosuit. This device has a small rope winch at the front of the hip connected to a functional textile waistband and thigh band. It applies an assistive torque in response to wearable sensor measurements.
223495298|NCT06231511|DEVICE|ReWalk ReStore soft exosuit|Participants will utilize the ReWalk ReStore ankle soft exosuit. This device provides dynamic plantarflexion and dorsiflexion during walking intended to restore paretic limb function resulting in improved gait symmetry, reduced energy cost of walking and improved stability. The exosuits consists of a body-worn actuation unit containing motors, gears, and pulleys that when powered generate forces that are transmitted via Bowden cables to functional textiles anchored proximal and distal to a joint. This actuation occurs in response to signals from embedded wearable sensors.
223495299|NCT06231511|OTHER|Conventional physical therapy|Participants will complete conventional physical therapy without use of exosuits during the course of their inpatient rehabilitation stay.
223495300|NCT07119619|PROCEDURE|Regenerative Endodontic Treatment Using a Blood Clot as a Scaffold|During the initial visit, the teeth were anesthetized using inferior alveolar block anesthesia. The endodontic access cavity was then opened. Each canal was irrigated with 2.5% NaOCl and saline. The canals were dried with paper points. Ca(OH)2 was placed in the canals with the objective of achieving an antimicrobial effect. After the application of root canal disinfectant, the opened cavity was sealed with a temporary filling material.The patient has been scheduled for a follow-up appointment within one to four weeks. During the second appointment, local anesthesia was performed using an anesthetic agent that did not contain a vasoconstrictor. The canals were irrigated with 17% EDTA and dried with paper points. Bleeding was induced by instrumentation with a K-type file, at 2 mm past the apical foramen, thus creating a blood clot within the canal. MTA was applied on the scaffold as capping material.
223495301|NCT07119619|PROCEDURE|Regenerative Endodontic Treatment Using a Chitosan as a Scaffold|"During the initial visit, the teeth were anesthetized using inferior alveolar block anesthesia. The endodontic access cavity was then opened. Each canal was irrigated with 2.5% NaOCl and saline. The canals were dried with paper points. Ca(OH)2 was placed in the canals with the objective of achieving an antimicrobial effect. After the application of root canal disinfectant, the opened cavity was sealed with a temporary filling material. The patient has been scheduled for a follow-up appointment within one to four weeks.~During the second appointment, local anesthesia was performed using an anesthetic agent that did not contain a vasoconstrictor. The canals were irrigated with 17% EDTA and dried with paper points.Chitosan in gel form was placed into the root canal space with the help of an injector.MTA was applied on the scaffold as capping material."
223495302|NCT07119619|PROCEDURE|Regenerative Endodontic Treatment Using a Platelet Rich Fibrin as a Scaffold|During the initial visit, the teeth were anesthetized using inferior alveolar block anesthesia. The endodontic access cavity was then opened. Each canal was irrigated with 2.5% NaOCl and saline. The canals were dried with paper points. Ca(OH)2 was placed in the canals with the objective of achieving an antimicrobial effect. After the application of root canal disinfectant, the opened cavity was sealed with a temporary filling material.The patient has been scheduled for a follow-up appointment within one to four weeks. During the second appointment, local anesthesia was performed using an anesthetic agent that did not contain a vasoconstrictor. The canals were irrigated with 17% EDTA and dried with paper points.Ten milliliters of venous blood was collected from the patient and immediately placed in a centrifuge at 3000 rpm for 10 minutes. The prepared PRF was placed in the canal space. MTA was applied on the scaffold as capping material.
223495303|NCT07120308|DRUG|ZKY001 eye drops|Administer to eyes
223495304|NCT07120308|DRUG|Vehicle (placebo)|Administer to eyes
223495305|NCT07119814|DEVICE|Conventional Separators placement|Safe T separators and conventional elastomeric separators will be placed in patients of fixed orthodontic treatment.
223495306|NCT07119814|DEVICE|Safe T separator|Safe T separators will be placed in patients of fixed orthodontic treatment
223495307|NCT07119450|DRUG|GZR18 injection、[14C]GZR18 injection|Participants will get a single dose of \[14C\]GZR18 injection
223495308|NCT07120646|OTHER|Questionnaire, actigraphy measurement and sleep diary|Baseline questionnaires (measuring socio-demographic and health-related information, as well as most outcome measures), followed by 2 weeks of actigraphy measurement and daily sleep diary.
223495309|NCT07121699|DRUG|Inotrope|Hypotensive attacks with MAP below 55 mmHg or prolonged duration (2 minutes or more) will be treated with ephedrine 0.1 mg/kg.
223495310|NCT07118956|OTHER|Active RAVANS|Real RAVANS was performed on the cymba conchae of left ear in the vicinity of the auricular branch vagus nerve according to the Participant's respiratory rhythm. Stimulation parameters: frequency = 100 Hz; pulse width = 200 us, once a day, 30 minutes each time, one second of stimulation occurs during exhalation.
223495311|NCT07118956|OTHER|Sham RAVANS|Sham RAVANS was performed on on the cymba conchae of left ear according to the Participant's respiratory rhythm. Stimulation parameters: frequency = 100 Hz; pulse width = 200 us, once a day, 30 minutes each time, one second of stimulation occurs during exhalation and the interval between stimulus is 29 seconds.
223589463|NCT05941260|DIAGNOSTIC_TEST|Computational fluid dynamics (CFD)|"\- Video recording starts in an antegrade manner starting from the bladder neck through the prostatic urethra and ends after the verumontanum at the external sphincter. Videos were taken with a very slow movement of the endoscope to ensure the sharpness of the data and to prevent complications in post-processing.~The focal length and zoom of the endoscope camera were set at the beginning and maintained throughout the capturing, while the angle of the lens changes to capture the widest field possible for each targeted area.~* Computational fluid dynamics (CFD) can then be used to numerically model the behavior of the flow inside the urethra by solving the governing equations of the flow using the finite volume method.~* Through which we can develop a urodynamic computer model to simulate the bladder-urethral passage and predict the success of the resection undertaken by the surgeon. No extra intervention will be provided to our patients apart from their routine surgery."
223589464|NCT00001136|BIOLOGICAL|ALVAC-HIV MN120TMG (vCP205)|
223589465|NCT05957029|DEVICE|NuEra Tight RF system|monopolar radiofrequency device
223589466|NCT02517372|DRUG|CRD007|
223589467|NCT02528357|DRUG|GSK3174998|Lyophilized powder 40 mg reconstituted to get a dose range of 0.003 to \<=10 mg/kg to be given as IV infusion for 30 minutes (min), Q3W
223495312|NCT07117851|DRUG|Disitamab Vedotin combined with Bicalutamide|Single Group Assignment
223495313|NCT07117071|OTHER|collection of medical data|collection of medical data : Age, Sex, Previous cataract surgery, Cellularity, Dermatological pathology, results of screening of Fuchs endothelial corneal dystrophy by Specular microscopy
223495314|NCT03762447|DRUG|INCB086550|INCB086550 will be orally administered once or twice daily in continuous or intermittent dose schedules.
223495315|NCT07119411|OTHER|ICU Beacon|Availability of a proprietary clinician awareness for potential organ deterioration software to treating clinicians (ICU Beacon) in addition to the standard of care.
223589468|NCT02528357|DRUG|Pembrolizumab|Pembrolizumab as 100 mg/4 milliliter (mL) solution (dose: 200 mg) to be given as IV infusion for 30 min, Q3W
223745773|NCT05839522|BEHAVIORAL|Interview-style survey|Interview-style survey regarding demographics, risk behaviours, BBV testing and treatment history, and point-of-care testing acceptability
224186479|NCT04037826|DIETARY_SUPPLEMENT|Placebo|Placebo
223495316|NCT05911269|OTHER|TiMBRe|"1 \& 2 Music Listening~* Live music played by the music therapist (e.g., guitar, voice) and AYA selected music will be used to facilitate attention to the present moment and provide cues for breathing/relaxation.~  3 \& 4 Music Facilitated Breathing~* The therapist will lead participants in music facilitated breathing exercises using rhythmic features of the music to cue structured breathing for relaxation and self-awareness~  5 \& 6 Music Facilitated Progressive Muscle Relaxation for Stress Reduction~* Using music as a structured auditory cue for tensing and releasing of muscles.~  7 Body Percussion~* The therapist will lead participants in a hands-on body percussion activity to bring attention to the sound of rhythm, sensation in their hands and body.~  8 Participants Choice~* will be selected by the participant."
223495317|NCT05911269|OTHER|Control|Standard of care study staff calls and cancer survivorship resources
223495318|NCT07120191|DEVICE|post op communication software|MyConnect Post Op is a communication tool that utilizes Technology Assisted Conversation to aid in the recovery of total knee and hip replacement patients
223495319|NCT07120282|DRUG|Tislelizumab 400 mg iv, q6w, for up to 1 year for pts in intervention group|Tislelizumab 400 mg iv, q6w, for up to 1 year; patients are permitted to receive concurrent adjuvant platinum-based doublet chemotherapy (q3w, up to 4 cycles) starting from the first dose of tislelizumab; during concurrent chemotherapy, a tislelizumab dosage of 200 mg iv, q3w is allowed.
223495320|NCT07122492|BEHAVIORAL|FoRtitude 2.0|A website and an interactive text-messaging feature
223495321|NCT07122492|BEHAVIORAL|Attention Control|Access to the non-interactive study intervention website that lists links to help you access websites that provide information to read and resources for breast cancer survivors.
223495322|NCT07123974|BEHAVIORAL|Dialectical Behaviour Therapy for Post-Traumatic Stress Disorder (DBT-PTSD)|DBT-PTSD is 45-week individual psychotherapy (DBT-PTSD) designed to treat adults presenting with both borderline personality disorder (BPD) and complex post-traumatic stress disorder (C-PTSD). The intervention integrates dialectical behavior therapy (DBT) skills, trauma-focused exposure-based interventions, and strategies from compassion-focused therapy and acceptance and commitment therapy. All participants will receive the full sequence of the therapy in outpatient settings, following the structured treatment protocol.
223495323|NCT07122544|BEHAVIORAL|Therapeutic stay in subterranean sanatorium chambers (microclimate therapy)|"Characteristics of the underground environment in the Wieliczka sanatorium chambers:~Stable climatic conditions: relative humidity ranging from 60-75%, temperature between 12.9-14.5°C; High chemical and biological air purity; Mineral content in the air: 2.7-8.1 mg/m³, consisting mainly of chloride, sodium, potassium, calcium, and fluoride ions; Air ionization: 1,200-4,700 aeroions/cm³ of air. Elevated atmospheric pressure: increased by approximately 16-20 mmHg compared to surface conditions."
223495324|NCT07122544|BEHAVIORAL|Breathing exercises|30 minutes daily. Breathing exercises will include active respiratory exercises, drainage and effective coughing techniques, resistance training of the respiratory muscles, chest mobilization and relaxation exercises, breathing through pursed lips, as well as short and prolonged exhalation exercises.
223495325|NCT07122544|BEHAVIORAL|General fitness exercises|30 minutes daily. General conditioning exercises will incorporate components aimed at improving overall aerobic capacity (e.g., walking-based activities, dance routines, step exercises), flexibility and coordination (e.g., stretching and balance exercises), and strength (e.g., exercises using resistance bands or dumbbells). The training will be conducted in interval, circuit, and free-form formats. Resistance levels will be individually adjusted to the patient's capacity.
223495326|NCT07122544|BEHAVIORAL|Relaxation training|30 minutes, once during the entire cycle. Relaxation training will include rest in a seated position, with dimmed lighting and calming music.
223495327|NCT07122544|BEHAVIORAL|Health education|"Educational materials in printed form for distribution covering the following topics:~COPD - information about the disease;~Breathing exercises and bronchial hygiene;~Benefits of physical activity, including examples of exercises that can be performed at home."
223495328|NCT07123701|DRUG|Tanshinone capsules|Tanshinone capsules were used in this intervention for COVID-19 patients
223495329|NCT07123779|BIOLOGICAL|HS235|Subcutaneous Injection
223495330|NCT07123779|OTHER|Placebo|Subcutaneous Injection
223495331|NCT07123714|PROCEDURE|Nebulization of magnesium sulfate|patient will be nebulized with 5 mg magnesium sulfate (5 ml) 15 minutes before induction of anesthesia
223589469|NCT05715515|DIAGNOSTIC_TEST|Panbio™|"The Panbio™ COVID-19/Flu A\&B Rapid Panel Professional use device is a visual lateral flow assay, for rapid immunochromatographic qualitative detection of COVID-19 antigen, Influenza A antigen and Influenza B antigen in nasopharyngeal swabs, collected by a trained health worker.~The Panbio™ COVID-19/Flu A\&B Rapid Panel Self-Test device is a visual lateral flow assay, for rapid immunochromatographic qualitative detection of COVID-19 antigen, Influenza A antigen and Influenza B antigen in self-collected mid-turbinate nasal swabs. The test is designed to be used by lay users"
223589470|NCT03989323|OTHER|Estimation of the incidence of the irAE|Assessment of the incidence of the irAE in patients treated with immunotherapy at the Hospices Civils de Lyon (irAE of all grades and from all organs) and creation of a biological collection of blood, plasma, serum and PBMCs from patients before treatment, under treatment and at the onset of irAEs.
223589471|NCT01073124|PROCEDURE|Saline Load Test|Intraarticular injection of dilute methylene blue dye (1 ml per 500 ml normal saline) or normal saline into the knee joint through a lateral suprapatellar injection site. Maximum injection of 180 ml.
223589472|NCT00412074|DRUG|400 IU Vitamin D3 (cholecalciferol)|400 IU vitamin D3/day given to lactating mother and 400 IU vitamin D3/day given as oral supplement to her infant
223589473|NCT00412074|DRUG|2400 IU Vitamin D3 (cholecalciferol)|2400 IU vitamin D3/day given to lactating mother and 0 IU vitamin D3/day (placebo) given as oral supplement to her infant
223589474|NCT00412074|DRUG|6400 IU Vitamin D3 (cholecalciferol)|6400 IU vitamin D3/day given to lactating mother and 0 IU vitamin D3/day (placebo) given as oral supplement to her infant
223495332|NCT07122557|DRUG|Biktarvy|this study applies secondary use of data collected from medical health records
223495333|NCT07123376|DRUG|HRS-9231|HRS-9231 was administered intravenously;
223495334|NCT07123376|DRUG|Placebo|Placebo was administered intravenously.
223495335|NCT07123935|DEVICE|RenalGuard® Therapy|RenalGuard Therapy®
223495336|NCT07123935|OTHER|Standard of Care (SOC)|Standard of care
224186480|NCT05697276|DRUG|Lidocaine|Patients will receive 20 ml of 1% lidocaine with 1:100,000 epinephrine (buffered 10:1 with 8.4% sodium bicarbonate). Thirty minutes before carpal tunnel release surgery, 10 mL will be injected subcutaneously, and 10 mL will be injected into the carpal tunnel.
224186481|NCT05697276|DRUG|Bupivacain|Bupivacaine: Patients will receive 10 ml of 0.5% bupivacaine + 10 ml of 1% lidocaine with 1:100,000 epinephrine (buffered 10:1 with 8.4% sodium bicarbonate). Thirty minutes before carpal tunnel release surgery, 10 mL will be injected subcutaneously, and 10 mL will be injected into the carpal tunnel.
224186482|NCT06426901|OTHER|Effects of Tan Tui Exercises on Strength and Performance of Football Players.|Tan Tui, Exercises Tan Tui, is a style of traditional Chinese martial art that emphasizes leg techniques, agility, and conditioning. Basic Kicking Drills. Stance Work. Forms (Taolu) Pattern Drills. Conditioning.Sparring (San Shou). This protocol will be implemented by District Physiotherapist who will visit the mentioned Football academies in group session.
224186483|NCT04165850|DRUG|Fixed dose combination Ciprofloxacin/Celecoxib|Fixed dose Ciprofloxacin and Celecoxib capsule to be taken thrice daily, total dose 909mg/day
224186484|NCT05117658|DRUG|HA121-28 tablet|HA121-28 tablet, 450 mg, po, QD×21 days, every 4 weeks (28 days)
223495337|NCT07123233|BEHAVIORAL|Pain Reprocessing Therapy|"One cohort of 30 patients (PRT+TAU group) will receive eight sessions of Pain Reprocessing Therapy (PRT) in addition to Treatment-as-Usual (TAU). PRT is a cognitive-behavioral-inspired approach aimed at helping patients reinterpret chronic pain as brain-generated rather than structurally caused.~A second cohort of 30 patients (TAU group) will undergo the same assessment phases but will receive only Treatment-as-Usual without PRT.~Use this module to add a description of each group or cohort in the study and to list any interventions of interest."
223495338|NCT07123233|BEHAVIORAL|Usual Therapy|Patients undergo yhe usual pharmacological tretment as prescrived by neurologist
224186485|NCT03698058|DIETARY_SUPPLEMENT|Toddler milk|Commercially available toddler milk
224186486|NCT01321086|BEHAVIORAL|Motivational Interviewing|9 sessions of MI from baseline to six months
224186487|NCT01321086|BEHAVIORAL|PACE|9 sessions of PACE delivered from baseline to six months
224186488|NCT06522763|DRUG|Sulfadoxine 500 MG / Pyrimethamine 25 MG dispersible tablets.|The 500/25 mg sulfadoxine/pyrimethamine tablet will be dispersed in approximately 10 mL of water in a cup, the mixture obtained will be shaken thoroughly and given immediately to the subject to drink the contents, then the cup will be rinsed with additional approximately 10 mL of water and have the subject drink the contents to assure that the whole dose is taken.
224186489|NCT06522763|DRUG|Sulfadoxine 500 MG / Pyrimethamine 25 MG dispersible tablets in SPAQ|The 500/25 mg sulfadoxine/pyrimethamine tablet will be dispersed in approximately 10 mL of water in a cup, the mixture obtained will be shaken thoroughly and given immediately to the subject to drink the contents, then the cup will be rinsed with additional approximately 10 mL of water and have the subject drink the contents to assure that the whole dose is taken.
224186490|NCT04704908|DRUG|Recombinant Human Papillomavirus Bivalent (Types 16, 18) Vaccine (Escherichia coli)|The bivalent HPV-16/18 vaccine was a mixture of two aluminum hydroxide adjuvant-absorbed recombinant L1 VLPs of HPV-16 and HPV-18 expressed in E. coli. A 0.5 ml dose of the bivalent HPV test vaccine comprised 40 μg of HPV-16 and 20 μg of HPV-18 L1 VLPs absorbed with 208 μg of aluminum adjuvant
223495339|NCT07123415|DRUG|APX-343A|Oral administration twice daily
223495340|NCT07123415|DRUG|Pembrolizumab|intravenous \[IV\]
223589475|NCT03871660|DEVICE|FreeStyle Libre Pro|Flash glucose monitoring device. Measures patients interstitial glucose levels continuously.
223589476|NCT04439994|OTHER|hypertonic saline|The participant will be given i.d. in 0.1 mL volumes of a hypertonic saline solution
223589477|NCT04439994|OTHER|Saline injection|The participant will be given i.d. in 0.1 mL volumes of a saline solution
223589478|NCT04439994|PROCEDURE|Blood sampling|Whole blood samples (5 mL per each time point, a total of 20 mL per subject) will be collected
223589479|NCT01399268|DRUG|Hydrocortisone|Prepared by pharmacy, 100 mg, IV, every 8 hours, 3 times
223495341|NCT07122128|DIAGNOSTIC_TEST|saliva a a diagnostic tool for early detection of oral cancer|Three groups will be compared on the basis of cytology, genes and biochemical analysis
223495342|NCT07122024|DRUG|Keverprazan 10 days|"Keverprazan dual therapy for 10 days (K10 group):~Keverprazan 20 mg per dose, twice daily (bid) + Amoxicillin 1 g per dose, three times (tid) daily, for 10 days."
223495343|NCT07122024|DRUG|Keverprazan 14 days|Keverprazan dual therapy for 14 days (K14 group): Keverprazan 20 mg, bid + Amoxicillin 1 g, tid, for 14 days.
223495344|NCT07122024|DRUG|Rabeprazole|Rabeprazole quadruple therapy for 14 days (R14 group): Rabeprazole sodium 10 mg + Amoxicillin 1 g + Clarithromycin 500 mg + Colloidal pectin bismuth 200 mg, bid, for 14 days.
223589480|NCT01399268|DRUG|Saline|Prepared by pharmacy same volume as study drug, IV, every 8 hours 3 times
223589481|NCT06175013|DEVICE|Sérum PURIFIANT|Application of Sérum PURIFIANT only, twice daily during 112 days
223589482|NCT06175013|DEVICE|Sérum PURIFIANT in association Sérum BOOSTER|Application of Sérum PURIFIANT twice daily during 112 days AND Application of Sérum BOOSTER before the Serum PURIFIANT, twice weekly
223589483|NCT04190524|OTHER|Application of cricoid pressure|The study first involves recording a baseline image of the neck anatomy using ultrasound, which is a non-invasive, non-irradiating, non-painful imaging modality. Once the baseline anatomy has been imaged, conventional cricoid pressure will be applied with fingers and/or with the ultrasound probe itself and an image will be recorded. The force applied to the cricoid cartilage will be 30 newtons, as determined by a thin force measurement sensor (Tekscan flexiforce sensor) placed in between the patient's skin and the finger (or ultrasound probe).
223745774|NCT04757727|OTHER|Decriptive study of EDB|data on EDB will be register
224186491|NCT04249908|DRUG|Besifovir Dipivoxil Maleate|Besifovir 150 mg q.d.
224186492|NCT04892875|DRUG|Zimberelimab|Zimberelimab will be administered at a dose of 360 mg IV on Day 1 of each 21-day cycle for up to 11 cycles.
224186493|NCT04892875|DRUG|Etrumadenant|Etrumadenant will be administered at a dose of 150 mg by mouth once daily on days 1-21 of each 21-day cycle for up to 11 cycles.
224186494|NCT04892875|DRUG|Cisplatin|Concurrent weekly cisplatin and radiation will be administered as part of the subject's standard of care. Cisplatin and radiation will be initiated on the same day and continue for up to 7.5 weeks.
224308798|NCT01118897|RADIATION|Tomotherapy|"Radiotherapy 57-60 Gy in 25 fraction to PTV boost (SIBV - simultaneous integrated Boost volume) (2.3-2.4Gy/Fr)~Concurrent chemotherapy Weekly concurrent CT schedule: Inj Gemcitabine 300 mg/m2 weekly during RT.~Surgery: All patients will be evaluated for surgery in the joint clinic by surgeons and other treating physicians at 6-8 weeks post CT-RT. PET CT Scan will be used as the imaging modality. Patients suitable for R0 resection will be planned for surgery. Inoperable patients will be treated with palliative chemotherapy."
224308799|NCT03710993|DEVICE|oximeter|Participants breathe a controlled gas mixture to induce several reduced oxygen states while oximeter measurements are taken for comparison to corresponding transfer standard and reference devices to assess oximeter calibration and accuracy.
224308800|NCT04389892|DIAGNOSTIC_TEST|Contrast enhanced harmonic endoscopic ultrasound|"During the echoendoscopy the image was fixed on the region of interest (pancreatic cyst) and the extended pure harmonic detection mode was selected. 2,4ml contrast enhancement (Sonovue-Bracco Italy) was injected in the right antecubital vein of the participants followed by a flush of 5ml 0.9% saline solution to ensure that the entire quantity of the agent goes in to the blood flow.~After the administration the pancreatic cyst was observed for at least 120 seconds.We followed the enhancing behavior of the cyst wall, the septa and the solid components. Arterial enhancement (contrast uptake) was considered the first 25-30 seconds after injection and the venous phase (wah-out) 30-45 seconds after injection.~EUS-FNA was performed in all patients without contraindications"
224308801|NCT02621749|DEVICE|Renal replacement therapy|Patients receive renal replacement therapy according to institutional standards
223495345|NCT07122245|BEHAVIORAL|Demographics and risk factors of lung cancer|A retrospective cohort study will be conducted on bronchogenic carcinoma patients who had been presented to and diagnosed at chest diseases department, Oncology Center Mansoura University (OCMU).
224186495|NCT04892875|RADIATION|Radiation|Concurrent weekly cisplatin and radiation will be administered as part of the subject's standard of care. Cisplatin and radiation will be initiated on the same day and continue for up to 7.5 weeks.
223495346|NCT07122947|DEVICE|Apple Watch: AFib History|The Apple Watch AFib History feature uses PPG pulse rhythm data to detect and quantify the burden of atrial fibrillation.
223495347|NCT07122947|DEVICE|Zio Patch|The 14-day Zio Patch monitoring device (iRhythm Technologies, Inc., San Francisco, CA) uses continuous ambulatory ECG monitoring to quantify the burden of atrial fibrillation.
223495348|NCT07125573|DRUG|Saline Solution (NaCl 0,9%)|Administer 0.5 ug/kg of dexmedetomidine 10 minutes before surgery, and maintain at 0.4 ug/kg/h after intubation until 30 minutes before the end of surgery,Administer saline solution one minute after induction of anesthesia and continue until 30 minutes before the end of surgery.
223495349|NCT07125573|DRUG|Low-dose esketamine infusion|Administer 0.5 ug/kg of dexmedetomidine 10 minutes before surgery, and maintain at 0.4 ug/kg/h after intubation until 30 minutes before the end of surgery, administer esketamine 0.2 mg/kg 1 minute after induction of anesthesia, maintain at 2 μg/kg/min after intubation until 30 minutes before the end of surgery.
223589484|NCT04190524|OTHER|Application of Left lateral paratracheal pressure|Next, left lateral paralaryngeal pressure will be applied at the level of the cricoid cartilage with fingers and/or the ultrasound probe itself, and the image will again be recorded. Left lateral paralaryngeal pressure will be 30 newtons, as determined by a thin force measurement sensor placed in between the patient's skin and the finger (or ultrasound probe).
224186496|NCT05626556|OTHER|SAVE system|The SAVE system will be implemented in end users' homes. Flood sensors will be installed in the bathroom and kitchen, presence sensors in the living room and bedroom, and the contact sensor will be installed at the entrance door. For the best user experience, the installation of the required software (for the sensors kit and the smartwatch) was done on the users' own smartphones. Thus, at the end of the installation, users will have the Aqara Home System in their homes (5 sensors and a sensor hub), a Samsung smartwatch and a SAVE Sensors Adapter, all of which are connected to a router with unlimited internet access.
224186497|NCT01054209|DEVICE|Warming with warming mattress|"Reusable pressure relieving warming mattress. Principle use is to warm patients to prevent hypothermia peri-operatively.~Inditherm Alpha systems, OTM1: 1900mm x 585mm"
224186498|NCT00821600|DRUG|risperidone IR and LAI formulation|1 mg risperidone IR single injection, followed after 7 to 14 days with 75mg risperidone 4-week-LAI single injection
224186499|NCT04786327|PROCEDURE|Minimal invasive flap technique|contained defect treated with Minimally invasive flap
224186500|NCT04786327|PROCEDURE|Minimally invasive flap with root conditioning (EDTA) and platelet rich fibrin|contained defect treated by Minimally invasive flap with root conditioning (EDTA) and platelet rich fibrin graft
224186501|NCT04786327|COMBINATION_PRODUCT|minimally invasive flap with root contioning by EDTA and growth factor enhanced matrix GEM21S|contained defect treated with Minimally invasive flap with root conditioning (EDTA) and growth factor enhanced matrix application in the defect
224186502|NCT04847427|OTHER|Core exercises training|"Participants will perform:~1. Squats, 4 sets of 5 repetitions at 60% 1RM~2. Deadlifts, 4 sets of 5 repetitions at 60% 1RM~3. Lunges, 4 sets of 5 repetitions at 60% 1RM~4. Step ups, 4 sets of 5 repetitions at 60% 1RM"
224186503|NCT04847427|OTHER|Structural exercises training|"Participants will perform:~1. Snatch, 4 sets of 5 repetitions at 60% 1RM~2. Hang clean, 4 sets of 5 repetitions at 60% 1RM~3. Push jerk, 4 sets of 5 repetitions at 60% 1RM~4. Split push jerk, 4 sets of 5 repetitions at 60% 1RM"
223589485|NCT02438813|DRUG|Deoxycholic acid|Deoxycholic acid (ATX-101) injection as the treatment of SMF as per standard of care in clinical practice.
224186504|NCT04847427|OTHER|Accentuated eccentric exercises training|"Participants will perform:~1. Deadlifts - squat jump, 4 sets of 5 repetitions at 30% body mass (BM)~2. Step down - squat jump, 4 sets of 5 repetitions at 30% BM~3. Step down - lunges, 4 sets of 5 repetitions at 30% BM~4. Bulgarian squat jumps, 4 sets of 5 repetitions at 30% BM"
224186505|NCT04847427|OTHER|Control trial|Participants will perform all the measurements that are comprised in the experimental conditions without performing any exercise protocol
224186506|NCT02226380|DRUG|mFOLFOX6 regimen|oxaliplatin 85 mg/m2 and folinic acid 400 mg/m2 are administered intravenously for 2 hours on day 1 following by 5-FU at 2,400 mg/m2 by continuous infusion for 46hours every 2 weeks for 3 cycles before performing surgery
224308802|NCT04888559|OTHER|Breakfast product: Whole grain|This intervention is a whole grain-based breakfast product containing oats and barley.
224308803|NCT04888559|OTHER|Breakfast product: Reference|This intervention is a rice-based breakfast product.
224186507|NCT00267826|DRUG|Rituximab|Intravenous infusion of 1000mg Rituximab (anti-CD20) on days 1 and 15 to patients with atopic dermatitis
224186508|NCT02027766|OTHER|Calf muscle stretching|
224186509|NCT04706065|GENETIC|SHMT1 polymorphism|It is to identify the role of SHMT1polymorphism in PD and examine the relationship between it and Severity of PD.
224186510|NCT00156624|DRUG|Balloon Angioplasty with or without drug administration|
224186511|NCT04136041|DEVICE|Smartphone Application|The experimental group will watch movies using the Smartphone application for at least 10 min a day for 5 weeks.
224186512|NCT01697124|BEHAVIORAL|SPARK-EC|The CIA study was a 5 month physical activity change intervention that utilized the SPARK-EC curriculum as the intervention. The SPARK-EC curriculum was designed to be a quality, comprehensive physical activity program for the preschool setting. Pre-and Post-intervention assessments were conducted
224186513|NCT02822118|DRUG|Chang'an I Recipe|Patients in this group were administered the Chang'an I Recipe, 150ml/bag, 3 times/day for 8 weeks.
224186514|NCT02822118|DRUG|Placebo|Patients in this group were administered the placebo, 150ml/bag, times/day for 8 weeks.
223495350|NCT07125573|DRUG|High-dose esketamine infusion|Administer 0.5 ug/kg of dexmedetomidine 10 minutes before surgery, and maintain at 0.4 ug/kg/h after intubation until 30 minutes before the end of surgery, Administer 0.2 mg/kg of esketamine 1 minute after induction of anesthesia, and maintain at 4 μg/kg/min after intubation until 30 minutes before the end of surgery.
224186515|NCT01096017|DRUG|Terbutaline Turbuhaler®|0.4 mg, inhalation, single dose
223589486|NCT02438813|PROCEDURE|Surgical Procedures|Surgical procedures for treatment of SMF as per standard of care in clinical practice.
223589487|NCT02438813|PROCEDURE|Laser Liposuction|Laser Liposuction for the treatment of SMF as per standard of care in clinical practice..
223589488|NCT02438813|DEVICE|Energy Devices|Energy Devices for the treatment of SMF as per standard of care in clinical practice.
223589489|NCT02438813|OTHER|Other Treatments|Other treatments for SMF as per standard of care in clinical practice.
223589490|NCT05833178|BEHAVIORAL|Drawn Blood Volume|Hemoglobine Changes
223589491|NCT04809350|DIETARY_SUPPLEMENT|Adjustable Human Milk Fortification|"BUN and sodium concentrations will be measured every week in infants on full enteral feeds with fortified human milk.~Liquid protein will be added based on serum urea."
223589492|NCT04809350|DIETARY_SUPPLEMENT|Targeted Human Milk Fortification|"Human milk will be analyzed twice weekly. Before the day of analysis, each mother will store fresh milk pumped from 10:00 AM until 8:00 AM of the previous day in a refrigerator and bring it to the hospital.~Protein, fat, and sodium supplementation will be added to the human milk to meet the recommended daily intakes."
223589493|NCT04891185|DRUG|Indocyanine green|Administration of the IMP: Indocyanine green, 0,25mg/kg of body weight, intravenous bolus injection
223589494|NCT01357460|DEVICE|Implantation of intrabronchial valves (IBV) (Spiration IBV)|"In advanced emphysema due to alpha1 antitrypsin deficiency even optimum treatment including drugs, physical training and possibly oxygen therapy is unable to influence exercise dyspnoea and exercise capacity.Implantation of intrabronchial valves in the most destroyed and hyperinflated lung lobe can improve the elastic recoil of the small airways by a reduction in lung volume and thus leading to more ergonomic breathing mechanics and diaphragm function.The one-way mechanism of these valves allows air to escape from the downstream lung segment without any influx of new air during inspiration."
224186516|NCT01096017|DRUG|Salbutamol pMDI|200 μg, inhalation, single dose
224186517|NCT01096017|OTHER|pMDI placebo pMDI|Placebo pMDI 2 inhalations
224186518|NCT01096017|OTHER|Placebo Turbuhaler®|Placebo Turbuhaler 1 inhalation
224186519|NCT02767908|OTHER|Intervention|Participants will receive a tailored support package which will include; Nicotine replacement products, behavioural support, including telephone support, Carbon dioxide measurements, home air quality measurements, signposting to support groups, and self-help materials.For participants who decline a home visit, the above support options will be offered as far as possible through telephone contact and delivered to the extent accepted by the participant. Those who report cessation at 4 weeks and/or three months will be requested to agree to a home visit for CO validation.
224186520|NCT04480359|DRUG|Bawei Shenqi Pill|5.1g, once a day, 3month, oral
224186521|NCT04480359|DRUG|Bawei Shenqi Pill placebo|5.1g, once a day, 3month, oral
224186522|NCT04480359|DRUG|Meloxicam|7.5mg, once a day, 3 month, oral
224186523|NCT01846442|DRUG|Placebo|Placebo vaginal suppository containing 0.0% (0 mg) DHEA; daily dosing with one suppository for 12 weeks.
224186524|NCT01846442|DRUG|DHEA (0.25%)|Vaginal suppository containing 0.25% (3.25 mg) DHEA; daily dosing with one suppository for 12 weeks.
224186525|NCT01846442|DRUG|DHEA (0.5%)|Vaginal suppository containing 0.5% (6.5 mg) DHEA; daily dosing with one suppository for 12 weeks.
224186526|NCT01846442|DRUG|DHEA (1.0%)|Vaginal suppository containing 1.0% (13 mg) DHEA; daily dosing with one suppository for 12 weeks.
224308804|NCT04434300|DRUG|Daptomycin|Compare the pharmacokinetic of subcutaneous (SC) and intravenous (IV) routes in the same patient.
224308805|NCT04434300|DRUG|Daptomycin|Compare the pharmacokinetic of subcutaneous (SC) and intravenous (IV) routes in the same patient.
224308806|NCT00851318|DRUG|Certolizumab pegol|Subcutaneous (SC) injection
224308807|NCT00851318|DRUG|Methotrexate|Methotrexate dose between 6 to 8 mg/week.
224308808|NCT01734200|DIETARY_SUPPLEMENT|Eriobotyra Japonica Lindley Extract|Eriobotyra Japonica Lindley Extract (1.5g/day)
223495351|NCT07125326|PROCEDURE|Intermittent catheterization|intermittent bladder catheterization every four hours, or shorter intervals if volume exceeds 500mL per expert recommendation
223495352|NCT07125326|PROCEDURE|Continuous catheterization|One catheter is placed in the bladder until pushing
223495353|NCT07125950|DRUG|SHR2554|SHR2554
223495354|NCT07125950|DRUG|HRS-8080|HRS-8080
223495355|NCT07125950|DRUG|HRS-1358|HRS-1358
223495356|NCT07125040|OTHER|Cardiac MRI|On a subset of adult patients
223589495|NCT04702113|DIAGNOSTIC_TEST|Cipherome Lighthouse Pilot|Preemptive pharmacogenomic testing
224308809|NCT01734200|DIETARY_SUPPLEMENT|Placebo|Placebo (1.5g/day)
224308810|NCT03063918|OTHER|Informational Intervention|Receive a workbook
224308811|NCT03063918|OTHER|Quality-of-Life Assessment|Ancillary studies
224308812|NCT03063918|OTHER|Questionnaire Administration|Ancillary studies
224308813|NCT03063918|OTHER|Survey Administration|Ancillary studies
224186527|NCT03080207|PROCEDURE|PRP method|It will first be placed on a 25 cc venous blood centrifuge in anticoagulated tubes containing acid citrate dextrose (ACD), and autologous venous blood will be centrifuged at 3200 rpm for 15 minutes. Using the PRP kit, the plasma rich in platelet volume of about 3 cc volume will be removed. This will be activated by the addition of platelet agonists such as thrombin, calcium gluconate or calcium chloride. Injections should be administered subcutaneously for 2-3 weeks, 3-4 times for inguinal, popliteal region and ankle for a total of 12 weeks. Also, all patients in this groups have received Complex Decongestive Physiotherapy (Manual lymph drainage (MLD), skin care, compression therapy and active therapeutic exercise).
224308814|NCT03063918|BEHAVIORAL|Telephone-Based Intervention|Receive personalized dietary intervention
224308815|NCT04077918|DIETARY_SUPPLEMENT|protein diet|100 CHD patients will be recruited and randomized into 2 groups with an additional animal or plant protein 18g per day
224186528|NCT03080207|PROCEDURE|Low Level Laser|"Low Density Laser treatment will be applied for the first 4 weeks every 12 weeks, the remaining 8 weeks 2 days / week. A total of 9 regions (6 point inguinal region and 3 points popliteal region) are to be applied by applying the laser head close to the skin (20000 Hz, 1.5 J / cm2) with the laser device and the regions where lymph nodes and lymph pathways are dense.~During the application, the patient will be in the supine position for the popliteal region, with the patient in the supine position for the inguinal region and the legs free in the abdomen.Also, all patients in this groups have received Complex Decongestive Physiotherapy (Manual lymph drainage (MLD), skin care, compression therapy and active therapeutic exercise)."
224308816|NCT00644852|OTHER|Retrospective chart review study|Retrospective study chart review long acting risperidone
224308817|NCT01839318|DEVICE|Nelfilcon A contact lenses|
224308818|NCT01839318|DEVICE|Omafilcon A contact lenses|
224308819|NCT01839318|DEVICE|Etafilcon A contact lenses|
224308820|NCT04400032|BIOLOGICAL|Mesenchymal Stromal Cells|The Mesenchymal Stromal Cells will be administered intravenously
224308821|NCT04495036|OTHER|data collection (21-items-patient descriptive survey)|"Dermatology patients are asked to complete a 21-items-survey while waiting for the doctor's consultation. Following variables will be addressed:~* Demographic data of telemedicine users and non-users~* Subjective disease perception of the dermatology patients~* Use of internet, telemedicine and telemedicine insurance model~* Patients´ willingness for additional features of telemedicine~* Advantages and disadvantages telemedicine and face-to-face consultation~* Suitable fields of dermatology for telemedicine from the patient's perspective~* Recommended structure of telemedical services by users and non-users"
224308822|NCT04495036|OTHER|data collection (23-items-physician descriptive survey)|"To obtain the view of Swiss dermatologists, other physicians and medical staff on telemedicine a 23-items-survey will be completed. Following variables will be addressed:~* Objective disease perception of the treating dermatologist (regarding the urgency of the patient's medical examination, the functional impairment and cosmetic burden due to patient's disease, the impairment of life quality due to patient's disease and the estimation of the course of the patient's disease)~* Suitable fields of dermatology for telemedicine from the physician's and medical staff's perspective"
224308823|NCT03183336|PROCEDURE|ridge split interpositional block graft|
224308824|NCT03183336|PROCEDURE|decortication Onlay block graft|
224308825|NCT01844856|DRUG|Eravacycline|
224308826|NCT01844856|DRUG|Ertapenem|
223495357|NCT07125092|DEVICE|compression group|"All patients enrolled in the study will be instructed to wear the compression garment for 8 weeks, as long as possible during the day. In parallel, all patients will receive the same advice about routine care: physical exercises, nutrition aspect that are part of the centre's current practice.~3 study visits are planned: the inclusion visit (V0) includes patient information and consent signature, measurements for custom-made compression stockings. The initial visit (V1) includes devices collection and fitting, patient questionnaires, physician assessment (medical and lipedema history, BMI, WHtR, blood sample collection, pain description, lipedema associated symptoms, leg perimeter measurements, Moisture Meter, pressure under the garment). The follow-up visit (V2) after 8 weeks includes: patient questionnaires and physician assessment.~After 8 weeks, another compression garment will be given to the patient with a new satisfaction e-questionnaire at 10 weeks of follow-up."
223495358|NCT07124780|BEHAVIORAL|Individual Placement and Support (IPS)|Individual Placement and Support is an evidence-based model of supported employment for individuals with mental illness. In IPS, participants will meet with an IPS specialist weekly who will help the study participant create resumes, conduct job searches online or in the community, complete job applications, role-play interviews, and, if requested, accompany them when visiting prospective employers.
223589496|NCT01848366|DEVICE|Biowave Treatment|Twelve weekly treatments
223589497|NCT01027260|DRUG|Itopride HCI 50 mg|Variable dosing
224308827|NCT01844856|DRUG|Placebo|Administered IV to maintain the blind.
223495359|NCT07124780|BEHAVIORAL|Standard Vocational Services|In Standard Vocational Services, participants will meet with a representative from the American Jobs Center (AJC) who will help them find a job by identifying their interests, assess their skills and abilities, and advise them on in-demand jobs and potential training opportunities.
223589498|NCT01027260|DRUG|Itopride HCI 100 mg|Variable dosing
223589499|NCT01027260|DRUG|Placebo|Variable dosing
223589500|NCT01008462|PROCEDURE|Allogeneic Bone Marrow Transplantation|Undergo donor HCT
223589501|NCT01008462|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo donor HCT
223589502|NCT01008462|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous PBSC transplant
223589503|NCT01008462|PROCEDURE|Autologous-Allogeneic Tandem Hematopoietic Stem Cell Transplantation|Undergo autologous-donor tandem HCT
223589504|NCT01008462|DRUG|Carmustine|Given IV
223589505|NCT01008462|DRUG|Cyclophosphamide|Given IV
223589506|NCT01008462|DRUG|Cytarabine|Given IV
223589507|NCT01008462|DRUG|Etoposide|Given IV
223589508|NCT01008462|DRUG|Fludarabine Phosphate|Given IV
223589509|NCT01008462|OTHER|Laboratory Biomarker Analysis|Correlative study
223589510|NCT01008462|DRUG|Melphalan|Given IV
223589511|NCT01008462|DRUG|Mycophenolate Mofetil|Given PO
224308828|NCT01001988|OTHER|Blood sample|Blood sample for immunogenicity assessment
224308829|NCT01001988|BIOLOGICAL|JE-CV administered in Study JEC02|Participants received a single dose of JE-CV at 12 to 18 months of age in Study JEC02. No vaccination was administered in Study JEC05
224308830|NCT03906578|DIETARY_SUPPLEMENT|Vivomixx®|Microbiotic food supplement with L. paracasei, L. plantarum, L. acidophilus, L. delbrueckii, B. longum, B. infantis, B. breve, S. thermophilus
223495360|NCT07125846|DEVICE|Bioactive Glass Bone Graft (UNIGRAFT)|A bioactive glass bone graft material (UNIGRAFT, Biomed Inc., USA) used for maxillary sinus floor augmentation via open sinus lift technique.
223495361|NCT07125846|DEVICE|Xenograft Bone Graft (Bio-Oss)|A commercially available bovine-derived xenograft material (Bio-Oss, Geistlich Pharma) used for maxillary sinus floor augmentation via open sinus lift technique.
223495362|NCT07124767|OTHER|6 weeks of diet with low insulin index diet|6 weeks diet period for the low insulin index group. this group has a diet programme assigned by the conductor dietitian.
223495363|NCT07124767|OTHER|6 weeks of dieting according to TÜBER nutrition recommendations|6 weeks of diet according to the TÜBER recomendations were applied to this group. Diets were assigned by the conductor dietitian.
223495364|NCT07122505|BEHAVIORAL|Orofacial myofunctional therapy|Orofacial myofunctional therapy consists of a set of oropharyngeal exercises to correct abnormal orofacial functions such as mouth breathing and a caudal tongue position, and strengthen upper airway muscles (e.g., muscles of the tongue and soft palate) that are involved in maintaining airway patency.
223495365|NCT05988190|BEHAVIORAL|Contextual Word Learning Intervention|Metalinguistic intervention consisting of meaning generation, explanation and feedback, with semantic diversity varying (no, medium, high).
224186529|NCT03080207|PROCEDURE|Complex Decongestive Physiotherapy|Complex Decongestive Physiotherapy (CDP) consists of four basic components and two phases. Four basic components; Manual lymph drainage (MLD), skin care, compression therapy and therapeutic exercise. Phase I (intense phase): It is also referred to as the phase of reducing the remission. In this phase, skin care and compression bandages are renewed after daily MLD application. The patient is taught how to bandage on his own. (Phase I, 4 weeks) The duration of phase I may vary according to the patient. In Phase II, MLD can be administered 2 or 3 times per week depending on the needs of the individual. In this case, the patient is followed by home program. Our cases will be treated in Phase I every day for 12 weeks in total and 2 days / week in Phase II according to KBF phases. All patients in this group have received only Complex Decongestive Physiotherapy.
224186530|NCT01387061|PROCEDURE|hepatic resection|surgical resection of the liver for multiple HCC
224186531|NCT03892876|DIAGNOSTIC_TEST|Auditory High Frequency Tetanizing Stimulation|50 ms tone pips presented at high frequency for 120 seconds
224186532|NCT03892876|DIAGNOSTIC_TEST|Sham Comparator|auditory tone pips with interstimulus interval (ISI) 1 sec
224186533|NCT01171794|DRUG|Ibuprofen|3 x 200mg (600mg total) x tid and one dosing on the subsequent day ( 4 doses total)
224186534|NCT01171794|DRUG|Placebo|identical number of visually identical tasteless pills as ibuprofen arm
224186535|NCT04753931|OTHER|Sensory Training in addition to Bobath Training|Trunk-focused exercises will be applied for different senses (tactile, proprioceptive, etc.) in addition to Bobath exercises. Bobath exercises will be determined individually according to the evaluation results. In general, exercises aiming to muscle tone regulation, increase balance, walking, and functionality will be applied. Trunk-focused Bobath exercises will be selected.
224186536|NCT04753931|OTHER|Bobath Training|Bobath exercises will be determined individually according to the evaluation results. In general, exercises aiming to muscle tone regulation, increase balance, walking, and functionality will be applied. Trunk-focused Bobath exercises will be selected.
224186537|NCT03792880|BEHAVIORAL|Telematic control and self-management program|"During 6 months with CPAP treatment, patients must complete some questionnaires about the presence of refreshing sleep and side effects with the frequency established, using a computing application. Patients can download this application on their own smartphone but, if they prefer, they can be provided with a tablet during the study with this application installed.~A set of variables will be collected using an automatic and wireless transmission from latest generation CPAP to control the CPAP compliance and tolerance. All data will be processed in a platform to generate alarms, which will be controled daily by a researcher, as well as solutions to the problems presented during the monitoring."
224186538|NCT03792880|BEHAVIORAL|Habitual follow-up in Healthcare System|According to the SEPAR regulation, patients treated with CPAP should be evaluated by the pulmonologist one month after beginning treatment, every 3 months during the first year, every 6 months during the second year and annually from the third year.
224186539|NCT00186173|BEHAVIORAL|After school sports program|After school team sports intervention designed specifically for overweight and obese children
224186540|NCT00186173|BEHAVIORAL|After school health education|After school health and nutrition education program
224186541|NCT01511367|DRUG|Flutiform|50/5ug (fluticasone/formoterol) 2 puffs twice daily
224186542|NCT01511367|DRUG|Seretide|50/25 ug (fluticasone/salmeterol) 2 puffs twice daily
224186543|NCT01511367|DRUG|Flixotide|50ug 2 puffs twice daily
224186544|NCT04884204|BEHAVIORAL|Lee Symptom Scala|Symptom identification and management with Lee Symptom Scale in follow up care
223495366|NCT07120087|BEHAVIORAL|Intervention|Virual Webinar and online personalised clinical visit
223589512|NCT01008462|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo donor HCT
223589513|NCT01008462|DRUG|Tacrolimus|Given IV or PO
223589514|NCT01008462|RADIATION|Total-Body Irradiation|Undergo TBI
223589515|NCT04361890|DIAGNOSTIC_TEST|perineal ultrasound|all women will have ultrasound measurements of the bladder neck descent, of the movement of the ano-rectal angle during a Valsalva maneuver and elastographic measurement before and after PFMT. All measurement will be conducted by perineal route, with is a non invasive ultrasound route
224186545|NCT00665366|DRUG|Aripiprazole|5-, 10-, or 15-mg oral tablets in titrated doses for 12 weeks
224186546|NCT00665366|DRUG|Placebo|Tablets, Oral, 0 mg, once daily, 12 weeks
224308831|NCT03906578|OTHER|Placebo|Placebo with similar appearance to probiotic
223495367|NCT07119788|DIETARY_SUPPLEMENT|Placebo|6g serving of a calorie-matched powder, artificially coloured and flavoured to resemble berry powder
224186547|NCT00665366|DRUG|Lithium|Participant's ongoing dose
224186548|NCT00665366|DRUG|Valproate|Participant's ongoing dose
223495368|NCT07119788|DIETARY_SUPPLEMENT|Pure haskap berry powder|6g serving of a pure, freeze-dried haskap berry powder
223495369|NCT07119788|DIETARY_SUPPLEMENT|Vitamin-and mineral-enhanced haskap berry powder|6g serving of a vitamin- and mineral-enhanced haskap berry powder (fortified with potassium iodide, zinc bisglycinate, vitamin B5, and vitamin B12
223495370|NCT07120971|DRUG|Metformin (open-label)|Enteric metformin 5mg/kg/day in two divided doses will be given for three days to two subjects
223495371|NCT07120971|DRUG|Metformin (open-label)|Enteric metformin 10mg/kg/day in two divided doses will be given for three days to two subjects.
223495372|NCT07120971|DRUG|Metformin (open-label)|Enteric metformin 20mg/kg/day in two divided doses will be given for seven days to three subjects.
223495373|NCT07120971|DRUG|Metformin (open-label)|Enteric metformin 25mg/kg/day in two divided doses will be given for 14 days to three subjects.
223495374|NCT07120971|DRUG|Metformin (open-label)|Enteric metformin 15mg/kg/day in a single daily dose will be given for three days to 3-6 subjects. Depending on tolerance, the next Cohort will increase to 25mg/kg/day (Cohort 2) or decrease to 10mg/kg/day (Cohort 3)
223495375|NCT07120971|DRUG|Metformin (open-label)|Enteric metformin 25mg/kg/day in a single daily dose will be given for three days to 3-6 subjects. Depending on tolerance, either 25mg/kg/day or 15mg/kg/day will be dose selected for the next Cohort (Cohort 4)
223495376|NCT07120971|DRUG|Metformin (open-label)|Enteric metformin 10mg/kg/day in a single daily dose will be given for three days to 3-6 subjects. Depending on tolerance, either 10mg/kg/day dose selected for the next Cohort (Cohort 4) or the study will be stopped due to excessive toxicity.
223495377|NCT07120971|DRUG|Metformin (open-label)|The dose for this cohort will be selected from either Cohort 2 or 3 based on tolerance. Enteric metformin 10-25mg/kg/day in a single daily dose will be given for seven days to 6 subjects.
223495378|NCT07120971|DRUG|Metformin (open-label)|The dose for this cohort will be the same as Cohort 4. Enteric metformin 10-25mg/kg/day in a single daily dose will be given for 14 days to 6 subjects.
223589516|NCT06308250|OTHER|MIME THERAPY|"Mime therapy consist of:~Self massage: patients will be taught to massage their face and neck daily for about 10 minutes which includes effleurage and kneading of both sides of face.~Breathing exercises: patient will be taught to recognize tension and feel the difference between tension and relaxation in facial musculature for 5 minutes. Expiration exercises will be used to induce relaxation.~Articulation: vowels such as a,e,i,o,u and consonants such as p and b will be used to teach position of the lips for 5 minutes.~Facial expression exercises: forehead wrinkle, smiling, eye closure, frowning, disgust, surprise, anger, sadness will be performed for 10 minutes"
223589517|NCT06308250|OTHER|ACTION OBSERVATION THERAPY|"Function of each of the muscle is observed for 3 minutes and then executed for 2 minutes.~Frontalis (Raising eyebrows and forehead wrinkling). Corrugator Supercili (Moving the eyebrow down and inward toward the nose and inner eye).~Orbicularis oculi (Closing the eyelids). Buccinator (Blowing air in and out of the mouth). Zygomaticus major (Smiling). Orbicularis oris (Lip pursing or puckering)."
223589518|NCT05718960|OTHER|Reassurance-alone|To be informed of the absence of organic disease and provided a diagnostic explanation of functional dyspepsia
223589519|NCT05718960|BEHAVIORAL|Traditional dietary advice|To receive the same information as reassurance-alone group but also recommended to eat smaller, regular meals and reduce the intake of caffeine/alcohol/fizzy drinks, fatty/processed/spicy foods, and fibre
223589520|NCT02068872|PROCEDURE|Sleeve Gastrectomy|To assess the safety, tolerability and feasibility of sleeve gastrectomy in the perioperative period following liver transplantation in obese (BMI of \> 40 or \> 35 kg/m2 in the presence of at least one major obesity related co-morbidities (e.g. type 2 diabetes, hypertension, sleep apnea, heart disease, etc) adult subjects aged 18-75 years of age.
223589521|NCT04588090|PROCEDURE|The concurrent 3 weeks TP regimen|paclitaxel + cisplatin regimen (TP-TAX: 150mg/m\^2, DDP: 70mg/m\^2 (35mg/m\^2, d1, d2), 1 time/3 weeks) chemotherapy for 2 cycles.
223589522|NCT04588090|PROCEDURE|The concurrent weekly TP regimen|paclitaxel + cisplatin regimen (TP regimen: TAX 50mg/m\^2, DDP: 25mg/m\^2) 6 cycles of chemotherapy
223589523|NCT04588090|RADIATION|External radiation plus intraluminal after-loading irradiation|External radiotherapy of linear accelerator, CT simulation positioning, and intensity modulated radiotherapy will be applied for external radiotherapy. The prescribed dose is 95% PTV 45-50.8Gy/25-28 times (1.8Gy/time), the maximum and minimum in the target area do not exceed ±10% of the prescribed dose, and the increase in enlarged lymph nodes will reach 50-66GY. At the same time, the total dose of 192Ir high-dose rate intraluminal after-loading irradiation is 30-36Gy (EQD2: 40-48GY), and external pelvic irradiation is not available on the day of intraluminal after-loading irradiation.
223589524|NCT00988481|DRUG|Topiramate|Topiramate titrated to 200mg/day over four weeks, for ten weeks
223589525|NCT04421209|DRUG|Propranolol Hcl 40mg Tab|40mg PO BID for the three days prior to surgery, 40mg PO BID the day of surgery and on post-op days 1 and 2.
223589526|NCT04421209|DRUG|Placebo oral tablet|Placebo tablets administered with the same schedule of Propranolol tablets
223495379|NCT07116616|DRUG|mRNA-2808|intravenous
223495380|NCT07119697|OTHER|Shacklock Neural Mobilization|In the SNM group, participants lay supine with hips neutral and knees flexed to 45 degrees. Therapists applied the remote slider technique by extending the knee near end-range and dorsiflexing the ankle to 15 degrees, performed in 3 sets of 15 reps with 30-second rests. Each session lasted 20 minutes including setup. Progression was made by increasing hip flexion in 5 degrees increments when a VAS pain reduction of ≥2 cm was observed. This technique, based on neurodynamic principles, was designed to reduce neural mechanosensitivity and improve mobility in patients with lumbar radiculopathy.
223589527|NCT00181610|DRUG|Recombinant Human Prolactin|60 mcg/kg every 12 hours
223589528|NCT00181610|BIOLOGICAL|Recombinant human prolactin|60 mcg/kg given every 12 hours or every 24 hours
224186549|NCT02616458|OTHER|ear pain counseling|The Ear Pain counseling materials reviewed concepts such as how to recognize ear pain and safely provide pain relief, and how to recognize danger signs that require urgent medical attention. Families were also encouraged to schedule an appointment in the CHC for a possible ear infection rather than going to the emergency department or urgent care facility after hours.
224186550|NCT02616458|OTHER|language power counseling|The Language Power materials explained the importance of frequent conversations between parents and children and of using encouraging rather than discouraging comments and the PRA reviewed age-appropriate activities in the Learning Games book, and the importance of daily reading using the provided children's book as an example.
223495381|NCT07119697|OTHER|McKenzie Extension Principle|MEP group was treated with MEP in a prone position, starting with 10 repetitions of active trunk extension, holding end-range for 3 seconds. If no symptom centralization occurred, therapists progressed from patient-applied overpressure (EIL-POP) to clinician-applied grade III mobilizations (3 oscillations/second), following McKenzie's force progression model. Each session included 3 sets of 10 repetitions with 1-minute rest between sets, totaling 15 minutes of active intervention. For unilateral symptoms, the approach advanced to hips-off-center techniques involving a 15 degree lateral shift. This graded sequence aimed to reduce nerve root compression and promote symptom centralization.
224186551|NCT04472910|DRUG|Modified Folforinox (mFFX)|Neo-adjuvant mFFX for up to 6 cycles, chemo-Adjuvant FFX q 2 weekly or other approach as per investigator to complete up to 6 months chemotherapy
224186552|NCT04177862|DRUG|Sublingual Sufentanil|30 mcg of sublingual sufentanil
224186553|NCT04177862|DRUG|IV Fentanyl|50 mcg of IV fentanyl
224186554|NCT02402556|BEHAVIORAL|MOCEP|Through parent support and an evidence-based curriculum, MOCEP uses education to reduce risk factors that hinder children's health and wellbeing.
224186555|NCT03233009|OTHER|Experimental Daily Defense Serum A|Participants will apply 0.02mL/cm2 of product topically via semi-occlusive patches onto dorsum (Scapular region).
224186556|NCT03233009|OTHER|Experimental Daily Defense Serum C|Participants will apply 0.02mL/cm2 of product topically via semi-occlusive patches onto dorsum (Scapular region).
224186557|NCT03233009|OTHER|Experimental Daily Defense Serum G|Participants will apply 0.02mL/cm2 of product topically via semi-occlusive patches onto dorsum (Scapular region).
224186558|NCT03233009|OTHER|Experimental Daily Defense Serum N|Participants will apply 0.02mL/cm2 of product topically via semi-occlusive patches onto dorsum (Scapular region).
224186559|NCT03233009|OTHER|Saline Solution Sodium Chloride|Participants will apply 0.02mL/cm2 of product topically via semi-occlusive patches onto dorsum (Scapular region).
224186560|NCT05735860|BEHAVIORAL|Virtual Reality Exposure Therapy (VRET)|Four VRET sessions of approx. one hour each session taking place in an individual setting accompanied by a therapist. The participants wear a head-mounted display showing different musical performance scenarios (i.e. audition in a concert hall/ recording studio/ in front of a professional jury/ an audience/ a class of music students) that are selected individually by a previously standardized, graded exposure procedure.
224186561|NCT05735860|BEHAVIORAL|Progressive Muscle Relaxation (PMR)|Four PMR sessions of approx. 45min each session taking place in an individual setting accompanied by a therapist. The sessions follow a previously standardized procedure.
223495382|NCT07119697|OTHER|Hydrocollator hot packs|Both groups received standardized thermotherapy using hydrocollator-heated moist hot packs (40 degrees centigrade, wrapped in 6-8 towel layers) applied to the lumbar region for 15-20 minutes to improve tissue compliance and reduce pain. Participants were positioned prone or side-lying based on comfort and symptom severity; semi-prone positions with pillow support were used for those with heightened sensitivity to maintain spinal neutrality. Thermotherapy was administered five times in week 1 and three times weekly during weeks 2-3. Skin condition and comfort were monitored. This pre-treatment method promoted transient pain relief and muscle relaxation, enhancing tolerance to subsequent therapeutic interventions.
223495383|NCT07121205|OTHER|This study is a retrospective study, and all data have been collected in advance with no active intervention required.|This study is a retrospective study, and all data have been collected in advance with no active intervention required.
224186562|NCT01058226|BIOLOGICAL|Malaria challenge (wild-type NF54 strain Plasmodium falciparum sporozoites)|Malaria sporozoite challenge with the wild-type NF54 strain of Plasmodium falciparum delivered by the bite of five infected Anopheles stephensi mosquitoes.
224186563|NCT06391047|OTHER|Mulligan's Squeeze Technique - manual therapy|This technique was introduced by Brian R. Mulligan. In this technique the therapist places thumb along the tender joint margin and applies force centrally. The patient actively flexes knee and therapist progressively enhances force and at end applies overpressure. This force is decreased as knee moves towards extension. This method helps to maintain the meniscus in its normal position and corrects the derangement of meniscus.
224186564|NCT06391047|OTHER|Conventional Physiotherapy|It includes stretching and strengthening exercises of muscles of the knee joint.
224186565|NCT00564876|DRUG|Dasatinib|Fresh frozen tumor tissue must be available prior to initiating dasatinib. Eligible patients will receive neoadjuvant dasatinib 70 mg PO twice daily for 3 weeks followed by surgery. The surgical specimen will be evaluated for pathologic response. The second tumor sample will be obtained after 3 weeks of dasatinib therapy at the time of definitive surgical resection which will be evaluated for changes in genomic expression profiles. Patients with at least a 15% decrease or better objective response, without evidence of progression (per tumor evaluation pre-surgery) or pathologic response (as defined as ≥30% tumor necrosis or cell death) to neoadjuvant dasatinib therapy will be eligible to receive dasatinib 70 mg twice daily for 90 days after the completion of standard adjuvant therapy.
223495384|NCT07120828|DRUG|Empagliflozin (oral)|Empagliflozin 10 mg oral tablet administered once daily for 6 months.
223495385|NCT07120828|DRUG|Dapagliflozin (DAPA)|Dapagliflozin 10 mg oral tablet administered once daily for 6 months
223495386|NCT07120828|DRUG|Metfomin|metformin 500-1000 mg/day administered as part of standard care, based on clinical indication.
223495387|NCT03599713|DRUG|Retifanlimab|INCMGA00012 administered at 500 milligrams (mg) by intravenous infusion once every 4 weeks
223495388|NCT05178862|DRUG|SCY-078|Oral ibrexafungerp (SCY-078) as step-down therapy.
223495389|NCT05178862|DRUG|Fluconazole|Oral fluconazole (SCY-078) as step-down therapy.
223495390|NCT05178862|DRUG|Echinocandin|Intravenous echinocandin
223495391|NCT06937476|DRUG|Escitalopram|Escitalopram will be administered orally at a fixed dose of 20 mg/day for 8 weeks. This SSRI antidepressant is used as baseline pharmacological treatment for patients with major depressive disorder (MDD), either as monotherapy or in combination with aripiprazole. No other psychotropic medications are allowed during the study period.
223495392|NCT06937476|DRUG|Aripiprazole 5mg|Aripiprazole will be administered as an adjunctive treatment to escitalopram at an initial dose of 2.5 mg/day, titrated up to 5 mg/day based on tolerability. Treatment will last 8 weeks, after which aripiprazole will be tapered and discontinued. This intervention aims to evaluate the efficacy of dopaminergic augmentation in reducing pathological rumination symptoms.
223495393|NCT06939283|DRUG|WTX-330|Investigational Product
224186566|NCT00916773|DEVICE|continuous positive airway pressure (CPAP)|CPAP of optimal pressure used during sleep for 3 months
224186567|NCT03352544|BEHAVIORAL|Exercise|Exercise training for 12 weeks (aerobic and resistance training trice a week)
223495394|NCT06936930|OTHER|Sex hormone monitoring|Sex hormone monitoring includes the concentrations of follicle-stimulating hormone (FSH), luteinizing hormone (LH), estradiol (E2), progesterone (P), prolactin (PRL), and testosterone (T).
223495395|NCT03452787|OTHER|None, cohort studies|this is a metanalysis of previously obtained observational data. there is not intervention on any of the cohorts.
223495396|NCT06380569|BEHAVIORAL|KF-STRIDE®|Treatment group will receive 10 web based sessions of a strength-based training tool (once or twice a week). Sessions are approximately 60 minutes long.
223495397|NCT06936891|COMBINATION_PRODUCT|Virtual Ward|Hospital-level care at home using remote vital sign monitoring, digital anamnesis via the Digizorg app, and integration with the Electronic Medical Record (HiX), managed by Virtual Ward staff following predefined care pathways.
223495398|NCT06945276|DRUG|ALG-097558|A selective, reversible, and potent inhibitor of the SARS-CoV-2 3CLpro with pan-coronavirus activity
223495399|NCT06945276|DRUG|Dabigatran|A direct thrombin inhibitor approved for the treatment and prevention of blood clots to reduce the risk of stroke
223495400|NCT06945276|DRUG|Itraconazole|A substrate and strong dual inhibitor of CYP3A4/P-glycoprotein (P-gp)
223495401|NCT06945276|OTHER|Placebo|Placebo
223495402|NCT06945237|DRUG|Flupentixol-Melitracen + Lansoprazole|Flupentixol-Melitracen and Lansoprazole for the treatment of GERD
223495403|NCT06945237|DRUG|Lansoprazole and placebo|Placebo and Lansoprazole for GERD
223495404|NCT06943066|OTHER|Reformer Pilates|Reformer Pilates
223495405|NCT06943066|OTHER|Pilates control|Pilates control
223495406|NCT06943066|OTHER|online pilates|online pilates
223495407|NCT05389215|DRUG|DWN12088|DWN12088 Xmg Tablet (BID)
224186568|NCT01008059|DRUG|Alfentanil|No drug treatment before alfentanil
224186569|NCT05086627|DRUG|Tislelizumab|Patients were treated with Tislelizumab on the first day of each cycle of CapeOX (Capecitabine+Oxaliplatin).
224186570|NCT05086627|RADIATION|Short-course radiotherapy|Patients were treated with short-course neoadjuvant radiotherapy
223495408|NCT05389215|DRUG|Placebo|Placebo 0mg Tablet (BID)
223495409|NCT05800145|BEHAVIORAL|Resource information Supplemental Nutrition Assistance Program (SNAP)|Participants randomized to the resource referral arm will receive a tailored list of information about community resources. The list will include information about local emergency food resources (e.g. local food pantries) and government programs to address FI (e.g. SNAP).
223495410|NCT05800145|BEHAVIORAL|community health worker (CHW)|Participants randomized to the CHW intervention will have an initial baseline visit scheduled at a mutually convenient location.
223495411|NCT05800145|BEHAVIORAL|medically tailored meals|Participants will receive 10 medically tailored meals delivery to their home weekly for 3 months
223495412|NCT07103044|BEHAVIORAL|Early Achievements - Shaping Early Language and Literacy Skills|EA-SHELLS is a professional development program that includes a 6-hour workshop and about 14 in-person coaching sessions using Practice-Based Coaching. Teachers will implement the EA-SHELLS instructional approach in their classrooms during whole-group book sharing activities to target vocabulary, syntax, story grammar, and listening comprehension. Teachers will also lead story retelling activities using pictures cards and 3D props to further target all four skills. Teachers will be provided with commercially available children's books augmented with supplemental text to explicitly define vocabulary and cue teachers' elicitation of children's verbal engagement for targeted vocabulary, syntactically elaborated sentences, and story grammar elements. Instructional strategies include naturalistic developmental behavioral intervention and language facilitating (e.g., focused stimulation) strategies. Teachers will read each provided book about four times over one to two weeks.
223495413|NCT06947304|DRUG|Miricorilant|100 mg administered orally, once daily
223495414|NCT07141563|DRUG|Nivolumab + platinum-based chemotherapy|According to the product label
223495415|NCT07141576|OTHER|Erbium laser (2940 nm): Infrared light energy|The lasers emit light energy in the infrared and visible spectrum, which is fundamentally different from ionizing radiation (like X-rays or gamma rays) that can damage DNA. Dental lasers work through photobiomodulation and thermal effects, not through radiation exposure.
223495416|NCT07141576|OTHER|Diode laser (650 nm): Visible red light energy|Non-ionizing radiation or more accurately as optical energy devices, not ionizing radiation.
223495417|NCT07141576|DRUG|Fluoride varnish|Biological Intervention
223495418|NCT06955871|OTHER|Toothpaste containing 1.05% Chitosan|Toothpaste containing 1.05% Chitosan
223495419|NCT06955871|OTHER|Silica-based NaF Toothpaste|Silica-based NaF Toothpaste
223495420|NCT06955871|OTHER|Toothpaste with 67% bicarbonate|Toothpaste containing 67% Bicarbonate
223495421|NCT02850406|DRUG|Voxelotor|"* Part A: Voxelotor will be administered as oral capsules or tablets~* Part B: Voxelotor will be administered as oral capsules or tablets~* Part C: Voxelotor will be administered as oral dispersible tablets or powder for oral suspension~* Part D: Voxelotor will be administered as oral dispersible tablets or powder for oral suspension"
223495422|NCT07120061|DIAGNOSTIC_TEST|First MWT|MWT during the first visit of the protocol
223495423|NCT07120061|DIAGNOSTIC_TEST|second MWT|MWT during the second visit of the protocol
223495424|NCT07120061|DEVICE|actimetry|In order to monitor compliance with the guidelines prior to each MWT, namely good sleep hygiene in the 14 days preceding the MWT, and in accordance with the recommendations of the AASM, an actimeter will be worn by the participant.
223495425|NCT07117890|DRUG|Sunvozertinib|sunvozertinib 300mg QD
223589529|NCT00181610|BIOLOGICAL|Normal Saline|twice per day
224186571|NCT05086627|DRUG|Capecitabine+Oxaliplatin|Patients were treated with neoadjuvant chemotherapy with CapeOX (Capecitabine+Oxaliplatin).
224186572|NCT00474994|DRUG|sunitinib malate|
224186573|NCT00278473|BEHAVIORAL|Meta-Cognitive Therapy|Cognitive Behavioral Group Treatment
224186574|NCT00278473|BEHAVIORAL|Supportive Therapy|Social Support Problem-Solving Group Treatment
224186575|NCT00040326|PROCEDURE|anteromesial temporal resection|surgical treatment for epilepsy
224186576|NCT00040326|DRUG|antiepileptic drugs|pharmacotherapy
224308832|NCT03908515|DEVICE|Foldable Capsular Vitreous Body (FCVB)|FCVB can be regarded as an artificial vitreous and consists of a thin vitreous-shaped capsule, a drain tube, and a valve. After foldable implantation into the eye, then silicone oil is injected into the capsule which inflated to support the retina. The capsular material of FCVB is silicone rubber. The capsule was fabricated a computer simulation of the human and rabbit vitreous cavities. The control of the intraocular pressure is achieved with adjusting the amount of injected medium through the tube-valve system. After the medium was injected into the capsule through the tube-valve system, the valve was subsequently fixed onto the sclera surface similar to the glaucoma valve.
224308833|NCT03340207|DEVICE|Pneumaglide|The device is designed to facilitate intubation and reduce the time to intubation. It works with traditional glidescope to make the process of intubation easier. In this study patients scheduled for surgery and intubation, will be randomized to two groups. The intervention group will be intubated with the help of the pneumaglide. Yet, the other group will receive standard intubation. We aim to evaluate the efficacy of the Pneumaglide to improve the ease of intubation in unskilled clinicians and skilled clinicians during difficult and routine intubations
224308834|NCT01442688|DRUG|Amoxicillin + MMX placebo|MMX placebo administered once a day (QD) orally on Days 1-3, then a single oral dose of Amoxicillin (500 mg) + MMX placebo on Day 4.
224308835|NCT01442688|DRUG|Amoxicillin + MMX mesalazine/mesalamine|MMX mesalazine/mesalamine (4.8 g) administered QD orally on Days 1-3, then a single oral dose of Amoxicillin (500 mg) + MMX mesalazine/mesalamine (4.8 g) on Day 4.
224308836|NCT05369728|OTHER|Coronary CT in 1st line compared to the strategy with functional test in 1st line in patient at Intermediate Risk of Developing Stable Coronary Disease:|Coronary CT in 1st line compared to the strategy with functional test in 1st line in Patients at Intermediate Risk of Developing Stable Coronary Disease:
224308837|NCT05691088|DEVICE|Paracetamol injection|"Patients were randomized to receive either paracetamol during mechanical ventilation. When patients were randomized to receive paracetamol (40 mg/kg per day in 4 doses), a placebo infusion of normal saline was administered continuously at the same rate as an equivalent infusion. Placebos could not be distinguished from the active study drug in color, odor, or viscosity.~In both study groups, IMV was maintained with sufentanil (0-0.2 mcg/kg/h), propofol (0-4 mg/kg/h), and dexmedetomidine (0-1 mcg/kg/h). Assessment of sedation levels by the bedside nurse using the FLACC pain scale to determine if the child is adequately comfortable or in need of more or less medication to maintain adequate ventilation. Assessment of sedation levels by the bedside nurse using the FLACC pain scale (every 6 hours as a minimum time interval)."
224308838|NCT00927394|DRUG|Aliskiren|Aliskiren 150 mg tablet
224308839|NCT00927394|DRUG|Valsartan|Valsartan 160 mg capsules
224308840|NCT00927394|DRUG|Placebo for Aliskiren|Placebo for Aliskiren 150 mg tablets
224308841|NCT00927394|DRUG|Placebo for Valsartan|Placebo for Valsartan 160 mg capsules
224308842|NCT02465294|DIETARY_SUPPLEMENT|Probiotic|This group will receive the Lactobacillus probiotic, which will be taken as a capsule once daily for 12 weeks.
224308843|NCT02465294|BEHAVIORAL|Behavioral lifestyle intervention|All participants will participate in weekly group meetings of 15 to 20 participants for a facilitated discussion of specific nutritional, behavioral, and physical activity topics chosen to promote weight loss.
224308844|NCT02465294|OTHER|Placebo|This group will receive the placebo and will be taken as a capsule once daily for 12 weeks. The placebo will contain encapsulated potato starch which is used the matrix in the probiotic supplements.
224308845|NCT02465294|OTHER|Blood Test|All subjects will have blood tests performed.
224308846|NCT02465294|DIETARY_SUPPLEMENT|Probiotic|This group will receive the blend of Bifidobacterium and Lactobacillus probiotic, which will be taken as a capsule once daily for 12 weeks.
224308847|NCT02720874|BEHAVIORAL|Rheumatoid arthritis educational booklet|Participants will receive a low-literacy rheumatoid arthritis educational booklet that provides general disease state information.
223495426|NCT07113782|DRUG|1. Magnesium Sulphate 2. Tramadol|"Magnesium Sulphate (Group M): 50 mg magnesium sulphate added to 12.5 mg of 0.5% hyperbaric bupivacaine, administered intrathecally.~Tramadol (Group T): 25 mg tramadol added to 12.5 mg of 0.5% hyperbaric bupivacaine, administered intrathecally."
224186577|NCT06466967|DEVICE|Advanced hybrid closed-loop CamAPS FX|Treatment with a strict programmed glucose target (80-99 mg/dL).
224186578|NCT02313246|BEHAVIORAL|Group Cognitive Behaviour Therapy|This 11-week group treatment will cover the following topics: psychoeducation about IBS and the role of stress in exacerbating IBS symptoms, progressive muscle relaxation, stress management, problem solving, identifying and modifying maladaptive thinking patterns, decreasing behavioural avoidance, and exposure to feared physical sensations.
224186579|NCT06344858|DRUG|Ketamine|One bolus of ketammine
224186580|NCT00721513|BIOLOGICAL|cetuximab|
224186581|NCT00721513|DRUG|cisplatin|
224186582|NCT00721513|DRUG|docetaxel|
224186583|NCT00721513|DRUG|fluorouracil|
224186584|NCT00721513|PROCEDURE|computed tomography|
224186585|NCT00721513|PROCEDURE|positron emission tomography|
224186586|NCT00721513|PROCEDURE|quality-of-life assessment|
224186587|NCT00721513|RADIATION|3-dimensional conformal radiation therapy|
224186588|NCT00721513|RADIATION|intensity-modulated radiation therapy|
223495427|NCT06545695|DRUG|Erlotinib|Part B will be the dose escalation component, in which the subject will initiate 50 mg erlotinib,8 weeks later escalate to 75 mg, and then 8 weeks later to 100 mg erlotinib pending tolerance after each 8-week period.
224186589|NCT02322866|DRUG|Sarecycline|1.5 mg/kg/day taken orally at the same time each day.
224186590|NCT02322866|DRUG|Placebo|Placebo-matching sarecycline tablets, taken orally at the same time each day.
224186591|NCT01778296|DEVICE|the neurocutaneous island flap|The neurocutaneous island flap of the dorsal branch of the digital nerve can be used for repair the defects of the proximal and middle phalanxes of adjacent fingers.
224186592|NCT06567834|DEVICE|Tecnis Symfony Optiblue/Tecnis Symfony Optiblue Toric (Models ZXR00V/ZXW150)|Multifocal IOL with violet light filtration and high-resolution lathing
224186593|NCT06567834|DEVICE|Tecnis Symfony/Tecnis Symfony Toric (Models ZXR00/ZXT150)|Multifocal IOL with ultraviolet filtration
224186594|NCT04792684|DIAGNOSTIC_TEST|Optimization of Plasma Circulating Free-DNA (cfDNA) Marker Panel|Evaluate the performance of a preliminary panel of biomarkers
224186595|NCT01793610|DRUG|Comparator Dose (40mg) MDMA HCl|An initial comparator-dose of 40 mg midomafetamine HCl orally given at the start of two separate psychotherapy sessions scheduled 3 to 5 weeks apart, with the initial dose possibly followed 1.5 to 2.5 hours later by a supplemental dose half the size of the initial dose (20 mg).
224186596|NCT01793610|DRUG|Active Dose 2 (100 mg) MDMA HCl|An initial dose of full-dose 100 mg midomafetamine HCl orally given at the start of two separate psychotherapy sessions scheduled 3 to 5 weeks apart, with the initial dose possibly followed 1.5 to 2.5 hours later by a supplemental dose half the size of the initial dose (50 mg).
224186597|NCT01793610|DRUG|Active Dose 1 (125 mg) MDMA HCl|An initial dose of full-dose 125 mg midomafetamine HCl orally given at the start of two separate psychotherapy sessions scheduled 3 to 5 weeks apart, with the initial dose possibly followed 1.5 to 2.5 hours later by a supplemental dose half the size of the initial dose (62.5 mg).
224186598|NCT01793610|BEHAVIORAL|Psychotherapy|Non-directive manualized therapy
224186599|NCT00794131|BIOLOGICAL|GL-ONC1|a genetically-engineered vaccinia virus (encoding Renilla luciferase-Aequorea green fluorescent protein fusion, β-galactosidase, and β-glucuronidase )
224186600|NCT01860456|DRUG|Imatinib/Nilotinib|Imatinib: 400 mg/day oral - Nilotinib: 600-800 mg/day oral
224186601|NCT03264560|BEHAVIORAL|Telepsychiatry|A total of 6 synchronous or asynchronous telepsychiatry interventions conducted via telecommunications done at baseline, 1 month, 2 months, 3 months, 6 months, and 12 months.
224186602|NCT03986905|DRUG|Scopolamine Nasal Gel|All subjects will receive both a patch and nasal gel: DPI-386 Nasal Gel + placebo patch, placebo nasal gel + placebo patch, or placebo nasal gel + TDS patch.
224186603|NCT03986905|OTHER|Placebo|placebo nasal gel + placebo patch
224186604|NCT00256490|PROCEDURE|PET/CT 20 days after the first cycle of chemotherapy|
224308848|NCT02720874|BEHAVIORAL|Multidisciplinary rheumatologic care|At each regularly scheduled clinic appointment, participants will receive treatment from their assigned rheumatologist, undergo an in-clinic physical therapy evaluation and, if indicated, a psychological evaluation. Physical therapy and psychology follow-up sessions will occur as directed by the individual services.
224308849|NCT02720874|BEHAVIORAL|Nurse education and monthly calls|Participants will meet one-on-one with a rheumatology nurse for a tailored educational session encompassing disease state education, an introduction of the treat to target concept, an overview of treatment options, and goal setting and planning. During monthly follow-up calls, participant educational needs will be addressed; goal setting, planning and review will also be conducted.
224308850|NCT02720874|BEHAVIORAL|Monthly healthcare coordinator calls|During monthly calls with the healthcare coordinator, specific questions and concerns raised by participants may be addressed. The primary purpose of these calls is to control for potential benefit derived from time on the phone with a health professional.
224308851|NCT02720874|BEHAVIORAL|Technology-based symptom monitoring and reporting|When at home patient self-monitoring reports indicate a significant increase in RA disease activity, participants will be promptly contacted and scheduled for an ad hoc evaluation with their treating rheumatologist.
224308852|NCT00630929|DRUG|Ibuprofen|800 mg oral tablet 3 times daily with meals for 6 weeks
224186605|NCT00848328|BIOLOGICAL|Rituximab|Injection for Intravenous Use, 375 mg/m2/wk x 4 weeks, to begin Cycle 1, Day 15.
224186606|NCT00848328|DRUG|Lenalidomide|Supplied as 5mg capsules; Dosage: 20 mg daily, days 1-21 of a 28 day cycle, to begin Day 1 of cycle 1 and continue until disease progression.
224186607|NCT00429546|BEHAVIORAL|Teaching, Raising, and Communicating with Kids (TRACK)|TRACK is cognitive-behavioral treatment designed to improve mother-child communication and parenting skills and prepare caregiver for disclosure of HIV serostatus to child. The treatment consists of three 75-minute sessions that focus on exploring mothers' concerns, determining children's readiness to receive the news, planning for disclosure, and practicing disclosure.
224308853|NCT00630929|DRUG|Placebo|Matched placebo orally for 6 weeks
224308854|NCT00630929|DRUG|Celecoxib|200 mg oral capsule once daily with morning meal for 6 weeks
224186608|NCT00429546|OTHER|Treatment as usual|Treatment as usual includes standard care for HIV infected mothers.
224186609|NCT01661426|BEHAVIORAL|Low-Carbohydrate Diet|Counseling/instruction on how to follow a healthy low-carbohydrate diet for 6 months. One evening class/week for 8 weeks (8 total classes). Then one class every other week for 8 weeks (4 total classes). Then one class every four weeks for 8 weeks (2 total classes): 14 evening classes, total.
224308855|NCT00274820|DIETARY_SUPPLEMENT|ascorbic acid|The dose of ascorbic acid will be 1000 mg PO 2-3 hours prior to ATO infusion. The treatment will follow the same schedule as arsenic trioxide.
224308856|NCT00274820|DRUG|arsenic trioxide|Treatment consists of a loading period of five 0.25 mg/kg ATO doses in the first week, followed by maintenance dosing with 0.25 mg/kg ATO twice weekly for 11 weeks. Loading is usually done Monday through Friday of the first treatment week. Maintenance should be started either 72 or 96 hours after the last loading dose. Thereafter, dosing is twice weekly, following an alternating pattern of 72 and 96 hours. For example, maintenance dosing may be done on Mondays and Thursdays, Tuesdays and Fridays, etc. The same pattern should be followed for the entire maintenance dosing period.
224308857|NCT00274820|DRUG|dexamethasone|Dexamethasone will be given at a dose of 4mg PO daily for five days every four weeks (i.e., days 1-5, 29-33, 57-61, 84-88, etc.).
223495428|NCT07121777|DRUG|Anti-CD19/BCMA CAR gene vector injection will be injected intravenously on a one-time basis|A single intravenous infusion of anti-CD19/BCMA CAR gene vector injection(dose-escalating infusion of 1.0-4.0 x10\^6 TU/kg）
223495429|NCT07121751|DRUG|use of combination of recombinant FSH and recombinant LH|in this arm the patients will use the combination of recFSH:recLH in the same dose as in her prior cycle
223495430|NCT07121751|DRUG|higher dose recFSH|in this arm the patient will use an additional 75 IU/day recFSH compared to her previous drug dose
223495431|NCT07121751|DRUG|unchanged dose|in this groups the patient will receive the same recFSH dose as in her prior cycle
223495432|NCT07116811|DRUG|Steroids therapy|Methylprednisolone sodium succinate 80 mg powder dissolved in 100 mL of sodium chloride solution (intravenous infusion, once daily) from the day of surgery to day 3, followed by 20 mg of prednisone acetate (oral intake, once daily) from day 4 to day 10.
223495433|NCT07116811|DRUG|Placebo|Methylprednisolone sodium succinate placebo powder dissolved in 100 mL of sodium chloride solution (intravenous infusion, once daily) from the day of surgery to day 3, followed by prednisone acetate placebo (oral intake, once daily) from day 4 to day 10.
223495434|NCT07120074|OTHER|Exercise|A low-activity exercise group, and highly active dual-task exercise group determined based on physical performance level, was subjected to 6 weeks of dual-task exercises aimed at improving balance and cognitive function. Dual-task refers to performing two different tasks simultaneously. In the first week, tasks included generating 3- and 4-letter words while standing in a tandem position, reciting the months and seasons in order while shifting weight forward and backward on a balance board, and performing addition and subtraction tasks while walking. The difficulty level of the tasks was increased each week.
223495435|NCT07121296|BEHAVIORAL|Contingency management for substance use|Participants receive escalating incentives for each consecutive negative weekly urine drug screen.
223495436|NCT07121296|BEHAVIORAL|Contingency management for attendance|Participants receive escalating incentives for each consecutive counseling session they attended.
223495437|NCT07121296|BEHAVIORAL|Group-based Matrix counseling|Group-based Matrix counseling
223495438|NCT07121296|BEHAVIORAL|Individual-based Matrix counseling|Individual-based Matrix counseling
223495439|NCT07119710|BEHAVIORAL|Cognitive Behavioral Therapy|Individual tele-therapy 12-16 weeks
223495440|NCT07119710|BEHAVIORAL|Cognitive Behavioral therapy with 2 check in calls|Cognitive Behavioral therapy with 2 calls a week
223495441|NCT07120581|OTHER|Hyperbaric Oxygen Therapy|Hyperbaric Oxygen Therapy at increasing pressure to 2.8 ATA for 2 hours sessions. Breaks of 5 every 20 minutes from the oxygen to air to avoid hyperoxia. Continued for the duration of the hospitalization in the ICU on a daily basis.
223495442|NCT03817398|PROCEDURE|Biospecimen Collection|Undergo blood collection
223495443|NCT03817398|OTHER|Drug Withdrawn|Stop taking TKI medication
223495444|NCT03817398|OTHER|Quality-of-Life Assessment|Ancillary studies
223495445|NCT03817398|OTHER|Questionnaire Administration|Ancillary studies
223495446|NCT03817398|DRUG|Tyrosine Kinase Inhibitor|Re-start TKI medication
223495447|NCT04804150|DEVICE|Vacuum suspension system active or inactive|The device will be plugged in, or won't be plugged in, depending of the randomization. The patient and the investigator will not know whether the device is plugged in or not, and if the medical device is active or not
223495448|NCT06105437|OTHER|BE-EMPOWERed program|The BE-EMPOWERed program entails a group program for older people, workshops for healthcare professionals and a 6-steps implementation plan for primary care areas. The group program for older people is based on the main principles of the Australian multifactorial falls prevention program 'Stepping On'. The workshops for healthcare professionals focus on the multifactorial falls prevention approach, reimbursement of healthcare costs, referrals to other healthcare professionals and motivational interviewing. The Implementation plan consists of 6-steps: 1. enable support, 2. map baseline situation, 3. define objectives and priorities, 4. plan implementation, 5. implementation and 6. evaluation, adjust and work towards sustainability. Last, to support the primary care areas, implementation facilitators were trained.
223495449|NCT01892852|PROCEDURE|Acupuncture|Acupuncture treatment will be performed by licensed doctors in Traditional Korean Medicine using 0.20 mm (diameter) X 0.40 mm (length) sized disposable acupuncture 3 times per week for 3 weeks. Acupuncture points are GV20, GB20 (bilateral), LI11 (bilateral), LI10 (bilateral), EX-UE9 (bilateral), ST36 (bilateral), ST40 (bilateral), and EX-LE10 (bilateral). Each session lasts 20-30 minutes.
223495450|NCT06002113|OTHER|GOCD Tool|Web-based tool with 4 components; pre-admission health status; current illness prognosis for hospital survival; in-hospital cardiorespiratory arrest prognosis; values and goals of care
223495451|NCT06002113|OTHER|Usual care|Attending physicians responsible for GOCD during hospitalization using their usual approaches
223495452|NCT06148883|PROCEDURE|Transcatheter Aortic Valve Implantation|Transcatheter Aortic Valve Implantation is the implantation of a biological aortic valve percutaneously
223495453|NCT06112145|OTHER|rehabilitation program|All fingers of the injured hand are fitted with a dorsal blocking orthosis. Early passive mobilization exercises in the form of passive flexion and extension and edema massage will be taught and it will be recommended to be applied every two hours during the day.
223495454|NCT02906618|DRUG|LY3039478|Administered orally
223589530|NCT01994993|DRUG|ampicillin and metronidazole and gentamicin|IV infusion of ampicillin and metronidazole and gentamicin for a total of 10 days. Dose based on postnatal age (PNA) and gestational age(GA)
223589531|NCT01994993|DRUG|ampicillin and gentamicin and clindamycin|IV infusion of ampicillin and gentamicin and clindamycin for a total of 10 days. Dose based on postnatal age (PNA) and gestational age(GA)
223495455|NCT02906618|DRUG|13C 15N 2H-LY3039478 IV|Administered IV
223495456|NCT04254211|OTHER|NLR|neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR)
223495457|NCT02874898|BEHAVIORAL|Brief Imaginal Exposure|Psychoeducation and imaginal exposure components of full prolonged exposure, in which patients relive the trauma vividly and process thoughts and feelings related to it
223495458|NCT04095013|DRUG|Bupivacaine, fentanyl|Group A: hyperbaric Bupivacaine 10mg with fentanyl 10micrograms,
223495459|NCT04095013|DRUG|Bupivacaine, dexmedetomidine|Group B: hyperbaric Bupivacaine 10 mg with dexmedetomidine5 micrograms
223495460|NCT01388426|DEVICE|7eye( Panoptx)™ moisture chamber glasses|moisture chamber glasses
223495461|NCT06256276|DIETARY_SUPPLEMENT|Whey protein powder and L-carnitine|Dietary supplement intervention for 16 weeks
223495462|NCT06256276|DIETARY_SUPPLEMENT|Maltodextrin placebo powder and Psyllium Husk capsules|Maltodextrin placebo powder and Psyllium Husk capsules
223495463|NCT02194075|DRUG|Fluvoxamine+Methylphenidate hydrochloride|
223495464|NCT02194075|DRUG|Fluvoxamine+sugar pill|
223495465|NCT00432432|DRUG|Infliximab and MTX|MTX 15mg weekly Infliximab 5mg/kg given at day 0, wk 2, wk6
223495466|NCT05057208|BIOLOGICAL|COVID|COVID vaccination
223495467|NCT02520973|OTHER|Sputum sample|
223495468|NCT05804903|DEVICE|(ALLEGRA Plus Transcatheter Heart Valve) TAVI in severe calcified aortic stenosis or in failed surgical aortic bioprosthesis|Implantation of the ALLEGRA Plus Transcatheter Heart Valve in severe calcified aortic stenosis or in failed surgical aortic bioprosthesis
223589532|NCT01994993|DRUG|gentamicin and Piperacillin- tazobactam|IV infusion of gentamicin and Piperacillin- tazobactam for a total of 10 days. Dose based on postnatal age (PNA) and gestational age(GA)
223589533|NCT01994993|DRUG|standard of care antibiotics and metronidazole|IV infusion of standard of care antibiotics and metronidazole for a total of 10 days. Dose based on postnatal age (PNA) and gestational age(GA)
223589534|NCT01994993|DRUG|metronidazole, clindamycin, or piperacillin-tazobactam|IV infusion of metronidazole, clindamycin, or piperacillin-tazobactam with scheduled CSF procedures per standard of care. Study drug will be given for for a total of 10 days. Dose based on postnatal age (PNA) and gestational age(GA)
223589535|NCT02228096|BIOLOGICAL|CTL019 T-cells|A target dose of CTL019 transduced cells will consist of a single infusion of 2.0 to 5.0 x 10\^6 CTL019 transduced cells per kg body weight (for patients ≤ 50 kg) and 1.0 to 2.5 x 10\^8 CTL019 transduced viable T cells (for patients \> 50 kg). The following cell dose ranges may be infused if all other safety release criteria are met: 0.2 to 5.0 x 10\^6 CTL019 transduced viable T cells per kg body weight (for patient ≤ 50 kg) and 0.1 to 2.5 x 10\^8 CTL019 transduced viable T cells (for patients \> 50 kg).
223589536|NCT02412059|DRUG|Prednisolone acetate|
223589537|NCT05517694|OTHER|Pelvic floor exercises and behavioral therapy|Pelvic floor exercises and behavioral therapy interventions include a 4-step treatment protocol: 1) awareness of the pelvic floor muscles, 2) teaching the specific contraction of the pelvic floor muscles, 3) teaching the timing of the contraction and maintenance of the pelvic floor muscles during the intercourse pre-orgasmic sensation with start-stop behavioral therapy, 4) the strengthening exercises of the pelvic floor muscles. For slow twitch fibers, 15 repetitive exercises including 10 seconds of submaximal contraction followed by 10 seconds of relaxation, and 10 repetitive exercises including 1 second submaximal contraction followed by 1 second relaxation for fast-twitch fibers will be given 2 times a day, 3 days a week, 8 weeks.
223589538|NCT05517694|OTHER|Respiratory exercises|"Pelvic floor exercises and behavioral therapy interventions include a 4-step treatment protocol: 1) awareness of the pelvic floor muscles, 2) teaching the specific contraction of the pelvic floor muscles, 3) teaching the timing of the contraction and maintenance of the pelvic floor muscles during the intercourse pre-orgasmic sensation with start-stop behavioral therapy, 4) the strengthening exercises of the pelvic floor muscles. For slow twitch fibers, 15 repetitive exercises including 10 seconds of submaximal contraction followed by 10 seconds of relaxation, and 10 repetitive exercises including 1 second submaximal contraction followed by 1 second relaxation for fast-twitch fibers will be given 2 times a day, 3 days a week, 8 weeks.~Respiratory exercises will be given 6 breaths/minute with expiration and inspiration times of 7 seconds and 3 seconds, respectively. At least 10 diaphragmatic breaths will be given in each session, 2 times a day, 7 days a week, 8 weeks."
223589539|NCT03150732|DRUG|Systemic nalbuphine|Patients will receive systemic nalbuphine 10 mg
223495469|NCT03991767|OTHER|"POP-UP electronic alert"|"Implementation of the POP-UP electronic alert for all patients with eligibility criteria"
223495470|NCT03991767|DIAGNOSTIC_TEST|Serology HIV|Realization of HIV serology for included patients.
223589540|NCT03150732|DRUG|Local nalbuphine|Patients will receive local nalbuphine 10 mg
224186610|NCT01661426|BEHAVIORAL|Low-Fat Diet|Counseling/instruction on how to follow a healthy low-fat diet for 6 months. One evening class/week for 8 weeks (8 total classes). Then one class every other week for 8 weeks (4 total classes). Then one class every four weeks for 8 weeks (2 total classes): 14 evening classes, total.
224186611|NCT06243679|DRUG|Immunotherapy|Monotherapy with PD-1 inhibitors, up to 1 year.
224186612|NCT00001568|DRUG|2-Fluoro-2-deoxyglucose|
224186613|NCT05935137|DIAGNOSTIC_TEST|Coagulation test on device ClotPro|The blood sample for coagulation test on device ClotPro will be take for both group and the test will be provided.
224186614|NCT06193343|BEHAVIORAL|Adaptive Daily Step Promotion|"Participants will wear a Fitbit monitor on their non-dominant wrist during a 10 to 14 day run-in screening to capture daily steps reported by the Fitbit but no daily step goals will be sent to the participant. The Fitbit monitor will be worn during all waking hours except water activities, and compliance will be considered as a day with ≥1,000 steps. Next, participants will undergo a 16-week intervention wearing the Fitbit monitor on their wrist and receive a text message each morning with a personalized, adaptive daily step count goal and a link used to confirm receipt of the goal. The preceding 10 days of step data will be rank ordered and the 60th percentile step count will be set as the goal for the next day. Goals will not exceed 10,000 daily steps."
224186615|NCT06045026|OTHER|Stannous fluoride|Anti-sensitivity toothpaste containing 0.454% Stannous Fluoride
224186616|NCT06173882|BEHAVIORAL|Ordinary moxibustion volume group|Moxibustion for 10 minutes per acupoint
223495471|NCT00876395|DRUG|Everolimus|Everolimus was administered in a continuous oral daily dosing of 10 mg (two 5-mg tablets).
223495472|NCT00876395|DRUG|Placebo|Everolimus placebo was administered in a continuous oral daily dosing of 10 mg (two 5-mg tablets).
223495473|NCT00876395|DRUG|Trastuzumab|Trastuzumab, 2 mg/kg weekly was used intravenously.
223495474|NCT00876395|DRUG|Paclitaxel|Paclitaxel, 80 mg/m2 weekly was used intravenously.
223495475|NCT03168724|BEHAVIORAL|GMT intervention|
223495476|NCT06031129|DRUG|Butorphanol|The pharmacological attributes of Butorphanol, characterized by its mild impact on cardiopulmonary dynamics and demonstrated efficacy in attenuating mechanical traction-induced discomfort, culminate in an ameliorative effect on postoperative nausea and vomiting rates. Importantly, it substantively attenuates visceral postoperative pain. However, sedation can also cause dizziness, drowsiness, and other adverse reactions during recovery
223495477|NCT06031129|DRUG|normal saline|normal saline contain 0.9% NaCl sodium.
223495478|NCT01405573|OTHER|Best Supportive Care|Therapy given according to clinical practices at participating centres. Experimental therapies not permitted.
223495479|NCT01405573|DRUG|sorafenib|400 mg twice a day
223495480|NCT01850329|OTHER|computed-assisted information program|
223495481|NCT06505148|DRUG|Acetaminophen|administered alternatively with other drug
223495482|NCT06505148|DRUG|Ibuprofen|administered alternatively with other drug
223495483|NCT02666599|RADIATION|18F-FDG PET/CT|"A 18F-FDG PET/CT will be done. A dose of 19 µSv/MBq will be received by the patient. Surgery will be conducted within 3 hours after the I.V. injection of 18F-FDG according to the standard procedure applied in the visceral surgery department. During the surgery, emission of β+ from the lesion (s) seen durint the PET/CT will be detected with the probe.~Resected pieces will be analysed histologically."
224186617|NCT06173882|BEHAVIORAL|First group of heavy moxibustion|Moxibustion for 20 minutes per acupoint
224186618|NCT06173882|BEHAVIORAL|Second groups of heavy moxibustion|Moxibustion for 30 minutes per acupoint
224186619|NCT00000740|DRUG|Sitamaquine|
224186620|NCT03379324|BIOLOGICAL|Superiority of augmented repairs|4cc of FlōGraft® injected into repair subject tissue divided evenly between repair site and muscle body
223495484|NCT03588520|DIAGNOSTIC_TEST|Home Blood Pressure Monitoring|Patients randomly assigned to the HBP-guided management group will perform home BP monitoring for 7 days with the use of a validated self-inflating automatic oscillometric device (HEM 705 CP, Omron Healthcare). Home BP monitoring will be performed according to the currently available European Society of Hypertension guidelines at the baseline visit and will be repeated 1 week before the prespecified follow-up visits (at Month 1, Month 2 and Month 4). Patients randomly assigned to the control group will receive conventional management of hypertension based on office BP recordings obtained with the same BP monitor (HEM 705 CP, Omron Healthcare) during the same prespecified follow-up visits.
224186621|NCT03379324|BIOLOGICAL|Fat degeneration of supraspinatus muscle|4cc of FlōGraft® injected into repair subject tissue divided evenly between repair site and muscle body
224186622|NCT04755751|DIAGNOSTIC_TEST|Cardiopulmonary exercise testing (CPET)|CPET using a cycle ergometer (COSMED, Rome, Italy) beginning with a no resistance warm up lasting 1 to 3 minutes and followed with an incrementing resistance adapted to the patient's functional capacities according to the examiner's free judgment and ranging from no resistance (20 Rounds Per Minute (RPM)/minute) 5 to 20 Watts/minute on ramps or by successive stages
224186623|NCT00495963|PROCEDURE|bronchoaleolar lavage|
223495485|NCT00482144|PROCEDURE|PDL 450 microseconds|The scar will be randomly divided into three equal fields. One third of the scar will receive PDL 585 nm using a 7 mm spot size at 4.0 J (Joules) for 450 microseconds. First treatment will be immediately after suture removal, and then monthly for 3 months.
223495486|NCT00482144|PROCEDURE|PDL 1.5 milliseconds|The scar will be randomly divided into three equal fields. One third of the scar will receive PDL 585 nm using a 7 mm spot size at 4.0 J (Joules) for 1.5 milliseconds. First treatment will be immediately after suture removal, and then monthly for 3 months.
223495487|NCT03807843|BIOLOGICAL|V184|Recombinant live Schwarz-strain measles-vectored vaccine expressing chikungunya virus structural proteins. Liquid frozen, life attenuated, measles vectored V184 vaccine administered via IM injection at 5 × 10\^5 TCID50 (+/- 0.5 log) per dose.
223495488|NCT03807843|OTHER|Placebo|Sterile physiological saline for IM injection
223495489|NCT00386698|BIOLOGICAL|Fluarix|
223495490|NCT00386698|BIOLOGICAL|adjuvanted influenza vaccine|
223495491|NCT01312129|DRUG|Sulfasalazine|500mg capsules of Sulfasalazine x 3 doses 12 hours apart.
223495492|NCT01312129|DRUG|Placebo|Placebo capsule x 3 doses 12 hours apart
224186624|NCT00495963|PROCEDURE|Bronchoscopy|
224186625|NCT02695758|PROCEDURE|Interscalene brachial plexus block|
224186626|NCT02695758|PROCEDURE|bupivacaine extended-release liposome injection|
224186627|NCT04550234|DRUG|Verinurad prolonged release HPMC capsule|Randomized subjects will receive oral dose of verinurad HPMC capsule.
224186628|NCT04550234|DRUG|Allopurinol Tablet|Randomized subjects will receive oral dose of allopurinol tablet.
224186629|NCT04550234|DRUG|Verinurad/Allopurinol FDC Capsule|Randomized subjects will receive oral dose of Verinurad/Allopurinol FDC capsule.
223495493|NCT02961725|BIOLOGICAL|UCMSC|UCMSC: umbilical cord mesenchymal stem cells 3-5\*10\^7/5 ml
223495494|NCT05053828|DRUG|Antiplatelet Drug|Antiplatelet drugs and agents
223495495|NCT03685513|OTHER|BioHPP PEEK-based single posterior crowns|BioHPP PEEK is 20% ceramic reinforced, semicrystalline, thermoplastic and radiolucent polymer for extreme durability especially for frameworks for fixed and removable dental prostheses. It has many advantages as low density, light weight, shock absorber, biocompatible and venerable with composite resin.
223495496|NCT03685513|OTHER|Metal ceramic single posterior crowns|Standard metal coping veneered with glass ceramics
223495497|NCT03975634|DEVICE|Transcutaneous Spinal Stimulation|Safety and feasibility will be monitored during transcutaneous spinal stimulation in children with spinal cord injury
223495498|NCT00496457|DRUG|Experimental|Capsules of TRO19622 (125 mg)- Once a day before noon meal during 6 weeks
223495499|NCT00496457|DRUG|Placebo comparator|4 Capsules of PBO per day before noon meal
223495500|NCT04674527|DRUG|Elemene|Elemene injectable emulsion will be given for 80 mg/day in each 14-day cycle.
223495501|NCT04674527|DRUG|Temozolomide|Maintenance chemotherapy with TMZ will be administered at 150 mg/m2/day for 5 days in each 28-day cycle.
223495502|NCT00104234|DRUG|N-acetylgalactosamine 4-sulfatase|
223495503|NCT00104234|DRUG|Placebo/rhASB|
223495504|NCT02315820|PROCEDURE|Induction of labor group (Group I)|Women at 38-40+3 weeks with estimated fetal weight 3800-4500 will be offered ripening and IOL.
223495505|NCT01233830|DRUG|AZD2423|oral solution
224186630|NCT04550234|DRUG|Verinurad prolonged release gelatin Capsule|Randomized subjects will receive oral dose of Verinurad gelatin capsule.
224186631|NCT03815201|DIETARY_SUPPLEMENT|Group 2|leucine-enriched protein supplementation during the first 1/2 hour post-training
224186632|NCT03815201|OTHER|Group 1|placebo, an energy-matched mixture, during the first 1/2 hour post-training
224186633|NCT00556309|DEVICE|Optical Coherence Tomography|Optical Coherence Tomography Imaging of Post Coil Aneurysm Healing.
224186634|NCT06366035|DEVICE|LoVE4MUM mobile application|LoVE4MUM is an innovative mobile application developed based on cognitive behavioral therapy and psychoeducation. The mobile application consist of 5 main modules which delivers information pertaining self-care, postpartum depression, handling negative thoughts, mood tracking and information for seeking help. The module consist of short notes, videos and worksheets for the participants to conduct.
224186635|NCT00081900|DRUG|DENSPM )|Each patient will receive DENSPM at an initial dose of 30mg/m\^2, then escalating to 120mg/m\^2, single IV infusion on D1,3,5,8,10,12 of every 28 days as one cycle, planned for 8 cycles if no withdrawn occur
224186636|NCT03398759|DRUG|Butorphanol|IV injection during induction
224186637|NCT03398759|DRUG|Placebos|IV injection during induction
224308858|NCT00274820|DRUG|thalidomide|The dose of thalidomide will be 50 mg PO daily starting day 1. The dose will be increased to 100mg PO daily after two weeks if tolerated and only if patients experience \< grade 1 thalidomide-attributed toxicity using CTC criteria.
223589541|NCT02619032|DRUG|Remifentanil|Intraoperative continuous infusion of remifenatanil. Remifentanil infusion was interrupted upon completion of surgical intervention.
223589542|NCT02619032|DRUG|Fentanyl|Fentanyl 50 μg iv bolus at the induction of anesthesia and before the start of surgery.
224186638|NCT06259825|OTHER|Omega-3 polyunsaturated fatty acid, naturally enriched, poultry foods (chicken-meat and eggs)|At least four portions of omega-3 PUFA enriched chicken-meat (whole chickens, breasts, thighs and drums) and at least four omega-3 PUFA enriched eggs will be consumed weekly for 4 months. The poultry meat and eggs will be enriched by feeding chickens a complete feed which includes algae, which is a rich source of omega-3 PUFAs (OmegaPro, Humanitiv, Meath, Ireland).
224186639|NCT06259825|OTHER|Control poultry foods (chicken-meat and eggs)|At least four portions of standard chicken-meat (whole chickens, breasts, thighs and drums) and at least four standard eggs will be consumed weekly for 4 months.
224186640|NCT00231322|DRUG|praziquantel|
224186641|NCT02654405|DIETARY_SUPPLEMENT|Sodium Butyrate|6.57 gms of sodium butyrate per day for 12 weeks
224186642|NCT02654405|OTHER|Placebo|placebo capsules containing approximately 9 mg of sodium butyrate/day
224186643|NCT01579682|BEHAVIORAL|Family-Based Therapy (FBT)|12 sessions of FBT over the course of 6 months.
224186644|NCT01579682|BEHAVIORAL|Family-Based Therapy with Intensive Family-Focused treatment|FBT for 4 weeks then Intensive Family-Focused treatment (IFT) should the participant not make adequate weight progress within the time frame.
224186645|NCT05637931|DIAGNOSTIC_TEST|plexinD1|evaluation of the serum level of plexinD1
224308859|NCT01345916|DRUG|CHF 1535 100/6 NEXT DPI® 2 months|CHF 1535 100/6 NEXT DPI® 2 months
224308860|NCT01345916|DRUG|CHF 1535 100/6 pMDI 2 months|CHF 1535 100/6 pMDI 2 months
223495506|NCT01233830|DRUG|Placebo|oral solution
223495507|NCT00236431|DRUG|Galantamine hydrobromide|
223495508|NCT02113566|DRUG|Acetaminophen 1000mg|Subjects who require rescue medication between hours 4 and 6 will be allowed to take Dose 2 of the study medication. If the subject chooses to take a rescue analgesic (acetaminophen 1000mg), they will be considered a treatment failure. This intervention will be use for the placebo and Ibuprofen arm.
223495509|NCT00924651|BEHAVIORAL|exercise|home based walking and progressive resistance training exercise
223495510|NCT05885958|OTHER|Time|Patients will be given up to 30 minutes to void.
223495511|NCT05885958|OTHER|Time|Patients will be given up to 60 minutes to void.
223495512|NCT02080130|DIETARY_SUPPLEMENT|Saccharomyces boulardii|FLORATIL®. Saccharomyces boulardii 200 mg sachet. One sachet orally, BID, for 5 days.
223495513|NCT02080130|DIETARY_SUPPLEMENT|Probiotics combination|LACTIPAN®. Probiotics combination sachet. One sachet orally, BID, for 5 days. Lactobacillus acidophilus............. 1.00 x 109 cfu Lactobacillus casei........................ 1.00 x 109 cfu Lactobacillus rhamnosus............. 4.40 x 108 cfu Lactobacillus plantarum............... 1.76 x 108 cfu Bifidobacterium infantis................ 2.76 x 107 cfu Streptococcus thermophillus....... 6.66 x 105 cfu
223495514|NCT02080130|OTHER|Placebo|Placebo
223495515|NCT02663986|BEHAVIORAL|Organizational Skills Training (OST) Intervention|
223495516|NCT02078466|OTHER|Assessment of functional ability and follow-up at home|Assessment of functional ability and follow-up at home
223495517|NCT06224049|BIOLOGICAL|hNeo-T|After subject screening, peripheral blood mononuclear cell （PBMC） donors matching half or more of the subject's HLA matching will undergo blood collection to prepare hNeo-T. hNeo-T preparation is expected to be 25-30 days after blood collection. In this study, the bridging therapy will be allowed before Chemotherapy preconditioning, and the investigators will decide whether to use it. Chemotherapy preconditioning will be performed before hNeo-T transfusion. If the absolute value of lymphocyte (LYM) before pretreatment is \<0.8×10\^9/L and the subject meets the criteria for cell transfusion, the chemotherapy preconditioning will not be performed and subsequent cell transfusion can be performed directly.
223495518|NCT06224049|DRUG|Cyclophosphamide|Chemotherapy preconditioning will be performed before hNeo-T transfusion.
223495519|NCT06224049|DRUG|Fludarabine|Chemotherapy preconditioning will be performed before hNeo-T transfusion
223495520|NCT00214435|DRUG|once daily minimum 3-drug regimen of anti-retroviral medications|
223495521|NCT05709080|OTHER|family-professional collaboration practice model|Online instructional sessions will be conducted in two sessions for six hours (3 hours per session) for the physical therapists in the experimental group. The instructional session focus on explaining the specific strategies and process to implement the Family-professional Collaboration (four step process) Model as ( Step 1: Mutually agreed-upon goals, Step 2: Shared planning, Step 3: Shared implementation and Step 4: Shared evaluation of child and family outcomes.
223495522|NCT01865851|DEVICE|Classic Face Mask and NuMask|
223495523|NCT06532942|DRUG|(Part A) MKND-201|Participants will receive single ascending doses (Target Dose, High Dose, and Very High Dose) of MKND-201 or placebo administered via oral inhalation on Day 1
223495524|NCT06532942|DRUG|Placebo|Participants will receive matching placebo across Part A and Part B of the study.
223495525|NCT06532942|DRUG|(Part B) MKND-201|Participants will receive multiple ascending doses (Target Dose and High Dose) of MKND-201 or placebo administered via oral inhalation, twice daily, from Day 1 to Day 7
224308861|NCT01345916|DRUG|BDP DPI 2 months|BDP DPI 2 months
224308862|NCT05508841|OTHER|tDCS and Cognitive Training|Participants will receive mild stimulation or no stimulation along with cognitive training
223495526|NCT04134871|BEHAVIORAL|Group walk and one to one coaching|Participants will be invited to attend a group education session, weekly group walks and fortnightly coaching sessions
223495527|NCT00563173|DRUG|CHRONVAC-C®|DNA vaccine, solution for injection, i.m. administration in combination with electroporation
223495528|NCT03445429|OTHER|3D-display system|The subjects will perform tasks on a minimal-invasive/laparoscopic training set-up. They will perform the tasks with a 3D-display system or a 4K-display system. The intervention type 3D-display system means that the training-set up is performed first with 3D-display system an after that with the 4K-display system.
223495529|NCT03445429|OTHER|4K-display system|The subjects will perform tasks on a minimal-invasive/laparoscopic training set-up. They will perform the tasks with a 3D-display system or a 4K-display system. The intervention type 4K-display system means that the training-set up is performed first with 4K-display system and after that with the 3D-display system.
223495530|NCT01991314|DRUG|Ferrous sulphate|200mg tablets.
224186646|NCT00405665|DRUG|L-arginine|Group 1 will receive the active treatment followed by the inactive treatment. The active treatment phase will consist of L-arginine 250 mg/ml dispensed in 2.2 ml vials, from which the patient will take 2ml (500mg) and dilute with 3ml of sterile water to give 5ml of a 100mg/ml solution. Dosing in the inactive treatment phase will consist of a placebo of similar osmolarity and appearance will be formulated and dosed in a similar fashion. It will consist of 2.2ml vials of 1110mmol/L hypertonic saline. Again, the patient will take 2ml and dilute with 3ml of sterile water to give a 445mmol/L solution which has similar tonicity (10%) to the L-arginine. Both treatment phases will be administered by inhalation with a PARI eFLOW device.
224186647|NCT00405665|DRUG|L-arginine|Group 2 will receive the inactive treatment followed by the active treatment.
224186648|NCT04765761|DEVICE|PLMA with introducer|The pro-seal laryngeal mask airway (PLMA) will be inserted along with introducer tool which will be kept in-situ throughout the duration of positive pressure ventilation
224186649|NCT04765761|DEVICE|PLMA without introducer|The pro-seal laryngeal mask airway (PLMA) will be inserted along with introducer tool which will be removed after insertion and patient will be ventilated using PLMA without the introducer in-situ throughout the duration of positive pressure ventilation
224186650|NCT01826305|PROCEDURE|Formal Rehabilitation Therapy|Patients that will be randomized to the formal rehabilitation therapy cohort will be prescribed formal therapy for twelve weeks with supervised exercises to regain knee strength and range of motion. Therapists will not be involved in the study design and therapists will not be informed that patients are participating in this study. The content, frequency, and duration of the rehabilitation program will be at the discretion of the treating therapist, consistent with usual practice.
224186651|NCT01826305|PROCEDURE|Independent Exercise Cohort|The patients who will be in the independent exercises cohort will be registered on www.careforpatients.com, an online rehabilitation resource that provides computer aided rehabilitative exercises. Patients will follow a prepared 12-week protocol of exercises to perform post-operatively to gradually regain their knee strength, flexion, extension, abduction, and adduction.
224186652|NCT02345499|PROCEDURE|Laparoscopic radical cystectomy with open urinary diversion|Laparoscopic surgical procedure in which the bladder is removed because of bladder cancer and a urinary diversion is performed
224186653|NCT02345499|PROCEDURE|Open radical cystectomy with open urinary diversion|Open surgical procedure in which the bladder is removed because of bladder cancer and a urinary diversion is performed
224186654|NCT00742404|DRUG|bortezomib|
224186655|NCT00742404|DRUG|dexamethasone|
223495531|NCT02190058|DRUG|DS-1971a|suspension
223495532|NCT02190058|DRUG|placebo|placebo matching DS-1971a
223495533|NCT00209482|DRUG|glucophage XR|
223495534|NCT03834012|DRUG|Beclomethasone 800 µg per day|Intervention: Drug: Beclomethasone 800 µg HFA per day
223495535|NCT03834012|DRUG|Placebo|Intervention: Drug: placebo
223495536|NCT03834012|DRUG|Beclomethasone 400 µg per day|Intervention: Drug: Beclomethasone 400 µg HFA per day
223495537|NCT03834012|DRUG|Beclomethasone 640 µg per day|Intervention: Drug: Beclomethasone 640 µg per day
223495538|NCT05502172|DIETARY_SUPPLEMENT|fish oil|healthy individuals will be taking the composition of fish-deraivd oils BioMarine®Medical Immuno \& Neuro Lipids at a dose of 0.5 ml / kg body weight per day in two / three divided doses for 90 days.
223495539|NCT06215495|RADIATION|reduced target volume|"Delineate residual tumor(GTVp) and tumor bed(GTVtb) on enhanced contrast CT-MRI(T2 fluid attenuated inversion recovery, T2 FLAIR) fusion images. GTVtb and GTVp are expanded by 1cm to CTV\_6000.~The clinical target volume\_6000 cGy (CTV\_6000) is partially reduced beyond the skull and midline. According to the CT-MRI(T2 FLAIR) fusion images, the edema area that cannot be seen on contrast-enhanced CT and only can be seen on MRI should be included.~If CTV\_6000 includes thalamus, basal ganglia, brainstem or motor cortex, dose of these areas will be limited no more than 54Gy"
223495540|NCT06215495|RADIATION|EORTC (European organisation for research and treatment of cancer) target volume|delineate according to EORTC guideline
223495541|NCT05408988|DIAGNOSTIC_TEST|hs-TnT (high-sensitive cardiac troponin T) plasma concentration|hs-TnT plasma concentration measured once every 12 hours
223495542|NCT05408988|DIAGNOSTIC_TEST|CK-MB (creatine kinase myocardial band) plasma concentration|CK-MB plasma concentration measured every 12 hours
223495543|NCT05408988|DIAGNOSTIC_TEST|CPK (creatine phosphokinase) plasma concentration|CPK plasma concentration measured every 12 hours
223495544|NCT05408988|DIAGNOSTIC_TEST|NT-proBNP (N-terminal prohormone of brain natriuretic peptide) plasma concentration|NT-proBNP plasma concentration measured every 12 hours
223495545|NCT05408988|DIAGNOSTIC_TEST|Metanephrine concentration in urine|Metanephrine concentration measured in 12-hour urine collection using spectrophotometry.
223495546|NCT01609972|DEVICE|Spinal Cord Stimulator|Non-inferior comparison of implantable spinal cord stimulators
223495547|NCT04621084|BEHAVIORAL|Eating habits|Questionnary online
223495548|NCT03382093|BEHAVIORAL|Personalized Feedback Intervention|Personalized Feedback Intervention for smoking and anxiety.
223495549|NCT03382093|BEHAVIORAL|Smoking Information Control|Smoking Information with no personalized feedback.
223495550|NCT00974870|PROCEDURE|needling treatment|Needling treatment applied to half of the face at each study visit
223495551|NCT02650752|DRUG|Lapatinib in Tandem With Capecitabine|
224186656|NCT00742404|DRUG|pegylated liposomal doxorubicin hydrochloride|
224186657|NCT00742404|GENETIC|protein analysis|
224186658|NCT00742404|OTHER|immunologic technique|
224186659|NCT04752007|RADIATION|ASLR; CT; SI joint movement: stright leg raise with 1 kg load|Measurement of the SI joint movement in mikrometer
224186660|NCT04752007|RADIATION|Fig.Four; CT; SI joint movement: One side figure of four position with 1 kg load|Measurement of the SI joint movement in mikrometer
224186661|NCT04752007|RADIATION|Supine; CT; SI joint movement: supine position|Baseline position
224186662|NCT04752007|RADIATION|ASLR; RSA; SI joint movement: stright leg raise with 1 kg load|Measurement of the SI joint movement in mikrometer
224186663|NCT04752007|RADIATION|Fig.Four; RSA; SI joint movement: One side figure of four position with 1 kg load|Measurement of the SI joint movement in mikrometer
224186664|NCT04752007|RADIATION|Supine; RSA; SI joint movement: supine position|Baseline position
224186665|NCT02857049|OTHER|Oral nutritional supplements (ONS) degustation|
224186666|NCT00408408|BIOLOGICAL|bevacizumab|15 mg/kg IV
223495552|NCT01936155|DEVICE|Custom-built, two-channel stimulator|Custom-built, two-channel stimulator for stimulation of the soleus calf muscle
223495553|NCT03201107|OTHER|Pilates|"Training based on a basic level Pilates exercise program will be as follows:~A duration of weeks with a frequency of 2 sessions a week and with a duration of 55 minutes each. The exercises to be performed will be divided into three distinct phases: warm-up, lasting 15 minutes; Main part with a duration of 30 minutes and the return to calm, based mostly on stretching and with a duration of 10 minutes. The repetitions of the exercises will be between 5 and 10 according to the difficulty."
223495554|NCT02126332|OTHER|ropivacaine and sufentanil|Thoracic epidural analgesia will be performed using ropivacaine (2 mg/ml), sufentanil (0.5 microg/ml) administered through a patient-controlled deviced (PCEA : patient-controlled epidural analgesia). PCEA parameters will be fixed as follows : continuous administration of 5 to 15 ml/h and bolus of 3 to 10 ml every 10 minutes. Iterative epidural administration of clonidine (1 mckg/kg) will be allowed to achieve analgesia goals.
223495555|NCT02126332|OTHER|acetaminophen, nefopam, tramadol, opidoids|Conventional analgesia will include enteral and/or parental administration of usual analgesics, ranging from step 1 to step 3 drugs according to WHO classification (including acetaminophen, nefopam, tramadol, opidoids). The route, dose and frequency of analgesics administrations will be based on participating ICUs protocols.
223495556|NCT00970944|DRUG|Amantadine Hydrochloride|184 patients who remain in VS or MCS 4 - 16 weeks post-TBI will be randomized in a stratified fashion to 4 weeks of amantadine (200 - 400 mg/day) followed by a 2-week washout period. The Disability Rating Scale (DRS) will be the primary dependent variable with the Coma Recovery Scale-Revised (CRS-R) serving as a supplementary measure.
223495557|NCT00970944|DRUG|Placebo|Placebo administered twice daily.
223495558|NCT06324591|OTHER|Collection biological sample and analysis|collection of a stool sample collected at clinical practice check-ups during the first year after diagnosis of Crohn's disease. This is followed by the evaluation of clinical, laboratory and instrumental data at the time of diagnosis
223495559|NCT00662259|DRUG|Alprazolam (Xanax)|Drug dose will be fixed across patients: alprazolam 0.5 mg b.i.d escalating to 1.0 mg b.i.d. The treatment duration will be approximately 28 days (4 weeks).
223495560|NCT00662259|DRUG|Placebo|Placebo, bid, p.o. for 28 +/- 2 days.
223495561|NCT05415657|DRUG|Denosumab|Denosumab 60 mg per 6 month were injected subcutaneously on the same day after lumbar fusion surgery, and all participants received calcium supplementation 1200 mg/D and vitamin D 800 IU/D.
223495562|NCT05415657|DRUG|Placebo|Equal volume of saline (0.9%) as placebo Q6M were injected subcutaneously on the same day after lumbar fusion surgery, and all participants received calcium supplementation 1200 mg/D and vitamin D 800 IU/D.
223495563|NCT02537496|PROCEDURE|Repetitive Transcranial Magnetic Stimulation|Active treatment will be delivered at 90% resting motor threshold intensity. Stimulation will be administered at 20 Hz with 25 stimulation trains of 30 stimuli each with an inter-train interval of 30 sec. Treatment will be applied in sequential order bilaterally to the left and right DLPFC.
223495564|NCT02537496|PROCEDURE|Repetitive Transcranial Magnetic Stimulation - Sham|Same stimulation parameters and site as active condition will be used, but with placebo coil which will have minimal direct brain effects
223495565|NCT02661724|BEHAVIORAL|TCBR-Pain|The interactive TCBR-Pain uses programmed learning, skill development and behavioral practice to engage persons with burn pain in self-management of pain and related problems. The TCB-Pain program includes 7 lessons addressing key dimensions of pain management for persons with burn injury. Each session is about 20 minutes and focuses on burn injury recovery and life style education. Sessions begin with a brief self-assessment and in later sessions, the participant is given graphical feedback on their progress. The lessons are narrated and include closed captioning, are animated, and include branching to provide personalized content.
223495566|NCT02323438|OTHER|Usual Brand Cigarette|Combustible cigarette brand style smoked most frequently by subject
223495567|NCT02323438|OTHER|Electronic Cigarette #1|Electronic cigarette
223495568|NCT02323438|OTHER|Electronic Cigarette #2|Electronic cigarette
223495569|NCT02323438|OTHER|Leading U.S. Nicotine Gum|4 mg nicotine polacrilex gum
224186667|NCT00408408|DRUG|capecitabine|825 mg/m2 orally
223495570|NCT01033942|DRUG|coformulated emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF) as PrEP|Subjects receive PrEP and receive clinical follow-up visits every four weeks for 24 weeks.
223495571|NCT01033942|DRUG|Placebo|Subjects receive placebo and receive clinical follow-up visits every four weeks for 24 weeks.
223495572|NCT01033942|BEHAVIORAL|Many Men, Many Voices (3MV)|Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.
223495573|NCT02693418|DRUG|Acidform 5 g|Effect of 5 g vaginally administered Acidform on pH over 7 days
223495574|NCT02693418|DRUG|Placebo 4 g|Effect of 4 g of vaginally administered HEC placebo gel on pH over 7 days
223495575|NCT02693418|DRUG|Acidform 4 g|Effect of 4 g vaginally administered Acidform on pH over 7 days
223495576|NCT02693418|DRUG|Acidform 3 g|Effect of 3 g vaginally administered Acidform on pH over 7 days
223589543|NCT00625638|BEHAVIORAL|Interactive Voice Response System|Phone calls made once daily, each taking about 3-5 minutes to complete.
223495577|NCT03558724|DRUG|Bevacizumab-IRDye800CW|Intravenous administration of 4.5, 10 or 25 mg of Bevacizumab-IRDye800CW prior to the endoscopic procedure
223589544|NCT00625638|OTHER|Standard Care|Participants will return with the caregiver on day 15 to complete a questionnaire lasting 30 minutes.
223589545|NCT00278811|PROCEDURE|mobile crisis team|
223589546|NCT03084354|OTHER|Semi-structured interviews|Semi-structure interviews to gain a deep understanding of women's experiences of maternity bladder care. Interviews will last between thirty minutes to a couple of hours and they will be digitally recorded and transcribed verbatim.
223589547|NCT04084821|OTHER|none - observation only|Observational retrospective cohort to describe data validity; and Data reliability; and Completeness of the data
224186668|NCT00408408|DRUG|cyclophosphamide|600 mg/m2 IV
224186669|NCT00408408|DRUG|docetaxel|100 mg/m2 IV
224186670|NCT00408408|DRUG|doxorubicin hydrochloride (Adriamycin)|60 mg/m2 IV
224186671|NCT00408408|DRUG|gemcitabine hydrochloride|1000 mg/m2 IV
224186672|NCT00983125|DRUG|Clonidine|"Addition of a non-labeled drug (clonidine) in one of the two arm of the study, with randomisation.~To compare the effects of a systematic addition of clonidine (150 µg added in the solution bag) in the local anesthetic solution), versus no addition, on the quality of analgesia for labour."
224186673|NCT02789566|DRUG|Primaquine|Primaquine 30 mg taken after meal in the morning.
224186674|NCT02662959|DRUG|Irinotecan|180 mg/m2, IV (in the vein) on day 1 of each 14 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
224186675|NCT04464876|DEVICE|SATURN TA System|SATURN TA TMVR Device implanted
224186676|NCT03249259|DRUG|Choline alfoscerate|Treatment duration is 6 months and can be extended to 12 months with participant's agreement.
224186677|NCT03249259|DRUG|Placebo|Treatment duration is 6 months and can be extended to 12 months with participant's agreement.
224186678|NCT00267202|DRUG|Placebo|Doses of placebo were administered subcutaneously every 2 to 4 weeks according to the US product label, depending on the patient's body weight and baseline serum IgE.
224186679|NCT00267202|DRUG|Omalizumab|Doses of omalizumab were administered subcutaneously every 2 to 4 weeks according to the US product label, depending on the patient's body weight and baseline serum IgE.
224186680|NCT00267202|DRUG|Immunotherapy|"Customized allergen extracts were prepared centrally for each patient based on his/her specific skin test results. Four vials containing dilutions of the patient's extract were provided. Investigators initiated dosing according to the protocol for the cluster dosing titration regimen, beginning with vial #4 (the most dilute) and progressing to vial #1, which was the most concentrated or maintenance solution. Each dose was administered subcutaneously into the deltoid region as a single injection. During study visits that required multiple IT injections, each injection was to be given at least 30 minutes apart. During weeks that required multiple visits for IT injections, each visit was to be separated by at least 48 hours."
224308863|NCT01420471|DRUG|Triamcinolone|Spacer will be impregnated with 2mL of Triamcinolone. The triamcinolone-impregnated spacer will be inserted into the middle meatal space after surgery. The spacer will be left in the middle meatus for a period of 6 days following surgery.
224308864|NCT01420471|OTHER|Saline-impregnated spacer|Spacer will be impregnated with 2mL of Saline solution. The saline-impregnated spacer will be inserted into the middle meatal space intraoperatively. The spacer will be left in the middle meatus for a period of 6 days following surgery.
224308865|NCT02665845|DRUG|5-ASA|5ASA treatment (oral 5ASA will be given to all patients in this arm, in addition to topical 5ASA in patients who tolerate it).
223495578|NCT03558724|DEVICE|Molecular Fluorescence Endoscopy platform|A flexible fluorescence fiber-bundle is attached to a fluorescence camera platform to enable the detection of fluorescence signals. The fluorescence fiber-probe is inserted through the standard working channel of the standard clinical endoscope. Fluorescence imaging will be performed prior to and post the chemoradiotherapy.
223495579|NCT01199614|DRUG|open-label PTH(1-84)|open label PTH(1-84) at either 25mcg every other day, 25mcg every day, 50mcg daily, 75mcg daily, or 100mcg daily
223495580|NCT02811107|OTHER|Questionnaires|Completion of questionnaires on tablet computers in the preoperative area by 6 nurse anesthetists, 1 hospital physician and 1 resident physician.
223495581|NCT01750346|DRUG|Topical acetyl hexapeptide-8|
223495582|NCT01750346|DRUG|Placebo|
223495583|NCT06553469|DEVICE|sacral neuromodulation|After screening according to the inclusion and exclusion criteria, the subjects were enrolled in the study. The sacral nerve regulation treatment was divided into two phases. Phase I was the testing phase, during which the sacral nerve stimulation electrode component was implanted. After the electrode was implanted, it was tested for 2-4 weeks. According to the urine diary and scale scores, if the symptoms improved by ≥ 50%, or if the patient requested to continue with Phase II and was evaluated by the researcher as suitable for implantation, Phase II (permanent implantation phase) treatment was performed, during which the sacral nerve stimulation pulse generator component was implanted
223495584|NCT02260986|DRUG|Dupilumab|Subcutaneous injection in the different quadrants of the abdomen (avoiding navel and waist areas) and upper thighs
223495585|NCT02260986|DRUG|Placebo (for Dupilumab)|Subcutaneous injection in the different quadrants of the abdomen (avoiding navel and waist areas) and upper thighs
223495586|NCT02260986|OTHER|Topical Corticosteroid (TCS)|All participants were required to treatment with a (TCS) using a standardized regimen. It was recommended that participants use triamcinolone acetonide 0.1% cream or fluocinolone acetonide 0.025% ointment for medium potency, and hydrocortisone 1% cream for low potency.
223495587|NCT02194491|OTHER|[11C]AS2471907|intravenous radiotracer
223495588|NCT02194491|RADIATION|Positron Emission Tomography (PET)|Imaging scanning procedure
223495589|NCT02194491|DRUG|ASP3662|oral
223495590|NCT05390554|BEHAVIORAL|Buteyko Breathing Technique|"* The child was instructed to sit and take a relaxed posture in a vertical chair, relax his shoulders and lean his lower back against the back of the chair.~* Until conducting CP, the child was told to avoid alternate breathing, the child was asked to take a small breath in (two seconds), a small breath out (three seconds) and clutch the nose with empty lungs but not too clear on the 'out-breath. To prevent air from escaping through the airways, clutching the nose is necessary.~* The researcher estimates how many seconds the child can continue safely before the need to breathe in again,~* The child was told to hold their breath until the first need to breathe in was felt. Release the nose then and naturally breathe through it smoothly.~* The first intake of breath after the CP should be no higher than the breath before taking the measurement; the child should not hold the breath for too long as this could lead the child to take a major breath after measuring the CP."
223495591|NCT02841735|DEVICE|Smartphone breathalyzer device/app use|Participants randomized to this condition will be able to blow into the smartphone breathalyzer after consuming each alcoholic drink, which produces an accurate breath alcohol reading on the app. These breath alcohol readings may inform participants' subsequent decisions regarding drinking.
223495592|NCT02841735|DEVICE|BAC estimator app use|Participants randomized to this condition will be able to make an entry into the BAC estimator app after consuming each alcoholic drink, which produces an estimated blood alcohol concentration based on the individual's sex, weight, number of alcoholic drinks and time spent drinking alcohol. These estimated blood alcohol concentrations may inform participants' subsequent decisions regarding drinking.
224308866|NCT02665845|DRUG|Corticosteroids|Corticosteroids will be given to all patients.
223495593|NCT02841735|DEVICE|Text messaging procedure|Participants randomized to this condition will be instructed to send a text to a smartphone they will use for the study after each alcoholic drink. A consideration of the number of texts sent may inform participants' subsequent decisions regarding drinking.
223495594|NCT00598403|DRUG|cefditoren pivoxil|400 mg, oral, single dose during 3 days
223495595|NCT00598403|DRUG|Ciprofloxacin|250 mg, oral, twice a day for 3 days
223495596|NCT04764604|DEVICE|Acapella Choice|3 minutes of exercise consisting of blowing through the device (on setting '5') and phonating at the same time.
223495597|NCT04764604|DEVICE|Tube-in-water|3 minutes of exercise consisting of blowing through a silicone tube (10mm internal diameter) submerged in 5 cm of water whilst phonating at the same time.
223495598|NCT00574652|DRUG|Proleukin|3 millions IU/day from day 1 to 5 every 21 days will be carried out at W1, W3, W6, and W9)
224186681|NCT00267202|DRUG|Immunotherapy|"Customized allergen extracts were prepared centrally for each patient based on his/her specific skin test results. Four vials containing dilutions of the patient's extract were provided. Investigators initiated dosing according to the protocol for the cluster dosing titration regimen, beginning with vial #4 (the most dilute) and progressing to vial #1, which was the most concentrated or maintenance solution. Each dose was administered subcutaneously into the deltoid region as a single injection. During study visits that required multiple IT injections, each injection was to be given at least 30 minutes apart. During weeks that required multiple visits for IT injections, each visit was to be separated by at least 48 hours."
224186682|NCT04197856|OTHER|Standard care encouraging family-mediated disclosure of hereditary cancer risk|At counseling, eligible at-risk relatives (who may benefit from disclosure of risk information) are listed on a specified protocol in collaboration between health care provider and the participant.
224186683|NCT04197856|OTHER|Offer of health-care assisted disclosure by sending direct letters to at-risk relatives|The participant is offered that the health care provider at the cancer genetic unit mail a direct letter with personalized family risk information to all at-risk relatives that participant approve contact with.
224186684|NCT05065840|BEHAVIORAL|CDC 4 Pillars Program|The CDC's 4 Pillars Transformation Program (4 Pillars Program) is a robust and empirically supported strategic approach that promotes the uptake of adult vaccinations and addresses facilitators and barriers at the patient, provider, and clinic level. This multi-level, evidence-based intervention has been successfully utilized to increase HPV vaccination in the general population and is primed to be tested in the high-risk HIV population, particularly PLWH in the rural South. This proposal seeks to expand the success of the 4 Pillars Program and tailor, refine, and implement in the HIV positive population who are at extraordinarily high risk for HPV-related cancers and can obtain the most benefit from the vaccine.
224186685|NCT02233673|BEHAVIORAL|Financial incentives|Participants receive a behavioral intervention and financial incentives for meeting gestational weight gain goals.
224186686|NCT01097174|DEVICE|CyPass Micro-Stent|The CyPass Micro-Stent is a small tube with a through-lumen designed to redirect aqueous fluid from the front into the back of they eye.
224186687|NCT03980665|DRUG|Arsenic Trioxide|a arsenic class of mineral, clinically approved for treating acute promyelocytic leukemia
223495599|NCT00109369|OTHER|Information and decision support for providers and patients|Laboratory-based decision support, reminders, and population report cards.
223589548|NCT05755802|PROCEDURE|PENG block|"A linear ultrasound probe will be placed longitudinally between the coracoid and the humeral head. After defining the humeral head, the tendon of the subscapular muscle and the deltoid muscle over it, the needle will be inserted using the in plane technique. When the needle will have passed through the deltoid muscle and touched the subscapularis tendon, a bone-like hard tissue will be felt and the needle could not be advanced further. The needle tip will be placed between the deltoid muscle and subscapularis tendon, and the injectate will be slowly administered."
223617775|NCT01293825|DRUG|ziprasidone|"Patients will identify which psychotropic they currently receive that causes the most weight-gain concern. For individuals on multiple drugs, one drug must be identified as the offending agent. Study psychiatrist will switch the offending agent to ziprasidone. Participants will be switched to ziprasidone per package insert. Patients will be maintained on ziprasidone for 12 weeks (active part of study). After the active part of the study they will return to the care of their normal clinical provider who will determine whether they will continue on ziprasidone."
224186688|NCT01480401|OTHER|low-sodium diet (1500 mg daily)|
224186689|NCT02806804|BIOLOGICAL|one dose test vaccine|
223495600|NCT03888690|DEVICE|Virtual Reality Headset|Standardized procedures, with or without Virtual Reality Headset.
223495601|NCT04893031|DRUG|Tocilizumab|400mg or 800 mg IV tocilizumab treatment according to patient clinical severity
223495602|NCT02310308|DIETARY_SUPPLEMENT|Chewing gum administration|Intervention chewing gum Each subject will be instructed to chew 1 or 2 pellets for 5 min 3 times a day (2 in the morning, 2 after the midday meal and 1 in the afternoon). Thus, the total daily intake of magnolol and honokiol in MX group will be 11.9 mg/day. The daily use of the two different chewing gums will be carried out for 12 months.
223495603|NCT02866448|DRUG|Vehicle control|Described in arm
223495604|NCT02866448|DRUG|Isoquercetin|Described in arm
223495605|NCT02866448|DRUG|Aspirin|Described in arm
223495606|NCT02866448|DRUG|Isoquercetin plus Aspirin|Described in arm
223495607|NCT02274428|DRUG|pneumostem|human umbilical cord blood derived mesenchymal stem cells
223495608|NCT01453647|OTHER|Guided Imagery|The intervention consists of three audio-recorded guided imagery scripts formatted as three separate tracks on one CD. Each track is 30 minutes in length and is to be used in a recommended order for the first 6 weeks of the intervention and then used in any order for the follow-up weeks, 7 through 10. Project participants will be instructed to use each CD track, as prescribed, a minimum of once daily. CD Track 1 is a basic relaxation entrainment script; CD track 2 is a pleasant scene imagery script; CD track 3 is a well body imagery script.
223495609|NCT00440024|DRUG|Tazorac|Tazarotene 0.1% cream applied to the face once daily before bed
223495610|NCT00440024|DRUG|Dove Mild Cleanser|Ultra mild cleanser: Dove Non-foaming cleansing lotion
223495611|NCT00440024|DRUG|Dove Facial Moisturizer|Moisturizing cream - Dove facial moisturizer with SPF 15
223495612|NCT03847077|BEHAVIORAL|iPad counseling|Women with leiomyomata confirmed on imaging who presented as a new patient to the gynecology clinic at a single institution were randomized to receive multimedia counseling using the drawMD OB/GYN iPad application.
224186690|NCT02806804|BIOLOGICAL|one dose commercially available trivalent influenza vaccine|
224186691|NCT02806804|BIOLOGICAL|One dose of Quadrivalent Influenza Virus Vaccine|
224186692|NCT03396172|OTHER|Control|The hospitalization will take place in the usual setting and the hospital discharge will be decided by pulmonologists according to the usual criteria
224186693|NCT03396172|DEVICE|FreeDom|Early return home, patients using an innovative device that automatically adjusts and wean the oxygen flow (FreeO2 system) coupled to telemedicine and tele-rehabilitation
224186694|NCT04318626|DRUG|PMPBB3|F-18 PMPBB3 PET Imaging
224186695|NCT04318626|DRUG|THK5351|F-18 THK5351 PET Imaging
224186696|NCT05670470|DRUG|CTP0303|Subjects who are randomized into group CTP0303 will receive bowel preparation from evening to next morning.
223495613|NCT03847077|BEHAVIORAL|Standard Counseling|Women with leiomyomata confirmed on imaging who presented as a new patient to the gynecology clinic at a single institution were randomized to receive standard counseling.
223495614|NCT05619419|BEHAVIORAL|Mindfulness-enhanced positive affect induction|Participants will receive brief psychoeducation about biopsychosocial pain management and practice with the MPAI via guided audio recording. They will then listen to the audio recording a final time before beginning the cold pressor test for experimental pain induction. They will be instructed to continue using the MPAI to manage pain during the cold pressor test.
223495615|NCT05619419|BEHAVIORAL|Breathing Meditation|Participants will receive brief psychoeducation about biopsychosocial pain management and practice with the BM via guided audio recording. They will then listen to the audio recording a final time before beginning the cold pressor test for experimental pain induction. They will be instructed to continue using the BM to manage pain during the cold pressor test.
223495616|NCT03942731|OTHER|Behavioral allergy testing protocol|skin tests followed by drug provocation test and skin retesting between 6 weeks and 6 months
223495617|NCT00679198|BEHAVIORAL|nurse-patient communication|"We will train home health nurses to act as patient advocates by communicating the risks and benefits of osteoporosis treatment to patients and their healthcare providers.~Thus, we will provide a comprehensive, integrated approach to the management of osteoporosis among patients with a history of insufficiency fractures that is highly generalizable to a national setting."
223495618|NCT02782468|DRUG|Pevonedistat 25 mg/m^2|Pevonedistat 25 mg/m\^2 intravenous infusion.
223495619|NCT02782468|DRUG|Pevonedistat 44 mg/m^2|Pevonedistat 44 mg/m\^2 intravenous infusion.
223495620|NCT02782468|DRUG|Pevonedistat 10 mg/m^2|Pevonedistat 10 mg/m\^2 intravenous infusion.
223495621|NCT02782468|DRUG|Pevonedistat 20 mg/m^2|Pevonedistat 20 mg/m\^2 intravenous infusion.
223495622|NCT02782468|DRUG|Azacitidine 75 mg/m^2|Azacitidine 75 mg/m\^2 intravenous or subcutaneous formulation.
223495623|NCT04114370|DRUG|18F-fluciclovine|Prior to beginning PET imaging, 18F-fluciclovine will be administered as an intravenous bolus injection followed by a 10mL saline flush. 18F-fluciclovine will be injected through a cannula (or indwelling catheter) in an antecubital vein or another vein that will provide access. The administration site will be evaluated pre- and post-administration for any reaction. Documentation of administration to a participant will be recorded or as part of the scan upload, including date, prescription number, dose activity (as measured at time of administration), total volume, and start/stop time of administration.
223495624|NCT03342859|DRUG|Vilaprisan, BAY1002670|Daily single oral doses of 2 mg vilaprisan over 8-12 weeks
223495625|NCT03342859|DRUG|Ulipristal|Daily single oral doses of 5 mg ulipristal over 8-12 weeks
223495626|NCT05220735|DIETARY_SUPPLEMENT|Omega-3 long chain polyunsaturated fatty acids (n-3 LCPUFA)|"3 three fish oil capsules providing 2.1 g n-3 PUFA; 1.27 g Docosahexanoic acid (DHA) and 0.86 g Eicosapentanoic acid (EPA) capsules.~The absorption study test meals will consist of white bread with butter and honey, 6mg of labeled iron as ferrous sulfate and 300 g of distilled water. The meal will be given on two days without and with ascorbic acid. The test meals without ascorbic acid will contain 6 mg 57Fe as ferrous sulfate whereas the meals containing ascorbic acid will contain 6 mg 58Fe as ferrous sulfate."
223495627|NCT05753475|OTHER|renal transplantation|patients undergoing renal transplantation
223495628|NCT00356590|BIOLOGICAL|Etanercept|Etanercept (TNFR:Fc) will be administered 50 mg per week as two 25 mg subcutaneous injections at separate sites, given either on the same day or 3 or 4 days apart.
223495629|NCT00744835|PROCEDURE|Ablation procedure and/or cardioversion|Ablation Frontiers Cardiac Ablation System
223495630|NCT00152230|DRUG|UFT (uracil, tegafur)|to receive oral uracil-tegafur 400 mg square meter for one year
223495631|NCT00152230|PROCEDURE|Surgery alone|Standardized mesorectal excision with selective lateral pelvic lymphadenectomy of stage III rectal cancer.
223495632|NCT00828256|PROCEDURE|arthroscopy of shoulder|arthroscopic repair of chronic rotator cuff tears
224186697|NCT05670470|DRUG|Orafang Tab|Subjects who are randomized into group Orafang Tab will receive bowel preparation from evening to next morning.
223617776|NCT06340022|OTHER|Children's Fear Survey Schedule-Dental Subscale (CFSS-DS) scale|Children's Fear Survey Schedule-Dental Subscale (CFSS-DS) scale was applied to determine the anxiety level before the procedure.
224186698|NCT03567811|PROCEDURE|Submaximal bicycle exercise stress test on Days 1 and 2|Identical submaximal stress tests were performed on both days to see if Day 1 exercise reduced performance on Day 2, or caused changes between BOLD scans during cognitive testing between Day 1 and Day 2.
224186699|NCT06368596|DIAGNOSTIC_TEST|Fusobacterium detection|"One vaginal and one cervical swab will be collected from participants (both cases and controls) before surgery.~During surgical intervention, routine biopsies of the endometriotic tissue will be done for all endometriosis types; further, small biopsies of apparently healthy endometrial tissue and of healthy peritoneum will be done, as per routine procedure.~In the control group routine biopsies needed for the specific condition and small biopsies of endometrial tissue will be carried out.~During these routine biopsies, a small additional quantity of tissue will be taken, which will be analyzed for the search for Fusobacterium."
224186700|NCT03080675|DIETARY_SUPPLEMENT|Nutrional blend of ingredients including vitamins and fish oil|
224186701|NCT03080675|DIETARY_SUPPLEMENT|Control|
224186702|NCT00132665|PROCEDURE|A: Radiotherapy alone|Procedure/Surgery: A: Radiotherapy alone
224186703|NCT00132665|DRUG|B: CBDCA and Radiotherapy|Drug: B: CBDCA and Radiotherapy
224186704|NCT06234501|DIETARY_SUPPLEMENT|Pyridoxal 5'-Phosphate (100 mg)|100 mg Pyridoxal 5'-Phosphate tablet once daily with food
224186705|NCT06234501|OTHER|Placebo|Placebo tablet once daily
224186706|NCT01716299|OTHER|application of a confirmation test|Addition of confirmation test to serial testing algorithm, including dilution test
224186707|NCT01716299|OTHER|application of a confirmation test|use of rapid confirmation test
224186708|NCT05702840|BEHAVIORAL|Resistance exercise training + weight loss group|Doing resistance exercises as well as following the weight watchers weight loss programme for a 12-week period
224186709|NCT05702840|BEHAVIORAL|Weight loss only group (WL)|Only following the weight watchers weight loss programme for a 12-week period
224186710|NCT01967992|BEHAVIORAL|Behavioral: Low Carbohydrate, Ketogenic Diet|
224186711|NCT01967992|BEHAVIORAL|American Diabetes Association Diet|
224186712|NCT01967992|BEHAVIORAL|Mindfulness and Positive Affect Skills|
224186713|NCT03820388|DRUG|Propofol 2mg/kg|2 mg/kg
223495633|NCT02887586|OTHER|auricular needling|Patients will be treated with auricular needling for 4 weeks. 4-8 specific auricular acupoints are selected unilaterally at a time, and alternate to another side every 2-3 days, treatment will last for 4 consecutive weeks. The following 4 ear acupoints points will be selected for every patient: Ear Shenmen, Stoma, Spleen, and Subcortex. Other ear acupoints including Triple Energizer, Liver, Sympathetic Nerve and Smallintestine will be selected based on the condition of patients. Treatment will be performed by a registered Chinese medicine practitioner.
223495634|NCT05144282|PROCEDURE|intravitreal injection of anti VEGF|The treatment for ROP was either primary intravitreal injection (IVI) of anti-vascular endothelial growth factor (anti-VEGF).
223495635|NCT05144282|PROCEDURE|laser photocoagulation|The treatment for ROP was either primary laser photocoagulation.
223495636|NCT04493177|BEHAVIORAL|Educational intervention|Monthly 45-minute sessions will be held, including dietary, and physical activity modification, early stimulation, exclusive breastfeeding for 6 months and the proper introduction of foods, and other support for the mother. The sessions will be supported by personalized contact by WhatsApp and programmed telephone calls, in addition to conventional treatment.
223495637|NCT04493177|OTHER|Conventional treatment Guia de Practica Clinica IMSS-029-08|Conventional treatment includes some early stimulation, monthly visits for height/weight measurement of the offspring.
223495638|NCT00002940|DRUG|hydroxyurea|
223495639|NCT02409901|BEHAVIORAL|Exercise Rehabilitation|12 month personalized exercise rehabilitation in addition to standard clinical care
223495640|NCT05104346|PROCEDURE|appendectomy|open or laparoscopic appendectomy
223495641|NCT03268863|DEVICE|Virtual Reality|Google Cardboard virtual reality headset
223495642|NCT03268863|OTHER|Cold Pressor|A cold ice water bath for use in pain/discomfort simulation
223495643|NCT04600037|DRUG|Pregabalin 150mg|"Patients in group I received pregabalin at a dose of 75 mg twice daily during the first week that was increased to 150 mg twice daily thereafter and maintained at that level for 12 weeks.~Patients in two groups received exercise therapy (stretching exercises for the trapezius muscle). Patients were instructed to perform 10 repetitions three times a day., 3 months"
223495644|NCT00138970|DRUG|Zenapax®, CellCept® and prednisolone|
223495645|NCT00138970|DRUG|Sandimmun Neoral®, CellCept® and prednisolone|
223495646|NCT01482221|DRUG|AZD6765 iv|50 mg (AZD6765 Solution for Infusion, 0.5 mg/mL) by iv infusion.
223495647|NCT01482221|DRUG|AZD6765 iv|100 mg (AZD6765 Solution for Infusion, 1.0 mg/mL) by iv infusion.
223495648|NCT01482221|DRUG|Placebo|0.9 sodium chloride \[normal saline\] solution for injection by iv infusion
223495649|NCT05827744|OTHER|Isokinetic evaluations|Peak torque and total amount of work of hip flexors and extensors will be determined by the Cybex 6000 model computer-aided isokinetic system.
223617777|NCT06340022|OTHER|Face Image Scale (FIS) scoring system|Face Image Scale (FIS) scoring system (1= not afraid at all, 2= very little afraid, 3= afraid, 4= quite afraid, 5= very much afraid) was used to determine the anxiety level before starting anesthesia and after the anesthesia.
224186714|NCT03820388|DRUG|Etomidate 0.3 mg/kg|0.3 mg/kg
223495650|NCT05827744|OTHER|Ultrasonographic evaluations|Ultrasonographic evaluations will be performed with a 5-12 MHz linear probe (Logic e portable; GE Healthcare, China). The thicknesses of the hip flexor (psoas major) and extensor (gluteus maximus) muscles will be measured while the patient is in the prone position, in accordance with the literature.
223495651|NCT03086343|DRUG|Abatacept|IV infusion
223495652|NCT03086343|DRUG|Placebo for abatacept (0.9% Sodium Chloride Injection or Solution for Infusion)|IV infusion
223495653|NCT03086343|DRUG|Upadacitinib|15 mg extended release tablet
223495654|NCT03086343|DRUG|Placebo for upadacitinib|Film-coated tablet
223495655|NCT04549441|PROCEDURE|Distal radius fracture plating surgery|We performed open reduction and plating surgery for the distal radius fracture.
223495656|NCT00226213|PROCEDURE|Peripherally Inserted Central Catheter Placement|
223495657|NCT01804907|BEHAVIORAL|Cognitive Behavioral Therapy|
223495658|NCT01804907|BEHAVIORAL|Behavioral Modification|
223495659|NCT01716195|RADIATION|Induction Chemotherapy followed by Response Adapted Chemoradiation|All patients receive induction chemotherapy with 2 cycles of paclitaxel and carboplatin followed by response adapted, de-escalated chemoradiation. Patients with a complete or partial response will receive 54 Gy with concurrent paclitaxel and patients with stable disease will receive 60 Gy with concurrent paclitaxel.
223495660|NCT01852903|DIETARY_SUPPLEMENT|calcium ascorbate|
223495661|NCT01852903|DIETARY_SUPPLEMENT|ascorbic acid|
223495662|NCT01852903|OTHER|placebo|
223495663|NCT05457543|DIAGNOSTIC_TEST|Adult|Investigational use of a novel liver function diagnostic test that involves a paper-based test device and a smartphone application.
223495664|NCT01667614|DRUG|spironolacone 25 mg tablets added to losartan|spironolactone 25 mg once daily added to losartan
223495665|NCT03962816|BIOLOGICAL|20 µg recombinant hepatitis B vaccine at months 0, 1, and 6|three-dose, 20 µg per dose
223495666|NCT03962816|BIOLOGICAL|20 µg recombinant hepatitis B vaccine at months 0, 1, 2, and 6|four-dose, 20 µg per dose
223495667|NCT03962816|BIOLOGICAL|60 µg recombinant hepatitis B vaccine at months 0, 1, 2, and 6|four-dose, 60 µg per dose
224186715|NCT03820388|DRUG|Propofol 1 mg/kg|1 mg/kg Propofol
224186716|NCT03820388|DRUG|Etomidate 0.15 mg/kg|0.15 mg/kg Etomidate
224186717|NCT04252560|PROCEDURE|Colectomy, CRS+HIPEC|No special interventions are going to be performed. Fecal samples are going to be taken and analysed
223495668|NCT03723824|DRUG|grazoprevir 100 mg/ elbasvir 50 mg, Zepatier®|grazoprevir 100 mg/ elbasvir 50 mg (Zepatier®, MSD) once daily for 12 weeks
223495669|NCT04051801|DRUG|Dose Escalation of VU319|dose levels of the cohorts will be increased step wise
223495670|NCT04051801|DRUG|Dose Escalation of Placebo|dose levels of the cohorts will be increased step wise
223495671|NCT03607084|BEHAVIORAL|School Health Worker Program|The intervention trains selected teachers to deliver health lessons to students, perform basic first aid, recognize common illnesses, refer student to skilled medical attention when needed. The intervention provides schools with basic medical supplies including pain relief medication, thermometers, bandages, antiseptics, and oral rehydration solution. Vitamin A supplementation and presumptive deworming medication are administered to students during biannual health screenings.
223495672|NCT01346553|DEVICE|ESVV device|wearing the ESVV device for 6 hours
223495673|NCT00219271|DRUG|Zoledronic acid|
223495674|NCT02049762|DRUG|Aspirin|Aspirin 100 mg vs. placebo in ACS patients on P2Y12 inhibitors a month following PCI.
223495675|NCT05607043|DEVICE|Testing for SARS CoV2 RNA|Device: Testing for SARS CoV2 RNA- lab-based RNA RT-PCR testing
223495676|NCT01785316|PROCEDURE|IHP|
223495677|NCT00741611|DEVICE|HD Mesh Ablation System|Ablation using the HD Mesh Ablation System
224186718|NCT04572464|OTHER|Mindfulness Based Guided Meditation|Mindfulness Based Guided Meditation will be practiced by nurses under the supervision of researcher for 15 min thrice a week for two weeks
224186719|NCT05949528|OTHER|no intervention|no intervention
224186720|NCT04193228|DEVICE|Carbon Fibre Ankle Foot Orthosis|Off teh shelf carbon fibre ankle foot orthoses worn bilaterally
224186721|NCT04193228|BEHAVIORAL|Exercise|Ankle muscle strength training
224186722|NCT01038544|PROCEDURE|Endoscopic Ultrasound (EUS)|Minimally Invasive Echo-Endoscopic Lymph Node Evaluation and Biopsy
224186723|NCT01038544|PROCEDURE|Endobronchial Ultrasound (EBUS)|Minimally Invasive Echo-Bronchoscopic Lymph Node Evaluation and Biopsy
224186724|NCT03687229|DIAGNOSTIC_TEST|A)microribonucleic acid-122(miRNA-122), B) Hepatitis C virus Real Time Polymerase chain Reaction (HCV RT-PCR)|measure level of serum micro ribonucleic acid -122 and insulin resistance in chronic hepatitis C patients using real time polymerase chain reaction
224186725|NCT03687229|DIAGNOSTIC_TEST|A)fasting serum glucose, B)Fasting serum insulin|measure level of insulin resistance
224186726|NCT00606931|DEVICE|Stereo Navigator Accessory to PEM Flex PET Scanner|For patients with suspicious breast abnormalities seen on high resolution PET image, the patients will be biopsied using commercial vacuum biopsy devices (pre-validated to work with Stereo Navigator) using Naviscan's Stereo Navigator (interventional device) for PET image guidance.
224186727|NCT01047215|DRUG|Aripiprazole; Quetiapine|Aripiprazole Quetiapine
224186728|NCT03436095|OTHER|bundle measures|Implementation of bundle measures to improve the successful rate of weaning ventilator
224186729|NCT03958409|DIAGNOSTIC_TEST|measurements to evaluate metabolic bone disease|The participants will be evaluated for a) Mineral metabolism: blood calcium, phosphorus, PTH, 25(OH) vitamin D; b) Bone turnover markers: bone-specific alkaline phosphatase, cross-linked C-telopeptide of type I collagen (CTx), and N-terminal propeptide of type I collagen (PINP); c) Bone Mineral Density using a Dual energy x-ray absorptiometry which is the standard method by which bone mass is measured clinically. The bone mass at the lumbar spine, wrist, hip and total body bone mass at 3, and 18 months.
224186730|NCT03958409|DIAGNOSTIC_TEST|standard care|Blood tests (Ca, Phos, PTH- mineral lab, 25OHVitD);Pregnancy Test (if applicable); dual energy X-ray absorptiometry (DXA); Bone Biopsy only if clinically indicated; treatment as clinically indicated.
224186731|NCT06035666|OTHER|Your World|Your World consists of a vitality session and use of the Your World app
224186732|NCT06035666|OTHER|Control app|Control app, no effect on stress/vitality
224186733|NCT04834375|DRUG|Weight-based dexamethasone dose|Weight-based dexamethasone dose in COVID-19 patients with hypoxic respiratory failure
224186734|NCT03026556|DRUG|Dabigatran vs. Rivaroxaban|observed for 6 years
224186735|NCT03026556|DRUG|Dabigatran vs. Apixaban|Observed for 6 years
224186736|NCT02715115|DRUG|NNZ-2566|Glycyl-L-2-Methylpropyl-L-Glutamic Acid (NNZ-2566) supplied as a lyophilized powder for reconstitution with strawberry flavored solution 0.5% v/v in Water for Injection.
224186737|NCT02715115|DRUG|Placebo|Strawberry flavored solution and Water for Injection
224186738|NCT01556503|DEVICE|VivaScope System|VivaScope System, Model#s 1500 and 2500
224186739|NCT01294319|DRUG|Mifepristone|
223495678|NCT00741611|DRUG|Anti-arrhythmic drugs|5 anti-arrhythmic drugs administered at the labeled dosage for atrial fibrillation
223495679|NCT04558827|OTHER|Low Carbohydrate Diet|Dietary choices are counseled to come primarily from lean meats, eggs, nuts, seeds, vegetables and berries.
223495680|NCT04558827|OTHER|Time Restricted Feeding|Participants will be asked to have 2 meals within an 8 hour period, preferably before 2pm.
223495681|NCT00505583|DRUG|MOA-728|
223495682|NCT02353741|DRUG|EGFR-TKIs|Beginning on day 2 of treatment, receive oral erlotinib 150mg per day.
223495683|NCT02353741|RADIATION|thoracic radiotherapy|From the beginning of EGFR-TKIs, within 2 weeks, receive concurrent thoracic radiotherapy, pGTV54～60Gy/27～30f/5.5～6w.
223495684|NCT04903977|DIAGNOSTIC_TEST|Laboratory tests: blood and faeces tests|To be performed at V2
223495685|NCT04903977|DIAGNOSTIC_TEST|Gynaecological and proctological examinations|To be performed at V1 (Examination with a gynaecological speculum, Bimanual examination, Rectal examination, and Anoscopy)
223495686|NCT04903977|DIAGNOSTIC_TEST|3-D Endoanal Ultrasound|To be performed at V1 (as a reference and for group assignment)
223495687|NCT04903977|DEVICE|ONIRY measurement|To be performed at V2 (the electrical impedance of anal sphincter muscles will be measured)
223495688|NCT04903977|DIAGNOSTIC_TEST|High-resolution anorectal manometry|To be performed at V3
224186740|NCT01294319|DRUG|Placebo|
224186741|NCT01294319|DRUG|Spironolactone|
224186742|NCT01294319|DRUG|Combined|
224186743|NCT01294319|DRUG|Dexamethasone|
224186744|NCT04793893|DEVICE|ReLex Smile|With the ReLex Smile the optical zone (lenticule diameter) and cap diameter are 6.5 and 7.5 mm respectively. After dissection of both anterior and posterior planes, the lenticule is extracted through 120 degree superior 3.5 mm incision and marked with a sterile marker (ViscotMedster).
224308867|NCT01565057|OTHER|sedimenting meal|The active system quickly forms a sedimenting layer of small particles that contain most of the caloric content of the system. This system is made by adding finely grated cheese (particle size 0.5-2 mm) to yoghurt and consumption is followed by drinking 327 ml water.
224308868|NCT02425163|DEVICE|Transrectal shear wave elastography of the prostate|Transrectal shear wave elastography of the prostate with SuperSonic Imagine Ultrasound System AIXPLORER and an endocavity sonic head SE12-3 (SuperSonic Imagine, Aix-en-Provence, France)
224308869|NCT02425163|PROCEDURE|Transrectal random biopsy of the prostate|TRUS-SWE-guided random biopsies of the Prostata with 18G-gun
224308870|NCT05773248|PROCEDURE|ERAS protocol|The main concepts of the ERAS protocol compared to standard care included the following aspects: preoperative counselling with a specially trained nurse, restrictive use of preoperative sedation, intraoperative fluid and opioid administration and drain placement, strict antiemetic prophylaxis, early mobilisation, bowel stimulation and removal of any catheters as well as early food intake. Additionally, the ERAS protocol included a 30-day telephone follow-up.
224308871|NCT04604886|DIAGNOSTIC_TEST|Passive Leg Raising|Passive leg raising is induced by rasing the legs of patients to 45° from horizontal position.
224308872|NCT04604886|DIAGNOSTIC_TEST|Dobutamine stress test|Dobutamine was infused intravenously at the initial dose of 2.5 ug/kg/min. hemodynamic data were recorded from PAC and LiDCO after 5-10 minutes of continuous infusion.
224308873|NCT03902886|DIAGNOSTIC_TEST|gait analysis|gait analysis using an optoelectronic system and a surface EMG
224308874|NCT00176423|DRUG|galantamine|see arm/group description
224308875|NCT05502081|DRUG|Casirivimab and Imdevimab Drug Combination|antiviral Monoclonal Antibodies
224308876|NCT05502081|DRUG|Remdesivir|antiviral drug
224308877|NCT05502081|DRUG|Favipiravir|antiviral drug
224308878|NCT04538625|DRUG|Crofelemer 125 MG [Mytesi]|Randomized, Double-blind, Placebo-controlled, two arm trial
224308879|NCT04538625|DRUG|Placebo|Matching placebo tablets
224308880|NCT02875652|BIOLOGICAL|Blood sampling|3 vials of 7,5 ml of peripherical blood will be collected at each blood sample.
224308881|NCT02397187|BEHAVIORAL|LOOP|"The LOOP conceptualizes the psyche by a three-dimension structure: the space (the potential of experiencing, the place where our experiences occur), the content (the experiences themselves; action, thoughts, feelings, experiences and being) and the order (the relationship between the various contents). The LOOP intervene with these three dimensions by a structures scheme, aimed at allowing the patient to quickly reclaim the responsibility on his psyche, stabilize and initiate long-term rehabilitation processes."
224308882|NCT02529644|BEHAVIORAL|Taking It to the Pews (Comparison)|Pastors and Health Action Team members will be trained and receive manualized pastor/church liaison trainings on study procedures, HIV basics and local resources and coordination of HIV screening events. Comparison churches will receive: a) non-tailored project materials (videos, brochures) collected from health organizations and b) standard, non-tailored activities (e.g., community-based HIV testing events) coordinated by their church liaisons. The comparison churches will offer 3 HIV screening events and deliver 1-2 standard materials per month for the 12 month study period. All comparison churches will receive all Taking It to the Pews HIV Tool Kit materials after the completion of 12-month assessments.
224308883|NCT02529644|BEHAVIORAL|Taking It to the Pews (Experimental)|Pastors and Health Action Team members will be trained in treatment implementation procedures using the scripted, study implementation manual. Intervention churches will receive the TIPS HIV Tool Kit, including a study manual. These churches will hold a Kick-off event, where tools will be distributed, and motivational strategies implemented. After the Kick-off, liaisons will deliver 1-2 Tool Kit materials/activities per month through targeted multilevel church activities minimum of 24 tools over the 12 month study period. Two additional HIV screening events will be planned (one for community members) and will be open to all persons seeking screening, including study nonparticipants. Both groups will receive manualized pastor/church liaison trainings on study procedures, HIV basics and local resources and coordination of HIV screening events.
224308884|NCT04492644|OTHER|No intervention|No intervention
224308885|NCT04318223|DRUG|Palbociclib|Patients will be enrolled into the study and assign to receive Palbociclib 125 mg/day orally for 3 weeks followed by 1 week off plus fulvestrant 500 mg intramuscularly on Days 1 and 15 of Cycle 1, every 28 days (+/- 7 days) thereafter starting from Day 1 of Cycle 1
224308886|NCT05523024|DIETARY_SUPPLEMENT|Probiotic|The probiotic group will receive one capsule of the probiotic mixture (dose:1x109 colony forming units (CFU) per day in one dose (before breakfast). The PRO preparation will contain the following bacterial strains: 50% Lactococcus lactis Rosell® - 1058, 25% Lactobacillus casei Rosell® - 215, 12,5% Lactobacillus helveticus Rosell® - 52, 12,5% Bifidobacterium bifidum Rosell® - 71). Probiotics will be administered orally.
224308887|NCT05523024|DIETARY_SUPPLEMENT|Berberine|The berberine group will receive 1500 mg of Berberine (Berberine hydrochloride 97% extract of Berberis aristata) per day in 3 doses. Berberine will be administered orally, before breakfast, dinner, and before supper.
224308888|NCT05523024|DIETARY_SUPPLEMENT|Placebo|The placebo group will receive a placebo. Placebo will contain only the excipients and will be administered orally for 24 weeks. Placebo in no way: color, taste, smell, form of taking, the dosage will not differ from the preparations tested. However, it will not contain probiotcs or berberine. Placebo will be orally administered three times a day: before breakfast, dinner, and supper (6.00-7.00 p.m.). To meet the GCP conditions, subjects from all groups will receive the same number of capsules (six) per day.
224308889|NCT05523024|DIETARY_SUPPLEMENT|Probiotc and Berberine|Probiotics and Berberine groupwill receive both: a probiotics mixture (as in PRO group: 1x109 CFU/day; in one dose) and 1500 mg/day of Berberine (Berberine hydrochloride 97% extract of Berberis aristata; in 3 doses). Probiotcs and berberine will be administered orally before breakfast, before dinner, and before supper.
224308890|NCT00462124|DEVICE|Absorbable perirectal spacer|biodegradable balloon implant to increase the distance between prostate and anterior rectal wall
224308891|NCT01329549|DRUG|BIBF 1120 (high) + PLD 30 mg/m2 + CBDCA AUC5 mg/mL*min|BIBF 1120 twice daily along with standard therapy of PLD + CBDCA
223495689|NCT04903977|DIAGNOSTIC_TEST|ECG|To be performed at V1 and V2 (for safety reasons)
223495690|NCT03355027|DRUG|Alirocumab 150 MG/ML|Dosing to be performed by subcutaneous injection in clinic
223495691|NCT03355027|DRUG|Ezetimibe 10Mg Tablet|Patients will be instructed to take once daily at night.
224186745|NCT03870139|DEVICE|Cerebral stimulation|Transcranial direct current stimulation (tDCS) is a noninvasive brain stimulation (NIBS) technique that has been investigated for the management of various health conditions. However, its ergogenic effect still has controversial results.
224186746|NCT03870139|DEVICE|Peripheral stimulation|Peripheral electrical stimulation (PES) activates a complex neural network involving a series of neurotransmitters and receptors capable of promoting segmental and extrasegmental analgesia. Moreover, recent evidence has shown that PES can activate brain motor areas such as primary motor cortex.
224186747|NCT01684085|BEHAVIORAL|Explanation encouraging sleep|An explanation will be given about sleep, encouraging the patient to sleep - lorazepam 1mg will be offered to promote sleep.
224186748|NCT01684085|BEHAVIORAL|Explanation discouraging sleep|An explanation about sleep will be given, discouraging the patient from sleeping in the first night after the traumatic event.
224186749|NCT01684085|DRUG|Lorazepam|Lorazepam 1 mg
224186750|NCT05434728|OTHER|20 ml venous blood collection|participant blood sample will be divided between sample EDTA sample tubes for thrombin generation testing and viscoelastic (ROTEM) testing of impaired hemostasis
224186751|NCT03718624|DRUG|apatinib|apatinib：500mg qd po, 28 days is a cycle. preoperative 2 cycles, 2 cycles after surgery.
224186752|NCT03718624|DRUG|paclitaxel|Paclitaxel: intraperitoneal paclitaxel 20 mg/m2 and intravenous paclitaxel 50 mg/m2 on days 1 and 8 ，21 days is a cycle. preoperative 3 cycles, 3 cycles after surgery.
224186753|NCT03718624|DRUG|S-1|S-1： According to the body surface area, BSA \<1.25m2，40mg bid; 1.25m2≤BSA≤1.5m2，50mg bid; BSA \>1.5m2, 60mg bid. Take the medicine twice daily for 2 weeks, then suspend for 1 week. preoperative 3 cycles, 3 cycles after surgery.
224186754|NCT05208749|DEVICE|Rotablation of shockwave|Patients will be randomized to treatment with rotablation or shockwave
224186755|NCT00063076|DRUG|Targretin Gel 1%|Alopecia lesions on one-half of the head including facial hair treated, and other half on head serves as control (untreated). Starting dose once every day till Week 3 then escalate to twice a day.
224186756|NCT00464126|OTHER|5% albumin|5% albumin in 10cc/kg aliquots for postoperative volume resuscitation
223495692|NCT03355027|DRUG|Atorvastatin 40Mg Tablet|Patients will be instructed to take once daily at night. Atorvastatin will be the preferred statin option for those with eGFR \< 60 ml/min/1.73m2. Patient may be required to complete a 4 week run-in period on a statin prior to entering the study (dependent on eligibility)
223495693|NCT03355027|DRUG|Atorvastatin 80Mg Tablet|Patients will be instructed to take once daily at night. Atorvastatin will be the preferred statin option for those with eGFR \< 60 ml/min/1.73m2. Patient may be required to complete a 4 week run-in period on a statin prior to entering the study (dependent on eligibility)
223495694|NCT03355027|DRUG|Rosuvastatin 20Mg Tablet|Patients will be instructed to take once daily at night. Rosuvastatin only to be prescribed if atorvastatin and simvastatin are not previously tolerated. Patient may be required to complete a 4 week run-in period on a statin prior to entering the study (dependent on eligibility)
223495695|NCT03355027|DRUG|Rosuvastatin 40Mg Tablet|Patients will be instructed to take once daily at night. Rosuvastatin only to be prescribed if atorvastatin and simvastatin are not previously tolerated. Patient may be required to complete a 4 week run-in period on a statin prior to entering the study (dependent on eligibility)
223495696|NCT03355027|DRUG|Simvastatin 80mg|Patients will be instructed to take once daily at night. Patient may be required to complete a 4 week run-in period on a statin prior to entering the study (dependent on eligibility)
223495697|NCT00478036|DRUG|Acular LS|Details covered in arm description
223589549|NCT05755802|PROCEDURE|Shoulder block|The probe will be kept over the scapular spine to identify the trapezius and the supraspinatus muscle. Then, it Will be moved laterally to identify the concavity of the supraspinatus fossa and the hyper-echoic fascia of the supraspinatus muscle. In the concavity of the fossa, the suprascapular artery and the suprascapular nerve run in close proximity. A 50 mm nerve block needle will be used in the long axis view for the block. After confirming extravascular placement of the needle, injectate will be given below the supraspinatus fascia and then during axillary nerve block,The posterior surface of the humerus will be visualised in the short axis view. So, the circumflex artery will be visualised longitudinally. After confirming extra-vascular placement of the needle, injectate will be given into space.
223589550|NCT04659694|OTHER|Wellness programme provided by Oomph! Wellness company|The Oomph! wellness programme empowers older adults to lead a full life for life. It focuses on building an individual-centred programme that consists of a varied exercise and activity plans including days out. All of these, aims in improving the physical and psychosocial wellness in older adults. This intervention is a three day training session for care home staff to understand and learn how to facilitate care activities within their care home.
223617778|NCT06340022|OTHER|Visual Analogue Scale (VAS)|In the Visual Analogue Scale (VAS), the patient was asked to rate the pain he/she felt during anesthesia on a 10 cm long ruler ranging from no pain=0 to unbearable pain=10.
223617779|NCT06340022|OTHER|pulse rate|Before starting anesthesia and after the anesthesia the patient's pulse rate was measured and recorded with a pulse oximeter.
223617780|NCT05004831|DRUG|fruquintinib plus TAS-102|fruquintinib 4mg/d, qd po, D1-21, Q4W; TAS-102 70mg/m2/d, bid po, D1-5, 8-12, Q4W
224186757|NCT00464126|OTHER|crystalloid|saline in 10cc/kg aliquots for postoperative volume resuscitation
224186758|NCT03216564|DRUG|Calcitriol|Active vitamin D (Calcitriol) 0.25 micrograms
224186759|NCT05994664|OTHER|Heartmath Intervention|The participants will all complete baseline surveys and paperwork including signed consent, psychometric surveys, demographic survey, and a brief, open-ended questionnaire about their feelings about living with VEDS. During the initial visit for the intervention group the same assessment will be included, however, they will also receive 10-15 of instruction on a basic Heartmath technique. Group participants will be asked to complete 5-10 minutes of HeartMath techniques 2x daily. Participants from both groups will have weekly virtual sessions that include the 3-step Protocol HRV assessment. However, each week the intervention group will receive an addition 10-15 minutes of training and advancement on HeartMath techniques as well as continued written and video reinforcement.
224308892|NCT01329549|DRUG|BIBF 1120 (medium) + PLD 30 mg/m2 + CBDCA AUC5 mg/mL*min|BIBF 1120 twice daily along with standard therapy of PLD + CBDCA
224308893|NCT01329549|DRUG|BIBF 1120 (low) + PLD 30 mg/m2 + CBDCA AUC5 mg/mL*min|BIBF 1120 twice daily along with standard therapy of PLD + CBDCA
224186760|NCT05994664|OTHER|Control Group|The participants will all complete baseline surveys and paperwork including signed consent, psychometric surveys, demographic survey, and a brief, open-ended questionnaire about their feelings about living with VEDS. The initial visit will include an HRV assessment using the HeartMath sensor via the 3-step Protocol developed by the HeartMath Institute. Participants from both groups will have weekly virtual sessions that include the 3-step Protocol HRV assessment. After the CG has completed 8 weeks, they will then have access to materials related to the techniques that were taught to the HMI group to allow for therapeutic equality.
224308894|NCT03277118|DEVICE|Wireless Wearable Device|Wireless Wearable Device will be placed on the wrist of the patient prior to extubation in the ICU to record patient activity in terms of steps and sleep quality.
223495698|NCT00478036|DRUG|Pred Forte|Details covered in arm description
223495699|NCT00478036|OTHER|Refresh Tears|Placebo
223495700|NCT04648176|DEVICE|Moses technology|Using Holmium laser with Moses technology or conventional one
223495701|NCT04407520|OTHER|No patient treatment is associated with the study|No patient treatment is associated with the study.
223495702|NCT03669679|PROCEDURE|Breast reduction|breast reduction surgery for breast hypertrophy using either superomedial or inferior pedicle technique
223495703|NCT05924932|DEVICE|Tandem t:slim X2 with hybrid closed loop system Control IQ, glucose sensor: Dexcom G6|type of hybrid close loop insulin delivery system
223495704|NCT05924932|DEVICE|MiniMed 780G, with hybrid closed loop system SmartGuard, sensor Guardien 4|type of hybrid close loop insulin delivery system
223495705|NCT02200081|DRUG|MGN1703|
223495706|NCT02200081|OTHER|Standard of care|Usual Standard of Care according to local investigators practise, e.g. Treatment break continous treatment and other
223495707|NCT00762905|DEVICE|LiquiBand Laparoscopic|LiquiBand Laparoscopic™ is a sterile, liquid adhesive made up of a blend of n-butyl and 2-octyl cyanoacrylate intended for soft tissue approximation of skin wounds. It is packaged in a sterile, single-use, nylon applicator with internal glass ampoule containing 0.8g of adhesive and sealed in a PETG/Tyvek blister pack. LiquiBand Laparoscopic™ is intended to be applied topically to pre-apposed wound edges. The tissue adhesive sets rapidly (5 - 10 seconds) to hold the wound closed. Following wound closure the product is designed to apply a broad coverage of adhesive to act as a liquid dressing to protect the wound.
223495708|NCT00762905|DEVICE|Dermabond|High viscosity DermaBond Topical Skin Adhesive is a sterile, liquid topical skin adhesive containing a monomeric (2-octyl cyanoacrylate) formulation and the colorant D \& C Violet #2. It is provided in a single use applicator packaged in a blister pouch. The applicator is comprised of a crushable glass ampule contained within a plastic vial with attached applicator tip. As applied to skin, the liquid is syrup-like in viscosity and polymerizes within minutes.
223495709|NCT00756301|OTHER|Lidocaine local anesthesia- Alternative|Local anesthetic (Lidocaine) injected using traditional technique (involves injecting Lidocaine into the skin first, then into the deeper tissues).
223495710|NCT00731198|DRUG|Drotaverine hydrochloride|Drotaverine hydrochloride 40mg was administered intravenously 15 minutes before ERCP
223495711|NCT00731198|DRUG|Hyoscine-N-butylbromide|Hyoscine-N-butylbromide 20mg was administered intravenously 15 minutes before ERCP.
223495712|NCT03787160|DIAGNOSTIC_TEST|initial VOC|Difference in VOC profile between patients with CDH and healthy controls (2 samples per patient will be obtained after obtaining informed consent).
223495713|NCT03787160|DIAGNOSTIC_TEST|initial fecal microbiome|Difference of alpha and beta diversity and relative fecal bacterial abundance between patients with CDH and healthy controls (1 stool sample will be taken per patient after obtaining informed consent)
223495714|NCT03787160|DIAGNOSTIC_TEST|initial pulmonary microbiome|Difference of alpha and beta diversity and relative pulmonary bacterial abundance between patients with CDH and healthy controls (1 deep induced sputum sample will be taken per patient after obtaining informed consent)
223495715|NCT03787160|DIAGNOSTIC_TEST|Maximum oxygen uptake|Comparison of the maximum oxygen uptake (corrected for body weight and gender) as determined by bicycle spiroergometry between patients with CDH and healthy controls
224186761|NCT04774029|PROCEDURE|Basivertebral nerve block|Temporary intraosseous basivertebral nerve block using lidocaine
224308895|NCT06505941|DRUG|umbilical cord mesenchymal stem cell|umbilical cord mesenchymal stem cell
224308896|NCT06505941|DRUG|Placebo|non-cell-containing placebo
223495716|NCT03787160|DIAGNOSTIC_TEST|Functional residual capacity|FRC will be determined by spirometry, bodyplethysmography and N2-breath wash out method. FRC will be compared between patients after CDH and healthy controls.
223495717|NCT03787160|DIETARY_SUPPLEMENT|Probiotic treatment|CDH patients will receive OmniBiotic 6(R) (Allergosan, Graz, Austria) probiotic supplementation 1 sachet daily for 3 months.
223495718|NCT03787160|DIAGNOSTIC_TEST|VOC probiotic|Determination of the VOC profile 3 months after discontinuing probiotic treatment. Comparison to the profiles before the treatment.
223495719|NCT03787160|DIAGNOSTIC_TEST|Fecal microbiome probiotic|Determination of the fecal microbiome from 1 sample per patient (alpha and beta diversity, relative bacterial abundance at the genus level) 3 months after discontinuing probiotic treatment. Comparison to the profiles before the treatment.
223495720|NCT03787160|DIAGNOSTIC_TEST|Pulmonary microbiome probiotic|Determination of the fecal microbiome from 1 deep induced sputum sample per patient (alpha and beta diversity, relative bacterial abundance at the genus level) 3 months after discontinuing probiotic treatment. Comparison to the profiles before the treatment.
223495721|NCT03357055|DRUG|Ketamine|IV infusion of 0.25mg/kg of ketamine over 10 minutes before pneumatic tourniquet inflation. Throughout procedure patient will receive 0.25mg/kg of ketamine infusion.
223495722|NCT03357055|DRUG|Normal saline|Control group will receive an intravenous (IV) infusion of 10 ml of normal saline in a 10 ml syringe over 10 minutes starting 10 minutes before pneumatic tourniquet inflation. Throughout the procedure, patients will receive 10ml/hour normal saline infusion until the end of operation
224186762|NCT04774029|DRUG|Lidocaine induced basivertebral nerve block|Intraosseous lidocaine basivertebral nerve block
224186763|NCT02924129|DEVICE|Evoke Spinal Cord Stimulator (SCS) System|Spinal Cord Stimulation that measures and records evoked compound action potentials (ECAPs).
224186764|NCT05089773|PROCEDURE|The arterial switch operation|"The ASO is a procedure that emerged as an anatomically as well as physiologically appropriate solution to the transposition of the great arteries. The aorta and pulmonary artery are detached from their native roots and reattached to the opposite root; thus, the pulmonary root becomes the neo-aorta, and the aortic root becomes the neo-pulmonary artery.~The coronary arteries are transplanted from the aorta/neo-pulmonary artery to the pulmonary artery/neo-aorta."
224186765|NCT05267327|OTHER|Verzenios|Study drug is Verzenios, it is an observational study.
224186766|NCT00630942|DRUG|Minocycline|Minocycline 100 mg capsules twice a day before breakfast and before dinner.
224186767|NCT04306627|DRUG|Perindopril/Amlodipine and Perindopril/Amlodipine/Atorvastatin treatment|comparative antihypertensive antilipidemic treatment assessment on carotid intima media thickness in both study groups
224186768|NCT03312127|DEVICE|ILIAC ENDOPROSTHESIS GORE EXCLUDER|Set up of GORE ® Excluder Iliac Branch Endoprosthesis in endovascular barring of complex aneurysms without distal neck. In the immediate post-operating follow-up visit and at the 3 months visit and the 12 months visit after surgery, an ultra-sound scan, a tomodensitometric exam and a walking test on a treadmill with oximetric gluteal region exploration will systematically be performed.
223495723|NCT06115980|DEVICE|lead extraction (Xtrac O.S. system)|"This is an open label, non-randomized, feasibility, prospective, interventional clinical trial of lead extraction. The Xtrac O.S. system is intended for transvenous removal of pacing or defibrillator leads, having an inner lumen, through a superior approach.~The decision upon lead extraction will be based upon the applicable Heart Rhythm Society guidelines or European Heart Rhythm Association (EHRA).~Each enrolled patient will undergo a pre procedural evaluation to enable planning of the extraction procedure. The evaluation includes an assessment of the CIED components to be removed, dwell time, anatomic course on radiography and patient characteristics that may require management prior to extraction.~A multidisciplinary team evaluation involving cardiac surgery, electrophysiologist, and cardiac anesthesiology should allow for a rapid and successful response to major complications"
223495724|NCT03787407|BEHAVIORAL|stress management and meditation|mindfulness training using mobile application
223495725|NCT05084326|PROCEDURE|Engagement of fetal head as a predictor of a successful vaginal delivery|"In addition to the fetal lie, presentation, and position, the level or station of the presenting part in the maternal pelvis is an important factors in the labor process.~In primigravida, Delayed engagement of fetal head has been theorized that it is more likely in women with a possible cephalo-pelvic disproportion, so far they are associated with higher risk of cervical dystocia, which led to increased rate of caesarean section."
223495726|NCT03823625|DRUG|Nivolumab plus Ipilimumab|Nivolumab will be administered at the standard dose of 360 mg every 3 weeks. Ipilimumab will be administered at the dose of 1 mg/kg every 6 weeks.
223495727|NCT03823625|DRUG|Platinum-based chemotherapy plus Nivolumab|"Nivolumab will be administered at the standard dose of 360 mg every 3 weeks.~Platinum-based chemotherapy will be chosen by the investigator among the following regimens:~* Cisplatin 80 mg/mq iv day 1 and Gemcitabine 1250 mg/mq iv days 1 and 8 every 21 days;~* Carboplatin AUC 5 iv day 1 and Gemcitabine 1000 mg/mq iv days 1 and 8 iv every 21 days;~* Carboplatin AUC 6 iv day 1 and paclitaxel 200 mg/mq iv day 1 every 21 days."
223495728|NCT04942873|OTHER|adherence|PDC value and MMAS-8 scale were used to evaluate the compliance of patients with dabigatran, rivaroxaban and wafarin
223495729|NCT02242344|DRUG|Telmisartan|
223495730|NCT02242344|DRUG|Placebo|
223495731|NCT04695678|DIAGNOSTIC_TEST|COVID-19 nasal/pharyngeal swab|each study participant receives a nasal/pharyngeal swab
223495732|NCT00420836|DRUG|Tobramycin|
223495733|NCT06403722|DIAGNOSTIC_TEST|Standard of care|No intervention. Clinical evolution was recorded, looking for perinatal complications.
223495734|NCT02184117|DRUG|Adenosine|Intracoronary or intravenous adenosine to induce hyperemia for reference FFR
224308897|NCT03337243|PROCEDURE|HAM and HUMCWJ Injections|SURGENEX SurForce® (1cc) allograft placental based tissue matrix, will be injected using a 22 gauge, 2-inch needle. The injection site (medial, lateral, patellar) will be determined based on the side with the most joint space from the findings of the most recent x-rays. The Physician will insert the needle fully into the joint space and begin to expel the fluid. He will achieve a continuous injection flow as he withdraws the needle back out of joint space. Immediately following the SURGENEX SurForce® injection, an injection of Predictive Biotech CORECYTE(TM) (1 cc) allograft umbilical cord-derived Warton's Jelly tissue matrix will be administered. This will be done using the exact same protocol as the SURGENEX SurForce® injection.
223495735|NCT02184117|DRUG|Contrast Media|"Intracoronary injection of contrast medium to induce hyperemia for contrast FFR"
223495736|NCT02184117|DRUG|Resting conditions|Baseline measurement of aortic and coronary pressures
223495737|NCT02875600|OTHER|Nutri Drink|To determine the difference in baseline MR flow measurements and post prandial MR flow measurements between patients diagnosed with CGI and patients not diagnosed with CGI
223495738|NCT00265278|DRUG|Modafinil|
223495739|NCT00675350|DRUG|Omacetaxine|1.25 mg/m2 subcutaneous twice daily for 14 days
223495740|NCT01385644|OTHER|Placental MSC|MSC will be derived from mothers donating their term placenta for clinical trial research purposes at Mater Mothers Hospital, Brisbane. The donation, isolation and expansion of placental-derived MSC for research purposes has been approved by the Mater Health Services (MHS) Human Research Ethics Committee (Reference No. 1292A). These volunteer donor mothers are unrelated to and will be HLA-unmatched with the IPF recipients.
223495741|NCT00800540|DRUG|Brinzolamide 10 mg/ml/Timolol 5 mg/ml eye drops suspension|Fixed combination ophthalmic suspension
223495742|NCT00800540|DRUG|Brimonidine 20 mg/ml/Timolol 5 mg/ml eye drops solution|Fixed combination ophthalmic solution
224186769|NCT00862927|OTHER|Breath Sample|Breathe into machine measuring carbon monoxide.
224186770|NCT00862927|OTHER|Saliva Sample|Chew cotton ball for 30 seconds for cotinine measurement.
224186771|NCT00862927|BEHAVIORAL|Questionnaire|6 surveys, taking approximately 30 minutes total.
224186772|NCT00862927|BEHAVIORAL|View Virtual Reality Scenes|Use virtual reality helmet and hand-held controller to answer questions about 4 viewing scenes while wearing physiological measurement skin sensors, approximately 6 minutes.
224186773|NCT03279731|DRUG|Liraglutide (Saxenda) 6Mg/Ml Inj Pen 3Ml|subcutaneous injection, pre-filled, multi-dose pen that delivers doses of 0.6 mg, 1.2 mg, 1.8 mg, 2.4 mg, or 3 mg (6 mg/mL, 3 mL). Matching the recommended dosage and administration guidelines of the FDA-approved labeling for the use of liraglutide (Saxenda), the medication will be initiated at 0.6 mg daily for 1 week, and then increased by 0.6 mg/day in weekly intervals until a dose of 3.0 mg/day is achieved.
224186774|NCT03279731|DRUG|Placebo|subcutaneous injection, pre-filled, multi-dose pen that delivers doses of 0.6 mg, 1.2 mg, 1.8 mg, 2.4 mg, or 3 mg (6 mg/mL, 3 mL). It is designed to be identical to the pen used for liraglutide (Saxenda). Placebo product inactive ingredients: disodium phosphate dihydrate, 1.42 mg; propylene glycol, 14 mg; phenol, 5.5 mg; and water for injection
224186775|NCT05776511|PROCEDURE|eVOG|video digital oculography
224308898|NCT05054478|DRUG|Daratumumab|Daratumumab added to induction, first consolidation and second consolidation
223495743|NCT05876494|DIAGNOSTIC_TEST|serum lactate|assessment of serum lactate and mean platelets volume
223495744|NCT01537796|BEHAVIORAL|In-Person weight loss|Participants will attend weekly group intervention meetings. These sessions will address barriers associated with altering physical activity participation and dietary intake. Group discussions will be facilitated by the interventionist and interactive participation will be encouraged. Participants will be provided with written materials at each meeting to supplement group discussions. Paper diaries will be provided each week to assist participants with self-monitoring of calorie and fat consumption, and physical activity minutes and intensity. Participants will return the diary to the intervention staff each week for review and constructive feedback.
223495745|NCT01537796|BEHAVIORAL|FIT weight loss|Intervention materials will be provided and mailed weekly to participants. Participants will be provided with the BodyMedia® FIT System that includes a wearable device to monitor physical activity and energy expenditure, a display device to provide feedback on achievement of energy expenditure and physical activity goals, and web-based software to assist with self-monitoring of dietary intake and to provide feedback on goal achievement. Participants will attend one introductory session in which a tutorial of the components of the enhanced FIT System will be provided. Participants will receive a one-hour lesson on basic guidelines of the weight loss intervention. Once per month participants will receive a scheduled 10 minute intervention telephone call with the intervention staff.
223495746|NCT01537796|BEHAVIORAL|FIT-BT weight loss|Participants will be provided with intervention materials that are mailed weekly to them. Participants will be provided with the enhanced BodyMedia® FIT System that includes a wearable device with Bluetooth® technology to allow participants to receive real-time feedback on calories expended and physical activity on their smart phone. This also supports self-monitoring of dietary behaviors and body weight. Participants will attend one introductory session in which a tutorial of the components of the enhanced FIT System will be provided. Participants will also receive a one-hour lesson on basic guidelines of the weight loss intervention. Once per month participants will receive a scheduled 10 minute intervention telephone call with the intervention staff.
223495747|NCT00078520|BIOLOGICAL|Dose Level 1|IL-2-B-CLL 2 x 10\^7; CD40L-B-CLL 0
223495748|NCT00078520|BIOLOGICAL|Dose Level 2|IL-2-B-CLL 2 x 10\^7; CD40L-B-CLL 2 x 10\^6
223495749|NCT00078520|BIOLOGICAL|Dose Level 2- Fixed Dose|IL-2-B-CLL 2 x 10\^7; CD40L-B-CLL 2 x 10\^7
223495750|NCT01244282|PROCEDURE|fMRI with sensory stimulation|BOLD fMRI study with sensory stimulation followed by fMRI in the presence of increasing concentrations of ferumoxytol (Feraheme™)
223495751|NCT01805050|PROCEDURE|Arthroscopically repair of the anterior shoulder instability|Arthroscopically repair of the anterior shoulder instability
223495752|NCT04687722|OTHER|High Intensity Aerobic Training.|Participants will perform 2-5 minutes of low to moderate intensity warm up exercises and then 20 minutes of high intensity aerobic training at 80-90% of heart rate maximum increased gradually on treadmill and elliptical trainer and then 2-5 minutes of low to moderate intensity cool down exercises.
223495753|NCT04687722|OTHER|Low intensity Aerobic Training|Participants will perform 2-5 minutes of low to moderate intensity warm up exercises and then 20 minutes of low intensity aerobic training at 40-60% of heart rate maximum increased gradually on elliptical trainer and jogging and then 2-5 minutes of low to moderate intensity cool down exercises.
223589551|NCT01569386|BEHAVIORAL|Daily low intensity physical activity by the half squat|They take a meal three times daily. They are a time to do the manual work every day. They watch the TV for two hours every day. And they do a walk of 30 minutes every day. They do a specific exercise. They were trained to conduct 40kcal period(about 20 min.) for adding to the amount of energy consumption of low-intensity physical activity at baseline.Specific exercise that was done the half squat(max knee flexion 70 degree). This squat is carried out in two seconds round trip. This squat is carried out in two seconds round trip. They grab the edge of the table. They put half the weight of the lower limbs paralyzed side. This observer once a week, to record their behavior over 24 hours. Intervention period is up to a maximum of 12 weeks.
223589552|NCT01569386|BEHAVIORAL|stretch exercise and usual activity|They take a meal three times daily.They are a time to do the manual work every day.They watch the TV for two hours every day.And they do a walk of 30 minutes every day.They do whole body stretch exercise for 20 minute in a day. An observer once a week, to record their behavior over 24 hours.Their behavior was used to calculate the amount of energy consumption.They are informed of the kcal a day from the viewer.
223617781|NCT00665665|DRUG|NNC 0070-0002-0182|4mg initial dose (12 subjects active; 3 subjects placebo); 2mg weekly maintenance dose; for s.c. injection 20mg/vial
223617782|NCT00665665|DRUG|placebo|Placebo for s.c. injection
223617783|NCT00665665|DRUG|NNC 0070-0002-0182|12mg initial dose (12 subjects active; 3 subjects placebo); 6mg weekly maintenance dose; for s.c. injection 20mg/vial
224186776|NCT04613076|BEHAVIORAL|"Me cuido y me siento mejor"|A multicomponent, collaborative, computer-assisted, psycho-educational intervention for the management of depressive symptoms in primary care patients with diabetes and/or hypertension.
224186777|NCT04613076|BEHAVIORAL|Enhanced Usual Treatment|Enhanced Usual Treatment
224186778|NCT00556283|DEVICE|STARR|Stapled Trans-Anal Rectal Resection for the treatment of ODS
224186779|NCT00556283|BEHAVIORAL|Biofeedback|electromyographic-based treatment sessions
224308899|NCT00788320|DRUG|Vitamin D3|Vitamin D3 50,000 IU three times a week for 8 weeks
224308900|NCT00788320|DRUG|Placebo|Placebo three times a week for 8 weeks
224308901|NCT06625567|OTHER|Animated video|Patients will watch an educational video describing the procedure before hysteroscopy without anesthesia
224186780|NCT00917943|BEHAVIORAL|Tailored Counseling Intervention Arm|Study staff contact women when they are between 28 and 34 weeks pregnant, confirm their non-smoking status, and make an appointment to explain the study further, obtain written informed consent, conduct the risk assessment, and collect baseline data. Bio-behavioral and pregnancy-specific factors are used to triage women in the treatment arm to one of four levels of stepped-care that includes one in-person counseling session and at least one telephone session during pregnancy and from 6 to 11 telephone sessions over the first 9-months postpartum.
224308902|NCT06252220|DRUG|DA-1726|Active
224186781|NCT02491918|PROCEDURE|cataract surgery|cataract surgery in children
224308903|NCT06252220|DRUG|Placebo to DA-1726|Placebo
224308904|NCT02264912|DRUG|antiplatelet drugs - P2Y12 antagonists|
224308905|NCT02208739|PROCEDURE|Nonsurgical periodontal therapy|All patients were instructed in oral hygiene methods using a soft bristled toothbrush, a compact-tuft toothbrush, interdental brushes and dental floss utilizing the modified Bass technique. Full mouth debridement, which consisted of scaling and root planing, was done in a single visit for all subjects using an ultrasonic scaler and gracey curettes. Additionally, all patients were given a 0.12% Chlorhexidine mouthrinse (Hexipro®). They were instructed to rinse three times a day using 15ml each time for a period of 14 days commencing immediately after completion of full mouth debridement. Thereafter at each recall visit, all participants were re-motivated and professional prophylaxis was performed.
224186782|NCT02491918|PROCEDURE|Intraocular lens implantation|intraocular lens implantation in the capsular bag or optic capture
224308906|NCT02208739|PROCEDURE|Oral hygiene instructions|All patients were instructed in oral hygiene methods using a soft bristled toothbrush, a compact-tuft toothbrush, interdental brushes and dental floss utilizing the modified Bass technique.
224308907|NCT05174195|DRUG|Desogestrel 0.075 milligram|Inserted after 3 months use of DESOGESTREL
224308908|NCT05174195|DRUG|Implanon NXT® subdermal implant|Inserted immediately
224308909|NCT03271723|OTHER|Observational study|No intervention
223495754|NCT03578913|OTHER|PEEK crown|The main concern of dental implants is their lack of elasticity, therefore with the use of PFM, all ceramic or zirconia crowns; the load is directly transferred to bone. That is why up till now researchers are in quest of different materials to enhance soft and hard tissue reaction around implant supported restorations. Recently the use of PEEK as a final restoration on dental implants has wide acceptance, due to its excellent biocompatibility and exceptional physical and chemical properties regarding toughness, hardness and elasticity. In term of load cushioning capacity of the prosthetic elements, PEEK has a comparable modulus of elasticity (4GPa) to that of bone (4.2GPa). Thus, the bone could allow bone stimulation favoring its remodeling without overloading.
224186783|NCT02120573|OTHER|Workshop using Lecture and human model|workshop to teach CPR with lecture and human models
224186784|NCT02120573|OTHER|Workshop using Educational Film|workshops using film review about CPR
224186785|NCT02120573|OTHER|Workshop using Lecture, human model as well as Educational Film|using educational films and human model and lecture for training
224186786|NCT02120573|OTHER|Workshop using Lecture, human model, Educational Film as well as reference book|training volunteers with lecture, films, and human models and giving them reference book for referral
224186787|NCT01135368|DRUG|Lansoprazole|Lansoprazole capsules
224186788|NCT03825848|PROCEDURE|trans jugular intrahepatic portal systemic shunt|Shunting left or right PV branch in the TIPS procedure
224186789|NCT01376076|DRUG|Cariprazine|Patients meeting all study eligibility criteria will be randomized to receive cariprazine (Group 1) 1.5 to 18 mg once daily, administered orally.
224186790|NCT01376076|DRUG|Risperidone/Moxifloxacin|Patients randomized to Group 2A will receive double blind placebo for Days 1-5, Moxifloxacin (400mg) on Day 6, Risperidone 4mg once daily Days 7-15, placebo Days 16-20, Risperidone Days 21-29, placebo Days 30-35.
224186791|NCT01376076|DRUG|Risperidone/Moxifloxacin|Patients randomized to Group 2B will receive double blind placebo for Days 1-6, Risperidone 4mg once daily Days 7-15, placebo Days 16-20, Risperidone Days 21-29, placebo Days 30-34, Moxifloxacin (400mg) on Day 35.
224186792|NCT04469140|DEVICE|SS-OCT imaging|All subjects will undergo retinal imaging using the Zeiss PlexElite SS-OCT, a non-contact, non-invasive ocular imaging instrument
224186793|NCT05363787|OTHER|therapeutic touch|Therapeutic Touch (TT) is an evidence-based holistic treatment method in which universal energy is used intentionally and with compassion for a specific purpose, in order to contribute to one's balance and recovery.In a world dominated by technology, one can lose touch with our inner self. We lose our intuitive abilities for beautiful everyday sensations of nature, the surrounding environment, and various visual and auditory elements. The Therapeutic Touch is an ancient Ayurvedic self-massage technique that connects your body to your soul.It is also used in therapeutic communication. Therapeutic communication is the process of influencing and being influenced by one another. It consists of individual-centered, purposeful, planned, effective and satisfying actions.
224186794|NCT01464073|BEHAVIORAL|LIPOXmax|Arm 1: LIPOXmax arm. Subjects will perform a physical activity 4x1 hour per week at the optimal intensity for fat oxidation (LIPOXmax) measured by indirect calorimeter.
224186795|NCT01464073|BEHAVIORAL|60% VO2peak|Arm 2: physical activity standard arm (60% of VO2max measured by cardio respiratory exercise test). Subjects will realize 4 sessions per week and duration of sessions will be adjusted so that arms 1 and 2 have the same total energy expenditure by session.
224186796|NCT01464073|BEHAVIORAL|Good Medical Practices|"Arm 3: The subjects initially receive the recommendations of good medical practice for physical activity (achieving at least 30min per day of moderate exercise)."
224186797|NCT01464073|DIETARY_SUPPLEMENT|supplementation in fruits and vegetables|all groups will be supplemented in fruits and vegetables (5 per day) during all the study
224186798|NCT06066463|BEHAVIORAL|questionnaires|Self reported female gender
224308910|NCT05019599|OTHER|low protein diet|Low protein diet (\<0.8g/kg/BW/day)
224308911|NCT04371094|DEVICE|a device to facilitate endotracheal intubation|a device to facilitate endotracheal intubation
223617784|NCT00665665|DRUG|NNC 0070-0002-0182|32mg initial dose (12 subjects active; 3 subjects placebo); 16mg weekly maintenance dose; for s.c. injection 20mg/vial
224308912|NCT03587324|DRUG|Whole blood aggregometry before and after vascular treatment (ASA/ Clopidogrel).|"To identify possible risk factors demographic data, concomitant medication, laboratory parameters, co-morbidities, severity of the condition and the type of procedure performed are documented.~Other Name: ASA (aspirin), Clopidogrel (Plavix)"
224308913|NCT06175988|OTHER|Visceral adiposity|Visceral adiposity assess by the visceral adiposity index
223495755|NCT03578913|OTHER|PFM Crown|Although metal free restorations are gained popularity recently, PFM restorations, whether they are tooth-supported or implant-supported are still considered as the gold standard due to their excellent biocompatibility, consistent esthetics, superior strength, and marginal adaptation.2 PFM restorations are also considered durable and long-lasting
224186799|NCT00302731|DRUG|Estradiol , estriol , progesterone|
224186800|NCT00302731|DRUG|estradiol, progesterone|
224186801|NCT00302731|DRUG|estriol, progesterone|
224186802|NCT00302731|DRUG|equine estrogens m-progesteroneacetate|
223495756|NCT05909423|DRUG|Influenza vaccine|Intratumoral influenza vaccine treatment, administered via endoscopic procedure
223495757|NCT05909423|DRUG|Pembrolizumab|Single dose pembrolizumab treatment
223495758|NCT02142543|DRUG|2-DeNT powder|powder included dexamethasone, diphenhydramine, tetracycline, metronidazole, nystatin, zinc oxide, and karaya gum
223495759|NCT02142543|DRUG|Placebo Comparator|
223495760|NCT00378859|BEHAVIORAL|Skim milk|
223495761|NCT00378859|BEHAVIORAL|Lean meat|
223495762|NCT02715557|BEHAVIORAL|Relapse prevention program|The relapse prevention program is an innovative computer-based coping skills educational program for adolescent substance abuse treatment completers.
223495763|NCT01922011|DRUG|Daptomycin|IV daptomycin Infusion A in 12 to \<18 years old (7 mg/kg); in 7 to \< 12 year olds (9 mg/kg); in 24 months to \<7 year olds (12 mg/kg); in 12 to \<24 month olds (12 mg/kg). Infused over 60 minutes ± 10 minutes once daily followed by up to 3 dummy infusions every 6 hours (q6h) infused over 60 (± 10) min to maintain the blind.
223495764|NCT01922011|DRUG|Vancomycin (or equivalent)|IV vancomycin (or equivalent) (Infusions A,B,C,D), 10 to 15 mg/kg, infused over 60 (± 10) minutes q6h (± 1 hour)
223495765|NCT01922011|DRUG|Nafcillin (or equivalent)|IV nafcillin (or β-lactam equivalent) (Infusions A,B,C,D) at 100-200 mg/kg/day, in divided doses infused over 60 (± 10) min q6h (± 1 hour)
223495766|NCT04575012|PROCEDURE|Deferred invasive strategy|PCI on 7 to 10 days after symptom onset
224186803|NCT06113731|BIOLOGICAL|COVID-19 mRNA Vaccine (ZSVG-02-O)|30 μg
224186804|NCT06113731|BIOLOGICAL|COVID-19 mRNA Vaccine (ZSVG-02-O)|60 μg
224308914|NCT02390128|OTHER|observational only|
224308915|NCT05580965|OTHER|20 N pressure for 1 minute|After blood collection, 20 N pressure applied for 1 minute
223495767|NCT04575012|PROCEDURE|Early invasive strategy|Primary PCI
223495768|NCT02197637|DRUG|ORAL VINORELBINE|Orally vinorelbine 60 mg/m2 D1, 8 and 15 Cycle of 28 days For a maximum of 12 cycles The dose of vinorelbine should be increased to 80 mg/m2 from the 2nd cycle If on D8 and D15, the administration conditions are not met, the administration is canceled and not delayed.
223495769|NCT02585167|PROCEDURE|operation|the fistula will be excised after dividing the sphincter and primary reconstruction will be performed with absorbable sutures, closing the internal opening and leaving the external opening unclosed for drainage.
223495770|NCT02585167|DEVICE|VAAFT|Karl Storz Video Equipment is used. The fistula tract will be visualized from the external to the internal opening, closing the internal opening with absorbable sutures, then brushing and cauterization of the tract(s) leaving the external opening unclosed for drainage.
223495771|NCT01721239|OTHER|Standardized Followup program|Standardized written information, patient photos and three followup consultations.
223495772|NCT04764253|BEHAVIORAL|Modified Sodium Watcher Program + Digital Self-Monitoring|Participants randomized to the experimental group will be asked to follow the modified Sodium Watchers Program intervention along with goal setting for low salt foods. Each participant will be registered to assign a unique ID in the Connected Health Platform developed by the Center on Smart and Connected Health Technologies at UT Health Science Center San Antonio and each account from the individuals' wireless and wearable devices (Fitbit and BP monitor) will be connected to his or her unique ID through this platform. Participants will be instructed to log their activities in real-time, including food intake and in-home BP monitoring using Fitbit and accompanied mobile app and BP monitor. Through the Connected Health Platform, the Fitbit app and BP monitor will transmit the data of the intervention group to the research team.
224308916|NCT05580965|OTHER|20 N pressure for 3 minute|After blood collection, 20 N pressure applied for 3 minute
223511822|NCT03276481|DIAGNOSTIC_TEST|Measurement of salivary flow|Both stimulated and un-stimulated salivation will be assessed by saliva collection in pre-weighed plastic containers. Participants will be seated with their back at a 90 degree angle and asked to swallow everything in their mouth. They will then be asked not to swallow and spit the accumulated saliva in the plastic container every 30 seconds for two minutes (unstimulated flow). For measurement of stimulated saliva, we will follow the same procedure except that after the initial swallow, participants will have their tongue swabbed twice with a cotton swab dipped in ascorbic acid solution or lemon juice.
224308917|NCT05580965|OTHER|20 N pressure for 5 minute|After blood collection, 20 N pressure applied for 5 minute
224308918|NCT02609074|PROCEDURE|Minimally invasive internal fixation surgeries|
224186805|NCT06113731|BIOLOGICAL|COVID-19 Vaccine (Vero Cell) ,Inactivated|COVILO
224186806|NCT02131142|DEVICE|BioFreedom drug coated coronary stent|Placement of a BioFreedom drug coated stent in a narrow coronary artery
224186807|NCT05921942|DRUG|Metformin|500 mg twice daily or 1000 mg once daily
224308919|NCT02609074|DEVICE|CPC/rhBMP-2 micro-scaffolds|
224308920|NCT02609074|DEVICE|CPC paste|
224308921|NCT04163510|BEHAVIORAL|Behavioral: Parent/Child Reading Program|A 9-week parent/child reading program will help parents to identify strategies to establish literacy routines with their children, and to engage with them in enjoyable literacy activities that promote skill building while reducing negative feelings associated with reading. Three large-group sessions will be held in a central location, to build community and rapport among researchers and participants. Six individual sessions will take place in the participants' homes, to customize reading strategies and routines to each family's home setting and personal interests. Intervention sessions will be held once per week for 60-90 minute sessions.
224308922|NCT02421224|BEHAVIORAL|Usual Care|Participants will receive in-person group counseling from a trained smoking cessation counselor. Participants will learn about reasons to quit smoking, strategies for quitting smoking, and additional resources available to support the quit attempt. Participants will also complete a quit plan.
224186808|NCT05901506|OTHER|a Nurse-led, Motivational Interview|Family member participants will receive three counselling sessions: (1) preparatory session, (2) motivation session, and (3) planning session. The preparatory session will take 10-15 minutes, and the following two sessions at weeks 2 \& 3, with 30-45 min, respectively. The sessions can be delivered via face-to-face, zoom meeting, or telephones. Before each session, the nurse will first assess the family member's readiness to engage in ACP based on the State to Change algorithm. Family members who have never thought about ACP will be in the pre-contemplation state. Family members who are willing to discuss end-of-life care will be in the contemplation state. Those who are ready to talk about end-of-life planning will be in the planning state. Readiness-based ACP goals will be established, and state-matched motivational interview counseling will be customized for each participant.
224186809|NCT01000311|BIOLOGICAL|MenACWY-CRM|One dose (0.5 mL) of MenACWY conjugate vaccine supplied as an extemporaneous mixing just before injection of the lyophilized component (MenA) reconstituted with the liquid component (MenCWY) was administered at 2, 4, 6 and 12 months of age as IM injections in the anterolateral area of the thigh.
224186810|NCT01000311|BIOLOGICAL|DTaP-IPV/Hib|IM injections of 3 doses of 0.5 mL each of DTaP-IPV/Hib supplied in prefilled vial were administered at 2, 4 and 6 months of age in the anterolateral area of the thigh.
224186811|NCT01000311|BIOLOGICAL|HBV|IM injections of 3 doses of 0.5 mL each of HBV supplied in prefilled vial were administered at 2, 4 and 6 months of age in the anterolateral area of the thigh.
223495773|NCT04764253|BEHAVIORAL|Usual care + Digital Self-Monitoring|Participants randomized to the control group will be asked to follow usual care which is based on their routine medical and nursing care for hypertension that consists of a recommendation to follow a sodium-restricted diet and take medications as prescribed. The participants will receive wireless and wearable devices (Fitbit wristband, BP monitor). Each participant will be registered to assign a unique ID in the Connected Health Platform at the baseline and each account from the individual's wireless and wearable devices (Fitbit and BP monitor) will be connected to their unique ID through this platform. Participants will be instructed to log their activities in real-time, including food intake and in-home BP monitoring using Fitbit and accompanied mobile app and BP monitor.
224186812|NCT01000311|BIOLOGICAL|PCV|IM injections of 4 doses of 0.5 mL each of PCV supplied in prefilled vial were administered at 2, 4, 6 and 12 months of age in the anterolateral area of the thigh.
224186813|NCT01000311|BIOLOGICAL|MMR|Subcutaneous (SC) injection of 1 dose of 0.5 mL of MMR obtained by extemporaneous mixing just before injection of powder and the solvent for solution was administered at 12 months of age in the anterolateral area of the thigh.
224186814|NCT00707551|DRUG|Ketoconazole|Tablet, administered as repeated doses.
224186815|NCT00707551|DRUG|Verapamil|Extended Release tablet, administered as repeated doses.
224186816|NCT00707551|DRUG|AZD1305|Extended Release tablet, administered as a single dose.
224186817|NCT03127072|DEVICE|Radiofrequency Ablation (RFA)|The radiofrequency generator has the capacity to deliver 200 watts of alternating current to the needle electrode for the coagulation necrosis of soft tissue
224186818|NCT03127072|DRUG|chemotherapy ± target therapy|chemotherapy ± target therapy
224186819|NCT02780869|DEVICE|HEMOBLAST Bellows|
223495774|NCT01295892|DRUG|Estrogen|transdermal 17-β-estradiol 1mg/day during three months
223495775|NCT04985656|DRUG|Pevonedistat|Pevonedistat IV infusion
223495776|NCT04985656|DRUG|Decitabine|Decitabine tablets
223495777|NCT04985656|DRUG|Cedazuridine|Cedazuridine tablets
223495778|NCT01133106|BEHAVIORAL|Brief pleasurable events/behavioral therapy|"Each participant in any arm will be given an American Stroke Association article about stroke and depression, a Stroke Smart Article about caregiver depression, and a pamphlet by the Beck Institute titled Coping with Depression.~Each participant in Arms 1 and 2 will be given their own manual for the intervention sessions. The intervention consists of one in-person orientation session and 6 weekly sessions with the following topics introducing behavioral therapy, the role of pleasant events, problem-solving skills and generalization techniques. All participants' primary care provider or stroke care provider will receive a letter informing them of their patient's participation (but not of study assignment). This letter will include recommendations for prescribing and adjusting antidepressant treatment using established guidelines adapted for treatment of medically-ill outpatients."
223495779|NCT01133106|OTHER|Standard care|The standard care group (Arm C, N=75) will receive standard medical treatment from their provider, including a recommendation for antidepressants. Participants or third-party payers will pay for their antidepressants, just as they would under regular care. All participants receive written materials regarding depression from the American Stroke Association, keep medication logs and receive follow-up assessment on the same time frame as the intervention groups
223495780|NCT03251599|DRUG|Glyceryl trinitrate 0.2|These patients will receive glyceryl trinitrate infusion at a rate of 0.2 mcg/kg/min throughout the rewarming period of cardiopulmonary bypass, which usually lasts for 30-45 minutes.
223495781|NCT03251599|DRUG|Glyceryl trinitrate 0.5|These patients will receive glyceryl trinitrate infusion at a rate of 0.5 mcg/kg/min throughout the rewarming period of cardiopulmonary bypass, which usually lasts for 30-45 minutes.
223495782|NCT04398134|DRUG|ABI-H2158|3 X 100 mg tablets for oral administration
223495783|NCT04398134|DRUG|Placebo|Sugar pill manufactured to mimic the ABI-H2158 tablets
223495784|NCT04398134|DRUG|Entecavir (ETV)|0.5 mg tablet for oral administration
223495785|NCT04482790|PROCEDURE|Conventional celluloid matrix technique in management of black triangle|conventional restorative technique in management of black triangle
223495786|NCT04482790|PROCEDURE|Bioclear cervical matrix with injection molding technique|New restorative technique in management of black triangle restorative papilla regeneration
223511823|NCT03276481|BEHAVIORAL|Surveys assessing taste disturbances|Surveys will be administered and examine taste disturbances pre and post HCT.
223617785|NCT00665665|DRUG|NNC 0070-0002-0182|60mg initial dose (12 subjects active; 3 subjects placebo); 30mg weekly maintenance dose; for s.c. injection 20mg/vial
224186820|NCT02780869|DEVICE|Absorbable gelatin sponge, USP with thrombin|
224186821|NCT03811782|BEHAVIORAL|Single-task Training|In each training session, all groups will have warm-up (5 minutes), balance training (5 minutes), body transport training (5 minutes), body transport with hand manipulation training (5 minutes), walking training with various difficulties in a 10 meters walkway with Single-task Training instructions (20 minutes) and cool down (5 minutes).
224186822|NCT03811782|BEHAVIORAL|Dual-task Training|In each training session, all groups will have warm-up (5 minutes), balance training (5 minutes), body transport training (5 minutes), body transport with hand manipulation training (5 minutes), walking training with various difficulties in a 10 meters walkway with Dual-task Training instructions (20 minutes) and cool down (5 minutes).
223495787|NCT03802110|DEVICE|commercially released subcutaneous implantable cardioverter defibrillator (S-ICD) and the Investigational S-ICD Adapter.|The S-ICD System is a Subcutaneous (under the skin) Implantable Cardioverter Defibrillator for people who are at risk of Sudden Cardiac Arrest. A new electrode configuration will be tested for Defibrillation testing ( DFT). The unit of measure will be in Joules. VF will be induced and the device will deliver a shock at a certain defined energy level as described in the protocol
224186823|NCT03811782|BEHAVIORAL|Analogy Training|In each training session, all groups will have warm-up (5 minutes), balance training (5 minutes), body transport training (5 minutes), body transport with hand manipulation training (5 minutes), walking training with various difficulties in a 10 meters walkway with Analogy Training instructions (20 minutes) and cool down (5 minutes).
224186824|NCT03284931|DRUG|SAGE-217 high dose|high dose
223495788|NCT04925323|BIOLOGICAL|BLOOD SAMPLES|BLOOD SAMPLES
223495789|NCT04925323|BIOLOGICAL|surgical tissue samples|unused surgical tissue removed during plastic surgeries
223495790|NCT04135651|PROCEDURE|Paratracheal pressure|To apply paratracheal pressure, the thumb was placed over the left side of the trachea cephalad to the clavicle and medial to the sternocleidomastoid muscle.
223495791|NCT04135651|PROCEDURE|Cricoid pressure|To apply cricoid pressure, the crocoid cartilage was compressed with a single-handed three-finger maneuvre towards the vertebral bodies.
223617786|NCT03068871|OTHER|ACT|Psycho-educational group
224186825|NCT03284931|DRUG|Placebo|placebo
224186826|NCT03284931|DRUG|SAGE-217 low dose|low dose
224186827|NCT01610752|BEHAVIORAL|SmartMoms|This intervention will cover many topics to help you learn about weight management during pregnancy. You will be taught how to use different tools provided to help you monitor your weight. We will ask you to record your body weight (using a scale we will provide) as well as your food intake and exercise habits.
224186828|NCT02438293|OTHER|rhinovirus diagnostics|rhinovirus PCR on a nasopharyngeal swab
224186829|NCT01343329|DRUG|Esmolol|The Esmolol arm is defined as a 48-hour intravenous infusion of esmolol (Brevibloc 20mg/ml), which will be started on enrollment. The infusion rate will begin at 50 micrograms/kg/min and be adjusted to achieve heart rates between 80 and 100 beats/min with standard dosing regimens used in our Neuro intensive care unit. The infusion will be started at a rate of 0.05 milligrams/kg/min (50 micrograms/kg/min) for 5 minutes. After the 5 minutes of initial infusion, maintenance infusion may be continued at 0.05 mg/kg/min or increased stepwise (e.g. 0.1 mg/kg/min, 0.15 mg/kg/min to a maximum of 0.2 mg/kg/min) with each step being maintained for 4 or more minutes until the target heart rate is achieved.
224186830|NCT01343329|DRUG|Propranolol|The comparison arm will be comprised of oral propranolol, starting with 20mg PO every 6 hours prn (as needed) to reduce heart rate into target range. If 20mg is ineffective, the dose will be doubled at each dosing interval until an adequate dose is found, not to exceed 120mg four times daily. (ex: 20mg, 40mg, 80mg, 120mg)
224186831|NCT02861521|DEVICE|Shoe lift|Subjects will be given a shoe lift post-knee replacement to correct leg length discrepancy
224186832|NCT02861521|DEVICE|Sham|Sham shoe modification
224186833|NCT03190304|DRUG|Neprilysin|To compare the effect of Enalapril and Neprilysin on exercise tolerance in patients with heart failure
224186834|NCT03190304|DRUG|Enalapril|To compare the effect of Enalapril and Neprilysin on exercise tolerance in patients with heart failure
224186835|NCT03658031|DRUG|Dapagliflozin 10mg|Dapagliflozin 10 mg administered each morning before breakfast
223495792|NCT02792634|PROCEDURE|Sleeve-Gastrectomy, Roux en Y gastric bypass|
223511824|NCT02559960|DRUG|Breviscapine Powder-Injection|Patients will be given Breviscapine Powder-Injection according to their disease condition in the real world. The investigator only can record the information on the usage of the drug and the relevant medications without any interventions.
223511825|NCT00002101|DRUG|Ethambutol hydrochloride|
223511826|NCT00002101|DRUG|Clarithromycin|
223511827|NCT00002101|DRUG|Rifabutin|
223511828|NCT00693108|DRUG|Transdermal testosterone|
223511829|NCT04032327|DRUG|Exparel plus plain bupivacaine|10 mL of extended release liposomal bupivacaine (Exparel) plus 10 mL of 0.25% plain bupivacaine mixed to be injected vaginally prior to the start of posterior colporrhaphy
223511830|NCT04032327|DRUG|Bupivacaine|20 mL of 0.25% plain bupivacaine to be injected vaginally prior to the start of posterior colporrhaphy
223511831|NCT00216658|DRUG|fentanyl|
223511832|NCT04065256|OTHER|Personalized music|Personalized music intervention will be conducted by research nurse independently. Firstly, the music preference will be confirmed by using predesigned music list. After confirming the music preference, participants will receive a music session for forty minutes through headphone and MP3 player.
223511833|NCT04065256|OTHER|Personalized music plus earplug|Personalized music intervention will be conducted by research nurse independently. Firstly, the music preference will be confirmed by using predesigned music list. After confirming the music preference, participants will receive a music session for forty minutes through headphone and MP3 player. In addition, participants will be worn earplug during night time sleep for decreasing the noise until next morning.
223511834|NCT06005831|OTHER|sandbag|The standard sandbag used in our clinic, 20 × 20 × 3 cm3 in dimensions and 3 kg in weight
223511835|NCT01348906|PROCEDURE|intermittent normoxia|3 cycles of 5/5 min normoxia/hyperoxic reperfusion during cardioplegia arrest in adult valve replacement
223511836|NCT06430411|PROCEDURE|Radical prostatectomy|Removal of the prostate and seminal vesicles.
223511837|NCT06430411|RADIATION|Prostate irradiation|Radiation therapy of the prostate.
223511838|NCT06430411|PROCEDURE|Surgical metastasectomy|Surgical removal of metastases.
223511839|NCT06430411|RADIATION|Irradiation of metastases|Radiation therapy of metastases.
223511840|NCT06430411|DRUG|Abiraterone acetate|Administered as part of multimodal treatment for oligometastatic prostate cancer
223511841|NCT06430411|DRUG|Enzalutamide|Administered as part of multimodal treatment for oligometastatic prostate cancer
223511842|NCT06430411|DRUG|Darolutamide|Administered as part of multimodal treatment for oligometastatic prostate cancer
224186836|NCT05058066|DEVICE|Baha® flange fixture (diameter 3.75mm; length 4mm) with 6mm abutment|The control implant included the previous generation as-machined titanium Baha® flange fixture (diameter 3.75mm; length 4mm) with 6mm conically shaped abutment.
224186837|NCT05058066|DEVICE|Baha® BIA300 Implant (diameter 4.5mm; length 4mm) with 6mm abutment|The test implant and the implant used for the 3-week loading trial included the wide diameter titanium implant (diameter 4.5mm; length 4mm) with 6mm rounded, apically converging titanium abutment developed by Cochlear Bone Anchored Solutions AB (Mölnlyncke, Sweden). This system with an additional minor change to the internal abutment connection design was later commercialized under the name Cochlear™ Baha® BIA300 Implant with abutment. In addition to the difference in abutment shape and the wider diameter, the test implant incorporates small-sized threads at the implant neck and the moderately rough TiOblast™ (Dentsply, Mölndal, Sweden) surface on the intraosseous part of the implant6-8.
223495793|NCT03664258|DIAGNOSTIC_TEST|Xpert Bladder Cancer Monitor|The Xpert Bladder Cancer Monitor Assay is a qualitative in vitro diagnostic test designed to monitor for the recurrence of bladder cancer in patients previously diagnosed with bladder cancer. It should be used in conjunction with other clinical measures to assess disease recurrence. The test provides a fast and accurate result, is non-invasive and easy to perform.The test utilizes a voided urine specimen and measures the level of five target mRNAs (ABL1, CRH, IGF2, UPK1B, ANXA10) by means of real-time, reverse transcription-polymerase chain reaction (RT-PCR).
223495794|NCT00523380|DRUG|recombinant interleukin-21|Administered i.v. in treatment cycles of 28 days.
223495795|NCT00523380|DRUG|caelyx (pegylated liposomal doxorubicin)|Administered i.v. in treatment cycles of 28 days.
223495796|NCT02565472|OTHER|White grape juice|
223495797|NCT02565472|OTHER|Apple juice|
223617787|NCT03068871|OTHER|CET|Psycho-educational group
223617788|NCT02122679|DRUG|Tranexamic Acid|
224186838|NCT05058066|PROCEDURE|Early loading|Loading the implant at 3 weeks after implantation (instead of 6 weeks after implantation)
224186839|NCT00573352|RADIATION|Far Infrared|Far Infrared Radiation (5μm to 20μm wavelength). Duration is 30 to 40 minutes per session
223495798|NCT04601285|DRUG|JS108 (recombinant humanized anti-Trop2 mAb-Tub196 conjugate for injection)|"Dose escalation period: JS108 is administered intravenously every three weeks (Q3W) at the dose corresponding to the enrolled dose cohort.~Dose expansion period: JS108 is administered intravenously Q3W at the corresponding dose.~Clinical expansion period: JS108 is administered intravenously Q3W at the recommended dose."
223495799|NCT04002271|DRUG|Propofol|Target controlled infusion (TCI) with modified Marsh effect site model (Fresenius Kabi) will be used for induction and maintenance of general anaesthesia. Level of anaesthesia will be titrated to produce a BIS value of between 40-60. For induction, remifentanil 1mcg/kg and rocuronium 0.6 mg/kg will be given intravenously prior to intubation. Sevoflurane will not be given. Air and oxygen will be given, and FiO2 will be kept at between 35-50%. Similarly, to the GAS group, remifentanil will be infused at a rate of between 0.1-0.2mcg/kg/min and titrated according to the haemodynamic parameters stated for the GAS group. Morphine sulphate will be given at a dose of 0.1mg/kg before skin incision. TCI propofol and remifentanil will be switched off at the end of the procedure. Reversal of muscle relaxation will be achieved as for the GAS group.
223511843|NCT06430411|DRUG|Apalutamide|Administered as part of multimodal treatment for oligometastatic prostate cancer
223511844|NCT06430411|DRUG|Docetaxel|Administered as part of multimodal treatment for oligometastatic prostate cancer
223511845|NCT06430411|DRUG|Lutetium-PSMA|Administered as part of multimodal treatment for oligometastatic prostate cancer
223511846|NCT06430411|DRUG|Androgen deprivation treatment|Administered as part of multimodal treatment for oligometastatic prostate cancer
223511847|NCT04483219|DRUG|TKI ± anti-PD-1 antibody|"After one cycle of TKI, evaluations would be performed according to RECIST v 1.1. (1) obvious response (A): CR, PR or shrunken SD, or cavitation in metastatic lung lesions, or decrease in the density of liver metastatic targets ≥15%; (2) general response (B): enlarged SD; (3) poor response (C): PD. TKI ＋ anti-PD-1 antibody will be administered in group A. The subjects in group C will exit the study. The subjects in group B will continue TKI for another one cycle, the obvious response subjects will entered group A, the general response subjects will keep in arm B and continue the TKI monotherapy, and the poor response subjects will exit the study.~1. Fruquintinib 5mg or regorafenib 120mg, qd po, 3 weeks, Q4w. (The investigators decide to choose fruquintinib or regorafenib)~2. Toripalimab injection 240mg, Q3w, until the disease progresses or lasts for two years."
223511848|NCT06366919|DIAGNOSTIC_TEST|Alexander Technique (AT)|The AT arm of study will involve participants receiving indivisual sessions. These sessions will typically focus on non specific neck pain management improving posture , movement coordination and body awareness through gentle hands on guidance
223511849|NCT06366919|DIAGNOSTIC_TEST|Feldenkrais Technique (FT)|The FT arm of study will involve participants recieving individual sessions. These sessions will typically focus on pain improvement, maintaining alignment, reducing muscle tension and promoting ease of movement.
223511850|NCT02440529|BEHAVIORAL|Intervention|Discussion
223511851|NCT02440529|BEHAVIORAL|Verbal Group|Detailed Discussion
223511852|NCT01104870|DRUG|UT-15C|oral
223511853|NCT00741221|DRUG|Pemetrexed|Pemetrexed (IV) 500 mg/m2 on day 1 every 3 weeks for 6 cycles
223511854|NCT00741221|DRUG|Bevacizumab|Bevacizumab (IV) 15 mgr/Kgr on day 1 every 3 weeks for 6 cycles After the end of the 6 cycles Bevacizumab will be administered alone at the dose of 15 mgr/Kgr (IV) every 3 weeks until disease progression
223511855|NCT03924076|DIETARY_SUPPLEMENT|UHT Milk + Lactobacillus plantarum IS-10506|125 ml UHT milk (+Lactobacillus plantarum IS-10506) given to treatment group
223511856|NCT03924076|DIETARY_SUPPLEMENT|UHT Milk|125 ml UHT milk given to placebo group
223511857|NCT02006615|DEVICE|Functional near infrared spectroscopy|Using high-sensitivity infrared to detect the active brain areas
223511858|NCT02006615|DEVICE|rTMS|To modulate brain cortex
223511859|NCT04287556|DIAGNOSTIC_TEST|In vitro contracture test (IVCT)|In vitro study of muscle contraction after exposure to different substances (caffeine and halothane).
223511860|NCT04287556|DIAGNOSTIC_TEST|In vitro test of hypermetabolism in B lymphocytes|In vitro study of the activation of lymphocytes B after being incubated with a cocktail of primary antibodies and measuring the acidification in response to the RyR1, 4-CmC agonist, using ryanodine as a positive control.
223511861|NCT04287556|DIAGNOSTIC_TEST|Genetic test|Analysis of genes related to MH (CACNA1S and RYR1).
223495800|NCT04002271|DRUG|Sevoflurane|Patients in the GAS group will be induced with intravenous bolus propofol 1.5-3mg/kg, remifentanil 1mcg/kg, and rocuronium 0.6mg/kg for induction of general anaesthesia and intubation of patient. General anesthesia monitoring will be used. Maintenance of general anesthesia to be provided using sevoflurane, together with air and oxygen. FiO2 will be maintained between 35-50%. Bispectral (BIS) monitoring will be applied and level of anaesthesia will be maintained at a BIS value of 40-60. Remifentanil infusion will be given at between 0.1-0.2mcg/kg/min, to be titrated to maintain mean arterial blood pressure within 20% of baseline (blood pressure in ward before surgery as baseline) and heart rate between 45 to 100 bpm. Morphine sulphate to be given at a dose of 0.1mg/kg before skin incision. Sevoflurane and remifentanil infusion will be switched off at the end. Reversal of muscle relaxation to be achieved using intravenous neostigmine 50mcg/kg and atropine 20mcg/kg after the operation.
223495801|NCT04002271|PROCEDURE|Spinal anaesthesia|Patients in the SA group will receive intrathecal (L4-5, or L3-4 if failed at L4-5) administration of 2.2-2.4ml 0.5% heavy bupivicaine using a 25G Whitacare needle. No intrathecal opioid will be given during the procedure. Light sedation will be given during surgery with target-controlled infusion of propofol using the Marsh effect site model (0.3 -1 mcg/ml). Supplemental oxygen 2L/min will be given via the nasal cannula.
223495802|NCT00153920|DRUG|bortezomib|
223495803|NCT03697356|DRUG|Lenalidomide, Bortezomib, Rituximab, Dexamethasone|"step 1; R-VRD induction : rituximab, bortezomib, lenalidomide, and dexamethasone induction~* Rituximab 375 mg/m2 intravenous on day 1~* Bortezomib 1.3mg/m2 subcutaneous on day 1, 8, 15~* Lenalidomide 15mg p.o on day 1-21~* Dexamethasone 20 mg/m2 intravenous or p.o on day 1-4~Step 2 ; Maintenance Beginning 8 weeks after completion of induction therapy, patients receive lenalidomide 10mg once day 1-21 for 4 weeks. Treatment repeats every 1 months for 24 months."
223495804|NCT02202616|DRUG|Glycopyrronium /Indacaterol maleate|Glycopyrronium 50mcg/Indacaterol maleate 110mcg once daily by a breezhaler device
223495805|NCT05735470|DEVICE|antibacterial bone traction needles|Whether to use bone traction needles containing antibacterial coatings
223495806|NCT02038426|BIOLOGICAL|BLOOD SAMPLES|
223495807|NCT02038426|DEVICE|Radiographs of the sacroiliac joints|
223495808|NCT02038426|DEVICE|Radiographs of heels|
223495809|NCT02038426|DEVICE|SCAN|
223495810|NCT04502524|BEHAVIORAL|Smoking Cessation Intervention (New website)|Complete the new website smoking cessation program
223589553|NCT00454649|DRUG|Axitinib + Paclitaxel + Carboplatin (Cohort 1)|Axitinib (AG-013736) 1 milligram (mg) tablet orally twice daily (BID) as lead in dose from Day -5, -4 or -3 through Day 2 of Cycle 1 (21 days). Axitinib (AG-013736) 5 mg tablet orally BID from Day 3 to Day 18 of Cycle 1 and Day 3 to Day 20 of Cycle 2 (21 days) and all subsequent cycles (21 days). Paclitaxel \[200 milligram/square meter (mg/m\^2)\] 3-hour infusion followed by carboplatin 30-minutes infusion at a dose to target area under the concentration-time curve (AUC) of 6.0 milligram\*minute/milliliter (mg\*min/mL) on Day 1 of Cycle 1 and all subsequent cycles.
223589554|NCT00454649|DRUG|Axitinib + Paclitaxel + Carboplatin (Cohort 2)|Axitinib (AG-013736) 3 tablets of 1 mg orally BID as lead in dose from Day -5, -4 or -3 through Day 2 of Cycle 1 (21 days). Axitinib (AG-013736) 5 mg tablet orally BID from Day 3 to Day 18 of Cycle 1 and Day 3 to Day 20 of Cycle 2 (21 days) and all subsequent cycles (21 days). Paclitaxel (200 mg/m\^2) 3-hour infusion followed by carboplatin 30-minutes infusion at a dose to target AUC of 6.0 mg\*min/mL on Day 1 of Cycle 1 and all subsequent cycles.
223589555|NCT00454649|DRUG|Axitinib + Paclitaxel + Carboplatin (Cohort 3)|Axitinib (AG-013736) 5 mg tablet orally BID as lead in dose from Day -5, -4 or -3 through Day 2 of Cycle 1 (21 days). Axitinib (AG-013736) 5 mg tablet orally BID from Day 3 to Day 18 of Cycle 1 and Day 3 to Day 20 of Cycle 2 (21 days) and all subsequent cycles (21 days). Paclitaxel (200 mg/m\^2) 3-hour infusion followed by carboplatin 30-minutes infusion at a dose to target AUC of 6.0 mg\*min/mL on Day 1 of Cycle 1 and all subsequent cycles.
223589556|NCT00454649|DRUG|Axitinib + Paclitaxel (Cohort 4)|Axitinib (AG-013736) 5 mg tablet orally BID from Day 1 to Day 25 of Cycle 1 (28 days) and then without interruption from Day 3 for Cycle 2 (28 days) and all subsequent cycles (28 days). Paclitaxel (90 mg/m\^2) 60-minute infusion on Day 1, 8, and 15 of each cycle.
223617789|NCT02122679|DRUG|placebo|
223617790|NCT00911248|DRUG|PTC299|PTC299 will be administered orally at 100 mg/dose twice per day for up to 1 year or until tumor progression
223617791|NCT01292941|DEVICE|Intermittent catheterisation|Speedicath, Intermittent catheterisation
223617792|NCT01292941|DEVICE|NonCE marked intermittent catheter/red|Paris, Intermittent catheterisation
224186840|NCT02815670|DRUG|Idarucizumab|
224186841|NCT01411917|PROCEDURE|Transversus abdominis plane block|Ultrasound guidance will be utilized to inject 30ml of 0.375% bupivacaine into the muscular plane between the internal oblique and transversus abdominis muscles.
224186842|NCT02208466|DEVICE|Active Repetitive Transcranial Magnetic Stimulation (rTMS)|Subjects will undergo active low-frequency rTMS (1Hz continuous). Each session will last 20 minutes and will be conducted at 100% of the motor threshold.
224186843|NCT02208466|DRUG|Fluoxetine|Subjects will receive active fluoxetine (20mg) and take orally consecutively for 90 days.
223495811|NCT04502524|BEHAVIORAL|Smoking Cessation Intervention (Standard of care website)|Complete the standard of care website smoking cessation intervention
223495812|NCT04502524|BEHAVIORAL|Health Education|Receive information about the cost of smoking, benefits of quitting, ways to prepare for quitting, ways to handle triggers and withdrawal symptoms, and available medications to help with quitting. And will receive additional resources available at the VA handout via email at the end of the study.
223495813|NCT04502524|OTHER|Health Promotion and Education|Receive motivational and reminder text messages
223495814|NCT04502524|OTHER|Questionnaire Administration|Ancillary studies
223495815|NCT05026918|OTHER|MCPT|Postural Drainagewith percussion and vibration
223495816|NCT05026918|OTHER|ACBT|ACBT includes Breathing control techniques, chest expansion exercises and Forced Expiration Technique
223495817|NCT02060162|OTHER|Standard of care|routine standard of care per Ministry of Health protocol including blood draws and examinations.
223617793|NCT01292941|DEVICE|NonCE marked intermittent catheter/green|Paris, Intermittent catheter
223617794|NCT01292941|DEVICE|NonCE marked intermittent catheter/blue|Paris, Intermittent catheter
223617795|NCT00404651|BIOLOGICAL|DTaP-IPV-HB-PRP~T vaccine|0.5 mL, intramuscular (IM)
223589557|NCT00454649|DRUG|Axitinib + Docetaxel + Carboplatin (Cohort 4a)|Axitinib (AG-013736) 5 mg tablet orally BID as lead in dose from Day -5, -4 or -3 through Day 2 of Cycle 1 (21 days). Axitinib (AG-013736) 5 mg tablet orally BID from Day 3 to Day 18 of Cycle 1 and Day 3 to Day 20 of Cycle 2 (21 days) and all subsequent cycles (21 days). Docetaxel (75 mg/m\^2) 60-minute infusion on Day 1 of every cycle. Carboplatin 30-minutes infusion at a dose to target AUC of 6.0 mg\*min/mL on Day 1 of Cycle 1 and all subsequent cycles.
223589558|NCT00454649|DRUG|Axitinib + Docetaxel (Cohort 5)|Axitinib (AG-013736) 5 mg tablet orally BID as lead in dose from Day -5, -4 or -3 through Day 2 of Cycle 1. Axitinib (AG-013736) 5 mg oral tablet BID administered from Day 3 to Day 18 of Cycle 1 (21 days) and then without interruption from Day 3 of Cycle 2 and all subsequent cycles. Docetaxel (100 mg/m\^2) 60-minute infusion on Day 1 of each cycle.
223589559|NCT00454649|DRUG|Axitinib + Capecitabine (Cohort 6)|Axitinib (AG-013736) 5 mg tablet orally BID from Day 1 to Day 18 of Cycle 1 (21 days) and then without interruption from Day 3 of Cycle 2 and all subsequent cycles. Capecitabine (1000 mg/m\^2) orally BID from Day 1 to Day 14 of each cycle.
223589560|NCT00454649|DRUG|Axitinib + Capecitabine (Cohort 7)|Axitinib (AG-013736) 5 mg tablet orally BID from Day 1 to Day 18 of Cycle 1 (21 days) and then without interruption from Day 3 of Cycle 2 and all subsequent cycles. Capecitabine (1250 mg/m\^2) orally BID from Day 1 to Day 14 of each cycle.
224186844|NCT02208466|DEVICE|Sham repetitive transcranial magnetic stimulation (rTMS)|Subjects will undergo sham low-frequency rTMS (using sham coil). This session will last 20 minutes, just as the active session would, however, no magnetic pulses will be delivered.
224186845|NCT02208466|DRUG|Placebo Fluoxetine|Subject will receive placebo fluoxetine (sugar pills) and will take orally consecutively for 90 days.
224186846|NCT02847364|DIETARY_SUPPLEMENT|chewing gum|The patient will chew one piece (1.45g) of regular chewing gum starting morning of post-operative day 1 for 30 minutes each time, three times per day, till the first bowel movement.
224186847|NCT01467817|BEHAVIORAL|Lifestyle Intervention|The intervention incorporates 6 months of active structured lifestyle intervention containing participant education, exercise, dietary intervention, and behavioral support
224186848|NCT01467817|BEHAVIORAL|Exercise Control|The control group intervention will test benefits of exercise alone while controlling for investigator contact.
223495818|NCT06196359|PROCEDURE|Combined Femoral and Popliteal nerve block|Patients who receive a combined femoral and popliteal nerve block during surgery, fill out a questionnaire and undergo a muscle strength test before surgery, undergo functional tests, a muscle strength test and are asked about pain intensity after surgery.
223495819|NCT03687697|BIOLOGICAL|Global vs. G-TL vs Cornell's C3 vs Cornell's C1/C2 media|A comparison between Global, G-TL, Cornell's C3, and Cornell's C1/C2 embryo culture media.
223589561|NCT00454649|DRUG|Axitinib + Gemcitabine + Cisplatin (Cohort 8)|Axitinib (AG-013736) 5 mg tablet orally BID from Day -5, -4 or -3 to Day 18 of Cycle 1 (21 days) and then without interruption from Day 3 of Cycle 2 and all subsequent cycles. Gemcitabine (1250 mg/m\^2) 30-minute infusion on Day 1 and Day 8 of Cycle 1 and all subsequent cycles followed by cisplatin (80 mg/m\^2) infusion on Day 1 of each cycle.
223589562|NCT00454649|DRUG|Axitinib + Pemetrexed + Cisplatin (Cohort 9)|Axitinib (AG-013736) 5 mg tablet orally BID from Day -5, -4 or -3 to Day 18 of Cycle 1 (21 days) and then without interruption from Day 3 of Cycle 2 and all subsequent cycles. Pemetrexed (500 mg/m\^2) 10-minute infusion followed by cisplatin (75 mg/m\^2) infusion on Day 1 of each cycle.
223589563|NCT03358940|OTHER|urine collection|For patient with miscarriage complications or not, or threatened miscarriage there will be a urine collection the day of the inclusion. In case of hospitalization, another urine collection will be done between 12 and 18 hours after the inclusion. For patient coming for voluntary termination of pregnancy using misoprostol, a urine collection will be done the day of the inclusion and another ones 1, 4, 12 and 24 hours after the inclusion.
223589564|NCT03943849|OTHER|Particulate bone graft|Creos allo.gain allogenic bone particulate mineralized cortical bone will be hydrated and placed in the extraction socket.
223589565|NCT03943849|OTHER|Autogenous dental pulp tissue|Dental pulp will be isolated from teeth extracted for non-periodontal reasons chairside, mixed with hydrated particulate bone graft, and then placed in the extraction socket.
223589566|NCT03943849|OTHER|Resorbable collagen membrane|After placement of particulate bone graft or particulate bone graft plus autogenous dental pulp tissue, socket will be covered by a resorbable collagen membrane and sutured.
223589567|NCT03943849|OTHER|Suture|Resorbable or non-resorbable suture material
224186849|NCT03648047|DEVICE|Digital kinematic biofeedback device|The system will be used independently by the patients to perform rehabilitation sessions at home, under remote monitoring from the clinical team.
224186850|NCT03648047|OTHER|Conventional rehabilitation|Patients will receive conventional face-to-face sessions by a Physical Therapist.
223495820|NCT01334515|BIOLOGICAL|hu14.18-IL2 fusion protein|Given IV
223495821|NCT01334515|DRUG|isotretinoin|Given PO
223495822|NCT01334515|BIOLOGICAL|sargramostim|Given SC
223495823|NCT01334515|OTHER|laboratory biomarker analysis|Correlative studies
223495824|NCT06473818|DEVICE|Non-invasive monitoring|Non-invasive cardiac output monitoring
223495825|NCT06473818|DEVICE|Invasive monitoring|Invasive cardiac output monitoring
223495826|NCT04327271|BEHAVIORAL|Text-based VMMC follow-up|2wT clients will receive automated daily texts from days 1-13. If a 2wT VMMC client responds that he suspects an AE, a VMMC nurse will exchange modifiable, scripted texts with clients to determine symptoms, frequency, and severity. Then, if deemed necessary, the client will be asked to return to clinic the following day or earlier. If 2wT patients do not respond to texts or return for any visit by day 14, they will be traced by SMS, phone or home visit. All study participants will be asked to come to the clinic for study-specific, Day 14 follow-up to review healing and verify adverse event reporting. At Day 21, we will implement a brief text-based survey with 2wT clients to ascertain complete healing, providing stronger inferences at study completion.
223495827|NCT01251679|BEHAVIORAL|Hand washing|hand washing education and material
223495828|NCT01251679|DEVICE|Hand washing and surgical mask|hand washing education and material and paper surgical face masks
223495829|NCT01554813|BIOLOGICAL|Influenza split vaccine of 15 μg HA|60 subjects were assigned (20 infants, 20 children and 20 adults) to receive influenza vaccine (split virion), inactivated, 0.5ml, one dose regime
223495830|NCT01554813|BIOLOGICAL|Influenza split vaccine of 15 μg HA|558 subjects were assigned to receive influenza split vaccine, 0.5ml, one dose regime
224186851|NCT03648047|OTHER|Additional face-to-face rehabilitation sessions|Patients will receive face-to-face sessions in addition to sessions performed with the Digital Rehabilitation Device
224186852|NCT02874222|OTHER|surveys completed by subject|Cohort study designed to validate previously identified associations between 10 specific SNPs and discontinuation of treatment with AIs due to the development of MSS among women with breast cancer.
224186853|NCT00658918|DRUG|Ciclesonide nasal|safety of Ciclesonide (200µg, 100µg, 25µg)
224186854|NCT00658918|DRUG|Placebo|placebo
224186855|NCT02791906|DRUG|ISMN|
224186856|NCT02791906|DIETARY_SUPPLEMENT|Vitamin C|
224186857|NCT06103266|DRUG|Rivaroxaban|Once daily rivaroxaban 20 mg or 15 mg with reduced kidney function (eGFR 15 - 49 mmol/L) for 6 months in case of percutaneous coronary intervention for stable coronary artery disease or 12 months in case of percutaneous coronary intervention for acute coronary syndrome without concurrent antiplatelet therapy
224186858|NCT03918356|DEVICE|electrical impedance myography|Electrical impedance myography (EIM) is a new electrodiagnostic method of quantitative muscle evaluation. It utilizes concepts of bio impedance, the ability of biological tissue to impede externally applied electrical current.
224186859|NCT03918356|OTHER|healthy control group|healthy control
223495831|NCT01554813|BIOLOGICAL|Influenza split vaccine|280 subjects were assigned to receive influenza split vaccine, 0.5ml, one dose regime
223495832|NCT02896023|DRUG|human menopausal gonadotropin|Induction of ovulation followed by ICSI
223495833|NCT03759184|DRUG|rhIL-15|Continuous intravenous (civ) Interleukin-15 (IL-15) at dose levels of 0.5,1 or 2 mcg/kg/day on days 1-5 of cycles 1-6
223589568|NCT02082106|OTHER|Alpine skiing|
223589569|NCT02082106|OTHER|cross country skiing|
223589570|NCT02082106|OTHER|Indoor training (cycling)|
223589571|NCT01789606|DRUG|Ibuprofen 600 mg Immediate Release/Extended Release Caplet|Ibuprofen 600 mg Immediate Release/Extended Release Caplet to be adminstered orally (i.e., one caplet every 12 hours, not to exceed 2 caplets per day) for pain.
223589572|NCT05035589|DRUG|Tocilizumab|Tocilizumab administered at a dose of 8mg/kg up to a maximum of 800mg
223589573|NCT00716742|DRUG|bimatoprost 0.03%, latanoprost 0.005%, and travoprost 0.004%|1 drop in eye(s) every evening
223589574|NCT01654809|BIOLOGICAL|evaluated vaccine|0.25 mL, Intramuscular (infant/children dose) 0.5 mL, Intramuscular (adult dose)
224186860|NCT05411731|OTHER|Conventional physical therapy treatment|"The control group (group A) will receive the exercise program which focused on improving the arm function as well as shoulder abduction and external rotation for 10 week.~stretching Aeroplan positioning"
223495834|NCT03759184|DRUG|rhIL-15|Continuous intravenous (civ) Interleukin-15 (IL-15) at the maximum tolerated dose or the maximum administered dose of 2 mcg/kg/day on days 1-5 of cycles 1-6
223495835|NCT03759184|BIOLOGICAL|Obinutuzumab|Intravenous (IV) Obinutuzumab will be administered at a dose of 100 mg on day 4, 900 mg on day 5, 1,000 mg on day 11, and 1,000 mg on day 18 of cycle 1: then 1,000 mg on day 4 of each subsequent cycle
223495836|NCT03947723|DEVICE|Radiofrequency ablation|The eyelid segments to be excised as part of their planned lateral tarsal strip procedure will be marked and divided into 4 equal sections (2 sections on each lid). A corneal shield will be placed into the fornix prior to treatment. Each section will be treated with the designated power setting in the following manner. The probe will be inserted into the follicle under direct visualization to a depth of approximately 1.4 mm. The designated power will be applied for 1 second. All lashes in each segment will be treated. The segments will then be excised and placed into labelled and coded containers of formalin.
223495837|NCT00708669|DEVICE|TAXUS stent|Compared two kinds of stents:TAXUS stent, approved for commercialization in Japan(March 30th, 2007)
223495838|NCT00708669|DEVICE|Cypher stent|CYPHER stent, approved for commercialization in Japan(March 25, 2004)
223495839|NCT01586182|RADIATION|Stereotactic Body Radiotherapy|Starting dose is 5.5 Gy x 2 boosts in addition to 57.24 Gy to the primary disease
223495840|NCT03469804|DRUG|Pembrolizumab|Route: intravenous infusion Dose regimen: 200 mg per infusion every 3 weeks Duration of treatment: 6 months (8 cycles)
223589575|NCT01654809|BIOLOGICAL|imported compared vaccine|0.25 mL, Intramuscular (infant/children dose) 0.5 mL, Intramuscular (adult dose)
223589576|NCT01654809|BIOLOGICAL|domestic compared vaccine|0.25 mL, Intramuscular (infant/children dose) 0.5 mL, Intramuscular (adult dose)
223589577|NCT02411370|BEHAVIORAL|phonetic tests|
223617796|NCT00404651|BIOLOGICAL|DTaP-IPV-HB-PRP~T vaccine|0.5 mL, IM
224186861|NCT05411731|OTHER|Constraint induced movement therapy|The study group (group B) who will receive Modified constraint induced movement therapy for 3 hrs. a day 12 hrs. a week in addition to the same exercise program given to the control group for 10 weeks.
224186862|NCT06405256|RADIATION|magnetic resonance imaging-guided adaptive radiotherapy|Stereotactic Radiotherapy (with the prescribed dose of PTV 52-52.5 Gy, 13-15 fractions and Boost (if any) 60Gy, 15 fractions)
224186863|NCT02114346|DRUG|Atorvastatin|
224186864|NCT02114346|DRUG|Placebo|
224186865|NCT02114346|DRUG|0.9% sodium chloride|Patients with estimated glomerular filtration rate of less than 60 mL/min/1.73 m2 are hydrated with 0.9% sodium chloride for 2 hours, from 1 hour before (3 mL/kg/hour) to 1 hour after (1 mL/kg/hour) operation. Patients with left ventricular ejection fraction less than 40% or New York Heart Association functional class III-IV, are hydrated with 0.5 mL/kg/hour.
224186866|NCT04391660|DRUG|0.5% sodium hypochlorite solution|Disinfection with a 0.5% sodium hypochlorite solution applied with a sterile compress. This same antiseptic will be used at each dressing change.
224186867|NCT04391660|DRUG|0.5% sodium hypochlorite solution and 70% ethanol|Disinfection with a 0.5% sodium hypochlorite solution applied with a sterile compress preceded by an application of 70% ethanol with a sterile compress, for its immediate bactericidal action. 0.5% sodium hypochlorite solution will be applied once the alcohol has evaporated and the skin is visually dried. These same antiseptics will be used at each dressing change.
224186868|NCT02482727|DEVICE|occlusion training with tourniquet (DELFI PTS ii portable tourniquet system)|A cuff will be wrapped around the most proximal portion of the arm of the involved extremity. In order to individualize the pressure for each subject, the limb occlusion pressure will be measured (with dopplar ultrasound over the radial artery at the wrist level) at the first scheduled therapy visit. The cuff pressure utilized during the post-operative exercises will be set at 50% of the limb occlusion pressure. The subjects' strength will be re-assessed approximately every 2-4 weeks and the load will be increased as tolerated.
224186869|NCT00004844|PROCEDURE|tissue implantation|
223495841|NCT04185727|OTHER|Supervised strength training|12 weeks supervised strength training exposure. The study will allocate patients to groups consisting of 4 members who receive strength training for 12 weeks. The strength training program will consist of three weekly supervised strength exercise sessions, each 40-60 min of duration, which starts with a 10 min warm-up and are completed with a meditation/relax session.
223495842|NCT01479530|DRUG|Placebo|Once daily; tablet; orally; 16 weeks
223495843|NCT01479530|DRUG|Azilect®|1 mg daily; tablet; orally; 16 weeks
223495844|NCT00312611|DEVICE|Transcend II Implantable Gastric Stimulator (IGS), Model 8848|
223495845|NCT02151201|BEHAVIORAL|Influenza vaccination video education|Influenza vaccination video education
223495846|NCT02151201|BEHAVIORAL|Hand washing video education|Hand washing video education
223495847|NCT01995435|DEVICE|Telemedicine refraction|
223495848|NCT01995435|DEVICE|Traditional refraction|
223495849|NCT04918628|DRUG|Sintilimab|A humanized anti-PD-1 monoclonal antibody
223495850|NCT00608738|OTHER|informational intervention|
223495851|NCT00608738|OTHER|medical chart review|
223495852|NCT00608738|OTHER|questionnaire administration|
223495853|NCT00608738|PROCEDURE|assessment of therapy complications|
223495854|NCT00608738|PROCEDURE|management of therapy complications|
223495855|NCT03804307|RADIATION|standard treatment|3000 cGy in 10 daily fractions
223495856|NCT03804307|RADIATION|short course treatment|2000 cGy in 4 fractions administered twice a day
223495857|NCT02703025|DIETARY_SUPPLEMENT|GCB-70|green coffee bean extract
223495858|NCT01457027|BIOLOGICAL|Inflexal V|"Inflexal V influenza vaccine, formulated for the WHO requirements ofr the 2011-2012 season, containing per 0.5 mL dose:~* 15 µg hemagglutinin (HA) antigen of A/California/7/2009 (H1N1)-like virus~* 15 µg HA antigen of A/Perth/16/2009 (H3N2)-like virus~* 15 µg HA antigen of B/Brisbane/60/2008-like virus~Dose: intramuscular administration (M. deltoideus) of a single dose of 0.5 mL on Day 1"
223589578|NCT04014127|DIAGNOSTIC_TEST|Coronary flow reserve assessment|Coronary flow reserve will be assessed using Doppler transthoracic echocardiograpy and myocardial contrast echocardiography.
224186870|NCT01157585|DRUG|paliperidone ER|8 week prospective study
223495859|NCT00303628|DRUG|oxaliplatin|Given IV
223495860|NCT00303628|DRUG|fluorouracil|Given IV
223495861|NCT00303628|DRUG|leucovorin calcium|Given IV
223495862|NCT00303628|DRUG|bevacizumab|Given IV
223495863|NCT02040064|DRUG|Gefitinib|Oral tablet
223495864|NCT02040064|DRUG|Tremelimumab|IV
223495865|NCT00032760|BEHAVIORAL|Meditation|
223495866|NCT04516200|DEVICE|transcranial direct current stimulation and traditional physical therapy program|Transcranial stimulation will be applied only for the study group.
223495867|NCT04516200|OTHER|designed physical therapy program|sensory training and balance training
223589579|NCT04014127|DIAGNOSTIC_TEST|Sphygmocor|Pulse wave analysis and pulse wave velocity will be assessed using the Sphygmocor device
223589580|NCT04014127|DIAGNOSTIC_TEST|Electrocardiogram|An electrocardiogram will be performed prior to administration of adenosine to ensure no resting conduction disease
223589581|NCT04014127|OTHER|Blood test|Blood tests will be performed for markers of renal function, bone mineral metabolism and myocardial stretch and injury
223589582|NCT04014127|OTHER|Urinary albumin/creatinine ratio|Urine will be analysed for albumin/creatinine ratio
223589583|NCT05097352|BEHAVIORAL|High Intensity Interval Training (HIIT)|Twenty minutes of HIIT will be completed three days a week for six weeks.
223495868|NCT02211742|DRUG|Dapagliflozin|euglycemic hyperinsulinemic clamp tests and euglycemic oral glucose tolerance clamp tests after the short-term (i.e.: 3 days, equals 10mg / 24h) intake of dapagliflozin
223495869|NCT01756703|DRUG|MT-3995 Low|MT-3995 Low dose for 8 weeks
223495870|NCT01756703|DRUG|MT-3995 High|MT-3995 High dose for 8 weeks
223495871|NCT01756703|DRUG|Placebo|Placebo for 8 weeks
223495872|NCT04858711|DRUG|ketamine-lidocaine-dexmedetomidine|In the KLD group, patients will be administered 0,25 mcg/kg Dexmedetomidine in 100 mL of normal saline within 10 minutes. Followingly, they will receive 1mL/10 kg of the solution containing ketamine, lidocaine and dexmedetomidine at predefined concentrations. As maintenance, they will be receiving 1mL/10kg/h of the aforementioned solution.
223495873|NCT04858711|DRUG|fentanyl|In the fentanyl group, patients will be administered 2 mcg/kg fentanyl in 100 mL of normal saline within 10 minutes. Followingly, they will receive 1mL/10 kg of normal saline solution 0.9%. As maintenance, they will be receiving 1mL/10kg/h of normal saline solution 0.9%.
223495874|NCT03053011|OTHER|Vibrating bracelet|A bracelet with vibrations triggered randomly overnight. The sleeper's awakening capability will be evaluated each time the bracelet vibrates (5 times in the night).
223495875|NCT03791372|DRUG|0.9% Sodium Chloride|0.9% Sodium Chloride in control group
223495876|NCT03791372|BIOLOGICAL|Autologous Umbilical Cord Blood|Autologous Umbilical Cord Blood Mononuclear Cells Therapy in Cerebral Palsy for safety and effect evaluation.
223495877|NCT02472093|OTHER|Physical exercises treatment|Includes different types of exercises: low-impact to moderate aerobic training; walking fast in a circle, alternating with periods of going up and down the stairs (3 steps for 10 minutes) for a total of 20 consecutive minutes; posture exercises for the back and proprioceptive exercises for the trunk in the supine position to improve axial stability, including diaphragmatic breathing. The heart rate was monitored through the use of a heart rate monitor, which allowed not to exceed the threshold.
223495878|NCT02472093|OTHER|Perceptive Rehabilitation Treatment|therapeutic system that is based on the interaction between the patient's back or painful area and a support surface, composed of small latex cones with various dimensions (height: 3-8 cm; base diameter: 2-4 cm) and elasticities. The inferior bases of these cones are applied to a rigid wood surface using elastic strips.
223617797|NCT00404651|BIOLOGICAL|DTaP-IPV-HB-PRP~T vaccine|0.5 mL, IM
224186871|NCT05670028|DRUG|Hypotensive Drugs and/or Vasoactive Drugs|To manipulate the blood pressure within a certain range with hypotensive drugs (e.g. nifedipine, benidipine, captopril, benazepril, irbesartan, labetalol, urapidil) and/or vasoactive drugs (noradrenaline or dopamine).
224186872|NCT05801016|BEHAVIORAL|Emerging Technologies and Training in Neurosciences|Combination of body-swapping technique, Virtual Reality Body Size estimation tasks and Autobiographic Recall
224186873|NCT00003736|DRUG|motexafin gadolinium|
224186874|NCT00003736|PROCEDURE|biopsy|
224186875|NCT00003736|PROCEDURE|breast imaging study|
224186876|NCT00003736|PROCEDURE|comparison of screening methods|
224186877|NCT00003736|PROCEDURE|magnetic resonance imaging|
224186878|NCT00003736|PROCEDURE|study of high risk factors|
224186879|NCT02035410|PROCEDURE|Hydrogen peroxide pretreatment group|Hydrogen peroxide pretreatment perform before cardiac devices Implantation. It disinfects the cardiac devices pocket using Hydrogen peroxide gauze.
223495879|NCT02472093|OTHER|Control group|The control group did brief educational sessions.
223495880|NCT01666652|BIOLOGICAL|4 µg TDENV-PIV with Alum adjuvant|
223495881|NCT01666652|BIOLOGICAL|1 µg TDENV-PIV with AS03B1 adjuvant|
223495882|NCT01666652|OTHER|Phosphate buffered saline|
223495883|NCT01666652|BIOLOGICAL|1 µg TDENV-PIV with Alum adjuvant|
223495884|NCT01666652|BIOLOGICAL|1 µg TDENV-PIV with AS01E1 adjuvant|
223495885|NCT02716090|DRUG|Adapalene and Benzoyl peroxide Dalap Duo®|
224186880|NCT03874208|OTHER|MRI sequence|An additional sequence to conventional MRI exam (Diffusion tensor imaging) lasting less than 10 min (depending on the MR scanner type and sequence used).
224186881|NCT03874208|OTHER|MRI|MRI exam
224186882|NCT05901142|BEHAVIORAL|Exercise-based multi-phasic, multi-modal intervention|"Pre-op: 2\*60min supervised; 1\*30min unsupervised walking sessions per week Supervised session: Aerobic: 8\*60secs star jump, squat thrust, high knees with 90sec rest. Elastic resistance: 2\*10-12reps of chest press, seated row, leg press, 'lat' pulldown, and either abdominal flexion or lumbar extension-alternated, with 60-90sec rest. Targeted physiotherapy: general breathing exercises, active-assisted range of motion (RoM) exercises, and active-resisted RoM exercises~Postop: 1\*60min supervised exercise; unsupervised walking \[2\*30min weeks 1-2; 3\*30min week 3; 4\*30min weeks 4-6\] session per week Supervised session: Aerobic: As above using full body extension, squat jump, static sprint in week 1-4. Progressed to those performed preoperatively from week 5. Elastic resistance: As above from week 4, performed 3\*week. Targeted physiotherapy: As above, with active-assisted RoM progressing from 1\*10reps in week 1, to 2\*10reps in weeks 2-4, and 3\*10reps in weeks 4-6"
224186883|NCT02605889|OTHER|Laser acupuncture|Laser acupuncture
224186884|NCT05807815|PROCEDURE|Titration of fraction of inspired oxygen (FiO2) guided by ORI and oxygen saturation|"FiO2 will be titrated by reducing 10% if Ori\>0.01 and oxygen saturation ≥ 98% until Ori is 0.00.~FiO2 will not be changed if Ori is 0.00 and %95\<oxygen saturation≤%98 FiO2 will be increased by 10% if oxygen saturation \<95 or PaO2\<60 mmHg"
224186885|NCT03550040|PROCEDURE|Radical prostatectomy|Surgical removal of the prostate
223495886|NCT02716090|DRUG|Adapalene and Benzoyl peroxide Epiduo®|
223495887|NCT01018979|DRUG|TG-0054 (2.24 mg/kg)|TG-0054: 2.24 mg/kg TG-0054 administrated via 15-min IV infusion(allow a maximum of six leukapheresis sessions)
223495888|NCT01018979|DRUG|TG-0054 (3.14 mg/kg)|TG-0054: 3.14 mg/kg TG-0054 administrated via 15-min IV infusion(allow a maximum of six leukapheresis sessions)
224186886|NCT05875909|PROCEDURE|corneal flap transplantation|Patients with macular holes underwent a 25-gauge, 3-port pars plana vitrectomy . Fluid-air exchange was performed in patients with pathologic myopia suffering from macular holes with retinal detachment. We used a flute needle to drain the subretinal fluid. A corneal flap was obtained by small incision lenticule extraction (SMILE). Stripping pliers were applied to spread corneal flap over the macular hole. A drop of fresh autologous whole blood was dripped over the corneal flap to immobilise it. The vitreous cavity was filled with 14% perfluoropropane (C3F8) for macular holes with retinal detachment . The surgical incision was self-closed or sutured with a 6-0 polyglactin 910 suture . The patients were instructed to maintain a prone position for 2 weeks postoperatively.
224186887|NCT00143728|DRUG|Lamivudine|See Detailed Description.
223495889|NCT04841265|DIETARY_SUPPLEMENT|Vitamin D3|The intervention arm will receive 400 IU vitamin D3 from routine antenatal multivitamin supplement tablet + 400 IU vitamin D3 daily until delivery.
223495890|NCT00113139|BEHAVIORAL|Telephone-based coping skills/stress management|Telephone-based coping skills/stress management: 12 weekly sessions.
223495891|NCT00113139|OTHER|Usual Care|Usual care participants continued their routine and usual treatments and do not receive the 12 telephone training sessions.
223495892|NCT04770974|OTHER|Biomarkers and proteomics|Biomolecular, proteomic, metabolomic and spectroscopy characterization of urothelial bladder neoplasia, on a 3D culture model (organoid) obtained from bladder tumor tissue
223495893|NCT04093999|PROCEDURE|Sensory nerve coaptation|A recipient sensory nerve branch of the 11th-12th intercostal nerve was reattached to a donor nerve in the chest area. The anterior cutaneous branch of the second or third intercostal nerve was used as the donor nerve. Direct, end-to-end nerve coaptation was performed.
223495894|NCT04790383|OTHER|Advanced Self-Adhesive resin composite hybrid restorations (Surefil one (Dentsply Sirona)).|Hybrid resin composite that doesn't need bonding system and releases calcium and flouride.
223495895|NCT04790383|OTHER|Conventional resin composite restoration. (Sphere Tec, (Dentsply Sirona|Conventional Nanohybrid resin composite
223589584|NCT05097352|OTHER|Waitlist|Waitlist participants will be tested on the outcomes at the same time points as the treatment group.
223617798|NCT00404651|BIOLOGICAL|DTaP-HBV-IPV vaccine|0.5 mL, IM
223617799|NCT02723812|BIOLOGICAL|GCFLU® Influenza vaccine (Split virion, Inactivated)|
224186888|NCT00045006|DRUG|vorinostat|
224186889|NCT04071028|PROCEDURE|warm-water footbath|"All the participants in the intervention group were arranged to stay in an air-conditioned, quiet room from 5:30 to 6:30 p.m. on their menstruation days 1 and 2. After sitting quietly for 20 minutes, the participants in the footbath group received legs soaking from the heel to the Sanyinjiao (SP6) acupoint (above the ankle) 24 in 42 ℃ water with air bubbles and vibration given to the soles for 20 minutes, whereas the participants in the control group kept on sitting quietly without legs soaking during the additional 20-minute period."
224186890|NCT04833972|OTHER|Survey questionnaire|Each version of the questionnaire has the same questions about perceived norms about substance use in the community but differs in how the response options are offered.
224186891|NCT02811367|DEVICE|HPV test|Women will perform the HPV self-test and will also undergo a physician-performed HPV test.
224186892|NCT03615586|OTHER|With Chaperone|Female patients examined by male physicians in the presence of a female (nurse) chaperone.
224186893|NCT03615586|OTHER|Without Chaperone|Female patients examined by male physicians without the presence of a female (nurse) chaperone.
224186894|NCT01001884|OTHER|caregiver psychoeducational consultation program (CPCP)|6-session caregiver psychoeducational consultation program (CPCP)
224186895|NCT03421236|BIOLOGICAL|Ty21a|intravesical administration of Ty21a
224186896|NCT02354599|DRUG|MT203 80 mg or matching Placebo|MT203 80 mg or matching placebo injection
224186897|NCT02354599|DRUG|MT203 150mg or matching Placebo|MT203 150mg or matching placebo injection
223495896|NCT03570424|DIETARY_SUPPLEMENT|Nutrient support to HIIT|3 groups of young (aged 18-35 y), healthy, recreationally active, aerobically untrained (VO2max \<50 ml.kg.min-1) males will undertake 3 weeks (9 sessions) of HIIT under different nutrient conditions following \>10h overnight fast: i) Placebo: Fasted artificially flavoured and textured placebo 45 minutes prior to exercise; ii) Whey protein 45 minutes prior to exercise; iii) Whey protein hydrolysate 45 minutes prior to exercise).
223495897|NCT03570424|DIETARY_SUPPLEMENT|Placebo|3 groups of young (aged 18-35 y), healthy, recreationally active, aerobically untrained (VO2max \<50 ml.kg.min-1) males will undertake 3 weeks (9 sessions) of HIIT under different nutrient conditions following \>10h overnight fast: i) Fasted artificially flavoured and textured placebo 45 minutes prior to exercise; ii) Fed Whey protein 45 minutes prior to exercise; iii) Fed Whey protein hydrolysate 45 minutes prior to exercise).
223495898|NCT02909426|DEVICE|Ultrasonography|Radiologists' hand-held bilateral breast ultrasonography for each participant for one time
223495899|NCT02909426|DEVICE|Digital mammography|Full-field digital mammography using one of the equipments from General Electric (GE), Hologic, and Medi-future companies for each participant for one time
223495900|NCT02287519|BEHAVIORAL|Group Session|
223495901|NCT02287519|BEHAVIORAL|Telephone Coaching Session|
223495902|NCT02287519|BEHAVIORAL|Webinar|
223495903|NCT02317549|DRUG|LB1148|
223495904|NCT02317549|DRUG|Placebo|
223495905|NCT05841576|OTHER|COMET monitoring device|Cellular Oxygen METabolism (COMET) mitochondrial oxygen tension monitoring device
223495906|NCT04354571|PROCEDURE|Erector spinae plane block|An ultrasound-guided Erector spinae plane block was performed with the patient lying on the his side and the surgical side on the top. After skin disinfection, sterile draping was be placed and the ultrasound probe was sheathed. The level of the block was the transverse process of L2. The block was performed using a 9-12 MHz linear probe (LOGIQe, GE Healthcare, USA), which was placed in a parasagittal plane 1 cm from the posterior midline. The deep plane to the erector spinae muscle (ESM) was identified, and a 22 G, 50 mm insulated needle (Sonoplex Stim, Pajunk, Germany) was inserted cranio-caudally in plane between the transverse process and the fascia of the ESM. After negative aspiration, 0.3 ml/kg of 0.25% bupivacaine was injected to confirm the correct position by visualizing the solution lifting the ESM off the transverse process.
223589585|NCT05408026|DRUG|Daratumumab|"Daratumumab (and hyaluronidase) will be given over 3-5 minutes subcutaneously (under the skin) in the clinic at alternating left/right abdominal sites. Patient will take dexamethasone orally (by mouth) either before coming to clinic or in clinic, before other medications.~Only for the first cycle, patient will receive on Day 1 daratumumab (which is mixed with a compound called hyaluronidase) and dexamethasone, 1 day before patient start the other 2 medications."
223589586|NCT05408026|DRUG|Pomalidomide|On day 2 of cycle 1, patient will start the other medications and will therefore receive bortezomib administered subcutaneously (SC) over 3-5 minutes and dexamethasone given orally (by mouth), either before coming to clinic or in clinic, before bortezomib. Patient will also start pomalidomide on the same day, which patient will take that evening at home and every evening for 21 days.
223589587|NCT03334383|DEVICE|Sponge|Compressed cellulose sponge for use in laparoscopic surgery to retract the intestines from the surgical field.
223589588|NCT05359601|PROCEDURE|Infusion set replacement intervals|24-hour or 96-hour infusion set replacement intervals
223589589|NCT01399008|DRUG|Arhalofenate|Arhalofenate 400 and 600 mgs over-encapsulated tablets once daily for 4 weeks or Allopurinol 300 mg once daily for 4 weeks
224186898|NCT02354599|DRUG|MT203 300 mg or matching placebo|MT203 300 mg or matching placebo injection
224186899|NCT05403775|OTHER|3D printing guide plate|3D-printed customized guide plate will be used to guide the puncture in TFESI combined with dorsal root ganglion PRF to help to reduce intra-operative radiation.
223589590|NCT01399008|DRUG|Allopurinol|Allopurinol 300 mg as active comparator
224186900|NCT05403775|OTHER|Conventional guidance|The surgeons would place the needle according to his/her previous experience under the guidance of C-arm fluoroscopy.
224186901|NCT04717856|OTHER|screening: HCV RNA test and risk factors questionaire|Screening by using a rapid finger prick test for HCV RNA and a questionnaire to assess risk factors.
224186902|NCT01756209|DRUG|Magnesium 400Mg|magnesium 400 mg + conventional treatment
224186903|NCT01756209|DRUG|Ibuprofen 10 mg/kg|ibuprofen 10 mg/kg oral single dose
224186904|NCT01756209|DRUG|acetaminophen 15 mg/kg|Acetaminophen 15 mg/kg oral single dose
224186905|NCT01999205|BEHAVIORAL|Physical activity promotion|A nominated team in each participating company develops a plan to promote physical activity and to reduce sedentary behavior of the employees.
224308923|NCT02421224|BEHAVIORAL|Deposits|Participants will have to deposit a certain amount of their own money at enrollment. Participants will be able to make additional voluntary deposits above the minimum amount during the intervention period. The participant will be refunded all deposits if he quits smoking at 3 months, as verified by a urine cotinine test. The participant will forfeit all deposits if he continues to smoke at 3 months, as verified by a urine cotinine test.
223495907|NCT04354571|PROCEDURE|caudal block|caudal block was performed using anatomical landmarks and ultrasound guided and confirmed with a concentration of bupivacaine of 0.25%.
223495908|NCT01371682|DRUG|Ropinirole XL|Ropinirole XL manufactured at Crawley will be compared to that manufactued at Aranda.
223495909|NCT02279251|BEHAVIORAL|VÅG|Low-intensity CBT intervention
223495910|NCT02279251|BEHAVIORAL|CHILLED|Standard length CBT intervention
223495911|NCT01802671|OTHER|Rehabilitation treatment and information|Patients will receive the traditional rehabilitation treatment (back school). This treatment will consist of a 4-session group therapy every week, with each session lasting 45 minutes. The content of the first session will be educational (ergonomics, pain demystification) and the other three will include physical therapy focused on stabilisation training: lower extremity stretching; finding the neutral spine position; spine stabiliser activation (transversus abdominis and multifidus); abdominal, spinal extensor and lower extremity strengthening; and proprioceptive control (stabilisation kinesitherapy)
224186906|NCT02229513|PROCEDURE|Uterine Cooling|Immediately following delivery of the fetus the uterus will be externalized in the usual fashion and the body of the uterus cephalad to the hysterotomy incision will be wrapped in sterile surgical towels saturated in sterile, iced normal saline. These towels will come from a sterile cooling pot set to 30 degrees Fahrenheit. Iced saline-soaked towels will be kept in place for a minimum of 5 minutes and replaced at the discretion of the attending obstetrician until the hysterotomy is closed and the uterus is replaced into the patient's abdomen.
224186907|NCT03397095|COMBINATION_PRODUCT|CSWT+BMMSCs|All participants will screened by D-SPECT to assess the myocardium viability. If the viable myocardium is detected, Patients will be randomized to receive cardiac shock wave therapy with an equipment (Modulith SLC; Storz Medical, Switzerland) followed the recommended protocol developed by Tohoku University of Japan and the protocol developed by the University of Essen, Germany. An over-the-wire catheter will be positioned in the target coronary artery and the cells resuspended in saline will be injected intracoronary.
224186908|NCT03397095|DEVICE|CSWT+Sham operation|Patients randomized to this group will receive a routine cardiac shock wave therapy and coronary angiography. No cells will be administered via the coronary artery.
224186909|NCT00958399|DIETARY_SUPPLEMENT|Placebo|Low fiber muffin, hot cereal and beverage (acute phase) or fiber bars and beverage (chronic phase)
224186910|NCT00958399|DIETARY_SUPPLEMENT|Resistant Starch|25 g resistant starch, administered in a muffin, hot cereal and beverage (acute phase) or fiber bars and beverage (chronic phase)
224186911|NCT00958399|DIETARY_SUPPLEMENT|Resistant starch + soluble fiber|25 g fiber as resistant starch and a soluble fiber, administered in a muffin, hot cereal and beverage (acute phase) or fiber bars and beverage (chronic phase)
224186912|NCT00958399|DIETARY_SUPPLEMENT|Fiber made from corn starch|25 g fiber made from corn starch, administered in a muffin, hot cereal and beverage (acute phase) or fiber bars and beverage (chronic phase)
224186913|NCT00958399|DIETARY_SUPPLEMENT|Fiber made from corn starch + soluble fiber|25 g fiber as a fiber made from corn starch and a soluble fiber, administered in a muffin, hot cereal and beverage (acute phase) or fiber bars and beverage (chronic phase)
224186914|NCT06119828|BEHAVIORAL|breastfeeding education for family members|The first breastfeeding skills of mothers who gave birth in the delivery room and the first breastfeeding skills after birth were evaluated using BEDÖ. After giving birth, mothers were taken to the maternity ward after being kept under control in the delivery room for 2 hours. After the mothers' 1-hour breastfeeding was evaluated in the delivery room, the training phase of family members began. CBT was administered to family members in the waiting room before the training, which lasted approximately 7-8 minutes. Then, breastfeeding training was given to family members for 20-25 minutes. BBST was applied after the mother transferred to the maternity ward. Before the mother and the baby were discharged from the hospital, BEDÖ and BBTÖ were administered to the family member. On the 15th postpartum day, the family member was called by phone and reminded about breastfeeding education. At the first month postpartum,Checklist were administered to the mother via telephone conversation
224186915|NCT06119828|OTHER|receiving routine breastfeeding training|After giving birth, mothers were taken to the maternity ward after being kept under control in the delivery room for 2 hours. Mothers' breastfeeding was evaluated at the 1st hour in the delivery room. CBT was administered to family members in the waiting room. BBST was applied after the mother transferred to the maternity ward. Before the mother and the baby were discharged from the hospital, BEDÖ and BBTÖ were administered to the family member. At the first month postpartum, BBTÖ was administered to the family member, and BBTÖ and EÖY scale and Breastfeeding Checklist were administered to the mother over the phone.
223495912|NCT01802671|BEHAVIORAL|cognitive behavioural therapy (CBT)|"Patients will receive the same treatment in physical therapy than the control group and additionally they will receive CBT. The aim of the CBT intervention is to produce changes in the beliefs and behaviors about physical activity and avoidance of activity. The treatment's components are:~* Psychoeducation to counteract the misconceptions about low back pain and to point on the relevance of maintaining an adequate level of activity.~* Cognitive restructuring techniques~* Behavioural therapy and activity pacing~* Training on self-management pain techniques (mindfulness and relaxation). It is a 6-session group therapy, with one session per week. Each group will be composed by 6-8 participants. It will be considered as a patient who receives the treatment when the patient attends to the assessment sessions and to at least 4 out of 6 CBT sessions."
223589591|NCT01399008|DRUG|Colchicine|0.6 mg colchicine daily as flare prophylaxis
223589592|NCT01399008|DRUG|Placebo|Placebo
223589593|NCT05556538|PROCEDURE|Transforaminal Epidural Steroid Injection|Patients are placed in the prone position, with a pillow under their abdomen (to reduce lumbar lordosis) and taken to the operating table. The procedure area is cleaned 3 times with povidone-iodine antiseptic and covered with a sterile cover. In order to view the foramen to be processed, the fluoroscopy arm is evaluated at AP-oblique / cranial or caudal angles to obtain an optimal image. Local anesthetic (3 cc 2% prilocaine) is injected into the skin and subcutaneous tissue. The spinal Quincke 21-gauge 90 mm needle is advanced by targeting the relevant foramen under the guidance of fluoroscopy image. Needle position is confirmed by taking a lateral view. Needle aspiration is checked for blood. 1-2 ml of contrast material is injected to confirm that there is no vascular distribution and that it is in the epidural space. When distribution without vascular invasion is observed, an injection of a mixture of 10 mg dexamethasone, 1 cc saline and 1 cc (0.5%) bupivacaine is performed.
223589594|NCT05104970|DRUG|SunnyD insta ampoule|Cholecalciferol 200000 IU insta ampoule
223589595|NCT05104970|DIETARY_SUPPLEMENT|SunnyD STAT softgel capsule|Cholecalciferol 200000 IU softgel capsule
223589596|NCT05104970|DRUG|Placebo SunnyD insta ampoule|Olive oil
223589597|NCT05104970|DIETARY_SUPPLEMENT|Placebo SunnyD STAT softgel capsule|Olive oil
223589598|NCT00115661|DRUG|Rosiglitazone|
223589599|NCT00658307|DEVICE|repetitive transcranial magnetic stimulation (rTMS)|"1 Hz~The rTMS device is the MagPro X100 Series (produced by Magventure A/S, Farum, Denmark)"
223589600|NCT00658307|DEVICE|repetitive transcranial magnetic stimulation (rTMS)|"20Hz~The rTMS device is the MagPro X100 Series (produced by Magventure A/S, Farum, Denmark)"
223589601|NCT00658307|DEVICE|sham repetitive transcranial magnetic stimulation (rTMS)|"The rTMS device is the MagPro X100 Series (produced by Magventure A/S, Farum, Denmark)"
223617800|NCT02785185|DRUG|IDP-122 Vehicle Lotion|Vehicle
223617801|NCT02785185|DRUG|IDP-122 Vehicle Cream|Vehicle
223617802|NCT02785185|DRUG|IDP-122 Lotion|Lotion
224186916|NCT02218346|DRUG|AG221|AG221 in fed and fasted conditions
224186917|NCT03935945|BEHAVIORAL|Personalized Feedback Intervention|Participants in the intervention group will receive a computerized personalized feedback intervention (PFI) lasting approximately 20-30 minutes. PFI highlights discrepancies between one's own drinking and typical drinking; reframes use in terms of personal, social, financial, and health consequences; and, offers strategies for reducing alcohol use. The feedback is non-confrontational in tone, seeks to increase motivation to reduce drinking and is based on the information provided during the baseline assessment
224186918|NCT01647477|BEHAVIORAL|interview|25 minutes of semi directive interview
224186919|NCT01647477|BEHAVIORAL|questionnaires|questionnaires to answer at baseline 45 minutes
224186920|NCT05845554|DIAGNOSTIC_TEST|The extracted DNA from bile samples will be analyzed by BileCAD to determine the level of CIN.|The extracted gDNA from bile sample will be analyzed by BileCAD to determine the level of CINs.
224186921|NCT04045431|DEVICE|PAAG-OA|Intra-articular injection of 6ml PAAG-OA in the target knee (incl. five (5) years follow-up) period.
224186922|NCT04045431|DEVICE|Synvisc-One|Intra-articular injection of 6ml Synvisc-One in the target knee
224186923|NCT01633398|GENETIC|Saliva Genetic testing|To compare the genetic variants between the two phenotypes of reduced versus preserved ejection fraction (HFrEF versus HFpEF)
224186924|NCT03984682|PROCEDURE|Joint Crisis Plan|A Joint Crisis Plan will be drafted with the patient and a nurse
224186925|NCT00159146|DRUG|Pindolol and venlafaxin|pindolol 20 mg and venlafaxin 150 mg
224186926|NCT04069026|DRUG|BAY2416964|Oral application of study drug daily in a predefined dose escalation scheme.
224186927|NCT04069026|DRUG|BAY2416964|Oral application of study drug daily at the dose defined in the dose escalation scheme to determine the recommended phase 2 dose (RP2D).
224186928|NCT05240872|BIOLOGICAL|PRP injection|Plantar fascia injection therapy with PRP
224186929|NCT05240872|BIOLOGICAL|ABI injection|ABI injection
224186930|NCT05405738|PROCEDURE|2 flap palatoplasty technique|cleft palate repair by 2 flap palatoplasty technique
224186931|NCT05405738|OTHER|normal group|control normal group
224186932|NCT05405738|PROCEDURE|Furlow with buccinator technique|cleft palate repair by Furlow with buccinator technique
224186933|NCT01811693|DRUG|Glycerly Trinitrate|5mg/24hour (0.2mg/hour) transdermal
223495913|NCT01802671|BEHAVIORAL|cognitive behaviour therapy supported by ICT|The patients of this group will receive the same interventions that the CBT group but will receive a reinforcements of the sessions' content through two different ways, both based on ICTs: a web tool named TEO (Emotional Therapy Online) specially designed to practicing the therapeutic strategies at home; and SMS that will send to the patients' mobile phone with reminders and reinforcements. The content of sessions will be related to the therapeutic components including on the CBT. Patients will access TEO from their home using a personal password. Besides TEO, messages will be sent through SMS three times per week during the treatment and once a week during the follow-up. The messages will consist on reminders to do the homework along with reinforcements of the working and effort made to improve their health.
223495914|NCT04087590|DRUG|Formoterol-glycopyrronium co suspension (PT003)|Formoterol-glycopyrronium co suspension (PT003) in a Metered Dose Inhaler, 2 puffs twice daily
223495915|NCT04005339|DRUG|Nanoliposomal Irinotecan|Nanoliposomal irinotecan 70 mg/ IV over 90 minutes, every 14 days
223495916|NCT04005339|DRUG|Leucovorin|Leucovorin 400 mg/ IV over 30 minutes, every 14 days.
223495917|NCT04005339|DRUG|Fluorouracil|Fluorouracil 2,400 mg/m IV over 46 hours.
223495918|NCT06405581|OTHER|Edmonton frailty scale calculation|"The frailty status of the patients will be assessed using the Edmonton frailty scale.~According to the Edmonton frailty scale;~* (0-5): not frail~* (6-7): sensitive~* (8-9): slightly fragile~* (10-11): moderately fragile,~* (12-17): extremely fragile"
223495919|NCT01772862|BEHAVIORAL|Intervention group|"The intervention components includes (real time sequence):~An educational session where the child is educated on his/her cancer disease. An education session in the child's school where the child´s teachers, classmates and their parents are educated on the child´s cancer disease.~Appointment of two classmates as ambassadors. An individualized physical training program combining supervised and non-supervised training 3-5 times per week.~Continued specialized physical training when relevant. At two weeks intervals joined education, physical and social activity days at the hospital with together with one of the ambassadors"
223617803|NCT02785185|DRUG|Ultravate Cream|Cream
223617804|NCT02028377|PROCEDURE|PET/MRI|PET/MRI
224186934|NCT01811693|DRUG|Glycerly Trinitrate|10mg/24hour (0.4mg/hour) transdermal
224186935|NCT01811693|DRUG|Glycerly Trinitrate|0.4 mg sublingual single metered spray
224186936|NCT04647929|DEVICE|Santen PRESERFLO MicroShunt|the PRESERFLO MicroShunt will be implanted to increase aqueous humor outflow
224186937|NCT04647929|PROCEDURE|Trabeculectomy|a fornix-based trabeculectomy with a 3x4mm flap will be performed to increase aqueous humor outflow
224186938|NCT04735289|OTHER|EPIC-COS Food Frequency Questionnaire diet Evaluation|Anthropometric measurements (Body mass Index, Lean and fat body composition evaluation) and diet habits evaluation with EPIC-COS-FFQ
224186939|NCT04735289|OTHER|Metabolome, Microbiota, Lymphocytes subpopulations|"At diagnosis before any treatment for bone sarcoma will be obtained :~1. a blood sample for metabolomics analyses~2. a stool sample for microbiota analysis~3. Lymphocyte subpopulations (CD3, CD4, CD8, NK) will be analyzed in blood samples"
224186940|NCT02939326|DRUG|EB-001 injection|
224186941|NCT02939326|DRUG|Placebo injection|
224186942|NCT00764530|DEVICE|Alumina/Alumina|CeramTec Acetabular Alumina Insert and CeramTec Alumina head used with Foundation Porous Coated Acetabular Shell
224186943|NCT00764530|DEVICE|Standard|Foundation Porous Coated Acetabular Shell with Polyethylene Insert with the CeramTec Alumina head
224186944|NCT04247724|BEHAVIORAL|Recreational handball|
224186945|NCT04247724|BEHAVIORAL|Control|
224186946|NCT01087944|DEVICE|Autoinjector|Participants received Peginterferon alfa-2a 180 microgram subcutaneously once a week by autoinjector for 3 weeks.
224186947|NCT01087944|DEVICE|Pre-filled syringe|Participants received Peginterferon alfa-2a 180 microgram subcutaneously once a week by pre-filled syringe for 3 weeks.
224186948|NCT02565303|PROCEDURE|Intervertebral space|
224308924|NCT02421224|BEHAVIORAL|Small Individual Bonus|Each participant will receive a monetary bonus from the study investigators if he or she quit smoking, as verified by a urine cotinine test.
224186949|NCT02565303|DRUG|Ropivacaine|The initial dose of ropivacaine is chosen as 12 mg in L2-3 group and 15 mg in L3-4 group with the volume of 3 mL in both groups. The testing interval is 0.5 mg with subsequent doses being determined by the outcome of the previous injection in the same group.If the previous response is ineffective, the next patient will receive 0.5 mg more than the last patient. If the response of the previous patient is effective, the next patient decrease 0.5mg.
223495920|NCT02229604|OTHER|EA|For BL33, insert the needle to the third posterior sacral foramina to a depth of 80-100mm. For ST25, EX-CA1 and RN4, the needle will be inserted vertically and quickly through the skin, and then slowly and vertically penetrate through the layer of fatty tissue, up into the muscles of the abdominal wall (until the moment of resistance is sensed on the tip of the needle and the participant feels a sting). The electric stimulator will be put on the BL33 and EX-CA1 with a continuous wave, 20 Hz, 1.0-4.0 mA.
223495921|NCT02229604|DRUG|HRT, DHEA and herb|HRT, dehydroepiandrosterone (DHEA) and herb decoction could be used for this group. Time frame of treatment is not fixed. Herb decoction will be given to participants based on the principle of syndrome differentiation (a diagnosing method in Traditional Chinese Medicine).
223495922|NCT05694585|DRUG|Esmolol|Esmolol 50μg/kg /min is intravenously administered before Operation beginning. If HR（heart rate）is greater than 90 beats/min, esmolol 50μg/kg/min is added each time, with interval more than 5 min and the peak value is 200 μg/kg/min. If the heart rate is lower than 60 times/minute, Stop medication.
223495923|NCT05694585|DRUG|saline|Saline 50μg/kg /min were iv administered before Operation beginning. If HR（heart rate）is greater than 90 beats/min, saline 50μg/kg/min is added each time, with interval more than 5 min and the peak value is 200 μg/kg/min. If the heart rate is lower than 60 times/minute, Stop medication.
223495924|NCT01470534|DIETARY_SUPPLEMENT|carbohydrate drink|carbohydrate drink
223495925|NCT01470534|PROCEDURE|Muscle biopsy|Open muscle biopsy
223495926|NCT01470534|PROCEDURE|Blood sampling|Venopuncture
223495927|NCT01470534|DIETARY_SUPPLEMENT|Placebo|
223495928|NCT05743972|DIAGNOSTIC_TEST|Contrast-enhanced ultrasound-guided core biopsy|Core biopsy was used to collect samples for pancreatic diseases under contrast-enhanced ultrasound-guided.
223495929|NCT05743972|DIAGNOSTIC_TEST|Conventional ultrasound-guided core biopsy|Core biopsy was used to collect samples for pancreatic diseases under conventional ultrasound-guided.
223495930|NCT02259322|BEHAVIORAL|Standard-of-Care|Standard-of-Care with bariatric team. Participants will be encouraged to continue their care with their bariatric team.
223495931|NCT02259322|BEHAVIORAL|Behavioral Weight Loss Treatment|Biweekly individual guided self-help sessions for 3 months
223495932|NCT02259322|BEHAVIORAL|Cognitive Behavioral Therapy|Biweekly individual guided self-help sessions for 3 months
223495933|NCT00120718|DRUG|fasudil|
223495934|NCT01320566|DEVICE|AeriSeal System|Not applicable. Follow-Up study only.
223495935|NCT02439619|OTHER|TechCare|The TechCare software is being developed specifically for use on a touch screen mobile phone. The mobile application will alert participants through notifications and ask a number of questions. Based on participant responses the app will provide a CBT based response to individuals or the service users preferred multimedia such as music, images and videos.
223495936|NCT00852878|BEHAVIORAL|Biofeedback|Biofeedback will teach resonant frequency breathing for 6-8 sessions
223495937|NCT00852878|BEHAVIORAL|Behavioral Protocol|Behavioral protocol will teach a variety of pain management techniques such as relaxation, distraction, and coping statements over 6-8 sessions
223495938|NCT05600959|DIAGNOSTIC_TEST|cytokine|Peripheral blood samples were collected at diagnosis, 2 weeks after the first cycle of chemotherapy and 2 weeks after the second cycle of chemotherapy to monitor cytokine level changes.
224186950|NCT01617356|OTHER|Injection of 20% dextrose/ 0.2% lidocaine|Injection at 0, 1, and 2 months of 1 ml of a solution consisting of 20% dextrose and 0.2% lidocaine.
224186951|NCT01617356|OTHER|Injection of 1 ml of 0.8 SW/0.2% lidocaine|Injection at 0, 1, and 2 months of 1 ml of a solution consisting of 0.8 sterile water and 0.2% lidocaine.
223495939|NCT05758454|BEHAVIORAL|Caries and Obesity Prevention|A culturally adapted oral health education intervention to prevent development of ECC and to improve parental oral health related knowledge and attitudes.
223495940|NCT02629458|PROCEDURE|Treatment by Surgical resection|
223495941|NCT02629458|PROCEDURE|Stereotactic Ablative Radiotherapy (SABR)|
223495942|NCT03251417|DRUG|Irinotecan|Irinotecan 150mg/m2, repeated very 2 weeks for 3 to 6 cycles.
223495943|NCT03251417|DRUG|Apatinib|Apatinib 500 mg oral take, daily
223495944|NCT06518226|RADIATION|Ultrahypofractionated MRgRT in 2 fractions|2x12 Gy with boost to GTV up to 13.5 Gy
223495945|NCT06518226|RADIATION|Standard of care: MRgRT in 5 fractions|5x7.25 Gy
223495946|NCT06287229|DRUG|Blinatumomab|Given by Infusion
223495947|NCT06287229|DRUG|Inotuzumab Ozogamicin|Given by IV
223495948|NCT06287229|DRUG|Hyper-CVAD|Given by IV Participants younger than 60 years of age, you will receive hyper-CVAD.
223495949|NCT06287229|DRUG|Mini-hyper-CVD|Given by IV Participants 60 years of age or older, you will receive mini-hyper-CVD
223495950|NCT04487236|DRUG|ZN-A-1041 50mg BID|Orally 21days for one cycle
223495951|NCT04487236|DRUG|ZN-A-1041 100mg BID|Orally 21days for one cycle
223495952|NCT04487236|DRUG|ZN-A-1041 200mg BID|Orally 21days for one cycle
223495953|NCT04487236|DRUG|ZN-A-1041 400mg BID|Orally 21days for one cycle
223495954|NCT04487236|DRUG|ZN-A-1041 600mg BID|Orally 21days for one cycle
223495955|NCT04487236|DRUG|ZN-A-1041 800mg BID|Orally 21days for one cycle
223495956|NCT04487236|DRUG|ZN-A-1041 1000mg BID|Orally 21days for one cycle
223495957|NCT04487236|DRUG|ZN-A-1041 Level 1 +Capecitabine 1000 mg/m2 + Trastuzumab 8 mg/kg iv. First Cycle|ZN-A-1041 level 1 BID; Capecitabine 1000 mg/m2 BID Trastuzumab 8 mg/kg iv. First Cycle
224186952|NCT05811143|DEVICE|Spinal Cord Stimulator|SOC Implantation of Spinal Cord Stimulator for Lipomatosis and Low Back Pain.
224186953|NCT03061864|BEHAVIORAL|Periviable Birth Plan|
224186954|NCT04144257|DRUG|[F-18]PBR06|PET radiopharmaceutical. Subjects will undergo \[F-18\]PBR06-PET (microglial activation).
224186955|NCT04144257|DRUG|[C-11]Methylreboxetine|PET radiopharmaceutical. Subjects will undergo \[C-11\]MRB-PET (norepinephrine transporter binding).
224186956|NCT01159665|DRUG|ocriplasmin|125µg ocriplasmin intravitreal injection
224186957|NCT01159665|DRUG|ocriplasmin|125µg ocriplasmin intravitreal injection
223495958|NCT04487236|DRUG|ZN-A-1041 Level 2 +Capecitabine 1000 mg/m2 + Trastuzumab 8 mg/kg iv. First Cycle|ZN-A-1041 level 2 BID; Capecitabine 1000 mg/m2 BID Trastuzumab 8 mg/kg iv. First Cycle
223495959|NCT04487236|DRUG|ZN-A-1041 MAD +Capecitabine 1000 mg/m2 + Trastuzumab 8 mg/kg iv. First Cycle|ZN-A-1041 MAD BID; Capecitabine 1000 mg/m2 BID Trastuzumab 8 mg/kg iv. First Cycle
223495960|NCT04487236|DRUG|ZN-A-1041+Capecitabine + Trastuzumab 8 mg/kg iv. First Cycle|Base on 1b ZN-A-1041 dose Base on 1b Capecitabine dose Base on 1b Trastuzumab dose
223495961|NCT04560842|DEVICE|A high flow oxygen device.|The HFNC group use high flow oxygen device for 48 hours
223495962|NCT04560842|DEVICE|Conventional oxygen therapy|Conventional oxygen device
223495963|NCT04341090|DRUG|Apatinib Mesylate|Single dose of apatinib mesylate after high-fat meal, low fat meal and fast
223495964|NCT03010501|OTHER|Food Energy Density|Food Energy density manipulated
223495965|NCT06068959|DEVICE|Photobiomodulation using LED|Photobiomodulation Using a Cluster of LEDs in the Red and Infrared Wavelengths in the Cervical Spine Region and Over the Masticatory Muscles
223495966|NCT06068959|DEVICE|Placebo|Photobiomodulation Placebo
223495967|NCT00640289|DRUG|Fibrogammin P|Prophylaxis treatment
223495968|NCT00864318|DRUG|Paclitaxel|200mg/m2 for 3 hours at Cycle 1 day 1 and Cycle 2 day 1 with 14 days between cycles
223495969|NCT00864318|DRUG|Ifosfamide|2g/m²/day in 1 liter of G5 for 3 hours at Cycle 1 and Cycle 2 from day 2 to day 4 with 14 days between cycles
223495970|NCT00864318|DRUG|Carboplatine|"From cycle 3 to cycle 5 :~Carboplatine is administered with AUC = 24 mg/mL x min from Day 1 to Day 3. Day 3 Carboplatine dose is calculated taking into account real creatinine clearance defined at day 1 for each patient"
224186958|NCT01159665|DRUG|ocriplasmin|125µg ocriplasmin intravitreal injection
224186959|NCT01159665|DRUG|ocriplasmin|125µg ocriplasmin intravitreal injection
224186960|NCT01159665|DRUG|ocriplasmin|125µg ocriplasmin intravitreal injection
224186961|NCT01209299|GENETIC|DNA methylation analysis|
224186962|NCT01209299|GENETIC|gene expression analysis|
224186963|NCT01209299|OTHER|laboratory biomarker analysis|
224186964|NCT06323629|BEHAVIORAL|Adaptive recursive self-feedback procedure|The intervention uses self-feedback alone to improve speech production. It adapts the complexity of the treatment tasks.
224186965|NCT06323629|BEHAVIORAL|Non-adaptive recursive self-feedback procedure|The intervention uses self-feedback alone to improve speech production. However, it does not adapt the complexity of the treatment tasks.
224186966|NCT03092141|OTHER|Physical training|
224186967|NCT06131931|OTHER|CLP Intervention|4 weekly sessions lasting approximately 60 minutes that will be audio recorded for quality assurance. Each couple will be assigned one RA who will serve as their facilitator and guide them through the Connecting Latinxs en Pareja (CLP) sessions. The RA will deliver the appropriate intervention in either Spanish or English at the couple's preference. Sessions will be delivered via zoom (or comparable secure platform), using established procedures from the team's prior studies. Each participant will complete Qualtrics assessments at baseline, 3-, 6- and 9-months post randomization and biological (hair biomarkers for PrEP and ART adherence) and behavioral and psychosocial data collected.
224186968|NCT06131931|OTHER|WP Intervention|4 weekly sessions lasting approximately 60 minutes that will be audio recorded for quality assurance. Each couple will be assigned one RA who will serve as their facilitator and guide them through the Wellness Promotion (WP) sessions. The RA will deliver the appropriate intervention in either Spanish or English at the couple's preference. Sessions will be delivered via zoom (or comparable secure platform), using established procedures from the team's prior studies. Each participant will complete Qualtrics assessments at baseline, 3-, 6- and 9-months post randomization and biological (hair biomarkers for PrEP and ART adherence) and behavioral and psychosocial data collected.
224186969|NCT00544674|DRUG|PR104|administered at a dose of 1100 mg/m\^2 by intravenous infusion over 1 hour and repeated every three weeks
224186970|NCT00544674|OTHER|F-18-fluoromisonidazole|administered intravenously prior to PET scan
224186971|NCT02683031|OTHER|Ca2+ ionophore|Ca2+ ionophore is a chemical agent used to perform oocyte activation after ICSI. It showed effective treatment to get better fertilization, pregnancy, and healthy livebirth in cases with total or partial fertilization failure.
224186972|NCT00540228|BIOLOGICAL|Influenza Vaccine GSK1247446A - 4 different formulations|Single dose, Intramuscular injection
224186973|NCT00540228|BIOLOGICAL|Fluarix™|Single dose, Intramuscular injection
224186974|NCT01866891|OTHER|Three months of regular perdialytic physical activity (cycling)|Cycling, in lying position, at a rate of thirty minutes per dialysis session (three a week), regardless of performance
224186975|NCT04205513|DEVICE|Medly|Medly is a mobile phone-based telemonitoring system that enables patients with heart failure to take clinically relevant physiological measurements with wireless home medical devices and answer symptom questions on the mobile phone. The measurements are automatically and wirelessly transmitted to the mobile phone and then to a data server.
224186976|NCT01623518|BIOLOGICAL|ChAdOx1-NP+M1|"Dose escalation in a 3+3 study plan;~5 x10\^8 vp, 5 x10\^9 vp, 2.5 x10\^10 vp, 5 x10\^10 vp"
224186977|NCT01273012|DRUG|Probiotic - Infloran|Drug:Probiotic - Infloran (TM) 1 cap (1 billion CFU of L. acidophilus and 1 billion CFU of B. bifidum) PO bid or tid
224186978|NCT01044095|BIOLOGICAL|FluMist® live, attenuated, intranasal seasonal influenza vaccine|FluMist® live, attenuated, intranasal seasonal influenza vaccine 0.2mL (0.1mL per nostril)
224186979|NCT01044095|BIOLOGICAL|Fluzone® inactivated influenza virus vaccine|Fluzone® inactivated influenza virus vaccine 0.5mL intramuscularly
224186980|NCT01377194|DRUG|Levomilnacipran ER|Drug: Levomilnacipran ER 40mg/day Study drug is to be given orally, in capsule form, once daily, for 8 weeks
224186981|NCT01377194|DRUG|Levomilnacipran ER|Drug: Levomilnacipran ER 80mg/day Study drug is to be given orally, in capsule form, once daily, for 8 weeks
224186982|NCT01377194|DRUG|Placebo|Matching placebo to be given orally, in capsule form, once daily, for 8 weeks.
224186983|NCT04040725|DRUG|Rogaratinib|Rogaratinib is an oral drug that inhibits FGFR. Mutations in FGFR help bladder cancer grow.
224186984|NCT04974294|BIOLOGICAL|PPV23|random allocation 1:1:1 IM injection
224186985|NCT04974294|BIOLOGICAL|PCV13|random allocation 1:1:1 IM injection
224186986|NCT04974294|OTHER|Saline for injection|random allocation 1:1:1 IM injection
223617805|NCT04458155|DEVICE|Siemens® Point-of-care high sensitive troponin I analyzer|Point-of-care (POC) high sensitive troponin I (HS cTnI) analysis in whole blood, plasma and capillary whole blood with the Siemens® device.
224186987|NCT04944966|DRUG|Maytenus Senegalensis|"* Maytenus senegalensis (Malherbal) has a very long history of safe medicinal use in Africa in adult as well as infants and children. It will be administered orally at a dose of 800mg 8 hourly for 4 days.~* Artemether 20mg/lumefantrine 120mg"
224186988|NCT00387621|DRUG|Nesiritide|The first 10 subjects in each group will receive a dose of 5 ug/kg and the next ten subjects will receive 10 ug/kg.
224186989|NCT00387621|DRUG|Placebo|The pharmacy created a placebo subcutaneous injection volume to match the volume of the nesiritide dose.
224186990|NCT00387621|DRUG|Saline|Normal saline 0.9% 0.25 ml/kg/min for 60 minutes
224186991|NCT02362295|OTHER|qualitative interview|some patient are interviewed.
224186992|NCT03193281|DRUG|Dasatinib|"In order to test the study hypothesis patients need to stay on dasatinib (Sprycel) treatment for the first 12 months of the study (Stage 1).~Patients who do not reach MR3.0 at 12 months will remain on dasatinib treatment."
224186993|NCT03193281|DRUG|Imatinib|Patients who reach MR3.0 at 12 months (and the result is confirmed at 13 months) will switch to imatinib (Imatinib-AFT) treatment.
224186994|NCT04033328|DRUG|ORIC-101|ORIC-101 once daily in each 28-day cycle
224186995|NCT04033328|DRUG|enzalutamide 40 MG oral capsule [Xtandi]|160 mg once daily in each 28-day cycle
224186996|NCT04186754|PROCEDURE|Comprehensive functional care plan|The treatment should be carried out INDIVIDUALIZED, in the hospital room or in a conditioned room, in sessions of approximately 30 minutes and on a daily basis. Carried out by professionals in the disciplines of nursing and occupational therapy.
223495971|NCT00864318|DRUG|Etoposide|From Cycle 3 to cycle 5, 400mg/m2/day from day 1 to day 3
223495972|NCT00864318|PROCEDURE|cytapheresis + transfusion of autologous peripheral blood stem cells|"Cytapheresis occured between day 11 and day 13 of the 2 first cycle (Taxol® +Holoxan®). Cytapheresis total objective is 9X106 CD34+/kg of patient weight.~At cycle 3, 4 and 5 at day 5 : Re-injection of stem cells (1/3 with minimum 2.106 CD34/kg) 48 hours after chemotherapy end"
223495973|NCT02103075|DEVICE|Neuromuscular electrical stimulation|All groups received an accumulated 30-minute NMES (25 Hz, on/off: 800ms/800ms) intervention on median nerve.
223495974|NCT00306488|DRUG|OT-551 antioxidant eye drop|0.45% concentration of OT-551 eye drops were given three times a day on participants with geographic atrophy area for up to three years. Participants had one eye randomized to receive the eye drop and the fellow eye was observed.
223495975|NCT02257151|DRUG|BMS-986142|
223495976|NCT02257151|DRUG|Placebo|
223495977|NCT04050605|DEVICE|somofilcon A toric contact lens|Contact Lens
223495978|NCT04050605|DEVICE|fanfilcon A toric contact lens|Contact Lens
223495979|NCT04546698|OTHER|blood sampling|Analyse of expression modulation of 5-HT7 receptor in correlation with the immunological context, in 3 differents groups : 2 with multiple sclerosis patients, one healthy volunteers group
223495980|NCT00544882|DRUG|DR-1021|Twenty-one 150 μg desogestrel/20 μg ethinyl estradiol (EE) combination tablets plus seven 10 μg EE tablets.
223495981|NCT00544882|DRUG|Mircette®|Twenty-one 150 μg desogestrel/20 μg ethinyl estradiol (EE) combination tablets plus two placebo tablets plus five 10 μg EE tablets.
223495982|NCT00544882|DRUG|Kariva®|Twenty-one 150 μg desogestrel/20 μg ethinyl estradiol (EE) combination tablets plus two placebo tablets plus five 10 μg EE tablets.
223495983|NCT07102719|DRUG|HD-P023|Single dose administration of HD-P023
223495984|NCT07102719|DRUG|Teneligliptin and Empagliflozin|Single does administration of Teneligliptin and Empagliflozin High
223495985|NCT07115238|DRUG|XTR006|all patients will receive one injection of \[18F\]XTR006, a PET radiopharmaceutical selective for NFTs. For the injection, subjects will receive a target dose of 4-6 mCi IV as a bolus injection. \[18F\]XTR006 injection will be followed by a 10 ml saline flush.
223495986|NCT07116044|DIAGNOSTIC_TEST|virological tests diagnostic tests|"The parameters collected will include blood sugar, HbA1c, complete blood count, lipid profile (total cholesterol, LDL, HDL, triglycerides), liver profile (ALT, AST, total and fractionated bilirubin, alkaline phosphatase, GGT) and renal profile (creatinine, azotemia), electrophoretic protein picture. Additionally, specific data for HDV and HBV infection will be collected, including HBsAg, anti-HBs, anti-HBc, HBV-DNA, and HDV-RNA. The glomerular filtration rate shall be calculated using the formula CKD-EPI.~• Instrumental Tests: Results of abdominal ultrasounds, Fibroscan®/CAP for the evaluation of liver fibrosis"
223495987|NCT07117955|OTHER|Autologous Platelet Rich Plasma|6 mL PRP intralesional injections will be administered. After the injections, participants will be instructed to perform penile stretching exercises daily until the next injection and to continue these exercises after the final injection until the 3-month follow-up.
223495988|NCT07117955|OTHER|Saline solution|6 mL saline solution intralesional injections will be administered. After the injections, participants will be instructed to perform penile stretching exercises daily until the next injection and to continue these exercises after the final injection until the 3-month follow-up.
223495989|NCT07117318|DRUG|NSAIDs|All patients without contraindications should receive 100mg rectal indomethacin or diclofenac within 30mins before ERCP procedure
223495990|NCT07117318|DEVICE|NSAIDs plus PDS|All patients without contraindications should receive 100mg rectal indomethacin or diclofenac within 30mins before ERCP procedure. When eligibility is met, PDS placement will be performed by ERCP colonoscopists.
223495991|NCT07118150|OTHER|Assessment of Pre-Hospital Neglect and Abuse in Elderly Trauma Surgery Patients|"This study is an observational research that does not involve any direct intervention (treatment, application, etc.). After obtaining informed consent from the patients or their legal representatives, data will be collected through hospital records, face-to-face interviews with the patients and/or their relatives, and standardized questionnaires.~Pre-hospital living conditions, care status, and signs of neglect and abuse will be assessed.~The relationship between clinical data, trauma severity, and the presence of neglect or abuse will be examined."
223495992|NCT07121764|DRUG|Bupivacaine %0.25 (isobaric)|1 ml/kg of 0.25% Bupivacaine will be used for caudal block.
223495993|NCT07121764|DRUG|Dexmedetomidine & Bupivacaine.|1 ml/kg of 0.25% Bupivacaine PLUS 1 μg/kg Dexmedetomidine in 1 ml Normal Saline will be used for caudal block.
223589602|NCT01776723|DRUG|Ruxolitinib|In Phase I, participants will be allocated to twice a day (BID) doses of 10 mg/d up to 40mg/d. The starting dose will be 10 mg/d (5mg BID). Each cohort will include up to 6 subjects. Once MTD is reached, 10 additional participants will be treated during the first stage of Phase II (stage 1) at the MTD.
223589603|NCT01269502|DEVICE|"Temp Touch Diabetica Solutions inc."|Daily measurement of skin temperature on feet for one year
223589604|NCT01269502|OTHER|Inspection|Inspection of feet daily for one year
223589605|NCT05784298|DEVICE|low-intensity rTMS|40 hz, 150 gauss, 1 session that lasts 45 minutes.
223745775|NCT03446742|OTHER|Cardiovascular rehabilitation|The cardiovascular rehabilitation program is performed three times weekly on alternate days and each session lasts approximately 60 minutes divided as follows: 5 minutes to the initial rest where blood pressure (BP), heart rate (HR) and signs and symptoms are assessed; 15 minutes of warm-up, composed by global stretches, lower and upper limb exercises, and exercises combining the two modes; then, patients go to the resistance phase (30 minutes), where are performed an individualized aerobic protocol according to their HR reserve values using bicycle and treadmill (at the 4th and 10th minute of both ergometers at HR is evaluated, and in the bicycle is also evaluated the BP of all the patients). The end of the protocol is composed of 10-minute relaxation, during which the patients perform a small cardiovascular deceleration (a few laps around the room, with free speed) and, finally, lie down at rest. The presence of signs and symptoms is assessed at all stages of the program.
223495994|NCT07121621|DRUG|PHArmacoKinetics of methYLphenidate in adult patients with ADHD: comparison between patients with and without OBesity.|"The pharmacological intervention, which will be the same for all patients in the study, will consist in administering MPH at CIC 1415 (URHC of Tours) in the form of Prolonged Release at the patient's usual dosage, in the early morning.~Pharmacokinetic study with repeated measurements at T0 (just before MPH administration) then T30 minutes, T1 hour, T2h, T3h, T4h, T6h, T8h (8 measurements) after MPH administration, in 15 patients with ADHD and obesity (BMI≥30 kg/m2) and in 15 patients with ADHD but without obesity (BMI\<30 kg/m2)."
223495995|NCT07120321|DRUG|Mineral Trioxide Aggregate (MTA)|Used as the capping agent after coronal pulp removal in primary molars.
223589606|NCT00491881|BEHAVIORAL|no added salt diet|
223589607|NCT00734721|BEHAVIORAL|Preoperative information and perioperative care|Patients receive different information and care in addition to the basic medical consultation.
223495996|NCT07120321|DRUG|Biodentine|Used as a bioactive pulpotomy agent following coronal pulp amputation.
223495997|NCT07120321|DRUG|Ferric Sulfate|15.5% Ferric Sulfate applied to pulp stumps for 15 seconds during pulpotomy procedure.
223589608|NCT00801021|DRUG|Frio Mouth Rinse|Rinse with 15ml twice daily then expectorate
223589609|NCT03281304|DRUG|CP-690,500 5 mg|CP-690,550 5 mg tablet BID
223495998|NCT07120321|DRUG|Sodium hypochlorite gel application|5% NaOCl gel applied to pulp tissue during pulpotomy for its hemostatic and disinfectant effects.
223495999|NCT07120620|DEVICE|TTFields before and during radiotherapy|Administration of TTFields before and during radiation therapy in patients with primary glioblastoma (Arm A)
223496000|NCT07120620|DEVICE|TTFields before and during radiotherapy|Administration of TTFields before and during radiation therapy in patients with primary glioblastoma (Arm B)
223496001|NCT07121413|DRUG|SV001|SV001 ： Multiple-dose
223496002|NCT07121413|DRUG|Placebo|Placebo ： Multiple-dose
223496003|NCT07121088|DRUG|(Intensive treatment) Chuanzhi Tongluo Capsules|4 capsules each time, orally, 3 times a day; administration from day 1 to day 14 of the disease.
223496004|NCT07121088|OTHER|Standard Treatment (Guideline-Based)|Combination therapy including: 1. Antiplatelet: aspirin 100 mg/day + clopidogrel 75 mg/day. 2. Lipid-lowering: atorvastatin 20 mg/day. 3. Antidiabetic: metformin 500 mg bid (max 2000 mg/day). \*Doses may be adjusted per local guidelines or patient tolerance.
223589610|NCT03281304|DRUG|CP-690,550 10 mg|CP-690,550 10 mg tablet BID
223589611|NCT01731093|DRUG|AT-001|
223589612|NCT01731093|DRUG|Placebo|
223589613|NCT04611802|BIOLOGICAL|SARS-CoV-2 rS/Matrix-M1 Adjuvant (Initial Vaccination Period)|Alternating intramuscular (deltoid) injections of SARS-CoV-2 rS co-formulated with Matrix-M1 adjuvant (0.5 mL) on Days 0 and 21 in Initial Vaccination Period.
223589614|NCT04611802|OTHER|Placebo (Initial Vaccination Period)|Alternating intramuscular (deltoid) injections of placebo (0.5 mL) on Days 0 and 21 in Initial Vaccination Period.
223496005|NCT07121088|DRUG|(Sequential treatment) Chuanzhi Tongluo Capsules|2 capsules each time, orally, 3 times a day; administration from day 15 to day 365.
223496006|NCT07121088|DRUG|TCM Syndrome Differentiation Decoction|Individualized herbal decoction based on TCM diagnosis (four diagnostic methods), administered for 14 days during intensive phase.
223496007|NCT07121829|DRUG|Tovorafenib|Tovorafenib tablet for oral use.
223496008|NCT07121829|DRUG|Tovorafenib Drug: Pimasertib|Tovorafenib tablet for oral use. Pimasertib capsule for oral use
223496009|NCT07123766|DEVICE|PoliaValve (Aortic)|Aortic Valve Replacement
223496010|NCT06927076|DRUG|N,N-Dimethyltryptamine|administration of a 2mg/min DMT perfusion over 20 min
223589615|NCT04611802|BIOLOGICAL|SARS-CoV-2 rS/Matrix-M1 Adjuvant (Crossover Vaccination period)|In Crossover Vaccination period, one dose of intramuscular (deltoid) injection of SARS-CoV-2 rS co-formulated with Matrix-M1 adjuvant (0.5 mL) on Day 0 or Day 21
223589616|NCT04611802|OTHER|Placebo (Crossover Vaccination period)|In Crossover Vaccination period, one dose of intramuscular (deltoid) injection of placebo (0.5 mL) on Day 0 or Day 21
223589617|NCT04611802|BIOLOGICAL|SARS-CoV-2 rS/Matrix-M1 Adjuvant (Booster Vaccination)|In Booster Vaccination period, one dose of intramuscular (deltoid) injection of SARS-CoV-2 rS co-formulated with Matrix-M1 adjuvant (0.5 mL) on Day 0
223589618|NCT04611802|BIOLOGICAL|SARS-CoV-2 rS/Matrix-M1 Adjuvant (Second Booster Vaccination)|In Second Booster Vaccination period, one dose of intramuscular (deltoid) injection of SARS-CoV-2 rS co-formulated with Matrix-M1 adjuvant (0.5 mL) on Day 0
223589619|NCT00626405|BIOLOGICAL|bevacizumab|Given IV over 30-90 minutes
223589620|NCT00626405|DRUG|carboplatin|Given IV over 30 minutes
223589621|NCT00626405|DRUG|paclitaxel albumin-stabilized nanoparticle formulation|Given IV over 30 minutes
223589622|NCT00626405|DRUG|temozolomide|Oral temozolomide on days 1-5
223589623|NCT02438345|BIOLOGICAL|PRO 140|Humanized monoclonal antibody to CCr5
223589624|NCT00934908|DIETARY_SUPPLEMENT|Green Tea|Green tea capsules taken twice a day.
224308925|NCT02421224|BEHAVIORAL|Large Individual Bonus|Each participant will receive a monetary bonus from the study investigators if he or she quit smoking, as verified by a urine cotinine test. The bonus is twice the value of that in the Small Individual Bonus group.
224308926|NCT02421224|BEHAVIORAL|Teammate|Each participant will be randomly assigned one teammate to provide social support during the quit attempt. Each participant will be assigned to a participating coworker who speaks the same primary language and works the same work shift as the participant.
224308927|NCT02421224|BEHAVIORAL|Team Bonus|If the participant and assigned teammate both quit smoking at 3 months, as verified by a urine cotinine test, then each will receive a monetary bonus. The team bonus is equal in value to that in the Large Individual Bonus group.
223496011|NCT06927076|DRUG|Placebo|administration of a placebo perfusion over 20 min
223496012|NCT06927076|PROCEDURE|Propofol|30 min propofol sedation
223496013|NCT06927076|PROCEDURE|no sedation|no sedation
223496014|NCT07124520|DEVICE|Iowa Oral Performance Instrument (IOPI)|The Iowa Oral Performance Instrument/IOPI is an instrument that objectively measures tongue strength using a standard-sized air-filled bulb. An individual presses the bulb against the roof of the mouth with the tongue to generate a pressure measurement in kilopascals (kPa). Maximum tongue strength can be determined using a measure of pressure.
223496015|NCT07124169|OTHER|Kinesiotape + home exercise|Kinesiotaping will be applied to the knee once weekly for 6 weeks. In addition, participants will perform a structured home exercise program three times per week, including strengthening, stretching, and balance exercises.
223496016|NCT07124169|OTHER|Home exercise|In addition, participants will perform a structured home exercise program three times per week, including strengthening, stretching, and balance exercises.
223496017|NCT05872126|PROCEDURE|VATS-Surgical pleurodesis|VATS drainage and surgical abrasion.
223496018|NCT05872126|PROCEDURE|Tube Drainage|Tube drainage for malignant pleural effusion
223496019|NCT07124884|DRUG|Administration of experimental treatment association (sotorasib, panitumumab 5FU)|Panitumumab is administered at a dose of 6 mg/kg via intravenous infusion over one hour during the first cycle, and over 30 minutes from the second cycle onward. The LV5FU2 regimen includes folinic acid (400 mg/m², or 200 mg/m² if levo-leucovorin is used) as a two-hour IV infusion, followed by a 5-FU bolus (400 mg/m² over 10 minutes), and a continuous 5-FU infusion (2400 mg/m² over 46 hours). Sotorasib is given orally at a dose of 960 mg once daily on a continuous basis.
223496020|NCT07124533|DRUG|Toothpaste Tablet|Denttabs toothpaste tablets
223496021|NCT07124533|DRUG|Conventional Toothpaste|Colgate Cavity Protection toothpaste
223496022|NCT00851487|DRUG|Amoxicillin|Oral Amoxicillin 15 mg/kg/dose 8 hourly
223496023|NCT00851487|DRUG|Placebo|The placebo was similar in colour, consistency and volume as oral amoxicillin
223496024|NCT07124572|OTHER|Imaging and ocular examinations|"2D and 3D Facial photography, blinking videos, orbital CT and MRI images, fundus images and images of nine gaze positions are taken.~Clinical information is recorded. Quality of life is assessed. Ocular examinations, such as visual acuity, levator function, exophthalmos measurement, strabismus test, visual field examination, axial length measurement, OCT, OCTA are made."
223496025|NCT07122596|DRUG|Meropenem Infusion|"Inclusion Criteria:~* 1 month to 16 years old~* Bacterial Infection (suspected or known) Admitted to PICU with suspected or known bacterial infection~* Prescribed intravenous meropenem~* Informed consent obtained from parent/guardian~Exclusion Criteria:~* Known allergy to carbapenems~* Severe renal impairment (eGFR \< 30 mL/min/1.73 m²)~* Use of other investigational antibiotics at the same time~* Prematurely Terminating the Treatment or Early Discharge Against Medical Advice Age Range: 1 month to 16 years old Gender: BOTH Sample Size (Number of participants): 150"
223496026|NCT07123857|DIAGNOSTIC_TEST|re-triage|Patients in the test group will be re-triaged into the orange MTS category.
223496027|NCT04524611|DRUG|Risankizumab|Intravenous (IV) Infusion
223496028|NCT04524611|DRUG|Risankizumab|Subcutaneous (SC) Injection
223496029|NCT04524611|DRUG|Ustekinumab|Intravenous (IV) infusion
223496030|NCT04524611|DRUG|Ustekinumab|Subcutaneous (SC) injection
223496031|NCT07081139|OTHER|observational study, no interventional|no interventions
223496032|NCT06901739|DIETARY_SUPPLEMENT|Synbiotic|The synbiotic supplement contains both tannins (350mg) and probiotic strains (Lactobacillus acidophilus, Lactobacillus casei, y Bifidobacterium lactis 2×10 9 UFC/g each) that have already demonstrated a positive health effect in obesity. Besides, participants will follow a dietary intervention to improve their dietary habits and reduce weight by a registered dietitian.
223496033|NCT06901739|DIETARY_SUPPLEMENT|Placebo|Subjects will recieve a placebo supplement, contained in an identical capsule form as the synbiotic, along with the same dietary intervention to improve their dietary habits and reduce weight by a registered dietitian.
223496034|NCT03043573|BEHAVIORAL|PATH-MCI|Problem Adaptation Therapy for Mild Cognitively Impaired Adults (PATH-MCI) differs from standard of care psychotherapy by offering a combination of emotion regulation techniques with the provision of environmental adaptation tools (notes, checklists, calendars, etc.), the use of the WellPATH app, and the participation of a willing and available caregiver.
223496035|NCT03043573|BEHAVIORAL|Supportive Therapy|ST focuses on: 1. facilitating expression of affect; 2. conveying to the patient that he or she is understood; 3. offering empathy; and 4. highlighting positive experiences. The ST manual aims to standardize nonspecific therapeutic factors.
223496036|NCT07084233|BEHAVIORAL|Mindfulness based, trauma informed, self-regulation skills training|"The study intervention, MMFT, consists of 7.5 hours of live, online courses, in three sessions, over three weeks. The entire intervention group (n=100) will participate in each session simultaneously, with four trainers and two translators.~Session 1 (3 hours): This session will introduce three mind fitness exercises. Session 2 (3 hours): This session will begin with mind fitness practice and discussion about participants' experience with the exercises during the previous two weeks.~Session 3 (1.5 hours): This session is for participants to integrate course content at an experiential level-no new content will be offered. The session will include some guided practice, but mostly focus on answering questions from participants and/or providing guidance to participants for how to navigate challenges with practice.~During the three weeks participants are in the course, they will be asked to practice the MMFT techniques for 5-60 minutes per day."
223589625|NCT00934908|OTHER|Placebo|"Non-active sugar pill."
224186997|NCT04186754|PROCEDURE|Traditional intervention without rehabilitation|Clinical control by nursing professionals and exclusively pharmacological treatment
224186998|NCT01126528|DIETARY_SUPPLEMENT|Vitamin D3|35,000 IU per week, started at 26-29 weeks gestation, until delivery.
224186999|NCT01126528|DIETARY_SUPPLEMENT|Placebo control|Miglyol 812, administered weekly from 26-29 weeks gestation until delivery.
223496037|NCT05291975|DEVICE|Erchonia® EVRL™|The Erchonia® EVRL™ is made up of (1) 635 nanometers red laser diode and (1) 405 nanometers violet laser diode mounted in a portable handheld device. The diodes are positioned approximately 3 to 6 inches from the top of the foot. The treatments will be self-administered by the subject at his or her's place of residence, two times per day for 21 days. Each procedure administration lasts 5 minutes per foot, for a total of 10 minutes.
223496038|NCT05291975|DEVICE|Placebo Laser|The Placebo Laser has the same appearance as the Erchonia® EVRL™ but does not emit any therapeutic light. The diodes are positioned approximately 3 to 6 inches from the top of the foot. The treatments will be self-administered by the subject at his or her's place of residence, two times per day for 21 days. Each procedure administration lasts 5 minutes per foot, for a total of 10 minutes.
223589626|NCT04487561|DEVICE|hemopatch|The patient will be randomized after performing the lymphadenectomy, according to a table of random numbers performed in excel kuytools, then a compression bandage will be performed on all the patients and it will be controlled 24 hours postoperatively, the subsequent control will be weekly until the drain is removed. and / or the disappearance of the seroma
223589627|NCT04487561|PROCEDURE|Aspirative drainage|The patient will be randomized after performing the lymphadenectomy, according to a table of random numbers performed in excel kuytools, then a compression bandage will be performed on all the patients and it will be controlled 24 hours postoperatively, the subsequent control will be weekly until the drain is removed. and / or the disappearance of the seroma
223589628|NCT02500446|DRUG|dolutegravir|Each film-coated tablet contains dolutegravir sodium equivalent to 50 mg dolutegravir.
223589629|NCT02500446|OTHER|Placebo|A film-coated tablet identical in appearance to the active drug tablet but not containing any dolutegravir or any other active ingredient
223589630|NCT03834220|DRUG|Debio 1347|Debio 1347 oral tablets.
224187000|NCT00639600|PROCEDURE|human pancreatic islet transplantation|human pancreatic islet transplantation
224187001|NCT02451137|DRUG|Insulin glargine, 300 U/ml|"Pharmaceutical form: solution~Route of administration: subcutaneous"
224187002|NCT02451137|DRUG|Insulin glargine, 100 U/ml|"Pharmaceutical form: solution~Route of administration: subcutaneous"
224187003|NCT02451137|DRUG|Insulin detemir|"Pharmaceutical form: solution~Route of administration: subcutaneous"
224187004|NCT02451137|DRUG|Background Therapy|Anti-diabetic drugs at investigator discretion and consistent with local labeling guidelines for use with insulin.
224187005|NCT03747497|DRUG|contezolid acefosamil|IV and oral contezolid acefosamil given twice a day for 10 to 14 days
224187006|NCT03747497|DRUG|linezolid 600 mg|IV and oral linezolid given twice a day for 10 to 14 days
224187007|NCT05277805|OTHER|EMPOWER-UP questionnaire|Participants are asked to respond to the EMPOWER-UP questionnaire to test the psychometric properties of the questionnaire.
224187008|NCT05794347|OTHER|Traction|Continuous mechanical traction will be applied to the lumbar area in 2 different positions.
223496039|NCT06387667|DIAGNOSTIC_TEST|Complete blood count|blood sample
224187009|NCT02834351|OTHER|Muscle Biopsy|"A distal and proximal biopsy of the sartorius muscles ( 0.5 cm3 each) will be performed during surgery for saphenous vein withdrawal (cardiac group) or arterial bypass (PAD group) The samples are then treated with neurovascular and mitochondrial biology laboratory.~the activity of the complex 1 is analyzed and compared between the 2 groups."
224187010|NCT03328962|BEHAVIORAL|Structured smoking cessation counselling based on motivational interviewing (MI) and adapted for the cancer setting eventually combined with provision of smoking cessation medication|structured smoking cessation counselling based on MI and adapted for the cancer setting eventually combined with provision of smoking cessation medication
223496040|NCT06387667|DIAGNOSTIC_TEST|C-reactive protein, urea, creatinine, Random blood glucose (RBG), aspartate aminotransferase (AST), alanine aminotransferase (ALT)|serum sample
223496041|NCT06387667|RADIATION|CT chest|Computed tomography of the chest
223496042|NCT06387667|DIAGNOSTIC_TEST|Microscopic examination|sputum and bronchoalveolar lavage (BAL)
223496043|NCT06387667|DIAGNOSTIC_TEST|culture and sensitivity|for bacterial and fungal
223496044|NCT05751668|DRUG|Paclitaxel|Given IV
223496045|NCT05751668|DRUG|Monosialotetrahexosylganglioside|Given IV
223496046|NCT05751668|OTHER|Questionnaire Administration|Ancillary Studies
223496047|NCT05751668|OTHER|Quality-of-life assessment|Ancillary Studies
223496048|NCT05751668|DRUG|Placebo Administration|Given IV
223589631|NCT01521377|DRUG|Placebo Moxifloxacin|Single dose placebo oral tablet Moxifloxacin
223589632|NCT01521377|DRUG|Moxifloxacin|Single oral dose tablet Moxifloxacin (400mg)
223589633|NCT01521377|DRUG|GSK573719/Vilanterol 125/25mcg|Single inhalation from GSK573719/Vilanterol 125/25mcg DPI once daily
223589634|NCT01521377|DRUG|GSK573719|Single inhalation from GSK573719 500mcg DPI once daily
223589635|NCT01521377|DRUG|GSK573719/Vilanterol 500/100mcg|Single inhalation from GSK573719/Vilanterol 500/100mcg DPI once daily
223589636|NCT01521377|DRUG|Placebo DPI|Single Inhalation from matching Placebo DPI once daily
224187011|NCT00000291|DRUG|Labetalol|
224187012|NCT06428929|OTHER|The musical and lighted baby crib mobile:|The musical and lighted baby crib mobile: It measures 43.5x33x9.5 cm and is made of plastic. It is recommended for use in infants 0-12 months. It has music that makes it easier for babies to fall asleep by reducing stress. This baby mobile has a projection and music function. In addition, the mobile has a 360° flexible swivel bracket that can be adjusted as desired. The surface of the apparatus of the mobile, which is designed to be environmentally and baby friendly, is smooth. There are four rattles on the mobile
224187013|NCT02983968|OTHER|Description of the cirrhosis management|
223496049|NCT07092267|DEVICE|ArtiFix® is a surgical dural sealant graft intended to close dural defects following cranial and spine surgeries.|ArtiFix® is a synthetic surgical dural sealant graft intended to close dural defects following cranial and spine surgeries. ArtiFix® adheres to the dura, so that sutures are not required to prevent cerebrospinal fluid (CSF) leakage.
224187014|NCT01977573|DRUG|GSK1278863|Film-coated tablets containing 0.5 mg, 1 mg, 2 mg, 5mg or matching placebo
224187015|NCT01977573|DRUG|rhEPO|Locally sourced rhEPO. All subjects who are randomized to the Control arm will receive rhEPO (epoetins or their biosimilars, or darbepoetin) as necessary per standard of care, to maintain Hgb levels within the target range. The decision around whether a subject requires rhEPO, selection of the type of rhEPO and rhEPO dose should be based on Investigator clinical judgment, with the historical rhEPO dose (where applicable) and the current Hgb value being considered..
224187016|NCT01385839|PROCEDURE|Hair transplantation|Hair transplantation is a procedure in which donor hair follicles are harvested from a section of a patient's scalp, and transplanted in another bald recipient area, at which time it will take root and continue to grow. Hairs generally continue to grow indefinitely.Hair transplant involves mild sedation with Valium, followed by local anesthesia of the donor and recipient areas. Donor hair is harvested using a scalpel to cut narrow strips of hair bearing areas. Follicular units are obtained by slicing the donor tissue into naturally occurring groupings. The follicular units are placed into holes made by a hypodermic needle in the alopecia areata affected areas of the subject. Grafts are held in place by coagulated blood. A bandage is applied after the procedure and left in place over night. The following day, the patient returns for follow up, bandage removal, cleansing, hair washing, and a check up.
224187017|NCT01385839|PROCEDURE|Hypodermic needle irritation|In the areas which are simply treated with irritation with the hypodermic needle, the procedure is the same, except no follicular units are placed into the holes.
224187018|NCT05507840|DEVICE|Valeda machine|Photobiomodulation treatment with Valeda machine will be applied every six months for 2 years in patients with dry age related macula degeneration.
224187019|NCT01106066|DRUG|Oxaliplatin, S-1, radiotherapy|Radiotherapy 4000cGy/20 fractions S-1 ( )mg/m2 po bid daily during radiotherapy Oxaliplatin at four dose levels (\_\_\_mg/m2 iv weekly x 4 weeks)
224187020|NCT04799821|OTHER|Control|Participants will be asked to refrain from walnut intake and to follow an isocaloric meal plan that complies with the recommendations of a healthy Mediterranean-style eating pattern.
224187021|NCT04799821|OTHER|Walnut intake|Participants will be asked to consume walnuts along with an isocaloric meal plan that complies with the recommendations of a healthy Mediterranean-style eating pattern.
224187022|NCT02094066|DRUG|tranexamic acid|preoperative ıv 50 mg/kg tranexamic acid infusion at 45 minutes
224187023|NCT02094066|DRUG|serum physiologic|preoperative 100 cc ıv serum physiologic
224187024|NCT04694079|PROCEDURE|Group 1, CMR-guided/aided VT ablation|"Ablation of the anatomical channels of heterogeneous tissue within the scar"
224187025|NCT04694079|PROCEDURE|Group 2, CMR-aided VT ablation|"Ablation of the electrical conduction channels within the scar"
224187026|NCT04694079|PROCEDURE|Group 3, Electroanatomical guided ablation|Ablation guided by an electro-anatomical system without the aid of CMR
224187027|NCT05539040|PROCEDURE|Right Atrial ganglionated plexus ablation|"A 3D electroanatomic map of the right atrium will be made. During sinus rhythm, the ablation catheter will be positioned at a spot to test with HFS. The right atrium will be paced at a fixed rate, for up to four beats to ensure that there is no ventricular capture then a short burst of HFS will be synchronized to each paced stimulus for up to 15 trains. This will be performed using a custom-built GP stimulator that has been validated for reproducibility against Grass Stimulator (AstroMed).~All Sites will be marked on the 3D map and the positive sites will be ablated at the end of the mapping. If the patient converts to AF, then DC cardioversion will be performed. If mapping in sinus rhythm is not feasible, HFS will be performed continuously for several seconds to identify atrioventricular dissociating GPs (AVD-GPs).~Every ablated GP site will be re-tested with HFS at the end of the procedure until they are all rendered non-functional."
224187028|NCT05539040|DIAGNOSTIC_TEST|Holter Monitor|"48 hour Holter monitors will be performed post procedure to monitor for recurrence of AF.~These will be performed at 3, 6, 9, 12 months"
224187029|NCT05539040|PROCEDURE|Pulmonary vein isolation|"Transseptal puncture for access into the left atrium will be guided by TOE and fluoroscopy.~ACT will be maintained at 300s with heparin. A 3D electroanatomic map of the left atrium will be created and all PVs will be identified. Touch-up radiofrequency ablation will be performed at electrical gaps around the reconnected PVs until complete PVI is achieved."
224187030|NCT05539040|PROCEDURE|Right cavo-tricuspid and left roof linear ablation|CONTROL ARM (Redo-PVI) only: If all Pulmonary veins are isolated at the start of the procedure, the operator will be allowed to perform a right cavo-tricuspid and left roof linear ablation.
223511862|NCT01515254|BEHAVIORAL|lifestyle counseling, parental feeding|Intervention group subjects will undergo a Feeding Dynamic Intervention (FDI). The intervention will be delivered in a closed group setting and will consist of 6 intervention sessions lasting 90 minutes each. Visits to physicians, WIC offices, nutrition program etc will be tracked. The subjects will undergo the energy regulation tests at baseline and 3 months. They will complete surveys and have their weight taken.
223511863|NCT00404300|DRUG|Optivate|Plasma-derived Factor VIII
223745776|NCT06332846|OTHER|oral examination|The oral health was assessed in each patient enrolled in the study. The examination was performed by using dental mirror and a calibrated periodontal probe in a day ight
223511864|NCT04985682|BIOLOGICAL|ADVATE|Antihemophilic factor (AHF) activity expressed in international units (IU) per vial.
223511865|NCT01694186|DRUG|FAI insert|
223511866|NCT01694186|DRUG|Sham injection|
223511867|NCT00501943|DRUG|Avonex (Interferon beta 1a)|
223511868|NCT00501943|DRUG|Riluzole|
223511869|NCT00501943|DRUG|Placebo|
223511870|NCT02134808|DRUG|Creatine|Creatine is a nutritional supplement.
223511871|NCT02134808|DRUG|Placebo|The placebo is an inactive ingredient similar in appearance, weight and density to the active treatment.
223496050|NCT07097584|DEVICE|Selecting the size of a Left Double-lumen endobronchialtube one size smaller than the traditional method|During tracheal intubation，choose a Left Double-lumen Endobronchial Tubethat is one size smaller than the traditional method.In this study, all patients planned to be enrolled are female. In experimental group the relationship between height and size is roughly as follows: For patients with a height between 152 - 165 cm, a 32Fr (French) tube is often selected. For patients with a height between 165 - 177 cm, a 35Fr tube is often selected. For patients with a height of more than 177 cm, a 37Fr tube is often selected.
223589637|NCT02593318|DRUG|Oxaloacetate (OAA) 1g|Pills to be taken orally in 500mg dose two times per day
224187031|NCT05539040|DIAGNOSTIC_TEST|Personal ECG recordings|All patients will be provided with an AliveCor KardiaMobile-6L ECG recorder. The device will continue to be used within its CE-marked and NICE-approved purpose. Patients will be asked to take a daily recording from this, once the blanking period is over, in addition to taking a recording if symptomatic. Patients will submit this to the connected care team at Hammersmith Hospital via a secure NHS.net email address, who will assess the recordings both for the study and clinical purposes.
223496051|NCT07097584|DEVICE|Selecting the size of a Left Double-lumen endobronchialtube according to traditional methods|"During tracheal intubation，choose the regular Left Double-lumen endobronchial tube according to the traditional method. The selection of double-lumen tube sizes using traditional methods relies on two factors: height and gender. In this study, all patients planned to be enrolled are female, so the traditional corresponding relationship is roughly as follows:~For patients with a height of less than 152 cm, a 32Fr (French) tube is often selected.~For patients with a height between 152 - 165 cm, a 35Fr tube is often selected. For patients with a height between 165 - 177 cm, a 37Fr tube is often selected. For patients with a height of more than 177 cm, a 39Fr tube is often selected."
224187032|NCT05539040|OTHER|Quality of life questionnaire|A Quality of life questionnaire will be performed at baseline, 6 and 12 months to assess the effect of the procedures on patients quality of life.
224187033|NCT02505789|OTHER|Determining the source of EBV in severe EBV infections|Blood units administered to patients with severe EBV infection will be traced back to the donors who in turn (with consent) will be serologically assessed for EBV, and all seropositive donors will have their EBV strain genotyped for comparison to the patient's strain.
224187034|NCT05529030|BEHAVIORAL|Salience of Omicron variant|The message mentions the Omicron variant, which can be a fear appeal or make salient the reason for the new booster
224187035|NCT05529030|BEHAVIORAL|Self-protection message|The message makes a reference to protecting one's self
224187036|NCT05529030|BEHAVIORAL|Other-protection message|The message makes a reference to protecting others (patients)
224187037|NCT04924608|DRUG|Selumetinib|Selumetinib oral capsules (10 mg and 25 mg)
224187038|NCT04924608|OTHER|Placebo|Placebo oral capsules for Selumetinib masking (10 mg and 25 mg)
223496052|NCT07090759|DRUG|GST-HG141|GST-HG141 50 mg BID
223496053|NCT07090759|DRUG|GST-HG141 Placebo|GST-HG141 Placebo BID
223496054|NCT07096830|DRUG|Topical Tetrachlorodecaoxide (TCDO/Oxoferin)|Topical Tetrachlorodecaoxide (TCDO), a solution with antimicrobial and oxygen-releasing properties, will be applied once daily to the wound bed for 21 consecutive days or until satisfactory healing.
223496055|NCT07096830|OTHER|Standard Wound Care|Standard wound care includes saline irrigation, wound debridement, antibiotic administration as necessary, and sterile dressing. Provided to all participants.
223496056|NCT06907953|OTHER|Observational - no intervention|Pilot, observational study - no intervention
223496057|NCT07091747|OTHER|Cannabis 50 mg of CBD and 5 mg of THC|Cannabis 50 mg of CBD and 5 mg of THC
223496058|NCT07093008|DRUG|AQ280 Capsule|AQ280 administered orally in capsule formulation.
223589638|NCT02593318|DRUG|Oxaloacetate (OAA) 2g|Pills to be taken orally in 1000mg dose two times per day.
223589639|NCT06262217|DEVICE|Mobile MRI scanner|Use of mobile MRI scanner in patients with suspected or confirmed acute stroke (including Transient Ischaemic attacks)
223589640|NCT02020408|DRUG|[11C]raclopride|1.\[11C\]raclopride -The change (Δ) in BPND (the difference between the \[11C\]raclopride BPND at baseline and post-AMPH treatment normalized to the baseline BPND
223589641|NCT02020408|DRUG|[11C]DASB|BPND of \[11C\]DASB.
223589642|NCT02020408|DRUG|amphetamine|The change (Δ) in BPND (the difference between the \[11C\]raclopride BPND at baseline and post-AMPH treatment normalized to the baseline BPND.
223589643|NCT03207802|DEVICE|Discontinuation of using device|Subject will be instructed to discontinuation of use of device
223589644|NCT02107157|DEVICE|755nm Laser with Cap Array|
223589645|NCT03262467|PROCEDURE|Aneurysmorrhaphy with or without external porous prosthesis (Provena©, BBraun)|In patients with aneurysm of native vascular access indicated for surgical treatment, aneurysmorrhaphy with or without external porous prosthesis (Provena©, BBraun) wil be performed.
223589646|NCT00156871|BEHAVIORAL|exercise|
223589647|NCT03688568|DRUG|Imatinib Mesylate|Imatinib given orally as dose escalation treatment.
223589648|NCT03878303|DRUG|AC0058TA|25 mg capsules
223589649|NCT03878303|DRUG|Placebo AC0058TA|equivalent dose of investigational product
223589650|NCT02868658|BIOLOGICAL|Blood sampling|
223745777|NCT06332846|OTHER|oral examination|The oral health was assessed in each patient enrolled in the study. The examination was performed by using dental mirror and a calibrated periodontal probe in the artificial lightning
224187039|NCT06165159|OTHER|children and adolescents with type 1 diabetes and their parents|"Children over the age of 8 with type 1 diabetes diagnosed more than 6 months ago in France, followed in one of the hospitals that are members of the Aide aux Jeunes Diabétiques (AJD) association.~Parents or people involved in the day-to-day life of children with type 1 diabetes diagnosed at least 6 months ago, whose child is being followed in France in one of the hospitals affiliated to the AJD association."
224187040|NCT00021554|DRUG|Enfuvirtide|
224187041|NCT05729035|RADIATION|POCUS|Point of Care Ultrasound is complementary to a medical examination performed by primary care physicians
223589651|NCT02868658|OTHER|Nasal swab|
223589652|NCT05498467|DRUG|Anakinra|100 mg Anakinra injections s.c.
223589653|NCT05498467|DRUG|Sodium Chloride 9mg/ml Injection|9 mg Sodium Chloride injections s.c.
224187042|NCT03606473|DRUG|d-amphetamine|is used to stimulate dopamine release in the brain
224187043|NCT03606473|RADIATION|[C-11]NPA|PET radiotracer
223496059|NCT07093008|DRUG|AQ280 Tablet for Oral Suspension|AQ280 administered orally in tablet for oral suspension formulation.
223496060|NCT07093008|DRUG|Placebo Capsule|Placebo administered orally in capsule formulation.
223496061|NCT07093008|DRUG|Placebo Tablet for Oral Suspension|Placebo administered orally in tablet for oral suspension formulation.
223496062|NCT07094425|DIAGNOSTIC_TEST|transthoracic echocardiography|"Transthoracic echocardiography (TTE) is a non-invasive method for assessing cardiac morphology and function. As part of the study protocol, TTE will be performed at the time of study inclusion (within the first 24 hours after ICU admission), on day 3, day 7, and day 14, followed by weekly assessments (until discharge from the ICU), as well as on the day of planned ICU or hospital discharge.~To verify skeletal muscle mass in relation to myocardial mass and its changes over the course of the ICU stay, bioelectrical impedance analysis (BIA) will be performed at the time points mentioned above."
223496063|NCT05609344|BEHAVIORAL|SBIRT|Low risk individuals will receive an educational pamphlet about alcohol use and the impact on health. Moderate Risk individuals will receive a brief alcohol intervention. High risk individuals will receive the brief alcohol intervention and be referred to specialty treatment.
223496064|NCT07095452|DRUG|Etentamig|Intravenous (IV) Infusion
223496065|NCT07095452|DRUG|Lenalidomide|Oral Capsule
223496066|NCT07095452|DRUG|Daratumumab|Subcutaneous Injection
223496067|NCT07095452|DRUG|Dexamethasone|Oral Tablet
223496068|NCT07095452|DRUG|Dexamethasone|IV Injection
223496069|NCT07103122|OTHER|Experimental Group|A Personalized Adaptive Mirror Therapy for Upper-Limb Post-Stroke Rehabilitation using Virtual Reality and Myoelectric Control for 24 sesion in 8 weeks in add on to standard therapy.
223496070|NCT07103122|OTHER|Control Group|Conventional Therapy
223496071|NCT07103603|DRUG|Menopausal hormone therapy|Menopausal hormone therapy including oral or transdermal estrogen, with or without progestin, administered based on clinical indications.
223496072|NCT07103200|BEHAVIORAL|COGED|The COGED task consists of the classic N-back task of working memory-based decision making, followed by a valuation phase. The N-back phase of the task allows calculation of cognitive performance of a working memory task. During valuation, participants receive titrating offers of differing amounts of money to perform different difficulty levels of the N-back. The result is an effort discounting curve used to measure the individual effort cost. Effort discounting curves show the perceived cognitive effort required to complete each level of the task relative to another (typically the 1-back).
223496073|NCT07103200|BEHAVIORAL|Restless Bandit|"Participants are presented with three targets (decks of cards) on the screen, which they select with a mouse movement. Each of the three targets is associated with a hidden probability of reward, which drifts unpredictably and independently across trials. This encourages participants to exploit good options when they are available, but also occasionally to explore other targets, which could become better at any time. Eye Tracking is done at each visit while the participant completes the Restless Bandit tasks."
223496074|NCT07104227|BEHAVIORAL|body mechanics training|"Randomization: The Demographic and Health Data Form will be applied to the participants by the researcher responsible for randomization, and the information obtained will be kept in consecutively numbered, closed, opaque envelopes. The block randomization method will be used when dividing the participants into intervention and control groups. In order to ensure balance in important demographic and health-related variables, the participants will be randomized by stratifying them according to age. The person responsible for collecting the study data will be unaware of the randomization process until the researcher responsible for randomization reports the results. Intervention group: After the initial data collection, the breastfeeding behaviors of the mothers in the intervention group will be observed. Then, the mothers will be given training on ergonomic breastfeeding, correct breastfeeding positions and body mechanics to strengthen the musculoskeletal system during the breas"
223496075|NCT07104227|OTHER|to inform|Kontrol grubundaki anneler, hastanenin rutin bakım hizmetleri kapsamında emzirme danışmanı ebe tarafından verilen bilgilendirme ve destek hizmetlerinden yararlanacaklardır. Ayrıca bu anneler için emzirme döneminde doğru duruş ve emzirme pozisyonlarında dikkat edilmesi gereken durumlar konusunda bir broşür hazırlanacak ve kendilerine verilecektir. Kontrol grubunun izlem verilerinin telefon görüşmesi yöntemi ile toplanacağı belirtilerek bir görüşme-izlem planı anne ile birlikte oluşturulacaktır. Kontrol grubundaki anneler müdahale grubu ile eşzamanlı olarak doğum sonu 6. Hafta ve 3.aylarda aranarak sırt ve boyun ağrıları değerlendirilecektir.
223496076|NCT07104487|DRUG|[18F]AlF-OC|Participants received a single intravenous (IV) bolus injection of 4 MBq/kg \[¹⁸F\]AlF-OC (Al¹⁸F-1,4,7-triazacyclononane-1,4,7-triacetate-octreotide), followed by a flush with 0.9% NaCl.
223496077|NCT07106034|DRUG|Ongericimab + Toripalimab + Bevacizumab + FOLFOX|Ongericimab, Toripalimab, Bevacizumab, Oxaliplatin, Calcium folinate, 5-FU, Q2W
223496078|NCT07106034|DRUG|Ongericimab + Toripalimab + Bevacizumab + FOLFIRI|Ongericimab, Toripalimab, Bevacizumab, Irinotecan, Calcium folinate, 5-FU, Q2W
223496079|NCT07105917|DRUG|SGLT-2 inhibitors|"Any of the following SGLT2 inhibitors (SGLT2i) can be selected for treatment:~Dapagliflozin 10 mg once daily (QD) or Empagliflozin 10 mg once daily (QD) If the patient has concurrent diabetes, the use of other antidiabetic drugs is not restricted.~The treatment should last for at least 14 days."
223496080|NCT07105917|OTHER|Standard medical treatment|According to the guideline-recommended standard treatment, if the patient has diabetes, there is no restriction on the use of other antidiabetic drugs (except SGLT-2 inhibitors).
223496081|NCT06589934|DIAGNOSTIC_TEST|Precise Image|Image reconstruction software
223589654|NCT02635997|DRUG|antiresorptive therapy|
223589655|NCT02343705|DEVICE|Latella Knee Implant System|
223589656|NCT00199823|GENETIC|Intracoronary aotologous stem cell transplantation|
223589657|NCT03883087|DRUG|HQP1351|40 mg tablet, taken orally once every other day of a 28-day cycle
224187044|NCT02760680|DEVICE|WatchPAT 200 (TM)|The WatchPAT 200 (TM) is a wrist worn diagnostic device for detecting SDB. Its main part is the measurement of the peripheral arterial tone (PAT) via a plethysmographic based finger-mounted probe. It can measure the level of sympathetic activation of the autonomic nervous system. Pulse rate, oxygen saturation and snoring/body position levels are calculated, too. A software program (zzzPAT (TM)) with a special algorithm analyzes the raw data and creates a sleep report. Therefore the property of the WatchPAT 200 (TM) proclaims that the WatchPAT 200 (TM) can detect sleep events and SDB.
224187045|NCT02760680|OTHER|Polysomnography|"The PSG is known as the Gold Standard for detecting SDB: experienced sleep physicians and technicians score events (apnea/hypopnea) using current AASM Guidelines."
224187046|NCT03157804|PROCEDURE|IV administration of Genetically Engineered Hematopoietic Stem/Progenitors Cells (HSPCs)|
224187047|NCT03157804|BIOLOGICAL|Genetically Engineered Hematopoietic Stem/Progenitor Cells|Undergo infusion of genetically modified hematopoietic progenitor cell therapy
224308928|NCT05969249|DEVICE|Upper limb in vibration training|"The stroke subjects were all involved in the training,wear upper and lower extremity vibrators,the posture for intervention is hemiplegic upper limbs with shoulder joints slightly bent and abducted at 45 degrees, with elbows bent at 90 degrees and wrists centered. The elbow angle of this posture is set by the elbow joint rotation axis of the upper limb vibrator.~The set angle is the movable angle range of 80-110 degrees of elbow bending. The vibration rehabilitation password accepted by all subjects is Try to keep the elbow joint bent at 90 degrees during the vibration process, Resist the force of the vibration and try not to move."
224308929|NCT04821700|BIOLOGICAL|Carotid Stenosis|To investigate if the concurrent presence of carotid stenosis has any effect on future outcomes of patients with ischemic stroke and atrial fibrillation
224308930|NCT01683292|DRUG|Inhaled VR040|
224308931|NCT01683292|DRUG|Placebo for VR040|Placebo arm
224308932|NCT00916760|BIOLOGICAL|Depigoid Parietaria judaica 1000DPP/ml|Subcutaneous monthly treatment
224308933|NCT00916760|BIOLOGICAL|Placebo|Subcutaneous monthly treatment
224308934|NCT04876365|OTHER|Non-Interventional|This is a Non-Interventional Study.
224308935|NCT02538380|PROCEDURE|EUS-B-FNA followed by EUS-FNA for LAG analysis|
223496082|NCT07100821|DIAGNOSTIC_TEST|Hemodynamic parameters was measured by using electric cardiometry (ICON)|Hemodynamic parameters was measured daily at 10 a.m by using ICON non-invasive cardiometer model C3 made in Germany by OSYPKA medical (figure 5) by placing the four sensors on the neck and left side of the thorax allow for the continuous measurement of the changes of electrical conductivity within the thorax parameters such as CO, TFC, SVV and FTC were calculated 3 times with 5-min intervals and stored on the device automatically.
223496083|NCT07105137|BEHAVIORAL|AI-GNW|This is a three-day writing intervention. Each session lasts 20 minutes. On the first day, participants in both GNW conditions will recount a negative experience and reflect on their thoughts and feelings; on the second day, they will focus exclusively on the negative aspects of that experience; and on the third day, they will explore its positive dimensions. AI-GNW participants would receive AI-generated feedback.
223496084|NCT07105137|BEHAVIORAL|NF-GNW|guided narrative writing without feedbacks
223496085|NCT07105137|BEHAVIORAL|NWG|In contrast, NWG participants will objectively document their previous day's daily routine.
223496086|NCT07103187|PROCEDURE|Zygomatico-Orbital reconstruction|Zygomatico-Orbital reconstruction was done by ORIF for the zygomatic complex fractures at multiple suture lines by mini plates and screws. Orbital floor reconstruction was done mainly by using a prebent titanium mesh on a 3D printed model.
223496087|NCT07108361|PROCEDURE|Osseodensification|Septum width will be directly measured post molar extraction confirming the premeasure of the CBCT. Measurement will be recorded at the narrowest width of the septum. Implant site preparation starts with a pilot drill, in clockwise motion, in the center of the septum, until 1 mm deeper than the planned implant length. Densah® Burs (Versah, LLC, Jackson, MI, USA) were then sequentially used in OD mode (counterclockwise, drilling speed 800-1500 rpm, with copious irrigation) in small increments to gradually expand the osteotomy, until reaching the desired width for the planned implant diameter, Osteotomy diameter as a reflection of septum width expansion will then be directly measured and recorded after site instrumentation. Implants of adequate diameter (4, 4.5, or 5mm) and length (selected using preoperative CBCT) will be inserted in the prepared osteotomies to engage the bone apical to the socket, insertion torque will be measured using the torque wrench and ISQ values
223496088|NCT07108361|PROCEDURE|conventional drilling|Septum width will be directly measured post molar extraction confirming the premeasure of the CBCT. Measurement will be recorded at the narrowest width of the septum. The initial (pointed) drill will be used to make a hole (starting point) in the interradicular bone to avoid slippage of the subsequent the drills in the socket of the remaining roots. The drills of increasing diameters will be used to complete the implant osteotomy according to manufacturer instructions. In case of limited interradicular bone volume, drilling will be made at the socket of mesial or distal roots. Osteotomy diameter as a reflection of septum width expansion will then be directly measured and recorded after site instrumentation. Implants of adequate diameter (4, 4.5, or 5mm) and length (selected using preoperative CBCT) will be inserted in the prepared osteotomies to engage the bone apical to the socket insertion torque will be measured using the torque wrench and ISQ values
223496089|NCT07104812|DRUG|Osilodrostat 1 MG|Osilodrostat 1 mg administered between noon and 6 pm daily, for 4 weeks
223589658|NCT01311440|OTHER|Modified Atkins diet treatment|Eat a diet containing 16 grams of carbohydrates per day, maximize on fat. Assure sufficient intake of micronutrients.
223589659|NCT00002077|DRUG|Fluconazole|
223617806|NCT00666666|DRUG|AT-101|AT101 will be administered orally 20 mg/day for 21 days of a 28 day cycle.
224187048|NCT03157804|OTHER|Laboratory Biomarker Analysis|Correlative studies
224187049|NCT03157804|BIOLOGICAL|Filgrastim|Given subcutaneously (SC)
224187050|NCT03157804|DRUG|Plerixafor|Given SC
224187051|NCT03157804|PROCEDURE|Bone Marrow Aspiration|
224187052|NCT05138458|BIOLOGICAL|MT-101|CD5 ATAK cells
224308936|NCT00735618|OTHER|Guided Relaxation|Following 5 minute questionnaire, 15 minute rest and 5 minute heart rhythm recording, 15 minute relaxation program (listening via headphone to audio recording) to be completed by second heart rhythm recording and same questionnaire. Entire procedure 45-60 minutes.
223589660|NCT05440214|BEHAVIORAL|Dialectical Behavior Therapy Skills Training|Dialectical Behavior Therapy Skills Training (DBT-ST) is a group-based intervention focused on teaching skills for improving emotion regulation. The sessions will be offered in-person or via approved telehealth services.
223589661|NCT03576859|OTHER|blood sample|Peripheral venous blood is collected before liver transplantation and after restoration of liver function
223589662|NCT04055779|OTHER|estimation method for arterial occlusion pressure|The patients will receive induced hypotensive anaesthesia and the tourniquet pressure will be based on the AOP.the tourniquet pressure will be determined based on the AOP which will be determined by the estimation formula (AOP=\[SBP+10\]/KTP) . The calculation is based on using initial SBP and tissue padding coefficient values , according to limb circumferences of the patient.After calculation of AOP, tourniquet pressures will be determined by adding a safety margin of 20 mmHg to AOP values(tourniquet pressure=AOP+20 mmHg).
223589663|NCT04055779|OTHER|the limb occlusion pressure|: using the ultrasound Doppler technique and the tourniquet will be inflated until the arterial pulsations disappear at the side of the operation. This pressure will be recorded as LOP.using the ultrasound Doppler technique and the tourniquet will be inflated until the arterial pulsations disappear at the side of the operation. This pressure will be recorded as LOP .the tourniquet cuff will be inflated to the pressure according to theguidelines of the Association of Perioperative Registered Nurses(AORN) which recommends that a safety margin of 40 mmHg should be added for AOP below 130 mmHg, 60 mmHg for AOP between 131 mmHg and 190 mmHg, and 80 mmHg for AOP above 190 mmHg for adult patients
223589664|NCT03130036|OTHER|[11C]Acetoacetate[18F]Fluorodeoxyglucose positron emission tomography scan|A PET scan to measure uptake of acetoacetate and glucose in the brain will be administered to all participants enrolled in the study
223589665|NCT01445197|BIOLOGICAL|Biostate|200 IU/kg administered daily
223589666|NCT02720692|DRUG|N1539|
223589667|NCT02720692|DRUG|Intravenous Placebo|
223589668|NCT05011513|DRUG|PF-07321332|PF-07321332 (tablet)
224187053|NCT05138458|OTHER|MT-101 + Conditioning (Lymphodepleting) Chemotherapy|IV administration of fludarabine and cyclophosphamide
224187054|NCT00636402|PROCEDURE|Cold Knife Tonsillectomy|Cold Knife Tonsillectomy (CKT) will be done on the other side.
224187055|NCT00636402|PROCEDURE|Vessel Sealing System Tonsillectomy|Intervention by Vessel Sealing System Tonsillectomy (VSST) will be randomized and will be performed on one side.
224187056|NCT04717310|DRUG|SHR0302 Ointment|SHR0302 Ointment Twice a day (BID)
224187057|NCT04717310|DRUG|SHR0302 Ointment|SHR0302 Ointment Twice a day (BID)
223496090|NCT07102771|PROCEDURE|Ultrasound guided erector spinae plane block|ESP block is most often performed using an in-plane ultrasound-guided technique. It is a paraspinal fascial plane block in which the needle placement is between the erector spinae muscle and the thoracic transverse processes, and a local anesthetic is administered, blocking the dorsal and ventral rami of the thoracic and abdominal spinal nerves
223496091|NCT07109713|DIETARY_SUPPLEMENT|Active|Cranberry Beverage
223496092|NCT07109713|DIETARY_SUPPLEMENT|Placebo|Placebo Beverage
224187058|NCT04717310|DRUG|SHR0302 Ointment|SHR0302 Ointment Twice a day (BID)
224187059|NCT04717310|DRUG|Vehicle|Twice a day (BID)
223496093|NCT07110896|DIETARY_SUPPLEMENT|Humiome Post LB (Postbiotic)|Heat-inactivated lactobacilli with fermented medium (a postbiotic) in 340mg powder format
223496094|NCT07110896|DIETARY_SUPPLEMENT|Placebo|Microcrystalline cellulose, 340mg powder format
223496095|NCT07113639|PROCEDURE|Injection|US-guided subacromial-subdeltoid injection with 1 mL triamcinolone acetonide (40 mg), 1 mL 2% lidocaine, and 8 mL normal saline (10 mL total)
223496096|NCT07113639|PROCEDURE|Injection|US-guided subacromial-subdeltoid injection with 1 mL triamcinolone acetonide (40 mg), 1 mL 2% lidocaine, and 1 mL normal saline (3 mL total)
223496097|NCT07115914|RADIATION|PSMA PET/CT scan|A PSMA PET scan, or prostate-specific membrane antigen positron emission tomography scan, is an imaging test that scans and takes pictures of the prostate. PSMA scans use a specialized radioactive imaging dye that sticks to the proteins that are typically found in prostate cancer cells. This imaging dye helps locate areas of prostate cancer anywhere in the body, both inside and outside prostate.
223589669|NCT05011513|DRUG|Ritonavir|Ritonavir (capsule)
223589670|NCT05011513|DRUG|Placebo|Placebo (tablet)
223589671|NCT05011513|DRUG|Placebo|Placebo (capsule)
223589672|NCT00582777|BEHAVIORAL|USUAL - take your BP Meds as you usually do|The patient's antihypertensive regimen at the baseline visit is the comparison (or control) regimen. All once a day medications will be administered in the morning.
224187060|NCT05723406|DRUG|Sugammadex 100 MG/ML [Bridion]|8 mg/ml
224187061|NCT05723406|OTHER|Placebo|Sodium 0.9% 5 ml
224187062|NCT05848518|OTHER|Rehabilitation program|The participants will be randomly assigned to the experimental groups: supervised endurance rehabilitation program (SEG, n = 30), supervised strength rehabilitation program (SSG, n = 30), supervised concurrent rehabilitation program (SCG, n = 30), and control group (CG, n = 30)
224187063|NCT05245266|DIAGNOSTIC_TEST|Redraw for analysis of blood samples from healthy pregnant women|If less than two fetal cells are recovered from maternal blood, a redraw is indicated
224187064|NCT03445936|DEVICE|Parietene Macro|Parietene Macro is placed and sutured on retro muscular space on closed posterior rectus sheath to prevent incisional hernia.
224187065|NCT03445936|DEVICE|Permacol|Permacol biologic implant is placed and sutured on retro muscular space on closed posterior rectus sheath to prevent incisional hernia.
224187066|NCT05725642|OTHER|Polysomnography|Polysomnography
224187067|NCT02501642|BEHAVIORAL|Concussion Coach|smart phone app with educational material on postconcussion symptoms and behavioral self-monitoring/strategies
224187068|NCT02501642|OTHER|Treatment as usual|Treatment as usual
224187069|NCT01451177|BIOLOGICAL|Autologous cultured dermal and epidermal cells|A piece of occipital scalp, plucked of hairs prior to excision, is taken from the subject. The epidermal and dermal cells from this tissue are expanded in culture. The cells are then harvested and, for certain types of product, combined. The cells are then injected into the balding area of the scalp of the original subject.
224187070|NCT05098678|DIETARY_SUPPLEMENT|Zinc gluconate|120 mg each tablet containing 30 mg elemental zinc
224187071|NCT05098678|DIETARY_SUPPLEMENT|Placebo|Placebo (microcrystalline cellulose): 1 tablet (120 mg each)
224187072|NCT02900131|DRUG|Jaungo|Participants in trial group 1 will apply Jaungo and placebo to the lesion once a day for three weeks. Participants in trial group 2 will apply Jaungo to the lesion twice a day for three weeks.
224187073|NCT02900131|DRUG|Placebo|Participants in trial group 1 will apply Jaungo and placebo to the lesion once a day for three weeks. Participants in control group will apply placebo to the lesion twice a day for three weeks.
224187074|NCT05241574|RADIATION|Radiotherapy boost|Additional endorectal high rate irydium brachytherapy boost, 2 fractions of 10 Gy each.
224187075|NCT05241574|DRUG|Additional consolidation chemotherapy|Three additional cycles of 5-fluorouracil, leucovorin and oxaliplatin (FOLFOX4) consolidation chemotherapy
224187076|NCT04456062|OTHER|Caring Contacts|Caring Contacts are brief email communications sent to the patient post-discharge. They convey messages of hope, support, promote a sense of belonging, and provide information on resources for care. They are not written uniquely for each patient but are purposefully crafted to intervene on those specific vulnerabilities that form the core of many patients' experiences with intense emotional distress and suicidal thoughts.
224187077|NCT00774774|DEVICE|control|"Non sterile surgical mask,high filtration AEROKYN,type 2 with eardrop"
224187078|NCT00774774|DEVICE|Face mask|"Non sterile surgical mask, high filtration AEROKYN, type 2 with eardrop Masks will be worn at home by the patient over a period of 5 days following inclusion, whenever a member of the household will attend the same room or in other confined space (eg car), and changed after 3 hours of consecutive use or sooner if they are tor~Masks will not be worn:~* during the night,~* when the patient is alone in the room. Moreover, for all households, an incentive in nocturnal isolation of index-patient will be recommended"
224187079|NCT00564473|BEHAVIORAL|questionnaire|"* questionnaire of demographic and medical data, use of and attituded toward herbal medicine.~* Beck Depression Inventory-Second Edition (BDI-II)- Hebrew Translation"
224187080|NCT00548340|DRUG|VEC-162 20 mg|20 mg VEC-162 (tasimelteon) capsules, PO daily for five weeks
224187081|NCT00548340|DRUG|Placebo|Placebo capsules, PO daily for five weeks
223496098|NCT07115563|DIETARY_SUPPLEMENT|Targeted Amino Acid Supplement|Blend of the essential amino acids (Leucine \& Tryptophan), a conditionally essential amino acids (Arginine \& Taurine), and non-essential amino acids (Glutamate \& Tyrosine) designed to meet the unique nutritional needs of people with Parkinson's disease (PD).
223496099|NCT07115563|DIETARY_SUPPLEMENT|Control (placebo)|The inert amino acid (alanine) will serve as an isonitrogenous control.
223496100|NCT07114744|OTHER|Take home tests|"These tests will test the discriminability of sounds that vary systematically along the frequency and temporal dimensions of sound. Over the course of the 3 months post-activation, subjects will self-complete take-home tests at location of their choosing. Each test session will include the entire test-battery will be repeated frequency as often as every day and then reducing frequency of testing corresponding to the rate of speech perception improvement."
223496101|NCT07116031|DRUG|Belumosudil|Pharmaceutical form:Oral suspension -Route of administration:Oral or nasogastric tube
223496102|NCT07116031|DRUG|Belumosudil|Pharmaceutical form:Tablet formulation-Route of administration:Oral
223496103|NCT07114406|DRUG|PBK_M2502 1-Day|Subjects who are randomized into group test 2 will receive bowel preparation on the same-day.
224187082|NCT00548340|DRUG|VEC-162 50 mg|50 mg VEC-162 (tasimelteon) capsules, PO daily for five weeks
224187083|NCT03110367|BEHAVIORAL|Pain Reframing Intervention|Parents and youth in the intervention group will receive instructions about adaptive ways of reminiscing about the in-hospital and post-surgery periods. The intervention will draw from existing narrative-based interventions that have taught parents to reminisce with their children about past negative events in more elaborative and emotion-rich ways (e.g., using more open-ended questions, to follow in on children's answers by providing new details about the event, to talk more about emotions, and to praise children's answers).
223496104|NCT07114406|DRUG|PBK_M2502 2-Day|Subjects who are randomized into group test 1 will receive bowel preparation from evening to next morning.
224187084|NCT03110367|BEHAVIORAL|Attention Control Group|Parents and youth in the attention control group will watch a neutral 20-minute video that is not related to surgery (Planet Earth). Importantly, they will not talk about pain or the past surgery experience.
224187085|NCT03128801|PROCEDURE|Global Stretching Program|Participants will be submitted to a GSP in self-management postures weekly for 40 minutes session conducted by one one physical therapist, certified to use the technique (Stretching Global Active). The GSP will last for a period of 8 weeks. The protocol is based on the study of Lawand et al (2015) who used all postures global therapeutic stretching. The investigators will use six self-management postures in a standardized manner, each of which will last for 10 to 20 minutes.
224187086|NCT03128801|PROCEDURE|Stabilization Exercises|The exercise protocol and criteria to increase exercise progression was previously described by Hicks et al (2005). It will be directed by a single therapist one to one session based on specific criteria (being able to maintain muscle contraction eight seconds during 30 repetitions in bilateral exercises or during 20 repetitions for unilateral exercises). Each session will be conducted weekly for 40 minutes.
223496105|NCT07115342|DRUG|Standard Allergic Rhinitis Treatment|Participants will receive standard-of-care treatment for allergic rhinitis, including oral antihistamines and/or intranasal corticosteroids, according to current clinical guidelines. No additional supplementation will be provided in the control group. This arm serves as the comparator for evaluating the effects of probiotic and vitamin D supplementation
223496106|NCT07115342|DIETARY_SUPPLEMENT|Combined Vitamin D and Probiotics Supplementation|Participants in this group will receive a combination therapy of Vitamin D3 plus a daily oral probiotic capsule containing a standardized blend of Lactobacillus and Bifidobacterium species. Both supplements will be administered once daily for 12 weeks. This intervention aims to assess the synergistic effect of vitamin D and probiotics on immune response and symptom relief in allergic rhinitis.
223496107|NCT07114445|OTHER|Diabetes Treatment|Training with virtual reality glasses
223589673|NCT00582777|BEHAVIORAL|HS DOSING|Take your usual BP meds at bed time
224187087|NCT05324839|DRUG|Botulinum toxin type A|injecting different dosage to different group
224187088|NCT05602558|BIOLOGICAL|LYB001|The antigen consists of receptor-binding domain (RBD) from wild-type SARS-CoV-2 displaying on virus-like particle (VLP) vector, adjuvanted with aluminium hydroxide.
224187089|NCT05602558|BIOLOGICAL|Placebo|Aluminium hydroxide adjuvant
223589674|NCT00582777|DRUG|ADD On Dosing|Take your usual BP meds but add one more med at bed time.
223496108|NCT07115758|PROCEDURE|control GBR|will have a full thickness papilla preservation FLAP, followed by an immediate implant placement using a surgical guide. Then a guided bone regeneration will be achieved by bone graft (autogenous bone chips and xenograft particles and a membrane barrier 1 mm thickness will be applied. The membrane shield then will be stabilized to the apical bone using 2 membrane tacks, customized healing abutment will be connected , then, the elevated flap will be sutured to its original position.
224187090|NCT03801863|PROCEDURE|Ultrasound-guided Erector Spinae Plane Block with Ropivacaine 0.375%|Ultrasound-guided Erector Spinae Plane Block will be done at L4 interspace. Ropivacaine 0.375% will be used.
224187091|NCT03801863|DRUG|Ropivacaine|Using 0.375% Ropivacaine in the nerve block
224187092|NCT02423746|BEHAVIORAL|Family Check Up Behavioral Parenting Training Program (BPT)|"The Family Check Up is an evidence-based Behavioral Parenting Training (BPT) program focused on harnessing parents' motivation to change and skills training.~Intervention parents receive the initial assessment session followed by 3 Family Check-up Sessions within one month of baseline assessment followed by a post-intervention assessment. All sessions will be delivered in the patients' usual hearing clinics and will last between 60 and 90 minutes. One month post-intervention, participants will complete post-test measures repeating baseline measures, plus acceptability ratings of intervention."
224187093|NCT02423746|BEHAVIORAL|Behavioral Placebo|"The Behavioral Placebo sessions will consist of presentations of information about healthy lifestyles.~Parents in the control group will receive an initial assessment session followed by three behavioral placebo sessions followed by a post-placebo-intervention assessment. All sessions will be delivered in the patients' usual hearing clinics and will last between 60 and 90 minutes. One month post-intervention, participants will complete post-test measures repeating baseline measures, plus acceptability ratings of intervention."
224187094|NCT06158295|OTHER|Voluntary apnoea|Walking apneas at low lung volume
224187095|NCT03580746|PROCEDURE|Taping and posteromedial release|
224187096|NCT03580746|PROCEDURE|Ponseti|
223496109|NCT07115758|PROCEDURE|VST|"Pre extraction procedure:~Prior to tooth extraction, cone beam computed tomography (CBCT) images will be taken to inspect the overall socket condition.~All patients will be scanned pre-operatively using an intra-oral scanner (IOS).~Extraction protocol:~incisal extraction technique, where atraumatic tooth extraction to the hopeless tooth will be performed using periotomes followed by conventional forceps."
223496110|NCT07113977|BIOLOGICAL|CAR-T(CD70)|In this clinical study, participants with advanced renal cell carcinoma will receive a novel humanized CD70-targeted CAR-T-cell product that incorporates the TLR2 co-stimulatory domain. Peripheral blood mononuclear cells will be collected from each subject, genetically modified to express the CAR construct, and expanded ex vivo; after passing multiple quality-control assays, the CAR-T cells will be administered intratumorally under CT guidance at the pre-specified dose. Following treatment, the efficacy and safety of CD70-directed CAR-T-cell therapy will be comprehensively assessed through clinical symptom evaluations, quality-of-life questionnaires, biomarker analyses, laboratory tests, imaging studies, adverse-event monitoring, and long-term follow-up.
223496111|NCT07113847|BIOLOGICAL|Resin-Based Desensitizer|resin desensitizing agent
223496112|NCT07113847|DEVICE|Laser Desensitizer|Low-power Diode laser
223496113|NCT07113847|BIOLOGICAL|Fluoride-Based Desensitizer|Fluoride-based varnish
223496114|NCT07115277|DRUG|Flotufolastat F-18 Injection|All patients will receive one injection of Flotufolastat F-18 Injection, a PET radiopharmaceutical selective for PSMA. For the injection, subjects will receive a target dose of 8 mCi (296 MBq) ± 20% IV as a bolus injection. Flotufolastat F-18 Injection will be followed by a 10 ml saline flush.
223496115|NCT07119060|PROCEDURE|Cystectomy|Surgical removal of the endometrioma by gently pulling the cyst wall away from the ovarian tissue (divergent traction technique)
223496116|NCT07119060|PROCEDURE|plasma vaporization|It consists of destroying the cyst wall (vaporization) using plasma energy
223496117|NCT07119060|PROCEDURE|Sclerotherapy|Ethanol sclerotherapy destroys the endometriotic tissue lining the inner wall of the cyst through prolonged contact with 96% alcohol
223496118|NCT07118410|DEVICE|Application of a vascular restriction device during resistance training|"In the BFR-RT group, sessions will consist of 30 repetitions, followed by 3 sets of 15 repetitions at 40% 1-MR (maximal repetition), interspersed with 60 sec of recovery. An arterial occlusion pressure of 50% of systolic pressure will be maintained constant using a digital tourniquet. The cuff will be deflated during the recovery phases.~In the control group (RT group) it will be the same intervention with same intensities but without using BFR."
224187097|NCT01892046|DRUG|SNX-5422|Capsule dosed every other day for 21 days out of a 28 day cycle. Dose escalation based on safety. Maintenance doses at the maximum tolerated dose.
224187098|NCT01899417|DEVICE|ConforMIS iTotal® Knee Replacement|Patients that received a ConforMIS iTotal knee replacement versus other knee replacement devices.
223496119|NCT07117604|OTHER|Virtual Reality|Standard virtual reality applications rely on computer-generated animation environments and avatars; however, in the present study, the content created by actors/actresses with theater training by using cameras and audio recording devices suitable for creating virtual reality content included images of real environments and people.
223496120|NCT07117604|OTHER|Control group|While the participants in the intervention group received training on virtual reality, those in the control group took the standard curriculum course. Students in the control group received no training. The students in the control group were told that the program would be implemented to those who volunteered after the study was completed.
223496121|NCT07117292|DEVICE|Xsens DOT|Wearable inertial sensor used to capture cervical range of motion in three planes.
223496122|NCT07117292|DEVICE|Trigno Avanti Sensors|Wearable inertial sensor used to capture cervical range of motion in three planes.
223496123|NCT07117292|DEVICE|Universal Goniometer|Standard clinical tool used to measure cervical spine motion angles manually.
223496124|NCT07117019|OTHER|Self-care and lifestyle intervention advice|All females in both groups will follow self-care and lifestyle advice for 4 weeks.
223589675|NCT02636023|DEVICE|SPhENo-Cardiograph|SPhENo-Cardiograph
223589676|NCT01455896|DRUG|ITCA 650|ITCA 650
223589677|NCT01455896|OTHER|ITCA placebo|ITCA placebo
223589678|NCT02412046|PROCEDURE|Muscle biopsy|
223589679|NCT01989247|BEHAVIORAL|Self-management programme|Seven weekly group-based sessions for people with anxiety and depressive symptoms
223589680|NCT03878758|DEVICE|BD Nano™ PRO|Insulin Pen needle
224187099|NCT04025736|DRUG|Tranexamic Acid 100Mg/Ml Inj Vil 10Ml|Tranexamic acid (TXA) is a synthetic analog of the amino acid lysine which acts by competitively blocking the plasminogen lysine-binding site and inhibiting fibrinolysis. Several studies showed that TXA could reduce both blood loss and the amount of blood transfusion after shoulder arthroplasty surgeries.
224187100|NCT04025736|DRUG|0.9% Sodium Chloride Injection|Normal saline is a mixture of sodium chloride in water and has a number of uses in medicine. We use the same volume of normal saline as placebo.
224187101|NCT01358266|DRUG|DE-109 44 ug|Low dose
224187102|NCT01358266|DRUG|DE-109 440 ug|Medium dose
224187103|NCT01358266|DRUG|DE-109 880 ug|High dose
224187104|NCT03195270|DRUG|[18F]FDG|10 mCi of \[18F\]FDG via the antecubital vein in a bolus injection
224187105|NCT03195270|DEVICE|PET/MRI|PET/MRI hybrid scanner used as diagnostic device
224187106|NCT04948606|DRUG|Diroximel Fumarate|Administered as specified in the treatment arm.
224187107|NCT01715493|DRUG|lysozyme 90 mg|Lysozyme 90 mg three times daily for 4 weeks followed by placebo for 4 weeks (plus usual COPD medication)
224187108|NCT01715493|DRUG|Placebo|Lysozyme Matching Placebo three times daily for 4 weeks followed by Lysozyme 90 mg three times daily for 4 weeks (plus usual COPD medication)
224187109|NCT01881711|DEVICE|ShuntCheck-Micro-Pumper (SCMP)|"ShuntCheck uses thermal dilution to detect flow in CSF shunts. CSF is cooled transcutaneously with an ice pack and ShuntCheck's thermosensor detects a temperature drop due to CSF flow downstream of the ice. Micro-Pumper is a handheld device which vibrates the shunt valve to generate a temporary increase in CSF flow in patent but temporarily non-flowing shunts. This flow increase can be detected by ShuntCheck."
224187110|NCT01881711|DEVICE|Imaging|Imaging of ventricle size
224187111|NCT00187005|DRUG|Prednisone, Dexamethasone, Vincristine, Daunorubicin, PEG-L-asparaginase|See Detailed Description section for details of treatment interventions.
224187112|NCT00187005|DRUG|L-asparaginase, Methotrexate, Idarubicin, Etoposide, Cyclophosphamide, Cytarabine, Mercaptopurine|See Detailed Description section for details of treatment interventions.
223496125|NCT07117019|OTHER|Myofascial release|Females in the experimental group will receive intravaginal myofascial release in lithotomic position. After ensuring empty bladder/bowel, therapist uses sterile gloves and lubricant to insert fingers 2-3cm into vagina, pressing vaginal walls bilaterally for 2 minutes. Perineal massage follows, targeting scar tissue and tender points with friction at right angles. Treatment duration starts at 5 minutes (due to pain tolerance) and gradually increases to 20 minutes. Hot pack or ultrasound may be used pre-treatment for pain relief. Therapist performs gentle U-shaped reciprocating massage movements up and down towards rectum for 20 minutes total. Sterile technique maintained throughout with hand washing and glove changes between procedures.
223496126|NCT07117019|OTHER|Acupressure|"Each female in the experimental group will receive acupressure on BL 23 as follows: Acupressure is also another branch of acupuncture. In this method, fingers press the key points on the skin to stimulate and induce the body's natural self-healing capabilities. In the present study, the BL23 point located 1.5 cm lateral to the lower border of the spinous process of the second lumbar vertebra was employed.~The therapist will apply pressure on BL 23 points with the thumb for 5 minutes in the counterclockwise direction. In the second 5 minutes, pressure was applied in the opposite direction for 5 minutes. Similarly, the pressure was continued for 20 minutes."
223496127|NCT07118787|OTHER|Active Release Technique|A manual therapy technique applied to release soft tissue tension in the hamstrings.
223496128|NCT07118787|OTHER|Proprioceptive Neuromuscular Facilitation|A stretching technique involving passive stretching and isometric contractions of the hamstrings.
223496129|NCT07117487|BIOLOGICAL|mRNA-1345|Suspension for injection
223496130|NCT07118657|OTHER|Vegan Diet|"Vegan diet would be defined as a diet based solely of plant products with exclusion of all animal products including meat, fish, dairy, honey and eggs.• Additional supplementation of vitamin B12 (500 µg/day) in the vegan diet group along with calcium (50-75 mg/kg/day), vitamin D (800-1600 IU/day) and iron supplementation (3-6 mg/kg/day) as per requirement.~o Monitoring- Based on vitamin B12 levels, 25(OH) vitamin D3 levels, serum calcium, and serum iron studies (complete hemogram, ferritin, iron, transferrin saturation, total iron binding capacity)."
223496131|NCT07118657|OTHER|Standard Diet|Standard Diet
223496132|NCT07117526|DEVICE|Aneurysm occlusion with an intrasaccular device|Intervention with HARBOR Occlusion Device
223589681|NCT03878758|DEVICE|33G Artsana Insupen Extr3me|Insulin Pen Needle
223589682|NCT03878758|DEVICE|34G Artsana Insupen Extr3me|Insulin Pen Needle
224187113|NCT02784730|PROCEDURE|Iterative PICC placement|Intervention is the catheterisation strategy (not the device)
224187114|NCT02784730|PROCEDURE|Long term PAC placement|Intervention is the catheterisation strategy (not the device)
224187115|NCT01435876|PROCEDURE|Post exercise Surgery|ORTHOPTICS/MINUS LENS THERAPY
224187116|NCT01435876|PROCEDURE|Orthoptics|MINUS LENS THERAPY/ ORTHOPTICS
224187117|NCT01435876|PROCEDURE|Postop orthoptics|ORTHOPTICS/MINUS LENS THERAPY
224187118|NCT01435876|PROCEDURE|Post exercises surgery|UNIOCULAR/BINOCULAR RECESSION/RESECTION
224187119|NCT04084860|DRUG|CI-581a|CI-581a during weeks 1 and 6 at 0.71 mg/kg
224187120|NCT04084860|DRUG|CI-581b|CI-581b during weeks 1 and 6 at 0.0125 mg/kg
224187121|NCT04084860|BEHAVIORAL|MBRP|MBRP will help with maintaining use reduction/abstinence.In this trial, 3 sessions will occur in the first 2 weeks following the second infusion (weeks 6 and 7), while one session a week will be administered in the latter 5 weeks (weeks 8 through 12).
224187122|NCT04084860|BEHAVIORAL|MET|MET may help with goal setting and enhancing engagement with MBRP. In this trial, a standard 5-week MET platform will be provided to individuals randomized to receive behavioral treatment, with an additional session after each infusion (7 sessions total).
224187123|NCT03577665|RADIATION|curative proton therapy|Patients who meet the selection criteria are selected, signed for consent, and treated with proton therapy alone at 7200 cGy / 15 fractions, 5 times a week for 3 weeks
224187124|NCT05423665|OTHER|sample collection|blood sample at 21 weeks of gestation clips of the fetal heart at 21 weeks of gestation, 30 weeks of gestation and 1-3 days after birth collection of umbilical cord blood at birth collection of the placenta at birth
224187125|NCT04331431|PROCEDURE|Spinal cord tumor resection|Excision of intradural tumors
224187126|NCT02151565|DEVICE|HTEMS|
224187127|NCT02151565|DEVICE|TENS|
224187128|NCT03353025|PROCEDURE|transsphenoidal surgery treatment|transsphenoidal surgery treatment
224308937|NCT03997279|DRUG|Saccharomyces boulardii|Rabeprazole 20 mg 2x1, for 14 days, followed by 1x1 for 14 days, Amoxicillin 1000 mg 2x1, for 14 days, Clarithromycin 500 mg 2x1, for 14 days, Metronidazole 500 mg 2x1, for 14 days, Saccharomyces boulardi 500 mg 1x1, for 3 week
224308938|NCT03997279|DRUG|Placebo|Rabeprazole 20 mg 2x1, for 14 days, followed by 1x1 for 14 days, Amoxicillin 1000 mg 2x1, for 14 days, Clarithromycin 500 mg 2x1, for 14 days, Metronidazole 500 mg 2x1, for 14 days, Placebo 1x1, for 3 week
224308939|NCT00998309|DRUG|Azithromycin SR|Zithromax SR 2g, taking once for treatment.
224308940|NCT01425411|DRUG|valsartan|80/160 mg dosage of valsartan or 160+12,5 mg valsartan+hydrochlorothiazide combination, once a day, for six months
224308941|NCT03936595|OTHER|Core exercises protocol|"Participants will perform:~1. Squats, 4 sets of 5 repetitions at 60% 1RM~2. Deadlifts, 4 sets of 5 repetitions at 60% 1RM~3. Lunges, 4 sets of 5 repetitions at 60% 1RM~4. Step ups, 4 sets of 5 repetitions at 60% 1RM"
224308942|NCT03936595|OTHER|Structural exercises protocol|"Participants will perform:~1. Snatch, 4 sets of 5 repetitions at 60% 1RM~2. Hang clean, 4 sets of 5 repetitions at 60% 1RM~3. Push jerk, 4 sets of 5 repetitions at 60% 1RM~4. Split push jerk, 4 sets of 5 repetitions at 60% 1RM"
224308943|NCT03936595|OTHER|Accentuated eccentric load exercises protocol|"Participants will perform:~1. Deadlifts - squat jump, 4 sets of 5 repetitions at 30% body mass (BM)~2. Step down - squat jump, 4 sets of 5 repetitions at 30% BM~3. Step down - lunges, 4 sets of 5 repetitions at 30% BM~4. Hip thrusts, 4 sets of 5 repetitions at 30% BM"
224308944|NCT03936595|OTHER|Control condition|Participants will perform all the measurements that are comprised in the experimental conditions without performing any exercise protocol
223496133|NCT07117331|BEHAVIORAL|Technology-Enhanced Continuous Nursing System|A multi-faceted behavioral and educational intervention lasting 6 months post-discharge. It utilized a smartphone app, WeChat, tele-monitoring (phone/video calls), and community health partnerships to provide structured education, personalized rehabilitation plans, and continuous professional nursing support.
223496134|NCT07117331|BEHAVIORAL|Routine Postoperative Care|Standard institutional care including standard discharge instructions and routine outpatient follow-up appointments.
224187129|NCT03353025|DRUG|dopamine agonist treatment|Minimum effective dose of dopamine agonist，bromocriptine，treat prolactinona
224187130|NCT03612869|DRUG|LYS-SAF302|Treatment will involve direct injections of the investigational product into both sides of the brain through image-guided tracks, in a single neurosurgical session.
224187131|NCT02924467|BEHAVIORAL|1 Notice|1 Reminder notification via autodialer
224187132|NCT02924467|BEHAVIORAL|2 Notices|2 Reminder notifications via autodialer
224187133|NCT02924467|BEHAVIORAL|3 Notices|3 Reminder notifications via autodialer
224187134|NCT02262572|DRUG|Telmisartan /HCTZ - compression tablet (DC)|
224308945|NCT02304497|OTHER|Platelet Rich Fibrin|Procedure: Platelet Rich Fibrin obtained
223496135|NCT07116941|BEHAVIORAL|Cognitive Exercises|Participants perform a 30-minute session of cognitive tasks during the sitting phase of early ICU mobilization. Activities include word games, attention exercises, and simple problem-solving tasks designed to engage memory and executive function.
223496136|NCT07116941|BEHAVIORAL|Auditory Stimulation|Participants listen to calming music or nature sounds through headphones for 30 minutes during early mobilization in the ICU. The auditory content is selected to reduce anxiety and promote relaxation.
223496137|NCT07116941|BEHAVIORAL|Multisensory Stimulation|Participants receive 30 minutes of combined sensory stimulation during the sitting phase in the ICU. This includes tactile stimulation using hand therapy balls and olfactory stimulation with lavender or mint-scented materials to enhance relaxation and sensory engagement.
223589683|NCT03878758|DEVICE|Simple Diagnostics Comfort EZ™|Insulin Pen Needle
223589684|NCT02138968|OTHER|Multidisciplinary intervention|Multidimensional intervention based on: good control of baseline diseases, review of medication adequacy, exercise program, nutritional assessment and control, social assessment and control.
224187135|NCT02262572|DRUG|Telmisartan /HCTZ - dry granulation tablet (DG)|
224187136|NCT02262572|DRUG|Telmisartan /HCTZ - present commercial formulation|
224187137|NCT03276858|DRUG|CRN00808|Investigational drug
224187138|NCT03276858|DRUG|Placebo Oral Solution|Placebo
224187139|NCT03276858|DRUG|Midazolam oral solution|Midazolam as part of the drug-drug interaction arm of the study
224187140|NCT03276858|DRUG|Placebo oral capsule|Placebo
224187141|NCT03498963|PROCEDURE|bronchoalveolar lavage|Carrying out a bronchoalveolar lavage (BAL) within 24 hours after admission to intensive care with analysis on standard and specific culture media of environmental germs, carrying out antibiograms, DNA extraction, amplification by universal 16 and 18S rDNA primers followed by high flow sequencing and phylogenetic analysis of pathogens found. Comparison of these results with the same analyses performed on seawater samples taken near the drowning site and during a new AML at 72h for patients still intubated and showing signs of pneumonia in order to determine if the pathogens detected at the entrance persist and are present in the environment.
224187142|NCT04191590|PROCEDURE|nasal brushing and bacteriological sample|A nasal brushing as well as a bacteriological sample using a swab under general anesthesia at the beginning of the endonasal surgery procedure
224187143|NCT01860066|DRUG|QVA149|QVA149 via inhaler twice a day
224187144|NCT01860066|DRUG|fluticasone/salmeterol|fluticasone/salmeterol via inhaler twice a day
224187145|NCT02156570|DRUG|Sofosbuvir and ribavirin|Sofosbuvir 400mg daily plus weight-based dosing ribavirin (1000mg \<75kg, 1200mg \>/= 75 kg) Treatment will be for 6 weeks in all participants.
224187146|NCT00732732|DIETARY_SUPPLEMENT|Green banana powder|Green banana in powder form, 10 grams/ day for children below 10 kg, 20 grams for those weighing 10 Kg or more. Protocol Modified on Aug 5th 2009 to give 20 grams irrespective of age.
224308946|NCT04731792|OTHER|Virtual Reality|a bronchial fibroscopy with a virtual reality helmet
224308947|NCT01831102|OTHER|none- observational study|
224308948|NCT05585021|DIETARY_SUPPLEMENT|Wonderlab Kids instant probiotics|"During study intervention, subjects are required to take the randomly assigned product based on the randomization list.~Taking assigned product directly or mix it with milk/water/other liquids below 37 ℃, take it half an hour after meal.1 bottle a day. Lasting for 24 weeks intervention period."
223496138|NCT07117357|BEHAVIORAL|Neuroathletic Training Protocol|This intervention involves a 20-minute neuroathletic training session using the Z-Health® kit. It includes visual reset exercises (eye massage, palming), star chart eye muscle training, saccade training with letter cards, convergence-divergence drills using Brock string, vestibular activation through lunges, spinal and hip extension exercises, slap tap coordination drills, and use of pinhole glasses. The aim is to stimulate sensory pathways and enhance neuromotor readiness acutely.
223496139|NCT07117357|BEHAVIORAL|Standard Warm-Up Protocol|This 20-minute warm-up consists of two components: 10 minutes of light walking at a moderate pace and 10 minutes of dynamic stretching (leg swings, hip flexor stretches, knee hugs, high knees, butt kicks, arm circles, and trunk rotations). It is intended to mimic standard pre-activity routines and serves as the comparator condition.
223496140|NCT07118930|DRUG|Sivelestat Sodium injection 2 h after OPCABG for 72 h|Sivelestat Sodium injection 2 h after OPCABG for 72 h
223496141|NCT07118930|DRUG|Saline (0.9% NaCl)|Saline (0.9% NaCl) instead of Sivelestat
223589685|NCT01996124|DRUG|Indacaterol Fumarate|150 mcg inhalation powder, hard capsules, once daily
224187147|NCT00732732|OTHER|Microcrystalline cellulose|Microcrystalline cellulose 10 gm/ day for subjects below 10 kg in weight, 20 gms/ day for those weighing 10 Kg or more
224187148|NCT06542393|DRUG|Erythropoietin|"* Treatment regimen for hospitalized patients awaiting non-urgent surgeries: Administer EPO 600 IU/kg/week via subcutaneous (SC) or intravenous (IV) route, followed by 300 IU/kg/day via SC or IV 10 days before surgery. If ferritin \< 100 ng/dL, supplement with IV iron (Iron hydroxide up to 600 mg/week or Ferric carboxymaltose up to 1000 mg/week).~* Treatment regimen for hospitalized patients awaiting non-urgent surgeries with less than 5 days until surgery: Administer 40000 UI of EPO intravenous (IV) attack and supplement with IV iron (Iron hydroxide up to 600 mg/week or Ferric carboxymaltose up to 2000 mg/week), then 300UI/Kg/day IV or SC of EPO until day of surgery."
224187149|NCT06542393|PROCEDURE|blood transfusion|"After surgery, this group will receive one unit of RBC at the moment of ICU admission.~Hb \> 8 g/dl: 1 unit of RBC. HB \< 8 g/dl: 2 units of RBC."
224187150|NCT04983628|OTHER|Tumor molecular profiling|targeted DNA NGS
224187151|NCT02131753|DRUG|Cladribine s.c. injection, HCL treatment|Patients with hairy cell leukemia and the need for treatment are given cladribine 0.14 mg/kg for 5 consecutive days as a s. c bolus injection
224187152|NCT03711747|PROCEDURE|Osteochondral allograft ankle|Open osteochondral allograft to replace the cartilage that is grade four on the tibia and/or talus
224187153|NCT02015312|DRUG|Epigallocatechin-3-gallate (EGCG)|"Pharmaceutical formulation: capsules~Dose:~400 mg/d for 3 months; 800 mg/d for 3 months, 1200 mg/d for 6 months Route of administration: p.o. Treatment duration: 12 months"
224187154|NCT02015312|DRUG|Placebo|"Pharmaceutical formulation: capsules~Dose:~400 mg/d for 3 months; 800 mg/d for 3 months, 1200 mg/d for 6 months Route of administration: p.o. Treatment duration: 12 months"
224187155|NCT00576667|DRUG|Rimonabant|Tablet, oral administration
224187156|NCT00576667|DRUG|Placebo (for Rimonabant)|Tablet, oral administration
224187157|NCT02396524|BEHAVIORAL|Hockey FIT Program|Active phase: a) Classroom-based education on successful weight management strategies and instruction on behaviour change techniques/dietary interventions; promote peer and other forms of social support; and b) Physical activity sessions in aerobic/strength/flexibility exercises. Maintenance phase: Participants independently set new lifestyle prescriptions and goals and track their exercise, physical activity, and healthy eating with the support of a suite of free-of-charge health technology support tools
224187158|NCT00067431|DRUG|Divalproex Sodium (Depakote® Sprinkle Capsules)|
224187159|NCT02468973|BEHAVIORAL|Life style counseling|Life style counseling for chronic patients by medical students
224187160|NCT00665327|DRUG|Avelox (Moxifloxacin, BAY12-8039)|Moxifloxacin 400 mg IV QD for a minimum of two doses followed by moxifloxacin 400 mg PO QD for a total treatment duration of 7 to 14 days
224187161|NCT00665327|DRUG|Levofloxacin|Levofloxacin 500 mg IV QD for a minimum of two doses followed by Levofloxacin 500 mg PO QD for a total treatment duration of 7 to 14 days. For patients who have a documented or calculated creatinine clearance of 20 - 49 ml/minute, the IV and PO dose of Levofloxacin will be a 500 mg loading dose followed by 250 mg QD for a total treatment duration of 7 to 14 days
223589686|NCT01996124|DRUG|Placebo|Fructose, dry inhalation powder, hard capsules via breezhaler
223589687|NCT05966948|DRUG|Dextrose Solution|Prolotherapy is a regenerative tissue therapy that is considered efficacious for reducing the symptoms and morbidity of Knee Osteoarthritis (KOA) using hypertonic dextrose as an injectable substance. Treatment will be given two times, on day 1st and 30th day.
223589688|NCT05966948|DRUG|Normal Saline|Normal Saline will be intra-articular injected and given two times, on day 1st and 30th day.
224187162|NCT02017782|DEVICE|Dust|Dust (250-300µg/m3),
224308949|NCT05585021|DIETARY_SUPPLEMENT|Instant probiotic placebo|"Subjects are required to take the randomly assigned Instant probiotic placebo based on the randomization list.~Taking assigned product directly or mix it with milk/water/other liquids below 37 ℃, half an hour after meal.~1 bottle a day. Lasting for 24 weeks intervention period."
223589689|NCT03841435|RADIATION|Hypofractionated Radiotherapy|Radiotherapy Treatment, totaling 15 Gy, will be given in 3 fractions over 2 weeks.
223589690|NCT02315560|DEVICE|TRANSCUTANEOUS ELECTRICAL NERVE STIMULATOR (TENS|electrical stimulation of the nerves in the foot on the incidence of nocturnal enuresis (bedwetting) in children
223589691|NCT03444935|BEHAVIORAL|Follow-up phone call|Please see arm/group description.
223589692|NCT05900492|PROCEDURE|cesarean section|caesarean delivery, is the surgical procedure by which one or more babies are delivered through an incision in the mother's abdomen
223589693|NCT06238206|OTHER|Focus group discussion|The participant will be asked to take part in three separate focus group discussions implementing the co-design principle. Following the co-design principle the participants will actively contribute towards the primary outcomes. Open questions will be asked to guide the discussion. Interaction between participants will be encouraged.
224187163|NCT02017782|DEVICE|Ozone|(0,1ppm ozone),
224187164|NCT02017782|DEVICE|Dust and Ozone|Active Dust (250-300 ug/m3)+Ozone(0,1ppm)
224187165|NCT02017782|DEVICE|Placebo (Filtered air)|Placebo treatment (Filtered air \<20 ug/m3)
224187166|NCT01985776|PROCEDURE|Exercise intervention|Functional stabilisation exercise for the trunk.
223589694|NCT03090555|PROCEDURE|Translational manipulation|After the patient receives an interscalene block on the affected side, a physical therapist performs a series of thrust manipulations on the participant's affected shoulder. The participant's identified limitations of physiological and accessory motion revealed during manual examination guided the physical therapist's choice of technique, which primarily consisted of an accessory superior to inferior accessory gliding motion performed in a physiological position of limited motion. Additional gliding manipulations in combined movement positions such as increased flexion or abduction plus internal or external rotation were utilized until full passive physiologic motion was restored.
223589695|NCT03090555|PROCEDURE|Manual therapy|The first clinic treatment session for all study participants included instruction in the home program of static stretching, resistive exercise, and ice, issue of an illustrated handout and digital video disc detailing the same program, and manual therapy (MT) by a physical therapist that included all indicated grades of non-thrust manipulation of the joints and soft tissue. The MT intervention was targeted toward any identifiable upper quarter pain or movement impairments. Subsequent clinic treatment sessions included additional MT, progression of the strengthening exercises, and reinforcement of the home program.
223589696|NCT02506023|DRUG|Desmopressin|Desmopressin or DDAVP will be administered intravenously (IV) via a nontraumatic peripheral IV line at a dose of 0.3 mcg/kg over 30 minutes.
223589697|NCT01115374|PROCEDURE|Manual lymphatic drainage|Application of manual lymphatic drainage (one session every work day during two weeks, total 10 sessions)
223589698|NCT01115374|DEVICE|low frequency sound waves|Application of low frequency sound waves (one session every work day during two weeks, total 10 sessions)
223589699|NCT03615339|DIETARY_SUPPLEMENT|Molkosan|Twice daily (AM and PM) 20ml of fermented whey concentrate consumed diluted in 200ml water
223589700|NCT05105217|OTHER|Slit2 biomarker|"1.Assessment of slit2 level in SLE patients and its correlation with disease activity.~2-Assessment of slit2 level in SSC patients and its correlation with disease activity"
223589701|NCT06434467|DRUG|Nelarabine injection|Nelarabine is a prodrug of the nucleotide metabolism inhibitor deoxyguanosine analogue 9-β-arabinoguanine (ARA-G). Nelarabine undergoes catalytic transformation by adenosine deaminase (ADA), resulting in the removal of its methoxy group and conversion into ARA-G, Subsequently, ARA-G undergoes sequential monophosphorylation by deoxyguanosine kinase and deoxycytosine nucleoside kinase, yielding the active compound 5'-Guanosine triphosphate (GTP), ARA-GTP. This active compound accumulates within leukemic blast cells and binds to deoxyribonucleic acid (DNA), effectively inhibiting DNA synthesis and ultimately leading to cell death.
223589702|NCT05082311|OTHER|Observational study|This is an observational study
223589703|NCT04488016|DRUG|Treatment A- Part 1|Subjects will receive 100 mg acalabrutinib capsule, fasted state;
223589704|NCT04488016|DRUG|Treatment B- Part 1|Subjects will receive 100 mg acalabrutinib tablet (Variant 1), fasted state
223589705|NCT04488016|DRUG|Treatment C - Part 1|Subjects will receive 100 mg acalabrutinib tablet (Variant 1), fed state
223589706|NCT04488016|DRUG|Treatment D- Part 1|Subjects will receive Rabeprazole 20 mg QD (fasted) at 2 hours before administration of 100 mg acalabrutinib tablet (Variant 1) and following prior administration of rabeprazole 20 mg Twice per day (BID) (with meals) on Days -3, -2 and -1.
223589707|NCT04488016|DRUG|Treatment A-Part 2|Subjects will receive 100 mg acalabrutinib tablet (Variant 1), fasted state
223745778|NCT05623267|DRUG|Sugemalimab|Recombinant anti-PD-L1 fully human monoclonal antibody
224187167|NCT01985776|PROCEDURE|Exercise and e-stim|Functional stabilisation exercise for the trunk and electrical stimulation at the same time.
224187168|NCT03131791|DEVICE|Shock Wave|42 chronic stroke patients with upper limb spasticity were randomly assigned to receive either 1 session of ESWT per week for 3 consecutive weeks or BoNT-A injection. The biceps, flexor carpi radialis, and flexor carpi ulnaris muscles were treated. Assessments were performed at baseline and at 1, 4, and 8 weeks after the intervention. The primary outcome measure was the change in the Modified Ashworth Scale (MAS) score for the elbow from the baseline to after 4 weeks of treatment.
224308950|NCT05817682|OTHER|Interprofessional education|"The study will be conducted among students of the Krakow Academy. The experimental group will consist of 35 students participating in the Interdisciplinary Circle of Medical Simulation from the following faculties: medicine, nursing and medical rescue.~Students will be divided into 7 interprofessional teams, in which they will take classes planned for small groups."
223589708|NCT04488016|DRUG|Treatment B - Part 2|Subjects will receive 100 mg acalabrutinib tablet (Variant 2), fasted state
223589709|NCT04488016|DRUG|Treatment C - Part 2|Subjects will receive 100 mg acalabrutinib tablet (Variant 3), fasted state
223589710|NCT04488016|DRUG|Treatment D - Part 2|Subjects will receive 100 mg acalabrutinib solution, (Variant 4), fasted state
223589711|NCT04984382|BEHAVIORAL|Standardized training on Helicobacter pylori eradication treatment|Standardized training on Helicobacter pylori eradication treatment
223589712|NCT01105273|BIOLOGICAL|anti-thymocyte globulin|On days -3 to -1
223589713|NCT01105273|BIOLOGICAL|filgrastim|Beginning on day 4 and continuing until blood counts recover
223589714|NCT01105273|DRUG|Fludarabine|30mg/M2 once daily IV on days -6 to -2
223589715|NCT01105273|DRUG|Cyclophosphamide|60 mg/kg IV on day-3 and -2
223589716|NCT01105273|PROCEDURE|CD3±CD19 depleted hematopoietic stem cell transplantation|Immunogenetic depletion on CliniMACS
223589717|NCT01831674|DRUG|Metformin Hydrochloride Extended-Release Tablets USP 750|Metformin Hydrochloride Extended-Release Tablets 750 mg once a day
223745779|NCT05623267|DRUG|Placebo|Placebo of Sugemalimab
223745780|NCT03018041|DRUG|Omacor|"As described in Arms."
223745781|NCT03018041|DRUG|Placebo Oral Capsule|"As described in Arms."
223745782|NCT03301194|OTHER|RAMP-HT|RAMP-HT was launched since October 2011 by the Hospital Authority with the support from the Food and Health Bureau. Standardized cardiovascular risk factor assessment, hypertensive complication screening and assessment on patient adherence to treatment are carried out on enrolled patients. Patients are stratified into low, medium or high risk groups according to the 10-year cardiovascular disease (CVD) risk calculated from their relevant risk factors by the Joint British Society 2005 Equation. A multidisciplinary team comprised of doctors, nurses, dieticians, physiotherapists and/or occupational therapists would then deliver individualized management targeted to the patient's risk factors according to standardized risk-stratified guidelines.
223745783|NCT00003463|DRUG|carmustine|
224187169|NCT03131791|DRUG|Botulinum toxin A|42 chronic stroke patients with upper limb spasticity were randomly assigned to receive either 1 session of ESWT per week for 3 consecutive weeks or BoNT-A injection. The biceps, flexor carpi radialis, and flexor carpi ulnaris muscles were treated. Assessments were performed at baseline and at 1, 4, and 8 weeks after the intervention. The primary outcome measure was the change in the Modified Ashworth Scale (MAS) score for the elbow from the baseline to after 4 weeks of treatment.
224187170|NCT06230276|OTHER|enteral nutrition (Resource Fibre, 2 kcal/ml) for breakfast|Participants who are already treated by one of the HCL systems (MiniMed 780G, Tandem Control-IQ, Ypsomed CamAPS) will have a precisely defined amount of enteral nutrition (Resource Fibre, 2 kcal/ml) for breakfast during eight different days under predetermined conditions. They will administer premeal bolus only for half of these meals.
224187171|NCT06361368|DIETARY_SUPPLEMENT|PS150|Participants took one capsule with PS150 after dinner for 30 days.
224187172|NCT06361368|DIETARY_SUPPLEMENT|Placebo|Participants took one capsule with placebo after dinner for 30 days.
224187173|NCT00061269|PROCEDURE|Videoscopic-Assisted Retroperitoneal Debridement (VARD)|
224187174|NCT03738462|DEVICE|Conformis Hip System|The Conformis Hip System is an FDA cleared, uncemented, primary total hip replacement device composed of femoral and acetabular components. The system incorporates the use of a pre-operative CT scan to design patient-specific implants and instruments. Using patient imaging (CT scan), a patient-specific implant is designed that best meets the geometric and anatomic requirements of the specific patient. In addition, each Conformis Hip System device is shipped with an additional (optional) femoral stem (Cordera Femoral Stem).
224187175|NCT01516060|DRUG|Efavirenz|400mg qd; 2 x 200mg
224187176|NCT01516060|DRUG|Efavirenz|600mg qd; 3 x 200mg qd
224187177|NCT02822729|DRUG|DE-117 ophthalmic solution|
224187178|NCT02822729|DRUG|Timolol ophthalmic solution|
224187179|NCT02132065|DRUG|TAP block|Patients will be scheduled to receive routine analgesic and an unilaterally dual TAP block with 2 points injections of 15 ml of 0,375 % Ropivacain( in total 30 ml 0,375% Ropivacain) in the same side of nephrectomy.
224308951|NCT02004015|DRUG|injection of placebo|0.5 mg/kg milligram(s)/kilogram
224308952|NCT02004015|DRUG|injection of NMBA|
223496142|NCT07117916|BEHAVIORAL|Supervised nutritional guidance, physical exercise, cognitive training, social engagement, and management of vascular and metabolic risk factors.|In addition to health advice, participants in the intervention group will receive a structured, multidomain lifestyle program comprising nutritional guidance, physical exercise, cognitive training and social engagement, and monitoring and management of vascular and metabolic risk factors. The STRONGER 60+ intervention is based on the FINGER protocol and has been specifically adapted for primary care to enhance feasibility and scalability. Key adaptations include 1) delivering physical exercise sessions at external gym facilities rather than at primary care centers, and 2) shortening the intervention duration from two years to six months.
223496143|NCT07118969|OTHER|Breast Cancer Awareness Training|A structured breast cancer education program consisting of five sessions, each lasting 90 minutes. The program covers breast cancer risk factors, early detection methods including breast self-examination (BSE), clinical breast examination, mammography, and health-promoting behaviors. The sessions are conducted in group settings within university faculties. The education aims to increase participants' knowledge and awareness of breast cancer and encourage early detection practices.
223496144|NCT07117630|DRUG|L-Ornithine L-Aspartate|3g orally three times daily
223496145|NCT07117630|DRUG|Dalpiciclib|150mg orally once daily (3 weeks on/1 week off per 28-day cycle)
223496146|NCT07117630|DRUG|Fulvestrant|500mg IM on Days 1 \& 15 of Cycle 1, then Day 1 of subsequent cycles
223496147|NCT07116746|DRUG|AR882 75 mg|Solid Oral Capsule
223496148|NCT07116746|DRUG|XOI Low Dose|Solid Oral Tablet
223496149|NCT07116746|DRUG|XOI High Dose|Solid Oral Tablet
223496150|NCT07117812|PROCEDURE|Laparoscopic purse-string forceps and multifunctional sealing ring|Performing totally laparoscopic radical total gastrectomy with R0 resection, completing esophagojejunostomy using purse-string forceps and multifunctional sealing ring.
223496151|NCT07117383|DEVICE|ASP-001.1|Bottle/pump containing ASP-001.1 suspension
223496152|NCT07117383|DRUG|ASP-001|Oral liquid suspension of sildenafil
223496153|NCT07117383|DRUG|Commercial Sildenafil and Sildenafil/Tadalafil Products|A selection of marketed sildenafil or sildenafil + tadalafil products used as comparators. Includes tablets and chewables such as Viagra®, Galotam, BlueChew, Aristo Sildaristo, Lemonaid Viagra, Ro Sparks, Hims Hard Mints, and Hello Cake ED Cake Meds.
224187180|NCT02122874|DEVICE|Percutaneous Neurostimulation (PENS) of dermatome T7|The patients undergo PENS of dermatome T7 and follow a 1200 Kcal diet
224187181|NCT02122874|OTHER|1200 Kcal diet|
224187182|NCT04149366|DEVICE|Retainer|Orthodontic retainer
224187183|NCT03426774|DEVICE|Gentle Jogger|Passive Simulated Jogging device (Gentle Jogger)
224187184|NCT03426774|DEVICE|Gentle Jumper|Passive Simulated Jumping Device ( Gentle Jumper)
224308953|NCT04113785|DEVICE|Klassic Knee System|At present, all TKA available for surgeons to use are asymmetric where there is a distinct femoral and tibial component for the left knee and a distinct femoral and tibial component for the right knee. The Klassic knee system is a symmetrical knee implant, where the same femoral and same tibial component can be used for either the right or left knee
224308954|NCT01314937|DRUG|Mebendazole|Single-dose 500 mg mebendazole tablet
223589718|NCT01831674|DRUG|GLUCOPHAGE®XR tablet 750 mg|GLUCOPHAGE®XR 750 mg once a day
223589719|NCT01969435|DRUG|Carmustine|
223589720|NCT01969435|DRUG|Etoposide phosphate|
223589721|NCT01969435|DRUG|Cytarabine|
223589722|NCT01969435|DRUG|Melphalan HCl (propylene glycol-free)|
223589723|NCT04139850|DRUG|Discontinuation of antiviral treatment in chronic hepatitis B cohort patients|For the selective patients in the cohort with long-term antiviral therapy and with conditions such as HBeAg negative or loss more than one year, antiviral therapy is able to be discontinued with an intensive inspection who agreed to the process. If there are need of this intervention, another multicenter IRB approval will be taken.
223589724|NCT02610946|BEHAVIORAL|Electronic application|Electronic application (app) based intervention to improve adolescent compliance with transplant care and readiness to transition to adult care.
223589725|NCT02610946|BEHAVIORAL|Paper-based|Paper-based intervention to improve adolescent compliance with transplant care and readiness to transition to adult care.
223589726|NCT04616222|DRUG|CELSIOR® group|Patient who received Celsior® during their transposition of the great vessels surgery according to the routine care.
223589727|NCT04616222|DRUG|Saint-Thomas group|Patient who received Saint-Thomas during their transposition of the great vessels surgery according to the routine care.
223745784|NCT00003463|DRUG|irinotecan hydrochloride|
223745785|NCT00003463|DRUG|polifeprosan 20 with carmustine implant|
224187185|NCT03264573|BIOLOGICAL|Stem cell|after scar revision PRP is injected intradermally, also adipose derived mesenchymal stem cells
224308955|NCT01314937|OTHER|Usual care|Routine child health interventions (e.g. age-specific immunizations, supplementations, etc.)
224308956|NCT05893069|DRUG|Oxandrolone|oral oxandrolone for 12 weeks
223589728|NCT03620084|DEVICE|Expiratory Muscle Strength Training (EMST)|The target home practice frequency on the EMST-150 is: 5 repetitions of forceful expiration each time, 5 times daily, 5 days a week for 8 weeks, following the training protocol used by Hutcheson et al. (2017).
223589729|NCT00358436|DRUG|Aclidinium bromide|Aclidinium bromide 200 μg once-daily via inhalation by the Eklira Genuair® inhaler: 1 puff in the morning for 52 weeks
223589730|NCT00358436|DRUG|Placebo|Placebo once-daily via inhalation: 1 puff in the morning for 52 weeks
223589731|NCT02369419|OTHER|Frailty|CRT device is implanted in all patients selected for the study. Frailty is evaluated before implant and defined as \<14/17 points using the ONCODAGE score
223589732|NCT00416325|DIETARY_SUPPLEMENT|lycopene|
223589733|NCT00416325|OTHER|laboratory biomarker analysis|
223589734|NCT02215135|DRUG|Corifollitropin alfa|In GnRH antagonist protocol, ovarian stimulation with single dose of 100μg (BW≦60 kg) or 150μg (BW\> 60 kg) corifollitropin alfa (Elonva, SC), followed 1 week later (stimulation day 8) by a daily dose of rFSH to the day of GnRH agonist triggering final oocyte maturation.
223589735|NCT00321464|BIOLOGICAL|Denosumab|Q4W 120 mg denosumab SC injection and 4 mg zoledronic acid (Zometa) placebo IV over a minimum of 15 minutes
223589736|NCT00321464|DRUG|Zoledronic Acid|Q4W 4 mg zoledronic acid IV over minimum 15 minutes and 120 mg denosumab placebo SC
223589737|NCT06238284|OTHER|no intervention|Since it is a retrospective study, no intervention is needed.
223589738|NCT02825524|DEVICE|Habib™ EndoHBP|During an endoscopic retrograde cholangiography, endobiliary application of radiofrequency through a dedicated probe named Habib.
223589739|NCT04039737|DRUG|Qingpeng Ointment|Take Qingpeng ointment (produced by Tibet Qizheng Tibetan Medicine Co., Ltd.) and apply it evenly on the shoulder joints, wrist joints and palms of the upper limbs. Press for 20 minutes and have rehabilitation training afer 10 minutes.
223589740|NCT03239080|DRUG|Denosumab|Subcutaneous injections of denosumab 60mg will be given in 4 doses at each visit (at baseline, 6, 12 and 18 months).
223589741|NCT03239080|OTHER|Placebo|Subcutaneous injections of placebo (0.9% Sodium Chloride solution) will be given in 4 doses at each visit (at baseline, 6, 12 and 18 months).
223589742|NCT06240104|DIAGNOSTIC_TEST|cardiac output index monitor|During the spontaneous breathing test phase, the cardiac index (CI) is continuously monitored from 15-30 minutes prior to the start of the test. Patients who have successfully completed the spontaneous breathing test and increased their CI by more than 30% and meet ordinary weaning indications can have their tracheal intubation removed.
223589743|NCT04204044|DRUG|Metformin Hydrochloride|Metformin Hydrochloride is used in PCO
223589744|NCT04204044|DRUG|Myo-inositol|Myo inositol used in PCO
223745786|NCT00003463|PROCEDURE|surgical procedure|
223745787|NCT04801771|DEVICE|Inspire Upper Airway Stimulation (UAS) System|The Inspire UAS System is an implantable device that provides hypoglossal nerve stimulation for the treatment of obstructive sleep apnea.
223745788|NCT04772222|DRUG|Dexmedetomidine Hydrochloride|Potent α2-adrenergic receptor agonist that provides sedation, analgesia, and prevents shivering but does not suppress ventilation.
224308957|NCT05893069|DRUG|Placebo|oral placebo for 12 weeks
224308958|NCT04998357|OTHER|Endovascular autologous mitochondrial transplantation|During standard-of-care endovascular reperfusion procedure, subjects will have autologous mitochondria infused via microcatheter into ischemic brain.
224308959|NCT06692400|PROCEDURE|endotracheal tube suctioning|Endotracheal tube suctioning occurs as part of normal care for intubated patients. This procedure will serve as the painful procedure to assess CPOT and biomarkers of hypoxia and oxidative stress.
224308960|NCT06349577|OTHER|Non-pulsatile blood flow|Non-pulsatile blood flow generated by constant centrifugal pump flow rate during cardiopulmonary bypass
223589745|NCT03842449|DIAGNOSTIC_TEST|BabyCO|An expired CO measurement will be performed by BabyCO and the result will be returned to the smoking pregnant woman by the consultant.
223589746|NCT03842449|OTHER|Biological samples|"The nature of the samples taken during the delivery are:~* maternal blood,~* cord blood~* placenta fragment"
223589747|NCT00582998|PROCEDURE|Standard Wound Dressing|Following repair of fracture of calcaneus, pilon or tibial plateau, a standard wound dressing is applied in the OR. Dressing is taken down post-op day 1 to evaluate draining, and if necessary, replaced. Dressing will be monitored for drainage every 48 hours until wound is clean, dry and intact.
223589748|NCT00582998|DEVICE|Vacuum Assisted Closure Device|Following repair of fracture of calcaneus, pilon or tibial plateau, a Vacuum Assisted Closure (VAC) device is applied in the OR. VAC cannister is evaluated for drainage, and if necessary, replaced. VAC sponge will be monitored for drainage every 48 hours, replaced if needed, until wound is clean, dry and intact.
223745789|NCT04772222|DRUG|Morphine Sulfate|Opioid agonist that provides analgesia, pain management and sedation and may suppress ventilation.
223745790|NCT00072618|DRUG|Exisulind|
224187186|NCT03264573|DEVICE|MSCs|manual separation of platelets rich plasma and undifferentiated mesenchymal stem cells
224187187|NCT02818582|DRUG|GS-5734|Daily GS-5734 delivered intravenously (IV) for 5 days
224187188|NCT02818582|OTHER|Placebo Comparator|Placebo delivered intravenously (IV) for 5 days.
224187189|NCT02557191|OTHER|Observational study|
224187190|NCT03392922|DEVICE|Uniblocker|The BBs have more advantages than DLT: easier insertion especially in patients with difficult airway18 and no need to exchange the tube when mechanical ventilation is required after surgery.
224187191|NCT03392922|DEVICE|Left-sided Double-lumen Tube|the double-lumen tube (DLT) is the most commonly used device for OLV
223589749|NCT06096675|BEHAVIORAL|• Cardiac Rehabilitation|Intervention group will have baseline 6-minute walk test and cardiopulmonary exercise test (CPET) testing followed by supervised cardiac rehabilitation program including planned 3 one hour sessions a week for a total of 12 weeks (planned 36 sessions). A post intervention 6-minute walk test and CPET test will be performed within 2 weeks of completion of the 12 week program.
224187192|NCT00475839|DEVICE|Tension-free Vaginal Tape|
224187193|NCT00475839|DEVICE|Monarc sub-fascial hammock|
224187194|NCT02196025|DEVICE|Transcranial magnetic stimulation|Patients will receive sequential bilateral bifrontal low frequency TMS stimulation daily on weekdays for three weeks. In addition, a Pittsburgh Sleep Quality Index (PSQI), Insomnia severity rating index, Montgomery Asberg Depression Rating Scale, and a sleep diary will be kept.
224187195|NCT00594334|DRUG|Risedronate|Weekly Risedronate
224187196|NCT02582216|DEVICE|3D augmented reality|Each treatment period included a 3DARS (3D augmented reality system)training session.All 3DARS training sessions were performed in the same quiet room under the supervision of the same single investigator.The 3DARS training session protocol included two virtual training procedures. The first virtual training procedure consisted of applying a vertical virtual mirror to the display screen, where the non-affected side of the patient's body (such as the right) was symmetrically duplicated by a vertical axis on the affected side (such as the left).The second virtual training procedure consisted of flipping the 3D image horizontally along a vertical axis. This allowed patients to observe the reflection of their non-affected upper extremity as if it was the affected one.
224187197|NCT06382324|BEHAVIORAL|mindfulness practice of body scan|Mindfulness intervention is one kind of psychological intervention. The founder of Mindfulness-Based Stress Reduction (MBSR), Jon Kabat-Zinn, described mindfulness as \&#34;awareness that arises through paying attention, on purpose, in the present moment, non-judgmentally\&#34; (Kabat-Zinn, 2003). Moreover, these attitudes can be nurtured through various practices such as body scan, meditation, yoga, mindful eating, and mindful walking. Mindfulness practices are recognized for their ability to alleviate stress among athletes and enhance their recovery capabilities (Li et al., 2019). Mindfulness practice has been shown to enhance athletes\&#39; performance (Chen et al., 2018)、 improve sleep quality (Rusch et al., 2019)，which in turn promotes emotional stability and physical recovery.
224187198|NCT06382324|BEHAVIORAL|listening to light music|listening to light music asa control
224187199|NCT03377803|COMBINATION_PRODUCT|VP-102 - Cantharidin, Topical Film Forming Solution|VP-102, a single-use drug device combination product containing (cantharidin) topical solution, 0.7% (w/v). Up to 4 applications of VP-102 will be administered to Molluscum lesions at 21-day intervals.
224187200|NCT03377803|COMBINATION_PRODUCT|Placebo -Topical Film Forming Solution without VP-102|Placebo a single-use drug device combination product containing only the vehicle. Up to 4 applications of Placebo will be administered to Molluscum lesions at 21-day intervals.
224187201|NCT03773159|BIOLOGICAL|Blood sampling|4 citrated/PPACK tubes and 1 EDTA tube maximum
224187202|NCT02687815|DRUG|vitamin D3 4000 IU|The vitamin D3 will be in oral gel cap form and contain 4000 International Units (IU) of cholecalciferol per gel cap.
224187203|NCT02687815|DRUG|Placebo|The placebo is a gel cap that is indistinguishable from the vitamin D3 gel cap.
224187204|NCT02854865|OTHER|echocardiography|assess whether GLPSS measured during cardiac surgery using AFI is superior to E/Ea ratio in estimation of LVFP measured as PCWP
224187205|NCT02900157|BIOLOGICAL|MEDI9090|MEDI9090 will be administered by IV infusion
223589750|NCT05147298|OTHER|eHealth phone program|The automated eHealth phone program uses text to speech technology to deliver educational content to increase awareness, confidence, and motivation for physical activity.
223589751|NCT05147298|OTHER|Environment program|The environment surrounding the PHDs will be changed to make it more amenable to walking by creating walking trails and walking maps and using Healthy Living Advocates (HLA)-led walking groups within the community. Also advocating for changes to the built environment.
223589752|NCT02272374|PROCEDURE|AVF creation|
223589753|NCT02272374|PROCEDURE|TCC placement|
223589754|NCT02272374|PROCEDURE|AVG creation|
223589755|NCT04849169|DEVICE|Experimental|Prolonged balloon inflation for hemorrhage management due to coronary artery perforation.
224187206|NCT02900157|BIOLOGICAL|Durvalumab|Durvalumab as a single agent will be administered by IV infusion after patients have completed the prescribed doses of Medi9090.
224187207|NCT03066466|DRUG|Atorvastatin|Oral medication given to prevent graft versus host disease in bone marrow transplant.
224187208|NCT03066466|DRUG|Methotrexate|IV medication given to prevent graft versus host disease in bone marrow transplant.
224187209|NCT03066466|DRUG|Tacrolimus|IV or Oral medication given to prevent graft versus host disease in bone marrow transplant.
224187210|NCT02727374|OTHER|Physiotherapy intervention|Physiotherapy intervention consists of conventional exercise program administered to this kind of patients at Hospital Clinico, including strengthening and balance exercises
224187211|NCT02727374|BEHAVIORAL|Cognitive-behavioural Intervention|Psychological treatment consists of group talks to treat the fear to fall
224187212|NCT05912192|DRUG|Elonide Nasal Spray|50mcg/dose One puff for each nostrils twice daily
224187213|NCT05912192|DRUG|Nasonex Nasal Spray|50mcg/dose One puff for each nostrils twice daily
224187214|NCT05912192|DRUG|Normal saline|50mcg/dose of 0.9% sodium chloride One puff for each nostrils twice daily
224187215|NCT02726516|DIETARY_SUPPLEMENT|PRJ-205|1 sachet per day
224187216|NCT02726516|OTHER|Placebo|1 sachet per day
224187217|NCT00211575|BEHAVIORAL|Disease Management Assessment|
224187218|NCT00806806|DRUG|SKY0402|Local administration of SKY0402 followed by noxious stimulus
223589756|NCT04906746|DRUG|Identify any dose-limiting toxicity (DLT) when ruxolitinib is administered to NSCLC cachexia patients.|There will be intra-patient dose escalation of ruxolitinib in every patient enrolled on study.
223589757|NCT04104880|DEVICE|Continuous positive airway pressure (CPAP)|Adults previously diagnosed with obstructive sleep apnoea will receive a three-month CPAP intervention
223589758|NCT03794674|OTHER|No intervention.|No intervention, since this is a validation study
223589759|NCT02843828|DEVICE|gait rehabilitation with Samsung Hip Assist v1|Participants will participate in 10 sessions of gait rehabilitation with Samsung Hip Assist v1 (5sessions-treadmill gait training / 5sessions-overground gait training), 30min per session
223589760|NCT02843828|OTHER|gait rehabilitation without Samsung Hip Assist v1|Participants will participate in 10 sessions of gait rehabilitation without Samsung Hip Assist v1 (5sessions-treadmill gait training / 5sessions-overground gait training), 30min per session
223589761|NCT04544579|DEVICE|Stent grafts anchored in different areas|Endovascular repair of ascending aortic dissection patients with stent grafts anchored in different areas
223589762|NCT00652951|BIOLOGICAL|GSK Biologicals´ Pneumococcal Conjugate Vaccine GSK1024850A (Synflorix™)|Intramuscular injection, 3 doses in the primary vaccination and 1 dose in the booster vaccination
223589763|NCT00652951|BIOLOGICAL|Infanrix™ hexa.|Intramuscular injection, , 3 doses in the primary vaccination and 1 dose in the booster vaccination
223589764|NCT00652951|BIOLOGICAL|Pediacel™|Intramuscular injection, , 3 doses in the primary vaccination and 1 dose in the booster vaccination
223589765|NCT00652951|BIOLOGICAL|Prevenar™|Intramuscular injection, , 3 doses in the primary vaccination and 1 dose in the booster vaccination
223589766|NCT03893162|DIETARY_SUPPLEMENT|Multi-strain probiotic|"The intervention in this study is a multi-strain probiotic which contains:~Bacillus subtilis, Bifidobacterium bifidum, Bifidobacterium breve, Bifidobacterium infantis, Bifidobacterium longum, Lactobacillus acidophilus, Lactobacillus delbrueckii ssp. bulgaricus, Lactobacillus casei, Lactobacillus plantarum, Lactobacillus rhamnosus, Lactobacillus helveticus, Lactobacillus salivarius, Lactococcus lactis ssp. lactis, Streptococcus thermophilus.~Each capsule contains minimum 2 billion live microorganisms per capsule, equivalent to 10 billion live microorganisms per gram."
223589767|NCT03893162|OTHER|Placebo|Visually identical capsules in identical packaging containing no active bacteria.
223589768|NCT01251835|DRUG|Sitaxsentan alone|Days 1-5: Sitaxsentan tablet, 100 mg, q24 h (once a day)
223589769|NCT01251835|DRUG|Sitaxsentan|Days 6-12: Sitaxsentan tablet, 100 mg, q24h (once a day)
223589770|NCT01251835|DRUG|Rifampin|Days 6-12: Rifampin capsule, 600 mg, q24h (once a day)
223589771|NCT01206582|BIOLOGICAL|Hemin|10 iv infusions for 8 weeks
223589772|NCT01206582|BIOLOGICAL|Albumin|10 iv infusions for 8 weeks
223589773|NCT04519346|OTHER|intradermal injection|Mesotherapy was performed by an experienced and trained physician using disposable 4 mm and 6 mm long 30 Gauge needles (Meso-relle, Biotekne SRL, Italy)to the pericarotid region, glabella, and the area between the eyes and ears, and to the area of the head where pain occurred (such as frontal, parietal, occipital region) for each patient
223589774|NCT01755455|DRUG|Ferrous sulfate 325mg|Ferrous sulfate 325mg tablet taken by mouth daily for 6 weeks
223589775|NCT01755455|DRUG|Placebo|Matching placebo capsule
223589776|NCT01318148|DRUG|caspofungin|Intermittent intravenous application of caspofungin
223589777|NCT06359080|DEVICE|Cognilum TM: Light Treatment Condition|The children will wear the CognilumTM device for up to 15 minutes at a time, twice a week, for a period of 10 weeks.
223589778|NCT04508153|DEVICE|Leva Pelvic Digital Health System|Pelvic floor muscle training using the pelvic digital health system to treat pelvic floor disorders, specifically stress urinary incontinence.
223589779|NCT04508153|OTHER|Kegel exercises|"Pelvic floor muscle training (PFMT), commonly referred to as Kegel exercises, is a first line conservative treatment for pelvic floor disorders, specifically stress urinary incontinence (SUI) or stress-predominant mixed urinary incontinence (SMUI)."
223589780|NCT04467034|BEHAVIORAL|Stanford Tobacco Prevention Toolkit curriculum|Stanford Toolkit curriculum delivered as a 5-session course in a school classroom setting.
223589781|NCT03558490|DEVICE|ZEMY software|"The ZEMY software medical device integrates specific algorithms based on international and validated guidelines. It provides individually customized information and defines for the patient an adapted action to follow for each of the following reported symptoms or anti-cancer treatment-related toxicities: diarrhea, fatigue, nausea, vomiting, cutaneous and mucosal toxicities, pain, fever/febrile neutropenia, high blood pressure, anxiety and depression.~During the 3-month study period, participants will be asked to enter their symptoms among the 10 symptoms listed in ZEMY on their smartphone dedicated to the study. Consequently, ZEMY software will provide to the participants adapted real-time information to advise them on the management of the experienced symptom and recommend hygienic-dietetic advice and symptomatic treatments."
223589782|NCT03558490|DRUG|Investigator's choice of anti-cancer treatment (except immunotherapy)|All anti-cancer treatments (except immunotherapy) will be left to the free choice of investigators. Participants shall be prescribed by the healthcare team both of the following symptomatic treatments: loperamide or any other anti-diarrheic treatment in case of diarrhea; and a prescription for any medication indicated in case of nausea/vomiting. A written prescription will be made by the investigator at screening for loperamide or any other anti-diarrheic treatment and symptomatic treatment for nausea/vomiting with documented dosage and duration.
223589783|NCT02591485|BEHAVIORAL|Attention Control Training|In the ACT, participants perform six computerized attention training sessions, 10 minutes per training session over six weeks. In each session the dot-probe task is administered. This task is consisted of 160 trials. Each trial began with a centrally-presented fixation cross that then replaced by a pair of words presented. Following that, a target probe appeared in the location previously occupied by one of the words, and participants are requested to discriminate the probe type via button press. Targets appear with equal probability at the location of threat and neutral stimuli, in order to modify the fluctuations in attention allocation.
223589784|NCT00122408|DIETARY_SUPPLEMENT|Ergyphilus|5 pills a day of Ergyphilus or placebo
223589785|NCT06413472|PROCEDURE|Mechanical ventilator adjustment for PCV|In pressure control ventilation (PCV) mode, patients will be ventilated for 5 minutes at a Tslope of 5% and another 5 minutes at 15% for both 1:1 and 1:2 I:E ratios. After each adjustment, screenshots of the mechanical ventilator (P-V loop screenshots) will be obtained . A total of 20 P-V loop screenshots will be captured over a 20-minute period (10 for the 1:2 ratio and 10 for the 1:1 ratio), which will be stored in the ventilators memory. The stored data will then be transferred from the ventilators memory to a computer via a flash drive.
223745791|NCT01318447|RADIATION|CyberKnife SBRT|Dose is 45 Gy (15 Gy in 3 fractions) and delivered over 5 to 10 days.
224187219|NCT00806806|DRUG|Placebo|Local administration of Placebo followed by noxious stimuli
224187220|NCT02550418|DRUG|Budesonide|
224308961|NCT06349577|OTHER|Pulsatile blood flow|Pulsatile blood flow generated by variable centrifugal pump flow rate during cardiopulmonary bypass
224187221|NCT04384887|BEHAVIORAL|covid-19 positive pregnant women|"It is planned to receive pregnant women who are admitted to the clinic or outpatient clinic and who are offered inpatient follow-up and treatment with the diagnosis of COVID-19.~Pregnant women who do not have covid-19 disease as a control group and who do not have a comorbid disease at similar gestational week will be included in the study. As a control group, covid-19 pcr negative patients will be admitted to our clinic in the same period."
224187222|NCT00617266|OTHER|tobacco cessation intervention|Active Health Education and Tobacco Cessation Programme for tobacco users using Behavioural Therapy only
224187223|NCT00617266|OTHER|Tobacco cessation intervention|Active Health Education and Tobacco Cessation Programme for tobacco users using Behavioural and Pharmaco-therapy
224187224|NCT00617266|OTHER|Tobacco cessation intervention|Distribution of pamphlets containing information on the hazards of tobacco
223496154|NCT07118293|BEHAVIORAL|MSE-PEACE|"The MSE-PEACE (Multi-Sensory Environment-Parent Empowerment and Child Engagement) intervention is a family-centered, therapist-guided sensory integration program specifically developed for children with developmental disabilities and their caregivers. Unlike traditional child-only sensory therapies, this intervention actively involves parents in all stages-assessment, goal setting, activity participation, and follow-up.~Each participant dyad (parent and child) attends 10 biweekly sessions (60 minutes each) in a structured sensory therapy space equipped with adjustable lighting, tactile materials, auditory inputs, and other multisensory tools. The intervention is tailored to each child's sensory processing profile and emotional regulation needs, while promoting parent-child co-regulation, bonding, and collaborative engagement.~Occupational therapists facilitate the sessions using individualized strategies to support child-led participation and empower parents with real-time coaching,"
223496155|NCT07117799|DRUG|PF-07248144|Period 1: Participants received Form 1 in a single dose of tablet fasted Period 2: Participants received Form 5 in a single dose of tablet fasted
223496156|NCT07117799|DRUG|PF-07248144|Period 1: Participants received Form 5 in a single dose of tablet fasted Period 2: Participants received Form 1 in a single dose of tablet fasted
223496157|NCT07117799|DRUG|PF-07248144|Period 1: Fasted participants received a single dose of tablet of Form 1 orally Period 2: Participants received a single dose of tablet orally of Form 5 in a fed state
223496158|NCT07117006|DEVICE|miniscrew- supported maxillary posterior segments' intrusion using clear aligners|maxillary posterior segments will be intruded with the aid of miniscrews and clear aligners
223589786|NCT06413472|PROCEDURE|Mechanical ventilator adjustment for VCV|In volume control ventilation (VCV) mode, patients will be ventilated for 5 minutes at a Tslope of 5% and another 5 minutes at 15% for both 1:1 and 1:2 I:E ratios. After each adjustment, screenshots of the mechanical ventilator (P-V loop screenshots) will be obtained . A total of 20 P-V loop screenshots will be captured over a 20-minute period (10 for the 1:2 ratio and 10 for the 1:1 ratio), which will be stored in the ventilators memory. The stored data will then be transferred from the ventilators memory to a computer via a flash drive.
223589787|NCT04520854|OTHER|Telehealth Protocol|"The first live-video session will orient participants to the features of the software, discuss the checklist to minimize environmental distractions, gauge how participants are managing their symptoms (pain, swelling) and provide non-pharmacological alternatives to supplement their current treatment strategies.~The second live-video session will be used re-examine how the participant is managing their symptoms (pain, swelling) and re-emphasize non-pharmacological alternatives.~The remaining live-video sessions will be focused on giving participants home-based therapeutic exercises. The therapeutic exercises will target the four main areas important to ankle sprain recovery: 1) range of motion; 2) balance; 3) gait; and 4) strength. All of the therapeutic exercises are based on previously published criteria for the rehabilitation of an LAS. The progression will start with single-plane, non-weight bearing or low-force activities and will advance at the same rate."
223745792|NCT03566368|DIAGNOSTIC_TEST|Electrocardiogram|a 12 lead surface electrocardiogram taken after connecting limb and chest electrodes
223745793|NCT03566368|DIAGNOSTIC_TEST|Transthoracic Echocardiogram|Transthoracic echocardiogram performed to evaluate Cardiac function in parasternal - long and short axis, Apical - 4 chamber and 5 chamber views.
223745794|NCT03566368|DIAGNOSTIC_TEST|Cardiac enzyme - Troponin I Levels|Blood sample - venous collected to measure blood troponin - I levels.
224187225|NCT00617266|OTHER|Tobacco cessation intervention|Active Health Education sessions (harmful effects of tobacco addiction) followed by focus group discussion for all BPO employees
224187226|NCT04354740|PROCEDURE|with percutaneous coronary intervention (PCI) are with new-generation drug-eluting stents (DES)|"II-PCI:~-Coronary angiography and intervention will be done according to the European guidelines of ACS revascularization.~III-CABG:"
223496159|NCT07117149|BEHAVIORAL|multicomponent, tiered intervention|"Kindergarten: Train teachers and integrate healthy weight management into kindergarten health policies; deliver health education sessions for children; monitor extra dietary intake and physical activity; conduct monthly height and weight measurements.~Family: Provide multi-format health education (lectures, short videos, articles) to communicate core intervention messages; set health behavior goals and deliver personalized feedback; conduct motivational interviewing in offline parent meetings or by phone.~Hospital: Offer professional health guidance and medical services. PKU-SMART online platform: Health Education Module; Growth Monitoring Module; Health Behavior Module; Home-Kindergarden Partnership Module."
224187227|NCT00350935|PROCEDURE|fMRI|One 30 minute session
224187228|NCT01092286|OTHER|neuromuscular warm-up|neuromuscular warm-up exercises that take 20 minutes to perform
224187229|NCT06651918|BEHAVIORAL|yoga practise|For the experimental study, the researcher will contact the participants to be included in the study and the intervention (yoga group) and control groups will be randomly created. The participants will be informed about the study by the researcher and their voluntary consent will be obtained. The researcher will provide information about the Identifying Characteristics Form for Children Diagnosed with Cancer and Their Families, the Quality of Life Scale for Children (PedsQL) and the Memorial Symptom Assessment Scale to be used in the study. The survey and scales will be applied to each participant individually one day before yoga. Then, the Yoga Group will be applied 3 sessions per week, 3 weeks in a row, each session will be 30 minutes. The researcher will repeat the survey and scale questions that he asked the participants before they started yoga at the end of the 3 weeks.
224187230|NCT04300049|DRUG|Glucagon Infusion|Study participants will receive glucagon infusion (6ug/kg/min for 12 hours) 12 hours.
224187231|NCT04300049|OTHER|Saline|Study participants will receive saline infusion for 12 hours.
223496160|NCT07118345|PROCEDURE|Early prophylactic decompressive hemicraniectomy|Early prophylactic decompressive hemicraniectomy (decompressive hemicraniectomy is required to initiate within 6 hours after completion of mechanical thrombectomy and within 4 hours after randomization).
223496161|NCT07119034|DIAGNOSTIC_TEST|Total cholesterol (TC), random blood glucose (RBG), triglyceride (TG), low-density lipoprotein cholesterol (LDL-C), and high-density lipoprotein cholesterol (HDL-C)|Blood samples were collected from the antecubital vein and processed at the TrueLab medical laboratory. The whole blood was initially collected in plain tubes, and subsequently centrifuged to obtain serum samples. Total cholesterol (TC), random blood glucose (RBG), triglyceride (TG), low-density lipoprotein cholesterol (LDL-C), and high-density lipoprotein cholesterol (HDL-C) Thioredoxin and 4-Hydroxynonenal quantification, malondialdehyde levels
223496162|NCT07118670|DRUG|Aflibercept 8mg|Solution in Vial, intravitreal (IVT) injection
223745795|NCT03213821|OTHER|protein intake|For each participant, weighed food records of 3 consecutive days will be analyzed for estimation of calorie and macronutrient intake and dietary preferences. To make sure good compliance, diets will be developed regarding patient's dietary habits and preferences individually. High calorie (30-35 kcal/kg Ideal body weight) diets including 6-8 small meals will be formulated. Intervention group will receive high protein diet as recommended to preserve muscle mass (1.2-1.5 g/kg IBW). Comparison group will receive protein based on GFR to preserve renal function. For older adults (\>65 years) protein content of diet will be as recommended by the international study group to review dietary protein needs with aging (PROT-AGE). In subjects with lower intake of protein, carbohydrate will be substituted. Both group will receive low fat diet.
223496164|NCT07116213|RADIATION|Moderately Hypofractionated Adaptive Radiotherapy|Moderately Hypofractionated Adaptive Postoperative Radiotherapy
223496165|NCT07115849|BEHAVIORAL|Physical training|Aerobic and resistance training three times per week. Two supervised training sessions.
223589788|NCT04520854|OTHER|Usual Care|The usual care group will be instructed to follow their treating physicians' orders. Participants will not receive instructions on how to self-manage symptoms nor a home-based exercise program.
223589789|NCT03654066|DRUG|Botulinum toxin type A|Botox injection in the LES
223589790|NCT03654066|DEVICE|Endoscope balloon dilator|Distal esophageal dilation
223589791|NCT03654066|OTHER|Patient reported outcomes|Subjects will complete two patient reported outcome measures (Eckardt and MADS).
223589792|NCT03654066|DIAGNOSTIC_TEST|Barium esophagram|Assess for radiologic severity of achalasia with barium column height measured 1 minute and 5 minutes after upright ingestion of barium
223589793|NCT04244721|OTHER|Preschool Autism Communication Therapy (PACT)|Professionals guide parents in the PACT therapy by videoconference. Sessions between parent and professionals are every 15 days for 6 months. Each session lasts one hour. At the end of the 12 sessions, additional booster sessions (one session per month over 6 months) will allow parents to maintain their skills. Parents will use therapy with their children in daily home practice. The aims of PACT therapy is to improve synchrony in the communication between the child and the parents. Improvement of the synchrony will mediate the decrease of autism symptoms of the child.
223589794|NCT04244721|OTHER|Treatment As Usual (TAU)|Children will receive therapies available in the community as speech language therapist or occupational therapist.
223745796|NCT04853745|DEVICE|AIR-FLOW® Master Piezon|AIR-FLOW® Master Piezon is intended for use in the cleaning and polishing of teeth by the projection of water,air, and dental powders onto the tooth surface. The device removes dental plaque, soft deposits, and surface stains from pits, grooves, interproximal spaces, or smooth surfaces of teeth. This air polishing device was used for all powder instrumentations.
223745797|NCT00402961|OTHER|Acupuncture|Acupuncture will be given twice daily for a total of three days (Day 1 to 3). The two acupuncture sessions will be separated by at least 4 hours, preferably given in the morning and late afternoon. Each session will last approximately 30 minutes, starting from the moment the first needle is inserted and ending the moment the first needle is removed. The last treatment will be given at the end of Day 3 or day of discharge.
224187232|NCT01700907|DRUG|Desflurane|The patients in this arm will be given the general anesthesia with desflurane and be used the Aysis as the anesthetic machine.
224187233|NCT01700907|DRUG|Sevoflurane|The patients in this arm will be given the general anesthesia with sevoflurane and be used the Aysis as the anesthetic machine.
224187234|NCT03632837|DEVICE|Hemoadsorption|see arm description
223589795|NCT06336915|BEHAVIORAL|Physician-Nurse Dyad Rounding|Collaborative Approach to Improve Unit-Level Metrics
223589796|NCT06584435|DRUG|Tremelimumab|Tremelimumab is administered intravenously at a fixed dose of 240 mg every 3 weeks for 1 treatment cycle until tumor recurrence or intolerable toxic effects.
223745798|NCT00402961|OTHER|Sham Acupuncture|Sham Acupuncture involves the acupuncturist tapping a plastic guiding tube on the surface of the true points to produce some discernible sensation and then immediately tapping a real needle sideways parallel to the skin surface without needle insertion. It will be given twice daily for a total of three days (Day 1 to 3). The two acupuncture sessions will be separated by at least 4 hours, preferably given in the morning and late afternoon. Each session will last approximately 30 minutes, starting from the moment the first needle is inserted and ending the moment the first needle is removed. The last treatment will be given at the end of Day 3 or day of discharge,
224187235|NCT06271798|OTHER|Life style modification advice|The lifestyle modification advice involves several key elements: reducing daily standing periods, avoiding excessive flexion of the knee joint during sitting, weight reduction, addressing cardio-respiratory conditions, incorporating venotonic agents, and utilizing below-knee elastic compression devices. These measures collectively aim to mitigate the development and progression of varicose veins, potentially preventing complications such as deep venous thrombosis and improving overall circulatory health.
224187236|NCT06271798|OTHER|Resistive exercise|Participants in group A will perform resistive exercise. The patients will be instructed to do seated toe raises exercise or standing toe raise exercise. The exercise will be performed for 30 minutes, three times per week for six weeks.
223496166|NCT07116018|BEHAVIORAL|Psychoeducation|The intervention comprises 8 individual psychoeducational sessions over 12 weeks, as an adaptation of the Psychoeducation, Paced Respiration, and Relaxation (PEPRR) (Laudenslager et al., 2015). The adaptation in the current study involves delivery by a trained nurse and omission of the biofeedback component.
223496167|NCT07115173|DRUG|This study aims to evaluate the efficacy and safety of a 14-day triple therapy regimen consisting of Zastaprazan 20 mg, clarithromycin, and amoxicillin for the eradication of Helicobacter pylori.|This study aims to evaluate the efficacy and safety of a 14-day triple therapy regimen consisting of Zastaprazan 20 mg, clarithromycin, and amoxicillin for the eradication of Helicobacter pylori.
223496168|NCT07113925|DRUG|TQB2101 for Injection|TQB2101 for Injection is an ROR1 ADC, an antibody-drug conjugate. It consists of three main components: a ROR1 monoclonal antibody responsible for selectively recognizing the surface antigen of cancer cells, a small molecule toxin responsible for killing cancer cells, and a linker connecting the antibody and the small molecule toxin. It is intended for clinical use in the treatment of advanced malignant tumors, including advanced malignant hematological tumors.
223496169|NCT07114913|DIAGNOSTIC_TEST|Nerve ultrasound|Ultrasonographic evaluation of the median nerve at the carpal tunnel and adjacent levels
223496170|NCT07114913|DIAGNOSTIC_TEST|Nerve conduction studies|Upper extremity nerve conduction studies including median-ulnar sensory and motor responses
223496171|NCT07114913|DIAGNOSTIC_TEST|Pressure pain threshold|Pain pressure threshold is used to measure deep muscular tissue pain sensitivity.
223496172|NCT07114757|PROCEDURE|Renal denervation after stroke|Renal sympathetic denervation (RDN) is a minimally invasive catheter-based procedure targeting renal sympathetic nerve fibers to achieve sustained reductions in blood pressure.
223496173|NCT07116330|OTHER|Vascuar risk factor screening (blood pressure, medical history, BMI, laboratory tests)|"The vascular risk assessment is outlined below, there may be slight variations according to local routines. Overall, the screening should include:~Family history of vascular disease~Tests/examinations (order or obtain from medical records \[past 3 months\]) Weight Height Waist circumference 12-lead ECG Resting and standing blood pressure Total cholesterol HDL cholesterol LDL cholesterol HbA1c High sensitivity CRP Serum creatinine Urine albumin-to-creatinine ratio~Medical history Atherosclerotic cardiovascular disease Atrial fibrillation Congestive heart failure Diabetes mellitus Hypertension Kidney disease Life-style risk factors (smoking, exercis"
223496174|NCT07115017|DRUG|[18F] FZTA|Participants will receive a single intravenous bolus injection of 7 ± 20% milliCurie (mCi) of the investigational radiotracer \[18F\]-FZTA. Participants will then undergo a brain \[18F\]-FZTA PET scan
223496175|NCT07116122|DEVICE|Tracking/finding system|Persons living with Alzheimer's Disease or Related dementias will wear the Care Companion smartwatch for approximately one month (stage I) or 6 months (stage 2). The Caretakers will utilize the smart phone application (app) to monitor the person wearing the watch and be alerted to elopements. The system will notify a caregiver if the person with dementia leaves a defined area (e.g., the home) via the application. In the tether mode (e.g., outside of the home), the system monitors the distance between the smartwatch and the caregiver's smartphone. When a separation distance exceeds a set threshold, the application will alert the caregiver and start tracking the location of the person with dementia by displaying the person's position on the caregiver's smartphone.
223496176|NCT07119008|DEVICE|Virtual reality|Patients will perform 12 virtual reality sessions at a rate of 2 sessions per week for 6 weeks. The patient will be offered to properly store food groceries by differentiating perishable or non-perishable foods from non-food items, or to prepare cooking recipes.
223496177|NCT07118579|DRUG|Remimazolam|remimazolam induction (0.3-0.5 mg/kg) + maintenance (1-3 mg/kg/h)
223496178|NCT07118579|DRUG|Propofol|Anesthesia induction (2-3 mg/kg) + Anesthesia maintenance (6-10 mg/kg/h)
223496179|NCT07118579|DRUG|Ciprofol|Anesthesia induction (0.4-0.5 mg/kg) + Anesthesia maintenance (0.8-1.2 mg/kg/h)
223496180|NCT07118202|DEVICE|TheraBionic P1|Amplitude-modulated electromagnetic fields will be self-administered and given continuously to patients in three 60-minute treatments per day, administered in the morning, middle of the day, and in the evening
223496181|NCT07116395|DRUG|Tranexamic Acid (TXA)|orthopedic trauma patients who are on anticoagulation
223496182|NCT07113665|DEVICE|ExAblate Neuro 4000|The ExAblate Neuro 4000 is an MRI-guided focused ultrasound (MRgFUS) system designed to perform noninvasive thermal ablation of targeted brain tissue. In this study, the ExAblate Neuro 4000 will be used to perform a bilateral capsulotomy by ablating the anterior limb of the internal capsule (ALIC) in patients with treatment-refractory anorexia nervosa (AN) and comorbid obsessive-compulsive disorder (OCD) and/or major depressive disorder (MDD). The procedure will be conducted under real-time MRI guidance and thermometry to ensure accurate targeting and controlled thermal delivery. This study aims to evaluate the safety, feasibility, and preliminary clinical benefit of MRgFUS in improving psychiatric symptoms and quality of life in this patient population.
223496183|NCT07116174|BIOLOGICAL|Xcell Amnio Matrix|A lyophilized amniotic membrane allograft
223496184|NCT07113730|OTHER|immune reconstitution|Detection of immune reconstitution in peripheral blood of patients by flow cytometry at 30-day intervals for 180 days post-transplantation.
223589797|NCT04976361|OTHER|PRP was done using visulas green laser machine (Carl Zeiss Meditec AG Geoschwitzer Str. 51-52,07745 jena, Germany)|PRP was done using visulas green laser machine (Carl Zeiss Meditec AG Geoschwitzer Str. 51-52,07745 jena, Germany)
223589798|NCT00306527|BIOLOGICAL|Cell culture derived influenza vaccine|as a single IM injection of 0.5 ml in the deltoid muscle, preferably of the non-dominant arm
223589799|NCT00306527|BIOLOGICAL|egg-derived influenza subunit vaccine|as a single IM injection of 0.5 ml in the deltoid muscle, preferably of the non-dominant arm
223589800|NCT01267942|DRUG|Enhancin|"Intravenous Enhancin at induction at a dose of 25 mg/kg amoxycillin equivalent.~Oral dose of the same at the same dosage for the active comparator arm."
223589801|NCT05663840|BEHAVIORAL|Progressive resistance exercise|Patients with predominant symptoms of cervical dystonia will receive exercise training. Patients will receive progressive resistance exercise focused cervical and shoulder training (PERFECT) plus standard-of-care (SOC) therapy. Resistance training will consist of mainly muscle-strengthening exercises for the neck, shoulder and arms and a few upper trunk muscles. Resistance training will be guided by physical therapists at twice a week schedule for 6 months. These participants will also receive SOC therapy.
223589802|NCT05663840|BEHAVIORAL|Standard of care|Subjects will receive SOC therapy only
223589803|NCT00125021|DRUG|Capecitabine|Given twice a day for 14 days followed by 7 days of no capecitabine (1 cycle is 21 days).
223589804|NCT00125021|DRUG|OSI-774|Given once daily
223589805|NCT01586455|DRUG|Human Placental Derived Stem Cell|Infusions of thawed HPDSC to be given following UCB infusion.
223496185|NCT07118384|DRUG|Cefoperazone-sulbactam injection|Two grams of Cefoperazone/sulbactam IV are administered every 8 hours, and each dose is administered as an extended infusion over 4 hours. The solution is diluted with a compatible solution (normal saline 0.9%) with a maximum final concentration of 250 mg/ml
223496186|NCT07118384|DRUG|Ampicillin - Sulbactam Injection|Two grams of Ampicillin/sulbactam IV are administered every 8 hours, and each dose is administered as an extended infusion over 4 hours. The solution is diluted with a compatible solution (normal saline 0.9%) with a final concentration not exceeding 45mg/ml.
223496187|NCT07114068|OTHER|Self mobilization of Obturator Internus Muscle using wand|Participants will be randomly assigned to the internal or external Obturator Internus mobilization groups. The internal mobilization group will access the Obturator Internus muscle via the vagina, which is common practice in Pelvic Health Physical Therapy. The external mobilization group will be accessing the Obturator Internus muscle with the same pelvic wand, but externally. Pelvic wands will be provided for each participant at no cost and will be used for only that participant. Prior to intervention with a pelvic wand, each participant will be provided education regarding the anatomy of the pelvic floor and hip and a protocol review of the intervention.
223496188|NCT07118605|PROCEDURE|Minimally Invasive Sagittal Split Ramus Osteotomy|This procedure involves a limited mucosal incision and tunnel dissection technique combined with low and short osteotomy and minimal soft tissue manipulation. The goal is to reduce surgical trauma, edema, blood loss, and operative time while maintaining clinical effectiveness.
223496189|NCT07118605|PROCEDURE|Conventional Sagittal Split Ramus Osteotomy|This procedure follows the traditional wide exposure technique with full-thickness mucoperiosteal flap elevation. This method is widely accepted and serves as the control for comparison.
223496190|NCT07116824|DRUG|HB1801|HB1801 is administered by intravenous infusion.
223496191|NCT07116824|DRUG|Trastuzumab|Trastuzumab is administered by intravenous infusion, 8mg/kg loading dose and then 6mg/kg per cycle, Q3W.
223496192|NCT07116824|DRUG|Pertuzumab|Pertuzumab is administered by intravenous infusion, 840mg loading dose and then 420mg per cycle, Q3W.
223496193|NCT07116824|DRUG|Docetaxel|Docetaxel is administered by intravenous infusion, 75mg/m\^2, Q3W.
223496194|NCT07116993|DEVICE|theraputic ultrasound|Ultrasound is a mechanical sound wave with frequencies above human hearing, requiring a medium like air or tissue to travel, commonly used in imaging.
223496195|NCT07116993|DEVICE|infrared radiation|Infrared, in contrast, is electromagnetic radiation associated with heat, doesn't need a medium, and is used in applications like thermal imaging and remote controls.
223496196|NCT07118696|DRUG|Extra 600mg of Rifampicin|Intervention group participants will receive standard treatment (RHZE), plus an optimised regimen consisting of RIfampicin at 20 mg/kg (additional 600mg rifampicin in each weight band) during a shortened treatment period of 16 weeks.
223496197|NCT07118696|DRUG|Placebo|The standard treatment regimen for DS-TB (rifampicin at 10 mg/kg and isoniazid for 6 months, plus pyrazinamide and ethambutol for the first 2 months; 2RHZE/4RH), with additional placebo for the first 4 months (16 weeks).
223496198|NCT05390541|BEHAVIORAL|Empowered to Test Yourself|There will be 5 sessions of the intervention, all of which will follow the same format. Participants will be sent push notifications for each session. Each session will begin with using relevant constructs from sIMB (i.e., information and behavioral skills). Next, participants will choose positive outcomes resulting from the behavior, barriers to performing the behavior (mental contrasting), select situational cues and action plans to overcome selected barriers (implementation intentions), and practice typing in implementation intentions and positive outcomes from memory (memory practice). To ensure participants retain the implementation intentions, the investigators will use memory practice. Participants will be asked to self-code if the participant is correct or incorrect. Lastly, participants will learn behavioral skills to engage in each of the 5 actions to increase self-efficacy.
223589806|NCT02078388|DRUG|Doxorubicin|
224308962|NCT03490344|DRUG|Daratumumab|"* Cycles 1 and 2: Daratumumab 16mg/kg weekly per cycle (28 days) as intravenous infusion (total duration: 8 weeks)~* Cycles 3-6: Daratumumab 16mg/kg once every 2 weeks per cycle (28 days) as intravenous infusion (total duration: 16 weeks)"
223589807|NCT03204422|OTHER|No intervention|no any other intervention
223589808|NCT05532891|OTHER|COVID-19 pandemic|Pandemic group underwent surgery during the COVID-19 pandemic. Pre-pandemic group underwent surgery prior to the pandemic.
223589809|NCT03603106|DRUG|P03277|"Part I: P03277 was administered intravenously with a flow rate ranging from 0.5 to 2 mL/s.~Part II: P03277 was administered intravenously with a flow rate of 2 mL/s."
223589810|NCT03603106|DRUG|Placebo|"Part I: Placebo was administered intravenously with a flow rate ranging from 0.5 to 2 mL/s.~Part II: Placebo was administered intravenously with a flow rate of 2 mL/s."
223589811|NCT00417963|DEVICE|Carotid Artery Stenting|placement of a bare metal stent at sites of stenosis in the carotid artery
223617807|NCT00666666|DRUG|Bicalutamide|Daily bicalutamide 50 mg po is encouraged for the first month of LHRH agonist therapy to prevent a flare. Continued bicalutamide use is optional. Bicalutamide will be administered orally at a dose of 50 mg po daily, Day 1 to 28 of each cycle.
223617808|NCT00666666|OTHER|LHRH agent|An LHRH agonist(Leuprolide Acetate or Goserelin)can be administered at standard dosing appropriate to the agent used.
223745799|NCT02307357|BEHAVIORAL|physical fitness tests|the subjects will perform 6 different tests to evaluate their physical fitness
223745800|NCT03696810|DIAGNOSTIC_TEST|Laboratory tests|• Laboratory tests (HbA1C levels and lipids)
224308963|NCT03490344|DRUG|Lenalidomide|Lenalidomide maintenance therapy to be administered as standard treatment to all participants. This is administered as 5-15 mg daily 21-28/28 day cycle.
223617809|NCT04004897|DIAGNOSTIC_TEST|Optic nerve sheath diameter measurement|Optic nerve sheath diameter measurement is performed with a linear ultrasound probe placed over the eyelid.
223617810|NCT04998071|DRUG|Bupivacaine hydrochloride|Analgesic efficiency comparison between two concentration of bupivacaine hydrochloride using for posterior quadratus lumborum block in LPEC
223745801|NCT05955118|DEVICE|Hydrus Microstent|Hydrus Microstent placed at the time of cataract surgery
223496199|NCT05390541|OTHER|Educational Control|Participants will receive the HIV/STI home testing kit, instructions to mail in the kit, notification when results are ready to check online, treatment from a provider at Kind Clinic for positive results, and referral to Kind Clinic for PrEP. Each session and assessment will occur every 3 days. Session 1: Basic information about STIs. Session 2: HIV and stigma, basic information about HIV, and HIV transmission facts and myths. Session 3: Four stories about different people who are HIV-positive, how HIV was contracted, and one story about a woman who contracted herpes and how to all cope and live healthy lives. Session 4: How to disclose positive STI status. Session 5: Basic information about PrEP, and information on how to correctly use a male condom, female condom, and dental dam.
223496200|NCT07117435|DRUG|paclitaxel cationic liposome for injection|Paclitaxel cationic liposome was administered through hepatic arterial catheter infusion, in a gradual increment dose range from 33 mg/m\^2 to 55 mg/m\^2
224187237|NCT06271798|OTHER|Aerobic exercises|Participants in group B will perform aerobic exercise. Each session will begin with 10 min of low-intensity treadmill walking for a warm-up. The subsequent aerobic component will involve incline treadmill walking for 20 min at a perceived exertion of 6-7 (i.e., somewhat hard) on Borg's 3-10 scale followed by 10 min of low-intensity treadmill walking for cool down. The exercise will be performed for 30 minutes, three times per week for six weeks.
224187238|NCT05219032|BEHAVIORAL|Professional Medical Interpreter|A professional medical interpreter accompanies patient to each appointment.
224187239|NCT06452290|DEVICE|brain 18F-FDG PET-CT|PET scanner, Philips VEREOS PET/CT scanner. Three Philips VEREOS digital PET/CT scanners are installed in the nuclear medicine department.
224187240|NCT04214483|OTHER|No intervention|There is no intervention for this study.
224187241|NCT05675579|DRUG|Sacituzumab Govitecan|Given by IV (vein)
223496201|NCT07117435|DRUG|Oxaliplatin|Oxaliplatin 130 mg/m2 i.v. on D1
223496202|NCT07117435|DRUG|Capecitabine|Capecitabine 1000 mg/m2 p.o. Bid on Day 1-14
223496203|NCT07117435|DRUG|Bevacizumab|Bevacizumab 7.5 mg/kg i.v. on D1
223496204|NCT07116707|BEHAVIORAL|Short Mental Health Literacy Program (SMHLP)|A single 45-minute behavioral health education lesson delivered by homeroom teachers. The session included a slide-based introduction to mental health, a 10-minute animated video about a student experiencing psychological stress, and a worksheet-based reflection activity. Teachers prepared using self-guided materials.
223496205|NCT07118059|DIETARY_SUPPLEMENT|Omega-3 (EPA+DHA)|In this study omega-3 will be the real thing mega omega supreme capsule, it will be used as an adjunct therapy with TB treatment in the intensive phase of treatment. Participant will receive x3, 1g capsules which will provide approximately 2g of EPA and DHA
223496206|NCT07118059|DIETARY_SUPPLEMENT|Placebo|This group will receive the placebo, which will be 3 x 1g capsules of high linoleic sunflower oil, the sunflower capsules have been encapsulated to match the dimension of the omega 3 supplement. The capsules will also be given as and adjunct to TB treatment of the intensive phase of TB treatment
223496207|NCT07118475|BIOLOGICAL|Autologous islet transplantation|"1. EUS-FNB or surgical procurement of pancreatic tissue~2. In vitro culture of adult pancreatic progenitor~3. In vitroinduction of islets~4. islet transplantation beneath the anterior rectus sheath~5. Post-transplant follow-up"
223496208|NCT06923423|BEHAVIORAL|Group Cognitive Processing Therapy (CPT)|Participants in CPT group therapy will learn about trauma and how to change upsetting thoughts related to it. Participants will attend up to a total of 12 sessions held 1-2x/week for 90 minutes. No more than 10 participants will be in a group. In this study, CPT provided is a version that was adapted for prisons.
223589812|NCT04909658|BEHAVIORAL|ACT Matrix|"The ACT protocol group performs exercises to improve the psychological well-being of parents. The matrix is an ACT protocol that is usually presented visually to patients and consists of two intersecting lines that make up four quadrants, which provide a point of view on one's psychological actions and experiences. The vertical line is the line of experience, the upper part corresponds to the experience of life linked to the five senses - sight, hearing, taste, smell and touch - (experience of the five senses), the lower part refers to the experiences internal as thoughts and feelings (internal/mental experience). The horizontal line is the behavior line, the left side concerns the actions that perform the function of moving us away from experiences, emotions, unwanted thoughts (experiential avoid-ance), the right side indicates the actions we take to get closer and go towards our values (committed action)."
223617811|NCT00934635|DRUG|Paliperidone ER|9 mg tablet once a day followed by PET scan in approximately 2 hours
223617812|NCT00934635|DRUG|Oral risperidone|6 mg tablet once a day followed by PET scan in approximately 2 hours
224187242|NCT05675579|DRUG|Pembrolizumab|Given by IV (vein)
224187243|NCT02461173|DRUG|Merional|On the 3rd day of menstruation women will have a vaginal ultrasound and will receive daily intramuscular 150 IU of human menopausal gonadotropins (hMG, Merional ®, IBSA, Lugano, Switzerland) starting from the 3nd day of menstruation.
224187244|NCT02461173|PROCEDURE|IUI|Semen will be processed and drawn into a shepherd catheter attached to a 1 mL syringe and injected into the uterus
224187245|NCT02461173|PROCEDURE|Ovulation detection|Women will be asked to test their morning urine specimen for luteinizing hormone daily starting 4 days before the expected day of ovulation. This will be done using a qualitative kit
223617813|NCT00934635|OTHER|PET Scan|PET Scan
224187246|NCT02461173|DRUG|Choriomon|Administration of 10000 IU of human chorionic gonadotropin (hCG; Choriomon®, IBSA) when at least 2 follicles measuring 18 mm are observed during vaginal ultrasound and is associated with serum E2 of 500-3000 Pg/mL
224187247|NCT02461173|DEVICE|shepherd catheter|
224187248|NCT04148222|OTHER|No intervention|There is no intervention for this study
224187249|NCT06119269|DIAGNOSTIC_TEST|Therapeutic drug monitoring|At each follow up visit, plasma concentrations of ponatinib will be measured and compared with therapeutic range (according to a lower concentration equal to 21 nM)
224187250|NCT06119269|DIAGNOSTIC_TEST|Molecular Response|BCR-ABl transcript levels will be assessed to evaluate molecular response to ponatinib
224187251|NCT01291420|BIOLOGICAL|autologous dendritic cell vaccination|4 biweekly intradermal DC injections of 10\*10E6 DCs (500 µL) at 5 sites (100 µL/site) in the ventromedial regions of the upper arm approximately 5-10 cm of the regional lymph nodes
224187252|NCT00241891|BEHAVIORAL|Single behavior intervention|Focused on changing beverage choices which may have a significant impact on weight.
223496209|NCT06923423|BEHAVIORAL|Control Group Individual trauma focused self-help via workbook|The self-help therapy is a therapy that people do on their own using a workbook. By reading and doing practice assignments in the workbook, people can learn skills to recover from trauma.
223496210|NCT07103668|DRUG|CAR T cells|better PFS/OS data comparing to the other studies.
223496211|NCT07103668|DRUG|Control|Chemo therapy by PI options.
223589813|NCT04909658|BEHAVIORAL|PT Protocol|The PT protocol group received behavioral tasks related to child management. Parent training interventions carried out in groups can be a good solution to modify parent behavior by providing social support and new coping strategies. The intervention includes 24 weekly meetings lasting 90 minutes each. The total intervention is six months.
223589814|NCT04878692|DRUG|Application of Onco-Rash cream|"The cream Onco-Rash will be administered topically. The patient will be asked to apply the cream twice a day in the morning and evening for 6 weeks to clean, dry skin on selected target areas of the body, namely: the face, the front of the neck, the front of the chest, the back of the neck and the back of the chest. The product penetrates by gentle massage."
223589815|NCT04878692|DRUG|Application of Onco-Neutre cream|"The cream Onco-Neutre will be administered topically. The patient will be asked to apply the cream twice a day in the morning and evening for 6 weeks to clean, dry skin on selected target areas of the body, namely: the face, the front of the neck, the front of the chest, the back of the neck and the back of the chest. The product penetrates by gentle massage."
223589816|NCT02319135|DRUG|Azacitadine|
223589817|NCT02319135|DRUG|Fludarabine|
223589818|NCT02319135|DRUG|Cytarabine|
223589819|NCT02319135|DRUG|Lenograstim|
223589820|NCT02319135|DRUG|Filgastrim|
223589821|NCT01023672|DRUG|Armodafinil|150-250 mg armodafinil by mouth daily
223589822|NCT02767661|DRUG|Capecitabine|Capecitabine, 500mg, orally three times daily (continuously)
223589823|NCT02767661|DRUG|Aromatase Inhibitor|Aromatase Inhibitor (Anastrozole, 1mg, orally once daily or Letrozole, 2.5mg, orally once daily or Exemestane , 25mg, orally once daily)
223589824|NCT05332652|DEVICE|trancranial magnetic stimulation|A trained research staff or physician will perform tDCS to the subject. Direct current will be delivered by a battery-operated, constant current stimulator, through 2 rubber electrodes embedded in a pair of saline-soaked sponge bag. Stimulation intensity will be ramped up to 1 mA over 30 seconds and maintain at 1 mA for 20 minutes, and then ramped down to 0 mA over 30 seconds.
223589825|NCT00006773|DRUG|bortezomib|Given IV
223589826|NCT05050656|DRUG|Duloxetine 60mg|Duloxetine is a selective SNRI prescribed in depression, anxiety, and chronic pain like diabetic neuropathy and fibromyalgia, it acts through central and peripheral pain modulation
223589827|NCT05050656|DRUG|Placebo|placebo tablets identical to duloxetine tablets
223589828|NCT06208111|BEHAVIORAL|cognitive behavioral therapy|cognitive behavioral therapy would be used as intervention strategy for women facing partner violence to Clear about actual problems, re-educate about the issue of domestic problems and mental health, Logical expectations, Identify negative automatic thoughts,Thinking errors, and Improve understanding to identify which stressors trigger negative emotions. Moreover, this intervention will help to Prepare women how to deal with stress and overcome the reaction.
223589829|NCT01058629|DEVICE|SynergEyes A2 Hybrid Contact Lens|SynergEyes A2 is a hybrid contact lens cleared by the US Food and Drug Administration (FDA) for daily wear correction of up to +20.00 and -20.00 in eyes with astigmatism up to 6.00D and for presbyopia.
223589830|NCT04766008|DRUG|Metformin|Diabetic patients treated with metformin undergoing coronary angiography will not suspend metformin before and after PCI.
223589831|NCT00777361|DRUG|AZD3480|Iv single dose, 4-hour infusion of 25 mg
223589832|NCT00777361|DRUG|AZD3480|Oral solution single dose of 50 mg
223589833|NCT00590343|DRUG|vatalanib|Subjects who meet all inclusion and exclusion criteria will receive an initial dose of PTK787/ZK222584 1,250mg once daily, and subjects will remain on the scheduled doses of Sandostatin LAR 30mg every 4 weeks.
223589834|NCT02783092|DRUG|Cannabidiol|Oral solution of cannabidiol 200 mg / mL dissolved in corn oil. Titration period: 5 mg / kg / day up to 25 mg / kg / day. Maintenance period: highest dose obtained during the titration period (maximum of 25 mg/kg / day)
223589835|NCT02783092|DRUG|Placebo|The placebo will be an oral solution of corn oil. Titration period: 5 mg / kg / day up to 25 mg / kg / day. Maintenance period: highest dose obtained during the titration period (maximum of 25 mg/kg / day)
223589836|NCT00387725|BIOLOGICAL|rLP2086|Vaccine administered at 0, 1, and 6 months
223589837|NCT00387725|BIOLOGICAL|rLP2086|Vaccine administered at 0, 1, and 6 months
223589838|NCT00387725|BIOLOGICAL|rLP2086|Vaccine administered at 0, 1, and 6 months
223589839|NCT00387725|BIOLOGICAL|rLP2086|Vaccine administered at 0, 1, and 6 months
223589840|NCT02479815|DIETARY_SUPPLEMENT|Micronutrient Powder (MNP)|Every month, 15 MNPs sachets will be provided to all children 6-23 months of age with the instruction to add them to their complementary food, to enable point-of-use fortification on every alternate day. The MNPs sachets will contain 6 mg Fe together with 14 other vitamins and minerals.
223589841|NCT06098248|DIAGNOSTIC_TEST|cCeLL - Ex vivo|Neoplastic brain tissue biopsied from participant will be visualized, and images will be captured using cCeLL - Ex vivo.
223589842|NCT04780412|DRUG|Misoprostol|Vaginal Misoprostol tablets in a dose of 50 microgram given 90-120 minutes before an elective caesarian section.
223589843|NCT04780412|DRUG|Placebo|Vaginal placebo pills given 90-120 minutes before an elective caesarian section.
223589844|NCT03873935|OTHER|Evaluation of periodontal status|Clinical examination
223589845|NCT00067379|PROCEDURE|interceptive orthodontic treatments|orthodontic procedures
223617814|NCT00934635|DRUG|Oral risperidone|4 mg tablet once a day followed by PET scan in approximately 24 hours
223617815|NCT00934635|DRUG|Oral risperidone|4 mg tablet once a day followed by PET scan in approximately 2 hours
223617816|NCT00934635|DRUG|Paliperidone ER|6 mg tablet once a day followed by PET scan in approximately 2 hours
223617817|NCT00934635|DRUG|Paliperidone ER|6 mg tablet once a day followed by PET scan in approximately 24 hours
223617818|NCT00934635|DRUG|Oral risperidone|6 mg tablet once a day followed by PET scan in approximately 24 hours
223617819|NCT00934635|DRUG|Paliperidone ER|9 mg tablet once a day followed by PET scan in approximately 24 hours
223496212|NCT07121231|OTHER|Motor Support Program|The MSP was implemented over 12 weeks, two days a week, 50 minutes per session. Based on pre-test results, 30% (15 minutes) of each session was devoted to individualized activities, and 70% (35 minutes) to group activities supporting peer interaction. This structure allowed for both personalized support and social engagement. The program was carried out by the research team and eight special education teachers at the children's rehabilitation centers. Each child received one-on-one support from at least one teacher. Activities were aligned with preschool motor development goals and followed a four-phase structure: (1) Warm-up (5 min): rhythmic movements (e.g., walking, running, jumping); (2) Preparation (5 min): functional exercises for flexibility and joint mobility; (3) Main activity (35 min): individual and group exercises to enhance motor, social, and pre-academic skills; (4) Cool-down (5 min): group games reinforcing learned skills and social interaction.
223496213|NCT07120126|DEVICE|EDDY Sonic Activation|Sonic activation was performed using the EDDY device with 2.5% NaOCl and 17% EDTA solutions during final irrigation, following root canal preparation.
223496214|NCT07120126|PROCEDURE|Conventional Syringe Irrigation|Final irrigation was performed using syringe irrigation with 2.5% NaOCl and 17% EDTA solutions, without any activation.
223496215|NCT07119866|OTHER|OXYGEN RESERVE INDEX|Noted for each patient.
223496216|NCT07119918|DRUG|Recaticimab|Recaticimab 300mg subcutaneous Q8W for 1 year.
223496217|NCT07119918|DRUG|Placebo|Matched placebo subcutaneous Q8W for 1 year.
223496218|NCT07120659|OTHER|soft touch massage|Soft superficial massage which follows the anatomy of the body without penetrating into the deeper tissues
223496219|NCT07120659|OTHER|vacuum massage|Intense stimulation through suction of the skin and deeper layers
223496220|NCT07119749|OTHER|Stable isotope tracer consumption|Daily consumption of oral deuterium oxide (0.3 ml per kg of lean body mass) to equilibrate in body water and become slowly incorporated into muscle protein, enabling measurement of muscle protein synthesis rates
223496221|NCT07119749|RADIATION|DXA scan|Whole body DXA scan to assess lean body mass for prescription of deuterium oxide tracer
223496222|NCT07119749|BEHAVIORAL|Controlled diet|Participant will be asked to consume a provided 6-day diet package that will be prepared by the research team. This package will include 3 meals per day plus snacks
223496223|NCT07119749|OTHER|Saliva sample|Obtained from participants by asking them to spit into a tube each day during the study, for 11 days in total.
223496224|NCT07119749|OTHER|Blood sample|Resting venous blood sample from a forearm vein on 6 separate occasions
223496225|NCT07119749|PROCEDURE|Muscle biopsy|A highly experienced researcher will sample a small section of muscle (\~200 mg) from the vastus lateralis muscle under local anaesthetic (5 ml, 1% Lidocaine)
223496226|NCT07119749|BEHAVIORAL|Resistance exercise|participants will complete 8 sets of 10 repetitions of unilateral eccentric knee extensions on an isokinetic dynamometer.
223496227|NCT07119749|OTHER|Isometric strength test|Bilateral isometric strength will be measured using a well-established protocol on an isokinetic dynamometer.
223496228|NCT07119749|DIETARY_SUPPLEMENT|Supplement|Consumption of 3 supplements a day for 3 days following resistance exercise. All supplements are commercially available.
223496229|NCT07116408|DRUG|Lidocaine (drug)|Tx 360/lidocaine
223589846|NCT06582927|BEHAVIORAL|Mindfulness-Based Attention Training (MBAT)|"MBAT is an evidence-based 8-hour mindfulness program that comprises 4 central topics and associated practices. The concentration topic introduces participants to mindfulness basics, including discussion of focused attention and mind wandering. The body awareness theme involves the cultivation of greater self-awareness, and the development of equanimity. The open monitoring theme emphasizes awareness of and receptivity to changing experiences and moments of uncertainty. The theme of connection addresses leadership and group cohesion, and the cultivation of kindness and connection with others.~The course content and materials in the present study will entail the foundational MBAT curriculum and other related content delivered virtually over Zoom but will consist of 8, 1-hour sessions delivered across 8 consecutive weeks."
223589847|NCT05604742|DRUG|Belimumab (Benlysta)|Belimumab will be administered intravenously every 2 weeks for 3 cycles and then every 4 weeks for a total of 5 cycles
223589848|NCT04573686|DRUG|Erythropoietin|Erythropoietin will be given subcutenous to all patients
223496230|NCT07116408|DEVICE|Tx 360|Tx 360 device
223496231|NCT07117682|DEVICE|Autologous Adipose-Derived Regenerative Cells (ADRCs) Intraovarian Injection|Under general anesthesia, patients undergo lower abdominal liposuction (aspirate: 100-360 mL). ADRCs are immediately prepared bedside using the Celution® system (Cytori Therapeutics): Lipoaspirate is processed in a sterile container with automated separation, centrifugation, and resuspension (90-120 min). From the 5mL ADRCs suspension obtained, 0.5mL is reserved for QC (cell count/viability/surface markers); 4.5mL is injected bilaterally into ovarian stroma (2-2.5mL/ovary). Post-procedure, patients are monitored supine for 30 min for local/systemic reactions before discharge if stable.
223589849|NCT02286635|DRUG|Deflazacort and rifampin|Deflazacort, a glucocorticoid with anti-inflammatory and immunosuppressive effects, is used in treating a variety of diseases. Pharmacologically it is an inactive pro-drug which is metabolized completely and rapidly to the active drug 21-desacetyldeflazacort (21 desacetyl-DFZ). The elimination of this metabolite is primarily via the urine in humans. Its potency is approximately 70 to 90% of prednisone and 6 mg of deflazacort has approximately the same anti-inflammatory potency as 5 mg of prednisolone or prednisone. Rifampin is a potent inducer of drug metabolism by inducing a variety of hepatic and intestinal CYP enzymes, especially CYP3A4. Rifampin is a semi-synthetic antibiotic.
223745802|NCT05694936|DRUG|Sodium Valproate|Sodium valproate oral continuously in a twice daily dose (Initial dose of 600mg/d up-titrated to target daily dose of 20 mg/kg/d at Cycle 1 Day 13, then dose adjusted to maintain serum VPA levels within the target range of 50-100 μg/mL); Refer to arm description.
223745803|NCT05694936|DRUG|Panitumumab|Panitumumab 6 mg/kg IV every 2 weeks or cetuximab 500 mg/m2 IV every 2 weeks; Refer to arm description.
223496232|NCT07117747|OTHER|Healthy volunteers|All subject belong to the same arm and ther is no intervention
223496233|NCT07119827|DIAGNOSTIC_TEST|Motor, cognitive and psychological assessment|Participants evaluated at T0 (Initial assessment upon admission to the rehabilitation facility), T1 (at discharge from the inpatient rehabilitation program, as long as at least 30 days have passed since the initial assessment (T0), T2 (at 12 months from the event for patients with stroke, and at 18 months from the event for patients with sABI).
224187253|NCT00241891|BEHAVIORAL|Multiple behavior interventions|Focused on multiple behaviors (nutrition, beverages, physical activity, and sedentary lifestyle) which may have a significant impact on weight.
224187254|NCT00241891|BEHAVIORAL|Control Intervention unrelated to weight|Focused on standard intervention strategies unrelated to weight including bullying prevention.
223496234|NCT07121920|DEVICE|Confocal Laser Endomicroscopy|"Patients will undergo Esophagogastroduodenoscopy (EGD) and/or Ileocolonoscopy (IC) EGD with CLE as per standard of care. Each participant will have 3-4 mucosal biopsies taken from the terminal ileum, rectosigmoid and cecum, ideally from the most affected areas of accessible segment.~Ex vivo staining of biopsied tissue will be expanded to include FITC-labeled antibodies to cytokines IL12 and IL12/IL23 and to cytokine receptors IL12R and IL23R and possibly other cytokines, receptors and adhesion molecules. All biopsies tested for membrane bound antibodies will be done using CLE technology with artificial intelligence (AI). The cellular landscape will be characterized by surveying surface markers using bar-coded antibodies and performing gene expression profiling on every cell within inflamed tissue of patients with IBD.~We will develop algorithm using AI to predict responders versus non-responders and to further subclassify IBD patients using phenotype data."
224187255|NCT05570214|OTHER|Virtual Reality|Virtual reality device will be viewing calming narrated scenarios with relaxing music of walking through a forest, along a beach, through a Chinese garden, a winter landscape or taking off in a spaceship or snorkeling through a reef
224187256|NCT04067804|BEHAVIORAL|Dynamic Adaptation Process|The Dynamic Adaptation Process draws from implementation science frameworks and methods, including the Exploration, Preparation, Implementation, and Sustainment model, to organize planning and implementation activities. The Dynamic Adaptation Process is a structured methodology designed to integrate new interventions within complex systems, such as schools.
223496235|NCT07122674|DRUG|18F-Pentixafor|Patients with hematological malignancies receive 55 MBq/kg of 18F-Pentixafor intravenously followed by PET/CT or PET/MR after 60min of injection.
223496236|NCT07122830|OTHER|Family Education and Parental Involvement|Parents will be oriented to the programme, tools provided for their own learning (pamphlets, information handouts, audio-visual resources), and a checklist of infant care topics to be completed. The primary caregiver will be asked to commit to spending one to two hours per day to attend education sessions on the topic(s) of their choice. Parents will be encouraged to provide progressively more daily care for their infants as they complete more education sessions. After each education session, parents will check off for each completed topic on their skills checklist.
223589850|NCT02286635|DRUG|Deflazacort and Clarithromycin|Deflazacort, a glucocorticoid with anti-inflammatory and immunosuppressive effects. It is an inactive pro-drug which is metabolized completely and rapidly to the active drug 21 desacetyl-DFZ. The elimination of this metabolite is primarily via the urine in humans. Its potency is approximately 70 to 90% of prednisone. Clarithromycin is a semi-synthetic macrolide antibiotic. Clarithromycin is active in vitro against a variety of aerobic and anaerobic gram-positive and gram-negative bacteria as well as most mycobacterium avium complex (MAC) bacteria. Additionally, the 14-OH clarithromycin metabolite also has clinically significant antimicrobial activity. Clarithromycin is indicated for the treatment of mild to moderate infections such as pharyngitis/tonsillitis.
223589851|NCT01474720|DRUG|Zostavax vaccine|Commercially available Zostavax vaccine will be administered subcutaneously according to package insert guidelines. Each 0.65-mL dose contains a minimum of 19,400 PFU (plaque-forming units) of Oka/Merck strain of VZV.
223589852|NCT01085435|DEVICE|S-ICD System|The S-ICD System is an implantable technology that uses a subcutaneous pulse generator and subcutaneous electrode system to treat ventricular tachyarrhythmias. The S-ICD System consists of the pulse generator, subcutaneous electrode, the programmer and electrode insertion tool.
223589853|NCT00133224|BIOLOGICAL|Immunotherapy allogeneic GM-CSF secreting cellular vaccine|Immunotherapy allogeneic GM-CSF secreting cellular vaccine
223589854|NCT00133224|DRUG|Chemotherapy (docetaxel and prednisone)|Chemotherapy (docetaxel and prednisone)
223589855|NCT06651528|BEHAVIORAL|TBRI|The adapted TBRI WRA (Prison Only Component) will consist of an individual introductory module (1 hour) and a series of group modules (a minimum of 4 sessions, approximately 1-2 hours in length, delivered over the course of 3 months, with the final number and frequency to be determined in R61) focused on the core components of TBRI. The original TBRI approach includes a focus on group skills training; similarly, it is anticipated that R61 phase adaptations will meet the need for tailored skills training reflected by anticipated differences in the target population of women - including how their early attachment and trauma histories influence their current self-image and behavior (which likely has a tremendous impact on their relational attachments as adults). Group sessions will provide opportunities to build skills for regulating emotions and building healthy connections.
223745804|NCT05694936|DRUG|Cetuximab|Panitumumab 6 mg/kg IV every 2 weeks or cetuximab 500 mg/m2 IV every 2 weeks; Refer to arm description.
223745805|NCT01592929|RADIATION|Magnetic Resonance imaging|11 MRI scans per subject will be taken, one for each mouthpiece design of an inhaler.
224187257|NCT04776941|BEHAVIORAL|Behavioral Intervention|Read positive messages
224187258|NCT04776941|BEHAVIORAL|Behavioral Intervention|Write about positive experiences
224187259|NCT04776941|BEHAVIORAL|Behavioral Intervention|Write about neutral topics
224187260|NCT04776941|BEHAVIORAL|Behavioral Intervention|Read neutral messages
224187261|NCT04776941|OTHER|Quality-of-Life Assessment|Ancillary studies
224187262|NCT04776941|OTHER|Questionnaire Administration|Complete questionnaires
224187263|NCT06423521|OTHER|Standard of Care (SOC)|The SOC intervention constitutes the common clinical practice of care that is habitually performed after cardiac surgery to manage anticoagulation therapies.
224187264|NCT06423521|OTHER|Remote Patient Monitoring (RPM)|The RPM intervention involves the use of a remote patient monitoring (RPM) system with a portable coagulometer for the clinical follow-up and self-management of International Normalized Ratio (INR) control in patients undergoing anticoagulant therapy post-cardiac surgery. Patients were provided with a Coagulometer-CoaguChek® (Roche Diagnostics, Switzerland) kit and test strips, along with written instructions for conducting measurements. They were also enrolled in a monitoring platform. Patients received regular text messages on their smartphones to report their INR values and symptoms related to anticoagulant therapy. The clinical team received notifications if patients\&amp;#39; reports fell outside therapeutic standards and then responded with medication adjustments via text message.
224187265|NCT05748145|DRUG|Metronidazole Oral|Metronidazole will be administered per os at 500 mg x 3/day, for 10 days prior to surgery.
224187266|NCT06522074|DIAGNOSTIC_TEST|Coronary angiography with OCT|Intravascular imaging with Optical Coherence Tomography (OCT) in patients with chronic coronary syndrome who have been indicated for coronary angiographic will be used at the operator's discretion, for diagnostic purposes and/or to guide possible coronary artery disease treatment.
224308964|NCT05865418|OTHER|Loaded high intensity training|Participants will be familiarized to all the exercises. All exercises will have 3 sets, and the participants will be asked to perform as many repetitions as they can in 30s for each set. They will have 30 seconds to rest between sets (if they want more rest, we can let them more time but not exceed 60 seconds to limit the total amount of time for completing the exercise protocol) and 90 seconds to rest between exercises. Training sessions will occur twice per week with at least 24 hours between sessions. From the week 3rd of the intervention, the participants will perform the exercises with an adjustable weight vest with 5% of their body weight. In the middle intervention (post week 6 of the intervention which will be week 9 of the study), adolescents will be reevaluated for all the measures tested at the baseline. Weight vest will increase to 10% of their body weight for the last 4 weeks of the intervention.
223496237|NCT07124338|OTHER|Exercise, supervised|nital nutrition plan by a trained dietician, based on Nutritional risk, identifying of nutrion impact symtomes, daily nutritional intake regristration and adjustments to the nutrion plan
223496238|NCT07124299|DRUG|Experimental: Alpha-blocker group|Participants in the experimental arm will receive an oral alpha-blocker (tamsulosin 0.4 mg) once daily for 7 consecutive days before undergoing flexible ureterorenolithotripsy. The medication is intended to relax ureteral smooth muscle fibers, potentially facilitating the insertion of the ureteral access sheath and reducing the need for a secondary procedure. The dose, route, and timing are standardized for all participants in this arm.
223496239|NCT07124299|DRUG|No intervention (observational study)|Participants in this arm will undergo flexible ureterorenolithotripsy without receiving any alpha-blocker prior to surgery. All other perioperative care and surgical procedures will follow the same protocol as the experimental group.
223496240|NCT07124091|BEHAVIORAL|Positive Event Writing Intervention|Mothers in the intervention group will be asked to write down three positive events each day for four weeks as part of a positive psychology journaling activity..
223496241|NCT07124858|DRUG|Fruquintinib|Fruquintinib will be administered according to the summary of product characteristics (SmPC) : 5 mg, 21 days of treatment followed by a 7-day break until progression, unacceptable toxicity, death, or patient refusal.
223589856|NCT06651528|BEHAVIORAL|TAU + TBRI + Re-entry Recovery Support|This condition includes the proposed adapted TBRI as well as on-going re-entry recovery support with the Safe Support Person (SPP). The SSP will be identified by the study participant as someone who will provide prosocial support during re-entry (e.g., support towards abstinence, establishing healthy recovery support relationships, rebuilding relationships with family and children) and in most cases will involve a close family member (mother, grandmother) or friend at the woman's identified home placement. This individual will be identified by the study participant as someone who is not involved in active substance use nor has a current legal system status (e.g., on probation).
223589857|NCT06651528|OTHER|Treatment as Usual (TAU)|Women in the TAU condition will not receive TBRI intervention services, but will receive traditional in-prison SUD treatment over 6 months as usual in the four targeted prison sites. The programs are separate units with the prisons and emphasize participation by all program members in the overall goal of addressing substance use and criminal thinking. Although trauma and violence are addressed as part of the holistic group process approach in these programs, these topics are not addressed from an on-going systematic or relational perspective and are not specifically addressed as part of re-entry planning.
223589858|NCT00700583|DRUG|combination therapy of terazosin and hydrochlorothiazide|25 mg of hydrochlorothiazide eight hours before bedtime and 4 mg of terazosin at bedtime for 4 weeks
223589859|NCT00006094|DRUG|oxaliplatin|Given IV
223589860|NCT00006094|DRUG|fluorouracil|Given IV
223589861|NCT00006094|RADIATION|external beam radiation therapy|Undergo external beam radiation therapy
223589862|NCT02785614|DRUG|trazodone hydrochloride prolonged-release tablet|150 mg, oral administration, 1 per day
223589863|NCT02785614|DRUG|trazodone hydrochloride tablet|50mg, oral administration 3 times per day
223589864|NCT05792917|DRUG|tafolecimab (a modified manufacturing process)|450mg，SC，single dose
223589865|NCT05792917|DRUG|tafolecimab (a original manufacturing process)|450mg，SC，single dose
223745806|NCT01592929|OTHER|Pharyngometry|Pharyngometry will be carried out in supine and upright position. 11 different mouthpieces will be evaluated in both positions.
224187267|NCT05854719|BEHAVIORAL|Speechreading training with an application|The Optic Track application developed for this intervention will be used in speechreading training. The target is that, during the eight intervention weeks, it would be used for 15 minutes at least three times a week.
224187268|NCT02176148|DRUG|fluocinonide 0.05% cream|
224187269|NCT05981443|DEVICE|Dermabond|Use of Dermabond to close surgical incisions instead of non-absorbable sutures
224187270|NCT05981443|OTHER|Non-Absorbable Sutures|Use of conventional non-absorbable sutures to close surgical incisions
224187271|NCT05874895|PROCEDURE|Manual Lymphatic Drainage|Manual lymphatic drainage massage involves gently manipulating specific areas of the body to help lymph move to an area with working lymph vessels.
223496242|NCT07123805|DEVICE|Acupuncture group|In the Acu group, acupuncture and auriculotherapy will be added to the standard treatment: patients will undergo three/four sessions of manual acupuncture lasting 20 minutes, the first in the immediate pre-operative period and the subsequent ones at a distance of 24, 48, 72 hours from surgery. The treatment includes manual acupuncture applied to specific points: LI4, LV3 and ST36 bilaterally and monolaterally SP6 and GB34, ipsilateral to the knee to be prostheticized. Furthermore, auricolar needles will be positioned, before surgery, for self-stimulation of the auriculotherapy points corresponding to Shen Men bilaterally and the knee point ipsilateral to the surgical side.
223496243|NCT07120451|DRUG|Senaparib|100mg qd
223496244|NCT07120451|DRUG|Bevacizumab|7.5mg/kg q3w
224187272|NCT05874895|PROCEDURE|Usual Care|Usual care provided for patients in septic shock.
224187273|NCT01874379|OTHER|'M'-Technique®|'M'-Technique is a series of gentle stroking movements performed in a set sequence, with a set pressure of 3 on a scale of 0-10.
223496245|NCT07117617|BEHAVIORAL|Dynamic Stability Training with Inertial load of water|A 10-week training program using AquaBag to enhance lower limb joint stability and neuromuscular coordination. Exercises included dynamic stepping, lunging, and landing tasks under water load-induced perturbations.
223496246|NCT07119905|GENETIC|genotyping assay by polymerase chain reaction|"Blood sample will be obtained from all participants by withdrawing 3 mL of blood via venipuncture in ethylenediaminetetraacetic acid tube.~Thereafter, DNA extraction will be obtained after centrifugation to be used for genotyping assay of MMP-9 gene with polymerase chain reaction"
224187274|NCT01874379|OTHER|Guided Imagery|Diane L. Tusek's Guided Imagery for Pre-Procedure/Surgery™ will be used.
224187275|NCT01874379|OTHER|Standard of Care|Normal Procedures, no complementary medicine intervention.
223496247|NCT07123584|DIETARY_SUPPLEMENT|Eye Empower|A multi-ingredient oral supplement formulated to support eye health. Daily dose (3 capsules).
223496248|NCT07123584|DIETARY_SUPPLEMENT|Placebo|Identical gelatin capsules filled with inert rice flour, administered in the same dosage (3 capsules daily).
223496249|NCT06834906|DIAGNOSTIC_TEST|EasyEyeFM-AutoML-AI-platform test|AI platforms using
223496250|NCT06834906|DIAGNOSTIC_TEST|AutoML-EasyEyeFM-AI-platform test|AI-platform using
223496251|NCT06480357|PROCEDURE|laparoscopic adrenalectomy|laparoscopic transabdominal approach.
223496252|NCT03477981|OTHER|Alginate bread|White bread with 4% alginate (wet weight of dough) included into the bread.
223496253|NCT01379209|DRUG|RGI-2001|A single administration of RGI-2001 on Day 0 post AHSCT.
223589866|NCT05354687|OTHER|Small-group Teaching|The Small-group Teaching will include theoretical lectures and laboratory practice. Theoretical training will be given in 2 hours and will last 2 week. After the theoretical training, laboratory practice will be made with mannequins, pressure injury models and photographs in the nursing skills laboratory. Laboratory practices will be done in groups of about 10 students. Laboratory application will take 1 week.
223589867|NCT05354687|OTHER|Self-directed Learning|The training will be given in two stages. The first stage of the training will be given via the mobile application for 2 weeks. Students will be able to access the training individually, wherever and whenever they want, via the mobile application. In the second stage, students will individually conduct laboratory practice. Students who start using the mobile application will make laboratory applications individually, whenever they want when the laboratory is available. Models and materials that students will need will be available in the laboratory. They will be able to get help from the trainer when they need it. Individual laboratory application will take 1 week.
223589868|NCT02114255|OTHER|Placebo|Administration of 0.9% NaCl.
223589869|NCT02114255|BIOLOGICAL|BCG|Vaccination with the live attenuated BCG vaccine.
223589870|NCT03007095|BEHAVIORAL|Evaluation of the children's social cognitive development|standardized neuropsychological tests
224187276|NCT03104361|BIOLOGICAL|Platelet-Rich Plasma|Patients who meet all eligible requirements for entry into the study will be treated with intravesical injection of PRP (extracted from 50ml whole blood ) at 20 sites
224187277|NCT00952146|PROCEDURE|Transgastric peritoneoscopy (NOTES)|Under general anesthesia an endoscope will be passed through the gastric wall into the peritoneal cavity to examine the peritoneal cavity. At the withdrawal of the endoscope, the gastric access in the stomach wall will be closed with T-tags.
224187278|NCT02809963|DRUG|Eplerenone|50 mg tablets, oral use.
224308965|NCT05865418|OTHER|High intensity circuit training (HICT)|Participants will be familiarized to all the exercises. All exercises will have 3 sets, and the participants will be asked to perform as many repetitions as they can in 30s for each set. They will have 30 seconds to rest between sets (if they want more rest, we can let them more time but not exceed 60 seconds to limit the total amount of time for completing the exercise protocol) and 90 seconds to rest between exercises. Training sessions will occur twice per week with at least 24 hours between sessions.
223496254|NCT01379209|DRUG|Calcineurin Inhibitors|GVHD prophylaxis according to institutional guidelines. Subjects could have received any number/combinations of treatments.
223496255|NCT01379209|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|According to institutional guidelines.
223496256|NCT01379209|DRUG|Conditioning Regimen|Myeloablative preparative treatment according to institutional guidelines. Subjects could have received any number/combinations of treatments.
223496257|NCT01379209|PROCEDURE|Allogeneic Bone Marrow Transplantation|According to institutional guidelines
223496258|NCT01379209|DRUG|Methotrexate|
223496259|NCT01379209|DRUG|Mofetil Mycophenolate|
223496260|NCT01379209|DRUG|sirolimus|Administered for GVHD prophylaxis as per institutional guidelines
223496261|NCT05011435|DEVICE|web-application for burnout|Use of burnout advisor web-application for detection of professional burnout
223589871|NCT04840329|BEHAVIORAL|Education|One-time educational session about menstrual health and endometriosis
223589872|NCT06386991|OTHER|Using ethylenediaminetetraacetic acid (EDTA), citric acid ((MONO/ANH) and etidronic acid (HEBP) to clean root canals during regenerative endodontic treatments|Regenerative endodontic treatment using different irrigation solutions
224187279|NCT02809963|DRUG|Placebo|50 mg tablets, oral use
224187280|NCT05666466|DIAGNOSTIC_TEST|extratympanic electrocochleograhy|electrophysiological test
224187281|NCT00519597|DEVICE|ResMed S8 (Auto-CPAP)|AutoCPAP during sleep
224187282|NCT04156464|DRUG|Phenobarbital|Phenobarbital loading dose followed by a taper will be given to control acute alcohol withdrawal syndrome
224187283|NCT04156464|DRUG|Lorazepam|Ativan will be given according to our institutional alcohol withdrawal protocol to control acute alcohol withdrawal syndrome
224187284|NCT05539664|DEVICE|Hydrogen-Oxygen Generator with Nebulizer, AMS-H-03|The experimental group used the experimental medical device Hydrogen-Oxygen Generator with Nebulizer(Shanghai Asclepius Meditec Co., Ltd. ) The flow rate was 3L/min, and the cumulative treatment time was not less than 6 hours per day.
224308966|NCT04480021|BEHAVIORAL|MITHRA|A mobile based application (app) in CBOs to screen, track and treat mild to moderate depression among low income women using Healthy Activity Program (HAP),a WHO-recommended evidence-based intervention.
223496262|NCT06451744|OTHER|Blood samples collection|50 mL blood sample
223496263|NCT06451744|OTHER|Skin or mucous membrane brushing|brushing on skin or mucous membrane lesions
223496264|NCT06451744|OTHER|Skin or mucous membrane biopsy|6 mm biopsy
224187285|NCT05539664|DEVICE|the hospital routine oxygen supply equipment (wall oxygen or cylinder oxygen)|the hospital routine oxygen supply equipment (wall oxygen or cylinder oxygen). The flow rate was 3L/min, and the cumulative treatment time was not less than 6 hours per day.
224308967|NCT04480021|BEHAVIORAL|EUC|Group education on depression by community health workers
224187286|NCT05294510|OTHER|STAR Sick Child Job Aid|The STAR Sick Child Job Aid is a modified ICCM protocol that includes the addition of a point-of-care C-reactive protein (CRP) test to inform antibiotic treatment decisions for children presenting with febrile acute respiratory illness who do not have any danger signs. If CRP ≥ 40 mg/L, the village health worker (VHW) will dispense amoxicillin per local guidelines. If CRP \< 40 mg/L, the VHW will advise symptomatic care alone including acetaminophen for fever and additional fluids to maintain hydration.
224187287|NCT00273260|BEHAVIORAL|individualised bone density feedback and education|
224308968|NCT06154200|DRUG|Testosterone gel 4.5%|Testosterone gel applied to eyelids twice per day
224308969|NCT06154200|DRUG|Vehicle gel|Vehicle gel applied to eyelids twice per day
224308970|NCT06970262|OTHER|Fecal suspension (provided by SShanghai Chengge Pharmaceutical Technology Co., Ltd.)|Prepare 300 ml of intestinal flora suspension from 100-150 g of feces. Administer vancomycin 500 mg via nasogastric tube every 12 hours for 48-72 hours before FMT. Clean the intestines with 2000 ml of polyethylene glycol 24 hours before FMT (except for patients with diarrhea). Subjects can eat and drink freely during preparation but must fast for at least 2 hours before FMT (water allowed). No food or water is permitted within 2 hours after FMT. Stop all antibiotics (intravenous, oral, nebulized) at least 24 hours before FMT.
224308971|NCT01844505|BIOLOGICAL|Nivolumab|
224308972|NCT01844505|BIOLOGICAL|Ipilimumab|
223496265|NCT06393452|DRUG|PP405 0.05% Topical Gel|PP405 is an inhibitor of mitochondrial pyruvate carrier (MPC)
223496266|NCT06393452|DRUG|PP405 Topical Vehicle Gel|PP405 Vehicle = placebo
224187288|NCT06566157|DIETARY_SUPPLEMENT|Prebiotic|WellBiome® prebiotic complex: Inulin 67%, XOS 27%, Magnesium Chloride (MgCl2) 9.8 %
224187289|NCT06566157|DIETARY_SUPPLEMENT|Maltodextrin (Corn)|Placebo
224308973|NCT01844505|BIOLOGICAL|Placebo for Nivolumab|
224308974|NCT01844505|BIOLOGICAL|Placebo for Ipilimumab|
224308975|NCT06666309|BEHAVIORAL|SBCM-PrEP + Text Messaging|Two sessions Strengths-Based Case Management intervention adapted for HIV PrEP related educational content delivered to individual clients in the syringe service program setting
223496267|NCT04604782|DRUG|Regadenoson|Regadenoson (Rapiscan®): Single i.v. bolus dose in stress rest CMR
223496268|NCT05937568|DRUG|Imetelstat|Participants will receive imetelstat, intravenously (IV) by infusion every 4 weeks.
223496269|NCT06478095|BEHAVIORAL|Visual aids|Diagrams, models, and videos
223496270|NCT01373229|DRUG|Lenalidomide + Plerixafor (+ Rituximab)|"1. Lenalidomide 5mg by mouth (PO) daily beginning cycle 1 day 1.~2. Stage 1: increase by 2.5mg every 7 days to a maximum dose of 10mg.~3. Stage 2: plerixafor will be added after 28 days of 10mg dose maintenance and white blood cell count (WBC) \<100.0 x 109 / L.~4. Dose cohorts of escalating subcutaneous (SC) thrice weekly plerixafor with continuous 10mg lenalidomide:~   * Cohort 1: 0.24 mg/kg~  * Cohort 2: 0.32 mg/kg~  * Cohort 3: 0.42 mg/kg~  * Cohort 4: 0.54 mg/kg~5. Stage 3: Rituximab 375mg/m2 will be added on day 1 of cycles 5-12, day 1 of combination therapy for subjects with PR.~6. Subjects will then continue single agent lenalidomide until disease progression."
223496271|NCT02849886|DRUG|T lymphocytes iCASP9 ΔCD19|Intravenous injection of the T lymphocytes armed with the iCASP9 suicide gene
223496272|NCT02849886|DRUG|Dimerizer drug AP1903|"AP1903 drug will be administrated at a dose of 0.4 mg/kg by intravenous route in the two following cases:~* Acute Grade ≥II or symptomatic Grade I GvHD justifying systemic immunosuppression therapy;~* Grade ≥3 toxicity attributable to GMC."
223496273|NCT05855759|OTHER|Acellular Dermal Matrix|Patinets will be treated with acellular dermal matrix with standard arthroscopic technique performed as per normal clinical practice. For the tendon repair the acellular dermal matrix patch will be placed over the repaired tendon with dedicated sutures and anchors.
223496274|NCT05855759|OTHER|Acellular Dermal Matrix with autologous orthobiologics|Patinets will be treated with acellular dermal matrix enriched with autologous humeral bone marrow concentrate and subacromial bursa with standard arthroscopic technique. Humeral bone marrow concentrate will be harvested from the proximal humeral head inthe operating room and concentrated by an automatic close system.
223496275|NCT02467816|BEHAVIORAL|SmartMeal application|The SmartMeal application is a smartphone application that will allow students to pre-order school meals, receive nutrition information about school meals, and provide feedback about school meals to Student Nutrition Services.
223496276|NCT02467816|BEHAVIORAL|Distributed points of sale|To increase points of sale for school meals (outside the cafeteria), school meals will be sold at hot and cold mobile food carts and vending machines throughout the school.
223496277|NCT02467816|BEHAVIORAL|Staff wellness curriculum|A wellness curriculum will be implemented that encourages teachers and staff members to eat school meals and promote them to students.
224308976|NCT06666309|BEHAVIORAL|CDC-PrEP + Text Messaging|1 session PrEP education based on CDC guidelines delivered to individual clients in syringe service program settings
224187290|NCT03397472|DEVICE|magnetic field modulation device|use the device with magnetic field modulation to treat insomnia
224187291|NCT03397472|DEVICE|placebo device|use the sleep pillow without magnetic field modulation treatment
224308977|NCT06666309|BEHAVIORAL|T-SBCM|Up to two post-linkage sessions of SBCM delivered by a peer support specialist in a format of the participants' choice (onsite, virtual/phone) in study month 2
223496278|NCT01730196|BEHAVIORAL|Fit Body and Soul|
224187292|NCT04324814|DRUG|SHR-1701|Anti-PD-L1/TGFβ fusion protein
224308978|NCT06666309|BEHAVIORAL|Mobile Outreach|Up to two in-person field session visits will be conducted by a peer support specialist for the purpose of offering direct support to arrange joint activities for overcoming identified barriers (e.g., transportation) to PrEP care initiation in study month 2.
224308979|NCT04232683|DRUG|Tamsulosin 0.4Mg Capsule|Tamsulosin given preoperatively to detect if rates of urinary retention after female pelvic floor surgeries are decreased
224308980|NCT04232683|DRUG|Placebo oral tablet|Placebo pill given preoperatively
224308981|NCT04375722|DEVICE|tACS|Active or Sham tACS will be applied.
224308982|NCT06039371|PROCEDURE|Biopsy Procedure|Undergo a biopsy
223496279|NCT01730196|BEHAVIORAL|Wellness Education|
223589873|NCT05270239|BEHAVIORAL|N-back Cognitive Training|N-back task mainly trains working memory and information processing speed. This training lasts 10 days (1 hour per day).
223589874|NCT05270239|BEHAVIORAL|Virtual Reality Motor and Cognitive Training|"Virtual Reality Ball Task mainly trains inhibitory control, attention, working memory and motor functions. This training lasts 10 days (30 minutes per day)"
223589875|NCT04079712|DRUG|Cabozantinib S-malate|Given PO
224187293|NCT00497822|PROCEDURE|Aerobic exercise training|
224187294|NCT06481215|BIOLOGICAL|GNR-068|The investigational product GNR-068 was administered as a subcutaneous injection at a single dose of 45 mg.
224187295|NCT06481215|BIOLOGICAL|Stelara®|The reference product Stelara® was administered as a subcutaneous injection at a single dose of 45 mg.
224187296|NCT05179811|PROCEDURE|Hypnosis sessions|"* Physical examination~* Psychiatric Assessment~* VHI, SF-36, IPQ-R questionnaires~* Standardized voice recording~* 3 Standardized Hypnotherapy sessions~* CGI-I-Patient Questionnaire"
224187297|NCT02270385|BEHAVIORAL|PU prevention programme|The PU prevention programme consists of two major components which are an intensive training course(a 2-hour lecture and two skill training sessions) and a PU prevention protocol.
224187298|NCT02270385|BEHAVIORAL|Usual PU prevention care|Usual PU prevention care that is a series of basic nursing care activities: repositioning of residents, moisturization , change of napkins to keep buttock dry.
224187299|NCT00003977|BIOLOGICAL|human papillomavirus 16 E7 peptide|
224187300|NCT00003977|PROCEDURE|in vitro-treated peripheral blood stem cell transplantation|
224187301|NCT01399619|DRUG|PegIFN/RBV|PegIFN/RBV for 24 or 48w
224187302|NCT01399619|DRUG|PegIFN/RBV|PegIFN/RBV for 24 or 48w
224187303|NCT01399619|DRUG|BI201335|BI201335 for 12w
224187304|NCT01399619|DRUG|BI201335 24W|BI201335 for 24w
224187305|NCT01399619|DRUG|PegIFN/RBV|PegIFN/RBV for 24 or 48w
224187306|NCT01399619|DRUG|Bi 201335|BI 201335 for 24 w
224187307|NCT02799576|DEVICE|Curved needle|In this arm, the curved block needle will be used for regional blockade
224187308|NCT02445768|OTHER|Cognitive multisensory rehabilitation|
224187309|NCT02024997|OTHER|Magnetic Resonance Imaging (MRI)|
224187310|NCT00462501|BIOLOGICAL|bevacizumab|
224187311|NCT00462501|DRUG|fluorouracil|
224187312|NCT00462501|DRUG|leucovorin calcium|
224187313|NCT00462501|DRUG|oxaliplatin|
224187314|NCT00462501|PROCEDURE|conventional surgery|
224187315|NCT00462501|RADIATION|radiation therapy|
224187316|NCT01413373|RADIATION|cone beam computed tomography|A preoperative CBCT is performed for all patients in this study for medical reason
223496280|NCT04213131|OTHER|Stem cell transplantation|The eligible patients with chronic spinal cord injury included in this study will receive intravenous, lumbar, and local administration of hUC-MSCs/hUCB-MSCs and routine rehabilitation treatment. At 1, 3, 6 and 12 months after treatment, patients will be followed up and evaluated.
223496281|NCT00143507|DRUG|Ivabradine|
223496282|NCT00143507|DRUG|Placebo|
223496283|NCT00330096|DRUG|Hesperidin|
223496284|NCT00330096|OTHER|Placebo|
223496285|NCT04136678|OTHER|walking training|15 minutes of conventional walking training 15 minutes of treadmill backward walking training 15 minutes of treadmil forward walking training
223496286|NCT00587457|DRUG|CAT-8015 5 mcg/kg|Participants received a single intravenous infusion of 5 mcg/kg moxetumomab pasudotox (CAT-8015) on Days 1, 3, and 5 of every 28-day cycle and continued cycles of therapy until progressive disease (PD) or until otherwise they become ineligible.
223589876|NCT04079712|BIOLOGICAL|Ipilimumab|Given IV
223589877|NCT04079712|BIOLOGICAL|Nivolumab|Given IV
223589878|NCT03034824|PROCEDURE|SRP+940±15 nm diode laser|In addition to Non-surgical periodontal treatment, the individuals diagnosed with Generalized Aggressive Periodontitis were applied the 940±15 nm diode laser.
224187317|NCT01413373|RADIATION|computer tomography|One cone beam computer tomography examination before surgery
224187318|NCT05888545|DEVICE|anti-adhesion diaphragm|Participants will be asked to place an anti-adhesion diaphragm in the uterus for 3-7 days after the abortion procedure.
224187319|NCT02861157|BEHAVIORAL|Planet T1D|Planet T1D is a mobile and web-based technology infrastructure specifically designed to (a) enhance youths' type 1 diabetes disease- and treatment-related knowledge through interactive and game-based educational materials; (b) support adherence to the treatment regimen through customized task prompts via mobile and web-based delivery; and (c) promote patient-provider communication through real-world data collection and feedback loops.
224187320|NCT00998166|DRUG|Pemetrexed|"1. Pre-hydration for 1-1/2 hours at 250 ml/hour~2. Pemetrexed 500 mg/m2 IV over 10 minutes~3. Return to hydration for 30 minutes at 250 ml/hour"
224187321|NCT00998166|DRUG|Cisplatin|4\. Cisplatin 75mg/m2 IV over 60-120 minutes
224187322|NCT00998166|DRUG|Bevacizumab|5\. Bevacizumab 15mg/kg IV over 90 minutes
224187323|NCT04613804|DRUG|Toripalimab Injection|"Qualified subjects will be treated with toripalimab 240mg q21d as a treatment cycle."
224187324|NCT04885842|OTHER|injection I-PRF|injection I-PRF with brackets
224187325|NCT00588120|DRUG|C-13 labeled oxalate|"A single prescribed dose of C-13 labeled oxalate will be given orally in capsule form or in jello. Urine will be collected for 24 hours after the dose.~Take one capsule by mouth for one day."
224187326|NCT02853097|OTHER|Cytology Specimen Collection Procedure|Undergo blood collection
224187327|NCT02853097|OTHER|Laboratory Biomarker Analysis|Correlative studies
224187328|NCT01670331|BEHAVIORAL|Psychological preparation|"Session 1: Help patients understand their relationship to food. Patients complete a 'food diary' as 'homework'. Give information about lifestyle changes after surgery. Presents the model of 'stress' and how it influences 'overeating', to develop a more balanced lifestyle and better QoL.~Session 2: 'Intervention' using Compassion Focussed Therapy model to understand relationship to food from their diary. Help develop a 'minimising overeating plan' (a 'relapse prevention' plan). Help learn to meet needs in other ways than food.~Session 3: Focus on physical body. Current body image, explore hopes and expectations for after surgery. Consider how to manage changes to social reactions and sexual relationships that may occur."
224187329|NCT00291109|DRUG|letrozole 2.5 mg|
224308983|NCT06039371|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
224308984|NCT06039371|PROCEDURE|Bone Scan|Undergo bone scan
224187330|NCT03554798|BIOLOGICAL|nOPV2 (monovalent oral polio vaccine)|"Cohort A: 150 IPV and/or OPV vaccinated participants aged 1 to 5 years vaccinated with candidate 1 or 2; two 10‸6 CCID50 (50% cell culture infective dose) doses separated by 28 days.~Cohort B: 972 infants enrolled at 6 weeks of age (-7 to +14 days) vaccinated with 3 doses of bOPV at 6, 10 and 14 weeks of age and 1 dose of IPV at 14 weeks of age, followed at 18-22 weeks of age with one 10‸5 CCID50 dose of candidate 1 or 2."
224187331|NCT03358017|DRUG|Zoledronate|4 mg i.v. every 3/4 weeks for 6 months
224187332|NCT03358017|DRUG|Atorvastatin 80mg|80mg /die os for 6 months
224187333|NCT03358017|DRUG|Standard neoadjuvant cht|Standard neoadjuvant cht chosen by the investigator and administered according to clinical practice
224187334|NCT05497570|DRUG|Tenoxicam Injectable Product|After arthrocentesis procedure, 2-ml injection of tenoxicam (Oksamen-L, Mustafa Nevzat İlaç Sanayi, Istanbul, Turkey) to the temporomandibular joint
224187335|NCT02008487|OTHER|Wound powder application|Powder application to wound per protocol.
224187336|NCT00971100|BIOLOGICAL|Monovalent A/H1N1 influenza vaccine|This trial will be performed at multiple study sites in a population of healthy children and adolescent. Subjects will be randomized to receive 2 IM injections of low dose of antigen \& adjuvant, or high dose of antigen \& adjuvant, or high dose of antigen, according to the study groups.
224187337|NCT02086240|DRUG|XBD173|XBD173 (Emapunil is an anxiolytic drug which acts as a selective agonist at the peripheral benzodiazepine receptor), a drug which binds the TSPO with high affinity.
224187338|NCT03724552|DEVICE|Transcranial LED Therapy (Participants ages 9-17)|Transcranial Laser Emitting Diode (LED) Therapy (TLT) is a noninvasive intervention in which near-infrared light (830nm-850nm) is applied to forebrain.
224187339|NCT03724552|DEVICE|Transcranial LED Therapy (Participants ages 18-59)|Transcranial Laser Emitting Diode (LED) Therapy (TLT) is a noninvasive intervention in which near-infrared light (830nm-850nm) is applied to forebrain.
224187340|NCT02427334|DRUG|Dienogest|women will receive oral dienogest 2mg for 14 days starting from the 15th day of menstruation
224187341|NCT02427334|DRUG|Fluoxetine|women will receive oral fluoxetine 20mg for 14 days starting from the 15th day of menstruation
224187342|NCT02427334|DRUG|Placebo|women will receive oral placebo for 14 days starting from the 15th day of menstruation
224187343|NCT05600101|BEHAVIORAL|Care.Coach|"Care.coach is a human-in the-loop conversational agent (avatar) used to interact and converse with patients through natural dialogue and text-to-speech software that is powered by a team of trained human staff, called health advocates."
224187344|NCT03794310|DRUG|NPF-08 （1-day treatment）|NPF-08 will be administered on the day of colonoscopy.
223496287|NCT00587457|DRUG|CAT-8015 10 mcg/kg|Participants received a single intravenous infusion of 10 mcg/kg moxetumomab pasudotox (CAT-8015) on Days 1, 3, and 5 of every 28-day cycle and continued cycles of therapy until progressive disease (PD) or until otherwise they become ineligible.
223496288|NCT00587457|DRUG|CAT-8015 20 mcg/kg|Participants received a single intravenous infusion of 20 mcg/kg moxetumomab pasudotox (CAT-8015) on Days 1, 3, and 5 of every 28-day cycle and continued cycles of therapy until progressive disease (PD) or until otherwise they become ineligible.
223496289|NCT00446875|OTHER|Administration of oral Sucrose|Participants received oral sucrose 2 minutes prior to the combind DTaP, IPV, and Hep B vaccine.
223496290|NCT00446875|OTHER|Administration of oral Placebo|Participants received Placebo 2 minutes prior to the combind DTaP, IPV, and Hep B vaccine.
223496291|NCT03881787|DRUG|anti-EGFR monoclonal antibody|Recombinant anti-EGFR human mouse chimeric monoclonal antibody injection
224187345|NCT03794310|DRUG|NPF-08 （2-day split dose）|NPF-08 will be administered at 2 days divided into the day before and on the day of colonoscopy.
224308985|NCT06039371|DRUG|Carboplatin|Given IV
224187346|NCT03794310|DRUG|Moviprep（1-day treatment）|Moviprep will be administered on the day of colonoscopy.
224187347|NCT03625102|DRUG|Antroquinonol|Antroquinonol will be provided as a capsule-shaped which contain 50 mg Antroquinonol.
224187348|NCT03625102|OTHER|placebo|The matching placebo will be packaged as Antroquinonol with appearance identical in all aspects
223496292|NCT03881787|DRUG|Cetuximab injection|Cetuximab injection
223496293|NCT04742699|DRUG|Lemborexant (LEM) 5 mg (Z-Drug-mono cohort)|"1. Pretreatment phase: Continue pre-registration treatment (Z-drug monotherapy) without LEM.~2. First treatment phase: Administer LEM 5 mg/day as a substitute for Z-Drug. Increasing LEM dose to 10 mg/day is allowed.~3. Maintenance phase: Succeed the treatment from the first treatment phase. Changing LEM dose is allowed. Rescue administration of Z-drug or RMT is allowed under a defined condition."
223589879|NCT03034824|PROCEDURE|SRP+Er,Cr:YSGG laser|In addition to Non-surgical periodontal treatment, the individuals diagnosed with Generalized Aggressive Periodontitis were applied the Er,Cr:YSGG laser.
223589880|NCT03034824|PROCEDURE|Scaling and root planing (SRP)-Control|Only Non-surgical periodontal treatment
224187349|NCT03171272|OTHER|Inspiratory Muscle Training|"Experimental: IMT will include training of the inspiratory muscles five times per week over six weeks, divided into two fiftten-minute sessions of inspiratory training totaling 30 minutes of training. Thresholds regulated at 50% of the subjects' maximal inspiratory pressure values, the load being increased weekly. Associated with the IMT, subjects will participate in the rehabilitation program, when they will perform 7 sessions of physiotherapy per week, totaling 42 sessions, as well as 180 minutes per week of aerobic exercise, for six weeks.~Sham Group: This group will underwent exactly the same protocol but the participants will receive the threshold devices with the minimum resistance of the spring, which will be also concealed. The control group will also participate in the rehabilitation program and undergo the same procedures, except for the load adjustments."
224187350|NCT00665418|DRUG|sevoflurane|sevoflurane 2.5% versus 4.7% (inhaled concentration) 10min each
224187351|NCT01428388|DRUG|Intravitreal injection of bevacizumab|1.25 mg per dose, delivered monthly by intravitreal injection for six months
224187352|NCT01428388|DRUG|Intravitreal injection of ranibizumab (0.5 mg per dose)|0.5 mg per dose, delivered monthly by intravitreal injection for six months
224187353|NCT01726556|DEVICE|Rigid thoracoscope (Richard Wolf GmbH, Knittlingen, Germany)|Pleuroscopy using a rigid thoracoscope manufactured by Richard Wolf GmbH, Knittlingen, Germany
224308986|NCT06039371|PROCEDURE|Computed Tomography|Undergo CT
224308987|NCT06039371|DRUG|Etoposide|Given PO
224308988|NCT06039371|OTHER|Quality-of-Life Assessment|Ancillary studies
224187354|NCT01726556|DEVICE|Semirigid thoracoscope (model LTF-160Y1, Olympus, Japan)|Pleuroscopy using a semirigid thoracoscope model LTF-160Y1, manufactured by Olympus Medical Systems Corporation, Tokyo, Japan
224187355|NCT02451631|OTHER|Traditional care with paper|Healthcare staff-driven care, Diabetes mgmt. guide-book provided. Patient self-monitoring of blood glucose(SMBG) with paper.
224187356|NCT02451631|DEVICE|Health-on G App. + Physician Web|Patients use their smart-phone or receive rental phone, and download Health-On G application. Algorithm-based personalized feedback are provided when patients' data are linked to Health-On G Application. Patient self-monitoring blood glucose data from glucometer are transferred to App. automatically by bluetooth, or input manually, check medication regimen, input food intake and exercise, and step counts are linked by Activity tracker. Personalized feedback are instantly provided based on data. Entered data are also connected to web-based physician portal. Physician web portal is provided, where they're able to review their patient's all data. Health-On G is defined as a U-Healthcare medical device consisting of gateway and decision support system.
224187357|NCT01769846|OTHER|Early mobilization protocol|Patients in the treatment group additionally received a cycling exercise session 7 days a week, using a bedside cycle ergometer (MOTOmed Letto 2, RECK-Technik GmbH \& Co. KG, Betzenweiler, Germany). The device offers the possibility to conduct passive or active cycling at six levels of increasing resistance. The aim of each session was to have the patient cycle for 30 mins at an individually adjusted intensity level. Patients were placed in a comfortable position in between the supine and the semirecumbent position.
224187358|NCT04626947|BIOLOGICAL|Bezlotoxumab|Bezlotoxumab infusion
224187359|NCT00672464|DRUG|Olanzapine|Olanzapine zydis 15 mg QHS for 28 days
224187360|NCT00672464|DRUG|Metformin|Metformin capsules will be started at 500 mg twice a day (before breakfast and before dinner) for days 1-3, then 500 mg before breakfast and 1000 mg before dinner for days 4-7, and then 1000 mg twice a day thereafter.
224187361|NCT00672464|DRUG|Simvastatin|Simvastatin will be started at 10 mg at bed time for the first week and 20 mg at bedtime thereafter.
224187362|NCT02545699|DEVICE|G-EYE™ Colonoscopy|G-EYE™ Colonoscopy
224187363|NCT02545699|DEVICE|Standard Colonoscopy|Standard Colonoscopy
223496294|NCT04742699|DRUG|Lemborexant (LEM) 5 mg (SUV-mono cohort)|"1. Pretreatment phase: Continue pre-registration treatment (SUV monotherapy) without LEM.~2. First treatment phase: Administer LEM 5 mg/day as a substitute for SUV. Increasing to LEM dose to 10 mg/day is allowed.~3. Maintenance phase: Succeed the treatment of the first treatment phase. Changing LEM dose is allowed."
223496295|NCT04742699|DRUG|Lemborexant (LEM) 5 mg (SUV-combination cohort)|"1. Pretreatment phase: Continue pre-registration treatment (SUV and BZRA combination therapy) without LEM.~2. First treatment phase: Administer LEM 5 mg/day as a substitute for SUV and continue BZRA. Increasing to LEM dose to 10 mg/day is allowed.~3. Maintenance phase: Succeed the treatment of the first treatment phase. Changing LEM dose is allowed. Decreasing dose or discontinuation of BZRA is allowed. Rescue administration of Z-drug or RMT is allowed under a defined condition."
223496296|NCT04742699|DRUG|Lemborexant (LEM) 5 mg (RMT-combination cohort)|"1. Pretreatment phase: Continue pre-registration treatment (RMT and BZRA combination therapy) without LEM.~2. First treatment phase: Administer LEM 5 mg/day as a substitute for RMT and continue BZRA. Increasing to LEM dose to 10 mg/day is allowed.~3. Maintenance phase: Succeed the treatment of the first treatment phase. Changing LEM dose is allowed. Decreasing dose or discontinuation of BZRA is allowed. Rescue administration of Z-drug or RMT is allowed under a defined condition."
223589881|NCT04724967|DRUG|CeraVe Hydrating Cleanser|topical cleanser applied twice a day for 28 days
223589882|NCT04724967|DRUG|CeraVe Moisturizing Cream|topical cream applied twice a day for 28 days
223589883|NCT05607667|DEVICE|Transcatheter aortic valve replacement|Transcatheter aortic valve replacement system
223589884|NCT05014867|PROCEDURE|Embryo transfer method|"1. Sequential embryo transfer on day 3 and day 5 in a frozen cycle~2. Sequential embryo transfer on day 3 and day 5 in a fresh cycle~3. Sequential embryo transfer on day 3 and day 5 after performing PGS~4. Conventional Day 5 frozen embryo transfer"
223589885|NCT01591356|DRUG|EphA2-targeting DOPC-encapsulated siRNA|Given IV
224187364|NCT04825639|OTHER|No intervention|no intervention
224187365|NCT03104270|DRUG|Elotuzumab|Elotuzumab IV at 10mg/kg Elotuzumab IV at 20mg/kg
224187366|NCT03104270|DRUG|Pomalidomide|Pomalidomide PO at 3mg
224187367|NCT03104270|DRUG|Carfilzomib|Carfilzomib 20mg/m2 IV Carfilzomib 56mg/m2 IV
224187368|NCT03104270|DRUG|Dexamethasone|Dexamethasone 28mg PO Dexamethasone 40mg PO or IV Dexamethasone 8mg IV
224308989|NCT06039371|OTHER|Questionnaire Administration|Ancillary studies
223496297|NCT02971826|DEVICE|REVIVETM SE thrombectomy|Mechanical thrombectomy using the REVIVETM SE device in patient with an ischemic stroke due to an intracranial arterial occlusion
223496298|NCT04569344|OTHER|Laboratory test positive for SARS-CoV-2 virus|Exposure/intervention: diagnosis of Covid-19, defined as positive laboratory test for SARS-CoV-2
223589886|NCT01591356|OTHER|Laboratory Biomarker Analysis|Correlative studies
223589887|NCT01591356|OTHER|Pharmacological Study|Correlative studies
224187369|NCT03496597|PROCEDURE|Retinal imaging assessment|"* OCT-angiography~* Automated measurement program: size of the avascular zone and perifoveolar vascular density of the superficial capillary plexus~* Eye fundus photography: macular image~* Measurement of the fractal dimension of the retinal foveolar retina from photographs of the fundus"
224187370|NCT03496597|PROCEDURE|blood glucose holter|for 40 subjects, implantation of a blood glucose holter monitor for 7 days
224187371|NCT02513680|DEVICE|Infrared Laser + Amber LED|This group will make the application on the machine program that uses laser and led together to photorejuvenation . Laser is applied for 30 seconds and soon after begins the LED by 2:30 minutes in each region to apply.
224187372|NCT02513680|DEVICE|Amber LED|This group will make the application on the machine program that uses LED photorejuvenation only 3 minutes of time for each area to be applied.
224187373|NCT01533974|OTHER|Acceptance & Commitment Therapy (ACT)|We will use a five-session (90 minutes per session) group-delivered adaptation of Dr. Bricker's ACT treatment program.
224187374|NCT01533974|OTHER|Cognitive Behavioral Therapy (CBT)|The control condition will be the current group-delivered CBT smoking cessation program at GH.
224308990|NCT06039371|DRUG|Testosterone Cypionate|Given IM
224308991|NCT06039371|OTHER|Radioconjugate|Given LuPSMA IV
224308992|NCT06039371|PROCEDURE|Dual X-ray Absorptiometry|Undergo DEXA
224187375|NCT01939015|DEVICE|3D titanium miniplate|for study group by using 3D titanium miniplate under open reduction under general anesthesia with mono cortical screw, while in control group single titanium miniplate at superior border with mono cortical screw according to ideal line of osteosynthesis of champy
224187376|NCT01939015|DEVICE|Standard titanium miniplate- single non compression miniplate|single non compression miniplate placed at superior border with monocortical screws via intraoral approach
224187377|NCT02311660|DEVICE|Vagus Nerve Stimulation Device|Cyberonics VNS System
224187378|NCT01136759|DRUG|Tenofovir 1% gel|One applicator of tenofovir 1% gel administered vaginally for 7 consecutive days
224187379|NCT01136759|OTHER|Placebo gel|One applicator of placebo gel administered vaginally for 7 consecutive days
224187380|NCT00399542|DRUG|Lubiprostone|
223496299|NCT01051284|RADIATION|Cyberknife radiation and gemcitabine|25 Gray of radiation will be given in 5 fractions using the Cyberknife Gemcitabine 1000 mg/m2 intravenously will be given once a week on days 1, 8, and 15 of every 28-day cycle for 6 cycles
223496300|NCT03219580|DRUG|5-Fluorouracil|50mg/ml concentration of 5-Fluorouracil to be injected intra-dermally in direct brow skin incisions
223496301|NCT03219580|DRUG|Normal Saline Flush, 0.9% Injectable Solution|0.9% concentration of Normal Saline Injectable Solution to be injected intra-dermally in direct brow skin incisions
223496302|NCT03234881|BEHAVIORAL|MOVE!|Participants randomized to the MOVE!(or TeleMOVE!) arm only. MOVE! is 16 weeks of 60-minute weekly groups that are led by a physical therapist, dietician, and/or clinical health psychologist. Clinicians utilize materials available online and encourage the use, but do not require or provide food diaries. TeleMOVE! is a 90-day program utilizing technology to provide home-based messaging focusing on health education and as needed clinician contact. \*TeleMOVE! was added as an option since many in-person MOVE! programs were on pause due to the pandemic.
223496303|NCT03234881|BEHAVIORAL|MOVE!+CBT|Participants randomized to the MOVE!+CBT arm will attend the 16 weeks of 60-minute weekly MOVE! or 90-days of the TeleMOVE! Treatment groups, along with up to 10 clinician-led individual sessions over a 3-month period. Participants will also be given a patient treatment manual to read at home, food diaries that will be expected to be completed on a daily basis, and gradually increase daily physical activity.
223496304|NCT03392857|OTHER|Assessment by caregivers of the quality of the end of life in intensive care units|Quality of the end of life in intensive care units perception will be explore from the side of the caregivers, trough the CAESAR scale.
223496305|NCT02071160|DRUG|Melatonin|Melatonin is administered to the melatonin/hypothermia group (n=15) in a dose of 10 mg/kg daily for a total of 5 doses starting immediately at enrollment. Melatonin tablets (1 or 3 mg/tablet) (Puritan's Pride,Oakdale, NY, USA) are crushed, then dissolved in 5-10 ml of distilled water , then administered via an orogastric tube.
223496306|NCT03011853|PROCEDURE|Non-invasive and/or invasive mechanical ventilation|Use of Non-invasive and invasive mechanical ventilation, focussing particularly on the first respiratory support mode in ICU
223496307|NCT01181882|DIETARY_SUPPLEMENT|Fish Oil and Aspirin|4 grams of fish oil each day for 28 days and 81 mg aspirin
223496308|NCT04200924|OTHER|Biodex Balance System|For the computerized evaluation of postural control, Biodex Balance System will be used.
223496309|NCT04200924|OTHER|Balance Error Scoring System (BESS)|For the clinical evaluation of postural control, the Modified Balance Error Scoring System (BESS) will be used.
223496310|NCT01178931|DRUG|Oral dydrogesterone|oral-2x10mg
223496311|NCT01178931|DRUG|Crinone 8% gel|vaginal-1x90mg
224187381|NCT00399542|DRUG|Placebo|
224187382|NCT05839366|DRUG|Esketamine|"Load dose of 0.25 mg/kg, and the fixed infusion rate of 0.15 mg/kg/h.The load dose will be injected intravenously within 1-2 minutes.Maintain the infusion at a fixed rate of 0.15 mg/kg/h for 72 hours; after 72 hours, change to a fixed rate infusion of 0.06 mg/kg/h.~Preparation: 46ml of saline + 4ml of eskeamine."
223496312|NCT05246748|OTHER|Human Caring Theory based Education|The intervention group was given a breastfeeding education program based on the HCT for six face to face sessionconducted in parallel with asynchronous distance education sessions in prenatal period and continued with web based sessions and telephone support in postnatal period.
223496313|NCT05246748|OTHER|Standard Education|The control group received solely standard education program for one sessions in prenatal period.
223496314|NCT00729586|OTHER|Laboratory Biomarker Analysis|Correlative studies
223496315|NCT00729586|DRUG|Megestrol Acetate|Given PO
224187383|NCT05839366|DRUG|Saline|As a placebo,normal saline at the same dose as esketamine.Saline is also administered intravenously.
223496316|NCT00729586|DRUG|Tamoxifen Citrate|Given PO
223496317|NCT00729586|DRUG|Temsirolimus|Given IV
223589888|NCT03567473|DRUG|Oral dexamethasone|Two doses of oral dexamethasone, 0.6 mg/kg (maximum single dose 10 mg). One at the time of emergency department enrolment immediately prior to first nebulized treatment and one at approximately 24 hour later
223589889|NCT03567473|DRUG|Nebulized Epinephrine|Two nebulized treatments of 3 mL 1:1000 epinephrine 30 minutes apart (+/- 15 minutes) at the time of emergency department enrolment
223589890|NCT03567473|DRUG|Oral placebo|Two doses of oral placebo, 0.6 mL/kg (maximum single dose 10 mL). One at the time of emergency department enrolment immediately prior to nebulized treatment and one at approximately 24 hour later . Oral placebo at Canadian sites is composed of OraBlendTM and in New Zealand and Australian sites will be a compounded solution.
223589891|NCT03567473|DRUG|Nebulized normal saline|Two nebulized treatments of 3 mL of normal saline 30 minutes apart (+/- 15 minutes) at the time of emergency department enrolment
224187384|NCT05839366|DRUG|Remifentanil + propofol|Remifentanil + propofol
224187385|NCT05839366|PROCEDURE|Pain and Sedation Assessment|"RASS Score:~After randomization success, a baseline Richmond Agitation-Sedation Scale (RASS) score is obtained before administering the investigational drug. Pain assessments are conducted every 1 hour within the first 6 hours after the initiation of the intravenous loading dose of the investigational drug, every 4 hours within the first 24 hours, and subsequently every 8 hours until the end of the study. In addition to the fixed time points mentioned above, researchers may conduct RASS scoring at any time based on the subject's actual condition (excessive or inadequate sedation). (No further RASS scoring is performed once the subject is fully awake.)~CPOT Score:~CPOT（Critical-Care Pain Observation Tool）Pain assessments are conducted concurrently with RASS scoring."
224187386|NCT02454387|DRUG|ONO-4474 Part A1|Healthy volunteers
224187387|NCT02454387|DRUG|Placebo Part A1|Healthy volunteers
224187388|NCT02454387|DRUG|ONO-4474 Part A2|Healthy volunteers
224187389|NCT02454387|DRUG|Placebo Part A2|Healthy volunteers
224187390|NCT02454387|DRUG|ONO-4474 Part B|Healthy volunteers
224187391|NCT02454387|DRUG|Placebo Part B|Healthy volunteers
224187392|NCT02454387|DRUG|ONO-4474 Part C|Healthy volunteers
224187393|NCT02454387|DRUG|Placebo Part C|Healthy volunteers
224187394|NCT02454387|DRUG|ONO-4474 Part D|Healthy volunteers
224187395|NCT02454387|DRUG|Placebo Part D|Healthy volunteers
224187396|NCT06111599|PROCEDURE|lumbar sympathetic blockade|Skiascopic-guided lumbar sympathetic blockade with the administration of local anesthetic
223496318|NCT03885063|BEHAVIORAL|Benjamin Rose Institute Care Consultation (BRI-CC)|The BRI-CC is a telephone-based intervention designed for adults with chronic conditions and has been used in persons with dementia and their caregiver (CG). This assessment is guided by the use of assessment tools with domains that trigger specific and pertinent needs of the dyad such as relationship strain, depression, financial concerns, memory problems, and difficult behaviors. To address unmet needs, the care consultant and dyad develop action plans with specific action steps pertinent to the dyad. The intervention involves maintenance and support where the care consultant (CC) continues the relationship with the dyad through regular telephone contact, email and mail. CC use a web-based reporting system, to maintain and track dyad information, assessments, action plans, completed tasks, and ongoing contacts. At a minimum, the care consultant will contact the dyad by telephone once per month over the duration of the study period (i.e. 6 months).
223496319|NCT03090906|PROCEDURE|Soft tissue augmentation palate|"Recipient site: Intrasulcular incision at the buccal side of the implant extending in one adjacent tooth for each side and a partial-thickness mucosal ﬂap raised. The connective tissue was secured with suture. Allocation to either treatment was performed according to a randomization table.~Donor site A double-bladed scalpel handle 1,5mm was used in both areas to obtain the same thickness.~Palate (CG) The double incision was made approximately 2 to 3 mm apical to the gingival margins of premolars. The donor tissue was removed and cross-mattress sutures were used to approximate the wound on the palate.~In both groups the epithelial collar removed. Graft required dimensions for both groups:10mm height, 12mm length and 1,5mm thick."
223589892|NCT03567473|DRUG|MDI Epinephrine|Two doses of Epinephrine given by MDI plus spacer at 625 mcg (5 actuations of 125mcg) 30 minutes apart (+/- 15 minutes) at the time of emergency department enrolment.
223589893|NCT03567473|DRUG|MDI placebo|Two doses of inhaled placebo given by MDI plus spacer, 30 minutes apart (+/- 15 minutes) at the time of emergency department enrolment.
223589894|NCT03179774|DEVICE|Endovascular revascularization|All interventions will be performed via 8F femoral sheath. Target common carotid artery will be engaged with 8F JR 4 guiding catheter. Intra-luminal wiring using coronary guidewires and microcatheters or alternative subintimal tracking with antegrade re-entry technique. Wiring would be abandoned after 30 minutes of futile effort, consumption of more than 300 ml of contrast, or when the wire tip is confirmed to be extravascular. Once wire enters distal true lumen, the microcatheter was exchanged to a 1.5 mm diameter coronary balloon for pre-dilatation. Distal embolic protection device would be deployed if an adequate landing zone can be identified. Properly sized balloon expandable stents and self-expanding stents were then deployed to scaffold the occlusion. Balloon post-dilatation may be done if stent expansion was inadequate.
223589895|NCT06024590|DEVICE|Irrisept|Standard of care wound treatment with 150 mL of IrriseptTM irrigation of the wound at each follow up visit.
223589896|NCT06024590|DEVICE|Saline|Standard of care wound treatment with 150 mL ration of Normal saline irrigation of the wound at each follow up visit
223589897|NCT04673916|DRUG|Healing evaluation|Treatments were topically applied for 5 days
223589898|NCT05635357|DRUG|Anastrozole|Anastrozole claim is used as the exposure group.
224187397|NCT04454021|PROCEDURE|hip arthroscopy|hip arthroscopy was performed when symptoms were not alleviated by nonsurgical treatment
224187398|NCT01693991|BEHAVIORAL|Meaning-Making intervention (MMi)|MMi and attention control sessions will take place weekly for 3 weeks at the patient's home or hospital, as the patient prefers. We will try to limit delays to no more than 1 week if needed (e.g., for recovery from treatment side-effects), but because the feasibility of this schedule is one of the research questions, if more flexibility is required we will not withdraw people from the study if the delay is longer, since a longer intervention period could be incorporated in a full-scale RCT. Dates and duration of each session will be tracked. MMi sessions will be conducted by 2 bilingual mental health professionals (nurse, social worker, or psychologist) with at least 1 year of clinical oncology experience and will be initiated within 1 week after randomization.
224187399|NCT01693991|BEHAVIORAL|Empathic visitor|This person will provide the basic ingredients fostering a good therapeutic relationship (i.e., trust, warmth, empathy, neutrality and authenticity) without further intervention or probing. The empathic visitor will be specifically instructed to avoid initiating discussions about meaning (e.g., how the patient interprets his feelings and thoughts, understands his/her illness and meaning in life), and focus discussions on what is currently happening (rather than on the interface between past and present).
224308993|NCT06039371|OTHER|Gallium Ga 68-PSMA-617|Given gallium 68Ga-PSMA-617
223589899|NCT05635357|DRUG|Exemestane/Letrozole|Exemestane/Letrozole claim is used as the reference group.
223589900|NCT00226135|DRUG|lithium or lamotrigine|
223589901|NCT00097890|DRUG|Replagal (Agalsidase Alfa)|
224308994|NCT06039371|PROCEDURE|Positron Emission Tomography|Undergo 68Ga-PSMA PET
223589902|NCT00097890|DRUG|Replagal|
223617820|NCT03104296|DIAGNOSTIC_TEST|Griffiths Mental Development Scales|"Griffiths Mental Development Scales investigate 5 main areas (locomotor, personal and social skills, hearing and language, eye and hand coordination, performance), providing a general developmental quotient (DQ) of infant's abilities and five sub-scale quotients (SQ) for each developmental area.~The assessments are performed individually in a quiet room, over a 45-min period, by the same professional trained psychologist for the whole study period and are implemented in the presence of the infant's parent. The obtained results are adjusted for corrected age, in order to consider the neurobiological maturation of the enrolled infants."
223745807|NCT01592929|RADIATION|Computed Tomography scan|One low dose CT scan of the upper airway will be taken. The scan will be taken at normal inhalation through a mouthpiece with moderate resistance.
224308995|NCT06039371|PROCEDURE|Single Photon Emission Computed Tomography|Undergo SPECT/CT
224308996|NCT04097158|OTHER|Sample Collection|The investigators will be collecting blood, urine, and spinal fluid samples.
224187400|NCT01408953|BIOLOGICAL|bevacizumab|"Bevacizumab will be diluted with 0.9% Sodium Chloride to achieve a concentration of 1 mg/0.3 ml. Bevacizumab will be injected inside ONE keloid tissue to result in a visual expansion of the keloid. Only 1 mg of bevacizumab is injected inside ONE keloid. The injections will be repeated every 14 days. Patients will receive maximum of 12 injections only.~A log will be kept for each patient indicating the date and the dose of bevacizumab that was delivered to each patient."
224187401|NCT03885817|BEHAVIORAL|Exercise training and nutritional guide|30 minutes of a combination of sensorimotor- and strength training guided by a physical therapist twice a week. In addition 90 minutes a week of moderate intensity aerobic training or 45 minutes a week of high intensity aerobic training. Once a month the participants will fill out the form, PG-SGA SF, and he or she will be referred to a nutritionist if the score is 2 or higher. The intervention period lasts as long as the participants receives adjuvant chemotherapy, i.e. 3 - 6 months.
224187402|NCT03885817|OTHER|Standard follow-up care|standard recommendations regarding physical activity and nutrition during the period with adjuvant chemotherapy.
224187403|NCT04450173|DRUG|Ibrutinib|Given PO
224187404|NCT04450173|BIOLOGICAL|Obinutuzumab|Given IV
224187405|NCT04450173|DRUG|Venetoclax|Given PO
224187406|NCT06148805|OTHER|pilates exercise and diaphragm manual technique|pilates exercises
224187407|NCT02400593|BEHAVIORAL|Meditation Workshop|Six weeks of formal instruction in Lovingkindness or Mindfulness meditation.
224187408|NCT00000610|DRUG|magnesium|
224187409|NCT04399434|OTHER|test gut microbiota, SCFAs and glucolipid metabolism and insulin sensitivity|test gut microbiota and SCFAs in mothers and their newborns and glucolipid metabolism and insulin sensitivity in mothers
224187410|NCT00308659|PROCEDURE|FOB protected distal microbiological samplings|
224187411|NCT05505487|OTHER|integrated care model|The interventions in this study were to implement basic patient care only and did not involve any invasive procedures. On the basis of routine nursing, the content of nursing intervention was integrated, and a standardized nursing model was formed for clinical application to control the severity of pulmonary infection in patients with simple tracheotomy in the non-acute phase of stroke.
224187412|NCT03831581|PROCEDURE|Erector Spinae Plane Block|In patients with chest pain, ultrasound-guided Erector Spinae Plane Block block was performed at T5 transverse process in the cephalo-caudal direction with Tuohy 18 gauge needle in plane until the needle tip was located in the interfascial plane between the transverse process and the erector spinae muscles, 20 ml of bupivacaine 0.5% was administered and a catheter was inserted if indicated.
224308997|NCT06263842|PROCEDURE|modified Elamrousy approach for socket shield technique|the jumping gap will be filled with AWTG
224308998|NCT06263842|PROCEDURE|conventional socket shield|the jumping gap will be left ungrafted
223496320|NCT03090906|PROCEDURE|Soft tissue augmentation tuberosity|"Recipient site: Intrasulcular incision at the buccal side of the implant extending in one adjacent tooth for each side and a partial-thickness mucosal ﬂap raised. The connective tissue was secured with suture. Allocation to either treatment was performed according to a randomization table.~Donor site A double-bladed scalpel handle 1,5mm was used in both areas to obtain the same thickness.~Tuberosity (TG) The double incision was made from the distal of the terminal tooth. A second incision was made perpendicular to the linear incision at a distal point, which joined the two linear incisions. The graft was removed and a crossed horizontal suspension suture was used.~Epithelial collar removed. Graft required dimensions for both groups:10mm height, 12mm length and 1,5mm thick."
223589903|NCT03771950|BEHAVIORAL|Early team based neuro-rehabilitation|A structured interview will be made by OT about activity level, and an examination of the patients bodily and neurological symptoms will be made by PT. Based on this result a rehabilitation plan is established consisting of the patient's goals, and the purpose that the patient shall be as active as possible without triggering symptoms. An individual exercise program is prescribed. Between each appointment the patient will have personal tasks to accomplish with the purpose of being active based on symptoms and the adaptation to the current level of energy. The perceived symptoms will be logged. A week-schedule will be created in the purpose of helping the patient to a balanced activity level in relation to their current capacity. The PT assesses physical activity level and reactions to physical strain. Adaptations are made to the exercise program and advice is given on physical activity and exercises. When appropriate OT advices about returning to work and adaptations concerning work.
224187413|NCT04896606|OTHER|Standard of Care|Patients will receive standard of care for COVID-19.
224187414|NCT04896606|BIOLOGICAL|SARS-CoV2-CTLS|Patients may receive up to 5 CTL infusions to treat SARA-CoV-2 in combination with standard of care.
224187415|NCT00809549|DRUG|Filgrastim|10 ug/kg sc once daily x 4 days. Repeated once, 6 weeks later.
224187416|NCT03765554|DRUG|PF-06700841 Immediate release tablets|Small molecule tablets in immediate release form
224187417|NCT03765554|DRUG|PF-06700841 Modified release tablets|Small molecule tablets in modified release form
224187418|NCT06077409|OTHER|Skin To Skin|"Skin to Skin Contact Group The temperature of the environment where kangaroo care will be carried out will be adjusted between 22-26 degrees C. The mother will be allowed to disinfect her hands and warm them until her hand temperature is at least 34 C. Only the baby's diaper, hat and socks will be left behind, and the baby will be placed face down on the mother's chest, with its head upright and its legs under the breasts in a frog position. The baby's face will be turned towards the mother and eye contact will be made. The baby will be in an upright position between the mother's breasts and skin to skin with the mother.~Skin-to-skin contact will begin 5 minutes before blood collection, continue throughout the procedure, and kangaroo care will continue until 5 minutes after the procedure."
224308999|NCT06263842|PROCEDURE|combined socket shild with xenograft|the jumping gap will be filled with xenograft
224309000|NCT06975943|DRUG|Progesterone 200 mg vaginal capsules|Participants in this group will receive daily vaginal micronized progesterone (Microgest®) of dose 200 mg for a duration of two weeks following arrested preterm labor. This micronized progesterone will be administered to assess its impact on pregnancy prolongation and changes of cervical length following arrested preterm labor.
224309001|NCT06273475|OTHER|Robot-assisted Training|Gait training and functional strength training facilitated by body weight unloading robotic technology yielding a dynamic unloading force applied to the body centre of mass. Gait training will be conducted both on treadmill and overground. Functional strength training exercises include sit-to-stand, stair-walking, step-ups etc. The goal is to gradually reduce body weight unloading as participants progress through the intervention period.
224187419|NCT06077409|BEHAVIORAL|Gentle Human Touch|Experimental Group (Gentle Touch/Gentle Human Touch-GHT); After the mother is dressed in a clean apron, her hands are washed and disinfected, and it is safe to warm the hand temperature with a non-contact thermometer device until the measured value is 34 ºC. The mother, who was previously informed about the method, will be placed on the eyebrow line with the crown piece that will separate the fingertips and tuft of one hand, while the other hand will be placed on the lower abdomen, which will mark the waist and hips (Figure 1). The blood collection amount of GHT application will be started 5 minutes before, make sure that the blood collection is done and the blood collection will continue until 5 minutes later.
224187420|NCT03679572|PROCEDURE|Robot assisted partial nephrectomy super-selective clamping|The device used to performe the surgery is a Da Vinci robot. After injection of infracyanine, the super-selective clamping is possible. The surgery is performed using a specific clamping of the tumor arteries. Super-selective ischemia is checked using near infrared fluorescence.
224187421|NCT03679572|PROCEDURE|Robot assisted partial nephrectomy with renal artery clamping|Partial nephrectomy is performed with the conventional method in wich a renal artery clamping is done.
224309002|NCT06273475|OTHER|Standard Training|Gait training and functional strength training facilitated without the use of body weight unloading robotic technology, thereby only allowing manual assistance from physiotherapists. The goal of training is the same as in the intervention group, however no body weight unloading device will be implemented in the active control group.
224309003|NCT03384654|DRUG|Daratumumab|Participant will receive daratumumab 16 milligram per kilogram (mg/kg) in cohort 1 and cohort 2.
223496321|NCT03090906|DEVICE|Intraoral optical scan|Intraoral optical scan was performed at both groups at baseline, 3 months, 4 months and 12 months to be able to compare volumetric changes.
223589904|NCT02017522|DEVICE|11C-PBR PET|"Subjects will have a positron emission tomography (PET) CT scan using 11C-PBR28 as a radiotracer. This study will evaluate inflammation due to cardiac sarcoidosis. The CT scan will improve the images. The total scan time will be about 30 minutes. There will also be some time required for prep, such as inserting an intravenous (IV) catheter in an arm or forearm. Including prep time, the scan will take approximately two hours.~Subjects will also undergo a cardiac MRI. Cardiac MRI uses strong magnetic fields to make pictures of the heart. We will use gadolinium containing contrast material, given through an intravenous (IV) catheter to highlight areas of scar in your heart which may be due to cardiac sarcoidosis. This scan will take about 60 minutes."
223589905|NCT04504942|DRUG|Leronlimab|Drug: Leronlimab 525mg
223589906|NCT04195555|DRUG|Ivosidenib|Given PO
223589907|NCT02166463|BIOLOGICAL|Bleomycin Sulfate|Given IV or SC
223589908|NCT02166463|DRUG|Brentuximab Vedotin|Given IV
223589909|NCT02166463|DRUG|Cyclophosphamide|Given IV
223589910|NCT02166463|DRUG|Doxorubicin Hydrochloride|Given IV
224187422|NCT03172026|DRUG|Maraviroc 300 mg|FDA approved chemokine receptor (CCR5) inhibitor. Maraviroc will be started within two weeks of discharge from inpatient rehabilitation, which most often will occur from 4-6 weeks after stroke onset.
224309004|NCT03384654|DRUG|Vincristine|Participant will receive vincristine 1.5 milligram per meter square (mg/m\^2) in cohort 1 and cohort 2.
224309005|NCT03384654|DRUG|Prednisone|Participant will receive prednisone 40 mg/m\^2 in cohort 1 and cohort 2.
224309006|NCT03384654|DRUG|Doxorubicin|Participant will receive doxorubicin 60 mg/m\^2 in cohort 2.
224309007|NCT03384654|BIOLOGICAL|Peg-asparaginase|Participant will receive peg-asparaginase 2500 units per meter square (U/m\^2) in cohort 2.
224309008|NCT03384654|DRUG|Cyclophosphamide|Participant will receive cyclophosphamide 1 gram per meter square (g/m\^2) once in cohort 2.
224309009|NCT03384654|DRUG|Cytarabine|Participant will receive cytarabine 75 mg/m\^2 in cohort 2.
224309010|NCT03384654|DRUG|6-mercaptopurine|Participant will receive 6-mercaptopurine 60 mg/m\^2 orally daily in cohort 2.
223496322|NCT01665027|PROCEDURE|vacuum|"Vacuum is an instrument that is using for helping delivery when there is no possibility of spontaneous delivery. First report of using vacuum was in 1962 by Solomon for delivery of fetal head (12). He suggested that using this instrument will lower pressure on fetal head and decrease delivery time (and then decrease fetal hypoxemia). Also it decreases spreading of incision and vascular injury (during manual maneuvers). Some studies confirmed these results (13, 14) and some others disagreed it (15, 16).~Considering with importance of fetal head delivery in a short time during C/S and to decrease maternal complications like lacerations and vascular injuries, this study was designed to compare the results of delivery by vacuum in C/S with routine methods for head extraction during difficult caesarean sections."
223589911|NCT02166463|DRUG|Etoposide|Given IV
223589912|NCT02166463|OTHER|Laboratory Biomarker Analysis|Correlative studies
223589913|NCT02166463|DRUG|Methylprednisolone|Given IV
223589914|NCT02166463|OTHER|Pharmacological Study|Correlative studies
223589915|NCT02166463|DRUG|Prednisone|Given PO
223589916|NCT02166463|OTHER|Quality-of-Life Assessment|Ancillary studies
223589917|NCT02166463|OTHER|Questionnaire Administration|Ancillary studies
223589918|NCT02166463|DRUG|Vincristine Sulfate|Given IV
223589919|NCT05074277|BEHAVIORAL|Simulated short term night shift work schedule|Participant sleep schedules (in the experimental arm) will be modified to simulate short-term (3 consecutive nights) night shift work schedule (kept awake at night and offered sleep opportunities during the day instead) in each of two inpatient stays.
223589920|NCT06007378|OTHER|Bupivacaine and ketamine|Bilateral erector spinae plane block (bupivacaine and ketamine)
223589921|NCT06007378|OTHER|Bupivacaine and transdermal fentanyl patch|Bilateral erector spinae plane block (bupivacaine) and transdermal fentanyl patch
223589922|NCT06007378|OTHER|Bupivacain|Bilateral erector spinae plane block (bupivacaine)
223589923|NCT04705766|OTHER|Urine Collection|A urine collection kit will be mailed to subjects' residence at 3 different timepoints over the course of 1 year to be returned to study team, upon which KIT score and other biomarkers will be assessed as outlined in the study design.
223589924|NCT05006599|DRUG|Insulin (Humulin® R U-100)|Participants will administer 40 IU of Humulin® U-100 insulin four times per day with an intranasal delivery device.
223589925|NCT05006599|DRUG|Placebo|Participants will administer placebo (insulin diluent) four times per day with an intranasal delivery device.
224309011|NCT03384654|DRUG|Methotrexate|Participant will receive methotrexate 5 g/m\^2 intravenously (IV) in cohort 2.
224187423|NCT03172026|BEHAVIORAL|Rehabilitation therapy|"All participants will have routine outpatient or home health physical and occupational therapy after inpatient discharge as prescribed by their physicians.~Each group will be contacted weekly by phone to help maintain interest in the trial, count the number of usual care physical and occupational therapy completed, assure use of the assigned medication, ask about possible adverse reactions, and to encourage them to be active. The coordinator will obtain this information and provide the feedback using a standard script and checklist. A unique aspect of this trial is a telerehabilitation component that aims to give feedback to all participants to practice with the affected arm and walk daily."
224187424|NCT03172026|DRUG|Placebo 300 mg|Matched placebo will be started within two weeks of discharge from inpatient rehabilitation, which most often will occur from 4-6 weeks after stroke onset.
224187425|NCT05300126|BEHAVIORAL|Hypnosis|Four sessions of 15 minute hypnosis, based on standardised script, focused on symptom management for the patients and of resource development for relatives.
224187426|NCT00004569|PROCEDURE|Non-invasive technique to diagnose and quantitate sleep-disordered breathing|
224187427|NCT04531436|OTHER|Brief mindful eating intervention|Over the 9-week intervention, participants will be introduced to various mindful eating and intuitive eating practices which are aimed at reducing overeating and facilitating weight loss. Each session will focus on one simple, evidence-based message, aimed at modifying a current weight-relevant eating behavior of the patient. The intervention will focus on two key elements: (1) the mindful awareness of body cues (intuitive eating) and (2) the mindful awareness of external cues (mindful eating).
224187428|NCT01728870|OTHER|Unique Diet+Partial Enteral Nutrition|Modulen - liquid dietary formula
224187429|NCT01728870|OTHER|Exclusive Enteral Nutrition (Modulen)|
224187430|NCT00612456|DRUG|Pazopanib|Pazopanib eye drops formulation
223589926|NCT05006599|DEVICE|Aptar Pharma CPS Intranasal Delivery Device|Participants will be assigned to receive Humulin® insulin or placebo administered through the Aptar Pharma CPS intranasal delivery device.
224073662|NCT04269226|PROCEDURE|Recruitment maneuver|Following intubation, patients will be ventilated according to the ideal weight within the scope of intraoperative protective ventilation strategy and in pressure-controlled ventilation (PCV) mode. Then, automatic recruitment maneuver will be applied to the recruitment group twice, after insufflation and desufflation. It will not be applied to the control group. During recruitment maneuver, PEEP (Positive end-expiratory pressure), where dynamic compliance is measured highest, will be the ideal peep for the patient, and PEEP will be adjusted at this value after recruitment.
224073663|NCT04269226|PROCEDURE|No recruitment maneuver|Usual ventilation procedures will be applied.
224309012|NCT03867955|OTHER|Collection of datas|Collection of datas by videopupillometer results: pupil diameter and variation of the pupillary diameter.
224309013|NCT05114837|DRUG|allogeneic CAR19 regulatory T cells (CAR19-tTreg)|A single dose administration of CAR19-tTreg
223496323|NCT01665027|PROCEDURE|routine manual maneuvers for fetal head extraction|fetal head techniques like fundal pushing, pulling technique or reverse breech extraction
223496324|NCT06355973|DEVICE|Using tablets and workbooks cognitive function.|Cognitive training programs corresponding to memory, attention, time and space, and orientation are conducted for 35 to 60 minutes.
223496325|NCT06355973|DEVICE|self-programming of physical function training.|The fitness program consisting of stretching, muscle strength, coordination, and aerobic exercise lasts 20 to 30 minutes, and additional 3-4 times/mainly 30 to 40 minutes of aerobic exercise.
224309014|NCT05114837|DRUG|Fludarabine|Fludarabine 30 mg/m\^2 is administered as an intravenous (IV) infusion per institutional guidelines once a day on 4 consecutive days (Day -5, Day -4, Day -3 and Day -2)
224309015|NCT05114837|DRUG|Cyclophosphamide|Cyclophosphamide 500 mg/m\^2 is administered as an IV infusion per institutional guidelines once a day on 2 consecutive days (Day -5, and Day -4)
224309016|NCT02180126|OTHER|Follow-up|Follow-up of of patients with borderline positive ANCA test results
224309017|NCT00827632|DRUG|Low dose formulation|"Participants are randomized to either Portia (levonorgestrel/ethinyl estradiol tablets, United States Pharmacopeia (USP)0.15 mg/0.03 mg or Lessina (levonorgestrel/ethinyl estradiol tablets, USP 0.1 mg/0.02 mg) for 3 months use.~Dose formula contains 20 ug of ethinyl estradiol (EE) and 100 ug of levonorgestrel (LN) per tablet."
224309018|NCT00827632|DRUG|High dose formulation|"Participants are randomized to either Portia (levonorgestrel/ethinyl estradiol tablets, United States Pharmacopeia (USP)0.15 mg/0.03 mg or Lessina (levonorgestrel/ethinyl estradiol tablets, USP 0.1 mg/0.02 mg) for 3 months use.~Dose formula contains 30 ug of ethinyl estradiol (EE) and 150 ug of levonorgestrel (LN) per tablet."
223496326|NCT06387316|OTHER|No Oral Stimulation|No oral stimulation
223496327|NCT06387316|OTHER|Oral water stimulation|Oral water stimulation
223496328|NCT06387316|OTHER|Oral Salt Stimulation|Oral Salt Stimulation
223496329|NCT06387316|OTHER|Oral Sucralose Stimulation|Oral Sucralose Stimulation
223496330|NCT06387316|OTHER|Oral Sucrose stimulation|Oral Sucrose stimulation
223496331|NCT05311865|OTHER|Club event|Participate in a club event without a mask, indoors, with vaccinated people.
223496332|NCT01718496|DRUG|Morphine|patient with advanced COPD will randomly receive single dose Morphine to assess its effect on dyspnea and exercise tolerance
223496333|NCT01718496|DRUG|Placebo|patients with advanced COPD on the other study arm will randomly receive Placebo
223496334|NCT04464772|DEVICE|FreeStyle Libre 3|FreeStyle Libre 3 Continuous Glucose Monitoring System
223496335|NCT00879359|DRUG|carboplatin, paclitaxel, and bevacizumab|All patients enrolled will receive carboplatin AUC 5 plus paclitaxel 175 mg/m2 (135 mg/m2 if prior radiation to greater than 25% of bone marrow) plus bevacizumab 15 mg/kg every 3 weeks.
223496336|NCT05314725|DRUG|SGLT2 inhibitor|10 days of SGLT2 inhibitor after surgery
223496337|NCT05314725|DRUG|Placebo|10 days of placebo after surgery
223496338|NCT00864071|DRUG|Griseofulvin 125 mg/5 mL Suspension, single dose|A: Experimental Subjects received Alpharma formulated products under fasting conditions
223589927|NCT05651126|DRUG|Psilocybin 5 mg|Partial Serotonin (5HT) 1A/2A Receptor Agonist Psilocybin
223589928|NCT05651126|DRUG|Psilocybin 2 mg|Partial Serotonin (5HT) 1A/2A Receptor Agonist Psilocybin
223589929|NCT05651126|DRUG|Placebo|Inactive placebo
224073664|NCT02070042|DRUG|Omega 3 Fatty Acid|Trunature® Triple Strength Omega-3, given twice a day. Each capsule contains 647 mg Eicosapentaenoic Acid (EPA) and 253 mg Docosahexaenoic Acid (DHA).
224187431|NCT05604859|DRUG|Methylprednisolone|Methylprednisolone:1-2mg/kg/d(or other glucocorticoid equivalent to methylprednisolone 1-2mg/kg/d),ivgtt,3-5 days.If disease progression occurs after completion of treatment, the dose of salvage therapy (methylprednisolone \> 2mg/kg/d or other glucocorticoid equivalent to methylprednisolone \> 2mg/kg/d) was continued for another 3-5 days.
224073665|NCT02070042|DRUG|Placebo|Placebo capsules (olive oil) twice a day
224073666|NCT02113735|DRUG|H.P. Acthar® Gel (repository corticotropin injection)|
224187432|NCT05604859|DRUG|intravenous immunoglobulin|intravenous immunoglobulin:0.2g-0.4g/kg/d,ivgtt, 3-5 days.If disease progression occurs after completion of treatment, the dose of salvage therapy (IVIG 0.4g/kg/d) was continued for another 3-5 days.
224187433|NCT05604859|DRUG|Tocilizumab|Tocilizumab:4mg/kg, once
224187434|NCT05604859|DRUG|Low molecular weight heparin|Low molecular weight heparin:100U/kg, qd or q 12h,IH,4-7 days
224187435|NCT05604859|OTHER|conventional treatment|conventional treatment，including symptomatic and supportive treatment, antiviral treatment etc.
223496339|NCT00864071|DRUG|Grifulvin V® 125 mg/5 mL Suspension, single dose|B: Active comparator Subjects received Ortho Neutrogena formulated products under fasting conditions
223496340|NCT01539200|DIETARY_SUPPLEMENT|ONS+JDR|Oral Nutritional Supplement with Jacques-Delacroze Eurythmic training
223496341|NCT01539200|DIETARY_SUPPLEMENT|JDR|Jacques-Delacroze Eurythmic training with placebo ONS
223496342|NCT00576615|DRUG|Placebo solution|On the day of the study infusion into the vein of a solution containing no drug, Complete about half a dozen memory tasks over the period of the study, each about 5-10 minutes in length, that involve identification of a list of words, or listen to a list of words/tones before, during, and/or after drug infusion. Allow the recording of your brain waves - the faint electrical activity constantly occurring in your brain- using the electroencephalogram (EEG) while completing memory tasks. Allow the imaging of your brain using functional magnetic resonance imaging (MRI), which measures images of water in your brain in a strong magnetic field, while completing memory tasks.
223496343|NCT00576615|DRUG|propofol|"On the study day you will receive study drug propofol. Complete about half a dozen memory tasks over the period of the study, each about 5-10 minutes in length, that involve identification of a list of words, or listen to a list of words/tones before, during, and/or after drug infusion.~Allow the recording of your brain waves - the faint electrical activity constantly occurring in your brain- using the electroencephalogram (EEG) while completing memory tasks. Allow the imaging of your brain using functional magnetic resonance imaging (MRI), which measures images of water in your brain in a strong magnetic field, while completing memory tasks."
223496344|NCT01949987|OTHER|two hours|
223496345|NCT01949987|OTHER|one hour|
223496346|NCT06306703|OTHER|group1, group2, group 3|to teaching with verbal instruction to teaching with digital vaginal palpation to teaching with perineometer
223496347|NCT03022175|DRUG|SPR741|"SAD: Double-blind dosing will occur in cohorts 1 through 8. Six participants will receive single doses of SPR741. The dose escalation steps may be altered following review of the safety data upon completion of each cohort.~MAD: The Safety Management Group will evaluate the safety and tolerability data obtained for the participants in Cohorts 1-5 to determine the appropriate dose level of intravenous q8h dosing of SPR741 to be utilized in the first cohort (Cohort 9) in the MAD. Dosing will commence on the morning of Day 1. Three doses will be administered per day at approximately 8 hours apart. Daily dosing will continue for a total of 14 consecutive days."
223496348|NCT03022175|DRUG|Placebo|0.9% sodium chloride for injection. SAD: Two participants in each cohort will receive matching placebo. MAD: Two participants in each cohort will receive matching placebo.
223496349|NCT05913947|DRUG|Lithium|The starting dose (day one) of lithium citrate is 12 mmol (one tablet of lithium citrate contains 6 mmol lithium) given once a day before bedtime. On day three the dose is increased to 18 mmol. Dose adjustments are permitted after 7 days in a flexible manner to result in a 12-hour se-lithium between 0.6 and 0.8 mmol/l, aiming for the upper limit at the treating physician's discretion.
223496350|NCT05913947|DRUG|Cariprazine|The starting dose for cariprazine is 1.5 mg daily in a single dose, and subsequently, after a minimum of two weeks, the dose can be increased to 3 mg and decreased again to 1.5 mg daily at the treating physician's discretion.
223496351|NCT00972738|DRUG|montelukast sodium|Montelukast 10-mg tablet orally once daily at bedtime for 2 weeks.
223496352|NCT00972738|DRUG|Comparator: loratadine|Loratadine 10-mg tablet orally once daily at bedtime for 2 weeks.
223496353|NCT00972738|DRUG|Comparator: Placebo|placebo tablet orally once daily at bedtime for 2 weeks
223496354|NCT03366753|PROCEDURE|acute normovolemic hemodilution|acute normovolemic hemodilution (ANH) is performed by using 5 ml/kg of blood salvage and intravenously administering 5 ml/kg of balanced hydroxyethystarch 130/0.42 (Tetraspan™) for 15 min
223496355|NCT03366753|PROCEDURE|In-vitro hemodilution|Blood sample after ANH 5 ml/kg undergoes further 30% in-vitro dilution by adding 1-1.5 ml hydroxyethystarch 130/0.42
223496356|NCT03499132|PROCEDURE|anesthesia|Different anesthetic procedures
223496357|NCT00033644|BIOLOGICAL|sargramostim|
223496358|NCT00033644|DRUG|cisplatin|
223496359|NCT00033644|DRUG|dacarbazine|
223496360|NCT00033644|DRUG|doxorubicin hydrochloride|
223496361|NCT00033644|DRUG|mitomycin C|
224073667|NCT02113735|DRUG|Placebo|
224073668|NCT02705638|DRUG|Rituximab|All subjects will receive Rituxan 1,000 mg intravenously on days 1 and 15.
224073669|NCT02705638|DRUG|Lenalidomide|All subjects will receive Revlimid 20 mg orally per day on days 1-21, 29-49, and 57-77.
224073670|NCT05459623|OTHER|Manual myofascial release|will receive Manual myofascial release to iliotibial band by having the subject to lie in the side lying position on the unaffected side. The upper leg to be tested was rested on the table with hip and knee flexion. Then the therapist applied a few kilograms of force weight along the iliotibial band course proximally to distally. The therapist will repeat this for 6 minutes.
224187436|NCT02224261|OTHER|Physical Therapy protocol|"Physical therapy protocol includes manual lymph-drainage technique in axilla, and proximal ipsilateral arm, specific thumb manual lymph-drainage on the taut cords to make them gradually more flexible, in conjunction with progressive active and action-assisted arm exercises stretching cords, and patient education."
224187437|NCT02224261|OTHER|Control|Control protocol includes standard progressive active and action-assisted arm exercises \& patient education.
224187438|NCT00824759|OTHER|pure oxygen breathing versus air|one group will breath pure oxygen; the other will breath air
224187439|NCT05699304|PROCEDURE|Thyroidectomy|Thyroidectomy
223496362|NCT00697164|DRUG|Placebo|Saline Admission, day 1, day 2 3 days
223496363|NCT00697164|DRUG|Erythropoietin|Erythropoietin, 1500 U/kg/day Admission, day 1, day 2 3 days
223496364|NCT05578547|OTHER|combined Kendell and McKenzie cervical posture correction exercises, ultrasound, hot packs, cervical extensors stretching and strengthening exercise.|"• The combined exercise will be done as follow:~1\) slowly pull the subject's neck to the head, thereby attaching the chin to the neck.~(2) the subject's eyes should be looking directly forward. (3) hold both hands on the back of the subject's head. (4) ask the subject to push his/her head backwards against the hands. (5) ask for the hands to be spread as wide as possible in order to stretch the pectoralis major.~Therapeutic ultrasound:~Moist heat packs:~Stretching Exercises:~Posture correction exercises training for forward head posture includes stretching of tight muscles such as Pectoralis major, levator scapulae, upper trapezius, suboccipital muscles, sternocleidomastoid Stretching exercises of pectoralis major, levator scapulae, upper fibres of trapezius, suboccipital muscles, sternocleidomastoid Strengthening Exercises Chin Tucks exercise Neck isometric exercises"
223496365|NCT05578547|OTHER|ultrasound, hot packs, cervical extensors stretching and strengthening exercise.|"Therapeutic ultrasound:~Moist heat packs:~Stretching Exercises:~Posture correction exercises training for forward head posture includes stretching of tight muscles such as Pectoralis major, levator scapulae, upper trapezius, suboccipital muscles, sternocleidomastoid Stretching exercises of pectoralis major, levator scapulae, upper fibres of trapezius, suboccipital muscles, sternocleidomastoid Strengthening Exercises Chin Tucks exercise Neck isometric exercises"
223745808|NCT01592929|RADIATION|Cone Beam Computed Tomography scan|One CBCT scan of the upper airway will be taken. The scan will be taken at normal respiration through a mouthpiece with moderate resistance.
224187440|NCT03159052|DRUG|SHR3824|Once daily, 52 weeks
223496366|NCT05855187|DRUG|Bravamax 200 mg (Modafinil)|Test drug
223496367|NCT05855187|DRUG|Vigil 200 mg (Modafinil)|Reference drug
223496368|NCT03915067|DRUG|BOTOX® purified neurotoxin complex|BOTOX® superficial intramuscular injections.
223496369|NCT03915067|DRUG|Placebo|Placebo injections.
223496370|NCT04011072|RADIATION|Far infrared radiation|The treatment group will receive FIR for 40 minutes on the skin above the fistula during each dialysis session for one year.
223496371|NCT00934882|DRUG|Regorafenib (BAY73-4506)|Administration of the multi-kinase inhibitor BAY73-4506 (160 mg once daily from Day 4 to Day 10 and from Day 18 to Day 24) as oral treatment in combination with the chemotherapy regimen mFOLFOX6 or FOLFIRI in patients with metastatic Colorectal Cancer
223496372|NCT00410488|DRUG|Palonosetron - Single Dose|0.25 mg by vein for 1 dose (day 0).
223496373|NCT00410488|DRUG|Palonosetron - Triple Dose|0.25 mg by vein for 3 doses (days 0, 2, 4).
223496374|NCT00410488|DRUG|Adriamycin|75 mg/m2 as an IV bolus OR 75 mg/m2 as continuous IV infusion over 72 hours (without zinecard) on Day 0.
223496375|NCT00410488|DRUG|Ifosfamide chemotherapy (AI)|Ifosfamide: 2.5 g/m2 IV bolus over 3 hours; days 0, 1, 2, 3 (total dose = 10 g/m2). Cycle is 3 weeks, up to 6 cycles.
223496376|NCT00410488|DRUG|Zinecard|750 mg/m2 as an IV bolus.
224187441|NCT03159052|DRUG|Placebo|Once daily, 24 weeks
224187442|NCT00265109|DRUG|Levetiracetam|The initial levetiracetam dose will be 250 mg/day, which will be increased to 250 mg BID after 1 week. The dose will then be increased by 500 mg/day each week (given in BID dosing) to a maximum of 3,000 mg/day. The dose will be raised more slowly or the maximum dose will not be reached if response occurs at a lower dose or side effects are problematic. Subjects who are unable to tolerate at least 500 mg a day of levetiracetam will be withdrawn from the study.
224187443|NCT01531049|DRUG|varenicline|days 1.-3 0,5mgx1/day, days 4.-7 0,5mgx2/day, day 8 to the 12weeks 1mgx2 /day
224187444|NCT01531049|DRUG|Nicotine cutaneous patch 15mg/16h|One patch for 16hours/day and duration of 8 weeks.
224187445|NCT01531049|DRUG|Nicotine cutaneous patch 10mg/16h|One patch 16hours/day and duration of 8 weeks
224187446|NCT01531049|OTHER|Placebo cutaneous patch|No active medication.O ne patch 16hours and duration for 8 weeks
224187447|NCT02463097|DEVICE|Insulin Pump|Closed Loop Algorithm
224187448|NCT04686591|DRUG|AZD9977 capsule 50 mg|100 mg dose of AZD9977 capsule 50 mg (as 2 x 50 mg capusles)
224187449|NCT04686591|DRUG|[14C]AZD9977 Solution for Infusion, 20 µg/mL (NMT 37.0 kBq/5 mL)|One 100 µg dose of \[14C\]AZD9977 Solution for Infusion, 20 µg/mL (NMT 37.0 kBq/5 mL)
224187450|NCT04686591|DRUG|[14C]AZD9977 Oral Suspension, 100 mg (NMT 9.9 MBq)|One 100 mg dose of \[14C\]AZD9977 Oral Suspension, 100 mg (NMT 9.9 MBq)
224187451|NCT03472339|DRUG|Diclofenac Sodium|Group A-Intramuscular diclofenac sodium+oral placebo Group B-Oral diclofenac sodium+ intramuscular placebo
224187452|NCT04039282|DEVICE|myfood24|online website for dietary analysis
224187453|NCT04212026|DRUG|Nivolumab|The patients start treatment with nivolumab on day 1 after IRE and will be given nivolumab at a flat dose of 240 mg every 2 weeks (q2wk) for 5 cycles until Week 8.
224187454|NCT06151821|BEHAVIORAL|Guided meditation|Meditation with guidance
224187455|NCT06080308|OTHER|No intervention|No intervention
224187456|NCT05674682|PROCEDURE|HIV testing|venipuncture or digital puncture for HIV testing
224187457|NCT05017116|DRUG|RBD1016|subcutaneous injection
224187458|NCT05017116|DRUG|Placebo|subcutaneous injection
224187459|NCT05017116|DRUG|Entecavir|Take orally.
224187460|NCT00381017|DRUG|Peg interferon alpha-2b|
224187461|NCT05677841|OTHER|Stabilization exercise+lifestyle recommendation|Exercise program was given both spinal stabilization exercises focusing on the pelvic floor 3 days a week for eight weeks and a booklet related to the lower urinary system symptoms, the structure of the pelvic floor and healthy behavioral strategies recommendations (fluid intake, diet, weight control etc. )
224187462|NCT05677841|OTHER|lifestyle recommendations|The control group will be given a booklet related to the lower urinary system symptoms, the structure of the pelvic floor and healthy behavioral strategies recommendations (fluid intake, diet, weight control etc. )
224187463|NCT01757821|DEVICE|real 6-Hz primed low-frequency rTMS|10 minutes of 6-Hz stimulation (real priming) followed by 10 minutes of 1-Hz low-frequency stimulation delivered to the nonstroke primary motor region
224187464|NCT01757821|DEVICE|Sham 6-Hz Primed low-frequency rTMS|10 minutes of sham priming stimulation followed by 10 minutes of 1-Hz low-frequency stimulation delivered to the nonstroke primary motor region
223496377|NCT00410488|DRUG|Mesna|500 mg/m2 given simultaneously with ifosfamide day 0; then 1500 mg/m2 over 24 hour for days 0, 1, 2, and 3 (infusion completing on day 4).
223496378|NCT00410488|DRUG|Vincristine|"2 mg IV by rapid administration on day 0 (for patients with small cell histology).~For patients with certain types of sarcoma, vincristine will be given through the catheter by rapid infusion on Day 0 only."
223496379|NCT00410488|DRUG|Dexamethasone|IV piggyback (IVPB) daily for 5 days (12 mg on day 0, and 8 mg on days 1-4) 30 minutes prior to chemotherapy.
223496380|NCT00296595|BEHAVIORAL|Nutrition|
223496381|NCT06334900|OTHER|GAD patients|Describe the clinical and demographic characteristics of patients with anti-GAD65 antibody associated cerebellar ataxia.
223496382|NCT03071744|DRUG|Lazanda|Lazanda is supplied in glass bottles, containing 8 sprays of 100 mcL containing 100 mcg/100 mcL or 400 mcg/100 mcL concentration solution.
223496383|NCT05875480|PROCEDURE|synchronized telerehabilitation|In the synchronized telerehabilitation group, the exercise program of the first 2 weeks was submitted via Albert Health Assistant application and patients were asked to do these exercises regularly during this process. after 2 weeks, they were treated 2 days a week until the 6th week by meeting with the physiotherapist in real time via the Albert Health Assistant application. In the remaining days, they were asked to follow the exercise videos uploaded to the Albert system, it will be checked whether they have done the daily exercises, and a daily reminder message will be sent through the system.
223496384|NCT05875480|PROCEDURE|asynchronized telerehabilitation|The exercise program for the asynchronized telerehabilitation group will be uploaded to the Albert Health Assistant in the form of 2-week programs in video form from the first Day. Whether the patients apply these videos on a daily basis will be checked through the system, a message reminding the daily routine exercise program will be sent through the system.
223496385|NCT05875480|PROCEDURE|supervised (face to face) rehabilitation|In the supervised physiotherapy group, the exercise program of the first 2 weeks was submitted via Albert Health Assistant application and patients were asked to do these exercises regularly during this process. After 2 weeks, they attended the rehabilitation program in the physical therapy department of the hospital accompanied by a physiotherapist, starting from the 14th postoperative day, 2 days a week until the 6th week. The ROM, pain, functional and general health evaluations of the patients in this group were carried out on the online platform. In addition, on the days when they did not come to treatment, their daily routine exercises were followed through the Albert system.
223496386|NCT04256408|DEVICE|Bronchoscopic transparenchymal interlobar fissure closure using Aeriseal|Transbronchial or transparenchymal injection of AeriSeal into the interlobar collateral ventilation channels region to convert CV-positive lobes into CV-negative lobes.
223496387|NCT01988415|DEVICE|VSS-Rx1 OPM vs Commercial iDesign Treatment|Commercially available iDesign treatment planning software used to calculate the LASIK treatment profile vs VSS-Rx1 OPM (includes a modified algorithm designed to reduce the induction of postoperative spherical aberration).
223496388|NCT00223431|DEVICE|all-ceramic fixed partial denture|
223589930|NCT06465693|DEVICE|Unblinded CGM plus nutrition therapy|"will receive evidence-based nutrition guidance by a certified and licensed registered dietitian (RD), including information on portion sizes, macronutrient types, and effect of carbohydrates on blood glucose.~will receive Dexcom G6 Pro CGMs to wear throughout the study. The CGM will be unblinded so that the glucose data will be available in real time to the participant and investigators. The dietitian and participant will review CGM data together"
223589931|NCT06465693|BEHAVIORAL|Nutrition therapy only|will receive evidence-based nutrition guidance by a certified and licensed registered dietitian (RD), including information on portion sizes, macronutrient types, and effect of carbohydrates on blood glucose.
223589932|NCT05210283|DEVICE|MRD|ctDNA MRD test
223745809|NCT01592929|OTHER|Dental impressions|Dental impressions will be taken. These will be optically scanned before registration in the 3D imaging modalities.
224073671|NCT05459623|OTHER|Emmett intervention|"will receive manual myofascial release and the Emmett intervention with the subject sitting upright on a 45cm wooden chair; light, constant pressure via the middle finger (at a perpendicular angle to the skin) will be applied at both points, three times for 10-20s with 5-10s breaks between. A light sweeping action over the sensory area that will treated will be performed once, using the back of the fingers. The rationale for this is that the light brushing action disperses the sensory awareness to move without being too heavy or specific enough to create muscular response. The sequence performed on one side will then repeated on the opposite leg. In Ross Emmett's teachings of the technique he insists on treatment of both sides when focusing on the lower body (for balance). Once both sides will be completed, the subject will be instructed to walk around the room for a minute."
224073672|NCT00516347|GENETIC|comparative genomic hybridization|
224073673|NCT00516347|GENETIC|genetic linkage analysis|
224073674|NCT00516347|OTHER|laboratory biomarker analysis|
224073675|NCT00516347|OTHER|questionnaire administration|
224073676|NCT00516347|PROCEDURE|study of high risk factors|
223589933|NCT06539195|DRUG|DZD8586|Daily dose of DZD8586 at 25 mg
223589934|NCT06539195|DRUG|DZD8586|Daily dose of DZD8586 at 50 mg
223589935|NCT06539195|DRUG|DZD8586|Daily dose of DZD8586 at 75 mg
223589936|NCT06777901|DEVICE|Auryon Atherectomy System|Auryon Atherectomy System is composed of a laser and catheter
223589937|NCT06777901|DEVICE|Balloon Angioplasty|Balloon Angioplasty alone
223589939|NCT05796921|DIETARY_SUPPLEMENT|Lacticaseibacillus rhamnosus CA15 (DSM 33960) probiotic strain|Patients allocated to the probiotic arm will take the dietary supplement, containing 10 billion of the Lacticaseibacillus rhamnosus CA15 (DSM 33960) probiotic strain, once a day for 10 consecutive days.
223589940|NCT05796921|DIETARY_SUPPLEMENT|placebo|Patients allocated to placebo arm will take placebo capsules once a day for 10 consecutive days.
223589941|NCT06583486|BIOLOGICAL|Rcombinant botulinum neurotoxin type A for injection (YY001)|Five sites will be injected at 0.05 mL each, 2 sites in corrugator muscle of each side and 1 site in the procerus muscle, for a total dose of 20U.
224073677|NCT06078969|DRUG|Prednisone|For the experimental group, the patient will be administrated oral prednisone (0.5mg/kg/day, first 5 days per month, 6 months)
224187465|NCT01757821|DEVICE|real 1-Hz rTMS only|20 minutes of low-frequency rTMS delivered to the nonstroke primary motor region
224309019|NCT04265430|OTHER|Contrast Agent|Given IV
223496389|NCT04808453|DRUG|CPI-300|CPI-300 will be administered via intravenous infusion on Day 1 of a 14-Day cycle
223496390|NCT06045260|DRUG|177Lu-DOTATOC|Administration of 4 cycles of therapy with 7.4 Gbq Dose for No risk factors Arm and 5.5 Gbq Dose for Risk Factor Arm. Both through slow intravenous infusion in 30 minutes with a dedicated pump system.
223496391|NCT01143792|BEHAVIORAL|Community Reinforcement Approach (CRA) + HIV prevention|12 sessions of the CRA and 2 sessions of HIV prevention.
223496392|NCT01143792|BEHAVIORAL|Case Management + HIV Prevention|12 sessions of case management and 2 sessions of HIV prevention.
223496393|NCT01143792|BEHAVIORAL|Motivational Enhancement Therapy (MET) + HIV prevention|2 sessions of MET and 2 sessions of HIV prevention.
223496394|NCT02204462|DRUG|FBnTP|A PET imaging radiotracer
223496395|NCT02548182|DEVICE|smartcare|Fit.life™ wireless physical activity tracker can measure daily physical activity including activity strength and time. It was chosen for its small size, accuracy in the measurement of physical activity, and convenient data upload via Bluetooth on participant mobile phone or wirelessly via a personal computer. Fit.life™ wireless physical activity tracker has been validated for measurement of free-living physical activity in adults \[REF\]. A smartphone application was customized for the use of the investigators' intervention, different for the 'smart care' group and 'smartcare plus financial incentive' group. The version for the latter group included the feature for the monitoring and feedback of financial incentives.
223496396|NCT02548182|OTHER|financial incentives|Financial incentives are provided in the form of process-based and outcome-based incentive.(maximum 320,000KRW) Process-based incentives were based on daily physical activity level. Participants in the 'smart care plus financial incentive' arms could earn incentives of up to 10,000 KRW per week according to the following schedule: 1,000 KRW if a participant reached target amount of physical activity in a day / An additional 3,000 KRW if a participant reached target amount of physical activity every day in a week. Outcome-based incentives were based on achievement of weight loss target at each visit. 50,000 KRW if a participant reached weight loss target of 3% from the baseline body weight at visit 2 (4 week)/ 50,000 KRW in weight loss target of 5% from the baseline body weight at visit 3 (8 week) / 100,000 KRW in weight loss target of 7% from the baseline body weight at final visit 4 (12 week)
223496397|NCT03545841|OTHER|HIT|Participants completed 6 weeks of HIT
223496398|NCT03545841|OTHER|MICT|Participants completed 6 weeks of MICT
223496399|NCT03137368|DRUG|Exemestane Tablets|drug therapy
223496400|NCT03137368|OTHER|ovarian function suppression/ablation|Gonadotropin-releasing hormone analogue Goserelin Injection 3.6mg or Leuprorelin Injection 3.75 mg, a subcutaneous injection should be done every 28±2 days; or Bilateral ovariectomy.
223496401|NCT03137368|GENETIC|CYP2D6*10 gene test|CYP2D6\*10 gene test
223496402|NCT03137368|DRUG|Tamoxifen|drug therapy
223496403|NCT04527250|DRUG|ASC41|ASC41,1mg/table;5mg/table
223496404|NCT04527250|DRUG|ASC41 placebo|ASC41 placebo,1mg/table;5mg/table
223496405|NCT03248895|DEVICE|Mobile Direct Observation of Therapy (MDOT)|Patients who are enrolled in the study will be randomised into two groups (I-med or D-med) to receive Mobile Direct Observation of Therapy (MDOT). Participants or parents/guardians of participants will be asked to capture a DOT video twice daily (morning and evening) on their mobile devices of ICS use by the patient. In the I-med group, participants will be asked to upload daily video recordings via the internet to a repository for a 6 week period at the start of the study. Participants in the D-med group will be free from DOT for the first 6 weeks of the study and will be asked to carry out their usual therapy management. After that, DOT as described above will be applied for the next 6 weeks.
223496406|NCT01860508|DRUG|pemetrexed /carboplatin|
223496407|NCT01381510|DRUG|5-alpha Reductase Inhibitor (5ARI)|A 5ARI: Either dutasteride or finisteride
223496408|NCT03657953|OTHER|surgical approach|
223496409|NCT00202150|BEHAVIORAL|Application of a management action plan|
223496410|NCT06430060|DRUG|zinc containing toothpaste|Toothpaste
223496411|NCT06430060|DRUG|MFP Fluoride toothpaste|toothpaste
223496412|NCT05143775|PROCEDURE|Awake craniotomy|Randomly select 30 participants to implement new surgical plan, which is using a monopolar stimulator to determine positive function sites and save tumors within 5 mm of the posterior superior longitudinal fasciculus/arcuate fasciculus
223496413|NCT03223194|GENETIC|AT342|AT342 is an AAV8 vector containing a functional copy of the UGT1A1 gene.
223496414|NCT02034591|DRUG|Apixaban|
224073678|NCT06253156|BEHAVIORAL|virtual reality|It is planned to provide 4 sessions of standard disaster preparedness training to nursing students in the intervention group. After the standard training sessions are completed, nursing students will be shown disaster simulation videos and visuals using virtual reality glasses within the scope of the virtual reality-based disaster preparedness training program.
223496415|NCT02034591|DIETARY_SUPPLEMENT|Boost Plus|
223496416|NCT00597675|BIOLOGICAL|Peanut OIT|Defatted peanut flour ingested daily as oral mucosal immunotherapy
223496417|NCT00597675|BIOLOGICAL|Placebo|Oat flour matched by weight and consistency that is ingested daily as a placebo
223496418|NCT05752409|DRUG|The median dose of esketamine|1mg•kg-1propofol and 0.5 mg•kg-1esketamine for general anesthesia induction.
223496419|NCT05752409|DRUG|The high dose of esketamine|1mg•kg-1propofol and 0.75 mg•kg-1esketamine for general anesthesia induction.
223496420|NCT05752409|DRUG|Propofol|2mg•kg-1propofol for general anesthesia induction.
224073679|NCT00540254|BEHAVIORAL|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy (CBT) + Insomnia plus Usual Care for Chronic Fatigue Syndrome -continues standard care for Chronic Fatigue Syndrome plus 4 sessions of CBT targeted for insomnia/sleep problems
224073680|NCT00540254|OTHER|Usual Care for Chronic Fatigue Syndrome (Active Control Group)|Usual Care for Chronic Fatigue Syndrome (Active Control Group) - continues standard care for Chronic Fatigue Syndrome and comes to the sleep lab for bi-weekly sessions to discuss sleep problems and to review weekly sleep logs
224075963|NCT05016245|PROCEDURE|conventional Transarterial Chemoembolization(cTACE)|conventional Transarterial Chemoembolization(cTACE) is comprised of an anti-neoplastic agent(s) (i.e. cisplatin), lipiodol and embolic agent(s). The choice of agent(s) to be used is per usual local site practice. Chemotherapy agents can be as a single agent or used in combination, as per local practice.
224075964|NCT03532191|OTHER|PrEP Optimization Intervention (PrEP-OI)|PrEP-Rx + PrEP Coordinator
224075965|NCT03206060|DRUG|Lu-177-DOTATATE|Lu-177-DOTATATE IV at weeks 1, 8, 16 and 24.
223496421|NCT01793935|DRUG|Sensoril®|Sensoril® is a proprietary extract of Withania Somnifera. Each Sensoril® capsules will contain 250 mg of standardized extract of Withania Somnifera
223496422|NCT01793935|DRUG|Placebo|Each Placebo capsule comprises inert ingredients; microcrystalline cellulose NF 102, croscarmellose Sodium NF, silicon Dioxide, Fumed NF (Cab-0-sil), magnesium sterate, NF matched in appearance and fill weight to Sensoril® capsules. Moreover, based on past experience, we will expose the placebo capsules to covered sachets containing Sensoril, so that the smell permeates the placebo capsules which then smell like the Sensoril capsules.
223496423|NCT02087592|BEHAVIORAL|Structured exercise training plus mediterranean diet|
223496424|NCT04697706|DIETARY_SUPPLEMENT|Moonstone|"Participants will take one packet of Moonstone powder reconstituted in 500 ml water, twice a day, to total 1 L per day (66 meq of potential alkali/day) plus ad lib fluids. Moonstone packets will be supplied by Dr. Arnie's, Inc.~Participants will follow their own self-chosen ad lib diets and complete a diet diary (Appendix) for days 6 and 7 in the first study period. On day 7, a 24-hour urine collection will be performed, and a 50-ml aliquot of urine will be sent to Litholink (Chicago, IL) via FedEx for analysis. Participants will then continue to the second study period and will use the diet diary completed in the first study period on days 6 and 7 to reproduce the identical diets for days 6 and 7 of the subsequent collection period."
223496425|NCT04697706|OTHER|Water|"Participants will take in 1L of tap water per day plus ad lib, self-selected fluids.~Participants will follow their own self-chosen ad lib diets and complete a diet diary (Appendix) for days 6 and 7 in the first study period. On day 7, a 24-hour urine collection will be performed, and a 50-ml aliquot of urine will be sent to Litholink (Chicago, IL) via FedEx for analysis. Participants will then continue to the second study period and will use the diet diary completed in the first study period on days 6 and 7 to reproduce the identical diets for days 6 and 7 of the subsequent collection period."
223496426|NCT00229528|DRUG|Paxil-CR|
223496427|NCT05074147|DRUG|Reduction in the duration of antibiotic therapy 3 weeks or 6 weeks|"Drugs :~* Rifampin (IP an PO) : 10mg/Kg/12h~* Ofloxacin (PO) : 200Mg/8h~* Levofloxacin (PO) : 500mg ot 1g/ twice a day~* Ciprofloxacin : IV : 400mg/8h if Pseud spp ; 400mg/12h for others Gram-negative bacilli strains; PO : 1gr/12h if Pseud spp ; 750mg/12h for others Gram-negative bacilli strains~* Clindamycin : 600-900mg/8h~* Fusidic Acid : 500mg/8h~* Teicoplanin : 10mg/kg/12h for 5 dosis in combination, then in monotherapy.~* Ceftasidim : 2g/8h if Pseud spp ; 2g/12h for others Gram-negative bacilli strains~* Trimethoprim-sulfamethoxazole (800mg/160mg) : once per day if patient \< 80Kg ; one and a half per day if patient \> 80Kg.~* Doxycyclin : 200mg/day~* Minocyclin : 100mg/8h to 12h~* Ceftriaxon : 1g to 2g/day in IV, IM or SC~* Cefotaxim : 1g to 2g/day in IV~* Pristinamycin : 1g thrice a day"
223496428|NCT04298385|OTHER|Traction orthosis|Traction applied to a finger using elastic thread and sports tape and attached to an orthosis
223496429|NCT02375503|DIETARY_SUPPLEMENT|Calcium/Vitamin D|Daily, calcium and vitamin D fortified snack bar
223496430|NCT02375503|DIETARY_SUPPLEMENT|Placebo|
223496431|NCT02254824|DRUG|Xuezhikang|Xuezhikang
223496432|NCT02254824|DRUG|Atorvastatin|Atorvastatin
223496433|NCT02254824|BEHAVIORAL|Lifestyle modification|Lifestyle modification
223496434|NCT01175720|PROCEDURE|Periodontal surgery to gingival recessions|Test and control technique to treat gingival recessions.
223496435|NCT01121926|DRUG|Trazodone HCl|"Dosage form:~Extended-release caplets containing 300 mg trazodone HCl and extended-release caplets containing 150 mg trazodone HCl (the 150 mg dosage form was only used for the up and down titration, and was not evaluated in the study).~Dose regimen:~75 mg trazodone HCl (½ x 150 mg extended-release caplet) on Days 1 and 11, 150 mg trazodone HCl (one extended-release caplet) on Days 2 and 10, 300 mg trazodone HCl (one extended-release caplet) on Days 3 to 9, each at 23:30 after a fast of at least 4 hours."
223496436|NCT01121926|DRUG|Trazodone HCl|"Dosage form:~Immediate-release tablet containing 100 mg trazodone HCl~Dose regimen:~100 mg trazodone HCl (one immediate-release tablet) once (at 23:30) on Days 1 and 11, 100 mg trazodone HCl (one immediate-release tablet) twice (at 23:30 and 11:30) on Days 2 and 10, 100 mg trazodone HCl (one immediate-release tablet) three times daily (at 23:30, 07:30 and 15:30) on Days 3 to 9. Evening doses were administered after a fast of at least 4 hours."
223496437|NCT04656119|OTHER|there is no intervention in our study|there is no intervention in our study
223496438|NCT01111370|DEVICE|DexCom™ G4 Continuous Glucose Monitoring System|Continuous Glucose Monitoring System
223496439|NCT05834153|DEVICE|kinesiotaping|"This group underwent a KT application on rectus abdominis muscle (RAM), oblique abdominal muscles (OAM) and cesarean incision twice a week for a period of 4 weeks. First, the scar technique will apply using I band with a tension of 50 % on cesarean incision when the patient will be in supine position. Then, tape will apply on RAM using muscle technique from origin to insertion of the muscle with a tension between 15 and 25 %.~Band will start on symphysis pubis with no tension, and then the patient was asked to stretch the abdominal region by deep abdominal respiration, and it will ended on xiphoid process.~Finally, it will perform on the right and left external oblique muscles. The procedure will start with no tension from the bottom end of the 6-12th ribs and then the hip will placed in flexion and rotation to the opposite direction and the band will taped on pubic bone with a tension between 15 and 25 %"
224073681|NCT05354986|OTHER|Toothpaste with hexametaphosphate, tripolyphosphate and polyvinylpyrrolidone (PVP)|"Subgingival instrumentation will be performed in two sessions, with a maximum interval of one week, with hand and automatic devices, under local anaesthesia. Full-mouth dental polishing (air-polishing) will be performed immediately after the second session, to eliminate any dental staining.~Experimental anti-staining toothpaste formulation (Dentaid, Barcelona, Spain) includes hexametaphosphate, tripolyphosphate and polyvinylpyrrolidone (PVP), within its ingredients. Participants will use the test or control toothpaste three times daily with a manual toothbrush followed by the use, twice daily, of a 0.12% chlorhexidine, commercially available, mouth rinse."
224073682|NCT05354986|OTHER|Toothpaste without hexametaphosphate, tripolyphosphate and polyvinylpyrrolidone (PVP)|"Subgingival instrumentation will be performed in two sessions, with a maximum interval of one week, with hand and automatic devices, under local anaesthesia. Full-mouth dental polishing (air-polishing) will be performed immediately after the second session, to eliminate any dental staining.~Experimental anti-staining toothpaste formulation without tripolyphosphate and polyvinylpyrrolidone (PVP), within its ingredients. Participants will use the test or control toothpaste three times daily with a manual toothbrush followed by the use, twice daily, of a 0.12% chlorhexidine, commercially available, mouth rinse."
224309020|NCT04265430|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223496440|NCT05834153|DEVICE|electrical muscle stimulation|"It consists of 24 patients who will receive NMES and core stabilization exercises.~The subjects will explain to relax their abdominal muscles while application Stimulation will apply by four large rectangular electrodes placed over the origin (pubic crest) and insertion (xiphoid process) of the rectus abdominis muscles bilaterally. Straps will used to fix the electrodes in place. A frequency of 80 pulses/min and with a pulse width of 0.1-0.5ms, will the parameter settings apply in this study. The total time for the application of stimulation will 30mins and until a good enough observable muscle contraction will achieve a gradual increase in intensity will perform"
223496441|NCT04038125|DRUG|Ozurdex Drug Implant Product|Intravitreal Ozurdex injection
223496442|NCT00416949|DEVICE|Patient-specific dosimetry|Patient-specific 3D-RD dosimetry was applied to the data collected
223496443|NCT04964232|DEVICE|Infrared Camera|The core-temperature is simultaneously measured by esophageal body temperature measurement methods, skin surface body temperature measurement methods, and thermal imaging camera.
223496444|NCT04964232|DEVICE|Esophageal Temperature Probe|In patients undergoing general anesthesia, the Esophageal temeperature parameters are measured using an Esophageal probe.
223496445|NCT04964232|DEVICE|Skin temperature probe|In patients undergoing general anesthesia, the skin spot temeperature parameters are measured using an skin adhesive probe.
223496446|NCT01149252|OTHER|Psoralait|Cream to be used as instructed.
223496447|NCT01149252|OTHER|Placebo cream.|Cream to be used as instructed
223496448|NCT04136301|OTHER|Informative Video group|Informative Video group before labor in nulliparous women
223496449|NCT00313170|DRUG|Fulvestrant|intramuscular injection 250 mg \& 500 mg
223496450|NCT05302232|DIAGNOSTIC_TEST|depomedrone 40mg/ml + 1% lidocaine|Response to intra-articular injection of lidocaine as a diagnostic marker of peripheral pain
223496451|NCT05302232|DIAGNOSTIC_TEST|depomedrone 40mg/ml+ 0.9% saline|Response to intra-articular injection of steroid only as a placebo
224073683|NCT00493038|DRUG|Moxifloxacin (Avelox, BAY12-8039)|Patients will be administered daily a single moxifloxacin 400 mg tablet for 7 days
224073684|NCT00493038|DRUG|Amoxicillin/Clavulanate|Patient will be administered daily Amoxicilline/Clavulanate 1000 mg tablets every 8 hours for 10 days
223496452|NCT05302232|OTHER|painDETECT questionnaire|painDETECT questionnaire
223496453|NCT05680701|OTHER|real tACS|The participant will receive one session of 10 Hz tACS for 20-minutes
223496454|NCT05680701|OTHER|sham tACS|The participant will receive one session of active-sham tACS for 20-minutes
223496455|NCT05531097|DRUG|HSK31679|Single or multiple oral doses of HSK31679
223496456|NCT05531097|DRUG|Placebo|Matching placebo
223496457|NCT01722799|DEVICE|Drug elluting Balloon (DEB)|Percutaneous transluminal coronary angioplasty with drug elluting ballon and Bare metal stent for rescue.
223496458|NCT01722799|DEVICE|Drug elluting coronary stent (DES)|Percutaneous transluminal coronary angioplasty (PTCA) with stent
224073685|NCT03440827|BEHAVIORAL|Focus Group|First (phase 1), collect experiences, perceptions, difficulties, needs and expectations of patients with slow-flow malformations (for the age group of 11 to 15 years-old), carried out with 3 categories of participants and then (phase 2) development and validation of the specific scale of life's quality of slow-flow vascular malformation in children aged 11 to 15 years-old.
224075966|NCT03206060|DRUG|Ga-68-DOTATATE|Ga-68-DOTATATE PET/CT at weeks 15 and 31, every 24 weeks during 3 years follow up period.
223496459|NCT06091384|OTHER|Inspiratory muscle strength training|Using a handheld device, participants will perform 30 breaths per day at 75% of maximal inspiratory pressure, six days a week, during 6 weeks.
223496460|NCT00074191|DRUG|cytarabine|
223496461|NCT00074191|DRUG|dexamethasone|
223496462|NCT00074191|DRUG|lomustine|
223496463|NCT00074191|DRUG|methotrexate|
223496464|NCT00074191|DRUG|procarbazine hydrochloride|
223496465|NCT00607594|DRUG|saracatinib|Patients receive AZD0530 (saracatinib) PO QD in the absence of disease progression or unacceptable toxicity.
223496466|NCT02591303|OTHER|Stress reactions measurement during stressful and neutral driving sessions|Stress effects will be measured during 3 driving sessions (training without events on Day 17, with neutral events on Day 18, with stressful events on Day19), through nighttime PSG and questionnaires.
223496467|NCT04003571|BEHAVIORAL|Augmented Reality with Functional Electrical Stimulation group|Experimental group contains 30 minutes augmented reality combined with functional electrical stimulation training, and 30 minutes traditional physiotherapy. Augmented reality includes treadmill and balance exercise. Functional electrical stimulation applies on tibialis anterior muscle. Traditional physiotherapy includes rolling, sitting, standing, overground walking, facilitation of the paretic limbs, and so on.
223496468|NCT04003571|BEHAVIORAL|Traditional physiotherapy|Traditional physiotherapy includes treadmill and balance training for 30 minutes as well as rolling, sitting, standing, overground walking, facilitation of the paretic limbs for another 30 minutes .
223496469|NCT01410604|DRUG|Metformin|Tablet of 500 mg metformin, oral every 12 hours (total metformin dose of 1 g/day) for 3 months.
223496470|NCT01410604|DRUG|Placebo|Tablet of 500 mg oral placebo every 12 hours for 3 months.
223496471|NCT04784975|OTHER|No intervention|No intervention
223496472|NCT05189002|DRUG|Dimolegin 40 mg|Dimolegin - DD217 - 40 mg
223496473|NCT05189002|DRUG|Dimolegin 60 mg|Dimolegin - DD217 - 60 mg
223496474|NCT05189002|DRUG|Fragmin|Fragmin 5000 IU in 0.2 ML Prefilled Syringe
223496475|NCT04856566|DRUG|Low Marijuana, Hash, THC, or Grass|Cannabis with low amount of THC
223496476|NCT04856566|DRUG|High Marijuana, Hash, THC, or Grass|Cannabis with high amount of THC
223496477|NCT04856566|DRUG|Placebo|Placebo drug with no THC
223496478|NCT04856566|DRUG|0.05 BAC Alcohol|Amount of alcohol when consumed leads to BAC of 0.05
223496479|NCT04856566|DRUG|0.08 BAC Alcohol|Amount of alcohol when consumed leads to BAC of 0.08
223496480|NCT05505890|OTHER|suprainguinal fascia iliaca block|Suprainguinal fascia iliaca block will be performed after the end of surgery for postoperative analgesia.
223496481|NCT06283030|DEVICE|Hypoglossal nerve stimulation|Device-mediated stimulation of the hypoglossal nerve
224075967|NCT03206060|DRUG|F-18-FDG|F-18-FDG PET/CT at weeks 15 and 31, every 24 weeks during 3 years follow up period.
224075968|NCT03206060|DRUG|Amino Acid solution|AA solution will be administered 60 minutes prior to each Lu-177-DOTATATE infusion.
223745810|NCT05112549|DRUG|Nivolumab [Opdivo]|Nivolumab (OPDIVO®) is a marketed pharmaceuticals material authorized in the European Union. This study uses an off-label route of administration of nivolumab. Subjects with leptomeningeal disease in solid tumours with an approved indication for intravenous treatment with the PD1 antibody will receive an intrathecal application of nivolumab. A total of six i.th. applications will be performed every 14 days. The intrathecal administration will be performed via an Ommaya reservoir or another intraventricular catheter.
223496482|NCT01264471|PROCEDURE|Skin biopsy|A small skin sample will be obtained from the patients arm which is approximately the size of the top of a thumbtack (a small circle no more than a 1/4 inch across)
224073686|NCT02630238|DIETARY_SUPPLEMENT|Branched-Chain Amino Acid Supplementation|All participants will partake in the same diet \& exercise regime but this group will also be placed on a BCAA intake level of 0.342g/kg of BCAA per day
223496483|NCT01264471|PROCEDURE|Blood Collection|Approximately 45ml or 3 tablespoons for blood will be drawn from a vein in the patient's forearm.
223496484|NCT02124226|DRUG|Methotrexate|7.5 mg/week + folic acid the day after
223496485|NCT02124226|DRUG|Placebo|matched placebo
223496486|NCT02199574|DRUG|EXPAREL|133 mg EXPAREL in 10 mL.
223496487|NCT03605056|DRUG|chidamide|20 mg/d, will be administered orally, on Days 1, 4, 8, 11 of each 21 day cycle
223496488|NCT03605056|DRUG|lenalidomide|25 mg/d, will be administered orally on Days 1-14 each 21 day cycle
223496489|NCT03605056|DRUG|dexamethasone|40mg weekly, will be administered orally or intravenously
223745811|NCT00005831|BIOLOGICAL|trastuzumab|Given IV
223745812|NCT00005831|DRUG|paclitaxel|Given IV
224073687|NCT02630238|OTHER|Placebo|All participants will partake in the same diet \& exercise regime but this group will receive an isocaloric placebo in form of carbohydrate solution
224073688|NCT02630238|OTHER|Exercise|Exercise will take place in a class based, circuit training setting run by a certified personal trainer composed of both aerobic and lifting exercises
224073689|NCT02630238|OTHER|Diet|Each participants will be placed on a daily energy deficit of 500 calories for the 8 week study period.
224073690|NCT06222125|DRUG|HB0025|HB0025 IV every 2 weeks (q2w)
224073691|NCT00010361|DRUG|cyclosporine|
224073692|NCT00010361|DRUG|fludarabine|
224073693|NCT00010361|DRUG|mycophenolate mofetil|
224073694|NCT02639780|OTHER|protein expression pattern of packed red blood cells|the proteome of packed red blood cells will be assessed at predefined time points
224073695|NCT03345472|DEVICE|Spinal Cord Stimulation System|Implanted neurostimulation system (neurostimulator and leads) with high dose stimulation parameters.
224073696|NCT01100944|DRUG|PXD101with cisplatin+doxorubicin+cyclophosphamide|PXD101 will be given as a 48h continuous intravenous infusion (CIVI) starting on day 1, doxorubicin as a slow intravenous (IV) injection on days 2 and 3, cisplatin will be infused over 1 hour on day 2 and cyclophosphamide as a slow IV infusion on Day 3. Treatment will be given every 21 days for no more than 6 cycles or until disease progression. Treatment with PXD101 alone may continue until disease progression.
224073697|NCT05581732|DIETARY_SUPPLEMENT|Nutrinidrink with Dietary Fiber|Nutrinidrink with Dietary Fiber is a specialized nutrition for children during illness and recovery period, as well as with increased protein and energy needs: mental and / or physical stress, chronic diseases, growth and / or weight deficiency
224073698|NCT03334331|OTHER|Six-minute step test|Volunteers will be instructed to go up and down one step for six minutes
223496490|NCT03281720|PROCEDURE|TAD|the same intervention as listed in the arm description
224073699|NCT03334331|OTHER|Six-minute walk test|Volunteers will walk the longest distance possible by performing turns in a 30 meter corridor for six minutes
224073700|NCT06446245|DRUG|Doxycycline|adjunctive doxycycline to standard anti-tuberculous treatment and corticosteroid therapy
224073701|NCT06446245|DRUG|Placebo|Placebo
224073702|NCT06446245|DRUG|Anti Tuberculosis Drug|Standard anti-tuberculous therapy
224073703|NCT06446245|DRUG|Adjunctive corticosteroid|Adjunctive corticosteroids to be dosed at 0.4mg/kg/day of dexamethasone or equivalent for week 1, then 0.3mg/kg/day for week 2, 0.2mg/kg/day for week 3, 0.1mg/kg/day for week 4, then tapered to stop over the next 4 weeks. Other forms of corticosteroids are also acceptable eg. hydrocortisone, methylprednisolone at the equivalent dosage
223496491|NCT03470766|DEVICE|Nevro Senza System (HF10 Therapy)|Nevro 10kHz High Frequency Spinal Cord Stimulation
223496492|NCT01491516|DEVICE|TELAMON P™ /INFUSE® Bone Graft/CD HORIZON® Spinal System|The TELAMON P™/INFUSE™ Bone Graft Implant in conjunction with the CD HORIZON® Spinal System for single level lumbar fusion from L1 to S1
223496493|NCT04215770|DRUG|inj co-amoxiclav 50 units/kg/day vs inj Benzyl Penicillin 25000 units/kg/day|Patients of both groups were examined and compared in terms of efficacy of treatment, safety and cost effectiveness
223496494|NCT01464762|DRUG|TMC207|400mg once daily by mouth for 2 weeks followed by 200mg by mouth three times per week for 22 weeks + individualized background of antibacterial drugs
223496495|NCT03469973|PROCEDURE|Partial adenoidectomy|"The procedure will be completely visualized with a 45 degrees, 4- mm nasal endoscope; the upper part of the adenoid will be removed using the microdebrider, while the lower part will be preserves to maintain the velopharyngeal competence.~• Adenoid enlargement causing Obstructive Sleep-Disordered Breathing (OSDB) with velopharyngeal insufficiency (proved or suspected)."
223745813|NCT00005831|DRUG|carboplatin|Given IV
223745814|NCT00005831|DRUG|gemcitabine hydrochloride|Given IV
223745815|NCT00005831|OTHER|laboratory biomarker analysis|Correlative studies
224073704|NCT04755946|DRUG|Roflumilast|adding one tablet of roflumilast 500 mcg to the standard ACEI (captopril) for diabetic nephropathy management
224073705|NCT04755946|DRUG|Placebo|Placebo
224073706|NCT01848535|DIETARY_SUPPLEMENT|GOS addition|GOS (2.5g 3x per day) supplemented during 12 days
224073707|NCT01848535|DIETARY_SUPPLEMENT|Placebo|Maltodextrine(2.5g 3x per day) supplemented during 12 days
224073708|NCT01175902|DRUG|dorzolamide/timolol|dorzolamide/timolol fixed combination eyedrop, 2 times a day
224073709|NCT01175902|DRUG|latanoprost|compare with dorzolamide/timolol fixed combination eyedrop one time a day
224073710|NCT04765280|DIAGNOSTIC_TEST|Central sensitization inventory|Standardized questionnaire to determine the level of central sensitization. Patients with a score of 40 and above are considered to have central sensitization.
224309021|NCT04265430|OTHER|Quality-of-Life Assessment|Ancillary studies
223496496|NCT00105378|BEHAVIORAL|Dutch EASYcare Study Geriatric Intermediate Care Programme|
223496497|NCT00529035|DRUG|Interleukin-2|Dose will vary depending upon when participant enters the trial: Given as a daily injection under the skin for 8 weeks.
223496498|NCT05470803|BIOLOGICAL|AstraZeneca/Fiocruz|4th dose of SARS-CoV-2 vaccine
223496499|NCT05470803|BIOLOGICAL|Pfizer/Wyeth|4th dose of SARS-CoV-2 vaccine
223496500|NCT05470803|BIOLOGICAL|Clover SCB-2019|4th dose of SARS-CoV-2 vaccine
223496501|NCT05400330|BIOLOGICAL|LX1001|Gene therapy
223496502|NCT05619341|DIETARY_SUPPLEMENT|psyllium|psyllium 20g
223496503|NCT05619341|DIETARY_SUPPLEMENT|inulin|long chain fructan
223496504|NCT03439514|DRUG|ARRY-371797 (PF-07265803)|400 mg twice daily (BID)
223496505|NCT03439514|OTHER|Placebo|BID
223496506|NCT04966429|DRUG|Maraviroc|Tablets
223496507|NCT05129202|DRUG|immune therapy|The patient receives immunotherapy
223496508|NCT05080270|BIOLOGICAL|Tolerogenic Fibroblasts|administrating single dose of 100 million tolerogenic fibroblasts via intravenous infusion
223496509|NCT01026597|DRUG|REGN727|5 IV cohorts (dose 1, 2, 3, 4, and 5)
223496510|NCT01026597|DRUG|Placebo|5 IV cohorts (dose 1, 2, 3, 4, and 5)
223496511|NCT02175758|DRUG|SOF|SOF administered orally once daily
223496512|NCT02175758|DRUG|RBV|RBV oral solution or capsules will be administered orally in a divided daily dose based on weight
223496513|NCT04213911|RADIATION|low-dose chest CT scan|The low-dose chest CT scan is now commonly used as a quick, painless, and non-invasive approach to screen for lung cancer. The radiation exposure from one low-dose CT scan of the chest (1.5 mSv) is comparable to 6 months of natural background radiation for a person living in the US.
223496514|NCT04213911|DEVICE|insertion of esophageal balloon|The esophageal catheter is a flexible thin plastic tube with an air-filled balloon at the distal end. The tube will be placed through the nasopharynx after local anesthesia.
223589942|NCT06166368|OTHER|Diurnal variation|Venous blood samples were obtained under standardized circumstances from 24 healthy young men every third hour through 24 hours, nine time points in total.
223589943|NCT00859937|DRUG|Dasatinib|Given PO
223589944|NCT00859937|OTHER|Laboratory Biomarker Analysis|Correlative studies
223589945|NCT05123963|BEHAVIORAL|High-intensity interval training|3 times per week high-intensity interval training (HIIT) on a cycle ergometer for 12 weeks.
223589946|NCT02478164|DRUG|Ponatinib|
223589947|NCT06481735|BIOLOGICAL|TCR reserved and Power3 (SPPL3) Gene Knock-out Allogeneic CD19-targeting CAR-T cell|Phase 1 dose escalation (3+3) : dose 1 (1 × 10\^6 cells/kg) , dose 2 (3 × 10\^6 cells/kg), dose 3 (6 × 10\^6 cells/kg); Phase 2 : dose of RP2D.
223589948|NCT06481735|DRUG|Fludarabine|Intravenous fludarabine 30\~50 mg/m\^2/day on days -5, -4, and -3.
223496515|NCT00652652|DRUG|nesiritide, furosemide|
223496516|NCT04791852|DIAGNOSTIC_TEST|Donor-derived Cell Free DNA|We will compare ddcfDNA with coronary angiogram determined CAV grading, according to ISHTL2010 classification
223589949|NCT06481735|DRUG|Cyclophosphamide|Intravenous cyclophosphamide 500\~1000 mg/m\^2/day on days -5, -4, and -3.
223589950|NCT06636162|DRUG|DSP-0390|DSP-0390 will be administered orally with preferably 200 mL of water, or approximately one-half cup water. The patient will take DSP-0390 after a minimum of a 6-hour fast and will fast for 1 hour after taking the dose.
223745816|NCT02063854|DRUG|NE-58095 IR|NE-58095 IR tablets
224309022|NCT04265430|OTHER|Questionnaire Administration|Ancillary studies
223496517|NCT00005769|DRUG|Hormone Replacement Therapy|
223496518|NCT06355921|PROCEDURE|radiofrequency ablation|"Anesthesia: Local (Novocaine, Lidocaine, Bupivacaine) Access: transcutaneous Navigation under CT control Cannulas are used: 22G 100 and 150 mm, the size of the electrode corresponds to the size of the cannula The starting power is 20W followed by steps of 10W every 2 minutes until the maximum power is reached, the maximum power is 60W.~In order to prevent infectious complications, two-day antibiotic prophylaxis of Cefazolin (1g) is carried out 3 times a day In order to prevent skin burns with superficially located DFS, the skin is cooled during the procedure."
223496519|NCT04428489|OTHER|Observation and necessary supportive care|For patients with ICUS and CCUS, necessary supportive care could be given. No addtitional treatment is administrated.
223496520|NCT05323851|BEHAVIORAL|COVID-surg-SPIGC questionnaire|The questionnaire aimed to evaluate how the COVID-19 pandemic determined a shift in daily practice through a multidimensional assessment of surgical clinical care in three different time frames.
223496521|NCT01098695|OTHER|Ecological Family Intervention and Treatment (EcoFIT)|Includes the Family Check-Up (in-person intake, family video observations and Assessment questionnaires used to provide and tailored feedback using motivational interviewing techniques) as well as continued tailored intervention services using the Everyday Parenting Curriculum.
223496522|NCT04822909|DRUG|Apremilast;Apremilast;Apremilast 10 MG; 20 MG; 30 MG Oral Tablet|"The study patients will be treated with oral apremilast, administered initially a dose of 10 mg once daily, gradually increasing to reach the maximal therapeutic dosage of 30 mg twice daily before end of 1st week of starting the therapy.~The treatment will be continued till 6 months and we will taper the steroids by 10mg/ 2 weeks till 20mg and then 5 mg/ 2 weeks till discontinuation of steroids.~If a patient worsens after treatment or develops any serious adverse event after initiation of treatment, he will be withdrawn from the study.~If there is no response to the treatment and we are unable to taper steroids after 12 weeks of therapy then the patient will be withdrawn from the study"
223496523|NCT00530166|DRUG|JNJ-18054478|3(100 mg) tablets once daily for 12 weeks
223496524|NCT00530166|DRUG|sham comparator|3(100 mg) tablets once daily for 12 weeks
223589951|NCT03385278|OTHER|rTMS|20HZ Repetitive Transcranial Magnetic Stimulation
223589952|NCT05245812|DEVICE|da Vinci SP Surgical System|This is a software-controlled, electro- mechanical system designed for surgeons to perform single port minimally invasive surgery.
223589953|NCT06182696|BIOLOGICAL|OriCAR-017|GPCRC5D-directed chimeric antigen receptor modified T cells
223589954|NCT05194267|DEVICE|transcranial direct current stimulation (tDCS)|tDCS alters brain excitability using a weak electric field induced through two electrodes and could potentially improve symptoms of depression
223589955|NCT00802893|DRUG|6R-BH4|6R-BH4 5mg/kg or Placebo BID for four weeks and then 8 week dose-escalation period
223589956|NCT00802893|OTHER|Placebo|placebo given BID for entire length of study
223745817|NCT02063854|DRUG|NE-58095 IR Placebo|NE-58095 IR placebo-matching tablets
223745818|NCT02063854|DRUG|NE-58095 DR|NE-58095 DR tablets
224187466|NCT06071351|OTHER|motivational interviewing based training program|In addition to the informative brochure prepared by the researcher; A 6-session training program based on motivational interviewing, including nutrition, physical activity, smoking and alcohol use, will be held.
224187467|NCT06071351|OTHER|Routine practice|An informative brochure prepared by the researcher was given.
224187468|NCT05635695|OTHER|Free Museum visit|People are tested when they arrive at the museum. Then, they freely visit the different rooms for 45 to 75 minutes. No instructions are given.
223496525|NCT00620919|DRUG|RG1068 (Synthetic Human Secretin)|Dose: 0.2 μg/kg of synthetic human or 18.5 µg for patients over 50 kg Route: Intravenous Frequency: Once Duration: Over 1 minute
223496526|NCT03372421|OTHER|Social Story|A short story written in the third person about what it's like to attend an assessment for ASD.
223496527|NCT03372421|OTHER|Standard Information|Information the host site currently sends out to patients informing them about what to expect from the assessment
223496528|NCT01484002|DEVICE|Total hip arthroplasty|Replacement of a patient's native hip with an artificial implant featuring a metal-on-polyethylene articulation
223496529|NCT02136589|DRUG|dicrofenac and travoprost|dicrofenac drop 3 times a day travoprost 0.005% once daily
223496530|NCT03512886|OTHER|Multi-task training|In the multitasking training group, a second motor task in the first two weeks, a cognitive task in the third and fourth week, both motor and cognitive tasks in the last two weeks will be added to these 10 different motor tasks.
223496531|NCT03512886|OTHER|Single task training|An exercise program consisting of 10 different motor tasks will be implemented in a single task training group.
223496532|NCT05880030|DRUG|Cholecalciferol|cholecalciferol 10000 UI
223496533|NCT05880030|OTHER|placebo|sunflower oil
223496534|NCT06373510|BIOLOGICAL|Blood collection|Collection of blood before and after a non mandatory vaccination
223496535|NCT01975441|DRUG|Diethylcarbamazine|Diethylcarbamazine 6mg/kg
223496536|NCT01975441|DRUG|Albendazole|Albendazole 400mg
223496537|NCT01975441|DRUG|Ivermectin|Ivermectin 200 mcg/kg
223496538|NCT01159847|DRUG|sitagliptin|sitagliptin tablet,100 mg p.o. qd,2 year
223496539|NCT01159847|DRUG|Insulin|
223496540|NCT00406380|DRUG|Bevacizumab|
223496541|NCT00406380|PROCEDURE|Intravitreal injection of Bevacizumab|
223496542|NCT05720247|DIAGNOSTIC_TEST|Fibroscan|Fibroscan is a safe and effective test using ultrasound to measure liver elasticity and can detect early signs of liver disease even before a patient shows symptoms.
223496543|NCT05720247|BEHAVIORAL|Brief Intervention|Short counselling session to discuss drinking behavior, risks to health and available sources of treatment and support.
223496544|NCT01458977|DRUG|Truvada® (300 mg tenofovir disoproxil fumarato/200 mg emtricitabine)|TDF/FTC 300/200mg daily during 3 months + Placebo during 6 months
223496545|NCT01458977|DRUG|Placebo|Placebo during 3 months + TDF/FTC 300/200mg daily during 3 months + Placebo during 3 months
223496546|NCT04163380|BEHAVIORAL|Resistance Training|Participants will exercise at the mid-point of each menstrual cycle phase (EFP- day 4, LFP- day 11, ELP- day 18 and LLP- day 25 for a 28 day menstrual cycle). Training will consist of a warm up. Intensity will be set at 70% of 1RM, and the circuit training will include 7 strength exercises: leg press, rows, back squat, weighted crunches, deadlifts, bench press, and weighted squat jumps. The participant will perform 3 sets f 10 repetitions with 30 seconds of rest
223496547|NCT00063037|BEHAVIORAL|Behavioral modification - nutrition education|
223496548|NCT04857710|DEVICE|Wide-pulse neuromuscular electrostimulation (WP NMES)|The WP NMES program consists of electrical stimulation trains of 1000 symmetrical biphasic pulses (1 ms, 100 Hz). The duration of a train is of 10 s and the rest between trains is of 30 s. A WP NMES session includes 30 evoked contractions. The stimulation intensity is monitored online and adjusted to the highest tolerable by the subjects.During the stimulation, subjects are seated with the knee joint fixed a 60° angle. Three self-adhesive electrodes are placed over the right thigh. The positive electrodes, measuring 25 cm² (5 x 5 cm), are placed as close as possible to the motor point of the vastus lateralis and vastus medialis muscles. The negative electrode, measuring 50 cm² (10 x 5 cm), is placed 5-7 cm below the inguinal ligament. Electrical stimulations are delivered by a stimulator BioStim (Mazet Santé).
223589957|NCT04606316|DRUG|Nivolumab-Placebo|Intravenous (IV) solution that has no therapeutic effect, used as a control in testing investigational drug. One dose is received prior to surgery.
223589958|NCT04606316|DRUG|Nivolumab|Given as intravenous (IV) infusion into a vein.
223589959|NCT04606316|DRUG|Ipilimumab-Placebo|Intravenous (IV) solution that has no therapeutic effect, used as a control in testing investigational drug. One dose is received prior to surgery.
223589960|NCT04606316|DRUG|Ipilimumab|Given as intravenous (IV) infusion into a vein.
223589961|NCT04606316|PROCEDURE|Surgery|Treatment of disease or injury by cutting, abrading, suturing, or otherwise physically changing body tissues and organs.
223589962|NCT06151288|BIOLOGICAL|31 valent pneumococcal conjugate vaccine|0.5 ml dose of VAX-31 was administered into the deltoid muscle at Day 1
223589963|NCT06151288|BIOLOGICAL|20 valent pneumococcal conjugate vaccine|0.5 ml dose of PCV20 was administered into the deltoid muscle at Day 1
223589964|NCT01164553|BIOLOGICAL|Trivalent Inactivated Influenza Vaccine|Either a standard pediatric dose (0.25 ml) or a larger dose (0.5 ml) of Trivalent Inactivated Influenza Vaccine (TIV) (Fluzone®) administered intramuscularly (IM) in the thigh with a 25 gauge 1 inch needle. Naive cohort (enrolled over two influenza seasons (2010-11 and 2011-12)) will receive vaccine in two IM doses 28-42 days apart, Fully Primed cohort (enrolled in one influenza season (2010-11)) will receive vaccine in one IM dose.
223589965|NCT04588389|DRUG|Ropivacaine injection Location 1|Ropivacaine .5% and lidocaine 1% to the area behind the muscle Quadratus Lumborum location 1
223589966|NCT04588389|DRUG|Ropivacaine injection Location 2|Ropivacaine .5% and lidocaine 1% to the area behind the muscle Quadratus Lumborum location 2
223589967|NCT04588389|DRUG|Multimodal Pharmacological Management|standard of care multimodal pharmacological management
223589968|NCT06584084|DEVICE|WPM-SEMG prototype|Measurements will be done with the rigid matrix. The flexible electrode matrix will be used only on a lower percentage of volunteers depending on the results obtained with the rigid matrix
223589969|NCT00230958|DRUG|Viramidine|
223589970|NCT00230958|DRUG|Ribavirin|
224187469|NCT05635695|OTHER|Cultural pathways App|Cultural pathways in the park of the museum will be proposed to people with a smartphone application that will give directions, cultural and sustainable health contents, points of interest with games and specific information about the pathways (distance, noise level, walkability, practical information). There will be two possible levels: contemplative or active.
224187470|NCT05071742|GENETIC|2ml peripheral venous blood was collected to detect genetic genes|"Extraction of whole genome DNA: 2 mL of peripheral fasting venous blood was extracted, and edTA disodium was anticoagulant.The whole-genome DNA was extracted strictly in accordance with the instructions of the blood genomic DNA extraction kit (Beijing Tiagen Biochemical Technology Co., LTD., China), and the DNA concentration and purity were detected by nanodrop-1000 spectrophotometer (Thermo, USA). The DNA was diluted to 10 ng/μL and stored in a refrigerator at -80℃ for future use.~(2) Primer design and synthesis: (3) Gene polymorphism detection 4) Resin purification 5) Spot chip and mass spectrometry detection"
223496549|NCT04857710|DEVICE|Conventional neuromuscular electrostimulation (CONV NMES)|"The CONV NMES program consists of electrical stimulation trains of 500 symmetrical biphasic pulses (0.2 ms, 50 Hz). The duration of a train is of 10 s and the rest between trains is of 30 s (duty cycle: 1/3). A WP NMES session includes 30 evoked contractions. The stimulation intensity is monitored online and adjusted to the highest tolerable by the subjects.~During the stimulation, subjects are seated with the knee joint fixed a 60° angle. Three self-adhesive electrodes are placed over the right thigh. The positive electrodes, measuring 25 cm² (5 x 5 cm), are placed as close as possible to the motor point of the vastus lateralis and vastus medialis muscles. The negative electrode, measuring 50 cm² (10 x 5 cm), is placed 5-7 cm below the inguinal ligament. Electrical stimulations are delivered by a stimulator BioStim (Mazet Santé)."
223496550|NCT04857710|DEVICE|Control (CONT) modality|Control (CONT) modality is used as a reference and is representative of a sedentary behaviour regularly observed in our populations.
223496551|NCT01047501|DRUG|AMR101 (ethyl icosapentate) - 4 g/day|AMR101 (ethyl icosapentate) 4 capsules/day for 12 weeks
223745819|NCT02063854|DRUG|NE-58095 DR Placebo|NE-58095 DR placebo-matching tablets
224073711|NCT04765280|OTHER|Short form-36|Standardized questionnaire to investigate the quality of life in patients. The score of the scale is between 0-100. The higher scores are associated with greater deterioration in quality of life.
224187471|NCT01604642|OTHER|blood tests and muscular biopsies|blood tests and muscular biopsies
224187472|NCT01873027|DEVICE|OFDI|"* OFDI-guided PCI and assessment by OFDI at pre-PCI and post-PCI~* Follow-up contact at the time of hospital discharge, 8 months and 12months after PCI"
224187473|NCT01873027|DEVICE|IVUS|"* IVUS-guided PCI and assessment by IVUS at pre-PCI and post-PCI~* Follow-up contact at the time of hospital discharge, 8 months and 12months after PCI"
224187474|NCT03029052|BEHAVIORAL|Reconciliation|In addition to standard healthcare procedures, the pharmacist will analyze discharge prescriptions and proceed to medication reconciliation. A patient's counseling session will also be provided by the pharmacist. A reconciliation mail will be addressed to the PCP.
223496552|NCT01047501|DRUG|AMR101 (ethyl icosapentate) - 2 g/day|AMR101 (ethyl icosapentate) 2 capsules/day with placebo 2 capsules/day for 12 weeks
224073712|NCT04765280|OTHER|Istanbul Low Back Pain Disability Index|Standardized questionnaire to investigate the disability in patients with low back pain. The score of the scale is between 0-90. It is accepted that the higher the score, the higher the disability.
224073713|NCT04765280|OTHER|Disabilities of the Arm, Shoulder and Hand (DASH)|Standardized questionnaire to investigate the disability in patients with upper extremity musculoskeletal disorders. The score of the scale is between 0-100 It is accepted that the higher the score, the higher the disability.
224073714|NCT04765280|OTHER|Neck Pain and Disability scale|Standardized questionnaire to investigate the disability in patients with neck pain. The score of the scale is between 0-100. It is accepted that the higher the score, the higher the disability.
224073715|NCT04765280|OTHER|Knee Injury and Osteoarthritis Outcome Score|Standardized questionnaire to investigate the disability in patients with knee pain. The score of the scale is between 0-100It is accepted that the higher the score, the higher the disability.
224187475|NCT01215045|DEVICE|AcrySof ReSTOR Aspheric +4|Implantation with the AcrySof ReSTOR Aspheric +4 Multifocal Intraocular Lens (IOL)
224187476|NCT03748628|DRUG|EDP-305|\[14C\]EDP-305
224187477|NCT03319602|DEVICE|Double trunk mask add above a nasal canulae|oxygenation only with nostril prongs
224187478|NCT00382434|PROCEDURE|presence of an emergency pharmacist in the ED|
224187479|NCT01070849|OTHER|educational booklet|"Participants will receive an educational booklet and the advice to return to normal activities as soon as possible from their rehabilitation practitioner in their dismissal examination. As educational booklet the German version of the back book of Burton et al. was chosen. This booklet provides information about the new approach to back pain, causes of back pain, dealing with an attack of back pain, risk factors for development of chronic back pain and the role of activity. All information that is provided is in accordance with actual scientific knowledge and is based on a bio-psycho-social model of back pain like described in Waddell."
224187480|NCT01070849|OTHER|IRENA|Participants will be introduced into the normal IRENA program (in German: Intensivierte Rehabilitationsnachsorge), which is usual care in Germany. Every patient will be assigned to a certified aftercare facility near their residential area. Aftercare practitioners and patients can compile an individual therapeutic package from certain appointed therapeutic services. Predominantly resistance training, gymnastics, aquatic exercise, back school and recreation exercises are prescribed by the physicians for aftercare. Most therapies are carried out in open access groups of at least 6 patients without being specific for medical indication. In the IRENA program it is possible to pass the intended 24 exercise sessions with different frequency per week. Usually participants do two or three exercise sessions per week with duration of 90 to 120 minutes per session. Every aftercare facility offers certain therapy combinations at different days in week.
223496553|NCT01047501|DRUG|Placebo|Placebo 4 capsules/day for 12 weeks
223496554|NCT00580281|OTHER|blood test, urine test, and bone density x-ray.|start of the study (month 0), and at months 3, 6, 9, 12 (1 year), 15, 18, 21, and 24 (2 years)
223745820|NCT00150839|DRUG|Mirtazapine|Patients receive mirtazapine 45mg and placebo.
223589971|NCT00230958|DRUG|pegylated interferon alfa-2b|
223589972|NCT02625870|DRUG|Omega-3-Acid Ethyl Esters 90 Soft Capsules|Omega-3-Acid Ethyl Esters 90 Soft Capsules will be provided in 1 g polyacrylate-coated soft gel capsules.Four capsules will be taken with breakfast once per day, for 12 weeks.
223589973|NCT02625870|DRUG|Corn Oil|Corn Oil will be provided in 1 g polyacrylate-coated soft gel capsules.Four capsules will be taken with breakfast once per day, for 12 weeks.
223589974|NCT05242952|BEHAVIORAL|Gaming in a virtual environment|To address the primary outcomes of feasibility and acceptability of the VE, we will capture process data using a computer-based virtual environment and self-report measures using an online survey.
223589975|NCT06186700|DRUG|Pentoxifylline 400mg plus chemotherapy|The patient will take 400 mg tablets of Pentoxifylline, 3 tablets per day, starting from the first day of the first cycle of doxorubicin/cyclophosphamide till finishing the cycles of neoadjuvant chemotherapy comprised intravenous Doxorubicin 60 mg/m²/cycle with intravenous cyclophosphamide 600 mg/m²/cycle for four cycles, followed by weekly paclitaxel, dose-dense paclitaxel or docetaxel.
223589976|NCT06186700|DRUG|Chemotherapy|The patient will take chemotherapy cycle comprised intravenous Doxorubicin 60 mg/m²/cycle with intravenous Cyclophosphamide 600 mg/m²/cycle for four cycles, followed by weekly paclitaxel, dose-dense paclitaxel or docetaxel..
223589977|NCT01443507|OTHER|endurance exercise of different duration and intensity|Two interventions are compared with aerobic capacity as the main outcome. one group exercise at 70% of maximal heart rate for 90 minutes 3 times per week. group two exercise performe10 minutes warm up at 70% of maximal heart rate 4 x 4 minutes intervals at 90-95% of maximal heart rate with 3 minutes active pause at 70% of maximal heart rate in between, and finally 5 minutes cooling down at 70 % of maximal heart rate.
223496555|NCT04491487|OTHER|pre-operative counselling|pre-operative Speech-Language Pathology (SLP) counselling before Total Laryngectomy
223496556|NCT04061629|DEVICE|Cuffed ETT|Cuffed endotracheal tube.
223496557|NCT04623151|BEHAVIORAL|Online leaflet about foot care|Short text-based leaflet about foot care, presented online
223496558|NCT06109688|DIETARY_SUPPLEMENT|Bovine Lactoferrin|Orally intake 1 sachet per day for 4 weeks. Lactoferrin will be dissolved in human milk or infant formula or in a 5% glucose solution.
223496559|NCT06109688|DIETARY_SUPPLEMENT|placebo|Orally intake 1 sachet per day for 4 weeks. Maltodextrin will be dissolved in human milk or infant formula or in a 5% glucose solution.
223496560|NCT04172272|DRUG|Systemic multimodal analgesia administered intravenously|"Paracetamol 1 gram and ketoprofen 100 mg every 8 hours for 24 hours. Analgesia will start immediately after surgery. If the pain persists, the patient will be given rescue analgesia: tramadol 50 mg intravenously up to a maximum dose of 400 mg / 24 h and other analgesics if needed."
223496561|NCT04172272|PROCEDURE|Transversus abdominis plane block (TAP block)|"The TAP block will be given postoperatively before waking. It will be given bilaterally in the before mentioned anatomic region (the so-called lateral TAP block) of 0.25% levobupivacin in 40 ml bilaterally. If the pain persists, the patient will be given rescue analgesia: tramadol 50 mg intravenously up to a maximum dose of 400 mg / 24 h and other analgesics if needed."
223496562|NCT04172272|OTHER|Combined transversus abdominis plane block (TAP block) with systemic multimodal analgesia administered intravenously|TAP block in addition to systemic, mutimodal analgesia. If such analgesia is not satisfactory, tramadol 50 mg intravenously, up to a maximum dose of 400 mg / 24h, and other analgesics will be given at the request of the patient.
223496563|NCT03027934|DRUG|Ticagrelor|Ticagrelor, 90mg twice daily
223496564|NCT03027934|DRUG|Prasugrel|Prasurgrel, 10mg once daily
223589978|NCT05240001|DEVICE|Thulium Fibre Laser|Participants will undergo treatment using the TFL
223589979|NCT05240001|DEVICE|MOSES Holmium Laser|Participants will undergo treatment using the MOSES Holmium laser.
223589980|NCT03161535|OTHER|exercise and dietary education|"1. A 12-week regimen of home-based walking exercises, comprising walking at a moderate intensity for 40 min, three times a week, was administered along with weekly exercise counseling. After collecting pretrial measurements, we explained the participants how to perform the exercises, according to an instruction manual for the exercise regimen. The detailed instructions, provided at the hospital clinics, included the determination of activity intensity, demonstration of pulse measurement, criteria for scores of 6-20 on the Borg's rating of perceived exertion (RPE), prevention of exercise-related injuries, and conditions necessitating termination of an exercise session. Participants were instructed that the exercises would be effective only if they reached 60%-80% of the target heart rate, as determined by the Karvonen method, and 13-15 on the RPE.~2. Diet-teaching program (using dietary education booklet)."
223745821|NCT00150839|DRUG|Venlafaxine|Patients receive mirtazapine 45mg and venlafaxine 300mg.
223745822|NCT01107587|BIOLOGICAL|GSK Biologicals' human rotavirus vaccine 444563|Oral, two doses.
223496565|NCT03940534|DEVICE|TAD|TAD is a device used to aid medication adherence.
223496566|NCT03061643|DRUG|Docetaxel|docetaxel 40 mg/m2 IV every 2 weeks plus ADT
223496567|NCT03061643|OTHER|Androgen-Deprivation Therapy (ADT)|docetaxel 40 mg/m2 IV every 2 weeks plus ADT
223496568|NCT02811978|DRUG|Bortezomib|Participants will receive 1.3 mg/m\^2 bortezomib on Days 1, 4, 8, and 11 of a 3 week cycle.
223496569|NCT02811978|DRUG|Dexamethasone|Participants will receive Dexamethasone at a dose of 20 mg PO on the day of and the day after bortezomib dosing (Days 1, 2, 4, 5, 8, 9, 11, and 12 of each cycle).
223496570|NCT03613870|DEVICE|PermeaDerm|Wound treatment with PermeaDerm
223496571|NCT03613870|DEVICE|Mepilex Ag|Wound treatment with Mepilex Ag
223496572|NCT02004795|RADIATION|BNCT + IG-IMRT|Single faction of BNCT (20 Gy) plus IG-IMRT (40 Gy/20 fractions)
223496573|NCT03917888|DIAGNOSTIC_TEST|lung ultrasound|lung ultrasound will be performed daily in mechanically ventilated patients after 48 hours of ventilation to screen for ventilator associated pneumonia
223496574|NCT01116531|DRUG|Tramadol|Initial dose of oral tramadol (depottabl Tramal retard, Orionpharma, Finland) will be 100mg once daily. If the subject is currently on opioid treatment with codeine, tramadol or buprenorphine, the opioid treatment will be stopped, and an equal dose of tramadol will be used as the initial dose. The dose will be titrated on visits V2 and V3 based on the adequacy of pain relief and tolerability. If pain intensity ≥ 4 on a numeric rating scale of 0-10 during V2 and V3 and tramadol is well tolerated, the daily dose will be increased by 100mg. The maximum daily dose of 400 mg tramadol will not be exceeded. If the subject does not tolerate the initial dose of tramadol, he/she will be dropped out of the study and replaced by another patient.
223496575|NCT01116531|DRUG|Duloxetine|The initial dose of duloxetine (Cymbalta, Eli Lilly, USA) will be 30mg once daily. The dose will be titrated on V2 based on the adequacy of pain relief and tolerability. If pain intensity during V2 is \< 4 on a scale of 0-10, the dose of duloxetine dose will be 30mg daily throughout the study. If pain intensity is ≥ 4 on a numeric rating scale of 0-10 and duloxetine is well tolerated, the daily dose will be increased to 60mg once daily. If the subject does not tolerate the initial dose of duloxetine, he/she will be dropped out of the study and replaced by another patient.
223496576|NCT01116531|DRUG|Pregabalin|The initial dose of pregabalin (Lyrica, Pfizer, USA) will be 75mg twice a day. The dose will be titrated on V2 based on the adequacy of pain relief and tolerability. If pain intensity during V2 is \< 4 on a scale of 0-10, the initial dose of pregabalin dose will be continued. If pain intensity is ≥ 4 on a numeric rating scale of 0-10 and pregabalin is well tolerated, the daily dose will be increased to 150mg twice a day. If the subject does not tolerate the initial dose of pregabalin, he/she will be dropped out of the study and replaced by another patient.
223496577|NCT03647007|OTHER|FIFA 11 for health|The training consists of various football exercises, such as passing, shooting, dribbling, etc., and small-sided games. The small-sided games are performed as e.g. 3v3 with small goals (2x5 m).
223496578|NCT02940379|DRUG|sotagliflozin (SAR439954)|"Pharmaceutical form: tablet~Route of administration: oral"
223496579|NCT02940379|DRUG|midazolam|"Pharmaceutical form: HCl syrup~Route of administration: oral"
223589981|NCT03161535|OTHER|weekly telephone consultations concerning exercise and diet.|For each participant, we discussed exercise regimen-related issues and diet weekly through the telephone. For instance, we discussed whether participants' exercise fulfilled the prescribed intensity, duration, or frequency and whether the participants experienced any adverse effects.
223589982|NCT02911142|DRUG|Lenalidomide|Lenalidomide taken orally, daily at assigned dose level on days 1 to 10, up to 25mg.
223589983|NCT02911142|DRUG|Rituximab|During cycle 1, rituximab will be administered on day 4 prior to the start of etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin (EPOCH). During cycles 2 to 6, rituximab will be administered on day 1 of each cycle.
223589984|NCT02911142|DRUG|Prednisone|During cycle 1, Prednisone 60 mg/m\^2 /day by mouth (PO) days 6 to 10. During cycles 2-6, Prednisone 60 mg/m\^2 /day PO days 1-5.
223589985|NCT02911142|DRUG|Etoposide|During cycle 1, Etoposide 50 mg/m\^2 /day continuous intravenous infusion days 6 to 9. During cycles 2-6, Etoposide 50 mg/m\^2/day continuous intravenous infusion days 1 to 4.
223589986|NCT02911142|DRUG|Doxorubicin|During cycle 1, Doxorubicin 10 mg /m\^2/day continuous intravenous infusion days 6 to 9. During cycles 2-6, Doxorubicin continuous intravenous infusion days 1 to 4.
223589987|NCT02911142|DRUG|Vincristine|During cycle 1, Vincristine 0.4 mg/m\^2 /day continuous intravenous infusion days 6 to 9. During cycles 2-6, Vincristine continuous intravenous infusion days 1 to 4.
224073716|NCT04765280|OTHER|Western Ontario and McMaster Universities Arthritis Index|Standardized questionnaire to investigate the disability in patients with hip osteoarthritis. The score of the scale is between 0-240. It is accepted that the higher the score, the higher the disability.
224073717|NCT04765280|OTHER|Visual analogue scale|global pain score on a 0 to 10
224073718|NCT04861220|BEHAVIORAL|Physical exercise|"The prescription will be divided into 3 phases:~Warm-up: with the object of removing the body from rest and preparing it to start the activity, it consists of exercises for upper and lower limbs, 1 minute each.~Physical exercise: Object of physical conditioning, it consists or aerobic training with walking and muscle activation through concentric contraction of the rectus abdominis in supine position, sit and get up from a chair and resistance exercises for upper members. The patient must perform 2 sets of 12 repetitions for each exercise with a 1-minute interval between the sessions.~Stretching and relaxing: Streching the arms above the head, stretching the legs and stretching the trunk to the left and right side will be oriented. Each stretching exercise should be done for 20 seconds. The relaxation should be performed in a sitting position, eyes closed, calm and silent place, soft breathing, for 5 minutes."
224073719|NCT02803021|DRUG|Coppertone (BAY987517)|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.(Formulation Number - SR15-47-Z13-076)
224073720|NCT00226551|DRUG|Isoproterenol|
224073721|NCT03247894|OTHER|Data search|Patients data were searched for the patients with MS, who laboured in tertiary perinatology center in the study period
224073722|NCT03090594|PROCEDURE|Biopsy|Is to obtain pulmonary parenchyma samples using a flexible bronchoscope.
224073723|NCT02955745|OTHER|Iodine-129|The present study is an observational study and does not therefore include an investigational product in the proper sense because the used tracer (semi-stable iodine isotope) has no physiological effect on the participants. 129I will be used as tracer to measure appearance in plasma, urine and stools after the oral administered of the 129I-tracer.
224073724|NCT00699907|DRUG|flutamide|Patients receive oral flutamide (125 MG/DAY) once daily for 6 weeks in the absence of unacceptable toxicity.
224073725|NCT04015895|OTHER|DEFCO tool|The Detection of social frailties and coordination of the path of patients in cancer: a new approach by an expert computer system DEFCO tool is questionnaire to identify their social vulnerabilities. A neural network instantly identifies the patient's fragility and sends the result by email to the professionals identified in the organization of each center. These professionals then relay to the social workers in order to take care of the patient's fragility.
224073726|NCT02087787|BEHAVIORAL|BMT Legal Clinic|2 hour consultation with an attorney in the BMT Legal Clinic with potential follow-up as needed.
223589988|NCT02911142|DRUG|Cyclophosphamide|During cycle 1, Cyclophosphamide 750 mg/m\^2 day 10. During cycles 2-6, Cyclophosphamide 750 mg/m\^2 day 5.
223589989|NCT02911142|DIAGNOSTIC_TEST|CT of neck, chest, abdomen and pelvis|Screening
223589990|NCT02911142|DIAGNOSTIC_TEST|18FDG-PET scan|Baseline
224073727|NCT01934088|DRUG|Propofol|
224073728|NCT01934088|DRUG|Midazolam|
224073729|NCT01934088|DRUG|Fentanyl|
223589991|NCT02911142|DIAGNOSTIC_TEST|MRI Brain|Screening
223589992|NCT02911142|PROCEDURE|Bone marrow biopsy|Baseline
223589993|NCT02911142|DIAGNOSTIC_TEST|EKG|Screening
223589994|NCT02911142|DIAGNOSTIC_TEST|Echocardiogram|Screening
224073730|NCT02680379|DRUG|Minocycline, then Minocycline/Lovastatin|Participants of this group will take 1 tablet of minocycline 50mg daily for 4 weeks, minocycline 100mg for the following 4 weeks and finally a combined treatment of minocycline 100 mg and lovastatin 40mg for the following 12 weeks.
223589995|NCT02911142|DIAGNOSTIC_TEST|Ultrasound|Day 6
223589996|NCT02911142|DIAGNOSTIC_TEST|Bronchoscopy|Baseline
223589997|NCT02911142|DIAGNOSTIC_TEST|Endoscopy|Baseline
223589998|NCT02911142|DIAGNOSTIC_TEST|CXR: PA/lat/decub|Screening
223745823|NCT01107587|BIOLOGICAL|Placebo|Oral, two doses.
224073731|NCT02680379|DRUG|Lovastatin, then Minocycline/Lovastatin|Participants of this group will take 1 tablet of lovastatin 20 mg daily for 4 weeks, lovastatin 40 mg for the following 4 weeks and finally a combined treatment of minocycline 100 mg and lovastatin 40 mg for the following 12 weeks.
224075969|NCT07013396|OTHER|TCD measurement|TCD measurement will be collected with TCD low frequency MHz probes. All TCD operations will be performed by a trained sonographer to assess bilateral MCA, ACA, PCA, Siph, and OA. TCD examinations will be performed as soon as possible after EVT, daily for 3 days and, when possible, as close to any reported neurological deterioration or CT brain scan performed within 72 hours of EVT.
224075970|NCT07013396|OTHER|TCD parameters|"TCD parameters are PSV, EDV, MFV, and PI. Sampling volume will be 5-10 mm, and the monitoring depth on transtemporal windows will be adjusted to gather appropriate vessel segment, e.g. 20-30 mm in the leptomeningeal flow, 40-50 mm in the distal MCA, 50-60 mm in the proximal MCA, 70-75 mm in the ACA, 62-70 mm in PCA, and transorbital, including 60-64 mm in the Siph and 50-60 mm in the OA. TAMMV and PI will be automatically derived from preset.~Additionally, flow diversion will be assessed as an indirect indicator of arterial occlusion or severe stenosis in the middle cerebral artery (M1). It will be identified by TCD based on the following criteria: (1) low-resistance flow pattern in the anterior or posterior cerebral artery, and (2) mean flow velocity in the ACA or PCA greater than or equal to that in the MCA."
224075971|NCT07013396|OTHER|Baseline characteristics|Baseline characteristics will be collected, including age, sex, ethnicity, history of HTN, DM, DLP, CHF, AF, CA, CKD, previous CAD, cirrhosis, mRS, previous stroke or TIA, current antiplatelet usage, current anticoagulant usage, smoking, and alcohol status. This data will be collected through a combination of verbal interviews with participants/LAR legally authorized representatives and a review of their medical history charts.
224075972|NCT07013396|OTHER|Clinical data will be collected|Clinical data will be collected, including blood pressure values before, during, and after TCD as well as, Door to needle, Door to groin, Groin to first pass, time from recanalization to TCD, baseline NIHSS, site of occlusion, infarct core volume, mismatch volume, mismatch ratio, and IVT treatment status. Classification of stroke etiologies will be collected based on widely accepted TOAST criteria categorized in large vessel atherosclerosis (LAA), cardio-embolism (CE), small vessel occlusion (SAO), Stroke of other determined etiology (SOC), and stroke of undetermined etiology (SUC) \[30\]. This data will be collected by reviewing medical charts from EHR coded as part of standard care.
224075973|NCT07013396|OTHER|All follow-up patients receive a phone call|All follow-up patients receive a phone call as part of standard post thrombectomy care from the stroke nurses to gather modified Rankin Scale at 7 days and 90 days since hospital discharge.
224075974|NCT06874699|BEHAVIORAL|Physical activity programme|"The physical activity programme will have the following features:~* 6-week programme~* 1-2 supervised physical activity sessions per week~* 60 minutes per session, including a mixture of physical activities (e.g. walking, other aerobic physical activity, resistance, balance and stretching exercises)~* Self-selected physical activity intensity~* Group-based (maximum of 10 students per session)~* Sessions supervised by a qualified exercise instructor. A member of the University's Wellbeing team will also be present to offer students mental health support, if needed.~* Physical activity behavioral strategies incorporated into the 6-week programme (e.g., goal setting, action planning, exploring barriers and enablers, setting cues or prompts for self-directed PA)~* Encouragement to be physically active away from the supervised sessions"
224075975|NCT04372641|DRUG|p97 Inhibitor CB-5339 Tosylate|Given PO
224075976|NCT05457634|OTHER|Combustible Cigarette|Subjects smoke their Usual Brand Combustible Cigarette, for 2 consecutive product use sessions. 1. Defined session: 10 puffs, each 30 seconds apart. 2. Ad libitum session: 60 minutes ad-libitum use.
224075977|NCT05457634|OTHER|blu Disposable A|Subjects use the blu disposable e-cigarette with flavor A, 2.4% nicotine, for 2 consecutive product use sessions. 1. Defined session: 10 puffs, each 30 seconds apart. 2. Ad libitum session: 60 minutes ad-libitum use.
224075978|NCT05457634|OTHER|blu Disposable B|Subjects use the blu disposable e-cigarette with flavor B, 2.4% nicotine, for 2 consecutive product use sessions. 1. Defined session: 10 puffs, each 30 seconds apart. 2. Ad libitum session: 60 minutes ad-libitum use.
224075979|NCT05457634|OTHER|blu Disposable C|Subjects use the blu disposable e-cigarette with flavor C, 2.4% nicotine, for 2 consecutive product use sessions. 1. Defined session: 10 puffs, each 30 seconds apart. 2. Ad libitum session: 60 minutes ad-libitum use.
224075980|NCT05457634|OTHER|blu Disposable D|Subjects use the blu disposable e-cigarette with flavor D, 2.4% nicotine, for 2 consecutive product use sessions. 1. Defined session: 10 puffs, each 30 seconds apart. 2. Ad libitum session: 60 minutes ad-libitum use.
224075981|NCT05457634|OTHER|blu Disposable E|Subjects use the blu disposable e-cigarette with flavor E, 2.4% nicotine, for 2 consecutive product use sessions. 1. Defined session: 10 puffs, each 30 seconds apart. 2. Ad libitum session: 60 minutes ad-libitum use.
224075982|NCT07024719|DEVICE|4D MIOCT integrated into a Zeiss Artevo 800|4D MIOCT integrated into a Zeiss Artevo 800 surgical microscope with an add-on investigational 3D OCT scanner
224075983|NCT06822712|DEVICE|Sirolimus-coated Balloon Dilatation Catheter|During PCI, percutaneous transluminal coronary angioplasty is performed on the target lesion using the Sirolimus-coated Balloon Dilatation Catheter in the test group, subsequently completing the remaining procedure
224075984|NCT06822712|DEVICE|Paclitaxel-coated Balloon Dilatation Catheter|During PCI, percutaneous transluminal coronary angioplasty is performed on the target lesion using the Paclitaxel-coated Balloon Dilatation Catheter in the control group, subsequently completing the remaining procedure
224075985|NCT06878248|BIOLOGICAL|Two Component Product CLBR001 + ABBV-461|Investigational switchable CAR-T cell therapy for breast cancer
224309023|NCT06982664|PROCEDURE|High Tie of Inferior Mesenteric Artery|IMA was ligated approximately 1 cm from its origin after dissection of the surrounding tissue to ensure clear visualization of the IMA root. Using this technique, the LCA and the inferior mesenteric vein were ligated near the lower border of the pancreas
224309024|NCT06982664|PROCEDURE|Low Tie of Inferior Mesenteric Artery|During this procedure, the LCA was identified and preserved, and the superior rectal artery was ligated. Before colonic transection or anastomosis, the preserved LCA underwent temporary, controlled occlusion. After assessing perfusion changes using LSCI, the occlusion was released to restore blood flow.
224309025|NCT06593054|DRUG|Ceftibuten|Ceftibuten dihydrate, formulated in capsules
224309026|NCT06593054|DRUG|Avibactam prodrug|Avibactam prodrug, formulated in capsules
224309027|NCT06593054|DRUG|CTB-AVP in Tablet|ceftibuten and avibactam prodrug, in Tablet formulation
223589999|NCT06359756|PROCEDURE|Ischemic postconditioning in carotid surgery|After the initial declamping of the carotid artery the procedure is performed with 6 cycles of reperfusion of 30 seconds each (clamping of the internal carotid artery) which are successively followed by 6 cycles of ischemia lasting 30 seconds (clamping of the internal carotid artery). Clamping is done on the unaltered ICA, at the clamping site prior to performing CEA above the plaque termination point.
223590000|NCT06359756|PROCEDURE|Eversion Carotid Endarterectomy|Standard Eversion Carotid Endarterectomy
223590001|NCT03871257|DRUG|Carboplatin|Given IV
223590002|NCT03871257|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223590003|NCT03871257|OTHER|Quality-of-Life Assessment|Ancillary studies
223590004|NCT03871257|OTHER|Questionnaire Administration|Ancillary studies
223590005|NCT03871257|DRUG|Selumetinib Sulfate|Given PO
223590006|NCT03871257|DRUG|Vincristine Sulfate|Given IV or IV push
223590007|NCT06211049|DRUG|Vitex agnus-castus BNO 1095 (20 mg)|1 tablet once daily for about 4 menstrual cycles (cramping windows of Cycles 3-6) (i.e.,113 days in case of a 28-day menstrual cycle).
223590008|NCT06211049|DRUG|Placebo|1 tablet once daily for about 4 menstrual cycles (cramping windows of Cycles 3-6) (i.e.,113 days in case of a 28-day menstrual cycle).
223590009|NCT05756569|PROCEDURE|Biospecimen Collection|Undergo collection of blood
223590010|NCT05756569|PROCEDURE|Computed Tomography|Undergo CT
223590011|NCT05756569|DRUG|Enfortumab Vedotin|Given IV
223590012|NCT05756569|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223590013|NCT05756569|BIOLOGICAL|Pembrolizumab|Given IV
223590014|NCT05756569|OTHER|Questionnaire Administration|Ancillary studies
223745824|NCT01792947|PROCEDURE|Percutaneous electroneurostimulation of dermatome T6|The patients underwent a percutaneous electroneurostimulation of dermatome T6 during 30 minutes, every week during 12 weeks. This intervention was associated to a diet 1200 Kcal
223745825|NCT01792947|BEHAVIORAL|Diet 1200 Kcal|The patients assigned to this group must follow a 1200 Kcal diet during months
224073732|NCT05430100|OTHER|The effect of usıng breast mılk pacıfıer ın reducıng the paın that occurs durıng orogastrıc tube ınsertıon ın preterm newborns|5 Minutes before the OGT insertion, the camera recording will be started and the preterm newborn will be given a breast milk pacifier. After the breast milk pacifier in the OGT intervention group is placed in the mouth as a leak from the edge of the given baby's mouth, the baby's esophagus will be placed by advancing from there to the stomach with the swallowing reflex. It will be checked whether the OGT is in the right place. Registration will be stopped after the evaluation period is completed and the baby is provided with comfort. But the recording will continue so that there are no time restrictions for tracking the crying time of the baby who continues to cry during placement. In terms of the reliability of the research results, nothing should be given orally to a preterm newborn at least 30 minutes before the procedure.
224073733|NCT05430100|OTHER|The effect of usıng sucrose pacıfıer ın reducıng the paın that occurs durıng orogastrıc tube ınsertıon ın preterm newborns|The camera recording will be started 5 minutes before the OGT insertion procedure and the newborn will be given a sucrose-sweetened pacifier. After the sucrose-sweetened pacifier in the OGT intervention group is placed in the mouth as a leak from the edge of the given baby's mouth, the baby's esophagus will be placed by advancing from there to the stomach with a swallowing reflex. It will be checked whether the OGT is in the right place. Registration will be stopped after the evaluation period is completed and the baby is provided with comfort. But the recording will be continued so that there are no time restrictions for tracking the crying time of the baby who continues to cry during placement. In terms of the reliability of the research results, nothing should be given orally to a preterm newborn at least 30 minutes before the procedure.
224075986|NCT06880198|DIETARY_SUPPLEMENT|Oral Impact®|One Arm: 2 Impact brick/d for 21 days + 1 brick/d for 14 days, starting exactly one week before Anti PD-1 treatment in patients with inoperable locally advanced or metastatic melanoma Treatment duration: 35 days
224309028|NCT06185608|DRUG|0.25% ropivacaine|A total of 15 ml of 0.25% ropivacaine will be administered and distributed strategically among the specific nerves: 6 ml for the tibial nerve, 3 ml for the deep peroneal nerve, and 2 ml each for the superficial peroneal nerve, saphenous nerve, and sural nerve.
223590015|NCT02963064|BIOLOGICAL|Humanized anti-CD117 Monoclonal Antibody (JSP191)|Procedure: single intravenous infusion of JSP191 antibody
223590016|NCT06299891|DRUG|Phentermine / Topiramate Extended Release Oral Capsule [Qsymia]|To assess safety and maximum tolerated dose as well as efficacy on weight loss of Phentermine/Topiramate in individuals with hypothalamic obesity.
223590017|NCT06299891|OTHER|Placebo|To assess safety and maximum tolerated dose as well as efficacy on weight loss of placebo treatment in individuals with hypothalamic obesity.
223590018|NCT05835401|DIETARY_SUPPLEMENT|Beetroot juice rich in nitrate|The participant will intake beetroot juice rich in NO3 (800mg). Two hours after intake the last bottle of juice, the participants will go to the laboratory for the handgrip and cardiovascular tests evaluation. Before crossover protocol a 7-day washout interval will be given for the purification of the compounds provided by the protocols.
223745826|NCT01053611|DRUG|propofol + remifentanil 0 ng/ml|remifentanil 0 ng/ml
223745827|NCT01053611|DRUG|propofol + remifentanil 2 ng/ml|
223745828|NCT01053611|DRUG|propofol + remifentanil 4 ng/ml|
223745829|NCT01053611|DRUG|propofol + remifentanil 6 ng/ml|
224187481|NCT01070849|OTHER|RÜCKGEWINN|For long term sustainability and the enhancement of intensity of the rehabilitation process this investigational aftercare intervention shows formal and didactic divergences from standard programmes in rehabilitation aftercare. Three important areas for multidimensional interventions are targeted: attitude and behaviour change concerning back pain, guidance to health enhancing physical activity, improvement of health related physical fitness. Every 90 minutes taking exercise session contains parts for mediation of knowledge, for behavioural modulation and for physical exercises and interlocks them in the mediation process. To take the time into account that is necessary for the process of behavioural change RÜCKGEWINN is planned for duration of six months in one session weekly for 26 weeks.
223496580|NCT02940379|DRUG|metoprolol|"Pharmaceutical form: tablet~Route of administration: oral"
223496581|NCT03457597|DRUG|Midazolam hydrochloride|Midazolam hydrochloride 2.5 mg
223496582|NCT03457597|DRUG|Metoprolol tartrate|Metoprolol tartrate 100 mg
223496583|NCT03457597|DRUG|Pioglitazone hydrochloride|Pioglitazone hydrochloride 15 mg
223496584|NCT03457597|DRUG|Tolbutamide|Tolbutamide 500 mg
223496585|NCT03457597|DRUG|Omeprazole|Omeprazole 20 mg
223496586|NCT03457597|DRUG|Relacorilant|Relacorilant 350mg
223496587|NCT04757584|DRUG|Beta blockers|"The intervention is a two-arm crossover withdrawal/ reversal design (On \[A\] vs Off \[B\]) with up to 4 periods, each period lasting up to 6 weeks. During the On period (A), subjects will be on their beta blocker. During the Off period (B), their beta blockers will be down-titrated and subsequently discontinued.~Subjects will be randomized into either ABAB or BABA sequences."
223496588|NCT00429299|DRUG|lapatinib|Arm B 1250mg/d PO Arm C 750mg/d PO
223496589|NCT00429299|BIOLOGICAL|trastuzumab|First dose 4mg/kg in 60mins, then weekly 2mg/kg in 30 mins
223496590|NCT00429299|DRUG|paclitaxel|80mg/sqm 1 hour infusion for 12 weeks
223496591|NCT00429299|DRUG|fluorouracil|600mg/sqm iv day 1 q21 days for four coursess
223496592|NCT00429299|DRUG|epidoxorubicin|75mg/sqm iv day 1 q21 days for four courses
223496593|NCT00429299|DRUG|cyclophosphamide|600mg/sqm day 1 q21 days for four courses
223496594|NCT05125497|PROCEDURE|In Vitro Fertilisation (IVF)|Natural Cycle In Vitro Fertilisation (IVF): without hormonal stimulation Conventional In Vitro Fertilisation (IVF): conventional hormonal stimulation Minimal Stimulation In Vitro Fertilisation (IVF): low dose of hormonal stimulation will be applied
223496595|NCT00306072|DRUG|nutritional herbal extract from Salacia oblonga|
223496596|NCT02992379|DEVICE|pivot splint|A 2-mm-thick, hard, clear sheet of resin will be adapted to the maxillary arch . Small amount of selfcuring acrylic will be added to the anterior portion of the appliance as a stop for the lower incisor. The area of this stop is approximately 4 to 6 mm. The patient is instructed to protrude the mandible slightly and to open and close the mouth In this position. Self-curing acrylic will be added to the occluding surface of the appliance. All occluding areas, except the contact on the anterior stop . Excess acrylic surrounding the centric contacts is removed with a hard rubber wheel on a lathe.
223496597|NCT02992379|DEVICE|stabilizing splint|A 2-mm-thick, hard, clear sheet of resin will be adapted to the maxillary arch . Small amount of self-curing acrylic will be added to the anterior portion of the appliance as a stop for the lower incisor. The area of this stop is approximately 4 to 6 mm. The patient is instructed to protrude the mandible slightly and to open and close the mouth In this position. Self-curing acrylic will be added to the occluding surface of the appliance. All occluding areas, except the contact on the anterior stop . Excess acrylic surrounding the centric contacts is removed with a hard rubber wheel on a lathe. intervention: pivot splint
223496598|NCT04604860|BEHAVIORAL|Fitness intervention|Patients will follow exercise plans designed to promote physical activity (exercise and behavioral coaching).
223496599|NCT05371704|DIETARY_SUPPLEMENT|Multivitamin Supplementation|Participants will supplement daily with an over-the-counter oral multivitamin pill
223496600|NCT05371704|OTHER|Dietary Replication|Patients will record their dietary intake in an estimated food diary during the first trial. During the second trial, participants will be asked to replicate their diet from the first trial
223496601|NCT01510756|DRUG|Sorafenib|Sorafenib 400mg orally twice daily will be administered for three cycles (1 cycle = 28 days). Subjects without significant toxicity or progressive disease may elect to continue treatment for a total of twelve cycles.
223496602|NCT02643784|DRUG|Rosuvastatin|"Randomized Treatment Period (Day 1 through Day 14): 20 mg once daily for 14 days.~Follow up Period (Day 15 through Day 90) Subjects in both groups who enter the follow up period will receive rosuvastatin 10mg/day."
223496603|NCT02643784|OTHER|Control|"Randomized Treatment Period (Day 1 through Day 14):~No treatment of rosuvastatin for control group. Follow up Period (Day 15 through Day 90) Subjects in both groups who enter the follow up period will receive rosuvastatin 10mg/day."
223496604|NCT04781465|DEVICE|Immersive Virtual Reality|"Dedicated virtual reality sessions.~* Duration 20 minutes per session.~* The virtual reality session will be supervised by a health professional trained in this tool after 1.5 hours of training by the team responsible for the equipment (use of the equipment, and use of the 20 minutes of VR). This supervising professional may be a doctor, an occupational therapist, a caregiver or any other health professional trained in the tool under this protocol.~* The exercises proposed will be standardized virtual reality exercises with the same exercises for all, but adapted to the level and abilities of each patient."
223496605|NCT03261258|OTHER|Questionnaire|
223496606|NCT05141994|DRUG|2.5mg of BAT5906|Specification: 2.5mg of BAT5906
223496607|NCT05141994|DRUG|4mg of BAT5906|Specification: 4mg of BAT5906
223496608|NCT00860925|DRUG|active clonidine|Prior to surgery (goal 2-4 hours) patients will ingest 1 tablet of clonidine (0.2 mg) and will have a transdermal clonidine patch (0.2 mg/day) applied. The patch will be removed at 72 hours after surgery.
223496609|NCT00860925|DRUG|active ASA|Prior to surgery (goal 2-4 hours) patients will ingest 2 ASA tablets (81 mg per tablet). After the first dose, patients will ingest 1 tablet daily for 7 or 30 days according to the stratum they are allocated to. Patients who are not able to take ASA orally will receive it rectally.
223590019|NCT05835401|DIETARY_SUPPLEMENT|Beetroot juice depleted in nitrate|The participant will intake beetroot juice depleted in NO3. Two hours after intake the last bottle of juice, the participants will go to the laboratory for the handgrip and cardiovascular tests evaluation. Before crossover protocol a 7-day washout interval will be given for the purification of the compounds provided by the protocols.
223745830|NCT01053611|DRUG|propofol + remifentanil 0 ng/ml|
224187482|NCT05331326|DRUG|RC48-ADC|RC48-ADC 2.0mg / kg, intravenous drip, once every 2 weeks
224187483|NCT00777439|DRUG|Domperidone|10 mg of oral domperidone will be administered 4 times daily. This dose may be increased to 20 mg 4 times daily or 30 mg 4 times daily, depending on how the subject responds to the drug.
224187484|NCT00920582|BIOLOGICAL|Teplizumab Herold Regimen|Full dose of teplizumab IV for 14 days, repeated at Week 26
224187485|NCT00920582|DRUG|Placebo|IV dosing daily for 14 days repeated at Week 26
224187486|NCT00920582|BIOLOGICAL|Teplizumab 33.3% Herold Regimen|One third full dose of teplizumab IV for 14 days, repeated at Week 26
224187487|NCT00920582|BIOLOGICAL|Teplizumab Curtailed Herold Regimen|Full dose of teplizumab IV for 6 days followed by placebo for 8 days, repeated at Week 26
224187488|NCT03881072|OTHER|Ultrasounicelastography|Observing the correlation between endometrial elasticity score, endometrial blood flow index (PI, RI, S/D, endometrial thickness, morphology) and clinical pregnancy rate.
224187489|NCT05277610|DIAGNOSTIC_TEST|iron studies|Pulmonary function testing was performed using standardized spirometry for asthmatic patients with iron deficiency anemia and those without iron deficiency anemia
224187490|NCT02405182|OTHER|Magnetic Resonance Imaging|
224187491|NCT03164031|DEVICE|Close-fitting orthotic shorts|The orthotic shorts will be custom-made by DM Orthotics, a UK based company that specialises in dynamic, elastomeric orthoses for healthcare and sport. They will provide both pairs of shorts for each participant, both constructed from a 275 g/m2 fabric, which is 51% Polyamide, 32% Dorlastan and 17% cotton. A company representative will assess each participant to decide the compression and fit of the shorts, such as whether support for the lower trunk is required. The shorts can be manufactured with a toileting hole, if preferred, allowing participants to toilet without removing the shorts. Shorts with a toileting hole are worn beneath usual underwear.
224187492|NCT03164031|DEVICE|Looser fitting shorts|Looser fitting shorts will be custom-made by DM Orthotics, a UK based company that specialises in dynamic, elastomeric orthoses for healthcare and sport. Shorts will be constructed from a 275 g/m2 fabric, which is 51% Polyamide, 32% Dorlastan and 17% cotton. A company representative will assess each participant to decide the fit of the shorts. The shorts can be manufactured with a toileting hole, if preferred, allowing participants to toilet without removing the shorts. Shorts with a toileting hole are worn beneath usual underwear.
224187493|NCT00117520|DRUG|Caffeine|
224187494|NCT02267421|BEHAVIORAL|Home based Aerobic exercise training|
224187495|NCT06249087|BEHAVIORAL|comprehensive rehabilitation therapy|"Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, empty swallowing training, and pronunciation training.~Pulmonary function training, including standing training, cough training, and diaphragm muscle training."
224187496|NCT06249087|DEVICE|Intermittent Oro-esophageal Tube Feeding|The observation group was given enteral nutritional support with Intermittent Oro-esophageal Tube according to the following procedure: Before each feeding, inside and outside of the tube was cleaned with water. During feeding, the patient should maintain a semi-reclining or sitting position with mouth opened, and the tube was inserted slowly and smoothly into the upper part of the esophagus by medical staffs while the appropriate depth of intubation was checked with the calibration markings on the tube wall. The distance from the incisors to the head part of the tube should be between 22-25 cm. However, the specific depth should be evaluated based on patients' feedback and adjusted accordingly. After insertion, the tail part of the tube should be put into a container full of water and the absence of continuous bubbles indicated a successful intubation. Then, the feeding was to be conducted three times per day with 50 ml per minute and 400-600ml for each feeding.
223590020|NCT06815302|BEHAVIORAL|Experimental intervention|Specific participant procedures in experimental and active control interventions are simplified to preserve study blinding.
223590021|NCT06815302|BEHAVIORAL|Active intervention|Specific participant procedures in experimental and active control interventions are simplified to preserve study blinding.
223590022|NCT00026312|BIOLOGICAL|Aldesleukin|Given IV
223590023|NCT00026312|BIOLOGICAL|Dinutuximab|Given IV
223590024|NCT00026312|DRUG|Isotretinoin|Given PO
223590025|NCT00026312|OTHER|Laboratory Biomarker Analysis|Correlative studies
223745831|NCT01053611|DRUG|propofol + remifentanil 2 ng/ml|
223745832|NCT01053611|DRUG|propofol + remifentanil 6 ng/ml|
224309029|NCT06185608|DRUG|0.5% ropivacaine|A total of 15 ml of 0.5% ropivacaine will be administered and distributed strategically among the specific nerves: 6 ml for the tibial nerve, 3 ml for the deep peroneal nerve, and 2 ml each for the superficial peroneal nerve, saphenous nerve, and sural nerve.
223496610|NCT00860925|DRUG|Clonidine Placebo|Prior to surgery (goal 2-4 hours) patients will take oral clonidine placebo and will have a transdermal placebo patch applied. The patch will be removed at 72 hours after surgery.
223496611|NCT00860925|DRUG|ASA Placebo|Prior to surgery (goal 2-4 hours) patients will ingest 2 ASA placebo tablets. After the first dose, patients will ingest 1 placebo tablet daily for 7 or 30 days according to the stratum they are allocated to. Patients who are not able to take placebo orally will receive it rectally.
223496612|NCT04874779|OTHER|non|follow up investigations
223496613|NCT00850577|DRUG|Paclitaxel|Solution, IV, 200 mg/m2, Q21days, 6 cycles
223496614|NCT00850577|DRUG|Carboplatin|Solution, IV, AUC=6, Q21days, 6 cycles
223496615|NCT00850577|DRUG|CT-322|Solution, IV, 2 mg/kg, Q7days, Until PD
223496616|NCT00850577|DRUG|Bevacizumab|Solution, IV, 15 mg/kg, Q21days, Until PD
223496617|NCT00850577|DRUG|Bevacizumab placebo (ie saline solution)|Solution, IV, 0 mg/kg, On days 8 and 15 of a 3-weekly cycle, Until PD
223496618|NCT05181384|OTHER|isolated pelvic floor muscles training|isolated pelvic floor muscles training was emphasized, consisting of both quick and sustained contractions.
223590026|NCT00026312|OTHER|Pharmacological Study|Correlative studies
223590027|NCT00026312|OTHER|Quality-of-Life Assessment|Ancillary studies
223590028|NCT00026312|BIOLOGICAL|Sargramostim|Given IV or SC
223590029|NCT06987383|DRUG|Vibegron|A drug in a class of medications called beta-3 adrenergic agonists; approved for use with Overactive Bladder; 75mg tablets will be used in this study
223590030|NCT06987383|DRUG|Placebo|Tablets made of inert substance that looks like the vibegron tablets but has no therapeutic value
223745833|NCT01053611|DRUG|propofol + remifentanil 6 ng/ml|
223745834|NCT01053611|DRUG|propofol + remifentanil 0 ng/ml|
223590031|NCT05432804|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
224187497|NCT06249087|DEVICE|Nasogastric Tube Feeding|The control group was given enteral nutritional support with Nasogastric Tube Feeding according to the relevant guidelines. Within 4 hours after admission, the placement of the feeding tube was conducted by professional medical staffs and after intubation, the tube was secured to the patient\&#39;s cheek with medical tape. The feeding was conducted once every 3-4 hours, with 200-300ml each time. The total feeding volume was determined based on daily requirements. The feeding content was formulated by the nutritionists based on the patient\&#39;s condition and relevant guidelines to reach the energy demand as 20-25 kcal/kg/day and protein supplementation of 1.2-2.0 g/kg/day for both two groups. For patients with limited tube feeding compliance, we made appropriate adjustments to ensure that they were not at risk of severe malnutrition as much as possible.
224187498|NCT01901952|BEHAVIORAL|Intensive education and lifestyle support|Group classes for 12 months (weekly for 4 months, biweekly for 4 months, monthly for 4 months), weekly peer supporter telephone calls, and diabetes education newsletters every 2 months.
224187499|NCT01901952|BEHAVIORAL|Standard of Care control group|Participants receive 2 diabetes education classes taught by a Certified Diabetes Educator. They also receive diabetes education newsletters every 2 months.
224187500|NCT05586789|DRUG|Ranquilon|Two 1 mg tablets 3 times per day for 28 days
224187501|NCT05586789|DRUG|Placebo|Two tablets 3 times per day for 28 days
224187502|NCT02113904|DRUG|Adalimumab|6 injections (one every 15 days during 3 months)
224187503|NCT02311075|BIOLOGICAL|Blood samples|Blood samples will be performed at baseline and during endothelial stimulation by hand skin heating to quantify metabolites of NO, EETs, ET-1 and ROS
224187504|NCT02672475|DRUG|Galunisertib|Given PO
224187505|NCT02672475|OTHER|Laboratory Biomarker Analysis|Correlative studies
224187506|NCT02672475|DRUG|Paclitaxel|Given IV
224187507|NCT01552408|DRUG|0.3 mg ranibizumab|Cohort 1: Subjects will receive 4 mandatory intravitreal injections of 0.3 mg ranibizumab every 28 days (+/- 7 days). They will then be seen monthly (+/- 7 days) and will receive intravitreal injections of 0.3 mg ranibizumab on a PRN schedule per retreatment criteria based on the evaluating Investigator's assessment of disease activity.
224187508|NCT01552408|PROCEDURE|Targeted Pan Retinal Photocoagulation|Cohort 2: Subjects will receive 4 mandatory intravitreal injections of 0.3 mg ranibizumab every 28 days (+/- 7 days). They will then be seen monthly (+/- 7 days) and will receive intravitreal injections of 0.3 mg ranibizumab on a PRN schedule per retreatment criteria based on the evaluating Investigator's assessment of disease activity. In addition, at V3 (Day 7) they will receive targeted pan retinal photocoagulation (PRP) based on ultra wide 200º field angiography. After the first session of PRP, subject's will have ultra wide 200º field angiography performed every 3 months to indicate areas of peripheral ischemia, which will be selectively treated at V9 (Month 6), V21 (Month 18), and V28 (Month 25), preserving areas of more perfused retina. This will minimize any visual field loss secondary to nonselective pan-retinal photocoagulation.
224187509|NCT01148875|BEHAVIORAL|Mammography appointment reminders; telephone counseling|Women randomly assigned to UCR, EAPR, ELR; repeated 4 times at yearly intervals. Using claims data, supplemented by self-report, verified if women had recent mammograms. Women who remained non-adherent after reminders received Barriers-Specific Telephone Counseling Call, or an enhanced call including focus on either positive or negative consequences of getting/not getting mammograms. Prior to calls, women in each of the three phone counseling groups received priming letters to prime them to process information in the call. Priming letters should prepare women to process information from subsequent counseling calls more deeply by focusing on the positive or negative consequences of getting/not getting mammograms or on identifying and overcoming their own barriers to being screened.
224187510|NCT04930562|DRUG|BN101|BN101 is an orally ROCK2 selective inhibitor
224187511|NCT01138709|DEVICE|Vitala|Vitala™ Continence Control Device
224187512|NCT02729597|OTHER|medical history|The complete medical history (including cardiovascular risk factors and medication) will be assessed at baseline and follow-up.
224187513|NCT02729597|OTHER|neurological clinical examination|Neurological examination will be performed at baseline and follow-up.
224187514|NCT02729597|OTHER|neuropsychological testing|Neuropsychological testing using a 13 item test battery will be performed at baseline and follow-up.
224187515|NCT02729597|OTHER|brain MRI|Brain MRI ( 3.0 T) will be performed using the same hard- and software at baseline and follow-up.
224187516|NCT04832243|OTHER|Survey questionnaire|Each version of the questionnaire includes a different number of true-false statements that study participants are asked to identify.
224187517|NCT04027582|OTHER|didactic teaching and simulator practice|the trainee will undergo didactic teaching on fiber-optic intubation followed by hands on practice on their assigned simulator
224187518|NCT03273088|DRUG|Etanercept|A single dose of etanercept (25mg/0.5ml prefilled syringe) was administered subcutaneously to healthy subjects.
224187519|NCT00967889|GENETIC|gene expression analysis|
224187520|NCT00967889|GENETIC|protein analysis|
224309030|NCT06185608|DRUG|1% ropivacaine|A total of 15 ml of 1% ropivacaine will be administered and distributed strategically among the specific nerves: 6 ml for the tibial nerve, 3 ml for the deep peroneal nerve, and 2 ml each for the superficial peroneal nerve, saphenous nerve, and sural nerve.
224309031|NCT01736748|BEHAVIORAL|Sensor based PA intervention|Children will be equipped with a heart rate monitor, a GPS receiver and an accelerometer for collection of heart rate, mobility and physical activity free-living data during a 7-day period. This will provide a 'spatio-behavioural diagnosis' using a map-based interactive web application. This data will be used to developed a tailored plan to promote physical activity in the child's every day environment.
224309032|NCT01736748|BEHAVIORAL|Traditional PA counseling|Children will be encouraged to enhance their physical activity levels using traditional behavioral approaches.
223590032|NCT05432804|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223590033|NCT05432804|DRUG|Selinexor|Given PO
223590034|NCT05432804|DRUG|Temozolomide|Given PO
223590035|NCT06328660|DEVICE|Lens 1|Frequent replacement silicone hydrogel contact lens for 14 ± 3 days on a daily disposable wearing modality
223590036|NCT06328660|DEVICE|Lens 2|Daily disposable silicone hydrogel contact lens for 14 ± 3 days on a daily disposable wearing modality
223590037|NCT00175266|DRUG|alemtuzumab|
223496619|NCT05181384|OTHER|comprehensive stabilization exercise program|incorporated the contraction of PFMs with other spinal or extremity muscles
223496620|NCT05181384|OTHER|education of pelvic girdle|educational session includes pelvic anatomy, mechanism of and risk factors for PPGP, and proper posture or body mechanism
223496621|NCT02140827|OTHER|IMP interactive education|The detail and FAQ (Frequently Asked Questions) of bowel preparation instructions is delivered by Wechat.
223496622|NCT03927157|BIOLOGICAL|Experimental: Tezepelumab|Tezepelumab subcutaneous injection
223496623|NCT03927157|OTHER|Placebo|Placebo subcutaneous injection
223496624|NCT05249751|DIAGNOSTIC_TEST|Assessement of serum copeptin by ELISA technique|Assessement of serum copeptin by ELISA technique
223590038|NCT00175266|PROCEDURE|islet transplant|
223590039|NCT00175266|DRUG|infliximab|
223590040|NCT07024524|OTHER|Rehabilitation training|This study constructed a novel multimodal assessment system to evaluate speech perception, music perception, and spatial hearing in congenital deafness patients , and subsequently generated targeted rehabilitation training plan based on the assessment data.
223590041|NCT07040423|PROCEDURE|PENG Block|Preoperative ultrasound giuded PENG block (ropivacaine 0,5% 20mL)
224073734|NCT05430100|OTHER|The effect of usıng pacıfıer ın reducıng the paın that occurs durıng orogastrıc tube ınsertıon ın preterm newborns|The camera recording will be started 5 minutes before the OGT insertion procedure and the newborn will be given a pacifier. After the pacifier in the OGT intervention group is placed in the mouth as a leak from the edge of the given baby's mouth, the baby's swallowing reflex will be placed by moving the esophagus from there to the stomach. It will be checked whether the OGT is in the right place. Registration will be stopped after the evaluation period is completed and the baby is provided with comfort. But the recording will be continued so that there are no time restrictions for tracking the crying time of the baby who continues to cry during placement.
224073735|NCT02161211|BEHAVIORAL|De-coupling|Six sessions of CBT for anxiety-alcohol de-coupling
224073736|NCT02161211|BEHAVIORAL|Anxiety Reduction|Six sessions of CBT for anxiety reduction.
224073737|NCT02161211|BEHAVIORAL|Combined|Three sessions devoted to anxiety reduction and to anxiety-alcohol de-coupling each.
224073738|NCT02948803|BEHAVIORAL|smartphone based intervention with Active Coach app|
224073739|NCT00003580|DRUG|amifostine trihydrate|
224073740|NCT00003580|DRUG|cisplatin|
224073741|NCT00003580|RADIATION|radiation therapy|
224073742|NCT01103674|DEVICE|Numeris®-AF Guided Coagulation System with VisiTrax®|Combined epicardial / endocardial procedure using the Numeris®-AF Guided Coagulation System with VisiTrax® epicardially and the Biosense Webster ThermoCool Catheter in conjunction with the Carto Navigation System endocardially.
224073743|NCT01637233|DRUG|Arm 1 TNucleotide Analogue Reverse Transcriptase Inhibitors and Boosted Protease Inhibitors|NRTI+PI
224073744|NCT01637233|DRUG|Arm 2 Maraviroc and Protease Inhibitors|maraviroc + PI
223496625|NCT04954144|DEVICE|Leap Motion Sensor|As a virtual reality treatment method, leap motion sensor was integrated with laptop computer and participants played object capture, firefly, bee-batting games to improve performance based hand skills.
223496626|NCT04954144|OTHER|Neurodevelopmental Treatment Approach|It is a method that tries to control sensorimotor components of muscle tone, reflexes, abnormal movement patterns, postural control, sensory-perception and memory problems with special techniques.
223496627|NCT01830686|OTHER|Sugarcane bagasse|One brownie containing 10 g of sugarcane bagasse and 2 cookies containing 3 g of sugarcane bagasse (total of 13 g of sugarcane bagasse per day)
223496628|NCT01830686|OTHER|Non-caloric, non-fermentable fiber|One brownie containing 10 g of fiber and 2 cookies containing 3 g of fiber (total of 13 g of non-caloric, non-fermentable fiber per day)
223496629|NCT01830686|OTHER|Minimal fiber|One brownie containing 3g of fiber and two cookies containing 1g of fiber (total of 4 g of dietary fiber per day)
223496630|NCT01594268|DRUG|Everolimus|A prospective, open-label study to assess safety of Certican in kidney transplant patients
223496631|NCT00118794|DRUG|Chlorproguanil-dapsone (Lapdap)|
223496632|NCT00118794|DRUG|Lumefantrine-artemether (Coartemether )|
223496633|NCT03315364|DRUG|Oral paclitaxel|Oral administration on D1, D8 and D15 of 4-week cycle until progression, unacceptable toxicity or withdrawal of informed concent
223496634|NCT03315364|DRUG|Paclitaxel injection|Premedication, intravenous infusion on D1, D8 and D15 of 4-week cycle until progression, unacceptable toxicity or withdrawal of informed concent
223496635|NCT04871113|BIOLOGICAL|GSK3810109A|GSK3810109A available as sterile aqueous solution.
223496636|NCT04871113|BIOLOGICAL|Dolutegravir+lamivudine SOC regimen|Dolutegravir+lamivudine regimen administered in consistence with investigator input and local guidelines
223590042|NCT07040423|PROCEDURE|Magnetic resonance imaging|The patient will undergo a pelvic MRI to assess anesthetic diffusion after PENG block
223590043|NCT05382611|DIAGNOSTIC_TEST|ngs next generation sequencing|the samples from aneurysmatic tissue and healthy aortic tissue will be investigated using NGS
223590044|NCT06728332|OTHER|No study intervention|No visits or examinations, laboratory tests or procedures are mandated or required for this study. Providers in the study recruitment network will recruit eligible patients through an existing visit. After this referral, the study is conducted entirely electronically.
224073745|NCT01637233|DRUG|Arm 3 Maraviroc and Nucleotide Analogue Reverse Transcriptase Inhibitors|maraviroc + NRTI
224073746|NCT05529914|OTHER|Myofascial release|It is a type of physical therapy often used to treat myofascial pain syndrome with pressure.
224073747|NCT05529914|OTHER|Neuromuscular exercises|Exercises commonly utilized in neuromuscular training programs to improve strength, balance , speed and agility. It will comprised of Warm-up, Lunges, Sideways exercises, Wall squats, Weight transfer exercise, Step up \& down, Cool-down
224073748|NCT05529914|OTHER|Cold pack|Application of cold pack around the patient's body, and covered with dry towel
224073749|NCT00810979|DRUG|SLx-4090|tablet
224073750|NCT00810979|DRUG|SLx-4090|tablet
224073751|NCT00810979|OTHER|Placebo|matching tablet
224073752|NCT00810979|DRUG|Statin|Subjects were dosed with the statin prescribed specifically by their prescribing physician.
224073753|NCT01698346|BIOLOGICAL|Pertussis vaccine|Vaccination during pregnancy with a pertussis containing vaccine
224073754|NCT01536860|OTHER|Dietary Intervention|300 ml of liquid food product
223496637|NCT04082520|RADIATION|Gallium Ga 68-DOTATATE|Given IV
223590045|NCT04195399|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223590046|NCT04195399|PROCEDURE|Computed Tomography|Undergo CT
223590047|NCT04195399|PROCEDURE|Echocardiography Test|Undergo ECHO
223590048|NCT04195399|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223590049|NCT04195399|DRUG|Nirogacestat|Given PO
223590050|NCT04195399|OTHER|Quality-of-Life Assessment|Ancillary studies
223496638|NCT04082520|DRUG|Lutetium Lu 177 Dotatate|Given IV
223496639|NCT04082520|PROCEDURE|Magnetic Resonance Imaging|Undergo PET/MRI
223496640|NCT04082520|PROCEDURE|Positron Emission Tomography|Undergo PET/MRI
223496641|NCT04082520|OTHER|Questionnaire Administration|Ancillary studies
223496642|NCT04082520|PROCEDURE|Computed Tomography|Undergo PET/CT and/or SPECT/CT
223496643|NCT04082520|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223496644|NCT04082520|PROCEDURE|Single Photon Emission Computed Tomography|Undergo SPECT/CT
223496645|NCT06054425|DRUG|Risankizumab|Infusion; intravenous
223496646|NCT05341245|PROCEDURE|Graphene oxide and open flap debridement|Using Graphene oxide with open flap debridement in management of periodontal intrabony defects in dogs
223496647|NCT05341245|PROCEDURE|Open flap debridement|Using Open flap debridement in management of periodontal intrabony defects in dogs
223496648|NCT04472741|DEVICE|difference between colonoscopes|patients have been randomly assigned for colonoscopy with FUSE or HD SFV endoscopes with or without Endocuff
223496649|NCT03848078|DEVICE|Optical Coherence Tomography|"OCT is an imaging technique, which is able to produce real-time, in vivo, cross-sectional images of lesions with a depth of 1,5-2 mm. OCT imaging is based on light-interferometry, calculating the interference of an optical beam reflected by the tissue with a reference. In such ways, microscopic details of lesions and tissues can be visualized. This information can be used to identify a lesion as BCC, and to specify the subtype. Therefore, we assume that the use of the OCT might reduce the number of biopsies and the accompanying morbidity.~The investigator scans 6mm of skin with the OCT (30 seconds) and decides whether the lesion is a BCC or not."
223496650|NCT02447029|DRUG|vaginal 2% Xylocaine|patient-administered vaginal lidocaine jelly versus provider-administered standard lidocaine paracervical block
223496651|NCT02447029|DRUG|standard lidocaine paracervical block|1% lidocaine paracervical injection
223496652|NCT04613869|DRUG|High-dose Esketamine hydrochloride+Hydromorphone|By adding different doses of esketamine to the postoperative analgesic pump, and the control group without adding this drug to observe the postoperative pain, anxiety and depression indicators of the surgical patients
223496653|NCT04613869|DRUG|Low-dose Esketamine hydrochloride+Hydromorphone|By adding different doses of esketamine to the postoperative analgesic pump, and the control group without adding this drug to observe the postoperative pain, anxiety and depression indicators of the surgical patients
223496654|NCT04613869|DRUG|Hydromorphone|No esketamine added
223496655|NCT06506955|DRUG|futibatinib|TAS-120 futibatinib monotherapy
223590051|NCT04195399|OTHER|Questionnaire Administration|Ancillary studies
223590052|NCT04195399|PROCEDURE|X-Ray Imaging|Undergo x-ray
223590053|NCT06732856|DRUG|zolbetuximab|"1. Neoadjuvant treatment~   : Zolbetuximab 800\*/600 mg/m2 Q3W on day (D) 1, Docetaxel 50 mg/m2 intravenously (IV) on D1, oxaliplatin 100 mg/m2 IV on D1, S-1 40 mg/m2 bid orally on D1-14, will be administered every three weeks for three cycles.~   (\*Loading dose of zolbetuximab (800 mg/m²) on C1D1, followed by subsequent doses of 600 mg/m² every 3 weeks)~2. Surgery~   : Total gastrectomy (TG) or distal gastrectomy (DG) accompanied with dissection of the D2 lymph node~3. Adjuvant treatment After 3-8 weeks from surgery, S-1 40/50/60 mg/m2 bid orally on D1-28 plus Zolbetuximab 600 mg/m2 on D1 and D22 will be administered every 6 weeks for 12 months as an adjuvant treatment."
223590054|NCT06732856|DRUG|Oxaliplatin|1\. Neoadjuvant treatment : Zolbetuximab 800\*/600 mg/m2 Q3W on day (D) 1, Docetaxel 50 mg/m2 intravenously (IV) on D1, oxaliplatin 100 mg/m2 IV on D1, S-1 40 mg/m2 bid orally on D1-14, will be administered every three weeks for three cycles. (\*Loading dose of zolbetuximab (800 mg/m²) on C1D1, followed by subsequent doses of 600 mg/m² every 3 weeks) 2. Surgery : Total gastrectomy (TG) or distal gastrectomy (DG) accompanied with dissection of the D2 lymph node 3. Adjuvant treatment After 3-8 weeks from surgery, S-1 40/50/60 mg/m2 bid orally on D1-28 plus Zolbetuximab 600 mg/m2 on D1 and D22 will be administered every 6 weeks for 12 months as an adjuvant treatment.
224187521|NCT00967889|OTHER|biologic sample preservation procedure|
224187522|NCT00967889|OTHER|laboratory biomarker analysis|
224187523|NCT02908815|DEVICE|rTMS active treatment|Repetitive Transcranial Magnetic Stimulation uses magnetic pulses to active neurons.
223496656|NCT06506955|DRUG|futibatinib, fulvestrant|TAS-120 futibatinib combination therapy with fulvestrant
223496657|NCT01239745|DRUG|Aromasin|Aromasin® one 25 mg tablet to be taken once daily
224187524|NCT02908815|DEVICE|rTMS sham treatment|A fake treatment designed to mimic the sensations of rTMS
224187525|NCT02583165|BIOLOGICAL|MEDI1873|Subjects will receive MEDI1873 by intravenous administration
223496658|NCT00726557|BIOLOGICAL|PegIntron (pegylated interferon alfa-2b; SCH 54031)|PegIntron 1.5 μg/kg/week administered for a minimum of 12 weeks. Patients who achieve early virologic response at Treatment Week 12, will continue PegIntron therapy for a total of 24 weeks for subjects infected with HCV genotype 2 or 3, and for a total of 48 weeks for subjects infected with HCV genotype 1 or 4
223496659|NCT00726557|DRUG|Rebetol (ribavirin; SCH 18908)|Rebetol administered at 10.6 mg/kg/day for a minimum of 12 weeks. Patients who achieve early virologic response at Treatment Week 12, will continue Rebetol therapy for a total of 24 weeks for subjects infected with HCV genotype 2 or 3, and for a total of 48 weeks for subjects infected with HCV genotype 1 or 4
223496660|NCT02011334|DRUG|tocilizumab [RoActemra/Actemra]|162 mg will be administered once weekly by subcutaneous injection.
223496661|NCT00933127|GENETIC|DNA analysis|
223496662|NCT00933127|GENETIC|polymerase chain reaction|
223496663|NCT00933127|GENETIC|polymorphism analysis|
223496664|NCT00933127|OTHER|laboratory biomarker analysis|
223496665|NCT02253498|DEVICE|deep brain stimulation (DBS)|
223496666|NCT00315822|OTHER|80% oxygen|Supplemental oxygen will be administered during surgery
223496667|NCT00315822|OTHER|30% oxygen|Subjects undergoing surgery will receive routine administration of oxygen
223590055|NCT06732856|DRUG|Docetaxel|1\. Neoadjuvant treatment : Zolbetuximab 800\*/600 mg/m2 Q3W on day (D) 1, Docetaxel 50 mg/m2 intravenously (IV) on D1, oxaliplatin 100 mg/m2 IV on D1, S-1 40 mg/m2 bid orally on D1-14, will be administered every three weeks for three cycles. (\*Loading dose of zolbetuximab (800 mg/m²) on C1D1, followed by subsequent doses of 600 mg/m² every 3 weeks) 2. Surgery : Total gastrectomy (TG) or distal gastrectomy (DG) accompanied with dissection of the D2 lymph node 3. Adjuvant treatment After 3-8 weeks from surgery, S-1 40/50/60 mg/m2 bid orally on D1-28 plus Zolbetuximab 600 mg/m2 on D1 and D22 will be administered every 6 weeks for 12 months as an adjuvant treatment.
223590056|NCT06732856|DRUG|S-1|1\. Neoadjuvant treatment : Zolbetuximab 800\*/600 mg/m2 Q3W on day (D) 1, Docetaxel 50 mg/m2 intravenously (IV) on D1, oxaliplatin 100 mg/m2 IV on D1, S-1 40 mg/m2 bid orally on D1-14, will be administered every three weeks for three cycles. (\*Loading dose of zolbetuximab (800 mg/m²) on C1D1, followed by subsequent doses of 600 mg/m² every 3 weeks) 2. Surgery : Total gastrectomy (TG) or distal gastrectomy (DG) accompanied with dissection of the D2 lymph node 3. Adjuvant treatment After 3-8 weeks from surgery, S-1 40/50/60 mg/m2 bid orally on D1-28 plus Zolbetuximab 600 mg/m2 on D1 and D22 will be administered every 6 weeks for 12 months as an adjuvant treatment.
223745835|NCT01053611|DRUG|propofol + remifentanil 2 ng/ml|
223745836|NCT01053611|DRUG|propofol + remifentanil 4 ng/ml|
223745837|NCT01053611|DRUG|propofol + remifentanil 6 ng/ml|
223745838|NCT06293885|DRUG|Dextrose 50|a solution of 50% glucose (D50) will be injected into your pleural space
223745839|NCT06293885|OTHER|Standard of Care - No Dextrose 50|Standard of Care
223745840|NCT03580850|OTHER|No intervention in this restrospective study|This study is an obervational study
223745841|NCT03118154|OTHER|Manual Physical Therapy|Manual Physical Therapy intervention using the Clear Passage Approach (CPA). The focus of the CPA is to deform adhesions throughout the body using a variety of manual therapy techniques and modalities.
224073755|NCT01536860|OTHER|Dietary Intervention|300 ml of liquid food product
224073756|NCT01536860|OTHER|Dietary Intervention|300 ml of liquid food product
224073757|NCT00242827|DRUG|Oral CEP-701|
224073758|NCT04863950|DRUG|Lomustine|"For surgical cohort patients, lomustine will be initiated (C1D1) within 6 weeks of surgery as soon as patient is deemed by the investigator (or designee) to be recovered enough for chemotherapy. Initiation of lomustine must be initiated within 6 weeks. If patient cannot be safely initiated on lomustine within this timeframe then they will be replaced.~For non-surgical cohort patients (the decision for surgery is made independent of study participation), lomustine will be initiated on C1D1.~For both cohorts, lomustine will be administered as 110 mg/m2 PO once every 6 weeks."
224075987|NCT07137923|BEHAVIORAL|Clinical decision support + education (CDS+)|Intervention clinic providers will experience nudges in the electronic medical record to encourage prescribing SMART where clinically-appropriate and intervention clinic providers, families/patients, and nurses will receive education (collectively CDS+).
223496668|NCT00075374|DRUG|docetaxel|"Patients receive docetaxel IV over 1 hour on day 1. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.~OR Patients receive docetaxel IV over 30 minutes on days 1, 8, and 15. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.~Quality of life is assessed at baseline, every 2 courses during study treatment, and then at study completion.~Patients are followed at 1 month and then every 2-3 months thereafter."
223496669|NCT01601795|DRUG|Sevoflurane|volatile Anaesthetic, duration during cardiopulmonary bypass
223496670|NCT01601795|DRUG|Isoflurane|volatile anesthetic, duration during cardiopulmonary bypass time
223496671|NCT01257542|DRUG|Dextromethorphan|A single 10 mL dose of Children's Triaminic Syrup (Dextromethorphan Hydrobromide 7.5 mg per 5 mL (total dose of 15 mg)
223496672|NCT01257542|DRUG|Placebo|A single 10 mL dose of matching placebo syrup
223496673|NCT01522547|DRUG|pomalidomide|Pomalidomide orally for 84 days daily in doses ranging from 0.5 mg to 4.0 mg
223496674|NCT04332120|PROCEDURE|tubal sterilization|
223496675|NCT04705571|DEVICE|MorpheusV Applicator|1 treatment with the MorpheusV Applicator
223496676|NCT01566162|DRUG|Lurasidone|Lurasidone 40-80 mg taken orally taken once daily
223496677|NCT04187521|OTHER|Meal A|A breakfast meal with a specific macronutrient proportions.
223496678|NCT04187521|OTHER|Meal B|A breakfast meal with a specific macronutrient proportions.
223745842|NCT03538158|BEHAVIORAL|Intervention Condition|Participants will have access to Fittle Senior which will provide guided exercises and social support from other participants of the study.
224075988|NCT07137923|OTHER|Control|Clinics in Arm 2 will not be exposed to the interventions.
224075989|NCT06701370|OTHER|Task Oriented Training|Task oriented training consists of opening the bottlecap, stacking cubes on different sizes, buttoning,screwing, wearing a coat.
223496682|NCT02413268|DRUG|Nitroglycerin|
223496683|NCT05340595|OTHER|Orthodontic retainer bonding|Self-etch primer (Transbond XT Primer; 3M Unitek, California) was administered to the teeth's lingual surfaces.
223496684|NCT00000678|DRUG|Zidovudine|
223496685|NCT00000678|DRUG|Zalcitabine|
223496686|NCT06190119|OTHER|none intervention|This study has no intervention
223496687|NCT00712049|DRUG|simvastatin|simvastatin 40 mg
223496688|NCT00712049|DRUG|Nicotinic Acid|daily dose starting with 500 mg, up to 2000mg
223496689|NCT01723943|OTHER|educational intervention|"Receive the What's Happening to the Woman I Love? booklet"
223496690|NCT01723943|OTHER|counseling intervention|Undergo Helping Her Heal educational counseling program
223496691|NCT01723943|OTHER|educational intervention|Undergo Helping Her Heal educational counseling program
223496692|NCT01723943|OTHER|psychosocial support for caregiver|Undergo Helping Her Heal educational counseling program
223496693|NCT02243826|DRUG|50:50 mixture of nitrous oxide/oxygen|
223496694|NCT04167800|OTHER|Exercise|Orthosis, mobilization, strengthening, posture and segmental breathing exercises
223496695|NCT03562507|DRUG|ESK981|ESK981: 160 mg (4 capsules) PO daily for 5 consecutive days followed by a 2-day off drug in each week, repeated weekly in 4-week (28-day) cycles
223496696|NCT03562507|DRUG|Nivolumab|480 mg/dose IV, Day 1 of each 28-day cycle
224075990|NCT06701370|OTHER|Conventional Rehabilitation|Bobath weightbearing and mobility exercises for upper extremity and 15 minutes Neuromuscular Electrical Stimulation.
223496697|NCT00792480|BEHAVIORAL|Dietary and lifestyle counseling|"The intervention group will undergo a complete history and physical with attention to prepregnancy weight, current weight, height, and BMI. At the initial visit, they will meet with a registered dietician to receive a standardized counseling session, including information on pregnancy-specific dietary and lifestyle choices. The patient will be instructed to engage in moderate intensity exercise at least 3 times per week and preferably 5 times per week. They will also receive information on the appropriate weight gain during pregnancy using the IOM guidelines. Each subject will meet with the dietician only at the time of enrollment.~At each routine obstetric appointment, the participant's weight will be measured and charted on an IOM Gestational Weight Gain Grid in front of the participant. The healthcare provider will inform the participant if her weight gain was at the appropriate level and counsel her accordingly regarding increasing or decreasing her intake and exercise."
224073759|NCT04863950|DRUG|Imipramine Hydrochloride|"For the surgical cohort, imipramine hydrochloride will be initiated within a minimum of 16 days to a maximum of 3 weeks prior to surgery. Imipramine hydrochloride will be administered as 50mg PO (oral) QHS (at bedtime) for 4 days followed by a dose increase (taper-up) of 50mg/day every fourth day to attain a maximum dose of 200mg/day in 16 days.~For non-surgical cohort patients (the decision for surgery is made independent of study participation), imipramine hydrochloride will be initiated on Cycle 1 Day 1. Imipramine hydrochloride will be administered as 50mg PO (oral) QHS (at bedtime) for 4 days followed by a dose increase (taper-up) of 50mg/day every fourth day, if tolerated, to attain a maximum dose of 200mg/day in 16 days."
223496698|NCT02132468|DRUG|fosbretabulin tromethamine|60 mg/m2, IV on Day 1, 8 and 15 of a 3-week cycle; 3 cycles or until progression or unacceptable toxicity
223496699|NCT01484366|PROCEDURE|intramedullary nailing and plating|Surgical intramedullary nailing of the ulna and plating of the radius
223496700|NCT01484366|PROCEDURE|plating|Surgical plating of both bonforearm fractures
223496701|NCT05702151|PROCEDURE|ESP Block|After induction of anesthesia in the operating room, the patient is positioned in lateral decubitus. Under strict aseptic conditions, and guided by ultrasound, an Erector Spinae Plane block is performed injecting ropivacaine 0.2% 20ml, and a catheter is placed. Ropivacaine 0.2% infusion at a 10ml/h rate is started during the surgery.
223496702|NCT05702151|DRUG|Morphine injection|Intravenous morphine infusion 50mcg/kg/h with Patient Controlled Analgesia extra bolus on demand (1mg bolus with 20 minutes lockout time), and paracetamol 1g every 8 hours.
223496703|NCT01108159|PROCEDURE|Blood Draw|
223496704|NCT01108159|PROCEDURE|Skin Biopsy|
224073760|NCT01164722|OTHER|clinical observation|Patients undergo observation
224073761|NCT01164722|DEVICE|infrared photocoagulation therapy|Anal infrared coagulator ablation
224073762|NCT02981680|PROCEDURE|Remote Ischemic Preconditioning (RIPC)|Remote ischemic preconditioning (RIPC) is a phenomenon in which brief ischemia of one organ or tissue, provokes a protective effect that can reduce the mass of infarction caused by vessel occlusion and reperfusion.
224073763|NCT02981680|PROCEDURE|sham-RIPC|
224073764|NCT05044156|OTHER|salivary sample|salivary sample
224073765|NCT00003426|DRUG|gemcitabine hydrochloride|
223496705|NCT00693303|BEHAVIORAL|Handwriting Training using My Scrivener|Subjects received 20 minutes of training per week which included writing letters and words with the My Scivener device.
223496706|NCT05188794|PROCEDURE|lateral tap block|In the axial plane on the midaxillary line between the subcostal margin and the iliac crest with a linear probe using a 12 cm insulated nerve block needle is advanced in planely from skin, external, and internal oblique muscles to the target of fascial plane between the internal oblique and the transversus abdominis muscles.
224073766|NCT00003426|RADIATION|radiation therapy|
224073767|NCT00685126|DRUG|Levalbuterol HCl Inhalation Solution|Nebulized unit dose vial for inhalation, low dose (0.15 mg, 0.31 mg or 0.63 mg), adjusted for body weight
224073768|NCT00685126|DRUG|Levalbuterol HCl Inhalation Solution|Nebulized unit dose vial for inhalation, high dose (0.31 mg, 0.63 mg or 1.25 mg), adjusted for body weight
223496707|NCT05188794|PROCEDURE|posterior tap block|In the axial plane on the midaxillary line a linear probe using a 12 cm insulated nerve block needle is advanced posteriorly to the most posterior limit of the TAP between the internal oblique and transversus abdominis muscles.
223496708|NCT02368236|BEHAVIORAL|Tailored Printout|The Cancer Risk Intake System (CRIS) is a tablet-based program through which patients answer detailed questions about their colorectal cancer risk prior to an appointment. Tailoring algorithms in CRIS generate printed information for patients and their physicians summarizing their risk factors and matching them with guideline-based screening options.
223496709|NCT00446784|DRUG|CE-224,535|
223496710|NCT00446784|DRUG|Methotrexate|
224073769|NCT00685126|DRUG|Albuterol HCl Inhalation Solution|Nebulized unit dose vial for inhalation, dose (0.31 mg, 0.63 mg or 1.25 mg), adjusted for body weight
224075991|NCT06701370|OTHER|Upper arm ergometer|The patients will be rode 5 minutes forwardly and 5 minutes backwardly
224075992|NCT07039630|BEHAVIORAL|Food Assistance Programs|Receive enhanced delivery half-price food boxes delivered by a community health worker
224075993|NCT07039630|BEHAVIORAL|Food Assistance Programs|Receive the standard half-price produce box delivery delivered by FreshFix staff
224075994|NCT07039630|OTHER|Health Promotion and Education|Receive nutritional education materials and resources
224075995|NCT07039630|OTHER|Questionnaire Administration|Ancillary studies
224075996|NCT07039630|OTHER|Survey Administration|Ancillary studies
224075997|NCT07039630|BEHAVIORAL|Telephone-Based Intervention|Receive a dietary recall phone call
224075998|NCT06717919|PROCEDURE|Hypothermic oxygenated perfusion|All study centres will use either VitaSmart, Liver assist or Perlife devices for machine liver perfusion, with a pressure controlled hypothermic oxygenated liver perfusion through the portal vein (HOPE) or through the portal vein and the hepatic artery (DHOPE), targeting a flow rate between 200-250 ml/min at a pressure of 3 mmHg, and a perfusate temperature between 8-12°C. The perfusate consists of 3L re-circulating Belzer MPS® (Bridge to Life Ltd.) with an active oxygenation (70-110 kPa). The minimum perfusion duration is defined at 2 hours, while perfusion is generally continued until the recipient hepatectomy is completed. The perfusion will exclusively be performed in the recipient centre after initial cold storage and bench preparation of the liver for implantation. The perfusion devices are routinely used in all participating centres.
223496711|NCT02617290|DRUG|Ticagrelor|Ticagrelor Loading dose of 180mg given after angiography and before PCI , followed by a 30 days treatment with the maintenance dose of 90mg bid.
223496712|NCT02617290|DRUG|Clopidogrel|Clopidogrel Loading dose of 300 or 600mg given after angiography and before PCI , followed by a 30 days treatment with the maintenance dose of 75mg per day.
223496713|NCT06426407|DRUG|Vasopressin|Fixed dosage vasopressin ordered as an adjunctive vasopressor to norepinephrine
223496714|NCT00205166|PROCEDURE|Cardiac SPECT imaging Rest and Stress|adenosine perfusion scintigraphy
223496715|NCT00205166|DRUG|Caffeine|Caffeine 400 mg po
223496716|NCT00205166|DRUG|Caffeine|Caffeine 200 mg po
223496717|NCT05224323|OTHER|Airway pressure, flow, esophageal pressure, ventilation distribution|After informed consent, baseline characteristics of patients will be collected. Airway pressure, flow and esophageal pressure will be recorded using high sampling rate and ventilation distribution using electrical impedance tomography will be recorded during the study. The ventilator will be set at a positive end-expiratory pressure of 15 cmH2O during 10 minutes. Then, respiratory rate will be decreased to 8 breaths/min, and positive end-expiratory pressure will be decreased to 5 cmH2O over one breath to measure the recruited volume. Then, three low-flow inflation and deflation pressure-volume curves will be performed before resuming clinical ventilator settings. Patients will be followed until Day 28 after inclusion or ICU discharge. Maneuvers performed are part of the usual care of patients with acute respiratory distress syndrome in our unit.
223496718|NCT02246894|BIOLOGICAL|Optivate® (Human Coagulation Factor VIII)|
223496719|NCT00993889|BEHAVIORAL|VR during Physical Therapy|Virtual Reality will be performed during a painful physical therapy procedure.
223590057|NCT05804149|DEVICE|acupuncture|study group take acupuncture Acupuncture was applied with a total duration of 35-45 minutes, 2 sessions per week for 4 months.
223745843|NCT03538158|BEHAVIORAL|Control Condition|Participants will have a paper booklet with suggested exercises that they may choose to complete for the duration of the study.
224073770|NCT03390062|DRUG|Apatinib|Apatinib, also known as YN968D1, is a tyrosine kinase inhibitor that selectively inhibits the vascular endothelial growth factor receptor-2 (VEGFR2, also known as KDR). It is an orally bioavailable, small molecule agent which is thought to inhibit angiogenesis in cancer cells; specifically apatinib inhibits VEGF-mediated endothelial cell migration and proliferation thus blocking new blood vessel formation in tumor tissue.
224073771|NCT06411275|DRUG|HTD1801|HTD1801 administered orally BID as two capsules
224073772|NCT06411275|DRUG|Placebo|Matching placebo administered orally BID as two to four capsules
223496720|NCT00993889|BEHAVIORAL|VR Background Pain|Virtual Reality is used at anytime during the day for the background pain, not during physical therapy.
223496721|NCT00993889|BEHAVIORAL|NO VR|The subject will receive the usual standard treatment. At the end of the study, before being discharged from the hospital, the subject can experience the VR, not during a procedure.
223496722|NCT02504203|BIOLOGICAL|BCG-Denmark 1331 (Statens Serum Institute)|See above
223496723|NCT04986969|BEHAVIORAL|Online cognitive behavioral therapy|online cognitive behavioral therapy delivered using one of two active methods
223496724|NCT00231192|DRUG|Repaglinide and Insulin|
224073773|NCT06411275|DRUG|HTD1801|HTD1801 administered orally BID as four capsules
224073774|NCT04940910|DIETARY_SUPPLEMENT|Black rice bran extract|2 times a day, 2 capsule for 1 time, after breakfast/dinner meal, for 8 week
224073775|NCT04940910|DIETARY_SUPPLEMENT|Placebo|2 times a day, 2 capsule for 1 time, after breakfast/dinner meal, for 8 week
224073776|NCT00868686|DEVICE|Volar aluminum splint|Alumafoam strip with padding removed, placed on the VOLAR aspect of the digit spanning the middle and distal phalanges only.
224073777|NCT00868686|DEVICE|Dorsal aluminum splint|Alumafoam strip with padding removed, placed on the DORSAL aspect of the digit spanning the middle and distal phalanges only.
224187526|NCT05850455|DRUG|Dexmedetomidine Hydrochloride 'Precedex' combined with|Dexmedetomidine Hydrochloride which is an Alfa 2 receptor agonist
224187527|NCT05850455|PROCEDURE|Lumbar epidural analgesia with Bupivacaine 0.25% 'Sunnypivacaine'|The epidural insertion point will be 2 segments upper than the surgical procedure level, 10 ml of Bupivacaine 0.25% will be injected in the epidural space to adjust the sensory level
223496725|NCT05196139|OTHER|retrospective study|vitrectomy performed in case of submacular bleeding
223496726|NCT00002390|DRUG|Abacavir sulfate|
223496727|NCT00776997|DEVICE|Magnetic Sphincter Augmentation|The area of the lower esophageal sphincter (LES) is accessed using a standard laparoscopic approach. The tubular esophagus, in the area of the LES, is sized and the appropriately sized sphincter augmentation device is placed circumferentially around the esophagus in the area of the LES. After confirming proper placement, the ends of the device are secured. At this point, the implant procedure is complete, laparoscopic instruments are withdrawn and access points are closed.
223590058|NCT05804149|DRUG|Thyroxine|Each woman in both groups (control and study) will receive thyroxine tablets (levothyroxine) (1tablet per day) describe by the physician. Levothyroxine is usually taken 30-60 minutes before breakfast, or four hours after food, as certain substance such as food and calcium can inhabit the absorption of levothyroxine
223745844|NCT01537510|BEHAVIORAL|STAR - Study of Technology to Accelerate Research|In 14 pediatric practices, to conduct a cluster-randomized controlled trial to examine the extent to which computerized point of care decision alerts to pediatric primary care providers, with or without direct-to-parent communications, will increase adoption of comparative effectiveness research evidence on childhood obesity for children 6 to 12 years of age with a BMI ≥ 95th percentile.
224073778|NCT00868686|DEVICE|Custom thermoplastic|Customized thermoplastic splint with circumferential contact proximal to the joint and volar contact distal to the joint. This is a similar design to the original Stack splint, except that it is custom molded.
224073779|NCT02121457|DIETARY_SUPPLEMENT|Brazil nut|Participants of the treatment group were instructed to take one Brazil nut daily during 6 months. Brazil nuts were supplied in 2-month allowances at no cost together with written nutritional information and a calendar to monitor the compliance. Compliance was monitored in intervals of 2 months by checking the calendar and counting returned nuts. Compliance was considered to be adequate if ≥85% of Brazil nuts were consumed. All subjects were instructed to maintain their normal diet and to avoid additional Brazil nuts during the study.
224073780|NCT02121457|DIETARY_SUPPLEMENT|selenium|
223496728|NCT03803696|BEHAVIORAL|Enhanced Standard Care|"* Baseline data collection, registration and randomization~* Inform primary transplant clinician of sexual dysfunction causing distress~* Receive American Cancer Society sexual educational material"
223496729|NCT03803696|BEHAVIORAL|Multimodal Intervention to Address Sexual Dysfunction|"Baseline data collection, registration and randomization~\- 3 Monthly visits with trained study nurse practitioners~* Referral to specialist if~* Psychological etiology~* Sexual Trauma~* Relationship Discord~* Concern for Malignancy or anatomic scarring requiring surgery"
223496730|NCT02292225|DRUG|IPI-145 (duvelisib)|25mg and/or 5mg oral capsule
223496731|NCT02292225|DRUG|Obinutuzumab|1000mg/40mL single-use vials
223496732|NCT02193893|OTHER|Biological: Cell-based therapeutics|Human autologous bone marrow-derived stem/progenitor cell transplantation in ALS patients.
223496733|NCT02193893|OTHER|Symptomatic treatment of ALS|Symptomatic neurological treatment of ALS
223496734|NCT01193985|DEVICE|TIGR Matrix Surgical Mesh|Lichtenstein repair of inguinal hernia using TIGR Matrix Surgical Mesh
223496735|NCT06511102|BEHAVIORAL|GPT Support|The computer interface used for the essay writing task follows a split-screen design. The writing instructions and text input field are administered on a survey platform, placed on the left half of the screen. ChatGPT is placed on the right half of the screen for technology assistance.
223496736|NCT05650697|BIOLOGICAL|Group 1 cannabidiol (CBD) with silicone ointment|"Vantage Hemp CBD Isolate + Silicone patch The study intervention is prospective in nature. This split scar study directly compares two parts of the healing scar during clinic visits. Photos will be taken at each visit to track progress. Assessments will be done over a period of around 7 months using the Modified Patient and Observer Scar Assessment Scale, followed by blinded photo evaluations using the Scar Cosmesis and Rating Scale."
223496737|NCT05650697|BIOLOGICAL|Group 2 silicone patch|"Silicone patch Standard of care silicone patch will be used as the control part of the split scar study. This split scar study directly compares two parts of the healing scar during clinic visits. Photos will be taken at each visit to track progress. Assessments will be done over a period of around 7 months using the Modified Patient and Observer Scar Assessment Scale, followed by blinded photo evaluations using the Scar Cosmesis and Rating Scale."
223496738|NCT06959888|DRUG|ALG-055009|"Single PO dose of 0.7 mg ALG-055009 softgel capsule (formulation 1)~Single PO dose of 0.7 mg ALG-055009 softgel capsule (formulation 2)"
223496739|NCT03487445|DRUG|Selatogrel 8 mg|Selatogrel is a reversible P2Y12 receptor antagonist for subcutaneous administration. It is supplied in sealed glass vials at a strength of 20 mg. The vials with ACT-246475A (hydrochloride salt of ACT-246475) will be reconstituted with 1 mL of water and further diluted with 1 mL sodium chloride (NaCl) 0.9%.
223496740|NCT03487445|DRUG|Selatogrel 16 mg|Selatogrel is a reversible P2Y12 receptor antagonist for subcutaneous administration. It is supplied in sealed glass vials at a strength of 20 mg. The vials with ACT-246475A (hydrochloride salt of ACT-246475) will be reconstituted with 1 mL of water for injection.
223496741|NCT00474513|DRUG|GSK239512|
223496742|NCT05821478|DRUG|ROCEPHIN, metronidazole, RIFADIN, IZILOX, placebo combination therapy|a 3-week course of ceftriaxone injection + oral metronidazole followed by a 3-week course of oral rifampicin + moxifloxacin +metronidazole followed by a 6-week course of oral rifampicin + moxifloxacin
223496743|NCT05821478|DRUG|Lymecyclin and corresponding placebos of the experimental arm|12-week course of oral lymecycline.
224187528|NCT05850455|PROCEDURE|General anesthesia|Propofol 2-3 mg/kg'Diprivan 1%', Fentanyl 'Fentanyl' 2 μg/kg, and Cisatracurium 'Cisatracure' 0.2 mg/kg will be administered to facilitate endotracheal intubation, and ventilation will be controlled to maintain the end-tidal carbon dioxide (CO2) between 32-38 mmHg, to maintain anesthesia, 2-3% Sevoflurane 'Sevoflurane', and 0.05 mg/kg of the muscle relaxant Cisatracurium will be added at 40-minute intervals according to the conditions of the operation. No other medication will be administered
224187529|NCT05850455|DRUG|Local infiltration with Lidocaine HCL 1%'Debocaine'|Lidocaine 1% which is a local analgesic as local infiltration
224187530|NCT00084188|BEHAVIORAL|Behavior Therapy|
224187531|NCT03201601|DRUG|D-chiro-inositol|Each participant will consume 2 capsules daily of each treatment, in the morning and at night without any restriction in the diet nor in their habits of life. The treatment will last 12 weeks.
224187532|NCT03201601|DRUG|Myoinositol|Each participant will consume 2 capsules daily of each treatment, in the morning and at night without any restriction in the diet nor in their habits of life. The treatment will last 12 weeks.
224187533|NCT04911361|DRUG|Dexamethasone|Patients will be randomized for either topical loteprednol suspension in both eyes (control group) or lower eyelid canaliculi DEXTENZA insertion (study group)
223496744|NCT06415331|PROCEDURE|Pulsed radiofrequency|Individualized dose of pulsed radiofrequency is given for 6 minutes.
223496745|NCT06415331|OTHER|Conventional therapy|"Conventional therapy for HNP consisting of:~* Acetaminophen~* NSAID: Etoricoxib, celecoxib, meloxicam, diclofenac, ibuprofen~* Muscle relaxant: eperisone, diazepam~* Opioid: codein, tramadol~* Adjuvant analgesics: Amitriptyline, pregabalin, gabapentin~* Physiotherapy: Short wave diathermy, ultrasound diathermy, transcutaneous electrical nerve stimulation, and exercise"
223496746|NCT05191784|DRUG|GX-I7|Administered by intramuscular (IM) injection
223496747|NCT05191784|DRUG|Bevacizumab|Administered by intravenous (IV) injection
223496748|NCT00733798|DRUG|131I-TM601|After a single 20mCi/0.4 mg Imaging Dose of 131I-TM601, patients in the Dose Escalation Phase will be administered between 2-5 weekly doses of 131I-TM601 at 1.2 mCi/kg of lean body mass (specific activity of 131I-TM601 will be maintained at 50 mCi 131I/mg TM601 for all doses administered in this study.) Patients in the Efficacy Phase of the study will be treated at the Maximum Tolerated Dose established in the Dose Escalation Phase.
223496749|NCT05803317|OTHER|usual care : Evaluation of walking on a baropodometric platform|Pure observationnal study
223496750|NCT05969691|DIAGNOSTIC_TEST|Validation of IDH1 mutations from the radiomics model|During surgery, clinicians will select several typical target sites for puncture based on the preoperative model outputs. After surgery, the acquired tumour tissues will be subjected to histological diagnosis and pathological diagnosis by professional pathologists, and the results will be compared with the model output to verify its accuracy.
223745845|NCT00390533|DRUG|Saredutant|oral administration (capsules)
224187534|NCT04941833|DRUG|Desogestrel Oral Tablet|Cerazette is the brand name of the desogestrel which contain of 0.075 mg of desogestrel
223590059|NCT05804149|DIETARY_SUPPLEMENT|low caloric diet|Each woman in both groups will follow a low caloric diet regime consisting of 1200 to 800Kcal/ day for 4 months. The regime will start with 1200 Kcal for the first month and 1100 for the second month then 900 Kcal for the third month until reach 800 Kcal in fourth month.
223590060|NCT01295424|OTHER|No intervention|Observational study, no interventions
223590061|NCT07056517|DRUG|M107 and Duvie - Cohort 1|Dosage form - Oral tablets Dosage - Duvie 0.415 mg and M107 ODT 0.4 mg Participants will receive each treatment once under fasted conditions in a randomized two-period crossover design.
223590062|NCT07056517|DRUG|M107 - Cohort 2|Dosage form - Orally disintegrating tablet Dosage - 0.8 mg Participants will receive M107 once under fasted conditions and once after a high-fat, high-calorie meal in a two-period crossover design.
223590063|NCT07056517|DRUG|M107 - Cohort 3|Dosage form - Orally disintegrating tablet Dosage - 1.2 mg Participants will receive a single oral dose of M107 under fasted conditions.
223590064|NCT06772168|DRUG|CMG190303(Dapagliflozin/Rosuvastatin)|0-8 week: Dapagliflozin 10mg and Rosuvastatin 5mg 8-16 week: Dapagliflozin 10mg and Rosuvastatin 10mg 16-24 week: Dapagliflozin 10mg and Rosuvastatin 20mg
223590065|NCT06772168|DRUG|Comparator 1: Dapagliflozin/Rosuvastatin placebo|0-24 week: Dapagliflozin 10mg and Rosuvastatin placebo
223590066|NCT06772168|DRUG|Rosuvastatin/Dapagliflozin placebo|0-8 week: Dapagliflozin placebo and Rosuvastatin 5mg 8-16 week: Dapagliflozin placebo and Rosuvastatin 10mg 16-24 week: Dapagliflozin placebo and Rosuvastatin 20mg
223590067|NCT07077109|DEVICE|Electrophysiological monitoring|electrofysiological CTG monitoring with the Nemo Fetal Monitoring System (Nemo Healthcare B.V., Veldhoven, the Netherlands). The NFMS consists of a wireless and beltless electrode patch on the maternal abdomen. It monitors fetal heart rate by fetal electrocardiography, maternal heart rate by maternal electrocardiography and the electrical activity of the uterine muscle by electrohysterography.
223590068|NCT07081308|DEVICE|NIRS-BCI-pneumoorthesis|"Patients recieve 10 NIRS-BCI-pneumoorthesis trainings of 16 minutes each over 2 weeks.~NIRS-BCI-pneumoorthesis Components: NIRScout hardware-software complex (16 light sources, 8 detectors); Software for brain activity classification; Korvit system for plantar support load reproduction; 22-inch monitor for task demonstration.~Training Procedure: Patient seated with lower limbs fixed in pneumatic orthoses; Task: kinesthetically imagine walking or relax; Feedback: visual (color change on screen) and tactile (support load through orthosis).~Training structure: 16 blocks alternating walking imagination and relaxation"
224187535|NCT00556140|DRUG|Aripiprazole|"Everyone in this study will receive aripiprazole and an antidepressant called a selective serotonin reuptake inhibitor (SSRI). There is only one arm for this study.~Aripiprazole is an antipsychotic medication that has been approved by the Food and Drug Administration (FDA) for the treatment of schizophrenia.~You will receive aripiprazole (Abilify) and one of the following SSRI antidepressant medications that will be determined by the study doctor and you: sertraline (Zoloft), citalapram (Celexa), or escitalopram (Lexapro). The dose of aripiprazole (Abilify) will be 10 milligrams a day, and the starting doses for the SSRI anti-depressants will be: sertraline (Zoloft) 50 milligrams a day, citalopram (Celexa) 20 milligrams a day, and escitalopram (Lexapro) 10 milligrams a day."
224187536|NCT01874821|DEVICE|Dynasplint|"Dynamic splinting utilizes the protocols of Low-Load Prolonged Stretch (LLPS) with calibrated adjustable tension to increase Total End Range Time (TERT)to reduce contracture. The Dynasplint or Experimental group will add this therapy to their standard of care regimen"
224187537|NCT01874821|OTHER|Standard of Care|The current Standard of Care for treating this condition includes corticosteroid injections and physical therapy.
224309033|NCT06454396|PROCEDURE|Endovascular therapy|Endovascular therapy is a minimally invasive interventional approach that utilizes the vascular system as a pathway to access and treat various pathological conditions within the body. By employing specialized catheters and devices, endovascular techniques enable precise delivery of therapeutic agents or interventional procedures directly to the target site, without the need for conventional open surgery.
224309034|NCT05974917|DEVICE|Serious Game (SG)|"SG which was conceived as a running game, in which an Avatar runs through the forest and overcomes obstacles through the player's performance of physical exercises.~Children will play while watching an imaginary Avatar, who shows the right movements to perform in order to collect rewards. SG will be projected with a 4K projector and controlled by the child's movements, which will be tracked in markerless mode using Azure's Kinect sensor. SG will include an adaptive tool to enable the experience based on the child's specific motor skills.~The dynamics of SG will be adapted by considering real motor and physiological data acquired during each SG session via a wristband. These data are necessary to keep the child in the aerobic zone (60-80% of maximum heart rate). The movements are:~1. Side bending: Moving an obstacle to open a passage.~2. High jump: Overcoming a low, frontal obstacle.~3. Side lunge: Avoiding a side obstacle.~4. Squat: Passing under a low, frontal obstacle."
223590069|NCT07083063|DRUG|Nitroglycerin (NTG)|All patients without chronic kidney disease (serum creatine \> 1.5 mg/dL) will receive rectal diclofenac 100 mg before the procedure. During the biliary cannulation, if twice or more times of pancreatic duct cannulation, a pancreatic plastic stent will be placed. Lactate ringer hydration will be provided to patients with pancreatic duct cannulation for 24 hours. After the EST and stone extraction, we will randomly assign the patients to either a control or an intervention group. After EST, if immediate bleeding occurs, we will apply standard endoscopic therapy by either local injection of diluted epinephrine or heater probe coagulation. Before the end of the exam, diluted 1mg nitroglycerin in normal saline (1mg/10cc) will be delivered to the major papilla in the intervention group, and 10cc normal saline will be delivered to the major papilla in the standard group.
223745846|NCT00390533|DRUG|Placebo|oral administration (capsules)
223745847|NCT03036787|BEHAVIORAL|family based intervention|behavioural advises to family for normal motor development
223745848|NCT03302988|OTHER|Everted closure|Suturing technique to obtain wound eversion. Type of suturing technique at surgeon's discretion
223745849|NCT03302988|OTHER|Planar closure|The planar side will be closed with traditional buried simple closure and running cuticular sutures
223745850|NCT00058604|BIOLOGICAL|Intravenous injection of EBV specific CTLs|Each patient will receive injections of 2x10e7 , 5x10e7 , or 10e8 CTLs/m2 via IV injection. 6 weeks = 1 course
224187538|NCT03122327|OTHER|Questionaires|Questionaires of cGA assessment. No other interventions would be carried out aside from the standard treatment for MM.
223496751|NCT03918200|OTHER|Serum amyloid A level|For determination of SAA level, a 5-ml sample of venous blood will be taken from each participant under aseptic conditions, and centrifuged at 2500 g for 15 minutes at 4°C c. separated into serum aliquots,and stored frozen at -80°C until analysis of SAA ,which will be done by a double-antibody sandwich Enzyme Linked Immunosorbent Assay (ELISA) kits supplied by cusabio,USA according to manufacturers instruction .Each sample was tested in duplicate and the average will be taken. A cut off level of 30 mg/L SAA level will be chosen to reflect a real increase in its level
223496752|NCT05011032|DIAGNOSTIC_TEST|Homocysteine|It is an amino acid which is synthesized by the demethylation of dietary methionine. It is a highly reactive, Sulfur-containing amino acid as a by-product of metabolism of essential amino acid specifically methionine. It was proved to be a strong risk factor causing many cardiovascular diseases, neurological disturbances and other health related issues
223496753|NCT03301714|BEHAVIORAL|Oral Health Education|Group-based oral health education vs Individual-based oral health education using motivational interviewing
223496754|NCT06322498|DIAGNOSTIC_TEST|Uterine lavage|Infusion of 2ml 0.9%NACL into the uterine cavity and aspiration of the fluid
223590070|NCT07083063|DRUG|Normal Saline (0.9% NaCl)|All patients without chronic kidney disease (serum creatine \> 1.5 mg/dL) will receive rectal diclofenac 100 mg before the procedure. During the biliary cannulation, if twice or more times of pancreatic duct cannulation, a pancreatic plastic stent will be placed. Lactate ringer hydration will be provided to patients with pancreatic duct cannulation for 24 hours. After the EST and stone extraction, we will randomly assign the patients to either a control or an intervention group. After EST, if immediate bleeding occurs, we will apply standard endoscopic therapy by either local injection of diluted epinephrine or heater probe coagulation. Before the end of the exam, diluted 1mg nitroglycerin in normal saline (1mg/10cc) will be delivered to the major papilla in the intervention group.
223590071|NCT07078942|DRUG|Tranexamic Acid|Tranexamic Acid 1 g intravenous preoperation
224073781|NCT05501353|OTHER|no intervention|This study is an observational study, which does not affect the routine diagnosis and treatment of patients and only requires the collection of biological samples at specific nodes
223496755|NCT01194310|PROCEDURE|phaco|Standard clear cornea phacoemulsification plsu intraocular lens Implantation (phaco) alone
223590072|NCT07078942|OTHER|Placebo|normal saline 20 ml intravenous preoperation
223745851|NCT06521359|DEVICE|flow cytometry|Two ml of peripheral venous blood samples will be collected in heparinized tubes from patients and controls for assessment of levels of TFH and TFReg cells by flow cytometry.
223745852|NCT00654407|DRUG|Rosuvastatin|
224073782|NCT05850221|OTHER|weight training|weight training
224073783|NCT06471270|DIAGNOSTIC_TEST|histologic evaluation|histologic evaluation
223745853|NCT00654407|DRUG|Atorvastatin|
223745854|NCT00654407|DRUG|Simvastatin|
223745855|NCT02311738|OTHER|Training intensity intervention|High intensity training group describes the group performing high intensity exercise intervention. Moderate intensity training group describes the the group performing moderate exercise intervention
224073784|NCT06471270|DIAGNOSTIC_TEST|biochemical analysis|IL-6, IL-8 and sCD44
224073785|NCT06471270|DIAGNOSTIC_TEST|clinical examination|clinical examination
224073786|NCT00006089|OTHER|Laboratory Biomarker Analysis|Correlative studies
224073787|NCT00006089|BIOLOGICAL|Trastuzumab|Given IV
224073788|NCT05792878|DRUG|Interferon|The naive treated patients with chronic hepatitis B were given antiviral treatment with interferon according to their condition.
224073789|NCT05792878|DRUG|nucleoside analogues|The naive treated patients with chronic hepatitis B were given antiviral treatment with nucleoside analogues according to their condition.
224073790|NCT01382732|DRUG|Carbetocin|Protocol A (carbetocin + placebo) Carbetocin: 100ug (1mL) + Ringer's Lactate 10mL directly into the vein in no less than two minutes.
224073791|NCT01382732|DRUG|Oxytocin|Oxytocin 20 U (4mL) diluted in a bag with 1000mL of Ringer's Lactate to be passed intravenously at a rate of 125mL/hr
224073792|NCT04388995|DIAGNOSTIC_TEST|volume expansion|volume expansion with 6% hydroxyethyl starch (7 mL/kg) at a rate of 0.4 mL/kg/min
224073793|NCT02501278|BIOLOGICAL|INO-3112 vaccine|"INO-3112 i.e. the combination of VGX-3100 and INO-9012, specifically:~* VGX-3100 (HPV16 and HPV18 E6-E7 DNA vaccine) will be administered at 3 mg per plasmid (6 mg total DNA)~* INO-9012 (IL-12 DNA plasmid) will be administered at 1 mg per dose will be administered using the CELLECTRA® electoporation device"
224073794|NCT02501278|RADIATION|Radiotherapy (Extrernal beam radiotherapy + brachytherapy)|"The whole pelvis will be irradiated with 45 - 50.4 Gy in 25-28 fractions in fractions of 1.8 Gy over 5 weeks daily.~Those patients with pelvis positive and/or para-aortic positive lymph nodes should be treated with an elective dose to the para-aortic area of 45 Gy in fractions of 1.6-1.8 Gy in 25-28 fractions.~Pelvic and para-aortic nodes known to contain gross/macroscopically visible disease and heavily involved parametria or tumor areas that may lie beyond the high-dose range of brachytherapy should be treated with additional small volume boost of EBRT to a total dose of 60-65 Gy using a combination of either sequential and/or concomitant boost. Fractions of 1.8-2 Gy can be used in the sequential boost."
224073795|NCT02501278|DRUG|Cisplatin chemotherapy|Cisplatin chemotherapy will be administered i.v. at a dose of 40 mg/m2 (total 5 cycles during week 1-5) weekly in concomitance with RT with the total dose not to exceed 70 mg per week.
224073796|NCT01662583|OTHER|Text Message|
224073797|NCT01662583|OTHER|Written reminder|
224073798|NCT03612271|BEHAVIORAL|mGlide|BP will be automatically transmitted to the providers. The transmitted BP will be used for adjustment of anti-HTN medications as it occurs in clinical practice.
224073799|NCT04264533|DRUG|VC|12g Vitamin C will be infused in the experimental group twice a day for 7 days by the infusion pump with a speed of 12ml/h.
224073800|NCT04264533|DRUG|Sterile Water for Injection|50ml sterile water for injection will be infused in the placebo comparator group twice a day for 7 days by the infusion pump with a speed of 12ml/h.
224073801|NCT01787357|DRUG|Canagliflozin (JNJ-28431754)|One 300 mg dose of canagliflozin (JNJ-28431754) (comprising one 100 mg over-encapsulated tablet and one 200 mg over-encapsulated tablet) taken orally (by mouth) on Day 1 of Treatment A. One 1,200 mg dose of canagliflozin (comprising six 200 mg over-encapsulated tablets) taken orally on Day 1 of Treatment B.
224187539|NCT04984161|OTHER|education|The aim of this project is to examine the effect of stoma care education on the knowledge and skill levels of pediatric surgery nurses about stoma care.
224187540|NCT04895423|DRUG|Methotrexate therapy|Methotrexate subcutaneously 10-15 mg/m2 once every 7 days within 12 months
224187541|NCT04895423|DRUG|Mycophenolate mofetil therapy|Mycophenolate mofetil per os 500-700 mg/m2 2 times a day within 12 months
224187542|NCT04895423|DRUG|Cyclosporine therapy|Cyclosporine per os 3 mg/m2 2 times a day within 12 months
224187543|NCT04895423|DRUG|Dupilumab therapy|Patients weighing \<30 kg received an initial dose of 600 mg (2 injections of 300 mg subcutaneously), then 300 mg every 4 weeks. Patients weighing 30 to \<60 kg received an initial dose of 400 mg (2 injections of 200 mg subcutaneously), then 200 mg every 2 weeks; Patients weighing 60 kg or more, the initial dose is 600 mg (2 injections of 300 mg subcutaneously), then 300 mg every 2 weeks.
224187544|NCT03754270|OTHER|Advice in lifestyle|Patients with moderate OSA according to a baseline nocturnal respiratory registration (NRR). Patients receive instructions and advice on lifestyle according to current clinical practice. Life style advice is quite subjective and it means that the patients are encouraged to stop smoking, to avoid alcohol, to lose weight, to be more physically active and to avoid sleeping on supine position.Patients fill in questionnaire 1 that includes questions about nocturnal respiratory disturbances, daytime sleepiness, insomnia, use of tobacco and alcohol, comorbidity and medication. After 6+/-2 weeks of treatment, patients fill in Questionnaire 2 which contains the same questions as Questionnaire 1 and also questions about any side effects, evaluation of treatment. In conjunction with visit 2 another NRR will be performed.
224187545|NCT03754270|DEVICE|Cervical collar|"Patients with moderate OSA according to a baseline nocturnal respiratory registration (NRR). Patients receive the same instructions and advice as in Arm lifestyle advice and also get a CC and instructions on how to sleep with it. CC is marketed for indications of various diseases such as traumatic cervical injury, cervical disc herniation and other neck problems and allows adjustment of the elevation level to achieve sufficient effect, i.e., extending the neck.Patients fill in questionnaire 1 that includes questions about nocturnal respiratory disturbances, daytime sleepiness, insomnia, use of tobacco and alcohol, comorbidity and medication. After 6+/-2 weeks of treatment, patients fill in Questionnaire 2 which contains the same questions as Questionnaire 1 and also questions about any side effects, evaluation of treatment. In conjunction with visit 2 another NRR will be performed."
224187546|NCT04187066|BEHAVIORAL|mindset induction|induction of a health mindset to measure changes in cue-dependent and goal-directed behavior
224187547|NCT05943132|BEHAVIORAL|Mediational Intervention for Sensitizing Caregivers (MISC)|MISC-CBO is a year-long semi-structured, manualized video-feedback caregiver intervention that targets key components in caregiver-child interactions known to improve caregiving quality and child outcomes. These components include emotional and cognitive components shown to improve socio-emotional and cognitive developmental outcomes in children.
224187548|NCT05943132|BEHAVIORAL|Treatment as Usual|Treatment as Usual includes general support for children in homework and nutrition.
224187549|NCT06012071|DEVICE|Zirconia dental implants|Dental implants produced from zirconia material, either wit tissue-level or bone-level platform.
224187550|NCT06369753|BEHAVIORAL|Biofeedback|Three sessions of biofeedback intervention will be performed during the first 3 weeks of the intervention period. Patients will be taught to control abdominal and thoracic muscular activity by providing instructions using an original video support. Patients will be instructed to perform the same exercises before and after breakfast, lunch and dinner during the 4-week intervention period
223496756|NCT01194310|PROCEDURE|phaco-ELT|Standard clear cornea phacoemulsification plsu intraocular lens Implantation (phaco) plus excimer laser trabeculotomy (ELT)
223496757|NCT01194310|PROCEDURE|phaco-Trabectome|Standard clear cornea phacoemulsification plsu intraocular lens Implantation (phaco) plus Trabectome
223496758|NCT01709344|BEHAVIORAL|PS-OT|
223496759|NCT01709344|OTHER|Usual care|Supportive and rehabilitation services available at DHMC
223496760|NCT04055519|DEVICE|Lehfilcon A contact lenses|Investigational silicone hydrogel contact lenses
223496761|NCT04055519|DEVICE|Comfilcon A contact lenses|Commercially available silicone hydrogel contact lenses
223496762|NCT04055519|DEVICE|Multi-purpose disinfection solution|Solution for cleaning, disinfecting, and reconditioning silicone hydrogel contact lenses
223496763|NCT05733299|DEVICE|aflo™ digital respiratory management platform|medical device, user app, clinician portal, data analytics hub
223496764|NCT05733299|OTHER|Standard care|Health service standard care will be continued
223496765|NCT01418898|OTHER|Dietary Intervention|Nutrient fortified oat beverage
223496766|NCT01669850|DEVICE|Clipped anastomosis|The vascular clip devise will be used to complete the anastomosis during fistula creation.
223496767|NCT01669850|PROCEDURE|Handsewn anastomosis|a handsewn anastomosis technique will be used during fistula creation.
223496768|NCT01326221|DRUG|tenofovir + emtricitabine|tenofovir 300mg + emtricitabine 200mg x one dose
223496769|NCT01460771|DEVICE|TDCS (Transcranial Direct-current Stimulation)|active TDCS
223496770|NCT01460771|DEVICE|sham TDCS (Transcranial Direct-current Stimulation)|TDCS at 0mA
223496771|NCT04627584|COMBINATION_PRODUCT|MW33 injection|a recombinant fully human antibody to coronavirus
223496772|NCT04627584|COMBINATION_PRODUCT|MW33 injection placebo|Placebo
223496773|NCT04419259|DRUG|AMG 334|30 subjects with rosacea will be allocated to receive monthly subcutaneous injections of 140 mg erenumab at three time points (week 0, week 4, week 8)
223496774|NCT04450875|DIETARY_SUPPLEMENT|Experimental group (with diet)|Two nutritionists performed both diet instruction and 24-hour reminder monitoring monthly. At the end of the three-month follow-up, the 24-hour reminder data such as food consumed, daily rations, and the monthly average of milligrams of consumed methionine contained in the food, were recorded in a database for subsequent analysis.
223496775|NCT05271487|OTHER|Multi-Step Botanical Skin Care Regimen|"The intervention includes 7 different topical products:~1. Cleanser~2. Toner~3. Oil Control Cream~4. Exfoliating Facial Scrub~5. Clay Mask~6. Acne Spot Treatment~7. Body Scrub"
223496776|NCT05838599|DRUG|Imiquimod|5% cream applied topically 5 days/week for 6 weeks
223496777|NCT05838599|RADIATION|Radiation Therapy|2 fractions of 4 Gys (total of 8 Gys) starting 1 week after Imiquimoid course over 2 days.
223496778|NCT04324840|DRUG|CC-90010|Specified dose on specified days
223745856|NCT06209892|PROCEDURE|Extended anticoagulation|This study plan will extend the duration of rivaroxaban 20mg in the experimental group to 12 months. The regular anticoagulation group will take the drug for 6 months
223745857|NCT01873001|DRUG|Pioglitazone HCl|15 mg tablet administered by mouth on Day 1, and Day 8 1 hour after study drug administration
223745858|NCT01873001|DRUG|Abiraterone acetate|1000 mg tablets administered by mouth on Day 8
224187551|NCT06369753|BEHAVIORAL|Placebo|Three sessions of placebo intervention will be performed during the first 3 weeks of the intervention period. Sham measurements of abdominal and thoracic motion will be performed, and a pill of placebo containing 0.21 g glucose will be administered; patients will be instructed to take a pill of placebo before breakfast, lunch and dinner during the 4-week intervention period.
223745859|NCT06267079|OTHER|core stability exercise|Each participant in the group (A) underwent eighteen sessions of core stability exercises very other day for one and half months, 3 sessions /week, each session for 1hour (30 minutes for core exercises then 30 minutes Selected physical therapy program).
223745860|NCT05188651|BEHAVIORAL|face masks|wearing face masks
223745861|NCT00772707|DEVICE|Multi-Purpose Disinfecting Solution (OPTI-FREE RepleniSH)|OPTI-FREE RepleniSH® used according to product labeled instructions for cleaning and disinfecting study contact lenses, 30 days.
224187552|NCT06372444|RADIATION|Positron emission tomography (PET)|Assessment of blood flow with marked water and assessment of neutrophil presence with neutrophil elastase tracer + CT
224187553|NCT04100863|OTHER|No Intervention|There is no intervention for this study.
224187554|NCT03110172|DRUG|Duloxetine Hydrochloride|The treatment group will receive duloxetine 60mg/24h to 8 weeks after operation
224187555|NCT01041742|PROCEDURE|fluid loading|fluid loading will be performed by using 6% hydroxyethyl starch solution , at 10 mL/kg.
224187556|NCT00383292|DRUG|tasisulam|Tasisulam dose is dependent on participant's height, weight, and gender and is adjusted to target a specific Cmax based on participant laboratory parameters. Tasisulam is administered intravenously every 28 days until disease progression or other criteria for participant discontinuation are met.
224187557|NCT06076902|DEVICE|Arthroscopic rotator cuff reconstruction using fixation with anchors augmented with a synthetic polyester patch (Pitch-Patch Tissue Reinforcement Device))|The Pitch-Patch is a single-use device intended to reinforce the rotator cuff following or during repair by sutures or suture anchors where weakness exists in the soft tissue.
224187558|NCT06076902|DEVICE|Arthroscopic rotator cuff reconstruction using fixation with anchors augmented without a synthetic polyester patch|Arthroscopic rotator cuff reconstruction using fixation with anchors and no augmentation with a synthetic polyester patch.
224187559|NCT06363552|DRUG|SC0191|The SC0191 tablet is taken orally at a dose of 300mg once daily. Each treatment cycle consists of 28 days. Medication is administered on days 1 to 3, days 8 to 10, days 15 to 17, and days 22 to 24 of each cycle.
224187560|NCT06363552|DRUG|SC0191 + Bevacizumab|"1. The SC0191 tablet is taken orally at a dose of 300mg once daily. Each treatment cycle consists of 28 days. Medication is administered on days 1 to 3, days 8 to 10, days 15 to 17, and days 22 to 24 of each cycle.~2. Bevacizumab injection is administered intravenously at a dose of 5mg/kg on day 1 and day 15 of each treatment cycle."
223745862|NCT00772707|DEVICE|Contact Lenses|Contact lenses per participant's habitual prescription removed nightly for cleaning and disinfecting.
223745863|NCT01454570|DEVICE|powered exoskeleton|
224187561|NCT06363552|DRUG|SC0191 + 5-FU/LV|"1. The SC0191 tablet is taken orally at a dose of 300mg once daily. Each treatment cycle consists of 28 days. Medication is administered on days 1 to 3, days 8 to 10, days 15 to 17, and days 22 to 24 of each cycle.~2. Calcium folinate 400mg/m2 intravenous infusion (over 2 hours or more), on the first day, followed by 5-fluorouracil 400mg/m2 intravenous bolus injection, then continuous intravenous infusion of 1200mg/m2/day for 2 days."
224187562|NCT06400823|OTHER|VR+TENS|"During the invention, patients will be in VR scenarios and play task-oriented games, interacting with elements that appear in the virtual world, to improve mobility and functional independence of the upper limbs.~The task-oriented games will target different components depending on the disability of the patient."
224187563|NCT06400823|OTHER|Conventional rehabilitation|Patients will perform conventional upper-limb stroke rehabilitation. The movement performed will be comparable with the movement performed in the VR+TENS group
223496779|NCT04324840|DRUG|Temozolomide|Specified dose on specified days
223496780|NCT04324840|RADIATION|Radiotherapy|Specified dose on specified days
223496781|NCT04547751|OTHER|targeted high-resolution mass spectrometry|"difference between the number of new substances identified using targeted analysis by liquid chromatography coupled with high-resolution mass spectrometry versus using targeted analysis. narcotics-new substance by liquid chromatography coupled with tandem mass spectrometry"
223496782|NCT04088253|PROCEDURE|umbilical herneal repair|reduction of the herneal content an repair of the defect with IPOM
223496783|NCT01052415|BEHAVIORAL|Cognitive behavioral sessions|Behavioral: Cognitive-behavioral, small group format sessions delivered in Chinese to service providers and HIV patients.
223496784|NCT01122953|DRUG|Phenytoin|Single dose of Phenytoin 125 mg/5 ml suspension made by Laboratorios Pfizer, S.A. de C.V.
223496785|NCT01122953|DRUG|Epamin|Single dose Epamin 125 mg/5 ml suspension made by McNeil LA LLC
223496786|NCT05411978|DRUG|Idebenone+ placebo|Participants will receive Idebenone 30 mg+ placebo 60 mg for 12 weeks.
223496787|NCT05411978|DRUG|Idebenone|Participants will receive Idebenone 90 mg for 12 weeks.
223496788|NCT05411978|DRUG|Placebo|Participants will receive Placebo 90 mg for 12 weeks
223496789|NCT01770964|DRUG|Pregabalin|
223496790|NCT01770964|DRUG|placebo|
223496791|NCT01770964|BEHAVIORAL|Training Type A|
223496792|NCT01770964|BEHAVIORAL|Training Type B|
223496793|NCT02883556|DRUG|Pembrolizumab|200 mg, administered as intravenous (IV) infusion every 3 weeks up to 24 months or until progression or unacceptable toxicity develops.
223496794|NCT00923312|BIOLOGICAL|CV9201|CV9201 is a vaccine consisting of five drug product components. Treatment will be administered on 5 timepoints.
223496795|NCT03205631|OTHER|Natural Frequency Patch|Participants will receive in randomized order the differing patches to wear during three nights separated by a washout period of 3-4 nights
223745864|NCT06057792|DEVICE|negative pulsed pressure AeroFlow system|"For the application of pulsatile negative pressure, the AeroFlow® equipment will be used, carried out by one of the researchers participating in the project.The application will be carried out addressing the structure of interest (scar), following the protocol established by INDIBA to release adhesions between the different depth planes. The work will consist of an application of pulsed negative pressure using suction cups, which will work automatically at a frequency and intensity tolerable by the patient.~Treatment protocol in 2 phases Total application time 15min~1. Static cup: preparation: Prepare the tissue surrounding the scar. 5min~2. Dynamic Cup: work: Lock the tissue around the scar and the scar itself.10min Suction mode: continuous with continuous sliding of the cup The number of treatment sessions will consist of a total of 6 sessions, so there will be two sessions over 3 weeks."
223590073|NCT07083414|DEVICE|elderly participant will receive digital educational oral health program.|"* Digital 3D Model Video: A custom-designed 3D animated video illustrating proper tooth brushing techniques tailored for elderly individuals, as well as comprehensive guidance on denture care.~* Written Educational Materials: Printed resources including posters and flyers that provide key messages and visual demonstrations related to maintaining good oral hygiene practices.~* PowerPoint Presentations and Educational Videos: Visual and audiovisual materials focusing on the importance of balanced nutrition in maintaining oral and general health, and early detection of oral cancer, including risk factors, signs, and recommended screening practices.~* Hands-on Brushing Technique Training: Practical sessions utilizing dental cast models to demonstrate and allow participants to practice effective brushing techniques under supervision."
223590074|NCT07083414|OTHER|elderly participant will receive the standard oral health education in geriatric institution.|The use of traditional health promotion materials, such as leaflets and posters, remains valuable in community settings. These tools are cost-effective, easy to produce, and continue to serve as effective educational resources for adults, including the elderly. Participants in the control group will receive standard oral health information. No education sessions will be conducted during the 6 months till the final assessment. However, after the final assessment at 6 months, the control group will be offered access to the digital educational program.
223590075|NCT07082959|BEHAVIORAL|Nursing Pillow|Although there are studies investigating the effects of breastfeeding pillow use on breastfeeding success, comfort, and positive outcomes for both mother and baby, no study has been found examining the effect of breastfeeding pillow use on nipple pain and maternal comfort in women who have undergone vaginal delivery. Therefore, the aim of this study is to evaluate the effect of breastfeeding pillow use on nipple pain and comfort during the postpartum period.
223590076|NCT07082894|DRUG|Magnesium|preoperative oral magnesium dose of 120 mg at one hour before surgery will be given.
223590077|NCT07082894|OTHER|Placebo control|preoperative oral lemon juice at one hour before surgery will be given.
223590078|NCT07087158|DRUG|IBR854|Every 21 days is one cycle, and IBR854 will be dosed in a route of intravenous infusion on day 1 and day 8 of each cycle with a fixed dose of 9.0×10\^9 cells.
223590079|NCT07087158|DRUG|Pazopanib|Pazopanib will be dosed orally once daily without food (at least 1 hour before or 2 hours after a meal) with a fixed dose of 800mg.
223590080|NCT00231413|BIOLOGICAL|HPV 16/18 L1 AS04|3 doses of 0.6 mL supplied as a liquid in individual pre-filled syringes administered intramuscularly in the deltoid muscle of the non-dominant arm, at Day 0, Month 1 and Month 6.
223590081|NCT00231413|BIOLOGICAL|HPV-16/18/31/45 L1 AS04 Formulation 1|3 doses of 0.6 mL supplied as a liquid in individual pre-filled syringes administered intramuscularly in the deltoid muscle of the non-dominant arm, at Day 0, Month 1 and Month 6.
223590082|NCT00231413|BIOLOGICAL|HPV-16/18/31/45 L1 AS04 Formulation 2|3 doses of 0.6 mL supplied as a liquid in individual pre-filled syringes administered intramuscularly in the deltoid muscle of the non-dominant arm, at Day 0, Month 1 and Month 6.
223745865|NCT05617560|OTHER|Telemedical care|Telemedical care will be provided to all participants after stationary hospital stay. This care will be in form of telephone consultations and / or videocall consultations with a medical physician. Depending on the individual medical history and the planned aftercare and procedure of the participants it will comprise of one or more such telephone consultations.
223745866|NCT04919954|DRUG|Tebipenem Pivoxil Hydrobromide|Tebipenem 300 mg or 600 mg will be administered orally every 8 hours for total of 3 to 7 doses
223745867|NCT01216579|OTHER|mannitol (an airway challenge agent)|
223745868|NCT06493864|DRUG|BL-B16D1|Administration by intravenous infusion for a cycle of 3 weeks.
223590083|NCT00231413|BIOLOGICAL|HPV-16/18/31/45 L1 AS04 Formulation 3|3 doses of 0.6 mL supplied as a liquid in individual pre-filled syringes administered intramuscularly in the deltoid muscle of the non-dominant arm, at Day 0, Month 1 and Month 6.
223590084|NCT00231413|BIOLOGICAL|HPV-16/18/31/45 L1 AS04 Formulation 4|3 doses of 0.6 mL supplied as a liquid in individual pre-filled syringes administered intramuscularly in the deltoid muscle of the non-dominant arm, at Day 0, Month 1 and Month 6.
223745869|NCT05824533|DEVICE|onlay patella button|Total knee arthroplasty (TKA) with a patella onlay button placed with a CORI Robotics System based on pre-operative 4DCT-imaging.
224073802|NCT01787357|DRUG|Placebo|Four over-encapsulated matching placebo tablets taken orally (by mouth) on Day 1 of Treatment A. Six over-encapsulated matching placebo tablets taken orally on Day 1 of Treatment C. Five encapsulated matching placebo tablets taken orally on Day 1 of Treatment D.
224073803|NCT01787357|DRUG|Moxifloxacin|One 400 mg over-encapsulated tablet of moxifloxacin taken orally (by mouth) on Day 1 of Treatment D.
224073804|NCT06016426|OTHER|Mass closure vs layer by layer closure of transverse laparotomy incisions in children and infants.|the transverse laparotomy incision in infants and children will be either closed as single layer included the peritoneum, posterior rectus sheath and anterior rectus sheath wit muscle sparing, or the laparotomy will be closed in layer by layer in which the peritoneum and posterior rectus sheath are closed as a layer and the anterior rectus sheath is closed as a seprate layer.
224073805|NCT05722665|OTHER|Categorization of chest xrays images|Use of Convolutional Neural Network Model to categorize chest xrays images in each group.
223745870|NCT05824533|PROCEDURE|Conventional procedure; NO onlay patella button|Total knee arthroplasty (TKA) placed with a CORI Robotics System based on pre-operative 4DCT-imaging.
223745871|NCT02165436|OTHER|Chewing gum|Subjective assessment - subjective assessment of abdominal pain and nausea.
223745872|NCT02165436|OTHER|Control|No intervention will be assessed for this group.
223745873|NCT01992861|PROCEDURE|Computed Tomography|Undergo FDG PET/CT
223496796|NCT02453022|DRUG|Danirixin HBr 50 mg IR Tablet|Danirixin HBr 50 mg IR Tablet is white, film-coated, oval-shaped tablet for oral administration.
223496797|NCT02453022|DRUG|Danirixin FB 50 mg IR Tablet|Danirixin FB 50 mg IR Tablet is white, film-coated, capsule-shaped tablet for oral administration.
223496798|NCT02453022|DRUG|Prilosec (omeprazole) 40mg Delayed-Release capsule|Prilosec (omeprazole) 40 mg delayed-release capsule is opaque, hard gelatin, apricot, and amethyst colored capsules, coded 743 on cap and PRILOSEC 40 on the body for oral administration.
223496799|NCT04801082|DRUG|Alcohol injection|Chemical ablation is performed by injection of 10 mL of 0.25% bupivacaine, followed by 10 mL of 98% dehydrated alcohol using a 22G FNA needle (Cook and Olympus)
223496800|NCT04801082|DEVICE|Radiofrequency Ablation|coeliac plexus is identified and punctured with 19G EUSRA RFA needle with 10W-30W of energy for 10-50s bilaterally or unilaterally depends on individual anatomical characteristics.
223496801|NCT00331487|DRUG|Pioglitazone|Pioglitazone 30 mg capsules, orally, once daily and placebo-matching capsules, orally, once daily for up to 12 weeks; increasing to pioglitazone 45 mg, capsules, orally, once daily and placebo-matching capsules, orally, once daily for up to 12 weeks
224187564|NCT04399499|DEVICE|MitraClip implantation|The MitraClip® procedure is performed under general anesthesia and orotracheal intubation. The procedure is usually guided by 2 and 3-dimensional transesophageal echocardiography and fluoroscopy. This catheter-based technology is inserted through femoral venous access and advanced in the left atrium through the transseptal puncture. The MitraClip® is provided by 2 arms able to grasp the anterior and posterior mitral leaflets. The goal is to approximate both leaflets creating a double orifice mitral valve mimicking the edge-to-edge surgical repair procedure (Alfieri stitch).
224187565|NCT06092112|DRUG|CD-801|The subjects with advanced HCC will be treated by 100 μg CD-801 through the hepatic artery injection at two-week intervals. The dosing interval will be adjusted based on subject tolerability, safety, and efficacy. For example, it may be adjusted to administer the medication once every three weeks or four weeks.
223496802|NCT00331487|DRUG|Rosiglitazone|Rosiglitazone 4 mg capsules, orally, once daily and placebo-matching capsules, orally, once daily for up to 12 weeks; increasing to rosiglitazone 4 mg, capsules, orally, twice daily for up to 12 weeks
223496803|NCT02797730|BEHAVIORAL|art-therapy sessions|
223496804|NCT07115355|PROCEDURE|Removable Uterine Compression Suture (RUCS)|Removable Uterine Compression Suture (RUCS) is a uterus-preserving surgical technique used to control postpartum hemorrhage (PPH) when medical management fails. The suture is placed in a way that allows for its removal after hemostasis is achieved, potentially reducing the risk of complications such as intrauterine synechiae. In this study, RUCS was applied to 11 patients following delivery-related hemorrhage.
223496805|NCT07115784|DRUG|Chlorhexidine Varnish|A 40% chlorhexidine varnish formulation (40% chlorhexidine, 36% sandarac, 24% ethanol) applied topically to the buccal surfaces of teeth in the selected upper quadrant. The varnish is applied using a blunt needle syringe before bonding and at monthly follow-up visits for three months. Teeth are dried before application, and patients are instructed not to eat or drink for 3 hours and to avoid brushing until the next day.
223590085|NCT00231413|BIOLOGICAL|HPV-16/18/31/45 L1 AS04 Formulation 5|3 doses of 0.6 mL supplied as a liquid in individual pre-filled syringes administered intramuscularly in the deltoid muscle of the non-dominant arm, at Day 0, Month 1 and Month 6.
223590086|NCT00231413|BIOLOGICAL|HPV-16/18/31/45 L1 AS04 Formulation 6|3 doses of 0.6 mL supplied as a liquid in individual pre-filled syringes administered intramuscularly in the deltoid muscle of the non-dominant arm, at Day 0, Month 1 and Month 6.
223590087|NCT07087938|DRUG|Cannabichromene|Participants will be assigned (using block randomization) to begin with one of the two study doses of CBC (400mg or 600mg). Participants will be blinded to dose. They will be asked to take half of their dose in the morning and half in the evening. Participants will be administered dose one for eight weeks. After this, participants will have a two-week timeframe where they will be asked not to take any study medication and to continue refraining from cannabis use, thus providing a washout period. Then, at visit three, they will receive dose two and will take it for eight weeks, concluding the study with another two-week washout period. At each clinic visit participants will complete assessments (self-report and physical examination), urine, and blood samples.
223590088|NCT07088588|DRUG|SYN608|Patients will orally receive SYN608
223590089|NCT07089446|DRUG|Hyaluronic Acid (HA)|Hyaluronic Acid
223745874|NCT01992861|PROCEDURE|Diffusion Weighted Imaging|Undergo DW MRI
223745875|NCT01992861|PROCEDURE|Dynamic Contrast-Enhanced Magnetic Resonance Imaging|Undergo DCE MRI
223745876|NCT01992861|RADIATION|Fludeoxyglucose F-18|Undergo FDG PET/CT
223745877|NCT01992861|PROCEDURE|Magnetic Resonance Spectroscopic Imaging|Undergo MR spectroscopy
223745878|NCT01992861|PROCEDURE|Positron Emission Tomography|Undergo FDG PET/CT
223496806|NCT07115784|DRUG|Placebo Varnish|A placebo varnish composed of 60% sandarac and 40% ethanol applied topically in the same manner and frequency as the chlorhexidine varnish. Used on the opposite quadrant of the same patient in a split-mouth design. Participants are blinded to whether chlorhexidine or placebo was applied.
223496807|NCT07114835|PROCEDURE|Cycling with Blood Flow Restriction (15 min at 40% VO₂max with 60-80% LOP)|This intervention involves low-intensity cycling exercise at 40% of VO₂max performed on an electronically braked Astrand cycle ergometer for 15 minutes per session. During each session, pneumatic cuffs (10 cm wide, manually adjustable) are applied to the upper thighs to restrict blood flow. Individualized limb occlusion pressure (LOP) is determined via Doppler ultrasound and set progressively at 60% (weeks 1-4), 70% (weeks 5-7), and 80% (weeks 8-9). Sessions are conducted three times per week over a 9-week period. The aim is to simulate the physiological effects of high-intensity training using a low-intensity protocol.
223590090|NCT07089446|DRUG|Platelet Rich Plasma|Platelet rich plasma
223590091|NCT07089446|DRUG|Hyaluronic Acid (HA) and Platelet rich plasma|Hyaluronic Acid and Platelet rich plasma
223590092|NCT07087392|PROCEDURE|Inverted-Ω Anastomosis|After meeting the inclusion and exclusion criteria, duodenum-preserving pancreatic head resection or mid-pancreatic resection will be performed, and inverted-Ω anastomosis will be carried out during the operation for the reconstruction of the digestive tract
223590093|NCT07089368|DRUG|Zn(II)-phthalocyanine gel|Topical application of RLP068/Cl 0.3% gel (Zn(II)-phthalocyanine) at a dose of 1 mL per 25 cm² under occlusion for 30 minutes, followed by red light irradiation at 630 nm (60 J/cm²) for 8 minutes. Sessions will be repeated twice weekly until clinical response is achieved.
223496808|NCT07114835|PROCEDURE|Cycling Exercise (40 min at 40% VO₂max)|This intervention involves standard low-intensity cycling exercise at 40% of the participant's VO₂max, performed for 40 minutes per session on an electronically braked Astrand cycle ergometer. Sessions are conducted three times per week for a total duration of 9 weeks. This group does not receive any blood flow restriction or external loading. The aim is to observe the effects of traditional low-intensity, long-duration aerobic exercise on VO₂max, muscle strength, and muscle thickness.
223496809|NCT07114835|PROCEDURE|Short-Duration Cycling Control (15 min at 40% VO₂max)|This intervention involves low-intensity cycling exercise at 40% of VO₂max performed for 15 minutes per session, using an electronically braked Astrand cycle ergometer. Participants exercise three times per week for 9 weeks. No blood flow restriction is applied. The aim of this control condition is to match the duration of the BFR intervention while omitting the occlusion component, to isolate the effect of BFR.
223496810|NCT07118735|DIETARY_SUPPLEMENT|A standardized extract of cultured Lentinula edodes mycelia (AHCC®)|3 grams of AHCC® taken orally once daily for 6 months or until disease progression or intolerance
223496811|NCT07118735|DIETARY_SUPPLEMENT|Placebo|3 grams of dextrin (placebo) taken orally once daily for 6 months or until disease progression or intolerance
223496812|NCT07116902|DEVICE|phone application|Participants in the digital twin arm will receive information on their disease progression which will be based on projected change in HbA1C in alternative realities and specific recommendations on medication dosing and lifestyle changes based on this data. The digital twin information will be presented on an iPad in a game- like manner. The alternate realities will include scenarios of change in medication adherence, physical activity metrics, dietary changes etc.
223496813|NCT07116902|OTHER|Standard of Care (SOC)|Participants in the control arm will receive standard of care which is medication change recommendations based on HbA1C and blood glucose values every 3 months and standard lifestyle education.
223496814|NCT07121270|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|Cognitive Behavioral Therapy for Insomnia (CBT-I) is delivered via 6 weekly 60-min sessions via telemedicine. CBT-I is a multisession treatment approach that focuses on sleep-specific behaviors and thoughts through various methods.
223496815|NCT07121270|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia and Nightmares|Cognitive Behavioral Therapy for Insomnia and Nightmares (CBT-I\&N) is a combination of CBT for Insomnia (CBT-I) and Exposure, Relaxation, and Rescripting Therapy used for the treatment of nightmares (ERRT). CBT-I\&N is delivered via 6 weekly 60-min sessions via telemedicine and includes the modification of sleep habits, exposure, and progressive muscle relaxation.
223496816|NCT07121270|BEHAVIORAL|Sleep Education|Sleep education is delivered via telemedicine via 6 weekly 60-min sessions. These sessions will be focused on psychoeducation on sleep after trauma, including common sleep disturbances that may emerge and sleep hygiene guidelines to minimize these disruptions (e.g., wind-down routine, avoid caffeine).
223496817|NCT07121270|BEHAVIORAL|Sleep Education enhanced with Nightmare Education|Sleep education enhanced with nightmare education will include all the components of normal sleep education, as described above, in addition to normalizing the experience of nightmares after trauma and providing psychoeducation on nightmares. The treatment is provided over 6 weekly 60-min sessions via telemedicine.
223496818|NCT07121075|DEVICE|Dynamic arm support|The participant will receive a new dynamic arm support.
223496819|NCT07118566|PROCEDURE|Hyperthermia|Each session of hyperthermia should be spaced at least 24 hours apart, with at least one session administered prior to ICI (immune checkpoint inhibitor) treatment. Five times q3w.
223590094|NCT07087678|DEVICE|Prodigy internal pulse generator occipital nerve stimulator|Electrical stimulation of the occipital nerves using an implantable device
223590095|NCT00885781|DRUG|lipid emulsion for TPN|1-2 g lipid emulsion /kgBW-day, for consecutive 5 days
223590096|NCT04980365|BEHAVIORAL|Mindfulness|Participants will be asked to use the app Mindfulness Coach daily for 10 minutes. Participants will follow app instructions for brief guided meditation sessions for 14 days.
223496820|NCT07118566|DRUG|Immunotherapy|iv，d1，q3w
223496821|NCT07119463|DRUG|Human Serum Albumin Infusion for LAT Group|Participants in this group will receive human serum albumin infusion when their serum albumin level falls below 25 g/L. The infusion is goal-oriented, with the aim of maintaining albumin levels above 25 g/L during the postoperative period. The dose is calculated based on the albumin deficit and patient weight to ensure optimal therapeutic effect.
223496822|NCT07119463|DRUG|Human Serum Albumin Infusion for HAT Group|Participants in this group will receive human serum albumin infusion when their serum albumin level falls below 30 g/L. The intervention aims to maintain albumin levels above 30 g/L during the postoperative period. The dose is similarly calculated based on the albumin deficit and patient weight.
223590097|NCT04980365|BEHAVIORAL|Gratitude|Participants will be asked to use the app Grateful daily for 10 minutes. Participants will follow app instructions and will be answering to prompts related to gratitude provided by the app daily, for 10 minutes for 14 days.
223590098|NCT04980365|BEHAVIORAL|Food Journal|Participants will be asked to use the app Day One daily for 10 minutes. Participants will be writing a daily journal entry describing what they ate during the previous day for 14 days.
223590099|NCT01916850|DRUG|LX4211 400 mg|
223590100|NCT01916850|DRUG|LX4211 800 mg|
223590101|NCT01916850|DRUG|LX4211 Placebo|
223590102|NCT01940393|DRUG|Cetirizine|Drug administration
223590103|NCT01940393|DRUG|Desloratadine|Drug Administration
223590104|NCT01940393|DRUG|Fexofenadine|Drug administration
223590105|NCT01940393|DRUG|Ebastine|Drug administration
223590106|NCT01940393|DRUG|Bilastine|Drug administration
223590107|NCT00652886|DRUG|Oxandrolone|Tablets, 10mg, single-dose
223590108|NCT00652886|DRUG|Oxandrin|tablets, 10mg, single-dose
223590109|NCT04690244|OTHER|Tai Chi Chuan trainings|10 weeks of Tai Chi Chuan practice by 6-year experienced training teacher, 2 times per week, 60 min per session.
223590110|NCT02207257|DRUG|PER977|Reversal of edoxaban-induced anticoagulation
223590111|NCT02207257|DRUG|Placebo|Reversal of edoxaban-induced anticoagulation
223590112|NCT02207257|DRUG|Edoxaban|
224073806|NCT01543087|PROCEDURE|blood sampling|Blood sample collection at different time points
224073807|NCT01543087|DRUG|bivalent rLP2086|A booster dose of bivalent rLP2086 at approximately 48 months following the final dose of the 2- or 3-dose primary bivalent rLP2086 vaccination series will be given at Visit 7.
224187566|NCT05997992|DEVICE|electroacupuncture|Electroacupuncture is a form of acupuncture where a small electric current is passed between pairs of acupuncture needles. According to some acupuncturists, this practice augments the use of regular acupuncture, can restore health and well-being, and is particularly good for treating pain.
224187567|NCT05997992|DEVICE|sham acupuncture|Acupuncture does not penetrate the skin, and the electroacupuncture machine is not plugged in.
224187568|NCT05297604|RADIATION|Vascular photobiomodulation (VPBM)|The participants received a 20-minute single session of VPBM. This noninvasive method involves the use of low-power laser coupled to a bracelet designed to transport the light beam transcutaneously over the radial artery. The laser device (DMC Therapy Ec) delivered irradiation with a power of 100 ± 20 mW, wavelength of 660 ± 10 nm (red light) and energy of 120 J applied continuously, with irradiance of 35 W/cm².
224187569|NCT05297604|RADIATION|Sham group (simulated vascular photobiomodulation)|Simulated radiation. The participants received a single session.
223496823|NCT07125482|OTHER|bed exercise group|"In the first interview, demographic data and other patient information will be collected from the patient record file between 07-08 in the morning before starting bed exercise and nutrition, and the Patient Information Form and Comfort Behavior Checklist, Wong-Baker Face Pain Scale, 'Enteral Nutrition Monitoring Form' will be filled in by the researcher before the intervention and nutrition (1st Interview).~* In the first interview, bed exercises will be applied by the researcher for approximately 15 minutes before nutrition between 07-08 in the morning (1st Interview).~* In the second interview, bed exercises will be repeated for approximately 15 minutes after filling out the 'Enteral Nutrition Monitoring Form' before bed exercise and nutrition between 07-08 in the morning (2nd Interview).~* In the third interview, bed exercises will be repeated for approximately 15 minutes after filling out the 'Enteral Nutrition Monitoring Form' before bed exercise and nutrition between 07-08 in"
223496824|NCT07125482|OTHER|abdominal massage|"* In the first interview, between 07-08 in the morning, demographic data and other information about the patients will be collected from the patient record file before the intervention and feeding by the researcher using the Patient Information Form and Comfort Behavior Checklist, Wong-Baker Facial Pain Scale, 'Enteral Feeding Monitoring Form' (Interview 1).~* In the first interview, between 07-08 in the morning, abdominal massage will be applied to the patient by the researcher for approximately 15 minutes before feeding (Interview 1).~* In the second interview, between 07-08 in the morning, abdominal massage will be repeated for approximately 15 minutes by filling out the 'Enteral Feeding Monitoring Form' before feeding and abdominal massage will be repeated (Interview 2).~* In the third interview, between 07-08 in the morning, the 'Enteral Nutrition Monitoring Form' will be filled out before abdominal massage and feeding, and the abdominal massage will be repeated for approxim"
223496825|NCT07125482|OTHER|control group|"In the first interview, between 07-08 am, demographic data and other patient information will be collected from the patient record file before feeding, using the Patient Information Form and the Comfort Behavior Checklist, Wong-Baker Facial Pain Scale, 'Enteral Feeding Monitoring Form', before the intervention and feeding (Interview 1).~* In the second interview, between 07-08 am, the 'Enteral Feeding Monitoring Form' will be filled out before feeding (Interview 2).~* In the third interview, between 07-08 am, the 'Enteral Feeding Monitoring Form' will be filled out before feeding (Interview 3).~* In the fourth interview, between 07-08 in the morning, data will be collected with the Comfort Behavior Checklist, Wong-Baker Facial Pain Scale and 'Enteral Feeding Monitoring Form' before feeding (Interview 4)."
223496826|NCT07124416|OTHER|No intervention|No intervention: observational case-control study
223496827|NCT06748547|PROCEDURE|scalp nerve block|scalp nerve block is performed bilaterally by an anesthesiologist after induction of anesthesia and 5 minutes before head immobilization, according to the technique described by Pinosky et al. Prepare a syringe (20 mL) for scalp blocks. It is performed using 0.35% bupivacaine and 5 mcg epinephrine (1:2,000,000) using a 23-gauge needle inserted at a 45° angle to the skin and penetrating deeply into the outer edge of the scalp.
223496828|NCT04377295|DRUG|Ranibizumab 0.5Mg/0.05Ml Oph Inj|All patients received one monthly intravitreal injection of Ranibizumab (0.5 mg/0.05 ml) through the pars plana under aseptic conditions until maximum visual acuity was achieved and there was no sign of macular edema at optical coherence tomography
223496829|NCT01173172|RADIATION|Boron Neutron Capture Therapy|Boronophenylalanine (BPA) 500 mg/kg on D1 and D30 followed by BNCT for 2 fractions (D1 and D30)
223496830|NCT06514131|PROCEDURE|Pre-moistened wipes|Patients receiving the experimental treatment will have perineal hygiene performed with the pre-moistened wipes without water
223590113|NCT05207683|OTHER|echocardiography|All the patients will be subjected to thorough medical history and clinical examination and the results of the previous investigations will be collected aiming for reaching the diagnosis of the etiology of pulmonary hypertension. ct pulmonary angiography and then right heart catheterization will be done in case of undiagnosed etiology.
223590114|NCT02700594|OTHER|Joint mobilization|"Mobilization and manipulation are manual therapy techniques comprising a continuum of skilled passive movements to the joints and/or related soft tissues that are applied at varying speeds and amplitudes, including a small-amplitude/high- velocity therapeutic movement.16 The term joint mobilization, or nonthrust mobilization, often refers to slow, rhythmic, repetitive passive movements to the patients' tolerance, in voluntary and/or accessory range and graded according to examination findings."
223590115|NCT03001687|DIETARY_SUPPLEMENT|enteral supplementation with vitamin D|"Patients allocated to the vitamin D + group receive enteral supplementation with high-dose vitamin D (250.000UI)"
224187570|NCT06361381|DEVICE|Active Transcutaneous Auricular Vagus Nerve Stimulation (TaVNS)|"Both concha will be swabbed with an alcohol wipe before applying a thin layer of conductive gel. An ear clip electrode will be placed in the concha of both ears.~A frequency of 25 Hz will be applied with a pulse duration of 200 µs. Every 5 minutes, the subject will be asked if the intensity can be increased, decreased or remain the same to maintain the same level of intensity. Participants will also receive active TENS, 100 Hz, 200 µsec on forearm."
224187571|NCT06361381|DEVICE|Placebo Transcutaneous Auricular Vagus Nerve Stimulation (TaVNS)|For placebo TaVNS, the intensity will be increased to a sensory level and then decreased to 0 mA. Participants will also receive active TENS, 100 Hz, 200 µsec on forearm.
224187572|NCT06361381|DEVICE|Transcutaneous Electrical Nerve Stimulation|TENS will be applied on subject's forearm at a strong but comfortable intensity
224187573|NCT05856916|DIETARY_SUPPLEMENT|Creatine monohydrate|Creatine monohydrate will be self-administered by an oral route at a dose of 5g/day in powdered form. Administration will begin on Study Day 1 and continue for 10 weeks.
224187574|NCT05856916|DIETARY_SUPPLEMENT|Placebo|Placebo (in the form of lactose) will be self-administered by an oral route at a dose of 5g/day in powdered form. Administration will begin on Study Day 1 and continue for 10 weeks.
224187575|NCT00000912|DRUG|Indinavir sulfate|
224187576|NCT00000912|DRUG|Abacavir sulfate|
224187577|NCT00000912|DRUG|Amprenavir|
224187578|NCT00000912|DRUG|Nelfinavir mesylate|
224187579|NCT00000912|DRUG|Efavirenz|
224187580|NCT00000912|DRUG|Levocarnitine|
223496831|NCT01741870|DIETARY_SUPPLEMENT|Nutritional supplement|Subjects will receive 50 g/day of a soy protein-based nutritional supplement containing 9.5 g protein, 250 kcal energy and all essential micronutrients
223496832|NCT01741870|OTHER|Treatment as usual|routine care
223496833|NCT07117032|OTHER|Simulation-free workflow|Pre-existing diagnostic images (CTs, PET/CTs, or MRIs) will be imported into the online treatment planning system called Ethos. The Ethos platform and online adaptive radiation therapy (ART) will be utilized at the time of treatment planning and delivery.
224187581|NCT00000912|DRUG|Adefovir dipivoxil|
224187582|NCT00000912|DRUG|Saquinavir|
224187583|NCT03301272|DRUG|Onabotulinumtoxin A Injection|Reconstituted 10 units/0.1 mL. Administered intramuscular once
224187584|NCT03301272|OTHER|Placebo|0.9% normal saline solution, mimicking Botox injection paradigm. Administered intramuscular once.
224187585|NCT04297111|DIETARY_SUPPLEMENT|Probiotic|GanedenBC30 (Bacillus coagulans GBI-30, 6086) capsule made of 1 billion colony forming units (cfu). Description: pure cell mass of an L-(+) lactic acid-producing, gram-positive, spore-forming shaped bacterium that is aerobic to microaerophilic. Maltodextrin used as filler.
223496834|NCT07117032|RADIATION|Celiac plexus SBRT|Participants will receive SBRT per standard of care. This treatment visit will take up to 1.5 hours.
223496835|NCT07125196|OTHER|Data collection and self-administered questionnaire|Exhaustive collection of data in a health data warehouse: collection of clinical, radiological examinations (standard of care), and self-administered questionnaire: a questionnaire concerning the psychological state of the patients (questionnaire according to DSM V) and a questionnaire on nutritional status.
223496836|NCT07085702|BIOLOGICAL|Low dose Strep A Alum|Low dose Strep A Alum vaccine will be administered intramuscularly (IM)
223496837|NCT07085702|BIOLOGICAL|Medium dose Strep A Alum|Medium dose Strep A Alum vaccine will be administered IM
223496838|NCT07085702|BIOLOGICAL|High dose Strep A Alum|High dose Strep A Alum vaccine will be administered IM
223496839|NCT07085702|BIOLOGICAL|Low dose Strep A AS37|Low dose Strep A AS37 vaccine will be administered IM
223496840|NCT07085702|BIOLOGICAL|Medium dose Strep A AS37|Medium dose Strep A AS37 vaccine will be administered IM
223496841|NCT07085702|BIOLOGICAL|High dose Strep A AS37|High dose Strep A AS37 vaccine will be administered IM
223496842|NCT07085702|DRUG|Strep A Alum Placebo|Strep A Alum Placebo will be administered IM
223496843|NCT06905067|OTHER|questionnaire and dental clinical examination|Assessment of the DMFT index
223496844|NCT07090863|DEVICE|AM manufacturing method|additively manufactured implant-supported prostheses
223496845|NCT07090863|DEVICE|SM manufacturing method|subtractively manufactured implant-supported prostheses
223496846|NCT06909110|BIOLOGICAL|Adenovirus Specific T- Lymphocytes|Peripheral blood mononuclear cells will be collected from the donor and loaded onto our Miltenyi Biotec CliniMACS Prodigy® or CliniMACS® Plus where they will be stimulated in vitro with Adenovirus viral-specific antigen(s). The cells are then immunomagnetically labeled with interferon gamma via the cytokine capture system, captured and infused.
223496847|NCT06909110|BIOLOGICAL|Cytomegalovirus Specific T-Lymphocytes|Peripheral blood mononuclear cells will be collected from the donor and loaded onto our Miltenyi Biotec CliniMACS Prodigy® or CliniMACS® Plus where they will be stimulated in vitro with Cytomegalovirus viral-specific antigen(s). The cells are then immunomagnetically labeled with interferon gamma via the cytokine capture system, captured and infused.
223496848|NCT06909110|BIOLOGICAL|Epstein-Barr Virus Specific T-Lymphocytes|Peripheral blood mononuclear cells will be collected from the donor and loaded onto our Miltenyi Biotec CliniMACS Prodigy® or CliniMACS® Plus where they will be stimulated in vitro with Epstein-Barr viral-specific antigen(s). The cells are then immunomagnetically labeled with interferon gamma via the cytokine capture system, captured and infused.
223496849|NCT06901687|DEVICE|Active tDCS|tDCS is a noninvasive brain stimulation technique that delivers a low-intensity electrical current (2.0 mA) through sponge electrodes placed on the scalp. For Active tDCS, the device is programmed to ramp up to 2.0 mA (for 30 seconds), provide constant current throughout session (29 minutes), and then ramp down (for 30 seconds) at the end.
223496850|NCT06901687|DEVICE|Sham tDCS|tDCS is a noninvasive brain stimulation technique that delivers a low-intensity electrical current (2.0 mA) through sponge electrodes placed on the scalp. For Sham tDCS (or placebo) the device is programmed to ramp up to 2.0 mA (for 30 seconds) followed by a ramp down (30 seconds), with no current delivery for 28 minutes, and then ramp up (for 30-s) and down (for 30-s) at the end.
223496851|NCT06332560|BEHAVIORAL|Anti-inflammatory diet (DI)|12-week personalized dietary advice based on the Dutch Dietary Guidelines under the guidance of a dietician.
223496852|NCT06332560|BEHAVIORAL|Cognitive behavioral therapy (CBT)|Seven individual sessions led by a psychotherapist. The content of the CBT will be psycho-education regarding pain mechanisms and DI.
223496853|NCT07090811|DEVICE|Aortic valve repair/replacement|TAVR or valvuloplasty using the Fusion System for delivery of the treatment system and for temporary rapid pacing
223590116|NCT03001687|OTHER|blood collection 3mL|all patients will have hepcidin levels measured in the first 24 hours after admission and one week after
223590117|NCT04029818|BIOLOGICAL|Bifidobacterium BSL_PS404|Each participant will consume 1 capsule daily at lunch for 8 weeks.
223590118|NCT04029818|BIOLOGICAL|Placebo|Each participant will consume 1 capsule daily at lunch for 8 weeks.
223590119|NCT00438334|DEVICE|Programmable directional/omni-directional hearing aid|
223590120|NCT01656694|DEVICE|DePuy Sigma HP Partial Knee|
224187586|NCT04297111|OTHER|Placebo|Maltodextrin capsule, no active ingredient
224187587|NCT05630326|OTHER|comparing, prevalence|Comparing infants with UTIs caused by ESBL organism, or non ESBL organism.
224187588|NCT05630326|OTHER|assessment|comparing infants with UTIs caused by ESBL organism, or non ESBL organism.
224187589|NCT05630326|OTHER|association|comparing ESBLUTI with COVID-19 and ESBL UTI without COVID-19
224187590|NCT05630326|OTHER|evaluation|comparing ESBLUTI with COVID-19 and ESBL UTI without COVID-19
223590121|NCT05191953|PROCEDURE|Bilateral ultrasound-guided ESPB|"Bilateral ultrasound-guided ESPB (total of 40 ml, 0.25% bupivacaine) will be performed.~Intraoperative analgesia:~At the end of the surgery, all patients will be given 0.05 mg/kg morphine IV. Postoperative analgesia: Paracetamol 1 gr IV (every 6 hours) and IV PCA of 0.5 mg/ml morphine (demand dose 20μg/kg; lock out interval 6-10 min.; the 4-hour limit will be 80% of the total calculated dose). In cases where rescue analgesia is required (NRS score ≥4) tramadol 100 mg IV will be infused within 30 minutes (max. 300 mg / day). For postoperative nausea and vomiting prophylaxis, patients will be routinely administered ondansetron 4 mg IV 20 minutes before extubation, in the intensive care unit."
223590122|NCT05191953|PROCEDURE|Bilateral ultrasound-guided ESPB and superficial PIPB|"Bilateral ultrasound-guided ESPB (total of 40 ml, %0.25 bupivacaine) and Superficial PIPB (total of 20 ml, %0.25 bupivacaine) will be performed.~Intraoperative analgesia:~At the end of the surgery, all patients will be given 0.05 mg/kg morphine IV. Postoperative analgesia: Paracetamol 1 gr IV (every 6 hours) and IV PCA of 0.5 mg/ml morphine (demand dose 20μg/kg; lock out interval 6-10 min.; the 4-hour limit will be 80% of the total calculated dose). In cases where rescue analgesia is required (NRS score ≥4) tramadol 100 mg IV will be infused within 30 minutes (max. 300 mg / day). For postoperative nausea and vomiting prophylaxis, patients will be routinely administered ondansetron 4 mg IV 20 minutes before extubation, in the intensive care unit."
224187591|NCT06112366|PROCEDURE|Surgery of impacted mandibular wisdom teeth|All surgical procedures were performed by the same surgeon using the standard surgical technique described below. The anesthetic used was 4% articaine with 1:100,000 adrenaline. In all patients, a sulcus incision was made in the lower second molar and an envelope incision in the third molar region, the mucoperiosteal flap was removed, and extraction was performed with a bone elevator and a third molar elevator. If necessary, the impacted molar was incised with a high-speed dental handpiece and a fissure bur. The wound was irrigated with saline and the wound edges were sealed with tissue adhesive containing cyanoacrylate.
223496854|NCT06864273|BEHAVIORAL|Pharmacy Technician Educational Training|Pharmacy Technicians will participate in a stepped-wedge educational training program. The first step will be a control condition where they will receive no training, the second step will include viewing online modules, the third step will include online discussions, and the fourth step will include practical experiences with adults with bilateral hearing loss. Pre-training quizzes and surveys will be completed before and after each step.
223496855|NCT06825702|DRUG|KIO-104|KIO-104 is an ophthalmic formulation for IVT injection of the active pharmaceutical ingredient (API) KIO-100, a novel, non-steroidal, small molecule inhibitor of dihydroorotate dehydrogenase (DHODH).
223496856|NCT06909565|DRUG|Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL|300 mg (equivalent to 284 mg inclisiran) in 1.5 mL subcutaneous injection at Day 0; Day 90; \& every 6 months thereafter
223496857|NCT06909565|DRUG|Normal Saline (Placebo)|Normal saline placebo subcutaneous injection given at Day 0, Day 90; \& every 6 months thereafter
223496858|NCT07100366|BEHAVIORAL|ChatGPT|Phase 3:In Experimental Group 1, participants will be invited to use the ICT app, which they are encouraged to engage with for at least 15 minutes daily. This app is designed to actively monitor the users' emotional status and automatically notify both the research team and family members if any negative mood is detected.
223496859|NCT07100366|BEHAVIORAL|community social|Phase 3:In Experimental Group 2, participants will be encouraged to increase their social participation through community-based activities, while the Control Group will continue with their routine lifestyle.
223496860|NCT07104240|OTHER|Best Practice|Offer standard of care adolescent vaccination promotion practices
223496861|NCT07104240|OTHER|Educational Intervention|Receive vaccination information
223496862|NCT07104240|OTHER|Health Promotion and Education|Receive all TweenVax components and trainings for the practice, providers and staff, parents and adolescents
223496863|NCT07104240|OTHER|Health Promotion and Education|Receive components and trainings for the practice and provider levels
223496864|NCT07104240|OTHER|Internet-Based Intervention|Receive access to TweenVax application
223496865|NCT07102940|DRUG|Eftilagimod Alfa (Efti)|Eftilagimod Alfa (Efti) will be administered subcutaneously at a dose of 30 mg beginning of week 1 of the trial for a total of 3 doses (week 1, 2 and 3). After 3 weeks, efti will be administered starting with week 4, every 2 weeks and combined with either TC or AC
223496866|NCT07102940|DRUG|Docetaxel-cyclophosphamide (TC) intravenous (i.v)|"TC will be administered at docetaxel 75mg/m2 IV and cyclophosphamide 600mg/m2 IV every 3 weeks for a total of 4 administrations starting on week 4 of the trial (weeks 4, 7,10, and 13).~Docetaxel is administered over 60min (dilute in 250 mL NS or D5W to a final concentration of 0.3 to 0.74 mg/mL and administer over 60 minutes).~Cyclophosphamide is administered over 30-60min (dilute in 250 to 500 mL NS or D5W and administer over 30 to 60 minutes after docetaxel).~G-CSF support for TC is per institutional SOC guidelines. Efti is to be given always ≥ 30 minutes after TC is finished if both regimens are administered the same day."
223496867|NCT07102940|DRUG|Dose dense Adriamycin-cyclophosphamide (AC) i.v|"AC will be administered at doxorubicin 60mg/m2 and cyclophosphamide 600mg/m2 IV every 2 weeks for a total of 4 administrations starting week 4 of the trial (weeks 4, 6, 8 and 10):~Doxorubicin is administered over 5 min (Dilute with NS to a final concentration of 2 mg/mL and administered as an IV bolus over three to five minutes into a free flowing IV infusion of NS or D5W).~Cyclophosphamide is administered over 30-60min (Dilute in 250 to 500 mL NS or D5W and administer over 30 to 60 minutes).~G-CSF support is per SOC/institutional guidelines.~Paclitaxel is given weekly for a period of 12 weeks (weeks 12 to 23) at 80mg/m2 (Dilute with 250 to 500 mL NS or D5W (final concentration of 0.3 to 1.2 mg/mL) and administered per institutional guidelines). Alternatively nab-paclitaxel weekly can be used (if paclitaxel cannot be used due to allergic reaction).~Efti is to be given always ≥ 30 minutes after AC or paclitaxel is finished if both regimens are administered the same day."
224187592|NCT06112366|PROCEDURE|Surgery of impacted mandibular wisdom teeth (the other side)|All surgical procedures were performed by the same surgeon using the standard surgical technique described below. The anesthetic used was 4% articaine with 1:100,000 adrenaline. In all patients, a sulcus incision was made in the lower second molar and an envelope incision in the third molar region, the mucoperiosteal flap was removed, and extraction was performed with a bone elevator and a third molar elevator. If necessary, the impacted molar was incised with a high-speed dental handpiece and a fissure bur. The wound was irrigated with copious amounts of saline, and the wound edges were carefully sutured with simple 4.0 silk braided non-absorbable sutures.
224187593|NCT03457701|DRUG|Daprodustat|Daprodustat will be available as 1 milligram (mg), 2 mg and 4 mg tablets strengths. One tablet to be taken daily without regard for food.
223496868|NCT07105384|COMBINATION_PRODUCT|Radiotracer|Patients will receive a brain tau radiotracer
223496871|NCT07104981|PROCEDURE|Mesenchymal Stem Cell Transplantation|intraoperative infiltration of micronized adipose tissue obtained using the Matrigen system.
223496872|NCT07103642|DRUG|BGF|BUDESONIDE/GLYCOPYRRONIUM/FORMOTEROL
223496873|NCT07105189|DEVICE|Wireless monitoring|"Patients included in the study will be continuous monitored by CPC12S is a wearable sensor that is worn on the chest using electrodes measuring electrocardiography single lead (ECG), Heart rate, respiratory rate, SpO2, blood pressure and temperature.~The system calculates the heart rate by analysing R-peaks of QRS-complexes in the raw ECG data.~Respiratory rate is recorded using impedance pneumography. SpO2 is determined by analysing the photoplethysmogram (PPG) wave. Blood pressure is derived by calculating the pulse transit time (PTT) using R-peaks from the QRS complexes, peaks in the photoplethysmogram (PPG) pulse waves, and timing of the second heart-tone corresponding to the dicrotic notch, measured by a stethoscope in the device.~Temperature is measured by a thermistor placed in the axilla. Vital signs are updated every 20 seconds and measurements are transmitted via Bluetooth to an Android cell phone that is uploading the data via WIFI to a secured server."
223496874|NCT07102927|DEVICE|Virtual reality-based training for the treatment of neglect syndrom in stroke|"An occupational therapist provided 1:1 assistance with fitting and removing the virtual reality headset (HMD), operating the software and explaining the procedures, as well as offering physical support and movement assistance when necessary to enable participants to engage in the virtual reality-based training program for neglect syndrome.~Following measurement of each participant's interpupillary distance, the headset (HTC VIVE PRO) was adjusted and fitted while the participant was seated. The lens distance was fine-tuned using adjustment knobs to match the individual's eyes.~The training for neglect was performed with participants seated and wearing the headset. The NEGTREA program provided a virtual environment along with visual fixation training."
223496875|NCT07102927|BEHAVIORAL|Conventional occupational therapy|"An occupational therapist conducted conventional neglect therapy in a 1:1 setting for 30 minutes per session. The therapy comprised therapist-supervised, table-top tasks carefully designed to parallel the virtual reality exercises as closely as possible.~These table-top tasks primarily focused on promoting visual scanning and sustained attention toward the neglected hemifield through practical, goal-oriented activities such as object search and manipulation. The therapist utilized a variety of tools to facilitate and optimize patient engagement in these training."
224187594|NCT03457701|DRUG|rhEPO|rhEPO (epoetin alfa OR darbepoetin alfa) is commercially available in various single dose vials and single-dose prefilled syringes. It will be given as subcutaneous injection.
224187595|NCT03457701|DRUG|Ferrous sulfate containing the stable iron isotope (57Fe)|57Fe will be available in oral solution. An oral solution will be administered containing 10 mg of 57Fe as ferrous sulfate.
223496876|NCT07098273|DEVICE|TMS and FES- based rehabilitation|"Each subject will receive 15 individual sessions (45 minutes each, 3 times per week for 5 weeks) of task-based hand and arm exercises.~Before movement execution, the hand area of the primary motor cortex will be stimulated using active rTMS. The rTMS protocol will use intermittent theta burst stimulation (iTBS), which delivers bursts of 3 pulses at 50 Hz every 200 ms (5 Hz) for 2 seconds, followed by 8 seconds of rest, totaling 600 pulses in \~3 minutes. The hand area will be identified as the optimal site for eliciting a motor evoked potential (MEP) in the abductor digiti minimi (ADM) muscle, contralateral to the dominant limb, with the lowest possible stimulation intensity.~Subsequently, FES will be applied to assist the subject's voluntary movements during the task-oriented activities. The stimulation will be triggered based on the achievement of the electromyographic (EMG) threshold of the selected muscles."
223496877|NCT07098273|DEVICE|FES-based rehabilitation|"Each subject will receive 15 individual sessions (45 minutes each, 3 times per week for 5 weeks) of task-based hand and arm exercises.~Before movement execution, the TMS coil will be positioned over the hand areas of the primary motor cortex, but tilted away from the scalp so as to produce a sound similar to the real intervention, but at a low intensity, without inducing current in the cortex.~FES will then be applied to assist the patient's voluntary movements during the task-oriented activities. The stimulation will be triggered based on the achievement of the electromyographic (EMG) threshold of the selected muscles."
223496878|NCT07104565|DRUG|INCA000585|Tafasitamab will be administered intravenously at protocol defined timepoints.
223496879|NCT07104357|DEVICE|Inspiratory muscle training|Participants will perform 20 sessions of respiratory muscle strengthening (20 minutes at 30-60% of MIP), using the Threshold Inspiratory Muscle Training device
223496880|NCT07104786|DRUG|Obeticholic Acid 10 MG|10mg OCA was given once daily for 6 months
223496881|NCT07104786|DIETARY_SUPPLEMENT|Vitamin E 400mg|Vitamin E 400mg was given twice daily for 6 months
223496882|NCT01251861|DRUG|Akt Inhibitor MK2206|Given PO
223496883|NCT01251861|DRUG|Bicalutamide|Given PO
223496884|NCT01251861|OTHER|Clinical Observation|Undergo clinical observation
223496885|NCT01251861|OTHER|Laboratory Biomarker Analysis|Correlative studies
223496886|NCT07107802|DRUG|ATX101|Single intravenous dose
223496887|NCT07107802|DRUG|Placebo|Single intravenous dose
223496888|NCT06911177|DIETARY_SUPPLEMENT|Yeast mannan|Yeast cell wall fraction of manno-oligosaccharides and mannoproteins supplemented at 12 g/day.
223496889|NCT06911177|DIETARY_SUPPLEMENT|Control (placebo)|A supplement containing yeast protein, yeast extract, and maltodextrin, provided at 12 g/day.
223590123|NCT02294734|DRUG|GSK2269557|Dry powder for inhalation via DISKUS 'device' with unit dose strength of 500 micrograms (mcg) per actuation with total dose of 1000 mcg daily
223590124|NCT02294734|DRUG|Placebo|Dry powder for inhalation via DISKUS 'device'
223590125|NCT04293302|OTHER|No intervention|No intervention
223590126|NCT03446417|DRUG|ZN-e4|Oral dose, tablet, daily dosing
223590127|NCT00002020|DRUG|Zidovudine|
223745879|NCT04823637|DIAGNOSTIC_TEST|Ultrasonography vs Osteopathic manipulative medicine structural exam|Structural examination of the thoracic spine using ultrasound and osteopathic palpatory examination on skin.
224187596|NCT03457701|DRUG|Ferrous sulfate containing the stable iron isotope (58Fe)|58Fe will be available in oral solution. An oral solution will be administered containing 3 mg of 58Fe as ferrous sulfate with 7 mg of 56Fe as ferrous sulfate (natural abundance Fe).
224187597|NCT03346109|RADIATION|medial group retropharyngeal node（MRLN） sparing|Patients in MRLN sparing group will not routinely receive MRLN irradiation; while patients in MRLN prophylactic irradiation group will always receive MRLN irradiation to 56Gy/33Fr.
224187598|NCT05554666|BIOLOGICAL|ASKG315|Injection with dose escalation stage of 3mg up to 45mg as well as dose expansion stage with recommended dose level from dose escalation stage.
224187599|NCT02243306|DRUG|GSK1278863|Round, biconvex, white film coated tablet containing 5 mg GSK1278863.
224187600|NCT01719718|PROCEDURE|Closure of hernia defect.|Laparoscopic ventral hernia repair with closure of the hernia defect (mesh augmentation technique).
223496890|NCT07104682|BIOLOGICAL|GCAR1|GCAR1 is a patient-specific cell therapy product containing a mixture of autologous lymphocytes transduced with a lentiviral vector encoding a chimeric antigen receptor (CAR) targeting GPNMB. The CAR comprises a single-chain variable fragment (scFv) binding domain derived from a fully human GPNMB-specific monoclonal antibody (CDX-011), a CD8 hinge and transmembrane domain, a myc sequence for product identification, and the CD137 (4-1BB) and CD3 zeta chain intracellular signaling domains. After infusion, the autologous GPNMB CAR T-cells expressing the genetically engineered anti-GPNMB CAR enable the specific targeting of GPNMB-expressing cells. Upon binding to GPNMB-expressing cells, the CAR transmits T cell activation signals that promote the elimination of target cells through CAR T cell degranulation and the release of cytotoxic molecules. The cellular signal also facilitates CAR T cell proliferation and persistence that may enable prolonged disease control through immunosurveillance
223496891|NCT07113327|DIAGNOSTIC_TEST|Artificial Intelligence-Assisted Staging and Grading for Diagnosis of Periodontitis|A deep learning diagnostic model (using DenseNet and VGG16 architectures) was applied to panoramic radiographs of 47 patients to classify the stage and grade of periodontitis. The model was trained on an external dataset and validated against expert-labeled outcomes. The purpose was to assess the accuracy of AI in replicating clinician-level diagnosis based on the 2017 classification system of periodontitis.
223496892|NCT06780800|OTHER|The Back Belief Questionnaire Tr (BBQ) and Backs-tr|200 people will be administered The Back Belief Questionnaire Tr (BBQ) and Backs-tr.
223496893|NCT06780800|OTHER|Backs-tr retest|100 people will fill in the Backs-tr again after 1 week.
223496894|NCT07116668|DEVICE|Colovac Anastomosis Protection Device placement following low anterior resection of colon cancer|Subjects in the Investigational cohort (SAFE-3CV) will undergo an LAR procedure followed by Colovac placement. Colovac retrieval will then occur at \~10 days post LAR procedure.
223496895|NCT07114224|DIAGNOSTIC_TEST|AV45/AV-1、AV1451 PET|"Use PET equipment to collect multimodal imaging data. Sixty to ninety minutes after intravenous injection of 3.7 MBq/kg of 18F-AV45 or 18F-AV1, perform PET imaging in list mode to simultaneously collect structural and functional information under the same pathophysiological conditions.~The next day, perform 18F-AV1451 PET imaging to obtain tau protein distribution information."
223496896|NCT07118501|DEVICE|Total Ankle Replacement|Incompass™ Total Ankle System
223590128|NCT03936647|PROCEDURE|surgical clipping, simple coiling, high-porosity stenting with/ without coiling, intra-arterial flow diversion with/ without coiling|Treatment may include the most appropriate amongst surgical clipping, simple coiling, high-porosity stenting with or without coiling, and intra-arterial flow diversion with or without coiling, which will be predetermined by the treating physician prior to randomization.
223590129|NCT03936647|DEVICE|WEB embolization device|WEB embolization device
223590130|NCT00624754|DRUG|Formoterol/Budesonide|Budesonide/Formoterol 400/12: 800 µg b.i.d for 1 month
223590131|NCT00624754|DRUG|lactose|Lactose 2 puffs b.i.d for 1 month
223590132|NCT04151277|DRUG|FOLFOX-A|Patients will recieve nab-paclitaxel, oxaliplatin, Folinic Acid and 5-FU in a 14 day cycle
223590133|NCT04151277|DRUG|Gemcitabe and Abraxane|Patients will receive gemcitabine and nab-paclitaxel 3 weeks out of 4
223590134|NCT04151277|DRUG|G-CSF|Patients in the FOLFOX-A arm will also receive daily G-CSF as primary prophylaxis for all cycles. This will be given as per local site policy for 14 day chemotherapy regimens
223590135|NCT01407796|DRUG|Endotoxin (E. coli O:113, Reference Endotoxin)|
223590136|NCT01407796|DRUG|[18F](+/-)NOS|
223590137|NCT05546255|DRUG|Eribulin Mesylate|The recommended dose of Eribulin is 1.4 mg/m2 administered intravenously over 2 to 5 minutes on Days 1
223590138|NCT05546255|DRUG|Lobaplatin|The recommended dose of lobaplatin is 25mg/m2 administered intravenously over on Days 1
223590139|NCT03657147|BEHAVIORAL|Educational Video and Question Prompt List|A short educational video will be presented on an iPad about the importance of encouraging patients to ask questions and to be involved during glaucoma visits to improve self-management skills. A question prompt list will also be completed where participants check questions of interest to ask the provider.
223590140|NCT03308149|DRUG|infiltration with triamcinolone and bupivacaine|facet joint infiltration
223590141|NCT00024011|DRUG|bortezomib|Given IV
223590142|NCT00024011|OTHER|laboratory biomarker analysis|Correlative studies
223590143|NCT01430676|PROCEDURE|differences in surgical techniques|follow the risk for morbidity after incisional hernia repair
223590144|NCT00821912|DRUG|Docetaxel|30 mg/m2, administered as a 30 min. i.v. infusion on cycle day 1, 8 and 15 or cycle day 1 and 8 in an alternating 3 weekly schedule
223590145|NCT00821912|DRUG|Capecitabine|1650 mg/m2 /day orally b.i.d., day 1-14 every 3 weeks.
223590146|NCT03442517|BEHAVIORAL|Behavior Lifestyle Intervention|Participants will be involved in group-based counseling. Sessions will be about 1 hour each and comprise up to 10 people. The sessions will be led by a trained health educator. The calls will be a chance for participants to discuss challenges with breastfeeding, problem solving skills, educational information, and discuss balanced diet topics.
223590147|NCT03442517|OTHER|Usual prenatal care|Participants will receive the standard education given by their OBGYN or other healthcare provider. No additional breastfeeding, nutrition or postpartum weight loss education will be provided to participants by the investigators during pregnancy. After delivery, participants will follow normal pediatric visit schedule.
223496897|NCT07117305|DRUG|CD7 CAR-T combined with autologous hematopoietic stem cell transplantation|"Phase I adopts a standard 3+3 dose-escalation design (with exploratory doses of 1×10⁶, 2×10⁶, and 2.5×10⁶ CAR⁺ cells/kg) to determine the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D). Phase II expands at the RP2D to further assess efficacy.~During screening, eligible patients will be identified and consented. In the collection phase, patients undergo two separate apheresis procedures: G-CSF-mobilized peripheral blood stem cell collection for ASCT and PBMC collection for CAR-T manufacturing. Bridging therapy and gut preparation may be performed. The pretreatment phase(recommended: BEAM therapy) starts from Day -8. Investigators may adjust the pretreatment regimen based on the patient's performance. On Day 0, autologous stem cells are infused. CD7 CAR-T cells are infused on Days 2-7 post-transplant. Follow-up visits occur on Days 10, 14, 21, 28, and Months 2, 3, 6, and 12."
223496898|NCT07118007|OTHER|adapted physical activity|adapted physical activity for 30 to 45 minutes twice per week
223745880|NCT04018833|DRUG|Ranibizumab 0.5 MG/0.05 ML Intraocular Solution [LUCENTIS]|
223745881|NCT04018833|DRUG|Aflibercept 40 MG/ML Intraocular Solution [EYLEA]|
224073808|NCT02167932|BEHAVIORAL|Walk With Ease|Walk With Ease is the Arthritis Foundation's evidence-based walking intervention to help with fatigue and pain. The intervention is a self-directed program that helps guide participants in a safe and comfortable paced walking program with an ultimate goal of walking for 30 minutes a day, five days a week.
224073809|NCT05536661|OTHER|Preservative free hyaluronic acid artificial tear|Ocular lubricant
224073810|NCT04467580|DIAGNOSTIC_TEST|abdominal [18F]FDG PET/CT|Patients will have within a maximum period of 15 days before the surgery (resection of intestinal stenosis), records by MRI and by digital PET/CT with low injected activity of \[18F\]FDG, focused on the abdomen, the MRI will be performed maximum 30 days before the intervention (if available and performed according to the procedure for the study, it will not be repeated for the study).
224073811|NCT01938144|DRUG|Advil Congestion Relief|Orally adminstered, 200 mg Ibuprofen/10 mg Phenylephrine tablet, 4x/day, up to 8 doses.
224073812|NCT01938144|DRUG|Advil Allergy and Congestion Relief|Orally adminstered, 200 mg Ibuprofen/10 mg Phenylephrine/4 mg Chlorpheniramine tablet, 4x/day, up to 8 doses.
224073813|NCT01938144|DRUG|Paracetamol|Acetaminophen 500 mg, 4x/day, up to 8 doses.
224073814|NCT01665118|DEVICE|Trusculpt (Radio Frequency) Device|
224073815|NCT03682978|DRUG|Arbaclofen|Arbaclofen tablet.
224073816|NCT03682978|DRUG|Placebo|Placebo tablet.
224073817|NCT00706030|DRUG|neratinib|
224073818|NCT00706030|DRUG|vinorelbine|
224073819|NCT01720537|BIOLOGICAL|PF-05335810 Dose A|Single SC Injection
224073820|NCT01720537|BIOLOGICAL|PF-05335810 Dose B|Single Subcutaneous Injection(s)
224187601|NCT01719718|PROCEDURE|No closure of the hernia defect.|Conventional laparoscopic ventral hernia repair without closure of the hernia defect (defect bridging technique).
224187602|NCT05116904|OTHER|Assessment|Pupil reflex and melatonin profile, circadian profile assessment
224187603|NCT01016912|DRUG|BMS-790052|Tablets, Oral, 10 mg, daily, 24-48 weeks
224187604|NCT01016912|DRUG|BMS-790052|Tablets, Oral, 60 mg, daily, 24-48 weeks
224187605|NCT01016912|DRUG|Placebo|Tablets, Oral, 0 mg, daily, 48 weeks
224187606|NCT01016912|DRUG|Peginterferon alfa-2b|Syringe, Subcutaneous, 180µg, weekly, 24-48 weeks
224187607|NCT01016912|DRUG|Ribavirin|Capsules, Oral, 600 to 1000 mg based on weight, daily, 24-48 weeks
224187608|NCT06464081|OTHER|Sleep quality assessment|1\. Pediatric Sleep Questionnaire.
224073821|NCT01720537|BIOLOGICAL|Placebo|Single Subcutaneous Injection(s)
224073822|NCT01720537|BIOLOGICAL|PF-05335810 Dose B|Single Intravenous Infusion
224073823|NCT01720537|BIOLOGICAL|Placebo|Single Intravenous Infusion
224073824|NCT01720537|BIOLOGICAL|PF-04950615 Dose A|Single Subcutaneous Injection(s)
224073825|NCT01720537|BIOLOGICAL|PF-04950615 Dose A|Single Intravenous Infusion
224073826|NCT01720537|BIOLOGICAL|PF-05335810 Dose C|Single Subcutaneous Injection(s)
224073827|NCT01720537|BIOLOGICAL|Placebo|Single Subcutaneous Injection(s)
224073828|NCT01720537|BIOLOGICAL|PF-05335810 Dose C|Single Intravenous Infusion
224073829|NCT01720537|BIOLOGICAL|Placebo|Single Intravenous Infusion
224073830|NCT01720537|BIOLOGICAL|PF-04950615|Single Subcutaneous Injection(s)
224073831|NCT01720537|BIOLOGICAL|PF-05335810 Dose D|Single Subcutaneous Injection(s)
224073832|NCT01720537|BIOLOGICAL|Placebo|Single Subcutaneous Injection(s)
224073833|NCT01720537|BIOLOGICAL|PF-05335810 Dose E|Multiple fixed dosages administered in subcutaneous injections, monthly for 3 months.
224073834|NCT01720537|BIOLOGICAL|PF-05335810 Dose D|Single Intravenous Infusion
224073835|NCT01720537|BIOLOGICAL|Placebo|Single Intravenous Infusion
224187609|NCT06464081|OTHER|Anthropometry|2\. Anthropometric data : 2.1 Height; 2.2 Weight; 2.3 Maximal mouth opening; 2.4 Maximal mouth opening with tongue to palate The measures 2.3 and 2.4 will be realized via the Quick Tongue-Tie assessment tool
224187610|NCT06464081|OTHER|Tongue strength assessment|3\. Tongue pressure while swallowing. 4. Tongue peak pressure during tongue elevation. 5. Tongue peak pressure during tongue protrusion. These measures will be realized via the IOPI (Iowa Oral Performance Instrument) device.
224187611|NCT06464081|OTHER|Tongue endurance assessment|6\. The tongue endurance during tongue elevation. 7. The tongue endurance during tongue protrusion. These measures will be realized via the IOPI (Iowa Oral Performance Instrument) device and a timer.
224187612|NCT06464081|OTHER|Orofacial praxis assessment|8\. Motricité Bucco-Linguo-Faciale (MBLF) test.
224187613|NCT05523648|DRUG|Chronic Hepatitis B|92 patients included in the study were randomly divided into 2 groups, 42 patients in the control group and 50 patients in the treatment group. Both groups of patients received conventional basic treatment such as liver protection. Moreover, in both groups, patients were instructed to change their dietary structure to control low-fat and low-sugar, and were instructed to perform appropriate aerobic exercise.
224187614|NCT02384096|DEVICE|Conventional single source programming|Precision Spectra SCS System using conventional single source programming.
224187615|NCT02384096|DEVICE|Precision Spectra SCS System advanced programming|Precision Spectra SCS System using advanced programming
223496899|NCT05006508|BEHAVIORAL|Lifestyle tool|Regular use of the digital Lifestyle tool
223496900|NCT07104669|OTHER|diet|diet adherence
223590148|NCT00741702|OTHER|Nurse administered treatment algorithm|Start with Irbesartan 150 mg/d; check BP in 6 wks, if BP \>=130/80 mm HF, 300 mg/d irbesartan; check BP at next visit, if BP\>= 130/80 mm Hg, add HCTZ 12.5 mg/d; check BP at next visit, if BP\>=130/80 mm Hg, add verapamil 180 mg/d; check BP at next visit, if BP\>=13/80 mm Hg, increase verapamil to 240 mg/d
223590149|NCT06216314|OTHER|Heart rate (HR)|Runners ran according to speeds and HR associated with ventilatory thresholds. Z1, zone 1: intensity zone below the first ventilatory threshold; Z2: zone 2, intensity zone between the first and second ventilatory threshold; Z3: zone 3, intensity zone above the second ventilatory threshold.
223590150|NCT06216314|OTHER|Race pace based approach (RP)|"Runners ran respecting three intensity zones.~The average speed achieved in the 7-km was calculated. From this, three intensity zones were calculated, adhering to the % of the race pace of the 7-km test.~Z1 corresponds to less than 80% of race pace, Z2 is between 80-95%, and Z3 corresponds to over 95% of race pace"
223590151|NCT06216314|OTHER|Heart rate + heart rate variability (HRV)|Runners completed training sessions based on HR values and velocities associated with ventilatory thresholds (i.e., Z1, zone 1: intensity zone below the first ventilatory threshold; Z2: zone 2, intensity zone between the first and second ventilatory threshold; Z3: zone 3, intensity zone above the second ventilatory threshold. The training sessions were based on physiological thresholds and daily HRV cues. High-intensity training was performed only under optimal HRV conditions, thus only when each participant had HRV values in their reference range. If HRV was not optimal, low-intensity training was prescribed. If HRV was not optimal for two days consecutively, rest was prescribed.
223590152|NCT01793259|DRUG|methotrexate prefilled pen|
223590153|NCT01793259|DRUG|methotrexate prefilled syringe|
223590154|NCT05003661|BEHAVIORAL|Parents' Voice|the intervention is recording of parents voice of reading children's book.
223590155|NCT02496923|DEVICE|High flow nasal oxygen therapy (Optiflow™)|
223496901|NCT07104669|OTHER|Physical activity|Physical activity level
223590156|NCT02496923|DEVICE|Standard oxygen therapy (Hudson Type face mask or nasal prongs)|
223496902|NCT07104669|OTHER|body composition|body composition assessment
223496903|NCT07104669|OTHER|hydration status|hydration status assessment
223745882|NCT02081482|RADIATION|18F-FDG PET|
223745883|NCT04708938|OTHER|High voltage electrical stimulation+exercise therapy|The effect of high voltage electrical stimulation on temporomandibular disorders
223745884|NCT04708938|OTHER|Exercise therapy|The effect of high voltage electrical stimulation on temporomandibular disorders
223496904|NCT07104669|OTHER|health status|perception of health status
223496905|NCT07120984|BIOLOGICAL|L19TNF|1 cycle of TNF before resection and 6 cycles after surgery
223496906|NCT07120984|BIOLOGICAL|L19TNF and TMZ|6 cycles of 28 days with L19TNF and TMZ
223496907|NCT07120984|BIOLOGICAL|L19TNF and CCNU|6 cycles of 6 weeks of L19TNF and CCNU every 6 weeks
223496908|NCT07120984|BIOLOGICAL|L19TNF monotherapy|6 cycles of 6 weeks with L19TNF
223496909|NCT07120984|BIOLOGICAL|L19TNF and TMZ in recurrent astrocytoma|6 cycles of 28 days with L19TNF (D1, D3, D5) and temozolomide chemotherapy TMZ (D1-5).
223496910|NCT07120984|BIOLOGICAL|L19TNF and CCNU in recurrent astrocytoma|6 cycles of 6 weeks of L19TNF (D1, D3, D5, D22, D24 and D26) and CCNU (D1) every 6 weeks
223496911|NCT07120984|BIOLOGICAL|L19TNF monothery in recurrent oligodendroglioma|6 cycles of 6 weeks with L19TNF
223496912|NCT07119736|DEVICE|VR relaxation|Relaxation with a VR glass and 360° video's of nature
223496913|NCT07119736|OTHER|Standard relaxation|Relaxation with music, reading a book, playing computer game
223590157|NCT03157583|OTHER|NGBUV000A, (Expected SPF 30)|A total of 2.0 ± 0.05 mg/cm2 (milligram per centimeter square of test site area) NGBUV000A (test product 1) will be spread at the topical test sites on the back of each participant. And a total of 1.3 mg/cm2 of test product 1 will be applied to the test plates.
223590158|NCT03157583|OTHER|NGBUV000B, (Expected SPF 30)|A total of 2.0 ± 0.05 mg/cm2 NGBUV000B (test product 2) will be spread at the topical test sites on the back of each participant. And a total of 1.3 mg/cm2 of test product 2 will be applied to the test plates.
223590159|NCT03157583|OTHER|NGBUV000C, (Expected SPF 30)|A total of 2.0 ± 0.05 mg/cm2 NGBUV000C (test product 3) will be spread at the topical test sites on the back of each participant. And a total of 1.3 mg/cm2 of test product 3 will be applied to the test plates.
223590160|NCT03157583|OTHER|NGBUV000D, (Expected SPF 30)|A total of 2.0 ± 0.05 mg/cm2 NGBUV000D (test product 4) will be spread at the topical test sites on the back of each participant. And a total of 1.3 mg/cm2 of test product 4 will be applied to the test plates.
223590161|NCT03157583|OTHER|P3 Standard, (Expected SPF 16)|A total of 2.0 ± 0.05 mg/cm2 reference P3 standard will be spread at the topical test sites on the back of each participant.
223745885|NCT00783445|BEHAVIORAL|Community-Based Exercise Program (C-FIT)|Participants will do 1 hour of exercise two to three times each week in a community setting for 1 year, while being supervised by a personal coach.
224073836|NCT01244880|OTHER|Saline|Saline infusion for 56 minutes
224073837|NCT01244880|DRUG|PF-02545920|PF-02545920 10 mg single dose
224073838|NCT01244880|OTHER|Ketamine|"Ketamine 0.23 mg/kg bolus over one min; and 0.58 mg/kg/hour maintenance for 56 minutes~PF-02545920 10 mg tablet"
224073839|NCT01244880|DRUG|PF-02545920|PF-02545920 10 mg tablet single dose
224073840|NCT01244880|OTHER|Saline|Saline infusion for 56 minutes
224073841|NCT01244880|OTHER|Placebo|Placebo tablet single dose
224073842|NCT01244880|OTHER|Ketamine|Ketamine 0.23 mg/kg bolus over one min; and 0.58 mg/kg/hour maintenance for 56 minutes
224073843|NCT01244880|OTHER|Placebo|Placebo tablet single dose
224073844|NCT05779072|DEVICE|Single Vision Soft Contact Lens|Subjects refit to Single Vision Soft Contact Lens for 1 year
224073845|NCT04638569|PROCEDURE|obturator nerve block|The ultrasound probe will be placed in the middle of the tuberculum pubis and femoral artery, 5-6 cm below the inguinal ligament, and 5 mL of 0.5% bupivacaine will be injected into the anterior and posterior branches of the ON with a needle. In the second group, after the patient is placed in the lithotomy position, 1.5 cm lateral tuberculum pubis and 1.5 cm caudal will be marked and needle entry will be made and 0.5% bupivacaine will be injected with 10 mL. The time elapsed until the first needle insertion and local anesthetic injection is completed will be recorded as the application time.
224187616|NCT00617942|DRUG|Cohort 1 neo-adjuvant|"Cohort 1 : Trastuzumab 6 mg/kg IV over 60 minutes day -14~Trastuzumab 2 mg/kg IV over 60 minutes weekly then Abraxane 100 mg/m2 IV over 30 minutes weekly x 18 weeks followed by Carboplatin at AUC 6 IV over 30 min weeks 1,4,7,10,13 and 16"
224187617|NCT00617942|DRUG|Cohort 2 neo-adjuvant|Cohort 2 :Abraxane 100 mg/m2 IV over 30 minutes days -14 and -7 Trastuzumab 2 mg/kg IV over 60 minutes weekly (4 mg/kg week 1) then Abraxane 100 mg/m2 IV over 30 minutes weekly x 18 weeks followed by Carboplatin at AUC 6 IV over 30 min weeks 1,4,7,10,13 and 16
224187618|NCT00617942|DRUG|Cohort 1 adjuvant|Trastuzumab 8 mg/kg x 1 dose, then 6 mg/kg q3wks x 11 doses Adjuvant chemotherapy, post-op radiation and hormonal therapy at discretion of treating physicians
224187619|NCT00617942|DRUG|Cohort 2 adjuvant|Trastuzumab 8 mg/kg x 1 dose, then 6 mg/kg q3wks x 11 doses Adjuvant chemotherapy, post-op radiation and hormonal therapy at discretion of treating physicians
223496914|NCT07120555|DEVICE|atherectomy|Conventional balloon angioplasty remains a first-line endovascular treatment but is limited by high restenosis and vessel recoil rates. Atherectomy, a plaque debulking technique, aims to improve luminal gain and vessel compliance prior to angioplasty, potentially enhancing outcomes in heavily calcified lesions. The combination of atherectomy and balloon angioplasty has shown promise in reducing dissection rates and improving technical success, yet its superiority over conventional angioplasty alone remains controversial.
223496915|NCT07120555|DEVICE|Percutaneous transluminal angioplasty of infra-popliteal arteries lesions with primary long|Percutaneous transluminal angioplasty of infra-popliteal arteries lesions with primary long
223496916|NCT07120503|DRUG|WIN378|WIN378 is a fully human, long-acting monoclonal antibody that binds to thymic stromal lymphopoietin (TSLP), blocking its activity and thereby reducing airway inflammation and improving asthma control over an extended dosing interval.
223496917|NCT07120503|DRUG|Placebo|A sham injection consisting of placebo to mask WIN378.
223496918|NCT06865391|BEHAVIORAL|Delayed cord clamping|
223496919|NCT07121595|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223496920|NCT07121595|DRUG|Carboplatin|Given IV
223496921|NCT07121595|DRUG|Cisplatin|Given IV
223496922|NCT07121595|PROCEDURE|Computed Tomography|Undergo CT and/or SPECT-CT
223496923|NCT07121595|PROCEDURE|Modified Barium Swallow|Undergo video fluoroscopic swallow study
223496924|NCT07121595|DRUG|Paclitaxel|Given IV
223496925|NCT07121595|PROCEDURE|Positron Emission Tomography|Undergo PET-CT
223496926|NCT07121595|OTHER|Questionnaire Administration|Ancillary studies
223496927|NCT07121595|RADIATION|Radiation Therapy|Undergo RT
223496928|NCT07121595|PROCEDURE|Sentinel Lymph Node Biopsy|Undergo SLNB
223496929|NCT07121595|PROCEDURE|Single Photon Emission Computed Tomography|Undergo SPECT-CT
223496930|NCT07121595|RADIATION|Technetium Tc 99m-labeled Tilmanocept|Given via injection
223496931|NCT07121595|OTHER|Technetium Tc-99m Sulfur Colloid|Given via injection
223496932|NCT07121543|RADIATION|Brachytherapy|Brachytherapy is a cancer treatment where radioactive sources are placed inside or near the tumor.
223496933|NCT07121023|DRUG|TRD205 tablets|Administered orally every 12 hours for a total of four times；Take TRD205 2 tablets and Placebo 4 tablets for the first time ，TRD205 1 tablets and Placebo 2 tablets each for the other three times.
223496934|NCT07121023|DRUG|TRD205 tablets|Administered orally every 12 hours for a total of four times；Take TRD205 4 tablets and Placebo 2 tablets for the first time ，TRD205 2 tablets and Placebo 1 tablets each for the other three times.
223496935|NCT07121023|DRUG|TRD205 tablets|Administered orally every 12 hours for a total of four times；Take TRD205 6 tablets and Placebo 0 tablets for the first time ，TRD205 3 tablets and Placebo 0 tablets each for the other three times.
223496936|NCT07121023|DRUG|Placebo|Administered orally every 12 hours for a total of four times；Take Placebo 6 tablets for the first time ，Placebo 3 tablets each for the other three times.
223496937|NCT07119242|DRUG|68Ga-DOTATATE Injection|The eligible subjects who participate in 68Ga study will be intravenously injected with 68Ga-DOTATATE Injection on Day1，and undergo PET/CT examination within 60 minutes after injection. Corresponding safety examination is performed before administration of 68Ga-DOTATATE Injection, 3h±1.0h after administration, and Day2. Telephone safety visit is conducted at Day7 after administration.
223496938|NCT07119385|OTHER|Multicomponent non-pharmacological interventions|Multicomponent non-pharmacological interventions to prevent delirium in frail patients
223496939|NCT07119385|OTHER|Usual care|Usual care
223496940|NCT07119359|OTHER|Home-based HIV self-testing|Integration of HIV self-testing into TB household contact investigation
223496941|NCT07119359|OTHER|Home-based initiation of PrEP|Integration of PrEP initation into TB household contact investigation
223496942|NCT07120815|DRUG|Metformin 1500 mg daily|metformin 500mg tablets, 3 times per day
223496943|NCT07120815|DRUG|Metformin 2250 mg daily|Metformin 750mg, 3 times daily
223496944|NCT07120542|DEVICE|Dermoscopy|dermoscopic assessment of skin aging signs
223496945|NCT07121036|DRUG|high - dose vitamin C|Different dose of high - dose vitamin C in arm1, 2 and 3
223496946|NCT07121452|BEHAVIORAL|Sleep Navigator|Sleep Navigator will provide education, troubleshooting, motivation, and support pertaining to any additional questions or concerns regarding OSA. They will consult closely with the board-certified sleep medicine physician to ensure that participant care needs are met.
223496947|NCT07119632|OTHER|RFE therapy|
223511872|NCT06537466|DIETARY_SUPPLEMENT|Mediterranean diet|This equilibrated diet has a caloric value 10% below the total metabolic expenditure of each individual. The total metabolic expenditure is calculated from the basal metabolic expenditure (based on the formula FAO/WHO/UN) multiplied by the coefficient of activity, which is calculated according to the physical activity of each participant. The calories provide to this group range between 1,400 and 1,800 kcal/day. The ration of macronutrients provided is 45-55 % arbohydrates,15-25 % proteins, and 25-35 % fat, in addition to a recommended intake of 20-40 g/day of fiber in the form of vegetables and fruits.
223590162|NCT03157583|OTHER|Sunscreen formulation S2|A total of 1.3 mg/cm2 of sunscreen formulation S2 will be applied to the test plates.
223496948|NCT07120854|OTHER|Decision aid with decision analysis model|Women will use the web version of the decision aid tool. They will have a supporting video to help them how to navigate the tool during. They will be able to access the tool through a specific link that will be shared with them by their central research team via e-mail. Each woman is expected to use the web tool and select her preferences (utilities) regarding different health conditions (e.g. hip fracture). The results of the exercises will be received automatically at the central level (by institutional e-mail to the researcher responsible for the data a PDF file will be sent from the web). The research team at the central level will apply the decision analysis model, using information on the baseline fracture risk and preferences of each participant entered into the tool. The results of the decision analysis model will be delivered to the women directly by e-mail in plain language, so that they can make the final decision together with their general practitioner in a second visit.
223496949|NCT07120854|OTHER|Decision aid alone|Participants will use the web tool. They will have a supporting video to help them how to navigate the tool during. They will be able to access the tool through a specific link that will be shared with them by the central research team via e-mail. Each woman is expected to navigate through the different functions of the web tool, at home or at a time other than the medical visit, and select her preferences (utilities) with respect to different health conditions (e.g. hip fracture). The women in this group would decide whether or not to take the pharmacological treatment based on the information provided by the tool but without the results of the decision analysis model described for the intervention group. Subsequently, those who wished to do so would make a final decision together with their physician at a second visit.
223496950|NCT07120854|OTHER|Usual Care|Women in this group will receive standard clinical practice, without the use of the shared decision support tool or the decision analysis model or any other support. At the end of the visit, their physician will provide them with a link to access the assessment questionnaires.
223496951|NCT07121647|PROCEDURE|renal replacement therapy.|veno-venous hemodiafiltration for emergency indications (CVVHDF).
223496952|NCT07121647|PROCEDURE|early isolated CVVHDF.|early isolated CVVHDF.
223496953|NCT07121647|PROCEDURE|combined extracorporeal blood purification therapy|Patients received early combined extracorporeal blood purification therapy (EBPT) (SPF and CVVHDF).
223496954|NCT07114679|DEVICE|Molecular Breast Imaging|MBI is a molecular imaging (nuclear medicine) technique using a low dose i.v. radiopharmaceutical injection and solid-state gamma cameras to image the breast, where cancer mitochondria avidly take up the radiopharmaceutical.
223496955|NCT07114679|DEVICE|MBI-guided biopsy|Two stereotactic MBI views of the breast produce a precise 3D location for each lesion targeted for biopsy. A vacuum-assisted core biopsy needle is guided to the lesion position.
223496956|NCT07120932|BEHAVIORAL|Effects of Emotional Freedom Techniques (EFT)|Effects of Emotional Freedom Techniques (EFT)
223496957|NCT07118462|DRUG|Acetazolamide|Administration of 1x125mg acetazolamide in the morning, 1x125mg in the evening, starting 24 hours before departure to 3600 m.
223496958|NCT07118462|DRUG|Placebo|Administration of equally looking placebo capsules in the morning and in the evening, starting 24 hours before departure to 3600 m.
223496959|NCT07117084|DIAGNOSTIC_TEST|CCTA-derived Plaque Quantification|Quantitative analysis of coronary plaque features based on coronary CT angiography using semi-automated software.
223496960|NCT07117500|BEHAVIORAL|Routine|"Inpatient Care: Continuously monitor vital signs (BP, HR, SpO₂), neurological status, and limb function; administer prescribed antihypertensives with thorough medication education and efficacy tracking. Strictly prohibit Valsalva maneuvers . Assess pain levels, wounds, and psychological state; deliver scheduled analgesics and emotional counseling to maintain stable mood. Implement lifestyle optimization: 7+hr sleep/night, portion-controlled nutrition, and gradual postoperative mobilization.~Discharge \& Follow-up: Enforce BP control through medication adherence. Ban vigorous activities (mountaineering/swimming/competitive sports); allow low-stress aerobics . Distribute Exercise Diaries (Appx 6) mandating daily logs with critical warnings: STOP immediately if nausea, chest pressure, dizziness, dyspnea, or arrhythmia occur and urgent revisit. Require complete tobacco cessation and secondhand smoke avoidance."
223590163|NCT03157583|OTHER|Glycerin|A total of 1.3 mg/cm2 of glycerin will be applied to the test plates.
224073846|NCT00884104|DRUG|Solifenacin|Oral
224073847|NCT06278909|DEVICE|Trigeminal Nerve Stimulation|Active trigeminal nerve stimulation
224073848|NCT02691780|DRUG|Sorafenib|
224073849|NCT02337088|PROCEDURE|Delayed cord clamping at 30 seconds|For subjects enrolled in the 30 second arm, the umbilical cord will be clamped at exactly 30 seconds after delivery
224073850|NCT02337088|PROCEDURE|Delayed cord clamping at 60 seconds|For subjects enrolled in the 60 second arm, the umbilical cord will be clamped at exactly 60 seconds after delivery
224073851|NCT02865330|OTHER|Registry|National Registry of patients with prostate cancer as monitored through active surveillance, with the intention of testing the hypothesis that cancer-specific mortality in very low-risk and low-risk patients is less than 5% at 15 years.
224073852|NCT04314960|DEVICE|Functional electrical stimulation device (NESS L300Plus, Bioness, Valencia, CA)|Functional electrical stimulation (FES) is the application of high-intensity intermittent electrical stimuli to generate muscle contractions that may bypass spinal and supraspinal inhibition, and which is coupled with a functional task such as gait. Gait training will be conducted on a treadmill.
224073853|NCT04868084|BEHAVIORAL|Physical literacy in the early years|Intervention nurseries received a 6-hour training session, covering the theory about FMS and practical demonstrations of age-appropriate ways to teach and develop FMS.
224073854|NCT04280432|PROCEDURE|CESAREAN|Women hospitalized for cesarean section
224073855|NCT01765101|OTHER|customized insoles|To study the immediate, short-term and intermediate-term therapeutic effects, including psychological function, physical activity , functional performance and quality of life, physical functional ability, pain and balance performance
224073856|NCT01765101|OTHER|ready made insoles|To study the immediate, short-term and intermediate-term therapeutic effects, including psychological function, physical activity , functional performance and quality of life, physical functional ability, pain and balance performance
224073857|NCT05044052|BEHAVIORAL|Emphasis on the Choosing Wisely Viral Prescription Pad|We will investigate the effects of emphasizing the use of materials developed by Choosing Wisely Canada (CWC) - namely the viral prescription pad - to help physicians act upon the feedback to reduce their prescribing.
224187620|NCT05342870|DRUG|Dexmedetomidine|Following a sequential allocation scheme, the dexmedetomidine dose for each patient was determined by the Dixon up-and-down method. The dexmedetomidine dose for the first patient was 0.5 µg/kg. The dose was then adjusted in 0.1 µg/kg increments for the following patients depending on the success of the previous patient's block. If a patient experienced tourniquet pain prior to T0 + 50 minutes the next patient received a higher dose. If a patient did not experience pain at T0 + 50 minutes of tourniquet time the dose for the following patient was decreased. Identical syringes containing the solution mix were prepared by the principal investigator and handed to the blinded anesthesiologist in the room. Stopping rules were set at 6 independent crossovers in the same direction (no pain to pain or pain to no pain), with a minimum number of 20 patients
224187621|NCT05600855|DRUG|Ruxolitinib|"Model-predicted high-risk patients: ruxolitinib 5mg bid po until at least day 60 post-transplant and terminated after day 100. If severe hematological signs occur such as when there is severe neutropenia (\<0.1×10\^9/L), ruxolitinib can be used at half dose or discontinued as appropriate, and can continue to be used after hematology recovery.~Model-predicted moderate-risk patients: ruxolitinib 2.5mg bid p po until at least day 60 post-transplant and terminated after day 100. If severe hematological signs occur such as when there is severe neutropenia (\<0.1×10\^9/L), ruxolitinib can be used at half dose or discontinued as appropriate, and can continue to be used after hematology recovery.~Model-predicted low risk: regular aGVHD prophylactic regimens."
224309035|NCT02102516|DRUG|SPRIX(intranasal ketorolac tromethamine)|"Dose: Subjects weighing 3.0 kg received 3.15 mg (1 spray/1 nostril), subjects weighing 5.1 - 10.0 kg received 5.25 mg (1 spray/1 nostril), subjects weighing 10.1 - 15.4 kg received 10.5 mg (1 spray/1 nostril), subjects weighing 15.5 - 31.7 kg received 15.75 mg (1 spray/1 nostril), and subjects weighing \>=31.8 kg received 31.5 mg (1 spray/2 nostrils).~Duration of Treatment: Subjects received a dose of SPRIX every 6 hours from the day of surgery until the morning of post-operative Day 2. Dosing may have resumed after final PK assessment of the morning of post-operative Day 3 until post-operative Day 4. A follow-up phone interview took place 14 days after the final dose of study drug."
224309036|NCT06983483|BEHAVIORAL|Community education and awareness, and personal lifestyle and cooling behavior modification|This component of the HAB will be achieved through community mobilization, which will encompass awareness and motivational activities throughout the intervention duration. Community groups (CGs) will be formed in each of the 11 clusters. Both male and female CGs will be formed separately and will be responsible for community mobilization activities, surveillance for primary outcome. Each CG will comprise of 6-8 members and will be a diverse group of people with varying qualifications, including local government members, local elders/elites, religious leaders, and prominent male and female members of the community. they could also name their respective CGs to enhance association, identity, and affiliation. These CGs will facilitate culturally tailored workshops, dissemination of early warnings regarding heat waves, awareness sessions, and door-to-door outreach focused on heat-health fundamentals. CGs will also maintain simple logbooks to track any incidence of heat related illness.
224309037|NCT06983483|OTHER|Participatory local structural and environmental heat mitigation solutions|"Participatory local structural and environmental heat mitigation solutions will be delivered through community participatory approach where the community and project will share the cost of intervention to improve ownership. This contribution can be monetary or non-monetary, for example, provision of labor or supplies. The modifications include:~1. Paints (Solar Reflective Paints, Lime Paints)~2. Shading (Façade, Roof)~3. Energy Sufficiency (Solar Panels with complete accessories)~4. Community Shading (Plantation, Street Shading, Field Shading space)~5. Ventilation (Windows, Wind catchers)~6. External Renders"
224309038|NCT06659679|DRUG|New use of oral semaglutide|New use of oral semaglutide dispensing claim is used as the exposure.
224309039|NCT06659679|DRUG|New initiation of sitagliptin|New use of sitagliptin dispensing claim is used as the reference.
224309040|NCT02415569|DRUG|Standard Bowel Prep (2L PEG-ELP)|Subjects whose bristol stool forms are type 1 or 2, will be asked to take standard bowel prep (2L PEG-ELP) the same-day of procedure.
224309041|NCT02415569|DRUG|2L PEG-ELP and 10mg bisacodyl|Subjects whose bristol stool forms are type 1 or 2, will be asked to take standard bowel prep (2L PEG-ELP) the same-day of procedure and 10mg bisacodyl the day before procedure.
224309042|NCT02415569|DRUG|Standard Bowel Prep (2L PEG-ELP)|Subjects whose bristol stool forms are type 3 to 7, will be asked to take standard bowel prep (2L PEG-ELP) the same-day of procedure.
224309043|NCT00511095|BIOLOGICAL|HEPLISAV|Intramuscular (IM) injections 0.5mL on Day 0 and Week 4
224309044|NCT01910389|DRUG|Tadalafil|
224309045|NCT01910389|DRUG|Placebo for tadalafil|
224309046|NCT01943110|DEVICE|ID adapter (autodisable)|Intradermal delivery device which fits on the end of a syringe to limit the depth and angle of needle penetration into the skin. Contains an autodisable feature to prevent reuse.
224309047|NCT01943110|DEVICE|ID adapter (side load)|Intradermal delivery device which fits on the end of a syringe to limit the depth and angle of needle penetration into the skin.
223496961|NCT07117500|BEHAVIORAL|BCW|"1.1 Assessment of physical fitness and formulation of individualized exercise rehabilitation plans 1.2 Inpatient Phase (Postoperative Day 1 - Week 1): Monitor via ICU Mobility Scale (IMS) before each session:▪ Score 0 : Passive range of motion (PROM) exercises▪ Scores 1-3 : Active bed-based joint mobility training▪ Scores 4-6 : Standing balance training▪ Scores 7-10 : Ambulatory walking training 1.3 Early Outpatient Phase (Weeks 2-4): Initiate when IMS=10:▪ Perform 6-Minute Walk Test (6MWT) ▪ If distance \>450m: Prescribe low-intensity aerobic walking  Speed: 3 km/h Progression: Start at 10 min/day (≈500 steps), increase by 10 min every other day up to 40 min/day 1.4 Intermediate Rehabilitation (Weeks 5-12): Moderate-intensity aerobic walking + Resistance training :▪ Walking: 4-6 km/h, 30 min/session, 3 sessions/week▪ Resistance training: Seated elastic band exercises, 20 min/session, 2 sessions/week"
223496962|NCT07119021|DRUG|Intravenous thrombolysis + edaravone|The patient underwent intravenous t-PA thrombolysis and sublingual administration of edaravone tablets in the prehospital ambulance. Intravenous t-PA thrombolysis was performed in accordance with international guidelines: t-PA dose was calculated according to 0.9mg/kg; 10% of the total dose was injected intravenously, and the remaining 90% was administered intravenously at a uniform rate within one hour.
223590164|NCT05643586|DRUG|Ticagrelor|Patient treated with 180 mg ticagrelor 12 hours before the procedure
224187622|NCT05281146|DIETARY_SUPPLEMENT|Chickpeas and crushed peanuts fortified biscuit|This group received one daily pack of three fortified biscuits as snakes between breakfast and lunch on daily basis for four months. The chickpeas and crushed peanuts fortified biscuit consisted of wheat flour (extract 72%), Chickpea flour, crushed peanuts, wheat germ, Skimmed milk, corn oil, egg, sugar, Cinnamon, baking powder, salt, and vanilla.
224187623|NCT05281146|OTHER|Cognitive stimulation for the mothers|"I. Sessions for mothers~* Informing mothers about the most common causes of poor school achievement~* Clarification of mother's and family roles in improving student's cognitive abilities~* Defining cognitive functions needed for learning and school achievement~  o Attention, perceptive reasoning, memory, problem solving, proper use of language~* Identifying sensory functions necessary for the growth of cognitive functions~* Explaining factors that assist in academic excellence"
224187624|NCT05281146|OTHER|Cognitive stimulation for students|"* Activities to improve focus and visual attention~* Activities to improve visual memory~* Activities to improve vigilance and auditory attention~* Explaining types of memory Causes of weak memory Factors helping in improving memory Nutritional elements improving memory~* Training on skills of problem-solving"
224187625|NCT05121129|DEVICE|iTBS|25 active iTBS sessions (5 sessions of 9.5 minutes/day, 1,800 pulses per session, 90% of resting motor threshold, placed over the left DLPFC)
224187626|NCT04920786|DRUG|TB006|TB006
224187627|NCT04920786|OTHER|Sterile saline (Placebo)|Sterile saline
224187628|NCT06006962|OTHER|Aging Well through Interactions and Scientific Education - Action Plan|20-week program designed to provide education and individualized planning with a goal of improving brain health.
224187629|NCT04928508|DRUG|OK-1|"OK-1 orally in the form of 50 mg capsules. Four dose levels will be evaluated:~5.4mg/kg 7.0mg/kg 9.0mg/kg 12mg/kg"
224187630|NCT02903121|DRUG|Tamoxifen|Tamoxifen 10 mg orally twice daily for 7 days. Treatment to be started after 3 consecutive days of bleeding and can be repeated every 30 days two more times in the first 90 days of the study
224187631|NCT02903121|DRUG|Placebo|Placebo orally twice daily for 7 days. Treatment to be started after 3 consecutive days of bleeding and can be repeated every 30 days two more times in the first 90 days of the study
224187632|NCT02903121|DRUG|Tamoxifen (open label)|Tamoxifen 10 mg orally twice daily for 7 days. Treatment to be started after 3 consecutive days of bleeding and can be repeated every 30 days two more times in the second 90 days of the study
224187633|NCT03635645|DEVICE|New visual processing unit (VPU) with asymmetric waveforms|A VPU will apply asymmetric and symmetric stimulation pulses.
224309048|NCT04331561|BEHAVIORAL|sensory re-weighting|Participants will be supported in quiet standing by a safety harness and crisscrossing strap system. A cervical collar will be used to maintain consistent alignment between the head and trunk. A virtual reality headset is used to create a virtual environment in which visual stimuli will be presented. Three different body positions will be used during training: earth-vertical and clockwise and counterclockwise tilted 16º in the frontal plane. Sensory re-weighting will be driven by priming upregulation of somatosensory cues. In each training trial, participants must determine the direction of gravity and then indicate if the rod being displayed is aligned with gravity or if it needs to rotate clockwise or counterclockwise for that to be so. Participants will be instructed to pay attention to what they feel from their feet, legs, and gut during training and to use that pressure, stretch, movement, and muscle tension feedback to help them sense gravity.
224309049|NCT00589329|DRUG|erythromycin and metronidazole (antibiotics)|"Erythromycin 250 mg IV q 6 hours x 8 doses, followed erythromycin 250 mg tabs, 1 PO q 8 hours for five days.~Metronidazole, 1 gm IV loading dose followed by 500 mg IV q 12 hours x 4 doses, followed by metronidazole 500 mg tabs, 1 PO q 8 hours for five days"
224309050|NCT00589329|DRUG|placebo|IV and pill placebo
224309051|NCT00420459|DRUG|Aripiprazole|All subjects will initially receive 2.5 mg/day of aripiprazole during the first week. The dosage may be increased to a maximum of 20 mg/day over 8 weeks.
224309052|NCT03178032|BIOLOGICAL|DNX-2401|Brain infusion of the virus through the cerebellar peduncle
224309053|NCT01324674|OTHER|Bach´s Flower Remedy|The subjects will have 4 drops 4 times per day, for approximately 8 months.
224309054|NCT01324674|OTHER|Placebo group|The subjects will have a solution non-drug type, 4 drops 4 times per day, for approximately 8 months
224309055|NCT03048188|OTHER|wound dressing|Manuka honey wound dressing
223496963|NCT07119021|DRUG|IV thrombolysis + placebo (control group)|Patients underwent intravenous t-PA thrombolysis + placebo sublingual administration. The method of intravenous t-PA thrombolysis is in accordance with the international guideline standards: t-PA dose is calculated according to 0.9mg/kg; 10% of the total dose is injected intravenously, and the remaining 90% is administered intravenously at a constant rate within 1 hour.
223496964|NCT07117422|DRUG|VEN + DEC|"Induction regimen~Venetoclax (VEN): Day1-10~Decitabine (DEC):20mg/m²/day, Day 2-4~20mg/m² every 8 hours, Day 5-6~FLT3 Inhibitors (for FLT3/ITD+ patients only):~Sorafenib or Gilteritinib, Day 8-14~Post-Remission Treatment~Venetoclax (VEN): 400 mg/day, Day 1-7~Decitabine (DEC): 20 mg/m² every 8 hours, Day 2-3 (Regimen repeated every 4-6 weeks)~FLT3 Inhibitors (for FLT3/ITD+ patients only):~Sorafenib or Gilteritinib, Day 8-14"
223511873|NCT06537466|DIETARY_SUPPLEMENT|Very Low Ketogenic Diet|The VLCKD ketogenic protocol entails: a caloric intake \< 800 calories, a protein intake calculated based on individual needs: 1.2 + 0.2 g/kg/ideal body weight, low carbohydrate content (approximately 45-55 g of carbohydrates per day), and low lipids (10-15g/day). Vitamins and minerals, Unlimited vegetables.
224187634|NCT03635645|DEVICE|New VPU with bipolar stimulation|A VPU will apply bipolar stimulus pulses.
224187635|NCT02370173|DEVICE|PTSD wavelength-1 bright light|6 weeks of daily light exposure, 30 minutes per morning.
224187636|NCT02370173|DEVICE|PTSD wavelength-2 bright light|6 weeks daily light exposure, 30 minutes per morning.
224187637|NCT04791111|OTHER|Questionnaire|validated questionnaire to assess side effects secondary to antimuscarinics treatment in neurogenic bladder
224309056|NCT00872638|PROCEDURE|Eversion|Surgical incisions will be closed in such a manner so as to evert the wound edges.
224309057|NCT00872638|PROCEDURE|Approximation|Surgical incisions will be closed in such a manner so that wound edges are approximated exactly, i.e. without eversion.
224309058|NCT06552143|OTHER|Stone needle therapy follows the Belt channel|Stone needle therapy follows the Belt channel involves the use of stones by the intervener to follow the path of the Belt channel by pushing and rubbing the abdomen of patients with postpartum diastasis rectus abdominis.
223590165|NCT05643586|DRUG|Prasugrel|Patient treated with 60 mg prasugrel 12 hours before the procedure
223590166|NCT01723540|PROCEDURE|Minilaparotomy vs laparoscopy|MC-group will undergo ultrasonic dissection assisted minilaparotomy cholecystectomy ans patients in the LC-grout will undergo laparoscopic cholecystectomy
223590167|NCT04025177|DRUG|Indomethacin Injection|The dose of indomethacin will be 0.1 mg/kg/dose, based on birth weight, intravenously every 24 hours for a total of 3 doses. Doses 2 and 3 may be administered between 23.5 and 24.5 hours after the previous dose. Doses will be rounded to two significant figures.
224073858|NCT02695511|OTHER|Caloric restriction|25% caloric restriction below baseline energy requirement
224073859|NCT02527980|OTHER|No intervention: observation only|For all participants: We will conduct a 2-year longitudinal cohort study comprising participants who smoke exclusively CCs (n=175) and dual users of e-cigs and CCs (n=275). We will use state-of-the-art ecological momentary assessments to determine: 1) dynamic patterns of e-cig and CC use and related outcomes (e.g., dependence, withdrawal symptoms, CC quit attempts and quitting success); 2) episodic (affective, contextual, social) and stable person-factor (lifestyle factors, demographics) variables that covary meaningfully with e-cig and CC use and related outcomes; and 3) biomarkers of tobacco and carcinogen exposure as well as other health-related outcomes (e.g., reduced pulmonary function.
224073860|NCT01472887|DRUG|SAR3419|"Pharmaceutical form:concentrate for solution for infusion~Route of administration: intravenous"
223496965|NCT07118085|DRUG|experimental Arm IMC-003|"Part 1: Single Dose Dose Escalation (SAD):~Dose and frequency: 0.03mg/kg, 0.1mg/kg, 0.3mg/kg, 0.7mg/kg, 1.0mg/kg for single administration, with the test drug or placebo administered respectively.~Part 2: Multiple Dose Dose Escalation (MAD):~Dose and frequency: Tentatively set at 0.3mg/kg, 0.5mg/kg, 0.7mg/kg. Administer once every 3 weeks for 5 consecutive times (unless the subject cannot tolerate, withdraw prematurely, or is lost to follow-up, etc.), with the test drug or placebo administered respectively."
223496966|NCT07118085|DRUG|The placebo Arm: The placebo of IMC-003|Part 1(SAD) subject will receive IMC-003 once ; Part 2 (MAD) subject will receive the placebo of IMC-003 for 5 times, with an interval of 21 days between each administration.
223496967|NCT07116785|DEVICE|BrainsWay Deep TMS HAC/H7-Coil|Rotational field TMS (rfTMS) is a novel technology where two orthogonal coils are operated with a 90 phase shift between them. The combined electric field vector of rfTMS from both coils rotates up to a complete cycle during the TMS pulse. This method overcomes the inherent limitation of conventional unidirectional TMS by influencing neurons in various orientations (Roth et al., 2020b). This unique advance bears enormous potential for therapeutic applications in various neuropsychiatric disorders. The coil Array includes the H7 coil as the lower coil, and an upper coil perpendicular to it. Hence, the HAC/H7 coil Array induces similar electric field distribution and affects the same brain structures as the H7 coil, but stimulates neurons in various orientations within these regions.
223496968|NCT07116785|DEVICE|BrainsWay Deep TMS Sham Coil|Participants assigned to this intervention will receive sham stimulation using a BrainsWay Deep TMS sham coil that mimics the sensation and acoustic properties of active stimulation but does not deliver effective magnetic pulses to the brain. This condition is used as a placebo control to blind participants and investigators.
223511874|NCT06429085|DEVICE|Rex robotic assisted balance exercises|Individual is supported by a Rex robotic exoskeleton which enables assisted and supervised practise of balance exercises. This intervention took place as a supported and supervised series of 5 sessions over 5 weeks as an Out-patient.
223511875|NCT02317042|DEVICE|Juno|Juno device set to ST mode with participant's current therapy settings.
223511876|NCT02317042|DEVICE|Juno|Juno device set to AutoEPAP iVAPS mode.
223511877|NCT02317042|DEVICE|Juno|Juno device set to Fixed EPAP iVAPS mode.
223511878|NCT04052126|OTHER|Individualized physical activity program|"Participants who agreed to participate in the study will participate in an individualized 6-month physical activity (PA) program, consisting of 3 periods: initiation (1st month), transition (2nd-3rd months) and autonomy (4th-6th months). It is based on 4 PA modalities:~The supervised PA session in a sterile room or at home once a week during the initiation and transition phases (20-45 min, low-to-moderate intensity, walking, muscle strengthening, balance and flexibility exercises).~The unsupervised PA session in a sterile room or at home once a week during the transition phase and twice a week during the autonomy phase (same as supervised session).~Follow-up by telephone once a month during the autonomy phase (30 min, support to PA).~Continuously wearing an activity tracker throughout the entire program (promotion of walking).~Activities are planned over a period of 6 months to achieve an intervention that meets the key principles of progression, specificity and empowerment."
223511879|NCT03093246|DIETARY_SUPPLEMENT|Omega-3 polyunsaturated fatty acids|3 g of omega-3 polyunsaturated fatty acids daily supplementation over a period of 180 days
223511880|NCT03093246|DRUG|Aspirin|100 mg of aspirin daily supplementation over a period of 180 days
223511881|NCT03093246|OTHER|Placebo|Placebo pills over a period of 180 days
223511882|NCT03093246|PROCEDURE|Full-mouth ultrasonic debridement|Full-mouth ultrasonic debridement will be performed in order to treat diseased sites
223511883|NCT05118438|OTHER|Health Promotion Nursing Intervention|A one-on-one program was conducted over six sessions, with each session ranging from 60 to 120 minutes. The caring program for health promotion included the following concepts: understanding the self; sharing traumatic events and negative emotions; re-framing the meaning of traumatic events; identifying thoughts and physical and emotional responses; developing health-promoting activities; and maintaining a positive attitude during the process of change .
223511884|NCT00043680|DRUG|Celecoxib|
223511885|NCT03644446|BIOLOGICAL|Bisoprolol plasma residual concentration dosage|Bisoprolol plasma residual concentration dosage will be subsequently studied by renal function (altered if creatinine clearance \< 30mL/min, mild altered between 30-60mL/min, normal \> 60mL/min as estimated by the CKD-EPI formula)
223511886|NCT05338450|DRUG|Clemastine Fumarate|4 mg of Clemastine Fumarate twice daily (8mg/day) orally for 6 months (180 days)
223511887|NCT05338450|DRUG|Placebo|Placebo equivalent to experimental arm
223511888|NCT00005898|DRUG|anti-thymocyte globulin|
223511889|NCT00005898|DRUG|cyclophosphamide|
223511890|NCT00005898|DRUG|cyclosporine|
223511891|NCT00005898|DRUG|filgrastim|
223511892|NCT00005898|DRUG|fludarabine|
223511893|NCT00005898|DRUG|methylprednisolone|
223511894|NCT05571163|DRUG|AMG 510|Tablets
223511895|NCT06548620|DRUG|RD06-04 cell infusion|CAR T Cells
223496969|NCT07117786|OTHER|CT Contrast|Participants will undergo a CT-based radiomics assessment as part of the intervention. This approach involves the extraction of high-dimensional quantitative imaging features from preoperative contrast-enhanced CT scans, which are then analyzed using machine learning algorithms to identify patterns predictive of early postoperative renal function decline. Unlike conventional radiologic evaluations that rely on visual inspection and basic metrics (e.g., tumor size or enhancement), this radiomics-based intervention captures subtle heterogeneity within renal tumors and surrounding parenchyma. The integration of these features with clinical variables distinguishes this study from other imaging or predictive model studies, enabling the development of a personalized nomogram for patients with localized RCC undergoing partial nephrectomy.
223496970|NCT07117786|OTHER|Computed Tomography|Participants will undergo a CT-based radiomics assessment as part of the intervention. This approach involves the extraction of high-dimensional quantitative imaging features from preoperative contrast-enhanced CT scans, which are then analyzed using machine learning algorithms to identify patterns predictive of early postoperative renal function decline. Unlike conventional radiologic evaluations that rely on visual inspection and basic metrics (e.g., tumor size or enhancement), this radiomics-based intervention captures subtle heterogeneity within renal tumors and surrounding parenchyma. The integration of these features with clinical variables distinguishes this study from other imaging or predictive model studies, enabling the development of a personalized nomogram for patients with localized RCC undergoing partial nephrectomy.
223496971|NCT07117474|DRUG|HRS-9563, placebo|A single subcutaneous injection of HRS-9563 injection or placebo was administered
223496972|NCT07116876|OTHER|Graft Application|Place the graft on the debrided DFU and secure. Follow with conventional care wound management (dressings and off-loading). Product may be applied weekly.
223496973|NCT07116876|OTHER|Wound Dressing Material|The wound will be debrided and undergo a moist-wound therapy and will be covered with a gauze that is appropriate for the type of wound (moist or dry). Dressings will cover each wound wound for at least 5 days, but no more than 9 days, (7 days +/- 2 days) until the next study visit. Off-loading of the wound is required.
223496974|NCT07118774|BEHAVIORAL|Behavioral: mindfulness and compassion training|Parallel randomized controlled trial
223496975|NCT07118774|BEHAVIORAL|Behavioral: caregiver skills training|Parallel randomized controlled trial
223496976|NCT07118774|BEHAVIORAL|Behavioral: Communication skills training|Parallel randomized controlled trial
223496977|NCT07118553|OTHER|classic facial massage|Powder was used as an intermediate product in facial massage application. Before the application, the participants were made to lie in the supine position on the patient's bed. The researchers performed the facial massage by standing at the participants' bedside. During the massage application, three stroking movements were applied to the chin, mouth, nose, eyes and forehead areas, respectively. Kneading motion was then applied to the same areas three times each. Then, stroking was applied to these five areas again and the facial massage application was terminated at the end of approximately 20-30 minutes. Friction movement was applied to the temporal region in each stroking and kneading application
223496978|NCT07120685|OTHER|maintaining mechanical load|"The method for maintaining mechanical load (artificially reproducing the stabilization of initial body weight) will involve the use of a weighted vest.~Participants will be asked to wear the weighted vest for at least eight hours a day over a four-week period without changing their lifestyle. Patients will also be contacted by phone every week after surgery to confirm that they are using the vest in accordance with the protocol and to collect information on any potential adverse events. During these calls, weight adjustments-based on body weight changes-will be discussed with the patient and regularly recorded to stay as close as possible to the initial body weight, with a tolerance of ±1 kg. However, the maximum weight of the vest will not exceed 15% of the patient's initial weight (weight at the time of surgery).~Between the 4th and 12th week, patients will be asked to wear the weighted vest loaded with the weight lost calculated at week 4 for at least four hours per day."
223496979|NCT07122908|DEVICE|repetitive transcranial magnetic stimulation|10Hz stimulation group will receive 1600 pulses of stimulation in a single session
223496980|NCT07122310|DEVICE|1064-nm Fractional Picosecond Laser (PicoWay)|Intervention Name: 1064-nm Fractional Picosecond Laser (PicoWay) Participants in this group received full-face treatments using a PicoWay® laser system (Candela, Wayland, MA, USA) equipped with a 1064-nm RESOLVE fractional handpiece. Treatment parameters included a 6 mm spot size, 6 Hz repetition rate, 450 ps pulse duration, and energy settings ranging from 1.5 to 2.3 mJ per microbeam. Each session consisted of 2-3 passes (approximately 2000-4000 pulses), adjusted based on individual response. Three sessions were delivered at 4-6-week intervals. Cold compresses were applied for 20 minutes immediately post-treatment.
223496981|NCT07122310|DEVICE|Intense Pulsed Light Therapy (M22 IPL System)|"Intervention Name: Intense Pulsed Light Therapy (M22 IPL System)~Intervention Description:~Participants in this group underwent full-face treatments using an M22® IPL system (Lumenis, Yokneam, Israel) with a 560 nm cutoff filter. Treatment parameters included a pulse duration of 3.5-4 ms, pulse delay of 25-30 ms, and fluence of 12-18 J/cm², adjusted based on individual response. Each treatment involved approximately 40-60 pulses. Three sessions were performed at 4-6-week intervals. A layer of medical ultrasound gel was applied before treatment and maintained for 15-20 minutes post-treatment."
224073861|NCT02097147|DRUG|Vilazodone 20 mg|Oral administration, once per day.
224073862|NCT02097147|DRUG|Vilazodone 40 mg|Oral administration, once per day.
224073863|NCT02097147|DRUG|Paroxetine 20 mg|Oral administration, once per day.
224073864|NCT02097147|DRUG|Placebo|Oral administration, once per day.
224073865|NCT04145401|DEVICE|Revision Knee implants|Primary knee arthroplasty or a revision knee that requires a revision procedure.
224073866|NCT00020540|BIOLOGICAL|recombinant CD40-ligand|
224073867|NCT00020540|BIOLOGICAL|recombinant flt3 ligand|
224073868|NCT02326779|DRUG|Acetylsalicylic acid|Acetylsalicylic acid (Aspirin) 100 mg OD for 3 years
224073869|NCT01251783|DIETARY_SUPPLEMENT|Infant Formula|Only Infant Formula without Lactobacillus, Metlin OR Metlos
224073870|NCT01251783|DIETARY_SUPPLEMENT|Exclusively breast milk|Children non randomized which mothers decided to feed them with exclusively breast milk
224073871|NCT01251783|DIETARY_SUPPLEMENT|Metlin+metlos+Lactobacillus GG|A prebiotic Agave Derivated Metlin+Metlos (6g/L) + 0.3x107 UFC Lactobacillus GG
223496982|NCT07119931|DRUG|lparomlimab and Tuvonralimab Injection in Combination with HAIC and bevacizumab|Iparomlimab and Tuvonralimab Injection（Q1706）: 7.5 mg/kg, q3w, given on Day 1 (±7 days) of each 21-day cycle; Bevacizumab: 7.5 mg/kg, q3w, administered on Day 1 (±7 days) of each 21-day cycle; HAIC:Oxaliplatin 85 mg/m² via arterial infusion over 2-3 hours, Levoleucovorin 200 mg/m² via arterial infusion over 1-2 hours, 5-Fluorouracil 400 mg/m² via arterial bolus injection, followed by continuous arterial infusion of 2400 mg/m² over 23 hours, q3w, with the treatment interval not exceeding 4 weeks.
224187638|NCT04939441|DRUG|Tenofovir alafenamide|Subjects will be treated for 96 weeks with TAF \[Vemlidy® 25mg QD\] monotherapy
224187639|NCT02020681|DEVICE|Curodont Repair|Self-assembling peptide, biomimetic re-mineralisation
224187640|NCT02020681|OTHER|Placebo|Formulation of Curodont Repair without the peptide P11-4
223496983|NCT07122791|OTHER|Home Exercise Group|In addition to the exercise program, Group 2 will receive motor imagery training. This will be carried out using the telerehabilitation method, under the supervision of a physiotherapist, and will be delivered twice a week for six weeks. A text containing posture exercises will be prepared by the physiotherapist for motor imagery training. The motor imagery text will be updated as the home exercise program is completed. The content of the motor imagery program will consist of 5 minutes of relaxation and 15 minutes of imagery training. Relaxation training will include relaxation and breathing exercises. After relaxation training, the patient will be asked to stand up with his eyes closed in a safe environment where he feels comfortable, and then a text containing posture exercises prepared by the physiotherapist for motor imagery will be read. The patient will be asked to perform the exercise by imagining it in his mind without moving his body.
223496984|NCT07122414|DRUG|FL115|FL115 single agent dose escalation,
223496985|NCT07122414|DRUG|FL115+BCG|FL115 in combination with BCG
223496986|NCT07122518|DEVICE|PALMAZ MULLINS XD™ Pulmonary Stent|The PALMAZ MULLINS XD™ Pulmonary Stent is indicated for the non-emergency treatment of pulmonary artery stenosis in pediatric patients who are at least 10kg in weight with two ventricle anatomy. The PALMAZ MULLINS XD™ Pulmonary Stent is a balloon-expandable, laser cut stent made from 316L stainless steel tubing. The stent is supplied unmounted and in five (5) nominal unexpanded lengths: 19 mm, 25 mm, 29 mm, 39 mm, and 59 mm.
223496987|NCT07122648|BIOLOGICAL|placebo|Participants will receive a single IV dose of 300 µg of placebo
223496988|NCT07122648|BIOLOGICAL|PN-101|Participants will receive a single IV dose of 300 µg of PN-101
223496989|NCT07122648|BIOLOGICAL|PN-101|Participants will receive a single IV dose of 600 µg of PN-101.
223496990|NCT07122713|RADIATION|Whole breast radiation with simultaneous integrated boost (WB-SIB) to primary breast tumor|Radiation with 26Gy to the whole breast and 40Gy simultaneous integrated boost to gross disease in the breast, in five fractions
223496991|NCT07122713|RADIATION|Whole breast radiation with simultaneous integrated boost (WB-SIB) to primary breast tumor and ipsilateral axillary lymph nodes|Radiation with 26Gy to the whole breast and regional nodes with a 40Gy simultaneous integrated boost to gross disease in breast and ipsilateral axillary nodal areas, in five fractions
223496992|NCT07123688|DEVICE|Tc-99mMDP bone scan|5 mCi of Tc-99mMDP is used for dynamic renography followed by 15 mCi for post 3-hr whole body imaging.
223496993|NCT07125222|DRUG|Gocovri (extended-release amantidine)|Gocovri is extended release formulation of amantidine. Starting on Day 1, patients will start Gocovri 137mg daily. If there is no dose-limited event after 28 days, the dose will be increased to 274mg daily which will become the new standard dose for the remaining 20 weeks of the patient's participation in the study.
223496994|NCT07124104|BEHAVIORAL|Positive Psychotherapy-Based Self-Compassion Training|Participants in the experimental group will receive Positive Psychotherapy-Based Self-Compassion Training, while participants in the control group will not receive any intervention.
223496995|NCT07124325|DEVICE|Pregnabit Pro device and PregnaOne platform|Remote CTG device and online dashboard for remote pregnancy care
223496996|NCT07124182|OTHER|shewing gum|Chewing gum is a cost-effective practice that can provide comfort to women. A Pap smear is an important test. Women experiencing pain, anxiety, or other symptoms may discourage testing. Chewing gum can reduce these sensitivities.
223496997|NCT07125144|BEHAVIORAL|Black Youth Suicide Prevention in Chicago|The Culturally Adapted intervention uses intervention video content that specifically addresses topics that shape Black youth's psychological wellbeing and development. The goal of this intervention is to share suicide prevention information in ways that are culturally responsive and attentive to the specific needs of Black adolescents.
223496998|NCT07125144|BEHAVIORAL|Signs of Suicide: Standard/Existing|Students attending schools assigned to the Standard/Existing Intervention condition will receive the Signs of Suicide curriculum.
223496999|NCT07125807|OTHER|upper extremity plyometric exercises|upper extremity plyometric exercises in neuro rehabilitation
224187641|NCT02020681|DEVICE|Fluoride|Single application on day D90
224187642|NCT00222066|PROCEDURE|Fetal ovarian cyst aspiration|Fetal ovarian cyst aspiration performed under ultrasound guidance and maternal local anesthesia
224187643|NCT00516945|DRUG|Lamivudine|
224187644|NCT00430235|DRUG|BAY 43-9006|BAY 43-9006, 400 mg, PO, BID in a 28-day cycle(morning and evening) Bicalutamide 50 mg po Once daily in a 28-day cycle (morning)
224187645|NCT02551601|OTHER|measure subfoveal choroidal thickness|measure subfoveal choroidal thickness using optical coherence tomography
224187646|NCT01430520|DRUG|Escitalopram|Tables with Escitalopram (10 mg), 1 tablet a day for 7 days, starting on the day of surgery
224187647|NCT01430520|DRUG|Placebo|Placebo tablets, 1 tablet a day for 7 days, starting on the day of surgery
224187648|NCT02074657|BIOLOGICAL|Activated and expanded natural killer cells (NKAEs)|Activated and expanded natural killer cells (NKAEs) from haploidentical donor
224187649|NCT05905354|BIOLOGICAL|NWRD08|Subjects in dose group 1 and 2 were intramuscularly injected with NWRD08 at week 0, week 4 and week 12 by electric pulse gene delivery instrument, respectively. Subjects in dose group 3 and 4 were intramuscularly injected NWRD08 at week 0, week 2, week 4 and week 12 by electric pulse gene delivery instrument, respectively.
224187650|NCT05932160|OTHER|5% glucose|Patients in the experimental group were infused intravenously with 5% dextrose (500 ml/h) in the PACU.
224187651|NCT05932160|OTHER|lactated ringers|Patients in the control group were infused intravenously with lactated ringers (500 ml/h) in the PACU.
224187652|NCT04224662|OTHER|No intervention|There is no intervention for this study
223497000|NCT07125807|OTHER|upper extremity resistance exercises|upper extremity resistance exercises in neuro rehabilitation
223497001|NCT07123662|BIOLOGICAL|Gamma-Delta T cell injection|Experimental group: Peripheral intravenous infusion of γδ T cells
223590168|NCT01395277|DIETARY_SUPPLEMENT|High Flavanol first then Low Flavanol|The high flavanol trial will be performed following consumption of a beverage containing 1,050 mg of commercially available Cocoa Flavanols which will be mixed into 250 ml of distilled water. The subjects will consume this beverage and measurements will be performed 2 hours after consumption. The low flavanol trial will be performed following consumption of a beverage containing 0 mg of Cocoa Flavanols which will be mixed into 250 ml of distilled water. The subjects will consume this beverage and measurements will be performed 2 hours after consumption.
224073872|NCT01251783|DIETARY_SUPPLEMENT|Metlin + Lactobacillus GG|A prebiotic Agave Derivated Metlin (6g/L) + 0.3x107 UFC Lactobacillus GG
224073873|NCT01251783|DIETARY_SUPPLEMENT|Metlos + lactobacillus GG|A prebiotic Agave Derivated Metlos (6g/L) + 0.3x107 UFC Lactobacillus GG
224073874|NCT01251783|DIETARY_SUPPLEMENT|Lactobacillus GG|An Infant Formula added with 0.3x107 UFC Lactobacillus GG with no Metlin or Metlos
224073875|NCT00001570|DRUG|PSC 833|
223497002|NCT07123662|OTHER|Standard prophylactic treatment|Standard prophylactic treatment
223497003|NCT07121907|DEVICE|TAVR using a guidance software|TAVR procedure with TAVIPILOT augmented reality guidance software operating during the procedure, enabling clinicians to assess the live analysis and recommendations provided by the software.
223497004|NCT07119398|COMBINATION_PRODUCT|Oxytocin plus Foley Catheter|Intravenous oxytocin and a transcervical Foley catheter
223497005|NCT07119398|DRUG|Oxytocin|Intravenous oxytocin
223497006|NCT06934252|DRUG|TRB-061|Single subcutaneous injection of TRB-061 at escalating doses
223497007|NCT06934252|DRUG|TRB-061|Subcutaneous TRB-061 administered every 4 weeks for a total of 4 doses
223497008|NCT06934252|DRUG|TRB-061|Subcutaneous TRB-061 administered every 4 weeks for 3 doses
223497009|NCT06934252|DRUG|Placebo|Single and multiple Subcutaneous doses of placebo matching TRB-061 in patients.
223497010|NCT03327467|BIOLOGICAL|Cord Blood Infusion|IV infusion of umbilical cord infusion (sibling, autologous, or unrelated donor)
223497011|NCT05630794|PROCEDURE|Biopsy Procedure|Undergo biopsy
223497012|NCT05630794|PROCEDURE|Biospecimen Collection|Undergo collection of blood
223497013|NCT05630794|PROCEDURE|Colonoscopy|Undergo colonoscopy
223497014|NCT05630794|DRUG|Dordaviprone|Given PO
223497015|NCT05630794|OTHER|Questionnaire Administration|Ancillary studies
223497016|NCT05630794|PROCEDURE|Sigmoidoscopy|Undergo sigmoidoscopy
223497017|NCT05623488|DRUG|huCART-meso cells|Autologous T cells lentivirally transduced with chimeric anti-mesothelin immunoreceptor M5 scFv fused to the 4-1BB and CD3ζ signaling domains
223497018|NCT05623488|DEVICE|Mesothelin Expression Testing|Laboratory Developed Test
223497019|NCT06937619|DRUG|Risankizumab|Subcutaneous Injection
223497020|NCT06937346|DEVICE|The Rehand Robotic Glove|"The exoskeleton hand system provides recovery and training for paralyzed fingers using an innovative method that mirrors the movements of a healthy hand. The system uses a sensor glove to read movements and transfer them to a rehabilitation glove. This forces the injured hand to repeat the same movements as the healthy hand, helping to restore motor skills.~The system combines flexible robotics with neuroscience to help patients retrain their muscles. It reduces muscle tension and swelling, relieves stiffness, improves blood circulation, and restores muscle performance after atrophy. It also reduces hypertension and joint pain, and activates neuroplasticity through passive and active techniques.~All patients received standard rehabilitation treatments in accordance with clinical protocol No. 94 for the third stage of medical rehabilitation, approved by the Joint Commission on Quality of Medical Services from the Ministry of Health of Kazakhstan on 14 May 2020."
223497021|NCT06937346|OTHER|Standard Rehabilitation|All patients received standard rehabilitation treatments in accordance with clinical protocol No. 94 for the third stage of medical rehabilitation, approved by the Joint Commission on Quality of Medical Services from the Ministry of Health of Kazakhstan on 14 May 2020.
223497022|NCT06766292|PROCEDURE|primary intervention|In the study group: 2.0 mm screws were fixed to the lateral wall of the sinus above the superior osteotomy and placed buccopalatally where the schneiderian membrane was elevated and maintained. this technique will suspends the membrane in position to allow the blood clot to organized and formation of bone.
223497023|NCT06766292|PROCEDURE|open sinus lifting with xenograft only|ll Patients in this group underwent open sinus procedures to lift the sinus membrane followed by application of the xenograft as an augmentation material xenograft is used instead of autogenous bone graft to avoid the morbidity of the donor side
223497024|NCT03580928|DRUG|Venetoclax|Venetoclax is an oral drug that blocks the function of a protein called BCL-2. CLL cancer cells are thought to depend on the BCL-2 protein for their survival. By blocking BCL-2, venetoclax may kill cancer cells or stop them from growing.
223497025|NCT03580928|DRUG|Obinutuzumab|Obinutuzumab is a type of drug called a monoclonal antibody. It targets a protein CD20 on the surface of the CLL cell, causing it to die
223497026|NCT03580928|DRUG|Acalabrutinib|Acalabrutinib is a type of drug called a kinase inhibitor. It blocks a type of protein called Bruton Tyrosine Kinase (BTK) that helps CLL cells live and grow
223497027|NCT06938529|DRUG|VCT220|Small molecule GLP-1RA tablet, film coated
224073876|NCT00001570|DRUG|vinblastine|
224073877|NCT02171975|PROCEDURE|pre-procedure ultrasound guided paramedian spinal|In group P, a portable ultrasound unit was used for initial pre-procedural marking. The interspinous space at which the clearest image of the anterior complex (ligamentum flavum dura complex- LFD) and posterior complex (posterior longitudinal ligament- PLL) was obtained, was selected. At the selected interspace, and with the probe positioned to obtain the clearest ultrasound image, a skin marker was used to mark the midpoint of the long border of the probe and the midpoints of the short borders of the probe . At the same horizontal level as the midpoint of the long border of the probe, the midpoint of the line drawn between the two short border midpoints of the probe was used as paramedian insertion point for the spinal needle.
224073878|NCT02171975|PROCEDURE|Conventional landmark guided midline spinal anaesthetic|Spinal anaesthesia was administered based on conventional landmark based midline approach.
224073879|NCT05599997|DRUG|Pecavaptan (BAY1753011)|30 mg, immediate release tablet, single dose, oral
224187653|NCT05804695|PROCEDURE|Arthroscopic TMJ disc repositioning under GA|a surgical procedure used to treat Tempro- mandibular disc displacement using arthroscope.
224187654|NCT01537458|PROCEDURE|follow-up of isolated tricuspid valve repair|follow-up of patients that underwent TV repair in the past.
224187655|NCT04576585|BEHAVIORAL|Lexicon training|Participants will receive training on the lexicon of appetite on up to 3 days during the training week. This will entail reading written definitions, watching an instructional video, eating exercises and completing training exams demonstrating they understand the distinctions between appetitive terms (hunger, desire to eat, fullness, and prospective consumption). The training will require about 30 minutes to complete. To ensure the success of training, participants must verbally describe the definitions of the outcome sensations to a member of the research team and complete a written quiz with at least 90 % correct responses. Failure to satisfactorily convey understanding of the concepts will result in an offer to repeat the training 2 more times or be rejected from the study.
224187656|NCT05365906|OTHER|Delphi-procedure consisting of four survey rounds|This study will use a modified Delphi approach, consisting of a set of iterative questionnaires. In round 1, an expert panel will grade the relevance of UTI-related items, after which a smaller core research team will compose a reference standard in a series of (online) meetings. In round 2, clinical vignettes will be used to party validate the reference standard and expert panel agreement with the new reference standard will be assessed.
224187657|NCT05138965|PROCEDURE|the mCP with alginates dressing|The method is to use gauzes folded onto the RVF wound surface to compact the deep wound so as to solid and durable,when the gauzes surface will be covered by alginates dressing.
224187658|NCT05138965|PROCEDURE|only alginates dressing|Only alginates dressing will be placed above the RVF wound without any pressure.
224187659|NCT05330195|OTHER|Bicycle Ergometer Training|Bicycle ergometer training will be performed 3 days a week for 12 weeks at 60% of their maximum hearth rate with 40 minutes total duration consisting of 5 min warm up and 5 min cool down period to children in treatment group.
224187660|NCT05330195|OTHER|Home-based exercise group|Children will be given a home program including stretching, breathing, normal joint movement, body weight and mildly resistant exercises, and children will be asked to do these for 3 to 5 days a week.
224187661|NCT04498585|OTHER|VR Stimulation|Participants in the intervention group will be provided with 30 minutes of relaxing, 360-degree virtual reality stimulation and corresponding sounds, three times a day (morning, midday, evening) everyday during their stay in the ICU, up to a maximum of 14 days.
224309059|NCT06824350|DEVICE|chlorination for water disinfection and surface disinfection|"* Installation of inline chlorine doser(s) for automated water disinfection.~* Provision of chlorine solution for water and surface disinfection (half of treatment facilities randomized to receive electrochlorinator, half receive bulk chlorine solution deliveries).~* Provision of mop(s), bucket(s), and spray bottles for surface cleaning."
223497028|NCT06938529|DRUG|Placebo|VCT220 Placebo tablet
223745886|NCT00783445|BEHAVIORAL|Self-Help Exercise Program (HOME)|After a fitness evaluation, participants will be given an exercise prescription and recommendations for home-based, self-mediated progressive exercise. Participants will be expected to do 1 hour of exercise two to three times each week for 1 year.
223497029|NCT06939426|BEHAVIORAL|Music therapy intervention|"The intervention protocol is based on four main themes, which are addressed over the course of eight sessions:~* Self-care~* Self-recognition and expression of emotions~* Empathy~* Teamwork~Each theme is related to factors from the HUMAS (affection, self-efficacy, emotional understanding, dispositional optimism, and sociability) and/or ProQOL (compassion satisfaction, burnout, and compassion fatigue). A variety of techniques related to the four main methods of music therapy will be used in the sessions: receptive, re-creative, composition, and improvisation."
223497030|NCT07103083|DIETARY_SUPPLEMENT|Beverage 1|Fruit juice with zero sugar
223497031|NCT07103083|DIETARY_SUPPLEMENT|Beverage 2|Fruit juice with low sugar - formulation 1
223497032|NCT07103083|DIETARY_SUPPLEMENT|Beverage 3|Fruit juice with low sugar - formulation 2
223497033|NCT07103083|DIETARY_SUPPLEMENT|Beverage 4|Fruit juice with full sugar
223497034|NCT07103083|DIETARY_SUPPLEMENT|Beverage 5|Fruit juice with full sugar
223497035|NCT07103083|DIETARY_SUPPLEMENT|Beverage 6|Glucose control beverage
223497036|NCT06943014|DEVICE|Actimetry Protocol|Our goal is to develop an actimetry protocol using both accelerometers and pressure insoles to quantify physical activity, involving the upper and/or lower limbs, as well as sedentary behavior in post-stroke individuals. Recent studies have explored the use of validated accelerometer configurations designed for healthy individuals, applied to the post-stroke population to monitor their physical activity and sedentary behavior. However, although these protocols have been validated for healthy individuals, they need to be adapted for post-stroke patients, who exhibit slower, asymmetric, and lower-amplitude movements compared to healthy subjects. This protocol could be valuable in both clinical practice and research, helping to optimize stroke rehabilitation and promote a healthy, active lifestyle.
223497037|NCT06805656|DRUG|Maraviroc|antiretroviral intensification
223497038|NCT06805656|DRUG|Dolutegravir|antiretroviral intensification
223497039|NCT06805656|BIOLOGICAL|Dendritic Cell Vaccine|therapeutic vaccination
223497040|NCT06805656|DRUG|Auranofin|purging
223497041|NCT06805656|DRUG|Sirtuin Histone deacetylase inhibitor|latency disruption
223497042|NCT06942247|DEVICE|Active Comparator: Fracture Fixation (Inion Freedom Screws)|Device: Absorbable screw for internal fixation of fracture. Patients were divided into the Inion Freedom Screws group and the Biological Hollow Bone Screws group according to the type of the screws they used.
223497043|NCT06942247|DEVICE|Experimental: Fracture Fixation (Biological Hollow Bone Screws)|Device: Absorbable screw for internal fixation of fracture. Patients were divided into the Inion Freedom Screws group and the Biological Hollow Bone Screws group according to the type of the screws they used.
223497044|NCT04358159|DEVICE|Ventralex|Repair of the hernia by a Ventralex patch in sublay position
223497045|NCT04358159|DEVICE|Progrip|Repair of the hernia by a Progrip mesh in onlay position
223497046|NCT07115472|DRUG|Fluoxetine|Refractory SMAS patients with SSD received oral fluoxetine treatment, initiated at 20 mg/day and increased to a maximum of 60 mg/day based on therapeutic response.
223497047|NCT07114081|DIAGNOSTIC_TEST|Diagnostic laparoscopy|Minimal access surgery to determine the presence of characteristic endometriosis lesions on visual inspection of the pelvis
224309060|NCT06824350|BEHAVIORAL|infection prevention and control messaging|Infection prevention and control guidance and messaging
224309061|NCT06606626|BEHAVIORAL|Sleep deprivation|Partial (4h) or total (0h) sleep deprivation
224309062|NCT06606626|BEHAVIORAL|Sleep place|8h sleep at home or in the laboratory
224309063|NCT06982742|OTHER|Mobile Health App for Neuropathic Pain Management in MS|This intervention is a self-management mobile health application specifically designed for patients with Multiple Sclerosis who experience neuropathic pain. Unlike general symptom tracking apps, this application provides structured educational content on anti-inflammatory nutrition, physical activity, sleep hygiene, stress management, and smoking cessation. It includes goal-setting features, personalized reminders, symptom tracking tools, and feedback mechanisms to promote behavior change and self-efficacy. The intervention is designed based on Social Cognitive Theory, aiming to empower patients to actively manage their pain and improve their quality of life. T
224309064|NCT06990763|DRUG|Remimazolam|Remimazolam, sufentanil and rocuronium were used during induction, and remimazolam and refentanil were used during maintenance
224309065|NCT06990763|DRUG|propofol|Propofol, sufentanil and rocuronium were used during induction, and propofol and remifentanil were used during maintenance
224309066|NCT06990646|BEHAVIORAL|VR-ACT|8 MODULES OF 3D VIRTUAL REALITY Modules 1 \& 2: Awareness Regulation Skills Modules 3, 4 \& 5: Acceptance of Pain and Internal Experiences Modules 6, 7 \& 8: Behavior Change and Valued Action
224309067|NCT06990646|BEHAVIORAL|Sham-VR|8 2D non-immersive distracting video-animations delivered through a VR headset.
223497048|NCT06950593|OTHER|Task Specific Training (TST)|Task specific training activities are types of activities that may be used in standard of care for stroke rehabilitation. Tasks will be completed in sitting or standing. As is usual in studies for upper limb hemiparesis, study participants will be picking up objects with their affected hands. They will work on grasp, grasp-lift of objects, release of objects, reaching and grasping, and reaching without grasping.
223497049|NCT06950593|OTHER|Transcutaneous electrical spinal cord stimulation (TESS)|The Digitimer DS8R Transcutaneous Spinal Cord Neurostimulator will deliver transcutaneous electrical spinal cord stimulation. The stimulus intensity used during the intervention will be determined based on individual maximum tolerance. We expect this current amplitude to be between 10mA and 100mA. Stimulation time will be standardized to a 30min duration during which the participant will perform task specific training tasks.
223497050|NCT06950593|OTHER|Sham transcutaneous electrical spinal cord stimulation (Sham TESS)|The Sham TESS intervention will utilize the same device and setup as the true TESS intervention. However, after turning on the stimulation and reaching the appropriate intensity, the stimulation will be ramped down and turned off for the remainder of the treatment session. The participant will be told that the stimulation was brought down to a sub-threshold level in order to maintain treatment group blinding.
223497051|NCT06952478|BIOLOGICAL|CT-P44(Daratumumab)|CT-P44 1800 mg will be administered as SC injection in combination with Rd until each patient's PD, unacceptable toxicity or Cycle 26, whichever occurs first.
223497052|NCT06952478|BIOLOGICAL|Darzalex Faspro(Daratumumab)|Darzalex Faspro 1800 mg will be administered as SC injection in combination with Rd until each patient's PD, unacceptable toxicity or Cycle 13, whichever occurs first.
223497053|NCT07123649|BEHAVIORAL|Shared Decision-Making Toolkit|The SDM toolkit is designed to support discussions on the continuation of surveillance mammography. It provides evidence-based guidelines, communication strategies, and education materials to aid in personalized decision-making.
223497054|NCT07124611|OTHER|Interview|Ancillary studies
223497055|NCT07124611|PROCEDURE|Nutritional Therapy|Attend nutritional appointments
223497056|NCT07124611|PROCEDURE|Physical Therapy|Attend physical therapy appointments
223497057|NCT07124611|BEHAVIORAL|Psychosocial Care|Receive psychosocial care
223497058|NCT07124611|OTHER|Questionnaire Administration|Ancillary studies
223497059|NCT07125014|PROCEDURE|Observational study|This is an observational study with no experimental or therapeutic interventions administered to participants. All data were collected retrospectively from existing hospital records for patients who underwent ERCP between January 2023 and December 2023 at Lady Reading Hospital, Peshawar. No drugs, devices, or procedures were assigned to participants as part of this research.
223497060|NCT07119554|BEHAVIORAL|HBM-Based Postpartum Contraceptive Counselling|This intervention involves providing a structured, individual contraceptive counseling session based on the Health Belief Model (HBM) to women in the postpartum period.The session is delivered face-to-face, lasts approximately 30 to 45 minutes, and is structured around the core components of the HBM: perceived susceptibility, perceived severity, perceived benefits, perceived barriers, self-efficacy, and cues to action. The aim of the intervention is to improve attitudes toward family planning and increase the intention to use contraceptive methods.
223497061|NCT07120997|DIETARY_SUPPLEMENT|Prunes|Participants randomized to the 50g prune group will consume 6 prunes per day for the duration of the 18-month intervention.
223497062|NCT07120997|DIETARY_SUPPLEMENT|Calcium supplement|All participants will consume calcium supplements daily for a baseline period and for the duration of the 18-month intervention.
223497063|NCT07120997|DIETARY_SUPPLEMENT|Vitamin D Supplement|All participants will consume Vitamin D supplements daily for a baseline period and for the duration of the 18-month intervention.
224073880|NCT05599997|DRUG|Pecavaptan (BAY1753011)|15 mg, immediate release tablet, single dose, oral
224073881|NCT03112239|DEVICE|Light-Emitting Diode Therapy (LEDT)|Light-emitting diode, has effects similar to the photobiomodulation by low-level laser intensity.
224073882|NCT05788679|DRUG|Azacitidine|Azacitidine
224073883|NCT05788679|OTHER|Donor lymphocytes|Donor lymphocytes in patients without immune suppression
224073884|NCT05788679|OTHER|Tapering of immune suppression|Tapering of immune suppression in patients who are on immune suppressive drugs
224073885|NCT06471764|DEVICE|FX+ and 12-Lead ECG Recording|While lying down, subjects will wear the FX+, a chest strap device which will measure cardiac electrical activity to generate a continuous heart rate measurement. Simultaneously, electrodes for the 12-Lead ECG will be placed on the chest and arms/legs to record the electrical activity. Two 30-second recordings from the FX+ will be taken simultaneously with the 12-lead ECG with no more than a 3-minute interval between the two recordings.
223745887|NCT04342845|BEHAVIORAL|Experimental: Motivational interviewing Placebo Comparator: Traditional lectures|Patients in the intervention group (n=117) received a four-session patient empowerment program in small groups over one month by trained nurses and doctors. he control group received traditional lectures that consisted solely of conveying healthcare information to patients.
223745888|NCT03449160|DEVICE|UPRIGHT|A small externally wearable device that is placed on the back, which gently vibrates when correct posture is not maintained. The device is removable, and used for only portions of the day
223745889|NCT03449160|OTHER|physical therapy|routine physical therapy
224073886|NCT05519735|DIAGNOSTIC_TEST|Multimodality Imaging|Patients receive CXCR4-targeted PET/CT, CMR and Echo
224073887|NCT00457327|PROCEDURE|protective ileostomy|
224073888|NCT06549491|BEHAVIORAL|Sleep Wizard|First, foster parents will fill out the child sleep questionnaire, which will screen for behavioral and medical sleep issues. Foster parents will then complete introductory modules focused on general sleep hygiene and education. Next, they will access tailored sleep strategy modules determined by an automated algorithm based on sleep challenges identified in the sleep screening. Participants will be notified to alert the child?s pediatrician if the screening indicates the presence of a medical sleep disorder, such as sleep disordered breathing. Participants will be asked to follow recommended sleep strategies for 2 weeks, and complete short morning daily diaries on the child?s sleep from the night prior within the Sleep Wizard platform. To reinforce intervention content and enhance adherence and integrity, participants will receive appropriately timed tailored text message reminders of strategies they should be utilizing.
223497064|NCT07118488|PROCEDURE|Multitarget PFA Ablation|"* Informed consent gave by the patient.~* Implantable loop recorder procedure~* Clinical procedure starts~* Electrophysiologycal study~* Non-invasive map is obtained.~* Electroanatomical map of both atria is generated.~* Intracavitary electrogram (EGM) driver assessment~* Pulmonary vein isolation~* Extra pulmonary drivers ablation based on EGM findings (rotational and high frequency sites).~* Non-invasive map is obtained to assess ablation impact on driver distribution.~* Remap and extra pulmonary lesions are carried out until activity. At drivers sites disappears or decreases in at least 2 hertz or up to physician criteria.~* Patient follow up"
223497065|NCT07115589|OTHER|Muscle Your Heart home-based program|2 one-hour sessions of adapted physical activity per week - HIIT and free adapted physical activity - 1 one-hour monthly therapeutic patient education session - A dedicated platform - Adapted physical activity educators - Dedicated education therapeutic nurses
223497066|NCT07120256|OTHER|locator attachment|mandibular single implant overdenture retained by locator attachment
223497067|NCT07120256|OTHER|ball and socket attachment|mandibular single implant overdenture retained by ball and socket attachment
223497068|NCT07114120|DRUG|Bailing Capsules in combination Guben Kechuan Granules|Bailing Capsules (four capsules each time, three times a day) in combination Guben Kechuan Granules (1 bag each time，three times a day,)
223497069|NCT07113613|RADIATION|Exemption from additional radiotherapy on the tumor bed after surgery|For patients who met the inclusion criteria and were enrolled, postoperative tumor bed boost radiotherapy was waived, and only whole breast and/or regional lymph node irradiation was administered.
223497070|NCT07120035|DIETARY_SUPPLEMENT|Lycopene-rich juice|We sought to deliver 8400 µg of lycopene per day, and so participants were asked to drink approximately 4 fluid ounces per day of the tomato-based, lycopene-rich juice.
224073889|NCT05103865|BEHAVIORAL|Animal-assisted therapy (AAT)|
224073890|NCT05103865|OTHER|usual treatment|
224073891|NCT04676737|DRUG|TTHX1114(NM141)|TTHX1114
224073892|NCT04378608|DRUG|OBV/PTV/r) ± ribavirin (RBV)|
224073893|NCT06419140|DRUG|Standard SOX/XELOX adjuvant chemotherapy plus multimodal rehabilitation|Motivational counseling to perform nutritional, psychological, and exercise inventions
224073894|NCT00130403|DRUG|risedronate sodium|
224073895|NCT05513989|DEVICE|modified Magill forceps|modified pediatric Magill forceps was used to assist nasotracheal intubation.
224073896|NCT05513989|DEVICE|Magill forceps|Magill forceps was used to assist nasotracheal intubation.
224073897|NCT05476159|DRUG|Indocyanine green solution|"Adequate perfusion was defined as the direct and clear visualization of the fluorescence along the gastric tube, relative to the excised specimen, after an estimated time of 150-180 s after i.v. administration injection"
224073898|NCT05476159|DEVICE|Gastric bypass|Roux and Y Gastric bypass
224073899|NCT03290833|DEVICE|Robotic|Participants will be placed in the robot and practice common hand tasks involving single finger range of motion exercise, grasping, and pinching objects.
224073900|NCT03290833|OTHER|Conventional therapy|An occupational therapist will provide one-on-one individualized programs focused on arm and hand function. Treatment will include function-oriented specific tasks, such as reach, grasp, transport and release of various objects between different targets.
224073901|NCT01512303|BEHAVIORAL|Sudarshan Kriya Yoga|SKY incorporates yoga, discussion periods and several types of breathing exercises for relaxation.
224073902|NCT01512303|BEHAVIORAL|Mindfulness-Based Stress Reduction|MBSR incorporates yoga, discussion periods, and several types of meditation, all involving attention to the present moment and acceptance of any feelings, sensations or thoughts
224073903|NCT03850912|OTHER|Stakeholder Survey (Control Period)|Before eSyM go-live, study team members from each site will solicit input via emailed survey, remote meetings and/or in-person meeting on the use of ePROs in oncology from stakeholders to obtain input regarding adaptation, anticipated challenges, and implementation.
224073904|NCT03850912|OTHER|Stakeholder Survey (Intervention Period)|After eSyM go-live and on an ongoing basis, we will evaluate the implementation process at each of the sites with a focus on adoption, appropriateness, acceptability, sustainability, penetration, and scalability. We will do so through emailed surveys and/or discussions with health system leadership, clinicians, clinic support staff, and informatics/IT staff.
224073905|NCT03850912|OTHER|Qualitative Interview|A small subset of patients and stakeholders were invited to take part in qualitative interviews after the eSyM trial rollout.
224073906|NCT03850912|OTHER|SASS Questionnaire|"A subset of control and intervention patients will be asked to complete a research questionnaire called the SASS Questionnaire asking about their Self-efficacy, Attainment of information needs, Symptom burden, and Satisfaction with care."
224073907|NCT03850912|OTHER|eSyM|The electronic symptom management (eSyM) program is the EHR-integrated ePRO program being evaluated through this trial.
223497071|NCT07120490|OTHER|FMT (fecal microbiota transplantation)|This intervention consists of a two-phase treatment for Clostridioides difficile infection in high-risk adults. First, participants receive a short-course (5 days) of oral vancomycin to reduce C. difficile bacterial load. Following antibiotic pretreatment, fecal microbiota transplantation (FMT) is administered to restore healthy gut microbiota. FMT is delivered primarily via encapsulated microbiota capsules, with alternative routes including colonoscopy, gastroscopy, nasojejunal tube, or rectal enema if capsules are contraindicated. A second FMT dose is given 7 days after the first, either as daily capsules over six days or as a single endoscopic administration. This approach aims to reduce CDI recurrence by combining targeted antibiotic reduction of pathogens with microbiome restoration.
223497072|NCT07120490|DRUG|Fidaxomicin|Participants receive a 10-day course of fidaxomicin administered orally at a dose of 200 mg twice daily. Fidaxomicin is a narrow-spectrum macrocyclic antibiotic specifically targeting Clostridioides difficile with minimal impact on the normal gut microbiota. This monotherapy aims to eradicate C. difficile infection while preserving the intestinal microbiome, thereby reducing the risk of recurrence. No additional interventions are provided during the treatment period. Biological samples are collected before and after treatment to evaluate clinical response, safety, and microbiome changes.
223497073|NCT07120490|DRUG|Vancomycin (VAN) treatment|Participants receive a 10-day course of oral vancomycin at a dose of 125 mg four times daily. Vancomycin is a broad-spectrum glycopeptide antibiotic commonly used as standard-of-care therapy for Clostridioides difficile infection. This monotherapy aims to eradicate C. difficile by reducing bacterial load in the colon. No additional interventions are applied during the treatment period. Biological samples are collected before and after treatment to monitor clinical outcomes, safety, and changes in the gut microbiome.
223497074|NCT07121361|DEVICE|Mouthwash Product|DNA mouthwash
223497075|NCT07121361|DEVICE|Control|Placebo mouthwash
223497076|NCT07119775|DRUG|Tideglusib|
223497077|NCT05339126|DEVICE|RNS System|The RNS System provides closed loop responsive brain stimulation. The Neurostimulator monitors the electrical activity of the brain to detect abnormal activity that could lead to a seizure. If abnormal activity is detected, the neurostimulator delivers electrical stimulation to the brain through the leads to help prevent the seizure before it occurs.
223497078|NCT01440920|DRUG|OCV-501|subcutaneously administered once a week, 4 times at the dose of 0.3 mg
223497079|NCT01440920|DRUG|OCV-501|subcutaneously administered once a week, 4 times at the dose of 1 mg
223497080|NCT01440920|DRUG|OCV-501|subcutaneously administered once a week, 4 times at the dose of 3 mg
223497081|NCT01420744|DRUG|BT086|"BT086 will be administered per intravenous infusion (IV). The dose to be administered is 3.65 mL /kg bw/day and is calculated by the mean Immunoglobulin M (IgM) content of BT086 which is 23%.~Infusion rate:~Starting rate is 0.1 mL/min. Maximum infusion rate is 0.5 mL/min (target infusion rate) Treatment will be administered over a 5-day period."
223497082|NCT01420744|DRUG|1% Human Albumin infusion|"1% Albumin will be administered per intravenous infusion (IV). The dose to be administered is 3.65 mL /kg bw/day.~Infusion rate:Starting rate is 0.1 mL/min. Maximum infusion rate is 0.5 mL/min (target infusion rate). Rate is to be raised in steps of 0.1 mL every 10 min until the target infusion rate is reached.~Treatment will be administered over a 5-day period.~Starting rate is 0.1 mL/min. Maximum infusion rate is 0.5 mL/min (target infusion rate)"
223497083|NCT02626611|DRUG|Omalizumab|Omalizumab is an anti-Immunoglobulin E antibody injection and will be administered per product insert from weeks 0 through 16 of the study.
223497084|NCT02626611|DRUG|Food Flour Buildup|Food flours identified as allergic (based on food challenge), will be introduced at week 8. The food dose will be escalated every 2 weeks up to 2000 milligrams of each of the food flours. Subjects are required to reach 300 milligrams at week 16 to continue to week 30. Subjects must tolerate 2000 milligrams per food by week 28 in order to be randomized.
223497085|NCT04568109|BEHAVIORAL|Cognitive-behavior therapy|The manualized protocol (Gloster et al., 2011) comprise of 12 weekly sessions of CBT focusing on therapist-guided interoceptive and in-situ exposure exercises.
223497086|NCT06551558|OTHER|global warming|A systematic pre- and post-operative warming associated with the optimization of per-operative warming.
223497087|NCT06551558|OTHER|per operative warming|"per-operative warming only thanks to the Optimized Forced air blanket with a prewarming of 10 minutes performed in the operating room."
223497088|NCT04652310|DEVICE|TFNA extended-short nail (235 mm)|The extended short version of the TFN-advanced proximal femoral nailing system (TFNA)
223497089|NCT04652310|DEVICE|TFNA long nail (260-480mm)|The long version of the TFN-advanced proximal femoral nailing system (TFNA)
223497090|NCT00347490|DRUG|Enoxaparine|
224073908|NCT01539590|DRUG|BB3|Daily intravenous administration of 2 mg/kg BB3 for four (4) days
224073909|NCT01539590|DRUG|Normal saline|Daily intravenous administration for four (4) days. The volume of normal saline will vary by estimated weight.
224073910|NCT02278172|DIETARY_SUPPLEMENT|Vitamin D|3000IU (75 μg) vitamin D in a commercially available oral spray solution
224073911|NCT02278172|DIETARY_SUPPLEMENT|Placebo|Placebo oral spray solution manufactured to mimic the vitamin D oral spray
224073912|NCT00820521|DRUG|active|
224073913|NCT00820521|DRUG|placebo|
224073914|NCT03569527|DIETARY_SUPPLEMENT|Kiwifruit|The total duration of the study will be 8 weeks (2- week baseline, 4-week intervention, and 2-week follow-up). Eligible patients will be randomized to receive kiwifruit (2 green kiwifruit per day for the 4 week intervention period.
224073915|NCT03569527|DIETARY_SUPPLEMENT|Fiber|The total duration of the study will be 8 weeks (2- week baseline, 4-week intervention, and 2-week follow-up). Eligible patients will be randomized to receive psyllium fiber (24 g/day, fiber=6g/day) for the 4 week intervention period.
224073916|NCT03569527|DIETARY_SUPPLEMENT|Prunes|The total duration of the study will be 8 weeks (2- week baseline, 4-week intervention, and 2-week follow-up). Eligible patients will be randomized to receive prunes/dried plums (100g, fiber=6 g/day) for the 4 week intervention period.
224073917|NCT04857255|BEHAVIORAL|Technology assisted language intervention|speech language therapy that has integrated technology delivered through specific software on an iPad
224073918|NCT04857255|BEHAVIORAL|Treatment as usual|No change will occur to the current ongoing speech-language therapy being delivered.
224073919|NCT00803075|DEVICE|Endovascular Repair of Abdominal Aortic Aneurysms Using TALENT AAA Stent Graft System|
224187662|NCT05984914|BEHAVIORAL|PSAI|The 8 sessions included biofeedback training in diaphragmatic breathing, information about distress, its symptoms, ways to manage stress through lifestyle modifications (physical activity, principals of Mediterranean diet without alcohol consumption, sleep hygiene, diaphragmatic breathing, conflict avoidance) \& instructions for lymphedema prevention, introduction to the Pythagorean Self-Awareness Intervention, instructions for the implementation of the technique, analysis of the Golden Verses,and their connection with lifestyle medicine as well as active involvement of the participants with group conversation and sharing of experiences.
224187663|NCT05984914|BEHAVIORAL|One day seminar|The one day seminar included biofeedback training in diaphragmatic breathing, information about distress, its symptoms, ways to manage stress through lifestyle modifications (physical activity, principals of Mediterranean diet without alcohol consumption, sleep hygiene, diaphragmatic breathing, conflict avoidance) \& instructions for lymphedema prevention.
224187664|NCT00688649|DIETARY_SUPPLEMENT|Standard Oral Nutritional Supplement (ONS)|Standard energy, oral nutritional supplement (a milk style nutritional supplement (1.5kcal/ml, 200ml) containing protein, fat, carbohydrate and micronutrients)
224187665|NCT00688649|DIETARY_SUPPLEMENT|High energy Oral Nutritional Supplement (ONS)|High Energy nutritional supplement (a milk style nutritional supplement (2.4kcal/ml, 125ml) containing protein, fat, carbohydrate and micronutrients)
224187666|NCT05532462|PROCEDURE|Trans-nasal complete nasalabial cyst excision|The surgery is carried out mainly using x5 magnification loupe and 0° degree sinoscope. Submucosal infiltration (lidocaine 2% and 1:100,000 adrenaline). An incision was made at the mucosal covering of the cyst wall and nasal floor in a transverse and anteroposterior direction. The mucosal flap is elevated and separated from the cyst wall and reflected toward the septum side. During dissection, cyst content is usually drained. The whole cyst wall was carefully dissected with sharp and blunt dissection from the mucous membrane, and laterally from the premaxillary area. Finally, endoscopic examination to check the operative bed and refashioning mucosal flap coverage. If mucosal flap is lacerated, then excised and operative bed left for healing by creeping from surrounding edges. Endoscopic trans-nasal complete excision has a shorter operative time, minimal intraoperative bleeding, and no postoperative pain or edema reported.
223497091|NCT03537430|PROCEDURE|TNT uniportal VATS mediastinal tumor resection|TNT uniportal video-assisted thoracoscopic surgery refers to the use of conventional uniportal video-assisted thoracoscopic surgery, the use of laryngeal mask anesthesia instead of tracheal intubation anesthesia, intraoperative catheter was not retained, postoperative chest catheter placement.
223497092|NCT03537430|PROCEDURE|Traditional uniportal VATS mediastinal tumor resection|The surgical procedures followed principles of mediastinal tumor resection，uniportal video-assisted thoracoscopic surgery in mediastinal tumor resection.
223497093|NCT05643794|DRUG|rozanolixizumab|Study participants will receive rozanolixizumab during the dosing periods as pre-defined.
223497094|NCT05643794|OTHER|Placebo|Study participants will receive Placebo during the dosing periods as pre-defined.
223497095|NCT06037915|DEVICE|low flow oxygen with nasopharyngeal tube|low flow oxygen with nasopharyngeal tube
223497096|NCT06037915|DEVICE|high flow oxygen with OptiflowTM Nasal High Flow|high flow oxygen with OptiflowTM Nasal High Flow
223497097|NCT02813447|DRUG|Sertraline|
223497098|NCT02813447|DRUG|Placebo|
223497099|NCT05607459|OTHER|Dry Needling|"Dry needling consists of a skilled intervention which uses a thin filiform needle (as those used in acupuncture) to penetrate the skin and stimulate underlying myofascial trigger points (defined as a hyperirritable spot in skeletal muscle that is associated with a hypersensitive palpable nodule in a taut band which is painful on manual compression and can give rise to characteristic referred pain, referred tenderness, motor dysfunction and autonomic phenomena.)~This intervention will be performed targeting the upper trapezius and cervical multifidus muscles"
223497100|NCT05607459|BEHAVIORAL|Therapeutic Exercise|Patients will include a supervised therapeutic exercise program in their daily life, based on strengthening exercises for neck muscles.
223497101|NCT05607459|OTHER|Manual Therapy|Patients will receive a manual compression (30 seconds) over myofascial trigger points located at the upper trapezius muscle, scalene muscles and cervical multifidus muscle.
223497102|NCT05607459|OTHER|Sham Dry Needling|"For the sham DN intervention, a similar approach will be used, but the skin will be not pierced since the material used will be a telescopic Park's sham device.~The guide tube will be pressed against the skin mark and the sham needle will be allowed to drop. The handle will be tapped briskly, but the (blunted) needle tip will not not break the skin."
223497103|NCT04167670|DRUG|Vonoprazan|Over-encapsulated tablets administered orally.
223497104|NCT04167670|DRUG|Amoxicillin|Capsules administered orally.
223497105|NCT04167670|DRUG|Clarithromycin|Tablets administered orally.
223497106|NCT04167670|DRUG|Lansoprazole|Over-encapsulated capsules administered orally.
223497107|NCT01127061|BEHAVIORAL|Exercise training|4 months of exercise training that is custom-designed based on individual cardiopulmonary stress test data. Regimen starts at low intensity (60% of heart rate reserve) and frequency (20 minutes, 3 days per week) and increases with a goal of 70% of heart rate reserve and exercising 60 minutes 4-7 days per week.
223497108|NCT01192698|DRUG|IV interferon|IV interferon 5MU during anhepatic phase
223497109|NCT05850689|DRUG|Lumateperone|Lumateperone 42 mg capsules administered orally, once daily
223497110|NCT05850689|DRUG|Placebo|Matching capsules administered orally, once daily
223497111|NCT06260748|DRUG|Chenodeoxycholic acid|250mg capsules
223497112|NCT06260748|DRUG|Chenodeoxycholic acid Placebo|Placebo to match
223497113|NCT06495554|DIAGNOSTIC_TEST|Measurement of circulating tumor-DNA|Liquid biopsies will be collected at baseline and prospectively during follow-up to measure circulating tumor-DNA.
223497114|NCT06495554|OTHER|Collection of patient-reported outcomes|Patient-reported outcomes will be collected at baseline and prospectively during follow-up.
223497115|NCT06495554|OTHER|Algorithmically determined telephone interview with a nurse|Dependent on the patient's responses on the patient-reported outcome measures.
223497116|NCT04827446|OTHER|Wearable Sensor|Patient is given a wearable device to wear for 12 weeks.
224187667|NCT02054624|BEHAVIORAL|Lifestyle intervention|"The weight-loss treatments will include two phases. Phase 1 will last 4 months and Phase 2 will last 12 more months.~Phase 1 will be 4 months of weight loss treatment~Phase 2 will be 12 months of follow-up contact by group telephone call.~The participants will learn about nutrition, physical activity, and safe methods to lose weight during Phase 1.~During Phase 2 participants will receive two phone calls per month from their group leader for the first 6 months, and one phone call per month for the next 6 months."
224187668|NCT02054624|BEHAVIORAL|Health education control|"The weight-loss treatments will include two phases. Phase 1 will last 4 months and Phase 2 will last 12 more months.~Phase 1 will be 4 months of weight loss treatment~Phase 2 will be 12 months of follow-up contact by email.~The participants will learn about nutrition, physical activity, and safe methods to lose weight during Phase 1.~During Phase 2 participants will receive a specially prepared newsletter two times per month. The newsletter will contain educational information about proper eating and physical activity. The newsletters will include low-fat and low-calorie recipes, along with tip sheets that describe strategies to help them maintain lost weight."
224187669|NCT02054624|BEHAVIORAL|Individual|"The weight-loss treatments will include two phases. Phase 1 will last 4 months and Phase 2 will last 12 more months.~Phase 1 will be 4 months of weight loss treatment~Phase 2 will be 12 months of follow-up contact by on-on-one telephone call.~The participants will learn about nutrition, physical activity, and safe methods to lose weight during Phase 1.~During Phase 2 participants will receive two phone calls per month from their group leader for the first 6 months, and one phone call per month for the next 6 months."
224187670|NCT02054624|BEHAVIORAL|All Groups|All participants will receive the following: Questionnaires, height, weight, waist measurement, blood pressure, heart rate, electrocardiogram, blood sample, urine sample, urine pregnancy test (for females only), 400 meter walking test
224187671|NCT01591044|DRUG|Placebo|1 puff bid or 2 puffs bid
224187672|NCT01591044|DRUG|R940343 1mg|R343 1mg, 1 puff bid
224187673|NCT01591044|DRUG|R940343 2mg|R343 2mg, 2 puffs bid
224187674|NCT01920165|OTHER|Smoke-free legislation|The intervention under study is the smoke-free legislation in England introduced overnight on 1 July 2007. As of this date virtually all enclosed public places and workplaces are by law required to be smoke-free. More detail can be found at: http://www.smokefreeengland.co.uk
224187675|NCT05254964|PROCEDURE|Cognitive rehabilitation|Intensive cognitive rehabilitation by cognitive therapist for 1 hour on every working 20 days (4 weeks) during the subacute stroke phase
223497117|NCT04827446|OTHER|Blue-blocking glasses|Patient is given blue-blocking glasses to wear at instructed times.
223497118|NCT04827446|OTHER|Clear glasses|Patient is given glasses that block no visible light.
223497119|NCT04827446|OTHER|Full SYNC app|Patient downloads the SYNC app and is given light interventions designed to have a targeted, personalized effect on the circadian clock.
223497120|NCT04827446|OTHER|"Dummy SYNC app"|Patient downloads the SYNC app and is given light interventions designed to have minimal impact on the circadian clock.
223745890|NCT04455269|DEVICE|AIRFLOW® with PLUS® powder and PIEZON® scaler|Air-polishing will be use as main instrument for biofilm and stains removal, followed by ultrasonic scaling
223745891|NCT04455269|DEVICE|PIEZON® scaler and rubber cup with abrasive paste|Application of ultrasonic scaler on the entire dentition, followed by residual biofilm and stains removal and polishing
223745892|NCT02975219|DRUG|Bevacizumab-800CW|4.5mg Bevacizumab-800CW will be administered intravenously three days prior to surgery
224187676|NCT03950505|DRUG|Nesinaact 25/15 (Alogliptin benzoate 25mg, pioglitazone hydrochloride 15mg) treatment for 24 weeks|All participants will be treated with Nesinaact 25/15 (Alogliptin benzoate 25mg, pioglitazone hydrochloride 15mg) for 24 weeks. Patients who have not been prescribed any other anti-diabetic drugs at least for 12 weeks and whose HbA1c ranges from 6.5\~8.5%, can be enrolled. If Patients has been prescribed metformin as monotherapy, they have to substitute metformin with nesinaact 25-15 for enrollment.
224187677|NCT00497744|DRUG|Intraperitoneal Cefepime|
223497121|NCT00962598|DRUG|Omega 3 Fatty Acids|The study medication will consist of combined EPA/DHA with a ratio of 2:1. Dosage will be titrated based on clinical response and side effects. The initial dose will be 1.2g/d. This will be increased gradually by 0.6 per 2 weeks to a possible maximum daily dose of 3.6 g/d. Patients will have to remain on a dose for 2 weeks to provide the opportunity to assess clinical response at any one dose. The total duration of the intervention will be 10 weeks.
223745893|NCT02740166|DRUG|propranolol|Patients randomized to propranolol group continue propranolol after eradication of esophageal varices.
223745894|NCT02047357|OTHER|Learning Through Play Plus|Learning Through Play (LTP) Plus is a low-literacy, sustainable program intended to provide parents with information on the healthy growth and development of their young children. The LTP research-based activities enhance children's development while simultaneously promoting attachment security through building parents' ability to read and be sensitive to their children's cues and through active involvement in their children's development. Plus the Thinking Healthy Program (THP) which adopts 'here and now' problem-solving approach. THP uses cognitive behavior therapy (CBT) techniques of active listening, changing negative thinking, and collaboration with the family.
224187678|NCT02249377|OTHER|Platelets-Rich-Plasma|Platelet-Rich Plasma
224187679|NCT02249377|DRUG|Corticosteroid|Corticosteroid
224187680|NCT00592644|PROCEDURE|Pulse Dye laser (PDL)|one-time PDL, in 10 subjects
224187681|NCT00592644|PROCEDURE|CO2 laser or other traditional surgeries|once-time CO2 laser or other conventional surgeries, in other 10 subjects
223497122|NCT00962598|DIETARY_SUPPLEMENT|Corn oil|The dosage will correspond to the titration schedule of the Omega-3 Fatty Acid experimental treatment. Placebo (corn oil) and omega-3FA capsules will be identical in color and smell.
223497123|NCT03719547|PROCEDURE|Abdominal radical hysterectomy|Radical hysterectomy (type B or C according to the Querleu\&Morrow classification) with pelvic lymphadenectomy
223497124|NCT03719547|PROCEDURE|Robot-assisted radical hysterectomy|Radical hysterectomy (type B or C according to the Querleu\&Morrow classification) with pelvic lymphadenectomy
223497125|NCT03719547|DIAGNOSTIC_TEST|Sentinel lymph node biopsy|Assessment of sentinel lymph nodes using either radiotracer or indocyanine green (ICG)
223497126|NCT06532916|OTHER|Experimental: Group1: Estelite Sigma Quick|Preheated conventional composite (Estelite Sigma Quick, Tokuyama Dental Corp, Tokyo, Japan). Estelite Sigma Quick is a resin composite with the following composition (Silica-zirconiasupra-nano, monodispersingc spherica, Bis-GMA, UDMA, TEGDMA).
223497127|NCT06532916|OTHER|Experimental: Group 2: Estelite Flow Quick|Second group: Injectable flowable (Estelite Flow Quick, Tokuyama Dental Corp, Tokyo, Japan). Estelite Flow Quick is a resin composite with the following composition (Silica-zirconia, supra-nano monodispersing spherical, Bis-GMA, UDMA,TEGDMA).
223497128|NCT04588077|BIOLOGICAL|Heplisav-B Injectable Product, 2-dose regimen|Investigators will randomly assign patients into a 2-dose regimen.
223497129|NCT04588077|BIOLOGICAL|Heplisav-B Injectable Product, 3-dose regimen|Investigators will randomly assign patients into a 3-dose regimen.
223497130|NCT01610388|DRUG|500mg IV GSK1322322/placebo|500mg IV
223497131|NCT01610388|DRUG|1000mg oral GSK1322322/placebo|1000mg oral
223497132|NCT01610388|DRUG|1000mg IV GSK1322322/placebo|1000mg IV
223497133|NCT01610388|DRUG|1500mg oral GSK1322322/placebo dose|1500mg oral
223497134|NCT01610388|DRUG|1500mg IV GSK1322322/placebo|1500mg IV
223497135|NCT01610388|DRUG|2000mg IV GSK1322322J/placebo|2000mg IV
223497136|NCT01610388|DRUG|3000mg IV GSK1322322J/placebo|3000mg IV
223497137|NCT01610388|DRUG|1000mg IV GSK1322322J/placebo|1000mg IV
223497138|NCT04375215|PROCEDURE|Selective caries removal|After caries removal restoration of tooth will be performed
223497139|NCT04375215|PROCEDURE|Stepwise caries removal|After caries removal restoration of tooth will be performed
223497140|NCT00003456|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|"Adults with a newly diagnosed Glioblastoma Multiforme will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
223497141|NCT06078293|BEHAVIORAL|Home-based Exercise Program|12-week home-based exercise program that involves individualized exercise prescription and motivational health coaching calls.
223497142|NCT05136664|DRUG|Patiromer Powder for Oral Suspension (Part A)|"Participants initiate patiromer at an oral dose of 1 packet/day (8.4g/day as powder for suspension). The dose is adjusted ate the following visit based on local serum potassium (sK+) levels.~The content of each packet should be mixed with water, apple or cranberry juice before administration."
223497143|NCT05136664|DRUG|Placebo (Part B)|Placebo is provided in packets, each containing 6 g of placebo as powder for suspension. Participants will take 1 packet per day, by mixing its content with water, apple or cranberry juice.
223497144|NCT05136664|DRUG|Patiromer Powder for Orals Suspension (Part B)|"Participants will continue to receive the same number of packets established during Part A, but dose may be up- or down titrated depending on sK+ levels.~The content of each packet should be mixed with water, apple or cranberry juice before administration."
223590169|NCT01395277|DIETARY_SUPPLEMENT|Low Flavanol first then High Flavanol|The low flavanol trial will be performed following consumption of a beverage containing 0 mg of Cocoa Flavanols which will be mixed into 250 ml of distilled water. The subjects will consume this beverage and measurements will be performed 2 hours after consumption. The high flavanol trial will be performed following consumption of a beverage containing 1,050 mg of commercially available Cocoa Flavanols which will be mixed into 250 ml of distilled water. The subjects will consume this beverage and measurements will be performed 2 hours after consumption.
223590170|NCT04316364|DRUG|SHR-1316、Paclitaxel (Albumin Bound)、Carboplatin|Drug: SHR-1316, an engineered anti-PD-L1 antibody will be administered as intravenous (IV) infusion on Day 1 of each 21-day cycle Drug: Paclitaxel (Albumin Bound) will be administered intravenously on Day 1,8,15 of each 21-day cycle Drug: Carboplatin will be administered intravenously on Day 1 of each 21-day cycle
223497145|NCT06957223|DRUG|Dextromethorphan-Bupropion|Participants will receive a fixed-dose combination of dextromethorphan-bupropion, dosed according to approved guidelines for major depressive disorder, administered orally for 6 weeks.
223497146|NCT06957223|DRUG|SSRIs|Participants will receive an SSRI at standard therapeutic doses, administered orally for 6 weeks.
223497147|NCT06955845|BEHAVIORAL|Eye Movement Desensitization and Reprocessing Therapy|Patients in this arm will receive weekly EMDR sessions for 6 weeks
223497148|NCT06955845|DRUG|Selective serotonin reuptake inhibitors|The patients will receive an SSRI medication daily for 6 weeks. The dose will be titrated by the clinician.
223497149|NCT04270955|PROCEDURE|Embolization of the Middle Meningeal Artery|Using established endovascular techniques and materials patient will have a diagnostic catheter based angiogram performed on the side(s) of the brain where the subdural hematoma is present. After verifying the vascular anatomy to ensure safety of the procedure the Middle Meningeal Artery will be embolized.
223497150|NCT04270955|PROCEDURE|Standard of care including possible surgical evacuation of subdural hematoma|Standard of care could include observation or intervention including surgical drainage of subdural hematoma by bedside drain, Subdural Evacuating Port System (SEPS), burr hole or craniotomy
223497151|NCT00297934|DEVICE|Pro-adjuster mechanical spinal manipulative device|
223497152|NCT03794856|OTHER|Functional and Structural Magnetic Resonance Imaging (research grade)|Brain structure and function will be compared in middle to late-age adults with asthma compared to healthy adults.
223497153|NCT03794856|OTHER|Cognitive Function Testing (non-diagnostic)|Multiple domains of cognitive functioning will be investigated, including processing speed, executive functioning/working memory and episodic memory.
223497154|NCT03794856|OTHER|Asthma and Psychological Questionnaires (non-diagnostic)|Participants will fill out asthma and psychological questionnaires (non-diagnostic)
223497155|NCT00479232|DRUG|vorinostat|
223497156|NCT00479232|DRUG|decitabine|
223497157|NCT03945136|BEHAVIORAL|Dynamic Interpersonal Therapy|Dynamic Interpersonal Therapy is a time-limited, manualized, interpersonal and affect-focused psychodynamic treatment that is frequently used to target depression and anxiety.
223497158|NCT05399771|DEVICE|Laser Doppler|Study team will use a PeriScan PIM 3 System Laser Doppler to scan for blood perfusion before and after the Thermofield treatment. The PeriScan PIM 3 System is for non-invasive two-dimensional imaging of peripheral tissue.
223590171|NCT04316364|DRUG|SHR-1316、Chemotherapeutic|Drug: SHR-1316, an engineered anti-PD-L1 antibody will be administered as intravenous (IV) infusion on Day 1 of each 21-day cycle Drug: Chemotherapeutic drugs will be administered on Day 1 of each 21day cycle, if applicable, they will also be administered on Day 8 and/or Day 15 according to the drug package insert
224187682|NCT04293081|DRUG|Preemptive chlorepheniramine maleate intravenous injection|Participants of group A will receive only one ampoule of 45.5 mg/ 2mL chlorepheniramine maleate diluted in 8 ml isotonic saline intravenous (I.V) prior to induction of general anesthesia by 30 minutes
223497159|NCT05399771|DEVICE|Radiofrequency Heating System|The radiofrequency will be set to achieve 42°C/107.6°F) and maintain this temperature consistently during the application time. This temperature is mild and may feel like a drugstore heating pad. The device will be turned on on one leg and will remain off on the other. The time for the heating will be 36 minutes, during which participants will remain in a reclined position, with their legs elevated. The device takes approximately 6 minutes to achieve a tissue temperature of 42°C, and the treatment time with consistent temperature application will be 30 minutes.
223590172|NCT04316364|DRUG|Placebo、Chemotherapeutic|Drug: Placebo, will be administered as intravenous (IV) infusion on Day 1 of each 21-day cycle Drug: Chemotherapeutic drugs will be administered on Day 1 of each 21day cycle, if applicable, they will also be administered on Day 8 and/or Day 15 according to the drug package insert
223590173|NCT00847015|DRUG|Sunitinib|Sunitinib will be administered at a dose of 25mg orally once daily for 2 consecutive weeks followed by a 1 week rest period.
223590174|NCT00847015|DRUG|Gemcitabine|Gemcitabine 1,000 mg/m\^2
223590175|NCT00847015|DRUG|cisplatin|cisplatin 35 mg/m\^2 will be administered intravenously on days 1 and 8.
223497160|NCT05399771|DEVICE|Thermal Imaging|Study team will take thermal imaging photographs of the treatment area following each treatment.
223497161|NCT05399771|OTHER|Healthcare Questionnaire & Measurement|"A survey tool created to collect info from participants including:~1. Name~2. Age~3. Weight/ height~4. Pregnant or nursing?~5. History of blood clots?~6. Any wound healing problems?~7. Any active open wounds on the legs?~8. Any autoimmune disorders?~9. Phone number~10. Email address~A measurement of the participants calf will be taken as well using a measuring tape."
223497162|NCT05879913|DEVICE|Coronary CT Angiography (CCTA)|Coronary computed tomographic angiography (CCTA) scan is a highly accurate noninvasive technique for detection of coronary artery plaque.
223497163|NCT00470613|GENETIC|SGT-53|For Phase Ib: SGT-53 (2.4 mg DNA per infusion) will be administered in combination with docetaxel at 40 mg/m2 starting dose, cohort 1, cycle 1. SGT-53 will be administered weekly, on day 1 in weeks 2, 3, 5, and 6, and biweekly on days 1 and 4 in weeks 1, 4, and 7. Docetaxel will be administered every 3 weeks (weeks 1, 4, and 7)on day 3. Patients completing cohort 1, cycle 1 without DLT at 40 mg/m2 docetaxel will be allowed to dose escalate to 60 mg/m2 docetaxel in cycles 2 and 3.Cohort 2 (2.4mg DNA/infusion;75mg/m2 Docetaxel) will open 3 weeks after demonstration of 0/3 or ≤1/6 DLTs at docetaxel 60 mg/m2. Cohort 3 (3.6 mg DNA/infusion; 75 mg/m2 Docetaxel) will open after demonstration of 0/3 or ≤1/6 DLTs at SGT-53 2.4 mg DNA/infusion and docetaxel 75 mg/m2.
223497164|NCT05253508|DRUG|Lidocaine 2% Injectable Solution|A digital nerve block by injections to the base of the finger
223590176|NCT01945684|DRUG|Botulinum toxin type A|Maximum dose 360 U
223590177|NCT01141478|RADIATION|Proton Beam Radiotherapy|Fifteen consecutive sessions
223590178|NCT01141478|DRUG|Sorafenib|400 mg po bid
223497165|NCT03112252|OTHER|no specifications. Depending on the patients|patients with allergic rhinitis
223497166|NCT00520000|DRUG|Carboplatin|standard dose of area under the curve (AUC) AUC of 6 in all arms
223497167|NCT00520000|DRUG|Abraxane|75mg/m2 - 150 mg/m2 given on days 1, 8, 15 of every 28 day cycle
223497168|NCT00520000|DRUG|Abraxane|180mg/m2 - 340mg/m2, repeated every 21 days
223497169|NCT00520000|DRUG|Abraxane|100mg/m2 - 175/mg/m2 given on days 1, 8 of every 21 day cycle
223497170|NCT06962579|BEHAVIORAL|Exercise intervention|"* 30-minute face-to-face session with physiotherapist outlining the state of the science on the importance and benefits of physical activity during and after cancer treatment and advising patients to engage in regular physical activity according to the general guidelines~* 12-week individually tailored exercise program~  * Home-based aerobic exercise, 3 times per week at moderate intensity~ * Supervised resistance and sensorimotor exercises, 2 times per week"
223590179|NCT00563862|PROCEDURE|Conventional RT|
223590180|NCT00563862|PROCEDURE|Accelerated RT|
223590181|NCT00563862|DRUG|Cisplatin|
223590182|NCT00563862|DRUG|5-fluorouracil|
223590183|NCT04180787|DIETARY_SUPPLEMENT|Beverage Consumption|Participants will consume either VPX Bang® Keto Coffee beverage or flavor-matched placebo beverage in each condition.
223590184|NCT03096873|BEHAVIORAL|Combined Exercise Training|The combined exercise training were consisted with 5 minutes of warm-up, 20 minutes of resistant band exercises (Upper: seated rows, biceps curl, shoulder flexion, elbow flexion, pushup; Lower: hip flexion, hip extension, calf raise, leg press, squat), 30 minutes of treadmill walking, and 5 minutes of cool-down. Intensity of the training was gradually increased from 40-50% heart rate reserve in 1-4 weeks to 60-70% HRR in 9-12 weeks.
223745895|NCT04426331|BEHAVIORAL|Voucher Without Value Information|"Patients being referred for follow-up received standard materials, counseling, and reminders as in the 'no information' group and were provided with a physical voucher they were told is redeemable for free follow-up appointment at Johns Hopkins Hospital. The voucher included the patient's name, the screener's name, and an expiration date 90 days from the date of screening.~These participants were told: I am going to give you this voucher for a completely free appointment and a free pair of glasses if you need them. So, with this voucher, both the exam and the glasses will be completely free."
224187683|NCT04293081|DRUG|normal saline|participants in group (B) will receive 10 ml isotonic saline (placebo) by the same route as control.
224187684|NCT01326481|DRUG|TRC105|IV
224187685|NCT01326481|DRUG|Capecitabine|oral
224187686|NCT01172795|BEHAVIORAL|Relaxation session|30 minutes relaxation session (audiotape)
224187687|NCT01172795|BEHAVIORAL|Neurocognitive test battery|the psychomotor vigilance task, span task and the stroop task on computer
224187688|NCT01729806|BIOLOGICAL|Ipilimumab|Given IV
224187689|NCT01729806|OTHER|Laboratory Biomarker Analysis|Correlative studies
224187690|NCT01729806|BIOLOGICAL|Rituximab|Given IV
223590185|NCT05236712|BEHAVIORAL|Mobile app|The app sends reminder 'push' notifications to complete weekly surveys. The survey is a series of questions about foods and drinks participants had in the last week. Once the weekly survey is completed the app generates a personalized weekly report showing foods we encourage participants to eat more of, eat less of, or keep eating the same amount of. The app will also show menu recommendations for breakfast, lunch, dinner, and snacks that will help participants to eat healthier. Finally, the app also has a feature that allows chatting with the research team by sending and receiving in-app texts.
224187691|NCT04927611|PROCEDURE|Biopsy, open or laparoscopic surgery|Collect NEN and PDAC biopsy or surgical fresh tissue to conduct single cell sequencing or model construction.
223590186|NCT05852821|OTHER|5STS remote assessment via videoconference|Patients will be asked to perform several times the 5STS test, from their home through videoconference, on 3 occasions (day 1, 24h later and 1month later).
223590187|NCT05013970|OTHER|Clinical assessment|Clinical assessment including Visual Analog Scale (VAS) for Knee Pain, and Knee Injury and Osteoarthritis Outcome Score (KOOS) questionnaire
223497171|NCT03284099|DRUG|ACEi, ARB|To take the ACEis or ARBs before bedtime instead of in the morning
223497172|NCT00484159|PROCEDURE|Radiofrequency denervation of medial branches|Radiofrequency of medial branches that innervate the lumbar facet joints
223497173|NCT00484159|DRUG|0.5% bupivacaine|Diagnostic medial branch block with 0.5% bupivacaine. Blocking the nerves that innervate the facet joints with a long-acting local anesthetic.
223497174|NCT00484159|DRUG|2% lidocaine|Diagnostic medial branch block with 2% lidocaine. Blocking the nerves that innervate the facet joints with a short-acting local anesthetic.
223497175|NCT00484159|PROCEDURE|Radiofrequency denervation|Radiofrequency lumbar facet denervation without a diagnostic block
223497176|NCT00484159|PROCEDURE|Radiofrequency denervation|Radiofrequency lumbar facet denervation only if positive response to 2 diagnostic blocks.
223497177|NCT00484159|PROCEDURE|Radiofrequency denervation|Lumbar facet radiofrequency denervation if positive response to a single diagnostic facet block
223497178|NCT00484159|PROCEDURE|Radiofrequency denervation|Radiofrequency lumbar facet denervation without a diagnostic facet block.
223497179|NCT00129896|DRUG|Myocet|Myocet®: 60-75 mg/m² ASC (vía IV) día 1 / c3s for 6 cycles
223497180|NCT00129896|DRUG|Taxotere|Taxotere® 70-75 mg/m² ASC (vía IV) día 1 / c3s for 6 cycles
223497181|NCT00129896|DRUG|Herceptin|Herceptin® (4) 2 mg/kg (vía IV) Semanal for 6 cycles
223497182|NCT03720847|DRUG|Estradiol Transdermal Patch 0.1 mg/24 hrs|Estradiol transdermal patch delivering 0.1 mg/24 hour administered by affixing to skin for 14 days starting on day 7 after ovulation
223497183|NCT03720847|DRUG|Oral Micronized Progesterone|100 mg oral micronized progesterone taken orally twice daily for 14 days starting day 7 after ovulation
223497184|NCT03720847|DRUG|Inactive Clear Patch|Matching placebo patch administered by affixing to skin for 14 days starting on day 7 after ovulation
223497185|NCT03720847|DRUG|Placebo capsule|Matching placebo capsules administered twice daily for 14 days starting day 7 after ovulation
223590188|NCT05013970|OTHER|Radiographic imaging|MRI of the knee
223590189|NCT04082286|OTHER|Yttrium-90 labelled monoclonal antibody against CD66|
223590190|NCT01165970|DRUG|Glandosane|according to the german law the sued saliva substitute is a drug (Glandosane) whereas Saliva natura is a medical product
223590191|NCT01165970|DEVICE|Saliva natura|Saliva substitute without restriction to be used
224187692|NCT03437811|DEVICE|Electro Flo Percussor, Model 5000|FDA 510K K031876 Regulation Number: 21 CFR 868.5665 Regulation Name: Percussor, Powered-Electric Regulation Class: II Product Code: BY1
224187693|NCT01289964|PROCEDURE|Dry Cupping or fire cupping|5 dry cupping treatments, application twice a week, non standardised procedure
224187694|NCT05502276|PROCEDURE|Endoscopic Full-Thickness Resection (EFTR)|Full Thickness Endoscopic Resection using the FTRD Ovesco Device
224187695|NCT05502276|PROCEDURE|Endoscopic Submucosal Dissection (ESD)|Standard Endoscopic Submucosal Dissection using standard procedure described in international guidelines.
224187696|NCT05732740|BEHAVIORAL|Empower@Home:Connected|Cognitive behavioral therapy
224187697|NCT04555876|DEVICE|high tone external muscle stimulation- stationary bicycle|high-tone external muscle stimulation (HTEMS), with Frequencies continuously will be scanned from 4096 Hz to 31768 Hz, allowing for a much higher power of up to 5000 mW to be introduced 3 times per week, for 10 weeks
224187698|NCT05884606|DEVICE|Allurion Digital Behaviour Change Intervention|The Allurion DBCI adheres to current National Institute for Health and Care Excellence (NICE) guidance for obesity.
224187699|NCT00307736|DRUG|5-fluorouracil|Given as a 24-hour infusion on days 1-14 of each 14-day cycle for a total of 3 cycles.
224187700|NCT00307736|DRUG|bevacizumab|Given intravenously on day 1 of each 14-day cycle for a total of 3 cycles.
224187701|NCT00307736|DRUG|erlotinib|Taken orally on days 1-14 of each 14-day cycle for a total of 3 cycles.
224187702|NCT00307736|PROCEDURE|External beam radiation therapy (EBRT)|Given on days 1-5 and 8-12
224187703|NCT01809028|PROCEDURE|EUS FNA with 2 passes|biopsy with 2 passes
224187704|NCT01809028|PROCEDURE|EUS FNA with 4 passes|biopsy with 4 passes
224187705|NCT04343027|BEHAVIORAL|Review|Physicians will review patient-reported outcome measurements with their patients during office visits.
224187706|NCT00418444|BEHAVIORAL|Group Therapy Intervention|
224187707|NCT05738928|DIAGNOSTIC_TEST|blood and sputum culture|Noninvasive sampling ( Endo Tracheal Aspiration) for staining and culture. Blood culture .
224187708|NCT02289144|DRUG|Ceritinib|750 mg orally daily on day 1. Continue every 4 weeks and every 2 cycles (1 Cycle is 28 days long) : until progression, new recurrence or distant metastasis, as well as enlargment of an existing metastasis on radiological Imaging.
224187709|NCT00166803|DRUG|Rosiglitazone|Rosiglitazone , 4 mg daily
224187710|NCT04484610|DRUG|Pharmacist Practice Change to Dispense Appropriate Opioid Quantities for Acute Pain|Pharmacist eLearning modules, support tools and resources to promote assessing and dispensing appropriate opioid quantities for acute pain.
224187711|NCT02038244|OTHER|Multimodal integrative medicine inpatient treatment program|
224187712|NCT00216112|DRUG|Imatinib Mesylate|Imatinib mesylate 600 mg po qd
224187713|NCT00216112|DRUG|Docetaxel|Docetaxel 30 mg/m2 (4 of 6 weeks); 1 cycle = 6 weeks
224187714|NCT03515499|BEHAVIORAL|Incentives|Subjects in the treatment arm will be paid up to $1 per day over 3 months for perfect medication adherence. Adherence rates will then be compared between the 2 groups.
224187715|NCT03515499|BEHAVIORAL|Medication device monitoring and reminders|Bluetooth enabled sensor device for medication reminders, as well as mobile app to track medication use.
224187716|NCT02948452|OTHER|fMRI|fMRI: reward task, anxiety provocation
223590192|NCT05115747|OTHER|weight off-loading aerobic exercise training.|"Mild to moderate intensity weight off-loading aerobic exercise training on the anti-gravity Alter-G treadmill. (speed 8-12 mph, 50%-70% heart rate reserve HRR, 12-16 score on the Borg's scale)"
224309068|NCT06990022|OTHER|Carbohydrate|CHO solution was a maltodextrin-based mixture containing 6.4% maltodextrin (Protein Ocean, Türkiye). An CHOMR was performed prior to SSGs. The solution was sweetened with non-caloric artificial sweeteners consisting of sucralose. The CHO solution was prepared in an equivalent saccharin base and shaken for 30 seconds in a vortex mixer to ensure distinguishability. Participants swished the solution in their mouth for 10 seconds before SSGs and then emptied it back into the container to be weighed again. To ensure that the solutions were not swallowed, the containers were measured before and after all MRs using a full precision balance (Etekcity, USA) accurate to 1 g/0.04 oz
224309069|NCT06990022|OTHER|Placebo|The PLA solution consisted of purified water. Both solutions were made indistinguishable by adding 50 mg of non-calorific artificial sweetener and 50 mg of sucralose (Fibrelle, Turkey). A 25 ml bolus of 6.4% maltodextrin solution was used in a pre-weighed plastic container and sucralose water was tested as PLA for each rinse solution.
223590193|NCT01872442|DRUG|Dasatinib|"Dasatinib 100mg daily starting at inclusion~If ANC ≤ 1.5.109/L, platelets ≤ 100.0.109/L or lymphocytes \> 4.0.109/L at 3 months, dasatinib will be continued alone, and patients will be still followed in the study"
223590194|NCT01872442|DRUG|Peg-Interferon alpha2b|30 µg weekly starting month 4- month 21
223590195|NCT02968628|OTHER|Video Electroencephalogram (EEG)|Single neonatal video EEG at 24 hrs to 5 days of life during birth hospitalization. Neonatal scalp leads, respiratory and nasal leads. Approximately 60 minute recording.
223590196|NCT02968628|OTHER|Point-of Care Blood Sugar Testing|One-time heel-stick point-of-care blood sugar testing at time of EEG.
223590197|NCT02968628|OTHER|Medical Record Data Extraction|Medical record data extraction from both maternal obstetric and neonatal medical record for variables known to impact EEG and neurodevelopmental outcomes.
224187717|NCT02967042|DEVICE|18F-PET-TT|can 18F-PET-TT be used as an diagnostic tool in patients with CKD-MBD
224187718|NCT02883894|OTHER|Blood sample for dosages of cytokines (IL-17 and IL-23) and of the protease MMP-9|
224187719|NCT03365531|OTHER|Alternate Daily Fasting (ADF)|See ADF arm for details
224187720|NCT03365531|OTHER|Caloric Restriction (CR)|See CR arm for details
224187721|NCT01475513|DRUG|Ortho Cyclen®|Ethinyl estradiol 35 mcg and norgestimate 0.25 mg (oral) will be taken as one tablet daily for 21 days per month followed by a 7-day pill-free period per cycle. Duration of the study is for 6 cycles of this birth control pill.
224309070|NCT06989008|OTHER|Observational Study: Relationships Among Glucose, Physical Activity and Environmental Influences|This is a single group observational study with no interventions.
224309071|NCT06990685|DRUG|Salidroside|In the salidroside group, oral administration of rhodiola capsules (Xizang Gaoyuan 'an Biotechnology Development Co., LTD.) was started on the day of entering the COS cycle, once a day, 2 pills at a time, and the drug was stopped on the trigger day.
224309072|NCT06990230|DEVICE|Radiofrequency Transseptal Puncture System and Auxiliary Device|"The intervention in this study stands out due to its specific focus on evaluating the safety and efficacy of a radiofrequency transseptal puncture system designed exclusively for use in the atrial septum, with the purpose of establishing a passage from the right atrium to the left atrium. This system incorporates an auxiliary radiofrequency puncture device, which serves as a crucial supportive component, enhancing the overall functionality and precision of the primary transseptal puncture system.~What further distinguishes this intervention from others is its utilization of radiofrequency energy to facilitate the transseptal puncture. Unlike traditional mechanical puncture methods, which can have a steep learning curve, potentially cause serious complications such as pericardial tamponade and cardiac rupture, and may be time-consuming and imprecise in predicting the puncture site, the radiofrequency puncture device provides a more controlled and predictable approach. The radiofrequenc"
224309073|NCT04375683|DRUG|Flumatinib|Flumatinib 600mg per day, taken on empty stomach
224309074|NCT04658836|DRUG|Triamcinolone Acetonide 40mg/mL|Intratympanic application of triamcinolone acetonide
224309075|NCT04669691|BIOLOGICAL|H5N1 antigen combined with MF59 adjuvant|Eligible subjects will be stratified by age at the time of enrollment into one of 2 age cohorts and within each age cohort will be randomly assigned (equally) to 1 of 6 study vaccine groups. Subjects in each study vaccine group will be scheduled to receive 2 injections of aH5N1 vaccine 3 weeks apart
224309076|NCT04841252|DEVICE|FDA approved GE LOGIQ E9 (LE9) ultrasound|Ultrasound
224309077|NCT04841252|DEVICE|Alpinion clinical ultrasound machine|Ultrasound
224309078|NCT00825136|BEHAVIORAL|relaxation|Participants were asked to log in the system to keep the muscle relaxation program every day and complete some self-rating scales on browser every week.
224309079|NCT00825136|BEHAVIORAL|biofeedback (finger temperature biofeedback)|Participants were asked to log in the system to keep the muscle relaxation program plus finger temperature biofeedback every day and complete some self-rating scales on browser every week.
224309080|NCT05841446|DRUG|test apixaban tablets|specification: 2.5 mg, manufacturer: Disha Pharmaceutical Group Co., Ltd., Shandong, China
224309081|NCT05841446|DRUG|reference apixaban tablets|specification: 2.5 mg, manufacturer: Bristol-Myers Squibb Manufacturing Company, USA
223497186|NCT01710085|DEVICE|Diffusion weighted MRI (DW- MRI)- Philips Achieva 3.0T X, Netherlands, 2011|Recurrence in cervical and endometrial cancer patients who were treated with curative surgery is routinely investigated by MRI examination. MRI is diagnostic technique not requiring ionizing radiation and is based on magnetic fields.
223497187|NCT04621201|OTHER|observation and biopsy|biopsy
223497188|NCT00653562|DRUG|zolpidem|Oral
223497189|NCT01239680|DRUG|Glutamine|Intravenous 25 grams once over 6 hours
223497190|NCT01239680|DRUG|Ringer's Lactate|Intravenous 1 liter once over 6 hours
224187722|NCT04839913|DIAGNOSTIC_TEST|Antibodies testing|Serologic test for both SARS-COV-2 IgG and IgM
223497191|NCT01239680|DRUG|Placebo (for Glutamine)|Given Intravenously in 1 liter Lactated Ringer's
223497192|NCT03033901|DEVICE|Polysomnography - Level 1 and Level 3|Participants will undergo simultaneous administration of Level 1 and 3 polysomnography on the rehabilitation unit with study funded sleep technologist present to meet Level 1 standards.
223497193|NCT03033901|DEVICE|Actigraphy monitoring|Participants will undergo actigraphy monitoring to assess habitual sleep duration to determine readiness for polysomnography and examine trajectory and duration of sleep.
223497194|NCT03033901|OTHER|Sleep Apnea Screening|Participants and their family member or proxy, and clinical staff will be asked to answer questions in order to complete the three standardized sleep apnea screening measures.
223497195|NCT05293470|OTHER|Piqray|There is no treatment allocation. Patients administered Piqray by prescription will be enrolled.
223497196|NCT03300765|DRUG|Apatinib|Apatinib will be used as induction therapy in experimental arm.
223497197|NCT03300765|RADIATION|Intensity modulated radiation therapy|Intensity modulated radiation therapy will be used for patients with progression disease during induction therapy or after induction therapy.
223497198|NCT02734667|DEVICE|CGM at diagnosis of T1D|Initiation of non-adjunctive CGM use at diagnosis of T1D
223590198|NCT02968628|OTHER|Maternal Questionnaire|One-time maternal questionnaire related to smoking practices, ETOH consumption, level of education, and body mass index.
223590199|NCT03574428|DRUG|GNbAC1|Monoclonal Antibody infused i.v.
223590200|NCT03574428|OTHER|GNbAC1 Placebo|Equivalent to GNbAC1 Buffer
223590201|NCT02636712|DEVICE|ImageReady™ MR Conditional Pacing System|
223590202|NCT03930407|PROCEDURE|The Hayman uterine compression suture.|Hayman suture is a common technique for uterine compression to stop bleeding due to uterine atony. Hayman described placement of two to four vertical compression sutures from the anterior to posterior uterine wall without hysterectomy. It is usually employed to overcome uterine atony during cesarean section.
223590203|NCT01088594|DRUG|pioglitazone/rosiglitazone/placebo|single oral dose of pioglitazone 45mg + single oral dose of rosiglitazone 8mg +single oral dose of placebo
223590204|NCT01088594|DRUG|rosiglitazone/pioglitazone/placebo|single oral dose of rosiglitazone 8mg + single oral dose of pioglitazone 45mg + single oral dose of placebo
223590205|NCT01088594|DRUG|placebo/pioglitazone/rosiglitazone|single oral dose of placebo + single oral dose of pioglitazone 45mg + single oral dose of rosiglitazone 8mg
223590206|NCT01088594|DRUG|pioglitazone/placebo/rosiglitazone|single oral dose of pioglitazone 45mg +single oral dose of placebo + single oral dose of rosiglitazone 8mg
223590207|NCT01088594|DRUG|rosiglitazone/placebo/pioglitazone|single oral dose of rosiglitazone 8mg + single oral dose of placebo + single oral dose of pioglitazone 45mg
224187723|NCT00278213|BIOLOGICAL|alemtuzumab|
224187724|NCT00278213|DRUG|cyclophosphamide|
223497199|NCT02513199|RADIATION|SBRT|Radiation is to be delivered to 30-45 Gy in 5 fractions. 40 Gy in 5 fractions will be utilized, unless dose constraints preclude it. Treatment will optimally be delivered every other day with no more than 3 fractions per week. The ideal treatment team will be less than 15 total days.
223497200|NCT02513199|DRUG|TACE|two sessions of standard TACE with ethiodol separated by a 4-week interval.
223497201|NCT04338997|DRUG|IZD174|Small molecule inhibitor of NLRP3
223497202|NCT02174172|DRUG|Atezolizumab|Participant will receive atezolizumab 600 milligrams (mg) or 1200 mg by IV infusion q3w.
223497203|NCT02174172|DRUG|Bevacizumab|Participant will receive Bevacizumab 15 milligrams per kilograms (mg/kg) IV infusion q3w.
223497204|NCT02174172|DRUG|Interferon alfa-2b|Participants will receive Interferon alfa-2b 3, 5, or 10 million international units subcutaneously every other day for up to 3 doses per week.
223497205|NCT02174172|DRUG|Ipilimumab|Participants will receive Ipilimumab 1, or 3 mg/kg IV, single dose, or multiple-dose regimen q3w for up to 4 cycles (Cycle = 21 days).
223497206|NCT02174172|DRUG|Obinutuzumab|Obinutuzumab 1000 milligrams will be administered as pre-treatment on 2 consecutive days (Day -13 and Day -12) prior to treatment start with atezolizumab on Cycle 1, Day 1 (cycle length=21 days). An additional two doses of obinutuzumab will be administered on Days 85 and 86 of study treatment (Cycle 5, Day 1 and Cycle 5, Day 2).
223590208|NCT01088594|DRUG|placebo/rosiglitazone/pioglitazone|single oral dose of placebo + single oral dose of rosiglitazone 8mg + single oral dose of pioglitazone 45mg
223590209|NCT04916379|DIETARY_SUPPLEMENT|Momordica charantia|Momordica Charantia: 2000 mg per day for 12 weeks
223590210|NCT04916379|OTHER|Placebo|Placebo: 2000 mg per day for 12 weeks
223590211|NCT03958708|DRUG|Rifaximin 550 MG|Rifaximin 550 MG, TWICE A DAY, FOR 7 DAYS
223590212|NCT00938522|DRUG|Cilostazol|Eligible patients were randomly assigned to cilostazol group or placebo group via the internet by the online randomization system. At least 12 h before the procedure, all patients received aspirin (300 mg loading if not taking before) and clopidogrel (300 mg loading dose). Patients in the cilostazol group received 200 mg of cilostazol (loading dose) 12 hours and 2 hours before the procedure, followed by 100 mg twice daily for 3 months.
223590213|NCT00938522|DRUG|Placebo|Eligible patients were randomly assigned to cilostazol group or placebo group via the internet by the online randomization system. At least 12 h before the procedure, all patients received aspirin (300 mg loading if not taking before) and clopidogrel (300 mg loading dose). Patients in the placebo group received 200 mg of placebo 12 hours and 2 hours before the procedure, followed by 100 mg twice daily for 3 months.
224187725|NCT00278213|DRUG|fludarabine phosphate|
224187726|NCT00278213|DRUG|mitoxantrone hydrochloride|
224187727|NCT00039936|BEHAVIORAL|Cognitive Behavior Treatment|
224187728|NCT00039936|BEHAVIORAL|Self Help|
224187729|NCT00039936|BEHAVIORAL|Partial Self Help|
224187730|NCT02260791|DRUG|FKB327|Solution of FKB327 for subcutaneous injection administered in a dose of 40 mg every 2 weeks for 22 weeks.
224187731|NCT02260791|DRUG|Humira®|Solution of Humira® for subcutaneous injection administered in a dose of 40 mg every 2 weeks for 22 weeks.
224187732|NCT02348931|DEVICE|Use of customized nasal brace (Nasella) for nose deformities|
224187733|NCT02348931|PROCEDURE|corrective surgery|
223497207|NCT02174172|DRUG|PEG-interferon alfa-2a|Participant will receive PEG-interferon alfa-2a 180 micrograms subcutaneous injection q3w for a total of 6 cycles (Cycle = 21 days).
223497208|NCT00580398|BEHAVIORAL|Smoking cessation counseling|Median of 9 tobacco treatment counseling sessions conducted in person or by telephone.
223497209|NCT00580398|DRUG|varenicline|varenicline (1mg bid, with initial titration up over week 1) for 12 weeks
223497210|NCT01635647|BIOLOGICAL|ChAd63 ME-TRAP and MVA ME-TRAP|ChAd63 ME-TRAP: 5 x 10\^10vp MVA ME-TRAP: 1 x 10\^8 pfu heterologous prime-boost immunisation
223497211|NCT01635647|BIOLOGICAL|Rabies vaccine|Two doses eight weeks apart into anterolateral thigh. 2 x 2.5IU Verorab
223497212|NCT03291015|DEVICE|radiographic|using plain x ray to determind the treatment plan
223497213|NCT03291015|DEVICE|arthroscopy|using wrist arthroscopy to determind the treatment plan
223497214|NCT04772547|DRUG|Vigabatrin Only Product|enteral medication administration, serial blood draws, and outcome assessment
223497215|NCT03464838|DEVICE|Transcranial direct current stimulation (tDCS)|Transcranial direct current stimulation (tDCS) is a form of noninvasive brain stimulation that applies a very low electrical current to the scalp. tDCS will be applied with intensity of 1.8 milliamps in real stimulation condition and 0 milliamps in sham condition, during 20 minutes, using a high density (HD) tDCS montage over the Prefrontal Cortex (PFC). Electroencephalography (EEG) resting state activity will be measured before and after tDCS.
223590214|NCT04607122|DRUG|Landiolol|Continuous infusion of landiolol starting at 1 µg/kg/min and increasing every 10-15 minutes with incremental doses of 0.5 µg/kg/min up to 2 µg/kg/min by maintaining MAP ≥ 65 mmHg and HR ≥ 50/min.
223590215|NCT04607122|DRUG|Saline|Continuous infusion of saline solution at the same rate as landiolol infusion.
223590216|NCT06061029|BEHAVIORAL|Brief Yoga- and Mindfulness-Based Psychoeducation Program|A unique mindfulness psychoeducation program incorporating features of Hatha yoga and mindfulness-based cognitive therapy, plus the main concepts of self-compassion
223590217|NCT04460846|DIETARY_SUPPLEMENT|Alkaline water|1.5 liters per day
223497216|NCT03464838|BEHAVIORAL|Cognitive Behavioural Therapy (CBT)|Cognitive Behavioural Therapy (CBT) is the current treatment available for disordered gamblers at the UK National Problem Gambling Clinic. During the therapy sessions patients acquire learning strategies, cognitive and motivational elements, and develop personal skills to help them improve the understanding of their problems.
223497217|NCT04307394|BEHAVIORAL|LifePlans|LifePlans is a video-based intervention, in which patients watch episodes starting during a psychiatric hospitalization and continuing through 1 month post-discharge.
223497218|NCT04119336|DRUG|Nivolumab|Given intravenously once per cycle
223590218|NCT04460846|DIETARY_SUPPLEMENT|Reverse osmosis water|1.5 liters per day
223590219|NCT01427634|BEHAVIORAL|Palliative Care|Receive ongoing counseling and symptom assessment as well as clarification and documentation of goals of care, starting before implantation and continuing throughout the course of the study. Intervention patients will also be followed by the inpatient palliative care consultation service when hospitalized for their initial VAD implantation and during any subsequent hospitalizations as needed
223590220|NCT01427634|OTHER|Usual Care|Receive usual care as provided by the VAD clinical team.
223590221|NCT00490620|DRUG|Combination antiviral therapy|Zidovudine 300mg and lamivudine 150mg BID for 6 months
223590222|NCT00490620|DRUG|Placebo|placebo BID for 6 months
223745896|NCT04426331|BEHAVIORAL|Voucher With Value Information|"Patients being referred for follow-up received standard materials, counseling, and reminders as in the 'no information' group and were provided with a physical voucher they were told is redeemable for free follow-up appointment at Johns Hopkins Hospital, which would normally cost $250. The voucher included the patient's name, the screener's name, an expiration date 90 days from the date of screening, and a statement about the $250 voucher value.~These participants were told: I am going to give you this voucher for a completely free appointment and a free pair of glasses if you need them. These services normally cost about $250, but with this voucher, both the exam and the glasses will be completely free."
224187734|NCT00158301|BEHAVIORAL|Cognitive behavioral therapy (CBT)|CBT sessions will focus on teaching participants skills to manage depressed moods and to identify situations which might put them at risk for a relapse in depressive symptoms.
224187735|NCT00158301|DRUG|Drug therapy|All participants will receive 12 weeks of treatment with antidepressant therapy. Responders to initial treatment will continue medication during the continuation phase (both treatment arms).
223497219|NCT04119336|DRUG|Ixazomib|Given orally on days 1, 8, 15.
223497220|NCT04119336|DRUG|Dexamethasone|Given orally on days 1, 8, 15, 22
223497221|NCT04119336|DRUG|Cyclophosphamide|Given intravenously on days 1, 8, 15.
223497222|NCT00164866|DRUG|Omeprazole|
223497223|NCT05467137|DEVICE|MSOT|MSOT imaging (after ICG injection)
223497224|NCT01733888|DEVICE|Office Bleaching|Teeth will be cleaned with pumice first, followed by placing cheek retractors and covering of the lip surface with petroleum gel. Thereafter, teeth will be dried and gingival barrier will be applied to both arches - slightly overlapping enamel and interproximal spaces. Light curing of the gingival barrier will be done in a fanning motion for 10-20 seconds. This is followed by homogeneous mixing of the powder and liquid in a powder pot the application of a thick layer of the resulting gel to all teeth undergoing treatment (35 % Hydrogen Peroxide, Pola Office, SDI, Australia). The gel will be left in place for 8 minutes and subsequently removed using a surgical aspirator tip.
223497225|NCT01733888|DEVICE|Resin Infiltration|Fluorosed teeth will be isolated using a rubber dam and the resin infiltrant (Icon, DMG, Hamburg, Germany) will be applied as per manufactures' instructions. In short, tooth surface will be dried using cotton rolls and air syringe. This is followed by an etching (Icon Etch) and drying step (Icon-Dry) to open the lesion surface. Resin infiltrant will then be applied and allowed to seep in for 3 minutes followed by light curing for 40 seconds and subsequent cleaning of the surface with pumice and rubber polishing cup as well as rinsing with water for 30 sec.
223497226|NCT01733888|DEVICE|Resin Infiltration twice|"The intervention will be done similar to the Resin infiltration arm, which the exception that the icon infiltration step will be done twice."
223590223|NCT03853070|DEVICE|ED Coil / Electro-detach Generator v4|The ED Coil is used for vascular embolization with a platinum coil at the target lesion in a patient's blood vessel. The ED Detach Generator is intended to for use solely to detach the platinum coil from the delivery catheter of the ED Coil.
224187736|NCT02912793|DRUG|Hydroxypropyl-beta-cyclodextrin|Used in the treatment of Niemann-Pick C1
224187737|NCT00719693|DRUG|ABT-143 ( rosuvastatin calcium and fenofibric acid )|one dose under low-fat meal condition
224187738|NCT00719693|DRUG|ABT-143 (rosuvastatin calcium and fenofibric acid )|one dose under fasting meal condition
224187739|NCT05442827|DRUG|SHR7280 tablets|SHR7280 tablets 300mg for 12 weeks
223497227|NCT01733888|DEVICE|Bleaching + Resin Infiltration|"In this arm, the fluorosed teeth of the patients will first be bleached using 35 % Hydrogen Peroxide (Pola Office, SDI, Australia) as explained in the intervention arm Office bleaching; followed by wash over period of 20 days. After these 20 days, patients will be recalled and the fluorosed teeth will treated according to the description in the Resin infiltrant intervention arm using the resin infiltrant (Icon, DMG, Hamburg, Germany) as per manufactures' instructions."
223497228|NCT05403073|PROCEDURE|Ultrasound guided Suprainguinal Iliac Fascia Nerve Block.|Pain management at ER Department will be as usually with iv drugs and ultrasound guided Suprainguinal Iliac Fascia Nerve Block.
223497229|NCT03715647|OTHER|Sepsis|Evaluation and monitoring with Electrical Impedance Tomography in order to conduct ventilatory therapy.
223497230|NCT03715647|OTHER|HELLP Syndrome|Evaluation and monitoring with Electrical Impedance Tomography in order to conduct ventilatory therapy.
223497231|NCT03715647|OTHER|Respiratory Distress Syndrome Adult|Evaluation and monitoring with Electrical Impedance Tomography in order to conduct ventilatory therapy.
223497232|NCT03928327|DRUG|TAK-788|TAK-788 Capsules
223497233|NCT03928327|DRUG|Itraconazole|Itraconazole Oral solution
223497234|NCT03928327|DRUG|Rifampin|Rifampin Capsules
223497235|NCT05036460|PROCEDURE|Ultrasonography|"The transducer will be placed over the anterior neck just above the suprasternal notch, in the transverse orientation. The position of the transducer could be adjusted to visualize both the esophagus and trachea. It will be considered as esophageal intubation if esophageal dilation or double-tract sign are noted."
223497236|NCT05036460|PROCEDURE|Direct visualization|While performing the intubation, the intubator will report ETI if visualizing the tracheal tube passing through the glottis. Otherwise, it will be regarded as esophageal intubation.
223497237|NCT01521364|DRUG|Addition of different doses of clarithromycin.|"At week 1, 250mg clarithromycin once a day will be added to linezolid therapy during two weeks.~At week 3, 500mg clarithromycin once a day will be added to linezolid therapy during to weeks."
223497238|NCT04408079|DRUG|TQB3558|TQB3558 is a kinase inhibitor of the TRK protein family.
224187740|NCT05442827|DRUG|SHR7280 tablets|SHR7280 tablets 400mg for 12 weeks
224187741|NCT05442827|DRUG|PlaceboSHR7280 tablets blank preparation|Placebo group: SHR7280 tablets blank preparation for 12 weeks
223497239|NCT02307500|DRUG|Regorafenib|oral therapy
223497240|NCT00198120|DRUG|D-cycloserine|D-Cycloserine 0.6mg/kg/day in week 1 D-Cycloserine 1.1mg/kg/day in week 2 D-Cycloserine 1.7mg/kg/day in week 3-8 Flexible dosing based on response. Capsule Strength: 10mg, 20mg
223497241|NCT00198120|DRUG|Placebo|Placebo: same dosing schedule and capsule strength
223497242|NCT04900272|BEHAVIORAL|VIPA and companion booklet|Participants will be asked to use the VIPA and accompanying second iteration of the instructional booklet focused on social-isolation. These participants will be surveyed over the phone for 16 weeks (baseline, 2 weeks, 4 weeks, 8 weeks, and 16 weeks) with outcomes measured at each time point.
223745897|NCT03945474|OTHER|Sham|See description in sham arm.
223745898|NCT03945474|OTHER|Osteopathic Manipulation, OMT|See description in OMT arm
224187742|NCT05572489|DIAGNOSTIC_TEST|visual pain scale Beck depression scale Pain catastrophizing scale Short Form-36 Standard Mini mental test Montreal cognitive assessment scale|evaluation of pain, fatigue, mood, quality of life, cognitive status
224187743|NCT03729128|DRUG|dextromethorphan and memantine (DM+MM)|Patients of Amphetamine-type stimulants use disorder (ATSUD) will take dextromethorphan 30 mg/day and memantine 5 mg/day combination (DM+MM) daily for 12 weeks.
223497243|NCT03940092|OTHER|MRI|"This is a prospective, non-randomised, exploratory study on healthy female volunteers (\>18 years), and female patients (\>18 years) diagnosed with primary breast cancer.~Healthy volunteers will be scheduled for an 23Na-MRI examination.~Patients scheduled for primary surgery will undergo an MR examination, involving 23Na-imaging prior to their planned surgery."
223497244|NCT03940092|OTHER|PET/MRI|Patients undergoing neo-adjuvant chemotherapy will undertake up to two (2) combined PET/MR examinations with FDG and 23Na-MRI
223497245|NCT01846871|DRUG|Tivozanib|
223497246|NCT03234452|DIETARY_SUPPLEMENT|Lactoflorene plus|2 vials with dosing cap (10 mL) a day per os
223497247|NCT03234452|DIETARY_SUPPLEMENT|Placebo Lactoflorene plus|2 vials with dosing cap (10 mL) a day per os
223497248|NCT00157625|BEHAVIORAL|Automatic stop order|
223497249|NCT00361153|DRUG|Colesevelam hydrochloride|Welchol tablet 625mg
223497250|NCT00361153|DRUG|placebo|placebo
223497251|NCT05549245|DEVICE|high-flow nasal cannula oxygen therapy,|Patients were treated with high-flow nasal cannula oxygen therapy for three nights
223497252|NCT05549245|DEVICE|CPAP|Patients were treated with CPAP for three nights
223497253|NCT04241731|DRUG|Raltitrexed|Raltitrexed 2.5mg / m2, intravenous infusion for 15min, d1,q2w.
223497254|NCT04241731|DRUG|Cetuximab|Cetuximab 500mg / kg, intravenous drip over 120min, d1,q2w.
223497255|NCT03570593|PROCEDURE|REMOVAL OF URINARY CATHETER AFTER RADICAL SURGERY|Removal of urinary catheter on the first day after radical surgery
223497256|NCT05527522|COMBINATION_PRODUCT|nutritional and educational intervention|individualized diet plus educational intervention with/without nutritional supplements
223497257|NCT05527522|OTHER|standard practice|The patients received the usual treatment and clinical practice
223497258|NCT02952677|BEHAVIORAL|Remind-to-move|Participants were required to wear sensory cueing wristwatch devices with vibration emitted on the affected arm for 3 consecutive hours daily, for a total of 4 weeks, at any time during the day, and received usual care as well.
223745899|NCT03326973|BEHAVIORAL|EuroQoL EQ-5D-3L|Overall QOL
224187744|NCT03729128|DRUG|Placebos|Patients of Amphetamine-type stimulants use disorder (ATSUD) will take placebos daily for 12 weeks.
224187745|NCT03513835|DIAGNOSTIC_TEST|Diagnostic screenings tests|Handgrip test, 12-minute walk test and 6-minute walk test. Biomarkers: acyl-carnitine profile and GDF-15.
223745900|NCT03326973|BEHAVIORAL|EORTC QLQ-C30|General symptoms; physical, role, emotional, cognitive, and social functioning scales; fatigue, nausea/vomiting , and pain scales
224187746|NCT02774499|DRUG|Methadone|0.3mg/kg of methadone given preoperatively (to maximum of 30mg)
224187747|NCT02774499|DRUG|Placebo|equivalent volume (5mL) of syrup given preoperatively
224187748|NCT01970384|DEVICE|Transcranial direct current stimulation|20 Minutes of transcranial direct current stimulation (20 min, 1 mA) administered over the contralesional cortical swallow motor area once daily over 4 consecutive days. In case of a brainstem stroke stimulation will be applied over the cortical swallow motor area of the right hemisphere.
223497259|NCT02952677|BEHAVIORAL|Sham|Participants were required to wear sensory cueing wristwatch devices without vibration emitted on the affected arm for 3 consecutive hours daily, for a total of 4 weeks, at any time during the day, and received usual care as well.
223745901|NCT03326973|OTHER|PRO-CTCAE|Additional potential immune-specific symptoms
223745902|NCT03326973|BEHAVIORAL|Fatigue severity score questionnaire|Fatigue severity
224187749|NCT01970384|DEVICE|Sham stimulation|20 Minutes of sham transcranial direct current stimulation (20 min, no current applied) administered over the contralesional cortical swallow motor area once daily over 4 consecutive days. In case of a brainstem stroke sham stimulation will be applied over the cortical swallow motor area of the right hemisphere.
224187750|NCT05246735|DIAGNOSTIC_TEST|MR-guided Near Infrared optical tomography|
223497260|NCT02952677|OTHER|Control|Participants received usual care
223497261|NCT04443829|BIOLOGICAL|CD19CAR T-cells|Infusion with: CD19CAR T-cells
223497262|NCT05679310|DIETARY_SUPPLEMENT|Hydroxytyrosol/Essential oils|A dietary supplement containing 10 mg of hydroxytyrosol, synthesised using genetically modified Escherichia coli strains and equal amounts (8.33 μL) of essential oils from oregano vulgaris, sage officinalis and crithmum maritimum.
223497263|NCT00159809|DRUG|Viagra (Sildenafil citrate)|
223497264|NCT01229553|DRUG|decolonization|The decolonization protocol for the patients will consist of two-week course of cephalexin (100 mg/kg/day divided TID) or oral T/S (20 mg/kg/day divided BID), HBW every other day for 2 weeks, and mupirocin ointment into both nares BID for 2 weeks.
223497265|NCT00396669|DRUG|Bupropion|We measure dopamine release at the striatum using 11 C Raclopride at baseline and after smoking a cigarette
223497266|NCT00396669|DRUG|Bupropion|Brain imaging after treatment with Bupropion
223497267|NCT02912377|BIOLOGICAL|Neulasta, B12019|GCSF, Growth Colony Stimulating Factor
223497268|NCT00000599|DRUG|colestipol|
223497269|NCT00000599|DRUG|niacin|
223497270|NCT00000599|BEHAVIORAL|diet, fat-restricted|
223497271|NCT01328119|OTHER|4-hour HD, 4-hour HDF, 8-hour HD and 8-hour HDF|Prevalent conventional HD (CHD) patients (dialysing 3 days a week during 4 hours per dialysis session) will undergo, in random order, a mid-week 4-hour HD session, a mid-week 4-hour HDF session, a mid-week 8-hour HD session, and a mid-week 8-hour HDF session with a 2-week interval between every session to assess the influence of treatment duration and of convection on the removal of uremic toxins and on the haemodynamic responses and autonomic nervous regulation. In between the study dialysis sessions these patients will receive routine CHD treatments.
223497272|NCT01551823|BIOLOGICAL|Influenza Virus Vaccine(no Preservative )|Influenza Virus Vaccine(no Preservative) 2×0.25ml intramuscular injections
223497273|NCT01551823|BIOLOGICAL|Influenza Virus Vaccine(contains Preservative)|Influenza Virus Vaccine(contains Preservative)2×0.25ml intramuscular injections
223497274|NCT00081458|DRUG|Placebo|placebo injectable subcutaneously daily into thigh or abdomen
223497275|NCT00081458|DRUG|Teduglutide 0.05 mg/kg/d|Teduglutide 0.05 mg/kg/d daily injectable subcutaneously into the thigh or abdomen
223497276|NCT00081458|DRUG|Teduglutide 0.1 mg/kg/d|Teduglutide 0.1 /g/kg/d daily injection subcutaneously into thigh or abdomen
223497277|NCT03474718|BIOLOGICAL|Platelet-rich Plasma Left Side|Group A will receive PRP on left side of scalp and placebo (saline solution) on right side of scalp.
223497278|NCT03474718|BIOLOGICAL|Platelet-rich Plasma Right Side|Group B will receive PRP on right side of scalp and placebo (saline solution) on left side of scalp.
223497279|NCT03177850|DRUG|ACETAZOLAMIDE oral capsule|Administration of 125mg acetazolamide in the morning, 250mg in the evening, starting 24 hours before departure to 3200m
223497280|NCT03177850|DRUG|Placebo oral capsule|Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3200m
223497281|NCT00915187|DRUG|CCS/C|Adjuvant to influenza vaccine
223497282|NCT00915187|BIOLOGICAL|Influenza Vaccine|Influenza vaccine
223497283|NCT02471742|PROCEDURE|NAC-sparing mastectomy|patients treated with mastectomy with conservation of nipple-areola complex
223497284|NCT02471742|PROCEDURE|conventional mastectomy|patients treated with mastectomy without conservation of nipple-areola complex
223497285|NCT00005790|OTHER|laboratory biomarker analysis|
223497286|NCT00005790|PROCEDURE|biopsy|
223497287|NCT00005790|PROCEDURE|magnetic resonance imaging|
223497288|NCT00005790|RADIATION|gadopentetate dimeglumine|
223497289|NCT05455866|DEVICE|central venous catheter|collection and descriptionof central venous catheter-related complications
223497290|NCT00549328|DRUG|Pazopanib (GW786034)|Pazopanib monotherapy
223497291|NCT00770484|DRUG|Propranolol then Placebo|Propanolol 20 mg, given orally within 1 hour prior to exercising
223497292|NCT00770484|DRUG|Placebo then Propranolol|Placebo, matching pill given orally within 1 hour prior to exercising
223497293|NCT00535834|PROCEDURE|diagnostic procedure|
223497294|NCT00535834|PROCEDURE|molecular diagnostic method|
223497295|NCT00535834|PROCEDURE|protein expression analysis|
223497296|NCT02196545|BEHAVIORAL|Exercise|
223497297|NCT03687255|DRUG|cefepime/AAI101 combination|cefepime 2 g / AAI101 500 mg
223497298|NCT03687255|DRUG|Piperacillin/tazobactam|piperacillin 4 GM / tazobactam 500 MG
223745903|NCT03326973|BEHAVIORAL|The COST|Financial toxicity; satisfaction with ability to work
224187751|NCT03089229|DRUG|HAT01H Cream|HAT01H Cream will be applied twice daily. The research team will provide instructions for the correct application of the treatment. If a lesion disappears, patients will continue applying the cream twice daily to the area. No additional creams, lotions or soaps other than provided test products will be allowed throughout the duration of the study.
224187752|NCT03089229|DRUG|Vehicle Cream|Vehicle Cream will be applied twice daily. The research team will provide instructions for the correct application of the treatment. If a lesion disappears, patients will continue applying the cream twice daily to the area. No additional creams, lotions or soaps other than provided test products will be allowed throughout the duration of the study.
224187753|NCT01985152|DRUG|Azilsartan Trimethylethanolamine|
224309082|NCT01796158|BEHAVIORAL|cASBI+cMET|In the cASBI protocol participants complete a computerized screen for alcohol and drug use, view their screen results on the computer, then see 10 pages of science and true life stories describing the health effects of alcohol and other substance use. The provider receives a report of the screen results and gives brief advice regarding alcohol and drug use during the office visit. The cMET protocol is a 2 session intervention composed of 8 exercises designed to encourage adolescents their alcohol and other substance use and develop a plan to stop or reduce their use.
223497299|NCT03963830|BEHAVIORAL|MOVE UP|Each of the 12-group-sessions will focus on incremental behavioral strategies for maintaining recommended healthy eating, activity, and weight loss behaviors. Participants will monitor body weight and weight loss behaviors. Body weight will be measured at each in-person session and participants will also be encouraged to measure their body weight on their own. Beginning in Session 3, participants are given a home physical activity goal of 10 minutes/day, 50 minutes/week. The goal is raised by 5 minutes/day, 25 minutes/week every other session, the final goal being 30 minutes/day, 150 minutes/week. All subjects will be recommended to engage in an energy restricted dietary intervention that evidence demonstrates has effectively reduced body weight by 5-7% within the initial 4 months of the intervention. This will include reducing energy intake to 1200 to 1800 kcal/d based on initial body weight (\<200 pounds = 1200 kcal/d; 200 to 250 pounds = 1500 kcal/d; \>250 pounds = 1800 kcal/d).
223497300|NCT02162433|DRUG|Normal Saline|to arms 2,4. Serves as the placebo.
223497301|NCT02162433|DRUG|Dexmedetomidine|to arms 1,3
223497302|NCT05616897|BEHAVIORAL|Physiological responses during sustained CPR|
223745904|NCT03326973|BEHAVIORAL|Physician information|Details on outside health providers
223745905|NCT01628601|DRUG|Fixed combination 0.3 mg bimatoprost and 5 mg timolol|Patients with POAG or OHT prescribed GANfort® (fixed combination 0.3 mg bimatoprost and 5 mg timolol) treatment in a dose determined by the physician prior to study entry
224187754|NCT01985152|DRUG|Placebo|
224187755|NCT00998933|DRUG|Testosterone gel 1.62%|5 grams applied topically to upper arms/shoulder and abdomen on Day 1
224187756|NCT00741624|OTHER|Bandage|one application for one week
224187757|NCT03784716|OTHER|Ketogenic Diet|Ketogenic diet for 28 days. Meals will be provided to all study participants for 28 days by a prepared meal delivery service. Daily caloric needs for each participant will be determined based on height, weight, gender, age, and activity level. Meals will be prepared based on compliance with the following macronutrient guidelines: 70% fat, 25% protein, and 5% carbohydrate for the ketogenic diet.
224187758|NCT03784716|OTHER|Standard Weight Loss Diet|Standard weight loss diet for 28 days. Meals will be provided to all study participants for 28 days by a prepared meal delivery service. Daily caloric needs for each participant will be determined based on height, weight, gender, age, and activity level. Meals will be prepared based on compliance with the following macronutrient guidelines: 30% fat, 20% protein, and 50% carbohydrate for the standard weight loss diet.
223497303|NCT02189447|PROCEDURE|Simultaneous Photorefractive Keratectomy and Collagen Cross-linking in patients with keratoconus|Photorefractive Keratectomy followed by Collagen Cross-linking in patients with keratoconus in the same surgical setting
223497304|NCT05183620|DEVICE|Feeling Hot sensor system|The Feeling Hot sensor system consists of two temperature probes placed on the penis and the outer thigh of the test subject to measure skin temperature during erection
223497305|NCT05463770|DRUG|SEP-363856|SEP-363856, 12.5 mg, 25 mg, and 50 mg tablets. The dose taken at the same time each day, in the evening and in the morning. Multiple tablets may be required to achieve a single dose.
223497306|NCT04680143|DRUG|Systemic erythropoietin injection|Systemic erythropoietin injections (eprax 10000 IU subcutaneous twice daily for three days).
223497307|NCT01946802|DEVICE|Frontal 4 channel EEG|Simultaneous conventional EEG and SEDline monitoring for 30 minutes during and after therapeutic hypothermia
223497308|NCT01332201|DRUG|Advagraf|oral
223497309|NCT01332201|DRUG|Prograf|oral
223497310|NCT03097315|DRUG|4 mg CLS-TA Suprachoriodal Injection|CLS-TA, 40 mg/mL (4 mg in 100 microliters), will be administered as a single injection at 2 timepoints
223497311|NCT03890939|DEVICE|BiPAP AutoSV Advanced System One|A mode of positive airway pressure used to treat sleep apnea. The difference between this device and the other experimental device is in the algorithm of the pressure settings.
223497312|NCT03890939|DEVICE|Dreamstation BiPaP AutoSV|A mode of positive airway pressure used to treat sleep apnea. The difference between this device and the other experimental device is in the algorithm of the pressure settings.
223497313|NCT03890939|DEVICE|ResMed S7 VPAP Adapt Device|A mode of positive airway pressure used to treat sleep apnea. This device is widely used by physicians to treat sleep apnea and will be the active comparator to the two experimental devices.
223497314|NCT00811109|DEVICE|Standard Hemodialysis|Gold standard bicarbonate hemodialysis therapy with constant ultrafiltration rate and dialysis conductivity performed with Fresenius 4008S monitor (Fresenius Medical Care, France)
223497315|NCT00811109|DEVICE|with Blood Volume Management (BVM®) only|Hemodialysis using Blood Volume on-line monitoring only. Hemodialysis will be performed with Fresenius 4008S monitor (Fresenius Medical Care, France) equipped with BVM® device (for blood volume monitor; Fresenius Medical Care, France)
223497316|NCT00811109|DEVICE|with Blood Volume (BVM®) and Temperature (BTM®) on-line monitoring|Hemodialysis using Blood volume and Blood temperature on-line monitoring. Hemodialysis will be performed with Fresenius 4008S monitor (Fresenius Medical Care, France) equipped with BVM® and BTM® devices (for blood volume monitor and blood temperature management, respectively; Fresenius Medical Care, France)
223497317|NCT00422435|DEVICE|CoStar™ Paclitaxel-Eluting Coronary Stent with SRX catheter|Paclitaxel-Eluting Coronary Stent
223497318|NCT02999321|OTHER|aspartame|will be given 5mg aspartame or 15 mg aspartame
223497319|NCT02999321|OTHER|water|control group
223497320|NCT05880043|DRUG|GIC-102|GIC-102 will be administered via IV infusion 3 times at intervals of 1 week, and 28 days is defined as 1 cycle
223497321|NCT05880043|DRUG|GIC-102|GIC-102 will be administered via IV infusion 3 times at intervals of 1 week, and 28 days is defined as 1 cycle
223590224|NCT00901810|DEVICE|Electronic Apex Locator|Electronic Apex Locator is used to find the apical foramen of the root canal. It uses a weak electrical current passed through the canal by endodontic file.
223590225|NCT00901810|DEVICE|Dental Radiography|Radiography is used to measure the length of root canal by putting an endodontic file in the canal and taking the radiography to measure the length.
223590226|NCT04122170|DRUG|Ticagrelor Oral Tablet - Pre-Treatment|Ticagrelor 90 mg oral tablet; administered as 180 mg (2 × 90 mg tablet) loading dose plus 90 mg every 12 hours for 4 additional doses.
224187759|NCT03795324|OTHER|Redlove Apple intervention|The bioactive compounds present in this product are anthocyanins (50mg per 80g of product).It was a 6 weeks nutritional intervention. Volunteers will eat 80g per day of lyophilized redlove apple.
224187760|NCT03795324|OTHER|Green Apple intervention|It was a 6 weeks nutritional intervention. Volunteers will eat 80g per day of lyophilized green apple.
224187761|NCT03795324|OTHER|Aronia drink intervention|The bioactive compounds present in this extract are anthocyanins (50mg per 1L of water).It was a 6 weeks nutritional intervention. Volunteers will drink 1L per day of an aronia drink
224187762|NCT03240666|OTHER|non applicable|non applicable
224187763|NCT05574920|DIAGNOSTIC_TEST|Al18F-NOTA-FAPI-04 PET/CT scan|Patients enrolled underwent PET/CT after injection of Al18F-NOTA-FAPI-04 to image lesions of breast cancer.
224309083|NCT01796158|BEHAVIORAL|cASBI|In the cASBI protocol participants complete a computerized screen for alcohol and drug use, view their screen results on the computer, then see 10 pages of science and true life stories describing the health effects of alcohol and other substance use. The provider receives a report of the screen results and gives brief advice regarding alcohol and drug use during the office visit.
223497322|NCT04881721|PROCEDURE|Urethropexy|Suture based (Mesh-free) surgery to stabilize the urethra for the treatment of stress urinary incontinence
223497323|NCT01805336|OTHER|Assessment of attentional functions by traditional tests|For assessment of attentional functions, traditional tests include : Symbol Digit Modalities Test (SDMT), Test d'Evaluation de l'Attention (TEA), Attentional Network Test (ANT).
223497324|NCT01805336|OTHER|Assessment of attentional functions by virtual reality tests|For assessment of attentional functions, virtual reality tests include : Monotonous task of driving on motorways, Task of city driving with accident scenarios, Monotonous driving task with divided attention test ; all tests realized on a driving simulator.
223590227|NCT04122170|DRUG|Aspirin (ASA) Oral Tablet - Pre-Treatment|Aspirin 81 mg oral tablet; administered daily between Day -7 to the morning before receiving study medication on Day 1, for a total of 8 tablets only.
223590228|NCT04122170|DRUG|Bentracimab (PB2452) Infusion|"Bentracimab (PB2452) 18 g Intravenous Infusion over a 16 hour duration~In subjects with potential drug interaction from concomitant use of moderate or strong CYP3A inhibitors with ticagrelor, the active treatment period may be 24 hours and 10 min if receiving the 36 g infusion."
223590229|NCT04122170|DRUG|Placebo (0.9% Sodium chloride) infusion|0.9% Sodium chloride Intravenous Infusion over a 16 hour duration
224187764|NCT06214039|BEHAVIORAL|Exposure in virtual reality and text based cognitive behavioral therapy (CBT) for public speaking anxiety|A 3-hour one session exposure therapy for public speaking anxiety
224187765|NCT03040180|DRUG|Electrochemotherapy with bleomycin|Systemic injection, once only treatment
224187766|NCT03040180|DEVICE|EndoVE|Electroporation using an endoscopic electroporation device
224187767|NCT06049823|PROCEDURE|Alveolar ridge preservation|Different grafting strategy of alveolar ridge preservation with different sealing materials
224309084|NCT04231734|OTHER|Ketogenic Diet|Prepared ketogenic meals, 3 per day for up to 12 weeks (Day 1 through Day 84)
223497325|NCT01805336|OTHER|Assessment of executive functions by traditional tests|For assessment of executive functions, traditional tests include : Wisconsin Card Sorting Test (WCST), Task verbal fluencies, Sequence Numbers Letters subtest of the Wechsler Adult Intelligence Scale (WAIS) III, Commissions.
223497326|NCT01805336|OTHER|Assessment of executive functions by virtual reality test|For assessment of executive functions, virtual reality test include : VAP-S.
223497327|NCT01805336|OTHER|Evaluation of cognitive complaint, fatigue, anxiety and depression|The following questionnaires will be completed by the participant at the inclusion visit : cognitive complaint RBN-SEP questionnaire to assess cognitive complaint, EMIF-SEP to assess fatigue, STAI (State Trait Anxiety Inventory) to assess anxiety and MADRS to assess depression.
223497328|NCT05309889|OTHER|no intervention|no intervention
223497329|NCT00247793|DRUG|Oral Impact (preoperative enteral nutritional supplement)|
223590230|NCT05363826|COMBINATION_PRODUCT|photochemotherapy using 3-(1-Butyloxy)ethyl-3-deacetyl-bacteriopurpurin-18-n-butylimide methyl ester(Photobac®)|"Intravenous injection of Photobac® 24 hours before surgical removal of recurrent GBMF.~Immediately after resection, the cavity will be treated with 50 joules/ square cm of 787nm light. This treatment will add a maximum of 50 minutes to the surgery"
223590231|NCT03222414|DEVICE|Non-invasive BP recording with conical Ultracheck Curve BP cuff|Non-invasive SBP, DAP and MAP will be measured in both arms using conical Ultracheck Curve BP cuff
223590232|NCT03222414|DEVICE|Non-invasive BP recording with traditional cylindrical BP cuff|Non-invasive SBP, DAP and MAP will be measured in both arms using traditional cylindrical BP cuff
223590233|NCT03222414|OTHER|Direct invasive arterial pressure|Direct invasive arterial pressure readings will be recorded simultaneously with non-invasive measurements
223590234|NCT03774342|PROCEDURE|Coronary Artery Bypass Grafting|Patients undergoing coronary artery bypass grafting
223590235|NCT03847909|DRUG|DCR-PHXC|Multiple fixed doses of DCR-PHXC by subcutaneous (SC) injection
223590236|NCT03847909|DRUG|Sterile Normal Saline (0.9% NaCl)|Sterile Normal Saline (0.9% NaCl) for subcutaneous (SC) injection, administered at same injection volume as DCR-PHXC, to serve as placebo
224309085|NCT02304458|BIOLOGICAL|Ipilimumab|Given IV
224309086|NCT02304458|OTHER|Laboratory Biomarker Analysis|Correlative studies
224309087|NCT02304458|BIOLOGICAL|Nivolumab|Given IV
224309088|NCT02304458|OTHER|Pharmacological Study|Correlative studies
224309089|NCT03516214|DRUG|EGF816|Continuous oral treatment (once daily) with the 3rd generation EGFR inhibitor EGF816.
224309090|NCT03516214|DRUG|Trametinib|Continuous oral treatment (once daily) with the MEK inhibitor trametinib.
224187768|NCT05179291|OTHER|Buzzy Group|The Buzzy device was placed 5-10 cm above the injection area and making sure that it was in contact with the skin. The ice pack was kept in the deep freezer and placed into the device before the application. Buzzy was introduced to the children pre-procedure. Cold application and vibration were started pre-procedure and maintained until the procedure was completed. Following the Buzzy application, the device was wiped with 70% alcohol and used for other children. The Buzzy devices were kept in the deep freeze and refrozen. The same person conducted the pain reduction methods during phlebotomy.
224187769|NCT05179291|OTHER|Virtual Realitiy-VR Group|VR glasses were introduced to the children pre-procedure. The children were made to watch a video with VR glasses 2-3 minutes before starting the application and it continued until the end of the phlebotomy procedure (three minutes on average). 3D video suggestions (Space Experience, Blue Whale 360 VR Experience) were offered to the children before the phlebotomy procedure and they were asked to choose one of them.
224187770|NCT05396196|DEVICE|Kinesio® Tape|Manual Fascial Glide Application
224187771|NCT03804138|OTHER|Anti-influenza and DTp pertussis vaccinations|Anti-influenza and DTp pertussis vaccinations will be performed during the visit by the clinical research nurse. The vaccine has been prescribed as part of the care either by the patient's physician (pulmonologist or general practitioner).
224187772|NCT00709813|BEHAVIORAL|Tailored assessments provided to physicians and nurses (CHOICE, the Computer-assisted Interactive Tailored Patient Assessment Tool (ITPA))|Both groups used CHOICE, the Computer-assisted Interactive Tailored Patient Assessment Tool (ITPA)for symptom assessments at in- and outpatient visits during and up-to nine months after treatment. In the intervention group physicians and nurses had assessment summaries available for care planning, displaying patients' symptoms, problems and concerns in rank-order of their needs for care. In the control group assessments were not available to care providers at any time.
224187773|NCT01828346|DRUG|Birinapant|"Dose escalation part: (Drug escalation dose levels)~* Dose Level (1) - 13mg/m2 (twice a week for 3 of 4 weeks)~* Dose Level (-1) - 11 mg/m2 (twice a week for 3 of 4 weeks)~* Dose Level (2) - 13mg/m2 (twice weekly x 4 weeks)~* Dose Level (3a) - 17mg/m2 (twice weekly × 4 weeks)OR~* Dose Level (3b) - 17mg/m2 (twice a week for 3 of 4 weeks)"
224187774|NCT01828346|DRUG|5-Azacitidine|Dose Level (0) - 75mg/m2 daily
224187775|NCT00002075|DRUG|Flucytosine|
223497330|NCT00277563|DEVICE|reduction of pain scores by magnetic energy|
223497331|NCT04328285|DRUG|Hydroxychloroquine|Hydroxychloroquine Oral Tablets
223497332|NCT04328285|DRUG|Placebo of Hydroxychloroquine|Placebo of Hydroxychloroquine Oral Tablets Placebo manufactured to mimic Hydroxychloroquine tablets
223497333|NCT04328285|DRUG|Lopinavir and ritonavir|LPV/r Oral Tablets
223497334|NCT04328285|DRUG|Placebo of LPV/r Tablets|Placebo of LPV/r Oral Tablets Placebo manufactured to mimic LPV/r tablets
223590237|NCT04302064|DRUG|Eplontersen|Eplontersen administered SC
224187776|NCT00002075|DRUG|Fluconazole|
224187777|NCT00002075|DRUG|Amphotericin B|
223497335|NCT06468917|BEHAVIORAL|1st day removal of abdominal drain|once POPF is excluded in middle-low risk pancreatic resection, abdominal drains can be removed
223497336|NCT03166176|DRUG|Vistusertib(AZD2014)|vistusertib(AZD2014) is selective inhibitor of mTOR kinases and inhibits signalling of both mTOR complexes, mTORC1 and mTORC2.
223497337|NCT04772430|RADIATION|snow globe|"Control group; The baby whose height and weight measurements will be taken will be taken to the stretcher, and the vaccine will be administered after the pain score is measured before the procedure. Pain scores will be recorded during and after the procedure.~Experimental group; The baby whose height and weight measurements will be taken will be taken to the stretcher, after the pain score is measured before the procedure, the snow globe will be operated and the vaccine will be applied. The snow globe will continue to work until the application is completed. Pain scores will be recorded during and after the procedure."
223497338|NCT03880409|DRUG|2% lidocaine with 1:000,000 epinephrine|2% lidocaine with 1:000,000 epinephrine is dental local anesthesia
223497339|NCT03880409|DRUG|4% articaine with 1:000,000 epinephrine|4% articaine with 1:000,000 epinephrine is dental local anesthesia
224187778|NCT05659342|OTHER|ELDOA Technique|"the patients treated with ELDOA technique, followed for 3 alternative days for 4 weeks.~the ELDOA techniques for level L4/L5 and L5/S1 were applied. the ELDOA positions hold for one minute, 3 alternative days for 4 weeks under supervision.~Hot pack (10-15 minutes) McKenzie Extension Exercises"
224187779|NCT05659342|OTHER|Mechanical Lumbar Traction|"Mechanical Traction Technique: traction unit, 50% of body weight was applied with the patients lying in supine position, with the hip and knee at 90 degree flexion, and legs were supported. Traction were applied for 3 alternative days for 4 weeks.~Hot pack (10-15 minutes) McKenzie Extension Exercises"
223497340|NCT05842707|DRUG|dualCAR-NK19/70 cell|Given by IV (vein)
223497341|NCT04279678|PROCEDURE|Mitral valve repair|surgical repair of moderate ischemic mitral regurgitation using pericardial patch or rigid semi-annular ring
223497342|NCT03996460|DRUG|Placebo|"Fifteen (15) patients in group 1 will receive the sachet of matching placebo ( equivalent to a capsule of placebosugar pill) orally daily for 12 weeks (90 days) without food."
223497343|NCT03996460|DRUG|192 mg powder of K0706|Fifteen (15) patients in group 2 will receive the sachet of 192 mg powder of K0706 ( equivalent to 96 mg capsule of K0706) orally for 12 weeks (90 days) without food.
223497344|NCT03996460|DRUG|384 mg powder of K0706|Fifteen (15) patients in group 3 will receive the 384 mg powder of K0706 (equivalent to 192 capsule of K0706) orally daily for 12 weeks (90 days) without food.
223497345|NCT00726427|DRUG|AZD1656|Dose escalation to achieve maximum tolerated dose
223497346|NCT00726427|DRUG|AZD1656|Oral single dose
223590238|NCT04302064|DRUG|Placebo|Eplontersen-matching placebo administered SC
223745906|NCT00791466|DIETARY_SUPPLEMENT|Placebo|Daily placebo supplementation from enrolment \<14 wk of gestation until delivery
223745907|NCT00791466|DIETARY_SUPPLEMENT|Iodine|Daily supplementation with 200 µg iodine from enrolment \<14 wk of gestation until delivery
223745908|NCT05133219|OTHER|Occupational Therapy|Occupational therapy is the only profession that helps people across the lifespan to do the things they want and need to do through the therapeutic use of daily activities (occupations). Occupational therapy practitioners enable people of all ages to live life to its fullest by helping them promote health, and prevent-or live better with-injury, illness, or disability.
223745909|NCT04356963|BEHAVIORAL|Virtual Reality Session (VR Blu)|20-30 minute session of virtual reality immersive content.
223497347|NCT06328231|BEHAVIORAL|Systematic simple swallowing training|"Systematic simple swallowing training includes the following:~Warm-up: including joint activities, chest expansion exercise, etc., totally 5 minutes.~Cognitive swallowing training: play video of food programs for five minutes. Lip training: Bounce the upper and lower lips to make a bo sound. 30-60 seconds.~Tongue training: Do the upper, lower, left, and right four-directional movements of the tongue muscle. 30-60 seconds.~Mandibular training: slowly open r mouth to the maximum, then slowly close it. 30-60 seconds.~Soft palate training: Make the sounds of g, k, and h for 1-2 minutes. Cheek puffing training: Close lips tightly and puff cheeks. 30-60 seconds. Swallowing training: We require the elderly to swallow small amounts of water intermittently and forcefully for 2-5 times.~Completing the above content in succession is called a round, and each training session includes 2-3 rounds. 2 sessions a day. Five days a week."
224187780|NCT02827773|OTHER|Talking Pill Bottle|Made by Talking Rx
224187781|NCT04873609|BEHAVIORAL|Patient portal message|Direct-to-patient message via the electronic patient portal (MyHealth) with HCV antibody lab order directed to their preferred laboratory
224187782|NCT03005691|RADIATION|Spectroscopy|"Spectroscopy is a noninvasive method to assess brain chemistry. The signal of the hydrogen atom attached to a certain molecule or metabolite has a particular frequency associated with a given metabolite. The utility of Spectroscopy is based on the fact thet the nuclei of atoms have magnetic properties that can be used to obtain chemical information regarding both the type of molecule and it is concentration.~The subjects will be scanned on a 3-T Siemens system and an 12-channel phased-array coil will be used to provide an optimum signal-to-noise ratio for spectroscopy data."
224187783|NCT03005691|OTHER|Questionnaires|Questionnaires are important to assess the chronic pain and their impact in the quality of life. For this reason, we will assess the Brief Pain Inventory (BPI), it is used to evaluate the subject's perception of pain severity and its interference. Moreover, we will assess neuropathic pain symptoms with the NPSI to detect paresthesia/dysaesthesia, evoked pain and paroxysmal pain. The catastrophizing score will be measured with the Pain Catastrophizing Helplessness Subscale. Also,we will assess the disability after whiplash using the Neck Disability Index.
224187784|NCT03005691|PROCEDURE|Conditioned Pain Modulation|Conditioned Pain Modulation over the tenar eminence. The test will be a heat tonic stimulus which evoke a 3-pain intensity. The conditioning stimulus will be a cold water immersion (12ºC)
224187785|NCT03185637|PROCEDURE|Various interventions for each of the conditions.|"This is an observational study. Patients were not allocated to different interventions.~Common interventions for each of the conditions, which will be compared during analysis include the following:~Gastroschisis - primary operative closure, surgical silo, preformed silo. Anorectal malformation - various types of stoma, anoplasty, PSARP, other. Appendicitis - antibiotics, open appendicectomy, laparoscopic appendicectomy. Intussusception - air enema reduction, hydro-enema reduction, laparotomy. Inguinal hernia - open repair, laparoscopic repair."
224187786|NCT04148976|DIETARY_SUPPLEMENT|Placebo|A mixture of maltodextrins and calcium caseinate divided into 30g individual packets.
224187787|NCT04148976|DIETARY_SUPPLEMENT|Dietary portfolio|A mixture of functional foods divided into 30g individual packets.
224187788|NCT03356327|DRUG|Actitan F|A molecolar complex of Tannins and Flavonoids used for acute diarrhea in children
224187789|NCT03356327|DRUG|Standard Oral Rehydration|Standard oral rehydration as suggested by ESPGHAN guidelines
224187790|NCT04434703|PROCEDURE|Platelet rich fibrin (PRF)|following atraumatic extraction of the tooth using periotomes , 10 ml of patient's blood will be drawn by vein puncture of the antecubital vein and prepared in a centrifuge at 3000 rpm for 10 minutes then criss horizontal mattress suture will be applied to close the extraction wound
224187791|NCT04434703|PROCEDURE|Advanced platelet rich fibrin (A-PRF)|following atraumatic extraction of the tooth using periotomes , 10 ml of patient's blood will be drawn by vein puncture of the antecubital vein and prepared in a centrifuge at 1300 rpm for 8 minutes then criss horizontal mattress suture will be applied to close the extraction wound
224187792|NCT04434703|PROCEDURE|blood clot|following atraumatic extraction of the tooth using periotomes, no bio-addative will be added and criss horizontal mattress suture will be applied to close the extraction wound
224187793|NCT04781946|PROCEDURE|Endoscopic pneumatic balloon dilation|Using endoscopy, pneumatic balloon dilation may be used to treat stenosis of the gastric sleeve.
224187794|NCT04781946|PROCEDURE|Gastric peroral endoscopic myotomy (G-POEM)|Gastric per-oral endoscopic myotomy (G-POEM) is a recent innovation offering a minimally invasive endoscopic approach. G-POEM allows for the creation of a tunnel and subsequent myotomy from the gastric cardia to the gastric pylorus.
224187795|NCT04781946|PROCEDURE|Roux-en-Y gastric bypass (RYGB)|The Roux-en-Y gastric bypass is a type of weight-loss surgery that involves creating a small pouch from the stomach and connecting the newly created pouch directly to the small intestine.
224187796|NCT00596622|DRUG|Lithium|Dosing will start as one 300-mg capsule per day and will be titrated up to four 300-mg capsules per day for a total of 8 weeks of treatment.
224187797|NCT01866280|BEHAVIORAL|Normal sleep|Normal sleep= sleep 2300-0700
223497348|NCT00559715|DRUG|bevacizumab|1.25 mg intravitreally monthly/on demand
223745910|NCT04356963|BEHAVIORAL|Tablet-based Session (Tablet Blu)|20-30 minute session of tablet-based content that mimics the content from virtual reality sessions.
223745911|NCT04356963|BEHAVIORAL|Use of Virtual Reality Head Mounted Display without Content (VR Blank)|20-30 minutes session using head mounted display to reduce light and sound.
223497349|NCT00559715|DRUG|ranibizumab|0.5 mg intravitreally monthly/on demand
223497350|NCT00351104|DRUG|Ketoprofen Topical Patch 20%|
223497351|NCT04900857|OTHER|Dry needle|Local twitch responses (LTRs) were obtained by multiple rapid insertions of the needle in and out of the point, similar to Hong's rapid-entry and rapid exit technique. Hong 1994). The needle was not removed from that site for the maximum stimulation time of 1 minute to 3 minutes after a local twitch response was obtained.
223497352|NCT04900857|DEVICE|Localize vibration|the vibration was applied with 110 Hz and 5.57 mm amplitude.
223497353|NCT03573765|PROCEDURE|Shoulder arthroplasty|Any form of joint replacement of the glenohumeral joint including prosthetic and excision.
223497354|NCT03573765|PROCEDURE|Elbow arthroplasty|Any form of joint replacement of the elbow joint including prosthetic and excision.
223745912|NCT04834947|PROCEDURE|prone position|Choice of prone positioning a patient is at the discretion of the anesthesia physician.
224187798|NCT01866280|BEHAVIORAL|Normal meals|Normal meal times=approximately 1.5, 5, and 11 h after wake up for breakfast, lunch, and dinner, and snack at 13 h after wake up time
224187799|NCT01866280|BEHAVIORAL|Late sleep|Late sleep=sleep at 0230-1030 hours
224187800|NCT01866280|BEHAVIORAL|Late meals|Late meal times= approximately 4.5, 7, and 13 h after wake up time for breakfast, lunch and dinner, and snack at 15 h.
224187801|NCT06205212|OTHER|high-flow nasal oxygen|preoxygenation using high-flow nasal oxygen, FiO2 1.0, 40 L/min, 3 min
223497355|NCT03573765|PROCEDURE|Hand and wrist arthroplasty|Any form of joint replacement of joints of the hand and wrist including prosthetic and excision.
223497356|NCT03573765|PROCEDURE|Nerve decompression|Open or endoscopic release of peripheral nerve entrapment - subdivided by anatomical site of compression. Specific subgroups will include carpal tunnel and cubital tunnel release.
223497357|NCT03573765|PROCEDURE|Tendon repair|Open or arthroscopic repair or reconstruction of tendons of the shoulder, hand and upper limb in general.
223497358|NCT03573765|PROCEDURE|Joint stabilisation|Any procedure designed to increase stability of a joint, including soft tissue and bony blocking procedures.
223497359|NCT03573765|PROCEDURE|Excision/division/release of palmar fascia|Any procedure performed for treatment of Dupuytren's contracture.
223497360|NCT03573765|PROCEDURE|Surgical fixation of fractures|Any internal or external fixation of upper limb fractures - analysed by anatomical site.
223497361|NCT03573765|PROCEDURE|Soft tissue release/debridement/excision|Any removal or release of soft tissue for treatment of stiffness, functional impairment or pain. Specific subgroups will include trigger finger release, subacromial surgery and surgery for frozen shoulder.
223497362|NCT03573765|PROCEDURE|Intra-articular injection|Any intra-articular injection
223497363|NCT03868566|DRUG|SNP-612 dose1|Subjects will take dose1 once a day orally for 12 weeks
223497364|NCT03868566|DRUG|SNP-612 dose2|Subjects will take dose2 once a day orally for 12 weeks
223497365|NCT01300520|DEVICE|Target Tape|Comparing procedures using Target Tape against procedures not using Target Tape
223497366|NCT00701194|BEHAVIORAL|Early Intervention Foster Care (EIFC)|The EIFC/MTFC-P intervention is delivered through a treatment team approach. Foster parents receive preservice training and ongoing consultation from program staff. Children receive individual therapy and attend a therapeutic playgroup. The intervention emphasizes the use of concrete encouragement for prosocial behavior; consistent, nonabusive limit-setting to address disruptive behavior; and close supervision of the child. The EIFC intervention employs a developmental framework in which the challenges of foster preschoolers are viewed from the perspective of delayed maturation and is oriented toward creating optimal environmental conditions to facilitate developmental progress. These conditions include a responsive and consistent caregiver and a predictable daily routine.
223497367|NCT04508413|OTHER|KB295|KB295 is a novel glycan
223497368|NCT01289535|PROCEDURE|Blood sample|Blood sample of 7 ml
223497369|NCT02403037|DEVICE|True auricular acupressure|A 5-day auricular acupressure at the specific ear acupoints using vaccaria seeds.
223497370|NCT02403037|DEVICE|Sham auricular acupressure|A 5-day sham auricular acupressure at the same acupoints as in the true auricular acupressure arm using Junci Medulla but no pressure will be applied.
223497371|NCT02403037|DRUG|Standard anti-emetic treatment (5-HT3 receptor antagonists and/or Dexamethasone)|5-HT3 receptor antagonists and/or Dexamethasone will be administered to manage chemotherapy-induced nausea and vomiting.
223497372|NCT04796467|DRUG|68Ga-PSMA-617|Intravenous injection of one dosage of 148-185 MBq (4-5 mCi) 68Ga-PSMA-617. Tracer doses of 68Ga-PSMA-617 will be used to image lesions of prostate cancer by PET/CT.
223497373|NCT04796467|DRUG|68Ga-P16-093|Intravenous injection of one dosage of 148-185 MBq (4-5 mCi) 68Ga-P16-093. Tracer doses of 68Ga-P16-093 will be used to image lesions of prostate cancer by PET/CT.
223497374|NCT00909974|DIETARY_SUPPLEMENT|UNIMMAP - multiple micronutrients|"Daily supplementation of one UNIMMAP tablet~multiple micronutrient supplements (MMN): UNIMMAP: vitamin A 800µg, vitamin E 10 mg, vitamin D 5 µg, vitamin B1 1.4 mg, vitamin B2 1.4 mg, niacin 18 mg, vitamin B6 1.9 mg, vitamin B12 2.6 µg, folic acid 400 µg, vitamin C 70 mg, iron 30 mg, zinc 15 mg, copper 2 mg, selenium 65 µg, and iodine 150 µg"
223497375|NCT00909974|DIETARY_SUPPLEMENT|Food supplement enriched with multiple micronutrients|"One dose of 72g per day during whole pregnancy~Recipe of food supplement: 33% peanut butter, 32% soy flour, 15% vegetable oil, 20% sugar, UNIMMAP in powdered form Nutritional composition (per dose of 72g) Energy 1.56 MJ, protein 14.7 g, vitamin A 881 µg, vitamin E 13 mg, vitamin D 5 µg, vitamin B1 1.4 mg, vitamin B2 1.4 mg, niacin 21 mg, vitamin B6 1.9 mg, vitamin B12 2.6 µg, folic acid 461 µg, vitamin C 70 mg, iron 30 mg, zinc 15 mg, copper 2 mg, selenium 65 µg, and iodine 150 µg"
223497376|NCT03862885|DRUG|Avapritinib|Avapritinib will be administered orally (PO) at a dose of 300 mg once daily (QD) in continuous 28-day cycles.
223497377|NCT02407015|OTHER|Nintendo 3DS gameplay|
223745913|NCT06015737|COMBINATION_PRODUCT|Anifrolumab|Anifrolumab will be provided as a solution for injection in accessorized pre-filled syringe (aPFS).
223745914|NCT06015737|OTHER|Placebo|Matching placebo solution for injection in aPFS.
224187802|NCT06205212|OTHER|facemask|preoxygenation using facemask, FIO2 1.0, fresh gas flow 10 L/min, 3 min
224187803|NCT01494727|DRUG|CJ Amlodipine/Valsartan 10/160mg|single dose
224187804|NCT01494727|DRUG|Novartis Exforge 10/160mg|single dose
224187805|NCT04720027|DIAGNOSTIC_TEST|Duplex imaging|Completion of AVVQ and EQ5D questionnairs
224187806|NCT04246996|DRUG|gentamicin sulfate|Subjects in the gentamicin arm will receive an bladder instillation of 80mg of gentamicin sulfate in 50 mL of normal saline through a standard-of-care Foley catheter.
224187807|NCT04246996|OTHER|Catheter clamping only|Subjects in the control arm will have their standard-of-care transurethral catheter clamped for 1 hour post-placement to maintain subject masking to study arm.
224187808|NCT01590095|BEHAVIORAL|Water quality|"Hardware: Free supplies chlorine tablets (Aquatabs; NaDCC) and a safe storage vessel to treat and store drinking water.~Promotion: Local promoters will visit study compounds at least monthly to deliver behavior change messages that focus on the treatment of all drinking water for children \< 36 months of age."
224187809|NCT01590095|BEHAVIORAL|Sanitation|Hardware: Free child potties, sani-scoop hoes to remove feces from household environments, latrine upgrades to a dual pit latrine Promotion: Local promoters will visit study compounds at least monthly to deliver behavior change messages that focus on the use of latrines for defecation and the removal of human and animal feces from the compound.
224187810|NCT01590095|BEHAVIORAL|Hand washing|"Hardware: Hand washing stations, soapy water bottles located at hand washing locations, detergent soap to supply soapy water bottles.~Promotion: Local promoters will visit study compounds at least monthly to deliver behavior change messages that focus on hand washing with soap at critical times around food preparation, defecation, and contact with feces."
223497378|NCT03313193|OTHER|Acupressure for Children in Treatment for a Childhood Cancer|This study will describe the benefits and risks of an acupressure intervention to decrease nausea/vomiting and other treatment-related symptoms compared to a control group receiving usual care. Children in Arm A will receive usual symptom management care + acupressure 5 days/week for \~20 treatments. Parents will be taught how to provide acupressure as well. Children in Arm B will receive usual care alone.
223497379|NCT05103592|DIAGNOSTIC_TEST|Tartrate- resistant Acid Phosphatase marker|marker could be diagnostic for osteoporosis
223497380|NCT05099406|DEVICE|Transcranial electrical stimulation|"By applying a low current over the cortex through the scalp, this technique can excite or inhibit the neural activity, thus modulating brain processes like pain perception and inducing relatively sustained changes in cortical excitability and neuroplasticity.~Home-based transcranial electrical stimulation device consists of a custom headgear with fixed electrode sites and built-in cabling made for a simplistic setup for tDCS/tACS stimulation. Systems are equipped with strict dose control feature that provide reliable control over the intensity and timing of stimulation, turning these devices into a feasible and safe clinical alternative. The equipment is specifically designed for easy and simplistic self-setup and allows the researchers to remotely check the position of electrodes and also monitor the stimulation session."
223497381|NCT04273789|DEVICE|Far infrared reflecting sleepwear|100% microlyocell sleepwear (shorts + shirt) with a ceramic print that reflects far infrared light (FIR, 5.6-1000 µm) emitted by the human body. Since FIR active garments are not powered, but reflect recycle light energy emitted by the body of the wearer, they have irradiances between 0.1-5 mW/cm\^2.
223497382|NCT04273789|DEVICE|Placebo sleepwear|100% microlyocell sleepwear (shorts + shirt)
223745915|NCT06015737|COMBINATION_PRODUCT|Anifrolumab|Anifrolumab will be provided as a solution for injection in accessorized pre-filled syringe (aPFS).
223745916|NCT06015737|OTHER|Placebo|Matching placebo solution for injection in aPFS.
223745917|NCT04419038|PROCEDURE|conjunctival autografting augmented with topical application of Mitomycin C|Group A included 32 eyes of 32 patients who underwent conjunctival autografting augmented with topical application of Mitomycin C (0.2 mg/mL).
224073920|NCT06194591|DEVICE|NephrospecTM, low-intensity extracorporal shockwave therapy device|"Patients will receive 6 Li-ESWT treatments with the NephrospecTM device over three consecutive weeks, with a minimal recess of 24 hours between treatments and a maximum of 3 sessions per week.~Three hundred shockwaves will be applied by the PI or co-PI to each one of 8 pre-selected regions of each kidney, under ultrasound control, with the patient in the prone position. No local anaesthesia is needed. Total treatment time of one session is 30 minutes. The participant will remain under supervision for another 30 minutes and will be discharged hereafter."
224073921|NCT06194591|DEVICE|Sham-Device|The sham device is the NephrospecTM applicator with an internal barrier to prevent shockwaves to pass through to the patient.
224073922|NCT02092571|DRUG|Progesterone vaginal ring,|Participants will be randomized to receive treatments in 1 of 2 treatment sequences (AB or BA)
224073923|NCT03299920|OTHER|Standardized instructions|Specific instructions related to peripheral nerve block.
224073924|NCT03299920|OTHER|Conventional instructions|Usual post-operative instructions.
224073925|NCT01520571|PROCEDURE|Non-Computer Assistance TKA|Non-Computer Assistance Total Knee Arthroplasty
224073926|NCT01520571|PROCEDURE|Computer Assistance TKA|Computer Assistance Total Knee Arthroplasty
224073927|NCT05024955|PROCEDURE|Discussion|Attend a focus group
224073928|NCT05024955|OTHER|Interview|Attend interview
224073929|NCT01086800|OTHER|Healthy Lifestyles and Sleep Education plus PAP|Participants randomized to this arm will be educated on PAP and then use PAP for 3 months. They will also receive optimized medical preventive therapy according to current American Heart Association guidelines for prevention of CVD and sleep guidelines.
224073930|NCT01086800|OTHER|Healthy Lifestyles and Sleep Education plus Supplemental Oxygen|Participants randomized to this arm will be educated on nocturnal supplemental oxygen and then use oxygen for 3 months. They also will receive optimized medical preventive therapy according to current American Heart Association guidelines for prevention of CVD and sleep guidelines.
224073931|NCT01086800|OTHER|Healthy Lifestyles and Sleep Education|Participants randomized to this arm will receive optimized medical preventive therapy according to current American Heart Association guidelines for prevention of CVD and sleep guidelines.
224073932|NCT01432691|PROCEDURE|Hemi (hemialloplastik)|THA vs hemi
224073933|NCT00270517|DRUG|EDP-420 / Duration of Treatment - 3 days|
224073934|NCT00270517|DRUG|Telithromycin / Duration of Treatment - 7 days|
224073935|NCT00678873|PROCEDURE|Single Incision Laparoscopic Cholecystectomy|A single trans-umbilical incision laparoscopic cholecystectomy will be performed by standard fashion and under general anesthesia.
224073936|NCT01962051|DEVICE|Amplatzer Cardiac Plug|
224073937|NCT02126709|DRUG|Repigel|Repigel will be used as the intervention in the treatment group
224073938|NCT03550482|DIETARY_SUPPLEMENT|ONCOXIN®|Adjuvant chemotherapy regimen (XELOX or paclitaxel+carboplatin) + Oncoxin 25 ml twice daily for 20 days. In case of nausea/vomiting after ONCX use patients were advised to dilute it in water, juice or milk. Patients with BMI \<20 and serum albumin levels \<30 g/l received nutritional support.
224073939|NCT00357500|DRUG|celecoxib|
224073940|NCT00357500|DRUG|cyclophosphamide|
224073941|NCT00357500|DRUG|etoposide|
224073942|NCT00357500|DRUG|fenofibrate|
224073943|NCT00357500|DRUG|thalidomide|
224187811|NCT01590095|BEHAVIORAL|Water quality, Sanitation, Hand washing (Combined WASH)|"Hardware: Free supplies Aquatabs; (NaDCC) and a safe storage vessel to treat and store drinking water. Promotion: Local promoters will visit study compounds at least monthly to deliver behavior change messages that focus on the treatment of all drinking water for children \< 36 months of age.~Hardware: Free child potties, sani-scoop hoes to remove feces from household environments, latrine upgrades to a dual pit latrine. Promotion: Local promoters will visit study compounds at least monthly to deliver behavior change messages that focus on the use of latrines for defecation and the removal of human and animal feces from the compound.~Hardware: Hand washing stations, soapy water bottles located at hand washing locations, detergent soap to supply soapy water bottles. Promotion: Local promoters will visit study compounds at least monthly to deliver behavior change messages that focus on hand washing with soap at critical times around food preparation, defecation, and contact with feces."
224187812|NCT01590095|BEHAVIORAL|Nutrition|"Supplement: Lipid-based Nutrient Supplement (LNS) delivered daily from ages 6 to 24 months.~Promotion: Local promoters will visit study compounds at least monthly to deliver behavior change messages modeled on those recommended in the Guiding Principles for Complementary Feeding of the Breastfed Child and the recent UNICEF Program Guide for Infant and Young Child Feeding Practices.General messages will include (1) practice exclusive breastfeeding from birth to 6 months of age and introduce complementary foods at 6 months of age while continuing to breastfeed; (2) continue breast feeding as you did before receiving LNS; (3) provide your child micronutrient-rich foods such as meat, fish, eggs, and vitamin A rich fruits and vegetables; and (4) feed your child at least 2-3 times per day when 6-8 months old and 3-4 times per day when 9-24 months old."
223497383|NCT06380608|PROCEDURE|Local anesthesia|Patients who will undergo a dental surgery under local anesthesia
223497384|NCT06380608|PROCEDURE|General anesthesia|Patients who will undergo a dental surgery under general anesthesia
223497385|NCT00417729|DRUG|Acarbose|After an 8-week period of metformin monotherapy (500 mg t.i.d.), all patients were randomised to add on either acarbose or glibenclamide. The doses of acarbose and glibenclamide were 50 mg t.i.d. and 2.5 mg t.i.d., respectively, for 4 weeks and force-titrated to 100 mg t.i.d. and 5 mg t.i.d., respectively, for the last 12 weeks.
223497386|NCT03384966|DRUG|Selatogrel|Selatogrel is a reversible P2Y12 receptor antagonist for subcutaneous administration. It is supplied in sealed glass vials at a strength of 20 mg. The vials with ACT-246475A (hydrochloride salt of ACT-246475) or matching placebo will be reconstituted with 1 mL of water for injection. Further dilution with 1 mL sodium chloride (NaCl) 0.9% will be performed for preparation of the dose of 8 mg selatogrel.
223497387|NCT03384966|DRUG|Placebo|Matching placebo for subcutaneous administration.
223590239|NCT04218396|DEVICE|Virtual Reality use during painful bedside procedure|Virtual reality (VR) will be used in addition to standard analgesic practices during painful bedside procedures. A head mounted display (HMD, Oculus Go Model #1KWPH812PN8354) and noise-cancelling headphones (Sony Model #MDRZ110B) will be provided to the patient during the procedure. This unit involves the patient wearing VR goggles, noise-cancelling headphones, and using a smartphone-based program with various applications the patient can choose from for analgesia/relaxation (eg: calming imagery/scenery of nature, activities involving mindfulness, interactive games or guided imagery, music and imagery, exercise imagery...etc). There are numerous, standard applications available for the patient to choose from, and the choice of most optimal application for analgesia, distraction, or anxiolysis will be left to the decision of the patient prior to their procedure.
223745918|NCT04419038|PROCEDURE|conjunctival autografting augmented with Ologen implantation|Group B included 31 eyes of 31 who underwent conjunctival autografting augmented with Ologen implantation.
223745919|NCT05379439|OTHER|Structured Family Deliberation|Intervention families will be guided through the six modules included in the web-based decisional aid using a Structured Family Deliberation Tool. Parents will view narrated videos corresponding to each module and will be asked a series of questions related to their own lives and values. The process will continue until all modules are reviewed and all questions are completed.
223497388|NCT03384966|DRUG|Selatogrel|Selatogrel is a reversible P2Y12 receptor antagonist for subcutaneous administration. It is supplied in sealed glass vials at a strength of 20 mg. The vials with ACT-246475A (hydrochloride salt of ACT-246475) will be reconstituted with 1 mL of water for injection.
223497389|NCT06330376|OTHER|Usual care of traditional treatment|Usual care of traditional treatment which is PT and/or OT when indicated Followed by Pulmonary rehabilitation when indicated
223497390|NCT06330376|OTHER|Specific DB program/Diaphragmatic manipulation program|12 weeks of 2 sessions/week: one session will be remote and one in-person
223497391|NCT01567514|PROCEDURE|Glass ionomer cement lining|Resin-modified glass ionomer lining
223497392|NCT06303817|OTHER|Double knots facia closure method during cesarean section|In Group I (double knots group), the edge of the fascia was identified with a Kocher clamp. A synthetic absorbable multifilament suture was used to close the fascia in a continuous fashion, starting from the opposite side up to the Kocher clamp. The knots were tied with the same single suture. I
223497393|NCT06303817|OTHER|Triple knots facia closure method during cesarean section|n Group II (triple knots group), the edge of the fascia was fixed with the same suture material instead of the Kocher clamp. The fascia was closed similarly, starting from the opposite corner via the second loop. The loops from the first suture were tied to the second suture.
223497394|NCT04067245|DEVICE|Tetrasodium EDTA catheter lock solution|Home parenteral nutrition patients who meets inclusion criteria is to receive tetrasodium edta catheter lock solution. Patient will receive standard catheter lock solution of heparin/saline for 1 month, followed by tetrasodium EDTA catheter lock solution using withdrawal method for 1 month and followed by tetrasodium EDTA catheter lock solution using flush method for 1 month. In total, patient will stay in the study for 3 months. A phone call will be conducted before the start of the study to give instruction to patient regarding the use of catheter lock solution. Time taken to connect and disconnect TPN will be recorded by patients, twice a month on first and last mondays of the month for 3 months. A survey regarding the ease of use of catheter lock solution will be conducted at the end of each month via phone by nurse coodinator.
223497395|NCT03841292|DRUG|Varenicline|Varenicline (Champix®), Pfizer Canada Inc., Kirkland, Quebec. Dispense for 12 weeks. One tablet (0.5mg) once daily for first three days, then one tablet (0.5 mg) twice daily for next four days, then 1 mg (one 1mg tablet) twice daily for the remainder of 12 weeks. Dose adjustments due to adverse events will be allowed (i.e. decrease to 0.5 mg twice daily).
224187813|NCT01590095|BEHAVIORAL|Nutrition, Water quality, Sanitation, Hand washing|Each of the interventions described above for Water Quality, Sanitation \& Hand washing (Combined WASH) Plus the intervention described above for nutrition.
224187814|NCT02442284|DRUG|ombitasvir/paritaprevir/ritonavir and dasabuvir|Tablet; ombitasvir coformulated with paritaprevir and ritonavir, dasabuvir tablet
224187815|NCT02442284|DRUG|Ribavirin|Tablet
224187816|NCT04391192|BEHAVIORAL|Virtual Overdose Response|All participants will be provided the phone number and encouraged to call when they use alone.
224187817|NCT01007227|OTHER|Lifestyle instruction|Instruction dietetic and exercise therapy
224187818|NCT03313700|PROCEDURE|Robotic Distal Gastrectomy|After exclusion of T4b, bulky lymph nodes, or distant metastasis case, robotic distal gastrectomy will be performed in the experimental group.
224187819|NCT03313700|PROCEDURE|Laparoscopic Distal Gastrectomy|After exclusion of T4b, bulky lymph nodes, or distant metastasis case, laparoscopic distal gastrectomy will be performed in the comparator group.
224187820|NCT04722731|BEHAVIORAL|Confident Parents - Brave Children (CPBT)|"Session 1: Psychoeducation.~Session 2: How to decrease criticism and rejection. Skills that provide a warm parenting style and acceptance of the child: validation and child directed play/activities.~Session 3: Strategies to increase the autonomy of the child. The parents will learn how to use a stepladder approach to decrease overprotective behaviours.~Session 4: How to decrease modelling of anxious behaviours and how to be a brave role model.~Session 5: How to recognise and respond when your child is anxious. How to help your child approach new or scary things by using a stepladder approach.~Session 6: Review of the principles and skills learned during the program. The group members will make a plan for how to continue the work on their own."
224187821|NCT04722731|BEHAVIORAL|"Self-help book What all parents ought to know"|Participants in the control group will receive a self-help parenting book containing general research-based parenting strategies. They will be instructed to read the book within the 10 weeks from baseline to post.
224187822|NCT04429269|DIAGNOSTIC_TEST|mammography and ultrasound screening|Patients screened by both mammography and ultrasound.
224187823|NCT03564860|PROCEDURE|Device data collection|Collection of device electrograms and 12-lead ECG during a device follow-up visit
224187824|NCT03086044|DRUG|Sofosbuvir/velpatasvir|2 weeks of treatment beginning on the day of transplant
224309091|NCT01109563|BEHAVIORAL|Marijuana Check-Ins|The MCI, an MET intervention, will include the provision of personalized feedback with a motivational interviewing style. The focus of these sessions will be individualized to participants based on recent marijuana use and related experiences. Feedback given to participants during the MCI session will review progress toward goals as self-reported in percent days abstinent, normative data regarding marijuana use, review of reported consequences of marijuana use, review of abuse and dependence criteria reported, comparison of consequences and abuse and dependence symptoms reported over time, review of the positive outcomes from reductions in use, and review of immediate and long-term life goals and how their marijuana goal will affect these. HEs will offer particular encouragement to take advantage of CBT sessions to participants who feel they currently need treatment.
224309092|NCT05504590|DEVICE|Tuohy needle group|Ultrasound-guided caudal epidural block with Touhy needle
223497396|NCT03841292|DEVICE|Active tDCS|Active 2mA tDCS (Nuraleve, Canada) with the anode placed over the left dorsolateral prefrontal cortex (dlPFC) and the cathode placed over the right dlPFC for 20 minutes per session
223497397|NCT03841292|DEVICE|Sham tDCS|Shame tDCS (Nuraleve, Canada) (30 seconds of 2mA and 19.5 minutes of 0 mA) with the anode placed over the left dorsolateral prefrontal cortex (dlPFC) and the cathode placed over the right dlPFC for 20 minutes per session.
223497398|NCT04658589|PROCEDURE|Laparoscopic versus open distal gastrectomy|Laparoscopic versus open distal gastrectomy after neoadjuvant chemotherapy for locally advanced gastric cancer
223590240|NCT04218396|DRUG|Standard Treatment during painful bedside procedure|Pharmacologic sedation or high dose opioids (e.g. nurse-administered IV opioids, anxiolytics and sedatives, patient-controlled analgesia, anesthesiologist administered sedation, general anesthesia if required)
224187825|NCT03086044|OTHER|Monitoring|Close HCV viral load monitoring Will receive direct acting antiviral treatment with 6 weeks of sofosbuvir/velpatasvir if the recipient develops HCV viremia during the post-transplant HCV viral load testing
224187826|NCT04185792|DIAGNOSTIC_TEST|NBSS, Qualiveen and SF-Qualiveen|NBSS, Qualiveen and SF-Qualiveen are self-reported questionnaires.
224187827|NCT02438111|GENETIC|metagenome|metagenome
224309093|NCT05504590|DEVICE|Quincke needle group|Ultrasound-guided caudal epidural block with Quincke needle
224309094|NCT03401450|DRUG|ACB within true AC with bupivacaine 0.5% 20cc|The adductor canal block (ACB) is more commonly being used to provide post-operative analgesia since it provides a sensory block with minimal motor block.
224309095|NCT03401450|DRUG|ACB proximal to true AC with bupivacaine 0.5% 20cc|Patients will receive ultra-sound guided single femoral triangle block injection with 20 mL of 0.5% bupivicaine
224309096|NCT03353623|DEVICE|Serious Game|"Serious Game (SG) refers to the use of immersive virtual environments and wearable haptic devices during the treatment. Two SG were specifically developed to allow a playful training of different, targeted Upper Limb (UL) movement based on typical rehabilitation exercises (reach-to-grasp, linear path tracking, hand orientation). The child interacts directly with a virtual environment through haptic feedback provided to his/her fingertips. In particular, moneybox game focused on pincer grasp and reaching tasks with pronation/supination od the hand while marble labyrinth game focused on pointing and tracking movements requiring both eye-hand and upper limb inter-joint coordination."
223497399|NCT05925634|BEHAVIORAL|RPE (usual care)|Patients in the active comparator group will follow standard exercise prescription protocols in cardiac rehabilitation.
223590241|NCT03404856|DRUG|ORL-1G - D-galactose|Oral ORL-1G - D-galactose
223590242|NCT00663845|DRUG|Levitra (Vardenafil, BAY38-9456)|10mg Vardenafil taken orally 1h prior to sexual intercourse
223590243|NCT00663845|DRUG|Placebo|Matching placebo
224187828|NCT00417495|BEHAVIORAL|Sentinel Lymph Node Technique|
224187829|NCT03824574|DEVICE|Clear Mandibular Advancement Appliance|Clear Mandibular Advancement Appliance for treatment of skeletal class II patients with retrognathic mandible
224187830|NCT02297672|RADIATION|Stranded palladium seed interstitial implant|Interstitial implantation of stranded palladium 103 seeds in seroma with a margin
224187831|NCT02297672|DEVICE|3 dimensional breast ultrasound|guidance of placement of interstitial needles in breast
224187832|NCT02297672|DEVICE|Computerized tomography (CT)|Breast CT for planning and assessing interstitial implantation of radioactive seeds
223590244|NCT00975143|DRUG|CIP-Isotretinoin|0.5 mg/kg/day for 4 weeks, and 1 mg/kg/day for 16 weeks, taken orally, twice daily.
224187833|NCT04083521|DIETARY_SUPPLEMENT|Bacillus subtilis DE111®|Subjects were administered a dose of Bacillus subtilis at levels of 1x10\^9 CFU once a day for 90-days.
224187834|NCT00986817|DRUG|Terlipressin|Albumin perfusions at the dose 8 g/l of removed ascites and Terlipressin (1mg), administrated before and at the end of the paracentesis.
224309097|NCT03353623|OTHER|Conventional Therapy|Conventional therapy (CONV) refers to the neurocognitive rehabilitation approach, with the purpose of improving pointing, tracking, reaching and grasping, and pronation/supination of the forearm. The therapeutic sessions were performed with the exception of the visual channel to ensure that the child focused his/her attention on tactile/kinesthetic information to complete the task. In particular, five different tasks have been proposed during the sessions: 1) recognize trajectories; 2) arm proprioception; 3) object manipulation; 4) recognize surfaces; 5) forearm orientation.
223590245|NCT00975143|DRUG|Isotretinoin|0.5 mg/kg/day for 4 weeks, and 1 mg/kg/day for 16 weeks, taken orally, twice daily.
223590246|NCT02153060|DRUG|Dexamethasone|Dexamethasone was given at a dose of 40 mg,daily for 4 consecutive days
224309098|NCT03143608|DEVICE|Esophyx|Laparoscopic hiatal hernia repair followed immediately by transoral incisionless fundoplication under general anesthesia using the Esophyx device
223497400|NCT05925634|BEHAVIORAL|GXT+THHR (intervention)|Patients in the personalized care group will perform a graded exercise test and the peak heart rate from the test will allow the researcher to calculate a target heart rate range (THRR). Then, the patients will receive psychoeducational feedback (PF) about their test results and exercise performance. After PF, their THRR will be reviewed and how it will be used to guide exercise intensity in CR will be discussed.
223497401|NCT04649983|BIOLOGICAL|CD19 and CD22 targeted CAR-T cells|A single infusion of CD19 and CD22 CAR-T cells will be administered intravenously
223497402|NCT01972828|DRUG|FLUID MANAGEMENT GUIDED WITH PRELOAD-DEPENDENCE PARAMETERS (VOLUVEN ®)|in this arm, fluid loading is administered with an algorithm using preload dependence indexes. This algorithm is used every hour during the first 6 hours after inclusion, then every 4 hours until vasopressor weaning, and whenever mean arterial pressure fell below 65 mm Hg. Fluid loading is performed with cristalloids or colloids at the discretion of the attending physician.
223497403|NCT01972828|DRUG|STANDARD-GUIDED FLUID MANAGEMENT (VOLUVEN ®)|in this arm, fluid loading is administered with an algorithm using central venous pressure. This algorithm is used every hour during the first 6 hours after inclusion, then every 4 hours until vasopressor weaning, and whenever mean arterial pressure fell below 65 mm Hg. Fluid loading is performed with cristalloids or colloids at the discretion of the attending physician.
223497404|NCT03976700|DRUG|Bufei Jianpi granule|Bufei Jianpi granule is composed of many kinds of traditional Chinese medicine. The granule will be administered twice daily for five days a week for 104 weeks.
223590247|NCT02153060|DRUG|Dexamethasone|Dexamethasone was given at a dose of 20 mg,daily for 4 consecutive days
223590248|NCT01375608|DRUG|Decitabine|0.2mg/kg (range, 0.05-0.3 mg/kg) 1-2X/wk for a period of 48 weeks. Dose and frequency will be determined by hematologic toxicity and the achievement of an HbF level of greater the or equal to 20 percent.
223590249|NCT05340166|PROCEDURE|Genicular nerve radiofrequency neurolysis|Neurolysis of superomedial, superolateral and inferomedial genicular nerves
223590250|NCT05340166|PROCEDURE|Genicular nerve chemical neurolysis|Neurolysis of superomedial, superolateral and inferomedial genicular nerves
223590251|NCT03139617|PROCEDURE|Fascia Iliaca Compartment Block (FICB)|"The FICB was done in the OT with standard monitoring with emergency airway intervention and resuscitation drug prepared before performing intended block. Patient was put in supine position, using aseptic technique, chlorhexidine solution and draped with sterile medical towel. Lignocaine 2% for local anaesthetic infiltration at punctured site.A blunted needle (Plexufix® 24G x 2, B Braun Melsungen AG 34209 Germany).A line was drawn from pubic tubercle to anterior superior iliac spine, the punctured point is 2-3cm distal to the point where medial 2/3rd and lateral 1/3rd of the line meet. Loss of resistance 2 times indicated the punctured of fascia lata and iliaca.A total volume of Ropivacaine 0.375% per body weight was given with repeated aspiration."
223745920|NCT04873752|BIOLOGICAL|UDI-001|2.5 x 10\^6 cells/kg of UDI-001 are administered intravenously. One cycle consists of twice a week administrations.
223745921|NCT03547388|DEVICE|Moderate whole body hyperthermia using water-filtered IR-A-radiation|four to six applications of whole Body hyperthermia concomitant to radiochemotherapy. Additional measurement of Perfusion and hypoxia by 18F-FMISO hypoxia PET and magnetic resonance Imaging
223745922|NCT01356797|DRUG|hypobaric levobupivacaine with fentanyl|SSSA with 4 mg hypobaric levobupivacaine 0,13% with 10 mcg fentanyl
224187835|NCT00986817|DRUG|Placebo|albumin perfusion at the dose 8 g/l of removed ascites and placebo, administrated before and at the end of the paracentesis.
224187836|NCT03767309|PROCEDURE|coronally advanced flap with abrasive de-epithelized graft.|SCTG will be harvested from the palate by abrasive de-epithelialization of palatal graft involves removing the epithelium of the selected area with a high-speed hand piece and diamond bur
224187837|NCT03767309|PROCEDURE|coronally advanced flap with de-epithelized graft.|SCTG will be harvested from the palate by abrasive de-epithelialization of palatal graft involves removing the epithelium of the selected area with a blade
224187838|NCT00193856|DRUG|Leuprorelin Acetate|LH-RH analogue (LH-RHa) (Leuprorelin acetate 22.5 mg) will be delivered as a depot injection every 3 months. This will be administered as an intramuscular injection (IMI).
224187839|NCT00193856|DRUG|Zoledronic Acid|Zoledronic acid 4 mg will be delivered as an intravenous infusion over 15 minutes once every 3 months for 18 months, in patients randomised to bisphosphonate therapy.
224187840|NCT00193856|RADIATION|Conventional external beam therapy|The prescribed dose will be 66 Gy in 33 fractions of 2 Gy to the ICRU 50 point utilising a minimum of three fields with \>= 6 MV photons.
224187841|NCT01342627|DRUG|Sorafenib|"Sorafenib will be orally administered at a daily dose of 400 mg taken twice daily without food, at least one hour before or two hours after eating. Four weeks of treatments will be considered as a cycle. Each patient enrolled in the study will received medications for topical therapy. Dermatological medications will be provided free.~In case of toxicities, dose reduction/interruption is permitted according to the protocol.~In case of disease progression Sorafenib administration will be discontinued."
223497405|NCT03976700|DRUG|Placebo Bufei Jianpi granule|Placebo Bufei Jianpi granule consists of dextrin, bitter and 5% of the Bufei Jianpi granule. The appearance, weight, color and odor of the preparation are the same as those of treatment group. The placebo granule will be administered twice daily for five days a week for 104 weeks.
223497406|NCT02029547|DRUG|Florbetapir (18F)|No Florbetapir (18F) will be administered in this study.
223497407|NCT04007900|BEHAVIORAL|Positive Affect Treatment|PAT was designed as a 15-week intervention delivered in 3 modules. Module 1 (Pleasant Events Scheduling) uses behavioral activation methods to enhance positive experiencing before, during, and after rewarding events. Module 2 (Attending to the Positive) applies cognitive training techniques to promote shifting attention towards rewarding aspects of daily situations and to learn behavior mood associations. Module 3 (Cultivating the Positive) uses mindfulness approaches to foster reward experiencing. Treatment length has been expanded to 20 sessions to enhance the suitability of the intervention for AN and target the reward mechanisms that characterize AN. Additional adaptations include: 1) An emphasis on a mindful balance between reward and inhibition; 2) Additional module on shifting attention away from AN-specific rewards; 3) Addition of exercises to work towards long-term life goals and enhance healthy experiences; and 4) Further focus on navigating social rewards.
223497408|NCT03637374|DEVICE|Visceral Manifold and Thoracic Bifurcation|Endovascular stent graft system
223497409|NCT03637374|DEVICE|Unitary Manifold|Endovascular stent graft system
223497410|NCT03637374|DEVICE|TAAA Debranching Stent Graft System|Endovascular stent graft system
223497411|NCT02158598|DRUG|Vitamin D chewable tablet supplementation|
223590252|NCT03139617|PROCEDURE|3 in 1 femoral block (FNB)|"The FNB was done in the OT with standard monitoring with emergency airway intervention and resuscitation drug prepared before performing intended block.Patient was put in supine position, using aseptic technique, chlorhexidine solution and draped with sterile medical towel.Lignocaine 2% for local anaesthetic infiltration at punctured site.An insulated stimulating needle (Stimuplex® D Plus 22g x 2, B Braun Melsungen AG 34209 Melsungen Germany). Ultrasound was used to locate the femoral vessel and nerve and by using 'in plane' technique, the skin was punctured with the insulated needle and advance in transverse plane at around 30 angle to the skin. Local anaesthetic solution as per ideal body weight given after negative aspiration of blood ."
224187842|NCT00681772|DRUG|Levitra (Vardenafil, BAY38-9456)|5mg, 10mg or 20mg taken 1 hours before sexual intercourse
223497412|NCT02158598|DRUG|Vitamin D pill supplementation|
223497413|NCT01248975|DRUG|FP/SAL 250/50mcg BID|FP/SAL 250/50mcg BID
223497414|NCT01248975|DRUG|GSK2190915 200mg QD (AM)|GSK2190915 200mg QD (AM)
223497415|NCT01248975|DRUG|GSK2190915 100mg QD (AM)|GSK2190915 100mg QD (AM)
223497416|NCT01248975|DRUG|Montelukast 10mg QD (PM)|Montelukast 10mg QD (PM)
223497417|NCT01248975|DRUG|Placebo tablets (2) (AM)|Placebo tablets (2) (AM)
223497418|NCT01248975|DRUG|Placebo capsule (PM)|Placebo capsule (PM)
223590253|NCT04235712|OTHER|Harmonized Depression Outcome Measures|This is an observational study where outcome measures will be extracted from patients' medical records and from questionnaires to provide information back to the clinician.
223590254|NCT03959202|BEHAVIORAL|ELDERFITNESS|In-person training with the exercise trainer ( 3 sessions for participants without cognitive impairments over 24 weeks \& 4 sessions for older adults with mild cognitive impairment over 16 weeks). Self-monitoring level of physical activity (steps \& minutes of moderate activity) using the smart watch. . The Google calendar and Fitbit apps will send messages and alerts to the subject's smart watch that encourage subjects to achieve subjects' daily goals. If a participant has low activity for 3 consecutive days, the research assistant will call the participant to either encourage the participant to adhere to the plan or provide a modified plan after consulting the exercise trainer. Phone consultation: Subjects will have biweekly phone consultation with the research team members to receive guidance and adjustment on activity plans.Financial incentives: when the daily activity goal is achieved for more than four days per week, a $5 reward will be given to subjects.
223590255|NCT03959202|OTHER|Control|General Education on physical activity for older adults and continue daily activity and healthcare routine. Participants will also receive a Go4Life Program book from the National Institute on Aging
223590256|NCT03544307|BEHAVIORAL|Taekwondo training|Exercise group
223590257|NCT00861718|DRUG|AZD7268|Capsule, Oral, QD
223590258|NCT00861718|DRUG|AZD7268|Capsule, Oral, BID
223590259|NCT00861718|DRUG|Placebo|Capsule, Oral BID
224187843|NCT05784142|RADIATION|hypofractionated radiation therapy|"* Part 1: Patients who have received induction immunotherapy plus chemotherapy for 2-6 cycles and met the hypoRT criteria will be enrolled into the study.~* Part 2: patients will be treated with hypofractionated radiation therapy in doses up to 48-60 Gy at 4 Gy per fraction.~* Part 3: patients with partial response or stable disease after part 2 will be eligible for immunotherapy maintenance, for up to 1 years or until disease progression or unacceptable toxicity."
224187844|NCT04373265|DRUG|Relacorilant|Relacorilant, 100 mg soft gel capsules orally once daily
224187845|NCT04373265|DRUG|Pembrolizumab|Pembrolizumab 400 mg infusion every 6 weeks
224187846|NCT05284162|BEHAVIORAL|Health coaching|The health coaching program includes four monthly health coaching sessions for three months.
224187847|NCT06400420|OTHER|Exercise|classic futsal training program
224187848|NCT00381602|DRUG|GHRP-1/AG 70 mg depot in ESRD|
224187849|NCT00381602|OTHER|Placebo|
224187850|NCT03742895|DRUG|Olaparib|Olaparib 300 mg administered BID as two, 150 mg oral tablets.
224187851|NCT04017416|BEHAVIORAL|I-PLAN|The I-PLAN is a behaviour change intervention that consists of; information on consequences of hearing aid use/non-use, reminder prompt and behavioural plan to promote hearing aid use.
223590260|NCT01571856|DRUG|Zinc Sulfate|zinc sulfate solution, contains 20 mg. per 5 mL. dosage 2.5 mL. per day.
223590261|NCT01571856|OTHER|placebo|cornstarch powder diluted in distilled water, dosage 2.5 ml per day
224187852|NCT02748096|PROCEDURE|Patient Specific Instrumentation|Patients will undergo a medial unicompartmental knee replacement. This knee replacement is implanted using patient specific cutting guides that have been produced based on the patient's individual anatomy (using plans from pre-operative MRI scans of the patient's knee).
224187853|NCT02748096|PROCEDURE|Conventional Instrumentation|Patients will undergo a medial unicompartmental knee replacement using standard conventional instruments.
224187854|NCT01756586|DRUG|Dexamethasone|
223497419|NCT03156140|OTHER|Motion|Volunteer has motion on right hand while with continuous pulse oximetry during three oxygenation plateaus
223497420|NCT01365611|DRUG|Ketorolac tromethamine|A single intranasal dose of 30 mg ketorolac tromethamine was administered to all subjects on Days 1 and 6.
223590262|NCT02678884|DRUG|18-F FDG|All patients enrolled in this study will receive 2 PET Scans: One prior to Radiation, and one during Radiation.
223590263|NCT00148785|DRUG|Indinavir/Ritonavir/Fosamprenavir|
223590264|NCT02049138|DRUG|Upadacitinib|Tablet taken orally
223590265|NCT02049138|BIOLOGICAL|Pneumococcal 13-valent conjugate vaccine (PCV-13)|Administered by intramuscular injection
223590266|NCT02925741|OTHER|Silk-Like Linens|Synthetic moisture-wicking fabric
223590267|NCT02901652|DEVICE|noninvasive respiratory support devices|
223590268|NCT05086510|PROCEDURE|Radiofrequency ablation|Both groups will undergo radiofrequency ablation of potentials likely responsible for the tachycardia. Those potentials are identified by the formentioned 2 distinct methods.
223590269|NCT02983994|DEVICE|TURBUHALER®|
223590270|NCT02983994|DEVICE|SPIROMAX®|
223590271|NCT03292276|DEVICE|Amadeo Training|"To understand the cortical modifications related to movement preparation and execution after robot-assisted training we will study the EEG modifications of cortical activity using time-frequency event-related EEG and task-related coherence (TRCoh).~Friedman ANOVA with post-hoc t-test (corrected for multiple comparisons) will be used to assess the significance of training-induced changes in the two groups."
223497421|NCT01365611|DRUG|Fluticasone Propionate|Daily intranasal dose of 200 ug fluticasone propionate on Days 2-6
223590272|NCT03465930|PROCEDURE|Supermicrosurgical lymphatico-venous anastomoses|Supermicrosurgical lymphatico-venous anastomoses (sLVA) require an accurate visualization of the lymphatic vessels that are still functional. Lymphatic vessels are visualized with lymphography using a fluorescent dye, indocyanine green. Adjacent superficial veins mapping is obtained with Accuvein device.
223745923|NCT01356797|DRUG|hyperbaric bupivacaine 0,5%|SUSA with 4 mg hyperbaric bupivacaine 0.5%
223745924|NCT05071859|OTHER|Whole Genome Sequencing|Saliva collection and request for banked blood and tumor samples for sequencing
224073944|NCT02107586|PROCEDURE|Biceps tenotomy|A biceps tenotomy procedure involves cutting of the long head of the biceps just prior to its insertion on the superior labrum of the glenoid.
223497422|NCT01356810|OTHER|Environmental Intervention|The environmental intervention consisted of daily reorientation, avoidance of sensorial deprivation, longer visiting hours, the availability of a clock, a calendar and the presence of familiar objects in the room.
223497423|NCT01356810|OTHER|Standard Care|Delirium management by the attending physician's preferences.
223497424|NCT02662920|OTHER|No Intervention|
223497425|NCT03459586|OTHER|9zest app facilitated exercise|The purpose of this study is to determine if the 9zest app for Parkinson's disease is feasible, safe, and efficacious when used independently by individuals with Parkinson's disease
223590273|NCT05600582|BIOLOGICAL|CodaLytic|CodaLytic is a virotherapeutic product based on the wild-type influenza strain A/California/07/2009
224073945|NCT02107586|PROCEDURE|Biceps tenodesis|Biceps tenodesis involves detaching the long head of the biceps from it's superior labrum in the shoulder and reattaching it to the humerus bone just below the shoulder.
224073946|NCT04865328|OTHER|Overactive Bladder-Validated 8-question Screener (OAB-V8)|OAB-V8 is an eight-item, self-reported questionnaire that assesses the burden of OAB and the degree of bother caused by the symptoms. Since its development as a subscale of the overactive bladder questionnaire (OAB-q), the OAB-V8 questionnaire has been used to screen for OAB and to assess OAB symptom burden and severity.
224073947|NCT03754426|DEVICE|Fluorescence Imaging Device|Hand-held, real-time fluorescence imaging device
224073948|NCT03739632|DRUG|Hypidone Hydrochloride tablets|Hypidone Hydrochloride tablets will be given orally, twice daily, for 6 weeks
224073949|NCT03739632|OTHER|Placebo|Placebo tablets will be given orally, twice daily, for 6 weeks
224187855|NCT01756586|DRUG|Bupivacaine|Control
223590274|NCT00870298|DRUG|Trimethoprim/Sulfamethoxazole and Warfarin|
223590275|NCT04635813|PROCEDURE|Thyroidectomy|Thyroidectomy
223590276|NCT02359227|DRUG|Cenderitide|Cenderitide is a dual receptor natriuretic peptide.
223590277|NCT00189904|BIOLOGICAL|IMVAMUNE (MVA-BN)|
223590278|NCT00295932|BIOLOGICAL|rituximab|Given IV
223590279|NCT00295932|DRUG|bortezomib|Given IV
223590280|NCT00295932|DRUG|cyclophosphamide|Given IV
223590281|NCT00295932|DRUG|prednisone|Given orally
223590282|NCT06508242|DRUG|Cholecalciferol|cholecalciferol
223590283|NCT06508242|OTHER|Placebo|placebo
224073950|NCT06017596|DEVICE|PEEK framework|All-on-4 implants with PEEK framework of fixed detachable prosthesis
224073951|NCT00303251|DRUG|TKI258|
224073952|NCT03296046|BIOLOGICAL|Blood test|30 ml
224073953|NCT05089500|OTHER|Endoscopic injection sclerotherapy|Patients were randomized assigned to the EIS group, preparing disposable endoscopic injections and sclerosing which were routinely administered with 1% polycinol.The transparent cap was fixed at the front end of the endoscope in inverted or orthofield of view.The stiffening agent or foam stiffer added to Meilan was injected with a disposable injection needle at 4-6 points at the oral end near the dentate line. Each point contained 0.2-1ml, and stopped after the hemorrhoid nucleus changed color. If necessary, a transparent cap was pressed to stop the bleeding to distribute the stiffening agent evenly.
224187856|NCT04742439|DEVICE|Sham transcranial direct current stimulation|Participants will receive 30 seconds of ramp up and down stimulation at the start and end of the 20 minute stimulation period.
224187857|NCT04742439|DEVICE|Individualized transcranial direct current stimulation|Participants will receive 20 minutes of transcranial direct current stimulation (tDCS) at the individualized dose (maximum of 4mA).
224187858|NCT04742439|DEVICE|2mA transcranial direct current stimulation|Participants will receive 20 minutes of transcranial direct current stimulation (tDCS) at a 2mA dose.
224187859|NCT04742439|DEVICE|4mA transcranial direct current stimulation|Participants will receive 20 minutes of transcranial direct current stimulation (tDCS) at a 4mA dose.
224187860|NCT03428139|PROCEDURE|pulsed radiofrequency|Each patient in this group was treated with PRFT on the affected DRG at 42°C for 120 seconds.
223590284|NCT00109577|DRUG|MCN36 (nutritional supplement)|nutritional supplement
223590285|NCT00109577|DRUG|Placebo|nutritional supplement
223590286|NCT06507683|RADIATION|simultaneous integrated boost intensity-modulated radiation therapy combined with ripretinib|"A cumulative radiation dose of 50 to 70 Gy is administered in 25-30 fractions, 5 fractions per week, to the target lesion(s).~ripretinib: oral 150mg QD"
224309099|NCT05149443|BEHAVIORAL|theory-based mHealth-intervention (app)|Measuring the effect of the buddy and gamification components separately. During the A1 phase (baseline) and the A2 phase (reversal), participants will be asked not to use the 'Move it, Move ID' intervention: the app will be blocked. After an A phase, the app will be unblocked. During the B1 and B2 intervention phase, participants use the 'Move My it, Move ID' intervention only consisting of the buddycomponent. During the intervention period, adolescents and buddies are asked to wear an accelerometer. During the first AB pair we examine whether the buddy component has an effect on PA compared to no intervention. In the A2 reversal phase possible carryover effects can be measured. It will be informative to investigate whether some parts of the intervention are automatized or internalized and will still have some effect even when participants have no access to the intervention anymore (i.e. A2 phase). The study duration is 32 days; each phase will have a duration of minimum 5 days.
223497426|NCT04632719|DEVICE|The use of the MentalPlus® digital game for assessment and rehabilitation of cognitive function after remission of the symptoms of COVID-19|Cognitive assessment and rehabilitation will be carried out on volunteers who have healed from COVID-19.
223497427|NCT05807503|DRUG|Cerebrolysin|Cerebrolysin administration in short period of time after TBI
223497428|NCT06397638|PROCEDURE|Rescue carotid stenting|Rescue carotid stenting in tandem occlusions
223497429|NCT04416542|DIAGNOSTIC_TEST|Home Sleep Testing|"Two-night Home Sleep Tests (HSTs) will be conducted using commercially available Home Sleep Test equipment. The HST will be ordered by the clinical center through a HIPAA compliant HST service that has been selected by the study sponsor.~The HSTs will be scored and interpreted according to AASM Guidelines by board certified sleep physicians affiliated with the HST service. The HST will be scored using the 4% oxygen desaturation rule."
223497430|NCT04256499|PROCEDURE|Acute water load test|The acute water load test consists in administering orally 20 mL/kg (of body weight) of water (ingested in less than 30 min) and then follow (during 4 to 6 hours) blood and urine parameters.
223497431|NCT02836769|BEHAVIORAL|Rehabilitation Consult (RC)|The RC was designed to foster key contributors to self management in the participants. The RC is administered by a rehabilitation professional and consists of an initial one-hour face-to-face consult and follow-up appointment(s) 2-12 weeks later, either telephone or face-to-face. The initial consult consists of orientation, consultation, goal-setting, teaching cognitive strategies, introduction to online resources/action planning/planning coping responses, review/implementation intentions/scheduling follow-up. The follow-up consists of a reminder, reorientation, checking of progress on goals and plans, re-planning as necessary, and discharge or scheduling of further follow-up as necessary.
223590287|NCT02839239|DIETARY_SUPPLEMENT|Drops with lactobacilli and vitamin D3|Oil suspension with lactobacilli and vitamin D3
223590288|NCT02839239|DIETARY_SUPPLEMENT|Drops with vitamin D3|Oil suspension with vitamin D3
223590289|NCT01888419|OTHER|Lipotransplantation|Lipotransplantation in general anaesthesia to the mastectomy site
223590290|NCT01150201|DRUG|Aliskiren|For CKD treatment
223590291|NCT01150201|DRUG|Losartan|Control
223590292|NCT00044889|DRUG|clofarabine (IV formulation)|
223590293|NCT00841932|PROCEDURE|Fractional Flow Reserve|Fractional Flow Reserve performed without anticoagulation
223590294|NCT01860898|OTHER|Skin Biopsy|Biopsy samples will be taken as a 2mm x 2cm excision of a wedge of skin at the edge of the incision during your surgery at the Mayo Clinic Rochester. Such excisions are frequently done as part of routine skin closure for optimal skin cosmesis following the surgical procedure.
223590295|NCT05320198|DRUG|DISC-0974|DISC-0974 is administered subcutaneously.
223590296|NCT02560298|DRUG|Capecitabine|
223590297|NCT02560298|DRUG|Carboplatin|Given IV
223590298|NCT02560298|DRUG|Cisplatin|Given IV
223590299|NCT02560298|DRUG|Fluorouracil|Given IV
223590300|NCT02560298|OTHER|Laboratory Biomarker Analysis|Correlative studies
224187861|NCT03428139|DRUG|pulsed radiofrequency plus alpha lipoic acid|Each patient in this group was treated with PRFT as in group I plus oral alpha lipoic acid (ALA) 600 mg (Thiotacid 600 mg, EVA PHARMA, Egypt) three times per day (1800mg/day) for 3 weeks then 600mg once daily for 2 weeks.
224187862|NCT04957316|DEVICE|Triple-effect blood purification filter|Blood purification using the oXiris filter to remove endotoxin, cytokines, and uremic toxins.
223590301|NCT02560298|DRUG|Paclitaxel|Given IV
223590302|NCT02560298|OTHER|Quality-of-Life Assessment|Ancillary studies
223590303|NCT05569694|OTHER|Movement-based pelvic health education|A single virtual education session led by a physical therapist trained in pelvic health. The virtual course was approximately one hour and included movement-based education through various positions, exercises, and movements with explanations for each pose as it relates to pelvic health.
223590304|NCT03679455|DRUG|Obinutuzumab 25 MG/ML|Study treatment, obinutuzumab is a Type II humanized anti-CD20 monoclonal antibody of the IgG1 subclass derived by humanization of the parental B-Ly1 mouse antibody and produced in the Chinese Hamster Ovary cell line by recombinant DNA technology. The Study Treatment, obinutuzumab is a liquid concentrate for infusion. Obinutuzumab vials are type 1 glass vials with a butyl rubber stopper. Obinutuzumab is provided as a single 1000 mg dose liquid concentrate with a strength of 25 mg/mL. It is supplied in 50 mL glass vials containing 40 mL of the 25 mg/mL liquid concentrate.
223497432|NCT02271802|DIETARY_SUPPLEMENT|Sodium butyrate|Patients recieved an enema containing butyrate or a placebo during upper abdominal surgery.
223497433|NCT02271802|DIETARY_SUPPLEMENT|NaCl|
223497434|NCT03039725|OTHER|Observational|Retrospective chart review on vaccine compliance
223497435|NCT06447896|DEVICE|Cardiovascular Autonomic Nervous Function Multi-Parameter Evaluation System (Model: R6000)|"Cardiovascular autonomic reflex tests (CARTs) and heart rate variability analysis (HRV) are conducted with Cardiovascular Autonomic Nervous Function Multi-Parameter Evaluation System (Model: R6000). CARTs include five standardized tests, which are heart rate response to lying-to-standing, Valsalva maneuver, deep breathing, and blood pressure response to lying-to-standing and sustained isometric handgrip. These series of movements act as standardized stimuli to trigger hemodynamic changes in the body, altering vagal and sympathetic activity through mechanisms such as the baroreflex, thereby producing changes in heart rate and blood pressure. The sensor-monitoring interactive design of the device ensures the standardization of these maneuvers."
223497436|NCT06447896|DIAGNOSTIC_TEST|Conventional method of CARTs|Conventional method are conduced using blood pressure kit with manual sphygmomanometer and ECG machine. Conventional method and the investigated device are used simultaneously to record electrocardiograms. Conventional blood pressure taking are carried out in sequence with the investigated device. CARTs results from the conventional method are used as control.
223497437|NCT06447896|DEVICE|Ambulatory holter station Model i12 plus|Model i12 plus (manufactured by RENCARE) is an ambulatory holter station, which was approved by the Center for Medical Device Evaluation (CMDE), China National Medical Products Association (NMPA). It can analyze electrocardiogram and generate HRV indices, which include SDNN, RMSSD, NN50, pNN50, triangular index, average RR, deceleration capacity (DC), deceleration runs (DRs), VLF, LF, HF, LF/HF, and total power. Model i12 plus is used to analyzed the same ECG signals as the investigated device.
223497438|NCT04783948|OTHER|Brace Treatment|Compliance to brace compression used for the correction of pectus carinatum will be evaluated.
223497439|NCT03003689|PROCEDURE|Scaling and Root Planing|Standard of care scaling and root planing using hand instruments and ultrasonic scaler
223497440|NCT03003689|DEVICE|Er:YAG Laser|Er:YAG laser as an adjunct therapy to standard of care scaling and root planing using hand instruments and ultrasonic
223497441|NCT02285972|DRUG|saline|before the anesthesia induction, 2mL saline iv injection
223497442|NCT02285972|DRUG|dexketoprofen|before the anesthesia induction, 50 mg (2mL) iv dexketoprofen
223497443|NCT02285972|DRUG|tenoxicam|before the anesthesia induction, 20 mg (2mL) iv tenoxicam
223497444|NCT00514527|DRUG|oritavancin|Oritavancin as a single, infrequent or daily dose.
224073954|NCT05089500|OTHER|Endoscopic Band Ligation|Patients were randomized assigned to the EBL group and were to be prepared before surgery.After the socket is mounted at the inner lens end, the socket is obviously tied at 1-2cm hemorrhoids at the mouth above the dentate line, usually 2-4 rings.With mucosal prolapse, pericyclic multiple dislocation ligation can be performed 2-3cm above the obvious prolapse.
224073955|NCT02681237|DRUG|Cediranib|Small-molecule inhibitor of several tyrosine kinases including VEGFR-1, VEGFR-2, VEGFR-3 and c-kit.
224073956|NCT02681237|DRUG|Olaparib|Poly (ADP-ribose) polymerase (PARP) inhibitor.
224073957|NCT01201239|DRUG|raltegravir|RAL 400 mg twice daily plus OBT (optimized background therapy) for 48 weeks
224073958|NCT02601339|PROCEDURE|ETV/CPC|endoscopic third ventriculostomy (ETV) combined with choroid plexus cauterization (CPC) is a surgical procedure to treat infant hydrocephalus
224073959|NCT00896376|BIOLOGICAL|trastuzumab|
224073960|NCT00896376|OTHER|laboratory biomarker analysis|
224073961|NCT00896376|OTHER|pharmacological study|
224073962|NCT02884778|DIAGNOSTIC_TEST|Detection of pain after nociceptive stimulus|We will evaluate the changes of the NoL index absolute values after different types of stimulations such as intubation and electrical tetanic stimulation of the forearm (applied with the standard muscle relaxation monitor) in a patient under general anesthesia + epidural anesthesia for abdominal surgery
224073963|NCT02301403|DRUG|Nicotine patch|8 weeks of nicotine patch
224073964|NCT02301403|BEHAVIORAL|in-person counseling and quitline counseling|a single brief, in-person counseling session plus a faxed referral to the Wisconsin Tobacco Quit Line (WTQL), for counseling, including the QUITNOW app and the Website
224073965|NCT02301403|DRUG|Preparation Nicotine Mini-Lozenges|Nicotine lozenge prior to attempting to quit smoking
224073966|NCT02301403|DRUG|Combination NRT (nicotine patch + nicotine mini-lozenges)|26 weeks of combination NRT as part of a quit smoking attempt
224073967|NCT02301403|BEHAVIORAL|Intensive In-Person Cessation Counseling|three 20-min In-person Cessation Counseling sessions
224073968|NCT02301403|BEHAVIORAL|Extended Maintenance Counseling Calls|8 Maintenance-phase smoking cessation counseling sessions
224073969|NCT02301403|BEHAVIORAL|Automated Adherence Calls|11 brief, automated calls reminding them to use their medications properly
224073970|NCT00730639|BIOLOGICAL|BMS-936558 (MDX-1106)|Solution, Intravenous, 0.1 mg/kg - 10 mg/kg, Every 2 weeks, 3 years depending on response
224073971|NCT00730639|BIOLOGICAL|BMS-936558 (MDX-1106)|Solution, Intravenous, 1 - 10 mg/kg, Every 2 weeks, 3 years depending on response
224073972|NCT00730639|BIOLOGICAL|BMS-936558 (MDX-1106)|Solution, Intravenous, 10 mg/kg, Every 2 weeks, 3 years depending on response
224073973|NCT00730639|BIOLOGICAL|BMS-936558 (MDX-1106)|Solution, Intravenous, 1 - 10 mg/kg, Every 2 weeks, 3 years depending on response
224073974|NCT00730639|BIOLOGICAL|BMS-936558 (MDX-1106)|Solution, Intravenous, 10 mg/kg, Every 2 weeks, 3 years depending on response
224073975|NCT05654831|DRUG|Placebo|Matching Placebo will be administered as oral tablet. Matching Placebo will be given orally during each dosing day.
224073976|NCT05654831|DRUG|ECC5004|ECC5004 will be administered as oral tablet(s) during each dosing day.
224073977|NCT06463600|DEVICE|Magseed|Tumour localizer
224073978|NCT06463600|DEVICE|Metallic clip and guide wire|Tumour localizers
224073979|NCT02665286|DRUG|Orphenadrine|Orphenadrine 100mg PO BID x 7 days
224073980|NCT02665286|DRUG|Methocarbamol|Methocarbamol 750mg 1-2 tabs po TID x 7 days
224073981|NCT02665286|DRUG|Naproxen|Naproxen 500mg PO BID x 7 days
224073982|NCT02665286|DRUG|Placebo|1/2 of placebo packages will be dosed to match methocarbamol: 1-2 tabs po TID x 7days 1/2 of placebo packages will be dosed to match orphenadrine: 1 tab PO BID x 7 days
224309100|NCT05149443|BEHAVIORAL|theory-based mHealth-intervention (app)|"After the first study, other participants will be recruited. In a second study, the set-up remains the same, but the A1 and A2 phase this time consist of the buddy component (i.e. control phase) and in the B1 and B2 phase the gamification component will be added. This way, we can determine whether the gamification component has an effect on PA compared to the baseline buddy component intervention.~The study duration is 32 days for all participants. The duration of the 4 different phases of the design will vary between participants, but each phase will have a duration of minimum 5 days."
224309101|NCT00675064|DRUG|GSK369796|Anti-malarial
224309102|NCT00675064|DRUG|Placebo|Placebo matching GSK369796
224309103|NCT06198036|OTHER|Hold-Relax Technique|Participants in this group will be treated with hold-relax PNF Technique
224309104|NCT06198036|OTHER|Muscle Energy Technique|Participants in this group will be treated with Muscle Energy Technique via Reciprocal Inhibition Mechanism
224309105|NCT03121378|OTHER|Blood sample 1|Blood taken before prosthesis implantation
224309106|NCT03121378|OTHER|Blood sample 2|Blood taken after prosthesis implantation
223497445|NCT02580071|DIETARY_SUPPLEMENT|Sheng-Yu-Tang|"Granulated formula will be prescribed by KO DA Pharmaceutical co., LTD (科達) composition of formula is as follows: Radix Rehmanniae Praeparata 4g Radix Paeoniae Alba 4g Radix Astragali 4g Radix Ginseng 4g Radix Angelice Sinensis 2g Rhizoma Chuanxiong 2g (for preperation method and concentration ratio's please refer to manufacturers information)~patients will be required to take 4.2gr, t.i.d (total of 12.6gr per day)"
223497446|NCT01119222|DRUG|Gabapentin|Capsule, single 1200mg dose
223497447|NCT01119222|DRUG|Diphenhydramine|Tablet, single 50mg dose
223497448|NCT01119222|DRUG|Morphine|IV, single 10mg dose
223497449|NCT01119222|DRUG|Placebo|Placebo formulations (Capsule, tablet, IV to match the active treatments and to be administered in a double-dummy fashion).
223497450|NCT04288791|OTHER|Equia Forte Fil|Glass hybrid innovation achieved through the introduction of ultrafine, highly reactive glass particles dispersed with conventional GI. The restoration is coated with Equia Forte coat which incorporates multi-functional monomer producing a tougher resin matrix. This system is designed as alternative of amalgam in posterior teeth.
223497451|NCT04288791|OTHER|Zirconomer Improved|Zirconia reinforced GI, Glass Polyalkenoate restoration; it is designed to exhibit high strength where the glass component of this GI undergoes finely controlled micronization to achieve optimum particle size and characteristics .
223497452|NCT04626336|PROCEDURE|Cystectomy|Cystectomy
223497453|NCT00380523|DRUG|MK0663, Arcoxia, etoricoxib / Duration of Treatment: 3 Days|
223497454|NCT01815619|OTHER|on-site specimen evaluation|The specimen will be evaluated on-site by a cytopathologist during the procedure to render a diagnosis
223497455|NCT01815619|OTHER|off-site specimen evaluation|The specimen will be evaluated off-site by a cytopathologist
223497456|NCT04077606|OTHER|ceramo-metallic crown prepartion|tooth will be prepared to receive ceramo-metallic crowns
223497457|NCT04077606|OTHER|full anatomical monolithic zirconia crown|tooth will be prepared to receive monolithic zirconia crowns
223497458|NCT04452006|DRUG|ACT-541478 10 mg|ACT-541478 will be provided in HPMC capsules for oral administration at a dose strength of 10 mg.
223497459|NCT04452006|DRUG|ACT-541478 30 mg|ACT-541478 will be provided in HPMC capsules for oral administration at a dose strength of 10 mg.
224073983|NCT06037330|DRUG|Nalbuphine|Nalbuphine was injected intravenously. The target CPOT score was \<2, and the target RASS score was -2 \~ 1. 40 mg of nalbuphine was diluted into 50 mL solution, the load was 0.1mg/kg, the maintenance dose was 0.04-0.08mg/kg/h, the CPOT score was \<2, and the maximum daily dose was 160mg.
224073984|NCT06037330|DRUG|Sufentanil|Sufentanil was injected intravenously, and the target CPOT score was \<2, and the target RASS score was -2 \~ 1. 0.1mg of sufentanil was diluted into 50 mL solution, the loading dose was 0.2-0.5μg/kg, the maintenance dose was 0.2-0.3μg/kg/h, and the CPOT score was \<2 points
224073985|NCT00038350|BEHAVIORAL|Lingual Strengthening|8 week lingual strengthening exercise protocol
224073986|NCT06087354|OTHER|The way of Cumulus-oocyte complexes (COC) CAPA-IVM culture condition|Cumulus-oocyte complexes (COC) will be cultured in CAPA-IVM 24 hrs capacitation followed by 30h maturation. The first group will be cultured in low oxygen concentration (5%Oxygen), 6% carbon dioxide at 37 degree. The second group will be cultured in air oxygen concentration (20%Oxygen), 6% carbon dioxide at 37 degree.
224073987|NCT00940264|PROCEDURE|transvaginal hybrid cholecystectomy|transvaginal hybrid cholecystectomy: using one trans-umbilical 5mm trocar and 2 (one 12mm trocar, one 5-mm trocar)inserted through the posterior colpotomy. Removal of the gallbladder through the transvaginal access.
224073988|NCT00002356|DRUG|Fomivirsen sodium|
224309107|NCT05769933|DEVICE|Simultaneous EEG-fMRI at 7 Tesla|Scalp electroencephalography (EEG) and functional magnetic resonance imaging (MRI) at 7 Tesla. These will be completely non-invasive techniques with no ionizing radiation and no injected contrasts.
224309108|NCT05769933|DEVICE|Structural MRI at 7 Tesla|Structural magnetic resonance imaging (MRI) at 7 Tesla. These will be completely non-invasive techniques with no ionizing radiation and no injected contrasts.
223497460|NCT04452006|DRUG|ACT-541478 100 mg|ACT-541478 will be provided in HPMC capsules for oral administration at a dose strength of 50 mg.
224073989|NCT01047657|BEHAVIORAL|Low caloric diet plus orlistat and sibutramine|All subjetcs
224073990|NCT02216461|DRUG|Low dose of BIBW 2948 BS for oral inhalation|
224073991|NCT02216461|DRUG|Medium dose of BIBW 2948 BS for oral inhalation|
224073992|NCT02216461|DRUG|High dose of BIBW 2948 BS for oral inhalation|
224073993|NCT02216461|DRUG|Placebo|
224073994|NCT05450146|OTHER|Partner in Balance|"The Partner in Balance intervention (Boots, 2018) consists of 1) a face-to-face intake session with a care professional (casemanagers, dementia nurses or district nurses) to familiarize participants with the program, set goals, and select preferred module themes; 2) tailored online thematic modules, including psychoeducation, behavioral modeling, reflective assignments, set goals, and online messaging feedback with the care professional over 8 weeks; and 3) a face-to-face evaluation session with the care professional evaluating previously set goals."
223497461|NCT04452006|DRUG|ACT-541478 300 mg|ACT-541478 will be provided in HPMC capsules for oral administration at dose strengths of 50 mg and 250 mg.
223497462|NCT04452006|DRUG|ACT-541478 1000 mg|ACT-541478 will be provided in HPMC capsules for oral administration at a dose strength of 250 mg.
223497463|NCT04452006|DRUG|ACT-541478 high or low dose (or placebo)|Cross-over design: ACT-541478 will be provided in HPMC capsules for oral administration at high or low dose strengths (to be defined after completion of Part A).
223497464|NCT04452006|DRUG|ACT-541478 dose E1|E1 is a dose level that has been investigated and well tolerated in the adult dose level groups C1 to C3. ACT-541478 will be provided in HPMC capsules for oral administration at dose strengths of 10, 50, and 250 mg.
223497465|NCT04452006|DRUG|Matching placebo|Matching placebo will be provided in HPMC capsules for oral administration.
223497466|NCT04116047|DRUG|Cisplatin|
223497467|NCT04116047|DRUG|Durvalumab|
223497468|NCT04116047|PROCEDURE|Radiotherapy|
223497469|NCT02905864|DRUG|Liraglutide 3 mg (Saxenda)|
223590305|NCT00884832|DRUG|Clonidine|Subjects randomized to Clonidine will take 0.1 mg of the medication orally twice a day for a total of 4 weeks.
223590306|NCT00884832|DRUG|Placebo|Subjects randomized to the placebo group will also take 0.1 mg of matching placebo pills orally twice a day for a total of 4 weeks.
223590307|NCT02365415|DRUG|Sirolimus|8 weeks oral sirolimus, following drug levels
223497470|NCT02905864|DRUG|Liraglutide 3 mg placebo|
223497471|NCT01223677|BEHAVIORAL|Rumination Focused CBT|see arms
223497472|NCT05658991|DIAGNOSTIC_TEST|Retinal electrophysiology|Retinal electrophysiology to assess retinal function before and with fasting during ramadan in both groups.
223497473|NCT02861976|OTHER|Opioid risk screen development & implementation|Development of a screening tool for the risk of opioid misuse in patients with traumatic injury.
223497474|NCT02723422|PROCEDURE|Prehabilitation visit/increased physical therapy post-TAVR|Prior to TAVR, patients randomized to the intervention arm will meet with a licensed physical therapist for a 30-minute session in the ambulatory setting. Following TAVR, patients randomized to the intervention arm will receive 4 days per week of home-based physical therapy by a licensed physical therapist working for Revival Home Health Care
223497475|NCT02723422|PROCEDURE|Standard of Care Arm|Patients randomized to the usual care arm will receive home-based physical therapy for 2 days per week by Revival Home Health Care, which is the current standard of care.
223497476|NCT02357433|DEVICE|High Doses CPFA|
223497477|NCT00585650|BIOLOGICAL|Etanercept|Subcutaneous injections 50 mg Etanercept will occur twice weekly over a 12-week treatment period.
223497478|NCT00585650|OTHER|Placebo injections|Placebo injections twice weekly for 12 weeks.
223497479|NCT00292994|BEHAVIORAL|Exercise|
223497480|NCT00292994|BEHAVIORAL|Weight Loss|
223497481|NCT02451319|PROCEDURE|Retrograde Intrarenal Surgery|Endoscopic treatment of Kidney Stones
223497482|NCT01573377|DRUG|Metformin|425mg bid for morning and evening after meals, one week after treatment, increase the dosage to 850 mg bid. If the patients have side effects such as nausea, diarrhea and other gastrointestinal symptoms, the dose would be reduced to 425mg bid for 1 week, and try the dosage to 425mg tid again, until the maximum tolerated dose.
224073995|NCT06420505|DEVICE|Percutaneous Coronary Intervention|The Vivo ISAR is indicated for improving coronary luminal diameter in patients with symptomatic ischemic heart disease.
223497483|NCT01573377|DRUG|Ethinylestradiol and Cyproterone Acetate|from the first day of bleeding of the menstrual cycle, daily oral administration of one pill for 21 days consecutively, then stopped taking the pill for seven days, and on the eighth day to start taking the pill again.
224073996|NCT00740350|PROCEDURE|Logan Basic|Logan Basic chiropractic adjustments during pregnancy.
224073997|NCT01524354|PROCEDURE|maintenance of anesthesia|intraoperative maintenance of anesthesia with propofol under control of cerebral state index at 40-60 points
224073998|NCT01524354|PROCEDURE|maintenance of anesthesia|intraoperative maintenance of anesthesia with propofol according to recommendations of the manufacturer
224073999|NCT00897078|OTHER|laboratory biomarker analysis|
224074000|NCT00897078|OTHER|medical chart review|
224074001|NCT00897078|OTHER|metabolic assessment|
224074002|NCT00897078|OTHER|questionnaire administration|will be obtained at a single clinic visit
224074003|NCT00897078|PROCEDURE|assessment of therapy complications|
224074004|NCT04405050|DEVICE|Restrata|Restrata® is a novel synthetic nanofabricated scaffold (Restrata Wound Matrix (RWM), Acera Surgical, St. Louis, Missouri) has been developed which is a sterile, single-use device intended for use in the local management of wounds. The RWM is a soft, white, conformable, non-friable, absorbable matrix that acts as a protective covering for wound defects, providing a moist environment for the body's natural healing process to occur (Figure 2). The RWM is made from synthetic biocompatible materials and was designed to include a fibrous structure with high porosity, similar to native ECM. As a viable wrap for surgical procedures, Restrata conforms to injured tissue, can be sutured, and is arthroscopic and robotic procedure friendly.
224074005|NCT04405050|DEVICE|Negative Pressure Wound Therapy (NPWT)|Negative Pressure Wound Therapy (NPWT) has dramatically changed the care of complex foot wounds. Compared to standard wound care, patients with diabetic foot wounds that are treated with NPWT are 5.9 times more likely to heal and 4.4 times less likely to require amputation. NPWT involves the delivery of sub-atmospheric pressure through a vacuum pump connected to a specialized dressing to maintain a closed environment. NPWT increases perfusion to the wound, accelerates granulation tissue formation, reduces edema, and reduces bio-burden
224074006|NCT03064841|DRUG|No Treatment|No treatment
224074007|NCT06617520|OTHER|Cigarillo flavor type|Participants will complete a within-subjects design that varies by cigarillo smoked: tobacco flavor, concept flavor, and characterizing flavor
224074008|NCT00217087|PROCEDURE|Endoscopic Mucosal Resection|Endoscopic mucosal resection at time of endoscopy if indicated.
224074009|NCT00217087|PROCEDURE|Photodynamic Therapy|Porfimer sodium 2mg/kg
224074010|NCT05531669|BEHAVIORAL|PLAY Project|PLAY consultants coached caregivers monthly for 12 months to improve caregiver-child interaction using videotape and written feedback within a developmental framework.
224187863|NCT05471141|OTHER|Cognition ECHO|Cognition ECHO is the intervention designed to be used by the study participants who are primary care practitioners. No involvement of patients in this study. The panel will consist of the CI and Co-PIs of this study, a neurologist as a co-moderator, a medical specialist who is the expert on the subject, an occupational therapist, a psychologist, and a speech and language pathologist with experience and expertise in CI. A patient with CI and a caregiver, family member, or community representative who is not a healthcare professional will join the panel because CI is frequently observed with lived experience of family members and loved ones, as two non-clinician panelists. The five topics with the integration of related diagnoses for Cognition ECHO are listed in Table 4. The time allocated for the didactic will be 15-20 minutes and the de-identified case discussion will be 40 - 45 minutes.
224187864|NCT04045041|BEHAVIORAL|Acceptance and commitment therapy|An acceptance based intervention with focus on exposure.
224187865|NCT05116410|DRUG|HS-20094|Administrated SC
224187866|NCT05116410|DRUG|Placebo|Administrated SC
224187867|NCT03076710|DRUG|Opioids delivered through PCA|IV up to 1 mg. morphine every 10 minutes on request and oral opioids up to 2 tablets of Percocet every 4 hours
224187868|NCT03076710|DRUG|EXPAREL® infiltration|"22 gauge / 3.5 needle, into dermal/fascial/muscular/subcutaneous layers and up to 4mg IV morphine every 60 minutes on request and standardized oral opioids on request"
224187869|NCT06448169|DRUG|PD-1 inhibitor|PD-1 inhibitor combined with neoadjuvant chemotherapy
223497484|NCT01344200|DRUG|Celecoxib|In Phase I twenty (20) children will receive either celecoxib 14 or 7 mg/kg 120-180 minutes prior to lumbar puncture (LP). In Phase II forty-five (45) children will receive celecoxib 14 mg/kg, 7 mg/kg or placebo in one of 5 time intervals, 1-24 hours prior to LP.
223497485|NCT01344200|DRUG|Placebo|In Phase II forty-five (45) children will receive celecoxib 14 mg/kg, 7 mg/kg or placebo in one of 5 time intervals, 1-24 hours prior to LP.
223497486|NCT01197898|BIOLOGICAL|Collagenase Santyl Ointment|Topical daily application
223497487|NCT01197898|OTHER|Placebo Comparator|Topical daily application
223497488|NCT01687933|DEVICE|three-dimensional glasses(manufactor Vuzix,wrap 920)|The samples were randomly allocated to use three-dimensional glasses for 30 minutes in order to reliving labor pain.
223497489|NCT01687933|OTHER|usual care|Women in Control group did not use the glasses.
223497490|NCT03786575|DIAGNOSTIC_TEST|Next Generation Sequencing (NGS) detection|The NGS detection panel is designed by our team and covers genes that are clinically useful and have definite guiding significance for endocrine therapy
223497491|NCT06007443|OTHER|pain related variables assessment|Pressure pain threshold, conditioned pain modulation, temporal summation, and two-point discrimination will be evaluated on the upper trapezius muscle. Average pain intensity will be asked.
223745925|NCT05071859|OTHER|Questionnaire Administration|Study questionnaire will include modules that collect information on maternal reproductive history, exposure to known teratogens, medical history, and previous genetic testing.
223745926|NCT05071859|OTHER|Biospecimen collection|Saliva collection and request for banked blood and tumor samples for sequencing and biomarker analysis
223745927|NCT05071859|OTHER|Laboratory Biomarker Analysis|Saliva collection and request for banked blood and tumor samples for biomarker analysis
224187870|NCT05156346|OTHER|LEAVES|LEAVES consists of 10 modules of readings and exercises. Readings are filled with evidence-based information on grief-related topics (e.g., how to positively influence thoughts, emotions and behaviours), followed by exercises which encourage mourners to actively reflect on what was learned and apply their new knowledge into their grief journey and coping strategies (e.g., how to change attentional focus). Users are encouraged to work through one module per week and complete the assignments.
224187871|NCT04828746|PROCEDURE|Ultrasound Guided Skin Marking|Using ultrasound for skin marking pre-procedure
224187872|NCT04234841|DIAGNOSTIC_TEST|Blood test|Blood test
224187873|NCT06514638|OTHER|Ultrasound imaging|Images of the vastus medialis were taken with the subject being lateral decubitus.
224187874|NCT02477319|OTHER|Observational|
224187875|NCT01283802|PROCEDURE|INTRAOPERATIVE CHOLANGIO-ULTRASOUND|"Techniques are as follows:~1. Direct ultrasound exploration without any contrast agents.~2. IOCUS injection into the bile duct of a mixture of air and saline (2 parts water and 1 part air);~3. IOCUS injection of an air bolus into the bile duct."
224187876|NCT00066859|DRUG|Zoloft 50 mg|Zoloft 50 mg by mouth daily for 1 week if tolerated dose may be increased to 100 mg daily for 4 months
223497492|NCT01354535|PROCEDURE|Isolated Locked Compression Plate|A lateral thigh incision will be used to expose the fracture site. Surgeons will attempt to minimize devascularization of the bone by meticulous dissection and indirect reduction techniques. An appropriate sized plate will be applied to the lateral aspect of the femur. Fracture reduction will be achieved with the use of intra-operative fluoroscopy and the plate will be secured with locking screws.
223497493|NCT01354535|PROCEDURE|Cable Plating and Strut Allograft with Cerclage Wiring|The plate will be placed laterally with the allograft strut placed on the anterior cortex. Screw fixation will be used distal to the stem and cables and screws will be used proximal to the stem tip. Cerclage cables or wires will be used to secure the strut.
223497494|NCT05540275|DRUG|Tislelizumab plus Bevacizumab|200mg Tislelizumab plus 3mg/kg bevacizumab every 3 weeks
223745928|NCT04790032|DRUG|Cangrelor|All patients receiving Cangrelor during PCI will be enrolled and analyzed for platelet function tests.
224187877|NCT00066859|DIETARY_SUPPLEMENT|St. John's Wort 600 mg|St. John's wort 600 mg daily for 1 week, if tolerated. Dose may be increased to 900 mg daily for 4 months.
224187878|NCT03903575|PROCEDURE|En masse anterior teeth retraction|After extraction of the four premolars the posterior teeth will be tied-together and the six anterior teeth will be retracted by sliding mechanics.
224187879|NCT03903575|PROCEDURE|Two-Step Retraction|After extraction of the four premolars the posterior teeth will be tied-together and the canines will be retracted by sliding mechanics. After the distalization of the canines they will be tied to the posterior teeth and the incisors will be retracted by sliding mechanics.
224309109|NCT05276882|OTHER|Hypnosis|"It will be an individualized hypnosis session of Ericksonian type. It consists in going through 3 phases: induction, dissociation, suggestion.~The principle is to focus the patient's attention by talking to her or by surprising her, or by making her do an incongruous gesture which will make her focus on a restricted idea. She will reduce her field of consciousness and concentrate. This is where her work will begin, allowing her unconscious to function in order to find her solutions. At this moment, she is particularly receptive to suggestions and the hypnotherapist accompanies and guides her thoughts and her associations of ideas on therapeutic paths. He provokes a unique personal work which aims to promote healing."
223497495|NCT03821532|OTHER|Constipation Action Plan|Action plan, adapted from Autism Speaks Network, demonstrating Red, Yellow, and Green levels of symptoms with corresponding steps for treatment or action by parent/guardian, tailored by care provider to the child's condition.
223497496|NCT06363500|OTHER|non applicable|Only blood sample collection
223497497|NCT02372084|DRUG|osilodrostat|
223497498|NCT01899703|DRUG|GSK2330672|GSK2330672 oral preserved solution 1.5mg/g will be supplied in amber glass bottles and as per randomization schedule subject will receive 45 mg BID from Day 1 to 3 and 90 mg BID from Day 4 to 14 of one of the two treatment periods.
223497499|NCT01899703|DRUG|Placebo|Placebo oral preserved solution will be supplied in amber glass bottles and as per randomization schedule subject will receive placebo BID from Day 1 to 14 of one of the two treatment periods. .
223497500|NCT01899703|DRUG|Ursodeoxycholic acid|UDCA 250 mg will be supplied in capsule form. The subjects, who are taking UDCA at the time of Run-in-period, will be continued on the same total daily dose of drug but converted to a standardized formulation and a standardized dosing regimen administering the entire daily dose once daily in the evening before bedtime. Once daily dosing of UDCA will continue for the duration of the study.
223497501|NCT06217146|DRUG|Medical Cannabis|MediCane's medical cannabis oil
223497502|NCT06217146|DRUG|Placebo Oil|Placebo Oil
223497503|NCT00376506|DEVICE|Neurostimulation device for dysphagia|A neurostimulation device that is surgically implanted in the swallowing muscles.
223497504|NCT00376506|DEVICE|External vibrotactile device|A vibrotactile device that is placed on the neck during swallowing.
223497505|NCT02962466|OTHER|CC-Test|classification of the oocyte based on the expression pattern observed in the cumulus cells
223497506|NCT05007509|BIOLOGICAL|COVID-19 vaccine HIPRA 10|One sentinel subject and 4 additional subjects will be assigned to COVID-19 vaccine HIPRA 10 µg
223497507|NCT05007509|BIOLOGICAL|COVID-19 vaccine HIPRA 20|One sentinel subject and 9 additional subjects will be assigned to COVID-19 vaccine HIPRA 20 µg
223497508|NCT05007509|BIOLOGICAL|COVID-19 vaccine HIPRA 40|One sentinel subject and 9 additional subjects will be assigned to COVID-19 vaccine HIPRA 40 µg
223497509|NCT05007509|BIOLOGICAL|Commercial COVID-19 vaccine|One subject in cohort 1 and 2 subjects in Cohort 2 and 3 will be assigned to Commercial COVID-19 vaccine
223745929|NCT05051189|DRUG|Fentanyl Citrate|Ventilatory response to fentanyl in patients with OSA Specifically: respiratory changes, CO2, RR, TV
223745930|NCT00525733|DRUG|darunavir 800 mg|darunavir 800mg tablet will be administered with 100 mg capsule of ritonavir once daily (may be taken with or without food)
224074011|NCT05531669|BEHAVIORAL|Parental Education|Each study center provides welcome course and parent guide for families with ASD children monthly.
224074012|NCT02849366|DEVICE|Cryosurgery|Percutaneous ablation under CT or ultrasound guidance
224074013|NCT02849366|BIOLOGICAL|NK immunotherapy|Each treatment: 8-10 billion cells in all, transfuion in 3 times, i.v.
224074014|NCT03208231|BIOLOGICAL|VRC01|40 mg/kg of VRC01 administered by subcutaneous injection.
224074015|NCT03208231|DRUG|Combination Antiretroviral Therapy (cART)|All infants received non-study provided cART selected by their primary care provider and supplied through non-study sources (i.e., cART not provided through the study).
224074016|NCT00691431|DEVICE|LASIK|
224074017|NCT01563887|BEHAVIORAL|DD.com|Internet intervention in which participants will complete 6 Cores, or classes over the internet, focusing on risk factors and prevention, detection, and management of hypoglycemia before and while driving.
224074018|NCT01563887|BEHAVIORAL|DD.com + MI|Prior to starting and immediately after finishing the DiabetesDriving.com internet intervention, a one hour motivational interview will be conducted with participants. Internet intervention in which participants will complete 6 Cores, or classes over the internet, focusing on risk factors and prevention, detection, and management of hypoglycemia before and while driving.
224074019|NCT03321097|DEVICE|condensed RT group|"BoNT-A injections Botox brand BoNT-A Purified Neurotoxin Complex, (Allergan Pharmaceuticals, Irvine, CA) will be prepared by diluting lyophilized toxin with 0.9% saline to a concentration of 33-100 U/ml. depending on the size of the target muscle. Location of the targeted muscle will be confirmed by using echo guide.~Training procedures There are total 24 training sessions following one week after injection. Participants in the condensed practice group will receive 4 sessions per week, for 6 weeks.~During each practice session, participants first receive 40 minutes of repetitive RT with the InMotion 3.0 robot (Interactive Motion Technologies Inc., Watertown, MA), followed by 40 minutes of transition-to-task practice."
224074020|NCT03321097|DEVICE|distributed RT group|"BoNT-A injections Botox brand BoNT-A Purified Neurotoxin Complex, (Allergan Pharmaceuticals, Irvine, CA) will be prepared by diluting lyophilized toxin with 0.9% saline to a concentration of 33-100 U/ml. depending on the size of the target muscle. Location of the targeted muscle will be confirmed by using echo guide.~Training procedures There are total 24 training sessions following one week after injection. Participants in the condensed practice group will receive 2 sessions per week, for 12 weeks.~During each practice session, participants first receive 40 minutes of repetitive RT with the InMotion 3.0 robot (Interactive Motion Technologies Inc., Watertown, MA), followed by 40 minutes of transition-to-task practice."
224074021|NCT05403125|DEVICE|silver diamine fluoride, 38%|Topical application to all surfaces of the teeth
224074022|NCT05403125|DEVICE|Sodium fluoride gel, 5000 PPM|Gel applied after application of silver diamine fluoride and dispensed for home use
224074023|NCT03861143|DRUG|BT-11 (440 mg)|Oral, once daily tablet
224074024|NCT03861143|DRUG|BT-11 (880 mg)|Oral, once daily tablet
224074025|NCT03861143|DRUG|Placebo|Oral, once daily tablet
224074026|NCT00281879|BIOLOGICAL|anti-thymocyte globulin|Intravenous, 1.5 mg/kg of body weight daily for 7 to 14 days The first dose should be administered over a minimum of 6 hours and over at least 4 hours on subsequent doses through a high-flow vein.
224187880|NCT04575233|PROCEDURE|laparoscopic-assisted Transversus Abdominis Plane (TAP) block|"The anterior axillary line is used as landmarks. After insertion of the optic trocar, the peritoneum is visualized. A 14 Gauge needle is inserted 2 cm cranially respect the taken landmark through the skin until the penetration of the internal and external oblique fascias, identified as sudden lowering of resistance. A solution of 15 ml of Ropivacaine (0.2%) is then injected. The procedure is performed then 2 cm caudal to the first landmark on the same side.~The procedure is than repeated identically on the contralateral side."
224187881|NCT04575233|PROCEDURE|ultrasound-assisted Transversus Abdominis Plane (TAP) block|Whilst the patient is in the supine position, a high frequency ultrasound probe is placed transverse to the abdominal wall between the costal margin and iliac crest. The needle is introduced in plane of the ultrasound probe directly under the probe and advanced until it reaches the plane between the internal oblique and transversus abdominis muscles. Then 15 ml of local anaesthetic solution is injected. The needle is than retracted until its tip is positioned in the fascial plane between the internal and the external oblique muscles and a second bolus of 15 ml of local anaesthetic is injected. The procedure is than repeated identically on the contralateral side.
224187882|NCT04575233|DRUG|Ropivacaine|a solution of 15 ml of Ropivacaine (0.2%) is injected for the treatment of post-operative pain after minimally invasive surgery (TAP block)
224187883|NCT02600559|DRUG|OTO-201 (ciprofloxacin)|
224187884|NCT04433000|DIAGNOSTIC_TEST|Butterfly|Standardized lung ultrasound scan with two different instruments
224187885|NCT00717899|DEVICE|Spirometry (Pony spirometer)|Spirometry at rest
224187886|NCT03790475|OTHER|Offering a choice for colorectal cancer screening|Persons randomized to the multiple options screening strategy group will receive a postal invitation offering a choice between FIT and colonoscopy.
224187887|NCT03790475|OTHER|Offering an alternative colorectal cancer screening method|Persons randomized to the sequential screening strategy group will receive a postal invitation to the colonoscopy followed by a postal invitation for screening using FIT for non-responders and subjects refusing colonoscopy.
224187888|NCT03359499|DRUG|Bacillus clausii|Oral suspension administered BID
224187889|NCT03359499|DRUG|Trimebutine|One tablet of 200 mg of trimebutine administered BID
224187890|NCT01710007|DRUG|1PC002|Subjects should be instructed to take 1 capsule of study drug (1PC002 or atorvastatin) orally once a day, with or without food. Administration before bedtime or at regular time-interval is recommended.
224187891|NCT01710007|DRUG|Lipitor|Subjects should be instructed to take 1 capsule of study drug (1PC002 or atorvastatin) orally once a day, with or without food. Administration before bedtime or at regular time-interval is recommended.
224187892|NCT03179137|OTHER|Standard therapy|Patients with therapy prescribed independent of the study
224187893|NCT01153971|DRUG|rituximab|1
224187894|NCT03740854|OTHER|Pressure Controlled Ventilation|Patients will be ventilated with a pressure level which supplies a tidal volume corresponding 8ml/kg, 12 breaths per minute, 1/2 inspiration/expiration ratio and %40 Fraction of Inspired Oxygen . These ventilator settings can be changed in order to adjust end tidal carbon dioxide and oxygen saturation levels.
224187895|NCT03740854|OTHER|Volume Controlled Ventilation|Patients will be ventilated with a tidal volume which corresponds 8ml/kg, 12 breaths per minute, 1/2 inspirastion/expiration ratio and %40 Fraction of Inspired Oxygen . These ventilator settings can be changed in order to adjust end tidal carbon dioxide and oxygen saturation levels.
224187896|NCT03410693|DRUG|Rogaratinib (BAY1163877)|Rogaratinib administered as oral (p.o.) tablets twice daily (b.i.d.) continuously
224187897|NCT03410693|DRUG|Chemotherapy|Chemotherapy as taxane (docetaxel or paclitaxel) or vinflunine administered through intravenous (i.v.) infusion every 3 weeks (on day 1 of a 21-day cycle) The choice of the chemotherapy is at the discretion of the investigator, taking into consideration the status of the authorization or treatment guidelines in the given country.
224309110|NCT05276882|OTHER|pre-surgery consultation|"Dialogue with the patient to clarify her expectations.~* Answers to the patient's questions~* Precision on the organization of the hospitalization if necessary~* Information on the postoperative period with postural advice to facilitate the first getting up with less discomfort, and postures promoting rest in the postoperative period~* Information on relaxation techniques and their interest (abdominal breathing)"
223497510|NCT02819388|BEHAVIORAL|Contraceptive counseling|A culturally adapted counselling session lasting up to 45 minutes at the community setting. The interview is based in WHO guidelines and communication tools, in social cognitive theory and in motivational interviewing. Along the interview, topics follow easy to read leaflets prepared to discuss the main benefits of contraception from the view of the immigrant communities, with guided discussions on family planning in the life course, the amount of time required to care children, the economic resources that newborn and children need, and an assessment of the knowledge on the contraceptive methods, and of their current use. Contraceptive methods, abortion and emergency contraception are discussed. Primary health care centre and sexual and reproductive health clinic access is reinforced.
223497511|NCT00689988|BEHAVIORAL|speech-language therapy with AAC intervention|speech-language intervention in weekly 40-minutes sessions, without the presence of parents or caregivers, and 5 to 10-minutes to parents training and orientation
224187898|NCT04747691|DIAGNOSTIC_TEST|Bedside gastric ultrasound|Bedside ultrasound exam of the stomach
224187899|NCT04952376|BEHAVIORAL|SMS delivery of information|Patients are informed via SMS that COVID-19 vaccine doses are available and advised to schedule an appointment. Links to information or phone for scheduling will be provided. Messages mimic the clinic's usual practice of information delivery to patients
224187900|NCT04952376|BEHAVIORAL|Personalized text message delivery of information|Patients are informed via SMS that COVID-19 vaccine doses are available and advised to schedule an appointment. The SMS message is personalized as a recommendation from the primary care clinician
224187901|NCT04952376|BEHAVIORAL|Interactive or 2-way SMS delivery of information|This intervention is same as in the Arm 2 using personalized messaging from the PCP. In addition, patients are given interactive or 2-way SMS options to obtain additional information about COVID vaccine and answers to frequently asked questions.
224187902|NCT00953576|DRUG|ketoconazole|
224187903|NCT00953576|DRUG|hydrocortisone|
224187904|NCT00953576|DRUG|dutasteride|
224187905|NCT00953576|DRUG|lapatinib|
224187906|NCT01165892|DRUG|Gadofosveset Triodium|Use of 0.03 mmol/Kg of gadofosveset trisodium (Ablavar)once with intravascular half life of up to 1 hr and optimal arterial imaging out to 20-30 minutes.
224187907|NCT00482976|DRUG|Ruboxistaurin|
224187908|NCT00482976|DRUG|Placebo|
224187909|NCT02965027|DRUG|Prazosin|
224187910|NCT02965027|DRUG|Placebo|
224187911|NCT04924465|OTHER|Follow-up|Follow-up of clinical data, laboratory tests, radiological data and pulmonary function tests
224187912|NCT05151874|DRUG|Abobotulinum toxin A|To measure ROM evolution in patients with post-stroke spasticity in the upper limb with spasticity pattern III.
224187913|NCT01315626|OTHER|Primary Care Educational event|The purpose of this study is to assess the accuracy of primary care physicians in diagnosing BE and evaluate the impact of an educational intervention targeting those primary care physicians and providing instruction in the recognition and treatment of BE. The hope is that a better understanding of the disease will result in more accurate diagnoses and ultimately in more appropriate care for these patients. In addition to better care for patients, earlier recognition of bronchiectasis may result in a decrease in health care costs.
224187914|NCT01969331|DIETARY_SUPPLEMENT|Normia|One capsule twice a day/14 days
224187915|NCT01969331|DIETARY_SUPPLEMENT|Placebo|maltodextrin, microcrystalline cellulose; hypromellose, silicium dioxide (E551), magnesium stearate, colouring agent: titanium dioxide ( E171)
224187916|NCT03218657|DRUG|levamisole hydrochloride|levamisole hydrochloride take orally 150mg qod
224187917|NCT03218657|DRUG|Androgens|Androgens take orally 80mg qd
224187918|NCT03218657|DRUG|Cyclosporins|Cyclosporines take orally 3-5mg/kg\*d qd
224187919|NCT03853226|PROCEDURE|All monitoring|For all patients, data from trans-esophageal Doppler, trans-thoracic echocardiography (TTE) and hemodynamic data are collected at the end of the procedure. During catheter withdrawal, pressure waveforms are recorded at two predefined aortic locations: in the ascending aorta and in the descending thoracic aorta just in front of the esophageal Doppler probe.
224187920|NCT02681991|DRUG|Renamezin capsule|
224187921|NCT05665257|DEVICE|Inspiratory muscle training|
224187922|NCT05665257|DEVICE|Mini-PEP|
223497512|NCT04626778|DRUG|Peroxyl Mouthwash|Mouthwash
223497513|NCT04626778|DRUG|Placebo Mouthwash|Mouthwash
223497514|NCT04311580|COMBINATION_PRODUCT|intravesical electromotive administration of mitomycin|
223745931|NCT00525733|DRUG|FTC 200 mg/TDF 300mg|Emtricitabine/tenofovir DF fixed-dose tablet containing 200 mg of emtricitabine and 300 mg of tenofovir DF will be administered orally as one tablet once daily (may be taken with or without food)
224187923|NCT03922048|DRUG|HTX-011|Single-dose instillation of approximately 0.17 mL/kg (total dose does not exceed 10.5 mL) of HTX-011.
223497515|NCT03073057|DRUG|Budesonide/formoterol|2 inhalations as a single dose
223497516|NCT03073057|OTHER|Charcoal|
223497517|NCT03073057|DRUG|Symbicort Turbuhaler|2 inhalations as a single dose
223497518|NCT03144635|DRUG|Grazoprevir plus Elbasvir|An oral dose of 100 mg/day of grazoprevir as well as an oral dose of 50 mg/day of elbasvir for 12 weeks.
223497519|NCT00001857|DRUG|BG9588|
223497520|NCT05916287|BIOLOGICAL|Blood and urine samples|Blood and urine samples
223497521|NCT05916287|GENETIC|Blood samples|Blood samples
223745932|NCT00525733|DRUG|Maraviroc|Maraviroc will be administered twice daily in 150 mg tablets (may be taken with or without food)
223745933|NCT00525733|DRUG|Raltegravir|Raltegravir will be administered twice daily as 1-400 mg tablets (to be taken with food)
224187924|NCT03922048|DRUG|Bupivacaine HCl|Bupivacaine HCl 0.25% (without epinephrine) (total dose not to exceed 75 mg).
224187925|NCT03922048|DRUG|HTX-011|Dose to be determined from Cohort 1.
224187926|NCT03922048|DRUG|HTX-011|Dose to be determined from Cohorts 1 and 2.
224187927|NCT03922048|DRUG|HTX-011|Dose to be determined from Cohort 1 Part A.
224187928|NCT03922048|DEVICE|Luer Lock Applicator|Applicator for instillation.
224187929|NCT02962440|DRUG|somapacitan|All subjects will receive one subcutaneous (s.c., under the skin) dose of somapacitan containing \[3H\]-somapacitan
224187930|NCT03641235|BIOLOGICAL|Sputum collection|Analysis of Sputum collection
224187931|NCT05250739|OTHER|Strength training|Strength training was performed with resistance bands. The band was fastened to the unaffected ankle, while the participant was told to perform front and back pulls, as well as adduction and abduction movements with the affected ankle. They were told to control the ankle movement and to make it slow. Since the first day, they were told to perform the exercise pulling the band as if they wanted to make the resistance of 5 on a scale from 0 to 10.
224187932|NCT05250739|OTHER|Neuromuscular training|consisted in a multi-station training with 6 exercises, increasing the difficulty progressively as the participants controlled the execution. The exercises were all performed barefoot and with the injured foot. These were a combination of standing and jumping exercises involving the injured ankle. The participants did not start the next progression until they perform a complete circuit in the level before.
224187933|NCT05654116|BEHAVIORAL|Caregiver Interaction Profile (CIP) training|The CIP training aims to boost six interactive skills in daycare providers: sensitive responsiveness, respect for children's autonomy, structuring and limit setting, verbal communication, developmental stimulation, and fostering positive peer interactions. The training takes place with 1 or 2 daycare providers at a time, and consists of 5 or 6 weekly sessions, respectively. In individual trainings, sessions 1-3 focus on two skills each, session 4 is a recap of two skills the daycare provider chooses, and the final session is shared with a colleague. In pairwise sessions, session 1 focuses on the first two skills, sessions 2-5 each focus on one skill, and the last session serves as a recap of two skills the daycare providers choose. The training uses a video-feedback method: daycare providers are filmed in interactions with children in daycare, the CIP trainer preselects relevant fragments of video recordings to discuss with the daycare provider(s) during the training sessions.
224187934|NCT01312363|DRUG|Rivastigmine patch|Rivastigmine patch (5-10cm2, daily, 24hr)
224187935|NCT02500134|OTHER|Optical coherence tomography study on limbus|Optical coherence tomography study on limbus
224187936|NCT05620186|OTHER|PROSPECT|PROficiency Based StePwise Endovascular Curricular Training
223497522|NCT05916287|OTHER|Cardiovascular assessment|Echocardiography, Lung ultrasound, pulse wave velocity, carotid stiffness and thickness, Central and peripheral blood pressure, carotid pulse pressure, abdominal aorta ultrasound, jugular vein ultrasound, liver elastography (Optional).
223497523|NCT05916287|BEHAVIORAL|Dietary intake|Food frequency questionnaires, ''Dutch eating behaviour questionnaire'' and dietary supplement questionnaire
223497524|NCT05916287|OTHER|Anthropometric parameters|Measurement of height, weight, abdominal circumference, hip circumference, arm circumference
223497525|NCT05916287|OTHER|Hemodynamic parameters|Systolic pressure index measurement
223497526|NCT05916287|OTHER|Hemodynamic parameters|Heart rate measurements, blood pressure measurements, orthostatic BP measurements
223497527|NCT05916287|OTHER|Hemodynamic parameters|"Blood pressure measurements by unattended BP monitor over 5 min"
223497528|NCT05916287|OTHER|Hemodynamic parameters|Electrocardiogram
223497529|NCT05916287|BEHAVIORAL|Assessment of compliance with antihypertensive treatments for treated participants|EVALOBS scale and compliance questionnaire
223497530|NCT05916287|OTHER|Ambulatory 24 hours measurment of blood pressure|For the first 100 patients willing to participate
223497531|NCT05916287|BIOLOGICAL|24 hours urinary collection|For the first 100 patients willing to participate. For biobank constitution and measurement of microalbuminuria, creatininuria, osmolarity, natriuresis, kaliuresis, urea, proteinuria and urine dipstick
223497532|NCT05916287|OTHER|General questionnaires|Collection of socio-demographic data such as age, level of education, profession, household income, smoking status, physical activity, perception of health, prematurity, height and weight at birth, family and personal history especially cardiovascular (history of stroke, myocardial infarction, heart failure, current pathologies, drugs, tobacco...)
223497533|NCT05916287|OTHER|Women specific questionnaire|Women specific questionnaire
223497534|NCT05916287|BEHAVIORAL|Women specific questionnaire|Women specific questionnaire
223497535|NCT05916287|DIAGNOSTIC_TEST|NYHA dyspnea questionnaire|Determination of NYHA class.
223497536|NCT05916287|BEHAVIORAL|Anxiety questionnaire|Assessment of anxiety
223497537|NCT05916287|BEHAVIORAL|Epworth Sleepiness Scale|sleep quality assessment
223497538|NCT05916287|OTHER|"A questionnaire on the perception of the management of cardiovascular risk factors"|Patient's evaluation of cardiovascular risk factors by the health system
223497539|NCT05916287|BEHAVIORAL|A questionnaire on eating behaviors|Assessment of eating behaviors
223497540|NCT05916287|BEHAVIORAL|A questionnaire on eating habits to determine consumer profiles|Assessement of eating habit to create a consumer profile
223497541|NCT05916287|DIETARY_SUPPLEMENT|A questionnaire on food supplements use|Evaluation od food supplements intake
224074027|NCT00281879|BIOLOGICAL|filgrastim|"Will be given IV at 5 µg/kg/day. The first injection will be administered on day +7, i.e. 7 days after the hematopoietic stem cells are infused.~Will be administered until the ANC is 1500 / µl for 2 days. Dose and schedule of G-CSF administration is left to each center's discretion."
224074028|NCT00281879|DRUG|busulfan|Patients who take the drug PO, busulfan will be administered at 1 mg/kg/ dose given by mouth every 6 hours for 16 consecutive doses. Pediatric patients who receive busulfan IV continuous infusion will receive a dose of 3.0 mg/kg/IBW if under the age of 2.Pediatric patients over the age of 2 will receive busulfan at a dose of 0.8 mg/kg/dose.
224074029|NCT00281879|DRUG|carmustine|300mg/m2 IV dissolved in 500 cc NS infused over 2 hours into right atrial catheter on day -6.
224074030|NCT00281879|DRUG|cyclophosphamide|For transplantation, the drug is diluted in 250 to 500 cc of NS or D5W and administered IV over 2 hours.
224074031|NCT00281879|DRUG|cyclosporine|Initial doses will be administered IV at a starting dose of 1.5 mg/kg BID. The infusion will vary from 2-24hr depending on the incidence of side-effects.
224074032|NCT00281879|DRUG|cytarabine|400 mg/m2 dissolved in 200cc D5W and infused over 30 minutes into right atrial catheter on days -5, -4, -3, -2.
223497542|NCT05916287|OTHER|SARS-CoV-2 Infection Questionnaire|SARS-CoV-2 Infection Questionnaire
223497543|NCT05916287|OTHER|Instantaneous expired air analysis|Carbon monoxyde analysis in expired air
223497544|NCT05916287|BIOLOGICAL|Capillary sampling|Capillary sampling for pollutant analysis (Optional)
223497545|NCT04787458|DEVICE|abdomen binder (Sejung Korea, Seoul, Republic of Korea)|abdomen binder with a standard height of 22 cm (Sejung Korea, Seoul, Republic of Korea)
223497546|NCT01430884|OTHER|Aspirated Coronary Blood|Coronary arterial blood is taken distal to the lesion before stent implantation and serve as control and coronary aspirate blood is obtained during stent implantation.
223497547|NCT02843607|DEVICE|Cryosurgery|Argon-helium cryosurgical system (percutaneous ablation under CT or ultrasound guidance)
223497548|NCT02843607|BIOLOGICAL|NK immunotherapy|Natural killer cell (each treatment: about 10 billion cells transfusion in 3 times, i.v.)
223497549|NCT06005155|DRUG|Lithium|Sustained long-term exposure
223497550|NCT05842980|OTHER|sepsis|collect 5ml blood from patient
223497551|NCT02306785|DRUG|TP05 Coating D|One radio-labelled tablet given to subjects
223497552|NCT02306785|DRUG|TP05 Coating E|One radio-labelled tablet given to subjects
223497553|NCT02306785|DRUG|TP05 Coating H|One radio-labelled tablet given to subjects
223497554|NCT04675281|OTHER|2 post-mortem transcutaneous lung biopsies (1 anterior ; 1 posterior) using anatomical landmarks|All specimens are fixed with 4% neutral formaldehyde and embedded in paraffin wax in the department of pathology of each participating centre. Afterwards, all samples are sent for analysis to the department of pathology of Nantes university hospital. All biopsies are independently analysed by a group of pathologists who are experts in lung tissue and blinded to clinical information. All biopsies will be analysed using a predetermined semi-quantitative histological scoring grid. The pathologists are asked to assess the degree of: edema, cell necrosis, hyaline membrane formation, proliferation of alveolar type 2 cells, fibrosis, capillary congestion, alveolar edema, neutrophilic infiltration, and microscopic thrombosis. Finally, the following patterns are recorded: exudative diffuse alveolar damage (DAD), proliferative DAD, fibrosis, intra-alveolar haemorrhage, lymphocytic pneumonia, organizing pneumonia, acute fibrinous organizing pneumonia (AFOP), thrombotic microangiopathy.
223745934|NCT00525733|DRUG|Ritonavir 100 mg|one tablet of ritonavir is taken with darunavir daily
223745935|NCT05779878|OTHER|Post Isometric Relaxation|Post-isometric relaxation (PIR) is a soft tissue stretching technique used by many health care professionals to lengthen both acute and chronic short muscles.
223497555|NCT04887038|DRUG|SRT-015|Each study part (A,B and C) will be completed sequentially, but with partial overlapping. The first cohort of Part B (Cohort B1) may be initiated after safety, tolerability and available PK data are assessed and deemed suitable to continue for a single dose on Part A that is equal to or greater than the total exposure of cohort B1. Part C (Cohort C1 \& C2) may be initiated after safety, tolerability and PK data are assessed and deemed suitable to continue for a single dose in part A that is at least double the specified dose from part C.
223497556|NCT04887038|OTHER|Matching Placebo for SRT-015|Matching Placebo
223497557|NCT03780387|BIOLOGICAL|Felis Catus|Inhalation of Felis Catus allergen in subjects allergic to Felis Catus
223497558|NCT05753969|DEVICE|MT1 Device|Pre-and post-evaluation in MT1 device following stimulant treatment or placebo control
223497559|NCT00006457|DRUG|oltipraz|
223497560|NCT05076786|DRUG|Chidamide|20mg, administered orally. Week 1/2: twice a week (d0, d4, d7, d11); Week 3: stop. Repeat every 3 weeks for 4-6 cycles.
223497561|NCT05076786|DRUG|Etoposide + Cisplatin/Carboplatin|"Etoposide (100mg/m2; intravenous infusion; d1-3) + Cisplatin (75mg/m2; intravenous infusion; d1). Repeat every 3 weeks for 4-6 cycles.~OR Etoposide (100mg/m2; intravenous infusion; d1-3) + Cisplatin (25mg/m2; intravenous infusion; d1-3). Repeat every 3 weeks for 4-6 cycles.~OR Etoposide (100mg/m2; intravenous infusion; d1-3) + Carboplatin (AUC=5; intravenous infusion; d1). Repeat every 3 weeks for 4-6 cycles."
223497562|NCT04715035|OTHER|Physical therapy interventions|mobilization, stretch, education, eccentric exercises
223497563|NCT02788227|BIOLOGICAL|rVSV-Zebov GP vaccine|primary vaccination for all participants, one-to-one randomization at Month 18 to receive booster vaccination or no booster.
223497564|NCT05266469|OTHER|Ofatumumab|There is no treatment allocation. Patients administered Ofatumumab by prescription will be enrolled.
223497565|NCT05266469|OTHER|Ocrelizumab|There is no treatment allocation. Patients administered Ocrelizumab by prescription will be enrolled.
223497566|NCT05229913|DRUG|Esketamine is not added|Postoperative intravenous analgesia pump formula：Sufentanil 1ug/kg+ Flurbiprofen Axetil 200mg
223497567|NCT05229913|DRUG|Esketamine 0.2mg/kg|Postoperative intravenous analgesia pump formula：Esketamine 0.2mg/kg + Sufentanil 1ug/kg+ Flurbiprofen Axetil 200mg.
223497568|NCT05229913|DRUG|Esketamine 0.4mg/kg|Postoperative intravenous analgesia pump formula：Esketamine 0.4mg/kg + Sufentanil 1ug/kg+ Flurbiprofen Axetil 200ml.
223497569|NCT05229913|DRUG|Esketamine 0.6mg/kg|Postoperative intravenous analgesia pump formula：Esketamine 0.6mg/kg + Sufentanil 1ug/kg+ Flurbiprofen Axetil 200mg.
223497570|NCT05229913|DRUG|Esketamine 0.8mg/kg|Postoperative intravenous analgesia pump formula：Esketamine 0.8mg/kg + Sufentanil 1ug/kg+ Flurbiprofen Axetil 200mg.
223497571|NCT02948400|BEHAVIORAL|pedestrian safety training in pedestrian virtual environment|pedestrian safety training
223497572|NCT02403271|DRUG|Ibrutinib|BTK Inhibitor
223497573|NCT02403271|DRUG|Durvalumab|Anti PDL-1
223497574|NCT02450136|DRUG|pazopanib|
223497575|NCT05463393|BIOLOGICAL|Xanthohumol - prenylated chalcone extracted from female inflorescences of hop cones (Humulus lupus). Hop-RXn™, BioActive-Tech Ltd, Lublin, Poland; http://xanthohumol.com.pl/|The appropriate dose of Xanthohumol was solved in 1 mL of propylene glycol
223497576|NCT05765734|DRUG|TAS3351 oral administration|TAS3351 will be administered orally
223497577|NCT01140139|BIOLOGICAL|HIV DNA Vaccine|0.4 mg of DNA plasmids encoding HIV env A, B, C and Rev B, gag A, B and RT mut formulated in PEI and glucose was applied topically with the DermaPrep procedure six times during cycles of 7 weeks of active HAART. Every immunization cycle was followed by four weeks of therapy interruption.
223497578|NCT05749185|DEVICE|radiofrequency high voltage|nvolved a high voltage PRF technique, where the voltage started at 65 V and could be adjusted up to 80 V based on patient tolerance. Both protocols involved two cycles of PRF application, with each cycle lasting 240 seconds and comprising alternating periods of current application and deactivation. The pulse rate frequency was set at 2 Hertz (Hz), resulting in two active phases/second (20 milliseconds (ms) of current application followed by 480 ms without stimulation)
223497579|NCT05749185|PROCEDURE|standard RF|A standard voltage PRF technique, administering PRF at a fixed voltage of 45 volts (V)
223497580|NCT05783050|DEVICE|Wei Nasal Jet Tube|The purpose of this procedure is to provide safe oxygenation and ventilation. While providing oxygen support, nasal cannula, classical oxygen mask can be used, as well as new generation oxygenation devices.
223497581|NCT05783050|DEVICE|Nasal Cannula Oxygen Support|The purpose of this procedure is to provide safe oxygenation and ventilation. While providing oxygen support, nasal cannula, classical oxygen mask can be used, as well as new generation oxygenation devices.
223497582|NCT04837521|BEHAVIORAL|Unified Protocol|Five session psychotherapy
224074033|NCT00281879|DRUG|etoposide|"Etoposide administration 200 mg /m2 dissolved in 1 liter NS and infused over 2 hours into right atrial catheter. Infusion to begin after cytarabine administration on days -5, -4, -3, -2.~Etoposide administration 50 mg/kg IV over 24 hours, divided into 3 doses. Dilute in normal saline at a concentration of 0.4 mg/ml (Observe for precipitation). Administered IV with continuous infusion over 24 hours. Diuretics may be given for fluid overload."
224074034|NCT00281879|DRUG|fludarabine phosphate|"Fludarabine administered at 30 mg/m2 IVPB infused over 30 minutes into right atrial catheter on days -4, -3, -2.~Fludarabine administered at 40 mg/m2 IVPB infused over 30 into the right atrial catheter on days -5, -4, -3, and -2."
224074035|NCT00281879|DRUG|melphalan|140 mg /m2 in concentration of 0.45 mg/ml of NS infused over 30 minutes into right atrial catheter on day -1.
224074036|NCT00281879|DRUG|methotrexate|Administered on days +1, +3, and +7.
224074037|NCT00281879|DRUG|methylprednisolone|Methyl-prednisolone is administered IV as a rapid infusion.
224074038|NCT00281879|DRUG|mycophenolate mofetil|Mycophenolate may be used as a substitute for Methotrexate
224074039|NCT00281879|DRUG|tacrolimus|A drug used to decrease the risk of graft versus host disease (GvHD).
224074040|NCT00281879|PROCEDURE|peripheral blood stem cell transplantation|The stem cells will be given to you by intravenous injection (through your vein) using a catheter that was placed prior to beginning chemotherapy. The stem cell infusion takes 1-6 hours.
224074041|NCT00281879|PROCEDURE|umbilical cord blood transplantation|The patient will receive ATG to improve the changes of engraftment and decrease their risk of graft versus host disease. The patient may receive ATG 3 times during their transplant regimen on days -3 through days -1
224074042|NCT00281879|RADIATION|radiation therapy|Radiation will be given to you 2 times a day for 3 or 4 days.
223497583|NCT06397781|DRUG|Skin Cleanser Combination No.1|"1. Mupirocin 2% nasal ointment to the anterior nares to be applied twice daily~2. Chlorhexidine 4% topical soap (Hibiclens) to be used every other day in the shower or bath from the neck down and then completely rinsed.~3. Sulfamethoxazole/trimethoprim (Bactrim): one double strength (DS) tablet (800 mg/160 mg) twice per day for adolescents and adults. Dosing for pediatric patients will be calculated to 5 to 6 mg/kg trimethoprim also given twice daily."
223497584|NCT06129760|DEVICE|Apple Watch|The wearable sensor device is the Apple Watch Series 6 or newer
223497585|NCT04092153|DEVICE|Total knee arthroplasy|Surgical implantation of prosthetic knee using robotic-arm assist
223497586|NCT06482996|OTHER|Intraocular pressure (IOP) was measured|The Frail Scale was used to assess the frailty of the patients.Intraocular pressure (IOP) was measured before anesthesia, 5 minutes after induction of anesthesia and 1 hour postoperatively. IOP was measured using a Tono-pen tonometer (AccuPen). The normal range of IOP is 11-21 mmHg (mean 16 mmHg) and values above 24 mmHg are pathologic.
223497587|NCT02611024|DRUG|Lurbinectedin|lurbinectedin (PM01183) 4 mg vials
223497588|NCT02611024|DRUG|Irinotecan|irinotecan 40 mg, 100 mg or 300 mg vials
223497589|NCT06223516|DRUG|Subcutaneous (SC) ABBV-383|SC Injection
223497590|NCT06223516|DRUG|Intravenous (IV) ABBV-383|IV Infusion
223497591|NCT05955378|DEVICE|DSR Ankle|This is the experimental ankle component used in the overall prosthetic intervention.
224074043|NCT02228863|OTHER|Early Inmotion and Botox|Concomitant use of Inmotion and Botox from the baseline
224074044|NCT02228863|OTHER|Botox, then Inmotion|At baseline Botox injection and 4 weeks after Inmotion
224074045|NCT02228863|OTHER|Inmotion, then Botox|Inmotion from the baseline, then Botox injection at 4 weeks after baseline
224074046|NCT02228863|OTHER|Late Inmotion and Botox|No intervention until 4 weeks from the baseline. Then Inmotion and Botox injection
224074047|NCT04442841|BIOLOGICAL|Hepatitis B vaccine|It may be GSk or MSD vaccine
224074048|NCT04679831|DIETARY_SUPPLEMENT|Ujiplus®|Ujiplus® flour, a nutritional supplement will be used to prepare porridge, and each child will be given a serving of 300 ml every school day for 90 days.
224074049|NCT04679831|DRUG|Praziquantel 400mg|400mg of Praziquantel will be given to each child once at the beginning of the study and maize flour porridge fortified only with micronutrients cooked and served to each child, 300 ml per every school day for 90 days,
224074050|NCT05634395|DEVICE|Activity tracker|"Participants will receive a Withings Steel activity tracker (Withings, Issy-les-Moulineaux, France), which they will be asked to wear 24 hours per day throughout the whole intervention (12 months). At baseline, the Withings Health Mate mobile phone application will be downloaded onto each participant's smartphone or tablet. The clinical research assistant will instruct the participant in the use of the activity tracker. The participant will then accept and activate the sharing of the data collected with the secure server dedicated to the GrannyFit study at the Institut Curie. Participants will be asked to synchronize the activity tracker regularly (ideally daily) via Bluetooth with the Withings Health Mate application, for automatic transfer of the data to the secure GrannyFit space."
224074051|NCT03188445|DRUG|Iron Isomaltoside 1000|Administered iv
224074052|NCT03188445|DRUG|ferrous fumarate with ascorbic acid|Oral administration
224074053|NCT05043467|DRUG|Duvie(Lobeglitazone) tab 0.5mg|patients with type 2 diabetes who received lobeglitazone 0.5mg for more than one year between February 1, 2014 and December 20, 2018
224074054|NCT04024267|OTHER|Eurythmy therapy|Mind-body therapy
224074055|NCT04024267|OTHER|CoordiFit|Fitness training
224074056|NCT04666272|DRUG|dabrafenib|There is no treatment allocation. Patients administered dabrafenib alone by prescription that have started before inclusion of the patient into the study could be enrolled.
224074057|NCT04666272|DRUG|trametinib|There is no treatment allocation. Patients administered trametinib alone by prescription that have started before inclusion of the patient into the study could be enrolled.
224074058|NCT05506059|DIAGNOSTIC_TEST|Ultrasound|Participants will have ultrasounds of the heart by two different emergency medicine doctors.
224074059|NCT01865331|DRUG|insulin degludec|Single dose administered subcutaneously (s.c., under the skin).
224074060|NCT01865331|DRUG|placebo|Administered subcutaneously (s.c., under the skin)
224074061|NCT01865331|DRUG|insulin degludec/insulin aspart 50|Single dose of IDegAsp 50 administered subcutaneously (s.c., under the skin)
224074064|NCT06269679|DIAGNOSTIC_TEST|CBCT|Cone Beam Computed Tomography (CBCT) has a better sensitivity and sensibility to detect OIF.
224074065|NCT02611089|PROCEDURE|Tissue biopsy|Sampling of tissue as described.
224074066|NCT03320759|BEHAVIORAL|Occupational therapy rehabilitation|Participants in the experimental arm will receive occupational therapy that is individualized to each participant's needs from week 4 post-decompression surgery until week 12.
224074067|NCT00455598|DRUG|ISIS 113715|doses of 100 and 200 mg per week
224074068|NCT06970405|DRUG|Garetosmab|Administered per the protocol
224074069|NCT06970405|DRUG|Matching Placebo|Administered per the protocol
224074070|NCT04417478|OTHER|Scaling and root planning|Periodontal debridement was performed in all patients.
224074071|NCT02065752|DRUG|Canagliflozin, 100 mg|Each tablet contains canagliflozin (CANA) of 100 mg to be taken orally (by mouth).
224074072|NCT02065752|DRUG|Metformin XR, 500 mg|Each tablet contains metformin extended release (MET XR), 500 mg, to be taken orally (by mouth).
224074073|NCT02065752|DRUG|CANA/MET XR FDC, Formulation 1, 50 mg/500 mg|Each tablet contains 50 mg of canagliflozin and 500 mg of metformin HCl granulate, formulation 1, in release-controlling polymers to obtain the XR granulation, to be taken orally.
224187937|NCT05276934|DIAGNOSTIC_TEST|Brain computed tomography|This study will use an established local protocol for DCI and intracranial arterial vasospastic stenosis screening, and follow-up to make sure that all patients have the same protocol and don't lose any chance of improvement and good outcome : CT perfusion at different time intervals
224187938|NCT04679116|PROCEDURE|Laparoscopic bilateral inguinal hernia repair|Laparoscopic bilateral inguinal hernia repair
224187939|NCT04679116|PROCEDURE|Open bilateral inguinal hernia repair|Open bilateral inguinal hernia repair
224187940|NCT02062541|OTHER|Funct. assessment+fast rehabilitation|
224187941|NCT02062541|OTHER|Funct. assessment+usual rehabilitation|
224187942|NCT02062541|OTHER|usual assessment+fast rehabilitation|
224187943|NCT03931902|DEVICE|intubation with Endotracheal tube|After masking ventilation with sevoflurane till the adequate anesthetic depth, intubation will be done with endotracheal tube (ETT).
224187944|NCT03931902|DEVICE|intubation with laryngeal mask airway|After masking ventilation with sevoflurane till the adequate anesthetic depth, intubation will be done with laryngeal mask airway (LMA).
224187945|NCT02554084|OTHER|Optical Coherence Tomography|Digital images of tear film
224187946|NCT06060912|DEVICE|Left Atrial Appendage Occlusion|Left Atrial Appendage Occlusion will be performed according to current international standards by experienced operators under TOE and angiographic guidance. Either a LAmbre occlusion device (group A) or an AMPLATZER Amulet occlusion device (group B) will be implanted depending on treatment allocation.
224187947|NCT03628781|OTHER|Behavioral tools integrated within mehealth for ADHD software|Integrated functionality within the mehealth for ADHD software allows parents and teachers to set up and deliver behavioral interventions such as daily report card systems and home-based program such as star charts. Automated wizards lead parents and teachers through the process of selecting target behaviors and setting up reward schedules. Baseline data is gathered online and algorithms derive a set of behavioral goals for the child. Thereafter, parents or teachers record the child's performance directly into the software. Once behavioral monitoring begins, parents and teachers receive daily email or text communications from mehealth for ADHD alerting them to the daily rewards earned by their child. Finally, online algorithms exist that detect how a child is doing in meeting behavioral goals and prompt users to modify goals accordingly.
224187948|NCT03628781|OTHER|mehealth for ADHD|"The mehealth for ADHD software has multiple functionalities including 1) online training regarding the American Academy of Pediatrics (AAP) ADHD guidelines; 2) an ADHD workflow wizard that guides pediatricians through the creation of an efficient office workflow to deliver quality ADHD care; 3) online collection of parent- and teacher-report ADHD rating scales for the assessment of ADHD as well as monitoring response to medication treatment; 4) integrated algorithms that automatically score rating scales in real time and provide pediatricians with assessment and treatment reports as well as immediate warnings; 5) a communication feature that allows parents, teachers, and pediatricians to communicate with each other; 6) an online pediatrician report card; and 7) a Plan-Do-Study-Act wizard that allows pediatricians to select a practice behavior to improve based on their report card and guides them through the creation of small tests of change to improve their office systems."
224187949|NCT00656669|DRUG|sunitinib alone|sunitinib alone (segment 1): During the first segment, patients will receive single-agent sunitinib for 2 weeks.
224187950|NCT00656669|DRUG|sunitinib plus paclitaxel|sunitinib plus paclitaxel (Segment 2): Following Segment 1, patients will begin the second segment, 4 cycles (16 weeks) of neoadjuvant treatment with the combination of sunitinib and paclitaxel.
224187951|NCT00656669|DRUG|doxorubicin and cyclophosphamide|doxorubicin and cyclophosphamide (Segment 3): Following Segment 2, patients will receive 4 cycles (8 weeks) of neoadjuvant treatment with AC.
223497592|NCT05955378|DEVICE|Predicate Ankle|This is the participant's prescribed ankle/foot complex used in the overall prosthetic intervention.
223497593|NCT02922036|DEVICE|WiSE System|The WiSE System is an implantable cardiac system to provide LV pacing stimulation in conjunction with a co-implanted system that provides right ventricular stimulation.
223497594|NCT00221104|DRUG|Pravastatin|
223497595|NCT02989389|DRUG|LY3323795|Administered orally
223497596|NCT02989389|DRUG|Itraconazole|Administered orally
223497597|NCT02989389|DRUG|Placebo|Administered orally
223497598|NCT00766818|DRUG|Kaletra|Kaletra 400/100mg BID, then increase at 30weeks to 500/125mg BID
224187952|NCT03541408|OTHER|Control|Standard Of Care without Preventative Delirium Protocol
224187953|NCT03541408|OTHER|Preventative Delirium Protocol|Preventative Delirium Protocol
224187954|NCT05865002|DRUG|AUR107|Once daily
224187955|NCT03778021|BEHAVIORAL|Behavioral Gardening Exposure|Assistance provided with planting and maintaining the school garden
224187956|NCT03778021|BEHAVIORAL|Healthy Eating and Gardening Curriculum|14 to 17 lessons (about 45 minutes each) throughout the school year, during the normal school day, that are focused on healthy eating and gardening, coordinated with the growing season
224187957|NCT04859959|DIAGNOSTIC_TEST|Gallium-68 Pentixafor PET/CT|Intravenous injection of one dosage of 74-222 MBq (2-6 mCi) Gallium-68 Pentixafor. Tracer doses of Gallium-68 Pentixafor will be used to image adrenal lesions by PET/CT.
223497599|NCT04857177|DRUG|CKD-701|CKD-701 (proposed ranibizumab biosimilar) 0.5mg via intravitreal injection every one month during the loading phase, and intervals of one month based on criteria during the PRN phase.
223497600|NCT04857177|DRUG|Lucentis®|Lucentis® (ranibizumab) 0.5mg via intravitreal injection every one month during the loading phase, and intervals of one month based on criteria during the PRN phase.
223497601|NCT04470427|BIOLOGICAL|mRNA-1273|Sterile liquid for injection
223497602|NCT04470427|BIOLOGICAL|Placebo|0.9% sodium chloride (normal saline) injection
223497603|NCT00164723|PROCEDURE|Capsule endoscopy|Capsule endoscopy and colonoscopy
223497604|NCT03682640|DRUG|Azithromycin Monohydrate|Azithromycin Monohydrate tablet (Azithromycin Sandoz) or oral suspension (Azithromax).
223497605|NCT03682640|DRUG|Insulin Lispro|Solution for intravenous or subcutaneous use
223497606|NCT03682640|BEHAVIORAL|Dietician support|Dietary advice
223497607|NCT01766284|DEVICE|NIRIS 1300e|Optical coherence tomography (OCT) is similar to ultrasound pulse-echo imaging, with optical scatter rather than acoustic reflectivity being measured. OCT employs harmless near-infrared light technology which uses low coherence interferometry to produce an image (based on optical scattering) of tissue microstructure.
224187958|NCT02081352|OTHER|DermaPure™|"A minimally manipulated human tissue regulated as human cells, tissues, and cellular and tissue-based products (HCT/Ps)"
224187959|NCT02081352|OTHER|Standard care|
224187960|NCT01545375|BIOLOGICAL|Pneumococcal vaccine GSK2189242A|4 doses administered intramuscularly
224187961|NCT01545375|BIOLOGICAL|Placebo|4 doses administered intramuscularly
224187962|NCT01545375|BIOLOGICAL|Prevnar 13®|4 doses administered intramuscularly
224309111|NCT04787874|BEHAVIORAL|Prehabilitation Program|"Nutrition component: Participants will receive information on how to follow a healthy diet (Mediterranean-style diet) with emphasis on whole foods, plants, lean protein, olive oil; restriction of red meats, processed meats, processed foods, added sugar)~Exercise component: Participants will receive an activity tracker to use during the study period (3+ weeks before surgery, and 30 days after surgery). Participants will be assigned strength exercises to work on core strength and proximal muscle strength (biceps/triceps, quads, hamstrings, calves).The exercises will mainly be focused on strengthening the abdominal wall. Exercises will be tailored to patients' individual capabilities. They will also be assigned cardio exercises - either low-intensity steady state cardio vs High Intensity Interval training. Level of cardio exercise will be tailored based on patient's Duke Activity score and baseline activity."
224309112|NCT01240213|DIETARY_SUPPLEMENT|Vitamin D|2000 IU per day of Vitamin D
224309113|NCT01240213|DIETARY_SUPPLEMENT|Placebo|1 Placebo per day
224309114|NCT04993014|DRUG|Pertuzumab|Adjuvant trastuzumab + pertuzumab (arm B of the 2 cohorts: 1: HER2 positive CTCs at baseline and 2: HER2 negative/absent CTCs at baseline)
223497608|NCT04490707|DRUG|Azacitidine|Elderly or unfit for intensive therapy patients with acute myeloid leukemia who had entered CR receive maintenance therapy contained Azacitidine
223497609|NCT04490707|DRUG|Lenalidomide|Elderly or unfit for intensive therapy patients with acute myeloid leukemia who had entered CR receive maintenance therapy contained Lenalidomide
223497610|NCT04041518|PROCEDURE|Autotransplantation|Autotransplantation of tooth with an almost fully or completely developed root with intraoperative extraoral apicoectomy.
223497611|NCT03415269|DRUG|Ambroxol Hydrochloride|single lozenge of 20mg ambroxol
223497612|NCT01855906|PROCEDURE|Gap balanced surgical technique|Gap balanced surgical technique
223497613|NCT01855906|PROCEDURE|Measured resection|Measured resection surgical technique
223497614|NCT00745160|OTHER|blood sample and questionnaire|After giving informed consent, all patients will be asked to complete questionnaire and will be asked to provide a blood sample for DNA analysis. The questionnaire will consist of a detailed smoking questionnaire, based on the most recent Centers for Disease Control and Prevention (CDC) Behavioral Risk Factor Surveillance System Survey Questionnaire.
223497615|NCT00872157|DRUG|BMTP-11|Starting Dose of 6 mg/m2 by vein over 2 hours on Days 1, 8, 15, and 22.
223497616|NCT04984408|BIOLOGICAL|BBIBP-CorV - Inactivated SARS-CoV-2 vaccine (Vero cell)|"* The Inactivated SARS-CoV-2 vaccine (Vero cell)- BBIBP-CorV manufactured by Beijing Institute of Biological Products (BIBP), China National Biotec Group (CNBG), Sinopharm, Beijing, People's Republic of China~* Dose formulation: A liquid formulation containing 4μg total protein with aluminum hydroxide adjuvant (0·45 mg/mL) per 0·5 mL (2-dose schedule followed by a booster dose).~* Mode of Administration: Intramuscular~* Storage Conditions: 2 to 8 degree Celsius"
224187963|NCT01545375|BIOLOGICAL|PedvaxHIB®|4 doses administered intramuscularly
224187964|NCT00707252|DRUG|Polyphenon E|Patients will be assigned to 3 sequential cohorts of three different dose levels of Polyphenon E (providing 200, 400 and 800mg of Polyphenon E given once daily) in a step-wise manner.
224187965|NCT00707252|DRUG|Tarceva|All patients will also receive Erlotinib 150mg po/day from Day 1.
224187966|NCT00679042|BIOLOGICAL|Islets of Langerhans transplantation|"Each subject may receive 1-3 transplantations of allogeneic human islets of Langerhans and the following medications:~Basiliximab 20 mg iv 2 hours before transplant and 20 mg iv 2 weeks post-transplant; Tacrolimus 1 mg p.o. bid adjusted to reach target trough levels of 3-6 ng/ml; Sirolimus 0.2 mg/kg loading dose, then 0.1 mg/kg p.o. daily adjusted to reach target trough levels of 10-15 ng/ml during the first 3 months post transplant and 7-10 ng/ml thereafter; Etanercept 50 mg iv 1 hour before transplant and 25 mg s.c. on days 3, 7,and 10 post-transplant; Exenatide 5-mcg s.c. bid for 1 week, then 10 mcg bid for 6 months after each transplant"
224187967|NCT03770806|PROCEDURE|Femoral Nerve Block|Standard Ultrasound-guided peri-neural femoral nerve block with Ropivacaine 0.5% and Dexamethasone 6-8mg.
224187968|NCT03770806|PROCEDURE|Adductor Nerve Block|Standard Ultrasound-guided peri-neural adductor nerve block, mid-thigh, with Ropivacaine 0.5% and Dexamethasone 6-8mg
224309115|NCT04993014|DRUG|Trastuzumab|Adjuvant trastuzumab (arm A of the 2 cohorts: 1: HER2 positive CTCs at baseline and 2: HER2 negative/absent CTCs at baseline) Association with pertuzumab in arm B of the 2 cohorts
224187969|NCT03770806|OTHER|No Block|routine iv and oral pain medication alone-observation only
224187970|NCT06539793|OTHER|Aerobic Exercises|Treadmill 20 minutes including 5 minutes warm up and 5 minutes cool.
224187971|NCT06539793|OTHER|Transcutaneous electrical nerve stimulation|"will be applied for all patients, which uses an asymmetrical biphasic alternating current in the continuous mode (pulse duration 100 µs, low frequency). TENS intensity will increase slowly, and patients will be instructed to indicate sensory threshold (ST); then, the intensity are going to increase until the sensation perceived as strong but comfortable (SC1). The duration will be for 30 minutes, 3times/ week for 4 weeks"
224309116|NCT04993014|OTHER|Circulating tumor cells|Blood sample collection for examination of CTCs at baseline of neoadjuvant therapy. Tests for HER2 positivity will be done.
224309117|NCT00804713|DRUG|BST|0.1 mcg/mL (1 dose) Battey skin test (BST) antigen administered using the Mantoux method.
223497617|NCT04984408|BIOLOGICAL|influenza season quadrivalent Influenza Vaccine (Flu Quadrivalent)|"* The southern hemisphere for the 2021 influenza season quadrivalent Influenza Vaccine (Flu Quadrivalent)~* Dose formulation: Purified Inactivated Influenza Virus Antigen H1N1, H3N2, Yamagata and Victoria (single dose, 0.5ml for adults)~* Mode of Administration: Intramuscular~* Storage Conditions: 2 to 8 degree Celsius"
223497618|NCT02635035|DRUG|Lisdexamfetamine|Vyvanse (Lisdexamfetamine Dimesylate) manufactured by Shire, is a Drug Enforcement Administration (DEA) class two,sympathomimetic amine, used for the treatment of attention-deficit hyperactivity disorder. The initial adult dosage is 30mg with allowed adjustments in increments of 10mg or 20mg at weekly intervals. Subjects are initiated on these doses and then they were titrated up by 20mg with a maximum dose of 70mg.
224187972|NCT04357756|DRUG|YH001|YH001 will be administered intravenously every three weeks (Q3W) for 15 weeks (5 cycles) at doses of Dose A, Dose B, Dose C, Dose D, Dose E, Dose F and Dose G.
223497619|NCT02635035|DRUG|Placebo|Placebo looks just like Vyvanse but has no active ingredients, like a sugar pill.
223497620|NCT01403584|DEVICE|AutoVPAP with addition of AutoEPAP|Implementation of automated algorithm for adjustment of conventional device parameter (EPAP0.
223497621|NCT01403584|DEVICE|AutoVPAP with EPAP manually selected|Conventionally applied Expiratory Positive Airway Pressure (EPAP)
223497622|NCT04913636|DEVICE|Treatment Gel|In the evening subjects will perform their regular denture cleaning routine. They will be instructed to sleep without dentures. Subjects will rinse out their mouth with water (if subjects brush their oral mucosa with brush, they will be allowed to continue doing so) and apply the gel to their mucosa where they normally wear upper or lower denture.
223497623|NCT04913636|OTHER|Sham Control|Subjects will perform their regular denture cleaning routine.
223497624|NCT04464447|BEHAVIORAL|Acceptance and Commitment Therapy|"The treatment ACT for Health in Adolescents (AHEAD) is an ACT-based Group intervention consisting of 9 modules (27 hours in total) delivered over a period of 3 months, with a follow-up meeting (3 hours) 3 months after the last module. Six to eight patients participate in each treatment Group. An information meeting (3 hours) for close relatives is held at the beginning of the Group treatment and the adolescents and their parents were invited to a 1½-hour individual consultation after the 8th module."
223497625|NCT01526382|DEVICE|PiCCO monitoring (PULSION)|Patients are monitored with PiCCO system.
223497626|NCT01526382|PROCEDURE|central venous catheter|patients in this arm can receive central venous catheter
223497627|NCT02763995|BEHAVIORAL|Pharmaceutical care|This is a quasi-experimental study and the same group will be evaluated before and after the follow up.
223497628|NCT06165874|RADIATION|[68Ga]Ga-NOTA-RW102 PET Imaging|Intravenous injection of 1.8 MBq\[0.05MCi\]/kg of \[68Ga\]Ga-NOTA-RW102 in a single dose.
223497629|NCT00474565|PROCEDURE|Placement of an aortic root pigtail catheter.|Seldinger technique for placement of catheter.
223497630|NCT03543774|DRUG|Simvastatin 40mg|Simvastatin mono-therapy at the dose of 40 mg/day for 12 months
223497631|NCT03543774|DRUG|Ezetimibe/simvastatin 10/20 mg/day|Ezetimibe/simvastatin combined therapy at the dose of 10/20 mg/day for 12 months
223497632|NCT03543774|DRUG|Ezetimibe/simvastatin 10/40 mg/day|Ezetimibe/simvastatin combined therapy at the dose of 10/40 mg/day for 12 months
223497633|NCT02247856|OTHER|Noninvasive ventilation|Bilevel positive pressure (BiPAP Synchrony, Respironics®, Murrysville, Pennsylvania, USA) was applied through face mask (Comfort Full 2, Respironics®, Murrysville, Pennsylvania, USA) attached with straps and pressure adjusted were 12 cmH2O of inspiratory pressure and 5 cmH2O of expiratory pressure after a period of adaptation before beginning the procedure to avoid ventilator-patient asynchrony
223497634|NCT02247856|DEVICE|Jet Nebulizer|"Both nebulizers were charged with 2.5 mg of salbutamol and 0.25 mg of ipratropium bromide and 3 mL of saline solution was added to complete 3 Ml. JN (Mist yMax, Air Life, Yorba Linda, USA) was positioned in the circuit using a T piece, particle size generation in a 5 µm range (according to the manufacturer information) and flow oxygen tritated at 8 L/min"
223497635|NCT02247856|DEVICE|Vibrating Mesh Nebulizer (VMN)|Both nebulizers were charged with 2.5 mg of salbutamol and 0.25 mg of ipratropium bromide and 3 mL of saline solution was added to complete 3 Ml. VMN (Aeroneb Solo, Galway, Ireland) was positioned in the mask using an elbow (Elbow Kit, Respironics®, Murrysville, Pennsylvania, USA), particle size generation in a 1 µm and connected to electrical energy.
223497636|NCT00318864|BEHAVIORAL|Cognitive behavioral therapy|
223590308|NCT01972698|OTHER|Self-directed and simulation-assisted training|"All participants will attend an ultrasound introductory course (lectures and illustrative interactive cases).~Participants randomized to the intervention group will undergo a completely self-directed lung and focused cardiac ultrasound curriculum.~* A set of video-lectures on how to perform US on a critically ill patient (video-tutorials on image acquisition, troubleshooting, and pitfalls) will be provided.~* Participant will have access to an ultrasound simulator.~* Finally, participants in the intervention group will be asked to perform self-directed lung and focused cardiac ultrasound examinations on critically ill patients.~An investigator will supervise the sessions but will not interfere with the self-learning process.~\- To support their learning, trainees will have access to on-line virtual FCU and LUS modules created by the Toronto General Hospital Department of Anesthesia Perioperative Interactive Education (http://pie.med.utoronto.ca/TTE/index.htm)."
223745936|NCT05779878|OTHER|Myofascial arm pull technique|Myofascial therapy is described as the promotion of psychophysiological, neurological and structural adaptive capability as multiplexed via the myofascial system. Fascia covers all body structures, particularly muscles and their constituent myofibrils
224187973|NCT04357756|DRUG|Toripalimab|Toripalimab will be administered by intravenously (Q3W) by the fixed dose of 240 mg from the 2nd cycle to 5th cycle.
224309118|NCT00804713|DRUG|TST|Administer TB Skin test (TST)
223497637|NCT03718260|DIAGNOSTIC_TEST|[18F]-DCFPyL PET/ CT scan (PSMA PET)|Participants will undergo re-staging with \[18F\]-DCFPyL PET/CT Scan (PSMA PET).
223497638|NCT04259489|BEHAVIORAL|Shared Care diabetes management|After the inclusion visit, the patients will be randomized to Shared Care group or traditional therapy group. Compared to conventional diabetes education in the traditional therapy group, the Shared Care group provides patients with online services and continuous diabetes management and education through a mobile application. It also addresses that it is important for patients to meet regularly with diabetes multidisciplinary team for better results. The total observation period is 3 years for each patient. The visits will be done every 3 months.
223497639|NCT03408145|DEVICE|Hyaluronic Acid|Injection of 3x 2.5ml of Hyaluronic Acid
224187974|NCT04001478|DIAGNOSTIC_TEST|Breath test|Patients will provide a breath test prior to gastroscopy or resection of Barrett's HGD lesion or oesophageal cancer.
224187975|NCT02991911|BIOLOGICAL|MEDI3726 Post-Chemo|Single agent MEDI3726 after abiraterone or enzalutatmide, with a prior taxane-based chemotherapy in the mCRPC setting
224187976|NCT02991911|BIOLOGICAL|MEDI3726 Pre-Chemo|Single agent MEDI3726 after abiraterone or enzalutatmide, without a prior taxane-based chemotherapy in the mCRPC setting
224309119|NCT00804713|OTHER|QFT|Perform QFT TB test
224309120|NCT00804713|OTHER|T-spot|Perform T-Spot TB test
224309121|NCT01214915|DRUG|Anagrelide Hydrochloride|Subjects will be started at 1.0 mg per day and titrated as necessary.
224187977|NCT02991911|BIOLOGICAL|MEDI3726 & Enzalutamide Combo|MEDI3726 in combination with Enzalutatmide after prior treatment with abiraterone, with or without a prior taxane-based chemotherapy in the mCRPC setting
224187978|NCT00807651|PROCEDURE|AHSCT|All study participants given written informed consent will perform autologous hematopoietic stem cell transplantation(AHSCT) and be treated with immunosuppression.
224187979|NCT00807651|DRUG|Insulin therapy|All study participants not accepted written informed consent will received insulin therapy with consistent or multiply subcutaneous injection.
224187980|NCT05152498|DRUG|Fu Zheng Jie Du Hua Yu therapy|Fu Zheng Jie Du Hua Yu is a Chinese herbal compound
224187981|NCT01393574|DRUG|Melatonin|3 mg for body weight \<40kg, 6 mg for body weight \>40kg, once a day 30-60 minutes before sleep
224187982|NCT01393574|DRUG|Methylphenidate|Drug formulary and dose will be decided by the treating neurologist from the available options in Israel (as would be given if not participating in the trial)
224187983|NCT05174429|BEHAVIORAL|Risk-Targeted Behavioral Activation|"The behavioral activation component of the treatment program focused on goal setting, structuring and scheduling activities, increasing success and achievement experiences, and problem-solving. In order to maximize the impact of behavioral activation on disability reduction, goal setting and scheduling of activities focused primarily on resumption of discontinued activities as opposed to focusing on the scheduling of pleasant activities. One objective of goal setting and activity scheduling was to reduce the discrepancy between the client's pre-injury activity repertoire and the client's current activity repertoire.~Behavioral activation was supplemented by a collection of techniques designed to reduce catastrophic thinking and perceptions of injustice, two psychosocial risk factors that have been shown to contribute to prolonged work-absence."
224309122|NCT04784754|DRUG|Melatonin|Melatonin capsules will be prepared using hypromellose capsules containing 3 mg or 30 mg of the active component and identical excipient (Microcrystalline Cellulose) used in the placebo preparation. Melatonin will be administered orally three times a day for 14 days.
223497640|NCT03408145|DEVICE|Amniotic Tissue Allograft|Injection of 1x 1ml of Amniotic Tissue Allograft
223497641|NCT03408145|DRUG|Saline|Injection of Saline
223497642|NCT03412890|DRUG|Relugolix|Relugolix 40-mg tablet administered orally once daily
224187984|NCT04141566|PROCEDURE|Perineal pseudocontinent colostomy|"The procedure is performed in 2stages: as a usual APR starting by a laparoscopic approach esnsuring a complete mesorectal excision,then a perineal approach ensuring an extended excision of the entire internal and external sphincter complex, allowing the excision of the specimen.~8to10cm of tof the colon is resected and harvested as a free graft, stripped of its meso and epiploics , then from its mucosa and placed in an antibiotic solution for 10min. This graft is wrapped snugly around the end of the colon 2-3 cm from its distal end for 1 and a half round. Absorbable 3.0 Sutures are taken to hold it in place. The end of the colon is brought out as a stoma in the perineum.~Colonic irrigations are started from the third day according to the protocol previously reported. Patients and one of their family members are daily educated and assisted while performing colonic irrigations by specialized nurses."
223497643|NCT03412890|DRUG|Estradiol/norethindrone acetate|Capsule containing co-formulated tablet of E2 (1 mg) and NETA (0.5 mg) administered orally once daily
223497644|NCT04131192|DRUG|Z650|250 or 300 or 200 mg/d, starting on the 2nd day, once a day, continuous administration, or about half an hour after a meal
223497645|NCT04131192|DRUG|Gemcitabine|Gemcitabine will be administered intravenously at 1000 mg/m2 on Days 1, 8, of a 21-day cycle ，for 4-6 cycles
223497646|NCT05320588|DRUG|BIO-106|BIO-106 is a novel antibody-drug conjugate (ADC) that targets the human trophoblast cell surface antigen 2 (Trop-2)
223497647|NCT05320588|DRUG|Pembrolizumab|Programmed death receptor-1 (PD 1)-blocking antibody
223497648|NCT02342951|OTHER|Lung clearance index determination|Lung clearance index determination
223497649|NCT05389839|DEVICE|Wechat program|The experimental group used wechat program to calculate insulin dose to guide insulin treatment .
223497650|NCT05582603|BEHAVIORAL|CCT Long COVID|A 15-day training protocol in which every 48 hours participants' complete a series of different cognitive tasks in the form of games selected among a pool of 12 games from CogniFit (CogniFit Inc., San Francisco, USA) whose difficulty level is tailored to each individual by the a patented Individualized Training System™ (ITS) software that automatically chooses the activities and difficulty levels for each person in every session.
223497651|NCT00515593|DRUG|Parathyroid hormone (PTH) (Preotact)|Patients with severe postmenopausal osteoporosis
223745937|NCT02778997|PROCEDURE|CSF Shunt treatment for hydrocephalus|State after CSF shunt implantation
224187985|NCT04141566|PROCEDURE|Permanent left iliac colostomy|After a usual laparoscopic APR, the perineal wound is closed and a permanent left iliac colostomy is performed
224187986|NCT00735748|DRUG|Tramadol per os (Tradonal Odis® orodispersible tablets)|Administration of 1 unit dose of 50 mg tramadol perorally given in 3 unit dosages
224187987|NCT00735748|DRUG|Tramadol IV (Tradonal® IV)|Administration of tramadol IV given in 3 unit dosage of 35 mg
224187988|NCT00739830|DRUG|ridaforolimus|40 mg once daily oral tablets for 5 days followed by 2 days without ridaforolimus
224187989|NCT00739830|DRUG|medroxyprogesterone acetate tablets OR megestrol acetate|oral medroxyprogesterone acetate tablets 200 mg daily OR oral megestrol acetate tablets 40 mg 4 times per day (160 mg daily)
224187990|NCT00739830|DRUG|chemotherapy|Chemotherapy - carboplatin, paclitaxel, doxorubicin, pegylated liposomal doxorubicin or topotecan administered as a single agent or as a doublet, and will be administered at doses and schedules chosen by the investigator
224187991|NCT03418025|BEHAVIORAL|Exercise Intervention|Undergo Exercise Together intervention
224187992|NCT03418025|OTHER|Questionnaire Administration|Ancillary studies
224187993|NCT03418025|OTHER|Survey Administration|Ancillary studies
224187994|NCT04383925|BIOLOGICAL|BCG-Japan|Infant (\<1 year) 0.05 ml dose of resuspended BCG-Japan (Tokyo strain 172, Japan BCG Laboratory, 1-5-21 Otsuka, Bunkyo-ku, Tokyo, 112-0012 Japan).
224187995|NCT04383925|BIOLOGICAL|BCG-Russia|Infant (\<1 year) 0.05 ml dose of resuspended BCG-Russia (Serum Institute of India)
224309123|NCT04784754|DRUG|Placebo|Placebo capsules will be prepared using hypromellose capsules, filled using microcrystalline cellulose. This is the same excipient used in the preparation of the interventional drug. Placebo will be administered orally three times a day for 14 days in the same regimen used for the intervention.
224309124|NCT02318238|OTHER|6 minutes walking test|
224309125|NCT02318238|OTHER|6 minutes step test|
224187996|NCT01156974|BEHAVIORAL|education and care guide|Patients receive education about care goals, and in-person and telephone counseling of unspecified frequency over one year to achieve goals
224187997|NCT01156974|BEHAVIORAL|education only|patients receive education about care goals
224187998|NCT01846039|DEVICE|Crosslinked hyaluronic acid gel|Up to 3 mL administered by intradermal injection
224187999|NCT00207025|DRUG|BMS-275183|
224188000|NCT04087486|DIAGNOSTIC_TEST|Implementation of a behavioural test for patients with TBI|"The following data will be collected: (1) sociodemographic variables (2); clinical and psychological data; (3) functional tests (neuropsychological testing, TEM version CRR and TEM-PRO).~On day one, patients will undergo standard neuropsychological tests and questionnaires listed hereafter, which are commonly used in the clinical practice at the CRR.~* The Patient Competency Rating Scale (PCRS)~* TEM (Multiple errands test)~* GREFEX~* 5 POINTS TEST~* TAP 2.3~* Behavioral Assessment of the Dysexecutives Syndrome (BADS)~On day two, the patients will perform the TEM-PRO test ambulatory in our vocation rehabilitation unit.~Predictors variables will be collected before testing: Sociodemographic: age, sex, education, marital status, mother language, time since TBI, severity of the TBI (moderate or severe), type of lesion (contusion, diffuse axonal injury grade 1-3, ischemic or other complications), history of TBI, stroke or meningitis."
224188001|NCT01980186|DEVICE|TUS transcranial 2D ultrasound|
224188002|NCT01719263|DEVICE|InterVapor® treatment plus Optimal Medical Therapy|Patients will be treated with the InterVapor System in 1 to 2 segments in the upper lobes of each lung (2 to 3 segments total). Patients will also receive Optimal Medical Therapy. Guidelines for prescribing medical treatment for emphysema are published by the American Thoracic Society (ATS) and the National Heart Lung and Blood Institute/World Health Organization (NHLBI/WHO GOLD workshop summary).
224188003|NCT01719263|OTHER|Optimal Medical Therapy|Patients will receive Optimal Medical Therapy. Guidelines for prescribing medical treatment for emphysema are published by the American Thoracic Society (ATS) and the National Heart Lung and Blood Institute/World Health Organization (NHLBI/WHO GOLD workshop summary).
224188004|NCT02558634|DEVICE|VIM Thalamic Deep Brain Stimulation ON|
224188005|NCT02558634|DEVICE|VIM Thalamic Deep Brain Stimulation OFF|
224188006|NCT05248919|DRUG|Epclusa (nucleotide HCV NS5B polymerase inhibitors).|Sofosbuvir (400mg/day) and Velpatasvir(100mg/day) for 12 weeks or 24 weeks
224188007|NCT02027246|BIOLOGICAL|Autologous bone marrow mononuclear cell transplantation|Bone marrow is aspirated by a standard procedure. Mononuclear cells are separated by density gradient method and then injected intrathecally by a standard lumbar puncture procedure
224188008|NCT02355314|OTHER|Doppler-based renal|Doppler-based renal : day 0 and day 3
224188009|NCT02355314|BIOLOGICAL|blood sample and urine sample|blood sample and urine sample : day 0 and day 3
224188010|NCT03333564|DIETARY_SUPPLEMENT|VD3|50,000 IU VD3 / week for 8 weeks
223497652|NCT01642160|BEHAVIORAL|additional educational material|The internet-based intervention group would receive a weekly text or an email (based on the subject's preference). The content of the message asks about their approximate compliance over the past week. Based on their response, they will be directed to one of two internet web pages.
223497653|NCT01642160|BEHAVIORAL|Standard of care|participants will receive education from staff nurses as needed.
223497654|NCT02941952|DEVICE|Cardiac output and stroke ejection volume monitoring with both ClearSight® and PICCO® in major abdominal surgery.|
223497655|NCT05756478|OTHER|Medication review|This is a feasibility study of implementing a pharmacist-led medication review using prescribing tools (e.g. STOPP/START, Beers Criteria)
223497656|NCT02450474|DEVICE|Intermittent pneumatic compression device|Flowtron, Circulation Booster and Sports XL devices will be used.
223497657|NCT02450474|DEVICE|Neuromuscular electrical stimulation|Flowtron, Circulation Booster and Sports XL devices will be used.
223497658|NCT01356056|DEVICE|Kinesia HomeView|Quantifies motor symptom severity in the home
223745938|NCT04324801|OTHER|Homeostatic plasticity induction using transcranial direct current stimulation|Homeostatic plasticity will be induced in the left primary motor cortex using tDCS applied for 7 minutes followed by an interval of 3 minutes and another block of 5 minutes of stimulation
223745939|NCT05409781|OTHER|No Intervention|No Intervention
224188011|NCT03333564|DIETARY_SUPPLEMENT|Omega3-FA|300 mg of omega3-FA once daily for 8 weeks
224188012|NCT03333564|DIETARY_SUPPLEMENT|VD3 and Omega-3FA|50,000 IU VD3 / week for 8 weeks and 300 mg of omega-3FA once daily for 8 weeks
224188013|NCT03333564|OTHER|Control|No intervention was given
224188014|NCT02231606|OTHER|Free Glasses|Provide free glasses
224188015|NCT02231606|OTHER|Upgrade Glasses 1|Provide optional purchase from range of spectacles, cheapest RMB100 (Mean price paid for glasses by Control families in Seeing is Learning I, subtracting one SD)
224188016|NCT02231606|OTHER|Upgrade Glasses 2|Provide optional purchase from range of spectacles, cheapest RMB200 (Mean price paid for glasses by Control families in Seeing is Learning I, adding one SD)
224188017|NCT03224169|BEHAVIORAL|Directly observed hand hygiene|Directly observed hand hygiene to the residents and staff
224188018|NCT03964896|OTHER|Survey|Complete survey
224188019|NCT03964896|OTHER|Survey Administration|Ancillary studies
224188020|NCT03964896|BEHAVIORAL|Telephone-Based Intervention|Receive telephone calls
224188021|NCT04061837|DEVICE|MitralStitch|With transesophageal echocardiographic guidance,implanting ePTFE sutures as artificial chordae or ege-to-ege repair using MitralStitch Mitral Valve Repair System
224188022|NCT03771391|DIETARY_SUPPLEMENT|PKU Sphere|PKU sphere is a powdered, low phenylalanine protein substitute containing a balanced mix of casein glycomacropeptide (GMP) isolate, essential and non-essential amino acids, carbohydrate, vitamins, minerals and docosahexaenoic acid (DHA). With sugar and sweetener.
224188023|NCT00632866|DRUG|Hydroxychloroquine|Hydroxychloroquine : 200mg / day since 24 weeks
224188024|NCT00632866|DRUG|Placebo|Placebo : 2cp/ day since 24 weeks
224188025|NCT00247416|DRUG|Gemcitabine|Gemcitabine 1000 mg/m\^2 intravenously over 30 minutes on days 5 and 12.
224188026|NCT00247416|DRUG|Dexamethasone|16 mg bid for 4 days prior to each chemotherapy start.
224188027|NCT00247416|DRUG|Carboplatin|AUC 6.0 intravenously over 30 minutes on day 5.
224188028|NCT04734366|PROCEDURE|"Uterine closure with Baseball suture technique"|"A simple running (continuous) baseball suture is essentially an interrupted sutures. Applied as inside to outside/inside to outside of incision."
224309126|NCT02318238|OTHER|4 meters gait speed|
224309127|NCT03155945|DRUG|Olorinab|Olorinab active treatment for 8 weeks.
224309128|NCT00810576|DRUG|Vorinostat|Dose of 200 mg by mouth twice daily on days 1-14 of each 21-day study.
224309129|NCT00810576|DRUG|Bortezomib|Dose of 1.3 mg/m\^2 by vein on days 1, 4, 8, and 11 of a 21 day cycle.
224309130|NCT01090830|DRUG|Belinostat, carboplatin, paclitaxel and bevacizumab|"Induction therapy will include 6 cycles of 5-days of medication administration followed by a 16 day rest period. Belinostat will be given once a day for 5 days total. Three dose levels will be evaluated (600mg/kg, 800 mg/kg, and 1000 mg/kg). In addition, participants will receive fixed doses of intravenous carboplatin (AUC 6), Paclitaxel (200 mg/m2), and bevacizumab (15 mg/kg) once on day 3 of each cycle. Serial disease status evaluations will be done throughout the study.~In the absence of significant toxicity or disease progression, participants may continue with a maintenance regimen of bevacizumab and Belinostat for an additional 6 cycles. The dose of Belinostat received during maintenance will be that tolerated in the initial 6 cycles."
224309131|NCT04719260|BEHAVIORAL|Nutrition Thinking®|In the first session, the nutritionist will carry out the anamnesis through the Empathy Map and assessment of the nutritional status to define the Nutrition Briefing. The steps described by Design Thinking as understanding, observation, and point of view comprise the first phase of this session. The ideation process will proceed from the definition of the Nutrition Challenge. Prototyping is the final stage of the first session, where an initial prototype of the diet will be co-created based on visual thinking tools and the description underlying the creation of diets. Within 24 hours the individual will receive a summary of the material developed by email. The period between sessions will comprise the testing phase and the follow-up sessions the iteration phase where the experience and previous steps are revisited in order to create new insights, anthropometric measurements will be seen as reflections of the experience and not as primary outcomes of the intervention.
224309132|NCT04719260|BEHAVIORAL|Standard Nutritional Approach|In the first session the nutritionist will carry out the food and nutritional anamnesis and assessment of the nutritional status. From this information, the nutritionist will generate the diagnostic hypothesis and determine the specific nutritional needs. The professional will be responsible for generating the dietary prescription defining the characteristics of the diet that will be delivered printed to the individual after a period of 15 days, in the second session of the protocol. The follow-up session will be based on adherence to the established conduct and monitoring of anthropometric variations.
224309133|NCT00661011|PROCEDURE|Lobectomy followed by concomitant mediastinal chemoradiotherapy|Lobectomy Radiotherapy 66 Gy in 2 Gy/ fraction, 5 fractions/wk Chemotherapy Cisplatin 60 mg/m² on days 1 and 22 and Vinorelbine 15 mg/m² on days 1, 8, 22 and 29
224309134|NCT05224934|RADIATION|ultra-hypofractionated radiotherapy|stereotactic ablative radiotherapy with 25 to 50Gy in five fractions given preoperatively
224074074|NCT02065752|DRUG|CANA/MET XR FDC, Formulation 2, 50 mg/500 mg|Each tablet contains 50 mg of canagliflozin and 500 mg of metformin HCl granulate, formulation 2, in release-controlling polymers to obtain the XR granulation, to be taken orally.
224309135|NCT06945926|DRUG|oxytocin nasal spray|Cases were included according to the inclusion and exclusion criteria, and induction, maintenance and resuscitation were performed according to the standard protocol for general anesthesia.Before the end of anesthesia, the experimenter administered oxytocin nasal spray (Oxytocin) that was 3 sprays in each nostril (4 IU each) for a total of 24 IU. Beginning 1 day postoperatively, administer 24 IU of oxytocin nasal spray 2 times/day in the morning and 24 IU in the evening.Until 7 days after surgery or discharge.
224309136|NCT04401865|COMBINATION_PRODUCT|PXL-330 Platinum device for crosslinking with Peschke riboflavin solution|Riboflavin will be used to load the cornea, followed by UV-A crosslinking of the cornea
224074075|NCT05560958|DEVICE|BIOTRONIK EP catheters (AlCath, MultiCath, ViaCath), external devices (Qubic RF, Qubic Stim, Qiona) and transseptal sheaths (Senovo bi-flex)|Ablations and diagnostic catheters are indicated for temporary transvenous application in patients with cardiac arrhythmias during electrophysiology study (EPS) or catheter ablation interventions. They will be used in combination with external devices like RF generators, external pacemakers cardiac stimulators and / or irrigation pumps.
224074076|NCT01870154|BEHAVIORAL|Training|The objective of the intervention is learning from the work experience of professionals attending the workshop to know and recognize the risk and process of the burnout syndrome and the characteristics specific to the health setting, as well as promoting prevention lines by transmitting strategies to manage and control the elements and consequences of the syndrome process (physical, psychological, and social).
224074077|NCT06195839|BEHAVIORAL|Remote Patient Monitoring|Participants will be given a home blood pressure machine and instructed to take their blood pressure twice/day (once in the morning and once at night) for the duration of the 2-month study. Blood pressure values will be immediately available in their patient-facing portal accessible via smartphone app, and patients will receive weekly feedback reports on their adherence to the home blood pressure monitoring protocol. Patients' blood pressure values will also be accessible to their clinical care team via an administrator portal, which will alert clinicians of any values above or below pre-specified clinical thresholds.
224074078|NCT06195839|BEHAVIORAL|Self-monitoring of hypertension-related factors|As part of self-monitoring of hypertension-related factors, the blood pressure monitoring patient-facing app will also prompt patients daily to report whether or not they took their blood pressure medication. in addition, participants will be provided with a wrist-worn sensor and instructed to wear it at night to track their sleep activity. Data on sleep activity will be available to patients through a separate patient-facing app accessible on their smartphone.
224074079|NCT06195839|BEHAVIORAL|Immediate financial incentives|Weekly financial incentives for measuring their blood pressure as instructed (up to $25/week: $5/day for up to 5 days/week)
224074080|NCT06195839|BEHAVIORAL|Delayed financial incentives|Financial incentives for measuring their blood pressure as instructed in one payment at the end of the study (up to $25/week: $5/day for up to 5 days/week)
224074081|NCT06085963|DRUG|ITULAZAX 12 SQ-Bet|Active ingredients: Birch (Betula verrucosa) extracts Dosage form: Oral lyophilisate (referred to as allergy immunotherapy tablet in text) Dose/strength: 12 SQ-Bet Excipients: Gelatine (fish source), mannitol and sodium hydroxide
224074082|NCT06085963|DRUG|Placebo tablet|Active ingredients: None Dosage form: Oral lyophilisate (referred to as allergy immunotherapy tablet in text) Excipients: Gelatine (fish source), mannitol and sodium hydroxide
224074083|NCT06085963|DRUG|Nacl|Sodium chloride solution 9mg/ml
224188029|NCT04734366|PROCEDURE|Single Layer Continuous Locked|Suturing is continued by passing through the previous stitch.
224188030|NCT04973670|DRUG|Sivelestat sodium|Sivelestat sodium 0.2mg/kg.h for 1-7 days
224188031|NCT04973670|DRUG|Placebo|The same amount of NS containing only sivelestat sodium excipients
224188032|NCT04964076|OTHER|No intervention|No intervention
224188033|NCT05433376|DEVICE|Shockwave Coronary Intravascular Lithotripsy (IVL) System C2|lithotripsy-enabled, low-pressure dilatation balloon to modify severely calcified lesions
224188034|NCT04423289|OTHER|Farmalarm|Monitoring after COVID-19 discharge from hospital via Farmalarm app
224188035|NCT06566144|OTHER|Standard treatment|The treatment to be used in the study is in accordance with the latest guidelines for chronic LBP \[George et al., 2021; Owen, et al., 2020\]. A warm-up will be performed by walking on a treadmill for 10 minutes, followed by 3 sets of 10 to 15 repetitions of exercise: bridge, cat, abdominal, straight leg raising, and oyster, and 3 sets of 30 to 60 seconds of each isometric exercise (front plank and side plank), where the therapist will assess the optimal amount of repetitions for each individual. The rest period between sets will be 40 seconds, and the rest period between exercises will be 1 minute. The total duration of the session will be 40 minutes \[Sipaviciene et al., 2020; Kim et al, 2020\].
223497659|NCT05431855|BEHAVIORAL|eWrapper-Engagement strategies to facilitate alcohol biosensor wearing|We will conduct a 30-day micro-randomized trial (MRT)--a clinical trial design for developing and optimizing mHealth interventions to test which engagement strategy works better, for who, and under what condition. A subset of the participants will be micro-randomized in the morning and in the evening, to either a prompt delivering non-contingent small reward (reciprocity); or a prompt containing feedback on self-monitoring progress based on dynamic self-regulation theories (personalized feedback); or no prompt.
223497660|NCT05138757|DRUG|Prebiotic|A prebiotic is a purified fiber of plant origin that has digestive health benefits by fostering the growth of beneficial microbes.
223497661|NCT05138757|DRUG|Placebo|A placebo is a substance that has no therapeutic effects used as a control while testing new drugs.
223497662|NCT05482191|BEHAVIORAL|Lifestyle intervention|"This intervention programme will target the influencing factors of childhood obesity to influence the knowledge, attitude and behaviours of school children. Students in the treatment group will receive the following interventions:~* Develop and implement school policies related to weight loss~* Distribute health education materials on diet and exercise to students~* Carry out student health education courses~* Diet and exercise instruction by professional nutritionist using internet applet~* Take part in sports activities that are organized by the sports health teacher during school hours."
223497663|NCT02685930|BEHAVIORAL|Antibiotic de-escalation by ICU stewardship team with decreased exposure to broad spectrum antibiotics and shorter duration of therapy|ICU stewardship team will provide recommendations to the ICU team regarding antibiotic de-escalation and duration of therapy in attempts of improving antibiotic stewardship practices without compromising patient outcomes.Recommendations will be based on patient showing clinical improvement combined with microbial culture data.
223590309|NCT01972698|OTHER|Traditional apprenticeship training|"All participants will attend an half-day ultrasound introductory course.~* Participants randomized to the conventional group will initially attend 2-hour hands-on session on healthy volunteers, fully supervised by an expert critical care ultrasonographer (acquisition of basic knowledge with US machine settings and probe positioning and orientation, normal view acquisition, and identification of normal anatomical structures and landmarks).~* Subsequently, participants will attend a 3-hours hands-on session on critically ill patients, fully supervised by an expert critical care ultrasonographer."
224188036|NCT06566144|OTHER|Osteopathy treatment|The osteopathy treatment group (OTG) will receive the same standard treatment for low back pain as the STG, which will be applied twice a week and osteopathy treatment every 15 days for 8 weeks, totaling 4 sessions. The duration of the osteopathy sessions
224188037|NCT02250157|DRUG|Oratecan|
224188038|NCT03730025|OTHER|Auscultation plus NeoTapAS|Pediatric resident responsible for HR assessment will estimate the HR by listening to the praecordium with a stethoscope. When using NeoTapAS, he/she will simultaneously tap the same pace on the screen of an iPad with the NeoTapAS app installed and will verbally communicate the HR displayed on the screen.
224188039|NCT03730025|OTHER|Auscultation without NeoTapAS|Auscultation without NeoTapAS
224188040|NCT04854421|DEVICE|VBC|Body Composition will be measured using the VBC system that takes under 60 seconds per scan. Image capture for VBC will include taking a series of four photos using a smartphone camera. Data from the camera will be downloaded to a local computer and then securely sent to the cloud for automated analysis and results generation. We will conduct two consecutive scans (image captures) for each research participant.
224188041|NCT03343002|DRUG|fentanyl at 10-15 min before end of surgery|Label 2 syringe is filled with 1mcg/kg of fentanyl, label 1 syringe is filled with same amount of saline solution. If the surgeon notifies the anesthesiologist 10-15 minutes before the end of the operation, the syringe drug labeled 1 will be administered intravenously(that is, normal saline ). At the end of the surgery, the syringe drug labeled 2 is administered intravenously((that is, 1mcg/kg of fentanyl)
224188042|NCT03343002|DRUG|fentanyl at end of surgery|Label 2 syringe is filled with 1mcg/kg of fentanyl, label 1 syringe is filled with same amount of saline solution. If the surgeon notifies the anesthesiologist 10-15 minutes before the end of the operation, the syringe drug labeled 1 will be administered intravenously(that is, normal saline ). At the end of the surgery, the syringe drug labeled 2 is administered intravenously((that is, 1mcg/kg of fentanyl)
224188043|NCT02154152|DRUG|Homoeopathic Medicine causticum 200c|
224188044|NCT00798161|DRUG|BI 1356|BI 1356 high dose tablet, once daily
224309137|NCT06955065|OTHER|battle rope training|Battle rope training is a dynamic, high-intensity exercise involving heavy ropes to improve strength, endurance, and coordination. It primarily targets the upper body, including the shoulders, arms, and core, through rhythmic, wave-like movements. This training is adaptable and effective for enhancing functional fitness in both general and adaptive athletes.
224309138|NCT06955065|OTHER|Bocce Throwing|Participants in the control group will engage in regular bocce training sessions as per their usual routine. These sessions will focus on standard bocce drills and techniques without additional battle rope exercise. A warm- up activity used in every training session and a proper warm-up should include Aerobic activity and Dynamic stretching . 15 to 20 repetitions of each exercise.
224188045|NCT00798161|DRUG|BI 1356 + metformin|BI 1356 low dose tablet + Metformin 500 mg tablet, twice daily
224188046|NCT00798161|DRUG|Bi 1356 + metformin|BI 1356 low dose tablet + Metformin 1000 mg tablet, twice daily
224188047|NCT00798161|DRUG|Metformin|Metformin 500 mg tablet, twice daily
224188048|NCT00798161|DRUG|metformin|metformin 1000 mg tablet, twice daily
224188049|NCT00798161|DRUG|matching placebo|matching placebo
224188050|NCT03542929|DEVICE|whole body vibration|whole body vibration training on a vibrating platform with healthy elderly and diabetic elderly
224188051|NCT06651203|OTHER|Follow-up|Clinical evaluation Blood sample Skin biopsy
224188052|NCT03334942|BEHAVIORAL|Child and Family Traumatic Stress Intervention|The Child and Family Traumatic Stress Intervention (CFTSI) is a 5-8 session intervention, initiated within 60 days of trauma exposure for youth reporting acute PTSS. CFTSI is designed for children age 7 and older, and requires the involvement of a caregiver who knows the child well enough to report changes in the child's behavior and symptoms. CFTSI targets modifiable risk and protective factors during the early post-trauma period to promote recovery and reduce PTSS via caregiver-child communication and cognitive and emotional processing. CFTSI uses skill modules (e.g., sleep disturbance, intrusive thoughts, anxiety) to teach effective strategies to decrease a child's PTSS. Coping and communication skills are taught and practiced in caregiver-child sessions and in the home.
224188053|NCT01971099|DRUG|tribulus terrestris|patients will use 750mg/day of tribulus terrestris
224188054|NCT01971099|OTHER|Placebo|patients will take one pill a day (the same shape of the drug)
224188055|NCT00761761|DRUG|Sensoril|
224188056|NCT00761761|OTHER|Placebo|
224188057|NCT00586677|BEHAVIORAL|Parent-Child Interaction Therapy|Sixteen one hour sessions done in-home for children ages 2-7. Proceed through protocol based on mastery of predefined skills.
224188058|NCT00586677|BEHAVIORAL|Health and Safety|Sixteen one hour sessions for children age 0-7 conducted in the home. Participants are quizzed on material to determine mastery.
224188059|NCT00586677|BEHAVIORAL|Early Relationships|Sixteen one-hour sessions for children age 0-2 provided in-home.
224188060|NCT02454413|OTHER|denture brushing with water and soap|denture brushing with water and soap
224309139|NCT00229320|BEHAVIORAL|Group therapy|
223497664|NCT01053832|DEVICE|VpS algorithm in EVIA and ENTOVIS pacemakers|For one group of patients, the VpS algorithm will be activated and for the other group, the VpS algorithm will be deactivated until the cross-over, where these conditions will be switched.
223497665|NCT05822466|BEHAVIORAL|Virtual tai ji quan: moving for better balance intervention (V-TJQMBB)|This intervention involves a tai ji quan exercise program, named tai ji quan: moving for better balance
223497666|NCT05822466|BEHAVIORAL|Virtual multimodal exercise intervention (V-Multimodal)|This intervention involves a multimodal exercise program that consists of balance, strength, light walking, and stretching exercises
223497667|NCT06464159|BIOLOGICAL|Biological collection|A collection of maternal plasma, serum and urine
223497668|NCT01522053|PROCEDURE|Catheter-over-needle|Patients in the experimental group will receive a perineural catheter placed by the catheter-over-needle method.
223497669|NCT01522053|PROCEDURE|Catheter-through-needle|Patients in the control group will receive a perineural catheter placed by the traditional catheter-though-needle method.
223497670|NCT03117270|DRUG|filgotinib|one filgotinib oral tablet q.d.
223497671|NCT03117270|DRUG|Placebo Oral Tablet|one placebo oral tablet q.d.
223497672|NCT04840719|DEVICE|RECO|
223497673|NCT04764890|OTHER|Electroacupuncture|Electroacupuncture in several point
224188061|NCT02454413|OTHER|ultrasonic denture cleaning|ultrasonic denture cleaning
224188062|NCT02454413|OTHER|cleansing tablet|addition of a cleansing tablet to the water in which the dentures are stored overnight
224309140|NCT06990113|OTHER|three dimensional lumbar myofascial release|Three-dimensional (3D) MFR is a novel approach toward reducing fascial restrictions. It recognizes that fascia exists not only in a linear plane but also in complex multidirectional networks throughout the body.
224309141|NCT06990113|OTHER|conventional treatment.|conventional treatment, including selected physical therapy, flexibility exercise for the back, static back and abdomen exercises, and electrotherapy
223497674|NCT04764890|OTHER|Manual therapy|Manual therapy in the lower spine.
223497675|NCT00247286|BEHAVIORAL|weighted vaginal cones|
223497676|NCT00247286|BEHAVIORAL|Biofeedback|Pelvic floor muscles exercises performed with a biofeedback machine
223497677|NCT00397241|DRUG|Drug: dorzolamide/timolol|
223497678|NCT00397241|DRUG|Drug: latanoprost/timolol|
223497679|NCT00397241|DRUG|dorzolamide/timolol and latanoprost|
223497680|NCT00397241|DRUG|placebo (artificial tears)|
224188063|NCT02621528|DEVICE|CeraFlex|The Lifetech CeraFlex™ study is a triple-arm study.
224188064|NCT02751372|DRUG|BAY 987517|50 μl/cm\*2 or 0.05 gm/cm\*2 of each test product is applied to duplicate skin sites (approximately 2 x 2 cm each). After the test articles have dried for 5 to 15 min, the sites are covered by the appropriate patch.24 hours later, the set of patches covering the product are removed. Three (3) μl/ cm2 or 0.003 gm/cm\*2 of the test product is reapplied to the test site, air dried for 5 to 15 minutes for volatilization and then the test site is exposed to UVA radiation.
224188065|NCT02751372|OTHER|Untreated Skin|This site is patched without treatment as irradiated control
224188066|NCT05154994|DRUG|Belinostat|Given IV
224188067|NCT05154994|BIOLOGICAL|Durvalumab|Given IV
224188068|NCT05548582|DRUG|OxyCODONE 5 mg Oral Tablet|No opioid prescription after laparoscopic hysterectomy
224188069|NCT05548582|DRUG|Acetaminophen 500 mg Tab|Standard prescription
224188070|NCT05548582|DRUG|Ibuprofen 600 mg|Standard prescription
224188071|NCT05081791|BEHAVIORAL|Exercise Training|12-week exercise training program including a combination of endurance and resistance training for 45 minutes, twice a week.
224309142|NCT06989944|BEHAVIORAL|Physical Activity (PA) program|"Participants assigned to the PA-arm will participate in at least three weekly 30-minute sessions of PA for a total of 12 weeks.~The PA program will be tailored to individuals' characteristics, skills and preferences, based on information collected in connection with the baseline assessment and physical examination. A PA program could preview some forms of aerobic/relaxation/anaerobic exercises"
224188072|NCT06326203|BIOLOGICAL|CELULAS TRONCO|Cellular Therapy Treatment: The treatment will consist of \*\*20 participants (n=20) who will receive treatment with expanded mesenchymal stem cells (MSCs). The patient will undergo a surgical debridement procedure for the ulcer to be in its optimal condition (Visit 1). Subsequently, the patient will receive MSC application via perilesional injections and a biocovering produced by the study team, also containing the same cells (single session - the MSC-containing dressing will remain in contact with the ulcer for 7 days). After removal of the biological dressing, the ulcer will receive local care with a topical hydrogel dressing, dry gauze, and a crepe bandage, with a minimum of one change per day.
224188073|NCT06326203|DEVICE|CONVENTIONAL DRESSING|The control group will consist of 20 participants (n=20) who will receive local care for the ulcer. The patient will undergo a surgical debridement procedure for the ulcer to be in its optimal condition (Visit 1). Subsequently, the patient will receive the application of a conventional dressing with Hydrogel, dry gauze, and a crepe bandage. The patient will be instructed to change the dressing at least once a day.
223497681|NCT05460247|DIETARY_SUPPLEMENT|Protein|Participants will receive a diet supplemented by the above protein
223497682|NCT05643508|DRUG|(D) DWC202206|Drug of DWC202206 A mg
223497683|NCT05643508|DRUG|(D) DWC202207|Drug of DWC202207 B/C mg
223497684|NCT05643508|DRUG|(P) DWC202206|Placebo of DWC202206 A mg
223497685|NCT05643508|DRUG|(P) DWC202207|Placebo of DWC202207 B/C mg
223497686|NCT02649933|DEVICE|Watch PAT 200|screening of OSA with Watch PAT 200
223497687|NCT01777724|BEHAVIORAL|Combination of Triple P Discussion Groups and Stress Control|The intervention consists of eight group sessions: two 120 minute Triple P Discussion Group sessions (http://www.triplep.net/), and six 90 minute Stress Control sessions (http://glasgowsteps.com/home.php).
223497688|NCT05759910|DIETARY_SUPPLEMENT|Brainphyt high dose|Participants will take BrainPhyt capsules during 3 months
223497689|NCT05759910|DIETARY_SUPPLEMENT|Placebo|Participants will take placebo capsules during 3 months
223497690|NCT02092935|DRUG|SMT19969|
223497691|NCT02092935|DRUG|Vancomycin|
223497692|NCT01415674|DRUG|Afatinib|Afatinib 40mg per os daily for 14 to 28 days, depending on the date of the surgery
223497693|NCT02612675|OTHER|ONS|
223497694|NCT03778372|DRUG|Methadone|see desc above
223497695|NCT03015701|DRUG|Mifepristone|a 19 norsteroid with anti-progesterone and anti glucocorticoid activity which competitively inhibits binding of the hormone to its receptor
223497696|NCT03015701|OTHER|Placebo|placebo matching mifepristone
223497697|NCT00021255|DRUG|Doxorubicin|
223497698|NCT00021255|DRUG|Cyclophosphamide|
223497699|NCT00021255|DRUG|Docetaxel|
223497700|NCT00021255|DRUG|Herceptin|
223497701|NCT00021255|DRUG|Carboplatin|
223497702|NCT01377506|BEHAVIORAL|lifestyle counseling|21 session group-based behavioral weight management program delivered in senior center over 12 months by lay health educators
224188074|NCT04812678|PROCEDURE|Fasciatherapy|Fasciatherapy, with manual therapy and/or gestual therapy.
224188075|NCT04812678|PROCEDURE|Physiotherapy|Conventional physiotherapy with massage, exercises, electrotherapy, vertebral traction, heat, cold.
224188076|NCT03757585|DRUG|Open-label Treatment with Omega-3 Fatty Acids + Inositol|Open-label Treatment with Omega-3 Fatty Acids + Inositol
224188077|NCT03757585|DRUG|Open-label Treatment with N-acetylcysteine|Open-label Treatment with acetylcysteine
224188078|NCT06785194|DEVICE|REVIVE samfilcon B custom toric contact lenses|REVIVE samfilcon B custom toric contact lenses
224188079|NCT03472586|BIOLOGICAL|Ipilimumab|Given IV
224188080|NCT03472586|BIOLOGICAL|Nivolumab|Given IV
223497703|NCT01377506|BEHAVIORAL|Cognitive Training|21 session group-based cognitive training program delivered in senior center over 12 months by lay health educators
223497704|NCT01651598|DRUG|Placebo to BI 144807|multiple dose (bid)
223497705|NCT01651598|DRUG|BI 144807|multiple dose (bid, low to high dose)
223497706|NCT04223037|BIOLOGICAL|Japanese Encephalitis Vaccine produced by IMBCAMS|Dosage form: 0.5mL/vial
223497707|NCT04223037|BIOLOGICAL|Japanese Encephalitis Vaccine produced by Liaoning Chenda|Dosage form: 0.5mL/vial
223497708|NCT01163656|DEVICE|Miller Laryngoscope|Device is used to facilitate tracheal intubation.
223497709|NCT01163656|DEVICE|Glidescope Cobalt Video Laryngoscopes|The laryngoscope design with the integration of video technology into the laryngoscope blade.
223497710|NCT01895998|DRUG|Albuterol|This medication will be used as routine part of pulmonary function testing to assess for airway hyperreactivity. This is routinely done in a clinical capacity for pediatric patients with various pulmonary disease processes.
223497711|NCT01132755|PROCEDURE|Diagnostic peritoneal lavage|The Veress needle will be inserted in the abdominal wall, at a site to be left up to the individual surgeon. Caudal traction will be applied to the abdominal wall to provide a firm abdominal wall to insert the needle through, minimizing the peritoneum from tenting down closer to visceral structures. Intraperitoneal placement of the catheter will be confirmed by injection of saline into the needle with no resistance and with the saline in the hub of the needle falling into the peritoneal cavity spontaneously. A guide wire will be placed through the Veress and utilizing the Seldinger technique, a 9Fr peritoneal catheter will be placed.
223497712|NCT00420264|DEVICE|Uterine Ablation|Uterine Ablation in the office setting to see if the procedure is tolerated w/o sedation
223497713|NCT02183974|PROCEDURE|Peptest|
223497714|NCT01182961|OTHER|gait training|subjects will walk on a treadmill while virtual obstacles will be displayed using a head mounted device
223497715|NCT01182961|OTHER|gait training 2|subjects will walk on a treadmill under a progressive intensive gait protocol
223497716|NCT01182961|OTHER|exercise group|standard of care exercise group to improve strength and balance
223497717|NCT01801254|OTHER|STRIDES|Self-Control TRaining for Increasing Delay of gratification through EEG operant conditioning with Source localization (STRIDES). Brain-computer interface training protocol designed to up-regulate specific types of neural activity, in regions including the left dorsolateral prefrontal cortex, the anterior cingulate cortex, and Brodmann area 6 bilaterally. Targeted neural activity types are positively associated with self-controlled behavior.
223497718|NCT01801254|OTHER|Sham Control|Brain-computer interface training protocol that is designed to have no effect on self-controlled behavior.
224188081|NCT03472586|DRUG|Embolization Therapy|Undergo immunoembolization
224188082|NCT03088995|DIAGNOSTIC_TEST|Pilot study|Pilot study of HIV and viral hepatitis B and C screening in surgery
224188083|NCT03342911|DRUG|Paclitaxel|Given IV
224188084|NCT03342911|DRUG|Carboplatin|Given IV
224188085|NCT03342911|BIOLOGICAL|Nivolumab|Given IV
224188086|NCT00622310|BEHAVIORAL|Walking exercise|Subjects will be randomly assigned to either a structured, vigorous-intensity endurance exercise training program or an intermittent, low-intensity exercise program. Individualized exercise prescriptions will be designed to target an increase of 2500 kcal/wk, and the theoretical weight loss will be approximately 15 pounds (\~6.8 kg) during the 6 month intervention.
224188087|NCT02528331|DEVICE|Transcranial magnetic stimulation|
224188088|NCT02528331|BEHAVIORAL|Cognitive behavioral therapy|
224188089|NCT05443633|BEHAVIORAL|individualized speech-language training|Language treatment might include lexical, semantic, and interactive treatment. During treatment, patients may be trained to name words by attempting to self-cue lexical retrieval. The therapy moves incrementally through semantic cuing. The semantic treatment will be implemented using the methods described in (Edmonds et al., 2009, 2014).
224188090|NCT05443633|BEHAVIORAL|standard language intervention|Participants will undergo standard speech-language naming therapy
224188091|NCT03833609|BEHAVIORAL|Online yoga training (Group A)|The yoga training program is a structured low-intensity Vishwas-Raj (18). This yoga program consists of stretching, strengthening, meditation and deep breathing, and has been shown to be effective among adults with RA. Participants will be asked to complete three individual 1-hour sessions per week for 12 consecutive weeks by watching a previously filmed session led by a qualified yoga instructor and posted on Facebook. They will also take part in a 1-hour virtual group session per week using a video-conferencing platform. Participants will also participate in weekly e-consultations with a research coordinator and discussions on Facebook with other participants.
224188092|NCT03833609|BEHAVIORAL|Online aerobic dance training (Group B)|The aerobic dance program is a low to moderate intensity level program and will also use a video. The video, adapted for youth with JIA, was developed with feedback from a JIA patient with experience in aerobic dance and a physiotherapist with experience in pediatric rheumatology. The aerobic dance program will have the same characteristics in terms of frequency, total number of sessions and total duration as the yoga program (i.e., three 1-hour individual sessions and one 1-hour virtual group session per week for 12 weeks). Participants will also participate in weekly e-consultations with a research coordinator and discussions on Facebook with other participants.
224188093|NCT03650218|DEVICE|THIODERM STRONG|Soft tissue filler containing crosslinked hyaluronic acid and Na-hyaluronate, supplemented with lidocaine hydrochloride as ancillary substance.
224188094|NCT06050928|DRUG|Oral EP262|Once daily
224188095|NCT06008938|GENETIC|HEMGENIX|HEMGENIX is a gene therapy medicinal product that aims to deliver a factor IX (FIX) gene expression cassette to the liver of patients with hemophilia B.
224188096|NCT06008938|BIOLOGICAL|Factor IX (FIX)|FIX prophylaxis therapy
224188097|NCT06145451|BEHAVIORAL|Family Success Network|The Family Success Network (FSN) is a community-based maltreatment prevention program that is being piloted to serve caregivers of children aged between 0-18 in the Trumbull, Mahoning, and Columbiana Counties in Ohio. FSN is a comprehensive multi-tier program providing information and referrals to community resources at Tier I (i.e., the initial contact stage), caregiver education, and financial literacy program along with concrete support at Tier II (i.e., enrollment in family coaching services in FSN), and a life skills program and monthly home visits for families with more intensive needs at tier III (most intensive level of FSN services).
224205755|NCT03916055|BEHAVIORAL|Education on tics|"The active comparator is designed to match the experimental intervention in all aspects except for the module content (same platform, same treatment length, same therapist support etc.). The intervention consists mainly of psychoeducational information about TD/PTD and common comorbid conditions, and reviews the definition of tics, natural history, common presentations, prevalence, aetiology, risks and protective factors, strategies for describing tics to other people, among others. Problem-solving and development of expertise in tic disorders is emphasised. The intervention does not include any information on ERP or functional analysis and interventions.~As in the experimental intervention, the parent is provided with her/his own separate login to the internet platform. The parent intervention consists mainly of information regarding parent coping strategies and social support. Both the child and the parent have individual access to the same therapist."
223497719|NCT02232698|DEVICE|Sensor Based Glucose Monitoring System|"Subjects will wear the Abbott Sensor Based Glucose Monitoring System (unmasked) for 6 months to monitor their glucose levels.~All subjects will wear a masked Abbott Sensor Based Glucose Monitoring System, for 14 days prior to randomisation (Sensor glucose measurements not visible during this time)."
223497720|NCT02232698|DEVICE|Standard Blood Glucose Monitoring|"Subjects will use an Abbott Blood Glucose Monitoring System (standard blood glucose meter) for 6 months to monitor their glucose levels. A 14-day masked wear of the Abbott Sensor Based Glucose Monitoring System is included for these subjects at the 3 and 6 month time point, to collect glycaemic variability data for comparison to the intervention group of the study (Sensor glucose measurements not visible during this time).~All subjects will wear a masked Abbott Sensor Based Glucose Monitoring System, for 14 days prior to randomisation (Sensor glucose measurements not visible during this time)."
223590310|NCT03327064|DRUG|UAB30|9cUAB30 promotes homodimer and heterodimer formation with retinoic acid receptors (RARs), and was shown to inhibit breast tumor development in the N-methyl-N-nitrosourea (MNU)-induced rat mammary gland carcinoma model. The compound has also shown efficacy in rodent models of skin cancer. Dose administration will be 160mg daily for 28 days.
223590311|NCT03327064|DRUG|Placebo|This matches the UAB30 in appearance. Frequency of dosing will be daily for 28 days.
223590312|NCT02337725|DRUG|TVP-1012|TVP-1012 1mg Tablets
223590313|NCT02337725|DRUG|Placebo|Placebo tablets
223590314|NCT02096263|BIOLOGICAL|Infanrix hexa|3 doses administered intramuscularly in the right thigh.
223590315|NCT02096263|BIOLOGICAL|Pediarix|3 doses administered intramuscularly in the right thigh
223590316|NCT02096263|BIOLOGICAL|ActHIB|4 doses administered intramuscularly in the upper left thigh
223590317|NCT02096263|BIOLOGICAL|Pentacel|4 doses administered intramuscularly in the right thigh
223590318|NCT02096263|BIOLOGICAL|Engerix-B|2 or 3 doses administered intramuscularly in the upper left thigh
223590319|NCT02096263|BIOLOGICAL|Infanrix|1 dose administered intramuscularly in the right thigh
224188098|NCT05807867|BEHAVIORAL|WMM-based intersectional stigma intervention|"Intervention components consist of:~1. psychoeducation: facilitating the achievement of good womanhood by adhering to psychiatric medications and ART post-discharge~2. cognitive restructuring to challenge stereotypes: involves reframing psychiatric and ART adherence postdischarge as enacting 'good womanhood' by countering stereotypes of being unable to care for the family or be a suitable marriage partner~3. Coping skills for discrimination: promoting safe disclosure of SMI and/or HIV status to facilitate psychiatric and ART adherence post-discharge.~Note: enhancing skills for discrimination sessions for women and family members are provided when female participants transition to outpatient care, thus enabling practice of skills in community-based situations. Intervention closes with a ceremony intended to convey WMM by bestowal of ceremonial shawls. The family member version will follow the same format, but each component will be covered in one session (3 sessions total)."
224188099|NCT05807867|BEHAVIORAL|Attention placebo control|To isolate intervention effects, our attention control is designed to mimic all salient features of the WMM-based intervention (i.e., group format, co-leaders, duration, inpatient followed by community location) except for the WMM stigma content.
224188100|NCT04748731|BEHAVIORAL|Internet mentalization-based video feedback intervention to improve parental sensitivity in mother-infant dyads with maternal depressive symptoms|a weekly online brief intervention using video-feedback and psycho-educational materials on early parenting
224188101|NCT04748731|BEHAVIORAL|Psycho-Educational Intervention|Reception of psycho-educational materials
224188102|NCT05524051|DRUG|TIN816|TIN816
224188103|NCT05524051|OTHER|Placebo|Placebo
224188104|NCT03983668|DRUG|CMP-001|Immunostimulatory therapeutic agent
224188105|NCT03983668|DRUG|Pembrolizumab|Humanized antibody used in cancer immunotherapy
224188106|NCT06847763|OTHER|Therapeutic Neuroscience Education|Therapeutic Neuroscience Education applied in the form of one-on-one seminar format, focused on pain neurophysiology, and in the form of speaking sessions. Within the scope of these speaking sessions, pictures, diagrams, graphs, examples, metaphors, and homework assignments explaining the neurophysiology of pain are used.
224188107|NCT06847763|OTHER|Conventional Program|Conventional physiotherapy includes hot packs (20 minutes), ultrasound (1 mHz frequency, 1,5 watt/cm², 5 minutes left/right lumbar region), TENS (100Hz, 20 minutes), and home exercises.
224188108|NCT06028373|DRUG|ATG-031|ATG-031 will be infused Q3W on Day 1 of each cycle, at the starting dose of 0.03 mg/kg and a maximum dose of 9 mg/kg in the Dose Escalation Phase, and the defined MTD if available or OBD in the Dose Expansion Phase. Based on the emerging PK, PDx, safety, and other relevant data, SRC may decide to explore alternative dosing schedules.
224188109|NCT06182358|DRUG|Lotilaner ophthalmic solution, 0.25%|XDEMVY (lotilaner ophthalmic solution) 0.25%, administered topically twice a day for approximately 43 days
224188110|NCT06182358|DRUG|Vehicle control|Vehicle of XDEMVY administered topically twice a day for approximately 43 days
224188111|NCT05866445|DEVICE|Wearable BP device|Wearable study BP device to be worn for 8 hours within study participation.
224188112|NCT05866445|DEVICE|24-hour ambulatory blood pressure monitor|24-hour ambulatory blood pressure monitor to be worn for 24-hours during study participation.
224188113|NCT06032091|OTHER|No intervention|The study is observational and will not include any specific interventions other than the regular care practice that the participants receive from their care providers. The study will use a wrist-mounted smartwatch for monitoring. Previous studies show acceptability toward wearable devices among persons with dementia; however, if the care staff recognize discomfort or distress caused by the device, it will be immediately removed.
224188114|NCT05320926|DRUG|Clopidogrel monotherapy|Patients will be randomized to stop aspirin and maintain clopidogrel after short-term DAPT.
224188115|NCT05320926|DRUG|Aspirin monotherapy|Patients will be randomized to stop clopidogrel and maintain aspirin after short-term DAPT.
224309143|NCT05103189|OTHER|4D-flow sequence|all patients will be referred for a complete cardiac MRI exam with the addition of a 4D Flow sequence (does not require supplementary injection of a contrast agent and does not extend the duration of the examination) followed promptly (within the same hour) by a Doppler-echocardiography.
223497721|NCT04490655|BEHAVIORAL|Active somatosensory training|Patients in the experimental group will be required to move the robotic handle using their paretic arm from the start position to a visual target shown on screen. However, patients' paretic arm will be occluded from vision throughout the training session. They will make the reaching movement by depending on their proprioception of the arm position in space, without relying too much on the vision of their arm. Haptic guidance will be provided as somatosensory cues while participants are actively moving. Positive reinforcement will also be given for each successful movement that reaches the target in the form of a pleasant audio tone, visual feedback, and a running score. Assessment will be performed before and after the completion of the whole 15 training sessions.
223497722|NCT04490655|BEHAVIORAL|Motor-based training|Patients in the control group will also be required to propel the robotic handle using their paretic arm to a target location. This training covers the same centre-out reaching movements but without any emphasis on proprioception, where the view of the paretic arm will not be occluded. However, no haptic guidance will be provided during the reaching movement. Positive reinforcement will still be given to inform the participants of their trial outcomes. Assessment will be performed before and after the completion of the whole 15 training sessions.
223497723|NCT01997931|DEVICE|Bispectral Index Sedation monitor|
223497724|NCT04058301|OTHER|Text message information|Geographically proximate resources delivered by text message
223497725|NCT02393755|DRUG|Capecitabine|Given PO
223497726|NCT02393755|OTHER|Laboratory Biomarker Analysis|Correlative studies
223497727|NCT02393755|DRUG|Nintedanib|Given PO
223497728|NCT02393755|OTHER|Pharmacological Study|Correlative studies
223497729|NCT05381870|BEHAVIORAL|Test Preparation-Reference preparation|Under fasting conditions, subjects randomly divided into TR group were given one tablet of test preparation first, and then one tablet of reference preparation after cleaning period.
224188116|NCT05320926|DEVICE|zotarolimus-eluting stent (Resolute Onyx ®)|zotarolimus-eluting stent (Resolute Onyx ®)
224188117|NCT06073782|OTHER|Education Group|"The training material will be created by researchers by reviewing national and international guidelines for colonoscopy practices. Using the Colonoscopy Patient Preparation Guide, individuals will be given face-to-face, information and preparation training on colonoscopy preparation, its importance, the preparation medication to be used and the procedure process for an average of 15-20 minutes in a private room in the unit."
224188118|NCT06073782|OTHER|Text Message Group|. Starting three days before the colonoscopy is performed, individuals will be informed via text messages about the foods and beverages that they can consume in their diet and those that are forbidden to consume until the morning of the colonoscopy, the amount of fluids they should consume daily, the use of medication, the use of soda and enema, appointment time reminders.
224188119|NCT05950269|DEVICE|Walking aid|A physiotherapist will identify the mobility needs and will indicate the most appropriate walking aid (cane or walker).
224188120|NCT05950269|OTHER|Telemonitoring|Telemonitoring will occur every two weeks for three months after the emergency department discharge, through video call (about 15 minutes). On these opportunities, the importance of using mobile devices and the guidance on safe gait will be reinforced.
224188121|NCT05950269|OTHER|Guidance on safe walking and risk of falling|Participants will receive verbal guidance and printed material with guidance on safe walking and fall prevention.
224309144|NCT03664518|DRUG|Eltrombopag|subjects will initiate treatment with 25 mg eltrombopag. Platelet counts is obtained weekly and dose adjustment should be done according to platelet counts. and maximum dose should not exceed 75 mg daily. Subjects whose platelet count between 50\~150×109/L，the eltrombopag dose Maintain. platelet count between 150\~250×109/L, need to reduce the dose of eltrombopag to the next lower dose or lower frequency. Subjects whose platelet count exceeds 250×109/L at any point during the treatment period, must have eltrombopag interrupted and increase the frequency of platelet monitoring to twice weekly, until platelet counts fall below 100×109/L.
223590320|NCT02096263|BIOLOGICAL|Hiberix|1 dose administered intramuscularly in the left thigh
223590321|NCT02096263|BIOLOGICAL|Prevnar13|3 doses administered intramuscularly in the lower left thigh
223590322|NCT02096263|BIOLOGICAL|Rotarix|2 doses administered orally
223590323|NCT03322423|DEVICE|Multifocal Contact Lens 1|Dailies Total 1 Multifocal Contact Lens
223590324|NCT03322423|DEVICE|Multifocal Contact Lens 2|Biotrue ONEday for Presbyopia Contact Lenses
223590325|NCT03322423|DEVICE|Spherical Contact Lens 2|BioTrue ONEDay Spherical
223590326|NCT00446186|DRUG|MK0476, montelukast sodium / Duration of Treatment: 2 Weeks|
224188122|NCT02468076|DEVICE|Radiofrequency ablation (StarMed)|Radiofrequency ablation into bile duct
224188123|NCT06099860|OTHER|Kinesio Taping|Kinesio tape with a 5 cm width was used. Participants were positioned on the side lying on the non-involved side with the hip joint of the involved side flexed to 45 degrees and the femur supported in neutral rotation. First, the tape was placed over the area between the ASIS and PSIS to protect the skin. Next, two strips of tape were applied over the first tape to correct anterior innominate rotation. The first piece was applied at the ASIS and pulled firmly to the PSIS in a straight anterior-to-posterior direction. The second piece was applied in an arching manner pulled firmly from the ASIS to the PSIS. the tape was changed once every 3 days
224188124|NCT06099860|OTHER|Balance Training (BT)|The balance training was performed on the Biodex balance system, participants wwere instructed to stand on a podium and stabilize themselves to keep the cursor in the middle of co-centered circle on the displayed screen/monitor. Stability level of platform was set on eight for first two sessions and then reduced to one level on every two sessions so that in the 9th and 10th session the stability level was four. From session four onwards, the participants performed the limit of stability exercises with Biodex Balance System. The participants performed this exercise protocol two times in each session. Total 12 sessions were given in time period of six weeks.
224188125|NCT06099860|OTHER|Hot Pack and Stretching Exercises|A hot pack was applied for 20 minutes, stretching exercises were performed.
224188126|NCT00938743|DRUG|Atomoxetine|40-80 mg atomoxetine once daily, including titration 10 weeks
224188127|NCT01674868|DRUG|fluoxetine|20 mg daily for 90 days starting day 5-10 after stroke.
224188128|NCT01674868|DRUG|placebo|subjects will take one pill po daily for 90 days.
224188129|NCT04153799|BIOLOGICAL|CXCR5 modified EGFR Chimeric Antigen Receptor Autologous T cells|The first dose group: 0.5 × 10\^6/kg CAR positive T cells; The second dose group: 1.58 × 10\^6 / kg CAR positive T cells; The third dose group: 5 × 10\^6/kg CAR positive T cells. The above dose allows a 20 % error; For subjects with body weight greater than 60 kg, the number of cells can only be calculated according to 60 kg of body weight.
223590327|NCT00446186|DRUG|Comparator: placebo / Duration of Treatment: 2 Weeks|
223590328|NCT01009190|DRUG|PF-01367338|Increasing doses of single lead-in (Day -10) intravenous and daily oral PF-01367338 administered from Day 1 to Day 14 every 3-week cycle
223590329|NCT01009190|DRUG|Carboplatin|Standard doses of intravenous Carboplatin administered every 3 weeks
223590330|NCT01009190|DRUG|PF-01367338|RP2 doses of oral PF-01367338 administered daily from Day 1 to Day 14 every 3-week cycle
223590331|NCT01009190|DRUG|Carboplatin|Standard doses of intravenous Carboplatin administered every 3 weeks
223590332|NCT04087161|OTHER|Nephrocheck bed side testing of AKI|Usage of Nephrocheck system to assess AKI after open TAAA repair
223590333|NCT03493789|DRUG|Fludeoxyglucose F-18|Given IV
223590334|NCT03493789|PROCEDURE|Positron Emission Tomography (PET)|Undergo FDG-PET
223590335|NCT03493789|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|Undergo SBRT
223590336|NCT03703323|OTHER|Rotative thromboelastometry analysis|Obtaining blood sample (one tube of blood)
223590337|NCT03364413|OTHER|Chocolate|Participants will be asked to taste commercially available chocolate varying in sugar, fat and percent cocoa (milk, 70%, 85% and 90% cocoa).
223590338|NCT00850941|BEHAVIORAL|Questionnaire|Information collection.
223590339|NCT04602923|DIAGNOSTIC_TEST|Corneal topography: OPD-Scan|Corneal topography photography, taken by specular reflection (OPD-Scan) by measuring corneal curvature, thickness and topography.
223590340|NCT04602923|DIAGNOSTIC_TEST|Corneal topography: Pentacam|Corneal topography photography, taken by Scheimpflug imaging (Pentacam) by measuring corneal curvature, thickness and topography.
224188130|NCT01224171|DRUG|vedolizumab|Vedolizumab for intravenous infusion
223590341|NCT00002447|DRUG|Ritonavir|
223590342|NCT00002447|DRUG|Efavirenz|
223590343|NCT00002447|DRUG|Saquinavir|
223590344|NCT00328471|BEHAVIORAL|care management|
223590345|NCT04370379|DRUG|IBI302 (the first dose level)|q4week (3 injections) followed by PRN dosing
223590346|NCT04370379|DRUG|IBI302 (the second dose level)|q4week (3 injections) followed by PRN dosing
223590347|NCT04370379|DRUG|Aflibercept|2mg, q4week (3 injections) followed by q8week
223590348|NCT05870683|DRUG|Tegoprazan|Included in dual eradication medication.
223590349|NCT05870683|DRUG|Amoxicillin|Included in dual eradication medication.
224188131|NCT01224171|OTHER|Placebo|Placebo intravenous infusion
224188132|NCT06158087|DEVICE|pEGASUS Stent System|Endovascular intervention with p64/p48 MW HPC pEGASUS Stent System was performed in patients diagnosed with intracranial aneurysms
224188133|NCT03646916|DRUG|Dexamethasone|Gluco-corticosteroid
223497730|NCT05381870|BEHAVIORAL|Reference preparation-Test Preparation|Under fasting conditions, subjects randomly divided into RT group were given one tablet of reference preparation first, and then one tablet of test preparation after cleaning period.
223590350|NCT05870683|DRUG|Esomeprazole|Included in dual eradication medication.
223590351|NCT06056856|PROCEDURE|Penile skin graft substituttion urethroplasty|substitution of long anterior urethral strictures using one-sided dorsal perineal approach
224188134|NCT03646916|OTHER|No dexamethasone|Nothing
224188135|NCT02409966|PROCEDURE|Quadrant-wise scaling|"Patients underwent quadrant scaling under local anesthesia in four weekly sections. Three experienced trained periodontists carried out debridement procedures of both protocols with manual Gracey and McCall curettes and Hirschfield files.~Oral hygiene instructions were given for all participants and oral supplies were provided for the duration of the study."
224188136|NCT02409966|PROCEDURE|Full-mouth 24-hour scaling|"Patients underwent full-mouth scaling under local anesthesia in two sections within 24 hours. Three experienced trained periodontists carried out debridement procedures of both protocols with manual Gracey and McCall curettes and Hirschfield files.~Oral hygiene instructions were given for all participants and oral supplies were provided for the duration of the study."
224188137|NCT00357643|DRUG|Calcium 500 mg/day and vitamin D 700 IU/day|
224205756|NCT01021696|DRUG|Paracetamol|Paracetamol Max. dose: 3g/d
224205757|NCT01021696|DRUG|Morphine|Morphine ret. Tab. 5mgx2/d; max. dose:10mgx2/d
223497731|NCT02337946|DRUG|oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, panitumumab|oxaliplatin (OXA), levofolinate calcium (l-LV), panitumumab: intra-venous infusion 5-FU: bolus and continuous intra-venous infusion
224205758|NCT01021696|DRUG|Buprenorphine plaster|5ųg/h, change each 7.day; max. dose: 10ųg/h
224205759|NCT01021696|DRUG|Pregabalin|25mgx1/d; max 300mg/d
223497732|NCT02337946|DRUG|oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, panitumumab|
223497733|NCT05954689|OTHER|Femoral artery block|Injection on the antero-medial side of the femoral artery of 10mL 0.5% ropivacaine with ultrasound guidance.
223497734|NCT06055179|DRUG|Xiao Chai Hu Tang (XCHT)|XCHT 9g, po qd, 3 days before each cycle of chemotherapy for 5 days, for 3 cycles of chemotherapy.
223497735|NCT06055179|DRUG|Placebo|Placebo 9g, po qd, 3 days before each cycle of chemotherapy for 5 days, for 3 cycles of chemotherapy.
223497736|NCT06055179|DRUG|Irinotecan regimen|"Patients will receive 3 cycles of irinotecan chemotherapy. FOLFIRI regimen:irinotecan (180 mg/m2) intravenous (IV) for over 90 minutes on Day 1. Folinic acid (400 mg/m2) IV over 2 hours on Day 1. 5-fluorouracil (5-FU) IV bolus (400 mg/m2) over 5 minutes on Day 1, followed by 5-FU (2400 mg/m2) IV continuously for 46-48 hours. Every 2 weeks.~mXELIRI regimen:irinotecan (200 mg/m2) intravenous (IV) for over 90 minutes on Day 1. Capecitabine (800 mg/m²) PO bid on day 1-14. Every 3 weeks.~CapIRI regimen:irinotecan (180 mg/m2) intravenous (IV) for over 90 minutes on Day 1. Capecitabine (1000 mg/m²) PO bid on day 1-14. Every 3 weeks.~FOLFOXIRI regimen:irinotecan (165 mg/m2) intravenous (IV) for over 90 minutes on Day 1. Oxaliplatin (85 mg/m2) intravenous (IV) for over 2 hours on Day 1.Folinic acid (400 mg/m2) IV over 2 hours on Day 1, followed by 5-FU (2400 - 3200 mg/m2) IV continuously for 48 hours. Every 2 weeks."
223497737|NCT06055179|OTHER|Raloxifene|Raloxifene 60mg po, used as probe for pharmacokinetic testing, on Day 3 (the day before chemotherapy), for 3 cycles of chemotherapy.
223497738|NCT02705157|PROCEDURE|Stabilisation of (impending) pathological fracture|Stabilisation of pathological fracture or impending fracture with prosthesis, plate, intramedullary nail, cement, or other stabilisation method
223497739|NCT02705157|RADIATION|Radiotherapy of bone metastasis|Radiotherapy of bone metastasis, single or multi-fractionated
223497740|NCT04225650|OTHER|Pulmonology consultation|In case of functional respiratory signs, a consultation with a pulmonologist will be booked. At the end of this consultation, if the doctor deems it necessary, other investigations will be proposed and/or regular follow-up will be organised.
223497741|NCT05278091|OTHER|None, pure observationnal study|None, pure observationnal study
223497742|NCT04124796|OTHER|Semi-structured interviews|Based on an interview grid previously built, the interviews will investigate the factors governing the decision to consult and methods of intervention to reduce the time to consult.
223497743|NCT00048659|DRUG|YM598|
223497744|NCT00728923|DRUG|NPL-2003|Minocycline (NPL-2003) daily for 12 weeks
223497745|NCT05324371|DEVICE|Watchman FLX Device|Left atrial appendage closure using the Watchman FLX device
223497746|NCT00731003|DRUG|Oxitriptan|100 mg 5-Hydroxytryptophan will be administered orally.
223497747|NCT00731003|OTHER|Acute tryptophan depletion|Acute tryptophan depletion employs the oral ingestion of an amino acid mixture devoid of tryptophan, the precursor of serotonin, which results in lowered serotonin levels.
223497748|NCT00731003|OTHER|Amino acid drink with tryptophan|Amino acid drink with tryptophan, placebo for the ATD procedure
223497749|NCT00731003|DRUG|Placebo capsule|Placebo for 5-HTP
223497750|NCT05232721|DIAGNOSTIC_TEST|The new instrument and colonoscopy with pathological examination|Detect hemoglobin in stool by the point-of-care testing instrument before colonoscopy, detect colon lesion using colonoscopy and pathological examination.
224188138|NCT04762420|OTHER|Dose of sugammadex according to SSD and QSD|At the time of pharmacologic reversal of the NMB, both the SSD and QSD, according to portuguese guidelines on the management of the NMB, were recorded. The QSD was then administered to the patient. The SSD was considered appropriate if it was within 10% of the recommended dose for the given depth of NMB, as measured by TOFscan® monitor. The results were analyzed descriptively.
224188139|NCT05338827|PROCEDURE|Polyvinyl Chloride Tube group|The anaesthesiologist will perform a visual screen for the SaCoVLM glottic exposure grade after the SaCoVLM is successfully inserted. The SaCoVLM glottic exposure grade was referred to the endoscopic view grading system. If the SaCoVLM glottic exposure grade is 1 or 2, a lubricated tracheal tube will be inserted in a conventional manner with the curvature of the tracheal tube aligned along the intrinsic curvature of the SaCoVLM. The passage of the tracheal tube into the glottis will be visualised. If there is a discrepancy in the alignment of the tracheal tube exiting from the SaCoVLM and the glottis that will prevent the passage of the tracheal tube into the glottis, the tracheal tube will be withdrawn and manipulations (rotation of the tracheal tube or up/down manoeuvre) will be performed in an attempt to align the glottis and tracheal tube tip to facilitate intubation. Such manoeuvres, if performed, will be recorded.
224188140|NCT05338827|PROCEDURE|Wire-Reinforced Tube group|The anaesthesiologist will perform a visual screen for the SaCoVLM glottic exposure grade after the SaCoVLM is successfully inserted. The SaCoVLM glottic exposure grade was referred to the endoscopic view grading system. If the SaCoVLM glottic exposure grade is 1 or 2, a lubricated tracheal tube will be inserted in a conventional manner with the curvature of the tracheal tube aligned along the intrinsic curvature of the SaCoVLM. The passage of the tracheal tube into the glottis will be visualised. If there is a discrepancy in the alignment of the tracheal tube exiting from the SaCoVLM and the glottis that will prevent the passage of the tracheal tube into the glottis, the tracheal tube will be withdrawn and manipulations (rotation of the tracheal tube or up/down manoeuvre) will be performed in an attempt to align the glottis and tracheal tube tip to facilitate intubation. Such manoeuvres, if performed, will be recorded.
224188141|NCT03539627|DRUG|Azilsartan Medoxomil 40 MG Oral Tablet [Edarbi]|patients are to receive azilsartan medoxomil
224188142|NCT02572492|DRUG|Induction with CAR-CY-DEX and conditioning with carfilzomib and highdose melphalan|"All patients entering the study receive four series of CAR-CY-DEX (Cycle 1 with iv carfilzomib 20 mg/sqm on days 1 and 2, and iv carfilzomib 36 mg/sqm on days 8, 9, 15 and 16. Cycle 2 - 4 with iv carfilzomib 36 mg/sqm on days 1, 2, 8, 9, 15 and 16. P.o. cyclophosphamide 300 mg/sqm on days 1, 8 and 15 and p.o. dexamethasone 20 mg on days 1, 2, 8, 9, 15 and 16 in each 28-days series)~Subsequently all patients receive the conditioning regimen:~Iv carfilzomib 27 mg/sqm on day -2 and -1 Iv melphalan 200 mg/sqm on day -2 \> 2.0 m CD34+ stem cells/kg body weight on day 0"
224188143|NCT02572492|DRUG|Carfilzomib/dexamethasone maintenance|Maintenance therapy two months after salvage HDT with iv carfilzomib 27 mg/sqm every second week and p.o. dexamethasone 20 mg every second week. The maintenance dose of carfilzomib will be escalated to 56 mg/sqm after 4 weeks provided acceptable side effects.
224188144|NCT02572492|DRUG|Observation without carfilzomib/dexamethasone maintenance|Observation without carfilzomib/dexamethasone maintenance
224188145|NCT02217020|DRUG|FOLFOXIRI|irinotecan\* 165 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5-FU 2800 mg/m² cont. inf. 46h all on day 1 of each 2 weeks cycle
224188146|NCT02227420|DRUG|Anakinra|Anakinra 100mg s.c. x 5
223497751|NCT03556306|PROCEDURE|Bariatric surgery|"The gastric bypass (simplified technique) was performed in an antecolic fashion, with a calibrated 2 cm gastro-jejunal anastomosis (linear stapler); biliary and alimentary limbs measured 70 and 150 cm respectively \[17\] . Mesenteric defects were closed and the omentum divided. The sleeve gastrectomy was performed at 5-6 cm from the pylorus over a 36 Fr. bougie, with oversuture of the staple line (2-0 polypropylene). Methylene blue test and the use of drains were done routinely."
223497752|NCT01949896|OTHER|NPO|Infants in this group will be made NPO for a period of time surrounding the packed red blood cell transfusion.
223497753|NCT01949896|OTHER|Control group: continue feedings|Feedings will be continued in this group.
223497754|NCT03447795|PROCEDURE|Alveolar ridge preservation|grafting procedure using autogenous tooth.
223497755|NCT02691338|OTHER|EEG|EEG analysis
223497756|NCT02691338|OTHER|Routine follow up tests|Routine tests for patients after CVA. This include: neurologic evaluation, Brain CT, Angiography
223497757|NCT02991521|PROCEDURE|Fast exam|Positional change before Fast exam
223497758|NCT01474187|DRUG|Irinotecan|initial from 50mg/m2/week and increased by 15mg/m2/week
223497759|NCT01474187|DRUG|Capecitabine|625mg/m2,bid,d1-5,qw
223497760|NCT01474187|RADIATION|Radiotherapy|50Gy for whole pelvis
223497761|NCT05112133|DIETARY_SUPPLEMENT|Mulberry leaf extract|Oral administration
223497762|NCT05112133|DIETARY_SUPPLEMENT|Water|Oral administration
223497763|NCT01060371|GENETIC|All Participants|If you decide to participate in this study, we will collect 1 tablespoon (15 milliliters) of blood during the first/screening visit in order to extract your DNA.
223497764|NCT05927415|BIOLOGICAL|Efgartigimod IV|Intravenous infusion of efgartigimod
223590352|NCT06056856|PROCEDURE|Buccal Mucosal Graft substitution urethroplasty|substitution of long anterior urethral strictures using one-sided dorsal perineal approach
223497765|NCT01166334|BEHAVIORAL|WebQuit study group|Description withheld to protect integrity of study
223497766|NCT01166334|BEHAVIORAL|WebQuit control group|Identity and description withheld to protect integrity of study
223497767|NCT02546141|OTHER|skimmed milk (UHT)|
223497768|NCT02546141|OTHER|skimmed milk (pasteurized)|
223497769|NCT02546141|OTHER|skimmed yoghurt|
223497770|NCT02546141|OTHER|full-fat milk (UHT)|
223497771|NCT02546141|OTHER|non-homogenized full-fat milk (pasteurized)|
223497772|NCT02546141|OTHER|full-fat cheese (semi-matured)|
223497773|NCT02546141|OTHER|whey protein|
223497774|NCT02546141|OTHER|micellar casein|
223497775|NCT02949934|DRUG|Tolcapone|
223497776|NCT02949934|DRUG|Placebo|
223497777|NCT05331924|PROCEDURE|IPL therapy|Intense pulsed light therapy (IPL) is a non-coherent large wavelength high-intensity light in the range of 500-1200nm. It has been used by many investigators for the treatment of evaporative dry eye safely and effectively.
223497778|NCT05331924|PROCEDURE|Punctal plugs|Silicone punctal plugs are small pieces of silicone designed to block tear drainage through occluding the lacrimal punctum.
224188147|NCT05714176|DRUG|Ferric Pyrophosphate Liposomal|30 pediatric patients who will receive oral liposomal iron (Novoferr) 30 mg/day for 12 weeks.
223497779|NCT02338830|DRUG|Progesterone|Women received vaginal progesterone suppositories (Cyclogest®, Actavis, Barnstaple, EX32 8NS, United Kingdom) in a dose of 400 mg daily beginning at 20-24 weeks gestational age
223497780|NCT03734094|DEVICE|Ceramic barrier|The use of a ceramic barrier to induce bone formation during GBR
223497781|NCT03734094|DEVICE|Titanium Mesh|The use of a titanium mesh to induce bone formation during GBR
223497782|NCT02615353|BEHAVIORAL|Intensive Lifestyle Intervention|6-months of lifestyle education
223497783|NCT02615353|OTHER|Usual Care Control|Medical visit and dietary counseling
223590353|NCT00119665|DRUG|MF101|
223590354|NCT04629027|DRUG|Immune checkpoint inhibitor|the patients receive necessary treatment without special intervention
223590355|NCT04083755|DRUG|Ferric Carboxymaltose Injection [Injectafer]|1000mg intravenous
223590356|NCT04083755|OTHER|no treatment or oral iron supplementation|No treatment or treatment oral with iron supplementation if iron-deficiency anemia
223590357|NCT03502174|DEVICE|FreeStyle Libre Flash Glucose Monitoring System|Subjects will wear the FreeStyle Libre Flash Glucose Monitoring System and will receive no treatment except for safety purposes.
223590358|NCT03468322|DRUG|AC-203|The investigational product is formulated as 1% topical ointment
223590359|NCT03468322|DRUG|Vehicle|Vehicle-only control study medication is the same formulation as investigational product without active ingredient
223590360|NCT05772910|BEHAVIORAL|EDUcation|The education intervention will consist of an individualized educative program based on intrinsic capacity optimization through lifestyle changes. To develop the program, the program creation team will be multidisciplinary (psychologists, medical doctor, dietitian…) and will discuss goal setting, the education strategy, and retention of motivation. The experts are required to create the education program such that the participants can manage their health by themselves. The goal will be self-management of dietary habits and increases in physical activity levels for each individual case. The education program will be in Spanish or in English; as it will consist in personal counselling, even with a low level of the language the communication will be possible. The nutritional education program will be conducted every 2 weeks for 10 consecutive weeks, with 20-min counselling sessions by an expert.
223590361|NCT05772910|OTHER|EXERcise|The intervention period will have 10 weeks, in which the EXER group will carry out 2-3 sessions a week (total of 20-30 sessions). In this concurrent program, exercises of the lower extremities (leg press, abduction and plantar flexion) will be performed mainly on weight training machines. Intensity in each exercise will be individualized for each participant through a test to determine muscle power. In addition, in the last part of each session the participants will perform an endurance training type high insensitive interval training on a cycle ergometer (60-80 rpm). The intensity will be individualized to each patient through an incremental stress test until volitional exhaustion, and the subjects will alternate intervals of 30 seconds at 90% of the maximum workload, with intervals of 90 seconds at 40% of the maximum. Each session is estimated to have a total duration of 30-50 minutes.
224188148|NCT05714176|DRUG|Lactoferrin|30 pediatric patients who will receive oral iron supported Lactoferrin (Provan) 100 mg/day for 12 weeks.
224188149|NCT05714176|DRUG|Iron Dextran Injection|30 pediatric patients who will receive IV iron dextran 50 mg /3 times weekly for 12 weeks.
223497784|NCT02448108|BEHAVIORAL|i-IPSRT|"internet IPSRT (a form of psychotherapy for individuals with bipolar disorder) will be offered via 12 specially-designed modules.~CH will have participated in a two day training about Bipolar Disorder and IPSRT."
223497785|NCT02448108|OTHER|Written Psychoeducation|Written material about the importance of social rhythm regularity to mood stability in bipolar disorder
223497786|NCT00848432|DRUG|risperidone|Patients with schizophrenia who were clinically stabilized following an acute episode were randomly assigned to a 'maintenance group' (optimal therapeutic doses continued for at least 1 year), a 4-week group (optimal therapeutic doses continued for 4 weeks followed by a 50% dose reduction that was maintained for at least 11 months) or a 26-week group (optimal therapeutic doses continued for 26 weeks followed by a 50% dose reduction for at least another 6 months)
223497787|NCT03837275|PROCEDURE|Sinus Floor Elevation Between Hydrodynamic Ultrasonic Maxillary Sinus Floor Elevation Technique|Sinus Floor Elevation Between Hydrodynamic Ultrasonic Maxillary Sinus Floor Elevation Technique (Intralift Technique) and implant placement
223497788|NCT03837275|PROCEDURE|closed maxillary sinus lift|transdcrestal sinus lift and immediate implant placment
223497789|NCT05201417|OTHER|adapted physical activity|The adapted physical activity will be administered remotely through the whatsApp or YouTube application. Two sessions will be done per week: Wednesday and Sunday. Walking seems to be appropriate for all participants We will account for 24 APA sessions. We will leverage the Step Tracker phone app and pedometer to get the number of steps done, number of calories spent, Workout duration and distance walked per participant per APA session; this data will be collected weekly (after every two sessions)
223497790|NCT06027437|DRUG|Danicamtiv|Specified dose on specified days.
223497791|NCT02719795|DRUG|Ropivacaine|Local injection of local anesthetic into the fascial spaces
223497792|NCT02719795|DRUG|Normal saline|Sodium chloride solution commonly used in clinical which equal to human plasma osmotic pressure.
223497793|NCT03611660|BEHAVIORAL|Traditional Healthy Lifestyle Program|Twice weekly meetings that focus on nutrition and exercise for 12 weeks.
223497794|NCT03611660|BEHAVIORAL|Mindfulness Meditation Instruction|Participants receive six mindfulness sessions.
223497795|NCT06277375|BEHAVIORAL|Massage|The application starts from the neck with small circular strokes with the thumbs. Surface strokes are performed with the palm of the hand from the base of the skull towards the sacral region. Then rhythmic strokes are repeated from the sacrum along the entire spine towards the skull.The application to the experimental group will be done 3 days a week for 10 minutes for a total of 30 minutes.
223497796|NCT06099483|OTHER|Action observation and motor imagery|EEG recording was taken while watching a 10-minute video recording of specified breathing exercises and imagining the exercises.
223497797|NCT06099483|OTHER|Active breathing exercise|EEG recording was taken while the physiotherapist performed active breathing exercises for 10 minutes.
224205760|NCT04203758|OTHER|Cereal products based on rye|Participants will receive a fixed amount of rye based cereals products, corresponding to approx 650 kcal/day.
224188150|NCT01777022|OTHER|A package of interventions|"A package of interventions consisting of strategies for increasing pregnant women's awareness of the need to report early when they perceive a reduction in fetal movements, followed with a management plan for identification and delivery of the at risk fetus in such women, will reduce rates of stillbirth"
224188151|NCT03107741|OTHER|Conventional Exercise|Subjects in this group will receive three 1-hour conventional exercise training sections per week for 12 weeks
224188152|NCT03107741|OTHER|Tai Chi|Subjects in this group will receive three 1-hour tai chi training sections per week for 12 weeks
224188153|NCT00511602|DRUG|Technosphere Insulin|Technosphere Insulin Inhalation Powder
224188154|NCT00511602|DRUG|Technosphere Placebo|Technosphere Inhalation Powder
224188155|NCT06566937|OTHER|E-health video|"Length: The video is approximately 10-15 minutes long, making it concise and easy to watch in one sitting.~Visuals: Includes engaging visuals, such as animations, graphics, and real-life footage, to illustrate key concepts and keep viewers engaged.~Tone: The tone is supportive, empathetic, and empowering, aiming to create a positive and encouraging atmosphere."
224188156|NCT01501019|OTHER|Exercise training|"Sjöegren arm: 30-60 minutes of combined aerobic and strength exercises, twice a week, moderate intensity.~Myositis arm: 30 minutes of resistance training combined partial blood flow restriction, twice a week, low intensity.~Takayasu's arteritis arm: 30-50 minutes of aerobic, twice a week, moderate intensity."
224188157|NCT03737812|DRUG|elezanumab|solution for infusion
224188158|NCT03737812|DRUG|placebo|solution for infusion
223497798|NCT06099483|OTHER|Control group|EEG recording was taken while resting with eyes closed for 10 minutes.
223497799|NCT02013427|DRUG|Naproxen|Take one 500mg naproxen capsule twice a day.
223497800|NCT02013427|DRUG|Placebo|Take one placebo capsule twice a day.
223497801|NCT02013427|DRUG|Omeprazole|Take one 20mg omeprazole capsule twice a day.
223497802|NCT03906994|OTHER|Video game Mario Kart Wii|Subjects will place a patch over the better-seeing eye and play the video game Mario Kart Wii for a total of 40 hours over a 1 month perior
223497803|NCT00430365|DRUG|lenalidomide|oral drug
223497804|NCT00430365|DRUG|placebo|oral placebo
223590362|NCT05772910|OTHER|EDU-EXER|This group will carry out the same two previous interventions together.
223590363|NCT05772910|OTHER|CONtrol|CONtrol group will continue the usual clinical treatment and their normal life
223590364|NCT03098745|DEVICE|Omafilcon A|contact lens
224188159|NCT05018390|OTHER|Osteopathic manipulative treatment|Participants will be positioned on an exam table supine, seated, or decubitus. Osteopathic manipulations will consist in corrective micro-movements applied on synovial joints, on the skull, the teeth and/or visceral structures of the abdomen or the thorax. Local pressures won't exceed a few tens of grams/cm². Practitioners will realize between 15 and 25 technical gestures per participant. Treatment will last 30 minutes (plus or minus 5 minutes) on average. The technical gestures are referenced in the Glossary of Osteopathic Terminology published by the American Association of Colleges of Osteopathic Medicine (2017).
224188160|NCT05018390|OTHER|Sham Osteopathic manipulative treatment|Participants will be positioned on an exam table supine, seated, or decubitus. They will receive 20 gestures that will be standardized and different from actual osteopathic manipulations (but not identifiable as sham manipulations by the participants). The duration of the sham treatment will be the same as the actual treatment.
224188161|NCT05267964|PROCEDURE|Epping resection arthroplasty|Follwing the described epping resection arthroplasty, The first ray was immobilized using an orthosis for four weeks postoperatively in both study groups followed by eight weeks of physical therapy.
223590365|NCT03098745|DEVICE|Somofilcon A|contact lens
223590366|NCT03098745|DEVICE|Omafilcon A - Proclear (PC)|contact lens
223590367|NCT00500760|DRUG|Cisplatin|Administered intravenously (IV; in a vein)
223590368|NCT00500760|RADIATION|Standard Fractionation Radiotherapy|70 Gy administered in 2 Gy fractions daily for 5 days a week for 7 weeks (35 fractions)
223590369|NCT00500760|DRUG|Panitumumab|Administered intravenously
223745940|NCT04287712|DIAGNOSTIC_TEST|Plasma lipids|Plasma lipids were detected by an Ultimate 3000 ultra-high-performance liquid chromatography (UHPLC) system coupled with Q-Exactive MS (Thermo Scientific) . Then a detection model was built based on plasma lipids using machine learning algorithm.
224205761|NCT04203758|OTHER|Cereal products based on wheat|Participants will receive a fixed amount of wheat based cereals products, corresponding to approx 650 kcal/day.
223497805|NCT00008177|RADIATION|iodine I 131 monoclonal antibody BC8|Given IV
223497806|NCT00008177|RADIATION|total-body irradiation|Undergo total-body irradiation
223497807|NCT00008177|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Undergo allogeneic peripheral blood stem cell transplantation
223497808|NCT00008177|PROCEDURE|peripheral blood stem cell transplantation|Undergo allogeneic peripheral blood stem cell transplantation
223497809|NCT00008177|DRUG|fludarabine phosphate|Given IV
223497810|NCT00008177|DRUG|cyclosporine|Given orally or IV
223497811|NCT00008177|DRUG|mycophenolate mofetil|Given orally or IV
223497812|NCT00008177|OTHER|laboratory biomarker analysis|Correlative studies
223497813|NCT02177357|DRUG|Pramipexole|
223497814|NCT02177357|DRUG|Placebo|
223497815|NCT05779644|DRUG|Liraglutide|Liraglutide is injected once a day.
223497816|NCT05779644|DRUG|Semaglutide|Semaglutide is injected once a week.
223497817|NCT05779644|DRUG|Metformin|Metformin is taken orally daily.
223590370|NCT03779074|DRUG|10d bismuth quadruple therapy|rabeprazole 20 mg b.i.d. plus tripotassium dicitrate bismuthate 300 mg, tetracycline 500 mg and metronidazole 250 mg q.i.d. for 10 days
223590371|NCT03779074|DRUG|14d hybrid therapy|a dual regimen with rabeprazole 20 mg and amoxicillin 1 g b.i.d. for 7 days followed by a quadruple regimen with rabeprazole 20 mg, amoxicillin 1 g, clarithromycin 500 mg and metronidazole 500 mg b.i.d. for 7 days
223590372|NCT03779074|DRUG|14D high-dose dual therapy|rabeprazole 20 mg and amoxicillin 750 mg q.i.d. for 14 days
223590373|NCT05435118|OTHER|EMONO + audiovisuals tool|EMONO + use of audiovisuals tool on smartphone or tablet
223745941|NCT01176266|DRUG|asfotase alfa|
223745942|NCT02229136|DRUG|Miracle Mouthwash Plus Hydrocortisone|Miracle Mouthwash Plus Hydrocortisone (16 oz recipe/480 ml)
223745943|NCT02229136|DRUG|Prednisolone|Prednisolone oral solution 15 mg/5 ml
224188162|NCT05267964|PROCEDURE|CMC I prosthesis|Follwing the described CMC I prosthesis procedure, The first ray was immobilized using an orthosis for four weeks postoperatively in both study groups followed by eight weeks of physical therapy.
224188163|NCT02624713|BEHAVIORAL|obesity treatment|"1. Parents' education groups for nutrition and healthy behavior with a dietician and a social worker every 2 weeks for5 months, for a total of 10 meetings. This part of the intervention aimed at providing parents with effective tools for modification of lifestyle and the family environment.~2. Children's individual therapy consisted of 6 individual meetings with a family physician, a physical therapist specializing in children's physical activity, and a dietician. This part of the intervention aimed at modifying nutrition and lifestyle; the physical therapist can help children incorporate physical activity into their routine.~3. Physical activity groups for the children, with individual physical fitness monitoring. twice a week for 6 months. ."
224309145|NCT05806918|DRUG|Recombinant Human Interferon α-2b Gel (After the Alteration)|Recombinant human interferon α-2b gel (after the alteration of the active ingredient manufacturer) will be applied to the lesions as a thin layer, at the frequency of four times a day, together with the therapy of valaciclovir hydrochloride.
224309146|NCT05806918|DRUG|Recombinant Human Interferon α-2b Gel (Before the Alteration)|Recombinant human interferon α-2b gel (before the alteration of the active ingredient manufacturer) will be applied to the lesions as a thin layer, at the frequency of four times a day, together with the therapy of valaciclovir hydrochloride.
224309147|NCT04232111|DEVICE|Heat|Heat applied to hand
224309148|NCT04232111|DEVICE|Vacuum|vacuum applied to hand
223497818|NCT03411551|PROCEDURE|regional anesthesia|The analgesic effectivity of the forearm intravenous regional anesthesia and the ultrasound-guided peripheral nerve block will be investigated in patients undergoing carpal tunnel release
223497819|NCT01653886|OTHER|Breakfast (1-2 hours, in the morning)|You will be required to taste small portions (1 to 2 bites) of 4 different breakfast meals. You will be asked to reate the taste after each meal. Meals will vary in fat and energy density, and will consist of two high fat diets and a high carbohydrate diet. Energy density is the ammount of enregy of kilocalories in one gram of the food.
223497820|NCT01653886|OTHER|Lunch (1-2 Hours, at midday)|You will be required to taste small portions of 4 different lunch meals. You will be asked to reate the taste after each meal. Meals will vary in fat and energy density, and will consist of two high fat diets and a high carbohydrate diet. Energy densityis the ammount of enregy of kilocalories in one gram of the food.
223497821|NCT01653886|OTHER|Dinner (1-2 hours, in the afternoon)|You will be required to taste small portions of 4 different dinner meals. You will be asked to reate the taste after each meal. Meals will vary in fat and energy density, and will consist of two high fat diets and a high carbohydrate diet. Energy densityis the ammount of enregy of kilocalories in one gram of the food.
223497822|NCT07114302|BEHAVIORAL|Interactive E-book BBTI Group|Researchers will guide you on how to use the interactive e-book and help install it on your smartphone. Over the next four weeks, you will be asked to record your sleep diary daily. You will use the e-book to perform sleep stimulus control, sleep restriction, and relaxation techniques to promote better sleep. Researchers will contact you via LINE during the second and fourth weeks, and may call you if necessary.
223590374|NCT05160818|RADIATION|Hypofractionated stereotactic radiotherapy (HFSRT) versus single fraction stereotactic radiotherapy radiosurgery (SRS)|intervention description see above
223590375|NCT00141115|DRUG|levetiracetam|Levetiracetam 1500 mg BID
223590376|NCT01008085|DEVICE|Stentys coronary stent|Self-expanding Nitinol stent
223590377|NCT01008085|DEVICE|Balloon-expandable stent|VISION/Driver
223590378|NCT03133312|DRUG|Chlorhexidine Gluconate|Pre-operative vaginal preparation with 4% Chlorhexidine Gluconate Intervention
223590379|NCT03133312|DRUG|Povidone-Iodine Scrub and Paint|Pre-operative vaginal preparation with 10% Povidone-Iodine Scrub and Paint Intervention
223590380|NCT06352255|PROCEDURE|Digital block|Frost's H technique
223590381|NCT04197388|DEVICE|Inspiratory muscle training device|Inspiratory muscle training, 6 cycles of 30 breaths for 12 weeks.
223590382|NCT04133194|DRUG|Mesalazine|1600 mg Asacol \[mesalazine\]
223590383|NCT04133194|DRUG|Mesalazine|800 mg Asacol \[mesalazine\]
223745944|NCT01140321|DRUG|Neridronate|"Neridronate is an aminobisphosfonate of third generation that has been proved in several clinical trials to have the ability to inhibit osteoclast-mediated bone resorption and it is generally well tollerated also at high doses. Thanks to these properties it has been used in the treatment of several bone disorders such as Paget's disease and Osteogenesis Imperfecta. Neridronate, given intravenously or orally (tablets), reduces both the levels of bone alcaline phosphatase and of the other markers of bone resorption activity. Recently it has been approved by the Italian Ministry of Health for the commercialization with the indication Osteogenesis Imperfecta."
223745945|NCT04783805|DIAGNOSTIC_TEST|Conservative management with regular follow-up|Women will be followed-up every 4 months, with colposcopy and cytology at each visit.
224309149|NCT04232111|DEVICE|sham|neither heat nor vacuum
223590384|NCT00775333|PROCEDURE|Outcome after carpal tunnel release|Follow the outcome after standard carpal tunnel release in diabetic and non-diabetic patients
223590385|NCT01242566|DRUG|Temozolomide|orally 150-200 mg/m2/day for 5 consecutive days every 4 week
223590386|NCT01344720|DRUG|etoricoxib|"At visit 2 eligible patients will then receive Etoricoxib 30mg for 2 weeks. Patients who achieve a clinically meaningful improvement in pain at the end of this period (defined as a ≥30% improvement in BPI avg daily pain intensity), will continue therapy up to week 5 (visit 4), if they become non-responders between week 4-5, they can be tapered off meds and then discontinued from the study. Patients who do not achieve a clinically meaningful improvement will be considered non-responders and will be randomized to receive either titration of their monotherapy or combination treatment.~Group 1 non-responders will receive an increase in monotherapy from etoricoxib 30mg to eterocoxib 60mg/die."
223745946|NCT04783805|PROCEDURE|Conization|Women with progression of HSIL, HSIL persistence after 24 months of follow-up, or that no longer meet the criteria for surveillance will have conization
223745947|NCT03265197|DRUG|Intra-tympanic injection of drugs|Intratympanic injection of combined lidocaine and dexamethasone in treatment of tinnitus
224309150|NCT06189638|DRUG|Antimicrobial Peptide PL-5 Topical Spray and Placebo|Antimicrobial Peptide PL-5 Topical Spray At about 5 cm vertically above the wound, the investigator sprays antimicrobial peptide PL-5 topical spray on the test wound. The cover area after spraying is a cone with a surface diameter of about 5 cm and area about 20 cm2. One spray dose is about 0.1 ml. The number of drug sprays is determined according to the wound area in the screening period, and the determined dose is applied consistently. During the operation, an effective spray operation is completely ejected with no leakage.
224309151|NCT03395405|DRUG|Nitazoxanide|One 500 mg tablet twice daily with food for 56 consecutive doses
224188164|NCT00690209|PROCEDURE|Autologous bone marrow derived stem cells myocardial transplantation|
224188165|NCT03803956|DEVICE|Active PBMT|The PBMT will be performed using the dose of 10J per diode, previously determined by a previous study and power output of 100 mW per diode, also previously determined. PBMT will be performed at nine different sites of the knee extensor muscles, six different sites of the knee flexor muscles and two different sites of the plantar flex muscles. As the cluster will be 5 diodes and 17 different sites will be irradiated, a total of 85 points will be irradiated in each lower limb, a total of 850 J of energy. The active PBMT will be performed before a progressive running test.
224188166|NCT03803956|DEVICE|Placebo PBMT|The placebo PBMT will per performed using the dose of 0 J per diode. Placebo PBMT will be performed at nine different sites of the knee extensor muscles, six different sites of the knee flexor muscles and two different sites of the plantar flex muscles. As the cluster will be 5 diodes and 17 different sites will be irradiated, a total of 85 points will be irradiated in each lower limb, a total of 0 J of energy. To ensure blinding, the device emitted the same sound regardless of the programmed mode (active or placebo PBMT). The placebo PBMT will be performed before a progressive running test.
224188167|NCT00987909|BIOLOGICAL|Specific allergen immunotherapy (placebo)|Drops for sublingual administration, 0 mcg (placebo), once daily administration for 16 weeks
223590387|NCT01344720|DRUG|oxycodone|"At visit 2 eligible patients will then receive Etoricoxib 30mg for 2 weeks. Patients who achieve a clinically meaningful improvement in pain at the end of this period (defined as a ≥30% improvement in BPI avg daily pain intensity), will continue therapy up to week 5 (visit 4), if they become non-responders between week 4-5, they can be tapered off meds and then discontinued from the study. Patients who do not achieve a clinically meaningful improvement will be considered non-responders and will be randomized to receive either titration of their monotherapy or combination treatment.~Group 2 non-responders will receive in addition to etoricoxib 30mg/day a dose of oxycodone CR 5mg q12hr (dose of 5mg tablet is available in Italy)."
223590388|NCT05622214|DIETARY_SUPPLEMENT|Else nutrition formula|Plant based nutrition from almond and buckwheat
223590389|NCT00224341|DEVICE|Pacemaker Vitatron Selection 9000|
223590390|NCT00224341|DEVICE|Pacemaker Vitatron T70|
224188168|NCT00987909|BIOLOGICAL|Specific allergen immunotherapy|Drops for sublingual administration, 4.5 mcg Fel d1/day, once daily administration for 16 weeks.
224188169|NCT00987909|BIOLOGICAL|Specific allergen immunotherapy|Drops for sublingual administration, 9.0 mcg Fel d1/day, once daily administration for 16 weeks
224188170|NCT00987909|BIOLOGICAL|Specific allergen immunotherapy|Drops for sublingual administration, 18.0 mcg Fel d1/day, once daily administration for 16 weeks
224205762|NCT00191256|DRUG|Gemcitabine|
224205763|NCT00191256|DRUG|Carboplatin|
224205764|NCT00191256|DRUG|Paclitaxel|
224205765|NCT00607906|DRUG|SB-756050 immediate release capsule|SB-756050 immediate release capsules will be size 0, white, opaque capsules with no identifying markings, containing white to off-white drug layered pellets. Each capsule will contain 5, 25 or 100 milligrams of SB-756050.
223590391|NCT04956588|COMBINATION_PRODUCT|surgical robot|The surgical robot completed the screw placement according to the surgical plan, and the researchers closely monitored the screw placement process.
224205766|NCT00607906|DRUG|SB-756050 modified release capsule|SB-756050 modified release capsules will be size 0, white, opaque capsules with no identifying markings, containing white to off-white enteric coated drug layered pellets. Each capsule will contain either 25or 100 milligrams of SB-756050.
224205767|NCT00607906|DRUG|Placebo|Subjects will also receive placebo capsules.
224205768|NCT02107807|BIOLOGICAL|Novartis Investigational H5N1 vaccine|2 doses of 0.5 ml, 3 weeks apart
224205769|NCT02107807|BIOLOGICAL|Novartis Investigational H5N1 vaccine|2 doses of 0.5 ml, 3 weeks apart
224205770|NCT02107807|BIOLOGICAL|Novartis Seasonal Influenza Vaccine|2 doses of 0.5 ml, 3 weeks apart
224205771|NCT02107807|BIOLOGICAL|Novartis Seasonal Influenza Vaccine|2 doses of 0.5 ml, 3 weeks apart
224205772|NCT00141479|DRUG|Bifeprunox|
224205773|NCT04141670|DRUG|S48168|A novel oral small molecule which is designed to repair leaky RYR1 channels
224205774|NCT06566859|OTHER|NRS 0. hour|Numerical rating scala
224205775|NCT06566859|OTHER|NRS 6. Hour|Numerical rating scala
224205776|NCT06566859|OTHER|NRS 12. Hour|Numerical rating scala
224205777|NCT06566859|OTHER|NRS 24. Hour|Numerical rating scala
224205778|NCT02656875|DRUG|TRV130|
224205779|NCT06354959|BEHAVIORAL|Prehabilitation|8-week community based prehab program
224205780|NCT06564467|DRUG|JMT202|subcutaneous injection
224205781|NCT06564467|DRUG|Placrbo|subcutaneous injection
224205782|NCT05669924|DRUG|Methylphenidate|0.35 mg/kg methylphenidate will be administered after baseline testing and 45 min-1 hr before post-intervention testing.
224205783|NCT05669924|DRUG|Placebo|Placebo for methylphenidate
224205784|NCT03681275|DRUG|Tofacitinib 10 MG [Xeljanz]|administered twice daily for two days
224205785|NCT03681275|DRUG|Placebo to match Tofacitinib|administered twice daily for two days
224205786|NCT05072145|OTHER|Telemedicine|Receiving care in a tele-ED hospital
224205787|NCT02184169|DEVICE|General Electric Healthcare E-COVX Gas Monitoring Module for VO2 Measurments|Breath to breath VO2 measurements
224205788|NCT02184169|DEVICE|Edwards Continuous SVO2 Catheter and Monitoring System - 4.5 fr|Edwards continuous SVO2 measurement system
224205789|NCT00719758|DRUG|TRK-100STP (BERASUS LA)|oral
224205790|NCT00719758|DRUG|AST-120 (Kremezin®)|oral
224205791|NCT02291172|BEHAVIORAL|Intervention JEP|A blend of JASP-EMT using SGDs with parent training intervention with the addition of individualized DTT to teach receptive language, imitation, and joint attention when children lack these skills at entry.
224188171|NCT03273933|DEVICE|DragONE|The DragONE application for iOS and Android, developed in collaboration with the Institute for Educational Technologies of the National Research Council of Palermo, allow children to daily fill electronically the C-ACT questionnaire and the symptom diary card.
224188172|NCT03273933|DEVICE|SmartOne|A little portable spirometer connected to DragONE allows daily PEF monitoring.
223497823|NCT07114302|BEHAVIORAL|BBTI-APP Group|Researchers will assist you in creating an account for the mobile application and will explain the interface and how to operate it. Over the next four weeks, you will be asked to record your sleep diary daily. You will use the mobile app to carry out sleep stimulus control, sleep restriction, and relaxation techniques to improve sleep. Researchers will contact you via LINE during the second and fourth weeks, and may call you if necessary.
223497824|NCT07116421|DRUG|2-phenylethanol rose scent|"Name: 2-phenylethanol (rose scent). Dose: 3 drops, diffused into room air over 24 hours. Frequency: Once over 24 hours. Route of administration: Essential oil diffuser. Manufactured by: The Essential Oil Company in Portland, OR. Manufacturing details: The rose scent is purified by hydrodistillation, shelf-stable, and in terms of verification of quality has been previously used in a peer-reviewed and IRB-approved study by Woo et al (2023) published in Frontiers in Neuroscience. Preparation: The Key Personnel listed in the study's IRB will prepare the rose essential oil scent by squeezing 3 drops of the product from the manufactured bottle into the essential oil compartment of the Aroma Ace™ MINI Diffuser essential oil diffuser, corresponding with both the rose essential oil and diffuser manufacturers' instructions for each product respectively."
223497825|NCT07114640|DRUG|Mirabegron 25mg|Taking 25 mg mirabegron in the nighttime
223497826|NCT07114640|DRUG|Solifenacin 5 mg|Taking 5 mg solifenacin in the nighttime
223497827|NCT07114640|DRUG|Tolterodine 4 mg|Taking 5 mg tolterodine in the nighttime
223497828|NCT07114640|DRUG|Oxybutynin ER 5 mg|Taking 5 mg oxybutynin ER in the nighttime
223590392|NCT04956588|COMBINATION_PRODUCT|controlled approach|The screw placement was performed using a controlled approach according to the surgical plan.
223590393|NCT03408210|RADIATION|total body irradiation|"Drug: Cyclophosphamide 60 mg/kg/day intravenous x 2 days pre-transplant, total dose 120 mg/kg~Drug: Cyclosporine or tacrolimus Beginning on Day -1 pre-transplant maintaining a level of 150-250 ng/ml or 5-10 ng/ml respectively. Cyclosporine or tacrolimus dosing will be monitored and altered as clinically appropriate by physician, and discontinue at approximately day + 180 post-transplant.~Drug: Methotrexate 15 mg/m2 intravenous on days 1, 10 mg/m2 intravenous on days 3, 6 and 11 after transplantation.~Intervention: Total Body Irradiation Dose of 10 Gy TBI (fraction size of 5 Gy given once a day on days -2 and -1).~Procedure: Peripheral blood stem cell transplantation product will be infused via intravenous drip on Day 0."
223590394|NCT03408210|RADIATION|total marrow and lymphoid irradiation|"Drug: Cyclophosphamide 60 mg/kg/day intravenous x 2 days pre-transplant, total dose 120 mg/kg~Drug: Cyclosporine or tacrolimus Beginning on Day -1 pre-transplant maintaining a level of 150-250 ng/ml or 5-10 ng/ml respectively. Cyclosporine or tacrolimus dosing will be monitored and altered as clinically appropriate by physician, and discontinue at approximately day + 180 post-transplant.~Drug: Methotrexate 15 mg/m2 intravenous on days 1, 10 mg/m2 intravenous on days 3, 6 and 11 after transplantation.~Intervention: Total Marrow and Lymphoid Irradiation Dose of 12 Gy TMLI (fraction size of 4 Gy given once a day on days -6, -5 and -4).~Procedure: Peripheral blood stem cell transplantation product will be infused via intravenous drip on Day 0."
223745948|NCT03265197|OTHER|Data management of intratympanic drugs|intervention by statistical analysis of Intratympanic injection of combined lidocaine and dexamethasone in treatment of tinnitus
223745949|NCT02413541|PROCEDURE|Polymyxin-B Hemoperfusion|Endotoxin removal
223745950|NCT02413541|PROCEDURE|Standard treatment|
224188173|NCT05896605|DRUG|Azathioprine|Before medication, TPMT activity was normal, and AZA was started at small doses and added every two weeks after no AEs, namely 50 mg qd for two weeks, 50mg bid for two weeks, and maintained at 50mg tid.
224188174|NCT02702115|BIOLOGICAL|SB-318|A single dose of each of the three components of SB-318 \[zinc finger nucleases (ZFN1, ZFN2, and hIDUA Donor)\] administered via intravenous (IV) infusion.
224188175|NCT03108560|PROCEDURE|sublobar resection|Patients receive sublobar resection, which includes wedge resection and segmentectomy.
224188176|NCT03108560|PROCEDURE|lobectomy|patients receive lobectomy
224188177|NCT03644862|DEVICE|etafill|Etafill is a HA formulation intended to be used in opthalmic anterior segment cataract surgery.
224188178|NCT00019565|PROCEDURE|magnetic resonance imaging|
224188179|NCT00019565|PROCEDURE|positron emission tomography|
224188180|NCT00019565|RADIATION|fludeoxyglucose F 18|
223497829|NCT07116980|DEVICE|'Transcranial Direct Current Stimulation - tDCS|"Participants will receive by trained personnel, transcranial direct current stimulation (tDCS) targeting the dorsolateral prefrontal cortex (DLPFC). According to the international 10-20 EEG system, the anodal electrode will be placed over the left F3 position and the cathodal electrode over the right F4 position. Active stimulation will be delivered using a constant current of 2 milliamperes (mA) for 20 minutes per session. The intervention will consist of twelve consecutive daily sessions (Monday to Friday), totaling four week of treatment. A certified tDCS device will be used, programmed to deliver a ramp-up and ramp-down period of 30 seconds.~In the sham condition, the same electrode montage will be used; however, the device will automatically ramp down the current after 30 seconds, mimicking the initial tingling sensation without producing lasting neuromodulatory effects. This sham protocol is commonly used to ensure participant blinding in tDCS studies."
223497830|NCT07118826|BEHAVIORAL|Standard Brief Intervention|Immediately following completion of the baseline assessment, participants will be texted a link to a secure website which contains the participant's personalized feedback. Personalized feedback is automatically presented via a programming algorithm that is based on the participants baseline survey responses. The personalized feedback component will include a personalized substance use profile, information on peer norms, prior substance-related consequences experienced by the participant, practical costs (e.g., money spent on substances, fees for a DUI), and standard protective behavioral strategies to limit substance-related risk.
224188181|NCT04642326|DEVICE|Test Group: experimental - UVC Therapy applied|in addition to traditional drug therapy, apply a surgical treatment procedures with using special UVC device.(Antiviral + Antimalarial + Antibiotic Treatment + UVC Therapy)
224188182|NCT05950399|PROCEDURE|Echocardiography|Undergo resting echocardiography
224188183|NCT05950399|OTHER|Electronic Health Record Review|Ancillary studies
224188184|NCT05950399|OTHER|Questionnaire Administration|Ancillary studies
224188185|NCT05950399|PROCEDURE|Stress Echocardiography|Undergo stress echocardiography
224188186|NCT06380985|BEHAVIORAL|Personalized VR Alcohol Approach Bias Modification (ApBM) Condition|The Personalized VR ApBM will consist of 2D pictures representing alcohol or positive images (e.g., representing family or friends enjoying time together; sports, pets; travel and holidays, etc.) presented in a unique format in VR (e.g., landscape/portrait orientation), which will serve as the cue requiring a stimulus response. Participants are instructed to push the images away from them if they are presented in one format (e.g., landscape) and grab (using lever on VR controller) the images and pull towards themselves in response to a separate format (e.g., portrait pictures) across a virtual table. Each training session starts with 10 practice trials showing neutral objects (containers), followed by 240 training trials (120 alcohol and 120 non-alcohol trials). Training effect is achieved by altering the contingency of push vs. pull by image type (alcohol vs. positive).
224188187|NCT06380985|BEHAVIORAL|Sham Condition|Sham training is identical to ApBM, except the contingency of each orientation (e.g., portrait or landscape) representing a push vs. a pull is altered to diminish training effect.
224188188|NCT02564094|DRUG|Epoetin beta|Participants will receive SC epoetin beta as 30,000 international units (IU) once weekly for 20 weeks.
224188189|NCT00285857|DRUG|Lovastatin|"Lovastatin 80 mg/day as 40 mg orally twice daily.~Lovastatin is approved by FDA as a cholesterol-lowering agent."
224188190|NCT06304064|BIOLOGICAL|Allogeneic Cardiosphere-Derived Cells (CAP-1002)|Intravenous infusion delivery of Allogeneic Cardiosphere-Derived Cells (CAP-1002; 75 million CDCs)
224188191|NCT04140942|BEHAVIORAL|Virtual Reality Job Interview Training|Participants will engage in training related to preforming well during a job interview as well as repeated job interview practice with a virtual hiring manager. Participants will receive feedback and tips on improving skills throughout training.
224188192|NCT04140942|BEHAVIORAL|Services as usual|Study participants will be receiving Vocational Village services as usual that may include but is not limited to vocational skill training, daily living skill training, and social skill training.
224188193|NCT01994070|DRUG|Electrical-first|Patients will be placed on cardiopulmonary blood pressure monitoring, and sedated with propofol 0.5 - 1.0 mg / kg. Once a Ramsay Sedation Scale score of 5 or greater is reached, the physician will attempt synchronized electrical cardioversion with 100 J, 200 J, 200 J. If the patient converts to normal sinus rhythm by the third shock, the physician may discharge the patient. If atrial fibrillation is maintained, the patient will receive intravenous procainamide 17 mg / kg over 30 minutes. If the rhythm has changed from atrial fibrillation to normal sinus within one hour, the attending physician may discharge the patient, otherwise a cardiologist will be consulted.
224188194|NCT01994070|DRUG|Chemical-first|Patients will be placed on cardiopulmonary blood pressure monitoring, and will receive intravenous procainamide 17 mg / kg over 30 minutes. If the rhythm has changed from atrial fibrillation to normal sinus within one hour, the attending physician may discharge the patient. If the rhythm has not changed, then the patient will be continue to have cardiopulmonary monitoring, but also be attended by a respiratory therapist. The patient will be sedated with propofol 0.5 - 1.0 mg / kg. Once a Ramsay Sedation Scale score of 5 or greater is reached, the physician will attempt synchronized electrical cardioversion with 100 J, 200 J, 200 J. If the patient converts to normal sinus rhythm by the third shock, the physician may discharge the patient, otherwise a cardiologist will be consulted.
224309152|NCT03395405|OTHER|Placebo|One tablet twice daily with food for 56 consecutive doses
224188195|NCT03927209|DRUG|BI 1467335|tablet
224309153|NCT06570044|DIAGNOSTIC_TEST|PerioMonitor|Collection of oral rinse specimen and perform the PerioMonitor test as per the method described in the instructions for use
224188196|NCT01161173|DRUG|Erlotinib|Erlotinib was provided in the retail versions of the product.
224188197|NCT00993382|DRUG|Celivarone|"Pharmaceutical form: capsule~Route of administration: oral"
224188198|NCT00993382|DRUG|Amiodarone|"Pharmaceutical form: capsule~Route of administration: oral"
224188199|NCT00993382|DRUG|Matching placebo|"Pharmaceutical form: capsule~Route of administration: oral~Matching placebo added to active drug if any for a total of 3 capsules per intake"
224188200|NCT03947073|OTHER|Education|Three cartoon illustrated educational videos with information on gestational diabetes will be provided to the patient in addition to standard of care.
224188201|NCT03693846|DRUG|Nivolumab|IV infusion per institutional guidelines and the Package Insert
224188202|NCT03693846|DRUG|Ipilimumab|IV infusion per institutional guidelines and the Package Insert
224309154|NCT05499286|OTHER|Mindfulness Program|Mindful Awareness and Resilience Skills for Adolescents (MARS-A) Curriculum
224309155|NCT02713919|BEHAVIORAL|Adapted German PRO-SELF© Plus Pain Control Program|Two in-home visits (60 minutes) with at least weekly follow-up (visit or telephone call according to algorithm): Structured and tailored components; review of pain diary with participant, provision of information on pain medication, nurse coaching regarding pain self-management, detailed side-effect management plan, if distressing side-effects arise, re-evaluation together with participant at each subsequent visit.
224309156|NCT01364181|DRUG|Udenafil|Udenafil 50mg qd po
224309157|NCT04345601|BIOLOGICAL|Mesenchymal Stromal Cells|Patients will be given the cell product by intravenous injection (into the vein through an IV line). Dose:1 x 10\^8 MSCs.
224309158|NCT04345601|OTHER|Supportive Care|Patients will receive supportive care per their treating physician
224309159|NCT00521534|DEVICE|CRT with atrial overdrive pacing|Both groups receive CRT, one group receives atrial overdrive pacing
224309160|NCT00403507|BEHAVIORAL|Participation in a monitored exercise program|No contact with control group during 20 weeks.
224309161|NCT00403507|BEHAVIORAL|Personalized aerobic and strength training.|Three-days per week for 20 weeks at hospital gym under supervision of exercise specialist.
224309162|NCT03330054|DEVICE|fundoscope|Fundoscope for eye examination
224309163|NCT01499459|GENETIC|autologous mesenchymal stem cell transplantation|Every patient is given 1x106 MSCs per kg infused via peripheral vein.
224309164|NCT00602368|OTHER|histological technique|
224309165|NCT00602368|OTHER|laboratory biomarker analysis|
224309166|NCT00602368|PROCEDURE|colposcopic biopsy|
224309167|NCT00602368|PROCEDURE|colposcopy|
224309168|NCT00602368|PROCEDURE|light-scattering spectroscopy|
224309169|NCT00602368|PROCEDURE|loop electrosurgical excision procedure|
224188203|NCT05463146|OTHER|Deep breathing excercises|Deep breathing, which is also known as diaphragmatic breathing, is a technique that is based on the notion that mind and body integration produces relaxation technique requires participants to contract the diaphragm, slowly inhaling and exhaling. Deep breathing appears to amplify blood oxygen levels, massages the inner organs located in or close to the abdomen, and possibly stimulates the vagus nerve
224188204|NCT05463146|OTHER|Deep breathing exercises +and progressive muscle relaxation techniques|Begin with a deep breathing exercise. Inhale deeply through your nose, feeling your abdomen rise as you fill your body with air. Then slowly exhale out the mouth, the navel pulling in toward the spine as you expel the stale air out. Repeat 3-5 cycles
224188205|NCT05463146|OTHER|Deep breathing exercises|Deep breathing, which is also known as diaphragmatic breathing, is a technique that is based on the notion that mind and body integration produces relaxation technique requires participants to contract the diaphragm, slowly inhaling and exhaling. Deep breathing appears to amplify blood oxygen levels, massages the inner organs located in or close to the abdomen, and possibly stimulates the vagus nerve
224188206|NCT01407068|BIOLOGICAL|AA4500 collagenase clostridium histolyticum|2 concurrent injections (0.58 mg) into 2 cords on the same hand
224309170|NCT00357253|DRUG|capecitabine|This is a dose escalation study. 375, 500, 650, or 850 mg/m2 capecitabine RDT is given orally daily in two divided doses approximately 12 hours apart beginning at the start of radiation therapy and continuing for 9 weeks. After a two week break, patients receive twice daily oral capecitabine, either 900 mg/m2 or 1250 mg/m2, approximately 12 hours apart for 14 days followed by a 7-day rest period for a total of 3 courses.
224309171|NCT00357253|RADIATION|radiation therapy|Participants receive local radiation once daily, 5 days/week for 9 weeks for a total dose of 5580 cGy.
224309172|NCT02897245|OTHER|No intervention|
224309173|NCT04011605|PROCEDURE|Biological Sample of Carious Dentin|Dental patient volunteers will have either areas of decayed tooth structure or recurrent caries defective fillings removed using conventional, routine procedures, which will include: local anesthesia; tooth isolation using rubber dam; removal of superficial decay, weakened tooth structure or defective filling materials with rotary tooth cutting instruments; and then removal of softened dentin using sterile sharp spoon excavators, by hand. The limit of dentin removal will be determined by the clinician's estimate of tooth hardness, that is, using present conventional and ethical practice.
224309174|NCT04127630|PROCEDURE|mobilization of the larynx|we aim to asses with an magnetic resonance imaging the compressibility of the oesophagus with LPEC
224309175|NCT03251339|DRUG|MSB11455|Participants received a single subcutaneous injection of MSB11455 6 milligram (mg) per (/) 0.6 milliliter (mL) on Day 1 in morning of treatment period 1 (28 Days) and 2 (28 Days). Period 1 and Period 2 are separated by a washout period of 35 Days.
223497831|NCT07118826|BEHAVIORAL|Trauma-Informed and Peer-Supported Brief Intervention|In addition to the components of the standard brief intervention, the TIPS-BI will include personalized feedback about participants use of substances to cope. Additionally, participants will be provided with psychoeducation about the link between substance use, trauma, and coping motives, and information highlighting the iatrogenic effects that substance use has on negative emotions. Participants will also be given a series of evidence-based alternative coping strategies for managing trauma-related distress such as anxiety, depression, and PTSD. Participants will be asked to set goals related to utilization of these alternative coping strategies. Participants will then be informed that a trained peer who is part of the research team will follow up with them via text message at the monthly time points to review adherence to their goals and offer support.
223497832|NCT07116850|DEVICE|Intermittent Theta-Burst Stimulation (iTBS)|Stimulation delivered using a Magstim RAPID2 stimulator. The target was the left DLPFC (F3 position). The protocol consisted of 20 sessions (5 days/week for 4 weeks) at 100% of the individual's motor threshold (MT), with each session delivering 2400 pulses.
223497833|NCT07116850|DRUG|Risperidone|Oral risperidone (Jiangsu Enhua Pharmaceutical Co., Ltd.) initiated at 1 mg/day and flexibly titrated based on efficacy and tolerability to a maximum of 6 mg/day.
223497834|NCT07116850|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|Manualized CBT administered twice weekly for 12 weeks. The therapy comprised an initial individual phase (4 weeks) focusing on psychoeducation and a subsequent group phase (8 weeks) targeting social and emotional skills.
223497835|NCT07117565|DRUG|Intervention 1: Intrathecal Dexmedetomidine with Bupivacaine|"Intervention 1: Intrathecal Dexmedetomidine with Bupivacaine~Detailed Description:~This intervention consists of a single intrathecal injection of 10 micrograms of dexmedetomidine combined with 15 mg (3 mL) of 0.5% hyperbaric bupivacaine, administered during spinal anaesthesia for lower limb surgery. The total volume administered is 3.5 mL. Dexmedetomidine is an alpha-2 non-opioid adjuvant used as a spinal adjuvant for enhancing analgesia"
223497836|NCT07117565|DRUG|Intervention 2: Intrathecal Fentanyl with Bupivacaine|This intervention consists of a single intrathecal injection of 25 micrograms of fentanyl combined with 15 mg (3 mL) of 0.5% hyperbaric bupivacaine, administered during spinal anesthesia for lower limb surgery. The total volume administered is 3.5 mL. Fentanyl is a lipophilic opioid commonly used as a spinal adjuvant for enhancing analgesia. This arm is being compared with dexmedetomidine to evaluate differences in POUR incidence, analgesic effectiveness, and side effect profiles.
223497837|NCT07118423|OTHER|Exercise|The intervention group performed twice per week, nonconsecutive, resistance training over 12 weeks. The sessions consisted of 1-3 sets of eight exercises at 50-70% of the estimated one-repetition maximum.
223590395|NCT03842072|DEVICE|Cervical collar|cervical collars prescribed will be use immediately following anterior cervical discectomy and fusion surgery.
223590396|NCT00468403|BIOLOGICAL|Allogeneic Pancreatic Islet Cells|Transplant of islet cells from a healthy pancreas. A dose of at least 5,000 Islet Equivalents (IEQ)/kg recipient body weight (BW) infused intraportally for the first transplant, and at least 4,000 IEQ/kg recipient BW infused intraportally for subsequent transplants.
223590397|NCT00468403|BIOLOGICAL|Belatacept|Belatacept is an inhibitor of the 2 signals that stimulate T-cells. Subjects will receive NULOJIX® (belatacept)10mg/kg through a peripheral vein on Day 0 and post-operative days 4, 14, 28, 56, 84. After Day 84 subjects will receive belatacept at a maintenance dose of 5 mg/kg every 4 weeks for the duration of study follow-up (2 years after the final islet transplant). Infusion doses will be based upon the subject's actual body weight at study Day 0 and will not be modified during the course of the study unless there is a change in body weight plus or minus 10% of Day 0 body weight.
224188207|NCT05984225|OTHER|Online learning|"The students performed a 10-week Online Learning (OL) program based on Professional Ethics. The program included:~1. Synchronous learning (1 session/week, 1 hour each).~2. Asynchronous learning: i) OL classes were recorded; ii) Moodle platform: for read breaking news, upload tasks or solve any doubt they may have through discussion forums; iii) An OL specific syllabus that consisted of five themes from the ethics knowledge; iv) An OL glossary, including the concept, explanation of the concept, and source; v) Bullet-point videos highlighting the most important issues of each theme; vi) Podcasts about Professional Ethics, Ethics in physiotherapy; vii) Links to websites; viii) Gamification using mobile Apps regarding ethical decision-making, healthcare, and Ethics or Professional Ethics, as well as an OL crossword; ix) OL activities were created and personalized comments about the activities were reported by the teachers to give feedback to the students."
223497838|NCT07119138|BEHAVIORAL|Emotional Freedom Technique|"Emotional Freedom Technique (EFT) is used as an effective method for managing various adverse conditions, including the reduction of exam anxiety. Although there are several studies in the literature on this topic, research conducted specifically with nursing students remains limited. In particular, the Surgical Nursing course is a fundamental subject offered in the second year of nursing education, encompassing both theoretical and clinical components. Academic success in this course is an important indicator of the quality of nursing education. Therefore, as a surgical nursing instructor, it is believed that reducing exam anxiety can positively influence student performance.~This study also aims to improve student success through anxiety management. To date, no studies addressing this issue with nursing students have been found in the literature."
223497839|NCT07119502|OTHER|Minimal-equipment progressive resistance training|The intervention consists of resistance training exercises that target major upper and lower body muscle groups with the use of portable equipment such as resistance bands and wrist/ankle weights. The exercise dosage will be progressively increased across the 16 weeks to achieve training adaptations. The exercise programme will be conducted three times per week, with each session lasting approximately 30 to 45 minutes.
223497840|NCT07114042|DIAGNOSTIC_TEST|Upper endoscopy|Prediction of upper gastrointestinal r\_bleeding and mortality
223590398|NCT00468403|BIOLOGICAL|Basiliximab|Immunosuppressive medication for prophylaxis of acute transplant rejection. Two Intravenous (IV) doses of basiliximab, a monoclonal antibody Interleukin 2 (IL-2) receptor blocker, will be given with the first and second (if necessary) transplants. The first dose will be 20 mg and will be given within two hours prior to islet transplant on the day of islet transplantation. The second 20 mg dose will be given on Day 4 after the transplant.If a third islet transplant is deemed necessary and performed more than 70 days after the second transplant, both doses of basiliximab will be repeated. No additional doses of basiliximab will be given with a third transplant that is performed between 30 and 70 days after the second transplant.
223590399|NCT00468403|DRUG|Mycophenolate Mofetil|Maintenance immunosuppressive therapy. Subjects will receive mycophenolate mofetil starting immediately pre-transplant on Day 0 at a dose of 1g orally twice a day for the duration of study follow-up (2 years after the final islet transplant).
223590400|NCT00468403|DRUG|Tacrolimus|Tacrolimus may be used only as a supplement to maintenance mycophenolate mofetil (MMF) in those cases where the trough level is below the therapeutic range. Tacrolimus will be administered orally twice a day to maintain trough levels of 3-5 ng/mL. Generic equivalents of Prograf® will not be permitted.
223590401|NCT00468403|PROCEDURE|Intraportal infusion of islet cells|The infusion of allogeneic pancreatic islet cells (islet transplant\[s\]) will occur intraportally.
223590402|NCT03806075|BEHAVIORAL|Second generation sequencing|Firstly, all Peutz-Jeghers patients accept second generation gene sequencing with their blood specimen
223590403|NCT03806075|BEHAVIORAL|16s rRNA gene sequencing|Secondly, All patients and Health persons accepted 16s rRNA gene sequencing with their feces specimen
223590404|NCT00790478|DRUG|Melatonin|Study Pill (5 mg/d) taken once daily, preferably an hour before bedtime, for 12 weeks.
223590405|NCT00790478|OTHER|Placebo|Study Placebo taken once daily, preferably an hour before bedtime, for 12 weeks.
223590406|NCT01583816|DRUG|Resiquimod 0.03%|topical application
223590407|NCT01583816|DRUG|Resiquimod 0.01%|topical application
223590408|NCT01583816|DRUG|placebo|topical application
223590409|NCT00455208|DRUG|Cura-100|
223590410|NCT02641067|DRUG|Doravirine|Following an overnight fast, a single coated tablet of 100 mg doravirine will be administered orally
223590411|NCT03464149|DIAGNOSTIC_TEST|One armed study, blood from each patient is analysed by four assays ( two 3rd generation and two 2nd generation assays)|Intact PTH Assay (Siemens Healthcare Diagnostics Inc); LIAISON 1-84 PTH Assay (Diasorin); PTH (1-84), biointact (Roche Diagnostics); PTH, intact (Roche Diagnostics)
223745951|NCT01756495|DRUG|Losmapimod|Wet granulation formulation, Film coated white, 7 mm round, biconvex, plain faced Tablet of 7.5 mg or 10 mg unit dose strength. Taken orally 7.5 mg BID / 20 mg QD for 5 days in one of the 4 study periods
223745952|NCT01756495|DRUG|Moxifloxacin|17.2mm x 7.1 mm capsule shaped pink biconvex tablet of 400 mg unit dose strength. Taken orally 400 mg on Day 5 in one of the 4 study periods
223745953|NCT01756495|DRUG|Losmapimod matched Placebo|Direct compression formulation (visually matched to GW856553), Film coated white, 7 mm round, biconvex, plain faced Tablet. Taken orally for 5 days in one of the 4 study periods
224188208|NCT03813316|DRUG|DPP-4 inhibitor|Adding sitagliptin (DPP-4i) add-on using a fixed-dose combination with metformin (Janumet® 50/1000 mg BID).
224188209|NCT03813316|DRUG|SGLT2 inhibitor|Adding ertugliflozin (SGLT2i) add-on using a fixed-dose combination with metformin(Segluromet® 2.5/1000 mg BID)
224188210|NCT03813316|DRUG|SGLT2 inhibitor and DPP-4 inhibitor|Adding both a DPP-4i as Fixed dose combination (Janumet) plus SGLT2i ertugliflozin (steglatro) as add-on to metformin.
224188211|NCT03952416|BEHAVIORAL|Enhanced Medical Rehabilitation (EMR)|"EMR is a set of behavioral skills that therapists can incorporate into their daily therapy sessions to increase patient engagement and achieve a high intensity of therapy, thereby improving functional and psychosocial outcomes of patients in medical rehabilitation. EMR was built on theories of behavior change, including social cognitive theory and self-regulatory theory, and their applications to patient engagement, such as the Health Action Process Approach and motivational interviewing. It has three foci: (1) a patient-directed, interactive approach stemming from patient-centered goals (Patient as boss); (2) frequent feedback to patients on their efforts and progress (Link activities to personal goals); and (3) increased rehabilitation intensity (Optimize intensity)."
224309176|NCT03251339|DRUG|US-Neulasta|Participants received a single subcutaneous injection of US-Neulasta 6 mg/0.6 mL on Day 1 in morning of treatment period 1 and 2. Period 1 and Period 2 are separated by a washout period of 35 Days.
224309177|NCT00004137|BIOLOGICAL|filgrastim|
224309178|NCT00004137|DRUG|carboplatin|
224309179|NCT00004137|DRUG|paclitaxel|
224309180|NCT00004137|DRUG|topotecan hydrochloride|
224188212|NCT05069623|BIOLOGICAL|VB10.2129|0.3 mg, 1 mg or 3 mg on Day 0 and Day 21 or 3 mg on Day 0
224309181|NCT00315887|DRUG|Buprenorphine transdermal delivery system|
224309182|NCT00000378|DRUG|Sertraline|12 week trial dose up to 200mgs
224309183|NCT00000378|DRUG|Nortriptyline|12 week trial dose adjusted to therapeutic level
224309184|NCT05746598|DRUG|Cisplatin injection|Cisplatin 75mg/m2
224309185|NCT03980574|DIETARY_SUPPLEMENT|R Drink|R Drink is a dietary supplement drink containing filtered reverse osmosis water and 150 mg/L of both USP Grade calcium chloride and magnesium chloride, 10 mg/L Biotin (vitamin B7), 500 mg/L of Niacinamide (B3) and 550 mg/L of Choline.
224309186|NCT04123626|DRUG|QR-1123|unilateral IVT injection
224309187|NCT04123626|OTHER|Sham procedure|Sham procedures (i.e. no penetration of the globe) closely mimic the active injection and serve to mask subjects to treatment assignment
224188213|NCT05069623|BIOLOGICAL|VB10.2210|3 doses (dose to be determined) on Day 0 and Day 21 or highest dose (TBD) on Day 0
224309188|NCT00362466|DRUG|Dasatinib|Tablets, Oral, Once daily, 5-7 years
224309189|NCT00362466|DRUG|Imatinib|Tablets, Oral, Once daily, 5-7 years
224309190|NCT04604340|PROCEDURE|transradial access for neuroangiography|The choice of right vs left radial artery approach would be determined by the vessels that require the highest quality of imaging (e.g. if the left vertebral artery is key to diagnosis, a left radial approach would be chosen, otherwise a right radial approach would be likely most appropriate) - this decision is at the discretion of the interventionist.
223497841|NCT07120139|PROCEDURE|episodic use of the desensitizing toothpaste|subjects assigned to episodic treatment will use the assigned toothpaste with the same previous instructions for two 8-week treatment periods, followed by an 8-week phase in which they will use the conventional fluoride dentifrice (Signal Complete 8 Original, Unilever, Egypt), which has no documented desensitizing efficacy
223497842|NCT07120139|PROCEDURE|continuous use of the conventional desensitizing toothpaste|The patients will be instructed to use 1 inch amount of the assigned desensitizing toothpaste and soft bristle toothbrushes with the same brushing technique they will be taught in the intervention visit for 2 minutes twice a day (morning and last thing at night ) without further rinsing, only spitting of the excess material every day along the whole study period for the continuous treatment group.
223590412|NCT04454944|BEHAVIORAL|LPG subsidy|Different subsidy rates, ranging between 0% and 100% (listed below) will be written on cards. Individuals will randomly select a card to display the subsidy rate for each household. The card will be concealed with a scratch-off sticker, with a higher likelihood of drawing a high price (low subsidy) than a low price (high subsidy) given that take up will be higher in the latter group.
223745954|NCT01756495|DRUG|Moxifloxacin Placebo|16 mm x 8 mm capsule shaped to white film coated tablet. Taken orally for 5 days in one of the 4 study periods
224188214|NCT00138281|BIOLOGICAL|FluMist|
224188215|NCT00138281|BIOLOGICAL|Fluzone|
224309191|NCT04604340|PROCEDURE|transfemoral access for neuroangiography|By convention, femoral access will be obtained on the right side, unless there is overlying disease or vessel abnormality detected by ultrasound/Doppler, as is usual clinical practice.
224309192|NCT06178003|BIOLOGICAL|Tpdelansbsalbac|Tpdelansbsalbac,which is Knockdown of ansB, a gene that expresses L-mentholase secreted into the extracellular region, on the basis of the genetic background of bacterium VNP20009, and construction of an ansB gene-deficient mutant strain, ΔansB.
224309193|NCT00511641|BEHAVIORAL|Questionnaire|Questionnaires lasting up to 30 minutes.
224309194|NCT04684238|DRUG|Midazolam|Solution for Injection/Infusion
223745955|NCT05602194|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
224188216|NCT06510023|BEHAVIORAL|Type of reward presented|Three different types of rewards were presented to both groups during the computerized task: one dollar, one penny, and no reward.
224188217|NCT01854502|BEHAVIORAL|Oral hygiene and fluoride use|Parents were given instructions how to brush and clean between teeth and to use fluoride toothpaste two times a day.
224188218|NCT01854502|BEHAVIORAL|Diet and use of xylitol|Parents were asked to fill in one-day diaries of their own diet in the waiting room. The dental professional pointed out the frequency of meals and snacks, as well as suggested the timing of xylitol products.
224188219|NCT04503109|DEVICE|Nalu Neurostimulation System|The Nalu Neurostimulation System is a Spinal Cord Stimulation system
224188220|NCT00792467|DRUG|ITF2357|ITF2357, supplied as hard gelatine capsules for oral administration at the strength of 50 mg each.
224188221|NCT03025295|DRUG|Dexmedetomidine|Dexmedetomidine is common used to improve the prognosis and life quality of patients.
224188222|NCT03025295|DRUG|Saline|It is safe Placebo.
224188223|NCT01321866|PROCEDURE|Cutting balloon angioplasty|Angioplasty of fistula stenosis using a cutting balloon
224188224|NCT01321866|PROCEDURE|Angioplasty|Angioplasty of fistula stenosis using a non-cutting balloon
224309195|NCT04684238|DRUG|Isoflurane|Inhalation vapour, liquid. Isoflurane delivered by the AnaConDa-S (Anaesthetic Conserving Device)
224309196|NCT04847518|DRUG|Kan Jang capsules|"One capsule contains a fixed combination of proprietary~* Andrographis paniculata Nees. herb, native extract, DER native 4,5-8,0 :1 260 mg (Diterpene lactones andrographolide and 14-deoxy, 11,12- didehydroadnrograholide) 15-20 mg~* Eleutherococcus senticosus (Rupr. et Maxim) Harms, root, native extract DER native 17-30:1 : 11.4 mg and other inactive excipients (Polycristalline cellulose, Magnesium stearate)."
224309197|NCT04847518|OTHER|Placebo capsules|Inactive excipients
224309198|NCT01377818|PROCEDURE|ventilation|"positive-pressure breathing bilevel (BiPAP ® Respironics, Inc.) Parameters initially programmed be: IPAP 10 cm H2O, EPAP 4 cmH2O, method ST setting yourself respirations 12 breaths minute. The IPAP was progressively increased to a maximum of 20 cm H2O, depending on patient tolerability, clinical response and arterial oxygen saturation was continuously monitored by pulse oximetry, trying to avoid possible leaks through the mask. It can also supply oxygen through a cannula connected to the mask at a flow rate of 2-4 liters per minute to maintain oxygen saturation at around 85-90%.~Patients aired uninterruptedly during nighttime (minimal between 6-8 hours night)."
224309199|NCT01377818|PROCEDURE|excecise training|"The training program (trained group) was carried out for 12 weeks and sessions of 40 minutes duration:~* 20 minutes of bicycle ergometer with an initial charge of about 70% of initial maximal oxygen consumption, increasing the load every two weeks as tolerated.~* Weightlifting in 2 sets of 6 replicates of 5 simple exercises. These are held at a station multigimnástica (CLASSIC Fitness Center, KETTLER)"
224309200|NCT01377818|PROCEDURE|Both|both types of intervention
224309201|NCT01560741|DEVICE|Telemonitoring tools|Patients will go home with telemedicine tools to monitor efficacy and compliance of non-invasive home mechanical ventilation
224309202|NCT01560741|DEVICE|Usual Care|The assessment of efficacy and compliance will be monitor at the end of third month. This is the date of the scheduled hospital visit.
224309203|NCT05239546|DRUG|Dostarlimab|Participants will receive Dostarlimab 500 mg IV every 3 weeks for 6 cycles followed by 1000 mg every 6 weeks for 8 cycles until 1.5 years
224074084|NCT06384001|BEHAVIORAL|Active MBM|The MBM is designed to be applied for 20 minutes per session daily for two weeks. The recording will instruct participants to close their eyes, connect to the openness of one's minds, and mindfully maintain and deepen the connection through breathing with more openness and awareness. The MBM intervention will include three recordings that gradually take the participant into a more profound meditation practice. Participants will be instructed to listen to Meditation 1 for the first three days of the intervention, then switch to Meditation 2 for days 4-6 and Meditation 3 for the remainder of the 2-week intervention. The participants will be asked to practice meditation for eight weeks (6 weeks after the initial two weeks of MBM practice).
224074085|NCT06384001|BEHAVIORAL|Sham MBM|The sham MBM intervention was also recorded. The sham recording will instruct participants to relax and take deep breaths every 3 minutes without the specific mindfulness-based instructions (e.g., practicing mindful attention to the breath in a non-evaluative manner). All other aspects of the sham MBM intervention (e.g., body position, time spent listening to instructions, eyes closed) will match the active MBM.
224074086|NCT05098210|BIOLOGICAL|Neoantigen Peptide Vaccine|Given IM
224074087|NCT05098210|BIOLOGICAL|Nivolumab|Given IV
224074088|NCT05098210|DRUG|Poly ICLC|Given IM
224074089|NCT05098210|PROCEDURE|Echocardiography|Undergo ECHO
224074090|NCT05098210|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
224074091|NCT05098210|PROCEDURE|Biopsy|Undergo tumor biopsy
224074092|NCT05098210|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
224074093|NCT05098210|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
224074094|NCT05098210|PROCEDURE|Positron Emission Tomography|Undergo PET or PET/CT
224074095|NCT06577116|DRUG|AK006 IV|Formulation for intravenous infusion
224075999|NCT06717919|PROCEDURE|Conventional cold storage|Conventional cold storage at 4°C will be performed with precooled preservation solution according to local standard of care. For cold storage at the Swiss centres, IGL-1 (Institute George Lopez) is used for cold storage. Liver transplant centres in other European countries, use mainly three other storage solutions (Histidine trypophan-ketoglutarat, HTK and University of Wisconsin, UW solution, Celsior) in accordance to their national guidelines.
224076000|NCT01355705|DRUG|Amrubicin|40, 60, or 80 mg/m2 intravenous (IV)
224076001|NCT01355705|DRUG|Lenalidomide|15 mg daily by mouth
224076002|NCT01355705|DRUG|Dexamethasone|40 mg weekly by mouth
224076003|NCT01355705|DRUG|Aspirin|81 or 325 mg daily by mouth
224076004|NCT01355705|DRUG|Pegfilgrastim|6 mg subcutaneous on Day 2
224076005|NCT06889597|OTHER|Experimental|Virtual Reality Exergame (VR) Participants will engage in a 5-minute fully immersive Virtual Reality (VR) exergame session using the PowerBeatsVR application. This intervention takes place in a virtual environment where participants perform rhythm-based physical activities such as punching targets and dodging obstacles. The VR session isolates participants from their real-world surroundings, offering a highly immersive experience designed to promote physical activity and assess its physiological and psychological effects.
224076006|NCT06889597|OTHER|Experimental|Mixed Reality Exergame (MR) Participants will engage in a 5-minute Mixed Reality (MR) exergame session using PowerBeatsVR in MR mode. Unlike VR, this intervention integrates virtual elements into the real-world environment, allowing participants to maintain awareness of their physical surroundings while interacting with digital content. This hybrid experience reduces the risk of cybersickness while providing a practical approach for workplace settings.
224076007|NCT06921733|DEVICE|Contrast enhanced ultrasound imaging (CEUS) and post processing with ULM|CEUS is a contrast based ultrasound technique and ULM (Ultrasound Localization Microscopy) is a post-processing bioinformatical method to quantify microvascular architecture and perfusion dynamics.
224076008|NCT06730945|DRUG|Oral isosorbide mononitrate 4+ amlodipine|Oral isosorbide mononitrate 40mg (if unable to tolerate, 20mg) once daily + amlodipine 5mg (if unable to tolerate, 2.5mg) once daily for 24 weeks after CABG
224076009|NCT06778135|PROCEDURE|Temporary implatation of large-scale intracranial electrode.|The Neuropixels probe (imec, Leuven, Belgium) is a new high resolution multi electrode technology that uses custom 130-nm complementary metal-oxide-semiconductor fabrication with high surface area but low-impedance titanium nitride recordings to produce high site count devices with extreme electrode density in a small package.
224076010|NCT06778135|DEVICE|brain electrode|Show that Neuropixels can safely and effectively record from large populations of neurons.
224076011|NCT03892447|DRUG|Alprostadil|Alprostadil 0.2\~0.3ug/kg.h,iv,1h/d,14d
224076012|NCT03892447|DRUG|Sodium Ferulate|Sodium Ferulate 2\~6mg/kg.d,iv,14d
224076013|NCT03892447|DRUG|Dopamine|Dopamine3～5 ug/kg·min,iv,3 h/d,14d
224076014|NCT06844487|BIOLOGICAL|MVA-BN standard regimen|The MVA-BN vaccine, with the active ingredient: Modified Vaccinia Ankara-Bavarian Nordic, will be administered as a standard two-dose regimen at 1x10\^8 TCID50 Inf.U./0.5 mL. The doses will be given 28 days apart (±3 days) via subcutaneous injection into the deltoid muscle, preferably in the non-dominant arm.
224076015|NCT06844487|BIOLOGICAL|MVA-BN half-dose regimen|The MVA-BN vaccine, with the active ingredient: Modified Vaccinia Ankara-Bavarian Nordic, will be administered as two half doses of the standard regimen; meaning infants/children allocated to Child Group 2 will receive 0.25 mL of the 0.5 mL. 1x10\^8 TCID50 Inf.U./0.5 mL standard regimen. The doses will be given 28 days apart (±3 days) via subcutaneous injection into the deltoid muscle, preferably in the non-dominant arm. Only one vial will be used per infant/child.
223745956|NCT05602194|DRUG|Calaspargase Pegol|Given standard of care calaspargase pegol
224074096|NCT03032601|DIETARY_SUPPLEMENT|N-acetyl Cysteine|The study consists of two arms. The first arm of this study will receive intravenous and oral NAC, a strong antioxidant that increases brain glutathione, which may be beneficial in MS. NAC, is the N-acetyl derivative of the naturally occurring amino acid, L-cysteine. It is a common over-the-counter supplement that is also available as an injectable pharmaceutical that protects the liver in cases of acetaminophen overdose. It has the potential to reduce markers of oxidative damage, protect against cell death, and to increase glutathione in blood, which might be useful in preventing oxidative damage in MS patients. The second arm will be a waitlist control receiving standard MS care. It should be noted that both arms will receive standard of care while enrolled into the study.
224074097|NCT02626260|OTHER|adhesive strip|Adhesive strip with a standard adhesive base
224074098|NCT03705728|DRUG|Propofol|"Propofol will be automatically administered according to the EasyTIVA device algorythm to maintain the BIS value within the 40-60 interval"
224074099|NCT03705728|DRUG|Sevoflurane|Sevoflurane will be manually administered to maintain the BIS value within the 40-60 interval
224074100|NCT03705728|DRUG|Remifentanil automatic|"Remifentanil will be automatically administered according to the EasyTIVA device algorythm to maintain the BIS value within the 40-60 interval"
224074101|NCT03705728|DRUG|Remifentanil manual|Remifentanil will be manually administered to maintain the BIS value within the 40-60 interval
224074102|NCT01283165|BEHAVIORAL|Health education intervention|Health education was conducted in two ways. (1) Teachers were taught how to use the flip chart that contained health education material about parasites. The lessons were done during free periods as this intervention had not been formally fitted into the school syllabus. (2) The research team provided health education to school children. Focus group discussions were conducted by the research team with school children all assembled outside their classes. Health education leaflets were distributed to all school children at the school. Children were asked to share the health information with their friends and families.
224074103|NCT03430921|DEVICE|Enlighten™ Laser and a MLA Attachment|Subjects will receive treatments with the Cutera enlighten laser with the Micro-Lens Array handpiece attachment.
224074104|NCT06240884|PROCEDURE|Infraspinatus-teres minor interfascial block|After identifying the infraspinatus and teres minor muscles on the posterior surface of the scapular neck. Under real-time ultrasound guidance, the needle is advanced into the interfascial plane between the infraspinatus and teres minor muscles using an in-plane technique, and after confirming the fascial opening with 3 to 5 mL of 0.375% ropivacaine (20 mL total dose), the remaining 0.375% ropivacaine is injected. After extubation and the patients were awake, anesthesiologists who were unaware of the study subgroups began to assess the analgesic effect of the patients' block at rest using the numeric pain rating scale (NRS) at 0.5h, 3h, 6h, 12h, 18h, 24h, and 48h postoperatively.
224074105|NCT06240884|PROCEDURE|interscalene block|The tip of the needle was placed between the C5 and C6 nerve roots, and after a bloodless retraction with 0.5 to 1 ml of 0.375% ropivacaine to confirm nerve displacement, the remaining 0.375% ropivacaine was injected (total dose of 20 ml). Subsequently, the catheter was inserted over the needle and the needle was withdrawn.After extubation and the patients were awake, anesthesiologists who were unaware of the study subgroups began to assess the analgesic effect of the patients' block at rest using the numeric pain rating scale (NRS) at 0.5h, 3h, 6h, 12h, 18h, 24h, and 48h postoperatively.
224074106|NCT04892836|OTHER|Training|Resistance training (4 different exercises, leg press, leg extension, leg curl, and seated calf raises)
224074107|NCT02224859|DEVICE|HCP will place the Invictus Cranial Support Device (CSD) on the patient|"There is no active therapeutic treatment (e.g., medication, stimulation, etc.) associated with this device or study. All supplies for this study will be supplied by the sponsor and returned to them upon completion of the trial.~The device used in this study is a soft gel based bonnet referred to as a Cranial Support Device (CSD). In this study, after obtaining written informed consent from the patient's parent(s) or guardian(s) and confirming that the patient meets all inclusion and no exclusion criteria, the study HCP will place the CSD on the selected patient."
224074108|NCT02224859|OTHER|human intervention|This study is designed to evaluate the safety of the Invictus Cranial Support Device (CSD) when worn by medically stable infants within a neonatal intensive care unit (NICU), to evaluate the form, fit, and ease of use/application of the CSD device (i.e., utility), as well as initial impressions of safety, by health care providers (HCPs) after placing the current CSD on infants for approximately six (6) hours in a NICU
224074109|NCT03271372|DRUG|Avelumab|Given IV
224074110|NCT03271372|OTHER|Peripheral Blood Collection|Correlative studies
224074111|NCT03271372|OTHER|Placebo|Given IV
224074112|NCT05790265|DEVICE|ANNE One|Chest sensor for single lead ECG and finger sensor for pulse oximetry.
224074113|NCT06351527|DRUG|ICP-248|ICP-248 will be administered orally once daily at escalated doses (starting dose 5/10 mg, maximum 150 mg).
224309204|NCT04779515|PROCEDURE|low-pressure pneumoperitoneum|insufflation of the abdomen for creation of pneumoperitoneum, pressure set points between 8 to 10 mm Hg
223745957|NCT05602194|DIETARY_SUPPLEMENT|Levocarnitine|Given PO or IV
224074114|NCT06351527|DRUG|Obinutuzumab (G)|Obinutuzumab will be administered by IV infusion at a dose of 100 mg or 1000 mg, depending on splitting rules, at Cycle 1, Day 1 (if 100 mg was received on Day 1, 900 mg will be administered on Cycle 1, Day 2); 1000 mg at Cycle 1, Day 8 and Day 15; 1000 mg at Day 1 for all subsequent cycles until the end of Cycle 6.
224074115|NCT06351527|DRUG|Rituximab (R)|Rituximab will be administered by IV infusion at a dose of 375 milligrams per square meter (mg/m\^2) at Day 1 per week for 4 weeks during cycle 1, then on day 1 of cycles 3-8, and thereafter once every other cycle up to 2 years.
224074116|NCT03198052|BIOLOGICAL|CAR-T cells targeting GPC3, Mesothelin, Claudin18.2, GUCY2C, B7-H3, PSCA, PSMA, MUC1, TGFβ, HER2, Lewis-Y, AXL, or EGFR|CAR-T cells injection: (1-10×10e6/kg CAR-T for each treatment; 3 or more cycles.
224074117|NCT04797832|DRUG|IV Sodium Ferric Gluconate Complex|125 mg of IV Iron per day to 3 to 5 days according to hospitalisation length.
224074118|NCT03376477|BIOLOGICAL|GM-CSF vaccine|Each vaccination will consist of three total intra-dermal injections, on day 14 of cycles 1, 2, 3, 6 and annually for a minimum of 36 months in the right and left anterior upper thighs, and one in the non-dominant upper arm (unless contraindicated). In the event that the specified limb is contraindicated, the dominant arm may be used. Vaccine injection sites shall be at least 5 cm at needle entry from the nearest neighbor. The approximate volume of each vaccination injection is approximately 0.7-0.8ml.
223745958|NCT05602194|DRUG|Pegaspargase|Given standard of care pegaspargase
224188225|NCT04594122|BEHAVIORAL|Improve hygiene practice of pork sellers|includes 5 keys actions (Handbook) and provision of equipment incentive and training on good hygiene practices, branding, and certification
223497843|NCT07123792|DRUG|Calcium Hydroxide (20%)|A 20% calcium hydroxide paste will be placed as an intracanal medicament following root canal instrumentation. Applied using a Lentulo spiral, excess is removed, and the tooth is sealed with a glass ionomer temporary restoration.
223497844|NCT07123792|DRUG|Chlorhexidine Gel (2%)|A 2% chlorhexidine gel will be used as an intracanal medicament following canal preparation. It will be delivered with a Lentulo spiral, cleaned from the chamber, and the tooth sealed.
223497845|NCT07123792|DRUG|Modified Triple Antibiotic Paste|A modified triple antibiotic paste consisting of ciprofloxacin, metronidazole, and clindamycin (1:1:1 by weight) will be placed in the canal using a Lentulo spiral. The excess paste will be removed, and the cavity will be sealed with temporary restorative material.
223497846|NCT07124026|OTHER|No Intervention: Observational Cohort|No intervention
223497847|NCT03768375|BIOLOGICAL|conventional chemotherapy(FORFIRINOX) combined with target agents|Drug: FORFIRINOX Conventional chemotherapy:gemcitabine and oxaliplatin Drug: Cetuximab Drug: Trastuzumab Drug: Gefitinib Drug: Lapatinib Drug: Everolimus Drug: Sorafenib Drug: Crizotinib
223497848|NCT03768375|BIOLOGICAL|conventional chemotherapy(FORFIRINOX)|conventional chemotherapy(FORFIRINOX)
223497849|NCT07125313|BEHAVIORAL|YOGA|The participants randomized to the yoga group will perform 16 weeks of yoga training, three times/week for 60 minutes.
223497850|NCT07125313|BEHAVIORAL|Control|Usual care
223497851|NCT07124819|DRUG|Sodium enoxaparin|"Subgroup 2A (Hip Arthroplasty): Patients undergoing total hip arthroplasty will receive Clexane® subcutaneously administered 12±1 hours before surgery starting 6-10 hours after surgery everyday for 35±2 days.~Subgroup 2B (Knee Arthroplasty): Patients undergoing total knee arthroplasty will receive Clexane® subcutaneously administered 12±1 hours before surgery everyday for 14±1 days."
223497852|NCT07124819|DRUG|Dimolegin|"Subgroup 1A (Hip Arthroplasty): Patients undergoing total hip arthroplasty will receive Dimolegin® starting 6-10 hours after surgery everyday for 35±2 days.~Subgroup 1B (Knee Arthroplasty): Patients undergoing total knee arthroplasty will receive Dimolegin® starting 6-10 hours after surgery everyday for 14±1 days."
223497853|NCT07124819|DRUG|Dimolegin placebo|Subgroup 2A (Hip Arthroplasty): Patients undergoing total hip arthroplasty will receive placebo Dimolegin® starting 6-10 hours after surgery everyday for 35±2 days. Subgroup 2B (Knee Arthroplasty): Patients undergoing total knee arthroplasty will receive placebo Dimolegin® starting 6-10 hours after surgery everyday for 14±1 days.
223497854|NCT07124819|DRUG|Sodium enoxaparine placebo|"Subgroup 1A (Hip Arthroplasty): Patients undergoing total hip arthroplasty will receive palcebo Clexane® subcutaneously administered 12±1 hours before surgery starting 6-10 hours after surgery everyday for 35±2 days.~Subgroup 2B (Knee Arthroplasty): Patients undergoing total knee arthroplasty will receive placebo Clexane® subcutaneously administered 12±1 hours before surgery everyday for 14±1 days."
223497855|NCT00112164|DRUG|Xigris|
223497856|NCT07115615|DEVICE|high-definition transcranial direct current stimulation|The tDCS device will deliver a direct current of 2mA during 20 minutes. Cathode electrode will be localized in front of the right OFC on the Fp2 point according to the EEG international reference. Four anode electrodes will be placed around FP2 (i.e. Fpz, AFz, AF4, AF8)
223497857|NCT07115615|DEVICE|Sham tDCS|To demonstrate the same stimulation sensation as under real conditions, only 40 seconds of real stimulation (2mA) are given at the beginning of the treatment. In the remaining 20 minutes, only about 15ms of short current pulses of 110uA occur every 550ms.
223497858|NCT07083843|BEHAVIORAL|Exercise|Intervention, will receive home based exercise multi times per week for 6 months
223497859|NCT07083843|OTHER|Standard medical treatment|Control group will receive the usual standard care.
223497860|NCT06928597|PROCEDURE|Global Postural Reeducation|"Global Postural Reeducation, better known as GPR, was developed by Philippe Souchard in the 1980s and involves a sequence of postures or treatment positions, including the main ones: frog on the ground with arms open; frog on the ground with arms closed; frog in the air with arms open; frog in the air with arms closed; standing against the wall; standing at the center; anterior tilt sitting; anterior tilt standing.~GPR is based on the concept of proprioception and inhibition. Souchard (2016) describes RPG as a proprioceptive method of inhibition, where proprioception refers to the body's ability to perceive its position in space, and inhibition refers to the muscle relaxation induced after intense contraction. This principle is applied through the postures and techniques used in treatment, aiming to correct postural deviations, promote one bigger conscious body, and relieve pain."
223497861|NCT06928597|PROCEDURE|Global Postural Reeducation Sham|Global Postural Reeducation Sham is the comparator group.
223745959|NCT05602194|OTHER|Quality-of-Life Assessment|Ancillary studies
224188226|NCT03355872|DRUG|HLX01|Biosimilar of Rituximab
224188227|NCT04784208|DIAGNOSTIC_TEST|Blood test for Thyroid stimulating hormone (TSH)|Blood test for Thyroid stimulating hormone (TSH)
224188228|NCT04203082|BEHAVIORAL|Exposure Intervention|Single session intervention of psychoeducation + exposure treatment to the operating room and procedural steps of a cesarean delivery
223745960|NCT06350773|DRUG|tadalafil 20 mg then 40 mg if tolerated|Patients will receive tadalafil for 12 week follow up period, in addition to the conventional anti failure therapy.
223745961|NCT05457881|DIETARY_SUPPLEMENT|Scandi-Shake|Scandi-Shake \[any of 4 flavors - vanilla, strawberry, banana cream, and caramel\] mixed with almond milk (85 grams Scandi-Shake mix to 240 cc almond milk), calculated individually for a total daily volume to achieve 30% caloric restriction and 70% protein restriction, based on ideal body weight. The Mifflin St. Jeor equation will be used to calculate the total 24-hour energy needs based on gender, age, height, weight, and activity factor for the PCR diet. Daily physical activity will be assessed by questionnaire to determine the activity factor for accurate calorie restriction calculations. Nutritionists will use this equation to create a unique shake for each individual patient. The shakes will be separated into 4 equal portions per day, for a total of 16 portions across the 4 pre-operative days. Patients can consume the 4 daily portions at whichever time of day they choose. The shakes are frozen 24 hours before distribution.
223745962|NCT03306680|RADIATION|SBRT|Patients will be assigned to treatment doses using the TITE-CRM model.
223497862|NCT07091578|BEHAVIORAL|Supervised toothbrushing|In supervised toothbrushing intervention, dental hygienists trained school staff, obtained consent forms, distributed the oral hygiene kits, and provided support and advice if needed. Teachers' training included guidelines for infection prevention and control, and toothbrushing in dry areas adapted from the Public Health England (PHD) toothbrushing programme toolkit. A dry toothbrushing model was employed. Toothbrushing sessions took place daily during regular school hours for one academic year. Each session lasted for approximately 10 minutes and occured after break time at 9:20 am. Oral hygiene kits that include soft toothbrushes and 1450ppm fluoridated toothpaste were disseminated every three months. Teachers and dental hygienists provided monthly oral health educational sessions to students during regular school time.
224309205|NCT04779515|PROCEDURE|standard-pressure pneumoperitoneum|insufflation of the abdomen for creation of pneumoperitoneum, pressure set points between 12 to 14 mm Hg
223590413|NCT04454944|BEHAVIORAL|Distance allocation|We will set up fuel supply depots to increase the convenience and lower costs and hassle associated with traveling to an established filling station. The supply depots will mirror a recirculation model of LPG distribution currently being piloted by the National Petroleum Authority of Ghana. Households will be randomly assigned to one of the supply depots in advance or to continue refilling their cylinder at the filling station.
223511896|NCT06548295|BEHAVIORAL|modified constraint induced movement therapy (mCIMT)|"Restraint the involved extremity by using a mitten. Repetitive task practice i.e filling a glass, drinking a glass of water, and eating with a spoon , stacking cones and stacking blocks, grasping and releasing of an object, reaching forward and sideways, lifting and dropping of an object from the one end of table to the other end.~The shaping exercises included cube stacking, card turning, throwing balls into a box, grasping/holding and placing objects of different sizes, and drawing and painting exercises. Intervention: 5 sessions per week for 50 minutes for 6 weeks"
224074119|NCT03376477|DRUG|Lenalidomide|Patients will be continued on the same dose of lenalidomide as they were prior to being enrolled in the study. Doses of lenalidomide for investigation can vary from 5-25 mg/day, orally on days 1 - 21 followed by 7 days rest (28 day cycle).
224074120|NCT03376477|DRUG|Prevnar13|Prevnar will be administered at the same time points as the GM-CSF vaccine (day 14 of cycles 1, 2, 3, 6 and annually for a minimum of 36 months), but on the opposite arm from GM-CSF vaccine.
224074121|NCT03376477|OTHER|Placebo Prevnar13|Saline will be used for placebo. Placebo prevnar will be administered at the same time points as the GM-CSF vaccine or Placebo GM-CSF Vaccine (day 14 of cycles 1, 2, 3, 6 and annually for a minimum of 36 months), but on the opposite arm from GM-CSF vaccine or placebo GM-CSF vaccine.
224074122|NCT03376477|OTHER|Placebo GM-CSF Vaccine|Saline will be used for placebo. Each placebo vaccine will consist of three total intra-dermal injections on day 14 of cycles 1, 2, 3, 6 and annually for a minimum of 36 months in the right and left anterior upper thighs, and one in the non-dominant upper arm (unless contraindicated). In the event that the specified limb is contraindicated, the dominant arm may be used. Placebo injection sites shall be at least 5 cm at needle entry from the nearest neighbor. The approximate volume of each injection is approximately 0.7-0.8ml.
224074123|NCT07132970|DEVICE|Monoplus Suture Material|Ileocolic Anastomosis Construction using Monoplus Suture Material after open or laparoscopic surgery
224074124|NCT02180360|OTHER|Capoeira training group|"Capoeira training: The experimental Capoeira training protocol, based in the modern styles of Capoeira was applied by an instructor with 17 years of experience in teaching Capoeira, followed the directions of the Basic Programmed Lesson, created by Geraldo Pereira d'Santana (Master Santana) in a Capoeira group called IUNA from the city of São Paulo, Brazil.~In order to perform the Basic Programmed Lesson program, the activities were divided in four stages, being composed of the main movement that characterizes Capoeira (the ginga) and by other movements such as: dodging, unbalancing, traumatizing and acrobatic.~An important thing to highlight in the experimental protocol is that the training performed in the present study used only specific movements of Capoeira, without applying any other traditional stretching exercises. Therefore, it is possible to infer that the results obtained are due to the experimental protocol."
224074125|NCT05237128|BEHAVIORAL|Very low-carbohydrate diet|"Participants in this arm will be taught to manage their type 2 diabetes using a very low-carbohydrate diet, also called a ketogenic or keto diet. This diet involves eating non-starchy vegetables, leafy greens, cheese, meats, berries, nuts, and seeds and avoiding starchy foods like pasta, bread, rice, beans, many fruits, etc.~There will be a core phase and a maintenance phase of this study; the core phase will last for about 4 months and will involve weekly or every other week classes, home assignments, and brief check-in surveys. The maintenance phase will last for the remaining time, with classes and check-in surveys approximately once a month."
224074126|NCT05237128|BEHAVIORAL|Moderate-carbohydrate plate-method diet|"Participants in this arm will be taught to manage their type 2 diabetes using a plate-method approach. This diet involves eating different categories of foods based on the proportions of a plate, balancing proteins, vegetables, fruits, starches, and fats.~There will be a core phase and a maintenance phase of this study; the core phase will last for about 4 months and will involve weekly or every other week classes, home assignments, and brief check-in surveys. The maintenance phase will last for the remaining time, with classes and check-in surveys approximately once a month."
224074127|NCT02868073|BIOLOGICAL|VXA-G1.1-NN (high dose) Oral Vaccine Tablet|The drug product will be provided as small white enteric-coated tablets. Multiple tablets will be administered to deliver the high dose.
224074128|NCT02868073|OTHER|VXA Placebo Tablets|The placebo will be provided as small white enteric-coated tablets that are similar in size and number to the active drug product tablets.
224074129|NCT02868073|BIOLOGICAL|VXA-G1.1-NN (low dose) Oral Vaccine Tablet|The drug product will be provided as small white enteric-coated tablets. Multiple tablets will be administered to deliver the low dose.
224074130|NCT04319107|OTHER|ophthalmological examinations using a slit lamp bio microscopy and a three-mirror lens, standard procedure.|Pupillary dilatation was performed with instillation of tropicamide and phenylephrine. The ophthalmological examination included visual acuity measurement, using a slit lamp biomicroscopy to analyse the anterior segment and a three mirror lens to appreciate the quality of the dilation validated by the absence of pupillary reflex and to search for ectopia lentis. Ectopia Lentis grade is evaluated according to the 5-grade classification.
224076016|NCT00931398|DRUG|methylphenidate HCl (Concerta)|Concerta 18 mg, 36 mg, 54 mg, and 72 mg q.am.
224188229|NCT04203082|OTHER|Usual Care|Standard of care for education about the cesarean /delivery planning varies across the two hospitals. At Children's Hospital Colorado, anesthesiologists are included in the delivery planning meetings where the patients have the opportunity to review anesthetic technique and ask questions.
224188230|NCT01813162|DRUG|Tenofovir 1% gel|
224188231|NCT01813162|DRUG|Vaginal product|
224188232|NCT03487120|PROCEDURE|facet joint denervation|Bipolar electrocautery
224188233|NCT00629135|DRUG|Moxifloxacin/Metronidazole or Piperacillin/Tazobactam|Antibiotic therapy for patients with intra-abdominal abscesses; Intervention consists of antibiotic treatment of the patients with intraabdominal abscess with either the combination of Moxifloxacin and Metronidazole or Piperacillin/Tazobactam.1. Moxifloxacin 400 mg, administered intravenously once daily in combination with Metronidazole 500 mg, administered two times daily intravenously, followed by an oral medication with Moxifloxacin 400 mg once daily and Metronidazole 500 mg twice daily. 2. Piperacillin / Tazobactam 4,5 g administered intravenously three times daily.
224188234|NCT05071521|OTHER|The Body Project: A Dissonance-Based Eating Disorder Prevention Intervention|The Body Project is a a selective dissonance-based prevention program that targets women with body image concerns. It has been developed with University and similar populations in mind, making it appropriate to the current research.The Body Project is based on a protocol, and aims to create cognitive dissonance that encourages participants to reduce pursuit of the thin-ideal. It involves the use of a scripted manual, covering four interactive weekly sessions. These involve role play, behavioural, verbal and written exercises.
224188235|NCT00857701|DEVICE|Knee Extension Dynasplint|Dynamic Splinting utilizes the protocols of Low-Load, Prolonged-Duration Stretch (LLPS) with calibrated, adjustable tension to increase the Total End Range Time (TERT) to reduce contracture. The Knee Extension Dynasplint for the Experimental group will have tension chambers delivering therapeutic treatment from the device.
224188236|NCT03911401|DRUG|0.3% OPA-15406|Twice daily
224188237|NCT03911401|DRUG|1% OPA-15406|Twice daily
224188238|NCT03911401|DRUG|Placebos|Twice daily
224188239|NCT02218034|DRUG|AGN-190168 Formulation 1|AGN-190168 Formulation 1 applied topically to the face, neck, upper chest, upper back, and shoulders once daily for 29 days.
224188240|NCT02218034|DRUG|AGN-190168 Formulation 2|AGN-190168 Formulation 2 applied topically to the face, neck, upper chest, upper back, and shoulders once daily for 29 days.
224188241|NCT02218034|DRUG|tazarotene gel 0.1%|Tazarotene gel 0.1% applied topically to the face, neck, upper chest, upper back, and shoulders once daily for 29 days.
224188242|NCT02218034|DRUG|tazarotene cream 0.1%|Tazarotene cream 0.1% cream applied topically to the face, neck, upper chest, upper back, and shoulders once daily for 29 days.
224188243|NCT00329706|PROCEDURE|FDG-PET brain scan|The difference in the two arms' interventions is the time at which the FDG-PET brain scan information is available for the subjects' managing physicians. Experimental arms will have an immediate release of the PET report, while the Active Comparator arms will have a delayed release of 2 years.
224188244|NCT02918968|DRUG|Enzalutamide|Oral Capsule
224309206|NCT03522610|BEHAVIORAL|ADAPT|Two hour, once a week in-person parenting program for 14 weeks plus use web-enhanced supplemental ADAPT materials
224309207|NCT02241421|DRUG|Amoxicillin|
223590414|NCT00871962|OTHER|OXYGEN SUPPLEMENTATION|Patients treated by LTOT, with or without clinically fulfilled criteria for LTOT, with PaO2\<55mmHg or less at rest or during sleeping or less during exercise, if supplemental oxygen is demonstrated to improve the exercise-associated hypoxia. Patients with PaO2 56-59mmHg if they also have dependent edema, pulmonary hypertension or hematocrit higher than 56%
223590415|NCT06386705|DRUG|TSN084|TSN084 will be administered at the assigned dose level, orally, until disease progression or intolerable toxicity.
224188245|NCT02918968|DRUG|Flutamide|Oral tablet
224188246|NCT02918968|OTHER|Androgen deprivation therapy|All subjects must undergo continuous Androgen deprivation therapy with GnRH agonist/antagonist or bilateral orchiectomy during the study period.
224188247|NCT05441722|BEHAVIORAL|Exercise prehabilitation|Exercise on a cycle ergometer 24 hours before chemotherapy infusion.
224188248|NCT06523348|DIAGNOSTIC_TEST|quadricipital muscle ultrasound|ultrasound depth measurement of the quadriceps muscle
224188249|NCT01139645|DRUG|Rabeprazole or Esomeprazole or Lanzoprazole|1/3 of the patients are taking Pariet (Rabeprazole) 20 mg once daily 1/3 of the patients are taking Nexium (Esomeprazole) 40 mg once daily 1/3 of the patients are taking Lanzor (Lanzoprazole) 30 mg once daily
224188250|NCT06148298|OTHER|Non-Human Subject Research study.|This is a Non-Human Subject Research study. There is no intervention. All participants are de-identified.
224188251|NCT05123066|OTHER|Aquatic Exercises|"These 3 sets were the following:~Set 1: warming up exercise as floating exercise 24 Set 2: Standing education/training Set 3: Walking education/training~The exercises will be conducted taking in consideration safety measures as:~1. Each participant will use Noodles to ensure safety.~2. Each participant will train individually to ensure safety and avoid distraction.~3. Each participant will use special swimming suit in case of lack of bowel and/or bladder control."
224188252|NCT05123066|OTHER|Land Exercises|All participants were physical therapy intervention according to their level of functional impairment :
224309208|NCT02241421|DRUG|Vancomycin|
224309209|NCT02241421|OTHER|Placebo|
224309210|NCT00000718|DRUG|Zidovudine|
224309211|NCT00000718|DRUG|Zalcitabine|
224309212|NCT03889067|BIOLOGICAL|Salmonella Typhi challenge|The challenge agents will be delivered in 30 ml of sodium bicarbonate solution, preceded by 120 ml of solution of sodium bicarbonate to neutralise gastric acid.
224309213|NCT00782574|DRUG|AZD2281|Tablets Oral BID
224309214|NCT00782574|DRUG|Cisplatin|IV every 3 weeks
224309215|NCT02448706|DEVICE|Hearing Aid Fitting A|
224309216|NCT02448706|DEVICE|Hearing Aid Fitting B|
224309217|NCT01476618|OTHER|No Intervention|No Intervention
224309218|NCT00020371|DRUG|BMS-247550|
224309219|NCT00020371|DRUG|filgrastim|
224309220|NCT03860662|DIAGNOSTIC_TEST|Nociceptor flexor reflex|The nociceptive flexion reflex (NFR) is a physiological, polysynaptic reflex allowing for painful stimuli to activate an appropriate withdrawal response
224309221|NCT03860662|DRUG|Botox|botox
224309222|NCT03860662|DRUG|Baclofen|baclofen
224309223|NCT02067468|DEVICE|HPV test|QIAGEN - The Digene HPV test®
224309224|NCT02067468|PROCEDURE|COLPOSCOPY|Colposcopy routine health services
223590416|NCT02925728|OTHER|Finger-Food|Finger-Food at lunch and having diner
223590417|NCT02925728|OTHER|Without Finger-Food|Without finger-food
223590418|NCT03468894|BEHAVIORAL|Treadmill desk walking|See intervention arm description
224074131|NCT04451421|BEHAVIORAL|Change of standing Angle|Change the patient's standing Angle by using an electric bed
224074132|NCT03443154|DIAGNOSTIC_TEST|VF-Test|A vaginal fluid test of interleukin-6 (IL-6) and alphafetoprotein (AFP).
224074133|NCT05788718|DRUG|Sugammadex|As this is a non-interventional study designed to collect data as part of routine clinical practice, the type and dose of neuromuscular blocking agents are all based on the clinician's judgment.
224074134|NCT06299293|OTHER|Facial Emotion Recognition Test|In this test, the ability to detect and recognize facial expressions of fear or anger will be investigated.
224074135|NCT06824363|DRUG|Tremelimumab|single dose, 300mg IV, day 1
224074136|NCT06824363|DRUG|Durvalumab|single dose, 1500 mg IV, day 1
224074137|NCT07009483|BEHAVIORAL|Patient education modules providing information on the psychological aspects of atopic dermatitis treatment and management.|Provision of online patient educational modules (in addition to patients receiving regular clinical action/ appointments at the Kaye Edmonton Clinic, the Stollery Children's Hospital, and the Rao Dermatology Clinic for Atopic Dermatitis).
224074138|NCT05049343|DRUG|SAGE-904|SAGE-904 oral solution.
224074139|NCT05049343|DRUG|Placebo|Placebo oral solution.
224074140|NCT05049343|DRUG|Ketamine|Ketamine intravenous (IV) infusion.
224074141|NCT05469386|DRUG|Methylphenidate Hydrochloride ER|Methylphenidate Hydrochloride ER (.3 mg/kg dose q.d.)
224074142|NCT05469386|BEHAVIORAL|Behavioral classroom|Enhanced positive behavior supports implemented in classroom
224074143|NCT05469386|DRUG|Placebo|Placebo capsule
224074144|NCT05469386|BEHAVIORAL|General Classroom|General education classroom procedures
224074145|NCT05469386|BEHAVIORAL|Academic Accommodations|Accommodations are introduced to support the child's independent seat work completion and quiz scores
224074146|NCT07010315|BEHAVIORAL|Cognitive Testing|Given by Survey and one-on one interviews
224074147|NCT07010315|BEHAVIORAL|Usability Testing|Given by surveys and one-on-one interview.
224074148|NCT03377907|DRUG|ketamine in hematoma block|ketamine used in local hematoma block only
224074149|NCT03377907|DRUG|ketamine in local intravenous anesthesia|ketamine will be used with lidocaine in local intravenous anesthesia
224074150|NCT03377907|DRUG|Lidocaine Hydrochloride|2.5 mg/kg of lidocaine 2% in intravenous regional anesthesia
224074151|NCT07015853|DRUG|Pembrolizumab|Pembrolizumab (MK-3475), 200 mg IV Q3W starting at C1D1/Week 1 for up to 2 years, until disease progression, or treatment intolerance.
224074152|NCT07015853|RADIATION|Radiotherapy|RT, 8 Gy x 3 fractions over 3 consecutive days at C1D8/Week 2;
224074153|NCT07015853|DRUG|Axatilimab|Axatilimab (SNDX-6352; INCA034176), 1 mg/kg, IV, Q2W starting 1 week post- RT C1D15/Week 3 until disease progression or treatment intolerance.
224074154|NCT06239220|BIOLOGICAL|PD-L1 t-haNK|Allogeneic, stable, clonal natural killer cell line product, via intravenous infusion (into the vein) per protocol.
224074155|NCT06239220|DRUG|Cetuximab|Epidermal growth factor receptor, via intravenous (into the vein) infusion per institutional standard of care.
224074156|NCT06239220|BIOLOGICAL|N-803|Recombinant human superagonist, via subcutaneous injection (under the skin) per protocol.
224074157|NCT07023705|DIAGNOSTIC_TEST|Monocyte to Large Platelet Ratio (MLPR)|Admission laboratory values were used to calculate the Monocyte-to-Large Platelet Ratio (MLPR) by dividing the absolute monocyte count by the large platelet count. These values were obtained from blood samples collected before any treatment was administered.
224074158|NCT07018466|OTHER|Tele-exercise|Exercise training 3x/week at home. Sessions include circuit exercises of aerobic and resistive training stations which are led remotely.
224074159|NCT07018466|OTHER|Standard of Care|Health education discussions and lectures 3x/week led remotely.
224074160|NCT07018245|DRUG|TJ0113|200 mg or 400 mg Capsule, Once Daily
224074161|NCT07018245|DRUG|Placebo|Capsule, Once Daily
224076017|NCT00931398|DRUG|Placebo|Matched placebo for all Concerta doses.
224076018|NCT07108621|DRUG|Choriongonadotropin alfa (hCG)|hCG 260 IU once daily for two menstrual cycles (aproximately 8 weeks) prior til standard IVF/ICSI.
224076019|NCT07108621|DRUG|Isotonic NaCl (Placebo)|Placebo priming (isotone NaCl) once daily for two menstrual cycles (approximately 8 weeks) prior to standard IVF/ICSI.
224076020|NCT07113561|OTHER|High-protein diet and resistance training|Participants will consume a low-energy high-protein diet for 10 weeks, and participate in supervised resistance training sessions. They will continue a maintenance diet up until the 1 year mark, with bi-monthly follow ups on diet and exercise.
224076021|NCT07113561|OTHER|Balanced control diet|Participants will consume a balanced low-energy diet for 10 weeks, and continue a balanced maintenance diet with bi-monthly follow ups up until the 1-year mark No active exercise intervention.
224076022|NCT07104318|DRUG|Bismuth quadruple therapy with optimized PPI|Bismuth 524mg QID, Metronidazole 500mg QID, Tetracycline 500MG QID, and Omeprazole 20 mg QID for 14 days.
224076023|NCT07104318|DRUG|Bismuth quadruple therapy with standard PPI|"Bismuth 524mg QID, Metronidazole 500mg QID, Tetracycline 500mg QID, and Omeprazole 20mg (active BID + placebo BID) for 14 days.~\*\*NOTE: placebo tablets are used to maintain the same number of pills in all study arms and preserve blinding"
224076024|NCT07104318|DRUG|Clarithromycin triple therapy with optimized PPI|Amoxicillin 1000mg (active BID + placebo BID), Clarithromycin 500mg (active BID + placebo BID), and Omeprazole 20mg QID for 14 days. \*\*NOTE: placebo tablets are used to maintain the same number of pills in all study arms and preserve blinding
224076025|NCT07104318|DRUG|Clarithromycin triple therapy with standard PPI|Amoxicillin 1000mg (active BID + placebo BID), Clarithromycin 500mg (active BID + placebo BID), and Omeprazole 20mg (active BID + placebo BID) for 14 days. \*\*NOTE: placebo tablets are used to maintain the same number of pills in all study arms and preserve blinding
224076026|NCT07104318|DRUG|Standard bismuth quadruple therapy|Bismuth 524mg QID, Metronidazole 500mg QID, Tetracycline 500mg QID, and Omeprazole 20mg (active BID + placebo BID) for 14 days. \*\*NOTE: placebo tablets are used to maintain the same number of pills in all study arms and preserve blinding
224076027|NCT06937203|DRUG|ARO-ALK7|SC injection
224076028|NCT06937203|DRUG|Placebo|calculated volume to match active treatment by SC injection
224188253|NCT05642091|DEVICE|ultrasound Elastography|application of shear wave force by ultrasound elastography
224188254|NCT01388946|DRUG|Ropivacaine 0.75|
224188255|NCT01388946|DRUG|Normal saline|
224188256|NCT04159740|OTHER|Tissue and blood collection|Tissue and swab (cells) collection for microbiome analysis. Blood collection for immune markers.
224188257|NCT04337827|DRUG|Rituximab|"Weekly x 4 weeks.~If diagnostic test reveals complete response, then participant will continue with one additional 28 day cycle. If partial response, then proceed with 3 additional 28 day cycles. If stable disease or progression of disease, then go off study treatment and proceed onto Long Term Follow Up (LTFU)."
224188258|NCT04337827|DRUG|Acalabrutinib|"100mg twice per day (BID) x 4 weeks (28 day cycle)~If diagnostic test reveals complete response, then participant will continue with one additional 28 day cycle. If partial response, then proceed with 3 additional 28 day cycles. If stable disease or progression of disease, then go off study treatment and proceed onto LTFU."
224188259|NCT04337827|DIAGNOSTIC_TEST|CT scans|2 weeks (day 36 ± 5 days) after end of cycle 1 treatment.
224188260|NCT00131001|PROCEDURE|contrast-enhanced magnetic resonance angiography|
224188261|NCT04312152|DIETARY_SUPPLEMENT|Q10 Ubiquinol|Q10 Ubiquinol (50 or 100 mg b.i.d. depending on body weight) in capsules containing also Vit. E and Vit. B complex, as described above. Capsules can be opened and the content drunk or chewed, if children have difficulties with swallowing capsules.
224188262|NCT04312152|DIETARY_SUPPLEMENT|Vitamin E|Vitamin E (30 mg b.i.d. regardless of body weight) in capsules containing also Vit. B complex, and, in the active arms, Q10 ubiquinol. Capsules can be opened and the content drunk or chewed, if children have difficulties with swallowing capsules.
224188263|NCT04312152|DIETARY_SUPPLEMENT|Multi-Vitamin B complex|Multi-Vitamin B complex including Vit. B1, B2, B3, B5, B6, B8, B9, and B12, in capsules containing also Vit. E and, in the active arms, Q10 ubiquinol. Capsules can be opened and the content drunk or chewed, if children have difficulties with swallowing capsules.
224188264|NCT05191199|DIAGNOSTIC_TEST|Penile Duplex Study|A penile duplex study will be done to assess PSV, EDV, RI, angle and degree of curvature and Erection quality using the erection hardness grading scale
224188265|NCT05375942|DRUG|Inflectra|1\. To describe the characteristics of patients newly initiated on Inflectra.
224188266|NCT05375942|DRUG|Inflectra|2\. To describe 6-month outcomes after initiating Inflectra, among patients who have 6 months follow-up information in the CorEvitas' RA Registry.
224188267|NCT01734499|BEHAVIORAL|Coping Class|"A 4-hour structured program which will be offered once a month as the Coping Class by a certified facilitator of The Change Cycle. The coping class uses standardized materials and skills training. Standardized materials for the intervention arm will include Change Moves Me Participant's Guide/Journal, Locator Assessment Profile, The Change Cycle Color Model, and class evaluation. The structure of the class includes a profile of each stage to gain perspective and understanding, teaching personal change skills for each stage and a primary focus for movement to the next stage. The overall design follows an act as if philosophy, guiding participants through each stage of The Change Cycle, irrespective of which stage they are actually in."
224188268|NCT01734499|BEHAVIORAL|Standard of Care|Standard of Care. Three components of this: (1)Surveillance Program: all patients diagnosed with breast cancer are seen every six months for the first two years and yearly thereafter to rule out disease recurrence by history and physical exam at each visit in addition to the annual mammogram. (2)Local support groups centered at community cancer centers. These are generally attended by 12-16 women monthly; all breast cancer patients receive the information about these groups. Associated with these programs, some classes are offered sporadically in nutrition, and exercise. (3)Comprehensive Postoperative Rehabilitation which offers physical and occupational rehabilitation to all women, thus provides prevention and treatment of lymphedema and monitored shoulder range of motion.
224188269|NCT01734499|BEHAVIORAL|FACT-B Quality of Life|The FACT-B Quality of Life is a 44-item instrument that was developed by combining nine breast cancer-specific QL items with the FACT general QL instrument. The FACT-B consists of the following subscales: physical wellbeing (PWB), functional wellbeing (FWB), emotional wellbeing (EWB), social/family wellbeing (SWB), and breast cancer specific concerns (BCS).
224188270|NCT00822185|DRUG|vatreptacog alfa (activated)|One single dose is injected i.v. over 2 minutes to 6 subjects, 5 mcg/kg
224188271|NCT00822185|DRUG|vatreptacog alfa (activated)|One single dose is injected i.v. over 2 minutes to 6 subjects, 10 mcg/kg
224188272|NCT00822185|DRUG|vatreptacog alfa (activated)|One single dose is injected i.v. over 2 minutes to 6 subjects, 20 mcg/kg
224188273|NCT00822185|DRUG|vatreptacog alfa (activated)|One single dose is injected i.v. over 2 minutes to 6 subjects, 30 mcg/kg
224188274|NCT00822185|DRUG|placebo|Single dose is injected i.v. over 2 minutes to 2 subjects per dose level: 5 mcg/kg
224188275|NCT00822185|DRUG|placebo|Single dose is injected i.v. over 2 minutes to 2 subjects per dose level: 10 mcg/kg
224188276|NCT00822185|DRUG|placebo|Single dose is injected i.v. over 2 minutes to 2 subjects per dose level: 20 mcg/kg
224188277|NCT00822185|DRUG|placebo|Single dose is injected i.v. over 2 minutes to 2 subjects per dose level: 30 mcg/kg
224188278|NCT02961361|DRUG|ropivacaine|40 ml 0.375% ropivacaine was injected after Locating brachial plexus.
224188279|NCT02961361|DRUG|ropivacaine mixed with dexmedetomidine|40 ml 0.375% ropivacaine mixed with dexmedetomidine was injected after Locating brachial plexus.
224188280|NCT03781167|DRUG|ABBV-951|Solution for continuous subcutaneous infusion (CSCI)
224188281|NCT03454191|PROCEDURE|Erector spinae plane block|Injection of local anaesthetics below the erector spinae muscle after induction of anaesthesia
224188282|NCT03454191|PROCEDURE|No injection|No injection
224309225|NCT02067468|DEVICE|cytology|Cytology routine health services
224309226|NCT01359969|DRUG|rhC1INH|Patients up to 84 kg will receive one i.v. injection of Ruconest at a dose of 50 U/kg. The reconstituted solution should be administered as a slow i.v. injection over approximately 5 minutes. Patients of 84 kg body weight or greater will receive one i.v. injection of Ruconest at the dose of 4200 U (2 vials).
223590419|NCT01096511|DRUG|Moxifloxacin (Avelox, BAY12-8039)|The treatment with Moxifloxacin 400 mg infusion should comply with the recommendations written in the local product information. The decision about the treatment with Moxifloxacin as well as the duration of treatment is solely up to the attending physician.
224188283|NCT05225701|BEHAVIORAL|Transdiagnostic guided internet-delivered intervention with synchronous assistance|Self-applied treatment web system based on transdiagnostic approach for emotional and stress and trauma-derived disorders. The system will contain seven modules: Module 0. Pre-evaluation; Module 1. Psychoeducation and motivation for change; Module 2. Emotional Coping Skills; Module 3. Acceptance and awareness-raising skills focused on the present moment; Module 4. Cognitive coping skills; Module 5. Behavioral coping skills; Module 6. Achievements, maintenance and prevention of relapses; Module 7. Post-evaluation. Each user will be assigned an advisor who will be health personnel (psychologists, social workers, and gerontologists). The function of the psychological advisor is to motivate, guide and listen to the doubts and comments of each participant by providing a weekly session of one hour in individual online format, in addition to the review of the module in platform in self-suggestive format.
224188284|NCT05225701|BEHAVIORAL|Transdiagnostic self-guided internet-delivered intervention|Self-applied treatment web system based on transdiagnostic approach for emotional and stress and trauma-derived disorders. The system will contain seven modules: Module 0. Pre-evaluation; Module 1. Psychoeducation and motivation for change; Module 2. Emotional Coping Skills; Module 3. Acceptance and awareness-raising skills focused on the present moment; Module 4. Cognitive coping skills; Module 5. Behavioral coping skills; Module 6. Achievements, maintenance and prevention of relapses; Module 7. Post-evaluation. Each module will include exercises and tasks for the practice of each technique. Automatic emails with notifications will be sent to access the program when participants have not entered in the last 15 days.
224188285|NCT04115501|OTHER|Fraction of Inspired Oxygen|Fraction of Inspired Oxygen during cardiac surgery, including cardiopulmonary bypass
224188286|NCT05671042|OTHER|Patients with Upper excretory tract tumors|Standard of care for patients with Sezary Syndrome
224188287|NCT04575909|BEHAVIORAL|Aprosodia Intervention|Intervention will focus on improving participants' use and understanding of emotional prosody using implicit and explicit cues, biofeedback, modeling, and feedback.
224188288|NCT04575909|BEHAVIORAL|No-Intervention|Sessions will comprise conversation about current events, recovery progress (including speech therapy goals targeted in outside intervention \[if relevant\]), hobbies, and other similar topics.
224188289|NCT02442427|DRUG|Palivizumab|A single dose of IV palivizumab 15 mg per kilogram body weight (maximum dose =100 mg). The study medication will be given by IV infusion over 30 minutes using a syringe infusion pump.
224188290|NCT02442427|OTHER|Placebo|An equal volume of 0.9% normal saline
224188291|NCT03562676|OTHER|weightlessness|parabolic flight
224188292|NCT01429194|PROCEDURE|ACE Stapler|The ACE Stapler is used endoscopically, and incorporates a unique tissue capture mechanism to produce large, permanent serosa to serosa plications in a completely trans-oral approach.
223497863|NCT07091578|BEHAVIORAL|Oral Health Education|In oral health education intervention, dental hygienists and school staff collaborated to educate students about oral health. Dental hygienists trained school staff to deliver this programme effectively and offer continued support and guidance to school staff during the programme implementation. An oral health education toolkit partly adapted from the PHE toothbrushing programme toolkit was provided to the school before the start of the programme. Educational materials including lectures, leaflets, and activities were dispensed monthly. Oral health education was conducted once a month during regular school hours in the classroom, and each session lasted for one hour. Students were provided with comprehensive knowledge about oral health, such as proper toothbrushing techniques, the importance of routine dental check-ups, and healthy nutrition. Moreover, toothbrushing kits that include soft toothbrushes and 1450ppm fluoridated toothpaste were distributed every three months.
223590420|NCT01313962|DRUG|Flufirvitide-3 0.05 mg single dose|Nasal Spray
223590421|NCT01313962|DRUG|Flufirvitide-3, 0.1 mg single dose|Nasal spray
223590422|NCT01313962|DRUG|Flufirvitide-3, 0.2 mg single dose|nasal spray
223590423|NCT01313962|DRUG|Flufirvitide-3, 0.4 mg single dose|Nasal spray
223590424|NCT01313962|OTHER|Placebo|Nasal spray
224076029|NCT06943664|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
224076030|NCT06943664|BIOLOGICAL|Cemiplimab|Given IV
224076031|NCT06943664|BIOLOGICAL|Cetuximab Sarotalocan Sodium|Given IV
224076032|NCT06943664|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
224076033|NCT06943664|OTHER|Electronic Health Record Review|Ancillary studies
224076034|NCT06943664|PROCEDURE|Endobronchial Ultrasound Bronchoscopy|Undergo EBUS
224076035|NCT06943664|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
224076036|NCT06943664|PROCEDURE|Photoimmunotherapy|Undergo EB-PIT
224076037|NCT06943664|PROCEDURE|Photoimmunotherapy|Undergo I-PIT
224076038|NCT06943664|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
224076039|NCT06943664|PROCEDURE|Robotic Bronchoscopy|Undergo robotic bronchoscopy
224076040|NCT06943664|PROCEDURE|Video-Assisted Thoracic Surgery|Undergo VATS
224076041|NCT07143123|BEHAVIORAL|Cloud-based learning platform|"The SimCapture system is the technological backbone of the intervention, transforming the way clinical skills are taught and learned.~1. System Access and Structure:Both faculty and students are provided with individual accounts to access the SimCapture platform.~2. The system facilitates the organization of students into groups, enabling collaborative learning and peer feedback.~3. Digital Evaluation Tools:Faculty develop standardized, digital tools within SimCapture to assess student performance of clinical skills.These tools ensure consistent and objective evaluation.~4. Recording and Feedback:Students record their practice sessions using personal devices (e.g., smartphones).These recordings are uploaded to the SimCapture cloud, creating a repository of learning resources.~5. Faculty use tablets to provide specific, time-stamped feedback on student performance directly within the SimCapture system."
224076042|NCT07143253|PROCEDURE|Preventive pit and fissure sealant application|"Preventive pit and fissure sealant application is a preventive procedure involving the use of flowable resin-based or glass ionomer-based materials to physically cover the occlusal surfaces of teeth, particularly in pits and fissures at high risk of caries development. This barrier prevents plaque accumulation and protects the enamel surface.~In this study, no procedures beyond the routine clinical application of the materials will be performed. However, partially erupted permanent teeth with challenging isolation will be specifically selected. Both materials will be applied using a split-mouth design to the teeth of the same participant. This approach will allow for an effective and comparative evaluation of the clinical retention of the material."
224188293|NCT04855682|OTHER|Retrospective observation after 24 months after the spinal procedure|Retrospective evaluation of patients before the procedure, and prospective evaluation of patients 24 months after the spinal procedure, comparing the MRI changes and procedure impact on fatty muscle degeneration process
224188294|NCT04855682|OTHER|Retrospective observation after 12 months after the spinal procedure|Retrospective evaluation of the patient status before the procedure, and prospective evaluation of patients for 12 months after the spinal procedure, comparing the MRI changes
224188295|NCT04855682|OTHER|Prospective evaluation of patients after 12 and 24 months after the spinal procedure|Prospective evaluation of patients after 12 and 24 months after the spinal procedure, comparing the MRI changes
224188296|NCT05598762|GENETIC|Tape strips|Tape strip is a minimally invasive method that captures the stratum corneum. It is use to identify skin biomarkers in atopic dermatitis.
223497864|NCT07100158|OTHER|Ultrasonographic Measurement of Optic Nerve Sheath Diameter (ONSD)|Non-invasive ultrasonographic measurement of optic nerve sheath diameter (ONSD) using a 7.5 MHz linear probe at predefined time points: preoperative and postoperative 6, 12, 24, 36, and 48 hours.
223497865|NCT07103408|DRUG|Immuno-chemotherapy|Immuno-chemotherapy regimen included etoposide, cisplatin, iparomlimab and tuvonralimab, and thymosin alpha 1.
223497866|NCT07103408|RADIATION|Radiotherapy|"Definitive dose of thoracic radiotherapy was delivered no later than the three cycle of immuno-chemotherapy.~Prophylactic cranial irradiation (PCI) was delivered with a total dose of 25Gy in 10 fractions. PCI was recommended for patients who achieved complete response or partial response after thoracic chemoradiotherapy."
223590425|NCT03189901|DRUG|Regular management+Levosimendan|Patients are treated with regular management recommended in guidelines and levosimendan.
223497867|NCT07103408|DRUG|Consolidative therapy|Consolidation therapy regimen included iparomlimab and tuvonralimab, and thymosin alpha 1, with a duration of one year.
224074162|NCT07025720|DEVICE|TMS|"The protocol involves delivering sessions of intermittent theta burst stimulation (iTBS) of 60 cycles of 10 bursts of three pulses at 50 Hz were delivered in 2-second trains (5 Hz) with an 8-second intertrain interval. Stimulation sessions will be delivered hourly. Ten sessions will be applied per day (18,000 pulses/day) for 5 consecutive days (90,000 pulses in total). Stimulation will be delivered at 90% resting motor threshold (rMT) adjusted for cortical depth.~MR brain imaging will be used with the Localite Neuronavigation System (Localite GmbH, Sankt Augustin, Germany) to position the TMS coil over the individualized stimulation target."
224074163|NCT07024966|DIETARY_SUPPLEMENT|Pterostilbene-silybin-nicotinamide riboside|Participants will take 2 sachets, each containing 340 mg of ccPT, silybin and nicotinamide riboside, and 1.91 g of excipients.
224074164|NCT07024966|DIETARY_SUPPLEMENT|Control Group|Participants will take 2 sachets, each containing 340 mg microcrystalline cellulose, and 1.91 g of excipients.
224074165|NCT04622046|DRUG|ALXN2060|ALXN2060 tablets will be administered twice daily at a dose of 800 milligrams.
224074166|NCT06712407|DRUG|TARPEYO®|6-months of TARPEYO® 16 mg QD then 9-month Treatment Period with TARPEYO® 8 mg QD and TARPEYO®4 mg QD for 2 weeks for tapering.
224074167|NCT06877234|PROCEDURE|Ultrasonic Nerve Ablation System|Treatment of patients with essential hypertension using the ultrasonic nerve ablation system
224074168|NCT02956161|DEVICE|Stimulation of up-phase of sleep slow oscillation|
224074169|NCT02956161|DEVICE|Random stimulation of up phase of sleep slow oscillation|
224074170|NCT02956161|DEVICE|No stimulation|
224074171|NCT07032844|BEHAVIORAL|Digital Health Coaching|This program will be developed using existing, evidence-based curricula for chronic disease self-management, with emphasis on diabetes, hypertension, and obesity. Prior to initiating health coaching with participants, coaches will review data collected related to SDoH to further tailor the intervention as appropriate for housing stability, access to food and transportation, and interpersonal safety. All coaches will have access to participants' EMRs such that they can view medical information throughout the intervention. Coaches will be trained using a curriculum developed by Family and Community Medicine's inter-professional care team and our partners at NCHPAD, making the coaching inclusive of people with physical disabilities, such that the coaches are proficient in motivating behavior change related to resilience, physical activity, nutrition, mindfulness, and relationship-building, among others.
224074172|NCT07032844|BEHAVIORAL|Phone Based Coaching|Weekly coaching calls that address topics related to goal setting, creating supportive environments for behavior change, physical activity, and nutrition.
224074173|NCT07032844|BEHAVIORAL|Combination of Digital Health coaching + Remote Patient Monitoring|Combination of both digital health coaching and remote patient monitoring
224074174|NCT06716307|DRUG|CagriSema (cagrilintide B and semaglutide I)|Cagrilintide and semaglutide will be administered subcutaneously using DV3384 pen-injector.
224074175|NCT06716307|DRUG|CagriSema A|Cagrilintide and semaglutide will be administered subcutaneously using PDS290 pen-injector.
224074176|NCT01934283|DEVICE|urine folly catheter|
224074177|NCT05907629|OTHER|MRI|Additional MRI to the CAPTIVA study at baseline and 12 months follow-up
224188297|NCT01305694|BIOLOGICAL|bone marrow derived mesenchymal stem cells|Intravenous administration of up to 6x10\^5 MSCs per kg,qw,for 4 weeks
224188298|NCT05737394|PROCEDURE|Laparoscopic-guided TAP Block|Laparoscopically-assisted placement of block
224188299|NCT05737394|PROCEDURE|Ultrasound-guided TAP Block|Ultrasound-assisted placement of block
224188300|NCT00638820|PROCEDURE|Stem Cell or Umbilical Cord Blood Transplantation|Stem Cell (unrelated or matched related donor grafts (both peripheral blood and marrow) infusion on Day 0 and 42; Umbilical Cord Blood on Day 0 and 42
224188301|NCT00638820|DRUG|Campath, Busulfan, Clofarabine|"* 12 Campath-1H 0.3 mg/kg intravenously (IV) over 2 hours~* 11 Campath-1H 0.3 mg/kg intravenously over 2 hours~* 10 Campath-1H 0.3 mg/kg intravenously over 2 hours~* 9 Busulfan \<12 kg: 2.2 mg/kg/dose IV every 12 hours \>12 kg: 1.6 mg/kg/dose IV every 12 hours~* 8 Busulfan \<12 kg: 2.2 mg/kg/dose IV every 12 hours \>12 kg: 1.6 mg/kg/dose IV every 12 hours~* 7 Rest~* 6 Clofarabine 40 mg/m2 intravenously over 2 hours~* 5 Clofarabine 40 mg/m2 intravenously over 2 hours~* 4 Clofarabine 40 mg/m2 intravenously over 2 hours~* 3 Clofarabine 40 mg/m2 intravenously over 2 hours~* 2 Clofarabine 40 mg/m2 intravenously over 2 hours"
224188302|NCT00638820|PROCEDURE|Total Lymphoid Irradiation|Dose 500 cGy via anteroposterior (AP) and posteroanterior (PA) fields (250 cGy AP and 250 cGy PA).
224188303|NCT05274620|BEHAVIORAL|IntelliCare|A mobile intervention that use principles of computerized therapy to decrease symptoms of depression
224188304|NCT03061162|RADIATION|pulsed low dose rate radiation therapy|Pulsed low dose rate 3-dimensional conformal radiation therapy
224188305|NCT02934126|OTHER|breast cancer patients|semi structured face to face interviews
224188306|NCT04106674|PROCEDURE|Open reduction internal stabilisation (ORIF)|Treatment allocated to surgical or non-surgical group. Implant choice pragmatic, surgeons choice.
224188307|NCT04245982|PROCEDURE|Gingival biopsy|Two gingival biopsies from each participant were collected.
224188308|NCT01256866|DRUG|Dexmedetomidine|
224188309|NCT01256866|DRUG|Midazolam|
224188310|NCT01367366|PROCEDURE|PET and EBUS-TBNA|PET and EBUS-TBNA once, respectively
224188311|NCT01449474|DEVICE|Patient matched instruments|The patients undergo TKA with using patient matched instruments
224188312|NCT01449474|DEVICE|Jig based instruments|The patients undergo TKA with using jig based instruments
223497868|NCT07106398|DEVICE|repetitive transcranial magnetic stimulation|"Six sessions of rTMS using the EXOMIND™ device, administered once or twice a week.~Each session will deliver 6,300 pulses at alternating frequencies of 12, 15, and 18 Hz, with a total duration of 24 minutes and 30 seconds.~The target site would be left dorsolateral prefrontal cortex (DLPFC), determined by the most common used 5-cm rule. The procedure would be conducted in the research centre with medical staff supported."
223497869|NCT06826599|DEVICE|Investigational Biometer|Investigational non-contact, non-invasive ophthalmic imaging and analysis device used for visualization of ocular structures and measurement of anterior segment and biometric parameters
223497870|NCT06826599|DEVICE|IOLMaster 700 Biometer|Commercially available non-contact instrument used to capture optical biometry measurements
223497871|NCT07118449|DRUG|XC001|22 injections will be administered at the end of the CABG procedure as a one time treatment.
223497872|NCT07118449|DRUG|A195/placebo|22 injections of A195/placebo will be administered at the end of the CABG procedure.
223497873|NCT07119086|BIOLOGICAL|Biological samples|Blood and urine samples
223497874|NCT07119086|OTHER|Questionnaires|Quality of life questionnaires
223497875|NCT07118176|PROCEDURE|Computed Tomography|Undergo PET/CT
223497876|NCT07118176|OTHER|Fludeoxyglucose F-18|Given IV
223497877|NCT07118176|RADIATION|Gallium Ga 68 FAPi-46|Given IV
223497878|NCT07118176|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
223497879|NCT07119047|BEHAVIORAL|"A Brazilian adaptation of the Irish intervention iHELP Stroke"|The intervention comprises a set of interactive experiential learning activities. A physiotherapist will serve as the coordinator, and other healthcare professionals will be invited to participate as guest speakers. The educational session aims to provide knowledge about stroke (what stroke and recurrent stroke are, their signs and symptoms, and lifestyle-related risk factors). The individual session aims: (1) to identify the current self-reported health status after stroke; (2) to recognize and raise awareness of risk factors associated with lifestyle-related behaviors, including the setting of behavior change goals, which are structured using the SMART Goals method; and (3) to identify the individual's preferences and ability to participate in the intervention program. Each group session comprises six components covered across the six sessions: education, goal setting, physical activity participation, emotional self-regulation, skill training, and peer learning.
223497880|NCT07119957|OTHER|Blood, urine and stool biocollection|Collection of blood, urine and stool sampling in order to build up a biocollection
223497881|NCT07121400|PROCEDURE|Interactive e-learning-group|The Interactive-E-learning group had full access to a pedagogical internet platform with online documents; national experts' recommendations on the management of diabetic patients in anesthesia, slide presentation lectures on the topic by local university teachers, and, the possibility to contact a virtual mentor (anaesthesiologist of our department) by email for interactive discussion or questions about the topic.
223497882|NCT07120893|BEHAVIORAL|brief culturally adapted behavioral activation|The brief culturally adapted behavioral intervention in this study is a three individual-session intervention, delivered in primary health care center by primary care psychologist. Each session will last 30-45 minutes in face-to-face. During each session, participants will learn about behavioral techniques to reduce depression and enhance well-being, and practice it in their daily life through homework activities.
223590426|NCT05533710|PROCEDURE|erector spinae plane block|Patients will receive ESB. In the lateral decubitus, after skin sterilization, ESP block will be performed at the level of T9
224188313|NCT03104465|BEHAVIORAL|Mindfulness Training|interactive. web-based mindfulness training complemented with mobile application
224188314|NCT05745974|DIAGNOSTIC_TEST|lymphocytic count|taking blood samples and COVID-19 swab
224188315|NCT00161148|DRUG|Probiotics|
224188316|NCT05597930|DEVICE|Wrist and Thumb orthosis|Custom 3D printed thumb and wrist orthosis
224188317|NCT01590628|DRUG|NiCord|NiCord® is a cell-based product composed of umbilical cord-derived ex vivo expanded stem and progenitor cells
224188318|NCT04451070|OTHER|Clinic First curriculum|"The Clinic First model was designed by the Association of Family Medicine Residency Directors (AFMRD) in collaboration with the University of California San Francisco's (UCSF) Center for Excellence in Primary Care. The components of the Clinic First model are summarized in the Association of American Medical Colleges' (AAMC) publication titled High-Functioning Primary Care Residency Clinics: Building Blocks for Providing Excellent Care and Training. Using the principles of Clinic First, the authors of this study drafted a Family Medicine residency curriculum to be implemented at David Grant Medical Center at the beginning of the 2020-2021 academic year."
224188319|NCT01006031|DRUG|Pegylated interferon alfa-2a and Ribavirin|"Pegylated interferon alfa-2a (360 ug per week) plus oral Ribavirin (800 mg b.i.d.) for 48 or 72 weeks. The treatment will be discontinued for patients who did not achieve a reduction with respect to baseline of at least 0.5 log10 IU/ml in plasma RNA-HCV levels at week 4 or 2 log10 UI/ml at week 12 and will be considered as viral failures.~Duration: 48 weeks for patients reaching an undetectable plasma RNA\_HCV at week12 and 72 weeks for those without a negative viremia at week 12 but a reduction of at least 2 log10 IU/ml in RNA-HCV levels."
224188320|NCT00475657|DRUG|pemetrexed|500 mg/m2, intravenous (IV), every 21 days x 6 cycles
224188321|NCT00475657|DRUG|cisplatin|75 mg/m2, intravenous (IV), every 21 days x 6 cycles
224188322|NCT04447963|DEVICE|Non-invasive treatment of facial wrinkles|Application of radiofrequency field which provides controlled heating to the skin.Therapeutic effect is observed when the tissue temperature reaches 40-45 degrees Celsius.
223497883|NCT07123831|OTHER|virtual reality supported privacy education|The experimental group was shown a video with virtual reality application for 15 minutes in an empty classroom environment determined in the primary school at a time and in a way that would not disrupt the lessons. Then, verbal expression, question-answer and feedback were given for 10 minutes. After this training session, the experimental group was repeated twice with virtual reality goggles at two-week intervals and their questions were answered. No intervention was made to the students in the control group. At the end of the sixth week, the researcher administered post-tests to each student in the experimental and control groups.
223497884|NCT07120594|DRUG|Unbuffered lidocaine 2% with epinephrine 1:80,000|Standard local anesthetic solution without pH modification. Used for maxillary extraction of infected primary molars in pediatric patients.
223497885|NCT07120594|DRUG|Buffered lidocaine 2% with epinephrine 1:80,000|Local anesthetic solution mixed with sodium bicarbonate to increase pH before injection. Used for maxillary extraction of infected primary molars in pediatric patients.
223497886|NCT07121790|DEVICE|Implant Mg-based RemeOs™ drillpins|"This is a first-in-human clinical feasibility study of a novel absorbable magnesium-zinc-calcium alloy DrillPin (RemeOs™) for internal fixation during surgical correction of hammertoe deformities in adult patients. The implant is investigational, not CE-marked, and represents an alternative to conventional stainless steel or titanium K-wires commonly used in toe correction surgery.~The RemeOs™ DrillPin is designed to provide mechanical stability during osteotomy healing and gradually resorbs over 2-3 years, potentially eliminating the need for secondary implant removal.~The study focuses on evaluating safety, performance, and implant resorption using standardized clinical and radiographic assessments. The DrillPin is made from the same magnesium alloy (ZX00) as the CE-marked RemeOs™ Screw, which has demonstrated clinical safety and performance in prior applications."
223497887|NCT07123181|OTHER|Control (Standard treatment)|Patients receive standard medical treatment.
223497888|NCT07123181|OTHER|Higher polyphenol intake by consumption of oregano and basil|Patients consume 4-5 grams of dried oregano and 4-5 grams of dried basil leaves daily for two months in addition to their usual medical treatment.
223497889|NCT07125001|OTHER|Ataulfo mango|4 weeks of Ataulfo mango intake
223590427|NCT05533710|PROCEDURE|transversus abdominis plane block|patients will receive TAP block in supine position after skin sterilization, TAP block will be performed between internal oblique and transversus abdominis muscles
223590428|NCT01191346|OTHER|3T MRI|3T MRI in addition to standard 1.5T MRI for treatment planning
223590429|NCT05098509|DRUG|RAD011|Cannabidiol Oral Solution (containing synthetic cannabidiol)
223590430|NCT05098509|DRUG|Placebo|Matching Placebo for RAD011
224074178|NCT06728410|DRUG|Pemigatinib|Pemigatinib 13.5 mg
224074179|NCT06728410|DRUG|Durvalumab|Durvalumab 1500 mg IV
224074180|NCT06738303|DRUG|Cabazitaxel and carboplatin|Given IV
224074181|NCT06738303|DRUG|Lu-PSMA-617|Given IV
224074182|NCT07046624|BEHAVIORAL|Infusion monitoring system developed for use by nurses in patient care|In the experimental group, the frequency of complications will first be determined and an infusion monitoring system will be developed and used by nurses in patient care.
224074183|NCT06736704|DRUG|SNV4818|SNV4818 is a tablet taken orally. Dose and frequency are dependent upon treatment arm.
224074184|NCT06736704|DRUG|Fulvestrant|Fulvestrant is administered via an intramuscular injection. It will be given at a dose of 500 mg (2-250 mg/5 mL injections)
224074185|NCT06744374|DRUG|BGF|Budesonide/glycopyrrolate/formoterol fumarate
224074186|NCT06744374|DRUG|MITT|Multiple-inhaler triple therapy
224074187|NCT07127081|BEHAVIORAL|Stress ball|The study was a randomised controlled trial showing the effect of watching cartoons and squeezing a stress ball on pain and fear in children admitted for intravenous catheter insertion.
224074188|NCT07127081|BEHAVIORAL|Cartoons|The study was a randomised controlled trial showing the effect of watching cartoons and squeezing a stress ball on pain and fear in children admitted for intravenous catheter insertion.
224074189|NCT06895941|DIAGNOSTIC_TEST|PET|Exploring the predictive value of PET/CT metabolic parameters for the efficacy of neoadjuvant immunotherapy in non-small cell lung cancer.
224074190|NCT03961945|DEVICE|Sponge Capsule|Subjects will swallow sponge capsule and esophageal cells will be collected on deployed sponge.
224074191|NCT06742723|DRUG|Baxdrostat/dapagliflozin|"baxdrostat tablet~dapagliflozin tablet"
224074192|NCT06742723|DRUG|Placebo/dapagliflozin|"dapagliflozin tablet~placebo tablet"
224074193|NCT07061522|OTHER|Behavioral/Physical Assessment|This study will not include any therapeutic or clinical intervention. Instead, participants will undergo a series of structured physical and questionnaire-based assessments to evaluate lower extremity motor performance. These include the Fagerström Test for Nicotine Dependence and DSM-IV-TR criteria to classify smoking addiction. Anthropometric measurements such as Body Mass Index (BMI) and bimalleolar diameter/circumference will be recorded to assess potential confounding structural factors. Lower extremity coordination will be evaluated using the Lower Extremity Motor Coordination Test (LEMOCOT), and movement speed will be assessed with a 30-meter sprint test. All assessments will be conducted once in a controlled laboratory setting and are intended solely for comparative analysis between smokers and non-smokers.
224074194|NCT06898814|DRUG|Ferric Derisomaltose|The active intervention is a single dose of Ferric Derisomaltose, 20mg/kg body weight, diluted in 100 mL isotonic sodium chloride 0.9%
224074195|NCT06898814|DRUG|Saline (NaCl 0,9 %) (placebo)|Single dose of 100 mL isotonic sodium chloride 0.9%
224074196|NCT06774547|OTHER|Heavy-slow resistance training|Heavy-slow resistance training consists of a progressive protocol of dynamic exercises where the relative load increases over time from a weight that can only be lifted 15 times (i.e., 15 repetition maximum) during the first week to a relative load of 6 repetition maximum from Week 9 to 12. The exercises are performed unsupervised three days per week separated by a minimum of 48 hours. There are two exercises that are performed for four sets separated by a 2-minute rest. Participants with Achilles tendinopathy or plantar fasciopathy perform seated and standing weighted heel raises and participants with patellar tendinopathy perform a free-standing squat and a seated leg press. Tolerable pain during the exercises is allowed.
224309227|NCT03174262|BEHAVIORAL|Ergonomic Computer Workstation Training|Training in proper body alignment and use of computer at computer workstations for people who spend 30% or more of a typical day at a computer. Training consists of learning proper positioning for head, neck, shoulders, arms, hands, and legs; proper arrangement of computer monitor, keyboard, mouse, and accessories.
224188323|NCT03248557|DIAGNOSTIC_TEST|Spectral analysis of ventricular fibrillation tracings|Up to 5-s long ventricular fibrillation segments will be extracted after segmentation and signal codification from artifact-free tracings. Signals will be band-pass filtered between 1.5 and 40 Hz. Averaged power spectral density will be obtained at each frequency using the non-parametric Welch method for using fast Fourier transform and normalized to the peak power in the 1.5-10 Hz band for each patient. Dominant frequency, HL-PSDR (the relative power between high and low frequency bands (cut-off: 3.9 Hz)) and HL-pKR ( relative number of spectral peaks above and below the 3.9 Hz threshold with power above 40% the frequency with the highest power), along with the number of DC shocks before ROSC, will be the variables used to obtain a model-derived risk score for outcome prediction.
224188324|NCT03230240|DRUG|HIPEC|heated intraIP chemotherapy
224188325|NCT00381680|DRUG|vincristine sulfate|Given IV
224188326|NCT00381680|DRUG|prednisone|Given PO
223497890|NCT07125872|BIOLOGICAL|CD19 t-haNK- IV Administration|"N-803 Subcutaneous (SQ): N-803 is a novel IL-15 superagonist immunotherapy administered subcutaneously. It is designed to enhance the proliferation and activation of natural killer (NK) cells and CD8+ T cells without stimulating regulatory T cells. N-803 SQ differs from other cytokine therapies due to its improved pharmacokinetic profile, enhanced in vivo activity, and reduced toxicity.~CD19-Directed Therapies: CD19-targeted therapies, are biologic agents specifically designed to recognize and eliminate CD19-expressing B-cell malignancies. These therapies differ from traditional chemotherapy or small molecule inhibitors by leveraging the patient's immune system to achieve targeted cytotoxicity. Their mechanism of action involves direct binding to the CD19 antigen on malignant B cells, leading to immune-mediated cell death."
223497891|NCT07125430|OTHER|strengthening exercise|a strengthening exercise program will be carried out for three weeks
223497892|NCT07125430|OTHER|shock wave|3 sessions of shock wave therapy, frequency of one session per week
223497893|NCT07125443|DRUG|"Prospective iNO Administration (After Group)"|Adult patients undergoing liver transplantation after the implementation of the iNO protocol, with prospective intervention involving intraoperative administration of iNO and prospective data collection. Inhaled nitric oxide will be administered via the anesthesia machine, under the supervision of the attending Anesthesiologist, at a concentration of 20 parts per million (ppm) starting at induction of anesthesia. At the onset of the anhepatic phase (i.e., after explantation of the native liver), the concentration will be increased to 80 ppm. Administration will be continued until the end of the surgical procedure, at which point iNO will be discontinued.
223497894|NCT07125443|OTHER|"No Intervention Retrospective Before Group"|Adult liver transplant recipients identified retrospectively from the institutional transplant database, including all patients who underwent orthotopic liver transplantation since the implementation of the OneChart electronic medical record (EMR) system between the time period of January 1, 2020 - May 31, 2025.
223497895|NCT00049595|BIOLOGICAL|bleomycin sulfate|
223497896|NCT00049595|BIOLOGICAL|filgrastim|
223497897|NCT00049595|BIOLOGICAL|pegfilgrastim|
223497898|NCT00049595|DRUG|ABVD regimen|
223497899|NCT00049595|DRUG|BEACOPP regimen|
223497900|NCT00049595|DRUG|cyclophosphamide|
223590431|NCT04033068|BIOLOGICAL|Two MV-ZIKA-RSP vaccinations (high dose)|"In this arm of the study, 14 participants will receive:~1. V1= day 0; dose vaccination with MV-ZIKA-RSP (high dose).~2. V2= day 28; dose vaccination with MV-ZIKA-RSP (high dose).~Description:~Visit 1: Participants will receive their first vaccination with MV-ZIKA-RSP (high dose) Visit 2: Participants will receive their second vaccination with MV-ZIKA-RSP (high dose)"
224188327|NCT00381680|DRUG|doxorubicin hydrochloride|Given IV
224188328|NCT00381680|DRUG|pegaspargase|Given IM
224188329|NCT00381680|DRUG|cytarabine|Given IT or IV
224188330|NCT00381680|DRUG|methotrexate|Given IT or IV
224188331|NCT00381680|DRUG|dexamethasone|Given PO
223497901|NCT00049595|DRUG|dacarbazine|
223590432|NCT04033068|BIOLOGICAL|Two MV-ZIKA-RSP vaccination (low dose)|"In this arm of the study, 14 participants will receive:~1. V1= day 0; dose vaccination with MV-ZIKA-RSP (low dose).~2. V2= day 28; dose vaccination with MV-ZIKA-RSP (low dose).~Description:~Visit 1: Participants will receive their first vaccination with MV-ZIKA-RSP (low dose) Visit 2: Participants will receive their second vaccination with MV-ZIKA-RSP (low dose)"
224188332|NCT00381680|DRUG|etoposide|Given IV
224188333|NCT00381680|DRUG|cyclophosphamide|Given IV
224188334|NCT00381680|DRUG|leucovorin calcium|Given IV or PO
224188335|NCT00381680|BIOLOGICAL|filgrastim|Given IV or SC
224188336|NCT00381680|DRUG|asparaginase|Given IM
224188337|NCT00381680|DRUG|mercaptopurine|Given PO
223497902|NCT00049595|DRUG|doxorubicin hydrochloride|
223497903|NCT00049595|DRUG|etoposide|
223497904|NCT00049595|DRUG|prednisone|
223497905|NCT00049595|DRUG|procarbazine hydrochloride|
223497906|NCT00049595|DRUG|vinblastine sulfate|
223497907|NCT00049595|DRUG|vincristine sulfate|
223497908|NCT05286762|DRUG|CTx-1301-Dexmethylphenidate 12.5 mg (titration only)|Subjects will be randomized at Visit 2 to CTx-1301 to 12.5mg
223497909|NCT05286762|DRUG|CTx-1301-Dexmethylphenidate 18.75mg (randomized fixed dose)|Subjects will be randomized at Visit 2 to CTx-1301 to 12.5mg, then week 1 to 18.75 mg
223497910|NCT05286762|DRUG|CTx-1301-Dexmethylphenidate 25mg (randomized fixed dose)|Subjects will be randomized at Visit 2 to CTx-1301 to 12.5mg, then week 1 to 18.75 mg, then week 2 to 25 mg
223497911|NCT05286762|DRUG|CTx-1301-Dexmethylphenidate 37.5 mg (randomized fixed dose)|Subjects will be randomized at Visit 2 to CTx-1301 to 12.5mg, then week 1 to 18.75 mg, then week 2 to 25 mg, then week 3 to 37.5 mg
223497912|NCT05286762|DRUG|Placebo|Subjects will be randomized at Visit 2 to Placebo
224188338|NCT00913874|DRUG|Divalproex Sodium 500 mg DR Tablets (Sandoz Inc., USA)|
224188339|NCT00913874|DRUG|Depakote 500 mg DR Tablets (Abbott Laboratories, USA)|
224188340|NCT00398476|DRUG|fluticasone propionate (FP)|200 micrograms (mcg); an aqueous suspension of microfine FP
224188341|NCT00398476|DRUG|fluticasone furoate (FF)|110 mcg; an aqueous suspension containing 0.05% w/w of micronized FF
224188342|NCT02513901|DRUG|Chidamide|Chidamide will be given by mouth on Day 0, 3, 7, 10, 14, 17, 21, 24.
224188343|NCT02926768|DRUG|CK-101|"Phase 1: CK-101 will be administered in escalating dosages in a period of 21-day cycles~Phase 2: CK-101 will be administered daily"
223497913|NCT06344572|DEVICE|SAT-001|Device: SAT-001(a Software as Medical Device) Using SAT-001 application for 48 weeks and wearing single vision spectacles
223497914|NCT06344572|OTHER|Single vision spectacles|Wearing single vision spectacles
224188344|NCT04899219|DRUG|ACT-1014-6470 40 mg|ACT-1014-6470 will be available as soft gelatin capsules for oral administration formulated at a dose strength of 20 mg.
224188345|NCT00646217|BEHAVIORAL|Self Care Talk|6 weekly telephone sessions
224188346|NCT05208398|DRUG|Apixaban|5 mg twice daily, on top of standards of care.
224188347|NCT05208398|DRUG|Warfarin|Warfarin, oral tablets, to achieve international normalized ratio (INR) of 2-3, on top of standards of care, as per updated guidelines of acue coronary syndrome management recommendations
224188348|NCT04737447|DEVICE|Whole Body Vibration Training|Galileo® Trainer is a vibration board. The movement alternating to different sides during walking correlates with the movement on the board due to variable amplitudes and frequencies. Movements of the vibration board are quickly changing and thus simulating the tilting movements of the pelvic during walking but with higher frequency. Muscles of legs and core are activated reflexively. In our study there are performed static practices and pelvic activating practices. Each physiotherapist is experienced in the technical and practical handling of the device.
224188349|NCT06231901|OTHER|CO-OP|With a task-specific and goal-focused CO-OP approach; it is aimed to increase one's skills, to teach to use self-generated cognitive strategies, and to encourage generalization and transfer to new situations and activities.
223497915|NCT03383575|DRUG|Azacitidine|Given IV or SC
223497916|NCT03383575|DRUG|Enasidenib|Given PO
223497917|NCT03383575|OTHER|Quality-of-Life Assessment|Ancillary studies
223497918|NCT06950190|BEHAVIORAL|Low-Intensity Walking Intervention|Participants in the experimental group will be asked to take part in a home-based, walking program. Each participant will receive a pedometer and will be instructed to increase their baseline daily step count by 100%. For example, if a participant typically walks 3,000 steps per day, they will be asked to increase their activity to 6,000 steps per day. Step counts will be regularly monitored, and participants will receive encouragement and support from study staff to help maintain adherence to the walking goals. In addition to the exercise intervention, participants in this group will undergo cognitive testing using the Montreal Cognitive Assessment (MoCA) at four timepoints: baseline, 6 months, 9 months, and 12 months. They will also complete self-reported questionnaires related to cognitive function at these same intervals. This group is designed to evaluate whether increased physical activity can improve or preserve cognitive function in patients undergoing chemotherapy.
224188350|NCT06231901|OTHER|GDT|Goal-directed training included the active implementation of task-specific activities related to the child's functional goals. Focusing on motor learning, GDT is an activity-based approach to therapy that uses meaningful, self-selected goals to provide opportunities for problem solving and indirectly guide the movements necessary to successfully meet task demands
223497919|NCT06950190|BEHAVIORAL|Control Group Intervention|Participants in the control group will receive standard care and will not be given any specific exercise instructions. They will be provided with pedometers to track their daily steps, but they will not be asked to increase or change their usual level of physical activity. These participants will continue with their routine activities and cancer care as directed by their treating physicians. Like the intervention group, they will complete the Montreal Cognitive Assessment (MoCA) at baseline, 6 months, 9 months, and 12 months, as well as self-reported questionnaires about cognitive function at each timepoint. This group will serve as a comparator to determine the impact of the walking intervention on cognitive outcomes.
223497920|NCT06558799|DEVICE|NovoTTF-200T|The NovoTTF-200T is a portable, battery operated system intended for continuous home use, which delivers TTFields at a frequency of 150kHz to the subject by means of insulated transducer arrays. TTFields exert electric forces intended to disrupt cancer cell division and induce immunogenic cell death.
223497921|NCT06558799|DRUG|Pembrolizumab|Pembrolizumab is an immune checkpoint inhibitor that helps the immune system recognize and attack cancer cells.
223497922|NCT05310552|OTHER|No interventions - observational study|No interventions - observational study
223497923|NCT02955394|DRUG|Enzalutamide|160mg of Enzalutamide will be given daily in conjunction with Fulvestrant.
223497924|NCT02955394|DRUG|Fulvestrant|500mg Fulvestrant will be given IM on days 1, 15, 28, then every 4 weeks as per standard of care (SOC)
223497925|NCT06198413|GENETIC|LX102 subretinal injection|LX102: AAV-based gene therapy comprised of codon-optimized sequence encoding VEGF-trap
223497926|NCT01334047|BIOLOGICAL|DC-006 vaccine|Vaccine is administered every 4 weeks during the first year. Only patients that show immunological response will continue vaccination every months during the 2nd and 3rd year.
224188351|NCT06231901|OTHER|traditional occupational therapy|The program included functional one-handed and two-handed training and consisted of advice and treatment aimed at reducing spasticity, improving hand function and activities of daily living, and providing appropriate orthoses. It also includes techniques aimed at improving impairment (e.g., stretching, sensory stimulation) and strengthening activities (e.g., motor training, environmental modification, performing specific target activities) to help participants achieve their individual goals.
224188352|NCT02173821|PROCEDURE|Blood sampling|Blood sample will be collected at a single visit
224188353|NCT01588899|DEVICE|MR-HIFU uterine fibroid treatment|A single treatment session for uterine fibroids with the MR-HIFU device.
224188354|NCT04940832|DEVICE|pulsed radiofrequency modulation|a percutaneous needle electrode to apply pulsed RF signals that modulate the activity of sensory nerves. The pulsing of the RF signal permits a maximum temperature to be achieved - usually 42 Celsius. This helps prevent collateral damage from occurring during the procedure and should help reduce procedural complications.
224188355|NCT04899362|DEVICE|BB-RIC-D1/LAPUL Medical Devices Co, Ltd, China|The RIC consisted of 4 cycles of extremities ischemia (5-minute blood pressure cuff inflation to 200 mm Hg, followed by 5-minute cuff deflation). The tourniquets were applied to one side upper arm. This intervention was undertaken twice a day for 7 days.
224188356|NCT04899362|PROCEDURE|Intravenous blood collection|Nurses will collect intravenous blood 3ml four times (at baseline and the first, seventh and eighth day of the study).The blood samples will be stored for laboratory test.The blood samples only use for the trial.
224309228|NCT00110136|DRUG|St. John's Wort|St. John's Wort 300mg tablet three times per day
224309229|NCT00154271|DRUG|Valsartan, Valsartan HCT|
224309230|NCT06031233|DRUG|Nivolumab|Gradual shortening of infusion times
224188357|NCT04899362|DEVICE|dCA measurement|Serial measurements of dCA were performed at 10 days, baseline, 1st, 2ed, 4th, 7th, 8th, 10th, 14th, 21th and 35th of the study.The continuous ABP was measured non-invasively using a servo-controlled plethysmograph (Finometer Pro, the Netherlands) at the middle finger. Two 2 MHz transcranial Doppler probe was used to measure continuous cerebral blood flow velocity (CBFV) simultaneously in the bilateral middle cerebral arteries at a depth of 45-60 mm Endtidal CO2 was monitored using a capnograph (MultiDop X2, DWL, Sipplingen, Germany). The probes were placed over temporal windows and fixed with a customized head frame. CBFV and continuous arterial blood pressure were recorded simultaneously from each subject in the supine position for 10 minutes. All data were recorded for further assessment and analysis.
224188358|NCT06260462|DRUG|dual-release hydrocortisone|Oral tablets 20-25-30-40 mg/day
224188359|NCT06260462|DRUG|Conventional glucocortidois|Oral tablets 10-15-20-25-37,5-50-62,5 mg/day
224188360|NCT02467543|OTHER|20% Ethanol|Unmedicated 20% Ethanol
224188361|NCT02467543|OTHER|Viburnum opulus 3X|Viburnum opulus 3X in a vehicle of 20% ethanol.
223497927|NCT04667169|PROCEDURE|Haemorrhoidal Artery Ligation|Post-operatively, all subjects were given tablet Paracetamol 1 gm six hourly and Capsule Celecoxib 200 mg 12 hourly as pain control for five days. They were given Syrup Lactulose 15 cc 12 hourly for one week to prevent constipation. Subjects were discharged on the same day or one day after surgery. All patients were assessed in the clinic by a nurse/medical officer blinded to the type of procedure performed on post-operative 24 hours, one week and six weeks.
223497928|NCT04667169|PROCEDURE|Laser Haemorrhoidoplasty|Post-operatively, all subjects were given tablet Paracetamol 1 gm six hourly and Capsule Celecoxib 200 mg 12 hourly as pain control for five days. They were given Syrup Lactulose 15 cc 12 hourly for one week to prevent constipation. Subjects were discharged on the same day or one day after surgery. All patients were assessed in the clinic by a nurse/medical officer blinded to the type of procedure performed on post-operative 24 hours, one week and six weeks.
223497929|NCT02729168|BIOLOGICAL|Human rabies vaccine|
223497930|NCT04041310|BIOLOGICAL|GAd-209-FSP low dose|GAd20-209-FSP IP, low dose
223497931|NCT04041310|BIOLOGICAL|MVA-209-FSP low dose|MVA-209-FSP IP, low dose
223497932|NCT04041310|BIOLOGICAL|GAd-209-FSP high dose|GAd20-209-FSP IP, high dose
223497933|NCT04041310|BIOLOGICAL|MVA-209-FSP high dose|MVA-209-FSP IP, high dose
223497934|NCT04041310|BIOLOGICAL|GAd20-209-FSP, RP2D|GAd20-209-FSP IP, RP2D
223497935|NCT04041310|BIOLOGICAL|MVA-209-FSP, RP2D|MVA-209-FSP IP, RP2D
223497936|NCT04041310|DRUG|KEYTRUDA®|anti-PD-1 checkpoint inhibitor (200 mg; Q3W)
223497937|NCT04372615|DRUG|Inebilizumab|"RCP: Blinded treatment on Day 1, Day 15,~* Inebilizumab group: Inebilizumab 300 mg intravenous (IV)~* Placebo group: IV matching placebo Prior to enrollment, all participants will receive standard of care, including high-dose corticosteroids (minimum of 3 days of treatment, 1 g methylprednisolone daily or equivalent) AND either IVIg (total dose range between 1.2 and 2 g/kg) OR plasmapheresis (defined as 5 or 6 exchanges).~Rescue therapy will be given to participants in either treatment group based on the results of the Week 6 assessments. Rescue therapy is cyclophosphamide 750 mg/m2 IV followed by additional doses every 28-30 days until the mRS score is ≤ 3 (at site Principal Investigator's discretion under standard of care)."
223497938|NCT04372615|DRUG|Placebo|The placebo group will receive IV matching placebo on Day 1 and Day 15,
223497939|NCT05846581|DEVICE|GORE® ACUSEAL Vascular Graft|"The device placement will be performed according to each participating site's standard practice. No specific procedures are required by the protocol.~At the time of the GORE® ACUSEAL Vascular Grafts implantation, procedural and adverse event information will be collected."
224188362|NCT02569502|DRUG|enfuvirtide|Participants will receive a total daily dose of 180mg of enfurtide administered twice daily as a subcutaneous injection.
224188363|NCT03950271|DRUG|SHR-1210 Combined With Trastuzumab , Oxaliplatin and Capecitabine|"1. Neoadjuvant chemotherapy： SHR-1210 (200mg, d1, q3w) + trastuzumab ( 8 mg/kg on day 1 of the first cycle, followed by 6 mg/kg every 3 weeks) + capecitabine (1000mg/m2 bid d2-15, q3w) + Oxaliplatin (130mg/m2, d2, q3w)；4cycle~2. postoperative adjuvant chemotherapy： Capecitabine (1000mg/m2 bid d1-14, q3w) + oxaliplatin (130mg/m2, d1, q3w)；The total number of chemotherapy cycles is 8 cycles."
224188364|NCT04548349|DRUG|Altreno|Acne patients will be assigned to Altreno once daily.
224188365|NCT04548349|DRUG|Benzoyl peroxide|Acne patients will be assigned to BPO leave-on gel once daily.
223497940|NCT05957107|BIOLOGICAL|Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection|The drug was administered once every 4 weeks.
224188366|NCT04256642|PROCEDURE|Erector Spinae Plane Block|A nerve block that injects local anesthetic in the Erector Spinae Plane
224188367|NCT04256642|DRUG|Intrathecal morphine|Intrathecal morphine at the time of spinal anesthesia
224188368|NCT01065077|DRUG|Cinaciguat (BAY58-2667)|Infusion of 150 µg/h during 48h
224188369|NCT01065077|DRUG|Cinaciguat (BAY58-2667)|Infusion of 100 µg/h during 48h
223497941|NCT03850587|DRUG|Celecoxib 200mg|comparator medication
223497942|NCT03850587|DRUG|Tramadol 37.5Mg+ Celecoxib 200mg|experimental medication
223497943|NCT03850587|DRUG|Tramadol 75mg+ Celecoxib 200mg|experimental medication
223497944|NCT03850587|DRUG|Tramadol 150mg+ Celecoxib 200mg|experimental medication
223497945|NCT06367114|BIOLOGICAL|ssCART-19|"Split-Dose of ssCART-19 cells will be infused, and classic 3+3 dose escalation will be applied."
223497946|NCT06367114|DRUG|Fludarabine|Fludarabine is used for lymphodepletion.
223497947|NCT06367114|DRUG|Cyclophosphamide|Cyclophosphamide is used for lymphodepletion.
223497948|NCT05277259|DEVICE|Extracorporeal Shock Wave Therapy|Device named 'Elettronica Pagani,Italy' and will be used with radial probe.
223497949|NCT05277259|OTHER|Kinesiotaping|Elastic band to be used to stretch the upper trapezius muscle in the desired direction.
223497950|NCT05277259|OTHER|Conventional Physical Therapy|Conventional physical therapy will be consisted of hotpack, therapeutic ultrasound and tens applications.
224188370|NCT01065077|DRUG|Cinaciguat (BAY58-2667)|Infusion of 50 µg/h during 48h
224188371|NCT01065077|DRUG|Placebo|Infusion of placebo during 48h
224188372|NCT05645939|OTHER|Diasgnosis of hypertrophic cardiomyopathy|Patients diagnosed with hypertrophic cardiomyopathy during study period
224188373|NCT03978949|DRUG|Bacillus Licheniformis|Two weeks prior to the start of radiation therapy, the probiotics is administered three times daily until the end of radiation therapy.
223497951|NCT05326100|OTHER|Conventional Therapy (CPT)|The exercises may include traditional vestibulo-ocular reflex (VOR) exercises, cervical musculoskeletal exercises, somatosensory exercises, habituation, gait exercises, and aerobic conditioning. The treating PT will modify specific exercises as appropriate based on the participant's symptoms.
224188374|NCT03978949|DRUG|Placebo|Two weeks prior to the start of radiation therapy, the placebo is administered three times daily until the end of radiation therapy.
224188375|NCT06152666|OTHER|None - qualitative interviews|These are qualitative interviews and involve no intervention
224188376|NCT04194138|PROCEDURE|Index or spine revision surgery for complex adult spinal deformity|Surgical interventions will be patient specified by treating surgeon.
224188377|NCT03037138|OTHER|Blood flow Rate profiling|Blood flow rate profiling during dialysis session
224188378|NCT04445454|BIOLOGICAL|Mesenchymal stromal cells|Bone marrow collection and MSC expansion cultures will be carried out at the Laboratory of Cell and Gene Therapy (LTCG) at the University of Liège as described in IMPD and its SOPs.
224188379|NCT02403427|DEVICE|VoiceDiab expert system|"Decision support system VoiceDiab this is computer-based system constructed for mobile phone devices working on the server.~Patients in experimental arm get the mobile phone application for 4 days. Glucose control will be done by two methods SMPG and CGM. Before every study's meal insulin dose with type of bolus will be indicate by VoiceDiab."
224188380|NCT04634565|DRUG|PF-06651600|oral PF-06651600 tablet 200 mg once daily
224188381|NCT01819012|DRUG|Isoflurane 1.0 MAC|10 min-inhalation of each concentration of isoflurane, 1.0 MAC
223497952|NCT05326100|DEVICE|CAREN Therapy|The CAREN, an FDA-registered exempted Class I device, is a VR-based system which includes a six degree-of-freedom motion platform with an embedded, instrumented treadmill surrounded by an immersive 180-degree screen. The CAREN can display a variety of virtual environments (VEs), where the difficulty level and task requirements can be easily modified by the treating clinician to target patient-specific needs.
223497953|NCT05326100|DEVICE|Augmented Reality (AR) Therapy|AR head-mounted displays are designed to provide immersive virtual environments similar to the CAREN, but with the portability to be used in most outpatient clinical settings and potentially for at-home therapy as well as significantly reduced cost compared to the CAREN. AR devices have integrated eye-tracking and inertial measurement units (IMUs) which can be used to objectively quantify characteristics of eye, head and body movement.
223497954|NCT05872399|OTHER|Attitudes Towards Psychiatry - 30|The participants will answer their beliefs in 30 statements about psychiatry and mental health.
223497955|NCT03846232|OTHER|No intervention|No intervention
223497956|NCT03698916|DRUG|Celecoxib cream 8%|transdermal delivery of 8% Celecoxib
223497957|NCT03172000|DIAGNOSTIC_TEST|Colonoscopy and biopsy|Colonoscopic biopsy were taken from the rectum, the sigmoid, descending, transverse, ascending colon, and the cecum of each patient.
223497958|NCT03400553|DIAGNOSTIC_TEST|Blood analysis|The blood of the patients will be analyzed for troponin T measured with 3 different devices: 1) a point-of-care (POC) test performed in the ambulance or MUG, a handheld cobas h232 POC system® (Roche Diagnostics, Switzerland), 2) a POC test at the emergency room, a table top AQT90 FLEX® (Radiometer, The Netherlands) and 3) a central laboratory test performed on cobas® 8000 (Roche Diagnostics, Switzerland).
223497959|NCT00517062|DRUG|Growth hormone (Genotropin)|Growth hormone 0.1 mg self-injected once a day subcutaneously at bedtime.
223497960|NCT00517062|DRUG|Placebo|Placebo self-injected once a day subcutaneously at bedtime.
223497961|NCT01363076|DRUG|Ketorolac Tromethamine|Single IN dose of 15 mg ketorolac tromethamine for subjects weighing \<50 kg.
223497962|NCT01363076|DRUG|Ketorolac Tromethamine|Single IN dose of 30 mg ketorolac tromethamine for subjects weighing ≥50 kg.
223497963|NCT01168180|OTHER|Traditional Thai massage|The participants will receive thirty minutes session of traditional Thai massage onto the scapular region for 9 sessions over a period of 3 weeks
223497964|NCT01168180|OTHER|Ultrasound therapy and hot pack|
224188382|NCT01819012|DRUG|Isoflurane 1.5 MAC|10 min-inhalation of each concentration of isoflurane, 1.5 MAC
224188383|NCT01819012|DRUG|Isoflurane 2.0 MAC|10 min-inhalation of each concentration of isoflurane, 2.0 MAC
223497965|NCT01769872|PROCEDURE|Autologous Adipose Tissue derived MSCs Transplantation|Intravenous injection of Autologous Adipose Derived Mesenchymal Stem Cells. Dose : 2x10e8 cells / 20mL Intrathecal injection of Autologous Adipose Derived Mesenchymal Stem Cells. Dose : 5x10e7 cells / 2mL Into a spinal cord injection of Autologous Adipose Derived Mesenchymal Stem Cells. Dose : 2x10e7 cells / 1mL
223497966|NCT04706403|BEHAVIORAL|Communication from a physician about the COVID-19 Vaccine|Participants who expressed hesitation about getting vaccinated against COVID-19 were randomized to receive one of five different versions of messages from a physician. The messages that participants in each group received varied slightly and systematically. Specific content and wording of these messages were developed to address and mitigate concerns of those at risk for not being vaccinated.
223497967|NCT04220281|DRUG|Propofol|propofol infusion during surgery
223497968|NCT04220281|DRUG|Nitroglycerin|nitroglycerin infusion during surgery
223511897|NCT06548295|COMBINATION_PRODUCT|conservative treatment|"The conservative rehabilitation program consisted of upper-limb range of motion exercises, positioning, stretching, and strengthening exercises, Passive mobilization of the shoulder ,elbow , wrist and small joints of hand Stretching of the affected arm including biceps, triceps and muscles of forearm and hand.~Strengthening exercises of upper arm and forearm muscles involved. Intervention: 5 sessions per week for six weeks and 50 mintues"
224188384|NCT03190252|OTHER|Exposure to oxygen partial pressure of 130 kPa|Open sea diving to a maximum depth of 100 msw while breathing Trimix.
224188385|NCT03190252|OTHER|Exposure to ambient pressure of maximum 11 ATA|Open sea diving to a maximum depth of 100 msw while breathing Trimix.
224188386|NCT04031352|OTHER|implementation of CATCH scale|subject completed the CATCH scale
224188387|NCT01614028|PROCEDURE|Total Hip Arthoplasty|
224188388|NCT00648765|DRUG|Anagrelide Hydrochloride Capsules 1 mg|1mg, single dose fed
224188389|NCT00648765|DRUG|Agrylin® Capsules 1 mg|1mg, single dose fed
224188390|NCT00933543|DRUG|Visonac PDT (MAL PDT)|Cream application followed by illumination with red light.
224188391|NCT00933543|DRUG|Vehicle cream (placebo)|Cream application followed by illumination with red light.
224188392|NCT00933543|PROCEDURE|PDT|Photodynamic Therapy - Light dose 37 J/cm2
224188393|NCT06008015|DRUG|BR1015|One tablet administered alone
224188394|NCT06008015|DRUG|BR1015-1|One tablet administered alone
224188395|NCT06008015|DRUG|BR1015-2|One tablet administered alone
224188396|NCT04988035|DRUG|Danicopan|Danicopan is a small molecule, orally administered complement factor D (FD) inhibitor
224188397|NCT04988035|OTHER|Placebo|Danicopan matching placebo tablet
224188398|NCT04988035|DRUG|Remdesivir|Remdesivir is a single diastereomer monophosphoramidate prodrug for the intracellular delivery of a modified adenine nucleoside analog GS-441524.
224188399|NCT03520361|DRUG|Oral sulfate solution (OSS)|Compositions/177ml : Sodium sulfate 17.5g, Potassium sulfate 3.13g, Magnesium sulfate 1.6g
224188400|NCT03520361|DRUG|2L PEG/Asc|Compositions/1L : Sodium chloride 2.89g, Potassium chloride 1.015g, Anhydrous sodium sulfate 7.5g, Polyethylene glycol 3350 100g, Ascorbic acid 4.7g, Sodium ascorbate 5.9g
224188401|NCT04433858|DRUG|Psilocybin|open-label
224188402|NCT04420559|OTHER|Intramuscular Injection|Intramuscular Benzathine Penicillin Injection Procedure
224188403|NCT06513494|BEHAVIORAL|Active Students Education plus Teacher Training|The teacher undergoes 30 hours of self-instructional training on vaccination through an online platform tailored for the relevant age group. Additionally, students receive active vaccinations and health education over two months
224188404|NCT06513494|BEHAVIORAL|Active Students Education|Students receive active vaccinations and health education over two months.
224188405|NCT06513494|BEHAVIORAL|Basic Health Unit Active Orientation|Nurses from basic health units will conduct an active orientation session at schools about vaccination for students.
224188406|NCT06513494|OTHER|Usual care|No project interventions will be carried out.
224188407|NCT05693233|DEVICE|EXO On, EXO Off, EXO Removed treadmill (Uphill_incline 10°) walking and simultaneous evaluation|"\- After filling out the consent form for 10 subjects who meet the selection criteria, a total of three evaluations are conducted: one pre-evaluation and one post-evaluation for the knee assist robot and hip assist robot.~Pre-evaluation: Evaluation simultaneously with walking on an inclined treadmill (Uphill\_incline 10°) for 5 minutes without wearing knee and hip assist robots (speed 1.5 m/s)."
224188408|NCT00439920|DRUG|High-dose anthracycline|
223497969|NCT04989738|BEHAVIORAL|THRIVE intervention|Parents learn responsive parenting skills, such as a) recognizing infant hunger and satiety cues and using feeding more selectively in response to hunger only, b) recognizing other reasons for crying or fussy behavior and using alternative soothing strategies when these other reasons apply, c) learning to lay the foundation for healthy infant sleep and respond to nighttime awakenings to promote self-soothing, and d) learning to introduce complimentary foods at 6 months, provide repeated exposure to a variety of healthy foods using positive role modeling, and allow infants to determine the amount consumed.
224188409|NCT04600531|DEVICE|1x1 Low Intensity Transcranial Direct Current Stimulation (tDCS)|"tDCS will be delivered through a pair of identical square rubber electrodes (size 35 cm2), placed in rectangular saline-soaked sponges. For the stimulation of M1, electrodes will be placed over C3 or C4 according to the 10-20 EEG system, matching with the M1 contralateral to the performing dominant hand. The reference electrode will be positioned on F1 or F2, ipsilateral to the dominant hand.~The current stimulation will be slowly ramped up from 0 mA to 2 mA in one minute. For the anodal tDCS condition, this intensity will be maintained for the duration of the SRT-task (approximately 20 minutes). This will result in a current density of 0,057 mA/cm2. For the sham tDCS condition - unbeknown to the subject - stimulation will be gradually decreased towards 0 mA immediately after the one-minute ramp-up. During the last block of the SRT-task, this gradual ramping-up and -down of the current stimulation will be repeated to optimize the process of blinding of participants."
224188410|NCT04600531|DEVICE|4x1 Multichannel Stimulation Adapter for High Definition Transcranial Direct Current Stimulation (HD tDCS)|"HD tDCS will be delivered over M1. By connecting the conventional tDCS device (described above) to this adapter, the direct current is delivered along the 4x1 HD tDCS configuration, allowing for more specific neuromodulation. Stimulation is delivered by means of one central gel-electrode and four return-electrodes placed in plastic encasings embedded in an EEG cap.~Stimulation of left M1 (right hand = performing): delivered via the central electrode corresponding with C3 and held in place using a synthetic cap to hold the HD-tDCS electrodes on the head. Return-electrodes are positioned at Cz, F3, T7 and P3 (10-20 EEG system).~Stimulation of right M1 (left hand = performing): central electrode will be positioned at C4 with the return-electrodes at Cz, F4, T8 and P4.~Strategies for anodal and sham stimulation are identical to the ones described above (conventional tDCS)."
224188411|NCT05341531|OTHER|elderly patients undergoing non-cardiac surgery|Elderly patients 60 years and older undergoing major non-cardiac surgery \> 2 hours
223497970|NCT04989738|BEHAVIORAL|Active Control|Parents learn about development, safety, and positive parenting without a specific emphasis on feeding, sleep, and soothing.
223497971|NCT04781985|PROCEDURE|cystoscopy|extraction of the bladder stone via suprapubic incision
223497972|NCT05220995|GENETIC|protocol|ovarian stimulation protocols on euploid rates were compared.
223497973|NCT04858529|DRUG|investigator-selected taxane/carboplatin/trastuzumab/pertuzumab (TCHP)|investigator-selected taxane/carboplatin/trastuzumab/pertuzumab (TCHP)
223497974|NCT04858529|DRUG|investigator-selected taxane/trastuzumab/pertuzumab (THP)|investigator-selected taxane/trastuzumab/pertuzumab (THP)
223497975|NCT03475563|PROCEDURE|Coronary angioplasty with stent implantation|Coronary angioplasty with BiOSS LIM C stent implantation
223590433|NCT04033068|BIOLOGICAL|One MV-ZIKA-RSP vaccination (high dose) and one placebo|"In this arm of the study, 12 participants will receive:~1. V1= day 0; dose vaccination with MV-ZIKA-RSP (high dose).~2. V2= day 28; treatment with placebo~Description:~Visit 1: Participants will receive their first vaccination with MV-ZIKA-RSP (high dose) Visit 2: Participants will receive their second treatment with placebo"
223590434|NCT04033068|OTHER|Two placebo injection|"In this arm of the study, 8 participants will receive:~1. V1= day 0; placebo treatment~2. V2= day 28; placebo treatment~Description:~Visit 1: Participants will receive their first treatment with placebo Visit 2: Participants will receive their second treatment with placebo"
223590435|NCT01872013|DRUG|ASP7991|oral
224188412|NCT04422301|OTHER|Blood flow restriction|an alternative method to produce strength and muscle hypertrophy with lower intensities
224188413|NCT01030731|DRUG|Ceftobiprole|Ceftobiprole 250mg single dose over 2 hours.
224309231|NCT06031233|DRUG|Pembrolizumab|Gradual shortening of infusion times
224309232|NCT06031233|DRUG|Ipilimumab|Gradual shortening of infusion times
224188414|NCT00051246|BEHAVIORAL|Mother-Infant Group Psychotherapy|Mother-infant group psychotherapy consists of weekly 2.5-hour psychotherapy sessions comprised of mother's group therapy, infant developmental therapy, and mother-infant dyadic psychotherapy. Group treatment will last 15 weeks.
224188415|NCT00051246|BEHAVIORAL|Interpersonal Psychotherapy|Individual psychotherapy treatment focuses on role transition, interpersonal relationships, and loss. Individual treatment period will last 15 weeks.
224188416|NCT06372262|OTHER|ergometer test|2000meter rowing ergometer test
224188417|NCT03490253|BEHAVIORAL|DIAMANTE Adaptive|In a three arm randomized controlled trial we will examine the effect of a text-messaging smartphone application to encourage physical activity in low-income ethnic minority patients with comorbid diabetes and depression. The adaptive intervention group receives messages chosen by a reinforcement learning algorithm.
223497976|NCT05998499|OTHER|Description|This study aimed to understand the situation of Latin American HIV-positive migrants seeking asylum in Spain and identify the challenges they encounter in getting HIV treatment. The main result measured was the proportion of participants with an HIV-1 RNA level of 50 copies/mL or higher at their first clinic visit
223497977|NCT00133211|PROCEDURE|Radiofrequency ablation|Pulmonary vein isolation
223497978|NCT00182637|DRUG|bortezomib|
223497979|NCT01050842|DRUG|bicalutamide|Given orally
223497980|NCT01050842|DRUG|raloxifene|Given orally
223497981|NCT01050842|PROCEDURE|quality-of-life assessment|Ancillary study
223497982|NCT03118271|DEVICE|lumbar traction|
223497983|NCT03118271|PROCEDURE|spinal manipulation|
223497984|NCT03118271|PROCEDURE|surgery|
223497985|NCT03850301|DRUG|XBD173|7 days treatment
223497986|NCT03850301|DRUG|Etifoxine|7 days treatment
223497987|NCT04373057|DIETARY_SUPPLEMENT|Galacto-oligosaccharide|GOS will be administered at determined dose levels per protocol once daily from about 30 days before transplant to about 4 weeks after transplant.
224188418|NCT03490253|BEHAVIORAL|DIAMANTE Static|The static intervention group receives health information text-messages, typical of existing text-messaging interventions for diabetes and depression.
224188419|NCT02247102|DIETARY_SUPPLEMENT|Isomaltulose|"Each subject receives isomaltulose on Study Day 1. After having completed the wash-out period, each subject receives sucrose on Study Day 2.~Dosage of 1 g/ kg body weight (rounded up to the nearest 0.5 kg)."
224188420|NCT02247102|DIETARY_SUPPLEMENT|Sucrose|"Each subject receives sucrose on Study Day 1. After having completed the wash-out period, each subject receives isomaltulose on Study Day 2.~Dosage of 1 g/ kg body weight (rounded up to the nearest 0.5 kg)."
224188421|NCT00920166|DIETARY_SUPPLEMENT|Pétunia 1|Infant formula used for non breastfed children
224188422|NCT00920166|DIETARY_SUPPLEMENT|Regular formula|Infant formula used for non breastfed children
224188423|NCT04673552|PROCEDURE|laparotomy|Any open procedure such as laparotomy or lumbotomy for acute necrotizing pancreatitis will be evaluated, with assessment of results, complications and deaths
224188424|NCT05489432|BEHAVIORAL|Exercise|A twelve-week prehabilitation program consisting of physical exercises, nutritional measures and psychosocial interventions based on the KTCs personal needs as indicated by an assessment consisting of questionnaires and physical tests. The prehabilitation program will be followed by a twelve-week consolidation program, in which the intensity and frequency of the interventions will be lower, in order to enhance the incorporation of the interventions into the daily life of the KTC. During the intervention period, participants will receive counseling by a lifestyle coach.
224188425|NCT04406259|DRUG|Verapamil|"Patients in groupe A require verapamil initiation as a preventive treatment and patients in group B are patients already undergoing a verapamil treatment for their Cluster Headache.~The doses of verapamil are increased for the patients in group A, after a clinical examination an electrocardiogram, and a blood test."
223497988|NCT04373057|DIETARY_SUPPLEMENT|Maltodextrin|Maltodextrin will be administered at comparable dose level as GOS (in Phase II) once daily from about 30 days before transplant to about 4 weeks after transplant.
223497989|NCT01576965|DRUG|Fleet Enema (sodium biphosphate and sodium phosphate)|Those assigned to the mechanical bowel prep group will be asked to administer a single sodium phosphate enema rectally before going to bed the night before surgery. If stool is not clear in the morning, mechanical bowel prep subjects will administer one additional enema the morning of surgery
223497990|NCT04239664|OTHER|Acceptance Based Telephone Support (ABS+UC)|Support based on Acceptance and Committment Therapy (Hayes, 1999)
223497991|NCT02689622|OTHER|research of disease-related factors|included in IPSS and IPSS-R, lactate dehydrogenase, ferritin level, transfusion- dependence, molecular markers as genes mutations
223497992|NCT02689622|OTHER|research of comorbidities|HCT-Comorbidity Index, MDS-Comorbidity Index, Adult Comorbidity Evaluation-27, Cumulative Illness Rating Scale-G
223497993|NCT02689622|OTHER|physical performance|Activities of Daily Living and physical performance
223497994|NCT02562885|DEVICE|Acoustic pulses|"Acoustic pulses applied during NREM sleep slow waves Up-phase or Down-phase. The acoustic stimulus will be delivered by speakers with a volume of about 50 dB."
223497995|NCT03542799|BIOLOGICAL|EGFR IL12 CART|EGFR IL12 CART cells will be administered using a split dose on day0 (10%),1(30%), and 2(60%)
223497996|NCT05579340|OTHER|Exercise|6 months of combined aerobic and resistance exercise
223497997|NCT01713517|OTHER|Indoor residual insecticide spraying (IRS)|Application of insecticide to interior walls of domiciliary structures to kill malaria vector mosquitoes which rest on walls after taking human blood meal
223497998|NCT01713517|DEVICE|Long Lasting Insecticidal Nets (LLIN)|Provision of LLIN to all community members in the clusters allocated to the study arm. LLIN protect individuals from bites by malaria vector mosquitoes by providing a physical barrier and insecticidal and repellent effect.
223497999|NCT05229601|DRUG|HFB301001|"Dose Escalation: Participants will be administered dose level 1 in Cohort 1. Participants in Cohorts 2-4 will receive dose levels 2-4, respectively.~Dose Expansion: Participants with certain cancer types will be administered the dose determined at dose escalation."
223511898|NCT01008046|DRUG|combined N-acetyl cysteine -CC|N-acetyl cysteine(1.8 g orally daily)for 5-6 weeks from the 1st day of spontaneous or induced menstruation followed by 100 mg CC for 5 days from day 3 of spontaneous or induced menstruation. With persistent anovulation,CC increased by 50 mg for the next cycle. Treatment continued for three successive cycles
223590436|NCT01872013|DRUG|Placebo|oral
224188426|NCT04190199|OTHER|Observational|Cross-sectional only
223745963|NCT05577403|BEHAVIORAL|Mulligan's mobilization with movement MWM added isometric strength training|"Mulligan's mobilization with movement added isometric exercise:~the participants in the experimental group will receive a Mulligan's mobilization with movement added isometric exercise.~Treatment will be given for the period of three weeks, for five days a week in both groups.~Data will be collected before intervention and after 2nd \& 4th week of intervention."
224188427|NCT03351426|DEVICE|Transcranial Direct Current Stimulation (tDCS)|Transcranial Direct Current Stimulation (tDCS) is a noninvasive form of neuromodulation that uses constant, low-intensity direct current delivered via electrodes that are placed on the head.
224188428|NCT04899531|OTHER|Longitudinal observation|No specific intervention, longitudinal (pre-post measurements) only
224188429|NCT03831282|DEVICE|RD SET Neo SpO2|All subjects are enrolled in the experimental group and receive the RD SET Neo SpO2 sensor.
224188430|NCT02090920|DRUG|Nifedipine|Nifedipine 10 mg immediate release tablet by mouth loading dose Nifedipine administered orally every 15-20 minutes for the first hour to a maximum loading dose of 30 mg, followed by a maintenance dose of 10-20 mg immediate release nifedipine administered orally every 6 hours
224188431|NCT00334893|DRUG|eribulin mesylate|Given IV
224188432|NCT04971018|DEVICE|Auricular vagus nerve stimulation|Patients will have 20-minutes stimulation sessions at home twice a day during 3 months.
224188433|NCT04971018|DEVICE|Sham Auricular vagus nerve stimulation|Patients will have 20-minutes stimulation sessions at home twice a day during 3 months.
224188434|NCT03484572|DIAGNOSTIC_TEST|Anthropometric measures|Weight (kg),Height (cm)Body mass index(kg/m²),Mid-upper arm-circumference(cm), tricipital skinfold (cm)
224188435|NCT02528149|PROCEDURE|tissue of adjacent part and aneurysm of renal aneurysm|the samples are collected during surgery of renal artery aneurysms. Th tissue is cryopreserved in liquid nitrogen before analysis
224188436|NCT02528149|OTHER|blood sample|
224188437|NCT00483782|BIOLOGICAL|bevacizumab|
224188438|NCT00483782|DRUG|carboplatin|
224188439|NCT00483782|DRUG|paclitaxel|
224188440|NCT00483782|OTHER|questionnaire administration|
224188441|NCT00483782|OTHER|study of socioeconomic and demographic variables|
224188442|NCT00483782|PROCEDURE|quality-of-life assessment|
224188443|NCT04182529|DEVICE|Photoneuromodulation therapy|low-level LED near-infrared (670-810nm) including MedX Health Model 1100 or WiseFori5-3800
224188444|NCT04182529|OTHER|Sham|Sham, no active stimulation will be given to subjects
224188445|NCT05638594|DRUG|Pyrotinib|320mg, qd
224188446|NCT05638594|DRUG|Trastuzumab|8 mg/kg first dose, then 6 mg/kg，q3w
224188447|NCT05638594|DRUG|Dalpiciclib|125mg , qd，d1-21, q4w
224188448|NCT05638594|DRUG|Letrozole|2.5mg，qd
224188449|NCT05638594|DRUG|Pertuzumab|840 mg first dose, then 420 mg, q3w
224188450|NCT05638594|DRUG|Docetaxel|75 mg/m2, q3w
224188451|NCT05638594|DRUG|Carboplatin|AUC 6, q3w
224188452|NCT05638594|DRUG|Gonadotropin-releasing hormone agonist|Every 4 weeks for 5 cycles, premenopausal patients only
224188453|NCT04819022|DEVICE|Acute and post-acute|These programs will cover patients suffering from acute or post-acute musculoskeletal conditions including, but not limited to, shoulder pain (tendinitis/impingement/bursitis), neck pain, low back pain, knee or hip pain/osteoarthritis, which significantly impact their quality of life, to the extent they seek specialised care in direct relation to these disorders.
224188454|NCT04819022|DEVICE|Chronic|These programs will cover patients suffering from chronic musculoskeletal conditions including, but not limited to, shoulder pain (tendinitis/impingement/bursitis), neck pain, low back pain, knee or hip pain/osteoarthritis, which significantly impact their quality of life, to the extent they seek specialised care in direct relation to these disorders.
224188455|NCT04819022|DEVICE|Post-surgical|These programs will cover patients submitted to surgery for a given musculoskeletal condition, including, but not limited to, shoulder tendon repair, shoulder replacement, spinal surgery, hip or knee replacement, meniscal repair, knee ligament reconstruction, undergoing physical rehabilitation programs after surgery.
224188456|NCT01025739|DEVICE|EsophyX™ system with SerosaFuse fasteners|The EsophyX™ system with SerosaFuse fasteners (EndoGastric Solutions, Redmond, WA, USA) was designed to reconstruct the gastroesophageal junction through anterior partial fundoplication with tailored delivery of multiple fasteners during a single-device insertion.
224188457|NCT01258803|DRUG|Formoterol Fumarate DPI|Two inhalations of Formoterol Fumarate DPI 10 mcg administered as a single dose
224188458|NCT01258803|DRUG|Mometasone Furoate/Formoterol Fumarate MDI (ex-actuator) without spacer|Two inhalations of Mometasone Furoate/Formoterol Fumarate MDI 50/5 mcg administered as a single dose without an AeroChamber Plus® Flow-Vu® Anti-Static Valved Holding Chamber (spacer)
224188459|NCT01258803|DRUG|Mometasone Furoate/Formoterol Fumarate MDI (ex-actuator) with spacer|Two inhalations of Mometasone Furoate/Formoterol Fumarate MDI 50/5 mcg administered as a single dose with an AeroChamber Plus® Flow-Vu® Anti-Static Valved Holding Chamber (spacer)
224188460|NCT01258803|DRUG|Placebo MDI with spacer|Two inhalations of placebo MDI administered as a single dose with an AeroChamber Plus® Flow-Vu® Anti-Static Valved Holding Chamber (spacer)
224188461|NCT01258803|DRUG|Placebo MDI without spacer|Two inhalations of placebo MDI administered as a single dose without an AeroChamber Plus® Flow-Vu® Anti-Static Valved Holding Chamber (spacer)
224188462|NCT01258803|DRUG|Mometasone Furoate DPI|Two inhalations of MF DPI 100 mcg administered as a single dose once daily at night. Used as maintenance therapy during screening and in between single doses of study drug.
224188463|NCT03262246|OTHER|medical report consultation|investigators consult medical report concerning patient identified for cerebral amyloid angiopathy
224188464|NCT03552172|OTHER|Physical activity|PHYSICAL ACTIVITY: Rhythm of meetings, number of meetings, place of meetings
223745964|NCT01715311|DRUG|Indacaterol|Indacaterol once daily via single-dose dry powder inhaler
224188465|NCT03552172|OTHER|Absence of or suspended physical activity|the brakes responsible for a stop or lack of practice
224309233|NCT06031233|DRUG|Durvalumab|Gradual shortening of infusion times
224309234|NCT06031233|DRUG|Atezolizumab|Gradual shortening of infusion times
224309235|NCT06031233|DRUG|Bevacizumab|Gradual shortening of infusion times
224309236|NCT06031233|DRUG|Trastuzumab|Gradual shortening of infusion times
224309237|NCT03875859|DRUG|Remetinostat|Topical 1% remetinostat gel
223498000|NCT06963983|DEVICE|Rehabilitation using virtual reality|During the four physiotherapy (PT) sessions (60 min for each session), a set of exercises from the conventional PT is replaced by multiple short sessions of 30 minutes each, where the patient will be equipped by a set of motion trackers mounted on a belt and on a set of straps to be worn around both arms and both forearms. The patient will also hold a controller in each hand and wear a commercial VR headset on his head. Then, thanks to the headset, the patient will be able to experience a set of VR environments, where he or she will be guided through a set of exergames. His/her movements in the real world will be used to move his/her avatar's body in the virtual world, and the exergames will be designed to push him/her to perform the motions required by the therapy in order to go through the games. Various strategies, including a virtual coach will also appear to prevent the patient from doing potentially hazardous movements.
224188466|NCT03817658|DRUG|SHR-1210|"First stage：~Concurrent chemoradiotherapy:~Cisplatin：25-30mg/m2 ivgtt d1;Capecitabine：800mg/m2, bid d1-5，qw，5weeks；Synchronous radiotherapy：1.8-2Gy/d，5d/W，45-50Gy。 Consolidation treatment： Cisplatin： 60-75mg/m2 ivgtt d1 Capecitabine：1000mg/m2, bid d1-14，q3w 6weeks。~Second stage:~SHR-1210 was administered intravenously (no prophylactic use), a fixed dose of 200 mg, and 3 mg/kg for subjects with a baseline weight \<50 kg. Each infusion for 30 min (not less than 20 min, no more than 60 min), once every 2 weeks, 1 cycle every 4 weeks, the cumulative longest medication period is 12 months."
224188467|NCT03817658|DRUG|Placebo|"First stage：~Concurrent chemoradiotherapy:~Cisplatin：25-30mg/m2 ivgtt d1;Capecitabine：800mg/m2, bid d1-5，qw，5weeks；Synchronous radiotherapy：1.8-2Gy/d，5d/W，45-50Gy。 Consolidation treatment： Cisplatin： 60-75mg/m2 ivgtt d1 Capecitabine：1000mg/m2, bid d1-14，q3w 6weeks。~Second stage:~Placebo was administered intravenously (no prophylactic use), a fixed dose of 200 mg, and 3 mg/kg for subjects with a baseline weight \<50 kg. Each infusion for 30 min (not less than 20 min, no more than 60 min), once every 2 weeks, 1 cycle every 4 weeks, the cumulative longest medication period is 12 months."
224188468|NCT03857126|OTHER|Signal acquisition|ECG-PCG-CTG synchronized signals acquisition over a monitoring phase of 30 minutes. These signals will be acquired with passive non invasive sensors (abdominal and thoracic).
223498001|NCT06964711|DRUG|GW117 ODT|Sublingual route ， 0.5mg/1mg/2mg/4mg，QD
223498002|NCT06964711|DRUG|Placebo|GW117 Placebo matching for Sublingual route ，QD
223498003|NCT04896021|DIAGNOSTIC_TEST|Cardiovascular disease risk assessment|Intervention in which the addition of guideline-recommended absolute cardiovascular disease risk assessment is embedded into point-of-care blood collection services for cholesterol measurement and results (including risk score) are reported to referring doctors.
223498004|NCT04896021|DIAGNOSTIC_TEST|Usual care assessment|Usual care in which blood cholesterol results are reported to referring doctors
223498005|NCT06218433|DIAGNOSTIC_TEST|Urothelial cancer screening using urine tumor DNA test|Urine sample DNA is analyzed using a targeted sequencing panel encompassing the coding regions of 21 genes that are recurrently mutated in urothelial cancer
223745965|NCT01715311|DRUG|Placebo to tiotropium|Placebo to tiotropium capsules for inhalation once daily
223745966|NCT01715311|DRUG|Tiotropium|Tiotropium capsules for inhalation once daily
224188469|NCT04084652|DIETARY_SUPPLEMENT|Mycoprotein ingestion|The ingestion of mycoprotein
224188470|NCT01889342|BEHAVIORAL|Metacognitive therapy|
224188471|NCT01889342|BEHAVIORAL|Cognitive behavioral therapy|
224188472|NCT02042742|DIETARY_SUPPLEMENT|punicalagin and hydroxytyrosol mixture|Antioxidant Supplement (punicalagin and hydroxytyrosol mixture) During one period of crossover study (I or II) volunteers consume daily of functional supplement during 8 weeks. Additionally, volunteers must follow guidelines for healthy diet and physical activity.
224188473|NCT02042742|DIETARY_SUPPLEMENT|Control supplement (maltodextrin)|During one period of crossover study (I or II) volunteers consume daily of functional supplement during 8 weeks. Additionally, volunteers must follow guidelines for healthy diet and physical activity.
224188474|NCT03678909|PROCEDURE|Norwood Palliation / DKS / Damus-Kaye-Stansel procedure|Norwood Palliation / DKS / Damus-Kaye-Stansel procedure
224188475|NCT04035707|DRUG|Rocuronium|using rocuronium as a relaxants during general anaesthesia
224188476|NCT04035707|DRUG|general volatile anaesthesia|method of anaesthesia
224188477|NCT02078557|DRUG|MK-8892|
224188478|NCT01094821|DRUG|ATI-7505|3 mg three times daily for 9 days
224188479|NCT01094821|DRUG|Placebo|Placebo capsule three times daily for 9 days
224188480|NCT01094821|DRUG|ATI-7505|10 mg ATI-7505 three times daily for 9 days
224188481|NCT01094821|DRUG|ATI-7505|20 mg ATI-7505 three times daily for 9 days
224188482|NCT05227404|DIAGNOSTIC_TEST|LumiraDX|Point-of-care test for SARS-CoV-2
224188483|NCT05227404|DIAGNOSTIC_TEST|RightSign|Point-of-care test for SARS-CoV-2
224188484|NCT05227404|DIAGNOSTIC_TEST|Case Control|Genscript assay performed on the plasma sample
224188485|NCT06028191|OTHER|Kabat Technique along with baseline treatment|"Group A will receive Kabat Technique along with baseline treatment. Electrical muscle stimulation for 15 min which includes faradic current to the facial nerve trunks given by DL-2 electro pulse stimulator, Effleurage and Kneading for 5 min and resistive exercise for 5 min and facial expression exercises for 5 min, which included eye closure, eyebrow raise, frown, smile, snarl, pucker and pout as baseline treatment.~Kabat Technique is neurorehabilitation technique that uses diagonal and spiralpatterns for movement in conjunction with stretch and resistance and other PNF techniques to reinforce neuromuscular recruitment. It mainly concerns the stimulation of these muscles: Orbicularis occuli, ztgomaticus, Levator labii, nasalis, buccinator, frontalis, corrugator"
224188486|NCT06028191|DEVICE|Kabat Technique and LLLT along with baseline treatment|Group B will receive Kabat Technique and LLLT along with baselinetreatment. Kabat technique is same as mentioned in group A. Laser treatment will be administered to eight points of the affected side for 2 min at each point at a wavelength of 830 nm, output power of 100 Mw, and frequency of 1 KHz. Endo laser 422 is the model name and number of device which will be used in this study to administered low level laser therapy.
224188487|NCT01274104|DIETARY_SUPPLEMENT|Vitamin D3|15,000 IU of Vitamin D3 every day for 14 days
224188488|NCT01274104|OTHER|Placebo|Placebo
224188489|NCT00015912|BIOLOGICAL|recombinant interferon alfa|Given IV
224188490|NCT00015912|DRUG|thalidomide|Given orally
224188491|NCT00015912|OTHER|laboratory biomarker analysis|Correlative studies
223745967|NCT01715311|DRUG|Placebo to indacaterol|Placebo to indacaterol capsules for inhalation once daily
223745968|NCT06174753|DRUG|Dapagliflozin 10mg Tab|Dapagliflozin 10 mg daily X 7 days
223745969|NCT06174753|DIAGNOSTIC_TEST|CMR|CMR 3-5 days post randomization
223745970|NCT06407544|PROCEDURE|peripheral nerve block|peripheral nerve block guided by ultra sound through Ultrasound-guided quadratus lumborum block versus FICB or fascia iliaca block
223745971|NCT06407544|DRUG|PCA device as rescue medication with IV morphine 1mg if VAS more than 4|PCA device as rescue medication with IV morphine 1mg if VAS more than 4 with a 10 min lock-out time
223745972|NCT05681871|DIETARY_SUPPLEMENT|Ferrous gluconate syrup or ferrous fumarate/folic acid tablets|Oral iron supplementation dosed based on body weight
223745973|NCT02914652|DRUG|Salbutamol|Ventoline(R), inhalation spray, 0,1 mg/dose, 9 doses administered as coherent single doses.
223745974|NCT02914652|DRUG|Norflouran (Placebo Evohaler(R) )|Placebo Evohaler(R) MDI, inhalation spray, 60 mg/dose, 9 doses administered as coherent single doses.
223498006|NCT06218433|DIAGNOSTIC_TEST|Urothelial cancer screening using urine cytology (comparator)|Urine cytology sample
223498007|NCT05402085|DIETARY_SUPPLEMENT|High Protein Diet|Subjects will be provided with high protein diet meals for breakfast, lunch, and dinner. A continuous glucose monitoring device will be used to measure post-prandial glycemic responses.
223498008|NCT05402085|DIETARY_SUPPLEMENT|High Fat Diet|Subjects will be provided with high fat diet meals for breakfast, lunch, and dinner. A continuous glucose monitoring device will be used to measure post-prandial glycemic responses.
223745975|NCT04489576|PROCEDURE|Keratin hair treatment (Keratin Cure ®) versus (QOD Max ®)|Hair will be treated with 2 different types of keratin in groups 1 \& 2. All steps of keratin application will be done in group 3 without keratin application as a control group.
223745976|NCT03933150|DEVICE|ultrasound guided caudal epidural injection|"A. Ultrasound-Guided CESI (Group 1) All the injection procedures were performed as an outpatient clinic setting. We used Acuson P300 (Siemens, Italy) with a linear transducer at 6 to 12 MHz as the US instrument, another curved transducer at 2-5 MHz was available for obese patients.~B. Fluoroscopy-Guided CESI (Group 2) All the injection procedures were performed in a specialized room with a FL device in the radiology department. We used a FL device GS 1004 with ALLURA XPER FD 20 system (Philips, Holland) with X-ray tube housing assembly, X-ray tube, beam limiting device and image receptor"
223745977|NCT05782673|DEVICE|wearable MAIJU for motor assessment|The novel multisensor wearable MAIJU will be used to measure infants' motor performance at home. The recordings are repeated at 2 months intervals betveen 6 and 18 months of age.
223745978|NCT03919071|PROCEDURE|Biospecimen Collection|Undergo collection of blood
223498009|NCT05402085|DIETARY_SUPPLEMENT|High Carbohydrate-Low Glycemic Index Diet|Subjects will be provided with high carbohydrate-low glycemic index diet meals for breakfast, lunch, and dinner. A continuous glucose monitoring device will be used to measure post-prandial glycemic responses.
223498010|NCT05402085|DIETARY_SUPPLEMENT|High Carbohydrate-High Glycemic Index Diet|Subjects will be provided with high carbohydrate-high glycemic index diet meals for breakfast, lunch, and dinner. A continuous glucose monitoring device will be used to measure post-prandial glycemic responses.
223498011|NCT05751863|OTHER|Analgesia First Sedation Strategy for Mechanically Ventilated (MV) Trauma Subjects|"The Intervention is using a sedation strategy for MV trauma that initially targets pain by intermittent boluses followed by an IV drip only if required. Sedatives are limited to agitation management and for a limited duration as needed. This analgo-sedation approach differs from the approach of using IV drips of analgesics and sedatives simultaneously and discontinuing both once daily to assess subjects."
223498012|NCT05751863|OTHER|Protocol Directed Sedation and Daily Sedation Interruption|The active comparator in this study is using a sedation strategy for MV trauma that uses IV drips of analgesics and sedatives simultaneously and discontinues both once daily to assess subjects.
223498013|NCT00957710|BEHAVIORAL|Errorless learning|Language testing,20 sessions of language therapy, and 2 neuroimaging sessions for participants with progressive aphasia Language testing and 1 imaging session for healthy controls
223498014|NCT05628389|BEHAVIORAL|Educational materials|Patient educational materials to address insufficient knowledge about harms of tobacco use and cessation.
223498015|NCT05628389|BEHAVIORAL|Phone counseling|Cessation counseling to address insufficient patient self-efficacy and motivation.
223498016|NCT05628389|DRUG|Nicotine Replacement Therapy|Nicotine patches to address nicotine withdrawal symptoms in patients.
223498017|NCT05628389|BEHAVIORAL|Provider training|Provider training to address insufficient knowledge and self-efficacy to deliver AAA/AAC to patients.
223745979|NCT03919071|DRUG|Dabrafenib Mesylate|Given PO
223745980|NCT03919071|PROCEDURE|Lumbar Puncture|Undergo lumbar puncture
223745981|NCT03919071|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223745982|NCT03919071|RADIATION|Radiation Therapy|Undergo RT
223745983|NCT03919071|DRUG|Trametinib Dimethyl Sulfoxide|Given PO
223745984|NCT05660928|OTHER|Multidimensional intervention|Multidimensional intervention, with mutidisciplinary approach.
223745985|NCT06325722|OTHER|Low-carbohydrate Diet|Consisting of 15 percent protein, 75 percent fat, and 10 percent carbohydrate
223745986|NCT06325722|OTHER|Low-fat Diet|Consisting of 15 percent protein, 10 percent fat, and 75 percent carbohydrate
223498018|NCT05628389|BEHAVIORAL|Electronic reminders|Electronic reminders to address the lack of integration of AAA/AAC into practice.
223498019|NCT05199272|DRUG|23ME-00610|23ME-00610 given by IV infusion
223498020|NCT05419011|BIOLOGICAL|Adenovirus 5 CEA/MUC1/Brachyury Vaccine Tri-Ad5|Given SC
223745987|NCT05687994|BEHAVIORAL|Audiovisual Speech Entrainment Practice|Speech Entrainment Practice is an aphasia rehabilitation treatment based on imitation of recorded speech in real time. Treatment includes repeated practice of speaking along with a recorded model, which provides contextual, temporal, auditory, and visual cues for speaking
223745988|NCT05687994|BEHAVIORAL|Auditory Speech Entrainment Practice|Speech Entrainment Practice is an aphasia rehabilitation treatment based on imitation of recorded speech in real time. Treatment includes repeated practice of speaking along with a recorded model, which provides contextual, temporal, and auditory cues for speaking
223745989|NCT06247787|PROCEDURE|Biospecimen Collection|Undergo blood and CSF sample collection
223745990|NCT06247787|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow biopsy and aspiration
224188492|NCT03360695|OTHER|Proactive Psychiatry Consultation (PPC)|Proactive Psychiatry Consultation and Case Management aims to improve communication among the patient, oncology team, and mental health clinicians, and increase engagement of family and community caregivers, which may help patients to receive the cancer care they need.
224188493|NCT03360695|OTHER|Enhanced Usual Care (EUC)|At enrollment, study staff will inform the treating oncologist of the psychiatric diagnosis and will inform the oncologist, patient, and caregiver of available psychosocial services.
224188494|NCT03797781|OTHER|Lower limb immobilisation (leg brace) with varying levels of protein intake|Single leg immobilisation via leg brace and crutches, the groups have different amounts of protein intake
224188495|NCT05664438|DIAGNOSTIC_TEST|MRI scan|MRI scan of cervical spine
224188496|NCT04693481|OTHER|nature exposure|Nature exposure has different ways, such as walk in the real nature environment; viewing nature photos. Two main reasons make this study will not use the real nature environment: (1) the limitation of time before or amid the soccer competition; (2) the pandemic situation does not allow people go outside as frequently as before. Therefore, the current study will select some nature photos, which are restorative environments and can restore directed attention to counteract mental fatigue.
224188497|NCT06564779|OTHER|New memory assessment|The intervention is part of the neuropsychological assessment carried out as part of routine care. It consists of carrying out the neuropsychological tests traditionally used to investigate the diagnostic hypothesis of Alzheimer's disease.
224188498|NCT04652245|DRUG|Treatment A (Dymista): Fixed drug combination of azelastine hydrochloride and fluticasone propionate nasal spray at Visit 3|Single dose, one spray in each nostril of Dymista nasal spray, approximately 137 μg of azelastine hydrochloride and 50 μg of fluticasone propionate per actuation, at Visit 3
224188499|NCT04652245|DRUG|Treatment B (Placebo): Nasal spray with no active dose (Dymista vehicle) at Visit 5|Single dose, one spray in each nostril of Placebo nasal spray at Visit 5
224188500|NCT04652245|DRUG|Treatment A (Dymista): Fixed drug combination of azelastine hydrochloride and fluticasone propionate nasal spray at Visit 5|Single dose, one spray in each nostril of Dymista nasal spray, approximately 137 μg of azelastine hydrochloride and 50 μg of fluticasone propionate per actuation, at Visit 5
224188501|NCT04652245|DRUG|Treatment B (Placebo): Nasal spray with no active dose (Dymista vehicle) at Visit 3|Single dose, one spray in each nostril of Placebo nasal spray, at Visit 3
224188502|NCT04312711|DIAGNOSTIC_TEST|3D-TOF-MRA|"The Principle of 3D-TOF-MRA is based on the flow effect of MR. In the GE sequence of MRA imaging, the effect of RF pulses makes the protons in the stationary tissue in the active layer in a saturated state, and the longitudinal magnetization disappears. When the inflow blood appears, its protons are in an unsaturated state and have a high degree of longitudinal magnetization. In this way, a clear difference is formed between saturated tissue and unsaturated flowing blood to display blood vessels. 3D-TOF-MRA is a non-invasive and safe method for diagnosing vascular diseases."
224188503|NCT06440876|BEHAVIORAL|Music and Imagery|See music and imagery arm description.
224188504|NCT02852876|DRUG|ASP2151|Oral
223498021|NCT05419011|PROCEDURE|Biopsy Procedure|Undergo biopsy
223498022|NCT05419011|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223498023|NCT05419011|PROCEDURE|Colonoscopy|Undergo SOC colonoscopy
223745991|NCT06247787|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy and aspiration
224188505|NCT02852876|DRUG|Placebo|Oral
224188506|NCT04311814|DIAGNOSTIC_TEST|Maximum urethral closure pressure during Valsalva (v-MUCP)|v-MUCP measurement was performed for all patients referred for urodynamic exploration of the lower urinary tract
224188507|NCT05609656|DEVICE|Irreversible electroporation|"Percutaneous ablation of a metastatic lesion.~Irreversible electroporation is delivered through the NanoKnife system (AngioDynamics, New York, USA). The system is CE approved for medical use."
224188508|NCT05609656|DEVICE|Calcium electroporation|"Just before the reversible electroporation, calcium chloride will be injected into the primary tumor. The electroporation will be delivered as at least four pulses and up to eight pulses. The device is repositioned after each pulse to ensure coverage of the entire surface area of the tumor.~The reversible electroporation regime will be delivered through the endoscopic device EndoVE®, while the ePORE® will be used for pulse generation, both CE approved."
224188509|NCT05609656|DRUG|Pembrolizumab|"Pembrolizumab 200 mg as an IV infusion every 3 weeks (+/- 3 days) for up to 12 months~Pembrolizumab is an immune checkpoint inhibitor (PD-1-inhibitor)."
223745992|NCT06247787|DRUG|Cytarabine|Given IV and IT
223745993|NCT06247787|PROCEDURE|Echocardiography Test|Undergo ECHO
224188510|NCT05778682|PROCEDURE|Suctioning based protocol|cf. arm The necessity of suctioning will be assed continuously by the nurses, respiratory therapist and the medical team. If the patient require 2 or less aspiration each 8 hours for 24 hours straight, an attempt of decanalution will be done.
223498024|NCT05419011|DRUG|Nogapendekin Alfa|Given nogapendekin alfa inbakicept (N-803) SC
223498025|NCT05419011|DRUG|Placebo Administration|Given SC
223498026|NCT05419011|OTHER|Questionnaire Administration|Ancillary studies
223498027|NCT02787291|DEVICE|Ellipse VR ICD and Durata/Optisure lead|Non-diagnostic MRI Scan sequence of head and chest
223498028|NCT04320667|DIAGNOSTIC_TEST|Flow cytometry analysis of urine samples|"Urine samples will be conserved and frozen upon arrival. All samples will be stained according to T cell and TEC (tubular epithelial cells) panel with fluorochromes.~T cell panel: CD3, CD4, CD8, CCR7, CD45RO, CD28, CD279; TEC panel: vimentin, cytokeratine, CD10, CD13, CD227, CD326"
223498029|NCT05623085|OTHER|Aerobic exercise|Individuals in this group will be given 8-week individualized exercise according to the Karvonen protocol (heart rate reserve percentage-% HR). Exercise training will be 30 minutes at 50% of HR between weeks 0-2, 45 minutes at 50% of HR between weeks 2-4, 45 minutes at 60% of HR between weeks 4-6 and 6-8 weeks It will be done on the treadmill 3 days a week, for 60 minutes at 60% of HR between weeks. The treadmill speed will be adjusted during exercise to maintain the set target heart rate level.
223498030|NCT05623085|OTHER|Yoga exercise|Individuals in this group will be given 8-week individualized yoga exercise including stretching, relaxing, strength training. Exercise training will be done 3 days a week. The duration of the exercise will be adjusted to be the same as the aerobic exercise group.
223745994|NCT06247787|DRUG|Fludarabine|Given IV
223745995|NCT06247787|DRUG|Hydrocortisone Sodium Succinate|Given IT
224188511|NCT05778682|PROCEDURE|Usual Care|Usual care in our center is tolerance to a capping trial.
224188512|NCT01830621|DRUG|BBI608|
224188513|NCT01830621|DRUG|Placebo|
224188514|NCT01830621|OTHER|Best Supportive Care|
224188515|NCT05200975|DIAGNOSTIC_TEST|Venapunction|Three venapunctures within a period of 72 hours, containing a maximum of 18ml of venous blood in total.
224309238|NCT04540406|DRUG|NBT-NM108|Taken in the form of drinks four times a day (before each main meal and 2 hours after dinner) for 28 days. Each drink is prepared by mixing one sachet (30 g) with 500 ml of water.
223498031|NCT01268735|DRUG|Lubricating eyedrops containing hydroxypropyl-guar|Eyedrops BID
223498032|NCT04241718|DEVICE|Aquadex FlexFlow System and BVA-100|Aquapheresis therapy with Aquadex FlexFlow System and Blood Volume Measurement with BVA-100
223498033|NCT05463055|RADIATION|Proton Therapy System (ProBeam)|All of subjects (tumor patients, including tumors of the nervous system, head and neck, chest, abdomen, spine, pelvic cavity, limbs and other tumors) will be treated with Proton radiation therapy using the medical device Varian ProBeam Proton Therapy System (ProBeam). The screening period from informed consent to enrollment is expected to be 4 weeks, while the treatment period is 1 to 8 weeks. The period after the last treatment is divided into short-term follow-up and long-term follow-up, in which short-term follow-up will be 3 months after the end of the last treatment. Total expected participation for each subject from screening to the completion of short-term follow-up is a maximum duration of 12 weeks + 3 months ( for this trial). Long-term follow-up continues after the end of short-term follow-up until the 5th year after the end of the last radiotherapy session.
223498034|NCT03819205|OTHER|kinesiotaping|The participants will receive kinesiotaping treatment on the affected side for the hemiplegic CP's and for diplegic, tetraplegic CP's the side of upper extremity which children have been used to but have obstacles in daily life for 1 week at least 2-3 hours a day, renewing if it's necessary. The participants will be also recomended dealing with the grasping and releasing activities in daily living at about 2-3 hours a day. In a way that every patient has to be the control of themselves, 1 week before kinesiotaping, immediately after kinesiotaping and 1 week after the period of kinesiotaping, patients will be evaluated with box and block test, nine hole peg test, modified house clasification and the active/passive wrist dorsiflexion range of motion
223498035|NCT04581746|OTHER|questionnaire|bi-monthly questionnaire and then one visit with questionnaire and covid-19 test
223498036|NCT05206539|DRUG|Self-assembling peptide (P11-4)|"Prior to application, teeth are isolated by cotton rolls and gently air dried. The surface of the lesion is conditioned with a 2% sodium hypochlorite solution for 20 s and then rinse with water. Application of 35% phosphoric acid etching gel for 20 sec followed by rinsing with water-air spray for 30 sec. Drying the surface with compressed oil-free air for 60 sec. Curodont Repair is dissolve in 0.05 ml of distilled water and applied to the surface and allowed to work for about 5 min.~Participants will receive oral hygiene instructions."
223498037|NCT05206539|DRUG|CPP-ACFP|"Prior to application, teeth are isolated by cotton rolls and gently air dried. Application of fluoride varnish with a brush applicator on the surface of the teeth for 5 minutes. Patients is advising not to brush their teeth or chew food for at least 4 h after treatment.~Participants will receive oral hygiene instructions"
223498038|NCT05206539|DRUG|Resin infiltration|The validated ICON Vestibular (DMG) infiltration lesion infiltration protocol is applied. Icon Etch (DMG) etching gel containing 15% hydrochloric acid is applied for 120 seconds using an applicator. It is then removed by rinsing thoroughly with water-air spray for 30 seconds. Then follows application of pure alcohol - Icon Dry (DMG) for 30 seconds for complete drying of the lesion and additional drying compressed oil-free air for 40 sec. Application of Icon Infiltrant (DMG) using a microapplicator allows it to penetrate for 3 minutes, during which, if necessary, it is reapplied several times. Excess material is removed with dry microbrushes and followed by light curing for 40 seconds. Re-applying of the infiltrate for 1 minute, removal of excess material, light curing for 40 seconds. Participants will receive oral hygiene instructions
223498039|NCT05206539|OTHER|Control Group, No Treatment|Everyday oral hygiene instructions Subjects will receive non-prescription fluoride toothpaste (1400 ppm Fluoride, Elmex junior) and oral hygiene instructions. The dosage will be 1/2 inch strip of paste 2x/day for 8 weeks. Subjects will apply paste to a toothbrush and brush teeth thoroughly for at least 1 minute then expectorate and rinse.
224309239|NCT04540406|OTHER|Usual Care Only|Control group will also follow the same schedule except they will drink the same volume of water without NBT-NM108.
223498040|NCT04766333|BEHAVIORAL|Healthcare Worker Focused Outreach|This a focused outreach intervention strategy specifically designed for healthcare workers.
223498041|NCT04766333|BEHAVIORAL|Community Organization Led Outreach|This is a standard community engaged outreach approach that has traditionally been used in previous research. Analogous to the standard of care for outreach.
223498042|NCT00171288|DRUG|fluvastatin, ezetimibe|
223498043|NCT06310629|DEVICE|High Flow Nasal Cannula|High Flow Nasal Cannula
223498044|NCT06310629|DEVICE|"Intrinseque Health Non-Rebreathing Mask (IHNRM)"|"Intrinseque Health Non-Rebreathing Mask (IHNRM)"
224188516|NCT04310852|DEVICE|BioCue Concentration Kit|The treatment will be carried out in the operating room under ordinary hospitalization and involves the application of 9 ml of autologous bone marrow concentrate in the knee affected by arthrosis. Specifically, 3 ml will be applied at the level of the bone-cartilage interface of the femur, 3 ml at the level of the bone-cartilage interface of the tibia, and 3 ml will be injected into the joint for a simultaneous action also at the level of the cartilage. To obtain the necessary amount of bone marrow concentrate, an aspirate of bone marrow will be taken from the iliac crest (60 ml) and homolateral tibia (30 ml) of the patient and concentrated by BioCue Concentration Kit, company Zimmer biomet, and centrifuge. This autologous bone marrow concentrate will be injected by means of the Perfuse at the level of the tibial and femoral bone-cartilage interface of the percutaneous arthrosis affected compartment under radiographic control.
224188517|NCT04111913|DRUG|Anlotinib Hydrochloride|anlotinib once daily on days 1-14 of 21days cycle.
224188518|NCT00230711|BEHAVIORAL|Physical activity counseling|
224309240|NCT02887456|DRUG|Endodontic treatment using Vitapex|Endodontic treatment using Vitapex
224309241|NCT02887456|DRUG|Endodontic treatment using MTA paste|Endodontic treatment using MTA paste
224309242|NCT04365777|OTHER|OAA/S=5|Prior to anesthesia induciton, EEG signatures will be recorded at Observer's Assessment of Alertness/Sedation (OAA/S) score of 5 (awake, eye-close state) for few minutes.
224188519|NCT02403115|OTHER|Serum collection|Clinical tests (renal function, complete blood count, CRP, ANA, dsDNA, urinalysis) will be performed at fixed time intervals (6, 12, 24 and 36 months) and the surplus of blood sample will form the serum bank used for the study
224188520|NCT05963685|OTHER|standardized MT alarming system|Standardized alarming system via telephone loop in the primary thrombectomy centre triggered immediately after decision to mechanical thrombectomy in stroke patients admitted in primary stroke centers
223498045|NCT00272090|DRUG|Insulin glargine|
223498046|NCT04257617|DRUG|ZL-1201|Part 1 \& 2: Escalating dose of ZL-1201, Part 3: three dose levels determined from Part 1 and Part 2.
224188521|NCT01493154|BIOLOGICAL|DNA Vaccine|Patients will receive intramuscular needle injections of pNGVL4a-CRT/E7 (detox) DNA vaccine using the TDS-IM device on Day 1, 22, and 43 for a total of three vaccinations per patient. One day prior to each DNA vaccination, the patient will receive a single low dose of 200 mg/m2 of cyclophosphamide intravenously. The DNA vaccine will be administered in a dose-escalating manner.
223498047|NCT03583346|DRUG|M6495|Participants will receive escalated dose of M6495 bi-weekly on Day 1, 15 and 29 in cohort 1 to 3 and weekly on Day 1, 8, 15, 22, 29 and 36 in cohort 4.
223498048|NCT03583346|DRUG|Placebo|Participants will receive placebo matched to M6495 bi-weekly on Day 1, 15 and 29 in cohort 1 to 3 and weekly on Day 1, 8, 15, 22, 29 and 36 in cohort 4.
223498049|NCT06784765|PROCEDURE|Intervention Group|Preventive pressurized intraperitoneal aerosol chemotherapy (PIPAC) with cisplatin (10 mg/m2) and doxorubicin (2.1 mg/m2) + perioperative chemotherapy (FLOT regimen) +gastrectomy with D2 lymphadenectomy
223498050|NCT06784765|PROCEDURE|Control Group|Retrospective cohort receiving standard perioperative chemotherapy (FLOT regimen) + gastrectomy with D2 lymphadenectomy
223498051|NCT05222815|OTHER|CGM|Continuous glucose monitor (CGM)-based glucose monitoring
223498052|NCT05222815|OTHER|SMBG|Self-monitoring of blood glucose (SMBG)-based glucose monitoring
223498053|NCT00298194|DRUG|Z-338|
223498054|NCT00639379|DEVICE|senofilcon A toric|silicone hydrogel toric lens, 2 wk replacement, daily wear
223498055|NCT00639379|DEVICE|alphafilcon A toric|hydrogel toric lens, 2 wk replacement, daily wear
223498056|NCT02090595|BEHAVIORAL|MBCT-C|A 12 week group therapy program for children with anxiety disorders. This involves teaching the children the pay attention to anxiety related cues with openness and non-judgment. Group leaders begin each session with: sitting meditation, review of the previous session and home practices, teaching a new mindfulness exercise, reading a group poem or story, distributing handouts, etc. There will be a new theme each week.
223498057|NCT02090595|BEHAVIORAL|Waitlist Control|Waitlist Control (WC) will be the comparison condition. Some of the children in the study will initially participate in a 12 week WC prior to their participation in the MBCT-C. At each visit during the waitlist control period, participants and their families will receive materials about mood and anxiety disorders in youth, bipolar disorders, familial risk for bipolar disorder and treatment strategies for anxiety and depression in youth.
223498058|NCT03096353|OTHER|Placebo|saline
223498059|NCT03096353|DRUG|Naloxone|We will be using naloxone at normal clinical doses as the study drug. Naloxone is an opiate antagonist and has been used since the 1960 s to reverse the effects of opiate overdoses.
223498060|NCT01452087|OTHER|Exercise|Subjects will exercise on a treadmill for 1 hour at moderate intensity (i.e., 90% of the exercise intensity found to elicit their ventilatory threshold during the preliminary testing, which is equivalent to approximately 60% of their maximal predicted heart rate).
223498061|NCT06486779|OTHER|Ofatumumab|This is an observational study. There is no treatment allocation. The decision to initiate ofatumumab will be based solely on clinical judgement.
223498062|NCT00263536|PROCEDURE|Interpersonal Psychotherapy|
223498063|NCT04268524|COMBINATION_PRODUCT|drug: miltefosine with thermotherapy|see previous
223498064|NCT06182995|BEHAVIORAL|Usual Care post-Intensive Care Unit (ICU)|routine clinic visits
223498065|NCT06182995|BEHAVIORAL|Anticipating Decline and Providing Therapy (ADAPT)|routine validated cognitive screen for high-risk older adults at 6 weeks and 6 months post-ICU discharge
223498066|NCT03832452|DRUG|Lucerastat (Treatment A)|2000 and 4000 mg; hard capsules for oral administration
224188522|NCT01493154|DRUG|Cyclophosphamide|A single low dose of 200 mg/m2 of cyclophosphamide (CTX) will be administered intravenously up to 24 hours (Day 0) prior to each DNA vaccination.
223498067|NCT03832452|OTHER|Placebo|hard capsules for oral administration
223498068|NCT03832452|DRUG|Moxifloxacin|400 mg; film-coated tablets for oral administration
223498069|NCT03832452|DRUG|Lucerastat (Treatment B)|1000 mg; hard capsules for oral administration
223498070|NCT03832452|DRUG|Lucerastat (Treatment C)|4000 mg; hard capsules for oral administration
223498071|NCT04716309|PROCEDURE|Open reduction and volar locking plate and closed reduction and K-wires.|DVR Anatomic Plate, K-wires
223498072|NCT05801978|BIOLOGICAL|Live Attenuated Yellow Fever 17D Vaccine|The FDA-approved YF-17D (YF-VAX®) is a live attenuated vaccine manufactured by Sanofi Pasteur as a one-dose vial. The vaccine is prepared by culturing the 17D-204 strain of yellow fever virus, contains sorbitol and gelatin as a stabilizer, and contains no preservative. Each vial of vaccine is supplied with a separate vial of sterile diluent, which contains sodium chloride injection USP (United States Pharmacopeia) without a preservative.
223498073|NCT05801978|BIOLOGICAL|Quadrivalent seasonal influenza vaccine|The FDA-approved quadrivalent seasonal influenza vaccine contains four distinct strains: two influenza A viruses and two influenza B viruses. The approved seasonal QIV will be purchased from the manufacturer to be given for each season of influenza.
223498074|NCT06838013|DEVICE|Transcranial direct current stimulation (tDCS)|tDCS will be delivered by a constant-current electrical stimulator (DC-stimulator; Eldith, Ilmenau, Germany). Rectangular electrodes covered with a saline-soaked sponge will be used for the anode and cathode. The anode will be placed over the leg area of the motor cortex, on the lesioned side, with the medial border of the electrode placed laterally to Cz on the international electroencephalogram 10-20 system. The cathode will be placed above the contralateral orbit. The stimulation intensity will be set at 2 mA for 30 minutes.
223590437|NCT03233035|DRUG|Ketamine|25mg of ketamine in 0.5 ml of serum saline in one pulverisation per nostril is received
224188523|NCT05376540|PROCEDURE|Direct gallbladder injection of ICG intraoperatively|Patients randomized to this arm will have 2.5 mg ICG injected directly into the gallbladder intraoperatively.
224188524|NCT05376540|PROCEDURE|Intravenous injection 2.5 mg|Patients randomized to this arm will have 2.5 mg ICG injected intravenously 1 hour prio to surgery
224188525|NCT05376540|PROCEDURE|Intravenous injection and direct gallbladder injection|Patients randomized to this arm will have 2.5 mg ICG injected intravenously 1 hour prior to surgery and another 2.5 mg ICG injected directly into the gallbladder, intraoperatively.
224188526|NCT05376540|PROCEDURE|Intravenous injection 5 mg|Patients randomized to this arm will have 5 mg ICG injected intravenously 0-8 hours prior to surgery
224188527|NCT01610726|PROCEDURE|Enhanced versus conventional recovery in colorectal surgery|Enhanced recovery (extended informations to the patients, change of anesthetic procedure, intravenous versus gas, and intensified mobilisation) versus conventional recovery
223498075|NCT06838013|DEVICE|Sham transcranial direct current stimulation (Sham-tDCS)|Sham tDCS will be delivered by a constant-current electrical stimulator (DC-stimulator; Eldith, Ilmenau, Germany). Rectangular electrodes covered with a saline-soaked sponge will be used for the anode and cathode. The anode will be placed over the leg area of the motor cortex, on the lesioned side, with the medial border of the electrode placed laterally to Cz on the international electroencephalogram 10-20 system. The cathode will be placed above the contralateral orbit. The stimulation intensity will The stimulator will only be applied for the first and last 30 seconds.
223498076|NCT06838013|DEVICE|Bilateral Transcutaneous electrical nerve stimulation (Bi-TENS)|TENS will be delivered to the common peroneal nerve of both intact and paretic leg for 30 minutes using a 120z Dual-Channel TENS Unit (ITO Physiotherapy \& Rehabilittaion, Co, Ltd, Tokyo, Japan). The TENS stimulation will be at 100 Hz, with 0.2 ms square pulses at an intensity of twice the sensory threshold (defined as the minimum intensity at which subject reported feeling a tingling sensation and below the motor threshold as indicated by the absence of muscle twitching.
223498077|NCT06838013|DEVICE|Placebo transcutaneous electrical nerve stimulation (Placebo-TENS)|Placebo-TENS will be applied to identical-looking TENS devices, with the electrical circuit disconnected inside the devices. Placebo-TENS will be delivered to the common peroneal nerve of both intact and paretic leg for 30 minutes that set at 100 Hz, with 0.2 ms square pulses.
223498078|NCT06838013|BEHAVIORAL|Lower-limb task-oriented training|The lower-limb task-oriented training comprises 5 exercises for 30 minutes, namely stepping up and down, heel lift a dorsiflexed position, partial squatting, gait re-education and transition training.
223498079|NCT02748993|DRUG|PAC-14028 Cream 0.1%|Topical application
223498080|NCT02748993|DRUG|PAC-14028 Cream 0.3%|Topical application
223498081|NCT02748993|DRUG|PAC-14028 Cream 1.0%|Topical application
223498082|NCT02748993|DRUG|PAC-14028 Cream Vehicle|Topical application
223498083|NCT01464138|DRUG|Fosmidomycin and Clindamycin co-administration|Fosmidomycin sodium syrup at a concentration of 250mg/5ml and clindamycin hydrochloride syrup at a concentration of 75mg/5ml. Administered in doses of fosmidomycin 30mg/kg/dose + clindamycin 10mg/kg/dose twice daily for three days (total daily dose fosmidomycin 60mg/kg, clindamycin 20mg/kg)
223498084|NCT03528031|OTHER|Intervention Daily Avocado|Participants follow their usual diet and lifestyle but also are provided with 1 avocado to consume per day for 6 months.
223498085|NCT01870596|DRUG|Cytarabine|Given IV
223498086|NCT01870596|DRUG|CHK1 Inhibitor SCH 900776|Given IV
223498087|NCT01870596|OTHER|Laboratory Biomarker Analysis|Correlative studies
224188528|NCT04648943|PROCEDURE|Ex-Press mini shunt insertion|
224188529|NCT04648943|PROCEDURE|Trabeculectomy|
224188530|NCT02267031|PROCEDURE|mechanical ventilation|"Patients subjected to scheduled laparoscopic cholecystectomy were enrolled to the ongoing prospective study and randomized into four groups: 1) normoxia and normocapnia (nO2-nCO2), 2) hyperoxia and normocapnia (hO2-nCO2), 3) normoxia and hypocapnia (nO2-lCO2), and 4) hyperoxia-hypocapnia (hO2-lCO2).~Normoxia PaO2 was referred to PaO2 of 70-140 mm Hg, hyperoxia 150-300 mm Hg, normocapnia PaCO2 of 35-48 mmHg and hypocapnia PaCO2 of 25-35 mmHg."
224188531|NCT03556202|DRUG|Mirikizumab|Administered SC
224188532|NCT04419558|DRUG|Pamrevlumab|Sterile solution for injection
224188533|NCT04419558|DRUG|Placebo|Sterile solution for injection
223498088|NCT00499213|PROCEDURE|Home Care Assisted Peritoneal Dialysis|
223498089|NCT01996995|DEVICE|Nd:YAG laser pulse therapy|
223498090|NCT01996995|DEVICE|Sham procedure|Sham procedure
223498091|NCT02166879|BEHAVIORAL|Questionnaire|Participants complete anesthesia questionnaire before elective surgical procedure.
223498092|NCT03754647|DIETARY_SUPPLEMENT|Vitamin C|One tablet of Vitamin C (500 mg) twice daily with SSRIs for 8 weeks
223498093|NCT03994432|BEHAVIORAL|intervention group|"follow a mediterranean diet and practice a regular aerobic exercise according to the 7-minutes workout model."
223498094|NCT05668247|OTHER|FOOT BATH|In general, foot bath is a type of relaxation and care performed by putting feet in water. Feet, as the organs carrying the whole body weight are the body parts where fatigue is felt most. In this study, a specially designed foot bath bucket was used in order to apply foot bath for the patients in the experimental group.
223498095|NCT03530228|DRUG|Tegoprazan (C1)|Tegoprazan QD, oral administration. Treatment A
223498096|NCT03530228|DRUG|Tegoprazan (C1)|Tegoprazan QD, oral administration. Treatment B
223498097|NCT03530228|DRUG|Treatment C: Tegoprazan (C1)|Tegoprazan BID, oral administration
223498098|NCT03530228|DRUG|Tegoprazan (C2)|Tegoprazan QD, oral administration, for 7 days. Group 1
223498099|NCT03530228|DRUG|Tegoprazan (C2)|Tegoprazan QD, oral administration, for 7 days. Group 2
223498100|NCT03530228|DRUG|Esomeprazole (C2)|Esomeprazole QD, oral administration, for 7 days. Group 3
223498101|NCT03530228|DRUG|Tegoprazan (C3)|Tegoprazan QD, oral administration
223590438|NCT03233035|DRUG|Placebo|0.5 mL of normal saline solution as a placebo in one pulverisation per nostril
223590439|NCT01759823|BIOLOGICAL|mesenchymal stem cell transplantation|20 - 30 ml of bone marrow will be aspirated and layered on density gradient medium (Ficoll - hypaque ) and stem cells will be separated. Separated mono nucleated cells will be dissolved in minimum essential medium and inoculated in culturing flask and mesenchymal will be allowed to adhere to culturing flask and mesenchymal stem cell will be injected into superior pancreatic duodenal artery . Patients will be urged to monitor and document blood glucose readings for next 6 months. Glucagon stimulated C - peptide HYPERGLYCEMIC CLAMP FOR ASSESSMENT OF BETA CELL FUNCTION , Homeostasis Model of Assessment - Insulin Resistance and Beta cell function ,HbA1c, lipid profile and biochemistry will be done at baseline and 6 months .
224188534|NCT03959306|DIETARY_SUPPLEMENT|Black Seed Oil|Black seed oil soft gelatin capsule
224188535|NCT03959306|DRUG|Anti-Diabetics|standard anti-diabetic treatment prescribed for the patient
224188536|NCT04916132|PROCEDURE|Kidney Biopsy|Harvesting of kidney tissue from people with type 2 diabetes and albuminuria for subsequent analysis
224188537|NCT02307695|DRUG|Saxagliptin|saxagliptin 5 mg p.o. qd, 24 week
224188538|NCT02307695|DRUG|Insulin|Patients will be treated according to routine clinical practice at the discretion of the treating physician.
224188539|NCT04466657|DIETARY_SUPPLEMENT|Antioxidation Therapy|Two proprietary formulations composed of reduced glutathione, N-acetylcysteine, superoxide dismutase, and bovine lactoferrin and immunoglobulins.
224188540|NCT04466657|OTHER|Standard of Care|SOC will be as determined by the clinical team at the treatment centres in line with the current National Interim Guidelines for Clinical Management of COVID-19
224188541|NCT00903357|DRUG|Montelukast first, then placebo|"Patients in Montelukast first, then placebo will receive 4 mg of montelukast under the age of 6 years (5 mg of montelukast at 6 years) once daily for 8 weeks. And after 2 weeks wash-out period, they will receive chewable ascorbic acid placebo for 8 weeks. Patients in Placebo first, then Montelukast are received chewable ascorbic acid placebo for 8 weeks. And after 2 weeks wash-out period, they will receive 4 mg of montelukast under the age of 6 years (5 mg of montelukast at 6 years) once daily for 8 weeks."
224188542|NCT00903357|DRUG|Placebo first, then Montelukast|"Patients in Montelukast first, then placebo will receive 4 mg of montelukast under the age of 6 years (5 mg of montelukast at 6 years) once daily for 8 weeks. And after 2 weeks wash-out period, they will receive chewable ascorbic acid placebo for 8 weeks. Patients in Placebo first, then Montelukast are received chewable ascorbic acid placebo for 8 weeks. And after 2 weeks wash-out period, they will receive 4 mg of montelukast under the age of 6 years (5 mg of montelukast at 6 years) once daily for 8 weeks."
224188543|NCT02219750|DRUG|switch twice-daily insulin|"compare two different insuiln regimen in basal insuln base and premixed insulin.~NovoMix 30, drug class:biphasic insulins Lantus, drug class: long-acting insuiln Levemir, durg class: long-acting insulin NovoRapid, drug class: rapid-acting insulin"
223498102|NCT04641637|PROCEDURE|TACE|Through a 7 French sheath placed through a single femoral arterial puncture, a guide catheter (Cobra 1 Guide Catheter, Mach 1, Boston Scientific Corporation, Marlborough, USA) is placed at the coeliac axis. From the digital subtraction angiography (DSA), the number of arterial tumor feeders to the HCC is identified. One or more feeder(s) is to be catheterized for delivery of therapeutic agent using a 2.4 French microcatheter (Merit Maestro, Merit Medical Systems, Utah, USA), and the other feeder(s) is occluded with a balloon catheter using 0.1 to 0.2mL diluted contrast for inflation (4mm x 10mm Temporary Occlusion Balloon Catheter, Occlusafe, Terumo Clinial Supply, Gifu, Japan). The occlusion target could be a feeder or a common trunk leading to a number of feeders. The therapeutic agent was delivered under fluoroscopic control until the vasculature of the whole tumors is entirely filled, which was assessed with DSA and non-contrast CT performed at the completion of the procedure.
223498103|NCT00095966|DRUG|sorafenib tosylate|Given orally
223498104|NCT00095966|DRUG|gemcitabine hydrochloride|Given IV
223498105|NCT03247244|DRUG|Cannabis|THC 10%, CBD \<0.5%
223498106|NCT03247244|DRUG|Cannabis|THC 8.6%, CBD 8.6%
223498107|NCT03247244|DRUG|Cannabis|THC 0.6%, CBD 14%
223498108|NCT03639389|DRUG|Bupivacaine|Spinal anesthesia with a combination of bupivacaine and fentanyl or sufentanil
223498109|NCT03639389|DRUG|Analgesics|Combination of paracetamol + non-steroidal anti-inflammatory drug + morphine to all patients
223498110|NCT02216409|DRUG|Hu5F9-G4|
223498111|NCT06848218|OTHER|Music Therapy|"This procedure is carried out using headphones installed in the child's ears. The music will be activated if the child is in the Music group, and will not be activated but present if the child is not in the Music group.~NIV implementation will begin after 10 min of listening. The listening period will continue until the nadir period (when the music is slowest, for maximum relaxation), until 10 min after the start of the NIV."
223745996|NCT06247787|BIOLOGICAL|Imetelstat|Given IV
223745997|NCT06247787|DRUG|Leucovorin Calcium|Given IV or PO
223745998|NCT06247787|PROCEDURE|Lumbar Puncture|Undergo lumbar puncture
224188544|NCT03389490|DRUG|Insulin Glargine 300 UNT/ML|Self titration of insulin glargine U300
224188545|NCT03389490|DRUG|Neutral protamine hagedorn insulin|Self titration of NPH insulin
224188546|NCT02182076|DRUG|BIBF 1120|150 mg of BIBF 1120 ES soft gelatine capsules
224188547|NCT05185908|PROCEDURE|Measurement of the optic nerve sheath diameter by ultrasound-guidance.|Measurement of the optic nerve sheath diameter (ONSD) by ultrasound guidance can be used in the diagnosis of increased ICP. The investigators interrogated the effects of lateral 45° downward position and CO2 insufflation on ONSD in patients undergoing laparoscopic transperitoneal nephrectomy.
224188548|NCT01699061|DRUG|Tivantinib|3 tivantinib tablets 120 mg administered twice daily with a meal starting on Day 2
224188549|NCT01699061|DRUG|Placebo|Placebo tablet administered with a meal twice a day on Day 1
224188550|NCT00981565|PROCEDURE|open carpal tunnel release|surgery to release the carpal tunnel
224188551|NCT00981565|OTHER|Night-cast|individual night time splinting
224188552|NCT02253849|DRUG|Carbamazepine|
224188553|NCT02253849|DRUG|Tipranavir|
224188554|NCT02253849|DRUG|Ritonavir|
224309243|NCT04365777|OTHER|OAA/S=3|Given sedative anesthetics (propofol, midazolam or dexmetomidine), EEG signatures will be recorded after reaching steady state of OAA/S=3 (responds only after name called loudly and/or repeatedly) for few minutes.
223498112|NCT06848218|PROCEDURE|Setting Up NIV|Non invasive ventilation is set up in several stages, with the help of at least two caregivers. The patient will be placed in a half-seated position or seated. Installation begins with the placement of the non invasive ventilation mask harness around the child's head, followed by the application of the mask to the face, held by a caregiver. Once the mask has been applied, ventilation is started by connecting the non invasive ventilation circuit to the mask. The harness is then tightened by the second caregiver.
223745999|NCT06247787|DRUG|Methotrexate|Given IT
223746000|NCT03412760|DIAGNOSTIC_TEST|Exome sequencing|Expansive genetic test performed for affected fetus or neonate.
224309244|NCT04365777|OTHER|OAA/S=1|Increasing drug concentration, EEG signatures will be recorded after reaching steady state of OAA/S=1 (does not respond to noxious stimuli) for few minutes.
224309245|NCT00470067|DRUG|carboplatin|IV
224188555|NCT03093129|DRUG|artesunate|"Artesunate (Trade name : Arinate®)~Artemisinins are a family of sesquiterpene trioxane anti-malarial agents derived from Sweet wormwood (Artemisia annua L) that have been used in traditional Chinese medicine for centuries to treat fevers. Artesunate, artemether and arteether are derivatives of artemisinin that are converted into their active metabolite dihydroartemisinin (DHA). Artesunate is approved for the treatment of uncomplicated and multidrug-resistant malaria and is on the WHO list of Essential Medicines (WHO., 2015)."
224188556|NCT03093129|OTHER|placebo|The matching placebo tablets contain lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, colloidal anhydrous silica and a magnesium stearate blend.
224188557|NCT05146999|BIOLOGICAL|QM1114-DP|QM1114-DP
224188558|NCT05146999|BIOLOGICAL|Placebo|Placebo
224188559|NCT01074060|DRUG|plerixafor|Given IV
224188560|NCT01074060|BIOLOGICAL|filgrastim|Given SC
224188561|NCT01074060|DRUG|cyclophosphamide|Given IV
224188562|NCT01074060|PROCEDURE|autologous hematopoietic stem cell transplantation|autologous hematopoietic stem cell transplantation
224188563|NCT01074060|OTHER|laboratory biomarker analysis|Correlative studies
224188564|NCT05940584|DEVICE|Tele-Reha provided with EvoPads|Exercises and cognitive training provided on an EvoPad
224188565|NCT05940584|OTHER|Paper-based exercises with option to do tele-reha afterwards|Similar exercises and cognitive training as Group 1 provided on paper. Patients receive the Tele-Reha afterwards
224188566|NCT05940584|OTHER|Only paper-based exercises|Same exercises and cognitive training as Group 2 provided on paper only.
224188567|NCT06196463|PROCEDURE|Erector spinale block (ESP block)|The Study has the Objective to analyze the efficacy of the ESP block in spine Surgery (juvenile idiopathic scoliosis) to control perioperative pain
224188568|NCT06196463|PROCEDURE|AG + sham block|General anesthesia
223498113|NCT03712852|PROCEDURE|PRF+CAF treated patients|Patients will be treated by coronally advanced flap with addition of PRF membrane
223498114|NCT03712852|PROCEDURE|SCTG+ CAF treated patients|Patients will be treated by coronally advanced flap with addition of SCTG graft
223498115|NCT03712852|PROCEDURE|CAF treated patients|Patients will be treated by coronally advanced flap
224188569|NCT05729516|BEHAVIORAL|Hope App immersive learning and telehealth platform|As part of the Hope App intervention, participants attend 10 skills sessions related to diabetes self-management. ITG participants will also receive monthly health coaching calls. After 6 months of active participation, participants enter a maintenance period, during which programming concludes but continued access to the program materials remains.
224188570|NCT03622320|OTHER|Blood sample|Blood sample for fasting blood sugar (FBS), High density lipoproteins (HDL), Triglycerides (TG) ,HOMA-IR, serum leptin
224188571|NCT03260322|DRUG|ASP8374|intravenous
224188572|NCT03260322|DRUG|Pembrolizumab|intravenous
223498116|NCT04894188|RADIATION|radiation therapy|Intensity modulated radiation therapy (IMRT), with 50 Gy in 25 daily fractions (2 Gy/fraction, 5 fractions weekly) for 5 weeks (week 1 - week 5).
223498117|NCT04894188|DRUG|Goserelin 3.6 MG|Gosereline 3.6mg sc injection at week 1, week 5, and week 9
223498118|NCT04894188|PROCEDURE|radical prostatectomy|Eligible patients will undergo robotic-assisted radical prostatectomy and pelvic lymph node dissection
223498119|NCT02321904|PROCEDURE|Corneal Confocal Microscopy|Close-up pictures of the front part of the eye (the cornea)
223498120|NCT02321904|PROCEDURE|Nerve Conduction Studies|The following assessments will be made: a) amplitude of nerve action potential (μV) and conduction velocity (m/s) of the sural sensory nerve by antidromic stimulation; b) motor nerve conduction velocity (m/s), maximum M-wave amplitude (mV) and motor nerve distal latency (ms) of the peroneal motor nerve; and c) tibial nerve conduction study will also be obtained if tolerated.
223498121|NCT02321904|PROCEDURE|Quantitative sensory testing|Standardized vibratory and thermal stimulation levels applied to the subject's non-dominant big toe.
223498122|NCT02321904|PROCEDURE|Neuropathy Symptom Score|A list of 18 motor, sensory and autonomic symptoms encountered in a diabetic patients with neuropathy obtained by interview.
224188573|NCT03541616|DEVICE|ECG Patch, pocket ECG monitor|Two consecutive 14-day ECG monitor patches or one single 28-day pocket ECG monitor (28-days total monitoring) implemented at the time of hospital discharge .
224188574|NCT06047886|DRUG|Infusion of CD34 selected hematopoietic stem cells|CD34 stem cell isolation and infusion to reduce alloreactive complication of stem cell infusion
224188575|NCT05587933|PROCEDURE|cholecystectomy|cholecystectomy
224188576|NCT05587933|DRUG|Antispasmodic|Antispasmodic
224188577|NCT02293720|DEVICE|EndoBarrier|The EndoBarrier is indicated as an adjunct to diet and exercise to achieve weight loss and improve glycemic control in obese adults with type 2 diabetes whose anti-diabetes medications have not achieved adequate glycemic control.
224188578|NCT03564977|BIOLOGICAL|CD19-targeted CAR-T cells|MDR+ patients after autologous stem cell transplantation were treated with CD19-targeted CAR-T cells.
224188579|NCT05593523|DRUG|Indocyanine green (ICG)|ICG is a well, known, FDA-approved dye
224188580|NCT05593523|DEVICE|Clinical Fluorescence Imaging Device|OnLume Clinical Imaging System or Commercially-available FDA approved clinical fluorescence imaging device (SPY Elite fluorescence imaging system, SPY-PHI portable handheld imaging system, or EleVision IR platform (also known as VS3-IR system)
224188581|NCT04327531|BEHAVIORAL|turkish physicians|turkish physicians, who work active in pandemic hospital.
224188582|NCT02173470|OTHER|CT scan|The intervention group receives both standard care (chest x-ray) and an ultra low dose CT thorax without contrast.
224188583|NCT02221882|DRUG|LY3164530|Administered IV.
224188584|NCT02395445|DEVICE|orotracheal intubation|
224188585|NCT00936052|OTHER|Hyperbaric Oxygen Therapy|in addition to standard radiation and chemotherapy, you will also receive the experimental hyperbaric treatment prior to each radiation treatment (Monday-Friday) during the initial six weeks of treatment. Prior to the first hyperbaric treatment. The hyperbaric treatment lasts approximately thirty minutes. During the hyperbaric treatment, the participant will lie on a stretcher in the hyperbaric chamber and breathe oxygen at greater than normal atmospheric pressure. The investigator will monitor the increased oxygen levels in the tissue by placing a noninvasive electrode on your skin. After each hyperbaric treatment, we will measure your blood sugar by finger-stick to check for hypoglycemia (low blood sugar). If detected, hypoglycemia will be treated by standard medical measures.
224188586|NCT00122395|BEHAVIORAL|Screening via pen and paper|
224188587|NCT00122395|BEHAVIORAL|Screening via audiotape|
224188588|NCT00212082|DRUG|doxorubicin, docetaxel|
223498123|NCT02321904|PROCEDURE|Clinical nerve examination|Summated score of the lower extremities. Neurological examination assessing muscle strength, knee and ankle reflexes, sensation in the great toes will be evaluated for light touch-pressure, temperature, pin-prick, vibratory sense and joint position sense.
223498124|NCT05225363|BIOLOGICAL|Chimeric Antigen Receptor T-cells|Receive TAG72-CAR T cells IP
223498125|NCT05225363|DRUG|Cyclophosphamide|Given IV
223498126|NCT05225363|DRUG|Fludarabine|Given IV
223498127|NCT05404061|OTHER|Gut hormones|"Their first visit will act as an acclimatisation visit and participants will be infused subcutaneously with a triple gut hormone infusion (GLP-1, PYY and OXM). This will not only allow us to acclimatise the study volunteer to the study visits, but also allow us to test for subject tolerability of the gut hormones.~For the next two visits participants will be randomised in a single-blinded fashion to a subcutaneous infusion of either:~1. 0.9% saline,~2. GLP-1"
223498128|NCT00586547|BIOLOGICAL|T-Cell Infusion Dose Level -1|(1 x 10\^3 T cells/Kg)
223498129|NCT00586547|BIOLOGICAL|T-Cell Infusion Dose Level 1|(1 x 10\^4 T cells/Kg)
223498130|NCT00586547|BIOLOGICAL|T-Cell Infusion Dose Level 2|(1 x 10\^5 T cells/Kg)
223498131|NCT00586547|BIOLOGICAL|T-Cell Infusion Dose Level 3|(1 x 10\^6 T cells/Kg)
223498132|NCT00586547|BIOLOGICAL|T-Cell Infusion- Dose Level 4|(5 x 10\^6 T cells/Kg)
223498133|NCT00009893|DRUG|fluorouracil|
223498134|NCT00009893|DRUG|gemcitabine hydrochloride|
223498135|NCT00009893|DRUG|leucovorin calcium|
223498136|NCT02756520|OTHER|Observational study: Supplemented protein-restricted diet|Observational study: Supplemented protein-restricted diet
223498137|NCT03549260|BIOLOGICAL|LIB003|LIB003 or placebo
223498138|NCT02636452|OTHER|cardiopulmonary exercise test|
223498139|NCT01764581|PROCEDURE|Tacrolimus regulation according to ImmuKnow values|Tacrolimus dose was reduced by 25% when ImmuKnow values were below 130 ng/mL ATP and increased by 25% when ImmuKnow values exceeded 450 ng/mL. Further reductions or increases were made after serial measures until ImmuKnow values stabilized between 130 and 450 ng/mL ATP. The values of 130 and 450 ng/mL ATP were previously documented as thresholds for risks of infection and rejection, respectively with a value of 280 ng/mL corresponding with the greatest negative predictive value for either event
223498140|NCT06457932|BEHAVIORAL|Heart rate variability biofeedback training|An 8-week intervention based on daily 10-minute HRV biofeedback training at rest using the Pulse HRV smartphone application.
223498141|NCT06457932|BEHAVIORAL|Guided meditation|An 8-week intervention based on daily 10-minute guided meditation sessions led by an instructor with over 20 years of experience in teaching meditation.
223498142|NCT05442931|DRUG|Pregabalin 150mg|The oral tablet half an hour preoperative 150 milligrams
223498143|NCT05442931|DRUG|Magnesium Sulfate|Intravenous administration half an hour preoperative 2 grams
223498144|NCT05442931|DRUG|Nitroglycerin|measure total dose of nitroglycerine in milligrams using a syringe pump
223498145|NCT05442931|OTHER|surgeon satisfaction|surgeon satisfaction measured according to Likert's scale
224188589|NCT01043809|BEHAVIORAL|Procter & Gamble school-based handwashing promotion program|Handwashing promotion lesson and materials targeting first grade students
224188590|NCT01043809|BEHAVIORAL|expanded school-based handwashing promotion|Procter \& Gamble's standard school-based handwashing promotion education and materials targeting first grade students, plus a program enhancement. In China, enhancement consists of a supply of soap for school sinks. In Pakistan, enhancement consists of soap for school sinks, plus enlistment of a peer hygiene champion in each first grade class. In the Philippines, enhancement consists of enlistment of a peer hygiene champion in each first grade class.
223498146|NCT06154473|PROCEDURE|Open heart surgery group.|Patients undergoing open heart surgery.
223498147|NCT06154473|PROCEDURE|Percutaneous cardiovascular surgery group.|Patients undergoing percutaneous cardiovascular surgery.
223498148|NCT02341469|OTHER|integrated ediagnostic approach (IeDA)|"IeDA is a package of several interventions with the objective of improving the quality of child health care in health centres to ultimately decrease child morbidity and mortality. The components of IedA are described as follows:~* REC: the IMCI protocol translated into a computer-based tool that aims to guide nurses during consultations.~* The training of nurses on IMCI and REC.~* A quality assurance mechanism through which each district and health centre is encouraged to find appropriate solutions in response to their local needs.~* A supervision system conducted implemented by district managers to provide support and guidance to health centres.~* A health information system based on data collected through the REC and fed back to the district managers and Heads of health centres."
223498149|NCT06104293|OTHER|Grass Pollen Allergen Exposure|"After the screening visit, subjects are randomized into 3 groups presenting a sequence of allergen concentrations with randomly defined concentrations of Ph l p 5 (0, 30, 60 and 90 ng/m3).~Each participant undergo four different 3-hour exposure sessions to grass pollen allergen corresponding to the four different allergen concentrations."
223498150|NCT00330018|DRUG|Valganciclovir|Valganciclovir
223746001|NCT05075850|DEVICE|Neuroblate System|"All subjects will undergo comprehensive neuropsychological assessment post-LITT per standard of care practice.~Visual field testing will be conducted in a subset of enrolled patients."
223498151|NCT00330018|DRUG|Acyclovir|Acyclovir
223498152|NCT02503930|DEVICE|Active tDCS|In this group subjects will receive 20 min of treatment.
224188591|NCT05295810|DRUG|Sequential Gas Delivery|Sequential Gas Delivery will be controlled using the RespirAct™ system (Thornhill Research Inc., Toronto, Canada)
223498153|NCT02503930|DEVICE|Sham tDCS|In this group subjects will receive 20 min of sham stimulation.
223498154|NCT05452512|OTHER|Self monitoring|Self monitoring using smart clinical trial application
223498155|NCT05452512|OTHER|Smart watch assisted monitoring|Smart watch-assisted adherence monitoring
223498156|NCT05452512|DRUG|Vitamin D|Vitamin D self-administration for 3 months
223498157|NCT01771913|GENETIC|centrifuged fat graft|fat from the abdominal subcutaneous tissue will be taken by vacuum assisted lipectomy and immediately prepared to be grafted in the reconstructed breast that presents contour irregularities and/or volume insufficiency. No adipose derived stem cells will enrich the fat grafts in this group.
224188592|NCT00307775|DRUG|oestradiol|
224309246|NCT00470067|DRUG|pegylated liposomal doxorubicin hydrochloride|IV
224188593|NCT05474482|OTHER|kinesio taping with exercises|Kinesio taping with full stretch of 75 to 100 % for 2 days session per week and exercises for 3 days session per week for total 8 weeks.
224188594|NCT05474482|OTHER|Kinesio taping without exercises|Kinesio taping with a full stretch of 75 to 100 % for 2 days session per week without exercises for 8 weeks.
224188595|NCT05474482|OTHER|Kinesio taping without stretch as control|kinesio taping without any stretch for 2 days session per week for total 8 weeks.
223498158|NCT01771913|GENETIC|ADSCs enriched fat graft|fat from the abdominal subcutaneous tissue will be taken by suction assisted lipectomy and stromal vascular fraction will be isolated and immediately added to the fat graft that will be employed to improve contour irregularities and volume insufficiency of reconstructed breasts.
223498159|NCT03852576|DRUG|KSP/QRH dimer|KSP-QRH-E3-IRDye800 (Peptide 919288G)
223498160|NCT03909503|DEVICE|Porcine-derived collagen wound dressing|Patients who meet the inclusion criteria will be treated with porcine-derived collagen dressings. The dressing will be used in accordance with its label. After cleansing the wound, the dressing will be placed on the wound. Appropriate primary and secondary dressings will be placed over the intervention product. Patients will visit the clinic once per week to have their dressings re-applied. Wound evaluations will take place once per week with the intervention lasting up to twelve weeks. Concomitant standard of care such as compression for venous ulcers will be provided according to individual patient needs.
223498161|NCT00447681|DRUG|ILV-094|
223498162|NCT06161090|BIOLOGICAL|CM310|CM310 injection
223590440|NCT01759823|OTHER|control|5 ml of bone marrow will be aspirated and 3 mL of Vitamin B complex will be injected through transfemoral route into superior pancreatico-duodenal artery. Patients will be urged to monitor and document blood glucose readings for next 6 months. Glucagon stimulated C - peptide,HYPERGLYCEMIC CLAMP TO ASSESS BETA CELL FUNCTION. Homeostasis Model of Assessment - Insulin Resistance and Beta cell function ,HbA1c, lipid profile and biochemistry will be done at baseline and 6 months .
223590441|NCT01759823|BIOLOGICAL|MNC's TRANSPLANTATION|20 - 30 ml of bone marrow will be aspirated and layered on density gradient medium (Ficoll - hypaque ) and stem cells will be separated. Separated mono nucleated cells will injected into superior pancreatico duodenal artery. Patients will be urged to monitor and document blood glucose readings for next 6 months. Glucagon stimulated C - peptide HYPERGLYCEMIC CLAMP FOR ASSESSMENT OF BETA CELL FUNCTION , AND EUGLYCEMIC CLAMP TO ASSESS INSULIN SENSITIVITY .Homeostasis Model of Assessment - Insulin Resistance and Beta cell function ,HbA1c, lipid profile and biochemistry will be done at baseline and 6 months .
223590442|NCT03841760|DIAGNOSTIC_TEST|PSMA PET/CT|"For 18F-DCFPyL PET/CT: Approximately 9 mCi (333MBq) of 18F-DCFPyL is injected intravenously. Approximately 60-90 minutes following 18F-DCFPyL injection, CT and PET images are consecutively acquired from the base of the skull to the toes.~For 68Ga-PSMA-11 PET/CT: Approximately 2.5 MBq/kg (0.068 mCi/kg) of 68Ga-PSMA, up to a maximum of 300 MBq (8 mCi), is injected intravenously. Approximately 60 minutes following 68Ga-PSMA injection, CT and PET images are consecutively acquired from the base of the skull to toes."
224188596|NCT06545708|OTHER|Patients|This group consists of children and adolescents between the ages of 5 and 14, diagnosed with self-limited epilepsy with centrotemporal spikes by a medical professional (epileptologist or neurologist), and in the active phase of the disorder.
224188597|NCT05664672|OTHER|OTDN Product 1|Mint on!® 2 mg nicotine pouches
224188598|NCT05664672|OTHER|OTDN Product 2|Mint on!® 4 mg nicotine pouches
224188599|NCT05664672|OTHER|OTDN Product 3|Mint on!® 8 mg nicotine pouches
224188600|NCT05664672|OTHER|No Tobacco|subjects completely stop all tobacco product usage for 7 days
223498163|NCT06161090|DRUG|Placebo|subcutaneous injection
223498164|NCT04403282|DRUG|Eflornithine Topical|Subjects will apply placebo to one side of beard and eflornithine to other side for 16 weeks.
223498165|NCT04403282|DRUG|Placebo Eflornithine Topical|Subjects will apply placebo to one side of beard and eflornithine to other side for 16 weeks.
223498166|NCT03243890|DIETARY_SUPPLEMENT|Menaquinone-7 720 µg/day including the recommended daily dose of vitamin D (25 µg/day).|Half of the patients are randomized to supplementation with MK-7 (720 µg/day) including the recommended daily dose of vitamin D (25 µg/day).
223498167|NCT03243890|DIETARY_SUPPLEMENT|Placebo|Half of the patients are randomized to placebo treatment (no active treatment).
223498168|NCT04949295|DEVICE|ocular surface analyzer|Using ocular surface analyzer for Inspection
223590443|NCT04303299|DRUG|Oral|Anti virus treatment
223590444|NCT03576573|DEVICE|PROCOTYL® C|Hip Arthroplasty
223590445|NCT02100306|BEHAVIORAL|Auditory Feedback 100%|Patients will receive constant auditory feedback across training trials.
223590446|NCT02100306|BEHAVIORAL|Auditory Feedback 50% alternate|Patients will receive alternating auditory feedback (1 trial auditory feedback; 1 trial no auditory feedback) across trials
223590447|NCT01510899|DRUG|RO4917838|Single dose of RO4917838
224188601|NCT05968157|DIAGNOSTIC_TEST|Breast MRI|Supplemental MRI (in addition to standard of care MRI).
224188602|NCT05968157|DEVICE|MIRAI|Artificial intelligence software
224188603|NCT02394457|DRUG|Cosyntropin|Intravenous Drug Infusion over 1 hour and a half
224188604|NCT02394457|PROCEDURE|Epidural Blood Patch|Blood drawn from subject and then same Blood placed into Epidural space by anesthesia personnel.
224188605|NCT01598831|DRUG|ART-123|Dose: 0.06 mg/kg/day up to a maximum dose of 6 mg/day for 6 days
224188606|NCT01598831|DRUG|Placebo|Dose: 0.06 mg/kg/day up to a maximum dose of 6 mg/day for 6 days.
224188607|NCT01916733|DRUG|standard insulin protocol post-op (continuous IV insulin)|concurrent, matched cohort study of moderate postoperative glucose control in patients undergoing LEB or open AAA repair.Propensity score matching is a statistical method used to reduce the confounding effects of covariates in an observational (non-randomized) study. In practice we will select a number of variables that impact wound infection; age, gender, diabetic and non-diabetic populations, renal insufficiency (defined at creatinine ≥1.8) and indication for surgery (claudication or critical limb ischemia with rest pain or tissue loss or open AAA repair); and chose a group of patients in the Vascular Study Group matched for these variables who have not been treated with an insulin infusion). Consecutive patients undergoing elective open AAA repair or infrainguinal LEB for claudication and critical limb ischemia will be invited to enroll in the study.
224188608|NCT01883596|DRUG|0.12% chlorhexidine solution|Bexident® (0.12% chlorhexidine solution)
224188609|NCT01883596|DRUG|Placebo|7.4% alcohol, glycerine, normal saline solution, applied topically, every 8 hrs.
224188610|NCT00364234|DEVICE|Low magnitude mechanical stimuli|20 minutes standing on low magnitude high frequency vibrating platform
224188611|NCT01263652|DRUG|Diclofenac hydroxyethylpyrrolidine|IM/PO
224188612|NCT01263652|DRUG|orphenadrine|IM/PO orphenadrine
224188613|NCT01263652|DRUG|Tramadol|IM/PO tramadol
224188614|NCT01263652|DRUG|Dipyrone|PO/IM Dipyrone
223498169|NCT05419440|PROCEDURE|laparoscopic drainage of appendicular abscess|access to caecum and remove any adhesions with surrounding by sharp \& blunt dissection , then access to appendicular abscess by sharp and blunt dissection after complete separation of the appendix from surrounding \& complete drainage of pus \& removal of all necrotic tissue , removal of the remnant appendix , in cases with healthy base of appendix ,we closed the stump with endo-loop , in case with unhealthy base , we closed the stump by suturing by ethibond 2/0 in two layers in case with little edema \& inflammation of caecum ( sutures not cut through ) , in cases with marked edema and inflammation of caecum , we close the site of base by omental patch fixed by taking full thickness sutures in wall of caecum and pass through omental patch , we examine any leak by pressing on caecum and observe any fecal matter comes \& air leak test , in all cases we put large drain at pelvis
223498170|NCT01784185|PROCEDURE|virtual bronchoscopy guided transbronchial needle aspiration|
223498171|NCT01784185|PROCEDURE|endobronchial ultrasound guided transbronchial needle aspiration|endobronchial ultrasound guided transbronchial needle aspiration (EBUS-TBNA) of mediastinal lesions
223498172|NCT05390606|COMBINATION_PRODUCT|Flourish HEC and BioGenesis|Flourish HEC is a 3-component system, including: 1) Balance feminine wash, used daily; 2) BioNourish vaginal moisturizer, used daily before bed except if having intercourse; 3) BiopHresh homeopathic vaginal suppository with probiotics, used once every 3 days before bed except if having intercourse. BioNourish is a class II medical device with FDA 510k clearance, on the market for 2 years. BioGenesis is also a class II medical device with FDA 510k clearance, and is designated as a fertility lubricant, safe for sperm and embryos.
223498173|NCT05376306|BEHAVIORAL|Stress Reduction: MBSR|Four activities, one each week - raising body awareness, sitting meditation, mindful yoga, expanding awareness meditation.
223498174|NCT05376306|BEHAVIORAL|Stress Reduction : PMR|Progressively tensing and releasing each muscle group from head to toe in a specific order.
223498175|NCT00174395|DRUG|eletriptan|
223498176|NCT00407511|DRUG|Pregabalin|Pregabalin will be administered orally, twice a day for 12 weeks, including 4-week dose adjustment phase followed by 8-week maintenance phase. The minimum allowable pregabalin dose during the trial will be 75 mg BID (150 mg/day) and the maximum allowable dose will be 300 mg BID (600 mg/day).
223498177|NCT02026349|DRUG|favipiravir|"Administered twice daily over 5 consecutive days for a total of 10 doses.~* Day 1: 1800 mg twice daily (loading doses)~* Days 2 through 5: 800 mg twice daily"
223498178|NCT02026349|DRUG|Placebo|Administered twice daily over 5 consecutive days for a total of 10 doses.
223498179|NCT04935515|DRUG|Oral Antibiotic, Antihistamine, Anti-inflammatory, Multivitamins|Oral Azithromycin , Cetirizine, Paracetamol, Zinc, Vitamin C, Vitamin D
223498180|NCT04935515|DRUG|Oral low dose steroid|Low dose oral methyl prednisolone was added.
223498181|NCT04935515|DRUG|Intravenous Antibiotics with Low dose steroid.|Intravenous ceftriaxone with either oral methyl prednisolone or intravenous dexamethasone was given
223498182|NCT04935515|DRUG|Oral anti-coagulant|Rivaroxaban was given for minimum 4 weeks depending on D dimer levels
223498183|NCT04987970|DRUG|CKD-386(2)|QD, PO
223498184|NCT04987970|DRUG|D013, D326, D337|QD, PO
223498185|NCT00747513|BEHAVIORAL|lifestyle program|a comprehensive program designed to encourage healthier food choices and eating habits and increased physical activity among children, by use of school, family and community measures.
223498186|NCT05786300|DEVICE|NMES+|"The Treatment Group will follow the rehabilitation protocol with the addition of the NMES+.~1st/2nd Week at 35 Hertz. 3rd/4th Week 50 Hertz. 5th/6th Week 70 Hertz."
223498187|NCT05786300|PROCEDURE|Rehab|"The Control Group will follow a protocol based on the latest available guidelines for the rehabilitation of the hamstrings lesions.~A weight-bearing protocol with a week by week progression on load, repetitions and sets."
223498188|NCT01776203|DRUG|Medroxyprogesterone 17-Acetate|MPA pills 20 mg (2 X 10 mg) twice daily for 3 weeks
223498189|NCT00465868|PROCEDURE|PCI (percutaneous coronary intervention)|Outcome of PCI following AMI
223498190|NCT03454958|OTHER|Measurements of body composition|Body weight (SECA digital weighing scale), height (SECA stadiometer), body composition (TANITA Bioelectrical Impedance Analyzer \& skin fold thickness measurements at the biceps, triceps, subscapular and suprailiac sites) and waist circumference (Cescorf measuring tape) will be objectively measured.
224188615|NCT00052403|DRUG|monoclonal antibody anti-anb3 integrin|
224188616|NCT00052403|PROCEDURE|anti-cytokine therapy|
224188617|NCT00052403|PROCEDURE|antiangiogenesis therapy|
224188618|NCT00052403|PROCEDURE|antibody therapy|
224188619|NCT00052403|PROCEDURE|biological response modifier therapy|
224188620|NCT00052403|PROCEDURE|growth factor antagonist therapy|
224188621|NCT00052403|PROCEDURE|monoclonal antibody therapy|
224188622|NCT00556088|DRUG|LBH589, Paclitaxel, Carboplatin, Bevacizumab|"LBH589 will be administered orally twice weekly. Paclitaxel and carboplatin will be administered intravenously every 21 days.~Once the MTD is established, drug dosages will be adjusted downward by one dose level and bevacizumab 15mg/kg intravenously every 3 weeks will be administered to a subset of patients with non-small cell lung cancer."
224309247|NCT02480868|DEVICE|ARTEBONE|4,3 g Bone Void Filler
224309248|NCT00460135|BEHAVIORAL|resistance training|2 times a week resistance training
224309249|NCT03400943|DRUG|Vilaprisan (BAY1002670)|2 mg of Vilaprisan once daily up to 2 x 12 weeks
224188623|NCT06427577|DRUG|ZhenQi FuZheng granules (ShiDaiYangGuang)|1 bag at a time, twice a day. Oral orally for 4 weeks.
224188624|NCT02952027|BEHAVIORAL|Use-recording, patient-reminder alarm for incentive spirometry|
224188625|NCT00019331|BIOLOGICAL|aldesleukin|
224188626|NCT00019331|BIOLOGICAL|ras peptide cancer vaccine|
224188627|NCT00019331|BIOLOGICAL|sargramostim|
224188628|NCT00019331|DRUG|DetoxPC|
224188629|NCT01467531|DRUG|Dolutegravir|50mg q 24h
224188630|NCT01467531|DRUG|Rlipivirine|25mg q24h
224188631|NCT01467531|DRUG|GSK1265744|30mg q24h
224309250|NCT03400943|DRUG|Placebo|Matching placebo was administered to group B1 and B2.
224188632|NCT05775666|BIOLOGICAL|UCLM802 Cell Injection|Anti-mesothelin CAR-T cells are autologous genetically modified T cells. A conditioning chemotherapy regimen of fludarabine and cyclophosphamide will be administered followed by UCLM802 cell injection.
224188633|NCT00287612|PROCEDURE|Lap. Fundo. with Mobilization of the Esophageal Junction|Complete mobilization of the esophageal junction
223498191|NCT00508508|BEHAVIORAL|Interactive Voice Response System|Participants using IVR will receive training in peer communication techniques and participate in an initial nurse-led interactive group visit. They will then be asked to communicate at least weekly with their partner using the IVR system. The IVR system will also automatically send reminder calls to participants and allow them to leave voice mail messages for their partner and their care manager.
224188634|NCT00287612|PROCEDURE|Lap. Fundo. without Mobilization of the Esophageal Junction|phrenoesophageal membrane left intact
224188635|NCT04236986|DRUG|Lipopolysaccharide|LPS will be administered intravenously (1.0ng/kg; IV)
224188636|NCT05245240|PROCEDURE|Dietary and physical intervention|"Low-caloric diet (energy deficit 600 kcal/day based on indirect calorimetry measurements), individually tailored by a nutritional specialist according to patients' individual food preferences.~Mild to moderate intensity exercise of aerobic/endurance type, performed 3 times a week for 30-90 minutes."
224188637|NCT04034225|DRUG|SNS-301|Day 0, Week 3, Week 6, Week 9 then every 6 weeks (±3 days) for 6 additional doses, thereafter every 12 weeks (±3 days) up to 24 months.
224188638|NCT04034225|DRUG|Pembrolizumab|Pembrolizumab (200 mg dose) IV infusion will be administered over 30 minutes every 3 weeks up to 24 months or Pembrolizumab (400 mg dose) IV will be administered over 30 minutes every 6 weeks up to 24 months.
224188639|NCT03490123|DRUG|R1-Total community treatment with azithromycin|At month 0, all study participants (regardless of their yaws status) will receive 30 mg/Kg (maximum 2 g) of azithromycin orally under direct observation. Benzathine benzylpenicillin will be reserved as a backup for patients who cannot be treated with AZI, and who are not allergic to penicillin.
224188640|NCT03490123|DRUG|R2-Total community treatment with azithromycin|At month 6, all study participants (regardless of their yaws status) will receive 30 mg/Kg (maximum 2 g) of azithromycin orally under direct observation. Benzathine benzylpenicillin will be reserved as a backup for patients who cannot be treated with AZI, and who are not allergic to penicillin.
224188641|NCT03490123|DRUG|R3-Total community treatment with azithromycin|At month 12, all study participants (regardless of their yaws status) will receive 30 mg/Kg (maximum 2 g) of azithromycin orally under direct observation. Benzathine benzylpenicillin will be reserved as a backup for patients who cannot be treated with AZI, and who are not allergic to penicillin.
223498192|NCT00508508|BEHAVIORAL|Nurse-Led Group Clinic Visits|At Months 1, 3, and 6, participants will take part in group visits led by nurses to discuss HF self-management strategies.
223498193|NCT02636283|DRUG|Entresto|Oral pills
223498194|NCT02636283|DRUG|Placebo group|The placebo pills
223498195|NCT03974490|OTHER|Rhythmic auditory stimulation|Rhythmic auditory stimulation 3 times in a week, and 2 hours of physiotherapy 6 days in a week.
223498196|NCT04153656|OTHER|Reading and studying Spiritual Flow|The Wellbeing Inventory will be administered to subjects and they will be compensated upon completion of the survey. Two months after the first survey, the Wellbeing Inventory will be administered to subjects and they will be compensated upon completion of the survey.
223498197|NCT05804968|OTHER|Digital HIV Self Disclosure Intervention|This project will develop a digital HIV disclosure intervention, drawing from the HEADSUP manual (Evangeli et al., 2020), which consists of four modules, including a HIV disclosure planning component. A SCED will be used to explore HIV disclosure intention, amongst other variables throughout baseline, intervention and follow up phases. Participants will further be asked to complete a participant experiences questionnaire to explore how they found the digital intervention and assess acceptability. This project will recruit a diverse sample of Sub-Saharan Africa adults living with HIV and residing in the U.K.
224188642|NCT03490123|DRUG|R2-Total targeted treatment with azithromycin|At 6 months, study participants will be screened for active yaws. Participants with yaws and their contacts will receive 30 mg/Kg (maximum 2 g) of azithromycin orally under direct observation. Benzathine benzylpenicillin will be reserved as a backup for patients who cannot be treated with AZI, and who are not allergic to penicillin.
224188643|NCT03490123|DRUG|R3-Total targeted treatment with azithromycin|At 12 months, study participants will be screened for active yaws. Participants with yaws and their contacts will receive 30 mg/Kg (maximum 2 g) of azithromycin orally under direct observation. Benzathine benzylpenicillin will be reserved as a backup for patients who cannot be treated with AZI, and who are not allergic to penicillin.
224188644|NCT01070511|DRUG|Tadalafil|Tadalafil will be administered orally on two consecutive days. The first dose-10 mg- will be administered the afternoon before the study. The second dose -20 mg-will be administered the morning of the study.
224188645|NCT01070511|DRUG|Placebo|A placebo pill will be administered orally on two consecutive days. The first pill will be administered the afternoon before the study. The second pill will be administered the morning of the study.
224188646|NCT04864197|BIOLOGICAL|platelet rich fibrin|prf membrane placement over implant site for gingival thickening
224188647|NCT00496574|BIOLOGICAL|Novo Helisen Depot, Phostal|subcutaneous immunotherapy
224188648|NCT02735772|PROCEDURE|transobturator approach for paravaginal repair|using TOT needle to apply suturs to white line
224188649|NCT03151200|DEVICE|Computer based binocular treatment|Binocular amblyopia treatment involves presenting stimuli over a computer screen to the amblyopic eye those are at higher contrast compared to the stimuli that are presented to the good eye, which balances the performances of the two eyes and over time improves the amblyopic eye vision.
224188650|NCT03151200|DEVICE|Transcranial magnetic stimulation|TMS is a non-invasive research method that generates electrical current at the cortex that can excite neuronal activities and neuronal plasticity.
224188651|NCT06597968|DEVICE|AI Based CAD Software (qXR-Ln)|All x-ray images have already been obtained and will then be run through CAD software for secondary nodule detection
224309251|NCT04863599|OTHER|Questionnaire|Patients will be asked to complete the Bauer and Brice questionnaire at post-operative day 1.
224309252|NCT02563106|DRUG|SYN-004|
224309253|NCT02563106|DRUG|Placebo|
224309254|NCT01290562|RADIATION|Stereotactic Body Radiotherapy (SBRT)|One or more high dose(s) of radiation to treat the tumour.
224309255|NCT01059539|DRUG|Cariprazine|Cariprazine was supplied in capsules.
224188652|NCT04374461|DRUG|N-acetylcysteine|Patients in both arms will receive N-acetylcysteine IV 6 g/day in addition to supportive and/or COVID-19 directed treatments at the discretion of the treating physician. Treatment interruptions for up to 48 hours are permissible if there is a clinical indication to hold the study drug. Patients can restart drug if they have been off drug for less than 48 hours. Patients are also eligible to restart N-acetylcysteine treatment on the same treatment arm without reconsent if they are within the 30 day followup period after their prior course of treatment on this protocol.
224309256|NCT00941148|DRUG|Insulin Glargin|
223498198|NCT02903654|OTHER|observational|
223498199|NCT04000256|BEHAVIORAL|Activity based rehabilitation|Activity based rehabilitation for the upper extremity involves various gross and fine movements, reach and object transportation, and object manipulation. The rehabilitation equipment used during training will include gaming and instrumented training equipment, conventional table-top tasks, and exercise aids.
223498200|NCT05935488|OTHER|EVOCs emulsion|Continuous breath sampling directly into SIFT-MS equipment. The instrument is equipped with a mouthpiece connected to the SIFT inlet where the subject blows in and the breath is analyzed in real-time
223498201|NCT01196611|BEHAVIORAL|Voice Amplification|Behavioral: Voice Amplification. Patients use VA over a course of 6 weeks Control group. No treatment over a course of 6 weeks.
223498202|NCT01196611|BEHAVIORAL|Function Voice Exercises|Function Voice Exercises Patients will receive 6 sessions of therapy over a course of 6 weeks, with one session per week.
223498203|NCT01576393|BEHAVIORAL|Home-based Family Therapy|12 home-based family therapy sessions
223498204|NCT01576393|BEHAVIORAL|office-based family therapy|12 office-based family therapy sessions
223498205|NCT01576393|BEHAVIORAL|WHE|12 Women's Health Education Sessions
223498206|NCT06125418|PROCEDURE|customized healing abutment|patients will undergoes one-stage implant placement with customized healing abutments with different macrogeometry and emergence angle made prior to the surgery and will be inserted without sutures, after osseointegration completed patients will received single crown on implant.
223498207|NCT06125418|PROCEDURE|standard healing abutment|patients will undergoes one-stage implant placement with standard titanium healing abutment made prior to the surgery and will be inserted without sutures, after osseointegration completed patients will received single crown on implant.
223498208|NCT03295448|OTHER|Low carbohydrate diet|Diet low in carbohydrates (38%E), but higher in total and saturated fat.
223498209|NCT03295448|OTHER|High carbohydrate, high sugar diet|Diet high in carbohydrates (53%E) and sugars, but low in wholegrain, rye and wheat fibre.
223498210|NCT03295448|OTHER|High carbohydrate, low sugar diet|Diet high in carbohydrates (53%E), wholegrain, rye and wheat fibre, but low in sugars.
223498211|NCT03055078|BIOLOGICAL|mesenchymal stem cells|Patients in the cell treated group were given umbilical cord derived mesenchymal stem cells by intravenous infusion besides conventional therapy. There was only conventional treatment in the control group. All patients after treatment for 1months, 3months, 6months and 9months were evaluated respectively the therapeutic effect.
223498212|NCT02565251|DEVICE|Flotrac/Ev1000|Hemodynamic resusucitation guided by the data obtained from the monitorisation with Flotrac/Ev1000 device in the first two hours
223498213|NCT02565251|DEVICE|Standard ICU monitorisation|Hemodynamic resusucitation guided by the data obtained from ICU standard hemodynamic monitoring (BP, CVP) in the first 2 hours
223590448|NCT01510899|DRUG|RO4917838|Single dose of RO4917838
223590449|NCT01154751|DEVICE|SUPERA Interwoven self-expanding nitinol stent|Insertion of stent at stenotic area
223590450|NCT04900285|DEVICE|Delta Dental Oral Device|"The oral device is designed to move the genioglossus forward, with interior attachments to maintain the placement of the tongue on the floor of the mouth forward. In addition, bite plates made of the Ethylene-vinyl acetate (EVA) plastic were fabricated and embedded with the mouthpiece to encourage subjects to bite down and push the tongue under the interior lower attachment. The upper plate is made of the same material and slightly opens the bite to improve oral air flow further. The primary component of the mouthpiece is fabricated with Vistamaxx material, which is semi-crystalline 2mm co-polymer that can be molded by the user with Nurse assistance to provide a custom fit.~The subject will be fitted by moistening and heating in a microwave. Tthe research staff member will assist to ensure proper fit with both the lower and upper dental devices.~The subject then completes the data collection portion regarding using the SnoreLab app and survey completion as previously described."
223590451|NCT00083928|DRUG|Å6 subcutaneous injection|
223498214|NCT02565251|DEVICE|VolumeView/Ev1000|Hemodynamic resusucitation guided by the data obtained from the monitorisation with VolumeView/Ev1000 device in the next four hours
223590452|NCT02986854|BIOLOGICAL|Meningococcal (groups A, C, W and Y) oligosaccharide diphtheria CRM-197 conjugate Vaccine (Menveo)|One intramuscular injection of MenACWY at Day 1.
223590453|NCT01840098|DIETARY_SUPPLEMENT|low leucine content drink|
223590454|NCT01840098|DIETARY_SUPPLEMENT|high leucine content drink|
223590455|NCT01840098|DIETARY_SUPPLEMENT|low leucine + HMB drink|
223590456|NCT01840098|DIETARY_SUPPLEMENT|Control/carbohydrate|
223590457|NCT01840098|BEHAVIORAL|36 hour fasting|
223590458|NCT00324233|DEVICE|Intermittent catheter|SpeediCath catherter (SC) for intermittent catherisation
223590459|NCT00324233|DEVICE|Compact intermittent catheter|SpeediCath Compact Male catheter (SCCM) is a compact intermittent catheter for males
224309257|NCT00941148|DRUG|NPH insulin|
224309258|NCT00941148|DRUG|Insulin detemir|
224309259|NCT00941148|DRUG|metformin|metformin (2000 mg/day)
224309260|NCT03717025|PROCEDURE|SUCTION BLISTER EPIDERMAL GRAFTING|"1. Preferred donor sites for making blister is lateral aspect of upper thigh. The area is shaved and cleansed with surgical spirit.~2. Blister formation is induced by using suction apparatus.~3. Recipient site is surgically prepared by doing dermabrasion.~4. After formation of blisters, each blister is gently cleansed with normal saline and cut all along its border with curved iris scissors parallel to the skin surface. The roof is everted over the thumb with dermal surface facing upwards and then with the help of blunt end of forceps it is placed on the recipient area.~5. The graft is firmly pressed with sterile moist gauze to remove any underneath serous collection.~6. The pressure dressing is done with double layer framycetin tulle, moist gauze and bandage.~7. Donor area is dressed with dry sterile pads.~8. The part is immobilized and Antibiotics and Analgesic are given till dressing are removed (after 5-7 days)."
224188653|NCT04374461|OTHER|Peripheral Blood|A total of 16mL of research whole blood will be collected in CPT tubes at baseline, Cycle 2 Day 1 (or as close as feasible, when still coordinating sample collection across patients in a critical-care unit), and at end of study.
224188654|NCT01716221|DRUG|bupropion & Citalopram|
224188655|NCT01716221|DRUG|Bupropion & Placebo|
224188656|NCT01716221|DRUG|Placebo & Citalopram|
224188657|NCT01716221|DRUG|Placebo & Placebo|
224188658|NCT02875743|DRUG|Posaconazole|
224188659|NCT02046551|DRUG|Atomoxetine|
223498215|NCT04400747|DRUG|Vitamin D3|one group will take weekly oral 50000 IU Vitamin D3, other group will take daily oral 6000 IU Vitamin D3.
223498216|NCT00609505|OTHER|Telemedicine|Telemedicine genetic counseling
223498217|NCT00609505|OTHER|Face-to-Face|Face-to-face genetic counseling
223498218|NCT00093938|DRUG|Cranberry juice|
223498219|NCT05852288|DIAGNOSTIC_TEST|Inflammatory markers|Participants in this cohort will undergo a comprehensive clinical and biochemical evaluation to assess the role of inflammation in CTS. The evaluation will include assessments of inflammatory markers, such as C-reactive protein (CRP), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-α), as well as clinical measures of CTS severity.
223498220|NCT02375997|OTHER|Palliative care|Early nutrition intervention and psychological intervention
223498221|NCT02617862|PROCEDURE|Examination under anaesthetic (EUA)|The EUA is scheduled as part of the routine clinical management of children with various ophthalmic conditions.
223498222|NCT02617862|DEVICE|RetCam|The RetCam is a pediatric wide-field retinal camera that has been the mainstay for pediatric ophthalmic imaging since 1997. Imaging using the RetCam (during the EUA) is conducted as part of routine clinical magagement.
223498223|NCT02617862|DEVICE|COSMOS|The COSMOS images will be captured (during the EUA) after the RetCam images. The COSMOS is designed to be used in the same way as the RetCam, but to produce higher quality images.
223498224|NCT01794975|DRUG|Ketamine|
223498225|NCT01794975|DRUG|Atomoxetine|
223498226|NCT01794975|OTHER|Cold pressor test|
223498227|NCT01794975|DRUG|Placebo|
223498228|NCT01565551|OTHER|N/A (Observational Study)|No Interventions: Observational Study
223498229|NCT04987905|OTHER|Mindfulness|"In the study, for 60 minutes once a week for 8 weeks MIND-BE program will be applied to nurses. The program includes formal and informal practices of mindfulness (Getting started, Introduction to MIND-BE, Noticing the autopilot, Power of attention, Simple awareness, Eating awareness, Body awareness, Breath awareness, Sitting awareness, Stress and reactions, Vision awareness, Challenging emotions and situations in business life, Awareness in business life, Awareness and communication, Awareness and compassion, Developing your own practice)."
223498230|NCT01118923|DIETARY_SUPPLEMENT|Magnesium supplement (magnesium hydroxide/ -oxide)|3 tablets of Mablet (360 mg per tablet) daily for 12 weeks Produced by: Gunnar Kjems APS
223498231|NCT01118923|DIETARY_SUPPLEMENT|Placebo|3 placebo-tablets daily for 12 weeks
223498232|NCT04379180|DRUG|Bosentan Tablets|2mg/kg, bid
223498233|NCT04379180|DRUG|Sildenafil Tablet|1mg/kg, q6h/q8h
223498234|NCT04379180|DRUG|Tadalafil Tablets|1mg/kg, qd
223498235|NCT01620346|PROCEDURE|Intracytoplasmic sperm injection (ICSI)|ICSI is routinely used to treat couples with infertility. Sperm selection in the ICSI group was analysed under a magnification of 400x using an inverted microscope. ICSI was performed in a micro-injection dish prepared with 4 µL droplets of buffered medium (Global® w/HEPES, LifeGlobal, Connecticut, USA) and covered with paraffin oil on a heated stage at 37.0 ± 0.5°C of an inverted microscope.
223498236|NCT01620346|PROCEDURE|Intracytoplasmic morphologically selected sperm injection|IMSI is an established modified ICSI procedure that used an unstained real-time observation of spermatozoa under high-magnification. Sperm selection in the IMSI group is examined at high magnification using an inverted microscope equipped with high-power differential interference contrast optics (DIC/Nomarski). The total calculated magnification is x6.600. The sperm cells exhibiting normally shaped nuclei and normal nuclear chromatin content are selected for injection.
223498237|NCT02821559|DRUG|TOMOX|
223498238|NCT02821559|DRUG|Bevacizumab|Bevacizumab was allowed and used at 7,5 mg/kg or 5 mg/kg every 2 weeks.
223498239|NCT00226733|BEHAVIORAL|Exercise training|Interval exercise training with high intensity five days per week for four weeks.
223498240|NCT00226733|BEHAVIORAL|Exercise training|Exercise training with moderate intensity, five days per week for four weeks.
223498241|NCT01837303|PROCEDURE|Pap smear|"A pap smear/cervical cytology is performed using a spatula and brush to obtain cells from the ectocervical and endocervical region of the cervix. The specimen will be collected twice to put in the standard clinical pap medium and another to put in the study pap medium.~These slides will be processed so that they may be reviewed by a single board certified pathologist.~There are no other interventions or follow up. All participants will undergo the above described procedures. There is no placebo."
223498242|NCT01508897|DRUG|liraglutide|Single dose administered as subcutaneous injection
223590460|NCT00534833|BIOLOGICAL|DTaP-HB-PRP~T vaccine|0.5 mL, Intramuscular
223590461|NCT00534833|BIOLOGICAL|Tritanrix-HepB/Hib™|0.5 mL, Intramuscular
224188660|NCT02046551|DRUG|Placebo|
224188661|NCT03802747|DRUG|Durvalumab|Durvalumab will be dosed at 1500 mg fixed dosing every 4 weeks and continued at this interval until progression or dose-limiting toxicity.
224188662|NCT03802747|DRUG|Durvalumab and Tremelimumab|Durvalumab will be dosed at 1500 mg fixed dosing every 4 weeks and continued at this interval until progression or dose-limiting toxicity. Tremelimumab will be dosed at 75 mg every 4 weeks (same day as durvalumab infusion) for a maximum of 4 doses.
224188663|NCT03802747|DRUG|Y-90 Selective Internal Radiation Therapy (SIRT)|Yttrium-90 microsphere therapy consists of resin beads loaded with Yttrium, a pure beta emitter with a 64.2 hour half-life. Radioembolization will be performed as standard of care therapy per current NCCN guidelines.
224188664|NCT03802747|DRUG|Stereotactic Body Radiation Therapy (SBRT)|High-dose hypofractionated conformal external beam radiation therapy that is considered a standard of care. SBRT will also be considered for metastases that are persistent and/or progressive after Y-90 based on MR imaging and pathology from tissue biopsies.
224188665|NCT02334891|OTHER|Standard|Standard management
224188666|NCT01018680|DRUG|Duloxetine|30 milligrams (mg) taken by mouth, once daily for 1 week, followed by 60 to 120 mg taken by mouth, once daily for 9 weeks.
224188667|NCT01018680|DRUG|Placebo|Taken by mouth, once daily for 10 weeks
224188668|NCT02930889|DEVICE|Prostate Artery Embolization|Prostate Artery Embolization
224188669|NCT05900674|DRUG|Reteplase Injection|To test the single dose of reteplase (9 U) and Maximum dose (18 U) in acute ischemic stroke patients.
224188670|NCT00250731|BEHAVIORAL|telephone support and behavior change|Diabetes self-management education provided over the telephone either for individuals or couples
224188671|NCT00250731|OTHER|Diabetes self-management education|Limited diabetes self-management education provided over the telephone, serves as an enhanced usual care control intervention
224188672|NCT05832073|DRUG|Natural full human monoclonal antibody CBB 1 injection|Active ingredient: natural full human monoclonal antibody CBB 1 containing 0.5 mg / ml per dose (2.5ml) Ingredients: 25 mM citrate buffer, 125 mM sodium chloride, 0.02% (w / v) polysorbate 20 and water for injection
224188673|NCT05832073|DRUG|Rabies Human Immunoglobulin (HRIG)|Active ingredient: Rabid human immunoglobulin
224188674|NCT05832073|DRUG|Natural full human monoclonal antibody CBB 1 injection placebo|Composition: 25 mM citrate buffer, 125 mM sodium chloride, 0.02% (w / v) polysorbate 20 and water for injection
224188675|NCT05832073|BIOLOGICAL|Lyophilized rabies vaccine for human use (Vero cells)|Active ingredient: inactivated rabies virus fixed poison
224188676|NCT04205773|DEVICE|CompuFlo|After priming with 5 mL saline, the catheter was connected to CompuFlo to record the occurrence of pulsatile waveforms and/or their disappearance during its removal
224188677|NCT00387101|DEVICE|Dermal - Living Skin Replacement (Dermal - LSR)|
223498243|NCT01508897|DRUG|liraglutide|Single dose administered as subcutaneous injection
223498244|NCT02874131|BEHAVIORAL|Behavioral Activation|Behavioral activation
223590462|NCT00534833|BIOLOGICAL|Oral Polio Vaccine|0.5 mL, Oral
223590463|NCT03385330|OTHER|LOWER oxygen saturation target group|We will randomize infants with moderate or severe BPD to lower SpO2 target ranges. The study team will then use novel technology to monitor infants starting at randomization, continuing after discharge and until 6 months corrected age, titrating supplemental oxygen to achieve these target SpO2 ranges.
223590464|NCT03385330|OTHER|HIGHER oxygen saturation target group|We will randomize infants with moderate or severe BPD to higher SpO2 target ranges. The study team will then use novel technology to monitor infants starting at randomization, continuing after discharge and until 6 months corrected age, titrating supplemental oxygen to achieve these target SpO2 ranges.
223746002|NCT05774015|DIETARY_SUPPLEMENT|Magnesium Oxide tablet 500 mg|To supplement T2DM with Mg oxide tablets (500 mg total, 302 mg elemental) regardless on their magnesium level
223746003|NCT03623360|DIAGNOSTIC_TEST|Free breathing DCE-MRI|Free breathing DCE-MRI
223746004|NCT01413555|OTHER|Blood Culture QI Program|The Blood Culture QI Program contains four components:(1) education: content knowledge and standardized experiential training on sterile technique designed for ED nurses; (2) process redesign: conversion of blood culture collection from a clean to a sterile technique using the Blood Culture Sterile Kit; (3) a checklist outlining optimal use of the Kit; (4) feedback of blood culture contamination rates to ED nurses who collect them.
224188678|NCT00720668|PROCEDURE|radiofrequency ablation|radiofrequency ablation for HCC
224188679|NCT02366546|DRUG|TBI-1301|TBI-1301(5\*10\^8 or 5\*10\^9) is administered.
224188680|NCT02366546|DRUG|Cyclophosphamide|Cyclophosphamide (750mg/m2/day x 2 days Intravenous (IV)) is administered as pre-treatment medication of TBI-1301.
224188681|NCT02366546|DRUG|Fludarabine|Fludarabine (20mg/m2 x 5 days Intravenous(IV)) is administered as pre-treatment medication of TBI-1301 in combination with cyclophosphamide.
224188682|NCT04277104|OTHER|Closed loop acoustic stimulation|The intervention consists of three consecutive nights of closed loop acoustic stimulation during slow wave sleep. An established closed-loop algorithm is utilized that detects slow oscillations in the electroencephalogram and is programmed to present short tones (50 ms) into their up-states. Tones will be presented via a headband with integrated speakers. The procedure does not wake participants
224188683|NCT04277104|OTHER|Sham acoustic stimulation|Sham acoustic stimulation: participants wear the headband but no stimuli are delivered during slow wave sleep. This ensures that in both the control and the intervention group the conscious experiences are the same.
223498245|NCT02874131|BEHAVIORAL|Cognitive Processing Therapy|Cognitive processing therapy
223498246|NCT06478628|BEHAVIORAL|Inpatient rehabilitation|Inpatient multimodal rehabilitation in specialist health care
223498247|NCT06478628|BEHAVIORAL|Outpatient day rehabilitation|Multimodal rehabilitation in specialist health care with program lasting whole work days
223498248|NCT02785705|BIOLOGICAL|poliovirus vaccine|Different vaccination schedules with bOPV, tOPV and cIPV would be provided for 6 arms respectively.
223498249|NCT00756834|DEVICE|Screening|The MammoDetector™ Pro is a computer-aided software intended to identify and mark regions of interest on standard mammographic views to bring them to the attention of the radiologist after the initial reading has been completed. Thus, the device assists the radiologist in minimizing observational oversights by identifying areas on the original mammogram that may warrant a second review
223498250|NCT02985281|DRUG|Sofosbuvir Oral Product|direct acting antiviral drug for HCV infection
223498251|NCT02985281|DRUG|Ribavirin|antiviral drug for HCV infection
223590465|NCT06377891|OTHER|Emotional Resilience training|Primiparous pregnant women in the experimental group will be given emotional resilience training in the last trimester.
223590466|NCT03005808|DRUG|Ropivacaine|Surgery for appendicitis
224188684|NCT04730024|OTHER|Not applicable(observational study)|Not applicable(observational study)
224188685|NCT04335084|DRUG|Hydroxychloroquine|Prophylaxis treatment for COVID-19
224188686|NCT04335084|DIETARY_SUPPLEMENT|Vitamin C|Prophylaxis treatment for COVID-19
224188687|NCT04335084|DIETARY_SUPPLEMENT|Vitamin D|Prophylaxis treatment for COVID-19
224188688|NCT04335084|DIETARY_SUPPLEMENT|Zinc|Prophylaxis treatment for COVID-19
224188689|NCT00895999|BEHAVIORAL|Interpersonal Therapy for Pain (IPT-P)|IPT-P focuses on improving relationships as a way to improve depression and pain. The patient and therapist work together to improve communication and enhance relationships and social support. Patients choose a problem focus and goal related to both their pain and depression. Up to 8 IPT-P sessions are provided regardless of ability to pay.
224188690|NCT00895999|BEHAVIORAL|Enhanced Support and Connection to Counseling|Research staff connect patients with the Strong Family Therapy Services, Women's Behavioral Health Service, or other appropriate mental health care and reduce potential barriers from making it to the initial appointment. This support includes navigating insurance issues, addressing issues of childcare and transportation, helping to schedule the initial appointment, reminder calls, and follow-up after the scheduled intake. Research staff will also check-in monthly to see if the patients require any additional support to remain in mental health treatment. Up to 8 therapy sessions are covered regardless of ability to pay.
223746005|NCT04051047|DRUG|Gemcitabine|Participants receive a one time IV dose of gemcitabine prior to having standard of care surgery.
224188691|NCT00579605|BEHAVIORAL|Motivational Interviewing|Client-centered strategy that may decrease ambivalence in behavior performance with attention intervention (infant safety) on: a) breastfeeding self-efficacy, b) intended length of breastfeeding, and c) duration of breastfeeding.
224188692|NCT04360538|OTHER|Quality of Life|Physical disability assessment tool
224188693|NCT04360538|OTHER|Impact Event Score|Psychological Sequelae assessment tool
224188694|NCT04360538|OTHER|Hospital anxiety and depression scale|Psychological Sequelae assessment tool
224188695|NCT06220929|DRUG|Mecobalamin|The drug Mecobalamin in the intervention group was divided into intravenous and oral formulations, with the intravenous formulation being used for the first 14 days of the experiment and the oral formulation for the second 14 days.
224188696|NCT06220929|DRUG|Ceftriaxone Sodium|Ceftriaxone sodium all intravenous formulations
224188697|NCT06220929|DRUG|Saline|The saline used in the control group was the same as the saline used in the experimental group to dispense the drug
224188698|NCT06220929|DRUG|Placebo|Placebo and Mecobalamin tablets look and smell the same.
224188699|NCT05965089|BIOLOGICAL|Placebo|Placebo
224188700|NCT05965089|BIOLOGICAL|AX-202|Humanized monoclonal antibody
224188701|NCT02598791|OTHER|IIGI+GIP|Glucose-dependent insulinotropic polypeptide (4 pmol/kg/min) during isoglycemia
223498252|NCT05985551|OTHER|SLND or TAD by the magnetic technique (SPIO)|All patients will receive Radioisotope according to standard of care. They will also receive SPIO in a timeframe of clinical convenience, depending on whether primary response is planned by means of MRI. For patients that are ycN0, SLND or TAD will be performed. For those that convert from cN1 to ycN0, the index lymph node will be marked with a paramagnetic marker. Axillary surgery will be undertaken with the magnetic technique and each retrieved lymph node will be controlled for radiation. Upon the completion of the procedure, a background control will be performed with the radioactive signal as guide, to ensure standard of care best practice. Any palpable lymph nodes that are not sentinels with either tracer may be removed at surgeon discretion but will be reported seperately.
223498253|NCT06252337|OTHER|bioceramic sealer group|epoxy resin based + carrier based technique group. The sealer was inserted in the canal and the carrier was warmed in a dedicated oven (thermaprep) and inserted within 60 seconds.
223498254|NCT03308643|DRUG|Oxytocin|Patients will receive intravenous oxytocin infusion just before the surgery after the induction of general anesthesia.
223746006|NCT04051047|PROCEDURE|Tumor biopsy and blood draw|As part of standard of care, all participants will undergo tumor biopsy and collection of peripheral blood.
223746007|NCT05130931|OTHER|Multimodal conservative treatment|"15 min of Pain education + 20 min of Specific mobilization of the forearm musculature, pronator teres, tendons of the palmar flexors of the wrist and fingers, transverse carpal ligament and palmar fascia through manual mobilization assisted by Diacutaneous Fibrolysis technique + 10min of self-management and explanation of home-based exercise.~3 sessions of 45 minutes will be taken to perform this protocol and the patient will be shown a self-treatment to be performed 3-5 times a day. The protocol will be carried out over 3 weeks (1 session per week)."
223498255|NCT03308643|OTHER|saline|Patients will receive intravenous normal saline infusion just before the surgery after the induction of general anesthesia.
223498256|NCT05804500|BEHAVIORAL|Cardiac Telerehabilitation (CTR) via the RecoveryPlus platform|RecoveryPlus has developed an innovative CTR platform for patients with CVD that leverages: (1) video conferencing functionality (Zoom) for synchronous telehealth sessions of CR instruction for patients and licensed exercise physiologists (EPs), (2) a patient-facing mobile application delivering asynchronous exercise videos, and (3) a health care provider web portal for clinicians and EPs. The RecoveryPlus platform includes the ability for EPs and clinicians to monitor patient clinical data (e.g., heart rate) and input (e.g., rating of difficulty for individual exercises) and tailor individual patient regimens regularly for increased safety and optimal outcomes.
224188702|NCT02598791|OTHER|IIGI+GLP-1|glucagon-like peptide-1 (1 pmol/kg/min) during isoglycemia
224188703|NCT02598791|OTHER|IIGI+NaCl (placebo)|i.v. NaCl during isoglycemia
224188704|NCT02598791|OTHER|OGTT|50 g oral glucose tolerance test
224188705|NCT02598791|OTHER|IIGI+GIP+GLP-1|i.v infusion of GIP and GLP-1 (4 + 1 pmol/kg/min) during isoglycemia
224188706|NCT00403429|DRUG|capecitabine|
224188707|NCT02662348|DRUG|Recombinant Human Interleukin-2|Given SC
224188708|NCT02662348|DRUG|HER2Bi-Armed T Cells|Given IV
224188709|NCT01301157|DRUG|M518101|Proper quantity twice a day
224188710|NCT01301157|DRUG|placebo|Proper quantity twice a day
224188711|NCT01301157|DRUG|Dovonex|Proper quantity twice a day
224188712|NCT01194765|OTHER|Distance-based Cognitive Behavioural Therapy|Participants will engage in cognitive behavioural therapy to treat high anxiety sensitivity. Treatment will be delivered over the telephone.
224188713|NCT03503565|PROCEDURE|intraoperative neuromuscular blockade|The intensity of intraoperative neuromuscular blockade
224188714|NCT04738799|BEHAVIORAL|Carbohydrate-Last Meal Sequence|Carbohydrates consumed last during mealtimes for 6 days
224188715|NCT04738799|BEHAVIORAL|Carbohydrate-First Meal Sequence|Carbohydrates consumed first during mealtimes for 6 days
224188716|NCT01347827|DEVICE|measurements of brain tissue oxygenation|different monitors((the Hutchinson InSpectra™ StO2 Tissue Oxygenation Monitor) and in cerebral (ForeSight® Cerebral Oximeter and the Somanetics INVOS® Cerebral Oximeter ) and renal tissue (the Somanetics INVOS® Cerebral Oximeter)of brain tissue oxygenation with each other, and assess the correlation between brain tissue oxygenation and oxygenation measurements in renal and muscular tissue, as well as with conventional hemodynamic and metabolic variables, such as central venous oxygen saturation
224188717|NCT01347827|DEVICE|measurements of brain tissue oxygenation|different monitors((the Hutchinson InSpectra™ StO2 Tissue Oxygenation Monitor) and in cerebral (ForeSight® Cerebral Oximeter and the Somanetics INVOS® Cerebral Oximeter ) and renal tissue (the Somanetics INVOS® Cerebral Oximeter) of brain tissue oxygenation with each other, and assess the correlation between brain tissue oxygenation and oxygenation measurements in renal and muscular tissue, as well as with conventional hemodynamic and metabolic variables, such as central venous oxygen saturation
224188718|NCT02181543|DRUG|Clonidine|1μg/Kg, IV (in the vein) intraoperative. Number of Cycles: single dose.
224188719|NCT03803371|DRUG|Ultracet Tablets|Ultracet tablet (Janssen Cilag Farmacêutica Ltda) equivalent to Tramadol hydrochloride 37.5 mg/Paracetamol 325 mg
224188720|NCT03803371|DRUG|Tramadol hydrochloride 37.5 mg/Paracetamol 325 mg tablets - tablet (Pfizer)|Tramadol hydrochloride 37.5 mg/Paracetamol 325 mg tablets (Pfizer)
224188721|NCT05469711|DEVICE|PlayPhysio|The gamification will be switched on at day 28 for the participants in arm 1. The trial will run for a further 84 days with the mid-point review half way through this section of the trial.
224309261|NCT03717025|PROCEDURE|MINI PUNCH GRAFTING|"1. Recipient area is prepared first after shaving and cleaning with surgical spirit. 2 % lignocaine with or without adrenalin will be infiltrated as local aneasthetic.~2. The punched out chambers are spaced at a gap of less than 5 mm (preferably 2 - 2.5 mm) from each other.~3. The donor area is either upper lateral portion of thigh or gluteal region.~4. Grafts are placed directly from donor to the recipient area. Care is taken, so that graft edges are not folded, the tissue is not crushed or placed upside down.~5. Hemostasis is achieved by pressing a saline soaked gauze piece over the area.~6. For the recipient area 3 layers of dressing from inside out are : paraffin embedded non adherent sterile gauze, sterile surgipad, and micropore.~7. For the donor area only surgipad and micropore are used.~8. Immobilisation of recipient area is advised along with antibiotics and analgesics till removal of dressing (after 4-7 days)."
224309262|NCT03717025|PROCEDURE|NON CULTURED EPIDERMAL CELL SUSPENSION|"1. About one-tenth the size of recipient area is selected as the donor site.~2. Split thickness skin graft is taken under aseptic precautions with the help of a shaving blade held firmly by a straight artery forceps.~3. The area is dressed with Bactigras gauze.~4. Split thickness skin specimen is transferred under aseptic conditions to a container with Normal Saline and transferred to laboratory for preparing suspension.~5. Recipient site is dermabraded under aseptic precautions until tiny pinpoint bleeding spots are seen.~6. Epidermal cell suspension is carefully transferred to a tuberculin syringe.~7. With 18 gauge needle attached to this syringe, suspension is spread evenly on dermabraded recipient site.~8. This is then covered with Collagen dressing, followed by bactigras, guaze and tegaderm dressings from inside to outside.~9. The patient is observed for 2 hours after performing the procedure and given antibiotics and analgesics for 5-7 days till dressing removal."
224309263|NCT03552835|PROCEDURE|no caries removal|occlusal caries were treated with no caries removal and placement of stainless steel crown
224188722|NCT03123627|DRUG|New profilaxis|Primary endpoint: incidence of CMV disease at 12 months after transplantation. Study the predictive value of the assay of CD8 + T cell immunity specific for defined CMV-patients in which they can stop prophylaxis. The definition of CMV disease was based on those recommended by the American Society of Trasnplantation for use in clinical trials (Humar A. Am J Transplant 2006; 6:262-74) criteria.
224309264|NCT03552835|PROCEDURE|partial caries removal upto soft dentin|occlusal caries were treated by partial caries removal upto soft dentin followed by Glass Ionomer Cement placement as a base and composite restoration
224309265|NCT03552835|PROCEDURE|partial caries removal upto firm dentin|occlusal caries were treated by partial caries removal upto firm dentin followed by Glass Ionomer Cement placement as a base and composite restoration
224309266|NCT04023162|BEHAVIORAL|Graded Activity|Active participation of participants, Overcoming and eliminating negative behaviors, Encouraging positive behavior in pain, Overcoming the fear of the movement, Motivation to implementation pre-set specific goals.
224309267|NCT04023162|BEHAVIORAL|Group-based Therapy Exercise|Aerobic exercise, Stretching exercise and flexibility, Range of motion, Balance and coordination, Breathing exercises Stabilization exercise Muscle strength training exercise
224309268|NCT04023162|BEHAVIORAL|Back School|Basic information of Low Back Pain - anatomy, physiology, causes, treatment. Correct postures - standing, sitting, driving, sleeping, Correct body movements - lifting, pushing, walking.
223498257|NCT04389138|OTHER|Physiotherapy Intervention|Physiotherapy intervention will include an assessment to identify individual areas that physiotherapy should target. Intervention will be based on the core areas recommended by the European Physiotherapy Guideline for Parkinson's Disease: physical capacity (muscle power, tone, joint range of movement, exercise tolerance and pain), transfers, manual dexterity, balance and gait. Posture is incorporated as part of these 5 core areas. The intervention will be delivered over 4 visits.
224188723|NCT03123627|DRUG|Profilaxis recommended|Secondary end points: percentage of patients developing T cell immunity in CMV-specific transplantation after receiving timoglubulina induction and valganciclovir prophylaxis. T cell development inmnunidad CD8 + CMV-specific is defined as production of γ\> 0.2 interferon by CD8 + T cells stimulated by CMV-specific CMV antigens (QF reagent).
224188724|NCT05614544|DRUG|HSK3486|HSK3486 for induction of general anesthesia
224188725|NCT05614544|DRUG|Propofol|Propofol for induction of general anesthesia
224188726|NCT05614544|DRUG|Placebo|Intralipid
224188727|NCT04551326|OTHER|manual hamstring stretching|Participants' lower limb will be positioned in maximal hip flexion and gradually moved to maximal knee extension by physical therapist. The procedure will take one minute for each lower limb.
224188728|NCT00116610|DRUG|picoplatin|
224309269|NCT05043844|DEVICE|abdominal binder|Wearing an abdominal binder postoperatively
224309270|NCT01838668|DRUG|Placebo|Two placebo capsules orally BID
224309271|NCT01838668|DRUG|dimethyl fumarate|Two dimethyl fumarate 120mg capsules orally BID
224309272|NCT05144490|OTHER|Exercise|A single session of bodyweight exercise
224309273|NCT06361979|DRUG|SHR-A1811|SHR-A1811: intravenous
223746008|NCT06516991|DEVICE|Temporal Interference Stimulation|"Specific electrode sites are customized for the subject through magnetic resonance scanning, the deep nucleus cluster to be stimulated-nucleus accumbens is calibrated through electric field simulation before treatment, and the stimulation target can be accurately positioned by stimulating the specific electrode sites of the subject during treatment.~During the treatment period, all subjects were treated with a fixed time interference stimulation (TI) device at a frequency of 30 minutes twice a day, 5 days a week, for a total of 10 treatments. The output current intensity during treatment is 3.64 mA+4.36 mA."
224188729|NCT02848781|DEVICE|Implantable Cardioverter Defibrillator (ICD)|An ICD is a battery-powered device placed under the skin that keeps track of heart rate. Thin wires connect the ICD to the heart. If an abnormal heart rhythm is detected, the device will deliver an electric shock to restore a normal heartbeat.
224188730|NCT02848781|PROCEDURE|Catheter Ablation|Catheter ablation is a procedure that uses radiofrequency energy to destroy a small area of heart tissue that is causing rapid and irregular heartbeats. Destroying this tissue helps restore the heart's regular rhythm.
224188731|NCT05368376|DRUG|Labetalol Hydrochloride Oral Tablet|Labetalol 200 mg
224188732|NCT05368376|DRUG|Metoprolol Tartrate Oral Tablet|Metoprolol 100 mg
224188733|NCT02950727|DEVICE|3 bicortical screws|after mandibular bilateral sagittal split ramus osteotomy surgery is performed in the first group the osteotomy will be fixed using 3 bicortical screws
224188734|NCT02950727|DEVICE|adjustable plate and 2 bicortical screws|after mandibular bilateral sagittal split ramus osteotomy surgery is performed in the second group the osteotomy will be fixed using adjustable plate and 2 bicortical screws
224188735|NCT04001166|OTHER|Non-interventional study|This is a non-interventional study. Patients will be treated with any treatment deemed appropriate by the patient's physician.
224188736|NCT02248272|OTHER|Isocaloric diet with 3 meals|Isocaloric diet with 3 meals in order to maintain volunteers' weight, tailored to individual energy needs, with the same macronutrient composition. The volunteers were free to choose the foods they used to consume before. However, in order to assist them to adapt to the different meal frequency, individualized instructions were given to all volunteers before their entry to the study. An example of a 7-day diet menu was prescribed for both diet programs and analytical food exchange lists of different food groups were also provided.
224188737|NCT02248272|OTHER|Isocaloric diet with 6 meals|Isocaloric diet with 6 meals in order to maintain volunteers' weight, tailored to individual energy needs, with the same macronutrient composition. The volunteers were free to choose the foods they used to consume before. However, in order to assist them to adapt to the different meal frequency, individualized instructions were given to all volunteers before their entry to the study. An example of a 7-day diet menu was prescribed for both diet programs and analytical food exchange lists of different food groups were also provided.
224188738|NCT01407627|DIETARY_SUPPLEMENT|Fructose|"Subjects will be randomized to one of 2 sequences:~Sequence 1: Fructose (intervention) 200g daily x 14d followed by Dextrose (control) 200g daily x 14d Sequence 2: Dextrose (control) 200g daily x 14d followed by Fructose (intervention) 200g daily x 14d"
224188739|NCT03374774|DRUG|BIAsp 30|Participants will receive commercially available BIAsp 30 according to routine clinical practice. The physician will determine the starting dose and any potential later change to the dose.
224188740|NCT02119858|DRUG|indocyanine green solution|Given transperineally
224188741|NCT02119858|OTHER|diffuse optical imaging|Undergo near infrared fluorescence imaging
224188742|NCT02119858|PROCEDURE|robot-assisted laparoscopic surgery|Undergo robot-assisted laparoscopic radical prostatectomy
224188743|NCT02119858|PROCEDURE|therapeutic lymphadenectomy|Undergo lymphadenectomy
224188744|NCT06446427|OTHER|Acute high altitude exposure|"Thirty minutes after arrival at the Research Station Jungfraujoch by train, a simulated scenario of patient care (intervention 1, high altitude at 3450 masl) is performed."
224188745|NCT06446427|OTHER|Acute high altitude exposure, with supplementary oxygen|"4 hours after arrival at the Research Station Jungfraujoch by train, a simulated scenario of patient care (intervention 2, high altitude at 3450 masl) is performed, while the participants receive 4 litres / minute of oxygen via nasal route."
224188746|NCT06446427|OTHER|Subacute high altitude exposure, after having spent a night at high altitude|"After having spent a night at the Research Station Jungfraujoch, a simulated scenario of patient care (Intervention 3, high altitude at 3450 masl) is performed."
224188747|NCT01370291|OTHER|active Risperidone and active rTMS|active Risperidone:------- active rTMS:auditory hallucinations:low-frequency(1Hz)applied over the left temporoparietal cortex(LTPC) negative symptoms:high-frequency（10Hz）applied over the left temporoparietal cortex(LTPC)
224188748|NCT01370291|OTHER|active rTMS and sham Risperidone|active Risperidone:------- ; active rTMS:auditory hallucinations:low-frequency(1Hz)applied over the left temporoparietal cortex(LTPC); negative symptoms:high-frequency（10Hz）applied over the left temporoparietal; cortex(LTPC)
224188749|NCT01370291|OTHER|sham rTMS and active Risperidone|active Risperidone:------- ; active rTMS:auditory hallucinations:low-frequency(1Hz)applied over the left temporoparietal cortex(LTPC); negative symptoms:high-frequency（10Hz）applied over the left temporoparietal; cortex(LTPC)
223746009|NCT00306605|BEHAVIORAL|Questionnaire|Participants will be asked to complete a questionnaire 3 times throughout the first 5 weeks after their infant's birth / hospitalization
223746010|NCT02187601|DEVICE|MPBA System|MPBA is the new generation Multi Purpose Breath Analyzer
223498258|NCT03873688|OTHER|expiratory muscle training|The intensity of training will been determined after assessment of maximal expiratory pressure (MEP). The first training session will perform under the supervision of a physiotherapist, patients will perform training at home. MEP measurement will reevaluate every two weeks and the intensity of training will set according to MEP levels.
223498259|NCT04190095|DEVICE|Motion Tracking in VR|Participant will wear motion sensors and VR devices
223746011|NCT02187601|DEVICE|BreathID|BreathID is the name of the original Exalenz breath analyzer system
223498260|NCT04190095|BEHAVIORAL|VR Interaction|Participant will perform VR interaction task
223498261|NCT04834115|DRUG|Ivermectin Tablets|Oral ivermectin at a one time dose
223746012|NCT05513495|OTHER|The effect of drip versus intermittent feeding on splanchnic oxygenation|After preterm delivery the infants were randomly assigned to one of two feeding modalities: drip (3-hour continuous) or intermittent (bolus in 10 minutes).
223746013|NCT05281991|DEVICE|Doppler ultrasonography|color flow Doppler ultrasonography
224188750|NCT05486975|BIOLOGICAL|CT0591CP Cells|CT0591CP cells
224188751|NCT01146340|RADIATION|Hypofractionated radiotherapy|40 Gy / 5 fractions / 29 days
224188752|NCT02027831|DRUG|Indocyanine Green|
223498262|NCT04834115|OTHER|Placebo|Oral placebo at a one time dose
223498263|NCT04135001|BEHAVIORAL|HBM Training|A computer-based training to reduce hostile bias and interpersonal conflict as a mechanism to improve trust and cohesion within an operational military unit across the deployment cycle. The computer training is based on the Go/No-Go task (Fillmore et al., 2006) and Lexical Decision Task (Lepore \& Brown, 2002). The training reduces HAB by affecting two cognitive mechanisms: prime seeking non-hostile concepts when presented with ambiguous cues and conditioning inhibition in response to hostile cues. Thus, the training induces a non-hostile attribution bias while simultaneously training the inhibition of hostile attribution bias and aggressive behavior in response to ambiguous cues.
223498264|NCT04135001|OTHER|Placebo Training|Volunteers in the placebo condition will be told to complete the fragments with the first word that comes to mind. This placebo still exposes volunteers to the training stimuli and computer task, but does not train inhibition or selectively prime non-hostility, which are the hypothesized mechanisms of the training.
223498265|NCT04034680|OTHER|TIME|The intervention of the TIME model includes two hours of lectures about dementia and NPS and three hours of training and roleplay in using TIME. The staff of the home care service will receive the TIME manual and access to the TIME website with access to additional educational materials. From each municipality, three staff members called TIME administrators, will receive additional three hours of lectures and roleplay in TIME, and will thereafter have the responsibility for performing the intervention.
223498266|NCT04034680|OTHER|Education-only intervention|Staff in the home care service in municipalities in the control group will receive thesame two hours lectures about dementia and NPS as the intervention grorp. After the cluster RCT pilot study is ended, municipalities in the control group will receive the same three-hour lessons in the TIME as the intervention group of municipalities.
223498267|NCT05665842|OTHER|Music Application|The Introductory Characteristics Form for Adolescents, the PedsQL and AIQ will be applied. After, the predetermined instrumental music will be shared with the adolescents every evening for 15 days via social media by the researcher and participants will be asked to listen to these music. Participants will listen to the instrumental music sent by the researcher for at least 20 minutes every evening during the music application. This whole process will be reminded to the adolescents with messages every evening and they will be asked to listen the music before the normal bedtime (before 23:00 at night). At the end of the music application (after 15 days), the Introductory Characteristics Form for Adolescents, the PedsQL and AIQ will be reapplied. In the music application, the selecting instrumental music will be used. To determine the music, the researcher will be advice received from the TÜMATA and the a music education expert.
223746014|NCT05281991|DEVICE|Tsui test|The stimulator is set at frequency of 1Hz with 0.2 msec pulse width and the current output ranging from 0 to 20 mA. The current output will be carefully increased from zero until motor activity is detected up to a maximum of 20 mA.
224188753|NCT01546701|DRUG|Buprenorphine|2 mg sublingual tablet
224188754|NCT01546701|DRUG|Morphine|0.1 mg/kg IV morphine
224188755|NCT01967810|DRUG|ANG1005|ANG1005 at a starting dose of 650 mg/m\^2 or 600 mg/m\^2 by intravenous infusion once every 3 weeks
224188756|NCT01967810|DRUG|Bevacizumab|For participants enrolled in the bevacizumab-refractory recurrent GBM arm (Arm 2), treatments with bevacizumab may be continued and administered every 2 or 3 weeks at the Investigator's discretion.
224188757|NCT01831297|DEVICE|measurement of blood pressure|measurement of pulse wave velocity
224309274|NCT06361979|DRUG|Bevacizumab|Bevacizumab:intravenous
223746015|NCT04675203|PROCEDURE|Tooth extraction|Tooth extraction
223746016|NCT03886012|DEVICE|Otoband|The Otoband will be used by participants during migraine associated vertigo (MAV). We expect the research subjects to use the device for at least 20 minutes, with the hardware limiting any one session to a duration of 30 minutes, up to 4 times per calendar day. The Otoband will be set to the effective power level during the course of a given calendar day.
223746017|NCT03886012|DEVICE|Otoband sham|The Otoband will be used by participants during migraine associated vertigo (MAV) for a maximum of 30 minutes, up to 4 times per calendar day. The Otoband will be set to an ineffective power level (considered a sham device) during the course of a given calendar day.
224188758|NCT02922231|BIOLOGICAL|RIXUBIS|Recombinant Factor IX (rFIX) for intravenous use
224188759|NCT05473546|OTHER|ARTIFICIAL NUTRITION|ARTIFICIAL NUTRITION
224188760|NCT05744635|DRUG|Tacrolimus|Tacrolimus received as part of routine clinical care
224188761|NCT03863821|DEVICE|HHHFNC|"HHHFNC setting:~1. Flow rate: 40L/min~2. FiO2: 0.4~HHHFNC will use immediately before 6MWT and remove at the end of 6MWT"
224188762|NCT00233675|DRUG|GABITRIL (tiagabine hydrochloride; CEP-6671)|
224188763|NCT02404675|DRUG|icotinib|
224188764|NCT04066842|OTHER|Observation|Evaluation of Vitamin D levels and correlation of Vitamin D levels level with periodontal and cardiovascular disease
224188765|NCT02989259|DRUG|Apatinib|apatinib 500mg p.o. qd
224188766|NCT04441437|BEHAVIORAL|Task-oriented training with a dynamic hand splint|In addition to conventional rehabilitation programs (therapy-as-usual), the subject in the splint group received 1-hour task-oriented training with wearing a customized dynamic hand splint, totally 15 times in a duration of one month. The content of task-oriented training contained picking cubes from side to side with three-jaw grasp, lifting the cone to the shoulder height with the cylindrical grip and an extended elbow, picking up pegs and inserting it into the hole with palmar pinch, and grasping a soap to simulate wiping the body. Among the four tasks, two were chosen to train the subjects according to the abilities of subjects.
224309275|NCT04091659|OTHER|Virtual Reality Education|Virtual Reality Education (Intervention): The experimental group of libraries will receive the virtual reality simulation, which is guided by the NLN Jeffries Simulation Theory, and lasts 9 minutes. The virtual reality education is based on scenes and dialogue conducted during the hybrid high-fidelity simulation, from a script developed using the existing hybrid simulation on opioid overdose intervention. This virtual reality education is an educational intervention.
224188767|NCT04441437|BEHAVIORAL|Task-oriented training without a dynamic hand splint|In addition to conventional rehabilitation programs (therapy-as-usual), the subject in the no-splint group received 1-hour task-oriented training, totally 15 times in a duration of one month. The content of task-oriented training contained picking cubes from side to side with three-jaw grasp, lifting the cone to the shoulder height with the cylindrical grip and an extended elbow, picking up pegs and inserting it into the hole with palmar pinch, and grasping a soap to simulate wiping the body. Among the four tasks, two were chosen to train the subjects according to the abilities of subjects.
224188768|NCT00544349|BIOLOGICAL|cetuximab|
224188769|NCT00544349|DRUG|fluorouracil|
224188770|NCT00544349|DRUG|leucovorin calcium|
224188771|NCT00544349|DRUG|oxaliplatin|
224188772|NCT02845037|DRUG|BIA 5-453|BIA 5-453 Gelatine capsule for oral administration (1, 10 or 20 mg). Single oral doses of BIA 4-543 2 mg, 10 mg, 20 mg, 50 mg, 100 mg, 200 mg, 400 mg, 600 mg, 900 mg and 1200 mg were administered to subjects in fasting conditions.
224188773|NCT02845037|DRUG|Placebo|Placebo Gelatine capsule for oral administration. The composition of the placebo is qualitatively the same but without BIA 5-453 pharmaceutical active ingredient (API).
224188774|NCT06104774|BEHAVIORAL|Tai Chi Exercise|The experimental group will receive Tai Chi exercise and routine treatment after the operation, and after discharge from the hospital, they will perform Tai Chi exercise three times a week, 50 minutes each time, for a total of eight weeks after discharge.
224188775|NCT06501625|DRUG|Ivosidenib|Two 250 mg tablets, totaling 500 mg, administered orally once daily, taken continuously throughout treatment duration
224188776|NCT06501625|DRUG|Durvalumab (for the first 8, 21-day, cycles)|1500mg intravenous (IV) infusion every 3 weeks, for a maximum of 8 (21-day) cycles
223498268|NCT05665842|OTHER|Sleep Hygiene Training|"After explaining the purpose of the study and the way it was applied to the adolescents in the music practice group, the Introductory Characteristics Form for Adolescents, the Pediatric Quality of Life Inventory (PedsQL) and Adolescent Insomnia Questionary (AIQ) will be applied.~Adolescents in this group will be trained on Zoom for 4 weeks, 2 times a week, for 8 sessions (1 session 40 min). Sleep hygiene training prepared based on expert opinions and literature (Halal \& Nunes, 2014; Dinis \& Bragança, 2018; İşsever et al., 2021) will be given by the researcher. A Sleep Hygiene Training Booklet will be prepared for use in education and to give to adolescents after education.The Sleep Hygiene training booklet to be prepared will be prepared by the researcher and submitted for expert opinions. Adolescents who received sleep hygiene training will be reapply 15 days after the training, with the PedsQL and AIQ."
223498269|NCT00823888|DEVICE|pneumatic brace|pneumatic knee brace with three trial conditions: air bladders inflated at 0psi, 7 psi, and 12 psi
223498270|NCT00195429|DRUG|Tacrolimus|
223498271|NCT00195429|DRUG|Sirolimus|
223498272|NCT00195429|DRUG|prednisone|
223498273|NCT03713788|OTHER|Cold pressor test|Participants placed their non-dominant hand into cold water for 2 minutes
223498274|NCT01535066|PROCEDURE|acupuncture therapy|Receive acupuncture
223590467|NCT01972789|DRUG|Ranibizumab|Ranibizumab solution for injection is commercially supplied in two presentations: as a pre-filled syringe (containing 1.65 mg of ranibizumab in 0.165 mL solution) and as a vial (containing 2.3 mg of ranibizumab in 0.23 mL solution) corresponding to a recommended dose of 0.5 mg (0.05 mL) given as a single intravitreal injection. It will be prescribed and administered by the investigator or designee
224188777|NCT06501625|DRUG|Gemcitabine (for the first 8, 21-day, cycles)|1000 mg/m2 IV infusion on days 1 and 8 of every 21-day cycle, for a maximum of 8 cycles
223498275|NCT01535066|PROCEDURE|sham acupuncture|Receive sham acupuncture
223498276|NCT05016050|DEVICE|HPDT-DA-013|Digital program with therapeutic interventions based on Cognitive Behavioral Therapy (CBT).
224188778|NCT06501625|DRUG|Cisplatin (for the first 8, 21-day, cycles)|25 mg/m\^2 IV infusion on days 1 and 8 of every 21-day cycle, for a maximum of 8 cycles
224188779|NCT06501625|DRUG|Durvalumab (starting from cycle 9)|1500mg intravenous (IV) infusion every 4 weeks, starting from cycle 9. Cycles are 28 days long, starting Cycle 9.
224188780|NCT06501625|DRUG|Ivosidenib Recommended Combination Dose (RCD)|RCD administered orally once daily, taken continuously throughout treatment duration
224188781|NCT03160131|DEVICE|Neuro Vision Technology|Training using Neuro Vision Technology
223498277|NCT00477217|DRUG|Zoledronic acid|
223498278|NCT00373711|DRUG|Iodine-124|2 mCi, oral
223498279|NCT00373711|DRUG|Iodine-123|2 mCi, oral
223498280|NCT00373711|DRUG|F-18 FDG|10-15 mCi, iv
223498281|NCT03313765|BEHAVIORAL|Motivational interviewing (MI)|Brief MI intervention
223498282|NCT03313765|OTHER|Standard-of-care|Standard-of-care education and counseling
223498283|NCT01495728|PROCEDURE|Thrust Manipulation - Thoracic Spine|Mid and Upper Thoracic Spine
224188782|NCT04450420|OTHER|Simulation based curriculum|See arm/group description
224188783|NCT04450420|OTHER|Standard training|See arm/group description
224188784|NCT06023472|DEVICE|microfluidic chip|Microfluidic chip method has been used for sperm sorting in order to select the most motile and morphologically normal sperm for use in assisted reproductive technologies (ART) such as in vitro fertilization (IVF) and intracytoplasmic sperm injection (ICSI).
223498284|NCT01495728|PROCEDURE|Sham Manipulation|Mid and Upper Thoracic Spine
223498285|NCT04775134|DIAGNOSTIC_TEST|Lung biopsy|Biopsy of residuary material from a medically indicated pulmonary resection
223498286|NCT00156130|RADIATION|Conventional radiotherapy schedule|50 Gy in 25 fractions over 35 days
223498287|NCT00156130|RADIATION|Accelarated radiotherapy schedule|42.5 Gy in 16 fractions over 22 days
223511899|NCT01008046|DRUG|combined metformin-CC|Patients received metformin HCl (1500 mg daily) for 5-6 weeks from the 1st day of spontaneous or induced menstruation, followed by 100 mg CC for 5 days starting from day 3 of spontaneous or induced menstruation. With persistent anovulation,CC increased by 50 mg for the next cycle. Treatment continued for three successive cycles
223590468|NCT03605290|DIAGNOSTIC_TEST|REHAGAIT ANYLIZER|Gait analysis instrumentation
223590469|NCT00859742|PROCEDURE|EBUS-TBNA, integrated PET/CT|EBUS-TBNA and integrated PET/CT will be performed for patients with non-small cell lung cancer after induction therapy. PET/CT will be performed before EBUS-TBNA. Negative findings of EBUS-TBNA will be evaluated by surgery.
223498288|NCT05219344|PROCEDURE|Tissue flossing|After the standardized warm-up, participants will be instructed to stand still with their legs shoulder-width apart. The floss band (1.3 mm thick, 50 mm wide, 2 meters long, and strength level 3), consisting of a thick elastic latex band (COMPRE Floss, Sanctband), will be applied bilaterally around the distal third of the thigh. The applied pressure will be individualized by thigh circumferences, whereas low target pressure was chosen for this study, showing potential to elicit the most beneficial outcomes following flossing. The pressure will be monitored by the PicoPress device, which was placed at the middle distance of the application of the floss band to ensure that the entire surface of the pressure sensors was always completely covered. The flossing will be applied for 2 minutes with 2 minutes rest between sets. During flossing application subjects will be instructed to conduct 10 deep squats followed by 15 repetitions of knee extensions without added weight.
223498289|NCT02892708|PROCEDURE|Surgery|partial or complete resection followed by radiotherapy
223498290|NCT02892708|RADIATION|radiotherapy|radiotherapy after a brain biopsy
223498291|NCT02965131|PROCEDURE|Temporary portocaval shunt|The hepatic artery, bile duct, and portal vein are dissected and clamped. The retrohepatic vena cava is preserved with selective clamping of the hepatic veins during total hepatectomy. Then, temporary portocaval shunt is constructed by end-to-end anastomosis of the portal vein stump to the middle and left hepatic vein trunk or by end-to-side anastomosis of the stump to the infrahepatic vena cava depending on the remaining length of the vessels.
223498292|NCT02352142|OTHER|Full Term EEG|Full-term infants assigned to this arm of the study will receive one sleep EEG (one hour in duration). These EEGs will be used as healthy control comparisons to those of premature infants at 40 weeks.
223498293|NCT02352142|BEHAVIORAL|Facilitated Infant Care|Family Nurture Intervention is facilitated by specially trained Nurture Specialists. The intervention involves calming interactions between mother and infant in the isolette via odor exchange, firm sustained touch and vocal soothing, through calming interactions during holding and feeding via the Calming Cycle and through family sessions designed to engage the help and support of family members for the mother.
223498294|NCT04956965|RADIATION|Cardiac electro-mapping|Perform an high-resolution three-dimensional maps of cardiac electrical activity using EnSite Precision system.
223498295|NCT05372939|DRUG|AMT-101 (oral)|AMT 101 is orally administered biological therapeutic taken once daily
223498296|NCT05372939|OTHER|Placebo (oral)|Orally administered placebo comparator taken once daily
223498297|NCT05372939|COMBINATION_PRODUCT|Humira (adalimumab)|Humira comparator is administered subcutaneously, on Humira frequency schedule.
223498298|NCT05811975|DRUG|KSX01-TCRT injection|individualization TCR-T cell injection
223498299|NCT02541903|DRUG|Gilotrif|Patients will take a single oral dose of Gilotrif each day starting at 40 mg. Dose escalation and reductions can occur.
223498300|NCT02019251|DRUG|perfluorinated gas/oxygen mixture|Subjects are imaged with MRI one time with the use of perfluorinated gas / oxygen mixtures as an MRI contrast agent for lung function.
223498301|NCT02019251|DEVICE|MRI|
223498302|NCT02080078|DRUG|Theophylline|
223590470|NCT01493856|DRUG|Cresto|tablet, rosuvastatin 20mg
223590471|NCT01493856|DRUG|Olmetec|tablet, olmesartan medoxomil(CS-866) 40mg
223746018|NCT00271609|DRUG|Bevacizumab|10 mg/kg intravenously over 90 minutes every 2 weeks on a 28 day cycle. First dose is given over 90 minutes and subsequent doses are given over 30 minutes.
223746019|NCT00369551|RADIATION|3-dimensional conformal radiation therapy|Undergo 3-dimensional conformal radiation therapy
223498303|NCT02080078|DRUG|Erlotinib|
223498304|NCT00696566|DRUG|Clopidogrel and Rifampicin|"Clopidogrel: loading dose of 600 mg, then 75 mg o.d. for up to 28 days~Rifampicin: 300 mg b.d. for up to 28 days"
223498305|NCT06407440|OTHER|control|There will be no interference ergonomics training
223498306|NCT06407440|OTHER|exercise|upper extremity strengthening exercises upper extremity stretching exercises ergonomics training posture training relaxation exercises
223498307|NCT06404528|OTHER|Blood glucose stress combined with low-dose chemotherapy|By controlling the patient's blood sugar, low-dose chemotherapy is used in a hypoglycemic state. Some necrotic tumor cells produced by chemotherapy can maintain their immunogenicity, further activate innate immunity, produce very strong anticancer effects, and have no cytotoxic reactions to chemotherapy.
223498308|NCT04645706|OTHER|Characteristics of innate T cells|functional and phenotypic characteristics of innate T cells
223498309|NCT04517539|DRUG|rhGM-CSF，Peginterferon alfa-b2，radiation|"Radiation:~If there are two measurable lesions totally, One lesion received radiotherapy for 30 Gy in 5 fractions and rested for one week; If there are three measurable lesions totally, two lesion received radiotherapy for 30 Gy in 5 fractions separately.~drug: Patients were injected subcutaneously rhGM-CSF 125mg/m2 per day from day1 to day 14, every three weeks, concurrent with radiotherapy. Peginterferon alfa-b2 90 ug in d8 in each cycle.~And the 1 month after the end of all radiotherapy courses, 4 weeks as a course of treatment, once per course of treatment, each dose is 90μg until desease progress."
223498310|NCT00363168|DRUG|Ranibizumab|0.3 mg/0.05 ml dose
223498311|NCT00363168|DRUG|Ranibizumab|0.5 mg/0.05 ml dose
223746020|NCT00369551|DRUG|paclitaxel|Given IV
223498312|NCT05303285|DRUG|Secukinumab 300mg s.c.|Induction: 5 x 150 mg secukinumab s.c. weekly. Maintenance: 300 mg secukinumab s.c. every 4 weeks
223590472|NCT01493856|DRUG|DWJ1276|tablet, Rosuvastatin 20mg and olmesartan medoxomil 40mg
223590473|NCT01877889|DRUG|Canagliflozin|One 300 mg over-encapsulated tablet taken orally (by mouth) once daily for 4 days during Part 1 and Part 2 (Sequence 1 \[treatment period 2\] or Sequence 2 \[treatment period 1\]).
223590474|NCT01877889|DRUG|Dapagliflozin|One 10 mg over-encapsulated tablet taken orally once daily for 4 days during Part 2 (Sequence 1 \[treatment period 1\] or Sequence 2 \[treatment period 2\]).
223590475|NCT03033199|DRUG|Probiotic Agent|probiotic capsules containing three viable and freezedried strains-Lactobacillus acidophilus,Lactobacillus casei, and Bifidobacterium bifidum：2 capsules, bid x 4 weeks for one cycle. It will be given for one or two cycles.
223746021|NCT00369551|BIOLOGICAL|bevacizumab|Given IV
223746022|NCT00369551|DRUG|carboplatin|Given IV
223746023|NCT00369551|OTHER|laboratory biomarker analysis|Correlative studies
223746024|NCT03391596|BEHAVIORAL|Internet-based ACT intervention|The Internet-based ACT intervention is a 12-week program based on the processes of Acceptance and Commitment Therapy.
224188785|NCT06023472|DEVICE|density gradient centrifugation|Density-gradient centrifugation is a commonly used method for sperm separation and purification. It is a technique that involves layering a semen sample on top of a gradient of different densities of a solution, typically a mixture of colloidal silica and sucrose, and then centrifuging the sample. The centrifugal force causes the sperm to migrate through the gradient, where they become separated based on their density.
224188786|NCT01513538|DEVICE|TherapyGuide|Use of TherapyGuide function to help programming the device
224188787|NCT04136769|PROCEDURE|Visceral Debranching|Visceral debranching is defined as a vascular reconstruction with the aim of ensuring a sufficient arterial blood flow to the mesentery and liver after the subsequently planned tumor resection, which usually comprises ligation of the gastroduodenal artery or other relevant collateral vessels. All open vascular procedures can be employed for visceral debranching. Examples are aorto-visceral or iliaco-visceral bypasses using autologous vein or an allogeneic graft, or re-insertion of the superior mesenteric artery or celiac trunk into the aorta.
224188788|NCT05008146|RADIATION|Baseline [C-11]NOP-1A PET Scan|Radiotracer
224309276|NCT04091659|OTHER|Standard Education|Standard Educational (Control): The public health department's training includes printed handouts on how to administer naloxone and youtube videos on how to spot signs and symptoms of overdose and administer naloxone. Additionally, staff are on hand to provide one on one verbal educational trainings to local community members voluntarily seeking education.
223498313|NCT05303285|DRUG|Secukinumab 150mg s.c.|Induction: 5 x 150 mg secukinumab s.c. weekly. Maintenance: 150 mg secukinumab s.c. every 4 weeks
223498314|NCT04795323|DEVICE|TARA v3.1, only non-pharmacological self-management support|Technology-Assisted Respiratory Adherence (TARA) is a digital behaviour change intervention (DBCI) intended to support patients with chronic obstructive pulmonary disease (COPD) in managing their condition by adopting and sustaining clinically recommended (evidence-based) self-management behaviours. TARA was used independently at home by patients via an internet-enabled device and was a fully online digital system that offered guidance on the self-management of COPD, targeting non-pharmacological self-management support (self-monitoring, pursed lip breathing, pacing and energy conservation, and adherence to prescribed rescue medication in TARA version 3.1 (v3.1). The study comprised a screening (pre-TARA) period (which included a 2-week run-in period), a 12-week intervention period (TARA study period), and a follow-up period (post-TARA).
223590476|NCT03033199|DRUG|Dexamethasone|Dexamethasone 40 mg per day, 4 consecutive days
223590477|NCT03992092|DEVICE|C-MAC VS|C-MAC Video Stylet
224188789|NCT05008146|DRUG|Hydrocortisone|Intravenous, 1mg/Kg
223590478|NCT03992092|DEVICE|Flexible Bronchoscopy|Flexible Bronchoscopy
223590479|NCT00971295|DRUG|Metformin|850 mg metformin hydrochloride, once as oral single-dose and once after pre-treatment with once-daily dose of ESL 1200 mg for 6 days
223590480|NCT00971295|DRUG|Eslicarbazepine acetate|
223590481|NCT01411384|PROCEDURE|Corneal collagen cross-linking|The same surgical procedure was applied to all keratoconus patients that included: Instillation of proparacaine hydrochloride 0.5% drops for topical anaesthesia, application of a sponge saturated with 10% alcohol to the central cornea for 30 seconds and subsequent de-epithelialization. Following de-epithelialization, a mixture of 0.1% riboflavin in 20% Dextran solution was instilled to the cornea for 30 minutes (2 drops every 2 minutes) prior to the irradiation, until the stroma was completely penetrated and aqueous was stained yellow. An 8.0mm diameter of central cornea was irradiated for 30 minutes by UVA light with a wavelength of 370nm and an irradiance of 3mW/cm2. Instillation of riboflavin drops (1 drop every 2 minutes) was continued during irradiation. Balanced salt solution (BSS) was applied every 6 minutes to moisten the cornea.
223590482|NCT01411384|DEVICE|Ocular Response Analyzer (ORA)|An air puff is released by a non-contact probe, which scanned the central area of the eye and send a signal to the ORA device. The air puff causes the cornea to move inward, past applanation, and into slight concavity. After milliseconds, the air pumps shut off, the pressure decreases, and the cornea begins to return in its normal state. The system monitors the entire process and measures two pressure values, which are determined from the inward and outward applanation processes. The aforementioned measuring procedure enables the determination of Corneal Hysteresis and Corneal Resistance Factor.
223590483|NCT01707381|DRUG|BOL-303259-X|Topical ophthalmic solution
223590484|NCT01707381|DRUG|Timolol maleate|Topical ophthalmic solution
223590485|NCT00955513|DRUG|diclofenac diethylamine gel 2.32%|diclofenac diethylamine gel 2.32% twice a day
223590486|NCT00955513|DRUG|diclofenac diethylamine gel 2.32%|diclofenac diethylamine gel 2.32% three times a day
223590487|NCT00955513|DRUG|Placebo|Placebo
223590488|NCT00086411|DRUG|nicotine transdermal system|starting with 21 or 14mg dependent on number of cigarettes per day smoked upon entry in the study; titrated down over 8 weeks.
223590489|NCT00086411|DRUG|bupropion|150 mg/day X 3 days 300mg/day for 60 days Total 9 weeks
223590490|NCT00086411|BEHAVIORAL|Medication Management|Brief manual based therapy; four 15 minute session over 10 weeks.
223590491|NCT00086411|BEHAVIORAL|Mayo Counseling|Manual based therapy; Weekly 30 minute sessions for 10 weeks
223590492|NCT00086411|DRUG|placebo patch|placebo patch containing no nicotine
223590493|NCT00086411|DRUG|placebo bupropion|placebo pills
223746025|NCT03391596|BEHAVIORAL|Standardized rehabilitation|Standardized institutional rehabilitation in a rehabilitation center
224188790|NCT05008146|RADIATION|Post-hydrocortisone [C-11]NOP-1A PET Scan|Radiotracer
224309277|NCT03775759|PROCEDURE|Tricuspid valve repair or replacement|Available rings used at Duke include the Tri-Ad™ Adams Tricuspid Ring by Medtronic, the TAILOR™ FLEXIBLE ANNULOPLASTY RING by St. Jude Medical/Abbott, and the Carpentier-Edwards Physio II Ring by Edwards LifeSciences. Available valves used at Duke include the Mosaic™ Mitral Orbutrator by Medtronic, the Carpentier-Edwardes PERIMOUNT Magna Mitral Ease Pericardial Bioprosthesis by Edwards LifeSciences, the On-X Mitral Valve, by CryoLife, the Carbomedics Prosthetic Heart Valve by LivaNova, and the St. Jude Medical™ Mechanical Heart Valve by St. Jude Medical/Abbott.
224309278|NCT03775759|OTHER|Medical management of tricuspid regurgitation|The medical therapy involved includes inotropic medications and diuretic medications, which are standard of care for patients in this population.
224309279|NCT00205244|BEHAVIORAL|Healing images, relaxation and distraction materials|
224309280|NCT01173081|DRUG|Teriparatide|20mcg once daily for 16 weeks or until study endpoint is achieved.
224309281|NCT01173081|DRUG|Placebo|matching dose of 20mcg of placebo once daily for 16 weeks or until study endpoint is achieved
224188791|NCT05214898|BEHAVIORAL|24/7 Dad|"The 24/7 Dad curriculum is an evidence-based, skills driven curriculum (12 group sessions). The following topics are included: Family History, What it Means to Be a Man, Showing and Handling Feelings, Men's Health, Communication, The Father's Role, Discipline, Children's Growth, Getting Involved, Working with \& Co-Parenting, Dads and Work, and the My 24/7Dad Checklist. Healthy Relationship topics include: Communication Skills, including expression, discussion, and negotiation skills; Conflict Resolution and Anger Management; Problem-Solving; and Knowledge of the Benefits of Marriage. Responsible Parenting areas of focus include: children's growth/development; non-violent discipline; co-parenting; building conflict resolutions skills (for the child and the family); and, enhancing family relationships."
224309282|NCT04934410|DRUG|Etomidate|Use of etomidate during induction as decided by attending anesthesiologist
224309283|NCT04934410|DRUG|Midazolam|Use of midazolam during induction as decided by attending anesthesiologist
224309284|NCT04934410|DRUG|Sevoflurane|Use of sevoflurane during induction as decided by attending anesthesiologist
224309285|NCT05532124|BIOLOGICAL|LAENNEC (Human Placenta Hydrolysate)|Intravenous Injection
223498315|NCT04795323|DEVICE|TARA v3.2, both non-pharmacological and pharmacological self-management support|Technology-Assisted Respiratory Adherence (TARA) is a digital behaviour change intervention (DBCI) intended to support patients with chronic obstructive pulmonary disease (COPD) in managing their condition by adopting and sustaining clinically recommended (evidence-based) self-management behaviours. TARA was used independently at home by patients via an internet-enabled device and was a fully online digital system that offered guidance on the self-management of COPD, targeting non-pharmacological self-management support (self-monitoring, pursed lip breathing, pacing and energy conservation, and adherence to prescribed rescue medication in TARA version 3.1 (v3.1). The study comprised a screening (pre-TARA) period (which included a 2-week run-in period), a 12-week intervention period (TARA study period), and a follow-up period (post-TARA).
223498316|NCT02079870|DRUG|semaglutide|Solution for subcutaneous (s.c. - under the skin) injection. 0.25 mg semaglutide once weekly for four weeks, 0.5 mg semaglutide once weekly for four weeks followed by 1.0 mg semaglutide once weekly for five weeks
223590494|NCT05781646|DIAGNOSTIC_TEST|Xpert MTB/RIF|CSF samples was centrifuged at 3,000 - 4,000 X g for 15 minutes. Supernatant was removed to leave a 1-ml precipitate, which was then used for Ziehl-Neelsen AFB staining (100 μl), inoculation of MGIT culture (100 μl), and Xpert MTB/RIF testing (800 μl).
224188792|NCT04076865|DRUG|EMLA (lidocaine) +Itch (Histamine and cowhage)|"Cutaneous anaesthesia: will be topically induced by using EMLA cream 5%, a local anaesthetic cream consisting of equal parts of lidocaine and prilocaine (1g contains 25 mg of lidocaine and 25 mg of prilocaine, AstraZeneca A/S, Albertslund, Denmark).~Histamine: To deliver histamine, standard allergy skin prick test (SPT) lancets are applied.~Cowhage: Cowhage spicules are 1-2 mm in length and have diameter of 1-3 um at their tip, once inserted into the epidermis, the spicules evoke a moderate sensation of itch and to a lesser extent sensations of burning and stinging pain."
223590495|NCT03914677|DRUG|Mecamylamine Oral Tablet|nicotinic antagonist (ganglionic blocker)
223590496|NCT05286216|BEHAVIORAL|effectiveness of education|"The education program will be prepared using power point presentations within the relevant scientific literature. The education program is planned to be given to each group as 1 session on 2 different days, between 09:30 and 13:00. Day 1 module 1; Module 2 will be shared on the 2nd day and all patients in the experimental group will participate in the education program. During and after the education, individuals will be provided with the opportunity to ask questions. In addition, after the education, the researcher's phone will be given and counseling will be provided by phone. The duration and subject of the telephone conversations will be recorded by the researcher.~In order to evaluate the training, all patients will be invited to the hospital on the day of the control at the end of 12 and 24 weeks, and evaluations will be made again with data collection tools."
223590497|NCT06089512|PROCEDURE|paravertebral block group|Paravertebral block was applied to the patients after induction of general anesthesia; Intraoperative opioid requirement and postoperative pain scores and analgesic requirement were evaluated.
223590498|NCT06089512|PROCEDURE|Mid point transverse process block group|Mid point transverse process block was applied to the patients after induction of general anesthesia; Intraoperative opioid requirement and postoperative pain scores and analgesic requirement were evaluated.
223590499|NCT06089512|PROCEDURE|Control group|Only general anesthesia was applied to the patients.
223746026|NCT03391596|BEHAVIORAL|Support by voluntary caregiver associations|Support given by voluntary caregiver associations
224188793|NCT00331058|PROCEDURE|Bronchoscopsy|Healthy and Asthmatic Volunteers
224309286|NCT05532124|OTHER|normal saline|Intravenous Injection
224309287|NCT05670535|OTHER|Visual analogue scale (VAS) for dyspareunia|Dyspareunia scores between 0 to 10 points
224309288|NCT05670535|OTHER|Visual analogue scale (VAS) for vaginal dryness|Vaginal dryness scores between 0 to 10 points
224309289|NCT05670535|OTHER|The European League Against Rheumatism Sjögren's Syndrome Disease Activity Index (ESSDAI)|Sjögren's Syndrome Disease Activity Index scores between 0 to 3 points
223498317|NCT02079870|DRUG|placebo|Solution for subcutaneous (s.c. - under the skin) injection
223498318|NCT01186406|DRUG|Gliadel|Patients will have 1-8 wafers of Gliadel inserted at the time of surgical resection.
223498319|NCT01186406|RADIATION|Radiation Therapy|At a minimum of four weeks, but not greater than eight weeks post-craniotomy, subjects will be treated with standard radiation therapy.
223590500|NCT06464419|DEVICE|ultrasound|Measurement of optic nerve sheath diameter by ultrasound
224309290|NCT05670535|OTHER|The European League Against Rheumatism Sjögren's Syndrome Patient Reported Index (ESSPRI)|Sjögren's Syndrome Patient Reported Index scores between 0 to 10 points
224309291|NCT04675619|DRUG|Oral pirfenidone|Treatment
224309292|NCT04675619|DRUG|Standard care|Treatment
224309293|NCT00772421|DEVICE|There was no intervention.|There was no intervention. This study was designed as an in-clinic testing protocol to identify recruitment rhythms.
224188794|NCT00331058|PROCEDURE|Prednisolone|Asthmatic Volunteers
224188795|NCT04511533|DRUG|Dacomitinib|Dacomitinib is a kinase inhibitor indicated for the first line treatment of patients with metastatic NSCLC with EGFR exon 19 deletion or exon 21 L858R substitution mutations.
224188796|NCT00843128|DEVICE|robot-assisted gait training (RAGT)|20 patients will be treated with RAGT, 12 sessions over three weeks.
224188797|NCT00843128|DEVICE|conventional walking training (CWT)|The control group will be treated by CWT, 12 sessions in three weeks.
224188798|NCT01851031|PROCEDURE|the minor approach|Thirty-six patients (the minor approach group) were treated with minor parotid anterior approach
224188799|NCT04632316|DRUG|Cyclophosphamide-Fludarabine (Cy/Flu)|Lymphodepleting conditioning regimen
224188800|NCT04632316|DRUG|oNKord®|Allogeneic ex vivo-generated Natural Killer (NK) cells from CD34+ umbilical cord blood progenitor cells
224188801|NCT00561041|BEHAVIORAL|Brief phone aftercare intervention|Interventions is composed of 5 integrated cognitive-behavioral and motivational enhancement therapies administered during a period of 3 months according to a similar schedule
224188802|NCT00561041|BEHAVIORAL|individual aftercare therapy|composed of 5 integrated cognitive-behavioral and motivational enhancement Therapies administered during a period of 3 months according to a similar schedule
224188803|NCT04941261|BIOLOGICAL|middle-dose Norovirus Bivalent (GI.1 / GII.4) Vaccine|Intramuscular injection of middle-dose Norovirus Bivalent (GI.1 / GII.4) Vaccine in the deltoid muscle of the upper arm
224188804|NCT04941261|BIOLOGICAL|high-dose Norovirus Bivalent (GI.1 / GII.4) Vaccine|Intramuscular injection of high-dose Norovirus Bivalent (GI.1 / GII.4) Vaccine in the deltoid muscle of the upper arm
224188805|NCT04941261|BIOLOGICAL|placebo|Intramuscular injection of placebo in the deltoid muscle of the upper arm
223498320|NCT01186406|DRUG|Avastin|"Avastin (10 mg/kg) will be given every 14 days, and will begin a minimum of 42 days post-operatively.~Beginning two to three weeks after the last radiation therapy, but not greater than eight weeks, subjects will be treated with Avastin (10mg/m2) every 14 days."
223498321|NCT01186406|DRUG|Temodar|At a minimum of four weeks, but not greater than eight weeks post-craniotomy, subjects will be treated with standard radiation therapy and daily Temodar (75mg/m2) for 6.5 weeks of the radiation. In addition, beginning 2-3 weeks after the last radiation therapy, but not greater than 8 weeks, patients will be treated with 5 day Temodar (200 mg/ m2).
223498322|NCT05967559|OTHER|Online Flipped Learning Group|The experimental group is the group that receives online flipped learning training.
223498323|NCT05967559|OTHER|Traditional learning Group|The control group is the group that received traditional learning training.
223498324|NCT01275027|DIETARY_SUPPLEMENT|Nutralin|7 capsules taken 15 minutes before each of the three main meals of the day
223498325|NCT04558242|DEVICE|Genix|Low Level Light (LEDs)
223498326|NCT04558242|DEVICE|Sham|Incandescent Bulbs Colored Red
223498327|NCT03033836|DRUG|ARV treatment|Dolutegravir 50 mg QD plus co-formulated emtricitabine 200 mg/tenofovir 300 mg QD.
223498328|NCT00111332|BEHAVIORAL|Progressive resistance and aerobic training|
223498329|NCT02960685|PROCEDURE|Echocardiography|
223590501|NCT03068208|PROCEDURE|Methylene blue-mediated photodynamic therapy|The 2% MB aqueous solution was applied to the lesion until saturation occurred, followed by a occlusive dressing and rest period of 30 minutes. After the rest period, the lesion was immediately illuminated with incoherent red light (peak emission spectrum at 630-640 nm)
223590502|NCT00279812|DIETARY_SUPPLEMENT|50ug selenium enriched yeast|Selenomethionine supplement (50ug/d Se) for 12 weeks
223590503|NCT00279812|DIETARY_SUPPLEMENT|100ug selenium enriched yeast|Selenomethionine supplement (100ug/d Se) for 12 weeks
223590504|NCT00279812|DIETARY_SUPPLEMENT|200ug selenium enriched yeast|Selenomethionine supplement (200ug/d Se) for 12 weeks
223590505|NCT00279812|DIETARY_SUPPLEMENT|Control onion|3 meals per week containing un-enriched onion (4ug/d) for 12 weeks
224188806|NCT06401798|DRUG|placebo gel|Methylcellulose gel was applied topically to the pocket
223498330|NCT05886023|DIETARY_SUPPLEMENT|High nitrate vegetables|Vegetable burger containing high nitrate vegetables
223498331|NCT05886023|DIETARY_SUPPLEMENT|Low nitrate vegetables|Vegetable burger containing to low nitrate vegetables
223498332|NCT03142750|DEVICE|Gastrostomy tube dressing|Two types of dressings to secure gastrostomy tube in children
223498333|NCT00653757|DRUG|goserelin acetate|
223498334|NCT00653757|DRUG|leuprolide acetate|
223498335|NCT00653757|RADIATION|image-guided radiation therapy|
223498336|NCT00653757|RADIATION|intensity-modulated radiation therapy|
223511900|NCT00079781|PROCEDURE|RNS® System implantation|Using standard neurosurgical techniques the surgical team implants the RNS® System, which includes the RNS® Neurostimulator and intracranial NeuroPace® Leads. Up to 4 Leads (Cortical Strips and/or Depth Leads) are placed in or near the epileptogenic focus/foci. The Neurostimulator is placed in the skull and connected to up to 2 Leads. At first the Neurostimulator is programmed to record brain activity (electrographic patterns). The neurologist or neurosurgeon reviews the recorded electrographic patterns and identifies abnormal (epileptiform, or seizure-like) activity. The Neurostimulator is then programmed to detect the abnormal activity.
223590506|NCT00279812|DIETARY_SUPPLEMENT|Enriched onion|3 meals per week containing un-enriched onion (50ug/d) for 12 weeks
223590507|NCT00279812|OTHER|Placebo|Placebo supplement for 12 weeks
223590508|NCT05856097|OTHER|kinesio taping with diaphragmatic breathing|.kinesio tape was applied on1st day of intervention with the 20 minutes session of diaphragmatic breathing 3 sessions were given
223590509|NCT05856097|OTHER|kinesio taping without diaphragmatic breathing|kinesio tape was applied day 1st of intervention. 3 sessions were given
223590510|NCT00005834|BIOLOGICAL|filgrastim|Arms 1 and 2: 300 mcg (pts \</= 60 kg) or 480 mcg (pts \> 60 kg), SC beginning day 5
223590511|NCT00005834|DRUG|cisplatin|Arms 1 and 2: 15 mg/m2/d continuous IV days 1-4
224188807|NCT06401798|DRUG|CWP gel|Methylcellulose gel combined with CWP was applied topically to the pocket
224188808|NCT06401798|DRUG|NCWP gel|Methylcellulose gel combined with NCWP was applied topically to the pocket
224188809|NCT05178290|BEHAVIORAL|CHILD back-to-ECE COVID-19 saliva testing|Preschool children and their parent will complete saliva COVID-19 tests at the start of the school year and after winter break as part of a back-to-ECE safely intervention. Tests may be completed during pick up, at drop off, or during school, depending on local on-campus regulations.
224188810|NCT05178290|BEHAVIORAL|ECE personnel back-to-ECE COVID-19 saliva screening|ECE personnel will complete saliva COVID-19 tests biweekly through the school year as part of a back-to-ECE safely intervention. Tests may be completed on the ECE campus or in the parking lot, depending on local on-campus regulations
224188811|NCT05178290|BEHAVIORAL|SAGE garden programming|The SAGE garden programming includes installation of a garden; teacher training via Zoom and/or short videos, a binder and website support along with other accompanying materials and teacher technical support (email, text, phone); gardening supplies and gear (e.g., hats, watering cans, gloves); and delivers active songs, games, science experiments and other outdoor learning opportunities.
224188812|NCT02434666|DRUG|CPC-201|
224188813|NCT03193424|DRUG|Apatinib|Subjects were randomly divided into two groups,A group:apatinib 500mg/d,po,qd, Docetaxel 75 mg / m2 was administered on day 1 repeated every 21 days until progressive Disease(PD) . B group:Docetaxel 75 mg / m2 was administered on day 1 repeated every 21 days until progressive Disease(PD) .
224188814|NCT01319422|DRUG|Pomalidomide|Comparison of different dosages and schedules of drug
224188815|NCT04246359|DRUG|Rituximab Biosimilar|To evaluate the short-term objective efficacy of HLX01 combined with Pegylated Interferon α-2b in patients with advanced idolent B-cell lymphoma.
224188816|NCT04246359|DRUG|Pegylated Interferon α-2b|To evaluate the short-term objective efficacy of HLX01 combined with Pegylated Interferon α-2b in patients with advanced idolent B-cell lymphoma.
224188817|NCT03116789|DIETARY_SUPPLEMENT|probiotics|Two capsules for daily
224188818|NCT02956226|DRUG|Cannabinoids - 99% pure cannabinoids mix|99% pure cannabidiol (CBD) and 99% pure Δ9-tetrahydrocannabinol (THC) in a 20:1 ratio (B.O.L Pharma, Israel), in a 160/8.0 mg per mL (CBD/THC) olive oil-based solution.
224309294|NCT01410500|DRUG|Carfilzomib|Carfilzomib was administered as an intravenous (IV) infusion over approximately 10 minutes on Days 1, 2, 8, 9, 15, and 16 of repeated 28-day cycles at a dose of 20 mg/m² on Days 1 and 2 of Cycle 1 and 27 mg/m² for all infusions thereafter until Cycle 12. For Cycle 13 and higher for those still receiving carfilzomib, the carfilzomib infusion schedule was abridged to Days 1, 2, 15, and 16 of each subsequent 28-day cycle. Carfilzomib treatment was continued until disease progression, diagnosis of a new malignancy, unacceptable toxicity, withdrawal of consent, or the study was terminated
224188819|NCT02956226|DRUG|Placebo|Olive oil and flavors solution.
224188820|NCT02956226|DRUG|Cannabinoids - whole plant extract|Whole plant extract enriched with cannabidiol (CBD) and Δ9-tetrahydrocannabinol (THC) to achieve 20:1 ratio (B.O.L Pharma, Israel), in a 160/8.0 mg per mL (CBD/THC) olive oil-based solution.
224188821|NCT00661310|OTHER|Drug review 80+ -To reduce usage of hospital care|drug review performed by multiprofessional team, including clinical pharmacist, in order to optimize drug therapy and reduce usage of hospital care. Also patient education and follow-up
224188822|NCT01128699|DRUG|Subconjunctival Avastin|Intraoperative Subconjunctival Avastin 1.25mg; single dose as an adjunct to 184 mm2 surface area Ahmed Glaucoma Valve (AGV Model FP7; New World Medical Inc., Rancho Cucamonga, California, USA)
224188823|NCT01128699|DEVICE|Ahmed Valve implant|184 mm2 surface area Ahmed Glaucoma Valve (AGV Model FP7; New World Medical Inc., Rancho Cucamonga, California, USA)
224188824|NCT02778893|DRUG|Conmana|125mg three times a day (TID) continuously
224188825|NCT02778893|DRUG|Thalidomide|100mg one a day（QD）at night continuously,If can tolerance after 1 weeks to add to 200mg;
224188826|NCT02040415|DRUG|DW-1030(eperisone HCl) 75mg|
224188827|NCT02040415|DRUG|Myonal Tab.(eperisone HCl) 50mg|
224188828|NCT02040415|DRUG|Placebo drug of DW-1030|
224188829|NCT02040415|DRUG|Placebo drug of Myonal Tab.|
223498337|NCT00983970|BEHAVIORAL|Interactive video game cycling|"Participants were required to exercise on a Gamebike® (Cat Eye Electronics Ltd, Boulder Col.) interactive video gaming system that was interfaced with a Sony Play Station 2® (Sony computer Entertainment America Inc. Foster, City, CA) and a 42 flat screen television monitor. The Gamebike® has a handlebar mounted game controller allowing the participant to play most Sony Playstation 2- race-based video games. The Gamebike® reads the participant's speed by cycling cadence and the faster the individual pedalled, the faster they moved in the virtual world on screen. Participants were told that they could exercise at any intensity and duration they desired. Participants were asked to come to the lab for two sessions per week for 60 minutes for 10 weeks. Although participants were required to stay in the lab for 60 minutes, they could take breaks or stop when they wanted, and reading materials were available for those who did not or could not cycle for the full 60 minute session."
223498338|NCT00983970|BEHAVIORAL|Cycling to Music|Each participant exercised twice weekly for 10 weeks on the Gamebike® but the games and controls were turned off. The Gamebike® was used by both groups to control for any differences between two cycle ergometers such as comfort or usability. However, participants were allowed to listen to music of their choice via radio, CD or personal music device. We incorporated music into the control condition because most youth and young adults exercise to music and this provides a more stringent test of the Gamebike® while improving the ecological validity of the research design. We also wanted to minimize drop-out and felt that expecting overweight/obese adolescents, who often report disliking aerobic exercise, to bike in a lab with no form of distraction would create a less than desirable exercise environment and result in high drop-out rates.
223498339|NCT04925934|DRUG|VIB7734|VIB7734
223498340|NCT04925934|OTHER|Placebo|Placebo
223590512|NCT00005834|DRUG|cyclophosphamide|Arms 1 and 2: 400 mg/m2/d continuous IV days 1-4
223590513|NCT00005834|DRUG|dexamethasone|Arms 1 and 2: 40 mg/d PO days 1-4
224309295|NCT04169542|OTHER|Questionnaire Administration|Complete questionnaires
223590514|NCT00005834|DRUG|etoposide|Arms 1 and 2: 40 mg/m2/d continuous IV days 1-4
223590515|NCT00005834|DRUG|thalidomide|Arm 2: 800 mg/d (max dose) PO daily
223746027|NCT02188589|DEVICE|INEX nasal implant|Treatment group may receive unilateral or bilateral INEX nasal implants (maximum of 4, 2 per side)
224188830|NCT04969653|OTHER|Exposure of venous thromboembolism|Composite of pulmonary embolism and deep vein thrombosis
224188831|NCT04447573|BIOLOGICAL|BCMA CAR-T|Biological: BCMA CAR-T; Drug: Cyclophosphamide,Fludarabine; Procedure: Leukapheresis;
224188832|NCT06089265|DRUG|PF-06801591|Active ketohexokinase inhibitor
224188833|NCT04111224|DIAGNOSTIC_TEST|pentraxin 3 marker|Assess the role of pentraxin3 (PTX3) in the early diagnosis of ventilator-associated pneumonia (VAP).
224188834|NCT05078658|OTHER|Low-carbohydrate diet|The diet will contain age- and gender-specific recommended amount of calories but the amount of carbohydrates would be limited to provide only 15% (+/- 5%) of the recommended energy a day.
224188835|NCT05078658|OTHER|Recommended-carbohydrate diet|The subjects will be delivered five pre-made ready meals per day throughout the period (5 weeks). These will contain age- and gender-specific recommended amount of calories with the amount of carbohydrates equal to 45% (+/- 5%) of the recommended energy a day.
224188836|NCT05734534|OTHER|BFR during training|Healthy participants and participants diagnosed with COPD will be randomized to either the BFR-ST and BFR-HIT or to HL-ST and HIT
224188837|NCT05734534|OTHER|BFR during rest|Participants experiencing acute exacerbation of their COPD requiring hospitalization will be randomized to either BFR-P, BFR-NMES or the control group throughout their hospitalization.
224188838|NCT03095365|OTHER|Dry needling|Insertion of solid filament needles in the muscle
224188839|NCT03095365|OTHER|Pain neuroscience education|Explanation of the functioning of the central nervous system, the differences between acute pain and chronic pain and the importance of thoughts and beliefs in the processing and chronification of pain
224188840|NCT03095365|OTHER|Conventional treatment|Electrotherapy: Transcutaneous electrical nerve stimulation and microwaves
224188841|NCT04468139|DRUG|Quercetin|Dietary Supplement: Quercetin Treatment a daily dose of quercetin (500 mg) will be taken orally by proven COVID-19 cases intervention
224188842|NCT04468139|DIETARY_SUPPLEMENT|bromelain|Dietary Supplement:Bromealin Treatment a daily dose of bromelain(500 mg) will be taken orally by proven COVID-19 cases intervention
224188843|NCT04468139|DRUG|Zinc|zinc 50 mg orally daily dose will be taken orally by proven COVID-19 cases intervention
224188844|NCT04468139|DRUG|Vitamin C|vitamin c 1000 mg orally daily by proven COVID-19 cases intervention
224188845|NCT04153526|PROCEDURE|Blood sampling|Blood samples will be obtained during routine clinical visits. Ideally, two 9mL blood samples (or equivalent volume) will be collected into EDTA or other appropriate blood collection tube at each time point except at baseline, where three EDTA 9mL tubes and one of 2.6mL (for study of whole blood) will be collected.
224188846|NCT04153526|PROCEDURE|Surplus Tumour Tissue sample collection from surgery|In surgical patients, lung tumour samples and normal lung tissue will be obtained from surplus tissue removed at the time of surgery. No extra procedures (biopsies or surgeries) are requested for the study.
224188847|NCT04153526|OTHER|Collection or archival tumour tissue (If available)|Where available surplus tumour and normal tissue from archival tissue will be collected for analysis.
224188848|NCT04238117|PROCEDURE|Laser acupuncture treatment|Laser acupuncture therapy (LAT) is a noninvasive technique that involves stimulation of traditional acupoints with low intensity, non thermal laser irradiation.
224188849|NCT05637827|OTHER|No intervention|There was no intervention in each group, and only the natural development was observed
224188850|NCT03145376|DIAGNOSTIC_TEST|geriatric assessment|"1. Clinical evaluation and geriatric assessment with:~   1. CIRS: CIRS (Cumulative Illness Rating Scale)~  2. ADL (Activities of Daily Living);~  3. IADL (InstrumentalActivities of Daily Living);~  4. Mini Nutritional Assessment;~  5. Evaluation of quality of life (Short Form 36, SF-36).~2. Making a traditional 12-lead ECG.~3. A single lead electrocardiographic registration (DI, D II and D III) of 5 minutes baseline and 5 minutes with controlled breathing (15 breaths / min), using the Spectralink 2011 program, which allows us to identify and calculate the variables object of study;~4. transthoracic echocardiogram."
224188851|NCT06515886|DIAGNOSTIC_TEST|Clinical Examination|Clinical examination of a dental implant
224188852|NCT06515886|PROCEDURE|Peri-implant crevicular fluid|Collection of a sample of peri-implant crevicular fluid
224188853|NCT02847663|DEVICE|Kryosauna Space Cabin|The whole body cryotherapy device is able to generatue temperatures up to -195°C for 3 minutes. In this study, we generate temperatures of -135°C for 2 minutes as proposed in the manual. The participant will enter the cabin in cold-resistant shoes and will remain in standing position during the whole procedure. The cold temperature is generated by vaporization of liquid nitrogen.
223498341|NCT04094389|OTHER|Orthotic continuous wear group|"Performed exclusively for research purposes, participants will be assigned at entrance to the study to either wear the orthotic continuously, only during waking hours, or only while sleeping. There will be three participants in each of the three groups.~Participants in the continuous wear group will be instructed to wear their orthotic continuously around the clock as tolerated with removal for hygiene and home exercise program (HEP) performance. Consistent with standard of care for the treatment of trigger finger with an orthotic, all nine of the participants will be instructed to wear their orthotic for at least six weeks, as tolerated, with continuation of orthotic wear up to 10 weeks if their triggering has not completely abated."
223590516|NCT03312205|BIOLOGICAL|Autologous CAR-T cells|Patients will be drawn 50-100 ml blood to obtain enough peripheral blood mononuclear cells (PBMC) for CAR-T manufacturing. The T cells will be purified from the PBMC, transduced with CAR lentiviral vector, expanded in vitro and then frozen for future administration. Chemotherapy will then be given. Following tumor burden reassessment, CAR-T cells will be infused.
224188854|NCT02847663|OTHER|cold water tub|The tub will be filled with cold water up to the sternal level of the participants. Adding ice will ensure a constant temperature. The participant will sit inside the tub during the whole procedure.
224188855|NCT00008216|PROCEDURE|Peripheral Blood Stem Cell Transplantation|
224188856|NCT03214016|OTHER|Aerobic Exercise|1 hour of aerobic training on a treadmill, 3 times a week, during 8 weeks.
224188857|NCT03214016|OTHER|Pilates|1 hour of Mat Pilates, 2 times a week, during 8 weeks.
224188858|NCT05754970|PROCEDURE|laser treated|"The second surgical stage was done after a healing period 12 ± 4 weeks (T1) where all the healing abutments were placed. Each healing abutment had repeated the two surfaces as twice follows: laser-treated/machined/ laser-treated/machined. Experimental healing abutment was removed after 30 ± 7 days, the same time as the soft tissue biopsy.~After the healing period (30 ± 7 days), before starting with the prosthetic restoration of the fixtures, an impression was taken of the small-diameter Has, and circular sections (diameter 5 mm) soft tissues around them were retrieved for analysis."
224188859|NCT03026426|BEHAVIORAL|CONEMO|"Participants will be offered a behavioral activation-based intervention delivered by an application for smartphones (CONEMO) oriented to encourage them to be more active and to incorporate more activities in participants' everyday life.~Nurses will train participants to use CONEMO, make phone calls when participants are non-adherent, and provide technical support when necessary. Nurses will be supervised by clinical psychologists."
224188860|NCT06102473|OTHER|Nutritional education|With prior authorization from the principals of the elementary schools, meetings will be held with parents to invite them to participate, and the aim, activities, and duration of the intervention will be explained to them. They will be invited to sign a consent and informed assent, clarifying that their participation is voluntary and they may not continue at any time they wish without affecting their activities at school.
224188861|NCT00295256|BEHAVIORAL|nurse case manager|
224188862|NCT05798624|DIAGNOSTIC_TEST|Ultrasound between 6+0 and 6+7 weeks of pregnancy - With Isthmocele|"Location of implantation of the GS (gestational sac) amended to Naji et al, defined as 3 possible implantation sites: (A: fundal, B: anterior, C: posterior)~Size of isthmocele:~* Depth of isthmocele~* Width of isthmocele~* Circumference of isthmocele~Distance between isthmocele and outer cervical os (measured with the trace line) Distance between CS scar and outer cervical os (measured with the trace line) Size of gestational sac Measurements of the isthmocele size / circumference / distance between isthmocele / CS and outer cervical os"
224188863|NCT05798624|DIAGNOSTIC_TEST|Ultrasound between 6+0 and 6+7 weeks of pregnancy - Without Isthmocele|Location of implantation of the GS amended to Naji et al, defined as 3 possible implantation sites: (A: fundal, B: anterior, C: posterior) Distance between CS scar and outer cervical os (measured with the trace line) Size of gestational sac
224188864|NCT05798624|DIAGNOSTIC_TEST|Ultrasound between 6+0 and 6+7 weeks of pregnancy|"Location of implantation of the GS (gestational sac) amended to Naji et al, defined as 3 possible implantation sites (A: fundal, B: anterior, C: posterior)~Size of gestational sac"
224188865|NCT03371602|PROCEDURE|surgery|a diaphragmatic biopsy (100 microgram) and a parietal biopsy will be performed by the surgeon during surgery.
223746028|NCT04971473|BIOLOGICAL|rhTSH|Scanning was done 48 hours after the radioiodine administration. Each patient was scanned first following rhTSH and then scanned after thyroid hormone withdrawal.
224188866|NCT03371602|PROCEDURE|multi-organ sampling|a diaphragmatic biopsy (100 microgram) will be performed by the surgeon during surgery.
224188867|NCT04037540|PROCEDURE|Operational approach|Operational approach was used to treat the Jones fracture in patients randomized into the respective study arm.
224188868|NCT04037540|PROCEDURE|Conservative approach|Conservative approach was used to treat the Jones fracture in patients randomized into the respective study arm.
224188869|NCT02840019|DEVICE|Investigational MRI coil designed for pregnant women|The investigational MRI receiver coil designed specifically for pregnant women will be used during the 60 minute full research MRI scan. An MRI receiver coil is part of the MRI machine that is placed over the body part being imaged during every MRI scan. A coil is required to obtain MR images, yet there isn't one designed for pregnant women. This investigational MRI receiver coil for pregnant women will be tested to see if it helps improve image quality and take images faster.
224188870|NCT02840019|PROCEDURE|MRI Scan|All participants will participate in an MRI scan. The add-on MRI scan will be 15 minutes. The full MRI scan will be 60 minutes.
224188871|NCT02129439|DRUG|SB012|"The treatment phase lasts 28 consecutive days. The IMP will be administered for the first time at the study site in the morning on Day 1 (IMP administration training by study site staff). The final administration will be performed at the study site in the morning of Day 28. On all other treatment days (Day 2 to Day 27), the IMP will be self-administered by the subject at home.~SB012 will be available in this clinical trial in a concentration of 7.5mg/ml hgd40 in 30ml PBS (Maximum daily dose: 225mg)~The IMP is formulated as an enema and will be administered in this clinical trial by the rectal route. The enema is a ready-for-use preparation. No further preparation steps are required.~No modifications are permitted to the dosing regimen except for premature study discontinuation."
224188872|NCT02129439|DRUG|Placebo|"Intervention of placebo-treated subjects does not vary to SB012-treated subjects.~The treatment phase lasts 28 consecutive days. Placebo will be administered for the first time at the study site in the morning on Day 1 (Administration training by study site staff). The final administration will be performed at the study site in the morning of Day 28. On all other treatment days (Day 2 to Day 27), the IMP/Placebo will be self-administered by the subject at home. Placebo will be administered with a volume of 30ml.~The IMP/Placebo is formulated as an enema (plastic rectal tube) and will be administered in this clinical trial by the rectal route. The enema is a ready-for-use preparation. No further preparation steps are required."
223498342|NCT04094389|OTHER|Orthotic wear during waking hours only group|"Performed exclusively for research purposes, participants will be assigned at entrance to the study to either wear the orthotic continuously, only during waking hours, or only while sleeping. There will be three participants in each of the three groups.~Participants in the waking hours only group will be instructed to wear their orthotic during all waking hours as tolerated, with removal for hygiene, HEP performance, but not at night while sleeping. Consistent with standard of care for the treatment of trigger finger with an orthotic, all nine of the participants will be instructed to wear their orthotic for at least six weeks, as tolerated, with continuation of orthotic wear up to 10 weeks if their triggering has not completely abated."
223498343|NCT04094389|OTHER|Orthotic wear only while sleeping group|"Performed exclusively for research purposes, participants will be assigned at entrance to the study to either wear the orthotic continuously, only during waking hours, or only while sleeping. There will be three participants in each of the three groups.~In the night-wear group, participants will be told to wear their orthosis only at night. Consistent with standard of care for the treatment of trigger finger with an orthotic, all nine of the participants will be instructed to wear their orthotic for at least six weeks, as tolerated, with continuation of orthotic wear up to 10 weeks if their triggering has not completely abated"
223590517|NCT03526510|RADIATION|Conventionally Fractionated versus Hypofractionated Boost|
223746029|NCT02333695|DEVICE|Spinal Magnetic Stimulation|Spinal Magnetic Stimulation (SMS) is a relatively new way to use magnetism to affect the spinal cord. It is non-invasive, meaning that the procedure does not require any type of surgery; rather, it is conducted by transmitting magnetic pulses through the Spinal Cord by pressing a machine against the back.
223746030|NCT05614375|PROCEDURE|endoscopic surgery|transnasal endoscopic surgery
224188873|NCT04211454|OTHER|No intervention|There is no intervention for this study.
224188874|NCT01488227|DIETARY_SUPPLEMENT|Vitamin D|4000 IU of Vitamin D daily for 6 months
224309296|NCT02926482|BEHAVIORAL|Prescriber Recruitment Bundle (PRB)|The Prescriber Recruitment Bundle (PRB) is a bundle pharmacotherapy capacity building practices. The PRB to be implemented contains the following elements, a) candidate identification strategies, b) prescriber education forums, c) prescriber-friendly workflow and risk-reduction strategies, d) academic detailing to recruit OUD prescribers, e) telemedicine, and f) organizational leadership and culture to support building OUD pharmacotherapy capacity.
224309297|NCT01507363|DRUG|Gabapentin|Tables with Gabapentin (1300 mg/ day) for 7 days, starting on the day of surgery
224309298|NCT01507363|DRUG|Gabapentin|Tables with Gabapentin (900 mg/day) for 7 days, starting on the day of surgery
224309299|NCT01507363|DRUG|Placebo|Placebo tablets for 7 days, starting on the day of surgery
224309300|NCT04451681|OTHER|Cardiopulmonary exercise test|Data such as oxygen consumption, cardiac parameters and speed of the patient are analyzed numerically on the treadmill in the KPET; Objective performance values such as maximum oxygen use (VO2max), maximum heart rate, respiratory capacity, and maximum rate will be obtained.
224309301|NCT05487534|OTHER|Observational|The same self-reported questionnaires and cognitive tests will be completed by both groups. There is no intervention.
223498344|NCT03158688|DRUG|Dexamethasone|Commercially available oral and IV formulas were obtained by investigative sites. Amgen supplied IV or PO dexa for some countries (Poland, Hungry, Romania, Bulgaria, Korea). Dosage modification rules applied based on participant age (participants \> 75 years were given lower doses), dexa-related toxicities, and discontinuation of carfilzomib.
223498345|NCT03158688|DRUG|Daratumumab|Daratumumab was supplied as a concentrated solution for infusion in single-use vials.
223590518|NCT00857974|OTHER|Physical Activity|The intervention is an individualized, structured, moderate intensity home-based physical activity program. During the first 12 weeks the program will focus on lower extremity strengthening, and thereafter incorporate cardiovascular activity. The target duration of activity is 150 minutes per week, i.e., 20-30 min on most days of the week. However, the program is adjusted based on each participant's progression, initial level of physical fitness and will be modified in response to illness, injury, or physical symptoms.
223498346|NCT03158688|DRUG|Carfilzomib|"Carfilzomib for infusion was supplied as a lyophilized, sterile product in single-use vials. The lyophilized product was reconstituted with preservative-free sterile water for injection, the reconstituted solution contained carfilzomib 2 mg/mL. IV injections lasted approximately 30 minutes.~Dose could be modified based on a \>20% change in body weight or toxicity."
223590519|NCT00598325|BIOLOGICAL|3'-aminomethyl-Nic r-EPA Conjugate (NicVAX®)|1.0 ml injection IM given every 4 weeks (weeks 0, 4, 8, 12, 16)
223590520|NCT02709876|BIOLOGICAL|Stem Cell Transplantation|Bone marrow-derived CD34+, CD133+, CD271+ stem cells in 1.0 ml normal saline will be injected into the vitreous cavity.
223590521|NCT04957056|PROCEDURE|Hospitalization|Hospitalization
223590522|NCT06368908|DEVICE|Transcutaneous Functional Magnetic Muscle Stimulation|Peripheral neuromuscular system stimulation will be conducted for the quadriceps femoris muscle using a magnetic stimulator (Tesla stym, Iskra Medical, Otoče, SLO). For magnetic stimulation, we will use pulse trains (20-50 Hz) with intensities ranging from 0.5 to 2.5 Tesla. The stimulation trains will be up to 3-6 seconds long, and the duty cycle will be varied from 1:1 to 1:10. Muscles will be stimulated with a magnetic field intensity that triggers visible contraction. The stimulation will last for 55 minutes per selected limb and will be performed 5 days a week.
223590523|NCT00076232|DRUG|Acyclovir|400 mg tablet taken orally twice daily
223590524|NCT00076232|DRUG|Acyclovir placebo|Oral tablet taken twice daily
224188875|NCT01488227|DIETARY_SUPPLEMENT|Placebo|Acts as a control for the Vitamin D intervention
224309302|NCT04297319|PROCEDURE|Laser diiodo|3 laser diiodo procedures of 5-10 minutes at intervals of 4 weeks It is an outpatient procedure, not anesthesia required.
223590525|NCT02385435|DRUG|Bupivacaine|Caudal Bupivacaine 2 mg/kg single shot
224188876|NCT01655368|BEHAVIORAL|psychotherapeutic STEM modules|psychoeducational and psychotherapeutical group intervention. 8 sessions of psychoeducation + 3 sessions + 1 booster session of STEM module for schizophrenia or depression)
224188877|NCT01655368|BEHAVIORAL|Interventional control of normal psychoeducational treatment|11 sessions + 1 booster session of psychoeducation (for schizophrenia or depression)
224188878|NCT05761158|OTHER|questionnaire|patients are asked to complete a questionnaire
224188879|NCT04107961|BIOLOGICAL|Vaccine|Single intramuscular injection into the deltoid region
224188880|NCT04107961|OTHER|Placebo|Single intramuscular injection into the deltoid region
224309303|NCT04297319|PROCEDURE|Laser Placebo|3 laser diiodo procedures of 5-10 minutes at intervals of 4 weeks. It is an outpatient procedure, not anesthesia required.
224309304|NCT02040506|DRUG|IGN523|Given intravenously every week for 8 weeks. Dosing beyond 8 weeks will be permitted for subjects meeting criteria for ongoing clinical benefit and acceptable safety.
224309305|NCT02651259|DRUG|Rifapentine (RPT)|900 mg of RPT
224309306|NCT02651259|DRUG|Isoniazid (INH)|900 mg of INH
224309307|NCT02651259|DIETARY_SUPPLEMENT|Pyridoxine (vitamin B6)|25 mg to 100 mg of pyridoxine, based on the current local, national, or international dosing guidelines.
224309308|NCT03756506|DEVICE|Novel Microbicidal Liquid Polymer|The polymer is a 510K FDA cleared medical device indicated for providing a covering over minor wounds and scrapes that are clean and dry. The microbicidal liquid solution consists of organic polymers . The unique formulation eradicates any organisms (bacteria, fungi, viruses) it comes in contact with. This is a result of the solvent's activity against an infinite number of organisms After eradication is complete, the solvent then transitions into a clear, elastomeric, non-odorous film for covering disrupted tissue. The film protects the wound against entry of water, dirt, and germs. The film is elastomeric and protects in difficult regions where flexing, bending and creasing skin occurs. The clear film forms in less than a minute.6 DuraDerm® should not be used to the treat deep infected wounds. DuraDerm® can be used to protect disrupted skin surface of wounds that are clean and dry.
224309309|NCT02031718|BEHAVIORAL|Virtual Counseling|
224309310|NCT03293407|DRUG|Iloprost (Ventavis, BAYQ6256)|Using Breelib device
224309311|NCT03293407|DEVICE|Breelib nebulizer|Used for inhalation of Ventavis
224309312|NCT03678285|OTHER|HIFRT Workout|A single high intensity functional resistance training (HIFRT) exercise bout.
224188881|NCT01220817|DRUG|3 POMx capsules|3 POMx capsules daily
224188882|NCT01220817|DRUG|1 POMx capsule|1 POMx capsule daily
224188883|NCT02127021|DRUG|Norzyme® 40000 IU|A kind of pancreatic enzyme supplement containing lipase: 40,000 FIP, amylase: 25,000 FIP, and protease: 1,500 FIP Single capsule of Norzyme® 40000 IU will be prescribed three times a day while taking a meal meal
224188884|NCT02127021|DRUG|Placebo|Single capsule of placebo drug with the same appearance of Norzyme® 40000 IU will be prescribed three times a day while taking a meal meal.
224188885|NCT00734318|DRUG|Flutiform 250/10 micrograms|
224188886|NCT00734318|DRUG|Flutiform 50/5 micrograms|
224188887|NCT00734318|DRUG|Flixotide pMDI 250 mcg + foradil pMDI 24 micrograms|
224188888|NCT00734318|DRUG|Flixotide pMDI 250 micrograms|
224188889|NCT06129851|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
224188890|NCT06129851|PROCEDURE|Bone Scan|Undergo bone scan
224188891|NCT06129851|RADIATION|Brachytherapy|Undergo brachytherapy
224188892|NCT06129851|PROCEDURE|Computed Tomography|Undergo CT
224188893|NCT06129851|PROCEDURE|Dual X-ray Absorptiometry|Undergo DEXA scan
224188894|NCT06129851|RADIATION|External Beam Radiation Therapy|Undergo external beam radiation therapy
224188895|NCT06129851|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
224188896|NCT06129851|PROCEDURE|PSMA PET Scan|Undergo PSMA PET
224188897|NCT06129851|OTHER|Questionnaire Administration|Ancillary studies
223590526|NCT02385435|DRUG|dexmedetomidine 1μg.kg-1|Caudal dexmedetomidine 1μg.kg-1, single shot
223590527|NCT02385435|DRUG|dexmedetomidine 2μg.kg-1|Caudal dexmedetomidine 2μg.kg-1, single shot
223590528|NCT02619721|DEVICE|PINS SNS|
223590529|NCT02858752|OTHER|Experience 1 : Auditory and Visual Discrimination|Neuropsychological tests consist in listening to sounds in various contexts and providing behavioral responses with response-buttons.
223590530|NCT02858752|OTHER|Experience 2 : Passive and Active Auditory Perception|Neuropsychological tests consist in listening to sounds under 2 conditions, an active or a passive one, during which different auditory stimuli will be presented: frequent stimuli (standard) and rare stimuli (deviants). These two stimuli differ in some of their feature (height, duration, …). A third, very rare (novel) stimulus will also be used (the subject's first name). Responses will be provided using a response-button and feedback will be given at each response. EEG will be recorded all along to measure Neurophysiological signals.
223590531|NCT02858752|OTHER|Experience 3 : Visual Attention Training|This experience aims at training visual attention through serious games. Children will play against an artificial intelligence and will focus their attention on one out of many possible targets (checkers, cards, boxes) presented on screen. Responses will be provided using a response-button, sometimes completed by an eye-tracking measure. Feedback will be given to the child after his response. EEG will be recorded all along to measure Neurophysiological signals.
223746031|NCT01687959|OTHER|tissue sampling from peritoneum of the gallbladder|tissue sampling from peritoneum of the gallbladder during laparoscopic cholecystectomy after an acute attack of acute biliary pancreatitis
224188898|NCT06129851|DRUG|Relugolix|Given PO
224188899|NCT05718895|DRUG|ATG-022|"Dose Escalation Phase:~A treatment cycle of ATG-022 will be defined as 21 days. Dosing will begin at 0.3 mg/kg once every 3 weeks (Q3W) with 1 subject ,the following dose cohorts (0.9, 1.8, 2.4, 3.0, and 3.6 mg/kg Q3W) will require at least 3 and up to 6 evaluable subjects by using dose escalation plan of 3+3 design."
224188900|NCT01766466|DRUG|cangrelor|Open-label cangrelor IV bolus (30 µg/kg), followed by an infusion of 4 µg/kg/min for two hours.
224188901|NCT01766466|DRUG|Ticagrelor|"Ticagrelor 180mg dose: administered 0.5 h or 1.5h after the initiation of cangrelor infusion~Ticagrelor 90mg: 6 or 7 doses (depending on study arm) taken every 12 hours post cangrelor infusion."
224188902|NCT01428882|DRUG|Midazolam|Midazolam (5 mg/5 mL) 2 mg before standard propofol induction (0.5-1.5 mg/Kg) and boluses-based sedation during colonoscopy, targeted to a moderate sedation level
224188903|NCT01428882|DRUG|Propofol|Placebo (normal saline 2 ml) before standard propofol induction (0.5-1.5 mg/Kg) and boluses-based sedation during colonoscopy, targeted to a moderate sedation level
224188904|NCT04589260|DRUG|TD-1058|Study drug to be administered by oral inhalation
224188905|NCT04589260|DRUG|Placebo|Placebo to be administered by oral inhalation
224188906|NCT05066906|DEVICE|Use of Identifor assessment tool and Companion app|"Identifor pinpoints what players excel at by using objective metrics and quantifiable data to collect information relevant to employment, including Multiple Intelligence, Executive Function, and personality themes.~Companion is a 24/7 personalized aide for teens and adults iwth special needs that uses and artificial intelligence avatar to have back-and-forth conversations with users in a meaningful way to support the user in different domains of their everyday lives including public transit, managing personal schedules, and money management."
224188907|NCT05066906|OTHER|Referral to employment agencies|Standard referral to employment agencies based on an individual's background, skillset, and preferences
224188908|NCT02967393|DRUG|ccIIV4|
224188909|NCT02967393|DRUG|IIV4|
224188910|NCT06280404|DEVICE|Lap cholecystectomy|Body first approach in laparoscopic cholecystectomy in cases with obscure Calot's triangle
224188911|NCT04278846|DRUG|Depofoam bupivacaine|The study drug Depofoam bupivacaine will be administered into the right and/or left breast of each patient 30 minutes prior to the creation of the subpectoral muscle pocket.
224188912|NCT04278846|DRUG|Bupivacaine hydrochloride (HCl)|The study drug bupivacaine HCl will be administered into the right and/or left breast of each patient 30 minutes prior to the creation of the subpectoral muscle pocket.
224188913|NCT00943007|DEVICE|Stealth Station|Neuronavigation based on preoperative MRI
224188914|NCT00943007|DEVICE|PoleStar N20|Intraoperative MRI guided surgery
224188915|NCT01770080|DRUG|Euminz®|3 to 5 time topical use of study drug.
224188916|NCT01770080|DRUG|Placebo|3 to 5 time topical use of study drug.
224188917|NCT05869188|DRUG|Isotretinoin|"* Evaluate serum irisin level in acne vulgaris and compare it with healthy control .~* Evaluate the effect of systemic isotretinoin on serum irisin in acne vulgaris patients ."
224188918|NCT00895817|DRUG|Swallowed fluticasone|440 µg twice daily for 8 weeks
224188919|NCT00895817|DRUG|Esomeprazole|40 mg once daily for 8 weeks
223590532|NCT02858752|OTHER|Experience 4 : Attention and Distractibility|Neuropsychological tests consist in listening to sounds preceded by a visual cue indicating (or not) in which ear the sounds will be played. The subject Child should detect the target sound (e.g. a dog barking). In some trials, a distracting distraction will be introduced between the visual cue and the target sound. Responses will be provided using a response-button. EEG will be recorded all along to measure Neurophysiological signals.
224188920|NCT03076827|PROCEDURE|Total hip replacement|Total hip replacement starts in the morning in group A and starts in the afternoon in group P.
223590533|NCT02858752|OTHER|Experience 5 : Sustained Visual Attention|Neuropsychological tests consist in watching visual stimuli presented in 3 blocks of 3 minutes each, with a break of one minute between each block. The child has to detect the presence of a red letter in a pattern made of four letters (the three other letters are black). Behavioral responses will be provided using a response-button. EEG will be recorded all along to measure Neurophysiological signals.
224188921|NCT03076827|PROCEDURE|Hemi-arthroplasty|Hemi-arthroplasty starts in the morning in group A and starts in the afternoon in group P.
224188922|NCT05544500|DIETARY_SUPPLEMENT|Functional Gum|Functional gum containing a proprietary composition of a herbal extract and vitamins
224188923|NCT05544500|DIETARY_SUPPLEMENT|Basic Chewing Gum|Sugar-free chewing gum
224188924|NCT05544500|DIETARY_SUPPLEMENT|Placebo|Sugar-free tablet
224188925|NCT06406959|PROCEDURE|Transversus abdominal plane block (TAP block)|Unilateral US-guided TAP-block lateral approach with 20 ml 0,375% Levobupivacaine before incision
224188926|NCT01539512|DRUG|Idelalisib|Idelalisib 150 mg tablet administered orally twice daily
224188927|NCT01539512|DRUG|Rituximab|Rituximab administered intravenously 8 times through Week 20: Day 1: 375 mg/m\^2, and 500 mg/m\^2 thereafter
224188928|NCT01539512|DRUG|Placebo to match idelalisib|Placebo to match idelalisib administered orally twice daily
224188929|NCT04668157|DRUG|TAK-536|TAK-536 granule formulation
224188930|NCT05156749|DEVICE|short-arm fiberglass cast|fracture stabilization of salter harris I/II fractures with a fiberglass short-arm cast
224188931|NCT05156749|DEVICE|long-arm fiberglass cast|fracture stabilization of salter harris I/II fractures with a fiberglass long-arm cast
224309313|NCT04641585|DIAGNOSTIC_TEST|Patients affected by Brugada Syndrome 1|ECG analysis by Machine Learning algorithms and blood collection for the transcriptomic study of markers possibly associated with the disease
224309314|NCT06498440|DRUG|Ketorolac 0.5% Eye Drops|Participants in this arm will receive ketorolac 0.5% eye drops, administered twice daily for one week following Selective Laser Trabeculoplasty (SLT). Ketorolac is a non-steroidal anti-inflammatory drug (NSAID) that works by inhibiting cyclooxygenase (COX) enzymes, which play a key role in the inflammatory process. This intervention aims to reduce postoperative inflammation and pain, promoting patient comfort and potentially improving outcomes following SLT.
223498347|NCT05635864|PROCEDURE|Catheter ablation|Catheter ablation of atrial tachyarrhythmia (atrial fibrillation, atrial flutter)
223498348|NCT05545787|PROCEDURE|Cold snare endoscopic mucosal resection|During CS-EMR, methylene blue-tinted epinephrine saline will be injected into the submucosal space around the lesion to lift the lesion. The polyp and 1-2mm of surrounding mucosa will then be closely snared and transected mechanically.
223498349|NCT05545787|PROCEDURE|Hot snare endoscopic mucosal resection|During HS-EMR, methylene blue-tinted epinephrine saline will be injected into the submucosal space around the lesion to lift the lesion. The snare will be placed around the lesion, and then cautery will be applied using the electrosurgical generator.
223498350|NCT05903443|DIAGNOSTIC_TEST|ancillary tests|electroencephalogram, short latency somatosensory evoked potential, transcranial Doppler
223746032|NCT04229615|DRUG|Fluzoparib; Apatinib|Drug: Fluzoparib Orally twice daily; Apatinib Orally once daily
223746033|NCT04229615|DRUG|Fluzoparib|Fluzoparib Orally twice daily
223746034|NCT04229615|DRUG|Placebo|Placebo
224188932|NCT02045940|DRUG|GSK2881078|Hot melt solution within Capsule for oral single ascending doses or repeat dose administration with planned dose level and strength of 0.1, 0.3, 1.0, 2.0, 4.0, 8.0, and 10.0 mg
224188933|NCT02045940|DRUG|Placebo|Hot melt solution within Capsule for oral single ascending doses or repeat doses administration.
224188934|NCT06094075|OTHER|Resistance training based on DSI value|The intervention consist of modifying the ongoing resistance exercises. Those with low DSI values will perform ballistics, explosive exercises. Those with high DSI will perform heavy-load training. The resistance training program will consist of 2 sessions per week for 5 weeks (10 sessions in total). The sessions will be separated by a minimum of 48 hours. The strength training group will consist mostly of exercises with high load, whereas the ballistic training group will perform ballistic exercises with low load or without any additional load. The training principle will be the same for both subgroups, consisting of 3 exercises per training session and a total of 6 exercises per week, with four of the exercises being bilateral, one unilateral, and one quasi-unilateral (Bulgarian split squat and scissor jumps).
224188935|NCT06094075|OTHER|Normal training group|The participants will do a general training program (not based on DSI values). The resistance training program will consist of 2 sessions per week for 5 weeks (10 sessions in total). The sessions will be separated by a minimum of 48 hours. The strength training group will consist mostly of exercises with high load, whereas the ballistic training group will perform ballistic exercises with low load or without any additional load. The training principle will be the same for both subgroups, consisting of 3 exercises per training session and a total of 6 exercises per week, with four of the exercises being bilateral, one unilateral, and one quasi-unilateral (Bulgarian split squat and scissor jumps).
224188936|NCT03449342|DRUG|turoctocog alfa|Patients will receive standard prophylaxis treatment and treatment of bleeding episodes, according to label. Trial product will be administered as intravenous injections (i.v.)
223498351|NCT04011709|COMBINATION_PRODUCT|VR647 Inhalation System + VR647 Smart Card 3 Secs|3 attempts of 19 inhalations, 3 second per breath. Attempts 1 and 2 will be made with air only. Attempt 3 will be made with isotonic saline (0.9% NaCl)
223498352|NCT04011709|COMBINATION_PRODUCT|VR647 Inhalation System + VR647 Smart Card 2 Secs|3 attempts of 28 inhalations, 2 second per breath. Attempts 1 and 2 will be made with air only. Attempt 3 will be made with isotonic saline (0.9% NaCl)
223498353|NCT04011709|COMBINATION_PRODUCT|VR647 Inhalation System + VR647 Smart Card 4 Secs|3 attempts of 14 inhalations, 4 second per breath. Attempts 1 and 2 will be made with air only. Attempt 3 will be made with isotonic saline (0.9% NaCl)
224188937|NCT02722902|DRUG|Carnitor|"CARNITOR® (levocarnitine) is a carrier molecule in the transport of long-chain fatty acids L-Carnitine will be administrated intravenously as continuous infusion during the 6-hour hyperinsulinemic euglycemic clamp. The administration will start with a bolus of 15mg/kg for 10 minutes. Subsequently, continuous L-carnitine infusion of 10mg/kg will start for the remaining 350 minutes.~across the inner mitochondrial membrane."
224188938|NCT02722902|DIETARY_SUPPLEMENT|IntraLipid|Lipid emulsion for infusion
224188939|NCT02722902|DIETARY_SUPPLEMENT|Placebo|Saline will be used as placebo
224188940|NCT03158532|DRUG|Nitroglycerin I|500 microgram of Nitroglycerin intra-arterially administered through the radial sheath, right after sheath placement and before catheterization.
224188941|NCT03158532|DRUG|Placebo I|Saline 0,9% intra-arterially administered through the radial sheath, right after sheath placement and before catheterization.
224188942|NCT03158532|DRUG|Nitroglycerin II|500 microgram of Nitroglycerin intra-arterially administered through the radial sheath, just before sheath removal and before hemostasis.
224309315|NCT06498440|DRUG|Ketorolac 0.5% and Fluorometholone 0.1% Eye Drops|Participants in this arm will receive a combination of ketorolac 0.5% eye drops and fluorometholone 0.1% eye drops. Ketorolac will be administered twice daily and fluorometholone four times daily for one week following SLT. Fluorometholone is a corticosteroid that reduces inflammation by stabilizing capillary permeability and inhibiting inflammatory cell activation. The combination aims to maximize anti-inflammatory effects and enhance patient comfort, potentially leading to better postoperative outcomes compared to ketorolac alone or no treatment.
224309316|NCT00616629|DRUG|AZD1305|Intravenous infusion
224309317|NCT04232280|BIOLOGICAL|mRNA-1647|Lyophilized product that is reconstituted with saline then diluted with a special diluent to reach the desired concentration
224309318|NCT04232280|OTHER|Placebo|0.9% sodium chloride (normal saline) injection
223590534|NCT00542061|DEVICE|half-yearly monitoring routine|A written expert advice for GPs on additional diagnostic, treatment, and referral of patients with asthma and COPD based on half-yearly monitoring routines (lung function assessments including extensive anamnese) supported by half-yearly visits of an AC nurse consultant to the general practices.
224309319|NCT05927948|DEVICE|Laight therapy, NICE V3.1 device|Laight therapy is a non-invasive method of treatment for HS and acne developed in Germany which utilizes a combination of radiofrequency and intense pulsed light exposure. Three passes of the device, all coupled with radiofrequency, are used in the proposed treatment area. The first pass encompasses wavelengths between 420 nm and 1200 nm, the second between 510 nm and 1200 nm, and the third pass between 690 nm and 1200 nm.
224309320|NCT06633172|PROCEDURE|laparoscopic ventral mesh rectopexy|performing ventral mesh rectopexy via laparoscopic surgery to correct the anterior rectocele.
224309321|NCT06633172|PROCEDURE|Trans vaginal repair|performing repair of the rectocele through the recto vaginal septum repair.
224309322|NCT03560648|DEVICE|High definition surface electromyography combined with accelerometer|HD-sEMG and accelerometer data will be collected by Mobita 32® (TMSi) device.
224309323|NCT00235196|DEVICE|Collagen ORC Antimicrobial Matrix (CAM)|
224309324|NCT04519034|OTHER|no intervention|There will be no intervention
224309325|NCT06124495|DRUG|Sitagliptin/Metformin HCl 50/500 mg extended release film-coated tablet|The subjects randomly received single oral dose of Sitagliptin/Metformin HCl 50/500 mg extended release film-coated tablet (Test or reference)
224309326|NCT00823108|DRUG|GIK|12 hour infusion of GIK solution
224309327|NCT02594670|OTHER|DU20 and HT7 combination|acupoints combination includes Baihui (DU20) and Shenmen(HT7),which was considered as the optimal clinical efficay among various combinations of acupoints.
223590535|NCT04485884|DRUG|IN-C005 dose A|One time dose of IN-C005 dose A taken orally.
223590536|NCT04485884|DRUG|IN-C005 dose B|One time dose of IN-C005 dose B taken orally.
223590537|NCT04485884|DRUG|IN-C005 dose C|One time dose of IN-C005 dose C taken orally.
223590538|NCT04485884|DRUG|IN-C005 dose D|Oral administration of IN-C005 dose D once daily for 7 days.
224309328|NCT02594670|OTHER|DU20 and SP6 combination|acupoints combination of Baihui (DU20) and Sanyinjiao (SP6), which should have some clinical efficay among various combinations of acupoints.
224309329|NCT02594670|OTHER|DU20 and SA combination|Combination of Baihui (DU20) and a Sham acupoint (SA), which should have least clinical efficacy among these three types of acupoints combinations.
224309330|NCT05384639|DEVICE|Dual-task Group|Participant will cycle and perform cognitive training simultaneously.
224309331|NCT05384639|DEVICE|Cycling Group|Participant will cycle only.
224309332|NCT05384639|DEVICE|Cognitive Group|Participant will perform cognitive training only.
224309333|NCT04292665|BEHAVIORAL|Classical Massage|During the first interview, a booklet explaining the introduction, purpose, benefits and application steps of hand-foot massage will be given to the patients in the classical massage group. Hand and foot massage will be applied to the patients for 30 minutes in the form of right hand five minutes, left hand five minutes, right foot ten minutes, left foot ten minutes, using liquid vaseline in each session twice a day in the patient's own bed with individual applied sessions by the researcher. Patients will receive a total of 14 sessions of classical massage, twice a day, for seven days.
224309334|NCT04292665|BEHAVIORAL|Benson Relaxation Exercise|During the first interview, patients will be given a booklet explaining the description, purpose, benefits and application steps of the Benson relaxation exercise. With individual counseling sessions, a total of 14 sessions of Benson relaxation exercises will be performed in a quiet room, twice a day for seven days, each session lasting 20 minutes. At the beginning of the application, patients will focus on their breaths by taking slow and natural breaths with the researchers' commands and will quietly say to yourself the words of the focus, sound, sentence or prayer they choose, which are meaningful to them.
224309335|NCT04292665|OTHER|Control|Patients will continue to receive standard nursing care and no further intervention will be made during the research.
224309336|NCT01777620|BIOLOGICAL|onabotulinumtoxinA|BOTOX® (onabotulinumtoxinA) injected into the areas of glabellar lines and crow's feet lines on Day 1.
223590539|NCT04485884|DRUG|IN-C005 dose E|Oral administration of IN-C005 dose E once daily for 7 days.
224188943|NCT03158532|DRUG|Placebo II|Saline 0,9% intra-arterially administered through the radial sheath, just before sheath removal and before hemostasis.
224309337|NCT01777620|DRUG|Normal Saline|Placebo (normal saline) injected into the areas of glabellar lines and crow's feet lines on Day 1.
223498354|NCT01115010|DEVICE|Colonoscope stiffening device|"Colonoscopy is performed with the unassisted colonoscope (Olympus CF-100TL). The standard stiffening wire is introduced only if there is difficulty advancing the colonoscope and only after the tip has passed the splenic flexure. Difficulty is defined as failure to advance the tip of the scope after 5 minutes of trying. If difficulty is again encountered, the firm wire replaces the standard wire. Further difficulty requires removal of the firm wire and so on until cecal intubation is achieved or the procedure is abandoned."
223498355|NCT01115010|DEVICE|Colonoscope stiffening device|"Standard stiffening wire introduced routinely on entry into transverse colon. If difficulty is encountered (as defined previously), the standard wire is removed and attempts made to advance the colonoscope without it. Further difficulty requires introduction of the firm wire and so on until cecal intubation is achieved or the procedure is abandoned."
223498356|NCT01115010|DEVICE|Colonoscope stiffening device|"Firm stiffening wire introduced routinely on entry into transverse colon. If difficulty is encountered (as defined previously), the wire is removed and attempts made to advance the colonoscope without it. Further difficulty requires introduction of the standard wire and so on until cecal intubation is achieved or the procedure is abandoned."
223498357|NCT04928586|DRUG|Pirfenidone|CTD-ILD patients treated with pirfenidone up to the maximum tolerable dose
223498358|NCT04928586|DRUG|DMARDs|CTD-ILD patients treated with DMARDs according to the condition of the disease
223498359|NCT00565864|DRUG|L-thyroxine (L-T4)|L-thyroxine (L-T4) is the intervention for each arm/group. In each arm/group, the dose of L-T4 is adjusted to achieve TSH levels in the randomly assigned arm. L-thyroxine at doses appropriate to attain target TSH levels for the different arms for 24 weeks
223498360|NCT06055556|PROCEDURE|Partial Heart Transplantation|"Partial heart transplantation involves surgical replacement of the semilunar heart valve with a fresh donor graft. The surgical procedure (homograft valve replacement) is common and standard of care. The investigational aspect of this is using a freshly procured valve rather than a cryopreserved, cadaveric one and also the use of limited immunosuppression to help maintain the freshly procured valve as living tissue."
223498361|NCT06055556|OTHER|Freshly procured valve|Fresh donor graft semilunar heart valve.
223498362|NCT04865276|BEHAVIORAL|Integrated tobacco cessation intervention delivered by Community Health Workers with the support of an App (mHealth) + Tobacco cessation program at the public health system|Integrated tobacco cessation intervention delivered by Community Health Workers with the support of an App (mHealth) + Tobacco cessation program at the public health system
223498363|NCT06266507|BEHAVIORAL|Ergotherapy Based Parent Coaching|Occupational Therapy Based Parent Coaching intervention will last 10 sessions and will be carried out on the online platform. Sessions are planned to last between 45-60 minutes. The interviews to be held during the sessions are considered as the basic principles of parent coaching; It will be carried out in line with the principles of joint planning, observation, implementation, reflection and feedback. This intervention aims to educate mothers on proper feeding strategies for their children and to enable them to carry out these practices independently.
223498364|NCT06266507|OTHER|Informative Brochure Distribution|No active intervention will be applied to mothers in the target group, and an informative brochure about nutritional problems will be distributed.
223498365|NCT06850727|DRUG|OD-07656|Experimental intervention
223498366|NCT06850727|DRUG|Vedolizumab|Active standard of care comparator
223498367|NCT06848400|DEVICE|AI-integrated Capsule Gastroscopy (ACG) examination|Product name: Gastric Capsule Endoscope System Specification model: GICE-1000 Manufacturer: Guangzhou Side Medical Technology Co., Ltd.
223498368|NCT06848400|DEVICE|Electronic gastroduodenoscopy (EGD) examination|"EGD was the reference standard against which ACG was compared, and it was performed within 24 hours post-ACG ingestion time.~Product name: Electronic gastrointestinal endoscope (EGD) Specifications and models: GIF-290 series Manufacturer: Olympus, Tokyo, Japan"
223498369|NCT06077604|OTHER|Assessment of exposure to air pollution|For each patient, exposure to air pollution will be assessed over a period immediately prior to any flare-up and over four periods at a distance from the flare-up.
223498370|NCT06847464|DRUG|EDP-323|Subjects will receive EDP-323 on Days 1 and 14
223498371|NCT06847464|DRUG|Itraconazole|Subjects will receive itraconazole QD Days 5-18
224309338|NCT02202070|DRUG|onabotulinumtoxinA|
223498372|NCT06847464|DRUG|EDP-323|Subjects will receive EDP-323 on Days 1 and 23
223498373|NCT06847464|DRUG|carbamazepine|Subjects will receive carbamazepine on Days 5 - 27
224309339|NCT04709770|DRUG|2-liters polyethylene glycol with citrate and simethicone|Low-volume polyethylene glycol-based bowel cleansing agent for colonoscopy.
224309340|NCT04709770|DRUG|4-liters polyethylene glycol with simethicone|High-volume polyethylene glycol-based bowel cleansing agent for colonoscopy.
224309341|NCT04709770|DIETARY_SUPPLEMENT|Low-residue diet|Diet before colonoscopy.
223498374|NCT06847464|DRUG|EDP-323|Subjects will receive EDP-323 on Days 1 and 8
223498375|NCT06847464|DRUG|Quinidine|Subjects will receive quinidine on Days 5-12
223498376|NCT06847464|DRUG|EDP-323|Subjects will receive EDP-323 on Days 1 and 14
223498377|NCT06847464|DRUG|fluconazole|Subjects will receive fluconazole on Days 5-18
223746035|NCT05127447|DEVICE|ES application|Electrical stimulation (ES) application will be given to the ES group
223746036|NCT05127447|OTHER|Sham application|Only vacuum was applied and no current was given from the applied device
223746037|NCT04234321|DRUG|basic fibroblast growth factor|Basic fibroblast growth factor,100ml/ bottle, (35000IU / 8ml) / 100cm2 / time,three times a day.
223746038|NCT04234321|DRUG|Kangfuxin Liquid|Kangfuxin Liquid,20ml / 100cm2 / time,three times a day.
223746039|NCT04234321|DRUG|0.9% Normal saline|0.9% Normal saline,20ml / 100cm2 / time,three times a day.
223746040|NCT03893812|DEVICE|MRI|diffusion weighted MR
223746041|NCT03893812|DEVICE|Ultrasound|Color Doppler ultrasound
223746042|NCT02090647|BEHAVIORAL|aesthetic outcome|
224309342|NCT03083080|PROCEDURE|VATS|VATS is the abbreviation of video-assisted thoracic surgery, which aims to minimize the wound for thoracic surgery and to enhance patient recovery after surgery
224309343|NCT03083080|DRUG|Ropivacaine|30 mL 0.5% ropivacaine is used to achieve VATS block
224188944|NCT05607056|DIETARY_SUPPLEMENT|Sinquanon|"This probiotic food supplement includes fourteen probiotic bacterial strains of Lactobacillus Spp, Bifidobacterium Spp., Bacillus coagulans, Saccharomyces boulardii, three prebiotics and Vitamin-B complex - B1, B2, B3, B6, B7, B9 in an enterosolvent cellulose capsule. The product includes supplementary substances: maltodextrin and magnesium stearate.~2 capsules once a day during the antibiotic dosing. 1 capsule a day for 14 days following completion of antibiotic dosing."
224188945|NCT05607056|DIETARY_SUPPLEMENT|Placebo|The placebo product will have the same appearance as the active product and the same composition but without the live bacteria, prebiotics, and vitamin-B complex. 2 capsules once a day during the antibiotic dosing. 1 capsule a day for 14 days following completion of antibiotic dosing.
224188946|NCT04885036|BEHAVIORAL|EFST intervention|EFST extended intervention is a stand-alone treatment that consist of a two days EFST group course followed by six weekly individual sessions of parental guidance by a licensed EFST therapist. The treatment is given indirectly to the child through work with the parent, thus it might remove or diminish the pressure on the children that suffer from mental health problems to solve their disorder themselves. In this condition a total of 19 hours of EFST treatment is provided.
224309344|NCT03083080|DRUG|Epinephrine|1:400000 epinephrine is mixed with ropivacaine (local anesthetic) to reduce the risk of local anesthetic systemic toxicity
224309345|NCT03173326|PROCEDURE|General anesthesia|General anesthesia will be delivered per standard procedure. General anesthesia will include induction with propofol 1-3mg/kg followed by placement of a laryngeal mask airway with maintenance anesthesia of sevoflurane 0.5-1 minimum alveolar concentration (MAC).
223498380|NCT06390436|DIAGNOSTIC_TEST|Blood sample|A blood sample will be taken, in addition to blood samples taken for the usual follow-up, with 4 dry tubes for the determination of ADA and anti-ADA antibodies and for bio-collection.
223498381|NCT06390436|DRUG|Adalimumab Injection|Adalimumab Injection
223498382|NCT04763291|DIETARY_SUPPLEMENT|Juice Plus+ Fruit, Vegetable and Berry blends|Encapsulated juice powder concentrate derived from 36 dried fruits, vegetables and berries.
223498383|NCT04763291|DIETARY_SUPPLEMENT|Juice Plus+ Omega blend|Encapsulated plant-based fatty acid supplement.
224309346|NCT03173326|PROCEDURE|Subarachnoid block|Neuraxial anesthesia will be performed at the L2-3 or L3-4 interspace with a 25-gauge Whitacre needle in the sitting position. After free flow of cerebrospinal fluid (CSF), 40-45mg of 2-chloroprocaine will be injected based on patient's height and discretion of attending anesthesiologist, needle withdrawn and the patient placed supine.
223498384|NCT03204123|DRUG|Ga-HBED-iPSMA PET|Patients will be injected with 100-300 MBq of 68Ga-HBED-iPSMA and after a waiting of 60-90 minutes patients will be scanned from mid-skull to mid-thigh.
223498385|NCT03204123|DIAGNOSTIC_TEST|PET/CT|PET/CT will be acquired using a GE 710 or 690 time-of-flight PET/CT scanner. Following a waiting period of 60-90 minutes post 68Ga-HBED-iPSMA administration, patients will be scanned from top of the skull to mid-thigh. Images will be acquired with patients in a supine position with their arms raised above their head. If patients cannot raise their arms above the head, the arms will be comfortably positioned and secured by the side of the patient. The PET may be combined with a CT scan as a PET/CT or a MRI scan as PET/MR.
223498386|NCT03204123|DIAGNOSTIC_TEST|MRI|Patients may undergo a diagnostic MRI of the prostate, other body parts or a whole-body MRI at the same imaging session as clinically indicated.
223498387|NCT05431608|BIOLOGICAL|MCARH125|MCARH109 and MCARH125 will be administered 2-7 days following the completion of conditioning chemotherapy. Each dose cohort will consist of 3-6 patients. MCARH109 and MCARH125 will be administered sequentially with 5-30 minutes between the two products.
223498388|NCT05431608|BIOLOGICAL|MCARH109|MCARH109 and MCARH125 will be administered 2-7 days following the completion of conditioning chemotherapy. Each dose cohort will consist of 3-6 patients. MCARH109 and MCARH125 will be administered sequentially with 5-30 minutes between the two products.
224188947|NCT04885036|BEHAVIORAL|Treatment As Usual|In the TAU condition, the families will receive treatment as usual that does not include EFST treatment. Recent research indicates that this is therapy of high quality carried out by highly qualified staff (Tilden et al., 2020; Zahl-Olsen et al., 2020).The therapists are educated psychologists, psychiatrist and family therapists. The TAU intends to be the best treatment for the child/ family based on the type of symptoms presented and requests from the patient and his/her family. We will measure the intensity and type of therapy given in this condition by information from the therapists and investigate that it did not include the main elements of EFST treatment.
224188948|NCT04479358|DRUG|Tocilizumab|Tocilizumab 40mg
224188949|NCT04479358|DRUG|Tocilizumab|Tocilizumab 120mg
224188950|NCT04479358|OTHER|Standard of Care|Tocilizumab-Free Standard of Care
224188951|NCT04479358|OTHER|Standard of Care|Tocilizumab 400mg or 8mg/kg
223498389|NCT02252263|DRUG|Elotuzumab|
223498390|NCT02252263|DRUG|Lirilumab|
223498391|NCT02252263|DRUG|Urelumab|
223498392|NCT01759914|DRUG|Potent topical steroid|
223498393|NCT01759914|DRUG|Superpotent topical steroid|
223498394|NCT05074537|DIAGNOSTIC_TEST|MRI exam|Participants who are receiving standard of care or investigational MRI exams at the Wright Center will be eligible for enrollment in this data bank.
223498395|NCT05074537|DIAGNOSTIC_TEST|PET/CT imaging exam|Participants who are receiving standard of care or investigational PET/CT exams at the Wright Center will be eligible for enrollment in this data bank.
223498396|NCT05074537|DIAGNOSTIC_TEST|CT imaging exam|Participants who are receiving standard of care or investigational CT exams at the Wright Center will be eligible for enrollment in this data bank.
223498397|NCT00374868|DRUG|pemetrexed|"Phase 1: 300 mg/m\^2, intravenous (IV), days 1 and 15 every 28 days x 2 cycles (dose escalation: 300 mg/m\^2, 400 mg/m\^2, and 500 mg/m\^2)~Phase 2: phase 1 determined dose, intravenous (IV), days 1 and 15 every 28 days until disease progression, unacceptable toxicity or patient decision to discontinue or 6 cycles of therapy"
223498398|NCT00374868|DRUG|cisplatin|"Phase 1: 50 mg/m\^2, intravenous (IV), days 1 and 15 every 28 days x 2 cycles~Phase 2: 50 mg/m\^2, intravenous (IV), days 1 and 15 every 28 days until disease progression, unacceptable toxicity or patient decision to discontinue or 6 cycles of therapy"
223498399|NCT03557944|OTHER|Medication reduction|Systematic approach to reduction in polypharmacy.
223498400|NCT03188185|DRUG|ALKS 5461|Samidorphan + buprenorphine, administered sublingually
223498401|NCT03188185|DRUG|ALKS 5461 Placebo|Placebo tablet, administered sublingually
224188952|NCT05705310|BEHAVIORAL|Self Management Strategies|During their maintenance stage cardiac rehabilitation programme, participants will be given a pedometer and asked to wear it during waking hours to record their daily step counts and/or time in physical activity each week. Participants will be encouraged to gradually achieve 150 minutes of moderate-intensity exercise per week and self-monitor their progress using the pedometer. At the end of every week, participants will review progress and set goals with an exercise professional. Group discussions will also take place, focusing on the benefits of regular physical activity, demonstrating lifestyle activities that can help accumulate activity and identifying various means of social support, and identifying local opportunities (groups or places) for physical activity after the cardiac rehabilitation programme has ended. Following this, they will receive a monthly phone call from the exercise professional to check progress and encourage them to continue with the programme.
224188953|NCT06279000|DRUG|Colchicine|"Colchicine Group:~IMP = Colchicine (0.5 mg, enteral) first application in the evening before day of surgery, following a 1-0-1 regimen until the third postoperative day, ending with the application of the ninth dose. Colchicine tablets are provided as 1 mg tablets with a score, which must be divided before ingestion."
224188954|NCT06279000|DRUG|Placebo|"Placebo Group:~Placebo (identical to IMP in appearance and application) first application in the evening before day of surgery, following a 1-0-1 regimen until the third postoperative day, ending with the application of the ninth dose. Placebo tablets are provided as tablets with a score, which must be divided before ingestion."
224188955|NCT06068790|PROCEDURE|HoLEP Surgery|HoLEP will be performed per standard clinical care with the instruments assigned at randomization - 22Fr or 28Fr.
224188956|NCT06068790|DEVICE|28 French sized rigid sheath|The 28Fr is the standard of care sheath size used at this site.
224188957|NCT06068790|DEVICE|22 French sized rigid sheath|The 22Fr is the smaller, investigational sheath size to be used in this study.
224188958|NCT06363461|DRUG|TDM-180935 topical ointment 1.0%|TDM-180935 topical ointment 1.0%
224188959|NCT06363461|DRUG|TDM-180935 topical ointment 2.0%|TDM-180935 topical ointment 2.0%
224188960|NCT06363461|DRUG|TDM-180935 topical vehicle ointment 1|TDM-180935 topical vehicle ointment 1
224188961|NCT06363461|DRUG|TDM-180935 topical vehicle ointment 2|TDM-180935 topical vehicle ointment 2
223498402|NCT02281877|PROCEDURE|Neuromuscular electrical stimulation (NMES)|5x/week, 2x/day, for 45 minutes/session
223498403|NCT02281877|BEHAVIORAL|Standard Rehabilitation Protocol|Standard physical therapy after TKA
223498404|NCT05862701|DRUG|Permethrin|5% permethrin cream
223498405|NCT05862701|DRUG|Sulphur|10% Sulfur ointment
223498406|NCT05219890|DIETARY_SUPPLEMENT|Fish oil|They will consume the fish oil equivalent to 4.8 g/day of EPA and DHA for 3 months, followed by a one-month period without treatment.
223498407|NCT03869021|OTHER|3D printed surgical guide constructed|A printed surgical guide ( to direct through the surgery and make results predictable), the guide is designed by Mimics 19.0, Materialise NV,Belgium and printed with self cure resin
223498408|NCT03869021|OTHER|free hand surgery|A control group in which patients are randomly assigned and surgeries are planned without surgical guides and performed free handed
223498409|NCT05546528|DEVICE|Photobiomodulation|G1 will receive the photobiomodulation application with the Laser Therapy XT device, (DMC, São Paulo, Brazil). The laser will be applied for 60 seconds per point, in 2 extraoral points and 2 intraoral points in the region of the parotid glands bilaterally, as well as 1 extraoral point for the submandibular and sublingual glands (totaling 16 points).
223498410|NCT05546528|DEVICE|Photobiomodulation- Sham|G2 will receive the photobiomodulation application with the Laser Therapy XT device off. The laser off will be applied for 60 seconds per point, in 2 extraoral points and 2 intraoral points in the region of the parotid glands bilaterally, as well as 1 extraoral point for the submandibular and sublingual glands (totaling 16 points).
223498411|NCT02661477|DRUG|pegylated interferon alfa 2|
223498412|NCT02661477|OTHER|Placebo|0,9% natrium chlorine solution
223498413|NCT04415905|DRUG|Propofol|The participants in the group P are anesthetized with propofol
224188962|NCT02213965|DEVICE|Peripheral IV catheter|Intravenous access according to Instructions For Use
224188963|NCT01348464|PROCEDURE|single port appendectomy, three port appendectomy|visual analog scale. questionnaire on wound satisfaction
223498414|NCT04415905|DRUG|Sevoflurane|The participants in the group S are anesthetized with sevoflurane.
223498415|NCT02522845|DEVICE|Class II Compression Stockings (no specific device used)|This study will be looking at the effect of compression therapy in patients having endothermal treatment for truncal incompetence of their varicose veins
223498416|NCT02525978|BEHAVIORAL|Video Task|Subjects are asked to watch a series of six two-minute video clips. The video clips are designed to induce sad or happy emotions or no emotion (neutral) and are taken from movies, documentaries, or instructional videos. There are two videos for each emotion condition. Videos and fixation cross screens are viewed on a laptop computer. In between video clips, patients are asked to quietly look at a fixation cross for one minute, describe their emotional reaction to the video for up to one minute, then again attend to a fixation cross for one minute. A video recording of the frontal view of the participant's face will be made during task performance.
223498417|NCT02525978|OTHER|Imaginal Task|Subjects are asked to think about happy or sad memories for 2 minutes. Subjects are asked to imagine performing neutral tasks, such as buying groceries. Subjects are then asked to think about a memory that makes them feel angry. A video recording of the frontal view of the participant's face will be made during task performance.
223498418|NCT04285411|DEVICE|Accuracy of the VitalDetect™ pulse oximetry system|The purpose of this study was to validate the SpO2 accuracy of the VitalDetect™ pulse oximetry system during non-motion conditions over the range of 70-100% SaO2 as compared to arterial blood samples assessed by CO-Oximetry. It was expected that the Accuracy Root Mean Square (ARMS) performance of the oximetry system would meet the required specification of ARMS of 3.0% or less.
223498419|NCT00694746|DRUG|Omega-3-acid ethyl esters|Participants will receive 2 capsules of 1 gram of fish oil with meals twice a day for a period of six months (including a ramp up period of three weeks)
223498420|NCT00694746|DRUG|Placebo|Participants will receive 2 capsules of 1 gram of placebo with meals twice a day for a period of six months (including a ramp up period of three weeks)
223498421|NCT02842021|DRUG|S2G6T-1|Twice a day topical cream
223498422|NCT02842021|DRUG|S2G6T-2|Twice a day topical cream
223498423|NCT02842021|DRUG|S2G6T-3|Twice a day topical cream
223498424|NCT02842021|DRUG|S2G6T-4|Twice a day topical cream
223498425|NCT04512872|BIOLOGICAL|CT-P41|60 mg/mL single dose, Solution for injection in PFS
223498426|NCT04512872|BIOLOGICAL|EU-approved Prolia|60 mg/mL single dose, Solution for injection in PFS
223498427|NCT04151732|BEHAVIORAL|Physical activity, alcohol, tobacco|Physical activity, alcohol, tobacco - selfreported in the 1990's
223498428|NCT04151732|OTHER|Hormonal factors|Hormonal factors - selfreported in the 1990's
223498429|NCT04151732|OTHER|Cardiovascular disease|Cardiovascular disease - selfreported in the 1990's
223498430|NCT04151732|OTHER|Anthropometric measures|Height, length, BMI
223498431|NCT04557761|DEVICE|microMend®|microMend® is a novel wound closure device that consists of arrays of tiny staples, known as Microstaples, which are attached to a backing material that is the size and shape of a butterfly closure. The Microstaples enable secure attachment of the device to the skin, allowing for the safe closure of wounds associated with surgery and traumatic injuries, such as lacerations. microMend is listed with the FDA and is available for sale in the United States.
223498432|NCT04557761|DEVICE|Closure with Sutures|The Subject's laceration will be closed with sutures per regular institutional policies and procedures.
223498433|NCT02422758|DEVICE|3M™ Bair Hugger™ Preoperative & Outpatient Care Blanket|3M™ Bair Hugger™Preoperative \& Outpatient Care Blanket will cover the whole body. Patients will be prewarmed for 20 minutes with forced air warming system. Unit will be at average power.
223498434|NCT02422758|OTHER|Passive Prewarming|
223498435|NCT05361837|PROCEDURE|Single level serratus anterior plane block|Serratus anterior plane block with local anesthetics at the third rib
223498436|NCT05361837|PROCEDURE|Single level serratus anterior plane block with dexmedetomidine|Serratus anterior plane block with local anesthetics and dexmedetomidine at the third rib
223498437|NCT05361837|PROCEDURE|Bilevel serratus anterior plane block|Serratus anterior plane block with local anesthetics at the third and fifth rib
223498438|NCT05361837|PROCEDURE|Bilevel serratus anterior plane block with dexmedetomidine|Serratus anterior plane block with local anesthetics and dexmedetomidine at the third and fifth rib
223498439|NCT03755466|DRUG|"Baricitinib, olumiant®"|To examine the effects of baricitinib in RA patients
223498440|NCT03755466|DRUG|"Biologics"|To examine the effects of biologics in RA patients
223498441|NCT03755466|DRUG|Tofacitinib 5 MG [Xeljanz]|To examine the effects of tofacitinib in RA patients
224188964|NCT04964882|DIAGNOSTIC_TEST|ultrasound examination of air insufflation in the upper esophageal region and stomach|Presence of air insufflation is assessed using ultrasound in the upper esophageal region and stomach during face mask ventilation
224309347|NCT04810026|BEHAVIORAL|Education|Healthy-lifestyle and diabetes-related virtual education (text and videos)
223498442|NCT05055596|BEHAVIORAL|Tai Chi|Qigong/Tai Chi Easy is a manualized intervention with formal training for instructors through the Institute of Integral Qigong and Tai Chi (IIQTC). The protocol can be modified based on participant needs and physical abilities. Qigong/Tai Chi Easy uses a series of repeated and simple-to-learn movements (rather than long forms with complicated choreography).
223498443|NCT05055596|BEHAVIORAL|Health Coaching|The Health Education group will be adapted from a previously developed time and attention control condition used in HIV research. Additional health education material will be based on information learned in the qualitative interviews conducted prior to the start of this study. Examples of session material include the following: sleep hygiene, healthy diet, sun safety, and healthy homes.
223498444|NCT01587404|DEVICE|THERMOCOOL® SMARTTOUCH™ Catheter (including Surround Flow)|Variable contact force as measured at the catheter tip within the left atrium
223498445|NCT02315625|DRUG|Sunitinib|37.5 mg once daily will continue until progression or unacceptable treatment-related toxicity
223498446|NCT02315625|DRUG|Everolimus|10 mg daily will continue until progression or unacceptable treatment-related toxicity
223498447|NCT06410131|DRUG|FTL008.16|IV infusion every 2 weeks
223498448|NCT06410183|OTHER|no intervention|no intervention
223498449|NCT03915457|OTHER|Dry immersion Control Group|Subjects are immersed up to the neck for 5 days in a specially designed bath filled with tap water.
223498450|NCT03915457|OTHER|Thigh cuffs intervention|Subjects are immersed up to the neck for 5 days in a specially designed bath filled with tap water. During the 5 days of dry immersion, the subjects will wear the thigh cuffs daily for 10 hours during the day (8 am to 6 pm). Thigh cuffs are strips of fabric with inserts of elastic fabric. Different sizes exist to adapt to different thighs. Each cuff has five tightening positions (from 1 to 5) and they will be tightened at the upper third of the thighs to create an occlusion pressure of about 30 mmHg.
223498451|NCT01836822|PROCEDURE|EBUS guided transbronchial forceps biopsy (EBUS-TBFB)|
223498452|NCT01836822|PROCEDURE|EBUS guided transbronchial needle aspiration (EBUS-TBNA)|
223498453|NCT01836822|PROCEDURE|large bore (19G) histologic needle biopsy of the mediastinal lymph nodes|
223498454|NCT01836822|PROCEDURE|Bronchoalveolar lavage (BAL)|
223498455|NCT01836822|PROCEDURE|Endobronchial forceps biopsy|
223590540|NCT04485884|DRUG|IN-C005 dose F|Oral administration of IN-C005 dose F once daily for 7 days.
223590541|NCT02086422|DRUG|ivabradine|
223590542|NCT02086422|DRUG|Placebo|
223590543|NCT02086422|OTHER|Exercise|
224188965|NCT00764465|DRUG|Maraviroc|300 mg BID
224188966|NCT00764465|DRUG|Fosamprenavir|1400 mg BID, 700 mg BID or 1400 mg QD
224188967|NCT00764465|DRUG|Ritonavir|100 mg BID, 100 mg QD
224188968|NCT01333501|DRUG|Fingolimod|0.5 mg in capsules for oral administration once daily
224188969|NCT01333501|DRUG|Interferon beta 1b|250 μg injected s.c. every other day
224188970|NCT00712634|BIOLOGICAL|CMVpp65-A*0201 peptide vaccine|Vaccine received on either days 0 and 28 or on days 0, 28, and 56 and perhaps day 90
223590544|NCT02945644|DRUG|Trazodone|take at bedtime for 14 days
223590545|NCT02945644|DRUG|Placebo|take at bedtime for 14 days
224309348|NCT04810026|BEHAVIORAL|Meal delivery|breakfast, lunch, and dinner adhering to the longevity diet macro-nutrient profiles
224309349|NCT04810026|BEHAVIORAL|Lifestyle coaching|calls with coach and/or nutritionist, access to Facebook community support group
224309350|NCT02194348|DRUG|BIBN 4096 BS - in single rising doses|
224309351|NCT02194348|DRUG|Placebo|
224188971|NCT04156113|OTHER|Yo-Yo intermittent recovery test (level 1)|The Yo-Yo intermittent recovery test (level 1) will be administered once.
224188972|NCT00674440|DRUG|F-DOPA|0.08-0.16 mCi/kg once
224188973|NCT00674440|RADIATION|PET scan|
224188974|NCT03329404|DEVICE|Mirasol Red Blood Cells (MIR RBCs)|Mirasol Red Blood Cells (MIR RBCs) derived from Mirasol-treated WB; WB will be Mirasol treated, centfifuged and leukoreduced and the derived RBCs will be stored before transfusion for up to 21 days and transfused according to the patient's transfusion schedule.
224309352|NCT02074917|PROCEDURE|Anatomical ACL reconstruction|Anatomical anterior cruciate ligament reconstruction in the anteromedial or central tunnels positions.
224309353|NCT02759601|DRUG|Tefinostat|Tefinostat is a novel type of HDACi used in cancer targeted specifically to cell of monocyte - macrophase lineage
224309354|NCT03101644|DRUG|Darunavir|The investigated drugs are Prezista (darunavir 600 mg twice-daily or 800 mg once-daily) and Rezolsta (darunavir 800 mg/cobicistat 150 mg once-daily)
224309355|NCT04005235|DEVICE|Thorasys Tremoflo C-100 Airwave Oscillometry System (FOT)|Ultrasonography will be used to confirm hemidiaphragm dysfunction after brachial plexus nerve block. In subjects with U/S confirmed hemidiaphragm dysfunction, FOT measurements will be taken before and after nerve block and post-operatively after upper extremity surgery.
224309356|NCT02634359|DEVICE|EarlySense home device|Passive contact-free monitoring at home measuring HR, RR and movements Arms: IVF Treatments- Frozen Embryo transfer IVF Treatments- Clinical Evaluation No IVF
223498456|NCT05639595|DEVICE|Web interface for health center staff and mobile application on smart phones for village health volunteers|The designated health center staff will receive a web interface that will allow them to offer job aid for supervision, including real-time information about VHSGs' performance in the form of process indicators and coverage of MCH services. The tool will also support health center staff in their daily tasks, such as high-risk patient tracking, low-supply-inventory alerts, supply chain management, electronic health records, vital events tracking, and automatic calculation of performance-based incentives and motivation for VHSGs. The mobile application will be offered to two female VHSGs from each of the 200 villages connected to their respective health centers in the intervention arm. The mobile application will provide job aid to VHSGs for scheduling home visit tasks, including ANC, home-based newborn care, reporting outcomes of pregnancies, and follow-up visits of complicated cases.
223498457|NCT06023797|DRUG|Neoadjuvant immunochemotherapy|Patients who received NAICT and were operated at the Department of Thoracic Surgery, Zhongshan Hospital Fudan University between 2017 and 2022.
223511901|NCT00079781|DEVICE|RNS® System responsive stimulation|The RNS® System is programmed to provide responsive stimulation (stimulation is ON or enabled). Upon detecting electrographic patterns, previously identified by the neurologist or neurosurgeon as abnormal (epileptiform, or seizure-like) activity, the Neurostimulator provides brief pulses of electrical stimulation through the Leads to interrupt those patterns. The typical patient is treated with a cumulative total of 5 minutes of stimulation a day.
223511902|NCT03386058|DEVICE|Temporary device deactivation|Patient-controlled, temporary deactivation of implanted device
224188975|NCT03329404|DEVICE|Reference Red Blood Cells (REF RBCs)|Reference Red Blood Cells (REF RBCs) will be acquired from routine use inventory and transfused according to the patient's transfusion schedule.
224188976|NCT00455039|DRUG|GW572016|Dose: 1500 mg daily
224188977|NCT03094468|DRUG|P-3058 (terbinafine hydrochloride 10%)|Patients will apply the P-3058 nail solution once weekly in a double blind fashion. The overall treatment phase is of 48 weeks.
224188978|NCT03094468|DRUG|Vehicle of P-3058|Patients will apply the Vehicle of P-3058 once weekly in a double blind fashion. The overall treatment phase is of 48 weeks.
224188979|NCT00914940|DRUG|Fludarabine Phosphate|Fludarabine will be administered in a dose of 25 mg/m2/day IV over approximately 30 minutes for 5 consecutive days (day -6 to -2). The total dose of fludarabine will be 125 mg/m2.
224188980|NCT00914940|DRUG|Tacrolimus|"Tacrolimus will be administered beginning on day -1 at a dose of 0.03 mg/kg/day by continuous IV infusion.~For the first cohort of 35 patients, if there is no evidence of grade II-IV acute GVHD on or prior to day 50, tacrolimus should then be tapered at the rate of approximately 5% of the day 50 dose each week for liquid, and 20% of the day 50 dose per month for capsules.~In the second cohort of 25 patients if there is no evidence of grade II GVHD on or prior to day 30, tacrolimus should then be tapered at the rate of approximately 8% of the day 30 dose each week for liquid, and 33% of the day 30 dose per month for capsules."
223511903|NCT04206943|BIOLOGICAL|Car-T Cell Therapy|"Lymphodepletion Protocol:~* -6. Day: Cyclophosphamide 300 mg / m\^2 i.v.~* -5. -4. and -3. Days: Fludarabine 30 mg / m\^2 i.v. In addition, one day before the lymphodepletion protocol, xanthine oxidase enzyme inhibitor tablets received 100 mg / day p.o. and 0.9% sodium chloride solution 2000 ml / day i.v. infusion on protocol day received and continues for 2 weeks~Car-T cells are administered in 3 split doses. Day 0: 20% or 40% (20% in patients with high tumor burden - in patients with bulky disease and / or more than 15% blast in bone marrow, 40% in patients with low tumor burden) Day 2: 30% or 50%, (the total amount of Car-T cell dose that should be given in the first 2 days should be 70%.) Third dose (%30);is given on the 7th day in the absence of cytokine release syndrome, or if cytokine release syndrome occurs, Car-T cells are given within 1 month if the number of copies falls below 5,000 / ml in 2 consecutive measurements."
223511904|NCT04641975|DRUG|Mirabegron|Oral/ Oral Suspension: Participants with a body weight of ≥ 35 kg are to receive the tablet form of IP unless unable to swallow tablets and will be provided the oral suspension as an alternative. Participants with a body weight \< 35 kg or those who cannot be dosed with the tablet will receive oral suspension.
223511905|NCT04641975|DRUG|Placebo|Oral/ Oral Suspension
223511906|NCT00124033|PROCEDURE|Transcystic Stenting (Facilitated ERCP)|
223511907|NCT02307435|BIOLOGICAL|MSC|subjects are implanted with allogenic mesenchymal stem cells from umbilical cord/ bone marrow/ adipose
223511908|NCT00592527|DRUG|insulin detemir|
223511909|NCT03543020|RADIATION|radiation therapy to brain|OSL placed over the scalp for initial 5 fractions for patients undergoing partial/ whole brain radiation therapy
223511910|NCT02350998|DRUG|OTO-201|
224188981|NCT00914940|DRUG|Thiotepa|Thiotepa will be administered in a dose of 5 mg/kg/day (adjusted body weight) IV over approximately 4 hours for 2 consecutive days (day -6 and day -5).
224188982|NCT00914940|RADIATION|Total-Body Irradiation (TBI)|TBI will be given as 165 cGy fractions twice per day x 4 days - total dose 1320cGy (days -10 to -7).
223590546|NCT02055287|DRUG|LY03004|
223590547|NCT02699567|OTHER|No intervention|
223590548|NCT00854815|PROCEDURE|Irrigation|Irrigation of the area with at least 500ml NS using the power suction/irrigator
223590549|NCT00854815|PROCEDURE|No Irrigation|Suction only using suction/irrigator
223590550|NCT06051903|OTHER|Mobilization wih movement|The purpose of this study is to determine the effect of talar mobilization with movement versus acupuncture on knee pain and function in the postmenopausal women
223590551|NCT06409247|BEHAVIORAL|iExposure|There will be 4 treatment sessions, covering the iExposure intervention. The intervention and assessment process is entirely self-guided. Each session will last approximately 60 minutes. Participants will complete 10 mock-interaction trials for each session.
223590552|NCT06409247|BEHAVIORAL|iExposure plus attention guidance|The attention guidance condition consists of two unique components in addition to the standard iExposure intervention: (1) the intervention rationale will include information about the importance of visually attending to the faces of the audience; (2) participants will be given a target audience member to focus their gaze on during each impromptu response. They will be told that they should look at and focus on the target audience member for the whole response. In each progressive session the number of trials where the participant is directed to focus on an uninterested audience member will increase.
223590553|NCT06409247|BEHAVIORAL|iExposure plus attention control|The attention control condition consists of two unique components in addition to the standard iExposure intervention (1) the intervention rationale will include information about the importance of developing attention control; (2) participants will be given a central region of the screen (non-audience member) to focus on. They will be told that they should look at and focus on the central region for the whole response.
223590554|NCT05044013|OTHER|Full access to JomPrEP app|All participants will receive the JomPrEP app with access to all of its features which include: customizable page (using avatars and pseudonyms); visual dashboard (track and visualize progress); HIV testing plan (create plan for HIV testing, order self-testing kits, testing site locator); PrEP Care Plan (PrEPxpress, automated reminders for follow-up care, labs, delivery); chat function and discussion forum; tailored messages and reminders; assessment center (weekly assessment on adherence to PrEP, HIV risk, mood); knowledge center (resources on HIV testing and PrEP); Mental health support (screen for P/SUD, counseling feedback, referral to support services); Integration of provider locator (provides users with a GPS enabled map for PrEP and mental health support providers in Malaysia) and Gamification (offers extrinsic motivation by rewarding points/milestones for doing activities within the app). Participants can also contact the RA using the chat function for support.
223590555|NCT05044013|OTHER|inactivated JomPrEP app|Only information and resources for PrEP services will be available along with access to risk assessment tools.
223590556|NCT01814124|OTHER|Manual therapy plus exercise|
223590557|NCT01814124|OTHER|Advice and home exercise|
224188983|NCT00914940|OTHER|Magnetic Affinity Cell Sorting|Device
224188984|NCT00914940|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Patient will undergo a PBSC transplantation
223498458|NCT01684592|BEHAVIORAL|Phone-based postpartum continuing care|PPCC Counselors will make initial contact with participants in the experimental group at 36 weeks gestation (i.e., one week prior to full-term), will call again within one week after the baby's birth, and eight additional times over the course of the first six months postpartum. The PPCC protocol will be developed based on the 5 A's (standard of care during pregnancy) and the Recovery Management Checkup model where relapse is expected and efforts are made to take a more proactive approach to identify women who are having cravings or have relapsed and re-intervene with them as soon as possible to assist them in regaining smoking abstinence. Women in the experimental group will also have the option of calling the PPCC line 24 hours a day, 7 days a week.
223590558|NCT03442218|DRUG|Clorhexidine|Vaginal wash with clorhexidine solution previous to cesarean section in patients with premature rupture of membranes.
223590559|NCT03442218|DRUG|Saline solution|Vaginal wash with saline solution previous to cesarean section in patients with premature rupture of membranes.
223590560|NCT01735981|OTHER|Video game exercise using Dance Dance Revolution|use of the video-game, Dance, Dance Revolution as an exercise to improve gait and balance
223590561|NCT01735981|OTHER|hand-held video game|hand-held video games
223590562|NCT04086914|PROCEDURE|Nerve Block|This group will receive a nerve block consisting of 20mL of 5mg/mL ropivicanine and 0.1mL of 10mg'mL dexamethasone.
223590563|NCT00932906|OTHER|Different self-training methods|Self training with MiniAnne Training Kit
223590564|NCT00932906|OTHER|Standard training|Instructor-based training meeting ERC directions
223590565|NCT05897892|DIETARY_SUPPLEMENT|Clinical study on the mangrove sword bean food bar effect for older people|The treatment group consumed 50 g mangrove sword bean food bar each day during 15 days.
223590566|NCT04062591|DRUG|Piroxicam group|patients will receive 0.4 mg/kg piroxicam IM
223590567|NCT04062591|DRUG|Placebo|saline IM in the same dose of piroxicam
223590568|NCT04847765|DEVICE|VIPUN Gastric Monitoring System prototype|"The VIPUN Balloon Catheter prototype is a nasogastric feeding tube with integrated balloon that can be inflated with a preset volume of air. Intraballoon pressure changes are recorded outside the body. Gastric contractions can be detected in the pressure profile.~The recording lasts 30 minutes and is combined with simultaneous cine magnetic resonance imaging."
224188985|NCT00914940|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Patients who are considered appropriate candidates for allogeneic hematopoietic stem cell transplantation
224188986|NCT00914940|BIOLOGICAL|T Cell-Depleted Hematopoietic Stem Cell Transplantation|Patients who are eligible will receive a T Cell-Depleted Hematopoietic Stem Cell Transplantation
224188987|NCT01899573|DEVICE|AccuCinch® Ventriculoplasty System|Percutaneous intervention for the treatment of functional mitral regurgitation
224188988|NCT00796367|DRUG|VI-0521|7.5 mg phentermine and 46 mg topiramate
224188989|NCT00796367|DRUG|Placebo|placebo
224188990|NCT00796367|DRUG|VI-0521|15 mg phentermine and 92 mg topiramate
224188991|NCT00281931|BIOLOGICAL|rituximab|
224188992|NCT00281931|DRUG|cyclophosphamide|
224188993|NCT00281931|DRUG|fludarabine phosphate|
224188994|NCT03332225|DRUG|Anakinra|Treatment with anakinra
224188995|NCT03332225|DRUG|Recombinant human interferon-gamma|Treatment with recombinant human interferon-gamma
224188996|NCT03332225|DRUG|Placebo|Treatment with Placebo
224188997|NCT05298527|BEHAVIORAL|Back Massage|The woman lies face down and a pillow is placed under her forehead. Massage begins with effleurage. Petrissage is started from the sacrum and the hands are lifted up to the nape and repeated 4 times. After the petrissage movement is completed, effusion is applied to the area once. Friction is applied. After rubbing, tapotement is applied to the entire back.
224188998|NCT01220921|PROCEDURE|Lumbar Discectomy|Microsurgical removal of disc that is compressing a nerve root
224188999|NCT01220921|PROCEDURE|Single-level lumbar fusion|pedicle screws with arthrodesis as directed by surgeon. Fusion can be posterolateral, interbody, or both.
224189000|NCT04746001|DIAGNOSTIC_TEST|Genomic sequencing|Sequencing data
224189001|NCT04746001|DIAGNOSTIC_TEST|Histological examination|Images for deep learning
224189002|NCT05889780|OTHER|Food pantry referrals|Clients receive food for up to 21 meals per person in the household each month.
224189003|NCT05889780|OTHER|No-prep, ready-to-eat meals|12 nutritious no-prep, ready-to-eat meals are provided each month.
224309357|NCT02634359|PROCEDURE|Vaginal ultrasound|Vaginal ultrasound for the purpose of determining follicle size Arms:IVF Treatments- Frozen Embryo transfer IVF Treatments- Clinical Evaluation No IVF
223590569|NCT05645965|DEVICE|ICD insertion|Patients who underwent implantable cardioverter-defibrillator (ICD) insertion between January 2015 and December 2020
224189004|NCT05889780|OTHER|Vouchers|A $75 voucher is provided each month and participants are instructed to use the voucher to purchase food or transportation to food retailers.
224309358|NCT02634359|PROCEDURE|Blood Test|Hormonal profile blood tests arms: IVF Treatments- Frozen Embryo transfer IVF Treatments- Clinical Evaluation No IVF
224309359|NCT01548118|BIOLOGICAL|HPV 16/18 vaccine, 0,5ml|Subjects were planned to receive HPV vaccine 0.5ml administered intramuscularly according to a 0, 2, 6 month vaccination schedule
223498459|NCT01684592|BEHAVIORAL|Standard care|All women will receive the standard of care approach (5 A's and referral to a 24/7 quit line postpartum) from MWC during pregnancy. The 5 A's brief intervention was modified by American College of Obstetricians and Gynecologists (ACOG) for use with pregnant women and is recommended to help pregnant women quit smoking. It includes the following steps: Ask about tobacco use, Advise to quit, Assess willingness to make a quit attempt, Assist in quit attempt, and Arrange follow-up.
223498460|NCT02395770|OTHER|Rehabilitation program|"Movement training: To re-educate control of movement, exercises of increasing difficulty in terms of movement plane, range of motion, speed and resistance were performed.~Strengthening: Using extremities weight, free weights or elastic bands, scapulothoracic and scapulohumeral strengthening was performed to increase strength and control of shoulder muscles.~Stretching \& Manual Therapy: These modalities, performed only if needed, were aimed at addressing stiffness of posterior and inferior glenohumeral capsule and pectoralis minor.~Patient education: Participants received education regarding posture and body mechanics. They were instructed on preferred shoulder positioning during sleep, activities, work and sports"
223498461|NCT02980653|DRUG|Megestrol acetate (MA) 400 mg/day|Megestrol acetate (MA) will be given on 400 mg/day as eligible patient begin CCRT. Total treatment period is for a maximum of 12 weeks calculated from the date of first dose.
223590570|NCT03492034|DEVICE|IUD during CS|IUD insertion during CS
223590571|NCT03492034|DEVICE|IUD after puerperium|IUD after puerperium
223498462|NCT03896620|DEVICE|Preoperative RT|Radiation delivered before surgery.
223498463|NCT03896620|DEVICE|Postoperative RT|Radiation delivered after surgery.
223498464|NCT03896620|DRUG|Chemotherapy|Physician's choice of chemotherapy.
223498465|NCT03896620|OTHER|Surgery|Surgical excision of tumor.
223498466|NCT04288037|DIAGNOSTIC_TEST|fetal heart rate variability|observational study. no intervention
223498467|NCT00945620|DRUG|ropivicaine|30mL containing 300mg ropivicaine 1% with addition of 1:300,000 epinepherine
223498468|NCT00945620|DRUG|placebo|Placebo
224189005|NCT05733208|PROCEDURE|Remote ischemic preconditioning|Remote ischemic preconditioning will consist of four cycles of 5-minute inflation of an blood pressure cuff on the upper arm to 200 mmHg followed by 5-minute deflation. RIPC will be performed twice, one at approximately 24 hours before anaesthesia and the other at approximately 1 hour before anaesthesia.
224189006|NCT05733208|PROCEDURE|Sham-remote ischemic preconditioning|The identical looking cuff will be placed around the upper arm but not actually inflated for 40 minutes. The control device's components and external appearance are identical to that of the RIPC. However, as compared to the RIPC, the blood pressure cuff's line of inflation is disconnected such that the cuff cannot be inflated. Control treatment will be performed twice, one at approximately 24 hours before anaesthesia and the other at approximately 1 hour before anaesthesia.
224309360|NCT01548118|BIOLOGICAL|Placebo control, 0.5ml|Subjects were planned to receive three doses of the placebo control 0.5ml administered intramuscularly according to a 0, 2, 6 month vaccination schedule.
224309361|NCT01548118|BIOLOGICAL|HPV 16/18 vaccine, 1.0ml|Subjects were planned to receive HPV vaccine 1.0ml administered intramuscularly according to a 0, 2, 6 month vaccination schedule
224309362|NCT01548118|BIOLOGICAL|Placebo control, 1.0ml|Subjects were planned to receive three doses of the placebo control 1.0ml administered intramuscularly according to a 0, 2, 6 month vaccination schedule.
224309363|NCT04308707|OTHER|Breaking bad news skills|Communication skills analyzed by a specialized questionnaire designed from a Breaking bad news protocol developed in 2018-2019 in Barcelona.
224309364|NCT00752648|DRUG|TMC435350|
224309365|NCT04639804|DRUG|Tegoprazan|Tegoprazan 50 mg tablet
224309366|NCT04639804|DRUG|Naproxen|Naproxen 500 mg tablet
224309367|NCT04639804|DRUG|Aceclofenac|Aceclofenac 100 mg tablet
224309368|NCT04639804|DRUG|Celecoxib|Celecoxib 200 mg capsule
224309369|NCT02965040|DRUG|Roxadustat|Oral
224309370|NCT04005352|BIOLOGICAL|Brolucizumab 6 mg|Intra-vitreal injection
224309371|NCT04005352|BIOLOGICAL|Aflibercept 2 mg|Intra-vitreal injection
223590572|NCT02900768|BEHAVIORAL|Exercise|Combination of resistance and aerobic exercises for 100 days.
223590573|NCT03580980|DRUG|Paracetamol and ketamine|intravenous paracetamol and ketamine followed by ketorolac
223590574|NCT03580980|PROCEDURE|Caudal levobupivacaine|an epidural injection of morphine and levobupivacaine through the caudal space
223590575|NCT03580980|DRUG|Morphine|patient controlled analgesia by morphine
223746043|NCT05706142|OTHER|Motor Imagery Education|"Within the scope of motor imagery training, a presentation will be made to the students of pediatric rehabilitation lecture in the intervention group about what motor imagery is. PETTLEP model will be used for imagery training. In this model, imagery training will be prepared in accordance with our purpose, taking into account the physical, environmental, time, task, learning, emotion and personal subheadings. In the training sessions, relaxation exercises will be given for 5 minutes first. After the relaxation exercises, special colic massage imagery training will be given to newborns for 10 minutes. The massage will also be shown as practically at class."
223746044|NCT03168308|DRUG|Sugammadex|Sugammadex 2 mg/kg
223746045|NCT03168308|DRUG|Neostigmine w/ Glycopyrrolate|Neostigmine 50 mcg/kg, maximum 5 mg Glycopyrrolate, 8 mcg/kg, maximum 1 mg
223746046|NCT01568931|DRUG|Urokinase|intracoronary, urokinase, 200,000 Units, bolus
223746047|NCT01568931|DRUG|Saline|intracoronary, saline, bolus 1 cc
223746048|NCT01718652|DRUG|Canagliflozin (JNJ-28431754)|One 300 mg capsule-shaped tablet taken orally (by mouth) on Days 1 through 8.
223746049|NCT01718652|DRUG|Cyclosporine|Four 100 mg capsules (400 mg total dose) taken orally 30 minutes before the last dose of canagliflozin (JNJ-28431754) on Day 8.
223746050|NCT06142435|DEVICE|Head and Intraocular Trauma Tool|HITT device to scan the eyes of participants up to 3 times (\~45 seconds each) at the time of admittance to study. The participant is to place the chin in the chin-rest and fixate on the illuminated light on the device.
223746051|NCT03019939|DRUG|Isavuconazole|Given PO or IV
223746052|NCT06317155|OTHER|Occupational therapy|Occupation Therapy, specifically interoception informed interventions which aim to improve sensory integration and emotional regulation. Additionally, occupational therapy models which focus on augmenting well-being and functionality, facilitating participation and engagement within communities, and promoting involvement in meaningful activity.
224189007|NCT04008290|DRUG|0.6 mg Liraglutide|For a duration of 5 consecutive days, subjects will receive a subcutaneous injection in the abdomen of 0.6 mg liraglutide. The injection will be placed by a trained nurse at 8 o'clock every morning. A wash out period of at least one week will be respected between the two treatment weeks.
224189008|NCT04008290|DRUG|Placebo|For a duration of 5 consecutive days, subjects will receive a subcutaneous injection in the abdomen of placebo (0.9% saline solution). The injection will be placed by a trained nurse at 8 o'clock every morning. A wash out period of at least one week will be respected between the two treatment weeks.
224205792|NCT03173521|BIOLOGICAL|AAV2/8.TBG.hARSB|"Adeno-associated viral vector serotype 8 with liver-specific thyroxinebinding globulin (TBG) promoter driving the expression of the human ARSB gene. Four dose levels are available:~* Starting dose is 6x1011 gc of vector per kg of body weight;~* High dose is 2x1012 gc of vector per kg of body weight and will be administered after at least two subjects at the starting dose have experienced no DLT;~* Very high dose is 6x1012 vector per kg of body weight and will be administered after three subjects at the high dose have experienced no DLT;~* Low dose is 2x1011 gc of vector per kg of body weight. Intermediate doses are also possible. The administration of the IMP will be performed into a peripheral vein. The IMP final volume to be injected is calculated based on the patient's weight (determined on the day of hospital admission), as 3 mL/kg."
224309372|NCT05900258|DRUG|Tirbanibulin|Klisyri® 10 mg/g Ointment (Tirbanibulin) patients receive Tirbanibulin on sun-damaged areas of the face for five days, according to the SmPC.
224309373|NCT06017479|DRUG|Fosfomycin 3000 MG|Fosfomycin 3 g single dosage 1 hour before the urodynamic examination
223746053|NCT04367688|DRUG|Tenofovir Disoproxil Fumarate 300 mg / emtricitabine 200 mg|daily use for PrEP
223746054|NCT03496948|BEHAVIORAL|TeGeCoach|"12-month long telephone health coaching carried out by specially trained coaches. The health coaching is a patient-centered approach based on motivational interviewing, shared decision-making and active listening techniques. Primary care physicians will be constantly involved receiving regular health reports from the coach.~The walking exercise is based on the principle of interval training. Patients will continuously wear an activity monitor device to review their exercise performance and for remote exercise monitoring by the coach. This activity information will be regularly reviewed by the coach to ensure that the patient adheres to the individual walking exercise prescription."
223746055|NCT05221333|DEVICE|Sorrel Wearable Injector|Use of Sorrel Wearable Injector in pilot study
224309374|NCT06017479|DRUG|Levofloxacin 500mg|Levofloxacin 500 mg single dosage 1 hour before the urodynamic examination
224309375|NCT02623283|OTHER|No intervention given|Participants will have a full dental examination but no operative intervention
223511911|NCT00926705|DRUG|Dexmedetomidine and Fentanyl|Dexmedetomidine in a dose of 1 ug/kg initial dose then continuous infusion of 0.7 ug/kg/hr . Combined with Fentanyl at a dose of 2 ug/kg initially plus boluses of fentanyl to keep the patient hemodynamically stable.
223511912|NCT00926705|DRUG|Fentanyl|This group received Fentanyl at a dose of 2 ug/kg initially, followed by boluses to keep the patient hemodynamically stable.
224309376|NCT03670693|DIAGNOSTIC_TEST|Muscle strength and fatigue assessment|Measurement of maximum voluntary isometric contraction of the quadricep muscle on a cybex isokinetic dynomometer. This will be followed by a fatigue assessment where the torque decrement over 20 isokinetic knee extensions at a fixed angular velocity will be quantified to assess muscle fatigue
223511913|NCT04365881|OTHER|Cross-sectional observational study|Survey
223511914|NCT01259024|DEVICE|transarterial chemoembolization using a drug-eluting bead|Up to 2 vials of LC Beads will be administered. One 2 mL vial each of 300-500 and 500-700 um LC Beads with 37.5 mg/mL doxorubicin will be prepared and mixed with radiographic contrast. Under fluoroscopic control, the vial of 300-500 um vial will be infused, followed by the vial of 500-700 um LC Beads. If the artery does not reach stasis prior to administration of both vials, and there is residual antegrade flow in the feeding artery, it will be treated with bland embolization similar to chemoembolization.
223511915|NCT06361446|DRUG|Zonisamide 50 MG|"The arm will include 300 migraine patients diagnosed according to ICHD3-beta criteria. all patients received zonisamide 100 mg daily and acetaminophen 500-1000 mg on migraine attack.~We will assess The change in migraine days per 28 days, the number of migraine days after three months of treatment, and the percentage of patients who achieved ≥ 50% reduction in the monthly headache days frequency compared to the baseline frequency (14). HIT-6 score reduction in each group after three months of treatment. The safety of zonisamide was evaluated by monitoring and documenting treatment-emergent adverse events (TEAE) in patients through regular follow-up procedures for three months."
224189009|NCT06248203|BEHAVIORAL|Tealeaf-Mansik Swasta (Tealeaf) as adapted for Adolescents|"The investigators will test Tealeaf (Teachers Leading the Frontlines - Mansik Swastha \[Mental Health in Nepali\]) as adapted for adolescents. Tealeaf is a task-shifting intervention in which teachers deliver transdiagnostic mental health care. Created in Darjeeling, Tealeaf centers on training and supervising teachers to deliver education as mental health therapy (Ed-MH) to children (age 5-12). Ed-MH is the investigators' novel, task-shifting, therapy modality that minimizes the time teachers need to deliver care by fitting it into their work. In Ed-MH, teachers use evidence-based therapeutic techniques adapted for use in their existing interactions with students in need (e.g., while teaching) and streamlined for care for any diagnosis (transdiagnostic). Tealeaf-A's adaptation (inclusive of Ed-MH) is supported by a Doris Duke Charitable Foundation (DDCF), Fund to Retain Clinical Scientists (FRCS), Caregivers at Carolina COVID award."
224189010|NCT06248203|BEHAVIORAL|Enhanced Usual Care (EUC)|Enhanced Usual Care (EUC) is a less intensive version of the Tealeaf intervention. The EUC service package has been designed to be the most intensive form of care that could be envisioned as viable in the study setting in the foreseeable future without a significant increase in resource investment.
224189011|NCT06137794|OTHER|"Use of I-Anticoagulation to make the decision and manage patients"|I-Anticoagulation will offer a flexible and efficient communication platform for healthcare professionals and AF patients. The tool is composed of two modules: an anticoagulation decision support system and a full-process patient management system.
223590576|NCT05426278|DEVICE|Bair hugger and Forces air warmer|The EQUATOR™ (EQ-5000) air-warmer is a convective warmer, with the average and maximum Contact Surface Temperatures of 39℃ \& 44℃ Respectively. Temperature on this device can be set at 36℃ , 40℃ , 44℃. The 3M™ Bair Hugger ™ (SW-2003) upper body blanket is used to warm the body from head till the xiphisternum
223590577|NCT01324791|PROCEDURE|anti-reflux surgery|
223590578|NCT02069119|DRUG|OPC-108459|
223590579|NCT02069119|DRUG|Placebo|
223590580|NCT04295239|PROCEDURE|MRI|Pre and Post operative MRI
223590581|NCT03562312|OTHER|high-intensive aerobe exercise|Aerobe bicycle ergometer training within 77-95% of maximum oxygen consumption; duration of each training session: 20 minutes; frequency of training: 6 sessions within 12 days
223590582|NCT03562312|OTHER|low-intensive aerobe exercise|Aerobe training below 70% of maximum oxygen consumption (including light stretching and simple exercises adapted from yoga figures); duration of training session: 20 minutes; frequency of training: 6 sessions within 12 days
223590583|NCT03244163|DEVICE|Spyglass DS cholangioscope|The 1.8Fr holmium:YAG laser fiber (Lumenis, Yokneam, Israel) will be inserted into the cholangioscope's working channel for lithotripsy under direct visualization. An EHL probe may alternatively be used depending on availability. Lithotripsy is applied until fragments of the targeted stone are no longer lumen filling, and can be dispersed easily with fluid irrigation. Fragmented stones are then removed by a combination of conventional techniques. To confirm stone clearance, the Spyglass DS cholangioscope will be re-introduced, and the bile duct will be examined for residual stones from the confluence of the right and left intrahepatic ducts to the papillary opening
223590584|NCT03244163|DEVICE|BML|Biliary sphincterotomy with/without EPBD to the size of the lower bile duct with a limit of 15mm will be performed. Stones are removed by a combination of conventional BML, extraction balloon and/or baskets, without laser lithotripsy. An occlusion cholangiogram is performed to confirm stone clearance. In cases where stone clearance is incomplete, a plastic biliary stent bridging the stone will be inserted for temporary drainage until definitive management, usually within one month.
223590585|NCT01413139|DEVICE|4F portfolio products from Biotronik|4F portfolio products from Biotronik: Astron pulsar / Astron Pulsar-18, Fortress, Passeo-18, Cruiser-18
223590586|NCT00191230|DRUG|gemcitabine|
223590587|NCT00191230|DRUG|carboplatin|
224189012|NCT00938457|RADIATION|stereotactic radiation therapy|Patients undergo stereotactic body radiation therapy
224189013|NCT00938457|PROCEDURE|implanted fiducial-based imaging|radiation therapy treatment planning
223590588|NCT00191230|DRUG|cisplatin|
223590589|NCT01237613|DEVICE|Artelon|Artelon Tissue Reinforcement
223590590|NCT03563196|RADIATION|Chest Radiograph|Chest radiogram will be obtained on day 1
223590591|NCT03563196|DIAGNOSTIC_TEST|Lung Ultrasound|Lung ultrasound will be done on day 1
223590592|NCT00837343|DRUG|quetiapine fumarate tablet (Seroquel)|Investigational product: quetiapine fumarate tablet (Seroquel) , 25 mg, 200 mg, 300mg, manufactured by AstraZeneca.The total daily doses of quetiapine fumarate will be increased to 600mg/d on the 6th since enrolment day. At day 7 or later, the dose can be adjusted in the range of 400- 800mg/day.
223590593|NCT01033916|OTHER|LIBERAL|The LIBERAL arm of the study will have a target Blood Glucose level ranging from 121-180 mg/dL. As opposed to the standard of less than 120 mg/dL.
223590594|NCT00214916|DRUG|intensive insulin therapy (Actrapid IV to normoglycemia)|intensive insulin therapy (Actrapid IV in continuous infusion to age-dependent normoglycemia)
223590595|NCT00214916|DRUG|conventional insulin therapy (Actrapid IV only for excessive hyperglycemia)|conventional insulin therapy (Actrapid IV in continuous infusion only to treat blood glucose levels exceeding 220 mg/dl)
223590596|NCT02902393|BIOLOGICAL|Thromboelastography|
223590597|NCT02270112|DEVICE|ECG|Patients receive a 5 Minute ECG recording and have their pulse recorded by an iPhone.
223590598|NCT02458781|DRUG|Metronidazole|Metronidazole 500mg given twice daily for 14 days
223746056|NCT00741039|BIOLOGICAL|inactivated influenza vaccine and the 23- valent pneumococcal vaccine|Patients \>65 years of age with a diagnosis of prostate, lung, and/or breast cancer will be immunized with the inactivated influenza vaccine (0.5 ml intramuscularly) and/or the 23-valent pneumococcal vaccine (0.5 ml subcutaneously or intramuscularly). Prior to vaccination, titers against influenza and pneumococcus will be measured, as will serum IgG levels and IgG subtypes. At 8-16 weeks after vaccination, post vaccine titers, CBC, lymphoid phenotype and function will be assessed.
224189014|NCT00938457|PROCEDURE|cone-beam computed tomography|radiation therapy treatment planning
223590599|NCT02458781|DRUG|Ciprofloxacin|Ciprofloxacin 500mg given twice daily for 14 days
223590600|NCT02458781|DRUG|Placebo|Placebo given twice daily for 14 days
223590601|NCT02041338|DRUG|Paclitaxel and carboplatin|
223590602|NCT02041338|DRUG|Paclitaxel|
223590603|NCT02041338|DRUG|Epirubicin and Paclitaxel|
224189015|NCT03433443|BEHAVIORAL|Case manager assisted rehabilitation|In addition to receiving usual physical rehabilitation the patients in the intervention group had a case manager assigned. A team of three case managers delivered the intervention: a medical doctor specialized in social medicine, an occupational therapist, and a social worker. The case managers were all experienced case managers for non-surgical low back pain patients. The allocation to the case manager was random, and all patients had a main case manager assigned. The case managers involved the other case managers if their special knowledge were needed. Barriers for the patient's rehabilitation were discussed with the multidisciplinary team also including a surgeon, a physiotherapist, and a nurse.
223498469|NCT03678662|OTHER|Hypoalgesia expectation|"Before and after the squat exercise, assessment of how you experience pressure pain with the 2 devices you have just become acquainted with will be repeated. While doing the squat exercise you will be asked to indicate pain in the thigh muscles.~What we currently know about the effect of exercise on the experience of pressure pain is that after eg. cycling or walking, more pressure can be applied before the pressure starts to hurt and more pressure is required before you can't withstand anymore.~Whether this applies to a squat exercise, as the one you are about to perform, has not yet been investigated, but we expect that the same applies here, namely, that more pressure is required before you feel the pressure begins to hurt you and you will be able to endure a greater pressure.~Supported by visual information."
223498470|NCT03678662|OTHER|Hyperalgesia expectation|"Before and after the squat exercise, assessment of how you experience pressure pain with the 2 devices you have just become acquainted with will be repeated. While doing the squat exercise you will be asked to indicate pain in the thigh muscles.~What we currently know is that exercise can cause muscle pain, both during and after training. You may have experienced muscle soreness yourself in relation to training? We expect that the same will apply here. Namely, after performing this squat exercise, which will likely hurt your thigh muscles while doing it, you will experience that the pressure applied afterwards, with the two devices you have just become acquainted with, should be less before it starts to hurt and that you can endure less pressure.~Supported by visual information."
223498471|NCT03678662|OTHER|Neutral|"Soon you are going to do a training exercise in a squat position up against the wall for 3 min. Following the squat exercise, we will repeat the measurement of how you experience pressure pain with the 2 devices you have just become acquainted with. While doing the squat exercise you will be asked to indicate pain in the thigh muscles."
223498472|NCT03634150|BIOLOGICAL|Nerofe is a first in class derivative of a human hormon-peptide(TCApF), with Cancer suppressive properties.|Once weekly treatment, with IV doses of Nerofe (96mg\\m2) and low dose (20 mg/m2) Doxorubicin 5 or 24 hours from one another) .
223498473|NCT02096913|DRUG|Dolormin® extra (Ibuprofen)|"Ibuprofen Tablets (as lysine-salt) 2400mg/d (400mg 2-2-2) applied orally for 4 weeks (Arm I; n=6).~In order to reduce the risk of damage to the gastrointestinal mucosa Pantoprazole is applied as concomitant medication in a dosage 40mg/d during the treatment period."
223498474|NCT02096913|DRUG|Dolormin® extra (Ibuprofen)|"Ibuprofen Tablets (as lysine-salt) 2400mg/d (400mg 2-2-2) applied orally for 12 weeks (Arm II, n=6).~In order to reduce the risk of damage to the gastrointestinal mucosa Pantoprazole is applied as concomitant medication in a dosage 40mg/d during the first 4 weeks of treatment and may be reduced to 20mg/d during the following treatment period after individual risk-benefit assessment."
223498475|NCT05414773|OTHER|measurement of axial length and keratometry by sonographers with a topographic module|measurement of axial length and keratometry by sonographers with a topographic module
223498476|NCT04777903|OTHER|collect date about all participants|a standardized and structured questionnaire that included information on age, residence, education, pregnancy history, disease history, height, and conception method, after obtaining the consent of all participants.
223498477|NCT00857051|OTHER|Hotline Service|A 24 hour hotline to answer questions about baby care or mother self-care. Hotline will be answered by a midwife and answers will be based on algorithms.
223498478|NCT00857051|OTHER|Film|A DVD addressing common stressors in the early postpartum.
223498479|NCT00680173|DRUG|pegylated interferon alpha 2a and plus ribavirin|pegylated interferon alpha 2a 180 mcg/week and Ribavirin 1000-1200 mg/day for 24 weeks, follow up for 24 weeks
223498480|NCT04573946|DIETARY_SUPPLEMENT|Vitamin D3 placebo|Vitamin D placebo
223498481|NCT04573946|DIETARY_SUPPLEMENT|Fish oil placebo|Fish oil placebo
223590604|NCT03725813|OTHER|Person-centred inpatient care|"The intervention comprises three sequential steps in the care process. The first two steps follow one after the other in conjunction with admission to the ward: 1) person-centred assessment, and 2) creation of a person-centred health plan. Persistent person-centred inpatient care, the third step, is practiced throughout the hospital stay, and is a component of the quality and patient safety program.~The model is systematically applied to all patients admitted to the unit. All staff are trained in PCC before implementation of the intervention."
223498482|NCT04573946|DRUG|Omega-3 fatty acids (fish oil)|Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid \[EPA\] and 375 mg of docosahexaenoic acid \[DHA\]).
223590605|NCT05795192|DRUG|SB17170|Taking SB17170 orally once a day
223590606|NCT05795192|DRUG|Placebo|Taking Placebo orally once a day
224189016|NCT03433443|BEHAVIORAL|Usual physical rehabilitation|The patients received usual physical rehabilitation at their community rehabilitation unit, and had no case manager assigned.
224309377|NCT03670693|DIAGNOSTIC_TEST|Dual-energy X-ray absorptiometry (DEXA scan)|Body composition will be assessed via DEXA scan (Lunar Prodigy, GE Medical Systems, Bucks, UK)
223498483|NCT04573946|DIETARY_SUPPLEMENT|Vitamin D3|"Vitamin D3 (cholecalciferol), 2000 IU per day.~Other Names: cholecalciferol"
223498484|NCT01868451|DRUG|Brentuximab vedotin (SGN-35)|
223498485|NCT01868451|DRUG|Doxorubicin HCL|
223498486|NCT01868451|DRUG|Vinblastine Sulfate|
223498487|NCT01868451|DRUG|Dacarbazine|
223590607|NCT06457867|PROCEDURE|microfragmented adipose tissue loaded on bovine graft|microfragmented adipose tissue loaded on bovine graft on ridge preservation
223590608|NCT05181124|DRUG|coadministration of JP-1366 and aceclofenac|An open-label, multiple-dosing, fixed sequence, 3-period design
223590609|NCT05181124|DRUG|coadministration of JP-1366 and meloxicam|An open-label, multiple-dosing, fixed sequence, 3-period design
224189017|NCT06172166|BEHAVIORAL|Transdisciplinary Care for Transition|Young adults with T1D will participate in three visits during which they will see a diabetes nurse educator, psychologist, and transition navigator/social worker who will co-deliver care. TCT Visits 1 and 2 will be before the first adult diabetes healthcare visit, during trial months 1 and 2 respectively. These visits will focus on improving transition readiness, establishing care with an adult T1D specialist, and navigating psychosocial barriers to successful transition. TCT Visit 3 will occur after the first adult T1D healthcare visit, within one month of the first adult T1D care visit or during trial month 7 if the visit has not yet occurred. TCT Visit 3 will focus on overcoming barriers to satisfactory adult T1D healthcare.
223498488|NCT01868451|RADIATION|Involved-Site Radiation Therapy (ISRT)|
223498489|NCT01868451|PROCEDURE|Interim PET|
224189018|NCT05718323|DRUG|Niraparib|200 mg orally once daily, until PD 300 mg once daily if body weight ≥77 kg and platelets ≥150 g/L, until PD
223498490|NCT01868451|RADIATION|consolidation volume RT (CVRT)|
223498491|NCT05705271|DRUG|Finerenone (Kerendia, BAY94-8862)|Film-coated tablet, oral administration, once daily (OD), dosage based on the eGFR and serum potassium thresholds
223498492|NCT03485417|DRUG|Aripiprazole|for oral or depot preparation
223498493|NCT03485417|DRUG|Paliperidone|for oral or depot
223498494|NCT03485417|OTHER|Treatment as Usual|to be decided by treating psychiatrist with Rx other than aripiprazole or paliperidone
223498495|NCT05621980|BEHAVIORAL|Actuated Virtual Keyboard (AVK) system|"The participant controls an avatar hand by the movement of their own digits. Each avatar digit corresponds to a given virtual key. Sufficient digit flexion results in playing of that key, with visual and auditory feedback of key strike. Participants will wear a soft exoskeleton, the PneuGlove, with embedded bend sensors to provide real-time measurement of digit flexion. Pneumatic resistance to flexion can be applied to each digit independently, along with extension assistance, through air chambers running through the glove. The FES is intended to assist finger flexion by activating extrinsic finger flexor muscles. A high-density 2×8 stimulation electrode grid will be placed over the median and ulnar nerves at the medial side of the upper arm. The stimulator can deliver electrical stimulation to any pair of electrodes. At the beginning of each session, the investigators will identify the electrode pairs which best produce flexion of each digit with minimal discomfort."
223498496|NCT05621980|BEHAVIORAL|Occupational Therapy (OT)|Traditional occupational therapy training sessions.
223498497|NCT05919056|OTHER|Frequent and automatic cardiovascular risk assessment|The 10-year cardiovascular risk scores using the 2019 World Health Organization (WHO) laboratory-based risk charts will be automatically calculated using the latest health information on an EHR-based system per month.
223498498|NCT05919056|OTHER|Dynamic risk monitoring|High-risk individuals will be reassessed by the Dynamic Risk-based Early wArning and Monitoring (DREAM) system to obtain the short-term risk. The DREAM system will send a text message about advice to the high-risk individual every month. The text message includes information on the health status (e.g., current cardiovascular risk, level of blood pressure and lipid) and real-time warning messages (e.g., high short-term risk).
223498499|NCT05919056|OTHER|Regular GP visits|"The general practitioners will communicate with the participants based on the information automatically generated from the DREAM system every three months: each participant's cardiovascular risk score, health status (e.g., diabetes mellitus and/or hypertension), and Chinese guidelines-based recommendations (e.g., for the management of dyslipidemia, to provide clear treatment targets for high-risk participants)."
223498500|NCT04822194|BEHAVIORAL|Cognitive Emotion Regulation Training|Cognitive emotion regulation training via cognitive reappraisal involves the ability to modify the trajectory of an emotional response by thinking about and appraising emotional information in an alternative, more adaptive way. Reappraisal to down-regulate negative emotion can be operationalized via two tactics: psychological distancing and reinterpretation. The current study will randomly assign participants to receive a brief course of reappraisal training using either psychological distancing or reinterpretation.
223498501|NCT04701996|BIOLOGICAL|serological surveillance|serological surveillance, detection of antibodies (Total Ig and IgM) developed against SARS-CoV-2 in a population living in a rural area (Kimpese, DRC)
223498502|NCT04057768|DEVICE|Venus Viva|The Venus Viva™ fractional RF device has been shown in clinical studies to improve various skin conditions related to aging and alter collagen structures such as wrinkles, rhytids and scars.
223498503|NCT03060681|DRUG|Bupivacaine 0.5% injected in the thoraco-lumber inetrfacial plane block|After attaching basic monitors (ECG, SpO2, NIBP), the patient will take the prone position. Using the superficial probe of the ultrasound machine, the probe will be placed in transversally in midline position at selected level. The spinous process and interspinalis muscles will be identified. The probe was then moved laterally to identify the mulifidus muscle (MF) and the longissimus muscles (LG) where the local anesthetic will be injected. The needle will be advanced under real-time in-plane ultrasound guidance till it reaches the interface between the two muscles then a 1-2 ml of saline will be inserted to confirm needle site. 15 ml of bupivacaine 0.25 will be injected each side.
223498504|NCT04078308|BIOLOGICAL|Intravenous Injection of autologous mesenchymal stem cells|Intravenous injection 1 millions of bone-marrow derived autologous Mesenchymal Stem Cells (MSCs) per kg of patient's body weight in each dose, weeks 0 \& 3
223498505|NCT04078308|OTHER|Intravenous injection of placebo|Intravenous injection of normal saline (sodium chloride 0.9%)
223498506|NCT01947933|BIOLOGICAL|Mirikizumab- IV|Administered IV
223498507|NCT01947933|BIOLOGICAL|Mirikizumab - SC|Administered SC
223498508|NCT01947933|BIOLOGICAL|Placebo - IV|Administered IV
223498509|NCT00130364|DRUG|Pimecrolimus|Pimecrolimus 1 % cream
223498510|NCT00130364|DRUG|Placebo|Pimecrolimus vehicle cream (placebo)
223498511|NCT04032223|PROCEDURE|Implant placemet in the mandibular canine regions|Implant placemet in the mandibular canine regions retained by cast metal copings or 3D printed metal copings to deliver Implant Supported telescopic overdenture in the mandible
223498512|NCT02700256|BEHAVIORAL|survey|All patients will submit a baseline survey following enrollment onto study. After successful completion of the AXR or 24-hour discharge pathway, the consented patient will be contacted by email or telephone for 5 days following discharge from surgery.
223498513|NCT00350285|BEHAVIORAL|Motivational enhancement therapy|Personal feedback with counselor using motivational interviewing strategies.
224189019|NCT03569241|RADIATION|whole pelvic radiotherapy|addition of prophylactic whole pelvic radiotherapy to a local metastasis-directed treatment
224189020|NCT03569241|RADIATION|metastasis-directed treatment|stereotactic body radiotherapy
224189021|NCT03569241|PROCEDURE|salvage Lymph Node Dissection|metastasis-directed treatment
224189022|NCT03569241|DRUG|androgen deprivation therapy|LHRH-agonist (+ anti-androgen) or antagonist for a duration of 6 months
224189023|NCT00921973|BIOLOGICAL|VAX102|All subjects receive TIV, one half of the subjects are randomized to receive VAX102 1 ug and one half are randomized to receive placebo
224189024|NCT00921973|BIOLOGICAL|Placebo|All subjects receive TIV, one half of the subjects are randomized to receive VAX102 1 ug and one half are randomized to receive placebo
224189025|NCT02792569|PROCEDURE|Biopsy of ovarian cortical tissue|Biopsies will be taken from either right or left side. The cortical tissue will be isolated and fragmented in 1x1 mm2 pieces, followed by auto-transplantation to a peritoneal pocket.
224189026|NCT05157009|PROCEDURE|implant placement|autogenous bone reconstruction of damaged socket \& simultaneous implant placement
224189027|NCT00749489|PROCEDURE|Femoral Nerve Block|Patients assigned to the intervention group will have a femoral nerve block administered by the attending emergency department physician. Twenty-four hours after the femoral nerve block or at the time of surgery, an anesthesiologist will insert a continuous fascia iliaca block. Both procedures (femoral nerve block and fascia iliaca blocks) are standard anesthetic techniques that are used in orthopedic procedures but their efficacy as compared to standard opioid therapy has not been evaluated in controlled clinical trials in hip fracture. The medications that will be used in each procedure are as follows: 1) femoral nerve block: 0.5% bupivacaine with 1:300,000 epinephrine; 2) fascia iliaca block: 0.2% ropivacaine will be infused at 5ml/hr.
224189028|NCT02003287|OTHER|VFSS|Videofluoroscopic Swallow Study
224189029|NCT02003287|OTHER|FEES|Fiberoptic Endoscopic Swallow Study
223498514|NCT00350285|BEHAVIORAL|Marijuana education|Information about health and behavioral effects of marijuana use.
224189030|NCT01361724|BEHAVIORAL|Physical therapy|Physical therapy program for people with PD--one on one with a PT
224189031|NCT01361724|BEHAVIORAL|Group Exercise Class|The participant will be in an exercise class for 3 days a week for 4 weeks.
224189032|NCT01361724|BEHAVIORAL|Home Program|The participant will meet one time with a physical therapist and will be given a home program--which is standard of care--to follow for 4 weeks.
224189033|NCT03661658|PROCEDURE|Using short dental implant|Using short dental implant for patients with atrophic posterior mandible.
223498515|NCT04021797|DEVICE|transcutaneous vagal nerve stimulation|The transcutaneous stimulator engages the cymba conchae in the left inner ear, compared to the left earlobe in the sham stimulation condition.
223498516|NCT00248547|DRUG|aprepitant|Loading dose of 125 mg capsule once a day for one day, then maintenance dose of 80 mg capsule daily through Day +4 of Bone Marrow Transplant
223498517|NCT00248547|DRUG|dexamethasone|For Cyclophosphamide Total Body Irradiation(CyTBI) patients: Dexamethasone study drug 1 capsule PO daily, 1 hour prior to chemotherapy with aprepitant on total body irradiation(TBI) and cyclophosphamide chemotherapy days; For Busulfan Cyclophosphamide(BuCy) patients: Dexamethasone 1 capsule orally once daily, discontinue after last dose of chemotherapy.
223498518|NCT00248547|DRUG|ondansetron|For CyTBI patients: Ondansetron 8 mg orally evert 12 hours, begin 1 hour prior to first TBI dose and discontinue after last dose; then Ondansetron 8 mg IV every 12 hours X 4 doses, begin 30 minutes prior to first cyclophosphamide chemotherapy; For BuCy patients: Ondansetron 8 mg orally every 6 hours, begin 1 hour prior to first busulfan dose and discontinue after last busulfan dose is given. then: Ondansetron 8 mg IV Q 12 hours X 4 doses, begin 30 minutes prior to first cyclophosphamide chemotherapy
223498519|NCT00248547|DRUG|placebo|Loading dose of 125 mg capsule once a day for one day, then maintenance dose of 80 mg capsule daily through Day +4 of Bone Marrow Transplant
223498520|NCT02965833|DEVICE|3% hydrogen peroxide solution with HydraGlyde® Moisture Matrix|For cleaning, disinfection and overnight storage of contact lenses
223498521|NCT02965833|DEVICE|Habitual Multi-Purpose Contact Lens Solution|
223498522|NCT02965833|DEVICE|Habitual Contact Lenses|Participant's habitual contact lens brand worn in a daily wear modality for 30 days.
223498523|NCT00408954|DRUG|UK-369,003|100 mg MR tablet once daily for 2 weeks
223498524|NCT00408954|DRUG|UK-369,003|UK-369,003-100 mg MR formulation for 2 weeks
223498525|NCT05015023|BEHAVIORAL|Behavioral intervention|A cluster-randomized controlled trial will be conducted.
223498526|NCT05708651|DEVICE|Investigational device [I-IV]|Intra-individual randomised paired crossover evaluation of airway patency with investigational device in volunteer study participants \[I-II\] and study patients \[III-IV\] at low, moderate and deep steady-state sedation \[I-II\] or procedural sedation according to SOC \[III-IV\].
223498527|NCT05708651|DEVICE|Comparator [I-IV]|Intra-individual randomised paired crossover evaluation of airway patency with comparator (biteblock \[I-II\] or no device \[II-IV\]) in volunteer study participants \[I-II\] and study patients \[III-IV\] at low, moderate and deep levels of steady-state sedation \[I-II\], and during procedural sedation according to SOC for scheduled colonoscopy \[III\] or ureteral catheterization \[IV\].
224189034|NCT03661658|PROCEDURE|Inferior alveolar nerve lateralization with simultaneous implant placement|Inferior alveolar nerve lateralization with simultaneous implant placement in atrophic posterior mandible.
224189035|NCT05707364|BEHAVIORAL|Pre-visit Lab Workflow|"1. Based on buy-in from the providers/staff one or both of the practices below will be introduced into the clinic workflow to order pre-visit labs.~   1. All procedures are within the standard of care, only the order of operations is being changed. After sharing lab results with patient from the most recent routine physical, physician records labs for the next calendar year in EMR.~  2. Prior to appointment, Medical Assistant (MA) will review notes and orders to setup pre-visit labs.~2. Patient contacted to complete labs prior to the scheduled routine physical.~3. Resulted labs are triaged based on urgency.~4. After Visit Summary used to communicate about labs and surveys."
224189036|NCT02054507|BEHAVIORAL|Cognitive evaluation (Wechsler IV tests)|Children born prematurely in a level III referral Center will undergo psychometric evaluation at 8 to 11 years of age by routine test (WISC IV). The relationship between cognitive scores and neonatal characteristics will be determined and compared with the results of schoolmate control children, born at term.
224189037|NCT06399172|DEVICE|OncoSil|Intra-tumoural implantation
224189038|NCT01230021|DRUG|catridecacog|Intravenous injection of a single dose of recombinant factor XIII, 35 IU/kg bodyweight
224189039|NCT06328192|BEHAVIORAL|Active Breathing Exercises|Active breathing exercises aim to enhance the strength and flexibility of respiratory muscles through a series of exercises, improving breathing patterns and increasing respiratory efficiency. The following are common components of active breathing exercises: 1) Deep Breathing. 2) Chest Expansion. 3) Diaphragmatic Breathing. 4) Coughing Techniques. 5) Expiratory Resistance Training. 6) Gradual Increase in Activity.
224189040|NCT01365182|BEHAVIORAL|BF+SUPPORT|A session of biofeedback-assisted pelvic floor muscle exercises (PFME) plus 6 group sessions of the Problem-Solving Therapy (teaching self-management skills).
224189041|NCT01365182|BEHAVIORAL|BF+PHONE|A session of biofeedback-assisted pelvic floor muscle exercises (PFME) plus 6 telephone sessions of the Problem-Solving Therapy (teaching self-management skills).
224189042|NCT05221658|DRUG|HLX07+HLX10+ Cisplatin+5-FU|HLX07 1000mg + HLX10 200mg + Cisplatin 50 mg/m2 + 5-FU 2400mg/m2
224189043|NCT05221658|DRUG|HLX07|HLX07 1000mg iv Q2w
224189044|NCT02828852|OTHER|Blood sample|"In washed platelets and whole blood, study shall determine the percentage of aggregation after activation by different agonists and the amount of certain membrane markers of platelet activation. Furthermore, an assay of estradiol plasma will be made.~In whole blood, study will evaluate the percentage of platelet adhesion to collagen matrix or fibrinogen and the volume of thrombies formed."
224189045|NCT00324519|DEVICE|Foley bulb|
224189046|NCT00324519|DRUG|misoprostol|
224189047|NCT01150942|BIOLOGICAL|JE vaccine|3 times, IM
224309378|NCT03670693|DIAGNOSTIC_TEST|Supine cardiorespiratory fitness assessment|VO2 peak will be quantified during completion of a continuous, incremental exercise test performed in the supine position on an MR adapted stepper machine (Ergospect, Innsbruck Austria)
223498528|NCT06286943|DIETARY_SUPPLEMENT|Short Chain Fatty Acids (SCFAs).|Colon-delivery capsules of SCFAs.
223498529|NCT06286943|DIETARY_SUPPLEMENT|Placebo|Microcrystaline cellulose placebo capsules.
223498530|NCT06286943|OTHER|Maastricht Acute Stress Task|The Maastricht Acute Stress Task. This 15-minute stress-inducing task consists of a 5-minute preparation phase where instructions about the upcoming tasks are given, followed by a 10-minute acute stress phase where the hand immersion trial (HIT) in ice-cold water and mental arithmetic (MA) task is given interchangeably.
223590610|NCT05181124|DRUG|coadministration of JP-1366 and naproxen|An open-label, multiple-dosing, fixed sequence, 3-period design
224189048|NCT01283061|DRUG|Zafirlukast|Zafirlukast tablets 20 mg
224189049|NCT01306682|BIOLOGICAL|Trivalent influenza vaccine|0.5 ml of trivalent influenza vaccine administered into deltoid muscle of non dominant arm
224309379|NCT03670693|DIAGNOSTIC_TEST|fMRI Exercise assessment|Measurement of cardiac output and, cerebral and regional perfusion using Blood-Oxygen-level-dependent (BOLD) measures and arterial spin-labelling (ASL)-MRI as well as fractional oxygen extraction using TRUST-MRI during supine exercise of the quadriceps with the MR compatible cardiostepper (Ergospect, Innsbruck, Austria) at 50% of relative VO2 peak as measured during the supine cardiorespiratory fitness assessment.
223498531|NCT06286943|OTHER|No-stress control task|The placebo version of the MAST follows the same structure of the MAST with none of the stress elements. It uses lukewarm water and simple arithmetic's.
224189050|NCT01306682|BIOLOGICAL|Normal saline|0.5ml normal saline administered into deltoid muscle of non dominant arm
224189051|NCT00160147|DRUG|bifeprunox|One week titration with dose adjustments
223746057|NCT00741039|BIOLOGICAL|inactivated influenza vaccine and the PPV23 vaccine (Pneumovax)|MSKCC employee volunteer controls \> or = to 65 years of age without a cancer diagnosis will be immunized with the inactivated influenza vaccine (0.5 ml intramuscularly)and/or PPV23 vaccine (Pneumovax), (0.5 ml subcutaneously or intramuscularly). Prior to vaccination, titers against influenza and pneumococcus will be measured. At approximately 8-16 weeks after vaccination, post vaccine titers will be measured again.
224189052|NCT00160147|DRUG|Placebo|Placebo
224189053|NCT01432470|DRUG|Oxytocin|Gel for intravaginal use, 600 IU once per day for 2 weeks followed by 600 IU twice a week for ten weeks
224309380|NCT03670693|DIAGNOSTIC_TEST|Muscle deconditioning assessment|Limb blood flow will be occluded with a cuff, whilst participants perform repeated plantar flexion exercise in a MRI scanner. This will drive PCr, (the available reserve of ATP) to zero. Once the cuff is removed, they will undergo non-invasive and well-established in vivo 31P magnetic resonance (31P MRS) measurements on the gastrocnemius to determine PCr re-synthesis rate during resting recovery.
224309381|NCT01016327|DRUG|NMS-1116354|Oral daily administration for 7 consecutive days every 14 days
223498532|NCT00120484|DRUG|Vitamin B12|
223498533|NCT02537470|DRUG|Biphasic Remogliflozin Etabonate|Experimental Drug
223498534|NCT02537470|OTHER|Placebo|Placebo Comparator
223498535|NCT02387918|DRUG|Dexamethasone|Patients will receive Intravenous dexamethasone 0.15 mg/kg immediately after induction of anesthesia.
223590611|NCT05181124|DRUG|single-dosing of JP-1366 in Korean and Caucasian|An open-label, single-dosing, parallel design
223590612|NCT02503501|DRUG|Insulin glulisine|
223590613|NCT02503501|DRUG|Placebo|Bacteriostatic 0.9% Sodium Chloride
224189054|NCT01432470|DRUG|Placebo|Gel for intravaginal use of identical appearance as active substance, once per day for two weeks followed by twice a week for ten weeks
224189055|NCT06103773|DRUG|TollB-001 tablets|TollB-001 treatment
224189056|NCT06103773|DRUG|TollB-001 placebo|TollB-001 Placebo
224189057|NCT02855996|OTHER|Fathers in Action/Padres Activos (FA/PA) program|The program focuses on increasing the father's role in the child's education, nurturing and bonding with the child, loving and respecting the child's mother, coaching the child, and serving as a role model. The program also includes employment coaching.
224189058|NCT01199874|BIOLOGICAL|Rotavirus vaccine|live attenuated oral rotavirus vaccine; lyophilized; 1 ml
224189059|NCT04856852|OTHER|Iodine-125+Chemotherapy|Iodine-125: Iodine-125 if necessary, 0.6-0.8mCi, PD:120-150Gy Temozolomide: 75 mg per square meter of body-surface area per day, 7 days per week,42 days.
224189060|NCT04856852|OTHER|Surgical resection+Radiochemotherapy|"Surgical resection: Maximal surgical resection, including gross total resection, subtotal resection, and partial resection.~Radiation: total 60 Gy, 2 Gy per daily fraction (Monday to Friday) for 6 weeks. Temozolomide: 75 mg per square meter of body-surface area per day, 7 days per week,42 days."
223590614|NCT01740401|DRUG|Cyclophosphamide|This study consists of a Treatment Period, D1 Zofran 8mg pre-Cyclophosphamide 300mg/mg2 po and D3 Ipilimumab 10mg/kg iv wks 1,4,7 and 10; Tumor assessment at week 12; Follow-Up period weeks 13,16,and 20 with no treatment; Maintenance Period, D1 10mg/kg iv wks 24,36,48 and 60. Week 40=end of treatment; week 60=end of study
223746058|NCT03343873|DRUG|Midazolam|Midazolam was administered intravenously at a dose of 0.1 mg / kg followed by continuous intravenous injection at 0.03 mg / kg / h and maintained until the course of the scan.
224189061|NCT05713019|DEVICE|Adenosine triphosphate (ATP) solution inhalation from nebuliser|ATP and 0.9% saline solution will be inhaled from a nebuliser on separate days, and their effects will be examined.
223498536|NCT02387918|DEVICE|Acupuncture|Acupuncture treatment (just after induction of anaesthesia and for approximately 20 minutes)
223498537|NCT03942055|DEVICE|Sonosite Edge II Ultrasound|Certified by UAB Biomedical and Clinical Engineering Dept- certification #9365 Mechanism of Action: Point of Care Bedside Ultrasound
223498538|NCT00162734|DRUG|Daily Infergen (Interferon Alfacon-1, CIFN) (9 or 15 µg) + Ribavirin (1000-1200 mg, based on body weight) PO Daily for up to 48 wks|
223498539|NCT00446277|PROCEDURE|cataract surgery|
223498540|NCT02285192|RADIATION|18F-Fluorodeoxyglucose (18F-FDG)|
223498541|NCT02285192|DEVICE|PET/CT imaging|
223498542|NCT02285192|DEVICE|PET/MRI imaging|
223498543|NCT05413551|DRUG|Low-dose isoniazid|Pharmacogenomic-modified dose of isoniazid - 5 mg/kg oral tablet (maximum 300 mg)
223498544|NCT05413551|DRUG|Standard dose of isoniazid|15 mg/kg oral tablet (up to 900 mg)
223498545|NCT05413551|DRUG|High-dose isoniazid|Pharmacogenomic-modified dose of isoniazid - 25 mg/kg oral tablet (maximum 1500 mg)
223498546|NCT03442569|DRUG|Panitumumab|6 mg/kg via IV every 2 weeks in combination with nivolumab and ipilimumab
223498547|NCT03442569|DRUG|Nivolumab|240 mg via IV every 2 weeks in combination with panitumumab and ipilimumab
223498548|NCT03442569|DRUG|Ipilimumab|1 mg/kg via IV every 6 weeks in combination with nivolumab and panitumumab
223498549|NCT04844775|BIOLOGICAL|Drep-HIV-PT1 0.2mg and CN54gp140/MPLA-L|"1. Drep-HIV-PT1 The DREP-HIV-PT1 is a vaccine designed to elicit an immune response against human immunodeficiency virus-1 (HIV-1) and prevent infection by HIV-1 and/or disease caused by HIV-1. It is an alphavirus-based DNA replicon in which the sequences coding for the viral capsid and envelope have been replaced by the sequences encoding HIV-1 gp140 (96ZM651) antigen.~2. CN54gp140+MPLA-L. Recombinant CN54gp140 is a HIV-1 envelope protein from the clade C strain 97/CN/54 isolate, which comprises a sequence of 634 amino acids. MPLA is a non-toxic version of LipoPolySaccharide (LPS), which is isolated from the LPS lipid A region of Salmonella Minnesota R595 and retains the immune-stimulatory properties of LPS, but exhibits low toxicity."
223498550|NCT04844775|BIOLOGICAL|DREP-HIV-PT1 1mg and CN54gp140/MPLA-L (see above)|"1. Drep-HIV-PT1 1mg (see above)~2. Drep-HIV-PT1 1mg (see above)"
223498551|NCT04844775|BIOLOGICAL|DNA-HIV-PT123 4mg and CN54gp140/MPLA-L|"1. DNA-HIV-PT123 HIV vaccine includes three DNA plasmids that encode clade C ZM96 Gag, clade C ZM96 Env, and CN54 Pol-Nef~2. CN54gp140/MPLA-L Recombinant CN54gp140 is a HIV-1 envelope protein from the clade C strain 97/CN/54 isolate, which comprises a sequence of 634 amino acids. MPLA is a non-toxic version of LipoPolySaccharide (LPS), which is isolated from the LPS lipid A region of Salmonella Minnesota R595 and retains the immune-stimulatory properties of LPS, but exhibits low toxicity."
223498552|NCT06106997|RADIATION|brain radiotherapy|brain radiotherapy planned on synthetic CTs
223590615|NCT02806960|DRUG|Nasal Glucagon|Administered intranasally.
223590616|NCT03825211|PROCEDURE|Continuous suture in the perineals lesions|A continuous suture of the vagina, muscle and skin is performed continuously, without knotting or cutting the suture thread.
223590617|NCT03825211|PROCEDURE|Discontinuous suture in the perineals lesions|Suture the muscle independently of the vagina and independently of the skin
224189062|NCT05713019|DIAGNOSTIC_TEST|Inhalational challenge with increasing concentrations of capsaicin solutions|Coughs are counted for one minute after single-breath inhalations of 0.9% sodium chloride and capsaicin solutions of increasing concentrations (0.98-500 μm) generated from a dosimeter (P.K. Morgan Ltd, Gillingham, UK) set at a dosing period of 1 s. The concentration that caused more than 2 or 5 coughs was recorded as C2 and C5, and the data is analysed as log10 C2 or C5.
223498553|NCT04549428|DRUG|Atezolizumab|Intravenous infusion every 21 days, until disease progression, intolerance or loss of clinical benefit.
223498554|NCT02193425|DRUG|F-18FDG|18F-Fluorodeoxyglucose (FDG)-PET session to assess the association between functional connectivity (FC) and glucose metabolism in the human brain.
223590618|NCT02602158|DIETARY_SUPPLEMENT|Octanoic acid (1-13C, 99%)|"13C-marker will be mixed with emulsions. 2 isovolumetric (200 ml) and isocaloric (200 kcal) lipid emulsions with different acid and shear stability Lipid emulsion 1: acid stable, particle size 0.6 µm~Optional study pending interim analysis:~Lipid emulsion 4: acid unstable, redispersible by mechanical processes during antral contractions and passage through the pylorus, particle size 0.6 µm"
223590619|NCT02602158|DIETARY_SUPPLEMENT|TRIOCTANOIN (1,1,1-13C3, 99%)|"13C-marker will be mixed with emulsions 2 isovolumetric (200 ml) and isocaloric (200 kcal) lipid emulsions with different acid and shear stability~Lipid emulsion 1: acid stable, particle size 0.6 µm~Optional study pending interim analysis:~Lipid emulsion 4: acid unstable, redispersible by mechanical processes during antral contractions and passage through the pylorus, particle size 0.6 µm"
223590620|NCT05729243|DRUG|Cytisine|Cytisine is a nicotinic acetylcholine receptor partial agonist and is a natural health product approved by Health Canada. Cytisine has been used for a long time in Europe for smoking cessation.
223746059|NCT03343873|DRUG|Propofol|Propofol group 1mg / kg intravenous injection, followed by 2mg / kg / h continuous intravenous injection, and maintained to the scanning process;
223746060|NCT03343873|DRUG|Dexmedetomidine|Dexmedetomidine group with total amount of 1μg / kg, infusion time 15min, followed by 0.6μg / kg / h, and maintained to the scanning process;
223498555|NCT02193425|DEVICE|MRI|Two MRI/MRS sessions to evaluate test-retest reliability of functional connectivity (FC) at rest as well as during task performance.
223498556|NCT03678753|DRUG|Cenobamate|12.5 mg tablet, 25 mg tablet, 50 mg tablet, 100 mg tablets, 150 mg tablets, 200 mg tablets. Adolescents will follow the same every two week regimen and receive cenobamate as an oral suspension based on weight.
223498557|NCT03678753|DRUG|Placebo|Matching Placebo
223590621|NCT05729243|OTHER|Placebo|A placebo identical in appearance to cytisine will be used
223590622|NCT00039858|DRUG|Argatroban|
223498558|NCT06091241|PROCEDURE|Pre-operative Erector Spinae Plane block prior to DIEP surgery|After obtaining informed consent to participate in the study, patients will be randomized by a computer 50/50 to either the Erector Spinae Plane group or the Transversus Abdominus Plane group at the time of their surgical clinic visit prior to their scheduled surgery. Then on the morning of surgery, the Erector Spinae Plane group will receive a bilateral ultrasound-guided Erector Spinae Plane peripheral nerve block. During this intervention, 0.25% bupivacaine with dexamethasone will be injected below the fascia of the erector spinae muscle group.
223498559|NCT06091241|PROCEDURE|Pre-operative Transversus Abdominus Plane blocks prior to DIEP surgery|On the morning of surgery, the patients in the TAPs group will receive a bilateral ultrasound-guided Transversus Abdominus plane peripheral nerve block. During this intervention, 0.25% bupivacaine with dexamethasone will be injected into the transversus abdominus plane above the transversus abdominus muscle.
223498560|NCT05598736|DEVICE|FlowOx 2.0|-40mmHg intermittent negative pressure for 60 minutes per day
223498561|NCT05324696|DEVICE|autoinflation device|The authors developed a new standardized, inexpensive and simple device, based on Moniri. The Device is formed by a T tube with a unidirectional valve. A mask with the capacity of covering the child's mouth and nose, providing hermetic seal, and a balloon are connected to 2 ends of the T tube. Blowing the balloon trough the mask, with different types of maneuvers, will force the opening of the Eustachian tube and subsequent reabsorption of the middle ear effusion.
223498562|NCT00776256|DIETARY_SUPPLEMENT|beta-glucan and fructooligosaccharide|1g beta-glucan or 8 g fructooligosaccharide or combination per meal replacement bar given twice on day 1 and once on day 2
223498563|NCT02347618|RADIATION|Preoperative SBRT|This will be a Phase 2, single center, prospective, single arm feasibility study of the use of stereotactic body radiotherapy (SBRT) for the preoperative treatment of surgically resectable pancreatic adenocarcinoma.
223498564|NCT00482092|DRUG|Prochymal®|Prochymal® IV infusion
223498565|NCT00482092|DRUG|Placebo|Prochymal® Placebo-matching IV infusion
223498566|NCT06430489|DRUG|Nitrous oxide|inhaled nitrous oxide (1 hour at 50% concentration)
223498567|NCT06430489|DRUG|Medical air|inhaled medical air (1 hour)
223498568|NCT04784689|BIOLOGICAL|COVID-19 Vaccine|COVID-19 Vaccine
223498569|NCT00523575|DIETARY_SUPPLEMENT|Cubitan|400 ml/d
223498570|NCT02756442|OTHER|Respiratory disorder assessment during sleep|
223498571|NCT03509090|PROCEDURE|erector spinae block|erector spinae block will be performed in this group as postoperative analgesia treatment.
223498572|NCT03509090|PROCEDURE|Control group|patients will receive only multimodal analgesic treatment including patient-controlled analgesia
223498573|NCT04501692|PROCEDURE|VivaSight|see above
224309382|NCT06019598|OTHER|Licorice|Ecologic sweet licorice pastilles made from Glycyrrhiza glabra grown in Calabria, Italy, with a GA content of 29.9 ±2.0 mg/g.
223498574|NCT04501692|PROCEDURE|Videolaryngoscopy|see above
223498575|NCT01170650|DRUG|EC145|IV bolus on days 1,3,5 and 15,17,19 of a 4-week cycle
223498576|NCT01170650|DRUG|Pegylated Liposomal Doxorubicin (PLD/Doxil®/Caelyx®)|50 mg/m2 (calculated on the basis of ideal body weight) every 4 weeks. Dose reductions permitted for toxicity.
223498577|NCT01170650|DRUG|placebo|IV bolus on days 1,3,5 and 15,17,19 of a 4-week cycle
223498578|NCT01170650|DRUG|EC20|During the screening period participants will receive a single intravenous administration of EC20 prior to SPECT imaging
223498579|NCT02049632|PROCEDURE|Omission of axillary clearance|
223498580|NCT03972228|COMBINATION_PRODUCT|Microdevice loaded with 19 chemotherapeutic agents|The microdevice containing 19 FDA-approved chemotherapeutic agents will be placed in the suspected tumor tissue at the time of surgical resection. Multiple chemotherapeutic agents will passively diffuse into local, confined regions (several microns) of the surrounding microenvironment. The agents are released at approximately one millionth of a systemic dose. The device(s) will be removed for analysis at the time of resection, which will be performed for clinical indications independent of enrollment in this study.
223498581|NCT04093076|DRUG|INO-4500|INO-4500 will be administered ID on Day 0 and Week 4.
223498582|NCT04093076|DEVICE|CELLECTRA™ 2000|EP using the CELLECTRA™ 2000 device will be administered following ID drug administration.
223498583|NCT04093076|DRUG|Placebo|Placebo will be administered ID on Day 0 and Week 4.
223498584|NCT05370482|DEVICE|Focal laser ablation|MRI-guided focal laser ablation for prostate cancer
223498585|NCT06147154|OTHER|16S rRNA amplicon sequencing and untargeted metabolomics|"16S rRNA sequencing is a method for large-scale identification of community composition, expression abundance, and phylogenetic analysis by polymerase chain reaction (PCR) amplification of specific variable regions of 16S rRNA, combined with high-throughput sequencing and bioinformatics analysis. It also enables large-scale identification of the entire flora in a given habitat to study microbial diversity.~Untargeted metabolomics refers to the use of Liquid Chromatograph Mass Spectrometer (LC-MS), Gas Chromatograph Mass Spectrometer (GC-MS), and nuclear magnetic resonance (NMR) technology. The dynamic changes of small molecular metabolites in cells, tissues, organs or organisms before and after stimulation or disturbance were detected without bias. The differential metabolites were screened by bioinformatics analysis, and the pathway analysis of differential metabolites was performed to reveal the physiological mechanism of their changes."
223498586|NCT06177353|OTHER|Sampling|Blood sampling Skin biopsy Collection of soiled bandages
223498587|NCT03770455|DRUG|Avelumab|Avelumab 10mg/kg every 2 weeks (Q2W) + 2nd generation ADT
223498588|NCT03770455|DRUG|2nd generation ADT (abiraterone or enzalutamide)|2nd generation ADT (abiraterone or enzalutamide)
223590623|NCT03042260|DRUG|Trimethoprim-Sulfamethoxazole|oral tablets, 3 times a week, for a minimum of 6 months and maximum of 1 year.
223498589|NCT02955082|DRUG|Carboplatin|Intravenous carboplatin infusion every 3 weeks.
223590624|NCT03042260|DRUG|Placebo Oral Tablet|oral tablets, 3 times a week, for a minimum of 6 months and maximum of 1 year.
223590625|NCT03667690|DRUG|Rezafungin for Injection|Intravenous antifungal therapy
223590626|NCT03667690|DRUG|Caspofungin|Intravenous antifungal therapy
223590627|NCT03667690|DRUG|Fluconazole|Oral antifungal therapy
223590628|NCT03667690|DRUG|intravenous placebo|Normal saline
223590629|NCT03667690|DRUG|oral placebo|Microcrystalline cellulose
223590630|NCT00184756|DRUG|somatropin|
223590631|NCT05651815|DEVICE|Graphene spectrum light wave therapy room|Undergo 30-min of graphene adjuvant therapy every day for 7 d.
224189063|NCT05713019|DEVICE|Recording of Cough Count and frequency using the Hyfe Cough Monitor|"All enrolled study participants will be provided with a dedicated Android phone or watch loaded with the Hyfe Research application to monitor and record their cough sounds. The participant will be provided with a carrying case to ensure the phone stays within five feet of their mouth. They will be asked to wear the phone for the duration of 3 weeks, and keep the phone within five feet of their mouth over nights - keeping it, i.e., on a bedside table.~Hyfe is a research use only tool which does not provide clinical diagnosis. Cough collection within this study will not lead to specific medical interventions or differential clinical management. Hyfe records only short snippets (\<0.5 seconds). As such, the recordings will not be identifiable. Conversations or acoustic environments are not recorded. The informed consent form will explicitly describe exactly what is recorded."
223746061|NCT01563718|DRUG|naltrexone for extended release injectable suspension|VIVITROL (naltrexone for extended-release injectable suspension) is supplied as a microsphere formulation of naltrexone for suspension, at a dose of 4cc (380mg of naltrexone base), administered by intramuscular injection to the buttocks (alternating sides monthly) for six months.
223746062|NCT01620710|RADIATION|hypofractionated helical IMRT|hypofractionated helical IMRT of the prostate bed, 18 x 3 Gy
224189064|NCT05713019|PROCEDURE|Collection of exhaled breath condensate|EBC will be collected by asking the subject to breathe normally onto a handheld breath collection apparatus from Respire Diagnostics, Imperial College, that will cool the exhaled breath to allow for condensation of the exhaled air. The subject will breathe for 2 periods of 5 minutes each separated by a 3-4 min rest to allow the collection of up to 500 uL of liquid. The liquid will be stored for later analysis.
224205793|NCT03056716|PROCEDURE|Silastic vs conventional drain in thoracic surgery|Apical drains will be identical in size and material, and the basal drains will be different in groups. The patients will be followed for daily amounts of fluid drainage, duration of air leaks and fluid drainage, and duration of hospitalization, and the results will be compared statistically to asses any possible relationships with the outcome and the type of basal drain used.
224205794|NCT00713622|DRUG|Zonisamide|Capsules of 25mg, 50mg and 100mg zonisamide will be supplied. Dosing will be twice a day.
224309383|NCT00936897|DRUG|Ibandronate|Ibandronate 150mg PO QM (tablet)
223498590|NCT07117643|OTHER|Ischemic Preconditioning|"The ischemic procedure will be carried out before the start of the WanT and eccentric exercises procedures and muscle damage in accordance with the detailed description of the RIPC procedure. Four-fold filling of the flotation flange will be performed by 5 minutes to the value of 200 mm Hg with 5 minutes' rest interval near the attachment of the initial straight thigh muscle. All performed procedures will be carried out under the Doppler USG control to perform full arterial blood flow restriction.~The whole research will be carried out in the Laboratory in morning hours. Each participant will be in a hydrated state and before the first meal."
223498591|NCT07117110|DIETARY_SUPPLEMENT|Supplement|Group will take 40 mg lycopene (2,5 pills of food supplement Vitabiotics Ultra Lycopene 15mg, potent extract).
223498592|NCT07117110|OTHER|Tomato soup|Group will take 250 ml of tomato soup (matching with 40 mg lycopene) with 20 ml olive oil.
223498593|NCT07117864|COMBINATION_PRODUCT|T-DXd concurrent brain radiotherapy|T-DXd：5.4mg/kg ivgtt Q3w SRT/WBRT
223498594|NCT07117695|OTHER|Referral to the Duke Cardiometabolic Prevention Clinic|Patients who are referred to the cardiometabolic prevention clinic within the intervention arm will be evaluated first by a cardiology provider (as each patient has a history of ASCVD). On this initial visit, the cardiology provider will assess the patient's risk factor profile - to identify the presence of co-morbid conditions or uncontrolled risk factors. The need for additional referrals to other clinicians within the cardiometabolic clinic will specifically outlined criteria. These referrals will be offered to the patient and facilitated after the first visit. Preventive care will follow routine, evidence-based care. Clinicians within the cardiometabolic prevention clinic will meet bi-weekly to discuss enrolled patients, thus every individual in the intervention arm will receive coordinated, multi-specialty care.
223498595|NCT07120048|DEVICE|Edwards INSPIRIS RESILIA Aortic Valve|Surgical replacement of the aortic valve with the Edwards INSPIRIS RESILIA Aortic Valve
223498596|NCT07120165|OTHER|Demographic data collection|Demographic data collection: age, gender, level of education/study, time spent in near vision, sports practice, medical history
223498597|NCT07120165|OTHER|Ophthalmological history|Ophthalmological history: age of myopia discovery, parental refraction, previous refractions, presence of a braking treatment
223498598|NCT07120165|OTHER|Ophthalmological data at each examination|Ophthalmological data at each examination: visual acuity, subjective refraction, cycloplegia with SKIACOL, axial length.
223498599|NCT07120165|OTHER|Potential adverse events|Potential adverse events: halos, photophobia, stinging, infections, etc.
223498600|NCT07120360|OTHER|Gender-Based Microaggression Awareness and Prevention Psychoeducation Program|The psychoeducation program consisted of six modules aiming to increase awareness of microaggressions, develop coping and assertiveness skills, enhance critical thinking regarding gender roles, and reduce gender role stress. The program included theoretical knowledge, experiential learning, assertiveness training, and stress management strategies.
223498601|NCT02777788|DRUG|JinFuKang|treated with chemotherapy
223498602|NCT02777788|DRUG|XingZaoRuanJian|treated with chemotherapy
223498603|NCT02777788|DRUG|pemetrexed,docetaxel,gemcitabine,paclitaxel or vinorelbine combined with carboplatin、cis-platinum or nedaplatin|
223498604|NCT01171599|BEHAVIORAL|Fit4Life|As previously described, the purpose of this study is to develop a web and text message based weight loss intervention for childhood acute lymphoblastic leukemia survivors (ALL) survivor. The web and text message based intervention that is being developed will be evaluated in a separate ACS (American Cancer Society) funded trial randomized control trial. The web and text message based intervention (there are other intervention features that do not relate to the web \& text based platforms that were developed as part of this NIH funded study) is a 16-week program that includes:
223498605|NCT07123558|DIAGNOSTIC_TEST|High resolution anoscopy|to study biomarkers for anal cancer screening
223498606|NCT07044830|DEVICE|CPAP|Automatically-adjusting continuous positive airway pressure (CPAP)
223746063|NCT01620710|RADIATION|hypofractionated helical IMRT|helical IMRT of the prostate bed (18 x 3 Gy) and the pelvic lymph nodes (18 x 2.5 Gy)
223746064|NCT00657007|BIOLOGICAL|belimumab|"1. 1 mg/kg, IV (in the vein) once on Day 0, with a final evaluation at Day 84 (Cohort 1).~2. 1 mg/kg, IV (in the vein) on Days 0 and 21, with a final evaluation at Day 105 (Cohort 5)."
224189065|NCT05713019|DIAGNOSTIC_TEST|Continuous laryngoscopic examination|Continuous laryngoscopy testing is performed based on previous methodology. Continuous laryngoscopy testing is performed by placing a fibreoptic nasendoscope in the posterior nasopharynx and securing it using specialist headgear. A small quantity of lubricating jelly is used to ease passage of the scope. Video images of the laryngeal inlet are, thereafter, continuously recorded whilst a subject performs various manoeuvres including respiratory movements and cough. These movements will be observed and recorded before and following the various aspects of the challenge protocol and thus allow us to evaluate laryngeal movement abnormalities and for example position of the vocal folds. The size and change in size of the glottic aperture will be evaluated.
224189066|NCT05713019|DIAGNOSTIC_TEST|Sputum induction|"Sputum is induced by inhalation of an aerosol of sterile 3% saline solution and subsequently increasing to 4% and 5% during 3 periods of 5 minutes each. Particular care is taken to avoid contamination with saliva and post-nasal drip by instructing subjects to rinse orally with water and to blow their nose after each inhalation. Sputum samples are collected into sterile pots. Peak flow measurements are made after each inhalation. If there is a fall in peak flow of 20% or more or if symptoms occurred during the procedure, the induction is stopped.~Sputum plugs are selected and one portion is used to perform differential cell counts. To perform differential cell counts, dithiothreitol is added to the sputum plug and mixed vigorously on a plate shaker to solubilize the sputum. Cytospins are then prepared, and differential cell counts obtained."
224189067|NCT05713019|DIAGNOSTIC_TEST|Spirometric measurements|Spirometry (FEV1 and forced vital capacity, FVC) is measured using a dry wedge spirometer (Vitalograph, Buckinghamshire, UK).
224189068|NCT05713019|DIAGNOSTIC_TEST|Blood sample collection|Venous blood (30 cc) will be taken from a vein in the forearm. This test causes a transient discomfort as a needle is used to obtain the blood sample. The blood sample will be used for measuring various proteins and for getting white blood cells to obtain some types of stem cells.
224189069|NCT05173532|OTHER|Balance Training|static and dynamic balance and gait stability exercises
224189070|NCT05173532|OTHER|Breathing and Stretching Exercises|static stretching while performing diaphragmatic breathing
224189071|NCT04357834|OTHER|Equipment with smartwatch throughout hospital stay on the general ward|Participants with confirmed SARS-CoV-2 infection or suspicion of COVID-19 will be equipped with a smartwatch and wear the device throughout the hospital stay on the general ward.
223498607|NCT07044570|BEHAVIORAL|Physical Activity Goals mHealth Intervention|On days participants plan to exercise, they engage in two daily goal sessions (morning and evening). Morning sessions provide an activity goal for the day and ask the participant to create a plan, anticipate barriers, and brainstorm solutions for achieving this goal. The affect-based goal condition asks participants to engage in either (1) a type (50% of daily goals) or (2) a context (50% of daily goals) of physical activity that allows them to experience positive affect. Goals focused on context are randomly generated to suggest that the participant performs activity (1) in a place; (2) in a social situation; or (3) while listening to something that makes them feel good. The intensity-based goal condition asks participants to maintain a certain target heart rate range during physical activity. Starting heart rate reflects the approximate age-adjusted heart rate max, with goals progressively increasing from 55% to 70% heart rate max.
223498608|NCT07044570|BEHAVIORAL|TYPE/CONTEXT enhancement|TYPE/CONTEXT augments intervention effects by providing tailored recommendations for activity types and contexts that satisfy personally-important psychological needs as rated by each participant at baseline. Ratings from a crowdsourced panel of adults on Amazon Mechanical Turk will be used to determine the potential for specific activity types and contexts to satisfy psychological needs; our tailoring algorithm will then recommend the corresponding activity type or context while accounting for reported constraints (e.g., ability, access). These details will be incorporated into a tailored recommendation provided to participants each Sunday as they make activity plans for the upcoming week. Specifically, the program will randomly select either type or context (i.e., location, audio, social) recommendations and will rotate every two weeks. For TYPE, participants' top 3 activity types are recommended; for CONTEXT, participants' top 3 activity contexts are recommended.
223498609|NCT07044570|BEHAVIORAL|SAVOR enhancement|SAVOR implements a brief savoring exercise on the smartphone that takes place either after the planned physical activity session or during the evening goal session (after the self-monitoring module). Participants will respond to questions that are intended to enhance and prolong positive experiences during physical activity. To trigger attentional deployment, a common savoring strategy that involves intensifying experiences by focusing on them, participants will answer three open-ended prompts. These prompts are drawn from a prompt pool with slightly varied wording to promote a sense of novelty. Savoring prompts will rotate daily and have a day lag built in every week (i.e., Week 1 Monday Savoring Prompts are Week 2 Tuesday Savoring Prompts).
223498610|NCT07046338|GENETIC|Lentiviral TYF-ARSA correction of patient's autologous HSCs|Infusion of lentiviral TYF-ARSA modified autologous HSCs at 1\~10x10\^6 gene-modified cells per kg body weight.
223498611|NCT06728488|OTHER|PENG Block|The patients in the PENG block group will provide their consent. Standard monitoring will be applied. The patients will be positioned supine. After antiseptic procedures, 2 ml of 2% lidocaine will be infiltrated into the needle insertion site. The linear ultrasound probe will be placed in the transverse plane over the AIIS. The position of the ultrasound probe will be verified by visualizing the iliopectineal eminence, iliopsoas muscle and tendon, femoral artery, and pectineus muscle. Using a Stimuplex® A 100 mm 20 gauge needle (Braun Melsungen AG, Melsungen, Germany) with the in-plane technique, the needle will be inserted laterally to medially into the space between the psoas tendon and the pubic ramus. Negative aspiration will be performed to ensure no blood is aspirated, and then 20 ml of 0.25% bupivacaine and 8 mg of dexamethasone will be injected to perform the PENG block. After the procedure, the cannula will be removed, and the insertion site will be cleaned and dressed.
223746065|NCT00657007|BIOLOGICAL|belimumab|"1. 4 mg/kg, IV (in the vein) once on Day 0, with a final evaluation at Day 84 (Cohort 2).~2. 4 mg/kg, IV (in the vein) on Days 0 and 21, with a final evaluation at Day 105 (Cohort 6)."
223746066|NCT00657007|BIOLOGICAL|belimumab|"1. 10 mg/kg, IV (in the vein) once on Day 0, with a final evaluation at Day 84 (Cohort 3).~2. 10 mg/kg, IV (in the vein) on Days 0 and 21, with a final evaluation at Day 105 (Cohort 7)."
224189072|NCT05998304|DRUG|[14C] Yiqibuvir|600 mg suspension containing 100µCi of \[14C\] Yiqibuvir
224309384|NCT00936897|DRUG|Denosumab|denosumab 60mg SC Q6M (pre-filled syringe)
224309385|NCT04482673|DRUG|Daily Vitamin D3|6000 IU vitamin D3 daily
224309386|NCT04482673|DRUG|Daily placebo|Placebo daily
224189073|NCT03164629|DEVICE|cone-beam CT 3D Emboguide|cone-beam CT with Embolization Guidance software (Emboguide) to identify prostatic arteries and assist endovascular navigation, by projecting a 3D road map of prostatic arteries on live fluoroscopy, in order to differentiate them from non-target vessels.
224189074|NCT04393987|BEHAVIORAL|Treatment Compliance Training|Treatment Compliance Training consist of: Introduction of Treatment Compliance Program and Information about the Disease, Therapies for Bipolar Disorder and Importance of Treatment Compliance, Drugs Used for Bipolar Disorder, Effects and Side effects, Strategies to Solve Treatment-Related Problems and Cope with Stress, Beliefs, Attitudes, and Stigmatization Towards Patient/Disease in Bipolar Disorder. The sessions were held in the form of PowerPoint presentations. In the Treatment Compliance Training, lecture, question-answer, homework, sharing experiences, video presentation, summarization were used.The day before each session, patients were phoned and reminded of the time of the session.
223590632|NCT04358965|DRUG|intravenous tranexamic acid|patients will be given a single bolus IV injection of 15 mg/kg of tranexamic acid (TXA) 20 minutes before surgical incision plus one vaginal placebo tablet 60 minutes before skin incision.
223590633|NCT04358965|DRUG|vaginal misoprostol|patients will be given one vaginal misoprostol tablet (200 mcg) 60 minutes before skin incision and a normal saline IV bolus 20 minutes before surgical incision
223590634|NCT04358965|DRUG|placebo|patients will be given one vaginal placebo tablet 60 minutes before skin incision and a normal saline IV bolus 20 minutes before surgical incision
223590635|NCT03060200|OTHER|Self-administered online CBT plus therapist check in|The app being tested is comprised of courses, exercises and a behavioural activation component. Courses represent the psycho-educational background of the program, comprising topics such as: information on depression, what is CBT, healthy/unhealthy negative emotions, rational/irrational thoughts, behaviour, social support, relaxation techniques, sleep hygiene, relapse prevention, treatment adherence, and suicide prevention plan. Exercises use the information presented in the courses and follow the structure of a regular therapy session/ therapeutic homework. The following exercises are included in the app: Emotional Pulse, Find Irrational Thoughts, and Change Irrational Thoughts. The behavioural activation component consists in two main exercises: My goals and My Activities.
223590636|NCT03060200|OTHER|Sham self-administered online CBT plus therapist check in|The active placebo intervention will be delivered via the same platform and largely in the same format as the tested app: it will include the same sections and features as the original app, except for the complete exercises. In addition, the psychoeducation section, although mirroring the structure of the corresponding section in the original app, will include different content, elaborating on common sense psychological well being aspects.
223590637|NCT05533320|DEVICE|Cold Cap Therapy|Undergo scalp cooling
223590638|NCT05533320|OTHER|Quality-of-Life Assessment|Ancillary studies
223590639|NCT05533320|OTHER|Questionnaire Administration|Ancillary studies
223590640|NCT05325346|DRUG|VLX-1005|Measurement and comparison of the effects and potential interactions between VLX-1005 and argatroban on safety, tolerability, PK and PD
223590641|NCT05325346|DRUG|Argatroban|Measurement and comparison of the effects and potential interactions between VLX-1005 and argatroban on safety, tolerability, PK and PD
223746067|NCT00657007|BIOLOGICAL|belimumab|"1. 20 mg/kg, IV (in the vein) once on Day 0, with a final evaluation at Day 84 (Cohort 4).~2. 20 mg/kg, IV (in the vein) on Days 0 and 21, with a final evaluation at Day 105 (Cohort 8)."
224189075|NCT01545401|OTHER|EMPOWER-PAR Intervention|"Implementation process is conducted in 3 phases:~I. Phase 1: Formation and training of the CDM team~II. Phase 2: Distributions of the intervention tools~* Global CV Risks Self-Management Booklets~* CPG to aid clinical decision making~III. Phase 3: Facilitation and support to implement the intervention"
223498612|NCT06728488|OTHER|PENG block and pulse radiofrequency ablation|After obtaining consent, the patients in the PENG block and pulse radiofrequency ablation group will be brought into the operating room. Standard monitoring will be applied (ECG, SpO2, NIBP). The patients will be positioned supine. After performing the necessary aseptic and antiseptic procedures, 2 ml of 2% lidocaine will be infiltrated into the needle insertion site. The Boston Scientific unified echogenic 10cmx10mmx20G (0.9mm) radiofrequency cannula will be advanced until it makes contact with the superior ramus near the iliopectineal eminence. Pulse radiofrequency ablation will be performed with two cycles of 90 seconds each, and after each cycle, the needle will be moved 2 mm medially. After pulse radiofrequency ablation, 20 ml of 0.25% bupivacaine and 8 mg of dexamethasone will be applied. After the procedure, the cannula will be removed, and the insertion site will be cleaned and dressed.
223498613|NCT07051928|DIAGNOSTIC_TEST|c-FLIP expression on MDSC|Longitudinal c-FLIP expression on circulating MDSC
223590642|NCT03051386|BIOLOGICAL|VEE Vaccine|0.5 mL of VEE vaccine administered subcutaneously in the upper outer aspect of the triceps region.
223590643|NCT06442670|DEVICE|Electroencephalography|Phase synchrony during the completion of the semantic memory task
223590644|NCT03495102|DRUG|Dulaglutide|Administered SC
223590645|NCT04802187|OTHER|RADx CHCs testing intervention strategy|The study team will support partner CHCs to implement workflows with some combination of dedicated testing staff, off-site testing, outreach/communications to priority populations, and linkage with local contact tracing systems. Implementation support will take the form of practice facilitation, rapid cycle testing (by supporting CHCs to review their internal data to assess the impact of workflow changes), and expert consultation from the research team on testing technology and testing location design.
223746068|NCT00657007|BIOLOGICAL|Placebo|"1. IV (in the vein) on Day 0 (Cohorts 1-4).~2. IV (in the vein) on Days 0 and 21 (Cohorts 5-8)."
223746069|NCT00878709|DRUG|neratinib|
223746070|NCT00878709|OTHER|placebo|
223746071|NCT04684381|DRUG|L-glutamine|Pharmacokinetic study
223746072|NCT01712854|DRUG|Budesonide|budesonide 80 mcg
223498614|NCT03033706|PROCEDURE|Pulse pressure variation guided fluid therapy|Pulse pressure variation obtained from invasive blood pressure waveform
223498615|NCT03033706|PROCEDURE|Traditional fluid therapy|4 ml/Kg/hr ringer solution plus rescue fluid bolus of 200 ml Ringer solution if Mean arterial pressure decreased by 20% with central venous pressure less than 4 mmHg.
223498616|NCT03033706|PROCEDURE|Brain tumor excision|Brain tumor excision under general anesthesia
223498617|NCT01039441|PROCEDURE|Intraperitoneal instillation of bupivacaine|A mixture of 50ml solution (20ml of 0.5% bupivacaine + 30ml normal saline) is instilled under the diaphragm.
224189076|NCT06036940|OTHER|Preoperative patient education given with three different methods|To determine the effect of preoperative patient education given by three different methods on the level of perioperative anxiety in children aged 4-7 years.
224189077|NCT06392282|DRUG|MV-140|MV-140 use - sublingual spray approved for recurrent UTI prevention
224189078|NCT04180956|OTHER|Bias-reduction Intervention|A training for doctors
224189079|NCT01061073|DRUG|Omexel|
224189080|NCT01061073|DRUG|spasfon|
224189081|NCT02377258|OTHER|Non Interventional|
224189082|NCT00032058|PROCEDURE|magnetic resonance imaging|
223498618|NCT01039441|PROCEDURE|CO2 removal by means of a pulmonary recruitment maneuver|CO2 is removed by means of a pulmonary recruitment maneuver consisting of five manual inflations of the lung with a maximum pressure of 30 cm H2O
223498619|NCT01039441|PROCEDURE|Intraperitoneal instillation of bupivacaine +CO2 removal by means of a pulmonary recruitment maneuver|
223498620|NCT01039441|OTHER|normal saline|
223498621|NCT04792892|OTHER|Questionnaires|Patients will be answering questionnaires at 0, 3, 12, 36, 60 and 120 months
223498622|NCT03157791|DRUG|Simethicone 180Mg Cap|Simethicone Group A will take a total of 360mg prior to colonoscopy of Simethicone 180Mg Cap.
223498623|NCT03780192|DEVICE|Inspiron Sirolimus Eluting Stent|Bifurcation treatment using provisional stent technique
223498624|NCT07125911|DRUG|Ibuprofen 400 mg (if necessary)|Single oral dose of 400 mg ibuprofen administered in a blinded capsule. Prior to dosing, baseline pulpal sensibility tests (cold test with Endo-Ice and Electric Pulp Test) and pain rating (VAS) will be recorded on a contralateral healthy tooth and the target tooth with symptomatic irreversible pulpitis. The drug is given orally and tests are repeated 30 minutes after ingestion. Participants are monitored for adverse effects. Participants who cannot take NSAIDs are excluded
223498625|NCT07125911|DRUG|Paracetamol 500 mg|A single oral dose of 500 mg paracetamol administered in a blinded capsule. Baseline pulpal sensibility testing (cold test with Endo-Ice and Electric Pulp Test) and pain level assessment using a Visual Analogue Scale (VAS) will be performed on both the tooth with symptomatic irreversible pulpitis and a contralateral healthy tooth prior to administration. The same tests will be repeated 30 minutes after ingestion to evaluate any masking effect on test results.
223498626|NCT07123051|DEVICE|right colectomy|Robotic-assisted right colectomy with the DEXTER robotic surgery system
223498627|NCT07124377|OTHER|A complete physical examination of all body systems, including height and body weight|These interventions will be carried out in a time-controlled population within a family cluster of VAL50MET
223498628|NCT07124377|OTHER|Neurological examination includes motor strength testing; sensory testing with pinprick, light touch, temperature, and proprioception; deep tendon reflexes; and gait assessment.|These interventions will be carried out in a time-controlled population within a family cluster of VAL50MET
223498629|NCT07124377|DIAGNOSTIC_TEST|Electrocardiogram (12-lead ECG)|These interventions will be carried out in a time-controlled population within a family cluster of VAL50MET
223498630|NCT07124377|DIAGNOSTIC_TEST|24-Hour Holter Monitoring|These interventions will be carried out in a time-controlled population within a family cluster of VAL50MET
223498631|NCT07124377|DIAGNOSTIC_TEST|"Color Doppler echocardiography with two-dimensional strain (longitudinal strain)"|These interventions will be carried out in a time-controlled population within a family cluster of VAL50MET
223498632|NCT07124377|OTHER|The Norfolk Quality of Life-Diabetic Neuropathy (QOL-DN)|These interventions will be carried out in a time-controlled population within a family cluster of VAL50MET
223498633|NCT07124377|OTHER|questionnaire, the NIS-LL (Neuropathy Impairment Score in the Lower Limbs)|These interventions will be carried out in a time-controlled population within a family cluster of VAL50MET
223590646|NCT04802187|OTHER|Usual care control|CHCs implement testing strategies in accordance with their usual supports.
223590647|NCT00258791|DRUG|Ibuprofen|
223590648|NCT02650063|DRUG|DE-117|
223746073|NCT01712854|DRUG|Symbicort|A combination of budesonide and long acting beta agonist: Budesonide 80 mcg and formoterol fumarate dihydrate inhaler 4.5 mcg
224309387|NCT04482673|DRUG|Bolus vitamin D3|Bolus 20,000 IU vitamin D3 daily for 3 days
223590649|NCT04153045|DEVICE|Radiograph interpretation for pulmonary abnormalities|"The pulmonary abnormalities detected by xrAI and included in the definition of abnormality are as follows: any linear scar or fibrosis, atelectasis, consolidation, abscess or cavity, nodule, pleural effusion, severe cases of emphysema and COPD (mild cases with hyperinflation but not significant emphysema are not flagged), pneumothorax.~Participants in the treatment group will interpret 500 images presented alongside the results of xrAI's processing in a dark room and asked to categorize each image into one of the following categories: lungs are clear, at least one pulmonary abnormality is present, not sure.~Participants in the control group will be asked to interpret the same 500 images as the treatment group but without xrAI's analysis."
223746074|NCT05297825|BEHAVIORAL|Vegan diet|Healthy vegan diet.
223746075|NCT05297825|BEHAVIORAL|Omnivore diet|Healthy omnivore diet.
223746076|NCT04094467|DRUG|Cetrorelix|0.25 mg subcutaneous injection daily for 6 days
224189083|NCT00032058|PROCEDURE|magnetic resonance spectroscopic imaging|
224189084|NCT06212960|BIOLOGICAL|DWP712|Clostridium botulinum Toxin
224189085|NCT06212960|BIOLOGICAL|BOTOX®|Clostridium botulinum Toxin
224189086|NCT06496698|PROCEDURE|Simple Interrupted Suture|In the control group, simple interrupted sutures will be used for wound closure after surgical repair of ankle fractures.
224189087|NCT06496698|PROCEDURE|Subcuticular Suture|In the experimental group, subcuticular sutures will be used for wound closure after surgical repair of ankle fractures.
224189088|NCT03145584|DRUG|Continuous Bupivacaine via Adductor Canal Saphenous Catheter|12.5 mg/hr of bupivacaine was administered continuously via a paraneural catheter for 48 hours following surgery to determine whether superior analgesia was obtained when compared to single shot block with a sham catheter.
224189089|NCT03145584|OTHER|Single Shot Adductor Canal Saphenous Block with Bupivacaine|A sham catheter was placed on the skin and covered in a dressing to blind the patient, data collector and investigator as to group allocation
224189090|NCT02023515|BEHAVIORAL|Emotional brain training|Stress management based program
224189091|NCT02023515|BEHAVIORAL|Behavioral weight loss|Standard behavioral weight loss
224309388|NCT04482673|DRUG|Bolus placebo|Bolus placebo daily for 3 days
224189092|NCT04227665|OTHER|Sea level|Sea level exposure / sea level exposure combined with microdoses of rHuEPO
223746077|NCT04094467|DRUG|Leuprolide Acetate|0.1 mg subcutaneous injection daily for 12 days
223746078|NCT00123591|DRUG|activated recombinant human factor VII|
223746079|NCT01347541|BEHAVIORAL|Cognitive Behavioral Therapy|Behavioral therapy includes standard cognitive behavioral therapy, with an emphasis on behavioral activation. Treatment is administered on the basis of the participants' individual needs and may continue for up to 12 months.
223746080|NCT01347541|BEHAVIORAL|Motivational Interviewing|Motivational interviewing is designed to address alcohol and drug use.
223746081|NCT01347541|DRUG|FDA-Approved Anti-Anxiety Medications|Participants assigned to receive the combination therapy may receive one or more of the following medications based on their individual needs: fluoxetine, sertraline, paroxetine, buspirone, propranolol, trazodone, and any of the benzodiazepines. Participants may begin receiving medication immediately or anytime within the 12 months post-injury. Form, dosage, frequency, and duration depend on patient need, but all are prescribed in accordance with standards of care.
224189093|NCT04227665|OTHER|Altitude|Altitude exposure / altitude exposure Iron metabolism
224189094|NCT05677373|DRUG|BRD4 Inhibitor PLX2853|Given PO
224189095|NCT05677373|DRUG|Trametinib|Given PO
224189096|NCT05677373|PROCEDURE|Computed Tomography|Undergo CT with contrast
224189097|NCT05677373|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI with contrast
224189098|NCT05677373|PROCEDURE|Biospecimen collection|Undergo collection of blood
223498634|NCT07124377|OTHER|COMPASS-31 (Composite Autonomic Symptom Score-31)|These interventions will be carried out in a time-controlled population within a family cluster of VAL50MET
223498635|NCT07124377|DIAGNOSTIC_TEST|Electromyogram (EMG)|These interventions will be carried out in a time-controlled population within a family cluster of VAL50MET
223498636|NCT07124377|DIAGNOSTIC_TEST|[99mTc]Tc-DPD scintigraphy|These interventions will be carried out in a time-controlled population within a family cluster of VAL50MET
223498637|NCT07124377|DIAGNOSTIC_TEST|Laboratory assessments|Laboratory assessments include blood and urine sample collection for serum chemistry, hematology, and urinalysis, with specific biomarker analyses (troponin T, NT-proBNP, Kappa, and Lambda light chains
223498638|NCT07086651|DRUG|Enzalutamide|As provided in real-world setting
223498639|NCT07086651|DRUG|Apalutamide|As provided in real-world setting
223498640|NCT07086183|OTHER|Observation|Observation of intraoperative and postoperative outcomes
223498641|NCT07117201|BEHAVIORAL|Culturally Tailored Cooking Classes|Cooking skills session will be offered by the Delicious Legacy Program. The Delicious Legacy program is a culturally tailored, community-based nutrition and wellness intervention designed to promote health equity. Rooted in the intergenerational transmission of knowledge, the program emphasizes family socialization practices related to food, health beliefs, and caregiving. It integrates evidence-based nutritional education with ancestral foodways to address diet-related chronic illnesses while fostering cultural pride and resilience. Through interactive workshops, individuals engage in hands-on learning that reinforces traditional roles in food preparation and shared meals as sites of emotional support and identity formation. Dr. Haynes will lead the cooking sessions and create cardiometabolic-appropriate recipes.
223498642|NCT07117201|BEHAVIORAL|Prescription Produce Plan|The standard PPP includes three major parts. 1) Screening and personalized referrals/support for social needs including food, housing, health insurance and transportation by a community health worker. 2) Bi-weekly wellness visits with an MHWP team of interprofessional healthcare students, supervised by a clinical faculty, and guided by the participants' health and social needs and interests. They include education and SMART-EST goals around nutrition, physical activities, chronic disease management, care coordination, and/or recipes. 3) Delivery of a bag of fresh fruits and vegetables as well as heart healthy food items every two weeks over a period of 12 months. The produce bags will be made by the Underground Kitchen, a local non-profit organization creating curated bags of healthy food items and recipes to support the prevention and management of chronic diseases.
223498643|NCT07118033|PROCEDURE|Specific Manual Therapy|Participants in this group receive a standardized physiotherapy program (exercise and education) plus 5 minutes of targeted lumbar postero anterior mobilizations. These mobilizations are selected using the Algo K decision algorithm, which guides the therapist to choose the most appropriate technique based on the patient's pain response during preliminary movement tests.
223746082|NCT01347541|BEHAVIORAL|Standard Care Control|Standard care control includes the usual treatment for injured trauma survivors
223746083|NCT02146547|DRUG|Aripiprazole|Administration in once-a-day schedule without regard to meals.
224189099|NCT05677373|PROCEDURE|Biospecimen collection|Correlative studies
224189100|NCT00633334|OTHER|Specimen bank|Patients will be asked to provide approximately 60-120 cc (4-8 tablespoons) of peripheral blood. Select patients who undergo surgical resection of their tumor will be asked to provide portions of the tumor and tumor draining lymph nodes for further analysis. In addition patients undergoing surgical resection may be asked to provide additional peripheral blood samples at time of routine follow-up (at least 4-6 weeks after initial blood draw and between subsequent draws).
224189101|NCT04553497|DEVICE|Interferential current|"Interferential current or sham were applied to the patients before the each exercise session. Pre-modulated bipolar method with the currier frequency of 4 kHz by a combination therapy unit (Sonopuls 692, Enraf-Nonius) with two electrodes (8×6 cm) was used. One electrode was placed on the lateral part of the deltoid muscle; the other was placed on the trapezium muscle close to the shoulder. Subjects were told that in order to produce an effect, the intensity of the stimulator must be maintained at a strong but comfortable level at all times. The sham interferential current therapy consisted of the placement of the same pads for the same time but no electrical stimulation was applied to the probes."
224205795|NCT00713622|DRUG|Sodium valproate|Crushable tablets of 100mg and enteric coated tablets of 200mg and 500mg will be supplied. Dosing will start at 600mg/day, increasing to the minimally effective dose, the maximum tolerated dose, or 2500mg/day, whichever is the lowest.
224205796|NCT06567522|DRUG|Lumbar Erector Spinae Plane Block. L bupivacaína 0.25%|Ultrasound-guided ESP-L shall be carried out at the L3-14 level with 30 mL of levobupivacaine 0.25%
224205797|NCT01216319|DEVICE|Nipple reconstruction|Biodesign® Nipple Reconstruction Cylinder
224205798|NCT00303134|DRUG|Islet Cell Transplantation|Islet Cell Transplantation for patients with type 1 diabetes mellitus
224189102|NCT04553497|OTHER|Rehabilitation program|The orthopedic rehabilitation programme was applied to all patients three times a week for 4 weeks under the guidance of the same physiotherapist. The first phase (0-3 weeks) involved the elbow, wrist, and hand active range of motion (ROM) and pendulum (clockwise and counterclockwise) exercises in the 0-2 weeks of the non-displaced fracture. For displaced fractures, elbow, wrist, and hand active range of motion was started immediately, but pendulum exercises were initiated two weeks later. The patients were instructed to continue exercises 3-5 times per day for 30 minutes. After two weeks, active assistive ROM and isometric exercises were performed supine position. During the second phase (3-6 weeks), active forward elevation in supine was carried out and then progressed to sitting and standing position. At the end of the sixth week, a home exercise program was given by the physiotherapist, including resistance exercises using an elastic band (Thera-Band).
224189103|NCT06679920|DEVICE|Optical coherence tomography|Measurement with opctical coherence tomography of tumour and normal bladder tissue during transurethral resection of a bladder tumour (TURBT)
223498644|NCT07118033|PROCEDURE|Non specific Manual Therapy|Participants in this group receive the same physiotherapy program, but the additional 5 minutes of mobilization are applied to the upper thoracic spine (T4-T7), away from the symptomatic lumbar region. This sham mobilization mimics the manual therapy without targeting the affected area or following the algorithm's logic.
223498645|NCT07121426|OTHER|Lower limb Intensive Functional Training|LIFT will help the child in motor learning, skill progression and resistance training to target the strength, proprioception and coordination impairments of the lower extremities. Motor learning will be based on Strength domain (Cycling) . Balance and Coordination domain involves activities such as (ball kicking with alternate legs and Static standing) Proprioception domain (Vertical jumping, sit to stand and cursing) while applying knee-immobilizers if needed.
223498646|NCT07121426|OTHER|Conventional physical therapy|Stretching followed by Strengthening program and traditional gait training at clinical setting. Stretching muscles were hip flexors, hip adductors, hamstrings and calf and stretching applied for 30 sec with 30 sec rest for 3-5 times for each muscle group with in pain limit followed by strengthening exercise for week muscle which includes the strengthening of anti-gravity muscles of lower limb they are: Quadriceps, Gluteus maximus and soleus performed in 3 groups. Each group contain 10 rep for each week muscle group.
223498647|NCT07121465|BEHAVIORAL|Education group|"First stage: Pregnant women will be administered a Personal Information Form, the Prenatal Breastfeeding-Self-Efficacy Scale, the Prenatal Hygiene Care Readiness Scale, and the Prenatal Self-Assessment Scale-Maternal Role Acceptance Subscale. Second stage: In this stage, pregnant women will be given a 60-minute breastfeeding education session.~Third stage: This stage will take place one week after the second stage, and pregnant women will receive baby care training. The training will be conducted face-to-face in the training room of the hospital where the study will be conducted, using the training manual prepared by the researchers according to Mercer's theory as a guide.~Fourth stage: In this stage, pregnant women will again be administered the Prenatal Breastfeeding-Self-Efficacy Scale, the Prenatal Hygiene Care Readiness Scale, and the Prenatal Self-Assessment Scale-Maternal Role Acceptance Subscale."
223498648|NCT07121465|BEHAVIORAL|Control group|"First stage: In this stage, pregnant women will be informed about the study and their voluntary written consent will be obtained. They will then complete a Personal Information Form, the Prenatal Breastfeeding Self-Efficacy Scale, the Prenatal Hygienic Care Readiness Scale, and the Prenatal Self-Assessment Scale-Maternal Role Acceptance Subscale.~Second stage: Pregnant women will be administered the Prenatal Breastfeeding Self-Efficacy Scale, the Prenatal Hygienic Care Readiness Scale, and the Prenatal Self-Assessment Scale-Maternal Role Acceptance Subscale."
223498649|NCT07119684|BEHAVIORAL|Short-Duration Walking Exercise|articipants performed three 10-minute walking sessions per day, 5 days per week for 6 weeks, at 60% of their maximum heart rate on a treadmill.
223498650|NCT07119684|BEHAVIORAL|Long-Duration Walking Exercise|Participants performed one continuous 30-minute walking session per day, 5 days per week for 6 weeks, at 60% of their maximum heart rate on a treadmill.
223590650|NCT02482116|OTHER|malaria or pneumonia diagnosis|Diagnostic approaches for malaria (lay diagnosis, as per IMCI guidelines by trained primary healthcare workers, clinical diagnosis by medically qualified doctor, rapid diagnostic tests, Giemsa microscopy); Diagnostic approaches for pneumonia (lay diagnosis, as per IMCI guidelines by trained primary healthcare workers, clinical diagnosis by medically qualified doctor, chest x-ray)
223590651|NCT00317304|BEHAVIORAL|Mindfulness-based stress reduction|MBSR is an 8-week group-based program of training in mindfulness and its application to the stresses and challenges of everyday life
223590652|NCT03487211|DRUG|Duloxetine|Duloxetine 30mg PO once daily for 1 week followed by an increase to 60mg PO once daily
223590653|NCT03487211|DRUG|Escitalopram|Escitalopram 10mg PO once daily for 1 week followed by an increase to 20mg PO once daily
223590654|NCT01669083|DRUG|GSK557296 10 mg|10 mg single oral dose. Each subject will receive 2 tablets of 5 mg GSK557296 four times a day (QID).
223590655|NCT01669083|DRUG|GSK557296 150 mg|150 mg single oral dose. Each subject will receive multiple tablets of 25 mg GSK557296 either 2, 3 or 4 times a day.
223746084|NCT02146547|DRUG|Aripiprazole depot|Abilify Maintena is an intramuscular (IM) depot formulation of oral aripiprazole. It provides the efficacy and safety profile of oral aripiprazole in a once-monthly injection.
223746085|NCT02146547|DRUG|Paliperidone|Administration once a day orally standardised in relation to food intake.
223590656|NCT01669083|DRUG|GSK557296 dose 3|Dose to be determined as a single dose tablet based on half-life demonstrated in Cohort 1 and Cohort 2.
223590657|NCT01669083|DRUG|GSK557296 dose 4|Dose to be determined by PK of prior doses, based on half-life demonstrated in prior cohorts.
223617821|NCT00793195|DRUG|Intralipid 20%|Dosing will be formulated according to a Nomogram for Parenteral Nutrition (PN) composition, which takes into account the percentage of the subject's caloric intake consumed parenterally. PN solution will be infused continuously over 12-24 hours by infusion pump, and the duration each day will depend on the enteral tolerance of the child. PN shall not be discontinued, unless the patient is taking 95% of calories enterally with good growth as evidence by appropriate weight gain. Subjects will receive the trial lipid for a total duration of 12 weeks or if they develop a serum conjugated bilirubin (sustained for 7 days) of 100 umol/l (6mg/dl) or full enteral tolerance prior to this end-point. Once the trial lipid is discontinued, in the event that PN is continued, subjects will return to the standard lipid preparation. A final follow-up data-point will be collected 4 weeks after the trial lipid is stopped.
224189104|NCT05084118|DRUG|Landiolol HCl|continous 2mcg/kg/min low dose application of Landiolol HCl for 72 hours
223498651|NCT07119255|PROCEDURE|PRP Pharmacopuncture|Participants in the PRP pharmacopuncture arm will receive a single administration of platelet-rich plasma (PRP) via intramuscular injection at acupuncture points corresponding to chronic neck pain in cervical myofascial syndrome in the upper trapezius muscle.
223498652|NCT07119255|PROCEDURE|Placebo Pharmacopuncture|Participants in the placebo pharmacopuncture arm will receive a single administration of normal saline via intramuscular injection at acupuncture points corresponding to chronic neck pain in cervical myofascial syndrome in the upper trapezius muscle.
223498653|NCT07121283|DEVICE|True AI|True output from bone age AI
223498654|NCT07121283|DEVICE|Fake AI|Randomized output from bone age AI
223498655|NCT07120607|BIOLOGICAL|CD7 CAR-γδT cell（QH106）|Allogenic CD7 CAR-γδT cell，Intravenous on day0; dose escalation (3+3) : dose 1 (1 × 10\^8 CAR+ cells) , dose 2 (3 × 10\^8CAR+ cells/kg，dose 3 (6× 10\^8 CAR+ cells）;
223498656|NCT07120607|DRUG|Fludarabine (FLU)|Intravenous fludarabine 30\~50 mg/m\^2/day on days-5, -4, and -3；
223498657|NCT07120607|DRUG|Cyclophosphamide (CTX)|Intravenous cyclophosphamide 500\~1000 mg/m\^2/day on days -5, -4, and -3.
223498658|NCT07120737|DEVICE|H.A.L.T. MAX spectacles|The Essilor® Stellest® 2.0 lens features a 2 times larger signal area, significantly enhancing the effect of slowing down myopia progression
223498659|NCT07119515|BEHAVIORAL|Third-Wave CBT via Teletherapy|Twelve weekly 40-minute remote sessions via video conferencing, including mindfulness, behavioral activation, and exposure therapy.
223498660|NCT07119515|BEHAVIORAL|Third-Wave CBT In-Person|Twelve weekly 40-minute face-to-face sessions with identical third-wave CBT content.
223498661|NCT07119970|BIOLOGICAL|Additional blood sampling|At inclusion (T0) and at 12 months (T1), venous blood will be drawn for plasma markers of NETosis
223498662|NCT07120633|OTHER|AntiCD19 CAR-T combined with BTKi in the treatment of newly diagnosed high-risk CLL/SLL patients|After chemotherapy, the tumors of the patients in the experimental group were re-graded to determine the basic burden status of the tumors. It should include imaging diagnosis, physical examination, laboratory tests of blood, assessment of bone marrow MRD and evaluation of the toxic and side effects of chemotherapy, etc
223498663|NCT07116889|BIOLOGICAL|GB-0895 (SC)|Single subcutaneous dose of GB-0895
223498664|NCT07116889|BIOLOGICAL|GB-0895 (SC)|Multiple subcutaneous doses of GB-0895
223498665|NCT07116889|DRUG|Placebo (SC)|Single subcutaneous dose of placebo
223498666|NCT07116889|DRUG|Placebo (SC)|Multiple subcutaneous doses of placebo
223498667|NCT07120347|OTHER|Remote Ambient Sensor System|Remote sensors (motion, door contact) deployed in participants' home connected through raspberry pi and mobile hotspot
223498668|NCT07119073|DRUG|Dexmethylphenidate|Subjects will be randomized to one of two sequences. Subjects will be dosed with 50 mg dose of Cox-1301 during each sequence. Subjects will serve as their own control.
224189105|NCT05084118|DRUG|Placebo|continous application of isotone saline solution for 72 hours
224189106|NCT05932420|DIETARY_SUPPLEMENT|Placebo|16.4g pure medium triglyceride oil mixed with 1 mM of bitter sucrose octaacetate. A dose of 25g of the placebo drink is provided immediately after each training session and 30 minutes before sleeptime throughout the training period.
223498669|NCT07116798|OTHER|Exercise|Strengthening Exercises Based on Proprioceptive Neuromuscular Facilitation Patterns
223498670|NCT07116798|OTHER|Exercise|Plyometric Exercises
223498671|NCT07119151|DEVICE|Dental Implant|Dental Implant placement and loading.
223498672|NCT07120672|OTHER|patients were monitored for reentubation for 48 hours.|patients were monitored for reentubation for 48 hours.
223498673|NCT07120672|OTHER|weaning group|patients were monitored for reentubation for 48 hours.
223498674|NCT07122531|OTHER|Medium chain triglyceride oil|Supplementation with 15 g of medium chain triglyceride oil, a food product commercially available over-the-counter in regular grocery stores, emulsified in beverage of choice, twice daily (morning and evening) for 12 weeks.
223498675|NCT07123896|DEVICE|Normal treatment with catheter ablation or medicine|Routine clinical care with catheter ablation and/or medicine; real-world clinical cases
223498676|NCT07123896|DRUG|Drug Treatment|Routine clinical care with medicine; real-world clinical cases
223498677|NCT07122804|OTHER|Assessment|Within the scope of the study, without any intervention, data regarding the participants' hyperventilation symptoms and physical capacities will be evaluated.
223498678|NCT07123610|BEHAVIORAL|Mediterranean Diet Education Program|"The intervention consists of a 4-week Mediterranean Diet Education Program designed specifically for nurses working rotating shifts.~The program included four weekly group sessions, each lasting approximately 60 minutes, delivered in-person by a registered dietitian with training in behavioral change and clinical nutrition. Sessions are interactive and supported by visual and printed educational materials.~Participants receive a printed handbook including a food pyramid graphic, portion guides, weekly shopping lists, and sample menus tailored to shift work schedules. They also gain access to a moderated online discussion group and receive weekly motivational text messages to reinforce key messages.~No food is provided directly."
223498679|NCT07122284|DIAGNOSTIC_TEST|13C-Urea Breath Test|Participants underwent the 13C-urea breath test following a standardized protocol to detect active Helicobacter pylori (H. pylori) infection. After an overnight fast (≥8 hours), baseline breath samples were collected by exhaling gently through a straw. Participants then ingested 75 mg of 13C-labeled urea dissolved in 50 mL of citric acid solution to delay gastric emptying and maximize urease exposure. A second breath sample was collected 30 minutes post-ingestion using identical procedures.
223498680|NCT07122284|DIAGNOSTIC_TEST|Hydrogen-Methane Breath Test|Participants underwent a standardized hydrogen-methane breath test to evaluate for small intestinal bacterial overgrowth (SIBO) or carbohydrate malabsorption. After a 12-hour overnight fast, baseline breath samples were collected via controlled end-expiratory exhalation. Participants then ingested a substrate solution.
224189107|NCT05932420|DIETARY_SUPPLEMENT|Ketone ester|A dose of 25g of ketone ester after each training session and 30 minutes before sleeptime throughout the training period.
224189108|NCT02691845|BEHAVIORAL|BA (brief advice)|
224189109|NCT02691845|BEHAVIORAL|SHE (supervised and home-based exercise)|
224189110|NCT02691845|BEHAVIORAL|HE (health education)|
224189111|NCT02691845|BEHAVIORAL|CBEX (cognitive-behavioral sessions focused on increasing and maintaining exercise)|
223590658|NCT05485623|DEVICE|PulseNmore FC|"Pulsenmore Ltd. has developed a small portable vaginal ultrasound device for personal use at home. The ultrasound device allows to scan and assess both the uterus and the ovaries. This ultrasound device connects to a smartphone and a user-friendly application simplifies its use. This ultrasound device is based on the company's 'Pulsenmore ES ultrasound system' which is a small abdominal ultrasound device for home and self-use by pregnant women. This (abdominal) ultrasound device allows scanning and detection of fetal pulse, count fetal movements, assess the amount of amniotic fluid and more. The device is an abdominal ultrasound probe that connects to a smartphone using a specially designed socket. The main difference between the devices is the different design of the ultrasound vaginal probe.~The device consists of 2 components: a cradle and an application (software). The cradle contains the electronic components and the ultrasound probe."
224189112|NCT05469451|PROCEDURE|Low level laser therapy|Irradiated with a low power density laser of 940 (nm), 100 megawatt, which will be calibrated and the result of the calibration will be checked with the use of the power meter. The equipment used will be a diode laser (BIOLASE™), the area to be irradiated will be the anterior segment of the lower arch, each tooth will be irradiated for a time of 10 seconds on the vestibular surfaces of the teeth and 10 seconds on the lingual surfaces of the teeth, both at gingival level and at apical level in scanning mode.
224189113|NCT04547452|RADIATION|Stereotactic body radiation therapy|Sintilimab Combined with SBRT
224189114|NCT04547452|DRUG|Anti-PD-1 antibody drug named Sintilimab|Sintilimab
224309389|NCT06349551|BIOLOGICAL|Patients of intensive care unit|Patients of intensive care unit having an arterial catheter undergoing arterial blood sampling
223498681|NCT07123948|DIAGNOSTIC_TEST|Wechsler Intelligence Test, performed by educated psychologists|"At the age of six, parents of children who meet the inclusion criteria will receive a notification about the study from the responsible paediatrician. If they agree to participate, they will sign an informed consent form. They will then be invited to the clinic for a neurological and neurodevelopmental assessment. The neurological examination will be conducted by the principal investigator or collaborators who are paediatric specialists. The neurodevelopmental evaluation will be performed by a qualified psychologist using the Wechsler Intelligence Test.~The Wechsler Intelligence Test for Children - Fourth Edition is a clinical tool for measuring the intelligence of children aged 6 to 16 years and 11 months. It assists in identifying specific learning difficulties, hyperactivity disorder, speech and language challenges, and intellectual impairments. The test comprises 15 subtests."
223498682|NCT07122726|PROCEDURE|Otago and PNF exercise|"Otago Exercise:~This 6-week protocol focuses on strengthening and balance exercises. It starts with supported exercises and progresses to unsupported ones. Exercises include knee flexors, extensors, and hip abductors with ankle weights, ankle plantar and dorsiflexors, knee bends, backward stepping, walking and turning, sideways walking, tandem stance, and one-leg stance. Repetitions increase over time, from 10-20 reps with support to 30 reps without support.~PNF Exercise The PNF protocol consists of 6 levels, progressing from simple to complex exercises. Level 1 involves D1/D2 patterns for ankle and hip with light resistance, while Level 2 focuses on seated D1/D2 patterns for the lower limb. Levels 3-6 introduce more dynamic exercises, including arm reaches while standing, PNF walking, dynamic step-ups, walking on unequal terrain, and obstacle navigation. The protocol emphasizes approximation, stabilization, resistance, and dynamic reversals to improve proprioception \& balance."
223498683|NCT07122726|PROCEDURE|Otago Exercise|Knee Flexors, Knee Extensors, Hip-abductors- 10 reps of each Exercise with ankle weights to provide muscle resistance. For ankle planter flexors and dorsi flexors starting from 20 repetitions at week 1 with hold support and ending at 30 repetitions without any support on 6th week. For knee bends starting with 10 reps at week 1 and ending at 30 reps without support at 6th week. Backward stepping 10 times 2 steps backward at week 1 progressing to 10 times x 4 Steps x No Support at week 6 gradually. Walking and Turning Around- (make a figure of 8), twice, first with support and then without support. Sideways Walking- 10 steps, 4 times x first with support and then without support over the time of 6 weeks. Tandem Stance- 10 seconds first with support and then without support. Tandem Walk/ 20 reps first with support and then without support over the period of 6 weeks.
223498684|NCT07122388|DIAGNOSTIC_TEST|Questionnaires about autism spectrum disorders and sleep and PSG.|Recruitment of subjects with autism spectrum disorder at all developmental ages and of all severity levels.
223498685|NCT07122388|DIAGNOSTIC_TEST|ADOS-2, ADI-R, SRS-2, PSG|Recruitment of subjects with autism spectrum disorder at all developmental ages and all severity levels.
223498686|NCT07123428|DRUG|TRD205|TRD205 tablet
223498687|NCT07123428|DRUG|Placebo|TRD205 placebo tablet
223498688|NCT07122778|DIETARY_SUPPLEMENT|Controlled energy-deficit diet|Participants receive a prepared diet providing approximately 50% of their estimated daily energy expenditure to induce a sustained energy deficit
223498689|NCT07122778|DIETARY_SUPPLEMENT|Habitual diet with surplus snacks|Participants continue their normal diet with the addition of high-calorie snack items to achieve an approximate daily energy surplus
223498690|NCT07121842|DIAGNOSTIC_TEST|Extended MRI|The MRI protocol for every clinical follow-up MRI scan is extended with 15 minutes to add the APTw-CEST scan.
223746086|NCT02146547|DRUG|Paliperidone palmitate|In selected patients with schizophrenia and previous responsiveness to oral paliperidone or risperidone, Xeplion may be used without prior stabilization with oral treatment if psychotic symptoms are mild to moderate and a long-acting injectable is needed.
224189115|NCT01728194|DRUG|Escitalopram|20 mg target dose for 12 weeks
224189116|NCT01728194|OTHER|Magnetic Resonance Imaging|Structural and functional MRI of the brain for research purposes.
224189117|NCT04493229|DRUG|Oxytocin|IM Oxytocin
224309390|NCT05180201|DIETARY_SUPPLEMENT|Synbiotic|Lactiplantibacillus plantarum ATCC 202195 with fructooligosaccharide
224189118|NCT04493229|DRUG|Placebo|Placebo IM
224189119|NCT01100203|DRUG|Eplerenone|25 mg once daily 1 week, then 50 mg once daily for another 23 weeks.
224309391|NCT05180201|DIETARY_SUPPLEMENT|Probiotic|Lactiplantibacillus plantarum ATCC 202195
224309392|NCT05180201|OTHER|Placebo|Maltodextrin
224309393|NCT02702570|BEHAVIORAL|CASA|Each participant serves as his/her own control. Measures administered before and after the behavioral intervention.
224309394|NCT06229678|DRUG|Empagliflozin 25 MG Oral Tablet|Empagliflozin 25MG will be administered orally once per day for 3 months
224309395|NCT06229678|DRUG|Placebo|The placebo will be administered orally once per day for 3 months
223590659|NCT03909308|BEHAVIORAL|Beach Tennis session|The Beach Tennis training session will be composed by a warm up of 5 min of BT in which technical exercises (i.e., serve, volley, forehand and backhand) will be performed After that, 3 BT small games of 12 min with a 2 minute interval between games using the conventional rules of sport will be performed. Before the session and after each small game, data regarding heart rate, blood pressure and rate perceived exertion will be recorded.
224189120|NCT03665233|DEVICE|VR|People in the VR-group get a VRH session during the CPM physiotherapy , people in the sham group get a VR sham session, while they both can enjoy Standard Treatment
223498691|NCT07123207|DIETARY_SUPPLEMENT|Bacillus subtilis Capsules|"Bacillus subtilis is a type of probiotic. Studies have found that supplementation with Bacillus subtilis can effectively maintain the remission of inflammatory bowel disease by protecting intestinal integrity, regulating epithelial proliferation, and reshaping the structure and function of the microbiota.~Bacillus subtilis capsules are a Bacillus supplement containing 3×10⁹ CFU of Bacillus subtilis per capsule. Patients in the Bacillus subtilis supplementation group take Bacillus subtilis capsules orally once a day, one capsule each time, for 12 weeks."
223498692|NCT07123870|DRUG|Sevofluorane|In this group of patients, \<0.5 MAC sevoflurane will be used in combination with TIVA. (TIVA method described above)
223498693|NCT07123870|DRUG|Desflurane|In this group of patients, \<0.5 MAC Desflurane will be used in combination with TIVA.
223498694|NCT07123870|DRUG|Total Intravenous Anesthesia(TIVA)|In this group, TIVA will be applied with the combination of BIS-guided propofol + remifentanil.
223498695|NCT07121816|DEVICE|ECG watch|ECG watch in palpitation assessment
223498696|NCT07118332|DRUG|Psilocybin (drug)|25mg of Psilocybin will be given to all subject
223498697|NCT07122934|DIAGNOSTIC_TEST|Assessment of cervico-cerebral arterial occlusion pattern|Assessment of cervico-cerebral arterial occlusion pattern for the development of a radiological score
223498698|NCT07123116|DRUG|Shenbai Granules|Dosage: bag 10g per , administered twice daily continuously for 180 days.
223498699|NCT07123116|DRUG|Placebo|Dosage: 10g per bag, administered twice daily continuously for 180 days.
223498700|NCT07122453|DRUG|CNTX-3001|non-opioid analgesic
223498701|NCT07122453|DRUG|Placebo|Placebo product
223498702|NCT07125066|DRUG|Sodium phenylbutyrate|open-label design with doses of sodium phenylbutyrate
223498703|NCT07125274|DIAGNOSTIC_TEST|Biomarker-guided diagnostic tests|mRNA-Signature from blood; immunophenotyping from blood; MBLA from sputum, PATHFAST-LAM and EclLAM from sputum, stool, urine; CRISPR-Cas from blood; stool PCR; QuantiFERON(R)-TB Gold Plus.
223590660|NCT02736916|RADIATION|HS-WBRT PCI|LD-SCLC patients with HS-WBRT PCI
223590661|NCT02736916|RADIATION|Conventional PCI|LD-SCLC patients with conventional PCI
224189121|NCT02309372|BEHAVIORAL|Beating the Blues|Computerized depression treatment intervention
223498704|NCT07125131|OTHER|Gamification-Enhanced Problem-Based Learning|An educational intervention combines principles of problem-based learning (PBL) with game design elements including scores, leaderboards, digital badges, challenges, immersive experiences, feedback and rewards into problem-based learning.
223498705|NCT07125131|OTHER|Conventional didactic lecture (usual practice)|A didactic teaching approach in which course content is delivered to nursing students primarily through PowerPoint presentation by lecturer.
223498706|NCT07124273|PROCEDURE|Standardized Mandibular Anesthesia Protocol|Participants receive an inferior alveolar nerve block (IANB) using 1.8 ml 4% articaine with 1:100,000 epinephrine (Ultracaine DS Forte) via a 27-gauge dental needle, followed by buccal and lingual infiltration anesthesia after 5 minutes. Topical 10% lidocaine spray is applied prior to injection. All procedures are performed by the same clinician between 09:00-12:00. Salivary cortisol, pulse oximetry, and pain assessments are conducted before and after the anesthesia.
224189122|NCT06351735|PROCEDURE|Deep cervical lymph node-vein bypass surgery|Deep cervical lymph node-vein bypass surgery, connecting deep cervical lymph node input lymphatic vessel
224205799|NCT01695837|BEHAVIORAL|Group A: Dietary counseling month 0-6 Group B: Dietary counseling month 3-6|
223498707|NCT07125625|DIETARY_SUPPLEMENT|Experimental arm: probiotic|a dietary supplement containing L. Rhamnosus GG 1x1010 CFU plus L. Plantarum 299V. 1x1010 CFU
223498708|NCT07125625|DIETARY_SUPPLEMENT|Placebo|Placebo (maltodextrine)
223498709|NCT07125989|DEVICE|non-invasive ventilation|During the patient's first three respiratory rehabilitation sessions, each test on the cycle ergometer will be performed at 70% of maximum power (defined during the initial oxygen consumption (VO2) test) with ventilatory assistance at a different intensity (Low, moderate or high intensity).
223498710|NCT07125794|PROCEDURE|Original Denis Browne splint|Patients who were managed with the original Denis Browne splint.
223498711|NCT07125794|PROCEDURE|Modified Denis Browne splint|Patients who were managed with the modified Denis Browne splint.
223498712|NCT07124507|DIETARY_SUPPLEMENT|PICOZYME ET|The investigational product is a dietary supplement containing aldehyde dehydrogenase (ALDH), administered orally twice daily (one packet in the morning and one in the evening) for 3 months before meals.
223498713|NCT07125391|DRUG|Cohort A|received propranolol hydrochloride (20mg, BID, QD), paclitaxel/paclitaxel liposome (135-175mg/m2, d1, Q3W), carboplatin (AUC=4-5, d1, Q3W) for 3-4 cycles of neoadjuvant therapy. Subsequently, interval debulking surgery (IDS) was performed. Propranolol hydrochloride was taken one week before neoadjuvant therapy
223498714|NCT07124962|PROCEDURE|Root Canal Therapy|Regenerative endodontic procedure using autologous platelet-rich plasma injected into the root canal space to promote pulp-dentin regeneration, followed by placement of MTA and composite restoration.
223590662|NCT05952388|OTHER|Behavioral Patient care|chart review
223590663|NCT01161537|DRUG|VX-770|Tablet.
223590664|NCT01161537|DRUG|Placebo|Tablet.
223590665|NCT04164420|BEHAVIORAL|Oral neuromuscular training and orofacial sensory-vibration|Oral neuromuscular training is performed by using an oral device. The device is placed pre-dentally behind closed lips, and the participant is sitting in an up-right position. The participant is the instructed to hold the device against a gradually-increasing horizontal pulling force for 5-10 s, whilst trying to resist the force by tightening the lips and pressing the head backward against a head rest.
224205800|NCT02357173|OTHER|electronic cigarette|
224205801|NCT02357173|OTHER|cigarette group|
224205802|NCT05663216|OTHER|Blood sampling|6 ml blood sampling at Day 0, 1, 3, 7. Broncho-alveolar sampling, if performed in routine care.
224189123|NCT05858567|DRUG|Envafolimab|"Drug: Envafolimab This product is administered by subcutaneous injection. The recommended dose of subcutaneous injection is 150 mg, administered weekly (QW).~Other Names:~KN053 Drug: Oxaliplatin 130mg/m2，ivgtt，d1~Drug: Capecitabine 1000mg/m2，po，bid，d1-14~Radiation: Short-course Radiation Short-course radiotherapy, using three-dimensional conformal or intensity-modulated radiotherapy, the dose is divided into 5Gy/f, the total dose is 25Gy/5f, 1f/d, and the irradiation is completed within 7 days.~Procedure/Surgery: Biopsy, local excision or TME surgery (total mesorectal excision) Biopsy can choose endoscopic or needle biopsy, colcal excision refers to excison of the local lession after total neoadjuvant therapy The total mesorectal excision can choose open, laparoscopic or robotic according to the specific condition of the patient."
224189124|NCT02054572|DRUG|[¹⁴C]Etelcalcetide|750 nCi of \[¹⁴C\]etelcalcetide formulated as a single 10 mg dose of etelcaletide in 2 mL liquid solution for bolus intravenous (IV) administration at the end of hemodialysis.
224189125|NCT01966406|DEVICE|Nasogastric tube|
223498715|NCT07124962|PROCEDURE|Platelet-Rich Plasma (PRP) Revascularization|Regenerative endodontic procedure using autologous platelet-rich plasma injected into the root canal space to promote pulp-dentin regeneration, followed by placement of MTA and composite restoration.
223498716|NCT07122297|PROCEDURE|Retraction cord|"A thin cord (type 00) was soaked in 15% ferric sulfate ferric sulfate hemostatic solution and carefully packed into the gingival sulcus. After 3 minutes, the cord was removed and the sulcus was rinsed. This is a traditional mechanical gingival displacement method."
223498717|NCT07122297|PROCEDURE|Retraction paste in capsule form|A retraction paste was applied using a capsule tip placed around the gingival margin. The paste remained in place for 3 minutes and was then rinsed off with air-water spray. This is a non-traumatic chemical displacement technique.
223498718|NCT07122297|PROCEDURE|Retraction paste in injector form|Retractrion paste in injector form with compression cap (15% aluminum chloride) was injected into the sulcus, and a cotton compression cap was placed over the tooth. Patients gently bit on the cap for 3 minutes to apply pressure. Afterward, the paste and cap were removed and the area was rinsed. This method combines chemical and slight mechanical displacement.
223590666|NCT04164420|BEHAVIORAL|Orofacial sensory-vibration stimulation|All participants in the control group is given orofacial sensory-vibration stimulation by using an electrical toothbrush. Instructions is given on how to stimulate the buccinator mechanism, lips, external floor, and the tongue three times daily before a meal.
223590667|NCT05993910|OTHER|Hyperthermie Register|"* die Höhe der Temperatur im Zielgebiet (42,5 bis 43 °C),~* die Dauer der Anwendung und~* die simultane Therapie mit Chemo- und/oder Strahlentherapie"
223590668|NCT00520910|DRUG|Polypodium leucotomos|Subject is given a 7.5 mg/kg oral dose of Polypodium leucotomos during Baseline visit, and again at 8 hours and 2 hours before the Follow-up visit #2.
223590669|NCT01629459|BEHAVIORAL|Resistance exercise and protein supplementation|Resistance exercise training will occur 3x/wk for 12 wks at a physical therapy or cardiac rehabilitation facility near the participant's home. Participant will take 42 grams of supplementation protein daily.
223590670|NCT00269555|DRUG|Genistein Combined Polysaccharide (GCP)|
223590671|NCT04764227|DRUG|Paclitaxel|paclitaxel 50mg/m2/d, ivgtt over 3 hours, d1, qw\*5
223590672|NCT04764227|DRUG|Carboplatin|carboplatin AUC=2, ivgtt, d1, qw\*5
223590673|NCT04764227|RADIATION|Radiotherapy|1.8Gy/d, d1-5/week, 28Fx
223590674|NCT06254287|DRUG|Avatrombopag|Avatrombopag was given 40 mg/ time, once a day, orally, for 3 months.
224074197|NCT06774547|OTHER|Plyometric exercise|The progressive plyometric programme consists of three different levels and is performed unsupervised three times per week separated by a minimum of 48 hours. Each level consists of several exercise sets that are separated by 2-minute rest intervals. Participants' self-evaluated readiness to progress to a higher level will guide the progression. Level 1 includes free-standing double-legged plyometric exercises where they push off the ground and lift their heels while maintaining contact with it. If the participant feels they can do more, they will progress to Level 2, where participants increase the relative load during the dynamic exercises and start performing plyometric double-legged jumps. At the highest level, Level 3, the relative load during the exercises is further increased, and the plyometric exercises are to be performed as single-legged hops. Tolerable pain during the exercises is allowed.
224189126|NCT01966406|OTHER|No nasogastric tube|
224189127|NCT00928642|DRUG|imatinib mesylate by mouth|imatinib mesylate - 400mg orally, daily on Days 1-5 and 8-12 of a 21 day cycle.
223590675|NCT06254287|DRUG|Avatrombopag +rhTPO|Avatrombopag: 40 mg/ time, once a day, orally; rhTPO: 15000U/ time, once a day, subcutaneous injection; Both were 3 months.
223590676|NCT04967404|DIETARY_SUPPLEMENT|Phosphatidylserine|800 mg per day for 10 days
223590677|NCT00544219|BIOLOGICAL|rituximab|375 mg/m2 i.v. per cycle
223590678|NCT00544219|DRUG|cyclophosphamide|750 mg/m2 i.v. per cycle
223590679|NCT00544219|DRUG|doxorubicin hydrochloride|50 mg/m2 i.v. per cycle
223590680|NCT00544219|DRUG|prednisone|100 mg/day p.o. per cycle
223590681|NCT00544219|DRUG|vincristine sulfate|1.4 mg/m2 (max. 2.0 mg) i.v. per cycle
224189128|NCT00928642|DRUG|Gemcitabine Intravenous|Gemcitabine - 1000 mg/m2 IV on Day 3 and Day 10 of a 21 day cycle
224309396|NCT06229678|DRUG|Acipimox 250 Mg Oral Capsule|subjects will be started on acipimox 250mg every 6 hours for 8 days while on continued empagliflozin/placebo therapy. This will be added at the end of 3 months after they finished baseline studies
223590682|NCT00544219|PROCEDURE|positron emission tomography|PET Scan during treatment
223590683|NCT01719133|DRUG|placebo|saline solution
223590684|NCT01719133|DRUG|Histamine|positive control
223590685|NCT01719133|DRUG|AllerT1|synthetic peptide T1
223590686|NCT01719133|DRUG|AllerT2|synthetic peptide T2
223590687|NCT01719133|DRUG|AllerT3|synthetic peptide T3
223590688|NCT01719133|DRUG|AllerT4|synthetic peptide T4
223590689|NCT01719133|DRUG|AllerT5|synthetic peptide T5
223590690|NCT01719133|DRUG|mix of AllerT1-T2-T3|mix of peptides T1, T2 and T3
223590691|NCT01719133|DRUG|mix of AllerT4-T5|mix T4-T5
224189129|NCT04838587|OTHER|No intervention will be done|No intervention,Only passive surveillance of Diarrhoea cases will be done
223498719|NCT07122297|PROCEDURE|Diode Laser|A 810-nm diode laser with a 400-micron fiber optic tip was used in contact mode to ablate the sulcular epithelium. The laser was operated at 1.0 W with pulsed settings. The procedure was completed by wiping the area with saline to remove residues. This technique enables precise, bloodless gingival retraction with minimal trauma.
223498720|NCT07126041|OTHER|Prescription for Action (SPHERES Model)|"A system-level intervention consisting of:~* a digital dashboard displaying local health services, outcome indicators, and operational data in a secure Public Health Data Theater;~* structured monthly prescription guides targeting service improvements across three priority program areas;~* monthly performance monitoring with district health leaders. The intervention is applied at the PHC level, all supported by digital capacity building, district-level deployment of implementation teams, and intersectoral secure health data exchange."
223498721|NCT04517838|PROCEDURE|Biospecimen Collection|Undergo collection of blood and tumor tissue samples
223498722|NCT05429840|DRUG|MT1980|single dose
223498723|NCT05429840|DRUG|Placebo|single dose
223498724|NCT06507917|DIAGNOSTIC_TEST|anal swabbing|anal swabbing
223498725|NCT06941818|DRUG|HS-IT101 Injection|Adoptive transfer of 5x10\^9-6x10\^10 autologous TIL to patients i.v. in 30-60 minutes.
223498726|NCT03537963|OTHER|mHealth Stepped-care Intervention|Test of the feasibility and acceptability of an mHealth stepped-care intervention for sleep disturbance in HCT survivors, to compare with the control group.
223498727|NCT03537963|OTHER|Educational Control Condition|General health education for cancer survivors provided in NCI booklets entitled Facing Forward: Life After Cancer Treatment and Coping With Advanced Cancer.
223498728|NCT03537963|OTHER|Questionnaire|After the intervention, participants will be asked to complete a questionnaire to provide feedback on the intervention.
223498729|NCT03537963|OTHER|Interview|Qualitative interviews will be gathered after the participants have completed participation in the new intervention to gather data to inform future refinements of the intervention.
223498730|NCT03537963|OTHER|Qualitative Interviews|To conduct qualitative interviews with patients, caregivers, and clinicians regarding sleep disturbance in HCT survivors and on preferences for a new mHealth intervention for sleep disturbance. Separate panels of 10 HCT survivors, 10 caregivers who were the primary caregiver of an HCT survivor during or after the inpatient HCT hospitalization, and 5-10 HCT clinicians will be recruited for individual qualitative interviews via telephone or in person.
223498731|NCT03537963|OTHER|Virtual Reality|The intervention will comprise six 360º videos of relaxing natural landscapes from which patients can choose (i.e., beaches, tropical scenes, calm thunderstorms, snowfall). Participants will also choose an audio accompaniment: a progressive muscle relaxation script, a deep breathing exercise script, a mindfulness meditation script, or scene-relevant audio (e.g., waves crashing for the beach scene).
223590692|NCT05446571|DRUG|Letermovir|Maternal daily administration of 240 milligrams of letermovir (1x240 mg-tablets) up-until delivery or TOP Placebo of Valaciclovir ; daily administration of 8 grams of valaciclovir (2 g (4 x500 mg-tablets) every 6 hours) up-until delivery or TOP
223590693|NCT05446571|DRUG|Valacyclovir|Maternal daily administration of 8 grams of valaciclovir (2 g (4 x500 mg-tablets) every 6 hours) up-until delivery or TOP Placebo of letermovir : (1x240 mg-tablets) up-until delivery or TOP
223590694|NCT06351254|PROCEDURE|Sine sound waves|Group A 8 participants will be given sine sound waves treatment with the frequency of 80 pulses on C1 vertebrae. Treatment session will be 6 session 3 times a week followed by 6 sessions 2 times a week.
223590695|NCT06351254|PROCEDURE|Kinesthetic exercises|Kinesthetic exercises was conducted for GROUP 2 8 patients for 6 weeks. Before and after assessment was taken to track patient progress. Cervicocephalic kinesthetic sensibility tests were performed. The first test was Head-to-Neutral Head Position(NHP) repositioning test. In the second repositioning test is Head-toTarget repositioning tests.
224074198|NCT07070076|PROCEDURE|Yttrium-90|Step 1: The MDT team conducts a routine preoperative assessment. Step 2: The interventional team performed tumor vascularity distribution and 99mTc simulation surgery. Step 3: Nuclear Medicine performs SPECT validation and yttrium-90 treatment activity calculation. Step 4: Infusion of yttrium-90 microspheres in the interventional department. Step 5: Nuclear Medicine uses PET/CT or SPECT to determine the distribution of nuclides. If the patient is unwell, he or she can be discharged after 24 hours without special protection. Follow-up examination 1 month after surgery, and then every 2 months, a total of 1 course of treatment. After yttrium-90 treatment, rest for 3-4 months, and arrange hepatectomy after excluding surgical contraindications. The patients in both groups were consulted and discussed by multidisciplinary experts in liver cancer, and elective hepatectomy was arranged after excluding surgical contraindications according to the standardized process.
223498732|NCT06948565|OTHER|observational study|This observational study aims to describe the clinical practices and the outcome of patients admitted in ICU.
223498733|NCT06954831|PROCEDURE|Cone-Beam Computed Tomography|Undergo CBCT
223498734|NCT06954831|RADIATION|Hypofractionated External Beam Radiation Therapy|Undergo UF-WBI with CB
223498735|NCT06954831|OTHER|Questionnaire Administration|Ancillary studies
223498736|NCT06954831|RADIATION|Radiation Boost|Undergo UF-WBI with CB
223498737|NCT06954831|RADIATION|Whole Breast Irradiation|Undergo UF-WBI with CB
223498738|NCT06946966|OTHER|Reformer Pilates|Reformer Pilates
223498739|NCT06946966|OTHER|Pilates control|Pilates control
223498740|NCT06946966|OTHER|pilates online pilates|pilates online pilates
223498741|NCT07125560|BEHAVIORAL|MyBRUSH module|oral health education module that comprises of booklet for educational material, oral health talk, toothbrushing demonstration and return demonstration, and small group discussion
223498742|NCT07125560|BEHAVIORAL|BEGIN program|BEGIN program that comprise of toothbrushing demonstration and return demonstration
223498743|NCT07124754|DIAGNOSTIC_TEST|Multimodal Artificial Intelligence Diagnostic Model for Lymph Node Metastasis in T1 Gastric Cancer|"This intervention involves the use of a custom-built artificial intelligence (AI) diagnostic model that integrates multimodal data-including clinical variables, histopathological features, and imaging data-to predict lymph node metastasis in patients with T1-stage gastric cancer.~The model provides risk probability scores and classification outputs that assist physicians in diagnostic decision-making.~The AI system will be compared with physician performance at different levels of experience (resident, attending, senior) to assess its impact on diagnostic accuracy and clinical decision support."
223498744|NCT07117903|DIETARY_SUPPLEMENT|Normal diet + vehicle|Participants in the control group were instructed to maintain their usual diet for the duration of the study. While they were free to choose their food, they were required to provide a detailed dietary record. After diet intervention, whole blood will be drawn and incubated with vehicle drug.
223498745|NCT07117903|DIETARY_SUPPLEMENT|Normal diet + aspirin|Participants in the control group were instructed to maintain their usual diet for the duration of the study. While they were free to choose their food, they were required to provide a detailed dietary record. After diet intervention, whole blood will be drawn and incubated with aspirin.
223590696|NCT06351254|PROCEDURE|Sine sound waves plus kinesthetic exercises|Group C 8 was given combine treatment of sine sound waves and kinesthetic exercises before and after measurement was taken.
224074199|NCT07070076|PROCEDURE|HAIC|After successful percutaneous hepatic artery cannulation, superior mesenteric arteriography and hepatic arteriography are performed, and after the hepatic artery is cannulated to a predetermined position, the patient is returned to the ward with an indwelling catheter. In the ward, a catheter syringe pump is continuously pumped into the following chemotherapy drugs: oxaliplatin 135mg/m2 over 3hrs, leucovorin 400mg/m2 over 1.5hrs, 5-FU 400mg/m2 over 2hrs, 5-FU 2400mg/m2 over 46hrs. After the chemotherapy is completed, the catheter is removed, and the patient can be discharged after 12 hours of compression bandaging to stop the bleeding. Repeat at intervals of 3\~4 weeks, a total of 2 or 4 strokes. For details, see 3.3.1.4 Grouping and Treatment Flow Chart. After the end of HAIC, rest for 3\~4 weeks for re-examination, and arrange liver resection after excluding surgical contraindications.
224074200|NCT07063251|GENETIC|HG005|Once subretinal injection; The duration of the study is about 52 weeks for each subject, including a 4 weeks screening period, enrollment visit, treatment visit, and 56 weeks follow-up period.
224074201|NCT06898905|OTHER|Bridging Radiation Therapy|Study seeks to compare the hypofractionated radiation therapy with hyperfractionated treatment within the same tumor. Each participant will be serving as their own control; half their tumor will receive once daily hypofractionated (QD) bridging radiotherapy, and the other half of their tumor will receive twice daily hyperfractionated (BID) bridging radiotherapy. Either schedule is considered standard of care and this study aims to determine which schedule may prove superior between the two standards.
224074202|NCT07072598|DEVICE|ClearPETRA suction access sheath|Ureteroscopy utilizing the ClearPETRA suction access sheath.
224074203|NCT07072598|DEVICE|ClearPETRA suction access sheath|Mini-PCNL utilizing the ClearPETRA suction access sheath
224074204|NCT02494869|BEHAVIORAL|Nonlinear Aerobic Training|
224074205|NCT02494869|OTHER|Height, Weight, BMI measure|
224074206|NCT02494869|OTHER|Blood draw|
224074207|NCT02494869|OTHER|Cardiopulmonary exercise test|
224074208|NCT06844500|BIOLOGICAL|MVA-BN standard regimen|The MVA-BN vaccine, with the active ingredient: Modified Vaccinia Ankara-Bavarian Nordic, will be administered as a standard two-dose regimen at 1x10\^8 TCID50 Inf.U./0.5 mL. The doses will be given 28 days apart (±3 days) via subcutaneous injection into the deltoid muscle, preferably in the non-dominant arm.
224074209|NCT06844500|BIOLOGICAL|MVA-BN standard regimen (Administered as PEP)|"MVA-BN. Post Exposure Prophylaxis (PEP)~The MVA-BN vaccine, with the active ingredient: Modified Vaccinia Ankara-Bavarian Nordic, will be administered as a standard two-dose regimen at 1x10\^8 TCID50 Inf.U./0.5 mL. The doses will be given 28 days apart (±3 days) via subcutaneous injection into the deltoid muscle, preferably in the non-dominant arm.~For Maternal Group 3, MVA-Bn will be administered as PEP as soon as possible after exposure, preferably within 4 days after exposure. However, as per WHO guidelines, PEP will be offered up to 14 days after exposure if the pregnant woman has not yet developed symptoms."
224074210|NCT01844986|DRUG|Olaparib 300mg tablets|Olaparib/placebo tablets p.o 300mg twice daily for up to 2 years or until objective radiological disease progression as per RECIST as assessed by the Investigator. Patients with evidence of stable disease (or those who have progressed), may continue on treatment beyond 2 years, if in the patient's best interest. Dose reduction to 250mg and subsequently 200mg is permitted following confirmation of toxicity.
224074211|NCT06887218|DRUG|Regorafenib (BAY 73-4506)|Regorafenib will be administered a starting dose of 80 mg per day with weekly 40 mg per day increases to a maximum of 120 mg per day for 3 weeks on / 1 week off continued until disease progression or unacceptable toxic effects occurred or consent was withdrawn, up to 12 cycles of treatment.
224074212|NCT06887218|DRUG|5FU/LV|5FU/LV administered as (LV \[400 mg/m² IV over 120 minutes\], followed by 5FU \[400 mg/m² IV bolus then 2400 mg/m² IV infusion over 46 hours\] in 2-week cycles)
224074213|NCT06887218|DRUG|Bevacizumab|Bevacizumab, at a dose of 5 mg per kilogram of body weight, will be administered intravenously on days 1 and 15.
224074214|NCT06887218|DRUG|Trifluridine-tipiracil|FTD-TPI, administered orally, BID, at a starting dose of 35 mg/m2 of body-surface area, on days 1 through 5 and on days 8 through 12 every 28 days.
224189130|NCT05366374|OTHER|Swallowing assessment with Swallis DSA™ Device|The WALLIS DSA™ investigative device is designed to capture and display pharyngolaryngeal activity in subjects with or at risk of swallowing disorders. The DM is non-invasive: a miniaturized microphone and accelerometer are integrated into the form of a necklace, which will be positioned around the patient's neck to capture the vibroacoustic signals of swallowing during mealtime.
223498746|NCT07117903|DIETARY_SUPPLEMENT|Ketogenic diet + vehicle|The calorie-restricted KD intervention consisted of a very-low-carbohydrate, high-fat diet (5% of calories from carbohydrates, 30% from protein, and 65% from fat, with an energy deficit of 600 kcal/day, 3 meals distributed over 24 h: breakfast, lunch, and dinner). This intervention was performed without schedule restrictions and supported by commercial replacement meals only for the first meal (100 kcal, 15 g of protein, 3 g of fat, of which 1 g was saturated fat, and 50 mg of docosahexaenoic acid, 2 g of carbohydrates, of which \< 1 g was simple sugars). After diet intervention, whole blood will be drawn and incubated with vehicle drug.
223746087|NCT02591147|DEVICE|Silver Diamine Fluoride 38%|Group 1 (SDF group) subjects will receive the application of silver diamine fluoride (38% SDF solution) in addition to 5% Fluoride varnish to each approximal incipiency, using super floss, for a duration of 3 minutes under rubber dam isolation.
224074215|NCT05624268|DRUG|Psilocybin|COMP360 Psilocybin administered under supportive conditions
224189131|NCT00111176|DEVICE|Endovascular repair|Endovascular repair.
224189132|NCT00111176|PROCEDURE|Surgical|Surgical endovascular repair
224189133|NCT01590810|DRUG|MK-8150 2.0 mg|Single oral 2.0-mg dose of MK-8150
224189134|NCT01590810|DRUG|MK-8150 10 mg|Single oral 10-mg dose of MK-8150
223498747|NCT07117903|DIETARY_SUPPLEMENT|Ketogenic diet + aspirin|The calorie-restricted KD intervention consisted of a very-low-carbohydrate, high-fat diet (5% of calories from carbohydrates, 30% from protein, and 65% from fat, with an energy deficit of 600 kcal/day, 3 meals distributed over 24 h: breakfast, lunch, and dinner). This intervention was performed without schedule restrictions and supported by commercial replacement meals only for the first meal (100 kcal, 15 g of protein, 3 g of fat, of which 1 g was saturated fat, and 50 mg of docosahexaenoic acid, 2 g of carbohydrates, of which \< 1 g was simple sugars). After diet intervention, whole blood will be drawn and incubated with aspirin.
223498748|NCT05155033|DRUG|Pembrolizumab|Pembrolizumab 200 mg IV over approximately 30 minutes on Day 1 of cycles 1 and 2 during Courses 1 and 2.
223498749|NCT05155033|DRUG|Aldesleukin|Aldesleukin (IL-2) administration \[600,000 IU/kg IV bolus every 8 hours continuing for up to 4 days (maximum 10 doses)\] starting on Day 1 of cycles 1 and 2 during Course 1.
223498750|NCT05672459|DRUG|Single Injection of IVS-3001- Anti - HLA-G CAR-T cells|Given by IV (vein)
223498751|NCT05672459|DRUG|Fludarabine phosphate|Given by IV (vein)
223498752|NCT05672459|DRUG|Cyclophosphamide|Given by IV (vein)
223498753|NCT05672459|PROCEDURE|leukapheresis|Given by IV (vein)
223498754|NCT04338204|DRUG|tofacitinib|Observational study
223498755|NCT05020275|DIAGNOSTIC_TEST|Blood Samples|"* Samples for ctDNA blood concentration and osimertinib plasma concentration~* Sample for genetic polymorphisms"
223498756|NCT04792073|DRUG|Avelumab|Avelumab 800 mg given intravenously over 60 minutes (+20 minutes / -10 minutes) every 2 weeks (+/- 3 days)
223498757|NCT04792073|RADIATION|Comprehensive Ablative Radiation Therapy|Comprehensive ablative radiation therapy 24 Gy in 3 fractions every 2-3 days
223590697|NCT04993443|DRUG|LQ036|"For Each part of the study, a staggered dosing schedule may be used for the first dose level, in each cohort including 2 sentinel subjects (1 active and 1 placebo) initiating dosing first and the remaining 6 subjects for Part A-C and 8 subjects for Part D initiating dosing no sooner than the next day. Each study part (A, B, C, and D) will be completed sequentially, but with partial overlapping. Part B and C may only be initiated after review of the safety, tolerability, and PK data following dosing of the SAD Cohort 3 or 4.~Part D may be initiated when safety tolerability and PK data are known and deemed acceptable by the SRC for multiple doses in Part B, at least at the same concentration to be administered in Part D."
223590698|NCT04993443|OTHER|Matching Placebo|Matching Placebo for LQ036: Matching Placebo
223590699|NCT05204030|OTHER|HPV Twitter Education Program - Narrative|This study will evaluate the efficacy of social media messages through Twitter, using a randomized controlled trial to determine what types of messages resonate with parents. The investigators will examine narrative messages (i.e., stories). The central hypothesis is that parents who read narrative-focused messages will be more likely to report narrative engagement, intention to vaccinate their child, and self-reported vaccination compared to parents who read non-narrative messages.
223590700|NCT05204030|OTHER|HPV Twitter Education Program - Non-Narrative|This study will evaluate the efficacy of social media messages through Twitter, using a randomized controlled trial to determine what types of messages resonate with parents. The investigators will examine non-narrative messages (i.e., scientific information - numbers and facts). The central hypothesis is that parents who read narrative-focused messages will be more likely to report narrative engagement, intention to vaccinate their child, and self-reported vaccination compared to parents who read non-narrative messages.
224074216|NCT07089654|BEHAVIORAL|A PMT rehabilitation nursing plan|Older adults will be engaged in a 12-week PMT rehabilitation nursing plan involving 2 phases of relaxation and breathing exercises, face exercises, hand exercises and mind exercises to promote cognitive health. Phase 1 (Weeks 1-6): Includes relaxation and breathing exercises (10 minutes), facial exercises (10 minutes), bead maze activities (10 minutes), geometric shape puzzles (10 minutes), and finger exercises (20 minutes). Phase 2 (Weeks 7-12): Includes relaxation and breathing exercises (10 minutes), Tai Chi ball exercises (10 minutes), screw and nut assembly activities (10 minutes), tangram puzzles (10 minutes), and upper limb music exercises (20 minutes). The experimental group will be given interventions, twice a week every Tuesday and Thursday 9-10 am along with the study intervention.
224074217|NCT07089654|BEHAVIORAL|General rehabilitation nursing|The control group will be given a standard health education on cognitive health.
224074218|NCT06923462|OTHER|Communication Application|Participants will receive the VoiceLove intervention versus the standard care which does not utilize VoiceLove.
224074219|NCT07126548|OTHER|Best Practice|Receive standard care
223498758|NCT02582632|DRUG|ombitasvir/paritaprevir/ritonavir|Tablet
223590701|NCT04327024|DRUG|Verinurad|"The treatment will be titrated in 3 steps for target low dose (3 mg), intermediate dose (7.5 mg) and high dose (12mg) of verinurad.~Drug: Allopurinol The treatment will be titrated in 3 steps. Low dose (100mg), intermediate (200mg) and high dose (300mg) of allopurinol."
224074220|NCT07126548|OTHER|Discussion|Ancillary studies
224074221|NCT07126548|OTHER|Survey Administration|Ancillary studies
224074222|NCT07126548|PROCEDURE|Virtual Reality|Receive access to ViRA application
224074223|NCT07131891|OTHER|Fatigue Severity Scale|"Individuals' fatigue severity will be assessed using the Fatigue Severity Scale (FSS). The scale consists of nine questions, and participants are asked about their fatigue level over the past week. Questions are scored from 1 to 7 using a Likert-type scale, where 1 corresponds to strongly disagree and 7 to strongly agree, with higher scores indicating greater agreement. The total score is calculated by taking the arithmetic mean of all items, with the highest possible score being 7. Scores of 4 and above indicate pathological fatigue. The validity and reliability of the FSS in Turkish have been previously established."
223498759|NCT02582632|DRUG|dasabuvir|Tablet
223498760|NCT03298061|DRUG|Mepolizumab|Mepolizumab will be available as lyophilized powder for injection to be reconstituted with sterile water for injection, prior to use. Subjects will be dosed with mepolizumab at a dose of 300 mg which will be administered as three separate 100 mg SC injections every 4 weeks. The injections will be administered into any of the upper arm, thigh or anterior abdominal wall.
223498761|NCT03298061|DRUG|Prednisolone|Subjects who require a dose of prednisolone (or equivalent) of 5 mg/day for adequate control of their EGPA will be included.
224189135|NCT01590810|DRUG|MK-8150 40 mg|Single oral 40-mg dose of MK-8150 without food (fasted) and with food (fed)
224189136|NCT01590810|DRUG|MK-8150 90 mg|Single oral 90-mg dose of MK-8150
224189137|NCT01590810|DRUG|MK-8150 5.0 mg|Single oral 5.0-mg dose of MK-8150
224189138|NCT01590810|DRUG|MK-8150 20 mg|Single oral 20-mg dose of MK-8150
224189139|NCT01590810|DRUG|MK-8150 60 mg|Single oral 60-mg dose of MK-8150
223498762|NCT00344825|DRUG|Alemtuzumab (MabCampath, BAY86-5045) and Fludarabine Phosphate (Fludara, BAY86-4864)|"Descriptive statistical methods applied for the whole study cohort and for subgroups according to QoL and the correlation of the following parameters: Age, Sex, Stage of disease, Time from first B-CLL diagnosis, number of previous B-CLL treatments, Reason of starting of the new B-CLL treatment (progression disease, relapse, no-response to the previous treatment, previous treatment toxicity), Therapeutic Regimen (Day Hospital, Hospital Admission, etc.), Type of Centre, B-CLL treatment lasting, Response to B-CLL treatment.~QoL at baseline, Change in QoL over time evaluated using an analysis of Variance."
223498763|NCT05639868|OTHER|Video-assisted CPR|Participants in V-CPR group get video-based (vocal and visual) instructions from the dispatcher.
223498764|NCT05639868|OTHER|Telephone-assisted CPR|Participants in T-CPR group get voice-based (vocal) instructions from the dispatcher.
223498765|NCT05474209|OTHER|"Tai-chi - a special program for patients with multiple sclerosis - once a week training with a Tai Chi instructor lasting 90 minutes"|"Tai-chi - a special program for patients with multiple sclerosis - once a week training with a Tai Chi instructor lasting 90 minutes for 12 months"
223498766|NCT05552131|DEVICE|T-wave coronary lithotripsy catheter system|Subjects who plan to receive possible interventional therapy meet all admission criteria and do not meet any exclusion criteria, and enter the screening stage of this clinical trial after signing informed consent. All subjects who sign the informed consent will be provided with a unique subject screening number. All subjects who met the inclusion criteria and did not meet the exclusion criteria were enrolled and lumen pretreated with a coronary shock catheter system followed by the implantation of drug-eluting stents.
223498767|NCT01617967|DRUG|Patisiran|Participants received a single dose of patisiran as an intravenous (IV) infusion on Day 0 and Day 28 (Q4W). Optional cohorts received an alternative dosing regimen (once every 3 weeks \[Q3W\]: Day 0 and Day 21) and an alternative premedication regimen.
223498768|NCT00552903|BEHAVIORAL|Health coaching|Personal health coach providing advice and counselling by telephone, weekly contacts
223498769|NCT04137315|DEVICE|Blood measurement|Single fingerprick to measure haemoglobin and haematocrit measurements using a potential haemoglobin home monitoring system.
223498770|NCT06169085|DRUG|Leritrelvir|Oral
223498771|NCT05703776|BEHAVIORAL|Nordic Walking|Nordic Walking (NW) is an aerobic physical activity where regular walking is enhanced by the addition of the active use of specifically designed NW poles. The physical strain is distributed in a balanced way to various muscle groups of the whole body.
223498772|NCT04764539|BEHAVIORAL|Video Assisted Speech Therapy (VAST)|Six children with ASD, between the ages of 4 and 8, participated in a 14-sessions-long study that utilized the VR-integrated and the tablet-based VAST application. Three subjects received a 3D VR-integrated, bone conduction VAST prototype, while the remaining group of three received a tablet with a 2D version of the software. Sessions were held twice a week with each lasting approximately 15 minutes (i.e. +/- 5 minutes).
223498773|NCT00005585|DRUG|cyclophosphamide|Given IV
223590702|NCT04327024|DRUG|Allopurinol|Study treatments will be titrated in 3 steps: Low dose (100mg), intermediate (200mg) and high dose (300mg) of allopurinol
223590703|NCT04327024|DRUG|Placebo for verinurad|Matching Capsule
223590704|NCT04327024|DRUG|Placebo for allopurinol|Matching tablet
223590705|NCT00668811|DRUG|SU011248, Sutent|Sutent 37.5 mg/day will be given orally after radioactive iodine therapy. Total time of Sutent drug administration will be 52 weeks, absent unacceptable toxicity or disease progression. Sutent is supplied as 12.5mg and 25 mg tablets. Patients are to swallow the tablets whole with approximately 250 ml (8 oz.) of water, fasting each morning. Patients will be given monthly calendars (patient diaries) to document the time when the Sutent pills are taken. At monthly visits, patients will bring back this record and the drug bottles.
223498774|NCT00005585|DRUG|cytarabine|Deoxycytidine analogue which is metabolized to ARA-CTP, a substance which inhibits DNA polymerase.
223498775|NCT00005585|DRUG|daunorubicin hydrochloride|Given IV
223590706|NCT02327988|OTHER|Cryotherapy|
223590707|NCT02327988|DEVICE|Laser therapy|
223746088|NCT02591147|DEVICE|Group 2 (Placebo)|Group 2 (Placebo) subjects will receive application of sterile water (placebo) in addition to 5% Fluoride varnish to each approximal incipiency, using super floss, for a duration of 3 minutes under rubber dam isolation.
223746089|NCT00642239|DRUG|placebo|placebo in 100 mL 0.9% NaCl intravenous drip in 30 minutes,then begin radiotherapy in 60 minutes.duration of treatment is 6 weeks.
224189140|NCT01590810|DRUG|MK-8150 120 mg|Single oral 120-mg dose of MK-8150
224189141|NCT01590810|DRUG|MK-8150 160 mg|Single oral 160-mg dose of MK-8150
224189142|NCT01590810|DRUG|MK-8150 320 mg|Single oral 320-mg dose of MK-8150
224189143|NCT01590810|DRUG|MK-8150 600 mg|Single oral 600-mg dose of MK-8150
224189144|NCT01590810|DRUG|MK-8150 900 mg|Single oral 900-mg dose of MK-8150
224189145|NCT01590810|DRUG|MK-8150 1200 mg|Single oral 1200-mg dose of MK-8150
224189146|NCT01590810|DRUG|Placebo for MK-8150|Single oral dose-matched dose of Placebo for MK-8150
224189147|NCT01590810|DRUG|MK-8150 50 mg|Single oral 50-mg dose of MK-8150
224189148|NCT01590810|DRUG|MK-8150 100 mg|Single oral 100-mg dose of MK-8150
224189149|NCT01590810|DRUG|MK-8150 200 mg|Single oral 200-mg dose of MK-8150
224189150|NCT01590810|DRUG|MK-8150 400 mg|Single oral 400-mg dose of MK-8150
224189151|NCT01590810|DRUG|MK-8150 500 mg|Single oral 500-mg dose of MK-8150
224189152|NCT01249521|DRUG|AMG386 and bevacizumab|AMG386 10mg/kg qw iv Bevacizumab 7.5mg/kg q3w iv
224189153|NCT05341609|DRUG|JT001|Day 1: 600mg, Q12H X 1 day; Day 2\~5: 300mg, Q12H X 4 days
224189154|NCT05341609|DRUG|Paxlovid|Day 1\~5: 300 mg of Nirmatrelvir and 100 mg of ritonavir, Q12H X 5 days
224074224|NCT07131891|OTHER|Depression, Anxiety and Stress Scale-21|"The 21-item Depression, Anxiety, and Stress Scale (DASS-21) will be administered to assess individuals' levels of depression, anxiety, and stress. The original scale was developed by Lovibond with 42 items. Subsequently, Brown et al. validated a shorter form for the same purpose and created the 21-item DASS-21. The Turkish adaptation of the DASS-21 was conducted by Yılmaz et al. The scale measures three subscales-depression, anxiety, and stress-consisting of seven items each. It is a 4-point Likert-type scale, with 0 indicating Does not apply to me, 1 Applies to me somewhat, 2 Generally applies to me, and 3 Applies to me completely. All items are scored positively, and each subscale is categorized as normal, mild, moderate, severe, or very severe."
224074225|NCT07131891|OTHER|Jenkins Sleep Scale|The Jenkins Sleep Scale consists of four questions that assess sleep problems over a four-week period. Each question is scored from 0 to 5, resulting in a total score ranging from 0 to 20, with higher scores indicating greater sleep disturbances.
224074226|NCT07131891|OTHER|Epworth Sleepiness Scale|The Epworth Sleepiness Scale (ESS) was developed to assess daytime sleepiness. It consists of eight items, each scored from 0 to 3, yielding a total score ranging from 0 to 24. Higher scores indicate greater daytime sleepiness. The Turkish version of the scale was validated for reliability and accuracy by İzci et al. in 2008..
224074227|NCT07131891|OTHER|Short Form-36|Quality of life will be assessed using the Turkish version of the Short Form-36 (SF-36). The SF-36 assesses quality of life under eight subscales: physical functioning, role limitations due to physical health, bodily pain, general health, vitality, social functioning, role limitations due to emotional problems, and mental health. Scores for each subscale are calculated separately, ranging from 0 to 100, with higher scores indicating better health status. A total score is not calculated.
224074228|NCT07142967|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|SBRT will be delivered with a prescription dose of 8 Gy x 5 fractions prescribed to the 95% isodose line encompassing the dominant recurrent intraprostatic lesion (DRIL) as seen on MRI and/or PET PSMA imaging plus 4mm (GTV+4mm=CTV\_40). Remainder of the prostate gland minus CTV\_40 (CTV\_25) will be prescribed to 5 Gy x 5 fractions at the 95% isodose line.
223498776|NCT00005585|DRUG|dexamethasone|Dexamethasone is a synthetic fluorinated glucocorticoid devoid of mineralocorticoid effects.
223498777|NCT00005585|DRUG|leucovorin calcium|Synthetic d,l-5 CHO tetrahydrofolate, which is used to bypass the inhibition of dihydrofolate reductase by Methotrexate (MTX)
223498778|NCT00005585|DRUG|mercaptopurine|An analogue of the nucleic acid constituent adenine and the physiological purine base hypoxanthine
223498779|NCT00005585|DRUG|methotrexate|A folate analogue which inhibits the enzyme dihydrofolate reductase, haltin g DNA, RNA, and protein synthesis
223498780|NCT00005585|DRUG|pegaspargase|E-Coli asparaginase deaminates asparagine, thus, is lethal for cells which cannot synthesize asparagine.
223498781|NCT00005585|DRUG|thioguanine|Given orally
223498782|NCT00005585|DRUG|vincristine sulfate|Given IV
223498783|NCT03228914|DRUG|Oxymetazoline|Pledgets will be soaked in 0.05% oxymetazoline solution Two pledgets with the associated medication will be placed into the nasal cavity; one along the floor of the nose and another directed towards the middle meatus.
223498784|NCT03228914|DRUG|Epinephrine|Pledgets will be soaked in 1:1000 epinephrine solution Two pledgets with the associated medication will be placed into the nasal cavity; one along the floor of the nose and another directed towards the middle meatus.
223498785|NCT00977184|PROCEDURE|50 HZ Repetitive TMS|
223498786|NCT00977184|PROCEDURE|Sham rTMS|
223498787|NCT05434676|DEVICE|Shockwave Medical Peripheral Intravascular Lithotripsy (IVL) System M5 & S4|To assess the safety and effectiveness of IVL treatment used in combination with DCB to treat moderate and severely calcified femoropopliteal arteries
223498788|NCT04763720|BEHAVIORAL|Dyadic Developmental Psychotherapy|DDP involves approximately twenty sessions with the family, conducted by a trained DDP therapist. DDP is developed to treat trauma-related and attachment difficulties. DDP is not a manualized treatment but involves using a set of core communication techniques (termed PACE; Playfulness, Acceptance, Curiosity and Empathy).
223498789|NCT06125782|DRUG|Omega 3 fatty acid|Omega 3 fatty acid 1 gm softgel capsule- 1 for children at or below 25 kg and two for above 25 kg.
223498790|NCT06125782|DRUG|Placebo of Omega-3 fatty acid softgel capsule|Placebo of Omega-3 fatty acid softgel capsule- colour and shape almost similar to the original drug- 1 for children at or below 25 kg and 2 for above 25 kg.
223498791|NCT05276804|DRUG|Sugammadex|The dosing for Sugammadex is 4mg/kg for a deep reversal and a 2mg/kg for a standard reversal, which will be more common for this study. Sugammadex comes in 200mg/2mL and 500mg/5mL vials. Because of the variability in weight of the patients and the type of reversal needed (deep vs standard), 140 5mL vials will be required.
223498792|NCT02827708|DRUG|semaglutide|Oral administration once daily.
223498793|NCT02827708|DRUG|placebo|Oral administration once daily.
223498794|NCT04100187|BIOLOGICAL|Anti-CD19-CAR|Cells extracted, followed by induction chemotherapy before CD19-CAR infusion (dose escalation.)
223498795|NCT01326936|BEHAVIORAL|Online education|A brief (2-hour) interactive online training program in substance abuse (SU) management using virtual patient (VP) technology. Each learner will take one of two similar online programs involving five VPs that represent the range of SU management issues that commonly arise in clinical practice.
223498796|NCT00801268|DRUG|tripterygium wilfordii|TW，60mg/d
223498797|NCT00801268|DRUG|Emodin|100mg/d
223498798|NCT00894725|PROCEDURE|laparoscopic left colonic resection|laparoscopic colonic resection
223498799|NCT00894725|PROCEDURE|open left colonic resection|conventional open colonic resection
223498800|NCT05858229|DRUG|RP1|Recombinant Herpes Simplex Virus Type 1 - hGM CSF/GALV-GP-R-
223498801|NCT05866328|OTHER|Cognitive Rehabilitation and Individual Placement and Support|Cognitive Rehabilitation and Individual Placement and Support
223498802|NCT04286958|DRUG|Camrelizumab|Camrelizumab: 200 mg was given intravenously over a period of 30 minutes (no less than 20 minutes and no longer than 60 minutes)
223498803|NCT00086125|DRUG|ridaforolimus|AP23573 12.5 mg IV as monotherapy once daily for 5 days, every 2 weeks
223498804|NCT01960478|BIOLOGICAL|(for each intervention)|
223498805|NCT01960478|OTHER|Blood test|
223498806|NCT00753142|DRUG|Intralipid 20%|Participants receive a 48-hour infusion with Intralipid at 40 milliliters per hour (mL/hr).
223498807|NCT00753142|DRUG|Glucose infusion|Participants receive a glucose infusion consisting of 10% dextrose infused intravenously at a rate of 200 mg/m\^2/min for 20 hours.
223498808|NCT03346512|PROCEDURE|Cardiac surgery|Cardiac surgery
223590708|NCT05169606|OTHER|Tissue Flossing|Tissue flossing is a technique that requires wrapping of a thick rubber band around a joint or muscle concomitantly performing ROM tasks for 1-3 minutes. The results include increase in range of motion and a decrease in pain of the effected muscles. The phenomenon behind getting results through this technique is hypothesized to be blood reperfusion to an occluded area via tissue flossing augments exercise performance mechanisms such as growth hormone, catecholamine responses, muscle force contractility and the efficiency of excitation-contraction coupling in the muscles. In addition, tissue flossing may influence fascia tightness via the fascial mechanoreceptors, therefore reducing muscle activity, resulting in a greater ROM. Nevertheless, the underlying mechanism for tissue flossing, these mechanisms remain speculative.
223590709|NCT05169606|OTHER|Active Isolated Stretch|"AIS is a specific stretching program developed by Aaron Mattes. This technique is based on these four basic principles:~Isolate the muscle to be stretched. Repeat the stretch eight to 10 times. Hold each stretch for no more than two seconds. Exhale on the stretch; inhale on the release."
224074229|NCT07142967|DRUG|Androgen Deprivation Therapy (ADT)|ADT would be given 0-1 months prior to planned SBRT to the prostate for total of 4-6 months. ADT will be administered via Leuprolide or Degarelix monthly injections or daily Relugolix pills.
224074230|NCT07143851|OTHER|Not applicable- observational study|There is no special intervention method
224074231|NCT07144605|OTHER|CAD-CAM, indirect restorations|Indirect restorations that we think will last longer than traditional filling materials in teeth with molar hypomineralization.
224074232|NCT07143968|DRUG|Resmetirom|Resmetirom - 80mg or 100mg based on participant weight
224074233|NCT07143968|DRUG|Placebo Control|Placebo - an identical looking tablet with no medicinal properties
224074234|NCT07144657|DRUG|Esomeprazole, Bismuth tripotassium dicitrate, Tetracycline, and Metronidazole|"1. Frontline antibiotics treatment (two weeks of quadruple HPE regimens followed by 4 weeks of clarithromycin).~2. If no response to frontline antibiotics treatment, second line immune-modulator regimens (CAMC, clarithromycin (CAM) and low-dose cyclophosphamide) will be prescribed"
224074235|NCT07144501|DIAGNOSTIC_TEST|Ultrasonography|Ultrasound, also known as sonography or ultrasonography, is a medical imaging technique that uses high-frequency sound waves to create real-time images of internal body structures
224074236|NCT07144501|PROCEDURE|Blood Sampling|"To assess hepatic function in congenital heart disease (CHD) patients, blood samples will be collected from all patients in our study for:~* Alanine Transferase (ALT).~* Aspartate Aminotransferase (AST).~* Gamma Glutamyl Transferase (GGT).~* Alkaline Phosphatase (ALP).~* Total/direct bilirubin.~* Albumin.~* Prothrombin time.~* International Normalized Ratio (INR).~* Platelet count."
224074237|NCT07143097|DRUG|capecitabine|capecitabine 650 mg / m2 twice per day for one year
224074238|NCT07144709|DRUG|Phytotherapy|Phytotherapy or alphablockers
224074239|NCT07144241|BIOLOGICAL|Mesenchymal Stromal/Stem Cells-Derived Exosomes (Exo-HWS + 1 vial Exo-HUVEC) Therapy|The intervention group will receive standard DM therapy plus an exosome combination of 1 vial Exo-HWS + 1 vial Exo-HUVEC, administered monthly for three months via intravenous bolus injection.
224074240|NCT07144241|BIOLOGICAL|Mesenchymal Stromal/Stem Cells-Derived Exosomes (Exo-HWS ) Therapy|The control group will receive standard DM therapy plus 1 vial Exo-HWS, administered monthly for three months via intravenous bolus injection.
224074241|NCT07143812|DRUG|MSC11FCD|Administration period: Single dose Route of administration: Intratumoral administration Dose: 1x10\^7, 3x10\^7cells/dose Summary: Administer the investigational drug in the amount of 1x10\^7, 3x10\^7cells per dose into the tumor or the tumor removal site using a syringe during surgery.
224074242|NCT07144345|DRUG|Reformulated Levulan Kerastick containing aminolevulinic acid hydrochloride (ALA HCl), 20%|Solution for topical use
224074243|NCT07144345|OTHER|Vehicle containing excipients only (VEH) without active ingredient|Solution for topical use
224074244|NCT07144345|DEVICE|Blue Light Photodynamic Therapy Illuminator device, BLU-U® model 4170E|BLU-U® blue light Photodynamic Therapy (PDT) illuminator
224074245|NCT07143266|OTHER|This is an observational study. No drugs will be administered|Data from objective sleep evaluation (actigraphy, polisomnography and MLST), subjective sleep evaluation (questionnaires), neuroimaging (MRI and PET-CT), ophthalmological evaluation and hormone evaluation (urine and blood) will be collected in a cross-sectional manner, without performing any additional intervention.
224074246|NCT07143162|BEHAVIORAL|LoveYourBrain Yoga|The LoveYourBrain Yoga program consists of various techniques, including: breathing, Yoga postures, meditation, and psychoeducation as well as a group discussion.
224189155|NCT05496166|COMBINATION_PRODUCT|chemotherapy and SHR-1316(Adebrelimab) comnined with surgery or radiotherapy|Induction treatment stage: SHR-1316(Adebrelimab)，20mg/kg,+Cisplatin 75mg/m2, d1+ etoposide 100mg/m2, d1,d2,d3, q3w, iv, 4 cycles. Patients who are able to receive surgery after assessed by two surgons would receive surgery or radiotherapy randomly. Adjuvant/ maintenance treatment stage: SHR-1316，20mg/kg, iv, q3w,up to 1 year
224189156|NCT00114257|DRUG|decitabine|
224189157|NCT00114257|DRUG|romidepsin|
224189158|NCT04604015|DIAGNOSTIC_TEST|NeuralBot Investigational System|The NeuralBot Investigational System when used with the Lucid M1 System is a medical ultrasound device which assists the user in the setup and acquisition of cerebral blood flow velocity via the patient's temporal windows. It is intended for use as an adjunct to standard clinical practices for measuring and displaying cerebral blood flow velocity and the occurrence of transient emboli within the blood stream.
223498809|NCT02383173|OTHER|Basic Implementation Approach|Comfort Care Education Intervention utilizing the established infrastructure of Palliative Care Consult Teams, using a Basic Implementation Approach with a teleconference to review educational materials and activate PCCTs to educate other providers.
224074247|NCT07144540|OTHER|NeuroBot|NeuroBot is an artificial intelligence online accessible chatbot that used machine learning and generative pretrained transformer model for supporting patients undergoing neurovascular surgery during perioperative period
224189159|NCT04604015|DIAGNOSTIC_TEST|Transthoracic Echocardiography (TTE)|A test that uses ultrasound to create a hemodynamic assessment for major cardiovascular events.
223590710|NCT05169606|OTHER|Proprioceptive Neuromuscular Facilitation|Proprioceptive neuromuscular facilitation (PNF) technique has already been found to have beneficial effects in improving hamstring flexibility and reducing pain in the knee joint of knee OA patients
223590711|NCT06307093|DRUG|RPH-075|"100 mg/4 mL (25 mg/mL) concentrate for solution for infusions in a single-dose vial~The required volume (8 ml) of the Drug concentrate solution should be withdrawn from the vials and transferred into an intravenous bag containing 0.9% Sodium Chloride Injection or 5% Dextrose Injection. (The final concentration of the diluted solution should be between 1 mg/mL to 10 mg/mL.)"
223590712|NCT06307093|DRUG|Keytruda®|"100 mg/4 mL (25 mg/mL) concentrate for solution for infusions in a single-dose vial~The required volume (8 ml) of the Drug concentrate solution should be withdrawn from the vials and transferred into an intravenous bag containing 0.9% Sodium Chloride Injection or 5% Dextrose Injection. (The final concentration of the diluted solution should be between 1 mg/mL to 10 mg/mL.)"
223590713|NCT02905630|OTHER|Exercise training|high intensity aerobic interval training
223590714|NCT00415922|DRUG|ELC200 (carbidopa+levodopa+entacapone)|
223590715|NCT02641470|DIETARY_SUPPLEMENT|DA9301 (Vaccinium uliginosum extract)|
223590716|NCT02641470|DIETARY_SUPPLEMENT|Placebo|
223590717|NCT02406911|DRUG|Ticagrelor|After randomization, each group will be treated as assigned dose of ticagrelor (ticagrelor 90mg once a day or 90mg twice a day) for 14 days. After 1 week wash-out period, cross-over study will be performed
223590718|NCT02849015|DEVICE|Cryosurgery|Argon-helium cryosurgical system (percutaneous ablation under CT or ultrasound guidance)
223590719|NCT02849015|BIOLOGICAL|NK immunotherapy|Natural killer cell(each treatment: about 10 billion cells transfusion in 3 times, i.v.)
223590720|NCT01192568|DRUG|Oxybutynin|10% Oxybutynin Chloride Topical Gel, 0.5 g, 0.75 g, and 1 g/day, administered transdermally.
223590721|NCT01192568|DRUG|Placebo|Topical gel
223590722|NCT01196351|OTHER|Dietary Supplement: water with noncalorie sweetener|
224074248|NCT07144540|OTHER|Standard Care (in control arm)|Standard care include face-to-face consultation in preoperative nurse clinic and provision of leaflet
224074249|NCT07144371|OTHER|Virtual Reality Training Group|Participants continued their routine football training program with no additional VR-based training. This group served as the active comparator to evaluate the relative effects of VR training on scanning frequency and passing performance.
224074250|NCT07144371|OTHER|Standard Football Training|Participants continued their routine football training program with no additional VR-based training. This group served as the active comparator to evaluate the relative effects of VR training on scanning frequency and passing performance.
224074251|NCT07143214|BEHAVIORAL|online dialectical behavior therapy|"Enrolled participants will be provided with credentials to access the mobile application for a 28-day therapist-supported DBT self-help intervention. Participants are required to engage with the application at least once daily throughout the 4-week intervention period, with each session requiring approximately 30 minutes of engagement. The application delivers automated daily reminders at user-configurable timepoints. Additionally, participants receive asynchronous text-based guidance via WeChat during the treatment phase, wherein therapists provide support, feedback, and clinical direction during predetermined response windows. Each participant's cumulative weekly guidance duration is capped at 15 minutes.~The application's therapeutic framework integrates core components from The Dialectical Behavior Therapy Skills for Emotional Eating and standardized DBT treatment manuals, structured across four evidence-based modules: (1) Mindfulness, (2) Distress Tolerance, (3) Interpersonal Eff"
224074252|NCT07143214|BEHAVIORAL|Waitlist and psychoeducation|The active control group serves as a rigorous placebo comparator condition. Participants allocated to this arm will receive daily psychoeducational communications regarding binge-eating pathology, encompassing epidemiological data, biopsychosocial determinants, clinical manifestations, and therapeutic approaches. Crucially, all disseminated content remains devoid of Dialectical Behavior Therapy (DBT)-related components or skill-building elements.
224074253|NCT07144566|OTHER|Nurse Led Sexual Health Clinical Program Intervention|In person visit with Advanced Practice Provider (APP) whom is an Advanced Practice Nurse Practitioner in Oncology. Visit will include a focused pelvic exam, sexual health treatment plan, sexual health education, and referrals that follow the current Sexual Health Survivorship NCCN guidelines. A post visit telephone will be provided by the APP 8 weeks after APP visit for follow up questions and further education if needed.
224074254|NCT03723083|DRUG|CC-2001|CC-2001 will be administered orally
224074255|NCT05392608|DRUG|Alpelisib 150 MG Oral Tablet [Piqray]|Alpelisib 300mg once daily (may be reduced to 1dd250 or 1dd200mg in case of toxicity)
224074256|NCT05392608|DRUG|Fulvestrant|Fulvestrant 300mg 1x/four weeks
224074257|NCT06707090|DRUG|TR987 0.1% gel + Standard of Care|6mg topical gel for application plus Standard of Care (wound cleansing/dressings and compression bandaging)
223590723|NCT01196351|OTHER|Activity: With noncalorie sweetener or glucose|
223590724|NCT02593825|BEHAVIORAL|START-Play intervention|The START-Play group is a perceptual-motor approach, which uses self-initiated goal-directed movements to bolster orienting and attending to objects, while understanding basic relationships of cause and effect through manipulation and focused attention. Generally, activities focus on helping the child attend to significant environmental information, which can be correlated to forces useful for controlling posture and movement. Unlike passive movement therapy, the investigator's approach encourages activity and learning to solve problems linked by movement and manipulation of objects, which then scaffold cognitive skill.
223590725|NCT02593825|BEHAVIORAL|Business as usual|May include active or passive movement, parent training, positioning, equipment modification, training other team members, functional skill training
223590726|NCT00708695|BEHAVIORAL|Nurse Home Visiting|Visits from nurses from mid-pregnancy to child age 2 years.
223590727|NCT00003364|DRUG|cisplatin|
223590728|NCT00003364|DRUG|cyclophosphamide|
223590729|NCT00003364|DRUG|doxorubicin hydrochloride|
223590730|NCT00003364|DRUG|etoposide|
223590731|NCT00003364|DRUG|vincristine sulfate|
223590732|NCT00003364|RADIATION|radiation therapy|
223590733|NCT04397562|DRUG|Levilimab|Levilimab 324 mg
223590734|NCT04397562|DRUG|Placebo|Placebo
223590735|NCT01054001|DRUG|sildenafil 100mg|sildenafil 100mg per oral twice a week
223590736|NCT01157026|DIETARY_SUPPLEMENT|Tocotrienol Rich Fraction (TRF)|Tocotrienol Rich Fraction (200mg), daily for five years
223590737|NCT01157026|OTHER|placebo plus tamoxifen|20mg tamoxifen daily
224189160|NCT05466604|DRUG|Hyaluronidase Injection mesomedica|injection of 150 IU hyaluronidase to perioperative region, submucosally.
223590738|NCT05411289|PROCEDURE|acupressure|"Pressures were applied on three points consecutively, firstly on two points bilaterally Hugo point (LI4) and He-7 (Shenmen), then pressure was applied on sanyinjiao (SP6).~pressure was applied gradually for 30 seconds on the above mentioned points. Then this pressure was slowly intensified to the extent that the patient felt tingling, numbness, heaviness, and strain in the surrounding area."
223590739|NCT05411289|PROCEDURE|sham acupressure|Pressures were applied on sham points consecutively
223590740|NCT01609998|BIOLOGICAL|Seasonal Influenza DNA vaccine|VRC-FLUDNA063-00-VP is composed of 3 closed-circular DNA plasmids that encode for the hemagglutinin (HA) from the following 3 strains: A/California/04/2009 (H1); A/Victoria/361/2011 (H3), and B/Wisconsin/2010. DNA vaccine vials will be supplied at 4 mg/mL in single use vials. The 1 mg dosage is administered as 0.25 mL volume and the 4 mg dosage as a 1 mL volume.
223590741|NCT01609998|BIOLOGICAL|TIV|2012/13 Seasonal Influenza Trivalent Inactivated Vaccine (TIV)
223590742|NCT02522325|DRUG|Phendimetrazine|Phendimetrazine will be administered in divided doses twice daily.
223590743|NCT02522325|DRUG|Cocaine|Intranasal cocaine will be administered during experimental sessions.
223590744|NCT02522325|DRUG|Placebo|Placebo capsules will contain only cornstarch.
223590745|NCT01209078|DRUG|GSK1322322|GSK1322322 1500mg BID
223590746|NCT01209078|DRUG|Linezolid|Linezolid 600mg
223590747|NCT01209078|DRUG|GSK1322322 placebo|Placebo
223590748|NCT01209078|DRUG|Linezolid placebo|placebo
223590749|NCT00924508|DEVICE|hydrogel patch|occlusion of eczema with a hydrogel patch composed of an adhesive, thin, flexible, hydrogel layer on an impermeable urethane surface.
223590750|NCT00924508|DRUG|Triamcinolone (TAC) 0.1% cream|Triamcinolone Acetonide (triamcinolone acetonide cream) is a topical corticosteroid used as anti-inflammatory and antipruritic agent. Each gram of TAC Cream USP, 0.1% contains 1 mg Triamcinolone Acetonide (triamcinolone acetonide cream) in a cream base consisting of cetyl alcohol, glyceryl monostearate, cetyl esters wax, isopropyl palmitate, polysorbate-60, polysorbate-80, propylene glycol and purified water.
223590751|NCT03070899|DRUG|OBE2109|OBE2109 100mg tablets for oral administration once daily
223590752|NCT03070899|DRUG|Placebo to match OBE2109|Placebo to match OBE2109 100mg tablets for oral administration once daily
223590753|NCT03070899|DRUG|Placebo to match Add-back|Placebo to match Add-back (E2 1 mg / NETA 0.5 mg) for oral administration once daily
224074258|NCT06707090|OTHER|Standard of care|Standard of Care (wound cleansing/dressings and compression bandaging)
224074259|NCT03266016|OTHER|Computerized Ventilator Protocol|Computerized Decision Support System which recommends changes to ventilator settings to promote physiologic levels of patient effort of breathing.
224074260|NCT03266016|DIAGNOSTIC_TEST|Esophageal Manometry|Esophageal Manometry Catheter to measure effort of breathing an transpulmonary pressure
224074261|NCT03266016|DIAGNOSTIC_TEST|Respiratory Inductance Plethysmography (RIP)|RIP bands to measure thoraco-abdominal synchrony during spontaneous breathing trials
224074262|NCT03266016|DIAGNOSTIC_TEST|Diaphragm Ultrasound|Daily measurement of diaphragm thickness and diaphragm contractile activity
224074263|NCT03266016|DIAGNOSTIC_TEST|Maximal Inspiratory Pressure|Prior to Spontaneous breathing trials, measurement of airway and esophageal maximal inspiratory pressure during airway occlusion
224074264|NCT06467084|DRUG|KVD900 150 mg|KVD900 Tablet 150 mg (2 x 75 mg)
223590754|NCT03070899|DRUG|Add-back|Add-back (E2 1 mg / NETA 0.5 mg) for oral administration once daily
223590755|NCT01462617|DRUG|GSK2269557|Study Drug
223590756|NCT01462617|DRUG|GSK2269557 matching placebo|Study Drug
223590757|NCT06438055|OTHER|Chemotherapy and targeted-therapy guided by organoid drug sensitivity test|This study conducts drug sensitivity tests on various clinically approved drugs. The most sensitive drug for the patient is selected for treatment. This study aims to evaluate the clinical effectiveness of treatment plans guided by organoid drug sensitivity tests.
223590758|NCT01510743|PROCEDURE|Catheterization of subclavian vein|Catheterization of subclavian vein
223590759|NCT01510743|PROCEDURE|Catheterization of internal jugular vein|Catheterization of internal jugular vein
223590760|NCT01152034|BEHAVIORAL|psychoeducation group therapy|This program consists of 15 sessions of closed group, with each session lasting 120 minutes, each aims at improving four main issues: illness awareness, early detection of prodromal symptoms and recurrences, treatment adherence, and lifestyle regularity. The program will be in groups of 6-12, conducted by two experienced therapists. The structure of each session consists of 30-40 minutes talk on the topic of the day, followed by an exercise related to the issue and a discussion.
223590761|NCT05727982|DIAGNOSTIC_TEST|Venous blood samples, Biological samples analysis, Cardiology visit.|These interventions are important to study all patients recruited
223590762|NCT03896945|DRUG|Placebo|oral capsules
223590763|NCT03896945|DRUG|AVP-786|oral capsules
224074265|NCT06467084|DRUG|KVD900 300 mg|KVD900 Tablet 300 mg (1 x 300 mg)
224074266|NCT06467084|DRUG|KVD900 600 mg|KVD900 Tablet 600 mg (2 x 300 mg)
224074267|NCT04519489|DEVICE|PAP therapy with telemonitoring|This study intends to investigate effect of PAP therapy on reducing AF recurrence rate in the patients in co-morbidity of OSA. The study will use 2 investigational devices: Philips DreamStation and Philips EncoreAnywhere. Philips DreamStation is used as the PAP therapy device to provide PAP therapy on the study subjects; Philips EncoreAnywhere is used as a telemonitoring service to provide monitoring by physicians that ensure good adherence to PAP. In addition, subjects in the intervention group will also receive AFib standard management and OSA general care.
224074268|NCT04519489|OTHER|AF standard management and OSA general care|Subjects in the control group will receive AF standard management and OSA general care. The treatment, medical care, and AF management for the subjects will be performed at the study hospitals following the newly updated Chinese AF management guideline 'Current knowledge and management recommendations of atrial fibrillation: 2018'.All subjects including the intervention group and the control group will receive the education materials to understand the disease, risk, and management of OSA. All subjects will also receive the general intervention for OSA, including suggestions for body weight control, smoking cessation, alcohol limiting, lateral position sleep, etc.
224189161|NCT05466604|DRUG|Dexamethasone dekort|injection of 8 mg dexamethasone to perioperative region, submucosally.
223498810|NCT02383173|OTHER|Enhanced Implementation Approach|"Comfort Care Education Intervention utilizing the established infrastructure of Palliative Care Consult Teams, using an Enhanced Implementation Approach with in-person, train-the-champion workshops to prepare PCCT members to be leaders and trainers at their home sites"
223498811|NCT01507727|DRUG|Tolvaptan|Tablet;15mg/tab; 30mg/tab; 15/30/60mg/day for 7 days Plus conventional therapy according to each patient's underlying disease, such as CHF, hepatic cirrhosis and SIADH or others.
223498812|NCT01507727|DRUG|Placebo|placebo plus conventional therapy according to each patient's underlying disease, such as CHF, hepatic cirrhosis and SIADH or others.
223498813|NCT04498507|DIAGNOSTIC_TEST|HADS questionnaire|Patients will be asked to answer to 3 questionnaires about anxiety and depression, post-traumatic stress disorder and health-related quality of life
224189162|NCT02678702|BEHAVIORAL|CBT-I|CBT-I
223498814|NCT05951842|DRUG|anesthetic method|Patients will be assigned to one of the groups, TIVA group or Balanced anesthesia group. In TIVA group, anesthesia will be maintained by propofol and remifentanil infusion under target controlled infusion. In contrast, anesthesia will be maintained by sevoflurane and remifentanil infusion in the balanced anesthesia group.
223498815|NCT01801332|DIETARY_SUPPLEMENT|intensive nutrition|"Patients randomized in  intensive enteral nutrition  arm will receive by feeding tube (with the use of a microsonde), and in continuous administration, 2 liters of Fresubin HP Energy (1500 kcal/liter, 75 gr prot/liter) for patients with a weight of more than 90 kgs (after ascites removal), 1.5 liters of Fresubin HP Energy for patients with a weight between 60 and 90 kgs, and 1 liter of Fresubin HP Energy for patients of less than 60 kgs. Patients with significant encephalopathy despite therapy against encephalopathy will receive Fresubin Hepa in place of Fresubin HP Energy (1300 kcal/liter, 40 gr prot/liter, 44 % branched AA). Duration of enteral nutrition by feeding tube will be 14 days. The adaptation to the targeted volume must be achieved in maximum 3 days. Enteral nutrition will be administered by nasogastric microsonde."
223498816|NCT01801332|DIETARY_SUPPLEMENT|usual meals|"Patients randomized in  classical oral nutrition  arm (control arm) will receive usual meals (estimated at 1750 kcal/day; 70 g protein/day), and alimentary supplements between meals to achieve the ESPEN recommandations (35-40 kcal/kg/day; protein 1.2-1.5 g/kg/day) (Plauth et al, Clinical Nutrition 2006). Calories and proteins intake must be recorded daily."
223498817|NCT01297244|DRUG|Tivozanib|Subjects will receive 1.5 mg tivozanib once daily beginning on Day 1 for 3 weeks followed by 1 week off treatment. One cycle will be defined as 4 weeks of treatment. Cycles will be repeated every 4 weeks.
224189163|NCT02678702|BEHAVIORAL|Treatment as usual|Treatment as usual
224189164|NCT03770936|DRUG|Candesartan|Candesartan 8 mg/day
224189165|NCT03770936|DRUG|Ramipril|ramipril 1.25 mg/day
224189166|NCT05724654|DIETARY_SUPPLEMENT|Skin roasted peanuts|Study volunteers will receive daily 60 g of skin roasted peanuts for 16 weeks.
224189167|NCT00187733|OTHER|Fasting blood and urine collection|Not applicable no drugs dispensed
224189168|NCT00354627|DRUG|TMC125|200 mg b.i.d. till commercially available.
223498818|NCT03677401|DRUG|5mg Serlopitant Tablets|Serlopitant Tablets
224189169|NCT02976194|DRUG|ranibizumab|Ranibizumab 0.5mg is injected into the vitreous cavity through the pars plana using 30 gauge (or narrower) needle-attached syringe.
224189170|NCT00459680|DEVICE|Laser acupoint treatment|Laser
224189171|NCT00459680|PROCEDURE|Acupuncture|Needle acupuncture on ST36 and LI11.
224189172|NCT06376942|DRUG|Glycopyrronium|Nebulized glycopyrronium 50 mcg
224189173|NCT06376942|DRUG|Ipratropium|Nebulized iptratropium 500 mcg
224189174|NCT06376942|OTHER|Saline|0.9% saline 2 ml
224189175|NCT01635387|DRUG|aliskiren|150 mg once a day per 2 week with forced uptitration to 300 mg once a day, if tolerated
224189176|NCT02129192|DRUG|Amlodipine 5mg capsule|Amlodipine 5mg capsule
224189177|NCT02129192|DRUG|T80/H12.5 mg FDC tablet|Telmisartan 80 mg/Hydrochlorothiazide 12.5 mg FDC tablet
224189178|NCT02129192|DRUG|T80/A5/H12.5 mg FDC tablet|Telmisartan 80 mg/Amlodipine 5 mg/Hydrochlorothiazide 12.5 mg FDC tablet
224189179|NCT01231620|DRUG|Zanamivir|Zanamivir aqueous solution, 10 mg/mL, will be provided as a single use, sterile clear, colorless preparation in 20 mL clear glass vials.
224189180|NCT01231620|DRUG|Placebo to match zanamivir|Placebo to match IV zanamivir will be provided as a normal saline solution of a matched volume.
224189181|NCT01231620|DRUG|Oseltamivir|Oseltamivir will be provided as over-encapsulated 75 mg capsules.
224189182|NCT01231620|DRUG|Placebo to match oseltamivir|Placebo to match oral oseltamivir will be provided as capsules with a common excipient of appropriate quality.
224189183|NCT01466972|DRUG|Pazopanib|Oral, 800mg tablet daily per cycle
224189184|NCT02400281|DRUG|Crenolanib besylate|
224189185|NCT02400281|DRUG|Idarubicin|
224189186|NCT02400281|DRUG|Cytarabine|
224189187|NCT02400281|DRUG|Azacytidine|
224189188|NCT02400281|DRUG|Mitoxantrone|
224189189|NCT02400281|DRUG|Etoposide|
224189190|NCT02400281|DRUG|Fludarabine|
224189191|NCT02400281|DRUG|G-CSF|
224189192|NCT00245869|PROCEDURE|Contrast-enhanced Ultrasound|
224189193|NCT01540006|OTHER|Physical activity|50min of endurance training combined with 45min of calisthenics; 1-3x/week; 6-24 weeks
224189194|NCT03627442|PROCEDURE|Mastectomy with PhotonBlade|One of the breasts of each patient undergoing double mastectomy will be randomly assigned to breast flap creation with PhotonBlade
224189195|NCT03627442|PROCEDURE|Mastectomy with Bovie|One of the breasts of each patient undergoing double mastectomy will be randomly assigned to breast flap creation with Bovie
224189196|NCT04030806|OTHER|Mirror therapy intervention and control intervention|"The exercise protocol will be composed of bimanual activities, performed by both the hands of the patient (paretic and healthy). The same protocol will be applied for both groups (intervention group and control group).~Initially, the desensitization of the limbs will be accomplished by brushing the skin with objects of different textures (sponge, brush, cloths). Afterwards, isolated exercises of fingers (flexion-extension, opposition), wrists (flexo-extension), forearms (prono-supination) and elbows (flexo-extension) and functional exercises such as cleaning a table with a cloth, tightening sponges, roll balls. Each exercise will be performed slowly and repeated for 15 times, totaling three series of each exercise. The protocol used will be based on the proposal of Rothgangel and Braun (2013). The intervention will be carried out by the author of the project and by students of scientific initiation."
224189197|NCT04038437|DRUG|CPX-351|CPX-351 will be administered on Days 1 and 3 of each cycle
224189198|NCT04038437|DRUG|Venetoclax|Venetoclax will be adminstered on Days 2 to 21 of each cycle
223498819|NCT03677401|DRUG|Placebo Tablets|Placebo Tablets
223498820|NCT05935020|OTHER|Usual care - Municipal exercise-based rehabilitation|"The patients in this group follow prescribed (by the orthopedic surgeon) usual care municipal exercise-based rehabilitation. The content of the rehabilitation is planned in collaboration between the patient and the physical therapist, based on the offered municipal treatment options (which varies between municipalities) and patient preferences (i.e., home-based exercise, outpatient exercise, group-based exercise, or a combination thereof). The contents of the municipal services offered will be described in detail in the trial report.~A prescribed therapeutic rehabilitation exercise plan could for instance be a 6-week combined home-exercise (1-2 times/week) and group-exercise (1 time/week) intervention, followed by encouragement to continue self-administered home exercise after the 6 weeks."
223590764|NCT01335269|DRUG|BI 853520|BI 853520 once daily in a dose escalation schedule
224074269|NCT03771586|DRUG|SAGE-718|SAGE-718 in combination with Ketamine
224074270|NCT03771586|DRUG|Placebo|Placebo in combination with Ketamine
224074271|NCT06390592|DEVICE|PD cycler|"Patients are treated continuously during Peritoneal dialysis with the PD cycler sleep•safe harmony with different FlexPoint settings.~According to their randomization the patients are treated with Treatment A, B or C in a different order:~* standard (default) FlexPoint settings (Treatment A)~* minimum value FlexPoint settings (Treatment B)~* maximum value for permitted peritoneal residual volume (50%) of FlexPoint settings (Treatment C)"
224074272|NCT05099471|DRUG|Venetoclax; Rituximab|Combination of venetoclax and rituximab
224074273|NCT05099471|DRUG|DRC|Combination of Dexamethasone / Rituximab / Cyclophosphamide
224074274|NCT04027972|DRUG|Combination of Neostigmine and Glycopyrrolate|Intravenous or transdermal
224074275|NCT04027972|DEVICE|I-Box by Dynatronics|Electric field conducting drugs through the skin without compromising its integrity
224074276|NCT05553080|GENETIC|Immunohistochemistry|immunohistochemical staining of colorectal carcinoma specimens by anti human fascin antibody.
224074277|NCT01149265|BEHAVIORAL|Online support group|Expressive writing involves people writing about their thoughts and feelings, often upsetting ones, for a short period of time.
224074278|NCT01149265|BEHAVIORAL|Expressive writing|Online support groups are internet forums where like-minded people give and receive both informational and emotional support.
224074279|NCT04938973|PROCEDURE|Robotic Assisted Minimally Invasive Esophagectomy (RAMIE)|Robotic Assisted Minimally Invasive Esophagectomy (RAMIE) will be performed using the Da Vinci Robotic Surgical Platform.
224074280|NCT04938973|PROCEDURE|Open Transthoracic Esophagectomy (OTE)|Open Transthoracic Esophagectomy (OTE) is the current standard of care.
224074281|NCT04938973|DEVICE|Robotic Assisted Minimally Invasive Esophagectomy (RAMIE)|Robotic Assisted Minimally Invasive Esophagectomy (RAMIE) will be performed using the Da Vinci Robotic Surgical Platform.
224074282|NCT03343275|COMBINATION_PRODUCT|Lit control pHDown|Patients within the experimental arm will receive dietary supplement Lit-control®pH Down to help them keep their urinary pH in the adequate levels, being these considered as the preventive ones to avoid stent calcification (pH\<6.2) being the 3 capsule per day indication. On the other hand, the control arm will receive a placebo product with similar organoleptic qualities and the same posology characteristics. Both arms wil use Lit-Control® pH Meter device to keep self- control of the urinary pH; also, both will receive the same hygienic-dietary indications about the care of the stent.
224074283|NCT06158165|DEVICE|Mostcare (Vytech, Vygon, Padua, Italy)|Parameters were observed through the utilization of the MostCare (Vytech, Vygon, Padua, Italy) device employing the Pressure Recording Analytic Method (PRAM).
224074284|NCT05181995|DRUG|NYX-783|NYX-783
224074285|NCT05181995|DRUG|Placebo|Placebo for 50 mg NYX-783
224074286|NCT04310046|PROCEDURE|PCI before TAVI|TAVI is performed using the Edwards SAPIEN Transcatheter Heart Valve®. PCI is performed in any suitable lesion with ≥70% diameter stenosis on coronary angiography in a coronary artery ≥2.5 mm in diameter.
224074287|NCT04310046|PROCEDURE|PCI after TAVI|TAVI is performed using the Edwards SAPIEN Transcatheter Heart Valve®. PCI is performed in any suitable lesion with ≥70% diameter stenosis on coronary angiography in a coronary artery ≥2.5 mm in diameter.
224074288|NCT03402776|DRUG|4th dose of hexavalent vaccine 1 month after the 3rd dose|4th dose of hexavalent vaccine 1 month after the 3rd dose
224074289|NCT04183335|DRUG|Dupilumab SAR231893|Pharmaceutical form:Injection solution Route of administration: Subcutaneous
224074290|NCT04183335|DRUG|Placebo|Pharmaceutical form:Injection solution Route of administration: Subcutaneous
224074291|NCT04183335|DRUG|Moisturizers|"Pharmaceutical form:~Route of administration: Topical"
224074292|NCT04183335|DRUG|Low to medium potent topical corticosteroids|"Pharmaceutical form:~Route of administration: Topical"
224074293|NCT04183335|DRUG|Topical calcineurin inhibitors|"Pharmaceutical form:~Route of administration: Topical"
224074294|NCT04906434|DRUG|ABSK-011|"During the escalation part, the administration of oral ABSK-011 will be guided by 3+3design based on safety data collected until a maximum tolerated dose (MTD) has been identified. The first dose level will be administered as QD, and different dosing frequencies (e.g., BID) may be explored in subsequent doses depending on emerging safety and pharmacokinetic data. A separate food effect cohort may be conducted. In expansion part, patients will be treated at the selected RDE dose level."
224074295|NCT01577485|DIETARY_SUPPLEMENT|Probiotics in an pastille|Test group
224074296|NCT01577485|DIETARY_SUPPLEMENT|Control pastille|Control group
224074297|NCT02944630|BEHAVIORAL|Psychotherapy|Individual psychotherapy
224074298|NCT05101018|DRUG|Romosozumab|Romosozumab (Amgen Inc., Thousand Oaks, CA) 210mg SQ administered each month
224074299|NCT05101018|DRUG|Denosumab|Denosumab (Amgen Inc., Thousand Oaks, CA) 60 mg SQ administered every six months
224074300|NCT02326805|OTHER|Laboratory Biomarker Analysis|Correlative studies
224074301|NCT02326805|OTHER|Placebo Administration|Given SC
224074302|NCT02326805|BIOLOGICAL|Rilimogene Galvacirepvec|Given SC
224074303|NCT04835012|OTHER|Medical debt forgiveness|A non-profit charity, RIP Medical Debt, bought and retired medical debt for individuals that were assigned to the treatment group.
224074304|NCT01772615|DRUG|Ciprofloxacin|Antibiotic
223590765|NCT01900587|DRUG|Tapentadol ER Tamper-resistant Formulation (TRF)|Single dose of tapentadol ER 50 milligram (mg), will be administered under fasted condition.
224205803|NCT06541106|OTHER|Multi-disciplinary assessment|"1. Comprehensive evaluation was performed by multi-disciplinary experts to assess the prognosis of unruptured VBDAs and develop appropriate treatment strategies.~2. Preoperative cranial MRI, CTA, DSA and other imaging tests were used to determine the aneurysm site, morphology, size, presence of compression symptoms, and whether it was accompanied by an intramural hematoma."
223498821|NCT05935020|OTHER|Return to Everyday life|"The patients in this group return to their desired pre-surgical activities, at their own speed, when they feel that they are ready for it. They are not prescribed any exercise-based rehabilitation (usual care) by their orthopedic surgeon.~This effectively means they will not receive a therapeutic progressive exercise plan; designed and prescribed to restore previous function or reducing pain or disability caused by injury, disease, or surgery - typically referred to as exercise therapy or therapeutic exercise."
223590766|NCT01900587|DRUG|Tapentadol ER Prolonged-Release 2 (PR2)|Single dose of tapentadol ER 50 milligram (mg), prolonged release tablet will be administered under fasted condition.
223590767|NCT01609504|PROCEDURE|ELRR BY TEM|The surgical technique of ELRR was as follows: mucosal incision included all the tatoo spots performed at admission staging, in order to excise a minimum of 1 cm of normal mucosa around the tumor, according to its diameter before NT
223590768|NCT01609504|PROCEDURE|LTME|LAPAROSCOPIC TOTAL MESORECTAL EXCISION INCLUDING MESORECTAL (ACCORDING TO HEALD CRITERIA)
223590769|NCT03870204|DIAGNOSTIC_TEST|POC-CCA rapid urine test|Fresh urine samples will be tested by POC-CCA
223590770|NCT00856726|DRUG|1-34 parathyroid infusion|1-34 parathyroid infusion at 0.055 mcg/kg/hr for 6 hours
223590771|NCT06030167|BEHAVIORAL|Insecure attachment and psychosocial functioning in autistic adults|Questionaires about attachment, psychosocial functioning, depressive symptoms, paranoid ideation, and emotion regulation were administered to 83 autistic adults (50 males, 33 females).
223590772|NCT01435629|DRUG|somatropin|Dosage and administration to be prescribed by the physician as a result of a normal clinical practice.
223590773|NCT03458650|DRUG|LXI-15028 50mg|In escalated single-dose study, the subjects in each dose group will receive single oral dose of 50 mg LXI-15028 tablet or 1 matching placebo tablet at fasted state,
223590774|NCT03458650|DRUG|LXI-15028 100mg|100 mg LXI-15028 tablet or matching placebo 1 tablet at fasted state, In multiple-dose study, the subjects who administered 100mg single dose will continuously receive oral 100 mg LXI-15028 tablet or 1 matching placebo tablet once daily (QD) for 10 times.
223590775|NCT03458650|DRUG|LXI-15028 200mg|single oral dose 2 100 mg LXI-15028 tablets or 2 matching placebo tablets at fasted state
223590776|NCT03458650|DRUG|Placebo|matching placebo tablets
223590777|NCT04119596|DIAGNOSTIC_TEST|16S rRNA gene sequencing|Taking a stool sample for gut microbiome DNA sequencing
223746090|NCT00642239|DRUG|Sodium Glycididazole|Sodium Glycididazole 700mg/m2 in 100 mL 0.9% NaCl intravenous drip in 30 minutes,then begin radiotherapy in 60 minutes.duration of treatment is 6 weeks.
223590778|NCT04119596|GENETIC|DNA-microarray genotyping|Taking a saliva sample for genotyping
223746091|NCT00768300|DRUG|Ambrisentan|Ambrisentan (5mg or 10 mg tablet) was administered orally once daily.
223746092|NCT00768300|DRUG|Placebo|Placebo to match ambrisentan was administered orally once daily.
224074305|NCT01772615|DIETARY_SUPPLEMENT|E. coli Nissle|Probiotic
224074306|NCT03280004|DRUG|Moxifloxacin Hydrochloride and Sodium Chloride Injection|Moxifloxacin group will be given Moxifloxacin Hydrochloride and Sodium Chloride Injection and β-lactams group will be given β-lactam antibiotics for injection +/- Azithromycin for Injection.
224074307|NCT02244710|DRUG|Ticagrelor vs Clopidogrel|
224074308|NCT04109495|OTHER|Smart phone application(NOOM)|The study population included first diagnosis of pancreatic cancer patients within 3 months of pancreatic cancer center visit, and randomly assigned to the use of Noom user group and non-use group. A total of 40 patients, 20 from each group, were used to examine nutritional status(PG-SGA), blood index analysis, and quality of life(EORTC QLQ) at 0, 4, 8, and 12 weeks. At the same time, the patients voluntarily record meals and receive feedback using Noom. The purpose and contents of this study are explained in detail to the subjects, and written consent is obtained. The questionnaire items included gender, age, weight, type of diagnosed digestive disease, treatment method, nutritional supplement, oral status and intake of oral supplement foods, and past medical history. To assess the nutritional status using laboratory data, blood(about 8ml) is collected for each visit.
224074309|NCT04109495|OTHER|Non-user|The patients dose not use Noom application. A total of 40 patients, 20 from each group, were used to examine nutritional status (PG-SGA), blood index analysis, and quality of life (EORTC QLQ) at 0, 4, 8, and 12 weeks. The purpose and contents of this study are explained in detail to the subjects, and written consent is obtained. The questionnaire items included gender, age, weight, type of diagnosed digestive disease, treatment method, nutritional supplement, oral status and intake of oral supplement foods, and past medical history. To assess the nutritional status using laboratory data, blood (about 8ml) is collected for each visit. At each visit, you will be assessed nutritional status and quality of life through the PG-SGA and EORTC QLQ.
224074310|NCT02270203|RADIATION|Pelvic CT at 5 years post-op|Pelvic CT at 5 years post-op
224074311|NCT04525716|OTHER|COVID-19 infection status|We will compare patients with/without confirmed COVID-19 infection
224074312|NCT00741156|DRUG|Enalaprilat|Enalaprilat will be administered intravenously i.v. 0.005 - 0.01 mg/kg i.v. over 1 minute
224074313|NCT01316172|BEHAVIORAL|5 Cs|education on consultation
224074314|NCT03388463|DRUG|Omeprazole|Omeprazole 80 mg continues infusion
224074315|NCT03388463|DRUG|Placebo group|Omeprazole 40 mg single daily dose.
224074316|NCT02463955|DEVICE|flexible video endoscope|Thoracoscopy is done using flexible video endoscope
224074317|NCT02463955|DEVICE|video-rigid thoracoscope|Thoracoscopy is done using video-rigid thoracoscope
224074318|NCT05873348|PROCEDURE|Fecal microbiota transplantation|Fecal microbiota transplantation (FMT) is the use of functional microorganisms in the feces of healthy people to form capsules and orally administer them to the intestinal tract of patients to reconstruct the intestinal flora of patients, so as to achieve the purpose of treating intestinal and exenteric diseases.
224074319|NCT05850208|BIOLOGICAL|Transplantation of self BMSCs|Bone marrow was collected, cultured in vitro and injected back into the body
223590779|NCT04338763|DRUG|RP72|RP72 is formulated as a sterile lyophilized powder which is reconstituted in sterile water for injection (WFI) prior to administration. IV injection of RP72 will be administered thrice weekly in the first 28-day treatment cycle (Cycle 1). RP72 will continue to be administered thrice weekly for 4 weeks for Cycle 2 and each subsequent 28-day treatment cycle.
223590780|NCT04338763|DRUG|Gemcitabine|Gemcitabine is an anti-cancer chemotherapy drug. IV infusion of Gemcitabine will be administered once weekly in the first 28-day treatment cycle (Cycle 1). Gemcitabine will continue to be administered once weekly for the first 3 weeks and then one week rest in Cycle 2 and each subsequent 28-day treatment cycle.
223590781|NCT00005085|DRUG|becatecarin|
223590782|NCT00973323|DRUG|Xarelto (Rivaroxaban, BAY59-7939)|2.5mg bid
223590783|NCT00973323|DRUG|Xarelto (Rivaroxaban, BAY59-7939)|5mg bid
223590784|NCT00973323|DRUG|Xarelto (Rivaroxaban, BAY59-7939)|10mg bid
223590785|NCT00973323|DRUG|Warfarin|Dose-adjusted warfarin based on target INR values
223590786|NCT04916912|PROCEDURE|coronary artery bypass grafting|Coronary artery bypass surgery is a surgical procedure to restore normal blood flow to an obstructed or stenotic coronary artery.
223590787|NCT02812719|DRUG|Glycolic acid peel alone|"One of two sides of the face will be randomly treated with glycolic acid peel 35% alone.~This treatment will be administered at visit 1 (but to entire face) and 3 subsequent visits (to one randomly selected side of the face), for a total of 4 treatments at 2 week intervals"
223590788|NCT02812719|DRUG|Glycolic and salicylic acid peel|"The other randomly chosen side of the face will be treated with glycolic acid peel 35% followed by salicylic acid peel 20%, as a combination treatment.~This treatment will be administered at visits 2, 3 and 4 (to one randomly selected side of the face), for a total of 3 treatments at 2 week intervals."
223590789|NCT04934657|OTHER|no intervention|no intervention
223590790|NCT00511134|DRUG|Eszopiclone|eszopiclone (lunesta) - 3 mg qd x 6 weeks, oral capsule
223590791|NCT00511134|DRUG|Bupropion|bupropion SR in oral capsule will be begun at the beginning of week 1 (150 mg qd x 7 days) with an increase to the full dose (150 mg bid x 6 weeks) at the beginning of week 2.
224189199|NCT05911893|DIETARY_SUPPLEMENT|high caloric oral nutritional supplements|High caloric oral nutritional supplements (which can supplement 30% of the energy requirement) is given daily, and the recommended amount of energy and protein is referred to the 2013 Chinese Dietary Nutrient Reference Intake Table. At 6 months of enrollment, participants will be asked to evaluate whether to continue feeding according to the experimental group protocol or to stop to ensure proper nutritional intake.
224189200|NCT05911893|BEHAVIORAL|nutritional education|After enrollment,health education information is pushed approximately every 4 weeks through the WeChat platform or/and short text messages to parents.
224189201|NCT05911893|BEHAVIORAL|dietary guidance|At follow-up visits at 0, 1, 2, 3, 6,and 12 months after enrollment, a professionally trained pediatrician give the participant's guardian dietary instructions appropriate to the age stage and physical condition of the child. Each session lasts approximately 10 minutes.
224189202|NCT05030662|OTHER|Walking stick exercise|"1. Education of walking stick exercise by research nurses twice before discharge (on the day before surgery and before discharge)~2. The video clip of walking stick exercise is available to the patients.~3. The research nurses encourage our patients to keep rehabilitation by phone calls once a week after discharge."
223498822|NCT05935020|BEHAVIORAL|Symptom guide and encouragement to follow DHA/WHO recommendations for physical activity|"Participants in both groups receive a recovery-guide pamphlet at discharge, containing the following information: 1) Recommendations to follow DHA/WHO guidelines for physical activity, 2) Figures and tables describing common post-operative symptoms (symptom guide), and when to react (when the symptoms may require attention from a health-professional), 3) What to expect from the post-surgical period in relation to activities of daily living, 4) Common short- and long-term complications to total knee arthroplasty and 5) Trial-participant and ethics-committee information documents. Parts 2-4 are usual clinical practice, with slight variations in descriptions between sites.~After surgery, participants in both groups are encouraged to resume their desired pre-surgical activities when they feel they are able (within the limits given from the orthopedic wards)."
223498823|NCT05595954|OTHER|Preoperative data collection|Preoperatively, patients will be assessed with Montreal Cognitive Assessment (MoCA), Geriatric Depression Scale (GDS), Clinical Frailty Scale, 3-minute Diagnostic interview for Confusion Assessment Method-defined delirium (3D-CAM, incl. severity score), modified National Institutes of Health Stroke Scale (mNIHSS), and hand grip strength measurement (using a hand dynamometer) to establish a baseline measurement of the physical, cognitive and mental status.
223498824|NCT05595954|DIAGNOSTIC_TEST|Intraoperative NIRS|Intraoperatively, NIRS data will be collected and recorded in real-time.
223498825|NCT05595954|DIAGNOSTIC_TEST|Intraoperative TCD|Intraoperatively, TCD data will be collected and recorded in real-time.
223498826|NCT05595954|DIAGNOSTIC_TEST|Intraoperative invasive MAP|Intraoperatively, invasive arterial blood pressure data will be collected and recorded in real-time.
223498827|NCT05595954|DIAGNOSTIC_TEST|Postoperative NIRS|Postoperatively, NIRS monitoring will be continued in the ICU after the surgery until (i) endotracheal extubation, or (ii) for the first 24 hours or (iii) until emergency re-operation, whichever occurs first.
223498828|NCT05595954|OTHER|Postoperative data collection|Postoperatively patients will be evaluated for POD with 3D-CAM or CAM-ICU and for clinical stroke with mNIHSS. Postoperative neurocognitive disorders will be assessed using MoCA.
223590792|NCT06403917|OTHER|Evaluation of breast screening|Evaluation of breast screening program at egyptian women health intiaive
223590793|NCT01949090|BIOLOGICAL|Investigational H7N1 vaccine GSK2789869A|Two doses of GSK2789869A H7N1 vaccine administered intramuscularly to the deltoid region at Day 0 and Day 21.
223590794|NCT01949090|BIOLOGICAL|Placebo|Two doses of placebo administered intramuscularly to the deltoid region at Day 0 and Day 21.
223590795|NCT03373838|OTHER|Census|Survey and interview
223590796|NCT02024139|OTHER|Chewing Sugarless Gum|Chewing sugar free gum three times per day for 5-10 minutes
223590797|NCT02024139|OTHER|Using Mouthwash|Rinse mouth with plax sensitive fluoridated mouthwash for 30 seconds, three times per day
223590798|NCT04694027|DRUG|Omega 3 fatty acid|omega 3 1000 mg
224189203|NCT02364362|DRUG|famitinib L + docetaxel|famitinib 15mg qd + docetaxel 60 mg/m\^2
224189204|NCT02364362|DRUG|famitinib M + docetaxel|famitinib 20mg qd + docetaxel 60 mg/m\^2
223590799|NCT04694027|DRUG|VitaE|vitamin e 400 mg
223498829|NCT05595954|DIAGNOSTIC_TEST|Collection of serum biomarker panel|The serum biomarker panel will consist of four markers of neurological injury glial fibrillary acidic protein (GFAP), neurofilament light chain (NfL), t-tau and ubiquitin-C-terminal-hydrolase-L1 (UCH-L1). Blood samples will be obtained preoperatively, after ICU admission, on postoperative day 1, 2, 6 (or hospital discharge, whichever occurs first) and between 6 and 12 weeks after surgery.
223498830|NCT05595954|DIAGNOSTIC_TEST|Collection of blood sample for genetic study|A blood sample for the genetic study will be obtained preoperatively.
223498831|NCT04697901|DEVICE|Active Transcranial Direct Current Stimulation (tDCS)|"Active simulation will be applied to the right PPC. To target this region for stimulation, the anode electrode will be placed on the subject using the 10-20 EEG system as reference location (Thair et al., 2017). Stimulation intensity for all conditions will be set to 2 mA, which was chosen based on previous studies that have compared 1 mA to 2 mA and found the higher intensity produced reliable changes to performance (e.g., Moos et al., 2012). Total time of active stimulation will be the same for each group (20 minutes). Delivery times of the stimulation will vary based on Group assignment:~Group A: During pre-flight brief/checklist, for 20 minutes. Group B: First delivered at 30 minutes into flight for 10 minutes, second delivered at 60 minutes into flight for 10 minutes."
223498832|NCT04697901|DEVICE|Sham Transcranial Direct Current Stimulation (tDCS)|"Sham simulation will be applied to the right PPC. To target this region for stimulation, the anode electrode will be placed on the subject using the 10-20 EEG system as reference location (Thair et al., 2017). Stimulation intensity for all conditions will be set to 2 mA, which was chosen based on previous studies that have compared 1 mA to 2 mA and found the higher intensity produced reliable changes to performance (e.g., Moos et al., 2012). Total time of active stimulation will be the same for each group (20 minutes). Sham stimulation will consist of active stimulation for 120s, including the ramping up to 2 mA and down to no stimulation. Delivery times of the stimulation will vary based on Group assignment:~Group A: During pre-flight brief/checklist, for 20 minutes. Group B: First delivered at 30 minutes into flight for 10 minutes, second delivered at 60 minutes into flight for 10 minutes."
223498833|NCT01177410|DRUG|Placebo|placebo capsules once daily for 12 weeks
223498834|NCT01177410|DRUG|Mesalamine Granules 750 mg|750 mg mesalamine granules once daily for 12 weeks
223498835|NCT01177410|DRUG|Mesalamine Granules 1500 mg|1500 mg mesalamine granules once daily for 12 weeks
223498836|NCT02000271|PROCEDURE|Vaginal packing|
223590800|NCT01478334|BEHAVIORAL|high intensity interval training|"First 10 week of high intensity interval training, twice a week. The interval training session consists of 10 minutes warm up at 70 percent of maximal heart rate and continues with 4 times 4 minutes of high intensity intervals at 90 to 95 percent of maximal heart rate separated by 3 minutes of active brakes in between at 70 percent of maximal heart rate. Training will be performed by cycling. Training intensity will be supervised through the use of polar puls monitors and the BORG scale of subjective perceived exhaustion.~Second 10 weeks participants are instructed not to change their dietary patterns or physical activity levels during the study period."
224074320|NCT04290702|PROCEDURE|regional analgesia for labor|three commonly used regional analgesic techniques are used, with local anesthetic ropivacaine, opioid fentanyl, parturient controlled epidural analgesia
224074321|NCT02848079|DRUG|combined TAS-102 and TAS-OX|Combination treatment with TAS-102 and oxaliplatin. TAS-102 is an oral medication; oxaliplatin (TAS-OX) is given by infusion.
223498837|NCT02000271|PROCEDURE|No vaginal packing|
224074322|NCT04313556|PROCEDURE|Lateral patellar release|Arthroscopic lateral patellar reticular release
224074323|NCT03390413|PROCEDURE|Robot|Renal cancer treated with robotic surgery
224074324|NCT03390413|PROCEDURE|Cryoablation|Renal cancer treated with cryoablation
224074325|NCT05093101|OTHER|case series review of clinical data|Extraction of pre-surgical and chemotherapy blood test laboratory data and clinical and instrumental data related to patient history from digitized medical records and analysis
224074326|NCT00859365|PROCEDURE|Real Acupuncture|Real acupuncture treatment in real acupuncture points
224074327|NCT00859365|PROCEDURE|Placebo Acupuncture|empty plastic acupuncture guide-tube located on the patients back in a non visable area and connected to a visible electric stimulator
224074328|NCT00859365|PROCEDURE|No intervention|Patients lay down for a period of 35 minutes without any treatment o intervention
224074329|NCT05410548|OTHER|Standard-of-Care|Participants with a major unilateral transfemoral or transtibial amputation will undergo a standardized medical history and medication review, complete questionnaires evaluating prosthesis use, comfort, and mobility, receive a clinical examination of height, weight and limb circumference, and complete three performance-based mobility outcome measures.
224074330|NCT05410548|OTHER|Clinical Screening|Participants will complete the following self-report questionnaires: (a) the Patient Health Questionnaire-9 item, which may suggest major depression and/or suicidal ideation; and (b) the STarT Back Screening Tool, a 6-item tool used to screen for greater than low-risk for persistent, bothersome and disabling low back pain. Prosthetists will perform palpation of the contralateral dorsalis pedis and posterior tibial pulses and note presence or absence, as an indicator of peripheral arterial disease. Prosthetists will evaluate protective sensation of the contralateral foot through Semmes-Weinstein monofilament assessment of the great toe, the 1st and 3rd metatarsal heads. The prosthetist will record the results in a letter that is sent to the patient's primary care provider, and provide a copy of the letter to the patient after discussing the results for each of the screens.
224074331|NCT01268293|DRUG|E7080|This arm will be a dose-escalation evaluation of 9-18 subjects to investigate the tolerability and safety of E7080 up to 24 mg when administered orally on a once daily continuous dose schedule in cycles (4 weeks as 1 cycle). Administration of the study drug can continue until subjects meet discontinuation criteria such as disease progression, intolerable toxicity, and withdrawal of study consent.
224074332|NCT03509220|DRUG|PBK-1701TC|The subject will receive PBK-1701TC for colonoscopy.
224074333|NCT03509220|DRUG|Standard oral preparation|The subject will receive the standard oral preparation for colonoscopy
224074334|NCT02599584|BEHAVIORAL|precritical staff|free pre critical scenario team staff
224074335|NCT06248957|COMBINATION_PRODUCT|Immunomodulation|Variable protocols for combined immunomodulatory therapies currently in use for different forms of immune dysregulation
223590801|NCT01478334|BEHAVIORAL|Control|"First 10 weeks participants are instructed not to change their dietary patterns or physical activity levels, and to continue their habitually lifestyle.~Second 10 week of high intensity interval training, twice a week. The interval training session consists of 10 minutes warm up at 70 percent of maximal heart rate and continues with 4 times 4 minutes of high intensity intervals at 90 to 95 percent of maximal heart rate separated by 3 minutes of active brakes in between at 70 percent of maximal heart rate. Training will be performed by cycling. Training intensity will be supervised through the use of polar puls monitors and the BORG scale of subjective perceived exhaustion."
224189205|NCT02364362|DRUG|famitinib H + docetaxel|famitinib 25mg qd + docetaxel 60 mg/m\^2
224189206|NCT03494140|DEVICE|Viscontour® Serum Med|Viscontour® Serum Med is a CE-certified preservative-free isotonic solution containing 5.0 mg sodium hyaluronate.
224189207|NCT01594424|DRUG|Tocilizumab|Tocilizumab 8mg/kg on Days 0, 15, 30, 45, 75, 105, 119, 135, 149, and 180
223590802|NCT06039748|OTHER|AngioQFA|FFR measured by pressure wire, AngioQFA computed by coronary angiographic images
224189208|NCT01594424|DRUG|Intravenous Immunoglobulin|All HS who meet criteria for desensitization will receive IVIG 10% (2.0 g/kg \[maximum 140 g per dose\] on days 1 and 30).
224189209|NCT03949816|OTHER|medical consultation: different doctor-patient-centered style of communication|Different doctor-patient communication
224189210|NCT03949816|OTHER|information letter / no medical consultation|In the control treatment participants receive all information about the herbal medical product in an information letter but have no contacted with the simulated doctor.
224189211|NCT02469506|DEVICE|Neuromuscular Electrical Stimulation (NMES)|The protocol will consist of a warm-up period (5 min), a stimulation period (30min), and a cooling-down period (5min). Stimulation will be provided by an Enraf Nonius TensMed S84 stimulation device.
224189212|NCT01143818|DRUG|AndroGel (testosterone gel) 1%|AndroGel is topical testosterone gel 1% and is prescribed for once daily use.
224189213|NCT02576652|OTHER|Tetracycline|Treatment during cycle 1 consists of a total oral dose of 1000 mg of tetracycline daily for a total of 3 days.
224189214|NCT02576652|OTHER|Demeclocycline|Treatment during cycle 2 consists of a total oral dose of 600 mg of demeclocycline daily for 3 days.
224189215|NCT02576652|PROCEDURE|Total Hip Replacement|Participants entering this study were prescheduled to undergo elective THR due to osteoarthritis. Surgery was to be performed according to local standard of care. During THR a fragment of femoral bone was acquired for histomorphometry evaluation.
224189216|NCT04152538|OTHER|not intervention but investigation|possible differences in quadriceps muscular activity
224189217|NCT00214942|DRUG|ORAVESCENT Fentanyl Citrate|
223498838|NCT02323815|DIETARY_SUPPLEMENT|Small-Quantity Lipid-based nutrient supplement|A monthly dose of SQ-LNS (31 sachets of 20g) will be distributed to mothers attending counselling sessions
223498839|NCT02323815|BEHAVIORAL|Child's health and nutrition topics|Monthly group counselling meetings organized at village level. Caregivers of participating children are invited to attend monthly counselling meetings that treat topics on child nutrition, health, hygiene and good sanitary practices. During these visits children are also screened for acute malnutrition measuring arm circumference.
223498840|NCT02901860|OTHER|Sleep, Dietary and Cardio-metabolic Measurements|"At home session: 2-weeks of wrist actigraphy and sleep diaries; a food diary for the three days preceding the lab session; 24-h period of ambulatory blood pressure on a non-work day for participant. Work schedules over a 4-week period will be collected and participants identified as traditional or non-traditional workers.~Subjects will begin the stay in the research unit in the evening and will remain for about 16-20 hr. Saliva samples will be taken every 30 min from admission until bedtime. Bedtime with polysomnography will be from 11:00pm to 7:00am. Questionnaires will be administered; height, weight and waist/hip circumference and bioimpedance measurement; standard 3-h oral glucose tolerance test and blood tests (CBC, electrolytes, renal, liver and thyroid function , hemoglobin A1c, SHBG levels). For individuals with diabetes only fasting blood samples will be taken."
223498841|NCT05643690|DIAGNOSTIC_TEST|UriFind Bladder Cancer Assay|The AnchorDx UriFind™ Bladder Cancer Assay is designed to detect 2 DNA methylation biomarkers in urine specimens from patients 22 years or older suspected of having bladder cancer. Results from the Assay are intended for use, in conjunction with current standard diagnostic procedures, as an aid for initial diagnosis of bladder carcinoma in patients.
223498842|NCT01230008|RADIATION|no drugs|Adjuvant radiotherapy 3.5 G will be administered or not (control group) in patients with mediastinal lymphoma,treated with R-CHOP
223498843|NCT02092103|PROCEDURE|Cord Milking|See description in cord milking arm.
223498844|NCT05382728|DRUG|TY-9591|"The dose of TY-9591 is 160 mg once daily. A cycle of treatment is defined as 21 days of once daily treatment.~Number of Cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria."
223590803|NCT06105268|OTHER|flipped learning training group|flipped learning training group. Applying a flipped learning model in addition to routine training in a fully equipped simulation
224189218|NCT05107700|PROCEDURE|Stay at altitude 2500 m above sea level (high altitude)|Patients with precapillary pulmonary hypertension stay a sojourn of 30 h at 2500 m.
224189219|NCT05107700|PROCEDURE|Stay at altitude 470 m above sea level (low altitude)|Patients with precapillary pulmonary hypertension stay a sojourn of 30 h at 470 m.
224189220|NCT03656315|OTHER|Airway Assessment|All patients recruited to this study will have an ultrasound of their cricothyroid membrane
224189221|NCT06403605|DEVICE|Mirragen Wound Matrix|"Offloading- patient will be offloaded in a diabetic CAM boot after treatment, or total contact cast if patient cannot be fit in a diabetic boot. Other names; pressure relief.~Additional outer dressing application-application of outer moisture retentive dressing, and a multilayer compression dressing. Other names; outer protective dressing.~Mirragen Wound Matrix-application of Mirragen to wound site along with standard of care treatment."
224189222|NCT06403605|DEVICE|Fibracol|"Offloading- patient will be offloaded in a diabetic CAM boot after treatment, or total contact cast if patient cannot be fit in a diabetic boot. Other names; pressure relief.~Additional outer dressing application-application of outer moisture retentive dressing, and a multilayer compression dressing. Other names; outer protective dressing.~Mirragen Wound Matrix-application of Mirragen to wound site along with standard of care treatment."
224189223|NCT01142960|DIETARY_SUPPLEMENT|Starch|1350mg/day
224189224|NCT01142960|DIETARY_SUPPLEMENT|Lycium Barbarum|1350mg/day
224189225|NCT05733468|DRUG|Theracal LC|After hemorrhage control , 1-1.5mm of TheraCal LC will be placed on the radicular pulp stumps followed by light curing, followed by the placement of IRM and composite restorative material after 2 weeks
224189226|NCT05733468|DRUG|MTA|After hemorrhage control , a small ball like consistency of 2-3mm of MTA will be placed on the radicular pulp stumps, followed by the placement of IRM and composite restorative material after 2 weeks
224189227|NCT02389868|DRUG|Lovastatin|
224189228|NCT02892357|DRUG|Treatment group|Jianpi Qinghua granules:twice a day,1 bag a time;10mg omeprazole and 10mg sham ,once a day,all for 4 weeks.
224189229|NCT02892357|DRUG|Control group|sham Jianpi Qinghua granules:twice a day,1 bag a time; 20mg omeprazole once a day ,all for 4 weeks.
224189230|NCT02200549|DEVICE|Control group|Neither cycle training nor inspiratory muscle training.
224189231|NCT02200549|DEVICE|calibrated cycle ergometer|The most common device to proform cycle training is calibrated cycle ergometer.
224189232|NCT02200549|DEVICE|calibrated cycle ergometer and threshold loading device|Combined cycle training and inspiratory muscle training.The threshold loading device is composed of a mouth -piece attached to a small plastic cylinder that contains a spring-loaded poppet value. The valve opens to permit inspiratory flow only once the person has generated adequate negative intrathoracic pressure to condense the spring.
224189233|NCT01421693|DRUG|Ceftriaxone|"* ≥2-\<14 years - 60mg/kg/ once daily for 7 days~* 14 years and older - 2g once daily for 7 days~* Intravenous infusion. Vials of crystalline powder."
224189234|NCT01421693|DRUG|Gatifloxacin|Gatifloxacin 10 mg/kg/day for 7 days. Tablets for oral administration.
224189235|NCT06203028|BEHAVIORAL|Cyberbullying Awareness Training|The 'Cyberbullying Awareness Training' program will be implemented in 2 sessions in 1 day for a total of 2 hours. The training program will be implemented in line with the headings 'Definition of cyberbullying, Cyberbullying tools and practices, Case studies on cyberbullying, Causes of cyberbullying, Academic, social, psychological and physical effects of cyberbullying, Coping strategies with cyberbullying'.
224189236|NCT00391911|DRUG|N-Acetylcysteine|Patients are assigned to either N-Acetylcysteine or placebo. Dose is weight based Placebo is normal saline or D5W
224189237|NCT00391911|OTHER|N-Acetylcystine and Non CRRT|Patients are assigned to N-Acetylcysteine and CRRT. The N-Acetylcysteine is blinded to everyone except pharmacy. The CRRT is open label as would be impossible to blind
224189238|NCT00391911|OTHER|Placebo and CRRT|Patients are assigned to Placebo and CRRT. The N-Acetylcysteine/Placebo is blinded to everyone except pharmacy. The CRRT is open label
224189239|NCT00391911|OTHER|Placebo and Non CRRT|Patients are assigned to Placebo and non-CRRT. The N-Acetylcysteine/placebo is blinded to everyone except pharmacy. The CRRT/non CRRT is open label as would be impossible to blind
224189240|NCT01749228|DRUG|Etodolac Capsules USP 300 mg|300 mg capsule once a day
224189241|NCT01749228|DRUG|Etodolac|500 mg tablet once a day
224189242|NCT03216499|DRUG|HIF-2alpha Inhibitor PT2385|Given PO
224189243|NCT03216499|OTHER|Pharmacological Study|Correlative studies
223498845|NCT05382728|DRUG|placebo Osimertinib|"The dose of placebo Osimertinib is 80 mg once daily. A cycle of treatment is defined as 21 days of once daily treatment.~Number of Cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria."
223498846|NCT05382728|DRUG|Osimertinib|"The dose of Osimertinib is 80 mg once daily. A cycle of treatment is defined as 21 days of once daily treatment.~Number of Cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria."
223498847|NCT05382728|DRUG|placebo TY-9591|"The dose of placebo TY-9591 is 160 mg once daily. A cycle of treatment is defined as 21 days of once daily treatment.~Number of Cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria."
223498848|NCT04208711|OTHER|biological sample|whole blood sample
223498849|NCT02794311|OTHER|Alcoolpredict|psychological (personality), neuropsychological (executive functions, memory), genetic (snp polymorphisms) and neuro-anatomical (fMRI)
224189244|NCT03216499|OTHER|Laboratory Biomarker Analysis|Correlative studies
224189245|NCT03216499|OTHER|Pharmacogenomic Study|Correlative studies
224189246|NCT00252798|DRUG|Gefitinib|
224189247|NCT00252798|DRUG|Carboplatin|
224189248|NCT00252798|DRUG|Paclitaxel|
224189249|NCT00252798|PROCEDURE|Radiation|
224189250|NCT06070831|DEVICE|Inspiratory muscle training|"Respiratory training, performed through IMT, was carried out with a pressure threshold device (Treshold IMT, Philips-Respironics, Pittsburg, PA, USA). Threshold IMT offers a constant and specific pressure for strength and endurance training of the respiratory muscles, regardless of the strength or speed with which patient breathes. A flow-independent one-way valve ensures constant resistance and allows you to specifically adjust workload (in cmH2O). The training must be supervised by a healthcare professional. During the inspiration, a spring-loaded valve resists to stimulate the training of the respiratory muscles. Before training began, the participants and primary caregivers completed one-session familiarization with a specialist to know the operation of the device.~Adult people with acquired brain injury carried out the training program for 8 weeks, 1 session every day, 5 days a week. The participants performed 5 series of 1 minute with 1-minute rest between them."
224189251|NCT06070831|DEVICE|Expiratory muscle training|"Respiratory training, performed through PEP, was carried out with a pressure threshold device (Treshold PEP, Philips-Respironics, Pittsburg, PA, USA). Threshold PEP offers a constant and specific pressure for strength and endurance training of the respiratory muscles, regardless of the strength or speed with which patient breathes. A flow-independent one-way valve ensures constant resistance and allows you to specifically adjust workload (in cmH2O). The training must be supervised by a healthcare professional. During the expiration, a spring-loaded valve resists to stimulate the training of the respiratory muscles. Before training began, the participants and primary caregivers completed one-session familiarization with a specialist to know the operation of the device.~Adult people with acquired brain injury carried out the training program for 8 weeks, 1 session every day, 5 days a week. The participants performed 5 series of 1 minute with 1-minute rest between them."
224189252|NCT03814876|BEHAVIORAL|Group session psycho-education|Active comparator - control group
224189253|NCT03814876|BEHAVIORAL|FITS|Manualized family intervention
224189254|NCT00708344|DRUG|Irbesartan - Hydrochlorothiazide|150/12.5 mg (1 tablet once daily) or 300/25 mg (1 tablet once daily) depending on the control of the blood pressure. Duration of treatment : 10 weeks
223590804|NCT05572359|DEVICE|cryo-and compression brace|patients in the intervention groups are instructed to use the cryo- and compression brace during the six postoperative weeks five times a day, for a maximum of 20 minutes. The amount of compression is dependent on a patients' own preference.
223590805|NCT05479812|DRUG|WTX-124|Investigation Product Monotherapy
223590806|NCT05479812|DRUG|pembrolizumab|Investigation Product in combination with approved therapy
223590807|NCT03650140|DIETARY_SUPPLEMENT|Tart cherry extract 60 mL|Subjects will receive a single 60 mL oral dose of tart cherry extract.
223590808|NCT03650140|DIETARY_SUPPLEMENT|Tart cherry extract 120 mL|Subjects will receive a single 120 mL oral dose of tart cherry extract.
223590809|NCT06797583|DEVICE|Active Transcranial Photobiomodulation (TPBM)|CytonBrite, 1064nm LED
223590810|NCT06797583|DEVICE|Sham Transcranial photobiomodulation (TPBM)|Sham condition using a randomized block design involving 2 (TPBM): 1(sham) randomization.
223590811|NCT04141449|OTHER|Potlako intervention|Combined provider, patient, and health system intervention to expedite cancer diagnosis and care.
223590812|NCT04141449|OTHER|Enhanced care|Provider education and limited patient counseling.
223590813|NCT03459365|DEVICE|Euflexxa|Aspirations performed before each injection and at six weeks.
223590814|NCT00769509|OTHER|energy expenditure in preterm fed with preterm formula|Assessment of energy expenditure by indirect calorimetry in preterm infant fed with preterm formula 24 hours before measurements.
223590815|NCT00769509|OTHER|assessment of energy expenditure|assessment of energy expenditure in preterm infant during fed with human milk with fortifier
223590816|NCT06583616|DIAGNOSTIC_TEST|Anion Gap|Patient with acute pulmonary embolism who not survive after hospitalization
223590817|NCT06583434|BEHAVIORAL|core-lower extremity Pilates Training Group|Participants in this group will engage in a stabilization-based Pilates exercise program focusing on core and lower extremity stabilization. The program consists of twice-weekly sessions, each lasting 50 minutes, over a period of 8 weeks. The primary goal of the intervention is to improve gait patterns and balance in women with flexible pes planus
223590818|NCT06583434|OTHER|Non-Training Group|Participants in this group will not receive any specific intervention during the study period. They will continue their usual activities without any additional exercises provided by the study.
223590819|NCT05603598|DRUG|LEAP-2 Protein, Human|Intravenous infusion, mixed meal test, ad libitum meal test
223590820|NCT02979223|DRUG|sodium picosulfate and magnesium citrate, polyethylene glycol with ascorbic acid|"sodium picosulfate and magnesium citrate and 2L polyethylene glycol with ascorbic acid are used as combination method.~There is a difference in the order of intake between two group"
223590821|NCT06530966|DRUG|ICP-332 Tablets|Eligible patients will receive ICP-332 tablets orally as per the protocol
223590822|NCT06530966|DRUG|ICP-332 Placebo Tablets|Eligible patients will receive ICP-332 placebo tablets orally as per the protocol
223590823|NCT02146001|OTHER|Reducing sedentary behavior group|This intervention will use individual counseling and the the BodyMedia armband to self-monitor sedentary behavior. The goal will be to decrease time spent in sedentary behavior by 60 minutes each day.
223590824|NCT02146001|OTHER|Moderate-to-vigorous activity group|This group will be administered an individual, behavioral intervention using the BodyMedia armband to self-monitor physical activity. The prescription will be 150 minutes of moderate exercise (e.g. brisk walking) each week.
223590825|NCT04431492|PROCEDURE|CABG|aminoacids and NO levels
223590826|NCT01356628|DRUG|PD-0332991|PD-0332991, 125mg, 3 cycles
223590827|NCT04949022|DEVICE|Medronic 780G insulin pump|Commercial hybrid closed loop system Medronic 780G
223590828|NCT04922138|DRUG|Aumolertinib|All subjects who meet the enrollment conditions will be included in the Aumolertinib monotherapy group: Orally 110 mg Aumolertinib tablets (55 mg/tablet, 2 tablets/day) once a day until recurrence or completion of treatment or reaching the standard of discontinuation.
223590829|NCT02575170|DRUG|Amino acid solution|a balanced mixture of 18 pure crystalline amino acids, eight of which are essential amino acids
224074336|NCT00883883|DRUG|Cefdinir 250 mg/5 ml Suspension (Sandoz, Austria)|
224074337|NCT00883883|DRUG|Omnicef Cefdinir 250 mg/5 ml Suspension (Abbott Laboratories, USA)|
224074338|NCT05273684|OTHER|High intensity interval training|Participants will undergo 4x4 and 1x10 minutes of interval training on two separate days.
224074339|NCT05446493|DRUG|Tadalafil 5mg|"* Estimate serum level of serum YKL-40, total testosterone and platelets indices in diabetic patients with erectile dysfunction treated by daily tadalafil 5mg for 3months.~* Penile color Doppler ultrasound examination before and after treatment"
224074340|NCT05995392|DRUG|Topical spironolactone ophthalmic solution, 0.005 mg/cc|Used four times a day in both eyes for 4 weeks.
224074341|NCT05995392|DRUG|Placebo|Used four times a day in both eyes for 4 weeks.
224074342|NCT01236456|DRUG|Cyclophosphamide|
224074343|NCT00002944|DRUG|carboplatin|Given IV
224074344|NCT00002944|DRUG|lomustine|Given IV
224074345|NCT00002944|DRUG|procarbazine hydrochloride|Given PO
224074346|NCT00002944|DRUG|thioguanine|Given PO
224074347|NCT00002944|DRUG|vincristine sulfate|Given PO and IV
224074348|NCT03592979|DEVICE|Simulated Altitude: (FiO2: 15.1)|"Inhalation of deoxygenated air through an altitude simulator (Altitrainer) for approximately 1 hour given by a facemask."
224074349|NCT03592979|DEVICE|Shamed Hypoxia (FiO2: 20.9)|"Inhalation of unmodified air through an altitude simulator (Altitrainer) for approximately 1 hour given by a facemask."
224074350|NCT01449708|DRUG|TIVA NoNarc|"* patients in both groups receive antiemetic prophylaxis~* patients in the TIVA NoNarc group will receive propofol, dexmedetomidine, ketamine, ketorolac and acetaminophen intraoperatively~* postop management in both groups is similar in both groups"
224074351|NCT03812809|DRUG|BPI-7711|BPI-7711: 180mg, QD, oral
224074352|NCT01231165|DRUG|Amiloride|5mg/daily for 12th months
224074353|NCT01231165|DRUG|Nitrates, clopidogrel, aspirin, statins|Comparative Efficacious Research
224074354|NCT04288570|PROCEDURE|suture anchor socket creation with punch|suture anchor socket creation with punch
224074355|NCT04288570|PROCEDURE|suture anchor socket creation with drill|suture anchor socket creation with drill
223590830|NCT02575170|DRUG|Ringer's lactate solution|200 ml of Ringer's lactate solution
223590831|NCT04688788|DRUG|Rituximab|Rituximab is a chimeric mouse/human monoclonal immunoglobulin gamma-1 (IgG1) antibody which depletes cluster of differentiation antigen 20 (CD20)-positive cells. Rituximab is approved for non-hodgkin lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, granulomatosis with polyangitis and microscopic polyangitis, and pemphigus vulgaris.
223590832|NCT04688788|DRUG|Ocrelizumab|Ocrelizumab is a recombinant humanised monoclonal IgG1 antibody which depletes CD20-positive cells. Ocrelizumab is approved for multiple sclerosis.
223590833|NCT04688788|DRUG|Fexofenadine|Premedication with oral fexofenadine 360 mg is given before every infusion to reduce frequency and intensity of infusion related reactions.
223590834|NCT04688788|DRUG|Paracetamol|Premedication with oral. paracetamol 1000 mg is given before every infusion to reduce frequency and intensity of infusion related reactions.
223590835|NCT04688788|DRUG|Methylprednisolone|Premedication with oral methylprednisolone 100 mg is given before every infusion to reduce frequency and intensity of infusion related reactions.
223590836|NCT06206018|PROCEDURE|PROM_R knee rehabilitation program|"The rehabilitation program consists of 5 weekly sessions for 4 weeks, supervised by a specialized physiotherapist at every session.~All patients follow the same order of treatment and exercises, starting with massage and mobilization, followed by the corresponding exercise program, and ending with Neuromuscular Electrical Stimulation (NMES) and cryotherapy."
223590837|NCT00785980|DRUG|Quinine Sulfate Capsules 324 mg|A single dose of quinine sulfate (2 x 324 mg capsules) administered on the morning of Day 1 after an overnight fast of at least 10 hours.
224189255|NCT00708344|DRUG|Irbesartan - Hydrochlorothiazide|150/12.5 mg (1 tablet once daily) or 300/25 mg (1 tablet once daily) depending on the control of the blood pressure. Treatment duration : 10 weeks
224189256|NCT01372020|OTHER|neuromuscular electrical stimulation|The application technique used will be bipolar, with electrodes of the type metal-tipped pen. The electrodes will be placed at the outer edges of the ulcer, on opposite sides of the same and the estimated time of 1 minute at each point. All the edge of the ulcer will be bypassed, thereby separating the injections every 1 cm, returning to the starting point at the end of the application. To ensure that the entire edge of the ulcer to receive the stimulation, the end points of the application, the application will be made for another minute sliding the pen around the whole edge. Thus the application time will be directly proportional to the ulcer area. The subjects will be received 10 applications, three times a week for a period of 4 weeks.
224189257|NCT05818202|OTHER|Questionannire|The questionannaires for both physiotherapists and stroke patients were formed in this study. The perspectives of the participants were recorded.
224189258|NCT02139709|DIETARY_SUPPLEMENT|Ganglioside|
224189259|NCT02139709|DIETARY_SUPPLEMENT|Placebo|
223498850|NCT02890888|OTHER|hyperbaric oxygen treatment|Patients are treated in a hyperbaric oxygen chamber for 1 hour at 2ATA, 10 times over 2 consecutive weeks, 5 times per week
223498851|NCT00211094|DRUG|Dapoxetine|
223498852|NCT04856618|BIOLOGICAL|Massive Transfusion of Allogeneic Blood|Massive Transfusion of Allogeneic Blood, \> pRBCs
223498853|NCT00442156|PROCEDURE|Laser photocoagulation|modified ETDRS focal photocoagulation generally completed in a single sitting on the day of enrollment, but if little or no improvement, may be repeated at 16 weeks
223498854|NCT01834794|BEHAVIORAL|MET/CBT/CM plus NRT|Behavioral Treatment for Cannabis plus Behavioral Treatment for Tobacco: both primarily delivered by computer. Additional NRT.
223498855|NCT02773628|DEVICE|Acar'up system|
223498856|NCT02773628|DEVICE|Acar'up placebo system|
223498857|NCT06309758|OTHER|Breinzorg|"The BreinZorg multidomain lifestyle website comprises 16 domains, namely (1) physical activity, (2) healthy diet, (3) smoking, (4) alcohol, (5) sleep, (6) cognitive activity (7) social activity, (8) diabetes, (9) blood pressure, (10) cholesterol, (11) heart- and vascular diseases, (12) kidney diseases, (13) hearing damage, (14) obesity, (15) anxiety, and (16) depression. These 16 modules are separated into three big themes: mood, lifestyle, and body.~Each module consists of the following:~1. General information on the risk factor;~2. Tips on how to improve and decrease the risk;~3. Quiz questions about the risk factor, giving extra knowledge/ in a playful and interactive manner;~4. Examples of SMART goals fitting the risk factor (goal examples are given in a Specific, Measurable, Achievable, Relevant, and Time-Bound manner)."
223498858|NCT04874168|DEVICE|TAP block|bilateral ultrasound-guided TAP block was performed using a 12-4-MHz linear array transducer (ClearVue 350; Philips, Bothell, WA) placed transversely between the iliac crest and costal margin in the anterior axillary line and slid medial-lateral to visualize the external oblique, internal oblique, and trans-versus abdominis muscles; the most lateral (posterior) position obtaining a satisfactory ultrasound image was used
223498859|NCT05202431|BEHAVIORAL|Treatment adherence|The patients were reminded to take drug by patient training, telephone follow-up, and daily sms. It was determined that the effect of the training and telephone follow-up provided to the TB patients and contacts on the treatment adherence.
223498860|NCT00315315|PROCEDURE|Nasolacrimal balloon catheter dilation|Balloon catheter nasolacrimal duct dilation consists of punctal dilation of at least one punctum and the passage into the nose of a semi-flexible wire probe with an inflatable balloon on the tip.
223498861|NCT00315315|PROCEDURE|Nasolacrimal intubation|Nasolacrimal duct intubation consists of punctal dilation of at least one punctum with the passage of a flexible lacrimal probe into the nose and the placement of a temporary stent in the nasolacrimal duct.
223498862|NCT00315315|PROCEDURE|Nasolacrimal duct probing|Simple nasolacrimal duct probing consists of punctal dilation of at least one punctum and the passage of a probe into the nose.
223498863|NCT00012246|BIOLOGICAL|carcinoembryonic antigen peptide 1-6D|
223498864|NCT00012246|BIOLOGICAL|incomplete Freund's adjuvant|
224205804|NCT03447054|BEHAVIORAL|Combined TDCS active and ICT active|Five 20-minute long sessions including TDCS (2 MicroAmperes during 20 minutes) and ICT, 5 consecutive days
224205805|NCT03447054|BEHAVIORAL|Combined TDCS sham and ICT active|Five 20-minute long sessions including TDCS sham (non active) and ICT, 5 consecutive days
223498865|NCT00012246|BIOLOGICAL|sargramostim|
223498866|NCT03791021|DIAGNOSTIC_TEST|draw a person (DAP)|the subjects will be given a blank sheet of white paper and a pencil, and will be asked to draw themselves with no other additional instructions.
223498867|NCT03791021|DIAGNOSTIC_TEST|Edinburgh Postnatal Depression Scale (EPDS)|measure of postpartum depression symptoms.
223498868|NCT03791021|DIAGNOSTIC_TEST|Beck Depression Inventory- II (BDI-II)|BDI-II is based on clinical observations of behaviors associated with depression, and it retains the somatic items in accordance with the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) criteria related to loss of energy. ansd sleep disturbances.
223498869|NCT03791021|DIAGNOSTIC_TEST|Traumatic Events Questionnaire (TEQ)|The TEQ assesses experiences with nine specific types of traumatic events (e.g., accidents, crime, adult abusive experiences) reported in the empirical literature as having the potential to elicit PTSD symptoms.
223498870|NCT01909102|BEHAVIORAL|ACT-based intervention|
223498871|NCT01909102|BEHAVIORAL|usual care|
223498872|NCT05363904|OTHER|Observation|Questionnaires, Clinical Scores, Biomaterial Sampling
223590838|NCT00785980|DRUG|Ciprofloxacin 500 mg|A single dose of quinine sulfate (2 x 324 mg capsules) co-administered with a single dose of ciprofloxacin (1 x 500 mg tablet) in the morning on Day 11 after an overnight fast of at least 10 hours.
223590839|NCT00785980|DRUG|Quinine Sulfate Capsules 324 mg|A single dose of quinine sulfate (2 x 324 mg capsules) co-administered with a single dose of ciprofloxacin (1 x 500 mg tablet) in the morning on Day 11 after an overnight fast of at least 10 hours.
223590840|NCT02459678|BEHAVIORAL|Enhanced Adherence Package|The enhanced adherence package is yet to be designed, but may target all HIV-infected women with methods that are currently reserved only for late clients or clients of unknown status.
223590841|NCT02459678|OTHER|Standard of Care|Currently, the standard of care is based on the 2010 national HIV care and treatment guidelines, health care providers are encouraged to use a number of different means to improve ART adherence.
223590842|NCT03055013|PROCEDURE|Nephrectomy|Undergo nephrectomy
223590843|NCT03055013|BIOLOGICAL|Nivolumab|Given IV
223590844|NCT03055013|OTHER|Patient Observation|Undergo observation
223746093|NCT00532584|DRUG|Beclomethasone|The treatment with inhaled beclomethasone will be administered to Group A from Day 1 to Day 7 via a metered dose inhaler (QVAR 80 HFA) delivering 80 micrograms of beclomethasone per puff. QVAR will be purchased by the Department of Genetic Medicine. The dose will be 2 puffs twice a day for 7 days
224189260|NCT04169620|OTHER|aquatic Ai Chi|"The sessions took place in a pool measuring 20 m x 6 m, at a depth of 110 cm. The water temperature was 30oC (with variations of less than 0.5o) and the room temperature was 27.5oC (with variations of less than 1o). The proportions of the pool were ideally suited for collective treatment.~The sessions were designed with a gradual increase in difficulty. Initially, a recreational warm-up activity was performed, followed by 30 minutes dedicated to practicing the Ai Chi Program. At the end of the session there was a calming down activity. The exercises were performed in a specific order, until completion of the 19 possible movements."
224189261|NCT04169620|OTHER|control|These sessions consisted of group sessions of supervised training lasting 45 minutes each. These comprised a 10-minute warm-up that included exercises for gait, trunk mobility and exercises involving the upper and lower limbs. The central part of the sessions consisted of 30-40 minutes of strength training and aerobic exercises, both individual and in groups. Each session was performed with a specific intensity goal, in order to end with a cooling down period, comprising 20 minutes of functional exercises based on activities of daily living, balance exercises, facial muscle exercises, proprioceptive exercises, muscle relaxation and stretching.
224189262|NCT04274972|DIAGNOSTIC_TEST|Microbiome evaluation|The oral and rectal microbiome samples will be collected preoperatively. The PDAC tissue from the surgical specimen, the intestinal mucosal tissue from the enteric side of the pancreatic anastomosis, and the bile sample will be collected intraoperatively. On the 30th postoperative day, the oral and rectal samples will be repeated
224189263|NCT01444989|OTHER|AKRQ questionnaire|The AKRQ is an experimental instrument composed of 10 questions that assess quality of life and risk factors
224189264|NCT01444989|OTHER|Skindex-16, DLQI, Skin Health Calculator|These are all previously validated questionnaires
223498873|NCT03494179|DRUG|ICP-022|The drug product is a white, round, uncoated tablet.
223498874|NCT04510168|DRUG|11C-ER176|PET imaging to measure 18kDa translocator protein; target imaging dose of up to 20 millicurie (mCi)
223498875|NCT04510168|DRUG|[F-18]MK-6240|PET imaging to measure tau; target imaging dose of 4 to 5 mCi
223498876|NCT04510168|DRUG|Florbetaben|PET radioligand that binds to amyloid plaques; target-imaging dose of up to 8.1 mCi
223498877|NCT04510168|OTHER|Magnetic Resonance Imaging|Brain MRI
223498878|NCT02852044|BEHAVIORAL|Rest|Allowed to watch television or read for one hour prior to oral glucose tolerance test
223498879|NCT02852044|BEHAVIORAL|Exercise|One hour of cycling at 50% of maximal power output
223590845|NCT03055013|OTHER|Quality-of-Life Assessment|Ancillary studies
223590846|NCT03055013|OTHER|Questionnaire Administration|Ancillary studies
223590847|NCT04459520|BEHAVIORAL|Positive COVID Test Result - Hypothetical Scenario|Participants will be asked to imagine that they have tested positive (PCR) for an active COVID-19 infection and that their physician has clinically diagnosed them with COVID-19.
223590848|NCT04459520|BEHAVIORAL|Negative COVID Test Result - Hypothetical Scenario|Participants will be asked to imagine that they have tested negative (PCR) for an active COVID-19 infection.
223590849|NCT04459520|BEHAVIORAL|Unavailable COVID Test Result - Hypothetical Scenario|Participants will be asked to imagine that testing is not available for active COVID-19 infections but that their physician has clinically diagnosed them with COVID-19.
223590850|NCT06066398|PROCEDURE|medical thoracoscope|Medical thoracoscopy will be performed during which pleural brush will be used first followed by forceps biopsy to obtain pleural specimens from suspect areas under visual control and pleural lavage will be performed by injecting 300 mL of normal saline
223590851|NCT06066398|DIAGNOSTIC_TEST|Forceps biopsy and pleural brush histopathology|Forceps biopsy and pleural brush will be obtained for histopathological examination for diagnosis
223498880|NCT02852044|OTHER|Dorsal Hand Vein Cannulation (heated hand technique)|
223498881|NCT02852044|OTHER|Venous Cannulation|
223498882|NCT00357162|DRUG|belinostat|Given IV
223746094|NCT05821842|DEVICE|Sonu|Acoustic energy delivery
223746095|NCT04703439|BEHAVIORAL|Medication-taking reminders & educational materials|The intervention has been described in arm/group descriptions, which lasted for 60 days for each participants.
223746096|NCT04703439|BEHAVIORAL|Educational materials|The intervention has been described in arm/group descriptions, which lasted for 60 days for each participants.
224189265|NCT04629235|OTHER|wonder around|wonder around after 8 hours of bedrest
224189266|NCT04629235|BEHAVIORAL|bedrest|24 hours of bedrest
224309397|NCT04728009|DIETARY_SUPPLEMENT|Longan and lingzhi mushroom syrup|Fresh fruit pulps of longan were stewed in hot water until they softened. No sugar and additives were added. The pulps were removed by filtration in order to obtain concentrated longan juice. After that, spray-dried powder of lingzhi mushroom extract was dissolved in water in the ratio of 1:2. To make the finished product, 99 g of longan juice was mixed with 1 g of the lingzhi extract in water. The sugar content of the syrup was 77 degrees Brix.
224189267|NCT01668017|DRUG|Pimasertib|Subjects with solid tumor will be administered with Pimasertib 30 mg twice a day (BID) in 21-day cycles until disease progression, intolerable toxicity, investigators decision to discontinue treatment or withdrawal of consent by the subject.
224189268|NCT01668017|DRUG|Pimasertib|Subjects with solid tumor will be administered with Pimasertib 45 mg BID in 21-day cycles until disease progression, intolerable toxicity, investigators decision to discontinue treatment or withdrawal of consent by the subject.
224309398|NCT04058067|DRUG|Brolucizumab|5 x every 6 weeks loading then every 12 weeks or every 8 weeks maintenance
224309399|NCT04058067|DRUG|Aflibercept|5 x every 4 weeks loading then every 8 weeks maintenance
223498883|NCT02738515|DRUG|0.75 % Boric Acid|After Scaling and Root Planing placement of 0.75% Boric Acid gel in Mandibular degree 2 Furcation defect.
223498884|NCT02738515|DRUG|placebo|After Scaling and Root Planing placement of Placebo gel in Mandibular degree 2 Furcation defect.
223498885|NCT00986141|PROCEDURE|Surgery|Selective Laser Trabeculoplasty for glaucoma
223498886|NCT00986141|PROCEDURE|Selective Laser Trabeculoplasty|Glaucoma Treatment
223590852|NCT06066398|DIAGNOSTIC_TEST|pleural lavage cytology|pleural lavage will be obtained for cytological examination for diagnosis
223590853|NCT04036526|BIOLOGICAL|Vaccine GamLPV|live intranasal vaccine for whooping cough prevention
223590854|NCT04036526|OTHER|Placebo|Placebo
224189269|NCT01668017|DRUG|Pimasertib|Subjects with solid tumor will be administered with Pimasertib 60 mg BID in 21-day cycles until disease progression, intolerable toxicity, investigators decision to discontinue treatment or withdrawal of consent by the subject.
224189270|NCT01668017|DRUG|Pimasertib|Subjects with HCC will be administered with Pimasertib 30 mg BID in 21-day cycles until disease progression, intolerable toxicity, investigators decision to discontinue treatment or withdrawal of consent by the subject.
224189271|NCT01668017|DRUG|Pimasertib|Subjects with HCC will be administered with Pimasertib 45 mg BID in 21-day cycles until disease progression, intolerable toxicity, investigators decision to discontinue treatment or withdrawal of consent by the subject.
224309400|NCT00417170|DRUG|Aliskiren|Aliskiren 300 mg tablets taken orally once daily
224309401|NCT00417170|DRUG|Amlodipine|Amlodipine 5 mg capsule taken orally once daily
224309402|NCT00417170|DRUG|Placebo Aliskiren|Placebo Aliskiren taken orally once daily.
224309403|NCT00417170|DRUG|Placebo Amlodipine|Placebo Amlodipine taken orally once daily
223498887|NCT02960789|OTHER|Formalized clinical assessment of hydration status|Undertake and record a standard formalized clinical hydration assessment
223498888|NCT02960789|OTHER|Take a measurement of body weight on calibrated scales|Standard body weight measurements conducted on calibrated scales
223498889|NCT02960789|DEVICE|"RF wristband hydration status measurement"|"Take measurements with RF wristband radio-frequency non-invasive wrist-based hydration status assessment device"
223498890|NCT02960789|OTHER|Measure capillary refill time with manual stopwatch|A standard visual assessment of capillary refill time, aided by the use of a stopwatch
223498891|NCT02960789|DEVICE|"CRT device hydration status measurement"|"Take measurements with CRT device for non-invasively quantitatively assessing Capillary Refill Time"
223590855|NCT00528801|BEHAVIORAL|NP Battery|Neuropsych Battery with 7 different tests that evaluate the patients neurological functioning.
223590856|NCT00528801|PROCEDURE|MRI|The MRI is a standard procedure involving 30 minutes under the machine in order to obtain various images of the patients brain.
223590857|NCT04342078|DIETARY_SUPPLEMENT|Vitamin D|To investigate the effect of one year vitamin D supplementation in preterm born adults (4000 IU = 100 micrograms a day if serum concentration is \< 30 nmol/l, 2000 IU = 50 micrograms a day if 30-50 nmol/l and 1000 IU = 25 micrograms a day if \> 50-80 nmol/l, and no additional supplement if \> 80 nmol/l) on health outcomes (bones, teeth, muscles, heart, lungs) . The target level of vitamin D concentration by every 4 months interval is 80 - 120 nmol/l .(Preterm Adult group)
223590858|NCT06354088|DRUG|Alpelisib 300 mg|All participants will ingest one dose of alpelisib 300 mg (2 x 150-mg overencapsulated tablets) on one of two study admissions.
223590859|NCT06354088|DRUG|Placebo|All participants will ingest one dose of placebo (2 overencapuslated doses of microcrystalline cellulose) on one of two study admissions.
224189272|NCT01880996|OTHER|Tai-chi/Qi-gong|Tai-chi/Qi-gong employs a series of positions and movements that are performed in a slow, flowing manner to help a person concentrate on breathing and motion. The treatments will take place once a week at the Dept. of the Gyneco-oncology and the patients will be instructed to practice tai-chi at home on a daily basis
224309404|NCT01932723|BEHAVIORAL|Lumbar stabilization exercises|The functional lumbar stabilization exercises was performed daily, 10 repetitions each, three times a day for three months consecutively.
224309405|NCT05005312|DRUG|PF-07321332|Tablet
224309406|NCT05005312|DRUG|Ritonavir|PK Boosting agent
224309407|NCT01085123|DRUG|Rapimelt|oral tablet , 2.5 and 5 mg, single dose. 10 mg (2x5 mg) visit 3, 5 mg visit 4, 2.5 mg visit 5.
224309408|NCT01085123|DRUG|[11C]AZ10419369|solution for iv injection. Will be injected within 2 to 5 hours after administration of ZOMIG® Rapimelt
224309409|NCT01283035|DRUG|Akt Inhibitor MK2206|Given PO
224309410|NCT01283035|OTHER|Laboratory Biomarker Analysis|Correlative studies
224309411|NCT06550258|OTHER|Equine-assisted therapy|Hippotherapy is a therapeutic intervention applied by physiotherapists that aims to improve impaired body functions. Hippotherapy is a therapy in which the rider receives stimuli from the horse that stimulate the sensory, neuromotor and cognitive systems during riding and exercise on the back of a horse. Hippotherapy is effective on posture control, balance, gross motor functions and functional performance in children with cerebral palsy.
223498892|NCT03033043|DEVICE|Relay Pro Stent-Graft|Endovascular treatment of an aortic dissection
224189273|NCT05311358|DEVICE|The engineer-built system, video-game based Kinect sensor|There are 3 computer games using Kinect sensor to detect movement of trunk and upper extremities of the children.
224189274|NCT05370235|DRUG|Afamelanotide|Patients will receive afamelanotide every two weeks for twelve weeks and undergo a follow up visit 6 months later.
224189275|NCT05762224|OTHER|Effect of kinesio taping on upper limb lymphedema|Group A received Kinesio taping 2 times a week for 3 weeks to reduce lymphedema and Group B received pressure garments(20-60 mm Hg) for at least 15 to 18 hours per day for 3 weeks
224189276|NCT02744963|OTHER|Free and convenient medicine access|
224189277|NCT02180035|DIETARY_SUPPLEMENT|Symbiotic|6g sachet composition: Lactobacillus paracasei, Lactobacillus rhamnosus, Lactobacillus acidophillus, Bifidobacterium lactis and fructooligosaccharides. Each patient was instructed to consume two sachets per day, one in the morning and another before bedtime, diluted in 100 ml of filtered or boiled water at room temperature. The dietary supplement should be taken every day for 6 months.
224189278|NCT02180035|DIETARY_SUPPLEMENT|Maltodextrin (placebo for symbiotic)|6g sachet of maltodextrin, a complex carbohydrate. Each patient was instructed to consume two sachets per day, one in the morning and another before bedtime, diluted in 100 ml of filtered or boiled water at room temperature. Placebo should be taken daily for 6 months.
224189279|NCT02180035|BEHAVIORAL|Nutritional intervention|Nutritional intervention consists of dietary prescription (nutritional eating plan) for healthy eating based on the Dietary Guidelines for the Brazilian Population and Clinical Manual on Food and Nutrition in HIV-infected Adults Care, both Brazil Ministry of Health guidelines, in addition to nutritional counseling for preexistent clinical conditions.
224189280|NCT04918524|DRUG|Prednisone|5-30mg, po, once per day(Qd) prescribed if needed and adjusted due to patient response
224189281|NCT04918524|DRUG|Hydroxychloroquine|100-200mg, po, twice per day (Bid) prescribed if needed and adjusted due to patient response.
224309412|NCT06550258|OTHER|Traditional Pediatric Physiotherapy|In traditional pediatric physiotherapy, cushions of appropriate hardness were used for proprioceptive input. Stools of different heights were used for sitting, squatting, standing up by holding on and standing, Bobath balls and balance boards were used for balance reactions. Triangular and roll cushions of different hardness were used for weight transfer. Surfaces with different patterns were used for sensory input. The child's wishes and interests were taken into consideration in the selection of materials. The treatment was planned according to the activities that were difficult in daily life and the aim was to transfer the knowledge learned to daily life.
224309413|NCT04182724|DRUG|Camrelizumab, Apatinib and Nab-paclitaxel|Camrelizumab was administered 200mg iv every 2 weeks, Apatinib was administered 250 mg p.o. qd Nab-paclitaxel was administered 125 mg/m2, 150 mg/m2, 175 mg/m2 or 200 mg/m2, iv. q2w
224309414|NCT01194817|DEVICE|High-Flexion Knee Replacement System using Cemented Fixation|
224309415|NCT01194817|DEVICE|High-Flexion Knee Replacement System using Cementless Fixation|
224309416|NCT02955758|BIOLOGICAL|Pembrolizumab|Given IV, 200mg fixed dose, every 3 weeks
223498893|NCT02057991|OTHER|educational intervention|Watch an educational video
223498894|NCT02057991|PROCEDURE|CAM exercise therapy|Watch a mindfulness exercise video
223498895|NCT02057991|OTHER|caregiver-related intervention or procedure|Watch mindfulness exercise video and/or educational video
223498896|NCT02057991|OTHER|questionnaire administration|Ancillary studies
223498897|NCT02057991|OTHER|laboratory biomarker analysis|Correlative studies
223590860|NCT06354088|DRUG|[1-13C] sodium acetate|All participants will receive continuous infusions of \[1-13C\] sodium acetate for up to 23 hours on both study visits in order to quantify de novo lipogenesis (DNL). (non-experimental)
223590861|NCT06354088|DRUG|[6,6-2H2] D-glucose|All participants will receive continuous infusions of \[6,6-2H2\] D-glucose for up to 15 hours on both study visits in order to quantify de novo lipogenesis (DNL). (non-experimental)
224189282|NCT04918524|DRUG|Aspirin|100mg, po, once per day (Qd) prescribed if needed and adjusted due to patient response to 32 weeks of pregnancy. 75mg po, once per day (Qd) to 34 weeks of pregnancy. 50mg po, once per day (Qd) to 36 weeks of pregnancy.
223498898|NCT00357604|DRUG|Ortho Tri-Cyclen (ethinyl estradiol + norgestimate)|Tablets, Oral, 35 mcg of EE + 0.18/0.215/0.25 mg of NGM, once daily, 28 days.
223498899|NCT00357604|DRUG|Ortho Tri-Cyclen LO (ethinyl estradiol + norgestimate) + Atazanavir/Ritonavir for 14 days then Ortho Tri-Cyclen for 7 days|Tablets + Capsules/Capsules, Oral, (25 mcg of EE + 0.18/0.215/0.25 mg of NGM) + 300/100 mg then 35 mcg of EE + 0.18/0.215/0.25 mg of NGM, once daily, 21 days.
223498900|NCT00694343|DRUG|HES 130/0.4 (6%) in sodium chloride (solution for infusion)|500 mL of HES 130/0.4 (6%) and 500 mL Ringer's Lactate Solution
223498901|NCT00694343|DRUG|Ringer's Lactate solution|1000 mL Ringer's Lactate solution
224189283|NCT04918524|DRUG|low molecular weight heparin Enoxaparin|40-60mg, ih, Subcutaneous injection, once per day (Qd) or twice per day (Bid) if needed and adjusted due to patient response.
224189284|NCT02486263|OTHER|Study Arm - acid suppression plus feeding bundle|"* Omeprazole 0.5-1.5 milligrams/kilogram/dose twice a day (BID)~* Total fluid volume restriction (120-140 milliliters/kilogram/day)~* Feeding duration over 30 minutes~* Infant feeds with right side down~* Infant is placed on back following feeds"
224189285|NCT02486263|OTHER|Conventional arm - acid suppression only|-Omeprazole 0.5-1.5 milligrams/kilogram/dose twice a day (BID)
224189286|NCT00004024|BIOLOGICAL|aldesleukin|
224189287|NCT00004024|BIOLOGICAL|autologous tumor cell vaccine|
224189288|NCT00004024|BIOLOGICAL|muromonab-CD3|
224189289|NCT00004024|BIOLOGICAL|sargramostim|
224189290|NCT00004024|BIOLOGICAL|therapeutic autologous lymphocytes|
224189291|NCT00004024|PROCEDURE|surgical procedure|
224189292|NCT00004024|RADIATION|radiation therapy|
224189293|NCT03083613|DRUG|Raltitrexed|Raltitrexed:3mg/m2,iv,d1, Every 3 weeks
224189294|NCT03083613|DRUG|Paclitaxel|Paclitaxel:80mg/m2,iv,d1,d8, Every 3 weeks
224189295|NCT00553319|DRUG|Placebo|Placebo group
224189296|NCT00553319|DRUG|Adderall-XR|Adderall-XR 60mg/day
224189297|NCT00553319|DRUG|Adderall-XR|Adderall-XR 80mg/day
224189298|NCT05321264|BEHAVIORAL|Educational nursing intervention|Four weekly individualized intervention sessions, with a duration of 40 minutes.
224189299|NCT05961514|DIAGNOSTIC_TEST|Target biopsies|MRI/Fusion target biopsies combine magnetic resonance imaging (MRI) with ultrasound-guided biopsy techniques to obtain tissue samples from areas of the prostate gland that appear abnormal on MRI.
223590862|NCT06354088|DIETARY_SUPPLEMENT|Nestlé BOOST Plus|All participants will ingest standardized mixed meals of Nestlé BOOST Plus on Study Day 1 and then smaller portions hourly x 8 hours on Study Day 2 of each study visit. (non-experimental)
224189300|NCT05961514|DIAGNOSTIC_TEST|systemic biopsies|transrectal ultrasound (TRUS) guided prostate systemic biopsies
224189301|NCT03890029|BEHAVIORAL|Intervention Training|After pre-testing and randomization, intervention participants will meet in small groups for 60 minutes/week over eight weeks for resilience training. Participants needing extra help will receive it at the end of each session. Controls will be on a minimal attention list, not being trained. After eight weeks, all participants will be post-tested.
224189302|NCT03890029|BEHAVIORAL|Control Condition|While intervention participants receive resilience training, the control group will not receive training but will receive minimal attention of a bi-monthly telephone call to indicate to participants that they are still enrolled in the study. A monthly flyer will be mailed to them about wellness and PTSD in recent news coverage. Following completion of an intervention group, participants and controls will be scheduled for post-testing that will be identical to the pre-testing and will occur within two weeks after the final treatment session. After the post-testing and 3-month follow up testing, the controls will be offered the resilience training.
224189303|NCT03838692|DRUG|Ponatinib|A daily oral dose at 30 mg.
224189304|NCT01078974|DRUG|pomalidomide|Taken orally once a day
224189305|NCT01078974|DRUG|dexamethasone|Given intravenously on weeks 1, 2, 3 and 4 and weeks 12, 13, 14 and 15
224189306|NCT01078974|DRUG|rituximab|Given intravenously on weeks 1, 2, 3 and 4 and weeks 12, 13, 14 and 15
224189307|NCT01787435|DRUG|Risk of asthma in offspring|"Exposure to PPI or H2RA, respectively during pregnancy~No exposure to acid suppressing drugs during pregnancy"
224189308|NCT01979003|DRUG|Fluorescein|
224189309|NCT00469443|DRUG|Irinotecan|Irinotecan 150mg/m2 IV on day 1 every 2 weeks for 10 cycles
224189310|NCT00469443|DRUG|5-Fluorouracil|5-Fluorouracil 400 mg/m2 infused over 10 min IV and 5-FU 600 mg/m2 infused over 22 hours IV, on Day 1 and 2 (De Grammont regimen), every 2 weeks for 10 cycles
223590863|NCT00344500|BEHAVIORAL|Behavioral Weight Loss Program|"Patients randomized to the behavioral weight loss program (Lifestyle Balance Program) will do the following: -Meet with their psychiatrist and a nutritionist who will go over diet recommendations with the patient~* Be given a 7% weight loss goal~* Be assisted in obtaining a 500 calorie reduction per day~* Exercise for at least 30 min/day, at least 5 days a week~* Maintain weekly food and exercise diaries~* Be quizzed on their knowledge of healthy eating habits and nutrition"
223590864|NCT02207491|DRUG|Timolol maleate Ophthalmic Solution 0.5% BID|1 drop BID, AM/PM, OU
223590865|NCT02207491|DRUG|AR-13324 Ophthalmic Solution 0.02%|1 drop once daily (QD), PM, OU
223590866|NCT02207491|OTHER|Placebo|1 drop QD, AM, OU
223590867|NCT04776863|DEVICE|optical biometry measurement|The measurements of the individuals using smokeless tobacco and those who do not were taken by optical biometry.
224189311|NCT00469443|DRUG|Leucovorin|Leucovorin 200 mg/m2 infused over 2 hours IV, on day 1 and 2 every 2 weeks for 10 cycles
224189312|NCT00469443|DRUG|Capecitabine|Capecitabine 2000mg/m2 p.o. daily, for days 1-14, every 3 weeks for 6 cycles
224189313|NCT00469443|DRUG|Bevacizumab|Bevacizumab 5mg/kg IV on day 1 every 2 weeks for 10 cycles
224309417|NCT06633939|BEHAVIORAL|Behavioral Treatment|The theoretical framework for the Move \&amp; Eat 2 Live intervention is guided by the health belief model (HBM), socioecological model (SEM) and motivational interviewing (MI) approach. Tailoring to the target community will include a standard cultural adaptation that will replace curriculum content and examples with Native American relevant foods, physical activities, and representation in materials. For this study, the intervention will be piloted in the target population and will include the first 5 sessions of the original 12-session program.
223590868|NCT05921838|OTHER||
223590869|NCT01958983|BEHAVIORAL|Music Therapy Group Session|
224189314|NCT00469443|DRUG|Bevacizumab|Bevacizumab 7,5mg/kg IV on day 1 every 3 weeks for 6 cycles
224189315|NCT00469443|DRUG|Irinotecan|Irinotecan 250mg/m2 IV on day 1 every 3 weeks for 6 cycles
224189316|NCT01299636|DRUG|PM060184|PM060184 administered intravenously (i.v.) over 10 minutes at a starting dose of 4 mg/m2/day on three consecutive days q2w (on Days 1-3 and 15-17) every 28 days.
224309418|NCT01890135|DRUG|Zibotentan (ZD4054)|10 mg
224309419|NCT01890135|DRUG|placebo|randomized double blind
224309420|NCT04530435|DEVICE|PEP flute|Participants are advised to use a PEP flute at least three times daily at an appropriate resistance. Ideally, each session consists of 15 breaths (for approximately 1 minute) repeated twice at an upright position.
224309421|NCT02083718|BIOLOGICAL|PBSC|
224309422|NCT02083718|BIOLOGICAL|MSCs|
224309423|NCT01680003|DRUG|Hepar-P|
224309424|NCT01680003|DRUG|Placebo for Hepar-P|
224309425|NCT06363903|DIAGNOSTIC_TEST|mesh allergy test|a 5 mm\^2 part of polypropylene mesh will be dissolved in 1 mL Methyl ethyl ketone (MEK), 25 microliters of this solution will be topically applied in a Finn chamber, and a reaction to the topical applicant will be assessed within 48 hours after application.
224309426|NCT06363903|DIAGNOSTIC_TEST|blood tests|Blood tests for diagnosis of autoimmune diseases will be performed
224309427|NCT06363903|PROCEDURE|Mesh removal|If wish for mesh removal persists, this procedure can be performed after separate informed consent (within the study), as standard practice of care.
224309428|NCT00867503|DRUG|Bendamustine HCL|bendamustine HCL 90 mg/m2 intravenously on days 1(± 1 day) and 2 (± 1 day) every 28 days. If no grade ≥3 hematologic adverse event appears the dose will be escalated to 120 mg/m2 on days 1(± 1 day) and 2 (± 1 day) every 28 days at cycle 2.
224309429|NCT05847803|OTHER|No intervention, questionnaire survey|No intervention, questionnaire survey
224309430|NCT02704403|DRUG|Elafibranor|
224309431|NCT02704403|DRUG|Placebo|
223590870|NCT06208995|OTHER|36-Item Short Form Survey Instrument (SF-36)|Answering 36 questions in a quality-of-life survey (RAND 36-Item Health Survey 1.0): https://www.rand.org/health-care/surveys\_tools/mos/36-item-short-form/survey-instrument.html
223590871|NCT05977764|OTHER|Ultrasound|Contrast enhanced ultrasound
223590872|NCT04738942|DRUG|Vedolizumab|Vedolizumab 300 mg, IV infusion
223590873|NCT04606095|DIAGNOSTIC_TEST|EEG|EEG with QST (evoked Pain and Visual Stimulation Assessment)
223590874|NCT04606095|DIAGNOSTIC_TEST|Neuroimaging EEG/fMRI (Aim 1)|This will be done to monitor areas of the brain that are involved in thinking and processing pain. The scanner stimulates the brain to send out signals that will be recorded and analyzed. Additionally, during the MRI the participants brain's electrical activity with will be measured with an EEG machine for part of the MRI. About halfway through the scan, participants will have the EEG equipment removed and then will return to the fMRI scanner for a few additional scans.
223590875|NCT04606095|DEVICE|HD-tDCS treatments|HD-tDCS treatments (5 active and 5 sham)
223590876|NCT04606095|DEVICE|Sham HD-tDCS treatments|HD-tDCS treatments (5 active and 5 sham)
223590877|NCT04606095|DIAGNOSTIC_TEST|Neuroimaging EEG/fMRI (Aim 3)|This will be done to monitor areas of the brain that are involved in thinking and processing pain. The scanner stimulates the brain to send out signals that will be recorded and analyzed. Additionally, during the MRI the participants brain's electrical activity with will be measured with an EEG machine for part of the MRI. About halfway through the scan, participants will have the EEG equipment removed and then (for participants prior to January 2025) will return to the fMRI scanner for a few additional scans.
224189317|NCT01353521|PROCEDURE|Contrast-enhanced ultrasound|A contrast-enhanced ultrasound utilizes intravenous gas-filled microbubbles to enhance visualization in real time.
223590878|NCT06570161|DEVICE|SEEUS95 Transparent mask|SEEUS95 developed transparent filtering mask
223590879|NCT06570161|DEVICE|CrystalGuard Mask|CrystalGuard transparent mask
223590880|NCT06570161|DEVICE|N95 face mask|Standard N95 style face mask
223590881|NCT06572124|PROCEDURE|universal adhesive without Acid resistant silane coupling agent|After cavity preparations, enamel margins will be etched for 30 seconds then rinsed and dried, then the Universal adhesive without acid resistant silane coupling agent will be actively applied for 20 seconds then air thinned for 5 seconds then cured for 20 seconds.Then the composite restoration will be placed.
223590882|NCT06572124|PROCEDURE|universal adhesive with Acid resistant silane coupling agent|After cavity preparations, enamel margins will be etched for 30 seconds then rinsed and dried, then the Universal adhesive which contains acid resistant silane coupling agent will be actively applied for 20 seconds then air thinned for 5 seconds then cured for 20 seconds.Then the composite restoration will be placed.
223590883|NCT05457868|DRUG|Salbutamol|Salbutamol claim is used as the exposure group.
223590884|NCT05457868|DRUG|LAMA|Long-acting muscarinic antagonists (LAMA) - umeclidinium, aclidinium, tiotropium, glycopyrolate, glycopyrronium - claim is used as the reference group.
223590885|NCT00599755|RADIATION|Comparator: CT or MRI and FDG-PET|Participants have 4 computed tomography (CT) or magnetic resonance imaging (MRI) scans at screening, baseline, at the end of each treatment cycle (day 21 and day 42.) They also have FDG-PET scans, 2 at Baseline and one at the end of each treatment cycle.
223590886|NCT00599755|DRUG|Gemcitabine and Cisplatin or Gemcitabine and Carboplatin|Gemcitabine administered intravenously at a dose of 1000-1250 mg/m\^2 on Day 1 and Day 8 of each cycle; Cisplatin administered intravenously at a dose of 60-85 mg/m\^2 or Carboplatin at a dose of 4-6 Area Under the Curve (AUC) on Day 1 of each cycle. Two cycles are given 3 weeks apart.
223590887|NCT06761170|PROCEDURE|Spray cryo therapy|normal flow, 5 seconds repeated for 3-5 cycles
223590888|NCT06761170|PROCEDURE|Standard of Care (SOC)|"1. Steroid injection~2. Radial mucosal incision~3. Balloon dilation (to normal airway diameter)"
223590889|NCT05092282|DEVICE|Head and Intraocular Trauma Tool|HITT device to scan eyes of participants up to 3 times (\~45 seconds each) at time of admittance to study. Participant is to place chin in chin-rest and fixate on illuminated light on device.
223590890|NCT05092282|DIAGNOSTIC_TEST|SCAT-5|Participant is to complete Step 2 (Symptom Evaluation) and Step 3 (Cognitive Screening) of SCAT-5 test.
223590891|NCT05364502|DEVICE|Embrace HES including Instylla™ Delivery Kit and Instylla™ Microcatheter|The Embrace Hydrogel Embolic System (HES) is indicated for embolization of peripheral arterial bleeds in vessels ≤6mm
223590892|NCT01107223|OTHER|Experimental: Training to antibiotic prescription|GPs assigned to the intervention group attended a two days didactic educational meeting on evidence-based guidelines for diagnosis and treatment of acute respiratory tract infection.
223590893|NCT01107223|OTHER|No education on antibiotic prescription rules.|GPs assigned to control group received no specific recommendations on antibiotic prescription.
223590894|NCT05333549|DRUG|Istradefylline medication|2 weeks on istradefylline 20mg daily, 2 weeks on istradefylline 40mg with the ability to adjust other antiparkinsonian medications, and 22 weeks on istradefylline 40mg and stable antiparkinsonian medications
223590895|NCT04985669|DRUG|Prucalopride 2mg|one group of patient will receive prucalopride once daily one group of patient will receive lubiprostone twice daily
224189318|NCT03364114|DEVICE|EndoRotor Mucosal Resection System|The EndoRotor® Endoscopic Mucosal Resection System is an automated mechanical endoscopic mucosal resection system for use in the gastrointestinal tract for benign neoplastic or pre-malignant tissue removal by interventional gastroenterologists and GI surgeons. The EndoRotor® System performs both tissue dissection and resection with a single device through an endoscope's instrument biopsy channel.
223590896|NCT01610986|DIETARY_SUPPLEMENT|Glucose-fructose|0.8 g/h glucose and 0.5 g/h fructose during training
223590897|NCT01610986|DIETARY_SUPPLEMENT|Water|Only water intake during training
223590898|NCT01701934|DRUG|Roflumilast|500 mcg, oral, once daily for 6 months
224189319|NCT03364114|DEVICE|Continued Ablation|Continued ablation control shall include either cryotherapy or continued radial frequency ablation.
224189320|NCT01641523|DEVICE|CustomBone Service|customized hydroxyapatite cranial prosthesis
224189321|NCT05677906|OTHER|Walking only (Step It Up!)|Participants will meet weekly for 60 minutes and walk together as a group. Participants will progressively build up to walking for 45 minutes at a brisk pace. Walks will start with a check-in and end with stretching as a group.
224205806|NCT03447054|BEHAVIORAL|Combined TDCS active and ICT inactive|Five 20-minute long sessions including TDCS sham and no-cue inhibition training, 5 consecutive days
224189322|NCT05677906|OTHER|Combined (Step It Up! plus Civic Engagement)|Participants in the combined groups will meet weekly for 90 minutes with group members. They will participate in a group walk for 60 minutes followed by 30 minutes of civic engagement aimed at improving walkability in the community
224189323|NCT03575975|DEVICE|Total Ankle Replacement Prosthesis|Comparison of functional range of motion in users of Stryker Scandinavian Total Ankle Replacement (STAR) prosthesis to users of INBONE 2 Total Ankle Replacement prosthesis and to matched controls with intact ankle joints.
224189324|NCT02220608|BIOLOGICAL|Bortezomib|
223498902|NCT06139640|OTHER|Damask Rose Essential Oil|Aromatherapy is a relaxation therapy media that uses aromatic essence extracts from plant parts. Aromatherapy is used to treat and improve physical and psychological health
223590899|NCT01701934|DRUG|Placebo|One placebo pill daily, for 6 months
223590900|NCT03502902|DRUG|HEC 68498|HEC68498 is a potent,highly selective inhibitor of class 1 isozymes of phosphoinositide 3-kinase/mammalian(PI3K) and of the mammalian target of rapamycin (mTOR). It has shown good activity against fibrosis and inflammation in vitro and in vivo, with a lower effective dose and better efficacy than pirfenidone and nintedanib.
223590901|NCT03502902|DRUG|Placebo|Placebo
223590902|NCT01364740|DEVICE|PMP-300E|Data collected from Level 3 device
223590903|NCT01364740|DEVICE|In-lab PSG|Data collected from Type I In-Lab Polysomnography
223590904|NCT02229929|DRUG|Part A: Placebo|Part A: Single i.v. dose of Placebo administered after each dialysis session over a 1 week treatment period (3 times per week)
223590905|NCT02229929|DRUG|Part A: CR845 0.5 mcg/kg|Part A: Single i.v. dose of CR845 administered after each dialysis session over a 1 week treatment period (3 times per week)
223590906|NCT02229929|DRUG|Part A: CR845 1.0 mcg/kg|Part A: Single i.v. dose of CR845 administered after each dialysis session over a 1 week treatment period (3 times per week)
223590907|NCT02229929|DRUG|Part A: CR845 2.5 mcg/kg|Part A: Single i.v. dose of CR845 administered after each dialysis session over a 1 week treatment period (3 times per week)
224189325|NCT02220608|DRUG|G-CSF|
224189326|NCT04801615|OTHER|Surgery|All patients in the database undergo surgery due to a suspicion of necrotizing soft tissue infections
224189327|NCT05191615|BEHAVIORAL|Job crafting training|"Consists of two main parts. In the first part, both managers and employees will be trained in the principles of SDT and JD-R. For managers, particular attention will be paid to the provision of need support and work values. For employees, particular attention will be paid to employees' opportunities for job crafting and promoting their basic psychological need satisfaction at work.~In the second part of the intervention, participants will have the opportunity to discuss their current health status and receive preventive health recommendations from a preventive care specialist."
224189328|NCT02768428|OTHER|Video-Audio Media|each arm spends 15 mins for watching the video or study the handbooks
224189329|NCT02651311|OTHER|intermediate cervical plexus block|ultrasound guided intermediate cervical plexus block with 0.25% ropivacaine 0.2 ml/kg
224189330|NCT02651311|DRUG|Fentanyl|fentanyl 0.5 µg/kg in postanesthetic care unit when more or equal to FLACC scale 4.
224189331|NCT02651311|DRUG|Ibuprofen|ibuprofen in ward when more or equal to FLACC scale 4.
223498903|NCT01124474|OTHER|goal directed therapy|Pulse contour waveform analysis derived stroke volume variation will be used to guide intraoperative fluid administration. Additional fluid boluses will be given to the patient when SVV\>12%.
223498904|NCT03608085|BEHAVIORAL|Pharmacist Heart failure MTM training|"The MTM training for pharmacists will consist of:~1. Online material for home self-study (10 contact hours);~2. Didactic coursework to obtain a national American Pharmaceutical Association (APhA) MTM certification (8 contact hours); and HF pharmacotherapy (4 contact hours);~3. 1 60-minute sessions of point of care training in the community pharmacy practice lab setting by URI faculty;~4. Monthly coaching conference calls/webinars with URI and Brown Faculty;"
223498905|NCT03608085|BEHAVIORAL|Patient Heart failure MTM intervention|"The baseline visit will take place \>= 7 but \<= 30 days post discharge from the HF hospitalization. Follow-up visits will occur either in person at the patients local pharmacy or via telephone at 30, 60, 90 and 120 days post baseline and will consist of the following:~Preparation: Develop personal medication record (PMR). Assessment: Medication therapy reconciliation; Education: Review heart failure basics and behavioral goals Planning: Documentation of a medication related action plan and identify medication related problems Implementation: Communication of medication related action plan and changes in heart failure symptoms to the patients providers.~Follow up: Monitor and evaluate the care plan in collaboration with the patient's providers."
223498906|NCT01422447|OTHER|regular intervention|the subjects in the control group live in the used model
223498907|NCT01422447|OTHER|community intervention|in addition to regular intervention, those subjects in the intervention group will be given education intervention.
223498908|NCT04656665|DRUG|Aspirin|For patients at high risk of pre-eclampsia, start taking aspirin from 12-20 weeks of pregnancy
223498909|NCT05003999|DEVICE|HPC - SpeediCath ®|The investigators measure the time taken to perform intermittent catheterization using a 13 step pre-determined intermittent catheterization protocol using a hydrophilic catheter
223498910|NCT05003999|DEVICE|Non-HPC - Self-Cath ®|The investigators measure the time taken to perform intermittent catheterization using a 13 step pre-determined intermittent catheterization protocol using a non-hydrophilic catheter; Lubrication jelly (MUKO ®, 3.5g package, Cardinal Health Canada Inc, Toronto, ON, Canada) was provided
223498911|NCT00924482|DEVICE|Placed ECOM endotracheal cardiac output monitor in patients undergoing cardiac surgery|Measure cardiac output during perioperative period and compare to pulmonary artery thermodilution cardiac output measurements.
223498912|NCT04508985|OTHER|Temporarily holding the RAAS inhibitor [intervention]|Temporarily holding the RAAS inhibitor. Among participants who will be randomized to the intervention arm, a possible guideline-directed alternative to anti-hypertensive medication alternatives will be provided to the treating physician team.
223498913|NCT04508985|OTHER|RAAS inhibitor [continued standard of care]|No intervention, Continuation RAAS inhibitor \[continued standard of care\].
224189332|NCT01962272|BEHAVIORAL|Weekly nutritional counseling|The counseling included assessment of food intake, advice about improvement, motivation and specific food plans, as well as motivation to comply to the recommended dose of Forticare®.
224189333|NCT01962272|DIETARY_SUPPLEMENT|Forticare®.|
223498914|NCT00515190|DRUG|S-1,oxaliplatin|"Arm A (continuous arm): S-1 80mg/m2/d p.o. twice daily(q 12-h)on D1(evening)-D15(morning)plus oxaliplatin 130mg/m2 IV(in the vein)on D1 every 3 weeks, until disease progression, unacceptable toxicity, or consent withdrawal.~Arm B (intermittent arm):Treatment will be stopped after the initial 6 cycles of S-1 plus oxaliplatin, and then S-1 plus oxaliplatin will be resumed at the disease progression during follow-up, as the same dose as the last chemotherapy of initial 6 cycles."
224189334|NCT05768360|DRUG|Savolitinib|The subjects will receive single dose of oral film-coated tablet of Savolitinib A dose on Day 1 of Period 2 within 25 minutes \[+ 5 minutes\] from the start of meal.
224189335|NCT05768360|DRUG|Digoxin|The subjects will receive single dose of oral uncoated tablet of Digoxin Dose B on Day 1 of Period 1 and Period 2 within 25 minutes \[+ 5 minutes\] from the start of meal.
223498915|NCT01948778|DEVICE|oXiris™ filter|
223590908|NCT02229929|DRUG|Part B: Placebo|Part B: Single i.v. dose of Placebo administered after each dialysis session over a 2 week treatment period (3 times per week)
223590909|NCT02229929|DRUG|Part B: CR845 1.0 mcg/kg|Part B: Single i.v. dose of CR845 administered after each dialysis session over a 2 week treatment period (3 times per week)
223590910|NCT04706156|BIOLOGICAL|COVID-19 Vaccine|Receiving coronavirus disease (COVID-19) vaccine e.g. Pfizer-BioNTech, Moderna, Oxford/AstraZeneca, or Sinovac COVID-19 Vaccine
223590911|NCT05899972|OTHER|Placebo technique|With the volunteer in a supine position, the researcher placed the palms of their hands on the patient's shoulders. The contact is made with the hands on the shoulder blades of the volunteer for 6 minutes.
223590912|NCT05899972|OTHER|Suboccipital inhibition technique|With the volunteer in a supine position, the investigator is sitting position at the patient's bedside. The investigator starts by placing both hands under the patient's head in the occipital region. After palpating the suboccipital muscles, the investigator uses the second, third and fourth fingers of both hands flexed against the muscle belly and remains in this position.
223590913|NCT05899972|OTHER|Frontal lift technique|With the volunteer in a supine position, the investigator is sitting position at the patient's bedside. The investigator positions the tips of both index fingers on either side of the metopic suture while the third finger remains resting on the frontal bone so that the tips of the fourth fingers contact the zygomatic processes bilaterally. A slight pressure is applied with the index fingers and an anterior pressure is performed.
223590914|NCT05899972|OTHER|Parietal lift technique|With the volunteer in a supine position, the investigator is sitting position at the patient's bedside. The investigator places the palms on the lateral edges of the parietal bones and the thumbs crossed at the sagittal suture. First, a medial pressure is administered with the second, third and fourth fingers and then a cephalic traction is performed.
223590915|NCT05899972|OTHER|IV ventricle technique|With the volunteer in a supine position, the investigator is sitting position at the patient's bedside. The investigator positions his hands in a shell and thumbs together at the level of the spinous apophyses of the patient's second or third cervical vertebra.
223590916|NCT00385749|DEVICE|RV apical vs RV septal defibrillation threshold testing|
223590917|NCT01966224|BIOLOGICAL|CryJ2-DNA-LAMP plasmid vaccine by intramuscular injection|"Immunomic Therapeutics Inc. CryJ2-DNA-LAMP vaccine is a frozen product formulated in physiological saline and contains no preservative. The study product is packaged in a 1 ml volume in a 3 ml glass vial, with label complying with FDA requirements.~Subjects will receive CryJ2-DNA-LAMP plasmid vaccine by intramuscular injection. The dosing regimen for the groups will be to receive one re-vaccination dose."
223590918|NCT02219373|DRUG|Gabapentin|Patients will be randomized to receive either Gabapentin or Oxcarbazepine. The assignment of the medications will be randomized and blinded to both the study investigators and the patient. If patients exhibit \>30% pain reduction on receiving the medication evaluated after 4 weeks, then they may continue to receive either the same medication or placebo. If patients exhibit \<30% pain reduction, the patient will crossover to the other medication option in the protocol.
223590919|NCT02219373|DRUG|Oxcarbazepine|Patients will be randomized to receive either Gabapentin or Oxcarbazepine. The assignment of the medications will be randomized and blinded to both the study investigators and the patient. If patients exhibit \>30% pain reduction on receiving the medication evaluated after 4 weeks, then they may continue to receive either the same medication or placebo. If patients exhibit \<30% pain reduction, the patient will crossover to the other medication option in the protocol.
223590920|NCT02219373|OTHER|Placebo|Patients taking placebo will have placebo dose escalated using similar frequency, periods of time, and volumes as those for the active drugs.
224189336|NCT05768360|DRUG|Metformin Hydrochloride|The subjects will receive single dose of oral film-coated tablet of Metformin Hydrochloride Dose D on Day 1 of Period 1 and Period 2 within 25 minutes \[+ 5 minutes\] from the start of meal.
224189337|NCT05768360|DRUG|Rosuvastatin|The subjects will receive single dose of oral film-coated tablet of Rosuvastatin Dose E on Day 1 of Period 1 and Period 2 within 25 minutes \[+ 5 minutes\] from the start of meal.
224189338|NCT05768360|DRUG|Furosemide|The subjects will receive single dose of oral solution of Furosemide Dose C on Day 1 of Period 1 and Period 2 within 25 minutes \[+ 5 minutes\] from the start of meal.
224189339|NCT00720291|DRUG|Metronidazole|Patients who are randomly assigned to receive Metronidazole will receive 500 mg po bid Metronidazole for 7 days
224189340|NCT00720291|DRUG|Placebo|Patients who are randomly assigned to receive a placebo will receive a placebo pill po bid for 7 days.
223498916|NCT01948778|DEVICE|Toraymyxin Filter|
223498917|NCT01948778|DEVICE|Standard of Care|
223498918|NCT05205395|DIAGNOSTIC_TEST|Transperineal ultrasound|Ultrasonography was used with curved linear-array transducer placed between the major labia and underneath the external urethral orifice. The measurement was done on the midsagittal plane to obtain the image of pubic symphysis, urethra, and bladder in a view. Ultrasonic measurement of the overall rest-stress distance was define as the linear distance of bladder neck position change from resting status to maximal strain.
223590921|NCT06385054|DIETARY_SUPPLEMENT|Probiotic|Participants will be taking 1 sachet a day, at a similar time every day, dissolved in 10 ml of lukewarm water.
224189341|NCT00495794|BEHAVIORAL|Clinical pharmacist-based intervention|Pharmacist proactive outreach to patients systematically identified as having adherence or intensification problems; their use of tailored adherence counseling strategies; and their authorization to titrate medications according to prespecified algorithms
223590922|NCT06385054|DIETARY_SUPPLEMENT|Placebo|Participants will be taking 1 sachet a day, at a similar time every day, dissolved in 10 ml of lukewarm water.
223590923|NCT05937789|DIETARY_SUPPLEMENT|Vitamin D3|Dose of vitamin D3 depends on participant's serum 25(OH)D levels, with one sample bottle contains 72,000 IU of vitamin D3; Intervention starts on ICU day 3 with a frequency of 1 ampule every 3 hours and is completed within the following 48 hours
224189342|NCT06089226|OTHER|Assessment Group|In our prospectively planned study, patients who meet the inclusion criteria will be evaluated by the researcher via face-to-face interview method and the evaluations specified in the outcome measurements. Patients participating in the study will first be given a general explanation about the purpose of the study and evaluation methods, and their written consent will be obtained.
224189343|NCT06249074|OTHER|Gluten-free diet|Diet with gluten elimination followed by all participants for 8 weeks
224189344|NCT06249074|OTHER|Gluten capsules supplementation|2 g of gluten given in 3 capsules daily for 4 weeks (week 5 to week 8)
224189345|NCT06249074|OTHER|Placebo capsules supplementation|Rice starch in gastrosoluble capsules given in 3 capsules daily for 4 weeks (week 5 to week 8).
224189346|NCT03405324|DEVICE|tDCS|a single session of tDCS over the primary motor cortex with constant current of 2mA intensity will be applied for 20 minutes with a 5-second ramp phase at the beginning.
224189347|NCT03405324|DEVICE|sham tDCS|sham tDCS
224189348|NCT04778696|PROCEDURE|PASO Pacemapping|Using the PASO pacemapping visualisation module of CARTO3
224189349|NCT04778696|PROCEDURE|Conventional Pacemapping|without visualisation in 3D mapping
224189350|NCT05577572|DIETARY_SUPPLEMENT|Probiotics packets|The treatment period is designed for 56 days: Bismuth containing quadruple therapy is performed from day 1\~10 and Probiotics packets is taken from day 1\~56.
224189351|NCT05577572|DIETARY_SUPPLEMENT|Placebo packets|The treatment period is designed for 56 days: Bismuth containing quadruple therapy is performed from day 1\~10 and Placebo packets is taken from day 1\~56.
224189352|NCT00396864|DRUG|NPI-0052|NPI-0052 IV injection at doses ranging from 0.0125 to 0.8 mg/m2 over 1 to 10 minutes on Day 1, Day 8, Day 15 of each 28-day Cycle; 11 dose cohorts during dose-escalation
224189353|NCT05910606|BEHAVIORAL|Digital Exercise|Fall Prevention Program: Our fall- risk reduction program overs digitally delivered exercise with real time feedback from expert instructors.
224189354|NCT04810806|PROCEDURE|Immediate coronary angiography within 2 hours after randomization|After achievement of informed consent in patients with NSTE-ACS complicated by ADHF, patients will be screened and randomized. Patients will be randomized to immediate CAG group or delayed CAG group. Immediate CAG group will receive CAG within 2 hours after randomization. Patients will receive treatment methods according to CAG results: percutaneous coronary intervention (PCI), coronary artery bypass graft (CABG) or medical therapy only by operators' discretion.
224189355|NCT04810806|PROCEDURE|Delayed coronary angiography after stabilization of heart failure|After achievement of informed consent in patients with NSTE-ACS complicated by ADHF, patients will be screened and randomized. Patients will be randomized to immediate CAG group or delayed CAG group. Delayed CAG group will receive CAG after stabilization of ADHF; improvement of symptoms and signs of heart failure. Patients will receive treatment methods according to CAG results: percutaneous coronary intervention (PCI), coronary artery bypass graft (CABG) or medical therapy only by operators' discretion.
223590924|NCT05937789|DIETARY_SUPPLEMENT|Medium Chain Triglycerides (MCT)|Dose of MCT depends on participant's serum 25(OH)D levels, with one sample bottle contains 5 cc. of MCT; Intervention starts on ICU day 3 with a frequency of 1 ampule every 3 hours and is completed within the following 48 hours
224189356|NCT02160509|DEVICE|IPhone based realtime remote ultrasound interpretation|
224189357|NCT03380806|DRUG|LHRH agonist|Standard LHRH agonist for 3 years
224189358|NCT03380806|RADIATION|Pelvic Radiation|Pelvic Radiation
224189359|NCT03380806|RADIATION|Stereotactic Body Radiotherapy (SBRT)|SBRT: 19.5 - 21 Gy in three fractions (1 treatment per week - over 22days)
224189360|NCT03380806|RADIATION|Conventional Radiotherapy (CRT) Prostate Boost|CRT: 33 - 35 Gy in 16 fractions (5 days per week - over 22 days)
224189361|NCT01183299|OTHER|Dietary salt intake|
224189362|NCT01996956|OTHER|volume expansion|fluid loading of 10 ml/kg colloid or blood product
224189363|NCT01791088|DRUG|sirolimus|Given PO
224189364|NCT01791088|OTHER|pharmacological study|Correlative studies
223498919|NCT03010865|DRUG|Sodium Butyrate|Sodium butyrate is being supplied by T.E. Neesby (Brain White, T.E. Neesby, Inc.) in 730 mg capsules. The company asserts that their material is 98% pure and food grade. We will have identical placebo capsules. Subjects will receive 3 capsules twice daily (morning and late afternoon or evening) for a total of 4380 mg/day.
223498920|NCT03010865|DRUG|Placebo Oral Capsule|Placebo Oral Capsule is also being supplied by T.E. Neesby (Brain White, T.E. Neesby, Inc.) and there is no difference from appearance, smell and taste. It contains 1.5 mg sodium butyrate per capsule. Subjects will receive 3 capsules twice daily (morning and late afternoon or evening) for a total of 9 mg/day.
223498921|NCT00243061|DRUG|cediranib maleate|Given orally
223498922|NCT00875667|DRUG|Lenalidomide|"For patients with a creatinine clearance of ≥ 60 mL/min: 25 mg daily x 21 days of a 28 day cycle until disease progression or unacceptable toxicity.~For patients who have a moderate renal insufficiency (creatinine clearance is ≥ 30 mL/min but \< 60mL/min: 10 mg daily x 21 days of a 28 day cycle (Cycles 1 and 2). After Cycle 2, if the patient remains free of Grade 3 or Grade 4 toxicity, the dose will be increased to 15 mg daily x 21 days of a 28 day cycle until disease progression or unacceptable toxicity."
223498923|NCT00875667|DRUG|Investigators choice single agent|Investigators choice single agent - Chlorambucil, Rituximab, Cytarabine, Gemcitabine, or Fludarabine
223498924|NCT03751787|OTHER|cranial osteopathy|two sessions at three weeks intervals
223498925|NCT03751787|OTHER|comfort massage|manipulation, comfort massage, standardized and not affecting the skull
223498926|NCT04241523|DRUG|Lenvatinib 4 mg Oral|"Planned doses of 8 mg of lenvatinib per day for patients with body weight \<60 kg, and 12 mg for those with body weight ≥60 kg.~In case of treatment-related adverse effects, interruption or reduction is allowed."
223498927|NCT00894647|DRUG|imiquimod cream|Imiquimod 3.75% cream (250 mg/packet) up to 2 packets applied daily Two 2-week treatment periods (Cycle 1 and Cycle 2) separated by a 2-week no-treatment period
223498928|NCT00894647|DRUG|placebo cream|cream applied once daily for two 2-week treatment periods (Cycle 1 and Cycle 2) separated by a 2-week no-treatment period
224189365|NCT01791088|OTHER|laboratory biomarker analysis|Correlative studies
224189366|NCT01406509|BIOLOGICAL|0.5ml/dose for a person|group A, C polysaccharide meningococcal and type b haemophilus Influenzal Conjugate vaccine of 0.5ml/dose for a person, on day0
224189367|NCT01406509|BIOLOGICAL|0.5ml/dose for a person|group A, C polysaccharide meningococcal and type b haemophilus Influenzal Conjugate vaccine of 0.5ml/dose for a person, on day0, 28
224189368|NCT06113276|RADIATION|Low dose computed tomography to evaluate biomechanical parameters in the lung|In the participating to the study, response to PEEP increase and tidal inflation are evaluated with a software computing biomechanical parameters (tidal hyperinflation and lung recruitability). Tidal hyperinflation and recruitment are computed on CT images acquired within 72 hours after ARDS onset or with 72h after ECMO onset.
224189369|NCT02902276|OTHER|additional blood sample|Two blood samples will be taken at ICU admission
224189370|NCT03491527|PROCEDURE|Absolute isolation|Absolute isolation with rubber dam
223498929|NCT01913470|DRUG|Losartan|Oral tablet to be taken once daily at 0.4mg/kg/day (max 25mg) for one week and then increased to 0.8mg/kg/day (max 50mg) for 7 additional weeks.
223498930|NCT00412451|DRUG|ocriplasmin|Intravitreal injection, single administration
223498931|NCT00412451|OTHER|Sham injection|Sham intravitreal injection
223590925|NCT06043908|DRUG|artificial tear eyedrops|The intervention group and control group were treated with artificial tear eyedrops four times a day.
223590926|NCT06043908|DRUG|0.05% cyclosporine eyedrops|The intervention group was treated twice a day.
223590927|NCT03720288|DRUG|Acetazolamide|Patient will follow the treatment according to inclusion sequence, receiving the corresponding number medication.
223590928|NCT03720288|DRUG|Placebo|Patient will follow the treatment according to inclusion sequence, receiving the corresponding number medication.
223590929|NCT04262076|OTHER|Pulpine with Polyamidoamine Dendrimer|Removal of infected dentin in class I Cavities followed by application of Polyamidoamine Denrimer on caries affected Dentin that is washed out of the cavity after 30 secs then finally place Pulpine .
223590930|NCT04267081|DRUG|Venetoclax|Ex vivo venetoclax sensitivity testing is used for patient selection.
223590931|NCT06480695|DIETARY_SUPPLEMENT|Nitrate-Rich Beetroot Juice|subjects will consume 1 bottle of nitrate-rich beetroot juice (\~400mg of nitrate each) 2x a day
223590932|NCT06480695|BEHAVIORAL|High Intensity Exercise|exercise at an intensity midway between the lactate threshold and VO2peak, from the screening test at an RPE of \~ 15-17
224189371|NCT03491527|PROCEDURE|Manipulation of the resin cement with MTA|Manipulation of the resin cement with MTA according to the manufacturer's recommendations.
224189372|NCT03491527|PROCEDURE|Manipulation of the resin cement without MTA|Manipulation of the resin cement without MTA according to the manufacturer's recommendations.
224189373|NCT03491527|PROCEDURE|Fiber Post cimentation|Insertion of the cement on the root canal and on post surface. Light-cured for 40 seconds on each surface.
223498932|NCT02950584|OTHER|Titanium dioxide denture|Patients will receive titanium dioxide denture (made from acrylic resin with titanium dioxide nanoparticles) for 1 month in the initial phase then in the second phase after one month they will receive (rapid heat cured acrylic resin)denture according to the principle of crossover design
223498933|NCT02950584|OTHER|Rapid heat denture|Patients will receive rapid heat denture for 1 month in the initial phase of the trial then in the later phase patients will receive titanium dioxide denture (made from conventional acrylic resin modified by titanium dioxide nanoparticles) according to the principle of crossover design
223498934|NCT04285684|DRUG|ketamine in lactation|2 dose IM by weight and assessing concentrations of ketamine in expressed milk at intervals
223498935|NCT02573467|DRUG|Bimagrumab|BYM338, a 150 mg/mL concentrate for solution for i.v. infusion, was provided in colorless glass vials with a rubber stopper and aluminum flip-off caps.
223498936|NCT02573467|DRUG|Placebo|Matching placebo to BYM338 was provided in colorless glass vials with a rubber stopper and aluminum flip-off caps.
223498937|NCT04361045|BEHAVIORAL|StriveWeekly|"The intervention (app.striveweekly.com) delivered eight modules: introduction module, six skills modules, and wrap-up module. The two program brand name versions had identical content, but different aesthetic schemes. Modules were released week-by-week, and participants self-guided through content. To facilitate skills practice, every module was accompanied by: a weekly intro email and reminder emails; an extras section for tips/suggestions; and a weekly prize drawing. The Dashboard section of the intervention displayed user progress. The Campus section of this dashboard provided: campus-specific announcements; referrals to relevant campus wellness resources; and an anonymous livestream of all campus users' activity.~Strategies/skills included: Psychoeducation; Self-monitoring; Behavioral activation; Cognitive restructuring; Sleep hygiene; Time management; Interpersonal avoidance exposures; Physical exercise; Mindfulness; Maintenance planning."
223498938|NCT01139372|OTHER|FID 115958D (Lubricant Eye Drop)|1 drop in each eye at least twice daily
223498939|NCT02269449|DEVICE|6Fr Glidesheath Slender sheath|6Fr sheath (Glidesheath slender: GSS), which is characterized with the same inner lumen diameter with contemporary 6Fr sheath as well as the sheath outer diameter similar with contemporary 5Fr sheath.
223498940|NCT02269449|DEVICE|5Fr sheath|5Fr Hydrophilic coating sheath from Terumo.
223498941|NCT02269449|PROCEDURE|Hemostasis with TR band|Hemostasis is achieved using TR band (TERUMO) Patent hemostasis.
223498942|NCT02269449|PROCEDURE|Any hemostasis procedure|Hemostasis is achieved by any hemostasis of each hospital's routine procedure.
223498943|NCT00923702|BIOLOGICAL|Prophylactic quadrivalent HPV vaccine Merck (Gardasil®)|The participants received either one, two or three doses of the avaccine. Each injection contains 20 microgram type 6, 40 microgram type 11, 40 microgram type 16, and 20 microgram type 18.
223498944|NCT00748930|OTHER|Retrospective Chart Review and Data collection|Retrospective Chart Review and Data collection
224189374|NCT03491527|PROCEDURE|Dental Prepare|Confection of a indirect crown prepare with diamand burs.
224189375|NCT03491527|PROCEDURE|Dental impression|Dental impression whith silicone.
224189376|NCT03491527|PROCEDURE|Crown cimentation|Insertion of the cement on the inner surface of the crown. Light-cured for 40 seconds on each surface.
224189377|NCT03491527|PROCEDURE|Occlusal adjustment|Analysis of the occlusion with carbon paper.
224189378|NCT03988465|DIAGNOSTIC_TEST|Quantra System|Diagnostic device to monitor coagulation properties of a whole blood sample at the point-of-care.
224189379|NCT04027504|DIETARY_SUPPLEMENT|Fitabisc|Biscuits containing antioxidants
224189380|NCT02441517|DRUG|Enzalutamide|Participants were administered four 40-mg capsules orally once daily and taken as close to the same time each day as possible and could be taken with or without food.
224189381|NCT05222516|DRUG|Broncho-Vaxom|Daily administration of Broncho-Vaxom 3.5mg capsules
224189382|NCT05222516|DRUG|Placebo|Daily administration of Placebo capsules
224189383|NCT02255942|OTHER|Ferric Pyrophosphate and Zinc Oxide|Rice fortified with Ferric Pyrophosphate and Zinc Oxide (ZnO)
224189384|NCT02255942|OTHER|Ferrous sulfate|Rice fortified with Ferrous Sulfate (ZnSO4)
224189385|NCT02255942|OTHER|Ferric Pyrophosphate and Zinc Sulfate|Rice fortified with Ferric Pyrophosphate and Zinc Sulfate
224189386|NCT02255942|OTHER|Ferric Pyrophosphate|Rice fortified with Ferric Pyrophosphate
224189387|NCT03814642|DRUG|Clopidogrel 75 mg|Clopidogrel 75 mg tablet
224189388|NCT03814642|DRUG|Tegoprazan 50 mg|Tegoprazan 50 mg tablet
224189389|NCT03814642|DRUG|Esomeprazole 20 mg|Esomeprazole 20 mg tablet
224189390|NCT03224442|PROCEDURE|PRF|soft tissue augmentation by prf
224189391|NCT03224442|PROCEDURE|Palatal Pedicle|soft tissue augmentation by palatal pedicle
224189392|NCT03604094|PROCEDURE|Ultrasonographic evaluation|Right internal jugular vein will be evaluated with ultrasound for anatomical variations and dimensions
224189393|NCT01393444|DEVICE|Implantation of ECoG sensors on the brain surface|One ECoG sensor will be implanted over the motor cortex of study participants
224189394|NCT03244280|DRUG|MOB015B|Topical formulation
224189395|NCT05879016|OTHER|Functional Correction Technique|A single I strip will be used for this technique. Taping will be done by applying moderate (25-35%) degree of stretching to the middle 1/3 of the tape, with the stretched area centered on the trigger point. The ends of the tape will be adhered without stretching.
223590933|NCT06480695|BEHAVIORAL|Moderate Intensity Exercise|exercise at the RPE at LT associated an \~ RPE of 10-12
223590934|NCT06480695|DIETARY_SUPPLEMENT|Nitrate-Depleted Placebo Beetroot Juice|Subjects will consume 1 bottle of nitrate-depleted beetroot juice 2x a day
224189396|NCT05879016|OTHER|Fascia Correction Technique|Y tape will be applied to prevent fascia adhesions. In the Y tape application, first the tail strips of the Y will be adhered with maximum tension so that the muscle fiber is transverse. Then it will be glued so that its base is in front of the pain point. No tension will be applied to the ends of the tape. The application will be applied when the patient is in a resting position and his joints are in a tense position.
224189397|NCT05879016|OTHER|Star Taping Technique|4 I tapes of the same length between 15 cm and 20 cm will be glued on top of each other. After the first I tape is adhered, the 2nd I tape will be adhered at 90 degrees, then the 3rd and 4th I tapes will be adhered at 45 degrees to obtain a star appearance. There will be no tension at the ends of the tapes
224189398|NCT05879016|OTHER|Sham Comparator|I shape tape will be adhered for sham purpose without applying any tension.
224189399|NCT02663024|BIOLOGICAL|idursulfase beta|IV, weekly infusion for 24 weeks
224189400|NCT02663024|BIOLOGICAL|idursulfase|0.5 mg/kg, iv, weekly infusion for 24 weeks
224189401|NCT02005458|DRUG|YPEG-rhG-CSF, 20μg/kg, single s.c. at 48hrs after chemotherapy for each experimental cycle|
224189402|NCT02005458|DRUG|YPEG-rhG-CSF, 30μg/kg, single s.c. at 48hrs after chemotherapy for each experimental cycle|
224189403|NCT02005458|DRUG|YPEG-rhG-CSF, 45μg/kg, single s.c. at 48hrs after chemotherapy for each experimental cycle|
224189404|NCT02005458|DRUG|PEG-rhG-CSF, 100μg/kg, single s.c. at 48hrs after chemotherapy for each experimental cycle|
224189405|NCT00208702|DRUG|Triiodothyronine|
224189406|NCT00208702|OTHER|Placebo|
224189407|NCT00208702|DRUG|Sertraline|
224189408|NCT05167955|BEHAVIORAL|Mindfulness based cognitive intervention based on the behavioural change techniques taxonomy|An online mindfulness-based cognitive intervention is used as a proposed treatment intervention for erectile dysfunction among African- Caribbean men based in the United Kingdom.
224189409|NCT03846323|OTHER|Visiting policies: 24 hours a day, 7 days a week|
224189410|NCT03846323|OTHER|Restriction of visiting policies < 6 hours|
224189411|NCT01526343|DEVICE|Reveal XT implantation|The implantation of the Reveal XT device will be performed at the time of surgery before the planned median sternotomy or thoracotomy.
224189412|NCT05223764|OTHER|Follow up survey|phone call follow-up to investigate women's decision not to return for embryo transfer after cancer treatment.
223498945|NCT02365129|OTHER|Exercise training based on recommendations for adults (WHO)|The length of the trial will be 6 months. the total time of aerobic exercise in both moderate-intensity and vigorous-intensity groups will be 150 minutes/week, whereas the time needed to complete the resistance training exercises will be ≈15-30 minutes for both groups.
223498946|NCT06444100|PROCEDURE|Impact of structural training on child abuse|"A focus group discussion to delve into teachers' perceptions of child abuse. Based on the findings, the training module will be modified as need-based.~Phase II: Randomly selected samples will be invited, with the researcher explaining the study procedures and obtaining verbal and written consent from teachers and assent from children. A dedicated room will be arranged for data collection, and participants will be instructed on how to respond to child abuse questions on tablets.~Phase-III A pretest will be conducted to assess the existing knowledge level and attitude of the teachers toward child abuse. A 5-hour training session, led by an expert team, will follow the pretest questionnaire administration to all participants. Teachers will also be educated on how to report instances of child abuse. A post-test will be administered using the same questionnaires two weeks after the training."
223590935|NCT06106763|OTHER|Mandala coloring|Mandala coloring page
224189413|NCT01201902|BIOLOGICAL|Adjuvanted influenza A(H1N1) vaccine|0.25ml, Intramuscular on Day 0 and 21
224189414|NCT01201902|BIOLOGICAL|Adjuvanted influenza A(H1N1) vaccine|0.5ml, Intramuscular on Day 0 and 21
224189415|NCT01201902|BIOLOGICAL|un-adjuvanted influenza A(H1N1) vaccine|0.5ml, Intramuscular on Day 0 and 21
224189416|NCT01201902|BIOLOGICAL|Adjuvanted influenza A(H1N1) vaccine|0.25ml, Intramuscular on Day 0 and 21
224189417|NCT01201902|BIOLOGICAL|Adjuvanted influenza A(H1N1) vaccine|0.5ml, Intramuscular on Day 0 and 21
224189418|NCT01884142|OTHER|Aerobic Exercise Training|
224189419|NCT03039699|DRUG|Ergoferon|
224189420|NCT03039699|DRUG|Placebo|
224189421|NCT03114475|RADIATION|CO2 laser irradiation|CO2 laser irradiation will be applied onto the enamel surrounding the orthodontic bracket
224189422|NCT03114475|OTHER|Placebo|No irradiation is going to be applied in the intervention. Just a red light will be used as placebo.
223590936|NCT06130111|PROCEDURE|Mastectomy|Mastectomy as a surgical procedure for breast cancer (regardless of perioperative treatment).
223590937|NCT01021904|BIOLOGICAL|Gardasil (VLP, HPV Quadrivalent prophylactic vaccine)|0.5cc I/M Site deltoid Lt Rt 3-dose regimen: 0, 2, 6 months
223590938|NCT06208774|PROCEDURE|Ultrasound-guided PENG or ISBP block|The diaphragmatic excursion will be measured in the supine position before the block and after surgery. A curvilinear US probe (5-7 MHz) will be placed at the subcostal area in the anterior axillary line, below the costal margin of the eighth and ninth ribs. The probe will be directed medially, cephalad, and dorsally to make the US beam reach the posterior third of the diaphragm perpendicularly. The probe will then be scanned along the long axis of the intercostal spaces, using the liver as the acoustic window on the right side and the spleen as on the left side. M-mode sampling line will be positioned perpendicularly to the diaphragm, and the diaphragmatic excursions could be measured during quiet and deep breathing.The measurement will be repeated three times, and the average value will be taken. After measurement of diaphragmatic excursion, patients will receive either a PENG block or an LV-ISBP block before induction of general anesthesia.
223590939|NCT00369499|DEVICE|PFO Closure|
223590940|NCT04965662|DRUG|Maraviroc|Maraviroc 300 mg, TWO tablets once daily.
223590941|NCT04965662|DRUG|Truvada|Truvada one tablet once daily
223746097|NCT00322842|DRUG|G-CSF Plus Plerixafor|Participants underwent mobilization with G-CSF 10 µg/kg/day for 4 days, administered by subcutaneous injection (SC) injection each morning. On the evening of Day 4, participants received a dose of plerixafor 240 µg/kg, administered by SC injection. On Day 5, participants returned to the clinic and received a morning dose of G-CSF 10 µg/kg and underwent apheresis approximately 10 to 11 hours after the dose of plerixafor (within 60 minutes after administration of G-CSF). Participants continued to receive an evening dose of plerixafor followed the next day by a morning dose of G-CSF and apheresis for up to a maximum of 5 aphereses or until ≥ 5\*10\^6 CD34+ cells/kg were collected.
223746098|NCT02518867|OTHER|high intensity iTBS|In intermittent theta burst stimulation pattern (iTBS) will intermittently give a 2 s train of TBS every 10s for a total of 20 times (high intensity , 100% of active motor threshold) TBS for 3 days.
223746099|NCT02518867|OTHER|low intensity iTBS|In intermittent theta burst stimulation pattern (iTBS) will intermittently give a 2 s train of TBS every 10s for a total of 20 times (low intensity, 80% of active motor threshold) TBS for 3 days.
223746100|NCT02518867|OTHER|sham iTBS|In sham burst stimulation pattern (sham TBS) will intermittently give a sham TBS treatment.
223746101|NCT02664909|DRUG|Tranexamic Acid|
223746102|NCT02664909|DRUG|Placebo (saline)|
223746103|NCT03518333|DEVICE|Injection of adipose derived cells into penis|Injection of Icellator-derived cells
223746104|NCT00983151|DRUG|Tramadol Hydrochloride & Placebo|89 mg or a lesser dose of 62 mg if side effects are experienced one tablet at least two hours before sexual intercourse (maximum of one tablet every 20 hours) Subject will take the study drug for about 27 weeks
224189423|NCT04781127|DEVICE|Soterix Medical mini-CT tDCS stimulator|Stimulation will last 30 minutes per day, 5 days per week, for 5 weeks, then 3 days per week for 1 week and then 1 day per week for 4 weeks.
224189424|NCT03804476|DRUG|AER-271|AER-271, the test article for this study.
224189425|NCT03804476|DRUG|Placebo|Placebo control for this study.
224189426|NCT04736966|DRUG|Guselkumab 30mg|30mg of Guselkumab administered by subcutaneous injection
224189427|NCT04736966|DRUG|Guselkumab 70mg|70mg of Guselkumab administered by subcutaneous injection
224189428|NCT04736966|DRUG|Guselkumab 100mg|100mg of Guselkumab administered by subcutaneous injection
223590942|NCT02337192|DRUG|Curcumin|
223590943|NCT02337192|DEVICE|LED|
223590944|NCT02337192|DRUG|Surfactant|
223590945|NCT02337192|DRUG|DMSO + water|
223746105|NCT02068222|DRUG|ABT-450/ritonavir (r)|Tablet
223590946|NCT02337192|DRUG|Chlorhexidine gluconate|
223746106|NCT02068222|DRUG|ABT-530|Tablet
223746107|NCT02068222|DRUG|Ribavirin (RBV)|Tablet
223746108|NCT02541747|BEHAVIORAL|massage|massage
223746109|NCT01057017|BIOLOGICAL|intervention|
224189429|NCT00129220|DRUG|olanzapine|5-20 mg, oral, once daily (evening), for 6 weeks
224189430|NCT00129220|DRUG|haloperidol|2.5-10 mg, oral, twice daily (morning and evening), for 6 weeks.
223590947|NCT04680975|DRUG|Belumosudil|10 participants with dcSSc received belumosudil 200 mg PO BID for 52 weeks
223590948|NCT06835699|DRUG|Psilocybin 25 mgs|All participants will be administered 25 mg psilocybin and undergo TMS
223590949|NCT06835699|DEVICE|TMS|All participants will be administered 25 mg psilocybin and undergo TMS
223746110|NCT00064207|DRUG|gemcitabine hydrochloride|
223746111|NCT00064207|PROCEDURE|adjuvant therapy|
223746112|NCT00064207|RADIATION|radiation therapy|
223746113|NCT05655182|BIOLOGICAL|PIV5-vectored RSV Vaccine (BLB-201) Low Dose|BLB201 10\^6 PFU
223746114|NCT05655182|BIOLOGICAL|PIV5-vectored RSV Vaccine (BLB-201) High Dose|BLB201 10\^7 PFU
223746115|NCT05655182|DRUG|Placebo|The placebo used for the trial will be the same as the diluent (0.9% sterile saline) used for the low dose group (10\^6 PFU).
224189431|NCT00129220|DRUG|placebo|placebo, oral tablets, twice daily (morning and evening), for 3 weeks
224189432|NCT01295073|DRUG|Trientine Hydrochloride|"Arm A's therapeutic intervention is the use of Trientine Hydrochloride for 10 days in the perioperative period.~All participating subjects will all receive cataract surgery according to present standards of care; however, subjects randomized the intervention group (trientine hydrochloride) will be on a 10 day course of oral Trientine at 1500mg administered for 7 days prior to and 3 days after surgery."
224189433|NCT01295073|OTHER|For Arm B there is no therapeutic intervention other than standard of care, which is cataract surgery.|see above
224189434|NCT02651038|DRUG|Micafungin|Measurement of PK
224189435|NCT02357108|OTHER|Video|Watch two short videos with a 4-minute interval between the two of them, estimate 8 minutes to watch both the videos.
224189436|NCT02357108|BEHAVIORAL|Survey|One set of surveys before first video and one set after each video played, estimate total of 30 minutes for all surveys.
224205807|NCT03447054|BEHAVIORAL|Combined Sham TDCS and inactive ICT|Five 20-minute long sessions including TDCS and no-cue inhibition training, 5 consecutive days
223498947|NCT00991432|DEVICE|INFUSE® Bone Graft|Patients will be treated with the commercially available INFUSE® Bone Graft material applied to an ACS concurrent with space maintenance devices for soft tissue management on Day 0 (Surgery). A follow-up visit will take place 2 weeks after implant of the INFUSE® Bone Graft material, or as regularly scheduled as per the standard of care (SOC) for the facility. Patients will return to the facility for final End of Study (EOS) assessments approximately 6 months after surgery. Between the follow-up visit and the EOS visit, patients will be seen as per the SOC schedule for the facility.
223498948|NCT04145934|BEHAVIORAL|ADSTEP|ADSTEP is a training program of six weekly one-on-one sessions with a physical therapist intended to reduce falls among people who use a hand-held walking aid, such as a cane or a walker. ADSTEP focuses on training in the use of the walking aid, and includes gait evaluation, walking aid selection and fitting, and progressive task-oriented training with the walking aid.
223498949|NCT00862901|DEVICE|CLIPT patch|A Diomed laser will deliver 630nm (red spectrum) light through a Fiber optic Patch. The Fiber Optic Patch will be compatible with the laser, delivering light to a designated region on the patient's skin. Patients will receive a single intravenous injection of Photofrin (0.8mg/kg body weight) 36 - 48 hours prior to the CLIPT procedure. PDT will be delivered over 24 hours for the dose of each arm. Patients will be enrolled in sequential cohorts of six, at increasing laser intensity until the maximum tolerated dose is reached.
223498950|NCT03426488|BEHAVIORAL|VIP - Västerbotten Intervention Programme|Intervention on CVD (cardiovascular disease) and diabetes
223498951|NCT02583009|DRUG|PAC-14028 cream 0.1%|Topical application
223498952|NCT02583009|DRUG|PAC-14028 cream 0.3%|Topical application
223498953|NCT02583009|DRUG|PAC-14028 cream 1.0%|Topical application
223498954|NCT02583009|DRUG|PAC-14028 cream vehicle|Topical application
223498955|NCT01243125|DRUG|NVC-422, 0.2%|0.2% NVC-422 (sterile), 25 ml instilled and retained in catheter for 15 min, 2x/day; 8 treatments administered over a 26 day period
223498956|NCT01243125|DRUG|Sterile normal saline, 0.9%|Saline (sterile), 25 ml instilled and retained in catheter for 15 min, 2x/day; 8 treatments administered over a 26 day period
223498957|NCT05874297|OTHER|Best Practice|Receive standard of care
223498958|NCT05874297|BEHAVIORAL|Internet-Based Intervention|Access to enhanced Cook for your life website
223498959|NCT05874297|OTHER|Questionnaire Administration|Ancillary studies
223590950|NCT05218642|DRUG|KX- 826 dosed at 2.5mg|2.5mg of the investigational drug to be applied topically to scalp twice daily for 24 weeks
224074356|NCT06292416|OTHER|Experimental: Mirror therapy with sensory motor training.|"Block design, finding shapes in pictures, puzzles, matching geometric shapes and letters, numbers, and classification.~Pointing to the body parts, life-size drawing, turning left and right side and awareness of the body parts through touch.~feeling various textures, touching boards, and feeling shapes. Ocular-pursuit training, moving ball and pegboard activities During the sessions, subjects were asked to try and do the same movement with the paretic hand simultaneously The patients will be asked to repeat each movement 20 times per set for three sets, with a 2-minute break between sets.~Session will last for 45 mins"
224074357|NCT06292416|OTHER|Experimental: Mirror Therapy with motor training|the participant is asked to perform a forearm movement sting on the paretic side while the subjects look into the mirror, watching the image of their non-involved hand and thus seeing the reflection of the hand movement projected over the involved hand. During the sessions subjects were asked to try and do the same movement with the paretic hand simultaneously. movement was repeated 20 times per set for three sets, with a 2-minute break between sets
224205808|NCT00388115|PROCEDURE|conventional surgery|Standard of care lumpectomy or mastectomy following RFA
224205809|NCT00388115|PROCEDURE|neoadjuvant therapy|Standard of care lumpectomy or mastectomy following RFA
224205810|NCT00388115|PROCEDURE|radiofrequency ablation|A small diameter needle is inserted through the skin and directly into the tumor for the purpose of supplying RF current. Initial power of the RF generator will start at 5-10 watts. The power will increase by 5-10 watts every minute until impedance of the system automatically stops the RF treatment.
223498960|NCT05898373|DRUG|vedicitumomab (Edisil, RC48）|intravenously for 6-8 cycles before surgery and postoperative radiotherapy, followed by Treatment with injectable recombinant humanized anti-HER2 monoclonal antibody-MMAE coupling agent vedicitumomab (Edisil, RC48) until 1 year or disease progression or intolerable toxicity in locally advanced patients , and until disease progression or intolerable toxicity in metastatic patients .
223498961|NCT05898373|DRUG|vedicitumomab in combination with pyrrolizidine|vedicitumomab in combination with pyrrolizidine
223498962|NCT05898373|DRUG|RC48 in combination with a platinum-based chemotherapeutic agent|RC48 in combination with a platinum-based chemotherapeutic agent
223498963|NCT05898373|DRUG|RC48 in combination with teraplizumab|RC48 in combination with teraplizumab
223498964|NCT00977873|DIETARY_SUPPLEMENT|Cholecalciferol|Cholecalciferol will be administered as 2-monthly oral bolus doses of Vigantol oil over a period of one year
223498965|NCT00977873|DIETARY_SUPPLEMENT|Miglyol oil|Miglyol oil will be administered in 2-monthly bolus doses over a period of one year
223498966|NCT01302171|DRUG|granulocyte colony stimulating factor (GCSF)|10mcg/kg per day 5 days
223498967|NCT01302171|PROCEDURE|bone marrow mononuclear cells|intra coronary injection of stem cells or placebo
223590951|NCT05218642|DRUG|KX-826 dosed at 5mg|5mg of the investigational drug to be applied topically to scalp once daily for 24 weeks
223590952|NCT05218642|DRUG|KX-826 dosed at 5mg|5mg of the investigational drug to be applied topically to scalp twice daily for 24 weeks
223590953|NCT05218642|DRUG|Matching placebo to KX-826|Placebo applied topically to scalp twice daily or once daily for 24 weeks
223590954|NCT03909152|DRUG|Onapristone ER|50 mg PO BID (with dosage adjustments) until POD, unacceptable toxicity or withdrawal of consent.
223590955|NCT03909152|DRUG|Onapristone ER + Anastrozole|Onapristone ER Patients will take 50 PO BID in the form of two 20 mg tablets and one 10 mg tablet taken with food and water twice daily. Patients will be prescribed anastrozole 1mg PO QD. Anastrozole will be taken once daily in the AM with patients morning dose of onapristone ER.
223590956|NCT05111353|BIOLOGICAL|Optimized neoantigen synthetic long peptide vaccine|Neoantigen vaccines will be provided on a patient-specific basis
224205811|NCT06568978|OTHER|Assessments of respiratory parameters|respiratory muscle strength, respiratory function test
223590957|NCT05111353|BIOLOGICAL|Poly-ICLC|Poly-ICLC will be supplied by Oncovir, Inc.
224189437|NCT05728528|DRUG|combination between moderate to vigorous-intensity physical activities and pharmacokinetic-guided extended half-life FVIII concentrates prophylaxis|combination between moderate to vigorous-intensity physical activities and pharmacokinetic-guided extended half-life FVIII concentrates prophylaxis
224189438|NCT05728528|DRUG|pharmacokinetic-guided extended half-life FVIII concentrates prophylaxis alone|pharmacokinetic-guided extended half-life FVIII concentrates prophylaxis alone
223498968|NCT03509597|BEHAVIORAL|Aerobic Exercise|Physical exercise training consisting of aerobic exercise and strength/resistance training.
223498969|NCT03509597|BEHAVIORAL|Cognitive Training|Cognitive remediation program using REHACOP rehabilitation program.
223498970|NCT03509597|BEHAVIORAL|Treatment as usual|Standard care for schizophrenia + Leisure and free time activities.
223498971|NCT03509597|BEHAVIORAL|Occupational Activities|Engagement in activities aimed to keep patients actively involved in demanding tasks.
223498972|NCT02327247|DRUG|Felodipine|Extended Release Tablets, 10mg
223498973|NCT02327247|DRUG|PLENDIL®|Extended Release Tablets, 10mg
223498974|NCT05140980|OTHER|Data collection|evaluation of women's knowledge concerning sexuality
223498975|NCT01033370|DRUG|clevidipine.|Clevidipine administered per IV infusion, starting dose of 2 mg/h (4 mL/hr) for 3 minutes \& titrated to the desired BP lowering effect to SBP goal of \< 120 mmHg, max infusion rate may not exceed 32 mg/h (64 mL/hr).
223498976|NCT05719597|OTHER|PEP (Positive Expiratory Pressure)|Group A containing 12 participants, will perform Positive expiratory pressure (PEP) technique for total 60 repetitions (15 repetitions 2 sets, twice) per a day (5 sessions/week and total 4 weeks).
223498977|NCT05719597|OTHER|IS (Incentive spirometry)|Group B containing 12 participants, will perform Incentive spirometry technique for total 60 repetitions (15 repetitions 2 sets, twice) per a day (5 sessions/week and total 4 weeks).
223498978|NCT04517058|OTHER|psychology therapy|If the symptoms are mild, patients will get the psychology therapy. If it's necessary according to patients' willings, patients will be given SSRIs antidepressant therapy.
223498979|NCT06632860|DRUG|68Ga-TATE-RGD|Intravenous injection of 68Ga-TATE-RGD with the dosage of 1.8-2.2 MBq (0.05-0.06 mCi)/kg. Tracer doses will be used to image lesions of by dual-targeted postive cancers PET/CT.
223498980|NCT06632860|DRUG|18-FDG|Intravenous injection of 18F-FDG with the dosage of 1.8-2.2 MBq(0.12-0.15mCi/kg). Tracer doses will be used to lesions therapy of dual-targeted postive cancers by SPECT/CT.
223498981|NCT04386148|PROCEDURE|Obsidian ASG®|As part of the elective laparoscopic colorectal surgery, an autologous fibrin matrix was used as part of anastomotic technique in conjunction with activated thrombocytes (Obsidian ASG®). During anastomosis, this matrix was applied after resection onto the colorectal tissue surfaces with the aim of triggering tissue regeneration and improved wound healing.
223498982|NCT00367458|DRUG|Atorvastatin|80 mg atorvastatin oral daily
224189439|NCT02557828|PROCEDURE|arterial line placement|radial arterial cannulation placed via palpation or ultrasound technique
224189440|NCT00676468|OTHER|Active Montelukast + Fish Oil Placebo|Montelukast (1 x 10 mg tablet) per day + 10 tablets of fish oil placebo (soy bean oil) per day for a duration of 3 weeks
224189441|NCT00676468|OTHER|Active Fish Oil + Montelukast Placebo|10 tablets (3.2 g EPA + 2.0 g DHA) per day and 1 x 10 mg Montelukast Placebo tablet per day for a duration of 3 weeks.
223498983|NCT00367458|DRUG|Placebo|patients will be administered placebo
223498984|NCT02556788|DRUG|CD5789 (trifarotene) 50µg/g Cream|CD5789 (Trifarotene) 50µg/g cream applied once daily during 12 weeks.
223498985|NCT02556788|DRUG|Placebo Cream|Placebo cream applied once daily during 12 weeks.
223498986|NCT03943082|BEHAVIORAL|Cancer Educational Materials|Receive FRP brochure
223498987|NCT03943082|OTHER|Follow-Up Care|Receive follow-up phone call
223498988|NCT03943082|BEHAVIORAL|Questionnaire|Ancillary studies
223498989|NCT03524144|OTHER|gastroscopy|Two endoscopists performed upper gastrointestinal endoscopy and biopsy on all patients; and histological review was performed by two pathologists. From each patient, 10 specimens were taken from 6 areas in the upper gastrointestinal tract and basic informations was collected.
223498990|NCT02473601|DRUG|Mivacurium Chloride|"Anesthesia induction:~Intravenous injection of midazolam 0.05 mg/kg,Etomidate 0.3 mg/kg,Sufentanil 0.5 g/kg,TOF detection and adjustment of the first twitch height (T1)100%, Mivacurium Chloramine 0.07 mg/kg intraveous injecting in 5 minutes.~Anesthesia maintenance:~Two groups of sevoflurance 1%\~8% inhalation anesthesia plus intravenous infusion of remifentanil 0.05～0.2 µg/kg/min,Mivacurium Chloramine 6mg/kg/h, Appropriate supplementary analgesia dose of sufentanil before skin incision and the abdomen was closed. The two groups were maintained until the Bis value was 40 \~ 60. PetCO2 was 30 \~ 35mmHg. Hemodynamic fluctuations did not exceed 20% of the baseline value.At least 20 minutes before the operation stopping Mivacurium infusion,Before the end of operation 5-10 minutes stopping infusion of remifentanil and sevoflurane."
223498991|NCT04560218|DRUG|sublingual Misoprostol|apply drug by Anesthesiologist
223498992|NCT04560218|DRUG|Intrauterine Misoprostol|apply drug by surgeon at uterine cornu
224189442|NCT00676468|OTHER|Active Montelukast + Active Fish Oil|1 x 10 mg Montelukast tablet per day and 10 tablets of active fish oil (3.2 g EPA + 2.0 g DHA) for a duration of 3 weeks.
224189443|NCT02230501|DIETARY_SUPPLEMENT|stringent diet regimen|
224189444|NCT02230501|DIETARY_SUPPLEMENT|moderate diet regimen|
224189445|NCT04881669|DEVICE|obturator|variable bulbs
224189446|NCT01883362|DRUG|Midostaurin|Midostaurin was supplied in 25mg soft gelatin capsule taken orally twice a day for 28 days of each cycle. Patients will be treated for 12 cycles.
224189447|NCT01883362|OTHER|Standard of Care|Standard of Care was not defined per protocol. The investigator prescribed based on the commonly used medications given in the post SCT setting.
224189448|NCT00016068|DRUG|ganciclovir|
224189449|NCT00016068|DRUG|valganciclovir|
224189450|NCT03606265|DEVICE|App+Web|Patients will use an app daily twice and physicians will use a website to consult the characteristics of the alarms the app will send them in the presence of an unwanted event
224189451|NCT03606265|DEVICE|Treatment as usual|Patients will be offered the usual treatment for their pain, which is not changed by study participation
224189452|NCT04568265|DRUG|APG-1387|Weekly intravenous infusion for 30 minutes
224189453|NCT04568265|DRUG|Entecavir 0.5 mg|Taken daily by mouth
224189454|NCT01349816|DRUG|PT003|PT003 MDI administered as two puffs BID for 7 days
223590958|NCT06307535|BEHAVIORAL|Meaning-Centered Psychotherapy for Caregivers|MCP-C is a stakeholder-informed, innovative, manualized intervention designed to assist caregivers to connect to a sense of meaning and purpose in life, despite the challenges of caregiving.
224189455|NCT01349816|DRUG|PT001|PT001 MDI administered as two puffs BID for 7 days
223590959|NCT06307535|BEHAVIORAL|Supportive Psychotherapy for Caregivers|Standard of care supportive psychotherapy
223590960|NCT01171391|DRUG|VA106483|1 mg VA106483 on Day 3, 2 mg VA106483 on Day 5 and 4 mg VA106483 on Day 7
223590961|NCT01171391|OTHER|Placebo|Placebo on Day 1
223590962|NCT05522257|DIAGNOSTIC_TEST|[18F]-JK-PSMA-7 PET/CT scan|A \[18F\]-JK-PSMA-7 PET/CT scan will be made to assess the level of tracer uptake in the malignant lesion(s). We expect to make a \[18F\]-JK-PSMA-7 PET/CT scan in 15 out of 60 patients per cohort.
223590963|NCT06520774|DEVICE|Concave Supra-arch Branched Stent-Graft System|To evaluate the efficacy and safety of Concave Supra-arch Branched Stent-Graft System for endovascular treatment of Aortic Arch Diseases
223590964|NCT00748254|PROCEDURE|Laser Based Photoacoustic Tomography, MRI, Ultrasound|Healthy subjects will have scans on finger joints with any of the scanning methods described above.
223590965|NCT00748254|PROCEDURE|laser based photoacoustic tomography, MRI, ultrasound|Subjects with arthritis will have scans on finger joints with any of the scanning methods described above.
223590966|NCT06446089|BEHAVIORAL|THP: cognitive behavior therapy and behavioral activation|The adapted THP takes into account cultural and linguistic characteristics of the participants. Participants will be invited to complete three modules on an Android based app on their mobile, populated with information and activities from the adapted THP.
223590967|NCT03887715|DEVICE|Vagus Nerve Stimulation (VNS)|VNS is an implantable device that delivers stimulation to the vagal nerve.
223590968|NCT06537414|DRUG|Daplusiran/Tomligisiran Dose Level 1|Daplusiran/Tomligisiran dose level 1 will be administered
223590969|NCT06537414|DRUG|Daplusiran/Tomligisiran Dose Level 2|Daplusiran/Tomligisiran dose level 2 will be administered
223590970|NCT06537414|DRUG|Bepirovirsen|Bepirovirsen will be administered
223590971|NCT06537414|DRUG|Placebo|Placebo will be administered
223590972|NCT06343909|OTHER|Hip abductor strengthening exercise|in this group 15 participants will perform hip abductor streghtning along with conventional exercises .protocol for 8 weeks 24 sessions (3 sessions in a weak) and 10 sec rest between each segment,3 sets and 10 reputations will be performed.
223590973|NCT06343909|OTHER|Intrinsic foot muscle strengthening along with conventional exercises|in this group 15 participants will perform Intrinsic foot muscle strengthening along with conventional exercises .protocol for 8 weeks 24 sessions (3 sessions in a weak) and 10 sec rest between each segment,3 sets and 10 repitations will be performed.
223590974|NCT05937581|DRUG|CSL040|IV Administration
223590975|NCT05937581|DRUG|Placebo|0.9% w/v NaCI, IV Administration
223590976|NCT02615691|BIOLOGICAL|PEGylated Recombinant Factor VIII|Polyethylene glycol (PEG)-ylated full-length recombinant FVIII (rFVIII).
224189456|NCT01349816|DRUG|PT005|PT005 MDI administered as two puffs BID for 7 days
224189457|NCT01766024|DRUG|Interferon beta-1a|Each volunteer will receive 1 subcutaneous (sc) injection of the study drug BCD-033 (interferon beta-1a) and 1 sc injection of active comparator Rebif (interferon beta-1a) at a dose of 44 µg with an interval of at least 14 days.
224189458|NCT02033486|DEVICE|TOBI + DBT|
223590977|NCT02615691|BIOLOGICAL|ITI|Immune tolerance induction therapy
224189459|NCT05433116|DRUG|Pembrolizumab|i.v., 200mg absolute, q3w, starting within 14 days after completion of radiochemotherapy
224189460|NCT05433116|DRUG|Lenvatinib|20mg once daily orally, start concomitant to cycle 2 of pembrolizumab
224189461|NCT00166595|DRUG|Risperidone|
224189462|NCT03740724|GENETIC|FCX-013|FCX-013 is a genetically modified cell product obtained from the subject's own skin cells (autologous fibroblasts). The cells are expanded and genetically modified to express metalloproteinase-1 (MMP-1) under the control of a RheoSwitch (RTS®) system. FCX-013 cell suspension is injected intradermally.
223590978|NCT06290661|DEVICE|Active electrostimulation|Maintain the electrical stimulation state, and according to the patient's feeling to set the appropriate stimulation parameter range (pain relief and no obvious numbness and discomfort), the programme will be written into the patient's self-control remote control, by the patient according to their own pain situation for the independent control of the stimulation current.
223590979|NCT06290661|DEVICE|Placebo electrostimulation|No actual electrostimulation
223590980|NCT05509166|BEHAVIORAL|LGBTQ-affirmative Cognitive Behavioral Therapy|10-session LGBTQ-affirmative psychotherapy using CBT techniques
223590981|NCT05509166|BEHAVIORAL|LGBTQ-affirmative Treatment-As-Usual|10-session LGBTQ-affirmative psychotherapy
223590982|NCT06287515|DEVICE|Stereotactic Radiosurgery|Given by Radiation Therapy
223590983|NCT06801236|DRUG|ACE-232 tablets|ACE-232 tablets will be administered orally daily as a continuous regimen together with Dexamethasone and Fludrocortisone. Subjects will continue to receive study treatment until PD as judged by local investigator review, development of unacceptable toxicity, or withdrawal of consent.
223746116|NCT03475966|OTHER|Exercise|A kinesiologist will provide each patient wih an individualized home-based exercise program including aerobic, resistance and stretching exercises. Patients will also exercise at our clinic once per week under the supervision of the kinesiologist (prehabilitation arm only)
224189463|NCT03740724|DRUG|veledimex|Veledimex, is a small molecule which activates the RTS to induce expression of MMP-1 and is and provided as a liquid filled gelatin capsule for oral administration
224189464|NCT04579458|PROCEDURE|Collection of tears and saliva.|Saliva and ocular tears will be collected.
224189465|NCT04421430|OTHER|Distraction cards|The distraction cards contain various hidden pictures and patterns which are visible only when looked at carefully. During a procedure, the child is expected to focus on the cards and answer the questions asked about what they see in them. Just before the venipuncture, the researcher showed the distraction cards participants the distraction cards and asked them to check them and then asked them questions about what they saw on the cards and kept asking questions until the end of the venipuncture. The distraction cards intervention and venipuncture were terminated at the same time.
224189466|NCT04421430|OTHER|Virtual reality|The virtual reality participants put on the virtual reality glasses and headsets about two minutes before the venipuncture and watched the 3D Dinosaur Animation movie throughout the procedure. The virtual reality intervention and venipuncture were terminated at the same time.
223498993|NCT01431846|BEHAVIORAL|Intervention|Informed by the interviews and best practices from the literature, pilot test the transitions of care intervention that targets patients and providers to evaluate the feasibility of the intervention to improve process of care measures, including: 1) PCP follow-up within 2-4 weeks of hospital discharge; 2) medications reconciled between pre and post-hospital discharge; 3) discharge summary available to PCP at time of visit; and 4) patient awareness of symptoms that require medical attention
223498994|NCT04339972|DEVICE|LIFUP|Low Intensity Focused Ultrasound Pulsation (LIFUP) is an interesting new form of brain stimulation that may be possible to stimulate non-invasively, safely, deep in the brain with focal precision.
223498995|NCT04339972|DEVICE|Sham LIFUP|The same as LIFUP but the device is not turned on and the subject does not receive any ultrasound.
223498996|NCT01651884|DEVICE|HD-tDCS (Soterix)|Subjects will be given individualized dose (number of electrodes and electrode placement) through High-Definition electrodes to target fMRI determined targets
223498997|NCT01651884|DEVICE|Transcranial Direct Current Stimulation (Neuroconn)|
223498998|NCT01899885|PROCEDURE|AHA (Acute Highrisk Abdominalsurgery): Optimized Course|"optimized course: Intervention before, during and after abdominal surgery.~Focus on fast track with multimodal standardized intervention:~1. standardized preparing for surgery including high dose antibiotics and epidural analgesia etc. and transfer to intermediate care before surgery (the post-anaesthesia care unit)~2. GDT-LiDCO fluid management pre-, per- and postoperative~3. Postoperative triage to 24 hour intermediate care based on ASA score and Surgical Apgar Score~4. Focus on early mobilization, fysiotherapy and optimal nutrition postoperatively"
223498999|NCT00741949|DRUG|Propofol|Sedation in TCI with propofol
223499000|NCT00741949|DRUG|Placebo|Isotonic saline solution infusion
223499001|NCT00932802|DRUG|Moxifloxacin (Avelox, BAY12-8039)|AECB patients under daily life treatment receiving moxifloxacin according to the local product information.
223499002|NCT01967953|PROCEDURE|EVLP Group|"EVLP technique: Steen solution; normothermia; low flow, open atrium, low hematocrit.~Endpoints of EVLP assessment of lungs suitability: oxygenation, respiratory mechanics, pulmonary vascular resistance, chest X-ray, fibrobronchoscopy"
223499003|NCT04790799|OTHER|Treatment at the skin department at Gentofte Hospital|Treatment in a hospital setting at Gentofte Hospital skin department
223499004|NCT05565547|DEVICE|META|The META device is used for a comprehensive ophthalmic examination.
223499005|NCT05565547|DEVICE|Commercial devices|Commercial devices (including near and far eye charts, refractometer, optical biometry, slit lamp microscopy, fundus camera and OCT) are used for a comprehensive ophthalmic examination.
223499006|NCT05491889|BIOLOGICAL|trans arterial chemoembolization|trans arterial chemoembolization in patient with partial portal vein thrombosis
223499007|NCT00127010|BIOLOGICAL|Measles, Mumps, Rubella and Chickenpox (live vaccine)|
223499008|NCT06033664|BEHAVIORAL|Fresh Funds|Participants will enroll in Instacart Fresh Funds program. Once enrolled participants will select foods that are eligible in the Fresh Funds to be delivered to their home each week for 12 weeks.
223499009|NCT04307563|BEHAVIORAL|Mindfulness session|1.5 hour weekly session with health educator
223499010|NCT05327738|BIOLOGICAL|Atezolizumab|Given IV
223499011|NCT05327738|PROCEDURE|Biopsy|Undergo biopsy
223499012|NCT05327738|DRUG|Cabozantinib S-malate|Given PO
224189467|NCT04421430|OTHER|Buzzy|Buzzy® applies high frequency vibration and concentrated cold at injection site for procedural pain management and distraction before the shot in children and adults. Buzzy® was placed on the injection site (antecubital fossa) of the Buzzy® participants, and cold application and vibration was turned on 60 seconds before the procedure. After the 60 seconds, the nurse moved Buzzy® about 3 cm above the injection site and applied a tourniquet and performed the procedure. Buzzy® was on throughout the procedure. The Buzzy® intervention and venipuncture were terminated at the same time.
224189468|NCT00529594|DRUG|placebo (Control Group)|Both medication have been given to the patients in both groups 1 hour prior the laser photocoagulation
224189469|NCT00529594|DRUG|Etoricoxib (Treatment Group)|Both medication have been given to the patients in both groups 1 hour prior the laser photocoagulation
224189470|NCT05813769|DIETARY_SUPPLEMENT|Dairy protein|During each visit, research subjects will receive the product dissolved in water, representing a 20g protein load.
224189471|NCT05813769|DIETARY_SUPPLEMENT|Plant protein|During each visit, research subjects will receive the product dissolved in water, representing a 20g protein load.
224205812|NCT00929864|DRUG|Abatacept|Syringes, Subcutaneous, 125 mg/syringe for Subcutaneous, Weekly Subcutaneous injections, 24 months (729 days)
223499013|NCT05327738|RADIATION|Yttrium Y 90 Glass Microspheres|Given intra-arterially
223499014|NCT03970512|DEVICE|Apioc-A and Apioc-S Contact Lenses|Appropriately fit, document and dispense a new spherical and toric contact lens design worn for up to 35 days.
223499015|NCT01305629|BEHAVIORAL|Spiritual Self-Schema Therapy|"The Spiritual Self Schema therapy (3S+) intervention will consist of a series of 12 one hour-long sessions delivered individually to participants over a four-month period. The 3S+ approach combines cognitive and behavioral therapy techniques with elements of non-theistic Buddhist philosophy to increase motivation for treatment adherence, alcohol and/or substance use reduction or abstinence and the prevention or reduction of HIV risk behaviors. 3S+ draws from self-regulation theory, self-schema theory, and self-discrepancy theory to assist participants in defining and perceiving their addict self, when their addict self is active, and its resulting negative affect state. 3S+ remediates the addict schema by proposing the construction of an alternate and competing schema: the spiritual self. This spiritual self schema is compatible with HIV self-care, alcohol and drug use reduction or abstinence, adherence to treatment, and a compassionate life."
223499016|NCT00057070|PROCEDURE|Smoking cessation information, collection, and dissemination|
223499017|NCT02614014|BEHAVIORAL|Cognitive-behavior interventional program|
223590984|NCT06172075|BEHAVIORAL|Brief video intervention (Black Woman)|A brief social contact-based video. The video presented a young Black woman in her early twenties, a professional actor, sharing her scripted personal story of struggles as a Black woman with depression and raising themes of recovery and hope.
223590985|NCT06172075|BEHAVIORAL|Brief video intervention (Latinx Woman)|A brief social contact-based video. The video presented a young Latinx woman in her early twenties, a professional actor, sharing her scripted personal story of struggles as a Latinx woman with depression and raising themes of recovery and hope.
223499018|NCT04995107|DEVICE|Electro Press needle|"Body acupoints will be stimulated by the press needles 0.25mm in diameter and 2mm in length and ear acupoints will be stimulated by the press needles 0.25mm in diameter and 0.9mm in length (all from ZhenXing Brand, Hangzhou Yuanli Medical Appliance Factory, China). After sterilization of the local skin, the needle will be pressed to the acupoints and the tape will be sticked to the skin. Then, the electric device (φ44×15.8mm Type ZXHPAMDZB-02C) together with the electrode patch will be sticked to the surface of skin (on top of the sticky tapes of the press needle) in the area of CV4 and bilateral EX-CA1, and bilateral SP6 respectively. The electric device will be switch to the mode of dense intermittent wave, and the current intensity will be increased gradually till the muscles around jumps slightly.All the needles on the body acupoints will be removed after each session, while those on the auricular acupoints can be kept for as long as 6 hours (removed before going to bed)."
223499019|NCT02691663|DIETARY_SUPPLEMENT|Oral bicarbonate supplementation|
223499020|NCT02691663|DIETARY_SUPPLEMENT|Placebo|
223499021|NCT04924790|BEHAVIORAL|COVID-19 Pandemic|Comparison of the intervention preferences of patients diagnosed with obstructive urinary stones in the urology clinic and recommended for intervention during and before COVID-19
223499022|NCT02271542|DRUG|propofol|Propofol, 1-2 mg / kg after the installation is 100 to 200 mg / kg / min infusion for 30-60 minutes after application will be made and EDTA tubes with 2 ml blood sample will be taken. Determined from blood samples obtained by studying the polymorphism genotypes of patients will be exposed.
223499023|NCT05790681|DRUG|Insulin icodec|Participants will receive subcutaneously fixed dose of insulin icodec (700 U/mL) that is 5.6 U/kg bodyweight.
223499024|NCT02120079|DRUG|Lotemax|Lotemax (loteprednol etabonate) 0.5% will be applied topically to both eyes for 6 weeks with the following regimen: four times a day for 2 weeks, twice daily for 2 weeks, and once daily for 2 weeks.
223499025|NCT02120079|DRUG|Soothe Tired Eyes Lubricant Eye Drop (Artificial Tears)|Soothe Tired Eyes Lubricant Eye Drop will be applied topically to both eyes for 6 weeks with the following regimen: four times a day for 2 weeks, twice daily for 2 weeks, and once daily for 2 weeks.
223499026|NCT02120079|DIAGNOSTIC_TEST|In Vivo Confocal Microscopy (IVCM)|In vivo confocal microscopy (IVCM) is a new imaging method, which allows visualization of the corneal structures at the cellular level. With a magnification of 800 times, it makes it possible to detect and quantify changes in the epithelial layers and sub-basal nerve plexus.
223499027|NCT01164605|DRUG|Raltegravir|60 tablets (30-day supply)
223499028|NCT06264622|DIETARY_SUPPLEMENT|Low dose|2 tablets per day during the morning for 12 weeks.
223590986|NCT06172075|BEHAVIORAL|Brief video intervention (White Woman)|A brief social contact-based video. The video presented a young White woman in her early twenties, a professional actor, sharing her scripted personal story of struggles as a White woman with depression and raising themes of recovery and hope.
223590987|NCT06172075|BEHAVIORAL|Vignette Control|A brief vignette control condition with a script about a young woman who describes her struggles with depression and raises themes of recovery and hope.
223590988|NCT06152341|DEVICE|ATC System|The ATC System is designed to mechanically remove emboli and restore blood flow through the pulmonary arteries in patients experiencing acute PE
223590989|NCT02546661|DRUG|AZD4547|AZD4547 Monotherapy vs. MEDI4736 (durvalumab) + AZD4547 1:1 Randomization.
223590990|NCT02546661|DRUG|MEDI4736|MEDI4736
223590991|NCT02546661|DRUG|Olaparib|MEDI4736 (durvalumab) + Olaparib
224074358|NCT06292416|OTHER|Experimental: Motor Training|"1. Holding object with two hands, clapping, banging objects together.~2. Stabilize objects with one hand while the other is manipulating (holding paper while coloring, holding a container while putting objects in)~3. manipulate objects with both hands simultaneously (stringing beads, tying a knot),~4. ask child to padlock in which a key can be put into, markers with caps to put on, a box with a lid and objects to put inside the box~5. hold a cup with one hand while putting object in with other hand~6. Buttoning with both hands, tying a bow. doing craft project, fitting blocks together"
224074359|NCT06638892|BEHAVIORAL|Using PrEP, Doing it for Ourselves (UPDOs)|An e-Health intervention that considers women's lived experiences and uses three components: beauty salons and stylists as opinion leaders (trusted gatekeepers who share health information in the community), theory driven edutainment videos and blogs, and a secure online platform for accessing pre-exposure prophylaxis (PrEP).
223499029|NCT06264622|DIETARY_SUPPLEMENT|High dose|2 tablets per day during the morning for 12 weeks.
223499030|NCT06264622|DIETARY_SUPPLEMENT|Placebo|2 tablets per day during the morning for 12 weeks.
223499031|NCT01420978|PROCEDURE|CSF Diversion|CSF drainage
223499032|NCT05312060|DEVICE|PC Pneumatic compression|Pneumatic compression of the operated limb
223499033|NCT05312060|OTHER|AE Antithromboembolic exercises|Exercises for the edema
223499034|NCT06296849|BEHAVIORAL|Financial Incentive Treatment (FIT)|In the present study, the investigators will provide financial incentives of $200 for biochemically verified abstinence at each of three time points (1 month, 3 month, and 6 month) following baseline. Additionally, the investigators will provide a bonus of $200 for participants who demonstrate abstinence at each of the time points. This incentive value is consistent with recent research using macro-level financial incentives and incorporates both short-term and long-term incentives to shape behavior.
223499035|NCT01334775|PROCEDURE|Open anterior inguinal hernia repair|Placement of a surgical mesh in open anterior inguinal hernia repair.
223499036|NCT03683901|DEVICE|TENS|Electrical Stimulation
223499037|NCT03683901|DEVICE|t-NMES|Electrical Stimulation
223499038|NCT03683901|OTHER|No stimulation|No stimulation
223590992|NCT02546661|DRUG|AZD1775|MEDI4736 (durvalumab) + AZD1775
223590993|NCT02546661|DRUG|Vistusertib|MEDI4736 (durvalumab) + Vistusertib
223590994|NCT02546661|DRUG|AZD9150|MEDI4736 (durvalumab) + AZD9150
223590995|NCT02546661|DRUG|Selumetinib|MEDI4736 (durvalumab) + Selumetinib
223590996|NCT03150784|OTHER|EPIC Club|Weekly exercise gym sessions. Participants will start with a warm-up of 20-25 mins cardiovascular training either doing cycling, treadmill running or cross-training. The remainder of the session consists of strength/resistance and weight-training involving leg press, leg extensor, pull downs, kettle bells, dumbbells. In addition to the above, a novel rhythmical stepping task will be performed over 10 mins.
223590997|NCT04721340|OTHER|Test Group|Individuals who meet the inclusion criteria will be evaluated for manual dexterity, performance, muscle strength and fatigue, respectively, on a predetermined day.
224189472|NCT00981266|DEVICE|Mentor Spectra/Becker 80 Breast Implant|The Mentor Smooth Spectra/Becker 80 Adjustable Breast Implant has a low bleed, gel-filled outer lumen and an adjustable saline-fillable inner lumen. The inner lumen can be gradually filled with saline over a period of time via the fill tube by injecting saline through the injection dome. Once filled to the desired volume, the fill tube and injection dome are removed, and the prosthesis remains in position as a breast implant. Its purpose is to provide volume flexibility and projection adjustability.
224189473|NCT02681692|DEVICE|Magnetic endoscopic imaging system|In the first part,patients would be randomly assigned to have colonoscopy examination performed by one inexperienced colonoscopist (having performed less than 200 procedures) with the assistance of magnetic scope navigation system In the second part colonoscopist would be randomized to perform conventional colonoscopy on a colon model with an MEI view while the force measurement device being used to collect data of colon force variation meanwhile. No patients would be involved in this part. All force variation data would be recorded by a image storage device.
224189474|NCT05023239|OTHER|UG-SZM Group|The patients will be receive Ultrasound-Guided Suprazygomatic Maxillary Nerve Blocks 10 mL of a local anesthetic mixture composed of 0.25% plain bupivacaine .
224205813|NCT00929864|DRUG|Adalimumab|Syringes, Subcutaneous, 40 mg, Biweekly Subcutaneous injections, 24 months (729 days)
223590998|NCT04721340|OTHER|Control Grup|Individuals who meet the inclusion criteria will be evaluated for manual dexterity, performance, muscle strength and fatigue, respectively, on a predetermined day.
223590999|NCT04081272|DRUG|Sodium Chromate Cr51|Sodium Chromate Cr 51 will be used to perform a red blood cell recovered study 24 hours post-transfusion.
223591000|NCT00219960|DRUG|North American Ginseng (Panax Quinquefolius)|
223591001|NCT00261573|DRUG|galantamine hydrobromide|
223591002|NCT00390663|PROCEDURE|Nasal Cautery|
223591003|NCT06232577|DRUG|Hydrocodone|Given by PO
223591004|NCT06232577|DRUG|Tramadol|Given by PO
223591005|NCT06232577|DRUG|Oxycodone|Given by PO
223591006|NCT02702414|BIOLOGICAL|Pembrolizumab|Intravenous (IV) infusion
223591007|NCT03291392|GENETIC|Gene expression or biomarkers exploration|
223591008|NCT05746156|DIAGNOSTIC_TEST|lymphatic mapping|"1. Peritumoral injection of \[99mTc\]Tc-nanocolloid in 6-8 evenly distributed depots on both sides of the tumor, during investigation under anaesthesia. Number of depots depending on the size and localisation of the tumor.~2. Planair and SPECT/CT imaging van de abdomen/pelvis 3h and 12-24h after injection at the department of radiology and nucleair medicine."
224074360|NCT06638892|OTHER|Standard of Care|CDC standard of care, e.g., CDC videos and website.
224074361|NCT06401018|PROCEDURE|No noise cancellation and no music playing|In this group of patients, no apparatus was used to prevent noise in the environment, and they were not exposed to any music in the environment.
224074362|NCT06401018|PROCEDURE|Noise cancelled but not allowed to listen to music|In this group of patients, only noise cancelling was performed during the operation, but no music was played in the environment.
224074363|NCT06401018|PROCEDURE|Music is played but noise is not cancelled|In this group of patients, ambient noise cancelling was not applied and music, which has been proven to reduce anxiety in studies, was played during surgery.
224074364|NCT05111262|DRUG|Adherence to symptom driven budesonide/formoterol as compared to adherence to maintenance ICS and symptom-driven SABA|In this study, we propose a pragmatic, pilot, open-label trial where we are comparing adherence to different inhaler regimens. Patients who were previously sub-optimally adherent to maintenance ICS inhalers will either continue receiving maintenance ICS inhalers and symptom-driven SABA inhalers or symptom-driven ICS/LABA inhalers only.
224074365|NCT00223496|DRUG|Aripiprazole|Aripiprazole5mg - 30mg, every day (QD), for 12 weeks.
223591009|NCT01272869|DEVICE|SenSura|The ostomy bag filter will be tested for a period of 14 days
224074366|NCT01931358|BIOLOGICAL|ALVAC-HIV|1 mL intramuscular injection containing 10\^6 CCID50/dose
223591010|NCT01272869|DEVICE|Morfeus|The new ostomy bag filter will be tested for a period of 14 days
223591011|NCT02343718|DRUG|Vinblastine|
223591012|NCT02343718|DRUG|Temsirolimus|
223591013|NCT03442582|BIOLOGICAL|Afluria Influenza Vaccine|"Afluria is a seasonal influenza vaccine~Vaccine exposure in routine care (no vaccination per protocol)"
223591014|NCT03320590|DIAGNOSTIC_TEST|Time Lapse (material to observe embryonic development)|The embryonic kinetics are recorded by Time lapse Primovision™ (Vitrolife). These kinetic parameters are analysed and annotated by only one person with expertise in this technology.
223591015|NCT05767190|BEHAVIORAL|Motivational interviewing|During the intervention, the trained-nurse will provide a motivational interviewing-based intervention consisting of one session divided into two parts: educational (the concepts of sleep apnea and the symptoms, and the CPAP treatment will be focused on) and training activity (using MI not directly advocate for behavioral change (i.e., use CPAP as prescribed), but asks key questions to help the patient explore conflicting feelings about the change, weighs the positive consequences and negatives of this change, and allows the patient to realize the discrepancy between current risk behavior (i.e. not using CPAP as directed) and the patient's self-identified goals. The intervention will be tailored on the patient's stage of change based on Prochaska and DiClemente transtheoretical model (1982), in fact, the nurse will use MI not only at the beginning of therapy but also in every contact with the patient throughout the treatment (subsequent follow-up visits, phone calls, etc.).
223591016|NCT00597493|DRUG|Sorafenib and Temozolomide|Temozolomide (50 mg per meter-squared of body surface area)every day by mouth in combination with sorafenib. Sorafenib will be taken by mouth twice every day. The dose of sorafenib will be 400 mg (2 x 200mg tablets).
223591017|NCT06014099|BEHAVIORAL|Long peripheral venous catheters for blood collection|used LPC for blood collection
223591018|NCT06014099|BEHAVIORAL|Midline catheter for blood collection|used MCs for blood collection
223591019|NCT06014099|BEHAVIORAL|SPCs for blood collection|used SPCs for blood collection
224074367|NCT01931358|BIOLOGICAL|AIDSVAX B/E|1 mL per injection (300 ug dose/antigen for a total of 600ug/dose administered)
224074368|NCT01931358|BIOLOGICAL|ALVAC-HIV Placebo|1 mL per injection
224074369|NCT01931358|BIOLOGICAL|AIDSVAX B/E Placebo|1 mL per injection
224074370|NCT00559507|DRUG|saracatinib|
224074371|NCT00559507|OTHER|laboratory biomarker analysis|Correlative studies
224074372|NCT02250014|PROCEDURE|cryotherapy|Undergo cryotherapy
224309432|NCT03259659|OTHER|ECG recording, inflammatory cytokines, microbiota, ulcerative colitis disease activity index|In this study, an electrocardiogram signal will be recorded for 30 min in the fasting state, and blood samples for inflammatory cytokines analysis (7 ml) will be taken at the end of the ECG recording; fecal samples will be taken on the experimental day before the study. In addition, ulcerative colitis disease activity index will be assessed using the Mayo scoring system.
224309433|NCT05682859|DRUG|Roflumilast 500 Mcg Oral Tablet|Randomized to either systemic roflumilast or placebo in phase 1. All participating patients will receive roflumilast in phase 2.
223499039|NCT05210946|DRUG|Pemigatinib|"Advanced non-small cell lung cancer patients with known FGFR 1-3 alterations (including but not limited to FGFR amplification, rearrangement/fusion, mutation, etc.) who have failed standard therapy will be enrolled in this study once they have signed the informed consent form (ICF) and been identified as eligible in screening. The patients will receive 13.5 mg of pemigatinib once a day (QD) orally following a 2-week administration/~1-week interruption regimen. They will be dosed until disease progression or intolerable toxicity. During treatment, clinical tumor imaging evaluation will be performed according to RECIST v1.1 every 6 weeks (± 7 days) and then every 9 weeks (± 7 days) after week 48. Safety will be assessed according to NCI-CTCAE 5.0."
223499040|NCT05331833|RADIATION|The enrollment was randomly (1:1) assigned into the study group with CTV-omitted IMRT under PET-CT guidance and the control group with CTV-delineated IMRT using a random number table.|
224074373|NCT02250014|BIOLOGICAL|sargramostim|Given subcutaneously
223499041|NCT02942407|DRUG|apixaban|oral anticoagulant
223499042|NCT02942407|DRUG|warfarin|oral anticoagulant
223499043|NCT03324958|DEVICE|Virtual reality Helmet|The virtual reality helmet will be installed by a radiotherapist or a radiotherapy manipulator, just before the intra vaginal applicator. The virtual reality headset will be connected to a dedicated computer. The virtual reality program will run for 10 minutes which will cover the entire procedure for setting up the brachytherapy device. In order to optimize the distractive potential of virtual reality, four different virtual reality programs will be offered to patients during each brachytherapy fraction. These programs will be contemplative so as not to compromise the immobility of the patients during the installation of the brachytherapy applicator.
223499044|NCT03324958|OTHER|No Virtual Reality Helmet|The radiotherapists can freely dialogue with the patients during the brachytherapy applicator' seating up, as in current practice.
223591020|NCT01167660|DEVICE|The Thrombo-Monitor (ThM)|Non-invasive measurement of coagulation status and comparison to standard blood coagulation tests. In healthy neonates - immediately after birth, before the administration of vitamin K. Coagulation tests will be done on an umbilical cord blood sample. In sick neonates, coagulation studies will be done according to the medical condition.
224074374|NCT06335550|PROCEDURE|Robotic mastectomy|Robotic mastectomy with or without reconstruction
224074375|NCT04418687|DEVICE|Orthoglide|Knee rehabilitation device.
224074376|NCT04418687|OTHER|Physiotherapy only|Physiotherapy only.
224074377|NCT01414257|DRUG|Methotrexate (MTX)|Methotrexate should be administered at the weekly dose of 6 mg orally once a week or twice or three times a week by subdividing the weekly dose into the relevant number of portions. When administering the subdivided doses, MTX should be administered at the interval of 12 hours on Day 1 to Day 2. When the weekly dose is subdivided into two portions, suspend the administration for the remaining 6 days. When the weekly dose is subdivided into three portions, suspend the administration on the remaining 5 days. Repeat this weekly cycle. The dose should be adjusted as appropriate depending on the age, symptom, tolerability, and response to the MTX Preparation in individual patients. The weekly dose should not be higher than 16 mg.
224074378|NCT06961357|DRUG|Cyclophosphamide|Part of lymphodepletion regimen.
224074379|NCT06961357|DRUG|Fludarabine|Part of lymphodepletion regimen.
224074380|NCT06961357|DRUG|Interleukin-2|Standard of care.
224074381|NCT06961357|DRUG|TIL Product|Tumor-infiltrating lymphocytes are an investigational, personalized adoptive cell therapy.
224074382|NCT04623983|DEVICE|bonding tray|Orthodontic bonding tray
224074383|NCT05313061|DRUG|MTX|MTX continuation
224074384|NCT01635114|DIETARY_SUPPLEMENT|resveratrol|150 mg resVida per day for 12 weeks
224074385|NCT01635114|DIETARY_SUPPLEMENT|Placebo|Placebo for 12 weeks
224074386|NCT04697407|BIOLOGICAL|Blood sampling|In all groups, 80 ml of blood will be collected. For patients, this will be done during routine cares.
224074387|NCT04697407|BIOLOGICAL|CSF sampling|Only in both patients groups whom will have a CSF sampling in routine care, some CSF will be collected for the study in addition, with a limit of 5 ml for routine care and study.
224074388|NCT02653768|BEHAVIORAL|Stepped Exercise Program|"STEP 1: Participants have access to an internet-based exercise program for knee OA.~STEP 2: Participants have access to an internet-based exercise program for knee OA plus telephone support.~STEP 3: Participants have access to an internet-based exercise program for knee OA plus in-person physical therapy visit"
224074389|NCT02653768|BEHAVIORAL|Arthritis Education|The arthritis education intervention will include bi-weekly mailings of low-literacy educational materials on a comprehensive set of topics related to OA and its management, based on established treatment guidelines.
224074390|NCT01784965|DRUG|liraglutide|Dosing begins at 0.6 mg subcutaneous injection and increases each week, to 1.2 mg and maximum dose of 1.8 mg.
224309434|NCT05682859|DRUG|Placebo|Placebo tablets
224074391|NCT01784965|DRUG|Placebo|Double blinded will receive study pen with same dosing instructions starting at 0.6 mg, and each week increase to 1.2 mg and finally 1.8 mg at week three.
224074392|NCT04110847|DRUG|JING CEIH SHERN YUAN EXTRACT PILL|Oral use, 3#BID
224074393|NCT00670592|DRUG|HCD122|
224074394|NCT04407767|BEHAVIORAL|Case Formulation plus Cognitive Processing Therapy|The CF approach alters the CPT protocol in two ways: expanding the protocol to intentionally and systematically address impairment in functioning, and enhancing the providers' latitude to navigate challenges to optimal therapy outcomes (COTOS). CF-CPT begins with a formal CF assessment session; elements of CF are then integrated throughout CPT. CF modifications to the original CPT protocol occur in each session by intentionally attending to cognitions that are impeding the patient's functional recovery. The second modification includes enhancing the provider's latitude to diverge from the protocol when clinically wise. CF-CPT provides guidance around the identification, monitoring and management of COTOs, and, importantly, the expedient return to the CPT protocol with continued attention to COTOs.
224189475|NCT04972773|BEHAVIORAL|Mindfulness meditation (MM)|"Towards this additional MM practice, participants will be able to use any combination of the MM apps: Insight timer, which focuses on community/group-like therapy, Healthy minds, which focuses on resilience that is essential in disability adjustment, and Smiling mind, that reminds patients of their family/support structures. These three options were chosen for delivering free MM with different focuses that would cater to the variety of SCI patients needs. Participants will be alerted if they are not achieving 30 minutes of additional MM per week. This will guarantee that the treatment group have a higher time spent on MM for dose-response analysis. Participants will receive a reminder email (see attached) on the Sunday evening of a week with \<30 minutes of additional MM encouraging them to use their mindfulness app."
224189476|NCT03752502|PROCEDURE|Transcranial direct current stimulation (tDCS)|Transcranial direct current stimulation (tDCS) is a noninvasive brain stimulation (NIBS) technique that has been investigated for the management of various chronic pain conditions. However, as a monotherapy for pain relief, this therapy still has controversial results.
224189477|NCT03752502|PROCEDURE|Peripheral electrical stimulation (PES)|Peripheral electrical stimulation (PES) activates a complex neural network involving a series of neurotransmitters and receptors capable of promoting segmental and extrasegmental analgesia.
224309435|NCT02455037|OTHER|Neck Strengthening|Targeted neck strengthening exercises
223499045|NCT05722795|DRUG|Imatinib 400 MG Oral Tablet|One tablet daily 10 days before surgery.
223499046|NCT01104298|DRUG|Doxorubicin|A maximum of 6 cycles every 3 weeks of doxorubicin monotherapy 75 mg/square meter will be given in the absence of progression or not acceptable toxicity.
223499047|NCT01104298|DRUG|Trabectedin|A maximum of 6 cycles every 3 weeks of the combination (Trabectedin 1,1 mg/square meter + doxorubicin 60 mg/square meter) will be given in the absence of progression or not acceptable toxicity.
223499048|NCT05424198|PROCEDURE|Cervical Medial Branch Radiofrequency Ablation|The skin and superficial tissues will be anesthetized at each site with 1-2 mL of lidocaine. Prior to the ablation up to 2 mL of lidocaine may be used at each site to ensure adequate pain control during the ablation. Once in position, a radiofrequency ablation lesion will be made using a 30 second ramp-up time to a maximum temperature of 80 °C, followed by an additional 90 seconds at maximum temperature.
223499049|NCT02750423|PROCEDURE|DHCA+RCP|During deep hypothermic circulatory arrest and retrograde cerebral perfusion (DHCA+RCP) the participant is placed on cardiopulmonary bypass (heart-lung machine) and their body temperature is lowered to a range of 14-18 °C. Once the goal temperature has been achieved, the circulation is stopped and aortic arch replacement is performed in a bloodless surgical field. Blood will be pushed to the brain through arterial vessels, much like the natural blood flow pattern. Once the aortic arch repair is complete, cardiopulmonary bypass is reinstituted, the participant is rewarmed, and separated from cardiopulmonary bypass.
223499050|NCT02750423|PROCEDURE|MHCA + SACP|During moderate hypothermic circulatory arrest and unilateral selective antegrade cerebral perfusion (MHCA + SACP) the participant is placed on cardiopulmonary bypass (heart-lung machine0 and the native blood flow to the brain is temporarily suspended. The body is cooled to temperatures of ≤28°C and blood is administered to the brain via an artery in the neck during the period of arch reconstruction. Once the aortic arch repair is complete, cardiopulmonary bypass is reinstituted, the participant is rewarmed, and separated from cardiopulmonary bypass.
223746117|NCT03475966|OTHER|Nutrition|Patients will be asked to fill in a 3-day food diary. A registered dietitian (RD) will review this diary, provide a full nutritional assessment, and ensure patients are following a high-protein diet (1.5 g of protein/kg/day). A whey-protein supplement may be provided to patients, should they require it. The RD will also ensure adequate calorie consumption for weight maintenance and will provided advice to help ease any GI issues the patients may be experiencing.
224074395|NCT04407767|BEHAVIORAL|Cognitive Processing Therapy|CPT is a brief therapy for PTSD predominantly based on cognitive theory. Traditionally delivered over 12 one-hour sessions weekly or twice weekly, CPT is now variable length depending on patient's recovery from PTSD. CPT is delivered in three phases: education, processing, and challenging and focuses on challenging beliefs and assumptions related to the trauma, oneself, and the world. Changing dysfunctional beliefs alters negative emotions emanating from those beliefs.
224074396|NCT02458196|DRUG|Prednisone|Prednisone: started with prednisone alone 0. 6-0. 8mg/kg.d for 1 month, decreased 5mg per 2 weeks, and maintained at 10mg/d to 12 months.
224074397|NCT02458196|DRUG|Prednisone and Mycophenolate mofetil|"Prednisone: started with prednisone 0. 6-0. 8mg/kg.d for 1 month, decreased 5mg per 2 weeks, maintained at 7.5mg to 10mg/d to 12 months.~Immunosuppressive drugs: Mycophenolate mofetil 1g/d-1.5g/d for 6 months and 0.5/d-1.0g/d for 6 months."
224074398|NCT03757988|BEHAVIORAL|Exercise Intervention- PACE-Life|Subjects will be provided with a Fitbit wristband and instructed how to use it. During the first group session, subjects will be taught how to use their heart rate (on the Fitbit) to determine how fast subjects should walk (to achieve the appropriate exercise dosage). Information on proper care, usage, and how to determine the appropriate heart rate from the watch, which will be used to guide the intensity of the walk will be provided to subjects and reviewed at each group session. For all clinic based group sessions, subjects will arrive at the STEP clinic to meet the entire group and leaders and be reminded of the HR that corresponds with the intensity of that group session. Next, the group will go outside and walk for 30 minutes.
224074399|NCT01033409|BIOLOGICAL|Salmonella Typhi-vectored pneumonia vaccine|Liquid, oral dosage administered once at 10\^7 CFU in 10 mL phosphate-buffered saline
224074400|NCT01033409|BIOLOGICAL|Salmonella Typhi-vectored pneumonia vaccine|Liquid, oral dosage administered once at 10\^8 CFU in 10 mL phosphate-buffered saline
224074401|NCT01033409|BIOLOGICAL|Salmonella Typhi-vectored pneumonia vaccine|Liquid, oral dosage administered once at 10\^9 CFU in 10 mL phosphate-buffered saline
224074402|NCT01033409|BIOLOGICAL|Salmonella Typhi-vectored pneumonia vaccine|Liquid, oral dosage administered once at 10\^10 CFU in 10 mL phosphate-buffered saline
224074403|NCT06286033|DRUG|AG-181|AG-181 tablets
224074404|NCT06286033|DRUG|Placebo|AG-181 matched-placebo tablets
223499051|NCT06069609|DEVICE|kalifilcon A Daily Disposable Toric|kalifilcon A Daily Disposable Toric
223499052|NCT06069609|DEVICE|Acuvue Oasys 1-Day for Astigmatism|Acuvue Oasys 1-Day for Astigmatism
223499053|NCT00891397|DRUG|Pregabalin|Dose of 150mg/day divided in two doses. Increased to 300mg/day then to 600mg/day, always divided in two doses for the day.
223499054|NCT00891397|OTHER|Placebo|Sugar pill
223499055|NCT02371005|RADIATION|Cone Beam Computed Tomography (CBCT)|
223499056|NCT01666977|DRUG|AMG 386|15mg/kg
223499057|NCT01666977|DRUG|AMG 386|30 mg/kg
223499058|NCT01666977|DRUG|AMG 386 Placebo|AMG 386 Placebo
223499059|NCT01666977|DRUG|Pemetrexed|Pemetrexed 500 mg/m2
223499060|NCT01666977|DRUG|Carboplatin|Carboplatin AUC 6
223499061|NCT06398587|DRUG|Onvansertib|Given PO
223499062|NCT06398587|DRUG|Gemcitabine|Given IV
223499063|NCT06398587|DRUG|Nab-paclitaxel|Given IV
223499064|NCT06398587|PROCEDURE|Electrocardiography|Undergo electrocardiography
223499065|NCT06398587|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223499066|NCT06398587|PROCEDURE|Positron Emission Tomography|Undergo PET
223499067|NCT06398587|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223499068|NCT06398587|PROCEDURE|Biospecimen Collection|Undergo tumor biopsy
223499069|NCT06398587|PROCEDURE|Computed Tomography|Undergo CT
224074405|NCT06201507|DRUG|Brentuximab vedotin|Day 1 and 15 Dose: 1.2 mg/kg/dose. (Maximum dose is 120 mg)
224074406|NCT06201507|DRUG|Rituximab|Days: 2 and 16 Dose: 375 mg/m2/dose.
224074407|NCT06201507|DRUG|Doxorubicin|Days: 1 and 15 Dose: 25 mg/m2/dose.
224074408|NCT06201507|DRUG|Vincristine|1 and 15 Dose: 1.5 mg/m2/dose (max: 2 mg/dose).
224074409|NCT06201507|DRUG|Dacarbazine|375 mg/m2 will be administered on days 1 and 15
224074410|NCT00003793|GENETIC|clonality analysis|
224074411|NCT00003793|GENETIC|microsatellite instability analysis|
224074412|NCT00003793|GENETIC|mutation analysis|
224074413|NCT02093442|PROCEDURE|Endometrial injury|Endometrial biopsy using a pipelle de Cornier
224074414|NCT00133523|BIOLOGICAL|Cold-adapted live attenuated influenza virus vaccine, trivalent|Live-attenuated influenza vaccine; single annual dose administered as an intranasal spray.
224074415|NCT00133523|OTHER|Placebo|Physiological saline administered as an intramuscular injection.
224074416|NCT00133523|BIOLOGICAL|Trivalent inactivated influenza vaccine|Inactivated influenza vaccine; single annual dose administered as an intramuscular injection..
224074417|NCT00133523|BIOLOGICAL|Trivalent inactivated influenza vaccine|Inactivated influenza vaccine; single annual dose administered as an intramuscular injection.
224074418|NCT00133523|OTHER|Placebo|Normal allantoic fluid administered annually as an internasal spray.
224074419|NCT02580500|PROCEDURE|epidural catheter|epidural anaesthesia application for spinal catheter will be used
224189478|NCT03752502|PROCEDURE|Sham tDCS|Transcranial direct current stimulation (tDCS) is a noninvasive brain stimulation (NIBS) technique that has been investigated for the management of various chronic pain conditions. However, as a monotherapy for pain relief, this therapy still has controversial results.
224189479|NCT02104232|BEHAVIORAL|THPP-I|
224189480|NCT02104232|BEHAVIORAL|EUC|
224189481|NCT01687985|DRUG|BLI801 laxative - low dose|BLI801 laxative - oral solution
224189482|NCT01687985|DRUG|BLI801 laxative - high dose|BLI801 laxative - oral solution
224189483|NCT05021159|OTHER|MTX, (but the investigator is not using any intervention, the participants are already taking it in their treatment protocol and the investigator is just analyzing p-gp expression)|the investigator is not using any intervention, the participants are already taking it in their treatment protocol and the investigator is just analyzing p-gp expression
223499070|NCT00528151|DRUG|curcumin|curcumin 250 mg twice a day in the first group. placebo 1 capsule twice a day in the second group.
223499071|NCT03892733|BEHAVIORAL|calorie health education knowledge and skills|45 minute intervention done by health educator to give participants skills to use calorie information posted in fast-food restaurants
223499072|NCT03060928|PROCEDURE|Arthroscopic Rotator Cuff Repair|Arthroscopic Rotator Cuff Repair
223499073|NCT03060928|PROCEDURE|Micro-perforations|Biological stimulation with micro-perforations
223499074|NCT03060928|PROCEDURE|Artelon®|Biological stimulation with Artelon® Tissue Reinforcement
223499075|NCT05467202|DRUG|CLL1 CAR-T|A single infusion of autologous CLL1 CAR-T cells administered intravenously
223499076|NCT00186511|BEHAVIORAL|workbook/journal on coping with breast cancer|
223499077|NCT00186511|BEHAVIORAL|supportive expressive group therapy using videoconferencing|
223499078|NCT05115253|BEHAVIORAL|HAPA behavioural counselling + SMS text message boosters|Behavioural counseling grounded in the Health Action Process Approach (HAPA; i.e., action planning and coping planning) paired with daily personalized HAPA guided SMS text message boosters to reduce consecutive workplace sedentary behaviour.
223591021|NCT00256516|OTHER|Eco-Atkins diet (high vegetable protein and vegetable fat)|
223591022|NCT00256516|OTHER|NCEP diet|
224074420|NCT02580500|PROCEDURE|spinal catheter|spinal anesthesia application for spinal catheter will be used
224074421|NCT06423079|PROCEDURE|Siepser knots|Surgical intervention involved creating a superior service keratotomy and using introflective sutures for IOL fixation
224074422|NCT05001347|DRUG|TJ004309|Antibody to CD73
224074423|NCT00485641|DEVICE|SaeboFlex Dynamic Hand Orthosis|
224074424|NCT00485641|PROCEDURE|Saebo F.T.M. Arm Training Program|
224074425|NCT02829021|DEVICE|FLIR ThermaCAM P-65|Women recalled for assessment after positive screening mammography were offered dynamic infrared thermography before clinical mammography and further tests.
224074426|NCT06502093|OTHER|Observational Malnutrition Screening and Foodservice Satisfaction|Patients asked Acute Care Hospital Foodservice Patient Satisfaction Questionnaire and malnutrition risk assessed with NRS-2002 screening tool.
224074427|NCT04385563|DRUG|TQ-B211|Participants will receive TQ-B211 8 milligrams/kilogram (mg/kg) intravenously(iv.) on day 1 in Cycle 1 followed by 6 mg/kg iv.on day 1 in Cycles 2 to 8.
224074428|NCT04385563|DRUG|Herceptin®|Participants will receive Herceptin® 8 milligrams/kilogram (mg/kg) intravenously(iv.) on day 1 in Cycle 1 followed by 6 mg/kg iv.on day 1 in Cycles 2 to 8.
224189484|NCT02911285|DRUG|N-acetylcysteine|1200mg bid (2400mg/day)
224189485|NCT02911285|DRUG|Placebo|Placebo pills bid
224189486|NCT02911285|BEHAVIORAL|Cognitive behavioral therapy|CBT for AUD/SUD, one hour/once a week
224189487|NCT01108588|DRUG|Placebo (to match Aspirin)|Placebo grossly matched Aspirin 300 mg daily
224189488|NCT01108588|DRUG|Aspirin|Aspirin 300 mg daily
224189489|NCT01108588|DRUG|Clopidogrel|Clopidogrel 75 mg daily
224189490|NCT01108588|DRUG|Comparator: Placebo (to match Clopidogrel)|Placebo (grossly matched Clopidogrel 75 mg) daily
224189491|NCT01068015|OTHER|behavior intervention and male circumcision|MSM in intervention arm can receive circumcision service for free, POL intervention, intensive HIV counseling and intensive condom promotion.
223746118|NCT03475966|BEHAVIORAL|Relaxation techniques|Patients will see a psychologist who will provide relaxation techniques (eg. imagery, visualization, deep breathing exercises) to help patients manage anxiety prior to surgery.
223746119|NCT01782664|DRUG|100 mg GSK2586184|100 mg GSK2586184 to be taken twice daily with food (as tablets) for up to 84 days.
223746120|NCT01782664|DRUG|200 mg GSK2586184|200 mg GSK2586184 to be taken twice daily with food (as tablets) for up to 84 days.
223746121|NCT01782664|DRUG|400 mg GSK2586184|400 mg GSK2586184 to be taken twice daily with food (as tablets) for up to 84 days.
223746122|NCT01782664|DRUG|Placebo|Placebo tablets to be taken twice daily with food for up to 84 days.
223746123|NCT00985842|DEVICE|Pe-Lite and sleeve suspension socket|Prosthetic socket worn by the amputee that has a Pe-lite foam liner between the socket and the residual limb. It is suspended from the residual limb using a sleeve at the top of the socket.
224189492|NCT01645215|DRUG|Fruquintinib|Fruquintinib is a capsule in the form of 0.25mg , 1mg and 5mg, oral, once a day.
224189493|NCT05798559|BEHAVIORAL|Sleep Training|These are the trainings given by the researchers in order to regulate the sleep routine and environment. Content will be presented to improve sleep processes by arranging living habits.
224189494|NCT04279509|PROCEDURE|Tumor Core Biopsy|"Performed up to a maximum of 3 time points - baseline upon study enrolment, at the completion of treatment, and upon disease progression.~Four to six tumour core samples will be obtained at each time point. At least two tumour cores will be sent fresh to Invitrocue Pte Ltd for generation of patient-derived organoids for drug-panel screening, at least 1-2 tumour cores at each time point will be stored in formalin and paraffin-embedded for immunohistochemistry analysis of biomarkers, while the remaining 1-2 tumour cores will be stored in liquid nitrogen for subsequent DNA, RNA and protein extraction for biomarker studies including gene expression and proteomics analyses."
224189495|NCT04279509|PROCEDURE|Blood sampling|Germline DNA at baseline for pharmacogenetics analysis. Serial plasma samples for circulating tumour cells and biomarkers, at baseline, prior to day 1 of each cycle while on treatment, at the end of treatment (either upon disease progression or upon completion of predetermined cycles of chemotherapy).
224309436|NCT05798026|DRUG|EU103|EU103 will be administered via intravenous infusion.
224309437|NCT06515236|BEHAVIORAL|Strategic Treatment Assessment for Youth (STAY)|Culturally tailored measurement based care
223499079|NCT05115253|DEVICE|JITAI|EMA monitoring mobile phone application that uses a phone's on-board accelerometer to monitor a participant's sedentary behaviour and deliver a push notification once a set condition has been met. This intervention will be utilized to reduce consecutive workplace sedentary behaviour.
223499080|NCT01092156|BEHAVIORAL|Education|Education on Infant-led latching
223499081|NCT00768677|DRUG|topiramate|
223746124|NCT00985842|DEVICE|Total Surface bearing a socket with a sleeve suspension but without suction|Prosthetic socket worn by the amputee where the fit of the socket touches every part of the residual limb. This socket is suspended from the residual limb using a sleeve at the top of the socket.
223746125|NCT00985842|DEVICE|Total surface bearing suction socket with a pin lock suspension|Prosthetic socket worn by the amputee where the fit of the socket touches every part of the residual limb. This socket is suspended from the residual limb using a pin that protrudes from the bottom of the liner into the socket that is then locked in place by the amputee.
223746126|NCT00985842|DEVICE|Total surface bearing suction socket with a sleeve suspension|Prosthetic socket worn by the amputee where the fit of the socket touches every part of the residual limb. This socket using vacuum suction plus a sleeve at the top of the prosthetic socket to enhance the security of the suspension.
224189496|NCT02449005|BIOLOGICAL|BM-MSCs/fibrin glue/collagen fleece|Xeno-free, clinical-grade, autologous alveolar bone marrow mesenchymal stem cells enriched with autologous fibrin glue and loaded into a commercially available collagen fleece.
224189497|NCT02449005|OTHER|Fibrin glue/collagen fleece|The biocomplex of autologous fibrin glue and collagen fleece devoid of stem cells will fill the osseous defect
224309438|NCT06515236|BEHAVIORAL|Measurement Based Care As Usual|Measurement based care as usual
223499082|NCT02177292|RADIATION|Radiation Therapy|A high dose of radiation to the pelvic lymph nodes of 56 Gy (Gy/Gray = measure of amount of radiation) and at the same time give a boost (additional) radiation to the prostate itself (to 70 Gy).
223499083|NCT03611270|DEVICE|Pulmonary Denervation|Pulmonary Denervation (PDN) using the TIVUS™ System will be performed in patient suffering from pulmonary hypertension after completion of screening and eligibility phase, The procedure will be performed during right heart catheterisation. Safety and effectiveness of the PDN treatment will be assessed during one year follow up.
223499084|NCT00899275|OTHER|Cytology Specimen Collection Procedure|Correlative studies
223499085|NCT03281915|PROCEDURE|High inguinal Varicocelectomy|Semen parameters after high inguinal varicocelectomy will be collected
223499086|NCT03281915|PROCEDURE|Subinguinal varicocelectomy|Semen parameters after subinguinal Varicocelectomy will be collected
223499087|NCT05409638|BEHAVIORAL|Cognitive Behavioral Therapy to manage cancer-related fatigue|Participation will consist of attending 90-minute virtual groups for 4 consecutive weeks on cancer-related fatigue. During the 4 weeks, participants will be asked to participate in activities, participate in group discussions, and complete homework.
223499088|NCT04242134|DEVICE|Drug-coating balloon|Provisional stenting technique with DCB
223499089|NCT01716156|DRUG|Grazoprevir|Grazoprevir, tablet, orally, 100 mg, once per day for 12 or 24 weeks, depending on Arm assignment
223499090|NCT01716156|DRUG|Ribavirin|Ribavirin capsules, orally, twice per day, at a total daily dose from 800 to 1400 mg based on participant weight
223499105|NCT05485558|DRUG|N-acetyl cysteine|10 mg/kg of N-acetyl cysteine capsules together with their standard antiepileptic drug for 6 months.
223499106|NCT05485558|DRUG|Placebo|15 patients will receive standard antiepileptic drug plus placebo capsules for 6 months.
223499107|NCT05485558|DRUG|NAc|40 mg/kg of N-acetyl cysteine capsules together with their standard antiepileptic drug for 6 months.
224189498|NCT02449005|PROCEDURE|Open flap debridement|Group C will receive minimally invasive surgery employing papilla preservation techniques in addition to retaining the soft tissue wall of the pocket. There will be no use of grafting materials
224189499|NCT02587845|DRUG|Tranexamic Acid (IV)|IV tranexamic acid group were administered intravenous 10 mg/kg dose of TXA after closing the ITB.
223499108|NCT03925220|BEHAVIORAL|The SUPPER Project|Substance Use Promoted by Eating family meals Regularly
223591023|NCT00376766|DRUG|levetiracetam|
223591024|NCT00386165|DRUG|larazotide acetate|larazotide acetate 4 mg capsules
223591025|NCT05150938|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Retrospective cohort analysis using Swedish registries including the Cancer Registry, National Patient Registry, Prescribed Drug Registry, and Cause of Death Registry.
224074429|NCT04385563|DRUG|docetaxel|Participants will receive docetaxel 75 milligrams/square meter (mg/m\^2) iv.on day 2 in Cycle 1 followed by 75mg/m\^2 iv.on day 1 in Cycles 2 to 8.
224074430|NCT03823391|DRUG|ABBV-3373|ABBV-3373 is administered as intravenous (IV) infusion
224074431|NCT03823391|DRUG|Placebo for ABBV-3373|Placebo for ABBV-3373 is administered as IV infusion
224074432|NCT03823391|DRUG|Adalimumab|Adalimumab is administered as subcutaneous (SC) injection
224074433|NCT03823391|DRUG|Placebo for adalimumab|Placebo for adalimumab is administered as subcutaneous (SC) injection
224074434|NCT03248726|DRUG|Polyethylene glycol and bisacodyl|Intervention: Take 3 tablets (15mg) of stimulant laxatives Dulcolax® (bisacodyl) at 10pm the day before examination. Take two pack of osmotic laxative Klean-prep® powder (Polyethylene glycol) mixed with 2000ml water at 5am on the morning of examination.
224074435|NCT03248726|DRUG|Split-dose polyethylene glycol|Take two pack of Klean-prep® powder mixed with 2000ml water at 6pm before the day of examination, and take another two pack of osmotic laxative Klean-prep® powder mixed with 2000ml water at 5am on the examination day.
224074436|NCT02257047|DIETARY_SUPPLEMENT|Tea|
224074437|NCT02257047|DIETARY_SUPPLEMENT|RYR|red yeast rice
224074438|NCT05689047|DRUG|M5717 330 mg|Participants will receive orally 330 mg granules of M5717 in combination with pyronaridine dispersed in water under fasting condition.
224074439|NCT05689047|DRUG|M5717 500 mg|Adolescent participants with weight less than (\<) 45 kilograms (kg) will receive orally 500 mg granules of M5717 in combination with pyronaridine dispersed in water once daily under fasting condition.
224074440|NCT05689047|DRUG|M5717 660 mg|Adult and adolescent participants with weight more than or equal to (\>=) 45 kg will receive orally 660 mg granules of M5717 in combination with pyronaridine dispersed in water once daily under fasting condition.
224074441|NCT05689047|DRUG|Pyronaridine 360 mg|Participants will receive 360 mg of pyronaridine tablets in combination with M5717 under fasting condition.
224074442|NCT05689047|DRUG|Pyronaridine 360 mg|Participants with weight \>=24 to \<45 kg will receive 360 mg of tablets in combination with M5717 under fasting condition.
224074443|NCT05689047|DRUG|Pyronaridine 540 mg|Participants with weight \>=45 to \<65 kg will receive 540 mg of Pyronaridine tablets in combination with M5717 under fasting condition.
224074444|NCT05689047|DRUG|Pyronaridine 720 mg|Participants with weight \>=65 kg will receive 720 mg of Pyronaridine tablets in combination with M5717 under fasting condition.
224074445|NCT04468126|OTHER|Standard oxygen|Standard low flow oxygen therapy through facemask or non-rebreathing mask at least 10 L/min.
224074446|NCT04468126|OTHER|High-flow nasal oxygen therapy|Humidified and heated oxygen with a gas flow at least 50 l/min through nasal cannula and inspired fraction of oxygen adjusted in order to maintain a SpO2 between 92 and 96%
224074447|NCT04175626|DEVICE|Orsiro DES|Orsiro is a device/drug combination product composed of two components, a device (coronary stent system including a cobalt chromium stent platform), and a drug product (a formulation of sirolimus) contained in a bioabsorbable polymer coating.
224074448|NCT05622110|PROCEDURE|Adhesive glue closure|Incision closure with adhesive glue
224074449|NCT05622110|PROCEDURE|Subcuticular closure|Incision closure with 3-0 vicryl subcuticular sutures
224074450|NCT05852704|DRUG|Dapagliflozin 10mg Tab|Dapagliflozin once daily for a minimum of seven days while awaiting scheduled CABG and up until discharge with a short interruption for surgery.
224189500|NCT02587845|DRUG|Tranexamic Acid (Topical)|Topical tranexamic acid group were administered 2.0 g TXA in 100 ml of normal saline into the hemovac line after closing the ITB.
224189501|NCT00808197|PROCEDURE|ocular blood flow measurement|Ocular blood flow will be determined by non-invasive methods, including laser Doppler flowmetry and laser interferometry
224189502|NCT05455060|DRUG|Chinese herbal formula (CHF)|Each CHF capsule, weighing 500mg, is composed of Xiao-Feng-San 200mg, Zhen-Ren-Huo-Ming-Yin 200mg, Dictamnus dasycarpus 50mg and Houttuynia cordata 50mg. Patients will take the medicine 2 times a day (6gm BID for BW≥40kg), for 12 weeks, and the dosage will be modified according to patients' body weight. (3gm BID for 20kg≦BW\<40kg; 1.5gm BID for BW\<20kg)
224189503|NCT05455060|DRUG|Placebo|The patients in control group will take the placebo capsules, which has the similar look, smell, and taste. The dosage, frequency, and duration are the same as CHF group.
224074451|NCT05852704|DRUG|Placebo Tab|Matching placebo once daily for a minimum of seven days while awaiting scheduled CABG and up until discharge with a short interruption for surgery.
224074452|NCT05882058|DRUG|BI 764532, dose 1|BI 764532, dose 1
224074453|NCT05882058|DRUG|BI 764532, dose 2|BI 764532, dose 2
224074454|NCT06328686|DIETARY_SUPPLEMENT|Arginine|Given IV or PO
224074455|NCT06328686|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
224074456|NCT06328686|PROCEDURE|Computed Tomography|Undergo CT
224074457|NCT06328686|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
224074458|NCT06328686|PROCEDURE|Spectroscopy|Undergo spectroscopy
224074459|NCT06328686|RADIATION|Whole-Brain Radiotherapy|Undergo WBRT
224074460|NCT01996800|PROCEDURE|Spinal Manipulative Therapy (SMT)|Spinal manipulation is a therapeutic intervention performed on spinal articulations which are synovial joints. These articulations in the spine that are amenable to spinal manipulative therapy include the z-joints, the atlanto-occipital, atlanto-axial, lumbosacral, sacroiliac, costotransverse and costovertebral joints.
224189504|NCT00757380|PROCEDURE|Trypan Blue|Membranepeeling with TB
224189505|NCT00757380|PROCEDURE|Brillant Blue|Membranepeeling and membrana limitans interna peeling with BB
224189506|NCT03427203|DEVICE|SenSura Mio|SenSura Mio is a marked ostomy device which is used as the comparator in this study
224309439|NCT00991419|DRUG|[18F]AZD4694|\[18F\]AZD4694 PET Ligand administered at Visit 1, 30 days following screening and at visit 4 for some of the participants.
223499109|NCT03925220|BEHAVIORAL|Improving nutrition and physical activity among youth|A brief intervention focused on improving nutrition and physical activity among youth
223499110|NCT03814356|DRUG|Methylphenidate|IV MPH
223591026|NCT05150938|DRUG|Low molecular weight heparin (LMWH)|Retrospective cohort analysis using Swedish registries including the Cancer Registry, National Patient Registry, Prescribed Drug Registry, and Cause of Death Registry.
224074461|NCT01996800|PROCEDURE|SMT and Neuromuscular Reeducation|Neuromuscular reeducation is a general term that refers to techniques that attempt to retrain the neuromuscular system to function properly. The basis of this idea is that the formation of certain patterns of communication between muscles and nerves allow people to perform simple everyday acts such as climbing stairs.
224074462|NCT02072655|PROCEDURE|socio-aesthetic care|"* care of the face~* skin cleansing with cleansing milk to remove impurities~* a gentle scrub to exfoliate and cleanse the skin~* a relaxing massage~* moisturizing mask~* application of a moisturizer suited to specific patient skin: skin reactivity, dehydration ...~* care manicure / pedicure,~* massages~* makeup, advice (scarves, wigs care products adapted to the skin changes ...) and helping relationship."
224074463|NCT03783520|DEVICE|Er,Cr:YSGG Laser|Er,Cr:YSGG Laser is used for disinfection of the root canals.
224074464|NCT03783520|OTHER|Sodium hypochlorite|Sodium hypochlorite is used for disinfection of the root canals
224074465|NCT06465589|OTHER|JOURNeY anonymous|"The anonymously usable version of the self-help program JOURNeY which does not require a login and does not collect personal data.~Includes 4 main components:~1. psychoeducation where participants learn about SAD and the treatment,~2. cognitive restructuring where participants challenge dysfunctional social cognitions,~3. attention training where participants learn to decrease self-focused attention, and~4. exposure where participants seek out and endure fear-inducing situations.~Additionally, there is a first module which discusses motivation and a conclusion module which encourages participants to keep practicing and using techniques they learned in the program in their daily life."
224074466|NCT06465589|OTHER|JOURNeY standard|"The standard version of the self-help program JOURNeY which requires a login and collects personal data.~Includes 4 main components:~1. psychoeducation where participants learn about SAD and the treatment,~2. cognitive restructuring where participants challenge dysfunctional social cognitions,~3. attention training where participants learn to decrease self-focused attention, and~4. exposure where participants seek out and endure fear-inducing situations.~Additionally, there is a first module which discusses motivation and a conclusion module which encourages participants to keep practicing and using techniques they learned in the program in their daily life."
224074467|NCT00634491|DRUG|sodium bicarbonate|150 meq/l Sodium bicarbonate 3cc/kg/hr before and 1cc/kg/hr after angiography
224074468|NCT00634491|DRUG|Acetazolamide|Acetazolamide 250 mg+ 1 cc/kg/hr normal salin before and after angiography
224074469|NCT00634491|DRUG|normal salin|1 cc/kg/hr 6 hour before and after angiography
224074470|NCT03375190|OTHER|Dressing|Transparent film dressing (TegadermTM CHG Chlorhexidine Gluconate IV Securement Dressing, 3M Health Care, St. Paul, MN, USA) alone
224074471|NCT03375190|OTHER|Dressing + adhesive|Transparent film dressing + topical skin adhesive (SwiftSetTM Topical Skin Adhesive, CovidienTM Devon, UK) at insertion site
224074472|NCT03375190|OTHER|Experimental: Dressing + adhesive + strips (parallel)|Transparent film dressing + topical skin adhesive + reinforced skin closure strips (Steri-StripTM, 3M Health Care, St. Paul, MN, USA) placed parallel to long axis of catheter
224074473|NCT03375190|OTHER|Experimental: Dressing + adhesive + strips (perpend)|Transparent film dressing + topical skin adhesive + reinforced skin closure strips (Steri-StripTM, 3M Health Care, St. Paul, MN, USA) placed perpendicular to long axis of catheter
224189507|NCT03427203|DEVICE|Coloplast Ostomy device 1|Coloplast Ostomy device 1 a newly developed ostomy device
224189508|NCT03427203|DEVICE|Coloplast Ostomy device|Coloplast Ostomy device 2 a newly developed ostomy device
223499111|NCT03220646|DRUG|abemaciclib|abemaciclib 200mg PO q12 hours (+/- 2 hours) on days 1-28 of each 28 day cycle.
223499112|NCT03220646|DRUG|abemaciclib|200mg PO q12 hours (+/- 2 hours) for 4-7 days prior to surgery. Upon recovery from surgery, patients will resume abemaciclib at the same dose and schedule as cohorts A and C.
223499113|NCT04074512|DRUG|copper histidinate|copper histidinate for subcutaneous injection
223499114|NCT05221866|BEHAVIORAL|Empowering Patient to Steer Their Pain Management After Surgery|Participants will be randomized to receive the consumer health informatics app (UControlPain) versus an app with only data collection function (no educational components) in an intent-to-treat design. Randomization will be implemented via REDCap by the study coordinators so that all investigators will remain blind to group assignment. Further, information on which type of app was installed will not be shared with providers or participants.
223591027|NCT05150938|DRUG|vitamin K antagonist (VKA)|Retrospective cohort analysis using Swedish registries including the Cancer Registry, National Patient Registry, Prescribed Drug Registry, and Cause of Death Registry.
223591028|NCT05150938|DRUG|other NOACs|Retrospective cohort analysis using Swedish registries including the Cancer Registry, National Patient Registry, Prescribed Drug Registry, and Cause of Death Registry.
224074474|NCT03375190|OTHER|Experimental: Dressing + adhesive + strips + benzoin|Transparent film dressing + topical skin adhesive + skin closure strips + topical benzoin (Compound Tincture of Benzoin USP 10%, Professional Disposables International, Inc., Orangeburg, NY, USA) spread in a 12 centimeter by 14 centimeter area around the insertion site
224189509|NCT03427203|DEVICE|Coloplast Ostomy device 3|Coloplast Ostomy device 3 a newly developed ostomy device
224189510|NCT02493829|BIOLOGICAL|AML Cell Vaccine|
224189511|NCT02511691|DRUG|18F-PSS232|Diagnostic PET Tracer
224189512|NCT05597189|DIETARY_SUPPLEMENT|Experimental product|Botanical extract
224189513|NCT05597189|OTHER|Control product consumption|Product with identical characteristics to the experimental product.
224309440|NCT00381160|BEHAVIORAL|Reduction of sugar-sweetened beverage consumption|Multi-component intervention aimed at reducing sugar-sweetened beverage consumption. Components include delivery of non-caloric beverages to home in combination with behavioral modification (telephone counseling with parent; check in visit with participant).
224189514|NCT05135494|OTHER|Inspiratory Muscle Training|"The Experimental Group will perform IMT which includes training of the inspiratory muscles with the PowerBreath Medic Plus regulated at 75% of the subjects' maximal inspiratory pressure (MIP) values, five times/week over five weeks 5 sets of 5 repetitions with 1 set increasing each week.~They will participate of the rehabilitation program that will consist of an average of 8 weekly sessions of physiotherapy and speech therapy, totaling 40 sessions. They will also perform 150 to 180 minutes of aerobic exercise of their choice and guidance on behavioral measures to manage OSA."
224189515|NCT05135494|OTHER|Control|The control group will participate of the rehabilitation program that will consist of an average of 8 weekly sessions of physiotherapy and speech therapy, totaling 40 sessions. They will also perform 150 to 180 minutes of aerobic exercise of their choice and guidance on behavioral measures to manage OSA.
224189516|NCT01230489|BIOLOGICAL|MediHoney|In this group a Medihoney 2 x 2 will be used in place of the standard dry 2 x 2 currently used as the wound dressing. Also all indentations of the wound will be filled with Medi-Honey ointment prior to the application of the dressing.
224189517|NCT00561262|OTHER|questionnaire administration|
224189518|NCT00561262|PROCEDURE|high-intensity focused ultrasound ablation|
224189519|NCT00561262|PROCEDURE|quality-of-life assessment|
224205814|NCT01403428|OTHER|Noninvasive positive pressure ventilation|Noninvasive positive pressure ventilation (NPPV) will deliver pressurized gas through a nasal or oronasal mask, connected to a pressure targeted ventilator. NPPV provides ventilator support without the use of an endotracheal tube. Standard of care includes use of corticosteroids, oxygen, short acting β-agonist and inhaled ipratropium bromide.
224205815|NCT05692739|DRUG|Insulin|see arm description
224205816|NCT05692739|DRUG|Cyclosporins|see arm description
224205817|NCT05692739|DRUG|Artificial tears|see arm description
224205818|NCT04507789|OTHER|exercise intervention|Exercise protocol will consist of the recommended special exercise sets for upper extremity problems on mastectomy patients. The upper extremity protocol has published in 2018 by Richmond and friends called prevention of musculoskeletal shoulder problems after breast cancer treatment UK-PROSPER protocol.this special protocol has unique exercise sets for to restore shoulder range of motion, to maintain good force level of upper extremity muscles and stretch exercises especially to the muscles around the radiotherapy area. Exercises will be done under the supervision of a specialized physiotherapist about upper extremity disorders.
224205819|NCT04507789|OTHER|routine radiotherapy protokol|This intervention is only an observation to patients during their routine radiotherapy protocol. There will be no exercise intervention for the upper extremity for the patient in this group.
223499115|NCT05221866|BEHAVIORAL|Provider-facing Prescription Aid|Providers will be given information to inform a participant-centered post-discharge pain management plan. This tool will be activated once half the subjects are enrolled. Participants will be masked when the provider-facing tool is turned on.
223499116|NCT05561140|DRUG|Voxelotor Oral Tablet|Synthetic small molecule supplied as 500 mg tablets, administered Orally
223499117|NCT05561140|OTHER|Placebo|Placebo
223499118|NCT06248671|DRUG|Atorvastatin 40mg|Each tablet will be taken once daily for 84 days.
223499119|NCT06248671|DRUG|Placebo|Each tablet will be taken once daily for 84 days
223499120|NCT06248671|DRUG|Atorvastatin 20mg|Each tablet will be taken once daily for 84 days.
223499121|NCT03522259|DRUG|Rivaroxaban 10 MG Oral Tablet [Xarelto]|Rivaroxaban 10mg per os is started on the first postoperative day. Patients receive Rivaroxaban 10mg QD for 7days (short arm) or 28 days (long arm)
223499122|NCT06538402|PROCEDURE|10 cm pouch|A 10 cm pouch will be constructed
223499123|NCT06538402|PROCEDURE|15 cm pouch|A 15 cm pouch will be constructed
223499124|NCT05658731|RADIATION|substructure informed planning|Radiation Therapy with substructure informed planning determined by the PI.
223499125|NCT05658731|OTHER|Neurocognitive Testing|California Verbal Learning Test (CVLT) and other cognition assessments.
223499126|NCT05658731|DIAGNOSTIC_TEST|MRI|Magnetic resonance imaging (MRI) using whole brain diffusion tensor imaging (DTI) and resting state functional MRI (rsfMRI).
223499127|NCT05098483|PROCEDURE|Regeneration in primary molars by using MTA|Regenerative endodontic procedure in nonvital primary molars using MTA capping material
223499128|NCT05098483|PROCEDURE|Regeneration in primary molars by using biodentine|Regenerative endodontic treatment in primary molars with biodentine as capping material
223499129|NCT05098483|PROCEDURE|Conventional Root canal treatment in primary molars|Removal of pulp tissue from the canals of primary molars
223499130|NCT02921022|DRUG|Gemcitabine|
223499131|NCT02921022|DRUG|Nab-paclitaxel|
223499132|NCT02921022|DRUG|PEGPH20|
223499133|NCT06216873|OTHER|multiple trauma|Review the medical record to gather the physical parameters, blood examination result and radiologic examination results
223499134|NCT05683496|DRUG|lonigutamab|subcutaneous injection
223499135|NCT05683496|DRUG|Placebo|subcutaneous injection
223499136|NCT05199480|DRUG|Tobacco flavored liquid type 1|A commercially available cartridge-based device with tobacco flavored liquid.
223499137|NCT05199480|DRUG|Tobacco flavored liquid type 2|A commercially available cartridge-based device with tobacco flavored liquid.
223499138|NCT05568706|DRUG|EDP-938|Subjects will take EDP-938 once daily for 5 days
223499139|NCT05568706|DRUG|Placebo|Subjects will take matching placebo, once daily for 5 days
223499140|NCT03781934|DRUG|MIV-818 (fostroxacitabine bralpamide) + pembrolizumab|MIV-818 - oral capsules; pembrolizumab - IV
223499141|NCT03781934|DRUG|MIV-818 (fostroxacitabine bralpamide) + lenvatinib|MIV-818 - oral capsules; lenvatinib - oral capsules
223499142|NCT05536297|DRUG|avacincaptad pegol|Intravitreal Injection
223499143|NCT06836128|DRUG|N-acetyl cysteine|N-Acetyl Cysteine (NAC) has antioxidant properties and is essential for the body's production of glutathione, and both glutathione and NAC are potent antioxidants.
223499144|NCT06836128|DRUG|Metfomin|metformin is commonly used for managing polycystic ovary syndrome (PCOS) due to its benefits in addressing several underlying features of the condition. While it is not officially approved by regulatory agencies like the FDA for PCOS, it is widely recognized and recommended in clinical practice guidelines as an off-label treatment for PCOS, particularly in women with insulin resistance and metabolic dysfunction.
223499145|NCT05250037|PROCEDURE|Home spirometry|Undergo spirometry measurements
224189520|NCT06010264|OTHER|Kinesiotape|"In the kinesiotaping group, kinesiotape was applied from the first postoperative day in addition to conservative treatment.~Kinesiobant application was performed regularly until the 6th week by a researcher with a certificate in kinesiobanting in accordance with the lymphatic correction and pain inhibition techniques described by Kenzo Kase.~Conservative Treatment Program. 1-10 days: Patient education Pendulum exercises Active hand and wrist exercises Cold Application 1-6 Weeks: Pendulum exercises are continued Active hand and wrist exercises are continued Cold application is continued Passive arm elevation with opposite hand support in supine position Elbow flexion/extension exercise at the limit of pain"
224205820|NCT01858129|DRUG|Experimental group: Budicort by Inhalation|Inhaled Budicort twice daily
224205821|NCT01858129|DRUG|placebo|
224205822|NCT02624349|DRUG|Quadravalent human papillomavirus vaccine|Vaccine will be administered to all transplant recipients. Controls will be recruited based on previous documented receipt of vaccine
223499146|NCT05250037|PROCEDURE|Biospecimen Collection|Undergo nasal and/or oral swabs, and blood collection
223499147|NCT05250037|OTHER|Questionnaire Administration|Complete questionnaires
223499148|NCT04225871|DRUG|zilucoplan (RA101495)|Daily subcutaneous (SC) injection
223499149|NCT01944774|DRUG|Nemonoxacin 500 mg|IV Infusion, once daily for 7\~14 days
223499150|NCT01944774|DRUG|Nemonoxacin 650 mg|IV Infusion, once daily for 7\~14 days
223499151|NCT01944774|DRUG|Moxifloxacin 400 mg|IV Infusion, once daily for 7\~14 days
223499152|NCT04095637|DEVICE|Medial knee arthroplasty|Surgical intervention where the medial portion of the knee is replaced by an artificial metal and polyethylene implant
223499153|NCT05459532|DRUG|Molnupiravir 200 mg|The drug is orally bioavailable (and is indicated for treatment of mild to moderate COVID-19 in adults with a positive SARS-COV-2 diagnostic test and who have at least one risk factor for developing severe illness. The recommended dose is 800 mg (four 200 mg capsules) taken orally 12-hourly for five days, and should be administered as soon as possible after diagnosis of COVID-19 has been made and within five days of symptom onset.
223499154|NCT03914703|PROCEDURE|EZ Pass Suture Passer|Instruments used to help with rotator cuff or ACL repair
223499155|NCT06961838|OTHER|Inspiratory muscle training programme|In addition to their standard treatment, individuals in the inspiratory muscle training group will participate in inspiratory muscle training for a total of 30 minutes with a threshold loading device (POWERbreathe®) for 15 minutes twice a day, 5 days a week for 4 weeks under the supervision of a physiotherapist.
223499156|NCT06961838|OTHER|control group|Individuals in the control group will continue their standard treatment. No changes will be made in the medical treatments (type, dosage and frequency) of the individuals in both groups (the inspiratory muscle training group and the control group) during the study.
223499157|NCT01188447|PROCEDURE|Canadian C-Spine Rule|Paramedics will apply a validated decision rule (the Canadian C-spine Rule) to determine whether or not immobilization is required for trauma patients being transported to the emergency department.
223499158|NCT02818803|OTHER|Propolis|
223591029|NCT04638114|PROCEDURE|Mini-open DAA|Direct anterior approach hip
223591030|NCT04638114|PROCEDURE|Hip arthroscopy|arthroscopic treatment of hip pathology
223591031|NCT04207437|DEVICE|Vibration therapy|vibration therapy using hand held vibration device
223591032|NCT04117243|DRUG|Misoprostol|patients will be given 400 microgram misoprostol (2 tablets - Cytotec, Pfizer, G.D. Searle LLC) sublingually immediately before starting skin incision (n=115)
223591033|NCT04117243|DRUG|Tranexamic acid|patients will be given 1 gm (10 ml) TXA (Kapron, Amoun, Egypt) diluted in 20 ml of Glucose 5% (administered as intravenous infusion over 5 minutes, at least 15 minutes prior to skin incision) (n=115)
223591034|NCT04117243|DRUG|Oxytocin|patients will receive an intravenous bolus of 5 IU oxytocin (Syntocinon, Novartis, Basel, Switzerland) and 20 IU oxytocin in 500 mL lactated Ringer's solution (infused at a rate of 125 mL/h) following the delivery of the baby (n=115)
223591035|NCT05052567|DRUG|CEND-1|The dose is specified according to the protocol. CEND-1+paclitaxel (albumin-bound type)+gemcitabine
223591036|NCT06019338|OTHER|Pain Diary use|Validation of a pain diary specifically designed to capture pain dimensions of Trigeminal Neuralgia
223591037|NCT06026501|DRUG|PE0116,PE0105|"1. PE0116: 4-1BB Agonist Antibody Drug~2. PE0105: PD-1 Monoclonal Antibody Drug"
223591038|NCT05479149|OTHER|Training protocol with the cervical device for treatment (CDAT).|Endurance training program of deep cervical flexors and deep cervical extensors with the cervical device for treatment.
223591039|NCT05479149|OTHER|Conventional training protocol|Endurance training program of deep cervical flexors and deep cervical extensors with the conventional protocol.
223591040|NCT00544622|PROCEDURE|structured therapeutic chain of stroke treatment|
223591041|NCT01307293|BEHAVIORAL|Cognitive behavior therapy|6 or 12 sessions of cognitive behavior therapy.
223499159|NCT02818803|DRUG|Miconazole|
223499160|NCT02941497|BEHAVIORAL|Social marketing and health promotion campaign|Students in the intensive intervention group developed a nine-month social marketing health campaign. The campaign included five costumed characters who interacted with students on campus in residence halls, dining halls, and other highly-trafficked public areas on campus. Photos and videos of interactions were put on social media. Student participants from the general population (the diffuse intervention group) were asked to set weekly healthy goals related to diet, physical activity, and stress management throughout the campaign and received email and text messages with goal-specific written and video health-promotion messages. Faculty partnered with the students throughout the intervention process to educate and give advice on the content of health promotion messages.
223591042|NCT01043588|PROCEDURE|TURP|TransUrethral Resection of the Prostate
223591043|NCT01043588|PROCEDURE|PVP|Photo selective Vaporization of the Prostate
223591044|NCT06508736|BEHAVIORAL|Storytelling|It is aimed that adolescents gain behavioral change through stories.
223591045|NCT06508736|BEHAVIORAL|Training|Participants will be trained on cyberbullying in 4 sessions.
223591046|NCT03908476|DEVICE|Burst-capable SCS system|Subjects will be given Burst stimulation using a market-released Abbott SCS system. Burst stimulation may be achieved through surgical or non-surgical means.
223591047|NCT03908476|DEVICE|DRG Stimulator|Subjects will be implanted with a market-released Abbott DRG stimulation system.
224205823|NCT03726242|DRUG|Levcromakalim|To investigate the role of levcromakalim compared with placebo after intradermal and intramuscular injection.
224189521|NCT06010264|OTHER|Shamtape|"In the sham taping group, sham tape was applied from the first postoperative day in addition to conservative treatment. Medical flasters were used as sham tape. Sham tapes were applied by cutting in the same fan shape as in kinesioband.~Conservative Treatment Program. 1-10 days: Patient education Pendulum exercises Active hand and wrist exercises Cold Application 1-6 Weeks: Pendulum exercises are continued Active hand and wrist exercises are continued Cold application is continued Passive arm elevation with opposite hand support in supine position Elbow flexion/extension exercise at the limit of pain"
224189522|NCT06010264|OTHER|Standard Physiotherapy Program|Conservative Treatment Program. 1-10 days: Patient education Pendulum exercises Active hand and wrist exercises Cold Application 1-6 Weeks: Pendulum exercises are continued Active hand and wrist exercises are continued Cold application is continued Passive arm elevation with opposite hand support in supine position Elbow flexion/extension exercise at the limit of pain
224189523|NCT01444638|DEVICE|Ultrasound examination|Trainees will receive pre-procedure U/S guided examination of the parturient's back.
224189524|NCT05814965|PROCEDURE|endodontic treatment in the form of root canal treatment|Patients will receive endodontic treatment, and inflammatory markers will be assessed
224189525|NCT05814965|PROCEDURE|endodontic treatment|Patients will receive endodontic treatment in the form of root canal treatment, and inflammatory markers will be assessed along with metabolic markers assessment
224189526|NCT05814965|DIAGNOSTIC_TEST|assessment of inflammatory marker|assessment of inflammatory markers
224189527|NCT05814965|DIAGNOSTIC_TEST|inflammatory markers will be assessed along with metabolic markers assessment|inflammatory markers will be assessed along with metabolic markers assessment
224189528|NCT01791543|DEVICE|Intramural Needle Ablation Catheter|
224189529|NCT04487275|DRUG|MLC901 or Placebo|groups randomly assigned to receive either MLC901 or placebo capsules three times per day over 6 months
224189530|NCT00967811|DRUG|Formulation E1 of L-PPDS|Control of IOP compared to baseline for Formulation E1 of the experimental dose of Latanoprost-PPDS for 6 weeks or until loss of efficacy.
224189531|NCT00967811|DRUG|Formulation E2 of L-PPDS|Control of IOP compared to baseline for Formulation E2 of experimental dose of Latanoprost-PPDS for 6 weeks or until loss of efficacy.
224189532|NCT05725174|OTHER|Sample Collection|Patients will have breath samples collected by blowing into a bag, and sweat samples collected by gauze. These samples will be collected at various timepoints whilst the patients are admitted on the ward.
224189533|NCT04366869|DEVICE|overdenture|removal of overdenture at night
224189534|NCT04366869|DEVICE|occlusal splint|occlusal splint on overdenture
224189535|NCT04366869|DRUG|Botox|Botox injection i masseter in temporalis
224189536|NCT01125852|PROCEDURE|Angiographic embolization|Patients in the intervention arm receive supplementary angiographic embolization within 24 hours from the therapeutic endoscopy.
224189537|NCT01125852|PROCEDURE|Therapeutic endoscopy|Patients are treated with standard therapeutic upper endoscopy including endoscopic combination therapy.
223499161|NCT02714647|BEHAVIORAL|Attentional prime|
223499162|NCT02714647|BEHAVIORAL|Sham prime|
223499163|NCT00355719|DRUG|Atazanavir (Reyataz)|Atazanavir (Reyataz): capsules 150 mg (2 capsules/24h)
223499164|NCT00355719|DRUG|Ritonavir (Norvir)|Ritonavir (Norvir): capsules 100 mg (1 capsule/24h)
223499165|NCT00355719|DRUG|Nevirapine (Viramune)|Nevirapine (Viramune): tablets 200 mg (1 tablet/12h\*)
223746127|NCT00985842|DEVICE|Vacuum-assisted socket system (Harmony System, Otto Bock)|Prosthetic socket worn by the amputee where the a vacuum pump, in this case a mechanically-activated pump, creates a vacuum between the socket and the limb. This vacuum suspends the prosthetic limb from the amputee's residual limb.
223499166|NCT01835756|DEVICE|Erchonia MLS|The Erchonia® MLS contains 10 independent diodes, each emitting 17 milliwatts (mW), 635 nanometers (nm) of red laser light. The Erchonia MLS is applied to the lower back and hips area for 15 minutes per treatment administration, 6 times across 3 weeks, 2 times per week.
223499167|NCT01835756|DEVICE|Placebo Laser|The Placebo Laser has the same appearance and administration application as the Erchonia MLS but does not emit any therapeutic light.
223499168|NCT06814054|DIAGNOSTIC_TEST|Carotid Artery Corrected Flow Time measurement|"* The cFT is defined as the time between the onset of systolic flow until closure of the aortic valve corrected for the HR and has been found to correlate with the intravascular volume.~* carotid ultrasound imaging will be performed 10 minutes before induction of general anesthesia in the preoperative holding area.~* Ultrasound measurements will be performed under a vascular setting with a 6.0 to 13.0MHz linear array transducer~* The right common carotid artery cFT will be measured in supine position with their heads tilted 30° to the left~* After that, a pulse wave Doppler will be chosen, and the sampling frame will be positioned at an angle of less than 60° in the region of the carotid artery with the best color flow to acquire the blood flow spectrum."
223511916|NCT06361446|DRUG|Propranolol|"The arm will include 300 migraine patients diagnosed according to ICHD3-beta criteria. All patients received propranolol 160 mg daily and acetaminophen 500-1000 mg on migraine attack.~We will assess The change in migraine days per 28 days, the number of migraine days after three months of treatment, and the percentage of patients who achieved ≥ 50% reduction in the monthly headache days frequency compared to the baseline frequency (14). HIT-6 score reduction in each group after three months of treatment. The safety of lacosamide was evaluated by monitoring and documenting treatment-emergent adverse events (TEAE) in patients through regular follow-up procedures for three months."
223746128|NCT00091273|BIOLOGICAL|incomplete Freund's adjuvant|
223746129|NCT00091273|BIOLOGICAL|ovarian cancer peptide vaccine|
223746130|NCT00091273|BIOLOGICAL|sargramostim|
223746131|NCT00091273|BIOLOGICAL|tetanus toxoid helper peptide|
224189538|NCT00963040|DRUG|Syntocinon|4 actuations in each nostril for a total dose of 32 IU
224189539|NCT00963040|DRUG|Sterile water|4 actuations in each nostril
224189540|NCT00963040|DRUG|Syntocinon|8 actuations in each nostril for a total dose of 64 IU
224189541|NCT00963040|DRUG|Sterile water|8 actuations in each nostril
224189542|NCT04115904|PROCEDURE|Ibuprofen for post operative pain|All treatment sessions were approximately 45 minutes in length to allow for acceptable time for completionof treatment and retreatment in one or two visits. Allthe clinical procedures were performed by the author.Following local anesthesia with 2% lidocaine with1:100,000 epinephrine (Septodont Saint-Maur desFossés, France) and rubber dam isolation the toothwas disinfected with 5.25% NaOCl (Ultra bleach,Bentonville, AR, USA).
224189543|NCT01446835|DEVICE|nelfilcon A contact lens with print|Investigational spherical contact lens
224189544|NCT01446835|DEVICE|etafilcon A contact lens with print|Commercially marketed (Singapore) spherical contact lens
224189545|NCT03779373|OTHER|Use of a decision support system on the EV1000 monitor (AFM mode)|The way to administer fluid is based on the same monitoring device but will differ by the way fluid is given ( following a manual GDFT protocol versus following recommendation from an active clinical deicsion support system for fluid administration called AFM (assisted fluid management)
224189546|NCT00957827|DRUG|keflex|keflex 500 mg BID 5 days
224189547|NCT00957827|DRUG|placebo|placebo BID for five days
224189548|NCT04271904|OTHER|Placebo Diet|"The dietitian will assist in developing a diet that is isocaloric to the anti-inflammatory diet and healthy (for the sake of the participants' well-being, and to blind participants), while allowing many foods that are (counterintuitively) pro-inflammatory (e.g. whole wheat bread, white beans, oats, soy, eggplant, raspberries, pumpkin seeds, popcorn, etc). Occasional cheat foods are built into the placebo diet but with more pro-inflammatory options (e.g. two glasses of wine per week)."
224189549|NCT05868031|OTHER|alternative teaching methods|This study aimed to explore the potential benefits of alternative teaching methods in anatomy education, as well as to investigate the effectiveness of traditional lecture-based education in comparison. By examining the outcomes of these different approaches, we hope to understand better how students can best learn and retain knowledge in this field.
224309441|NCT05412238|DIETARY_SUPPLEMENT|micro-and macro-nutrients fortified sachets|Every subject receives daily fortified sachets containing micro-and macronutrients for 6-9 months
223499169|NCT06814054|DIAGNOSTIC_TEST|Inferior vena cava collapsibility index|"* The IVC will be examined while the patient has been spontaneously, quietly breathing and lying in the supine position for at least 5 min before assessment.~* A two-dimensional image of the IVC as it entered the right atrium will be obtained through the paramedian long-axis view via a subcostal approach using a curvilinear phased array probe (2-5 MHz)~* Then, using M-mode imaging produced at a medium sweep speed, changes in IVC diameter with breathing will be evaluated 2 to 3 cm distal to the right atrium.~* During the same respiratory cycle, measurements will be made of the IVC's greatest expiratory diameter (dIVC expiration) and lowest inspiratory diameter (dIVC inspiration). The formula IVCCI = (dIVC expiration - dIVC inspiration) × 100/dIVC expiration will be used to determine IVCCI as a percentage. (12)~* IVCCI will be assessed by the same trained anesthesiologist who was blinded to postin duction hemodynamic measurements."
223499170|NCT01837342|PROCEDURE|Surgical reserction|
223499171|NCT01837342|OTHER|Radiological percutaneous drainage and washing drainage|
223499172|NCT02460731|BIOLOGICAL|Fresh Frozen Plasma|Fresh Frozen Plasma \[young (\<30 years of age) healthy male donors\] Solution for intravenous infusion
223499173|NCT05830279|GENETIC|Pharmacogenetic testing|Genotyping for CYP2D6 and CYP2C19
223499174|NCT05830279|OTHER|Drug-Drug interaction analysis|Evaluating potential drug interactions with CYP2D6, CYP2C9 and CYP3A4 inhibitors and inducers using the Medical Letter.
223499175|NCT06290713|DRUG|Tadalafil|Patients will be given either the intervention medication or a placebo (double-blinded, randomized trial) and will be asked to take the medication every day for 6 months in conjunction with weekly exercise sessions.
223499176|NCT06290713|DRUG|Placebo|Patients will be given either the intervention medication or a placebo (double-blinded, randomized trial) and will be asked to take the medication every day for 6 months in conjunction with weekly exercise sessions.
223499177|NCT06290713|OTHER|Exercise Training|The home-based cycling exercise training program is designed to improve muscle strength and endurance. Participants will engage in individualized exercise sessions up to four times per week, lasting up to 40 minutes each. Live video and heart rate monitoring will ensure proper exercise performance and allow for adjustments to the program throughout the study. The participants will receive the exercise equipment for use at home.
223499178|NCT03815305|DRUG|Centella Asiatica Extract|centlla asiatica oral drug at 1100 mg dose
223499179|NCT03815305|DRUG|Topical CA|1% centella asiatica ointment
223499180|NCT03815305|DRUG|Petroleum jelly|vaseline album
223499181|NCT00112333|PROCEDURE|fMRI|A liquid meal (Ensure 1Kcal/cc) will be infused into the stomach via a nasogastric tube at a rate of 60cc/min till the subject reaches maximal satiety. The amount of liquid meal will differ per subject.
223499182|NCT03325439|DRUG|Brivaracetam (BRV) intravenous (iv)|"Exploratory Cohort:~Subjects will be dosed with BRV (0.5 mg/kg twice daily (bid)) according to the sites standard procedures. Treatment with 1 or more of the following antiepileptic drugs (AEDs): phenobarbital (PB), midazolam (MDZ), phenytoin (PHT), levetiracetam (LEV), or lidocaine (LDC) (first-line, second-line, or subsequent treatment) will continue in parallel with BRV treatment.~Confirmatory Cohort:~For subjects who enter the Confirmatory Cohorts, for the strength of BRV 1 mg/kg bid (2 mg/kg/day) has been determined based on the Pharmacokinetic (PK) findings of the Exploratory Cohort. Based on further monitoring of PK and safety findings dosing may be adjusted as new data are available. Administration of BRV is proposed as approximately 15-minute intravenous (iv) infusions. Treatment with previous antiepileptic drugs is permitted to continue if the subject is on a stable dose from 1 hour prior to initiation of the BRV treatment."
223499183|NCT03325439|DRUG|Brivaracetam (BRV) oral|Subjects can switch from intravenous (iv) to oral brivaracetam (BRV) at any time during the BRV Extension Period
223499184|NCT05624541|DIAGNOSTIC_TEST|Measurements|All infants at high risk of cp will be assessed by Specific Test of Early Infant Motor Performance (STEP) Version 3.0 at term age and at corrected age 3 months, by Hammersmith Infant Neurological Examination (HINE) a corrected age 3 and 6 months, also BAYLEY-III Infant and Toddler Development Assessment Scale (BAYLEY-III) at corrected 6 months.
224189550|NCT00031616|DRUG|brivudine phosphoramidate|
224189551|NCT00402506|DRUG|(MC-1) Pyridoxal 5'-phosphate|
224309442|NCT02792699|DRUG|ABP 798|Supplied as a 10 mg/mL liquid concentrate for intravenous (IV) administration.
224309443|NCT02792699|DRUG|Rituximab (US)|Supplied as a 10 mg/mL liquid concentrate for IV administration.
224309444|NCT02792699|DRUG|Rituximab (EU)|Supplied as a 10 mg/mL liquid concentrate for IV administration.
224309445|NCT01140399|DRUG|Furosemide or Furosemide and Dopamine|"Patients randomized to pharmacological treatment receive~* either intravenous diuretics at escalating doses up to 20 mg/h~* or intravenous diuretics up to 20 mg/h and dopamine infusion at a constant rate of 3 mcg/Kg/m."
224189552|NCT00280839|DRUG|Topiramate|
224189553|NCT00280839|DRUG|Placebo|
223499185|NCT00369759|OTHER|Emergency Dept. Subjects with LRI or Apnea|No intervention; Epidemiological Study
223499186|NCT03297697|PROCEDURE|Tumor biopsy|Biopsy specimen can be from bone marrow, blood, or lymph node. This specimen should have a high disease load
223499187|NCT03297697|PROCEDURE|Peripheral blood draw|-Baseline, C1D1, C1D8, C1D15, C2D1, C3D1, C4D1, C5D1, C6D1, end of treatment, 3 month follow-up (optional), 6 month follow-up, 9 month follow-up (optional), 12 month follow-up, 15 month follow-up (optional), 18 month follow-up, 21 month follow-up (optional), 24 month follow-up, and at relapse
223499188|NCT03297697|PROCEDURE|Lymphotrack TCR clonality assay|-Assay with high sensitivity that can be performed with peripheral blood
223499189|NCT04620538|DIAGNOSTIC_TEST|Breath Analysis|Participants will be asked to provide 500mls of exhaled breath which will be loaded on to thermal desorption tubes and analysed via Mass Spectrometry.
223499190|NCT03754543|OTHER|Labeled iron salt Fe54|Ferrous fumarate enriched with Fe 54 isotopes contains 2.25 mg of iron source and 13.5 mg of Vitamin C per serving
223499191|NCT03754543|OTHER|Labeled iron salt Fe57|Ferrous fumarate enriched with Fe 57 isotopes contains 2.25 mg of iron source and 13.5 mg of Vitamin C per serving
223499192|NCT03754543|OTHER|Labeled iron salt Fe58|Ferrous bisglycinate enriched with Fe 58 isotopes contains 2.25 mg of iron source and 13.5 mg of Vitamin C per serving
223499193|NCT01460472|BIOLOGICAL|Racotumomab|Patients will receive best support treatment and vaccination with racotumomab. The vaccination schedule is as follows: 5 doses (1mg/mL each), intradermally, every 2 weeks (induction period) followed by monthly vaccinations until any criteria for discontinuation are met. If disease progression occurs and further onco-specific therapy is indicated, the patient will be able to continue in the study and vaccination will not be interrupted unless criteria for vaccine discontinuation are met.
223499194|NCT01460472|OTHER|Best Support Treatment|Patients will receive best support treatment for advanced NSCLC as per each institution's standards, including onco-specific therapies when disease progresses.
223499195|NCT00117819|DRUG|[123I]ß CIT and SPECT imaging|To assess \[123I\]ß CIT and SPECT imaging
223499196|NCT02036723|DRUG|Bevacizumab|Patients will receive bevacizumab at a dose 1.25 mg (in 0.05 ml of solution) as an intravitreal injection on day 1 and then every 28 days during 12 months.
223499197|NCT02036723|DRUG|Ranibizumab|Patients will receive ranibizumab at a dose 0.50 mg (in 0.05 ml of solution) as an intravitreal injection on day 1 and then every 28 days during 12 months.
223499198|NCT04045171|DRUG|Tacrolimus|Tacrolimus, oral, 0.05-0.075 mg/kg/d, Q12h, 6～12 months
223499199|NCT00774748|DEVICE|Insuflon|Indwelling subcutaneous catheter indicated for subcutaneous infusion of medication by injection. Maximum lifespan: 7 days or 75 injections.
223499200|NCT06101446|OTHER|Lavander Aromatherapy|Aromatherapy is one of the potential non-pharmacological methods. Lavender oil has been known to have calming properties and is one of the most effective aromatherapy oils. It reduces blood pressure and anxiety by stimulating the parasympathetic system
223499201|NCT06151938|DRUG|Standardised allergen extract from house dust mites|Drug: Allergen immunotherapy \[ACARIZAX® (12-SQ HDM) house dust mite (HDM) sublingual allergy immunotherapy (SLIT) tablet\] for moderate to severe house dust mite allergic rhinitis with or without allergic asthma for 12 months.
223499202|NCT04976972|DEVICE|NAVIO/CORI Surgical System|Total knee replacement with robotic assistance
223499203|NCT04976972|PROCEDURE|Non-robotic conventional instrumentation|Total knee replacement with non-robotic conventional instrumentation
223499204|NCT04072471|DRUG|Zurampic®|non-interventional study where patients are exposed to Zurampic® plus a xanthine oxidase inhibitor (allopurinol or febuxostat) during the normal course of clinical practice
223499205|NCT04072471|DRUG|Control group: xanthine oxidase inhibitor monotherapy|non-interventional study where patients are exposed to xanthine oxidase inhibitor monotherapy (allopurinol or febuxostat) during the normal course of clinical practice
223499206|NCT00866320|DRUG|sorafenib tosylate|Sorafenib (BAY 43-9006) is an oral multi-kinase inhibitor targeting both tumor cells and the tumor vasculature. Patients with metastatic RCC meeting eligibility criteria will receive 400 mg BID of sorafenib in a single-arm phase II study. Treatment will be administered on an outpatient basis.
223499207|NCT04385992|DRUG|177Lu-Dotatate|Peptide Receptor Radionuclide Therapy (PRRT) is based on specific somatostatin receptor targeting with radiolabelled analogues 90Y-DOTATOC and 177Lu-DOTATATE
223499208|NCT06030882|OTHER|Biologic Care Pathway|Receiving care administered through a biologic care pathway.The central biologic intake nurse will touch base with the IBD program nurse navigator at preselected time points as per the pathway in order to coordinate the baseline pre- biologic work-up, clinical and biomarker assessments, and clinical assessments. Clinical management decisions will be informed by a combination of data points including clinical risk factors, TDM, fecal calprotectin concentrations, endoscopic and clinical disease activity indices as well as drug tolerance and adverse events. Within the care pathway, time- bound clinical and biomarker data will be provided to the treating clinician to help inform their clinical decisions.
223499209|NCT04384874|OTHER|Exercise therapy|A 12 week multi-stage exercise rehabilitation program
223746132|NCT00091273|PROCEDURE|adjuvant therapy|
224189554|NCT01411124|DRUG|gabapentin enacarbil|600 mg investigational compound
224189555|NCT01411124|DRUG|diphenhydramine|50 mg active comparator
224189556|NCT01411124|DRUG|placebo|placebo
224189557|NCT02985541|DRUG|Levonorgestrel IUS (Mirena, BAY86-5028)|Levonorgestrel (LNG) intrauterine delivery system (IUS) with an initial in vitro release rate of 20 μg levonorgestrel per day.
224189558|NCT03556254|DRUG|GGT|In the absence of 23S rRNA mutation, clarithromycin based sequential therapy will be given. In the presence of 23S rRAN mutation but the absence of gyrase A mutation, levofloxacin based sequential therapy will be given. In the presence of both 23S rRNA and gyrase A mutations or if genotyping fails, bismuth quadruple therapy will be given
224189559|NCT03556254|DRUG|SGT|In the absence of clarithromycin resistance, clarithromycin based sequential therapy will be given. In the presence of clarithromycin resistance but the absence of levofloxacin resistance, levofloxacin based sequential therapy will be given. In the presence of both clarithromycin and levofloxacin resistance or if culture fails, bismuth quadruple therapy will be given.
224205824|NCT03726242|DRUG|Saline|To investigate the role of levcromakalim compared with placebo after intradermal and intramuscular injection.
224309446|NCT01140399|DEVICE|Ultrafiltration|"All loop diuretics will be discontinued. Rate of fluid removal will be based on the extent of fluid overload as assessed by increase in body weight vs the patient's known dry weight~* less than 3 kg 200 ml/h~* more than 3 kg and less than 5 kg 300 mlh~* more than 5 kg 500 mlh~Criteria for achievement of target UF goals are removal of \> 50% and \<70% of fluid excess based on the estimated increase in body weight Diuretic infusion is allowed provided that a minimum of 3 hours after the end of the UF session have elapsed, at a maximum cumulative dose of 100 mg furosemide, till start of the next UF session The use of inotropic agents is prohibited"
224309447|NCT01755767|DRUG|Tivantinib|Tivantinib tablets
224309448|NCT01755767|DRUG|Placebo|Matching placebo tablets
223499210|NCT03125733|PROCEDURE|Submucosal tunneling endoscopic septum division|"STESD includes 4 steps:~1. Mucosal incision: submucosal injection of normal saline-indigo carmine solution is performed 2-3cm proximal to the diverticular septum and a 1.5-2cm longitudinal mucosal incision is made using the endoscopic knife.~2. Submucosal tunneling: a submucosal tunnel is created using the same technique as applied by Peroral Endoscopic Myotomy (POEM) at both sides of the septum until 1-2cm distal to the bottom of the diverticulum.~3. Septum Division: cricopharyngeal myotomy is performed longitudinally along the mid-line of the septum and ends in the normal esophageal muscle.~4. Mucosal Closure: the mucosa incision, as well as any accidental mucosotomy if present, is closed with hemostatic clips."
223499211|NCT01676662|DEVICE|Solace Bladder Control System|Subjects may undergo treatment every 12 months until study completion.
223499212|NCT01676662|DEVICE|Solace Sham Treatment|Sham procedure that resembles treatment with the Solace Bladder Control System
223499213|NCT03349515|DRUG|Provodine-Iodine Solution|Group A will receive three drops of povidone-iodine ophthalmic solution in each eye, with the right eye to receive the drops first. The eye drops will be administered by the study anesthesiologist. After application of either solution to the eyes of the patient, any change in ventilation can be detected and timed by observation of the capnography (end-tidal carbon dioxide) and direct observation of the chest wall with use of the iPhone stopwatch feature again. The capnograph is a standard monitor of respiration used during the administration of general anesthesia. Data collected at this time will include whether or not there was a change in respiration, what this change in respiration was, if assisted ventilation was required, how long assisted ventilation was required (if applicable), HR, BP, RR, SaO2 , ETCO2, InspSevo, and ExpSevo. This study intervention and data collection will take less than 5 minutes.
223499214|NCT03349515|DRUG|Group B will receive three drops in each eye of ophthalmic balanced salt solution.|Group B will receive three drops in each eye of ophthalmic balanced salt solution. The eye drops will be administered by the study anesthesiologist. After application of either solution to the eyes of the patient, any change in ventilation can be detected and timed by observation of the capnography (end-tidal carbon dioxide) and direct observation of the chest wall with use of the iPhone stopwatch feature again. The capnograph is a standard monitor of respiration used during the administration of general anesthesia. Data collected at this time will include whether or not there was a change in respiration, what this change in respiration was, if assisted ventilation was required, how long assisted ventilation was required (if applicable), HR, BP, RR, SaO2 , ETCO2, InspSevo, and ExpSevo. This study intervention and data collection will take less than 5 minutes
223499215|NCT03933033|DEVICE|Fractional Erbium Yağ Laser|Multiple sessions of Fractional Erbium Yağ Laser
223499216|NCT03933033|PROCEDURE|Platelet Rich Plasma|Multiple injections of Platelet Rich Plasma
223499217|NCT02503865|DRUG|Xenical, Pionorm, Diroton, Diltiazem, Atorvastatin|Xenical (Orlistat) - 120 mg/day in integration of Pionorm (Pioglitazone hydrochlorid) - 30 mg/day, Diroton (Lizinopril) - 20 mg/day, Diltiazem - 90 mg/day, Atorvastatin (Liprimar) - 40 mg/day
223499218|NCT02503865|DIETARY_SUPPLEMENT|"Analimentary detoxication"|Vegetable and salt diet
223499219|NCT06462612|DRUG|Lumateperone|Lumateperone 42 mg capsules administered orally, once daily
223499220|NCT06462612|DRUG|Placebo|Matching capsules administered orally, once daily
223499221|NCT06350071|BEHAVIORAL|Kangaroo Care|Kangaroo care will be applied so that the infant and mother will have skin-to-skin contact, and heel blood will be taken.
223499222|NCT06350071|BEHAVIORAL|Swaddling|Heel blood will be taken while the infant was swaddled in the maternal holding.
223499223|NCT05999968|DRUG|Abemaciclib|Administered orally.
223499224|NCT05999968|DRUG|Darolutamide|Administered orally.
223499225|NCT05999968|DRUG|LHRH agonist/antagonist|Physician's choice. Administered in accordance with the prescribing information.
223499226|NCT06199492|DEVICE|tVisio-1|Standard of Care Biopsy
223499227|NCT04777760|DRUG|one dose of surfactant replacement|the preterm infants diagnosed with NRDS and/or NARDS will be administrated with only one dose of surfactant
223499228|NCT04777760|DRUG|two and more doses of surfactant replacement|the preterm infants diagnosed with NRDS and/or NARDS will be administrated with two and more doses of surfactant
223499229|NCT00002835|BIOLOGICAL|Bleomycin Sulfate (BLM)|
223499230|NCT00002835|BIOLOGICAL|Filgrastim (G-CSF)|Arm 1: Administered subcutaneously (SC) beginning on day 5 and continuing until blood counts recover through Course 1 then 2 courses administered before PBSC harvest and same regimen with Course 2, then daily with Day 0 of infusion.
223499231|NCT00002835|BIOLOGICAL|Recombinant Interferon Alfa|
223499232|NCT00002835|DRUG|Carmustine|Arm 1, Course 3, IV over 1 hour on day -6.
223499233|NCT00002835|DRUG|Cisplatin (CDDP)|
223499234|NCT00002835|DRUG|Cyclophosphamide|
223499235|NCT00002835|DRUG|Cytarabine (ARA-C)|Arm 1, Course 3, every 12 hours on days -5 to -2.
223499236|NCT00002835|DRUG|Etoposide (VP-16)|Course 1, IV over 2 hours every 12 hours on days 1-3; Course 3, every 12 hours on days -5 to -2.
224074475|NCT03375190|OTHER|Experimental: Dressing + adhesive + strips + spray|Transparent film dressing + topical skin adhesive + skin closure strips + medical adhesive spray (AdaptTM Medical Adhesive, Hollister Incorporated, Libertyville, IL, USA) in a 12 centimeter by 14 centimeter area around the insertion site
224309449|NCT04665466|DEVICE|Quantitative Flow Ratio derived PPG|"From coronary angiographic images, QFR will be calculated and virtual pullback curve will be abstracted and PPG index will be calculated as:~PPG index={MaxPPG20mm/△QFRvessel+(1-length with functional disease/Total vessel length) }/2."
224205825|NCT06185556|PROCEDURE|Irreversible electroporation|Percutaneous (CT-guided) irreversible electroporation of 1-3 perivascular and peribiliary colorectal liver metastasis.
223499237|NCT00002835|DRUG|Idarubicin|
223499238|NCT00002835|DRUG|Ifosfamide|During Course 1, IV continuously; Course 2, IV continuously on days 1-3.
223499239|NCT00002835|DRUG|Leucovorin Calcium|
223499240|NCT00002835|DRUG|Melphalan|
223499241|NCT00002835|DRUG|Methotrexate|
223499242|NCT00002835|DRUG|Methylprednisolone|
223499243|NCT00002835|DRUG|mitoxantrone hydrochloride (DHAD)|Arm 1, Course 2, IV on day 1.
223499244|NCT00002835|DRUG|Vincristine Sulfate|
223499245|NCT00002835|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Infusion of stem cells on Day 0.
223499246|NCT00002835|RADIATION|Radiation Therapy|
224074476|NCT02127437|DRUG|Lanreotide|120 mg, subcutaneously, once every 4 weeks
224074477|NCT02127437|DRUG|saline|0,5 ml, subcutaneously, once every 4 weeks
223499247|NCT06478186|DRUG|triamcinolone acetonide extended-release injectable suspension; TCA-ER|Mode of Administration: IA Knee Injection Nominal 32 mg TCA, intra-articular (IA) injection, administered as a 5 mL injection
223499248|NCT06478186|DRUG|Triamcinolone Acetonide- Immediate Release;TCA-IR|Mode of Administration: IA Knee Injection Triamcinolone Acetonide- Immediate Release (TCA-IR)
223499249|NCT06372561|DRUG|Mineral trioxide aggregate (dressing material)|MTA (Angulus Industrial de productus Odontologists S/a, Brazil) that applied on dental pulp for tissue regeneration
223499250|NCT06372561|DRUG|Melatonin (dressing material)|melatonin powder 250mg (sigma, Aldrich)- white powder mixing with saline and applied on dental pulp
223511917|NCT03403127|DIAGNOSTIC_TEST|PET/CT Scans|PET Imaging requires the use of an investigational drug, a radioactively-labelled sugar called 18F-Fluorodeoxyglucose (FDG). FDG is glucose labelled with a radioactive fluorine atom. It is given by intravenous injection and is particularly absorbed by cancer cells. The radioactive signal given off by the FDG can then be detected by the PET scanner providing an image of the cancer (or tumour).
224074478|NCT01445028|DRUG|Isotretinoin|Isotretinoin 20mg daily for 12 weeks
224074479|NCT00153582|BIOLOGICAL|WT1 126-134 peptide|
224074480|NCT01716910|DIETARY_SUPPLEMENT|Combination of Lactobacillus acidophilus NCFM and cellobiose|
224074481|NCT04158037|BEHAVIORAL|mHealth App|The app uses smartphones' global positioning software (GPS) that recognizes a user's location to within 15 feet. The app will construct a customizable geofence (e.g., 3 miles) around a gambler's favored gambling venue (e.g., casino, gas station). If the individual crosses the fence boundary his or her phone will raise the alarm with a personalized motivational message.
224074482|NCT04427215|OTHER|Complementary and alternative medicines|Five types of Complementary and alternative medicines (Music Therapy, Art Therapy, Dance-Movement Therapy, Bibliotherapy, Physical Activity) will be applied twice a week.
224074483|NCT01262846|BIOLOGICAL|Fluzone®|Fluzone® Standard dose in a blinded manner as single-0.5mL injection intramuscularly into one of the subject's deltoid muscles.
224074484|NCT01262846|BIOLOGICAL|Fluzone®|Fluzone® High dose or Standard dose in a blinded manner as single-0.5mL injection intramuscularly into one of the subject's deltoid muscles.
224074485|NCT05357300|DEVICE|Peripheral Nerve Stimulation|Implant of percutaneous leads for peripheral nerve stimulation of the rami dorsales of the SIJ and gluteal or abdominal implant of impulse generator
224074486|NCT01562548|DRUG|Guaifenesin|high and low dose of Guaifenesin each given twice daily over a 4-day treatment period
224074487|NCT01562548|DRUG|Placebo|no active ingredient
224074488|NCT00798746|BEHAVIORAL|Telephone Questionnaire|Ten questions regarding symptoms of reflux
224074489|NCT01355939|PROCEDURE|Clinically-Indicated Abdominal Re-Exploration Surgery|This is a prospective observational study. Abdominal re-exploration surgery is clinically-indicated and planned as the standard of care for the patients regardless of their decision to participate in the study.
224074490|NCT03406221|BEHAVIORAL|Information Communication Technology Continuum of Care Service|Mobile phones were made available to community health workers in the intervention arms that integrated a comprehensive set of functions to assist them in their duties, including registration and tracking of beneficiaries, automated scheduling of home visits, provision of health information through videos, guided protocols for conducting home visits through checklists, a feature to track child immunizations, and supervisory tools.
224074491|NCT03406221|OTHER|Control Condition|Standard of care
224074492|NCT01496066|DEVICE|LAL (Light Adjustable Lens) and Light Deliver Device (LDD)|LAL implanted and adjusted with LDD
224074493|NCT01496066|DEVICE|Monofocal control IOL|Commercially available monofocal intraocular lens (IOL)
224074494|NCT02010164|DIETARY_SUPPLEMENT|Co-enzyme Q10|600mg for 3 months
224074495|NCT04226404|OTHER|CSD1905-11|Flavor variant CSD1905-11 of a 4.8% nicotine ENDS product
224074496|NCT04226404|OTHER|CSD1905-12|Flavor variant CSD1905-12 of a 4.8% nicotine ENDS product
224074497|NCT04226404|OTHER|CSD1905-13|Flavor variant CSD1905-13 of a 4.8% nicotine ENDS product
224074498|NCT04226404|OTHER|CSD1905-14|Flavor variant CSD1905-14 of a 4.8% nicotine ENDS product
224074499|NCT04226404|OTHER|CSD1905-15|Flavor variant CSD1905-15 of a 4.8% nicotine ENDS product
224074500|NCT04226404|OTHER|CSD1905-16|Flavor variant CSD1905-16 of a 4.8% nicotine ENDS product
224074501|NCT04226404|OTHER|CSD1905-17|Flavor variant CSD1905-17 of a 4.8% nicotine ENDS product
224074502|NCT03237065|DRUG|Iron isomaltoside/ferric derisomaltose|"Iron isomaltoside/ferric derisomaltose (Monofer®/Monoferric®; 100 mg/mL) was the test product in this trial.~The dose of iron isomaltoside/ferric derisomaltose for the individual subject was a single IV infusion of 1000 mg (10 mL containing 1000 mg iron isomaltoside/ferric derisomaltose diluted in 100 mL 0.9 % sodium chloride), given over approximately 20 minutes (50 mg iron/min) at baseline (cumulative dose: 1000 mg)."
224074503|NCT03237065|DRUG|Ferric carboxymaltose|Ferric carboxymaltose (Injectafer®; 50 mg/mL) was the comparator in this trial. The dose of ferric carboxymaltose for the individual subject was 750 mg, infused over at least 15 minutes at baseline and on day 7 (cumulative dose: 1500 mg).
224074504|NCT00039988|DRUG|Glatiramer acetate|20 mg administered subcutaneously daily
224074505|NCT00039988|DRUG|Albuterol|2 mg or 4 mg oral capsules taken daily
224074506|NCT00039988|DRUG|Albuterol placebo|Oral placebo capsules will be taken daily
224189560|NCT01746082|BIOLOGICAL|Influenza A/H3N2 variant Vaccine|Investigational influenza virus H3N2v vaccine, a monovalent type A inactivated vaccine (H3N2v MIV) for intramuscular use, is a sterile clear and slightly opalescent suspension prepared from influenza virus propagated in embryonated chicken eggs. The H3N2v MIV contains no preservative. Subjects will be stratified by age (approximately 100 (up to 120) subjects 18-64 years old and approximately 100 (up to 120) subjects \>/=65 years old) to receive two doses of H3N2v MIV, delivered intramuscularly as 15 micrograms (mcg) of hemagglutinin (HA)/0.5 milliliter (mL) dose, 21 days apart
224189561|NCT03996694|DRUG|Belbuca 300 µg|Belbuca 300 µg buccal film
224189562|NCT03996694|DRUG|Belbuca 600 µg|Belbuca 600 µg buccal film
224189563|NCT03996694|DRUG|Belbuca 900 µg|Belbuca 900 µg buccal film
224189564|NCT03996694|DRUG|Oxycodone 30 mg|Oxycodone 30 mg capsule
224189565|NCT03996694|DRUG|Oxycodone 60 mg|Oxycodone 60 mg capsule
224189566|NCT03996694|DRUG|Placebo|placebo buccal film and oral placebo
224189567|NCT05070494|BIOLOGICAL|Egg-derived standard dose trivalent influenza vaccine (surface antigen, inactivated)|study of immunologic response to different dose and duration of Egg-derived standard dose trivalent influenza vaccine (surface antigen, inactivated)
224189568|NCT02032394|DRUG|Povidone-iodine|15 ml 10%, 3 imes a day for 10 days /external use for Washing perinea area and catheter first 5 centimeters
224189569|NCT02032394|DRUG|Chlorhexidine|15 ml .2%, 3 imes a day for 10 days /external use for Washing perinea area and catheter first 5 centimeters
224189570|NCT02032394|DRUG|Normal saline|15 ml .9%, 3 imes a day for 10 days /external use for Washing perinea area and catheter first 5 centimeters
224189571|NCT01685320|PROCEDURE|Forces applied by laryngoscope|Force and pressure distribution applied by direct or indirect laryngoscope during glottis visualization and intubation were measured using film pressure transducers.
224189572|NCT03990012|PROCEDURE|IR Imaging|Subjects will undergo steady steady state and video IR imaging of the breasts.
223499251|NCT05311969|OTHER|cognitive evaluations and non cognitive evaluations|"Cognitive evaluations with executive functions evaluations :~* Mini Mental State Examination~* Stroop Victoria Test~* Hayling test~* Frontal Assessment Battery test mental flexibility:~* Trial Making Test (TMT) A and B~* Connection test~* Alphaflex test~* Verbal and visuospatial working memory~* Wechsler Adult Intelligence Scale (WAIS) span~* Visuo-spatial span~* Visuo-spatial span simplified version~* Month Of the Year Backwards (MOTYB) Planning~* Tinker Toy test~* Clock Test~Non-cognitive evaluations:~The Katz Autonomy Scale Neuropsychiatric Inventory version Care team Geriatric Depression Scale 15-item version Apathy inventory"
224189573|NCT03990012|PROCEDURE|3D Scanning|Subjects will undergo 3D scanning of the breasts.
224189574|NCT02477072|PROCEDURE|ACT|Blood samples for ACT will be collected following induction of anesthesia, 30 minutes after heparin administration, and on arrival in the recovery room.
224189575|NCT02477072|PROCEDURE|TEG|Blood samples for TEG will be collected following induction of anesthesia, 30 minutes after heparin administration, and on arrival in the recovery room.
224189576|NCT02477072|PROCEDURE|Ankle-brachial index|Peripheral blood flow will be assessed prior and after surgery using the ankle-brachial and toe-brachial indexes.
224189577|NCT02477072|PROCEDURE|Toe-brachial index|Peripheral blood flow will be assessed prior and after surgery using the ankle-brachial and toe-brachial indexes.
224189578|NCT02477072|DRUG|Heparin|Heparin doses will be administered according to the assigned group.
224189579|NCT03143712|DRUG|GLPG1690|Oral administration of GLPG1690 in three different treatment conditions (treatment A through C)
223499252|NCT00619463|BEHAVIORAL|Exercise|Eight weeks in an aerobic exercise program- 50 minutes of aerobic exercise on a treadmill - 3 days a week for 8 -16 weeks.
223499253|NCT00619463|BEHAVIORAL|Exercise|Aerobic exercise program - 55 min aerobic exercise on the treadmill 3 days a week for either 8 or 16 weeks
223499254|NCT00087802|DRUG|gemcitabine/Eloxatin (GEMOX)|GEMOX \[gemcitabine/Eloxatin™ (Oxaliplatin) - 21 day cycle\] Gemcitabine 1000 mg/m2 will be administered over 30 minutes on Days 1 and 8 and Eloxatin™ 130 mg/m2 will be administered over 2 hours on Day 1, after gemcitabine administration, every 21 days \[3-week cycle\]
223499255|NCT00087802|DRUG|carboplatin/paclitaxel (CP)|"CP \[carboplatin/paclitaxel - 21 day cycle\]~o Paclitaxel 225 mg/m2 will be administered over 3 hours on Day 1 followed by carboplatin at a dose calculated to produce an area under the concentration-time curve (AUC) of 6.0 over 30-60 minutes on Day 1 every 21 days \[3-week cycle\]"
223499256|NCT00962962|BEHAVIORAL|Aerobic Exercise|Aerobic exercise at 50% peak oxygen use/consumption expending approximately 1,000 calories per week equaling approximately 10 miles per week OR 2.5-3.5 hours per week
223499257|NCT00962962|BEHAVIORAL|Aerobic Exercise|Aerobic exercise at 50% peak oxygen use/consumption expending approximately 1,600 calories per week equaling approximately 16 miles per week OR 4-6 hours per week
223499258|NCT00962962|BEHAVIORAL|Aerobic Exercise|Aerobic exercise at 75% peak oxygen use/consumption expending approximately 1,600 calories per week equaling approximately 16 miles per week OR 2-3 hours per week
223499259|NCT00962962|BEHAVIORAL|Exercise and Diet|"* Exercise - 150 minutes per week (30 minutes / 5 days per week) of aerobic exercise at 50% peak oxygen use/consumption equaling approximately 10 miles per week~* Diet - The Clinical Lifestyle Intervention sessions will provide training on needed skills (e.g., calorie counting, portion size estimation) as well as motivation and support in a group counseling setting designed to achieve a weight loss goal of 5 to 7% of baseline body weight."
224189580|NCT06567444|OTHER|Working memory intervention|During the intervention, the participants in the ADHD group received five computerized working memory training sessions per week over five weeks, and each session lasted 20 minutes. This training paradigm is based on previous studies which show improvements in working memory capacities after a 5-week training period.
224189581|NCT03534817|BEHAVIORAL|Early Access CR|Participants in the Early Access CR group will begin CR within 1-week post-hospital discharge following their MI, as opposed to Standard Access CR group which begins 7-weeks post-hospital discharge, and the Canadian average (10-14 weeks post-hospital discharge). No further intervention or differentiation between groups is applied; the actual CR program is standardized between groups, and follows the guidelines regularly practiced by the institution.
224189582|NCT00403962|DRUG|vestipitant/paroxetine|
224189583|NCT05679193|DRUG|Propranolol|"Propranolol capsules 20mg taken orally.~Day: 1-3:~20mg twice daily~Day: 4-19 (25 , In cases of delayed RALP an extension of up to 6 days is allowed.in cases of delayed surgery).~2x 20mg twice daily~Day 20-22 20mg twice daily"
224189584|NCT00662974|OTHER|perineal massage with Wheat Germ Oil during the second stage of labor|30 ml of oil applied during labor
223499260|NCT00218959|BEHAVIORAL|Narrative Exposure Therapy|Exposure based treatment for PTSD developed especially for refugees. Built upon Prolonged exposure treatment (Edna Foa) and Testimonial Therapy (Cientifuegos \& Monelli).
223499261|NCT00218959|BEHAVIORAL|treatment as usual|
224189585|NCT00662974|OTHER|perineal massage with almond oil during the second stage of labor|30 ml of oil applied during labor
224189586|NCT04125082|DRUG|Afrezza Inhalant Product|Participants will be titrated from usual pre-meal insulin plus basal to Afrezza® inhaled insulin plus basal, and will continue on treatment for 14 weeks.
223499262|NCT05073315|DRUG|Adalimumab|Participants will receive subcutaneous (SC) injection of adalimumab
223499263|NCT05073315|DRUG|ABP 501|Participants will receive SC injection of ABP 501
223499264|NCT01290328|DRUG|Epoetin Alfa|150 units/kg/weekly
223499265|NCT05166096|DRUG|Rho-11|Subjects will be administered 325 mg aspirin by rapid IV push
223499266|NCT05166096|DRUG|aspirin 325mg|Subjects will be administered 325 mg aspirin orally
223499267|NCT01529268|DRUG|DR cysteamine bitartrate capsule|"* 600 mg/day (four 75 mg capsules twice daily) for patients ≤ 65 kg at baseline~* 750 mg/day (five 75 mg capsules twice daily) for patients \>65 - 80 kg at baseline~* 900 mg/day (six 75 mg capsules twice daily) for patients \>80 kg at baseline"
223499268|NCT01529268|OTHER|DR cysteamine bitartrate placebo|"* 600 mg/day (four 75 mg capsules twice daily) for patients ≤ 65 kg at baseline~* 750 mg/day (five 75 mg capsules twice daily) for patients \>65 - 80 kg at baseline~* 900 mg/day (six 75 mg capsules twice daily) for patients \>80 kg at baseline"
223499269|NCT02660099|BEHAVIORAL|Internet-delivered Cognitive Behavior Therapy|The treatment consists of standard cognitive behavior therapy for obsessive-compulsive disorder and is delivered via an internet platform and regular therapist contact several times per week via email and telephone. The treatment is 12 weeks. Both parents and adolescents are involved in treatment. Parents will also receive three lectures on 1, Autism spectrum disorder, 2, CBT and functional analysis and 3, Parental strategies
223499270|NCT04240873|BIOLOGICAL|Catholic MASTER cell|Injection of CATHOLIC MASTER cells 1 x 10\^8 cells/DMEM 5cc into knee of patents with osteoarthritis
223499271|NCT04240873|OTHER|Saline|Injection of saline 5cc into knee of patents with osteoarthritis
223499272|NCT01610843|OTHER|Survey|Longitudinal surveys
223499273|NCT00692016|DRUG|Naproxen sodium|Administered under fasting condition
223499274|NCT00692016|DRUG|Naproxen sodium|Administered under fed condition
223499275|NCT05290675|DIAGNOSTIC_TEST|Quantra QPlus System|Whole blood coagulation testing system
223499276|NCT01014676|DIETARY_SUPPLEMENT|Probiotic|
223499277|NCT01014676|OTHER|Placebo|
223499278|NCT03181555|OTHER|Exploratory|
223499279|NCT00002308|DRUG|Stavudine|
223499280|NCT00807872|BIOLOGICAL|124I-labeled monoclonal antibody Mu 11-1F4|Single infusion of radiolabeled antibody: 2 mCi (1 mg)
223499281|NCT00120744|DRUG|Ondansetron Oral Disintegrating Tablet|
223499282|NCT06530693|OTHER|OPUS-i algorithm|A novel pre-hospital algorithm.
223499283|NCT05942222|BIOLOGICAL|dupilumab|Subcutaneus injections in standard doses, i.e. 300 mg s.c. every 2 weeks.
223499284|NCT05942222|BIOLOGICAL|mepolizumab|Subcutaneus injections in standard doses, i.e. 100 mg s.c. every 4 weeks.
223499285|NCT03502109|OTHER|Medication review with follow-up|Medication review with follow-up: trained pharmacists will conduct consecutive medication reviews by detecting and resolving drug related problems, educational interventions and applying pharmacotherapy changes made in collaboration with physicians.
223499286|NCT05598268|BIOLOGICAL|T3011|T3011 will be administered through IV drip
223499287|NCT02522741|BEHAVIORAL|Parenting STAIR|Parenting-STAIR is an adaptation of a 16 session study therapy entitled Skills Training in Affective and Interpersonal Regulation/Modified Prolonged Exposure (STAIR/MPE). It generally is comprised of approximately 23 sessions and includes seven didactic interaction parenting sessions. There are threskill building in areas such as e modules within Parenting STAIR: 1) Module 1 focuses on skill building (awareness of emotional states, management of negative feelings, regulation of emotional intensity, etc.); 2) Module 2 involves the processing of memories of trauma and creating a coherent and meaningful life narrative; 3) Module 3 includes both the mother and child, and focuses on increasing maternal attunement and improving parenting skills.
223499288|NCT00717080|PROCEDURE|IOL surgery|IOL surgery using capsular tension ring (AURORING)
223499289|NCT00717080|PROCEDURE|IOL surgery|IOL surgery without CTR
223499290|NCT05817604|RADIATION|SBRT|"Tumors ≤ 4cm: Single SBRT 26Gy dose or Multifraction SBRT dose 14Gyx3 fraction-squeme.~Tumors ≥ 4cm: Multifraction SBRT dose 14Gyx3 or 9Gyx5 fraction-squeme."
223499291|NCT05993104|DIAGNOSTIC_TEST|Intrachamber ultrasound|Ultrasound left atrial geometry collecting using AcQMap.
223499292|NCT05993104|OTHER|Statistical shape analysis|Statistical shape analysis tools used to investigate left atrial geometry
223499293|NCT02641834|OTHER|Vegetarian diet|7-days dietary profile with an isocaloric Vegetarian diet for 3 months
223499294|NCT02641834|OTHER|Mediterranean diet|7-days dietary profile with an isocaloric Mediterranean diet for 3 months
223499295|NCT03038139|OTHER|Cervical exercises|Cervical correction program consist of 3 strengthening and 2 stretching exercises for neck and scapula Lumbosacral correction program consist of strengthening and stretching exercises for lumbar and sacral regions
224189587|NCT00251680|DRUG|Lapaquistat acetate and lipid-lowering therapy|Lapaquistat acetate 50 mg, tablets, orally, once daily and stable lipid-lowering therapy for up to 24 weeks.
224189588|NCT00251680|DRUG|Lipid-lowering therapy|Lapaquistat acetate placebo-matching tablets, tablets, orally, once daily and stable lipid-lowering therapy for up to 24 weeks.
224189589|NCT00329225|DRUG|rosiglitazone|
224189590|NCT05531916|OTHER|Pressurized gloves and foot caps|Using pressurized gloves and foot caps in order to prevent chemotherapy-induced peripheral neuropathy (CIPN).
224189591|NCT04612712|DRUG|Donafenib Tosilate Tablets|In the dose exploration phase (phase I) : three doses of Donafenib tosylate tablets \[50 mg twice a day; 100 mg twice a day; 200 mg twice a day \] will be explored. In the dose expansion phase (phase II), patients with advanced hepatocellular carcinoma will be treated at the recommended dose for phase 2(RP2D).The RP2D will be determined by the dose escalation study.
224189592|NCT04612712|BIOLOGICAL|KN046 Injection|5mg/kg Q3W
223591048|NCT05550948|DEVICE|Transcranial photobiomodulation (tPBM) - Mobile System|The Vielight NeURO device delivers 810 nm near infrared light via four (4) transcranial LED modules. The LED modules target brain regions associated with a variety of cognitive functions. It can deliver light at two frequencies: Alpha (10 Hz) and Gamma (40 Hz). Alpha oscillations are prominent in healthy brains during wakeful resting and gamma oscillations are associated with activities associated with focus, memory, and cognition.
223591049|NCT02868229|DRUG|COR-001|
223591050|NCT02868229|OTHER|Placebo|
224189593|NCT03053102|DRUG|Danicopan|Danicopan was administered as multiple oral doses over a period of at least 28 days.
223499296|NCT03038139|OTHER|Lumosacral exercises|Cervical and Lumbosacral correction program Lumbosacral program consist of 2 strengthening and 4 stretching exercises
223746133|NCT02400502|BEHAVIORAL|I-CAT Therapy|I-CAT is a novel therapeutic intervention combining mindfulness and meditation strategies to improve stress reactivity and increase meaningful coping, as well as a range of possible proximal (e.g. autonomic, endocrine, immune indices of stress reactivity, symptom severity) and distal measures (function, relapse, quality of life). Participants meet weekly with a master's level clinician over the course of 20 weeks.
224189594|NCT04518800|DRUG|Jin Youli(PEG-rhG-CSF)|Jin Youli(PEG-rhG-CSF) was given 24 hours after the completion of intravenous infusion of albumin paclitaxel during the treatment period, 6 mg was given to patients with body weight ≥45 kg, and 3 mg was given for body weight \<45 kg. Inject once every chemotherapy cycle
224189595|NCT03405545|BEHAVIORAL|High-intenstiy interval training|High-intensity interval training is a training of 30 minutes involving 10 bouts of 1 minute high intensity cycling (80-90% of maximum heart rate) interspersed by 2 minutes rest.
224189596|NCT00252668|DRUG|Etanercept|
223499297|NCT03673358|BEHAVIORAL|Cognitive Behavioural Therapy|"Participants who are randomized to the CBT intervention will be encouraged to begin CBT immediately following randomization. The CBT intervention will focus on addressing maladaptive beliefs related to pain and recovery as well as teaching skills to enhance coping and management of pain symptoms. The specific focus of CBT sessions will be informed by each individual patient's responses to baseline questionnaires. All other aspects of post-operative care will be at the discretion of participant's surgeon.~Other Name: CBT"
223499298|NCT03491917|DEVICE|DBT plus S-View|DBT plus S-View images
223499299|NCT03491917|DEVICE|FFDM alone|FFDM alone images
223499300|NCT00250003|BEHAVIORAL|Preventive home visits|
223499301|NCT04831112|DRUG|Honey|Dressing of necrotizing fascitis wounds with honey.
223499302|NCT04831112|COMBINATION_PRODUCT|EUSOL|Dressing of necrotizing fascitis wounds with EUSOL.
223499303|NCT00069745|DRUG|Satraplatin|
223499304|NCT00069745|DRUG|Prednisone|
223499305|NCT03040531|DIETARY_SUPPLEMENT|Genistein aglycone|27mg bid in tablets
223499306|NCT03040531|DRUG|Alendronate Oral Tablet|70 mg/week in tablets
223499307|NCT03040531|DIETARY_SUPPLEMENT|Calcium + vitamin D3 tablet|500mg Calcium + 200 IU Vitamin D3 bid in tablets
223499308|NCT00657605|DRUG|Recombinant methionyl human leptin|Recombinant methionyl human leptin, subcutaneous, once a day, 0.02 to 0.04 mg/kg (adjusted according to weight loss), indeterminate duration.
223499309|NCT06047327|DIAGNOSTIC_TEST|EUS guided liver biopsy|Procedure will be performed by 19G Franseen needle.
223499310|NCT06047327|DIAGNOSTIC_TEST|Percutaneous Liver Biopsy|procedure will be done by 18G BioPince Needle
223499311|NCT01449487|DRUG|PPC-5650|Solution for administration in the rectum Single dose of 25µg/ml at a volume of 50ml
223499312|NCT01449487|DRUG|Placebo|Solution for administration in the rectum Identical tp active solution but without active drug
223499313|NCT00395382|DRUG|Alendronate|70mg weekly orally
223499314|NCT00395382|DRUG|Placebo|weekly orally
223499315|NCT04776772|DIETARY_SUPPLEMENT|Synbiotic complement|"On two separate days, the baseline-tests and final-tests were conducted. All participants performed a series of tests, before which they had to fast. The order and schedule (8 am) of the tests was the same for the final-test and the same materials and procedures were used. A period of 30 consecutive days elapsed between the base-line and final tests, during which the participants had to ingest their supplement (synbiotic)."
223499316|NCT04776772|DIETARY_SUPPLEMENT|Placebo|"On two separate days, the baseline-tests and final-tests were conducted. All participants performed a series of tests, before which they had to fast. The order and schedule (8 am) of the tests was the same for the final-test and the same materials and procedures were used. A period of 30 consecutive days elapsed between the base-line and final tests, during which the participants had to ingest their supplement (placebo)."
223499317|NCT04069520|OTHER|aNMT Biofeedback|"aNMT biofeedback is created by calculating kinematic and kinetic data in real-time from the athlete's own movements. These values determine real-time transformations of the stimulus shape the athlete views via augmented-reality (AR) glasses during movement performance. The athlete's task is to move so as to create (animate) a particular stimulus shape that corresponds to desired values of the biomechanical parameters targeted by the intervention. The aNMT biofeedback occurs during neuromuscular training sessions. The neuromuscular training is a 18 session, pre-season training program occurring over 6 weeks."
223499318|NCT04069520|OTHER|Sham Biofeedback|Sham biofeedback provides a similar phenomenological experience to aNMT biofeedback for athletes-both groups experience a shape that changes with their movements-but the sham biofeedback will not provide usable information to modify movement parameters during critical movement phases. The sham biofeedback occurs during neuromuscular training sessions. The neuromuscular training is a 18 session, pre-season training program occurring over 6 weeks.
223499319|NCT01068912|DRUG|Favipiravir|1000 mg favipiravir BID x 1 day, and 400 mg favipiravir BID x 4 days
223591051|NCT05653817|DRUG|Carrilizumab|Carrilizumab 200mg Q3W d1
223591052|NCT05653817|DRUG|Albumin-bound paclitaxel|Albumin-bound paclitaxel 125 mg/m2 d1,8
223591053|NCT05653817|DRUG|Apatinib|Apatinib mesylate tablets for treatment: 250mg
223591054|NCT04514133|BEHAVIORAL|Participating in Action Civics program|Students in school classrooms participating in Action Civics program
223591055|NCT03367741|PROCEDURE|Biopsy Procedure|Undergo tumor biopsy
223591056|NCT03367741|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223591057|NCT03367741|DRUG|Cabozantinib S-malate|Given PO
224189597|NCT00252668|DRUG|Methotrexate|
224189598|NCT05649865|DIAGNOSTIC_TEST|Blood sample|Blood samples for analysis of circulating tumour HPVDNA
224189599|NCT05392920|OTHER|assessment study|there is no intervention in this study
223499320|NCT01068912|DRUG|Favipiravir|High-dose favipiravir regimen: 1200 mg favipiravir BID x 1 day, and 800 mg favipiravir BID x 4 days
223499321|NCT01068912|DRUG|Placebo comparator|Placebo BID x 1 day, and Placebo BID x 4 days
223499322|NCT00512863|DRUG|Humira (adalimumab)|
223499323|NCT04423874|BEHAVIORAL|Cold pressor task (CPT)|"The cold pressor test is among the most common and established methods for studying human reactions to pain and pain tolerance.~Participants submerge a hand in cold water (approx. 5°C) and are asked to keep their hand submerged for as long as can (until the sensation is intolerable), up to a maximum of 5 min.~The procedure is safe because the hand is removed before adverse effects can occur.~The participant will be given a break of 5 min in between trials, and will interchange hands between trials.~During this break hand may to be place in warm water (25-35°C) for up to 4 min to normalise hand temperature, which will be measured before and after each trial using a digital thermometer held firmly in the palm of the hand. Each participant will complete no more than three trials (conditions) in a randomised order."
223499324|NCT04423874|DIAGNOSTIC_TEST|index NOL|Measurement of the index NOL™: Four sensors, placed non-invasively on one of the four participants' fingers, will make it possible to calculate a dozen physiological parameters converts in real time into a pain index called NOL (for Nociception Level Index).
223499325|NCT04423874|BEHAVIORAL|Playback Experiments|During the experience, participants are led to listen, via headphones, to aversive non-verbal vocalizations (baby crying). The sound levels used to broadcast the non-verbal vocalisations will be scrupulously measured using approved and certified equipment during the preparation of the experiments. These sound volumes will be chosen so as not to inconvenience participants.
223499326|NCT04423874|DIAGNOSTIC_TEST|Video-pupillometry|This technique is based on the observation of the dilatation of the pupil during the perception of a nociceptive stimulus in test persons.
223591058|NCT03367741|PROCEDURE|Computed Tomography|Undergo CT scan
223591059|NCT03367741|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223591060|NCT03367741|BIOLOGICAL|Nivolumab|Given IV
223591061|NCT07013799|OTHER|BasketUp Warm-up|BasketUp is a basketball-specific warm-up program designed to meet the sport's physical and physiological demands. Based on the FIFA 11+ structure, it includes three blocks: mobility, strength and plyometrics, and agility with neurocognitive exercises. The program progresses weekly and can be adapted in duration and volume to fit different training needs.
223591062|NCT03194438|BEHAVIORAL|Urban Zen Integrative Therapy (UZIT)|Multi-modal components integrative therapy program (UZIT) that includes essential oil, gentle body movement, body-awareness meditation, and Reiki.
223591063|NCT05273554|DRUG|Pembrolizumab|Given by IV
223591064|NCT05273554|DRUG|lenvatinib|Given by PO
223591065|NCT06692738|DRUG|Rilvegostomig|Administered intravenously (IV) on Day 1 of each 21-day cycle
223591066|NCT06692738|DRUG|Pembrolizumab|Administered intravenously (IV) on Day 1 of each 21-day cycle
223591067|NCT06692738|DRUG|Carboplatin|Administered intravenously (IV) on Day 1 of each 21-day cycle up to 4 cycles
223591068|NCT06692738|DRUG|Paclitaxel|Administered intravenously (IV) on Day 1 of each 21-day cycle up to 4 cycles
223591069|NCT06692738|DRUG|Nab-paclitaxel|Administered intravenously (IV) on Days 1, 8, and 15 of each 21-day cycle up to 4 cycles
223591070|NCT05901103|OTHER|Serratus posterior superior intercostal plane block (SPSIPB)|Serratus posterior superior intercostal plane block is the intervention used in this study. It was performed when the patient is in lateral decubitis position. A high frequency (7-12 MHz) linear transducer of the ultrasound device is placed at the spinae scapula level in the transverse plane, and the upper medial border of the scapula, the trapezius muscle, rhomboid muscle, serratus posterior superior muscle (SPSM) and the second and third ribs are visualized. The sonovisible needle is then advanced immediately medial to the scapula, aiming for the area between the second and third ribs in order to reach the fascial plane between the SPSM and intercostal muscles. After contact of the needle with the rib gently, 1-2mL of saline is used to confirm the correct plane, and a total of 30 mL of 0.25% bupivacaine is administered to the superficial to the intercostal muscle.
224189600|NCT02195882|PROCEDURE|Exercise program of the scapular muscle stabilizers|
224189601|NCT01458535|DRUG|ABT-450|tablets
224189602|NCT01458535|DRUG|ABT-267|tablets
224189603|NCT01458535|DRUG|ribavirin|tablets
224189604|NCT01458535|DRUG|ritonavir|capsules
223499327|NCT06853145|DRUG|Hyperpolarized Xe129|Hyperpolarized Xe129-MRI: Patients will undergo hyperpolarized Xe129-MRI at the University of Virginia Radiology Imaging Core (Charlottesville, VA, USA). The entire procedure visit takes approximately 3 hours based on our team's experience.
223499328|NCT04611815|PROCEDURE|Total knee arthroplasty|Participant will undergo robotic-assisted or conventional total knee arthroplasty
223499329|NCT04611815|DIAGNOSTIC_TEST|Computer tomography scan|CT scans of the affected knee joint before and after the surgical procedure
223499330|NCT04611815|DIAGNOSTIC_TEST|biomechanical assesment|Participants will be asked to perform biomechanical assesment before and following surgery at baseline, 6-8 weeks and 6-months postoperatively
223591071|NCT07083349|DRUG|NK510 : allogeneic genetic modified NK|NK510 is an allogeneic genetic modification of NK cell. NK510 will be administered at a dose of 4x10\^7 NK/kg, 8x10\^7 NK/kg and 1.2x10\^8 NK/kg by a dose-escalation design and administered IV.
223591072|NCT07088627|PROCEDURE|Intervention 1: UG|Participants perform UG targeting SN and C\&J exercises, varying intensity at 80% of 1RM and volume (5 sets of 5, 4, 3, 2, 1 repetitions) over weeks. Rest between sets: 90 seconds.
223591073|NCT07088627|PROCEDURE|Intervention 2: SG|Participants perform SG with SN and C\&J at consistent 80% 1RM intensity, 5 sets of 5 repetitions each session. Rest between sets: 90 seconds.
223591074|NCT07088627|PROCEDURE|Intervention 3: MG|Participants engage in MG training focusing on SN and C\&J at 100% 1RM, 5 sets of 1 repetition, with 180 seconds rest between sets.
224189605|NCT02689713|DRUG|Voriconazole (topical)|The voriconazole (Vfend®-IV 200mg) will be applied topically to one of two skin graft sites at a concentration of 150 micromolar. Dialysates will be collected over 12 hours post-skin graft/voriconazole application for analysis in the lab of OLAM concentrations.
224189606|NCT02689713|DRUG|Topical Sterile Water Placebo Group|Sterile water will be applied topically to the other of the two skin graft sites. Dialysates will be collected over 12 hours post-skin graft/sterile water application for analysis in the lab of OLAM concentrations.
223499331|NCT01346306|DEVICE|Eldith Company - direct current stimulator|Direct current stimulation montage 1.
223499332|NCT01346306|DEVICE|Eldith Company - direct current stimulator|Direct current stimulation montage 2.
223591075|NCT07087496|OTHER|Insulin application training with mobile augmented reality|Intervention Group 2 (MAR group): Before the training, the participants were briefly informed about how the application would be performed, and their written consent was obtained. Before the insulin administration training was started, the MAR program was shown to them on the tablet by the researcher and the process steps containing QR codes prepared for insulin administration were provided on a blue flat surface and information was given about the use of the application, and a pre-test was administered to determine their knowledge levels on insulin administration. Then, the education application program prepared for insulin administration was opened and the patients were allowed to use it. The training application was performed 20-25 times. Then the post-test was administered to the participants immediately after the training. At the post-test, they were administered the Knowledge Test and Scale for Satisfaction with Patient Education.
223591076|NCT07087496|OTHER|insulin administration training with brochure|"The Intervention Group 1 (Brochure group): Before the training, the participants were informed about the study, and their written consent was obtained.~Before insulin administration training, a knowledge test was given as a pre-test to determine the participants' knowledge levels on insulin administrations. After the pre-test, a 15-20 minute practical training was given using the brochure prepared for insulin administrations. Immediately after the training, the knowledge test and Scale for Satisfaction with Patient Education were administered as a post-test. After the post-test, the participants were asked to self-administer insulin. The insulin administration skills of the patients were assessed by the researcher using the Insulin Administration Skill Assessment Checklist. After the assessment, the participants were informed about their deficiencies, or incorrect performances."
223591077|NCT07087847|BIOLOGICAL|TCRαβ+/CD45RA+depleted haploidentical hematopoietic stem cell transplantation (haplo-HSCT)|Approximately 28 days post-CAR-T therapy, a hematologic assessment will be performed. Eligible patients meeting the inclusion criteria will subsequently undergo TCRαβ+/CD45RA+depleted haploidentical hematopoietic stem cell transplantation (haplo-HSCT).Collect peripheral blood stem cells (PBSC) from the haplo-donor.Split the graft into two fractions at a 9:1 ratio, 90% fraction: subject to TCRαβ+ T-cell depletion, 10% fraction: subject to CD45RA+ T-cell depletion. Primary graft (TCRαβ+depleted and partial CD45RA+ depleted): Freshly infused into the recipient. Residual CD45RA-depleted lymphocytes: Cryopreserved for prophylactic donor lymphocyte infusion (DLI) as needed.
223591078|NCT07089576|DEVICE|Arcevo™ LSA Hybrid Stent Graft System|The Arcevo LSA Hybrid Stent Graft System is an implantable aortic stent graft with LSA branch which is preloaded onto a delivery system and implanted during an open surgical procedure, or more specifically a total arch replacement procedure. The device is intended for use with a proximal surgical graft (not supplied). If additional coverage is needed, a protocol specified thoracic endovascular aortic repair (TEVAR) device may be used.
223746134|NCT04110093|DRUG|Regorafenib and PD-1 inhibitor|All Colorectal cancer patients received regorafenib (80mg qd d1-d21,q4w) and PD-1 inhibitor. The patients could receive one type of PD-1 inhibitors according to oneself circumstance consideration including nivolumab (3mg/kg, ivgtt, q2w), Carelizumab (200mg, ivgtt, q3w), Sintilimab (200mg, ivgtt, q3w), Toripalimab(240mg ivgtt, q3w).
223746135|NCT01067222|DRUG|BF2.649|BF2.649 oral capsules at 10 or 20 or 40 mg per day
223746136|NCT01067222|DRUG|Modafinil|Modafinil oral capsules at 100 or 200 or 400 mg per day
223746137|NCT01067222|DRUG|Placebo|Placebo oral capsules, 4 capsules per day
223746138|NCT00651755|DRUG|Aprepitant|125 mg By Mouth (PO) On Day 1, followed by 80 mg PO Daily On Days 2-3.
223499333|NCT01452256|DRUG|Desflurane|4-6 Vol %
223499334|NCT01452256|DRUG|Propofol|TIVA to achieve BIS value of 40-60
223499335|NCT02745730|OTHER|Glucose|
223499336|NCT02745730|OTHER|Fructose|
223499337|NCT02745730|OTHER|Sucralose|
223499338|NCT02745730|OTHER|Allulose|
223746139|NCT00651755|DRUG|Cyclophosphamide|750 mg/m\^2 By Vein On Day 1
223746140|NCT00651755|DRUG|Doxorubicin|25 mg/m\^2 By Vein Over 48 Hours On Days 1-2
223746141|NCT00651755|DRUG|Vincristine|2 mg By Vein On Day 1
224189607|NCT01396252|DRUG|BMS-820836|Tablets, Oral, 0.5 mg, Once daily, 14 days
224189608|NCT01396252|DRUG|BMS-820836|Tablets, Oral, 1 mg, Once daily, 14 days
224189609|NCT01396252|DRUG|BMS-820836|Tablets, Oral, 2 mg, Once daily, 14 days
224189610|NCT01396252|DRUG|Placebo matching BMS-820836|Tablets, Oral, 0 mg, Once daily, 14 days
224189611|NCT01396252|DRUG|BMS-820836|Tablets, Oral, (initiated at 1 mg and dose escalated to the target dose of 2 mg), Once daily, 14 days
224189612|NCT06562556|DEVICE|the breather device|investigate the effect of the breather device on ventilatory effort and in patients with myogenic temporomandibular joint disorders
223499339|NCT02178332|OTHER|Yhteispeli, whole school programme|
223499340|NCT02178332|OTHER|Two theoretical lectures|
223499341|NCT03594552|DRUG|Arbaclofen_15|Single oral dose (15mg)
223499342|NCT03594552|DRUG|Arbaclofen_30|Single oral dose (30mg)
223499343|NCT03594552|DRUG|Placebo|Single oral dose placebo (oral tablet)
223499344|NCT05574985|BIOLOGICAL|Recombinant Omicron-Delta COVID-19 Vaccine (CHO Cell)|Injected one dose of research vaccine
223499345|NCT05574985|BIOLOGICAL|Inactivated COVID-19 vaccine (Vero Cell)|Injected one dose of control vaccine
223499346|NCT05232669|DIETARY_SUPPLEMENT|Cocoa extract|2 capsules each day containing a total of 500 mg cocoa flavanols, including 80 mg (-)-epicatechin, and 50 mg theobromine
223499347|NCT05232669|DIETARY_SUPPLEMENT|Cocoa extract placebo|Cocoa extract placebo
223499348|NCT05232669|DIETARY_SUPPLEMENT|Multivitamin|Multivitamin
223499349|NCT05232669|DIETARY_SUPPLEMENT|Multivitamin placebo|Multivitamin placebo
223499350|NCT03195556|DEVICE|Ultrasound|Ultrasound exposure of Definity microbubbles infused over 10 min. Ultrasound administered at 1.3 MHz, mechanical index of 1.3, and pulsing interval of 10 s.
223499351|NCT03407456|OTHER|Gastroesophageal reflux symptoms questionnaire|Reflux Symptom Questionnaire, 7-day recall (RESQ-7).
223746142|NCT00651755|DRUG|Prednisone|100 mg PO for 5 Days
223499352|NCT05309772|DIAGNOSTIC_TEST|Basophil activation test (BAT)|"Basophils and mast cells are the key drivers of food allergic reactions and anaphylaxis to foods. The study team have developed new tests that measure the reaction of mast cells and basophils by flow cytometry following stimulation with allergen, the BAT and the MAT:~• BAT uses fresh whole blood from patients added to allergen and antibodies in a test tube. The tube containing the allergic cells are then analysed one by one to estimate how many and how much express activation markers on their surface, CD63 and CD203c.~MAT uses a human mast cell line (LAD2 cells) which are human mast cells grown in the laboratory to which patients' plasma is added in order to mimic the patients' own mast cells. Sensitised LAD2 cells are then stimulated with allergen or controls and analysed by flow cytometry to assess the expression of the activation marker CD63 on the cell surface, similar to what happens in the BAT. Results of MAT will be considered only in cases of non-responding basophils."
223499353|NCT05309772|DIAGNOSTIC_TEST|Oral food challenge (OFC)|Consumption of the food suspected of causing an allergic reaction in a medically supervised environment, starting with small amounts and progressively increasing the dose at regular intervals up to a cumulative dose corresponding to an age-appropriate portion of the food.
223499354|NCT04571034|PROCEDURE|Sham Therapeutic Ultrasound|A standard ultrasound machine (Vectratm by Chattanooga Group, Inc.) with inactive probe will be used to deliver sham massage.
223499355|NCT04571034|PROCEDURE|Medium-Intensity Roller Massage|This group will receive a single bout of roller massage at medium intensity (25 newtons of force directed perpendicular to the surface of the thigh).
223499356|NCT04571034|PROCEDURE|High-Intensity Roller Massage|This group will receive a single bout of roller massage at medium intensity (45 newtons of force directed perpendicular to the surface of the thigh).
223499357|NCT03509155|OTHER|National portion & IYCF counseling|Eight or twelve pieces of Biscuits supplementation per day as serving size recommendation based on the requirement from Ministry of Health, accompanied by IYCF Counseling emphasizing on local food optimization. The difference in serving size recommendation will be evaluated to see the efficacy of Biscuits supplementation on wasting children age 6-23 months of age
223499358|NCT03509155|OTHER|Adjusted portion & local food counseling|four pieces of Biscuits supplementation per day as serving size recommendation, accompanied by IYCF Counseling. The difference in serving size recommendation will be evaluated to see the efficacy of Biscuits supplementation on wasting children age 6-23 months of age
223499359|NCT03588468|OTHER|Electrophysiological biomarkers|Motor and sensory nerve conduction study will be performed on median, ulnar, tibialis, peroneal and sural nerves.
223499360|NCT03588468|OTHER|MRI biomarkers|T1, T2, STIR and magnetisation transfer ratio (MTR) will be performed unilaterally on the thigh and the leg.
223499361|NCT00294398|OTHER|ICS Prescription + Standard Asthma ED Discharge Therapy|"Subjects are given a prescription for a 30 day supply of an inhaled corticosteroid based on age:~1-4 year olds Budesonide 0.5mg via nebulizer once daily; 5-11 year olds Fluticasone propionate 44mcg 2 puffs via spacer twice daily; 12-18 year olds Fluticasone propionate 110mcg 2 puffs via spacer twice daily"
223499362|NCT00294398|OTHER|Standard Asthma ED Discharge Therapy|Subjects are instructed to use albuterol as needed (up to every 4 hours), may be prescribed prednisone and to follow-up with their primary doctor in 3-5 days. All view an educational video about asthma control and are provided a home nebulizer if needed.
223499363|NCT03620279|BEHAVIORAL|Magic camp intervention|Hand-arm bimanual motor skills training
223499364|NCT01769365|DRUG|7-day quadruple therapy|pantoprazole 40 mg twice daily, clarithromycin 500 mg twice daily, amoxicillin 1 g twice daily and metronidazole 500 mg twice daily for 7 days
223499365|NCT01769365|DRUG|10-day sequential therapy|pantoprazole 40 mg twice daily and amoxicillin 1 g twice daily for 5 days, followed by pantoprazole 40 mg twice daily, clarithromycin 500 mg twice daily and metronidazole 500 mg twice daily for a further 5 days
223499366|NCT01769365|DRUG|7-day standard triple therapy|pantoprazole 40 mg twice daily, clarithromycin 500 mg twice daily, and amoxicillin 1 g twice daily for 7 days
223746143|NCT00651755|DRUG|Rituximab|375 mg/m\^2 By Vein On Day 1.
223746144|NCT00651755|DRUG|Ondansetron|8 mg daily for 2 days
223499367|NCT03860480|PROCEDURE|ESP with Bupivacaine 0.5%|Regional anesthesia procedure with Bupivacaïne 0.5%
223499368|NCT03860480|PROCEDURE|ESP with Saline 0.9%|Regional anesthesia procedure with Normal Saline
223499369|NCT05726136|DRUG|acetated Ringers|After insufflation of carbon dioxide during an abdominal laparoscopic procedure, the first fluid bolus is infused. Circulatory and volume effects are studied. If cardiac output increase a second bolus is infused and studied.
223499370|NCT05726136|DRUG|albumin 5%|After insufflation of carbon dioxide during an abdominal laparoscopic procedure, the first bolus of fluid is infused. Circulatory and volume effects are studied. If cardiac output increases a second bolus is infused and studied.
223499371|NCT05726136|DRUG|albumin 20%|After insufflation of carbon dioxide during an abdominal laparoscopic procedure, the first bolus of fluid is infused. Circulatory and volume effects are studied. If cardiac output increases a second bolus is infused and studied.
223499372|NCT00118287|DRUG|azacitidine|Given SC or IV
223499373|NCT00118287|BIOLOGICAL|etanercept|Given SC
223511918|NCT01657500|OTHER|Corneal donor storage in Optisol GS media solution|Donor tissue is preserved in the Optisol media until ready for implantation
223511919|NCT01657500|OTHER|Life 4°C solution for cornea storage|Donor cornea is stored in the Life 4°C media prior to implantation.
223511920|NCT00638079|DRUG|Megestrol acetate oral suspension 625 mg/5 mL|Megestrol acetate oral suspension 625 mg/5 mL. Single dose (5 mL) administered with a high fat meal
223511921|NCT00638079|DRUG|Megestrol acetate oral suspension 625 mg/5 mL|Megestrol acetate oral suspension 625 mg/5 mL. Single dose (5 mL) administered following an overnight fast
223511922|NCT04817800|DRUG|140/100 μg Azelastine hydrochloride/Beclomethasone Dipropionate)|It will be nasaly administered
223511923|NCT00631241|PROCEDURE|Single Photon Emission Computed Tomography|First 3 Patients = Performed 30-45 minutes, 2-3 hours, and 20-24 hours after injections of the radioactive material or just before surgery; Remaining 17 Patients = Performed only one at a time as was found to be best based on the scans from first 3 patients.
223511924|NCT00631241|PROCEDURE|Intraoperative Lymphatic Mapping|Isosulfan Blue and India ink will be injected into the cervix to help the surgeon identify the sentinel nodes by their blue color and their level of radioactivity.
224189613|NCT06562556|OTHER|conventional exercise program|"-Therapeutic Ultrasound (US): Ultrasound therapy will be applied at the site of pain over the TMJ area with Frequency: 1 MHz, Mode: continuous, Duration: 6 min. each session 2-Myofascial release for masticatory muscles 3-The self-exercise Self exercise: include simplified myo-functional therapy. 10 repetitions, three: five times per day 4-Techniques to correct deglutition: swallowing a small amount of water and speaking while holding a semi-hard small object between the dental arches 5-Relaxation exercise of Masticator Muscle:10 repetitions, three.~6-Strain-counterstain (SCS): applied on the tender or trigger points of neck muscles on improving pain and pressure pain sensitivity in neck muscles"
224189614|NCT03415815|PROCEDURE|Surgeries|Radical resection of esophageal cancer
224189615|NCT01238861|BIOLOGICAL|Benralizumab 2 mg|EOS+ participants received single benralizumab 2 milligram (mg) injection followed by a single placebo injection subcutaneously.
224189616|NCT01238861|BIOLOGICAL|Benralizumab 20 mg|EOS+ participants received single benralizumab 20 mg injection followed by a single placebo injection subcutaneously.
224189617|NCT01238861|BIOLOGICAL|Benralizumab 100 mg|EOS+ and EOS- participants received two benralizumab 50 mg injections subcutaneously.
224189618|NCT01238861|OTHER|Placebo|EOS+ and EOS- participants received two placebo injections subcutaneously.
224189619|NCT04993547|OTHER|Parent and peer presence|Does the presence of fellow pupils and parents improves a pupil's resistance to undergo a nasopharyngeaal swab test?
224189620|NCT04822727|DEVICE|1 or more AndraTec devices (see description for list of devices)|1 or more AndraTec devices (Lokum L-Quest guidewire, Lokum Amplatz guidewire, Slider Hydrophilic Nitinol Guidewire, AltoSa-XL PTA Balloon, Alto-Sa-XL Gemini Balloon, Optimus-CoCr stent, Optimus-CVS PTFE covered stent)
224189621|NCT01662076|OTHER|Homeopathic Remedies|The homeopathic remedy will be administered as either 1 globule sublingual or 0.2 mL oral (depending on chosen formulation) up to 3 times per day. The homeopath will decide which formulation will be used. Homeopathic remedies prepared according to the standards as set out by Health Canada. The caregiver or patient will be asked to administer the homeopathic remedy at least 30 minutes before or after taking other medications, food and strong smelling substances (such as camphor, mint, or coffee).
223499374|NCT02606539|PROCEDURE|Total abdominal hysterectomy and methotrexate|After written consent laparotomy will be done then pelvic examination for extra uterine spread, palpation of liver, omentum for any gross lesions and then hystrectomt bilateral salpigooophrectomy will be done) plus single course methotrexate(anti folate chemotheraputic agent, vial form given by intramuscular injection) 1mg/kg every other day alternating with calcium folinate 0.1 mg/kg for 4 doses each cycle then measuring B-HCG (the cycle may be repeated until normalization of B-HCG)
223499375|NCT02606539|DRUG|Methotrexate plus folinic acid alone|methotrxate 1mg/kg every other day alternating with calcium folinate 0.1 mg/kg for 4 doses each cycle then measuring B-HCG and cycle repeated until normalization of B-HCG
223499376|NCT03017664|OTHER|Peptide-based enteral formula|Peptide-based, higher protein and higher calorie enteral formula
223499377|NCT03017664|OTHER|Retrospective review of enteral tube feeding formula|Enteral formula tube feeding will be retrospectively reviewed
223499378|NCT03478995|DRUG|GX-I7|GX-I7 25mg/ml/vial
223499379|NCT02639533|DRUG|Pregabalin|Pregabalin 150 mg PO, single dose.
223499380|NCT02639533|OTHER|Placebo|Pill of same physical characteristics as the one used for the intervention, containing starch only. Administered PO in single dose.
223591079|NCT07087691|DEVICE|OneMark device|"The OneMark device system consists of a tumor marker preloaded in a delivery system, a handheld probe, and a display console.~The OneMark marker is a metal clip with microparticles embedded in gelatin forming a hydrogel pellet. The pellet is implanted with a preloaded injector percutaneously in soft tissues, such as breast or lymph nodes, to mark a biopsy site or tissue intended for surgical removal. It can be used as a fiducial implant post-biopsy for future identification or monitoring of the tissue, and as an intra-operative localization mark. The microparticles of OneMark marker can be detected by Doppler ultrasound, magnetic resonance imaging (MRI), radiography, and OneMark Detector. During surgery, the OneMark marker may be removed with the target tissue. If patients do not require surgery, the OneMark marker can be left in place."
223591080|NCT07088224|OTHER|Observational studies without intervention|Observational studies without intervention
223591081|NCT04318600|DRUG|human amniotic mesenchymal stem cell|human amniotic mesenchymal stem cell (hA-MSC) for the treatment of lupus nephritis patients with WHO class III, IV or V LN were given hA-MSC (Peripheral intravenous infusion, dose 1×106/kg cells, once every month for three times).
224189622|NCT06050382|OTHER|PROGRESSIVE RELAXATION TRAINING|"Both intervention groups were instructed and trained by a physiotherapist 2times a week for 30 minutes each over 6 weeks, The sessions were held in a well-lit, clean and comfortable room with a temperature of 22-24 degrees. Women were asked to stop eating and wear comfortable clothes at least two hours before the sessions. Before the training, relaxation exercises and breathing techniques explained to the women.~The women lied in the supine position firstly. Then the therapist instructed them to contract and release different muscle groups. They practiced tensing a muscle group until they felt the slight contraction and then released it, simultaneously relaxing other muscle groups. During the session, women were instructed to contract the muscles for 10-20 seconds during deep diaphragmatic breathing and to relax for 30-40 seconds while exhaling."
223591082|NCT03414294|DRUG|K-755 Part A (SAD)|Single ascending dose (SAD). There will be 7 cohorts in the Part A. Three quarters of subjects will receive K-755 tablet orally in a double-blind fashion.
223591083|NCT03414294|DRUG|Placebo Part A (SAD)|Single ascending dose (SAD). In Part A, one quarter of subjects will receive placebo tablet orally in a double-blind fashion.
224189623|NCT06231992|PROCEDURE|opioid anaesthesia|I.V Fentanyl (1-2ug/kg) before induction of general anesthesia with I.V propofol (1-2mg/kg), atracurium (0.5mg/kg). Intermittent boluses of fentanyl will be given intraoperatively when needed to maintain the change in hemodynamics within 20 % of the baseline.
223499381|NCT04645056|OTHER|Stretching and Mobility exercises for neck and shoulder|9 specific stretching and mobility exercises performed 3 times every day the first 4 weeks after surgery.
223499382|NCT02049879|DRUG|Corticosteroids injection|A solution of triamcinolone 40 mg (Kenalog) mixed with 3 cc of 2% xylocaine without epinephrine.
223499383|NCT05194488|DEVICE|Low level laser therapy|Patients will receive low-level laser therapy on the temporomandibular joint disc
223499384|NCT05194488|DRUG|Botulinum toxin type A|Patients will receive Botulinum toxin type A injection into the lateral pterygoid muscle under Electromyography (EMG) guidance.
223499385|NCT05194488|DEVICE|Anterior repositioning appliance|Patients will receive hard maxillary anterior repositioning appliance.
223499386|NCT03407482|DRUG|GDC-0853|Participants received GDC-0853 at a dose of 200mg, as per the dosing schedule described above.
223499387|NCT00533988|DEVICE|Antimicrobial impregnated catheter (5593)|Comparison of 14-day placement of a standard triple lumen (ARROW Standard Triple Lumen Catheter, Arrow International Inc., Reading, PA, US) versus an antimicrobial impregnated catheter (Chlorhexidine-silver sulfadiazine)(ARROWgard Triple Lumen Catheter, Arrow International Inc., Reading, PA, US)
223499388|NCT02741778|PROCEDURE|Minimally invasive group|In this group, all manipulations are finished by laparoscopy and thoracoscopy.
223499389|NCT02741778|PROCEDURE|Open group|Right lateral position, Traditional thoracotomy through the 7th intercostal incision.
223499390|NCT05143502|DRUG|Montelukast|"Montelukast is a leukotrienes antagonist which has proven efficacious in chronic inflammatory conditions of the airways, including allergic rhinitis, asthma, and aspirin-exacerbated respiratory disease (AERD), all diseases that often coexist with CRSwNP.~We will use oral Montelukast (montelukast 10 mg, once a day) for 3 monthes"
223499391|NCT05143502|DRUG|Prednisolone|Oral Prednisolone 40 mg/day for two weeks.
223499392|NCT05143502|DRUG|Fluticasone Furoate|fluticasone furoate nasal: (50 micrograms /spray ) 100 micrograms (2 sprays) in each nostril twice daily
223499393|NCT00627978|DRUG|ixabepilone|ixabepilone 40 mg/m2 Q3w over 3 hours
223499394|NCT03967327|DRUG|Buprenorphine transdermal patches|It should be applied to non-irritated, intact skin of the upper outer arm, upper chest, upper back or the side of the chest. The skin should be relatively hairless. If none are available, the hair at the site should be clipped, not shaven.
223499395|NCT03967327|DRUG|Morphine Sulfate Sustained-Release Tablet|It will be administered orally twice (q12h) daily.
223499396|NCT05089357|BIOLOGICAL|AbobotulinumtoxinA|Participants received a total dose of AbobotulinumtoxinA (Dysport®), 50 U (0.25 mL total; 10 U \[0.05 mL per injection site\] of study drug into 5 injection sites intramuscularly.
223499397|NCT06803654|DRUG|BTOS-HA|Brimonidine tartrate ophthalmic solution 0.025% with sodium hyaluronate (BTOS-HA) administered as 1 topical ocular drop instilled into each eye (OU), 4 times daily (QID), approximately 4 hours apart
223499398|NCT06803654|DRUG|Lumify®|Brimonidine tartrate ophthalmic solution 0.025%, administered as 1 topical ocular drop instilled into each eye (OU), 4 times daily (QID), approximately 4 hours apart
223499399|NCT03734185|OTHER|Learning and Coping|'Experienced patients' plan, teach and evaluate, in cooperation with health professionals.
223591084|NCT03414294|DRUG|K-755 Part B (MAD)|Multiple ascending dose (MAD). There will be 4 cohorts in the Part B. Three quarters of subjects will receive K-755 oral tablet in a double-blind fashion.
223591085|NCT03414294|DRUG|Placebo Part B (MAD)|Multiple ascending dose (MAD). In Part B, one quarter of subjects will receive placebo tablet orally in a double-blind fashion.
223591086|NCT03414294|DRUG|K-755 Part C (FE)|Food effect (FE). All subjects in Part C will receive K-755 oral tablet both under fed and fasted condition in a open-label, crossover fashion.
223591087|NCT03414294|DRUG|K-755 Part D (FE)|Food effect (FE). All subjects in Part D will receive K-755 oral tablet both under fed and fasted condition in a open-label, crossover fashion.
223591088|NCT03414294|DRUG|K-755 Part E (MAD)|Multiple ascending dose (MAD). There will be 2 cohorts in the Part E. Three quarters of subjects will receive K-755 oral tablet in a double-blind fashion.
223591089|NCT03414294|DRUG|Placebo Part E (MAD)|Multiple ascending dose (MAD). In the Part E. One quarter of subjects will receive placebo tablet orally in a double-blind fashion.
224189624|NCT06231992|PROCEDURE|Opioid free anaesthesia|"* IV Ketamine (0.25-0.5 mg/kg) before induction of general anesthesia with I.V propofol (1-2 mg/kg), atracurium (0.5mg/kg) followed by(0.25mg /min) infusion of ketamine for maintenance~* Dexamethasone I.V (8 mg) will be given before induction of general anesthesia.~* magnesium sulphate (20 mg/kg)in 100ml saline within 10 mints Followed by infusion of magnesium sulphate at rate of (10mg/kg/h)."
224189625|NCT01269346|DRUG|Eribulin Mesylate|"Eribulin mesylate 1.4 mg/m2 administered as an intravenous (IV) infusion (over 2 to 5 minutes) on Days 1 and 8 of each 3-week cycle.~Trastuzumab 8 mg/kg will be administered as in IV infusion over a 90-minute period on Day 1 of Cycle 1. Thereafter, trastuzumab 6 mg/kg will be administered as an IV infusion over a 30-minute period on Day 1 of each subsequent cycle."
224189626|NCT06649916|BEHAVIORAL|Parentese Speech|Novel words are introduced in parentese, a type of speech that is typically characterized by greater pitch variation, longer duration, and louder volume
224189627|NCT06649916|BEHAVIORAL|Adult Registered Speech|Novel words are introduced in standard adult register.
223591090|NCT00547040|OTHER|no intervention|no intervention
223591091|NCT01032824|BEHAVIORAL|Individual Telephone Counseling Intervention|10-session, 5-month HIV adherence and chronic disease self-management individual telephone counseling intervention.
223591092|NCT01032824|OTHER|Group Arm|10-session didactic telephone group
223591093|NCT01032824|OTHER|Book Arm|Book only.
223591094|NCT06171074|BIOLOGICAL|CM310|CM310 injection
223591095|NCT00618605|BIOLOGICAL|Ad26.ENVA.01 HIV-1 vaccine|Recombinant adenovirus serotype 26 HIV-1 vaccine
223591096|NCT05633329|PROCEDURE|single level|injection of 40 ml bupivacaine 0.25 at T8 (20 ml on each side)
223591097|NCT05633329|PROCEDURE|dual level|injection of 40 ml of bupivacaine 0.25 at two level T7 and T9 (10 ml on each level of both side)
223591098|NCT02250664|OTHER|Very low nicotine content cigarettes|Very low nicotine content cigarettes
223591099|NCT03514563|DIAGNOSTIC_TEST|MRI imaging|MRI recordings of the craniofacial region
223591100|NCT03514563|DIAGNOSTIC_TEST|Optical scan|Optical intraoral scans
223591101|NCT03514563|DIAGNOSTIC_TEST|3D photography|Facial stereophotogrammetry
224189628|NCT05248854|OTHER|Sensorimotor exercise training|The program included side stepping, tandem walking, perturbation exercise, overcoming mini obstacles, walking different surfaces and traditional hip and knee exercise. Participants applied these exercise as home program between postoperative second weeks and 8th weeks, 3-5 day /week , 20 25 min every session.
224205826|NCT06185556|RADIATION|Stereotactic body radiotherapy|Stereotactic body radiotherapy (CT- or MRI-guided) of 1-3 perivascular and peribiliary colorectal liver metastases.
223746145|NCT01496547|DRUG|intensive chemo - RIC preparation|The intensive chemotherapy is composed of fludarabine 35mg/m2 + high-dose cytarabine 2g/m2 D1-5 + idarubicin (12mg/m2) D5-7. The reduced intensity preparation regimen will start 7 days after the chemotherapy with fludarabine 35mg/m2 for 5 days + iv busulfan 3.2mg/kg/day for 3 days followed by stem cell infusion 2 days later.
223746146|NCT00888095|PROCEDURE|deep brain stimulation|electrode implantation in either STN or cZI
224189629|NCT05248854|OTHER|Core stabilization exercise training|Core stabilization exercise program was also prepared parallel to the sensorimotor training group intensity; the program contained traditional hip and knee exercise combining the core stabilization as mat activities depending on previous research.core stabilization exercise program was also prepared parallel to the sensorimotor training group intensity; the program contained traditional hip and knee exercise combining the core stabilization as mat activities depending on previous research
224189630|NCT00274573|DRUG|Tiotropium bromide|
223591102|NCT02168985|BEHAVIORAL|TFH program|The Faithful House (TFH), is a three-day faith-based skills-building curriculum. The curriculum aims to increase household resilience by strengthening families and couples' relationships through enhanced couple communication
224189631|NCT02753608|OTHER|Collection of exhaled breath condensate|An sampling device (authorized for this use) will be connected to the expiratory line of the ventilator. Exhaled breath condensates accumulate in a cooled container.
224189632|NCT01097759|PROCEDURE|Surgery|Hemorrhoidectomy using the LigaSure sealing device or hemorrhoidopexy using the stapler
224189633|NCT04501159|OTHER|blood sample pre, during and post HD|Assessment of ABG pre, during and post HD
224189634|NCT04501159|DEVICE|Non invasive cardiac output assessment|Four ECG style electrodes are placed on the thorax which indirectly measures cardiac output.
224189635|NCT03678649|DRUG|Capecitabine|1000-1250 mg/m2 orally twice daily for 14 days followed by a 1-week rest period, given as 3- week cycles for a total of 6 cycles .
224189636|NCT01855607|DRUG|topical menthol|7.5% Methylsalicylate / 2% Menthol Lotion
224189637|NCT01855607|DRUG|placebo lotion|The control (placebo) product has same amount of Methylsalicylate (7.5%) and no menthol.
224189638|NCT03696537|DRUG|Fludarabine|Fludarabine 30 mg/m2/day IV (total 5 doses) administered days -7 through -3 of conditioning regimen
223591103|NCT01528748|BEHAVIORAL|Cognitive Behavioral Analysis System of Psychotherapy|Cognitive Behavioral Analysis System of Psychotherapy (CBASP) is a behavioral intervention that addresses the unique behavioral characteristics of chronically depressed individuals, most of which are highly relevant for alcoholics as well. CBASP has a structured, individualized, and collaborative (patient and clinician) design. The intervention emphasizes teaching effective coping strategies and employing motivational, cognitive, behavioral, and interpersonal techniques. Individual therapy (1 hour) sessions occur on a weekly basis for a total of 20 sessions over a period of 21 weeks.
223591104|NCT02882386|OTHER|Strength Training|
223591105|NCT02882386|DIETARY_SUPPLEMENT|Milk 1%|
223591106|NCT02882386|DIETARY_SUPPLEMENT|Whey protein concentrate 80 (WPC-80)|
223591107|NCT02882386|DIETARY_SUPPLEMENT|Microparticulated whey|
223591108|NCT02882386|DIETARY_SUPPLEMENT|Hydrolyzed whey|
223746147|NCT02287064|DRUG|Intravenous Immune Globulin (IVIG)|"IVIG will be infused over a course of five days in the form of GAMMAGARD LIQUID 10% solution, available from Baxter. For neurological and autoimmune diseases 2 grams per kilogram of body weight is implemented for three months over a five day course once a month.~There is very limited reliable dose ranging data for IVIG in the treatment of any condition, and most dosing has been empiric. In our experience, we have empirically observed a more potent immunomodulatory effect from induction dose IVIG (2 g/kg) continued each month, than with the booster dose maintenance dose of 1gm/kg. Though there is no category one evidence to support this practice, neither is there such evidence to refute it. Additionally, results from previous trials of IVIG in SCAs show this dosage to be relatively safe and effective at this rate of infusion"
224189639|NCT03696537|RADIATION|Total Marrow Irradiation (TMI)|TMI will be delivered twice a day, at least 6 hours apart, on days -7 through -3 (total of 10 fractions) of conditioning regimen
224189640|NCT05513807|DRUG|Nicotinamide treatment|3g Nicotinamide orally (1g immediately pre transplant, then immediately 1g post-transplant after the recovery room and 1g 24 hours later)
223591109|NCT02882386|DIETARY_SUPPLEMENT|Native whey|
223591110|NCT06027021|DIAGNOSTIC_TEST|18F-Fluoromisonidazole PET|Imaging of hypoxia before radioembolization with 18F-Fluoromisonidazole PET.
223746148|NCT03822208|BIOLOGICAL|AL003|"Single-doses of AL003 in dose-escalating cohorts~Multiple doses of AL003 in a single cohort"
223746149|NCT03822208|OTHER|Saline Solution|Saline Solution will be administered as a single infusion for each dose escalation cohort in a ratio of 6 active and 2 placebo and as multiple infusions in the single cohort in a ratio of 10 active and 2 placebo
223746150|NCT02694406|DEVICE|MRI perfusion|contrast-enhanced MR imaging including perfusion weighted imaging (PWI)
224189641|NCT05513807|DRUG|Placebo treatment|3g Placebo orally (1g immediately pre transplant, then immediately 1g post-transplant after the recovery room and 1g 24 hours later)
224189642|NCT02854215|OTHER|Collection of additional data with questionnaires|"* questionnaires for quality of life measurements: QLQC30; QLQ-OV28~* questionnaires for medico-economic purposes: ADL (activities of daily living); IADL (instrumental activities of daily living); EQ-5D3L; absenteeism questionnaire.~These questionnaires will be completed during the study time (5 or 6 times during the treatment, next every 4 months during the first two years and then every 6 months during the third year of follow-up)."
224189643|NCT00460421|DRUG|Palifermin|Palifermin will be administered as an IV bolus injection (40, 60 or 80 µg/kg/day)once daily for 3 consecutive days before the start of conditioning regimen and after HCST (Day -10, -9, -8 and Day 0, +1, +2 respectively).
224189644|NCT00460421|RADIATION|Total Body irradiation|
224189645|NCT00460421|DRUG|Chemotherapy|High dose etoposide, Cyclophosphamide
224205827|NCT05131282|DIAGNOSTIC_TEST|Blood test of PE risk|A blood test is applied to women between 11weeks and 13 weeks+6 days of GA at the first visit to evaluate risk of developing PE
224205828|NCT05131282|DIAGNOSTIC_TEST|Blood test of Preterm PE risk|A blood test is applied to women between 11 weeks and 13 weeks+6 days of GA at the first visit to evaluate risk of developing Preterm PE
224205829|NCT05565872|BEHAVIORAL|Urban training|A community-based exercise intervention (Urban Training) by using public spaces and urban walkable trails, adapted to each patient needs and capabilities
223591111|NCT05518526|DRUG|Liposomal Annamycin (L-Annamycin)|Study drug consists of L-Annamycin as a lyophilised powder in 50-mL single-use vials containing 45 mg of L-Annamycin must be reconstituted with 45 mL of 0.9% sodium chloride injection between 34 to 42℃, USP, and then diluted 1:1 with 0.9% sodium chloride injection between 34 to 42℃ in non-polyvinyl chloride IV bags before intravenous infusion. The dose of L-Annamycin will be intravenously applied during 2 hours infusion on D1, D8, and D15 of each 28-day cycle (up to Cycle 6th).
224189646|NCT05918952|DIAGNOSTIC_TEST|Covid-19 Antibody Test|"The investigators propose to use the iHealth® Rapid COVID-19 Antigen Rapid Test. Per the EUA guidance, study participants will complete one test at a study location and receive one test to take home with instructions to complete it within 48 hours.~Each testing site will have a private designated space for customers to self-collect and test themselves privately. The edutainment video will serve as a resource for information on accurate test performance. Test one will be done in a private setting and results entered into REDcap and will also be written on a testing card with contact information for the purpose of follow-up. For test number two the customer will self-collect within 48 hours (per the FDA EUA for this particular test) and results will be entered into RedCap."
224189647|NCT05918952|OTHER|Short Clip videos|Designed to discuss the testing process, the importance of getting tested and accessing care, and how COVID-19 has disproportionately affected the Black/African-American community.
224189648|NCT06422299|BEHAVIORAL|Online, couples-based intervention|During Phase 1 of the present study, the intervention will be iteratively developed using a rigorous, user-centered design approach through integration of knowledge gained from Phase 1 dyadic analyses and qualitative interviews, and existing gold-standard treatments for substance use among couples, including Integrative Behavioral Couples Therapy (IBCT; Christensen \& Doss, 2016) and Behavioral Couples Therapy for Alcohol (ABCT; McCrady et al, 1995) and substance use brief interventions for young adults (Halladay, et al., 2019; Tanner-Smith et al., 2015).
224189649|NCT05136859|PROCEDURE|preserve|preserve the perivascular fat of the target cephalic vein
224189650|NCT05310396|OTHER|Experimental formula|Cow's milk-based infant formula with a specific blend of nutrients at pre-defined levels
224189651|NCT05310396|OTHER|Control Formula|Cow's milk-based infant formula with standard nutritional composition
223499400|NCT06971354|BEHAVIORAL|Biofeedback|Three sessions of biofeedback before and after a standardized meal.
223499401|NCT06971354|DIETARY_SUPPLEMENT|Placebo|Three sessions of placebo followed by standardized meal.
223499402|NCT06417411|DRUG|Aspirin 100mg|Daily use of low dose aspirin.
223499403|NCT05325008|DRUG|Immunosuppression reduction/modification + intravenous immunoglobulin|Participants will receive intravenous immunoglobulin along with immunosuppression reduction/modification.
223499404|NCT05325008|OTHER|Immunosuppression reduction/modification|Participants will receive immunosuppression reduction/modification.
223499405|NCT06059846|DRUG|TBP-PI-HBr|TBP-PI-HBr film-coated immediate-release tablets.
223499406|NCT06059846|DRUG|Imipenem-cilastatin|Sterile powder for reconstitution administered as IV.
223499407|NCT06059846|DRUG|Dummy Infusion|0.9% sodium chloride administered as IV infusion.
223499408|NCT06059846|DRUG|Dummy Tablets|TBP-PI-HBr matching dummy tablets.
223499409|NCT04376229|OTHER|Registry|Registry of cancer patients who receive proton radiation therapy
223499410|NCT05537571|DRUG|SLN360|SLN360 is a double-stranded small interfering ribonucleic acid (siRNA) targeting LPA messenger RNA (mRNA)
223499411|NCT05537571|DRUG|Placebo|Sodium chloride, solution for injection
223499412|NCT06485336|DRUG|Atorvastatin 40mg|Each tablet will be taken once daily for 84 days.
223499413|NCT06485336|DRUG|Placebo|Each tablet will be taken once daily for 84 days.
223499414|NCT05542056|OTHER|Data and biosample collection|Collection of spot urine, blood sampling, vital parameters, body weight, medical history, patient questionnaires, drinking protocol, drug diary at at Visit 1 (before thiazide initiation), at Optional 2 hours-challenge, at Visit 2 (4 weeks after thiazide initiation), at Visit 2.1 (4 weeks after dose change), at Visit 3 (3-months after thiazide initiation)
223591112|NCT01979939|DRUG|DCV/ASV/BMS-791325|
223591113|NCT00758641|DEVICE|L-PRP Injection|L-PRP produced with Biomet Recover L-PRP Platelet Separation Kit
223499415|NCT05651919|BIOLOGICAL|Blood test|During the routine blood test of the patient, 4 more tubes of 4 milliliters (mL) will be collected to make a biological collection of PBMC and plasma for further analysis.
223499416|NCT05651919|BEHAVIORAL|quality of life Questionnaire|"During the routine medical visit, the patient will be asked to fill in a short questionnaire about quality of life.~This is a descriptive system comprises the following five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 3 levels: no problems, some problems, and extreme problems. This decision results into a 1-digit number that expresses the level selected for that dimension. Each patient's health state is referred to in terms of a 5-digit code;~Levels of perceived problems are coded as follows:~* Level 1 is coded as a '1' (indicating no problem)~* Level 2 is coded as a '2' (indicating some problems)~* Level 3 is coded as a '3' (indicating extreme problems) For example, state 11223 indicates no problems with mobility and self-care, no problems with performing usual activities, moderate pain or discomfort and extreme anxiety or depression, while state 11111 indicates no problems."
223499417|NCT05651919|BEHAVIORAL|Diet habits questionnaire|"During the routine medical visit, the patient will be asked to fill in a short questionnaire about his diet habits.~This is an exploratory questionnaire that describes and quantifies the foods (pro- or anti-inflammatory) ingested by patients."
223499418|NCT06975748|DRUG|STSP-0902 ophthalmic solution|Eye drop, 3 times daily for 8 weeks
223499419|NCT06975748|DRUG|STSP-0902 ophthalmic solution|Eye drop, 6 times daily for 8 weeks
223499420|NCT06975748|DRUG|STSP-0902 Placebo|Eye drop, 3 or 6 times daily for 8 weeks
223591114|NCT00758641|DRUG|Corticosteroid Injection|kenacort 40 mg/ml triamcinolon acetonide
223591115|NCT01820312|RADIATION|Low-Dose Fractionated Radiation Therapy/Paclitaxel|
223591116|NCT02554708|DEVICE|implantation of the pCONus Bifurcation Aneurysm Implant|The device will be introduced through a regular microcatheter. After deployment of the device with the crown positioned in the aneurysm neck the aneurysm will be entered with a microcatheter to perform endovascular coil occlusion. After completion of the coiling procedure the pCONus device will be electrolytically detached from the insertion wire and only the crown and the shaft will remain as a permanent implant.
224189652|NCT05725785|BEHAVIORAL|FOCUS participants|Participants using FOCUS will be given access to the FOCUS application and trained by the mHealth support specialist on how to use the functions of the smartphone (i.e. using a touchscreen, call, text) and different features of the FOCUS intervention.
224189653|NCT04602078|DRUG|Atezolizumab 1200 mg/m2|Fixed dose of 1200 mg/m2 by intravenous (IV) infusion on D1 of each cycle up to disease progression, unacceptable toxicity or absence of clinical benefit.
224189654|NCT04602078|DRUG|Gemcitabine 1000 mg/m2|Gemcitabine 1000 mg/m2 IV on D1 and 1000 mg/m2 IV on D8 of each 21-day cycle for up to 6 cycles.
224189655|NCT04602078|DRUG|Cisplatin 70 mg/m2|Cisplatin 70 mg/m2 by IV on split-dose schedule of 35 mg/m2 on day 1 (D1) and 35 mg/m2 on day 8 (D8) for up to 6 cycles.
224189656|NCT06426680|BIOLOGICAL|ILB-3101|There are eight escalating dose cohorts.
224189657|NCT02361372|OTHER|Placebo|Placebo daily for 6 months
224189658|NCT02361372|OTHER|CaCO3|CaCO3 daily for 6 months
224189659|NCT02361372|OTHER|Kefir|Kefir daily for 6 months
224189660|NCT06501885|BEHAVIORAL|Ethnodrama Intervention|The intervention is six drama performances that are designed to transform community member beliefs about and foster support of young women's PrEP use, reduce PrEP-related enacted stigma toward young women, and reduce PrEP-related anticipated and internalized stigma among young women.
224189661|NCT06468007|DRUG|Methylprednisolone Tablet|Patients receiving equipotent doses of methylprednisolone or prednisolone . Dosages will be determined at the discretion of the treating physician, customized for the specific clinical need in accordance with local guidelines.
223499421|NCT06559189|BIOLOGICAL|CD19x22 CAR T|The CD19 CAR contains an FMC63 binding domain, a CD28 hinge/transmembrane/endodomain, and a CD3 zeta endodomain. The CD22 CAR contains the binding domain (m971), a CD8alpha hinge and transmembrane domain, a 41BB endodomain, and a CD3 zeta endodomain.
223499422|NCT05211986|DRUG|IMM01-STEM|IMM01-STEM is a secretome product derived from partially differentiated pluripotent stem cells that contains regenerative molecules.
223499423|NCT06198010|OTHER|Best Practice|Receive enhanced usual care
223499424|NCT06198010|OTHER|Educational Intervention|Receive ASCENT guide
223499425|NCT06198010|OTHER|Questionnaire Administration|Ancillary studies
223499426|NCT06198010|OTHER|Electronic Health Record Review|Ancillary studies
223499427|NCT06198010|PROCEDURE|Health Telemonitoring|Attend video or phone calls with a CHW and/or PCM
224189662|NCT04542304|DRUG|Metolazone|Participants receive a single dose of metolazone.
224189663|NCT04542304|DRUG|Placebo|Participants receive a single dose of placebo to match metolazone.
224189664|NCT06959017|GENETIC|Gene Expression Analysis|Each subject analysed for SERPİNH1 and ROCK1 gene exppression
224189665|NCT06077344|PROCEDURE|WALANT in Ankle Fractures (Wide-Awake Local) Anesthesia No Tourniquet) and Applied Under Spinal Anesthesia Comparison of Clinical Results of Surgical Treatment;ANT Procedure comparation|WALANT in Ankle Fractures (Wide-Awake Local) Anesthesia No Tourniquet) and Applied Under Spinal Anesthesia Comparison of Clinical Results of Surgical Treatment;ANT Procedure comparation
224189666|NCT06077344|PROCEDURE|Applied Under Spinal Anesthesia of Clinical Results of Surgical Treatment|Applied Under Spinal Anesthesia of Clinical Results of Surgical Treatment
224189667|NCT04881799|DRUG|Phentermine/Topiramate (Qsymia)|Maximum dose of 15 mg/92 mg orally once daily in the morning. The dose will be titrated to this level (described earlier).
224189668|NCT04881799|DRUG|Placebo|Daily injection
224189669|NCT02471898|DRUG|HTX-011|
224189670|NCT02471898|DRUG|Placebo|Saline
223499428|NCT06198010|BEHAVIORAL|Cancer Pain Management|Receive personalized pain management plan
223499429|NCT05494632|DEVICE|Treatment-modifications to CI speech processor program. Specifically reducing interaural frequency mismatch in experienced SSD-CI recipients.|We will modify the CI speech processor program to reduce interaural frequency mismatch between the CI ear and the contralateral ear in experienced CI recipients with SSD.
223499430|NCT05494632|DEVICE|Treatment-modifications to CI speech processor program to reduced interaural frequency mismatch in newly implanted SSD-CI recipients.|We will modify the CI speech processor program to reduce interaural frequency mismatch between the CI ear and the contralateral ear in newly implanted CI recipients with SSD.
223499431|NCT05494632|DEVICE|Treatment-modifications to CI speech processor program to reduced interaural loudness mismatch in experienced SSD-CI recipients.|We will modify the CI speech processor program to reduce interaural loudness mismatch between the CI ear and the contralateral ear in experienced CI recipients with SSD.
223499432|NCT02099734|BEHAVIORAL|Questionnaires|
223499433|NCT02099734|OTHER|sample of blood or saliva|A sample of blood or saliva will be obtained for DNA extraction. Approximately 2-4 tubes of blood will be collected or one tablespoon of saliva. If a participant has already provided a DNA sample for another MSKCC IRB approved protocol, they may not need to provide an additional sample.
223499434|NCT05167721|BIOLOGICAL|Autologous Mesenchymal Stem Cells|Autologous Mesenchymal Stem Cells administered intrathecally
223499435|NCT05167721|OTHER|Placebo|Placebo administered intrathecally
223591117|NCT00117793|DEVICE|Total Surface Bearing Suction Socket|Current clinical practice
224189671|NCT04934228|DRUG|Hydrochlorothiazide 12.5Mg Tab|"Will receive 4 week supply (35 days) of Hydrochlorothiazide Pills (12.5 mg twice a day)~Planned use in this study~1. Condition/disease indication(s): Hypertension~2. Subject population: Hypertension~3. Dose(s): 25 mg/day~4. Administration: Oral~5. Dosing regimen: 12.5 mg twice per day"
224189672|NCT04934228|DRUG|Clonidine Pill|"Will receive 4 week supply (35 days) of Clonidine Pills (0.1 mg twice/day)~Planned use in this study~1. Condition/disease indication(s): Vascular function and blood flow~2. Subject population: Hypertension~3. Dose(s): 0.1 mg (oral)~4. Administration: Oral~5. Dosing regimen: 0.1 mg twice daily by mouth"
224189673|NCT04934228|DRUG|Placebo|Will receive a 4 week supply (35 days) of Placebo Pills; has no active ingredients but is made to look like the study drug.
224189674|NCT06015789|OTHER|Questionnaire|Administration of questionnaires for the evaluation of self-care
224189675|NCT05888740|DEVICE|VibratoSleeve Therapeutic Ultrasound Device|The VibratoSleeve is compromised of a 16-transducer array that is mounted within a wrap that conforms to the posterior calf
224189676|NCT04963231|DRUG|Setmelanotide|SC injection
224189677|NCT04963231|DRUG|Placebo|SC injection
224189678|NCT02928900|BEHAVIORAL|Clinician training intervention|This intervention is a clinician training using SP actors to improve communication and empathy skills of HIV care providers who serve HIV-positive adolescents and youth in Kenya.
224189679|NCT05755958|DEVICE|HIFU treatment in rectal Endometriosis|HIFU treatment of rectal endometriosis
223499436|NCT00871013|DRUG|Melphalan|"Given by vein, Day 3~First Inter-Therapy Treatment Bortezomib (Velcade) By vein Days 1 and 4~Second Inter-Therapy Treatment Bortezomib (Velcade) By vein Days 1 and 4~Second Transplant Bortezomib (Velcade) By vein Day -5 and Day -2~Year 1 Maintenance Velcade (bortezomib) By vein Days 1, 8, 15, 22(weekly) Every 28 days~Years 2 \& 3 Maintenance Velcade (bortezomib) By vein Days 1, 8, 15, 22(weekly) Every 56 days"
223499437|NCT00871013|DRUG|Velcade|Given by vein, Days 1, 5, 8, 11
223499438|NCT00871013|DRUG|Thalidomide|Given by mouth at bedtime, Days 5-8
223591118|NCT00117793|DEVICE|Vacuum assisted socket system|Novel socket system
223591119|NCT00000652|DRUG|Zidovudine|
223591120|NCT00000652|DRUG|Didanosine|
223591121|NCT02365571|DRUG|LY3154207|Administered orally
223591122|NCT02365571|DRUG|Placebo|Administered orally
223591123|NCT02365571|DRUG|Itraconazole|Administered orally (twice daily on Day 3 and then once daily to Day 12) as a 10 mg/mL solution
223591124|NCT06754098|DRUG|Doxecitine and Doxribtimine|A combination of doxecitine and doxribtimine is administered orally in 3 equal doses given approximately 6 to 8 hours apart .Dose will be increased if the tolerability profile is good.
223591125|NCT02488642|DRUG|Isosorbide Dinitrate|
223591126|NCT02488642|DRUG|Misoprostol|
223591127|NCT02488642|DRUG|Oxytocin|Oxytocin was infused in a balanced electrolyte solution beginning with an infusion rate of 2 milli-International Units per minute (mIU/min) and doubling the dose every 15 minutes.
223591128|NCT06102772|DRUG|Adebrelimab，Fruquintinib|Adebrelimab，Fruquintinib combined with chemotherapy
223746151|NCT02294344|OTHER|DFPP&CTX|"First,patients received methylprednisolone pulse therapy followed by oral prednisone and intravenous cyclophosphamide (IV-CTX) pulse therapy.~Then double volume of plasma was processed during each DFPP session every two day. A fraction plasma separator(Asahi Kasei Medical, surface area 2.0 m2,pore size 0.03 mm)and another fraction plasma separator (Asahi Kasei Medical, surface area 2.0 m2, pore size 0.01 mm)were used as first and second filter for plasma fractionation, respectively. 1.5 volume of plasma was processed, and 35\~45g human albumin and blood plasma was supplemented during each session. The patients were treated with DFPP every two days for at least 3 times. After DFPP, 300-500ml blood plasma was supplemented."
223591129|NCT05458453|DRUG|Esketamine|Self-controlled intravenous analgesia pump was used for continuous injection, and it was prepared according to sufentanil 1.5ug/ml+ esketamine 0.75ug/ml+16mg ondansetron. After the operation, the analgesic pump was connected, and sufentanil 0.1ug/kg/h+ esketamine 0.05mg/kg/h was pumped continuously for 24 hours. The continuous infusion of analgesia pump is (kg body weight/15) ml/h. (e.g. 60kg, pump speed 4ml/h, total amount 96ml).
223591130|NCT02643589|DRUG|ATG|ATG will be intravenously infused via a central venous catheter in 3 or 4 days, from day -4 or -3 until day 0. The other conditioning drugs administered before transplantation include cytosine arabinoside (Ara-C), busulfan (Bu),cyclophosphamide (Cy), Semustine(Me-CCNU), and ATG. All transplant recipients will receive cyclosporine A (CsA), mycophenolate mofetil(MMF), and short-term methotrexate for aGVHD prevention.
223746152|NCT02294344|DRUG|CTX|"First,patients received methylprednisolone pulse therapy followed by oral prednisone and intravenous cyclophosphamide (IV-CTX) pulse therapy.~After three months therapy, if the renal function was not recover, the patient would be withdrawn from the study. The other patients after CTX pulse therapy for 6 months and achieve remission to receive oral maintenance therapy with azathioprine (AZA).~The dosage of AZA was 1.0-2.0mg/kg/d(more than 50mg/d) and adjusted by white cell count and liver enzyme. If white cell count \<3×109/L or an increase in liver enzyme to more than twice the normal upper limit, the dosage of AZA should be reduced. If white cell count \<3×109/L or liver enzyme increased repeatedly, the patient would be withdrawn from the study."
224189680|NCT05755958|DEVICE|SHAM HIFU procedure|SHAM HIFU procedure
224189681|NCT06509425|PROCEDURE|salpingectomy during caesarean section|Salpingectomy will be done by clamping, division and ligation using adsorbable suture material (2-0 Vicryl) and excising the tube till it's isthmic part by scissors.
224189682|NCT06509425|PROCEDURE|tubal ligation during caesarean section|Tubal ligation will be done by Parkland technique. An opening is made in an avascular section of the mesosalpinx by electrocautery. Two absorbable suture ties (2-0 Vicryl) are passed through the opening and used to ligate the proximal and distal ends of the segment (at least 2 cm) which will get excised by scissors.
224189683|NCT04936776|BEHAVIORAL|Text messaging|Text parents of children (age 0-2yrs) who are due and due soon for a vaccine across the entire NYU-Brooklyn FHC network to increase vaccination rates.
224189684|NCT01982942|DRUG|ibudilast|Subjects randomly assigned to the ibudilast (MN-166) cohort will receive up to 100 mg/day for 96 weeks.
224189685|NCT01982942|DRUG|Placebo oral capsule|Subjects randomly assigned to the placebo cohort will receive placebo oral capsule for 96 weeks.
223499439|NCT00871013|DRUG|Dexamethasone|Given by mouth, once per day Days 5-8
223499440|NCT00871013|DRUG|Cisplatin|Given by vein, Days 5-8 continuous infusion
223591131|NCT04268173|OTHER|Community-Based, Client-Centered Prevention Home|Prevention Navigators at Vivent Helath offices will engage participants in risk assessments, goal planning, and treatment referrals based on their needs and desires.
223591132|NCT03855852|PROCEDURE|Xenograft and Collagen membrane|Placing the implant with collagen membrane and xenograft at esthetic zone of maxillary ridge with 2-4 mm thread exposure .
223591133|NCT03855852|PROCEDURE|Xenograft and APRF|Placing the implant with APRF and xenograft at esthetic zone of maxillary ridge with 2-4 mm thread exposure .
223591134|NCT00442325|DRUG|Atorvastatin (Lipitor)|
223591135|NCT03158350|OTHER|Instructed Brushing Method|Stationary Bristle Technique
223499441|NCT00871013|DRUG|Adriamycin|Given by vein, days 5-8 continuous infusion
223499442|NCT00871013|DRUG|Cyclophosphamide|Given by vein days 5-8 continuous infusion
223499443|NCT00871013|DRUG|Etoposide|Given by vein days 5-8 continuous infusion
224189686|NCT01347359|BEHAVIORAL|One-on-one peer support|The peer support intervention will take the form of a one-on-one peer mentoring program, using a mutually agreed upon method of communication between each pair of peer mentor and EIA participant (either by telephone or face-to-face meeting at a neutral public location). The research team will pair trained peer mentors and individuals with EIA as closely as possible based on such characteristics as sex, age, working status, and specific disease/type of IA. Peer mentors will be responsible to initiate and maintain contact with individuals with EIA. Individuals with EIA and peer mentors will be asked to have contact once a week for 30 minutes during the 12-week study period. Meetings/ interactions will not be prescribed; rather they will be defined by the individual with EIA. Peer mentors will provide support based on the needs of the individual they are mentoring. As such the nature of each interaction is likely to vary among pairs and from one interaction to the next.
224189687|NCT01347359|BEHAVIORAL|Standard of care|"Standard of care is at the discretion of the treating rheumatologist. In addition to information and patient education about the underlying disease process provided at the time of diagnosis, it may include referral to allied health professionals (e.g., physiotherapist, occupational therapist, podiatrist, social worker). This may be via referral to The Arthritis Society or directly to individual practitioners. In addition, it may include referral to voluntary support programs in the community (e.g., Arthritis Self-Management Program)."
224189688|NCT04576702|BIOLOGICAL|Investigational aIIV4c|Investigational MF59 Adjuvanted Cell-derived Quadrivalent Influenza vaccine, containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO (World Health Organization) for quadrivalent vaccines for the respective season.
224189689|NCT04576702|BIOLOGICAL|IIV4c|Licensed, Non-adjuvanted, Cell-derived Quadrivalent Influenza Vaccine containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO for quadrivalent vaccines for the respective season.
224189690|NCT04576702|BIOLOGICAL|aIIV4|Licensed, MF59-Adjuvanted, egg-derived Quadrivalent Influenza Vaccine containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO for quadrivalent vaccines for the respective season.
224189691|NCT04576702|BIOLOGICAL|RIV4|Licensed, Recombinant Quadrivalent Influenza Vaccine containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO for quadrivalent vaccines for the respective season.
224189692|NCT01390376|DRUG|DAAOI-1|DAAOI-1 1g
224189693|NCT01390376|DRUG|DAAOI-1|DAAOI-1 2g
224189694|NCT01390376|DRUG|placebo|starch pill
224189695|NCT00926146|BEHAVIORAL|NCMIT|Nurse Case Management Plus Contingency Management and Tracking (NCCMT) Program includes 20 minute case management, delivered by the NCCMT nurse and a separate 45 minute culturally competent specialized education, delivered by the two assigned nurses and research assistants weekly over 8 weeks. Participants of this group will also receive the HBV vaccine subsequently at one month and four months after baseline and incentives for three-weekly urine samples.
223499444|NCT05752487|DEVICE|Pulsed Field (PF) /Radiofrequency (RF) Catheter ablation|Participants will undergo catheter ablation with the PF /RF ablation system consisting of the TRUPULSE Generator (delivers RF or PF energy through the study catheter) and the THERMOCOOL SMARTTOUCH SF (STSF) Catheter (indicated for use in catheter-based cardiac electrophysiological mapping (stimulating and recording) and, when used with a Generator, for cardiac ablation).
223499445|NCT02457091|BEHAVIORAL|Resistance exercise|strength training consists of 1-3 sets , 10-15 repetitions of 10 exercises targeting lower body, upper body and core muscle groups
223499446|NCT02457091|BEHAVIORAL|Stretching exercise|The stretching condition will consist of 1-3 sets, 30-40 seconds of 12 stretching movements targeting lower body, upper body, and core areas performed 2 days per week.
223591136|NCT02128945|OTHER|[18F] - Fludarabine PET/CT|\[18F\] - Fludarabine PET/CT before treatment
223591137|NCT03218579|DIETARY_SUPPLEMENT|Probiotic treatment|4 weeks of probiotic treatment after 7 days of antibiotics (Metronidazole+Ciprofloxacin)
223591138|NCT03218579|BIOLOGICAL|Bacteriotherapy|Bacteriotherapy (autologous fecal microbiota transplantation) after 7 days of antibiotics (Metronidazole+Ciprofloxacin)
223591139|NCT00545103|DRUG|SPD476, MMX™ mesalazine, 1.2g extended release tablet|SPD476 1.2g administered Once Daily (QD)
223591140|NCT00545103|DRUG|SPD476, MMX™ mesalazine, 2.4g extended release tablet|SPD476 2.4g administered Once Daily (QD)
223591141|NCT00545103|DRUG|SPD476, MMX™ mesalazine, 4.8g extended release tablet|SPD476 4.8g administered Once Daily (QD)
223591142|NCT00545103|DRUG|Placebo|Placebo administered Once Daily (QD)
223591143|NCT03041363|DRUG|Triheptanoin|Triheptanoin will be administered for 7 days 4 times daily.
223591144|NCT02170766|DRUG|BIBR 1048 low1|
223499447|NCT02748772|DRUG|Two Anti-angiogenesis Drugs（Endostar and Thalidomide）|Endostar:30 mg/d, CIV (continous intravenous pumping) on day 7 of each 21 day cycle，5 days before the chemotherapy is the first day; Thalidomide:100-200mg/d,PO (peros) on day 14 of each 21 day cycle Number of Cycles: 6 cycle or progression or unacceptable toxicity develops.
223499448|NCT02748772|DRUG|Pure chemotherapy（Xelox）|"CapeOX (also called XELOX) is a chemotherapy regimen consisting of capecitabine (trade name Xeloda) combined with oxaliplatin.~Oxaliplatin 130mg/m2 IV over 2 hours,day1 Capecitabine 850-1000mg/m2 twice daily PO for 14 days Repeat every 3 weeks Number of Cycles: 6 cycle or progression or unacceptable toxicity develops."
223499449|NCT03356093|OTHER|complete questionnaire|Patients were asked to complete a questionnaire at baseline, and week 1, 2, 3, 4, 5 and 6 after starting of radiotherapy.
223499450|NCT03238131|DRUG|Ivermectin|Participants are either given Ivermectin alone or Ivermectin in combination with Albendazole
223499451|NCT03238131|DRUG|Albendazole|Albendazole will be given to participants in Arm 2 and 3 in combination with Ivermectin at varying time points.
223499452|NCT04976725|OTHER|Osteopathic Manipulative Therapy|"75 individuals will be included in our study, including 3 groups: control group (N= 25), osteopathic manipulative technique (n= 25), myofascial relaxation group (n=25). Which group of individuals will be determined by randomizing them with closed envelope method.~Osteopathic Manipulative Therapy and myofascial relaxation treatment applications will be applied 2 days a week, for periods of 30 min for 4 weeks."
223591145|NCT02170766|DRUG|BIBR 1048 low2|
223591146|NCT02170766|DRUG|BIBR 1048 medium|
223591147|NCT02170766|DRUG|BIBR 1048 high|
223591148|NCT02170766|DRUG|Pantoprazole|
223591149|NCT00427882|DRUG|ALFUZOSIN|
223591150|NCT02418104|DRUG|CHS-1701|
223499453|NCT01243281|DRUG|PEG-IFN and entecavir|The patients will be randomized in approximately 1:1 ratio into one of 2 treatment regimens; to receive PEG-IFN alpha-2b (1.5 microgram/kg/week) plus entecavir (0.5 mg/day) or PEG-IFN alpha-2b (1.5 microgram/kg/week) alone for 48 weeks by using pre-generated randomization schedule.
223499454|NCT03091439|DRUG|Dalbavancin|Participants received Dalbavancin 1500 mg, intravenous (IV) administration over 30 minutes on Day 1 and on Day 8.
223499455|NCT03091439|DRUG|Standard of Care|Participants received an antibiotic consistent with standard of care (SOC) for osteomyelitis based on Investigator judgment. The duration of treatment was 4-6 weeks.
223499456|NCT03922685|COMBINATION_PRODUCT|Dietary manipulation (25% carbohydrate diet) and behavioral (exercise)|The 25% carbohydrate diet consisted of Pulmocare-vanilla liquid, white roll, butter, and string cheese in proportions to achieve 33% of weigh-maintenance diet containing 25% carbohydrate, 20% protein, and 55% fat. Exercise was walking 1 hour on level treadmill at 50% of maximal effort starting 40 minutes after the beginning of the meal
223499457|NCT03922685|COMBINATION_PRODUCT|Dietary manipulation (25% carbohydrate diet) and behavioral (sedentary)|The 25% carbohydrate diet consisted of Pulmocare-vanilla liquid, white roll, butter, and string cheese in proportions to achieve 33% of weigh-maintenance diet containing 25% carbohydrate, 20% protein, and 55% fat. There was no exercise during this trial.
223499458|NCT01922583|DRUG|AUY922|AUY922 will be administered via IV over 1 hour once weekly in a 21 day cycle until disease progression
223499459|NCT02198352|DRUG|BIBN 4096 BS - in single rising doses|
223499460|NCT02198352|DRUG|Placebo|
223499461|NCT02698293|DRUG|Gliolan|orally, 40 mg/kg 4-6 hours prior to light application
223499462|NCT02698293|DRUG|Vitamin D3 cholecalciferol)|Vitamin D3 (cholecalciferol) supplementation (10,000 IU daily) will be provided from 3 days prior through 14 weeks after light delivery for PDT.
223499463|NCT02698293|OTHER|Photodynamic Therpay|"Approximately 4-6 hours after photosensitizer administration, activating light will be applied.~The target mucosal lesion will be identified based on the initial clinical evaluation. Treatment light will be generated using a Modulight ML7710-630-6K diode laser, This laser produces up to 6W total power, with a peak wavelength of 630nm and 90% of laser power within 630-633 nm.~The light fluence (doses) will be 50 and 100 Joules per square centimeter."
223499464|NCT03808766|OTHER|embolization|Patient with a diagnosis of HCC and a treatment plan to receive partial hepatectomy will receive transarterial embolization under local anesthesia 2 weeks before the surgery. Angiographic examinations of the tumor before and after embolization of the tumor will be performed. Histological examination of the tumor in the surgical specimens will be performed.
223499465|NCT00822471|BEHAVIORAL|Diabetes Self-Management Education|"DSME intervention consisting of two interactive 2-1/2 hour classes taught by a diabetes educator focusing on the ABCs of diabetes and training in how to talk to your doctor."
223499466|NCT06328088|DIETARY_SUPPLEMENT|Non vegetarian|Non vegetarian diet plus supportive treatment including lactulose and/or rifaximin
223499467|NCT04075149|DRUG|Spironolactone|Spironolactone is an androgen-receptor commonly used (off-label) for hyperandrogenism in girls and women. It is used in this study to determine if androgen blockade can improve ovulation rates in girls with androgen excess, who often have low rates of ovulation in the years following menarche. The spironolactone dose will be as follows: If ≤ 60 kg, 50 mg twice daily; if \> 60 kg, 100 mg twice daily.
223499468|NCT03391895|OTHER|Home based exercise program|Program will include deep diaphragmatic breathing exercises, local expansion exercise on the collapsed areas in scoliosis concave sides with elastic exercise bands, dynamic lumber stabilization exercises for core stabilisation, strengthening of interscapular muscles with elastic bands and stretching exercises for lumbar extensor, hip flexor and hamstring muscles. Exercises will be applied 2 sets of 10 repetitions and once a day.
223499469|NCT03391895|OTHER|Inspiratory Muscle Training|Threshold IMT device will be used for the training. Training intensity will set at 30% of the maximum inspiratory pressure after assessment of respiratory muscle strength for each patient every week.
223591151|NCT02418104|DRUG|Pegfilgrastim (Neulasta)|
223591152|NCT03841370|PROCEDURE|endodontic treatment|Color measurements of endodontically treated teeth (incisors, canines or premolar) will be collected regardless of technique, treatment time and sealer used.
223591153|NCT04755452|PROCEDURE|Low intra-abdominal pressure|7 mm Hg pneumoperitoneum during robot-assisted laparoscopic surgery
223591154|NCT04755452|PROCEDURE|High (standard) intra-abdominal pressure|12 mm Hg pneumoperitoneum during robot-assisted laparoscopic surgery
223591155|NCT04545710|DRUG|Abemaciclib|Abemaciclib 150mg BID
223591156|NCT04545710|DRUG|Osimertinib|Osimertinib 80mg daily
223746153|NCT02404285|DRUG|Next Science Acne Gel|Subjects will be instructed to apply a thin layer of the product to the entire face every evening after washing with Cetaphil cleanser and gently patting the skin dry. Product should not be applied around the eyes or near the mucous membranes. No other acne treatments will be applied to the face during study participation. Hands should be washed following application of study gel.
223499470|NCT01860989|DRUG|KAE609|KAE609 75mg single dose
223499471|NCT01860989|DRUG|KAE609|KAE609 150mg single dose
223499472|NCT01860989|DRUG|KAE609|KAE609 225mg single dose
223499473|NCT01860989|DRUG|KAE609|KAE609 300mg single dose
223499474|NCT00941343|DRUG|Alfuzosin (XATRAL® - SL770499)|One tablet of XATRAL® 10mg OD once a day at the end of an evening meal. The tablets had to be swallowed whole without being chewed or crushed
223499475|NCT02425085|PROCEDURE|multi-endodiathermy retinectomy|patients will receive multi-endodiathermy retinectomy; 6 months later, patients will receive the removal of intraocular silicone oil.
223499476|NCT02425085|PROCEDURE|relaxing retinectomy|patients will receive relaxing retinectomy; 6 months later, patients will receive the removal of intraocular silicone oil.
223499477|NCT04023708|DRUG|CYD-TDV Dengue Vaccine|Pharmaceutical form:Solution Route of administration: Intramuscular
223591157|NCT03885050|OTHER|Ross score|modified score used for evaluation of heart failure in children, as a diagnostic tool for severity of heart failure
223591158|NCT04891107|DEVICE|Walking Program with a Music-based, Rhythm-modulating Wearable Sensor System|Participants will walk using the music-based, rhythm-modulating wearable sensor system (foot sensors, mobile device with mobile app and headphones) for thirty (30) minutes at a time, 5 times a week for 4 weeks.
224189696|NCT00926146|BEHAVIORAL|SCMIT|Standard with Contingency Management and Tracking (SCMT) Program. Participants in the SCMT group will interact three times a week over the four-month intervention period with the research nurse and research assistant and will be offered: 1) a brief HBV/HCV education program; 2) receipt of the vaccine subsequently at one month and four months after baseline; and 3) voucher incentives for three-weekly urine samples. The SCMT participants will not receive the specialized education sessions nor the case management delivered weekly over the first 8 weeks sessions.
224189697|NCT04515602|PROCEDURE|Primary debulking surgery|Primary debulking surgery with a maximum cytoreduction, then followed by 6 cycles of Paclitaxel 175mg/m2 or Docetaxel 60-75 mg/m2 plus Carboplatin AUC (area under the curve) 5.
224189698|NCT04515602|PROCEDURE|Neoadjuvant chemotherapy|3 cycles of Paclitaxel 175mg/m2 or Docetaxel 60-75 mg/m2 plus Carboplatin AUC (area under the curve) 5, Interval debulking surgery with a maximal cytoreduction of complete gross resection, then followed by another 3 cycles of chemotherapy.
224189699|NCT04515602|DRUG|PARPi|For patients with gBRCA/sBRCA mutation and CR/PR after first-line chemotherapy, maintenance therapy of PARP inhibitors.
224189700|NCT00722618|BEHAVIORAL|Written materials, telephone based education|4 new written materials, 15-20 minute educational session by telephone
224189701|NCT00722618|OTHER|Written materials|2 written materials available on public website
224189702|NCT03844282|DIAGNOSTIC_TEST|Clinical assessment (SCAT5)|The SCAT5 is a standardized tool for evaluating sports-related concussions designed for use by physicians and licensed healthcare professionals in patients aged 13 years and above. It is a ten minute paper-based assessment which includes immediate and office/off-field assessments. SCAT5 incorporates the Maddocks' questions, Glasgow Coma Scale (GCS), cervical spine assessment and symptom evaluation, in addition to cognitive and neurological screening.
224189703|NCT03844282|DIAGNOSTIC_TEST|ImPACT|ImPACT (Immediate Post-Concussion Assessment and Cognitive Testing) is a neurocognitive assessment administered online or using desktop software in a controlled environment. ImPACT has two components: baseline testing and post-injury testing, both of which are used to determine if a patient can safely return to sporting activity post-concussion.
224189704|NCT03844282|BEHAVIORAL|CANTAB|"Originally developed at the University of Cambridge, the Cambridge Neuropsychological Test Automated Battery (CANTAB) platform includes highly sensitive, precise and objective measures of cognitive function, correlated to neural networks. These tests have demonstrated sensitivity to detecting changes in neuropsychological performance and include tests of working memory, learning and executive function; visual, verbal and episodic memory; attention, information processing and reaction time; social and emotion recognition, decision making and response control.~The CANTAB touchscreen battery (www.camcog.com) will be utilised to perform neuropsychological assessments within RESCUE-RACER, whose study-specific protocol may include assessments of: Spatial Working Memory (working memory and strategy), Reaction Time (processing and psychomotor speed), Paired Associated Learning and the Multi-Tasking Test."
224189705|NCT03844282|DIAGNOSTIC_TEST|I-PAS/Dx100|I-PAS™ (now re-named Dx 100) is a portable, head-mounted, neural functional assessment tool. With its integrated clinical eye tracking and digital display, the FDA has cleared (K171884) fourteen tests and an unmatched list of variables for clinical use for a variety of conditions. This utility of this device will be investigated for motorsport-related concussion.
224189706|NCT03844282|BIOLOGICAL|Saliva sample|Micro RNA's (miRNA's) are easily measured in saliva and have proven to have both diagnostic and prognostic use in sports-related concussion across the adolescent and adult populations, with levels persisting for some weeks after the concussive event. RESCUE-RACER will collect saliva samples for analysis of biomarkers of concussion, which may include miRNA and other markers of injury.
223591159|NCT06429189|BEHAVIORAL|Home-based combined exercise program with self-selected intensity|Before the beginning of the exercise program, participants will receive an education session on how to use Borg's Perceived Rate of Exertion Scale (RPE) to monitor their effort during aerobic and resistance training and tips on when they may increase the exercise intensity. During the training sessions, participants in the intervention group will be asked to choose their preferred load to execute each exercise in the resistance component, told to perform the aerobic exercises at their preferred speed, and informed that they can stop exercising whenever they need to rest. The exercise professional may suggest increasing loads in specific exercises, but these increases will not be imposed on the participants. Attendance to the sessions in the intervention and control groups will be registered. Additionally, women in this group will be encouraged to perform brisk walking at their preferred intensity and receive a pedometer to increase walking motivation.
224189707|NCT03844282|OTHER|fMRI|RESCUE-RACER participants will be invited to complete a functional MRI scan, whose 90-minute protocol may include: multi-parametric mapping (MPM), susceptibility weighted imaging (SWI), diffusion weighted imaging (DWI), proton spectroscopy and functional MRI (fMRI) with blood oxygenation-level dependent contrast (BOLD), completed at 7T (Tesla), or 3T if this is not possible.
224189708|NCT01100931|DRUG|YM155|"Phase I: Doses were given at different dose levels until the maximum tolerated dose (MTD) was reached. Dose level 1: 3.6 mg/m\^2, dose level 2:5 mg/m\^2 , dose level 3:6 mg/m\^2, dose level 4:8 mg/m\^2, dose level 5:10 mg/m\^2 (MTD), dose level 6:12 mg/m\^2. Doses were given by continuous intravenous infusion over 72 hours every 21 days.Three patients were enrolled at each dose level in the absence of dose limiting toxicity (DLT). A DLT is defined as adverse events occurring during the first cycle of therapy (e.g. every 21 days).~Phase II: 10 mg/m\^2 (MTD)intravenous infusion over 72 hours every 21 days."
224189709|NCT01100931|DRUG|Carboplatin|Area under curve (AUC) of 6 intravenous on day 1
224189710|NCT01100931|DRUG|Paclitaxel|200 mg/m\^2 intravenous on day 1
223591160|NCT02819401|OTHER|pediatric formula|high-fiber enteral formula
223746154|NCT02404285|DRUG|Vehicle|Subjects will be instructed to apply a thin layer of the product to the entire face every evening after washing with Cetaphil cleanser and gently patting the skin dry. Product should not be applied around the eyes or near the mucous membranes. No other acne treatments will be applied to the face during study participation. Hands should be washed following application of study gel.
223746155|NCT00263068|DRUG|Rotigotine|"Transdermal Patch 1 per day for 24 hours containing:~1.125mg/day 2.25mg/day 4.5mg/day 6.75mg/day"
224189711|NCT05609838|OTHER|Hot water foot bath|A 15 minutes hot water foot bath was applied to the experimental group patients 3 hours after the cesarean section.
224189712|NCT06347458|BIOLOGICAL|BG1805|A single infusion of BG1805 Injection administered intravenously.
224189713|NCT03776435|RADIATION|Abdomen CT|Patients are divided into CT-exposed or unexposed group according to the presence of claims codes of abdominopelvic CT conducted within seven days before and after appendectomy. The seven-day threshold is arbitrarily determined considering the delay in the diagnosis of appendicitis and the postoperative examination for surgical complication.
224309450|NCT06359639|BEHAVIORAL|Cognitive restructuring|Five 50-60-minute videoconferencing sessions of cognitive restructuring based on Mind Over Mood: Second Edition (MOM2) (Greenberger \& Padesky, 2016) and The Clinician's Guide to CBT Using MOM2 (Padesky \& Greenberger, 2019) as guides. The sessions will consist of understanding the cognitive model, filling in Thought Records, and complementary coping strategies of looking for evidence, action planning, and acceptance.
224309451|NCT06359639|BEHAVIORAL|Supportive counselling|Five 50-60-minute videoconferencing sessions of supportive counselling consisting of psychoeducation on breakup effects, validation of breakup experiences and emotions, introduction to deep breathing and progressive muscle relaxation, and identification of existing coping strategies.
224309452|NCT04131738|DRUG|Baricitinib|Baricitinib may be taken without regard to food. It should be taken at the same time every day.
224309453|NCT00551018|DRUG|Vicriviroc|one 30 mg tablet QD
223499478|NCT01512888|GENETIC|CL20-i4-EF1α-hγc-OPT|Participants will undergo infusion with autologous CD34+ bone marrow cells transduced with a lentiviral vector that contains a normal copy of the human γc gene.
223499479|NCT01512888|DRUG|Busulfan|Given intravenously (IV).
223591161|NCT06033872|COMBINATION_PRODUCT|Focused education, medication adjustment and telemonitoring|"1. Focused diabetes education session for Ramadan fasting~   Participants will be taught to record~  1. Meal plans~  2. Physical activities~  3. Blood glucose monitoring, and~  4. Monitoring for diabetes complications. Then perform a trial fasting day prior to Ramadan when control is not optimal or medication with risk of hypoglycemia.~2. Medication adjustment for Ramadan fasting Participants will be provided regimen modified for Ramadan fasting.~3. Telemonitoring~Participants will be taught to perform blood glucose monitoring 4 times daily using a glucometer and upload recordings of glucose levels onto the data software."
223591162|NCT06303895|BEHAVIORAL|Routine rehabilitation training|"Balance function training: Patients were instructed to achieve weight shift between the left and right sides of the balance bar in a standing position.~Walking function training: based on hip, knee, and ankle control training, patients were instructed to take steps training.~Core muscle strength training: Patients were instructed to maintain 3 minutes of training in Bridge-style movement.~Functional training of daily living: including training on dressing and undressing, independent eating, painting, and writing.~Routine rehabilitation training was performed 30-45 minutes/time, 1-2 times/day, 5-7 days/week."
223591163|NCT06303895|BEHAVIORAL|Swallowing rehabilitation training|"Swallowing-related organ training involves various exercises targeting the lip, mandibular muscle, cheek, tongue muscle, soft palate, as well as exercises for vocal cord closure, laryngeal lifting, and pharyngeal muscle training. These exercises are performed for 5-15 minutes each session, 1-2 times per day, and 5-7 days per week.~Sensory stimulation training is conducted using a self-made popsicle, where medical staff gently stimulate the patient's cheek, soft palate, posterior pharyngeal wall, tongue surface, and sublingual area repeatedly. Each session lasts 5-25 minutes, performed 1-3 times per day, and 3-7 days per week.~Once the patient's swallowing function improves to a certain extent, allowing for safe oral intake, direct training or oral feeding training can be gradually introduced."
223591164|NCT06303895|PROCEDURE|Acupuncture therapy|"The whole acupuncture therapy was performed once daily for 5 days per week, including acupuncture needle and tongue needle.~Acupuncture needle:~Main acupoints: Lianquan, Shanglianquan (depression between the hyoid bone and the lower border of the mandible), Yifeng; Auxiliary acupoints: Fengchi, Wangu, Fengfu, Yamen, Neidaying (depression of 1 inch below the anterior margin of the mandible).~Tongue needle (pricking):~Acupoints: Jinjin, Yuye, posterior pharyngeal wall (both sides of the uvula)."
223591165|NCT01571453|DRUG|Vortioxetine (Lu AA21004)|10 mg/day
223591166|NCT01571453|DRUG|Venlafaxine extended release|150 mg/day
224189714|NCT01090648|DRUG|etravirine|One etravirine (ETR) 200 mg uncoated oral tablet and one etravirine (ETR) 200 mg film-coated tablet
224189715|NCT00006292|DRUG|Infliximab|
224189716|NCT01527331|BEHAVIORAL|video decision aid|cpr video decision aid
224189717|NCT02319265|DRUG|Melatonin|Oral liquid
224189718|NCT06056076|OTHER|Mini Squats Training|Mini Squats at a rate of ten squats at minimum range around 10-15 degrees at start along with Interferential Therapy for 10 minutes.
224189719|NCT06056076|OTHER|Endurance Training|Endurance training by the use of medium resistance therapeutic band at start along with Interferential Therapy for 10 minutes.
224189720|NCT02929017|OTHER|SUPPORT|Members of this group will receive personal, enhanced printed materials, as well as face-to-face support, and digital information provided by the interventionist.
224189721|NCT02929017|OTHER|Currently Available Printed Material|Subjects will receive their usual standard of care, including currently available printed patient material.
224189722|NCT04985916|BIOLOGICAL|Vehicle|topical liniment without investigational product
224309454|NCT00551018|DRUG|emtricitabine and tenofovir disoproxil fumarate|one 200/300 combination tablet QD
224309455|NCT06277232|OTHER|Nutrition care|Nutrition care is designed to include nutrition assessment (e.g., malnutrition screening, monitoring weight changes, etc.), optimization of individual dietary patterns, and evaluation. Through the Diet4painrelief platform, a dietician will follow up the progress of each participant in different timepoints and also plan meetings with other professionals in IPRP. A dietitian together with a physician in rehabilitation are responsible for the administration of the procedure.
223499480|NCT01512888|DEVICE|CliniMacs|Isolation and purification of CD34+ stem cells will be done after the unmodified frozen backup is obtained and in accordance with our FDA IND and in accordance with the CliniMacs manual of operations.
223499481|NCT04812158|OTHER|standard ankle physiotherapy or rehabilitation for chronic ankle instability|6 weeks of combined interventions of video aided mindful deep breathing and standard ankle physiotherapy in rehabilitating the chronic ankle instability for participants with chronic ankle instability
223499482|NCT02943213|DRUG|Chlorpromazine Hydrochloride|Chlorpromazine Hydrochloride (25 mg Tablet) - Generic US Applicant holder is USL Pharma Inc.
223499483|NCT03028441|OTHER|Placebo|Placebo
223499484|NCT03028441|BIOLOGICAL|VRC-CHKVLP059-00-VP|Measles-vectored Chikungunya vaccine
223499485|NCT01762787|DRUG|Cantharidin solution|5 microlitres of 0.025 to 0.5% topically on Day 1, 2 and 3
223499486|NCT01762787|DRUG|Aspirin|300mg three times daily orally over a course of 4 days (starting Day -3) Part 2 only
223499487|NCT01762787|DRUG|Prednisolone|30mg orally once a day over a course of 4 days (starting Day -3) Part 2 only
223499488|NCT01762787|DRUG|Placebo to aspirin|0mg three times daily orally over a course of 4 days (starting Day -3) Part 2 only
223499489|NCT01762787|DRUG|Placebo to prednisolone|0mg orally once a day over a course of 4 days (starting Day -3) Part 2 only
223499490|NCT00080262|DRUG|Ixabepilone|Solution, IV, 40 mg/m2, every 21 days, extended, until PD or discontinued for other reasons.
223499491|NCT00003723|DRUG|gemcitabine hydrochloride|Gemcitabine 1000 mg/m\^2 days 1, 8 15 (q 28 days)
223499492|NCT01481493|BIOLOGICAL|BT061|subcutaneous administration of the monoclonal antibody BT061
223499493|NCT01481493|BIOLOGICAL|Placebo|subcutaneous injection of placebo
223499494|NCT01529996|PROCEDURE|Pulse Dye Laser/YAG laser|This study involves treatments with two types of lasers, Pulsed dye lasers (PDL) and the 1064 nm Nd: YAG. Both lasers are FDA approved to treat vascularities in the skin.
223746156|NCT02474108|PROCEDURE|surgical prevention of atrial fibrillation|Prophylactic surgical ablation is performed to prevent AF in patients during mitral valve surgery. Ablation is performed by radiofrequency electrode or cryoprobe. Pulmonary veins, posterior wall of the left atrium will be isolated by the scheme box-lesion with additional lines to the mitral valve and appendage of left atrium.
223746157|NCT02474108|DEVICE|cardiomonitor|in both groups cardiac rhythm will be controlled by a cardiomonitor
223499495|NCT04507321|DRUG|GSK3640254 Oral tablet|GSK3640254 will be available as white film-coated round tablets to be administered via oral route with meal in the morning with 240 milliliter (mL) of water at room temperature.
223499496|NCT04507321|DRUG|[14C]-GSK3640254 intravenous infusion|\[14C\]-GSK3640254 will be available as clear, colorless solution free from visible particulates to be administered via the IV route.
223499497|NCT04507321|DRUG|[14C]-GSK3640254 powder|\[14C\]-GSK3640254 will be available as white powder to be reconstituted into a suspension with 25 mL of vehicle before dosing so as to administer 85 mg dose with meal in the morning.
223499498|NCT03561207|DIAGNOSTIC_TEST|EV3D Assay|The EV3D assay uses freshly obtained tumor specimen to predict tissue drug response.
223499499|NCT01685437|BIOLOGICAL|AA4500|2 injections separated by approximately 24 hours to 72 hours, repeated after 42 days (± 5 days) for up to 4 treatment cycles
223499500|NCT03579537|OTHER|Intradyalisis without exercise programe|patients on hemodialysis are evaluated with all the variables at first (T1) and without intervening in the treatment for 3 months they are evaluated again (T2).
223499501|NCT03579537|OTHER|Intradyalisis with exercise programe|After 3 first month without intervention and also during the time of hemodialysis, the patients star the exercise programe, the first part of the session, an exercise was carried out for cardiovascular work (pedaling on ergometer) and muscle toning, with special attention to the muscular development of the lower limbs (exercises with elastic bands and / or weighted ankles). The session increased in duration and intensity as the physical action program progressed throughout the duration of the permitted period (3 months) and always attending to the individual needs of each subject. In addition, each of the participants will be given a series of recommendations of exercise practice to be carried out during non-hemodialysis days, in order to complement the work done during the sessions.3 month later the investigator evaluated all the variable again (T3)
223499502|NCT03965364|DEVICE|INCRAFT|Device: Endovascular abdominal aortic aneurysm repair Subjects with infrarenal abdominal aortic aneurysms who meet all inclusion criteria and none of the exclusion criteria will be treated with the INCRAFT Stent Graft System.
223499503|NCT01590875|DRUG|Adenosine arm|In the adenosine arm, 25 patients will be randomized to received 2 doses of adenosine 12 mg IV, 5 minutes apart after pulmonary vein isolation. During this time, will monitor for pulmonary vein reconnection, second dose of adenosine will be given only if no reconnection after initial dose. In the observation arm, 25 patients will be randomized to 10 minute period of observation for pulmonary vein reconnection after documentation of pulmonary vein isolation.
223499504|NCT03399084|DRUG|Ferric carboxymaltose|750 mg/15 mL
223499508|NCT00174668|DRUG|Insulin Glulisine|insulin glulisine 3 x daily (TID) subcutaneously 15 min before the start of a meal
223499509|NCT00174668|DRUG|Insulin Therapy|NPH (70%) plus regular insulin or insulin aspart (30%)
223499510|NCT00174668|DRUG|Insulin Glargine|1 x daily (OD) subcutaneously at any time (but every day at the same time) according to BG
223499511|NCT06121505|RADIATION|low-dose radiation therapy and stereotactic body radiation therapy|Patients will receive radiation therapy.
223499512|NCT06121505|DRUG|chemotherapy|Patients will receive sintilimab combined with standard platinum-based doublet chemotherapy for a total of 4 cycles. Patients subsequently received maintenance treatment with sintilimab, and continued treatment until disease progression (PD), intolerable toxicity, withdrawal of informed consent, initiation of other anti-tumor treatments, death, or other circumstances that should stop treatment as specified in the protocol. Whichever occurs first. The maximum treatment time with sintilimab is 24 months (or 35 cycles).
223499513|NCT06121505|DRUG|Sintilimab|Patients will receive sintilimab combined with standard platinum-based doublet chemotherapy for a total of 4 cycles. Patients subsequently received maintenance treatment with sintilimab, and continued treatment until disease progression (PD), intolerable toxicity, withdrawal of informed consent, initiation of other anti-tumor treatments, death, or other circumstances that should stop treatment as specified in the protocol. Whichever occurs first. The maximum treatment time with sintilimab is 24 months (or 35 cycles).
223499514|NCT02957643|DRUG|Iron|oral treatment
223499515|NCT01819662|OTHER|Enhanced standard management|Echocardiogram followed by letter to GP about results.
223499516|NCT01819662|OTHER|Optimised heart failure management|Echocardiogram followed by referral to comprehensive heart failure service for those with left ventricular dysfunction
223499517|NCT01819662|OTHER|Standard management|Usual care
223499518|NCT02482844|OTHER|pacemaker implantation|
223499519|NCT02482844|OTHER|holter implantation|
224189723|NCT04985916|BIOLOGICAL|botulinum toxin, Type A|ET-01 topical liniment
224189724|NCT03207516|DIETARY_SUPPLEMENT|Sourdough --> Brewer's Yeast|Impact of bakery products with sourdough or brewer's yeast on digestive function
224189725|NCT03207516|DIETARY_SUPPLEMENT|Brewer's Yeast --> Sourdough|Impact of bakery products with sourdough or brewer's yeast on digestive function
224189726|NCT03538496|DRUG|Bupivacaine Hcl 0.25% Inj|Single shot 20 ml 0.25 bupivacaine
223499520|NCT00323219|DRUG|Cefazolin and Moxifloxacin|See Detailed Description.
223499521|NCT01214720|DRUG|bevacizumab [Avastin]|Intervenous repeating dose
223499522|NCT05534672|OTHER|Rapamycin|Rapamycin in liquid administered orally
223499523|NCT05534672|OTHER|Placebo|Placebo in liquid administered orally
223499524|NCT02347787|BEHAVIORAL|IMPaCT|"The IMPaCT intervention has three stages:~1. Goal-setting: CHWs will help patients to deconstruct the chronic disease management goal they set with their PCP into patient-driven short-term goals and action plans.~2. Tailored Support: CHWs will conduct weekly follow-up for 6 months through either telephone or home visit in order to support the achievement of patients' short-term goals.~3. Connection with longitudinal support: IMPaCT CHWs will also facilitate a weekly patient support group."
223499525|NCT02347787|OTHER|Usual care|
223499526|NCT06524518|DRUG|Chemotherapy combined with immunization|MRD positive patients receive chemotherapy ± immune for 4 cycles before adaptive therapy
223499527|NCT02399020|BEHAVIORAL|Social Cognition and Interaction Training|manualized group treatment providing training in facial emotion recognition, understanding the role of emotion in social situations, training with videoed vignettes to avoid jumping to conclusions in order to avoid attributional biases, tolerating ambiguity and distinguishing facts from guesses, skill consolidation and generalization to everyday life situations.
223499528|NCT02416141|DRUG|fast release oro dispersible tramadol 50 mg|idem arm 1
223499529|NCT00709670|PROCEDURE|MSCT and stress echocardiography|tests MSCT and stress echocardiography
223499530|NCT01456117|DRUG|Pioglitazone|Pioglitazone once daily for up to 14 days.
223499531|NCT01456117|DRUG|Pioglitazone|Pioglitazone once daily for up to 14 days.
223499532|NCT01456117|DRUG|Pioglitazone|Pioglitazone once daily for up to 14 days.
223499533|NCT01456117|DRUG|Placebo|Pioglitazone matching placebo once daily for up to 14 days.
223499534|NCT01059851|DRUG|Suvorexant|single oral dose of 20 mg (administered as 2 x 10 mg tablets) of suvorexant administered with \~240 mL of water after an 8 hour fast
223499535|NCT04992533|PROCEDURE|Long-duration tourniquet|Tourniquet is used in arthroscopic exploration and high tibial osteotomy
223499536|NCT04992533|PROCEDURE|Short-duration tourniquet|Tourniquet is only used for arthroscopic exploration
223499537|NCT04245163|BEHAVIORAL|Educational program|The intervention program will include 3 phases. At phase 1 a presentation on Microsoft PowerPoint in order to increase the general knowledge about glaucoma. At phase 2 a video and a one on one teaching to develop skills of administering the eye drops in a correct and systematic way. At phase 3, a discussion in order to identify cues to action that can easily be adopted by the patient in his/her daily routine, (such as, how to remember to put in drops) will take place.
223499538|NCT04142827|DEVICE|High Flow Humidification|myAirvo2 gives at home for long therapy treatment
223499539|NCT06476249|OTHER|without|without
223499540|NCT04483037|DRUG|Bowklean|assigned intervention
223499541|NCT01886560|DRUG|Doxycycline|Tablets Doxycycline 50mg bid for 2 weeks,50mg qd for 10 weeks.
223746158|NCT00624052|DRUG|fixed-dose combination of telmisartan 40mg+amlodipine 10mg|
224189727|NCT04346017|DIAGNOSTIC_TEST|Cytokines dosage|Dosage of inflammatory cytokines and other markers of systemic inflammatory syndromes (TNFa, IFNg, IL1, IL7, IL10, IL12, IL17, sCD25, sCD163, sCD14, IL-6, IL6-R, complex IL6-IL6R, glycolsylated ferritin...).
223499542|NCT01886560|DRUG|Placebo|Tablets placebo one PO per day for 12 weeks
223499543|NCT05213130|OTHER|Information|A reminder to inform donors that their blood has saved patient's life in a questionnaire.
223499544|NCT03735342|OTHER|Audio Recording|All participants will be provided with a re-playable audio recording of the discharge discussion on a portable electronic device. In addition, participants will have the option to record the discharge discussion on a personally-owned smartphone or receive access to the recording online, via the Open Recording Automated Logging System (ORALS).
223499545|NCT00295685|DRUG|Antacids|
223499546|NCT00031993|DRUG|erlotinib hydrochloride|Given PO
223499547|NCT00031993|OTHER|laboratory biomarker analysis|Correlative studies
223499548|NCT02475447|DRUG|Asimadoline|kappa-opioid receptor agonist
223499549|NCT02475447|DRUG|Placebo|placebo-matched control
223499550|NCT05955833|DIAGNOSTIC_TEST|89Zr-DFO*-trastuzumab PET scan|Patients will be administered 37 MBq 89Zr-DFO\*-trastuzumab and undergo 3 PET scans on the total body PET scanner at day 1, day 2 and day 4 post-injection (p.i.). The first 3 patients will undergo an additional PET 1-2 h p.i. for dosimetry purposes. Three scans are needed for PK modelling and day 4 p.i. is chosen because it is the same time point as in historical controls. Blood samples for (radioactive) PK analysis will be taken at 10 min, 30 min, 1 h and 2 h p.i., and at every PET scan.
223499551|NCT04880317|DIAGNOSTIC_TEST|Cardiac Magnetic Resonance|All enrolled patients will undergo a contrast-enhanced CMR examination for the assessment of extracellular volume
223499552|NCT04880317|DIAGNOSTIC_TEST|Additional CT acquisition|All enrolled patients will undergo an additional CT scan at 5 minutes post-contrast injection to evaluate myocardial relative enhancement
223499553|NCT04880317|DIAGNOSTIC_TEST|Blood tests|Patients will undergo blood tests to review hematocrit, Sars-CoV-2 antibody status and cardiac fibrosis biomarkers
223499554|NCT00223821|DRUG|Oxybutynin chloride, extended-release, individually-titrated|Individually-titrated, extended-release oxybutynin chloride with management of side-effects.
223499555|NCT00223821|BEHAVIORAL|Behavior Training|Behavioral training consists of teaching urge suppression strategies and pelvic floor muscle training.
223746159|NCT00624052|DRUG|fixed-dose combination of telmisartan 80mg+amlodipine10mg|
223746160|NCT02576288|DRUG|Sitagliptin|anti-inflammatory properties
224189728|NCT04346017|DIAGNOSTIC_TEST|Complement dosage|Dosage of the complement parameters: CH50, C3, C4, C3d, C5a, SC5b-9, C4a, MASP-2.
224189729|NCT00453076|DEVICE|Paclitaxel eluting covered metal stent and control covered metal stent|Paclitaxel eluting covered metal stent and control covered metal stent are inserted with standard ERCP technique
224189730|NCT01558466|DRUG|Sildenafil|50 mg tablet will be thoroughly crushed into powder form and diluted in 10 ml ora base suspension syrup agent and a dilution will be performed to prepare 5 mg/ml. All doses required for 48 hours will be available; solutions will be stored at 2-8 degrees C where solution should be stable for at least a month.
223591167|NCT05243303|DEVICE|Active taVNS|A bipolar clip electrode is placed at the cymba conchae of the ear. Through this bipolar clip electrode, afferent nerve fibers within the auricular branch of the vagus nerve will be stimulated. Subjects self-administer the stimulation on a daily basis for 3 months.
223591168|NCT05243303|DEVICE|Sham taVNS|A bipolar clip electrode is placed at the cymba conchae of the ear. However, active stimulation of the afferent nerve fibers within the auricular branch of the vagus nerve will not occur, because the electrode wire is electrically interrupted. Subjects self-administer the sham taVNS on a daily basis for 3 months.
223591169|NCT02453555|DRUG|Linagliptin|
223746161|NCT02576288|DRUG|Placebo|No anti-inflammatory properties
223746162|NCT03541265|DRUG|Exparel|long-acting Bupivacaine extended release liposome compound
223746163|NCT03541265|PROCEDURE|Adductor block protocol|Adductor block using Exparel
224189731|NCT01558466|DRUG|diluent|The placebo will have an equal volume of diluent - Orabase syrup of the same colour and viscosity as the active comparator. Infants in this group will receive normal saline as placebo every 6 hours
223499556|NCT05414188|BEHAVIORAL|Pulmonary rehabilitation|Pulmonary rehabilitation runs for 60 minutes per session. The pulmonary rehabilitation program is based on a comprehensive approach, not simply providing regular exercise. And it includes patient education, active encouragement, and psychological support by investigators. Exercise is performed more than twice a week. Each session is performed for 60 minutes and includes breathing exercises, low to medium-intensity aerobic exercises, and muscle exercises under the guidance of a investigator. After radiation therapy is completed, investigators will recommend that patients perform pulmonary rehabilitation at home more than twice a week and for 60 minutes or more. The patients will record whether and when exercise is performed every day in the diary for pulmonary rehabilitation.
223499557|NCT02366416|BEHAVIORAL|Exercise training|Physical activity
223499558|NCT02790177|DRUG|Hyaluronic Acid|
223499559|NCT02790177|DRUG|NORMAL SALINE|
223499560|NCT01578265|DRUG|Ondansetron Tablets USP 8 mg|8 mg tablet once a day
223499561|NCT01578265|DRUG|Ondansetron Hydrochloride|8 mg tablet once a day
223499562|NCT01801540|DIETARY_SUPPLEMENT|L-arabinose - effect on glucose metabolism|L-arabinose is mixed into the dough of the buns and cup cakes
223499563|NCT02602327|DRUG|Tas-102|Oral nucleoside antitumor agent consisting of α,α,α-trifluorothymidine (FTD) and 5-chloro-6-(2-iminopyrrolidin-1-yl) methyl-2,4 (1H,3H)-pyrimidinedione hydro chloride (TPI) at a molar ratio of 1:0.5.
223499564|NCT02602327|DEVICE|SIR-Sphere|20-60mm resin microspheres containing Yttrium-90 (90Y, Y90) radioisotope
223499565|NCT03676829|DEVICE|Arterial Embolization of the Shoulder|Arterial Embolization of the Shoulder (AES) is a new procedure that is being used to reduce pain and improve range of motion (ROM) caused by adhesive capsulitis. Embolization is a procedure where physicians intentionally block the blood vessels to specific areas of the body to prevent blood flow to that region. By doing this, the decrease in blood flow will decrease the size of the area of interest. In this case, the goal is to decrease the size of inflammatory tissue around the shoulder, resulting in improvement of pain, stiffness and from adhesive capsulitis.
223499566|NCT04705584|DRUG|Prednisolone (as Acetate)|Standard treatment protocol includes Topical steroids for 8 weeks with gradual dose tapering.
223499567|NCT04705584|DRUG|CycloSPORINE Ophthalmic Suspension|This treatment arm includes the use of topical cyclosporine A after 2 weeks of topical steroid use.
223499568|NCT04705584|DRUG|LTacrolimus Topical|This treatment arm includes the use of topical Tacrolimus after 2 weeks of topical steroid use.
223499569|NCT01753063|BEHAVIORAL|Patient Expectations|Baseline Expectations survey (parent/guardian and adolescents 12 and older)
223499570|NCT01753063|BEHAVIORAL|Patient Expectations|3 month follow up survey (parent/guardian and adolescents 12 and older)
223499571|NCT00207688|DRUG|Infliximab 5 mg/kg|Patients who received infliximab 5 mg/kg from C0168T37, C0168T46, C0168T72 studies will be observed.
223499572|NCT00207688|DRUG|Infliximab 10 mg/kg|Patients who received infliximab10 mg/kg from C0168T37, C0168T46, C0168T72 studies will be observed.
223499573|NCT00207688|DRUG|Placebo|Patients who received placebo from C0168T37, C0168T46, C0168T72 studies will be observed.
223499574|NCT02895737|DEVICE|TAVI: Edwards SAPIEN 3, Edwards Lifesciences, Edwards Sapien Ultra|
223499575|NCT02895737|DEVICE|TAVI: Edwards SAPIEN 3, Edwards Lifesciences, Edwards Sapien Ultra; Sentinel™ Cerebral Protection Systems|
223499576|NCT02895737|DEVICE|TAVI: CoreValve® Evolut R™, CoreValve Medtronic|
223499577|NCT02895737|DEVICE|TAVI: CoreValve® Evolut R™, CoreValve Medtronic; Sentinel™ Cerebral Protection Systems|
223499578|NCT03463447|DEVICE|Electronic Dynamometer|Mensuration of the handgrip strength of each volunteer using an electronic dynamometer.
223499579|NCT03463447|DEVICE|Hydraulic dynamometer|Mensuration of the handgrip strength of each volunteer using a hydraulic dynamometer.
223499580|NCT00562341|OTHER|Bariatric Surgery|one time lapb-band gastric bypass surgery
223499581|NCT04146883|DRUG|Antibiotics|Post-procedural one-day iv cefazolin then 3-day prophylactic cephalexin
223499582|NCT04302597|PROCEDURE|Staples|Skin closure using surgical stapler.
223499583|NCT04302597|PROCEDURE|Tissue adhesive|Skin closure using 2-octylcyanoacrylate tissue adhesive.
223499584|NCT01039675|DRUG|500mcg/25mcg once daily|GSK573719/GW642444
223499585|NCT01039675|DRUG|Placebo once daily|Inactive, excipients only
223591170|NCT02453555|DRUG|Empagliflozin placebo + linagliptin placebo low dose|Matching placebo empagliflozin + linagliptin
223591171|NCT02453555|DRUG|Empagliflozin + linagliptin low dose|tablet
223591172|NCT02453555|DRUG|Linagliptin placebo|Matching placebo linagliptin
223746164|NCT03541265|PROCEDURE|peri-articular injection protocol|peri-articular injection using Exparel
224189732|NCT00603824|DRUG|fondaparinux|fondaparinux subcutaneous injection once daily until INR stable in therapeutic range, at least five days: 5 mg if less than 50 kg, 7.5 mg if 50-100 kg, 10 mg if \>100 kg
224189733|NCT00603824|DRUG|argatroban or lepirudin|continuous infusion titrated into therapeutic range and for at least 5 days and until INR stable in therapeutic range
224189734|NCT00367224|PROCEDURE|6 to 9 ultraviolet B treatments|Treatments with ultraviolet B with gradually progressive doses
224189735|NCT00367224|PROCEDURE|Skin biopsies|4 mm punch biopsies of the skin
224189736|NCT02110589|DEVICE|Epidetect|Topically aplied muscle tonicity monitor (EMG recording)
224189737|NCT03010046|DRUG|ANX005|Single ascending dose intravenous infusion
224189738|NCT03010046|DRUG|IVIg|IVIg infusion in Cohorts 4b and 5b only. Randomized to ANX005 followed by IVIg or placebo followed by IVIg.
224189739|NCT03010046|DRUG|Placebos|0.9% saline intravenous infusion
224189740|NCT06104423|DRUG|Nebivolol 5 mg|1 tablet of study medication (5mg) to be administered orally according to instructions of Investigator.
224189741|NCT06104423|DRUG|Ramipril 2.5/5/10 mg|1 tablet of study medication (2.5mg or 5mg or 10mg) to be administered orally according to instructions of Investigator.
224189742|NCT02509429|DEVICE|Insulin therapy (aspart, lispro ou glulisine) with Control-to-Range algorithm|The insuline used is usual patient insuline. There is no specific insulin for this protocol
224189743|NCT02509429|DEVICE|Insulin therapy ((aspart, lispro ou glulisine) withThreshold Low Glucose Suspend|The insuline used is usual patient insuline. There is no specific insulin for this protocol
224189744|NCT00266617|DRUG|epoetin alfa|
224189745|NCT02751658|OTHER|mouth swab|Levy to make inside of the mouth with a swab on the day of admission to hospital and the day of release at the patients in the Otorhinolaryngology
224189746|NCT03551158|DIAGNOSTIC_TEST|Echocardiography|Cardiac imaging for the assessment of the left atrium anatomy and function.
224189747|NCT00750061|DRUG|Lithium Carbonate|"The subject start at a dosage regime of three times a day and one tablet of lithium carbonate, 250mg/table, oral administration each time for three days. The daily dose will be adjusted according to the serum lithium level and the clinical findings. Target serum lithium level is 0.6-1.2mM.~The course of medication is 6 weeks."
224189748|NCT00750061|DRUG|Placebo|Matching placebo
224189749|NCT03950947|DEVICE|Amplatzer vascular plug|See above
224189750|NCT03950947|OTHER|Sham Controll|Angiography of the RIMA without occlusion
224189751|NCT03853993|BIOLOGICAL|Quadrivalent influenza vaccine|Received single dose QIV (15µg/0.5ml)
224189752|NCT03853993|BIOLOGICAL|Trivalent influenza vaccine (contains B/Victoria strain)|Received single dose TIV which contains B/Victoria strain (15µg/0.5ml)
224189753|NCT03853993|BIOLOGICAL|Trivalent influenza vaccine (contains B/Yamagata strain)|Received single dose TIV which contains B/Yamagata strain (15µg/0.5ml)
224189754|NCT04689126|PROCEDURE|surgical or nonsurgical endodontic treatment|Change in diagnosis and treatment plans between the two imaging - periapical radiography and cone beam computed tomography
224189755|NCT00727246|DRUG|CDP-Choline|1000 mg CDP-Choline 2 x per day for 6 weeks.
224189756|NCT00727246|DRUG|Placebo|Treatment with placebo for 6 weeks
224189757|NCT03661346|DRUG|Labetalol|"Aliquots of 20mg of Labetol~• Maximum Dose - 300mg total for case"
224189758|NCT03661346|DRUG|Esmolol|"Infusion - 0.1mg/kg/min~• Maximum Dose - after 30 minutes, 0.3mg/kg/min"
224189759|NCT02696382|BEHAVIORAL|Progressive High Intensity Therapy (PHIT)|"Participants in the Progressive High Intensity Therapy (PHIT) group will receive high intensity physical therapy following discharge from acute hospitalization. The activities of training will include progressive resistance training, multi-planar motor control and gait exercises, and high intensity activities of daily living training. Like the Usual Care group, the PHIT participants will receive 12 intervention visits over 4 weeks (3 visits per week). Participants will also receive a standardized home exercise program."
223499586|NCT00153842|DRUG|Bexarotene (targretin)|"Bexarotene oral capsules will be administered daily beginning on the initial day of chemotherapy (day 1).~Level 1: 300 mg"
223499587|NCT00153842|DRUG|Bexarotene (targretin)|"Bexarotene oral capsules will be administered daily beginning on the intitial day of chemotherapy (Day 1).~Level 2: 400 mg"
223499588|NCT01990781|DRUG|LD: Lidocaine and dexamethasone|LD: intravenous lidocaine 1.5 mg/kg and dexamethasone 8 mg before induction of anesthesia
223499589|NCT01990781|DRUG|L:Lidocaine|Intravenous lidocaine 1.5 mg/kg before induction of anesthesia
223499590|NCT01990781|DRUG|D: Dexamethasone|D:intravenous dexamethasone 8 mg before induction of anesthesia
223499591|NCT01990781|DRUG|N: Normal saline (placebo)|Normal saline: 2ml
223499592|NCT03555929|DRUG|Dexamethasone|80 minutes after achievement of axillary block, if the surgery is not ended, patients will be randomly assigned to one of the two groups : DEXA or Control. Injection will be done 90minutes after achievement of axillary block.
223499593|NCT03555929|DRUG|Normal saline|80 minutes after achievement of axillary block, if the surgery is not ended, patients will be randomly assigned to one of the two groups : DEXA or Control. Injection will be done 90minutes after achievement of axillary block.
223499594|NCT05695391|BIOLOGICAL|Coagulation Factor VIIa (Recombinant)|LR769
223499595|NCT06389461|OTHER|4th Ventricular Compression Technique|"The investigator who applied the technique stood on top of the headboard of the table, with feet flat on the floor, at an appropriate level in relation to the volunteer's headboard.~The investigator joins hands in a cupping position, with the pads of the 1st fingers forming a triangle. The pads of the 1st fingers make contact with the spinous processes of the 2nd and 3rd cervical vertebrae. The thenar eminences make contact with the occipital squama, avoiding contact with the occipito-mastoid sutures during 5 minutes.~A second Investigator was sitting on a chair, placed on the opposite side of the head of the table with a stopwatch in his dominant hand, in order to time the application time of each technique."
223499596|NCT06389461|OTHER|"Sham Therapy"|"The investigator who applied the technique stood on top of the headboard of the table, with feet flat on the floor, at an appropriate level in relation to the volunteer's headboard.~The investigator places hands on the patient's shoulders during 5 minutes. A second Investigator was sitting on a chair, placed on the opposite side of the head of the table with a stopwatch in his dominant hand, in order to time the application time of each technique."
224189760|NCT02696382|BEHAVIORAL|Usual Care (UC)|"Participants in the Usual Care group will receive standard physical therapy following discharge from acute hospitalization. The activities of therapy will include basic strength training, single-planar motor control and gait exercises, and activities of daily living training. Participants will receive 12 intervention visits over 4 weeks (3 visits per week). Participants will also receive a standardized home exercise program."
224189761|NCT03417245|DRUG|fitusiran|by SC injection
224309456|NCT06277232|BEHAVIORAL|Dialogue and education (part of Interdisciplinary Pain Rehabilitation Program)|Dialogue and education consists of patient education, training in wellness and healthy living habits, meetings with families, video feedback, and couples therapy and self-training (e.g., home lessons, activity diary, physical self-training, reflection time, and self-analysis. . In addition, lectures in basic pain science and pain management are offered for both patients as well as for relatives, friends, and colleagues.
224309457|NCT06277232|BEHAVIORAL|activity training (part of Interdisciplinary Pain Rehabilitation Program)|Activity training includes graded activity training, and exposure training, which are delivered by an interdisciplinary team (i.e., a physiotherapist, an occupational therapist, and a psychologist).
223591173|NCT02453555|DRUG|Empagliflozin + linagliptin high dose|tablet
224189762|NCT03417245|DRUG|factor concentrates|by intravenous (IV) injection
224189763|NCT02035891|DRUG|colchicine 0.5mg/d|on the basis of standard therapy to manage hyperglycemia, hypertension,dislipidemia etc.
224189764|NCT02035891|DRUG|placebo 0.5mg/d|on the basis of standard therapy to manage hyperglycemia, hypertension,dislipidemia etc.
223591174|NCT02453555|DRUG|Empa + lina highdose placebo|
223591175|NCT05484284|PROCEDURE|two-stage primary total knee arthroplasty with low-dose antibiotics|Briefly, investigators completely debrided all necrotic soft tissue in the first stage of the operation. The surgical site was flushed twice with hydrogen peroxide, iodine, and saline solutions. Then, the antibiotic-loaded cement spacer was inserted. After surgery, a 10-day course of intravenous organism-specific antibiotics or vancomycin was administered, followed by oral antibiotic therapy. Second-stage reimplantation was performed once there was no sign of infection. The spacer was removed and the new prosthesis was implanted without the use of antibiotic-containing bone cement.
223591176|NCT00205816|DRUG|Tigecycline|
223591177|NCT00905203|OTHER|exercise|exercise training
224189765|NCT01079260|DIETARY_SUPPLEMENT|Standard ONS|Standard ONS
224189766|NCT01079260|DIETARY_SUPPLEMENT|High Energy, low volume ONS|High energy, low volume ONS
224189767|NCT06347848|OTHER|Psychoeducation Focused on Reducing Internalized Stigma|"Participants will be randomized and divided into experimental and control groups. Initial measurements will be collected through a face-to-face meeting. While the control group will continue to receive routine Community Mental Health Center service, the experimental group will receive a psychoeducation program focused on reducing internalized stigma in addition to the routine Community Mental Health Center service. After the program is completed, final measurements of the experimental and control groups will be collected.~The program is planned to consist of 7 sessions, once a week, and approximately 60-90 minutes are expected to be allocated for each session. Sessions will be divided into two sessions: a 30-40 minute session and a 15 minute break."
224189768|NCT04491955|BIOLOGICAL|CV301|CV301 vaccine consists of MVA-BN-CV301 and FPV-CV301. MVA-BN-CV301 (4 x 10\^8 infectious units/0.5 mL each) will be administered as four subcutaneous injections on D1 and D15. Starting on D29, FPV-CV301 (1 x 10\^9 infectious units/ 0.5mL) will be administered as a single subcutaneous injection every 4 weeks on Arm 1 or every 6 weeks on Arm 2A and 2B for up to one year.
224189769|NCT04491955|DRUG|MSB0011359C|"Subjects will receive M7824 via IV infusion over 1 hour (-10 minutes / +20 minutes, that is, over 50 to 80 minutes) once every 2 weeks. M7824 will be administered as a flat dose of 1,200 mg or 300 mg independent of body weight. M7824 is administered as an intravenous infusion with a mandatory 0.2 micron in-line filter."
224309458|NCT06277232|BEHAVIORAL|meetings (part of Interdisciplinary Pain Rehabilitation Program)|The meetings consist of conferences with patients, rehabilitation team, vocational guidance, rehabilitation coordinator, goal-setting meetings, and meetings to check goal achievement.
223499597|NCT06867003|OTHER|physical therapy with bracing|"Strengthens the upper back muscles and reduces tension:~1. Stand or sit with an upright posture and shoulders pulled back~2. Squeeze your shoulder blades together as tightly as you can and hold for five to ten seconds"
223499598|NCT06867003|OTHER|physical therapy without bracing|"Strengthens the upper back muscles and reduces tension:~1. Stand or sit with an upright posture and shoulders pulled back~2. Squeeze your shoulder blades together as tightly as you can and hold for five to ten seconds"
223499599|NCT02845427|DEVICE|closed suction drain|using closed suction drain system postoperative
223499600|NCT02845427|PROCEDURE|no suction drain|the surgical wound will be closed with no suction drain
223591178|NCT03403023|DEVICE|Tear Film Imager|The TFI is an imaging device based on standard camera that uses white light to image the tear film in an ultra high resolution. DES patients in this study will be imaged before and 3 months after initiation of treatment with Restasis (the treatment indicated for their condition).
223746165|NCT01438918|DRUG|SD-6010|200 mg tablets once a day for 2 years
223746166|NCT01438918|DRUG|SD-6010|50 mg tablets once a day for 2 years
224309459|NCT06277232|BEHAVIORAL|Cognitive behavioral therapy (part of Interdisciplinary Pain Rehabilitation Program)|Acceptance and Commitment Therapy (ACT, e.g., goal compass, training in ACT principles, and mindfulness) is mainly delivered by psychologist in a group-treatment (e.g., training in coping strategies). The cognitive behavioral principles are also used in physiotherapy, ergonomics, and education in pain management.
224309460|NCT06277232|BEHAVIORAL|Relaxation techniques (part of Interdisciplinary Pain Rehabilitation Program)|This group-treatment is mainly format by a physiotherapist and psychologist in an interdisciplinary team.
223499601|NCT06261242|DEVICE|Tripod-Fix Vertebral Body Augmentation System (Tripod-Fix)|The Tripod-Fix is a permanent implant used for vertebral augmentation in patients with osteoporotic vertebral compression fractures.
223499602|NCT06977633|BEHAVIORAL|Temporary Insulin Suspension|Participants will suspend insulin delivery from their personal insulin pumps for up to 3 hours. Insulin suspension is temporary and participant-driven under supervision.
223499603|NCT06977633|DEVICE|Glucose and ketone sensor|The participants wear a prototype continuous glucose-ketone monitoring (CGM-CKM) device using painless hydrogel microneedles for 4 hours.
224189770|NCT04491955|DRUG|N-803|N-803 will be given via subcutaneous injection at a dose of 15 mcg/kg every four weeks on Arm 1. N-803 will be administered at as dose of 10 (Micro)g/kg by SC injection every 4 weeks on Arm 2A and Arm 2B.
224189771|NCT04491955|DRUG|NHS-IL12|NHS-IL12 will be given via subcutaneous injection at a dose of 8 mcg/kg every 4 weeks or 16 mcg/kg for the first 4 injections and 8 mcg/kg thereafter on Arms 2A and 2B.
224189772|NCT02910895|OTHER|tumor biopsy|biopsy
224189773|NCT03661281|DIAGNOSTIC_TEST|Jebsen Taylor Hand function test|consists of seven test items, which are felt to represent various hand activities. These test items include: writing a short sentence; turning over 365 inch cards; picking up small objects and placing in a container; stacking checkers; simulated eating; moving empty large cans; and moving weighted large cans.
223499604|NCT07037680|DRUG|Anlotinib|"For patients treated with conventional Intensity-Modulated Radiation Therapy (IMRT), the median prescribed dose was 60 Gy/30 fractions (range: 50.0-70.0 Gy, in 25-35 fractions) (median BED10 72 Gy, range: 60-84 Gy) to the planning target volume (PTV). As for patients with IMRT-based simultaneously integrated boost (SIB), the median prescribed dose was 59.92 Gy/28 fractions (range: 50.0-70.0 Gy, in 25-33 fractions) (median BED10 72.74 Gy, range: 60-84 Gy) to the planning gross tumor volume (PGTV), and 50.4 Gy/28 fractions (range: 45-59.4 Gy, in 25-33 fractions) (median BED10 59.47 Gy, range: 53.1-70.1 Gy) to the PTV. It should be noted that the PTV in the SIB group contains the PGTV.~Anlotinib was administered orally concurrently with the first day of radiotherapy, at a dose of 12 mg for a maximum of three cycles. Each cycle was defined as 2 weeks on-treatment followed by 1 week off-treatment. If intolerance occurs, the dose may be reduced to 8-10 mg/day or stopped."
223591179|NCT03403023|DRUG|Restasis|Restasis therapy is given to all of the patients as indicated for moderate-severe DES. TFI imaging is performed before and 3 months after initiation of therapy.
223591180|NCT01416480|DRUG|Theobromine 300mg|Capsule, b.i.d.
223591181|NCT01416480|DRUG|Levodropropizine 10mg|Syrup, t.i.d.
223499605|NCT07043686|DRUG|Cerebrolysin treatment|The patients will receive Cerebrolysin treatment, 10 days consecutively, 30 ml/day, intravenous infusion diluted up to 100 ml of 0.9% saline in 15 minutes.
223499606|NCT07043686|OTHER|Standard treatment (including neurorehabilitation) of acute ischemic stroke|"Standard treatment entails acute ischemic stroke reperfusion treatment according to international guidelines and local policies, instituting secondary preventive treatment, a proper management of stroke risk factors and neurorehabilitation according to patient's needs: locomotor physiotherapy, occupation therapy, speech therapy, and neuropsychological assessment."
223499607|NCT07046325|DRUG|dexametedomidine|1\. Group DB: are administered Ultrasound guided STB with bupivacaine and dexametidomedine.
223591182|NCT04248023|BEHAVIORAL|Practice Facilitation|A practice facilitator will be assigned the each participating practice to assist with the development of a workflow, screening process, counseling resources, and referral resources for unhealthy alcohol use. Practices in control group will receive delayed intervention at 3 months after their matched cohort of practices.
223591183|NCT03148015|OTHER|Biomarkers|Evaluate the intracellular and intraluminal distribution of autophagy and calcium efflux markers in each breast lesion in comparison to the HER2, proliferation (Ki-67, PCNA), p53, inflammatory, and apoptotic (Annexin-1) markers in the same patient. Determine the qualitative amount and localization of PMCA2 and Vitamin D Receptor in each breast lesion with intraductal calcium spicules compared to lesions without microcalcifications.
223591184|NCT04839445|PROCEDURE|General anesthesia + TAP block|Post induction TAP block for intra and postoperative analgesia.
223591185|NCT04839445|PROCEDURE|General anesthesia + ESP block|Pre induction ESP block for intra and postoperative analgesia.
223591186|NCT02424292|OTHER|Physical activity|Physical activity in a personalised program.
223591187|NCT00037154|DRUG|Saw Palmetto|
224189774|NCT03661281|DIAGNOSTIC_TEST|Pinch strength|Measured in every splint position using a standard dynamometer
223591188|NCT05505526|OTHER|Electroacupuncture|BL33 is located in the third posterior sacral foramen; BL35, 0.5 cun (≈10mm) lateral to the extremity of the coccyx; and SP6 posterior to the medial border of the tibia, 3 cun superior to the prominence of the medial malleolus. BL33 will be inserted by needles of 0.30×75mm size at the angle of 45°, inward and downward, till the depth of 60-70mm. BL35 will be inserted by needles of 0.30×75mm size, slightly outward and upward, till the depth of 60-70mm. SP6 will be inserted by needles of 0.30×40mm till the depth of 25-30mm. All the needles will be lifted, thrust and twisted evenly for three times, right after insertion, to induce the sensation of deqi. Electronic acupuncture apparatus (Yingdi KWD 808 I electro pulse acupuncture therapeutic apparatus, Changzhou Yingdi Electronic Medical Device Co., Ltd) will be connected to the three pairs of needles transversally, with continuous wave of 20 Hertz (Hz), electric current of 2-6.5 milliampere (mA) for BL33 and BL35, and 1mA-3.5mA for SP6.
223746167|NCT01438918|DRUG|Placebo|Placebo tablets once a day for 2 years
223746168|NCT03084887|BEHAVIORAL|manuals and follow-up|distribute manuals for patients before discharge and telephone follow-up per week until secondary hospital
223746169|NCT03190655|DEVICE|Aluminaid|Aluminaid wound dressings is a hydrogel based wound dressing that is integrated with aluminium
223746170|NCT03190655|DEVICE|Hydrogel|Hydrogel based wound dressing
223746171|NCT04064918|OTHER|Netarsudil 0.02% QD|This is a randomized, single-center, investigator-masked, 2-period, 8-week treatment study with washout and crossover between treatment periods. There will be 2 treatments in this study: netarsudil 0.02% QD and timolol maleate 0.5% BID.
223746172|NCT04064918|OTHER|Timolol maleate 0.5% BID|This is a randomized, single-center, investigator-masked, 2-period, 8-week treatment study with washout and crossover between treatment periods. There will be 2 treatments in this study: netarsudil 0.02% QD and timolol maleate 0.5% BID.
223746173|NCT02685631|OTHER|Yttrium-90 Resin Microspheres|Data collection into the RESIN registry
224189775|NCT03661281|DIAGNOSTIC_TEST|Grooved pegboard test|Time will be measured and compared between control, MP splint and IP splint
224189776|NCT00892710|DRUG|Pemetrexed|500 mg/m2 IV given over 10 minutes every 21 days
223499608|NCT07046325|DRUG|Bupivacain|2\. Group B: are administered Ultrasound guided STB with bupivacaine.
223499609|NCT07045545|PROCEDURE|- Group A: Platelet-rich fibrin membrane prepared intraoperatively and applied over neourethra|In this arm, a platelet-rich fibrin membrane will be prepared intraoperatively from the patient's blood using centrifugation. The prepared PRF membrane will then be applied directly over the neourethra following urethroplasty to promote healing and tissue regeneration.
224189777|NCT00892710|DRUG|Bevacizumab|15 mg/kg IV every 21 days
224189778|NCT00892710|DRUG|Carboplatin|AUC=5 IV every 21 days
223499610|NCT07045545|PROCEDURE|Group B: Ventral dartos flap rotated over neourethra|Participants in this arm will undergo hypospadias repair with the application of a ventral dartos fascia flap. The procedure involves elevating a vascularized flap of ventral dartos fascia from the penile shaft, rotating it over the neourethra to provide additional tissue coverage and promote healing. This flap helps in reducing the risk of fistula formation and enhances vascular support to the neourethra. The surgical steps include dissecting the dartos fascia carefully, rotating it over the neourethral reconstruction, and securing it in place, followed by standard postoperative care and follow-up.
223499611|NCT06733376|BEHAVIORAL|Cognitive Processing Therapy|Cognitive Processing Therapy is a first-line intervention for the treatment of PTSD that focuses on changing unhelpful patterns of thinking.
223499612|NCT06733376|BEHAVIORAL|Prolonged Exposure|Prolonged Exposure is an evidence-based treatment for PTSD that helps to reduce the intensity of distress by gradually exposing participants to trauma-related memories, feelings, and situations in real life.
223499613|NCT06733376|BEHAVIORAL|Skills Training for Affective and Interpersonal Regulation|Skills Training for Affective and Interpersonal Regulation (STAIR) is a evidence-based treatment geared towards helping regulate emotional and interpersonal needs of those with PTSD.
223499614|NCT07118917|OTHER|Prehabilitation|Patients with COVID-19 history postponed for the surgery according to multidisciplinary decision.
223746174|NCT00698581|DRUG|Brivaracetam|25 mg tablet - 50 mg daily for 17 weeks (or 21 weeks if down-titrated (50 mg \> 20 mg) for subjects not participating in the follow-up study)
224189779|NCT01334281|PROCEDURE|Blood Draw|Three tubes of blood will be drawn (three 10ml-green top), 7 times (total of 210 ml for study) at the indicated time points: 1) enrollment, 2) anticipated midpoint of desensitization, 3) prior to transplant, 4) three months post-transplant, 5) six months post-transplant, 6) 12 months post-transplant, and 7) 24 months post-transplant.
224189780|NCT01334281|PROCEDURE|Blood Draw|Three tubes of blood will be drawn (three 10ml-green top) twice (60 ml total for study), 8-12 weeks apart. Can be drawn during clinic visit or separate standard of care dialysis visit.
223499615|NCT07118917|OTHER|No postponement|Patients who were COVID negative proceeded for surgery
223499616|NCT07113210|DRUG|pilocarpine HCL ophthalmic solution|Qlosi will be given to participants and quality of life will be determined.
223499617|NCT07119606|DIAGNOSTIC_TEST|SHANK3 mutation|blood sampling for diagnostic test
224189781|NCT02708524|DEVICE|Senofilcon C Contact Lens|
223499618|NCT07116928|DRUG|ganagliflozin|50 mg Once daily, 120 weeks
223499619|NCT07116928|DRUG|Placebo|50 mg Once daily, 120 weeks
224189782|NCT02708524|DEVICE|Comfilcon A Contact Lens|
224189783|NCT02708524|DEVICE|Lotrafilcon B Contact Lens|
223499620|NCT07123909|DEVICE|Patients will undergo a combined hemodialysis and hemosorption procedure. The study cartridge for hemosorption by Jafron HA130 contains the original adsorbing material.|The test cartridge will be used in addition to the ongoing program hemodialysis three times a week in the first month, twice a week in the next month, once a week in the third month
223499621|NCT06400914|DEVICE|Lens A (ocufilcon D)|15 minutes of daily wear.
223499622|NCT06400914|DEVICE|Lens B (fanfilcon A)|15 minutes of daily wear.
223499623|NCT06947720|PROCEDURE|stenting|All individuals are anesthetized, with local or general anesthesia depending on the patient's level of cooperation. During the surgery, heparin must be injected intravenously to control the activated clotting time between 250-300 seconds. The surgery is performed via the femoral artery, and the choice of stent type and size, as well as any required equipment, are determined by the intervention personnel themselves.
224189784|NCT02708524|DEVICE|Samfilcon A Contact Lens|
224189785|NCT05227534|DEVICE|OverC multi-cancer detection blood test|Blood collection for the OverC multi-cancer detection blood test and standard-of-care screening with return of results
224189786|NCT04249934|DIETARY_SUPPLEMENT|Caffeinated Coffee|A single 8 ounce cup of regular starbucks coffee will be given to the participant in the am post operative day two. Participants will have 15 minutes to consume the coffee. Additionally, medical record data will be collected up to 30 days after surgery.
224189787|NCT04249934|DIETARY_SUPPLEMENT|DecaffeinatedCoffee|A single 8 ounce cup of decaffeinated starbucks coffee will be given to the participant in the am post operative day two. Participants will have 15 minutes to consume the coffee. Additionally, medical record data will be collected up to 30 days after surgery.
224189788|NCT04056234|PROCEDURE|Joint puncture|Patient requiring joint puncture for diagnostic or therapeutic reasons.
223499624|NCT02831777|DEVICE|non-invasive blood pressure monitor|Equivalence of CareTaker blood pressure to classical sphygmomanometry
223499625|NCT01211171|DRUG|Telmisartan (Kinzal/Pritor, BAY68-9291)|Patients treated with telmisartan tablets under the real-life setting. Dosing regimen customised to the needs of each participating patient according to the investigators assessment
223499626|NCT04720833|DIETARY_SUPPLEMENT|dried plum|Dried plum
224189789|NCT03426735|OTHER|Dry heat|Dry heat will be applied in the extravasation zone for 10 minutes. Let it rest for 20 and proceed to make a second application of dry cold for another 10 minutes. The control is after 24 hours.
223499627|NCT04720833|DIETARY_SUPPLEMENT|Calcium and vitamin D|Calcium and vitamin D supplement
223499628|NCT01010100|DRUG|Acarbose (Glucobay, BAYG5421)|50 mg TID
223499629|NCT01010100|DRUG|Placebo|50 mg TID
223499630|NCT05420740|DEVICE|Aerobika OPEP|Subjects given Aerobika OEP to assess changes in small airway disease parameter , CAT Score , 6 minute walking test and exacerbation
223499631|NCT02242006|OTHER|serial serum sampling for quantification of drug concentration|
223499632|NCT05702268|DRUG|ICP-332|Tablet, 40 mg
223499633|NCT05702268|DRUG|ICP-332 Placebo|Tablets, in appearance, size, color, dosage form, packaging, instructions, labels and other aspects of the corresponding specifications of ICP-332.
223499634|NCT04488185|BIOLOGICAL|Secukinumab 300 mg|Secukinumab 300 mg administered s.c. (2 single-use prefilled syringes of 150 mg/mL), on Days 1, 8, 15, 22, 29, 57, 85.
223499635|NCT04488185|OTHER|Placebo|Placebo administered s.c. (2 single-use prefilled 1 mL syringes) on Days 1, 8, 15, 22, 29, 57, 85.
223499636|NCT00705822|DRUG|Docetaxel + Estramustine + Hydrocortisone|"Docetaxel iv 80 mg + Oral estramustine-pills 140 mg + Oral hydrocortisone-pills 20 mg.~Combination of these 3 drugs every 3 weeks"
224189790|NCT03426735|OTHER|Dry cold|Dry cold will be applied in the extravasation zone for 10 minutes. Let it rest for 20 and proceed to make a second application of dry cold for another 10 minutes. The control is after 24 hours.
224189791|NCT02301949|DRUG|Thalidomide|Patients are randomly assigned to receive a second course of four-month treatment of thalidomide (Pharmaceutical Co., Ltd. of ChangZhou, China). Medications are taken orally 25mg four times daily at 6 a.m., 12 noon, 6 p.m., and 10 p.m.
224189792|NCT02301949|OTHER|Placebo|Patients are randomly assigned to receive placebo tablets (Pharmaceutical Co., Ltd. of ChangZhou, China) four times daily at 6 a.m., 12 noon, 6 p.m., and 10 p.m.
224189793|NCT02491333|OTHER|true acupuncture|True acupuncture treatment will be given three times per week. Each treatment session lasts for 30 minutes and can be separated by an interval of 1-3 days, with a maximum of 48 treatment sessions during 4 month.
224309461|NCT06277232|BEHAVIORAL|Physical exercise (part of Interdisciplinary Pain Rehabilitation Program)|This group-treatment is mainly format by a physiotherapist in an interdisciplinary team.
224309462|NCT03464630|BEHAVIORAL|Mom & Baby Net|CBT skills based mobile intervention targeting maternal depression and sensitive responsive parenting practices for optimizing infant social-communication promotion and provision of community resources and referral
223499637|NCT00705822|DRUG|Docetaxel + Prednisone|Docetaxel iv 80 mg + oral prednisone-pills 5 mg. Combination of these 2 drugs every 3 weeks.
223499638|NCT04665232|DRUG|aqueous subcutaneous progesterone|25 mg/die of aqueous subcutaneous progesterone from the day of oocytes retrieval for two weeks.
223499639|NCT01956942|DEVICE|Micropulse Laser Trabeculoplasty|
223499640|NCT01956942|DEVICE|Selective Laser Trabeculoplasty|
223499641|NCT00209820|BEHAVIORAL|Supervised Nordic Walking|
223499642|NCT00209820|BEHAVIORAL|Unsupervised Nordic Walking|
223499643|NCT00209820|BEHAVIORAL|Advice to stay active|
223499644|NCT01407419|OTHER|Treatment Acceleration|"Subjects in the intervention group will be seen as frequently as monthly for subjects not achieving low disease activity (LDA) as defined as CDAI ≤10. Treatment acceleration will be expected to occur as frequently as monthly and at least every 3 months in these subjects, unless contraindicated.~Treatment acceleration for the purposes of this trial include the following options: Change in prescribed treatment or dosage of traditional or biologic Disease Modifying Anti Rheumatic Drugs (DMARDs) or a change in the route of Methotrexate administration (from oral to subcutaneous)"
223499645|NCT01407419|OTHER|Monthly Assessment|Monthly disease assessments are expected to be scheduled until the subject has achieved a CDAI of 10 or less (low disease activity).
223499646|NCT00138294|BIOLOGICAL|live attenuated and inactivated influenza vaccines|Live Attenuated Influenza Vaccine (LAIV) and Inactivated Influenza Vaccine (IIV) were administered to eligible children through a research program to improve vaccination coverage in school-aged children. Children 4 years of age and older in the intervention cites (Temple, Belton, Academy, Troy, Salado, Rogers, and Holland) will be offered LAIV or IIV through a school-based research vaccination program. Children living in the comparison cities (Waco, Bryan and College Station) which are within 90 miles of the intervention cites received LAIV or IIV from the local healthcare providers
223591189|NCT05505526|OTHER|Sham electroacupuncture|Sham BL33 is in the area of 1 cun (≈20mm) horizontally outside BL33; sham BL35, 1 cun (≈20mm) horizontally outside BL35; Sham SP6, in the middle of SP6 and tendons. The three pairs of acupoints will be inserted by needles of 0.30×40mm size to a depth of 2-3mm till the needles can stand still. No manipulations will be conducted, and the sensation of deqi will not be induced. Electronic acupuncture apparatus (Yingdi KWD 808 I electro pulse acupuncture therapeutic apparatus, Changzhou Yingdi Electronic Medical Device Co., Ltd) will be connected to the three pairs of needles transversally, with continuous wave of 20Hz and minimal electric current (ideally at a degree which participant can just percept). In about 30 seconds, the electric current will be turned down, leaving the indicator light and ticking sound on.
223591190|NCT05950620|OTHER|Medical obesity management.|Dietician visits, education, anti-obesity medications, and/or referral for metabolic-bariatric surgery as indicated by American Academy of Pediatrics guidelines for obesity management.
224189794|NCT02491333|OTHER|sham acupuncture|Sham acupuncture treatment will be given three times per week. Each treatment session lasts for 30 minutes and can be separated by an interval of 1-3 days, with a maximum of 48 treatment sessions during 4 month.
224189795|NCT02491333|DRUG|metformin|Metformin will be given at 0.5g/times, 3 times one day and for 4 month.
224189796|NCT02491333|DRUG|Placebo metformin|Placebo metformin will be given at 0.5g/times, 3 times one day and for 4 month.
224189797|NCT06162611|DRUG|Etonogestrel implant with Oral Levonorgestrel emergency contraception 1.5mg|Single pill of oral levonorgestrel 1.5mg X 1 dose (e.g. Plan B) same day as contraceptive implant insertion
224189798|NCT06162611|DEVICE|Etonogestrel implant with oral placebo|Single pill of placebo same day as contraceptive implant insertion
224189799|NCT02764606|BIOLOGICAL|Serum and plasma samples|Serum and plasma are collected at time of diagnosis, after surgery, and at time of progression to evaluate the value of new serum markers to predict the occurrence of metastases.
224189800|NCT04629209|DRUG|ONC201|ONC201 is a orally active, small molecule DRD2 antagonist that kills cancer cells but not normal cells.
224189801|NCT02430545|DRUG|Glasdegib|Subjects receive a 100mg oral dose of glasdegib under fasted conditions with washout, then single 100mg oral dose of glasdegib under fasted following dosing to steady state with rifampin
224189802|NCT02430545|DRUG|Rifampin|Subjects receive rifampin 600 mg oral dose daily \[Day -6 to day 4\]
224189803|NCT00016211|RADIATION|radiation therapy|
224189804|NCT00271297|BEHAVIORAL|Pelvic floor muscle training|
224189805|NCT04647773|DRUG|HSK16149 20mg BID|HSK16149 20mg, orally twice a day, treatment period; 13-weeks fixed dose.
224309463|NCT03464630|BEHAVIORAL|Depression & Developmental Awareness System|Supportive, person-centered mobile intervention targeting maternal awareness of maternal depression symptoms, infant developmental milestones, and provision of community resources and referral (active control condition)
223499647|NCT01724190|DRUG|Vitamin D|
223499648|NCT01724190|DRUG|Placebo|
223499649|NCT00992836|BIOLOGICAL|Influenza A (H1N1) 2009 monovalent vaccine|Two doses of vaccine, delivered 21 days apart, with each dose consisting of two 15-microgram intramuscular injections
224309464|NCT04774744|OTHER|Educational Intervention|Receive digital health coaching program
224309465|NCT04774744|OTHER|Questionnaire Administration|Ancillary studies
224189806|NCT04647773|DRUG|HSK16149 40mg BID|HSK16149 40mg, orally twice a day, treatment period; 13-weeks fixed dose.
224189807|NCT04647773|DRUG|HSK16149 60mg BID|HSK16149 60mg, orally twice a day, treatment period; 1-week titration and 12-weeks fixed dose.
223591191|NCT01851785|BEHAVIORAL|Decision Aid (DA) Intervention|"Patients randomized to the DA Intervention will watch a Knee OA Decision Aid (DA) developed by the Foundation for Informed Medical Decision Making and then receive a brief counseling session called AskMe3. The DA is a video that provides viewers with information about OA, treatment choices such as lifestyle changes, non-drug treatments, medication, injections, complementary therapies, and surgery, as well as the pros and cons of each type of treatment. The AskMe3 is a communication, skill-building intervention, which instructs patients to ask 3 questions to the doctor: 1) What is my main problem? 2) What do I need to do? 3) Why is it important for me to do this?"
223591192|NCT00448305|DRUG|EndoTAG-1 + paclitaxel|EndoTAG-1 22 mg/m² + Paclitaxel 70 mg/m² weekly
223591193|NCT00448305|DRUG|EndoTAG-1|EndoTAG-1 44 mg/m² twice weekly
223591194|NCT00448305|DRUG|Paclitaxel|Paclitaxel 90 mg/m² weekly
223499650|NCT02463877|PROCEDURE|Minimally-Invasive Procedure|Laparoscopy
223499651|NCT01864694|BEHAVIORAL|TLC-Diet|Participants receive diet intervention through an automated telephone system
223499652|NCT01864694|BEHAVIORAL|WEB-Diet|Participants receive diet intervention through a web-based system
223591195|NCT00332553|DRUG|Raloxifene|
223499653|NCT01864694|OTHER|Assessment-only control|Assessment-only control
223499654|NCT05830630|DRUG|Bupivacaine methylene blue|"Patients in this group will receive the following regimen through the perineural catheter:~Bolus dose of 1 ml methylene blue 1% (10 mg) plus 19 ml bupivacaine 0.25% will be given intraoperatively before wound closure, and perineural infusion of methylene blue plus bupivacaine 0.25% (1 ml of methylene blue added to each 49 ml of bupivacaine 0.25%) will be started in the recovery room at a rate of 2-5 ml/hour for 72 hours postoperatively"
223591196|NCT00332553|DRUG|medroxyprogesterone acetate|
223591197|NCT00332553|DRUG|estrogen|
224189808|NCT04647773|DRUG|HSK16149 80mg BID|HSK16149 80mg, orally twice a day, treatment period; 1-week titration and 12-weeks fixed dose.
224189809|NCT04647773|DRUG|Pregabalin 150mg BID|Pregabalin 150mg, orally twice a day, treatment period; 1-week titration and 12-weeks fixed dose.
224189810|NCT04647773|DRUG|Placebo BID|Placebo, orally twice a day, treatment period; 13-weeks fixed dose.
224309466|NCT04774744|OTHER|Supportive Care|Receive standard of care support services
223499655|NCT05830630|DRUG|bupivacaine saline|"Patients in this group will receive the following regimen through the perineural catheter:~Bolus dose of 1 ml normal saline plus 19 ml bupivacaine 0.25% will be given intraoperatively before wound closure, and perineural infusion of bupivacaine 0.25% will be started in the recovery room at a rate of 2-5 ml/hour for 72 hours postoperatively"
223499656|NCT04694638|OTHER|Body position change|combined use of prone positioning and high-flow nasal cannula (HFNC) and non-invasive positive pressure ventilation (NIPPV) can reduce the rate of intubation in acute hypoxemic and/or hypercapnic respiratory failure secondary to COVID-19 infection.
223499657|NCT01643187|DIETARY_SUPPLEMENT|Beverage fortified with 21 vitamins and minerals|The serving contains 4 grs. of protein, 12 grs. of carbohydrate, 1 gr of fat 9 mg of zinc, 12.5 mg iron, 160 µg of folic acid, 90 µg of iodine, 250 mg of vitamin A, 40 mg of vitamin C, 0.5 mg of vitamin B6, 0.9 µg of vitamin B12, 6 mg of niacin, 0.5 mg of vitamin B2, 0.5 mg of vitamin B1, 0.3 mg of copper, 5 mg of vitamin D3, 5 mg of vitamin E, 200 mg ofcalcium, 150 mg of phosphorous, 40 mg of magnesium, 17 µg of selenium, 0.17 µg of manganese, 1.8 mg of pantothenic acid and 8 µg of biotin.
223499658|NCT01643187|DIETARY_SUPPLEMENT|Lactose-free milk|Serving contains 4 grs. of protein, 12 grs of carbohydrate and 1 gr of fat
223499659|NCT02557789|DRUG|Lefamulin|Lefamulin administered iv or orally in the fasted state and orally in the fed state
223499660|NCT02786667|DRUG|Rotigotine|6 months treatment with Rotigotine up to 8 mg per day with a titration period for one month
224309467|NCT00191165|DRUG|Somatropin|Doubled dosage with respect to the pre-enrollment (in-label) dosage
223499661|NCT02786667|DRUG|Placebo|6 months treatment with Placebo up to 8 mg per day with a titration period for one month
223499662|NCT00739570|DEVICE|AAI signature IV AMCT|Chiropractic adjustments of the lumbar spine following the activator basic scan protocol
223499663|NCT01783782|BEHAVIORAL|DIET|clear liquid diet for 12 hours on the day before CE, followed by an overnight fast
223499664|NCT01783782|DRUG|polyethylene glycol 4000 solution with simethicon|patients received a high volume regime consisting of a 50 mL/Kg (up to 2 Lt/die) of PEG solution the evening before the examination, followed always by an overnight fast
223591198|NCT00332553|DRUG|17 beta estradiol|
223591199|NCT06065592|DRUG|Palbociclib|Palbociclib will be administered at a dose of 125 mg oral on a 21/7 cycle.
223591200|NCT06065592|DRUG|Rivaroxaban|Rivaroxaban will be administered at a dosage of 15 mg intravenously twice a day for 21 days, followed by 20 mg once daily for the subsequent 21 days.
223591201|NCT06065592|GENETIC|SNP|diagnostics of patients' carriers or not of the risk allele(s)
223591202|NCT03267914|OTHER|Tray|Control intervention Patients will use the custom-made tray to apply the fluoride locally to the teeth and wear for 5 minutes each day.
223591203|NCT03267914|OTHER|Brush|Patients will brush with the fluoride for 2 minutes each day.
223591204|NCT01900288|BEHAVIORAL|HPN Group Clinic Appointments using Mobile Devices (experimental)|Visual meetings with geographically distant professionals and peers using a mobile device (iPad mini).
223591205|NCT01900288|BEHAVIORAL|Mobile Device Access (placebo)|Use of iPad mini unrelated to the intervention until last contact with one connection to professionals for comparison.
223591206|NCT00003691|BIOLOGICAL|filgrastim|
223591207|NCT00003691|DRUG|cisplatin|
223591208|NCT00003691|DRUG|doxorubicin hydrochloride|
223591209|NCT00003691|DRUG|paclitaxel|
223591210|NCT04284774|DRUG|Tipifarnib|Tipifarnib tablets
223591211|NCT00493961|DRUG|gonadotropin releasing hormone (GnRH)|Pulsatile GnRH (25 ng/kg per bolus every two hours via microinfusion pump)
223591212|NCT01501123|DRUG|Haloperidol|5mg IM
223591213|NCT01501123|DRUG|Midazolam|IM midazolam
223591214|NCT02879578|DRUG|Valbenazine|
223746175|NCT00698581|DRUG|Brivaracetam|25 mg tablet - 100 mg daily for 17 weeks (or 21 weeks if down-titrated (100 mg \> 50 mg \> 20 mg) for subjects not participating in the follow-up study)
224189811|NCT05867186|BEHAVIORAL|Exercise training|Exercise training during intensive cancer treatment, maintenance therapy and aftercare. Training mainly consists of age-appropriate and personalised endurance, strength, flexibility, balance/coordination and gait training. Exercise is provided 3 to 5 times a week lasting for 45 to 60 minutes under supervision during inpatient and outpatient stays, as well as at home. At home, patients train independently according to the exercise recommendations of the exercise professionals, receive supervised telemedical exercise sessions and/or combine their training with digital tools.
224189812|NCT03320031|DRUG|Linagliptin|Take linagliptin 5mg a day.
224189813|NCT03320031|DRUG|Humalog Mix 75/25|Administer subcutaneous premixed insulin twice a day.
224189814|NCT00727675|BEHAVIORAL|Integrated Cognitive Behavioral Therapy|CBT is provided by skilled psychologists in weekly sessions for 12 weeks and focuses on reducing illicit drug use and increasing pain management.
224189815|NCT06341582|DIAGNOSTIC_TEST|End-tidal carbon monoxide-corrected (ETCOc)|Early postnatal ETCOc levels
224189816|NCT04860531|DRUG|Lumbar Facet Joints intra-articular injection with Platelet Rich Plasma|Floroscopy guided by C-arm Intraarticular injection in Lumbar facet Joints
224189817|NCT04860531|DRUG|Lumbar Facet Joints intra-articular injection with a mixture of 0.5% lidocaine and 5mg/ml of betamethasone|Lumbar Facet Joints intra-articular injection
224189818|NCT00881374|DRUG|LACTIC ACID(ND)|Dermacyd Infantile (Lactic Acid)
224189819|NCT02168465|BEHAVIORAL|teaching self-management of an intermittent catheter|Specifically, we will teach awareness, self-monitoring and self-management strategies to CIC uses with SCI in an online format. Nurse telephone consultation for teaching self-management will be combined with peer leaders for online forums.
223499665|NCT01783782|DRUG|simethicon|Patients received 20 mL oral simethicone (Panamir, DMG, Italy, containing 40 mg simethicone in 1mL emulsion) and 200mL water 30 minutes before capsule ingestion
223499666|NCT02087683|OTHER|Vitamin D Supplementation|Participants in this group will receive vitamin D supplements of 5 000 International units per day for 12 months. Each patient will attend their respective clinic for clinical evaluation by their cardiologist, whom will give them the vitamin supply for a month.
223499667|NCT02087683|OTHER|Control group (Placebo)|Participants in this group will receive a placebo made of gelatin and corn oil per day for 12 months. Each patient will attend their respective clinic for clinical evaluation by their cardiologists, whom will give the vitamin supply for a month.
223499668|NCT00474032|DRUG|Botulinum Toxin (Type A) injection (10 U/Kg)|See Detailed Description.
223499669|NCT04329741|BEHAVIORAL|6-week basic dog obedience training course|The class focused on teaching owners how to better communicate with their dog and covered basic commands (e.g., sit, down, watch), loose leash walking, and polite greetings, among other skills. The importance of dog walking was implied, but not specifically emphasized. Classes were held once per week for 45 minutes, with 5-8 students per class.
223591215|NCT00288327|BEHAVIORAL|Lifestyle behavior change program|Intervention included a six-month intensive intervention of 2 individual counseling sessions, 3 group sessions, and 3 phone calls from a peer counselor followed by a maintenance phase (6 months) including 1 individual counseling session and 7 monthly peer counselor calls.
223591216|NCT00288327|BEHAVIORAL|Pamphlets|Nutritional and physical activity pamphlets from American Heart Association
223591217|NCT04100941|DIAGNOSTIC_TEST|standard suction|After the needle is inserted in the mass, removing the stylet before performing EUS-FNA. Then attach a 10mL syringe to the end of needle. 20 times of for-backward Suction was applied after the lesion was punctured.
223591218|NCT04100941|DIAGNOSTIC_TEST|slow pull|After the needle is inserted in the mass, slowly pull the stylet out while performing EUS-FNA with 20 times for-backward.
223591219|NCT04100941|DIAGNOSTIC_TEST|wet suction|After removing the stylet, the needle was flushed with 5mL of saline solution to replace the column of air with saline. A 10mL syringe was attached to the end of the needle. 20 times of for-backward Suction was applied after the lesion was punctured.
223591220|NCT05856565|OTHER|Photo|Photography intake
224189820|NCT04555772|OTHER|factors evaluation|They investigated mortality and morbidity in patients who underwent emergency operation within 24 hours after traumatic brain injury.
224189821|NCT00139269|DRUG|Docetaxel|
224189822|NCT00139269|DRUG|Cisplatin|
224189823|NCT00139269|DRUG|5-Fluorouracil|
224189824|NCT05685446|OTHER|Ice water|Ingestion of 175 ml iced tap water 15 minutes prior to elective gastroscopy
224309468|NCT00191165|DRUG|Somatropin|In-label dosage
223591221|NCT02299284|OTHER|Intensive Home-based Bimanual and Lower-limb Training in Young Children With Hemiplegia|
224189825|NCT02951143|DRUG|SPECTRUM cigarettes|Across six laboratory sessions, participants will consume 10 puffs of either their usual brand of cigarette (one session) or a SPECTRUM cigarette (five sessions) with a nicotine yield varying from 0.03 to 0.70 and either menthol (TPMF codes NRC 103, NRC 201, NRC 301, NRC 401, and NRC 601) or tobacco (TPMF codes NRC 102, NRC 200, NRC 300, NRC 400, and NRC 600) flavor, depending on preference. This will be followed by the collection of blood nicotine content and a cigarette purchase task.
224309469|NCT03152734|PROCEDURE|Surgical or non-surgical intervention|Each kind of surgical or non-surgical intervention with anesthesia applied by an anesthetist
224309470|NCT00073710|DRUG|Zemplar|
224309471|NCT00073710|PROCEDURE|42 Ca carbonate absorption via single tracer method|
224309472|NCT00073710|DRUG|Calcijex|
224309473|NCT05554081|DEVICE|Peezy urine collection device|use peezy collection to obtain urine sample
224309474|NCT02033538|DRUG|nanoparticle albumin-bound paclitaxel|Paclitaxel protein-bound particles for injectable suspension (albumin-bound) 125 mg/m2 (IV over 30 min) (days 1 and 8) on 21 day cycle
223499670|NCT02063269|DRUG|Rivastigmine|9-18mg/rivastigmine for 52 weeks
223499671|NCT06013085|BEHAVIORAL|cognitive behavioral therapy|6 weeks cognitive behavioral therapy
223499672|NCT06088446|PROCEDURE|Supplementary anesthetic injections|Supplementary anesthetic injections after failed primary nerve block
223499673|NCT01363271|DRUG|Linezolid|IV and oral forms of linezolid are identified through a pre-specified list of National Drug Codes (NDCs).
223499674|NCT01363271|DRUG|Vancomycin|IV form of vancomycin is identified through a pre-specified list of National Drug Codes (NDCs).
223591222|NCT00265031|DRUG|Cyclophosphamide|
223591223|NCT00265031|DRUG|Adriamycin|
224189826|NCT02951143|DRUG|SPECTRUM cigarettes between|Participants will be assigned one of the nicotine concentrations of a SPECTRUM cigarette. They will complete a cigarette purchase task and make real purchases for the next week. Participants will return and make purchases again, repeating 4 times.
224189827|NCT01077908|BIOLOGICAL|Adoptive Cellular Therapy|CMV-specific T-cells, single infusion at 27 days post-HSCT
224189828|NCT01077908|DRUG|Best available antiviral drug therapy|"1. Intravenous ganciclovir 5mg/kg twice daily~2. Oral valganciclovir 900mg twice daily~3. Intravenous foscarnet 90 mg/kg twice daily"
224189829|NCT06097416|DRUG|Neoadjuvant Chemoradiotherapy|"5-FU is a fluoropyrimidine antimetabolite considered to act primarily as an inhibitor of thymidylate synthase. 5-FU is supplied as a colourless-to-faint yellow solution in 10-mL single use vials. Each 10 mL of solution contains 500 mg 5-FU, with pH adjusted to approximately 9.2 with sodium hydroxide.~The CRT regimen consists of the standard algorithms: a total of 5400-5600 cGy of radiation (4500 cGy to the pelvis, with an integrated boost to the primary tumour and involved nodes of 500 cGy followed by an option boost to the primary tumour and involved nodes) delivered in 27-28 fractions, respectively, of 180-200 cGy each over a 5-6 week period."
224189830|NCT06097416|DRUG|Total Neoadjuvant Therapy|"5-FU is a fluoropyrimidine antimetabolite considered to act primarily as an inhibitor of thymidylate synthase. 5-FU is supplied as a colourless-to-faint yellow solution in 10-mL single use vials. Each 10 mL of solution contains 500 mg 5-FU, with pH adjusted to approximately 9.2 with sodium hydroxide.~Oxaliplatin is an organoplatinum complex in which the platinum atom is complexed with 1,2- diaminocyclohexane with an oxalate ligand as a leaving group. Platinum content is 48.1% to 50.1%.~All patients received the same chemotherapy (FOLFOX) and long-course chemoradiotherapy (50.4 Gy in 28 fractions) before surgery."
224189831|NCT04163419|DRUG|Tanezumab|Tanezumab 10 mg SC
224189832|NCT04163419|DRUG|Placebo|Placebo 10 mg SC
224189833|NCT00682006|DRUG|4% Chlorhexidine|4% Chlorhexidine was provided to be applied in this arm to Mothers through TBAs.
224189834|NCT00682006|OTHER|Hand washing Soap|Hand washing soap was provided to Mothers through TBAs.
224189835|NCT00682006|DRUG|4% Chlorhexidine|4% Chlorhexidine was provided to be applied by Mothers through TBAs.
224189836|NCT00229931|DRUG|Triamcinolone acetonide|4mg of intravitreal triamcinolone at time of cataract surgery with option to repeat at one month if no response
224189837|NCT00229931|PROCEDURE|laser|Laser treatment 1 month after cataract surgery with option to repeat once if no improvement.
224189838|NCT02068001|PROCEDURE|Roux-en-Y Gastric Bypass|
224189839|NCT03445325|BEHAVIORAL|LiGHT v2.1|"The LiGHT mobile program strives to support youth and their families to adopt lifelong healthy behaviours in four areas - eating, physical activity, recreational screen time and sleep - to foster healthy growth and development, to prevent chronic diseases and manage unhealthy weights.~The program includes content that involve the family, and focus on behavioural therapy as well as dietary and physical activity patterns. LiGHT is intended to be engaging and fun, provide virtual and tangible rewards, and interact with participants multiple times per day. In addition, it will feature a mobile social support network and interaction with a live coach with specialized training in motivational interviewing to support youth/families in changing their health behaviours through messaging and phone calls."
224189840|NCT00591916|DRUG|Application of donor site dressing [scarlet red, Microbial Nanocellulose (NC), or hyaluronan and thrombin (HT)]|Application of donor site dressing: scarlet red, Microbial Nanocellulose (NC), or hyaluronan and thrombin (HT).
224189841|NCT00591916|PROCEDURE|Blood sample|Obtain blood specimen at surgery donor site harvest, 14 days post surgery and 6 months post surgery
224189842|NCT00591916|PROCEDURE|Biopsy|Tissue biopsy of donor site treated area at admission, wound healing and 2-6 months post burn.
224189843|NCT02992743|DRUG|letetresgene autoleucel (GSK3377794)|Letetresgene autoleucel (GSK3377794) as an IV infusion.
224189844|NCT02992743|DRUG|Cyclophosphamide|Cyclophosphamide will be used as a lymphodepleting chemotherapy.
224189845|NCT02992743|DRUG|Fludarabine|Fludarabine will be used as a lymphodepleting chemotherapy.
224189846|NCT04108416|PROCEDURE|Cleft lip and palate repair|The intervention is the currently used cleft lip and palate repair technique at the University Hospital Basel and University Childrens Hospital Basel
224189847|NCT02682966|RADIATION|Coronary Computed Tomography Angiography|Coronary Computed Tomography Angiography will be performed in all participants
224189848|NCT04980196|DIAGNOSTIC_TEST|urodynaemic studies|The Urodynamic studies carried out were : uroflowmetry and cystometry. The Uroflowmetry was performed by the gravimetric method Detrusor over activity was diagnosed when the patient has involuntary detrusor contractions during filling with or without leakage which may be spontaneous or provoked,
224189849|NCT05858216|DRUG|Chlor-Trimeton.|Package dose of Chlor-Trimeton will be administered
223499675|NCT01363271|DRUG|Linezolid|IV and oral forms of linezolid are identified through a pre-specified list of National Drug Codes (NDCs).
223499676|NCT01363271|DRUG|Vancomycin|IV form of vancomycin is identified through a pre-specified list of National Drug Codes (NDCs).
223499677|NCT01266928|DRUG|vitamine C and E|Eligible and consenting women were randomly assigned to capsules containing a combination of 1,000 mg vitamin C (ascorbic acid) and 400 international units of vitamin E (RRR alpha tocopherol acetate)
223499678|NCT04259242|PROCEDURE|SRP|scaling and root planing with ultrasonic scaler and manual instruments
223499679|NCT00361244|DRUG|SU011248|Given orally in the morning for two weeks followed by a one week rest period (one cycle equals 21 days). Participants may continue to receive study treatment as long as their disease does not progress and they do not experience any serious side effects.
223499680|NCT00361244|DRUG|Irinotecan|Given intravenously on days 1 and 8 of each 21-day cycle. Participants may continue to receive study treatment as long as their disease does not progress and they do not experience any serious side effects.
223591224|NCT00265031|DRUG|Etoposide|
223591225|NCT00265031|DRUG|Procarbazine|
223591226|NCT00265031|DRUG|Prednisone|
223591227|NCT00265031|DRUG|Vincristine|
224189850|NCT03373656|BIOLOGICAL|Vaccination|"Patients with higher antibody titers will accept vaccination. There are two vaccines provided in this study:~hepatitis B vaccine measles-rubella combined vaccine"
223591228|NCT00265031|DRUG|Bleomycin|
223591229|NCT00265031|PROCEDURE|radiation therapy|
223591230|NCT06028360|OTHER|Progressive Muscle Relaxation|Intervention will be applied for 15-20 minutes 3 consecutive days a week for 1 week
224189851|NCT03373656|OTHER|No Vaccination|Patients with higher antibody titers will NOT accept vaccination. But we will keep monitoring their antibody titers.
224189852|NCT06188351|DEVICE|Three-Dimensional Navigation Atrial Septal Puncture|Atrial septal puncture will be performed using a three-dimensional navigation intracardiac guidance kit
224309475|NCT03196635|DEVICE|Patient-Assisted (PA) Breast Compression|The technologist will properly position the breast and apply minimum compression. The subject will be instructed to apply compression as the technologist ensures the breast tissue is in appropriate position and tautness. The technologist will then guide the subject to achieve appropriate compression level, sufficient but not excessive, and the image will be acquired. This will be done for both standard views CC \& MLO.
224309476|NCT03196635|DEVICE|Technologist-Controlled (TC) Breast Compression|TC compression will be conducted per standard of care practices at the site.
224309477|NCT05340829|BIOLOGICAL|ThisCART19A|ThisCART19A is a new type CAR-T cells therapy for patients with lymphoma and lympholeukemia
224309478|NCT01023048|OTHER|preimplantation diagnosis|genetic testing on embryos to identify embryos that are affected by a single gene disorder (e.g. cystic fibrosis, Tay-Sachs, sickle cell anemia)
224309479|NCT05801718|DIAGNOSTIC_TEST|Growth parameters & body mass index|measuring the anthropometric measurements including: Weight, height/ length, head circumference, mid arm circumference\& skin fold thickness and measuring body mass index.
224309480|NCT05705037|OTHER|CPP-ACPF|CPP-ACPF mousse (MI Paste®) was applied with a microbrush on the cervical buccal surface of each tooth for 5 minutes and it was subsequently distributed for 20 seconds with a rubber cup coupled to a low speed handpiece. Right after, a sham therapy was performed, using RAFFAELLO 980 BIO - Dental Medical Technologies - DMT S.r.l. Although the device was switched on, the hand piece did not work and the sound was emitted by a mobile phone. The tip of the laser device was positioned on two areas for each dental element, located one in the center of the cervical region and the other in the middle third of the crown.
224309481|NCT05705037|OTHER|PBMT|A placebo mousse (Elmex Junior®) was applied with a microbrush on the cervical buccal surface of each tooth for 5 minutes and it was subsequently distributed for 20 seconds with a rubber cup coupled to a low speed handpiece. Right after, a PBMT was performed, using RAFFAELLO 980 BIO - Dental Medical Technologies - DMT S.r.l. The tip of the laser device was positioned on two areas for each dental element, located one in the center of the cervical region and the other in the middle third of the crown. The parameters used were: wavelength 980 nm, power 4 W, irradiation area1 cm2, application time 15 sec per 1 cm2, energy density 60 J/cm2
224309482|NCT05705037|OTHER|CPP-ACPF+PBMT|CPP-ACPF mousse (MI Paste®) was applied with a microbrush on the cervical buccal surface of each tooth for 5 minutes and it was subsequently distributed for 20 seconds with a rubber cup coupled to a low speed handpiece. Right after, a PBMT was performed, using RAFFAELLO 980 BIO - Dental Medical Technologies - DMT S.r.l. The tip of the laser device was positioned on two areas for each dental element, located one in the center of the cervical region and the other in the middle third of the crown. The parameters used were: wavelength 980 nm, power 4 W, irradiation area1 cm2, application time 15 sec per 1 cm2, energy density 60 J/cm2.
224309483|NCT01316315|DRUG|Active|A 5 mg single dose given intravenously via syringe pump over 1 minute.
223499681|NCT00361244|DRUG|Cetuximab|Given intravenously on days 8 and 15 of each 21-day cycle. Participants may continue to receive study treatment as long as their disease does not progress and they do not experience any serious side effects.
224309484|NCT01316315|DRUG|Placebo|Same as active
224309485|NCT02525237|DRUG|Apatinib|Apatinib (500 mg qd p.o.) until disease progression or intolerable toxicity
224309486|NCT02525237|DRUG|S-1|S-1 (40 mg/m2 qd days 1-14 q3w p.o.) until disease progression or intolerable toxicity
223499682|NCT05176574|BEHAVIORAL|Questionnaire|A questionnaire will be developed via the Delphi method, will be pilot tested and implemented to assess physicians' perceptions and behaviors on physical activity and exercise in chronic, non-communicable diseases.
223499683|NCT03081078|BEHAVIORAL|Volunteer support|Each participant will be matched with a pair of trained volunteers (under pre-determined safety measures), who will initiate caring contact via telephone or text messages at least twice a month for two months. Participants will be free to respond or not.
223499684|NCT03081078|OTHER|Mobile app|Participants will receive programmed care messages and reminders of community resources and healthcare contacts on a regular basis. The app will also provide simple self-help mood checking and relaxation exercises.
223499685|NCT05364255|DRUG|[14C]AZD9833 Oral Solution, 75 mg|Oral Solution, 75 mg (NMT 0.67 MBq) - oral, fasted
223499686|NCT04358562|DRUG|Gefitinib|If persistence of plasma ctDNA EGFRm after 8 weeks of gefitinib first-line treatment
223499687|NCT04358562|DRUG|Anlotinib|If clearance of plasma ctDNA EGFRm after 8 weeks of gefitinib first-line treatment
223591231|NCT06028360|DEVICE|Virtual Reality Therapy|Therapy through VR will be given for 8 minutes 3 times a week on consecutively for 1 week
223591232|NCT00233012|DRUG|Topiramate|
223591233|NCT02193113|DRUG|KVD001 Injection|A novel plasma kallikrein inhibitor
224189853|NCT06188351|DEVICE|Conventional Atrial Septal Puncture|Atrial septal puncture will be performed using traditioanl two-dimensional atrial septal puncture kit using traditional method.
223499688|NCT03079583|DIETARY_SUPPLEMENT|Intervention-group|Biofortified Rice is grown by foliar Zn application
223499689|NCT03079583|DIETARY_SUPPLEMENT|Control-group|Control Rice with normal zinc levels
223499690|NCT03918343|OTHER|Blood sample|blood samples (4 times; 14ml per visit)
223499691|NCT04841876|OTHER|rugby matches|standard rugby-7s match
223591234|NCT00980304|DRUG|Rituximab|
223591235|NCT01608841|DRUG|Erlotinib|Erlotinib 100 mg 1# PO qd till disease progression
223591236|NCT00803062|BIOLOGICAL|Bevacizumab|Given IV
223591237|NCT00803062|DRUG|Cisplatin|Given IV
223591238|NCT00803062|OTHER|Laboratory Biomarker Analysis|Correlative studies
223591239|NCT00803062|DRUG|Paclitaxel|Given IV
223591240|NCT00803062|OTHER|Quality-of-Life Assessment|Ancillary studies
223591241|NCT00803062|OTHER|Questionnaire Administration|Ancillary studies
223591242|NCT00803062|DRUG|Topotecan Hydrochloride|Given IV
223591243|NCT02782767|OTHER|Wound catheter infusion|Wound catheter has multiple holes spread around 360 degrees throughout its active length. It is placed in the musculofascial plane during closure of the wound. Local anaesthetic infusion will be delivered through the catheter.
223746176|NCT00736008|OTHER|Observational|Data summary only
224189854|NCT04490551|DIAGNOSTIC_TEST|Risk-based logistic regression model|The intervention will be a risk-based logistic regression model that takes multiple variables into account to calculate the risk of advanced neoplasia as an outcome.
224189855|NCT04490551|DIAGNOSTIC_TEST|FIT|FIT is a stool-based test that detects human blood in faeces.
224189856|NCT03082040|BEHAVIORAL|home-based breathing training|The intervention group will undergo a home-based breathing training 20 minutes twice daily for four weeks. Participants in the control condition will participate the same breathing training after a four-week waiting list period.
224309487|NCT03769207|DEVICE|Ambulatory ECG|Eligible participants are asked to wear the ambulatory ECG monitor
223499692|NCT03165903|BEHAVIORAL|Cue and Implementation Intention-Based Intervention|Families from a school assigned to Cue and Implementation Intention-Based Intervention received an intervention targeting increased levels of healthy snacking and reduced levels of sugar sweetened beverage consumption. The intervention consisted of a 90-minute meeting with a trained Health Coach, two 20-minute phone calls, 4 tailored newsletters, and a series of emails and text messages. Cues for snacking and sweetened beverage consumption were removed or relocated and implementation-intentions were created to trigger alternative behaviors to snacking and sweetened beverage consumption in the presence of cues. Both interventions were delivered over 3-10 weeks depending on the self-directed pace of the participants. All participants completed a follow-up assessment 3 months after consent.
223499693|NCT03165903|BEHAVIORAL|Control arm|Families that were from a school assigned to Control received an intervention on sun safety that consisted of a 10-minute meeting with a trained Health Coach, 2 generic newsletters, an email, and a text message. Both interventions were delivered over 3-10 weeks depending on the self-directed pace of the participants. All participants completed a follow-up assessment 3 months after consent.
223499694|NCT01137812|DRUG|Sitagliptin 100 mg|One 100 mg capsule once daily for 52 weeks with protocol-specified doses of metformin and sulphonylurea
223499695|NCT01137812|DRUG|Canagliflozin 300 mg|One 300 mg capsule once daily for 52 weeks with protocol-specified doses of metformin and sulphonylurea
223499696|NCT01137812|DRUG|Metformin|Patients will continue to take background therapy with Metformin for T2DM at maximally or near-maximally effective protocol-specified doses for the duration of the study.
223499697|NCT01137812|DRUG|Sulphonylurea|Patients will continue to take background therapy with Sulphonylurea for T2DM at maximally or near-maximally effective protocol-specified doses for the duration of the study.
223499698|NCT01168440|DRUG|Sunitinib|Sunitinib, 50 mg PO daily, 6 weeks courses with schedule 4/2 (4 weeks of treatment followed by 2 weeks of rest).
223499699|NCT00042978|BIOLOGICAL|oblimersen sodium|Given IV
223499700|NCT00042978|DRUG|carboplatin|Given IV
223499701|NCT00042978|DRUG|etoposide|Given IV
223499702|NCT02537925|DRUG|Celecoxib|Celecoxib 200mg bid po, to the end of concurrent radiotherapy
223499703|NCT02537925|DRUG|Nedaplatin|40 mg/m2, IV (in the vein) on day 1 of each 7 day cycle. Number of Cycles: to the end of concurrent radiotherapy
224189857|NCT00728273|DIETARY_SUPPLEMENT|worm treatment and multiple micronutrient fortified biscuits|"A single dose of intestinal anthelminthic treatment as orange-flavored chewable tablets containing 400 mg Albendazole (Vidoca, Thephaco, Vietnam) was given. Deworming was repeated with Albendazole for all children at the end of the study (after 4 months).~The composition and amount of nutrients in each serving of fortified biscuit were 6 mg iron, 5.6 mg zinc, 35µg iodine, 300 µg RAE vitamin A, 1.0 mg thiamin, 0.9 mg riboflavin, 1.1 mg vitamin B6, 10.5 mg NE niacin, 1.5 µg vitamin B12, 120 µg folic acid, 28 mg vitamin C, 150 mg calcium, 74 IU vitamin D, 40 mg magnesium, 6.8 µg selenium, 378 mg potassium, 70 mg phosphorus, 3.0 mg pantothenic acid, 2.8 µg vitamin E, 10 µg vitamin K and 18 µg biotin."
224309488|NCT01680107|DRUG|d-cycloserine|
224309489|NCT01680107|DRUG|placebo|
224309490|NCT01680107|BEHAVIORAL|cognitive-behaviour therapy|
224309491|NCT06453252|OTHER|we are aiming to develop a Scoring system based on certain variables derived from both groups|We are aiming to develop a Scoring system based on certain variables derived from both group
223499704|NCT02537925|RADIATION|Concurrent Radiotherapy|The standard radiotherapy schedules were available as conventional radiotherapy and Intensity Modulated Radiotherapy (IMRT). The cumulative radiation dose was 68\~74 Gy for primary tumor (2.0\~2.3 Gy/f/day, 5 day/ week, /6\~7 weeks), and 50\~54 Gy for lymphatic positive area (1.8 \~ 2 Gy/f/day, 5 day/week, /5.0\~5.5 weeks).
223499705|NCT04393428|OTHER|[TIMP-2]*[IGFBP-7]|\[TIMP-2\]\*\[IGFBP-7\] mesurement in urine sample relicates of COVID-19 patients admitted to the Montpellier University Hospital
223511925|NCT05792345|PROCEDURE|Transversus Thoracic Muscle Plane Block|The transversus thoracic muscle plane block It is most commonly performed following cardiothoracic surgeries (or any surgeries requiring sternotomy) to provide analgesia to the anterior chest wall. he TTMPB, and thoracic fascial plane blocks, are increasingly being employed as part of enhanced recovery after surgery (ERAS) protocols for cardiothoracic procedures. They have been shown to significantly reduce both the time to extubation and the incidence of acute and chronic perioperative pain
224074507|NCT03589378|PROCEDURE|PEAF|PEAF that is therapeutic plasma exchange (TPE) with 20ml/kg/d Fresh frozen plasma (Blood pump: 120ml/min, replacement pump 20ml/kg/min, dialysate pump 0ml/kg/min, waste pump 20ml/kg/min, plasma exchange 1 hour) plus plasma filtration adsorption (PFA ) with acute multitherapeutic system( AMPLYA™ ITALY) ≥30ml/min lasting 15 hours plus High volume plasma diafiltration (HVPDF) with CUREFLO™(ACF180W Japan) or Ultraflux® (AV1000S Fresenius Germany) Blood pump: 120ml/min, replacement fluid pump 2000ml/h, dialysate pump 2000ml/h, waste pump 4000ml/h,and with high-volume plasma diafiltration for 15 hours）in the first 3 days. the treatment after three days later is same as the control group.
224309492|NCT04260555|DRUG|DW1601|Total 7 days of treatment and The daily dose is tid. (DW1601 20ml + Placebo of DW16011 20ml + Placebo of DW16012 9ml)
224309493|NCT04260555|DRUG|DW16011|Total 7 days of treatment and The daily dose is tid. (Placebo of DW1601 20ml + DW16011 20ml + Placebo of DW16012 9ml)
224309494|NCT04260555|DRUG|DW16012|Total 7 days of treatment and The daily dose is tid. (Placebo of DW1601 20ml + Placebo of DW16011 20ml + DW16012 9ml)
224309495|NCT05233852|OTHER|"Do not do recommendation"|A drug prescription or procedure included in 'do not do' recommendations
223591244|NCT02782767|OTHER|Epidural infusion|Epidural catheter will be placed in the level T7-T9 , and local anaesthetic infusion will be given
223591245|NCT00705887|BEHAVIORAL|Brief Motivational Enhancement Intervention|The motivational enhancement intervention lasted 5-8 minutes and consisted of gaining the client's permission to address the topic of skin cancer prevention, exchanging information through the elicit-provide-elicit strategy of information exchange, and summarization/ conclusion based on verbal and nonverbal cues from the participant.
223591246|NCT00787501|DRUG|SSRI|SSRI: 25 patients will receive 14 weeks of an FDA approved selective serotonin reuptake inhibitor (SSRI), administered under the supervision of a staff psychiatrist. After an initial 30-45 minute session patients will be seen for 15-30 minute sessions for 16-20 sessions over 14 weeks. Medication will begin with 10mg escitalopram daily (or its equivalent), increased to 30 mg/day (or its equivalent) by week 6 if pt has not achieved a minimum level of response (i.e., CGI \< 2) and tolerability is adequate. Nonresponse at week 10 (CGI \< 2) will be cause for medication switch or augmentation.
223591247|NCT00787501|BEHAVIORAL|CBT|Cognitive Behavior Therapy: 40 patients will receive 16- 20 60 minute sessions of procedurally determined Cognitive Therapy (Beck, 1979) over 14 weeks. Patients will begin with 2 sessions per week which may be reduced to once per week in the latter part of the study period if the patient is responding to the therapy. Cognitive Therapy is designed to teach skills that help to reduce depressive severity. Each session will be videotaped and will include homework to be completed and brought to the following session.
223591248|NCT03589755|BEHAVIORAL|Mindfulness meditation|The intervention consist of a weekly session of mindfulness meditation provided by a clinical psychologist trained in this area. She will provide weekly session to a group of 10 patients at a time for a total of 8 weeks. Upon completing the course, the other 10 people will start
223591249|NCT04650425|BEHAVIORAL|Cognitive tasks|Patients will perform the coffee-tea task and the virtual T-maze task, both in the acute and chronic phase after stroke.
223591250|NCT03066167|OTHER|Validation of different dysphagia scores|
223591251|NCT01836393|DRUG|Plavina cream|The essential plai cream has anti-inflammatory and antimicrobial effects (Wasuwat1989, Giwanon 2000, Pithayanukul 2007, and Tripathi 2008). Active chemicals of plai cream are composed of sabinene, alpha and gamma tepinenes, terpinen 4-ol and (E)-1-(3,4-dimethoxyphenyl butadiene (DMPBD). The DMPBD has a property of anti-inflammatory activity(Ozaki 1991, Jeenapongsa 2003). Plavina® 40 mg in 100 gm (contains DMPBD of …%). This product was supplied in lacquered aluminum collapsible tube containing 100 gram cream packing.
223591252|NCT05117177|DRUG|Inupadenant|Oral administration
223591253|NCT05117177|DRUG|Inupadenant|Oral administration
223591254|NCT05117177|DRUG|Inupadenant|Oral administration
223591255|NCT01310829|BEHAVIORAL|Questionnaires|Questionnaires completed before and after viewing virtual reality scenes, taking about 30 minutes to complete.
223591256|NCT01310829|BEHAVIORAL|Physiological Measurements|Small sensors applied to skin will measure heart rate and sweat amounts while participants view a virtual reality scene.
223591257|NCT01310829|BEHAVIORAL|Virtual Reality Scene Viewing|Prototype virtual reality application that demonstrates a provider-patient communication scenario commonly encountered in genetic counseling for hereditary cancers.
223591258|NCT01873651|DEVICE|Implantation of a Delta III Prosthesis|Implantation of a Delta III Prosthesis
223591259|NCT01112111|DRUG|mode of gonadotropin administration|Low dose step-up administration Step down administration sequential administration
223591260|NCT04453176|OTHER|Patient Satisfaction|Patient satisfaction evaluated with EVAN G questionnaire
223591261|NCT02943616|DEVICE|Absorb BVS|"Commercially approved Absorb GT1 BVS, herein referred to as Absorb.~* Scaffold diameters: 2.5, 3.0, and 3.5 mm~* Scaffold lengths: 8, 12, 18, 23 and 28 mm~Absorb is a temporary scaffold that will fully resorb over time and is indicated for improving coronary luminal diameter in patients with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm."
223591262|NCT00554762|DRUG|GW842166X|Administer
223591263|NCT04375176|DIAGNOSTIC_TEST|Study of immune-mediated mechanisms in patients tested positive for SARS-CoV-2|Phenotypic and functional analysis of monocytes and NK cells
223591264|NCT02098889|DRUG|hyoscine-N-butyl bromide(HBB)|A single dose intravenously(IV) 20 mg (20ml) hyoscine-N-butyl bromide(HBB) versus placebo ( a single dose of 20ml IV NaCl) on the active phase of labor
223591265|NCT02098889|DRUG|Saline|placebo ( a single dose of 20ml IV NaCl) versus A single dose intravenously(IV) 20 mg (20ml) hyoscine-N-butyl bromide(HBB)on the active phase of labor
223591266|NCT05345028|DIETARY_SUPPLEMENT|lecithin-based delivery form of Boswellia serrata|250 mg for 5 days
223591267|NCT05345028|COMBINATION_PRODUCT|Placebo|250 mg for 5 days
223591268|NCT04117698|DRUG|Antitubercular treatment (RIFATER ©)|"Treatment of ocular inflammation by antitubercular treatment  add-on of local corticosteroid therapy comprising:~* RIFATER © (Isoniazid + Rifampicin + Pyrazinamide) + Ethambutol (13.5-20 mg / kg / day) for 2 months then RIFINAH © (Isoniazid + Rifampicin) for 4 months~* associated with a treatment similar to the control group."
223591269|NCT04117698|DRUG|Ethambutol|Ethambutol
223591270|NCT04117698|DRUG|RIFINAH ©|RIFINAH ©
223591271|NCT02759991|DRUG|Hecolin|0.6ml Hecolin vaccine im. on day 0, 1 month and 6 months.
223591272|NCT02759991|DRUG|Hepa-B|1ml Hepa-B vaccine im. on day 0, 1 month and 6 months.
223591273|NCT06098664|DIAGNOSTIC_TEST|AI-enabled ECG score for Atrial Fibrillation (DNN score)|"A 12-lead ECG, performed within 24 hours before the Pulmonary Vein Isolation (PVI) procedure, will be used to calculate the DNN score.~(DNN score details: https://doi.org/10.1016/j.jacep.2023.04.008)"
223591274|NCT06098664|DIAGNOSTIC_TEST|Atrial voltage map in sinus rhythm|An atrial voltage map will be constructed prior to the PVI procedure.
223591275|NCT02672592|DRUG|Anakinra|Anakinra 100mg s.c. bid
223591276|NCT02672592|DRUG|Sodium Chloride 0.9%|Sodium Chloride 0.9% s.c. bid
224074508|NCT00209339|DEVICE|Percutaneous mitral valve repair (MitraClip Implant)|Phase I evaluation of the safety and effectiveness of an endovascular approach to the repair of mitral valve regurgitation using the Evalve MitraClip Cardiovascular Valve Repair System.
224189858|NCT04746495|DRUG|Placebo|Participants will go through a 2-week wash-in period. During the wash-in period, the participant will be asked not to take their usual antihypertensive medications for their mild hypertension. After the 2-week wash-in period, the participants will begin a 4-week treatment period and will take a placebo once a day for 4 weeks. After the 4 weeks, the participants will have a 2-week wash-out period where they will be off the study treatment. After the 2-week wash-out period, the participants will begin the Eplerenone treatment for another 4 weeks.
223591277|NCT03302286|DIAGNOSTIC_TEST|Heart-lung machine primining solution which includes Mannitol|This study group will undergo cardiopulmonary bypass with priming solution of Ringer's acetate 1000 ml, Mannitol 200 ml, Heparin 10000 units and 80 mmol sodium.
224189859|NCT04746495|DRUG|Eplerenone 50mg|Participants will go through a 2-week wash-in period. During the wash-in period, the participant will be asked not to take their usual antihypertensive medications for their mild hypertension. After the 2-week wash-in period, the participants will begin a 4-week treatment period of Eplerenone for 4 weeks. After the 4 weeks, the participants will have a 2-week wash-out period where they will be off the study treatment. After the 2-week wash-out period, the participants will then begin the Placebo treatment for another 4 weeks.
224189860|NCT03647995|DIETARY_SUPPLEMENT|Probiolife by Green Made (Pharma M)|A box containing 30 capsules of a dietary supplement containing 25 Bn CFU (detailed in previous sections)
224189861|NCT03647995|OTHER|Placebo|A box containing 30 capsules containing an inactive substance with 0 Bn CFU.
224189862|NCT04582968|OTHER|Pyrotinib Plus Capecitabine combined with brain radiotherapy|Drug combined with radiation
223499706|NCT04621760|BEHAVIORAL|HIV Prevention Decision Support Tool (DST)|The tool is founded on principles of decision-science and developed in a systematic manner including pilot testing. The tool will present HIV prevention information through a tablet in the clinical setting. The decision support tool will address barriers to PrEP delivery, including 1) limited client knowledge about PrEP, 2) limited time to educate patients in busy clinics, 3) women's lack of knowledge of their own HIV vulnerability, and 4) hesitancy of women to initiate discussions about PrEP with providers due to judgmental attitudes and stigma. Also, the tool emphasizes the highly variable and individual nature of baseline risk.
224189863|NCT02900508|OTHER|Exergaming training|
224189864|NCT02900508|OTHER|Physical therapy intervention|
224189865|NCT04303741|DRUG|Camrelizumab|Camrelizumab 200mg (3mg/kg for patient whose weight is below 50kg) will be administered as an intravenous infusion over 30 minutes every three weeks until unacceptable toxic effects or disease progression or other termination criteria appeared. Patients received up to two years of treatment.
224189866|NCT04303741|DRUG|Apatinib|Apatinib 250mg will be administered daily until unacceptable toxic effects or disease progression or other termination criteria appeared. Patients received up to two years of treatment.
224189867|NCT04303741|DRUG|Eribulin|Eribulin Mesylate will be administered as a 1.4 mg/m2 intravenous (IV) injection over 2 to 5 minutes on day 1 and day 8 of each 21-day cycle until unacceptable toxic effects or disease progression or other termination criteria appeared. Patients received up to two years of treatment.
223499707|NCT04621760|BEHAVIORAL|Standard Counseling|Participants in this arm will receive usual care.
223499708|NCT05234333|DRUG|SARS-CoV-2 vaccine|SARS-CoV-2 vaccination
223499709|NCT01953276|DEVICE|Serial Electrocardiograms|All participants will have serial electrocardiograms performed.
223499710|NCT04664114|BEHAVIORAL|Virtual Reality|Ultrasound images of the fetus in the 28th week of pregnancy of the women in the intervention group were recorded. These images were shown to the woman through virtual reality glasses during the labor. Routine practices in the hospital were made to the women in the control group. VAS (Visual Analog Scale) was applied to women in both groups when cervical dilatation was 4 and 9 cm. Approximately two hours after giving birth (to allow mothers to breastfeed their babies and to stabilize the mother's vital signs), the Women's Perception of Supportive Care at Birth Scale (POBS) and Perinatal Anxiety Screening Scale (PASS) were administered.
223499711|NCT06322303|OTHER|Placebo (CBD 0%)|Participants are required to vaporize placebo at 0% CBD concentration
223499712|NCT06322303|OTHER|CBD 15%|Participants are required to vaporize CBD at a concentration of 15%.
223499713|NCT06322303|OTHER|CBD 30%|Participants are required to vaporize CBD at a concentration of 30%.
223499714|NCT02421211|DRUG|Simeprevir (SMV)|Participants will receive 150 milligram (mg) of SMV (Treatment A) once daily in Panel 1 and Panel 2.
223499715|NCT02421211|DRUG|Ledipasvir (LDV)|Participants will receive 90 mg of LDV once daily as FDC tablet with SOF (Treatment B) in Panel 1 and Panel 2.
223499716|NCT02421211|DRUG|Sofosbuvir (SOF)|Participants will receive 400 mg of SOF alone (Treatment C) in Panel 1 and as FDC tablet with LDV (Treatment B) once daily in Panel 2.
223499717|NCT05796817|DEVICE|Ventilator modification|The ventilator modification will be fitted to a ResMed Lumis 150, Breas® Nippy 4+ or Vivo 1, 2 or 3 ventilator. The participants oxygen level will be measured with and without the modification in place at their baseline ventilation, and with 1, 2 and 3 litres oxygen extra to their baseline. the researcher will then leave the modification on and slowly reduce the oxygen going into the ventilator, maintaining the participants SP02 at an acceptable level (\>95%)
223499718|NCT04576546|DIETARY_SUPPLEMENT|D-chiro-inositol|Supplementation of D-chiro-inositol (1000 mg/die), starting at least 4 weeks before rFSH administration
223499719|NCT04576546|DIETARY_SUPPLEMENT|Myo-inositol|Supplementation of myo-inositol (4 g/die), starting at least 4 weeks before rFSH administration
223499720|NCT04602000|BIOLOGICAL|CT-P59|CT-P59 (40 mg/kg) by IV infusion administered over 90 minutes, once (Part 1)
223591278|NCT03302286|DIAGNOSTIC_TEST|Heart-lung machine primining solution which does not include Mannitol|This study group will undergo cardiopulmonary bypass with priming solution of Ringer's acetate 1200 ml, Heparin 10000 units and 80 mmol sodium.
223591279|NCT01608451|DRUG|Cholecalciferol|Inj Arachitol 300,000 I.U/ml IM before each cycle of NACT (for total 4 cycles) and one injection before surgery.
224309496|NCT06136000|OTHER|Sacral erectör spinae plane block|Group S will be placed on their side. Asepsis is fifth in the transverse plane under antisepsis standards. high-frequency linear USG probe into the spinous process . The USG probe will be shifted caudally to visualize the first and second median sacral crest. The USG probe is then placed on the second medial It will be placed 3-4 cm lateral to the sacral apex and the mid-sacral apex will be imaged. On the USG screen, from top to bottom, erector spinae muscle, multifidus muscle and sacral intermediate The crest will be displayed. 0.25% bupivacaine will be administered in a total volume of 0.5ml/kg (maximum 20 cc ) by applying negative aspiration with the in-plane technique with a 50 mm Stimuplex A needle.
223499721|NCT04602000|BIOLOGICAL|CT-P59|CT-P59 (80 mg/kg) by IV infusion administered over 90 minutes, once (Part 1)
223499722|NCT04602000|BIOLOGICAL|Placebo|Placebo (80 mg/kg) by IV infusion administered over 90 minutes, once (Part 1)
223499723|NCT04602000|BIOLOGICAL|CT-P59|CT-P59 (40 mg/kg) by IV infusion administered over 60 minutes, once (Part 2)
223499724|NCT04602000|BIOLOGICAL|Placebo|Placebo (40 mg/kg) by IV infusion administered over 60 minutes, once (Part 2)
223499725|NCT03729440|BEHAVIORAL|development of complications or not|assessment of development of complications
223499726|NCT06118320|DRUG|Potassium sodium hydrogen citrate|"Medication: Potassium sodium hydrogen citrate granules (MADAUS GMBH, Germany, 2.5g/package).~Method: Preprandial urine pH was monitored to maintain an effective range of 6.2 to 6.8. One package should be taken after breakfast, one after lunch, and two after dinner. If the pH falls below 6.2, a half-package dose should be added; if it exceeds 6.8, a half-package dose should be reduced accordingly. Oral medication will be administered for a duration of three months.~Medication requirements: Abstain from alcohol and smoking during treatment period and avoid using any probiotics or drugs that lower uric acid levels."
223499727|NCT02967887|DRUG|cisplatin and 5-fluorouracil|Hepatic arterial infusion of Cisplatin (60mg/m2 for 2h on day 2) and 5-fluorouracil (500mg/m2 for 5h on days 1-3) through implanted port system (chemoport)
223499728|NCT01324180|DRUG|Metformin|Will be dosed orally BID as per dose level of subject as defined in dose escalation schema. Both liquid and tablet forms are allowed and can be chosen based on convenience. Metformin will be continued throughout the cycle until Day 28 or until the patient is removed from study (e.g. to pursue new lines of therapy such as transplant), whichever occurs sooner.
223499729|NCT01324180|DRUG|Vincristine|1.5 mg/m\^2/dose IV push (maximum single dose 2 mg) on days 2, 9, 16 and 23
223499730|NCT01324180|DRUG|Dexamethasone|"* 10 mg/m\^2/day divided BID~* Take dexamethasone by mouth days 2-15"
223499731|NCT01324180|DRUG|PEG-asparaginase|"* 2500 IU's/m\^2/day~* Intramuscular injection (IM) or intravenous infusion per institutional standard on days 3, 9, 16 and 23~* If the patient develops an allergic reaction to PEG while being treated on this protocol, eliminate all future doses of PEG and substitute Erwinia if not intolerant of Erwinia and has no history of pancreatitis.~* Patients will receive Erwinase® 25,000 IU/m\^2 x 6 doses intramuscularly (IM) on a Monday/Wednesday/Friday schedule as a replacement for each scheduled dose of PEG-asparaginase on the original protocol."
223499732|NCT01324180|DRUG|Doxorubicin|60 mg/m\^2/day IV over 15 minutes on day 2
223499733|NCT01324180|DRUG|Intrathecal chemotherapy|"IT cytarabine given intrathecally to all patients on day 1 of each cycle. Dose defined by age. May be given with staging lumbar puncture before enrollment, but must be within 72 hours of starting therapy. If not done at study entry or before, may be done on Day 2 prior to doxorubicin administration.~* 30 mg for patients age 1-1.99~* 50 mg for patients age 2-2.99~* 70 mg for patients greater than 3 years of age IT methotrexate given Intrathecally to all patients who are CNS negative at study entry on day 16 at the dose defined by age."
223499734|NCT06091033|DIETARY_SUPPLEMENT|Fermented rice|1,000 mg of black rice (Oryza Sativa L.) extract fermented with Lactobacillus for 8 weeks
223499735|NCT06091033|DIETARY_SUPPLEMENT|placebo|1,000 mg of a placebo for 8 weeks
223499736|NCT01025050|PROCEDURE|Intrastromal Correction of Presbyopia|On all patients an intrastromal pattern consisting of concentric rings will be applied.
223499737|NCT00471354|DRUG|Atomoxetine|atomoxetine 0.5 mg/kg/day once a day (QD), by mouth (PO) starting dose titrated over 1 week to target dose 1.2 mg/kg/day QD, PO for 23 weeks.
223499738|NCT03522168|DRUG|Risperidone|Medications prescribed as standard of care for Schizophrenia, Bipolar mania/acute treatment of manic and mixed episodes associated with Bipolar I disorder, Tourette's disorder, persistent (chronic) motor or vocal tic disorder and Irritability associated with autistic disorder
223499739|NCT03522168|DRUG|Aripiprazole|Medications prescribed as standard of care for Schizophrenia, Bipolar mania/acute treatment of manic and mixed episodes associated with Bipolar I disorder, Tourette's disorder, persistent (chronic) motor or vocal tic disorder and Irritability associated with autistic disorder
223499740|NCT00265291|DRUG|fluoxetine or desipramine|fluoxetine 5-40 mg/day desipramine 50-150 mg/day
223499741|NCT04855812|DEVICE|MyoMo|To evaluate the usefulness of an upper extremity (UE) assistive device, called (MyoPro) in improving upper extremity activities in people with incomplete spinal cord injury (iSCI).
223499742|NCT04855812|OTHER|Myo-SB|To evaluate the usefulness of an upper extremity (UE) assistive device, called (MyoPro) in improving upper extremity activities in people with incomplete spinal cord injury (iSCI).
223499743|NCT04855812|OTHER|Control|To evaluate the usefulness of an upper extremity (UE) assistive device, called (MyoPro) in improving upper extremity activities in people with incomplete spinal cord injury (iSCI).
223499744|NCT02949453|BEHAVIORAL|Semi-directed interview performed by a social sciences researcher|"Two semi-directed interviews performed by social sciences researcher:~* first interview performed 6 weeks after the suicide attempt, in an suicide prevention unit, duration 1 to 1.5 hour~* second interview performed 3 month after the suicide attempt, in a suicide prevention unit, duration 1 to 1.5 hour"
223499745|NCT03050489|PROCEDURE|On-Pump CABG.|Standard On-Pump CABG.
223499746|NCT03050489|PROCEDURE|Off-Pump CABG.|Standard Off-Pump CABG.
223499747|NCT03050489|PROCEDURE|BH-CABG MSC.|Patients with coronary artery bypass graft (CABG) surgery performed on beating heart with mechanical support of circulation
223499748|NCT02328274|PROCEDURE|A Modified Technique for Laparoscopic Subtotal Hysterectomy|incorporation of two methods of vessels ligation and laparoscopic in situ morcellation
223499749|NCT02153827|OTHER|Eccentric Shoulder External Rotator Training|Eccentric training exercise for the external rotators, 3 sets of 15 daily.
223499750|NCT02153827|OTHER|General Shoulder exercise|general exercise consisting of active shoulder movements
224189868|NCT02983357|RADIATION|CT, X-Ray|2 anterior-posterior (AP) radiographs of the glenohumeral joint, one in internal rotation and the other in external rotation, along with axillary lateral films, will be completed of the affected operated shoulder. Also, a computed tomographic scan without contrast performed of same shoulder.
224189869|NCT02983357|OTHER|Physical assessment|Physically evaluate for shoulder function and pain using American Shoulder Elbow Score (ASES) Constant score and the Simple Shoulder Test to obtain specific shoulder functional, motion,and strength outcomes.
224189870|NCT02983357|OTHER|Questionnaire|Rand Short Form Health Survey (Rand SF-36) which is a patient completed quality of life measurement
224189871|NCT00584610|DEVICE|Levonorgestrel-containing IUD (Mirena®)|Levonorgestrel-containing intrauterine device insertion
224189872|NCT00584610|DEVICE|Copper-containing IUD (Paraguard®)|Copper-containing intrauterine device insertion
224189873|NCT06130618|OTHER|Ozone|After localizing the piriformis muscle and sciatic nerve with ultrasound guidance, 5 ml - 20 μg/mL ozone will be injected.
224189874|NCT06130618|DRUG|Lidocain|After localizing the piriformis muscle and sciatic nerve with ultrasound guidance, 5 ml - 2% lidocaine will be injected.
224189875|NCT00761735|BIOLOGICAL|Peginterferon alfa-2b|In the previous treatment protocol (P02538 Part 1), peginterferon alfa-2b was administered at a dose of 60 μg/m\^2 by subcutaneous injection weekly for up to 48 weeks. No treatment was administered on the current follow-up study (P02538 Part 2).
224189876|NCT00761735|DRUG|Ribavirin|In the previous treatment protocol (P02538 Part 1), ribavirin was administered at a dose of 15 mg/kg/day orally in two divided doses for up to 48 weeks. No treatment was administered on the current follow-up study (P02538 Part 2).
224189877|NCT03290131|DRUG|Arbaclofen|Arbaclofen Extended Release Tablet
224189878|NCT03290131|DRUG|Placebo|Placebo comparator
224189879|NCT03176576|BEHAVIORAL|Patient Navigator (PN)|Patient navigation (PN) is an intervention model designed to assist vulnerable patients in overcoming health system, personal and/or logistical barriers to care throughout the cancer care continuum. The strategic aims of PN are to reduce barriers and improve disease outcomes while also reducing distress and enhancing quality of life for the patient and family. Participants in the PN group will meet with a patient navigator.
224189880|NCT03176576|OTHER|Baseline Questionnaire|Complete a baseline questionnaire online or by meeting with a member of the study team. This questionnaire has items asking about the participant's health, distress levels, satisfaction with their care at Moffitt Cancer Center, and what support services they have used since their diagnosis. This questionnaire will take about 15 to 20 minutes of their time.
224189881|NCT03176576|OTHER|Follow-up Questionnaire|After participants complete the baseline questionnaire, they will be asked to complete a follow-up questionnaire approximately 6 weeks from when they completed the baseline questionnaire. The follow-up questionnaire will take about 15 to 20 minutes to complete.
224189882|NCT03176576|OTHER|Patient Navigator Satisfaction Survey|Evaluation of Patient Navigator intervention process.
224189883|NCT00465101|DEVICE|GreenLight HPS|Greenlight HPS laser system for treatment of BPH
224189884|NCT04959682|OTHER|Music Intervention|After rating levels of fatigue and relaxation, the professional health care musicians will play 30 minutes of patient-tailored, pleasant instrumental music with a combination of relaxing (on average 60-80 bpm) and lively, slightly more up-beat tempo to regulate arousal-levels
224189885|NCT00483574|BIOLOGICAL|Menactra®: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, IM at age 9 and 12 months
224189886|NCT00483574|BIOLOGICAL|Measles-mumps-rubella-varicella vaccine|0.5 mL, intramuscular at 12 months of age
224189887|NCT00483574|BIOLOGICAL|Routine paediatric vaccine - Pneumococcal conjugate (PCV)|0.5 mL, Intramuscular at age 12 months
224189888|NCT00483574|BIOLOGICAL|Routine paediatric vaccine - Hepatitis A|0.5 mL, Intramuscular at age 12 months
224205830|NCT06647693|BEHAVIORAL|Motor Synchrony Games (MSG)|"The motor synchrony games (MSG) intervention uses fun but progressively more challenging gross motor and imitation games to promote behavioral self-regulation. Primary activities include: songs and fingerplays, stop and go games, and imitation games. These games get progressively more challenging over time by varying signal/modality. For example, going from a verbal and gestural paired stop and go signal to only a gestural stop signal. A fidelity checklist is used to ensure the intervention is appropriately used with the following criteria (uses \>10 imitation trials, \>10 Stop \& Go games, \>3 trials/min on average with \>5 trials/min preferred, use of progressive challenge, opportunities for Child Choice, environmental arrangement, and therapeutic strategies such as modeling)."
223499751|NCT01158404|DRUG|LY900009 - Dose Escalation Phase (Part A)|"2 milligrams (mg), 4 mg, 8 mg, 15 mg, 30 mg, 45 mg and 60mg LY900009 administered orally 3 times per week (Monday, Wednesday, Friday) for 4 weeks of a 28-day cycle.~Participants experiencing clinical benefit may continue treatment unless discontinuation criteria are met."
223499752|NCT01158404|DRUG|LY900009 - Dose Confirmation Phase (Part B)|"30 mg LY900009 orally 3 times per week (Monday, Wednesday, Friday) for 4 weeks of a 28-day cycle.~Participants experiencing clinical benefit may continue treatment unless discontinuation criteria are met."
223499753|NCT03949231|DRUG|PD1/PDL1 inhibitor|Infusion of PD1/PDL1 inhibitor through peripheral vein or hepatic artery.
223499754|NCT04763408|DRUG|Lenvatinib|Oral capsules.
223499755|NCT04763408|DRUG|Sorafenib|Oral tablets.
223499756|NCT00326040|DEVICE|Glaucoma Surgery|
223499757|NCT03360487|RADIATION|Photobiomodulation in the sublingual region|In the group submitted to sublingual irradiation, disposable plastic wrap will cover the application pen for the purposes of hygiene, and irradiation will take 10 minutes.
223499758|NCT03360487|RADIATION|Photobiomodulation in the spinal cord|Transcutaneous irradiation of the spinal cord will be performed on segments corresponding to the nerve roots of the lumbosacral plexus (T12-S5) and cervicothoracic plexus (C5-T1-2). Twenty points will be irradiated for 30 seconds (total treatment time: 10 minutes).
223499759|NCT03360487|RADIATION|Photobiomodulation in the radial artery|Intravascular laser irradiation will be applied to the skin in the region of the radial artery with a specific bracelet of the DMC laser Therapy EC model.
223499760|NCT01123525|DRUG|Adenosine|1.2 mM adenosine instead of supranormal potassium in the cardioplegic solution
223499761|NCT02454582|DEVICE|Somanetics INVOS Cerebral Oxymeter 5100C|Non- invasive transcranial near infrared cerebral oxygenation with or without CPAP
223511926|NCT05792345|PROCEDURE|Control|Infiltration by surgeon
224189889|NCT04060901|BEHAVIORAL|CCSH Intervention for Teams|"CCSH Interventions for Teams will be a six session intervention. The groups meet once per week for 60 minutes for 4 weeks, coupled with 2 booster sessions over the following 2 months. Participants will receive the CCSH interventional approach, adapted for a group setting, which follows four stages: 1) Preparing the care responder; 2) Attuning to the Relationship; 3) Accessing Compassion, and 4) Entrusting the Careseeker.~The CCSH approach will be used to assess group dynamics, individual member sources of distress, as well as existing resources for resilience and compassion. Through the intervention, resources will then be identified and accessed in order to respond to team (and individual) sources of distress with greater resilience and increased compassion toward self and others. CCSH clinicians will utilize group process skills to encourage team communication about work-related challenges, enhance team cohesion, and enable interpersonal support among members of the team."
223499762|NCT03971526|OTHER|MRI images review|MR images were reviewed by one junior radiologist and one senior neuroradiologist, both blinded to clinical, therapeutic and follow-up data.
223591280|NCT01608451|DRUG|Inj. Progesterone|Injection Progesterone 500 mg deep IM before each cycle of NACT (for total 4 cycles) and one injection before surgery.
224074509|NCT02188030|OTHER|Group Exercise Program|The participants allocated into the GET Group will receive a general exercise training realized in group of workers. Each training session started with a five minute swarm-up by slowly moving the neck, upper back, shoulder, arms and hands through pain-free range of motion; followed by 30 minutes of stretching and strengthening exercises for neck, upper back, shoulder, arms and hands, performed in the standing posture, sitting or lying. For resistance exercise, will be adopted 3 sets of 10 repetitions with a load of 80% of 1 repetitions maximum. Dumbbells and elastic bands and will be used as accessories to perform the resistance exercises.
223499763|NCT05560321|OTHER|Sani24|Disinfectant
223499764|NCT05560321|OTHER|Routine Disinfection|Routine disinfection at the study hospital
223499765|NCT06049277|OTHER|Mulligan techniques with manual traction|group A will be treated with Mulligan techniques with manual traction.16 patients in group A will be treated with Mulligan Techniques SNAGS in sitting, standing and prone position by applying Antero cranial glide in the direction of treatment plane over the spinous or transverse process and Spinal mobilization with leg movement at 6 to 8 repetitions per sessions and spinal mobilization with leg movement will be performed in side lying, patient facing the physiotherapist while the leg movement may assisted by another person (Physiotherapist/assistant). Sustained transverse glide is given on the desired spinous process with 10 repetitions of offending movement in first session while 10 reps in each of 3 sets in further sessions.
223499766|NCT06049277|OTHER|McKenzie extension exercises with manual traction|group B will be treated McKenzie extension exercises with manual traction.16 patients in group B will be treated with McKenzie active EEP in prone position with repeated movements along with standard protocols. McKenzie Extension Exercises performed actively in prone position. Extension exercises performed in three stages, initially patient instructed to be just lift the neck and look on front at the eye level, then progressed next and weight bearing on the elbow by lifting up the shoulder and then moved on third and final steps in which complete trunk extension is performed and weight bearing is on the hands.
223499767|NCT03132259|DRUG|high dose dexmedethomidine|Dexmedethomidine continuous drip 0.5 mcg/kg/hr a
223499768|NCT03132259|DRUG|low dose dexmedethomidine|Dexmedethomidine continuous drip 0.2 mcg/kg/hr
223499769|NCT02143778|DEVICE|Methacetin Breath Test|13C labelled methacetin solution for breath test monitoring
223499770|NCT00738517|DEVICE|Immunoadsorption / Immunoglobulin substitution|Immunoadsorption with protein-A columns on five consecutive days with subsequent human polyclonal immunoglobulin G substitution after day 5 (0,5g /kg bodyweight)
223499771|NCT05476718|OTHER|Kinesio taping|Patients will be informed about the study on the first day of their hospitalization and the Introductory Information Form, Visual Analogue Scale, and Oswestry Disability Index will be filled in by the patients. 24 hours after the operation, 20 minutes of training will be given to the patient and their relatives on the use of a pedometer and home care, and the first tape will be applied. After discharge, the renewal of the bands will be carried out on the postoperative 1th- 5th-10th-15th days when the patients come to the hospital for post-op evaluation. The clinical recovery of the operation area will be done by the investigative physician. In the follow-ups, evaluations will be made with the Visual Analog Scale, Medication Tracking Form, Oswestry Disability Index,Functional Low Back Pain Scale, Kinesio Tracking Form, and Gait Tracking Form.
223499772|NCT05476718|OTHER|placebo taping|Patients will be informed about the study on the first day of their hospitalization and the Introductory Information Form, Visual Analogue Scale, and Oswestry Disability Index will be filled in by the patients. 24 hours after the operation, 20 minutes of training will be given to the patient and their relatives on the use of a pedometer and home care, and the first tape will be applied. After discharge, the renewal of the bands will be carried out on the postoperative 1th-5th-10th-15th days when the patients come to the hospital for post-op evaluation. The clinical recovery of the operation area will be done by the investigative physician. In the follow-ups, evaluations will be made with the Visual Analog Scale, Medication Tracking Form, Oswestry Disability Index,Functional Low Back Pain Scale, Kinesio Tracking Form, and Gait Tracking Form.
223499773|NCT00050427|DRUG|ET743|580 mcg/m2, 3-hour i.v. infusion, on Days 1, 8, and 15 every 28 days for up to approximately 52 weeks in the absence of disease progression. Dexamethasone, 10 mg i.v, will be administered 30 minutes prior to each trabectedin infusion.
223499774|NCT00050427|DRUG|ET743|1,300 mcg/m2, 3 hour i.v. infusion once every 21 days for up to approximately 52 weeks in the absence of disease progression. Dexamethasone, 10 mg i.v, will be administered 30 minutes prior to each trabectedin infusion.
223499775|NCT00848315|BEHAVIORAL|Cognitive Behavioral Intervention|The intervention emphasizes patients' ethnic preferences and traditions (e.g., adapting ethnic recipes to meet dietary goals) and the use of available community resources (e.g., available areas for exercise), and is delivered utilizing strategies and materials appropriate for low-literate/illiterate patients.
223499776|NCT05706402|DRUG|N-acetylcysteine|Patients will be randomized to receive oral N-acetylcysteine at 600 mg twice daily for 1 week. The randomization will be done via computer software with half of the patients randomized to receive NAC. Patients will also be given standard treatment for your COPD exacerbation and can continue the use of usual inhalers for COPD.
223499777|NCT05706402|DRUG|Placebo|Patients will be randomized to receive placebo for 1 week. The randomization will be done via computer software with half receive placebo. Patients will also be given standard treatment for your COPD exacerbation and can continue the use of usual inhalers for COPD.
223499778|NCT04938674|DEVICE|ultrasonic guidance|Standard process for blood collection using Ultrasonic Guided puncture
223499779|NCT03623490|OTHER|managment of oral therapy|Initial consultation with a trio oncologist / pharmacist / nurse
223499780|NCT02746731|OTHER|Cardiorespiratory and resistance training.|"A cardiorespiratory and resistance training program for at least 2 to 3 weeks will be conducted 3-times per week, of which two sessions will be supervised by a qualified person of the institute of physiotherapy and one session will be unsupervised and home-based.~Physiotherapy consists of one hour, moderate to intense interval training combined with muscle strength training."
223499781|NCT02746731|OTHER|Reference|No preoperative physical therapy training. Patients will be informed to remain physically active (as usual) until surgery.
223499782|NCT00625378|DRUG|Sorafenib (Nexavar, BAY43-9006)|At the same dose and schedule as in the participants' original clinical trials
223499783|NCT03270241|DEVICE|Phototherapy (NB-UVB) via the 3 Series PC & SP phototherapy cabinet|This is an investigator-initiated, single-blinded, ascending dose study of NB-UVB treatment for Vitiligo in adults of 3 treatments for one week. It is designed to measure the molecular changes and re-pigmentation in affected and normal skin of participants with Vitiligo and normal skin in healthy participants.
223499784|NCT05339061|DEVICE|Endovascular Treatment of Complex abdominal or Thorocoabdominal aneurysms (TAAA).|"Modification~* Deploy the graft on the sterile, surgical table~* Mark out on the graft the locations of the fenestrations on the graft adjusting as necessary~* Using handheld electrocautery, fashion the fenestration in the appropriate location on the moistened graft material in order to prevent inadvertent progression of the fenestration size~* If the fenestration is going to remain as such, then a snare is used to fashion the marker on the fenestration with 5-0 stitch~* If the fenestration is going to be made into a branch, then an appropriately sized, self-expanding stent is beveled and fashioned to be 15 mm long and sewn to the fenestration in addition to a snare with the 5-0 stitch~* Two orientation markers are placed at the proximal edge and distal edge of the graft consisting of portions of the snare sewn to the anterior portion of the graft in a J fashion with a 5-0 stitch"
223499785|NCT03391323|DEVICE|Medacta GMK Sphere® Medial-Pivot Knee Prosthesis|
223499786|NCT03391323|DEVICE|Medacta GMK PS Posterior Stabilized Knee Prosthesis|
223499787|NCT05787509|DRUG|Progesterone Sustained-release vaginal gel|the treatment time of vaginal progesterone
223499788|NCT02639559|DRUG|BL-8040|
223499789|NCT02639559|PROCEDURE|Leukapheresis|
223499790|NCT02639559|PROCEDURE|Hematopoietic cell transplant|
223499791|NCT03880565|DEVICE|Early Extracorporeal Membrane Oxygenation (ECMO) Facilitated Resuscitation|Early use of ECMO
223499792|NCT03880565|DEVICE|Standard Advanced Cardiac Life Support (ACLS) Resuscitation|Standard life support resuscitation
223499793|NCT01692756|DRUG|Kenalog or placebo|
223499794|NCT01692756|DRUG|Kenalog then Placebo|
223499795|NCT01692756|DRUG|Kenalog|
224074510|NCT02188030|OTHER|Individual Exercise Program|"The participants allocated into the IET Group will receive a individual and specific strength training with seven different exercises, based in training programme describe by Andersen et al.3 and Sundstrup et al4.~During the intervention period, the training intensity were progressively increased according to the principle of periodization and progressive overload5. Dumbbells and elastic bands and will be used as accessories to perform the resistance exercises. Experienced instructors supervised every other training session."
224074511|NCT05449600|DEVICE|Thermotape|Thermotape will be applied along the left and right forearm. One piece of tape, one inch wide by two inches long, will be applied to each arm. The location the tape, when applied, will be randomized. Altogether, two pieces of this particular tape will be applied, one to each forearm.
223499796|NCT01692756|DRUG|Placebo|
223499797|NCT02969018|DRUG|PF-06700841|
223499798|NCT02969018|OTHER|Placebo|
223499799|NCT02292251|BEHAVIORAL|Device-assisted therapy|
223499800|NCT02292251|BEHAVIORAL|Therapy-based occupational therapy|
223499801|NCT01723605|PROCEDURE|insitu repair|closure of the uterine incision while the uterus initu
223499802|NCT01723605|PROCEDURE|exteriorisation of the uterus|uterine closure while the uterus is exteriorised
223499803|NCT01731496|OTHER|Telephone reminder|One week prior to when a child is due for either their 2nd or 3rd HPV vaccine, their parent will receive a telephone reminder to call to make an appointment to receive their next dose. A total of 3 reminders will be sent.
223499804|NCT01731496|OTHER|Text Message reminder|One week prior to when a child is due for either their 2nd or 3rd HPV vaccine, their parent will receive a text message reminder to call to make an appointment to receive their next dose. A total of 3 reminders will be sent.
223499805|NCT01616927|DRUG|Lanreotide|Lanreotide will be administered once every 4 weeks as a subcutaneous injection
223499806|NCT04664309|OTHER|No intervention|No intervention
223499807|NCT01381640|DRUG|Marketed paracetamol|marketed formulation
223499808|NCT01381640|DRUG|Experimental paracetamol formulation|Experimental formulation
223499809|NCT02217033|OTHER|'R' (Electro-kinetically altered beverage)|
223499810|NCT02217033|OTHER|Placebo (water)|
223499811|NCT06095531|DEVICE|Tetranite for Cranial Flap Fixation (TN-CFF)|Bioresorbable bone adhesive for cranial flap fixation following a craniotomy.
223499812|NCT02334189|BEHAVIORAL|Letter|Patients receive an information letter following an avoidable visit to the Emergency Department.
223511927|NCT03728231|OTHER|Complete blood count|taking blood sample from venous blood
223511928|NCT02669641|DIETARY_SUPPLEMENT|Combination Silimarin, Phyllanthus niruri and Choline|Combination of one capsule: Phyllanthus niruri (225 mg), Silybum marianum (150 mg), Choline (60 mg) The dose: 3 capsules per day.
223511929|NCT04403126|OTHER|forgiveness education intervention|The forgiveness education intervention primarily teaches the concept of forgiveness through stories. We chose the kind of stories that should appeal to children ages 10 through 12. Each lesson is planned according to the following procedure: story-telling/movie-watching, discussion, and in-class activities.
223511930|NCT02920047|DRUG|Fimasartan/Amlodipine|Treatment B
224189890|NCT04044404|DIAGNOSTIC_TEST|Ultrasound Integrated Precision Diagnosis Technology(ultrasound elastography)|Compare the ultrasound Integrated Precision Diagnosis Technology(ultrasound elastography) with the diagnostic gold standard of kidney disease---kidney biopsy
224189891|NCT05573425|DRUG|Tazarotene gel 0.1%|Tazarotene gel 0.1% applied daily on Acne Scars.
224189892|NCT05573425|DEVICE|Microneedling|Microneedling via dermaroller device performed on Acne Scars monthly.
224189893|NCT04804579|BEHAVIORAL|Fall Prevention Intervention|The intervention will aim to reduce fall risk through weekly virtual group meetings and at-home exercise assignments to address physical and environmental factors that may put participants at a higher risk of experiencing a fall.
223499813|NCT06229834|PROCEDURE|Chiropractic Care|The chiropractic care protocol can be personalized to the patient's clinical needs and follows the scope of chiropractic care practice in the Commonwealth of Massachusetts and the State of Connecticut. Components of the chiropractic intervention include: posture correction / spinal stabilization exercises; soft tissue relaxation techniques; spinal manipulation (i.e. chiropractic adjustment) / mobilization; breathing and relaxation techniques; stretches, self-care; ergonomic modifications; bracing and supports.
223499814|NCT06229834|BEHAVIORAL|Headache Health Education|"Participants randomized to the HHE arm will receive 14 interactive 15-minute education sessions delivered via video conference.~To partially control for attention and expectation associated with chiropractic care, participants randomized to the control group will receive a modified version of a headache education intervention we employed in our pilot study. Participants randomized to HHE will receive 14 interactive 15-minute education sessions delivered via VA or MGB Teams. Material to be covered will focus on pre-defined migraine-specific topics, compared with the control for our pilot study, in addition to greater contact time, HHE will be delivered in a more interactive manner utilizing active learning principles known to support adult learning. We will also utilize publicly available short videos (e.g., from the American Headache Society) followed by scripted discussions with the participant. Example topics include the physiology of migraine or the contribution of life."
223499815|NCT05553912|BEHAVIORAL|QBSafe|an intervention comprised of (a) a set of conversation cards (QBSafe ASK) designed to enable patients to identify aspects of life with diabetes important to them and to share them with their clinician to obtain their input; and (b) materials that help clinicians respond to patient concerns.
223499816|NCT03521596|OTHER|MRD and clonal evolution|Patient evaluation at the time of diagnosis and during the disease course using highly sensitive techniques
223499817|NCT03361345|DRUG|Tranexamic Acid|Topical tranexamic acid in cream form applied to dark spots on right side of face.
223499818|NCT03361345|DRUG|Vehicle|The Vehicle is going to be a cream without any active medication that will be applied as a control substance for the topical tranexamic acid cream, and will be applied to the contralateral side of the face.
223499819|NCT01857518|OTHER|-Diagnostic, clinical and psycho-behavioral assessments -Neuroimaging: T1-MRI, DTI-MRI, fMRI|"* Visit V1: Diagnostic and clinical assessments~* Visit V2: psycho-behavioral assessment and neuroimaging~* Visit V3: Diagnostic and clinical assessments~* Visit V4: psycho-behavioral assessment and neuroimaging"
223499820|NCT04655872|DRUG|[14C]TPN171H|A single 10 mg oral dose of \[14C\]TPN171H containing approximately 100 microcurie of \[14C\]-TPN171H.
223499821|NCT01017497|RADIATION|Stereotactic Radiosurgery|PTV Diameter \< 2.0 cm receives 24 Gy; PTV Diameter 2.0-3.0 cm receives 18 Gy; PTV Diameter 3.1-4.0 cm receives 15 Gy;
223499822|NCT00471120|OTHER|P2x7 assay|compare P2X7 assay to biopsy
223499823|NCT05606016|BEHAVIORAL|Facilitated Self-Sampling Intervention (FSSI)|CHWs will consent and enroll participants to the FSSI from the randomized PBGs. FSSI will consist of Community Health Worker (CHW) delivered education intervention about COVID-19 testing at a home visit. In addition, the participant will receive a batch of 4 rapid antigen tests which can be shared with people in the household or other close contacts if needed. The CHWs will provide low-literacy instructions for administering the tests, including print and video. The CHWs will also provide guidance if they tested positive (e.g. quarantine, notify contacts, wearing a mask). The CHWs will also be available by phone to the participants for any follow-up questions. CHW will follow-up via text and phone with the participants during the two months post intervention. In addition to the intervention, the participants will be asked to complete the pre and post test surveys. Post surveys will be administered online or over the phone two months after the initial intervention.
223591281|NCT06949969|DEVICE|OSA LLLT treatment device|The Alesis OSA-1 is a LLLT that uses 635nm wavelength to stimulate the mitochondria to open cell spaces and allow oils, lipids, and fluids to drain into the body systems.
223591282|NCT06949969|DEVICE|Sham Comparator|A modified device utilizing a pigtail connector to bypass active treatment while allowing the cooling fans to operate for the treatment period, giving the appearance of treatment with invisible light.
224189894|NCT06055452|DRUG|Empagliflozin 10 MG|Each participant in the empagliflozin treatment group takes a daily dose of 10mg.
224189895|NCT06055452|DRUG|Placebo|Each participant in the placebo group takes matching placebo.
224189896|NCT03099096|DRUG|Mepolizumab|It is a clear to opalescent, colorless to pale yellow sterile solution for SC injection, supplied in a single-use, prefilled syringe containing 100 mg/mL mepolizumab with sodium phosphate, citric acid, sucrose EDTA and polysorbate 80 within an autoinjector.
224189897|NCT03788317|DRUG|Botulinum toxin type A|Injections to hypertonic muscles
224189898|NCT04290871|DRUG|Nitric Oxide Gas|Inspired NO/N2 will be delivered at 80 parts per million (ppm) in the first 48 hours of enrollment (within 48 hours after initiation of mechanical ventilation). Weaning from NO will start after 48-h consecutive NO inhalation. The physicians will follow their own institutional weaning protocols.
224189899|NCT04290871|OTHER|The delivery system will be set up anyway without study gas administration|The delivery system will be set up anyway without study gas administration
224205831|NCT02609932|DRUG|Administration of drug (Interferon-gamma 1-b) subcutaneously|SD = group who has received a single dose of IFN-gamma (10, 25, 50, and 100 mcg/m2) given once with subsequent analysis of effects (serum IL-10, Neuropterin, and IFN levels as well as neutrophil Nox2 activity and gene expression by Affimetrics Chip analysis). One month is allowed between doses. SS = administration of four doses (50 mcg/m2) of IFN-gamma given on Monday, Wednesday Friday schedule with neutrophil or monocyte function studies performed before the first and after the fourth dose to determine steady state effects.
224205832|NCT00208000|DRUG|Marine active|
223499824|NCT05606016|BEHAVIORAL|Testing Navigation Intervention (TNI).|CHWs will consent and enroll participants to the TNI from the randomized PBGs. The TNI will consist of CHW-led intervention at a home visit where they will provide low health literacy materials about how and when to conduct a COVID 19 test (including antigen and PCR) using a decision tree model and provide navigation to nearby PCR testing sites, locations to purchase antigen tests and support in accessing federal government antigen tests if not already obtained by the participant. In addition to the intervention, the participants will be asked to complete the pre and post-test surveys. Post surveys will be administered online or over the phone two months after the initial intervention.
223591283|NCT02033239|DRUG|Faster-acting insulin aspart|Subjects will receive different dose levels of faster acting insulin aspart and NovoRapid®. Single dose of trial products will be administered subcutaneously (s.c. under the skin).
223591284|NCT02033239|DRUG|insulin aspart|Subjects will receive different dose levels of faster acting insulin aspart and NovoRapid®. Single dose of trial products will be administered subcutaneously (s.c. under the skin).
223591285|NCT03475329|OTHER|adenotonsillectomy|adenoidectomy with bilateral tonsillectomy versus adenoidectomy with unilateral complete tonsillectomy
223499825|NCT05606016|BEHAVIORAL|Control|Participants in the Control arm will receive CDC-designed COVID-19 testing brochures, and pre and post surveys only.
223499826|NCT04088955|OTHER|DigiMeds|Digitized Capecitabine
223499827|NCT02518269|PROCEDURE|Hip Arthroplasty|Hip Arthroplasty comparing 3 different bearings.
223499828|NCT04790201|BEHAVIORAL|Friendship Bench Delivered by Professional Counselor|Participants randomized to this arm will receive the Friendship Bench protocol delivered by a professional counselor.
223499829|NCT04790201|BEHAVIORAL|Friendship Bench Delivered by Lay Counselor|Participants randomized to this arm will receive the Friendship Bench protocol delivered by a trained lay counselor.
223499830|NCT04790201|BEHAVIORAL|Enhanced Usual Care|Enhanced usual care (EUC) will include general training of the HIV providers and clinics about CMD identification and management, and feedback to the HIV provider of the status of their enrolled patient to allow follow-up per the clinic's standard care. Information will be collected in follow-up interviews to characterize the care that patients receive. These activities will occur in all three arms, but they are the only activities in the EUC arm.
223499831|NCT02320292|OTHER|Quality-of-Life Assessment|Ancillary studies
223499832|NCT02320292|BIOLOGICAL|Rituximab|Given IV
223499833|NCT02320292|RADIATION|Yttrium Y-90 Ibritumomab Tiuxetan|Given IV
223499834|NCT02650557|PROCEDURE|angiography|angiography or arteriography is a medical imaging technique used to visualize the inside, or lumen, of blood vessels and organs of the body, with particular interest in the arteries, veins, and the heart chambers. This is traditionally done by injecting a radio-opaque contrast agent into the blood vessel and imaging using X-ray based techniques such as fluoroscopy.
223499835|NCT05762679|DIAGNOSTIC_TEST|Imaging|Phase 1 is an imaging biomarker study.
223499836|NCT06510582|DRUG|Bevacizumab 2 mg/kg|Single 2mg/kg dose of bevacizumab to treat unilateral cSDH
223499837|NCT06510582|DRUG|Bevacizumab 4 mg/kg|Two 2mg/kg doses (cumulatively 4mg/kg) of bevacizumab to treat bilateral cSDH
223499838|NCT02842099|DRUG|TA or TAC|Taxol, Epirubincin, with or without Cyclophosphamide
223499839|NCT02842099|DRUG|X|Capecitabine
223499840|NCT05621473|DEVICE|PICC|Tunnel PICC puncture technology is a perfect combination of ultrasound-guided puncture, ECG lead technology, PICC and subcutaneous tunnel. The valve conduction PICC is equipped with an integrated ECG lead Doppler ultrasound machine. Before the catheter is placed, in the yellow area, in the ultrasound mode, evaluate the blood vessel condition, measure the blood flow velocity, and correctly select the puncture site. When the catheter is pushed close to the superior vena cava, the electrocardiograph mode is switched to complete the precise positioning of the catheter according to the principle of ECG positioning technology. A subcutaneous tunnel was prepared in the green area, and the PICC at the puncture site in the yellow area was introduced to the green area and carefully bandaged. Whole-process integrated operation, simple and efficient operation.
223499841|NCT00144885|BEHAVIORAL|Modification of therapy|Modification of the surgery date if adapted, modification of the antibiotics if adapted, based on RMI results
223499842|NCT04542564|DEVICE|telemedicine|a mobile app and telemedicine platform to confirm good blood pressure control and may save doctor face-to-face consultation
223499843|NCT04542564|OTHER|usual care|These patients have unrestricted access to healthcare resources such as general outpatient clinics and emergency departments
224074512|NCT05449600|DEVICE|Tegaderm|Tegaderm™will be applied along the left and right forearm. One piece of tape, one inch wide by two inches long, will be applied to each arm. The location the tape, when applied, will be randomized. Altogether, two pieces of this particular tape will be applied, one to each forearm.
223591286|NCT01608373|DRUG|Intravenous lidocaine injection|Patients in Group I (intravenous lidocaine injection group) received an intravenous bolus injection of 1.5 mg/kg lidocaine followed by a continuous lidocaine infusion of 2 mg/kg/hr
224074513|NCT05449600|DEVICE|Kind|Thermotape will be applied along the left and right forearm. One piece of tape, one inch wide by two inches long, will be applied to each arm. The location the tape, when applied, will be randomized. Altogether, two pieces of this particular tape will be applied, one to each forearm.
224074514|NCT01587079|DRUG|PT003|PT003 MDI administered as two puffs BID for 7 days
224074515|NCT01587079|DRUG|PT001|PT001 MDI administered as two puffs BID for 7 days
224074516|NCT01587079|DRUG|PT005|PT005 MDI administered as two puffs BID for 7 days
224074517|NCT01587079|DRUG|Tiotropium inhalation powder|Taken as 1 capsule containing 18 µg of Tiotropium via the Handihaler DPI for 7 days
224074518|NCT02796378|DRUG|Training+Simvastatin+Q10-placebo|8 weeks of exercise training on a bycycle ergometer 3 times/week combined with Simvastatin 40 mg/day and Q10-placebo.
224074519|NCT02796378|DRUG|Training+Simvastatin-placebo+Q10-placebo|8 weeks of exercise training on a bycycle ergometer 3 times/week combined with Simvastatin-placebo and Q10-placebo.
224074520|NCT02796378|DRUG|Training+Simvastatin+Q10|8 weeks of exercise training on a bycycle ergometer 3 times/week combined with Simvastatin 40 mg/day and Q10 400 mg/day.
224074521|NCT01654510|BEHAVIORAL|Cognitive Behavioral Therapy Group|This is a cognitive behavioral therapy group designed for homeless, unemployed people utelizing vocational rehabilitation services. The group is administered on a bi-weekly basis for four weeks, totalling eight sessions.
224074522|NCT01654510|OTHER|Vocational Services as Usual|
223499844|NCT05745298|DEVICE|Xcite Clinical Station|The abdominal functional electrical stimulation (AFES) will be conducted using the Xcite system. This is a battery-powered stimulator with up to 12 channels of cyclical stimulation. It is a task-specific modality to enhance mass practice during neurological re-education. The electrical stimulation will be applied to the abdominal and back muscles. In addition, participants will receive two specific respiratory muscle training exercises performed 3 days per week.
223499845|NCT03670628|DEVICE|Shockwave therapy|Each therapy session, lasting about 20 minutes, will deliver 720 shockwave therapy applied to the penis and to the left and right crus (shaft near the base)
223499846|NCT03670628|OTHER|Sham shockwave therapy|Each therapy session, lasting about 20 minutes, will deliver sham shockwave therapy applied to the penis and to the left and right crus (shaft near the base)
223499847|NCT02228122|DEVICE|Aquacel® Ag+ Extra|Aquacel® Ag+ Extra dressing will be applied to wounds as per instructions for use, dressing to be changed at least one per week for 4 weeks.
223499848|NCT03595891|OTHER|Non-Interventional|Non-Interventional
223499849|NCT01251458|DRUG|Torisel|Torisel will be administered intravenously as an IV infusion over a 30-minute period in adult clinical studies.
223499850|NCT06545864|DRUG|Streptokinase Injection|250000 IU as a loading dose over 30 min. Followed by 100000 IU/hour over 12:24hours or accelerated regimen 1.5 million IU over 2 hours
223499851|NCT06545864|DEVICE|Penumbra System|"which comprised of several devices:~* RED Reperfusion Catheters~* Penumbra JET Reperfusion Catheters~* ACE Reperfusion Catheters~* MAX Reperfusion Catheters~* 3D Revascularization Device~* Penumbra ENGINE Aspiration Source~* Penumbra ENGINE Canister~* Aspiration Tubing"
223499852|NCT04806425|DRUG|Intralipid|intralipid is given as a preconditioning drug during off bump coronary artery bypass grafting surgery to measure efficacy in decreasing post operative ischemia
223499853|NCT04806425|DRUG|Placebo|normal saline is given in same volume to normal saline group over the same duration
223499854|NCT01748682|OTHER|A very low calorie diet of two different consistencies|Liquid and normal consistency diet with a very low calorie diet will be given to patients pre-operatively in bariatric surgery
224074523|NCT00555100|DRUG|lenalidomide|10mg-25mg PO/day,day1-day21 of each 28day cycle. Number of Cycles:until progression or unacceptable toxicity develops.
223511931|NCT02920047|DRUG|Fimasartan + Amlodipine|Treatment A
223511932|NCT05900349|OTHER|Carbohydrate mouth rinsing|the carbohydrate solution was prepared by dissolving 6.4 g of colorless and odorless maltodextrin in 93.6 mL of water; the mixtures were then adjusted to a 6.4% maltodextrin solution for the participants to rinse their mouths for 20 seconds
224074524|NCT00555100|DRUG|dexamethasone|40mg PO/day, day1-4,9-12,17-20 of each 28day cycle. Number of Cycles:until progression or unacceptable toxicity develops.
223511933|NCT05900349|OTHER|200 mg caffeine gum|Chewing caffeinated gum for 20 minutes
224074525|NCT01339546|OTHER|no intervention|
224074526|NCT02824744|DEVICE|treatment by 2l/min/kg in High Flow Nasal cannula (HFNC)|
224074527|NCT02824744|DEVICE|treatment by 3l/min/kg in High Flow Nasal cannula (HFNC)|
224074528|NCT01692548|OTHER|Neurofeedback|
224074529|NCT03257787|OTHER|new adhesive strip|This is a strip made of a newly developed adhesive
224074530|NCT03529292|DEVICE|AmeaCell|Lipoaspirate obtained from liposuction is treated by the AmeaCell® device in order to obtain Matrix and Cells which contains cellular phase and matrix phase. The Matrix ancd Cells are injected in the same patient as facial wrinkles filler.
224074531|NCT05339672|OTHER|Blood sampling - Pharmacokinetic assessment|Two pharmacokinetic assessements will be performed (before start of enzalutamide and 4-6 weeks after start of enzalutamide). Each pharmacokinetic assessment consists of 9 samples (3mL blood)
224074532|NCT01764633|BIOLOGICAL|Evolocumab|Administered subcutaneously using a spring-based prefilled 1.0 mL autoinjector/pen.
224074533|NCT01764633|DRUG|Placebo|Administered subcutaneously using a spring-based prefilled 1.0 mL autoinjector/pen.
224189900|NCT00660153|DRUG|Tivozanib (AV-951) plus FOLFOX6|"Investigational product, dosage and mode of administration (1 cycle = 4 weeks of treatment):~Tivozanib (AV-951): 0.5 mg, 1.0 mg, and 1.5 mg oral once daily On Day -5 (± 2 days) subjects will receive a single dose of tivozanib (AV-951) for pharmacokinetic sampling. Beginning on Day 1 of Cycle 1, subjects will receive tivozanib (AV-951) once daily for 3 weeks followed by 1 week off. Tivozanib (AV-951) dosing repeats every cycle in the absence of disease progression or unacceptable toxicity. On days when both tivozanib (AV-951) and the FOLFOX6 chemotherapy regimen are co-administered, tivozanib (AV-951) will be administered immediately prior to the start of the FOLFOX6 chemotherapy regimen.~Subjects will receive FOLFOX6 chemotherapy every 2 weeks starting on Day 1 of Cycle 1. Subjects will receive 2 treatments of FOLFOX6 in each treatment cycle, starting on Day 1 and Day 15."
224189901|NCT05931094|OTHER|Augmented Reality based games|Games of Wonder Tree Augmented Reality
224189902|NCT05931094|OTHER|Traditional therapy|Traditional therapy based on play activities utilizing blocks, colors, Velcro-based toys.
224189903|NCT03106701|PROCEDURE|Ablation|Epicardial Radiofrequency ablation
224189904|NCT03296592|DIAGNOSTIC_TEST|MRI with DBSI technology|The MRI will be done with diffusion basis spectrum imaging
224189905|NCT00731640|DEVICE|ReSTOR|AcrySof ReSTOR +4 Intraocular Lens (IOL) unilaterally implanted
224189906|NCT00361504|DRUG|Oxycodone CR|Oxycodone CR 10 mg oral tablet BID administered for first 3 days, 20 mg oral tablet BID administered for next 4 days, 20 to 50 mg oral tablet BID administered for the next 51 weeks.
224189907|NCT00361504|DRUG|Tapentadol (CG5503) ER|Tapentadol (CG5503) ER 50 mg oral tablet BID administered for first 3 days, 100 mg oral tablet BID administered for next 4 days, 100 to 250 mg oral tablet BID administered for the next 51 weeks.
224189908|NCT02256956|DRUG|Amitriptyline|25 mg / day for 10 days
224189909|NCT02256956|DRUG|Tolterodine|Placebo 1 mg / day for 10 days
224189910|NCT00604760|DRUG|MEM 3454|Capsule 5 mg once a day
223511934|NCT02998320|DRUG|Genvoya|Oral use (one tablet each day); 150/150/200/10 mg; 28 days
223511935|NCT05489458|PROCEDURE|Resection|Type A BR-PDAC patients who had a favorable tumor/vascular structures relationship confirmed during surgical exploration underwent resection.
224074534|NCT01913392|PROCEDURE|laparoscopic sleeve gastrectomy|
224074535|NCT00001193|PROCEDURE|high dose melphalan and autologous bone marrow transplantation|
224074536|NCT02268058|DRUG|Acetaminophen|routine administration of medication for a 72 hour period
224189911|NCT00604760|DRUG|MEM 3454|Capsule 15 mg once a day
224189912|NCT00604760|DRUG|MEM 3454|Capsule 50 mg once a day
223746177|NCT06189222|DEVICE|virtual reality glasses|The population of the study consisted of children who were aged between 7- 12 and were on treatment using an intravenous catheter in the pediatric emergency unit of a state hospital in Turkey.Participants were divided into two groups, namely experimental and control groups, by using simple randomization software. The design and implementation of the study were based on the principles in the CONSORT list (Consolidated Standards of Reporting Studies). Descriptive data form for children,this form was prepared to collect information about the children included in the sample. It consists of seven questions on children's sociodemographic characteristics and previous intravenous catheter insertion experience.The Children's Emotional Manifestation Scale (CEMS), this scale was developed by Li \& Lopez (2005) to measure children's emotional responses during stressful medical procedures. The VR glasses we used in our study were connected to a mobile phone.
224074537|NCT02268058|DRUG|Ibuprofen|routine administration of medication for a 72 hour period
224074538|NCT04567550|GENETIC|ABBV-RGX-314 Dose 1|AAV8 vector containing a transgene for anti-VEGF fab (Dose 1)
224074539|NCT04567550|GENETIC|ABBV-RGX-314 Dose 2|AAV8 vector containing a transgene for anti-VEGF fab (Dose 2)
224074540|NCT04567550|GENETIC|ABBV-RGX-314 Dose 3|AAV8 vector containing a transgene for anti-VEGF fab (Dose 3)
224189913|NCT00604760|DRUG|Placebo for MEM 3454|Capsule once a day
224189914|NCT04389294|DIAGNOSTIC_TEST|SARS-CoV2 serum antibody testing|Participants will have SARS-CoV2 serum antibody testing performed twice within 4 months of each other.
223499855|NCT04947787|BEHAVIORAL|Physical activity referral scheme (PARS)|Participants of the intervention group will receive brief physician advice and be referred to an exercise professional (e.g., physiotherapist, sports therapist) for a more intensive counseling intervention. The counseling intervention consists of an initial assessment, individual physical activity counseling (360'), a final assessment after 12 weeks, and a follow-up assessment after 24 weeks.
223499856|NCT04947787|BEHAVIORAL|Physical activity advice (PAA)|Participants of the control group will only receive brief physician advice regarding the promotion of physical activity and as an information sheet with tips on how to adopt a more physically active lifestyle.
223499857|NCT03745469|DEVICE|Smartphone|A standard smartphone will be used for browsing the internet for two different durations (10 and 30 minutes)
223499858|NCT04938947|DEVICE|Blood Flow Restriction Cuffs|This intervention consists of inflatable cuffs that are designed to partially occlude veinous blood return from the lower extremities during resistance training.
223499859|NCT04938947|OTHER|Low-Intensity Resistance Training|This intervention consists of performing low-intensity bilateral (both legs at the same time) leg extensions using 30% of a participants 1 repetition maximum (the maximum weight an individual can complete 1 repetition with, but not 2) to volitional failure.
223499860|NCT04938947|OTHER|High-Intensity Resistance Training|This intervention consists of performing high-intensity bilateral (both legs at the same time) leg extensions using 80% of a participants 1 repetition maximum (the maximum weight an individual can complete 1 repetition with, but not 2) to volitional failure.
223499861|NCT01116843|DRUG|PF-00299804|PF-00299804 or Placebo given pre-operatively for 7 to 11 days depending on surgery schedule.
223499862|NCT03240380|BEHAVIORAL|joint crisis plan|"Joint crisis plans are consensual written patient-clinic-agreements for future crisis intervention, especially for people with recurring severe mental illnesses. In case of relapse, they provide the hospital with contact information and detailed patient's preferences regarding medical, psychological and psychosocial measures. Thus JCPs aim to implement patient self-determination rights, prevent psychiatric coercion and foster self-management and recovery.~Between the patient and the clinic represented by the attending physician a joint crisis plan is to be negotiated and agreed upon on individual basis as part of inpatient care. If possible this is to be facilitated by peer counselors or another third party. If for an in-patient the process is not completed until the end of the hospital stay it becomes part of regular outpatient aftercare."
223511936|NCT05489458|PROCEDURE|No Resection|Type A BR-PDAC patients who did not have a favorable tumor/vascular structures relationship confirmed during surgical exploration did not undergo resection.
223511937|NCT00470808|DRUG|POMx|
223511938|NCT04304196|OTHER|TEMPO|TEMPO is designed as a 7- to 10-week, web-based intervention containing 5 modules to pace patient-caregiver dyads' learning, avoid information overload, and allow sufficient practice time in-between modules . Each module is organized along six key components: needs assessment, tailored information and skills training, goal setting and action planning, motivational and social support, monitoring, automated feedback, and addressing time demands. Overall, modules aim to a) increase dyads' confidence in using strategies to address key psychosocial issues in the acute survivorship phase (e.g., dealing with stress and worry, communicating with partner and family, uncertainty management) and b) assist dyads in developing the self-regulatory skills necessary to meet the physical activity guidelines. Each module specifies a series of online (i.e. didactic material and interactive worksheets) and offline activities (i.e. practicing the proposed skills).
224074541|NCT04567550|DRUG|Topical Steroid|Topical Steroid
224074542|NCT04567550|GENETIC|ABBV-RGX-314 Dose 4|AAV8 vector containing a transgene for anti-VEGF fab (Dose 4)
224074543|NCT04567550|BIOLOGICAL|Aflibercept|Aflibercept
224189915|NCT03045926|DRUG|Diosmectite (Smecta®)|
224189916|NCT05288335|DEVICE|Circular cylindrical mirror modulated frame glasses (compact)|Circular cylindrical mirror modulated frame glasses (compact)
224189917|NCT05288335|DEVICE|Circular cylindrical mirror modulated frame glasses (strong defocus)|Circular cylindrical mirror modulated frame glasses (strong defocus)
224189918|NCT05288335|DEVICE|single vision frame glasses|single vision frame glasses
224189919|NCT01147432|DRUG|PF-04427429|Single dose IV infusion up to 300mg
224189920|NCT01147432|OTHER|Capsaicin challenge|Capsaicin challenge: 110 mg (0.075% capsaicin) to be applied at pre-dose and at 2h, 5h, 8h and 24h post-dose as well as 1 week and 4 weeks post final treatment period
223511939|NCT04304196|OTHER|Usual care|Patients will receive usual care throughout the study. Dyads in this group will not receive any information resources from the research team, but will have access to all of those available at their participating center (sites will be asked to provide a description of usual care practices). Participants will be given access to the TEMPO website after having completed their final questionnaire, as thanks for participating.
224074544|NCT02263833|DRUG|Mircera|Participants received Mircera according to individualized physician-prescribed regimen.
223499863|NCT03240380|BEHAVIORAL|crisis card|"Crisis cards are credit card-sized booklets to be kept preferably always at hand. They can contain important information: persons to contact, current medication, basic treatment preferences and hints to advance directives or other existing legal documents. They may be of use in the event of a mental health crisis and help to quickly receive appropriate support.~When the in-patient is to be released from the clinic, the attending physician and the patient together fill out a crisis card. Out-patients get their crisis cards during the next routine visit to their clinic doctor's office."
223499864|NCT05227235|OTHER|3D Telemedicine|Clinical consultation with patient performed with 3D Telemedicine
223499865|NCT05227235|OTHER|2D Telemedicine|Clinical consultation with patient performed with 2D Telemedicine as standard of care
223499866|NCT05698212|DIAGNOSTIC_TEST|MetriDx|Biopsied tissue will be analyze by proprietary LDT, MetriDx, and compared to laparoscopy diagnostic report on record
223499867|NCT03986268|DRUG|Vit D|The aim of this study is investigating pathologic response to neoadjuvant therapy if we give replacement therapy with vitamin D3 50.000 IU weekly dosage concurrent with chemotherapy in breast cancer patients.
223499868|NCT04184908|DRUG|gel xerostomia|Apply 2-3 cm of the gel on the tongue, gums and oral mucosa, at least three times a day, if necessary it can be applied at night
223499869|NCT04184908|OTHER|gel placebo|Apply 2-3 cm of the gel on the tongue, gums and oral mucosa, at least three times a day, if necessary it can be applied at night
223499870|NCT02242110|BEHAVIORAL|ERRT-Bipolar Disorder|The nightmare treatment, called Exposure, Relaxation, and Rescripting Therapy for Bipolar disorder, is a weekly 5-session treatment aimed at reducing chronic trauma nightmares and sleep disturbances in adults diagnosed with bipolar disorder.
223499871|NCT02817204|BEHAVIORAL|Aerobic Exercise|Cycle ergometer exercise for 3 sessions a day (3 minutes Warm up,45 minutes Resistance Exercise at 75% of HRmax;10 minutes Recovery). 5 days a week(about 2000kcal) and continues 12 weeks
223499872|NCT02817204|BEHAVIORAL|Health Education|Lower salt,fat and calorie diet,Recommendation of regular exercise,No smoking and alcohol
223499873|NCT03152890|DRUG|Insulin|If blood glucose level after reperfusion of liver graft exceeds 180 mg/dL, the insulin dose proposed by the linear mixed effects analysis is given as a bolus.
223499874|NCT02282033|DEVICE|The Moderato System|The BackBeat Moderato System incorporates traditional pacing modes and algorithms to provide pacing support to patients with all conditions currently indicated for dual chamber pacing. In addition, a special pacing algorithm was developed to reduce blood pressure.
223499875|NCT05480371|DEVICE|Conventional tracheal suctioning|"Group 1 allocated to conventional tracheal suctioning,all patiemts will be followed up until discharge from ICU or death~Tracheal suctioning will be performed following the American Association for Respiratory Care recommendations."
223499876|NCT05480371|DEVICE|Mechanical insufflation/exsufflation|Group 2 will be allocated to mechanical insufflation-exsufflation which will be performed with the which will be applied 5 times in 5cough cycles in automatic mode, with insufflation and exsufflation pressures of + 40/-40 cmH2O, respectively. The duration of each phase was 3 s, without pause. Hyperoxygenation (100% O2) will be performed for 1 min before applying each technique and a 20 s interval will be allowed between repetitions.
223499877|NCT06961058|OTHER|referral to telehealth treatment|the intervention tested will be referral to get outpatient treatment via telehealth. Participants in the telehealth arm will receive the intervention.
223499878|NCT06961058|OTHER|referral to in person treatment|participants in the in person arm will be referred to in person OUD treatment after they leave the ED
223499879|NCT06406296|BEHAVIORAL|Acceptance and Commitment Therapy (ACT)|Acceptance and Commitment Therapy methods were focused on promoting Values clarification, Acceptance, Cognitive defusion, Committed action and Flexible attention to the present moment, and included methods such as the Garden Metaphor, Funeral exercise or Mindfulness training.
223499880|NCT03912519|PROCEDURE|Parallel placement of 16 gauge electrodes|Parallel technique
223499881|NCT03912519|PROCEDURE|Perpendicular placement with 22 gauge electrodes|Perpendicular technique
223499882|NCT06377488|DEVICE|JJVC Investigational Multifocal Toric Contact Lens manufactured in Senofilcon A (C3) material with UV blocker / HEV filter|Test Lens
223499883|NCT02787369|DRUG|ACY-1215|
224189921|NCT01147432|DRUG|Placebo|Placebo IV infusion (saline) to be administered during two of the three treatment periods
223499884|NCT02787369|DRUG|Ibrutinib|
223499885|NCT02787369|DRUG|Idelalisib|
223499886|NCT00254085|DRUG|Insulin Aspart|
223499887|NCT01179516|DRUG|Vortioxetine|Encapsulated vortioxetine immediate release tablets
223499888|NCT01179516|DRUG|Placebo|Vortioxetine placebo-matching capsules
223499889|NCT03965650|OTHER|Video coaching exercises|Patients will perform physical exercises following a specifical video coaching program during 6 months.
223499890|NCT03965650|OTHER|Routine exercises|"Routine method by advising and encouraging patients to perform exercises according to the WHO recommendations during the first 3 months of the study.~Thereafter, patients will have access to the video coaching program of physical activities during the following 3 months."
223499891|NCT00634972|DRUG|ACULAR|infants enrolled in the study will receive 1 drop of the ROP Study drug in each eye 3 times a day (every 8 hours.
223499892|NCT00634972|DRUG|REFRESH TEARS|infants enrolled in the study will receive 1 drop of the ROP Study drug in each eye 3 times a day (every 8 hours.
223499893|NCT00634972|DRUG|placebo|
223499894|NCT02112552|DRUG|Paclitaxel|Given IV
223499895|NCT02112552|DRUG|Carboplatin|Given IP
223499896|NCT02112552|RADIATION|3-Dimensional Conformal Radiation Therapy|Undergo 3D conformal radiation therapy
223499897|NCT02112552|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
223499898|NCT02112552|OTHER|Quality-of-Life Assessment|Ancillary studies
223499899|NCT02112552|OTHER|Laboratory Biomarker Analysis|Correlative studies
223511940|NCT06540495|BEHAVIORAL|Salaso Virtual Exercise Program|Salaso is a digital health technology company that has online, mobile and telehealth solutions enabling providers to 'prescribe' evidence-based exercise programs for patients to complete virtually.
223511941|NCT04975165|PROCEDURE|Total knee arthroplasty|Bilateral surgery in one arm and staged surgery in another arm during total knee arthroplasty
224189922|NCT01147432|OTHER|Capsaicin challenge|Capsaicin challenge: 110 mg (0.075% capsaicin) to be applied at pre-dose and at 2h, 5h, 8h and 24h post-dose as well as 1 week and 4 weeks post final treatment period
224189923|NCT01147432|OTHER|EMLA positive control|2g EMLA cream to be applied ONCE during study period 1
224189924|NCT02484209|DRUG|Metformin|Metformin 1500 mg daily for 16 weeks
224189925|NCT02484209|DRUG|Glimepiride|glimepiride 2-4 mg twice daily for 16 weeks
224189926|NCT02484209|DRUG|Metformin|metformin 1500 mg daily for 16 weeks
224189927|NCT04011891|PROCEDURE|Robotic Partial Nephrectomy|Robotic partial nephrectomy using da Vinci robot.
224189928|NCT04011891|PROCEDURE|Open Partial Nephrectomy|Standard open partial nephrectomy
224189929|NCT05523427|DIETARY_SUPPLEMENT|Two probiotic strains (L. plantarum and L. acidophilus)|A capsule containing the L. plantarum and L. acidophilus strains is to be administered twice daily for three months in addition to the standard treatment of IBS.
224189930|NCT01982539|DRUG|Zipsor®|Administration of Zipsor® (liquid filled capsules) to patients with mild to moderate acute pain: 25 mg/every 6 hours/up to 4 days treament. Drug taken by mouth.
224189931|NCT00359866|RADIATION|IMRT with tomotherapy|
224189932|NCT00031096|DRUG|Azelaic Acid Gel 15% (Finacea, BAY39-6251)|Azelaic Acid 15% gel (SH H 655 BA) applied topically two times per day.
224189933|NCT00031096|DRUG|Vehicle gel (SH H 655 PBA)|Vehicle gel (SH H 655 PBA) applied topically two times per day.
223499900|NCT06544590|DEVICE|taVNS|TaVNS device (Elmmedicare, EC100, Shenzhen, China) was used to apply stimulation for patients. Stimulation parameters comprised an electrical current of 1 mA at a frequency of 20 Hz, with a waveform width of 1 ms \[18,28\]. Repurposed off-the-shelf devices were utilized for this purpose, with the stimulator generating single square-wave pulses lasting 1 ms each. Enhancing conductivity was achieved by wiping the ear with tap water. In the taVNS group received 12 weeks of treatment (30 min each time, once daily, 5 times per week).
223499901|NCT06544590|DRUG|Betahistine Mesylate tablet|Betahistine Mesylate tablet (Merislon, Eisai Co., Ltd., China) with the treatment of 6 mg 3 times a day.
223499902|NCT05518552|OTHER|Manual lumbar traction|Patient in the group were treated with manual traction
223591287|NCT01608373|DRUG|Intraperitoneal lidocaine irrigation group|Patients in Group P(intraperitoneal lidocaine irrigation group) receive a peritoneal lidocaine irrigation with 3.5mg/kg lidocaine and normal saline 100cc. 50cc of irrigation fluid will be spread below diaphragm and 50cc of irrigation fluid will be spread around the gall bladder.
223591288|NCT01608373|DRUG|Intravenous normal saline injection|The patients in Group C (placebo control group) received normal saline intravenous injection
223591289|NCT00140959|DRUG|MK0954, losartan potassium/Duration of Treatment: 18 weeks|
224189934|NCT01904266|PROCEDURE|GA + paravertebral block|20 cc ropivacaine 0.2% will be administered in an ultrasound-guided paravertebral block
224189935|NCT01904266|PROCEDURE|GA + sham block|Injection of 1 cc saline subcutaneously
224189936|NCT00401414|DRUG|Warfarin|2 mg tablets take as directed by study staff (based on INR)
224189937|NCT03514823|OTHER|Inspiratory Muscle Training (IMT)|Inspiratory muscle training (IMT) are breathing exercises used to increase strength and endurance of the respiratory muscles.
224189938|NCT03514823|OTHER|No Inspiratory Muscle Training (IMT)|No inspiratory muscle training.
224189939|NCT06332924|BEHAVIORAL|motivational discussion group|There will be 3 interviews with the motivational interview group, one week apart.
224189940|NCT05110118|DRUG|LY01008|Single intravenous injection
224189941|NCT05110118|DRUG|Avastin|Single intravenous injection
224189942|NCT05875337|OTHER|Acupressure|Before starting the acupressure point application, the area around the area where the pressure will be applied for 20-30 seconds will be gently rubbed with the palm of the hand. By gently rubbing the surrounding tissue, tension and tissue sensitivity will be reduced and the tissue will be relaxed by heating, relaxing and preparing the point area. Pressure will be applied to the determined points (LI4, LI11 and HT7) with the thumb, index or middle finger manually for 5 seconds to create a depth of 1-1.5 cm and rest for 2 seconds. Each point will be applied for 2 minutes and the application will last 12 minutes.
224189943|NCT05875337|OTHER|Placebo acupressure|Before starting the application to the placebo acupressure point, the area around the area where pressure will be applied for 20-30 seconds will be gently rubbed with the palm of the hand. By gently rubbing the surrounding tissue, tension and tissue sensitivity will be reduced and the tissue will be relaxed by heating, relaxing and preparing the point area. Light pressure will be applied to the determined points (1.5 cm away from LI4, LI11 and HT7 points) with the thumb, index or middle finger. Each point will be applied for 2 minutes and the application will last 12 minutes.
224189944|NCT04722627|DRUG|AT-752|Parallel Assignment
224189945|NCT04722627|DRUG|Placebo|Parallel Assignment
224189946|NCT03736122|DRUG|BSG-001|"BSG-001 is in solution form, 4mg per vial (2mg/mL) with Inhalation as route of administration using nebulizer.~BSG-001 will be administrated as an approximately 5 - 30 minutes inhalation session daily for 3 cycles (in repeated 28 days cycle)."
224189947|NCT03648073|DRUG|[68Ga]DOTATATE-PET/MRI|\[68Ga\]DOTATATE-PET/MRI
224189948|NCT01575158|DRUG|Citalopram|
224189949|NCT01575158|DRUG|Clomipramine|
224189950|NCT01575158|DRUG|placebo|
224189951|NCT06335394|OTHER|NVD003|Autologous osteogenic implant NVD-003 for bone reconstruction
223499903|NCT05518552|OTHER|Prone traction|Patient in the group were placed on prone traction
223499904|NCT06575452|DIAGNOSTIC_TEST|Blood, urine and tumoral tissue samples|Blood, urine and tumoral tissue samples
223499905|NCT06575452|DIAGNOSTIC_TEST|Tumoral tissue samples|tumoral tissue samples
223499906|NCT06493942|OTHER|BioCoat® by Premier®|BioCoat is a 56% filled resin formula that provides added strength and excellent long-term resistance to wear ؤomparable to flowable composites.
223499907|NCT06493942|OTHER|UltraSeal XT™ plus by Ultradent|UltraSeal XT plus is a 58%-filled resin fluoride-releasing sealant. It is strong and has high wear resistant
223591290|NCT00140959|DRUG|Comparator: losartan, HCTZ, amlodipine, atenolol/Duration of Treatment: 18 weeks|
223591291|NCT02186704|DEVICE|ICD with DX system|Implantable cardioverter defibrillator (ICD) system implantation with single lead with ventricular sensing and pacing and defibrillation combined with dedicated atrial sensing dipole.
223591292|NCT02851823|DEVICE|Periodontal curettes|
223591293|NCT02851823|DEVICE|Er-YAG+Nd-YAG lasers|
224189952|NCT04755491|DEVICE|Continuous veno-venous hemofiltration|Treatment of KDIGO stage 3 AKI by CVVH, in which renal replacement therapy is applied using a convection technique (ultrafiltration). Indication, choice of CRRT modality, and CRRT settings are made by the clinician in charge, following international recommendations. The measurement of chloride transfer over 24h is performed during CVVH treatment.
223499908|NCT06169397|DRUG|XTMAB-16|XTMAB-16 infusion
223499909|NCT04714580|OTHER|Animal Fun Program|This program permits the operators to propose different activities, by following the needing of the children. As the name of this program suggests, all the activities involve an animal description, and ask the children to move like this animal, in a proper, correct and supervised way.
223499910|NCT05311163|PROCEDURE|MitraClip|Transcatheter Mitral Edge-To-Edge Repair
223499911|NCT01220063|RADIATION|Radiation|10 Gy for 4 times (total 40 Gy)
223499912|NCT01220063|DRUG|Irinotecan|40 mg/m² : Day 1 and day 8
223499913|NCT06312930|DEVICE|Transcranial pulse stimulation|A single session of TPS will be performed, applying 1000 pulses in the session (single ultrashort (3 μs) ultrasound pulses, 0.2-0.25 mJ mm-2, \~5 Hz pulse frequency)
223499914|NCT03704207|OTHER|nNO testing|Collection of already performed clinical data and nNO testing
223499915|NCT04752462|BEHAVIORAL|Telemedicine Intensive Motivational Enhancement|Participants will attend a telemedicine motivational enhancement visit to improve PAP adherence along with regular follow up for sleep apnea
223499916|NCT05716022|DIAGNOSTIC_TEST|Blood Collection|Prior to subject's surgical procedure, blood (about 3 tablespoons (44 mL)) will be collected through a needle in vein for research purposes. The UVA researchers will analyze the biomarkers that are expressed in subject's blood.
223499917|NCT05716022|DIAGNOSTIC_TEST|Bronchoscopy|Following blood collection, the subject will undergo the bronchoscopy for research purposes. While in the operating room, a bronchoscope will be inserted through the breathing tube that is already been placed for the surgery. Subject's airways will be examined with the bronchoscope in both lungs. Ten tablespoons (150 mL) of saline solution will be injected into one of subject airways. The fluid will be re-collected by suctioning it back up with the bronchoscope. The fluid will be collected from the bronchscope.
223499918|NCT02496429|DEVICE|BrownieForSymphony use|Professional will use the BrownieForSymphony Pumpset in their daily work. hospitalized lactating woman will pump with the BrownieForSymphony Pumpset
223499919|NCT02965456|DRUG|IDP 121 Lotion|IDP-121 lotion will be applied as per the instructions provided by the investigational center staff.
223499920|NCT02965456|DRUG|IDP-121 Vehicle Lotion|IDP-121 vehicle lotion will be applied as per the instructions provided by the investigational center staff.
223499921|NCT02642900|PROCEDURE|Photodynamic Therapy|evaluate the effectiveness of photodynamic therapy (PDT) in the treatment of denture stomatitis in complete denture wearers.
223499922|NCT02642900|DRUG|Nystatin 100.000 units|Control group treated with nystatin
223499923|NCT02585765|DRUG|Pioglitazone|8 weeks of daily pioglitazone (30 mg/d).
223499924|NCT02585765|DRUG|Placebo|8 weeks of daily placebo capsules.
223499925|NCT04724057|DEVICE|AutocathFFR|The MedHub Autocath FFR device is a software only medical device. The FFR is computed from several standard DICOM format 2D angiography images retrieved from the C-arm imaging system, which display the structure of the vessels. The MedHub AutocathFFR device software analyzes these images and automatically (without the need for user selection or markings) and computes and displays the FFR on the viewed blood vessel.
223499926|NCT02529332|DIETARY_SUPPLEMENT|Omega-3|Nature Made Ultra Omega3 Fish Oil 1400mg softgels contains 1000mg of omega 3 per serving. Participants will be instructed to take twice daily for 6 months.
223499927|NCT00303953|DRUG|belinostat|Given IV
223499928|NCT02661971|DRUG|Docetaxel|Docetaxel 50 mg/m², d1
223591294|NCT03203291|DEVICE|TPAD (Tethered Pelvic Assist Device)|Each day of intervention will include a 1-hour treadmill based intervention to promote increased loading onto the affected limb. Visual feedback will be provided and faded over the course of the 5-day training. Immediately on completion of the treadmill intervention, participants will receive an additional 5-10 minutes of overground intervention reinforcing weight shifting onto the affected limb.
223499929|NCT02661971|DRUG|Oxaliplatin|Oxaliplatin 85 mg/m², d1
223499930|NCT02661971|DRUG|Calciumfolinat|Leucovorin 200 mg/m², d1
223499931|NCT02661971|DRUG|5-Fluorouracil|5-FU 2600 mg/m², d1
223499932|NCT02661971|BIOLOGICAL|Ramucirumab|Ramucirumab 8mg/kg, d1
223499933|NCT03651492|BEHAVIORAL|questionnaire administration|All the patients will be administered the Pittsburgh Questionnaire after completion of ABPM.
223499934|NCT01909271|BEHAVIORAL|Stroke Education Film Viewing|A novel, culturally tailored intervention using storytelling (narrative persuasion) in the form of two professionally produced 12-min films (in English and Spanish), in minority populations in New York City.
223499935|NCT01909271|OTHER|Stroke Education Pamphlet Exposure|"Usual Care: Stroke Education pamphlet and brochure distribution."
223499936|NCT04465955|BIOLOGICAL|NGM621|NGM621 Dose 1
223499937|NCT04465955|BIOLOGICAL|NGM621|NGM621 Dose 2
223499938|NCT04465955|OTHER|Sham Comparator|Sham Comparator
223499939|NCT02122276|PROCEDURE|Ankle continuous passive motion machine.|A rehabilitation program of machine driven passive stretch exercise on ankle.
223499940|NCT00410527|DRUG|Merrem|
223499941|NCT00085579|BIOLOGICAL|aldesleukin|
223499942|NCT00085579|BIOLOGICAL|sargramostim|
223499943|NCT00085579|PROCEDURE|adjuvant therapy|
223499944|NCT03692962|BEHAVIORAL|Sleep restriction|Time in bed will be restricted to 5 hours per night for 7 nights.
223499945|NCT03692962|OTHER|Acoustic stimulation|Brief tones will be presented time-locked to ongoing slow waves during deep sleep.
223499946|NCT00056264|DRUG|Infliximab|
223499947|NCT03052673|DRUG|Fentanyl|Fentanyl 1mcg/kg will be given at induction of anaesthesia followed by intraoperative infusion of 0.5 mcg/kg/hr in both the arms . Postoperatively IV-PCA pump containing fentanyl will be attached to patients in both the arms
223499948|NCT03052673|DRUG|ketamine|Ketamine 0.5 mg/kg will be given post-induction of anaesthesia followed by infusion of 0.5 mcg/kg /hr in the Ketamine + Fentanyl group arm
223499949|NCT02280954|DRUG|Indocyanine Green (ICG)|
224189953|NCT04755491|DEVICE|Continuous veno-venous hemodialysis|Treatment of KDIGO stage 3 AKI by CVVD, in which renal replacement therapy is applied using a diffusion technique (dialysis). Indication, choice of CRRT modality, and CRRT settings are made by the clinician in charge, following international recommendations. The measurement of chloride transfer over 24h is performed during CVVD treatment.
224189954|NCT04755491|DEVICE|Continuous veno-venous hemodiafiltration|Treatment of KDIGO stage 3 AKI by CVVHDF, in which renal replacement therapy is applied using a combination of diffusion technique (dialysis) and convection technique (ultrafiltration). Indication, choice of CRRT modality, and CRRT settings are made by the clinician in charge, following international recommendations. The measurement of chloride transfer over 24h is performed during CVVHDF treatment.
224189955|NCT01671462|DEVICE|BD HPV assay on Viper LT|
224189956|NCT05119101|DRUG|Dexamedotomidine added to Magnesium sulfate|we will give dexamedotomidine and mg sulphate and then measure intracranial pressure at different intervals by measuring Optic nerve sheath diameter (ONSD).
224189957|NCT05119101|DRUG|Magnesium sulfate|we will give mg sulphate and then measure intracranial pressure at different intervals by measuring Optic nerve sheath diameter (ONSD).
224189958|NCT05879341|OTHER|High intensitiy interval training|The participants will perform HIIT at 85% of their heart rate reserve. There will be 8 cycles of high intensity with four minutes of rest intervals in between.
224189959|NCT05026424|OTHER|Balance oral nutritional drink - control|Drink 1 cup of liquid nutrition product that contains protein, carbohydrate and fat intended for use as supplemental nutrition.
223499950|NCT02960906|DRUG|Nivolumab|"For Arms 1A and 4A:~Nivolumab alone administered IV over 60 minutes at 240 mg every 2 weeks until disease progression, unacceptable toxicity or other reasons specified in the protocol.~For Arms 1B, 2B, 3B and 4B:~Nivolumab administered IV over 60 minutes at 3 mg/kg combined with ipilimumab administered IV over 30 minutes at 1 mg/kg every 3 weeks for 4 doses followed by nivolumab administered IV over 60 minutes at 240 mg every 2 weeks until disease progression, unacceptable toxicity or other reasons specified in the protocol.~Starting from the Cycle 7 possibility to switch from nivolumab 240 mg every 2 weeks to 480 mg every 4 weeks according to the Investigator's preference."
223499951|NCT02960906|DRUG|Ipilimumab|"For Arms 1B, 2B, 3B and 4B:~Ipilimumab administered IV over 30 minutes at 1 mg/kg every 3 weeks combined with Nivolumab administered IV over 60 minutes at 3 mg/kg for 4 doses until disease progression, unacceptable toxicity or other reasons specified in the protocol."
223499952|NCT02960906|DRUG|Pazopanib|"For Arms 2C and 3C (TKI pazopanib or sunitinib):~Pazopanib 800 mg orally QD until disease progression, unacceptable toxicity or other reasons specified in the protocol"
223499953|NCT02960906|DRUG|Sunitinib|"For Arms 2C and 3C (TKI pazopanib or sunitinib):~Sunitinib 50 mg orally QD until disease progression, unacceptable toxicity or other reasons specified in the protocol"
223499954|NCT01486433|DRUG|Simvastatin|40 mg (1 tablet) simvastatin once a day
223499955|NCT01486433|DRUG|acetylsalicylic acid (ASA)|81 mg aspirin (1 tablet), once a day, co-administered with simvastatin
223499956|NCT01486433|DRUG|omefas|4 g (4 capsules) Epanova once a day, co-administered with simvastatin and aspirin
223499957|NCT00594737|DRUG|memantine hydrochloride|memantine hydrochloride oral tablets, 10mg po bid
223499958|NCT00464464|BEHAVIORAL|cognitive-behavioral therapy|The therapy will consist of 10 weekly individual cognitive-behavioral treatment sessions, lasting 1 hour each and modified to meet the unique needs of each individual with PD.
223499959|NCT04607759|DIETARY_SUPPLEMENT|nutraceutical|Subjects will consume two capsules for eight weeks
223499960|NCT05710822|DEVICE|pulmonary vein isolation|pulmonary vein isolation utilizing the QDOT Micro ablation catheter
223499961|NCT05788198|OTHER|Integrated care|"The intervention will be modelled based on the most frequently reported patient, family physician and specialist barriers in depression management. In this project, multiple interventions aiming to tackle these barriers will be set up, with the WHO Framework on Integrated People-Centred Health Services (IPCHS) serving as conceptual backbone to the study (Table 1). The IPCHS distinguishes five interdependent strategies supporting a shift in healthcare delivery, management and funding towards universal health coverage. These strategies are:~1. empowering and engaging people and communities;~2. strengthening governance and accountability;~3. reorienting the model of care;~4. coordinating services within and across sectors;~5. creating an enabling environment."
223499962|NCT00019123|DRUG|thalidomide|
223499963|NCT01779661|OTHER|Infant Aquatics|Infant Aquatics in this study is composed of a set of pre-structured movements and techniques of relaxation, through harmonic integration of various approaches, each having a role in a specific time-window or in the infant's developmental sequence along study interventional timeline
223499964|NCT01779661|OTHER|Infant Massage|Infant Massage
223499965|NCT04678102|DRUG|PHI-101 administration|Escalated doses of PHI-101 will be administered to each cohort.
223499966|NCT04170933|PROCEDURE|Magnetic recanalization|"1. Establish a percutaneous transhepatic cholangio drainage (PTCD) fistula.~2. Perform endoscopic sphincterotomy (EST).~3. Place one magnet above the stricture through the PTCD fistula.~4. Introduce another magnet below the stricture through the common bile duct with ERCP.~5. Place the magnets at the appropriate point to attract each other.~6. The patient will be strictly followed, and the magnets will be taken out out of the mouth by the thread connected with the magnets.~7. A plastic stent will be placed in the bile duct for lasting support."
223499967|NCT05737147|DEVICE|Zero Heat Flux Thermometer|Comparison of the accuracy and precision of a Zero Heat Flux Thermometer (SpotOn) Versus Pulmonary Artery Temperature Measurement
223499968|NCT05711147|PROCEDURE|Abutment removal|4 times healing abutment removal during prosthesis making (impressions, metal try-in, ceramic try-in, prosthesis loading)
223499969|NCT05711147|PROCEDURE|Placement of definitive abutment|Placement of the final prosthetic abutment at the moment of implantation
223499970|NCT02076841|DEVICE|interferon beta-1a|Administered as specified in the treatment arm
223499971|NCT02273453|DRUG|Songha® Night|
223499972|NCT02273453|DRUG|Oxazepam|
223499973|NCT02273453|DRUG|Placebo|
223511942|NCT03748472|PROCEDURE|Continuous gavage feeding|Each subject will serve as his or her own control. In this arm infants will receive their feed over 2 hours and the next feed will be given over 30 min and then over 2 hours again.
224309497|NCT06136000|OTHER|Ring Block|The patient is under general anesthesia. Before the surgical procedure begins, the pediatric surgeon administers 0.5ml/kg (maximum 20cc) 0.25% bupivacaine to the base of the root of the penis with a 25-gauge needle at 3, 6, 9, and 12 o'clock.
224309498|NCT01040598|BIOLOGICAL|Omalizumab|Omalizumab, an anti-IgE monoclonal antibody is dosed on the basis of subject's weight and IgE levels. It is administered as a subcutaneous injection every 2 weeks or 4 weeks based on the total dose required.
223499974|NCT04565938|PROCEDURE|Application of adhesive for the restoration of dental lesions with resin composite|"1. Mechanical removal of sclerotic dentin with a round bur~2. Enamel beveling~3. Enamel (30sec) and dentin (15sec) etching with phosphoric acid~4. Application of ExciTE (Ivoclar/Vivadent, AG, Shaan, Lichtenstein) and curing for 10sec with 800mW/cm2 light intensity (Cure TC-01, Spring Health Products, Inc, Norristown, PA, USA)~5. Composite-resin application using a transparent cervical matrix (Kerr-Hawe, Orange, CA, USA) and curing for 40sec~6. Finishing and polishing"
223499975|NCT04565938|PROCEDURE|Application of adhesive for the restoration of dental lesions with resin composite|"1. Mechanical removal of sclerotic dentin with a round bur~2. Enamel beveling~3. Application of AdheSE One (Ivoclar/Vivadent, AG, Shaan, Lichtenstein) and curing for 10sec~4. Composite-resin application using a transparent cervical matrix and curing for 40sec~5. Finishing and polishing"
223499976|NCT04565938|PROCEDURE|Application of adhesive for the restoration of dental lesions with resin composite|"1. Mechanical removal of sclerotic dentin with a round bur~2. Enamel beveling~3. Enamel (30sec) etching with phosphoric acid~4. Application of AdheSE One and curing for 10sec~5. Composite-resin application using a transparent cervical matrix and curing for 40sec~6. Finishing and polishing"
223499977|NCT00387127|DRUG|Lapatinib oral tablets|Lapatinib is administered orally once daily.
223499978|NCT00387127|DRUG|radiotherapy|Radiotherapy is given either as conventional fractionation using Two-dimensional (2D) or conformal techniques, or as Intensity Modulated Radiation Therapy (IMRT). Radiation therapy will be standardised throughout the study. Radiation therapy is given only once daily, with a dose/fraction not exceeding 2.5Gy, to a total dose of 65 Gy (IMRT) or 70 Gy (2D or 3D RT) to the gross site of disease .
223499979|NCT00387127|DRUG|cisplatin chemotherapy|Cisplatin is administered intravenously at a dose of 100mg/m2 on days 1, 22 and 43 of radiotherapy (approximately Study Days 8, 29 and 50).
223499980|NCT06473129|BEHAVIORAL|Food for Life Culinary Workshops|Whole food, plant based 2hr workshop, which includes background information on diabetes, how to shop for food, etc and then a culinary demonstration and tasting of whole food, plant based dishes.
223499981|NCT03590002|DEVICE|Electronic ICU Medical Transfer Tool|Patient transfers of care from the ICU to inpatient wards prepared using the electronic ICU medical transfer tool within the health zone's clinical information system, Sunrise Clinical Manager.
223499982|NCT04396275|OTHER|Food-1|Cooked whole navy beans (300 kcal)
223499983|NCT04396275|OTHER|Food-2|Cooked whole yellow split peas (300 kcal)
223499984|NCT04396275|OTHER|Food-3|Cooked rice considered as control (300 kcal)
223499985|NCT03090269|DRUG|Methylphenidate Pill|3-month follow-up to study the effective dose as a treatment for cocaine dependence in toxicity and reduction in cocaine use
223499986|NCT04023253|DRUG|Mirabegron|Mirabegron 25 mg
223499987|NCT04023253|DRUG|Solifenacin|Solifenacin 5 mg
224074545|NCT04421625|DIAGNOSTIC_TEST|Diagnostic test for SARS-Cov2 for patients and health staff|"Diagnostic test for SARS-CoV2 :~* Blood test to analyse the IgG and IgM with an immediate qualitative analysis (serological test) and a differed quantitative analysis (ELISA test)~* Results of nasal swab that will allow extracting the RNA and realizing a RT-PCR (only if the participants present symptoms). It will be obtained by standard local laboratories.~* Questionnaires (based on serology, clinic, economy (socio-demographic and lifestyle questionnaire) and epidemiology)"
224309499|NCT00380744|DRUG|LY2189102|
223499988|NCT03737019|BEHAVIORAL|Education with Acceptance and Commitment Therapy|Group education with Acceptance and Commitment Therapy of the personnel at each center.
223499989|NCT03737019|OTHER|Control, no intervention|Control, no interventions.
223499990|NCT00849329|DRUG|lapatinib|1250mg lapatinib
223499991|NCT00849329|DRUG|lapatinib plus esomeprazole|1250mg lapatinib plus esomeprazole 40mg
223499992|NCT03608332|DEVICE|diaphragmatic ultrasound|Diaphragmatic excursion; Diaphragmatic movement will be measured with a 3.5-MHz US probe (Mindray machine, DC-N6).
223499993|NCT05442632|DRUG|Hetrombopag|The patients received Hetrombopag 5mg orally d1-14 days, surgery will be conducted at d6-14 day
223499994|NCT05442632|DRUG|Placebo|The patients received Placebo 5mg orally d1-14 days, surgery will be conducted at d6-14 day
223499995|NCT05763316|OTHER|CRIB II|Calculate Clinical Risk Index for Babies II score
223499996|NCT05763316|OTHER|SNAP-II|Calculate Score for Neonatal Acute Physiology II
223499997|NCT05763316|OTHER|SNAPPE-II|Calculate Score for Neonatal Acute Physiology Perinatal Extension II
223499998|NCT05763316|OTHER|STOPS|Calculate Sensorium, temperature, oxygenation, perfusion, skin color, and blood sugar score
223499999|NCT05763316|OTHER|MSNS|Calculate Modified Sick neonatal Score
223500000|NCT05763316|OTHER|nSOFA|Calculate neonatal sequential organ failure assessment
223500001|NCT01370915|DRUG|Pregabalin (Lyrica)|Patients receive oral Pregabalin 150 mg 1 hour before septal surgery, and 12 hours later
223500002|NCT01370915|DRUG|Vitamin complex (placebo)|Patients receive oral Placebo(Vitamin complex) 150 mg 1 hour before septal surgery, and 12 hours later
224309500|NCT00380744|DRUG|placebo|
223500003|NCT01713127|DRUG|remifentanil infusion|
223500004|NCT01713127|DRUG|Placebo|
223500005|NCT05789342|DRUG|GP681|GP681, tablet, oral
223500006|NCT05789342|DRUG|Rosuvastatin|Rosuvastatin, tablet, oral
223500007|NCT05789342|DRUG|Digoxin|Digoxin, tablet, oral
223500008|NCT05789342|DRUG|Itraconazole|Itraconazole, capsule, oral
223500009|NCT05789342|DRUG|Oseltamivir|Oseltamivir, capsule, oral
223500010|NCT01642966|DRUG|Prasugrel|Prasugrel 10mg/day for 15 days
223500011|NCT01642966|DRUG|Ticagrelor|Ticagrelor 90mg twice a day for 15 days
224309501|NCT06287138|DRUG|ciprofol|Ciprofol will be infused at 0.3，0.4，0.5，0.6，0.7，0.8 mg/kg/h in sequence for 30 minutes at each dose.
224189960|NCT05026424|OTHER|Balance oral nutritional drink - test|Drink 1 cup of liquid nutrition product that contains protein, carbohydrate and fat designed for people living with diabetes and intended for use as supplemental nutrition.
224189961|NCT00442741|DRUG|Patupilone|
224309502|NCT02005835|OTHER|Community based peer support|"Community-based Support from Peer Mothers (Expert mothers):~Routine standard clinical care based on the MoH guidelines Mentor mothers provide education and psychosocial support in community prior to each visit Monthly support groups in community Home visits for each missed appointment"
223591295|NCT03023163|OTHER|Longitudinal|Participants that completed the Impact of Age on Cardiovascular, Cerebrovascular, Cerebrovascular and Cognitive Health study, will be re-assessed again to compare longitudinal (3-5 years) change in blood pressure, cerebral blood flow, arterial stiffness and cognitive health.
223591296|NCT03672786|DIETARY_SUPPLEMENT|Multicentrum|The multivitamin supplement (Multicentrum® (Pfizer, Spain) 1 tablet/day) will be maintained during 2 months
223591297|NCT02530736|OTHER|4 metre gait speed|Measurement of usual walking speed over 4 metres. Change in walking speed is measured at baseline (pre-pulmonary rehabilitation assessment) and 8 weeks later (post-pulmonary rehabilitation assessment)
223591298|NCT00003027|BIOLOGICAL|aldesleukin|
223591299|NCT00003027|BIOLOGICAL|filgrastim|
223591300|NCT00003027|BIOLOGICAL|recombinant interferon alfa|
223591301|NCT00003027|DRUG|cisplatin|
223591302|NCT00003027|DRUG|dacarbazine|
223591303|NCT00003027|DRUG|vinblastine|
223591304|NCT04780789|PROCEDURE|Transarterial Chemoembolization|A contrast agent (Xenetix350, Guerbet, France) was applied under local anaesthesia via the common femoral artery using a 5F sheath. Selective catheterization of the coeliac trunk and other arteries supplying the liver was then performed under fluoroscopic control. A pathological vascularization pattern was identified and chemoembolization material consisting of DC beads (BTG International Ltd) was injected by the treating angiographist using micro instrumentation. Follow-up CT or MRI was performed after 1-3 TACE sessions according to the extent of the lesion, 3 weeks following the last procedure. Patients with completed treatments were scheduled for an imaging follow-up every 3 months, allowing evaluation of the effect of treatment. In case of a positive response to the treatment another session of TACE was indicated. Chemoembolization sessions were performed as inpatient procedures with the mean hospitalization time of 4 days.
223591305|NCT04272333|DRUG|Motolimod|Intratumoral microdose injection by the CIVO device.
223591306|NCT04272333|BIOLOGICAL|Nivolumab|Intratumoral microdose injection by the CIVO device.
224189962|NCT00442741|DRUG|Patupilone + Omeprazole|
223591307|NCT04272333|COMBINATION_PRODUCT|Motolimod + Nivolumab|Intratumoral microdose injection by the CIVO device.
223591308|NCT01158209|PROCEDURE|Endocervical samples|Endocervical samples collection during routine gynaecological examinations.
223591309|NCT02127177|DEVICE|Continuous Positive Airway Pressure Ventilator|CPAP group received fixed-level CPAP titration using an automated pressure setting device for one night. The optimal CPAP pressure for each patient in the CPAP group was set at the minimum pressure required to abolish snoring, obstructive respiratory events, and airflow limitation for 95% of the night, according to a previous validation by our study.
223591310|NCT04679909|BIOLOGICAL|AdCOVID|Administered intranasally
223591311|NCT04679909|OTHER|Placebo|Administered intranasally
224189963|NCT02708446|DRUG|Mifepristone|200mg oral mifepristone to both study arms
223591312|NCT05678452|PROCEDURE|HOLEP for treating BPH|HoLEP will be performed using 100W Versapulse, Luminis Inc., with 2J/25Hz for LP-HoLEP and 2J/50Hz for HP-HoLEP.
223591313|NCT03695965|PROCEDURE|magnetic resonance imaging.|1.5 Tesla magnet system is going to be utilized for ankle imaging. A dedicated extremity surface coil (Foot/Ankle 16-Channel Coil; Siemens Medical Solution) is used to enhance spatial resolution.
223591314|NCT01237782|DRUG|Denture soaking solution|Immersion of complete dentures in 200ml of a denture soaking solution for 20 minutes. Propolis solution: Spa Dent (Nissin Dental Products Inc., Kyoto, Japan).
223591315|NCT01237782|DRUG|Saline solution|Immersion of complete dentures in 200ml of a placebo denture soaking solution for 20 minutes.
223591316|NCT03254550|OTHER|PrEP Promotion Package|A PrEP promotion package will be developed to test if this will change uptake, acceptance, retention and PrEP knowledge
223591317|NCT01725243|DRUG|Carbetocin|Carbetocin IV, over 1 minute following delivery. Doses: 10, 20, 40, 60, 80, 100, 120 or 140mcg
223591318|NCT03553082|DRUG|Sevoflurane|Fentanyl 2 µg/kg for induction of anesthesia and sevoflurane 2% for maintenance
223591319|NCT03553082|DRUG|Propofol|Propofol 5-6 mg/kg and fentanyl 2 µg/kg for induction of anesthesia and propofol 250-300 µg/kg/min for maintenance
223591320|NCT04787562|DRUG|XNW4107, Imipenem/Cilastatin|"Drug: XNW4107 250mg IV over 60 minutes as a single dose~Drug: Imipenem/Cilastatin 500mg/500mg IV over 60 minutes as a single dose"
223591321|NCT04787562|DRUG|XNW4107, Imipenem/Cilastatin|"Drug: XNW4107 250mg IV over 60 minutes as a single dose~Drug: Imipenem/Cilastatin 500mg/500mg IV over 60 minutes as a single dose"
224189964|NCT02708446|DRUG|Buccal misoprostol|doses of buccal misoprostol every 3 hours beginning 24 hours after mifepristone
224189965|NCT02708446|DRUG|Sublingual misoprostol|doses of sublingual misoprostol every 3 hours beginning 24 hours after mifepristone
224205833|NCT03086980|OTHER|Automatic Self Transcending Meditation|Automatic Self Transcending Meditation (ASTM) is a class of meditation that helps quiet the mind. Research suggests that ASTM helps reduce depression, anxiety, stress, and may improve health related quality of life. Further, ASTM is easier to learn and to teach.
224205834|NCT03086980|OTHER|Treatment as Usual|Usual Care will be provided.
224205835|NCT03949946|PROCEDURE|Magnetic resonance imaging (MRI)|MRI scan uses radio waves in a magnetic field to obtain images of the breast. It is non-invasive and participants will not be exposed to harmful radiation. An image contrast agent will be used to enhance image clarity. Participants will be scanned lying face-down on a specially-designed bed and ear protectors will be provided to screen out background noise.
224205836|NCT04434534|DIETARY_SUPPLEMENT|Hipocaloric Diet with Açaí Juçara|Daily consumption of Açaí Juçara pulp (200g) and nutritional adequacy of meals in individualized diet plans calculated for each participant.
224205837|NCT04434534|OTHER|Hipocaloric Diet|Nutritional adequacy of meals in individualized diet plans calculated for each participant.
224309503|NCT02005835|OTHER|Facility-based Peer Support|"Facility-based Peer Support to provide the following at the clinic~Routine standard clinical care based on the MoH guidelines Mentor mothers provide education and psychosocial support at facility Weekly support groups provided in clinic Phone call, SMS, or home visit for each missed appointment"
224309504|NCT06104943|OTHER|Heredity for cardiovascular disease|First degree relatives with a diagnosis of Cardiovascular disease.
224309505|NCT06104943|OTHER|Heredity for pancreatitis|First degree relatives with a diagnosis of pancreatitis.
224309506|NCT06104943|OTHER|Heredity for type 2 diabetes|First degree relatives with a diagnosis of type 2 diabetes.
224309507|NCT06104943|OTHER|Heredity for hypertriglyceridemia|First degree relatives with hypertriglyceridemia
224309508|NCT03412799|DRUG|SBP-101|Administered as subcutaneous (SC) injection, escalating dose cohorts
224309509|NCT03412799|DRUG|nab-paclitaxel|Administered as intravenous (IV) infusion
223500012|NCT02891330|BEHAVIORAL|Dietary and nutritional recommendations conducted by a nurse|Supplementary dietary and nutritional education
223500013|NCT02095860|DRUG|DCV 3DAA FDC|Fixed Dose Combination of Daclatasvir (DCV), Asunaprevir (ASV) and BMS-791325
223500014|NCT06296693|DEVICE|Pocket-size lung ultrasound for etiological definition of pneumonia and surveillance of complications in children hospitalized|The investigators will study the diagnostic accuracy of a pocket-size POCUS device vs. CXR for the etiological diagnosis of CAP, in paediatric age. During 1 year, all children aged \>12 months and \<18 years admitted to the Paediatric Department with the diagnosis of CAP on admission will be included. At least 76 participants will be required. Two investigators will perform, independently, a POCUS at admission, daily during hospitalization, 15 days and 1 month after discharge. All children will also undergo a CXR upon admission and whenever necessary. A third investigator will classify the CXR independently. It will be used the General Electrics Vscan AirTM®, with Bluetooth connection to smartphone/tablet. It will be collected the systematized description of POCUS and CXR, sociodemographic, clinical and therapeutic variables.
223500015|NCT02581423|DRUG|Capecitabine|Participants will receive oral capecitabine, 1250 miligrams per meter-squared (mg/m\^2) twice daily, in 3-week treatment cycles for up to 8 cycles. Treatment will be administered for 2 weeks followed by 1 week of rest without medication.
223500016|NCT03485456|DRUG|Tobramycin|Tobramycin dry powder inhalation with 30, 60 and 90 mg. Nebulisation with 300 mg tobramycin
223500017|NCT02263690|PROCEDURE|Group Drops|The patients in the group Drops received a drop of proparacaine 0.5% before receiving a peri-ocular drop of povidone iodide 5%. The patients in the group Drops received a second drop of proparacaine 0.5% 5 minutes after the drop of povidone iodide 5%
223500018|NCT02263690|PROCEDURE|Group SC|The patients in the group SC received a drop of proparacaine 0.5% before receiving a peri-ocular drop of povidone iodide 5%. In the patients in the group SC, a subconjunctival bleb of anesthesia was created by injecting 0,4 mL of lidocaine 1% into the subconjunctival space 4 mm posterior to the superotemporal limbus with a 30-gauge, 1/2-inch needle attached to a 1-mL syringe.
223500019|NCT02263690|PROCEDURE|Group gel|For the patients in group gel, the gel was placed on the eye before receiving the peri-ocular drop of povidone iodide 5%.
223500020|NCT00812097|DEVICE|Mentor Siltex® Contour Profile Gel Mammary Prosthesis|The MENTOR® MemoryShape™ Breast Implant is a silicone elastomer mammary device with a textured surface.
223500021|NCT02369250|DRUG|Rosuvastatin|Rosuvastatin, is a statin group of drug.
223500022|NCT02369250|BIOLOGICAL|platelet rich fibrin|AUTOLOGUS PLATELET GROWTH FACTOR
223500023|NCT00004785|DRUG|dexamethasone|
223500024|NCT00004785|DRUG|methylprednisolone|
223500025|NCT01786109|DRUG|Dronabinol|Dronabinol is a synthetic delta-9-tetrahydrocannabinol, a nonselective cannabinoid agonist. Subjects received one dose of either 2.5 mg or 5 mg orally with water.
223500026|NCT01786109|DRUG|Placebo|Placebo will match study drug; taken as one dose orally with water.
223500027|NCT05599932|DRUG|Siremadlin|HDM201 capsule
223500028|NCT06350084|BEHAVIORAL|Mother's Touch|Heel blood will be taken while the infant was Mother's Touch. Mother's touch will be applied to the infants before, during and after the procedure.
224309510|NCT03412799|DRUG|Gemcitabine Injection|Administered as intravenous (IV) infusion
224309511|NCT00642252|DRUG|Fluoride|Over-the-counter level of fluoride (226 ppm) in a fluoride mouthrinse; FDA considers fluoride in a rinse formulation as a 'drug'; dosage is 10 mL per treatment.
224309512|NCT00642252|DRUG|Fluoride|Over-the-counter level of fluoride (226 ppm) plus calcium (30 ppm) in a fluoride mouthrinse; FDA considers fluoride in a rinse formulation as a 'drug'; dosage is 10 mL per treatment.
224309513|NCT01971437|PROCEDURE|Cystodistension & Cystoscopy|Women with refractory OAB receiving Cystoscopy and cystodistension
224309514|NCT01338870|DRUG|Placebo|Tablets (n=4), 0 mg twice daily for 84 days
224309515|NCT01338870|DRUG|25 mg PF-04991532|Tablets (n=1), 25 mg strength + tablets (n=3) 0 mg twice daily for 84 days
223500029|NCT06350084|BEHAVIORAL|Nurse's Therapeutic Touch|Heel blood will be taken while the infant was Nurse's Therapeutic Touch.Therapeutic Touch will be applied to the infants before, during and after the procedure.
223500030|NCT05719688|DEVICE|Mechanical thrombectomy|Treatment of ischemic stroke patients with Mechanical thrombectomy
223500031|NCT00317369|DRUG|OPC-6535(Tetomilast)|
223500032|NCT00191880|DRUG|atomoxetine|
223500033|NCT02974504|DRUG|evogliptin|evogliptin 5mg tablet qd + placebo tablet matching to linagliptin 5mg
223500034|NCT02974504|DRUG|Linagliptin|linagliptin 5 mg tablet qd + placebo tablet matching to evogliptin 5mg
223500035|NCT04145817|GENETIC|BRIDGES gene panel testing|"The Breast and Ovarian Analysis of Disease Incidence and Carrier Estimation Algorithm-BOADICEAV5/PLUS predicts lifetime and age-specific breast cancer (BC) risks on the basis of family history, all known BC genes test-results, common single nucleotide polymorphisms (SNPs) combined in a PRS, and other non-genetic risk factors. This model is developed within the BRIDGES consortium."
224309516|NCT01338870|DRUG|75 mg PF-04991532|Tablets (n=3), 25 mg strength + tablets (n=1) 0 mg twice daily for 84 days
224309517|NCT01338870|DRUG|150 mg PF-04991532|Tablets (n=1), 150 mg strength + tablets (n=3) 0 mg twice daily for 84 days
224309518|NCT01338870|DRUG|300 mg PF-04991532|Tablets (n=2), 150 mg strength + tablets (n=2) 0 mg twice daily for 84 days
224309519|NCT01338870|DRUG|Sitagliptin 100 mg|Tablets (n=1), 100 mg strength + tablets (n=3) 0 mg once daily in the morning for 84 days; and tablets (n=4) 0 mg once daily in the evening for 84 days.
224189966|NCT02049008|OTHER|Photodynamic Therapy|After a full-mouth scaling and root planning (SRP), the periodontal pockets of teeth selected to receive antimicrobial photodynamic therapy (aPDT) will be irrigated with distilled water. Shortly thereafter, the dye will be applied (phenothiazine hydrochloride- 10mg/mL) from the bottom of the pocket. After 1 minute, irrigation will be performed with distilled water to remove the excess of dye. The stained area will be irradiated with a diode laser (660 nm and a 60 mW/cm²). Six sites per tooth under treatment will be irradiated (10 seconds/ site). The applications of aPDT will be repeated in the same way until the second week (days: 2, 7,14). Before the application, the supragingival plaque will be removed.
224189967|NCT02049008|OTHER|Sham Photodynamic Therapy|After a full-mouth scaling and root planning (SRP), the periodontal pockets of teeth selected will receive a simulation of antimicrobial photodynamic therapy (aPDT): irrigation with distilled water and simulated laser application. The simulations of aPDT will be repeated in the same way until the second week (days: 2, 7,14). Before the application, the supragingival plaque will be removed.
224189968|NCT01175408|OTHER|Remote Blood Glucose Monitoring|The subjects enrolled in the Internet Therapeutic Intervention arm receive standard care by testing their blood glucose at least 3 times daily and visit the endocrinologist every 3 months; however, they are also asked to upload their blood glucose readings online every 2 weeks for the health practitioner to view and comment upon.
224189969|NCT01175408|OTHER|Continuous Glucose Monitoring|The use of CGMS (Sensor, receiver, transmitter) (Medtronic Diabetes) plus the uploading of results to the Internet-based software utility of CareLink Personal and generating reports that can be viewed and used at the patient's own preference. This group will not receive feedback or suggestion based on the uploaded glucose data.
224189970|NCT01175408|OTHER|SMBG|The SMBG patients will be told that we are testing a new meter to check the accuracy of the meter. They will be asked to test at least 3 times a day and to keep a written diary of their sugar levels. The SMBG group will not know that we are counting strips and can not know about the SMBG With Knowledge group as it may bias the frequency that they test.
224189971|NCT01175408|OTHER|SMBG With Knowledge|The SMBG With Knowledge patients will be given a new meter and will be asked to test at least 3 times a day and to keep a written diary of their sugar levels. We will inform this group that we are measuring the frequency of SMBG testing.
224189972|NCT00958659|OTHER|laboratory biomarker analysis|Correlative studies
224189973|NCT01471600|PROCEDURE|group drink|group glucose drink : 200 ml of fruit juice without pulp, ± 200ml coffee or tea, 2 at 4 hours before induction of anaesthesia
224189974|NCT01852565|DRUG|Darapladib|Enteric coated, free base (micronized) white round tablet, 160mg, Oral/repeat dose/10 days (Treatment Period 1), 14 days (Treatment Period 2)
224189975|NCT01852565|DRUG|Diltiazem|Extended release, Blue capsule imprinted with cardizem CD and 240mg on one end, 240 mg, Oral/repeat dose/17 days
224189976|NCT02325206|DRUG|dapagliflozin|one administration in the morning
224189977|NCT02325206|DRUG|Placebo|one administration in the morning
224189978|NCT03852446|DRUG|Indoximod HCL (F2) tablets|The doses will be ascending per cohort from 600 mg to 2400 mg
224189979|NCT03852446|DRUG|Indoximod base formulation|Single oral administration of 1200 mg
223500036|NCT04145817|GENETIC|Breast cancer risk polygenic risk score (PRS)|"The Breast and Ovarian Analysis of Disease Incidence and Carrier Estimation Algorithm-BOADICEAV5/PLUS predicts lifetime and age-specific breast cancer (BC) risks on the basis of family history, all known BC genes test-results, common single nucleotide polymorphisms (SNPs) combined in a PRS, and other non-genetic risk factors. This model is developed within the BRIDGES consortium."
223500037|NCT04145817|BEHAVIORAL|Questionnaires|Self-administered questionnaires for counselees to evaluate Psychosocial Aspects of Hereditary Cancer (PAHC), Breast Cancer risk perception adequacy, risk communication within the family and cancer risk management choice,
223500038|NCT00781950|DIETARY_SUPPLEMENT|Flaxseed|30 grams of milled flaxseed per day in food products or on its own.
223500039|NCT00781950|DIETARY_SUPPLEMENT|Placebo|Wheat and Mixed Dietary Oils
223500040|NCT00780832|BEHAVIORAL|Dietary Caffeine reduction|Participants are counseled about reduction of dietary caffeine, given written information and a bladder control log.
223500041|NCT00780832|DRUG|Anticholinergic medication|Detrol LA 4mg. orally, once daily for 30 days
223500042|NCT03826615|DRUG|Gabapentin|Patients receive gabapentin 100mg orally for 3 times a day during the period of first and second cataract operations
223511943|NCT03748472|PROCEDURE|Bolus feeding|Each subject will serve as his or her own control. In this arm infants will receive their feed over 30 min and the next feed will be given over 2 hours and then over 30 minutes again.
223511944|NCT03102528|OTHER|No intervention|No intervention
224189980|NCT03852446|OTHER|Placebo|The matching placebo doses will be ascending per cohort from 1 to 4 tablets
224189981|NCT03852446|DRUG|Indoximod HCL (F2) tablets|Single oral administration of 1200 mg
224189982|NCT02765906|OTHER|Graphic card|A randomized controlled trial comparing patient education on preeclampsia with a graphic card vs. patient education with a written pamphlet vs. no patient education showed that patient education improved significantly when patients were provided with a graphic card depicting signs and symptoms of preeclampsia and that this improvement occurred regardless of health literacy score (You WB, Wolf MS, Bailey SC, Grobman WA. Improving patient understanding of preeclampsia: a randomized controlled trial. American Journal of Obstetrics \& Gynecology. 2012;206:431.e1-431.e5.). The graphic card is now available on the Preeclampsia Foundation's website (http://www.preeclampsia.org/market-place/educational-illustrated-signs-symptoms-pad-detail).
224189983|NCT02765906|OTHER|Video|This an informational video available on the Preeclampsia Foundation's website (http://www.preeclampsia.org/component/allvideoshare/video/featured/7-symptoms-every-pregnant-woman-should-know?Itemid=479). The effectiveness of this video has not yet been tested as an educational tool.
224189984|NCT05574673|OTHER|Standard of care|Patients receive standard of care treatment according to local and national guidelines
224189985|NCT03677973|DRUG|AB680|AB680 is a Cluster of Differentiation (CD)73 Inhibitor
224189986|NCT03677973|OTHER|Placebo|Matching Placebo
224189987|NCT05003206|OTHER|Functional magnetic resonance imaging|Preoperative and postoperative functional magnetic resonance imaging (fMRI) scanning. fMRI is a new neuroimaging method. Its principle is to use magnetic resonance imaging to measure the changes of hemodynamics caused by neuronal activity.
224189988|NCT05003206|DEVICE|Deep Brain Stimulation|For PD patients treated with DBS, the neurologist will turn off the stimulator before MRI scan
224189989|NCT00450814|DRUG|Cyclophosphamide|Given IV
224189990|NCT00450814|OTHER|Laboratory Biomarker Analysis|Correlative studies
224189991|NCT00450814|BIOLOGICAL|Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter|Given IV
224189992|NCT00450814|OTHER|Pharmacological Study|Correlative studies
224189993|NCT04145531|DRUG|IM JZP-458|IM JZP-458 will be administered in Part A, Cohorts 1 \& 2
224189994|NCT04145531|DRUG|IV JZP-458|IV JZP-458 will be administered in Part B
224189995|NCT00940719|DIETARY_SUPPLEMENT|vitamin D3|Oil-based solution, 1 dose of 500 microgram each day, during 3 months.
224189996|NCT05177666|DRUG|Targeted therapy|Based on next-generation sequencing (NGS) detection, after discussion by the Molecular Steering Committee (MTB), intervention guidance suggestions are given based on domestic and foreign guidelines and clinical experience, and finally the patient and clinician jointly choose the treatment plan.
224189997|NCT02067728|BEHAVIORAL|FNPA tool|Intervention practice will train to use FNPA screening paired with Brief Action Planning. They will implement this approach during well child visits.
224189998|NCT02067728|BEHAVIORAL|Usual Care|Practices not undergoing intervention with FNPA tool will provide usual care to patients during well-child visits.
224189999|NCT05866614|DRUG|Remsima IV|Patient will be treated with Remsima IV as per the SmPC or
224190000|NCT05866614|DRUG|Remsima SC|Patient will be treated with Remsima SC as per the SmPC
224190001|NCT05263973|OTHER|Music|The infants in the music group (Acem Aşiran Maqam music prepared by TÜMATA group) will be applied music for a about total of 12 minutes, starting 3 minutes before the ROP examination and continuing during the ROP examination, 3 minutes after ROP examination
224190002|NCT01015170|DRUG|bupropion HCl|150mg BID for up to 8 weeks + counseling
224190003|NCT03225339|DIETARY_SUPPLEMENT|Low Energy Diet|Low Energy Diet
224205838|NCT06426992|PROCEDURE|Microwave ablation|Following the existing procedure of our institute, we aim to treat the tumor by applying up to 150W of microwaves within the tumor using a StarWave microwave generator and a 13-gauge antenna under fusion ultrasound guidance. If necessary, the antenna is reinserted 1-2 times to create sufficient ablation lesions until an echogenic band of 5-10mm is formed around the tumor and its periphery, implementing overlapping microwave ablation (MWA). Afterward, the antenna is removed while applying microwave energy to prevent bleeding.
223500043|NCT03094728|DIAGNOSTIC_TEST|HLA cross matching|"HLA Typing and Mismatch~Cross matching (total and autocross):~Cross match involves placing recipient serum onto donor lymphocytes and a cytotoxic reaction (deemed 'positive') suggests the presence of preformed donor specific antibodies (DSAs),Second, the original crossmatch should be repeated with the addition of the agent Dithiothreitol (DTT). DTT reduces the disulfide bonds in IgM thereby preventing IgM antibodies from generating a positive result."
223500044|NCT03516981|BIOLOGICAL|Pembrolizumab|200 mg pembrolizumab solution for intravenous (IV) infusion administered Q3W
223500045|NCT03516981|BIOLOGICAL|Favezelimab|200 mg or 800 mg favezelimab solution for IV infusion administered Q3W
223500046|NCT03516981|DRUG|Lenvatinib|20 mg lenvatinib capsules administered orally once daily
224205839|NCT02325193|DEVICE|Minimed®640G system|Sensor augmented insulin therapy with and without use of Predictive low glucose management (PLGM)
223500047|NCT03516981|DRUG|Quavonlimab|Quavonlimab solution for IV infusion administered at the RP2D (dose and schedule based on study NCT03179436)
223500048|NCT01741662|OTHER|neuropsychological evaluation|
223500049|NCT03108690|DRUG|Continuous infusion of beta-lactam antibiotics .|Beta-lactam antibiotic will be administered as continous infusion.
223500050|NCT03108690|OTHER|Therapeutic drug monitoring of beta-lactam antibiotics.|Dosage of beta-lactam antibiotics will be adjusted according to serum concentration.
223500051|NCT05362084|PROCEDURE|lumbar medial branch block|lumbar medial branch block
223500052|NCT03006679|DRUG|Meropenem-Vaborbactam|meropenem 2 g and vaborbactam 2 g
223500053|NCT03006679|DRUG|Piperacillin/Tazobactam|piperacillin 4 g and tazobactam 0.5 g
223511945|NCT06223009|DRUG|cNP8|cNP8 for injection is provided as a sterile lyophilizate for solution for infusion. Subjects will receive a single 30 minute IV infusion of cNP8 at their assigned dose.
223511946|NCT06223009|OTHER|Placebo|Subjects not randomized to cNP8 will receive a single 30 minute IV infusion of placebo.
223511947|NCT02067156|DRUG|G-202|G-202 administered by intravenous infusion (IV, in the vein) on Days 1, 2 and 3 of each 28-day cycle until progression or development of unacceptable toxicity
223511948|NCT06566365|OTHER|Subcostal Transversus Abdominis Plane Block|After ensuring airway safety under general anesthesia, a bilateral Transversus Abdominis Plane Block using 20 cc of 0.25% bupivacaine with a subcostal approach under ultrasound guidance will be administered
223511949|NCT06581692|OTHER|This is a routine procedure, no intervention will be provided.|This is a routine procedure, no intervention will be provided.
223511950|NCT03596983|BEHAVIORAL|Sleep Intervention|"* Sleep Diaries (Daily)~* Fitbit 24/7~* Phone/ video conference calls (weekly with study team)~* Epworth Sleepiness Scale (weekly)~* PROMIS fatigue scale-evening (weekly)"
223511951|NCT03596983|BEHAVIORAL|Week 2 Intervention|"* Sleep Diaries (Daily)~* Phone Calls (weekly with study team)~* Wrist Accelerometry and fitbit 24/7 for 14 days~* SAFTEE Questionnaire~* ASA24~* Behavioral risk factor surveillance system (smoking and alcohol use questions)~* Psychological well-being (SF36)~* Index of Self Regulation~* PROMIS fatigue scale-morning (weekly)~* PROMIS fatigue scale-evening (weekly)~* Epworth Sleepiness Scale (weekly)"
223511952|NCT06396403|OTHER|Collection of venous blood samples|collection includes 1 EDTA tube and 1 Sarstedt S-Monovette tube of 5 mL
223511953|NCT06246721|BEHAVIORAL|Self-management of vaginal pessary|Self-management of vaginal pessary
223511954|NCT06642987|DRUG|Vonoprazan Test 20mg|1 tablets orally once a day
223511955|NCT06642987|DRUG|Vonoprazan Reference 20mg|1 tablets orally once a day
223511956|NCT06354764|OTHER|no intervention|no intervention
223511957|NCT05144997|DRUG|Lorlatinib|ALK-positive NSCL treatment
223511958|NCT01932463|DEVICE|ExAblate Transcranial System|MR Guided Focused Ultrasound
223511959|NCT00358280|DRUG|Ropivacaine|
223511960|NCT00358280|DRUG|Bupivacaine|
223511961|NCT04008069|DRUG|Sarilumab|Sarilumab 200 mg administered subcutaneously
223511962|NCT04008069|DRUG|Placebo|Placebo administered subcutaneously
223511963|NCT00005995|DRUG|shark cartilage extract AE-941|
224205840|NCT05144971|DIAGNOSTIC_TEST|Glucose, Creatinine|Compare diagnostic tests to reference methods
224205841|NCT01425515|BEHAVIORAL|Complex quality improvement intervention|We are implementing a complex quality improvement intervention that includes changes in practice processes to enhance hypertension care, provision of home blood pressure monitors to patients, and telephone coaching around hypertension self-management.
224205842|NCT00138827|DRUG|Biotene (mouth care)|
224205843|NCT00919932|BEHAVIORAL|Paper and pen homework|Homework will be standardized through the use of Judith Beck's dysfunctional thought record (DTR), which is a primary tool for patients to evaluate and respond in writing to their automatic thoughts (Beck 126). The homework will be done on a preprinted form which is assigned weekly and reviewed with their therapists at weekly sessions for 4 weeks.
223500054|NCT04433312|OTHER|Questionnaire|The questionnaire is developed based on a literature review and clinical experience. Initial testing of the questionnaire will be performed with 20 patients to assess the reliability and inter-rater variations. After initial testing, the final questionnaire will be formulated. The first sector of the questionnaire includes patient demographics and baseline characteristics; the second sector is regarding patient clinical condition, diagnosis, and scheduled surgery. The following sector examines the process of delivering the cancellation to the patient and requirements for re-scheduling. Patients will be classified into satisfied or dissatisfied according to the responses in this sector. The following sector addresses the course of care after cancellation and whether the patient conducted the surgery elsewhere or not. The last sector explores the impact of cancellation on patient health, career, and financial aspects.
223500055|NCT02993900|DEVICE|Image-Guided Brachytherapy|Brachytherapy will be precisely inserted with the assistance of magnetic resonance (MRI) scans
223500056|NCT01615718|PROCEDURE|low-intensity transcranial electrical stimulation|Subjects will undergo 20 minutes of low-intensity transcranial electrical stimulation of up to 2mA. During active stimulation, the current will be active for 20 minutes - however, during sham stimulation (placebo) the current will not be active for the full 20 minutes.
223500057|NCT01615718|PROCEDURE|transcranial ultrasound|Subjects will undergo 20 minutes of transcranial ultrasound. During active stimulation, the ultrasound will be active for 20 minutes - however, during sham stimulation (placebo) the ultrasound will not be active for the full 20 minutes.
223500058|NCT05926531|DEVICE|CBTI online programe|20 MIN VR RELAX PROGRAME
223500059|NCT05478746|DEVICE|BioNourish, a component of the Flourish HEC kit|BioNourish is a vaginal moisturizing gel which obtained FDA 510k clearance in 2020. It is one component of the full system being tested. The main intervention is to use this kit to improve the vaginal microbiome.
223500060|NCT05478746|OTHER|Control - no intervention|No intervention; participants only receive routine care.
223500061|NCT06375889|OTHER|blood test|During the routine blood test of the patient, 5 more tubes of 2.7 milliliters (mL) will be collected to make Platelet Activation Analysis
223500062|NCT04606719|PROCEDURE|Advanced Platelet Rich fibrin|Preparing of A-PRF by drawing 5 mL of venous blood from the patient in dried glass test tube and immediately centrifuging it at 1500 rpm for 14 minutes
223500063|NCT02096224|DRUG|Sevoflurane|Sevoflurane will be used.
223500064|NCT02096224|DRUG|Desflurane|Desflurane will be used
223500065|NCT00588224|OTHER|3D ultrasound|measurement of stomach volume by 3D ultrasound
223500066|NCT03324009|DIAGNOSTIC_TEST|2-stage screen|Pap smear is currently the standard of care for cervical cancer screening in Botswana. In this study, participants will undergo HPV DNA testing at the time of Pap smear collection. If HPV DNA test is positive, they will be referred for colposcopy. Patients who have an HPV negative test but positive Pap smear will be referred for colposcopy per Botswana cervical cancer screening guidelines.
223500067|NCT03073447|OTHER|Specific blood sample of women under 50 years with acute MI|The specific assays, corresponding to the tests carried out as part of the WAMIF study will be sampled before discharge. Some assays, including hormonal and thrombophilia will be centralized in order to standardize the results and their interpretation. All the biological data will be pooled and analyzed by IVS. a sample of blood will be made for later analysis in the context of a serum bank.
223500068|NCT04761991|DIAGNOSTIC_TEST|CMR and CTCA with CT-FFR|multi-parametric CMR assessment and CT coronary angiography with FFR assessment
223500069|NCT00200824|DRUG|Soy Isoflavone Nutritional Supplements|
223500070|NCT04498104|OTHER|Psychological assessment|Psychological assessment with the repertory grid technique (RGT) in order to quantify cognitive conflicts.
223500071|NCT00834938|OTHER|No intervention|No intervention
223500072|NCT05141799|DEVICE|high intensity laser therapy|Laser treatment is noninvasive and painless and can be easily administered in therapy units for a wide range of conditions. High-intensity laser therapy (HILT) has gained importance for the treatment of different kinds of sports injuries such as tendon injuries, contusions, and muscle spasms.
223511964|NCT01345942|DRUG|RO5428029|Single oral dose
223511965|NCT03847805|OTHER|Scapulothoracic and glenohumeral stabilization exercises|The experimental group followed a program that included three scapulothoracic stabilization exercises and three for glenohumeral stability, while subjects in the control group only performed the glenohumeral stabilization exercises. Two weekly sessions were carried out over a period of 6 weeks, and each session lasted 30 minutes. The intervention was conducted before starting the training session, to avoid muscle fatigue. Three series, with 10 repetitions of each exercise, with one minute rest between series.
223511966|NCT03847805|OTHER|Glenohumeral stability exercises|the control group only performed the glenohumeral stabilization exercises. Two weekly sessions were carried out over a period of 6 weeks, and each session lasted 30 minutes. The intervention was conducted before starting the training session, to avoid muscle fatigue.
223511967|NCT05853159|OTHER|Basic Laboratory investigations , Cerebrospinal fluid analysis|to detect severity and prognostic factors of Acute Necrotizing Encephalopathy
223511968|NCT05860868|DRUG|2 cycles induction chemotherapy|"Drug: 2 cycles Induction Chemotherapy Induction regimens: TP (docetaxel 75 mg/m²; cisplatin 75 mg/m²) Q3w, TPF (docetaxel 60 mg/m²; cisplatin 60 mg/m²; 5-fluorouracil 600-750 mg/m² per day, continuous intravenous infusion d1-5) Q3w, or GP (gemcitabine: 1000 mg/m2 d1, d8; cisplatin 80 mg/m2) Q3w.~Drug: Concurrent Chemotherapy Cisplatin 100 mg/m², Q3w.~Radiation: Definitive Radiotherapy For all patients, the prescribed dose is 66-70 Gy (once a day, 5 times a week)."
223500073|NCT05252975|OTHER|Setup and Imaging for at CT radiation planning|Patients will undergo an additional CT scan acquisition at CT radiotherapy planning in order that all participating patients have a prone and supine CT scan available to compare radiation therapy plans.
223591322|NCT04787562|DRUG|XNW4107, Imipenem/Cilastatin|"Drug: XNW4107 250mg IV over 60 minutes as a single dose~Drug: Imipenem/Cilastatin 500mg/500mg IV over 60 minutes as a single dose"
223591323|NCT04787562|DRUG|XNW4107, Imipenem/Cilastatin|"Drug: XNW4107 100mg IV over 60 minutes as a single dose~Drug: Imipenem/Cilastatin 200mg/200mg IV over 60 minutes as a single dose"
223500074|NCT06370975|DRUG|3% hypertonic Saline|"the patients received 3% HS at the rate of 4 mL/kg for 30 minutes. the intervention period for the study ran for the first hour of treatment, and serial monitoring and lab tests were done during this period, measurement lactate levels will done at 0, 30, 60 mins and 24 hour, the ABG parameters were recorded 30 and 60 min after the completion of the calculated dose infused with fluids and serial monitoring of vital parameters was done at 0, 15, 30, and 60 mins. The lactate clearance was calculated as follows:~-hour lactate clearance (%) = (0-hour lactate - 1-hour lactate) / 0-hour lactate × 100"
223500075|NCT06370975|DRUG|Ringer's lactated solution|"the patients received ringer's lactated solution at the rate of 20 ml/kg for 30 minute. the intervention period for the study ran for the first hour of treatment, and serial monitoring and lab tests were done during this period, measurement lactate levels will done at 0, 30, 60 mins and 24 hour, the ABG parameters were recorded 30 and 60 min after the completion of the calculated dose infused with fluids and serial monitoring of vital parameters was done at 0, 15, 30, and 60 mins. The lactate clearance was calculated as follows:~-hour lactate clearance (%) = (0-hour lactate - 1-hour lactate) / 0-hour lactate × 100"
223500076|NCT06370975|DRUG|0.9% Normal saline|"the patients received 0.9% Ns at the rate of 20 ml/kg for 30 minute. the intervention period for the study ran for the first hour of treatment, and serial monitoring and lab tests were done during this period, measurement lactate levels will done at 0, 30, 60 mins and 24 hour, the ABG parameters were recorded 30 and 60 min after the completion of the calculated dose infused with fluids and serial monitoring of vital parameters was done at 0, 15, 30, and 60 mins. The lactate clearance was calculated as follows:~-hour lactate clearance (%) = (0-hour lactate - 1-hour lactate) / 0-hour lactate × 100"
223500077|NCT06465901|OTHER|Chlorhexidine Gluconate 2.0% to 4.0% (e.g. Hibiscrub) preoperative shower|Chlorhexidine Gluconate 2.0% to 4.0% (e.g. Hibiscrub) preoperative shower
223500078|NCT06465901|OTHER|Intraoperative wound wash (e.g. Granudacyn)|Intraoperative wound wash (e.g. Granudacyn)
223500079|NCT06465901|OTHER|DACC surgical wound dressing (e.g. Leukomed Sorbact)|DACC surgical wound dressing (e.g. Leukomed Sorbact)
223500080|NCT02286830|DRUG|Zoledronic acid|Zoledronic acid will be given to all participants for two years. Then patients will be randomized to A receive 2 more years of treatment or B stop treatment.
223500081|NCT02918799|BEHAVIORAL|Mpowerment|MP is a multi-level intervention that reaches out to all YMSM in a community by mobilizing men to encourage their friends to reduce risk behavior and join the program (informal outreach), along with holding social activities that promote safe sex (formal outreach). MP provides YMSM with skills, support and confidence to find solutions within themselves for sexual health, and seeks to affirm the validity and rights of same-sex behavior and identities.
223500082|NCT06141681|OTHER|photoplethysmography|Photoplethysmography (BluePoint, Frankfurt, Germany) is the pulse wave measured by a pulse oximeter. It is obtained based on the absorbance of red/infrared light in a given tissue. The signal is made up of two components: 1) the alternating component (AC), which is the pulse wave itself, which is determined by the absorbance of pulsatile arterial blood. 2) The continuous component (DC), which represents the absorbance of venous blood and the rest of the tissues. Within these tests the investigators find vascular occlusion, elevation of the legs, raising or lowering the tested hand above/below the phlebostatic level, cold/heat test, etc. Each of them evaluates different aspects of circulation such as endothelial function, myogenic response to blood flow, perfusion pressure, autonomic reflexes, preload-dependence, or venous flow among other aspects of microcirculation.
223500083|NCT00291915|DRUG|Adalimumab|
223500084|NCT00291915|DRUG|Methotrexate|
223500085|NCT05484167|DRUG|Natesto Nasal Product|Nasal Gel used for 90 days then crossed over to placebo gel
223500086|NCT05484167|DRUG|Placebo|A nasal gel with no active ingredients
223500087|NCT00902967|DRUG|Atorvastatin|Atorvastatin 10 mg, once a day dosing at night after meals
223500088|NCT00902967|DRUG|Placebo|Placebo tablets of similar shape size and color given once a day at night time after meals
223500089|NCT00825175|BEHAVIORAL|Treadmill Training|Parents hold their infants on an infant treadmill for 8 minutes a day, 5 days a week. The treadmill speed is set at 0.2 m/s.
223500090|NCT00825175|DEVICE|Supramalleolar Orthoses|In addition to treadmill training the infants receive Supramalleolar orthoses. They wear the orthoses for 8 hours a day, 5 days a week.
223500091|NCT03544164|OTHER|Manual Ventilation|Manual ventilation via endotracheal tube using adult manual resuscitation device
223500092|NCT02762604|BEHAVIORAL|Imagined Gait Intervention|Phone-based imagined gait intervention: participants will be called by the experimenter three times a week and be asked to imagine walking, imagine talking and imagine walking-while-talking. They will also be asked to rate their visual and kinesthetic qualities of their images on a 1-5 scale following each trial.
223500093|NCT02762604|BEHAVIORAL|Visual Imagery Intervention|Phone-based visual imagery intervention: participants will be called three times a week by the experimenter and be asked to imagine concrete objects (e.g. octopus, teapot, and shovel). They will also be asked to rate their visual qualities of their images on a 1-5 scale following each trial.
223591324|NCT04787562|DRUG|XNW4107, Imipenem/Cilastatin|"Drug: XNW4107 100mg IV over 60 minutes as a single dose~Drug: Imipenem/Cilastatin 200mg/200mg IV over 60 minutes as a single dose"
223591325|NCT05635474|DIETARY_SUPPLEMENT|Bacillus Coagulans|Bacillus coagulans is a Gram-positive bacterium belonging to the genus Bacillus and does not exist in the intestinal microbiota, because it has the characteristics of spore production and lactobacillus lactic acid production, and has the ability to maintain the health of intestinal bacteria, acid and alkali resistance, With the advantages of high temperature resistance and high stability, it is currently one of the commonly used probiotic strains.
223591326|NCT05635474|DIETARY_SUPPLEMENT|Placebo|The placebo was also administered in the form of capsules consisting of maltodextrin, silicon dioxide, and magnesium stearate.
223591327|NCT00825721|DRUG|LiquiTears|4 drops applied daily for 360 days
224190004|NCT06497595|BEHAVIORAL|Wegovy (2.4 Mg Dose) + exercise & nutrition|Participants will participate in a 26-week, tri-weekly, exercise program. One 45-minute exercise session will be provided via a virtual meeting platform each week and recorded. The participants will be asked to independently repeat each recorded session twice on separate, non-consecutive days of the week without supervision. The program will focus on progressive resistance exercises using body weight, a resistance band and various household items. A weekly follow-up call will be conducted to gather feedback and monitor adherence along with a personal exercise diary that each participant will fill out and bring to each on-site visit. Each exercise session will be performed in small groups and will be administered by a fitness specialist. In addition, participants will receive personal individualized nutritional counseling which will be administered every 2-4 weeks online via ZOOM. A certified dietitian will conduct all diet sessions.
224190005|NCT06497595|OTHER|Wegovy (2.4 Mg Dose) + usual care|Participants will receive dietary guidance as customary among patients with type 2 diabetes (T2D) and obesity monitored in a diabetes clinic. Additionally, general recommendations for physical activity (PA) according to the medical guidelines for PA for T2D will be given. Guidelines recommend 150 minutes or more of moderate to vigorous-intensity aerobic activity per week, spread over at least 3 days/week, with no more than 2 consecutive days without activity, or engage in 75 minutes/week of vigorous-intensity or interval training (for more physically fit individuals). Incorporate 2-3 sessions/week of resistance exercise on nonconsecutive days, decrease sedentary behavior and add flexibility and balance training 2-3 times/week. Participants in the GHRG will be requested to fill out an exercise diary (report on unsupervised training days) and a 2-day food diary for periodic monitoring which they will bring with them to each on-site visit.
224190006|NCT02267343|DRUG|ONO-4538|
224190007|NCT02267343|DRUG|Placebo|
223500094|NCT04424680|BEHAVIORAL|Advanced Care Planning program of health decisions|Application of an Advanced Care Planning program program for decision-making in patients with advanced Heart Failure, in comparison to usual follow up and care.
223500095|NCT05132946|PROCEDURE|Nerve block|unilateral ultrasound-guided erector spinae plane block using bupivacaine 0.25% (on the left side) with total volume 0.5 ml/kg and a maximum dose of 2 mg/kg of bupivacaine in erector spinae plane block group patients
224190008|NCT02419443|DRUG|Gabapentin|Gabapentin is a structural analogue of GABA that decreases activation of voltage-activated calcium channels which may decrease release of excitatory neurotransmitters such as glutamate. Its analgesic mechanisms have been utilized effectively for the treatment of chronic pain in several disorders such as cancer, fibromyalgia and diabetic peripheral neuropathy.
224190009|NCT02419443|DRUG|Placebo|Control group
224190010|NCT04047459|OTHER|Tissue samples collection and cells isolation|During surgery, leftover samples of bone (femoral head/ trabecular bone tissue) and muscle will be collected. Then they will be sent to the laboratory where isolation of cells will be performed.
224190011|NCT06198179|OTHER|upper limb children action-observation training (UPCAT)|upper limb children action-observation training (UPCAT) without visual Feedback
224190012|NCT06198179|OTHER|upper limb children action-observation training (UP-CAT) with visual feedback|upper limb children action-observation training (UP-CAT) with visual feedback: Mirror therapy as visual feedback
224190013|NCT03762642|PROCEDURE|Mastectomy|Removal of the whole breast
224190014|NCT03762642|PROCEDURE|Breast-Conserving Surgery|Removal of the cancerous tissue only
224309520|NCT00559806|OTHER|2 weeks of unilateral immobilisation and 4 weeks of resistance training|2 weeks of whole leg casting (side randomized)followed by 4 weeks of unilateral resistance training. The non-imm side served as a within-subject control
224309521|NCT00559806|OTHER|2 weeks of unilateral immobilisation and 4 weeks of resistance training|2 weeks of unilateral whole leg casting (side randomized)followed by 4 weeks of unilateral resistance training. The non-imm side served as a within-subject control
223500096|NCT03838874|DRUG|Low-Dose Bupivacaine|10 mg (2 mL of 0.5%) administered as an isobaric spinal anesthetic
223500097|NCT03838874|DRUG|Mepivacaine|70 mg (3.5 mL of 2%) administered as an isobaric spinal anesthetic
223500098|NCT06302283|OTHER|Survey|Survey (online or paper) on caregiving burden and bereavement
223500099|NCT04099420|BEHAVIORAL|Lifestyle counseling|An in-depth analysis of the lifestyle of Italian and Spanish university students will be carried out for the first time, with assessment of the frequency of self-medication and use of drugs and supplements/nutraceuticals. The composition of the oral microbiota in relation to eating habits will be determined for the first time. The results of this study will be useful for designing promotion programs for the correct use of drugs/supplements and for healthy diets and lifestyles in university students
223591328|NCT00825721|DRUG|C-KAD Ophthalmic Solution|4 drops applied daily for 360 days
223591329|NCT00825721|DRUG|C-KAD Ophthalmic Solution|4 drops applied daily for 360 days
223591330|NCT00825721|DRUG|C-KAD Ophthalmic Solution|4 drops applied daily for 360 days
223591331|NCT04119102|DRUG|Duobrii|duobrii applied daily for 4 weeks followed by every other day for 4 weeks.
224309522|NCT04150770|DRUG|infliximab|
224309523|NCT01115478|DIETARY_SUPPLEMENT|Vitamin A|Daily oral dose of 2500 IU from enrollment until delivery
224309524|NCT01115478|DIETARY_SUPPLEMENT|Zinc|Daily oral dose of 25 mg from enrollment until delivery
223500100|NCT03476512|OTHER|Adherence Education|Patients were given adherence education to resolve the identified deficits
223500101|NCT05378321|DIAGNOSTIC_TEST|Non-invasive diagnostic testing|Non-invasive diagnostic testing consists of the use of the FibroScan device and the calculation of non-invasive blood-based scores for the diagnosis of NAFLD
223591332|NCT02874027|OTHER|The TBI patients with depression|The study is to investigate whether exist the relationship between depression and circadian rhythm of patients with TBI or not.
223591333|NCT05172674|DIAGNOSTIC_TEST|ultrasound according routine antenatal care|ultrasound examinations at 11-14, 19-22 and 33-35 weeks
223591334|NCT05383534|DRUG|Propofol Injection|propofol injections were used for the induction of anesthesia according to the body weight of the patients.
223591335|NCT01042652|DRUG|Raltegravir|Raltegarvir 400mg bid
223591336|NCT00259207|PROCEDURE|Pulmonary valve insertion|Pulmonary valve insertion
223591337|NCT00259207|PROCEDURE|medical surgery hybride|medical surgery hybride
224309525|NCT01115478|OTHER|Placebo|Daily oral dose from enrollment until delivery
224309526|NCT03986411|OTHER|Phase 1: Qualitative interviews: Health care professionals|Semi-structured interviews of health care professionals to explore current management of urinary incontinence in the community
224309527|NCT03986411|OTHER|Phase 2: Physiotherapy for urinary incontinence|Tailored physiotherapy assessment and management for athletic women who self-report urinary incontinence
224309528|NCT03986411|OTHER|Phase 3: Qualitative Interviews: Participants|Semi-structured interviews of a purposeful selection of the participants from Phase 2 to explore reaction to the recruitment process and the intervention
224309529|NCT04409483|DRUG|Lopinavir-Ritonavir Drug Combination|400mg/100mg taken orally twice daily for 14 days.
224309530|NCT04409483|COMBINATION_PRODUCT|Standard Care|Paracetamol as needed for the symptomatic treatment of fever and vitamin C 1000 mg daily
223500102|NCT05293834|BEHAVIORAL|Virtual Reality Aggression Prevention Training (VRAPT)|"VRAPT consists of sixteen 45- to 60-minute sessions that take place once or twice per week (total duration of the intervention = 8 to 16 weeks). Session time and intensity will be adapted to the individual participant and the sessions will be delivered by specially trained VRAPT therapists in individual settings. The immersive and interactive three-dimensional virtual environment will be presented via headphones and head-mounted displays, using software developed by CleVR. In the virtual environment, participants will interact with virtual characters that are controlled by the psychotherapist and practice new skills . The therapy program is targeted at factors and processes related to aggression and the underlying theoretical framework is based on cognitive behavioural therapy and the General Aggression Model (GAM).~The VRAPT consists of 4 phases:~1. Introduction (Session 1)~2. Inventory phase (Sessions 2-6)~3. Skills-training (Sessions 6-15)~4. Evaluation (Session 16)"
224190015|NCT03391258|PROCEDURE|Bone Regeneration with GLAM technique|Bone regeneration with GLAM technique in full arch implant supported rehabilitation
224190016|NCT00226226|PROCEDURE|Peripherally Inserted Central Catheter Placement|
224190017|NCT01789307|DIETARY_SUPPLEMENT|corn syrup solids|oral ingestion 50 grams, 2 doses
224190018|NCT01789307|DIETARY_SUPPLEMENT|sucrose|oral ingestion 50 grams, 2 doses
224190019|NCT01424631|PROCEDURE|single incision laparoscopic appendectomy|
223500103|NCT05100342|DIAGNOSTIC_TEST|Point score prediction tool for 30-day survival|"This tool requires laboratory data including white blood cell count, neutrophil-lymphocyte ratio, blood urea nitrogen, bilirubin, albumin, lactate dehydrogenase, and red cell distribution, as well as number of attendances to the emergency room in the past 100 days, the site receiving radiation therapy, and the primary cancer type. Each data point correlates with a point value, which are tallied to generate a final score.~The scores range from 0-20, with 0 giving the highest chance for survival at 30 days and 20 giving the lowest chance for survival at 30 days"
223500104|NCT04359888|OTHER|Multi-Modality Balance Intervention|Three one-hour training sessions 2-3x per week for six weeks in Multi-Modality Balance Intervention (MMBI). (See Study Design)
223500105|NCT04359888|OTHER|Balanced Reach Training (BRT)|One-hour training sessions 2-3x per week for six weeks in the Balanced Reach Training Protocol (BRTP) (See Study Design).
223591338|NCT02774304|DEVICE|arterial line|In mechanically ventilated patients systolic pressure variation will be captured and passive leg raising with positive result fluid filling will be initiated.
223591339|NCT02774304|DEVICE|Cheetah®|In mechanically ventilated patients systolic pressure variation will be captured and passive leg raising with positive result fluid filling will be initiated.
223591340|NCT04915417|RADIATION|Stereotactic Ablative Body Radiotherapy (SABR)|Patients will receive 27-30 Gy in 3 fractions to the planning target volume (PTV) with a simultaneous in-field boost to the metabolically active areas of the gross tumor volume (GTV) to a maximum of 45 Gy. Patients will be treated every other day.
223591341|NCT03175146|RADIATION|Stereotactic Body Radiation Therapy|5 treatments given over 2 weeks
223591342|NCT00661947|OTHER|Dr Pepper sweetened with sucrose or high fructose corn syrup|Comparison of different formulations of fructose.
224190020|NCT01424631|PROCEDURE|conventional laparoscopic appendectomy|
224190021|NCT02770534|PROCEDURE|blood test|10mls extra mls of blood taken during usual phlebotomy procedures
224190022|NCT03325569|DIAGNOSTIC_TEST|oral glucose tolerance test|GLP1 response to oral glucose load during oral glucose tolerance test was assessed.
224190023|NCT05719701|DRUG|ICP-490|Several dose groups of ICP-490 are planned for the dose exploration.
224190024|NCT05719701|DRUG|Dexamethasone|Oral Dexamethasone is administered on Days 1, 8, 15, and 22 of each 28-day cycle.
224309531|NCT00258128|DRUG|Salsalate|Active
224190025|NCT00106769|DRUG|VRC-WNVDNA017-00-VP|
224190026|NCT01582932|DRUG|Calcipotriene 0.005% Foam|All treatments will be administered topically twice daily (morning and evening) for 8 weeks to areas affected with psoriasis (excluding face).
224309532|NCT00258128|DRUG|Placebo|Placebo for salslate, used only in the third trial
224309533|NCT03977714|DEVICE|Zirconia implants with G3-coated abutments (test implants and abutments)|"Test and control interventions correspond to those usually applied in dental implantology. The two-step protocol will be followed. Local anesthesia will be applied. A flap will be raised to perform a progressive perforation with a gradual increase of the orifice and a profuse irrigation until the bone preparation adapts perfectly to the implant. Implants will wear a closure cap and will be covered within the gingival flap during osseointegration (eight weeks), after which they will be exposed to evaluate secondary stability and to place the abutment, for which local crestal anesthesia will be applied. To expose the closure cap, a tissue punch will generally be used. Once placed, the abutments will not be removed from the implants. All abutments will be covered with a PEEK healing cap during prosthesis fabrication. Finally, the implants will be rehabilitated with fixed prostheses according to the needs of each patient. A follow-up period of 1 year is expected."
224190027|NCT01169623|OTHER|Assessing the Effect Of Educational Intervention Based On Supportive Leadership Behavior on Iranian head nurses leadership performance|55 of head nurses who will participate in educational Intervention arm based on supportive leadership behaviour model
224190028|NCT05180071|DEVICE|TEMA elbow system|Total elbow replacement
224190029|NCT00785252|DEVICE|Powered Intraosseous device (EZIO)|EZIO
224190030|NCT00785252|DEVICE|standard central line|placement of a central line
224190031|NCT00923299|DRUG|cetuximab|Cetuximab at the initial dose of 400 mg/m² (J1S1) as a 2-hour infusion and then at the 250 mg/m² dose as a 1-hour infusion in subsequent weeks.
224190032|NCT00923299|DRUG|trastuzumab|"Two dose levels of trastuzumab will be evaluated for Phase 1:~* Level 1: a loading dose of 3 mg/kg as a 90-minute intravenous infusion at J1S1 and then 1.5 mg/kg as a 30-minute intravenous infusion for all subsequent weekly administrations;~* Level 2: a loading dose of 4 mg/kg as a 90-minute intravenous infusion at J1S1 and then 2 mg/kg as a 30-minute intravenous infusion for all subsequent weekly administrations."
224190033|NCT03331952|OTHER|Prospective study|To identify and characterise patients with culture proven invasive pneumococcal disease or probable bacterial meningitis over the first three years after PCV13 introduction in Cambodia in January 2015.
224190034|NCT03331952|OTHER|Prospective study|To identify and characterise patients hospitalised with clinical and/or radiologic pneumonia over the first three years after PCV13 introduction in Cambodia in January 2015
224309534|NCT03977714|DEVICE|Zirconia implants with control abutments (test implants, negative control abutments)|"Test and control interventions correspond to those usually applied in dental implantology. The two-step protocol will be followed. Local anesthesia will be applied. A flap will be raised to perform a progressive perforation with a gradual increase of the orifice and a profuse irrigation until the bone preparation adapts perfectly to the implant. Implants will wear a closure cap and will be covered within the gingival flap during osseointegration (eight weeks), after which they will be exposed to evaluate secondary stability and to place the abutment, for which local crestal anesthesia will be applied. To expose the closure cap, a tissue punch will generally be used. Once placed, the abutments will not be removed from the implants. All abutments will be covered with a PEEK healing cap during prosthesis fabrication. Finally, the implants will be rehabilitated with fixed prostheses according to the needs of each patient. A follow-up period of 1 year is expected."
224309535|NCT03977714|DEVICE|Titanium implants with G3-coated abutments (control implants, test abutments)|"Test and control interventions correspond to those usually applied in dental implantology. The two-step protocol will be followed. Local anesthesia will be applied. A flap will be raised to perform a progressive perforation with a gradual increase of the orifice and a profuse irrigation until the bone preparation adapts perfectly to the implant. Implants will wear a closure cap and will be covered within the gingival flap during osseointegration (eight weeks), after which they will be exposed to evaluate secondary stability and to place the abutment, for which local crestal anesthesia will be applied. To expose the closure cap, a tissue punch will generally be used. Once placed, the abutments will not be removed from the implants. All abutments will be covered with a PEEK healing cap during prosthesis fabrication. Finally, the implants will be rehabilitated with fixed prostheses according to the needs of each patient. A follow-up period of 1 year is expected."
223500106|NCT05709132|BEHAVIORAL|iPeer2Peer Program|Behavioral: iPeer2Peer Support Mentorship Program is an online peer support mentorship program that has been established in multiple chronic disease populations as a self-management intervention, including chronic pain and juvenile idiopathic arthritis. The iPeer2Peer program provides modeling and reinforcement by pre-screened and trained young adult peer mentors to adolescent mentees.
223500107|NCT05029063|DRUG|Rivaroxaban 10 MG|Identical comparator drug
223500108|NCT06508827|DRUG|Iron dextran 1000 mg IV|Iron dextran 1000 mg IV will be administered once, about 7 days prior to standard of care treatment.
223591343|NCT02449590|DIETARY_SUPPLEMENT|Onion powder|Hot meals with onion powder; 10 g/day onion powder corresponding to 100 g/day fresh onion in meals with potato and beef Intervention period 14 days.
223591344|NCT02449590|DIETARY_SUPPLEMENT|Placebo|Hot meals without onion powder; Control meal with potato, beef, soy protein, and sucrose to match macronutrient composition of active treatment
223591345|NCT04901091|OTHER|Not Provided|Not Provided
223591346|NCT03220386|OTHER|Decolonization by nasal Octinidin treatment and skin washings|Patients receive nasal Octinidin treatment and skin washings for five consecutive days
223591347|NCT02039856|OTHER|Multilevel stakeholder engagement|Structured, in-person stakeholder panel meeting of VA network, VA medical center, and primary care and women's health leaders using modified Delphi panel techniques to come to consensus on a quality improvement (QI) roadmap within each participating VA network, followed by intermittent progress reporting and post-24 months in-person capstone stakeholder panel meetings
223591348|NCT02039856|OTHER|Quality improvement (QI) education/training|Initial in-person and ongoing virtual team training in QI principles, methods, and project proposal development and refinement
223500109|NCT06495489|OTHER|Detection of preload responders by a PLR test|Detection of preload dependency by using PLR test and echocardiography
223500110|NCT01767415|DRUG|Indigo carmine|During resection, a small quantity of a special dye called indigo carmine will be infused at the margins of the tumor using computer-guided stereotactic navigation equipment. This dye will be visible during the tumor resection and it can potentially serve as an additional marker of the tumor margins. A post-operative MRI scan -which is part of the standard care- will accurately measure the extent of tumor resection.
223591349|NCT02039856|OTHER|Technical support|Research team provided technical review of and feedback on local QI project proposals, helped develop and/or recommend process/outcome measures, identified and shared relevant published literature (e.g., measures, interventions), and provided general technical support (e.g., how to analyze local data, how to conduct a local focus group)
223591350|NCT02039856|OTHER|Formative feedback|Research team provided aggregated all-site and local data from baseline patient and provider/staff surveys, 12-month patient surveys, and other data and findings to local teams for ongoing and new QI project idea development
223591351|NCT02039856|OTHER|External practice facilitation|Within and across site calls with local teams to review progress, identify needs, help solve problems, discuss current and new projects, as well as potential for spread
224309536|NCT03977714|DEVICE|Titanium implants with control abutments (negative control implants and abutments)|"Test and control interventions correspond to those usually applied in dental implantology. The two-step protocol will be followed. Local anesthesia will be applied. A flap will be raised to perform a progressive perforation with a gradual increase of the orifice and a profuse irrigation until the bone preparation adapts perfectly to the implant. Implants will wear a closure cap and will be covered within the gingival flap during osseointegration (eight weeks), after which they will be exposed to evaluate secondary stability and to place the abutment, for which local crestal anesthesia will be applied. To expose the closure cap, a tissue punch will generally be used. Once placed, the abutments will not be removed from the implants. All abutments will be covered with a PEEK healing cap during prosthesis fabrication. Finally, the implants will be rehabilitated with fixed prostheses according to the needs of each patient. A follow-up period of 1 year is expected."
224309537|NCT03977714|DEVICE|Zirconia implants and titanium implants, for histological and histomorphometric evaluation.|"6 implants (3 tests and 3 controls) will be used to evaluate and compare osseointegration, via histological and histomorphometrical analysis, in the area of the wisdom teeth (non useful sites that will not interfere with the rest of the study or the patient's life) - it can only be performed in patients who no longer have these teeth. The procedure will match that described for Groups A-B-C-D. In this case, implants will only remain in the mouth for 2 months, after which they will be removed for analysis. The extraction will be performed with local anesthesia. A flap will be raised to expose the implant and, using a trephine bur (1 mm wider than the implant diameter), a bone cylinder containing the implant will be extracted. The resulting bone defect and regeneration process will be similar to those following a normal molar extraction. The flap will be sutured and primary curing is expected. A new implantation will not be carried out since in this area it is totally unnecessary."
224309538|NCT04982302|PROCEDURE|Non-surgical periodontal treatment|Subgingival instrumentation with ultrasonic devices and curettes of all periodontal pockets
224309539|NCT02940808|DIETARY_SUPPLEMENT|Caffeine (200mg)|Oral consumption of capsule containing 200mg caffeine.
223500111|NCT05893823|DIAGNOSTIC_TEST|Pelvis CT scan|Post-THA hip pelvis CT scan execution for pain, noise or THA planning for the controlateral hip, with identification of acetabular cup protrusion. Comparation of cases and controls to identify radiological factors that could potentially lead to symptomatic psoas impingement prediction.
223500112|NCT06964737|BIOLOGICAL|Anti-GARP Chimeric Antigen Receptor-T Cells|Given intracavitary
224190035|NCT03331952|OTHER|Cross-sectional surveys|Three annual surveys, enrolling 450 children each year, will be done to identify and characterise pneumococcal nasopharyngeal colonisation in AHC out-patient department (OPD) attendees
224190036|NCT06038370|BEHAVIORAL|Self-induced cognitive trance|The cognitive trance-based intervention will consist of a two-day workshop in groups of approximately 10 participants, where they will learn how to induce the cognitive trance, with the use of different sound-loops that can induce trance in untrained people in a safe way. After two weeks of home practice, participants will redo a two-day consolidation training. At-home practice is encouraged between sessions.
224190037|NCT03156946|BEHAVIORAL|breastfeeding mother-to-mother support|The mother-infant dyads in the intervention arm will receive breastfeeding mother-to-mother support from the hospitalization in the maternity and NICU up to 1 month after discharge. The intervention will be in addition to the usual or routine care. Breastfeeding counselors will be voluntary mothers who breastfed their own preterm infant (aged between 6 months and 5 years at the time of the study) for a minimum of 2 months, and who have had a positive personal breastfeeding experience, and who have undertaken a training course.
224190038|NCT03156946|BEHAVIORAL|Control|The mother-infant dyads in the control arm will continue to receive the usual/routine care provided by participating centers during the hospitalization and Mother and Infant Protection service after discharge.
224190039|NCT01489345|DRUG|ONO-2952|30 mg to 100 mg QD at a multiple dose, and 21 days duration
224190040|NCT01489345|DRUG|ONO-2952 Matching Placebo|30 mg to 100 mg QD at a multiple dose, and 21 days duration
224309540|NCT02940808|OTHER|Placebo|Oral consumption of capsule containing a placebo substance.
224309541|NCT02348255|PROCEDURE|Electric Field Therapy|Undergo NovoTTF-100A
224309542|NCT02348255|BIOLOGICAL|Bevacizumab|Given IV
224309543|NCT02348255|DRUG|Carmustine|Given IV
224309544|NCT02348255|OTHER|Quality-of-Life Assessment|Ancillary studies
224309545|NCT03147625|BEHAVIORAL|SHAPE Intervention|SHAPE seeks to identify, equip and strengthen resources in elderly residing in elderly-only households. The content will be further developed according to the findings of an existing descriptive qualitative study, literature review and a multi-disciplinary expert panel review. The home visit will involve assessment, observation and evaluation of elderly' health status, lifestyle and home environment, followed by guidance on health-promoting behaviour and emphasis on strengthening inner health resources. This provides an individualized approach to enhance personal health skills. Group-based activity sessions are directed to facilitate group interaction among peers as well as equipping and enhancing external resources.
224309546|NCT05939583|OTHER|Shock Wave Therapy|Receiving Shock wave therapy + US, TENS, IR and exercises.
224309547|NCT05939583|OTHER|US, TENS, IR and exercises.|Receiving US, TENS, IR and exercises only.
223500113|NCT06964737|PROCEDURE|Biospecimen Collection|Undergo collection of CSF and blood samples
223500114|NCT06964737|PROCEDURE|Chest Radiography|Undergo chest x-ray
223500115|NCT06964737|PROCEDURE|Echocardiography Test|Undergo ECHO
223500116|NCT06964737|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223591352|NCT02039856|OTHER|National policy guidance|VA Handbooks on policy and practice for PACT implementation guidance and on delivery of comprehensive women's health services disseminated to all VA facilities
223591353|NCT03911024|BEHAVIORAL|HIV|At the completion of each EMA, participants in the intervention group (n=50) will receive messages that address:1) unsafe sexual behaviors, 2) alcohol/drug use, 3) PrEP interest, and 4) HIV testing. In addition, participants will have access to a button in the app that will link them to resources when/if they are the victim of sexual assault. Finally, intervention arm youth will be asked to set a behavioral goal related to HIV prevention during this session. Those goals will include increasing condom use, PrEP use, non-occupational post-exposure prophylaxis (nPEP) use, reducing number of sexual partners, not having sex with using drugs or drinking alcohol, avoiding IV drug use, getting testing for HIV, and testing and treating sexually transmitted infections (STIs) as needed
223591354|NCT03911024|BEHAVIORAL|General health|Participants in the attention control condition (n=50) will answer the same EMA items as the Intervention group. However, the intervention messages will contain content related to nutrition, physical activity, sleep hygiene, and tobacco use. Finally, control arm youth will be asked to set a behavioral goal related to general health during this session.Those goals will include getting 7+ hours of sleep, eating \>= 5 servings of fruits or vegetables, not using tobacco products, exercising at least 60 minutes.
223591355|NCT06502938|DEVICE|Pan-vascular interventional robotic system|Pan-vascular interventional robotic system assited PCI for delivery and manipulation of guidewires, catheters, and quick exchange balloon dilatation catheters/stents.
224190041|NCT03866811|BEHAVIORAL|Dr. Erica|The 10 week texting intervention contains the follow characteristics to increase engagement: (1) Dr. ERICA (Emergency Room Interventions to Improve the Care of Adolescents): The persona and brand of the intervention is Dr. Erica, a relatable, empathetic, straightforward and reliable female doctor; (2) Personalization: Information collected at baseline will be incorporated into each individualized program; (3) Interactivity: The majority of text message algorithms contain 3-4 two-way automated messaging conversations. (4) Feedback loops: The investigators will collect feedback from participants to prompt action; (5) Visual stimuli: Texts include emojis, memes, and other visual stimuli, similar to current teen texting behaviors; (6) Social media: The investigators designed sexual health comic strips posted as an Instagram story; (7) Links and role modeling: Texts contain links to testimonials, influencers, and evidence-based websites.
224190042|NCT03602976|DRUG|Ursodeoxycholic Acid|weight-based dosing
224190043|NCT01377857|BEHAVIORAL|Monetary Incentive|$1, $5, or $10 incentive
224190044|NCT01377857|BEHAVIORAL|Questionnaire Timing|Timing of the questionnaire--either before or after testing is offered.
224190045|NCT01377857|BEHAVIORAL|HIV Test Offering|HIV Test will be offered as opt-in, opt-out, or active choice.
224190046|NCT02605135|DEVICE|Continued Pessary Use|Pessary Fitting
224190047|NCT06175871|OTHER|OTAGO exercises|Exercices for improvement postural control and mobility and decrease falls risks
224190048|NCT06175871|OTHER|Conventional therapy|Exercice and education from physical therapy practice conventional from Hospital.
223500117|NCT06964737|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
223500118|NCT06964737|PROCEDURE|Pheresis|Undergo apheresis
223500119|NCT06964737|PROCEDURE|Surgical Procedure|Undergo surgery and placement of CSF reservoir
223500120|NCT05575011|DRUG|BIIB115|Administered as specified in the treatment arm
223591356|NCT06502938|PROCEDURE|Traditional artificial percutaneous coronary intervention|Doctors perform traditional percutaneous coronary intervention
223591357|NCT04892108|PROCEDURE|STARR (Stapled Trans Anal Rectal Resection)|Patients randomly assigned to surgical intervention of STARR (Stapled Trans Anal Rectal Resection)
223591358|NCT04892108|PROCEDURE|LVR (Laparoscopic Ventral Rectopexy)|Patients randomly assigned to surgical intervention of LVR (Laparoscopic Ventral Rectopexy)
223591359|NCT03675984|BEHAVIORAL|asymmetrical stabilization exercise|Exercise is combined to form an appropriate combination of motion (Side-lying, Bird-dog, Prone arm lift, Prone leg lift) according to the curve pattern and muscle weakness of each patient's.
223591360|NCT06342596|DRUG|[14C]-LY3473329|Administered orally
223500121|NCT05575011|DRUG|BIIB115-Matching Placebo|Administered as specified in the treatment arm
223591361|NCT06342596|DRUG|[14C]-LY3473329|Administered IV
223591362|NCT06342596|DRUG|LY3473329|Administered orally
223591363|NCT04839120|DRUG|MDPK67b|Two subgroups (Panels A and Panel B) of four subjects were to be randomly allocated either to placebo or to three increasing doses of MDPK67b, administered as single infusion at intervals of at least two weeks during the first three periods with the last period involving four repeated doses administered at three-day intervals.
223500122|NCT05920005|DRUG|candesartan cilexetil + chlorthalidone + amlodipine|Antihypertensive drugs in a single tablet (association candesartan cilexetil 16mg + chlorthalidone 12.5mg + amlodipine 5mg)
223500123|NCT05920005|DRUG|Exforge HCT® (valsartan 160mg + hydrochlorothiazide 12.5mg + amlodipine 5mg)|Antihypertensive drugs in a single tablet (association valsartan 160mg + hydrochlorothiazide 12.5mg + amlodipine 5mg)
223500124|NCT04412889|BIOLOGICAL|BCMA/CD19 dual-target CAR-T cell immunotherapy|The intervention is a CAR-T cell immunotherapy targeted CD19 and BCMA. The dosage ranges from 2×10\^5 to 1×10\^6 CAR+T/Kg.
223591364|NCT04839120|DRUG|Placebo|Two subgroups (Panel A and Panel B) of four subjects were to be randomly allocated either to placebo or to three increasing doses of MDPK67b, administered as single infusion at intervals of at least two weeks during the first three periods with the last period involving four repeated doses administered at three-day intervals.
223591365|NCT02409342|DRUG|Atezolizumab (MPDL3280A) [TECENTRIQ], an engineered anti-PDL1 antibody|Atezolizumab 1200 milligram (mg) will be administered as intravenous infusion every 21 days until loss of clinical benefit (as assessed by the investigator), unacceptable toxicity, or death (maximum up to approximately 58 months).
224190049|NCT01273246|BIOLOGICAL|100U inactivated Enterovirus Type 71 Vaccine|Inactivated Enterovirus Type 71 Vaccine, 100U per 0.5ml per dose. Vaccine will be administered as a single 0.5 mL intramuscular injection in the deltoid muscle of the arm
224190050|NCT01273246|BIOLOGICAL|200U inactivated Enterovirus Type 71 Vaccine|Inactivated Enterovirus Type 71 Vaccine, 200U per 0.5ml per dose. Vaccine will be administered as a single 0.5 mL intramuscular injection in the deltoid muscle of the arm
224190051|NCT01273246|BIOLOGICAL|400U inactivated Enterovirus Type 71 Vaccine|Inactivated Enterovirus Type 71 Vaccine, 400U per 0.5ml per dose. Vaccine will be administered as a single 0.5 mL intramuscular injection in the deltoid muscle of the arm
224190052|NCT01273246|BIOLOGICAL|Placebo|Placebo, all components of the trial vacccine except for the Enterovirus Type 71 virus antigen, 0.5ml per dose. Placebo will be administered as a single 0.5 mL intramuscular injection in the deltoid muscle of the arm
224190053|NCT00003758|DRUG|cytarabine|
224190054|NCT00003758|DRUG|idarubicin|
224190055|NCT00003758|PROCEDURE|allogeneic bone marrow transplantation|
224190056|NCT00003758|PROCEDURE|autologous bone marrow transplantation|
224190057|NCT00003758|PROCEDURE|peripheral blood stem cell transplantation|
224190058|NCT05136482|DEVICE|Cryocompression|A cryocompression device will be attached to the lower limb of participants using a cuff spanning from the mid-thigh to mid-calf. The device will exert a constant pressure of 25 mmHg throughout each test session. The device will pump temperature-controlled cold water through the cuff in order to reduce the skin temperature around the knee (and intra-articular temperature). Depending on the condition, the temperature of the water being pumped through the device will be either 6, 8, 10, or 12℃. Each test session will last for 30 minutes. Participants will take part in all conditions, with at least 24 hours rest in between test sessions. Skin temperature around the knee will be measured prior to the cryocompression device being applied; every 5 minutes during the 30 minute test; and every 5 minutes after the test until skin temperature \>15℃.
224190059|NCT05158972|DRUG|Dymista|1 spray per nostril twice daily up to four weeks
224190060|NCT03096249|DRUG|Oxytocin|Syntocinon nasal spray: single dose of 24IU (3 puffs of 4IU per nostril)
224190061|NCT03096249|OTHER|Placebo|Placebo spray: single dose (3 puffs per nostril).
224190062|NCT03260621|DIAGNOSTIC_TEST|stress CMR|additional stress CMR to the established clinical diagnostics
224190063|NCT03131375|DRUG|Dexmedetomidine|Group A and B: Anesthesia induction drugs:propofol, fentanyl, rocuronium . After induction of anesthesia: Group A receives a 50 ml NS infusion containing 1 mcg kg-1 Dexmedetomidine drug Group A and B: Atropine as an antisialagogue, dexamethasone, ondasetrone for the prevention of postoperative nausea and vomiting. Anesthesia maintainance: propofol, remifentanil and oxygen in air. End of surgery, the infusion of propofol and remifentanil stop and sugammadex for reversal of neuromuscular block is given. Postoperative analgesia by nalbuphine 0.2 mg kg-1 given before the end of surgery in Group B, and 0.16 mg kg-1 in Group A. Monitoring: ECG, NIBP, ETCO2, SpO2, Bispectral index , Train of four ratio.
224190064|NCT03131375|DRUG|Normal saline|Group A and B: Anesthesia induction drugs:propofol, fentanyl, rocuronium . After induction of anesthesia: Group B receives a volume matched Normal saline infusion. Group A and B: Atropine as an antisialagogue, dexamethasone, ondasetrone for the prevention of postoperative nausea and vomiting. Anesthesia maintainance: propofol, remifentanil and oxygen in air. End of surgery, the infusion of propofol and remifentanil stop and sugammadex for reversal of neuromuscular block is given. Postoperative analgesia by nalbuphine 0.2 mg kg-1 given before the end of surgery in Group B. Monitoring: ECG, NIBP, ETCO2, SpO2, Bispectral index, Train of four ratio.
224190065|NCT03131375|DEVICE|Bispectral index|Group A and B: Monitoring depth of anesthesia by BIS device and adjusting propofol infusion according to measurements, aiming to BIS values: 40-60
224190066|NCT03131375|DEVICE|Train of four ratio|Group A and B: Monitoring recovery of neuromuscular function with TOF-Watch device, to ensure TOFR equals or greater than 90% at the end of the procedure
224190067|NCT04837807|DRUG|Systane Hydration PF|This is an over-the-counter preservative free artificial tear that can be purchased at most retail stores and pharmacies.
224190068|NCT04899570|DRUG|Zanubrutinib|160mg Bid, oral, d1-21 in a 21-day cycle for 8 cycles.
224190069|NCT04899570|DRUG|Rituximab|Rituximab 375mg/m2 intravenous infusion d1, every 21 days for 1 cycle. 8 cycles will be prescribed as protocol
224190070|NCT04899570|DRUG|Cyclophosphamide|Cyclophosphamide 750mg/m2 intravenous infusion d1, every 21 days for 1 cycle. 8 cycles will be prescribed as protocol
224309548|NCT03101865|DEVICE|FlorenceM|The automated closed loop system (FlorenceM) will consist of: Next generation sensor augmented Medtronic insulin pump 640G (Medtronic Minimed, CA, USA) incorporating the Medtronic Enlite 3 family real time CGM and glucose suspend feature. An Android smartphone containing the Cambridge model predictive algorithm and communicating wirelessly with the insulin pump using a proprietary translator device.
223500125|NCT06372535|BEHAVIORAL|Tai Chi Chuan （dose 1）|"Participants would take 24-form simplified Tai Chi Chuan 0.5 hour/session, 5 sessions/week for 8 weeks.~There were 10 minutes warm-up, 30 minutes Tai Chi Chuan lesson and 10 minutes cool-down exercises in the Tai Chi Chuan training."
223500126|NCT06372535|BEHAVIORAL|Tai Chi Chuan （dose 2）|"Participants would take 24-form simplified Tai Chi Chuan 0.5 hour/session, 5 sessions/week for 16 weeks.~There were 10 minutes warm-up, 30 minutes Tai Chi Chuan lesson and 10 minutes cool-down exercises in the Tai Chi Chuan training."
223500127|NCT06372535|BEHAVIORAL|Tai Chi Chuan （dose 3）|"Participants would take 24-form simplified Tai Chi Chuan 0.5 hour/session, 5 sessions/week for 24 weeks.~There were 10 minutes warm-up, 30 minutes Tai Chi Chuan lesson and 10 minutes cool-down exercises in the Tai Chi Chuan training."
223500128|NCT06372535|BEHAVIORAL|Tai Chi Chuan （dose 4）|"Participants would take 24-form simplified Tai Chi Chuan 1 hour/session, 5 sessions/week for 8 weeks.~There were 10 minutes warm-up, 60 minutes Tai Chi Chuan lesson and 10 minutes cool-down exercises in the Tai Chi Chuan training."
223500129|NCT06372535|BEHAVIORAL|Tai Chi Chuan （dose 5）|"Participants would take 24-form simplified Tai Chi Chuan 1 hour/session, 5 sessions/week for 16 weeks.~There were 10 minutes warm-up, 60 minutes Tai Chi Chuan lesson and 10 minutes cool-down exercises in the Tai Chi Chuan training."
224190071|NCT04899570|DRUG|Epirubicin|Epirubicin 70mg/m2 intravenous infusion d1, every 21 days for 1 cycle. 8 cycles will be prescribed as protocol
224190072|NCT04899570|DRUG|Vindesine|Vindesine 4mg intravenous infusion d1, every 21 days for 1 cycle. 8 cycles will be rescribed as protocol
224190073|NCT04899570|DRUG|Prednisone|Prednisone 60mg/m2 orally d1-5, every 21 days for 1 cycle. 8 cycles will be rescribed as protocol
224190074|NCT04408326|DRUG|Angiotensin II|Exogenous angiotensin II acts on angiotensin II type 1 receptor and raise blood pressure by vasoconstriction, salt and water retention, and stimulation of aldosterone hormone
224190075|NCT04408326|DRUG|Interleukin-1 receptor antagonist|Interleukin-1 receptor antagonist is an immunomodulating drug aiming to mitigate cytokine storm in COVID-19 patients
224190076|NCT05333861|DRUG|hetrombopag|According to prescription
224190077|NCT06457659|BEHAVIORAL|Early Rehab Group|The first group of 25 Patients was fitted with Prosthesis with in 6months of duration after amputation. The basic theme was to check the physical psychological and QOL in early prostheic-fitted patients through WHO\_QOL.
224309549|NCT02213653|DRUG|ARM A : IV iron + epoietin zeta|"* Epoietin zeta at a dose of 450 IU / kg per week subcutaneously~* Carboxymaltose ferric (Ferinject ®) at week 1; Intravenous infusion not exceeding 1000 mg (administered once if weight\> 50 kg, 500 mg twice otherwise, with an interval of one week between each administration).~  * Renewable with a minimum of 4 weeks depending on the iron status (if CST \<20% and absence of serum ferritin\> 800) in the same manner as week 1."
224190078|NCT06457659|OTHER|Delayed Rehab Group|The 2nd group of 25 patients was fitted with Prosthesis after 6 months after amputation. No physical rehab was done during this period including physiotherapy and prosthetic treatment. The main aim was to check the significant impact of delayed rehabilitation.
224190079|NCT01412411|BEHAVIORAL|Nutritionl Education|to assess the change in behaviour
224190080|NCT01412411|DIETARY_SUPPLEMENT|Oral Iron Supplementation along with Nturition Eductaion|
224190081|NCT01412411|DIETARY_SUPPLEMENT|Multiple micronutrient fortification plus Nutrition Education|
224190082|NCT02780180|DRUG|QGC001|
224190083|NCT02780180|DRUG|Placebo|Lactose capsule manufactured to mimic QGC001 50 mg and 250 mg
224190084|NCT03073642|OTHER|Pain Education|Together with hydrotherapy, patients will receive pain therapeutic education
224190085|NCT03073642|OTHER|Hydrotherapy|Hydrotherapy sessions, lasting 45 minutes, twice a week for 12 weeks.
224190086|NCT05811507|DIAGNOSTIC_TEST|serum total testosterone, serum androsterone, serum androstenedione and serum dehydroepiandrosterone sulfate|Venous blood samples will be collected into sterile EDTA tubes around 10 am. Blood taken from controls will be collected at the same time. All samples will be delivered into the laboratory immediately after collection and centrifuged at 3000 × g, 4 °C for 10 min. Plasma samples were stored at -80 °C until the analysis using ELIZA
224190087|NCT05811507|DIAGNOSTIC_TEST|The Childhood Autism Rating Scale (CARS)|It is done by rating the child's behaviors from 1 to 4. 1 being normal for your child's age, 2 for mildly abnormal, 3 for moderately abnormal, and 4 as severely abnormal. Scores range from 15 to 60 with 30 being the cutoff rate for a diagnosis of mild autism. Scores 30-37 indicate mild to moderate autism, while scores between 38 and 60 are characterized as severe autism
224190088|NCT05811507|DIAGNOSTIC_TEST|DSM-5 Diagnostic Criteria for ASD|Persistent deficits in social communication and social interaction across multiple contexts. Restricted, repetitive patterns of behavior, interests, or activities. Symptoms must be present in the early developmental period, Symptoms cause clinically significant impairment in social, occupational, or other important areas of current functioning.These disturbances are not better explained by intellectual disability or global developmental delay.
224190089|NCT05811507|DIAGNOSTIC_TEST|Assesment of IQ: The Stanford-Binet V (Stanford-Binet Intelligence Scales):|"IQ Score ranges for the Stanford-Binet:~Low average: 80-89 Average: 90-109 High average: 110-119 High achiever: 120-129 Moderately gifted: 130-144 Highly gifted: 145-160+"
224190090|NCT04629534|DRUG|High dose Cholecalciferol|Mothers in experimental group will receive 6,000 IU of vitamin D in addition to their prenatal vitamin, daily for 3 months. Infants in this group will receive placebo vitamin D drops
224190091|NCT04629534|DRUG|Cholecalciferol|Mothers in placebo control group will receive 600 IU of vitamin D in the form of their prenatal vitamin along with placebo vitamin D. Infants of the mothers in this group will receive standard 400 IU of vitamin D
224190092|NCT03294811|DEVICE|Telemonitoring|The telemonitoring interference in the telemonitoring arm consists of a smartphone application that helps the patient to take their medication in time and to take their blood pressure and weight on a daily basis in order to improve the medication uptitration and medication compliance.
224190093|NCT03732534|DRUG|NBI-98854|vesicular monoamine transporter 2 (VMAT2) inhibitor
224190094|NCT02190604|DRUG|Placebo|Capsule- oral dose
223500130|NCT06372535|BEHAVIORAL|Tai Chi Chuan （dose 6）|"Participants would take 24-form simplified Tai Chi Chuan 1 hour/session, 5 sessions/week for 24 weeks.~There were 10 minutes warm-up, 60 minutes Tai Chi Chuan lesson and 10 minutes cool-down exercises in the Tai Chi Chuan training."
223500131|NCT06372535|BEHAVIORAL|Tai Chi Chuan （dose 7）|"Participants would take 24-form simplified Tai Chi Chuan 1.5 hour/session, 5 sessions/week for 8 weeks.~There were 10 minutes warm-up, 90 minutes Tai Chi Chuan lesson and 10 minutes cool-down exercises in the Tai Chi Chuan training."
223500132|NCT06372535|BEHAVIORAL|Tai Chi Chuan （dose 8）|"Participants would take 24-form simplified Tai Chi Chuan 1.5 hour/session, 5 sessions/week for 16 weeks.~There were 10 minutes warm-up, 90 minutes Tai Chi Chuan lesson and 10 minutes cool-down exercises in the Tai Chi Chuan training."
223500133|NCT06372535|BEHAVIORAL|Tai Chi Chuan （dose 9）|"Participants would take 24-form simplified Tai Chi Chuan 1.5 hour/session, 5 sessions/week for 24 weeks.~There were 10 minutes warm-up, 90 minutes Tai Chi Chuan lesson and 10 minutes cool-down exercises in the Tai Chi Chuan training."
223500134|NCT02490579|BEHAVIORAL|Responses to Brief Video Messages (Facebook)|Participants view 1 of 6 brief video messages about health in pregnancy, then answer survey questions that will assess their a) acceptability, b) understanding of core messages, and c) self-efficacy about healthy eating, exercise and weight gain during pregnancy.
223500135|NCT02490579|BEHAVIORAL|Response to Brief Video Messages (Clinic)|Participants view 1 of 6 brief video messages about health in pregnancy, then answer survey questions that will assess their a) acceptability, b) understanding of core messages, and c) who in her social network she turns to for non-clinical health advice and what kinds of advice she gotten in the past.
223500136|NCT02490579|BEHAVIORAL|Response to Brief Video Messages (Social Network)|Participants view 1 of 6 brief video messages about health in pregnancy, then answer survey questions that will assess their a) acceptability, b) understanding of core messages, and c) how they advise their pregnant friend about different health topics.
223500137|NCT05853887|BEHAVIORAL|iNUDGE|Electronic health record nudge which prompts physicians to order plasma-based NGS testing for eligible patients with newly diagnosed lung cancer.
223500138|NCT04808037|DRUG|Belantamab mafodotin|Belantamab mafodotin in combination with Lenalidomide and Dexamethasone in patients with newly diagnosed Multiple Myeloma transplant-ineligible
223500139|NCT02265653|DRUG|BIIL 284 BS tablet C|
223500140|NCT02265653|DRUG|BIIL 284 BS tablet D|
224190095|NCT02190604|DRUG|QBW251|Capsule - oral dose
224190096|NCT02888782|OTHER|Pharmacist Consultation|
224190097|NCT00683462|DRUG|Placebo|
224190098|NCT00683462|DRUG|AZD3480|Capsules 5 mg/day (once a day) for 2 weeks
224190099|NCT00683462|DRUG|AZD3480|Capsules 50 mg/day (once a day) for 2 weeks
224190100|NCT01664260|DRUG|N-acetylcysteine|0 - 8 week: 10 mg escitalopram a day + 1200 mg N-acetylcysteine twice a day
224190101|NCT01664260|DRUG|Placebo|0 - 8 week: 10 mg escitalopram a day + 1200 mg Placebo twice a day
223591366|NCT02409342|DRUG|Carboplatin|Carboplatin will be administered as intravenous infusion at a dose of area under the concentration-time curve (AUC) 6 when given in combination with pemetrexed or at a dose of AUC 5 when given in combination with gemcitabine, every 21 days for 4 or 6 cycles as per local standard of care.
223591367|NCT02409342|DRUG|Cisplatin|Cisplatin will be administered as intravenous infusion at a dose of 75 mg per meter squared (mg/m\^2) every 21 days for 4 or 6 cycles as per local standard of care.
223591368|NCT02409342|DRUG|Gemcitabine|Gemcitabine will be administered as intravenous infusion at a dose of 1250 mg/m\^2 (in combination with cisplatin) or 1000 mg/m\^2 (in combination with carboplatin), on Days 1 and 8 of each 21-day cycle for 4 or 6 cycles as per local standard of care.
223591369|NCT02409342|DRUG|Pemetrexed|Pemetrexed will be administered as intravenous infusion at a dose of 500 mg/m\^2 on Day 1 of each 21-day cycle as per local standard of care until disease progression (per RECIST v1.1), unacceptable toxicity, or death (maximum up to approximately 58 months).
223591370|NCT02486250|OTHER|Validation Study|
223500141|NCT02265653|DRUG|BIIL 284 BS WIF tablet|
223500142|NCT02768181|BEHAVIORAL|Nutrition-specific Behaviour change communication (BCC)|Door-to-door counseling on nutrition during pregnancy and exclusive breastfeeding from enrolment into study till birth; exclusive breastfeeding and nutrition of lactating mothers during post-natal 6 months; timely and appropriate complementary feeding with continued breastfeeding until 2 years of child's age, and nutrition of lactating mothers during post-natal 6-24 months; all counseling would be supplemented with associated issues including hygiene and sanitation, mother's sleep and rest, maternal and child healthcare seeking etc.
223500143|NCT02768181|DIETARY_SUPPLEMENT|Nutrient supplement to pregnant women (PNS)|"A lipid-based micronutrient supplement (LNS) is packed in \~10g sachets. Formulation: Vegetable fat (soy), skimmed milk powder, peanuts, vitamin and mineral complex, sugar, stabilizer: fully hydrogenated vegetable fat, and antioxidant : tocopherols. Each sachet contains 70-75% of recommended dietary allowance for most of the micronutrients, including iron, folic acid, zinc, calcium, iodine, vitamins A, B1, B2, niacin, B12 etc.~Dose: 1 sachet/pregnant woman/day starting from the first counseling session (GA \~125∓15 days) continued till birth of baby. Supplement should be taken with food in room temperature, and must not be heated, or mixed with hot food. To avoid overdose, respondents receiving this supplement should stop taking any other micronutrient supplement or drink."
223591371|NCT02402283|DRUG|Metronidazole benzoate oral granules|Single oral dose of 400 mg
223591372|NCT02402283|DRUG|Flagyl 400 mg Tablets|Single oral dose of 400 mg
223591373|NCT03908970|DRUG|1% OPA-15406|Twice daily
223591374|NCT03908970|DRUG|Placebos|Twice daily
223591375|NCT04671992|DEVICE|Out of-Plane Technique and In-Plane on|A comparison of out of-plane technique and in-plane
223591376|NCT02280317|DRUG|VAL201|VAL201-001 Sub-cutaneous injection.
224074546|NCT02011009|OTHER|HIV seropositive patients|During a routine visit, a self-administered anal swab will be proposed as well as an anonymous questionnaire about sexual practices. In addition to usual outpatient treatment an examination and an evaluation of a possible sexually transmitted infection (STI) will be realized. Some questions about risk factors traditionally associated with carriage of resistant bacteria will also be investigated with the aid of the questionnaire such as: use of antibiotics during the year, travel in areas at risk.
224074547|NCT01415427|DRUG|BMN 110 - Weekly|"In Part 1, patients will receive intravenous (IV) infusions of study drug at a dose of 2.0 mg/kg/qw administered over a period of approximately 4 hours once a week.~In Part 2, patients will continue to receive 2.0 mg/kg of BMN 110 every week, with no placebo."
224074548|NCT01415427|DRUG|BMN 110 - Every Other Week|"In Part 1, patients will receive intravenous (IV) infusions of study drug at a dose of 2.0 mg/kg administered over a period of approximately 4 hours every other week. Patients randomized to the 2.0 mg/kg/qow arm will receive infusions of placebo on alternating weeks, to mask active drug weeks.~In Part 2, patients will receive 2.0 mg/kg of BMN 110 every week, with no placebo."
224074549|NCT05055193|DRUG|Evaluation at 24 months corrected age: respiratory outcome, Neurodevelopmental outcome, Growth outcome|Data concerning the 24 months corrected age outcomes were collected from the medical records of the ECL'AUR preterm infants follow-up network.
224074550|NCT01503255|BEHAVIORAL|cognitive behavioral group therapy|6 weekly 90-minute group sessions
224074551|NCT01503255|BEHAVIORAL|health education group|6 weekly 90-minute group sessions
224074552|NCT03639090|DIAGNOSTIC_TEST|mass spectrometry|mass spectrometry for bladder cancer cells
224074553|NCT02929264|DRUG|ABX-1431|Capsules, 40 mg, single dose
224074554|NCT02929264|DRUG|Placebo|Capsules, single dose
224074555|NCT05506761|PROCEDURE|ultrasound-guided erector spinae plane block|Patients will receive 20 ml plain bupivacaine 0.25 % bolus, then 10 ml per hour plain bupivacaine 0.125 % continuous infusion via ultrasound-guided erector spinae plane block
224074556|NCT05506761|PROCEDURE|ultrasound-guided rhomboid intercostal block combined with sub-serratus plane block|Patients will receive 20 ml plain bupivacaine 0.25 % bolus, then 10 ml per hour plain bupivacaine 0.125 % continuous infusion via ultrasound-guided rhomboid intercostal block combined with sub-serratus plane block
224074557|NCT00128869|PROCEDURE|spine mobilizations|
224074558|NCT00128869|PROCEDURE|spine manipulations|
224074559|NCT03355183|OTHER|Isokinetics|Isokinetics, or accommodating resistance, is a form of exercise where a person provides a maximum muscle contraction against a resistance or lever arm, (isokinetic dynamometer) at a fixed speed through a given range of motion. This type of muscle action can be done either concentrically or eccentrically at the given joint.
224074560|NCT00704964|BIOLOGICAL|PegIntron|PegIntron (peginterferon alfa-2b) pen administered at a dose and frequency in accordance with approved labeling in Germany
224074561|NCT00704964|DRUG|Rebetol|Rebetol (ribavirin) administered at a dose and frequency in accordance with approved labeling in Germany
224074562|NCT03302754|DRUG|Alemtuzumab|Alemtuzumab (Campath®) is a recombinant DNA-derived humanized monoclonal antibody directed against CD52. Alemtuzumab is produced in mammalian cell (Chinese hamster ovary) suspension culture in a medium containing neomycin. Neomycin is not detectable in the final product. Alemtuzumab is a sterile, clear, colorless, isotonic pH 6.8-7.4 solution for injection. Alemtuzumab is supplied in single-use clear glass ampules containing 30 mg of Alemtuzumab in 3 mL of solution. Single use vial of alemtuzumab contains 30 mg alemtuzumab, 8 mg sodium chloride, 1.44 mg dibasic sodium phosphate, 0.2 mg potassium chloride, 0.2 mg monobasic potassium phosphate, 0.1 mg polysorbate 80, and 0.0187 mg disodium edetate dihydrate.
224190102|NCT05158907|OTHER|Patient reported Adverse event scale|Participants will be given a patient reported AE scale with numbers from 0 to 10 before start of each chemotherapy cycle. The PRAE scale will be like a Visual Analogue Scale and the patients will be given instructions how to record AEs that they experience after each chemotherapy cycle, until the first radiological assessment is done (palliative settings) or after 4 cycles of chemotherapy in adjuvant settings. Participants will take scale home to record the adverse effects and give it a number. Only the most severe will be analyzed. When patient reports for the next cycle of chemotherapy they will be asked to deposit the scale before meeting the physician. The physician will ask patient about the AEs experienced with the chemotherapy and record them using CTCAE grade. The study participants, at the start of chemotherapy cycle, will be informed, as a standard practice, to report to the emergency or contact nearest local clinic/hospital if the AE is severe or can't be managed at home.
224190103|NCT02797951|DRUG|Galcanezumab|Administered SC
224190104|NCT02583594|DRUG|Acyclovir|Pharmaceutical form:tablet Route of administration: oral
224190105|NCT02583594|DRUG|Methylprednisolone|Pharmaceutical form:tablet Route of administration: oral
224190106|NCT02583594|DRUG|alemtuzumab GZ402673|Pharmaceutical form:solution for infusion Route of administration: intravenous
224190107|NCT02583594|DRUG|alemtuzumab GZ402673|Pharmaceutical form:injection Route of administration: subcutaneous
224190108|NCT02583594|DRUG|Paracetamol|Pharmaceutical form:tablet Route of administration: oral
224190109|NCT02583594|DRUG|Loratadine|Pharmaceutical form:tablet Route of administration: oral
224309550|NCT02213653|DRUG|ARM B: IV iron + epoietin zeta sequence|"* Epoietin zeta at a dose of 450 IU / kg per week subcutaneously started in week 7~* carboxymaltose ferric (Ferinject ®) at week 1~  * Intravenous infusion not exceeding 1000 mg (administered once if weight\> 50 kg, 500 mg twice otherwise, with an interval of one week between each administration).~ * Renewable with a minimum of 4 weeks depending on the iron status (if CST \<20% and absence of serum ferritin\> 800) in the same manner as week 1."
224309551|NCT02213653|DRUG|ARM C : single epoietin zeta|Epoietin zeta at a dose of 450 IU / kg per week subcutaneously begun in week 1
224309552|NCT06968208|DRUG|Puerarin|75 mg of puerarin injection, dissolved in 0.9% sodium chloride solution. The puerarin injection is manufactured under Good Manufacturing Practice (GMP) conditions by \[Harbin Medisan Pharmaceutical Co., Ltd.\], with identical appearance, size, and packaging to the blank 0.9% sodium chloride solution to ensure blinding. Stability testing confirms integrity under standard storage conditions (25°C, 60% RH).
223500144|NCT02768181|DIETARY_SUPPLEMENT|Nutrienr supplement to children 6m to 2 years|"A lipid-based micronutrient supplement (LNS) is packed in \~10g sachets. Formulation: Vegetable fat, skimmed milk powder, peanuts, sugar, vitamin and mineral complex, maltodextrin, and emulsifier: lecithin. Each sachet contains 70-75% of recommended dietary allowance for most of the micronutrients, including iron, folic acid, zinc, calcium, iodine, vitamins A, B1, B2, niacin, B12 etc. Each 20 g of LNS provide ≥4.46g LA (Linoleic Acid) and ≥0.42g ALA (α-Linolenic Acid).~Dose: 2 sachets \~(10+10=20g)/child/day from 5th completed months (181 days) to 24 completed months of child's age. Supplement should be taken with food in room temperature, and must not be heated, or mixed with hot food. Supplement should be taken with food in room temperature, and must not be heated, or mixed with hot food. To avoid overdose, respondents receiving this supplement should stop taking any other micronutrient supplement or drink."
223500145|NCT04474106|DEVICE|Shock waves|The shockwave generator orthogold 100® generates high-energy acoustic waves that behave much like other sound waves except that they have much greater pressure and energy. As with sound waves, Spark Waves® can easily travel great distance as long as the acoustic impedance stays the same.
223500146|NCT04474106|DEVICE|dummy head|The shockwave generator orthogold 100® will be used in combination with a dummy head, to Refrain shock waves
223500147|NCT02691572|PROCEDURE|Spinal anesthesia|Performed at the L3-4 or L4-5 interspace using 27- or 25-gauge spinal needle.
223500148|NCT02691572|DRUG|Intrathecal bupivacaine|Bupivacaine 12.5 mg will be administered in the subarachnoid space.
223591377|NCT02342080|OTHER|Training sessions|A group with spinal cord injury will be trained in a 30-minute session 5 times weekly for 6 weeks. Each session will be supervised by qualified staff. Patients will undergo training with gradual increase in load and speed, according to the tolerance of each patient. The body weight support progression will start at 50 % of the patient body weight. It will be changed every 2 weeks and the load will decrease 10%. The progression of speed may be accompanied during the training period.
223591378|NCT02342080|DEVICE|Lokomat system (Hocoma AG Switzerland)|For the robot locomotion therapy, the Lokomat system (Hocoma AG Switzerland) will be used.
223591379|NCT04457492|OTHER|Application of FES to the Face|Functional electrical stimulation (FES) for facial paralysis is a technique in which muscles are electrically stimulated.
223591380|NCT02903732|OTHER|observational|registry
223591381|NCT03100110|DEVICE|NeuroCognitive Communicator|Comprises an electrode array in prefrontal cortex, another in motor cortex, Blackrock NeuroPort system and connectors, augmentative assistive communication application, robotic arm, and virtual reality environment.
223591382|NCT02380898|DRUG|Ketorolac|30 mg ketorolac immediately before induction of anesthesia
223591383|NCT02380898|DRUG|Normal saline|4 mL normal saline 0.9% immediately before induction of anesthesia
224190110|NCT02583594|DRUG|Ceterizine|Pharmaceutical form:tablet Route of administration: oral
224190111|NCT02583594|DRUG|Dexchlorpheniramine|Pharmaceutical form:tablet Route of administration: oral
224190112|NCT04595617|BIOLOGICAL|Antibodies screening|All included GT patients will be enrolled from different national centres during a 6 months period. Antibodies screening will be systematically realized every six months (+/- 2 weeks) and after each last blood transfusion at 7-10 days and one month (+/- 2 weeks), during a period of 18 months.
224190113|NCT03235063|OTHER|routinely care- no intervention|routinely care- no intervention
224190114|NCT02244385|OTHER|no intervention|
224190115|NCT03709342|DRUG|CM4620-IE|single IV infusion on Day 1 over 4 hours
224190116|NCT06536478|OTHER|exercise|50 minutes of exercise twice a week, including stretching, core exercises, gross motor movements and balance exercises for 5 weeks
224190117|NCT06536478|OTHER|education|The patient will be given a one-time exercise education session and a 50-minute video that included stretching, core exercises, gross motor movements and balance exercises that could be practiced at home.
223500149|NCT02691572|DRUG|Intrathecal fentanyl|Fentanyl 15 µg will be administered in the subarachnoid space.
223500150|NCT02691572|PROCEDURE|Cesarean delivery|Lower segment cesarean section using the Pfannenstiel incision and exteriorization of the uterus.
223591384|NCT01274429|DRUG|Peanut flour|Peanut flour that is ingested daily and administered in gradually increasing amounts up to a maximum maintenance dose.
223591385|NCT02423980|DRUG|Glucagon|
223591386|NCT02760641|OTHER|Egg-based diet (EBD)|Participants will be asked to consume a carbohydrate-restricted diet including whole eggs for 8 weeks. Eggs will be provided.
223591387|NCT02760641|OTHER|Carbohydrate-based diet (CBD)|Participants will be asked to consume a low fat, carbohydrate-based diet for 8 weeks. Breakfast food items will be provided.
223591388|NCT03528226|BEHAVIORAL|Exercise Training Procedure|Exercise training: 3 sessions - 2 supervised and 1 unsupervised - per week of 30-60 min at 65% - 80% of maximum heart rate (4 months)
224190118|NCT02796365|OTHER|Exercise|Intervention will include 10 weeks of a standard cardiac rehabilitation program consisting of thrice a week aerobic exercise and 1-2 days per week resistance exercises.
224190119|NCT04506658|DEVICE|high-frequency radio wave electrotherapy with a frequency of 448 kHz on the penis structures.|"Patient in lithotomy position (supine) with return plate at lumbar level.~Start with high power (within the allowed range) to get a faster hyperthermia and slowly decrease this percentage as the current builds up in the patient's body.~Patients are undergoing high-frequency radio wave electrotherapy 2 times a week (12 procedures at all)."
224190120|NCT04506658|DEVICE|high-frequency radio wave electrotherapy with a frequency of 448 kHz on the penis structures.|Doctor uses sham sensor to reduce efficiency to zero.
224190121|NCT03521674|DEVICE|pregnancy termination|Second trimester pregnancy termination for fetal anomali or in utero mord fetus will be done
224190122|NCT05936788|OTHER|Active cycle of breathing technique|Group A will receive ACBTs with 1 session a day for total 2 days in a week.
223500151|NCT02691572|PROCEDURE|Wound infiltration|30 mL bupivacaine 0.25% will be injected subcutaneously in the surgical wound (15 mL on the upper and lower sides) by the obstetrician before skin suturing.
223500152|NCT02691572|PROCEDURE|Sham procedure|Sham procedure will be performed after surgery by moving the ultrasound probe and pressing a covered spinal needle on both sides of the patients' abdomen.
223591389|NCT03528226|BEHAVIORAL|Normal life procedure|No supervised exercise training during the 4 month period.
223591390|NCT00583687|DEVICE|Vigileo TM / Flotrac TM (Minimally invasive cardiac output system consisting of arterial line sensor and cardiac output monitor)|Attachment of the arterial line sensor and pulse contour cardiac output monitor to the arterial line of the patient.
223591391|NCT00583687|OTHER|Passive leg raising|Passive leg raising for prediction of fluid responsiveness with arterial pulse contour analysis.
223591392|NCT00583687|OTHER|Volume challenge / Change of vasoactive drugs or inotropics|Either a volume challenge (using colloids or crystalloids) or a change in the dosage of of vasoactive drugs or inotropics, or a combination of them, as proposed by the treating physician.
224190123|NCT05936788|OTHER|diaphragmatic breathing|Group B will receive diaphragmatic breathing for 1 session a day for total 2 days in a week.
224190124|NCT00752063|DRUG|Sorafenib with Capecitabine and Oxaliplatin|Regimen 1: Oxaliplatin 85 mg/m2 (50 mg per vial) administered intravenously on day 1 of each cycle Regimen 2: Capecitabine 1700 mg/m2 p.o. (850 mg/m2 BD) day 1 to 7 Regimen 3: Sorafenib 400 mg (200 mg/tablet) orally BD day 1 to 14
224190125|NCT04985825|DRUG|Imgatuzumab|Imgatuzumab administered as an intravenous infusion on Day 1 and Day 8 of the first 21-day cycle, and on Day 1 of each subsequent 14-day cycle.
224190126|NCT00312650|DRUG|liposomal doxorubicin and gemcitabine|
224190127|NCT06531343|PROCEDURE|LDCT scan and simultaneous [18F]FDG PET/CT on new-generation long axial field of view scanner|"18F\]FDG will be injected intravenously, and PET/CT images will be acquired after 60 minutes (± 10 minutes). PET/CT images will be first analysed with the lung window to detect any findings suggestive of a lung tumour.~Whole-body PET/CT images will be then analysed to detect any incidental finding in the chest as well as other anatomical areas included in the field of view. PET/CT images will be considered positive if there is at least one non-calcified lung nodule or any suspicious finding on CT scan characterised by focal \[18F\]FDG uptake deviating from physiological distribution or above physiological background activity."
223500153|NCT02691572|PROCEDURE|Transversus abdominis plane block|Bilateral ultrasound-guided TAP block using 20 mL bupivacaine 0.25% on each side. A 7-12 MHz linear array probe and 22-gauge needle will be used. The probe will be placed transversely above the iliac crest in the anterior axillary line and the needle will be introduced in-plane with the probe from medial to lateral.
223591393|NCT00583687|DEVICE|Inspectra TM/O-To-See TM (Tissue oxymetry with near infrared spectroscopy and laser-Doppler)|Tissue oxymetry continuously measured with near infrared spectrometry and laser Doppler during the whole study period.
224190128|NCT06531343|PROCEDURE|LDTC only|The LDCT scan will be performed in single deep inspiratory breath hold. No intravenous contrast will be administered.
223500154|NCT02691572|DRUG|Ketorolac|IV ketorolac 30 mg/8 h starting at the end of surgery.
223500155|NCT02691572|DRUG|Paracetamol|Oral paracetamol 1 gm/8 h starting 4 h after surgery.
223591394|NCT04063969|OTHER|Assessment of radiation safety climate|"The rating tool contains 28 statements which cover 5 dimensions (Leadership, communication, commitment, resources, risk awareness) of the radiation safety climate. Participants are asked to indicate on a scale of 1 (completely disagree) - 3 (neutral) - 5 (completely agree) whether they agree with each statement. A composite radiation safety climate score is calculated by adding ratings on all items.~Minimum scale score 28 - Maximum scale score 140"
224190129|NCT03735849|BIOLOGICAL|VRC07-523LS|Administered by intravenous (IV) infusion
224190130|NCT05277987|DRUG|HEC-016(0.5×10^6 CAR-T Cells)|The initial dose is set to 0.5 × 10\^6 car-t cells / kg, and 3 \~ 6 subjects are expected to be included in the dose group. DLT was observed within 28 days after cell infusion.
224190131|NCT05277987|DRUG|HEC-016(0.5×10^6.5 CAR-T Cells)|The Second dose is set 0.5 × 10\^6.5 car-t cells / kg, and 3 \~ 6 subjects are expected to be included in the dose group.
224190132|NCT05277987|DRUG|HEC-016(0.5×10^7 CAR-T Cells)|The Third dose is set 0.5 × 10\^7 car-t cells / kg, and 3 \~ 6 subjects are expected to be included in the dose group.
224190133|NCT04035993|OTHER|Controlled hypoglycaemic state while driving with a driving simulator|"Patients will arrive in the morning after an overnight fast. During the controlled hypoglycaemic state, participants will drive on a designated circuit using a driving simulator. Initially, euglycaemic state (5.0-8.0 mmol/L) will be kept stable and then blood glucose will be declined progressively targeting at a level between 2.0-2.5mmol/L by administering an insulin bolus. Glucose will be kept stable at the hypoglycaemic level for 30 minutes. Thereafter, it will be raised again and kept stable for another 30 minutes at an euglycaemic level between 5.0-8.0mmol/L. During the procedure, we will analyse counterregulatory hormones. Heart rate, skin conductance, CGM values, eye movement and facial expression, will be recorded by a smart-watch, a CGM device, an eye-tracker and an onboard camera, respectively.~Participants will be blinded to the glucose values during the procedure. They will have to rate their symptoms and their performance on a 0-6 scale every 15 minutes."
224190134|NCT01439776|DRUG|Vit D|800IU/day
224309553|NCT06968208|DRUG|Placebo|0.9% sodium chloride solution formulated to match the appearance, size, and taste of the active puerarin solution, with no other active pharmaceutical ingredients. 0.9% sodium chloride solution is manufactured under identical Good Manufacturing Practiceconditions by \[Shijiazhuang No.4 Pharmaceutical Co., Ltd.\] and changed to the same batch processes and packaging as the intervention group. Stability testing confirms equivalent integrity under standard storage conditions (25°C, 60% RH). Blinding is ensured through indistinguishable outer packing characteristics and labeling.
224190135|NCT05113277|BEHAVIORAL|Tonic Immobility Psychoeducation (TIP)|TIP is a 45-minute computerized psychoeducation intervention aimed at addressing maladaptive cognitions and emotions associated with TI while using educational and behavioral techniques commonly used in the treatment of trauma-related disorders. Throughout the psychoeducation program vignettes will be presented to clarify concepts and promote participant engagement. In addition, practice exercises and rating scales will be integrated, where applicable, to increase the interactive nature of the program. The following modules will be addressed in the TI psychoeducation intervention: education, myth busting, and behavioral experiments.
223500156|NCT02691572|PROCEDURE|Fentanyl patient-controlled analgesia|Intravenous fentanyl: bolus dose = 20 µg, lockout interval = 7 min, 4-h dose limit = 200 µg, with no background infusion.
223500157|NCT01148732|PROCEDURE|ultrasonography|a Toshiba 3.75 MHz convex ultrasonography transducer (Toshiba SSA-550A, Tochigi-ken, Japan) was placed transversely on the anterior neck just superior to the suprasternal notch and bilateral hemithorax by one of two emergency physician during emergency intubation investigators.
223500158|NCT00699751|DRUG|Radium-223 dichloride (Xofigo, BAY88-8223)|Radium-223 dichloride 50 kBq/kg b.w., 6 IV administrations separated by 4 weeks intervals.
223500159|NCT00699751|DRUG|Placebo|Isotonic saline 6 IV administrations separated by 4 weeks intervals.
223500160|NCT00699751|DRUG|Best standard of care (BSoC)|Best standard of care is regarded as the routine standard of care at each center, for example local EBRT (External Beam Radiation Therapy), corticosteroids, antiandrogens, estrogens (e.g., stilboestrol), estramustine or ketoconazole.
223500161|NCT00649688|DRUG|Metoprolol Tartrate/Hydrochlorothiazide Tablets 100/50 mg|100/50mg, single dose fasting
223500162|NCT00649688|DRUG|Lopressor HCT® Tablets 100/50 mg|100/50mg, single dose fasting
223500163|NCT01148485|OTHER|Nasal, throat, inguinal and skin lesions swab samples will be performed|Nasal, throat, inguinal and skin lesions swab samples will be performed
223500164|NCT03206138|BIOLOGICAL|GX-188E, GX-I7|Experimental: 1mg of GX-188E administered IM using EP device 3 times and 3mg of GX-I7 administered in cervix 4 times.
223500165|NCT03206138|BIOLOGICAL|GX-188E, Imiquimod|1mg of GX-188E administered IM using EP device 3 times and 12.5mg of Imiquimod application at cervix 8 times.
223500166|NCT02313714|DEVICE|stimulation wave (2.5 kHz, burst at 50Hz, on/off: 3/9 sec),|All patients in the treatment arm will receive electric muscular stimulation with a Russian current protocol twice a week for 7 weeks.
223500167|NCT02313714|DEVICE|Sham|very low electric muscular stimulation
223500168|NCT00661440|DRUG|Neramexane mesylate|2 double-blind, cross-over treatment periods of 7 weeks separated by a wash-out phase, up to 75 mg Neramexane mesylate per day
223500169|NCT02327481|PROCEDURE|3D Laparoscopic Surgery|After exclusion of T4b, bulky lymph nodes, or distant metastasis case by diagnostic laparoscopy, 3D laparoscopic gastrectomy will be performed with curative treated intent. The type of reconstruction will be selected according to the surgeon's experience.
223500170|NCT02327481|PROCEDURE|2D Laparoscopic Surgery|After exclusion of T4b, bulky lymph nodes, or distant metastasis case by diagnostic laparoscopy, 2D laparoscopic gastrectomy will be performed with curative treated intent. The type of reconstruction will be selected according to the surgeon's experience.
223500171|NCT06441799|DEVICE|Home radiofrequency skin treatment instrument|Subjects in the experimental group were treated with the test instrument combined with medical ultrasonic coupler for 5 days a week according to the prescribed use method (duration of use: 10 minutes for the whole face, continuous use twice a day, a total of 20 minutes) for 12 weeks. To evaluate the reduction of wrinkles before and after treatment and the changes of laboratory instruments.
223500172|NCT06441799|OTHER|Ultrasonic coupler for medical purposes|In control group, medical ultrasonic coupler was evenly applied on face and orbit for 5 days a week (duration: 20 minutes) for 12 consecutive days Week. To evaluate the reduction of wrinkles and the change of laboratory instruments before and after use.
223500173|NCT03575156|BIOLOGICAL|blood sample|36 ml whole blood for Peripheral blood mononuclear cell (PBMC) and monocytes isolation
223500174|NCT03575156|BIOLOGICAL|urine sample|6 ml
223500175|NCT05503069|BEHAVIORAL|Interventions with social and cultural components|"Intervention Components~* Enrollment: We are expecting an enrollment rate of 20 participants per week, and completing enrollment in 6 weeks (n=120 participants)~* Baseline Data Collection~* Distribution of Educational Materials~* Lactation Training~* Dietary Literacy Training~* Follow Up Data collection: Infant's information on growth and development and Medical History of Infections, GI problems (diarrhea, constipation, colic, vomits, reflux) will be collected at 3, 6 and 12 months.~* Follow UP Surveys: Mothers will complete a short survey at 3, 6, and 12 months exploring their breastfeeding behaviors and challenges.~* Exit survey: Mothers will be asked to complete an exit survey on month 12 post-enrollment to explore their perception on the participation in the study."
224190136|NCT05113277|BEHAVIORAL|Health Education Training (HET)|The Healthy Education Training intervention was developed as a 45-minute online intervention that provides education about physical health habits that can impact mental health, such as diet, exercise, and sleep. This intervention has been used in prior clinical trials to control for effects of general education, general coping techniques, and use of technology. Participants in past clinical trials have reported that HET is engaging and beneficial. However, HET is not expected to have an effect on the main symptom outcomes of the current study (guilt, shame, PTSD symptoms).
224190137|NCT06567314|DRUG|Ivonescimab|Given by PO
224190138|NCT03931707|GENETIC|Genomic sequencing|Both sick and high-risk newborn un-randomized to receive genomic sequencing will receive a Genomic Newborn Sequencing Report which will include pathogenic or likely pathogenic variants identified in genes associated with childhood-onset disease.
224190139|NCT01652482|DRUG|5-fluorouracil|Standard 5-fluorouracil (5-FU) chemotherapy (400 milligram per square meter \[mg/m\^2\] administered as intravenous bolus and then 5-FU 2400 mg/m\^2 administered as continuous intravenous infusion over 46 +/- 2 hours) or according to local standard-of-care prescribing information's, every 2 weeks until documented disease progression or unacceptable toxicity.
224190140|NCT01652482|DRUG|Cetuximab|Cetuximab 400 mg/m\^2 intravenous infusion as a loading dose on Day 1 Cycle 1, followed by 250 mg/m\^2 intravenous infusion weekly until documented disease progression or unacceptable toxicity.
224309554|NCT00077857|DRUG|capecitabine (Xeloda®)|825 mg/m\^2 or 1250 mg/m2 orally twice a day on days 1 to 14 of each 3 week cycle.
224309555|NCT00077857|DRUG|docetaxel (Taxotere®)|75 mg/m\^2 intravenous on day 1 of each 3 week cycle
224309556|NCT06823804|DRUG|10ml of 10% saline is injected centrally|"The first phase of the study is an observational study that does not alter the clinical treatment plan.~The experimental group（Sample size of 48 cases） in the second phase of the study needs to receive a central venous injection of 10ml of 10% saline to demonstrate pulmonary blood flow, while the control group （Sample size of 48 cases）requires no intervention.~The experimental group select the optimal pulmonary blood flow PEEP By Electrical impedance tomography.Change in ventilation-perfusion ratio measured by EIT during PEEP trials from baseline to 30 minutes at each PEEP level (5, 10, 15 cmH2O).~The control group was selected Best PEEP according to the PEEP table ."
224309557|NCT06283862|BEHAVIORAL|Educational Session|The initial session will last about 45 to 60 minutes. The subsequent 3 sessions are anticipated to take about 20-30 minutes.
224309558|NCT05838430|DRUG|Solriamfetol 75 MG|Solriamfetol (trade name Sunosi), is a norepinephrine-dopamine reuptake inhibitor available in 75mg and 150mg tablets for oral administration during the day. Solriamfetol's primary indication is to treat excessive daytime sleepiness (EDS) in patients diagnosed with obstructive sleep apnea or Narcolepsy. It binds to the dopamine and the norepinephrine transporters with affinities (Ki) of 14.2 μM and 3.7 μM, respectively),does not undergo significant metabolism in humans, and has a Tmax of \~2 hours (range 1.25-3.0 hours) and a T1/2 of \~7.1 hours.
224309559|NCT05838430|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia (CBT-I)|"Treatment will be conducted via a HIPAA compliant video link (Zoom). Sessions 1-8 will follow our published protocol (published in 2005 by Springer).~Each session will be conducted individually and have a singular focus per session.~All sessions following the delivery of sleep restriction therapy \& stimulus control instructions (post Session 2) will include, as needed, management of non-adherence and/or time-in-bed titration."
224309560|NCT05838430|OTHER|Monitoring|No CBT-I will be administered, however, the tracking system used for CBT-I will be used for all subject conditions. This includes a sleep disorder symptoms screener, the administration of several questionnaires on a weekly basis, and the administration of daily sleep diaries online or via iPhone. Note: it is a common effect that regular monitoring of this type produces perceived clinical benefit.
224309561|NCT05838430|OTHER|Placebo|Placebo, identical in appearance to the active drug.
223500176|NCT01257438|DEVICE|Fluency Plus Endovascular Stent Graft|Treatment of in-stent restenosis
223500177|NCT01257438|DEVICE|Percutaneous Transluminal Angioplasty only|Treatment of in-stent restenosis
223500178|NCT03783806|DIAGNOSTIC_TEST|Posturography measurements|Determination of functional status, Posturography measurements, postural tests
223500179|NCT05713448|OTHER|No intervention|No intervention
223500180|NCT03370302|DRUG|TAK-228|TAK-228 Capsules.
223500181|NCT00377481|DRUG|darbepoetin alfa|30 micrograms sc weekly (2 doses)
223500182|NCT00377481|DRUG|epoetin beta [NeoRecormon]|6000 IU sc weekly (2 doses)
223500183|NCT01054248|DRUG|dihydroartemisinin-piperaquine|Standard 3 days regimen DHA-piperaquine: (DHA/PPQ 40 mg/320 mg) 2.4 mg/kg DHA and 20 mg/kg PPQ once daily for 3 days
223500184|NCT01054248|DRUG|Artesunate-mefloquine|Standard three day regimen of artesunate-mefloquine (12/24 mg/kg) given as artesunate 4mg/kg/day and mefloquine 8mg/kg/day on Days 0, 1 and 2.
223500185|NCT01054248|DRUG|arthemeter-lumefantrin|Augmented 4 day regimen of artemether lumefantrine 2 doses per day for 4 days. Each dose consists of 5 tablets (20/120 mg of artemether/lumefantrine per tablet).
223500186|NCT01370889|DRUG|resveratrol|Given PO
223500187|NCT01370889|OTHER|laboratory biomarker analysis|Correlative studies
223500188|NCT02411136|DRUG|AMG 623|Multiple doses of AMG 623 administered as subcutaneous and intravenous doses
223500189|NCT02411136|DRUG|Placebo|Multiple doses of AMG 623 administered as subcutaneous and intravenous doses
223500190|NCT04217356|BIOLOGICAL|Hematopoietic stem cell transplant|Intravenous infusion of hematopoietic stem cells from a donor.
223500191|NCT04217356|DRUG|Ruxolitinib|Ruxolitinib is type of drug called a janus kinase (JAK) inhibitor. Ruxolitinib is taken orally (by mouth).
223500192|NCT04217356|DRUG|Hydroxyurea|Hydroxyurea is a type of drug called an antimetabolite. Hydroxyurea is taken orally (by mouth).
223500193|NCT02944266|OTHER|Pre operative Focus assessed Transthoracic echocardiographic assessment.|
223500194|NCT01011725|DRUG|MK 0773|25 mg oral tablet b.i.d. MK 0773 or 100 mg oral tablet b.i.d. MK 0773, for 12 weeks
223500195|NCT01011725|DRUG|Placebo|Placebo oral tablet b.i.d for 12 weeks
223500196|NCT02474706|DRUG|Cefoxitin|
223500197|NCT02474706|DRUG|imipenem|
224309562|NCT06971016|OTHER|Mulligan Mobilization technique|"i. Mulligan Mobilization for Medial Glide: During the treatment, the patient will be positioned in a prone (face-down) posture. To execute a medial glide, the therapist will position themselves on the side opposite to the target knee. They will place a belt around the patient's waist and lower leg, aligning the upper edge of the belt with the margin of the tibial joint. Using one hand to stabilize the thigh above the knee and the other hand to support the lower leg, the therapist will apply a medial force to the knee using the belt. The therapist will then instruct the patient to flex their knee while maintaining the glide.~ii. Mulligan Mobilization for Lateral Glide: To administer a lateral glide to the knee, the therapist will position themselves next to the affected knee. They will employ the belt to facilitate the glide by applying force from the opposite side."
224190141|NCT01652482|DRUG|Irinotecan|Standard Irinotecan chemotherapy (180 milligram per square meter \[mg/m\^2\] administered as intravenous infusion over 60 +/- 30 minutes) or according to local standard-of-care prescribing information's, every 2 weeks until documented disease progression or unacceptable toxicity.
224309563|NCT06971016|OTHER|Proprioceptive Exercises|"i. One leg balance- It requires flexing the opposite leg at the knee, hip, and ankle while standing on the affected foot. This position will be hold for one minute (60 seconds), followed by rest for 10 to 20 seconds, then continue this process twice more. Three repetitions of the same exercise will be performed with the unaffected leg after a brief break.~ii. Blind advanced one leg balance- The task will resemble one-legged balance, but the participant will be required to close their eyes while executing the routine, and then repeat it two more times.~iii. Toe walking- In this activity, the participant will be instructed to walk a 20-meter distance while balancing on their toes with their toes pointing straight ahead. They will then be asked to walk the same distance again, but this time with their toes pointing outward. After a brief rest, the entire procedure will be repeated once more."
223500198|NCT01428128|DRUG|Arsenic Trioxide|IV; 0.005mg/kg. Infusion on Days -3, -2 and -1 of Chemo Cycles 2, 4, and 6 (if more than 4 cycles received).
223500199|NCT00807404|PROCEDURE|histopathologic examination|
224190142|NCT01652482|DRUG|Leucovorin|Standard Leucovorin chemotherapy (400 mg/m\^2 \[racemic form\] or 200 mg/m\^2 \[L-isomer form\] administered by intravenous infusion over 120 +/- 10 minutes) or according to local standard-of-care prescribing information's, every 2 weeks until documented disease progression or unacceptable toxicity.
224190143|NCT01652482|DRUG|MEHD7945A|MEHD7945A 1100 milligram (mg) intravenous infusion every 2 weeks until documented disease progression or unacceptable toxicity.
224190144|NCT04585906|BEHAVIORAL|Common Elements Treatment Approach|The intervention integrates psychoeducation and addresses safety (when identified as a problem area). It also includes relaxation techniques, problem solving, and cognitive coping.
224190145|NCT05851924|DRUG|NALIRIFOX|"Patients will receive NALIRIFOX for a total of 4 months. NALIRIFOX will be administered on days 1 and 15 of a 4-week cycle for 4 cycles until completion of therapy, intolerable toxicity, or until the development of criteria for removal from the study.~Liposomal irinotecan: 50 mg/m2 IV over the course of 90 minutes (±10 minutes) on days 1 and 15 of every 4-week cycle.~Oxaliplatin: 60 mg/m2 IV over the course of 120 minutes (±10 minutes) on days 1 and 15 of every 4-week cycle.~Leucovorin: 400 mg/m2 IV over the course of 30 minutes (±5 minutes) on days 1 and 15 of every 4-week cycle.~5-FU: 2400 mg/m2 IV over the course of 48 hours (or until the infusion is complete) on days 1 and 15 of every 4-week cycle"
223500200|NCT00807404|PROCEDURE|optical coherence tomography|
223591395|NCT04063969|OTHER|Assessment of radiation safety behavior|The rating tool contains 2 statements which cover 2 dimensions of the radiation safety behavior. Participants are asked to indicate on a scale of 1 (completely disagree) - 3 (neutral) - 5 (completely agree) whether they agree with each statement. A composite radiation safety behavior score is calculated by adding ratings on both items Minimum scale score 2 - Maximum scale score 10
223591396|NCT04063969|OTHER|Assessment of radiation safety knowledge and motivation|"The rating tool contains 2 statements which cover the radiation safety knowledge and behavior. Participants are asked to indicate on a scale of 1 (completely disagree) - 3 (neutral) - 5 (completely agree) whether they agree with each statement.~Minimum item score 1 - maximum item score 5"
223591397|NCT04063969|OTHER|Data collection|Collection of patient-related data points Demographic information: ASA-classification, BMI Procedure related information: Procedural time, approach, contrast usage case difficulty Radiation safety parameters: Air Kerma, DAP, fluoroscopy time
224190146|NCT05851924|COMBINATION_PRODUCT|AD-XRT and Capecitabine|The interval between completion of induction chemotherapy and initiation of AD-XRT will be 2-6 weeks. The patient will be concurrently treated with capecitabine (1000-1500 mg flat BID PO Monday to Friday) with radiation, as per standard dosing regimens at MSK.
223500201|NCT00452257|DRUG|enzastaurin|1125 mg loading dose then 500 mg, oral, daily, up to 3 years or until progressive disease
223500202|NCT04071886|BEHAVIORAL|Mindfulness-Based Training|Mindfulness-Based Training comprises of mindful walking, body scanning and raisin meditation exercise. Participants will receive a guided session of mindfulness meditation, and will be asked to finish at least 30 minutes of Mindfulness-Based Training every day as homework as well as keep a diary describing their experiences and reflections. An expert in mindfulness practice will offer feedback and answer any questions online.
224190147|NCT00004199|DRUG|cisplatin|
224190148|NCT00004199|DRUG|gemcitabine hydrochloride|
224190149|NCT00004199|DRUG|prinomastat|
224190150|NCT05986955|OTHER|Diet|Participants will be assigned prospectively to microbial or non-microbial diet for first phase of trial and will then cross over to the alternate diet following a washout period.
224190151|NCT05212246|DRUG|5% Imiquimod cream|Topical 5% Imiquimod cream will be applied once daily to the face in a thin layer for 12 weeks. Three packets of cream will be defined as one dose or application. The cream should be applied to the face prior to normal sleeping hours (it is readily absorbed) and left on the skin for 6-10 hours (i.e. overnight). Rest periods will be allowed if bothersome side effects occur.
224074563|NCT06303609|DEVICE|nonablative radiofrequency|The active electrode from the nonablative radiofrequency will be applied to the urogenital- and uroanal trigone and the dispersive electrode will be attached to the back of the patient. The water-soluble gel will be applied to the active electrode and to the non-lubricated condom which will involve the electrode. There will be a gradual increase in temperature, monitored by a digital infrared thermometer, to reach temperature between 36°C and 38°C, keeping the movement for two minutes in each area, spending in total around 10 minutes.
224309564|NCT06971016|OTHER|Traditional Physical therapy|"• Stretching of the Gastrocnemius and Soleus Muscles~* Frequency: 3-5 times per week.~* Intensity: Stretch to the point of mild discomfort, not pain.~* Time: Hold each stretch for 30 seconds and repeat 3 times on each leg.~* Type: Static stretching. Gastrocnemius Stretch: Stand facing a wall with one foot forward (slightly bent) and the other foot back (straight). Press the back heel into the floor and lean forward to feel the stretch in the calf.~Soleus Stretch: From the same position, slightly bend the back knee while keeping the heel on the ground to target the lower calf (soleus muscle).~• Stretching of the Hamstrings~* Frequency: 3-5 times per week.~* Intensity: Stretch to a tolerable point of tension without causing pain.~* Time: Hold each stretch for 30 seconds and repeat 3 times on each leg.~* Type: Static stretching. Seated Hamstring Stretch: Sit on the floor with one leg straight and the other bent."
224074564|NCT06303609|DEVICE|Vaginal dilator|Both groups will use the vaginal dilator at the end of each session for 15 minutes and all patients will be advised to use it for 15 minutes daily in a home based treatment.
224074565|NCT06303609|DEVICE|Sham nonablative radiofrequency|The active electrode from the nonablative radiofrequency will be applied to the urogenital- and uroanal trigone and the dispersive electrode will be attached to the back of the patient. The water-soluble gel will be applied to the active electrode and to the non-lubricated condom which will involve the active electrode. As the device will not deliver the radiofrequency wave, the gel will be heated so the patient has the feeling of the temperature change, keeping the movement for two minutes in each area, spending in total around 10 minutes.
224074566|NCT02741102|PROCEDURE|Uterine Transplant|Treating Absolute Uterine Factor Infertility by Uterus Transplant. Potential recipients undergo IVF to obtain 6 embryos for cryopreservation followed by live donor uterine transplant. After 1 year, embryo transfer is done to achieve pregnancy. Delivery is by Caesarian section. The recipient may have up to 2 children by these methods and then the uterus is removed so that immunosuppression can be stopped.
224074567|NCT04418765|DRUG|Eptinezumab|Eptinezumab, concentrate for solution for infusion 100 mg/milliliter (mL)
224190152|NCT05212246|DRUG|Placebo Vehicle Control Cream|The placebo vehicle control cream will be a virtually identical cream (to the Imiquimod cream) that contains no Imiquimod. This cream will be applied once daily to the face in a thin layer for 12 weeks. Three packets of cream will be defined as one dose or application. The cream should be applied to the face prior to normal sleeping hours (it is readily absorbed) and left on the skin for 6-10 hours (i.e. overnight). Rest periods will be allowed if bothersome side effects occur.
224190153|NCT03975465|BEHAVIORAL|Expiratory Muscle Strength Training|8 weeks of EMST at 75% maximum expiratory pressure (MEP)
224190154|NCT03975465|BEHAVIORAL|Pharyngeal Muscle Strengthening Exercises|8 weeks of exercises designed to increase pharyngeal muscle strength for swallowing
224190155|NCT05630638|DRUG|Doravirine|Fixed dose combination of doravirine, lamivudine and tenofovir disoproxil
224190156|NCT05630638|DRUG|Dolutegravir|Fixed dose combination of dolutegravir, lamivudine and tenofovir disoproxil
224190157|NCT05138614|OTHER|Medication for Opioid Use Disorder|medication management
224190158|NCT05138614|BEHAVIORAL|MISSION Critical Time Intervention|offering intensive community-based services that decrease in intensity over time
224190159|NCT05138614|BEHAVIORAL|MISSION Peer Support|including 11 recovery-oriented sessions from someone with lived experience of co-occurring disorders
224190160|NCT05138614|BEHAVIORAL|MISSION Dual Recovery Therapy|comprised of 13 structured co-occurring disorders treatment sessions
224190161|NCT03975218|OTHER|Patients With Stroke|In addition to the usual care, the patient will have to complete a questionnaire analyzing the regularity of his follow-up by a physician.
224190162|NCT01939236|DRUG|traditional Chinese medicine|1 bag of drug 2 times per day for 28 days according to syndrome differentiation. For example, the syndrome of one patient is qi deficiency and blood stasis, he will take drugs of qi deficiency and blood stasis each bag 2 times per day for 28days.
223500203|NCT04071886|BEHAVIORAL|Relaxation Training|Participants will listen to a 15-minute Relaxation Training tape twice a day.
223500204|NCT03893214|BEHAVIORAL|virtual reality exposure for acrophobia|"The setting of the virtual reality is the Gasometer Oberhausen, Europe's largest disc-type gas container which is one of the most famous high buildings in the area. After a baseline phase, participants will undergo a gradual exposure. Participants will first look up to the building and then be guided upstairs to have an exposure phase on 11 floors. On the highest floor they will walk around a gallery. In the end, there will be a recovery phase."
223500205|NCT03893214|BEHAVIORAL|movie|Participants will watch a movie without height content for the same amount of time as the virtual reality exposure will need.
223500206|NCT05729191|BIOLOGICAL|Anti Covid 19 vaccination campaign for pregnat women|Assessment of vaccine hesitancy and Covid-19 disease knowledge
223500207|NCT06025370|OTHER|Prone Position|"All healthy volunteers will be positioned in prone position, on a bed equipped with a mapping pressure system.~The volunteers will spend 5 minutes in each of the positions corresponding to the study groups."
223500208|NCT02475837|DRUG|Vorapaxar sulfate|The study drug (12-week supply of study drug) will be dispensed to enrolled patients on the first day following surgery.
223500209|NCT02475837|DRUG|Placebo|The placebo will match the study drug, vorapaxar sulfate, in appearance. A 12-week supply will be dispensed to enrolled patients on the first day following surgery.
223500210|NCT01505335|DEVICE|US depth measurements|Measurement of the distance between the apex of the drilled implant site and the IAC
224309565|NCT05642130|OTHER|exersice program (Muscle energy technique)|Post isometric relaxation for upper trapezius and sternocleidomastoid muscles. the therapist moved the subject's head into the position that put each muscle in stretch, once resistance/ barrier was felt, that position was held and subjects were asked to isometrically contract the target muscle with 20% of maximal contraction for 5 sec against mild resistance from the therapist, relax for 5 sec followed by passive stretch until reaching a new barrier for 30 sec, 3 repetitions for each muscle, 3sessions /week over a period of 4 weeks, In addition to the program designed for control group
223500211|NCT04519398|GENETIC|Complete thrombophilic profile testing by multiplex PCR|"Complete thrombophilic profile testing by multiplex PCR and reverse hybridization of DNA to assess the presence of prothrombotic genotypes:~* Factor V Leiden~* Factor V 4070 A\>G (Hr2)~* Factor II G20210A~* Methylenetetrahydrofolate reductase (MTHFR) C677T~* MTHFR A1298C~* Cystathionine β-synthase (CBS) 844ins68~* PAI-1 4G/5G~* Glycoprotein IIIa T1565C (HPA-1a/b)~* ACE-DEL/INS~* Apolipoprotein E (ApoE)~* AGT M235T~* Angiotensin II type 1 receptor (ATR-1) A1166C~* Fibrinogen - 455 G\>A~* Factor XIII Val34Leu"
223500212|NCT06523790|BEHAVIORAL|Yoga|Participants in the yoga group will attend 90-minute yoga sessions, 3 times per week, for 8 months. The sessions will include a combination of asanas (postures), pranayama (breathing exercises), and meditation.
223500213|NCT06523790|BEHAVIORAL|Brisk walking|Participants in the brisk walking group will engage in one-hour fast-paced walking sessions, 6 times per week, for 8 months. The walking regimen is designed to improve cardiovascular fitness, endurance, and support weight loss.
224074568|NCT04418765|DRUG|Placebo|concentrate for solution for infusion, intravenously
224074569|NCT03315832|DRUG|Valsartan|The active treatment is valsartan, an orally active, potent, and specific angiotensin II receptor antagonist. The treatment will be initiated (80 mg, daily) at 5±4 days following aortic valve intervention. The dose will be increased at 160 mg daily 13±2 days after aortic valve intervention and, if well tolerated, for the remaining period of the study.
223500214|NCT02710747|GENETIC|CYP2C9;VKORC1|
223500215|NCT02990377|BEHAVIORAL|RL-supported IVR intervention|Participants in the intervention group receive interactive voice response calls where they are asked to report information about their health and medications using their touch-tone phone. Based on their responses, participants may receive brief or extended motivational messages during the call, or they may be assigned to receive a 20 minute motivational enhancement session with a study therapist over the phone.
223500216|NCT00679601|DRUG|AN2690|AN2690 7.5% Solution, once daily for 28 days
223500217|NCT02663505|PROCEDURE|Patients receiving the surgery planned for them|"For each patient the following potential influence (risk) factors are documented:~sex, urgency of the operation, BMI, age, ASA classification, preconditions, physical fitness, Hb value.~In phase 2 only selected influence factors will be recorded.~No intervention will be performed apart from the surgery planned for each patient."
223500218|NCT05297838|OTHER|Stationary Bike|Stationary Bike while hand is submerged in ice bath
224074570|NCT03315832|DRUG|Placebo Oral Tablet|The comparative treatment will be a placebo; tablets of valsartan and placebo have a similar appearance and administration mode. Patient in the control group will receive a placebo using the same protocol as the valsartan group.
224074571|NCT01558661|DRUG|AG-013736 (AXITINIB)|All eligible patients will receive a starting axitinib dose of 5 mg twice daily (BID) taken orally in 4-week (28-day) cycles. Patients who tolerate axitinib with no adverse events related to study drug above CTCAE v. 4.0 Grade 2 for a consecutive 2-week period may have their dose increased by one dose level according to the discretion of the treating physician (NOT allowed for patients with blood pressure (BP) \> 150/90 mm Hg or who are receiving antihypertensive medication). This dose escalation is not mandatory. RECIST v1.1 tumor assessments will be made at baseline (CT or MRI) and then approximately every 2 cycles (or every 8 weeks (+/- 1 week)). After 10 months, imaging will be done every 3 cycles (or every 12 weeks (+/- 1 week)). Patients may remain on study until progression of disease or unacceptable toxicity.
224074572|NCT05020600|DRUG|Duloxetine|First-line fibromyalgia treatment
224074573|NCT05020600|DRUG|Pregabalin|First-line fibromyalgia treatment
223500219|NCT05297838|OTHER|Virtual Reality (VR) Headset|VR headset containing gameplay
223500220|NCT05297838|OTHER|Ice Bath|Pain was elicited via a cold pressor test, which is an established method of producing controlled and repeatable painful stimuli in an experimental setting
223500221|NCT00985790|BIOLOGICAL|Influenza vaccine GSK2321138A|Intramuscular injection
223500222|NCT00985790|BIOLOGICAL|Fluarix™|Intramuscular injection
223500223|NCT00918450|DRUG|ABT-263|"Continuous dosing until disease progression using one of the following formulations:~25 mg/mL oral solution OR 50 mg/mL oral solution OR 2.0 grams/bottle powder for oral solution of 25 mg/mL when mixed OR 2.0 grams/bottle powder for oral solution of 50 mg/mL when mixed"
223500224|NCT01888588|DRUG|Risk of symptomatic peptic ulcer|Current use of drugs (ASA; NSAIDs, SSRI,PPI, H2RA) versus non-use
223500225|NCT03185507|DEVICE|CryoHelmet|Cryotherapy was administered using the Catalyst CryoHelmet™ (All-Star Sporting Goods®, Shirley, Massachusetts, USA). The CyroHelmet is a flexible helmet equipped with gel ice packs meant to cool the head and neck.
223500226|NCT00762177|DRUG|Fluoride|Brush twice a day for 14 days
223500227|NCT00762177|DRUG|Fluoride, Triclosan|Brush twice daily for 14 days
223500228|NCT00762177|DRUG|Stannous Fluoride|Brush twice daily for 14 days
224074574|NCT05020600|DRUG|Amitriptyline|First-line fibromyalgia treatment
224074575|NCT00341250|DRUG|AMA1-C1/Alhydrogel Malaria Vaccine|
224074576|NCT02217566|DRUG|Abiraterone acetate|Participants will receive abiraterone acetate 1000 mg (4\*250 mg tablets) orally once daily until PSA progression, clinical progression, consent withdrawal, or the occurrence of unacceptable toxicity.
224074577|NCT02217566|DRUG|Prednisone|Participants will prednisone 5 mg orally once daily from Day 1 of Cycle 1 and continues until PSA progression, clinical progression, consent withdrawal, or the occurrence of unacceptable toxicity.
224074578|NCT02217566|DRUG|Androgen deprivation therapy (ADT)|Participants will remain on a stable regimen of ADT, that is, luteinizing hormone-releasing hormone (LHRH) agonists including leuprolide acetate and goserelin acetate as per Investigator's discretion.
223500229|NCT04846257|OTHER|Dynamic contrast-enhanced MRI|Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) is the acquisition of sequential images during the passage of a contrast agent within a tissue of interest.
223500230|NCT05111964|DEVICE|High Intensity Focused Ultrasound Ablation|"The focused ultrasound exposure will be performed using the Haifu® Model-JC200 Focused Ultrasound Tumour Therapeutic System at the Churchill Hospital site, CE-approved for tumour therapy (or subsequent CE-approved device upgrades by Haifu®). The participant will be positioned over the therapeutic device and water bath used to transmit the focused ultrasound to the target tumour. No anaesthesia or any combination of local anaesthesia, nerve block, epidural, conscious sedation or general anaesthetic may be used, depending on anatomical location, size of tumour, preference of HIFU team, patient and anaesthetist and other patient factors.~In therapy mode, the tumour volume is treated with focused ultrasound to ablate the tumour tissues to high temperatures (in excess of 60ºC) using focused ultrasound targeted from outside the body.~Patients are typically discharged with 24 hours."
224074579|NCT00883246|DEVICE|SilverHawk & TurboHawk Peripheral Plaque Excision System|Removal of atherosclerotic plaque from artery walls.
224074580|NCT01077973|DRUG|Novel Ibuprofen|Single-dose of novel ibuprofen (equal to 400 mg ibuprofen) plus placebo
224074581|NCT01077973|DRUG|Standard Ibuprofen|Single-dose of standard ibuprofen (400mg) plus placebo
224074582|NCT01077973|DRUG|Placebo|Single-dose of placebo
224074583|NCT02828410|DIETARY_SUPPLEMENT|SBI|Serum bovine immunoglobulin protein isolate 10 g twice per day
224074584|NCT03563937|DRUG|Phenprocoumon|Follow the physician's prescription.
224074585|NCT03563937|DRUG|Apixaban|2.5 mg or 5 mg, twice daily
224074586|NCT03563937|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|15 mg or 20 mg, once daily
224074587|NCT03563937|DRUG|Edoxaban|30 mg or 60 mg, once daily
224074588|NCT00328146|OTHER|Observation of sternal reentry|Observation of sternal reentry
224074589|NCT04453579|BEHAVIORAL|Telephonic interview during the Italian lockdown.|The interview was composed of socio-demographic items lockdown, and dichotomous questions about physical and mental health in relation to the COVID-19 emergency
224074590|NCT00157612|PROCEDURE|a clinical pathway nursing home acquired pneumonia|treatment in nursing homes according to a clinical pathway, which included use of oral anti-microbials, portable chest radiographs, oxygen saturation monitoring, rehydrations and close monitoring by research nurse
224074591|NCT04358783|BIOLOGICAL|Plasma|The plasma unit will be fractionated in 200 mL aliquots for storage at -80°C until use. After thawing, it shall be administered in a single 200 mL dose to subjects who are randomized to that arm.
224074592|NCT04358783|OTHER|Best Available Therapy|It shall include, but not be limited to, oxygen therapy by means of a nasal cannula; high-flow nasal cannula; invasive or non-invasive mechanical ventilation; intravenous hydration; antibiotic therapy; thrombus prophylaxis; pain and fever management.
224074593|NCT01895127|DRUG|Eculizumab|
224074594|NCT01895127|BIOLOGICAL|Immunoglobulin|
224074595|NCT01895127|PROCEDURE|Plasmapheresis|
224074596|NCT04516473|PROCEDURE|Abdominal Body Contouring|These are surgeries that correct for excess skin and its adverse consequences. The surgeries that focus on central area to remove a large hanging pannus is usually called panniculectomies or abdominoplasties; the former is focused on the excision of excess tissue to relieve impairment while the latter is generally considered a cosmetic surgery. The form of the surgery is case dependent and can range from removing apron of skin to complete contouring of the abdomen with tightening of the abdominal muscle and moving the belly button.
224074597|NCT00131625|BEHAVIORAL|Health education according to WHO recommendations|
224074598|NCT03361397|DRUG|Lidocaine Hydrochloride|Lidocaine hydrochloride will be used via mask nebulizer before LMA insertion
224074599|NCT03361397|DRUG|Distilled Water|Distilled Water will be used via mask nebulizer before LMA insertion
224074600|NCT05786092|DEVICE|Telemonitoring|Monitoring of the required parameters by means of the data provided by the devices used by patients. The data (weight, body composition, blood pressure, oxygen saturation, physical activity, heart rate and blood glucose) collected according to the predetermined schedule are then saved in a cloud accessible to researchers.
224074601|NCT00584480|OTHER|Hyperbaric Oxygen Treatment (HBOT)|1.5 ATA at 100% Oxygen of HBOT
224074602|NCT02656628|DEVICE|Dynamic Locking Screw 3.7mm and 5.0mm|Treatment with DLS and locked plate constructs (small or large fragments)
224074603|NCT04674566|DRUG|COR-101|Administered intravenously (IV) single dose
224074604|NCT04674566|DRUG|Placebo|Administered intravenously (IV) single dose
224074605|NCT02548026|BEHAVIORAL|High Eating Frequency (High EF)|Free-living participants complete a 21-day high eating frequency (high EF) Phase in which they consume all daily energy at 8 eating occasions.
224074606|NCT02548026|BEHAVIORAL|Low Eating Frequency (Low EF)|Free-living participants complete a 21-day low eating frequency (low EF) Phase in which they consume all daily energy at 3 eating occasions.
224074607|NCT05152797|BIOLOGICAL|Autologous tumor-infiltrating lymphocytes|Fresh tumor samples will be resected from enrolled patients. Autologous TILs will be extracted and reinfused to corresponding patients after ex vivo stimulation, activation and extensive expansion.
224074608|NCT02266030|DRUG|Cilostazol|Pletaal as an active drug
224074609|NCT02266030|DRUG|Aspirin|Aspirin as an active comparator
224074610|NCT04851600|DEVICE|prosthesis|Casting and delivery of a cosmetic upper limb prosthesis at 3-4 months old of age.
224074611|NCT01999582|BIOLOGICAL|Sotatercept|Sotatercept is dosed intravenously every 14 days. The dose a subject receives will depend on the randomization arm and the dose group.
224074612|NCT01999582|BIOLOGICAL|Sotatercept|Sotatercept is dosed subcutaneously every 14 days. The dose a subject receives will depend on the randomization arm and the dose group.
224074613|NCT05116800|DRUG|Gemcitabine|Patients will receive 9.3 mg/kg 9-ING-41 twice weekly with 900 mg/m2 gemcitabine on days 1 and 8 and 75 mg/m2 docetaxel on day 8 of a 21-day cycle until disease progression or unacceptable toxicity.
224074614|NCT05116800|DRUG|9-ING-41|Patients will receive 9.3 mg/kg 9-ING-41 twice weekly with 900 mg/m2 gemcitabine on days 1 and 8 and 75 mg/m2 docetaxel on day 8 of a 21-day cycle until disease progression or unacceptable toxicity.
223500231|NCT05111964|DIAGNOSTIC_TEST|Tumour Biopsy and Venous Blood Tests|"Where appropriate, participants are also encouraged to undergo a pre-HIFU (and in the case of unresectable STS, post-HIFU) ultrasound biopsy of the target tumour and additional blood tests to inform the immunological aspects of the study. Having the biopsy does not mandate enrolment on the trial, and patients will be free to leave the trial at any stage. The pre-HIFU (and post-HIFU) biopsies are altruistically encouraged but not absolutely essential to enrolment on the trial.~Biopsies will be performed under ultrasound guidance by an experienced radiologist using local anaesthetic."
223500232|NCT04120779|DEVICE|The EMPOWER-SUSTAIN e-Health Self-Management Intervention|Multifaceted chronic disease management strategies involving web-based self-management intervention mobile apps based on chronic care model and persuasive technology theory to improve patient activation and self-management behaviours among patients with metabolic syndrome.
223500233|NCT05015634|OTHER|Active Arm|Patient develops possible cardiac symptoms, takes an ECG, BP and oxygen saturation as per their training. Patient will receive a phone call by the trial cardiologist who will have access to a high-quality ECG trace, as well as blood pressure and oxygen saturations, and coupled with the clinical history, can decide on the most appropriate course of further management. With remote follow up over the phone at 3, 6 and 9 months.
223500234|NCT05015634|OTHER|Control Arm|Standard routine clinical care will be carried out, with remote follow up over the phone at 3, 6 and 9 months.
223500235|NCT05792488|BEHAVIORAL|Coach|Coaching to a healthy lifestyle
223500236|NCT05792488|BEHAVIORAL|App|The app will coach people to a healthy lifestyle
223500237|NCT05792488|OTHER|Standard of care|Patients will receive standardized lifestyle advice by their specialist
223500238|NCT06971939|COMBINATION_PRODUCT|NT-501/revakinagene taroretcel-lwey|NT-501 is surgically implanted into the vitreous cavity to continuously release recombinant human ciliary neurotrophic factor (CNTF).
223500239|NCT06965309|DRUG|HN2301 injection|Description: Three dose groups were set up, starting from the low dose group and climbing to explore the safe and effective dose.
223500240|NCT02179619|DEVICE|Dermalax(Deep)|Dermalax(Deep) injection into one nasolabial fold (NLF) of one side of the face (blinded, split-face study design) in the Initial Treatment period
223500241|NCT02179619|DEVICE|Restylane|Restylane Injection into one nasolabial fold (NLF) of one side of the face (blinded, split-face study design) in the Initial Treatment period
223500242|NCT02111044|DRUG|Octreotide|octreotide 100 mcg sc t.i.d. for 4 weeks
223500243|NCT02111044|DRUG|ITF2984 500 mcg|ITF2984 500 mcg sc b.i.d for 4 weeks
223500244|NCT02111044|DRUG|ITF2984 1000 mcg|ITF2984 1000 mcg sc b.i.d for 4 weeks
223591398|NCT00696046|PROCEDURE|Intrabone Marrow Injection|Cord blood CB units will be thawed in a 37° CB cells will be resuspended in 20ml salinesolution + dextran/albumin, and aliquoted in 4 syringes of 5ml Pts were prepared in a surgical \& steril room The anaesthesia consist in a short propofol sedation The injection will last 8-15 minutes. 1° sedation is established, a standard needle for bone marrow aspiration (14 gauge) was inserted few cms in the supero-posterior iliac crest then, an aspiration of about 0.5-1 ml will be performed to assess that the needle was securely introduced in the bone marrow cavity After, we will insert the syringe containing 4-5ml of CB cell suspension which will be gently infused This procedure will be then repeated for all the remaining aliquots at a distance of 2-3cm from the previous one following the iliac crest
223591399|NCT03221686|DIETARY_SUPPLEMENT|Intervention|The patients in the intervention group are given 55 mg zinc, 1251 mg vitamin C, and 15 g arginine once daily 14 days pre-operatively and post-operatively together with a high quality protein supplement.
223591400|NCT03221686|DIETARY_SUPPLEMENT|Control|High quality protein supplement 14 days pre-operatively and post-operatively.
224074615|NCT05116800|DRUG|Docetaxel|Patients will receive 9.3 mg/kg 9-ING-41 twice weekly with 900 mg/m2 gemcitabine on days 1 and 8 and 75 mg/m2 docetaxel on day 8 of a 21-day cycle until disease progression or unacceptable toxicity.
223500245|NCT02111044|DRUG|ITF2984 2000 mcg|ITF2984 2000 mcg sc b.i.d for 4 weeks
223500246|NCT00867880|DRUG|IVIb|800mg IVIb diluted in 200mL NS will be given IV (in the vein) concurrently with an oral placebo on Day 1 and 200ml Normal Saline will be given IV (in the vein)concurrently with 800mg oral ibuprofen on Day 8
223500247|NCT02839317|BIOLOGICAL|Biological|comparison of microbiota, genetic profile between pediatric- and elderly-onset CD
224074616|NCT05074758|DIAGNOSTIC_TEST|alveolar dead-space quantification|measurement of alveolar dead-space based on volumetric capnography
224074617|NCT05074758|DIAGNOSTIC_TEST|Coagulation activation and impaired fibrinolysis explorations|"blood sampling:~* Fibrinolytic components~* NETs components~* Elastase-derived fragments of proteins of interest"
224074618|NCT05074758|DIAGNOSTIC_TEST|Endothelial activation / endothelial senescence|circulating endothelial cells, E-selectin, endoglin, LVEF-A, LVEFR-2, Angiopoietin -1 and -2, cKit and SDF-1 Willebrand factor (activity, antigen, multimeric analysis )
224074619|NCT05082103|OTHER|Enzyme lozenge 1|Participants are instructed to take one enzyme containing lozenge three times daily, at least 30 min after a meal, for 14 days. No normal oral hygiene procedures are allowed during the intervention period.
224074620|NCT05082103|OTHER|Enzyme lozenge 2|Participants are instructed to take one lozenge with 3x higher enzyme concentration three times daily, at least 30 min after a meal, for 14 days. No normal oral hygiene procedures are allowed during the intervention period.
224074621|NCT05082103|OTHER|Placebo lozenge|Participants are instructed to take one placebo lozenge three times daily, at least 30 min after a meal, for 14 days. No normal oral hygiene procedures are allowed during the intervention period.
224074622|NCT02237430|DEVICE|MynxGrip|Closure device for femoral artery access closure
224074623|NCT02237430|OTHER|Manual compression|Conventional manual compression
224074624|NCT02841215|DRUG|Ivermectin 200 µg/kg|Oral ivermectin 200 µg/kg three times (D0, D7 and D14) + topical treatment (permethrin 5% cream) on skin, hair and genital organs (D0 and D7) + emollient cream (Dexeryl® or other) daily on skin (D0 to D28)
224074625|NCT02841215|DRUG|Ivermectin 400 µg/kg|Oral ivermectin 400 µg/kg three times (D0, D7 and D14) + topical treatment (permethrin 5% cream) on skin, hair and genital organs (D0 and D7) + emollient cream (Dexeryl® or other)daily on skin (D0 to D28)
223500248|NCT02213783|DRUG|Imipenem|Each patient will receive 0.5 g of imipenem, 0.5 hr infusion every 6 hr at room temperature
223500249|NCT02213783|DRUG|Imipenem|Each patient will receive 0.5 g of imipenem, 4 hr infusion every 6 hr of at room temperature
223591401|NCT06080685|BEHAVIORAL|Character Strengths Intervention|Session 1. Getting Started: Introducing and Exploring Character Strengths Session 2. Boost a Lower Strength Session 3. Cultivate your inner self + Loving-Kindness Meditation Session 4. Gratitude Letter + Three Good things Session 5. Conclusion Each session will consist of 1-hour, which will be delivered once a week for 5 weeks. Moreover, participants will be given homework which they will practice the rest of the week.
224309566|NCT05642130|OTHER|exersice program (stretching and strengthening exercises ) In addition to postural advices|static stretching exercise for upper trapezius and sternocleidomastoid . Repetitions: 3times/day, 3days/week over a period of 4 weeks, in addition to strengthening exercises of deep cervical flexors and scapular retractor muscles, 3sets of 12 repetitions with 6 sec hold. In addition to postural advices
224309567|NCT01443936|BIOLOGICAL|Ad4-H5-VTN vaccination-tonsillar route|
224309568|NCT01443936|BIOLOGICAL|Ad4-H5-vaccination-oral route|
223500250|NCT01449084|PROCEDURE|immediate stent removal|"The stent used was a 5-Fr polyethylene duodenal pigtail pancreatic stent without an inner flange. The stent length was 4 or 5 cm (Zimmon stent, Cook Endoscopy, Winston-Salem, NC, USA): selection was based on the degree of flexion and the length of the Wirsung duct in the head of the pancreas.~THE STENT WAS REMOVED AT THE END OF THE ERCP PROCEDURE"
223500251|NCT01449084|OTHER|Leaving the stent in place|"The stent used was a 5-Fr polyethylene duodenal pigtail pancreatic stent without an inner flange. The stent length was 4 or 5 cm (Zimmon stent, Cook Endoscopy, Winston-Salem, NC, USA): selection was based on the degree of flexion and the length of the Wirsung duct in the head of the pancreas.~THE STENT WAS LEFT IN PLACE AT THE END OF THE ERCP PROCEDURE"
223500252|NCT03393572|DRUG|Bupivacaine 0.25%|Patients will receive 30 mL of intraperitoneal bupivacaine 0.25%
223500253|NCT03393572|DRUG|Magnesium sulphate.|Patients will receive intraperitoneal 30 mg/kg of magnesium sulphate.
223500254|NCT03393572|DRUG|nalbuphine|Patients will receive intraperitoneal 5 mg nalbuphine
223500255|NCT04012645|PROCEDURE|application of near infrared-indocyanine green imaging system|Underwent laparoscopic TME and colon-rectum or colon-anal anastomosis. near infrared-indocyanine green imaging system was used to evaluate the anastomotic flood perfusion during the operation; The operator may decide whether to change the surgical programme based on the outcome of the evaluation.
223500256|NCT04012645|PROCEDURE|Non-application of near infrared-indocyanine green imaging system|Underwent laparoscopic TME operation, and the operator judged anastomotic blood supply with naked eyes and performed the surgical intervention based on the experience
223500257|NCT02319382|RADIATION|PET with the tracer 18F-DPA-714|
223500258|NCT02319382|RADIATION|PET with the tracer 11C-PE2I|
224074626|NCT02481388|OTHER|Maximal exercise ramp test|The maximal exercise ramp test, symptom-limited, performed by all patients in the study was performed based on treadmill ramp protocol through ErgoPC Elite® software associated with 12-channels electrocardiogram. Respiratory variables were obtained in standard conditions of temperature, pressure and humidity (StPD), breath-by-breath, with the patient breathing through a face mask without leaks coupled to gas analyzer (Cortex - Metamax 3B, Germany).To ensure that patients reached maximum effort during the examination, only the tests which patients obtain a respiratory exchange ratio (RR) ≥1.1 were accepted .
224074627|NCT03075566|BIOLOGICAL|Healthy subjects|\- 207 healthy subjects were donors,(33.2±12.2 years) recruited from the Blood Bank Department of the University Hospital (Mahdia, Tunisia).
224074628|NCT03075566|BIOLOGICAL|Patients|\- 310 subjects with CAD (60.3±11.0 years) were admitted to the Department of Cardiology, University Hospital (Monastir, Tunisia).
224074629|NCT03511131|BEHAVIORAL|Queer Sex Ed|Comprehensive sexual health education program condition (Informational)
224074630|NCT03511131|BEHAVIORAL|Keep It Up|Culturally/situation-relevant HIV-prevention experimental condition (Motivational/behavioral)
224074631|NCT03511131|BEHAVIORAL|Keep It Up-Control|HIV knowledge control condition, attention-matched to KIU (Informational)
224074632|NCT03511131|BEHAVIORAL|Young Men's Health Project|Motivational enhancement video interviewing condition (Motivational/behavioral)
224074633|NCT01887977|OTHER|MRI examination|The vocal and nasal tracts from the lips and nostrils to the beginning of the trachea are imaged with Siemens Avanto 1.5T MRI machine using carefully optimized, externally triggered imaging sequences that are synchronized with the rest of the experimental setting. A sound sample, given by the test subject, is recorded simultaneously to obtain a coupled data set: the speech sound and the precise anatomy which produces it.
224074634|NCT01014741|DRUG|Ibutilide|0.25mg IV ibutilide after PV isolation prior to CFE ablation
224074635|NCT01014741|DRUG|Placebo|Placebo after PV isolation prior to CFE ablation.
224074636|NCT03639844|BIOLOGICAL|rivogenlecleucel|BPX-501 T cells are genetically modified with a suicide safety switch. The cells are infused after T cell-depleted HSCT to potentially enhance immune reconstitution while reducing severity and duration of GVHD.
224074637|NCT03639844|DRUG|rimiducid|Rimiducid induces activation of the Caspase 9 suicide gene in BPX-501 T cells inducing apoptosis of the modified T cells in case of GVHD
224074638|NCT05404308|OTHER|Consultation with Manipulator in Medical Radiology and a radiotherapist|Weekly consultation with Manipulator in Medical Radiology and a radiotherapist
224074639|NCT05404308|OTHER|Consultation with a radiotherapist|Weekly consultation with a radiotherapist
224074640|NCT01913080|OTHER|Health Log|"The Health Log consists of a permanent booklet and a refillable health log version that is filled out before each doctor's appointment. The permanent booklet has areas to record:~* Personal information and emergency contact(s)~* Physician names and contact information~* Insurance information~* Medications, vitamins and supplements~* Surgeries~* Health history The booklet also includes suggested questions you may want to ask your Rheumatologist about medications, lifestyle, or future/status.~The refillable health log includes questions about pain, fatigue,overall status from the Multi-Dimensional Health Assessment Questionnaire (MDHAQ), and a modified Arthritic Pain and Joint Evaluation. It also has space to write questions for the doctor's visit and prescription refills needed."
224309569|NCT01062737|DRUG|ASU|
224309570|NCT06270212|DEVICE|STAIRWAY|Evaluation of STAIRWAY (new airway device) during sedation.
224309571|NCT06270212|DEVICE|NO DEVICE|Evaluation of NO DEVICE during sedation
224190163|NCT01939236|DRUG|Placebo (gummeline)|"Placebo of each syndrome differentiation has the same weight and smell as traditional Chinese medicine of corresponding syndrome differentiation.~1 bag of drug 2 times per day for 28 days according to syndrome differentiation.~For example, the syndrome of one patient is qi deficiency and blood stasis, he will take drugs of qi deficiency and blood stasis each bag 2 times per day for 28 days."
224190164|NCT03329053|BEHAVIORAL|The EAPC Exercise Prescription (EXPERT) Tool|"During the 30-minute long consultation subjects will receive standard, usual-cardio-care lifestyle, hypertension and cardiovascular instructions, except recommendations for physical activities. This domain will be consulted exclusively through the digital training and decision support tool.~The EXPERT tool is an interactive digital training and decision support system for optimized exercise prescription in cardiovascular disease patients. The EXPERT tool was designed to provide optimized exercise prescription based on detailed overview of patient´s diagnosis, prognostics, complications and medication."
224190165|NCT03329053|BEHAVIORAL|Standard Cardio-Care Lifestyle Counselling|During the 30-minute long consultation subjects will receive standard, usual-cardio-care lifestyle, hypertension and cardiovascular instructions also in the domain of recommendations for physical activities. The exercise prescription process during consultation will be constructed in accordance with published guidelines and recommendations for secondary prevention of cardiovascular diseases.
224190166|NCT06049004|OTHER|Activities of Daily Living Protocol|The protocol is a performance-based objective measurement method based on repetition of daily activities. Participants are asked to perform the activities defined in the protocol at the same speed they do at home. The Londrina Protocol includes 5 stations: Station 1 Arranging Objects on the Table, Station 2 Walking with Bags, Station 3 Organizing Shelves, Station 4 Clothesline Task, Station 5 Walking. The completion time of the protocol is recorded.
224190167|NCT06033352|DEVICE|KTP laser|Treatment with KTP 532 nm laser. Laser fluence depends on erythema intensity and ranges from 7.0 J/cm2 to 11 J/cm2 with a 4-11 mm spot size and 8-12 ms pulse duration.
224190168|NCT06033352|DRUG|Ivermectin 1% cream|Application of ivermectin 1% cream 1x/day. Interruption for 4 days in case of irritation/redness.
224190169|NCT05707494|DEVICE|Efferon LPS NEO|Efferon LPS NEO, a medical device, which is a cylindrical body filled with a polymeric hemosorbent that selectively absorbs LPS and excess cytokines. The device is used for extracorporeal therapy to relieve septic shock in the treatment of sepsis.
224190170|NCT04148378|OTHER|No intervention|There is no intervention for this study.
224190171|NCT06592924|DRUG|Abiraterone|Assigned prior to enrollment
224190172|NCT06592924|DRUG|Enzalutamide|Assigned prior to enrollment
224190173|NCT06592924|DRUG|Apalutamide|Assigned prior to enrollment
224190174|NCT06592924|DRUG|Darolutamide (BAY 1841788)|Assigned prior to enrollment
224190175|NCT06592924|DRUG|Docetaxel|Assigned at enrollment
224190176|NCT06592924|DRUG|ADT|Physician's choice. Assigned prior to enrollment
224190177|NCT03800121|BIOLOGICAL|Blood samples|"Localized sarcoma group : 1 blood sample during inclusion (7 ml) + 1 blood sample before surgery (32 ml) + 1 blood sample 1 month after surgery (32 ml) + 1 blood sample 3 month after surgery (32 ml) + 1 blood sample 6 month after surgery (32 ml)~Metastatic sarcoma group : 1 blood sample during inclusion (7 ml) + 1 blood sample during chemotherapy cure 1 (32 ml) + 1 blood sample during chemotherapy cure 3 (32 ml) + 1 blood sample during chemotherapy cure 6 (32 ml)"
224190178|NCT05419765|DIAGNOSTIC_TEST|Peripheral blood withdrawn|"Peripheral blood will be withdrawn in order to measure haematic lipids (total cholesterol and fractions, triglycerides), total blood LAL activity, to perform genetic analysis and finally to evaluate lipase activity into the platelets.~Hepatic elastography will be also executed, in 100 patients, according to the presence/absence of the PNPLA3 variant, in order to weigh up the genetic predisposition on NAFLD development or progression"
224190179|NCT04986865|DRUG|ATG-101|ATG-101 will be administered intravenously once every 21 days. During the Escalation Phase, the dose levels will be determined by the starting dose and the escalation steps taken in the trial. The Dose Expansion Phase will begin at the defined MTD, RP2D, or biologically optimal dose.
224190180|NCT03706027|DEVICE|radiation therapy-3 fractions|Radiation therapy given in a 3 fraction schedule (over 3 days). Total dose is 54 Grays.
223500259|NCT02319382|OTHER|MRI|Magnetic field
223500260|NCT00019071|DRUG|chemotherapy|
223500261|NCT00019071|DRUG|cladribine|
224190181|NCT03706027|DEVICE|Radiation therapy-5 fractions|Radiation therapy given in 5 fractions (over 5 days). Total dose is 60 Grays.
224190182|NCT03055208|RADIATION|gamma knife radiosurgery (15 Gy to 50% isodose)|Radiosurgery with a gamma knife resembles the application of a precisely focused, high single dose of ionizing irradiation.
224190183|NCT01952821|OTHER|Six-Minute Walk Test|
224190184|NCT01952821|OTHER|10-Meter Walk Test|
224309572|NCT06141161|DRUG|corticosteroids|inhailed or oral corticosteroids
224309573|NCT00423319|DRUG|Enoxaparin|Subcutaneous, 40 mg, once daily, 5 weeks
223500262|NCT00019071|RADIATION|radiation therapy|
223500263|NCT04387968|DIAGNOSTIC_TEST|Covid-19 presto test|Use an auto-test in 15 minutes get the results about covid-19 anticorps
223511969|NCT05860868|DRUG|3 cycles induction chemotherapy|"Drug: 3 cycles Induction Chemotherapy Induction regimens: TP (docetaxel 75 mg/m²; cisplatin 75 mg/m²) Q3w, TPF (docetaxel 60 mg/m²; cisplatin 60 mg/m²; 5-fluorouracil 600-750 mg/m² per day, continuous intravenous infusion d1-5) Q3w, or GP (gemcitabine: 1000 mg/m2 d1, d8; cisplatin 80 mg/m2) Q3w.~Drug: Concurrent Chemotherapy Cisplatin 100 mg/m², Q3w.~Radiation: Definitive Radiotherapy For all patients, the prescribed dose is 66-70 Gy (once a day, 5 times a week)."
223511970|NCT02201628|DEVICE|Nasopharyngeal and oesophageal temperature probes|
223511971|NCT02983942|DIETARY_SUPPLEMENT|ketogenic diet|Ketogenic diet is given to maintain blood ketone level above 2 mmol/L.
223511972|NCT02983942|DIETARY_SUPPLEMENT|Routine diet|Routine diet is given without blood ketone requirement
223511973|NCT00803907|DRUG|Imiquimod 5% cream|Imiquimod 5% cream (Aldara ®), once daily, 5 days per week for 8-16 weeks (average)
223511974|NCT02134028|DRUG|Dupilumab|Pharmaceutical form: Solution for injection Routes of administration: Subcutaneous
223511975|NCT01891838|PROCEDURE|Volume controlled ventilation|
223511976|NCT01891838|PROCEDURE|Pressure-controlled ventilation|
223511977|NCT02517138|OTHER|Parabolic flight|
223511978|NCT02517138|OTHER|Measurements of eye movements and perception|
224190185|NCT01952821|OTHER|30-Second Chair Stand|
224190186|NCT01952821|OTHER|Linear Analog Scale of Function|
224190187|NCT01952821|OTHER|Modified Brief Fatigue Inventory|
224190188|NCT01952821|OTHER|FACIT-Fatigue|
224190189|NCT01345227|PROCEDURE|Intra bone marrow islet infusion|A needle for bone marrow aspiration (14 G) will be inserted into the superior-posterior iliac crest and islet suspension (1:2.5; tissue:Ringer's Lactate solution) will be infused. The entire intraBM-injection procedure last 8-15 min from the beginning of anaesthesia (short propofol sedation).
223591402|NCT06376578|BEHAVIORAL|Exercise intervention|Exercise training will progress incrementally, increasing the duration of exercise on the treadmill by 5 minutes every 2 weeks whereby the final duration on the treadmill will be 35 minutes and the total duration will map onto recommended guidelines of 150 minutes per week. Throughout the 8-weeks, the duration of exercise on the cycle ergometer will remain at 15 minutes. Exercise intensity will progress throughout the 8-week intervention on both the treadmill and the cycle ergometer by 5% every 2 weeks, whereby exercise during the final week will be at 70% VO2max.
223591403|NCT06376578|BEHAVIORAL|Polar A380 wristwatch physical activity tracker|The research team will monitor individual exercise training weekly using virtual/electronic methods and a 30 minute telephone call. The researcher will provide feedback about how the participant's activity compares to physical activity recommendations, and encouragement and support will be provided verbally.
224190190|NCT06415188|BEHAVIORAL|Video game with headset|Half an hour before the first treatment in the morning, the screens around the patients' beds were closed by the researcher. The child was asked to choose one of the introduced games and the game he/she chose from the tablet was turned on. Children were asked to wear headphones for sound isolation and the sound was adjusted at the appropriate decibel setting. Half an hour before the treatment, children were allowed to play the video game until the treatment without any different warning. Physiologic Parameter Assessment Form, Child Anxiety and Fear Scale, Child Pain Scale were filled by the researcher 1 minute before and 1 minute after the procedure. Finally, Parental Satisfaction Scale was completed at the end of the intervention.
224190191|NCT04438980|DRUG|Methylprednisolone|-A dose of 120 mg/day of methylprednisolone for 3 days, administered by intravenous infusión
224190192|NCT04438980|OTHER|Placebo|-An infusion bag of 100 mL of 0.9% saline
223500264|NCT02705703|BIOLOGICAL|TAPA-pulsed DC vaccine|A cycle of low-dose cyclophosphamide (100mg/day) by mouth for 5 days starting seven 7 days prior to the DC vaccine cycle to reduce Treg activity. Low-dose cyclophosphamide will be taken every 14 days for six 6 cycles. A total of 6 vaccines containing 1 x 10\^7 TAPA-pulsed DC will be administered SQ every 14 days. The DC vaccine is given on Day 1 of the DCV cycle plus low-dose GM-CSF 50mcg/day SQ x 5 days (Day 1 to Day 4). GM-CSF is administered for 5 days to increase monocyte production and dendritic cell precursors to optimize immune responses.
223591404|NCT03052244|DEVICE|tDCS+VI|2mA will be delivered over 20min to M1 via neuroConn DC stimulator combined with video presenting walking legs.
223591405|NCT03052244|DEVICE|tDCS Sham+VI Sham|2mA will be delivered up to 30 sec to M1 via neuroConn DC stimulator combined with video presenting graphical illustration or nature movie for total duration of 20 min.
223591406|NCT05958680|BEHAVIORAL|ASDactive|An integrated theory-based intervention to promote habitual physical activity behaviours in autistic youth
223591407|NCT05127239|BEHAVIORAL|Smartphone Application with lifestyle modification Intervention|The study will introduce a health-promoting lifestyle through the combination of a smartphone app (MyFitnessPal) for the experimental group, emphasizing the use of behavior change techniques to reduce weight, thereby improving the obstructive sleep apnea with overweight and obese employees in the workplace. The self-monitoring, instant feedback, and social support, as well as individualized tailor-made functions are used in intervention programs. The intervention process adopts a healthy weight reduction plan, focusing on a balanced diet, moderately reducing the calories of the food, and combining weight loss methods such as increasing exercise as the main axis, emphasizing the concept of self-monitoring of weight, calorie intake, and exercise .
224190193|NCT02630615|OTHER|Blood draw|Whole blood will be collected using standard phlebotomy procedures
224190194|NCT02254876|OTHER|Standard physical therapy program|Standard physical therapy program in this study involves joint health and passive mobility at the level of the shoulder girdle and upper limb affected by Painful Shoulder Syndrome associated with the modulation of hypertonic muscle groups.
224190195|NCT02254876|OTHER|NeuroMuscular Taping (NMT)|"The NeuroMuscular Taping (NMT) consists of the application on the skin of an adhesive tape with a particular structure to elastic waves and with characteristics comparable to those cutaneous. Because of these characterises it allows activation of endogenous analgesic, structural and muscular support, vascular and lymphatic activation.~In this study the NMT is applied with decompressive mode on Pectoralis Major, Deltoids, Supraspinatus."
224190196|NCT04176172|DRUG|Varenicline|Participants will receive open-label varenicline for 12 weeks.
224190197|NCT04176172|DRUG|Nicotine patch|Participants will receive open-label nicotine patch for 12 weeks. (Participants in the NMR-tailored treatment arms will receive either varenicline OR patch; they will not receive both)
224190198|NCT04176172|BEHAVIORAL|Standard treatment|Standard behavioral smoking cessation treatment is an effective treatment for nicotine dependence. Treatment focuses on self-monitoring of smoking behavior, identifying smoking triggers and alternative trigger management strategies, relaxation, social support for non-smoking, and relapse prevention. Participants will receive up to 5 therapy sessions (2 in person, 3 over the phone) over 8 weeks.
224205844|NCT00919932|DEVICE|Text message system homework.|Homework will be standardized through the use of Judith Beck's dysfunctional thought record (DTR), which is a primary tool for patients to evaluate and respond in writing to their automatic thoughts (Beck 126). The novel text-messaging system allows homework to be submitted directly through an adolescent's cellular phone, includes text-messaged homework reminder prompts, and collates all homework for therapists to review with patients during therapy sessions. This is assigned and reviewed weekly for 4 weeks.
223500265|NCT04124965|DRUG|Rozanolixizumab|Rozanolixizumab will be administered by subcutaneous infusion in dosage regimen 1 or 2.
223500266|NCT02978807|PROCEDURE|Point of care and venous screening|
224205845|NCT04288739|DIAGNOSTIC_TEST|flow cytometric immunophenotyping|Flow cytometric (FCM) immunophenotypic analysis of peripheral blood or bone marrow aspiration samples will be performed using a panel of monoclonal antibodies (HLA DR, CD34, CD117, Cyto MPO, CD13, CD33, CD3, CD4, CD8, CD10, CD19, CD5, CD14, CD64, CD36, CD235a, cyto CD41, cyto CD61).
224190199|NCT04176172|BEHAVIORAL|Standard treatment + Managed Problem Solving (MAPS) adherence intervention|Standard behavioral smoking cessation treatment is an effective treatment for nicotine dependence. Treatment focuses on self-monitoring of smoking behavior, identifying smoking triggers and alternative trigger management strategies, relaxation, social support for non-smoking, and relapse prevention. Managed Problem Solving (MAPS) is a therapeutic process that involves the systematic delineation of a participant's medication adherence problems and construction of a series of individualized solutions that therapists and participants explore together. Participants will receive up to 5 therapy sessions (2 in person, 3 over the phone) over 8 weeks. The first session will directly address potential medication adherence barriers, and therapist and participant will collaboratively brainstorm ways to overcome these barriers.
224190200|NCT05758701|COMBINATION_PRODUCT|Iodinated Contrast Agent (Omnipaque)|Standard dosage of Omnipaque for CT imaging is 100 ml. Cohort will be given a reduced dosage.
224190201|NCT05758701|DEVICE|Dual Energy CT|Dual energy CT scanners enable monoenergetic CT image reconstruction which allows for improved iodine image contrast.
224190202|NCT06105983|DRUG|Sisunatovir|Single Dose
224190203|NCT06105983|DRUG|Rabeprazole 40 mg|Tablets once daily for 7 days
224190204|NCT06105983|DRUG|Sisunatovir suspension|Tablets once daily for 7 days
224190205|NCT06105983|DRUG|Rabeprazole 20 mg|Tablets once daily for 7 days
224190206|NCT06016556|DRUG|nirmatrelvir, ritonavir|single cohort
224190207|NCT00629343|DRUG|Azacitidine|Azacitidine will be delivered sub-cutaneously for 5 days
224190208|NCT00629343|DRUG|Temozolomide|Temozolomide will be given starting on day 8 for 5 days at a dose of 200 mg/m2 po qd x 5 days
224190209|NCT04160949|OTHER|No Intervention|There is no intervention for this study.
223591408|NCT06543888|BEHAVIORAL|passive exoskeleton- assisted gait training programs|Participants will wear an exoskeleton during the training. Each 30-minute Passive exoskeleton-assisted gait training session include range of motion exercise, movement facilitation, strengthening exercise, coordination exercise, and task-oriented training for activities of daily living
224190210|NCT03643224|DEVICE|Radiofrequency Ablation|A procedure will be performed using a radiofrequency ablation catheter.
224190211|NCT04028739|DIETARY_SUPPLEMENT|curmin|curcumin 90mg/day cross-over
224190212|NCT04240782|BEHAVIORAL|Nutrition and hands on cooking classes for parents and their children|The adults and children will learn how to prepare the fresh produce during an age appropriate, evidence-based, family cooking school. The class will provide participants with a no-cost, low-risk incentive to try new vegetables, and will empower them to build healthier lives through nutrient-rich, locally sourced meals. Participants will also receive nutrition education and information on how they can integrate local produce into their food budget. One of the class sessions will focus solely on how to budget for healthy food, comparison shop, and make the most of their food dollars. Participants will learn how to use their SNAP benefits at local farmers markets.
224190213|NCT04240782|BEHAVIORAL|Produce allocations|Participants will also receive a produce allocation from a local farm during each session of the class.
224190214|NCT06339268|BEHAVIORAL|Cognitive training, CogniFit App|A patient will receive preoperative cognitive stimulation and physical therapy for one month before surgical treatment.
224190215|NCT03704285|DRUG|Propofol|Patients undergoing general anesthesia using target controlled infusion of propofol. Initial bolus of 1-2 mg/kg and then a continuous infusion of 10 mg/kg/hr that will be adjusted adjusted to maintain a BIS between 40 and 60.
224190216|NCT03704285|DEVICE|BIS|GeneralAnesthesia maintenance with propofol+remifentanil guided by BIS monitoring.
224190217|NCT05588193|BEHAVIORAL|PVO|post-visit outreach
224190218|NCT05588193|BEHAVIORAL|TSH|tele-sexual health visit during the ED visit
224190219|NCT05577689|OTHER|Tissue|Tissue will be derived from patients during a standard of care procedure
224190220|NCT05690230|OTHER|Virtual reality|Patients will be provided with a wireless virtual reality headset that contains a guided meditation application. The application allows users to select their preferred music, visual setting, and a topic for meditation.
223500267|NCT04486144|OTHER|Proprietary extract of Nerium oleander|This is a proprietary extract of Nerium oleander that is 6.25 ug per 0.5 ml of suspension. It is administered sublingually every six hours for 5 days. The daily dose is 25 ug and the 5 day dose is 125 ug.
223500268|NCT03789006|DRUG|Antithymocyte Immunoglobulin (Rabbit)|Induction agent for living donor kidney transplantation
223500269|NCT03789006|DRUG|Interleukin 2 Receptor Antagonist|Induction agent for living donor kidney transplantation
223500270|NCT03665324|OTHER|Evaluation of the relationship between atrial remodeling evaluated by ECG and ETT with the occurrence of supraventricular arrhythmias|"Subjects will be retrospectively retrieved from the Sport Medicine Service of Rennes University Hospital database.~Medical data will then be collected from the athletes' medical records. The ECG present in the medical file will be reinterpreted to obtain the resting heart rate, the amplitude of the P wave, the morphology of the P wave and the duration of the PR space.~The data from the stress test will be found from reports in the medical records: resting heart rate, maximum heart rate, sustained peak load, arrhythmia during the test.~ETTs will be retrieved from the local server. They will be reinterpreted to collect anatomical and functional cardiac data necessary for the study."
224190221|NCT05690230|OTHER|Environmental changes|A nature themed wall mural decal will be installed in the procedure room and the in-room computer will play music from Pandora. A selection of suggested stations will be provided, with the option for outside selections.
224309574|NCT00423319|DRUG|Apixaban|Oral tablets, 2.5 mg, twice daily, 5weeks
223500271|NCT04754295|OTHER|Goal-Directed Therapy|Administration of fluids and vasoactive drugs guided by non-invasive haemodynamic monitoring
223500272|NCT04754295|OTHER|STANDARD|Administration of fluids and vasoactive drugs guided by standard vital signs monitoring
223500273|NCT02184156|BIOLOGICAL|4 mL injection of Ampion|4 mL injection of Ampion
223500274|NCT02184156|DRUG|4 mL injection of Placebo|
223500275|NCT02272101|DIETARY_SUPPLEMENT|Vitamin D versus placebo|Cross-over design
223500276|NCT05324202|DEVICE|Cynosure Cynergy Nd:YAG Laser 1064nm|The Nd:YAG Laser 1064nm is intended to be used as a treatment option in individuals suffering from low-risk basal cell carcinoma(s).
223500277|NCT00874133|PROCEDURE|Acupuncture|Acupuncture treatment for 12 weeks.
223500278|NCT00874133|DRUG|Motilium|20 mg motilium thrice daily
223500279|NCT02115477|PROCEDURE|Lymphadenectomy|Pelvic and/or paraaortic lymphadenectomy
224190222|NCT04792528|OTHER|Computerized cognitive training.|COGMED RM program (Pearson Inc., UK)
224190223|NCT04792528|OTHER|Generalized brain training / Active control|Solitaire
224190224|NCT03367091|OTHER|Ekso GT gait training with high swing assistance|"Participant will walk for 20-minutes in the Ekso GT SmartAssist with the swing assistance set at high assistance"
224190225|NCT03367091|OTHER|Ekso GT gait training with neutral swing assistance|"Participant will walk for 20-minutes in the Ekso GT SmartAssist with the swing assistance set at neutral"
224190226|NCT03367091|OTHER|Ekso GT gait training with high swing resistance|"Participant will walk for 20-minutes in the Ekso GT SmartAssist with the swing assistance set at high resistance"
224190227|NCT04843189|PROCEDURE|Da Vinci Robotic Surgery|Da Vinci Robotic Surgery
224190228|NCT03608124|BEHAVIORAL|Behavior management techniques|Pediatric dentists will be questionnaired regarding their adopted behavior management techniques for pediatric patients
224190229|NCT06046937|DRUG|Monolaurin|applied thinly twice a day
224190230|NCT06046937|DRUG|Mupirocin ointment|applied thinly twice a day
224190231|NCT02183948|DRUG|Oxytocin|
224190232|NCT02183948|DRUG|Placebo|
224190233|NCT00429026|DRUG|Fludarabine|25 mg/m\^2 intravenous (IV) daily for 5 Days
224190234|NCT00429026|DRUG|Melphalan|70 mg/m\^2 IV Daily for 2 Days
223500280|NCT05359068|DRUG|SPH3127 tablet|1 tablet
223500281|NCT05359068|DRUG|SPH3127 tablet|2 tablets
223500282|NCT05359068|DRUG|SPH3127 tablet|4 tablets
223500283|NCT05359068|DRUG|Valsartan|1 valsartan capsule
223500284|NCT05359068|DRUG|SPH3127 tablet|2 tablets
224190235|NCT00429026|DRUG|Cyclophosphamide|60 mg/kg IV Daily for 2 Days
223500285|NCT05359068|DRUG|Valsartan|1 valsartan capsule
223500286|NCT04351971|OTHER|Intervention Group|The patient's position is in the supine position. The therapist identifies the arches of the atlas and positions one hand at this level with the fingers extended. The other hand is located in the occipital region. Subsequently, the therapist makes a pressure with his shoulder assessing the movement and applies a pressure to the back. This technique is performed by mobilization cycles of 15 seconds and 3 seconds of rest for a total period of 5 minutes.The patient's position is in the supine position. The therapist identifies the arches of the atlas and positions one hand at this level with the fingers extended. The other hand is located in the occipital region. Subsequently, the therapist makes a pressure with his shoulder assessing the movement and applies a pressure to the back. This technique is performed by mobilization cycles of 15 seconds and 3 seconds of rest for a total period of 5 minutes.
223500287|NCT04351971|OTHER|Placebo group|The technique consists of placing the patient in the supine position, one hand is located in the arches of the atlas, the other hand is located in the occipital. The therapist's shoulder is located in the anterior region. This position is maintained for 5 minutes without exerting pressure.
223500288|NCT00002874|DRUG|bicalutamide|One (150 mg) tablet by mouth daily for two years beginning immediately upon, or just prior to, the initiation of irradiation.
223500289|NCT00002874|RADIATION|radiation therapy|64.8 Gy in 36 fractions (1.8 Gy in 5 daily sessions per week) to the original prostate volume, the tumor resection bed, and the proximal membranous urethra.
223500290|NCT00002874|DRUG|placebo|One tablet by mouth daily for two years beginning immediately upon, or just prior to, the initiation of irradiation.
223500291|NCT02680275|DRUG|Dead Sea Peloid Gel|intravaginally
223500292|NCT04249778|DRUG|Dapagliflozin|Dapagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Participants will receive 10 mg/day of dapagliflozin, beginning at hospital discharge, for 26 weeks.
223500293|NCT04249778|DRUG|Placebo|Participants will receive a placebo to match 10 mg/day of dapagliflozin, beginning at hospital discharge, for 26 weeks.
223500294|NCT01732900|OTHER|Morphology|Embryos selected for transfer will be based upon morphology alone.
223500295|NCT01732900|OTHER|GemART assay|Embryos selected for transfer will be based upon morphology and GemART assay.
223500296|NCT03602781|DRUG|Placebo|Placebo at a dose setting of 75 mcg/kg IBW/hr
223500297|NCT03602781|DRUG|iNO|iNO at a dose setting of 75 mcg/kg IBW/hr
223511979|NCT06278298|DEVICE|Shockwave|CDT and different dose of shockwave
224190236|NCT00429026|PROCEDURE|Stem Cell Transplant|Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation Using HLA-Matched Related Donor
224190237|NCT04959162|DEVICE|E-learning|Development of theoretical knowledge using a E-learning platform before attending a hands-on course in musculoskeletal ultrasound
224190238|NCT04959162|DEVICE|Conventional preparation|Attending a hands-on course in musculoskeletal ultrasound with no preparation before course start
224190239|NCT04742868|PROCEDURE|ANTERIOR CRUCIATE LIGAMENT RECONSTRUCTION WITH QUADRICEPS TENDON WITH BONE GRAFT|Quadriceps tendon with pattlar bone will used for grating
224190240|NCT04742868|PROCEDURE|ANTERIOR CRUCIATE LIGAMENT RECONSTRUCTION WITH HAMSTRING TENDON GRAFT|Hamstring tendon with will used for grating
224190241|NCT04742868|PROCEDURE|ANTERIOR CRUCIATE LIGAMENT RECONSTRUCTION WITH QUADRICEPS TENDON WITHOUT BONE GRAFT|Quadriceps tendon without pattlar bone will used for grating
224190242|NCT04742868|OTHER|Rehabilitation protocol|All patients will receive six months rehabilitation program which aim to recover the strength and function
224190243|NCT02487524|OTHER|Cold water test|The patients immerse their hand into cold water for a maximum of 90 seconds and report their pain intensity every 15 seconds during the test.
224190244|NCT02487524|OTHER|Autonomic nervous system monitoring|The autonomic nervous system is monitored during the cold water test and 15 minutes thereafter.
224190245|NCT02487524|OTHER|QST|Quantitative sensory testing.
224309575|NCT00423319|DRUG|Enoxaparin-matching placebo|Administered as injection
224309576|NCT00423319|DRUG|Apixaban-matching placebo|Administered as oral tablets
224309577|NCT02373748|DEVICE|BioGaming YuGo System|Subjects will perform a customized training program predefined in the BioGaming YuGo system.
224309578|NCT00009009|DRUG|immunosuppressive regimen designed to complement HAART|
224309579|NCT01962480|PROCEDURE|The hernia gap is sutured intracorporally|The hernia gab is closed with non-absorbable suture (Ethibond Excel 2-0, Ethicon, Johnson \& Johnson©) performed by an intracorporally interrupted sutured technique using an Auto Suture© Endo-Slide knot-tying instrument. The stitches are placed with a distance of 0.5 - 1 cm from the fascial edges and with a distance of 0.5-1 cm. between the stitches, performed under a 6-8 mmHg intrabdominal pressure.
224190246|NCT04772339|OTHER|Heel-Rise Test|The Heel Rise test for endurance will be performed while the participant stands on a box with 10 ° inclination on one leg. Participants will be allowed to get support from the wall at the point at shoulder level with two fingertips in order to maintain balance. A metronome of 30 beats per minute will be used to maintain the heel-rise frequency every 2 seconds. The participant will be asked to rise as high as possible with each heel rise, then lower the heel to the starting position, and with the next warning, he/she will be asked again. The participant will be asked to adapt to the pace of the metronome as much as possible and to continue the test as much as possible. The test will be terminated when the participant stops, fails to maintain frequency, or performs a proper heel raise. The number of heel raises obtained at the end of the test will be used for data analysis.
224309580|NCT02877459|DEVICE|AeriSeal System|Subjects will undergo two bronchoscopy procedures two months apart and will be treated with AeriSeal foam unilaterally, in two sub-segments during each bronchoscopy (4 segments treated in total).
224309581|NCT04622215|DIAGNOSTIC_TEST|ICIQ questionnaire|questionnaire
224309582|NCT00276861|DRUG|gemcitabine hydrochloride|
224309583|NCT00276861|DRUG|oxaliplatin|
224309584|NCT06013410|DIAGNOSTIC_TEST|colonoscopy|colonoscopy
224309585|NCT03859141|BIOLOGICAL|Quadrivalent influenza vaccine|One dose of quadrivalent influenza vaccine: 0.25 ml per dose containing 7.5μg antigen.
224309586|NCT03859141|BIOLOGICAL|Quadrivalent influenza vaccine|One dose of quadrivalent influenza vaccine: 0.25 ml per dose containing 7.5μg antigen.
224309587|NCT03859141|BIOLOGICAL|Trivalent influenza vaccine (contains B/Victoria strain)|One dose of trivalent influenza vaccine (contains B/Victoria strain): 0.25 ml per dose containing 7.5μg antigen.
224309588|NCT03859141|BIOLOGICAL|Trivalent influenza vaccine (contains B/Yamagata strain)|One dose of trivalent influenza vaccine (contains B/Yamagata strain): 0.25 ml per dose containing 7.5μg antigen.
224309589|NCT04056286|DIETARY_SUPPLEMENT|Whey|45 g whey protein + 20 g maltodextrin
224309590|NCT04056286|DIETARY_SUPPLEMENT|3-OHB/whey|50 g 3-OHB + 45 g whey protein + 20 g maltodextrin
224309591|NCT00653679|OTHER|exercise|1 hour of endurance or resistance exercise
223500298|NCT04558528|DIAGNOSTIC_TEST|Novel in vitro diagnostics and medical applications|Novel in vitro diagnostics and medical applications
224190247|NCT04772339|OTHER|Paper Grip Test (PGT)|In the paper grip test, a paper is placed under the individual's thumb and the person is asked to squeeze this paper strongly between the big toe and the ground. The paper is pulled by the person performing the test and the individual is asked to hold the paper with his/her thumb as much as he/she can. When the person applies the maximum force, the height of the medial longitudinal arch is measured with a digital caliper in millimeters. The time that the individual can maintain the MLA height with this maximum force is recorded with a stopwatch.
224190248|NCT01263366|DRUG|Norepinephrine|Approximately 1.6 or 4.6 mL of a 400 mM norepinephrine solution will be applied topically to a portion of the radiation treatment field prior to each radiation treatment (20-33 treatments)
224190249|NCT02809872|OTHER|Diagnostic Thoracic Ultrasound|
224190250|NCT01611142|BIOLOGICAL|KW-0761 (mogamulizumab)|1 mg/kg administered intravenously weekly x 4 then every other week until progression
224190251|NCT06318494|OTHER|jumping performance|"Patients suffering from chronic ankle instability symptomatic of recurrent subjective and objective instability will be considered. Patients will be compared to a control group of healthy volunteer subjects.~T0 Explanation of the study and written informed consent.~* Verification of inclusion/exclusion criteria and verification of previous or ongoing treatments.~* AOFAS Rating Scales,~* Tegner activity level~* Vertical Jump Test (CMJ) by foot pedal"
224190252|NCT00631228|DEVICE|XIENCE V® Everolimus Eluting Coronary Stent|Drug eluting stent implantation stent in the treatment of coronary artery disease
224190253|NCT05797467|DRUG|FOLFOX chemotherapy regimens|Chemotherapy regimens recommended include oxaliplatin-based CapeOx or FOLFOX regimens, or single-agent 5-FU/LV, capecitabine, or combination with targeted therapy.
224309592|NCT06438809|BIOLOGICAL|Mesenchymal Stem Cells (MSCs)|MSC suspension single does injection.
224309593|NCT05302830|BEHAVIORAL|Snackability app|This app allows user to search for a snack (scan barcode or type snack name), add a portion size consumed based on a portion size guide, and then provide a snack score and breakdown scores with a specific feedback message about the score.25 A score ranging from 0-10 points was designed taking into account the first ingredient, the nutrient standard by portion size, and the processing of foods (score ranging from -1 to 1 was subtracted or added depend on processed food classification). The final score ranged from -1 to 11 points. The higher the score, the more compliant it is to the guideline; therefore, the healthier the snack is. The app also provides gamification features as self-motivation (level up and achievement gained) and reporting features as goal-setting and self-monitoring (average daily score and consumed snack history).
224309594|NCT05302830|BEHAVIORAL|Control group|The control group received a 1-page with information on what is a healthy snack from the USDA: https://www.fns.usda.gov/cn/tools-schools-focusing-smart-snacks. They were given access to the app after the 12-week study period.
224309595|NCT02539862|OTHER|cognitive behavioral therapy online|The cognitive behavioral therapy online program is delivered through an accessible web application on a web browser with a personal password
224309596|NCT02539862|OTHER|psychoeducation|the psychoeducation is delivered by a doctor
223500299|NCT00387842|PROCEDURE|Laparoscopic surgery|
223500300|NCT00387842|PROCEDURE|Conventional surgery|
223511980|NCT06278298|OTHER|CDT|CDT
223511981|NCT00305279|OTHER|Dietary|Dietary
223511982|NCT00305279|OTHER|Dietary|Dietary
223500301|NCT05926492|DRUG|Surufatinib plus chemotherapy|"Surufatinib: (1) for patients aged \> 21 years old and ≤70 years old, surufatinib 200 mg, qd, oral, continuous administration; (2) For patients aged ≥2 years and ≤21 years, starting from the low dose of patient BSA (body surface area), Stevenson's formula developed according to the Chinese population was used: BSA = 0.0061H+0.0128W-0.1529 (H: BSA = 0.0061H+0.0128W-0.1529). Height /cm; W: body weight /kg); Chemotherapy : 1) Doxorubicin 60 mg/m2, or liposome doxorubicin 45mg/ m2, day 17; 2) Cisplatin: 100 mg/m2, day 15; 3) Ifosfamide; 2.5g/m2, day 8-12;~The above drugs were used in turn, and 30 days were regarded as a treatment cycle."
223500302|NCT05926492|DRUG|Chemotherapy|"1\) High-dose methotrexate : 8-12 g/m2 (MTX chemotherapy requires blood drug concentration monitoring), day 1 and 8; 2) Doxorubicin 60 mg/m2 or liposomal doxorubicin 45mg/ m2, day 17; 3) Cisplatin: 100 mg/m2, day 15;4) Ifosfamide; 2.5 g/m2, day 8-12.~The above drugs were used in turn, and 30 days were regarded as a treatment cycle."
223500303|NCT03251105|DEVICE|supraglottic airway intubation|
223500304|NCT00690651|PROCEDURE|Early mobilization|pt to get out of bed and mobilize with physiotherapist within 24 hours of surgery. they will be allowed toilet privileges and will go home when safe (as per medical staff and allied health)
223500305|NCT00690651|PROCEDURE|Standard mobilization|this group will rest in bed with their leg elevated above their heart for 48 hours post surgery to ankle fracture and will then mobilize with physiotherapist with aim to discharge home.
223500306|NCT04393012|OTHER|Provide alternative nurse call and communication device|Evaluate impact of providing access to the nurse call system and a speech generating device.
223500307|NCT01626313|BEHAVIORAL|FOCUS Individualized Family Resiliency Training|Eight session psycho educational training for families to enhance communication and reduce stressors related to return to post-military life.
223500308|NCT03828383|DEVICE|In-home technology|Intelligent bots monitor the in-home sensors, learn typical patterns, and provide caregivers with text messages via cell phone and alerts via the tablet when worrisome behaviors occur. Social contact is encouraged using a trusted circle of friends and family who are encouraged to stay in contact and share photos and videos with the caregiver and person with dementia via the digital display.
223500309|NCT03828383|DEVICE|Limited in-home technology|Intelligent bot monitors the in-home water leak sensor and provide caregivers with text messages via cell phone and alerts via the tablet when worrisome conditions occur.
223500310|NCT00540267|OTHER|No Intervention|No Intervention
223500311|NCT02858258|DRUG|R-CHOP/R-DHAP|Drug: R-CHOP/DHAP Alternating 3x R-CHOP (Rituximab , Cyclophosphamide ,Doxorubicine ,Vincristine , Prednisone) / 3x R-DHAP (Rituximab , Dexamethasone, Ara-C, Cisplatine, G-CSF)
223500312|NCT02858258|DRUG|Ibrutinib (Induction)|Ibrutinib: only in cycle 1,3,5 on Day 1-19
223500313|NCT02858258|DRUG|ASCT conditioning|"ASCT conditioning THAM or BEAM, stratified per site before trial activation at site~THAM (TBI (total body irradiation), Ara-C, Melphalan) or~BEAM (BCNU, Etoposide, Cytarabine, Melphalan)"
223500314|NCT02858258|DRUG|Ibrutinib (Maintenance)|Ibrutinib (Maintenance), daily 560 mg for 2 years;
223500315|NCT05122715|DEVICE|Additional PET/CT Scan|The subject will undergo two PET/CT scans, one on the DMI scanner and one on the OMNI scanner.
223500316|NCT00308685|DRUG|Albuterol|Albuterol 90mcg
223500317|NCT00308685|DRUG|Placebo|Placebo
223500318|NCT04713995|OTHER|Dietary recommendations|Dietary recommendations based on microbiome analysis of samples will be given and expected to receive and report in \~3 months survey after following recommendations.
223500319|NCT06413329|BEHAVIORAL|preoperative physical activity level within 3 months|The exercise compliance criteria are moderate exercise of at least 150 minutes per week or high-intensity exercise of at least 75 minutes per week.
223500320|NCT00321412|DRUG|AST-120|oral, sachet, 2 grams three times daily for 8 weeks
223500321|NCT01957800|BEHAVIORAL|Website|Website will have action planning with social interactions and support features for sharing, reusing, and recommending strategies for improving habits.
223500322|NCT01957800|BEHAVIORAL|Usual Care|Participants will record their weight and complete surveys online.
223500323|NCT05838170|DRUG|Lotilaner Gel, 2.0%|Lotilaner Gel, 2.0% (TP-04) is an aqueous gel formulation of lotilaner, a member of the isoxazoline family of compounds and parasiticide that selectively inhibits parasite-specific gamma-aminobutyric acid (GABA)-gated chloride channels (GABA-Cls).
223500324|NCT05838170|OTHER|Vehicle control gel|Aqueous gel
223500325|NCT06060886|DRUG|Aripiprazole|Oral dose range 5-30 mg/day (100 mg- 600 CPZeq). Long -acting injectables will be highly recommended in order to certify adherence.
223500326|NCT06060886|DRUG|Paliperidone|Oral dose range 3-12 mg/day (150mg-600 CPZeq). Long -acting injectables will be highly recommended in order to certify adherence
223500327|NCT03694652|BEHAVIORAL|PACE|Patient-centered Assessment and Counseling for Exercise \[PACE\] program
223500328|NCT03694652|BEHAVIORAL|Diet|Motivating healthy dietary habits
223500329|NCT03694652|OTHER|App|Using an app to deliver communication to the participant.
223500330|NCT03694652|OTHER|Face-to-face|Using in person meetings and/or phone communication with the participant.
223500331|NCT03158311|DRUG|QVM149|Indacaterol acetate / glycopyrronium bromide / mometasone furoate
223500332|NCT03158311|DRUG|Salmeterol/fluticasone plus tiotropium|Free triple arm of salmeterol / fluticasone plus tiotropium
223500333|NCT01849809|PROCEDURE|Gamma Ventral Capsulotomy|
223500334|NCT02102737|DRUG|6-DIG|injection of 6-DIG
223500335|NCT02102737|PROCEDURE|clamp|hyperinsulinemic euglycemic clamp
223511983|NCT00305279|OTHER|Dietary|Dietary
223511984|NCT01585701|BIOLOGICAL|AT13148|Days 1, 3, 5 of a weekly schedule in dose escalation cohorts of three patients. Continuous dosing until progression or unacceptable toxicity develops up to a maximum of 12 cycles.
223511985|NCT06333158|DIETARY_SUPPLEMENT|Cholesfytol NG|3 capsules a day with dinner.
223511986|NCT06333158|OTHER|Placebo|3 capsules a day with dinner
223511987|NCT00449007|DRUG|fluoxetine|6 months
223511988|NCT00449007|DRUG|bupropion|6 months
223511989|NCT03941262|BIOLOGICAL|SNK01|Patient-specific ex vivo expanded autologous natural killer cells
223511990|NCT03941262|DRUG|Avelumab|Avelumab is a humanized monoclonal antibody immune checkpoint blockade immunotherapy that targets the programmed cell death-ligand 1 (PD-L1).
223511991|NCT03941262|DRUG|Pembrolizumab|Pembrolizumab is a humanized monoclonal antibody immune checkpoint blockade immunotherapy that targets the programmed cell death receptor-1 (PD-1).
224190254|NCT05797467|DRUG|Bevacizumab|Targeted therapy regimens are recommended based on gene testing results. For colorectal cancer patients with KRAS/NRAS/BRAF gene mutations, it is recommended to use Bevacizumab in combination with chemotherapy. For right-sided colon cancer patients with wild-type KRAS/NRAS/BRAF genes, it is recommended to use Bevacizumab. For left-sided colon and rectal cancer patients with wild-type KRAS/NRAS/BRAF genes, it is recommended to use Cetuximab.When using targeted therapy in combination with chemotherapy, the treatment course should be synchronized with chemotherapy (Bev 5mg/kg iv d1 or Cet 500mg/m2 iv d1).
224190255|NCT05663749|DRUG|Metformin|1000mg for 8 weeks
224309597|NCT04081766|BEHAVIORAL|SUGAR Handshake|"An interactive patient counselling session delivered by a pharmacist which mainly focuses on medication-related instructions towards preventing hypoglycaemia in addition to recommendations about hypoglycemia early recognition, causes, and treatment. The SUGAR Handshake is individualised according to shared decision making and each participant's characteristics.~Components of the SUGAR Handshake intervention will be covered under five main domains:~1. Signs and symptoms of hypoglycemia.~2. Understanding the underlying causes of hypoglycaemia such as misuse of anti-diabetic medications.~3. Good glycaemic control and self-monitoring, which mainly includes instructions on handling the anti-diabetic medications.~4. Acknowledgement by the patient~5. Recap and summary~The pictogram contains the main recommendations for easy recall by the participant. Moreover, the intervention will be reinforced by a phone call at week 6 of the inclusion visit."
223591409|NCT06543888|BEHAVIORAL|Conventional gait training|Each 30-minute conventional gait training session include range of motion exercise, movement facilitation, strengthening exercise, coordination exercise, and task-oriented training for activities of daily living.
223591410|NCT01591187|OTHER|Text messaging|Participants report on the smoking that takes place in their presence for a period of 7 days by responding to daily texted messages sent by the research team to their mobile phones. Parents will also be asked to report on the child's SHSe during the same 7-day period so that child and parent reports can be compared.
223591411|NCT01591187|OTHER|Questionnaire|Child and parent questionnaire data about attitudes, behavioral practices to control SHSe, and other socio-environmental factors will be obtained.
223591412|NCT01591187|OTHER|Interviews|Individual interviews with youngsters will provide additional qualitative information about the social context and conditions in the child's environment that maintain or contribute to avoidance of exposure.
223591413|NCT00226824|DRUG|galantamine|
223591414|NCT03840707|BEHAVIORAL|LIFEwithIBD|"LIFEwithIBD programme is a psychotherapeutic programme based on Acceptance, Mindfulness and Compassion for inflammatory bowel disease patients~Treatment as Usual (TAU): Standard personalized treatment of inflammatory bowel disease"
224190256|NCT05663749|DRUG|Topiramate|50mg for 8 weeks
224190257|NCT01325376|BEHAVIORAL|Technology assisted health behavior|Web-based interactive program using an hpod sensor that tracks physical activity as well as biometric parameters into the iWell server and is transmitted to the internet site via the users PC. Also serves as a social networking site.
224309598|NCT03272061|OTHER|Aerobic-based exercise program|Aerobic-based exercise will be carried out on a cycling ergometer three times a week for 30 minutes at 70% of the maximal workload. Every two weeks, the maximal workload will be reassessed, and training loads will be readjusted accordingly. Fully supervised training sessions will be performed with three-to-four study participants at a time. Subjects should maintain their body weight during the intervention period.
223591415|NCT00475748|PROCEDURE|Early and late surgery for traumatic central cord syndrome|Surgical decompression of the spinal cord, either front, back or combined
223591416|NCT02885246|OTHER|Data collection|The ICGES database of Panama will be checked for all seasonal influenza A and/or B positive cases reported via influenza surveillance programs from 2010 to 2015.
223591417|NCT00752193|OTHER|Probiotic lactobacilli|Probiotic lactobacilli in combination with antibiotic therapy
223591418|NCT00752193|OTHER|Placebo|Placebo in combination with antibiotic therapy
223591419|NCT01965730|DRUG|epsilon-aminocaproic acid (EACA)|
223591420|NCT00575965|DRUG|Simvastatin|Oral tablets taken daily
223591421|NCT04294030|DEVICE|Diagnostic Test: NOWDx HSV-2 Test|For this observational trial, the intervention of interest is the NOWDx HSV-2 Test.
223591422|NCT00183326|BEHAVIORAL|Trauma-focused cognitive behavioral therapy (TF-CBT)|TF-CBT is a psychotherapeutic intervention designed to help children, youth, and their parents overcome the negative effects of traumatic life events. It was developed by integrating cognitive and behavioral interventions with traditional child abuse therapies that focus on enhancement of interpersonal trust and empowerment. It targets PTSD symptoms, which often co-occur with depression and behavioral problems. TF-CBT also targets other issues experienced by those suffering a trauma including poor self-esteem, mood instability, and difficulty trusting others.
223591423|NCT00183326|BEHAVIORAL|Child-centered supportive therapy (CCT)|CCT demonstrates an empathic approach to healing. An environment consisting of empathy, unconditional positive regard and acceptance are key elements in this mode of therapy.
223591424|NCT02618161|RADIATION|HDR Brachytherapy|HDR Brachytherapy, a single dose of 15 Gy delivered to prostate
223591425|NCT02618161|RADIATION|External beam Radiotherapy|External beam Radiotherapy, a dose of 46 Gy in 23 fractions delivered to prostate
224190258|NCT01325376|BEHAVIORAL|Self directed|Receives support and encouragement with minimal contact. Receives printed lifestyle guidelines with diet and physical activity recommendations.
224190259|NCT00635362|DEVICE|Levonorgestrel-releasing intrauterine system (LNG-IUS)|Immediate postplacental insertion of the LNG-IUS through the uterine incision during cesarean, within 10 minutes after delivery of the placenta
224190260|NCT00635362|DEVICE|Levonorgestrel-releasing intrauterine system (LNG-IUS)|Insertion of the LNG-IUS 4-8 weeks after cesarean delivery
224190261|NCT06006481|OTHER|Survey|Extended Nordic Musculoskeletal Questionnaire Pain Management Inventory Maslach Burnout Scale Vocational Satisfaction Scale
224190262|NCT05287165|DRUG|IM96 CAR-T cells|treatment with anti-GUCY2C chimeric antigen receptor T-cell infusion
224190263|NCT00935675|DRUG|Escitalopram|Escitalopram 10 mg once a day
224190264|NCT01858402|DRUG|Paracetamol|15 mg/kg IV (premixed with 0.9% sodium chloride to a total of 50 ml), preoperative single dose
224190265|NCT01858402|DRUG|Dipyrone|15 mg/kg IV (premixed with 0.9% sodium chloride to a total of 50 ml), preoperative single dose
224309599|NCT02939833|PROCEDURE|Scalp Nerve Blocks With Ropivacaine|
224309600|NCT02939833|PROCEDURE|Scalp Nerve Blocks With Saline|
224190266|NCT03045107|PROCEDURE|Laparoscopic right colectomy with intracorporeal ileocolic anastomosis (IIA)|After complete right colon mobilization and ileocolic and right colic vessels ligation, the proximal transverse colon and the terminal ileum are transected with a laparoscopic EndoGIA TM stapler (Covidien Medtronic). The antimesenteric side of the stapled ends of the transverse colon and terminal ileum are approximated by a stay suture tied intracorporeally and then held by the assistant. An antimesenteric enterotomy and an antimesenteric colotomy are made about 10 cm distal to the stapled ends of the transverse colon and terminal ileum, respectively. A side-to-side anastomosis is fashioned with a laparoscopic EndoGIA TM stapler (Covidien Medtronic). The enterotomies are then closed by two layers of reabsorbable sutures tied intracorporeally. The specimen is delivered through a small Pfannenstiel or a median incision. A big dressing covering all incisions will be applied, similar to that used for the EIA group.
224190267|NCT03045107|PROCEDURE|Laparoscopic right colectomy with extracorporeal ileocolic anastomosis (EIA)|After complete right colon mobilization and ileocolic and right colic vessels ligation, the terminal ileum, right colon, and proximal transverse colon are exteriorized for bowel division through a small midline skin incision in the upper abdomen. A primary ileocolic side-to-side handsewn or mechanical (with GIA stapler - Covidien Medtronic) anastomosis is fashioned and the bowel returned to the abdominal cavity. After reinduction of pneumoperitoneum, the lack of twists of the ileocolic anastomosis is checked. A big dressing covering all incisions will be applied.
224190268|NCT01139138|DRUG|Panitumumab|Panitumumab 6mg/kg IV every 14 days
224190269|NCT01139138|DRUG|Irinotecan|Irinotecan 200mg/m2 IV every 14 days
224309601|NCT06633237|OTHER|Core training program in female amateur basketball players|The intervention consists of a core training program specifically designed to improve core and trunk stability in female amateur basketball players. The program is integrated into the warm-up routine and is applied twice a week over an 8-week period. Each session lasts approximately 12-15 minutes and includes five exercises. The training program is divided into three phases of progression, gradually increasing the difficulty of the exercises over the 8 weeks by incorporating more dynamic and functional movements.
224309602|NCT02445274|PROCEDURE|Anterior lens capsule was reserved|The anterior lens capsule was reserved after continuous curvilinear capsulorhexis. The reserved anterior capsule was pressed flattened by the optical surface of the IOL and attached onto the posterior lens capsule.
223500336|NCT01018953|DRUG|BIM 23A760|BIM 23A760 is a solution at a concentration of 5 mg/mL ready for subcutaneous injection. BIM 23A760 dose of 1, 2, 4, 6 and 8 mg can be given to the patient according to a dose escalation and titration process. Patients will receive 24 weekly injections of BIM 23A760 during the treatment period. Patients eligible to continue the extension phase will be administered BIM 23A760 for further 52 weekly injections.
223500337|NCT02665455|DEVICE|FreeStyle Libre Flash Glucose Monitoring System|"Subjects will wear the FreeStyle Libre Flash Glucose Monitoring System masked for 14 days.~During these 14 days subjects will be asked to perform 4 blood glucose tests (pre-meals and before bedtime) per day. At the same time as the blood glucose test a sensor scan is performed."
223500338|NCT03331588|PROCEDURE|Subxiphoid uniportal VATS|Patients were placed in a supine position, and the operating table was manipulated as needed to elevate the appropriate side of the body for surgery. The surgical procedures followed principles of pulmonary resections
223500339|NCT03331588|PROCEDURE|Intercostal uniportal VATS|The surgical procedures followed principles of pulmonary resections
223500340|NCT05814497|OTHER|Multisensory Task|Reversing checkerboard, tones, and finger opposition.
223500341|NCT05814497|OTHER|Graphesthesia|Trace numbers on skin.
223500342|NCT05814497|OTHER|Divided attention|Divide attention between two noxious stimuli.
223500343|NCT01922414|DEVICE|Laser|Patients will undergo laser lithotripsy durin PNL
223500344|NCT01922414|DEVICE|Ultrasonic|Patients will undergo ultrasonic lithotripsy during PNL
223500345|NCT02756468|OTHER|pts operated for pancreatic cancer|measuring CRP and PCT in 3rd and 5th POD after pancreatic cancer resection
223500346|NCT06126978|DEVICE|Vibration Therapy (Galileo Dela Interface)|Vibration Therapy uses vibration as a physical tool during the treatment. It can be applied with different devices that transmit mechanical vibration throughout the whole or a part of the body. Focal Muscle Vibration (FMV) is a safe, well-tolerated and non-invasive technique, which may be an efficient intervention in reducing the upper extremity spasticity, whereas Whole Body Vibration (WBV) can provide proper somatosensory stimulation, and improve muscle strength and postural control in stroke patients (Oliveira et al., 2018).
223500347|NCT06126978|DEVICE|Mirror Therapy ( Mirror Box)|Mirror Therapy is a structured, inexpensive, simple and patient-directed treatment. The principle of Mirror Therapy is the use of a mirror to create a reflective illusion of an affected limb, in order to trick the brain into thinking the movement has occurred without pain. It has shown to improve movements of the affected upper limb and the ability to carry out daily activities, in addition to reducing pain (Dhami et al., 2019).
223500348|NCT04393948|RADIATION|Phase 1|Dose Level 1 - 100 cGy irradiation to a single (right-sided) lung using 6 MV photons delivered using a clinical linear accelerator
223500349|NCT04393948|RADIATION|Phase 1|Dose Level 2 - 100 cGy irradiation to both lungs using 6 MV photons delivered using a clinical linear accelerator
224309603|NCT02260297|DEVICE|Wrist Actigraphy(motion sensors)with light sensors-Jawbone Up 2|
224309604|NCT02052050|OTHER|core stability|
223500350|NCT04393948|RADIATION|Phase 2|Arm A - No irradiation
223500351|NCT04393948|RADIATION|Phase 2|Arm B - 100 cGy irradiation to a single (right-sided) lung using 6 MV photons delivered using a clinical linear accelerator
223500352|NCT04393948|RADIATION|Phase 2|Arm C - 100 cGy irradiation to both lungs using 6 MV photons delivered using a clinical linear accelerator
223591426|NCT02771717|DRUG|Budesonide (Pulmicort)|Budesonide (Pulmicort) - inhaled low dose inhaled steroid - I puff to be taken twice daily
223591427|NCT02771717|DRUG|Placebo - dummy inhaler|Placebo - dummy inhaler to be taken 1 puff twice daily.
223591428|NCT04407741|DRUG|SHR2554+SHR1701|SHR2554: recommended dose from phase I trial, PO, twice a day. SHR1701: 30mg/kg, IV, over 30 minutes
223591429|NCT04407741|DRUG|SHR1701|SHR1701: 30mg/kg, IV, over 30 minutes
223591430|NCT04149561|OTHER|communication skill measurement with self report questionnaire|Demographic information form, Communication Function Classification System, Functional Communication Classification System, The Gross Motor Function Classification System and Manual Ability Classification System will be filled in for the patients.
224190270|NCT01139138|DRUG|Everolimus|Everolimus daily po (dosage varies with cohort)
224190271|NCT03684343|OTHER|Filmed consultation with a dermatologist|"Patient will be seen by a dermatologist for a consultation which will be filmed. During the consult, a laterality test and a tactile sensitivity test will be performed.~After the consult, videos will be analysed by scientists to identify the frequency of occurrence of each behavior and the percentage of time passed to express each behavior."
224190272|NCT01757795|DRUG|SP-8203|SP-8203 injection at single ascending doses of 10 mg, 20 mg, 40 mg, 80 mg, 160 mg and 240 mg (optional) SP-8203 injection at multiple ascending doses for 7 days at least 2 dose levels below the MTD in the single ascending portion of the trial
224190273|NCT01757795|DRUG|Placebo|Placebo will be intravenously administered
224190274|NCT01484691|DRUG|Budesonide|Inhaled powder of inhaled corticosteroid, 1 puff (180mcg) twice a day for 8-10 weeks
224190275|NCT02777866|DRUG|Infiltration of 0.5% Bupivacaine|Patients who will be non urgent operated of an open gastrointestinal surgery, where an opening of the gastrointestinal lumen occurs (bile duct, stomach, small bowel or colon), who will be infiltrated in the total thickness of the abdominal wall (Peritoneum-muscle fascia- Subcutaneous tissue) with 0.5% Bupivacaine, every 1 cm, on each side of the surgical wound
224190276|NCT02777866|DRUG|Placebo: Infiltration of 0.9% Saline Solution|Patients who will be non urgent operated of an open gastrointestinal surgery, where an opening of the gastrointestinal lumen occurs (bile duct, stomach, small bowel or colon), who will be infiltrated in the total thickness of the abdominal wall (Peritoneum-muscle fascia- Subcutaneous tissue) with 0.9% Saline Solution, every 1 cm, on each side of the surgical wound
224190277|NCT03423004|PROCEDURE|Biopsy|the sample will be taken by superficial cutaneous biopsy in psoriasic patients
223591431|NCT04102995|DRUG|Sepranolone injection low dose|Subcutaneous (SC) administration
223591432|NCT04102995|DRUG|Sepranolone injection high dose|Subcutaneous (SC) administration
223591433|NCT04102995|DRUG|Placebo injection|Subcutaneous (SC) administration
223591434|NCT03268941|DRUG|TAK-906 Maleate|TAK-906 Maleate Capsules
223591435|NCT03268941|DRUG|Metaclopramide|Metaclopramide Tablets
223591436|NCT03268941|DRUG|TAK-906 Maleate Placebo|TAK-906 placebo-matching Capsules
223591437|NCT05639192|BIOLOGICAL|Asunercept|Asunercept (APG101) will be administered once per week as an i.v. infusion
223591438|NCT05639192|OTHER|Placebo|Placebo will be administered once per week as an i.v. infusion
223591439|NCT03749772|BEHAVIORAL|Cognitive Training|The intervention was carried out with the PC game Brain Exercise TM (Bandai Namco Games Ltd.). Participants held the training sessions on an HP 250 G3 Notebook PC (Windows 10), with a 15-inch screen, and a resolution of 1366x768x40 Hz. The performance achieved by each participant in each session was recorded to analyze the evolution of the subjects. The participants made a total of 12 practice exercises, which implies approximately 30 minutes of duration per session.
223591440|NCT04327947|OTHER|Hyaluronic acid - Research product 1|Health care product (intimate gel)
224190278|NCT01695707|DRUG|Pioglitazone|see Arm Description
224190279|NCT01695707|DRUG|Placebo (for pioglitazone)|see Arm Description
224190280|NCT05705544|DEVICE|ILLUMISITE™ Platform (EMN bronchoscopy)|Providers will utilize the ILLUMISITE™ Platform (EMN) machine to perform a diagnostic bronchoscopy procedure.
224190281|NCT05705544|DEVICE|Ion™ Endoluminal System (SSCB bronchoscopy)|Providers will utilize the Ion™ Endoluminal System (SSCB) machine to perform a diagnostic bronchoscopy procedure.
224190282|NCT06239207|BIOLOGICAL|Exosomes GFC CELL EXO SCALP KIT (Leuco Exo 97%)|Exosomes used are GFC CELL, consist of Leuco exo 97% having GFC CELL EXO SCALP 9700 powder and EXO SCALP Pep9 solution
224190283|NCT06239207|BIOLOGICAL|Platelet Rich Plasma|PRP is prepared under aseptic precautions, around 10ml of blood is collected in PRP tubes which are rotated in a centrifuge machine at 1500 RPM for 10 minutes. Which separates the blood into 2 layers: the lower RBC layer; the upper acellular plasma layer. The buffy coat along with the plasma was collected with a pipette and transferred into another test tube underwent 2nd spin at 4000 RPM for 10 min. This PRP was collected in another clean tube to be used as plasma
224309605|NCT05041881|DEVICE|Trifocal lens AT LISA TRI, Zeiss|lens is made of hydrophilic acrylic material with square edge technology and having diffractive optic design
224309606|NCT05041881|DEVICE|Accommodating Tetraflex HD lens, Lenstec inc.|lens is made of hydrophilic acrylic material with square edge technology and having monofocal optic design
224309607|NCT05041881|DEVICE|Monofocal lens, Softec HD|lens is made of hydrophilic acrylic material with square edge technology and having monofocal optic design
223591441|NCT04327947|OTHER|Hyaluronic acid - Research product 2|Health care product (intimate gel)
223591442|NCT04327947|OTHER|Hyaluronic acid - Comparator product|Health care product (intimate gel)
223591443|NCT01216683|BIOLOGICAL|rituximab|Given IV
223591444|NCT01216683|DRUG|Bendamustin|Given IV
223591445|NCT01216683|DRUG|bortezomib|Given IV
223591446|NCT01216683|DRUG|lenalidomide|Given orally
223591447|NCT00223483|GENETIC|Isolation of genomic DNA|One time blood draw
223591448|NCT03774030|PROCEDURE|several virtual 3-D complex audio environments|The focus is a comparison of 3 hearing aid algorithms in a virtual 3-D complex audio Environment.
223591449|NCT01526395|DRUG|Propofol|"The major intervention proposed in this study is the introduction of low dose IV propofol for sedation prior to ECT treatment at C.S.M Medical University. The investigators will use a dose of 0.25 to 0.50 mg/kg of IV propofol. The maximum dose of 0.50 mg/kg is not sufficient for anesthesia (i.e., to make unconscious), but should provide a light level of sedation and be amnestic, meaning the patient should have memory loss for the period of time around the ECT procedure itself. The propofol dose will be titrated upwards (from an initial dose of 0.25 mg/kg) with successive treatments in increments of 0.05mg/kg, until it is just sufficient to be lightly sedating. ECT will be administered 30 to 60 seconds after propofol is injected. ECT may be given up to three times per week."
224190284|NCT06446453|DIAGNOSTIC_TEST|Echography-guided Surfactant THERapy (ESTHER)|Decision to administer surfactant therapy using a semi-quantitative lung ultrasound score.
224309608|NCT05109338|DEVICE|Ben-Guard Garment|Wearable device designed to secure CVCs and gastrointestinal feeding tubes. The Ben-Guard Catheter Securement Device was designed specifically to better secure and conceal CVC tubing, protecting the patient by keeping tubing closer to the body.
224309609|NCT02299115|DRUG|Prednisolone|Corticosteroid
224309610|NCT02299115|DRUG|Vigabatrin|Antiepileptic
224190285|NCT06074341|BEHAVIORAL|Mindfulness-based relapse prevention|"Mindfulness-based relapse prevention (MBRP) is a group-based treatment to provide individuals with skills intended to foster increased awareness of triggers, destructive habitual patterns, and automatic reactions to triggering experiences. Mindfulness practices in MBRP are designed to help individuals pause, observe present experience, and bring awareness to the range of choices available in every moment. Through MBRP individuals learn to respond in ways that serve them, rather than react in ways that are detrimental to their health and happiness."
224190286|NCT06074341|BEHAVIORAL|Online Mutual Support Groups|Mutual support groups are free, peer-led organizations that are designed to help individuals with substance use disorders and other addiction-related problems. Mutual support groups often focus on communication and exchange of addiction and recovery experience and skills. Individuals participate in activities that engage, educate, and support patients recovering from substance use disorder from others facing similar challenges. Mutual help organizations that will be offered as referrals include: Alcoholics Anonymous (AA), In The Rooms, and SMART Recovery.
224309611|NCT02348723|DRUG|Warfarin|Patients receiving Warfarin to keep International Normalized Ratio (INR)between 2.0 - 3.0
223500353|NCT04029597|BEHAVIORAL|Remote Patient Monitoring|Families participating in the study will receive standard medical care as well as the RPMS. The RPMS was developed in collaboration with the University of Mississippi Medical Center (UMMC) Center of Telehealth. Patients enrolled in this open trial of the RPMS will interact with the RPMS system on a daily basis and with UMMC's Center for Telehealth nurse care coordinators and research and clinical staff on an as needed basis. The RPMS will provide patients with include an electronic tablet (i.e., iPad) and the ability to receive data from the patient's weight scale and pedometer. Patients will be asked to wear the pedometer daily to track engagement in physical activity and weigh themselves weekly to track weight during the 3 month period. Educational information specific to pediatric obesity and healthy eating and engagement in physical activity will be presented daily through brief presentations and video clips.
223500354|NCT04115228|DEVICE|Implantation and neuromodulation therapy|The study device is an autonomous permanent implant for neuromodulation targeting the posterior tibial nerve. It does not require an external power source or charger.
223500355|NCT00004897|BIOLOGICAL|recombinant interferon alfa|
223500356|NCT00004897|DRUG|cisplatin|
223500357|NCT00004897|DRUG|fluorouracil|
223500358|NCT00004897|DRUG|hydroxyurea|
223500359|NCT00004897|DRUG|leucovorin calcium|
223500360|NCT00004897|PROCEDURE|conventional surgery|
223500361|NCT00004897|RADIATION|radiation therapy|
223500362|NCT02622685|DRUG|DWP10292|Drug: DWP10292 tablets, oral administration, multiple administration
223500363|NCT02622685|DRUG|DWP10292 Placebo|Placebo tablets, oral administration, multiple administrations
223500364|NCT02622685|DRUG|Ursodeoxycholic acid (UDCA)|Drug: Ursodeoxycholic acid (UDCA) tablets, oral administration, multiple administration
223500365|NCT02622685|DRUG|UDCA Placebo|Placebo tablets, oral administration, multiple administrations
223500366|NCT02452411|BEHAVIORAL|Cognitive Behavioral Treatment approach supported by virtual reality and positive psychology strategies.|The CBT program consists of 6 weekly sessions (and 2 additional ones depending on the patient's needs) with the following main therapeutic components: educational component, exposure/processing of the stressful event with VR (EMMA's World) and relapse prevention. EMMA's World is an open and flexible VR system that uses symbols (e.g., 3D-objects, pictures, sounds) to reflect and evoke the negative emotions associated to the stressful event. Also, several strategies from Positive Psychology (e.g., My best virtues or strengths exercise) and others based on Neimeyer's (2000) suggestions for pathological grief (e.g., projection letter to the future) are also included in the protocol.
223500367|NCT05072951|DIAGNOSTIC_TEST|Urine Biomarker for Kidney Transplant Rejection|Biomarker for active kidney transplant rejection.
223500368|NCT04510753|DEVICE|Arterial catheterization kit|Invasive monitoring of blood pressure via catheterization of the radial artery, displaying a continuous pressure waveform and blood pressure values.
223500369|NCT04510753|DEVICE|GE Datex-Ohmeda Finger Clip Pulse Oximeter Sensor|PPG fingertip mounted sensor, that measures the oxygen level (oxygen saturation) of the blood and generates a waveform
223500370|NCT04510753|DEVICE|NIBP Cuff (GE Healthcare)|A blood pressure cuff is used to measure blood pressure. The cuff has an inflatable rubber bladder that is typically fastened around the arm. A pressure meter indicates the cuff's pressure.
223500371|NCT00645931|BEHAVIORAL|protein and calorie controlled diet and self-hypnotic relaxation|daily
223500372|NCT00415259|DEVICE|Laterally wedged shoe insoles|Full-length 5 degree lateral wedged insoles worn inside the shoes daily for 12 months
223500373|NCT00415259|DEVICE|Control insole group|Flat control insoles worn inside the shoes daily for 12 months
223500374|NCT06980337|OTHER|Conventional treatment program|"Ultrasound, hot packs, cervical postural stretching and strengthening exercise will be done for all groups.~Stretching Exercises Posture correction exercises training will include stretching of tight muscles such as Pectoralis major, levator scapulae, upper trapezius, suboccipital muscles and, sternocleidomastoid.~Strengthening Exercises Exercises will include Chin Tucks exercise and Neck isometric exercises"
223500375|NCT06980337|OTHER|Scapulothoracic exercises|Scapulothoracic exercises It is a strengthening exercises of the serratus anterior muscle, as well as the middle and inferior fibres of the trapezius muscle
223500376|NCT06980337|OTHER|Kendall exercises|"The exercise techniques used by Kendell were as follows:~1\. Stretching of the Cervical Extensors: By sitting with the head down and putting both hands across the occipital area, the cervical extensors can be stretched by adopting a flex neck position 2- Strengthening of the Deep Cervical Flexors Positioning supine with the chin tucked in and lifting the head for 2 to 8 s 3- Strengthening the Shoulder Retraction Maintaining an upright posture, keep the resistance band circling with strong support and stretching it with the upper limbs of both sides so that there is full retraction of the scapula 4-Stretching the Pectorals muscle Assigning both hands on the occipital area and pulling the elbows back up (bilateral) and performance arm abduction and external rotation (unilateral)."
223591450|NCT03123016|DRUG|Apremilast|Apremilast 30 mg orally, twice daily. (oral tablet)
224190287|NCT05654740|DEVICE|Virtual Reality Experiences|Virtual Reality experiences including stress reduction, distraction and entertainment
224190288|NCT03754595|PROCEDURE|3D Laparoscopic pancreatoduodenectomy|Patients with pancreatic cancer treated by 3D Laparoscopic pancreatoduodenectomy
224190289|NCT03754595|PROCEDURE|2D Laparoscopic pancreatoduodenectomy|2D Laparoscopic pancreatoduodenectomy
224190290|NCT01820169|DEVICE|;Accu-Chek Compact Plus LCM bulk Japan|HbA1c would be changed by more careful control in blood glucose with SMBG.
224190291|NCT03977922|OTHER|Diet group|The diet group will be involved in a 12-week pilot nutrition program that will be based on the anti-inflammatory diet previously studied by Allison and Ditor (2015).
224309612|NCT02348723|DRUG|Dabigatran Etexilate 150mg|Patients receiving Dabigatran Etexilate 150mg twice daily dosing (BID)
224309613|NCT01268501|DEVICE|Lotrafilcon B multifocal contact lens|Commercially marketed, silicone hydrogel, multifocal, soft contact lenses FDA-approved for up to 4 weeks recommended replacement schedule and up to 6 nights of extended (overnight) wear.
224190292|NCT01062529|DRUG|Somatostatin|4 h of 150 microgram infusion
224190293|NCT05603975|DRUG|Esketamine 0.1mg/kg intravenous injection|"The Esketamine was administered intravenously at 0.1mg per kilogram of body weight 1min before the dressing change."
224190294|NCT05603975|DRUG|Normal saline|"The Normal saline was administered intravenously at 0.1ml per kilogram of body weight 1min before the dressing change."
224190295|NCT02155816|DIETARY_SUPPLEMENT|Omega 7 + 3|Ingestion of omega 7 + 3 daily for 8 weeks.
224190296|NCT02155816|DIETARY_SUPPLEMENT|Omega 3|Omega 3 daily for 8 weeks.
224190297|NCT02155816|DIETARY_SUPPLEMENT|Placebo|Medium chain triglycerides
224190298|NCT05689801|OTHER|"Questionnaire recovery time after a dialysis session."|A very short questionnaire just after the dialysis session
224190299|NCT05689801|OTHER|SF-12 questionnaire|Questionnaire about quality of life of the patient
224190300|NCT05689801|OTHER|EQ-5D-5L Questionnaire|Questionnaire about quality of life of the patient
224309614|NCT05913089|DRUG|TQB2450 injection + Chemotherapy|"TQB2450 injection is a humanized monoclonal antibody targeting programmed death ligand -1 (PD-L1).~Chemotherapy is a systematic treatment that kill fast growing cells."
223500377|NCT02629302|OTHER|animal assisted therapy|physiotherapy, speech therapy and occupational therapy in the presence of an animal
223500378|NCT02629302|OTHER|standard therapy|standard physiotherapy, speech therapy and occupational therapy
223500379|NCT01928771|BIOLOGICAL|Benralizumab|Benralizumab subcutaneously on study week 0 until study week 44 inclusive.
223591451|NCT03123016|PROCEDURE|NB-UVB phototherapy|treatment with narrowband UVB two to three times weekly to one half of their body for a total of 16 weeks
223591452|NCT04712708|DEVICE|Rebound Therapy|Rebound therapy is the therapeutic use of full sized trampoline or mini sized trampoline. It provides opportunities for exercise recreation and therapy; and it is distinct from gymnastic trampolining. It is used for facilitating movements, improving balance, enhancing coordination and promoting motor performances in children with different disorders includes learning disabilities, communication disorders and motor dysfunction (Rebound Therapy South Africa, 2020; The Chartered society of Physiotherapists, 2016).
224190301|NCT05689801|OTHER|Pittman, John et McIntyre questionnaire|Questionnaire about quality of life of the patient under dialysis
223591453|NCT04712708|OTHER|Physical Therapy Program|"The Mat Exercises:~Stretching exercises to all spastic muscle groups (Kalkman et al., 2018). Gentle exercises was applied for 40-60 seconds and repeated from 3-5 times/ movement as supported by (Fragala et al., 2003).~Strengthening Exercises:~Dynamic Rising Positioning~The Gym Exercises:"
224190302|NCT05689801|PROCEDURE|Conventional hemodialysis|patient on polyethersulfone membrane dialysis (Revaclear®, Baxter) with HemoControl™ for 12 weeks
224190303|NCT05689801|PROCEDURE|Optimized hemodialysis|patient on Medium Cut-Off membrane dialysis (Theranova®, Baxter) with HemoControl™ for 12 weeks.
224309615|NCT05913089|DRUG|TQB2450 injection + Anlotinib Hydrochloride Capsule|"TQB2450 injection is a humanized monoclonal antibody targeting programmed death ligand -1 (PD-L1).~Anlotinib hydrochloride is a muti-target tyrosine kinase inhibitor."
224309616|NCT05495828|DRUG|Orelabrutinib|Orelabrutinib, 150mg, po, qd
223500380|NCT01928771|BIOLOGICAL|Placebo|Placebo subcutaneously on study week 0 until study week 44 inclusive.
223500381|NCT04518059|PROCEDURE|punch skin biopsy|An anesthetic medication is injected to numb the areas of skin and two samples of skin are obtained from punch biopsy.
223591454|NCT03157284|DIETARY_SUPPLEMENT|Rice Flour|For 12 weeks, a group of children will receive 7gr fermented rice flour according to a randomised, double-blind design.
224190304|NCT02043002|PROCEDURE|18F-FDG-PET scan|
224190305|NCT04081727|DEVICE|Zip-stitch(TM)|The assigned intervention is used to close the cuff following colpotomy.
224190306|NCT05707702|BIOLOGICAL|Probiotic oral lozenges|Participants in this arm will be be instructed to take a lozenge daily for 6 weeks. They will also receive oral dysplasia standard of care.
224190307|NCT05707702|OTHER|Standard of care for oral dysplasia|Oral dysplasia standard of care includes clinical surveillance and risk factor reduction (such as smoking cessation).
224190308|NCT06260995|OTHER|Social Prescribing Link Worker Intermediary Intervention|Social prescribing link workers \[SPLW\] receive referrals from healthcare professionals, community services, or through self-referral. Individuals are referred for social isolation or social needs, frequent healthcare attendance, or to address a pre-existing health issue. SPLW carry out an in-depth assessment of the individual's needs, and then work with the individual over weeks and months to connect them to community services and supports, which can include local physical activities. They use several strategies during this follow-up period, such as instrumental support (doing things for the individual), empowerment and motivation techniques and/or attending activities with the individual. After the SPLW establishes a connection to a local physical activity, the individual enrols and participates in the chosen activity. Local physical activities can include walking groups, local gyms and leisure centres, chair-based exercise, outdoor activities, yoga and tai chi.
224309617|NCT05396261|DEVICE|Film forming silicone gel (7-0940)|Anecdotal evidence suggests that genital conditions in women associated with vaginal atrophy improve with the use of film-forming silicone dressings.
224309618|NCT00355810|DIETARY_SUPPLEMENT|placebo followed by Lactobacillus plantarum MF 1298|placebo during 3 weeks, washout period 4 weeks, Lactobacillus plantarum MF1298 during 3 weeks
224309619|NCT00355810|DIETARY_SUPPLEMENT|Lactobacillus plantarum MF1298 followed by placebo|Lactobacillus plantarum MF1298 during 3 weeks, washout period 4 weeks, placebo during 3 weeks
224190309|NCT06260995|OTHER|Local Sports Partnership Community Development Officer Intervention|Local sports partnership community development officers \[LSPO\] mainly receive self-referrals, or can receive referrals, to improve physical activity levels of individuals through participation in physical activity groups delivered by the partnership. LSPO do not carry out an in-depth assessment but may carry out screening before explaining/signposting to local physical activities. They use several strategies to connect the individual to local physical activities, such as attending the first session of the group, providing reassurance and practical support, and keeping the person updated and informed as to upcoming groups. After the LSPO establishes a connection to a local physical activity, the individual enrols and participated in the chosen activity. The LSPO continues to support this engagement during the follow-up period. Local physical activities can include walking groups, local gyms and leisure centres, chair-based exercise, outdoor activities, yoga and tai chi amongst others.
224190310|NCT04231903|DEVICE|Aortic clamp|In the firs group an endo-aortic clamp is used and in the second group an external clamp is used.
224190311|NCT05745987|DRUG|Bavarian Nordic smallpox vaccine|A single dose of the Bavarian Nordic smallpox vaccine will be given at baseline.
224190312|NCT05745987|DRUG|Typhoid VI Polysaccharide Vaccine Injectable Solution|A single dose of the typhoid vaccine will be given at baseline.
224190313|NCT04428723|OTHER|Entry of demographic and medical history data into a deidentified database|Entry into repository for analysis.
224190314|NCT04428723|GENETIC|Blood sample for DNA analysis|Targeted resequencing of DNA to identify variants associated with hypoglycemia, comparing participants with hypoglycemia (both surgical and non-surgical) and healthy controls.
224190315|NCT04428723|DIAGNOSTIC_TEST|Stool sample for microbiome analysis|Participants will be asked to provide a fecal sample, collected at home, which will be analyzed to determine the types of bacteria present in the feces.
224190316|NCT04428723|DIAGNOSTIC_TEST|Mixed meal tolerance test|For a subset of participants: After an overnight fast, participants will be given a standard liquid mixed meal; blood samples will be collected at baseline (fasting) and at defined time points after a meal for metabolic and hormonal analyses.
224190317|NCT04428723|DIAGNOSTIC_TEST|Continuous glucose monitoring|A CGM sensor (Dexcom G4 or other professional version available at onset of study) will be placed in blinded (masked) mode, and will be worn for 10 days. Data will be analyzed to determine patterns of glucose during both day and night intervals.
224190318|NCT04428723|DIAGNOSTIC_TEST|activity monitor|The activity monitor (Fitbit Charge 2) will be worn by participants for 10 days, to assess activity, concurrent with CGM sensor wear.
224190319|NCT04293211|OTHER|Simulation|To measure the efficacy of adding a high-fidelity simulation versus low fidelity simulation to the current B-Con Course. This will be assessed by evaluation of applying tourniquets properly and packing traumatic wounds as well as retention of these skills over a period of time amongst school teachers and security personnel.
224190320|NCT03894111|OTHER|decesased patients|mortality ratio
224190321|NCT04064047|PROCEDURE|Trans rectal ultrasound guided prostate biopsy|The investigators checked visual analogue scale of pain at different time periods: prior to probe insertion, during probe insertion. during probe manipulation in the rectum, during performance of periprostatic nerve block, during actual biopsy collection and at termination of procedure.
224190322|NCT04064047|PROCEDURE|Trans rectal ultrasound|Performing a prostate biopsy using a transrectal ultrasound probe - the BK pro focus 2202 transrectal ultrasound and the 8808 bi-plane transrectal probe
224190323|NCT04064047|PROCEDURE|Prostate biopsy|Prostate biopsy guided by a transrectal ultrasound with an 18 gauge needle
224190324|NCT04064047|PROCEDURE|Periprostatic nerve block|Performing a bilateral peri-prostatic nerve block with 10 mL of 1% lidocaine (5 mL on each side)
224190325|NCT04095039|PROCEDURE|Hemodialysis|Patients in both arms will undergo hemodialysis to remove phosphate from the blood; however, patients in the Hi Arm will only be titrated down to no lower than 6.5mg/dl
224190326|NCT01612949|OTHER|photographing head and neck|Taking three photographs of head and neck-one photograph from front, one from left and one fron right. The photographs are analyzed by facial structure software to create face model.
224190327|NCT04148339|OTHER|No Intervention|There is no intervention for this study.
224190328|NCT02350868|DRUG|MPT0E028|The starting dose in the Dose Escalation Phase will be 50 mg/day.Dose escalation from the first cohort to the second cohort will be doubled; and from the second cohort to the fourth cohort will proceed at no more than 50% increments.
224309620|NCT03891030|OTHER|Checklist Based Box system intervention|The intervention has both behavioural change and service utilization drop out tracing mechanism. Special type of boxes designed to schedule health educations and continued service utilization monitoring boxes will be placed at health posts and health centers respectively. Community level survey will be conducted to identify suspected pregnant mothers using stanback et al, 1999 checklist, and mothers are linked to health centers. Then, they will be followed for their subsequent attendance of consecutive maternal health services (ANC 2nd-third PNC). Mothers who fail to utilize the service will be traced; will get person-centered health education to continue the service.
224309621|NCT00718913|DRUG|Docetaxel|Docetaxel will be given at 60 mg/m2, as a 60-minute infusion every 3 weeks for 2 cycles before chemo-radiation. Four to five weeks after completion of chemo-radiation therapy, all patients will receive two more cycles of Docetaxel 60 mg/m2.
223500382|NCT06981715|OTHER|Conservative treatment|"Night Splint Resting splint fixing the ankle in neutral position~Worn every night before going to bed, used for 6-8 hours~Objective: To reduce the pressure on the median nerve~Exercise Programme:~Applied 1-2 times a day~Each exercise 10 repetitions, 2 sets~Content:~Nerve mobilisation exercises (median nerve sliding and stretching)~Wrist stretching and flexor-extensor tendon sliding exercises~Finger opening-closing, fist making exercises"
223500383|NCT06981715|OTHER|ESWT|"ESWT Protocol:~Device Radial ESWT device Area of application Wrist volar surface (carpal tunnel area) Parameters Frequency: 5 Hz 4 Bar Number of beats 2000 pulses/session Application time 5-10 minutes per session"
223511992|NCT03115463|OTHER|Titration of oxygen during neonatal resuscitation|Resuscitation will be initiated at 30% O2 and target goal saturations will be the 10th to 25th percentile saturations in OX25 and 75th percentile in OX75 group. The control group will be resuscitated with the OX50 strategy in which resuscitation will be initiated with 30% O2 and target goal saturations will be the approximated median SpO2 observed in healthy term newborns as per current NRP guidelines. For the first 6 minutes after birth, target ranges of of all 3 arms are different. After 6 min, the target ranges are are identical.
224190329|NCT00281736|DRUG|HPPH|Given IV
224190330|NCT04657627|BEHAVIORAL|PACE plus calorie labelling information|The intervention group will be exposed to PACE plus calorie labelling information via Instagram and Twitter social media posts every day for 13 weeks.
224190331|NCT04657627|BEHAVIORAL|Calorie-only labelling information|The comparator group will be exposed to calorie-only labelling information via Instagram and Twitter social media posts every day for 13 weeks.
224190332|NCT02679300|OTHER|Virtual reality exercise group|
224190333|NCT02679300|OTHER|Conventional exercise group (control group)|
224190334|NCT05330728|OTHER|Suggestions for lifestyle changes+ Abdominal massage|Suggestions for lifestyle changes+ abdominal massage will be applied. Suggestions including regular and balanced diet, fluid consumption, regular walking and abdominal exercises and correct toilet habits will be given once. Abdominal massage will be applied 3 times a week for 4 weeks.
224309622|NCT00718913|DRUG|Cisplatin|Cisplatin will be given at 60 mg/m2, as 2-hour infusion every 3 weeks for 2 cycles before chemo-radiation. Four to five weeks after completion of chemo-radiation therapy, all patients will receive two more cycles of Cisplatin at 60 mg/m2.
224309623|NCT00718913|DRUG|Capecitabine|Capecitabine will be given orally at 1800 mg/m2 days 1 through 14 divided in two daily doses before chemo-radiation. Four to five weeks after completion of chemo-radiation therapy, all patients will receive two more cycles of Capecitabine at 1800 mg/m2 days 1 through 14 (divided in two daily doses).
224309624|NCT00718913|RADIATION|Radiation|At the end of the second cycle of chemotherapy and one week of rest (day 27), a total of 45 Gy (1.8 Gy fx/d) of radiotherapy will be given.
223500384|NCT06981715|OTHER|Kinesiotaping|Kinesio taping was performed with the Button hole technique described by Dr Kenzo Kase. In this technique, a kinesio tape was measured and cut from the medial and lateral epicondyle level on the palmar side of the forearm, from the base of the proximal phalanges to the epicondyles of the humerus on the dorsal side of the forearm. The tape was folded and the midpoint was found, 2 short incisions were made and 2 button holes were obtained through which the 3rd and 4th finger would pass. The paper behind the band was torn and the 3rd and 4th fingers were passed through the holes. The patient's wrist was brought to extension and radial deviation and the tape was glued with a slight (15-25%) tension towards the medial epicondyle on the palmar side of the forearm. Then the wrist was flexed and ulnar deviated and the tape was glued with a slight (15-25%) tension towards the lateral epicondyle.
223500385|NCT07046182|BIOLOGICAL|CEP + Dasatinib + Azacitidine|CEP + Dasatinib + Azacitidine as the first-line treatment regimen for patients with Angioimmunoblastic T-cell Lymphoma
223500386|NCT07052071|PROCEDURE|TAVI|Transcatheter Aortic Valve Implantation (TAVI) is a minimally invasive method for replacing the aortic valve in patients with severe aortic stenosis. The procedure involves the placement of a bioprosthetic valve within the patient's degenerated aortic valve via a catheter.
223500387|NCT07049809|COMBINATION_PRODUCT|Focal Muscle Vibration|"The focal vibration machine will be used. The device has 6 muted transducers that generate power between 30-300 Hz, but for this study we will use between 100-150 Hz for 30 minutes.~The application of the 6 transducers or heads is at the level of the lower extremities, since those muscle groups present the most clinical correlation with functional parameters such as gait and balance. 3 transducers will be placed on one leg (vastus medialis, vastus lateralis and rector anterior) and the other 3 transducers on the other leg, on the same muscles. To speed up the intervention program and cover more participants, 4 focal vibration machines will be used. Each participant wil use 1 machine and 6 transducers, so during the 30 minutes that the intervention lasted, the groups will be of 4 participants with t"
223500388|NCT07049809|OTHER|Multicomponent Exercise|The program consists of a multi-component approach, integrating aerobics, resistance, and balance training. The weekly schedule include three intervention days: one day focused on aerobic exercise, one day dedicated to resistance training and one day centered on balance training. The combined program is individualized based on the intrinsic capabilities of each individual.
223500389|NCT07052526|OTHER|Prevention|Conventional Hydrophobic Sealant (Helioseal F - Control) will be used as a positive control; applied to partially erupted molars with and without bonding in a split-mouth design.
223500390|NCT07052526|OTHER|Prevention of caries|Embrace WetBond sealant will be applied to partially erupted first permanent molars using a split-mouth design with and without bonding agent.
223500391|NCT07052526|OTHER|Prevention therapy|DENU Seal applied using a split-mouth design to evaluate bonding and non-bonding application outcomes from retention and caries prevention
223500392|NCT07052201|DRUG|Dexamethasone|"DART regimen group (cumulative dose 0.89 mg/kg over 10 days): intravenous dexamethasone administered as follows:~0.075 mg/kg/dose every 12 hours for 3 days 0.05 mg/kg/dose every 12 hours for 3 days 0.025 mg/kg/dose every 12 hours for 2 days 0.01 mg/kg/dose every 12 hours for 2 days, then discontinue.~If extubation is not successful within one week after completing the treatment, the regimen may be repeated."
223500393|NCT07052201|DRUG|Dexamethasone|"Low-dose tapering regimen group (cumulative dose 0.45 mg/kg over 3 days): intravenous dexamethasone administered as follows:~0.1 mg/kg/dose every 12 hours on Day 1 0.075 mg/kg/dose every 12 hours on Day 2 0.05 mg/kg/dose every 12 hours on Day 3 If extubation is not successful within one week after completing the treatment, the regimen may be repeated."
223500394|NCT07052201|DRUG|Dexametasone|"Medium-dose tapering regimen group (cumulative dose 2.35 mg/kg over 7 days): intravenous dexamethasone administered as follows:~0.5 mg/kg/dose once daily for 3 days 0.25 mg/kg/dose once daily for 3 days 0.1 mg/kg/dose once daily for 1 day If extubation is not successful within one week after completing the treatment, the regimen may be repeated."
224190335|NCT05330728|OTHER|Suggestions for lifestyle changes+ Kinesio taping|Suggestions including regular and balanced diet, fluid consumption, regular walking and abdominal exercises and correct toilet habits will be given once. Kinesio taping will be applied 3 times a week for 4 weeks.
224190336|NCT05330728|OTHER|Suggestions for lifestyle changes|Suggestions including regular and balanced diet, fluid consumption, regular walking and abdominal exercises and correct toilet habits will be given once.
224190337|NCT05946174|OTHER|Intervention Set A|exercise sessions and meals over approximately 12 weeks
224190338|NCT05946174|OTHER|Intervention Set B|exercise sessions and meals over approximately 3 weeks
224309625|NCT00718913|DRUG|Capecitabine|Capecitabine will be administered orally during radiotherapy for radiosensitization(1650 mg/m2 per day divided in two daily doses, 5 days/week, on Monday through Friday).
224309626|NCT02959424|OTHER|Spanish Northwestern Esophageal Quality of Life questionnaire|
224190339|NCT05946174|OTHER|Intervention Set C|meals over approximately 3 weeks
224190340|NCT00650975|DEVICE|Laser Thromboablation|Laser Thromboablation using the Spectranetics CVX-300® excimer laser system
224190341|NCT00650975|DEVICE|PTCA (Direct Stenting)|Balloon predilatation or Direct Stenting using conventional techniques according to local standards and device specific instructions for use
224190342|NCT01738672|DRUG|Inhaled nitrous oxide|Administration of nitrous oxide for labor analgesia
224190343|NCT04887012|BIOLOGICAL|anti-CD19 CAR-NK|lentiviral vector-transducted HLA haploidentical NK cells to express anti-CD19 CAR
224190344|NCT02398292|OTHER|M3 Program|Participants and their study partners will learn about food, movement, and mindfulness through hands-on curriculum.
224190345|NCT02398292|OTHER|Control|Participants will not participate in M3 program but will have same outcomes measured at same time points (baseline, 6 weeks, 12 weeks).
224190346|NCT05555134|BEHAVIORAL|educational intervention|will also have an extra educational intervention, a group intervention (4-6 people) through a one-hour training session via zoom, which will be given by the PI (extensive experience in the subject) a week after discharge from the ER. Information will be reinforced and doubts will be solved
224190347|NCT04112862|OTHER|sodiumlactate|intravenous sodiumlactate 600mmol/L
224190348|NCT01465984|DRUG|Paracetamol|paracetamol , 1 gram Iv infusion Morphine Sulfate0.1 Mg/Kg Iv
224190349|NCT04096781|BEHAVIORAL|SDMT|The intervention involves a clear pathway centered on the use of a web-based decision tool. This tool aims to support the shared decision-making process for anticoagulation for stroke prevention in atrial fibrillation. This web-based tool will be used both by the participants as well the physician responsible for atrial fibrillation decision making.
224190350|NCT04096781|BEHAVIORAL|Usual Care|The participants will receive usual care.
224190351|NCT04253652|OTHER|Fasted breath samples|Will be completed pre and post iron therapy
224190352|NCT04253652|OTHER|IBS-SSS|Will be completed pre and post iron therapy
224190353|NCT04253652|OTHER|Daily diary|Monitoring stool form, consistency and frequency on a daily basis for 4 weeks
224190354|NCT04253652|OTHER|Exploratory research: stool samples|Completed pre and post iron therapy for a subset of patients enrolled in the study
223500395|NCT07052409|DIETARY_SUPPLEMENT|Inkomazi|Pasteurized fermented milk
223500396|NCT07057440|OTHER|High-dose Nicotine Pouch|"A High Dose Nicotine Pouch are placed and held in the oral cavity (between the gum and lip) for 20 minutes, as per standard use instructions.~After 20 minutes pouches are removed from the oral cavity and disposed."
223500397|NCT07057440|OTHER|Low Dose Nicotine Pouch|A Low Dose Nicotine Pouch are placed and held in the oral cavity (between the gum and lip) for 20 minutes, as per standard use instructions. After 20 minutes pouches are removed from the oral cavity and disposed.
223500398|NCT07057440|OTHER|Placebo Pouch|A Placebo Pouch are placed and held in the oral cavity (between the gum and lip) for 20 minutes, as per standard use instructions. After 20 minutes pouches are removed from the oral cavity and disposed.
223500399|NCT07056231|DIETARY_SUPPLEMENT|Caffeine|A single oral dose of 3 mg of caffeine per kilogram of body weight form approximately 60 minutes before performance testing. Supplied by Oxford Vitality, ISO-certified.
223500400|NCT07056231|DIETARY_SUPPLEMENT|Placebo|polydextrose used as Placebo
223500401|NCT07056582|DRUG|Dexmedetomidine|patients in this group will receive nebulized Dexmedetomidine before onset of surgery
223500402|NCT07056582|DRUG|Ketamine|patients in this group will receive nebulized ketamine before onset of surgery
223500403|NCT07056582|DRUG|0.9%sodium chloride|patients in this group will receive nebulized 0.9% normal saline before onset of surgery
224190355|NCT00411606|PROCEDURE|Thermography|Subjects will have a picture of their face taken with a thermal camera
224190356|NCT03655951|BEHAVIORAL|Web-based resource on adolescent sexual health|Web-based resource on adolescent sexual health than the intervention.
224190357|NCT03655951|BEHAVIORAL|Alternate web-based resource on adolescent sexual health|This is a different web-based resource on adolescent sexual health than the intervention.
224190358|NCT02811640|OTHER|Study Participants|IAP will be observed and measured with a hand held Stryker Pressure Monitor during laparoscopic surgery and compared to the standard IAP measurements obtained with the insufflator at the time of PD catheter insertion
224190359|NCT01329991|DRUG|PLX5622|PLX5622 drug substance is an achiral,small molecule Fms kinase inhibitor. The drug product is available in capsule form, to be taken orally, in a dosage strength of 100 mg with matching placebo
224190360|NCT01329991|DRUG|Placebo|Matching placebo for PLX5622
224190361|NCT00508118|DRUG|Nicardipine|on bypass
223511993|NCT00819832|PROCEDURE|Kyphoplasty|A small fluid balloon will create a hole in the broken back bone where tumor is located. After balloon deflation and removal, hole is filled with medical cement.
223511994|NCT00819832|PROCEDURE|Vertebroplasty|Medical cement will be injected into broken back bone.
223511995|NCT00819832|DEVICE|Cavity SpineWand|Removes tissue (soft tissue, bone tissue, or both, but this will vary from person to person), including all or part of the cancerous tumors in the area of the broken back bone(s).
223511996|NCT00940511|BEHAVIORAL|Coordinated care|
224190362|NCT00508118|DRUG|0.9% saline|on bypass
224190363|NCT00976521|DRUG|Abciximab local infusion|Local infusion of abciximab using the ClearWay™ RX Infusion Catheter
224190364|NCT00976521|OTHER|No local infusion|Intervention without local infusion
224190365|NCT00976521|PROCEDURE|Thrombus aspiration|Thrombus aspiration
224190366|NCT01732380|DRUG|Raltitrexed|
224190367|NCT01732380|DRUG|Oxaliplatin|
224190368|NCT01732380|RADIATION|Radiotherapy|
224190369|NCT02701907|OTHER|Blood sampling|
224190370|NCT06515847|OTHER|End of Life Nursing Care Plan|the patients of experimental group were cared according to the nursing care plan based on Kolcaba's comfort theory,
224190371|NCT05372991|DRUG|CBT-009|This is a Two-Stage Phase 1/2 study to evaluate the safety, tolerability and pharmacodynamics of CBT-009 eye drop in healthy volunteers.
224190372|NCT05372991|DRUG|Vehicle|This is a Two-Stage Phase 1/2 study to evaluate the safety, tolerability and pharmacodynamics of CBT-009 eye drop in healthy volunteers.
224190373|NCT05372991|DRUG|Atropine Sulfate|This is a Two-Stage Phase 1/2 study to evaluate the safety, tolerability and pharmacodynamics of CBT-009 eye drop in healthy volunteers.
224309627|NCT03680066|OTHER|Oral food challenge to foods with traces|"Subjects will undergo an open food challenge to 3 processed foods labeled with may contain traces. The following foods (similar for all patients) will be given in one dose in the size of a regular serving:~* cookies, max 30 g;~* chocolate, max 30 g;~* breakfast cereals, max 50 g.~Each meal will be administered with a 1 hour observation period in between and at the end."
224190374|NCT01031667|DRUG|Cilostazol, Probucol / placebo of probucol|An investigator-initiated, placebo-controlled, randomized, multi-center study. Enrolled patients will be randomized after PCI either to the combination therapy group or to the control group. In the combination therapy group, cilostazol 200 mg and probucol 500 mg will be administered daily, whereas the control group will receive cilostazol 200 mg daily only.
224309628|NCT00678886|BIOLOGICAL|otelixizumab infusion plus physician determined standard of care|infusion
224190375|NCT03717220|PROCEDURE|flap transferring|we use regional dorsal digital flaps for simultaneous reconstruction of multiple-digit soft-tissue defects
224309629|NCT00678886|BIOLOGICAL|placebo infusion plus physician determined standard of care|infusion
224309630|NCT06227026|BIOLOGICAL|Anti-CD19 CAR-T cells|Anti-CD19 CAR-T cells are autologous T cells, engineered to express an extracellular single chain variable fragment (scFv) derived from a murine anti-human CD19 hybridoma clone FMC63 linked in frame to hinge region derived from human CD8, transmembrane domain derived from Tumor Necrosis Factor Receptor Super Family 19 (TNFRSF19) the transactivation costimulatory domain 4-1BB, and CD3 zeta signaling domain (Miltenyi Biotec Inc). Anti-CD19 CAR-T cells will be cryopreserved in infusible cryomedia for a later infusion. Anti-CD19 CAR-T cells will be administered in 1 to 3 bags. Bag aliquoting, cell content and cryomedia composition will be done according to specifications in the CMC.
224309631|NCT00206323|DRUG|Topiramate (drug)|Topiramate 25 mg titrated to 200 mg
224309632|NCT00206323|DRUG|placebo/sugar pill|placebo
224309633|NCT04151901|OTHER|Resistance Exercise Rehabilitation|Following disuse, the REHAB groups (M-REHAB, F-REHAB) will complete monitored resistance exercise rehabilitation sessions using an isokinetic dynamometer at a similar relative load at each rehab visit.
224309634|NCT04151901|OTHER|Walking-based rehabilitation|Following disuse, the CON groups (M-CON, F-CON) will complete 30 minutes of monitored walking at a moderate intensity at each rehab visit.
224309635|NCT04522947|OTHER|Milkshake fMRI|While in the MRI scanner, the participant is shown a cue indicating the impending delivery of either milkshake or tasteless solution, followed by a brief blank screen, then delivery of the sip, and then a swallow cue. This procedure is repeated throughout the task.
224309636|NCT06474715|BEHAVIORAL|Arms|The intervention includes a task-based interaction (volunteer activities) where cognitive demand is low and interactional roles are clear. The focus is on the task, rather than developing relationships, reducing the pressure of interaction. As the volunteer activities continue, they also offer the opportunity for group members to enhance empathy, another salient component of cross-group relational development. Mediated interaction supports new relational development through a disinhibiting effect, lowering inhibitions and increasing comfort and disclosure
224309637|NCT05580653|OTHER|Controlled feeding study of beef and/or pinto beans|Crossover feeding study of three, 7-day feeding periods with plant and/or animal proteins (beef, pinto beans, and half beef/half pinto beans) completed in random order.
224309638|NCT05580653|OTHER|Controlled feeding study of eggs and/or black beans|Crossover feeding study of three, 7-day feeding periods with plant and/or animal proteins (eggs, black beans, and half eggs/half black beans) completed in random order.
224309639|NCT05694780|BEHAVIORAL|Sleep intervention|Standard obstetric care plus the sleep intervention which is a 8-week program based on sleep hygiene education and cognitive-behavioral training.
224309640|NCT01943994|DRUG|Psilocybin-assisted treatment|Participants will be administered 30 mg/70 kg psilocybin. Preliminary evidence from our ongoing psilocybin dose-effects study suggests that this dose is associated with mystical-type experiences.
224309641|NCT01943994|DRUG|Nicotine Replacement Therapy (NRT)|
224309642|NCT04969510|DRUG|10 mg PRAX-114|Once daily oral treatment
224309643|NCT04969510|DRUG|20 mg PRAX-114|Once daily oral treatment
224309644|NCT04969510|DRUG|40 mg PRAX-114|Once daily oral treatment
224309645|NCT04969510|DRUG|60 mg PRAX-114|Once daily oral treatment
224309646|NCT04969510|DRUG|Placebo|Once daily oral treatment
224309647|NCT05054413|OTHER|Questionnaire Administration|Complete questionnaires
224309648|NCT01404832|DRUG|Treat with lansoprazole 30 mg BID for 2 weeks, endoscopic examination with esophageal biopsy for patients with persistent symptoms|Treat with lansoprazole 30 mg BID for 2 weeks, perform endoscopic examination with esophageal biopsy
224309649|NCT04646941|OTHER|regular treatment|The patients with or without OSA received regular hypoglycemic drugs.
224309650|NCT04084600|OTHER|Kinesiotherapy Protocol|Kinesiotherapy Protocol is an specific exercise based treatment designed to strengthening, gaining range of motion and stretching the muscles.
224309651|NCT04084600|OTHER|Manual Therapy Protocol|Manual therapy protocol: is a manual treatment intended to the release of fascias and soft tissues.
224309652|NCT04084600|OTHER|Traditional Massage|Traditional Massage is a gentle and superficial massage.
224309653|NCT02264470|OTHER|Not relevant|Not relevant
224309654|NCT05400408|DIAGNOSTIC_TEST|VOX|Breath Biopsy Analysis
224309655|NCT03460314|DRUG|Buprenorphine|Patients are tested for their normal prescription buprenorphine medication
224309656|NCT06657456|DIETARY_SUPPLEMENT|Phytosterol-rich extract|Experimental product: extract rich in phytosterols
224190376|NCT01588873|DRUG|oc:E-E-desogestrel/vaginal ring:E-E -ethonogestrel|"The OC or vaginal ring will be used in 9 weeks periods followed by one week's break each.~After a wash-out period of at least 2 months of any previous hormonal contraceptives all examinations will be performed at the 1st to 5th day of the menstruation cycle at baseline and then at the 9th, 29th and 59th week and the last 1 month after stopping contraception.~Blood samples will be collected between 07 and 10 AM after an overnight fast and during the follicular phase or at any time in cases of amenorrhea. After centrifugation serum is filled in eight tubes with at least 2 ml of serum in each, and immediately frozen at -70ºC as well as one tube of plasma. Every tube will be marked appropriately. Fasting plasma glucose and HbA1c will be analysed at once at every appointment."
224190377|NCT01384773|OTHER|Riboflavin Solution|This solution is used to saturate the corneal stroma prior to its photochemical activation by the IROC UV-X illuminator.
224190378|NCT01384773|DEVICE|UV-X Illumination System|IROC UV-X irradiation system creates a uniform 11 mm circle of UVA light that is focused onto the corneal surface. This system is designed to irradiate the riboflavin saturated cornea with a uniform field of UVA light centered at 365 nm.
224190379|NCT00547404|DRUG|P276-00|IV drug infusion over a period of 30 min on day 1,4,8 and 11 in21 day cycle for 6 cycles
224190380|NCT03717441|DIAGNOSTIC_TEST|chromosome numeration of embryos|Use genomic technologies to analyze the discarded media drop for chromosome counting
224190381|NCT03635541|OTHER|observational group of NAFLD|there's no intervention for patients for it is a observational study
224190382|NCT00696332|DRUG|Talampanel|capsules Talampanel, 3 times per day, 52 weeks
224190383|NCT00696332|DRUG|Talampanel|capsules Talampanel, 3 times per day, 52 weeks
224190384|NCT00696332|OTHER|placebo|capsules, placebo, 3 times a day, for 52 weeks
224190385|NCT02778477|DRUG|PF-06423264|Multiple ascending dose of PF-06423264
224190386|NCT02778477|OTHER|Placebo|Multiple dose of placebo
224190387|NCT02627157|DEVICE|Dynamic Scheimpflug Analyzer|Measurements of Corneal Biomechanical Properties Using a Dynamic Scheimpflug Analyzer
224190388|NCT03427931|OTHER|Continuous Glucose Monitor (CGM)|Study subjects will collect Continuous Glucose Monitor data for a minimum of 28 days but may continue for up to 3 months.
224190389|NCT05834894|OTHER|exposure(s) of interest : intensive care unit|Low muscle mass is highly prevalent at hospital admission, and muscle mass generally decreases during hospital stay, especially in critically-ill patients. We would like to mesure muscle mas in critically ill patients and determine the association between outcomes.
224190390|NCT03194594|DRUG|Ketamine Hydrochloride, dexamethasone, and combination of two drugs|After receiving by IRB approval and obtaining informed consent from patients, 93 patients who were aged between 18 and 70 years old and classified as American Society of Anesthesiologists (ASA) classes I and II. Afterward, the patients are randomly (sealed envelopes) allocated into one of three treatment; Group K (n = 31) receives a single dose of ketamine 0.5 mg/kg i.v. plus 2 ml normal saline, Group D (n = 31) receives dexamethasone 0.5 mg/kg i.v. and a maximum dose of 8 mg plus 2 ml saline, and Group KD (n = 31) receiveds ketamine 0.5 mg/kg i.v. and dexamethasone 0.5 mg/kg i.v. at 5 minutes after the induction of anesthesia in a double-blinded method.
224309657|NCT06657456|DIETARY_SUPPLEMENT|Placebo|Product with identical characteristics to the experimental product.
224309658|NCT06978140|BEHAVIORAL|Personalized feedback|Material includes feedback on alcohol-related consequences with elements from Acceptance Commitment Therapy, Relapse Prevention, Cognitive Behavioral Therapy, and Behavioral Activation. Focus of the intervention is learning about personal environmental cues.
224309659|NCT06978556|DIAGNOSTIC_TEST|No intervention is subject of the study. Only standard pre- and postoperative data will be evaluated.|No intervention is subject of the study. Only standard pre- and postoperative data will be evaluated. Including data from testing refraction, visual acuity, biometry, tomography, and OCT.
224309660|NCT06979635|DEVICE|Tandem Mobi Hybrid Closed Loop (HCL) pump|Tandem Mobi Hybrid Closed Loop (HCL) pump with an integrated Control-IQ algorithm (CIQ), the Dexcom G7 continuous glucose monitoring sensor (CGM ) and Tandem Mobi Mobile App
223511997|NCT00930787|DEVICE|Strattice Reconstructive Tissue Matrix (Hernia Repair)|Hernia repair will be performed, in an open fashion and defect will be closed or reduced in size using musculofascial centralization procedures to reestablish midline.
223511998|NCT00930787|DEVICE|Proceed Surgical Mesh (Hernia repair)|Hernia repair will be performed, in an open fashion and defect will be closed or reduced in size using musculofascial centralization procedures to reestablish midline.
223511999|NCT02229292|DRUG|Tranexamic Acid|"Active group:~Undergoes elective bi-maxillary orthognathic surgery consisting of a (un)/segmented LeFort I osteotomy combined with a bilateral sagittal split osteotomy, under the influence of 10ml tranexamic acid (100mg/ml) administered iv. prior to the onset of the surgical procedure."
224190391|NCT05599373|DEVICE|Bilateral Active Repetitive transcranial magnetic stimulation (rTMS)|Active treatments with repetitive transcranial magnetic stimulation (rTMS) over bilateral dorsolateral prefrontal cortex (DLPFC) took the form of intermittent theta burst stimulation (iTBS). For iTBS the stimulation parameters were: frequency = triplet 50 Hz bursts, repeated at 5 Hz; train duration = 2 s ON and 8 s OFF, total pulses/session = 600; total number of treatments = 20(5 sessions per week) at 80 % of each side resting motor threshold (MT). The rTMS target was first randomized to the left or right DLPFC, then switched to the opposite side.
224190392|NCT05599373|DEVICE|Left Active Repetitive transcranial magnetic stimulation (rTMS)|Active treatments with repetitive transcranial magnetic stimulation (rTMS) over left dorsolateral prefrontal cortex(DLPFC) took the form of intermittent theta burst stimulation (iTBS). For iTBS the stimulation parameters were: frequency = triplet 50 Hz bursts, repeated at 5 Hz; train duration = 2 s ON and 8 s OFF, total pulses/session = 600; total number of treatments = 20(5 sessions per week) at 80 % of left resting motor threshold (MT). Sham rTMS stimulation was delivered over right dorsolateral prefrontal cortex(DLPFC) using the same stimulation parameters, except for using the sham stimulation coil. The rTMS target was first randomized to the left or right DLPFC, then switched to the opposite side.
224190393|NCT05599373|DEVICE|Sham rTMS over bilateral dorsolateral prefrontal cortex|Sham rTMS stimulation was delivered over bilateral dorsolateral prefrontal cortex (DLPFC) using the same stimulation parameters, except for using the sham stimulation coil. The rTMS target was first randomized to the left or right DLPFC, then switched to the opposite side.
224190394|NCT00161031|DRUG|Atomoxetine|
224190395|NCT05382026|DIETARY_SUPPLEMENT|Nutritional supplementation during a 6 month resistance training program|1% chocolate milk
224190396|NCT05382026|DIETARY_SUPPLEMENT|Nutritional supplementation during a 6 month resistance training program|Pea-based beverage
224190397|NCT05382026|DIETARY_SUPPLEMENT|Nutritional supplementation during a 6 month resistance training program|Maltodextrin placebo
224190398|NCT03085940|DRUG|Hydroxychloroquine|Hydroxychloroquine 400mg once daily initially
224190399|NCT03085940|DRUG|Placebo|Placebo
224190400|NCT00766129|DEVICE|Taxus stent implantation|Patients will be treated with implantation of Taxus stent
224190401|NCT00766129|DEVICE|Luc-Chopin stent|Patients will be treated will implantation of Luc-Chopin stent
224190402|NCT04058665|DEVICE|Floseal|Hemostatic agent
224190403|NCT02672748|OTHER|Garden|Two years of financial and technical home gardening support for new gardeners
224190404|NCT00847002|DEVICE|Standard Wound Care|
224190405|NCT00847002|DEVICE|Flexitouch System with Standard Wound Care|
224190406|NCT01796899|OTHER|Brivaracetam 10 mg oral tablet|
224309661|NCT06981338|COMBINATION_PRODUCT|Allogeneic Wharton's jelly mesenchymal stem cells (WJ-MSCs)|This experimental treatment combines intrathecal administration of allogeneic Wharton's jelly mesenchymal stem cells (WJ-MSCs) with transcutaneous spinal cord stimulation (tSCS) and neurorehabilitation. Participants will receive three doses of cryopreserved WJ-MSCs (30×10⁶±30% viable cells per dose) derived from umbilical cord tissue, delivered via lumbar puncture at 6-week intervals in a saline-albumin solution. The intervention includes concurrent tSCS, a non-invasive electrical stimulation technique, paired with standardised neurorehabilitation. As the first clinical study evaluating this specific combined therapy for chronic spinal cord injury (AIS A-C grades), safety monitoring incorporates regular cerebrospinal fluid analysis to assess potential immune responses.
223500404|NCT07055776|COMBINATION_PRODUCT|non-invasive vagus nerve stimulation (nVNS)|Group 1 will receive non-invasive vagus nerve stimulation (nVNS) targeting the auricular branch of the vagus nerve (ABVN) using a TENS device with specialized ear clip electrodes. The electrodes will be placed on the cymba conchae or tragus region of the ear, where the ABVN is accessible. The stimulation parameters will be set to a frequency of 1 Hz (significantly reduced migraine headache), pulse width of 200-300 µs, and intensity adjusted to a strong but comfortable level without causing pain, applied for 15-30 minutes per session, 5 days a week for 12 weeks, based on protocols supported by evidence from studies such as Badran et al. (2018) and Yakunina et al. (2017), which demonstrated positive neuromodulatory effects through auricular stimulation. Baseline conventional physiotherapy for both groups will include: thermotherapy (e.g., moist hot packs for 15 minutes), range of motion (ROM) exercises, stretching of involved muscles, and strengthening exercises.
223500405|NCT07055776|COMBINATION_PRODUCT|non-invasive transcutaneous electrical nerve stimulation (TENS)|Group 2 will receive non-invasive transcutaneous electrical nerve stimulation (TENS) applied to the other areas to target other nerves stimulation (e.g., neck, upper trapezius, or occipital area). Surface electrodes will be placed paravertebrally, using a conventional TENS protocol: frequency of 20-25 Hz, pulse width of 200-300 µs, and intensity set to produce a strong but comfortable tingling sensation without muscle contraction. Each session will last 20-30 minutes, administered 5 days a week for 12 weeks. Baseline conventional physiotherapy for both groups will include: thermotherapy (e.g., moist hot packs for 15 minutes), range of motion (ROM) exercises, stretching of involved muscles, and strengthening exercises.
223500406|NCT07056491|OTHER|mRNA level of REST4 in serum;|"1. mRNA level of REST4 in serum The mRNA expression level of REST4 was measured in serum-derived exosomes using RT-qPCR at the time of patient enrollment.~2. Computed tomography angiography (CTA) Baseline maximum internal diameter of the abdominal aortic aneurysm (AAA) was determined by CTA at enrollment. During follow-up, CTA was performed to assess the increase in maximum AAA diameter."
223500407|NCT07057206|DEVICE|PFM-guided cortical stimulation|Abbott Eterna IPG and Lamitrode 44 paddles with accessory extensions and clinical programmers
223500408|NCT07057349|DRUG|[18F]CSB-321|\[18F\]CSB-321 is a PET imaging agent that is bound to released granzyme B from T-cells
223591455|NCT03157284|DIETARY_SUPPLEMENT|Placebo|For 12 weeks a group of children will receive a 7gr of a placebo (maltodextrin), according to a randomised, double-blind design.
223591456|NCT06366360|OTHER|Immersive Virtual Reality Intervention|"The immersive virtual reality rehabilitation protocol is an experimental protocol based on musical practice. This protocol will be based on the Piano Vision application, which allows several modes of music production: free or guided musical practice."
224190407|NCT01796899|OTHER|Brivaracetam 50 mg oral tablet|
224190408|NCT01796899|OTHER|Brivaracetam 75 mg oral tablet|
224190409|NCT01796899|OTHER|Brivaracetam 100 mg oral tablet|
224190410|NCT01796899|OTHER|10 mL of Brivaracetam intravenous bolus injection (10 mg/mL)|
224190411|NCT03240042|PROCEDURE|nasotracheal intubation|The participants either receive intubation via nasal route.
224190412|NCT03240042|PROCEDURE|orotracheal intubation|The participants either receive intubation via oral route.
224190413|NCT00137306|PROCEDURE|Facilitate evidence-based treatment for depression|
224190414|NCT01725100|DRUG|GSK1120212B (Standard DMSO content)|Each tablet contains GSK1120212B equivalent to 2 mg of GSK1120212 as drug substance. The coated tablets have a standard DMSO content of theoretical 11.3%.
224190415|NCT01725100|DRUG|GSK1120212B (Lower DMSO content)|Each tablet contains GSK1120212B equivalent to 2 mg of GSK1120212 as drug substance. The coated tablets have a lower DMSO content approximately 9.5%.
224190416|NCT00198107|DRUG|Aripiprazole|Participants will receive 8 weeks of initial treatment with aripiprazole. If responsive to treatment, participants may be assigned to an additional 16 weeks of aripiprazole and then an additional 8 more weeks of aripiprazole with D-cycloserine. Dosing schedule for participants less than 50 kg maximum dose will be 10 mg per day. Dosing schedule for participants greater than 50 kg maximum dose will be 15 mg.
224190417|NCT00198107|DRUG|Placebo|Participants assigned to placebo will take a placebo pill for the initial 8 weeks of treatment.
224190418|NCT00198107|DRUG|D-cycloserine|D-cycloserine will be dosed in the range of 25 to 200 mg daily for the final 8 weeks of treatment.
224190419|NCT03292770|DEVICE|Flushing Catheter|A catheter will be used to performed a flushing of the cervical canal with culture media.
224190420|NCT04836637|DIETARY_SUPPLEMENT|Maltodextrin|Three capsules are to be consumed with one sachet dissolved in 200 ml. of water for breakfast and later for dinner resulting in a total of six capsules and two sachets via oral consumption daily.
224309662|NCT06982196|DRUG|Sulodexide|Sulodexide group：Starting after the last injection of secukinumab, oral treatment with sulodexide soft capsule (Alpha Weissmann Pharmaceuticals, Italy, approval number H20140119, specification 250 LSU) was given as 1 tab bid for 120 days or discontinued after judged to be a relapse.
224190421|NCT04836637|DIETARY_SUPPLEMENT|Calcium-carbonate|Three capsules are to be consumed with one sachet dissolved in 200 ml. of water for breakfast and later for dinner resulting in a total of six capsules and two sachets via oral consumption daily.
224190422|NCT04836637|DIETARY_SUPPLEMENT|Calcium-enriched permeate|Three capsules are to be consumed with one sachet dissolved in 200 ml. of water for breakfast and later for dinner resulting in a total of six capsules and two sachets via oral consumption daily.
224190423|NCT04836637|DIETARY_SUPPLEMENT|Calcium-enriched permeate with Inulin|Three capsules are to be consumed with one sachet dissolved in 200 ml. of water for breakfast and later for dinner resulting in a total of six capsules and two sachets via oral consumption daily.
224190424|NCT00475527|DRUG|omeprazole,clarithromycin,amoxicillin (or metronidazole)|
224190425|NCT02279082|DRUG|DFN-02|Active Experimental Drug
224190426|NCT00990782|DIAGNOSTIC_TEST|PillCam ESO Capsule Endoscope|Utilization of the PillCam ESO capsule endoscope to evaluate the condition of a patient's esophagus before and after RFA therapy to treat atrial fibrillation.
224190427|NCT01718574|OTHER|Self-help book|Participants have 6 weeks to complete a 12 chapter self-help workbook. The workbook addresses: (i) The enhancement of a sense of personal control; and (ii) The learning of emotional and instrumental coping responses
224190428|NCT06010576|PROCEDURE|EUS-guided rendezvous|A linear array echoendoscope would be used to evaluate the common bile duct and left intrahepatic duct in order to identify the optimal route for biliary access by fine needle. Using a 19 gauge EUS needle, the dilated biliary tree will be accessed by either a transduodenal puncture to the common bile duct or a transgastric puncture to the left intrahepatic duct under direct EUS guidance. The optimal access route will be based on patient's anatomy after EUS assessment and left to the discretion of the investigator. Next, a guidewire would be advanced through the needle into the bile duct and out of the papillary orifice. The echoendoscope would then be exchanged to a duodenoscope for ERCP. The EUS rendezvous ERCP procedure will be completed by retrieving the rendezvous guidewire into the duodenoscope or by cannulation alongside the rendezvous guidewire to obtain biliary access.
224190429|NCT06010576|PROCEDURE|Early precut papillotomy group|The precut papillotomy would be performed with 1 of the following acceptable techniques per the usual practice of the study investigator and institution: 1) conventional precut papillotomy by needle knife, 2) precut fistulotomy by needle knife, or 3) transpancreatic precut papillotomy by papillotome
223500409|NCT07056075|DEVICE|Nasal PAP Ventilation System|medical devices that provide nasal positive airway pressure ventilation during endoscopy
224190430|NCT00908362|DRUG|fluticasone|Participants inhale fluticasone (250 µg) via discus. Before and after this therapy, a bronchoalveolar lavage is performed.
224190431|NCT00908362|DRUG|fluticasone/salmeterol|Participants inhale fluticasone/salmeterol (250/50µg) via discus. Before and after this therapy, a bronchoalveolar lavage is performed.
224190432|NCT00908362|DRUG|placebo|Participants inhale placebo twice daily via discus. Before and after this therapy, a bronchoalveolar lavage is performed.
224190433|NCT02047929|OTHER|Asthma Shared Decision Making (SDM) Toolkit|A potential solution to improving asthma outcomes is the use of patient-centered approaches like Shared Decision Making (SDM), In the SDM process, patients and their health care providers are engaged jointly in making decisions about medical tests and treatments. The research team for this proposal was funded by the Agency for Health Care Research and Quality to build, disseminate and evaluate a novel Asthma SDM Toolkit - The Asthma Comparative Effectiveness Study. The Toolkit development was completed in 2010 and has been in evaluation for 2 years. This study will continue to evaluate the Toolkit in a wide array of practices across NC while testing a new method of dissemination.
224190434|NCT00602082|DRUG|capecitabine|
224190435|NCT00602082|DRUG|cisplatin|
224190436|NCT00602082|DRUG|streptozocin|
224190437|NCT00602082|GENETIC|DNA analysis|
224190438|NCT00602082|GENETIC|RNA analysis|
224190439|NCT00602082|GENETIC|protein analysis|
224190440|NCT00602082|GENETIC|proteomic profiling|
224190441|NCT00602082|OTHER|laboratory biomarker analysis|
224190442|NCT01294280|OTHER|Laboratory Biomarker Analysis|Correlative studies
223500410|NCT07056075|DEVICE|Low Flow Oxygen|low flow oxygen though nasal cannula
223500411|NCT07056075|DEVICE|Capnometry|capnometry measurement
224190443|NCT04063748|BEHAVIORAL|Audiological rehabilitation|Experimental: tablet-based take-home auditory-cognitive training, which consists of phoneme tasks, words in quiet and in different types of noise
224190444|NCT04063748|BEHAVIORAL|Placebo Rehabilitation|CI-users: Placebo, tablet-based take-home psychophysical tasks, reading (non auditory)
224190445|NCT04063748|BEHAVIORAL|Passive Control|No intervention in the passive control group for HA-users.
224190446|NCT04895904|OTHER|No intervention|Our study is an observational study and the main purpose of our study is to observe the efficacy of endoscopic hemostasis and drug therapy
223500412|NCT07056699|DRUG|Dapagliflozin 10mg Tab|Dapagliflozin (10 mg/day)
223500413|NCT07056699|DRUG|Pioglitazone 15 MG and 30mg|Pioglitazone (15 mg/day for 2 weeks, then 30 mg/day for 14 weeks)
223500414|NCT07056699|OTHER|Placebo|Inert placebo for Pioglitazone
223500415|NCT07055880|BIOLOGICAL|Rabies Vaccine (Serum-free Vero Cell), Freeze-dried|"Receiving five doses of rabies vaccine manufactured by Sinovac using the Essen PEP schedule"
223500416|NCT07055880|BIOLOGICAL|Verorab®|"Receiving five doses of marketed rabies vaccine manufactured by Sanofi using the Essen PEP schedule"
223500417|NCT05508256|DEVICE|CE-marked Catheter Ablation|Once patients have been randomized to the catheter ablation (CA) group, the ablation procedure must be performed within 4 weeks. CA will initially aim at pulmonary vein isolation.
223500418|NCT06398691|DEVICE|Nazal CPAP|
223500419|NCT06398691|DEVICE|Heated humidified high-flow air support with nasal cannula|
223500420|NCT02896842|DRUG|Posology dose modification|
223500421|NCT02896842|OTHER|active comparator|
223512000|NCT02229292|DRUG|Saline|"Placebo group:~Undergoes elective bi-maxillary orthognathic surgery consisting of a (un)/segmented LeFort I osteotomy combined with a bilateral sagittal split osteotomy, under the influence of 10ml sodium chloride (9mg/ml) administered iv. prior to the onset of the surgical procedure."
223512001|NCT04062604|OTHER|surgery|surgical treatment of femur fracture, hip and knee alloplasty, knee arthroscopy
223512002|NCT02636036|BIOLOGICAL|enadenotucirev|
223512003|NCT02636036|BIOLOGICAL|nivolumab|
223746178|NCT03204513|DEVICE|Vanderbilt Powered Knee-Ankle Prosthesis|The Vanderbilt powered prosthesis is a transfemoral prosthesis with powered and coordinated knee and ankle joints. The Generation 3 prosthesis is actuated by two brushless direct current (DC) motors, providing up to 100 Nm of torque at the knee joint, and with the assistance of a parallel stiffness, up to 200 Nm in plantar flexion at the ankle. Sensors measure knee and ankle joint angles, axial load in the shank, and position and orientation of the prosthesis in space (via a 6-axis inertial measurement unit). An onboard lithium-ion battery provides sufficient energy for approximately 10,000 steps between battery charges. The prosthesis prototype weighs approximately 4.3 kg (9.5 lb), the mass of which is approximately equivalent to the intact limb of a 48 kg (105 lb) person.
223746179|NCT03204513|DEVICE|Microprocessor (MP) Knee Prosthesis|Participants enrolled will already have their own microprocessor controlled (MP) non-powered knee prostheses as per inclusion criteria. Examples: OttoBock's C-Leg, Ossur's Rheo, Freedom Plie, Endolite Orion,etc.
223746180|NCT04980677|DEVICE|Tangiball|"To enable baseline scores comparison, children will be matched according to age and score on the four-strand Hands-On assessment tool which takes 30 minutes to complete. Children will then play with the Smart Toy during a 20 minute session. Sessions will be recorded using an SD card within the Smart Toy which captures information on user speed and accuracy of placement of the detachable segments of the toy when placed into the main hub of the toy, allowing comparison between neuro-typical children and children with Autism. The intervention will run either in clinic (preferred option) or in children's homes-and in this case will be sent to them via post with the Standard Operating Procedure which can then be employed when children are taking part in the intervention via online video link (not recorded)."
223591457|NCT06366360|OTHER|Conventional rehabilitation|The conventional rehabilitation corresponds to the classically performed in the cognitive treatment of unilateral spatial neglect. It involves training visual scanning using barrage exercises, sequence identification, scene description, and pointing.
223746181|NCT01286012|DRUG|Soluble Ferric Pyrophosphate in liquid bicarbonate|Subjects will receive hemodialysis containing SFP at 2 µM (11 µg iron/dL of dialysate) at every dialysis session, for a total duration of 36 weeks.
223746182|NCT01286012|DRUG|Placebo: Conventional liquid bicarbonate|Subjects will receive hemodialysis containing conventional liquid bicarbonate lacking SFP at every dialysis session, for a total duration of 36 weeks.
223591458|NCT00742716|DRUG|CTA018 Injection|Comparison of different dosages of drug
223591459|NCT01185977|DRUG|Fluoxetine|one-week single-blind PBO-lead-in phase, FLX 10 mg/d for 4 days then 20 mg/d of FLX thereafter
223591460|NCT01185977|DRUG|Placebo|One pill of PBO for 4 days then two pills of PBO thereafter
223591461|NCT06455865|OTHER|TPACK-Based Blended Learning Instruction|The control group employed traditional in-person teaching methods, including face-to-face classroom instruction, reading from printed textbooks, and completing homework assignments. The curriculum covered the fundamental theories and skills related to information resource retrieval and usage but did not specifically utilize the TPACK framework. Students primarily received lectures and guidance from the instructor during class and completed assignments and learning tasks independently after class.
223591462|NCT01706588|DRUG|Diclofenac sodium|One single diclofenac injection into the surgical area before surgery but as soon as the anaesthetic has taken effect.
223591463|NCT05921175|DEVICE|RGT+ tSCS + conventional physiotherap|Subject will undergo 16 sessions of robotic gait training (RGT) + tSCS+ conventional physiotherapy in 8-10 weeks. Subject will walk with EksoGT for gait training during RGT training. Components of conventional physiotherapy will include upper/lower limb ergometry and strength training as prescribed by the attending physiotherapist based on their assessment. During tSCS, cathodes will be placed on the T11 and L1 spinous process. Reference/Ground electrodes placed over the ASIS It will be on biphasic mode with an overlap frequency of 10kHz, Burst Frequency of 30Hz, Pulse width of 1ms. Stimulation intensity ranges from 5-100 mA and will be adjusted according to the patient's response. The tSCS stimulation duration for each session will be 45 minutes in conjunction with the RGT training.
223591464|NCT05921175|DEVICE|RGT+ conventional physiotherapy|Subject will undergo 16 sessions of robotic gait training (RGT) + conventional physiotherapy in 8-10 weeks. Subject will walk with EksoGT for gait training during RGT training. Components of conventional physiotherapy will include upper/lower limb ergometry and strength training as prescribed by the attending physiotherapist based on their assessment.
223591465|NCT02684149|PROCEDURE|relational touch|
223591466|NCT02906267|OTHER|Diagnostic ultrasonography of gastric volume|Ultrasonic measurement of gastric insufflation during positive pressure ventilation (secondary endpoint) and final gastric volume after positive pressure ventilation (primary endpoint)
223591467|NCT01964625|OTHER|PET-CT Scan|PET-CT scan will be done at baseline (per standard of care), at onset and confirmation of chronic GvHD and after initiation of therapy to assess response.
223591468|NCT02737345|OTHER|Rotem|
223591469|NCT00309270|DRUG|Campath-1H|
223591470|NCT00306059|PROCEDURE|Early goal directed therapy during 6 hours after occurence of the early phase of acute kidney injury|Directed therapy during 6 hours after occurence of the early phase of acute kidney injury.
223591471|NCT02754258|DRUG|MPH|60 days on oral methylphenidate administered 2 times daily before lunch and supper.
223591472|NCT02754258|DRUG|Placebo|60 days on oral placebo administered 2 times daily before lunch and supper
223591473|NCT05912972|OTHER|Patient registry|Clinical data, specific procedures and treatments will follow the Institutional standard operative procedures
223746183|NCT01286012|DRUG|Erythrocyte Stimulating Agent (ESA)|ESA was administered according to the recommendation of a blinded central anemia management center (CAMC) based on the weekly hemoglobin value and its rate of change.
223591474|NCT04188704|PROCEDURE|Interference screw|Anterior cruciate ligament reconstruction (anterior screw fixation or posterior screw fixation)
223591475|NCT00463619|DRUG|Retarded release phosphatidylcholine|2g phosphatidylcholine, given QTD
223591476|NCT05334407|PROCEDURE|Implant-supported full-arch fixed dental prostheses（dental intervention,DE）|Implant-supported full-arch fixed dental prostheses in at least one jaw and appropriate treatment in the opposing jaw regarding periodontal diseases, caries, replacement of missing teeth and soft tissue disorders to get at least 10 pairs of occluding teeth. The intervention is designed to provide rehabilitation of masticatory function.
223746184|NCT01286012|DRUG|Intravenous (IV) Iron|Approved IV iron preparations were administered per a protocol driven algorithm when patients serum ferritin value decreased below 200 ug/L.
223746185|NCT03567707|BIOLOGICAL|C-section -Vaginal seeding|"Mother-infant pair randomized to vaginal microbiota intervention. As soon as the infant is delivered, the infant will be brought to the neonate lamp, and unless the obstetrician or pediatric staff believes it is not in the best interest of the infant, s/he will be swabbed with the vaginal microbiota soaked gauze. Swabbing will take place ideally within 1 minute after delivery (but no longer than 5 minutes). The swabbing should take approximately 15 seconds. Infants will only undergo the seeding procedure once.~Additional Intervention:~Following the seeding procedure, infants will then receive the standard detailed examination for newborns and standard of care, except that the first infant bath will occur at least 12 hours after delivery."
224190447|NCT04718363|OTHER|PNF stretching|A contract-relax PNF stretching technique will be applied to hamstring muscle.
224190448|NCT04718363|OTHER|Non-vibration foam rolling prior to PNF stretching|Prior to PNF stretching, participant will perform unilateral hamstring non-vibration foam rolling.
224190449|NCT04718363|OTHER|Vibration foam rolling prior to PNF stretching|Prior to PNF stretching, participant will perform unilateral hamstring vibration foam rolling (48 Hz).
224190450|NCT04537286|DRUG|nab-paclitaxel plus cisplatin plus carilizumab (AP+PD-1)|Nab-paclitaxel 125 mg/m2，ivgtt，d1, 8 Cisplatin 75 mg/m2，ivgtt，d1 Carilizumab 200mg, ivgtt，d1，q2w
224190451|NCT02311764|DRUG|Carboplatin|Carboplatin will be administered weekly
224190452|NCT02383966|DRUG|Cetuximab|Participants received Cetuximab as an intravenous infusion at an initial dose of 400 milligrams per square meter (mg/m\^2) on Day 1 and a subsequent dose of 250 mg/m\^2 on Day 8 and Day 15 of each 21-day treatment cycle.
224190453|NCT02383966|DRUG|Cisplatin/Carboplatin|Cisplatin or Carboplatin (at an equivalent dose in case of intolerability of cisplatin) was administered at a dose of 75 mg/m\^2 as an intravenous infusion on Day 1 of each 21-day treatment cycle.
224309663|NCT06982196|DRUG|Placebo|Control group: Oral treatment with placebo capsule, 1 tab bid starting after the last injection of secukinumab, discontinued after 120 days of continuous oral administration or judged to be discontinued for relapse.
224190454|NCT02383966|DRUG|5-fluorouracil|Participants received 5-fluorouracil (FU) at a dose of 750 mg/m\^2/day as a continuous intravenous infusion over 24 hours a day from Day 1 to Day 5 of each 21-day treatment cycle.
224190455|NCT04866602|DRUG|Atoguanil|Atovaquone + Proguanil free base:125 mg: 87 mg, 4 tablets
224190456|NCT04866602|DRUG|Malarone|Atovaquone + Proguanil HCl: 250 mg: 100 mg, 4 tablets
224190457|NCT00364338|BEHAVIORAL|gourment cooking workshop|
224190458|NCT02163759|DRUG|Adalimumab|Adalimumab 160 milligrams (mg) will be administered subcutaneously (SC) at Week 0; 80 mg SC at Week 2; 40 mg SC at Weeks 4, 6, and 8.
224190459|NCT02163759|OTHER|Adalimumab Placebo|Placebo matching to adalimumab will be administered SC at Weeks 0, 2, 4, 6, and 8.
224190460|NCT02163759|DRUG|Etrolizumab|Etrolizumab 105 mg will be administered SC every 4 weeks (Q4W) up to Week 12 (at Weeks 0 \[Day 1\], 4, 8, and 12 \[clinical remitters only\]).
224190461|NCT02163759|OTHER|Etrolizumab Placebo|Placebo matching to etrolizumab will be administered SC once every 4 weeks (Q4W) up to Week 12 (at Weeks 0 \[Day 1\], 4, 8, and 12 \[clinical remitters only\]).
224190462|NCT01382875|OTHER|Multi-disciplinary management program|conventional healthcare program for fragility fracture patients plus vibration treatment, exercise class and educational talk
224190463|NCT06181552|DIAGNOSTIC_TEST|fundus photograpgy|All the participants will undergo fundus photography.
224190464|NCT06181552|DIAGNOSTIC_TEST|optical coherence tomography|All the participants will undergo OCT examination.
224190465|NCT06181552|DIAGNOSTIC_TEST|optical coherence tomography angiography|All the participants will undergo OCT-A examination.
224190466|NCT02883400|DRUG|Spironolactone|spironolactone 25 mg up to 50 mg
224309664|NCT06983314|OTHER|Observation|Observation of pharmacological prescriptions in patients with ABI
224309665|NCT06983626|PROCEDURE|micro-dissection testicular sperm extraction|dissection of the seminefrous tubules under microscope to extract sperms
223512004|NCT02993432|DEVICE|Foley catheter filled to 80cc|A Foley catheter is inserted through the cervix and filled to 80cc
223512005|NCT02993432|DRUG|prostaglandin of the clinician's choice|Insertion of the prostaglandin (Prostin (1mg dinoprostone vaginal gel) or Cervidil (10mg vaginal slow release insert)) of the clinicians choice into the vagina for the purpose of cervical ripening
223512006|NCT01002729|OTHER|Patients with a BMI < 30 given Oseltamivir|Patients with a BMI \< 30 given Oseltamivir
223512007|NCT01002729|OTHER|Patients with a BMI > 40 given Oseltamivir|Patients with a BMI \> 40 given Oseltamivir
223512008|NCT00338000|DRUG|Epoetin alfa|
223512009|NCT06148285|DEVICE|Hyperbaric Oxygen Therapy|Hyperbaric Oxygen Therapy
223512010|NCT04885010|DIETARY_SUPPLEMENT|probiotics|participants will be given probiotics twice a day for 15 days
223512011|NCT04885010|DIETARY_SUPPLEMENT|placebo|participants will be given a placebo twice a day for 15 days
223512012|NCT04367454|OTHER|Use of Personal Protective Equipment|As described in the arm descriptions
223512013|NCT01880775|DRUG|Prilocaine|experimental
223512014|NCT01880775|DRUG|Bupivacaine|marcaine heavy 0.5% 7.5 mg intrathecal
223512015|NCT03656614|DRUG|Sugammadex|"At the end of surgical procedure at a depth of neuromuscular blockade at the reappearance of train-of-four 0.3, single intravenous injection of either :~Sugammadex 0.125 mg/kg (sugammadex 0.125) Sugammadex 0.25 mg/kg (sugammadex 0.25) Sugammadex 0.5 mg/kg (sugammadex 0.5) Sugammadex 1.0 mg/kg (sugammadex 1.0) Sugammadex 2.0 mg/kg (sugammadex 2.0)"
223512016|NCT03656614|DRUG|Neostigmine|"At the end of surgical procedure at a depth of neuromuscular blockade at the reappearance of train-of-four 0.3, single intravenous injection of either :~Neostigmine 10 µg/kg (Neostigmine 10) Neostigmine 25 µg/kg (Neostigmine 25) Neostigmine 40 µg/kg (Neostigmine 40) Neostigmine 55 µg/kg (Neostigmine 55) Neostigmine 70 µg/kg (Neostigmine 70)~Atropine will be administered with Neostigmine at a half dose of Neostigmine administered through an intravenous line with brisk flow."
224190467|NCT02305199|DRUG|Hartmann's solution|Hartmann's solution containing 200 mg/L of calcium chloride, 300 mg/L of potassium chloride, 6 g/L of Sodium chloride, 3.1 g/L of Sodium lactate.
224190468|NCT02305199|DRUG|Normal saline|Fluid containing Sodium chloride 9 g/L
224190469|NCT04787575|PROCEDURE|Oxygen-ozone therapy|"Oxygen-ozone therapy (group a) will be performed by:~i) Self-haemoinfusion of 200 cc. with concentrations of 40-50 μg/ml, to be performed two/three times a week, for a time of 6 weeks (for a maximum of 15 sessions); ii) Subcutaneous injections in the perilesional site at the dose of 5 cc. with concentrations of 4 μg,/ml, Cleanse wounds with 100 cc of 5-10 ug ozone gas"
224190470|NCT05684042|OTHER|Data analysis: Accuracy measurement of the classifications of the distal radius fracture in the fracture database.|An expert panel (3 in-house experienced specialists) carries out a new fracture classification based on the anonymous radiological images in the interface of the REDCap fracture database. The degree of discrepancy between the expert panel and the database in fracture classifications is analyzed. By evaluating the extracted data, it is analyzed how valid the quality of the collected fracture classifications are, which the medical staff carry out in everyday clinical practice.
224190471|NCT04334356|BEHAVIORAL|Mobile Web App|App for preventing development of posttraumatic stress based on cognitive behavioral techniques.
224190472|NCT00333437|DRUG|Mycophenolate mofetil|
224190473|NCT02032433|DRUG|Extended-Release Naltrexone|Extended-Release Naltrexone (Vivitrol®)
224190474|NCT02032433|DRUG|Buprenorphine-Naloxone|Buprenorphine-Naloxone (Suboxone®)
224190475|NCT06242262|OTHER|Deep neuromuscular block|Patients will receive deep neuromuscular block by using cis-atracurium. After tracheal intubation for 15 min, a cis-atracurium pump will be started, and its rate will be adjusted to maintain a post-tetanic count (PTC) in the 1-2 range.
223591477|NCT05334407|BEHAVIORAL|Dietary intervention tailored to the dental status (dietary intervention, DI)|"Dietary intervention based on the health Belief Model (HBM) with the behavioral goal of increasing an individual's likelihood of food intake regarding fresh vegetables, fresh fruits, and high quality protein for the potential intervention strategies.~Participants will receive 20 minutes' coordinated dietary advice in the form of the slideshow presentation . A pamphlet prepared with reference to the Supplementary Guidelines for Elderly Populations, the 4th edition of the Dietary Guidelines for Chinese will be given to the participant separately. If a participant does not prepare his or her own meals, the person who does the cooking receives the dietary advice as well."
224190476|NCT06242262|OTHER|Moderate neuromuscular block|Patients will receive moderate neuromuscular block by using cis-atracurium. Pump delivery of cis-atracurium will be started when the TOF count returned to 2. The TOF count is maintained between 1 and 3 by adjusting the pump rate
224190477|NCT05347173|DRUG|Dexmedetomidine|patients who will receive 2.5 mL hyperbaric bupivacaine (0.5%) plus Dexmedetomidine (10 µg in 0.5 mL normal saline)
224190478|NCT05347173|DRUG|Nalbuphine|patients who will receive 2.5 mL hyperbaric bupivacaine (0.5%) plus Nalbuphine (1 mg in 0.5 mL normal saline)
224190479|NCT04973527|DRUG|Efficacy of LCAR-T2C CAR-T cells|CD4-directed CAR-T cells administered with lymphoid depletion, and to obtain the preliminary efficacy results in subjects who have been diagnosed with relapsed or refractory CD4 positive T lymphocyte tumor
224190480|NCT02696980|DEVICE|Positive Expiratory Pressure|Patient will exhale against positive expiratory pressure 0 mm or 10 mm while inhaling methacholine
224190481|NCT00475774|BEHAVIORAL|Long-chain (C18:2) and medium chain fatty acid (C8 and C10).|
224190482|NCT03022526|PROCEDURE|CSE|
223500422|NCT05492240|OTHER|i-STRONGER|An 8RM is the dose necessary for most effective strength gains in community-dwelling older adults, and is equivalent to 80% of a one repetition max, which is the maximal load needed to voluntarily complete one repetition of a given exercise with proper form. Clinicians will tailor the intervention for each activity, so the patient achieves 8 repetitions with failure on the 9th repetition. Failure is the inability to complete a repetition through the full, available range of motion without significant compensation. Further, high-intensity dosing requires continuous, volitional effort from the patient; therefore, incorporation of motivational interviewing strategies across sessions will maximize patient effort and self-efficacy.
223500423|NCT05492240|OTHER|Usual Care|Usual Care SNFs will continue with routine collection and documentation of physical performance outcomes (gait speed, SPPB, Modified Barthel ADL Index) as standard practice. Furthermore, a combination of chart reviews and on-site or remote observation will allow for characterization of usual care components for descriptive comparison. Importantly, the Usual Care SNF including the facility, rehabilitation clinicians, and patients will not have access to i-STRONGER materials.
223500424|NCT03495440|BEHAVIORAL|Center Sessions|Program to support relationships and communication between parents and typically developing adolescent siblings of individuals with intellectual and/or developmental disabilities.
223500425|NCT03495440|BEHAVIORAL|At-home|Self-study resources paired with regular contact with study personnel.
223500426|NCT06263738|PROCEDURE|Whole Body Hyperthermia|Participants in the heat exposure alone group will receive a single heat session using the Clearlight Sauna Dome lasting up to 140 minutes
223500427|NCT06263738|PROCEDURE|Cold Water Plunge|Participants in the heat exposure and cold plunge group will receive a single heat session using the Clearlight Sauna Dome lasting up to 140 minutes followed by a cold plunge session in 55 degree (Fahrenheit) water, lasting up to 10 minutes.
223500428|NCT04503122|PROCEDURE|pulmonary vein isolation|pulmonary vein isolation : cryoablation or radiofrequency
224190483|NCT03022526|PROCEDURE|Epidural|
224190484|NCT03022526|DRUG|Bupivacaine / fentaNYL|
223500429|NCT03921541|DRUG|Pegzilarginase|Individualized disease management which includes severe protein restriction, essential amino acid supplementation and the ammonia scavengers when indicated
223500430|NCT03921541|DRUG|Placebo|Individualized disease management which includes severe protein restriction, essential amino acid supplementation and the ammonia scavengers when indicated
223500431|NCT06808854|PROCEDURE|Dental implant treatment (variable-thread implants)|Replacement of a missing tooth with a dental implant with variable-thread implants
223500432|NCT06808854|PROCEDURE|Dental implant treatment (standard implants)|Replacement of a missing tooth with a dental implant with standard implants
224190485|NCT03734874|DIETARY_SUPPLEMENT|hesperidin|500 mg hesperidin as two capsuls
224190486|NCT03734874|OTHER|control|no supplementation
224190487|NCT01013116|BIOLOGICAL|modified allergen extract of house dust mites|subcutaneous injections
224190488|NCT01013116|BIOLOGICAL|placebo|subcutaneous injections
224190489|NCT00591552|DEVICE|Harmonic ACE23P Scalpel|Lymph node dissection
224190490|NCT00591552|DEVICE|Electrocautery|
224190491|NCT00206700|DRUG|Sargramostim (Leukine)|Open Label, 8 week cycle
224190492|NCT05018533|DRUG|TAKC-02|Inhalation Solution
224190493|NCT05018533|DRUG|Placebo|Inhalation Solution
224190494|NCT04768283|OTHER|Additional balance and resistance training - 1|"Additional exercise program with balance and resistance training three times per week.~The balance training included exercises to improve static as well as dynamic balance ability, for 15-20 minutes.~The resistance training included exercises with weights (0,5, 1 or 2 kg), elastic resistance rubbers, intensity 30-50% 1-RM, 10 repetitions with 3 sets and 3 minute rest between sets."
224190495|NCT04768283|OTHER|Additional balance and resistance training - 2|"Additional exercise program with balance and resistance training three times per week.~The balance training included exercises with static and dynamic balance training device Biodex Balance System TM SD, for 15-20 minutes. Exercises are performed with the following programs: Postural stability training, Limits of stability training, Weight shift training, Maze control training, Random control training, Percent weight-bearing training.~The resistance training included exercises with HUR strength training machines, intensity 30-50% 1-RM, 10 repetitions with 3 sets and 3 minute rest between sets. Strength training was performed with the following exercises: Leg press, leg extension, leg abduction, leg adduction."
224190496|NCT00452127|DRUG|PRO131921|Escalating doses by IV infusion
224190497|NCT04718792|DRUG|Psilocybin|A single administration of PEX010 (psilocybin 25 mg, opaque capsule for oral ingestion). PEX010 contains psilocybin (25 mg) naturally extracted from Psilocybe cubensis mushroom fruiting bodies, manufactured under current Good Manufacturing Practices (cGMP)
223500433|NCT04611412|OTHER|Risk Factors|BMI in children and adolescents was compared with percentile charts developed by who for children from 5 to 19 years of age (WHO Growth Reference, 2007). Body mass index was defined as the ratio of body weight (in kg) to body length in the supine position or height in the standing position (m2).
223500434|NCT04975919|DRUG|Decitabine and Cedazuridine|Given PO
223500435|NCT04975919|DRUG|Venetoclax|Given PO
223500436|NCT00000839|DRUG|Didanosine|
223500437|NCT01712464|DRUG|Oxytocin vs. Placebo|FMRI measurement and blood examinations after 26 IU Oxytocin (Syntocinon)or placebo on two consecutive days
223500438|NCT04597112|OTHER|Myofascial Release Technique|Myofascial release focuses on reducing pain by easing the tension and tightness in the trigger points. Therapist will gently massage the myofascia and feel for stiff or tightened areas. Normal myofascia should feel pliable and elastic. The therapist will begin massaging and stretching the areas that feel rigid with light manual pressure. The therapist then aids the tissue and supportive sheath in releasing pressure and tightness. The process is repeated multiple times on the same trigger point and on other trigger points until the therapist feels the tension is fully released.
223500439|NCT04597112|OTHER|Exercise|"Exercise is recommended by physical therapists for most cervical radiculopathy patients.~In this study, a customized exercise program will be applied for patients with cervical radiculopathy."
223500440|NCT02642679|DEVICE|Opticell Ag|Opticell Ag+ applied to STSG donor site
223500441|NCT02763748|PROCEDURE|Laparoscopic endoscopy combined surgery|
223500442|NCT02763748|PROCEDURE|laparoscopic and endoscopic cooperative surgery|
223500443|NCT02763748|PROCEDURE|Single-arch laparoscopic and endoscopic cooperative surgery|
223500444|NCT04411095|OTHER|Measuring thoracic rotation mobility|Measuring the thoracic rotation mobility with a goniometer, from a standardized position
223500445|NCT02148770|DEVICE|Neurofeedback|Networks involved in eating behaviour can be modified by neurofeedback training. We will perform a neurofeedback task using the technology of fMRI-based Brain Computer Interface (BCI). BCI approaches based on real-time fMRI (rtfMRI) allow voluntary regulation of brain regions. For the rtfMRI, a well-established setup will be used which translates the blood oxygen level dependent (BOLD) signal of a specific brain region of interest into a visual signal (e.g. moving bar) in real time using brain voyager® and matlab. The study will include 1 training-sessions In the up-regulation condition subjects will learn to up regulate their dlPFC. In the sham-condition subjects are get the same instructions, however they will receive sham feedback.
223500446|NCT01653262|DRUG|Brivaracetam|
223500447|NCT01454557|OTHER|Auditory Stimuli|Auditory Stimuli during rest and during physical activity
223500448|NCT02975453|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|As prescribed by the treating physician
223500449|NCT00371631|BIOLOGICAL|Insertion of urinary catheters coated with E. coli 83972|All patients in this pilot study were in the treatment arm, which consisted of receiving a urinary catheter that had been pre-coated with a biofilm of E. coli.
224190498|NCT03448562|PROCEDURE|CPVI|ablate around the pulmonary vein orifice
224190499|NCT03448562|PROCEDURE|STABLE-SR|homogenization of the low voltage zones and elimination of the complex electrograms from the transitional zones during sinus rhythm
223500450|NCT03930108|OTHER|SOFA score|Variables of sequential organ failure assessment score, including: P:F ratio; MAP or vasoactive treatment; creatinine or 24-h diuresis; platelet count; serum bilirubin; GCS.
223500451|NCT02182700|DRUG|salbutamol sulfate + ipratropium bromide|120 mcg (salbutamol sulfate) + 20 mcg (ipratropium bromide), inhalation (metered aerosol plus spacer)
223500452|NCT02616952|DIETARY_SUPPLEMENT|Chinese herbal therapy|Participants take a Chinese herbal decoction, Yiqi Suoquan Tang, 200ml orally twice a day for 12 weeks. The Yiqi Suoquan Tang are composed of Radix Astragali 30 g, Radix Codonopsis pilosula 10g, Radix Angelica sinensis 10g, Radix Atractylodis Macrocephalae 10g, Fructus Alpiniae Oxyphyllae 10g, Radix Lindera aggregata 6g, Rhizoma Dioscoreae 10g, pericarpium citri reticulatae 10g, Rhizoma Cimicifuga 10g, Radix Bupleuri 10g, Fructus Rubi 15g, and Semen raphani 10g. All the decoctions are provided by the Department of Pharmacy, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, and are packed in opaque plastic bags with 200 ml for each one.
223500453|NCT02616952|BEHAVIORAL|Pelvic floor muscle training|In intensive exercises, participants are taught how to identify the muscles: 1) identify anal sphincter/feel anus, and try to raise it from chair (without adding abdominal, thigh, and buttock muscles) with a position of sitting; 2) identify levator ani and try to raise vagina from chair (without adding abdominal, thigh, and buttock muscles) with a position of Sitting, bent forward, elbows on knees; 3) contract levator ani with a position of sitting, lying, and standing; 4) contract anal sphincter with a position of sitting, lying, and standing. Once the participants can identify the muscles, they are asked to do a set consists of 10 contractions, each lasting 5 seconds, with a 5 seconds break between contractions. Then they need to do same procedure 3 times daily as the home exercises.
224190500|NCT00887562|DRUG|Idebenone|900 mg/day for 1 month
224190501|NCT00887562|DRUG|Idebenone|2250 mg/day for 1 month
224190502|NCT00887562|OTHER|Placebo|Placebo - No idebenone
224190503|NCT03367676|DRUG|Trastuzumab|Trastuzumab is administered at a loading dose of 8 mg/kg IV followed by 6 mg/kg every 21 days for 4 cycles.
224190504|NCT03367676|DRUG|Docetaxel|Docetaxel 100mg/m2，d1，iv，q3w\*4
224190505|NCT00451191|DRUG|botulinum toxin type A (BoNT/A)|100 unit and 300 unit dosages: Dilute each 100 U vial with 1.3 ml of normal saline. Each reconstituted vial is then drawn up into a single syringe with a total of 4 ml = 300 U. The instrument used to inject the botulinum toxin is an ultrasound device with a transrectal ultrasound probe specially designed for prostate biopsies which has a special canal to introduce and direct a needle in to the selected prostatic area.
224190506|NCT00103389|DRUG|PI-88|PI-88+docetaxel
224190507|NCT00103389|DRUG|docetaxel|docetaxel only
224190508|NCT00542165|DRUG|Alfuzosin|
224190509|NCT05169866|DRUG|Nifekalant|Patients identified with new-onset atrial fibrillation with a sustained duration of greater than 1 minutes and less than 48 hours will be considered for the study. Patients randomized to nifekalant arm will receive a bolus of 0.3mg/kg IV in the first 5 minutes and a maintenance dose of 0.2-0.4mg/kg/h for 24 hours.
223500454|NCT02046187|DIETARY_SUPPLEMENT|Ketogenic Diet|Patients/families meet with the study dietician after surgery to discuss the ketogenic diet (KD), ask questions and plan clinic visits. Before radiation and chemotherapy begins, training takes place about the diet, meal planning and ketone/glucose monitoring. Ketosis will begin with the help of the dietitian one week before radiation begins. The patient will follow a classic 4/1 KD during chemo-radiation, followed by a modified Atkins diet during monthly chemotherapy. At the end of this period patients will follow a normal low carbohydrate diet similar to a Diabetic diet. The dietitian will follow the patient over the course of treatment. The patient will take and record ketone and glucose blood levels daily from start to end of treatment MRI scan, and meet with the dietitian weekly during radiation, at follow-up visits and on an as-needed basis.
224190510|NCT05169866|DRUG|Amiodarone|Patients identified with new-onset atrial fibrillation with a sustained duration of greater than 1 minutes and less than 48 hours will be considered for the study. Patients randomized to amiodarone arm will receive a bolus of 150mg IV in the first 10 minutes and a maintenance dose of 0.5-1mg/min for 24 hours.
224190511|NCT01483365|DRUG|Vaginal tablet Endometrin twice a day|Endometrin 100 mg twice a day
224190512|NCT02316574|BEHAVIORAL|Cognitive Behavioral Coping Skills Therapy|"Cognitive Behavioral Coping Skills Therapy (CBCST) is an individual psychotherapy for alcohol dependence that helps individuals to reduce drinking by addressing the ability to regulate, or cope with alcohol cravings and other emotions that promote alcohol use."
224190513|NCT01972282|DEVICE|WATCHMAN Left Atrial Appendage Closure|
223500455|NCT02046187|RADIATION|Radiation therapy|Patients receive standard dose (60Gy/30 fractions) external beam radiation
223500456|NCT02046187|DRUG|Temozolomide|patients receive standard dose (75 mg/kg/day) temozolomide by mouth daily with radiation for 6 weeks. patients will also have standard maintenance dose (150-200 mg/kg/day) for five days each month for 12 cycles following radiation course.
223500457|NCT01112267|DRUG|Tramadol HCl/acetaminophen Extended Release|Participants will receive 1 tablet containing 75 mg of tramadol HCl and 650 mg of acetaminophen, once daily on Days 1to 3, then 1 tablet twice daily on Days 4 to 7
223500458|NCT01112267|DRUG|Placebo|Participants will receive 1 matching placebo tablet once daily on Days 1 to 3, then 1 tablet twice daily on Days 4 to 7
223500459|NCT01112267|DRUG|Tramadol HCl/acetaminophen Extended Release|Participants will receive 1 or 2 tablets containing 75 mg of tramadol HCl and 650 mg of acetaminophen, twice daily on Days 8 to 28
223500460|NCT01112267|DRUG|Placebo|Prticipants will receive 1 or 2 matching placebo tablet once daily on Days 1 to 3, then 1 tablet twice daily on Days 8 to 28
224190514|NCT03871231|DEVICE|Unpinning Termination Therapy|The Cardialen External Stimulation System (CESS) is the research delivery system for the proprietary Cardialen Unpinning Therapy (UPT) therapy. The CESS is a custom designed and built research device. It is comprised of off-the-shelf commercial components (power supplies, waveform generators, laptop computer, monitor, rack, ECG system, leads, etc.) combined with a custom electrical circuit board and custom software.
224190515|NCT01639625|DRUG|CIGB300|CIGB300: 15 mg, 35 mg and 70 mg All groups will receive CIGB-300 for local application.
224190516|NCT01976325|OTHER|Ottawa Malaria Decision Aid|The Ottawa Malaria Decision Aid is a tool that helps patients become involved in decision making about which malaria prophylaxis pill is right for them to take. The decision aid provides information about the options for malaria chemoprophylaxis, information about the financial costs and time required to adhere to the course of preventative medication, and clarifies personal values. The decision aid is designed to complement counseling from a health practitioner.
224190517|NCT06397248|OTHER|No intervention|No intervention
224190518|NCT03857425|DRUG|Clostridum Butyricum Capsule|Clostridum Butyricum Capsule 3\*420mg,twice daily for 8 weeks
224190519|NCT03857425|DRUG|Bacillus Coagulans Tablets|Bacillus Coagulans Tablets 3\*350mg, three times daily for 8 weeks
224190520|NCT03857425|DRUG|Clostridum Butyricum Capsule plus Bacillus Coagulans Tablets|Clostridum Butyricum Capsule 3\*420mg, twice daily for 8 weeks and Bacillus Coagulans Tablets 3\*350mg, three times daily for 8 weeks
224190521|NCT04275830|BEHAVIORAL|Baseline Surveys|Baseline surveys contained a series of scaled questions, including sociodemographic variables (age, sex, cancer type, and etc), profile of mood states, social well-being, emotional processing and acceptance.
223500461|NCT05378542|BEHAVIORAL|Mobile application usage|The implementation of the research was carried out in two stages. In the first stage, a mobile application was created, in the second stage, training and counseling was given to the experimental group with the mobile application, and no attempt was made to the control group.
223500462|NCT02731859|DEVICE|Insertion of EndoBarrier for approximately one year|Insertion of EndoBarrier for approximately one year then explantation and follow-up
223500463|NCT00398905|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|2,5 mg twice daily (5 mg total daily dose)
223500464|NCT00398905|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|5 mg twice daily (10 mg total daily dose)
223500465|NCT00398905|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|10 mg twice daily (20 mg total daily dose)
223500466|NCT00398905|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|20 mg twice daily (40 mg total daily dose)
224190522|NCT04275830|BEHAVIORAL|Heart rate variability biofeedback|"Participants randomized to the intervention arm will receive exactly the same four digital stories via REDCap, a standardized HRV sensor and accompanying smart phone app, and a 30-minute HRVB training to use the biofeedback signals to generate a resonant frequency pattern of HRV (coherence) after collecting data at baseline in person. Participants will be given a take-home manual and specifically asked to practice their HRVB skills at home for 5 minutes prior to viewing stories once each week and upload a log of their time practiced to the cloud. The main purpose of adding HRVB practice as a priming experience (i.e., to teach participants to practice HRV prior to viewing stories) is to optimize results by focusing patients' and caregivers' skills and experience on HRV as a mechanism of improved emotion regulation, and then combine this achieved coherent pattern with DS intervention."
224309666|NCT06983431|BEHAVIORAL|technology driven self coaching|subject will be provided with the technology driven lifestyle coaching based on the real time data from the wearables
224309667|NCT06983431|BEHAVIORAL|Health coaching|participants will be provided with the health coach (expert) driven lifestyle coaching based on the real-time data from the wearables
224309668|NCT06983431|BEHAVIORAL|Peer coaching|participants will be provided with the peer coach (expert) driven lifestyle coaching based on the real-time data from the wearables
224309669|NCT06983431|BEHAVIORAL|Active Control|participants will be provided with the wearable, but not exposed to any of the coaching strategies. Real-time data provided by the wearable will be available to them.
224309670|NCT06983119|OTHER|Case-finding for Neurocognitive Disorders|The intervention targets individuals reporting cognitive concerns without a prior diagnosis of MCI or dementia, with participants accessing three different settings for evaluation. The first setting involves General Practitioner (GP) offices, where GPs, trained in dementia risk factors and cognitive assessment tools (such as GPcog), will identify at-risk patients and refer them for further evaluation at a Center for Cognitive Disorders and Dementia (CCDD). The second setting is the Dementia Operations Center (COD) Information Desk, a public service where neuropsychologists assess citizens who independently report cognitive disturbances. The third setting includes Open Days, public events aimed at detecting early signs of cognitive decline, where neuropsychologists will assess participants using the Addenbrooke's Cognitive Examination-III (ACE-III) and the LIBRA Index. Individuals identified as at-risk in any of the three settings will be referred for further evaluation at a CCDD.
224309671|NCT06982651|DRUG|MI078|"Dosage Form: Capsule Specification: 25 mg Administration and Dosage: Oral. 1 capsule per dose, once daily. Duration of Treatment: 1 day~Dosage Form: Capsule Specification: 50 mg Administration and Dosage: Oral. 1 capsule per dose, once daily. Duration of Treatment: 1 day~Dosage Form: Capsule Specification: 200 mg~Administration and Dosage: Oral. Options include:~* 1 capsule per dose, once daily;~* 2 capsules per dose, once daily;~* 3 capsules per dose, once daily;~* 4 capsules per dose, once daily; Duration of Treatment: 1 day .~Dosage Form: Capsule Specification: 200 mg~Administration and Dosage: Oral. Options include:~* 1 capsule per dose, twice daily;~* 2 capsules per dose, twice daily; Duration of Treatment: 7 days .~Dosage Form: Capsule Specification: 50mg~Administration and Dosage: Oral. Options include:~\- 5 capsule per dose, Three times a day Duration of Treatment: 3 days ."
224309672|NCT06982651|DRUG|Placebo|Placebo of MI078 Capsule
223500467|NCT00398905|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|30 mg twice daily (60 mg total daily dose)
223500468|NCT00398905|DRUG|Enoxaparin|40 mg once daily (40 mg total daily dose)
223500469|NCT03889795|DRUG|Metformin|Metformin oral pill will be taken daily at breakfast (cohort 1) and breakfast and dinner (cohort 2 and 3).
223500470|NCT03889795|DRUG|Simvastatin|Simvastatin oral pill will be taken daily in the evening.
223500471|NCT03889795|DRUG|Digoxin|Digoxin oral pill will be taken once daily.
223500472|NCT02030639|DRUG|rigosertib|A single dose of 450 mg of rigosertib containing 250 microcuries of carbon 14-labeled rigosertib (\[14C\]-rigosertib) administered as a continuous intravenous (CIV) infusion over 24 hours to healthy volunteers.
223500473|NCT02798952|BIOLOGICAL|Engerix-B Kinder|Subjects previously primed and boosted with 4 doses of Infanrix hexa vaccine in the first 2 years of life received a single dose of Engerix-B Kinder vaccine as an intramuscular (IM) injection into the deltoid region of the non-dominant arm at 14-15 years of age.
223500474|NCT04103606|DEVICE|GGBI: Positive Body Image (Mobile App)|Brief, game-like, training exercise for challenging body image disorder symptoms and associated psychological features
223500475|NCT04745988|DRUG|Lenvatinib 20mg|Lenvatinib will be administered at a dose of 20mg as oral dose, once a day.
223500476|NCT04745988|DRUG|Pembrolizumab|Pembrolizumab will be administered at a dose of 200mg as a 30-minutes IV infusion, Q3W (25 minutes to 40 minutes are acceptable).
223500477|NCT04745988|DRUG|Lenvatinib 8mg|Lenvatinib will be administered at a dose of 8mg as oral dose, once a day.
223500478|NCT04745988|DRUG|Docetaxel|Docetaxel will be administered at a dose of 50mg/m\^2 as a IV infusion, Q2W.
223500479|NCT04745988|DRUG|Oxaliplatin|Oxaliplatin will be administered at a dose of 85mg/m\^2 as a IV infusion, Q2W.
223500480|NCT04745988|DRUG|Levofolinate|Levofolinate will be administered at a dose of 200mg/m\^2 as a IV infusion, Q2W.
223500481|NCT04745988|DRUG|Fluorouracil|Levofolinate will be administered at a dose of 2600mg/m\^2 as a IV infusion, Q2W.
223500482|NCT00420407|DRUG|normal saline control|no vasopressin added to bolus or 5 hour continuous infusion
223500483|NCT00420407|DRUG|vasopressin|vasopressin bolus 4 units followed by continuous infusion 2.4units/hr for 5 hours
223500484|NCT02424786|OTHER|STOPP/START criteria|Evaluation of medication lists
223500485|NCT05044611|DRUG|Anhydrous Amiloride Hydrochloride|"Amiloride is a blocker of ENaC that is administered patients with various disorders, such as primary or secondary hyperaldosteronism. It does not have the market authorization in the indication of lithium-induced NDI.~Dose : 5 mg Pharmaceutical form: Tablets Daily Posology : 10 mg Route of administration : oral Procedures and duration of treatment: 2 months during the double blinded phase and 10 additional months for the open label phase"
223500486|NCT05044611|DRUG|Placebo|Route of administration : oral the control arm will receive a placebo twice daily during 2 months
223500487|NCT04762589|DRUG|RT001|RT001 8.64 g/d (3 capsules TID) for 1 month followed by 5.76 g/d (3 capsules BID) for an additional 5 months
224190523|NCT04275830|BEHAVIORAL|Heart rate variability waitlist and Digital storytelling Control intervention|Four Digital Stories Intervention (4 patient stories about hematopoietic cell transplantation (HCT) over the course of 2 weeks (2 videos per week) with a weekly email notification and reminder phone call. Each story was made with voice, images, and sound (3-5 minutes each). The 4 digital stories patients produced contained the following content: (1) a leukemia patient expressed and controlled her depression and anxiety and described how she dealt with the intensive treatment and recovery through a positive attitude and active coping; (2) a mother of 3 children, who was experiencing severe pain due to MS, coped with HCT through family support and positive reframing; (3) a lymphoma patient coped with the HCT procedures by praying during the treatment; and (4) a father of young twins had a HCT twice, and his wife helped him cope with emotional distress through open communication and expressing emotions.Participants will receive a 30-minute HRVB training session at T2.
224190524|NCT05141422|DRUG|SHR2150 tablet、efavirenz|SHR2150 tablet single dose, Efavirenz single dose.
224190525|NCT02869373|BEHAVIORAL|spinal stabilizaton exercise|In Exercise group, spinal stabilization exercise program was carried out 3 days a week for 8 weeks.
224190526|NCT00846573|DRUG|Hyperpolarized Helium-3|Patients will be required to breath in individual 1 liter bags of gas while in an MRI to produce lung images. These bags of gas are each made up of 333mL of Helium-3 gas and 667mL of Nitrogen. Three bags will be administered to acquire three different scans.
224190527|NCT01225458|OTHER|shorter tests|Geriatric evaluation with MMS, GDS and ADL scoring
224190528|NCT01225458|OTHER|initial complete geriatric tests|evaluation of cognitive functions, psychological functions, dependency in activities, vision, audition, mobility and nutritional status : only at the first visit
224190529|NCT01225458|OTHER|follow-up complete geriatric tests|evaluation of cognitive functions, psychological functions, dependency in activities, vision, audition, mobility and nutritional status : every 6 month for 3 years
224190530|NCT02077868|OTHER|Usual Maintenance|Usual maintenance therapy according to local investigator's practice, e.g. treatment break, reduced treatment, continued treatment, and other
224190531|NCT02077868|DRUG|MGN1703 treatment|MGN1703 will be used as single agent maintenance treatment
224190532|NCT04851704|BEHAVIORAL|Tuning in to Kids|A parenting program that includes 6 group supervisions of parents, where emotion coaching and promotion of kids emotional competence are main focus.
224190533|NCT00455572|BIOLOGICAL|Immunotherapeutic GSK1572932A|Intramuscular injection, 8 doses
224190534|NCT00455572|DRUG|Cisplatin (CDDP)|Four cycles with doses based on patient's body surface area, intravenous administration
224190535|NCT00455572|DRUG|Vinorelbine|Four cycles with doses based on patient's body surface area , intravenous administration
224190536|NCT00455572|PROCEDURE|Radiotherapy|Regimen will be based upon the site's own standard procedures
224190537|NCT04971486|BEHAVIORAL|Motor Sequence Task|"Participants will be seated at a laptop with the right hand on a standard joystick. The movement of the joystick will move a cursor on the computer screen. Targets will appear on the laptop screen as a circle in one of twelve spatially distinct locations. The learner must move the joystick cursor to inside the target before the next target will appear."
224190538|NCT04538716|PROCEDURE|transconjunctival lower blepharoplasty|transconjunctival lower blepharoplasty associated with stromal vascular fraction gel (SVF-gel)
224190539|NCT02789241|BIOLOGICAL|Endotoxin|Reference Endotoxin is a purified LPS prepared from Escherichia coli O:113 (US Standard Reference Endotoxin); Clinical Center Reference Endotoxin (CCRE) Lot #94332B1 manufactured and vialed under GMP guidelines by List Biological Labs, Inc., 540 Division St., Campbell, CA 95008, for the Pharmacy Development Service, Clinical Center, National Institutes of Health, Bethesda, MD, USA. The material has been approved by the FDA (Food and Drug Administration) for 'Investigational Use Only'. This specific Lot from List Biological Labs specified for use in this study contains 1 mcg/vial.
224190540|NCT02789241|OTHER|Placebo|Normal saline will be administered as the control to evaluate the effects on the biomarkers over time and to compare the responses following LPS to those following the control injection of normal saline.
224309673|NCT06983145|OTHER|Olive Leaf tea|Individuals will consume 2-3 pieces of biscuits with caramel coloring (total 120 g) and a glass (250 mL) of tea (natural mineral water with 1.25 g. dried olive leaves)
224190541|NCT02872584|DRUG|Prednisone|prednisone treatment as required by dermatological condition (pemphigus/pemphigoid)
224309674|NCT06982053|DIAGNOSTIC_TEST|Received 68Ga-NOTA-GZP PET scanning|Received twice 68Ga-NOTA-GZP PET scanning before neoadjuvant therapy and radical surgery.
224309675|NCT06983795|PROCEDURE|PFO closure using approved PFO closure devices, Surgical PFO closure|PFO closure using approved PFO closure devices, Surgical PFO closure
224309676|NCT06983795|DRUG|Medical management|"Antiplatelet therapy~* ASA, also called acetylsalicylic acid (Aspirin, Asaphen, Entrophen, Novasen)~* clopidogrel (Plavix)~* ticagrelor (Brilinta)~* dipyridamole (Persantine)~* cilostazol~Anticoagulation therapy~* apixaban (Eliquis)~* dabigatran (Pradaxa)~* edoxaban (Lixiana)~* rivaroxaban (Xarelto)~* warfarin (Coumadin)"
223591478|NCT05334407|PROCEDURE|Delayed implant-supported full-arch fixed dental prostheses（dental intervention,DE）|Delayed (4 months) implant-supported full-arch fixed dental prostheses in at least one jaw and appropriate treatment in the opposing jaw regarding periodontal diseases, caries, replacement of missing teeth and soft tissue disorders to get at least 10 pairs of occluding teeth. The intervention is designed to provide rehabilitation of masticatory function.
224190542|NCT05732610|DIAGNOSTIC_TEST|MGC Health COVID-19 & Flu A+B Home Multi Test|self-collected direct anterior nares swab samples
224309677|NCT06984315|OTHER|The effects of the groups on perioperative inflammation changes were compared.|Between January 2020 and April 2025, data from 849 patients who underwent total knee arthroplasty were retrospectively reviewed. Preoperative hemogram values were obtained during routine anesthesia clinic evaluation, typically one day prior to surgery. Postoperative hemogram samples were collected on the day of surgery (postoperative day 0), within 4 to 12 hours after the procedure. Blood parameters included neutrophil, lymphocyte, monocyte, and platelet counts. Based on these values, inflammatory indices such as the neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), systemic immune-inflammation index (SII), and systemic inflammatory response index (SIRI) were calculated.
224309678|NCT06983977|OTHER|Measurement of physical activity|Measurement of physical activity by accelerometer
224190543|NCT05732610|DIAGNOSTIC_TEST|MGC Health COVID-19 & Flu A+B Home Multi Test (2 to 13 y/o)|adult lay user collected anterior nares swab sample
224190544|NCT02399046|DEVICE|Total Knee System made in China (Sigama, CoCr, PFC)|SIGAMA PS FEMUR; TIB tray Cem Cocr; SIGAMA STAB XLK INS; PFC SIG ROUND DOME PAT 3PEG
224190545|NCT02399046|DEVICE|Total Knee System made outside of China (Sigama, NP, PFC)|SIGAMA PS CEM FEM; PFC MOD TIB TRAY NP; SIGAMA STAB XLK INS; PFC SIGAMA/RD/DOME PAT
224190546|NCT04717323|DEVICE|mPAD (or TPAD) Pelvic Assist Device|Gait retraining device that applies pelvic forces and measures response
224190547|NCT04717323|DEVICE|No Intervention|Gait with no pelvic assistance
224190548|NCT01553708|DRUG|Epidermal growth factor with silver sulfadiazine cream|Compare the duration for complete partial thickness burn wound healing between sample (epidermal growth factor with silver sulfadiazine cream) and control (silver zinc sulfadiazine cream)
224190549|NCT01553708|DRUG|Silver zinc sulfadiazine cream|Compare the duration for complete partial thickness burn wound healing between sample (epidermal growth factor with silver sulfadiazine cream) and control (silver zinc sulfadiazine cream)
224190550|NCT04943523|DIETARY_SUPPLEMENT|Krill Oil|Krill oil supplements 4g/day
224190551|NCT04943523|DIETARY_SUPPLEMENT|Vegetable Oil|vegetable oil supplements 4g/day
224190552|NCT03575806|COMBINATION_PRODUCT|TACE plus autologous Tcm immunotherapy|"TACE:transcatheter arterial chemoembolization.~Autologous Tcm immunotherapy: to collect patient's own immune cells and then given back to the patient after amplified in vitro."
224190553|NCT03575806|PROCEDURE|TACE|TACE:transcatheter arterial chemoembolization.
224190554|NCT00219349|BEHAVIORAL|Cognitive Behavioral Therapy|14 weekly sessions of individualized CBT
224190555|NCT00219349|DRUG|escitalopram|10-20 mg per day for 12 weeks
224190556|NCT01737203|DRUG|Viagra|50 mg tablet on Day 1 of each period
224190557|NCT01737203|DRUG|sildenafil ODT|50 mg tablet on Day 1 of each period
224190558|NCT01737203|DRUG|sildenafil ODT|50 mg tablet on Day 1 of each period
224190559|NCT06450990|DRUG|BGY-1601-VT|Live biotherapeutic product. The active product ingredient of the Investigational Medicinal Product (IMP) is the bacterial strain Lacticaseibacillus rhamnosus Lcr35.
224309679|NCT06983977|OTHER|Digital nudging|Digital feedback and nudging to participants (patients) and staff, based on participants' physical activity measurements, aiming to increase patients' physical activity and reduce sedentary time
224309680|NCT06977620|OTHER|Closed kinetic chain exercises|Closed kinetic chain (CKC) exercises emphasize weight-bearing movements where the distal segment of the extremity is fixed, and motion occurs as the proximal segment moves over the stabilized distal segment.
224309681|NCT06977620|OTHER|Weight shifting exercises|Weight-shifting is a crucial aspect of dynamic postural control, which refers to the ability to maintain one's bodyweight within the base of support. Lateral weight-shifting, in particular, is essential for maintaining posture under dynamic conditions and is commonly performed in various activities of daily living
224309682|NCT06977620|OTHER|Complete Decongestive Therapy|CDT includes (skin care, manual lymphatic drainage, compression bandages, compression garments and exercises).
223500488|NCT04762589|DRUG|Placebo|Placebo Comparator: Placebo Inactive comparator capsule 960 mg/capsule: 3 capsules TID for 4 weeks, followed by 3 capsules BID for the remaining 20 weeks.
223500489|NCT04566731|DEVICE|Transcranial Direct Current Stimulation (tDCS)|tDCS is a type of non-invasive brain stimulation in which small electrical currents are applied to the scalp via 2 electrodes. The current, 1.5 mA, is approximately of the same intensity as the current provided by a 9-volt battery. To deliver the current, electrodes that are placed in saline soaked sponges. They will be attached to the left side of your head; they will be held in place with an elastic cap. For both real and sham stimulation the electrodes will be placed on the scalp.
224190560|NCT06450990|OTHER|PLACEBO|Placebo
223512017|NCT03656614|DRUG|Saline 0.9%|At the end of surgical procedure at a depth of neuromuscular blockade at the reappearance of train-of-four 0.3, single intravenous injection of saline 0.9%.
223512018|NCT00259701|DEVICE|Laser Doppler Flowmetry with topical acetylcholine and nitroglycerin|
223512019|NCT02924402|BIOLOGICAL|XmAb13676|Biological
224190561|NCT02772159|DRUG|TD-4208|One dose each of treatments A: \[14C\] TD-4208 20 μg IV administered in a fasted state over 30 minutes. B: \[14C\] TD-4208 200 μg oral solution administered in a fasted state.
224190562|NCT01634399|DRUG|Torrent's Quetiapine Fumarate Tablets|
224190563|NCT05246852|BEHAVIORAL|healthy lifestyle education|A total of 6 sessions on physical activity, nutrition, substance abuse, sexual life, check-up, accidents and injuries will be organized for the adolescents in the intervention group. The sessions will be organized every other week. Each session will be conducted in three stages. First Stage: The researcher will provide training on the subject of the session for nearly 15 minutes. Second Stage: The researcher will show animation film (nearly 3 to 5 minutes) developed by him/her related to the session. Third Stage: Groups of six will be created for the Philips 66 technique application and a spokesman will be chosen. Each group will have an online meeting and discuss the session subject in six minutes under the administration of the researcher. The spokesman of each group will present the discussion outcome in the big group meeting at the end of the discussion. The researcher will summarize the subject after the presentation of each spokesman and terminate the session.
224190564|NCT05461742|BEHAVIORAL|Physical activity intervention|While the final content and structure of the intervention will be informed by community advisory board, participants will receive a culturally adapted, Social Cognitive Theory and Transtheoretical Model-based PA intervention. The evidence-based, theory guided aerobic physical activity intervention will systematically build upon the investigators' prior studies and includes the following components: goal setting, in-person physical activity sessions, and written materials.
224190565|NCT00270400|DRUG|nesiritide|
224190566|NCT03361709|DRUG|Dexamethasone|Dexamethasone will be injected intracamerally at the conclusion of Phacoemulsification
224190567|NCT03361709|DRUG|Saline Solutions, Intraocular|Only saline will be injected intracamerally at conclusion of Phacoemulsification
224190568|NCT05352607|DEVICE|Transcutaneous Electrical Nerve Stimulation (TENS)|"Put the patient in comfort position as long sitting on bed with a supported back and a pillow under the forearm, clean the skin by alcohol swab, setup the parameter, put a gel on electrodes then placed the negative electrode (black wire) over biceps belly and positive electrode (red wire) 3 cm distally from negative electrode , turn on TENS device .~With increase the intensity gradually until patient feel a tingling sensation (no muscle contraction) and every 10 minutes ask patient about the feeling until complete 30 minutes."
224190569|NCT05352607|OTHER|Conventional physiotherapy treatment|Application of a hot pack for 20 minutes to enhance muscle flexibility and get overall spastic muscle relaxation. Anti-spastic muscles (elbow extensors) facilitation: tapping followed by movements (three sets of 15 repetitions per session). Hand weight-bearing with bodyweight (two 5-minute per session). Passive stretching of tight muscles (elbow flexors) is used (this must be a slow and gradual stretch for 20 seconds, followed by 20 seconds of rest, five times per session). Upper-limb active exercises should be done gradually. include (finger flexion and extension exercises, elbow and shoulder (three sets of 20 reps for each session).
224190570|NCT06364007|DRUG|HAIC+STRIDE+Len|patients will be administrated with STRIDE plus lenvatinib (8 mg or 12 mg) once daily plus HAIC- modified FOLFOX (oxaliplatin, 85 mg/m2; leucovorin, 400 mg/m2; 5-fluorouracil bolus, 400 mg/m2 on day 1; 5-fluorouracil infusion, 2400 mg/m2 for 46 h).
224190571|NCT02066909|DRUG|0.15 mg PF-06649751|Oral dosing of 0.15 mg PF-06649751 extemporaneously-prepared solution given once-daily for 14 days.
224190572|NCT02066909|DRUG|0.5 mg PF-06649751|Oral dosing of 0.5 mg PF-06649751 extemporaneously-prepared solution given once-daily for 14 days.
224190573|NCT02066909|DRUG|0.5 mg PF-06649751|Oral dosing of tablets up to 0.5 mg PF-06649751 given once-daily for 14 days.
224190574|NCT02066909|DRUG|1.5 mg PF-06649751|Oral dosing of tablets up to 1.5 mg PF-06649751 given once-daily for 14 days.
224190575|NCT02066909|DRUG|1.5 mg PF-06649751 21 Days|Oral dosing of tablets up to 1.5 mg PF-06649751 given once-daily for 21 days.
224190576|NCT02066909|DRUG|3.0 mg PF-06649751|Oral dosing of tablets up to 3.0 mg PF-06649751 given once-daily for 28 days.
224190577|NCT02066909|DRUG|5.0 mg PF-06649751|Oral dosing of tablets up to 5.0 mg PF-06649751 given once-daily for 28 days.
224190578|NCT02066909|DRUG|8.0 mg PF-06649751|Oral dosing of tablets up to 8.0 mg PF-06649751 given once-daily for 28 days.
224190579|NCT02066909|DRUG|1.5 mg PF-06649751 in healthy Japanese subjects|Oral dosing of tablets up to 1.5 mg PF-06649751 given once-daily for 14 days given in healthy Japanese subjects.
224309683|NCT06982976|PROCEDURE|ALA-PDT|use ALA\_PDT to treat the disease
224309684|NCT06983873|BEHAVIORAL|adapted Canadian C-Spine rules|The CCRa are decision rules for pre-hospital cervical spine collar immobilization. They include three high-risk criteria indicating imaging, 5 low-risk criteria allowing assessment of cervical spine rotation, and finally the ability of patients to achieve limited active rotation. They have been designed and validated to avoid immobilization during transport to the emergency department without any significant cervical injury being missed.
224309685|NCT06983197|DIAGNOSTIC_TEST|blood test|Blood samples are drawn every 3-5 days in the RRT group but only once in the control group
224309686|NCT06683573|BEHAVIORAL|3D Kidney model|Brief provider led counseling and education on Chronic Kidney Disease (CKD) and hypertension guided by use of 3D kidney model visual aid
223591479|NCT05334407|BEHAVIORAL|Delayed dietary intervention tailored to the dental status (dietary intervention, DI)|"Dietary intervention based on the health Belief Model (HBM) with the behavioral goal of increasing an individual's likelihood of food intake regarding fresh vegetables, fresh fruits, and high quality protein for the potential intervention strategies.~Participants will receive 20 minutes' coordinated dietary advice in the form of the slideshow presentation . A pamphlet prepared with reference to the Supplementary Guidelines for Elderly Populations, the 4th edition of the Dietary Guidelines for Chinese will be given to the participant separately. If a participant does not prepare his or her own meals, the person who does the cooking receives the dietary advice as well."
223746186|NCT03567707|DRUG|C-section - Placebo Seeding|"Mother-infant pair randomized to placebo microbiota intervention. As soon as the infant is delivered, the infant will be brought to the neonate lamp, and unless the obstetrician or pediatric staff believes it is not in the best interest of the infant, s/he will be swabbed with the placebo gauze. Swabbing will take place ideally within 1 minute after delivery (but no longer than 5 minutes). The swabbing should take approximately 15 seconds. Infants will only undergo the seeding procedure once.~Additional Intervention:~Following the seeding procedure, infants will then receive the standard detailed examination for newborns and standard of care, except that the first infant bath will occur at least 12 hours after delivery."
224190580|NCT02716415|DRUG|Calmoseptine Ointment|"A full structured skin care regimen is provided in a consistent fashion either by study personnel or by the participant's primary carer (family or ward staff) at each diaper change. Study nurse sub-investigator visit each participant twice per nursing shift (six times per day) either to deliver the care regimen or to observe that it is being delivered.~The regimen includes:~* regular diaper changing,~* gentle cleansing~* application of the trial ointment"
224190581|NCT02716415|DRUG|Destin Maximum Strength 40% Zinc|"A full structured skin care regimen is provided in a consistent fashion either by study personnel or by the participant's primary carer (family or ward staff) at each diaper change. Study nurse sub-investigator visit each participant twice per nursing shift (six times per day) either to deliver the care regimen or to observe that it is being delivered.~The regimen includes:~* regular diaper changing,~* gentle cleansing~* application of the trial ointment"
224190582|NCT04243811|DEVICE|Diode Laser|LLLT with dental needle for local anesthesia during dental treatment
224190583|NCT04243811|OTHER|topical anesthesia|topical anesthesia with dental needle for local anesthesia during dental treatment
224190584|NCT06724861|OTHER|Explicit Sensory Retraining for the lower extremities|Sensory retraining of detection, discrimination, quantification of a stimuli and recognition of stimuli and objects with the leg and mainly with the foot. Top-down awareness of bottom-up sensory experience in the treatment session and in everyday life.
224190585|NCT06724861|OTHER|no treatment|Usual care
224190586|NCT01761461|DRUG|TS-1, oxaliplatin|
224309687|NCT06683573|BEHAVIORAL|Standard medical treatment|Standard provider led counseling and education on CKD and hypertension
224309688|NCT03469505|BEHAVIORAL|COPES|Cooperative Pain Education and Self-Management for chronic pain therapy.
224309689|NCT03469505|BEHAVIORAL|CBT-CP|Cognitive Behavioral Therapy for Chronic Pain
224190587|NCT04114461|DRUG|HL-TOF tab. 5mg|HL-TOF
224190588|NCT04114461|DRUG|Xeljanz tab. 5mg|Xeljanz
224190589|NCT00135811|DRUG|Cyclosporin|Participants assigned to this group will initiate treatment with CSA, 5-6 mg/kg per day with a 250 mg/day maximum starting dose, divided into two daily doses. The CSA dose will be adjusted based on drug levels determined at specified study visits in order to achieve a 12-hour trough concentration in the therapeutic range of 100-250 ng/ml.
224190590|NCT00135811|DRUG|MMF and Dexamethasone|"MMF, 25-36 mg/kg per day with a maximum dose of 2 g/day divided into two daily doses. The dose range reflects the use of fixed size (250 mg) capsules and application of defined daily doses to specific weight ranges (see Table below). In younger children or those participants who are unable to swallow capsules, a liquid formulation will be used to provide 36 mg/kg per day to a maximum of 2 g per day. The starting MMF dose will be 0.5-0.67 of the full dose for 2 weeks before advancing to the full dose for the duration of the 12-month treatment period.~Dexamethasone, 0.9 mg/kg per dose, with a maximum dose of 40 mg"
223591480|NCT02567565|OTHER|LipiView|tear film lipid layer thickness measured by LipiView interferometer (TearScience Inc, Morrisville, NC)
224190591|NCT00220311|DRUG|Fludarabine Phosphate (Fludara)|6 cycles (1 cycle: 5 treatment days every 28 days)
223500490|NCT04566731|DEVICE|Sham tDCS|tDCS is a type of non-invasive brain stimulation in which small electrical currents are applied to the scalp via 2 electrodes. During sham stimulation, the current, 1.5 mA, will be delivered for a short amount of time and then turn-off. To deliver the current, electrodes that are placed in saline soaked sponges. They will be attached to the left side of your head; they will be held in place with an elastic cap. For both real and sham stimulation the electrodes will be placed on the scalp. Most people cannot tell the difference between real and sham stimulation.
223500491|NCT04566731|BEHAVIORAL|Modified Contraint-Induced Language Therapy (mCILT)|Modified constraint-induced language therapy (mCILT) is a behavioral language therapy that invokes use-dependent learning in communicative interactions by requiring spoken output and restricting use of alternative forms of communication, such as gestures, as a substitute for spoken output. Other key elements of CILT include massed practice of goal-directed speech and shaping of desired responses by increasing response demands as participants improve. MCILT differs from traditional constraint-induced language therapy (CILT) in three ways: 1) it will be done as an individual therapy with the examiner in the role of a communication partner; 2) treatment will be delivered in short sessions (1 hour rather than a more typical 3-4 hour session); 3) targeting nouns + semantically related verbs to generate noun + verb phrases in treatment, a modification that may be better suited to addressing syntactic structure.
223591481|NCT02290041|DRUG|Infusion of MSC|Intravenous infusion of 4 doses of adipose tissue derived allogeneic adult mesenchymal stem cells (1 million MSCs/Kg, weeks 0-4-8-20).
223591482|NCT02290041|DRUG|Infusion of placebo|Infusion of placebo (weeks 0-4-8-20)
223500492|NCT04928339|DRUG|Bupivacaine Injection|10mL of 0.25% bupivacaine
224190592|NCT01809847|DRUG|Ofatumumab|"Study treatment comprises eight weeks of induction therapy with ofatumumab in combination with high-dose dexamethasone. The first dose of ofatumumab is 300 mg followed by seven infusions of 2000 mg ofatumumab. Dexamethasone will be given orally at doses of 40 mg on days 1-4 in weeks 1, 3, 5, and 7. Patients who achieved a CR, PR shall proceed to maintenance therapy. Maintenance therapy consists of 6 monthly infusions of 1000 mg ofatumumab.~An HLA-matched sibling donor or HLA-matched unrelated donor can be identified for approximately 70% of patients. Donor search will be completed within six weeks for 95% of the patients. Patients with a donor will proceed to allogeneic HCT as soon as possible prior to, or during maintenance therapy."
224190593|NCT02777554|DRUG|Apremilast IR|Apremilast immediate release tablet
224190594|NCT02777554|DRUG|Apremilast XL|Apremilast extended release formulation tablet
224190595|NCT00270205|BIOLOGICAL|LC002 standard vaccination|0.1 mg DNA/participant, 0.8 ml total administered subcutaneously
224190596|NCT00270205|BIOLOGICAL|LC002 high-dose vaccination|0.4 mg DNA/participant, 3.2 ml total administered subcutaneously
223500493|NCT04928339|DRUG|Liposomal bupivacaine|15mL of 133mg liposomal bupivacaine
223500494|NCT04928339|OTHER|Saline|25mL saline control
223500495|NCT04536103|DIAGNOSTIC_TEST|MRI|Observational Study of novel MR imaging and image processing techniques that will provide reliable and fully quantitative evaluation of inflammation, chronic structural changes and vascularity in healthy patients and patients with ACL injury.
223500496|NCT05638737|DRUG|AZD4831|AZD4831
223500497|NCT05638737|OTHER|Placebo|Placebo
223500498|NCT06425081|DIETARY_SUPPLEMENT|Limosilactobacillus reuteri AMBV339|Limosilactobacillus reuteri AMBV339 is a probiotic strain
223500499|NCT06425081|DIETARY_SUPPLEMENT|Humiome B2|Colon-delivered Riboflavin
223500500|NCT06425081|DIETARY_SUPPLEMENT|Limosilactobacillus reuteri AMBV339 + Humiome B2|Combination of supplements used in arm 1 and 2
223500501|NCT06425081|DIETARY_SUPPLEMENT|Placebo|Microcrystalline cellulose
223500502|NCT03990844|DIETARY_SUPPLEMENT|Okra seed|Noodle enriched with 10% and 20% Okra seed flour.
223500503|NCT05743374|OTHER|Normal diet|These patients will be given advice about a normal healthy diet.
223500504|NCT05743374|DIETARY_SUPPLEMENT|E400 elimination|Patients in the intervention group will be given advice how to eliminate E440 additives with regard to carragenan, CMC and polysorbates.
223500505|NCT00142597|DEVICE|Acupuncture|"Involves the insertion and manual stimulation of thin acupuncture needles into specific points in the body.~Fibromyalgia participants will be randomized to receive 9 acupuncture treatments over the course of four weeks.~All participants will be scanned twice using the fMRI scanner. The PET portion of the study is optional."
223500506|NCT00142597|OTHER|Sham treatment|"Fibromyalgia participants will be randomized to receive 9 sham treatments over the course of four weeks.~All participants will be scanned twice using the fMRI scanner. The PET portion of the study is optional."
223500507|NCT01482728|DRUG|Dasatinib|100 mg dasatinib, the day before surgery and the day of surgery
223500508|NCT01482728|DRUG|Dasatinib|200 mg dasatinib the day before surgery and the day of surgery
223500509|NCT04633447|DRUG|Guselkumab|Guselkumab will be administered subcutaneously.
223500510|NCT04633447|DRUG|Placebo|Matching placebo will be administered subcutaneously.
223500511|NCT06438471|DRUG|EC5026 oral tablet|"There will be two ascending dose regimens of EC5026, which will be administered over two consecutive Treatment Periods. During each Treatment Period, EC5026 will be administered orally once daily for 7 consecutive days, with a loading dose on Day 1 and a maintenance dose on Days 2-7 of each treatment period. All study subjects will be enrolled in both Treatment Periods and will receive both dose regimens consecutively, for a total duration of 14 days.~Oral doses of EC5026 tested in each Treatment Period:~Treatment Period 1: 6 mg loading dose on Day 1 / 2 mg Maintenance dose on Days 2-7 Treatment Period 2: 8 mg loading dose on Day 8 / 4 mg Maintenance dose on Days 9-14"
223500512|NCT06438471|DRUG|Placebo oral tablet|Participants will be administered a matching oral placebo for 14 consecutive days.
223591483|NCT01421953|DEVICE|CT-simulation and 4D PET-CT|Patients will do a CT-simulation and 4D PET-CT in radiotherapy treatment position. The target volumes and the dosimetries obtained with both modalities will be compared.
224190597|NCT00270205|BIOLOGICAL|LC002 placebo vaccination|Placebo vaccination administered subcutaneously
224190598|NCT05872165|DEVICE|phonophoresis|1 MHz, 1 W/cm2continuous mode of ultrasound therapy for 5 min. using ozonated gel as a coupling medium
224190599|NCT05872165|OTHER|conventional physical therapy|conventional TENS (100 Hz) for 30 min - hot pack for 20 min- stretching and strengthening exercises, wrist rest splints 3times per week for 4 weeks.
223500513|NCT05417776|DRUG|[68Ga]CBP8|An injection of up to 350 MBq of \[68Ga\]CBP8 will be administered intravenously followed by PET-MRI.
223500514|NCT05417776|DRUG|Dotarem|Dotarem will be administered during MRI portion of study.
223500515|NCT05793125|DEVICE|Ultrasonography|"A full obstetrics ultrasound scan will be performed within 24 hours before delivery to document fetal biometry, estimated fetal weight and correlate it to fetal growth charts to exclude IUGR, amniotic fluid index and umbilical artery Doppler studies.~Fetal echocardiography will be done.Pulmonary artery Doppler ﬂow waveforms, including pulsatility index, resistance index, systolic-to-diastolic ratio, peak systolic velocity, and acceleration time to ejection time (At/Et) ratio will be measured in the main pulmonary artery."
223500516|NCT06173843|OTHER|PFAS / heavy metal testing, exposures|PFAS / heavy metal concentrations, exposure survey
223500517|NCT06957847|DEVICE|Blood pressure measurement|The patient will be measured alternatively with a reference mercury sphygmomanometer (four times) and the device under study (3 times)
223500518|NCT06957210|BEHAVIORAL|EMDR|Participants will receive structured EMDR therapy sessions conducted by trained therapists following standard EMDR protocols. Sessions will occur weekly over a 6 week period.
223500519|NCT06957210|DRUG|SSRIs|Participants will receive pharmacotherapy with an SSRI prescribed according to standard clinical guidelines for PTSD, monitored by a psychiatrist over a 6-week period.
223500520|NCT04636307|OTHER|Biomarkers|To identify biomarkers obtained using non-invasive procedures that can predict disease progression and progression to sight-threatening stages of the disease and to characterize the retinal changes that occur in NPDR.
223500521|NCT03641924|BEHAVIORAL|Cognitive Processing Therapy|Cognitive Processing Therapy is an evidence-based psychotherapy for PTSD.
223512020|NCT03246594|DEVICE|Placement of oesophageal probe for temperature measurement|The oesophagus probe is used to measure the intraluminal temperature inside the oesophagus
223512021|NCT03246594|DEVICE|Power limitation of RF generator|no probe utilized; Limit the RF Generator Output to 25W
223512022|NCT00666575|DRUG|Gabapentin|Gabapentin 500 mg oral capsule 30 minutes prior to bedtime for 28 days
223512023|NCT00666575|DRUG|Placebo|Matched placebo oral capsule 30 minutes prior to bedtime for 28 days
223512024|NCT04269187|DRUG|Theophylline|Theophylline oral 200 mg daily for 12 days
223512025|NCT02719366|DEVICE|comfilcon A Extended Range test lens|contact lenses
223512026|NCT02719366|DEVICE|comfilcon A control lens|contact lenses
223512027|NCT03378934|DRUG|Berberine|Berberine 200 mg twice daily for 4±1 weeks (Stage 1); then, 300 mg twice daily for 4±1 weeks (Stage 2); then, 400 mg twice daily for 4 weeks (Stage 3).
223512028|NCT03378934|DRUG|Standard treatment|Standard treatment for 12±1 weeks.
223512029|NCT03378934|DRUG|Aspirin|Aspirin 100 mg once daily for 12±1 weeks.
223512030|NCT03378934|DRUG|Clopidogrel|Clopidogrel 75 mg once daily for 12±1 weeks.
223512031|NCT01400152|DEVICE|Additional active warming|Chemical heat pad applied to the upper torso
223512032|NCT04130425|DEVICE|Hely & Weber MTC Fracture Brace|Prefabricated muenster orthosis
223512033|NCT04130425|DEVICE|Thermoplastic orthosis|Muenster orthosis fabricated out of thermoplastics and secured with Velcro
223512034|NCT04130425|DEVICE|Delta cast orthosis|Muenster orthosis fabricated out of Delta Cast and secured with Velcro
223512035|NCT02241915|PROCEDURE|Open Colorectal Surgery|
223512036|NCT02241915|PROCEDURE|Laparoscopic Surgery|
223512037|NCT05377814|BEHAVIORAL|Volitional help sheet|Participants are asked to choose from a list of strategies for increasing physical activity
223512038|NCT01946646|DRUG|S-1-CCRT|
223512039|NCT06232031|BEHAVIORAL|Active Breathing Exercises|Active breathing exercises aim to enhance the strength and flexibility of respiratory muscles through a series of exercises, improving breathing patterns and increasing respiratory efficiency. The following are common components of active breathing exercises: 1) Deep Breathing. 2) Chest Expansion. 3) Diaphragmatic Breathing. 4) Coughing Techniques. 5) Expiratory Resistance Training. 6) Gradual Increase in Activity.
223512040|NCT06010108|BEHAVIORAL|Heroes for Her|Market outreach intervention- daily awareness creation through public market announcements, and distribution of educational fliers in local dialects. Community women will also be involved in the spread awareness through door to door approach. Thee will be repeated radio jingles to promote awareness. Interested women and girls will be provided with screening and vaccination services at a designated community health facility. All samples will be returned to the facility by the women and sent to a designated laboratory for testing. Participants contact information will be collected for follow up
224190600|NCT03662477|BIOLOGICAL|NK cells|"NK cells were generated in good manufacturing practice (GMP) condition. In brief, PBMCs were isolated from 50mL patient's blood with Ficoll-Hypaque(Morecell Biomedical Co. Ltd., Shenzhen, China). Then the Human NK Cell Culture Kit (Cat. No.~MCF-004, Morecell Biomedical Co. Ltd., Shenzhen, China) and Serum-free Medium for NK Cells (MCM-002, Morecell Biomedical Co. Ltd., Shenzhen, China) was used for induction of NK cells according to the manufacturer's instructions. Three days before NK cell transfusion, the NK cells were sampled and sent to detect the NK cell quality."
224190601|NCT00066573|DRUG|anastrozole|Given orally
224190602|NCT00066573|DRUG|exemestane|Given orally
224190603|NCT02800382|OTHER|Take samples|Fiberoptic bronchoscopy was performed under local anaesthesia and sedation for taking Bronchoalveolar Lavage Liq for Paraoxanase activity. Blood samples were taken too.
224190604|NCT04270331|OTHER|PADS protocol|Assessment and management per PADS protocol
224190605|NCT02510131|BEHAVIORAL|Exercises|To compare Hyacinth exercise with Kegel's exercise in improving urinary incontinence
224190606|NCT00165191|DRUG|Doxorubicin|
224190607|NCT00165191|DRUG|Cisplatin|
224190608|NCT00165191|DRUG|5-fluorouracil|
224190609|NCT03744494|PROCEDURE|Bilateral simple orchidectomy (BSO)|
224190610|NCT03744494|PROCEDURE|Bilateral Subcapsular Orchidectomy|
224190611|NCT03744494|PROCEDURE|Bilateral Epididymal-sparing Orchidectomy|
224190612|NCT05472480|DIAGNOSTIC_TEST|anthropometric and psychosocial measurements|"Different types of measurements will be evaluated: body mass index (BMI), weight, height, waist circumference, waist / hip ratio (WHR), waist / stature (WSR) and the ABSI a body score shape index . To complete the study, the personal experiences of the patients will be analyzed through the administration of a psycho-social questionnaire, Body Image Disturbance Questionnaire (BIDQ)."
224190613|NCT00869362|OTHER|Diabetes management team|MD evaluation followed by NP education and and medication titration
224190614|NCT02584972|OTHER|no intervention required|no intervention required
224190615|NCT03049592|OTHER|HIBISCUS counseling|Third trimester prenatal appointment with a family planning specialist for contraceptive counseling utilizing the Contraceptive CHOICE counseling script - emphasizing the WHO birth-to-pregnancy recommendation of 18 months, and a follow up postpartum contraception visit with a family planning specialist.
224190616|NCT03878368|DIETARY_SUPPLEMENT|Sulforaphane|Intervention soup with dietary sulforaphane
224190617|NCT03878368|DIETARY_SUPPLEMENT|Placebo|Control soup without dietary sulforaphane
224190618|NCT02179580|DRUG|Xiang-Sha-Liu-Jun-Zi-Tang|Xiang-Sha-Liu-Jun-Zi-Tang at a rate of 3.0 g three times per day for 28 days. We use the Chinese herb for the treat of IBS patient
223500522|NCT06829160|BEHAVIORAL|Communication with exercise therapist|A personalized exercise program will be designed. The assigned therapist will identify potential barriers to this plan and develop mitigation strategies. The assigned therapist will then make phone contact with participants weekly for the duration of the study. Exercise recommendations will be titrated during calls based on review of activity data.
223500523|NCT06829160|BEHAVIORAL|mHealth-CR|mHealth-CR software (currently, from Corrie Health) will permit 1) participant data entry about exercise; 2) viewing of educational material pertinent to the condition.
223500524|NCT06829160|BEHAVIORAL|Wearable activity monitoring device|Participants will be offered the Fitbit Charge 5. This commercially available product measures physical activity.
223500525|NCT05713630|DRUG|Tranexamic acid (TXA)|Marcan-Tranexamic Acid 500 mg oral tablet over-encapsulated to match the placebo. Sandoz-Tranexamic Acid 100 mg/mL solution for injection via intravenous (IV) added to a 100mL infusion bag of NaCl 0.9% and infused by slow intravenous injection over 20 minutes.
223746187|NCT03567707|OTHER|Standard care|Mother-infant pair where mother undergoes spontaneous vaginal delivery, with both receiving standard of care.
223746188|NCT01395329|DRUG|Nebivolol|5 mg tablet to be taken by mouth once per day for 12 weeks
223746189|NCT01395329|DRUG|Metoprolol|100 mg tablet to be taken by mouth once per day for 12 weeks
224190619|NCT02179580|DRUG|Placebo|Xiang-Sha-Liu-Jun-Zi-Tang at a rate of 3.0 g three times per day for 28 days. Placebo drug is 1/10 dose of experiment drug .
224190620|NCT02956980|BIOLOGICAL|Blood Plasmacytoid dendritic cells (pDCs) absolute number|Two 7 ml tubes will be necessary to perform the functional assays as well as the quantification of blood pDCs absolute number. Functional assays will be performed on isolated PBMC by Ficoll procedure. Quantification of blood pDCs absolute number will be performed on whole blood. After written parental consent, blood sample will be performed on children participating to the study.
224190621|NCT05214976|DRUG|Camrelizumab for Injection, Famitinib malate capsule, Paclitaxel For Injection(Albumin Bound)|Firstly Dose Escalation of Camrelizumab for Injection in combination with Famitinib malate capsule and Paclitaxel For Injection(Albumin Bound) should be conducted. According to the DLT data in the dose escalation period, dosage of Famitinib malate capsule or Paclitaxel For Injection(Albumin Bound) would be adjusted. After dose escalation period, in order to evaluate the tolerance, study would choose the dosage regimen to complete the Dose Expansion period. The indication expansion would be conducted after that. The study would select specific indications based on the previous efficacy data with the RP2D of the combination therapy.
224190622|NCT04260594|DRUG|Arbidol|Arbidol tablets: take 2 tablets/time, 3 times/day for 14-20 days
224190623|NCT04260594|OTHER|basic treatment|basic treatment
224190624|NCT02516462|DEVICE|IVM media|Media to support the nuclear maturation and cytoplasmic competence of human oocytes in culture.
223746190|NCT01395329|DRUG|Placebo|gelatin capsule to be taken by mouth once per day for 12 weeks
223746191|NCT01395329|OTHER|Forearm Blood Flow (FBF) response to BQ-123 (100 mol/min)|The forearm blood flow response to the endothelin (ET) -1 A receptor blocker BQ-123 (100 nmol/min) for 60 minutes at baseline and at 12 weeks.
224190625|NCT02516462|DRUG|Follicle Stimulating Hormone (FSH)|Low dose FSH is administered to stimulate follicle growth.
224190626|NCT02724189|DEVICE|MyPreOp assessment|MyPreOp is an online preoperative assessment programme created by a medical software company called Ultramed.
224190627|NCT02724189|OTHER|Nurse led assessment|Standard practise is where patients undergo a face to face preoperative assessment led by a qualified nurse specialising in this field.
224190628|NCT02524262|DIETARY_SUPPLEMENT|Slow-release L-cysteine|Bind and inactivate acetaldehyde formed from ethanol by covalent binding to L-cysteine
224190629|NCT02259426|DRUG|Dihydroartemisinin-piperaquine combination (Artekin)|
224190630|NCT02259426|DRUG|Primaquine|Single-dose 0.25mg/kg
224190631|NCT02137473|OTHER|Human milk-based fortifier|
224309690|NCT06983912|BEHAVIORAL|Preoperative Rehabilitation Training|"Initiate preoperative Physical Rehabilitation Training (PRT) starting from the preoperative period, with training five days a week up until the day before surgery. This includes:~Muscle Strength Training: Isometric contractions of the quadriceps, straight leg raises, etc., for 15-20 minutes per session, twice daily.~Joint Mobility Training: Flexion and extension exercises of the knee joint, ankle pump exercises, etc., for 10-15 minutes per session, twice daily.~Balance Training: One-legged standing, center of gravity shifting exercises, etc., for 10-15 minutes per session, twice daily.~Activities of Daily Living Training: Transfer training from sitting to standing, walking exercises, etc., for 10-15 minutes per session, twice daily."
223500526|NCT05713630|DRUG|Placebo|Placebo 500 mg consisting of an identical capsule to over-encapsulated tranexamic acid oral tablet entirely filled with microcrystalline cellulose, and sealed. Placebo 100 mg/mL solution for injection via intravenous (IV) consisting of 0.9% sodium chloride (saline).
223500527|NCT04098081|DRUG|galeterone|Therapeutic
223500528|NCT04098081|DRUG|Gemcitabine|Therapeutic
224309691|NCT04314414|OTHER|PRC brief motivational interview intervention|The intervention will involve the following elements: establishing rapport, asking permission to discuss drugs, discussing the pros and cons associated with drug use, uncovering the gaps between current and desired quality of life and determining readiness to change. The intervention will last approximately 20 minutes and take place at the time of the clinical visit while participants are waiting to be seen by a clinician or are awaiting laboratory testing.
224309692|NCT04314414|OTHER|Phone contact|The PRC will remain in at least weekly contact by phone with each participant.
223500529|NCT04333498|BEHAVIORAL|Feedback on DBS Concentrations|The study team will examine the feasibility and acceptability of a feedback system based on DBS concentration amounts.
223500530|NCT05994183|DRUG|Dexamethasone Oral|Dexamethasone 0.6 mg/kg/dose orally (max 16 mg/dose)
223591484|NCT05246800|OTHER|Structured 8-week mHealth mindfulness program|The mindfulness application was developed by Minddistrict The content of the app was developed by professionals in the field of mental healthcare and based on the principles of MBSR and MBCT The app consisted of a structured program, with chapters on psycho-education on mindfulness and the importance of practicing; acting on auto-pilot, conscious attention; non-judgmental attention, awareness; doing versus being-modus; attention for breath and body, conscious response; acceptance; a mindful attitude towards thoughts; applying mindfulness in daily life and staying mindful.
223746192|NCT01395329|OTHER|FBF response to BQ-123 (100 nmol/min)+BQ-788(50 nmol/min)|The FBF response to the nonselective endothelin (ET) -1 receptor blockade BQ-123 (100 nmol/min) + BQ-788 (50 nmol/min)for 60 minutes at baseline and at 12 weeks.
223746193|NCT01395329|OTHER|FBF response to Acetylcholine|The FBF response to the endothelium-dependent vasodilator ACh (4, 8 and 16 ug/100 mL tissue/min) at baseline and at 12 weeks.
223746194|NCT01395329|OTHER|FBF response to Sodium Nitroprusside|The FBF response to the endothelium independent vasodilator NTP (1,2 and 4 ug/100 mL tissue/min) at baseline and at 12 weeks.
223746195|NCT01395329|OTHER|FBF response to BQ-123+BQ-788+ACh|The FBF response to the nonselective endothelin (ET) -1 receptor blockade BQ-123 (100 nmol/min) + BQ-788 (50 nmol/min)for 60 minutes at baseline and at 12 weeks.
223746196|NCT06292780|DRUG|Linvoseltamab|anti-B-cell maturation antigen x anti-Cluster of differentiation 3 bispecific antibody
224190632|NCT02137473|OTHER|Bovine protein-based fortifier|
224190633|NCT02384031|DEVICE|Traumatic needle|Lumbar puncture is performed with a traumatic needle
223500531|NCT05896124|DRUG|2mg CS0159|Oral QD
223500532|NCT05896124|DRUG|Placebo|Oral QD
223746197|NCT01722253|PROCEDURE|Electroacupuncture|Electrical stimulation device with frequency 2 Hz and 'frequency scanning mode'
224190634|NCT02384031|DEVICE|Atraumatic needle|Lumbar puncture is performed with an atraumatic needle
223746198|NCT00663052|DRUG|Etanercept|ETN 50 mg QW + PBO QW for 12 weeks followed by ETN 50 mg QW for 12 weeks.
223746199|NCT00663052|DRUG|Etanercept|ETN 50 mg BIW for 12 weeks folowed ETN 50 mg QW for 12 weeks.
223500533|NCT04851015|DRUG|trimethoprim-sulfamethoxazole|10mg/kg/day of TMP component
223500534|NCT04851015|DRUG|trimethoprim-sulfamethoxazole|15mg/kg/day of TMP component
223500535|NCT01565694|DRUG|Solifenacin succinate|Oral suspension administered once a day via syringe.
223500536|NCT03594838|OTHER|HCV viremia testing approaches|Blood draw and HCV viremia testing is done at point of service (Intervention A) Blood draw at point of service and HCV viremia testing at a centralized laboratory (Intervention B)
223591485|NCT00994006|DIETARY_SUPPLEMENT|Magnesium oxide|520 mg of elemental magnesium q.d.
223591486|NCT00994006|DIETARY_SUPPLEMENT|Magnesium citrate|Magnesium citrate , 98.6 mg of elemental magnesium t.i.d.
223591487|NCT01037686|RADIATION|Injection of 15mCi of Tc-ECD and scanning by SPECT camera|All subjects (PD patients with or without DBS and healthy controls) will be injected with 15mCi of Tc-ECD and afterwards will be scanned by an Irix SPECT camera.
223746200|NCT06002958|DEVICE|Horyzons USA|Client participants will be onboarded to the digital platform, including the different spaces and how to use the site. The site includes therapeutic content that is tailored to each individual and their current needs and experiences, including social anxiety, generalized anxiety, mood, and social functioning, and distress intolerance. Further, the platform includes a moderated social media function, where individuals and peer support specialists can post text, images, videos, and comments to connect and share their experiences. The site is monitored by graduated students and trained clinicians.
223746201|NCT04781088|DRUG|Lenvatinib|Given PO
223746202|NCT04781088|DRUG|Paclitaxel|Given IV
223746203|NCT04781088|BIOLOGICAL|Pembrolizumab|Given IV
224190635|NCT05820880|DRUG|Fixed [Per/Ind/Aml]|Fixed Dose combination of Perindopril/Indapamide/Amlodipine
224190636|NCT05820880|DRUG|Free [Per/Ind + Aml]|Free dose combination of Perindopril/Indapamide and Amlodipine
224190637|NCT01241591|DRUG|CP 690,550 5 mg|CP-690,550 5 mg orally dosed twice daily and placebo subcutaneously dosed twice weekly for 12 weeks
223746204|NCT04481893|BEHAVIORAL|Use of a virtual reality headset|"The intervention will consist of 2 sessions of 30 minutes each, based on the use of a virtual reality headset with the AQUA® application.~* The 1st session will take place on the day of the surgical intervention, upon arrival in hospital, after reception in the room.~* The 2nd session will take place the same day, post-operatively, once the awakening is satisfactory (within 3 to 6 hours after the intervention)"
223746205|NCT06497556|DRUG|Divarasib|Divarasib will be administered orally QD
224309693|NCT06980233|BEHAVIORAL|reentry assistance mobile health app|R-Assist features will include: 1) daily self-reported symptom and medication management monitoring; 2) a 29-session MISSION-CJ self-help curriculum, with an accompanying library of recovery resources to support COD symptom management and promote prosocial thinking and behavior; 3) SDOH resource finder; and 4) a dashboard to track R-Assist engagement.
223500537|NCT03690544|DRUG|Apremilast 30mg|Apremilast is an oral small-molecule inhibitor of phosphodiesterase (PDE) 4 that works intracellularly to modulate a network of pro-inflammatory and anti-inflammatory mediators. PDE 4 is a cyclic adenosine monophosphate (cAMP)-specific PDE and the dominant PDE in inflammatory cells. PDE4 inhibition elevates intracellular cAMP levels, which in turn down-regulates the inflammatory response by modulating the expression of TNF-alfa, IL-23, IL-17 and other inflammatory cytokines. Cyclic AMP also modulates levels of anti-inflammatory cytokines such as IL-10. Apremilast has immunomodulatory activity and, therefore, has the potential to be effective in the treatment of RAS.
223500538|NCT05862584|OTHER|Questionnaires|Distribution of questionnaires to patients to be completed on a weekly basis.
223500539|NCT06964490|DEVICE|determination of working length|Compare the effect of WL determination using different apex locator devices (ProPex Pixi, Root ZX, and Raypex 6) on the incidence and intensity of postoperative pain following endodontic retreatment in single-rooted teeth
223591488|NCT01037686|BEHAVIORAL|Semantic verbal fluency task performance|All Subjects (PD patients with or without DBS and healthy controls) before one of the two scans will perform the semantic verbal fluency task during the Tc-ECD uptake for 9 minutes. Before the other scan subjects will be at rest.
223591489|NCT01037686|DEVICE|Turning off the stimulator|For PD patients treated with DBS, the neurologist will turn off the stimulator after the injection of Tc-ECD for ten minutes and then turn it back on.
223591490|NCT04927403|OTHER|multimodal integrative naturopathic therapy concept|Use of conventional medicine, naturopathic approaches and complementary medical therapy methods
223591491|NCT03430960|OTHER|Phone Call|Participants will be followed-up via phone call by Acute Pain Research Nurse
223591492|NCT03430960|OTHER|Mobile App Survey|Participants will be followed-up via mCare mobile app
223591493|NCT04188093|OTHER|PACU discharge criteria and continuous monitoring on the ward|"* PACU discharge criteria (modified aldrete score).~* Continous monitoring of vital signs 96 postoperative hours"
223591494|NCT03764306|PROCEDURE|Carotid Artery Stenting|Carotid artery stenting was considered successful if there was no residual stenosis greater than 20%, and there was no dissection of target artery following the procedure.
223591495|NCT03764306|PROCEDURE|Endarterectomy carotid artery|Surgical endarterectomy was considered successful if there was no residual stenosis after procedure, without symptoms.
223591496|NCT05865717|BEHAVIORAL|Quantitative sampling|A questionnaire asks about demographics, lifestyle (including cigarette smoking) \& desk job hours, eating habits, sleep patterns, mental health, and motivation. Data on the frequency and size of regular food consumption will be gathered by completing a survey. Physical activity will be measured using a questionnaire developed by the American College of Lifestyle Medicine and Loma Linda University (Lifestyle Assessment Short Form, 2018).
223591497|NCT05865717|OTHER|Qualitative interviews|Thematic analysis will be done dividing into 4 different themes Personal life, professional life, Concept of Healthiness, Improving Lifestyle
223591498|NCT00765063|DRUG|Fragmin|Pre-filled syringes containing a single dose of 5000 IU Fragmin/ Dalteparin Sodium
223591499|NCT00757822|DRUG|Dronabinol|Dronabinol (5mg) will be administered orally (p.o.) 20-60 min pre-operatively.
223746206|NCT06497556|DRUG|Sotorasib|Sotorasib will be administered orally QD
223746207|NCT06497556|DRUG|Adagrasib|Adagrasib will be administred orally BID
223746208|NCT05228886|BEHAVIORAL|SINCERE|"Each goal setting session will involve templated prompts in 211's ServicePoint to guide the creation of a patient-centered action plan specifying what, when, how much, and how often patients will engage in a behavior (e.g., I will work on filling out eligibility paperwork for 30 minutes on Wednesday evening). Again, following clear prompts, ISs negotiate the action plan with patients until patients can rate their level of confidence for achieving this behavior a 7 on a scale from 0 to 10."
223746209|NCT05228886|BEHAVIORAL|Scheduled Follow-Up|Adding to the standard Call + Resources protocol, those assigned to scheduled follow-up will receive a proactive call from 211 every 2 weeks for 3 months to explore additional service needs. These calls will be unstructured, guided by participant requests and 211 IS prompts.
223500540|NCT06118073|OTHER|Headspace|Headspace is a smartphone-based application that guides individuals through various mindfulness sessions and has been shown to reduce symptoms of depression, anxiety, and pain. Participants will be required to answer questions regarding anxiety levels and pain for 6 weeks after surgery.
223500541|NCT06118073|PROCEDURE|Total Knee Replacement|Participant will have total knee replacement surgery
223500542|NCT05017155|DRUG|Mexiletine|Mexiletine is a sodium channel blocker shown to be effective in reducing myotonia in a multi-centre randomised trial.
223591500|NCT00757822|DRUG|Ondansetron|Ondansetron (4mg) will be administered intravenously (iv) intraoperatively in those patients not receiving Dronabinol.
223591501|NCT05447481|DIETARY_SUPPLEMENT|chicory inulin-type fructan|Dietary supplement: chicory inulin-type fructan
223591502|NCT06222528|BEHAVIORAL|Brief video intervention (Black Girl)|A brief social contact-based video. The video presented a young Black girl, a professional actor, sharing her scripted personal story of struggles with depression and raising themes of recovery and hope.
223591503|NCT06222528|BEHAVIORAL|Brief video intervention (Black Boy)|A brief social contact-based video. The video presented a young Black boy, a professional actor, sharing his scripted personal story of struggles with depression and raising themes of recovery and hope.
224190638|NCT01241591|DRUG|CP 690,550 10 mg|CP-690,550 10 mg orally dosed twice daily and placebo subcutaneously dosed twice weekly for 12 weeks
224190639|NCT01241591|BIOLOGICAL|Etanercept 50 mg|Placebo orally dosed twice daily and etanercept 50 mg subcutaneously dosed twice weekly for 12 weeks
223746210|NCT05228886|OTHER|Standard of Care|211 ISs contact referred patients, provide referral services, and follow up in an ad-hoc manner.
224190640|NCT01241591|OTHER|Placebo|Placebo orally dosed twice daily and placebo subcutaneously dosed twice weekly for 12 weeks.
224190641|NCT03521622|BEHAVIORAL|brief counseling|Brief counseling for motivated smoker 5 As model Brief counseling for not motivated smokers 5 Rs model Brief counseling for motivated risky drinkers simple advice Brief counseling for not motivated risky drinkers brief alcohol intervention
224190642|NCT00862667|DRUG|Treatment A|PF-00241939 300ug using Inhaler A
224190643|NCT00862667|DRUG|Treatment B|PF-00241939 300ug using Inhaler B
224190644|NCT00862667|DRUG|Treatment C|PF-00241939 300ug using Inhaler C
223500543|NCT05017155|DRUG|Lamotrigine 25Mg Oral Tablet, Extended Release|Lamotrigine is an alternative sodium channel blocker that has been shown to be effective in one randomised controlled trial. It is currently used as a licensed medication for other neurological conditions.
223500544|NCT06963450|DIAGNOSTIC_TEST|Taking photos of a baby's eye|Taking photos of a baby's eye and using the color of the sclera to estimate the bilirubin level, which determines if the baby is significantly jaundiced.
223500545|NCT06963398|DRUG|HS-10529|Participants in all subjucts will receive HS-10529
223591504|NCT06222528|BEHAVIORAL|Brief video intervention (Latinx Girl)|A brief social contact-based video. The video presented a young Latinx girl, a professional actor, sharing her scripted personal story of struggles with depression and raising themes of recovery and hope.
223591505|NCT06222528|BEHAVIORAL|Brief video intervention (Latinx Boy)|A brief social contact-based video. The video presented a young Latinx boy, a professional actor, sharing his scripted personal story of struggles with depression and raising themes of recovery and hope.
223591506|NCT06222528|BEHAVIORAL|Brief video intervention (White Girl)|A brief social contact-based video. The video presented a young White girl, a professional actor, sharing her scripted personal story of struggles with depression and raising themes of recovery and hope.
223591507|NCT06222528|BEHAVIORAL|Brief video intervention (White Boy)|A brief social contact-based video. The video presented a young White boy, a professional actor, sharing his scripted personal story of struggles with depression and raising themes of recovery and hope.
223591508|NCT06222528|BEHAVIORAL|Brief video intervention (Nonbinary or transgender)|A brief social contact-based video. The video presented a young nonbinary or transgender adolescent, a professional actor, sharing their scripted personal story of struggles with depression and raising themes of recovery and hope.
223746211|NCT06057441|DEVICE|Auditory noise stimulation|Auditory white noise stimulation delivered at 78dB through earphones
223746212|NCT06057441|DEVICE|Visual noise stimulation|Visual white pixel noise stimulation, backgound pixel noise visible at computer screen
224190645|NCT00076544|DRUG|Ziconotide|
224190646|NCT04662424|OTHER|music in labor|Women in the intervention group will be offered music in labor, defined listening to music from the randomization until the delivery of the baby. Women had the possibility to select the songs at their discretion
224190647|NCT01945034|DRUG|Topical IBU twice daily|Topical gel administered as 4 inch strip twice daily for 7 days, and as needed for an additional 3 days
224190648|NCT01945034|DRUG|Placebo twice daily|Topical gel administered as a 4 inch strip twice daily for 7 days, and as needed for an additional 3 days
224190649|NCT01945034|DRUG|Topical IBU three times daily|Topical gel administered as a 4 inch strip three times daily for 7 days, and as needed for additional 3 days
224190650|NCT01945034|DRUG|Placebo three times daily|Topical gel administered as a 4 inch strip three times daily for 7 days, and as needed for additional 3 days
223500546|NCT06963320|DRUG|H001 Capsule 200mg-qd|H001 Capsule, 50 mg/capsule, 200 mg orally once daily for 10-14 days.
223500547|NCT06963320|DRUG|Enoxaparin Sodium Injection|Enoxaparin Sodium Injection,0.4 mL: 4000 AXaIU, 40 mg subcutaneously once daily for 10-14 days
223500548|NCT06963320|DRUG|H001 Capsule 300mg-qd|H001 Capsule, 50 mg/capsule, 300 mg orally once daily for 10-14 days.
223500549|NCT06963320|DRUG|H001 Capsule 200mg-bid|H001 Capsule, 50 mg/capsule, 200 mg orally twice daily for 10-14 days.
223500550|NCT06963931|BEHAVIORAL|Change4Better (C4B) mobile app|The content of the C4B app is designed to teach key CBT strategies to address gambling behaviors. The content targets concerns that people with gambling problems often experience (gambling debts, cognitive distortions related to gambling - for example, how unrelated events might be related to gambling outcomes). We have designed the content such that people using the app can see the pattern of progress, identify mistakes and setbacks, and learn from common experiences of people with gambling disorder
223500551|NCT06963502|DRUG|HS-10370|Participants will receive HS-10370 dose 1 administered orally
223500552|NCT06963502|DRUG|HS-20117|Participants will receive HS-20117 given as dose 3 intravenous infusion(IV) once every 14-day cycle.
223500553|NCT06963502|DRUG|Adebrelimab|Participants will receive Adebrelimab intravenous infusion(IV) once every 21-day cycle
223591509|NCT06222528|BEHAVIORAL|Control Condition|A video that will provide information about depression and how to seek help but does not include a personal story.
223591510|NCT03614325|OTHER|Virtual Reality Immersive Relaxation|The software developed by VRHealth allows patients to select from scenery such as mountains, the beach or from a selection of short videos, which are intended to promote relaxation.
224190651|NCT00395317|OTHER|Placebo|placebo tablet
224190652|NCT00395317|DRUG|Firategrast 150 mg|150 mg tablet
224190653|NCT00395317|DRUG|Firategrast 300 mg|300 mg tablet
224190654|NCT02147132|DRUG|Nicotine Nasal Spray|7 days. 1 mg/dose, up to 40x/day.
224190655|NCT02147132|DRUG|Varenicline|14 days. Days 1-3: 0.5 mg once daily; Days 4-7: 0.5 mg twice daily; Days 8-14: 1 mg twice daily.
224190656|NCT02147132|DRUG|Placebo Nasal Spray|7 days. 1 mg/dose, up to 40x/day.1 mg/dose, up to 40x/day. This will appear similar to the Nicotine Nasal Spray, but will be a placebo.
224190657|NCT02147132|DRUG|Placebo Varenicline|14 days. Days 1-3: 0.5 mg once daily; Days 4-7: 0.5 mg twice daily; Days 8-14: 1 mg twice daily. This will appear identical to the drug Varenicline, but will be a placebo.
224190658|NCT01961778|DEVICE|Radio-Frequency Ablation|
224190659|NCT01961778|DEVICE|Cryotherapy|
224190660|NCT02665754|BIOLOGICAL|ILIT with extract of causal allergen|0.5 ml of allergen extract from D. farinae, D. pteronyssinus, cat, and/or dog for allergen specific immunotherapy (Tyrosine S, Allergy Therapeutic, UK) will be injected into inguinal lymph node through guidance by ultrasonography three times with 4-week interval.
224190661|NCT02665754|BIOLOGICAL|ILIT with normal saline|0.5 ml of normal saline will be injected into inguinal lymph node through guidance by ultrasonography three times with 4-week interval.
224190662|NCT02665754|DRUG|Rescue medication for allergic rhinitis|Subjects are requested to administer oral antihistamine (cetirizine) or nasal glucocorticosteroid (ciclesonide) as rescue medication for allergic rhinitis in accordance with severity and frequency of allergic rhinitis symptoms according to Allergic Rhinitis and its Impact on Asthma (ARIA) guideline.
224190663|NCT03721614|DEVICE|BioMime™ Morph - Sirolimus Eluting Coronary Stent System|Study Device :- BioMime™ Morph - Sirolimus Eluting Coronary Stent System Approximately 200 patients will be randomly enrolled in a 2:1 ratio \[BioMime™ Morph (n=133) vs. XIENCE family (n=67)\].
224190664|NCT03721614|DEVICE|Xience family Everolimus Coronary Stent Systems|Active Control Device :- Xience family Everolimus Coronary Stent Systems Approximately 200 patients will be randomly enrolled in a 2:1 ratio \[BioMime™ Morph (n=133) vs. XIENCE family (n=67)\].
224190665|NCT01738282|DRUG|Baclofen|
224190666|NCT01738282|DRUG|Placebo (for baclofen)|
224190667|NCT03976674|BEHAVIORAL|Cognitive Behavioural Therapy (CBT)|5 group sessions (2h30/session) before the surgery
224190668|NCT02853825|BEHAVIORAL|Relationship Skill Enhancement|Receive relationship classes with access to parenting, employment services, and financial services.
224190669|NCT01821508|OTHER|Clinical Treatment|metabolic surgery for diabetes and weight control
224190670|NCT01821508|PROCEDURE|Roux-En-Y gastric bypass surgery|laparoscopic surgical procedure with Endoscopic Surgical Stapler
224190671|NCT03487159|DEVICE|MRE (Magnetic Resonance Elastography)|The device is using to evaluate liver fibrosis stage
224190672|NCT02108132|BIOLOGICAL|Cellular therapy|bone marrow derived mesenchymal stem cells for normal subjects will be separated and induced to adopt the hepatocyte phenotype then injected through the portal vein to hemophilia patients
224190673|NCT02108132|BIOLOGICAL|cellular therapy|Allogenic bone marrow derived MSCs will be isolated and subjected to induction of hepatic phenotype. After proof of in vitro secretion of albumin and factor 8 from the cell population. It will be injected into the portal vein via the spleen
224190674|NCT05294133|BEHAVIORAL|physical activity|physical activity
224190675|NCT04962191|DIAGNOSTIC_TEST|Idylla EGFR Mutation Test|This diagnostic test is performed on the BioCartis Idylla System for qualitative detection of exon mutations.
224190676|NCT04001790|BEHAVIORAL|Project Search plus ASD Supports|Nine month job training program embedded on Fort Eustis military base.
224190677|NCT06039449|DRUG|VYD222 (pemivibart)|Participants will be dosed on Day 1 followed by redosing at Month 3 (approximately 90 days) with VYD222.
224190678|NCT06039449|DRUG|Normal saline|Participants will be dosed on Day 1 followed by redosing at Month 3 (approximately 90 days) with Placebo.
223591511|NCT05553392|DEVICE|StrataXRT|"StrataXRT is a full contact flexible wound dressing for the prevention and treatment of radiation dermatitis. StrataXRT is a semi-occlusive, self-drying and transparent gel.~When used as directed StrataXRT dries to form a protective layer that is gas permeable and waterproof which hydrates and protects compromised skin areas and superficial wounds from chemical and microbial invasion. StrataXRT may be directly applied to radiation dermatitis, compromised skin surfaces, superficial wounds and first and second degree burns."
224190679|NCT02876185|OTHER|Monitoring by an orthoptist then by an ophthalmologist|At each visit, the usual monitoring tests will be collected and viewed by the orthoptist then by the ophthalmologist concerning the necessity of an anticipated ophthalmological consultation
224190680|NCT06954467|DRUG|JS207|10 mg/kg q3W or adjust the dose (e.g. 15 mg/kg) based on accumulated data on the safety and efficacy of JS207 from clinical studies.
224190681|NCT06954467|DRUG|JS007|Dose exploration stage: C1-C4, group 1:3 mg/kg, C1D1 once (single dose); Group 2:3 mg/kg, D1, Q6W; Group 3:1 mg/kg,D1, Q3W; ≥C5, 1 mg/kg, Q6W; Dose expansion stage: according to the group medication confirmed in the dose exploration stage.
224190682|NCT04448028|DRUG|Placebo|Patients with a pre-existing PPI therapy discontinue PPI therapy and replace it with placebo over a period of 346 days after a 14 day dose tapering phase.
224190683|NCT04448028|DRUG|Esomeprazole 20mg|Patients with a pre-existing PPI therapy stop their prior PPI medication and have it replaced with esomeprazole 20mg/day for 360 days.
224190684|NCT05604976|DEVICE|Percutaneous coronary intervention|Primary PCI for ST elevation myocardial infarction initiating with a universal guiding catheter or an angiographic catheter
224190685|NCT02706327|DEVICE|CAD/CAM Insole|A computer numerical control machine was used to product insoles according to pedobarographic pressure data;35 Shore A hardness ethyl vinyl acetate was used for the main insole, and 3 mm, 15 Shore A hardness ethyl vinyl acetate was used for covering. Orthotic insoles have been implemented in a pair of sports shoes.
224190686|NCT02706327|DEVICE|Semi-custom Insole|Plantar surfaces of each patient's metatarsophalangeal joints were marked with a thick broad marker, and the participants were asked to stand on a clean paper. The borders of the foot were then drawn, and the medial longitudinal arch length was marked from the anterior aspect of the heel to the first metatarsophalangeal joint. These marks were used in designing and production. 35 Shore A hardness ethyl vinyl acetate was used for the main insole, and 3 mm, 15 Shore A hardness ethyl vinyl acetate was used for covering. Orthotic insoles have been implemented in a pair of sports shoes.
224190687|NCT02706327|OTHER|Control|15 Shore A hardness ethyl vinyl acetate, implemented in a pair of sports shoes as a placebo insole.
224190688|NCT06135493|DRUG|Losartan|Using losartan to prevent paclitaxel-induced peripheral neuropathy
224205846|NCT04288739|GENETIC|Xist gene by fluorescence insitu hybridization|"Fluorescence in situ hybridization (FISH) is a kind of cytogenetic technique that allows the visualization of defined nucleic acid sequences in particular cellular or chromosomal sites by hybridization of complementary fluorescently labeled probe sequences within intact metaphase or interphase cells.~The fluorescent probes are nucleic acid labeled with fluorescent groups and can bind to specific DNA/RNA sequences. Fluorescence microscopy can be used to find out where the fluorescent probe is bound to the chromosomes."
224205847|NCT05324800|DIETARY_SUPPLEMENT|Curcuma Longa Extract Mixture|2 times a day, 2 capsule for 1 time, after breakfast/dinner meal, for 8 week
224190689|NCT04464746|OTHER|implementation of a specific program to improve therapeutic adherence|"1. Discussion of risks associated with high BP;aims,healthy lifestyle options.~2. Individualized educational intervention:verbal, written,audiovisual information. Evaluation of knowledge of prescribed drugs.~3. Behavioral counseling.training patients to participate in their own care, while positively modifying their skills or routines (i.e. pill boxes,calendars,specific measures to remind the patient taking drugs,adapt the regimen to atient's daily routine).~4. Socio-psycho-affective interventions.~5. Reminder systems: phone,email,alarm on the mobile phone.~6. Simplification as far as possible of therapeutic scheme.~7. Explanation of prescribed medications (name\&dosage), correct intake.~8. Explanation of possible side effects and what to do if they happen. Facilitate a contact.~9. Advise and training on home blood pressure self-measurement.~10. Verbal, written and/or audiovisual information and the online patients'section of scientific societies addresses will be provided."
224190690|NCT03921008|DRUG|Paclitaxel|-Commercial supply
224190691|NCT03921008|RADIATION|Radiation therapy|-Patients may be treated with electrons, 3D conformal photon radiotherapy, intensity modulated photon radiotherapy (IMRT), proton radiation therapy, or a combination of these.
224190692|NCT03921008|PROCEDURE|Research blood draw|-Within 1 week (prior to cycle 1 of paclitaxel preferred but not required), pre-radiation therapy (any time weeks 5-7 as long as radiation therapy has not started), post-radiation therapy (day of last fraction), 14 days post-radiation therapy, and within 2 weeks post-surgery
224190693|NCT06327113|DRUG|CeFAZolin Injectable Solution|One gram Cefazolin reconstituted in 100 mL 0.9% Sodium Chloride (normal saline)
224190694|NCT02669173|DRUG|Capecitabine|Drug given orally. Dose to be determined by phase 1 dose escalation, cycle length 28 days. Treatment until progression
224190695|NCT02669173|DRUG|Bevacizumab|Drug given by IV, 10 mg/kg days 1, 15 every 28 days, until progression.
224190696|NCT06013384|DEVICE|Low-Intensity Focused Ultrasound Pulsation|Low-intensity focused ultrasound pulsation will be directed towards the target region at FDA-approved intensity levels in treatment sessions one and two.
224190697|NCT06013384|DEVICE|Sham Low-Intensity Focused Ultrasound Pulsation|Sham low-intensity focused ultrasound pulsation will be given.
224190698|NCT00873496|DRUG|Hydroxychloroquine|
224190699|NCT04123743|DRUG|Trigonella foenum-graceum extract topical cream|Topical cream containing Trigonella foenum-graceum extract
224190700|NCT04123743|OTHER|Facial Wash|Wardah brand facial wash
224190701|NCT04123743|OTHER|Sunscreen Cream|Parasol sunscreen cream SPF 33
224190702|NCT04123743|OTHER|Placebo|Placebo topical cream
223500554|NCT06963502|DRUG|Capecitabine|Participants will receive Capecitabine administered orally
223500555|NCT06963502|DRUG|Oxaliplatin|Participants will receive Oxaliplatin intravenous infusion(IV) once every 21-day cycle.
223500556|NCT06963502|DRUG|Folinic Acid, Fluorouracil and Oxaliplatin/Irinotecan|Participants will receive Folinic Acid, Fluorouracil and Oxaliplatin/Irinotecan intravenous infusion(IV) once every 14-day cycle.
223591512|NCT05553392|DRUG|Aquaphor|"Aquaphor is a brand of over-the-counter (OTC) skin care ointments manufactured by Beiersdorf Inc.~Aquaphor contains 41 percent petrolatum (or petroleum jelly), the active ingredient, temporarily protects minor cuts, scrapes, and burns; protects and helps relieve chapped or cracked skin and lips; helps protect from the drying effects of wind and cold weather."
224190703|NCT03050879|DRUG|Indocyanine Green Tracer|Laparoscopic gastrectomy with lymph node dissection for gastric cancer using Indocyanine Green Tracer
224190704|NCT02131805|RADIATION|Electronic Skin Surface Brachytherapy|
224190705|NCT02131805|BEHAVIORAL|Quality of life assessment|
223500557|NCT06963502|DRUG|HS-20093|Participants will receive HS-20093 intravenous infusion(IV) once every 21-day cycle
223500558|NCT06963502|DRUG|platinum (cisplatin or carboplatin)|Participants will receive platinum (cisplatin or carboplatin) administered IV in 21-day cycles.
223500559|NCT06963879|DEVICE|Bgaze Therapy|BGaze Therapy is a digital intervention by Braingaze designed to enhance attention and memory in individuals with Alzheimer's Disease (AD) and Mild Cognitive Impairment (MCI). It uses an interactive video game controlled through eye-tracking, allowing users to play using only their gaze. The therapy is based on research linking eye vergence and pupil responses to cognitive processing-physiological markers that may indicate neurodegeneration. During gameplay, these responses are modulated, potentially inducing gamma brain oscillations associated with reduced AD pathology. Patients play at care-center for 5-10 minutes daily over two months. Equipment is provided, and both in-person and remote support ensure usability. The game adapts difficulty in real time and provides feedback to keep users engaged and stimulate cognitive function.
223500560|NCT06963879|DIAGNOSTIC_TEST|Bgaze Attention Task|For the validation of diagnosis of AD with vergence method the Attention Test (B-Gaze) will be used. This is an odd ball paradigm where visual target has to be detected among blue distractors. The test consist of 100 trials of 1 second and last about 3 minutes. The task uses remote eye infra-red tracking to measure eye vergence. Subjects merely have to fixate at the computer screen during the task.
224190706|NCT04260698|BIOLOGICAL|omidubicel|hematopoietic stem cell transplant
224190707|NCT06457152|OTHER|EHR-Emedded Alert|For patients randomized to the intervention group, an automated, EHR-embedded alert will be visible in the patient's chart that promotes appropriate medical therapy for patients with HFrEF.
224190708|NCT04951544|OTHER|LetSync v1.0|Study B will entail a pilot randomized, controlled trial (RCT) of an mHealth behavioral intervention, LetSync, with 80 couples (N=160) to assess its acceptability, feasibility, and preliminary impact on retention in care and ART adherence as measured by antiretroviral concentrations in hair. Participants in the intervention arm will use LetSync v1.0 for 6 months and provide acceptability and feasibility data. Participants will then continue to use LetSync v1.0 while the Waitlist-Control group begins to use LetSync v2.0.
224190709|NCT04951544|OTHER|LetSync v2.0|LetSync v2.0 will be developed by taking feedback from participants regarding LetSync v1.0. Participants in the waitlist-control group will be given LetSync v2.0 to use during the last 6 months of the trial.
224190710|NCT05442840|COMBINATION_PRODUCT|Behavioral and drugs already approved and available for diabetes management|Pharmacists will review the patients information and medical history as well as drug coverage to discuss preferred treatment options to manage diabetes based on recommendations from Diabetes Canada treatment guidelines; all drugs have been approved and are available on the market; pharmacists will offer frequent follow up and provide basic diabetes education to the patient at each follow up appointment
224190711|NCT01913613|DEVICE|IASD|IASD device implantation
224190712|NCT03278834|DEVICE|Neuromuscular muscle stimulation machine- Strength Setting|Muscle stimulation to strength skeletal muscle
224190713|NCT03278834|DEVICE|Neuromuscular muscle stimulation machine - TENS Setting|Muscle stimulation to mimic the intervention but without the strength gains.
224190714|NCT02710825|OTHER|Osteopathy|"The treatment begins, if possible, on the body part of the child whose osteopathic score is the highest , with the least elasticity and mobility. Then the other restricted joints will be treated. The set of techniques will be carried out after palpation and appropriate tensioning. The various actions will be carried out on the tissues and joints who have been particularly affected by the operation.~When a joint or tissue has a restricted mobility in a direction or a specific movement, it will require appropriate and gently manual correction, in order to reduce and improve its functionality."
224190715|NCT02710825|OTHER|superficial palpatory agreement|The simulated treatment also begins with the body part of the child whose osteopathic score is the highest. Then the other restricted joints will be treated. The set of techniques will be carried out with the same investments as the tests , with a superficial palpatory agreement and without tensioning so that the restricted articulation or tissue will not be corrected
224190716|NCT03373422|DRUG|BAY1128688|Various dosing OD (once daily) and BID (twice daily)
223500561|NCT02727803|BIOLOGICAL|Allogeneic Natural Killer Cell Line NK-92|Given IV
223500562|NCT02727803|BIOLOGICAL|Anti-Thymocyte Globulin|Given IV
223500563|NCT02727803|DRUG|Busulfan|Given IV
223500564|NCT02727803|DRUG|Clofarabine|Given IV
223500565|NCT02727803|DRUG|Cyclophosphamide|Given IV
223500566|NCT02727803|DRUG|Fludarabine Phosphate|Given IV
223591513|NCT03874039|DEVICE|Gas sensor|The gas sensor is an airtight gas capsule attached with a floating solid phase microextraction (SPME) tube. SPME uses a fiber coated with a nontoxic liquid (polymer), and a nontoxic solid (sorbent). The fiber coating extracts the compounds from the gas being released from the skin. Only the glass sample is in contact with the skin.
223591514|NCT03874039|DEVICE|Sweat Sensor|The sweat sensor is a soft, flexible device that rests on the skin and collects secreted sweat through capillary action. The device is held in place by medical-grade acrylic adhesive film.
223591515|NCT03775746|DRUG|Clopidogrel 75Mg Tablet|Prevention of atherothrombotic events in percutaneous coronary intervention (adjunct with aspirin) in patients not already on clopidogrel
223591516|NCT03775746|DRUG|Rivaroxaban 2.5Mg Tablet|Prophylaxis of atherothrombotic events following an acute coronary syndrome with elevated cardiac biomarkers (in combination with aspirin alone or aspirin and clopidogrel)
223591517|NCT03775746|DRUG|Ticagrelor 90Mg Tablet|Prevention of atherothrombotic events in patients with acute coronary syndrome \[in combination with aspirin\]
224190717|NCT03373422|DRUG|Placebo|Matching placebo tablets
224190718|NCT03311295|DEVICE|ARTO System|The ARTO System directly reshapes the mitral annulus promoting leaflet coaptation and amelioration of regurgitation.
224190719|NCT06365164|BEHAVIORAL|Tactile stimulation|The procedure consists of brief perioral tactile stimulation. The procedure is filmed in order to record and evaluate the response of the newborn to the stimulation. During the same intervention, each newborn will receive external stimulation (the experimenter repeatedly and regularly touches the corner of the infant's mouth slowly with the tip of his index finger) followed by facilitated self-stimulation (the experimenter will place the newborn's elbow close to his body, allowing him to touch his face alone with his hand). There will also be an initial phase and a final 30-second phase in which the newborn is observed without any stimulation.
224190720|NCT01254734|PROCEDURE|transoral robotic surgery|Undergo transoral robotic microsurgery
224190721|NCT01254734|OTHER|laboratory biomarker analysis|Correlative studies
223500567|NCT02727803|OTHER|Laboratory Biomarker Analysis|Correlative studies
223500568|NCT02727803|DRUG|Melphalan|Given IV
223500569|NCT02727803|BIOLOGICAL|Rituximab|Given IV
223500570|NCT02727803|RADIATION|Total-Body Irradiation|Undergo total body irradiation
223500571|NCT02727803|PROCEDURE|Umbilical Cord Blood Transplantation|Undergo umbilical cord blood transplantation
223500572|NCT05416203|BEHAVIORAL|Brief Enhanced Anxiety Sensitivity Treatment|BEAST is a CBT-based intervention that includes psychoeducation, identifying and challenging maladaptive thoughts, and interoceptive exposure. The intervention is delivered through a single virtual face-to-face session supplemented with a mobile app for two weeks after the face to face session.
223500573|NCT05203679|GENETIC|Single dose intravenous injection of BBM-H901|Single dose intravenous infusion of BBM-H901, an adeno-associated virus (AAV) vector derived from recombinant DNA techniques to contain an expression cassette of the human factor IX (hFIX) transgene in liver.
223500574|NCT05035693|DEVICE|MOVE®-C|Momo- or bisegmental implantation of MOVE®-C cervical prothesis.
223500575|NCT06059066|PROCEDURE|Standard number of injection sites|200 units or 300 units BTX-A reconstituted in 20 mL normal saline, injected into the bladder detrusor in 20 separate injections of 1 mL including the trigone.
223500576|NCT06059066|PROCEDURE|Reduced number of injection sites|200 units or 300 units BTX-A reconstituted in 5 mL normal saline, injected into the bladder detrusor in 5 separate injections of 1 mL including the trigone.
223591518|NCT03870399|DRUG|Tamoxifen|The treatment to be used will be tamoxifen 20mg orally once daily.
223591519|NCT05378737|DRUG|BAT8006 for Injection|Intravenous infusion, once every 3 weeks (Q3W), the recommended infusion time of the first cycle is ≥90 minutes, if no infusion reaction occurs, the subsequent cycle can be completed within 30\~120 minutes.
223591520|NCT04924270|BIOLOGICAL|Faecal microbiota transplantation|The capsule FMT transplant consists of faeces obtained from a thoroughly screened, unpaid, anonymous stool donor. Each FMT product is made from 50g faeces diluted in sterile saline (0.9% NaCl) and glycerol, blended, centrifuged and filtered to remove particulate material before transfer to double-layered capsules. The FMT capsules will be stored at - 80 ⁰C until use. On the day of the FMT, the FMT capsules will be thawed to room temperature before treatment.
223591521|NCT04924270|OTHER|Placebo|Placebo capsules consist of NaCl (0.9%) and glycerol added brown food colouring.
223591522|NCT04920383|DRUG|ALPN-202|Various doses
224190722|NCT01254734|PROCEDURE|quality-of-life assessment|Ancillary studies
224190723|NCT03471507|DRUG|Bonipar|Apply 2 pumps 2 times a day to be applied topically on the affected area during a two week treatment period.
224205848|NCT05324800|DIETARY_SUPPLEMENT|placebo group|2 times a day, 2 capsule for 1 time, after breakfast/dinner meal, for 8 week
223500577|NCT06318715|PROCEDURE|modified deep extubation (mDE)|The proposed study is to compare a modified DE technique, which is regularly used for low-risk patients by staff anesthesiologists at our institution, to a standard awake extubation.
223500578|NCT06318715|PROCEDURE|standard awake extubation|awake extubation (AE) is still considered the standard practice.
223500579|NCT01787903|DEVICE|Real-time continuous glucose monitor|Active Comparator: MiniMed Paradigm® Veo™-system Placebo Comparator: iPro™2 Continuous Glucose Monitor (masked)
223500580|NCT06149013|DEVICE|MindAhead Active|MindAhead's Active app focuses on increasing meaningful and enjoyable cognitive, physical, and social activities specifically adapted to patients with early cognitive decline (MCI or mild dementia). These techniques include psychoeducation (explaining the rationale, the components of behavioral activation, and protective activities), action planning (selecting activities, goal setting, activity scheduling, graded task assignment, written schedules, and step-by-step sequencing) and action/self-monitoring (assessing execution of and enjoyment in activities, monitor mood and cognitive problems), as well as value-based activation (understanding most important values, selecting activities according to these values). This process aims to enable the users to understand which activities are enjoyable and meaningful to them and how to implement these activities into their daily lives. MindAhead's Active app consists of one to five sessions per week.
223500581|NCT06149013|OTHER|Treatment-as-usual|Depending on patient-specific clinical findings it includes antidementive medication (e.g., acetylcholinesterase inhibitors), advice on protective lifestyle factors, vitamin supplementation, ergotherapy, cognitive training (including digital health apps), or statins.
223591523|NCT04920383|DRUG|pembrolizumab KEYTRUDA®|Varies
223591524|NCT03986528|DRUG|Kanglaite Injection+Chemotherapy|Patients will receive investigator's choice of paclitaxel (135mg/m2 by IV infusion on Day 1 of each 21-28 day cycle) or pemetrexed (500mg/m2 by IV infusion on Day 1 of each 21-28 day cycle) or gemcitabine(1000mg/m2 by IV infusion on Days 1,8 of each 21-28 day cycle) PLUS cisplatin (75mg/m2 by IV infusion on Days 1 to 3 of each 21-28 day cycle) or carboplatin (AUC 6 by IV infusion on Days 1 of each 21-28 day cycle) according pathologic types. Patients with CR, PR, or SD after 4-6 cycles of platinum-based double chemotherapy regimens will receive non-platinum single-agent chemotherapy. The patients will also receive Kanglaite injection 200ml by IV infusion per day continuously for 14 days, commencing on the first day of chemotherapy.
223746213|NCT06428305|OTHER|Providing hygiene education based on the method of teaching what has been learned in the context of a genital hygiene guide|As shown in the Flow Chart of the study, research data were collected from pregnant women who were in the control group at the December intervals with the experimental group. After the completion of the study, this group will also be given an education and training booklet.
223746214|NCT05330325|DRUG|Somapacitan|Somapacitan will be administered subcutaneously (s.c.) once weekly using PDS290 pen-injector.
224190724|NCT03471507|DRUG|Diclofenac sodium topical solution 1.5%|Apply 2 pumps 2 times a day to be applied topically on the affected area during a two week treatment period.
224190725|NCT04617379|BEHAVIORAL|Stretching|One-year stretching program for 15 minutes every day
224190726|NCT04679064|DRUG|Niraparib|PARP-inihibitor
224190727|NCT04679064|DRUG|Dostarlimab|PD-1 inihibitor
224190728|NCT04679064|DRUG|Pegylated liposomal doxorubicin|Chemotherapy drug
224190729|NCT04679064|DRUG|Paclitaxel|Chemotherapy drug
224190730|NCT04679064|DRUG|Gemcitabine|Chemotherapy drug
224190731|NCT04679064|DRUG|Topotecan|Chemotherapy drug
224190732|NCT04679064|DRUG|Bevacizumab|Chemotherapy drug
224190733|NCT02675699|BEHAVIORAL|Optimisation + HENRY|"HENRY HENRY is an 8-week childhood obesity prevention programme delivered in Children's Centres in the UK by trained practitioners, aiming to provide parents with skills and knowledge to support healthy lifestyles in preschool children and their families. The programme aims to build parents' skills, knowledge and confidence to change old habits and provide healthier nutrition.~OPTIMISATION A tailored 'Optimisation' intervention has being developed to support local authorities and Children's Centres to promote HENRY implementation, based on an ethnography of Children Centres, including interviews with staff and other stakeholders and input from parents. Development was underpinned by strong theories of behaviour change and will be guided by the intervention planning framework; the Behaviour Change wheel using a systematic approach. Strategies have been developed to improve parent motivation to enrol on to HENRY and promote parent self-efficacy to continue to attend."
224190734|NCT02675699|BEHAVIORAL|HENRY as standard|Local Authorities / Children's Centres that are assigned to the control group will continue with standard HENRY practice. Current HENRY QA practice involves the review of process data by HENRY central office with provision of written and oral feedback. This will continue in both trial arms and will be monitored.
224190735|NCT02213666|DEVICE|Intracardiac Imaging|Imaging of the RAA and LAA with ICE and assessment of thrombus.
224190736|NCT02103608|DEVICE|Glide|6 facial hair reduction treatments with the Glide device, two weeks apart.
224190737|NCT05261906|BEHAVIORAL|LIBERATE|"Five bi-weekly, followed by three monthly, one-hour videoconferencing group education classes via Microsoft Teams video platform will be offered. Participants will be given the choice to communicate with the LIBERATE clinical team (exercise specialist, MD, and/or RN) weekly between the group classes using their preferred method of communication i.e., email.~Classes will offer FreeStyle® Libre-assisted behavioural coaching (i.e., nutrition and exercise). FreeStyle® Libres will be used during the first three months of the program and optionally in the last three months of the intervention. The FitBit Inspire 2™ monitors will be worn for six months. Participants are provided the option to receive individualized aerobic and resistance training prescriptions."
223500582|NCT02466542|DRUG|Placebo group|Patients will receive regular general anesthesia
223500583|NCT02466542|DRUG|Esmolol group|Patients will receive regular general anesthesia plus esmolol infusion
223500584|NCT04664088|PROCEDURE|Acupuncture|"Patients in this group will receive acupuncture once every other day (3 days per week) over an 8-week period (a total of 24 sessions). In each session, needles will be retained for 30 minutes. The acupoints will include Baihui (DU20), Qianding (DU21), Houding (DU19), Yintang (DU29), Fengchi (GB20), Shuaigu (GB8), Tongli (HT5), Hegu (LI4), Taichong (LR3), Fenglong (ST40), Xuanzhong (GB39) and Zulinqi (GB41). The selection of acupoints is on the basis of meridian theory and patients' clinical symptoms.~Patients are not allowed to take prophylactic medications. But in case of intolerable acute VM attacks, the patients will be instructed to take triptans as rescue medication, and the dosage of medication will be documented in the patient diary."
224190738|NCT01878708|DRUG|PEG-L-asparaginase|
224190739|NCT01878708|DRUG|Dexamethasone acetate|-dexamethasone 40mg daily for 4 days with every cycle.
224190740|NCT01546311|DEVICE|Pro Active Dynamic Accommodating Socket|Socket with bladders that instantaneously adjusts to volume fluctuations in the residual limb
224190741|NCT01811004|DEVICE|miraDry|miraDry
224190742|NCT01811004|DEVICE|Nd:YAG Laser|Nd:YAG 1440 nm Laser
224190743|NCT01811004|DEVICE|Botox®|Botox®
224190744|NCT05334576|OTHER|Crizanlizumab|Crizanlizumab 5.0 mg/kg infusions will be administered over 24 months
224190745|NCT04009122|DIETARY_SUPPLEMENT|IGEN0206|Group A
224190746|NCT04009122|OTHER|Placebo|Group B
224190747|NCT03027258|OTHER|mHealth|"HBI participants who consent will be enrolled in this study and will have data collected from their community screening stored in a secure, web-based database. The stored data will be encrypted into a Quick Response code embedded in a smart card. A unique identification number and participant's blood group type will be on the outside of the card. There will be no names or any other identifiers. Each participating center will identify a dedicated delivery room staff that will be trained to read the contents of the card using the cell phone application as well as enter new data in the participant's profile. When a participant presents at delivery without the card, information can still be obtained from the secure, web-based database and confirmed using the participant's name, date of birth and cell phone number. This information is provided to the clinician to guide management of the infant."
224190748|NCT04158518|RADIATION|Toxicities reduced treatment|"Drug: docetaxel and cisplatin (Induction chemotherapy) Patients receive docetaxel (75 mg/m2 d1) and cisplatin (25mg/m2 d1-3) every 3 weeks for 3 cycles before IMRT.~Omitting concurrent cisplatin chemotherapy when responses to induction chemotherapy are ≥ 50% Partial Response(PR).~Radiation: IMRT Intensity modulated-radiotherapy (IMRT) is given as 2.2 Gy per fraction with five daily fractions per week for 6-7 weeks to a total dose of 66 or 70.4 Gy to the primary tumor."
224190749|NCT04158518|RADIATION|Conventional treatment|"Drug: docetaxel and cisplatin (Induction chemotherapy) Patients receive docetaxel (75 mg/m2 d1) and cisplatin (25mg/m2 d1-3) every 3 weeks for 3 cycles before IMRT.~Concurrent cisplatin chemoradiotherapy delivered when responses to induction chemotherapy are less than 50% Partial Response(PR).~Radiation: IMRT Intensity modulated-radiotherapy (IMRT) is given as 2.2 Gy per fraction with five daily fractions per week for 6-7 weeks to a total dose of 66 or 70.4 Gy to the primary tumor."
224190750|NCT04606797|DRUG|Nicotine patch|Nicotine transdermal patches as per product monograph
224190751|NCT05709392|PROCEDURE|Delayed cord clamping and early skin-to-skin contact|A new method for taking care of remature infants born in gestational weeks 30+0-34+6 will be introduced with delayed cord clamping and early skin-to-skin-contact with a parent. If the infant needs help with the breathing this can be given during the time when the cord is still intact.
224309694|NCT06506214|OTHER|Questionnaires|"Responses to questionnaires:~* Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI)~* Medical Adherence Self-Report Inventory (MASRI)~* Morisky Medication Adherence Scale (MMAS4)~* Visual analog scale (VAS) on the perception of disease control~* Belief on Medicine Questionnaire (BMQ)~* Care patient Feedback measure~* Hospital Anxiety and Depression Scale (HAD)~* Dermatology Life Quality Index (DLQI)"
223500585|NCT04664088|DRUG|Venlafaxine|Participants in this group will receive oral administration of venlafaxine 50 mg once a day for 8 weeks. In case of intolerable acute VM attacks, the patients will be instructed to take triptans as rescue medication, and the dosage of medication will be documented.
224190752|NCT04885218|DRUG|SHR-1209 ;placebo|SHR-1209 and placebo 150 mg subcutaneous injection once every 4 weeks for 48 weeks
224190753|NCT04885218|DRUG|SHR-1209 ;placebo|SHR-1209 and placebo 300 mg subcutaneous injection once every 8 weeks for 48 weeks
224190754|NCT04885218|DRUG|SHR-1209 ;placebo|SHR-1209 and placebo 450 mg subcutaneous injection once every 12 weeks for 48 weeks
224190755|NCT01347905|OTHER|Stable-isotope techniques|Iron absorption will be estimated using stable-isotope techniques where incorporation of 57Fe and 58Fe into erythrocytes is measured 14 days after administration. The subjects will provide an initial blood sample (20ml) and then receive a test drink, containing 6 mg of 57Fe labeled ferrous sulphate. One hour later, 2 ml of an aqueous solution containing 100 μg 58Fe, as iron citrate in 250cc of normal saline will be infused over 50 min. Post infusion a 4ml blood sample will be taken. This procedure will be performed at baseline (6 weeks post-surgery) and at the end of the study (6-7 months post baseline).
224190756|NCT02906527|DRUG|Non-exposed group|Non-exposed group / Patients receiving VKA
224190757|NCT02906527|DRUG|Exposed group|Exposed group / Patients receiving DOAC
224190758|NCT04704791|PROCEDURE|PA-LAA shunt|At the time of surgery a covered stent will be inserted through the atriotomy into the left pulmonary artery and balloon dilated to stabilize the device. The target shunt diameter will be 3.5-4 mm to minimize LAA stasis.
224190759|NCT00193076|DRUG|Gemcitabine|Gemcitabine
224190760|NCT00193076|DRUG|Carboplatin|Carboplatin
224190761|NCT00193076|DRUG|Trastuzumab|Trastuzumab
223500586|NCT03128086|PROCEDURE|Protocol-directed weaning|A protocol-directed weaning in neurological patients undergoing mechanical ventilation will reduce the rate of extubation failure and associated complications comparing with a conventional weaning (control group)
223500587|NCT00409760|DRUG|valsartan+amlodipine combination, valsartan, amlodipine|
223500588|NCT00541229|DRUG|sitagliptin phosphate|sitagliptin 100 mg tablets q.d. (once daily) for 7 days.
223500589|NCT00541229|DRUG|sitagliptin phosphate|sitagliptin 200 mg tablets q.d. (once daily) for 7 days.
223500590|NCT00541229|DRUG|Comparator: Placebo|sitagliptin 100 mg \& 200 mg matching Placebo tablets q.d. (once daily) for 7 days.
223500591|NCT00134719|BIOLOGICAL|MenHibrix (Hib-MenCY-TT)|One intramuscular dose at 2, 4 and 6 months of age ( group A) and one intramuscular dose at 12 to 15 months of age (groups A and B)
223500592|NCT00134719|BIOLOGICAL|Infanrix® Penta|One intramuscular dose at 2, 4 and 6 months of age
224190762|NCT05915507|OTHER|pranayama plus acupoint stimulation by laser|"This group will receive 3-session per-week laser stimulation (for eight weeks) to some selected acupoints and daily pranyama exercises (nearly every session will be one hour), the stimulated bilateral acupoints will be (LI 19, LI 20, ST2, and ST4. ST6, ST7, ST17, ST36, SI18, BL2, GB14, GV24 and EXHN5). Every acupoint will be stimulated with laser power of 100 mw that will be used on a spot area of 1 cm2 for 1 minute.~this group will receive also pranayama session (applied daily, one hour approximately, for eight weeks) composed from (alternate nostril pranayama, diaphragmatic pranayama, rapid abdominal pranayama, Bhramari pranayama )"
224190763|NCT05915507|OTHER|acupoint stimulation by laser|This group will receive 3-session per-week laser stimulation (for eight weeks) to some selected acupoints, the stimulated bilateral acupoints will be (LI 19, LI 20, ST2, and ST4. ST6, ST7, ST17, ST36, SI18, BL2, GB14, GV24 and EXHN5). Every acupoint will be stimulated with laser power of 100 mw that will be used on a spot area of 1 cm2 for 1 minute.
224190764|NCT05776407|DRUG|ThisCART19A|Single dose of Allogeneic Anti-CD19 CAR T cells (ThisCART19A) will be infused after the lymphodepletion conditioning of Fludarabine, Cyclophosphamide and Etoposide.
224190765|NCT05776407|DRUG|Fludarabine|Fludarabine is used for lymphodepletion.
224190766|NCT05776407|DRUG|Cyclophosphamide|Cyclophosphamide is used for lymphodepletion.
224190767|NCT05776407|DRUG|Etoposide|Etoposide is used for lymphodepletion.
224190768|NCT01193478|DRUG|GS-5885|tablet, oral, 3 mg once daily for 3 days
224190769|NCT01193478|DRUG|Placebo|tablet, oral, once daily for 3 days
224190770|NCT01193478|DRUG|GS-5885|tablet, oral, 10 mg once daily for 3 days
224190771|NCT01193478|DRUG|Placebo|tablet, oral, once daily for 3 days
224190772|NCT01193478|DRUG|GS-5885|tablet, oral, 30 mg once daily for 3 days
223500593|NCT00134719|BIOLOGICAL|Prevenar®|One intramuscular dose at 2, 4 and 6 months of age
223500594|NCT00134719|BIOLOGICAL|ActHIB®|One intramuscular dose at 2, 4 and 6 months of age
223500595|NCT00134719|BIOLOGICAL|Meningitec®|One intramuscular dose at 2, 4 and 6 months of age
223500596|NCT00134719|BIOLOGICAL|M-M-R®II|One subcutaneous dose at 12-15 months of age
224190773|NCT01193478|DRUG|Placebo|tablet, oral, once daily for 3 days
223500597|NCT00134719|BIOLOGICAL|Varivax®|One subcutaneous dose at 12 to 15 months of age
223500598|NCT00134719|BIOLOGICAL|PedvaxHIB®|One intramuscular dose at 12 to 15 months of age
223500599|NCT03310515|BEHAVIORAL|Risk reduction counseling|Subjects will receive comprehensive prevention package including HIV and safe sex counseling, provision of condoms and water-based lubricant, and STI screening and referral for treatment.
224190774|NCT01193478|DRUG|GS-5885|tablet, oral, up to 90 mg once daily for 3 days
223500600|NCT03310515|OTHER|Social harm interview|Information regarding social harms (loss of privacy, stigmatization, interference with gainful employment, and coercion) will be solicited during bi-monthly study visits after enrollment in the study and will be recorded. Subjects who report social harms will be referred to speak with a social worker and/or a study counselor.
224190775|NCT01193478|DRUG|Placebo|tablet, oral, once daily for 3 days
224190776|NCT01193478|DRUG|GS-5885|tablet, oral, up to 90 mg once daily for 3 days
224190777|NCT01193478|DRUG|Placebo|tablet, oral, once daily for 3 days
223500601|NCT03310515|OTHER|Computer-Assisted Self Interviewing technique|Demographic, behavioral, and psychosocial factors associated with HIV acquisition will be assessed by CASI.
223500602|NCT00780039|DRUG|Pegylated Liposomal Doxorubicin|Subjects will receive Caleyx 30 mg/m2 intravenously on Day 1 of each 4-week cycle, during 6 cycles. Patients still achieving clinical benefit after a total of 6 cycles may continue therapy.
223500603|NCT00780039|DRUG|Carboplatin|Subjects will receive carboplatin dosed to target AUC of 5 mg/mL.min, intravenously, on Day 1 of each 4-week cycle, after the Caelyx infusion, during 6 cycles. Patients still achieving clinical benefit after a total of 6 cycles may continue therapy.
224190778|NCT01193478|DRUG|GS-5885|tablet, oral, up to 90 mg once daily for 3 days
223500604|NCT01765491|OTHER|Split-dose polyethylene glycol|Half gallon of polyethylene glycol to be taken between 7-9 pm on the day before colonoscopy and the remaining half between 7-9 am on the day of colonoscopy
223500605|NCT01765491|OTHER|Morning-only polyethylene glycol|One gallon of polyethylene glycol to be taken between 5am and 9am on the day of colonoscopy
223500606|NCT02214082|OTHER|Same Day Discharge|This group will be discharged home, on the same day after their elective angioplasty
223500607|NCT04866108|DRUG|fruquintinib plus capecitabine|oral fruquintinib plus capecitabine
223500608|NCT01331902|OTHER|Maximal Hyperemia with Adenosine Followed by Nicorandil|Firstly FFR was measured with intravenous adenosine infusion (140 μg•min-1•kg-1) via femoral vein or antecubital vein. Secondly with intracoronary adenosine bolus injection (80μg, 40μg to LCA and RCA, respectively). Lastly with intracoronary nicorandil bolus injection (1mg followed by 2mg).
223500609|NCT01331902|OTHER|Maximal Hyperemia with Nicorandil Followed by Adenosine|Firstly FFR was measured with intracoronary nicorandil bolus injection (1mg followed by 2mg). Secondly with intravenous adenosine infusion (140 μg•min-1•kg-1) via femoral vein or antecubital vein. Lastly with intracoronary adenosine bolus injection (80μg, 40μg to LCA and RCA, respectively).
223500610|NCT01203371|DRUG|Naftopidil|0,25 mg (2weeks) and 0,50 mg (10 weeks)
223500611|NCT01203371|DRUG|Tamsulosin|0,4 mg/day
223500612|NCT03439839|DRUG|iptacopan|iptacopan bid orally administered
223746215|NCT05330325|DRUG|Norditropin®|Norditropin® will be administered s.c. once daily using FlexPro® pen-injector.
224190779|NCT01193478|DRUG|Placebo|tablet, oral, once daily for 3 days
224190780|NCT04398797|OTHER|PATINA algorithm|Once a week community nurses receive a list of community dwelling citizens deemed at risk of deterioration that can lead to hospital admission. Nurses assess each citizens situation and initiate intervention if needed (not part of the intervention).
224190781|NCT05480046|DRUG|Risperidone ISM|Risperidone ISM is administered every 4 weeks
224190782|NCT03772210|DEVICE|tDCS|Current will be administered to subject groups as specified in arm descriptions.
224190783|NCT03772210|OTHER|Sham|Apparent Stimulation administered
224190784|NCT03246152|DRUG|Bevacizumab|Repeated intravitreal injections of Bevacizumab monthly
224190785|NCT04001374|DRUG|Ticagrelor|90mg tablet bid for 12 months
224190786|NCT04001374|DRUG|ASA|enteric coated aspirin 81mg-100mg daily p.o. for 12 months
224190787|NCT05629260|DRUG|ATG|Patients with intermediate-high risk hematologic malignancy who are indicated for allogeneic hematopoietic stem cell transplantation (allo-HSCT) and absence of HLA matched donors will be treated with haplo-HSCT, with G-CSF/ATG based protocol.
224190788|NCT05629260|DRUG|Post-transplantation cyclophosphamide|Patients with intermediate-high risk hematologic malignancy who are indicated for allogeneic hematopoietic stem cell transplantation (allo-HSCT) and absence of HLA matched donors will be treated with haplo-HSCT with PT-Cy based protocol.
224190789|NCT06159946|DEVICE|Access-H2O faucet|The assigned invention was developed to test the feasibility of the prototype of the Access-H2O faucet by assessing whether subjects can activate the faucet to control water outputs via the motion sensor, eye gaze, and a speech speaker. To activate the faucet via the motion sensor, each subject was asked to place his or her hand near the motion sensor. To activate the faucet via the eye gaze, each subject was asked to look directly at the eye gaze sensor. To activate the faucet via the speech speaker, each subject was asked to speak to the speaker. Each subject performed the same function three times. The water from the faucet was used for drinking, rinsing, and grooming.
224190790|NCT03205839|BEHAVIORAL|Acceptance-based self-help intervention|"Surviving to Thriving: ACT self-help for living well with a visible difference in appearance.~A self-help booklet, based upon Acceptance and Commitment Therapy (ACT). The booklet includes some ACT techniques and encourages participants to set themselves behavioural tasks, based upon their values. There is a suggested timetable for participants to navigate through the self-help during the four-week intervention period.~In addition to the pdf booklet, there are accompanying audio exercises and a lived experience video."
224190791|NCT03301207|DRUG|Ibrutinib|Ibrutinib capsule (at dose of 420 or 560 mg) will be taken orally QD.
224190792|NCT03301207|DRUG|OC: Ethinylestradiol (EE) 30 mcg and Levonorgestrel (LN) 150 mcg|Single dose of oral contraceptives (OC) (1 tablet containing 30 mcg EE and 150 mcg LN) will be taken orally on Study Days 1 and 22.
224190793|NCT03301207|DRUG|Bupropion|Bupropion 75 mg tablet as a part of CYP cocktail will be taken on Study Days 3 and 24.
224190794|NCT03301207|DRUG|Midazolam|Midazolam 2 mg (1 milliliter \[mL\]) oral solution will be taken on Study Days 3 and 24 (as a part of CYP cocktail) and on Study Day 8 (alone).
224190795|NCT01374516|BIOLOGICAL|Live, attenuated, dengue serotype 1, 2, 3, 4 virus|0.5 mL, Subcutaneous
224190796|NCT01374516|BIOLOGICAL|Placebo: (NaCl) 0.9% solution|0.5 mL, Subcutaneous
224190797|NCT03219372|DRUG|Pravastatin Pill|statin
224190798|NCT03219372|DRUG|Placebo Oral Tablet|placebo
223500613|NCT03439839|COMBINATION_PRODUCT|Standard of Care|Standard of Care (SoC) is defined as an antibody with anti C5 activity. At the time of study start, eculizumab was the only available SoC; eculizumab will be hereafter referred to as SoC.
224190799|NCT00683852|DRUG|Aripiprazole 5mg|Tablet dose of aripiprazole will be 2 mg/day during the first phase (30 days) of the study, and 5 mg/day in the second phase (30 days)
223500614|NCT06145074|DRUG|Propranolol|Oral administration.
223500615|NCT06145074|DRUG|Placebo|Oral administration.
223500616|NCT02355834|OTHER|IBD nurse intervention|Two IBD nurse specialists at each centre (8 in total) will deliver the IBD nurse intervention
223746216|NCT06273891|DRUG|Erythromycin|"Erythromycin 250 mg IV every 6 hours for 48 hours, followed by 250 mg PO or 333 mg PO every 8 hours for 5 days~in addition to Ampicillin 2 gm IV every 6 hours for 2 days followed by Amoxicillin 250 mg PO every 8 hours for 5 days"
223746217|NCT06273891|DRUG|Azithromycin|"Azithromycin 1 gm PO once or 500 mg PO followed by 250 mg PO daily for a total of 5 days~in addition to Ampicillin 2 gm IV every 6 hours for 2 days followed by Amoxicillin 250 mg PO every 8 hours for 5 days"
223746218|NCT01719666|PROCEDURE|MPFL reconstruction and lateral retinaculum release|MPFL is performed with a standard technique using gracilis tendon. A tunnel is performed at the femoral part with a bioabsorbable screw fixation and 2 bundles with suture fixation at the patellar side
223746219|NCT01719666|PROCEDURE|conventional surgery|conventional surgery: MPFL reconstruction
224190800|NCT00683852|DRUG|Aripiprazole 2mg|For patients randomly assigned to the placebo/drug sequence, the dose of aripiprazole will be 2 mg/day during the second phase of the study (30 days)
224190801|NCT00683852|DRUG|Placebo|for patients randomly assigned to the placebo/placebo sequence, study medication will be placebo during both phases of the study (60 days)
223500617|NCT06552026|DEVICE|repeated transcranial magnetic stimulation|repetitive transcranial magnetic stimulation by use of high-frequency (10 Hz) left-side DLPFC stimulation is currently widely used in the treatment of depression17.Intermittent theta burst stimulation (iTBS) is a newer form of rTMS that can be delivered with shorter duration of stimulation sessions and apparent efficacy at lower stimulation intensities18. Both 10 Hz and intermittent theta burst stimulation pulses have an excitatory effect on cortical excitability
223746220|NCT05059067|DEVICE|Direct laryngoscopy for endotracheal intubation|Patients in operative room, intensive care unit and emergency department requiring direct laryngoscopy for endotracheal intubation
223746221|NCT00877058|BEHAVIORAL|preventive home visit|
223500618|NCT03247114|OTHER|Water|Water, 300 ml at room temperature
223500619|NCT03247114|OTHER|Glucose|Glucose, 50 grams in 300 ml water at room temperature
223500620|NCT03247114|OTHER|Fructose|Fructose, 50 grams in 300 ml water at room temperature
223500621|NCT03247114|OTHER|Sucrose|Sucrose, 50 grams in 300 ml water at room temperature
223500622|NCT03247114|OTHER|Sucralose|Sucralose, 0.33 grams in 300 ml water at room temperature
223500623|NCT01807520|BIOLOGICAL|Secukinumab|Study treatment was provided in pre-filled 1 mL syringes.
223500624|NCT01807520|BIOLOGICAL|Placebo|Placebo was provided in pre-filled 1 mL syringes.
223500625|NCT00990288|DRUG|Hemostatic Matrix|FloSeal will be administered following the cementing of all knee components. Prior to release of the tourniquet and after the cement has cured, it will be applied to cut, exposed bone ends as well as the intra-articular soft tissues by the use of a delivery syringe, Direct manual pressure with a gauze sponge will be applied following its application for 2 minutes, ensuring that it adheres to the bleeding bone surface.
223746222|NCT00877058|BEHAVIORAL|senior meetings|
223746223|NCT00284661|PROCEDURE|FAST FIX|Fast fix repair of a meniscal tear
223746224|NCT00284661|PROCEDURE|Meniscal suturing|standard suturing of meniscal tear
224190802|NCT03964142|OTHER|Cardiac rehabilitation|"Integrated cardiac rehabilitation program that includes supervised exercise training\*.~\* Due to the COVID-19 pandemic, supervised physical exercise training had to be conducted telematically (through live guided training sessions conducted online, with the same design, frequency, and dosage of exercise)."
224190803|NCT03598075|OTHER|Amylin (Pramlintide)|Pramlintide is a amylin analog. It will be given intravenously at the rate of 120 micrograms over 20 minutes .
224190804|NCT03598075|OTHER|CGRP|CGRP It will be given intravenously at the rate of 30 microgram over 20 minutes.
224190805|NCT01741727|DRUG|ABT-414|ABT-414 will be administered by intravenous infusion.
224190806|NCT02290652|OTHER|Prospective - Factors affecting sexual function pre-THR|"A prospective assessment of factors affecting sexual function in patients whom are awaiting a total hip replacement.~Patients will carry out a prospective 23 question questionnaire: 'Arthroplasty \& Sexual Function Questionnaire (ASFQ) - Pre-operative' with validated questionnaire Female Sexual Function Index (FSFI), before their operation.~Then at 6 months and 12 months post-operatively they will fill out a retrospective 30 question questionnaire: 'Arthroplasty \& Sexual Function Questionnaire (ASFQ) - Post-operative', again with FSFI."
224190807|NCT02290652|OTHER|Retrospective- Factors affecting sexual function post-THR|"A retrospective assessment of factors affecting sexual function in patients whom have undergone a total hip replacement (THR) in the preceding year.~Patients will carry out a retrospective 30 question questionnaire: 'Arthroplasty \& Sexual Function Questionnaire (ASFQ) - Post-operative' with validated questionnaire Female Sexual Function Index (FSFI), at 6 months and/or 12 months (wherever possible).~Maximum retrospective collection of data 12 months."
224190808|NCT06271226|OTHER|acupressure|With acupressure, massage or pressure is applied to certain points on the body with fingers, hands or palms. The pressed points are the points on the skin that are sensitive to bioelectrical impulses and can easily transmit them.
224190809|NCT06271226|OTHER|placebo acupressure|n the placebo group, the preparations and forms applied to the experimental group will be applied in the same way, but in accordance with the literature, an area 1.5 cm away from the acupressure point that has no connection with the acupressure point will be selected and the application will be made in the form of light touch
224190810|NCT06271226|OTHER|control group|During the study, pain and physiological parameters will be monitored and recorded twice a day (morning and evening) for 2 days, without any application (other than the routine treatment given by the physician).
224190811|NCT01000909|PROCEDURE|Ultrasound (venous pressure measurement)|increased venous pressure is predictive for chronic venous insufficiency
224309695|NCT03996642|BEHAVIORAL|Avatar Life Review|VoicingHan will screen-capture patient's storytelling performances as video files. Immediately before the first intervention, patients will complete an array of self-reported questionnaires to assess physical, spiritual, and psychological well-being and elicit relevant demographic and medical information. The assessments include the ESAS, FACIT-Sp subscale, and EORTC PAL 15. Subsequent administration of these questionnaires spaced 2-4 weeks apart will occur before each avatar session (pre-intervention). This will determine if intensity of the patient's symptoms have changed over the course of the intervention. Following completion of the Avatar session, a member of the research team will conduct a semi-structured, open-ended interview to assess patients' perception of intervention components and identify possible factors influencing intervention feasibility and any technical barriers.
223500626|NCT04663672|OTHER|Experimental Scent|Participants will sleep in the presence of the exposure scent, delivered by an Airwick Essential Oils diffuser
223500627|NCT04663672|OTHER|Control Scent|Participants will sleep in the presence of a novel scent, delivered by an Airwick Essential Oils diffuser
223500628|NCT04663672|OTHER|No-Scent Control|Participants will sleep in the presence of an odorless control vehicle, delivered by an Airwick Essential Oils diffuser
223500629|NCT04663672|BEHAVIORAL|In-Vivo Exposure|Participants will receive 40 minutes of in-vivo exposure therapy to feared targets in the presence of a distinctive exposure scent.
223500630|NCT03348397|PROCEDURE|right ventricular outflow tract reconstruction with contegra|Contegra pulmonary valved conduit is an animal jugular vein that contains a valve with three leaflets that are similar to a human heart valve.
223500631|NCT03348397|PROCEDURE|right ventricular outflow tract reconstruction with pulmonary homograft|cryopreserved pulmonary homografts
223500632|NCT05037383|OTHER|Video recordings|The surgery of the patient will be recorded by cameras placed on the top of the displays used by the operating staff. The recordings will be only carried out while the patient is draped for the surgery, thus completely covered.
223500633|NCT05134818|OTHER|observer tool|comparison of the efficacy of an observer tool to enhance learning of technical skills of CVC insertion in anesthesiology residents The resident will complete an observer tool each time another resident is observed to insert a CVC on the simulator.
223500634|NCT01000714|DRUG|Psirelax|
224190812|NCT00814502|DRUG|Zolpidem CR|After a 48-hour period of baseline actigraphy and clinical measurements, study subjects were randomized to take either Zolpidem CR 6.25mg by mouth (1 pink tablet) or Placebo by mouth (also 1 pink tablet) for up to 3 weeks or the end of the subjects' hospital stay.
224190813|NCT00814502|DRUG|Placebo|After a 48-hour period of baseline actigraphy and clinical measurements, study subjects were randomized to take either Zolpidem CR 6.25mg by mouth (1 pink tablet) or Placebo by mouth (also 1 pink tablet) for up to 3 weeks or the end of the subjects' hospital stay.
223500635|NCT05124184|DEVICE|GORE® PROPATEN® Vascular Graft|Patients that have had treatment with GORE® PROPATEN® Vascular Graft
224190814|NCT02694393|DRUG|sodium nitrite|inhalation of 46 or 80 mg of sodium nitrite by electronic nebulization
224190815|NCT01211210|DRUG|fluorouracil|Drug: fluorouracil Given IV continuously Radiation: radiation therapy Given 5 days a week for 5-6 weeks
224190816|NCT01211210|DRUG|fluorouracil, oxaliplatin|Drug: fluorouracil Given IV continuously Drug: oxaliplatin Given IV Radiation: radiation therapy Given 5 days a week for 5-6 weeks
224190817|NCT01211210|DRUG|fluorouracil, oxaliplatin|Drug: fluorouracil Given IV continuously Drug: oxaliplatin Given IV
224309696|NCT00294463|DRUG|Tibolone|
224309697|NCT00294463|DRUG|Estradiol|
224309698|NCT00294463|DRUG|Estradiol + Medroxy Progesterone Acetate|
224190818|NCT01225029|OTHER|Amount of total fluids|Term neonates receive either total fluids of 60 mL/kg/day (standard) or 40 mL/kg/day (restricted) on day of life (DOL) 1. Preterm neonates receive total fluids of 80 mL/kg/day (standard) or 60 mL/kg/day (restricted) on DOL 1. Each group receives an extra 20 mL/kg/day daily until total fluids of 150 mL/kg/day are achieved.
224190819|NCT05288400|COMBINATION_PRODUCT|Amlodipine 5mg + bisoprolol fumarate 5mg + perindopril arginine 5mg|1 capsule/day Oral administration
224190820|NCT05288400|DRUG|Norvasc 5mg tablet|Norvasc (amlodipine) 5mg, 1 tablet/day
224190821|NCT05288400|DRUG|Concor 5mg tablet|Concor (bisoprolol fumarate) 5mg, 1 tablet/day
224190822|NCT05288400|DRUG|Coversyl 5mg tablet|Coversyl (perindopril arginine) 5mg, 1 tablet/day
224190823|NCT03713515|BEHAVIORAL|ALTA|The study will involve each site starting with the usual care phase, followed by a period of 6 months during which practice facilitators will conduct the pre-implementation evaluation (e.g., workflow analysis, environmental scan), refine the practice facilitation strategies that will be used in the implementation phase, and train staff in the Advancing Medication Adherence for Latinos with Hypertension through a Team-based Care Approach (ALTA) intervention model. ALTA is an efficacious systems-level intervention designed to help patients improve their ability to take their high blood pressure medications and control their blood pressure. Practices and the Project ALTA team will work together to implement the ALTA model into routine care to improve blood pressure control and medication adherence in Latinx patients.
224190824|NCT05658133|OTHER|Survey of sports nutrition knowledge|Questionnaire
224190825|NCT01050998|BIOLOGICAL|Mavrilimumab 10 mg|Mavrilimumab (CAM-3001) 10 mg injection subcutaneously every other week for 12 weeks.
224190826|NCT01050998|BIOLOGICAL|Mavrilimumab 30 mg|Mavrilimumab (CAM-3001) 30 mg injection subcutaneously every other week for 12 weeks.
224190827|NCT01050998|BIOLOGICAL|Mavrilimumab 50 mg|Mavrilimumab (CAM-3001) 50 mg injection subcutaneously every other week for 12 weeks.
224190828|NCT01050998|BIOLOGICAL|Mavrilimumab 100 mg|Mavrilimumab (CAM-3001) 100 mg injection subcutaneously every other week for 12 weeks.
224190829|NCT01050998|OTHER|Placebo|Placebo matched to mavrilimumab injection subcutaneously every other week for 12 weeks.
224190830|NCT06312501|DEVICE|Satelia®Cardio|Use of a remote patient monitoring system by NP Medical.
224190831|NCT06312501|OTHER|Conventional care|No use of RPM solutions for follow-up
224190832|NCT00370994|PROCEDURE|Caudal epidural injection|Caudal epidural injection with catheterization
224190833|NCT00370994|PROCEDURE|Percutaneous adhesiolysis|Percutaneous adhesiolysis with hypertonic saline neurolysis
224190834|NCT01791166|BIOLOGICAL|Blood test for detecting the circulatory anti-HLA antibodies by ELISA and LUMINEX tests|
224190835|NCT02219477|DRUG|ombitasvir/paritaprevir/ritonavir|tablet; paritaprevir co-formulated with ritonavir and ombitasvir
224190836|NCT02219477|DRUG|dasabuvir|tablet
224190837|NCT02219477|DRUG|ribavirin|tablet
224190838|NCT02272738|DRUG|Gemcitabine|Gemcitabine is administered with 30 min intravenous infusion on day 1,8 and 15 every 4 weeks.
224190839|NCT02272738|DRUG|Nab-Paclitaxel|Nab-Paclitaxel is administered with 30 min intravenous infusion on day 1,8 and 15 every 4 weeks.
224190840|NCT02561689|OTHER|Fissure sealing|"Procedure:~* The included teeth of the participating patients will in any case be sealed, but in this study, the operator is not free to choose the material, the material choice is determined by randomisation~* Standardized radiographs (bitewings) will be taken before treatment and after 1, 2, 3 years and possibly after 5 years. Baseline radiograph can be taken up to six months before treatment. If using conventional radiography, double-film packs will be used. A maximum of 8/10 bitewings will be taken during the study period of 3/5 years~* The occlusal surface is sealed by the dentist or dental hygienist.~* Clinical evaluation of the quality of sealants and the need for re-treatments during the follow-up will be performed after 1, 2 and 3 years and possibly after 5 years"
224190841|NCT04274569|OTHER|NaF vanish|A disposable micro-brush will be used to apply the varnishes to all tooth surfaces. The fluoride varnish will be applied every 3 months, from baseline to 24-months follow-up.
223500636|NCT05124184|DEVICE|GORE-TEX® Vascular Grafts|Patients that have had treatment with GORE-TEX® Vascular Grafts
223500637|NCT01886157|PROCEDURE|Corticosteroid injection + Trigger Splint+ Education and Home exercises|Standard corticosteroid injection. Hand based, single digit trigger splint will be applied. Education and instructions about home exercises.
223500638|NCT01886157|PROCEDURE|Corticosteroid injection|Standard trigger finger corticosteroid injection.
223500639|NCT06288178|DIETARY_SUPPLEMENT|Bread consumption|There were four groups: whole wheat (WWB), buckwheat (BWB), corn bread (CB) and reference bread.
223500640|NCT03979989|DRUG|Tapentadol IR capsule|Tapentadol IR capsule containing 93 mg tapentadol hydrochloride.
223500641|NCT03979989|DRUG|Omeprazole capsule|Omeprazole capsule containing 40 mg omeprazole.
223500642|NCT01797185|DRUG|SPARC1104 modified dose regimen I|Subjects who exited study CLR\_09\_21
223500643|NCT01797185|DRUG|SPARC1104 modified dose regimen II|Subjects who received prior treatment regimen I
223500644|NCT01797185|DRUG|SPARC1104 modified dose regimen III|Subjects who received no prior treatment regimen
224190842|NCT04274569|OTHER|NaF-TCP|A disposable micro-brush will be used to apply the varnishes to all tooth surfaces. The fluoride varnish will be applied every 3 months, from baseline to 24-months follow-up.
224190843|NCT04274569|OTHER|NaF-CPP-ACP|A disposable micro-brush will be used to apply the varnishes to all tooth surfaces. The fluoride varnish will be applied every 3 months, from baseline to 24-months follow-up.
224190844|NCT02598362|DRUG|ciprofloxacin|Serum and urine concentrations after ciprofloxacin administration. pharmacokinetic testing after ciprofloxacin administration
224190845|NCT02071823|DRUG|BIA 9-1067|A single oral dose of 50 mg (2 x 25 mg capsules) was administered in the morning of each study period under fasting or fed conditions. The two single dose administrations were separated by a wash-out of 7 days.
224190846|NCT01985555|DRUG|Volitinib(HMPL-504)|Volitinib(HMPL-504) is a tablet in the form of 25 mg ,100mg and 200 mg,oral,once daily or 2 times a day.
224190847|NCT02787655|BEHAVIORAL|Aerobic exercise + Cognitive Training Group|stationary bicycling
224190848|NCT02787655|BEHAVIORAL|Cognitive training Only|20 minutes of cognitive training using Mindfit program
224190849|NCT02185131|DRUG|Mirtazapine|Gelatin capsules mirtazapine 15 mg, 1 capsule every a.m. Medication will be increased by one capsule, to a dose of 2 capsules barring side effects, at Week 2.
224190850|NCT02185131|DRUG|Placebo|Gelatin capsules Placebo capsules, identical to mirtazapine capsules, 1 capsule every a.m. Medication will be increased by one capsule to 2 capsules at Week 2, barring any side effects.
224190851|NCT00883402|PROCEDURE|CEA, CAS|Carotid Artery Stenting (CAS) Carotid endarterectomy (CEA)
224190852|NCT00283517|DRUG|antipsychotics|as prescribed
224190853|NCT00234533|DRUG|Somatropin (rDNA origin)|Daily subcutaneous injections, 0,025 - 0,05 mg/kg/day for 6 months.
224190854|NCT00976989|DRUG|Pertuzumab|840 mg loading dose intravenously (IV), then 420 mg IV 3-weekly.
224190855|NCT00976989|DRUG|Trastuzumab|8 mg/kg loading dose IV, then 6 mg/kg every 3 weeks.
224190856|NCT00976989|DRUG|FEC|5-fluorouracil 500 mg/m\^2, epirubicin 100 mg/m\^2 and cyclophosphamide 600 mg/m\^2.
224190857|NCT00976989|DRUG|Docetaxel|75 mg/m\^2 for the first dose; 100 mg/m\^2 if no dose limiting toxicity occurs.
224190858|NCT00976989|DRUG|TCH|Trastuzumab followed by carboplatin at target area under the plasma concentration-time curve (AUC) 6 and docetaxel at a starting dose of 75 mg/m\^2. All treatments were given every three weeks by the IV route.
224190859|NCT00010634|DRUG|Connective Tissue Nutrient Formula|
224190860|NCT00010634|DRUG|Adaptogenic herbs|
224190861|NCT00010634|DRUG|glutamine|
224190862|NCT03134001|DEVICE|patients receiving oral analgesics via the PCoA™ Acute|PCoA™ Acute is an oral PCA device, designed to provide safe and easy-to-use pain medication at the bedside. It identifies patients by Radio Frequency Identification (RFID) technology and provides pill dispensing upon patient's request.
223500645|NCT00723944|DEVICE|Osseotite Certain Prevail|Root form titanium dental implant
223500646|NCT00723944|DEVICE|Osseotite Certain|Dental implant without the lateralized design
223591525|NCT03986528|DRUG|Chemotherapy|Patients will receive investigator's choice of paclitaxel (135mg/m2 by IV infusion on Day 1 of each 21-28 day cycle) or pemetrexed (500mg/m2 by IV infusion on Day 1 of each 21-28 day cycle) or gemcitabine(1000mg/m2 by IV infusion on Days 1,8 of each 21-28 day cycle) PLUS cisplatin (75mg/m2 by IV infusion on Days 1 to 3 of each 21-28 day cycle) or carboplatin (AUC 6 by IV infusion on Days 1 of each 21-28 day cycle) according pathologic types. Patients with CR, PR, or SD after 4-6 cycles of platinum-based double chemotherapy regimens will receive non-platinum single-agent chemotherapy.
224190863|NCT00272194|DEVICE|Ambu Laryngeal Mask|
224190864|NCT00272194|DEVICE|Aintree Exchange Catheter|
224190865|NCT00272194|DEVICE|Laryngeal Mask Airway|
224190866|NCT01487109|DRUG|CTP-499|600 mg tablet twice daily
224190867|NCT01487109|DRUG|Placebo|Matching placebo tablet
224190868|NCT00889928|DEVICE|NOTES GEN 1 Toolbox|"* Articulating Hook Knife~* Articulating Snare~* Articulating Needle Knife~* Articulating Graspers~* Articulating Biopsy Forceps~* Steerable Flex Trocar with Rotary Access Needle~* Flexible Bipolar Hemostasis Forceps~* Flexible Maryland Dissector"
224190869|NCT03495765|DRUG|Ranibizumab|Ranibizumab 0.5mcg via intravitreal injection to study eye up to monthly
223500647|NCT04947722|BEHAVIORAL|PREVENT Program|A standardized PREVENT educational program will be offered to each intervention LTC home and health-care staff. The curricula includes video modules with fracture-prevention care recommendations and an orientation to the Fracture Prevention Toolkit. Using the Fracture Risk Scale (i.e., a clinical decision support tool embedded in the RAI-MDS 2.0), the LTC team will identify residents at high-risk for fracture and will implement the fracture prevention recommendations into care plans on an individual resident basis.
223500648|NCT03799367|DEVICE|Drug delivery during breastfeeding|This study aims to give a vitamin B12 supplement to babies during breastfeeding. 30 mother-infant pairs will be recruited. The supplement will be placed into a nipple shield, both of which are commercially available, and the mother will breastfeed her baby as usual. Before and after the feed, we will 1) collect a small blood sample from the baby to see whether the vitamin levels in the infant have increased, 2) ask the mother to participate in two short interviews about her expectations and experiences using the Therapeutic Nipple Shield.
223500649|NCT03274258|BIOLOGICAL|Ipilimumab|Given IV
223500650|NCT03274258|BIOLOGICAL|Nivolumab|Given IV
223591526|NCT04435028|DRUG|Ketotifen 1 MG|Ketotifen is added to patients on anthracycline-containing chemotherapy for 6 months
223591527|NCT06583915|PROCEDURE|TENS|Non-pharmacological method which is widely used by medical and paramedical professionals for the management of acute and chronic pain using electric pulse generator, lead wires and electrodes.
223746225|NCT06228560|BIOLOGICAL|LP-003|Liquid in vial
223746226|NCT06228560|BIOLOGICAL|Placebo|Liquid in vial
224190870|NCT00678652|BIOLOGICAL|10 μg Group B Meningococcal 8570 HOPS-G NOMV Vaccine|10 μg of Meningococcal 8570 HOPS-G NOMV Vaccine given at 0, 6, and 12 weeks, administered intramuscularly to healthy subjects for duration of study
224190871|NCT00678652|BIOLOGICAL|25 μg Group B Meningococcal 8570 HOPS-G NOMV Vaccine|25 μg of Meningococcal 8570 HOPS-G NOMV Vaccine given at 0, 6, and 12 weeks, administered intramuscularly to healthy subjects for duration of study
223746227|NCT06228560|BIOLOGICAL|Omalizumab|Liquid in vial
223746228|NCT06812481|OTHER|Anticholinergic load was calculated using anticholinergic cognitive load (ACB)|"Bone mineral density was measured using a Dual Energy X-ray Absorptiometry (DEXA) device.~Fracture Risk Assessed with Fracture Risk Assessment Tool (FRAX)."
224190872|NCT00678652|BIOLOGICAL|50 μg Group B Meningococcal 8570 HOPS-G NOMV Vaccine|50 μg of Meningococcal 8570 HOPS-G NOMV Vaccine given at 0, 6, and 12 weeks, administered intramuscularly to healthy subjects for duration of study
224190873|NCT00678652|BIOLOGICAL|75 μg Group B Meningococcal 8570 HOPS-G NOMV Vaccine|75 μg of Meningococcal 8570 HOPS-G NOMV Vaccine given at 0, 6, and 12 weeks, administered intramuscularly to healthy subjects for duration of study
224190874|NCT01033110|BEHAVIORAL|Exercise and Nutrition Education|Guided nordic walking training and 12 presentations about diet and health.
224190875|NCT00037908|PROCEDURE|Strength training|
224190876|NCT05596409|DRUG|Elacestrant|Starting dose 400 mg elacestrant dihydrochloride administered orally once daily for an estimated 6 months of treatment.
224190877|NCT05712603|DIAGNOSTIC_TEST|FIB4-score|A score which estimates the risk for advanced liver fibrosis, based on: age, ALT, AST and thrombocytes
224190878|NCT05712603|DIAGNOSTIC_TEST|Vibration controlled transient elastography|VCTE measures the speed of a mechanically generated shear wave across the liver to derive a liver stiffness measurement (LSM), a marker of hepatic fibrosis
224190879|NCT05712603|DIAGNOSTIC_TEST|Enhanced Liver Fibrosis test|The ELF-test is a non-invasive blood test that measures three direct markers of liver fibrosis: hyaluronic acid (HA), procollagen III amino-terminal peptide (PIIINP), and tissue inhibitor of matrix metalloproteinase 1 (TIMP-1).
224190880|NCT01687127|DIETARY_SUPPLEMENT|Folic acid|Supplement
223500651|NCT06093711|DIAGNOSTIC_TEST|Description|All patients were briefed about the research purpose and procedure. They were also informed about the following points: (1) participation is voluntary, (2) they can withdraw from the study at any stage without explanation, (3) the data will be used only for scientific purposes and will not be shared with third parties, and (4) they will remain anonymous throughout the research. Informed consent was obtained from those who agreed to participate. It took each participant 20-25 minutes to fill out the data collection tools.
224190881|NCT01687127|DIETARY_SUPPLEMENT|5-methyltetrahydrofolate, calcium salt|Supplement
224190882|NCT06165471|BEHAVIORAL|Online and offline blended teaching|The Chaoxing app is an interventional tool, a professional mobile learning platform for smartphones, tablet computers, and other mobile terminals. They will learn the online course on the Chaoxing app and carry out offline classroom learning. The online courses focus on teaching design to make teaching PowerPoint, teaching videos, micro-lessons, homework library, and so on.
223591528|NCT06583915|PROCEDURE|Dry Needle|Invasive procedure where a fine needle or acupuncture needle is inserted into the skin and muscle.
223500652|NCT01803386|DEVICE|EIM Measurements|EIM measurements are taken by applying saline to the skin and placing a sensor on patients' muscles that will record electrical activity. Electrical current is generated by this machine, but patients will not be able to feel it. The electrical activity recorded is returned to the machine and analyzed by a computer.
223500653|NCT04461392|DIAGNOSTIC_TEST|Cardiorespiratory exercise test|"* Cardiorespiratory exercise test to evaluate the exercise tolerance~* Cardiac imaging for the assessment of the left atrium anatomy and function."
223591529|NCT01041287|DRUG|Nebivolol|Nebivolol 5 mg PO qday for 2 weeks, titrated up to Nebivolol 10 mg PO qday if BP is \>125/80 for the 2 more weeks, and then titrated up to Nebivolol 20 mg PO qday if BP is \>125/80 for the remaining 8 weeks
223591530|NCT01041287|DRUG|Metoprolol succinate|Metoprolol 50 mg PO qday for 2 weeks, titrated up to Metoprolol 100 mg PO qday if BP is \>125/80 for the 2 more weeks, and then titrated up to Metoprolol 200 mg PO qday if BP is \>125/80 for the remaining 8 weeks
224190883|NCT06165471|BEHAVIORAL|Traditional teaching|The researchers will implement the traditional teaching intervention of a surgical nursing practice course to the control group, and the teacher will demonstrate the operation procedure to the students face to face offline, and the students will practice. The whole intervention time is two months.
224190884|NCT05206305|DEVICE|GammaSense Stimulation device|Cognito Therapeutics GammaSense Stimulation device delivers sensory (auditory and visual) stimuli at a rate of 40 Hz to the wearer for one hour each day.
223500654|NCT03945890|OTHER||
223500655|NCT05177094|DRUG|LY3526318|Administered orally
223500656|NCT05177094|DRUG|Placebo|Administered orally
223500657|NCT03546959|OTHER|Lycra sleeve|custom-fitted lycra sleeve extending from axilla to wrist
223591531|NCT04087577|OTHER|conventional physical therapy|includes electrical stimulation for denervated muscles, and soft tissue massage, joint range of motion exercises to maintain the flexibility of the affected joint, muscle or connected tissues, sensory relearning
223591532|NCT04087577|OTHER|mirror therapy|mirror therapy
223591533|NCT01257945|BEHAVIORAL|Aerobic Exercise|
223591534|NCT01257945|BEHAVIORAL|Flexibility and Function exercise program|
223591535|NCT01257945|BEHAVIORAL|Home exercise program|
223591536|NCT02269930|DRUG|peginterferon beta-1a|Administered as subcutaneous injection
223591537|NCT02269930|DRUG|Rebif|Administered as subcutaneous injection
223591538|NCT03261609|OTHER|preterm birth|The study compares young adult subjects born premature (\< 29 weeks) versus term (-\> 37 weeks)
223591539|NCT02501499|OTHER|Breastfeeding Buddies|a 2 hour breastfeeding workshop and if mother chooses, she is matched with a buddy who will contact her and offer breastfeeding support
223591540|NCT02814175|DRUG|methotrexate (MTX)|
223591541|NCT02814175|BIOLOGICAL|adalimumab (ADA)|
224190885|NCT01379404|DEVICE|Bioelectric Impedance Analysis|Bioimpedance devices are compact, portable, easy to use, relatively inexpensive and can be used to make repeated non-invasive measurements. Bioimpedance measures the impedance to the flow of an electric current through body fluids and consists of two components, resistance and reactance. Resistance is a measure of electrical current a substance will oppose and is inversely related to tissue fluid content. Reactance is the capacitative component of impedance and indicates energy stored by cell membranes and organelles; due to this property, reactance is associated with tissue cell mass. These raw measures provide a measure of volume as determined by vector length and the RXc graph method.
224190886|NCT00477542|DRUG|clofarabine|"Cohort- n- Clofarabine (mg/m2/day)~-1 3-10 20~1. 3-6 30~2. 3-6 40~3. 3-6 50~4. 3-6 60~5. 6-10 70"
223500658|NCT03546959|OTHER|Rehabilitation|Passive, active and active assistive range of motion and stretching exercises for shoulder, elbow, wrist, facilitation and inhibition techniques, neuromuscular electrical stimulation for wrist extensors, strengthening exercises for affected upper extremity, occupational therapy
223500659|NCT03546959|DRUG|Botulinum Toxin|Botulinum toxin injection for upper limb spasticity after stroke
223591542|NCT06256263|PROCEDURE|total laryngectomy|pharyngeal repair after total laryngectomy
223591543|NCT00305539|DRUG|adalimumab|40 mg sc / for 3 months
223591544|NCT00305539|DRUG|placebo|placebo
223591545|NCT01438450|DRUG|Oral|"Capecitabine : 500 mg OD x 1 week 500 mg BD x 1 week 500 mg (2 morning, 1 evening) x 1 week After attaining the max dose of 1500 mg, a cycle of Capecitabine 1500mg every day for 2 weeks and 1 week off to be maintained.~Thalidomide: 50 mg OD x 1 week 100 mg OD x 1 week 200 mg OD x 1 week, 300 mg OD x 1 week"
224190887|NCT05150392|BIOLOGICAL|Investigational live attenuated varicella vaccine|The investigational vaccine was manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd.And the live varicella-zoster virus in 0·5 mL of sucrose, sodium glutamate,sodium chloride,potassium chloride,sodium dihydrogen phosphate, potassium dihydrogen phosphate and injection water per injection
224190888|NCT02585089|OTHER|Spanish cured-pork ham|"Dry-cured ham with reduced salt will be used in order to decrease the sodium intake that could affect blood pressure too. Such ham contains 25% lower salt than similar products on the market (3,7g vs 4,5g/100g).~Volunteers will receive 80g of cured pork ham daily for 28 consecutive days. They can eat the interventional product at any time of the day."
224190889|NCT02585089|OTHER|Cooked pork ham|Volunteers will receive 100g of cooked pork ham daily for 28 consecutive days. They can eat the product (placebo product) at any time of the day.
224190890|NCT06174792|DRUG|Drospirenone 4 MG|Patients who met all inclusion criteria and had no exclusion criteria would receive one tablet of Drospirenone 4mg daily for 20 weeks, starting from day 2 to day 5 of their menstrual cycle.
224190891|NCT03205605|DRUG|oxybutynin|patch
224190892|NCT03205605|DRUG|oxybutynin|gel
224190893|NCT05786027|BEHAVIORAL|PDI|A 12-week in-prison peer-driven intervention to increase the uptake of primary HIV prevention strategies (readiness to initiate addiction treatment (MMT or Atlantis), initiation of MMT/Atlantis, retention in MMT/Atlantis; or the use of SSP), and reduce the use of opioids and HIV risk behaviors, in HIV-negative PWID in prison.
223500660|NCT01620099|DRUG|Extrafine treatment (Clenilexx(R) or Foster(R))|Following the initial evaluation (cross-sectional) patients will be switched to an extrafine equipotent dose of the same compound (extrafine beclomethasone dipropionate - Clenilexx(R) - if the patient was on ICS) or combination (extrafine beclomethasone dipropionate/formoterol - Foster(R) - if the patient was on ICS/LABA combination). After 3-months patients will be reassessed for lung function and asthma control
223500661|NCT06553820|BEHAVIORAL|Intervention group I, Yoga 20 minutes x2 pr week|App-based MediYoga exercises, 20 minutes per session, twice a week for a total of 10 weeks.
223500662|NCT06553820|BEHAVIORAL|Intervention Group II, Yoga 40 minutes x2 pr week|App-based MediYoga exercises, 40 minutes per session, twice a week for a total of 10 weeks.
223500663|NCT06553820|OTHER|Control Group, No intervention|standard of care only
223500664|NCT02400736|BEHAVIORAL|Individual Placement and Support (IPS)|Individual Placement and Support (IPS) is the evidenced based model of supported employment.
223500665|NCT02400736|OTHER|Treatment as Usual Vocational Rehabilitation/Transitional Work (TUA-VR)|Vocational Rehabilitation Treatment as Usual includes pre-vocational counseling, Community Based Supported Employment, or most commonly Transitional Work assignments (TW).
223500666|NCT00778414|DRUG|Amoxicillin-Clavulanic acid 600mg - 42.9 mg/ 5 mL oral suspension|
223500667|NCT00899457|GENETIC|proteomic profiling|Collection of tissue, blood, urine, mouth cells, spit, nasal airway cells and breath
223500668|NCT00899457|OTHER|biologic sample preservation procedure|Collection of tissue, blood, urine, mouth cells, spit, nasal airway cells and breath
224190894|NCT03054311|BEHAVIORAL|Lifestyle Matters|
224190895|NCT03528811|DIAGNOSTIC_TEST|Five points test of Tongji university|"In each group, we will evaluate the microcirculation of diabetic foot using the newly-established Five points test of Tongji university before or after the operation, and then compare the temperature of the five points with the other data."
224190896|NCT06987916|BIOLOGICAL|ssCART-19|autologous T cells transduced with a lentiviral vector containing anti-CD19 CAR and small hairpin RNA to silence the IL-6 gene
224190897|NCT06984432|DEVICE|XELA REDERM (non-cross-linked hyaluronic acid 1.1%, 1.8%, or 2.2%)|Injectable implant containing 1.1%, 1.8%, or 2.2% non-cross-linked hyaluronic acid with succinic acid, sodium succinate, sodium chloride, and water for injection. Intended for redermalization to improve skin quality through biorevitalization.
223500669|NCT00899457|OTHER|laboratory biomarker analysis|Collection of tissue, blood, urine, mouth cells, spit, nasal airway cells and breath
223500670|NCT00899457|PROCEDURE|bronchoscopy|Collection of breath condensate.
223500671|NCT03693898|OTHER|Observeational|No intervention, observational
223591546|NCT01438450|OTHER|Supportive|No specific therapy will be given
223591547|NCT00119366|RADIATION|iodine I 131 monoclonal antibody BC8|Given IV
223591548|NCT00119366|DRUG|fludarabine phosphate|Given IV
223591549|NCT00119366|RADIATION|total-body irradiation|Undergo TBI
223591550|NCT00119366|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Undergo PBSC transplantation
223500672|NCT02233153|OTHER|Elder-Friendly Surgical Unit|
223500673|NCT05345587|OTHER|THESS monitoring|Consultation with the pharmacist to look for possible medication interactions between the oral therapy and the patient's usual treatments and to inform the patient about his treatment to improve QOL and compliance. Consultation and follow-up by a nurse. Weekly notification by THESS Application of the symptoms experienced by the patient over the last 7 days
223500674|NCT00882765|DIETARY_SUPPLEMENT|genistein|Given orally
223500675|NCT03520569|DRUG|Octreotide|we are using it to block insulin secretion from the pancreas
223500676|NCT03520569|DRUG|Insulin|we are using to replace basal insulin and in two protocols to raise insulin concentrations during the insulin clamp
223500677|NCT03520569|DRUG|Dextrose 20% solution|We are using dextrose to maintain glycemia level
223500678|NCT05911386|OTHER|study of biological samples and echocardiographic data and link with need of hemodynamic support|observational study : there is no intervention
223500679|NCT04939389|DIAGNOSTIC_TEST|Orthelligent Pro|The sensor is attached to the knee of the participant and eight different movement exercises are performed
223500680|NCT05827120|DEVICE|Mechanical / pharmacomechanical thrombectomy plus local catheter directed thrombolysis|"* Catheter directed thrombolysis (CDT): dedicated thrombolytic catheter with side holes is placed across the acute thrombus, and slow, continuous infusion (through the catheter, or both through the catheter and sheath) of a chemical thrombolysis agent is applied - alteplase 1mg/hour plus unfractionated heparine in anticoagulation dosage;~* Mechanical thrombectomy: mechanical aspiration of fresh thrombus;~* Pharmacomechanical thrombectomy (PMT): combination of mechanical disruption of the thrombus, and its aspiration, with simultaneous application of alteplase via dedicated catheter - instilation of acute/subacute thrombus with its subsequent aspiration;"
223591551|NCT00119366|PROCEDURE|peripheral blood stem cell transplantation|Undergo PBSC transplantation
223591552|NCT00119366|DRUG|cyclosporine|Given IV or PO
223591553|NCT00119366|DRUG|mycophenolate mofetil|Given PO
223591554|NCT00119366|OTHER|laboratory biomarker analysis|Correlative studies
224190898|NCT06984432|DEVICE|Electri (non-cross-linked hyaluronic acid 0.55%)|Injectable implant containing 0.55% non-cross-linked hyaluronic acid with succinic acid, sodium succinate, sodium chloride, and water for injection. Intended for redermalization aimed at improving skin hydration, elasticity, and appearance.
224190899|NCT03572153|BEHAVIORAL|Self-Administered Hypnosis|Participants will be listening to six 20-minute hypnosis audio recordings with hypnotic induction. Participants will be encouraged to practice daily, and each recording will build on the content of the previous recordings. They will also be provided with booklets of information about hot flashes, including treatment options.
224190900|NCT03572153|BEHAVIORAL|Self-Administered White Noise Hypnosis|Participants will be listening to the same 20-minute white noise audio recordings for 6 weeks and will be encouraged to practice daily.They will also be provided with booklets as well as an audio recording with information about hot flashes including treatment options.
224190901|NCT03328325|BIOLOGICAL|Influenza Virus Quadrivalent Inactivated Vaccine|A seasonal quadrivalent inactivated influenza vaccine (IIV4), prepared from influenza viruses propagated in embryonated chicken eggs, protecting against 2 influenza A subtypes and 2 influenza B subtypes: A/Singapore/GP1908/2015 (H1N1) IVR-180 (an A/Michigan/45/2015 \[H1N1\] pdm09-like virus), A/Singapore/INFIMH-16-0019/2016 (H3N2) IVR-186, B/Maryland/15/2016 NYMC BX-69A, (a B/Colorado/06/2017-like virus), and B/Phuket/3073/2013.
224190902|NCT03328325|BIOLOGICAL|Influenza Virus Quadrivalent Inactivated Vaccine|A seasonal quadrivalent inactivated influenza vaccine (IIV4), prepared from influenza viruses propagated in embryonated chicken eggs, protecting against 2 influenza A subtypes and 2 influenza B subtypes: A/Singapore/GP1908/2015 (H1N1) IVR-180 (an A/Michigan/45/2015 \[H1N1\] pdm09-like virus), A/Singapore/INFIMH-16-0019/2016 (H3N2) NIB-104, B/Maryland/15/2016 NYMC BX-69A (a B/Colorado/06/2017-like virus), and B/Phuket/3073/2013.
224190903|NCT01337440|DRUG|UDCA|"Sitagliptin: 50 mg, po, qd for 12 weeks, then UDCA add-on therapy for additional 12 weeks.~UDCA dosage: dosing from 600 mg for initial 4 weeks. Then, if there is no adverse effect, UDCA is escalated to 900 mg, po, tid."
224190904|NCT01337440|DRUG|Sitagliptin|"UDCA for 12 weeks, then Sitagliptin add-on therapy for additional 12 weeks.~UDCA dosage: dosing from 600 mg for initial 4 weeks. Then, if there is no adverse effect, UDCA is escalated to 900 mg, po, tid."
224190905|NCT00984958|DEVICE|Bulkamid|injection of Bulkamid in the urethra
224190906|NCT00984958|DEVICE|Bulkamid expectation|expectance
224190907|NCT04794491|DRUG|JZP-258|Maximum nightly dosage of 9 grams, administered once, twice or thrice nightly, with no single dose \> 6 g
224190908|NCT02205229|DRUG|Multi-ingredient, topical compounded medications|
224190909|NCT00483600|DRUG|fondaparinux|injections of 2.5mg every other day for 4 weeks
224309699|NCT06989801|BEHAVIORAL|Urban Walk|"For each session, participants will take a 30-minute walk in an urban environment along a designated looped route. They will walk at a comfortable pace and follow the assigned path. During the walk, participants will be instructed to experience their surroundings as naturally as possible. No specific activities beyond walking are required.~To fully immerse in the experience, participants will be asked to avoid using their phones unless necessary (e.g., in case of an emergency). They should keep the GPS app recording throughout the walk without interacting with it-just allow it to run in the background.~Once the loop is completed, participants will stop the GPS recording and return to the starting point, where a research team member will be waiting. They will then be guided indoors to complete a brief post-walk survey and participate in a short interview to share their experience."
223500681|NCT05827120|DEVICE|Local catheter directed thrombolysis alone|\- Catheter directed thrombolysis (CDT): dedicated thrombolytic catheter with side holes is placed across the acute thrombus, and slow, continuous infusion (through the catheter, or both through the catheter and sheath) of a chemical thrombolysis agent is applied - alteplase 1mg/hour plus unfractionated heparine in anticoagulation dosage;
223500682|NCT03418675|DRUG|Rexulti|Atypical antipsychotic
223591555|NCT05490940|DRUG|Tisseel®|"The investigational medical product (IMP) in this study is Tisseel®, which is a tissue sealer consisting of two components:~1. Sealer protein: Human fibrinogen as glue component and synthetic Aprotinin, which delays fibrinolysis.~2. Human thrombin: Thrombin is an unique molecule that functions both as a procoagulant and anticoagulant. It activates platelets through its receptor on the platelets and regulates its own. generation by activating coagulation factors V, VIII and even XI resulting in a burst of thrombin formation.~Its indications are a better hemostasis, enforcement of vessel/gastrointestinal sutures and tissue sutures (mesh grafts, flaps etc)."
223591556|NCT01716741|OTHER|Enzyme analysis|
223591557|NCT04406025|PROCEDURE|participation in Regional Anesthesia Seminar|this group of anesthesiologists attended the Regional Anesthesia Seminar
224190910|NCT05685537|DRUG|Levosimendan|Initiation of levosimendan 48 hours before surgery
224190911|NCT00002625|DRUG|topotecan hydrochloride|
224190912|NCT00002625|RADIATION|low-LET electron therapy|
224190913|NCT00002625|RADIATION|low-LET photon therapy|
223500683|NCT03418675|DRUG|Placebo|Pill that contains no medicine
223500684|NCT04248569|DRUG|DNAJB1-PRKACA peptide vaccine|"1. DNAJB1-PRKACA peptide vaccine: Day 1, 8, 15 of cycle 1 and on Day 1 of cycle 2, 3 and 4 (priming phase). Boost vaccinations: every 3 cycles beginning C5D1.~2. Drug: 0.3 mg DNAJB1-PRKACA peptide vaccine + 0.5mg Poly-ICLC"
223500685|NCT04248569|DRUG|Nivolumab|"1. Nivolumab 3mg/kg will be administered as a 30 minute IV infusion (-10/+15min) on Day 1 of Cycle 1-4 during the priming phase. Boost/maintenance vaccinations will be administered as a flat dose of 480mg every 4 weeks starting on Day 1 of Cycle 5.~2. Drug: 3mg/kg and 480mg IV"
223500686|NCT04248569|DRUG|Ipilimumab|"1. Ipilimumab (1 mg/kg) will be administered as a 30 minute IV infusion (-10/+15min) on Day 1 of Cycles 1, 2, 3 and 4 of the study, every 3 weeks of the priming phase.~2. Drug: 1mg/kg IV"
223500687|NCT03555344|OTHER|Mantra Chikitsa|Specific Mantra were given to chants for 15 mins and resting in the impact of chants for following 15 mins.
223500688|NCT01178411|DRUG|Tivantinib|Tivantinib 360 mg (3 x 120 mg tablets or capsules) twice daily by mouth.
223500689|NCT01178411|DRUG|Anti-Cancer Combination Therapy|Tivantinib 360 mg twice daily in combination with other anti-cancer therapy (eg, erlotinib,sorafenib, pemetrexed, docataxel, gemcitabine, irinotecan, and/or cetuximab) at the same dose and schedule in which they were administered in the original (previous) study.
223500690|NCT04387214|OTHER|survey|online survey
224190914|NCT05275309|OTHER|Exploration of optimal PEEP in supine and prone position|"1. General anesthesia is done in routine manner~2. A sensor for electrical impedance tomography (EIT) is applied around the patient's chest.~3. In supine position, lung recruitment maneuver is done, followed by decremental PEEP trial. Based on EIT parameter, optimal PEEP which induces minimal overdistension and collapse of lungs is determined.~4. One hour after prone position, optimal PEEP is determined again."
224190915|NCT02856295|DRUG|clexane (LMWH)|to compare tow doses of clexane for preventing VTE in postpartum women
224190916|NCT01510392|DEVICE|OCT imaging, the FDA Cleared iVue|The OCT system scans a beam of light across the eye to take a picture. OCT imaging does not touch the eye. This is a test that is performed using an FDA approved system, and is regularly used to take pictures of the back of the eye.
224190917|NCT03601611|DRUG|Tocilizumab (RoACTEMRA®)|Prednisolon will be given in case of worsening of symptoms
224190918|NCT01081002|DRUG|Lidocaine 10%|3 min before the endoscopy under propofol sedation 4 puffs of lidocaine 10% will be sprayed on the pharynx as a pharyngeal anesthesia
224190919|NCT01081002|DRUG|Diluted gentian root solution|As a basis, an infusion of water (45%), ethanol (35%) and gentian root cut will be used. The gentian root infusion is approved as a natural flavor in the food industry.3 min before the endoscopy under propofol sedation 4 puffs of this gentian root infusion will be sprayed on the pharynx as a pharyngeal anesthesia
224190920|NCT05228873|DRUG|Shen Cao Gan Jiang Tang (Gan Cao Gan Jiang Tang with Ginseng)|Patients take Shen Cao Gan Jiang Tang (Gan Cao Gan Jiang Tang with Ginseng), one bag of decoction (90ml) two times a day for 10 days. Ingredients per formula (tang): 12 grams of honey-fried Radix Glycyrrhizae, 6 grams of Rhizoma Zingiberis (stir-baked), 6 grams of Panax Ginseng. The decoction of concentrated extract is packed into aluminum foil vacuum bag, 90ml per bag, 1 formula (tang) is equivalent to 2 bags. Patients use the decoction directly from the bag.
223591558|NCT04406025|PROCEDURE|no participation in Regional Anesthesia Seminar|this group of anesthesiologists did not attend the Regional Anesthesia Seminar
223591559|NCT02406170|DRUG|Regorafenib|The dose of regorafenib will be escalated in fixed increments to establish the maximum tolerated dose (MTD) from day 1-21 against a cytotoxic backbone of paclitaxel 80mg/m2 on days 1, 8 and 15 of a 28 day cycle
223591560|NCT02406170|DRUG|Paclitaxel|Paclitaxel will be administered in combination with regorafenib to serve as a cytotoxic backbone, it will be given in a dose of 80mg/m2 on days 1,8 and 15 of a 28 day cycle.
223591561|NCT05332132|DEVICE|Heracure Device|Intrauterine Morcellation of Uteri Post-Surgery (Ex Vivo Study)
223591562|NCT00674414|BIOLOGICAL|trastuzumab|Trastuzumab (Herceptin®) IV once weekly
223591563|NCT00674414|DRUG|everolimus|Oral everolimus once daily
224190921|NCT05756062|DIETARY_SUPPLEMENT|Highly-concentrated DHA triglyceride (Tridocosahexanoin-AOX 70%)|Daily administration of 2 capsules of the study product (1000 mg DHA triglyceride) for 3 months
224190922|NCT00736840|DEVICE|c13 methacetin solution with breath analyzer|Carbon 13 methacetin 75mg dissolved in 150 ml is given to the subject and metabolism is measured by a breath analyzer after decomposed by the liver
224190923|NCT01359319|DRUG|Sialic Acid Extended Release (SA-ER) Tablets|Patients will receive SA-ER tablets orally at one of five (5) dose levels in the single-dose phase,phase and one of four (4) dose levels in the repeat-dose phase. During repeat dosing, the total daily dose will be divided evenly into three doses given in the morning, in the evening, and at bedtime (qHS). No placebo or active comparator will be administered and the study drug will be administered on an open-label basis.
223591564|NCT00674414|PROCEDURE|therapeutic conventional surgery|Patients undergo surgery
223591565|NCT05242172|DIAGNOSTIC_TEST|CRP/Albumin ratio|it is aimed to investigate prognosis and severity of covid-19 infection with using CRP/Albumin ratio in pregnant patient
223591566|NCT03158441|DIAGNOSTIC_TEST|Breast MRI|comparison of DTI to dynamic MRI
223591567|NCT04406558|OTHER|Questionnaire|An online questionnaire on the experience of the period of confinement and deconfinement will be sent to the cohort of adolescents followed at the CHI Creteil for a chronic disease or not. Forty adolescents will be randomly selected for a remote interview on the experience and memorization of the period of confinement and deconfinement.
223591568|NCT06537947|PROCEDURE|Endovascular intervention using the SENTANTE endovascular robotic system|"1. Diagnostic procedure - placement of diagnostic catheter to intended vessel and performing angiography.~2. Percutaneous transluminal angioplasty (PTA)/stenting procedure - placement of balloon catheter or balloon expandable stent to intended vessel and effectively expanding it up to nominal pressure.~3. Coiling procedure - implantation of pushable coils or liquid embolization materials (such as microspheres) to an intended vessel."
223591569|NCT01318837|DRUG|solifenacin|oral
223591570|NCT05582174|DRUG|Vonoprazan|Vonoprazan 40 mg bid orally for 72 hours, and from day 4-30 VPZ 20 mg daily
223591571|NCT05582174|DRUG|esomeprazole|A high dose PPI infusion (esomeprazole 80mg iv bolus followed by 8mg per hour for 72 hours), and frorm day 4-30 oral esomeprazole daily
223591572|NCT01673620|DRUG|Montelukast 10 mg/loratadine 10 mg|Montelukast 10 mg/loratadine 10 mg tablet administered once daily
223591573|NCT01673620|DRUG|Placebo|Matching placebo tablet administered once daily
223591574|NCT02643238|DEVICE|BrainPort|This system is a novel, bionic, non-invasive, vision bypass system that conveys environment images from a spectacle-frame-mounted video-camera to the brain via an electro-tactile tongue array. The electro-tactile stimulation delivered by the tongue-array placed on the tongue allows users to interpret the images of objects in their camera's visual field
223591575|NCT03887273|BIOLOGICAL|Q-Cells|cellular therapeutic comprised of human cells of the glial lineage
223591576|NCT02693041|DRUG|probiotic|Low-risk women, women with prior preeclampsia and women with a prior preterm birth will be randomized to be treated with LGG during pregnancy. Effect on maternal and perinatal outcome as well as the effect of treatment on immunological and inflammatory biomarkers will be evaluated.
224190924|NCT01359319|DRUG|Sialic Acid Extended Release (SA-ER) Tables|PPatients will receive SA-ER tablets orally at one of five (5) dose levels in the single-dose phase,phase and one of four (4) dose levels in the repeat-dose phase. During repeat dosing, the total daily dose will be divided evenly into three doses given in the morning, in the evening, and at bedtime (qHS). No placebo or active comparator will be administered and the study drug will be administered on an open-label basis.
224190925|NCT01359319|DRUG|Sialic Acid Extended Release (SA-ER) Tablets|Patients will receive SA-ER tablets orally at one of five (5) dose levels in the single-dose phase,phase and one of four (4) dose levels in the repeat-dose phase. During repeat dosing, the total daily dose will be divided evenly into three doses given in the morning, in the evening, and at bedtime (qHS). No placebo or active comparator will be administered and the study drug will be administered on an open-label basis.
224190926|NCT01359319|DRUG|Sialic Acid Extended Release (SA-ER) Tablets|Patients will receive SA-ER tablets orally at one of five (5) dose levels in the single-dose phase,phase and one of four (4) dose levels in the repeat-dose phase. During repeat dosing, the total daily dose will be divided evenly into three doses given in the morning, in the evening, and at bedtime (qHS). No placebo or active comparator will be administered and the study drug will be administered on an open-label basis.
224190927|NCT01359319|DRUG|Sialic Acid Extended Release (SA-ER) Tablets|Patients will receive SA-ER tablets orally at one of five (5) dose levels in the single-dose phase,phase and one of four (4) dose levels in the repeat-dose phase. During repeat dosing, the total daily dose will be divided evenly into three doses given in the morning, in the evening, and at bedtime (qHS). No placebo or active comparator will be administered and the study drug will be administered on an open-label basis.
224190928|NCT04790214|OTHER|CHF Patients|Cardiac rehabilitation program on CHF patients on 06-08 weeks. Program will include: physical aerobic re-training, therapeutic education on CHF, psychological follow-up, nutritional education
224190929|NCT01692457|DRUG|No intervention|This is an observational study. Golimumab will be administered as per the recommended doses. Golimumab 50 mg will be given as a subcutaneous injection once a month, on the same date each month. For rheumatoid arthritis: Golimumab 2 mg/kg will be given as a 30 minute intravenous infusion at Weeks 0 and 4, then every 8 weeks thereafter.
224190930|NCT04996212|PROCEDURE|Walking APP Group|"The participants of this group will be explained their treatment plan by a physiotherapist who will contact them through a video call. This treatment will consist of breathing exercises (abdominodiaphragmatic and pursed lips breathing) and 3 days of aerobic exercise: walking.~Participants will consult their treatment plan through an application that will be installed on their mobile phone. They will start with 25 minutes of walking and will increase progressively until they reach 45 minutes.~A biweekly follow-up will be carried out through a phone call by the research team to find out their health status and evolution with the assigned treatment.~Participants must perform the proposed exercises, 5 days a week, once a day In addition to the respiratory physiotherapy guideline, they will be given the health education manual."
224190931|NCT04996212|PROCEDURE|Functional APP group|"The participants of this group will be explained their treatment regimen by a physiotherapist who will contact them through a video call. This treatment planwill consist of breathing exercises (abdominodiaphragmatic and pursed lips breathing) and 3 days of functional exercise which involve the activation and performance of large muscle groups. Participants will consult their treatment plan through an application that will be installed on their mobile phone.~A biweekly follow-up will be carried out through a phone call by the research team to find out their health status and evolution with the assigned treatment."
224190932|NCT00265876|DRUG|AZD0530|Taken daily every 4 weeks
224190933|NCT00265876|DRUG|gemcitabine hydrochloride|1000mg/m2 IV weekly
223500691|NCT02305459|DEVICE|Yttrium-90 loaded SIR-Spheres microspheres|Selective internal radiation therapy (SIRT), also called radioembolisation (RE), with SIR-Spheres microspheres is an endovascular procedure, included within the interventional oncologic technologies to treat primary and secondary liver tumours. Using a microcatheter, a precise dose of resin microspheres is released in the hepatic artery, where they are carried into the arterioles and selectively lodge in the tumour microvasculature. The microspheres are loaded with the radioactive yttrium-90, a high-energy beta-emitting isotope with a half-life of 64.1 hours. SIR-Spheres microspheres are manufactured by Sirtex Medical.
223591577|NCT02693041|DRUG|placebo|Low-risk women, women with prior preeclampsia and women with a prior preterm birth will be randomized to be treated with placebo during pregnancy. Effect on maternal and perinatal outcome as well as the effect of treatment on immunological and inflammatory biomarkers will be evaluated.
223591578|NCT04137185|DRUG|Recombinant Human Thyroid Stimulating Hormone for Injection|rhTSH was dissolved in 1.2 mL of sterile water for injection to obtain a solution containing 0.9 mg/mL rhTSH.
223591579|NCT04156035|DRUG|Lamotrigine|Orally; 300 mg
223591580|NCT04156035|DRUG|Ketamine|Intravenously; 0.12 mg/kg during the first minute followed by a continuous infusion of approximately 0.31 mg/kg/h over approx. 40 min
223591581|NCT04156035|DRUG|Placebo Pretreatment|Lamotrigine Placebo
223591582|NCT04156035|DRUG|Placebo Infusion|Ketamine Placebo
223591583|NCT04729335|DIAGNOSTIC_TEST|phonocardiac spectrometry|Detection and application of organic disease with phonocardiac spectrometry
223591584|NCT05432401|BIOLOGICAL|T cell injection targeting FLT3 chimeric antigen receptor|The subjects, who sign the informed consent forms and been screened by inclusion/exclusion criteria, will be assigned into 1.0 × 10\^8, 2.0 × 10\^8 and 4.0 × 10\^8 CAR-T groups in order of sequence. And the subjects will be administered once.
223591585|NCT01597635|DRUG|Dose 1 GSK2586881|Low dose GSK2586881 administered intravenously
223591586|NCT01597635|DRUG|Dose 2 GSK2586881|Medium dose GSK2586881 administered intravenously
223591587|NCT01597635|DRUG|Dose 3 GSK2586881|Medium-High dose GSK2586881 administered intravenously
223591588|NCT01597635|DRUG|Dose 4 GSK2586881|High dose GSK2586881 administered intravenously
223591589|NCT01597635|DRUG|Placebo (saline)|Administered intravenously to match intervention
223591590|NCT06114927|BEHAVIORAL|Validation of a questionnaire|The Conceptualization of Pain Questionnaire (COPAQ-S) Spanish version consist of 15 items and asks respondents to respond if they believe the items/statements to be true or false, although they are allowed to respond undecided. A score of 0 is given to incorrect responses and those marked as undecided; the sum of all the correct answers gives the total score. The higher the score, the better the participant understands the concept of pain.
223591591|NCT05728268|DRUG|dose-dense nab-paclitaxel followed by EC|dose-dense nab-paclitaxel followed by EC
223591592|NCT00495625|DRUG|Sunitinib Malate|Once daily oral doses on days 1-28 of each 42-day cycle. The dose for the first 2 cycles will be 37.5 mg daily for 28 days, every 42 days. Dose may be escalated to 50 mg daily for 28 days at the treating investigator's discretion.
224190934|NCT00592423|OTHER|Continuous Positive Airway Pressure during MRI|10 cm H20 pressure for CPAP while lateral neck positioning is done for MRI - each side should take 5 minutes.
224190935|NCT05007236|DRUG|RP7214 + Standard of care (SOC)|RP7214 tablets will be administered orally twice a day for 14 days
224190936|NCT05007236|DRUG|Placebo + Standard of care (SOC)|Placebo will be administered orally twice a for 14 days
224190937|NCT07007221|DRUG|Metformin|12 weeks of Metformin 1000mg
224190938|NCT07007221|DRUG|Metformin|12 weeks of Metformin 1500mg
224190939|NCT07007221|DRUG|Metformin|8 weeks of Metformin
224309700|NCT06989801|BEHAVIORAL|Nature Walk|"For each session, participants will take a 30-minute walk in a natural environment along a designated looped route. They will walk at a comfortable pace and follow the assigned path. During the walk, participants will be instructed to experience their surroundings as naturally as possible. No specific activities beyond walking are required.~To fully immerse in the experience, participants will be asked to avoid using their phones unless necessary (e.g., in case of an emergency). They should keep the Gaia GPS app recording throughout the walk without interacting with it-just allow it to run in the background.~Once the loop is completed, participants will stop the GPS recording and return to the starting point, where a research team member will be waiting. They will then be guided indoors to complete a brief post-walk survey and participate in a short interview to share their experience."
224309701|NCT06989801|BEHAVIORAL|Active Nature Walk|"For each session, participants will take a 30-minute walk in a natural area, following a designated looped route. Unlike a regular walk, participants will be encouraged to engage with nature (e.g., listening to natural sounds, looking for birds, and touching flowers).~To make the most of the walk, participants will be asked to avoid using their phones unless necessary (e.g., in case of an emergency). They should keep the Gaia GPS app recording throughout the walk without interacting with it-just letting it run in the background.~Once the loop is completed, participants will stop the GPS recording and return to the starting point, where a research team member will be waiting. They will then be guided indoors to complete a brief post-walk survey and participate in a short interview to share their experience."
224309702|NCT06989372|PROCEDURE|serratus posterior superior block|patients were placed in the lateral decubitus position for SPSIPB. The blocks were performed under the guidance of ultrasonography (USG), a high-frequency linear probe (SonoSite HFL50x, 15-6 MHz, 55-mm broadband linear array, USA) transducer was placed at the level of the spine scapula in the transverse plane, and the upper medial border of the scapula, trapezius muscle, serratus posterior superior muscle (SPSM), 2nd and 3rd ribs were visualized. The ultrasound probe is rotated 90 degrees in a parasagittal orientation to identify the first rib. After its identification, the second and third ribs are confirmed. An 80 mm sono visible needle (type) was inserted in the caudocranial direction just medial to the scapula with the in-plane technique and driven between the 2nd and 3rd ribs targeting the inferior part of the SPSM. The target was confirmed by injecting the test dose with saline. Thirty ml of 0.25% bupivacaine was subsequently injected
223500692|NCT02305459|BEHAVIORAL|QLQ-C30 with HCC module|In order to measure the palliative aspect of RE with SIR-Spheres microspheres, CIRT will incorporate a quality-of-life questionnaire. CIRT will be using EORTC's QLQ-C30 with HCC Module to measure changes in the quality of life of the patient. The quality-of-life questionnaire will be offered to the patient before the treatment, shortly after the treatment (as soon as possible) and at every follow-up. Filling out the quality-of-life questionnaire is entirely voluntary for the patient.
223500693|NCT05932030|OTHER|Survey|Submission of a survey to solid organ transplant patients and health professionals working in transplantation to assess their knowledge and perception of the use of artificial intelligence in transplantation
223500694|NCT03590470|OTHER|Implementation of a nurse-led model of care|A nurse-model of care consisting of a specifically trained geriatric nurse expert, communication and quality improvement tools will be implemented in 11 nursing homes in the German speaking part of Switzerland
224190940|NCT07007221|OTHER|Placebo|8 weeks placebo drug
223500695|NCT01147835|DIETARY_SUPPLEMENT|Chinese Licorice Root|Chinese Licorice Root lollipops are given to the subjects in the study group to ingest twice daily for 10 days. Then the subjects must wait 3 months, and then again ingest the lollipops twice daily for 10 days.
223500696|NCT06469268|DEVICE|Epro software|EPRO software：patients with symptoms will fill in report forms via the software, when the data upload to the terminal, the doctor according to the results of the upload ePRO corresponding medical assessment,and give advises.
223500697|NCT00298857|DRUG|Valproic acid|
223500698|NCT03278145|GENETIC|Genetic analyses|Patients treated at the Institute of Hematology and Pediatric Oncology (IHOPe), a department of Prof. Y. Bertrand, for acute leukemia (LA) at the time of diagnosis initial, or relapse, after obtaining signed parental consent. The same patients will benefit from a new sample at the time of their remission balance. Analyses for this research will be made from bone marrow aspiration samples performed for diagnosis and treatment of these patients. The medical team will investigate whether RDs, in particular DCC, are expressed in acute leukemia cells at the time of diagnosis or relapse and then in these patients at the time of the remission balance. This research will be both qualitative and quantitative. Next, investigators will characterize the existence and then the level of expression of the ligand specific for DCC, Netrin-1, in these same leukemic cells, at the time of diagnosis / relapse and remission.
224190941|NCT07007221|DRUG|Metformin|12 weeks of Metformin
224190942|NCT07007221|DRUG|Fluoxetine|12 weeks of Fluoxetine
224190943|NCT07007221|DRUG|Metformin+Fluoxetine|12 weeks of Metformin+Fluoxetine
224190944|NCT07007221|OTHER|double placebo|12 weeks of double placebo
224190945|NCT06623032|OTHER|Medium-Chain Fatty Acid (MCFA)|The participants will consume Medium-Chain Fatty Acid (MCFA) followed by Long-Chain Fatty Acid (LCFA)
224190946|NCT06623032|OTHER|Long-Chain Fatty Acid (LCFA)|The participants will consume Long-Chain Fatty Acid (LCFA) followed by Medium-Chain Fatty Acid (MCFA).
224190947|NCT03580707|DRUG|BRV vs LEV in randomized double blinded, crossover fashion|Single dose intravenous administration of BRV 100 mg over a 15 minutes period. On a subsequent occasion, (approximately 2 weeks later), the patient is crossed over to the other drug at a singular dose. On both occasions, intermittent photic stimulation is done 10 times in a two hour period. IPS is again conducted in the cross over portion as well. Coincident with IPS stimulation 10 blood samples will be drawn for BRV or LEV plasma concentration.
224190948|NCT02576106|DEVICE|Cryoablation|
224190949|NCT01476982|DEVICE|ClearView Scan|Assessment with ClearView device
224190950|NCT01990339|DRUG|Lansoprazole|"• Reflux esophagitis The usual adult dosage is 30 mg of lansoprazole administered orally once daily for up to 8 weeks.~For maintenance therapy of repeatedly recurring/relapsing reflux esophagitis, the dosage is 15 mg of lansoprazole administered orally once daily. If insufficient efficacy is observed, the dosage may be increased to 30 mg administered orally once daily.~• Nonerosive gastroesophageal reflux disease Non-erosive gastroesophageal reflux disease The usual adult dosage is 15 mg of lansoprazole administered orally once daily for up to 4 weeks."
224190951|NCT05809219|OTHER|1 hour combined intervention ( Exercise and nutrition)|Subjects take oral supplement after exercise in the time period between 1-2 hours. They will take oral supplement during hemodialysis treatment.
224190952|NCT05809219|OTHER|3 hours combined intervention ( Exercise and nutrition)|"All procedures between 1 hour combined intervention and 3 hours combined intervention are the same. The only one different is the time interval between exercise and nutrition. In this arm, the time interval of exercise and nutrition is 2.5 to 4 hours. When we recruiting subjects, all interventions will be clearly introduced to them, including the same and the different parts among them."
224190953|NCT05809219|DIETARY_SUPPLEMENT|Nutrition intervention|"Subjects only take oral supplement during hemodialysis treatment. The oral supplement is the same as the 1 hour combined intervention and 3 hours combined intervention."
224190954|NCT01038609|DRUG|Hydrocodone/Acetaminophen Extended Release|
224190955|NCT01038609|DRUG|Acetaminophen|
224190956|NCT01038609|DRUG|Morphine Extended Release|
224190957|NCT01038609|DRUG|Placebo|
224190958|NCT01609608|PROCEDURE|whole body vibration|to deliver mechanical oscillation to individuals at various frequencies, amplitudes, and accelerations for different durations. This technique has been applied for years to enhance strength, and improve bone mineral density and balance
224190959|NCT06377449|DIAGNOSTIC_TEST|Ultrasound examination of the lungs|Experimental: Standard ultrasound examination of the lungs based on modified BLUE protocol Active Comparator: Standard ultrasound examination of the lungs based on modified BLUE protocol
224190960|NCT03241485|DRUG|Intrathecal morphine|5 micrograms/kilogram of intrathecal morphine administered in the spinal space, not to exceed 1mg
224190961|NCT03241485|DRUG|Placebo|Saline intrathecal given in the same manner as the intervention groups.
224190962|NCT02237573|OTHER|Written medical report and standardized medical advices|"The intervention will include: 1) handing the patient at the end of the consultation a copy of the consultation report which will be composed of:~1. a detailed report of the consultation (motive, case history, clinical examination, conclusion)~2. written standardized medical advices from evidence published in the literature. Interventions will be designed by several general practitioners and tested by few patients."
224190963|NCT02237573|OTHER|Control|"Other:~Oral standardized medical advices from evidence published in the literature. Physicians will be trained by a single investigator."
224190964|NCT06237361|OTHER|Pilates exercises|participants underwent a 12-week intervention involving three Pilates sessions per week. The Pilates exercises comprised warm-up activities, Pilates routines, and cool-down exercises.
224190965|NCT06237361|OTHER|traditional physical therapy program|The program included a variety of exercises such as range of motion exercises, aerobic exercises, resistance exercises, scar management, occupational therapy, and hand therapy.
224190966|NCT02357524|DRUG|Oritavancin|
224190967|NCT02517606|OTHER|Conventional physical therapy plus HPCS|Conventional physical therapy plus the addition of hip posterolateral complex strengthening
224190968|NCT02517606|OTHER|Conventional physical therapy|Conventional physical therapy (combination of manual therapy techniques and exercises for spinal segmental stabilization)
224190969|NCT00552006|BEHAVIORAL|Narrative Exposure Therapy|"Narrative Exposure Therapy (NET) is based on Testimony Therapy in combination with cognitive behavioural exposure techniques and elements of client-centered counselling. In cooperation with the therapist the clients can restore their autobiographic memories about their traumatic experiences. In this way fragmentary memories are transformed into a coherent narrative structure. This practice enables the processing of painful emotions and the construction of clear contingencies of dangerous and safe conditions, generally leading to significant emotional recovery. Therapeutic aims are the reduction of PTSD-Symptomload via activation of fear-network and habituation of fear and the placement of traumatic experiences in a reconstructed, detailed and consistent autobiography.~NET will be applied in eight sessions (90-120min/session) in a standardized, manualized manner."
224190970|NCT00552006|BEHAVIORAL|Academic Counseling|"Missing time in educational life is one major issue for formerly abducted people. The Academic Counseling (AC) intervention is an active Control condition and improves English skills and works at the same time on concentration, learning and memory abilities. The clients will gain some of the abilities and skills they might have lost or developed weaknesses in due to their abduction.~AC will be applied in eight sessions (90-120min/session) in a standardized, manualized manner."
223500699|NCT01992471|BEHAVIORAL|Pre-test Assessment|Subjects who consent to the study will complete a pre-test instrument that elucidates their baseline response to genetic testing (BRCA1/2) as measured by the Multidimensional Impact of Cancer Risk Assessment (MICRA), and their current cancer surveillance and prevention behaviors, as well asintentions to undergo surveillance and prevention in the next 6 months. The instrument will either be completed at the time of the counseling for multiplex testing, or by phone within approximately 7 days of sample donation.
223512041|NCT06010108|BEHAVIORAL|The Reach Initiative|School based intervention-The Reach Initiative involves the organisation of the Mother-Daughter Day (MDD) by Mother-Daughter Planning Committee (MDPC) who are volunteer young school girls and their mothers and provision of a Key-Card which is a cervical cancer awareness card attached to a key chain for awareness creation. HPV vaccination and HPV -self sampling will be carried out in private rooms within the venue of the intervention and all samples will be sent to designated laboratory for testing. Participants contact information will be collected for follow up and communication of results
224190971|NCT00715039|DRUG|lorazepam|1.0 mg p.o. three times a day for three days, then 1.5mg p.o. three times a day for 25 days
224190972|NCT00715039|DRUG|placebo|placebo p.o. t.i.d. for 28 days; placebo matching lorazepam and paroxetine
224190973|NCT00715039|DRUG|paroxetine|20mg p.o. daily for 28 days; and matching placebo twice a day to maintain blind
224190974|NCT06326164|PROCEDURE|kinesio-taping.|A therapeutic tape that's applied strategically to the body to provide support, reduce pain, swelling and improve performance. Kinesio taping will be applied on both lower limbs. Taping will be applied for 4 days, 24 hours a day, on the lower limbs, and it will be removed for only one day per week.
224190975|NCT06326164|PROCEDURE|A designed physiotherapy program.|The designed physiotherapy program included passive stretching, weight bearing, muscle strengthening, functional exercises, neurodevelopmental treatment, splinting, balance training, and gait training. The treatment protocol will be repeated each session per weeks for twelve weeks.
224190976|NCT02138552|DRUG|Octenidine dihydrochloride|Mouthrinsing - comparison of different dosages of Octenidine dihydrochloride over 4 days vs. Placebo
224190977|NCT02138552|DRUG|Placebo|Mouthrinsing - comparison of different dosages of Octenidine dihydrochloride over 4 days vs. Placebo
224190978|NCT00558961|DRUG|Gleevec and Chlorambucil|The first cohort will receive Gleevec at 300 mg daily on days 1-10 and chlorambucil 8mg/m2/d from day 3-7. This will be repeated every 28 days. Cohort 2 will receive 400 mg Gleevec and Cohort 3 will receive 600 mg Gleevec. Each dose level may be expanded up to 6 patients if 1 of 3 patients experiences any dose limiting toxicities.
224190979|NCT02987166|RADIATION|High-Dose Conformal Radiation Therapy|"24 Gy in 3 fractions of 8Gy each for bone and/or soft tissue lesions~30 Gy in 5 fractions of 6 Gy each for prostate gland"
224190980|NCT02987166|DRUG|Pembrolizumab|200 mg
224190981|NCT01475981|DRUG|JTK-853 or Placebo|Tablets, single dose, fasted, fed or high-fat fed condition
224190982|NCT00086164|DRUG|edifoligide (E2F Decoy)|
224190983|NCT00039104|DRUG|rebimastat|Given PO
224190984|NCT00039104|DRUG|zoledronic acid|Given IV
224190985|NCT00039104|OTHER|laboratory biomarker analysis|Correlative studies
224190986|NCT04700891|DIAGNOSTIC_TEST|Olfactory identification test|"Burghart Sniffin' Sticks Screening 12 Test Olfactory function will be evaluated through the Sniffin' Sticks test which is a validated psychophysical testing method. Sniffin' Sticks test is based on pen-like odor dispensing devices that will be presented to the patients. The short version of this test will be used and will consist solely of a test of odor identification function."
224190987|NCT04700891|DIAGNOSTIC_TEST|Edmonton Frail Scale|The Edmonton Frail Scale (EFS) involves nine domains of frailty : functional performance, cognitive function, general health, functional independence, social support, used medications, nutrition, mood and continence. It has been validated with respect to comprehensive geriatric assessment and to other screening tools related to frail state. EFS test is considered most appropriate for use in routine preoperative screening and only requires 5 minutes.
224190988|NCT04700891|DIAGNOSTIC_TEST|Handgrip strength|Handgrip strength is a simple and reliable measurement technique for the assessment of maximal voluntary hand force. Handgrip strength is used as a reflect of nutritional status and muscle mass, physical function and health status. Measurement will be realized using a digital handgrip dynamometer. Patients will be asked to grip the dynamometer with the second finger node at 90° angle to the handle and to grab the handle as strongly as they can. Maximal grip strength will be checked with the forearm away from the body in standing position.
224190989|NCT03599284|DRUG|Vicagrel 5mg|Experimental group 1 : Vicagrel 20mg loading followed by 5mg/day for 28 days
224190990|NCT03599284|DRUG|Vicagrel 6mg|Experimental group 2 : Vicagrel 24mg loading followed by 6mg/day for 28 days
223500700|NCT01992471|BEHAVIORAL|Pre test Counseling|Subjects will receive appropriate pre-test counseling that will describe the range of outcomes that may results from the multiplex testing. The subject will be asked for permission to audiotape the session for later qualitative review. An outline of the pretest counseling that will be provided. In addition to a description of the genes and syndromes being tested, subjects will receive specific education regarding the following categories and subcategories of possible results a. Definitive (informative) results, b. Variants of uncertain clinical significance (VUCS), c. Uninformative negative test results, d. d. Incidental results. Then Post-counseling selection of desired information After counseling, subjects will complete an instrument indicating which genetic test results they wish to receive. They will complete this instrument in the presence of a genetic counselor, so that the subject may ask questions in order to make the choice most consistent with their preferences.
223500701|NCT01992471|OTHER|Blood draw|After choosing the information they wish to receive, subjects will provide a blood sample (2 x 7 cc EDTA tubes, which will be sent to Myriad Genetics Laboratory for analysis.
223746229|NCT04105933|OTHER|CS-CBT|Culturally sensitive Cognitive Behavioural Therapy was delivered individually, focused on potential cultural beliefs and attitudes that might collide with core values of CBT.
224190991|NCT03599284|DRUG|Vicagrel 7.5mg|Experimental group 3 : Vicagrel 30mg loading followed by 7.5mg/day for 28 days
224190992|NCT03599284|DRUG|Clopidogrel 75mg|Control group : Clopidogrel 300mg loading followed by 75mg/day for 28 days
224190993|NCT02896959|PROCEDURE|Arthroscopic rotator cuff repair|
224190994|NCT05178511|DRUG|Ensartinib|Ensaritinib was taken orally once 225mg, on an empty stomach or with food, until the patient developed disease progression, developed unacceptable toxicity, the investigator or subject decided to drop out, lost follow-up, initiated other antitumor therapy, or died
224190995|NCT05891301|OTHER|Questionnaires set|The contents of the questionnaire included gender, age, BMI, previous operation history, previous medication history, smoking history,patient mobility in the hospital, etc.Questionnaire was completed on the first postoperative day.From the third day to the end of the seventh day, patients were evaluated daily for gastrointestinal dysfunction.Postoperative mobility was assessed daily.
224190996|NCT03527927|DRUG|Any LABA/LAMA|Following consent, patients will be taken off their current ICS/LABA/LAMA combination inhalers and shown 4 single inhaler LABA/LAMA devices and asked to choose a preferred device to use, provided they can demonstrate effective use.
224190997|NCT04541836|DIAGNOSTIC_TEST|18F-PMPBB3|single intravenous injection 5mCi 18F-PMPBB3 per scan
224190998|NCT03756805|DEVICE|upper airway stimulation|One group of patients with UAS
224190999|NCT03756805|DEVICE|continuous positive airway pressure|One group of patients with CPAP
224191000|NCT03289676|COMBINATION_PRODUCT|Storytelling Narrative Intervention|"In the first phase, three sections of a video, each for 5-7 minutes will be produced by Star story tellers who are eloquent and have authentic personal experiences of quitting smoking. Participants who receive 8-weekly 30-minute cessation counseling sessions along with NRT are randomly assigned to watch either the smoking cessation video or attention-control video of women taking about their HIV infection."
224191001|NCT04421105|DRUG|Lysergic acid diethylamide (LSD) 5µg|
224191002|NCT04421105|DRUG|Lysergic acid diethylamide (LSD) 10µg|
224191003|NCT04421105|DRUG|Lysergic acid diethylamide (LSD)20 µg|
224191004|NCT04421105|DRUG|Placebo|
224191005|NCT03445780|DRUG|Ethyl chloride spray|Skin cooling with ethyl chloride spray 5 seconds prior to injection
224191006|NCT03445780|PROCEDURE|Pinching|Skin between the distal palmar crease and the palmo digital crease will be pinched for 5 seconds prior to injection
224191007|NCT03445780|PROCEDURE|No Site of Procedure|Subjects will sit behind a screen with a small opening large enough to introduce the injected hand. They will not see any of the procedure
224191008|NCT01568957|BEHAVIORAL|Gait training|Twelve 30-minute sessions plus 10-minute stretching and warm up, provided 3 times per weeks for 4 weeks. Up to 6 weeks are allowed to complete the 12 sessions.
224191009|NCT00889031|OTHER|No Intervention|Patients with Chronic Lymphocytic Leukemia (CLL)
224191010|NCT04166136|OTHER|Transition from the Rearfoot to the Forefoot and Midfoot|Participants in this group will perform a training aimed at the transition of foot strike pattern from the rearfoot to the forefoot and midfoot progressively. Initially a ten-minute race will be held at a comfortable warm-up speed. Then the participants in this group will run continuously at the usual treadmill speed for thirty minutes in a 12-week progressive training program. Participants will run shod and barefoot alternately. Each week the barefoot running time increased to 30 minutes.
224309703|NCT06989372|PROCEDURE|erector spinae block|US-guided ESPB, a commonly performed interfascial plane block, was first defined by Forero et al. (21). In this technique, LA is injected in the plane between the erector spinae muscles and the thoracic transverse processes. Thus, multiple thoracic levels are anesthetized by the LA spreading in a craniocaudal direction. The transducer was then placed approximately 3 cm lateral to the midline parasagittally. The T5 transverse process and the erector spinae, rhomboid major, trapezius muscles were viewed (i.e., from deep to superficial). The block needle was advanced in a craniocaudal direction using an in-plane approach through the trapezius, rhomboid major, and erector spinae muscles. After establishing contact with the hyperechoic transverse process, 30 mL of 0.25% bupivacaine was injected in small aliquots after hydrodissection (2-3 mL, 0.9% NaCl) and checking for negative blood aspiration after every 5 mL of injection.
224309704|NCT06990958|PROCEDURE|Erector Spinae Plane Block (ESPB) group|ultrasound guided erector spinae plane block (at lumbar level) in lateral position .
224309705|NCT06990958|PROCEDURE|Fascia iliaca compartment block (FICB)|ultrasound guided suprainguinal approach in supine position
223500702|NCT01992471|BEHAVIORAL|Post-test counseling, and post-test assessment|When results are available, subjects will be asked to return for in-person communication of the results. Results will be disclosed after confirmation of information preferences in a standard genetic counseling session.
223746230|NCT04105933|OTHER|CBT|CBT was delivered at an individual level, dealing with thoughts, feelings and behaviours in the present. Thoughts are identified and then challenged, to make them more objective and rational.
224191011|NCT04166136|OTHER|Usual Treatment Group|This group will perform standard physiotherapeutic treatment performed at the Naval School. This treatment consists of the application of conventional TENS whose parameters are: alternating current, rectangular pulse, pulse duration 100μs, frequency of 100Hz for 12000 seconds. Laser therapy with an energy of 5 J at each point, irradiation area of 1cm², irradiation time of 20 seconds, 30 repetitions and total time of 6000 seconds.
224191012|NCT04166136|OTHER|Muscle Strengthening Group|The participants of this group will perform muscle strengthening exercises for trunk and lower limbs divided into four phases of three weeks each. The total period of the program strength will be 12 weeks. Elastos® elastic bands of weak, medium and strong intensity will be used to provide progression to the exercises. The exercises will be supervised and supervised by two physiotherapists. A Phase 1 will consist of four exercises; a phase 2, phase 3 and phase 4 will consist of five different exercises each one. In addition to the muscle strengthening le strengthening protocol, this group will have free access to the standard physiotherapeutic treatment performed at the Naval School during and after the study.
224191013|NCT00808184|DRUG|CPT-11, Raltegravir (Isentress®), Midazolam|
224309706|NCT06990672|OTHER|Standard care|Receiving standard dietary and regular recommendations such as education profile and counseling to achieve a fluid intake ≥ 2500 ml, providing verbal health education counseling regarding urological calculi prevention during the hospitalization, and adequate fluid intake in person on the day of discharge. Prepare a fixed-capacity water bottle. Phone calls will be given at each follow-up phase to collect primary and secondary data via the questionnaires.
223746231|NCT06576843|DRUG|INDV-6001|Extended-release subcutaneous injection
223500703|NCT01992471|BEHAVIORAL|Follow-up assessments (6 and 12 months)|At 6 and 12 months post-results transmission (+/- 4 weeks), subjects will be contacted by telephone by the study RSA to complete follow-up instruments (Assessments 3 and 4; They will complete, by phone, the MICRA. They will also describe the surveillance and prevention behaviors of the preceding 6 months, and their intentions for the next 6 months. Subjects who express a high degree of distress will be offered referral to the Counseling Service, facilitated by Dr. Hay.
223500704|NCT00799669|BEHAVIORAL|smoking cessation intervention|Standard quit-smoking counseling to help decrease their risk of cancer.
223500705|NCT00799669|OTHER|counseling intervention|Counseling focusing on decreasing risk of getting cancer by decreasing smoking and alcohol use.
223500706|NCT00799669|OTHER|preventive intervention|
223500707|NCT00799669|OTHER|questionnaire administration|
223746232|NCT06576843|DRUG|Suboxone|Oral sublingual film
223746233|NCT06576843|DRUG|Sublocade|Extended-release subcutaneous injection
224191014|NCT00757159|DEVICE|Ostim|Ostim® is synthetically manufactured and comprises nanocrystalline hydroxyapatite. The small particle size facilitates resorption. Ostim is an aqueous watery paste and can be used to fill bone defects or to build up bony structures in the region of the jaws. Ostim is osteoconductive, facilitating bone growth. It will act as a scaffolding for the new bone. Ostim is absorbed during the healing process, in the beginning it is osseously interweaved and finally replaced by natural bone.
224191015|NCT00757159|DEVICE|Emdogain|Emdogain® consists of sterile lyophilised Enamel Matrix Derivative with sterile aqueous solution of Propylene Glycol Alginate, 30 mg/ml.
224191016|NCT01914042|DRUG|Morphine|
224191017|NCT01914042|DRUG|Milnacipran|
224191018|NCT02840552|DRUG|18F-Fluoromethylcholine (18F-FCH)|FCH PET/CT
224191019|NCT02917161|DEVICE|Prostatic Artery Embolization (PAE)|PAE is performed 6 weeks before radical prostatectomy
224191020|NCT01169233|DEVICE|Bright Light Box|Increased lighting used during night shifts to prevent sleepiness.
224191021|NCT01314261|DRUG|ABT-267|5 mg or 25 mg tablets
224191022|NCT01314261|DRUG|Pegylated interferon (pegIFN)|Syringe, 180 µg/0.5 mL for subcutaneous injections administered weekly
224191023|NCT01314261|DRUG|Ribavirin (RBV)|200 mg tablet dosed at 1000 or 1200 mg daily divided twice a day
224191024|NCT01314261|OTHER|Placebo for ABT-267|Participants received matching placebo tablet at each dose level for ABT-267.
224191025|NCT01018069|DRUG|AEG35156|2 hr infusion of 650 mg of AEG35156 on days 1, 2, 3 and 8. Idarubicin 12 mg/m2 over 30 minutes daily on each of days 4, 5 and 6. The dose of cytarabine will be 1.5 g/m2 daily by continuous infusion x 4 days (days 4-7) in patients under age 65 and x 3 days (days 4-6) in patients age 65 and above.
224191026|NCT05331547|DEVICE|BioFreedom BA9 (SS) Ultra DCS|BioFreedom Ultra stent for treatment of STEMI patients. Besides, in patients who are clinically indicated for a stage procedure, we aim to assess the angiographic and endovascular healing of BioFreedom Ultra stent at one month
223500708|NCT06337409|DRUG|Generic empagliflozin 25 mg film-coated tablets|Empagliflozin 25 mg film-coated tablets
223746234|NCT05304585|PROCEDURE|Biopsy|Undergo tumor biopsy
224191027|NCT03907085|OTHER|HILT + exercise|High intensity laser therapy-Patients received pulsed laser treatment, using a HIRO 3 device (ASA Laser, Arcugnano, Italy), five times a week for a period of three weeks, and one session per day for a total of 15 sessions. A 3-phase treatment program was performed in each session, and the patients were then given a daily exercise program once a day by a physiotherapist. Exercise program; A physiotherapist-assisted exercise program was performed by the two groups, five times a week for three weeks, for approximately 25 minutes. The exercise programs consisted of stretching exercises to the plantar fascia and Achilles tendon, active range of motion (ROM) exercises, and strengthening exercises to the tibialis posterior and peroneus muscles. The patients were also taught to collect the foot and towel.
224191028|NCT03907085|OTHER|Placebo HILT + exercise|Placebo HILT group; Placebo therapy was applied in five sessions a week for three weeks, with a total of 15 sessions a day, with no current flowing through the device. This was followed by the exercise programs described above, performed once a day with the physiotherapist. Exercise program; A physiotherapist-assisted exercise program was performed by the two groups, five times a week for three weeks, for approximately 25 minutes. The exercise programs consisted of stretching exercises to the plantar fascia and Achilles tendon, active range of motion (ROM) exercises, and strengthening exercises to the tibialis posterior and peroneus muscles. The patients were also taught to collect the foot and towel.
224191029|NCT00485615|DRUG|Omega 3 Joy enteric coated concentrated fish oil|1500-3000mg; one per day
223500709|NCT03097159|PROCEDURE|Costoclavicular block|Group C for costoclavicular block Group S for supraclavicular block
223746235|NCT05304585|PROCEDURE|Bone Scan|Undergo bone scan
223500710|NCT03168087|OTHER|Plasmalyte-148|Venous blood is taken from 12 healthy volunteers and divided into four specimen bottles, which were diluted with different levels (0%, 20%, 40%, and 60%) using a plasmalyte-148 solution.
223500711|NCT05174507|DRUG|empagliflozin|Empagliflozin (Jardiance®; Boehringer Ingelheim (Schweiz) GmbH) is a highly selective, reversible inhibitor of the sodium glucose co-transporter 2 (SGLT2). Treatment consists of a single oral tablet of 25 mg of empagliflozin (Jardiance®) two hours before ingestion of the mixed-meal (Ensure plus® 375 ml, 75 g carbohydrates, 562 kcal, drinking time 5 minutes).
223746236|NCT05304585|PROCEDURE|Computed Tomography|Undergo CT scan
223746237|NCT05304585|DRUG|Cyclophosphamide|Given IV
223746238|NCT05304585|BIOLOGICAL|Dactinomycin|Given IV
223746239|NCT05304585|PROCEDURE|Magnetic Resonance Elastography|Undergo MRI
223746240|NCT05304585|PROCEDURE|Positron Emission Tomography|Undergo PET scan
223746241|NCT05304585|RADIATION|Radiation Therapy|Undergo radiation
223746242|NCT05304585|DRUG|Vincristine|Given IV
223746243|NCT06591949|OTHER|BETY|The cognitive Exercise Therapy Approach (Bilişsel Egzersiz Terapi Yaklaşımı-BETY) will be applied for 24 one-hour sessions, two days a week.
223746244|NCT06591949|OTHER|Control group|Control group will be followed up with a home exercise program, and notes will be taken.
224191030|NCT04524507|BIOLOGICAL|High-titer Convalescent COVID-19 Plasma (CCP1)|At least two units of CCP transfused 4-24 hours apart on Study Day 0. A third unit may be administered, if available.
224191031|NCT04524507|BIOLOGICAL|Standard-titer Convalescent COVID-19 plasma (CCP2)|At least two units of CCP transfused 4-24 hours apart on Study Day 0. A third unit may be administered, if available.
224191032|NCT05241756|DEVICE|FLACS using FEMTO LDV-Z8|Performance of femtosecond laser-assisted capsulotomy in the anterior capsule.
224191033|NCT02251574|OTHER|Low Calorie Diet|Weight management program designed around a low calorie diet.
224191034|NCT02251574|OTHER|Very Low Calorie Diet|Weight management program designed around a very low calorie diet.
224191035|NCT02251574|OTHER|Standard Care|Care provided that would normally be given to people meeting eligibility criteria for this study.
224191036|NCT03195231|DRUG|Wuling Powder|Patients of Wuling Group are instructed to take Wuling Powder 3 times a day and 3 pills each time for 12 weeks.
224191037|NCT03195231|DRUG|Placebo|Patients of Placebo Group are instructed to take placebo drug 3 times a day and 3 pills each time for 12 weeks.
224191038|NCT00412360|BIOLOGICAL|Single Umbilical Cord Blood Unit Transplant|Unrelated donor, single umbilical cord blood unit; conditioning regimen: TBI/cyclophosphamide/fludarabine; GVHD prophylaxis: cyclosporine/MMF
224191039|NCT00412360|BIOLOGICAL|Double Umbilical Cord Blood Unit Transplant|Unrelated donor, double umbilical cord blood unit; Conditioning regimen: TBI/cyclophosphamide/fludarabine; GVHD prophylaxis: cyclosporine/MMF
224191040|NCT00412360|RADIATION|Total Body Irradiation|The TBI will be delivered from either a linear accelerator or cobalt source at a dose rate of between 4 and 26 cGy/minute using energies of between 1 and 25 MV.
224191041|NCT00412360|DRUG|Cyclophosphamide|Cyclophosphamide 60 mg/kg/day will be administered as a 2 hour intravenous infusion with a high volume fluid flush on Days -3 and -2.
224191042|NCT00412360|DRUG|Fludarabine|Fludarabine 25 mg/m2/day will be administered over 30-60 minutes intravenous infusion on Days -10 through -8. Fludarabine will not be dose adjusted for body weight.
224191043|NCT00412360|DRUG|Cyclosporine A|CSA will be administered beginning on Day -3 and doses will be adjusted to maintain a level of 200-400 ng/mL by TDX method (or 100-250 ng/mL by Tandem MS or equivalent level for other CSA testing methods). CSA can be administered per institutional practice.
224191044|NCT00412360|DRUG|Mycophenolate Mofetil|MMF will be given at a dose of 1 gram IV q 8 hours if \> 50 kg or 15 mg/kg IV q 8 hours if \< 50 kg beginning the morning of Day -3.
224191045|NCT01861158|BEHAVIORAL|Parenting Wisely|Computer-based, online, interactive parenting intervention
224191046|NCT05393986|DRUG|CT048 Autologous Injection (CT048)|up to 3 times CT048 Autologous Injection infusion
224191047|NCT02711306|DIETARY_SUPPLEMENT|Glucomannan noodle|The participants received two servings (400 g) of GMN every day to replace their daily carbohydrate intake for 4 weeks.
224191048|NCT02711306|DIETARY_SUPPLEMENT|Placebo noodle|In the placebo noodle diet, the participants received the same amount of noodles without glucomannan for 4 weeks.
224191049|NCT01897779|DRUG|RPX7009|Two (2) groups of 15 subjects (12 active and 3 placebo) are planned for evaluation in cohort 1. Cohorts 2-5, 14 subjects (11 active and 3 placebo) are planned for evaluation in each cohort. 14 subjects (12 active and 2 placebo) are planned for evaluation in cohort 6.
224191050|NCT01897779|DRUG|RPX2014|Two (2) groups of 15 subjects (12 active and 3 placebo) are planned for evaluation for cohort 1. Cohorts 2-5, 14 subjects (11 active and 3 placebo) are planned for evaluation in each cohort. 14 subjects (12 active and 2 placebo) are planned for evaluation in cohort 6.
224191051|NCT01897779|DRUG|Placebo|Two (2) groups of 15 subjects (12 active and 3 placebo) are planned for evaluation for cohort 1. Cohorts 2-5, 14 subjects (11 active and 3 placebo) are planned for evaluation in each cohort. 14 subjects (12 active and 2 placebo) are planned for evaluation in cohort 6.
224191052|NCT01897779|DRUG|Combination RPX7009 and RPX2014|Two (2) groups of 15 subjects (12 active and 3 placebo) are planned for evaluation in cohort 1. Cohorts 2-5, 14 subjects (11 active and 3 placebo) are planned for evaluation in each cohort. 14 subjects (12 active and 2 placebo) are planned for evaluation in cohort 6.
224191053|NCT05314621|DRUG|olopatadine hydrochloride ophthalmic solution 0.7%)|Pataday® Once Daily Relief Extra Strength (eyedrop)
224191054|NCT05314621|DRUG|Fluticasone Propionate|Flonase® Allergy Relief (nasal spray)
224191055|NCT05314621|DRUG|Tears Naturale|Tears Naturale® II (eye drop)
224191056|NCT05314621|DRUG|Saline nasal spray|Saline nasal spray (nasal spray)
224191057|NCT01874587|RADIATION|adaptative radiotherapy|weekly replanning
224191058|NCT03799133|DEVICE|Florence device|The Florence catheter will be placed at the beginning of the surgery and up to 72 hours in ICU.
224191059|NCT03572699|OTHER|diabetic retinopathy|This is an observational study of patients with diabetes. Patients undergoing routine care will undergo retinal imaging using a nonmydriatic fundus camera. The images will be run on an artificial intelligence (AI) algorithm. The diagnosis of the artificial intelligence algorithm will be compared to the image diagnosis given by the ophthalmologists. The ophthalmologists will be blinded to the diagnosis of the AI and vice versa. The data will be analyzed to evaluate the performance of the AI.
224191060|NCT03309215|OTHER|Experimental stimulation with nickel discs|"All participants will be exposed to 8 metal discs, 3 cm in diameter, 4 on each arm, placed on the volar side of the forearms (figure 1). Three of the metallic discs consists of \>99 wt.% nickel one consist of \>99wt.% Aluminium.The latter is used as a negative control. The discs will be applied under occlusion and with initial pressure and friction.~One metallic disc with nickel, and one with aluminium, will be randomized for the earlobes on the patients with nickel allergy"
224191061|NCT06083428|DRUG|Ropivacaine 0.2% Injectable Solution Erector Spinae Plane Block|ultrasound guided ESPB - L4 level, unilateral
223500712|NCT05174507|DRUG|anakinra|Anakinra (Kineret®; r-metHuIL-1ra, Swedish Orphan Biovitrum AB) is a recombinant, non-glycosylated form of the human interleukin-1 receptor antagonist (IL-1Ra) in a 100 mg/0.67ml solution for SC injection. Treatment consists of a single subcutaneous injection of 100 mg Anakinra (Kineret®) three hours before ingestion of the mixed-meal (Ensure plus® 375 ml, 75 g carbohydrates, 562 kcal, drinking time 5 minutes).
223500713|NCT05174507|OTHER|saline subcutaneous (s.c.) (placebo)|Placebo for anakinra is 0.67 ml of sterile 0.9 % saline solution s. c. Treatment consists of a single subcutaneous injection of matched placebo (0.67 ml of 0.9 % saline) three hours before ingestion of the mixed-meal (Ensure plus® 375 ml, 75 g carbohydrates, 562 kcal, drinking time 5 minutes).
223500714|NCT05174507|OTHER|tablet per oral (p.o.) (placebo)|Placebo for empagliflozin is Winthrop P® (Zentiva, Frankfurt/Main) lactose tablet. Treatment consists of a single oral tablet of matched placebo two hours before ingestion of the mixed-meal (Ensure plus® 375 ml, 75 g carbohydrates, 562 kcal, drinking time 5 minutes).
224191062|NCT06083428|DRUG|Ropivacaine 0.2% Injectable Solution - PENG block|ultrasound guided PENG block
224191063|NCT06083428|DRUG|Control Test|Only spinal anesthesia
224191064|NCT04333628|DRUG|chloroquine|oral treatment of chloroquine
224191065|NCT04333628|OTHER|standard care|Currently, there is no specific treatment for novel coronavirus. The treatment is mostly supportive in character and is given, based on patient's clinical state. Antibiotics do not help patients fight novel coronavirus.
224191066|NCT00004166|DRUG|amifostine trihydrate|
224191067|NCT00004166|PROCEDURE|quality-of-life assessment|
224191068|NCT03878420|DEVICE|Valeda PBM treatment|The Valeda Light Delivery System delivers 590, 660 and 850 nm wavelengths of light to the study eye. The Valeda Light Delivery System will treat through the open eyelid with the 590 nm and 850 nm wavelengths together. The 660 nm wavelength will be treated through the closed eyelid.
224191069|NCT03878420|DEVICE|Valeda Sham treatment|The sham mode emits an approximate 100x reduction in the highest dose for the 660 nm wavelengths as compared to the treatment mode, producing a slightly duller light. The 850 nm (NIR) wavelength (which is not visible light) is not provided in the sham treatment.
224191070|NCT04490902|PROCEDURE|Limbal transplantation combined with central penetrating keratoplasty|Limbal transplantation combined with central penetrating keratoplasty with single donor cornea
224191071|NCT04490902|PROCEDURE|Limbal transplantation combined with central penetrating keratoplasty|Limbal transplantation combined with central penetrating keratoplasty with mixed component cornea
224191072|NCT04313595|DEVICE|RespirHó|"The system is a wearable, unobtrusive inertial-sensor-based device for long-term breathing pattern monitoring, also during daily life activities. It consists of three IMU-sensor units (3-axis accelerometer, 3-axis gyroscope, 3-axis magnetometer), positioned respectively on the patient's abdomen and thorax, and on a body area integral with thorax but not affected by espiratory movements. The peripheral units, placed on thorax and abdomen are used to record orientation changes during respiratory movements. The third unit is a central reference unit (hereafter CRU) that receives data from the other two units, save them on an SD card and communicate via Bluetooth with a smartphone / tablet / PC. Moreover, this unit detects only non-respiratory movement, representing not only a pure source of noise that must be removed from the thoracic and bdominal signals, but also a pure source of additional information regarding the state of ctivity of the subject ."
224191073|NCT03908723|OTHER|Panretinal photocoagulation|Intravitreal Aflibercept with PRP to the peripheral vascular lesions
224191074|NCT01359813|DRUG|Human Albumin|Administration: 1,5 g/kg at Day 1 and 1g/kg at Day 3 In case of a new infection appears in the 3 months, the same doses will be administrated.
224191075|NCT01643889|DRUG|Treatment A (domperidone 10 mg)|1 domperidone 10 mg capsule four times a day (q.i.d.) + 1 domperidone placebo capsule q.i.d. on Days 1 to 3 and a single dose on Day 4 (13 doses in total), and 1 moxifloxacin placebo capsule in the morning of Day 1.
224191076|NCT01643889|DRUG|Treatment B (domperidone 20 mg)|2 domperidone 10 mg capsules four times a day (q.i.d.) on Days 1 to 3 and a single dose on Day 4 (13 doses in total), and 1 moxifloxacin placebo capsule in the morning of Day 1.
224191077|NCT01643889|DRUG|Treatment C (placebo)|2 domperidone placebo capsules four times a day (q.i.d.) on Days 1 to 3 and a single dose on Day 4 (13 doses in total), and 1 moxifloxacin placebo capsule in the morning of Day 1.
224191078|NCT01643889|DRUG|Treatment D (moxifloxacin)|2 domperidone placebo capsules four times a day (q.i.d.) on Days 1 to 3 and a single dose on Day 4 (13 doses in total), and 1 moxifloxacin 400 mg capsule in the morning of Day 1.
224191079|NCT05230992|DEVICE|Cryoprobes First|In this experimental group, the Cryoprobe is used in first and the classic biopsy forceps in a second time. This medical device under study is the flexible, single-use Cryoprobe, supplied in sterile condition, 1.1 mm in diameter, 1150 mm long, with extraction tube, 817 mm long (reference 20402-401), or 757 mm long (reference 20402-402) marketed. These cryoprobes are covered by a CE marking. Cryoprobes must be used in conjunction with the Erbecryo®2 device and its accessories.
224191080|NCT05230992|DEVICE|Cryoprobes Second|In this second experimental group, the same medical devices are used but in the other order.
224191081|NCT02073149|DIETARY_SUPPLEMENT|Low-dose iron as NaFeEDTA|Daily home fortification for 30 days with 3 mg iron as NaFeEDTA, vitamin A (300 RE μg as retinyl palmitate) and 5 mg zinc (as gluconate)
224191082|NCT02073149|DIETARY_SUPPLEMENT|Conventional dose iron as ferrous salt|Daily home fortification for 30 days with 12.5 mg iron as encapsulated ferrous fumarate, vitamin A (300 RE μg as retinyl palmitate) and 5 mg zinc (as gluconate)
224191083|NCT02073149|DIETARY_SUPPLEMENT|Placebo|Daily home fortification for 30 days with vitamin A (300 RE μg as retinyl palmitate) and 5 mg zinc (as gluconate)
224191084|NCT00208715|DRUG|Provigil|
224191085|NCT04852809|OTHER|No intervention|This is an observational study
224191086|NCT01931020|DRUG|Sucrose|The enrolled neonates will be administered 1ml of 24% sucrose. After 2 minutes heel lancing will be performed after cleaning the heel of neonate with a sterile spirit swab, with an auto lancet. Neonate's faces and monitor screen will be filmed in real time by using two independent video cameras during the entire procedure i.e. staring 2 minutes prior to heel lance and continue 2 minutes after the procedure. The PIPP will be assessed at 30 seconds, 1 minute and 2 minute after the procedure.
224191087|NCT01931020|DRUG|Glucose|The enrolled neonates will be administered 1ml of 25% gluose. After 2 minutes heel lancing will be performed after cleaning the heel of neonate with a sterile spirit swab, with an auto lancet. Neonate's faces and monitor screen will be filmed in real time by using two independent video cameras during the entire procedure i.e. staring 2 minutes prior to heel lance and continue 2 minutes after the procedure. The PIPP will be assessed at 30 seconds, 1 minute and 2 minute after the procedure.
223500715|NCT05340660|RADIATION|[ 18 F]PSS232|\[ 18 F\]PSS232 for imaging metabotropic glutamate receptor subtype 5 and comparing expression of the receptor in healthy persons and ALS patients
223500716|NCT03215615|PROCEDURE|Periodontal surgery|Coronally advanced flap for root coverage
224191088|NCT03385395|DRUG|OctaAlpha1|For OctaAlpha1 the standard weekly dose of 60mg/kg will be given for 24 consecutive infusions
224191089|NCT03385395|DRUG|Glassia|For Glassia the standard weekly dose of 60mg/kg will be given for 24 consecutive infusions
224191090|NCT01422395|PROCEDURE|Freezing|Vitrification
224191091|NCT02536209|DRUG|MT-8554 low dose|
224191092|NCT02536209|DRUG|MT-8554 high dose|
224191093|NCT02536209|DRUG|Oxycodone hydrochloride|
224191094|NCT02536209|DRUG|Placebo|
224191095|NCT00005627|DRUG|carboplatin|
224191096|NCT00005627|DRUG|docetaxel|
223500717|NCT03215615|PROCEDURE|Total Etch adhesive|Total-etch adhesive system (two step)
223500718|NCT03215615|PROCEDURE|Universal Adhesive|One-step self-etching adhesive system
223500719|NCT03215615|PROCEDURE|Nanofilled Composite|Partial nanofilled-resin composite restoration
223500720|NCT03215615|PROCEDURE|Micro-Hybrid Composite|Partial micro-hybrid composite restoration
223500721|NCT04293965|DRUG|Single ascending dose of X842|A total of 7 dose groups will be set for the ascending dose: 5.6 mg, 12.5 mg, 25 mg, 50 mg, 100 mg, 150 mg, 225 mg. In the 5.6 mg dose group, 4 subjects will receive X842; in the 12.5 mg, 25 mg, 50 mg, 100 mg, 150 mg, 225 mg dose groups, 8 subjects in each group will receive X842. Each subject can only receive a certain dose level and cannot enter in multiple dose groups repeatedly.
224191097|NCT00005627|DRUG|estramustine phosphate sodium|
224191098|NCT03212872|DIAGNOSTIC_TEST|Endoscopy|
224191099|NCT06205459|PROCEDURE|deep marginal acquisition using thermacut bur|thermacut bur is a tool which doesn't contain any abrasives so it is much safer on the root surface of both prepared and adjacent teeth, and yields better treatment outcome in cases when exposing deep margins is needed.
224191100|NCT02579889|DEVICE|DDD+CLS|Device will be programmed in a dual-chamber DDD pacing mode with the Closed Loop Stimulation (CLS) function ON
224191101|NCT02579889|DEVICE|DDD(R)|Device will be programmed in a dual-chamber DDD(R) pacing mode with the Closed Loop Stimulation (CLS) function OFF
224191102|NCT01052558|DEVICE|iStent Inject (GTS400)|Subjects will be randomized to one of two groups. In this case, subjects will undergo cataract surgery with subsequent implantation of GTS400 stents.
224191103|NCT01052558|PROCEDURE|Cataract Surgery|Subjects will be randomized to one of two groups. In this case, subjects will undergo cataract surgery only.
224191104|NCT00000758|DRUG|Fluorouracil|
224191105|NCT03851302|OTHER|Active Remote Ischemic Conditioning|The active RIC protocol involves 5 cycles of 5-min inflation and 5-min deflation on the non-target arm. The active RIC will be achieved via blood pressure cuff inflation to 200 mmHg.
224191106|NCT03851302|OTHER|Sham Remote Ischemic Conditioning|The sham RIC protocol involves 5 cycles of 5-min inflation and 5-min deflation on the non-target arm. The sham RIC will be achieved via blood pressure cuff inflation to 10 mmHg below the subjects' diastolic blood pressure which would not cause the blood occlusion.
223500722|NCT04293965|DRUG|Multiple ascending dose of X842|Two dose groups will be set, including the groups receiving the recommended phase II dose and a higher dose; Eight subjects will be enrolled in each group, with half male and half female, who will receive X842 once daily for 5 consecutive days. Each subject can only receive a certain dose level and cannot enter in multiple dose groups repeatedly.
223500723|NCT04293965|OTHER|Food Effect|Twelve subjects (appropriate ratio of male to female) screened for eligibility will be randomized into Group A and B. The 6 subjects in Group A will take the study drug (X842) in fasted condition and subject in Group B will take the study drug in fed condition in the 1st cycle. In the 2nd Cycle, subjects in Group A will take the study drug in fed condition, and subjects in Group B will take the study drug in fasted condition. The interval between the two cycles is at least 7 days.
223500724|NCT04201210|OTHER|TCRα/β+ and CD19+ depleted haploidentical stem cell transplantation|Haploidentical 5+/10 HSCT from a relative, α/β T-depleted
223500725|NCT04201210|OTHER|Matched sibling donor transplantation|10/10 HSCT - matched family donor
223500726|NCT04428905|OTHER|Quality-of-Life Assessment|Ancillary studies
223500727|NCT04428905|OTHER|Questionnaire Administration|Ancillary studies
223500728|NCT04428905|OTHER|Survivorship Care Plan|Receive personalized care plan/resource manual
223500729|NCT04428905|OTHER|Telemedicine|Participate in telehealth sessions
223500730|NCT01149967|DRUG|Citalopram Hydrobromide|Citalopram Hydrobromide Tablets 40 mg of Dr.Reddy's Laboratories Limited
224191107|NCT03851302|OTHER|Isometric hand exercise|Participants will be instructed to pinch a dynamometer with thumb and index finger at different intensities and durations. The intensities of pinch force will be 10%, 25%, and 50% of the maximal voluntary contraction (MVC). For each intensity, durations of 2, 4, and 6 s will be employed, which resulted in nine different combinations delivered in pseudorandom order. Participants will perform 2 sets of the isometric hand exercise (18 pinches in total). The interval between each pinch will be 2 seconds, with 30 second intervals between each set.
224191108|NCT01297621|PROCEDURE|reduction mammaplasty|conventional reduction mammaplasty
224191109|NCT01297621|OTHER|control|follow up, questionnaire responses
224191110|NCT03339622|COMBINATION_PRODUCT|PPP001|1 pellet smoked three times a day with titanium pipe (280 mg dried cannabis pellet - 9% THC / 2% CBD per pellet)
224191111|NCT03339622|COMBINATION_PRODUCT|placebo|1 pellet smoked three times a day with titanium pipe (280 mg dried cannabis pellet - 0% THC / 0.6% CBD per pellet)
223512042|NCT06010108|BEHAVIORAL|W.H.I.T.E project|Community based intervention- This will involve the engagement of women's trade unions and organisations in the community to create awareness and women and girls interested in the uptake of HPV prevention services will be directed to receive these services at a designated community facility accessible to women and girls in the community. Participants contact details will be collected for follow uo and communication of results
223512043|NCT06010108|BEHAVIORAL|Project Shield|Utilization of community based structures (pharmacy and health center)- The intervention will involve the creation of a branded self-sampling kit for HPV screening and a free vaccination voucher to encourage mother-daughter uptake of cervical cancer prevention measures. Awareness will be raised through banners at the points of access of the vaccines and kits, use of jingles, and the involvement of the Community Development Association (CDA) to help mobilize girls, women and the men. Women and girls will be referred to community health centers to receive the HPV vaccination and carry out the screening
224191112|NCT04196231|DRUG|IDegLira|IDegLira will be started at 16 dose steps (16 U insulin degludec plus 0.58 mg liraglutide, once daily). On the basis of prebreakfast self-monitored blood glucose measurements doses of IDegLira will be titrated individually twice per week to achieve a prebreakfast plasma glucose of 80-130 mg/dL by use of an algorithm (adding 2 dose steps for prebreakfast plasma glucose \>130 mg/dL; no dose change for prebreakfast plasma glucose of 80-130 mg/dL; reducing 2 dose steps for prebreakfast plasma glucose \< 80 mg/dL). The daily dose of IDegLira could be titrated to 50 dose steps (50 U insulin degludec plus 1.8 mg liraglutide).
224191113|NCT04196231|DRUG|IGlarLixi|IGlarLixi will be started at 10 dose steps (10 U insulin glargine plus 5 mcg lixisenatide, once daily). On the basis of prebreakfast self-monitored blood glucose measurements, doses of IGlarLixi will be titrated individually once per week to achieve a prebreakfast plasma glucose of 80-130 mg/dL by use of an algorithm (adding 2 dose steps for prebreakfast plasma glucose \>130 mg/dL; no dose change for prebreakfast plasma glucose of 80-130 mg/dL; reducing 2 dose steps for prebreakfast plasma glucose \< 80 mg/dL). The daily dose of IGlarLixi could be titrated to 60 dose steps (60 U insulin degludec plus 20 mcg lixisenatide).
224191114|NCT04196231|DRUG|Insulin/Canaglifozin|Patients in this arm will continue the basal insulin used before the randomization, with dosage titration on the basis of the following algorithm: adding 2 units for prebreakfast plasma glucose \>130 mg/dL; no dose change for prebreakfast plasma glucose of 80-130 mg/dL; reducing 2 units for prebreakfast plasma glucose \< 80 mg/dL. Moreover, they will be assigned to canaglifozin, according to the current clinical practice and the drugs' data sheet. Canagliflozin will be started at 100 mg daily per oral administration, and augmented to 300 mg/per day if required (HbA1c \>7.5 after 12 weeks).
224191115|NCT04196231|DRUG|Insulin/Dapaglifozin|Patients in this arm will continue the basal insulin used before the randomization, with dosage titration on the basis of the following algorithm: adding 2 units for prebreakfast plasma glucose \>130 mg/dL; no dose change for prebreakfast plasma glucose of 80-130 mg/dL; reducing 2 units for prebreakfast plasma glucose \< 80 mg/dL. Moreover, they will be assigned to dapaglifozin, according to the current clinical practice and the drugs' data sheet. Dapagliflozin will be started at 10 mg daily per oral administration
224191116|NCT04196231|DRUG|Insulin/Empaglifozin|Patients in this arm will continue the basal insulin used before the randomization, with dosage titration on the basis of the following algorithm: adding 2 units for prebreakfast plasma glucose \>130 mg/dL; no dose change for prebreakfast plasma glucose of 80-130 mg/dL; reducing 2 units for prebreakfast plasma glucose \< 80 mg/dL. Moreover, they will be assigned to empaglifozin, according to the current clinical practice and the drugs' data sheet. Empagliflozin will be started at 10 mg daily per oral administration, and augmented to 25 mg/per day if required (HbA1c \>7.5 after 12 weeks).
224191117|NCT04196231|DRUG|Basal Bolus|Patients in this arm will continue the basal insulin (glargine, degludec or glargine-300) used before the randomization. The insulin titration will be guided by the medical staff, according to the following algorithm: adding 2 units of basal insulin for prebreakfast plasma glucose \>130 mg/dL; no dose change for prebreakfast plasma glucose of 80-130 mg/dL; reducing 2 units of basal insulin for prebreakfast plasma glucose \< 80 mg/dL. The short acting insulin analogue (lispro, aspart or glulisine) will be started at the dosage of 4 units before meals (3 times per day) and will be titrated twice a week until achieving pre-prandial glucose values ranging from 80-130 mg/dL.
224191118|NCT05107557|BIOLOGICAL|Experimental Group|The COVID-19 vaccine was manufactured by Sinovac Research \& Development Co., Ltd, and the EV71 vaccine was manufactured by Sinovac Biotech Co.The COVID-19 vaccine:600SU inactivated virus in 0.5mL of aluminium hydroxide solution per injection;The EV71 vaccine:Inactivated EV71 virus antigen no less than 3.0EU in 0.5 mL of aluminium hydroxide solution per injection.
224191119|NCT02183220|DRUG|Metamizol|
224191120|NCT02183220|DRUG|Acetylsalicylic acid (ASA)|
224191121|NCT02183220|DRUG|Metamizol placebo|
224191122|NCT02183220|DRUG|ASA placebo|
224191123|NCT02569996|DRUG|Rituximab|Rituximab will be administered at 375 mg/m\^2 every 8 weeks for 24 months or until progression, relapse, death, or institution of a new anti-lymphoma treatment.
224191124|NCT01383317|DEVICE|Thigh Tourniquet (VBM Single Use Tourniquet Cuff Items 20-34-722SLZ-1)|Disposable sterile thigh tourniquet
223500731|NCT05007444|DRUG|P2Et (Caesalpinia spinosa extract)|Patients who meet inclusion criteria will begin taking 4000mg daily, distributed in 2 doses with meals of 2000mg of P2Et extract during neoadjuvant treatment. In case of presenting toxicity, it will be lowered to the next dose level, that is, 2000 mg under the same dosage schedule and 1000 mg following the same principle. The taking of the phytomedicine will only be suspended 3 days before each cycle of standard neoadjuvant therapy and will restart 3 days after having passed the cycle. That is, in the anthracyclines and cyclophosphamide (AC) phase, the patient will start taking the phytomedicine 3 days after having received their standard chemotherapy cycle and will suspend it 3 days after the next cycle begins. For the taxane phase, the patient will take the P2Et without suspension during the treatment cycles.
223500732|NCT05007444|DRUG|Placebo|After determining the optimal biological dose (OBD), the patients will be divided into the placebo arm or the treatment arm. In the anthracyclines and cyclophosphamide (AC) phase, the patient will start taking according to the asignation as stated in the drug intervention.
223500733|NCT01713738|DRUG|rituximab|infusion of 4 weekly doses of 375 mg/m2 rituximab
223500734|NCT04447248|DEVICE|QDSP Protocol|Computerized expert system for fetal monitoring, based on cardiotocogrpaphy
223500735|NCT00167271|BEHAVIORAL|Cognitive Behavior Therapy|Experimental: Computerized cognitive, behavioral therapy with Body Media armband to collect data about activity, which subjects could review each evening.
223500736|NCT02832999|DRUG|sub cutaneous liraglutide|Liraglutide 1.2mg/day
223591593|NCT06051344|DRUG|Zoledronic acid|. Total 92 primary knee OA patients will be enrolled by following the inclusion criteria of ages 50 years and above with primary knee OA informed written consent. Then randomization will be done into group A and group B following a randomization table, each consist of 46 patients. Consecutive sampling technique will be followed. Primary knee OA will be diagnosed on the basis of ACR clinical and radiological criteria. Relevant laboratory investigations will be done. Baseline pain status will be measured by Bangla version of Western Ontario and McMaster Universities Osteoarthritis index (WOMAC), visual analog scale (VAS) and numerical rating scale (NRS) and quality of life will be measure by European quality of life scale (EQ-5D-5L). Then one group will receive single infusion of 5mg zoledronic acid and another group will receive the placebo
223746245|NCT00170716|DEVICE|Cortical Stimulation and rehabilitation|Cortical stimulation is provided concomitantly with rehabilitation therapy. Rehabilitation is for 2.5 hrs per day for 26 days over a period of 6 weeks.
223746246|NCT00170716|OTHER|Rehabilitation|Rehabilitation is for 2.5 hrs per day for 26 days over a period of 6 weeks.
224191125|NCT01383317|DEVICE|Sham RIPC|Disposable sterile thigh tourniquet
224191126|NCT02730234|DEVICE|JetStream XC with balloon angioplasty|JetStream XC to treat femoropopliteal in-stent restenosis followed by adjunctive balloon angioplasty (same arm). The control arm in this study is historic.
224191127|NCT04367324|DEVICE|Low-level laser therapy|The low-level laser was applied to each patient in low-level laser therapy group.
224191128|NCT01129219|OTHER|Strength training|Strength training for 24 weeks
223500737|NCT02832999|DRUG|Oral Vildagliptin|Vildagliptin 50mg/day
224191129|NCT04350034|OTHER|Xbox training|"patients in this group received routine physical therapy protocol plus Xbox training.~Before the intervention started, the Xbox group was given a 45 min introductory session on how to use the xbox adventure games and its tools. All sessions were led by a single experienced physiotherapist (different to the physiotherapist who performed the assessments tests) in order to provide instruction on how to perform each exercise."
224191130|NCT04350034|OTHER|Control group|routine physical therapy protocol (RPTP) including joint range of motion exercises (ROM), muscle stretching technique, splinting, daily walking, and ADL training.
224191131|NCT05239390|DRUG|SCI -110|"Dronabinol - Manufactured by Pharmaceutics International, Inc., Hunt Valley, MD 21031, USA. Dronabinol Capsules (dronabinol solution in sesame oil in soft gelatin capsules) are 2.5 mg - cream, oblong, soft-gel capsules. In an NDC 49884-867-02 Bottle of 60 capsules packaged in a well-closed container and stored in a locked refrigerator, 2° to 8°C. Protect from freezing, in accordance with the Israeli legal requirements (Israel Narcotic Drugs Act). Storage conditions should be monitored on a daily basis.~PEA - Manufactured by Pharmacies Inc. 767 Front st. Suite 202. Catasauqua, PA 18032 www.pharmacures.com. 1-888-334-3130. 400 mg PEA tablets, in a 60 mL barrier bottle, 30/400 mm, Bottle of 30 capsules packaged in a well-closed container and stored in RT (20° to 25°C). Storage conditions should be monitored on a daily basis."
224191132|NCT06381024|DEVICE|remote patient monitoring|"Cureety is a digital telemonitoring platform, specifically designed to monitor signs and symptoms of disease progression and AEs in cancer patients. The digital tool is adaptable to specific treatments and disease settings. The platform collects various data including treatment delays, dose reductions, quality of life and safety data. In terms of safety, once configured for the treatment and disease setting, the patient responds to an electronic PRO (ePRO) questionnaire based on the NCI-CTCAE version (v)5.0.10 Depending on the responses, an algorithm classifies patients as either correct, compromised, state to be monitored, or critical state. Depending on the classification, patients are notified of the actions to be taken."
224191133|NCT04824118|DIAGNOSTIC_TEST|Thromboelastometry|Point of Care Test for clotting parameters (ClotPro device)
224191134|NCT04824118|DIAGNOSTIC_TEST|Clotting Studies|"Standard laboratory tests for clotting:~* International normalised ratio (INR)~* Prothrombin time (PT)~* adjusted partial thromboplastin time (aPTT)~* fibrinogen"
224191135|NCT04824118|DIAGNOSTIC_TEST|Full Blood Count|For platelet count
224191136|NCT04824118|DIAGNOSTIC_TEST|Quantitative hCG|Serum human chorionic gonadotrophin
224191137|NCT04824118|DIAGNOSTIC_TEST|Pregnancy Test|Point of care urinary pregnancy test
224191138|NCT06326138|DRUG|Edoxaban Pharmacokinetics and Pharmacodynamics|Participants will be received single oral doses of edoxaban 60 mg.
224191139|NCT02361606|BEHAVIORAL|An Internet Cognitive-Behavioral Intervention|We developed a cognitive behavioral program for adolescents with type 1 Diabetes and their parents, that consists of six virtual sessions at https://minustress.com/diabetes/gate.asp.
224191140|NCT01343121|OTHER|sample collection|Blood samples will be collected on days 1, 8, 15 and 22. They will be taken 30 minutes and 2 hours post Gemcitabine infusion.
224191141|NCT01343121|OTHER|sample collection|Urine will be collected on days 1, 8, 15 and 22. They will be taken pre gemcitabine and 2 hours post Gemcitabine
224191142|NCT01343121|OTHER|Sample Collection|Quality of Life (QOL) questionnaires given to the patient at each visit
224191143|NCT03162302|DIAGNOSTIC_TEST|Magnetic Resonance Imaging (MRI)|Magnetic resonance imaging (MRI) is a non-invasive imaging technique that uses a magnetic field and radio waves to create detailed images of the organs and tissues within the body.
224191144|NCT03578341|BIOLOGICAL|Orally Colostrum|Group 1, Will receive colostrum 0.3 mL every 4 hours in the oropharyngeal mucosa, for 3 days.
224191145|NCT03204331|DRUG|Relugolix|Relugolix 40-mg tablet administered orally once daily.
224191146|NCT03204331|DRUG|Estradiol/norethindrone acetate|Capsule containing co-formulated tablet of E2 (1.0 mg)/NETA (0.5 mg) administered orally once daily.
224191147|NCT03204331|DRUG|Estradiol/norethindrone acetate placebo|E2 (0 mg)/NETA (0 mg) placebo capsule administered orally once daily and designed to match the E2/NETA capsule in size, shape, color, and odor.
224191148|NCT03204331|DRUG|Relugolix placebo|Relugolix (0 mg) placebo tablet administered orally once daily and manufactured to match the relugolix tablet in size, shape, color, and odor.
224191149|NCT01941160|DIETARY_SUPPLEMENT|Lacidofil® STRONG|Lacidofil® STRONG capsule twice daily
224191150|NCT01941160|DIETARY_SUPPLEMENT|Placebo|Placebo capsule twice daily
224191151|NCT00411229|DRUG|Capecitabine|1,000 mg/m² twice daily. Film coated tablets of 500 mg, 150mg.
224191152|NCT00411229|DRUG|Oxaliplatin|IV infusion, 130mg/m²
223500738|NCT03423472|BEHAVIORAL|Orange Fleshed Sweet Potato (OFSP) agriculture promotion and nutrition education on vitamin A intake|Support to farmers to grow and store OFSP in the form of agricultural extension, community based trainings and supplies, while simultaneously increasing community demand for OFSP through community-based Healthy Living Clubs. The Clubs promote OFSP, provide nutrition education, and conduct community mobilization events and social marketing of OFSP and OFSP-based processed products. Special emphasis is on women and children \< 2y; especially diet diversity and vitamin A intake.
223500739|NCT03423472|BEHAVIORAL|Healthy Baby Toolkit|The toolkit consists of a demarcated bowl, a slotted spoon, and a counseling card. The demarcations on the bowl guide caregivers on age-specific meal volume and frequency. The slotted spoon promotes thicker food consistency - and therefore nutrient density - by cuing caregivers when food drips through the slots. The counseling card relies on images rather than text to reinforce messages of the previous two instruments, promote dietary diversity, and promote hygienic food preparation.
224191153|NCT04967729|DEVICE|Device: Butterfly iQ|The Butterfly iQ is an ultrasound system that enable diagnostic ultrasound imaging and measurement of anatomical structures and fluids of adult and pediatric patients. It is a non-invasive device and does not impose any health hazards.
224191154|NCT00773994|OTHER|Normal Velopharyngeal Mechansim|The amount of radiation exposure that you will receive from this procedure is about 0.3 rem to the head and neck, with minimal exposure of the other body areas.
224191155|NCT02661789|DRUG|Goserelin 3.6 mg implant|Pharmacologically induced biphasic sex-steroid hormone fluctuation
224191156|NCT02661789|DRUG|Placebo|Injection of saline
223500740|NCT03423472|BEHAVIORAL|Standart of care|Government standard of care for nutrition education through the Health Development Army
224191157|NCT04862689|DEVICE|Ringer Perfusion Balloon Catheter|Non-emergent Percutaneous Coronary Intervention (PCI) for treatment of a coronary artery lesion with Ringer Perfusion Balloon Catheter.
224191158|NCT01011959|BIOLOGICAL|REGN88|This study will be conducted in 3 parts, and will include a total of 6 dose cohorts. Part B will not begin until the safety of Part A has been assessed. Part C will begin when enrollment into Part B is complete.
224191159|NCT01397409|DRUG|AGN-150998|AGN-150998 Intravitreal injection.
224191160|NCT01397409|DRUG|ranibizumab|Ranibizumab 0.5 mg given by intravitreal injection.
224191161|NCT01397409|OTHER|Sham Injection|Stage 3: Sham injection at Weeks 12 and 16.
224191162|NCT00422227|DRUG|Etanercept , Methotrexate|"* Etanercept: 25 mg twice weekly over 16 weeks, SC~* Methotrexate: \> 7.5 mg/week and no more than 25 mg/week, PO"
224309707|NCT06990672|OTHER|Experimental|Receive the same standard dietary counseling and education handout but also the WeChat applet intervention. A WeChat-based applet will be developed for fluid intake adherence improvement and self-monitoring to prevent urinary calculi, including fluid intake reminders, fluid value recording, urine value and coluor recording, and health education, an interactive platform for communication among post-operative patients with urinary stones. The applet will tailor the daily notification to participants of fluid intake to increase their fluid consumption to more than 2,500 ml. Extra education information regarding the benefits of adherence will be provided to the experimental group only via the applet. Phone calls will be given at each follow-up phase to collect primary and secondary data via the questionnaires.
223591594|NCT01912339|DEVICE|Rezum System|"The Rezūm System uses sterile water vapor (steam) to treat BPH by delivering targeted, controlled doses of stored thermal energy directly to the transition zone of the prostate gland.~A narrow sheath, similar in shape and size to a cystoscope, is inserted transurethrally and positioned within the prostatic urethra between the bladder neck and the verumontanum.~A thin needle is deployed through the urethra into the transition zone, and a very short (8-10 second) treatment of water vapor is delivered directly into the hyperplastic tissue and immediately disperses through the tissue interstices.~Upon contact with the tissue, the vapor condenses, or phase shifts, into its liquid state, releasing the stored thermal energy contained within the vapor. This thermal energy is released directly against the walls of the tissue cells within the treatment zone, gently and immediately denaturing the cell membranes, thereby causing instantaneous cell death."
223591595|NCT01912339|PROCEDURE|Rigid Cystoscopy|Endoscopy of the urinary bladder via the urethra.
223591596|NCT01771796|BEHAVIORAL|Aerobic and muscle resistance training|After having been allocated randomly to one of the two groups, patients of Intervention Group are encouraged to follow a training program (aerobic and endurance muscle training) during 8 weeks.
223591597|NCT04647097|BEHAVIORAL|Standard intervention only|Standard intervention (SI) will be a part of standard care in all participating centers, and will be provided for all acute pancreatitis patients, who are hospitalized and their condition is alcohol induced. A specially trained study nurse will deliver the intervention, since they were found to be the most effective regarding the decrease in alcohol consumption and smoking. The cost- effectiveness of the intervention and the feasibility were also taken into account. The Assist-linked brief intervention according to the World Health Organization (WHO) will serve as the base for the intervention, with an avarage of 30 minutes, based on a review containing 69 randomized controlled trials, which concluded that longer intervention do not have additional benefit. The patients will be also educated about the disease course of acute pancreatitis during the standard intervention.
223591598|NCT04647097|BEHAVIORAL|Standard intervention plus repeated intervention|Standard intervention (SI) will be performed as described above. The repeated intervention will be delivered by the former mentioned same nurse and will be structured similarly to the standard intervention. Every visit and intervention will be individually altered according to the motivation of the patient, but they will follow the same structure. The sessions can be divided into three main parts: first, highlighting the harmful effects of smoking and alcohol on the pancreatic functions. Secondly, a discussion about the motivation of the patient will happen. The last portion of the session will focus on the responsibility of the individual to reach the desired goal will be highlighted. To enhance the efficacy of our intervention we wish to provide feed-back for the patient based on laboratory testing: the mean corpuscular volume (MCV) and gamma glutamyl-transferase (GGT) values will be measured right before the interview. The study nurse will not take part in patient care.
223591599|NCT03666689|PROCEDURE|surgical technique|surgical reconstruction
223591600|NCT01811134|DEVICE|PIPELINE flow diverter stent|endovascular procedure using the medical device PIPELINE
223591601|NCT01811134|DEVICE|Coils, with or without expendable stent|endovascular embolization procedure using microspires, with the possibility of using a balloon temporary and / or implantation of a stent complementary intracranial before implementation of microspires
223591602|NCT01623375|DRUG|insulin degludec|A single dose of 0.4 U/kg body weight will be administered subcutaneously (s.c., under the skin).
223591603|NCT01623375|DRUG|insulin degludec|A single dose of 0.04 U/kg body weight will be administered intravenously (i.v., into the vein).
223591604|NCT00001954|DRUG|Etanercept|
224191163|NCT00422227|DRUG|Methotrexate; sulfasalazine; hydroxychloroquine;leflunomide|"* Methotrexate: at least 7.5 mg/wk and not more than 25 mg/wk.;PO~* Sulfasalazine: Start treatment w/500 mg daily for 1 wk, thereafter increase dose by 1 tab each wk to a max of 3 g/day;PO~* Hydroxychloroquine:400 mg daily in divided dose, may be reduced to 200 mg. Max: 6.5 mg/kg/day~* Leflunomide: Initially, loading dose 100 mg daily for 3 days. Maintenance: 20 mg daily"
224191164|NCT01207427|DRUG|Placebo|
224191165|NCT01207427|DRUG|ADL5945 0.1 mg|
224191166|NCT01207427|DRUG|ADL5945 0.25 mg|
224191167|NCT03081494|DRUG|spartalizumab (PDR001)|100 mg lyophilisate in vial received 400 mg every 4 weeks
224191168|NCT03081494|DRUG|regorafenib|120 mg once daily first 21 days of each 28-day cycle (=4 weeks)
224191169|NCT05359094|DIETARY_SUPPLEMENT|Placebo|Placebo (Microcrystalline α-cellulose) supplement with a Plant-Dominant Low-Protein Diet
224191170|NCT05359094|DIETARY_SUPPLEMENT|Probiotics|Probiotics(Pediococcus acidilactici GKA4) supplement with a Plant-Dominant Low-Protein Diet
224309708|NCT06990607|PROCEDURE|Pars plana Vitrectomy|Pars plana Vitrectomy using 23 Gauge
224309709|NCT06990607|PROCEDURE|Silicone Oil|Silicone Oil injection after PPV
224191171|NCT04531891|OTHER|Fatigue protocol|During the fatigue protocol, participants will sprint forward 5 m, cut at a 90° angle, sprint forward another 5 m, and backpedal 5 m. This activity will be repeated 4 times before participants will complete a series of hurdle activities. First, they will perform 2-legged jumps over 5 hurdles that are 30 cm high, turn, and repeat the jumps. Second, they will perform side-stepping exercises over the 5 hurdles. Third, they will complete four 5-m lateral shuffles.
224191172|NCT01230073|DEVICE|Home-Monitoring|Home-Monitoring
224191173|NCT01230073|DEVICE|Follow-up by Home-Monitoring|Follow-up by Home-Monitoring
224191174|NCT02609529|OTHER|Medical Food|Serum-derived bovine immunoglobulin protein isolate will be supplied by EnteraHealth. The product is manufactured in accordance with Good Manufacturing Practice (GMP) and U.S. Food and Drug Administration (FDA) guidelines for medical food ingredients (21 CFR Part 110). Serum-derived bovine immunoglobulin protein isolate (SBI) is generally recognized as safe (GRAS). The FDA has reviewed the safety dossier for SBI as a medical food product.
224191175|NCT02609529|OTHER|Placebo|
224191176|NCT02473029|RADIATION|Vascular tomodensitometry|
224191177|NCT02473029|OTHER|Magnetic resonance angiography|
224191178|NCT02473029|OTHER|Vascular ultrasonography|
224191179|NCT02473029|OTHER|Retinal angiography|
224191180|NCT02473029|OTHER|Retinal optical coherence tomography|
224191181|NCT03473821|BEHAVIORAL|MOTIFS|o MOTor Imagery to Facilitate Sensorimotor re-learning (MOTIFS) is an individualized and physical activity-specific integrated model that includes aspects of both neuromuscular training, as used in rehabilitation practices, and Dynamic Motor Imagery (DMI). DMI is a form of mental training in which the participant images him-/herself performing a task from a first-person perspective in order to maximize functional equivalence to the task in question. This includes dynamic, physical movement, as well as mental imaging. The intervention provides a framework for designing individualized, physical activity-specific rehabilitation exercises for knee-injured people.
224191182|NCT02986321|DRUG|CHF6001|Dose response: Test one of 4 different doses of CHF6001
224191183|NCT02986321|DRUG|Budesonide|active control
224191184|NCT02986321|DRUG|Placebo|placebo control
224191185|NCT00430703|BEHAVIORAL|body weight support treadmill training|Gait training: Gait robot (Lokomat®, Hocoma, Switzerland) is adjusted to the patient/healthy volunteer individually with chest strap, pelvic straps, harness, leg cuffs and foot lifters. Weight is adjusted individually, so there is a minimum weight support (i.e. when one foot is standing on the treadmill the other foot lifts free from the treadmill thereby simulating normal gait). Gait speed is 1,7-2,3 km/hour (speed can be changed and adjusted that the normal step length is achieved).The duration of the training session is 20 minutes.Blood pressure and pulse are monitored.
223500741|NCT05791084|OTHER|mobile application with breathing instructions and a sensor to attach around the chest. To be able to train at home before radiotherapy with DIBH starts.|The DIBH-App consists of 1) a mobile application that patients download to their own smart mobile phone, and 2) associated stretch-sensors that are attached around the chest and connected to the mobile phone via Bluetooth. Visually, the graphics is similar to the software used for DIBH in the RT department. Coaching takes place through instructional videos, text, and audio recordings (Image 2). The following information will be recorded and stored: date and time of practice, outcome of each session (including sensor data and calibration parameters), and user behavior within the application (such as screen visits, FAQ sections viewed, and key button presses).
224191186|NCT01632007|DRUG|SYR-472|
224191187|NCT01632007|DRUG|Alogliptin 25 mg|
224191188|NCT01632007|DRUG|Placebo|
224191189|NCT04095611|PROCEDURE|SPAIRE|To perform the hip surgery called hemiarthroplasty surgeons need to cut through some muscles to expose the hip joint and perform the partial replacement. Currently this often performed using a technique which involves cutting muscles and tendons from the side of the hip and this is called the lateral approach. SPAIRE is a modified technique that accesses the surgical area through a different route.
224191190|NCT04095611|PROCEDURE|LATERAL|surgery in adults with a displaced intracapsular hip fracture requiring hemiarthroplasty, the standard lateral approach.
224191191|NCT04301271|DRUG|Simvastatin 40mg|12 weeks 40 mg Simvastatin add-on
224191192|NCT04301271|DRUG|Placebo oral tablet|12 weeks Placebo add-on
224191193|NCT02514109|OTHER|Neurological assessment and Blood sample|Neurological assessment (physical examination, electroneuromyography , International Prognostic Score (ISS), Overall Disability Scale (ODS)) and 2 blood collection tubes for antibody screening
224191194|NCT03783884|DEVICE|Lungpacer Diaphragm Pacing Therapy|Transvenous phrenic nerve stimulation to induce diaphragm contraction.
224191195|NCT03187314|DRUG|Radiation|RT to 60 Gy, 5 x per week，for 6 weeks. Radiation begun the day after the first dose of SHR-1210
224191196|NCT03187314|DRUG|SHR-1210|SHR-1210 (200mg fixed dose every 2 weeks for 5 cycles) will be administered as an intravenous infusion over 60 minutes.
224191197|NCT04974853|COMBINATION_PRODUCT|Cardio-complement|Ayurvedic combination of Terminalia Arjuna, Withania Sominifera, Garcinia Cambogia and piperine (as bioenhancer) in pre-specified dosage.
224191198|NCT02828098|DRUG|Part 1: BO-112|Cohorts of three patients per dose level will be treated consecutively in the absence of Dose Limiting Toxicity (DLT).
224191199|NCT02828098|DRUG|Part 2: BO-112|"BO-112 at a fixed dose will be administered as an intratumoral injection for up to 5 doses over 12 weeks and continue as long as there is benefit.~Nivolumab will be administered as an intravenous infusion every 2 weeks at a dose of 3 mg/kg for up to a total period of one year.~OR Pembrolizumab will be administered as an intravenous infusion every 3 weeks at either 200 mg or at 2 mg/kg depending on the indication, for up to a total period of one year."
224191200|NCT01652651|BEHAVIORAL|I Can Succeed ICS|ICS is a manual-based psychological intervention aimed to address both emotional and academic-executive functions aspects of LD.It consists of acute phase (13 once a week sessions) and follow-up phase (6 sessions over 18 months). ICS focuses on developing intrapersonal skills (e.g. self awareness, goal setting, organizational skills), interpersonal skills (e.g. communication, problem solving)and school/community skills (i.e. strengthening the family-school relationship) (Kopelman-Rubin et al., 2011).
224191201|NCT01475539|BIOLOGICAL|Injectable inactivated types 1, 2 and 3 poliovirus + Live oral Polio|0.5 mL, Intramuscular + 1g dragee candy oral dose
224191202|NCT01475539|BIOLOGICAL|Injectable inactivated types 1, 2 and 3 poliovirus + Live oral Polio|0.5 mL, Intramuscular + 1g dragee candy oral dose
224191203|NCT01475539|BIOLOGICAL|Live oral poliovirus type 1, 2 and 3|1g dragee candy, oral
224191204|NCT00283673|BEHAVIORAL|Exercise|
224191205|NCT00781001|DRUG|Cannabis|400mg placebo or active cannabis administered via the Volcano vaporizer 1x per study visit
224191206|NCT04185766|DIETARY_SUPPLEMENT|Administration of a placebo solution (0.5 ml / kg)|43 newborns at risk of hypoglycaemia to which a placebo solution will be administered (0.5 ml / kg)
224191207|NCT04185766|DIETARY_SUPPLEMENT|Administration of a placebo solution (1 ml / kg)|43 newborns at risk of hypoglycaemia to which a placebo solution will be administered (1 ml / kg)
224191208|NCT04185766|DIETARY_SUPPLEMENT|Administration of 40% glucose in gel (0.5 ml / Kg)|43 newborns at risk of hypoglycaemia to which a solution of dextrose 40% in gel will be administered (0.5 ml / Kg)
224191209|NCT04185766|DIETARY_SUPPLEMENT|Administration of 40% glucose in gel 1 ml / Kg)|43 newborns at risk of hypoglycaemia to which a solution of dextrose 40% in gel will be administered (1 ml / Kg).
224191210|NCT04908696|PROCEDURE|routines|"For early stage laryngeal carcinoma and hypohparyngeal carcinoma (T1 and T2), transoral laser microsurgery (CO2 laser resection), open partial laryngectomy (vertical partial laryngectomy, cricohyoidoepiglottopexy, cricohyoidopexy, horizontal partial laryngectomy), partial hypopharyngectomy, radiotherapy, and transoral robotic surgery were performed for patients with proper indications (NCCN 2020).~For advanced stage laryngeal carcinoma and hypohparyngeal carcinoma (T3 and T4), surgical treatment ± postoperative adjuvant therapy, concurrent chemoradiotherapy, neoadjuvant therapy + radiotherapy/chemoradiotherapy, or neoadjuvant therapy + surgery + radiotherapy or chemoradiotherapy were performed for patients with proper indications (NCCN 2020)."
224191211|NCT04666935|OTHER|The Oslo Sports Trauma Research Center (OSTRC) Injury Prevention Program|Sport Injury Prevention Program.
224191212|NCT04666935|OTHER|Usual warm up|Usual warm up is defined as any basic exercises performed before a performance or practice to prepare the muscles for vigorous actions.
224191213|NCT03229902|BEHAVIORAL|mantra meditation|see study description
224191214|NCT00106717|PROCEDURE|Narrative medicine|
224191215|NCT03341559|DEVICE|Spatial Frequency Domain Imaging (SFDI)|Observational study to measure perfusion in lower extremities for prediction of both healing and formation of diabetic foot ulcers using Reflect RS
224191216|NCT01798056|BIOLOGICAL|GSK 1437173A|2 doses administered by intramuscular (IM) injection into the deltoid muscle of the non-dominant arm.
224191217|NCT01798056|DRUG|Placebo|2 doses administered by IM injection into the deltoid muscle of the non-dominant arm.
224191218|NCT01406327|DRUG|Ambrisentan|Ambrisentan
224191219|NCT04148027|OTHER|Treatment recommendation by emergency department physicians|Standard treatment after admission in the emergency department from a team of residents in internal medicine, neurology and general surgery.
224191220|NCT04148027|OTHER|Treatment recommendation by telemedical geriatric co-evaluation|Treatment recommendation from a board-certified geriatrician linked for co-evaluation by means of video transmission
224191221|NCT02563574|BEHAVIORAL|Motivational Interviewing|A type of counseling aimed at reducing consumption of alcohol.
224191222|NCT02563574|OTHER|Questionnaire assessment|Several different types of questionnaires will be fill out by the participants.
224191223|NCT02563574|OTHER|Neurocognitive assessments|Several different types of neurocognitive assessment will be performed.
224191224|NCT02563574|OTHER|Blood specimens|Blood specimens will be used to measure the immunological, virologic, and hepatic status, as well as other biomarkers.
224191225|NCT02265991|PROCEDURE|Fibula Explantation|surgical harvest of an osteomyocutaenous transplant consisting of a part of the fibula and surrounding soft tissues
224191226|NCT03182972|OTHER|Medication reconciliation|Pre-post intervention
223746247|NCT04246333|OTHER|Mode of Delivery of Feeds|Eligible infants will be recruited and enrolled and randomized to either duodenal feeds (DF) or gastric feeds (GF), which will occur just prior to the infants advancing beyond 50mL/kg/day of enteral feeds. All enrolled infants will be fed per our institutional feeding protocol. Once infants advance past a volume of 50mL/kg/day of enteral feeds, at this point infants will be randomized to DF or GF groups.
223746248|NCT06906965|OTHER|Carob beverage|The participants consumed a carob beverage made with 30gr of Imera carob cultivar powder in water
223746249|NCT06906965|OTHER|Sucrose beverage|The participants consumed a sucrose beverage made with 14gr of sugar in alike concentration with sugars in the experimental beverage
224191227|NCT04177901|DEVICE|Near infrared spectroscopy|It is used for detection of tissue oxygenation
224191228|NCT06582680|OTHER|Ambient Heat|Subjects will spend 3-hours in a heat chamber at 41°C and 40% humidity.
224191229|NCT04070157|DRUG|Lofexidine|Lofexidine 0.18 mg tablets. Dosing will begin with 1 tablet administered every 5-6 hours, up to 4 times day. The dose may be titrated but not to exceed 4 tablets 4 times a day.
224191230|NCT04070157|DRUG|Placebo|Matching placebo tablets. Dosing will begin with 1 tablet administered every 5-6 hours, up to 4 times day. The dose may be titrated but not to exceed 4 tablets 4 times a day.
224191231|NCT00213486|DRUG|irinotecan|
224191232|NCT02842736|DEVICE|Cerene(R) Cryotherapy Device|
224191233|NCT00453336|DRUG|Porfimer Sodium|Day 1 of Therapy. An IV access (of 20 gauge or larger) is started and 2 mg/kg of Porfimer Sodium (Photofrin®) is given intravenously. Once completed the patient puts on the light protective gear and is sent home.
224191234|NCT00453336|PROCEDURE|Photodynamic Therapy|Laser Activation. The time of exposure and the power of the laser are computed based on the dosimetry in appendix A using a computed energy dose of 75 to 150 joules, depending on the depth of penetration desired.
224191235|NCT00314275|DEVICE|Coronary Artery Stenting|Drug eluting stent
224191236|NCT00314275|DEVICE|Endeavor|Drug eluting stent
224191237|NCT00856570|DRUG|warfarin|Oral
224191238|NCT00856570|DRUG|YM178|Oral
224191239|NCT01535209|RADIATION|stereotactic body radiotherapy (SBRT)|18Gy in 1 fraction for resection cavity \<2cm in maximum diameter, 15Gy in 1 fraction for resection cavity 2.1-3cm in maximum diameter, 15Gy in 1 fraction or 25 Gy in 5 fractions over 5 days for resection cavity 3.1-4cm in maximum diameter, 25 Gy in 5 fractions over 5 days for resection cavity \>4cm in maximum diameter
224191240|NCT01535209|RADIATION|Whole-Brain Radiotherapy (WBRT)|10 x 3 Gy to whole brain
224191241|NCT05245461|OTHER|Assessments|Muscle Strength, Proprioception, Kinesiophobia
224191242|NCT02719093|DRUG|recombinant FSH|Subcutaneous injection
224191243|NCT00093327|PROCEDURE|Acupuncture|
224191244|NCT05069376|DEVICE|Ureteral Stent of 5-16 or 5-18|Boston Scientific Polaris™ Ultra Ureteral Stent
224191245|NCT05069376|DEVICE|Ureteral Stent of 5-22 or 5-24|Boston Scientific Polaris™ Ultra Ureteral Stent
224191246|NCT02857062|DEVICE|E45 Eczema Repair Emollient|E45 Eczema Repair Emollient
224191247|NCT03651440|OTHER|PNF|PNF
224191248|NCT03651440|OTHER|lumbar stabilization training|lumbar stabilization training
224191249|NCT03651440|OTHER|Physical Therapy|Physical Therapy
224191250|NCT03651440|OTHER|Control|Control group
224191251|NCT01111968|BIOLOGICAL|pandemic vaccine 1|7,5µg of A/H1N1 with MPLA adjuvant - IB, suspension (5µg) + Al(OH)3
224191252|NCT01111968|BIOLOGICAL|pandemic vaccine 2|3,75µg of A/H1N1 with MPLA adjuvant - IB, suspension (5µg) + Al(OH)3
224191253|NCT01111968|BIOLOGICAL|pandemic vaccine 5|7,5µg of A/H1N1 with MPLA adjuvant - IB, emultion (5µg) + Al(OH)3 + Squalene 2% emulsion
224191254|NCT01111968|BIOLOGICAL|pandemic vaccine 6|3,75µg of A/H1N1 with MPLA adjuvant - IB, emultion (5µg) + Al(OH)3 + Squalene 2% emultion
224191255|NCT01111968|BIOLOGICAL|pandemic vaccine 9|7,5 µg of A/H1N1 with Al(OH)3 + Squalene 2% emultion
224191256|NCT01111968|BIOLOGICAL|pandemic vaccine 10|3,75 µg of A/H1N1 with Al(OH)3 + Squalene 2% emultion
224191257|NCT01111968|BIOLOGICAL|pandmeic vaccine 11|7,5µg of A/H1N1 with Al(OH)3
224191258|NCT01111968|BIOLOGICAL|pandmeic vaccine 12|3,75µg of A/H1N1 with Al(OH)3
224191259|NCT01111968|BIOLOGICAL|pandmic vaccine 13|15µg of A/H1N1 with no adjuvant
224191260|NCT01111968|BIOLOGICAL|placebo group 14|All elements of the vaccine but antigen and adjuvant
224191261|NCT03323034|DRUG|Irinotecan|Given IV
224191262|NCT03323034|DRUG|Pevonedistat|Given IV
224191263|NCT03323034|DRUG|Temozolomide|Given PO
224191264|NCT03628534|DEVICE|Saline Enhanced Radiofrequency (SERF) ablation|Ablation of ventricular tachycardia with a saline-enhanced radiofrequency ablation catheter
224191265|NCT00388713|PROCEDURE|carotid intima-media thickening ultrasound|
224191266|NCT02646566|DRUG|APD421|
224191267|NCT02646566|DRUG|Placebo|
223512044|NCT06010108|BEHAVIORAL|Project SHADE|"Community-based approach- health education of girls and women. The use of a uniquely designed bag Eno Iban to package and distribute the self-collection tool, vaccination of the adolescent girls. Screening and HPV will be provided at designated areas within the community for women and girls. A simple app (d-SHADE) will be used to collect data of the girls and women by the health professionals and volunteers, as well as send the reminders for next screening dates and test results"
223512045|NCT06010108|BEHAVIORAL|Operation Reach Her (ORH) program|"Faith based approach- Awareness programs would be conducted in the chosen religious centres to educate women and girls about their health, cervical cancer, its prevention, and the benefits of screening and HPV vaccination. This would be achieved by organizing a  Health Day  for free health check-ups for all members of the congregation. The self-sampling kit would be distributed to women aged 30-65 in mobile tents stationed in churches in Akoka and HPV vaccinations would be administered to girls aged 9-14 in mobile tents stationed at churches and mosques in Akoka, Lagos"
224191268|NCT02825979|PROCEDURE|Cryoballoon-based PVI|Patients randomized to first-line cryoballoon (CB) ablation will have the pulmonary vein isolation procedure performed according to standard clinical practice using the Arctic Front Cryoballoon ablation catheter. No anti-arrhythmic drugs will be prescribed in this arm.
224191269|NCT02825979|DRUG|Anti-Arrhythmic Drug Therapy|Antiarrhythmic drug therapy (Class I - flecainide, propafenone; Class III - sotalol, dronedarone) will prescribed and monitored based on local clinical practice, and according to guideline-suggested drug management for symptomatic patients with paroxysmal AF.
224191270|NCT03267199|DRUG|Thrombolytic|Thrombolytic therapy
224191271|NCT03267199|PROCEDURE|Primary PCI|Primary percutaneous coronary intervention
224191272|NCT03267199|DIAGNOSTIC_TEST|Complete blood count|Blood sample for complete blood count
224191273|NCT03267199|DIAGNOSTIC_TEST|Platelet function test|Blood sample for platelet function test
224191274|NCT03267199|DIAGNOSTIC_TEST|ECG|Electrocardiogram
224191275|NCT05924009|PROCEDURE|Transcranial Magnetic Stimulation, TMS|"The best location for evoking an electromyographic (EMG) response of the first dorsal interosseus (FDI) muscle in the dominant hand and the minimum stimulation intensity required to evoke a certain EMG response amplitude (Motor Threshold, MT) are used as reference to determine the best location and stimulation parameters to evoke GEPs.~After identification of the GEP hot-spot, a water load test is administered to determine whether satiety shapes GEP responses.~In subsequent study visits, the water load test is preceded by application of neuromodulatory repetitive TMS (rTMS), targeted to the GEP hotspot."
223512046|NCT06010108|BEHAVIORAL|Project Care|Community pharmacy intervention-Trained community volunteers will be involved in creating awareness of HPV prevention services and cervical cancer. There will be distribution of cervical cancer self-sampling kits to community pharmacies which will serve as service points for screening (self-collection point) and vaccination point for girls in the community,
223512047|NCT01923974|DRUG|Melatonin 10 mg|
223512048|NCT01923974|DRUG|Melatonin 100 mg|
223512049|NCT01923974|DRUG|Placebo|
223512050|NCT02800746|DRUG|Ferric carboxymaltose|Ferric carboxymaltose 15 mg/kg mg is intravenously administered on 7-10 day before surgery.
223512051|NCT02800746|DRUG|Placebo|normal saline 100 ml is intravenously administered on 7-10 day before surgery
223512052|NCT02448173|BIOLOGICAL|OncoVAX and Surgery|OncoVAX is comprised of sterile, live but non-dividing tumor cells obtained following standard-of-care surgical tumor resection for Stage II colon cancer
223512053|NCT02448173|PROCEDURE|Surgery|Surgical resection of Stage II colon cancer
224191276|NCT02191033|BEHAVIORAL|Smoking counseling|
224191277|NCT02191033|BEHAVIORAL|Text messaging|
224191278|NCT02191033|DRUG|Nicotine patch|
224191279|NCT05668377|DEVICE|PulseAI ECG Platform|Cloud-based AI-enabled ECG analysis platform
224191280|NCT00190476|DRUG|Weekly docetaxel alone|
224191281|NCT00190476|DRUG|Weekly docetaxel + cisplatin combination|
224191282|NCT06116357|DEVICE|External Ultrasonic Micro-bubble|The enrollmented hypertensive patients should aceepted CB modulation therapy by external ultrasonic micro-bubble
223746250|NCT03089801|OTHER|Tablet-Enabled Video Telehealth|Veterans referred for tablet-enabled video telehealth will receive a VA-issued tablet that can be used to communicate via video with health care providers (e.g., for chronic disease management, mental health treatment, palliative care).
224191283|NCT06538376|DIAGNOSTIC_TEST|Portable Dynamic Digital Radiography (DDR)|"(DDR imaging has already been described in the arm/group description). Each patient in the study will receive at least one set of DDR images, which consists of one 7-second scan in which the patient breaths normally, and a second 7-second scan in which the patient holds their breath (or for ventilated patients, an inspiratory pause is placed by the care team).~If the patient's conditions warrant it, up to two sets of follow-up scans may be acquired. For instance, in a patient with diaphragmatic dysfunction, imaging may be completed pre- and post- diaphragmatic plication."
224191284|NCT02815540|PROCEDURE|12-Lead ECG|Subjects will be monitored while on cannabidiol with a 12-Lead ECG and/or Holter monitoring
224191285|NCT02815540|DRUG|Cannabidiol|Subjects who are planning to take state dispensed medical cannabidiol, or are already taking state dispensed medical cannabidiol.
224191286|NCT00285259|BIOLOGICAL|VCL-CB01|5 mg/mL, Intramuscular (IM.) 3 vaccinations for donors; 1 vaccination pretransplant, up to 3 vaccinations after transplant for recipients
224191287|NCT00285259|OTHER|Phosphate-buffered Saline (PBS)|1 mL, IM. 3 vaccinations for donors; 1 vaccination pretransplant, up to 3 vaccinations after transplant for recipients
224191288|NCT04590482|DRUG|letrozole|Letrozole 2.5 mg each 12 hours for 2 days followed by vaginal misoprostol 800 mcg for induction of abortion
224191289|NCT04590482|DRUG|placebo|placebo given twice daily for 2 days followed by 800mcg misoprostol vaginally to induce abortion
224191290|NCT05635682|OTHER|Observational and anthropometric assesments|Plantar sensation, foot reaction time, head and trunk proprioceptions, posture, balance and gait assesments
224191291|NCT03317691|DIAGNOSTIC_TEST|electrocardiogram diagnosed by artificial intelligence|According to coronary angiogram results, the accuracy of STEMI patients' electrocardiogram diagnosis by artificial intelligence was evaluated.
224191292|NCT04092491|OTHER|blood sample|"1 blood sample during a consultation carried out as part of a medical follow-up:~* 2 PAXgene RNA tubes of 2 ml each~* 1 dry tube for creatinine and IgA assay~* 1 tube of NFs (5ml)"
224191293|NCT04268394|DRUG|CC-99677|CC-99677
224191294|NCT04268394|DRUG|Methotrexate|Methotrexate
223500742|NCT03779607|OTHER|Celtra Press|"new class of zirconia-reinforced lithium silicate material available to labs for pressing. This unique material provides top aesthetics and is virtually impossible to tell apart from a natural tooth.~Celtra Press is a multiphase ceramic consisting of a glass matrix and lithium disilicate crystals having a crystal length of about 1.5 µm plus nano-scale lithium phosphate . In addition to Li2O and SiO2, Celtra Press contains about 10% zirconia (ZrO2), which is dissolved completely in the glass phase rather than in crystalline form. Celtra Press is characterized by a high strength of about 500 MPa and excellent flow properties during pressing."
223500743|NCT05575427|DRUG|Minocycline|The patients will receive minocycline oral between 7-28 days
223500744|NCT05575427|DRUG|Levofloxacin or Cotrimoxazole|The patients will receive levofloxacin or cotrimoxazole oral between 7-28 days
223500745|NCT05575427|DRUG|Placebo|Capsule without active compound
223500746|NCT02714959|DRUG|Proleukin|
223500747|NCT01168479|RADIATION|FLAME boost|In the experimental arm patients receive in addition to the current gold standard of 77 Gy to the prostate an integrated boost to the macroscopically visible tumour to reach a total dose of 95 Gy in 35 fractions of 2.7 Gy, 5 times per week.
223500748|NCT01168479|RADIATION|standard arm|The standard arm receives the current gold standard, namely 77Gy to the prostate in 35 fractions of 2.2 Gy, 5 times per week.
223500749|NCT01069640|BIOLOGICAL|HLA-A*0201 or HLA-A*0206-restricted URLC10 peptides|Escalating doses of every peptide will be administered by subcutaneous injection on days 1, 8, 15 and 22 of each treatment cycle. Planned doses of peptides are 1.0mg, 2.0mg and 3.0mg.
223500750|NCT01875237|DRUG|Fludarabine|40 mg/m2 by vein on Days -6 to -3.
223500751|NCT01875237|DRUG|Melphalan|140 mg/m2 by vein on Day -2.
224191295|NCT04268394|DRUG|Sulfasalazine|Sulfasalazine
224191296|NCT04268394|DRUG|Itraconazole|Itraconazole
224191297|NCT04268394|DRUG|Rifampin|Rifampin
224191298|NCT04268394|DRUG|Midazolam|Midazolam
224191299|NCT04268394|DRUG|Digoxin|Digoxin
224191300|NCT04268394|DRUG|Metformin|Metformin
224191301|NCT04268394|DRUG|Rosuvastatin|Rosuvastatin
224191302|NCT05880069|OTHER|Pathogen resistant phenotype|Drug resistant phenotype of the target pathogen under study
224191303|NCT02222246|DRUG|Hydromorphone (Standardized, weight-based dosing)|Standardized analgesic management using a SCD specific standard protocol based on NHBLI guidelines (initial opioid dose weight-based).
224191304|NCT02222246|DRUG|Morphine Sulfate (Standardized, weight-based dosing)|Standardized analgesic management using a SCD specific standard protocol based on NHBLI guidelines (initial opioid dose weight-based).
224191305|NCT02222246|DRUG|Hydromorphone (Patient Specific dosing)|Patient specific analgesic management, with specific opioid dosage and frequency based on a protocol developed by a patient's healthcare team.
223500752|NCT01875237|DRUG|Alemtuzumab|50 mg by vein on Day -1.
223500753|NCT01875237|PROCEDURE|Stem Cell infusion|Stem cell infusion on Day 0. Goal is to administer more than 3 x 10\^6 CD34+ cells/kg of peripheral blood progenitor cells (PBPC).
223500754|NCT01875237|DRUG|Tacrolimus|Starting dose of 0.015 mg/kg (ideal body weight) as a 24 hour continuous infusion daily adjusted to achieve a therapeutic level of 5-15 ng/ml (target is 10 ng/ml) between Day +1 and Day +45. Tacrolimus is changed to oral dosing when tolerated. Tacrolimus tapering should start on approximately Day +35 with the intention for the patient to be completely off the drug by approximately Day +45.
223500755|NCT01875237|DRUG|Mini Methotrexate|5 mg/m2 by vein on Days +1, +3, +6.
224191306|NCT02222246|DRUG|Morphine Sulfate (Patient Specific dosing)|Patient specific analgesic management, with specific opioid dosage and frequency based on a protocol developed by a patient's healthcare team.
224191307|NCT02001662|PROCEDURE|Intervention group, block no. 1 - Ropivacain|Intervention group: 1. block ropivacaine - 2. block saline
224191308|NCT02001662|PROCEDURE|Control group: 1. block - saline|Control group: 1. block saline - 2. block ropivacaine
224309710|NCT06988878|OTHER|Evidence-based practice competence training based on the flipped learning model|This training was carried out for six weeks (11 September 2024 - 16 October 2024). Once a week, participants first watched the videos uploaded by the researcher to the Edpuzzle application and participated in the offline training. Participants who had watched the videos then attended the face-to-face/traditional training. The nurse information form, the evidence-based practice knowledge test and the evidence-based practice evaluation competence questionnaire were administered to the participants before the training (4 September 2024), at the end of the training (16 October 2024) and two months after the training (18 December 2024).
224309711|NCT06989554|DEVICE|mechanical feedback insole|A 3-mm rubber insole containing four 15-mm spring-steel snap buttons aligned along the heel-mid-foot axis. Each insole is statically calibrated on a hydraulic press so that the buttons collapse at 20 % ± 1 % of the individual's body weight, producing an unmistakable plantar cue when the load limit is exceeded. The device is purely mechanical, requires no batteries, and is fitted on postoperative day 1. Participants wear the insole during every supervised walking session until discharge (≈ 14 days).
223500756|NCT01875237|DRUG|G-CSF|5 mcg/kg/day subcutaneously beginning on Day +7, and continuing until the absolute neutrophil count (ANC) is \> 500 x 10/L for 3 consecutive days.
224191309|NCT04888780|OTHER|The web-based Watson's Human Care Theory oriented training|Video calls were held every 15 days via the skype program with complete adherence to the schedule. In these interviews, the clinical picture of diabetes and the psychosocial status of adolescents were discussed. A total of 14 interviews with 15-day intervals were made with each adolescent. All video interviews were carried out by the first researcher and they were all recorded.
224191310|NCT01659762|BIOLOGICAL|autologous mesenchymal stromal cell|
224191311|NCT05635929|COMBINATION_PRODUCT|Composition comprising olive oil, xylitol and betaine|Topical composition in the form of a gel.
224191312|NCT02660489|DRUG|OC459|
224191313|NCT02660489|DRUG|Placebo|
224191314|NCT02660489|OTHER|Rhinovirus|Inoculation with rhinovirus serotype 16
224191315|NCT01679691|OTHER|epidural anesthesia|the group in whom all patients will be subjected to epidural anesthesia intra- and post-operative
224191316|NCT02064231|DEVICE|Coloplast Test A|Coloplast Test A is a new ostomy appliance developed by Coloplast A/S
224191317|NCT02064231|DEVICE|Coloplast Test B|Coloplast Test B is a newly developed ostomy appliance developed by Coloplast A/S
224191318|NCT02064231|DEVICE|Own product|Own product is tested to get baseline results. Own product can be any 2-piece product that is commercially available. The manufactures can be Coloplast, Hollister, Convatec, Dansac, B. Braun and others.
224191319|NCT02064231|DEVICE|Coloplast Test C|Coloplast Test C is a new ostomy appliance developed by Coloplast A/S
224191320|NCT02064231|DEVICE|Coloplast Test D|Coloplast Test D is a new ostomy appliance developed by Coloplast A/S
224191321|NCT02043626|OTHER|DISTRICT WELLNESS COMMITTEE|Three Targeted Schools (N+PA) will expand the District's school based wellness initiative, PAW-Physical Activity and Wellness. With District support, PAW schools develop School Wellness Teams (SWTs) to identify school health priorities, implement and sustain health initiatives through school campaigns, promote healthy behavior, and support wellness policies. Results from a 3-year evaluation suggest significant and sustained positive impact on school health culture, student behavior, time-on-task, and increased physical activity among students.
224191322|NCT02043626|OTHER|NUTRITIONAL QUALITY OF FOODS AND BEVERAGES ON CAMPUS|Policy changes will focus on 6 target schools. District will expand nutrition education by integrating other opportunities to learn and practice healthy behaviors across disciplines. Farm-to-School programs will include school visits by farmers to teach students about agriculture, healthy foods and nutrition, coinciding with Farmer's Market Menu Days. Schools will receive four 45 minute nutrition workshops per year. Community educators will offer culturally appropriate, interactive nutrition workshops and cooking demonstrations. Cafeterias will receive youth friendly nutritional messaging, regular promotion of new menu foods, and a variety of monthly nutrition-focused activities. The goals are to: increase number of students who try new menu items regularly, increase acceptance of healthy foods, and improve nutrition literacy. Policy states schools will limit celebrations that involve food to no more than 1 per class/month: 6 schools will pilot alternatives to food for celebrations.
224191323|NCT02043626|OTHER|HEALTH PROMOTION AND MARKETING|SWP addresses health promotion and marketing by limiting product marketing in schools, expanding nutrition education and broadening health communication with parents. In 3 targeted schools, we expand to include Staff Wellness Promotion. Adults in schools are trusted and influential role models for students; by increasing their positive health behaviors, students may be influenced to adopt similar behaviors. The District will work with the City's Employee Wellness Program to increase school staff participation.
224191324|NCT02043626|OTHER|OPPORTUNITIES FOR PHYSICAL ACTIVITY|District-wide policies include mandates for daily physical activity and PE and development of policies that prohibit withholding PE for punitive reasons. To further increase physical activity, the School Wellness Policy specifies expanding programs/activities that meet need, interest, and abilities of students. Exer-gaming consoles will be provided to 6 schools and will be integrated into 5th-8th grade PE classes and after-school programs. New and innovate gym equipment will be purchased for the 6 target schools for use in gym class and after school programming. Various pedometer and interactive programs encouraging physical activity in and outside of school are planned for the 6th grade.
224191325|NCT01310725|PROCEDURE|Coronary artery bypass grafting|Bypass of stenoses in coronary arteries using different types os vessels as conduit.
224191326|NCT00322530|PROCEDURE|Renal replacement therapy|ICU patients with acute renal failure were prospectively randomized to either CVVHD or SLED
224191327|NCT03436940|OTHER|On Demand Discharge Planning (DDP)|Patients with an intermediate score, according to the simplified Blaylock Risk Assessment Screening Score, are addressed to the NOCC team (hospital Continuity of care team) only in case of a specific request by the unit of hospitalization.
223500757|NCT01875237|PROCEDURE|Donor Lymphocyte Infusion (DLI)|iCasp9 (BPZ-1001)-Modified T-cells) of 3 X 10\^6/kg in 100 ml infused over approximately a one hour period between Day + 56 to Day +64.
223512054|NCT04969107|PROCEDURE|taTME|Resection of rectal cancer with preparation of the mesorectal plane along the TME-plane in a rendezvous procedure of an abdominal and a transanal approach.
223512055|NCT04969107|PROCEDURE|abdTME|Resection of rectal cancer with preparation of the mesorectal plane along the TME-plane in an abdominal Approach.
223500758|NCT01875237|DRUG|AP1903|0.4 mg/kg as a 2 hour infusion for patients that present with a clinical diagnosis of grade I GvHD. For patients with a clinical diagnosis of grade \> 2 GvHD, a single dose of AP1903 0.4 mg/kg as a 2 hour infusion will be administered. Patients who fail to achieve a complete response within 72 hours of an initial dose of AP1903, or within 48 hours of a second dose of AP1903, will be maintained on this dose for no less than 7 days. Patients who experience a partial response within 72 hours may receive a second dose of AP1903. Patients whose GvHD is progressing after 7 days, have no response by 14 days, or are not in a complete response at day 28 can receive secondary therapy.
223500759|NCT01875237|DRUG|Methylprednisolone|1.6 mg/kg per day by vein divided in 2 to 3 daily doses. Patients whose GvHD resolves as defined by a complete response within 72 hours, would have steroids stopped immediately. Patients who fail to achieve a complete response within 72 hours of an initial dose of AP1903, or within 48 hours of a second dose of AP1903, will be maintained on this dose for no less than 7 days. Steroids can then be tapered as tolerated to no less than 0.6 mg/kg per day at day 28.
223500760|NCT01875237|BEHAVIORAL|Questionnaire|Completion of a quality of life questionnaire that will take 10-15 minutes between Days + 28 and + 56, about twice a week until about 2 months after the T-cell infusion, and then 6 and 12 months after the stem cell transplant.
223500761|NCT01374789|DRUG|GemCis + Panitumumab|Gemcitabine: 1250 mg/m², day 1 and 8, i.v., q3 Cisplatin: 70 mg/m², day 2, i.v., q3 Panitumumab 9 mg/kg/body weight, i.v., day 1,q3
223500762|NCT01374789|DRUG|GemCis|Gemcitabine: 1250 mg/m², day 1 and 8, i.v., q3 Cisplatin: 70 mg/m², day 2, i.v., q3
223500763|NCT00979511|OTHER|milk and exercise|"* milk fortified with 1000mg calcium or low-calcium milk~* weight-bearing exercise or passive exercise"
223500764|NCT03558672|DEVICE|Flexitouch system with Head and Neck Garments|Flexitouch system or Flexitouch Plus Head and Neck Treatment, as prescribed
223500765|NCT03792997|COMBINATION_PRODUCT|combination therapy for high peripheral NK cells|lipid emulsion \& prednisolone \& LMWH
223500766|NCT00743262|DEVICE|Provox voice prosthesis|The current voice prosthesis (Provox ActiValve)of the patients will be removed and a new prosthesis (Provox Vega) will be inserted
223500767|NCT03517020|DRUG|Torrent's Nebivolol Tablets|
223500768|NCT03517020|DRUG|Forest Pharmaceuticals Inc's Bystolic Tablets|
223500769|NCT02276833|OTHER|intra-articular space injection of SVF|intra-articular injection of autologous adipose SVF derived in the same surgical procedure
223500770|NCT05474677|PROCEDURE|closure of the abdominal fascia|The abdomen will be closed in intervention group with continuous PDS 2\\0 sutures and size zero in control group.
223500771|NCT02551575|DRUG|Treatment of MTX and HCQ|"Methotrexate: 10-15mg per week according to patient's weight, oral, for 24 weeks.~Hydroxychloroquine: 200mg, 2 times a day, oral, for 24 weeks. Qingre Huoxue granule placebo: 10g, 2 times a day, oral, for 24 weeks. Qingre Huoxue external preparation placebo: 20g, 1 times a day, external, for 4 weeks, then 10g, 1 times a day, external, for 8 weeks."
223500772|NCT02551575|DRUG|Treatment of TCM|"Qingre Huoxue granule: 10g, 2 times a day, oral, for 24 weeks. Qingre Huoxue external preparation: 20g, 1 times a day, external, for 4 weeks, then 10g, 1 times a day, external, for 8 weeks.~Methotrexate placebo: 10-15mg per week according to patient's weight, oral, for 24 weeks.~Hydroxychloroquine placebo: 200mg, 3 times a day, oral, for 24 weeks."
223500773|NCT02551575|DRUG|Integrative Medicine|"Qingre Huoxue granule: 10g, 2 times a day, oral, for 24 weeks. Qingre Huoxue external preparation: 20g, 1 times a day, external, for 4 weeks, then 10g, 1 times a day, external, for 8 weeks.~Methotrexate: 10-15mg per week according to patient's weight, oral, for 24 weeks.~Hydroxychloroquine: 200mg, 3 times a day, oral, for 24 weeks."
223500774|NCT00421733|DRUG|Zemplar (paricalcitol ) capsules|Group 2 - paricalcitol 1 mcg capsules once daily (one paricalcitol 1 mcg capsule once daily and one matching placebo capsule once daily)
223500775|NCT00421733|DRUG|Zemplar (paricalcitol) capsules|Group 3 - paricalcitol 2 mcg capsules once daily (two paricalcitol 1 mcg capsules once daily)
223500776|NCT00421733|DRUG|Placebo|Group 1 - Placebo once daily (two placebo capsules once daily)
223500777|NCT02898441|DEVICE|Low Dose Computed Tomography|LDCT were performed in screening arm. The abnormal nodules were defined as noncalcified nodules (NCN) larger than 4 mm.
223500778|NCT06194669|OTHER|Blood and urine sample collection|One whole blood sample per individual (3 ml) will be collected. Up to 5 urine samples per individual will be collected
223500779|NCT06413394|OTHER|environmental education|environmental education
223500780|NCT03429205|OTHER|No external heating used during surgery|Deviation from external heating for all surgery standard
223500781|NCT03429205|OTHER|External heating blanket used during surgery|Standard external heating plan used in all surgery types
223500782|NCT06485180|PROCEDURE|Active comparator|"Participants from conservative group were selected as uterine curettage (D\&C) cohort , hysteroscopy cohort, Uterine Artery Embolization (UAE) in Combination with D\&C, without MTX cohort, UAE in Combination D\&C with MTX cohort and UAE+ D\&C+hysteroscopy.~Participants from CSP excision plus hysterotomy closure group were selected as transvaginal CSP excision cohort, hysteroscopy-assisted laparoscopic CSP excision cohort and abdominal CSP excision cohort."
223500783|NCT02810327|GENETIC|Genetic Sequencing|Sequencing of the SERPINA1 gene
223500784|NCT04368910|DRUG|Pyronaridine - artesunate|Oral pyronaridine artesunate (180:60 mg tablets), plus chloroquine-placebo once a day for 3 consecutive days.
223500785|NCT04368910|DRUG|Chloroquine|Oral chloroquine (155 mg tablets), plus pyronaridine artesunate-placebo, once a day for 3 consecutive days.
223500786|NCT02265744|DRUG|BMS-931699|
223500787|NCT02265744|DRUG|Placebo matching BMS-931699|
223500788|NCT04505917|DRUG|dinoprostol|2 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia \& Upjohn, Puurs, Belgium) inserted by the study nurse 3 hours before IUD insertion.
223500789|NCT04505917|DRUG|misoprostol|2 vaginal tablet of misoprostol (200 mcg) (Misotac®; Sigma Pharma, SAE, Egypt) inserted by the study nurse 3 hours before IUD insertion.
223500790|NCT04505917|DRUG|placebo|2 tablet of placebo inserted by the study nurse 3 hours before IUD insertion
223500791|NCT04983732|DRUG|FL-101-Intravenous|150 mg administered via the IV route
223500792|NCT04983732|DRUG|FL-101-Subcutaneous|150 mg administered via the SC route
223500793|NCT04181645|DRUG|Biological: SHR-1210 Drug: Gemcitabine Drug:Paclitaxel-albumin|SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody. Gemcitabine Other Name: Gemcitabine Hydrochloride for Injection Paclitaxel-albumin Other Name: Paclitaxel-albumin Injection
224309712|NCT06989554|PROCEDURE|Standard physiotherapy without feedback device|Routine inpatient physiotherapy consisting of verbal instruction to limit loading to 20 % body weight, initial bathroom-scale training, and assisted ambulation with walker or crutches. No tactile, visual, or electronic feedback device is provided. Session frequency, walking aids, analgesia, and discharge criteria are identical to the intervention arm; duration ≈ 14 days.
224309713|NCT06989151|BEHAVIORAL|Cognitive Remediation Therapy|8 session psychological intervention.
224309714|NCT06989333|DRUG|GM-CSF (granulocyte-macrophage colony-stimulating factor)|Bronchoscopy under general anesthesia or sedation; The predetermined dose of recombinant GM-CSF was dissolved in normal saline. The diseased lung segments were located through bronchoscopy and the liquid medicine was sprayed.
224191328|NCT03436940|OTHER|Routine Discharge Planning (RDP)|All patients with an intermediate threshold value of the simplified Blaylock Risk Assessment Screening Score are submitted to discharge planning by the NOCC team (Hospital Unit of Continuity of Care)
224191329|NCT05019872|BEHAVIORAL|(Components of) pasta meal|Samples will be provided one by one in cups labeled with an unique code.
224191330|NCT03573843|OTHER|Prevention software|All patients will have a tablet with the software PREVEDEL between 09:00-19:00 hrs.
224191331|NCT03573843|OTHER|Placebo|All patients will have a tablet without the software PREVEDEL between 09:00-19:00 hrs.
224191332|NCT05170217|DRUG|THC|Inhaled cannabis containing 10mg THC
224191333|NCT05170217|DRUG|Cannabidiol|Inhaled cannabis containing 10mg CBD
224191334|NCT05170217|DRUG|Cannabidiol|Inhaled cannabis containing 20mg CBD
224191335|NCT05170217|DRUG|Cannabidiol|Inhaled cannabis containing 30mg CBD
224191336|NCT04715321|OTHER|CT perfusion examination|CT perfusion was performed with a 64-section multidetector CT scanner. The following CT parameters were used to acquire dynamic data: blood flow (BF), blood volume (BV), mean transit time (MTT), permeability-surface area product (PS), hepatic artery ejection fraction (HAF), hepatic artery perfusion (HAP), and hepatic portal vein perfusion (PVP). And we used these parameters to predict the vascular pattern.
224191337|NCT01278823|PROCEDURE|laparoscopic roux en y gastric bypass operation|roux en y gastric bypass operation
224191338|NCT01278823|OTHER|medical management|latest type 2 diabetes medications, lifestyle/behavior modification and dietary regimen
224191339|NCT00717808|DRUG|Tranilast|Tranilast (300mg twice a day) for a period of seven days whilst taking their weekly prescribed dose of methotrexate. Followed by a 7 day washout period before starting arm 2
224191340|NCT00717808|DRUG|Placebo comparator|The patient will receive the placebo capsule twice a day whilst receiving their weekly dose of methotrexate
224191341|NCT03252236|BEHAVIORAL|Tai Chi|Modified 12-form Yang style Tai Chi.
224191342|NCT03252236|BEHAVIORAL|Conventional exercise|Conventional exercises included mobilization, stretching, muscle strengthening, and walking training.
224191343|NCT00859352|DRUG|AZD1981|oral tablets during 14 consecutive days.
224191344|NCT00859352|DRUG|Midazolam|Each subject will receive two single doses of 7.5 mg midazolam given as oral solution. The Midazolam dose will be given on Day 1 and on day 16.
224191345|NCT04275375|OTHER|observation study about the autonomic response after spinal anesthesia|ECG waveforms were continuously recorded using a multichannel polygraphic system (Embla N7000, Natus, Pleasanton, CA). The data were saved at a rate of 1024 Hz directly to a memory card within the device for offline analysis of heart rate variability (HRV) and PPG. All data included in the analysis were obtained from continuous artifact-free ECG recordings for analysis of the immediate effects of spinal anesthesia.
224309715|NCT06988787|BEHAVIORAL|webSTAIR|"Ten web-based modules that are completed independently by participants (\~2 modules per week) and receive therapist support via video-telehealth after the completion of every 2 skill modules (1x per week for a total of 5 meetings).~The first five modules review emotional awareness, emotion management, and distress tolerance while the final five modules raise awareness about relationship patterns and provide interpersonal skills training regarding effective assertiveness, interpersonal flexibility, and compassion for self and others."
223500794|NCT04785885|DIAGNOSTIC_TEST|iStat Handheld Blood Analyzer|An easy-to-use blood analyzer that provides monitoring of heparin anticoagulation quickly for point-of-care testing. Testing will be done at baseline, 30s, 90s and 180s after heparin administration.
223500795|NCT04785885|DIAGNOSTIC_TEST|Hemochron|An easy-to-use blood analyzer that provides monitoring of heparin anticoagulation quickly for point-of-care testing. Testing will be done at baseline, 30s, 90s and 180s after heparin administration.
223500796|NCT05098990|DRUG|Jinfukang oral liquid|Jinfukang koufuye is a Chinese herbal prescription, which is used in treatment for patients with NSCLC in clinical practice. It has been proved to be capable of preventing the occurrence of metastasis, stabilizing tumor lesions, improving the response rates when combined with chemotherapy, and prolonging the survival period of lung cancer patients.
223500797|NCT05098990|DRUG|Platinum-based doublet chemotherapy|Platinum-based doublet chemotherapy as first line therapy has been shown to be efficacious against non-small cell lung cancer.
223500798|NCT04698486|OTHER|Hyperinsulinemic euglycaemic clamp|"Infusion of constant intravenous insulin to achieve hyperinsulinemia and concomitant infusion of glucose to maintain euglycemia (plasma glucose at 5 mM).~Infusion of palmitate and VLDL-triglyceride tracer. PET/CT scans of heart and liver, both in basal period and during intervention."
223500799|NCT06403501|DRUG|Clascoterone|Clascoterone Cream 1% (Winlevi) is indicated for the topical treatment of acne vulgaris in patients 12 years of age and older.
223500800|NCT06403501|DRUG|Vehicle cream|Vehicle cream manufactured to mimic look and feel of Clascoterone Cream 1% but without the active ingredient.
223500801|NCT00299221|DRUG|Tacrolimus|tacrolimus
223500802|NCT00299221|DRUG|combination therapy|MMF
223500803|NCT00720200|BEHAVIORAL|Facilitator-Based intervention|Family Members receiving facilitator-based intervention
223500804|NCT00720200|BEHAVIORAL|Usual Care|Family Members receiving usual care/clinical interaction
223500805|NCT01666600|DRUG|BIBF 1120|BIBF 1120 is given as 2 x minimal tolerated dose per day as long as as a clinical benefit is considered by the treating physician.
223500806|NCT01666600|RADIATION|radiotherapy|36 Gy, 2 Gy / fraction, 18 fractions
224191346|NCT04281849|BEHAVIORAL|BAMS-HF Program|"BAMS-HF Program (intervention) arm will consist of 3 in-home sessions (45-60 min ea) per week for 12 weeks with the study physical therapist. The study physical therapist will transition appropriate participants to virtual in-home visits (i.e. telerehabilitation) for some visits. The study physical therapist will design individualized exercise programs first targeting strength, then mobility and balance, and finally, aerobic capacity. Exercises will be progressive, with the goal of an 8 repetition maximum for each strength component, 80% completion rate for balance/mobility components and targeting a moderate rate of perceived exertion for aerobic components.~Interviews: There will be a recorded interview after the last session of the study to get participants' opinion of the program, suggestions for improvement and description of any barriers to participating in the program fully."
224191347|NCT02676232|BEHAVIORAL|DARWeb|Psychosocial Intervention from the cognitive-behavioral model, including different but related units for parents and children with recurrent abdominal pain.
224191348|NCT06379061|OTHER|Adult and Pediatrics|This is an observational study. This protocol is for blood draw enrollment. These samples will be collected and binned by their results from the MeMed BV assay. Samples collected will be used for an analytical comparison study under a future testing protocol. These samples will be used to establish the diagnostic performance of MeMed BV test on BEC Access Immunoassay Systems for differentiating bacterial from viral infection.
224191349|NCT00249600|BEHAVIORAL|Contingency management|
224191350|NCT01065246|DRUG|catumaxomab|4 intraperitoneal infusions within 11 days administered over 3 hours via an indwelling catheter at the following doses: 10 - 20 - 50 - 150 µg catumaxomab
224191351|NCT03140813|DRUG|AZD7325 (High-Dose)|15mg PO BID
224191352|NCT03140813|DRUG|AZD7325 (Low-Dose)|5mg PO BID
224191353|NCT03140813|DRUG|Placebo oral capsule|Placebo will be dosed similar to AZD7325, in terms of dosage form, frequency and duration.
224191354|NCT03467919|BIOLOGICAL|Micro Fragmented Adipose Tissue|Harvesting of Micro Fragmented Adipose Tissue with intra-articular injection
224191355|NCT03467919|BIOLOGICAL|Corticosteroid injection|Sham harvesting of adipose tissue without intra-articular injection. Intra-articular injection of corticosteroid.
224191356|NCT02487459|BIOLOGICAL|BPX-501|T cells transduced with CaspaCIDe suicide gene
224191357|NCT02487459|DRUG|AP1903|dimerizer drug administered to treat GVHD
224191358|NCT03189199|OTHER|a cohort using Dazhuhongjingtian injection|All patients will be measured and assessed at the time Dazhuhongjingtian Injection is administered to them until they discharge. Patients using Dazhuhongjingtian Injection will be registered on a registration form including disease background, Dazhuhongjingtian Injection's administration, and extraction information from hospital information system. An adverse event or drug adverse reaction form also will be used to describe any doubted symptoms or signs from patients. A judgment will be made by doctors directly and a further analysis will be conducted by researchers to decide those potential side effects of Dazhuhongjingtian Injection.
224191359|NCT02395393|DEVICE|Alveoflex Confocal MiniprobeTM|-Alveolar imaging
224191360|NCT05793788|BEHAVIORAL|Outreach Text Messages|"The investigators will send randomized participants an SMS message encouraging them to click provided link and close their outstanding, overdue preventive care measures.~The provided link will take them to their MyChart login page; after logging in, they would see their personalized My Action Plan Letter detailing their personalized, overdue preventive care measures. Message content will vary based on randomization arm as noted below."
224191361|NCT05793788|BEHAVIORAL|Specific|The message will inform patients that the care team has identified tests/screenings that they are due for.
224191362|NCT05793788|BEHAVIORAL|General|The message will inform patients that the care team has identified a care gap in their record.
224191363|NCT05793788|BEHAVIORAL|Elevating Intentions|The message will point out that even if patients feel healthy, their doctor recommends them to take care of their health gaps.
224191364|NCT05793788|BEHAVIORAL|Prompting Action|The message will prompt patients to take care of their health gaps right away before they forget.
224191365|NCT06212427|DIETARY_SUPPLEMENT|HMO supplement|Liquid supplement containing 2 specific HMOs. Supplement will be given 3-4 times a day, not mixed with any feeding.
224191366|NCT05933655|BEHAVIORAL|Peer Coach|Peer coaching session to support shared decision making among patient with limited health literacy.
224191367|NCT02392078|DEVICE|NeuroBlate System|
224191368|NCT02652793|DRUG|Boosted atazanavir|Atanazir 300 mg once dailly boosted with 100 mg of ritonavir once dailly
224191369|NCT02652793|DRUG|Lamivudine|Lamivudine 300 mg once dailly
224191370|NCT05899166|OTHER|Ketogenic diet, food delivery and education|Meals and groceries will be delivered and participants will receive education on nutrition, meal preparation, and diabetes care strategies. Participants will consume study-prescribed foods exclusively.
224191371|NCT05899166|OTHER|Standard diet, food delivery and education|Meals and groceries will be delivered and participants will receive education on nutrition, meal preparation, and diabetes care strategies. Participants will consume study-prescribed foods exclusively.
224191372|NCT05903690|DRUG|RAG-17|RAG-17 60mg is used
224191373|NCT04643431|DIAGNOSTIC_TEST|Perflutren|The ultrasound contrast agent is used to improve the quality of ultrasound imaging and is infused over 5-10 minutes. The contrast agent consists of the gas-filled microbubbles smaller than the capillary size which circulate in the vascular system. The contrast agent is cleared from the body naturally within 30 minutes.
224191374|NCT04914975|OTHER|Neuromuscular electrical stimulation|The stimulation will be conducted at home or at the SPC for half an hour about 30 minutes before the usual bowel emptying time. Four adhesive electrodes are attached to the abdominal wall for the neuromuscular electrical stimulation. The abdominal muscles are stimulated in such a way that activation occurs, i.e. the muscle alternately contracts and relaxes again. The stimulation sessions will be documented with a defined protocol. In addition, the stool consistency is rated according to the Bristol Stool Form Scale.
223746251|NCT06914076|COMBINATION_PRODUCT|Structured Psychosocial Counseling|"Group A (Experimental Group):~Participants in the Experimental group will be divided into groups with the persons having visual acuity 6/60, counting fingers and light perception will receive low vision aids etc and structured psychosocial counseling tailored for individuals with low vision. Counseling will be delivered over a 12-week period, consisting of weekly 60-minute sessions conducted by trained counselors. The program will focus on the following:~Coping mechanisms for depression and anxiety. Strategies to improve functional independence and daily living skills. Social integration techniques to enhance participation in community activities. Low visions aids under supervision of low vision specialist."
224191375|NCT01940757|BIOLOGICAL|Necator americanus Hookworm Larvae|Infectious larvae of the human hookworm Necator americanus
224191376|NCT06419634|DRUG|BMS-986497|Specified dose on specified days
224191377|NCT06419634|DRUG|Azacitidine|Specified dose on specified days
224191378|NCT06419634|DRUG|Venetoclax|Specified dose on specified days
224191379|NCT05450198|BIOLOGICAL|MK-6194|MK-6194 administered subcutaneously (SC)
224191380|NCT05450198|BIOLOGICAL|Placebo|Placebo comparator to MK-6194 administered SC
224191381|NCT00722462|PROCEDURE|Active acupuncture|Acupuncture 25 minutes before and after embryo transfer
224191382|NCT00722462|PROCEDURE|Sham acupuncture|Acupuncture at neutral points, 25 minutes before and after embryo transfer
224191383|NCT03142464|OTHER|Suspension of the IV fluids|No IV fluids prescription, IV catheter filled with saline solution
224191384|NCT04131465|DIAGNOSTIC_TEST|Home HIV self-testing|Offer of 3 OraQuick HIV self-test kits
224191385|NCT04131465|DIAGNOSTIC_TEST|Home HIV rapid testing|Offer of HIV rapid testing with Alere Determine HIV-1/2
224191386|NCT04131465|DIAGNOSTIC_TEST|Home HIV self-testing and rapid testing|Offer of 3 OraQuick HIV self-test kits and HIV rapid testing with Alere Determine HIV-1/2
224191387|NCT02059265|DRUG|Dasatinib|Given PO
224191388|NCT02059265|OTHER|Laboratory Biomarker Analysis|Correlative studies
224191389|NCT00845351|DRUG|Bexarotene|bexarotene at 300 mg/m2/day
224191390|NCT06309069|OTHER|None, purely observational study|None, purely observational study
224191391|NCT06023485|OTHER|stress ball use during subcutaneous injection|The effect of stress ball use on pain during subcutaneous injection
224191392|NCT04381793|DIETARY_SUPPLEMENT|Recovery Factors|Porcine serum amino acid/peptide
224191393|NCT05460195|DRUG|sintilimab combined with anlotinib|Sintilimab (200mg/time, every 3 weeks) combined with anlotinib (12mg, once daily on day 1 to 14 per cycle) for 2 cycles (42 days). Radical surgery is performed within 4 - 6 weeks treatment. Sintilimab combined with anlotinib therapy repeats every 3 weeks until one year after surgery.
224191394|NCT05460195|DRUG|sintilimab monotherapy|Sintilimab (200mg/time, every 3 weeks) combined with anlotinib (12mg, once daily on day 1 to 14 per cycle) for 2 cycles (42 days). Radical surgery is performed within 4 - 6 weeks treatment. Sintilimab monotherapy repeats every 3 weeks until one year after surgery.
224191395|NCT02409225|DEVICE|Home Monitoring|Remote monitoring of ICD/CRT-D function and patient condition allow decreasing costs of treatment of patients with ICD/CRT-D (hospitalization, visits in outpatient clinic) and reducing waiting time for medical intervention (remote or in outpatient clinic).
224191396|NCT02409225|DEVICE|no Home Monitoring|Patients with ICD/CRT-D devices provided by St Jude Medical, Biotronik or Medtronic with HM option switched off.
224191397|NCT02638818|PROCEDURE|minimally invasive pancreaticoduodenectomy|Surgical technique (minimally invasive versus open) will be at the discretion of the operating surgeon. Patients will not be randomized to a treatment arm.
224191398|NCT02638818|PROCEDURE|traditional pancreaticoduodenectomy|Surgical technique (minimally invasive versus open) will be at the discretion of the operating surgeon. Patients will not be randomized to a treatment arm.
223746252|NCT06914076|DIAGNOSTIC_TEST|Standard Care|Group B (Control Group): The control group will continue receiving standard care, including referrals and informational support.
223746253|NCT06914037|DRUG|CHT101|CD70 UCAR-T
224191399|NCT02434029|DRUG|Budesonide 1mg orodispersible tablet twice daily|
224191400|NCT02434029|DRUG|Placebo orodispersible tablet twice daily|
224191401|NCT05420402|DRUG|Propofol bolus|A bolus dose of propofol 1 mg/kg was administered intravenously at 3 minutes before the end of the surgery.
224191402|NCT05420402|DRUG|Propofol continuous infusion|1 mg/kg propofol was started by continuous infusion 3 minutes before the end of surgery, and the infusion time was 3 minutes.
224191403|NCT05420402|DRUG|Propofol bolus|A bolus dose of propofol 1 mg/kg was administered intravenously at the end of the surgery.
224191404|NCT06241131|DRUG|Desflurane Inhalant Product|The Desflurane was inhaled at a starting concentration of 1 MAC, and remifentanil 0.1 μg/kg/min was continuously pumped intravenously.
224191405|NCT06212973|DRUG|Epinastine Hcl Oph Soln+Simulating Azelastine Hcl Oph Soln|Epinastine Hydrochloride Eye Drops + Simulating Azelastine Hydrochloride Eye Drops are used: both eyes are administered twice daily, once in the morning and once in the evening, with an interval of 8-12 hours between administrations; each time, 1 drop of each of the two eye drops is placed in each eye into the conjunctiva, and the two eye drops are applied at intervals of more than 5 minutes.
224191406|NCT06212973|DRUG|Azelastine Hcl Oph Sol+Simulating Epinastine Hcl Oph Soln|Azelastine Hydrochloride Eye Drops + Simulating Epinastine Hydrochloride Eye Drops are used: both eyes are administered twice daily, once in the morning and once in the evening, with an interval of 8-12 hours between administrations; each time, 1 drop of each of the two eye drops is placed in each eye into the conjunctiva, and the two eye drops are applied at intervals of more than 5 minutes.
224191407|NCT03587740|DRUG|T-DM1|T-DM1 is an antibody-drug conjugate; it is made up of an antibody (trastuzumab) linked to a cytotoxic drug, DM1 (chemotherapy). T-DM1 functions as a targeted cancer therapy because it targets HER2-positive breast cancer cells directly, limiting exposure of the rest of the body to chemotherapy.
224191408|NCT06063382|BEHAVIORAL|Exam|Academic exam based on the Brazilian National High School Exam (ENEM).
224191409|NCT01213121|DRUG|Quetiapine|oral tablet/25-600mg per day/once a day/six weeks
224191410|NCT00798902|DEVICE|Prefix (AMPLEX) B2A Peptide Enhanced Ceramic Granules|150 micrograms/cc BVF
224191411|NCT00798902|OTHER|Iliac crest autograft|autograft
223746254|NCT06912750|OTHER|4-7-8 Breathing Exercise with Teach-Back Method|"In the experimental group, patients will be provided with information regarding the purpose and significance of the 4-7-8 breathing technique using the Teach-Back method one day before surgery. To confirm comprehension, patients will be asked to repeat the information. The exercise will be demonstrated in a one-on-one session using the Teach-Back method, and patients will be guided through practical application. Following the training, patients will be instructed to perform the exercise independently, with the researcher monitoring its correct implementation. Each patient will be given a 4-7-8 Breathing Exercise Application Guide, which outlines the exercise steps based on relevant literature.~Before surgery, patients will complete the Patient Information Form, the Visual Analog Scale (VAS) for pain, the State-Trait Anxiety Inventory (STAI), and the Richards-Campbell Sleep Questionnaire (RCSQ). Postoperatively, the VAS and STAI will be administered both before (pre-test) and after"
224074641|NCT03326141|BEHAVIORAL|Otago Exercise Program|The program has been adapted for groups and includes 5 flexibility movements (e.g., back extension and ankle, head, neck, trunk movements), 5 leg strengthening exercises (knee extensor, knee flexor, hip abductor, ankle plantar flexes, ankle dorsiflexes), 12 balance movements (knee bends, backwards walking, walking and turning, sideways walking, tandem stance, tandem walk, one leg stand, heel walking, toe walking, heel-toe walking backwards, sit to stand, stair walking), and a walking plan. The number, intensity and duration of movements are individualized according to preference and ability and they are gradually progressed.
224191412|NCT05297162|DIAGNOSTIC_TEST|PSMA PET/TRUS (trans-rectal or trans-perineal) fusion biopsy|"The prostate profile and ROIs will be drawn on PSMA PET and mpMRI and fused in real time with the TRUS image stack during biopsy. Biopsies, transrectal or transperineal according to lesion site, will be performed with patients in the dorsal lithotomy position, under antibiotic prophylaxis and local anesthesia, using 3D triplane transrectal ultrasound system (BK Medical, Analogic Ultrasound Group, Pro Focus, Transducer 8818, 6/9 MHz).~Biopsy cores will be numbered according to ROI number and topography. Specimens will be processed and evaluated by a genitourinary pathologist. Tumor foci will be quantified and graded according to the ISUP consensus conference on Gleason grading."
224191413|NCT03482388|BEHAVIORAL|Crowdsourced materials|Among participants randomized to the intervention arm, intervention images and videos promoting HBV and HCV testing will be delivered through the WeChat platform. Men will also be invited to submit suggestions for how to improve intervention videos and images.
224191414|NCT03482388|OTHER|Control|Participants will not view any images or videos promoting HBV and HCV testing.
224191415|NCT01284842|OTHER|24-Hour-Call|one 24-Hour-Call within the regular surgical schedule
224191416|NCT01172327|BEHAVIORAL|Multicomponent exercise|This intervention is a self-directed, multicomponent, exercise intervention. Participants exercise on their own and follow a progressive stepped program that occurs in the following order: cardiorespiratory exercises, flexibility exercises, strength (upper and lower body) exercises, and balance exercises. Participants also complete a daily log of their exercises and return the logs every week for 12 weeks. The active intervention phase is 12 weeks.
224191417|NCT01172327|BEHAVIORAL|Nutrition|This arm is a self-directed nutrition intervention. Participants follow a progressive stepped program that occurs in the following order: fruits, vegetables, grains, meat and beans. Participants also complete a daily log of their dietary intake and return the logs every week for 12 weeks. The active intervention lasts for 12 weeks.
224191418|NCT03412448|OTHER|observation|Observation,
224191419|NCT05034146|DRUG|68Ga-FAPI|68Ga-FAPI was injected intravenously to each subject, and the dose is calculated according to body weight of subject (approximately 1.85-3.7MBq/kg).
224191420|NCT05034146|DEVICE|PET/CT|68Ga-FAPI PET/CT scan were performed 20\~60 min after 68Ga-FAPI (1.85-3.7MBq/kg) injection intravenously.
224191421|NCT05252507|BEHAVIORAL|Paint Night|There will be 8 Sessions (4 paint nights and 4 educational sessions alternating weeks). For the painting sessions, participants will paint for 45 minutes and then participate in a combined presentation/discussion session (45 minutes). For the educational sessions, they will attend a 30-minute presentation presented by a researcher on heart health and then have the opportunity to discuss with the researcher and other members of the group (60 minutes).
224191422|NCT05252169|OTHER|Proprioceptive training|"Proprioceptive Training will include some active exercises such as stair climbing up and down,one leg standing,Walking heel to toes,rising from a standard chair.~And swiss ball training will be applied passively by therapist in which child will sit on the ball and ball will be rolled from side to side,Extension rotation and flexion rotation will be performed to facilitate trunk rotation,Trunk rotation will be performed with stabilized pelvis and hip."
224191423|NCT05252169|OTHER|Routine Physical therapy|"Group A will be given routine physical therapy which will be of 60 minutes each session. The routine physical therapy will include~* Passive stretching exercises~* Weight bearing exercises~* Functional strength training Duration of the treatment will be 3 days a week for 12 weeks i.e., 36 sessions. Each session will be of 60 minutes."
224191424|NCT04604353|DIAGNOSTIC_TEST|Polygenic Risk Score|Risk description to patient based on PRS
224191425|NCT04604353|DIAGNOSTIC_TEST|Coronary Calcium Score|Risk description to patient based on CCS
223512056|NCT03376412|DEVICE|Raindrop Near Vision Inlay|A maximum of 60 consecutive non-dominant eyes will be implanted with the Raindrop Near Vision Inlay.
223512057|NCT02187081|PROCEDURE|radiofrequency ablation plus Sorafenib|To treat HCC with the combination of radiofrequency ablation and sorafenib
223512058|NCT02187081|PROCEDURE|Radiofrequency ablation|To treat HCC with radiofrequency ablation alone.
223512059|NCT00021359|DRUG|dexamethasone|
223512060|NCT00021359|DRUG|isotretinoin|
223512061|NCT02226783|DRUG|AZD1722 salt tablet|AZD1722 will be administered as 14 mg (salt tablet). tablet for oral use. Subjects will receive a 14 mg tablet in the morning and evening on Days 1 to 4 (Period 1), Days 7 to 10 (Period 2), and Days 13 to 16 (Period 3).
223512062|NCT02226783|DRUG|AZD1722 free base tablet|AZD1722 will be given as four 14 mg free-base tablets (56mg) in the morning and evening on Days 1 to 4 (Period 1) and Days 10 to 13 (Period 2).
223746255|NCT06914414|PROCEDURE|Using the flow model in cerebral aneurysm embolization|"Since the 1970s-1980s, surgical techniques for intracranial aneurysms have evolved. In recent years, endovascular embolization of aneurysms has demonstrated a better approach to the pathology, as well as better results in terms of both vital prognosis, but also in terms of quality of life (disability, logical disorders, etc.). However, this treatment modality remains little known to the general public, and generates a high level of anxiety for patients.~The anxiety of these patients could be reduced by the addition of a paramedical consultation and the use of a flow model to explain and visualize the procedure.~The study will include 72 patients per group (i.e. a total of 144 patients, with a 10% loss of blood pressure) to achieve a two-point reduction in the anxiety score measured by the APAIS grid."
224191426|NCT00204711|OTHER|SNAP II EEG System|A portable EEG monitor (SNAP II EEG System, Everest -St. Louis) is unique in that it monitors both low frequency EEG signals (1-40 Hz), which are typically used, and high frequency EEG signals (80-420 Hz), which are not usually used, and calculates a derived EEG parameter (the SNAP Index). The SNAP Index ranges from 100 (completely awake) to 0 (no brain activity) and has been shown in a few studies to correlate with increasing sedation and loss of consciousness in human volunteers and patients receiving general anesthesia during surgery.
224191427|NCT06280092|DRUG|AMSCs|A single dose of 5x10\^6 AMSCs will be resuspended in 1ml of LRS and infused via intraparenchymal at the time of DBS surgery
224191428|NCT03842865|BIOLOGICAL|Vigil|Vigil is composed of autologous tumor cells harvested from the patient at the time of initial de-bulking surgery which are then transfected extracorporeally, with a plasmid encoding for the gene for GM-CSF, an immune-stimulatory cytokine, and a bifunctional, short hairpin RNA which specifically knocks down the expression of furin, the critical convertase responsible for production of the two TGβ isoforms (TGFβ-1 and TGFβ-2).
224191429|NCT00830310|BEHAVIORAL|Psychoeducation module|"Individuals will be assigned the psychoeducation module if they are identified as having opposition to prophylaxis, denial of illness severity or therapeutic effectiveness, negative attitudes towards drugs in general, or lack of information about mood stabilizers operationalized as a score of 1 or higher on any of these AMSQ subscales. Additionally, those individuals who are non-adherent/sub-optimally adherent because of stigma or embarrassment over medications or in relation to the use of complementary or alternative treatments will be assigned to participate in the psychoeducation module (ROMI stigma item or complementary/alternative treatment supplemental item)."
224191430|NCT00830310|BEHAVIORAL|Substance use module|Individuals will be assigned the substance use module if they endorse the ROMI substance use item or if substance use is identified as problematic on the clinician assessment.
224191431|NCT00830310|BEHAVIORAL|Improved communication/rapport with provider module|"Individuals will be assigned the provider communication/rapport module if they are identified as having fear of side effects operationalized as a score of 1 or higher on these AMSQ items. Additionally, those individuals who are non-adherent/suboptimally adherent because of concern regarding change in appearance appearing medicated or who experience side-effect-related distress as identified by the ROMI will be assigned the provider communication module."
223500807|NCT04086459|DEVICE|Repetitive transcranial magnetic stimulation|Those receiving experimental treatment will receive 20 sessions of rTMS, stimulation protocol included 20 sessions within 30 days (once a day, 5 days/week, 4 weeks, 10 Hz frequency, pulse intensity 100% of the resting motor threshold, 50 pulses per train, inter train pause of 10 s, 40 stimulation trains, 2000 pulses/ session)
223591605|NCT01663064|DEVICE|Endovascular treatment (Zenith® p-Branch™ endovascular graft)|Instead of making a large incision in the chest, the physician makes a small incision near each hip to insert, and guides the study device(s) into place in the aorta.
223500808|NCT01297790|OTHER|Cough Challenge Tests|Inhalational cough challenge tests with capsaicin, bradykinin, Citric acid and prostaglandin E2
223746256|NCT06913543|COMBINATION_PRODUCT|Group 1 (Experimental Group - OKC + NMES)|"OKC Knee Extension Exercises:~Seated Knee Extensions:~Resistance bands or machine, 10-15 reps, 2-3 sets.~Straight Leg Raises:~With or without ankle weights, 12-15 reps, 2-3 sets.~Quadriceps Isometric Holds:~Held for 5-10 seconds, 10 reps, 2-3 sets.~Neuromuscular Electrical Stimulation (NMES):~Electrode Placement:~Over the motor points of the quadriceps.~Frequency:~35-50 Hz.~Pulse Duration:~200 microseconds.~Intensity:~Adjusted for strong yet tolerable contractions.~On-Off Cycle:~10 seconds on, 20 seconds off."
223500809|NCT01297790|OTHER|ambulatory cough recording|Cough recording with a portable device to capture cough sounds
223500810|NCT01297790|OTHER|Cough questionnaires|Questionnaires designed to study cough. These include Leicester cough questionnaire, cough visual analogue score and cough quality of life questionnaire.
223500811|NCT05161936|DRUG|Lumasiran|Lumasiran will be administered by SC injection.
223500812|NCT05161936|DRUG|Placebo|Placebo will be administered by SC injection.
223500813|NCT01086475|DRUG|D-cycloserine|50 mg dose administered 30 minutes prior to each of the ten Social Skill Training Sessions
223500814|NCT01086475|DRUG|Placebo|Placebo pill administered 30 minutes prior to each of the ten Social Skill Training Sessions
223500815|NCT00999011|PROCEDURE|once daily mobility activity|in bed and out-of-bed activity including range of motion, chair sitting, sitting at edge of bed without weightbearing, standing, walking.
223500816|NCT00999011|PROCEDURE|twice daily mobility activity|as with once daily. Goal is to progress intensity and duration of activity over time as patient condition improves for both arms
223591606|NCT03464019|DRUG|Etripamil|Etripamil administered via the Aptar Pharma Nasal Spray Bidose System, supplied as prefilled devices packaged into child-resistant boxes with instructions for use provided in the study drug box.
223591607|NCT03464019|DRUG|Placebo|Placebo administered via the Aptar Pharma Nasal Spray Bidose System, supplied as prefilled devices packaged into child-resistant boxes with instructions for use provided in the study drug box.
223500817|NCT05371197|DRUG|Neoadjuvant therapy with PD-L1 inhibitor|Neoadjuvant therapy with PD-L1 inhibitor (Envafolimab), 300mg, Q3W for 4 cycles
223746257|NCT06913543|DIAGNOSTIC_TEST|Group 2 (Control Group - OKC Only|Open Kinetic Chain Knee Extension Exercises without NMES. Method \& Details: The same OKC exercises as the experimental group but without NMES. All exercises are supervised by trained physiotherapists.
224191432|NCT00830310|BEHAVIORAL|Medication routines management module|"Individuals will be assigned the medication routines management module if they are identified as having difficulties with medication routines operationalized as a score of 1 or higher on this AMSQ sub-scale, or if they are identified as experiencing outside opposition to medications by the ROMI."
224191433|NCT06428734|DIAGNOSTIC_TEST|hydrocephalus group|Diagnostic Test: high throughput sequencing and electromyography Whole Genome Sequencing, Whole Exome Sequencing, Transcriptomics, Proteomics, Metabolomics and imaging, such as DTIALPS
224191434|NCT06428734|OTHER|normal group|Whole Genome Sequencing, Whole Exome Sequencing, Transcriptomics, Proteomics, Metabolomics and imaging, such as DTIALPS
223500818|NCT00505362|PROCEDURE|Rectus closure|Reapproximation of the rectus muscles with three-interrupted sutures
223500819|NCT02289378|DRUG|Docetaxel, Oxaliplatin and 5-Fu|To investigate the triplet regimen in the first-line therapy of advanced chemotherapy
223500820|NCT02384460|DRUG|SD-101-6.0 cream|applied topically once a day for 90 days
223500821|NCT02384460|DRUG|Placebo (SD-101-0.0) cream|applied topically once a day for 90 days
223500822|NCT02839460|PROCEDURE|Outpatient Muscle Biopsy|Outpatient Muscle Biopsy involving skeletal muscle sample collected from the vastus lateralis muscle
223500823|NCT04105660|OTHER|Training for EEG monitoring|Training for reading EEG curves during anaesthesia
223500824|NCT04105660|OTHER|Standard monitoring|Standard monitoring including clinical parameters and BIS index
224191435|NCT04054713|DIAGNOSTIC_TEST|Acetic acid chromoendoscopy|Acetic acid is prepared at a concentration of 2.5% in a 20ml syringe, it will be applied with a 7 french spray catheter compatible with a working channel 2.8mm onwards, starting the proximal application When distally performing a uniform application on the area of intestinal metaplasia and the timed time for mucous visualization in search of areas of loss of acetowhitening begins, in case of finding such area will be registered the time in which there was loss of acetowhitening, the distance at which it is located from the upper dental arch in addition to the face on which the area is located, subsequently evaluation of the glandular pattern is performed only by classifying as normal or abnormal, once this evaluation has been carried out, biopsies are directed to these areas to be sent to the pathology service.
224191436|NCT04054713|DIAGNOSTIC_TEST|Seattle protocol|Take random biopsies by quadrants every 2 centimeters. Biopsy of the intestinal metaplasia areas 1cm above the esophagogastric junction will be initiated, taking tissue every 2cm from the four quadrants, separating the biopsies in different bottles based on the length in which they were taken, to later be sent to the pathology service.
224191437|NCT05889156|DRUG|NST-1024|400 mg BID
224191438|NCT05889156|OTHER|Placebo|matched placebo to active arm
224191439|NCT02570945|PROCEDURE|Pharmacist-physician intervention to reduce high-risk medication use by elderly inpatients|
224191440|NCT05644080|RADIATION|177Lu-PSMA I&T|Patients demonstrating a high tumor uptake of 68Ga-PSMA on the diagnostic PET/MRI examination in the screening part of the study are eligible for a standard of 3 cycles, with a possible extension to maximum number of 6 cycles, of 177Lu-PSMA radionuclide therapy sessions. SPECT/CT will be performed after each cycle of treatment for dosimetry calculations, while 68Ga-PSMA PET/MRI, quality-of-life schemes and clinical examinations will be used to monitor therapeutic effects during the therapy cycles and up to 1.5 year after treatment initiation. The main endpoints of the study are progression-free survival and overall survival.
224191441|NCT00635193|DRUG|M200 (Volociximab)|7.5 mg/kg, IV infusion every week until disease progression
224191442|NCT00635193|DRUG|Liposomal Doxorubicin|40 mg/m2, IV infustions every 4 weeks until disease progression, the maxium number of doses a subject can receive is 12.
224191443|NCT00635193|DRUG|M200 (Volociximab)|15 mg/kg, IV infusions every week until disease progression
224191444|NCT00635193|DRUG|M200 (Volociximab)|15 mg/kg, IV infustions every other week until disease progression
224191445|NCT03677102|OTHER|higher chloride crystalloid|Normal saline (chloride concentration 154 mmol/L)
224191446|NCT03677102|OTHER|lower chloride crystalloid|Ringer's Lactate (chloride concentration 110 mmol/L)
224191447|NCT06438549|BEHAVIORAL|HCP-CHW Integration into Prenatal Care for Smoking Cessation|CHWs will be integrated into primary care, and subjects will receive CHW home visits (up to 8) that will provide brief behavioral smoking cessation interventions before, during, and after a quit date. This brief behavioral intervention will include watching a video and reviewing self-help materials.
224191448|NCT06438549|OTHER|Control Arm|Standard of Care which provides referrals to community-based smoking cessation resources.
224191449|NCT06961916|DEVICE|Active rTMS|Active H-coil delivered rTMS sessions will be given three times per treatment visit for up to 10 visits within about 2 weeks. There are about 30 minutes breaks between adjacent TMS sessions. Each TMS session takes about 3 to 4 minutes to complete.
224191450|NCT06961916|BEHAVIORAL|Cognitive Training|For the cognitive training sessions, patients will be asked to play cognitive computer games involving processing speed tasks for about 15 to 30 minutes.
224191451|NCT03164304|DRUG|Magnesium Sulfate|intravenous
224191452|NCT00804323|PROCEDURE|Patter Scan Laser System (OptiMedica, Santa Clara, CA, USA)|Pattern Scan Laser trabeculoplasty
224191453|NCT00634933|DRUG|TRU-015|IV 800 mg TRU-015 at Baseline (both arms) and Week 24 (both arms); corresponding IV Placebo at Week 12 and Week 36 (both arms).
224191454|NCT00634933|DRUG|Methylprednisolone|IV 100 mg Methylprednisolone at Baseline (both arms), Week 12 (arm 1a) and Week 24 (both arms); corresponding IV Placebo at Week 12 (Arm 1b) and Week 36 (both arms).
224191455|NCT00634933|DRUG|Prednisone|Oral 20 mg tablets Prednisone at Baseline (both arms), Week 12 (arm 1a), and Week 24 (both arms); corresponding Oral Placebo at Week 12 (Arm 1b) and Week 36 (both arms)
224191456|NCT00634933|DRUG|TRU-015|IV 800 mg TRU-015 at Baseline (both arms), Week 12 (both arms), and Week 36 (both arms); corresponding IV Placebo at Week 24 (both arms).
224191457|NCT00634933|DRUG|Methylprednisolone|IV 100 mg Methylprednisolone at Baseline (both arms), Week 12 (both arms), and Week 36 (both arms); corresponding IV Placebo at Week 36 (both arms).
224191458|NCT00634933|DRUG|Prednisone|Oral 20 mg tablets Prednisone at Baseline (both arms), Week 12 (arm 2a) and Week 36 (both arms); corresponding Oral Placebo at Week 12 (Arm 2b) and Week 24 (both arms).
224191459|NCT00634933|DRUG|TRU-015|IV 800 mg TRU-015 at Week 24 (both arms) and Week 36 (arm 3a); corresponding IV Placebo at Baseline (both arms), Week 12 (both arms) and Week 36 (arm 3b).
224191460|NCT00634933|DRUG|Methylprednisolone|IV 100 mg Methylprednisolone at Baseline (both arms), Week 12 (arm 3a), Week 24 (both arms), and Week 36 (arm 3a); corresponding IV Placebo at Week 12 (arm 3b) and Week 36 (arm 3b).
224191461|NCT00634933|DRUG|Prednisone|Oral 20 mg tablets Prednisone at Baseline (both arms), Week 12 (arm 3a), Week 24 (both arms) and Week 36 (arm 3a); corresponding Oral Placebo at Week 12 (Arm 3b) and Week 36 (arm 3b).
224191462|NCT03374059|OTHER|Exercise program|
224191463|NCT03374059|OTHER|Life modification|
224191464|NCT05038397|DEVICE|Theraspere|Prior to the administration of TheraSphere, the patient should undergo hepatic arterial catheterization using balloon catheterization or other appropriate angiographic techniques to prevent extrahepatic shunting. Following the placement of the hepatic catheter, 75 MBq to 150 MBq (2 mCi to 4 mCi) of Tc-99m MAA is administered into the hepatic artery to determine the extent of A-V shunting to the lungs and to confirm the absence of gastric and duodenal flow. When the possibility of extrahepatic shunting has been evaluated and the patient deemed acceptable for treatment, TheraSphere may be administered.
224191465|NCT02058849|DRUG|Beetroot|10g Beetroot powder mixed with 4-8 oz.
224191466|NCT02058849|OTHER|Placebo|Placebo
224191467|NCT03588494|COMBINATION_PRODUCT|concurrent chemoradiotherapy (CCRT)|"Chemotherapy: Cisplatin (50 mg/m2) on days 1, 8, 29, and 36 and etoposide (50mg/m2) on days 1～5 and 29～33.~Radiotherapy: Thoracic radiotherapy (TRT) started with a linear accelerator (6MV-X) on the first day of chemotherapy.A minimum dose of 60 Gy (2 Gy per fraction, Monday～Friday) was delivered, and a range of 60-66 Gy in 2 Gy fractions was allowed."
224191468|NCT03588494|DRUG|Endostar for one cycle|Endostar(15mg/m2) was durative transfused during the normalization window of the first chemoradiotherapy cycle(days -5～-1).
224191469|NCT03588494|DRUG|Endostar for two cycles|Endostar(15mg/m2) was durative transfused during the normalization window of the first and the second chemoradiotherapy cycles(days -5～-1 and 24～28).
224191470|NCT02895386|DEVICE|ROX Coupler|ROX Coupler will be used to create an anastomosis in the iliac region (between the iliac artery and vein).
223500825|NCT01060111|DRUG|Topiramate Standard|Topiramate 25 mg will be administered once daily and the dose will be increased by 25 mg per day at an interval of 1-week up to a dose of 50 mg to 100 mg up to Week 6. A maintenance dose of 50 mg to 100 mg will be administered twice daily up to Week 10 as per Physician's discretion.
223500826|NCT01060111|DRUG|Topiramate Slow|Topiramate 25 mg will be administered once daily and the dose will be increased by 25 mg per day at an interval of 2-weeks up to a dose of 50 mg to 100 mg up to Week 6. A maintenance dose of 50 mg to 100 mg will be administered twice daily up to Week 10 as per Physician's discretion.
223746258|NCT06914687|DRUG|Tislelizumab|recombinant humanized anti-PD-1 monoclonal antibody for injection; 200mg ivdrip，d1, q3w
224191471|NCT02895386|OTHER|Sham procedure|Sham procedure + continuing current antihypertensive medications.
224191472|NCT03774069|DEVICE|DreaMed Advisor Pro|Insulin pump settings (i.e, basal plan, correction factor, carbohydrate ratio and insulin activity time) will be adjusted using the DreaMed Advisor Pro and sent directly to the patient
224191473|NCT03774069|OTHER|Medical guided recommendation|Insulin pump settings (i.e, basal plan, correction factor, carbohydrate ratio and insulin activity time) will be adjusted by the medical team according to standard of care
224191474|NCT01572129|DRUG|Clopidogrel|600 mg clopidogrel loading dose 6-8 h before diagnostic coronary angiogram
224191475|NCT01572129|DRUG|Placebo|Placebo in addition to the chronic daily dose of 75 mg
224191476|NCT03434665|PROCEDURE|Transradial celiac artery angiography|"* After completion of transradial diagnostic coronary angiography and/or PCI, before removal of the radial arterial sheath, selective angiography of the celiac artery will be performed.~* Technically, a 0.35-inch wire is advanced into the descending aorta. A 125 cm 5-French Judkins right catheter is inserted over this wire, which is then removed. The distal tip of the catheter is brought in front of the ostium of the celiac artery and positioning is confirmed with angiography of the celiac artery. Two or three views will be obtained to determine the optimal view to visualize the left gastric artery anatomy. All material is removed and hemostasis is obtained as per clinical routine for coronary angiography."
224191477|NCT03698032|DIETARY_SUPPLEMENT|Water|Participants will consume water only
224191478|NCT03698032|DIETARY_SUPPLEMENT|1.5 oz Pistachios|Participants will consume water plus 1.5 oz of pistachios as the intervention
223500827|NCT01060111|DRUG|Propranolol booster|Propranolol 80 mg will be administered once daily, 40 mg in the morning and 40 mg in the evening up to Week 6.
223500828|NCT05824676|DEVICE|Variable Angle LCP Patella Plating System|FDA approved device, 510K number of, K210408. The Variable Angle LCP Patella Plating System is a device that can be formed to a patients specific need with various anchoring points to best fix what is needed for fixation.
223500829|NCT05824676|DEVICE|Traditional Fixation|Traditional fixation methods for patellar fracture (screws, suture fixation, wire fixation, other plates).
223500830|NCT01277068|PROCEDURE|Surgical and medical procedures|this study want to compare the differential effect of the 3 bariatric surgery procedures on the production rates of the intestinal TRL: the adjustable gastric banding the sleeve gastrectomy the gastric bypass
223746259|NCT06914687|DRUG|S-1|40\~60mg Bid，d1\~14, q3w
223746260|NCT06914687|DRUG|Oxaliplatin|130mg/m2，iv drip for 2h，d1, q3w
224191479|NCT03698032|DIETARY_SUPPLEMENT|3.0 oz Pistachios|Participants will consume water plus 3.0 oz of pistachios as the intervention
224205849|NCT03050528|BEHAVIORAL|Supervised Exercise|Participants will attend the weekly supervised exercise sessions for a period of eight weeks. The classes will be delivered to groups of up to ten participants and will be led by a physiotherapist. The classes will be one hour and thirty minutes in duration and will feature two components: education/advice and exercise. The education/advice sessions will cover topics such as pacing and goal setting and the physiotherapist will answer any queries from the participants in relation to physical activity over the course of the eight weeks. The exercise component will involve the provision of individualised exercises based on each participant's personal goals and the sessions will feature a combination of aerobic, stretching and strengthening exercise in a pool and a gym setting.
224309716|NCT06988787|BEHAVIORAL|ExpoTx|A real-time, present-focused, intervention that does not require participants to relive or focus on past trauma(s), but rather on current social functioning; ie, how they are doing in day-to-day life, and current cognitive and psychological functioning. Therapist will meet individually with the participant for 5 sessions, 60 minutes each conducted virtually. During the 5 sessions, participants will be guided to use in vivo or in the moment ExpoTx to identified fear-based triggers. In each consecutive session, the therapist will engage the Veteran to explore cognitions that interfered with, reinforced, or diminished fear responses. Participants will be asked about their use of coping skills during exposure practice. Intentional participation in exposure for one target at least 30 minutes per day, or until SUDs lower by half. At the end of ExpoTx, the therapist will engage the Veteran in self-determining future goals and offer referrals in the community or at VA for additional support.
224309717|NCT06988787|OTHER|PsychoEd|Psycho-education (PsychEd) orientation that provides an overview of PsychEd as a process for learning about mental health symptoms and disease management related to trauma. During PsychEd sessions, therapists will focus on the following 5 areas: 1) Defining trauma and PTSD. 2) Brain Basics and Brain Injury. 3) Understanding the Role of Stress and Its impact on trauma symptoms. 4) The Role of Nutrition and Exercise in Disease Management. 5) Information on other Programs.
224309718|NCT06989398|BEHAVIORAL|Advancing Supervisors' Capacity for Mental Health at Work (ASCEND)|"The intervention will consist of a training that incorporates evidence-based content and interactive exercises. Advancing Supervisors' Capacity for Mental Health at Work (ASCEND) covers five core topics designed to equip supervisors with the knowledge and practical skills needed to effectively support the mental health of their employees. The full training is delivered over approximately 8 hours in an in-person group setting. Trainings are facilitated by a trained professional.~To support learning and skill application, participants will also receive a Manager Reference Booklet during the training. This booklet consolidates key information from the ASCEND training, serving both as a learning aid during the sessions and a practical, quick-reference tool afterward. It includes summaries of key concepts, tips, and exercises, along with space for participants to record notes."
224309719|NCT06990074|DEVICE|cataract surgery|Robot-assisted cataract surgery
224309720|NCT06990074|DEVICE|cataract surgery|Robot-assisted cataract surgery, designed to provide superior precision and increase the safety profile of the current standard of care.
224309721|NCT06988631|OTHER|Sensory treatment|Participants were asked to practice the foot sole sensory training program at home every day for 2 weeks.
224309722|NCT06988631|OTHER|foot care booklet|Participants were given a booklet about healthy feet and were informed.
224191480|NCT03672565|BEHAVIORAL|Phase One: Standardized Brief Intensive ERP|Participants will be randomized to receive ERP sessions at the hospital or at relevant community locations. In the introductory session, participants will be provided with psychoeducation about OCD and the treatment model, will develop a list of potential exposures, and will attempt initial exposure and response prevention (ERP) exercises. The session will end with an assignment of ERP homework. In the seven days following the introductory session, youth and parents will receive two 3-hour sessions, separated by a three day break. The sessions will begin with a brief review of homework completion and success. Following this, with parent observation, the clinician will guide the youth through escalating ERP exercises. The session will end with ERP homework planning. Other evidence-based treatment strategies (e.g., addressing motivation, discussing parental accommodations) may be implemented as deemed necessary by the clinician in order to encourage effective engagement in ERP exercises.
224191481|NCT03672565|BEHAVIORAL|Phase Two: Flexible Patient Driven Intensive ERP|"Families will have the opportunity to access up to four additional once/week 3-hour intensive ERP sessions.~Three days prior to each additional ERP session (sessions 3-6), families will be prompted to fill out online forms and decide how to proceed with treatment for that week with the following options:~* They may select that they would like to receive and complete the next ERP session, and up to four 3-hour ERP sessions during Phase Two. Completion of all four ERP session will automatically end Phase Two.~* They may opt to delay receiving a treatment session by one week for any reason. Families will be allowed to take a week off up to two times during Phase Two. If both weeks off are utilized, at the next decision point families must either opt to complete an ERP Session or end their participation in Phase Two.~* They may select to end their participation in Phase Two at any decision point and for any reason (e.g., don't perceive it as helpful, have improved substantially)."
224191482|NCT03672565|BEHAVIORAL|Follow-Up Phase: Booster Calls|Upon achieving remission at any remission assessment or completion of remission assessment five, youth will enter the follow-up phase. Youth will receive three weekly 30 minute post-treatment booster phone calls. Calls will focus on homework completion, ERP planning, and relapse prevention skills.
224191483|NCT03781050|DRUG|Rapamycin|"For children: rapamycin, 1 mg per square meter of body surface area a day, orally, for at least 6 months~For adults: rapamycin, 2 mg a day, orally, for at least 6 months"
224191484|NCT01379911|OTHER|Yogurt|
223500831|NCT01004393|DRUG|Methylnaltrexone bromide|Methylnaltrexone bromide, dosage based on weight (0.15 mg/kg (round dose up to nearest 0.1 mL of volume) for weight less than 38 kg or greater than 114 kg; 8 mg (0.4 mL) for weight 38 kg to less than 62 kg; and 12 mg (0.6 mL) for weight 62 kg to 114 kg), single dose
223746261|NCT06914687|DRUG|Docetaxel|Docetaxel at a dose of 20 mg/m2 or paclitaxel at a dose of 40 mg/m2 dissolved in 3-5 L of normal saline heated to 43 ± 0.5 °C for HIPEC.(d01-d03,qd,before first cycle of Tislelizumab and SOX)
223746262|NCT06914687|DRUG|Paclitaxel|Paclitaxel at a dose of 40 mg/m2 or docetaxel at a dose of 20 mg/m2 dissolved in 3-5 L of normal saline heated to 43 ± 0.5 °C for HIPEC.(d01-d03,qd,before first cycle of Tislelizumab and SOX)
223500832|NCT02116062|DEVICE|1. Amniotic membrane transplantation on the cornea with the Da Vinci Si HD© robot (Inlay or overlay technique)|
223500833|NCT02116062|DEVICE|Pterygium removal and autograft of the conjunctiva with the Da Vinci Si HD© robot (Kenyon technique)|
223500834|NCT02116062|DEVICE|Penetrating keratoplasty using Baron trephine and nylon stitches with the Da Vinci Si HD© robot|
223500835|NCT03281538|DRUG|CR845|IV CR845 0.5 mcg/kg administered after each dialysis session (3 times/week)
224191485|NCT05850637|RADIATION|adjuvant ultra-hypofractionated radiotherapy|adjuvant ultra-hypofractionated radiotherapy for the treatment of early and locally advanced breast cancer
224191486|NCT00038428|DRUG|TLK286|
224191487|NCT05926687|BEHAVIORAL|Social Communication|Intervention: Social Communication Who: Parent \& Child \& Therapist Frequency: 1-hour twice/week
224191488|NCT05926687|BEHAVIORAL|Disruptive Behavior|Intervention: Disruptive Behavior Who: Parent \& Therapist only Frequency: 1-hour once/week
224191489|NCT05926687|BEHAVIORAL|Social Communication + Reduce Frequency|Intervention: Social Communication Who: Parent \& Child \& Therapist Frequency: 1-hour once/week
224191490|NCT05926687|BEHAVIORAL|Social Communication + Add Tools|Intervention: Social Communication Who: Parent \& Child \& Therapist Frequency: 1-hour twice/week
224191491|NCT05926687|BEHAVIORAL|Disruptive Behavior + Reduce Frequency|Intervention: Disruptive Behavior Who: Parent \& Therapist only Frequency: 1-hour every other week
224191492|NCT05926687|BEHAVIORAL|Disruptive Behavior + Add Tools|Intervention: Disruptive Behavior Who: Parent \& Therapist only Frequency: 1-hour once/week
224191493|NCT01694849|DRUG|GFT505 80mg|
224191494|NCT01694849|DRUG|GFT505 120mg|
224191495|NCT01694849|DRUG|Placebo|
224191496|NCT00528294|RADIATION|GRID radiotherapy|GRID-radiotherapy followed by biological imaging guided IMRT
224191497|NCT03222180|BEHAVIORAL|Website|Participants in the Website condition will be provided with password-protected access to the online resource created for this trial that provides a variety of information, support and guidance that could permit them to adapt more effectively to the demands of parenting a very young child with type 1 diabetes.
224191498|NCT06465394|PROCEDURE|Exercise|Neck exercises in a cross over design that the participants will do both types of interventions with a washout period inbetween.
224191499|NCT04806178|BIOLOGICAL|Bacillus Calmette Guerin|0.1 ml of lyophilized, live, and attenuated BCG intradermal vaccine, containing between 2 and 8 x 1.000.000 C.F.U in a single dose.
224191500|NCT04806178|OTHER|PLACEBO|0.1 ml 0.9% saline in the same volume as the BCG vaccine in a single dose.
224191501|NCT00241566|DEVICE|implantation of stimulator|
224191502|NCT00942669|DEVICE|SleepStrip OTC(TM)|self contained SAS screening device
224191503|NCT00126321|DRUG|cladribine|2-chlorodeoxyadenosine, 2-CdA
224191504|NCT01629121|BEHAVIORAL|education intervention|"The brain injury prevention education intervention included case scenarios as well as education about the benefits of bicycle helmet use. The intervention was designed to be sensitive to the age and educational level of the study participant and his or her parents. Educational materials were chosen to provide use of the five senses to enhance the learning experience. The intervention took place in the privacy of the patient's hospital room. The study was designed so as not to interfere with the hospital standard of care.~The proper way to fit the bicycle helmet was demonstrated."
224309723|NCT06990308|PROCEDURE|Inflated Cuff Extubation|The adjustable pressure limiting valve will be set to 20 centimeters water pressure. To blind the Anesthesiologist Associate Investigator from the patient's group allocation, sham deflation of the endotracheal tube cuff pilot balloon will be performed with a 10 milliliter syringe. The endotracheal tube will be withdrawn into an opaque blue towel while the reservoir bag is simultaneously compressed to generate at least 20 centimeters water pressure positive airway pressure. In the rare event significant resistance is met with attempted extubation, the principal investigator will deflate the cuff in one milliliter increments until extubation is possible. This process does not unblind the Anesthesiologist Associate Investigator.
223500836|NCT01691742|DRUG|MiraLax|MiraLax 17g powder daily for 5 days postoperatively following urogynecologic surgery
223500837|NCT01691742|DRUG|Placebo|Placebo maltodextrin 17g powder daily for 5 days postoperatively following urogynecologic surgery
223500838|NCT01691742|DRUG|Rescue Laxative|All participants will be instructed to take Milk of Magnesia with standard over-the-counter dosing as a recue laxative if the subject has not had a bowel movement by postoperative day 6.
223500839|NCT04000711|OTHER|Outpatient oral treatment.|Participants allocated in oral outpatient group were discharged home with oral antibiotic to continue management. Participants were given Cefixime oral suspension (100 mg/5 mL). Antibiotic was given to the caretakers with written instructions about dosage and time of administration. Dosage indicated was 8 mg/kg/day to be given orally as a single dose (max dose 400 mg/day). Oral antibiotic treatment was given until documented ANC \> 500, failure to treatment (restart of fever) or when 14 days of antibiotic were completed (whichever occurred first).
223500840|NCT04000711|OTHER|Inpatient intravenous treatment.|Participants allocated in the intravenous inpatient group continued receiving Cefepime 150 mg/kg/day every 8 hours (max dose 2 grams per dose or 6 grams per day) according to local standard of care guidelines. Intravenous antibiotic treatment was given until documented ANC \> 500, failure to treatment (restart of fever) or when 14 days of antibiotic were completed (whichever occurred first).
223500841|NCT02105142|BEHAVIORAL|ADHD Group Visits|Parents and children attend separate but concurrently run group visits every three months; groups are facilitated by general pediatricians
223746263|NCT06600321|DRUG|ALN-BCAT|Administered by intravenous (IV) infusion
223746264|NCT06600321|DRUG|Pembrolizumab|Administered by intravenous (IV) infusion
223746265|NCT06914427|DIAGNOSTIC_TEST|PET/CT|Scanning time: acquisition starts 60±10 minutes after 68Ga/18F probe injection; 10-20 minutes after 11C-MET injection; 60 minutes after 11C-CFT injection; Scanning parameters: whole-body imaging (cranial vault to mid-thigh), routine single-nuclide 3 min/bed; dual-nuclide 5-10 min/bed.
223746266|NCT06911385|DEVICE|Arm Remote Ischemic Conditioning plus Pneumatic Compression lower limb|Arm Remote Ischemic Conditioning (4 cycles) plus Pneumatic Compression lower limb (100 mmHg for 1 hour)
223746267|NCT07112872|DRUG|RO7795081|RO7795081 will be taken orally once daily (QD), according to the randomized dosing regimen, during the 30-week treatment period.
224191505|NCT03334604|DIETARY_SUPPLEMENT|Multispecies probiotic|Multispecies probiotic consisting of Bifidobacterium bifidum W23, Bifidobacterium lactis W51, Lactobacillus acidophilus W37, Lactobacillus acidophilus W55, Lactobacillus paracasei W20, Lactobacillus plantarum W62, Lactobacillus rhamnosus W71 and Lactobacillus salivarius W24 at a dose of 5x10\^9 Colony Forming Units (CFU), twice daily, orally.
224191506|NCT03334604|OTHER|Placebo|Placebo identical in taste, smell and color to the multispecies probiotic.
224309724|NCT06990308|PROCEDURE|Deflated Cuff Extubation|The adjustable pressure-limiting valve will be set to 20 centimeters water pressure. All air will be removed from the endotracheal tube cuff pilot balloon with a 10 milliliter syringe. The endotracheal tube will be withdrawn into an opaque blue towel, to prevent the Anesthesiologist Associate Investigator from identifying the patient's allocation, while the reservoir bag is simultaneously compressed to generate at least 20 centimeters water pressure positive airway pressure.
224309725|NCT06990945|DEVICE|Hi-Bond Universal Adhesive|"A bioactive glass adhesive containing mesoporous bioactive glass designed to promote dentin remineralization, manufactured by Mediclus, Korea. It releases calcium and phosphate ions to enhance dentin sealing and reduce hypersensitivity~The adhesive will be applied after selective caries removal following a standardized protocol:~Selective enamel etching with 37% phosphoric acid for 15 seconds.~Application of HI Bond Universal adhesive with agitation for 20 seconds.~Light curing for 20 seconds using a LED curing device.~Incremental application of a nano-hybrid composite (Optishade Universal Kerr Dental, USA).~Occlusal adjustment, finishing, and polishing."
224191507|NCT01269138|DRUG|plasma derived Factor VII|Treatment of bleeding episodes,treatment during surgery and prophylaxis
224191508|NCT01269138|DRUG|recombinant FVIIa|Treatment of bleeding episodes,treatment during surgery and prophylaxis
224191509|NCT01269138|DRUG|Fresh Frozen Plasma|Treatment of bleeding episodes,treatment during surgery and prophylaxis
224191510|NCT01269138|DRUG|Activated Prothrombin Complex Concentrates|Treatment of bleeding episodes,treatment during surgery and prophylaxis
224191511|NCT01269138|DRUG|Virus Inactivated plasma|Treatment of bleeding episodes,treatment during surgery and prophylaxis
224191512|NCT00003695|DRUG|chemotherapy|
224191513|NCT00003695|PROCEDURE|surgical procedure|
224191514|NCT01439308|DRUG|Placebo|SB-705498 placebo
224191515|NCT01439308|DRUG|SB-705498|12mg intranasal SB-705498
224191516|NCT02688881|DRUG|sirolimus|Rapamune
224191517|NCT05674461|OTHER|WhatsApp Group|Each of the women will be informed about the purpose and content of the study at the first meeting, and informed consent will be obtained from the women who meet the conditions for participation and agree to participate. The pre-test data in the research will be obtained with the Participant Identification Form and WHOQOL-BREF-TR Trainings will be sent to the women in the WhatsApp experimental group in the form of videos via the WhatsApp application. The videos will be prepared with the researchers' own voice and image. Each training video will be sent for 15-30 minutes (in the form of short videos, if necessary, divided into parts). At the end of the 2nd and 6th months, the final test data will be obtained by completing the Participant Identification Form and WHOQOL-BREF-TR
224191518|NCT05674461|OTHER|Face-to-face Group|Each of the women will be informed about the purpose and content of the study at the first meeting, and informed consent will be obtained from the women who meet the conditions for participation and agree to participate. The pre-test data in the research will be obtained with the Participant Identification Form and WHOQOL-BREF-TR The trainings will be given to the women in the experimental group face-to-face by the researchers in the form of 15-30 minutes of training in their own home environment. At the end of the 2nd and 6th months, the final test data will be obtained by completing the Participant Identification Form and WHOQOL-BREF-TR
224309726|NCT06990945|DEVICE|OptiBond Universal Adhesive|"conventional universal adhesive designed for bonding composite restorations to enamel and dentin.~The adhesive will be applied after selective caries removal following a standardized protocol:~Selective enamel etching with 37% phosphoric acid for 15 seconds.~Application of OptiBond Universal adhesive with agitation for 20 seconds.~Light curing for 20 seconds using a LED curing device.~Incremental application of a nano-hybrid composite (Optishade Universal Kerr Dental, USA).~Occlusal adjustment, finishing, and polishing."
223746268|NCT07112872|DRUG|Semaglutide|Semaglutide 14 mg will be taken orally QD, with up-titration as per label, during the 30-week treatment period.
224191519|NCT05674461|OTHER|Control Group|Each of the women will be informed about the purpose and content of the study at the first meeting, and informed consent will be obtained from the women who meet the conditions for participation and agree to participate. The pre-test data in the research will be obtained with the Participant Identification Form and WHOQOL-BREF-TR No intervention will be applied to the mothers in the control group. The end of the 2nd and 6th months, the final test data will be obtained by completing the Participant Identification Form and WHOQOL-BREF-TR
224191520|NCT01734070|OTHER|Cherry consumption|Volunteers will eat 280 grams/day of pitted Bing cherries by replacing an equivalent amount of carbohydrate calories.
224191521|NCT00918489|DRUG|Vorinostat|Daily administration of 400mg vorinostat on 28 days (one therapy cycle). Seven days of therapy break between two consecutive cycles.
224191522|NCT00712608|OTHER|Infant formula|Marketed cow's milk base infant formula 20 kcal/oz
224191523|NCT00712608|OTHER|Infant formula|cow's milk based infant formula with prebiotics, different level of fatty acids and fat and a different calcium source
224191524|NCT00712608|OTHER|Cow's milk infant formula|Cow's milk based formula with prebiotics, different level of fatty acids and fat and a different calcium source
224191525|NCT02144311|PROCEDURE|PET/CT Scan|
224191526|NCT02144311|PROCEDURE|MRI|
224191527|NCT05908474|DIETARY_SUPPLEMENT|Enriched fibre water|Blend of scientifically substantiated ingredients has been demonstrated to contribute to the reduction of body weight and aid the sustainability of weight loss by providing a healthy, hunger-free weight management system. iofibrewater, makes fibre and gut health simple and refreshing. Each 500 ml bottle of ió fibrewater provides 20%\* of your recommended daily fibre intake and 100%\* of your daily prebiotic fibre intake with minimal calories and carbohydrates, making us suitable for people on a variety of diets. ió fibrewater is a functional water infused with prebiotic fibre (aka prebiotics), which leads to sub-optimal gut health and often the onset of digestive disorders. By adding more prebiotic fibre to our diet, we can quickly change the environment in our gut for the better healthy living.
223746269|NCT07112872|DRUG|Placebo|Placebo will be taken orally QD during the 30-week treatment period.
223746270|NCT06913348|PROCEDURE|Popliteal sciatic nerve block|Procedure/Surgery: Patients will receive either an ultrasound-guided sciatic popliteal nerve block or an ultrasound-guided erector spinae plane block for anesthesia during endovascular management of critical lower limb ischemia.
223746271|NCT06913218|BIOLOGICAL|AK154|AK154 is neotigeon personalized mRNA vaccine
223746272|NCT06913218|BIOLOGICAL|Cadonilimab|a PD-1/CTLA-4 bispecific antibody
223746273|NCT06913218|BIOLOGICAL|Ivonescimab (SMT112 or AK112) Injection|a PD-1/VEGF bi-specific antibody
223746274|NCT06913218|DRUG|mFOLFORINOX|mFOLFIRINOX:Fluorouracil+leucovorin+Irinotecan+Oxaliplatin
224074642|NCT03326141|DEVICE|Physical activity monitors (e.g., Fitbit)|We will use Fitbit Charge 2 (or an equivalent). Features essential for this research include built-in accelerometers that accurately measure steps and physical activity (PA) duration.Participants will have a brief orientation to these during baseline data collection and have the opportunity to return demonstrate. In addition, RAs will be available to help participants troubleshoot, as needed, via telephone and in person, after intervention meetings. Intervention meetings include discussions about the PAMs, but topics vary according to assigned study condition.
224191528|NCT03321773|DRUG|triple therapy plus bismuth therapy|pantoprazole 40mg twice daily for 14 days, amoxicillin 1g twice daily for 14 days, clarithromycin 500mg twice daily for 14 days, bismuth subcitrate 240mg twice daily for 14 days.
224191529|NCT03321773|DRUG|reverse hybrid therapy|(pantoprazole 40mg twice daily for 7 days, amoxicillin 1 g twice dailyfor 7 days, clarithromycin 500 mg twice daily for 7 days, and metronidazole 500 mg twice daily for 7 days) followed by (pantoprazole 40mg twice daily for 7 days and amoxicillin 1 g twice daily for 7 days)
224191530|NCT02223520|DRUG|Mupirocin and Chlorhexidine|
224191531|NCT02223520|DRUG|Placebo ointment and placebo cloths|
224191532|NCT02489682|OTHER|Long-form written Informed consent information|
224191533|NCT02489682|OTHER|Short-form written Informed consent information|
224191534|NCT02489682|OTHER|Video Informed consent information|
224191535|NCT02707562|DRUG|GLPG1837 dose 1|two GLPG1837 tablets in the morning and two GLPG1837 tablets in the evening, for one week
224191536|NCT02707562|DRUG|GLPG1837 dose 2|two GLPG1837 tablets in the morning and two GLPG1837 tablets in the evening, for one week
224191537|NCT02707562|DRUG|GLPG1837 dose 3|two GLPG1837 tablets in the morning and two GLPG1837 tablets in the evening, for two weeks
223500842|NCT02105142|BEHAVIORAL|ADHD Group Visits plus Online Discussion Portal|Parents and children attend separate but concurrently run group visits every three months; groups are facilitated by general pediatricians. Parent participants will be granted access to the online discussion portal to allow for communication in between in-person group visits.
223500843|NCT02105142|BEHAVIORAL|Computer Decision Support|ADHD Module of the Child Health Improvement through Computer Automation (CHICA) system Designed to facilitate physician adherence to clinical care guidelines for ADHD identification and chronic care management
223500844|NCT04031768|OTHER|Timing of rest prior to blood pressure measurement|Each participant will have 4 sets of 3 blood pressure measurements taken. The participants will be randomized to the order in which they rest prior to each set of measurements.
223500845|NCT06262373|DIAGNOSTIC_TEST|Ultrasound|Ultrasound based observational study
223500846|NCT03723239|DEVICE|TricValve® System|The TricValve® Delivery System is inserted from the femoral vein to access the inferior vena cava (IVC) and superior vena cava (SVC) of the heart under fluoroscopy guidance. The appropriately sized TricValve® is unsheathed at the implantation site and positions itself as per the anatomy - self expanding frame.
223500847|NCT03921437|RADIATION|decision support intervention|CKD Guardian is the decision-maker and uses the e-book software to develop medical decision-assist tools, and applies this tool and decision-directed mode to introduce and select. The implementation steps include team discussion, option discussion and decision-making. The group is introduced with traditional care instructions for routine care.
223500848|NCT02420574|DRUG|albendazole BENDEX|randomized clinical trial with 2 parallel arms
223500849|NCT02420574|DRUG|albendazole OVIS|
223500850|NCT04553094|OTHER|Endurance training|Aerobic circuit training
223500851|NCT04553094|OTHER|Muscle building training|Muscle strengthening circuit training
223500852|NCT04999020|DRUG|Ravulizumab|Intravenous dosing will consist of a loading dose followed by maintenance doses administered every 8 weeks (q8w). The maintenance dosing will be initiated 2 weeks after the loading dose is administered.
223500853|NCT04999020|DRUG|Placebo|Intravenous dosing will consist of a loading dose followed by maintenance doses administered q8w. The maintenance dosing will be initiated 2 weeks after the loading dose is administered.
223500854|NCT01865773|PROCEDURE|HFR dialysis|HFR is a dialysis technique that combines the processes of diffusion, convection and adsorption. In this double chamber hemodiafiltration system, the ultrafiltrate is reinfused after its passage (and opportune modification) through a resin cartridge.
223500855|NCT04664296|OTHER|Review of medical patient file|Review of medical patient file, including patient tracing, brief summary of the disease course, barrier gestures, social distancing.
223500856|NCT04664296|OTHER|Phone call interview|less than 15 minutes phone call
223500857|NCT01635140|RADIATION|Hypofractionated radiotherapy|A total dose of 39 Gy in daily fractions of 3 Gy, 5 Fractions per week
223500858|NCT01635140|RADIATION|Conventional arm|A total dose of 54 Gy in 30 fractions giving 1.8 Gy per fraction.
223500859|NCT04530123|DRUG|Placebo|TAK-101 placebo-matching intravenous infusion
223500860|NCT04530123|DRUG|TAK-101|TAK 101 intravenous infusion
223500861|NCT04530123|DIETARY_SUPPLEMENT|Gluten|Powder form (vital wheat gluten)
223500862|NCT03608969|OTHER|NOT-S|Participants are assessed for the orofacial function using the Nordic Orofacial test- screening (NOT-S), Gross Motor Function Classification System (GMFCS), Manual Ability Classification System (MACS) and Communication Function Scale (CFS). Oral health related quality of life is assessed using the Parental- Caregiver Perceptions Questionnaire (P-CPQ). Caries experience was measured by identifying decayed, missing, and filled teeth for deciduous and permanent teeth (dmft). Gingival index and type of occlusion will be recorded.
223500863|NCT03279315|DIETARY_SUPPLEMENT|iodized table salt, non-iodized table salt|During the first 3 weeks, the diet was provided with non-iodized salt, while the diet with iodized salt was only offered in the last week.
223500864|NCT03359083|OTHER|Correlation|Correlation between assesment parameters
224191538|NCT01959282|DRUG|Placebo|Participants will receive placebo once daily
224191539|NCT01959282|DRUG|JNJ-54781532 25 mg once daily|Participants will receive 25 mg of JNJ-54781532 once daily
224191540|NCT01959282|DRUG|JNJ-54781532 75 mg once daily|Participants will receive 75 mg of JNJ-54781532 once daily
224191541|NCT01959282|DRUG|JNJ-54781532 150 mg once daily|Participants will receive 150 mg of JNJ-54781532 once daily
224191542|NCT01959282|DRUG|JNJ-54781532 75 mg twice daily|Participants will receive 75 mg of JNJ-54781532 twice daily
224191543|NCT03279120|DRUG|TFV/LNG IVR|Used for 90 days (Continuous or Interrupted)
224191544|NCT03279120|DRUG|Placebo|Used for 90 days (Continuous or Interrupted)
223500865|NCT04640402|BIOLOGICAL|Low-dose Recombinant COVID-19 vaccine (Sf9 cells) (18-59 years) & Two dose regimen|18-59 years group, two doses of low-dose (20µg/0.5ml) Recombinant COVID-19 vaccine (Sf9 cells) at the schedule of day 0, 21.
223500866|NCT04640402|BIOLOGICAL|Low-dose Recombinant COVID-19 vaccine (Sf9 cells) (18-59 years) & Three dose regimen|18-59 years group, three doses of low-dose (20µg/0.5ml) Recombinant COVID-19 vaccine (Sf9 cells) at the schedule of day 0, 14, 28.
223500867|NCT04640402|BIOLOGICAL|High-dose Recombinant COVID-19 vaccine (Sf9 cells) (18-59 years) & Two dose regimen|18-59 years group, two doses of high-dose (40µg/1.0ml) Recombinant COVID-19 vaccine (Sf9 cells) at the schedule of day 0, 21.
223591608|NCT03464019|DRUG|Etripamil Test Dose|During the Test Dose, etripamil administered via the Aptar Pharma Nasal Spray Bidose System, supplied as prefilled devices packaged into child-resistant boxes with instructions for use provided in the study drug box.
223591609|NCT04371939|DRUG|Romiplostim|"Participants will receive romiplostim at an initial dose of 9 µg/kg subcutaneously per week for at least 1 month depending on their response to study drug.~Patients failing to achieve a complete platelet response cross over to arm II."
223591610|NCT04371939|DRUG|Eltrombopag|"Participants will receive eltrombopag at a dose of 2-3mg/kg daily (ages 0 to 5 years) and 75 mg/daily (\>6 years) for at least 1 month depending on their response to study drug.~Patients failing to achieve a complete platelet response switch to arm I."
223591611|NCT05099666|DRUG|Lurbinectedin|Dosage per protocol, escalation per protocol, IV over 60 minutes (± 5 minute infusion window), schedule per protocol
224191545|NCT01343238|BEHAVIORAL|Diet|12 week diet behavior modification
224191546|NCT01343238|BEHAVIORAL|Exercise|12 week exercise behavioral intervention
224191547|NCT01343238|BEHAVIORAL|Diet and Exercise|12 week diet and exercise behavioral modification intervention
224191548|NCT00138723|DRUG|SPM 907|
224191549|NCT00937430|OTHER|Bowel preparation (Fleets enema)|Use of Bowel preparation (Fleets enema)
224191550|NCT06117163|BEHAVIORAL|Collaborative Care Model|"The investigators propose a CCM called Tunawiri, meaning thrive in Kiswahili, that will be integrated within an existing multidisciplinary team of clinicians, mentor mothers, and other clinic staff in Kenyan antenatal care clinics. CCM includes: 1) clinic-level sensitization and integration, 2) Screening for CMD including anxiety, depression, and trauma symptoms, 3) Problem-solving type cognitive behavioral therapy delivered by lay health workers, 4) Decision Support and monitoring via an Electronic Health Registry, and 5) Psychiatrist case review and nurse-managed mental health medication."
224191551|NCT02304484|BIOLOGICAL|Evolocumab|Administered by subcutaneous injection once a month
224191552|NCT03801070|PROCEDURE|endoscopic drainage of walled off pancreatic necrosis|transmural drainage and mechanical debridement of solid debris (necrosectomy)
224191553|NCT04435652|DRUG|QL1604|3mg/kg, D1,8,15,Q4w, IV infusion
224191554|NCT04435652|DRUG|Nab-paclitaxel|100mg/m2, D1,8,15,Q4w, IV infusion
224191555|NCT04435652|DRUG|Paclitaxel|80mg/m2, D1,8,15,Q4w, IV infusion
224191556|NCT04338685|DRUG|RO7119929|RO7119929 will be administered orally as a capsule
224191557|NCT04338685|DRUG|Tocilizumab|"Tocilizumab will be administered in case of severe steroid-refractory cytokine release syndrome.~Tocilizumab will be administered as concentrate for solution for IV infusion at a dose: for participants \> 30 kg: 8 mg/kg, for participants \< 30 kg: 12mg/kg IV"
224191558|NCT01143129|DRUG|Dexamethasone|Single dose (1 mg/kg) at start of cardiac surgical procedure
224191559|NCT01143129|DRUG|Placebo|Placebo solution in a comparable amount to the experimental drug (0.05 mL/kg)
224191560|NCT03389217|DEVICE|Real-tDCS + rehabilitation programme|tDCS stimulation will be delivered using a constant current stimulator, with rechargeable batteries. The active electrode will be placed on the left dorsolateral prefrontal cortex (DLPFC) and the reference electrode will be placed over the controlateral supraorbital region. The direct current will be delivered through a pair of sponge electrodes with a surface of 35 cm2 (7 × 5), soaked in saline solution. This continuous stimulation will last 30 minutes, with an intensity of 1 mA. Rehabilitation programme will last for 30 minutes and includes specific exercises for prevention and management of pain. All the subjects enrolled will receive treatments for 4 weeks. During the first week the experimental group underwent tDCS daily (Monday-Friday) and rehabilitation programme 3 days per week. tDCS will be delivered before rehabilitation treatment. During the second, third and fourth week subjects will receive only rehabilitation treatment, 3 days per week.
224191561|NCT03389217|DEVICE|Sham-tDCS + rehabilitation programme|The control group will receive the same protocol treatment but they underwent sham-tDCS during the first week of treatment. For sham condition tDCS, current was delivered for only 30 seconds and then the current was discontinued, but the tDCS apparatus was left in place for the same time as active tDCS (30 minutes)
224191562|NCT04213690|OTHER|No Intervention|There is no intervention for this study
223500868|NCT04640402|BIOLOGICAL|High-dose Recombinant COVID-19 vaccine (Sf9 cells) (18-59 years) & Three dose regimen|18-59 years group, three doses of high-dose (40µg/1.0ml) Recombinant COVID-19 vaccine (Sf9 cells) at the schedule of day 0, 14, 28.
223500869|NCT04640402|BIOLOGICAL|Low-dose Recombinant COVID-19 vaccine (Sf9 cells) (60-85 years) & Two dose regimen|60-85 years group, two doses of low-dose (20µg/0.5ml) Recombinant COVID-19 vaccine (Sf9 cells) at the schedule of day 0, 21.
224191563|NCT00012350|DRUG|FTI|
224191564|NCT00145795|DRUG|Kaletra + Current Dual NRTI Backbone|
224191565|NCT00145795|DRUG|Current Regimen|
224191566|NCT00570492|DRUG|Fluticasone furoate nasal spray|Fluticasone furoate nasal spray 110mg QD
224191567|NCT00570492|DRUG|Placebo nasal spray|Placebo nasal spray
224309727|NCT06989125|BEHAVIORAL|Internet-based cognitive behavioral therapy|"The internet-based CBT treatment arm is delivered via the online treatment platform SpilleFri and consists of nine internet-delivered modules delivered over 10-12 weeks. Modules contain written assignments and multiple-choice lists, combined with psychoeducation delivered in text, illustrations, and videos. The treatment is assisted by a therapist. The therapist contact is primarily written and takes place in an embedded secured message system on the platform. Participants can use the written message function whenever they want, and the therapist will respond on a specific day each week. Further, participants are offered up to three sessions of face-to-face or video-based therapist support during the treatment, depending on their preference.~Treatment is regarded as completed if the participant has worked actively (logged in to the module and filled in at least one interactive exercise) in the first 6 modules of the treatment program."
224309728|NCT06989125|BEHAVIORAL|Synchronous cognitive behavioral therapy|In the sCBT condition, participants receive 9 individual sessions spread over 14-20 weeks, in a 1 to 1 format with a therapist, delivered either face-to-face or via video connection, depending on the participant's preference (there may be a mix). Treatment sessions take place weekly at the start of the course. After week 4, the aim is to have sessions at least every other week to maintain continuity in treatment. Further, participants are offered up to three additional sessions that can be included on request of participant or when therapists deem it necessary. Treatment is regarded as completed if the participant has attended 6 sessions of the treatment program.
224309729|NCT06989034|OTHER|Child Sensory Profile 2 (SP2) for Sensory processing abilities|Sensory processing abilities are evaluated using the Child Sensory Profile 2 (SP2), an 86-item caregiver questionnaire assessing six sensory systems (auditory, visual, touch, movement, body position, and oral) and three behavioral domains (conduct, social-emotional, and attentional).
224309730|NCT06989034|OTHER|HUMAC Balance System for Postural stability evaluation|"Postural stability is assessed using the HUMAC Balance System, incorporating tests such as:~* The Modified Clinical Test of Sensory Integration of Balance (mCTSIB)~* Limits of Stability (LOS) at difficulty levels 4 and 6~* Center of Pressure (COP) metrics"
224309731|NCT06989034|OTHER|Selective Motor Control Evaluation for the upper and lower extremities|"Selective voluntary motor control is evaluated using the following tools:~* Test of Arm Selective Control (TASC) for the upper extremities~* Selective Control Assessment of the Lower Extremity (SCALE) for the lower extremities"
224309732|NCT06990334|GENETIC|Whole genome sequencing analysis|RNAseq
224074643|NCT03326141|BEHAVIORAL|Interpersonal Behavior Change Strategies|The interpersonal content will include facilitated discussed about including PA into social routines, identifying and problem-solving social and environmental barriers to PA, social support for exercise, and friendly social comparisons about practicing PA outside the small group setting and interpreting/ sharing data.
224074644|NCT03326141|BEHAVIORAL|Intrapersonal Behavior Change Strategies|The intrapersonal content will include encouragement and guidance to identify baseline PA patterns, develop and refine personally meaningful goals and plans, identify and problem solve personal barriers to staying physically active, integrate PA into personal routines, and monitor goal outcomes
224074645|NCT03326141|OTHER|Information about Health and Wellness|Information about health and wellness varies in dose, according to time spent in each condition that addresses behavior change. Topics in condition 1 include sleep, vaccinations, supplements, fall risk factors, memory, hearing and pain guided by information for older adults available on the NIA and CDC websites. Topics in conditions 2 and 3 include fall risk factors and sleep. Topics in condition 4 include fall risk factors.
223500870|NCT04640402|BIOLOGICAL|Low-dose Recombinant COVID-19 vaccine (Sf9 cells) (60-85 years) & Three dose regimen|60-85 years group, three doses of low-dose (20µg/0.5ml) Recombinant COVID-19 vaccine (Sf9 cells) at the schedule of day 0, 14, 28.
223500871|NCT04640402|BIOLOGICAL|High-dose Recombinant COVID-19 vaccine (Sf9 cells) (60-85 years) & Two dose regimen|60-85 years group, two doses of high-dose (40µg/1.0ml) Recombinant COVID-19 vaccine (Sf9 cells) at the schedule of day 0, 21.
224074646|NCT01679041|DRUG|Alemtuzumab|Alemtuzumab 10 mg given IV on day 1 of the 5 day conditional regimen
224074647|NCT01679041|DRUG|Fludarabine|Fludarabine 25mg/m2 daily given IV on days 1-5 of the 5 day conditioning regimen
224074648|NCT01679041|DRUG|Cyclophosphamide|Cyclophosphamide is given 3 gm/m2 for mobilization, and then repeated during 5 day conditioning regimen w/ doses of 50mg/kg/day on days 1-4
224074649|NCT03489798|PROCEDURE|6 misoprostol|Up to 6 doses of 25ug of misoprostol applied every 6 hours. End point is cervical Bishop score \> 6.
224074650|NCT03489798|PROCEDURE|3 misoprostol|Up to 3 doses of 25ug of misoprostol applied every 6 hours. End point is cervical Bishop score \> 6.
224074651|NCT03607760|DEVICE|ECMO|the patients with severe respiratory failure were supported by ECMO
224074652|NCT03607760|DEVICE|conventional mechanical ventilation|the patients with severe respiratory failure were supported by conventional mechanical ventilation
224074653|NCT03452566|DRUG|Ingenol mebutate gel|3+3 phase 1 design as described above. After the maximum tolerated dose is defined, the phase 2 segment of the study will take place. Simon's Phase 2 study design tool was used, reinforced by Jung's admissible study designs for phase 2 clinical trials. Considering the margin of error of 0.05 and study power of 80%, and estimating the probability of placebo partial response of 15% and partial response to ingenol mebutate in 45%, the optimized number of patients to be recruited is 19. Six patients will be seen in the first stage of this segment of the study, and if only one patient or none has a partial response, the study will be promptly discontinued. Otherwise, the second and final stage of segment of the study will include an additional thirteen patients who will be treated.
224074654|NCT00731172|DRUG|glatiramer acetate|20 mg daily subcutaneous injection through week 12
224074655|NCT00731172|DRUG|placebo|subcutaneous daiky injection through week 12
224074656|NCT06319105|OTHER|Standard intervention: Offer PrEP choice|This hybrid observational-implementation study will observe the implementation of a choice of oral pre-exposure prophylaxis or long-acting injectable cabotegravir for pre-exposure prophylaxis for all participants.
223591612|NCT05099666|DRUG|Doxorubicin|Dosage per protocol, IV per institutional standards of practice and the FDA package insert, schedule per protocol
223591613|NCT02392455|DRUG|treatment|Docetaxel plus nintedanib until progression or intolerability
223591614|NCT06087198|DIAGNOSTIC_TEST|T-TAS 01 HD Assay|Disposable flow chamber microchip containing thrombogenic path to facilitate thrombus formation and occlusion
223591615|NCT06799013|BIOLOGICAL|10 ug HDT 321|HDT-321 Investigational Vaccine (a Nanoparticle Carrier-Formulated self-amplifying RNA encoding the NP of CCHFV)
223591616|NCT06799013|BIOLOGICAL|25ug HDT-321|HDT-321 Investigational Vaccine (a Nanoparticle Carrier-Formulated self-amplifying RNA encoding the NP of CCHFV)
223591617|NCT06799013|BIOLOGICAL|50ug HDT-321|HDT-321 Investigational Vaccine (a Nanoparticle Carrier-Formulated self-amplifying RNA encoding the NP of CCHFV)
223591618|NCT06211738|OTHER|no intervention|no intervention
223591619|NCT04927897|DIAGNOSTIC_TEST|Ultrasound|3D endorectal ultrasound.
223591620|NCT04927897|DIAGNOSTIC_TEST|Rectoscopy|Rigid rectoscopy.
223591621|NCT04927897|OTHER|Scan, e.g. CT (resection specimen)|For some patients, images of the resection specimen (note: NOT of the patients) during the pathological process will be acquired.
223591622|NCT03291990|DRUG|Temozolomide|5 fraction hypofractionated stereotactic radiosurgery along with standard temozolomide
223591623|NCT06095609|OTHER|Early mobilization plus chest physiotherapy|"Early mobilization:early mobilization has been confirmed its positive effectiveness on cutting down the MV use days and mortality rate, attenuating the side effect such as muscle strength loss and functional activity dysfunction resulting from ICU acquired weakness among the patients with mechanical ventilation.~Chest physiotherapy:a common technique to reduce the respiratory complications in ICU, has been proved certain positive influence on airway clearance and hospital lengths of stay."
223591624|NCT06186258|DEVICE|percutaneous pulmonary valve implantation (PPVI)|The only inclusion criterion is a successful PPVI to treat RVOT dysfunction. Procedural techniques were at each operator's discretion as well as post-procedure treatments and patient's follow-up. As we sought to assess IE incidence during follow-up, patients who underwent catheterization for intended PPVI but who did not had a successful valve implantation were not included. Successful PPVI was defined as patient discharged alive without valve surgery after successful valve implantation in the RVOT.
223591625|NCT03877302|OTHER|reflexology|foot reflexology
223591626|NCT00377208|BEHAVIORAL|Web-Based Intervention|"My Expert Doctor is a web-based program that helps patients to ask the right questions regarding specific tests and treatments during their doctor visits. Upon entering medication and treatment information into the web site, patients are provided with individualized feedback and recommended questions to ask their doctor."
223591627|NCT03106974|DEVICE|orotracheal intubation Macintosh Laryngoscope|orotracheal intubation (OTI) after induction of anesthesia and complete relaxation
223591628|NCT03106974|DEVICE|orotracheal intubation Totaltrack VLM|orotracheal intubation (OTI) after induction of anesthesia and complete relaxation
223591629|NCT04130672|PROCEDURE|Hot nasal packing with hot saline irrigation for hemostasis after adenoidectomy|After hot packing nasopharyngeal irrigation with 50 C saline
223591630|NCT04130672|PROCEDURE|Cold nasal packing with cold saline irrigation for hemostasis after adenoidectomy|After cold packing nasopharyngeal irrigation with 22 C saline
223591631|NCT03515356|BEHAVIORAL|MI-Walk Intervention|Eight-week motivational enhancement therapy and home-based aerobic walking intervention
223591632|NCT03515356|BEHAVIORAL|Physical Activity Education Pamphlet|Physical activity education pamphlet only
223591633|NCT01078649|DRUG|Debio 1143 (AT-406)|Oral Debio 1143 (AT-406) will be administered in a dose escalation study to determine the maximally tolerated dose in humans. Patients will receive Debio 1143 (AT-406) on days 1-5, and 15-19 of a 28 day cycle, or days 1-5 of a 21 day cycle, repeated until progression or unacceptable toxicity occurs.
223591634|NCT03691870|PROCEDURE|Standard Trans-Arterial Embolization (TAE)|"The standard TAE, without TVE, is used in patient allocated standard treatment. The arterial approach will consist of at least one attempted catheterization for trans-arterial injection of liquid embolic.~If the operator deems, on the table, for a trans-arterial injection to be too dangerous, no arterial injection is necessary. Treatment, where indicated, can be completed through other means."
223591635|NCT03691870|PROCEDURE|Trans-Venous Embolization (TVE)|"The experimental treatment is an attempt to completely occlude the AVM using venous catheterization and retrograde EVOH injection during the final session.~The trans-venous strategy will consist of at least one transvenous injection of ethyl vinyl alcohol (EVOH), with the choice of delivery microcatheters and other technical details left to the individual operator's discretion."
224074657|NCT03106623|DRUG|ONO-8577|Oral administration of ONO-8577 once a daily for 4 weeks
224074658|NCT03106623|DRUG|solifenacin succinate + mirabegron|Oral administration of solifenacin succinate and mirabegron once a daily for 4 weeks
224074659|NCT03106623|DRUG|Placebo|Oral administration of Placebo once a daily for 4 weeks
224074660|NCT01889290|DRUG|Methylnaltrexone|Methylnaltrexone 12mg s.c. administered once daily until treatment stop of sufentanyl
224074661|NCT03572556|BIOLOGICAL|Blood samples|"* 5 mL dry tube to separate serum~* Two 6 mL EDTA tubes for plasma separation~* Eight 6 mL heparinized tubes for flow cytometry (quantification of TANG such as CD3+CD31+CXCR4+ and CEC) and quantification of angiogenesis markers."
224074662|NCT03572556|OTHER|Epistaxis charts|Three monthly epistaxis charts to be completed
224074663|NCT02776800|DEVICE|Allevyn Life|
224074664|NCT02776800|DEVICE|Foam dressing with an integrated adhesive border|Foam dressing normally used by the home health agency
224074665|NCT04814394|DIAGNOSTIC_TEST|flowcytometry|The study of CD4,CD25,FOXP3 and PD-1 on peripheral blood sample
224074666|NCT06312475|DRUG|KN057|KN057 will be administered subcutaneously once a week.
224074667|NCT02076542|BEHAVIORAL|Education - Diabetes and Sports|"Based on the treatment and education programme PRIMAS a problem-specific education module regarding Diabetes and Sports was created. The module covers specific and detailed aspects of the topic sports such as insulin reduction, hypoglycemia awareness during physical activity, and blood glucose values prior to physical activity. With this module, a more comprehensive education of patients with specific interest is possible."
224191568|NCT00908375|DRUG|Pregabalin|One pregabalin 75mg capsule will be prescribed twice daily for the first week of the study (150mg/day). For the subsequent 2 weeks, the dose will be increased to 2 pregabalin capsules twice a day (300mg/day). The total duration of the treatment will be 3 weeks.
224191569|NCT00908375|DRUG|Sugar Pill|One sugar pill will be prescribed twice daily for the first week of the study. For the subsequent 2 weeks, 2 placebo(sugar pills) capsules twice a day. The total duration of the treatment will be 3 weeks.
224191570|NCT04647175|OTHER|Fermented aronia|Given twice daily for 8 weeks
224191571|NCT04647175|OTHER|Aronia|Given twice daily for 8 weeks
224191572|NCT04647175|OTHER|Placebo|Given twice daily for 8 weeks
224191573|NCT04850170|PROCEDURE|manual therapy|"1. release and stretch the muscles and fascia around shoulder girdle、upper arm and forearm;~2. massage the masseter muscle and temporalis muscle;~3. mobilization of the temporomandibular joint, the thoracic and cervical spine, shoulder, and elbow."
224191574|NCT04850170|PROCEDURE|Speech therapy|include the stretching of the neck, facial and oral movement training, and swallowing training
224191575|NCT01521975|DRUG|Telbivudine, Adefovir dipivoxil|All patients will take Telbivudine 600 mg PO daily from baseline. Some patients will take Adefovir dipivoxil 10 mg PO daily if they meet the criteria of adding Adefovir dipivoxil.
224191576|NCT03236701|OTHER|Egg White replacement|Nutritional intervention: the meat or fish of two meals will be replaced twice a week with an equivalent amount (in protein content) of egg white.
224191577|NCT02288949|OTHER|stratification|Patients will be stratified based on the values of relevant demographics, pulmonary and systemic variables in relation to mortality in the intensive care unit.
224191578|NCT04678726|DIAGNOSTIC_TEST|Lung ultrasound assessment for ruling out pneumothorax|Patients who have undergone heart surgery and have decided to enroll in our study, will have the standard chest x-ray and an additional lung ultrasound. Within a maximum of two hours of the chest tube removal, the standard chest x-ray will be performed, and then a different nurse will perform the lung ultrasound to check for pneumothorax.
223591636|NCT05096000|BEHAVIORAL|InterMob: a randomized controlled trial aimed at reducing car use in regular car users|Intermob is a theory- and evidence-based behavioral intervention that combines public transport/bicycle and motivational techniques (action planning, personalized transport advice, goal setting).
223591637|NCT05096000|OTHER|Active control: Air pollution information|The active control intervention is based on a discussion about air pollution, the effects of air pollution on health, the association between air pollution and transport.
223591638|NCT05083312|DRUG|APT-1011|APT-1011 is an orally disintegrating tablet that includes fluticasone propionate as its active ingredient.
223591639|NCT05083312|DRUG|Placebo oral tablet|Placebo orally disintegrating tablet
223591640|NCT05705362|PROCEDURE|Simple Crossover|Regardless of allocated arms, stent implantation in the MV (selected 1:1 according to the distal MV size) followed by systematic proximal optimization technique (POT, post-dilatation of the stent at the level of proximal MV with a balloon diameter sized 1:1 according to the proximal MV) or POT like procedure is strongly recommended.
223591641|NCT05705362|PROCEDURE|Side branch opening|According to the latest European Bifurcation Club (EBC) consensus document, distal SB rewiring followed by kissing balloon inflation (eventually conducted with short non-compliant balloons) and repeat POT procedures are highly recommended. An additional stent will be allowed if major dissection or decreased TIMI flow of SB occurs during SB treatment.
223591642|NCT04361578|DIAGNOSTIC_TEST|Magnetic resonance elastography|All patients enrolled will receive magnetic resonance elastography of the brain.
223591643|NCT05973253|DRUG|prepared drop of medroxy progestrone acetat 1%|In 37 patients who are candidates for photorefractive keratectomy, at the end of the procedure, in one eye randomly, in addition to the antibiotic drop that is routinely placed at the end of the procedure, a drop of prepared medroxyprogesterone is also placed. Then, a bandage contact lens is placed on the eyes, and the patient receives the routine post-procedure drops that include betamethasone and ciprofloxacin drops for both eyes.
223591644|NCT04348981|DEVICE|Wearable fitness tracking device|Patients having a wearable fitness tracking device will be monitored for their level of activity after surgery. Declines in activity level will prompt a phone call from the surgical provider.
223591645|NCT01237236|DRUG|LEE011|
223591646|NCT00126776|BEHAVIORAL|case management|case/self management for COPD vs usual care
224191579|NCT00031265|PROCEDURE|Family Intervention Telephone Tracking|
224191580|NCT03133429|DEVICE|MER|carotid artery stenting
224191581|NCT05746195|BEHAVIORAL|Dietary intervention via Text Messaging|Text messages will be sent to participants cell phones using the HealthySMS platform
224191582|NCT05746195|OTHER|Survey Administration|Various questionnaires evaluating participants dietary habits and use of study intervention will be administered
224191583|NCT05746195|BEHAVIORAL|Nutrition Education|Participants will receive nutrition education materials
223591647|NCT00126776|BEHAVIORAL|usual care|usual care for COPD
224191584|NCT05128656|OTHER|serology|serology at M3 and serology at M6
224191585|NCT05781204|OTHER|Survey|Each participant completed an anonymous 62-item online survey.
224191586|NCT03462628|PROCEDURE|CPVI plus low-voltage substrate modification|CPVI plus low-voltage substrate modification in the left atrium during SR
224191587|NCT03462628|PROCEDURE|CPVI alone|circumferential pulmonary vein isolation
224191588|NCT00752206|DRUG|Saracatinib|Oral Agent
224191589|NCT00752206|DRUG|Placebo|Oral Agent
224191590|NCT05463978|DEVICE|Sculptra Aesthetic|Sculptra Aesthetic in non-facial areas
224191591|NCT05541107|DRUG|MAT2203|oral lipid nanocrystal amphotericin B
224191592|NCT05541107|DRUG|Amphotericin B|Intravenous Amphotericin B
224191593|NCT00473187|DRUG|somatropin|
224191594|NCT02478606|OTHER|Muscle Stretching Exercises|The training consists of a four-week program of passive stretching exercise with three times week/sessions with interval of 48 hours between them. Each session will consist of carrying out a single repetition of stretching exercise with 30s of duration, static or PNF, according to the group to which voluntary membership. The two lower members receive training but only the lower limb data drawn will be used for analysis.
224309733|NCT06988696|OTHER|The Effect of Warm Sock Application on Hypothermia After admission to the urology ward, patients who meet the sample selection criteria will be identified one day prior to the surgical intervention.|"The Effect of Warm Sock Application on Hypothermia After admission to the urology ward, patients who meet the sample selection criteria will be identified one day prior to the surgical intervention. Eligible patients will be informed about the study by reading the voluntary informed consent form, which includes information about the purpose, content, and methodology of the research. Both verbal and written consent will be obtained from patients who agree to voluntarily participate in the study.~Initially, the Descriptive Characteristics Form will be administered to the patients. One group will be given heated socks, one group will be given regular socks, and one group will not receive any intervention. The effect of these interventions on hypothermia will be examined."
224309734|NCT06990516|DRUG|SHR-A1811|"Dose: 3.2 mg/kg, 4 mg/kg, or 4.8 mg/kg, administered intravenously (IV) every 3 weeks (Q3W).~Infusion Duration:~First infusion: 90 ± 10 minutes. Subsequent infusions: May be shortened to approximately 30 minutes (minimum 20 minutes, maximum 60 minutes, including flush phase) if no infusion-related reactions occur after the first dose."
224309735|NCT06990516|DRUG|Carboplatin|"Dose: Area Under the Curve (AUC) 5 mg/mL/min, administered IV Q3W.~Infusion Duration:~Should be completed within 30-60 minutes (including flush phase).~Treatment Schedule:~Up to 6 treatment cycles, with each cycle lasting 3 weeks."
224309736|NCT06990516|DRUG|Oxaliplatin|"Dose: 85 mg/m², administered IV Q3W.~Infusion Duration:~Should be infused over \>120 minutes (including flush phase).~Treatment Schedule:~Up to 6 treatment cycles, with each cycle lasting 3 weeks."
224309737|NCT06990516|DRUG|Bevacizumab|"Dose: 15 mg/kg, administered IV Q3W.~Infusion Duration:~First dose: 90 minutes. Second dose: If the first infusion is well-tolerated, may be shortened to 60 minutes.~Subsequent doses: If the 60-minute infusion is well-tolerated, all following infusions may be administered over 30 minutes (including flush phase)."
224309738|NCT06990191|BEHAVIORAL|Partnered Prolonged Exposure (PPE)|The PPE condition adapts the PE protocol with strategies from Integrative Behavioral Couples Therapy (an evidence-based couple therapy. PPE involves twice-weekly 60-minute sessions, with some sessions completed by both the Veteran and their partner while others are with the Veteran only.
224191595|NCT00734188|DRUG|PTI-6D2|monoclonal antibody
224191596|NCT06421662|BEHAVIORAL|Attachment Training|"The study group was trained online by a psychologist on attachment in two sessions. In order to measure the level of attachment knowledge before and after the training, a test form prepared by the researcher based on the literature and expert opinion was used as pre-test and post-test. In the 8th week after delivery, Maternal Attachment Inventory  developed by Mary Muller in 1994 and Turkish validity and reliability study was conducted by Şirin and Kavlak."
224309739|NCT06990191|BEHAVIORAL|Prolonged Exposure (PE)|The PE condition will follow the standardized PE manual and involve weekly 90-minute sessions and a 30-minute check-in attended only by the Veteran and the therapist.
223500872|NCT04640402|BIOLOGICAL|High-dose Recombinant COVID-19 vaccine (Sf9 cells) (60-85 years) & Three dose regimen|60-85 years group, three doses of high-dose (40µg/1.0ml) Recombinant COVID-19 vaccine (Sf9 cells) at the schedule of day 0, 14, 28.
223500873|NCT04640402|BIOLOGICAL|Low-dose placebo (18-59 years) & Two dose regimen|18-59 years group, two doses of placebo(0.5ml) at the schedule of day 0, 21.
223500874|NCT04640402|BIOLOGICAL|Low-dose placebo (18-59 years) & Three dose regimen|18-59 years group, three doses of placebo(0.5ml) at the schedule of day 0, 14, 28.
223500875|NCT04640402|BIOLOGICAL|High-dose placebo (18-59 years) & Two dose regimen|18-59 years group, two doses of placebo(1.0ml) at the schedule of day 0, 21.
223500876|NCT04640402|BIOLOGICAL|High-dose placebo (18-59 years) & Three dose regimen|18-59 years group, three doses of placebo(1.0ml) at the schedule of day 0, 14, 28.
223500877|NCT04640402|BIOLOGICAL|Low-dose placebo (60-85 years) & Two dose regimen|60-85 years group, two doses of placebo(0.5ml) at the schedule of day 0, 21.
223500878|NCT04640402|BIOLOGICAL|Low-dose placebo (60-85 years) & Three dose regimen|60-85 years group, three doses of placebo(0.5ml) at the schedule of day 0, 14, 28.
223500879|NCT04640402|BIOLOGICAL|High-dose placebo (60-85 years) & Two dose regimen|60-85 years group, two doses of placebo(1.0ml) at the schedule of day 0, 21.
223500880|NCT04640402|BIOLOGICAL|High-dose placebo (60-85 years) & Three dose regimen|60-85 years group, three doses of placebo(1.0ml) at the schedule of day 0, 14, 28.
223500881|NCT05309005|BEHAVIORAL|VR TASIT|Consists of a Norwegian adaptation of the 59 videos of social scenes that constitute the A Form in the original TASIT. The stimulus material in the Virtual Reality version is perceived through a head mounted display. This allows the test person to watch the scenes in three dimensions and a 360 degree angle, increasing the sense of social presence.
223500882|NCT05309005|BEHAVIORAL|DT TASIT|Consists of a Norwegian adaptation of the 59 videos of social scenes that constitute the A Form in the original TASIT, with identical content as the VR TASIT. The stimulus material in the desktop version is perceived on a two dimensional desktop computer screen.
224309740|NCT06990126|DRUG|bronchoscope|We will perform bronchoscopy and collect bronchoalveolar lavage fluid(BALF)
223500883|NCT02495675|DEVICE|High flow nasal cannulas|Comparison of different flow levels
223500884|NCT02495675|DEVICE|Conventional flow via nasal prongs|Low flow of air delivered through conventional nasal prongs
223500885|NCT02448043|DRUG|Bimatoprost 0.01%|Bimatoprost drops added to the proximal nail folds of the randomized study hand digits two times per day for 30 days
223500886|NCT02448043|OTHER|Placebo: saline|Placebo drops added to the proximal nail folds of the hand digits opposite the study hand two times per day for 30 days
223500887|NCT04341051|OTHER|Case|Mesure with NIRS regional saturation in patients undergoing popliteal block during vascular surgery for chronic obliterating arteriopathy (IIa to III Fontaine Classification)
223591648|NCT04940962|PROCEDURE|Sampling of adipose tissue|Removal of less than 1 cm3 of adipose tissue during visceral surgery
224191597|NCT01615965|OTHER|tumor marker detection in lymph nodes|tumor marker detection in lymph nodes by quantitative PCR
224191598|NCT00830726|DRUG|Pharmacologic and mechanical heart failure treatment|Optimised, standard, evidence based heart failure therapy including the use of biventricular pacing.
224191599|NCT00830726|PROCEDURE|Aortic valve replacement|Standard aortic valve replacement as per standard criteria in the department of thoracic surgery.
224191600|NCT00830726|PROCEDURE|Revascularisation in Acute Coronary Syndrome|Standard percutaneous or surgical revascularisation in ACS.
224191601|NCT00830726|PROCEDURE|Revascularisation in chronic stable angina pectoris|Standard percutaneous or surgical revascularisation
224191602|NCT06149000|DEVICE|Avulux Lenses|Avulux lenses are specialized eyewear designed to reduce specific wavelengths of light to alleviate symptoms in individuals who experience light sensitivity and migraines
224191603|NCT06149000|DEVICE|Placebo Lenses|Lenses that will look identical to Avulux lenses without the medical benefits
224191604|NCT06639477|OTHER|Treatment As Usual|In this trial, all participants will have depression symptoms and will be receiving TAU from their own doctors.
224191605|NCT06639477|BEHAVIORAL|Active Condition|Participants receive eight \~40 minute sessions (one per week) with a therapist/health coach. Specific information regarding the nature of the interventions is withheld to protect the scientific integrity of the study design.
224191606|NCT06639477|BEHAVIORAL|Active Comparator|Participants receive eight \~40 minute sessions (one per week) with a therapist/health coach. Specific information regarding the nature of the interventions is withheld to protect the scientific integrity of the study design.
224191607|NCT04717466|BIOLOGICAL|Secukinumab|300mg subcutaneous injection
224191608|NCT00004107|BIOLOGICAL|filgrastim|as prescribed by physician
224191609|NCT00004107|PROCEDURE|autologous bone marrow transplantation|1-2 weeks before treatment
224191610|NCT00004107|PROCEDURE|peripheral blood stem cell transplantation|1-2 weeks before treatment
224191611|NCT00004107|RADIATION|indium In 111 monoclonal antibody MN-14|intravenous infusion over 30 min; single dose
224191612|NCT00004107|RADIATION|yttrium Y 90 epratuzumab|intravenous infusion over 30 min; single dose
224191613|NCT05416333|DRUG|azelaic acid|Subjects will use the topical formulation once daily on the scalp. The subjects will use the treatment for a total of 6 months
224191614|NCT05416333|OTHER|usual medication for CCCA|Subjects will continue to use their already prescribed topical formulation once daily on the scalp. The subjects will use their treatment for a total of 6 months
224191615|NCT06316817|DEVICE|FloPatch|A novel, hands-free ultrasound patch for continuous monitoring of quantitative Doppler in the carotid artery.
224191616|NCT05530499|OTHER|Almond supplementation|Daily consumption of 57g of whole almonds
223500888|NCT03983005|PROCEDURE|EUS-B-FNA|Endoscopic ultrasound with bronchoscope fine needle aspiration (EUS-B-FNA) is an endoscopic technique based on a trans-esophageal needle aspiration performed by an interventional pulmonologist with the echo-bronchoscope
223500889|NCT02219204|PROCEDURE|Acupuncture|
223500890|NCT02219204|OTHER|Herbal treatment|
223500891|NCT00997126|DRUG|Propofol|Propofol 1 mg/kg IV followed by 0.5 mg/kg prn sedation
224191617|NCT05530499|OTHER|Cookie supplementation|Daily consumption of cookie snack calorically equivalent to 57 grams of whole almonds.
224191618|NCT05471791|DEVICE|Back2Play App|This App uses the Apple watch to monitor activity level and heart rate and combines this with self reported symptoms and stage of recovery to send notifications, suggestions and provide resources to help participants adhere to the guidelines.
224191619|NCT06799455|DEVICE|Endotracheal tube|participants either receive the ETT during the procedure
223500892|NCT00997126|DRUG|Alfentanil|Alfentanil 10 ug/kg IV followed by 5 ug/kg prn sedation
224191620|NCT05405530|DEVICE|nasal mask oxygen kit|Using the nasal mask oxygen kit for oxygenation.
224191621|NCT05405530|DEVICE|regular nasal cannula|Using nasal cannula for oxygenation.
224191622|NCT05876923|PROCEDURE|Biospecimen Collection|Undergo collection of blood
224191623|NCT05876923|OTHER|Cardiopulmonary Exercise Testing|Undergo CPET
224191624|NCT05876923|PROCEDURE|Dual X-ray Absorptiometry|Undergo DEXA scan
224191625|NCT05876923|OTHER|Electronic Health Record Review|Ancillary studies
224191626|NCT05876923|OTHER|Exercise Intervention|Undergo aerobic based training program
224191627|NCT05876923|PROCEDURE|Physical Examination|Undergo measurement of height/weight and vital signs
224191628|NCT05876923|OTHER|Questionnaire Administration|Ancillary studies
224191629|NCT05876923|PROCEDURE|Spirometry|Undergo spirometry
224191630|NCT05876923|OTHER|Physical Performance Testing|Undergo muscular strength and functional endurance measurements
224191631|NCT05876923|OTHER|Best Practice|Receive usual care
224191632|NCT06246669|BEHAVIORAL|Treadmill Walking|A treadmill will be used for participant to walk on. The frequency of exercise will be 5 times per week until they report symptom-free. The intensity will be determined via random group allocation (RPE of 13 or 9). The type of exercise is treadmill walking. The time of the intervention will depend on the the time it takes an individual to reach a specific caloric expenditure as a function of their weight and treadmill incline. This is based on the most recent American Congress of Sports Medicine's guidelines for estimating gross energy expenditure during common physical activities.
224191633|NCT04843098|DRUG|TL117|TL117 capsules orally once daily
224191634|NCT04843098|DRUG|Paclitaxel|Paclitaxel (80 mg/m2) administered intravenously (IV) on Days 1, 8, and 15 of a 28-day treatment cycle.
224191635|NCT06456151|DIAGNOSTIC_TEST|Invasive candidiasis test|The combination of acute phase marker monitoring and the T2Candida assay will be assessed.
224191636|NCT06456151|OTHER|Urine sample collection for future research|Patients will be asked to provide a urine sample for future research (urine biobank).
224191637|NCT05346887|BEHAVIORAL|Home-based Therapy|The 18-week caregiver-delivered intervention involves daily 30-minute home-practice and weekly sessions with a therapist over video call or in-person at a local rehabilitation centre. During weekly sessions, the therapist will coach the caregiver(s), problem-solving with them and supporting their autonomy as agents of change in their child's care. The first 13-weeks of the program will be exclusively constraint-induced movement therapy, with bimanual therapy introduced in the last five weeks depending on child age. Intervention content will be individualized based on child age, ability, and interests.
224191638|NCT05219110|OTHER|Infusion of 200% maintenance fluids as balanced crystalloid IV solution|Infusion of 200% of maintenance fluids x 24 hours provided, ideally, as a balanced crystalloid (PlasmaLyteTM, Ringer's Lactate) IV solution. Electrolytes and dextrose may be administered as required and desired by the clinical care team; customized solutions are permitted if so desired. Intravenous fluid solutions containing \< 130 mEq/L sodium may increase risk for hyponatremia and may be less effective in achieving intravascular volume expansion and should be avoided.
224191639|NCT05219110|OTHER|Oral fluids; infusion of up to 110% maintenance fluids as balanced crystalloid IV solution|Administration of less than or equal to 110% of maintenance fluids as oral or balanced crystalloid IV solution.
224191640|NCT03958045|COMBINATION_PRODUCT|Rucaparib and Nivolumab|Rucaparib (600mg BID) and Nivolumab (480mg IV q4 wk)
224191641|NCT06072586|DRUG|BDTX-1535|BDTX-1535 is an inhibitor of EGFR mutations
224191642|NCT06072586|DRUG|BDTX-1535 combined with radiation therapy|During Phase 1, BDTX-1535 concurrently with standard of care upfront RT, followed by adjuvant monotherapy with BDTX-1535 continuously in 28-day cycles after RT.
224191643|NCT06072586|DRUG|BDTX-1535 combined with temozolomide and radiation therapy|During Phase 1, BDTX-1535 concurrently with standard of care upfront RT and TMZ, followed by adjuvant BDTX-1535 combined with standard of care TMZ continuously in 28-day cycles after RT.
224191644|NCT04772417|DIAGNOSTIC_TEST|Standardized 1-minute sit-to-stand test|The individuals perform two tests from a standardized chair (seat height 46cm).
224191645|NCT04772417|DIAGNOSTIC_TEST|Individualized 1-minute sit-to-stand test|The individuals perform two tests from an individualized chair (seat height adjusted so that the starting position elicits a knee flexion angle of 90°).
224191646|NCT02283411|DEVICE|Abbott Sensor Based Glucose Monitoring System|Subjects will wear the Abbott Sensor Based Glucose Monitoring Systems and will receive no treatment except for safety purposes.
224309741|NCT06990165|DEVICE|Photobiomodulation|Photobiomodulation applications will be performed within 1 hour after the radiotherapy session, covering the entire irradiated area, three times per week, starting from the first day of radiotherapy. The procedure will be conducted using the Antares/IBRAMED® device, with a cluster applicator featuring a 20 cm² contact area and two distinct wavelengths: four infrared laser diodes (808 nm), each with a power of 180 mW, and three red light diodes (630 nm), each with a power of 150 mW. Each diode will deliver 3 J of energy, with the wavelengths applied separately and sequentially.
224309742|NCT06990165|OTHER|Sham Control|Group B will have the device in contact with the irradiated area, following the same protocol as Group A, but with the device turned off, receiving no therapeutic light and, therefore, experiencing no biological effects from the light.
224309743|NCT03347006|DIETARY_SUPPLEMENT|SPM Active|"Supplement or placebo will be administered orally between 9 am to 9:30 am.~* Each participant will give a baseline blood sample then they will be given one of the randomly allocated three doses of fish oil supplement, or a matching placebo in one of 8 study groups \[this will be on a 1:1:1:1:1:1:1:1 ratio\]. Blood will be collected again at 2h, 4h, 6h and 24h after supplementation/placebo, 12ml per time interval."
224309744|NCT03045471|DRUG|R-EPOCH|Rituximab: an anti-CD20 monoclonal antibody, which has the ability to kill B cells, be they normal or malignant; Etoposide: a topoisomerase inhibitor from the group of epipodofyllotoxins; Prednisolone: a glucocorticoid hormone that can cause apoptosis and lysis of both normal and malignant lymphocytes; Oncovin, also known as vincristine: a vinca alkaloid that binds to the protein tubulin, thereby preventing the formation of microtubules and mitosis; Cyclophosphamide: an alkylating antineoplastic agent; Hydroxydaunorubicin, also known as doxorubicin: an anthracycline antibiotic that is able to intercalate DNA, damaging it and preventing the cell division.
224309745|NCT03045471|DRUG|R-CHOP|Rituximab: an anti-CD20 monoclonal antibody, which has the ability to kill B cells, be they normal or malignant; Prednisolone: a glucocorticoid hormone that can cause apoptosis and lysis of both normal and malignant lymphocytes; Oncovin, also known as vincristine: a vinca alkaloid that binds to the protein tubulin, thereby preventing the formation of microtubules and mitosis; Cyclophosphamide: an alkylating antineoplastic agent; Hydroxydaunorubicin, also known as doxorubicin: an anthracycline antibiotic that is able to intercalate DNA, damaging it and preventing the cell division.
224309746|NCT03504280|DRUG|Cholecalciferol|
224309747|NCT03918109|DRUG|OTO-313|single intratympanic injection of gacyclidine
224309748|NCT03918109|DRUG|Placebo|single intratympanic injection of placebo
224309749|NCT04499365|DRUG|68Ga-DOTA/NOTA-FAPI-04|Each patient receive a single intravenous injection of 68Ga-DOTA/NOTA-FAPI-04, and undergo PET/CT scan within specified time.
224309750|NCT04499365|DIAGNOSTIC_TEST|PET/CT scan|PET/CT scan
224191647|NCT05382715|DRUG|Ozanimod|Specified Dose on Specified Days
224191648|NCT05956951|DEVICE|Closed-loop auditory stimulation|Closed-loop auditory stimulation will be administered by a wearable EEG device (Philips SmartSleep Deep Sleep Headband). The EEG device will deliver auditory stimulation when slow-wave (deep) sleep is detected. Auditory stimulation will consist of 50ms long tones separated from each other by a fixed one-second inter-tone interval. The volume of each tone will be linearly modulated by sleep-depth such that louder (or softer) tones were played during deeper (or shallower) sleep.
224191649|NCT05956951|DEVICE|Sham auditory stimulation|Sham auditory stimulation consists of closed-loop auditory stimulation not being administered. A wearable EEG device (Philips SmartSleep Deep Sleep Headband) will not deliver closed-loop auditory stimulation and tones will not be played.
224191650|NCT05761860|DRUG|OxyCODONE 5 mg Oral Tablet|Oxycodone 5mg oral administration
224191651|NCT05761860|DRUG|OxyCODONE 2.5 mg Oral Tablet|Oxycodone 2.5mg oral administration
224191652|NCT05761860|OTHER|Placebo oxyCODONE Oral Tablet|Oxycodone 0mg (placebo) oral administration
224191653|NCT05761860|DRUG|Oxytocin Nasal Spray (48 IU)|Intranasal oxytocin administration (48 IU)
224191654|NCT05761860|OTHER|Placebo Oxytocin Nasal Spray|Intranasal oxytocin placebo administration
224191655|NCT04893720|PROCEDURE|Lumbar fusion|Transforaminal Lumbar Interbody Fusion of the SPECT/CT positive lumbar degeneration
224191656|NCT03237910|DIAGNOSTIC_TEST|AMSA|A non-invasive and real time VF (Amplitude Spectrum Area) AMSA analysis is performed during chest compression pauses for delivery of 2 ventilations, from the ECG acquired from the conventional defibrillatory pads
224191657|NCT03237910|PROCEDURE|Defibrillation|delivery of the defibrillation is attempted to terminate VF either based on AMSA value (in the AMSA-CPR arm) or every 2-min CPR cycle as recommended by current guidelines (in the Standard-CPR arm)
224191658|NCT03237910|PROCEDURE|CPR|chest compressions and ventilations at a rate of 30:2
224191659|NCT02434640|DRUG|BAY1128688|Part A: Single dose and multiple dose for 14 days (postmenopausal women)
224191660|NCT02434640|DRUG|Placebo|Part A: Single dose and multiple dose for 14 days (postmenopausal women)
223591649|NCT05221229|DRUG|Liraglutide plus upstream risk factors modification advice and consultation|Patients will be on treatment with daily injections of Liraglutide for a total of 65 weeks. During initial consultation for AF ablation, patients' BMI, risk factors status and baseline blood tests were performed and reviewed. Then the patients were discussed and encouraged to achieve optimal goal of risk factors modifications by non pharmacological and pharmacological measures.
223591650|NCT06251427|DIETARY_SUPPLEMENT|Multiple micronutrient fortified maize with milk|The study product is a multiple micronutrient fortified maize pap with milk
223591651|NCT06259734|BEHAVIORAL|Transfusion Camp Rwanda education|Transfusion Camp Rwanda 3 day education intervention covering all aspects of safe blood transfusion practices as per the Rwanda Biomedical Centre National Transfusion Guidelines
224191661|NCT02434640|DRUG|BAY1128688|Part B: Multiple dose for 28 days (premenopausal women)
224191662|NCT05434741|BEHAVIORAL|Weekly Group Skills|The topics covered in group CBT sessions are: 1.) Domains of Healthy Aging; 2.) Stress and anxiety; 3.) Adherence and Engagement in Primary/Preventative Care; 4.) Depression and Distress; 5.) Physical Activity; 6.) Stigma/Self-Compassion; 7.) Substance Use; 8.) Acceptance of Uncertainty and Uncomfortable Emotions; 9.) Diet; 10.) Behavioral Activation; 11.) Frailty and Memory/Cognition; and 12.) Wrap-Up and Maintaining Gains.
224191663|NCT05434741|OTHER|"One-time Trifold Brochure titled HIV: 50 Years or Older"|"Participants in the education only group will receive a one-time trifold brochure titled HIV: 50 Years or Older. This brochure contains information on the prevalence of HIV among people aged 50 and older, defines medication adherence and drug resistance, encourages physical activity and proper nutrition, and addresses the health risk behavior of tobacco-smoking for people living with HIV. Participants receive one brochure in the information-only group."
224191664|NCT03735056|OTHER|MS Nurse Support|MS Nurse Support intervention is multi-faceted, involving various components (i.e. information provision and emotional support), and a range of strategies and techniques (e.g. psychoeducation, acceptance and commitment), delivered by MS Nurse Specialists, to provide standardised support and advice to patients at diagnosis, to establish and sustain coping strategies. MS Nurse Support intervention is person-centred and tailored to the needs and lifestyle of each participant.
224191665|NCT03735056|OTHER|Peer Support|Peer Support will be delivered by Peer Support Workers using information provision and supportive listening to provide support and advice to patients at diagnosis, and to provide patients the opportunity to talk freely, extensively and confidentially about their experiences, thoughts and feelings about MS diagnosis and its effects on their lives in a non-judgmental and safe environment. Peer Support intervention is person-centred and tailored to the needs and lifestyle of each participant.
224191666|NCT00305292|DRUG|Modafinil-Alcohol Interactions|
224191667|NCT03271580|DIAGNOSTIC_TEST|Finger prick test for HbA1c measurement|HbA1c measurement with finger prick method
223500893|NCT03967314|OTHER|TLIP block group (group T)|In group T, the block was performed bilaterally under aseptic conditions using the US device with a high-frequency 12-MHz linear US probe. The probe was covered with a sterile sheath and placed vertically at the L3 vertebrae level. After visualizing the hyperechoic shadow of the spinous process and interspinous muscles as an anatomical guide point, the probe was moved forward in a lateral direction to visualize the longissimus and iliocostal muscles. Using the in-plane technique, a 22-G, 50-mm block needle was inserted between the muscles in a medial-to-lateral direction in the interfascial plane. Once the needle tip was placed within the interfacial plane and after careful aspiration to rule out intravascular needle placement, 2 ml of saline was injected to confirm the accuracy of the injection site. A dose of 0.25% bupivacaine (20 ml) was then injected in each side (total 40 ml).
223500894|NCT03967314|OTHER|Wound infiltration group (group W)|In group W, a dose of 0.5% bupivacaine (20 ml) was injected for wound infiltration into the surgery site.
223500895|NCT03536962|OTHER|no intervention|no intervention
223500896|NCT01560130|BEHAVIORAL|Shape Up Rhode Island + Online weight loss program|Participants assigned to this arm will receive the standard Shape Up Rhode Island statewide intervention and an Internet-based behavioral weight loss program.
224191668|NCT03271580|PROCEDURE|Punch Biopsy|Wound site will be anaesthetized, by punch biopsy tissue will be collected, wound site will be monitored for bleeding(if bleeding Cautery will be used to stop bleeding).
224191669|NCT03271580|OTHER|Vac Sponge Collection|NPWT sponge which is discarded as biological waste, will be collected for wound macrophage isolation
224191670|NCT03271580|OTHER|Ankle Brachial Index|Blood pressure test
224191671|NCT00078663|BEHAVIORAL|Oral Care|
224191672|NCT05005923|PROCEDURE|Non-surgically performed scaling and root planing|Treatment of patients with periodontitis was performed using manual and ultrasonic instruments.
223500897|NCT01560130|BEHAVIORAL|Shape Up Rhode Island + Online weight loss program + Groups|Participants assigned to this arm will receive the standard Shape Up Rhode Island statewide intervention, an Internet-based behavioral weight loss program, and the option to attend group sessions.
223500898|NCT01560130|BEHAVIORAL|Shape Up Rhode Island + Online weight loss + Incentives|Participants assigned to this arm will receive the standard Shape Up Rhode Island statewide intervention, an Internet-based behavioral weight loss program, and monetary incentives for submitting self-monitoring information and for achieving clinically significant weight loss.
223500899|NCT02111356|DEVICE|Phinhole glasses|Wearing the pinhole glasses (Trayner Pinhole Glasses, Trayner Glasses, U.K.)
223500900|NCT00236678|DRUG|Epoetin alfa|
223512063|NCT02226783|DRUG|AZD1722 free base tablet + Omeprazole|AZD1722 free base tablet administered 5 to 10 minutes before intake of breakfast and evening dose 5 to 10 minutes before start of intake of dinner; omeprazole was administered twice daily from Days -5 to -1 or Days 5 to 9 (depending on assigned treatment period), 1 hour before breakfast and dinner, and from Days 1 to 4 or Days 10 to 13, 1 hour prior to the administration of AZD1722
223512064|NCT03555097|PROCEDURE|incremental pressure support|Inspiratory positive airway pressure (IPAP) gradually increases from 10 to 24 cm water column (cmH2O) with 2 water column (cmH2O) increments. The expiratory positive airway pressure (EPAP) remains 4 water column (cmH2O), and each pressure level is maintained for 5 to 10 minutes.
224191673|NCT03808415|DEVICE|EMG-driven|The EMG signals are processed and can be visualized with visual feedback to make sure the user actively engaging throughout a therapy session.
224191674|NCT01135251|DRUG|dimiracetam|400 mg capsules for oral use to be administered twice a day for a total of 8 weeks
224191675|NCT01135251|DRUG|sugar pill|capsules containing 400 mg of inert material will be orally administered twice a day, one pill for 2 weeks, 2 pills for other 2 weeks and 4 pills for the last 4 weeks.
224191676|NCT00740129|DRUG|Zoledronic Acid|Zoledronic acid 5 mg intravenous infusion once
224191677|NCT03965416|OTHER|White Coat|We included the first and last patients in consultation every day for 10 consecutive days, and every other day the doctor consulted with the use of a white coat or without the use of a white coat.
224191678|NCT03965416|OTHER|Without White Coat|We included the first and last patients in consultation every day for 10 consecutive days, and every other day the doctor consulted with the use of a white coat or without the use of a white coat.
224191679|NCT06505330|DIETARY_SUPPLEMENT|Probactiol Baby|Dietary Supplement: Probactiol Mini 6 droplets of Probactiol Mini daily intake for 13 months
224191680|NCT01298323|BEHAVIORAL|Patient outreach|Patients will be contacted at week 1 and then every 2 weeks until completion of 52 weeks to detect/treat AEs sooner
224191681|NCT01298323|DRUG|Vandetanib|Treatment 300mg vandetanib opel label.
224191682|NCT03335228|DEVICE|Eclipse Easy Spin for PRP|Autologous platelet rich plasma is prepared from subject's blood with the Eclipse Easy Spin centrifuge and injected into affected areas.
224191683|NCT01379599|BEHAVIORAL|brief motivation intervention|Brief motivation intervention consisting of brief psychosocial counseling (20 minutes at the time of an ER visit)
224191684|NCT04189874|DIAGNOSTIC_TEST|Conventional Stool Testing|Stools are tested using conventional culture techniques
223512065|NCT02261532|DRUG|TAS-102|TAS-102 (35 mg/m2/dose) orally, twice daily on days 1-5 and 8-12 of each 28-day cycle. Number of cycles: until at least one of the discontinuation criteria is met.
223512066|NCT05124236|RADIATION|preoperative radiosurgery|single fraction radiosurgery
224191685|NCT04189874|DIAGNOSTIC_TEST|BioFire FilmArray Gastrointestinal Panel|Molecular-based stool assay
224191686|NCT05568212|DRUG|Durvalumab|Durvalumab concentrate for solution for infusion will be supplied in glass vials containing 500 mg durvalumab at a concentration of 50 mg/mL
224191687|NCT05568212|DRUG|Olaparib tablet|Olaparib tablets (100 mg and 150 mg strengths) supplied in high-density polyethylene (HDPE) bottles.
224191688|NCT05568212|DRUG|Single-agent chemotherapy|Investigator's choice single-agent chemotherapy regimen
224191689|NCT05568212|DRUG|Platinum doublet chemotherapy|Investigator's choice platinum doublet chemotherapy
224191690|NCT03737617|DRUG|Cuvitru 20 % Injectable Solution|Active
224191691|NCT01429142|BEHAVIORAL|Treatment as usual|In this multi-center trial, the content of usual adherence care is not known prior to the study, but it is part of our data collection to examine the content and variability between clinics and professionals afterwards.
224191692|NCT01429142|BEHAVIORAL|AIMS intervention|"The AIMS-intervention is counseling intervention, using MEMS-data printed in simple plots. The following intervention steps will be followed:~-Discussion of practical, tailored information about adherence -Identification of desired adherence level and motivations -Print of patients' MEMS-report and comparison with desired level -ID causes of non-adherence and how to deal with problems -Designing a tailored action plan. -Follow-up: evaluation of accomplishments, remaining problems and solutions, until desired level of adherence has been accomplished. -Formulation of goals for behavioral maintenance.~Among patients starting treatment, the same elements will be delivered but MEMS-feedback can only be incorporated in the second session (after medication has been used). Moreover, a readiness element is added at treatment initiation, where patients discuss the necessity and concerns of initiating medication and are offered the possibility to practice intake for 2 weeks with placebo."
224191693|NCT02706015|DRUG|Cefaliv® & Placebo|02 tablet of Cefaliv® + 02 tablet of comparator placebo, VO, after the beging of migraine with with mild to moderate pain
224191694|NCT02706015|DRUG|Neosaldina® & Placebo|02 tablets of Neosaldina® + 02 tablet of comparator placebo, VO, after the beging of migraine with with mild to moderate pain
224191695|NCT04567771|OTHER|Quality-of-Life Assessment|Complete quality of life questionnaires
224191696|NCT04567771|OTHER|Questionnaire Administration|Complete adverse event assessments
224191697|NCT04567771|RADIATION|Radiation Therapy|Undergo proton or intensity modulated radiation therapy
224191698|NCT05714839|DRUG|Belantamab|Belantamab will be administered.
224191699|NCT05714839|DRUG|Belantamab mafodotin|Belantamab mafodotin will be administered.
224191700|NCT05714839|DRUG|Belantamab and belantamab mafodotin|Belantamab and belantamab mafodotin used in combination (delivered as separate drugs) will be administered.
224191701|NCT05312411|BIOLOGICAL|SCRI-E2CAR_EGFRtv1|Autologous CD4+ and CD8+ T cells that have been genetically modified to express antiFL(FITC-E2)
224191702|NCT05312411|DRUG|UB_TT170|Bispecific small molecule adapter formulated with phosphate buffered saline
224191703|NCT04875611|DRUG|Opdivo|Dose of Nivolumab is constant and is 240 mg .All patients will undergo maximum of 12 cycles of investigation product's infusion ( around 6 month of treatment).Each cycle will be done in intervals of 14 day (no less than 12 days after previous infusion and no longer than 42 day/6 weeks after previous infusion).
224191704|NCT00239694|BIOLOGICAL|Pneumococcal Vaccine|One time preventative vaccine
224191705|NCT00239694|BIOLOGICAL|Meningococcal Vaccine|One time preventative vaccine
224191706|NCT01243437|DRUG|ciprofloxacin|"* For adults and children aged \> 15 years: 500 mg orally every 12 hours for 10 days or until the patient has been fever-free for 24 hours, whichever is longer;~* For children aged 8-15 years: 15 mg/kg (maximum 500 mg per dose) orally every 12 hours for 10 days or until the patient has been fever-free for 24 hours, whichever is longer."
224191707|NCT01243437|DRUG|doxyxcycline|"* For adults and children weighing 45 kg or more: 200 mg orally one time as an initial loading dose, followed by 100 mg orally every 12 hours for 10 days or until the patient has been fever-free for 24 hours, whichever is longer;~* For children weighing less than 45 kg: 4.4 mg/kg orally one time as an initial loading dose, followed by 2.2 mg/kg orally every 12 hours for 10 days or until the patient has been fever-free for 24 hours, whichever is longer."
224191708|NCT06452316|BIOLOGICAL|CSB-001 Ophthalmic Solution 0.1%|CSB-001: human recombinant dHGF (5-amino acid deleted hepatocyte growth factor)
223591652|NCT05286892|OTHER|Diabetes LIVE JustICE|Diabetes LIVE JustICE will be an adaptation of the current Diabetes LIVE persistent multi-user online virtual environment built on the Unreal Engine (Epic Games, Inc., Cary, NC) that allows users to talk to each other in real-time and participate in instructor-led synchronous sessions. Users can access the virtual environment through IOS/Android devices. Instructors can show learning material such as Google Docs and PowerPoint. The LIVE JustICE community will contain a community center, a tranquility center, and a message board. This will be an interactive community where participants will communicate in real-time on their mobile device or, if preferred, using their computer via text or audio chat. Access to LIVE will allow participants to utilize resources and links in the application, leave a message on the message board for the diabetes educators, or engage with other participants. Research team members will add and trial gaming activities to the VE during this feasibility study.
224191709|NCT02118467|DRUG|Norepinephrine|Dose range 0.03 to 0.3 mcg/kg/minute, titrated to target blood pressure.
224191710|NCT02118467|DRUG|Epinephrine|Dose range 0.03 to 0.3 mcg/kg/minute, titrated to target blood pressure.
224191711|NCT02118467|DRUG|Phenylephrine|Dose range 0.3 to 3.0 mcg/kg/minute, titrated to target blood pressure.
224191712|NCT02118467|DRUG|Vasopressin|Dose range 0.1 to 0.6 milliunits/kg/minute, titrated to target blood pressure.
224191713|NCT04902378|DEVICE|Tandem t:slim X2 insulin pump with Control IQ technology|The intervention group will be fitted with the Tandem t:slim X2 insulin pump with Control IQ technology during pregnancy.
224191714|NCT06321471|DEVICE|AeviceMD|AeviceMD is a remote patient monitoring system consisting of a wearable stethoscope, silicone patches, a docking station, and a mobile application.
224191715|NCT05847751|DEVICE|Aortic valve replacement|Trans Aortic Valve Replacement (TAVI)
224191716|NCT06647966|DIAGNOSTIC_TEST|PET/CT|\[11C\]CH PET/CT
224191717|NCT02786368|BEHAVIORAL|Control group|A comparison group; no intervention for year 1, EHFP after 1 year of program implementation.
224191718|NCT02786368|BEHAVIORAL|EHFP group|Intervention group: training; inputs cost-sharing for EHFP activities.
224191719|NCT01546909|BIOLOGICAL|Diphtheria, tetanus, polio and pertussis vaccination|1 dose of TETRAVAC-ACELLULAIRE (0.5 mL) at Day 0
224191720|NCT05421559|PROCEDURE|thyroidectomy|removal of the diseased thyroid gland by conventional method vs transection method of sternothryroid muscle
224309751|NCT05993117|DEVICE|G114R VNS system|All patients treated with Rechargeable Implantable Vagus Nerve Stimulation System (G114R)
224309752|NCT00570882|DRUG|Sunitinib 2/1|Sunitinib 50 mg PO 2 weeks followed by 1 week rest
224309753|NCT00570882|DRUG|Sunitinib 4/2|Sunitinib 50 mg PO 4 weeks followed by 2 week rest
223500901|NCT05334979|OTHER|Kidney stones Normal controls Consuming a special drink (sodium oxalate) during an all day visit to the University of Chicago research clinic|"Consuming a special drink (sodium oxalate) during an all day visit to the University of Chicago research clinic~Subjects in both arms will be asked to partake in the same activities, as follows: The day before presenting to the research clinic subjects will collect urine at home. Subjects will will come in to the research clinic at the University of Chicago in Hyde Park, where they will spend most of the day. We will give them a special liquid that contains oxalate, and they will receive a specially prepared breakfast that is low in oxalate and citrate. After this, we will collect urine and blood throughout the day. While at the clinic, subjects will also receive specially prepared snacks."
223500902|NCT06246955|BEHAVIORAL|Behavioral Intervention: Group Therapy Session|Attend virtual group therapy sessions
223591653|NCT05286892|OTHER|Enhanced Education|See control group description above
224191721|NCT06977646|PROCEDURE|Surgical transaortic left ventricular cavity remodeling in patients with apical hypertrophic cardiomyopathy without left ventricular outflow tract obstruction|The proposed intervention is a variation of classical myectomy, but unlike it, the main substrate for resection is not only the hypertrophied interventricular septum, but the abnormal papillary muscles and interpapillary trabeculae in the left ventricular cavity
224191722|NCT02500732|DRUG|Atomoxetine|40mg PO the night before and the morning of the study tilt table test.
224191723|NCT02500732|DRUG|Placebo|oral placebo capsule designed to blind the atomoxetine intervention
224191724|NCT04409262|DRUG|Remdesivir|Participants will receive intravenous (IV) RDV
224191725|NCT04409262|DRUG|Tocilizumab|Participants will receive IV TCZ
224191726|NCT04409262|DRUG|Placebo|Participants will receive IV placebo matched to TCZ
224191727|NCT03188276|DRUG|Ledipasvir-Sofosbuvir|15 CHC patients were treated with Sofosbuvir (400mg, qd)/Ledipasvir (90mg, qd) for 12 weeks
224191728|NCT03188276|DRUG|Daclatasvir-Sofosbuvir|17 CHC patients were treated with Sofosbuvir (400mg, qd)/Daclatasvir (60mg,qd) for 12 weeks.
224191729|NCT02713100|BEHAVIORAL|level of agitation|psychological pain
224191730|NCT05733013|OTHER|Surveillance Visit|Follow-up visits will be carried out at intervals per usual clinical practice. Tolerance of medication and adverse events will be recorded in every visit.
224191731|NCT06815055|OTHER|Quality of life questionnary|Subjects will be call 1 month and 6 months after prostetectomy to evaluate the type of reeducation received and they will be evaluated with the help of QoL questionnaries : KHQ-HR QoL and ICIQ-SF QoL
224191732|NCT04129879|PROCEDURE|ABC technique|The intraperitoneal use of methylene blue diluted isotonic sodium chloride solution to visualize endometriotic lesions
224191733|NCT05525559|DRUG|ET0038|ET0038 for oral administration
224191734|NCT00154986|PROCEDURE|immunohistochemical staining, transfection, invasion assay|
224191735|NCT02396849|DEVICE|Continuous Positive Airway Pressure (CPAP)|Subjects assigned to this group will be asked to use the CPAP machine for a minimum of 4 hours/night at least 5 days/week for a total of 4 weeks.
224191736|NCT02396849|DEVICE|Continuous Positive Airway Pressure (CPAP) Sham|Subjects assigned to this group will be asked to use the CPAP Sham machine for a minimum of 4 hours/night at least 5 days/week for a total of 4 weeks.
224191737|NCT06661694|DRUG|Treatment A|Single 875 mg dose of mevrometostat standard tablet formulation
224191738|NCT06661694|DRUG|Treatment B|Single 875 mg dose of mevrometostat alternative tablet formulation
224191739|NCT06661694|DRUG|Treatment C|Single 875 mg dose of mevrometostat alternative tablet formulation
224191740|NCT06661694|DRUG|Treatment D|Single 875 mg dose of mevrometostat alternative tablet formulation
224309754|NCT03077035|OTHER|glass ionomer sealants|
224309755|NCT03077035|OTHER|resin-based sealant|
223591654|NCT06579911|DEVICE|High-frequency micro-ultrasound target biopsy|"1. High-frequency micro-ultrasound (transrectal ultrasound, 29 Hz, ExactVu) of the prostate. If suspicious lesions (PRIMUS \>= 3) other than those already detected in multiparametric MRI are found, target biopsy will be performed. Maximum of four cores per lesion.~2. Multiparametric MRI target biopsy (PI-RADS \>= 3) of the prostate (transrectal ultrasound, 29 Hz, ExactVu). Maximum of four cores per lesion.~3. Systematic biopsy (twelve cores) of the prostate"
223591655|NCT06579911|DEVICE|conventional Multiparametric MRT target biopsy|"1. Multiparametric MRT target biopsy (PI-RADS \>= 3) of the prostate (conventional transrectal ultrasound, 8-10 Hz). Maximum of four cores per lesion.~2. Systematic biopsy (twelve cores) of the prostate"
223591656|NCT00550381|DRUG|HKI-357|Single-dose capsule
224191741|NCT01882166|DRUG|fostimon|
224191742|NCT01882166|DRUG|puregon|
224191743|NCT01315158|DRUG|Propofol Alone|"Recommended Propofol doses before considering crossover:~* Induction: 2-2.5 mg/kg~* Maintenance: 0.1-0.2 mg/kg/min"
223591657|NCT06042699|DIETARY_SUPPLEMENT|Oral ferrous sulfate|Oral ferrous sulfate 325mg is used as a dietary supplement providing 65mg elemental iron.
223591658|NCT06042699|DIETARY_SUPPLEMENT|Oral placebo tablet|Oral placebo tablet provided as placebo comparator.
223591659|NCT06487975|DIETARY_SUPPLEMENT|Bacillus Subtilis|Bacillus Subtilis 1 capsule once daily in the morning (consisting of 10x10\^9 Colony Forming Units)
223591660|NCT06487975|OTHER|Placebo|1 visually identical placebo capsule once daily in the morning using the same carrier (microcrystalline cellulose) as the active (but not containing Bacillus Subtilis)
223591661|NCT04963075|DEVICE|multisensory rehabilitation paradigm|"In initial (training) sessions, subjects will be exposed (and respond) to spatiotemporally congruent pairs of visual-auditory stimuli presented within their blinded field, with occasional probes of unisensory visual stimuli on both sides of space. Once recovery of visual responsiveness in the contralesional field is observed, sessions will alternate between training/testing and testing only sessions in which performance on the visual battery will be re-assessed."
223591662|NCT03267888|BIOLOGICAL|Pembrolizumab|Given 200 mg IV.
224074668|NCT00278681|DRUG|Zinc and ORS|"One strip containing 14 dispersible zinc tablets (20 mg each) along with 2 ORS packets were prescribed to all children aged 1 month to 5 years visiting that channel with diarrhea.~Infants aged less than 6 months were advised half a zinc tablet in a teaspoonful of breast milk; older children were advised 1 tablet in breast milk or clean water."
224074669|NCT05528510|DRUG|Guselkumab Dose 1|Guselkumab (Dose 1) will be administered as SC injection.
224074670|NCT05528510|DRUG|Guselkumab Dose 2|Guselkumab (Dose 2) will be administered as SC injection.
224074671|NCT05528510|DRUG|Guselkumab Dose 3|Guselkumab (Dose 3) will be administered as SC injection.
224074672|NCT05528510|OTHER|Placebo|Placebo will be administered as SC injection.
224074673|NCT04302532|DRUG|Coenzyme Q10|antioxidant used to decrease oxidative stress and improve fertility prospects
224074674|NCT04302532|DRUG|clomiphene citrate|ovulation induction drug
224074675|NCT00486408|BIOLOGICAL|MRKAd5 HIV-1 gag/pol/nef|1.5x10\^10 Ad vg
224074676|NCT00999908|DRUG|Indacaterol 150 μg|Indacaterol was supplied in powder filled capsules together with a single dose dry powder inhaler (SDDPI) device.
224074677|NCT00999908|DRUG|Tiotropium 18 μg|Tiotropium was supplied in powder filled capsules together with a single dose dry powder inhaler (SDDPI) device.
224074678|NCT00999908|DRUG|Placebo|Placebo (matching indacaterol) was supplied in powder filled capsules together with a single dose dry powder inhaler (SDDPI) device.
224074679|NCT06501287|DIAGNOSTIC_TEST|Postprandial triglyceride|impact of postprandial triglyceride level on coronary atherosclerosis
224074680|NCT00733707|BEHAVIORAL|Text messaging reminders|Subjects in this arm will receive daily text message reminders once per day at the same time each day. Messages will remind the subject to take their oral contraceptive pill.
224074681|NCT04951258|OTHER|Multicomponent exercise|The intervention is a 60-minute session, 3 times/week, totaling 9 weeks. Multicomponent exercise included strengthening, balance training, aerobic dance, and stretching
224074682|NCT04951258|OTHER|Video home exercise group|The intervention is a 60-minute session, 3 times/week, totaling 9 weeks. Video home exercise included four limbs mobility exercise, stretching, strengthening, and aerobic exercise
224074683|NCT00110565|DEVICE|Pulsed magnetic field pad|
224074684|NCT01675960|DRUG|Gabapentin|The active drug is in a flavored glycerin based solution. The drug will be given orally or through a gastrointestinal tube. Titration up to a stable dose will take 22 days. The total stable dose is 40mg/kg/day. Once 7 days on this dose are finished, children will take 6 days to reduce their dose and begin their 3 day washout period.
224074685|NCT01675960|DRUG|placebo|The placebo is a glycerin-based clear solution that is flavored similarly to the commercial product. The placebo will be given orally or through a gastrointestinal tube.
224074686|NCT03552341|OTHER|Maternal iodine status|Urinary iodine concentration during pregnancy at 26 weeks' gestation (Bord in Bradford study) and at 12, 26 and 36 weeks' gestation, 6, 18 and 30 weeks postpartum (Hiba longitudinal study). This is primarily in the form of Iodine to Creatinine ratio, to take spot urine volume into account. There is no intervention in this observational study.
224074687|NCT05697328|DRUG|Pseudoephedrine Pill|One-time 60mg dose given orally between 45-120 minutes prior to hyperbaric oxygen therapy
224074688|NCT05697328|DRUG|Placebo|One time dose given orally between 45-120 minutes prior to hyperbaric oxygen therapy
224074689|NCT00523588|PROCEDURE|laser treatment (Candela Vbeam Perfecta™)|This laser has an adjustable pulse duration (0.45-40 ms), fixed wavelength 595 nm, spot size (3 mm, 5 mm, 7 mm, and 10 mm), and incident fluence range of 10-40 J/cm2. The laser is also equipped with a dynamic cooling device (DCD) (FDA cleared under K001589) that delivers cryogen (R-134a) from a small nozzle positioned 4 cm above the skin at an angle of approximately 70 degrees with respect to the skin surface. All patients will be treated with the laser device on which the varying cooling device parameters will be selected based on the clinical judgment of the treating physician. Factors used in this decision include patient age, skin type and epidermal pigmentation, size and depth of vessels, color of lesions, anatomic location, etc. In all instances, a test-dose in an inconspicuous location on the skin will be conducted prior to the first treatment.
224074690|NCT03889639|DRUG|SAR442168|Pharmaceutical form: Film coated tablet; Route of administration: Oral
224074691|NCT03889639|DRUG|Placebo|Pharmaceutical form: Film coated tablet; Route of administration: Oral
223746275|NCT06060860|BEHAVIORAL|Cognitive-Behavioral Therapy (CBT)|"The UP incorporates common principles among empirically supported CBT protocols, including restructuring maladaptive cognitions, changing maladaptive behaviors, preventing emotion avoidance, and incorporating exposure. It consists of five core treatment modules:~1. emotion awareness,~2. cognitive appraisal \& reappraisal,~3. emotion avoidance \& emotion-driven behaviors,~4. awareness and tolerance of emotion-related physical sensations, \&~5. interoceptive and situational emotion-focused exposures.~There are two introductory modules on enhancing motivation and understanding of emotional experiences. A final module is on maintenance and relapse prevention. Modules are delivered at a flexible pace and some patients may spend multiple sessions on the same module. The total number of sessions varies from patient to patient, generally ranging from 12-18 sessions (50-60 minutes) delivered weekly. All sessions are 1:1 via telehealth."
223746276|NCT06060860|BEHAVIORAL|Mindfulness-Based Cognitive Therapy (MBCT)|The study MBCT protocol is a 9-week program (90-120 minute sessions) with home-based practice between sessions. MBCT sessions incorporate formal mindfulness meditation practices such as sitting meditation, mindful movement, and body scan (with a focus on mindful and non-judgmental attention to sensations, thoughts, and feelings), as well as informal practices and homework to integrate mindful awareness into everyday life, such as mindful eating, mindful walking, and mindful breathing. All sessions are 1:1 via telehealth.
223746277|NCT06913751|BEHAVIORAL|standard of care|standard of care therapy with behavioural and occupational therapy along with other pharmacological therapy as required
224191744|NCT01315158|DRUG|Propofol+Benzo/Opioids|"1. Recommended Versed:~   a. Prior to intubation~  * patient is \< 50 kg = 1 mg Versed~  * patient is 50-75 kg = 1.5 mg Versed~  * patient is \> 75 kg = 2 mg Versed~2. Recommended Fentanyl~   1. Prior to intubation = 0.5 ug/kg~  2. Total procedural dose = 1 ug/kg"
224191745|NCT06663384|OTHER|Evaluation of Augmented Reality technology in TKA compared to standard TKA|Evaluation of effectiveness of AR system used to perform bone cuts when compared to traditional jigs in primary TKA
224191746|NCT06606561|DRUG|NANOVAE - Acellular Allogenic Human Amniotic Fluid (hAF)|A total of 24 subjects meeting all inclusion/exclusion criteria will be divided into two groups. Group 1 will be an open-label lead-in phase. Group 2 will be a randomized, double-blinded, placebo-controlled cohort. Group 1 will receive one dose of 2ml of NANOVAE, and Group 2, in a randomized and double-blinded fashion, will receive two doses of 2ml NANOVAE. Neither the patients nor the researchers will know who is getting the placebo and who is getting the NANOVAE; only the product manufacturing staff will be unblinded. The ratio of placebo to NANOVAE is 1:1 for a total of 16 subjects in Group 2. Only the knee with the more severe symptoms of OA will be treated. The allogenic-HAF
224191747|NCT06606561|DRUG|0.9% Sodium Chloride Injection, USP|In lieu of AF, the saline for injection will be used as a placebo. Vials acquired from the manufacturer is pipetted into glass vials, stoppered, capped, placed in labeled header foil pouches, and sealed. These are transferred to a quarantine freezer to await post-production testing.
224191748|NCT06986109|DRUG|Ketamine|Ketamine (concentration 5mg/ml) will be administered at 0.05-ml/kg over 5-minutes followed by continuous intraoperative ketamine infusion of 0.05-ml/kg /h.
224191749|NCT06986109|DRUG|Propofol|Propofol administration rate will be controlled by a feedback loop facilitated by BIS monitoring using the conventional closed loop anaesthesia delivery system (CLADS). A BIS value of 50 will be used as the target point for induction and maintenance of anaesthesia.
224191750|NCT06986109|DRUG|Placebo|Normal saline bolus 0.05-ml/kg will be administered over 5-minutes and it will be followed by continuous intraoperative normal saline infusion at 0.05-ml/kg /h.
224191751|NCT04809142|DRUG|TQB2450 Injection|TQB2450 1200 mg administered intravenously (IV) on Day 1 of each 21-day cycle.
223500903|NCT06246955|OTHER|Survey Administration|Ancillary study
223500904|NCT03034928|DEVICE|Contact lens with investigational coating 1|Contact lens with investigational coating 1 pre-cycled in OPTI-FREE® RepleniSH® Multi-Purpose Disinfecting Solution (MPDS)
223500905|NCT03034928|DEVICE|Balafilcon A contact lens|Balafilcon A contact lens pre-cycled OPTI-FREE® RepleniSH® MPDS
224191752|NCT04809142|DRUG|Anlotinib hydrochloride|Anlotinib capsules 12 mg given orally, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21).
224191753|NCT04809142|DRUG|Oxaliplatin injection|Oxaliplatin injection 130 mg/m2 administered IV on Day 1 of each week in 3-week cycles;
224191754|NCT04809142|DRUG|Capecitabine tablets|Capecitabine tablets total dose 2000 mg/m2, oral twice a day from Day 1-14 of each 3- week cycles;
224191755|NCT04809142|DRUG|Gemcitabine hydrochloride injection|Gemcitabine hydrochloride injection administered 1000 mg/m2 IV on Day 1 and Day 8 of each week in 3-week cycles.
224191756|NCT00931515|DEVICE|NuBac|NuBac device implanted at the L4/5 level.
223500906|NCT03034928|DEVICE|OPTI-FREE® RepleniSH® MPDS|Multipurpose contact lens solution
223500907|NCT03034928|DEVICE|Contact lens with investigational coating 2|Contact lens with investigational coating 2 pre-cycled in OPTI-FREE® RepleniSH® MPDS
223500908|NCT05283447|OTHER|Osteopathic Medicine|The clinical protocol subject to analysis for the intervention group consists of manual approach techniques for the myofascial and viscerofascial structures of the anterior face of the neck, maneuvers for the mediastinal region, techniques for normalizing the tone of the thoracic diaphragm and its pillars, on the peritoneal ligaments, and caudal traction of the stomach for manual correction of hiatal hernia.
224191757|NCT00931515|DEVICE|Prodisc-L|Prodisc-L implanted at the L4/5 level.
224191758|NCT03539120|OTHER|Follow up for survival|No intervention, this is an observational study of survival outcomes.
223500909|NCT05283447|OTHER|Control|The physiotherapeutic treatment on the control group consists of an approach to the lumbopelvic joint restrictions and a massage on the inframesocolic abdominal region with minimal pressure, which does not affect the activity and position of the stomach.
224191759|NCT03759340|DRUG|ATI 502 0.46% Topical Solution|apply ATI-502 Topical Solution, 0.46% Twice a day (BID) to the entire scalp and if applicable, the eyebrow(s)
224191760|NCT05905692|DRUG|L Carnitine|L carnitine will be given to group 1 (20 mg/kg/day) 3 times per week
224191761|NCT03987165|OTHER|Music Therapy|"Music therapy will be conducted once daily using a Song of Kin, a familiar song used to lull the infant to sleep. If no Song of Kin is provided, Twinkle Twinkle Little Star will be the default lullaby."
224191762|NCT03802500|DIAGNOSTIC_TEST|Nerve conduction study|"Physical examination of muscle strength is conducted using the Medical Research Council (MRC) scale in 6 muscles bilaterally.~Patients with an MRC score of less than 48 of 60 are diagnosed with critical illness polyneuromyopathy (CIPNM).~The evaluation is completed by a routine neurological examination. In patients meeting the inclusion criteria, the screening Peroneal nerve test (PENT test) is performed on the day of study enrollment and subsequently in 1 week intervals until pathologic findings are detected or patient is discharged from the ICU.~PENT measures the peroneal nerve Compound muscle action potential (CMAP) amplitude in one leg. If the PENT is normal, the contra-lateral peroneal nerve is measured. An abnormal condition is identified if the peroneal nerve CMAP amplitude is reduced below the normal limits of the participating centre in at least one leg. In Lausanne, the abnormal response is \< 2,5 mV."
224191763|NCT03174028|DEVICE|laparoscopic pull-through|laparoscopic pull-through
224191764|NCT05672810|DIAGNOSTIC_TEST|serum level of Ferritin and D-dimer|Blood venous sample
224191765|NCT03845426|OTHER|Root canal treatment.|Once pulpal necrosis has been diagnosed, root canal treatment will be carried out by the patient's general practitioner. This is an end point for the tooth in the study.
224191766|NCT00300976|BEHAVIORAL|Lifestyle consultation: weight control, diet, exercise|"Behavioral: Lifestyle modification including weight control, with the goal of BMI 22.~Drug: Drugs are added in a stepwise manner to control blood glucose, blood pressure and lipid metabolism, using mainly hypoglycemic drugs, ACEI/ARB and statins, respectively. Management goals are: HbA1c \< 6.2%, BP \< 120/75 mmHg, HDL-C 40 mg/dL , LDL-C \< 80 mg/dL, TG \< 120 mg/dL.~Follow-up study (Not provided)"
223591663|NCT03267888|RADIATION|Radiation Therapy|Patients will receive radiotherapy (8 Gy/1 fx) to an extra-osseous site and/or any bony site containing myeloma deposit.
223591664|NCT02893917|DRUG|Cediranib|Given PO
223591665|NCT02893917|DRUG|Olaparib|Given PO
223591666|NCT06140459|DEVICE|Conventional Toothbrushes|Oral-B Stages 3
223591667|NCT06140459|DEVICE|Pulsating Toothbrushes|Oral-B Pulsar, Colgate 360º Micro Sonic Power
223591668|NCT03626545|DRUG|Canakinumab|Canakinumab, 200 mg, subcutaneous. The initial dose regimen was once every 3 weeks (on Day 1 of each 21-day cycle)
223591669|NCT03626545|DRUG|Docetaxel|Docetaxel 75mg/m\^2, intravenous, administered on Day 1 of each 21-day cycle
223591670|NCT03626545|OTHER|Placebo|Placebo, sub-cutaneous, admnistered at the RP3R defined in Part 1-safety run-in.
223746278|NCT06913361|DIAGNOSTIC_TEST|Gongs Mobilization|The treatment begins with moist heat for 10 minutes, Gong's mobilization with conventional therapy for 8 minutes. The total treatment time was 45 minutes once a day for four days per week for four weeks.
223746279|NCT06913361|COMBINATION_PRODUCT|Reverse Distraction Technique|The treatment begins with moist heat for 10 minutes, Reverse Distraction technique with conventional therapy for 8 minutes. The total treatment time was 45 minutes once a day for four days per week for four weeks. Position of the patient: side-lying. The patient is lying at the plinth's edge on the unaffected side. In front of the patient is the therapist's position.
224191767|NCT00300976|BEHAVIORAL|Lifestyle consultation: weight control, diet, exercise|"Behavioral and Drug: The physician in charge is to administer appropriate therapy in accordance with the Guidelines.~Follow-up study (Not provided)"
224191768|NCT04551248|BIOLOGICAL|10 or 13-valent pneumococcal conjugate vaccine|a four-dose series that is indicated for use at 2, 4, 6, and 12 to 15 months of age.
224191769|NCT04551248|BIOLOGICAL|23-valent pneumococcal polysaccharide vaccine|Single 0.5-mL dose administered intramuscularly or subcutaneously only.
224191770|NCT04551248|BIOLOGICAL|Influenza vaccine|One dose of trivalent influenza vaccine in flu seasons.
223591671|NCT00793169|PROCEDURE|Blood Draw|Serum levels were measured
223591672|NCT04274556|OTHER|Post-dialysis recovery group|Before the hemodialysis session, the patients were asked by the investigators how long it took them to recover from a dialysis session, taking the last treatment month into account.
223591673|NCT05809063|OTHER|observational|document the number , disease pattern\& outcome of neonates admitted to the neonatal intensive care units
223591674|NCT01324869|BIOLOGICAL|KH902|Intravitreal injection of 0.5mg/eye/time KH902
223591675|NCT02489669|DEVICE|RenalGuard system™® (PLC Medical Systems, Inc. Franklin, MA, USA)|Patients in the RenalGuard group will be treated by hydration with normal saline controlled by the RenalGuard system™® (PLC Medical Systems, Inc. Franklin, MA, USA). The RenalGuard system includes a) a closed loop fluid management system; b) a high volume fluid pump, c) a high accuracy dual weight measuring system; d) motion detection artifact reduction; e) a single use intravenous set and urine collection system that interfaces with a standard Foley catheter; f) real-time display of urine and replacement fluid volume; g) a timely alerts to drain the urine bag or to replace the hydration fluid bag; f) and safety features such as automatic air and occlusion detection.
223591676|NCT06161480|DEVICE|Weighted Blanket|Weighted Blanket is an occupational therapy modality which has been associated with significant increases in grounding, orientation to reality, soothing, and quality of life.
223591677|NCT00369642|BEHAVIORAL|Cognitive-behavioral therapy|
223591678|NCT05035836|DRUG|Zanidatamab|Given IV
223591679|NCT05035836|DRUG|Letrozole|Given by PO
223591680|NCT05035836|DRUG|Tamoxifen|Given by PO
223591681|NCT03450382|OTHER|Hans Kai Education|9 weeks of health education classes preceding social group formation into Hans Kai. Peer led support focused on behavioural change.
223591682|NCT05391022|DRUG|Pelabresib|Pelabresib monohydrate tablets
223591683|NCT01019850|DRUG|Vorinostat|Patients on study will receive vorinostat orally once daily on days 1 to 14 of treatment.This is a single course treatment. The study has a planned dose escalation schedule, the starting dose level is 180 mg/M2.The maximum absolute dose of vorinostat is 400 mg.
223591684|NCT01019850|RADIATION|131- I Metaiodobenzylguanidine|Patients will receive 131-I MIBG on day 3 , one hour after vorinostat dosing.Patients will initially receive 8 mCi/kg 131-I MIBG with 180 mg/m2/dose vorinostat. The dose of 131-I MIBG will be escalated in subsequent cohorts to 15 mCi/kg and then to 18 mCi/kg.If the starting dose exceeds the maximum tolerated dose, patients will be treated with a lowering of vorinostat dose initially (150 mg/m2/day . Dose level -1). If this combination still exceeds the maximum tolerated dose, then a dose level using reduced dose 131-I MIBG will be studied (6 mCi/kg. Dose level -2).
224191771|NCT02950831|OTHER|Accelerometry|Record of activity levels using a wrist worn accelerometer
224309756|NCT02983136|BEHAVIORAL|Dialogue and inter-professional learning|"The middle and front-line leaders of the study OR will participate in an intervention based on an iKT model. Components of the intervention will include:~* Two workshops, consisting of educational sessions covering the state of the art regarding person-centeredness, prevention of infections, leadership, and implementation. The educational component and results of pre-studies will work as frameworks for the dialogues between the front-line leaders and the research group. In dialogues the participants will be given the opportunity to reflect on barriers to and enablers of change; and~* The participants will be supported in creating an action plan aimed at facilitating the anaesthesia providers' change of practice."
224191772|NCT05164068|BEHAVIORAL|Information video|The video contents were clear and adapted to the characteristics of the population of Guatemala. The video provided a simple description of the biopsy, its risks and benefits, complications and general recommendations, and was presented preoperatively
224191773|NCT00945815|BIOLOGICAL|epratuzumab|
224309757|NCT01463436|DIETARY_SUPPLEMENT|soy isoflavone|100 mg soy isoflavone tablet containing genistein 55%, daidzein 39% and glycitein 6% and calcium carbonate 500 mg in the experimental group for 6 months and 12 months
224309758|NCT01463436|DIETARY_SUPPLEMENT|control group|the control group receiving tablet contain calcium carbonate 500 mg/day for 6 months and 12 months
224309759|NCT05433727|DIAGNOSTIC_TEST|videodermoscopy, lesional capillaroscopy|videodermoscopy and lesional capillaroscopy will be performed under different magnification levels to the skin lesions and data will be recorded.
224309760|NCT05277623|DRUG|Mannitol|During the anhepatic phase, the patients in the mannitol group (30) will receive 1 g/kg
224309761|NCT05277623|OTHER|0.9% normal saline|the same amount of 0.9% normal saline
224309762|NCT03253523|PROCEDURE|Occipital neurolysis|Surgical occipital nerve decompression
224309763|NCT01414595|GENETIC|DNA analysis|
224309764|NCT01414595|GENETIC|DNA methylation analysis|
224309765|NCT01414595|GENETIC|RNA analysis|
224309766|NCT01414595|GENETIC|gene expression analysis|
224309767|NCT01414595|GENETIC|polymorphism analysis|
224191774|NCT00945815|DRUG|clofarabine|
224191775|NCT00945815|DRUG|cytarabine|
224309768|NCT01414595|OTHER|laboratory biomarker analysis|
224309769|NCT01414595|OTHER|medical chart review|
224309770|NCT00532818|DRUG|Hydralazine and magnesium valproate|Cisplatin + Topotecan plus hydralazine valproate
224191776|NCT00945815|OTHER|laboratory biomarker analysis|
224191777|NCT02861248|PROCEDURE|Fractional micro-plasma radiofrequency treatment|After the patient's scars were subjected to a mild cleanser and 70% alcohol, a topical cream of 5% lidocaine hydrochloric acid (Beijing Ziguang Medication Manufacture Corporation Ltd, Beijing, China) was applied to the entire scar surface under occlusion for 60-90 min before treatment to achieve local anesthesia. Fractional micro-plasma radiofrequency treatment (Pixel RF, Accent XL; Alma Lasers, Caesarea, Israel) was applied using a roller tip at 50-80 watts. Three or four passes were made in different directions over each affected area. A high rolling speed of roughly 5 cm/s was manually controlled. This treatment was accompanied by an air cooler (Cryo 5; Zimmer, Warsaw, IN, USA) for pain control. All patients attended three to five treatment sessions at intervals of 8-16 weeks.
224191778|NCT03528265|DEVICE|Lateral flow immunoassay|Biospecimens of patients with melioidosis-like symptoms will be tested with lateral flow immunoassay to detect Burkholderia pseudomallei, bacterium causing melioidosis
224191779|NCT06995131|DIAGNOSTIC_TEST|Del 1|During cataract surgery, approximately 0.1-0.2 mL of aqueous humor will be sampled with a sterile 27 gauge syringe before viscoelastic is introduced into the anterior chamber. DEL 1 will be analyzed by ELISA
224309771|NCT00532818|DRUG|Placebo|Cisplatin + Topotecan plus placebo
224309772|NCT04856150|DRUG|Q-1802|Q-1802 will be administered intravenously.
224309773|NCT00630019|DRUG|1.5% levofloxacin ophthalmic solution|Topical application
224309774|NCT00630019|DRUG|0.5% moxifloxacin hydrochloride ophthalmic solution|Topical application
224309775|NCT04284995|DRUG|RUC-4 Compound|All patients will receive a single subcutaneous dose of RUC-4 in the Cardiac Catheterization Lab (CCL) before coronary angiography/percutaneous coronary intervention.
224309776|NCT02821052|DRUG|insulin degludec/insulin aspart|Enrolled patients will be treated with Ryzodeg® under routine clinical practice.
224309777|NCT02287207|DEVICE|transcranial direct current stimulation (tDCS)|
224309778|NCT03370809|RADIATION|Brain PET/CT step|a cerebral PET/CT will be registered on the 45th minute after 18F-FDG injection and just before the whole body recording. This recording does'nt need a new injection but needs a low dose scanner
223500910|NCT00016172|DRUG|pegylated liposomal doxorubicin hydrochloride|
223500911|NCT00016172|DRUG|picoplatin|
223500912|NCT00104715|DRUG|antiandrogen therapy|
223500913|NCT00104715|DRUG|docetaxel|
223500914|NCT00104715|DRUG|goserelin acetate|
223500915|NCT00104715|PROCEDURE|orchiectomy|
223500916|NCT00393146|DRUG|GW856553|Study drug
223500917|NCT02583477|DRUG|MEDI4736 in combination with nab-paclitaxel and gemcitabine|MEDI4736 in combination with nab-paclitaxel + gemcitabine chemotherapy regimen via IV infusion
223500918|NCT02583477|DRUG|MEDI4736 in combination with AZD5069|MEDI4736 via IV infusion and oral AZD5069
223500919|NCT03943485|DEVICE|The uterine manipulator which is primarily used in laparoscopic hysterectomy to accurately locate the colpotomy site. We adopted this device in abdominal hysterectomy.|The uterine manipulator is primarily used in laparoscopic hysterectomy to accurately locate the colpotomy site. We hypothesized that adoption of a uterine manipulator would help the surgeon to better identify the colpotomy site by moving the uterus cranially and thus providing better visualization of the colpotomy site.
223500920|NCT06144801|DEVICE|CoolSense Group|Patients in the CoolSense group received a CoolSense device that had been pre-chilled in the freezer for a minimum of one hour. The cover of the CoolSense device was removed, and the arteriovenous fistula, whose metal tip had been cleaned with batikon, was brought into contact with the area where the arteriovenous fistula cannulation would occur. This contact was maintained for 5 seconds, involving circular movements, and the fistula cannulation took place promptly.
223500921|NCT05399355|DEVICE|Active Pulsed Shortwave Treatment with BioElectronics Model 088|Application of 7-30 days of nonthermal, pulsed shortwave (radiofrequency) therapy with BioElectronics Model 088
224309779|NCT00639847|BEHAVIORAL|In-home asthma management program (AMP) provided by nurses|The AMP included asthma education (medications use, monitoring, triggers, steps to manage asthma attacks), demonstration and training (peak flow meter use, MDI and nebulizer use, asthma diary), home environment assessment and suggestions for environmental changes (mattress covers, control of dust, pets, fumes, cleaning materials, cock roach control, etc.)
224191780|NCT06995131|DIAGNOSTIC_TEST|IL 17|During cataract surgery, approximately 0.1-0.2 mL of aqueous humor will be sampled with a sterile 27 gauge syringe before viscoelastic is introduced into the anterior chamber. IL 17 levels will be analyzed by ELISA
224191781|NCT00439010|DRUG|[123I] AV 39|
224191782|NCT02140268|DRUG|Midazolam|Volunteers will receive a single dose of Midazolam 7.5 mg on Day 1
224191783|NCT02140268|DRUG|AZD1722|Volunteers will receive twice daily, oral doses of AZD1722 15 mg on Days 2-14
224191784|NCT02140268|DRUG|AZD1722 and Midazolam|On Day 15 volunteers will receive AZD1722 15 mg and Midazolam 7.5 mg at the same time in the morning. In the evening on Day 15 AZD1722 15 mg will be administered alone.
224191785|NCT00288431|DRUG|ridaforolimus|Different schedules and routes of administration of AP23573 will be examined. For each schedule, AP23573 + Doxorubicin will be co-administered on Day 1 of a 3-week cycle. AP23573 will be given orally and will range in dose from 10-30 mg per dose.
224191786|NCT00288431|DRUG|Doxorubicin|administered at 60 mg/m2 intravenously every 3 weeks
224191787|NCT06377267|DRUG|Bevacizumab|Bevacizumab dosing is at 15 mg/kg every 3 weeks as an intravenous infusion.
224191788|NCT06377267|DRUG|Olaparib|Olaparib dosing is oral at 300 mg twice daily
224191789|NCT04716205|OTHER|Mulligan Bent Leg Raise Technique|Participant will be in supine lying on a high couch with the resting on the shoulder. A distraction (longitudinal traction force along the long axis of femur) will be investigator in walk stand position lateral to the leg, which to be stretch. Hip and Knee of the side to be stretch will bent at 90˚- 90 ˚. Participant's flexed knee will be placed over the shoulder, the popliteal fossa of the knee applied at the lower end of femur and the participant will ask to push the shoulder with his or her leg followed by voluntary relaxation.The traction will maintained throughout the technique.
224191790|NCT04716205|OTHER|Static Stretching|It will be given in supine position by performing passive SLR and end range will hold in 30sec.
224191791|NCT06997133|DIETARY_SUPPLEMENT|sucralose|Encapsulated sucralose po BID
224191792|NCT06997133|OTHER|Placebo|Encapsulated lactose po bid
224191793|NCT01156129|DRUG|stool softener|ducosate sodium, Milk of Magnesia, dulcolax
224191794|NCT01156129|DEVICE|Arm B: Acupressure bracelet|Bioband
224191795|NCT01156129|DIETARY_SUPPLEMENT|sugar free gum|Orbit
224191796|NCT03115723|PROCEDURE|Percutaneous coronary intervention|
224191797|NCT03115723|PROCEDURE|Coronary angiography|
224309780|NCT00639847|BEHAVIORAL|In-home asthma management program (AMP) provided by respiratory therapists|The AMP included asthma education (medications use, monitoring, triggers, steps to manage asthma attacks), demonstration and training (peak flow meter use, MDI and nebulizer use, asthma diary), home environment assessment and suggestions for environmental changes (mattress covers, control of dust, pets, fumes, cleaning materials, cock roach control, etc.)
223500922|NCT05399355|DEVICE|Sham Treatment|Application of 7-30 days of a nonfunctional sham device(s)
223746280|NCT07110519|DRUG|[18F]-fluoromannitol|\[18F\]-fluoromannitol is an investigational, novel radiotracer for use with PET scan imaging to help detect disease or infection.
223500923|NCT05573282|OTHER|Regorafenib combine with ICIs|Regorafenib: 80mg/day, PO, QD, d1～d21, Q4W ICIs: 200mg/day, IV, d1,Q3W
223500924|NCT06210295|COMBINATION_PRODUCT|Laboratory investigtions|To study causes of anemia in SLE in our environment and causes of refractory type and its relation to bone marrow affection and different drugs used in SLE
223500925|NCT03257397|DEVICE|theta-burst stimulation (TBS) using a MagPro X1000|iTBS over left and cTBS over right dorsolateral prefrontal cortex for a period of three weeks. iTBS: 3-pulse 50 Hz bursts will be given every 200ms (at 5 Hz) in 2-second trains with an inter-train interval of 8 seconds. cTBS: 3-pulse 50 Hz bursts will be given every 200ms (at 5 Hz) in a single 40s train; one session will comprise left iTBS and right cTBS. There will be two sessions daily with 60 min in between sessions
223512067|NCT05124236|RADIATION|postoperative hypofractionated stereotactic radiotherapy|5 fraction stereotactic radiotherapy /fractionated radiosurgery
224191798|NCT05173025|DRUG|Fimasartan|\- Fimasartan group: fimasartan, 60 mg once a day, oral administration
224191799|NCT05074459|DRUG|Eptinezumab Mammalian Cell Line|Concentrate for solution for IV infusion
224191800|NCT05074459|DRUG|Eptinezumab Yeast Cell Line|Concentrate for solution for IV infusion
224191801|NCT02909127|OTHER|SWALLOWING EVALUATION|Swallowing function of the CP patients will be imaged and recorded with Videofluoroscopic Swallowing Study (VFSS). The oral cavity, pharynx, larynx and just below the upper esophageal sphincter are visible. 3 trials of 3 ml of liquids will be used and the worst score will be considered for calculation. The Penetration-Aspiration Scale (PAS) will be used to assess dysphagia severity. The PAS is an ordinal scale consisting of eight scores. Scores are determined primarily by the depth to which material passes in the airway and by whether or not material entering the airway is expelled.
224191802|NCT02909127|OTHER|The Functional Independence Measure|The Functional Independence Measure for Children (Wee-FIM) will be used to assess the functional independence level of the CP children. The Wee-FIM is developed to emphasize habilitative and developmental aspects of children with special health care needs, genetic disorders, developmental disabilities, and acquired disabilities.
224191803|NCT02909127|OTHER|The PEDI-EAT-10|The PEDI-EAT-10 will also be administered.
224191804|NCT01965600|DRUG|PF-06282999|Tablet, 125 mg, TID, 3 days, 1 of 2 periods
224191805|NCT01965600|DRUG|Placebo|Tablet, 0 mg, TID, 3 days, 1 of 2 periods
224191806|NCT01965600|OTHER|LPS|IV bolus, 4 ng/kg, 1 day, QD, 2 of 2 periods
223512068|NCT03413449|DIAGNOSTIC_TEST|Frailty model|"1. Grip strength~2. 30 second chair sit stand test~3. Psoas muscle area~4. Six minute walk"
223512069|NCT06439706|BEHAVIORAL|HPV Self-Sampling|HPV self-sampling kit
223512070|NCT06439706|BEHAVIORAL|Group Education|Small-group education led by bilingual health educator
224191807|NCT01965600|DRUG|PF-06282999|Tablet, 500 mg, BID, 3 days, 1 of 2 periods
223591685|NCT01019850|PROCEDURE|Peripheral Blood Stem Cell Infusion|Stem cell infusion is planned for 2 weeks after MIBG infusion (day 17). However, stem cells may be infused on day 18 or day 19 to avoid weekend or holiday stem cell infusions.The dose for Purged PBSC is a minimum of 2 x 106 viable CD34+ cells/kg and for Unpurged PBSC: a minimum of 2 x 106 viable CD34+ cells/kg must be available. Stem cells must be infused over 15-30 minutes and within 1.5 hours of thawing.Stem cells will be infused following institutional guidelines for prophylaxis of hypersensitivity reactions and monitoring.
224191808|NCT01965600|DRUG|Placebo|Tablet, 0 mg, BID, 3 days, 1 of 2 periods
224191809|NCT01965600|OTHER|LPS|IV bolus, 4 ng/kg, 1 day, QD, 2 of 2 periods
224191810|NCT00363272|DRUG|ispinesib|Given IV
224191811|NCT00363272|OTHER|laboratory biomarker analysis|Correlative studies
224191812|NCT00363272|OTHER|pharmacological study|Correlative studies
224191813|NCT04235673|DIETARY_SUPPLEMENT|melatonin|orally administered drops
224191814|NCT04235673|DRUG|placebo|orally administered drops
224191815|NCT01402882|DRUG|Tranexamic Acid|2 grams (1 gram over 10 minutes and 1 gram over 8 hours)
224191816|NCT00735839|BIOLOGICAL|V710|V710 vaccination (60 mcg, 0.5 ml) single injection on Day 1
224191817|NCT00735839|BIOLOGICAL|Placebo|Saline placebo (0.5 ml) single injection on Day 1
224191818|NCT00282373|DEVICE|mild hypothermia|
224191819|NCT07000214|DEVICE|Peripheral magnetic stimulation|During the warm-up exercise, 10-Hz rPMS will be applied to the tibialis anterior with an on-time of 4 seconds (40 pulses per train), followed by an off-time (inter-train interval) of 8 seconds, for a total of 25 trains for each leg. During the one-leg stance exercise, 20-Hz rPMS will be applied to the plantar surface of the standing foot for 3 seconds of on-time (60 pulses per train), followed by 12 seconds of off-time, for a total of 20 trains for each foot. Stimulation intensity will be set at 110% of MCT for the warm-up exercise and 120% of MCT for the treatment during the one-leg stance exercise.
224309781|NCT02938754|BEHAVIORAL|VR-based motor training|Subjects will perform 3 different training protocols in Virtual Reality that imply performing tasks of vertical and planar reaching and hitting spheres, or hockey pucks, spaced at different time, speed and color.
224309782|NCT02938754|BEHAVIORAL|Conventional Therapy|Subjects will perform conventional rehabilitation tasks for the upper-extremities that imply vertical and planar reaching movements.
223591686|NCT01019850|DRUG|Filgrastim|All patients will receive filgrastim following hematopoietic stem cell infusion according to institutional guidelines (section 4.2.3 of protocol).
223591687|NCT00057369|DRUG|dalbavancin|
223591688|NCT04039152|OTHER|locally adapted neonatal sepsis treatment protocol|the neonatal sepsis treatment protocol was modified according to the local antibiotics susceptibility patterns
223591689|NCT03951909|BEHAVIORAL|Physiotherapy activity and awareness intervention: PAAI|10 to 12 persons will be invited to each group. The intervention will consist on 8 weekly sessions including the same key elements each time: introduction with a mindfulness exercise and a ball game, several movements while sitting on a chair, standing proprioceptive exercises with wooden sticks and exercises to raise awareness of muscle tensions in the body, active movements stimulating the balance, coordination and breathing and finally relaxation and a short closing round.
224074692|NCT03889639|DRUG|Locally approved intravenous contrast medium for contrast enhanced magnetic resonance imaging (MRI)|Pharmaceutical form: Solution for injection; Route of administration: Intravenous
224074693|NCT06345456|DEVICE|End-tidal capnography|The value of end-tidal capnography
224074694|NCT03060070|DRUG|Ketamine|Ketamine at a dose of 0.5mg/kg will be added to bupivacaine 0.25 (total volume 20ml) in each side using sonar guided TAP block
224074695|NCT03060070|DRUG|dexmedetomidine|dexmedetomidine at a dose of 1ug/kg will be added to bupivacaine 0.25 (total volume 20ml) in each side using sonar guided TAP block
224074696|NCT03060070|DRUG|control group|20ml of 0.25% bupivacaine will be injected in each side of the TAP block
224074697|NCT05808244|BEHAVIORAL|tgCBFI|Six weekly sessions CBT-based family intervention programme
224074698|NCT05808244|BEHAVIORAL|Usual psychiatric care|Integrated community psychiatric care with medical follow-up
224074699|NCT03038425|DRUG|Normal Saline|This is the placebo intervention - normal saline infused in the adductor canal via a catheter. There are no anticipated therapeutic effect
224074700|NCT03038425|DRUG|Ropivacaine|This is the treatment intervention - ropivacaine 0.2% infused in the adductor canal via a catheter. This will provide analgesia to the knee after TKA
224074701|NCT03618511|BEHAVIORAL|Financial Incentive|Financial Incentive: Participants will receive monthly financial incentives each time they refill the ART medication on time for six months
224074702|NCT03618511|BEHAVIORAL|Reminders|Reminders: Participants will receive monthly reminder phone calls before their ART medication refill is due for six months.
224074703|NCT03618511|BEHAVIORAL|Financial Incentive and Reminders|Interaction: Participants receive both the Financial Incentives and Reminder Calls.
224074704|NCT03618511|BEHAVIORAL|Information|Information: show the participants a video about HIV progression, mechanism of ART, the benefit of adhering to ART.
224074705|NCT03618511|BEHAVIORAL|Stigma-relieving|Stigma-Reliving: Upon recruitment, inform the participants of the results of a recent population survey regarding people's attitudes towards HIV, if they overestimate the social stigma related to HIV. This intervention intends to reduce the stigma-concern faced by the patients.
224074706|NCT03618511|BEHAVIORAL|Information and Stigma-relieving|Information and Stigma-relieving: Upon recruitment, show the participants a video about HIV progression, mechanism of ART, the benefit of adhering to ART. In addition, inform the participants of the results of a recent population survey regarding people's attitudes towards HIV, if they overestimate the social stigma related to HIV. This intervention intends to reduce the stigma-concern faced by the patients.
224074707|NCT00290966|DRUG|XRP6976|
224074708|NCT01703858|DRUG|BI 113608 PIB|powder for oral solution
224074709|NCT01703858|DRUG|BI 113608|conventional tablet formulation
224074710|NCT01703858|DRUG|BI 113608|conventional tablet formulation
224074711|NCT01703858|DRUG|BI 113608|conventional tablet formulation
224074712|NCT01703858|DRUG|pantoprazole 40 mg STADA|film-coated tablet
224074713|NCT01703858|DRUG|BI 113608|conventional tablet formulation
224074714|NCT01789450|PROCEDURE|Section of Periareolar Dermis in Breast Reduction.|
224191820|NCT07000214|BEHAVIORAL|Balance training|The warm-up exercise consists of 25 repetitions of 4-second active contractions of the tibialis anterior muscle in each leg while seated. Following the warm-up, participants will stand on the MAGBATA platform and perform 20 cycles of one-leg stance exercises under the supervision of a physiotherapist. Each cycle lasts 20 seconds, consisting of 3 seconds of one-leg stance while the other leg is raised about 10 centimeters above the ground, followed by 12 seconds of rest during which the participant stands on both legs, keeping their arms close to their body and hands free. The same sequence will then be repeated for the other leg. To prevent falling, participants will wear a safety belt around the waist, allowing the physiotherapist to assist if they lose balance. Participants will also be allowed to grab the walker positioned in front of them to prevent falling.
224191821|NCT07000214|OTHER|Sham stimulation|During the warm-up exercise, the stimulation coil will be placed perpendicular to the participants' shin. The same parameter settings will be used, except for the intensity, which will be set at 30% of the maximum stimulator output (MSO). Sham stimulation during the one-leg stance exercise is achieved by disconnecting the coil mounted in MAGBATA and placing an alternate coil, connected to the magnetic stimulator placed behind the participants so they can hear a clicking pattern similar to that of the rPMS-BT arm.
224191822|NCT02632097|PROCEDURE|Lichtenstein Hernioplasty with Histoacryl|"Procedure/Surgery: Lichtenstein Hernioplasty with Histoacryl:~0.5 ml of cyanoacrylate glue is used for mesh fixation"
224191823|NCT02632097|PROCEDURE|Lichtenstein Hernioplasty with Sutures|Procedure/Surgery: Lichtenstein Hernioplasty with Sutures: non-absorbable suture (polypropylene 2/0) is used for mesh fixation Other Name: prolene 2-0
224191824|NCT04323345|DIETARY_SUPPLEMENT|Natural Honey|Natural Honey supplement 1gm/kg/day divided into 2 to 3 doses for 14 days either orally or through nasogastric tube.
224191825|NCT04323345|OTHER|Standard Care|Supportive measures and lopinavir/ritonavir tablets or Arbidol or chloroquine phosphate or Hydroxychloroquine or oseltamivir with or without azithromycin.
224191826|NCT06858085|OTHER|Turkish Version of the Late Life Function and Disability Instrument|The Late Life Function and Disability Instrument (LLFDI) was developed to assess significant changes in functional and disability categories
224309783|NCT03550105|DEVICE|Gentle Jogger|Gentle Jogger is a passive simulated jogging device to be used 3 times per day for at least 30 mins for 7 days in this study
224309784|NCT02426853|BEHAVIORAL|Questionnaires|Participants complete 1 questionnaire at beginning of study, 1 after receiving education about how to protect skin from sun and how to avoid tanning beds, and 1 at about 3 months after receiving skin protection education.
224309785|NCT02426853|OTHER|Photos|At beginning of study, 2 photos taken of the face. One photo is a standard photo, the other photo is taken with an ultraviolet (UV) filter.
224309786|NCT02426853|BEHAVIORAL|Pamphlets|At beginning of study, handouts given that discusses skin cancer prevention, sun protection, and how to avoid tanning beds.
224309787|NCT01208220|DEVICE|Negative Pressure Wound Therapy|NPWT changed 3 times weekly
224191827|NCT07005882|DRUG|Elacestrant|Preoperative treatment
224191828|NCT07005882|RADIATION|PULSAR|Preoperative treatment
224191829|NCT07006038|DEVICE|Veinlite PEDI2|The Veinlite PEDI2 used before the catheter insertion.
224309788|NCT01208220|BIOLOGICAL|Collagenase Ointment|Apply TIW
224309789|NCT00758680|DRUG|MK-1006|MK-1006 capsules (10 mg and 20 mg) administered orally from 20 mg to 120 mg per dose over a multiple dosing period.
224309790|NCT00758680|DRUG|Comparator: Placebo comparator|Dose-matched MK-1006 placebo capsules (1 mg, 10 mg and 20 mg) administered orally over a multiple dosing period.
224309791|NCT04174976|PROCEDURE|wall hernia repair|Wall hernia repair with mesh
224309792|NCT00761865|DEVICE|Air Cast Stirrup Brace & High Tide Fracture Boot|Subjects will be randomly assigned to one of two treatment braces. All patients will be given instructions to use fracture boot or air cell brace at all times of ambulatory activity until follow-up until 2 week post-strain follow-up.
224309793|NCT00319982|DRUG|Diltiazem|Sustained release formulation titrated to a target dose of 360 mg daily, or a maximum of 5 mg/kg/day in pediatric subjects for the duration of the study period
224309794|NCT00319982|DRUG|Placebo|Placebo comparator (double-blind allocation of study medication)
224309795|NCT02565173|DRUG|trabodenoson 4.5% BID|Trabodenoson 4.5% administered twice per day in both eyes for 12 weeks.
224191830|NCT06867367|BEHAVIORAL|Isha Kriya and Naddi Shuddhi|Isha Kriya, a 15-minute guided meditation, and Nadi Shuddhi, a 3-5-minute alternate-nostril breathing practice. Participants in the intervention groups will be instructed to practice ideally twice or at least once daily.
224191831|NCT07005180|DRUG|HBI-002|Oral liquid containing carbon monoxide
224191832|NCT07005180|DRUG|Vehicle (placebo)|Vehicle control (placebo)
224191833|NCT07006337|OTHER|Surgical Operating Room Enrichment Course|The intervention consists of multiple structured training sessions delivered during the gynecology rotation. Sessions include lectures on surgical principles and gynecologic procedures. The course is taught by OBGYN physicians and is designed to enhance students' proficiency in surgical techniques, perioperative care, and management of gynecologic emergencies. Educational materials are based on relevant surgical guidelines and textbooks
224191834|NCT07006337|OTHER|Active Comparator #1|Active Comparator #1
224191835|NCT00620672|DIETARY_SUPPLEMENT|omega 3 fatty acids|The supplements are taken orally with a meal, each day. The amount of the omega 3 fatty acid docosahexaenoic acid is 400 mg/day; taken in two 500 mg capsules each providing 200 mg docosahexaenoic acid. The placebo is two 500 mg capsules soybean/canola oil. Both the supplement and placebo are a total of 1 gm/day (2x500 mg) and about 10 calories per day.
224191836|NCT00620672|DIETARY_SUPPLEMENT|vegetable oil|The supplement is a dietary supplement of vegetable oil as a placebo
224309796|NCT02565173|DRUG|trabodenoson 6.0% QD|Trabodenoson 6.0% administered once per day in the morning in both eyes followed by matching placebo administered once per day in the evening in both eyes for 12 weeks.
224309797|NCT02565173|DRUG|trabodenoson 3.0% QD|Trabodenoson 3.0% administered once per day in the morning in both eyes followed by matching placebo administered once per day in the evening in both eyes for 12 weeks.
224309798|NCT02565173|DRUG|timolol 0.5% BID|Timolol 0.5% administered twice per day in both eyes for 12 weeks.
224309799|NCT02565173|DRUG|placebo BID|Placebo administered twice per day in both eyes for 12 weeks.
224309800|NCT03463382|PROCEDURE|Erector Spinae Plane Block|Erector Spinae Plane block will be administered under general anesthesia before the surgery
223746281|NCT03207945|DRUG|Alirocumab|Alirocumab (Sar236553/REG 727) is a fully humanized monoclonal antibody against the proprotein convertase subtilisin kexin type 9 (PCSK9) enzyme responsible for the degradation of the low-density lipoprotein receptor (LDLR), and is developed by Regeneron Pharmaceuticals/Sanofi.
224074715|NCT04828408|PROCEDURE|Bariatric surgery|Patients with a body mass index (BMI) ˃35, age interval of 18-65, and ASA score II-III undergoing laparoscopic bariatric surgery were included in the study. Patients with neuromuscular, cardiopulmonary, and cerebrovascular diseases, phrenic nerve damage or diaphragm paralysis, those who have undergone thoracic surgery, who could not communicate, who did not want to participate in the study, who used alcohol, those who needed postoperative intensive care, those who had surgical complications during surgery, and those who were switched to open surgery were not included in the study.
224074716|NCT04080895|DRUG|Artemether-lumefantrine|Artemether-lumefantrine on Day 0, 1 and 2 Washout period: more than 6 weeks
224191837|NCT00656981|DRUG|YAZ (DRSP 3 mg/EE 0.02 mg, BAY86-5300)|The study medication was packaged in 28-tablet blister packs. Each subject kit contained 6 blister packs plus 1 reserve blister pack.Subjects randomly assigned to the active treatment group received 24 consecutive days of hormonally active tablets (3mgDRSP/0.02mgEE) followed by 4 consecutive days of inactive tablets. The treatment period was 6 cycles (28 tablets per cycle).
224191838|NCT00656981|DRUG|Placebo|The subjects randomly assigned to the placebo group received 28 inert but identical-appearing, color-matched tablets. The treatment period was 6 cycles (28 tablets per cycle)
224191839|NCT00299091|DRUG|Efavirenz capsules 200 mg and 600 mg|Modification of doses of efavirenz guided by its plasma concentration (therapeutic drug monitoring)
224191840|NCT01066624|DRUG|0.9% Sodium Chloride irrigation solution|Patients randomized to this group will be instructed to rinse their mouths twice, with 1 ounce (30 ml) of room temperature 0.9% NaCl (normal saline), 4 times daily after admission and until end of study
223500926|NCT03257397|DEVICE|theta-burst stimulation (TBS) using a MagPro X1000|iTBS over left and right dorsolateral prefrontal cortex for a period of three weeks. iTBS consists of 3-pulse 50 Hz bursts which will be given every 200ms (at 5 Hz) in 2-second trains with an inter-train interval of 8 seconds. One session will comprise left and right iTBS. There will be two sessions daily with 60 min in between sessions
223500927|NCT01327703|DRUG|Panzytrat® 25,000|Panzytrat® 25,000 capsule will be given orally daily at a stabilized dose, as per investigator's discretion, for 14 days. Stabilized dose for a participant will be the optimal dose determined during a qualification phase that precedes the first treatment period and will be based upon the participant's usual lipase and lipid intake. Total dose will not exceed 10,000 European Pharmacopoeia (Ph.Eur.) units lipase/kilogram (kg) body weight/day in either first treatment period or second treatment period.
223500928|NCT01327703|DRUG|Kreon® 25,000|Kreon® 25,000 capsule will be given orally daily at a stabilized dose, as per investigator's discretion, for 14 days. Stabilized dose for a participant will be the optimal dose determined during a qualification phase that precedes the first treatment period and will be based upon the participant's usual lipase and lipid intake. Total dose will not exceed 10,000 Ph.Eur. units lipase/kg body weight/day in either first treatment period or second treatment period.
223500929|NCT04235075|DEVICE|ECG/PCG and ultrasound signal acquisition|"The ECG - PCG signals are acquired over a 20-minute monitoring phase with passive non invasive sensors (abdominal and thoracic). The volunteer's abdomen is photographed when the electrodes and sensors are installed. An ultrasonography is also performed for 10 minutes.~The session is filmed for 5 volunteers accepting the video. Any distinctive elements will be removed from photos and videos to prevent the identification of participants."
223500930|NCT01419925|BIOLOGICAL|Two Multimeric-001 administrations followed by TIV|Two administrations of non adjuvanted M-001, 500 mcg followed by TIV at intervals of 19-23 days
224074717|NCT04080895|DRUG|Amodiaquine|Amodiaquine on Day 0, 1 and 2 Washout period: more than 6 weeks
224074718|NCT04080895|DRUG|Artemether-lumefantrine|Artemether-lumefantrine on Day 0, 1 and 2 Washout period: more than 6 weeks
224074719|NCT04080895|DRUG|Artemether-lumefantrine + Amodiaquine|Artemether-lumefantrine + Amodiaquine on Day 0, 1 and 2
223500931|NCT01419925|BIOLOGICAL|One administration of Multimeric-001 followed by TIV|One administration of non adjuvanted Multimeric-001, 500 mcg, followed by TIV at intervals of 19-23 days
223500932|NCT01419925|BIOLOGICAL|One administration of adjuvanted M-001 followed by TIV|One administration of adjuvanted (Aluminum phosphate) Multimeric-001, 500 mcg, followed by TIV at intervals of 19-23 days
223500933|NCT01419925|BIOLOGICAL|One administration of placebo followed by TIV|One administration of saline (Placebo)followed by TIV at intervals of 19-23 days (serving as an active comparator)
223746282|NCT03207945|OTHER|Placebo|Placebo
223746283|NCT06924957|OTHER|3D HRAM|The test will be performed both in supine and sitting position successively, using 3D HR-ARM. Resting, squeeze pressures, and bear down manoeuvre variables will be obtained. Diagnosis of dyssynergic defecation requires \< 20% relaxation of anal sphincter and/or intrarectal pressure\>40 mmHg during bear down manoeuvre.
224074720|NCT03158870|PROCEDURE|Surgery complications|Assessment of the influence of surgeon-anesthesiologist collaboration on surgery complications during and up to 30 days after pheochromocytoma surgery.
224074721|NCT01993693|DEVICE|Ultrasonic Diathermy Device|The Ultrasonic Diathermy Device provides low intensity therapeutic ultrasound to musculoskeletal tissues and joints for the purpose of pain relief, relief of muscle spasm, treatment of joint contraction, and local increase of circulation. The device is FDA-cleared for up to 4 hours of continuous use per treatment. It is a stationary hands-free device.
224074722|NCT01993693|DEVICE|Sham Ultrasonic Diathermy Device|Sham therapy delivered by Ultrasonic Diathermy Device that appears identical to active device but does not deliver ultrasound
224074723|NCT01158521|DRUG|pazopanib hydrochloride|Oral pazopanib hydrochloride once daily for up to 18 weeks in the absence of disease progression or unacceptable toxicity.
224074724|NCT01158521|PROCEDURE|therapeutic conventional surgery|Patients undergo either partial or radical nephrectomy at least 7 days after completion of pazopanib hydrochloride.
224191841|NCT01066624|OTHER|Cryotherapy (ice chips)|Patients randomized to this group, on day -2 and -1, will be instructed to place approximately 1 ounce of crushed ice in their mouths 15 minutes prior to the initiation of melphalan infusion. The ice will be allowed to melt and should be replenish as soon as it had completely melted. Patients will be instructed to continue this procedure during the melphalan infusion and for 90 minutes after the end of the infusion.
223500934|NCT01131585|PROCEDURE|Active laser photocoagulation|Active laser photocoagulation procedure at baseline and reapplied if needed at intervals no shorter than 3 months from the last treatment.
224191842|NCT01066624|DEVICE|Calcium phosphate (Caphosol) Ca2+/PO43- mouth rinse|Patients randomized to this group will be instructed to rinse their mouths with Caphosol 4 times daily after admission and until end of study.
224191843|NCT04373616|BIOLOGICAL|ACI-24|injections
224191844|NCT04373616|BIOLOGICAL|Placebo|injections
224191845|NCT05577351|DEVICE|RapidPulseTM Aspiration System|The RapidPulseTM Aspiration System paired with a single-use, disposable tubing set specific for use with the RapidPulseTM Aspiration System
224191846|NCT02490111|DRUG|DWJ1319|
224191847|NCT02490111|DRUG|Placebo|
224191848|NCT04198376|PROCEDURE|Group A The Laterally Closed Tunnel Technique with SCTG|Following the administration of local anaesthesia 2% lignocaine hydrochloride.In the LCT technique a bevelled intrasulcular incisions will be made around the necks of the affected teeth with Orban Knife.The tunnelling will be accomplished with tunneling instrument (TKN2).A mucoperiosteal tunnel will be prepared using a specially designed tunneling instrument.The muscle and collagen fibres will be released using surgical blades and gracey curettes.Subepithelial CTG will be harvested from palate using single incision technique.The graft will be removed and will be placed on saline soaked gauze and kept wet until its transfer to the recipient bed.An immediate closure of the donor site is performed using modified mattress sutures.The graft will be adapted to the CEJ by means of sling suture.Finally the margins of the pouch will be pulled together over the graft and sutured with interrupted sutures.The surgical sites will be protected with a non eugenol periodontal dressing.
224191849|NCT04198376|PROCEDURE|Group B Modified Coronally Advanced Tunnel Technique with SCTG.|In MCAT technique all the buccal tissues will be undermined and connected only the papillary region will be left attached.A full thickness preparation of the papillary region will be created this will be done with a small elevator.A second surgical site to obtain the subepithelial CTG using single incision technique.A support suture will be performed to guide the CTG into the recipient site.The graft will be gently pushed into the pouch with a packing instrument and by pulling the support suture.The entire gingivopapillary complex will be moved coronally using a vertical mattress suture anchored in the lingual gingiva.The anchorage in the lingual gingiva will be placed far apically.The suture must capture the buccal flap and graft to avail optimal stabilization.The surgical sites will be protected with a non eugenol periodontal dressing.
224191850|NCT00002362|DRUG|Abacavir sulfate|
224191851|NCT00002362|DRUG|Efavirenz|
224309801|NCT03463382|PROCEDURE|Quadratus Lumborum Block|Quadratus Lumborum Block will be administered under general anesthesia before the surgery
224309802|NCT03463382|DRUG|Bupivacaine (Block Drug)|0,25% Bupivacaine was used 0,5ml/kg (max. 20cc) for block performances
224309803|NCT00943267|DRUG|Drotrecogin alpha|Drotrecogin alpha is given intrabronchially by bronchoscopy at t=0
224309804|NCT00943267|DRUG|Saline (NaCl 0.9%)|Normal saline is given intrabronchially by bronchoscopy at t=0
224309805|NCT00943267|DRUG|Endotoxin|Endotoxin (4 ng/kg body weight) is given intrabronchially in one subsegment at t=0
224309806|NCT00943267|PROCEDURE|Bronchoscopy|Bronchoscopies are performed at t=0 (for instillation of LPS and Drotrecogin alpha) and at t=6 (for performing a bronchoalveolar lavage)
224309807|NCT00943267|PROCEDURE|Blood sampling|Blood sampling is done by venapuncture at t=0 and t=6
223500935|NCT01131585|DRUG|Sham injections|Sham intravitreal injections at baseline, 30, 60 and 90 days and if needed, reapplied at intervals no shorter than 28 days from last treatment.
223500936|NCT01131585|DRUG|Ranibizumab 0.5 mg|Ranibizumab 0.5 mg/0.05 ml intravitreal injection at baseline, 30, 60 and 90 days and if needed, reapplied at intervals no shorter than 28 days from last treatment.
223500937|NCT05914285|DRUG|5ml of inhaled normal saline|After the initiation of OLV, 5ml of normal saline is inhaled for 20 minutes using ultrasonic nebulizer, which is connected to the inspiratory limb of the ventilator system. Arterial blood gas analysis is performed 30 minutes after the completion of drug inhalation.
223500938|NCT05914285|DRUG|2.5mg (2.5ml) of inhaled salbutamol and 2.5ml of inhaled normal saline|After the initiation of OLV, mixture of salbutamol 2.5mg and normal saline 2.5ml is inhaled for 20 minutes using ultrasonic nebulizer, which is connected to the inspiratory limb of the ventilator system. Arterial blood gas analysis is performed 30 minutes after the completion of drug inhalation.
223500939|NCT00927082|DRUG|peginterferon alfa-2a [Pegasys]|90 or 180 micrograms/week sc for 24 or 48 weeks in original study (WV19432). No study treatment in long-term post-treatment follow-up study (MV22430)
223500940|NCT03833258|BEHAVIORAL|Rehabilitation with no precautions|Patients will recover from total hip replacement surgery being guided by pain only and not by the precautions imposed upon them by clinicians.
223500941|NCT00729807|DRUG|pentamidine|
224191852|NCT00002362|DRUG|Emtricitabine|
224191853|NCT00002362|DRUG|Stavudine|
224309808|NCT00386763|DRUG|Artemether-lumefantrine|
224309809|NCT01094886|DRUG|Rivaroxaban|10mg tablet daily, receiving the first dose within two days after admission to the subacute unit. The total duration of combined venous blood clot prevention therapy with enoxaparin and rivaroxaban may not exceed 35 days for patients with total hip replacement or 14 days with total knee replacement
224309810|NCT05480163|OTHER|Measurement records|Recordings of spirometry, acoustics, movement (chest volumetry) parameters for FVC and LVC exercises.
224309811|NCT02955381|DEVICE|Restylane Silk, 1.0 ml|Restylane® Silk was approved in 2014 submucosal implantation for lip augmentation and dermal implantation for correction of perioral rhytids in patients over the age of 21.
224309812|NCT02955381|DEVICE|Saline, 1.0 ml|Simple saline solution. To be used as placebo (control). No active ingredients.
224309813|NCT04681066|DRUG|CM-4620 Injectable Emulsion or CM-4620-IE|Auxora is to be administered as an IV infusion and is supplied as a translucent, white to yellowish colored, sterile, non-pyrogenic emulsion containing 1.6 mg/mL of the active pharmaceutical ingredient CM4620. CM4620-IE is supplied as an 80 mL fill in a 100 mL, single-use glass vial. The drug product is formulated as an emulsion due to the low solubility of CM4620 in aqueous solution. CM4620-IE contains egg phospholipids, medium chain triglycerides, glycerin, edetate disodium salt dehydrate (EDTA), sodium hydroxide (as needed to adjust pH), and sterile water for injection.
224191854|NCT01712529|BEHAVIORAL|Supervised physical exercise|Women with systemic lupus erythematosus with availability to perform physical exercise were allocated in exercise group (EG) to practice supervised physical exercise for one hour, three times a week for 16 weeks. Those who were not available for this activity were allocated in the control group (CG). Intervention consisted of walking at speed of the ventilatory threshold-1 heart rate obtained from cardiopulmonary exercise test and monitored by frequency meter.
224191855|NCT05040867|OTHER|Physical exercise program|"The physical exercise programme will last 16 weeks where participants will do three weekly sessions of 60 minutes, approximately. In these training sessions, cardiovascular and strength components will be worked out, planned from moderate to high intensity in the TEG and unique high intensity in the HRVG. The training programme will be divided into three mesocycles from neuromuscular adaptation to reach, in last period, the highest loads and cardiovascular levels. Each session will include a warm-up, a main part and a cool-down with stretching and mobility exercises.~The difference between the interventions of the HRVG and TEG will be in the planning of the intensity of the cardiovascular exercises and the weight to be lifted in the strength exercises. The first session of both programmes will have the same intensity but depending on how the heart rate variability of the HRVG patients reacts to, the weight and the intensity will be individualised each day."
224191856|NCT01212666|PROCEDURE|Ropivacain|Ultrasound-guided ACB; 30 mL Ropivacain 7,5 mg/mL. Single dose.
224191857|NCT01212666|PROCEDURE|Saline|Ultrasound-guided Adductor Canal Block; 30 mL Saline. Single dose.
224191858|NCT05730049|DEVICE|Transcutaneous auricular vagus nerve stimulation|Stimulation will target the auricular branch of the vagus nerve by applying stimulation to the cymba conchae region of the ear using the NEMOS® taVNS device (taVNS Technologies, Erlangen, Germany). To achieve adequate stimulation while avoiding unpleasant or painful sensations, the stimulation intensity will be gradually increased in increments of 0.1mA until the subjective pain threshold is reached, and then reduced to a stimulus intensity just below the individuals pain threshold (expected range based on prior studies 1 - 3.2mA(3). Pulse width will be set at 100μs and frequency will be set at 25Hz as performed in a previous protocol in stroke patients(3). The control group will receive the same stimulation parameters but will have the earpiece placed in the sham position such that stimulation is applied to the earlobe and does not activate the vagus nerve(4).
224191859|NCT03820804|OTHER|Diet|A specific dietary treatment for patients with Phenylketonuria.
224191860|NCT03820804|DRUG|Sapropterin|A pharmacological treatment for patients with Phenylketonuria, used alone or in combination with dietary treatment.
224191861|NCT03914924|BEHAVIORAL|Exercise Program|"On-site delivery: The supervised exercise sessions will be offered twice a week from the first to fourth weeks and once a week from the fifth week onwards. Each session lasts approximately 60 minutes.~Remote delivery: The participants will attend an initial supervised exercise session delivered on-site. After this session, they will receive the exercise intervention through a website specific to the Ex program. Participants will receive weekly WhatsApp messages to remind them about the exercise routine.~Independent of the delivery format all participants will receive counseling to accumulate at least 150 min of aerobic exercise per week."
224191862|NCT03914924|BEHAVIORAL|Lifestyle Education Program|"On-site delivery: The supervised exercise sessions will be offered twice a week from the first to fourth weeks and once a week from the fifth week onwards. Each session will last approximately 60 minutes. Participants will receive a printed version of the Diabetes College Guide containing twenty chapters and they will attend eighteen thirty-minute education classes.~Remote delivery: The participants will attend an initial supervised exercise session delivered on-site. After this session, they will receive the interventions (exercise and education) through a website specific to the ExLE program. Participants will receive a printed version of the Diabetes College Guide, as well as, guidance on accessing the educational content on the website and weekly WhatsApp messages with reminders about educational content scheduled for that week.~Independent of the delivery format all participants will receive counseling to accumulate at least 150 min of aerobic exercise per week."
224191863|NCT03506464|PROCEDURE|Myofascial Release Technique|The same described in the arm description
224191864|NCT01255449|DRUG|albuterol|400 mcg by inhalation
224191865|NCT03871803|DRUG|Controlled withdrawal of beta-blockers|Controlled withdrawal of previos doses of beta-blockers after diagnosis of chronotropic incompetence
224191866|NCT03871803|DIAGNOSTIC_TEST|Cardiopulmonary Exercise Testing|Cardiopulmonary Exercise Testing to evaluate the chronotropic incompetence and the primary endpoint (functional capacity)
224191867|NCT05138731|OTHER|treatments according guidelines|different group intervened with different treatment following guidelines/consensuses accordingly
224191868|NCT05166031|BIOLOGICAL|bOPV and nOPV2|Approximately 265 subjects will receive 2 doses of bOPV, nOPV2 or bOPV + nOPV2 per arm separated by 28 days between doses.
224191869|NCT00113321|DRUG|Decitabine|20 mg/m2 IV over 1 hour daily x 5 days.
224191870|NCT05521828|DRUG|Follitropin delta (Rekovelle)|12 mcg/day will be used for ovarian stimulation in both arms
223500942|NCT06075290|BEHAVIORAL|internet plus model|Intelligent transcutaneous bilirubin meter and Internet plus model for neonatal jaundice monitoring at home and remote follow-up
223500943|NCT06075290|BEHAVIORAL|control|follow-up by conventional methods; hospital or community follow-up depending on arrangement
224191871|NCT05521828|DRUG|Duphaston|20 mg/day will be used for pituitary suppression in both arms
224191872|NCT05521828|DRUG|GnRH agonist (Gonapeptyl)|(2 ampules:0.2 mg) will be used for ovulation triggering in both arms
224191873|NCT00106860|DRUG|a benzodiazepine drug|
224191874|NCT03943524|DEVICE|Interax-AI|Interax-AI is a drug interactions detection module for the electronic clinical history software DrApp
223512071|NCT03242070|OTHER|Theory-based PP eLearning Program(T-PeP)|"Theory-based PP eLearning Program (T-PeP) was developed based on self-efficacy theory42-44 to improve older adults' use of PPs for managing their care and includes learning modules, discussion boards, and other resources. Considering variations in the types and usability of PPs used by patients nationwide, T-PeP was developed as a vendor-agnostic (not tied to a specific vendor) program."
223512072|NCT02842281|OTHER|Fructan|Short-chain oligosaccharide primarily composed of fructose polymers
223512073|NCT02842281|OTHER|Maltodextrin|Polysaccharide produced from starch
224191875|NCT04870294|DEVICE|Teeth treated with composite resin, control group|The teeth grouped in group R were treated with composite resin restoration without liner material.
224191876|NCT04870294|DEVICE|Teeth treated with lining, pulp wall with PBS DTA® cement and composite resin restoration|The teeth grouped in group D received PBS CIMMO DTA® as indirect capping material of the cavity, followed by restoration of composite resin.
224191877|NCT05398939|DIAGNOSTIC_TEST|Blood test and skin evaluation|The patients received blood tests for serum 25-hydroxyvitamin D level and skin evaluation for severity of acne vulgaris and lesion counts.
224309814|NCT04681066|OTHER|Placebo|Matching Placebo is to be administered as an IV infusion and is supplied as a translucent, white to yellowish, sterile, non-pyrogenic emulsion carrier containing no active pharmaceutical ingredient. Placebo is supplied as an 80 mL fill in a 100 mL single-use vial. Placebo contains the same ingredients as Auxora except that it does not contain CM4620.
223500944|NCT06646848|DEVICE|Vibration|The vibration device was placed on the infant's left extremity in the mid/lateral region just below the knee where the sural nerve passes. The device was secured to the extremity with a gauze bandage. The vibration device was operated for 30 seconds with reference to previous studies. While the vibration continued, the nurse punctured the heel with a needle. Then, the vibration device continued to work in the waiting phase for 10 seconds. The vibration device was removed from the infants's extremity and routine heel blood collection procedure was performed.
223500945|NCT06646848|DEVICE|Heel Warming|The heel warning group will warm the heel of the infants using a hot thermal bag 3-5 minutes before the application. Then, the thermal bag will be removed and the nurse will take the heel blood.
224309815|NCT03866902|BEHAVIORAL|Nutrition and Physical Activity Intervention|"Mothers. Twelve weekly classes for one hour focused on nutrition and exercise education and coping skills training followed by a forty five minute exercise class for mothers. Then they will return for one hour for continued support and a forty-five minute exercise class.~Children. Twelve weekly classes for one hour focused on Color Me Healthy and one hour of free play. Then 6 monthly continued support classes where a Color Me Healthy class will be reviewed and they will have one hour of free play."
223500946|NCT06646848|DEVICE|Shotblocker|The protruding surface of the Shotblocker was placed on the heel lance procedure site. While applying pressure on the skin through the Shotblocker, the nurse performed heel lancing with the needle through the opening in the center of the Shotblocker. During the 10-second waiting phase, the Shotblocker was kept at the procedure site with the same pressure. Then Shotblocker was removed from the skin and routine capillary heel collection procedure was performed.
223500947|NCT06099600|PROCEDURE|Reconstructive surgery of the anterior cruciate ligament|surgical reconstruction after rupture of the anterior cruciate ligament is widely proposed as first-line treatment, with the aim of restoring knee joint stability and facilitating functional recovery
223500948|NCT03299309|DRUG|PEP-CMV|Patients receive temozolomide (TMZ) 200 mg/m2/day x 5 days. On day 20, patients will receive a Tetanus-diphtheria pre-conditioning vaccination with Td (tetanus, diphtheria toxoid, adsorbed). Immunotherapy begins the following day, on day 21, with injection of the PEP-CMV vaccine as follows: PEP-CMV Component A mixed with Montanide ISA-51 intradermally administered half in the RIGHT groin and half in the LEFT groin.
223500949|NCT05445336|BEHAVIORAL|PREVENT Program|PREVENT (Person-centred Routine Fracture PreEVENTion) is a scalable model for delivering routine assessments and interventions on diet and supplements, multifactorial fall and fracture prevention strategies, and medications to long term care teams to treat residents at high risk of fracture.
223500950|NCT01860404|DRUG|Branched Chain Amino Acids|The three BCAA's will be combined together and dissolved in a flavored solution.
223500951|NCT01860404|DRUG|Placebo solution|The placebo solution will have similar taste, texture, consistency and appearance as the BCAA solution.
223500952|NCT06633289|OTHER|Experimental formula|New hydrolyzed rice protein-based formula
223500953|NCT06633289|OTHER|Control formula|Commercially available amino acid-based formula.
223500954|NCT01761344|OTHER|Intraoperative cortisol measurement.|Levels of cortisol in blood samples will be determined using a rapid cortisol assay. This is not standard procedure
223500955|NCT04668963|DEVICE|MIRROR THERAPY|patients were seated on a chair, with the mirror positioned between the upper limbs perpendicular to the subject's midline and with the unaffected upper limb facing the reflective surface. Following the physiotherapist indications, the patients observed the reflection of their unaffected limb while performing the following movements with the both arms, the affected one as good as possible: flexion and extension of the shoulder, elbow, wrist and finger, prone supination of the forearm.
223500956|NCT01721902|DEVICE|Autologous CD133+ Bone Marrow Stem Cells|Intra-myocardial injection of 2-3 x 10E6 CD133+ Bone Marrow Stem Cells
223500957|NCT01721902|OTHER|Carrier Solution|Intra-myocardial injection of carrier solution
223500958|NCT05652842|BEHAVIORAL|Work-type|Participants are categorized by the type of work hours they must maintain. For example, regular work hours, shift work, and rotational work.
223500959|NCT02823561|DIETARY_SUPPLEMENT|Garcinia mangostana|
224191878|NCT03556644|RADIATION|CTCA imaging|All the studied patients will have CTCA before percutaneous coronary intervention and 3 vessel NIRS-IVUS imaging during percutaneous coronary intervention
223500960|NCT02823561|BEHAVIORAL|Control group|
223591690|NCT03951909|BEHAVIORAL|Psychological intervention: Teaching recovery techniques (TRT)|TRT is composed of five two-hour group teaching sessions with up to 15 participants. The first two sessions deal with intrusive thoughts and feelings: problems such as bad memories, nightmares, and flashbacks. The third session deals with arousal, coming to the surface as difficulties in relaxing, concentrating and sleeping. The fourth and fifth sessions deal with avoidance: ones fears, and difficulties in facing up to reminders of the war and violence.
224191879|NCT05945173|PROCEDURE|Evaporation time for 5 seconds|Composite resin restorations of non-carious cervical lesions will be performed with an adhesive with solvent evaporation for 5 seconds.
224191880|NCT05945173|PROCEDURE|Evaporation time for 25 seconds|Composite resin restorations of non-carious cervical lesions will be performed with an adhesive with solvent evaporation for 25 seconds.
224191881|NCT05945173|DEVICE|alcohol/water-based universal adhesive|Composite resin restorations of non-carious cervical lesions will be performed with an alcohol/water-based universal adhesive (Scotchbond Universal Plus; 3M).
224191882|NCT05945173|DEVICE|acetone-based universal adhesive|Composite resin restorations of non-carious cervical lesions will be performed with an acetone-based universal adhesive (Gluma Universal Bond; Kulzer).
224191883|NCT03418727|DRUG|Brimonidine|Two products delivered in sequence twice daily.
224191884|NCT03418727|DRUG|Brimonidine Mono Therapy|Brimonidine given twice daily along with placebo drops
224191885|NCT03418727|DRUG|sodium carboxymethylcellulose|Placebo given twice daily.
224191886|NCT03418727|DRUG|Corticosteroid Eye Drop|Eye drop to be administered after Brimonidine in treatment arm 1
224191887|NCT01941472|OTHER|fluid challenge|A bag of 500ml of normal saline or 4% gelatin (Gelofusine, B. Braun Medical (Suzhou) Company Limited, Suzhou, China) is infused within 15 minutes using a bag pressurized to 300 mmHg. All other treatments, including maintenance fluids, dose of vasoactive agents and ventilator settings, remain unchanged during the study period.
224191888|NCT00686894|PROCEDURE|PDUS|PDUS scored for each enthesitis every 2 weeks for 24 weeks.
224191889|NCT00686894|DRUG|Infliximab|"* 5 mg/kg~* IV~* Frequency : weeks 0,2,6"
224191890|NCT03997695|OTHER|Core stabilization exercise group|The CSE program was carried out 2 days a week for 6 weeks (12 sessions) by supervisor physiotherapist. The CSE program aimed to perform neutral spine and activation of core muscles. Prior to the CSE program, participants were informed about core musculature and their function.The 6-weeks CSE program was performed in stages with gradual progression according to the stages of motor learning and sensory motor integration as static, dynamic, and functional.
224191891|NCT03997695|OTHER|Core stabilization exercise plus kinesio taping group|The CSE program was carried out 2 days a week for 6 weeks (12 sessions) by supervisor physiotherapist. The CSE program aimed to perform neutral spine and activation of core muscles. Prior to the CSE program, participants were informed about core musculature and their function.The 6-weeks CSE program was performed in stages with gradual progression according to the stages of motor learning and sensory motor integration as static, dynamic, and functional.
224191892|NCT05782738|PROCEDURE|Percutaneous Coronary Intervention|Use dedicated two stents technique for treatment of coronary bifurcation stenosis
224191893|NCT04032002|OTHER|Explorations|On Day 1 vascular fonctions explorations performed
224191894|NCT04032002|OTHER|Blood samples|On Day 1 35ml taken
224191895|NCT05682638|BIOLOGICAL|LVRNA009|100μg/1.0ml/dose(50 μg/0.5ml/Vial), 2 injection with 28 days apart
224191896|NCT05682638|OTHER|0.9%NaCl|1.0ml/dose, 2 injection with 28 days apart
224191897|NCT03138707|OTHER|patients who die|
223500961|NCT01656746|PROCEDURE|therapeutic laparoscopic surgery|Undergo single incision laparoscopic surgery
223500962|NCT05375799|OTHER|Clinical Observation|"This is an observational study, so there are no interventions. Data will be recruited from adult patients diagnosed with COVID-19, described in medical records, by laboratory detection of SARS-CoV-2 RNA, who used the Assisted Breathing Helmet - ELMO.~All the following predictor variables will be collected: demographic and anthropometric data; clinical characteristics of patients (comorbidities, date of onset of symptoms and initial symptoms, hospital admission, laboratory tests, chest X-ray tests, need for intubation or ICU admission); start date of ELMO use, blood gas analysis before and after the first application of ELMO and data related to its use (number of applications, number of days of therapy, total time of therapy, as well as reasons for the interruption and adverse effects )."
223500963|NCT05225168|PROCEDURE|laparoscopic burch colposuspension operation|By pushing the urethra medially, two sutures are placed on the bladder at trigon level and midurethral and suspended on the bilateral iliopectineal ligament and colposuspension is supplied.
223500964|NCT05225168|PROCEDURE|minisling suburethral sling|A vertical vaginal incision is made 1 cm below the external urethral meatus. It is followed by minimal vaginal dissection from the inferior portion of the ascending ramus of the ischiopubic bone to the obturator muscle. The arms of the mesh are fixed on both sides of the obturator internus muscle with the help of a trocar. After leaving a 1-2 mm gap between the mesh and the urethra, the vaginal wall is closed by suturing.
223500965|NCT00890318|DRUG|ABT-072|Powder contents from capsules mixed in an alternative vehicle, for additional information refer to Arm Description.
223500966|NCT00890318|OTHER|ketoconazole|Tablet, see Arm Description for intervention information.
223500967|NCT00890318|DRUG|Placebo|Capsule or powder drug substance from the capsule mixed in an alternative vehicle, for additional information refer to Arm Description.
223500968|NCT03270488|OTHER|Laser|Laser (power of 3.0w).
223500969|NCT03270488|OTHER|Placebo|Laser (power 0,0w)
223500970|NCT04836130|PROCEDURE|patient specific guide|patient specific guide reduction
223500971|NCT04836130|PROCEDURE|conventional technique|conventional anatomical reduction
223500972|NCT06480955|DEVICE|Cryoablation system|Any cryoablation system from Boston Scientific that has received CE Mark and/or FDA clearance for the ablation of bone malignancies.
223500973|NCT05331898|BEHAVIORAL|Education|the education given increased the rational drug use of the parents.
223500974|NCT00819195|DRUG|Glatiramer acetate|20 mg daily subcutaneous injection. Six-month duration.
223500975|NCT05133570|DEVICE|vista care|Prospective, open-label, multi-centre study evaluating the performance of the VistaCare® wound healing device in routine practice.
223500976|NCT03432429|OTHER|REIMS iKnife|Use of REIMS iKnife in breast conserving surgery
224191898|NCT04227678|DRUG|Heparin|an intravenous (i.v.) heparin bolus (50 IU/kg i.v.) followed by 250 IU/h i.v. during 6 hours, starting 15 minutes before ingestion of liquid meal
224191899|NCT04227678|DIETARY_SUPPLEMENT|liquid meal|low fat meal: (500 mL, 898 Kcal, 13% fat, 20.3% protein and 62.3% carbohydrates) will be ingested over 20 minutes
224191900|NCT02924311|DRUG|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|Eylea 40 mg/mL - recommended dose of 2 mg - intravitreal injection monthly for five consecutive months, which constitutes the loading dose. The loading dose is followed by one injection every two months. After 12 months of treatment, the interval between two injections can be prolonged or adapted according to visual and anatomical results.
224191901|NCT02554409|BIOLOGICAL|Quadrivalent Intradermal Influenza Vaccine (QIV)|No Intervention as part of this protocol
224191902|NCT00195117|BEHAVIORAL|Intervention Group|Subjects were randomly assigned to either the control or the intervention group. The intervention included receiving an additional educational workbook about using positive affect and self affirmation, as well as participating in using positive affect and self-affirmation to motivate behavior change, which in this case was to increase their physical activity level. Patient also received small token gifts to remind them of their participation in the study and to induce positive affect. The control group also set a physical activity goal and received the same follow-up, but did not participate in the positive affect and self-affirmation portion.
224191903|NCT02809651|DEVICE|Infrascanner|bilateral measurement cerebral blood flow with near infrared spectroscopy using the Infrascanner on the frontal, temporal, parietal and occipital region of the head.
224191904|NCT05814744|DRUG|dexmedetomidine|adding dexmedetomidine as adjuvant with bupivacaine in Ultrasound-guided Intermediate Cervical Plexus Block for Thyroidectomy surgery.
224191905|NCT05814744|DRUG|bupivacaine 0.25%|patients will receive bilateral Intermediate Cervical plexus block with 20 ml bupivacaine 0.25%.
224191906|NCT05814744|PROCEDURE|Thyroidectomy Surgery|surgical removal of all or part of thyroid gland.
224191907|NCT05814744|PROCEDURE|Ultrasound-guided intermediate Cervical Plexus Block Technique|the injection of local anesthetic in intermediate cervical plexus nerve block is made between the investing layer of the deep cervical fascia and the prevertebral fascia. Following negative aspiration, 1-2 mL of local anesthetic is injected to confirm the proper injection site.
224191908|NCT04176809|OTHER|Routine Assessment of HRQoL coupled with Therapeutic Information|Participants will complete the EORTC-QLQ-C30 and EORTC-QLQ-BR23 questionnaires before their consultation via the CHES software. The scores will then be generated and provided to clinicians in a graphic form, describing scores course. Access to CHES web portal will also be open to participants outside consultation time points, to enable them to monitor HRQoL if necessary. Workshop 1, will help patients to recognize and react to the occurrence of possible adverse effects, and anticipate their occurrence through appropriate preventive means. In workshop 2, participants will have the opportunity to express their representations and experiences related to their diet and the consequences of disease and treatments on diet. In workshop 3, participants can describe their experiences of fatigue and how their life is affected by it. Moreover, they can identify possible causes and finally discuss solutions to better this symptom. Every month, a reminder letter will also be sent to participants.
224191909|NCT03576807|DRUG|CD20 CAR-T cells|A total of 1 - 20×10\^6 CD20 CAR-T cells/kg will be administered by IV infusions.
224191910|NCT01439932|DEVICE|algometer|"Pressure algometer (Algometry) - This is an instrument that measures pain threshold (the minimum pressure required to produce pain). The instrument consists of a flat disk size centimeter square attached to pressure transducer and measuring electrodes. The disk is placed vertically on the point of pain and therapist increases the intensity of the pressure until initial pain appears (when sense of pressure becomes sense of pain.) Score is determined by average of three repeated measurements with 30 seconds break between each.~The algometer allows an objective assessment of pain in addition to LEFS score which is a subjective tool. The algometer test was found to be valid and reliable in repeated measurements (interrater, intrarater) by Andrew A. Fischerin 1987 with healthy people \[Andrew 1987\]. In another study high reliability was found for averaging between three repeated tests: ICC = 0.91 (CI 0.82; 0.97 95%). \[Linda et al 2007\]"
224191911|NCT04257656|DRUG|Remdesivir|RDV 200 mg loading dose on day 1 is given, followed by 100 mg iv once-daily maintenance doses for 9 days.
224191912|NCT04257656|DRUG|Remdesivir placebo|RDV placebo 200 mg loading dose on day 1 is given, followed by 100 mg iv once-daily maintenance doses for 9 days.
224191913|NCT05119751|DRUG|tree 12 SQ-Bet|DAILY DOSE OF AIT TABLET
224191914|NCT05119751|DRUG|GRASS 2800 BAU|DAILY DOSE OF AIT TABLET
224191915|NCT05119751|DRUG|RAGWEED 12 AMB A 1-U|DAILY DOSE OF AIT TABLET
224191916|NCT05119751|DRUG|HDM 12 SQ-HDM|DAILY DOSE OF AIT TABLET
224309816|NCT03866902|OTHER|English for Second Language Intervention|"Mothers. Control group mothers will receive 12 weekly English for Second Language classes for one hour and forty-five minutes. Then 6 monthly one hour and forty minute follow-up classes receiving English for Second Language material.~Children. Control group children will receive 12 weekly one hour and forty five minutes of having books read to them. Followed by 6 monthly meetings for one hour and 45 minutes being read to and coloring with crayons."
223500977|NCT00849472|DRUG|doxorubicin + cyclophosphamide|4 cycles of doxorubicin + cyclophosphamide followed by 4 cycles of paclitaxel + pazopanib.
223500978|NCT00849472|DRUG|paclitaxel + pazopanib|4 cycles of paclitaxel + pazopanib
223500979|NCT00849472|PROCEDURE|surgery|neoadjuvant surgery for breast cancer
223500980|NCT00849472|DRUG|pazopanib monotherapy|6 months of treatment with pazopanib monotherapy
223500981|NCT02173951|DRUG|Deferiprone|"in arm 1 ( active comparator) will receive a starting dose of Deferiprone (DFP) 50mg⁄ kg ⁄ d, administered orally 3 times daily. Routine dose adjustments will be made according to serum ferritin trends and safety.~Patients reaching serum ferritin ≥1000 will be subjected to dose escalation of DFP to 75 mg/kg/d.~Patients in Placebo Comparator arm when reaching end point elevation of SF to around 1000 ng/ml or more or Tsat \> 90 % and or LPI \> 0.6 will start deferiprone 75 mg/kg/d"
223500982|NCT03468127|OTHER|Soy foods|Isolated soy protein, soy protein, soybean products, soy milk
223746284|NCT06758232|OTHER|Exercise|It will consist of sessions that include neck anatomy, biomechanics, proper posture, ergonomics and neck exercise training.
223746285|NCT01964703|DRUG|Rubus occidentalis extract|
223746286|NCT04690751|DRUG|Cenobamate 200Mg Tab Fasted|Cenobamate (YKP3089) is a small molecule approved in the United States (US) for the treatment of partial onset seizures (POS) in adult patients.
224191917|NCT00821847|OTHER|DEXA scan|DEXA scan
224191918|NCT00211198|DRUG|ONTAK (denileukin difitox, DAB389IL-2)|
224191919|NCT06287554|OTHER|PRONE POSITION|early placed in prone positions within 24 hours of intubation
224191920|NCT06724822|DEVICE|RF Vapor Ablation|RF Vapor ablation of the duodenum
224191921|NCT05578040|PROCEDURE|Auricular acupressure|To conduct this intervention, we used adhesive patches without Vaccaria seed to sham auricular acupressure at the cervical vertebra acupoint in the first trial phase and auricular acupressure at the cervical vertebra acupoint in the other two trial phases in 2 groups of auricular acupressure acupoints of the left and right cervical vertebra.
224191922|NCT06721988|DRUG|oxycodone and parecoxib sodium combinations|Participants will receive 0.1ml/kg oxycodone (1mg/ml) and 2 ml parecoxib sodium (20 mg/ml) combinations after the anesthesia induction but before the surgical incision. Oxycodone is administered 5 minutes after parecoxib sodium administration.
224191923|NCT06721988|DRUG|Placebo and parecoxib sodium combinations|Participants will receive 0.1ml/kg placebo (0.9% saline) and 2 ml parecoxib sodium (20 mg/ml) combinations after the anesthesia induction but before the surgical incision. Placebo is administered 5 minutes after parecoxib sodium administration.
224191924|NCT06722885|RADIATION|Standard radiotherapy treatment|"* 3 x 17 Gy for peripheral NSCLC~* 4 x 12 Gy in centrally located NSCLC or at \< 1cm from the thoracic wall~* 8 x 7,5 Gy if with the predefined dose for NSCLC, the constraints of the organs at risk cannot be met~* 5 x 8,5 Gy in case of oligometastases"
224191925|NCT06724289|DRUG|Psilocybin 25 mg|25 mg psilocybin administered to each participant in single arm, open-label trial
224191926|NCT06724627|DIAGNOSTIC_TEST|Dermatology/Skin - Other|Belle AI for skin image assessment.
224191927|NCT06722391|DEVICE|Neuromuscular Electrical Stimulation (Sensory)|Group will receive Electrical Stimulation up to sensory level
224191928|NCT06722391|DEVICE|Neuromuscular Electrical Stimulation|Group will receive Electrical Stimulation up to maximum tolerable level
224191929|NCT06722391|OTHER|Resistance Training|Group will receive exercise training.
224191930|NCT06724237|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo ASCT
224191931|NCT06724237|OTHER|Best Practice|Receive standard of care observation
224191932|NCT06724237|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223500983|NCT05823857|OTHER|Aquatic Therapy|Participants in this experimental intervention group will perform trunk stabilization, which will be based on a variety of aquatic exercises in different positions, intended to activate the multifidus and transverse abdominis in a co-contraction. Additionally, hip exercises will be completed to promote the strengthening of the gluteus maximus, gluteus medius, and gluteus minimus muscles. The aim of these exercises is to enhance the strength and dynamic stability of the spine and its surrounding musculature in a functional and yet non-weight-bearing way. Each exercise will be performed 10 times while sustaining the muscles co-contraction for 5-10 seconds and will be progressed gradually. Each training session (60 minutes) will be supervised by a Certified Athletic Therapist and take place in the PERFORM AT Clinic/Swim Ex pool.
224191933|NCT06724237|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration and biopsy
224191934|NCT06724237|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow aspiration and biopsy
224191935|NCT06724237|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
224191936|NCT06724237|DRUG|High Dose Chemotherapy|Receive high dose chemotherapy
224191937|NCT06724237|PROCEDURE|Leukapheresis|Undergo leukapheresis
224191938|NCT06724237|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
224191939|NCT06724237|DRUG|Stem Cell Mobilization Therapy|Receive stem cell mobilization therapy
224191940|NCT06724874|OTHER|Web-Based Deep Relaxation Exercise|Web-based deep relaxation exercise videos have been prepared online. Each video lasts approximately 20-25 minutes. The 4-week applications will be sent to pregnant women one video each week and they will be asked to continue the exercises at home 4 times a week.
224191941|NCT01790633|OTHER|ELISA|Enzyme-linked immuno-assay (ELISA) will be used to determine hepatitis B surface antigen (HBsAg), anti-HBsAg antibody (anti-HBs Ab), anti-HCV antibody, and anti-HIV antibody status. Results will be given after test results are available (8-10 days).
224191942|NCT01790633|OTHER|Rapid Test|A rapid test will be performed to determine the subjects' hepatitis B surface antigen (HBsAg, using VIKIA®), anti-HCV antibody (HCV, using OraQuick®), and anti-HIV antibody (HIV, using VIKIA®) status. Results will be given the same day.
224191943|NCT05596864|DIAGNOSTIC_TEST|gastric contrast ultrasound|"Gastric contrast ultrasound (GCUS) refers to that the patient fills the stomach cavity with oral water, contrast agent and ultrasound contrast agent before the examination to remove the gas in the stomach cavity and fill the stomach cavity to become a homogeneous echo area and form a good acoustic sound. Interface contrast, more clearly showing the gastric wall hierarchy and the ultrasound examination method of the lesions.~In this way, not only the changes of the gastrointestinal mucosa can be found, but also the submucosal tumors of the gastrointestinal tract can be clearly displayed, the internal structural characteristics of the tumor, the extent of the lesions, the depth of infiltration, the TNM staging of the tumor, and the lesions of the surrounding organs can be displayed."
223500984|NCT05823857|OTHER|Standard Care|Participants in this experimental intervention group will receive the standard LBP treatment in the PERFORM Athletic Therapy clinic.Two Certified Athletic Therapists (AT) will be conducting the sessions. The ATs will complete a thorough assessment of the eligible participants with chronic LBP and administer a range of interventions including stretching, strengthening and stabilization exercise, aerobic conditioning, and manual mobilization techniques. Other modalities could include application of ice and heat, ultrasound, and transcutaneous electrical nerve stimulation (TENS).
223500985|NCT05433350|DRUG|Acoziborole|"Two different mode of administration will be used during the study depending on the body weight and on the step of the study:~whole tablets of 320 mg dose for paediatric patients weighing 30 to 40 kg in step 1 whole or crushed tablets for paediatric patients weighing 10 to 40 kg in step 2"
223746287|NCT04690751|DRUG|Cenobamate Oral Suspension Fed|Cenobamate (YKP3089) is a small molecule approved in the United States (US) for the treatment of partial onset seizures (POS) in adult patients.
224191944|NCT05734040|BIOLOGICAL|OVX836 480µg|One single administration intramuscularly at Day 1
224191945|NCT05734040|BIOLOGICAL|Fluarix Tetra|One single administration intramuscularly at Day 1
224191946|NCT05734040|BIOLOGICAL|Afluria Quad|One single administration intramuscularly at Day 1
224191947|NCT05734040|BIOLOGICAL|Placebo|One single administration intramuscularly at Day 1
224191948|NCT06722729|DRUG|KDT-3594|Oral administration
224191949|NCT06722729|DRUG|Placebo|Oral administration
224191950|NCT06722001|BEHAVIORAL|"The Brief insomnia intervention interactive e-book"|The control group learned through paper health education leaflets and traditional oral explanations; the experimental group used interactive e-books to intervene in learning Brief Behavioral Treatment of Insomnia.
224191951|NCT06722001|BEHAVIORAL|traditional paper handout|The control group learned through paper health education leaflets and traditional oral explanations; the experimental group used interactive e-books to intervene in learning Brief Behavioral Treatment of Insomnia.
224191952|NCT06722105|BIOLOGICAL|2 infusions of MSC|1 MSC(AT) (2x10\^6 cells/kg) injection at M0 and 1 MSC(AT) (2x10\^6 cells/kg) injection at M3
224191953|NCT06722105|BIOLOGICAL|1 infusion of MSC|1 MSC(AT) (2x10\^6 cells/kg) injection at M0 and 1 placebo injection at M3
224191954|NCT06722105|OTHER|Placebo|Placebo at M0 and M3
224191955|NCT06722300|DEVICE|Ultrasonic teeth cleaning plus Tinidazole microneedle patches applying|After gargling with compound chlorhexidine rinse or 3% hydrogen peroxide rinse for 1 minute, ultrasonic teeth cleaning was performed. After teeth cleaning, the wound was rinsed with 3% hydrogen peroxide and bleeding was stopped. After ultrasonic teeth cleaning, two metronidazole oral composite microneedle patches were immediately applied to the upper and lower gums near the inner side of the first molar, especially where the teeth were lost or damaged. The mouth was kept closed for 15 minutes. After the microneedles were fully degraded, the patient could leave the clinic.
224191956|NCT04691518|OTHER|Acute Intermittent Hypoxia|30 minute session of Acute Intermittent Hypoxia
224309817|NCT04943484|PROCEDURE|imaging fluorescence NIR/ICG|"Preoperative upper GI endoscopy (UGE) UGE with submucosal injection of 2ml of ICG 0.125mg/ml solution to four peritumoral sites 15-20 hours before surgery Surgery D2 Distal gastrectomy with dissection of 1, 3, 4sb, 4sd, 5, 6, 7, 8a, 9, 11p, 12a lymph node stations (LNS) D2 Total gastrectomy with dissection of 1, 2, 3, 4sa, 4sb, 4d, 5, 6, 7, 8a, 9, 11p, 11d, 12a LNS Intraoperative NIR/ICG technology, change of surgical conduct (CSC) A visualization of the operative field (OF) with NIR/ICG technology is performed at the beginning of surgery and before to dissect each LNS. Subsequently, surgery is performed with the naked eye.~At the end, a visualization of the OF is performed using NIR/ICG technology to verify whether residual lymph nodes in each D2 nodal station exist. CSC is defined as the occurring of the following situation: in case of persistence of nodal fluorescence in D2 nodal stations, the completion of the dissection of the residual nodal fluorescent structures."
224309818|NCT06349252|PROCEDURE|Radical resection|Patients should undergo radical resection.
224309819|NCT04275882|DIAGNOSTIC_TEST|Electrocardiogram|There will be no new intervention performed for the patients.
224309820|NCT06283576|DIAGNOSTIC_TEST|Liquid biopsy|"Blood will be drawn upon clinical diagnosis / prior to biopsy/surgical resection for ground truth"
224309821|NCT02799368|DRUG|CJ Plasma Solution A Injection|Intravenous plasma solution (Chloride 90 mmoL/L) at 3 mL/kg over 1 hour pre-contrast, followed by the same solution intravenously at 1.5 mL/kg/hr for 4 hours. Intra-vascular low-osmolal or iso-osmolal contrast will be used.
224309822|NCT02799368|DRUG|CJ 0.9% Normal Saline Injection|Intravenous plasma solution (Chloride 154 mmoL/L) at 3 mL/kg over 1 hour pre-contrast, followed by the same solution intravenously at 1.5 mL/kg/hr for 4 hours. Intra-vascular low-osmolal or iso-osmolal contrast will be used.
223500986|NCT06034392|DEVICE|CHAMP App|CHAMP® App is a downloadable software mobile Application with a Software Platform. CHAMP® App is an electronic version of data entry for children with conditions that require close monitoring from their homes. The primary Intended Use is to relay monitoring information from homes to the health care team. This monitoring includes data options that can facilitate the collection of monitoring data of children in the home setting to improve communications between parents at home and remote caregivers. The CHAMP® App itself does not do home monitoring of the child's medical condition. It is not designed to alert parents if data entered has reached a red flag (problem) level. Users of the CHAMP App are advised in writing and in the informed consent process that urgent medical conditions should not be managed through the CHAMP App, and that appropriate emergency care should be obtained directly rather than through the CHAMP App.
223746288|NCT04690751|DRUG|Cenobomate Oral Suspension Fasted|Cenobamate (YKP3089) is a small molecule approved in the United States (US) for the treatment of partial onset seizures (POS) in adult patients.
224191957|NCT04691518|OTHER|Sham Acute Intermittent Hypoxia|30 minute session of Sham Acute Intermittent Hypoxia
224191958|NCT01734967|DEVICE|needle based CLE|"EUS-nCLE will be performed after EUS identification of the pancreatic tumor / lymph node / liver metastasis:~The confocal microprobe will be preloaded in a 19G FNA needle as previously described and advanced into the lesion under EUS guidance.~nCLE examination will follow after the intravenous administration of the contrast agent (2.5 ml fluorescein 10%).~Image data will be stored digitally for offline analysis."
224191959|NCT01734967|PROCEDURE|EUS-FNA|Endoscopic ultrasound (EUS) is an established tool in pancreatic masses used both for diagnosis, but also for staging purposes. Additionally, EUS enables guided fine needle aspiration (FNA), which is currently recommended as the first-line procedure whenever a pathological diagnosis is required.
224309823|NCT00839592|OTHER|Electroacupuncture|Acupuncture at bilateral Ear Shenmen, Sishencong EX-HN1, Anmian, and unilateral Yintang EX-HN3 and Baihui GV20. The needles will be left for 30 min and then removed. Acupuncture treatment will consist of three sessions per week for 3 consecutive weeks.
224309824|NCT03473769|OTHER|Vital Signs at 2 Hours|Patients vital signs assessed at 2 hours of arrival at ICU
223500987|NCT04373525|OTHER|Genome analysis|Venous blood will be obtained for later genome analysis
223500988|NCT06436924|DEVICE|Left Atrial Appendage Device Implant|The Watchman Device is implanted into the left atrial appendage and is designed to close it off and keep blood clots from escaping that area.
223500989|NCT05048472|DIAGNOSTIC_TEST|Abbott HIV-1/2 VL Point of care Device|Point of care viral load monitoring
223500990|NCT00338078|DEVICE|nocturnal oxygen treatment from oxygen concentrators|
223500991|NCT00564239|BEHAVIORAL|Cognitive Behavioral Group Therapy|12 children group sessions, 8 parent group sessions
223500992|NCT00564239|BEHAVIORAL|Cognitive Behavioral Group Therapy|12 children group sessions
223500993|NCT04530851|PROCEDURE|ERAS|"* Counseling~* H2- antagonist and metroclopramide for prevent aspiration~* Drink clear liquid until 2 hour before surgery~* First generation cephalosporin in 60 minute before surgery~* Clorhexidine for skin cleansing and Povidine for vaginal cleansing~* Regional anesthesia~* Keep warming~* Blunt expansion of uterine incision~* Do not peritoneal suture and subcuticular suture if less than 2 cm~* Local wound anesthesia.~* Paracetamol and NSAIDs for for pain control~* Early remove catheter and ambulation~* 5-HT3 antagonist for prevent nausea"
223746289|NCT05819515|PROCEDURE|Tunneled coronally advanced flap|Describes the flap design for both treatment arms
224309825|NCT03473769|OTHER|Confusion Assessment method for the ICU (CAM-ICU)|patient must have altered mental status/fluctuating course and inattention, and either disorganized thinking or altered level of consciousness to be CAM positive; these features are determined by observing the patient during bedside cognitive testing.
224309826|NCT02448264|DRUG|BCX7353|
224191960|NCT04613687|DEVICE|Compression bandage|Compression bandage URGO BD001 for the management of venous leg ulcers with ABPI (Ankle Brachial Pressure Index) ≥ 0.8, venous
224191961|NCT06704243|BEHAVIORAL|Peer Support|"The intervention will be a monthly online AYA peer support group (1 hour) that will run for six months via Microsoft Teams.~In an effort to evaluate a patient-driven real-world intervention, the support group has been designed with the following features: 1) participants will be asked to commit for a six month period, but are able to miss sessions if necessary; and, 2) each session will be facilitated by a Nurse Practitioner and Social Worker from the Allo-HSCT program, but the topics of discussion will be determined by the AYA participants present at each session. Participants in the group will then be invited to share their thoughts and experiences about these topics, with as much information as they feel comfortable."
224191962|NCT01157819|DRUG|0.3% Ciprofloxacin Ear Drops|4 gtt b.i.d. for 7 days.
224191963|NCT01157819|DRUG|FoamOtic Cipro|0.3% Ciprofloxacin Otic Foam, 1 application, q.d. for 7 days
224191964|NCT03575741|DIAGNOSTIC_TEST|Balance Tests|"Following balance exercises will be performed by the participants:~1. Bipedal, hip wide stand, eyes open and hands on hips, 60sec~2. Bipedal, hip wide stand, eyes closed, hands on hips, 30sec~3. Tandem-stand, eyes open, hands on hips, 60sec (front foot chosen by participant)~4. Tandem-stand, eyes closed, hands on hips, 30sec (same front foot)~5. One-leg-stand, eyes open, hands on hips, 30sec (randomized supporting leg)~6. One-leg-stand, eyes open, hands on hips, 30sec (other leg)~7. Bipedal, hip wide stand, eyes open, hands on hips, counting backwards in steps of two (367 - 365 - 363 - ...), 60sec~The rest between the trials will last for at least 30sec, but can be extended by the participants as long as they want. The overall measurement will not exceed 30 minutes."
224191965|NCT00350610|OTHER|Treatment as usual (TAU)|Standard treatment as usual in a community based treatment setting
224191966|NCT00350610|BEHAVIORAL|CBT for CBT|Standard treatment as usual (TAU) plus computer based therapy using CBT
224309827|NCT02448264|DRUG|Placebo to match BCX7353|
224309828|NCT05525793|OTHER|Transitional care model|The patients who were assigned to this group with the transitional care model, 6 weeks of counseling and intervention training provided continuity of care and a safe transition, and patients were encouraged about symptom management and a healthy lifestyle.
223500994|NCT04912817|OTHER|Off the Shelf VR|"Operates using Oculus quest VR HMD and uses auditory and visual stimuli during the pain rehabilitation treatment. The Off-the-shelf VR program for Oculus Quest VR features a suite of off-the shelf applications that can be tailored by the PT and used with participants including. PR-VR sessions will be 30 minutes in total with approximately 20 minutes in the virtual experience and 10 minutes for set-up, screening, instructions, and rest breaks. The Off-the-shelf VR intervention group will also receive 30 minutes of usual care, and Standard Virtual Physiotherapy Treatment (SVPT) during the same appointment, for a total 1-hour usual care session length."
223591691|NCT05933590|DIAGNOSTIC_TEST|Cervical Joint Repositioning Error Assessment|The cervical joint repositioning error assessment is a non-invasive diagnostic test used to measure the ability of an individual to accurately reproduce a specific head position in different orientations (flexion, neutral position, 50% range of motion of left rotation, and 50% range of motion of right rotation). Participants in both the chronic migraine group and the control group will undergo this assessment using a digital inclinometer. The primary outcome of this study is the difference between the initial and repositioned cervical joint angles, measured in degrees.
224191967|NCT05949827|DEVICE|Dynamic Light Therapy Device, LSA-1|Dynamic Light Therapy
224191968|NCT05949827|DEVICE|Dynamic Light Therapy Device, LSA-2|Dynamic Light Therapy
224191969|NCT05949827|DEVICE|Dynamic Light Therapy Device, LSA-3|Dynamic Light Therapy
224191970|NCT04843228|BEHAVIORAL|Cognitive Bias Modification|There will be four sessions of CBM. Each session will consist of two different part. The first part of the intervention will be the training based on the ambiguous scenario paradigm for perfectionism developed by Dodd (2019). Participants will need to complete word fragments in the last part of the scenario to resolve the ambiguity of the scenario. Then, a comprehension question will be presented to them to underscore the interpretation condition. Feedback will be given after each question. For the second part of the intervention aimed to intervene intolerance to uncertainty, word sentence association paradigm for intolerance to uncertainty developed by Oglesby (2017) will be used. In this intervention, participants will be asked to judge the relatedness of words and sentences which will be presented to them. Feedback will be given after each word-sentence.
224191971|NCT04843228|BEHAVIORAL|Cognitive Bias Modification for Control Group|For the first part of the intervention, the control group will be presented with the same procedures as the active group; however, feedbacks will be given to resolve the scenarios in a neutral way. When it comes to the second part of the intervention, different word-sentence pairings will be presented to the control group.
224309829|NCT04549753|DEVICE|Transcranial direct current simulation|Four sessions of stimulation over C3 (patient with left-sided lesion) or C4 (patient with right-sided lesion) based on 10-20 system
224309830|NCT02078427|BIOLOGICAL|ADVATE|Antihemophilic Factor (Recombinant) - Plasma/Albumin Free Method
224309831|NCT02078427|BIOLOGICAL|ADYNOVI|Antihemophilic Factor (Recombinant) Pegylated
224309832|NCT06009627|DRUG|Dalcelli、Exemestane、Gosserine|"Dalcelli: once a day, 125 mg each time, taken for 3 weeks, stopped for 1 week, 1 for 4 weeks~Period. It is recommended to take the medication at approximately the same time every day, delivered in warm water, on an empty stomach, at least before taking the medication~Fasting for 1 hour before and after.~Exemestane: 25mg, oral, once a day, continuous administration.~Gosserine: 3.6mg, subcutaneous injection, once every four weeks, continuous administration"
224309833|NCT06009627|DRUG|Docetaxel for injection、Epirubicin hydrochloride for injection、Cyclophosphamide for injection|"Docetaxel for injection: 75mg/m2, intravenous drip, approximately 30 minutes. Dose reduction and delayed administration are allowed every three weeks, with a maximum of three weeks of delayed administration allowed since the last administration time~Calculate, otherwise terminate treatment.~5\. Epirubicin hydrochloride for injection: 75mg/m2, intravenous drip. Once every three weeks, allowing for dose reduction~And delayed administration, with a maximum allowable delay of 3 weeks, calculated from the last administration time. Otherwise~Stop treatment.~6\. Cyclophosphamide for injection: 500mg/m2, intravenous drip. Once every three weeks, allowing for dose reduction and~Delayed administration, allowed up to 3 weeks, calculated from the last administration time, otherwise terminated treat"
223591692|NCT01939366|DRUG|Cebranopadol 100 µg|Participants randomized to 100 μg cebranopadol will start with 100 μg per day and will remain on 100 µg per day.
223591693|NCT01939366|DRUG|Cebranopadol 300 µg|Participants randomized to 300 μg cebranopadol will start with 100 μg per day and increase to 300 µg per day on day 4 and will remain on 300 µg per day.
223591694|NCT01939366|DRUG|Cebranopadol 600 µg|Participants randomized to 600 μg cebranopadol will start with 200 μg per day and increase to 400 µg per day on day 4 and to 600 µg on day 7, thereafter they will remain on 600 µg per day.
224191972|NCT04169126|DRUG|F-18 PMPBB3|The study will enroll 200 patients with prodromal AD and AD dementia and 100 normal controls, men and women aged 55-80 years across core clinical criteria of prodromal AD and mild AD dementia based on IWG-2 criteria.
224191973|NCT00749866|DRUG|Gentamicin|Nebulised 80mg twice daily
224191974|NCT00749866|DRUG|Saline|Nebulised 4mls 0.9% Saline twice daily
223591695|NCT01939366|DRUG|Pregabalin|Stepwise titration from 75 mg twice a day to 300 mg twice a day over 2 weeks.
224191975|NCT00157157|BIOLOGICAL|Recombinant Antihemophilic Factor Manufactured and Formulated without Added Human or Animal Proteins (rAHF-PFM)|"Treatment regimens were determined by the investigator, and may have been any combination of standard prophylaxis (25 to 50 IU/kg body weight, 3 to 4 times per week), investigator-determined prophylaxis, and/or on-demand treatment (dose selected by investigator).~The treatment of bleeding episodes and perioperative management was at the discretion of the investigator and consistent with the institution's standard of care.~For incremental recovery assessments, a single infusion at 50 +/- 5 IU/kg was to be given.~Immune tolerance induction (ITI) therapy for subjects who developed factor VIII inhibitors was at the discretion of the investigator, based on the institution's guidelines or described in peer-reviewed literature, and was to be approved by the sponsor's medical director.~rAHF-PFM was to be administered intravenously via bolus infusion, except for perioperative management when it may have been given either by continuous or bolus infusion."
224191976|NCT06091891|DRUG|Tranexamic acid|Without ROTEM-guidance, we maintain tranexamic acid infusion at 10mg/kg/h until the end of the surgery.
224309834|NCT00049582|DRUG|decitabine|Given IV
224191977|NCT06091891|DRUG|Tranexamic acid infusion under ROTEM-guidance|If diffuse bleeding occurs during surgery, we perform ROTEM testing and administer tranexamic acid based on the test results.
224191978|NCT06768138|DRUG|Intra-arterial infusion of Alteplase|Patients enrolled in the experimental arm will receive intra-arterial thrombolysis with Alteplase. The dose of Intra-arterial Alteplase is 0.225 mg/kg body weight with a maximal dose of 20 mg
224191979|NCT04657809|COMBINATION_PRODUCT|Insulin film|Insulin suspension vials
224309835|NCT00049582|OTHER|laboratory biomarker analysis|Correlative studies
224309836|NCT00049582|OTHER|pharmacological study|Correlative studies
224309837|NCT03677076|OTHER|Ancillary/Correlative|Collection of research blood and urine
224309838|NCT04651894|DEVICE|reactive hyperaemia index measurement|"reactive hyperaemia index with EndoPAT®~Pulse wave velocity measurement with Sphygmocor®"
224309839|NCT01069991|BEHAVIORAL|Patient education group|Patient education delivered to high school students with persistent asthma in group and individual sessions. Academic detailing was also provided to the students' primary care providers.
224309840|NCT01069991|BEHAVIORAL|Wait list control group|No intervention was provided for this group until the one year study period was completed, and then the patient education intervention was provided.
224191980|NCT04657809|DEVICE|Fast dissolving film|Fast dissolving film
224191981|NCT03537417|PROCEDURE|for thoracoscopic ablation of cervical sympathetic chain|bilateral thoracoscopic ablation of cervical sympathetic chain as a treatment for hyperhidrosis
224191982|NCT02723539|DRUG|MBN-101|Topical application
224191983|NCT02723539|DRUG|Placebo|Topical application
223591696|NCT01939366|DRUG|Matching Placebo|Placebo will be matched to pregabalin and cebranopadol.
224191984|NCT05831956|PROCEDURE|Laparoscopic colectomy|Patients who under went laparoscopic colectomy
224191985|NCT01678794|DRUG|Candesartan|4 mg once a day up to 13 day. dose will be doubled every 14-18 days as tolerated to a goal of 16 mg a day or highest dose tolerated
224309841|NCT01023191|PROCEDURE|Percutaneous Insertion catheter|Insertion of CAPD catheter using percutaneous seldinger technique under local anaesthetic +/- sedation as required
224309842|NCT01023191|PROCEDURE|Open insertion Catheter|Present technique of open insertion under general anaesthetic. Incision to lower abdomen and direct visualisation of catheter tip placement into pelvis.
223591697|NCT00680797|DRUG|Testosterone|Testosterone gel
223591698|NCT00680797|DRUG|Estrogen|Estrogen patch
223591699|NCT03122782|DRUG|Topical application Tranexamic acid|Tranexamic acid (TXA) will be injected to distinction media during hysteroscopy in myomectomy
223591700|NCT03122782|DRUG|Placebo (Normal saline)|5ml of normal saline will be added to every 500 ml of distension media
223591701|NCT01743742|DRUG|Vitamin E, Vitamin C|
223591702|NCT03747679|DRUG|200 Mg capsules of bosutinib in Water solution|200 mg (4X50) Capsules in water
223591703|NCT03747679|DRUG|bosunitib sorbitol|200 Mg of bosutinib sorbitol solution
223591704|NCT03747679|DRUG|Bosutinib Mannitol|Bosutinib mannitol solution
223591705|NCT03747679|DRUG|bosutinib in mannitol low sweet|bosutinib in mannitol solution low sweet
223591706|NCT03747679|DRUG|bosutinib in mannitol high sweet|bosutinib in mannitol high sweet
224191986|NCT01678794|DRUG|Placebo|4 mg once a day up to 13 day. dose will be doubled every 14-18 days as tolerated to a goal of 16 mg a day or highest dose tolerated
223591707|NCT03747679|DRUG|bosutinib taste low flavour|bosutinib solution low flavour
224191987|NCT04793126|DIAGNOSTIC_TEST|Urodynamic study|comparison between the urodynamic study of the patients before pelvic prolapse surgical repair and 6 months later.
224191988|NCT06735755|DRUG|BEAM-301: Single dose of BEAM-301 administered by IV|BEAM-301 is designed to correct the G6PC1 c.247C\>T allele via an A:T-to-G:C base-pair substitution, resulting in restoration of G6Pase-α catalytic activity.
224191989|NCT06912984|BEHAVIORAL|Aerobic Exercise Training|The aerobic exercise training intervention will consist of moderate-intensity aerobic exercise training program consisting of treadmill walking/running and upright cycling. The training program involves 3 training sessions per week for 12 weeks. Each session will be ≈ 60 minutes in duration.
224191990|NCT06917027|OTHER|education|clean intermittent catheterization education
224191991|NCT06913283|PROCEDURE|Pulp Therapy with Mineral trioxide aggregate (MTA)|MTA allowed to set for twenty four hours
224191992|NCT06913283|PROCEDURE|Pulp Therapy with Biodentine|Biodentine is triturated before use
224191993|NCT01600677|DEVICE|Computerized medication delivery unit|The patient's prescriptions and refills are packaged in standard-sized blister cards and loaded into EMMA units. EMMA identifies each medication automatically-no patient input is required. When activated by the patient, the medications are selected from the blister cards and released into the delivery tray. EMMA will remain in the patient's home for a period of 90 days immediately following hospitalization. After 90 days, the EMMA MDU will become available for the next eligible patient. This maximizes the number of patients that can benefit form the MDU, while addressing the transition period when medication-reconciliation problems are most common.
224191994|NCT01600677|OTHER|Usual care|Those hospitalized patients that meet all inclusion and exclusion criteria will receive medications from a dedicated pharmacy, but continue to make their medications in their usual way for the 90-day period immediately following discharge.
224191995|NCT01836900|DEVICE|Endoscopic hemostasis|Hemostasis with Standard Therapy (standard clip or thermal therapy + injection of adrenaline solution) or by application of the Over The Scope Clip and injection of adrenaline solution
224191996|NCT02801487|RADIATION|Carbon ion radiotherapy (CIRT)|Five dose levels (52.5GyE, 55GyE, 57.5GyE, 60GyE, 62.5GyE) are planned within the Phase I part. Daily fraction of 2.5 GyE will be delivered for all dose levels. After the recommended dose (RD), i.e., MTD, is determined or if the treatments to 62.5 GyE are safely delivered, the recommended dose (or 62.5 GyE) will be the prescribed dose in the Phase II part of the study. Ninety-five percent (95%) of the isodose line should cover the GTV+3\~5mm.
224191997|NCT02801487|DRUG|Cisplatin|Cisplatin (40mg/m\^2) monotherapy will be given weekly along with radiotherapy.
224191998|NCT00121251|DRUG|Capecitabine|Given PO
224191999|NCT00121251|DRUG|Gemcitabine Hydrochloride|Given IV
224192000|NCT00121251|DRUG|Sorafenib Tosylate|Given PO
224192001|NCT06155851|PROCEDURE|Upper Endoscopy|Endescopy
224192002|NCT00526214|DRUG|celecoxib medication|In the celecoxib group, patients will take celecoxib 400mg twice (per day), orally for 14 days.
224192003|NCT00390741|BEHAVIORAL|Exercise Plus Program|Those assigned to the treatment group were visited by an exercise trainer three times a week for the first two months of the study, two times per week during months three and four, one time per week during months five and six, two times a month during months seven and eight, and one time a month during months nine through twelve. During months seven through twelve of the study the trainer contacted the participant by telephone once each week during the weeks that he or she did not go the participants' home.
224192004|NCT00140816|BEHAVIORAL|Increased intake of dairy products|
224192005|NCT02899884|OTHER|No Intervention|
224192006|NCT02189538|DIETARY_SUPPLEMENT|ω-3 PUFA|The patients are fed as long as the clinically required with the randomly attributed enteral solution.
224192007|NCT02189538|DIETARY_SUPPLEMENT|Low fat enteral diet|The patients are fed as long as the clinically required with the randomly attributed enteral solution
224192008|NCT06931197|BEHAVIORAL|Contingency management|"If the urine sample is methamphetamine negative, participant will be positively reinforced and offered incentives. Participants immediately draw the reinforcement slip of paper to receive a prize from a selection kept on-site. Approximately 50% of the slips offer written praises (i.e. great job!). The other 50% of slips are the divided between low value (i.e. food gift cards, bus passes), medium value (i.e. prepaid cellphone, clothing gift cards), and a few large value rewards (i.e. electronic tablet, jewelry). Should the sample be positive for methamphetamine, no reinforcement and/or incentive to be provided. Participant will be encouraged to continue to participate in CM program and follow-up on the next CM date."
224192009|NCT02260804|BIOLOGICAL|CT-P10|375mg/m2, IV on day1 of 4 cycles in induction period, and 12 cycles in maintenance period.
224192010|NCT02260804|BIOLOGICAL|Rituxan|375mg/m2, IV on day1 of 4 cycles in induction period, Rituxan for the first 6 cycles and CT-P10 for the last 6 cycles in maintenance period.
224192011|NCT01099670|DRUG|NRL001|Rectal suppository Placebo
223591708|NCT03747679|DRUG|bosutinib high flavour|bosutinib solution high flavour
223591709|NCT03747679|DRUG|bosutinib capsules in applesauce|Bosutinib capsules in applesauce
223591710|NCT03747679|DRUG|Bosutinib capsules in yogurt|bosutinib capsules in yogurt
224192012|NCT01099670|DRUG|Placebo|Placebo
223591711|NCT03747679|DRUG|bosutinib capsules in water|sham comparator, bosutinb in water retest
223591712|NCT03747679|DRUG|Bosutinib capsules in low sweet|bosutinib capsules in low sweet
223591713|NCT03747679|DRUG|bosutinib capsules high sweet|Bosutinib capsules high sweet
223591714|NCT03747679|DRUG|bosutinib capsules low flavour|Bosutinib capsules low flavour
223591715|NCT03747679|DRUG|bosutinib capsules high flavour|bosutinib capsules in high flavour
224192013|NCT06934421|DEVICE|Ultrasound-Guided Genicular Nerve Radiofrequency Ablation|This intervention involves a single-session ultrasound-guided thermal radiofrequency ablation of the superomedial, superolateral, and inferomedial genicular nerves in patients with moderate to severe knee osteoarthritis. Target points follow anatomical references described by Fonkoue et al. and validated in cadaveric studies, differing from classical approaches. Under ultrasound guidance, monopolar RF cannulas are placed, with sensory and motor stimulation confirming accurate positioning. Local anesthesia (2% lidocaine) is applied. Lesions are performed at 85°C for 90 seconds per site. The radiofrequency generator used is CE-marked for pain procedures. The study evaluates a novel targeting protocol, not the safety or effectiveness of the device itself. No fluoroscopy is used. The procedure is performed once. Participants are followed for two years to assess outcomes.
224192014|NCT06273046|BEHAVIORAL|Biofeedback|Three visits will be made throughout the study. The first visit (Day -14) will consist of an evaluation of the inclusion criteria. A pre-treatment anorectal manometry will be performed, and a daily symptom questionnaire will be given to the patient. The second visit will take place 14 days later (Day 0). During this visit, the daily clinical symptom questionnaire will be collected and it will be verified that the patient meets the inclusion criteria. Patients who meet the criteria will be randomized 2:1 to active treatment or placebo. Patients will receive instructions, by means of psychoeducational videos on the exercises to be performed daily at home. A final visit will be performed at the end of the study (3 months in incontinence studies and 4 weeks in dyssynergic defecation studies). In incontinence study a final phone call will be performed at 6 months.
224192015|NCT06273046|BEHAVIORAL|Placebo|Three visits will be made throughout the study following the same procedure as patients in the active arm. Patients randomized to placebo treatment will receive instructions to take a pill of placebo containing 0.3 g glucose daily at home. A final visit will be performed at the end of the study alike the active treatment group.
224192016|NCT04160884|PROCEDURE|Indocyanine Green Injection through Peripheral Vein|After ligation of the segmental pulmonary artery supplying the targeted segment, indocyanine is injected intravenously at a specific concentration intraoperatively.
224192017|NCT05907343|DEVICE|Sham TBS|A BCI records and analyzes the participant's EEG as they perform cognitively demanding video game tasks. The BCI delivers TBS with a sham coil when its output indicates that the participant is not properly engaged in the video game.
224192018|NCT05907343|DEVICE|Closed-loop TBS|A BCI records and analyzes the participant's EEG as they perform cognitively demanding video game tasks. The BCI delivers TBS with a real coil when its output indicates that the participant is not properly engaged in the video game.
224192019|NCT05907343|DEVICE|Open-loop TBS|A BCI records and analyzes the participant's EEG as they perform cognitively demanding video game tasks. TBS with the real coil is delivered irrelevant of the BCI decoder output.
224192020|NCT00394173|DRUG|DNK333|DNK333 25mg b.i.d. given orally for 4 weeks
224192021|NCT00394173|DRUG|Placebo|Matching placebo
224192022|NCT06942091|OTHER|Traumatic Brain Injury (TBI)|Presence of TBI identified by intracerebral hemorrhage on brain computed tomography (CT) at emergency department; not actively assigned by investigators but used to stratify comparison groups.
224192023|NCT06943365|OTHER|Repeat plasma screening for the presence or absence of anti-TREK-1 autoantibodies|Semiquantitative measure of circulating anti-TREK-1 autoantibodies in plasma of study participants using a peptid microarray
224192024|NCT06943365|GENETIC|DPP6 risk haplotype|Systematic genetic screening for the Dutch DPP6 risk haplotype in all study participants and correlation of results with the presence or absence of anti-TREK-1 autoantibodies
224192025|NCT06942390|DEVICE|Micro-Needling Combined with ketofin and metformin|After micro-needling, topical ketotifen is applied to one half of the face and topical metformin to the other half. Between sessions, patients continue daily application of both treatments.
224192026|NCT06942390|DRUG|ketofin and metformin Alone|This arm includes 51 patients receiving daily applications of topical ketotifen on one half of their face and topical metformin on the other half without undergoing micro-needling sessions.
224309843|NCT02771886|BEHAVIORAL|Surf the Urge|"The intervention teaches clients to be aware of and accept their feelings, thoughts, and sensations in a non-judgmental manner. Clients learn to remain present within the moment, become aware of their urges, and focus on accepting thoughts and feelings rather than suppressing or changing them. It utilizes visual imagery to assist clients in utilizing more acceptance skills; the client imagines his urges as waves within the ocean and then imagines surfing the waves.~Some interventionists also provide psychoeducation. Clients learn that urges will not last forever; clients are also taught information about reinforcing urges. The interventionist explains that if clients do not reinforce urges (e.g., do not smoke when an urge to smoke arises) they will eventual subside; however, reinforcing urges (smoke when an urge to smoke arises) will produce stronger urges. Emphasis is placed on the belief that clients have the choice to refrain from engaging in urge-related behaviors."
224309844|NCT05004584|OTHER|Wheat home-based appetite assessment|Home-based appetite assessment with diet based on wheat cereal products.
224309845|NCT05004584|OTHER|Rye home-based appetite assessment|Home-based appetite assessment with diet based on rye cereal products.
224309846|NCT05004584|OTHER|Wheat clinic-based appetite assessment|Clinic-based appetite assessment with diet based on wheat cereal products.
223500995|NCT04912817|OTHER|Custom VR|Operates using Oculus Quest VR HMD with PR-VR software developed with two gaming options: Fruity Feet and Space Burgers 2. Game settings are manipulated by the physiotherapist in session to target specific limb movements and intensity and also motivates participants to cycle using a leg ergometer. Motion sensors on the ergometer track the participants revolutions per minute. For participants in this study arm, a leg ergometer (DeskCycle) will be provided to them during the study phase alongside the Actigraph and Oculus Quest HMD. During the 30min VR portion of the session, 20 minutes will be dedicated to gaming and exercise, and 10 minutes dedicated for set up, tear down, and rest breaks. During the 20 minutes gaming time, a minimum of 15 minutes will be dedicated to Custom VR, with 5 minutes for 'free play' where the participant can opt to try an off-the-shelf VR game.
223500996|NCT05933460|DIETARY_SUPPLEMENT|dietary supplement with probiotics, prebiotics, magnesium and saffron extract|A sachet of a combination of 4 strains of probiotics (1billion CFU) (Lactobacillus rhamnosus, Bifidobacterium animalis subscp. lactis, Bifidobacterium breve, Bifidobacterium longum), Fructooligosaccharides 100mg, Magnesium 75mg and Saffron extract 28mg was administered 3 times per day
223591716|NCT04857957|DRUG|Oral dose CNTX-6016 or oral dose Placebo|CNTX-6016 or Placebo
223500997|NCT05933460|DIETARY_SUPPLEMENT|dietary supplement with probiotics, prebiotics, magnesium|A sachet of a combination of 4 strains of probiotics (1billion CFU) (Lactobacillus rhamnosus, Bifidobacterium animalis subscp. lactis, Bifidobacterium breve, Bifidobacterium longum), Fructooligosaccharides 100mg, Magnesium 75mg was administered 3 times per day
223746290|NCT06912971|BEHAVIORAL|Self-Knowledge Training Program|The intervention consists of a self-knowledge training program based on the Enneagram framework. Participants attend 7 sessions, focusing on self-awareness, emotional regulation, and personal development. The sessions include theoretical explanations, guided self-reflection exercises, and group discussions to help participants better understand their personality patterns and how these influence their perception of pain and well-being.
223746291|NCT06941324|BEHAVIORAL|Behavioral Intervention|Undergo SFBT-C
223500998|NCT06183190|OTHER|No intervention|No intervention
223500999|NCT04892277|BIOLOGICAL|Autologous Anti-CD19 CAR-expressing T-lymphocytes IC19/1563|Given IV
223501000|NCT04892277|DRUG|Bendamustine|Given IV
223501001|NCT04892277|PROCEDURE|Biospecimen Collection|Undergo collection of blood and tissue samples
223501002|NCT04892277|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
223501003|NCT04892277|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
223501004|NCT04892277|PROCEDURE|Computed Tomography|Undergo CT
223501005|NCT04892277|DRUG|Cyclophosphamide|Given IV
223501006|NCT04892277|DRUG|Fludarabine|Given IV
223501007|NCT04892277|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
224309847|NCT05004584|OTHER|Rye clinic-based appetite assessment|Clinic-based appetite assessment with diet based on rye cereal products.
223501008|NCT04892277|PROCEDURE|Positron Emission Tomography|Undergo CT/PET
223501009|NCT00714480|DRUG|anti-thymocyte globulin|Administration of anti-thymocyte globulin at post-operative days -6, -4, -2 and 0
223501010|NCT00714480|DRUG|anti-thymocyte globulin|anti-thymocyte globulin post-operative days -2, 0, 2 and 4
223501011|NCT00714480|DRUG|anti-thymocyte globulin|Post-operative days 0, 2, 4 and 6
223501012|NCT01422902|OTHER|Plasticity-based Cognitive Training|
223501013|NCT01422902|OTHER|Non-plasticity-based Training|Computer games
223501014|NCT01142921|DEVICE|Anti-reflux Tannenbaum biliary stent|Anti-reflux Tannenbaum biliary stent
223501015|NCT01142921|DEVICE|Ordinary Tannenbaum biliary stent|Ordinary Tannenbaum biliary stent
223501016|NCT03148340|DIAGNOSTIC_TEST|VIPS Monitoring|Bioimpedance asymmetry
223501017|NCT05890820|OTHER|Preoperative nutritional assessment|Preoperative nutritional assessment and postoperative pulmonary complications
223501018|NCT04520100|BEHAVIORAL|Clinical Hypnosis performed by the PI|The patient will receive clinical hypnosis by the PI prior to examination and listen to recorded session during their MRI.
223501019|NCT04520100|BEHAVIORAL|Care by technician trained in empathic communication|The patient will be taken care of by an MRI technician who has been previously trained in empathic communication.
223501020|NCT02085551|DEVICE|Mechanical Thrombectomy by the Indigo System|
223501021|NCT02916329|OTHER|68Ga-NODAGA-Ac-Cys-ZEGFR:1907|68Ga-NODAGA-Ac-Cys-ZEGFR:1907 (Ac-Cys-ZEGFR:1907 : Ac-CVDNKFNKEMWAAWE EIRNLPNLN GWQMTAFIASLVDDPSQSANLLAEAKKLNDAQAPK-NH2)
223501022|NCT06159036|DEVICE|Inertial Strength training|Low speed strength training with classic movements, derived from Olympic lifting and jumping
223501023|NCT04508075|BIOLOGICAL|SARS-CoV-2 vaccine (inactivated)|SARS-CoV-2 vaccine (inactivated) manufactured by Sinovac
223501024|NCT04508075|BIOLOGICAL|Placebo|Placebo manufactured by PT. Bio Farma
223501025|NCT05594238|BEHAVIORAL|Telephone Engagement|Brief phone session with a study counselor.
223501026|NCT05594238|BEHAVIORAL|Portal Engagement|Access to a virtual portal where participant messages with study counselors.
223501027|NCT05594238|BEHAVIORAL|MI-CBT|8 one-on-one sessions done over the phone or video chat with a study counselor
223501028|NCT03052036|PROCEDURE|Coronary Angiography|Coronary angiography to determine location of blocked or narrowed arteries.
223501029|NCT03052036|PROCEDURE|Coronary revascularisation|PCI or CABG will be performed following coronary angiography at the discretion of the treating cardiologist.
223501030|NCT03052036|OTHER|Optimal Medical Therapy|Patients to receive conservative treatment in the form of guideline recommended secondary prevention therapy including antiplatelet therapy, statins, ACE Inhibitors and beta blockers.
223501031|NCT06255743|DIAGNOSTIC_TEST|Anti-Ribosomal P Protein,Anti-U1 RNP, Anti-Nucleosome and Anti-Double Strad DNA Antibodies|determine Anti-Ribosomal P Protein,Anti-U1 RNP, Anti-Nucleosome and Anti-Double Strad DNA Antibodies) and its relation to the degree of Depression and Anxiety in Systemic Lupus Erythematosus Patients
223501032|NCT00191750|DRUG|Pemetrexed|
223501033|NCT06432439|PROCEDURE|microneedling followed by CAF procedures|microneedling will be done on gingiva of RT1 recession tooth in 4 sessions followed by CAF 2months later for root coverage
223501034|NCT06432439|PROCEDURE|CAF procedure|RT1 gingival recession coverage by CAF procedures alone.
223501035|NCT01648959|OTHER|EEG Recording|
223501036|NCT03884764|PROCEDURE|pulsed radiofrequency|patients with chronic pelvic pain due to chronic prostatitis will receive pulsed radiofrequency on sacral root number 3 and ganglion impar denervation and the patients will be followed for 6 months to assess pain severity radiofrequency procedure: patients will positioned prone on the operating table and under x-ray guidence sacral foramen number 3 will be identified and through it radiofrequency needle will be advanced to target the sacral root ganglion impar procedure: under x-ray guidance the sacrococcygeal junction is identified and spinal needle will be introduced through it to target ganglion impar and 4 ml of alcohol 50% will be injected
223501037|NCT03884764|PROCEDURE|ganglion impar denervation|patients with chronic pelvic pain due to chronic prostatitis will receive ganglion impar denervationand and the patients will be followed for 6 months to assess pain severity ganglion impar procedure: under x-ray guidance the sacrococcygeal junction is identified and spinal needle will be introduced through it to target ganglion impar and 4 ml of alcohol 50% will be injected
223501038|NCT04143048|OTHER|DNA extraction of tumer tissue samples and high-throughput sequencing of small panels|DNA extraction of stromal tumor tissues and high-throughput sequencing of small panels were performed, and the relationship between the mutation spectrum of each sample and the corresponding patient clinical data (staging) was analyzed
224192027|NCT06935643|OTHER|Birth Ball|Written and verbal consent will be obtained by giving information about the study.The Pregnant Diagnosis Form will be filled out.When the cervical opening is 4-5 cm, 6-7 cm and 8-10 cm, the pregnant woman will have a birth ball application for 10 minutes. Visual Analog Scale (VAS) will be completed before and after each application. During labor, the Labor Monitoring and Perineal Trauma Assessment Form will be completed and the presence/degree of perineal trauma will be evaluated.Visual Analog Scale (VAS) will be completed at the 1st hour postpartum.At the 4th hour postpartum, the Visual Analog Scale (VAS) and The Scale for Measuring Maternal Satisfaction in Birth will be completed.
224192028|NCT06935643|OTHER|Perineal Massage|Written and verbal consent will be obtained by giving information about the study.The Pregnant Diagnosis Form will be filled out. When the cervical opening is 4-5 cm, 6-7 cm and 8-10 cm, 10 minutes of perineal massage will be applied to the pregnant woman. Visual Analog Scale (VAS) will be completed before and after each application. During labor, the Labor Monitoring and Perineal Trauma Assessment Form will be completed and the presence/degree of perineal trauma will be evaluated.Visual Analog Scale (VAS) will be completed at the 1st hour postpartum.At the 4th hour postpartum, the Visual Analog Scale (VAS) and The Scale for Measuring Maternal Satisfaction in Birth will be completed.
224192029|NCT06935643|OTHER|Control Group|"Pregnant women in the control group will not receive any intervention. Pregnant women in this group will only receive routine midwifery care.~Written and verbal consent will be obtained by giving information about the study.Pregnancy Diagnosis Form will be filled.When the cervical opening is 4-5 cm, 6-7 cm and 8-10 cm, Visual Analog Scale (VAS) will be completed. During labor, the Labor Monitoring and Perineal Trauma Assessment Form will be completed and the presence/degree of perineal trauma will be evaluated.Visual Analog Scale (VAS) will be completed at the 1st hour postpartum.At the 4th hour postpartum, the Visual Analog Scale (VAS) and The Scale for Measuring Maternal Satisfaction in Birth will be completed."
224192030|NCT06942299|DRUG|AK0529|Active Substance: AK0529, Pharmaceutical Form: Enteric pellets, Route of Administration: Oral, fasting
224192031|NCT06942299|DRUG|AK0529|Active Substance: AK0529, Pharmaceutical Form: Enteric pellets, Route of Administration: Oral with meal
224192032|NCT06942299|DRUG|Placebo|Active Substance: Placebo, Pharmaceutical Form: Enteric pellets, Route of Administration: Oral with meal or fasting
224192033|NCT06937385|DRUG|0.5% Bupivacaine HCl|bilateral cervical injections of 0.5% bupivacaine into the paraspinous muscle at the c6-7 location for headache treatment
224192034|NCT06937385|DRUG|standard IV treatment for headache|physicians choice of IV medications in treatment of headache
223501039|NCT04143048|OTHER|DNA extraction of tumer tissue samples and blood sample and high-throughput sequencing of small panels|DNA extraction and small panel sequencing were performed for the two types of samples of the patients respectively, and the DNA sequencing results of the two types of samples were compared, and the clinical data of the corresponding patients were referenced to evaluate the consistency of the results of peripheral blood cfDNA and tissue gDNA for the gene detection of gastrointestinal stromal tumor
223501040|NCT04143048|OTHER|DNA extraction of tumer tissue samples and blood sample and high-throughput sequencing of small panels|DNA extraction and small panel sequencing were conducted for each patient sample. Based on the indicator results of the previous mutant spectrum for each stage of gastrointestinal stromal tumor, the clinical stage classification of patients and the benign and malignant nodules were determined by the mutant spectrum, and compared with the real clinical data of patients
223501041|NCT04759547|DEVICE|handheld ultrasound-assisted technique|Ultrasound with 3D navigation function is used to determine the needle insertion point and the insertion angle.
223501042|NCT04759547|OTHER|conventional palpation-guided technique|The interspinous space is detected by palpation
223501043|NCT01470807|DEVICE|portable artificial pancreas system with CTR algorithms|The investigators will test the new portable CTR system in CRC conditions for 10h followed by 18h of CTR in a hotel.
223501044|NCT01495247|DRUG|BEZ235|Doses of oral BEZ235 (BID), supplied as 50mg, 200mg, 300mg or 400mg in SDS sachets, together with standard weekly paclitaxel at a fixed dose (80mg/m²) during 1h by i.v. in infusion.
223501045|NCT01495247|DRUG|Paclitaxel|"The paclitaxel infusion will be given in the morning and directly thereafter the BEZ235 dose will be given.~BEZ235 doses will be escalated in cohorts of 3 to 6 patients guided by an adaptive Bayesian logistic regression model with overdose control until MTD/RP2D has been established. The initial dose level for the first cohort will be 200mg (BID), and then based on the Bayesian model the dose may be escalated to 300mg, 400mg, 500mg or 600mg for the next cohorts."
223501046|NCT01246323|PROCEDURE|Spinal anesthesia with Fentanyl+ Morphine|Fentanyl 15 microgram Morphine 0.1-0.5 mg
223501047|NCT06058156|DRUG|SAR444656 (KT-474)|Oral Tablet
223501048|NCT06058156|DRUG|Placebo|Oral Tablet
223501049|NCT05935449|DEVICE|Formaderm Lidocaine|Dermal filler injection to facial areas
223501050|NCT05935449|DEVICE|Formaderm Dermal Filler Injection|Dermal filler injection to facial areas
223501051|NCT04514458|OTHER|Best practice alert for the notification of patient HFrEF and recommended evidence-based therapies (NO drugs are being administered in this trial)|Providers will receive a best practice alert for each of their eligible patients upon opening of the order entry screen in the patient's medical record. The alert will inform the provider to the presence of HFrEF and of the patient's current left ventricular ejection fraction and current evidence-based medications for HFrEF. It will also provide access to an order set with recommended evidence-based HFrEF therapies as well as a link to the best available guideline-recommended information regarding the treatment of heart failure.
223501052|NCT05259033|DRUG|IcoSema|"IcoSema once weekly subcutaneously (s.c., under the skin) using a needle and a pen.~For about 1 year and 1 month."
223501053|NCT05259033|DRUG|Semaglutide 1 mg|Semaglutide once weekly subcutaneously (s.c., under the skin). Dose titrated to 1mg over 8 weeks (0.25 mg for 4 weeks, 0.5 mg for 4 weeks). For about 1 year and 1 month.
223501054|NCT04023552|DRUG|TQJ230|TQJ230 80 mg injected monthly administered subcutaneously
223501055|NCT04023552|DRUG|Placebo|Placebo to match TQJ230 prefilled syringe to be injected subcutaneously
223746292|NCT06941324|OTHER|Best Practice|Receive eTAU
223746293|NCT06941324|OTHER|Communication Intervention|Receive check in calls from clinician
223746294|NCT06941324|OTHER|Discussion|Participate in discussions
223746295|NCT06941324|OTHER|Health Promotion and Education|Receive educational manual
223746296|NCT06941324|OTHER|Health Promotion and Education|Receive educational book
224192035|NCT06942130|OTHER|Artificial intelligence|Incorporating artificial intelligence as an aid to video-based skill learning
224192036|NCT06942130|OTHER|Video|Skill learning solely through videos
224192037|NCT06942988|BIOLOGICAL|intracavernous platelet rich plasma therapy|intracavernous platelet-rich plasma therapy for erectile dysfunction
224192038|NCT04406324|OTHER|No intervention|No Intervention. The study consists in a prospective clinical longitudinal follow-up
224309848|NCT05004584|OTHER|Rye/Wheat clinic-based appetite assessment with blood sampling|Clinic-based appetite assessment with diet based on rye or wheat cereal products and continuous blood sampling.
224309849|NCT04180163|DRUG|Lanadelumab|Lanadelumab solution, SC
224309850|NCT03945669|PROCEDURE|Intramedullary Nailing|fracture fixation of the tibial shaft fracture with an intramedullary nail.
223501056|NCT06434883|BEHAVIORAL|Anxiety/Depression Program|Participants will complete the Headspace Anxiety/Depression Program, which is a 21 day program based on CBT, combined with mindfulness. The program is trans-diagnostic in nature (i.e. addresses both anxiety and depression symptoms).
223501057|NCT06434883|OTHER|Waitlist|Participants will continue their regular routines for an 21 day period and will not be assigned to an intervention.
223501058|NCT06471569|BEHAVIORAL|Low/Mod|Aerobic exercise at 50% peak oxygen consumption for the number of weekly minutes prescribed in the original STRRIDE trial
223501059|NCT06471569|BEHAVIORAL|High/Mod|Aerobic exercise at 50% peak oxygen consumption for the number of weekly minutes prescribed in the original STRRIDE trial
223501060|NCT06471569|BEHAVIORAL|High/Vig|Aerobic exercise at 75% peak oxygen consumption for the number of weekly minutes prescribed in the original STRRIDE trial
223501061|NCT04180696|DEVICE|aCRT ON|CRT device with AdaptivCRT enabled
223501062|NCT04180696|DEVICE|aCRT OFF|CRT device with AdaptivCRT disabled
223501063|NCT06638385|PROCEDURE|DCE + SPACE SHIELD|Patients receive a DCE with implantation of a space-expanding shield.
223501064|NCT06638385|PROCEDURE|DCE + CP|Patients in the control group receive a DCE similar to the intervention group, but without implantation of a space-expanding shield. Cranioplasty (CP) is performed after \~ 90 days in the customary manner.
223501065|NCT04210375|DRUG|JK07|Recombinant fusion protein consisting of a fully humanized immunoglobulin G1 monoclonal antibody and an active polypeptide fragment of the human growth factor NRG-1
223501066|NCT04210375|DRUG|Matching Placebo|Vehicle control
223501067|NCT03414866|BEHAVIORAL|EQ-5D-5L QOL questionnaire|Written questionnaire
223501068|NCT03895489|DEVICE|Journey II|Smith and Nephew Richards (SNR) Journey II Knee prosthesis
223501069|NCT03895489|DEVICE|Stryker|Stryker Triathlon Total Knee prosthesis
223501070|NCT03895489|DEVICE|Zimmer|Zimmer Persona® The Personalized Knee prosthesis
223501071|NCT05954728|BEHAVIORAL|Cognitive-Behavioral Therapy for Avoidant/Restrictive Food Intake Disorder (CBT-AR)|CBT-AR is a four-stage modular treatment for ARFID delivered by a mental health clinician. The four stages include: 1) Psychoeducation and early change; 2) Treatment planning; 3) Addressing maintaining mechanisms; and 4) Relapse prevention. For participants ages 10-15 years, patients/guardians attend the sessions. For patients ages 16 and up, the therapy is individual.
223501072|NCT05954728|BEHAVIORAL|Nutrition Counseling for Avoidant/Restrictive Food Intake Disorder|Nutrition counseling will be provided by skilled registered dietitians at the MGH Translational and Clinical Research Center (TCRC). Sessions focus on the foods necessary for a healthy diet, how to meet nutritional needs, how to incorporate healthy exercise, and support for making these changes. For participants ages 10-15 years, patients/guardians attend the sessions. For patients ages 16 and up, the therapy is individual.
223501073|NCT05135169|DRUG|Definity Suspension for Injection|Administration of Definity
223501074|NCT00424008|DRUG|Mometasone furoate/formoterol (MF/F) MDI|MF/F 200/10 mcg via a metered dose inhaler (MDI) twice daily for 52 weeks.
223746297|NCT06941324|OTHER|Interview|Ancillary studies
223746298|NCT06941324|OTHER|Questionnaire Administration|Ancillary studies
223746299|NCT06936943|DRUG|ONO-4538|every 4 weeks
224192039|NCT02277418|DEVICE|VAVL|Videolaryngoscope
224192040|NCT02277418|DEVICE|MIL|Direct laryngoscopy
224192041|NCT05760781|DRUG|STSG-0002 Injection|Intravenous infusion
224192042|NCT02412241|OTHER|LEF measures|Patient-reported outcome measure; clinician-reported outcome measures
224192043|NCT02412241|PROCEDURE|Technical measure|Undergo standard CT scan
224192044|NCT02412241|PROCEDURE|Technical measure|Undergo standard ultrasound
224192045|NCT06170359|PROCEDURE|robotic surgery under general anaesthesia|During robotic surgery, the standard 45-degree upright Trendelenburg position and for postoperative analgesia, 0.06 mg/kg morphine, 1 gram (g) paracetomol and 8 mg onasetron are administered iv to all patients 30 minutes before the end of the operation. At the end of surgery and after extubation, patients are taken from the recovery unit to the service. In the service, all patients are given paracetamol 1g every 8 hours and tenoxicam 20 mg every 24 hours for pain treatment. Tramadol 1 mg/kg iv is administered as rescue analgesic to patients with a VAS score \>4.
224309851|NCT03945669|PROCEDURE|External Ring fixation|fracture fixation of the tibial shaft fracture with an external ring fixator.
224309852|NCT04730349|BIOLOGICAL|Nivolumab|Specified dose on specified days
224309853|NCT04730349|BIOLOGICAL|NKTR-214|Specified dose on specified days
224309854|NCT01980966|DRUG|MHAA549A|IV dose
224309855|NCT01980966|DRUG|Placebo|IV dose
224309856|NCT01980966|DRUG|oseltamivir [Tamiflu]|Orally b.i.d, 5 days
224309857|NCT05392335|OTHER|Myofascial stretch|Myofascial stretch will be applied at hip adductors, hamstrings and calf muscles for 10 -15 repetitions on each muscle. 2-3 sessions will be performed in a week for 8 weeks.
224309858|NCT05392335|OTHER|Functional massage along with myofacial stretch|In this group during the first 20 minutes, ten minutes FM will be applied to each lower extremity of the subject. The muscle groups to which FM would be applied were hip adductors, hamstrings and calf muscles. During the remaining period traditional physiotherapy involving myofascial strecth will be given. 2-3 session will be performed in a week for 8 weeks.
224309859|NCT04352387|BEHAVIORAL|Montessori Method for Dementia|The Montessori Method highlights the importance of considering the past experiences, identifying interests and maximizing spared capacity and abilities of each individual.
224309860|NCT04352387|BEHAVIORAL|Usual care|Activities delivered regularly in the usual care, such as reading out newspapers, physical activities, and watching videos, in the 1-hour sessions.
224192046|NCT03973775|DRUG|Permethrin Cream 5%|Patients will be assigned to the test product Permethrin Cream 5% to the Reference Listed Drug Product Elimite cream.
224192047|NCT06525987|BEHAVIORAL|Physical activity|Randomization to a 24-week physical exercise program
224192048|NCT06526104|DRUG|Tremelimumab|Priming dose of tremelimumab 300 mg IV once (Cycle 1, Day 1 only)
224192049|NCT06526104|DRUG|Durvalumab|Durvalumab 1500 mg IV on Day 1 of each 4-week cycle.
224192050|NCT02372539|OTHER|Diabetes|All patients enrolled in study will be given dexamethasone for prophylaxis of chemotherapy-induced nausea and vomiting. This will already be a part of their chemotherapy regimen and will not be prescribed by study investigators
224192051|NCT02372539|OTHER|Control Group|All patients enrolled in study will be given dexamethasone for prophylaxis of chemotherapy-induced nausea and vomiting. This will already be a part of their chemotherapy regimen and will not be prescribed by study investigators
224192052|NCT04964739|BEHAVIORAL|Cognitive Behavioral Therapy (CBT4CBT)|Participants will receive one therapist-led motivational interviewing/goal setting session followed by 7 sessions of computerized CBT4CBT.
224192053|NCT00077727|DRUG|Extended-release galantamine hydrobromide|
224192054|NCT04109573|PROCEDURE|high resolution anal manometry|functional studies before and after anal laser ablation
224192055|NCT06371573|DIAGNOSTIC_TEST|ULTRASOUND EXAM AND MRI SCAN|Within two weeks from the US, each patient underwent an MRI of the upper abdomen to evaluate the splenic volume. MRI examinations were performed using a 3T Biograph mMR scanner (Siemens Healthcare, Erlangen, Germany) with 4-channel flex phased-array body coil. Routine clinical abdominal MRI acquisition includes coronal T2W Half-Fourier Acquisition Single-shot Turbo spin Echo imaging (HASTE), axial T1 Dual-echo FSE, axial T2 TSE Fat Sat, and an axial diffusion-weighted imaging (DWI).
224192056|NCT02860650|BIOLOGICAL|Ad26.Filo|Ad26.Filo intramuscular (IM) injection at a dose of 9\*10\^10 viral particles (vp).
224192057|NCT02860650|BIOLOGICAL|MVA-BN-Filo|MVA-BN-Filo intramuscular (IM) injection at a dose of 5\*10\^8 infectious units (Inf U).
224192058|NCT02860650|BIOLOGICAL|Ad26.ZEBOV|Ad26.ZEBOV intramuscular (IM) injection at a dose of 5\*10\^10 vp.
224192059|NCT02860650|BIOLOGICAL|Placebo|IM injection of 0.9 percent saline.
224192060|NCT02860650|BIOLOGICAL|MVA-BN-Filo|MVA-BN-Filo intramuscular (IM) injection at a dose of 1\*10\^8 Inf U.
224192061|NCT03383406|DRUG|Ifosfamide, Etoposide, Cytarabine, and Methotrexate (IVAM) Chemotherapy|"Every cycle(4weeks)~Subject will receive Ifosfamide 1.5 g/m2 over 2 hours for Day1\~Day5 by Intravenous infusion, Etoposide 150 mg/m2 over 3 hours on Day1\~Day3 by Intravenous infusion, Cytarabine 100 mg/m2 over 1 hour on Day1\~Day3 by Intravenous infusion."
224192062|NCT02513732|DEVICE|XIENCE Xpedition 2.25 mm stent|Patients receiving XIENCE Xpedition 2.25 mm stent
224192063|NCT05598411|DRUG|Oral Glucocorticoids|methylprednisolone 24mg qd, 2-week duration
224192064|NCT05598411|DRUG|Oral placebo|oral placebo 24mg qd, 2-week duration
223501075|NCT00424008|DRUG|Fluticasone propionate/salmeterol (F/SC) DPI|Fluticasone propionate 250 mcg and salmeterol 50 mcg fixed dose combination dry powder inhaler taken twice daily for 52 weeks.
223501076|NCT02759458|DEVICE|Smith & Nephew Healicoil Anchor|
223501077|NCT02759458|DEVICE|Smith & Nephew Twinfix Anchor|
224192065|NCT05079711|DEVICE|SavvyCheck Vaginal Yeast Test (rapid, point-of-care diagnostic test)|The SavvyCheck Vaginal Yeast Test is a lateral flow immunochromatographic qualitative test for detection of Candida antigen in vaginal secretions, sampled by a swab as an aid for identification of vulvovaginal candidiasis (VVC), as a primary cause of vaginal yeast infections. The SavvyCheck Vaginal Yeast Test is designed for use by women experiencing vaginal symptoms, including: increased vaginal discharge, vaginal itching, vaginal soreness and irritation, rash on the labia, and genital burning that may worsen during urination. The SavvyCheck Vaginal Yeast Test is indicated for OTC use.
224192066|NCT01789333|DEVICE|UVA Light with irradiance exposure of 9 mW/cm2|"The device's light emitting diode (LED) is used to deliver a metered dose of Ultraviolet A (UVA) light to a targeted treatment area for illuminating the cornea during corneal collagen cross-linking.~The aperture setting will be set at 10 mm, and the eye will be irradiated for 10 minutes for the high irradiance exposure of 9 milliwatts (mW)/cm2. During the exposure, instillation of riboflavin will continue (1 drop every 3 minutes)."
224192067|NCT01789333|DRUG|Riboflavin 0.1% ophthalmic solution|"The speculum is removed and one (1) drop of Riboflavin 0.1% ophthalmic solution will be instilled topically in the eye every 3 minutes for 30 minutes. At the end of the 30 minute riboflavin pre-treatment period, the eye will be examined to assure the presence of a yellow flare in the anterior chamber, indicating riboflavin saturation of the corneal tissue. If the yellow flare is not detected, riboflavin will continue to be instilled until the presence of the yellow flare in the anterior chamber is confirmed.~During UVA irradiation, instillation of riboflavin will be continued every 3 minutes. For a 30-minute pre-treatment and 30-minute irradiation, the total dose of riboflavin solution is approximately 32 drops, or 1.6 ml (1 drop = 0.05 ml; 1.6 mL = 1.6 mg riboflavin)."
224192068|NCT03724305|BEHAVIORAL|Mindfulness-Based Therapy for Insomnia|Mindfulness-based therapy for insomnia (MBTI) will use mindfulness-based stress reduction techniques to specifically target cognitive-emotional arousal associated with non-refractory insomnia.
224192069|NCT01740297|DRUG|Talimogene laherparepvec|Talimogene laherparepvec administered by intratumoral injection on Day 1 of Week 1, Day 1 of Week 4, then every two weeks thereafter.
224192070|NCT01740297|DRUG|Ipilimumab|Ipilimumab administered intravenously every 3 weeks for a total of 4 infusions.
224192071|NCT01061398|PROCEDURE|Cardiac CT Angiography|Patients randomized to CT Arm will undergo 64-slice cardiac CT angiography (single scan) in addition to the stress imaging test ordered by their physician
224192072|NCT01061398|PROCEDURE|Stress Imaging Test (Stress Myocardial Perfusion Study or Stress Echocardiogram)|Stress imaging test as ordered by the subjects provider without option for cardiac CT angiography (no CT arm)
224309861|NCT05060354|OTHER|Blood draw|Approximately 120 mL whole blood will be collected from each subject at each timepoint
223501078|NCT03565289|DIAGNOSTIC_TEST|Blood sample collection|During a routine blood draw an additional tube of blood will be taken for the study.
223501079|NCT03406663|BEHAVIORAL|Group 1|"Patients will be instructed to daily adjust their dose of Gla-300 based on fasting SMPG values. Fasting SMPG will be measured daily by the patient before breakfast and any intake of antihyperglycemic agents.~Fasting SMPG in the range of~≥ 5.6 mmol/L, increase 1 unit of Gla-300 dose, \> 4.4 and ≤ 5.6 mmol/L, no change, \< 4.4 mmol/L, reduce 1 unit of Gla-300 dose"
223501080|NCT03406663|BEHAVIORAL|Group 2|"Fasting SMPG (median of the last 3 days including current day) in the range of~* 7.8 mmol/L, increase 6 units of Gla-300 dose, \> 5.6 and \< 7.8 mmol/L, increase 3 units of Gla-300 dose, \> 4.4 and ≤ 5.6 mmol/L, no change,~* 3.3 and \< 4.4 mmol/L, reduce 3 units of Gla-300 dose, \< 3.3 mmol/L or occurrence of ≥ 2 symptomatic or 1 severe hypoglycemic episode in the preceding week, reduce 3 units of Gla-300 dose or at the discretion of the investigator"
224192073|NCT04082416|BIOLOGICAL|Placebo plus standard therapy|"Standard therapy comprises any of the following (alone or in combination):~corticosteroids, antimalarials, non-steroidal anti-inflammatory drugs (NSAIDs), and immunosuppressive and immunomodulator therapy(i.e.,azathioprine,mycophenolate ,cyclophosphamide,methotrexate,Tacrolimus ,ciclosporin )"
224192074|NCT04082416|BIOLOGICAL|RC18 160 mg plus standard therapy|Standard therapy comprises any of the following (alone or in combination): corticosteroids, antimalarials, non-steroidal anti-inflammatory drugs (NSAIDs), and immunosuppressive and immunomodulator herapy(i.e.,azathioprine,mycophenolate ,cyclophosphamide,methotrexate,Tacrolimus ,ciclosporin )
223501081|NCT02664493|DRUG|Methylprednisolone|Steroid pulse therapy : Methylprednisolone 0.5 g daily for 3 days, followed by a tapered dose of 60 mg per day for a period of five days.
223501082|NCT05662995|DIAGNOSTIC_TEST|Lung ultrasound|Lung ultrasound will be performed with the patient in supine position (with or without left uterine displacement, depending on clinical circumstances). A phased-array transducer will be used for lung ultrasound and will be used for the assessment of B-lines, which arise from the pleural line and extend to the bottom of the screen and move with the sliding lung
223501083|NCT05522530|OTHER|Assessment scale|Evaluation scale to carry out its cross-cultural adaptation and study its validity
223501084|NCT06805097|OTHER|Self-assessment of bleeding events|After each transfusion, the patient completes a daily bleeding event self-assessment (adapted from the WHO bleeding event scale) until the next transfusion or over a period of 10 days.
223501085|NCT02331420|PROCEDURE|Gastric bypass|A subcardial gastric pouch with a 30±10 ml capacity will be created by sectioning the stomach with a linear stapler 3-4 cm horizontally on the lesser curve, 4 cm distal to the e-g junction, and then vertically until attainment of the angle of Hiss. After identification of the Treitz ligament, the jejunum will be transected at 100 cm from the ligament of Treitz and the two stumps will be closed. The distal stump will be anastomosed to the distal end of the gastric pouch. The preferred gastro-jejunal anastomosis is the totally hand-sewn one, but it can be performed using any other the technique the surgeon is more familiar with. Finally, the proximal stump of the transacted bowel will be joined end-to-side to the jejunum 150 cm distal to the gastro-enterostomy.
223501086|NCT02331420|BEHAVIORAL|Medical therapy|"* Assessment and treatment by a multidisciplinary team (diabetologist, dietitian, nurse);~* Planned visits at baseline and at 1, 3, 6, 9, 12, and 24 months after study entry;~* Oral hypoglycemic agents and insulin doses optimized on an individual basis with the aim of reaching a glycated hemoglobin level of less than 7%;~* Programs for diet and lifestyle modification, including reduced overall energy and fat intake (\<30% total fat, \<10% saturated fat, and high fiber content) and increased physical exercise (≥30 minutes of brisk walking every day, possibly associated with moderate-intensity aerobic activity twice a week);~* low-calorie diet (every day: 50% carbohydrate, 30% protein and 20% lipids)."
223501087|NCT02593864|DEVICE|Variable-Stiffness Shoe|A load-modifying variable-stiffness shoe previously shown to reduce joint loading
223501088|NCT00008424|DRUG|irinotecan hydrochloride|
223501089|NCT04199520|COMBINATION_PRODUCT|surgery combined with systemic therapy|surgery combined with systemic therapy
223501090|NCT04199520|OTHER|systemic therapy|systemic therapy
223501091|NCT01405911|DRUG|Placebo for Sitagliptin 25 mg|1 tablet orally once daily before breakfast for 8 weeks
223501092|NCT01405911|DRUG|Placebo for Sitagliptin 50 mg|1 tablet orally once daily before breakfast for 8 weeks
223501093|NCT01405911|DRUG|Sitagliptin 25 mg|1 tablet orally once daily before breakfast for 8 weeks
223501094|NCT01405911|DRUG|Sitagliptin 50 mg|1 tablet orally once daily before breakfast for 8 weeks
223501095|NCT01282788|DIETARY_SUPPLEMENT|Caterpillar Cereal|Infants will receive once-daily servings of caterpillar cereal (30 g from 6-12 months of ages and 45 g from 12-18 months of ages). Study food will be delivered to homes weekly by Community Coordinators, who will also observe feedings of the cereal during the home visit. Feedings will be observed 3x/week for the first 3 weeks after enrollment, then 1x/week until 18 months of age. Parents and other care providers will receive specific instructions about cereal preparation and general education about feeding practices, food preparation and hygiene. This information will be reinforced during weekly visits.
223501096|NCT01650376|DRUG|Olaparib|Olaparib will be administered orally on Days 1, 2, and 3 of each week until DLT or disease progression. A minimum of 3 patients will be enrolled into each cohort. The anticipated dose escalation sequence of olaparib is 50, 100, 150 and 200 mg, taken twice a day will be used.
224192075|NCT01966458|DEVICE|HeartWare® VAS (HVAD)|The HeartWare® VAS is an implantable centrifugal pump that was designed to provide flows up to 10 L/min in a small device that is both lightweight and simple to use.
224192076|NCT01966458|DEVICE|Control LVAD|Any FDA-approved LVAD for destination therapy.
224192077|NCT05317923|OTHER|Flow Controlled Ventilation|Anesthesia management in patients with subglottic tracheal stenosis with flow-controlled ventilation using an intubation tube with an inner diameter of less than 3 mm
224192078|NCT02670356|DIETARY_SUPPLEMENT|Fish oil|two 750 mg/capsules/day
224192079|NCT02670356|DIETARY_SUPPLEMENT|Krill oil|one 300 mg capsule/day
224192080|NCT05703009|DRUG|Sacrosidase Oral Solution|Study drug
224192081|NCT05703009|DRUG|Placebo|Placebo
224192082|NCT04340739|OTHER|online patient education teach mindfulness based stress reduction|This is an online self management chronic pain curriculum that presents adapted Mindfulness Based Stress Reduction through videos, audios, and written materials
224192083|NCT00940446|DEVICE|Insorb staples|absorbable staples required for wound closure
224192084|NCT00940446|DEVICE|metal staples (Ethicon metal stapler)|wound closure with metal staples
224192085|NCT01149174|DRUG|Mitomycin-C 40 mg|Intravesical instillation of Mitomycin-C
224192086|NCT06084442|PROCEDURE|Evaluation of The Techniques of Lateral Rectus Muscle Combined Recession with Hang Back and Combined Recession with Z-Tenotomy in Correcting Large-Angle Exotropia|"Patients will be divided into 2 groups:~* Group (A): Patients will undergo combined LR recession 7mm and hang back technique.~* Group (B): Patients will undergo combined LR recession 7mm and Z-tenotomy technique."
224192087|NCT02806700|BEHAVIORAL|Twitter Diabetes Intervention|This group will be asked to use twitter for heart health ( e.g. tweeting, following, receiving tweets)
224192088|NCT01511562|DRUG|carmustine|Given IV
224192089|NCT01511562|DRUG|cytarabine|Given IV
224192090|NCT01511562|DRUG|etoposide|Given IV
224192091|NCT01511562|DRUG|thiotepa|Given IV
224192092|NCT01511562|PROCEDURE|stem cell transplant|
224192093|NCT01511562|DRUG|G-CSF|
224192094|NCT05666765|DRUG|Isotretinoin ,silymarin|20mg/day isotretinoin for 3 months. 140 mg/day silymarin for 3 months. 20mg/day isotretinoin and 140mg/day silymarin for 3 months.
224192095|NCT02259166|OTHER|EHFP+|Enhanced-homestead food production program including home gardening and poultry rearing + WASH interventions + SBCC around the essential nutrition actions and WASH/malaria prevention with a gender component.
224192096|NCT04491474|DRUG|Lidocaine Hydrochloride|While performing these procedures, 1 ml of 2% lidocaine hydrochloride and 1 ml of %0.9 saline will be used for creating a solution of 2 ml of 1% lidocaine for nerve block. Also 2 ml of saline will be used for placebo effect. For blocking the GON region 0.75 ml of 1% lidocaine will be applied and 0.75 ml of saline for placebo effect(8). During applying to the SON region 0.25 ml of 1% lidocaine for blockage and 0.25 ml of saline for placebo effect will be used(8). The GON injection site was planned to be 2 cm lateral and 2 cm below the occipital protrusion and the SON injection site was planned as the area with frontal incisor in the orbital arch
224192097|NCT04491474|DRUG|Placebo|There will be injection of %0.9 saline to bilaterally great occipital nerve and to bilaterally supraorbital nerve.
224192098|NCT01152931|DRUG|Amodiaquine + Artesunate|Intervention:the intervention in this group involves the use of standard antimalarial therapy for uncomplicated malaria based on WHO recommendation. artemisin based combination therapy will be used. amodiaquine will be administered via the oral route at a dose of 10mg/kg daily while artesunate will be administered orally at Artesunate 100mg stat, 50mg 8hrs later and 50mg bd x 3days
224192099|NCT01152931|DRUG|Amodiaquine + Artesunate|Intervention:the intervention in this group involves the use of standard antimalarial therapy for uncomplicated malaria based on WHO recommendation. artemisinin based combination therapy will be used. amodiaquine will be administered via the oral route at a dose of 10mg/kg daily while artesunate will be administered orally at 100mg stat, 5omg 8hrs later and 50mg 12hrly for 3 days
224192100|NCT01152931|DRUG|Lumefantrine + Artemether|Lumefantrine and artemether combination will be administered orally at a dose of 120/20mg daily for 3days
224192101|NCT01152931|DIETARY_SUPPLEMENT|Artesunate + vitamin A|Artesunate will be administered orally at a dose of 100mg stat then 50 mg 8hrs later and 50mg 12hrly for 3days. vitamin A will be administered orally at a dose of 2000IU daily for 3 days
224192102|NCT01152931|DIETARY_SUPPLEMENT|Artesunate + vitamin E|Artesunate will be administered orally at 100mg stat, then 50mg 8hrs after and 50mg 12hrly for 3 days. Vitamin E will be administered orally at 100mg dly for 3 days.
224192103|NCT01152931|DIETARY_SUPPLEMENT|Artesunate + Zinc|Artesunate will be administered orally at a dose of 100mg stat then 50mg 8hrs after and 50mg 12mg 12hrly for 3 days. Zinc gluconate will be administered orally at a dose of 50mg dly for 4 days
224192104|NCT01152931|DIETARY_SUPPLEMENT|Artesunate + selenium|Artesunate will be administered orally at 100mg stat and 8hrs later 50mg. then 50mg 12hrly for 3 days. selenium will be administered orally at a dose of 100ug dly for 4 days
224192105|NCT01152931|DIETARY_SUPPLEMENT|Amodiaquine + vitamin A|Amodiaquine will be administered orally at a dose of 10mg/kg dly for 3days. Vitamin A will be administered orally dly at a dose of 2000IU for 4 days
223501097|NCT01650376|DRUG|Carboplatin|AUC 2 weekly for 3 weeks of a 4 week cycle. For patients who experience a complete response, the carboplatin and paclitaxel will be discontinued and olaparib monotherapy (400 mg, taken twice a day) will continue until disease progression and as long as the investigator feels they are benefiting from the treatment.
223501098|NCT01650376|DRUG|Paclitaxel|60mg/m2 weekly for 3 weeks of a 4 week cycle. For patients who experience a complete response, the carboplatin and paclitaxel will be discontinued and olaparib monotherapy (400 mg, taken twice a day) will continue until disease progression and as long as the investigator feels they are benefiting from the treatment.
223501099|NCT01697046|DRUG|Truvada and Isentress|"Subjects with reported high-risk behavior (and anticipated future high-risk behavior) but no exposure in the immediate past will be the focus of this study.~Participants will be prescribed raltegravir 400 mg BID + Truvada once daily. All study participants will receive a 4-days starter pack. Study participants will be instructed to start study drugs if they expect or experience an exposure of any mucous membrane (oral, urethral, anal) to semen. Subjects who expect or experience these exposures will be instructed to take 1 pill of Raltegravir 400mg and one pill of truvada, followed by a second dose of Raltegravir 12 hours later. From the second day onward, participants will be instructed to take Raltegravir 400 mg BID + Truvada once daily. The first dose should be taken no more than 6 hours before or 6 hours after the expected or actual exposure and continued for 28 days."
223501100|NCT02640209|BIOLOGICAL|CART 19|The target dose range administered in this study is 1-5x108 CART-19 cells administered via split dosing: 10% on Day 1 (1-5x107 CART19), 30% on Day 1 (3x107-1.5x108 CART19), 60% on Day 2 (6x107-3x108 CART19).
224192106|NCT01152931|DIETARY_SUPPLEMENT|Amodiaquine + Vitamin E|Amodiaquine will be administered orally at a dose of 10mg/kg dly for 3days. vitamin E will be administered orally at a dose 100mg daily for 4 days
224192107|NCT01152931|DIETARY_SUPPLEMENT|Amodiaquine + Zinc|Amodiaquine will be administered orally at a dose of 10mg/kg dly for 3days. Zinc gluconate will be administered orally at a dose of 50mg dly for 4 days.
224192108|NCT01152931|DIETARY_SUPPLEMENT|Amodiaquine + Selenium|Amodiaquine will be administered orally at a dose of 10mg/kg daily for 3days. Selenium will be administered orally at a dose of 100ug daily for 4 days if \> 1year. 50ug daily for 4 days if \< 1 year.
224192109|NCT01152931|DIETARY_SUPPLEMENT|Artesunate + vitamin A + vitamin E|Tab Artesunate 50mg orally daily for 4 days. Vitamin A, 5000IU orally daily for 4days if \< 1 year. 10,000 IU orally daily for 4 days if \> 1 year.
224192110|NCT01152931|DIETARY_SUPPLEMENT|Artesunate + Vitamin A + Zinc|Tab Artesunate 50 mg daily for 4 days. Vitamin A 5OOOIU daily for 4 days if \< 1 year. 10,000IU daily for 4 days if \> 1 year. All administered orally.
224192111|NCT01152931|DIETARY_SUPPLEMENT|Artesunate + Vitamin A + Selenium|Tab Artesunate 50 mg orally, daily for 4 days. Vitamin A 5000IU orally daily for 4 days if \< 1 year. 10,000IU orally daily for 4 days if \> 1 year.
224192112|NCT01152931|DIETARY_SUPPLEMENT|Artesunate + Vitamin E + Selenium|Tab Artesunate 50 mg orally daily for 4 days. Vitamin E 100 mg orally daily for 4 days. Tab selenium 100 ug orally daily for 4 days if \> 1 year. 50 ug orally daily for 4 days if \< 1 year.
224192113|NCT01152931|DIETARY_SUPPLEMENT|Artesunate + Vitamin E + Zinc|Tab Artesunate administered orally at 50 mg daily for 4 days. Vitamin E 100 mg orally daily for 4 days. Tab Zinc 50 mg orally daily for 4 days if \< 1 year. 25 mg orally daily for 4 days if \> 1 year.
224192114|NCT00564382|PROCEDURE|Cardiac magnetic Resonance study|Routine cardiac MR study including contrast application
224192115|NCT02494882|DRUG|Ruxolitinib|
224192116|NCT02494882|DRUG|Dasatinib|
224192117|NCT02494882|DRUG|Dexamethasone|
224192118|NCT00696826|DRUG|sitagliptin phosphate|sitagliptin phosphate 100 mg MK0431 (2 x 50 mg tablets) taken orally after overnight fast; Duration of Treatment: 5 Weeks
224192119|NCT02544126|DEVICE|Electronic Self-Management Resource Training for Mental Health|eSMART-MH is a software, which is set in a 3-D virtual primary care office environment in which a subject interacts with avatar virtual healthcare staff (medical receptionist, medical assistant, providers, and a virtual healthcare coach). The avatars are programed to behave like humans. The subject moves through the 3-D virtual primary care office and encounters virtual healthcare staff and providers. The subject practices discussing depressive symptoms with avatar healthcare providers and practices self-management skills related to symptoms of depression.The subject also interacts with the health care coach. The health care coach provides the subject with real-time strategies to enhance communication with healthcare providers during their virtual office visit. Overtime, coaching is decreased to build the the subject's self-confidence. eSMART-MH will be used once a month, for three months.
224192120|NCT02544126|BEHAVIORAL|Screen-based health education|Screen-based health education will be used and cover topics like depression, nutrition, physical activity, and sleep hygiene at the same frequency as the eSMART-MH intervention, which is used once a month, for three months.
223501101|NCT05410067|OTHER|Cervicothoracic Junction Mobilization Technique|It is a part of manual therapy technique. Patient would be in prone position with his forehead in the palm of the therapist. Maitland mobilization to the C7- T1 level, according to their primary movement restriction (for flexion-extension restriction- central PA glide, for rotation restrictions unilateral PA glide) is given. For central PA glide, a central pressure angled towards the participant's head was given with overlapping thumbs of the therapist placed on the spinous process of C7. The therapist's thumbs were placed on the posterior surface of the articular process to be mobilized (C7 on the side of restriction), and anteriorly directed oscillatory pressure was applied for unilateral PA mobilization.
223501102|NCT05410067|OTHER|Eccentric Muscle Energy Technique|Eccentric muscle energy technique would be applied to the patient's cervical spine. The cervical spine would be brought to the barrier of motion in each plane i.e. flexion/extension, lateral bending and rotation. Then patient would be asked to push their heads into the direction opposite that of the barrier.
223501103|NCT05401851|DEVICE|Left Bundel Area Pacing|RV Lead will be placed deep in the interventricular septum
223501104|NCT00093028|DRUG|CC-5013 (Revlimid™)|N/A Study Complete
223501105|NCT00093028|DRUG|bortezomib|N/A Study Complete
223501106|NCT01614223|PROCEDURE|ACP|Within two weeks of the initial visit, the RN, will retrieve a 10-12 mL blood sample from all patients. After the sample is retrieved, the patient will be asked to lie prone on the plinth to assist with blinding. The blood sample will be retained in the Arthrex ABS-10010S Double Syringe with Syringe Cap and then separated using a soft spin centrifuge for 5 min at 1500 rpm/rcf. Three to four mL of platelet rich plasma will be pulled into a smaller syringe that is wrapped in opaque tape to conceal the contents of the syringe. The ACP is injected into the torn region of the tendon.
223501107|NCT01614223|DRUG|Corticosteroid (celestone) injection|Preparation of the blood sample is identical for patients in this group except that the blood sample will ultimately be discarded instead of injected. The syringe is blinded with opaque tape making it identical to the ACP group syringe and injected into the torn area of the tendon.
223501108|NCT00864981|DRUG|Bupropion HCI ER Tablets, 150 mg; EON Labs Inc.|
223501109|NCT00864981|DRUG|WELLBUTRIN SR (Bupropion HCI) Sustained-Release Tablets, 150 mg; GlaxoSmithKline|
223501110|NCT01182363|BEHAVIORAL|Project Solve Education|Problem solving education (PSE), a brief skills-building psychotherapeutic intervention that focuses on specific daily problems, and applies to these problems a structured approach to finding and evaluating solutions, is one such problem solving approach. Problem solving education differs from other problem solving interventions in that it can be conducted by a variety of health providers, who do not have specific training as mental health clinicians. Sessions are fairly brief (approximately 30 minutes in length) and positive, sustained effects have been achieved in 6-8 sessions. Problem solving education's success is based on premise that strong problem solving abilities promote a sense of control and self-efficacy and buffer the negative effects of life stressors.
223501111|NCT01843231|DEVICE|g-CathTM EZ Suture Anchor Delivery Catheter|Use of the g-Cath EZ Suture Anchor Delivery Catheter for the placement of g-cath EZ suture anchors as an early weight loss intervention + diet and exercise as compared to those in the diet and exercise control group
223501112|NCT01843231|OTHER|Diet and Exercise Control Group|Patients in a diet and exercise only control group that will be compared to those in the g-Cath EZ Suture Anchor Delivery Catheter treatment group
224192121|NCT01657591|DRUG|XL888|Level -1: XL888 30 mg; Level 1: XL888 30 mg; Level 2: XL888 45 mg; Level 3: XL888 90 mg; Level 4: XL888 135 mg
224192122|NCT01657591|DRUG|Vemurafenib|Level -1: Vemurafenib 720 mg; Level 1: Vemurafenib 960 mg; Level 2: Vemurafenib 960 mg; Level 3: Vemurafenib 960 mg; Level 4: Vemurafenib 960 mg
224192123|NCT00231530|DRUG|topiramate|
224192124|NCT02341339|PROCEDURE|Laparoscopic Surgery (Biopsies of fallopian tube lumen) using a laparoscopic brush/biopsy device|
224192125|NCT04887922|DEVICE|MIR Spirobank G|FDA-approved, Bluetooth digital spirometer
224192126|NCT04887922|DEVICE|ZEPHYRx®|ZEPHYRx® has developed a 1) digital Bluetooth-enabled IS that allows for the continuous and objective remote monitoring of patient compliance with pre- and postoperative IS via a smartphone app and online provider dashboard.
224192127|NCT04887922|DEVICE|Conventional spirometer|Will be provided to participants
224192128|NCT04182386|PROCEDURE|Portal vein embolization|Selective preoperative portal vein embolization
224192129|NCT00973167|DEVICE|Low-magnitude high-frequency vibration treatment|Stand on a vibration platform at 35Hz, 0.3g, 20mins/day and 5 days/week
224192130|NCT02921646|OTHER|Measure of resting energetic expenditure|measure of resting energetic expenditure
224192131|NCT06509217|BEHAVIORAL|Moderate-intensity Group|Water aerobics sessions involved exercises performed at a moderate intensity, between 60% and 70% of the participant's maximum heart rate predicted by their age.
224192132|NCT06509217|BEHAVIORAL|High-intensity Group|Water aerobics sessions involved exercises performed at a high intensity, between 80% and 90% of the participant's maximum heart rate predicted by their age.
224192133|NCT00953017|DRUG|Miralax (PEG 3350)|Miralax 255gm bottle
224192134|NCT00953017|DRUG|Amitiza (Lubiprostone)|Amitiza 24mcg gelcap
224192135|NCT00953017|DRUG|Dulcolax (Bisacodyl)|Bisacodyl 5mg tab x2
224192136|NCT00953017|DRUG|Golytely (polyethylene glycol)|Golytely 1 gallon
223501113|NCT05307107|BEHAVIORAL|SHINE|Intervention group will use a 8-workweeks the digital Smart Break SHINE program with workplace support (encouragement and time-support) including daily 3 minutes break exercises twice a day; 1) physical exercise - break and 2) body/mind breathing exercise - break earning stars for exercise completed. The program includes weekly self-reflective task of individual well-being during working hours with weekly changing theme (avoiding sitting time, nature benefits, relaxation exercises, increasing physical activity in workplace etc.) earning diamonds for every weekly task completed. Participants self-monitors their weekly individual resources levels asked in every Thursday (1-5, 1= very poor. 5= very good). Program includes e-mail remainders set by participant themselves for suitable time frame These individual well-being actions takes approximately 15 minutes/workday. Control group will receive this program after this study (waitlist protocol).
223501114|NCT02479282|PROCEDURE|natural cesarean section|
223501115|NCT02479282|PROCEDURE|traditional cesarean section|
223501116|NCT01181479|DRUG|AG200-15 (cycles 1-13)|AG200-15 containing ethinyl estradiol and levonorgestrel
223501117|NCT01181479|DRUG|Lessina crossover to AG200-15|Low dose oral contraceptive containing 20 mcg ethinyl estradiol and 100 mcg Levonorgestrel in 21 day regimen for 6 cycles followed by AG200-15 for 6 cycles.
223501118|NCT03179267|DEVICE|SNAP40|SNAP40 ambulatory monitoring device
223501119|NCT05769101|DIETARY_SUPPLEMENT|Ingestion of a Post-Workout Supplement|The Post-Workout Supplement is administered 15 minutes after the completion of training sessions. No supplementation is administered in non-training days. The Resistance Training is performed in alternate days. The training Protocol is: 10 minutes of standardized warm-up, Strength Circuit training using free weights (Alternate Box Step-Ups, Bench Press; Parallel Squat; Up-right Row; Deadlift; Alternate Lunges; Shoulder Press; Leg Extension). The participants perform 16 repetitions of each exercise, with 30 seconds rest and 3 minutes rest after every set. If they can complete 16 repetitions easily, 2.5 to 5 kg are added for the next set. Also, whole-body Perceptual Response is assessed using the 0-10 OMNI-RES Scale, after every set and 15 minutes after finishing.
223591717|NCT04910035|OTHER|Exercises Training|SSE is performed on a thin exercise mat divided into 40 small squares in 250 cm x 100 cm of size (25 cm each part). Participants are given patterns of a few steps and asked to take steps that match them. Participants must, in principal, move ahead in line with the length forward with no contact on the lines forming the squares. Forward, backward, lateral and oblique stepping patterns are required. Stepping patterns get increasingly difficult. Each pattern consists of 2 to 16 steps; participants are asked to repeat step pattern till the end of exercise mat. Upon completing a pattern, another pattern in the same mirror-image is repeated. In essence each pattern is reiterated for 3-5 times and next its mirror-image pattern is repeated but if participants face challenge in performing the pattern it is repeated till the pattern is learnt
223591718|NCT04368702|RADIATION|Viewray MRIdian® Linac|MR-image guided radiation will be administered per disease site standards.
223591719|NCT01370759|OTHER|Cleaning capsule|Capsules containing the tested materials aimed to improve colon cleansing
223591720|NCT06167876|RADIATION|Stereotactic Body Radiotherapy (SBRT) Treatment|The intervention in this study utilizes Stereotactic Body Radiotherapy (SBRT) for treating Hypertrophic Obstructive Cardiomyopathy (HOCM). The process begins with precise localization and planning, employing CT scans, Cardiac MRI (CMR), and echocardiography to accurately identify the target area in the interventricular septum, while avoiding critical structures like the aortic valve, His bundle, and left ventricular papillary muscles. Pre-treatment preparation involves using customized fixation devices to limit patient movement and breathing, coupled with cone-beam CT scans for accurate alignment with the Treatment Planning System (TPS). The treatment itself is delivered using image-guided linear accelerators, administering a single, focused dose of 25 Gy to the targeted area. This approach ensures precise radiation delivery, maximizing treatment efficacy while minimizing risks to surrounding cardiac tissues.
223746300|NCT03899948|BEHAVIORAL|Teacher Anxiety Program for Elementary Students|TAPES consists of three core components: 1) training in evidenced-based anxiety reduction strategies that teachers will implement to identify and assist specific anxious students and classroom-wide strategies helpful to all students, 2) evidenced-based material for teachers to review with parents regarding how to reduce student anxiety at home, thus improving school-home communication and shared goals and 3) training in how to conduct 5 brief (30 minute) teacher-parent-student meetings to teach and practice the TAPES anxiety-reduction strategies.
224192137|NCT05518058|OTHER|device and exercises|strengthening exercises plus balance training program conducted with type of functional electrical stimulation for muscles
224192138|NCT03456986|BEHAVIORAL|PATH neurotraining|Tunes up the center of the motion discrimination (dorsal stream) working range
224192139|NCT03456986|BEHAVIORAL|Orientation Discrimination|Tunes up the ventral stream most sensitive to high contrast and colored patterns.
224192140|NCT01711424|DRUG|OPTIVE PLUS®|Patients with dry eye prescribed OPTIVE PLUS® in accordance with physician standard practice.
224192141|NCT00020995|PROCEDURE|therapeutic dietary intervention|
224192142|NCT05446116|PROCEDURE|partial splenic artery embolization|embolization of the splenic artery for the treatment of hypersplenism
224192143|NCT03099616|DRUG|Propofol|Propofol delivery will be controlled using automated closed loop anaesthesia delivery system which will control propofol delivery rate to consistent anaesthetic depth (BIS-50) feedback from the patient.
224192144|NCT03099616|DRUG|Desflurane|Desflurane delivery will be controlled using a agent specific vaporiser. The dial concentration of the vaporiser will be adjusted to maintain a BIS of 50-55 in the patients.
224192145|NCT05638438|PROCEDURE|transarterial therapies|transarterial therapies combine with donafenib and Anti-PD-1 Antibody
224192146|NCT02804295|OTHER|Collaborative Care Intervention|All eligible subjects that meet the eligibility requirements for approach and consent and have a positive screen for PDM will complete a baseline survey and will be enrolled into the intervention condition. This is an open trial and thus all consenting eligible subjects will receive the intervention.
224192147|NCT04656249|DRUG|Lenvatinib|Drug doses for BTC are identical, being orally administered at 8mg/d to patients weighing \<60 kg and 12mg/d to those ≥60 kg.
224192148|NCT05232318|OTHER|Leveling and alignment|Root resorption comparison through the use of CBCT
224192149|NCT01055184|BIOLOGICAL|2009 H1N1 Virus Vaccine|Single 0.2 mL dose of live monovalent vaccine, delivered through nasal spray
224192150|NCT06567600|DRUG|Low-dose Gemcitabine and Cisplatin Chemotherapy plus PD-1/PD-L1Antibody|"Low-dose Gemcitabine and Cisplatin Chemotherapy:~Gemcitabine 500 mg/m2 Cisplatin 12.5 mg/m2 on day 1 and day 8 of each 21-day cycle for up to eight cycles~PD-1/PD-L1Antibody:~Pembrolizumab 200mg on day 1 of each 21-day cycle Durvalumab 1500 mg on day 1 of each 21-day cycle After completion of gemcitabine and cisplatin, 200mg of Pembrolizumab or 1500 mg of Durvalumab may administer once every 3 or 4 weeks until clinical or imaging (per RECIST v1.1) disease progression or until unacceptable toxicity, withdrawal of consent, or any other discontinuation criteria were met."
224192151|NCT03143075|DIETARY_SUPPLEMENT|Eicosapentaenoic acid enriched omega-3 fatty acids, 2 g/day|Eicosapentaenoic acid enriched omega-3 fatty acids, 2 g/day, added to pre-stabilized antidepressant medication
224309862|NCT00229983|BEHAVIORAL|Motivational Enhancement Therapy|Three 60 minute counseling sessions using a structured, developmentally appropriate approach to identification of drug- and alcohol- related risks and problems, and establishment of goals for behavioral change.
223501120|NCT05769101|DIETARY_SUPPLEMENT|Ingestion of a Maltodextrin Supplement|The Maltodextrin Supplement is administered 15 minutes after the completion of training sessions. No supplementation is administered in non-training days. The Resistance Training is performed in alternate days. The training Protocol is: 10 minutes of standardized warm-up, Strength Circuit training using free weights (Alternate Box Step-Ups, Bench Press; Parallel Squat; Up-right Row; Deadlift; Alternate Lunges; Shoulder Press; Leg Extension). The participants perform 16 repetitions of each exercise, with 30 seconds rest and 3 minutes rest after every set. If they can complete 16 repetitions easily, 2.5 to 5 kg are added for the next set. Also, whole-body Perceptual Response is assessed using the 0-10 OMNI-RES Scale, after every set and 15 minutes after finishing.
223501121|NCT04359212|DRUG|thromboprophylaxis with low-molecular-weight heparin or fondaparinux|thromboprophylaxis with low-molecular-weight heparin or fondaparinux
224192152|NCT03010332|BIOLOGICAL|Cytomegalovirus-specific Cytotoxic T Lymphocytes (CMV-CTLs)|ATA230 (third-party donor-derived CMV-CTLs) are cytotoxic T lymphocytes that specifically kill cells presenting CMV protein antigens.
224192153|NCT01212432|DRUG|Daptomycin|Daptomycin kinetics in CRRT
224192154|NCT05007652|DRUG|KRN125(pegfilgrastim), PLR001(plerixafor)|7.2 mg of KRN125 in Day 1 Single subcutaneous administration The concomitant drug PLR001 is administered subcutaneously once daily at a dose of 0.24 mg/kg when meets the criteria. The dosing period is 12-9 hours before apheresis on the following day.
224192155|NCT05007652|DRUG|KRN8601(filgrastim), PLR001(plerixafor)|400 ug/m2 of KRN8601 from Day 1 to the end date of the Apheresis Once daily subcutaneous administration The concomitant drug PLR001 is administered subcutaneously once daily at a dose of 0.24 mg/kg when meets the criteria. The dosing period is 12-9 hours before apheresis on the following day.
224309863|NCT03346486|OTHER|Control diet|Regular diet
223501122|NCT02969278|PROCEDURE|18FDG-PET/TC|Nuclear medicine exam (18FDG-PET/TC) to assess the status of the regional groin and pelvic lymphnodes
223501123|NCT02969278|PROCEDURE|Sentinel node biopsy|Intradermal injection of 0.2 ml 37-148 MBq of radiocolloid and a blue dye near the tumor to locate the position of the sentinel lymph node. Intraoperatively, sentinel node localization is guided by a gamma probe and by the eyes of the surgeon who detects the lymph nodes that are stained with the blue dye.
223501124|NCT02967575|DEVICE|cTDR|"The surgical procedure for the Triadyme-C total disc replacement corresponds to the standard surgical technique for cTDR:~* Implantation through a standard anterior cervical approach~* Midline identification~* Routine discectomy with endplate preparation and decompression~* Implant sizing and trial implantation~* Keel preparation~* Implant preparation and loading of the appropriate Triadyme-C implant~* Triadyme-C insertion, positioned as close to the midline as possible"
223501125|NCT06515782|OTHER|Med Diet. Investigators would like to see what differences a Mediterranean Diet makes to the status of patients with Multiple Sclerosis.|"In one group investigators will look at the Med diet alone for 6 months. Then investigators will have the patients add on 3 rounds of FMD.~In the other group, patients will do Med diet and FMD for 6 months followed by Med diet alone for 6 months. This will allow investigators to look for a diminution in effect of the Med diet 6 months after the last FMD."
223501126|NCT04896294|COMBINATION_PRODUCT|Hygienic procedure (toothbrushing using HAP-containing toothpaste)|Toothbrushing using standardised technique and pear-sized amount of HAP-containing toothpaste twice daily for 1 month.
223501127|NCT04896294|COMBINATION_PRODUCT|Hygienic procedure (toothbrushing using Zn Mg HAP-containing)|Toothbrushing using standardised technique and pear-sized amount of Zn Mg HAP-containing toothpaste twice daily for 1 month.
223501128|NCT04896294|COMBINATION_PRODUCT|Hygienic procedure (toothbrushing using FAP-containing toothpaste)|Toothbrushing using standardised technique and pear-sized amount of FAP-containing toothpaste twice daily for 1 month.
223501129|NCT01045200|OTHER|Comparison of follow-up|Comparison of follow-up by nurse or surgeon after rectal cancer surgery
223501130|NCT00759096|DEVICE|RESTOR IOL Model SA60D3|Implanted into the study eye following cataract extraction surgery
224309864|NCT03346486|OTHER|Intervention diet|Brainfood dietary regime planned to be optimal for metabolism and cognitive function; having focus on regular meal frequency (breakfast, lunch and afternoon snack) and well-balanced light lunch at work according to the so-called plate model and optimized recipes- will be provided.
223501131|NCT02131688|DRUG|Mitoxantrone Hydrochloride Liposome|
223501132|NCT04253860|DEVICE|Transcutaneous electrical neurostimulation|Sessions of 30 minutes of TENS will be applied three times a week during 90 days
223501133|NCT03932331|DRUG|Acalabrutinib|Acalabrutinib 100 mg orally twice daily
224192156|NCT01587807|DRUG|GSK1995057|inhaled dose (volume based on cohort)
224192157|NCT01587807|PROCEDURE|bronchoalveolar lavage|BAL
224192158|NCT01587807|DRUG|LPS|50 μg
224192159|NCT01587807|DRUG|Placebo|Sucrose, glycine, sodium dihydrogen phosphate and polysorbate 80 (volume to match active dose)
224192160|NCT02950285|OTHER|Baseline alert|PCP notification at baseline that patient has atrial fibrillation, high stroke risk, and is not anticoagulated.
224192161|NCT00718809|DRUG|saracatinib|Given orally
224192162|NCT06167759|OTHER|Opioid Use Agreement|This was previously developed specifically for surgical patients using a modified Delphi method with a group of experts (including surgeons, nurses, advanced practices providers, quality improvement experts, and patients).
224192163|NCT00870415|PROCEDURE|quality-of-life assessment|
224192164|NCT00870415|PROCEDURE|therapeutic conventional surgery|
224192165|NCT00463385|DRUG|Pomalidomide|
224192166|NCT00463385|DRUG|Prednisone|Participants will take oral prednisone in the evening for 3 cycles of 28 days each (up to 84 days). The dose will be as follows: 1st cycle = 30 mg daily, 2nd cycle = 15 mg daily, 3rd cycle = 15 mg every other day.
224192167|NCT00463385|DRUG|Placebo to pomalidomide|Matching pomalidomide placebo tablets
224192168|NCT00463385|DRUG|Placebo to prednisone|Matching prednisone placebo tablets
224192169|NCT01966185|OTHER|Tutor function on|The simulator-integrated tutor function with volumetric green lighting of the intended volume to be drilled.
224192170|NCT04308356|BEHAVIORAL|Dedicated Discussions on Anticipating preferences of care in the event of Aggravation (DDA)|interview 2
224192171|NCT04308356|OTHER|Autonomy Preference Index (API ) questionnaire - Information|part of interview 1
224192172|NCT04308356|OTHER|anxiety and depression (HADS) questionnaire|part of interview 1
224192173|NCT01473537|DRUG|calcium lactate solution|Calcium lactate solution 75 mM, 150 mM, 175 mM and placebo
223501134|NCT01937117|PROCEDURE|Positron emission tomography (PET)|PET will be performed at baseline and on day 15
223501135|NCT01937117|DRUG|Trastuzumab|8 mg/kg loading dose, then 6 mg/kg every 3 weeks, IV
223501136|NCT01937117|DRUG|Pertuzumab|840 mg as a loading dose, then 420 mg every 3 weeks, IV
223501137|NCT05722236|BEHAVIORAL|IBD Strong Peer2Peer|Mentee participants will experience the intervention: this group will partake in peer-led sessions (peer calls) consisting of up to 10 virtual sessions on Zoom lasting approximately 20-30 minutes in duration over eight weeks. Individual peer calls will be unstructured whereby trained mentors (patients with IBD who have undergone training to be a mentor) and mentees will be given the freedom to discuss whatever issues they choose. Psychological and emotional support is provided to the mentee by the mentor.
223501138|NCT05722236|OTHER|Waitlist control|Wait list controls will be offered participation in the IBD Strong Peer2Peer intervention once post-control outcome measures have been completed.
223501139|NCT00193908|DRUG|Cavilon (TM) Durable Barrier Cream|Cavilon (TM) Durable Barrier Cream will be applied to either the medial or the lateral side of the treated breast. Side will depend on randomisation.
223501140|NCT00193908|DRUG|Sorbolene|Sorbolene will be applied to either the medial or the lateral side of the treated breast. Side will be determined by randomisation
224192174|NCT06540937|DRUG|Leflunomide Pill|This is a single-arm, single-center, phase II clinical study. Primarily evaluated in advanced MEN-1 neuroendocrine tumors. The initial efficacy of leflunomide tablets in second-line treatment provided evidence for phase III clinical trials.
224192175|NCT00449761|DRUG|LBH589|
223501141|NCT00193908|RADIATION|Radiotherapy|Minimum prescribed dose to the chest wall is 45Gy in 25 fractions. Planning and Treatment is per the study protocol
223501142|NCT01455519|DRUG|Hydromorphone ER|Total target dose of 32 mg/day. All subjects will have a lead in for 2 weeks; then begin a 'forced' 2-week up-titration schedule as follows: 8mg/d (1 pill, 5 days), 16mg mg/d (2 pills, 5 days), and 24mg/d (3 pills, 5 days) then finally 32 mg/d (4 pills a day) for the 'stable dose' phase of the study, or identical placebo pills. If intolerable side effects occur, the dose may be reduced to last tolerable does, a minimum of 8 mg/day (or one pill a day), at the discretion of the PI. Subjects unable to tolerate 8 mg/day will be discontinued from the study. A 2-week down-titration will be used.
223501143|NCT01455519|DRUG|Sugar pill|Sugar pill
224192176|NCT01108861|DEVICE|GORE VIABAHN® Endoprosthesis|GORE VIABAHN® Endoprosthesis
224192177|NCT01108861|DEVICE|Plain old balloon angioplasty|Plain old balloon angioplasty
224192178|NCT03288428|DRUG|Nalbuphine|patient controlled analgesia with Nalbuphine
224192179|NCT03288428|DRUG|Morphine|patient controlled analgesia with Morphine
224192180|NCT03143933|DRUG|Propofol|I.V propofol
224192181|NCT03143933|DRUG|Fentanyl|
224192182|NCT04785846|DEVICE|Percutaneous Coronary Intervention|Percutaneous Coronary Intervention
224192183|NCT04398680|DRUG|Belantamab mafodotin|Belantamab mafodotin will be administered
224192184|NCT02863874|DEVICE|VicrylPlus®|Suture
224192185|NCT02863874|DEVICE|Vicryl®|Suture
224192186|NCT03025360|DRUG|Larotrectinib (Vitrakvi, BAY2757556)|Larotrectinib will be administered orally as capsule or liquid solution as specified by the treating physician.
224192187|NCT01969201|DRUG|Urofollitrophin|
224192188|NCT01969201|DRUG|Follitrophin alpha|
224192189|NCT00939068|DRUG|Telbivudine|Subjects start dosing Telbivudine orally at 20-32 gestational weeks, with 600 mg daily, continued to one month after delivery.
224192190|NCT00939068|BIOLOGICAL|engineered HB vaccine|All the newborns in control group are given HBIG 200IU by injection immediately after born and at day 15. They are also injected with genetically engineered HB vaccine 20 ug respectively at age of 0, 1 and 6 months.
224192191|NCT00625768|DRUG|AS1409|Study drug
224192192|NCT00344968|DRUG|fluocinolone acetonide|0.5 mg fluocinolone acetonide intravitreal insert
224192193|NCT00344968|DRUG|Fluocinolone Acetonide|0.2 mg fluocinolone acetonide intravitreal insert
224192194|NCT00344968|PROCEDURE|Standard of care laser photocoagulation|Laser photocoagulation
224192195|NCT02943369|DRUG|Ticagrelor 180 mg loading dose|Ticagrelor 180 mg
224192196|NCT02943369|DRUG|Cangrelor 30 mcg/kg bolus + 4 mcg/kg/min|Intravenous Cangrelor 30 mcg/kg bolus + 4 mcg/kg/min for 2 hours
224192197|NCT01788969|DRUG|Lexapro|Agent + training vs Placebo + training
224192198|NCT01788969|DRUG|Placebo|Agent + training vs Placebo + training
224192199|NCT03735680|DRUG|ONM-100|A polymer micelle covalently conjugated to indocyanine green.
224192200|NCT01198327|DRUG|ranibizumab|Intravitreal ranibizumab, .5mg dose, PRN but not less than 21 days apart.
224192201|NCT01198327|OTHER|Peripheral Laser|Areas of nonperfusion identified on wide field angiograms will receive laser, if the patient is continuing to require ranibizumab injections.
224192202|NCT01422876|DRUG|high dose FDC|once daily
224192203|NCT01422876|DRUG|BI 10773 high dose|once daily
224192204|NCT01422876|DRUG|high dose FDC placebo|once daily
224192205|NCT01422876|DRUG|low dose FDC placebo|once daily
224192206|NCT01422876|DRUG|high dose FDC placebo|once daily
224192207|NCT01422876|DRUG|high dose FDC placebo|once daily
224192208|NCT01422876|DRUG|low dose FDC placebo|once daily
224192209|NCT01422876|DRUG|low dose FDC placebo|once daily
224192210|NCT01422876|DRUG|high dose BI 10773 placebo|once daily
224192211|NCT01422876|DRUG|low dose FDC|once daily
224192212|NCT01422876|DRUG|high dose FDC placebo|once daily
224192213|NCT01422876|DRUG|BI 10773 low dose|low dose once daily
224192214|NCT01422876|DRUG|high dose BI 10773 placebo|once daily
223501144|NCT05486273|OTHER|interviews with coachs, semi-structured interviews and questionnaires|You will be offered 6 coaching sessions at a rate of one session per month and the first interview will be conducted on the day of inclusion or within one month of inclusion, the others will take place at R6 and R12. Questionnaires will be administered on the day of inclusion and then at R1, R6, R9 and R12. RO is the day of inclusion and it corresponds to M3 (3 months post transplant)
223501145|NCT05486273|OTHER|semi-structured interviews and questionnaires|The first interview will be conducted on the day of inclusion or within one month of inclusion, the others will take place at R6 and R12.Questionnaires will be administered on the day of inclusion and then at R1, R6, R9 and R12. RO is the day of inclusion and it corresponds to M3 (3 months post transplant)
223501146|NCT03065660|DRUG|Mifepristone, Oral, 200 Mg|The Investigational Medicinal Product (IMP) is a single dose of 200mg mifepristone to be taken orally after confirmation of missed miscarriage by pelvic ultrasound scan.
223501147|NCT03065660|DRUG|Placebo Oral Tablet|The placebo will be an oral tablet in the same form as the IMP, and identical in appearance.
224074725|NCT06101615|OTHER|IASTM (FAT)|Group-A participants would receive Facial Abrasion Technique (FAT) with an Instrument, FAT-Tool. Treatment sessions will be carried out three times per week for eight weeks after an initial warm-up session. All the sessions will be performed at the same time of day (i.e., between 4-6 pm), to avoid possible confounding circadian effects. The FAT group will receive 2 min application on the quadriceps and hamstring muscles with a FAT-tool Pro Large model, which consists of a handle and 20cm treatment surface. The muscles will be treated in a pre-stretched position, meaning a knee flexion in a supine position for the quadriceps muscle and a hip flexion and knee extension in a side-lying position for the hamstring muscles.
224192215|NCT01422876|DRUG|high dose BI 10773 placebo|once daily
224192216|NCT01422876|DRUG|linagliptin|once daily
224192217|NCT01422876|DRUG|low dose FDC placebo|once daily
224192218|NCT01422876|DRUG|linagliptin placebo|once daily
223501148|NCT02528227|OTHER|Know Your Baby Language Curriculum|Early language activities that parents can do with their infants
224192219|NCT01422876|DRUG|BI 10773 low dose placebo|once daily
224192220|NCT01422876|DRUG|linagliptin placebo|once daily
224192221|NCT01422876|DRUG|low dose BI 10773 placebo|once daily
224192222|NCT01422876|DRUG|linagliptin placebo|once daily
224192223|NCT01422876|DRUG|high dose BI 10773 placebo|once daily
224192224|NCT01422876|DRUG|BI 10773 low dose placebo|once daily
224192225|NCT01422876|DRUG|low dose BI 10773 placebo|once daily
224192226|NCT01422876|DRUG|linagliptin placebo|once daily
224192227|NCT02566460|OTHER|Resuscitation|First, either crystalloid or colloid could be given to achieve a CVP of 8 to 12 mm Hg. Second, if the mean arterial pressure (MAP) was less than 65 mm Hg, norepinephrine was administrated to maintain MAP ≥65 mm Hg. If the mean arterial pressure was higher than 90 mm Hg, vasodilators were given until it was 90 mm Hg or below. Finally, SCVO2 or lactate clearance will be checked to determine red blood cells transfused or not to achieve a haematocrit of at least 30%. If ScvO2 or lactate clearance remains unmet target value, dobutamine could be used in the treatment.
224192228|NCT03755960|PROCEDURE|acupuncture|semistandardized selection of acupuncture points according to the clinical presentation of diabetic peripheral neuropathy (DPN) symptoms; 12 treatments over 8 weeks
224192229|NCT03755960|DRUG|routine care|pharmacological routine care (antidepressants, anticonvulsants, opioids, nonsteroidal antiinflammatory drugs)
224192230|NCT01222962|DRUG|Eurartesim|Tablet containing 40 mg of Dihydroartemisinin (DHA) and 320 mg of Piperaquine phosphate (PQP). 4 Tablets a Day for body weight above 75 kg.
224192231|NCT00701012|PROCEDURE|preservation of nerve fibers around IMA|low ligation
224192232|NCT00701012|PROCEDURE|resection of nerve fibers around IMA|high ligation
224192233|NCT00374465|DRUG|Verapamil|
224192234|NCT00374465|DRUG|Carvedilol|
224192235|NCT01166074|BIOLOGICAL|Subcutaneous IgG (SCIG)|Administered according to normal clinical practice
224192236|NCT03019666|BIOLOGICAL|Nicotinamide Expanded Haploidentical or Mismatched Related Donor Natural Killer Cells|"* Cyclophosphamide 40 mg/kg x 1 day on Day -5~* Fludarabine 25 mg/m\^2 x 3 days (Day -5, Day -4, day-3)"
224192237|NCT00305331|DRUG|Domperidone (drug)|
224192238|NCT01905631|DRUG|Aurstat Anti-Itch Hydrogel (Aurstat)|Subjects will apply Aurstat Anti-Itch Hydrogel 2 times daily or as needed for up to three days to reduce itching. Subjects will also fill out a study diary assessing adverse events or other events they experience during the trial.
224192239|NCT05814224|DIAGNOSTIC_TEST|Liquid biopsy and CT scan|"CT scan and liquid biopsy blood sample are performed at baseline, after 8 weeks from baseline and, then, every 12 weeks.~Between two subsequent CT scan another liquid biopsy blood sample is performed.~CEA and CA 15.3 will be performed at baseline and then concomitantly to the radiological evaluation"
224192240|NCT05278624|DRUG|Roflumilast Cream|Topical Cream
224192241|NCT03930524|BEHAVIORAL|Personalized Normative Feedback (PNF)|Personalized normative feedback is generated by a process in which: (1) baseline surveys gather respondent information; (2) a computer program links the data with algorithms to select feedback messages; (3) a format for feedback presentation is specified; and (4) the program generates output. Norms will focus on prevalence of drinking, consuming 4/5+ drinks, total number of drinks consumed each week, and maximum drinks consumed. Normative information will be from the national Monitoring the Future (MTF) study college student sample and the University of Minnesota Twin Cities campus. Students will be sent a link to a website where they see their own personal responses in the feedback. Feedback will detail quantity and frequency of drinking (a) reported by the participant him/herself, (b) according to the participant's perception of the descriptive norm for drinking quantity and frequency for the reference group, and (c) reflecting the actual descriptive norm for the reference group.
224192242|NCT03930524|BEHAVIORAL|Self-Monitoring (SM)|Students will be asked to self-report their alcohol use every 2 weeks in response to two main questions (frequency of 4/5+ drinking in the past 2 weeks, frequency of past 2-week 8/10+ drinking), as well as consequences of their drinking. The therapeutic role of SM is two-fold. First, SM facilitates deliberate attention to and reflection on the person's actions, the conditions under which these actions occur, and their consequences (Bandura, 1998; Kanfer, 1970). Hence, SM of drinking behaviors and consequences has the potential to promote awareness of problematic drinking and need for health services. Second, SM affords the opportunity to obtain ongoing information concerning the target behavior, which can be used to inform timely intervention decisions (Nahum-Shani et al., 2016)
224192243|NCT03930524|BEHAVIORAL|Web-BASICS|Web-BASICS is delivered online and responds to individual participant input with the same motivational information and feedback as used in the in-person BASICS intervention. In-person BASICS content (Dimeff et. al., 1999) was developed for online use in studies conducted by Drs. Larimer and Lee (e.g., LaBrie et al., 2013; Lee et al., 2014; Neighbors et al., 2012a). Web-BASICS feedback contains text and graphical feedback regarding students' reported drinking quantity, frequency, peak alcohol consumption, and blood alcohol content (BAC), risks for alcohol problems based on participant family history and consumption patterns, protective behaviors the participant already uses and others he/she might consider, and a tips page with a BAC chart, information on reduced-risk drinking, and where to get more information. Participants can print and/or view their individualized content online for up to 3 months.
224192244|NCT03930524|BEHAVIORAL|Health Promotion Consultation|A health promotion consultation via a campus clinic is a confidential exploration of student drug and alcohol use. Health Promotion Consultants help students assess how their alcohol and other substance use affects their life and learn how to make healthier decisions.
224192245|NCT03930524|BEHAVIORAL|M-Bridge Online Health Coach|A health coach will correspond with students via a secure online chat platform, utilizing motivational interviewing strategies to encourage students to consider their values and goals, the possibility of behavior change, and available services. The goal of the dialogue is to motivate the student to access alcohol use interventions (Web-BASICS or an in-person health promotion consultation).
224192246|NCT00540735|PROCEDURE|photodynamic therapy|
224192247|NCT00567086|DRUG|TEZAMPANEL|Single Administration of: TEZAMPANEL 40 mg; TEZAMPANEL 70 mg; TEZAMPANEL 100 mg; Placebo (Sterile Water for Injection)
224192248|NCT02505841|OTHER|TAP block with Ropivacaine|Ultrasound-guided transversus abdominis plane block wih Ropivacaine injection 0.2% at 0.3 ml/kg
224192249|NCT02505841|DRUG|Curare|Atracurium injection at 0.5 mg/kg at least 3 minutes before the surgical incision
224192250|NCT02430155|DEVICE|Bakri balloon|is a 100% silicone construction, dual channel balloon catheter specifically designed and approved by FDA for intrauterine placement in cases of PPH. The Bakri balloon contains no latex, and therefore can be safely used in patients with latex allergies
224192251|NCT02430155|DEVICE|Condom loaded foley's catheter|Under aseptic precautions a sterile rubber catheter was inserted within the condom and tied near the mouth of the condom by a silk thread.
223501149|NCT02528227|OTHER|Reading Aloud Language Curriculum|Early language activity that parents can do with their infants
223501150|NCT02528227|OTHER|Sing A Long Language Curriculum|Early language activity that parents can do with their infants
223501151|NCT02528227|OTHER|Mimicking First Sounds Language Curriculum|Early language activity that parents can do with their infants
223501152|NCT02528227|OTHER|Language Games and Narrating Your Day Language Curriculum|Early language activity that parents can do with their infants
223501153|NCT02528227|OTHER|Feeding Safety|Part of Health and Safety Curriculum
223501154|NCT02528227|OTHER|Car Seat Safety|Part of Health and Safety Curriculum
223501155|NCT02528227|OTHER|Bath Safety|Part of Health and Safety Curriculum
223591721|NCT06167876|OTHER|Sham Procedure|The sham procedure in this study is designed to closely mimic the actual Stereotactic Body Radiotherapy (SBRT) process without delivering any radiation. Participants in this arm are subjected to the same initial steps as those in the SBRT group, including precise alignment with the linear accelerator using CT scans and the application of customized fixation devices to limit movement and breathing. However, in this sham intervention, the linear accelerator is activated but does not emit any radiation. The procedure replicates the environmental aspects of the actual treatment, such as the equipment's sounds and lighting, to maintain the study's single-blind nature. This method ensures that participants in the sham group experience a procedure identical in appearance and feel to the SBRT treatment, without receiving any therapeutic dose, thereby serving as an effective control for evaluating the true impact of SBRT in treating HOCM.
223501156|NCT02528227|OTHER|Back to Sleep/SIDS prevention|Part of Health and Safety Curriculum
223501157|NCT02528227|OTHER|Taking a Temperature and Signs of Infection|Part of Health and Safety Curriculum
223501158|NCT02528227|OTHER|Infection Control Measures and Vaccine Information|Part of Health and Safety Curriculum
223501159|NCT01271855|DRUG|Belladonna and opioid suppository|Belladonna and opioid suppository 16.2mg/30mg per rectum every 8 hours for 24 hours following delivery
223501160|NCT01271855|DRUG|Glycerin Suppository|A vegetable oil suppository (placebo) per rectum every 8 hours for the first 24 hours following delivery.
223501161|NCT04979013|OTHER|Smoking Abstinence|Smokers will be switched to smoking abstinence for 14 days
223501162|NCT01617109|DIETARY_SUPPLEMENT|Ca/Vit D|800IU vitamin D3 and 2000mg elemental calcium (as calcium carbonate); administered as 5 pills daily or 2 snack bars
223501163|NCT01617109|OTHER|Placebo|administered as 5 pills daily or as 2 snack bars
223501164|NCT03910946|DRUG|Tuberculin, Purified Protein 5Unt/0.1 mL Solution|Tuberculosis (diagnosis)-Tuberculin, purified protein derivative (PPD) is indicated as a diagnostic aid in the detection of Mycobacterium tuberculosis infection. It is also indicated when BCG vaccination or isoniazid prophylaxis is being considered
223501165|NCT06381843|BIOLOGICAL|Recombinant COVID-19 Vaccine (Sf9 Cell)|1dose, Intramuscular Injection
223501166|NCT06381843|BIOLOGICAL|COVID-19 Vaccine (Vero Cell), Inactivated|1dose, Intramuscular Injection
223501167|NCT06569355|DRUG|VCT220|A small molecule GLP-1R agonist tablet, orally administration, once daily
223501168|NCT06569355|DRUG|Placebo|Placebo tablet
223501169|NCT06811844|DRUG|Two-cycle induction chemotherapy + immunotherapy|Two cycles of nab-paclitaxel at 260 mg/m2 on day 1, cisplatin at 25 mg/m2 from days 1 to 3, and oral S1 twice daily from days 1 to 14 (40 mg twice daily on patients with a body surface area \[BSA\] less than 1.25 m2, 50 mg twice daily for patients with a BSA between 1.25 and 1.5 m2, and 60 mg twice daily for patients with a BSA \>1.5 m2). Camrelizumab was administered intravenously at a dose of 200 mg on the first day of each cycle.
223501170|NCT06811844|DRUG|Three-cycle induction chemotherapy + immunotherapy|Three cycles of nab-paclitaxel at 260 mg/m2 on day 1, cisplatin at 25 mg/m2 from days 1 to 3, and oral S1 twice daily from days 1 to 14 (40 mg twice daily on patients with a body surface area \[BSA\] less than 1.25 m2, 50 mg twice daily for patients with a BSA between 1.25 and 1.5 m2, and 60 mg twice daily for patients with a BSA \>1.5 m2). Camrelizumab was administered intravenously at a dose of 200 mg on the first day of each cycle.
223591722|NCT04615884|DIETARY_SUPPLEMENT|Chinese herbs formula: Shu Yu Wan|Shu Yu Wan Formula is a combination of 23 natural chinese herbs.This formula may be used to relieve chemotherapeutic side effects or cancer-related symptoms.
223591723|NCT04615884|OTHER|Placebo capsules|Placebo
223591724|NCT02271945|DRUG|MEDI-551 12 mg/kg|Participants will receive intravenous (IV) infusion of MEDI-551 12 mg/kg on Days 1 and 8 of Cycle 1 and Day 1 of Cycle 2 through Cycle 13
223591725|NCT02271945|DRUG|MEDI0680 2.5 mg/kg|Participants will receive IV infusion of MEDI0680 2.5 mg/kg on Days 2 and 15 of Cycle 1 and Days 1 and 15 of Cycle 2 through Cycle 13.
223591726|NCT02271945|DRUG|MEDI0680 10 mg/kg|Participants will receive IV infusion of MEDI0680 10 mg/kg on Days 2 and 15 of Cycle 1 and Days 1 and 15 of Cycle 2 through Cycle 13.
223591727|NCT00615030|DRUG|Indacaterol|300 µg dosed in the morning/evening via single dose dry powder inhaler (SDDPI)
223591728|NCT00615030|DRUG|Salmeterol|50 µg twice daily delivered via dry powder inhaler (DPI)
223591729|NCT00615030|DRUG|Placebo to Indacaterol|Placebo matching indacaterol was delivered via SDDPI.
223591730|NCT00615030|DRUG|Placebo to Salmeterol|Placebo matching salmeterol was delivered via DPI
223591731|NCT02021903|OTHER|V1: HGPO + meal and V2: placebo + meal|"* Ambulatory polysomnography for the night preceding each test~* Usual antiparkinsonian treatments at their usual dose and timing~* Randomisation to receive an oral solution of glucose load or a placebo (fructose). Standard meal 4 hours after the test~* During two hours following the oral solution administration and the standardized meal, we will perform the followings for each patient :~  * continuous digital blood pressure monitoring by Nexfin®~ * blood pressure monitoring at brachial artery~ * continuous polysomnographic recording~ * synchronized continuous digital audiovisual recording~ * glucose and insulin blood level monitoring Additional blood samples will be taken in order to assay the intestine-pancreatic neuropeptides including incretins GLP- 1 and GIP"
223591732|NCT02021903|OTHER|V1: placebo 75mg + meal and V2: HGPO 75mg + meal|"* Ambulatory polysomnography for the night preceding each test~* Usual antiparkinsonian treatments at their usual dose and timing~* Randomisation to receive an oral solution of glucose load or a placebo (fructose). Standard meal 4 hours after the test~* During two hours following the oral solution administration and the standardized meal, we will perform the followings for each patient :~  * continuous digital blood pressure monitoring by Nexfin®~ * blood pressure monitoring at brachial artery~ * continuous polysomnographic recording~ * synchronized continuous digital audiovisual recording~ * glucose and insulin blood level monitoring Additional blood samples will be taken in order to assay the intestine-pancreatic neuropeptides including incretins GLP- 1 and GIP"
223591733|NCT00151476|DRUG|Celecoxib|800 mg total daily dosing
223591734|NCT00151476|OTHER|Routine Medical Care|
223591735|NCT06250335|OTHER|Prebiotic Food-Enriched Diet|Given by PO
223591736|NCT06250335|DRUG|Ipilimumab|Given by IV
223591737|NCT06250335|DRUG|Nivolumab|Given by IV
223591738|NCT03446456|DRUG|Arginine vasopressin|Intranasal vasopressin will be administered shortly before the fMRI experiment.
223591739|NCT03446456|OTHER|Saline|Intranasal saline will serve as a placebo for participants in the Saline Arm
223591740|NCT03446456|BEHAVIORAL|Observational learning|During the observational learning intervention, participants will learn the experience of analgesia in another person via a video. Participants will learn the analgesia nature of the placebo cream and the neutral nature of the control cream.
223591741|NCT03446456|OTHER|fMRI data aquisition|All participants from the intranasal vasopressin and intranasal saline groups will go through a fMRI data acquisition to obtain the brain structural, brain resting-states and functional MRI scans.
223591742|NCT06139289|PROCEDURE|EVD placements in the OR versus the bedside.|Reducing EVD-related complications
223591743|NCT02982876|PROCEDURE|Dynamic Flexible Bronchoscopy|The bronchoscope will be introduced into the proximal trachea at the level of the cricoid. At that point, patients will be instructed to take a deep breath, hold it and then blow it out (forced expiratory maneuver). Maneuvers will be done at the following six sites: proximal trachea at the level of the cricoid; mid-trachea 5 cm proximal to the carina; distal trachea 2 cm proximal to the carina; right main stem bronchus at the right tracheobronchial angle; bronchus intermedius and left main bronchus at the left tracheobronchial angle
223591744|NCT02982876|PROCEDURE|Rigid Bronchoscopy|Under general anesthesia, a rigid bronchoscope (Bryan-Dumon Series II; Bryan Corporation; Woburn, MA) will be introduced, and respiration will be maintained through jet ventilation.
223591745|NCT02982876|DEVICE|Stent placement|Silicone Y stent or uncovered self-expanding metallic stent will be placed in the standard fashion and good fit will be confirmed visually.
224192252|NCT06286995|PROCEDURE|Chemomechanical preparation for root canals|After working length determination ,root canal preparation was made by two different NiTi File systems to both group ( the first group using Trunatomy file and the second one using edgeendo x7 file) and assessment of pain was made preoperatively and postoperatively and also apical fluid samples
224192253|NCT02423564|DIETARY_SUPPLEMENT|Digesta Lac|
224192254|NCT02423564|OTHER|Placebo|
224192255|NCT01564810|DRUG|Cetuximab|On day 1 of a 14 day treatment cycle, patients received a 2-hour infusion of cetuximab (initial dose 400 mg/m2 in week 1, and 250 mg/m2 weekly during 1 hour thereafter) followed after 1 hour by chemotherapy of FOLFOX or FOLFIRI until progressive disease or unacceptable toxicity.
224192256|NCT01564810|DRUG|chemotherapy of mFOLFOX6 or FOLFIRI|FOLFOX-4 (oxaliplatin, 85mg/m2 on day 1 infused during 2 hours;LV200mg/m2ondays 1and 2 infused during 2 hours, together with or following oxaliplatin; followed by FU 400 mg/m2 intravenous bolus then 600 mg/m2 intravenous infusion over 22 hours on days 1 and 2) FOLFIRI(irinotecan 180mg/m2 on day 1 infused during 2 hours; fluorouracil in a bolus of 400 mg/m2 and then continuous infusion for 46 hours of 2400 mg/m2)
224192257|NCT05542212|DEVICE|Transcranial Magenetic Stimulation|Intermittent Theta Burst Stimulation (iTBS) treatment plan: iTBS treatment for the left dlPFC were used for a total of 20 treatments (one time each Monday to Friday, continuous treatment for 4 weeks).
224192258|NCT05542212|DEVICE|Sham Transcranial Magenetic Stimulation|Sham stimulation: The coil angle is set at 90° to the scalp for Sham stimulation of the left dlPFC for a total of 20 treatments (one time each Monday to Friday, continuous treatment for 4 weeks).
224192259|NCT03047512|BEHAVIORAL|Experimental: Internet-based program|"* Adolescents who obtain a score between 2 and 4 on the PHQ-3 will be invited to use the information module, the psychoeducational material and the symptom monitoring with personalized automatic feedback.~* Adolescents who obtain a score between 5 and 6 on the PHQ-3 will be invited to use, in addition to the above, group forum activities (peer support moderated by mental health professionals) and the possibility of a chat (individualized support by mental health professionals).~* Adolescents who obtain a score greater than 6 on the PHQ-3 or that have suicidal thoughts will be invited to see the mental health counselor of the institution and the possibility of their reference to face-to-face professional attention will be considered."
224309865|NCT03613727|DRUG|Intravenous (IV) and oral Vitamin C|"Intravenous (IV) vitamin C 50 mg/kg/day divided in 3 doses beginning on posttransplant Day +1 and continuing through Day +14; each dose (16.7 mg/kg) given in 50 mL of 5% dextrose and water over 30 minutes every 8 hours~• After completion of the IV vitamin C doses, oral vitamin C 500 mg twice each day beginning on Day +15 and continuing until Day +180"
223501171|NCT06821737|DEVICE|Diagnostic ultrasound|A portable wireless ultrasound system (Vscan Air, General Electric Healthcare) with dual probes-linear array (3-12 MHz) for neck scanning and curved array (2-5 MHz) for subxiphoid scanning-will be used. The linear probe is placed transversely on the anterior neck, slid left at the thyroid level to focus on the esophagus, then rotated for longitudinal views. The curved probe is applied subxiphoid, using the liver as a landmark, and tilted left to image the stomach. A positive result is confirmed by visualizing the NGT shadow in the esophagus and stomach, followed by dynamic upsurge fogging after injecting 50cc of air. Ultrasonography and X-ray results will be compared.
223501172|NCT06821737|DEVICE|Diagnostic X-ray|This study will employ chest radiography as the reference standard for verification of correct nasogastric tube placement. Radiographic imaging will be conducted following NGT insertion and interpreted by physicians to verify positional accuracy.
223501173|NCT06659991|DRUG|alcohol condition|Ethanol
223501174|NCT06659991|OTHER|control condition|sparkling water
223501175|NCT05382962|BEHAVIORAL|iCanCope Post Op Application|The iCanCope program is designed to enhance pain self-management and self-efficacy, defined as perception of one's ability to successfully produce a desired effect in a task or behavior affecting their life. The intervention will be delivered on the iOS or Android smartphone platform depending on the participant's device. Usage of app features will be centrally tracked by the research team using Analytics Platform to Evaluate Effective Engagement (APEEE), developed at the Centre for Global eHealth Innovation. Participants will receive alerts through iCanCope to complete a pain diary check-in once per week preoperatively, twice per day over the initial 2-week postoperative period, and once per day for the subsequent 2-week period.
223501176|NCT05164263|DRUG|Empagliflozin|Empagliflozin + Metformin (Diampa™-M): 5mg+500mg, 5mg+850mg, 5mg+1000mg, 12.5mg+1000mg, 12.5mg+500mg, 12.5mg+ 850mg Empagliflozin Alone (Diampa™): 10mg, 25mg
223501177|NCT04211896|DRUG|Anlotinib|Anlotinib will be given at a dose of 12mg once daily on days 1-14 of a 21-day cycle.
223501178|NCT04211896|DRUG|Nivolumab|Nivolumab will be given at a dose of 240 mg every 2 weeks (Odd Cycles: Days 1 and 15 and Even Cycles Day 8) per 21 day Cycle.
223501179|NCT04705753|DIETARY_SUPPLEMENT|Cretan IAMA|Cretan IAMA (CAPeo) soft gels, 1 ml/day of a 1.5% essential oil combination from three aromatic plants (Thymbra 59 capitata (L.) Cav., Origanum dictamnus L., Salvia fruticosa Mill.) in extra virgin olive oil
223501180|NCT04663516|OTHER|Exergaming|games provided by the console requiring the movement of upper body, lower body and trunk.
223591746|NCT06414278|OTHER|Non-Interventional Study|Non-interventional study
223591747|NCT04545957|DEVICE|MRI Simulator|Radiation mapping to define the target for radiation.acquiring MR data at the specified timepoint in a patient's care plan and ability to identify the radiation target and develop a radiation therapy plan on the MR data.
224192260|NCT05044910|DIETARY_SUPPLEMENT|Ready to Use supplementary food (RUSF)|Children with malnutrition will be given RUSF
223501181|NCT03844737|DEVICE|VisuXL®|Treatment of discomfort forms of the ocular surface, in professional water-polo athletes exposed to pool water for prolonged periods.
223501182|NCT00097968|DRUG|everolimus|
223591748|NCT04545957|RADIATION|Radiation Therapy|In Phase I, radiation will be institutional standard per disease site. In Phase II, either radiation according to MR-based dose painting or adjusted RT. These adjusted doses and/or RT will vary per disease site and will be pre-specified in the subprotocols.
223591749|NCT06295783|OTHER|MDASI-HN|Given by Questionnaire
223591750|NCT06295783|OTHER|EORTC QLQ-C30|Given by Questionnaire
223591751|NCT06295783|OTHER|EORTC HN35|Given by Questionnaire
223591752|NCT04532931|DRUG|Paracetamol|SOC - 2 tablets (1000 mg) to be taken 6-hourly as needed
224192261|NCT01541410|DEVICE|Vascutek Hybrid Graft|Single Group Assignment
224309866|NCT00638027|DRUG|placebo|matched tablets bid
224309867|NCT00638027|DRUG|memantine|10 mg bid
224192262|NCT06491719|OTHER|NCR300（Allogenic Ipsc-derived Natural Killer cells ）|"Patients will receive iNK cells i.V. infusion at 1.0x10\^8/kg on days +14d, +21d, +28d, and +35d post-transplant.~Continuation of the infusion after +35d post-transplant is at the discretion of the physician based on the patient's benefit."
224192263|NCT06326723|DRUG|Daridorexant|"25 mg group: Daridorexant group: strength 25 mg, administered at a dose of 25 mg; administered orally under fasting conditions, single dosing on Day1, and daily dosing on Day 4-8.~Placebo control group: administered in the same manner as the test drug.~50 mg group: Daridorexant group: strength 50 mg, administered at a dose of 50 mg; administered orally under fasting conditions, single dosing on Day 1, and daily dosing on Day 4-8.~Placebo control group: administered in the same manner as the test drug.~Drug is to be administered at the same time every day, and the dosing window is recommended to be at 08:00 AM (±1 h) on the dosing day. Drinking water and other liquids should be avoided for 1 hour before and after dosing on the day of blood collection (except the water used to swallow the tablets.)."
224192264|NCT01102608|DRUG|Ifosfamide|3 cycles of Ifosfamide (12g/m2) associated to Mesna (6g/m2), in i.v infusion 6 days, every 3 weeks
224192265|NCT01440608|DRUG|Albendazole|Pill form, to be given once, 200 mg dosage for children 1-2 years of age, 400 mg dosage for children 2-3 years of age
224192266|NCT01440608|DRUG|Placebo|Pill form, 400 mg dose to be given once per day for 14 days in Placebo arm and 13 days in Albendazole arm following one dose of Albendazole.
224192267|NCT01440608|DIETARY_SUPPLEMENT|High-dose Zinc|Pill form, equivalent to 20 mg elemental zinc, to be given once per day for 14 days
223501183|NCT05877105|OTHER|Ventilator-associated pneumonia prevention Evidence-based practices (VAPPEBP) which consists of ten items bundle|VAP prevention EBP which consists of ten items bundle; hand hygiene, head-of-bed elevation, oral care with cetylpyridinium chloride, avoidance of oversedation, proper breathing circuit management, appropriate maintenance of endotracheal tube cuff pressure, closed system and subglottic suctioning, daily assessment for extubation, early ambulation and rehabilitation, and peptic ulcer and deep vein thrombosis (DVT) prophylaxis.
224192268|NCT00998621|OTHER|Adherence questionnaire|Adherence questionnaire
224192269|NCT06653049|DEVICE|Reinforcement Learning (RL) Personalised Exercise Prescription via i80 BPM App|This intervention involved the use of a smartphone app, i80 BPM, which delivered personalised exercise prescriptions using a reinforcement learning (RL) model. The RL algorithm tailored the exercise sessions by adapting variables such as intensity, duration, and exercise type based on individual user preferences, real-time feedback, and performance data. This dynamic personalisation was designed to enhance user satisfaction and engagement over the 12-week study period. Participants completed three exercise sessions per week.
224192270|NCT06653049|DEVICE|Generic Non-Personalised Exercise Prescription via i80 BPM App|This intervention used the same i80 BPM smartphone app to deliver generic, pre-designed exercise sessions that did not adapt based on user preferences or feedback. The exercise sessions were standardised for all participants, with no customisation. The control arm served as a comparator to evaluate the impact of personalised, RL-driven exercise prescriptions. Participants completed three exercise sessions per week.
224192271|NCT00312936|BEHAVIORAL|Mindfulness-based Stress Reduction (MBSR)|8 week program
224192272|NCT04330066|DIAGNOSTIC_TEST|Abdominal ultrasound measurement of the endometrial lining|On the day of the participants frozen embryo transfer, an endometrial thickness measurement (T2) will obtained from an abdominal ultrasound during the embryo transfer.
224192273|NCT01284413|DRUG|S-1, Gemcitabine, Cisplatin|S-1 is given daily for 7 consecutive days and gemcitabine and cisplatin are infused on day1. The cycle is repeated every 2 weeks.
224192274|NCT03251443|DRUG|Apatinib|500mg, once a day, oral of each 28 day cycle. Number of cycle: until progression or unacceptable toxicity develops.
224192275|NCT04922164|BEHAVIORAL|Cue intervention|"Around 30 pieces of narrative information about how a mother behaves in specific decision context will be derived from our qualitative study to construct social normative cues.~For goal-related cues, words relating to each category of breastfeeding-related values, benefits and goals will be identified and used to construct the messages (e.g. attractive body shape, smart baby, natural, strong immunity and etc.). Each goal-priming message will be presented with brief priming words and a picture of an image of the desirable goal."
224192276|NCT04279002|OTHER|Brief 15-question questionnaire|Questionnaire is mailed retrospectively to the respiratory rehabilitation program and aimed at targeting 17 psycho-social traits. Response time is estimated at 10 minutes
224192277|NCT01079000|BEHAVIORAL|Opinion Leader letter|The patients' PCP will be notified by fax about the ED visit and management. The Opinion Leader letter will contain a summary of the current asthma guidelines for ambulatory care (including: asthma education, long-term recommendations, smoking cessation, and action plan) signed by a local opinion leader. A review of the patient's management within a week of the ED visit will be recommended. The patient will also receive information regarding their acute exacerbation and will be told to review the current management of their disease with their PCP.
224192278|NCT01079000|BEHAVIORAL|Involvement of a care manager|The involvement of a care manager will encourage patients' to pursue follow-up, provide management review and offer brief education via telephone within a week of being discharged
223501185|NCT03092232|DRUG|PF-06865571|Single ascending dose of PF-06865571 as extemporaneously prepared solution/suspension, once every 2 week in a cross over study: 5 mg, 50 mg, 500 mg, TBD (to be determined)/2000 mg.
223501186|NCT03092232|DRUG|PF-06865571|Single ascending dose of PF-06865571 as extemporaneously prepared solution/suspension, once every 2 week in a cross over study: 15 mg, 150 mg, 1000 mg, TBD/2000 mg.
223501187|NCT03092232|DRUG|PF-06865571|Single repeated (TBD mg) dose as extemporaneously prepared solution/suspension of PF-06865571.
223501188|NCT03092232|DRUG|Placebo|Matching Placebo for PF-06865571 for each cohort.
223501189|NCT02150005|PROCEDURE|Periodontal treatment|
223501190|NCT04692818|DIAGNOSTIC_TEST|GE Logiq E10 clinical ultrasound scanner|2D B-mode, Doppler, and shear wave elastography images of the lesion
223501191|NCT04692818|DIAGNOSTIC_TEST|Verasonics research scanner|3D B-mode imaging, microvessel imaging, and shear wave elastography
224192279|NCT01079000|BEHAVIORAL|Usual care|Usual care provided to asthma patients when discharged from the ED
224192280|NCT05259059|OTHER|No intervention is involved|No intervention is involved
224192281|NCT06652906|DRUG|Sodium phosphate powder|After admission, the patient underwent comprehensive renal function and electrolyte tests. The first medication was taken at 7pm the day before the examination. One bag of sodium phosphate powder was diluted with 800ml or more of warm and cool water before taking. The second dose of medication should be taken at 7am on the day of operation or examination (or at least 3 hours before the examination), with the same usage as the first dose, with a 12 hour interval between each dose. The standard dose for each dose is 1 bag, until clear water like stool appears.
224192282|NCT06652906|DRUG|Polyethylene glycol electrolyte dispersion|After admission, the patient underwent comprehensive renal function and electrolyte examination. The evening before the intestinal examination, 2000ml of polyethylene glycol electrolyte San III isotonic solution was taken, 250ml every 10-15 minutes, and it was taken within 2 hours. On the day of examination, 2000ml of polyethylene glycol electrolyte San III isotonic solution was taken 3-4 hours in advance until clear water like stool appeared.
224192283|NCT01556659|DRUG|Absence of vitamin K antagonist|Dual anti-platelet therapy
223501192|NCT03658967|DRUG|Lymfactin® (1x10E11 vp)|Lymfactin® will be administered as a single dose via perinodal injection in a volume of 2 mL.
223501193|NCT03658967|DRUG|Placebo|Placebo will be administered as a single dose via perinodal injection in a volume of 2 mL.
223591753|NCT04532931|DRUG|Artesunate-amodiaquine|SOC plus artesunate-amodiaquine (ASAQ) - 2 tablets (200/540 mg artesunate/amodiaquine) daily for 3 days
223591754|NCT04532931|DRUG|Pyronaridine-artesunate|SOC plus pyronaridine-artesunate (PA) Weight 45 to \<65 kg: 3 tablets (540/180 mg pyronaridine/artesunate) daily for 3 days Weight ≥65 kg: 4 tablets (720/240 mg pyronaridine/artesunate) daily for 3 days
223591755|NCT04532931|DRUG|Favipiravir plus Nitazoxanide|SOC plus favipiravir plus nitazoxanide (FPV-NTZ) Favipiravir: 1600 mg 12-hourly for 1 day then 600 mg 12-hourly for 6 days Nitazoxanide: 2 tablets (1000 mg) 12-hourly for 7 days
223746301|NCT03899948|BEHAVIORAL|Teacher Anxiety Training|The TAT is a 3-hour professional development training for teachers. Training focuses on recognizing the signs and symptoms related to child anxiety and utilizing classroom-wide strategies to help reduce anxiety in the classroom.
223746302|NCT04364620|DRUG|AB-16B5|AB-16B5 is an inhibitor of the epithelial to mesenchymal transition. It is a fully humanized monoclonal antibody of IgG2 isotype against tumor-associated secreted clusterin (TA-sCLU).
224192284|NCT02952300|PROCEDURE|neolix|single rotation file
224192285|NCT02952300|PROCEDURE|wave one|single reciprocation file
224192286|NCT02515175|BIOLOGICAL|Matrix-M2|Matrix-M2 is derived from fractionated Quillaja saponins, phosphatidylcholine, and cholesterol.
224192287|NCT02515175|BIOLOGICAL|GEN-003|HSV-2 protein subunit vaccine consisting of 2 recombinant T cell antigens: internal fragment of the immediate early (IE) protein ICP and glycoprotein D
224192288|NCT02515175|DRUG|Placebo|0.9% Normal Saline
223501194|NCT04645108|BEHAVIORAL|Noom Healthy Weight; mobile behavior change program for weight loss with 1:1 coaching|"The intervention consists of a curriculum, provided through daily articles that users are encouraged to read; logging features for weight, meals, and physical activity; in-app groups; and a virtual coach, who will communicate with participants via in-app messaging. During the first week of the study, participants will be introduced to the program, the Noom app, and their coach.~Coaches will use a secure dashboard to monitor patient progress, which is used to increase engagement and motivation. Participants are encouraged to log their weight and physical activity on a weekly basis, and meals daily."
223501195|NCT04645108|BEHAVIORAL|Noom Healthy Weight; mobile behavior change program for weight loss|The intervention consists of a curriculum, provided through daily articles that users are encouraged to read; logging features for weight, meals, and physical activity. During the first week of the study, participants will be introduced to the program, and the Noom app.
223501196|NCT04863521|OTHER|MHP|MyHealthyPregnancy app (MHP 3.0) is a mHealth app specifically focused on detection and referral for depression and IPV (Intimate Partner Violence) risk, in addition to its other pregnancy risk detection and support features.
223501197|NCT01452347|DRUG|warfarin 1mg|comparator warfarin
223501198|NCT01452347|DRUG|dabigatran etexilate intermediate dose|active treatment (medium)
223501199|NCT01452347|DRUG|dabigatran etexilate low dose|active treatment (low)
223501200|NCT01452347|DRUG|warfarin 5mg|comparator warfarin
223591756|NCT04532931|DRUG|Sofosbuvir/daclatasvir|"SOC plus sofosbuvir/daclatasvir (SOF/DCV)~1 tablet (400 mg/60 mg sofosbuvir/daclatasvir) daily for 7 days"
224192289|NCT02008552|GENETIC|Sampling of blood|Sampling of blood was taken and analyse to research factor genetic
224192290|NCT02602470|DRUG|Azelaic Acid Gel including: Finacea (Azelaic Acid Gel 15%, BAY39-6251)|Azelaic Acid Gel 15%, Azelaic Acid Gel 15% w/Cleanser \& Moisturizing
224192291|NCT02602470|DRUG|Azelaic Acid Cream|Azelaic Acid Cream 20%
224192292|NCT02602470|DRUG|Metronidazole gel|Metronidazole Gel 1%, Metronidazole Gel 1% w/ Cleanser, Metronidazole Gel 0.75%, Metronidazole Gel 0.75% w/ Cleanser
224192293|NCT02602470|DRUG|Metronidazole cream|Metronidazole Cream 1%, Metronidazole Cream 0.75%, Metronidazole Cream 0.75% w/ Cleanser
224192294|NCT02602470|DRUG|Metronidazole Emulsion|Metronidazole Emulsion 0.75%
224192295|NCT02602470|DRUG|Metronidazole Lotion|Metronidazole Lotion 0,75%
224192296|NCT02602470|DRUG|Brimonidine Tartrate Gel|Brimonidine Tartrate Gel 0.33%
223501201|NCT01452347|DRUG|dabigatran etexilate high dose|active treatment (high)
223501202|NCT01452347|DRUG|warfarin 3mg|comparator warfarin
223591757|NCT02917733|DRUG|LY3039478|Administered orally
223746303|NCT04364620|DRUG|Docetaxel|Docetaxel is an anticancer chemotherapy drug approved in the treatment of non-small cell lung cancer
223746304|NCT07162922|OTHER|8 mmHg pressure group|Laparoscopic cholecystectomy will be performed with intra-abdominal pressure maintained at 8 mmHg during insufflation. Standard anesthesia and surgical protocols will be followed.
224192297|NCT00403611|DRUG|Praziquantel 60 mg/kg|Praziquantel (Distocide) 60 mg/kg single oral dose
224192298|NCT00403611|DRUG|Praziquantel 40 mg/kg|Praziquantel (Distocide) 40 mg/kg single oral dose
224309868|NCT00370812|PROCEDURE|amniotic membrane transplantation|AMT with conventional medical therapy (group A) or medical treatment only (group B). AMT will be performed within 24h of presentation. Amniotic membrane will remain in place for 7-14 days.
224309869|NCT04008654|BEHAVIORAL|ERAS Protocol|"Preoperative measures:~Counseling before hospital admission Fluid, and carbohydrate loading Avoiding prolongation of the fasting period Avoiding bowel preparation or its application only in selective cases Application of antibiotic prophylaxis Application of thromboprophylaxis Avoiding premedication~Intraoperative measures:~Use of short-acting anesthetic agents Application of midthoracic, epidural anesthesia/analgesia Refraining from using drains Refraining from salt, and water overload Maintenance of normothermia (heating the body, and use of warmed up intravenous fluids)~Postoperative:~Application of midthoracic, epidural anesthesia/analgesia Refraining from use of nasogastric tube Prevention of nausea, and vomiting Refraining from salt, and water overload Earlier removal of catheters Initiation of oral intake at an early period Use of nonopioid oral analgesics/NSAIDs Early mobilization Adherence to the protocol, and auditing results"
224309870|NCT04008654|BEHAVIORAL|Conventional care|This group of patients will not receive the specific ERAS protocol but will receive conventional care.
224309871|NCT00593047|DRUG|KB2115|tablet formulation given once daily for 12 weeks
224192299|NCT04246411|BEHAVIORAL|Ultrasound-guided determination of cuffless RAE tube depth|"1. Measurement of Carina-T2 mid-vertebra length from preoperative Cheat PA~2. Ultrasound-guided detection of endobronchial intubation depth by loss of lung sliding sign in the left lung field.~3. Withdrawal of the cuffless RAE tube using the Carina-T2 mid-vertebra length for optimal positioning"
224192300|NCT04246411|BEHAVIORAL|Auscultation-guided determination of cuffless RAE tube depth|"1. Measurement of Carina-T2 mid-vertebra length from preoperative Cheat PA~2. Auscultation-guided detection of endobronchial intubation depth by loss of breathing sound in the left lung field~3. Withdrawal of the cuffless RAE tube using the Carina-T2 mid-vertebra length for optimal positioning"
224192301|NCT05242107|DIETARY_SUPPLEMENT|Omega-3 supplement group|35 Neonates were given Omega 3 in a dose of 40mg/kg/day (8), after establishment of full-feeding and for 2 weeks duration. Omega-300 (Montana pharmaceutical industry) capsule was used which contains 1000mg Omega 3 fatty acids.
224192302|NCT05242107|OTHER|Full feeding without receiving any supplementation group|35 full term Growth Restriction( IUGR) neonates who were followed up to full feeding without receiving any supplementation.
224309872|NCT00371397|BEHAVIORAL|Hatha Yoga Classes|Iyengar yoga, the form of hatha yoga used in this study, emphasizes the use of props to help students achieve precise postures safely and comfortably according to their particular body types and needs. The yoga activity sessions were directed by four experienced yoga teachers following a script. The poses used were (in order) Supta Baddha Konasana (Reclining Bound Angle Pose), Adho Mukha Svanasana (Downward Facing Dog), Supported Uttanasana (Intense Forward Stretch), Parsvotanasana (Intense Side Stretch Pose), Prasarita Padottanansana (Wide-Legged Forward Bend), Janu Sirsasana (Head to Knee Pose), Bharadvajasana (Simple Seated Twist Pose), Viparita Karani (Restful Inversion), Supported Setu Bandha Sarvanagasana (Bridge Pose), and Savasana (Corpse Pose). Blood draws occurred during the last two minutes of Supta Baddha Konasana (pose held 10 minutes), Viparita Karani (10 minutes), and Savasana (15 minutes).
224309873|NCT00371397|BEHAVIORAL|Movement Control|Walking on a treadmill at .5 miles per hour was used to control for general physical movement/cardiovascular expenditure because it best approximated the heart rates during the restorative yoga session. To match the lower heart rate, women also rested supine on a bed for several minutes after walking, before and after getting their blood drawn.
224309874|NCT03139227|PROCEDURE|Bio specimen Collection|Patients undergo collection of blood and urine
224309875|NCT03139227|DIETARY_SUPPLEMENT|Dietary Intervention|Consume celery-banana bread
224309876|NCT03139227|OTHER|Laboratory Biomarker Analysis|Correlative studies
223591758|NCT06257173|BEHAVIORAL|Education|The experimental group will receive 2 hours of patient safety training with a peer educator.
223591759|NCT06650839|DEVICE|NIUT|Treatment of moderate aortic stenosis using non-invasive ultrasound therapy delivered by Valvosoft
223591760|NCT06447506|DRUG|GSK1070806|Participants will receive GSK1070806.
223591761|NCT04099511|BEHAVIORAL|Usual Care Occupational Therapy-Outpatient|The control group in the proposed study will receive usual care occupational therapy services. The dosage between the experimental group and usual care will be identical with each group receiving ten 45- minute treatment sessions. The treating therapists will be unfamiliar with the experimental group intervention to avoid contamination. Each therapist will be instructed to provide care in the same manner as they typically provide in day-to-day practice for patients with similar characteristics as those in the study. The therapists will be encouraged to provide home action plans to participants. Usual care services will be monitored through a log of number of sessions, time spent in each session, and what activities were the focus of each session. The therapists will be instructed that they can address any participant goals they wish other than transfer goals identified by the participant.
224192303|NCT02016027|DRUG|Carica folia|
224192304|NCT03078504|DEVICE|continuous renal replacement therapy using System One (TM) setup (Nxstage)|Participants who have been prescribed continuous renal replacement therapy will have hemodynamic parameters measured at various blood flow rates
224192305|NCT04723329|BEHAVIORAL|Web-based exercise training based on the transtheoretic model|Motivating interviews will be provided to the patients to receive training on the website by contacting them one-on-one. In the following 1st and 3rd months, patients will be contacted individually again to confirm whether they follow the website, and they will be asked to fill in the scales on the website by providing consultancy on the issues they need. In the 6th month, the final test data will be obtained from the website using the same data collection forms.
224192306|NCT01141569|DRUG|Gamma-Secretase Inhibitor RO4929097|Given PO
224192307|NCT01141569|OTHER|Laboratory Biomarker Analysis|Correlative studies
224192308|NCT04726631|DRUG|Basal insulin analogue|Analogue insulin is a sub-group of human insulin
224192309|NCT04726631|DRUG|rapid acting insulin|Rapid acting insulins are usually taken just before or with a meal. They act very quickly to minimise the rise in blood sugar which follows eating.
224192310|NCT04726631|DRUG|Neutral Protamine Hagedorn|is an intermediate-acting insulin
224192311|NCT04726631|DRUG|regular insulin|is a type of short-acting insulin.
224309877|NCT03463473|DRUG|3 mg/kg Q3W MSB2311 Injection|An intravenous infusion with concentration from 3 mg/kg (Q3W)
224309878|NCT03463473|DRUG|10 mg/kg Q3W MSB2311 Injection|An intravenous infusion with concentration from 10 mg/kg (Q3W)
224309879|NCT03463473|DRUG|20 mg/kg Q3W MSB2311 Injection|An intravenous infusion with concentration from 20 mg/kg (Q3W)
224192312|NCT05151991|OTHER|Fixed orthodontic treatment with stainless steel brackets|"Orthophosphoric acid 37% acid (Gerhò Etchant gel 37%, Gerhò spa, Terlano, Italy) will be applied for 30 s for the etching of the vestibular surfaces of teeth. The, after rinsing and drying, a thin layer of Transbond XT Light Cure Adhesive Primer (3M Unitek, Monrovia, CA, USA) will be applied and then cured for 10 s with a LED unit. At last, Transbond XT Light Cure Adhesive Paste (3M Unitek) will be applied on the base of stainless steel brackets (Queen Series Low Profile Brackets MBT 0.022, Aestetika, Terni, TR, Italy); brackets will be applied on the vestibular surfaces of teeth with a light pressure and the extra paste will be removed. Curing will be performed with the LED unit at 2 mm distant from the enamel-bracket interface for 40 s, 10 s per each surface (mesial, distal, gingival and occlusal). The following sequence of archwires will be adopted for the first six months: 0.012-in Niti, 0.014-in Niti, 0.016-in NiTi, 0.018 SS, 0.020 SS, 0.017X0.025-in NiTi, 0.019X0.025-in SS."
224192313|NCT05151991|OTHER|Fixed orthodontic treatment with ceramic brackets|"Orthophosphoric acid 37% acid (Gerhò Etchant gel 37%, Gerhò spa, Terlano, Italy) will be applied for 30 s for the etching of the vestibular surfaces of teeth. The, after rinsing and drying, a thin layer of Transbond XT Light Cure Adhesive Primer (3M Unitek, Monrovia, CA, USA) will be applied and then cured for 10 s with a LED unit. At last, Transbond XT Light Cure Adhesive Paste (3M Unitek) will be applied on the base of ceramic brackets; brackets (Super Clear Series Brackets MBT 0.022, Aestetika, Terni, TR, Italy) will be applied on the vestibular surfaces of teeth with a light pressure and the extra paste is removed. Curing will be performed with the LED unit at 2 mm distant from the enamel-bracket interface for 40 s, 10 s per each surface (mesial, distal, gingival and occlusal). Then, the following sequence of archwires will be adopted for the first six months: 0.012-in Niti, 0.014-in Niti, 0.016-in NiTi, 0.018 SS, 0.020 SS, 0.017X0.025-in NiTi, 0.019X0.025-in SS"
224192314|NCT00536991|DIETARY_SUPPLEMENT|Calcitriol|Given PO
224192315|NCT00536991|DRUG|Ketoconazole|Given PO
224192316|NCT00536991|OTHER|Laboratory Biomarker Analysis|Correlative studies
224192317|NCT00536991|OTHER|Pharmacological Study|Correlative studies
224192318|NCT00536991|DRUG|Therapeutic Hydrocortisone|Given PO
224192319|NCT06264076|DEVICE|A novel instrument for ligament balancing in total knee arthroplasty|Patients will be evaluated perioperatively for ligament balance. When indicated, the novel instrument will guide puncturing of the medial collateral ligament in a systematic and step-wise fashion. Achieved ligament balance will be observed and controlled by computer navigation and a ligament tensor.
224192320|NCT00840762|OTHER|VircoType HIV-1 genotypic interpretation|VircoType HIV-1 genotypic interpretation
224192321|NCT00840762|OTHER|Local Expert Review of HIV Genotypic resistance testing|Local Expert Review of HIV Genotypic resistance testing
224192322|NCT04984694|BEHAVIORAL|Computerized virtual reality training programs group (Hot-Plus group)|"In this study, the investigators utilised interactive-video games called Xavix Hot Plus(Hot-plus, Shinsedai\[SSD\] Co. Ltd, Shiga Japan), which was designed specifically for rehabilitation and reported high participant motivation and enjoyment while playing."
224192323|NCT04984694|BEHAVIORAL|Social interaction group|The social interaction group will get together as a group for social interaction one hour weekly for 12 weeks.
224192324|NCT00655226|BEHAVIORAL|Hepatitis C educational support groups|Hepatitis C educational support groups
224192325|NCT00655226|BEHAVIORAL|Cognitive Behavioral Therapy skills based group sessions|Eight CBT group sessions tailored for hepatitis C patients conducted by a clinical psychologist: 3 sessions conducted prior to IFN/ribavirin initiation, 1 session the day of IFN/ribavirin initiation, and 4 sessions during IFN/ribavirin treatment.
223501203|NCT01952951|DRUG|Capecitabine Oxaliplatin|after completion of chemoradiation, two cycles of capecitabine (850mg/m2 twice daily from D1 evening to D15 morning) and oxaliplatin (100mg/m2 on D1) will be administered every 3 weeks.
223591762|NCT04099511|BEHAVIORAL|Cognitive Orientation to daily Occupational Performance|The Cognitive Orientation to daily Occupational Performance (CO-OP) approach was developed within the field of occupational therapy and is a performance-based, problem-solving approach to address activity performance limitations. Subjects will be taught to use the global problem-solving strategy of Goal-Plan-Do-Check: identifying a specific goal (Goal), outlining a practical plan for reaching that goal (Plan), accurately performing the plan (Do), and analyzing whether the plan led to achievement of the goal and altering the plan accordingly (Check). The Goal-Plan-Do-Check process will be iteratively applied to each of the activity goals. Therapists will use guided discovery to allow the subject to self-identify their own potential solutions within an activity (develop the plan). The therapists will be instructed that they can address any participant goals they wish other than transfer goals identified by the participant.
224192326|NCT06254131|DRUG|Ondansetron lozenge (Ondalenz ©)|Patients will receive ondansetron lozenge 4 mg (Ondalenz ©), 2 hours before surgery.
223501204|NCT01952951|RADIATION|pelvic radiation capecitabine 5-fluorouracil|50.4Gy of pelvic radiation with capecitabine or 5-fluorouracil
223501205|NCT02265835|OTHER|no intervention|no intervention
223501206|NCT06862960|DRUG|Ozanimod|A sphingosine-1-phosphate receptor regulator
223501207|NCT06862960|DRUG|Conventional medication|Conventional medications for moderate AD
223591763|NCT06234436|BIOLOGICAL|Plasma exchenge|Plasma exchange will be conducted. The substitution fluid will be plasma from ha healthy donor.
223591764|NCT00512018|DEVICE|NMES|"In the contralateral limb, the same protocol was repeated; however, each contraction was associated with overlapped NMES (Ex+NMES limbs).For the NMES, a symmetric double-phase sine-wave was used. Bearing wave frequency was of 2500 Hz, modulated in 50 bursts/s, with pulse duration of 200 µs, interburst interval of 10 ms. This configuration is known as Russian current."
223746305|NCT07162922|OTHER|14 mmHg pressure group|Laparoscopic cholecystectomy will be performed with intra-abdominal pressure maintained at 14 mmHg during insufflation. Standard anesthesia and surgical protocols will be followed.
224192327|NCT06254131|DRUG|Ondansetron IV|Patients will receive 4 mg of ondansetron IV approximately 30 minutes before the end of surgery.
224192328|NCT01763125|OTHER|Blood collection|Blood sample is collected during routine blood collection by a medical doctor. No more than 60ml (max.) at one timepoint.
224192329|NCT00054639|BIOLOGICAL|oblimersen sodium|Given IV
224192330|NCT00054639|BIOLOGICAL|rituximab|Given IV
224192331|NCT00054639|OTHER|laboratory biomarker analysis|Correlative studies
224309880|NCT03463473|DRUG|10 mg/kg Q2W MSB2311 Injection|An intravenous infusion with concentration from 10 mg/kg (Q2W)
223746306|NCT07164183|DRUG|Indole-3-carbinol|Indinol Forto (indolecarbinol (indole-3-carbinol)) 200 mg capsules orally twice a day during 24 weeks
224192332|NCT01237704|BEHAVIORAL|Traditional rehabilitation (TR)|TR rehabilitation will be scheduled three 45-minute sessions per week for 4 weeks with a total of 12 sessions that include Mendelsohn manoeuvre, Shaker's exercise, Effortful swallow and Masako manoeuvre.
224192333|NCT01237704|BEHAVIORAL|Transcutaneous electrical stimulation (ES)|Subjects will receive three 45-minute sessions per week for 4 weeks with a total of 12 sessions.
224192334|NCT03157934|OTHER|not applicable (observational study)|Observational study without study related intervention
224192335|NCT04631055|DEVICE|drug coated balloon|paclitaxel coated balloon catheter for intracranial PTA treatment
224192336|NCT04631055|DEVICE|stent system|The Intracranial Stent System comprises of a balloon expandable stent and a delivery catheter that features a rapid exchange catheter design with a semi-compliant balloon located at its distal end.The product, APOLLO™ stent system, has the indication of endovascular treatment for intracranial stenosis approved by NMPA.
224309881|NCT03014180|DEVICE|"In-Clinic LVAT"|Algorithm offers automatic threshold measurement of differents vectors of left ventricular stimulation.
223501208|NCT06998199|OTHER|Dual Task Balance Exercise|"The content of the DT training is summarized below with 30 minutes of routine PT. Participants will receive total of 16 sessions, 2 sessions per week for 8 weeks.~1. Walking 3 m on hard/soft ground while performing a motor task (carrying an empty box) and then combined with a cognitive task (saying the names of some fruits and vegetables),~2. Sitting on a Pilates ball for 1 min with eyes open/closed while performing a motor task (arms flexed to 90 degrees) and then combined with a cognitive task (saying the names of friends)~3)2-feet Jumping forward with both feet for 3 m while performing a motor task (carrying an empty box) then with a cognitive task (naming the colors in the room)~4)Standing on one leg for 30 s while arms abducted to 90 degrees and then combined with a cognitive task (saying the names of relatives)~5)Sit-to-stand using a stool 15 repetitions with a motor task (carrying an empty box) and then with a cognitive task (saying the names vegetables etc)"
223501209|NCT06998199|OTHER|Vestibular Stimulation|The child will place in sitting position on the swing and his hands grasping the ropes at the sides then the therapist stand behind him and begin pushing the platform in fast and jerky movement in back and front, side to side and in spinning directions with the child trying to maintain his balance in all different directions. The subject will receive pushing for each direction for five minutes; the total mechanical vestibular session duration was 15 minutes with 30 minutes of routine physical therapy. Participants will receive total of 16 sessions, 2 sessions per week for 8 weeks.
223501210|NCT06675708|DIETARY_SUPPLEMENT|Creatine|From the total sample obtained after recruitment, randomization will be performed using the SPSS statistical program, creating two groups. One experimental group will receive creatine supplementation, and the other group will receive a placebo through dextrose administration. In both cases, the doses will be administered in the same manner to both groups
223501211|NCT06675708|DIETARY_SUPPLEMENT|Dextrose|From the total sample obtained after recruitment, randomization will be performed using the SPSS statistical program, creating two groups. Dextrose group will be administered in the same manner as creatine to the experimental group. The doses will be prepared in the same way for both groups.
223501212|NCT07008638|DRUG|Bortezomib|Bortezomib at assigned study dose in mg/m2 will be given subcutaneously on days 1, 4, 8, and 11
223501213|NCT07008638|DRUG|CPX-351|CPX-351 given intravenously on day 1, 3, and 5
223501214|NCT06625606|DRUG|Bupivacaine 0.5% Injectable Solution|The patient's back was prepared for surgery. They were positioned on their side, with the operative side facing upward. The L3-4 spinal interspace was identified, and numbed, and a thin spinal needle was inserted. After confirming Cerebrospinal Fluid (CSF), 12.5 mg of isobaric bupivacaine 0.5% was injected into the spinal canal.
223501215|NCT06625606|DRUG|Bupivacaine 0.5% Injectable Solution|The L3-4 spinal interspace was identified, numbed, and a thicker needle (Tuohy needle) was inserted. After confirming Cerebrospinal Fluid (CSF), a thin catheter was inserted into the spinal canal and secured. An initial dose of 1 ml isobaric bupivacaine 0.5% was injected, followed by additional doses as needed to maintain the block height.
223501216|NCT06625606|DRUG|Isoflurane Inhalant Product|General anesthesia was initiated with propofol and rocuronium. Anesthesia was maintained with isoflurane, with additional rocuronium and fentanyl as needed. Breathing was controlled by the ventilator, and muscle relaxation was reversed at the end of surgery.
223501217|NCT07012343|RADIATION|Photodynamic Therapy with Conventional Methylene Blue|Methylene Blue mediated photodynamic therapy
223501218|NCT07012343|DRUG|urea 40% cream|40% Urea cream with occlusion
223501219|NCT07015671|DRUG|10 mg Torsemide tablet|Single dose 10 mg Torsemide tablet
223501220|NCT07015671|DRUG|25 mg Aldactone (Spironolactone) tablet|Single dose 25 mg Aldactone® (Spironolactone) tablet
223501221|NCT07015671|DRUG|FDC (12 mg ER Torsemide + 15mg Spironolactone) tablet|Single dose FDC (12 mg ER Torsemide + 15 mg Spironolactone) tablet
223501222|NCT03119974|DRUG|Tpo-RA discontinuation|a standardized strategy of dosage reduction will be implemented according to a predetermined scheme on persistent and/or chronic ITP patients who have previously achieved a stable and prolonged (\> 2 months) complete response (platelets counts \> 100 x 109/L) period on Tpo-RA treatment.
223501223|NCT04356924|BEHAVIORAL|Psychological treatment|The treatment is an adjusted (to the cognitively impaired individual) combination of CBT, ACT, validation strategies, and psychoeducation. One focus is to increase motivation to lifestyle changes, and to a larger degree live life in correspondence with internal goals.
223501224|NCT04356924|BEHAVIORAL|Cognitive training|Computer based training tasks implemented with adaptive intensity. The cognitive training method that will be used is mainly related to executive control (i.e., ability to coordinate thoughts and actions in accordance with internal goals).
223501225|NCT04174261|DRUG|Ticagrelor|Preprocedural ticagrelor loading and standard dose thereafter
223746307|NCT07164183|DRUG|Dienogest|Visanne (dienogest) 2 mg tablets orally once a day during 24 weeks
224309882|NCT00517127|DRUG|Lactated Ringer's Solution|Arm Nr 1: If corrected flow time (fTc), measured by esophageal doppler, falls below 350 msec, 250 ml of Lactated Ringer's Solution will be administered.
224309883|NCT00517127|DRUG|Hydroxyethylstarch 6% 130/0.4|Arm Nr 2: If corrected flow time (fTc), measured by esophageal doppler, falls below 350 msec, 250 ml of Hydroxyethylstarch 6% 130/0.4 will be administered.
223591765|NCT00512018|OTHER|Isokinetic exercise|Subjects realized training sessions twice a week with a 2-day minimum interval between the sessions, for 4 weeks. Each session included 5 min period of warm-up in a stationary bicycle, followed by 3 series of quadriceps stretching, as previously described. After being positioned at the isokinetic dynamometer, just as in the evaluation sessions, subjects firstly performed 3 sets of 10 maximum isokinetic concentric repetitions at the speed of 30º/s with one limb (EX limb), respecting the rest interval of 3 minutes between the sets.
224192337|NCT02843490|DRUG|Ranibizumab|Three injections (o.5 mg Ranibizumab) within the first three months is followed by an individual therapy interval based on the clinical progress (PRN)
224192338|NCT01600755|BIOLOGICAL|Iltamiocel|Single intrasphincteric injection of iltamiocel at a dose of 250 x 10\^6 cells
224192339|NCT02413710|OTHER|Soy protein containing foods|Daily consumption of 2 food products, each providing 15g of soy protein per day.
223591766|NCT00065806|DRUG|Atorvastatin|Participants weighing more 50 kg will receive 10 mg of atorvastatin po qd as a starting dose, which will be increased to 20 mg po qd at the Day 30 visit and continue through month 36. Participants weighing less than 50 kg will receive a maximum of 10 mg po qd for 36 months.
223591767|NCT00065806|DRUG|Placebo atorvastatin|Participants weighing more 50 kg will receive 10 mg of placebo po qd as a starting dose, which will be increased to 20 mg po qd at the Day 30 visit and continue through month 36. Participants weighing less than 50 kg will receive a maximum of 10 mg po qd for 36 months.
224192340|NCT02413710|BEHAVIORAL|Dietary Guidance|Subjects will be instructed on the 2010 Dietary Guidelines for Americans including publically available information from the United States Department of Agricultural (USDA) MyPlate program (www.choosemyplate.gov). Subjects in this intervention group will not receive study provided foods.
224192341|NCT04461912|DEVICE|Eye Scan Ultrasound System (ESUS)|"• For the ultrasonic signals acquisitions, an ophthalmic probe working in A-mode scan, must be coupled to the cornea. To reduce the discomfort generated by coupling the probe, topical anaesthesia (oxybuprocaine hydrochloride) will be applied before starting acquisitions. However, if the participant has some known contraindication to this anaesthetic, in replacement, a disposable neutral contact lens will be used as coupling medium between the probe and the cornea.~The acquisitions are initiated through a starting button in the system's user interface, and the probe must be kept by few seconds for automatic signals records. During this period, signals are visualized in the user interface. Finally the probe is uncoupled, and the acquired signals are saved."
224192342|NCT03464110|BEHAVIORAL|Communication Intervention|. The intervention will contain elements of Motivational Interviewing coaching but also will teach providers how to address patient emotion and increase the efficiency of their visits. Clinicians randomized to the intervention will receive a tailored communication coaching intervention that includes didactic elements, audio recording encounters and providing feedback, and role-playing.
224192343|NCT04551612|RADIATION|Multislice computed tomography temporal bone|Patients with cholesteatoma will undergo multislice computed tomography (MSCT) temporal bone images. Then The Tegmen level will be determined and compared with the other normal ear at the same patient
224192344|NCT01752608|BEHAVIORAL|eCBT Mood|A handheld, computerized, electronic cognitive behavioral therapy (CBT) application
224192345|NCT02020421|DEVICE|rTMS|Low frequency (1Hz) repetitive transcranial magnetic stimulation (rTMS) over the center of the right Pars Triangularis for 15 minutes (900 pulses) prior to each Speech-Language therapy session. Stimulation intensity will be set at 90% of the resting motor threshold (RMT) of the left first dorsal interosseous (FDI) muscle.
224192346|NCT02020421|DEVICE|tDCS|2mA cathodal transcranial direct current stimulation (tDCS) over the right Pars Triangularis. The anode will be placed on the forehead over the contralateral eye. tDCS will start immediately before the speech-language therapy session and last throughout the session.
224192347|NCT02020421|DEVICE|Sham rTMS|Low frequency (1Hz) repetitive transcranial magnetic stimulation (rTMS) over the Vertex for 15 minutes (900 pulses) prior to each Speech-Language therapy session. Stimulation intensity will be set at 10% of the resting motor threshold (RMT) of the left first dorsal interosseous (FDI) muscle.
224309884|NCT04494880|DRUG|Bupivacaine Injection|Treatment group receives Marcaine (Bupivacaine) injected into one breast following breast reduction surgery and a saline injection in the other group.
223591768|NCT00581867|DRUG|Insulin Aspart|40IU insulin aspart applied intranasally
223591769|NCT00581867|DRUG|Placebo|Placebo
224192348|NCT02020421|DEVICE|Sham tDCS|Sham cathodal transcranial direct current stimulation (tDCS) over the right Pars Triangularis. The anode will be placed on the forehead over the contralateral eye. To elicit the typical skin sensation of real tDCS (tingling sensation on the skin when tDCS is turned on and off), the current will be turned on for 30 seconds and then turned off for the duration of the speech-language therapy session. The same procedure will be done at the end of the session.
224309885|NCT04592835|DRUG|DWRX2003|"Intramuscularly injection at predefined injection sites~Drug: Placebo Intramuscularly injection at predefined injection sites"
223746308|NCT07181395|BEHAVIORAL|Hip Internal Rotation Mulligan Mobilization|Mulligan mobilization applied to hip internal rotation using a mobilization belt. Performed in 3 sets of 10 repetitions, twice weekly for 4 weeks, in addition to conventional physiotherapy.
223746309|NCT07181395|BEHAVIORAL|Straight Leg Raise Mulligan Mobilization|Mulligan mobilization applied to straight leg raise under manual traction. Performed in 3 sets of 10 repetitions (15-20 seconds hold), twice weekly for 4 weeks, in addition to conventional physiotherapy.
224192349|NCT05511155|OTHER|Oxygen therapy|Oxygen therapy will be given for 15 minutes with a non-rebreathing mask.
224192350|NCT00238108|DRUG|Melatonin|2,5 mg melatonin, by mouth, 1 per day, for 3-4 weeks
224192351|NCT00238108|DRUG|Placebo|Placebo
224309886|NCT03261986|RADIATION|Radiostereometric Analysis|RSA exams of the operative hip are received post-op day 1, and at 6 weeks, 3 months, 6 months, 1 year and 2 years following surgery
224309887|NCT03261986|PROCEDURE|total hip arthroplasty with RSA bead implantation|Patients receive RSA beads inserted into the bone surrounding the Trident II implant.
224309888|NCT02416414|DEVICE|QuantiFERON Monitor Assay|Assay to measure cell-mediated immune function using QuantiFERON Monitor assay.
224309889|NCT02416414|DEVICE|Existing methodology|Assay to measure cell-mediated immune function using existing methodology.
224309890|NCT03777423|DEVICE|PEEK framework partial dentures|Polymer-based framework recently introduced made of polyetheretherketone polymer frame combined with acrylic resin denture teeth and a conventional acrylic resin denture base.
224192352|NCT05844995|DRUG|Acetaminophen/Naproxen Sodium|Fixed dose combination of acetaminophen/naproxen sodium tablet will be administered orally.
224192353|NCT04615338|OTHER|no intervension|no intervention needed just observation and description
224192354|NCT02729350|BEHAVIORAL|Guided Relaxation video clip|This intervention is a 12-minute guided relaxation intervention for reducing pain and stress in adult inpatients with sickle cell disease.
224192355|NCT02729350|BEHAVIORAL|Sickle Cell Disease Experience Discussion|This intervention is a 12-minute sickle cell disease experience discussion.
224192356|NCT03727113|PROCEDURE|Optimization cohort|Recipients of an allogeneic hemopoietic stem cell transplant in Centers using an optimization/antibiotic strategy.
224192357|NCT03727113|PROCEDURE|Control cohort|Recipients of an allogeneic hemopoietic stem cell transplant in Centers using a classical strategy of administration of antibiotics.
224192358|NCT05872113|COMBINATION_PRODUCT|Hs-hWE cream|The cream was applied to the faces of subjects, the left facial area was put on the 0.5% Hs-WE cream.
224192359|NCT05872113|COMBINATION_PRODUCT|Placebo cream|The cream was applied to the faces of subjects, the right facial area was put on the placebo cream.
224192360|NCT03291249|DRUG|Foralumab|Anti CD3 mAb
224192361|NCT03291249|OTHER|placebo|Placebo oral solution
224192362|NCT03291249|DRUG|Omeprazole 20mg|Omeprazole is a proton pump inhibitor used to neutralize stomach PH
224192363|NCT02823587|OTHER|Pulmonary Rehabilitation|The exercise program will consist of an individual exercise prescription on the treadmill or bike, the initial intensity of 85% VO2max and active exercises or active-resistance for upper and lower limbs according to the capacity of each volunteer.
224192364|NCT02823587|OTHER|Control|No supervised exercise session, only will be informed at the beginning of the study to perform thirty minutes of physical activity of moderate intensity several days a week is associated with health benefits
224192365|NCT00702975|DRUG|Paclitaxel, Carboplatin and Bevacizumab,Erlotinib|4 cycles (or less in case of progression) with carboplatin AUC 6 -paclitaxel 200mg/m2 -bevacizumab 15 mg/kg i.v. At (early) progress Bevacizumab 15 mg/kg i.v. q 21 days plus Erlotinib 150 mg/day orally
224192366|NCT03207607|OTHER|Control snack|Isovolumetric (238.4g) gel snack prepared by real fruits (186.2kcal)
224192367|NCT03207607|OTHER|Maltodextrin snack|Isovolumetric (238.4g) gel snack with maltodextrin (271.8kcal)
224192368|NCT03207607|OTHER|Whey protein snack|Isovolumetric (238.4g) gel snack with whey protein (201.8kcal)
224192369|NCT03207607|OTHER|Oat snack|Isovolumetric (238.4g) gel snack with oats and maltodextrin (275.8kcal)
224192370|NCT03207607|OTHER|Coconut oil snack|Isovolumetric (238.4g) gel snack with coconut oil (276.4kcal)
223501226|NCT04174261|PROCEDURE|Remote Ischemic Preconditioning|Preprocedural remote ischemic preconditioning on the non-dominant arm
224192371|NCT03207607|OTHER|Snack skipping|no snack
224192372|NCT01686607|DRUG|Parenteral micafungin application|Parenteral
224192373|NCT01686607|DRUG|Other parenteral antifungal drugs|Parenteral
224192374|NCT02192307|DEVICE|Potassium oxalate|
224192375|NCT04575415|DRUG|Bevacizumab|Bevacizumab 15mg/kg or clinical routine dose by intravenous drip infusion on day 1 of a 21-day cycle
224192376|NCT04575415|DRUG|Erlotinib|Erlotinib 150mg, orally once a day
224192377|NCT04575415|DRUG|Gefitinib|Gefitinib 250mg, orally once a day
224192378|NCT04575415|DRUG|Icotinib|Icotinib 125mg three times a day
224192379|NCT04575415|DRUG|Afatinib|Afatinib 40 mg or clinical routine dose once daily
224192380|NCT04575415|DRUG|Dacomitinib|Dacomitinib 45mg or clinical routine dose once daily
224192381|NCT04575415|DRUG|Osimertinib|Osimertinib 80 mg once daily
224192382|NCT03176628|DIETARY_SUPPLEMENT|Basis|NR is a form of vitamin B3; Pterostilbene is a natural dietary compound and the primary antioxidant component of blueberries
224192383|NCT03176628|DIETARY_SUPPLEMENT|Placebo|Placebo capsule(s)
223501227|NCT04174261|DRUG|Clopidogrel|Preprocedural clopidogrel loading and standard dose thereafter
223501228|NCT07044869|PROCEDURE|FACILITATED POSITIONAL RELEASE TECHNIQUE|Participants in experimental group A receive FPRT as a main intervention along with piriformis stretches. 30 minutes' session starts with application of 10 minutes hot pack, followed by FPRT and stretches respectively. For FPRT, the patient position was prone with the hip flexion approximately (60°-90°) and abduction. The therapist was seated on the side that was affected, and the treated leg was hanging off the table with the knee bent resting on the therapist thigh. The painful tender area was felt in the piriformis muscle's belly around midway between the greater trochanter and the inferior lateral angle of sacrum. At the point when tender area was palpated, therapist applied ischemic pressure over the area with finger pads. Pressure hold for 1 minute and two repetitions were performed (2 minutes' pressure for whole was given). After that piriformis stretches were performed with 5reps\*5 sec hold\*1set.
223501229|NCT07044869|PROCEDURE|MANUAL MYOFASCIAL RELEASE TECHNIQUE|Experimental Group B participants received MFRT as a main intervention along with application of hot pack and piriformis stretches. They also received 30 min session started with application of hot pack for 10 minutes followed by MFRT and piriformis stretches. For application of MFRT patient was in prone lying position. The therapist was standing at the affected/unaffected side of the patient. Myofascial release was provided, using the therapist's palm, finger pads or elbow directly on the piriformis muscle, pressure was provided on the tender area directly and held for a while (60 seconds approx.) and 3 repetitions were performed. Back and forth little kneading motions were applied in accordance with the muscle fiber's direction. After MFRT piriformis stretches were performed with frequency of 5 repetitions \*5 second hold\* 1 set.
223501230|NCT07044895|OTHER|Diode laser and Immediate implant|patients with non-restorable teeth in the maxillary esthetic zone will be included in this prospective single-arm study. The non-restorable tooth will be atraumatically extracted and immediate implant placement will be placed. The extraction socket will be sealed with diode laser photocoagulation and customized healing abutments fabrication.
223501231|NCT07049133|OTHER|T-DXd toxicity marker identification|to find potential predictive markers associated with T-DXd-related toxicities
223501232|NCT07046052|OTHER|continuous infusion of levobupivacaine|Participants in this arm will receive a continuous infusion of levobupivacaine via a regional anaesthesia catheter placed in the PENG fascial space. The total dose over 24 hours will be equivalent in both arms of the study.
224192384|NCT06023511|DEVICE|Electrical muscle stimulation|While study subjects are connected to standard ICU monitors, electrical muscle stimulation will be applied at the level of the quadriceps muscle to induce palpable or visible muscle contraction. (No control group or sham procedure in this study).
224192385|NCT05268718|DRUG|Hollow gold and silver alloy cuprous oxide shell nano-shell hydrogel|Hollow gold and silver alloy cuprous oxide shell nano-shell hydrogel was excited by NIR laser to release functional silver ions, copper ions and ROS.
224192386|NCT05268718|DRUG|Voriconazole eye drops|Voriconazole eye drops (1%) were administrated to infectious eye very frequently (once half an hour)
224192387|NCT05268718|OTHER|Normal saline|To be placebo, normal saline were administrated to infectious eye
224192388|NCT06539078|OTHER|Maximal exercise test|Participants will undertake an incremental ramp test on a cycle ergometer to determine maximal oxygen uptake (V̇O2max) and the gas exchange threshold (GET). Throughout the exercise test, muscle oxygenation and deoxygenation will be monitored by NIRS.
224192389|NCT06539078|OTHER|3D Ultrasound|Muscle volume and morphological characteristics will be assessed via 3D ultrasound imaging.
224192390|NCT06539078|OTHER|Dynamometry|To determine the contractile properties of the knee extensors, participants will perform maximal isometric and isoinertial contractions of the knee extensors on a dynamometer.
224309891|NCT03777423|DEVICE|Cobalt- chromium framework partial dentures|It's a bio-compatible metal used in thin sections so less bulky, provide high strength and stiffness ,conduct heat and cold for a more natural experience, enable designs that minimize the covering of the gingival margins, allow for a stable denture base, and resistance to corrosion.Drawbacks of metal frameworks can include hypersensitivity, aesthetics because of metal metal display, oral galvanism, adverse tissue reactions, osteolysis of abutment teeth, and biofilm production
224309892|NCT01284621|DRUG|BI 10773|medium dose, oral administration
223591770|NCT03002311|DEVICE|Epharmix/CareSignal eHealth|The self-scheduling text and phone messaging system was built by Epharmix/CareSignal. Participants in the intervention group began receiving text or voice messages (for landlines) starting 1 hour following ED discharge if during normal business hours, or at 1000 the next business morning. Automated messages were sent up to 3 days in a row or until the participant responded or opted out. The phone system would ultimately connect them directly to their referral provider or clinic to schedule an appointment. Once participants hung up with the referral clinic, the intervention texted or called back to solicit the appointment date. If a date was entered, the system sent reminders at 14 days, 7 days, 3 days, and 1 day before the appointment. After the appointment, the intervention texted or called participants to confirm if they attended.
223591771|NCT01936415|DEVICE|Vanguard|A prospective randomized study where the patients are randomized to receive one of two prostheses (tibial components) with different coating: Vanguard pourous coating, Biomet and Regenerex® Primary Tibial Tray, Biomet. Both prostheses are available and approved by the FDA. The main difference between the implants is the coating of the tibial tray
223591772|NCT01936415|DEVICE|Regenerex|
223591773|NCT02618668|DRUG|Ketamine / Propofol Admixture|propofol-ketamine 3:1 mixture(%1 15 ml propofol + 1 ml 50mg/ml ketamine+4 ml saline in a 20-ml syringe which resulted in0.25 mg.ml-1 ketamine and 0.75 mg.ml-1 propofol
223591774|NCT02618668|DRUG|Propofol|2 mg/kg I.V
223591775|NCT00773890|DRUG|TRF-1101|once daily treatment with 300 mg orally for 12 weeks
223591776|NCT00773890|DRUG|Placebo|Daily treatment with TRF-1101 vehicle for 12 weeks
223591777|NCT03247725|OTHER|pain app|Pain Monitor app has been developed by a multidisciplinary pain expert panel, including physicians, psychologists, and nurses. Content has been validated in a previous study and usability has been shown to be excellent.
223591778|NCT03247725|OTHER|Treatment as usual (medical)|Patients will be offered the usual treatment for their pain, which is not changed by study participation
223591779|NCT04124003|DRUG|rosuvastatin|Specified dose on specified days
223591780|NCT04124003|DRUG|BMS-963272|Specified dose on specified days
223591781|NCT00320424|DRUG|Fondaparinux|
223591782|NCT05466331|OTHER|Mobile Tele-HCV Care|Study participants receive HCV care via telemedicine. Telemedicine appointments are performed on a mobile van.
224192391|NCT06539078|OTHER|Exercise test and occlusions|Participants will perform a series of moderate-intensity constant power output exercise bouts on a cycle ergometer following which the recovery rates of muscle V̇O2 will be determined via a series of intermittent arterial occlusions. Throughout all tests, pulmonary gas exchange and ventilation will be determined and muscle oxygenation and deoxygenation will be monitored by NIRS.
224192392|NCT06539078|OTHER|Exercise test in MRI|Exercise will be performed on a custom-built magnetic resonance-compatible cycle ergometer in supine position for determination of muscle phosphocreatine recovery kinetics using 31phosphorous magnetic resonance spectroscopy \[31P-MRS\].
224192393|NCT06539078|PROCEDURE|Muscle biopsy|A muscle biopsy will be obtained from the vastus lateralis using a modified Bergström needle technique with suction.
224192394|NCT04621227|DRUG|PF-06882961|120 mg and 200 mg BID
224192395|NCT04621227|DRUG|Rosuvastatin|10 mg single dose
224192396|NCT04621227|DRUG|Midazolam|2mg single dose
224192397|NCT02064374|DRUG|Metformin 500 mg q12h|Metformin will be supplied as 500 mg tablet to be administered orally.
224192398|NCT02064374|DRUG|Dolutegravir 50 mg q24h|Dolutegravir will be supplied as 50 mg tablet to be administered orally. To be taken once a day in the morning in Period 2 (Total daily dose 50 mg per day for Cohort 1 only)
224192399|NCT02064374|DRUG|Dolutegravir 50 mg q12h|Dolutegravir will be supplied as 50 mg tablet to be administered orally. To be taken 50 mg tablets every 12 hours in Period 2 (Total daily dose 100 mg per day for Cohort 2 only).
224192400|NCT05517291|DEVICE|paclitaxel-coated balloon angioplasty or bare mental stents implantation|paticipants who enrolled in this study will received paclitaxel-coated balloon angioplasty plus bailout stenting or primary bare mental stents implantation randomly
224192401|NCT03585894|OTHER|Sumatriptan|Receive intravenous infusion of sumatriptan
224192402|NCT03585894|OTHER|Ketorolac|Receive intravenous infusion of ketorolac
224309893|NCT01284621|DRUG|Ramipril|Medium dose oral administration on day 2-5
224309894|NCT01284621|DRUG|BI 10773|medium dose oral administration
224309895|NCT01284621|DRUG|Ramipril|Low dose oral administration on day 1
223591783|NCT05466331|OTHER|Enhanced Usual Care|Study participants are referred to a clinician in their area for HCV care.
224192403|NCT06412380|PROCEDURE|Implant insertion|All patients received a single Tapered Screw implant (Bioinnovation Dental®, Brazil). The implants were placed according to the manufacturer's instructions by using the appropriate burs with a final master drill of 3.5 or 4.5 mm in diameter by one senior oral surgeon. These implants were multi-threaded, and their surfaces were both sandblasted and acid etched. Of the 230 participants, 172 received a single 5 x 10-mm implant, and 58 received a 4 x 10-mm implant.
223591784|NCT01086371|OTHER|Rhythmic auditory stimulation|Recorded music with embedded beat set 10% above the subject's baseline walking cadence.
223501233|NCT07046052|OTHER|Programmed Intermittent Bolus of Levobupivacaine|Participants in this arm will receive a timed pre-set bolus dose of levobupivacaine via a regional anaesthesia catheter placed in the PENG fascial space. The total dose over 24 hours will be equivalent in both groups.
223501234|NCT07045272|BEHAVIORAL|Experimental|The intervention team provides lifestyle guidance to the subjects according to the behavioural intervention programme, and the subjects record information on diet, exercise and weight on the platform on a daily basis. Subjects are required to learn relevant health education knowledge on the platform by themselves, and they can also exchange experience in the group and receive motivational counselling from the instructors.
223501235|NCT07046546|PROCEDURE|Thyroid artery embolization|A minimally invasive procedure where one or more thyroid arteries are occluded to shrink the thyroid gland or thyroid nodules
223591785|NCT01086371|OTHER|Walking exercise|Subjects will be walking daily for a total of 20 minutes (may be broken down to smaller time periods.
223591786|NCT03768128|DEVICE|Journey™ II UNI Unicompartmental Knee System|"Journey™ II UNI UKS is a CE Marked medical device. The device has been designed to treat both medial and lateral unicompartmental disease.~It is a comprehensive system designed to allow surgeons to perform UKA. It is comprised of the following anatomic components: Oxidized zirconium femoral components Titanium tibial components with a grit-blasted surface Polyethylene tibial insert components The device is asymmetric and is available in oxidized zirconium to reduce wear and increase implant longevity."
223591787|NCT06362928|DEVICE|ATC System|The ATC System is designed to mechanically remove emboli and restore blood flow through the pulmonary arteries in patients experiencing acute PE
223501236|NCT07045610|DIAGNOSTIC_TEST|re-biopsy tumor with primary ALK tKI resistance for NGS|Lung cancer patients who initially use ALK TKI as first-line treatment will be invited to enroll and sign the consent form. Only those who meet the criteria for primary resistance or rapid progression will proceed with tumor sample collection for genetic analysis. Alternatively, patients who develop primary resistance or rapid progression after using ALK TKI and are about to undergo tumor re-biopsy can also sign the subject consent form to be included in this study.
223501237|NCT07044505|PROCEDURE|Uterine Lavage|Saline is introduced into the uterine cavity and retrieved during surgery to collect cells and fluid for downstream molecular and cellular analyses.
223501238|NCT07048184|DEVICE|Negative Pressure Wound Therapy (NPWT) Dressings|During wound closure, skin glue is not permitted as this interferes with the NPWT suction mechanism. The NPWT is a mesh-based dressing that will be applied following the transparent occlusive dressing as per the manufacturer's instructions. Patients assigned to NPWT will have their dressing connected to a suction device (ActiV.A.C.®, KCI) providing a constant negative pressure of 125mmHg and left in situ for between 5 and 7 days. The dressings and suction device are all CE-marked medical devices that are being used within their intended usage.
223501239|NCT07048184|DEVICE|Standard Absorbent Dressings|The wound will be closed as per the standard surgical technique and the operating surgeon's preference. Following wound closure of sarcoma tumour resection, standard absorbent dressing will be applied as per local protocols and the pre-op plan
223501240|NCT07056569|DEVICE|047_TD Dermatitis cream twice a day for 28 days|047\_TD Dermatitis cream will be applied twice a day for 28 days on the affected skin zone in sufficient amount of cream and let it dry.
223591788|NCT04802720|OTHER|Cognitive Behavioral Therapy for Cancer Caregivers (CBT-C)|"The sessions are outlined as follow:~1. psychoeducation, goal-setting, and describing the rationale for CBT (Session 1);~2. coping effectiveness training (Session 2);~3. identifying unhelpful cognitions and dysfunctional beliefs (Session 3);~4. challenging and restructuring unhelpful cognitions (Session 4);~5. behavioral activation within the limitations of the caregiving context (Session 5);~6. problem-solving (Session 6);~7. communication strategies and assertiveness training (Session 7);~8. consolidating gains, maintenance, and relapse prevention (Session 8)."
223591789|NCT04802720|OTHER|Emotion Regulation Therapy for Cancer Caregivers (ERT-C)|"The sessions are outlined as follow:~1. psychoeducation and motivation/dysregulation cue detection within caregiving contexts (Session 1);~2. attention regulation skills training (Sessions 1-2);~3. training in metacognitive skills (Sessions 3-4);~4. exposure to proactive living in the face of risk and loss while applying skills (Sessions 5-7);~5. consolidating gains, taking larger proactive steps, and relapse prevention (Session 8)."
223591790|NCT06015724|DRUG|Daratumumab|anti-CD38 monoclonal antibody (mAb)
223591791|NCT06015724|BIOLOGICAL|KRAS vaccine|Stimulon QS-21 and Targovax TG01
223591792|NCT06015724|DRUG|Nivolumab|anti-PD-1 (programmed cell death protein 1) monoclonal antibody (mAb)
224192404|NCT00995462|BEHAVIORAL|Lifestyle intervention seminars|The first sessions emphasize acquisition of new knowledge during interactive group seminars designed to maximize attendant's participation by adapting wellknown quiz-show or parlour games to deliver key concepts. A number of sessions are aimed at increasing self-efficacy through problem-solving, time-management strategies, individual self monitoring and goal-setting.During the second year, the intervention focuses on maintenance of healthy behaviour with empowerment of the participants using problem-solving, goal-setting, planning, and self-monitoring skills.
224192405|NCT04137926|DIAGNOSTIC_TEST|MicRNAs battery|for MCI due to AD diagnosis
224192406|NCT01548573|DRUG|Dexamethasone|Given PO
224192407|NCT01548573|PROCEDURE|Tandem autologous stem cell transplant|
224192408|NCT01548573|DRUG|Cisplatin|Given IV
224309896|NCT01284621|DRUG|Ramipril|Low dose oral administration on day 1
224309897|NCT01284621|DRUG|Ramipril|Medium dose oral administration on day 2-5
223591793|NCT01297725|PROCEDURE|Blunt right, sharp left|Blunt fascial entry on the right side of the midline and sharp fascial entry on the left side of the midline.
224192409|NCT01548573|DRUG|Doxorubicin|Given IV
224192410|NCT01548573|DRUG|Cyclophosphamide|Given IV or PO
224309898|NCT03630250|BIOLOGICAL|N. lactamica|Genetically modified N. lactamica
224192411|NCT01548573|DRUG|Etoposide|Given IV
224192412|NCT01548573|DRUG|Bortezomib|Given IV
224192413|NCT01548573|DRUG|Thalidomide|Given PO
224192414|NCT01548573|DRUG|Melphalan|Given IV
224192415|NCT05560230|DRUG|Clonidine|A single dose of intraoperatively administered intravenous clonidine 150 μg will be infused over 5-10 min., immediately after intubation
224192416|NCT05560230|DRUG|Isotonic saline|A single dose of administered intravenous isotonic saline will be infused over 5-10 min., immediately after intubation
224192417|NCT01249625|DEVICE|N95 Respirator|Participants in this arm will be asked to wear an N95 respirator for the extent of the 12 week study period.
224192418|NCT01249625|DEVICE|Medical/surgical mask|Participants in this arm will be asked to wear a medical/surgical mask for the extent of the 12 week study period.
224192419|NCT06172569|DEVICE|Spartan Stem, World Acetabular Cup and World Liner|"The Spartan Stem is a wedge-shaped fit and fill design stem with Titanium Plasma Spray(TPS) and Hydroxyapatite (HA) coating.~The World Acetabular cup is Porous coated and mated with cross-linked polyethylene World Liner"
224192420|NCT04833569|BIOLOGICAL|ICG-PDT|An 810 nm diode laser (A.R.C. laser GmbH, Nurnberg, Germany) with a power of 200 mW (continuous mode) and total energy of 4 J was used to excite the ICG by starting from the papilla for 30 s followed by the insertion inside the peri-implant pocket depth for 10 s from both buccal and lingual side moving to coronal direction. The treatment was applied according to the manufacturer's recommendation. The PDT was performed by a single operator in all test patients
224192421|NCT04833569|DEVICE|peri-implant mechanical debridement|The peri-implant mechanical debridement was done with the help of ultrasonic carbon tip (Vector, Durr Dental, Bietigheim-Bissingen, Germany).
224192422|NCT04391686|DIAGNOSTIC_TEST|indirect calorimetry|to determine and compare the resting energy expenditure of each group
224192423|NCT03032939|PROCEDURE|endotracheal intubation|standard endotracheal intubation of surgical patients after induction of anesthesia
224192424|NCT04666012|BIOLOGICAL|AdCLD-CoV19|Replication-defective human adenovirus type 5/35 vector based vaccine expressing S protein of SARS-CoV-2.
224192425|NCT01366846|OTHER|Avoidance of peanut|All participants will be assigned to peanut avoidance as per United Kingdom (UK) public health recommendations and will avoid exposure to peanut protein during the study until the last study visit when they will receive the Oral Food Challenge.
224192426|NCT00925509|PROCEDURE|Therapeutic assessment -Radio-surgical guidance.|"The first steps of the procedure include the production of a radiosurgical guide and the preparation of a mask in order to allow precise, non invasive repositioning of the guide.~Secondarily, the patient undergoes a CT-scan with the mask on and the radiosurgical guide in place. This provisional scan is used for preimplantation evaluation and drilling of the guide hole.~Under general anaesthesia, the mask is placed on the patient and the guide is fixed to the mask. A hole is drilled with a burr in the mandible through the hole in the guide. Implants are placed and the guide and mask are removed.~A second, post-implantation CT-scan is planned 3 months after implantation. Comparison of pre- and post-implantation CT-scans allows to evaluate the precision of the placement."
224192427|NCT05393830|BEHAVIORAL|Sleep Restriction|Three nights of sleep restricted to 4 hours per night.
224192428|NCT04162301|DRUG|CS3002|CS3002 tablet will be orally administered daily for 3 weeks followed by 1 week off treatment, defining a treatment cycle of 28 days in duration.
224192429|NCT02190968|BEHAVIORAL|Usual Depression Care|Usual Depression Care will be based on the Kaiser Permanente Adult Depression National Guidelines - an adaptation of STAR\*D (Rush et al., 2006) for antidepressant management and the IMPACT (Unitzer et al., 2002; 2008) model for therapy.
224192430|NCT02190968|BEHAVIORAL|Mindful Mood Balance|Mindful Mood Balance is an individually tailored, web-based version of Mindfulness-Based Cognitive Therapy, a manualized, group skills training program (Segal et al., 2002) that is based on an integration of aspects of cognitive therapy for depression (Beck, 1979) with components of the mindfulness-based stress reduction program (Kabat-Zinn, 1990). Patients participated in 8 internet sessions, each of which incorporates didactic and experiential learning, along with home practice of skills taught in the program.
224309899|NCT02392351|DEVICE|Renal Denervation (Vessix)|Percutaneous renal denervation using the Vessix Reduce™ Catheter and Vessix™ Generator
223501241|NCT07055672|COMBINATION_PRODUCT|Modified WalkFlex DB Splint (Intervention Arm)|"Application of the Modified WalkFlex Denis Browne (DB) Splint~Children with corrected idiopathic clubfoot will use the Modified WalkFlex DB Splint for maintenance. This splint allows knee and some hip movement and includes a detachable bar for walking. It will be used after Ponseti casting, and patients will be followed at 1 and 3 months to check splint tolerance, maintenance of correction (using Pirani score), and any signs of relapse"
223501242|NCT07055893|BIOLOGICAL|Rabies vaccine|"Receiving five doses of rabies vaccine manufactured by Sinovac using the Essen PEP schedule"
223501243|NCT07055893|BIOLOGICAL|Verorab®|"Receiving five doses of marketed rabies vaccine manufactured by Sanofi using the Essen PEP schedule"
223501244|NCT07055737|COMBINATION_PRODUCT|supervised aerobic activities|Participants performed supervised aerobic activities including warm-up (15 min), brisk walking, jogging, or cycling (30 min), squats on exercise ball (10 min), and cool down (5 min). Sessions were conducted three times a week
223501245|NCT07055737|COMBINATION_PRODUCT|Barre group performed light warm-up|Barre group performed light warm-up (15 min), lower abdominal crunches, leg raises, wall push-ups, and planks (3 sets each), followed by cool-down stretches (5 min). Sessions were conducted three times a week.
223501246|NCT02591368|PROCEDURE|Ligament reconstruction tendon interposition|In this procedure the trapezium is removed and one of the patient's own tendons (or portion of the tendon), usually the flexor carpi radialis or abductor pollicis longus, is passed through a drill hole in the thumb metacarpal and is used to suspend the first metacarpal base.
223501247|NCT02591368|PROCEDURE|Suspensionplasty with one-suture construct|In this procedure the trapezium is removed and an Arthrex mini tightrope system using Fiberwire suture is drilled across the first metacarpal to the second metacarpal and is used to suspend the first metacarpal base instead of a tendon.
223591794|NCT01297725|PROCEDURE|Blunt left, sharp right|Blunt fascial entry on the left side of the midline and sharp fascial entry on the right side of the midline.
223591795|NCT00558298|DRUG|risperidone|
224309900|NCT02392351|DEVICE|Renal Angiography|Percutaneous renal angiography
224309901|NCT02802631|DRUG|Minocin (minocycline) for Injection|Intravenous formulation of minocycline, a derivative of tetracycline
224309902|NCT02802631|OTHER|Placebo|Placebo - Normal Saline
223591796|NCT03539991|OTHER|Internet-Based Intervention|Complete online courses
224192431|NCT06568874|COMBINATION_PRODUCT|Virtual Reality (VR) Therapy|"Intervention: Patients in this group will receive therapy using VR technology. This involves engaging in various sensorimotor training exercises and tasks in an immersive virtual environment. The VR sessions are designed to be interactive and adaptive, providing real-time feedback to the user. The exercises will target the improvement of motor functions, coordination, and strength of the affected upper extremity.~Duration and Frequency: The specific regimen may involve sessions several times a week, with each session lasting between 30 to 60 minutes, over a period of several weeks or months, depending on the study design."
223501248|NCT02591368|PROCEDURE|Suspensionplasty with two-suture construct|In this procedure the trapezium is removed and two Arthrex mini tightrope systems using Fiberwire sutures are drilled across the first metacarpal to the second metacarpal and are used to suspend the first metacarpal base instead of a tendon.
223501249|NCT06933472|DRUG|AP301|Three times a day, administered orally with three meals at a daily dose level from 2.7g to 9.0g
223501250|NCT06933472|DRUG|AP301 Low Dose|Three times a day, administered orally with three meals at a daily dose level from 0.075g to 0.25g
223501251|NCT05642325|DRUG|Vamikibart|Participants will receive vamikibart IVT injection
223501252|NCT05642325|OTHER|Sham|Participants will receive a sham procedure that mimics an IVT injection.
223501253|NCT07125105|BEHAVIORAL|Adapted Physical Activity Only|This intervention consists of 10 individual Adapted Physical Activity (APA) sessions over five weeks, each lasting 45 to 60 minutes. Sessions are delivered by a trained APA instructor and focus on muscle strengthening, endurance, and body awareness. Exercises are tailored to the functional capacities and fatigability of patients living with Myasthenia Gravis. The delivery format includes a mix of in-person and remote sessions, with individualized adaptation based on patient needs.
223501254|NCT07125105|BEHAVIORAL|Adapted Physical Activity + Art Therapy|This intervention includes 10 individualized sessions of APA integrated with movement-based Art Therapy, delivered over five weeks (45-60 minutes each). The program incorporates creative and expressive methods (e.g., role play, improvisation, dramatized movement, dramatherapy) within a therapeutic physical activity framework. It is designed to support both physical functioning and psychosocial well-being. The artistic dimension is adapted to the patients' preferences and capacities, as identified during the baseline anamnesis interview.
223501255|NCT06152081|DEVICE|LumiCare rinse|The teeth being assessed will be cleaned of any debris ,plaque and calculus. The areas being assessed will be air dried. A dry field will be maintained using cotton rolls and a saliva ejector. Lumicare rinse will be applied onto the test areas for 30 seconds and the excess removed using a saliva ejector. The sites will then be rinsed with plain water for 10 seconds and excess will be removed using high volume suction. A blue curing light will then be held 1-2 inches from the test surfaces while the examiner assesses the surfaces for the presence or absence of fluorescent illumination.
223501256|NCT06152081|DEVICE|QLF Inspektor Pro Imaging|The teeth being assessed will be cleaned of any debris ,plaque and calculus. The areas being assessed will be air dried. A dry field will be maintained using cotton rolls and a saliva ejector. The QLF device will be positioned over the tooth surface to be tested and an image will be taken. The images will be stored automatically and assessed by the examiners for the presence of green fluorescence using the QA2 program (Version 1.25, Inspektor Research systems BV, Amsterdam, The Netherlands) . The trend in green fluorescence will also be calculated using this software algorithm.
223512074|NCT06549868|BEHAVIORAL|Yoga-based bedtime routine|"Dyads in the yoga intervention group receive a picture book outlining a bedtime-themed yoga routine and are instructed to incorporate it into their bedtime routine at least four nights per week for four weeks. The routine guides children through a sequence of yoga poses, starting with the mountain pose and ending in child's pose, designed to calm them as the story progresses. Parents are given a bedtime diary to record the date, whether the child completed the yoga routine each evening, and any comments about their experience with the book.~At week 6, families return to the lab, complete anthropometric assessments and questionnaires, and are fitted with accelerometers to wear for the next week. The accelerometers are returned and data is downloaded a week later. Families are then encouraged to continue using the yoga routine as often as they wish for an additional four weeks, although the frequency of use is not tracked during this maintenance period."
223512075|NCT04739345|DRUG|Pentoxifylline|400 mg of pentoxifylline orally TID with the standard COVID-19 protocol of the Egyptian Ministry of Health
223512076|NCT03159442|DRUG|AZD8871|Powder for inhalation administered via single dose DPI 300 and 600 µg/inhalation.
223512077|NCT03159442|DRUG|Placebo|Powder for inhalation administered via single dose DPI
223512078|NCT05725525|BEHAVIORAL|Remote PCIT augmented with wearable devices|Participants will be enrolled in remote PCIT and be asked to wear a Garmin watch throughout the course of the study in order to measure biometric fluctuations
223512079|NCT05756309|DEVICE|Electrocardiogram measurements by holter device and patch-type electrocardiographic at the same time|The patient is measured electrocardiogram simultaneously through a holter device and patch-type electrocardiograph
223512080|NCT01558375|DRUG|Water for injection|Placebo syringes will contain 0.67ml of sterile water for injection. This will be injecteda daily for 12 weeks.
223512081|NCT01558375|DRUG|Anakinra|Anakinra will be supplied in single use pre-filed glass syringes with 27-gauge needles. Anakinra syringe will contain 100mg of anakinra at a volume of 0.67 ml. This will be injected subcutaneously daily for 12 weeks.
223512082|NCT05823883|DRUG|DW6014|"Drug: DW6014 Single oral administration of DW6014 in fed condition~Drug: Empagliflozin and Metformin Combination oral administration of Empagliflozin and Metformin in fed condition"
223512083|NCT05813834|PROCEDURE|Genicular Nerves Block|US guided genicular nerves block
223512084|NCT02777190|DRUG|Misoprostol|Comparing dosing of misoprostol 25 mcg orally every 2 hours versus 25 mcg vaginally every 4 hours.
223512085|NCT00707304|DRUG|Talactoferrin|Oral, 1.5 grams twice per day
223512086|NCT00707304|DRUG|Placebo|Oral, twice per day
223591797|NCT03539991|OTHER|Meeting|Participate in virtual meetings
223591798|NCT03539991|OTHER|Survey Administration|Ancillary studies
223591799|NCT04228094|OTHER|TDApp1: an eHealth intervention|TDApp1 is a tool that uses GRADE heuristics to formulate participatory, individualized and automated therapeutic recommendations for patients with Attention Deficit Hyperactivity Disorder
224192432|NCT06568874|DIAGNOSTIC_TEST|Conservative Treatment|"Intervention: Patients in this group will receive traditional rehabilitation therapies, which may include:~Physical Therapy (PT): Exercises and activities aimed at improving strength, flexibility, and coordination of the upper limb.~Occupational Therapy (OT): Functional task training to enhance daily living skills and independence, focusing on the use of the upper extremity.~Manual Therapy: Techniques such as massage or joint manipulation to improve mobility and reduce pain.~Home Exercise Programs: Prescribed exercises to be performed at home to reinforce therapy sessions.~Duration and Frequency: Similar to the VR group, this regimen may involve regular sessions several times a week, with each session lasting between 30 to 60 minutes, over a comparable period."
224192433|NCT00558831|DRUG|Benzoyl Peroxide|Benzoyl Peroxide 2.5%
224192434|NCT00558831|DRUG|Moisturizing Lotion|
224192435|NCT06455930|DEVICE|Stand-on ride-on power mobility device|Children will receive the adapted toy car (individually-adapted stand-on PMD) to take home and use for three months. PMD will be used at their house and familiar environments to the family (e.g., neighborhood, parks, schools).
223501257|NCT00652132|DRUG|cisplatin|
223501258|NCT00652132|DRUG|sodium thiosulfate|
223501259|NCT05208047|DRUG|CGT9486 plus sunitinib|Participants will receive both CGT9486 and sunitinib orally until study stopping rules are met.
223501260|NCT05208047|DRUG|CGT9486|Participants will receive CGT9486 until steady state then both CGT9486 and sunitinib orally until study stopping rules are met.
223501261|NCT05208047|DRUG|Sunitinib|Participants will receive sunitinib until steady state then both sunitinib and CGT9486 orally until study stopping rules are met.
223501262|NCT05208047|DRUG|Sunitinib|Participants will receive sunitinib orally until study stopping rules are met.
223501263|NCT05208047|DRUG|Midazolam|Participants will receive a single-dose of midazolam on Day 1 and Day 16
223501264|NCT05208047|DRUG|CGT9486 plus sunitinib|Patients will receive CGT9486 orally starting on Day 2 and sunitinib starting on Day 16 until study stopping rules are met.
223501265|NCT06964451|PROCEDURE|Extraction tooth|Extraction of MIH Grade 4 molar
223501266|NCT05718518|DRUG|ASC11 tablets|"Part 1: Subjects will receive ASC11 tablets on single ascending doses with proposed dose levels of ASC11 tablets: 100mg (cohort 1), 200 mg (cohort 2), 400mg (cohort 3) and 800 mg (cohort 4).~Part 2: Subjects will receive ASC11tablets 100 to 300 mg (including 3 cohorts) and ASC11 tablets 300 mg(cohort 4) twice daily (BID) for 5 consecutive days and receive a single dose in the early morning of Day 6.~Part 3: Subjects will be randomized to receive ASC11 tablets two single 200 mg or 300 mg doses (fed or fasted)"
223501267|NCT05718518|DRUG|Placebo|Part 1 and 2: Subjects will be randomized to receive placebo.
223501268|NCT05718518|DRUG|RTV tablets|"Part 1: Subjects will receive RTV tablets on 100 mg (cohort 1-4). Part 2: Subjects will receive RTV tablets 100 mg (including 3 cohorts) twice daily (BID) for 5 consecutive days and receive a single dose in the early morning of Day 6.~Part 3: Subjects will be randomized to receive two single 100 mg doses (fed or fasted)"
223501269|NCT02188732|BEHAVIORAL|CBHH+AT|"Community Based Health Home + Automated Telehealth (CBHH+AT):~Community-Based Health Home (CBHH) PLUS Automated Telehealth: a wireless telehealth device programmed with psychiatric content corresponding to the primary psychiatric diagnosis, and medical content tailored to the primary medical diagnosis. Daily interactive sessions last 5-10 min. Branching logic tailors questions or feedback to the user's responses (e.g., if a participant endorses medication nonadherence, a question appears asking why medications were not taken). The device automatically provides specific instructions to participants demonstrating signs of high risk."
223501270|NCT02188732|BEHAVIORAL|CBHH+SMT|Illness Management and Recovery (IMR) for psychiatric illness combines (1) psychoeducation, which improves knowledge about mental illness management, (2) behavioral tailoring, which improves medication adherence, (3) relapse prevention training, which decreases relapses and rehospitalizations, and (4) coping skills training, which reduces distress related to symptoms. Illness Management and Recovery (I-IMR) by adding chronic medical illness self-management to psychiatric illness self-management. For each psychiatric self-management skill module, there is a corresponding medical illness self-management training component using established methods in self-management of common chronic health conditions (e.g., diabetes, hypertension, congestive heart failure, chronic obstructive pulmonary disease, etc.).
223501271|NCT02188732|BEHAVIORAL|CBHH|Community-based Health Home (CBHH): Each team has a staff-to-participant ratio of approximately 1:12, with each team serving approximately 120 participants with SMI using person-centered planning and recovery-oriented, flexible service models. Each team provides mobile outreach and includes a team leader; a peer counselor; a psychiatric nurse coordinator; a clinical care coordinator; specialists in substance abuse (dual diagnosis), community integration, rehabilitation, employment, and housing; and a medical nurse practitioner (MNP) and a health outreach worker (HOW).
223501272|NCT06519175|OTHER|Conservative treatment|Patients are provided with physiotherapy support and the provision of prostheses with the goal of ensuring as much walking functionality as possible.
223501273|NCT06519175|PROCEDURE|Single or multi-stage surgery|Correction of the deformity is pursued by one or more surgical procedures with the timing and the techniques (growth modulation, acute correction, gradual correction, soft tissues procedures, combined techniques) chosen according to the surgeon's preference to achieve the maximum possible walking functionality without orthopedic aids.
223501274|NCT06519175|PROCEDURE|Amputation|Limb surgery, whether or not associated with realignment or soft-tissue surgery, is performed, aimed at providing the maximum possible walking function through a prosthesis.
223501275|NCT05417113|DRUG|Liposomal bupivacaine|liposomal bupivacaine
223501276|NCT05417113|DRUG|Bupivacaine|bupivacaine 0.25% in ESP blocks
223501277|NCT01022580|DRUG|Infasurf surfactant (ONY, Inc.)|Late doses of Infasurf 3ml/kg will be given to infants on study days 0, 2, 4, 6 and 8 as long as infant remains intubated.
223501278|NCT01022580|DRUG|Sham (No Treatment)|Late doses of Sham (No treatment) will be given to infants on study days 0, 2, 4, 6 and 8 as long as infant remains intubated.
223501279|NCT00637182|DRUG|Anastrozole|
223501280|NCT05539508|BEHAVIORAL|Psychophysical evaluation|All participants will be required to perform a short experiment on a computer (15 minutes) where they will look at different photographs of scenes of different luminance and spatial frequencies. They will have to perform various tasks on these images using the keys on the keyboard.
223501281|NCT00461968|DRUG|Ezetimibe and Simvastatin|
223501282|NCT03600129|PROCEDURE|Qadratus Lumborum Block|Bilateral, ultrasound - guided Quadratus Lumborum Block
224309903|NCT04579016|OTHER|PAIGE2 lifestyle intervention|Education session during pregnancy. provision of fitness tracker, referral to commercial weight management organization, text and phone support
224309904|NCT04579016|OTHER|Standard care|Care routinely provided to all pregnant women diagnosed with GDM
224192436|NCT04926467|DRUG|Anakinra|"Pre-operative treatment: Nab-paclitaxel (125 mg/m2), gemcitabine (1000 mg/m2), and cisplatin (25 mg/m2) will be given on Day 1 and 8 of a 21-day cycle. Patients will receive anakinra 100 mg injection twice a day starting on day 1 of chemotherapy. Anakinra will be self-administered by the patients and will be discontinued 2 days prior to surgery. Total number of cycles = 4.~Post-operative treatment: 5-Fluorouracil (2400 mg/m2 CI for 48 hours), oxaliplatin (85 mg/m2), and irinotecan (150 mg/m2) will be given once every 2 weeks (1 cycle =14 days). Patients will receive anakinra 100 mg injection subcutaneously twice a day starting on day 1 of chemotherapy (initiated within 4-8 weeks after surgery). Anakinra will be self-administered by the patient throughout the treatment without any break. Total number of cycles = 8."
224309905|NCT02377427|DRUG|Mepolizumab|Mepolizumab is supplied as 100 mg lyophilised cake in sterile vials for subcutaneous administration in upper arm or thigh. The vial will be reconstituted with sterile water for injection prior to individual use.
223501283|NCT03600129|DRUG|30 milliliters of 0.375% Ropivacaine|30 milliliters of 0.375% Ropivacaine used for Quadratus Lumborum Block
223501284|NCT03600129|DRUG|30 milliliters of 0.9% NaCl|30 milliliters of 0.9% NaCl used for Quadratus Lumborum Block
223501285|NCT04529980|DIETARY_SUPPLEMENT|Lactobacillus rhamnosus GG (LGG) Probiotic|Lactobacillus rhanmosus GG(LGG®)(Culturelle) is an over the counter dietary supplement that can help to restore the balance in the gut by promoting colonization to support better digestion and immune health.
223501286|NCT04529980|DIETARY_SUPPLEMENT|Placebo|Placebo
223501287|NCT01500096|DRUG|American ginseng|American ginseng 1000 mg/day and 3000 mg/day will be evaluated in the intervention arms for this study. Participants will be randomized to American ginseng 1000 or 3000 mg/day capsules taken daily for four weeks.
223501288|NCT01500096|DIETARY_SUPPLEMENT|Placebo for American ginseng|"Placebo for American ginseng 1000 mg/day and 3000 mg/day will be evaluated in the control arms for this study. Participants will be randomized to placebo for American ginseng 1000 or 3000 mg/day capsules taken daily for four weeks.~Arms: Placebo for American ginseng 1000 mg/day, Placebo for American ginseng 3000 mg/day"
223501289|NCT04649554|DEVICE|Exablate treatment|Ablation
223501290|NCT04651088|DRUG|Potassium citrate|Slow release potassium citrate UroCit-K. Participants will take 20mEq twice daily.
223501291|NCT04651088|DRUG|Sodium bicarbonate|650mg tabs. Take 3 tabs twice daily.
223501292|NCT04651088|DIETARY_SUPPLEMENT|Litholyte|One packet is taken with 170ml of water. Two packets daily.
223501293|NCT04651088|DIETARY_SUPPLEMENT|Crystal Lite|The classic lemonade contains 21.7mEq/liter of alkali Therefore, patients will take 2 litres daily to have the 40mEq of alkali daily needed.
223591800|NCT00880594|DRUG|Desipramine|"Desipramine 25 mg/day administered in the evening. Dosing may be increased dependent upon side-effects and clinical response to a maximum of 100 mg/day. Absent significant side-effects, all patients are increased at the one week visit to 50 mg/day at bedtime if they have not achieved a report of Adequate relief. Thereafter, up to week 4, the daily desipramine dose may be increased weekly by 25 mg up to the 100 mg/d maximum."
223591801|NCT00658814|DRUG|Azacitidine|Given IV or SC during induction; given SC during consolidation and maintenance
223591802|NCT00658814|DRUG|Gemtuzumab Ozogamicin|Given IV
224192437|NCT04761523|BEHAVIORAL|Dietary intervention: reduced fat diet|Participants will receive a dietary intervention, and will be proposed to adhere to a diet with a 15% fat, 65% carbohydrate, 20% protein content.
224309906|NCT01377376|DRUG|ARQ 197 and Erlotinib|Oral twice daily administration of ARQ197 and oral once daily administration of erlotinib
224309907|NCT01377376|DRUG|Placebo and Erlotinib|Oral twice daily administration of placebo and oral once daily administration of erlotinib
224309908|NCT05596565|OTHER|Supervised Exercise by a physiotherapist via face to face|"Participants in group-1 will be included in an exercise program for 6 weeks, 2 days a week and 45 minutes each session with supervised by a physiotherapist via face to face.~Participants in group-2 will be included in an exercise program for 6 weeks, 2 days a week and 45 minutes each session with supervised by a physiotherapist via video conference"
223501294|NCT04651088|DRUG|Potassium Bicarbonate|20 mEq tablets, one tablet twice daily
223501295|NCT03706352|PROCEDURE|tunneling epidural catheter|The epidural needle was used to horizontally tunnel the catheter for a length of five centimeters on either side of the insertion point.
223501296|NCT00229216|DRUG|Tinidazole|
223501297|NCT01734928|DRUG|Pomalidomide|Pomalidomide 4 mg will be taken orally on Days 1-14 of a 21-day cycle.
223501298|NCT01734928|DRUG|Bortezomib|Bortezomib 1.3 mg/m2 will be administered subcutaneously on Days 1, 4, 8 and 11 of 21 days for cycles 1 -8 and on Days 1, 8 of 21 days for cycle 9 and onward until disease progression.
223501299|NCT01734928|DRUG|Dexamethasone|Dexamethasone 20 mg/day \[≤ 75 years old\] or 10 mg/day \[\>75 years old\] will be taken orally on Days 1, 2, 4, 5, 8, 9, 11, 12 of 21 days for cycles 1-8 and on Days 1, 2, 8, 9 of 21 days for cycles 9 and onward until disease progression.
223501300|NCT02372032|PROCEDURE|percutaneous lumbar discectomy|process percutaneous lumbar discectomy
223501301|NCT02372032|PROCEDURE|ozone therapy|percutaneous intradiscal ozone injection
223501302|NCT02760511|DIETARY_SUPPLEMENT|Anthocyanin|Capsules with different anthocyanin content
223501303|NCT02760511|DIETARY_SUPPLEMENT|Placebo|Placebo capsules
223501304|NCT01765621|OTHER|DDI+ System and Pharmacogenetic Data|
223501305|NCT03587116|DRUG|Standard of Care FIX Replacement therapy|There is no investigational product being administered. Subjects will be administering their own standard of care FIX replacement therapy.
223591803|NCT06401044|DRUG|AMG 732|SC injection
223591804|NCT06401044|OTHER|Placebo|SC injection
224309909|NCT01356264|BEHAVIORAL|multimodal prehabilitation|multimodal prehabilitation program based on exercise, supplemental nutrition and psychological support starting 3-5 weeks before surgery and continuing postoperative for up to 8 weeks
224309910|NCT01356264|BEHAVIORAL|multimodal prehabilitation|multimodal prehabilitation program based on exercise, supplemental nutrition and psychological support beginning postoperative and continuing for up to 8 weeks
224309911|NCT02342639|DRUG|Rifaximin|550mg pills
224309912|NCT02342639|DRUG|Placebo|Placebo pill
224192438|NCT04761523|BEHAVIORAL|Dietary intervention: standard healthy diet|Participants will receive a dietary intervention, and will be proposed to adhere to a diet with a 30% fat, 50% carbohydrate, 20% protein content.
224192439|NCT02846987|DRUG|Abemaciclib|
224192440|NCT03162276|BEHAVIORAL|Inquiry Based Stress Reduction (IBSR) program|"The IBSR (Inquiry-based stress reduction) intervention, developed by Byron Katie, trains participants to reduce their perceived level of stress by self-inquiry of their thoughts and beliefs connected to stressful circumstances or symptoms. This meditative process, named The Work, enables the participants to identify and question the stressful thoughts that cause their suffering. The core of IBSR is simply four questions and a turnaround, which is a way of experiencing the opposite of what the participant believes. This process is simple, powerful and provides skills for self-inquiry and management of stressful thoughts that can be easily implemented in daily life"
224192441|NCT03162276|BEHAVIORAL|Control|At end of intervention, the control group will receive a brief intervention consisting of a home kit for practicing IBSR techniques.
224192442|NCT01974869|DRUG|Anti-tumor necrosis factor alpha agents|Treatment with biologics
224192443|NCT03525769|DIAGNOSTIC_TEST|FibroTouch|"FibroTouch is a non-invasive image-guided integrated detection system, providing an integrated detection and comprehensive evaluation program for hepatic fibrosis and hepatic steatosis.~The FibroTouch is a completely non-invasive liver testing device that can obtain the following results: 1. Liver Fibrosis: quantitative results of hepatic fibrosis; 2. Fatness: quantitative result of hepatic steatosis; 3. Liver tissue morphology: detected by ultrasound imaging."
224192444|NCT02395094|BEHAVIORAL|Child Life|"Child Life preparation in surgical daycare can include:~* role-play using dolls and medical equipment (either toy doctor kits or true medical materials)~* the use of books/storyboards that show pictures of operating room and daycare routines~* teaching \& rehearsing coping and relaxation skills such as deep breathing and guided imagery~* age-appropriate explanation of what to expect throughout the day in SDCU"
224192445|NCT01544465|BEHAVIORAL|Structured Physical Activity|Rehabilitation evaluation and 8 weeks of physical therapy
224192446|NCT01544465|BEHAVIORAL|Sleep hygiene education|Educational materials on insomnia published by the American Academy of Sleep medicine
224192447|NCT00447265|DRUG|Etanercept|1.) Immune suppressant. 2.) Tumor necrosis factor (TNF) inhibitor.
224309913|NCT02418663|DRUG|Fluid challenge (250 ml Lactated Ringer's solution)|"When VE is prescribed to a patient, a fluid challenge of 250mL Lactated Ringer's solution will first be administered. The ccNexfin system will be used to predict FR (SV increases by at least 15% in response to a fluid challenge). The remaining amount of fluid ordered by the treating team will then be administered, and SV will again be measured.~Additionally, a daily fluid challenge with 250mL of Lactated Ringer's will also be administered, with FR recorded as above"
223501306|NCT03587116|DRUG|Standard of Care FVIII Replacement therapy|There is no investigational product being administered. Subjects will be administering their own standard of care FVIII replacement therapy.
223501307|NCT05266950|BIOLOGICAL|CI-135 CAR-T cells (0.5 x 10^6 CAR-T+ cells/kg，1.0 x 10^6 CAR-T+ cells/kg)|Recommended lymphodepletion regimen: cyclophosphamide (250 mg/m2/d, ×3d) and fludarabine (30 mg/m2/d, ×3d). If the patient has a hematological toxicity of grade 3 or higher, the alternative regimen is: cyclophosphamide (125mg/m2/d, ×3d) and fludarabine (15 mg/m2/d, ×3d). During lymphodepletion, physicians can give anti-myeloid drugs such as demethoxydaunorubicin or daunorubicin as appropriate.
223501308|NCT04165980|DEVICE|transcranial direct current stimulation|Transcranial direct current stimulation delivers a low intensity current of up to 4 mA per session through small and circular shaped electrodes applied over the scalp. This induces a weak but focal electrical field that may modify the excitability of the underlying cortical target in a polarity and activity dependent fashion.
223501309|NCT01778985|DRUG|Premarin|
223501310|NCT01778985|OTHER|Placebo|
223501311|NCT02379897|OTHER|Diet|
223501312|NCT06514248|DEVICE|V5med Lung AI|"During the second reading session (concurrent read), the radiologist will be presented with a standard appearing CT with CADe marks placed on the left window and the same original without any AI mark with be display on the right window. Deeming a nodule, the radiologist will mark location. These may or may not correspond to the locations of the CADe markers. As in the baseline study, the radiologist will assign a level of suspicious to each mark and provide a Lung-RADS score and the size of longest dimension."
223501313|NCT03879109|DRUG|Chemotherapy FOLFIRINOX, 6 cycles|"* oxaliplatin: 85 mg/m2~* irinotecan: 180 mg/m²~* folinic acid: 400 mg/m2~* 5FU : 400 mg/m2 (bolus)~* 5FU : 2400 mg/m2 (continuous infusion)"
224192448|NCT00447265|DRUG|Lupus Treatment- Standard of Care|Individualized standard of care treatment for lupus with corticosteroids and with mycophenolate mofetil (MMF), mycophenolic acid, or azathioprine (AZA)
224192449|NCT00447265|DRUG|Placebo|
224192450|NCT00910065|DRUG|D,L-lysine acetylsalicylate (Aspirin, BAY81-8781) 500 mg IV|Single IV dose of aspirin at a dose of 500 mg as bolus infusion injection in approximately 30 seconds through the vein on Day 1.
224192451|NCT00910065|DRUG|D,L-lysine acetylsalicylate (Aspirin, BAY81-8781) 250 mg IV|Single IV dose of aspirin at a dose of 250 mg as bolus infusion injection in approximately 30 seconds through the vein on Day 1.
224309914|NCT02212379|DRUG|raltegravir and etravirine|"Raltegravir (RAL, ISENTRESS®) 400 mg tablets will be administered as one 400 mg oral tablet PO twice daily (800 mg per day) after a meal.~Etravirine (ETR, INTELENCE®) 200 mg tablets will be administered as one 200 mg oral tablet PO twice daily (400 mg per day) after a meal."
223501314|NCT03879109|RADIATION|Radiochemotherapy|Reirradiation consists in conformational intensity modulated external irradiation (Intensity-modulated radiotherapy Volumetric Modulated Arc Therapy or tomotherapy) delivering a 30.6 Gy dose with high-energy photons in fractions of 1.8 Gy per day (17 fractions) 5 days a week With Concomitant chemotherapy including Capecitabine 1600 mg/m²/day, five days a week.
223501315|NCT03879109|PROCEDURE|Surgery|"Surgery will be performed at:~* Arm A: 8 weeks (±1) after the end of treatment~* Arm B: 6 weeks (±1) after the end of treatment~Surgical procedures are defined into three categories:~* Total mesorectal excision (TME)~* Extended-TEM (e-TME)~* Pelvic exenteration (PE)"
223501316|NCT03012945|DRUG|Combined epidural-general anesthesia|Combined epidural-general anesthesia and postoperative epidural analgesia. General anesthesia is performed as that in the general anesthesia group. Epidural anesthesia is performed with ropivacaine. Epidural analgesia is performed with a mixture of ropivacaine and sufentanil.
223501317|NCT03012945|DRUG|General anesthesia|General anesthesia and postoperative intravenous analgesia. General anesthesia is performed with propofol induction and propofol and/or sevoflurane maintenance. Intravenous analgesia is performed with morphine.
223501318|NCT04197505|BEHAVIORAL|FLIR E95 camera|Video will be recorded during the thermal reading for later computer analysis. The following variables will be analyzed: (1) the difference between the mean temperature between the injured and healthy extremities, (2) the difference between the maximum temperatures of both the injured and healthy extremities (ΔTmax), and (3) the difference between the area covered by each isotherm in both the injured and uninjured extremities (Δpix). FLIR software tools and MATLAB software will be used for the analysis.
223501319|NCT06166641|PROCEDURE|Surgical procedure at operating room|A surgical procedure in an operating room is a medical intervention that involves making incisions or using minimally invasive techniques to treat a specific condition or perform a diagnostic procedure. The operating room, also known as the operating theater or surgical suite, is a sterile environment specifically designed to minimize the risk of infection and ensure the safety of both the patient and the surgical team.
224192452|NCT00910065|DRUG|Acetylsalicylic acid (Aspirin, BAYe4465) 300 mg Tablet|Single oral dose of aspirin tablet at a dose of 300 mg on Day 1.
224192453|NCT05556031|OTHER|Standard care|Standard clinical care
224192454|NCT00317031|DRUG|Acamprosate or Naltrexone|mg\&d 90 days
224192455|NCT04992780|RADIATION|Hypo-Fractionation|62.5 Gy in 25 fractions of 2.5 Gy/fraction
223501320|NCT05226689|DEVICE|POROUS TIBIA BASEPLATE W/ JRNY LOCK|Fixed-bearing POROUS TIBIA BASEPLATE W/ JRNY LOCK and a Legion cruciate-retaining High-Flex or Deep-dish XLPE tibial insert
223501321|NCT00088881|BIOLOGICAL|rituximab|Given IV
223501322|NCT00088881|DRUG|prednisone|Given orally
223501323|NCT00088881|DRUG|cyclophosphamide|Given IV
223501324|NCT00088881|DRUG|doxorubicin|Given IV
223501325|NCT00088881|DRUG|vincristine|Given IV
223501326|NCT00088881|RADIATION|indium In 111 ibritumomab tiuxetan|Given IV
223501327|NCT00088881|RADIATION|radiation therapy|Undergo radiotherapy
223501328|NCT00088881|PROCEDURE|positron emission tomography|Undergo PET scans
223501329|NCT04567355|BEHAVIORAL|Migraine Manager|Answers provided during the online assessment will result in certain intervention recommendations. Once assessments are completed, a treatment plan will be automatically generated for patient and parent guidance.
223501330|NCT05966597|BEHAVIORAL|Written persuasive leaflet|Additional written behavioural persuasive technique leaflet and a standard referral leaflet provided at the end of the home-based health screening.
223501331|NCT05966597|BEHAVIORAL|Standard referral leaflet|Standard referral leaflet provided at the end of the home-based health screening.
223501332|NCT06797466|PROCEDURE|3D imaging technique on the PCNL|Establishing a percutaneous access route for the stone is the first and most important step in PCNL surgery. Choosing the perfect route, position and direction largely depends on surgical experience and the ability to understand renal/peri-renal anatomy. In general, a good CT scan of the abdomen and pelvis and an experienced surgeon are sufficient, but this requires significant time in the learning curve. The aim of our study is to investigate the effect of 3D imaging technique on the PCNL learning curve in specialist training.
224192456|NCT04992780|RADIATION|Standard-Fractionation|60 Gy in 30 fractions of 2 Gy/fraction
224192457|NCT01201122|DRUG|Mesalamine|"Dosing: The current standard of care for pediatric UC is 75mg/kg/day of mesalamine (Pentasa) and should be in multiplications of 500mg (half sachets).~Patients will be randomized in blocks of six stratified by weight groups: 15- \<30 kg, 30-40kg, \>40kg.~For body wt. 15- \<20kg Arm: Once daily, 1000 mg (morning) and Placebo (0.5 sachet) (evening). Arm: Twice daily, 500mg (morning) and 500mg (evening).~For body wt: 20- \<30 kg Arm: Once daily, 1500mg (morning) and Placebo (0.5 sachet) (evening). Arm: Twice daily, 1000mg (morning) and 500mg (evening).~For Body wt. 30- \<40 kg Arm: Once daily, 2000mg (morning) and Placebo (1 sachet) (evening). Arm: Twice daily, 1000mg (morning) and 1000mg (evening).~For body wt. ≥40 kg Arm: Once daily, 3000mg (morning) and Placebo (1.5 sachet) (evening). Arm: Twice daily, 1500mg (morning) and 1500mg (evening)."
224192458|NCT03724422|RADIATION|Radiation|A dose of 500cGy will be delivered in 1 fraction to the isocenter. Radiation will be administered no later than 72 hours postoperatively
224192459|NCT03716440|OTHER|Nature exposure|Participants will view images of nature.
223501333|NCT06550453|DRUG|Pabolizumab+ bevacizumab and CapeOX (bevacizumab + oxaliplatin + capecitabine)|"Pabolizumab is an lgG4 subclass monoclonal antibody humanized against PD-l molecules thatblocks the immune escape mechanism of cancer cells by inhibiting the PD-l receptor oflymphocytes, thereby allowing the immune system to destroy them.~In the single-arm study, all enrolled patients received a combination of chemotherapy and immunotherapy, as outlined below:~Pembrolizumab:~Day 1：Pembrolizumab injection 200mg was administered once and repeated every 21 days, expected to last 2-4 cycles. Two vials (200 mg) of pembrolizumab injection should be diluted into 100-200 mL of saline, and the infusion time should be more than 30 minutes.~Chemotherapy (CapeOX regimen):~Day 2: Bevacizumab (7.5 mg/kg) + Oxaliplatin (135 mg/m2) + Capecitabine (1 g/m2, did, d1-d14). Treatment repeated every 3 weeks (q3w) until disease progression or intolerable toxicity."
223501334|NCT03761914|BIOLOGICAL|galinpepimut-S|"* Induction phase: the first two GPS + Montanide injections are administered Q3W on Week 0 and Week 3. Thereafter, GPS + Montanide is co-administered with pembrolizumab Q3W (Weeks 6, 9, 12, 15, 18).~* Early immune booster phase: A single administration of pembrolizumab (Week 21), and then GPS + Montanide resumes Q3W for six additional doses (Weeks 24, 27, 30, 33, 36, 39).~* Following the early immune booster, there is a 12-week interval of pembrolizumab administration (Weeks 42, 45, 48, 51), and then GPS is resumed every 12 weeks for an additional four doses.~* After 84 weeks, participants who had not progressed will continue in the study and be treated with pembrolizumab alone."
224192460|NCT03716440|OTHER|Non-nature exposure|Participants will view non-nature images.
224192461|NCT06651710|OTHER|Zynamite|Two doses of Mangifera indica leaf extract in its soluble form, Zynamite® S, 100 mg of which 60 mg is mangiferin and 150 mg of which 90 mg is mangiferin, will be tested against a placebo. On the day of the test, the supplements will be administered 30 minutes before the start of the test. The supplements or placebo will be administered in cellulose capsules or similar and accompanied by a glass of water.
223591805|NCT02916810|DEVICE|Active rTMS stimulation|Participants will receive two rTMS sessions in each treatment visit for up to 22 visits within about 6 weeks. There is a 30-minute rest between the two rTMS sessions.
224192462|NCT04121169|DRUG|IM-01|Antibodies react with C. difficile toxin, C. difficile bacteria and spores; neutralizes the toxin and inhibit the growth of spores and vegetative forms of C. difficile
224192463|NCT02204449|BEHAVIORAL|Cardiac Rehabilitation Peer Mentorship|
223501335|NCT03761914|BIOLOGICAL|pembrolizumab|Pembrolizumab is administered at a dose of 200 mg intravenously every 3 weeks on Day 1 of each cycle (3-week cycles) starting on Study Week 6 and continuing for up to 2 years thereafter (Study Week 108). Pembrolizumab is to be administered no earlier than 30 minutes after the administration of GPS on Day 1 of each cycle.
223501336|NCT03761914|OTHER|Montanide|Adjuvant
223501337|NCT03761914|BIOLOGICAL|GM-CSF|Participants receive 70 μg GM-CSF SC on Day -2 and on Day 1 before each GPS injection. The GM-CSF injections occur at the same anatomical site of the next planned study treatment injection.
223501338|NCT05930938|DRUG|Xevinapant|Xevinapant is a multi-IAP antagonist that blocks the activity of several IAPs including X-linked IAP (XIAP), cellular inhibitor of apoptosis proteins (cIAP) 1, cIAP2 and ML-IAP
223501339|NCT05930938|DRUG|Placebo|Xevinapant without active substance
223501340|NCT05930938|DRUG|cetuximab|cetuximab
223501341|NCT05930938|RADIATION|IMRT|IMRT (69.96 Gy in 33 fractions, 2.12 Gy/fraction)
223501342|NCT02885753|DRUG|Oxaliplatin intravenous|85 mg/m² in intravenous. 1 cycle each 15 days
223501343|NCT02885753|DRUG|5 FU bolus|5 fluorouracil : 400 mg/m² in bolus of 10 minutes (intravenous) following by 2400 mg/m² during 46 hours in intravenous
223501344|NCT02885753|DRUG|Folinic acid|400 mg/m² in intravenous
223501345|NCT02885753|DRUG|Oxaliplatin intra-arteriel|85 mg/m² in intra-arterial. 1 cycle each 15 days
223501346|NCT02885753|DRUG|Panitumumab|Only for patient RAS wild: 6 mg/Kg at each cycle in intravenous
223501347|NCT02885753|DRUG|Bevacizumab|5 mg/kg at each cycle in intravenous
223501348|NCT02885753|DRUG|5 FU continuous|2400 mg/m² intravenously over 46 hours
223501349|NCT02885753|DRUG|Irinotecan|150 mg/m² intravenous
223501350|NCT06959420|OTHER|Questionnaire|Anonymous self-administered questionnaire on the Limesurvey platform.
224192464|NCT00503035|DRUG|Celecoxib|400 mg by mouth twice daily x 6 months
224192465|NCT00503035|PROCEDURE|Colonoscopy Biopsy|Up to 23 additional colon tissue biopsies (the size of a pencil tip), additional 20 minutes on colonoscopy procedure
224192466|NCT05051384|DIAGNOSTIC_TEST|Doppler technology|The study of tumor vascularization can help in the differential diagnosis and follow-up of tumors, and therefore can impact the management of patients with tumors
224192467|NCT04645342|DEVICE|Baylis Versacross RF wire|Baylis Versacross radiofrequency wire is used for transseptal puncture during cardiac ablation procedure.
224192468|NCT04645342|DEVICE|Baylis RF needle|Baylis radiofrequency needle is used for transseptal puncture during cardiac ablation procedure.
224192469|NCT02173132|DRUG|Acetyl-L-carnitine|
224192470|NCT02173132|OTHER|Placebo|
224192471|NCT02473107|OTHER|Advanced caries lesions detection (no activity assessment)|The diagnosis strategy will based on detection of only moderate and advanced caries lesions (ICDAS scores 3 to 6). Initial caries lesions will be considered as sound surfaces. Caries activity status will not be evaluated. Clinical decision-making will be proposed for all lesions detected, based on evidence-based protocols.
224192472|NCT02473107|OTHER|All caries lesions detection (+activity assessment)|The diagnosis strategy will based on detection of initial, moderate and advanced caries lesions (ICDAS scores 1 to 6). Caries activity status will be also evaluated. Clinical decision-making will be proposed for all active lesions detected, based on evidence-based protocols. inactive caries lesions will not be treated.
224192473|NCT04861207|DRUG|Cladribine|The conditioning regimen used will be cladribine-based at a dose of 5 mg / m2 for 5 days (iv.) and total body irradiation at a total dose of 12 Gy in three fractions.
224192474|NCT05859126|DIETARY_SUPPLEMENT|Maternal Choline Supplementation 930 mg/d|Mothers were supplemented with choline (930mg/d) from second trimester through birth. This is a 13 year follow up of their offspring.
224192475|NCT05859126|DIETARY_SUPPLEMENT|Maternal Choline Supplementation 480 mg/d|Mothers were supplemented with choline (480 mg/d) from second trimester through birth. This is a 13 year follow up of their offspring.
224309915|NCT01129843|DRUG|Directly observed home based daily iron therapy|Directly Observed Home based Daily Iron( ferrous sulphate) therapy (DOHBIT) will be provided to the anemic women by the local village volunteers. Dose of elemental iron therapy will be 100 mg once daily for mild to moderate anemia and twice daily for severe anemia for a cumulative duration of 90 days
223501351|NCT04204642|OTHER|CAA patients data collection|Demographic and clinical data of each patient, including index event that led to the diagnosis (cerebrovascular disease, dementia, gait disturbance, TFNE, seizures, headache), vascular risk factors, history of brain injury or neurosurgery, familial history, and pharmacological treatment will be collected by neurologists in charge.
223501352|NCT05107934|BIOLOGICAL|RPH-104|solution for subcutaneous injection, 40 mg/mL
223501353|NCT05107934|DRUG|Placebo|0.9% Sodium Chloride solution for Injection
223501354|NCT02394834|DRUG|oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, panitumumab|oxaliplatin (OXA), levofolinate calcium (l-LV), panitumumab: intra-venous infusion 5-FU: bolus and continuous intra-venous infusion
223501355|NCT02394834|DRUG|oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, bevacizumab|oxaliplatin (OXA), levofolinate calcium (l-LV), bevacizumab: intra-venous infusion 5-FU: bolus and continuous intra-venous infusion
223501356|NCT05803499|BEHAVIORAL|Targeted Cognitive Behavior Therapy for Insomnia|This intervention consists of six, 50-min. online individual sessions delivered via video conference. Content was developed by tailoring standard cognitive behavioral therapy for insomnia (CBT-I) to the specific needs of people who recently lost spouses/long-term partners, by using qualitative data gathered in focus groups. The intervention incorporates key concepts of CBT-I (sleep restriction; stimulus control) and positive emotion psychology (everyday mindfulness; gratitude and self-compassion). Individualized sleep plans (including weekly sleep windows) will be created for intervention participants, and each weekly session will involve a discussion about participants' progress in improving sleep disturbance. Support and recommended coping skills for loss and bereavement will also be provided.
223591806|NCT02916810|DEVICE|Sham rTMS stimulation|Participants will receive two sham rTMS sessions in each treatment visit for up to 22 visits within about 6 weeks. There is a 30-minute rest between the two sham rTMS sessions.
224192476|NCT06786091|OTHER|Pelvic floor muscle training rehabilitation|The intervention consists of both exercise training, including pelvic floor muscle training, and information about the use of a dilator. At the baseline assessment participants are individually instructed in correct voluntary pelvic floor muscle contractions and how to perform intensive pelvic floor muscle training. The pelvic floor rehabilitation is supported with written information. The exercise program is provided with supervised digital group exercise sessions twice weekly and a home exercise program 4-5 weekly for 16 weeks. The home exercise program will be individualized if needed. The pelvic floor muscle training is following the recommendations for effective training dosage i.e. 3 sets of 10-12 repetitions, 5-7 times per week.
224192477|NCT04766632|DEVICE|Brain PET-CT of 18F-DOPA|PET-CT is a nuclear medicine exam with radiopharmaceutical injection of 18F-DOPA for the patient
224192478|NCT05578586|DRUG|Meropenem 1000 mg|given as 6 or 3 infusions in 15 minues or 3 hours.
224192479|NCT06225674|DEVICE|Episealer Talus implant|This is an observational study, no intervention will be done. The aim for the clinical investigation is to collect data from approximately 25 adult subjects who were treated for focal osteochondral defect with Episealer Talus implant in 6 clinics (Sweden and Germany) since January 2020.
224192480|NCT06269965|DEVICE|Regeneten® adding|Arthroscopic shoulder repair, in double row, with complete coverage of the foot print and addition of Regeneten®
224192481|NCT06467916|BEHAVIORAL|Behavioral Treatment|anticipatory guidance, brief behavioral intervention, or referral to community mental health provider
224192482|NCT05266976|BEHAVIORAL|10 Weeks of Supervised Resistance Exercise Training|Participants will be randomized to complete 10 weeks of either resistance (weight lifting, hopping) supervised exercise. Exercise will be 3x per week for 1 hour each session. There are a total of 30 exercise sessions.
224192483|NCT05266976|BEHAVIORAL|10 Weeks of Supervised Endurance Exercise Training|Participants will be randomized to complete 10 weeks of endurance (stationary cycling) supervised exercise. Exercise will be 3x per week for 1 hour each session. There are a total of 30 exercise sessions.
224192484|NCT05258500|OTHER|Ghostly app|For the Ghostly app, we include three different trainings (standard, cluster set 1, cluster set 2). The standard training consists of three sets in which twelve muscle contractions are performed with 120 seconds of rest between each set. Each set of twelve contractions will be considered as one level in the game that needs to be ended before taking rest of 120s. Subsequently, the 'Cluster set 1' training is based on the training modalities of cluster set training since evidence shows that similar results can be obtained using cluster set training compared to standard training. The Cluster sets 1 and 2 also consist of 3 sets of twelve repetitions, but with ten seconds of rest between each contraction or 30 seconds of rest after three consecutive contractions respectively. The intensity at which will be trained is 75% of maximum voluntary contraction.
223501357|NCT05803499|OTHER|Information-Only Control|The control session (approx. 50-min. in length) will be delivered online in a one-to-one format (participant and facilitator) via videoconference. Educational brochures based on recommendations provided by the American Academy of Sleep Medicine focused on sleep and health and sleep hygiene education will be used. No specific or individualized recommendations will be given to control participants.
223501358|NCT06958861|DRUG|Low-dose H057+standard-of-care|Subjects are administered low-dose inhaled H057, combined with standard-of-care treatment, which included anti-infective therapy, expectorant therapy, hemostasis, oxygen therapy, and other supportive measures.
223501359|NCT06958861|DRUG|High-dose H057+standard-of-care|Subjects are administered high-dose inhaled H057, combined with standard-of-care treatment, which included anti-infective therapy, expectorant therapy, hemostasis, oxygen therapy, and other supportive measures.
223501360|NCT06958861|DRUG|H057 placebo+standard-of-care|Subjects are administered inhaled H057 placebo, combined with standard-of-care treatment, which included anti-infective therapy, expectorant therapy, hemostasis, oxygen therapy, and other supportive measures.
223501361|NCT04214782|DIAGNOSTIC_TEST|Artificial Intelligence Enabled Transvaginal Ultrasound Imaging algorithm|AI Enabled Transvaginal Ultrasound diagnosis for ovarian cancer
223501362|NCT03053323|BEHAVIORAL|Lifestyle Intervention|The lifestyle intervention consists of three components: nutrition, physical activity, and other areas of wellness. The intervention is administered individually each week for 10 weeks and is tailored for women with a history of depression who are in the first trimester of pregnancy or trying to conceive.
223501363|NCT04926584|DRUG|induction therapy|induction immuno-chemotherapy or immunotherapy prior to resection or definitive chemoradiotherapy
223501364|NCT04783662|DEVICE|Intraoperative frontal electroencephalogram|Intra operative frontal electroencephalogram registration with 1 age adjusted Minimum Anesthetic Concentration of Sevoflurane
223501365|NCT03079492|DEVICE|Magnetic resonance imaging|Magnetic resonance imaging will be used to estimate brain temperature and cerebral blood flow
223501366|NCT01631188|PROCEDURE|Minimally Invasive Aortic Valve|Patients having minimally invasive aortic valve surgery will have a pacing wire placed through the endovent catheter. The anesthesiologist will attempt to pace the ventricle with this wire if needed to wean from bypass.
223501367|NCT01631188|PROCEDURE|Minimally Invasive Aortic Valve Surgery|The Anesthesiologist will advance a pacing wire through the Endovent Catheter under TEE in order to pace the heart when the subject is coming off the Cardiopulmonary bypass machine
224192485|NCT05258500|OTHER|Blood flow restriction|Patients will complete four sets of 15 repetitions, with each contraction lasting three seconds. Similar to the first experimental group and control group, the training intensity will be set at 100%MVC with two minutes of rest between sets. The cuff pressure will be set at 50% of arterial occlusion pressure.
223501368|NCT01631188|DEVICE|Manipulation in OR surgical technique|Endovent and pacing wire when coming off cardiopulmonary bypass
223501369|NCT02127541|OTHER|Ga -exendin PET/CT, In- exendin SPECT/CT, MRI|Comparison of different imaging modalities
223501370|NCT05487495|BIOLOGICAL|CD5 CAR T (CT125B)|Subjects will be pretreated with chemotherapy prior to infusion of CAR T cells: After the collection of PBMC and about 5 days before infusion, lymphodepletion (fludarabine at 30 mg/m\^2/day and cyclophosphamide at 250 mg/m\^2/day; for prior-SCT donor-derived CAR T-cell infusion) or intensified lymphodepletion (fludarabine at 30 mg/m\^2/day and cyclophosphamide at 30 mg/kg/day; for new donor-derived CAR T-cell infusion) will be administrated for 3 days.
223501371|NCT03600350|BIOLOGICAL|pTVG-HP|Plasmid DNA vaccine encoding Prostatic Acid Phosphatase (PAP)
223591807|NCT03263260|DEVICE|implant|coronary stent implantation
224192486|NCT05258500|OTHER|Leaflet|This training program will be matched with the Ghostly game in terms of repetitions, sets and inter-set rest and will be given to the patient to complete without supervision of the therapist.
224192487|NCT02193620|DRUG|PHN131 soft capsule with Nalbuphine HCl 60 mg/cap|Multiple dose of oral PHN131 soft capsule with Nalbuphine HCl 60 mg/cap, initial dose : 120 mg ( 2 capsules), then 60 mg (1 capsule); t.i.d.
224192488|NCT02193620|DRUG|Placebo soft capsules|Multiple dose of oral Placebo soft capsules, initial dose: 2 capsules, then 1 capsule; t.i.d.
223501372|NCT03600350|DRUG|Nivolumab|Nivolumab is a human programmed death receptor-1 (PD-1)-blocking antibody indicated for the treatment of patients with multiple different types of cancer.
223501373|NCT03600350|DRUG|GM-CSF|Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a growth factor that supports the survival, clonal expansion and differentiation of hematopoietic progenitor cells including dendritic antigen presenting cells.
223501374|NCT03643991|OTHER|Weighted Blanket|Weighted blanket will be given to patients based on the patient weight (10% of patients body weight) for three nights while on inpatient unit.
223501375|NCT00001270|DRUG|interleukin-1|
223501376|NCT02131883|BEHAVIORAL|Group-Cognitive Behavioral Therapy|psychoeducation, stress management, cognitive restructuring, response prevention, exposure, relapse prevention
223501377|NCT02131883|OTHER|Wait-List with treatment as usual|Intervention typical supportive talks from general practitioner. No restrictions for interventions for patients here.
223501378|NCT01561105|OTHER|IMPACT|IMPACT is a collaborative care management program for late-life depression
223501379|NCT01051167|DRUG|Cetuximab|500 mg /m² cetuximab as an intravenous infusion over 120 minutes on day 1 every 2 weeks
223501380|NCT04599218|OTHER|Prostate Biopsy|Standard of care
223501381|NCT04599218|OTHER|MR US Fusion Guided Prostate Biopsy|Trans-rectal ultrasound (TRUS) guided fusion prostate biopsy (Arm 1) or a Transperineal Ultrasound guided fusion prostate biopsy (Arm 2). All patients will under go a standard ultrasound guided biopsy at the time of their targeted (fusion) biopsy.
223501382|NCT04599218|DEVICE|MR/TRUS Fusion Guided Prostate Biopsy|TRUS images are overlaid on a previously obtained prostate MRI, combined with an electromagnetic tracking system. The urologist then performs directed prostate biopsies at MR-identified targets in addition to the standard prostate biopsies.
223501383|NCT03480074|PROCEDURE|Staple Ligation|Using a stapler that staples the DVC and then cuts it.
223501384|NCT03480074|PROCEDURE|Selective Suture Ligation|Suture the DVC, suspend it to the pubic bone, and then cut.
223501385|NCT03480074|PROCEDURE|Single Suture Ligation|Cut the DVC, then pinpoint a specific blood vessel needed to sew/suture.
223591808|NCT05664880|DRUG|Paricalcitol|2 MCG Oral Capsule
223591809|NCT05664880|DRUG|Placebo|Matching capsule to 2 MCG Paricalcitol Oral Capsule
223591810|NCT05837884|DIAGNOSTIC_TEST|blood sampling|Participants will provide a blood sample that will be used to determine whether they have a monoclonal protein
223591811|NCT03270891|DIAGNOSTIC_TEST|PGx test|A laboratory developed genetic test that differentiates common and uncommon alleles in genes that have been previously identified as being involved in either the metabolism or response of drugs used in the treatment of depression and/or anxiety. The results are provided as a report that contains information related to the allele status of the patient's genes, translates this into a phenotype, and relates this phenotype to recommendation classes for drugs.
224192489|NCT02193620|DRUG|Dicofenac|All subjects will receive diclofenac by IM injection for analgesia as rescue pain control.
224192491|NCT05205109|DRUG|ATG-037|"Part I : ATG-037 will be administered orally once a day (QD) on D-2, then multiple doses of ATG-037 will be administered orally BID for every day from C1D1. A treatment cycle will be defined as 21 days.~Part II: ATG-037 will be administered orally BID for every day from C1D1."
224192492|NCT05205109|DRUG|KEYTRUDA ®( Pembrolizumab)|"Part I: After 2 cycles of ATG-037 monotherapy, eligible participants will receive ATG-037 combination therapy with Keytruda ®(Pembrolizumab) 200mg/Q3W fixed dose for up to 35 administrations (approximately 2 years).~Part II: Keytruda ®(Pembrolizumab) will be administered from C1."
224192493|NCT03978936|BEHAVIORAL|Medication Therapy Management (MTM) Video Telehealthcare|"MTM is an individualized approach to optimize medication use for improved patient outcomes and is designed to empower patients to take an active role in managing patients' medications thus, providing a favorable strategy for addressing adherence issues. Five core elements define MTM: complete medication therapy review (CMR), creation of a personal medication list (PML), development of a medication action plan (MAP), intervention and/or referral for drug therapy problems, and documentation and follow-up"
224192494|NCT03978936|BEHAVIORAL|Electronic Adherence Self-Management (EAM)|Participants will have a sensor which monitors their adherence to medication use
224192495|NCT05047237|BEHAVIORAL|Pharmacist-Led Optimization Intervention|Educational information mailed to participants and up to three pharmacist visits.
224192496|NCT06567275|PROCEDURE|Erector Spinae Plane Block|Ultrasound-guided erector spinae plane block will be done by injecting 0.4 ml/kg (1:1 solution of bupivacaine 0.25% and lidocaine 1%)
224192497|NCT06567275|PROCEDURE|Serratus Anterior Plane Block|Ultrasound-guided serratus anterior plane block will be done by injecting 0.4 ml/kg (1:1 solution of bupivacaine 0.25% and lidocaine 1%)
224192498|NCT06392737|PROCEDURE|MRI-AI guided cognitive prostate targeted biopsy|Before prostate biopsy, the MR images of patients in the AI-cTB group were uploaded to the AI software. Then the images with suspicious lesions highlighted by AI software were viewed by urologists. Biopsies were performed under the guidance of TRUS through the transrectal or transperineal route.
224192499|NCT06392737|PROCEDURE|Routine cognitive prostate targeted biopsy|Before prostate biopsy, the MR images and reports were viewed by urologists preceding the biopsy. Biopsies were performed under the guidance of TRUS through the transrectal or transperineal route.
224192500|NCT04051606|DRUG|Regorafenib|Regorafenib is a monotherapy during the study, oral administration at 160 mg once daily will be administered for 3 weeks on /1 week off.
224192501|NCT05617495|OTHER|Mindfulness + fMRI Neurofeedback|Prior to neurofeedback, participants will receive 45 minutes of mindfulness training. Participants will then receive mindfulness-based fMRI neurofeedback targeting the default mode network and frontoparietal control network.
224192502|NCT03687957|DRUG|rhIL-7-hyFc|-Given by intramuscular injection
224192503|NCT03687957|DRUG|Placebo|-Given by intramuscular injection
223501386|NCT05412420|OTHER|Patient Self-Reporting of Symptoms|"At baseline, clinical research staff will:~* verify the possibility of an internet connection at the patient's home~* help the patient to fill in the 1st questionnaire (baseline questionnaire - frailty)~Every two weeks for 3 months:~* patients complete questionnaires via app (toxicity; quality of life, medication adherence)~* responses are verified by clinical research staff~* In case of severe symptoms, the clinician contacts the patient and arranges for management.~At the end of the study :~\- patients answer a satisfaction questionnaire"
224192504|NCT03687957|DRUG|Temozolomide|-Standard of care
224192505|NCT03687957|RADIATION|Radiation therapy|-Standard of care
223501387|NCT03763383|PROCEDURE|Lateral Arm Flap|Its a kind of flap that is harvested from the lateral aspect of the arm to cover defects in different parts of the body
224192506|NCT03687957|PROCEDURE|Blood sample|"* Week 1 (prior to the 1st dose of rhIL-7-hyFc)~* Week 2 (one week after rhIL-7-hyFc)~* Week 3 (two weeks after rhIL-7-hyFc)~* Week 4 (three weeks after rhIL-7-hyFc)~* Week 13 (prior to the 2nd dose of rhIL-7-hyFc)~* Week 14 (one week after rhIL-7-hyFc)~* Week 16 (three weeks after rhIL-7-hyFc) - optional~* Week 45 (eight weeks after the last dose of rhIL-7-hyFC)~* If ADA or NADA is observed in week 45, additional blood collections will be required every 2 months in order to monitor ADA/NADA levels until it decreases to the basal level~* At the time of tumor progression"
224192507|NCT00823563|PROCEDURE|30 cc blood draw|
224192508|NCT00823563|PROCEDURE|Intravascular ultrasound (IVUS)|
224192509|NCT00823563|PROCEDURE|Coronary pressure/flow wire testing|
224192510|NCT00823563|PROCEDURE|Coronary pressure/flow testing: Acetycholine challenge|
224192511|NCT00823563|PROCEDURE|Procedure: Coronary pressure/flow testing: Nitroglycerin challenge|
224192512|NCT00823563|PROCEDURE|Procedure: Procedure: Coronary pressure/flow testing: Adenosine challenge|
224192513|NCT03319901|DRUG|Venetoclax|"Venetoclax is an inhibitor of Bcl-2. Bcl-2 is critical for keeping cancer cells alive.~By inhibiting Bcl-2, venetoclax promotes cancer cell death."
224192514|NCT03319901|DRUG|Standard Chemotherapy|Standard treatment of chemotherapy is administered
224192515|NCT06785064|BEHAVIORAL|Reduced Food Variety (RFV)|Participants engaged in reduced food variety (RFV) will be asked to choose a few high-calorie, low nutrient main meals and snacks to eat regularly. At the beginning of each month, they will choose one main meal (entrée) to eat at least 2 times a week and one snack food to eat at least 4 times a week within the month. They will have the option to keep or change their main meal and snack options from month to month.
223501388|NCT01217450|DRUG|selumetinib|Given orally
223501389|NCT01217450|BIOLOGICAL|cetuximab|Given IV
223501390|NCT01217450|OTHER|laboratory biomarker analysis|Correlative studies
223501391|NCT01217450|OTHER|pharmacological study|Correlative studies
223501392|NCT04895280|DRUG|Ketorolac|Ketorolac: will receive an injection of 4 cc 0.25% Marcaine without epinephrine and 30 mg ketorolac x 1
223501393|NCT04895280|DRUG|Marcaine|Marcaine (control): will receive an injection of 4 cc 0.25% Marcaine without epinephrine
223501394|NCT04895280|DRUG|Kenalog|Kenalog: 4 cc 0.25% Marcaine without epinephrine and 40 mg triamcinolone x 1.
223501395|NCT05524909|GENETIC|Genetic Risk Estimate|The genetic risk information includes individual remaining-lifetime and 10-year genetic risk estimates for T2D as well as a dichotomized genetic risk category: 'increased genetic risk' (if their genetic risk is higher than the average population risk) or 'no increased genetic risk' (if their genetic risk is not higher than the average population risk).
223512087|NCT04342546|DEVICE|NovaGray RILA Breast® test|The test consists of a blood sample of 2x4 mL. This test will be performed between day -30 and until the first day of radiotherapy (before the start of this one) and then 12 months after the end of radiotherapy and between day -30 and until the first day of chemotherapy (before any injection) in the case of neoadjuvant chemotherapy and between day -30 and until the first day of chemotherapy (before any injection) in the case of adjuvant chemotherapy.
223512088|NCT02708368|OTHER|blood withdrawal|3 times
223512089|NCT04757857|DRUG|Rivaroxaban 10 mg|Rivaroxaban pharmaceutical form will be tablets of 10 mg
224192516|NCT06785064|BEHAVIORAL|Home-based Resistance Training (HBRT)|Participants assigned to receive home-based resistance training (also called strength training or lifting weights) will be asked to engage in at-home exercises that strengthen muscles at least 2 days each week (≤45 minutes per home session) and track their progress. They will be asked to attend 6, 1-hour group-based skills training workshops (in-person and/or remotely via Zoom) during the first two months of Phase 2 to learn these skills. They will receive exercise plans and equipment (sets of dumbbells, a rack to hold the dumbbells, and an exercise mat) needed to complete exercises.
224192517|NCT06785064|BEHAVIORAL|Buddy Training and Support (BTS)|"Participants assigned to buddy training and support will be asked to identify an eligible friend or family member who is over 18 years old that can be their buddy. Study staff will contact the buddy to be sure they are eligible, willing, and have all the details they need. The participant's buddy will be asked to attend up to 6 training sessions with the study staff, so they can learn the best ways to support the participant during the program. After the buddy completes training, they will be asked to check in with the participant 1-2 times each week about their progress."
224192518|NCT06785064|BEHAVIORAL|Acceptance and Commitment (ACT) Workshops|Participants assigned to receive Acceptance and Commitment (ACT) Workshops will be asked to attend 6, 1-hour group-based skills training workshops (in-person and/or remotely via Zoom) during the first three months of Phase 2. These workshops will help them develop skills to handle tough thoughts about weight control, keep their values in mind, and be mindful of their decisions and the impact of their decisions related to weight control. They will also be asked to apply ACT skills regularly during the rest of Phase 2.
224192519|NCT06835127|PROCEDURE|Infrainguinal peripheral endovascular revascularization|Percutaneous endovascular angioplasty and/or stenting of infrainguinal arteries (femoropopliteal and/or infrapopliteal arteries) under local anesthesia and adjunct mild conscious sedation.
224192520|NCT06190912|DRUG|Bryostatin 1|Eligible participants will be treated with bryostatin over a 26-week period. Doses 1, 2, 8, and 9 of the study drug will be a loading dose 20% higher (i.e., 24 µg) than the assigned fixed dose and will be administered one week apart. Otherwise, the assigned fixed dose is 20 µg. Drug is administered intravenously (IV) by continuous infusion over 45(±5) minutes. Participants are scheduled to receive 14 doses over 26 weeks.
224192521|NCT05567601|DRUG|DOXIL/CAELYX|40 mg/m2 as a 90-minute IV infusion via a central venous catheter or peripheral vein
224192522|NCT05028816|DEVICE|Side 1: Final layer closure with force modulating tissue bridges (FMTB)|Brijjit is a non-invasive wound closure device that reduces tension on scars and aids improving scar appearance.
223591812|NCT03596684|DIETARY_SUPPLEMENT|citrulline supplementation|2.5 g per os of citrulline on the morning and the evening (5 g/ jour) during 4 weeks.
224192523|NCT05028816|OTHER|Side 1: Final layer dermal closure with poliglecaprone 25 suture|Current method of wound closure
224192524|NCT05028816|DEVICE|Side 2: Final layer closure with force modulating tissue bridges (FMTB)|Brijjit is a non-invasive wound closure device that reduces tension on scars and aids improving scar appearance.
224192525|NCT05028816|OTHER|Side 2: Final layer dermal closure with poliglecaprone 25 suture|Current method of wound closure
224192526|NCT06964425|PROCEDURE|Endoscopic retrograde cholangiopancreatography (ERCP)|Insertion of a endoscopic fiber-optic Raman probe under fluoroscopic control during endoscopic retrograde cholangiopancreatography to measure Raman spectra of extrahepatic cholangiocarcinoma and healthy bile duct.
224192527|NCT05064436|DRUG|11C-BMS-986196|Specified dose on specified days
224192528|NCT06008808|DRUG|Ruxolitinib|Ruxolitinib is provided by Incyte Corporation.
224192529|NCT06008808|DRUG|Abatacept|Abatacept is commercially available.
224192530|NCT05462834|OTHER|Compressed Air|Participants will be instructed to use compressed air during sleep as a placebo control.
224192531|NCT05462834|OTHER|Supplemental Oxygen|Participants will be instructed to use supplemental oxygen at rate of 2lpm during sleep.
224192532|NCT04711655|PROCEDURE|ARMA (antireflux ablation of the cardiac mucosa)|is an endoscopy in which argon gas ablation of the cardiac mucosa
223501396|NCT05524909|DEVICE|Genetic Risk Estimate + Fitbit Functions|"The genetic risk information includes individual remaining-lifetime and 10-year genetic risk estimates for T2D as well as a dichotomized genetic risk category: 'increased genetic risk' (if their genetic risk is higher than the average population risk) or 'no increased genetic risk' (if their genetic risk is not higher than the average population risk).~The two unique Fitbit functions are step goal setting and prompts. Individualized daily step goals will be set to be 10% higher than participants' own baseline Fitbit step counts. The 'Reminder To Move' function of Fitbit will be used as a prompt to remind participants to reduce sedentary time and walk at least 250 steps/hour within a specified timeframe (i.e., from 9am to 10pm in the proposed research). If the user has not accumulated at least 250 steps/hour, a reminder (for example, 150 steps to go) will appear on the Fitbit screen at 10 minutes before the hour (for example, at 10:50 a.m.) and cause the device to vibrate."
223501397|NCT06780943|OTHER|Biomechanics|"Amputees and controls will be equipped with measurement sensors to record spatio-temporal, kinetic, kinematic, pressure, electromyographic and physiological parameters of gait in the movement analysis laboratory (GRAIL System).~16 Anatolog FSR sensors will be installed in the amputee population (transtibial, transfemoral on the medial, lateral, anterior and posterior parts of the stump, 4 per side, aligned in the proximal/distal axis. The Anatolog sensors have a sampling frequency of 100Hz. Electromyographic data recording is performed by setting up a number of EMGs depending on the healthy population or the level of amputation. Surface electromyography (sEMG) signals will be recorded from 10 muscles on each lower limb for control subjects and transtibial amputees"
223501398|NCT06780943|OTHER|Physiological|Energy consumption (VO2), will be performed using the VO2 Master Pro (VO2 Master Health Sensors Inc., Vernon, British Columbia, CA). Each participant will wear a face mask connected to the VO2 Master, which will measure oxygen consumption in real time during the assessment. The mask will be adjusted to prevent air leakage and ensure accurate measurements.
223501399|NCT06780943|OTHER|Proprioceptive|For amputees, the joint above the amputation will be measured due to the presence of the proximal insertions of the bi-articular muscles and the absence of their distal insertion (i.e., knee joint for transtibial amputees and hip joint for transfemoral amputees).
223501400|NCT01789021|DEVICE|4 blood glucose monitoring systems|
223501401|NCT05998239|OTHER|Bootle Boot Camp Home Exercise App - with Virtual Coach Botley|Bootle Boot Camp exercise sessions offered with movement tracking feedback will be provided for a maximum of two consecutive sessions before being alternated with the no feedback condition for a period of 4 weeks (4 sessions/week). Movement feedback will be guided by skeletal data captured by the 3D motion tracking camera and based on predefined movement acceptability criteria for each exercise. Feedback will take the form of visual markers, text/audio cues and rewards.
223501402|NCT05998239|OTHER|Bootle Boot Camp Home Exercise App - without Virtual Coach Botley|Bootle Boot Camp exercise sessions offered without movement tracking feedback will be provided for a maximum of two consecutive sessions before being alternated with the movement tracking feedback condition for a period of 4 weeks (4 sessions/week).
223501403|NCT03269006|DEVICE|Inesfly Paint|"Inesfly 5AIGRNG TM paint contain Alphacypermethrin 0.7%; D-Allethin 1.0% and Pyriproxyphen (0.063%).~Others intervention such as IRS, ITN and IDWLcontain Delthamethrin"
223501404|NCT03269006|DEVICE|IDWL (1m)|Install durable wall lining up to one meter from the floor of the intervention room containing deltamethrin to kill immature stage and as well as adult sand flies
223501405|NCT03269006|DEVICE|ITN (KO-Tab 123)|Impregnation of existing bed net by the insecticide tablet, K-O Tab 1-2-3 containing deltamethrin
223501406|NCT03269006|DEVICE|IRS (Delthamethrin)|Indoor residual spraying with Delthamethrin in the living rooms
223501407|NCT00835978|DRUG|axitinib|axitinib 5mg BID (open-label) + axitinib dose titration (blinded)
223501408|NCT00835978|DRUG|axitinib|axitinib 5mg BID (open-label) + placebo dose titration (blinded)
223501409|NCT00835978|DRUG|axitinib|axitinib 5mg BID (open-label)
224192533|NCT04711655|PROCEDURE|upper digestive endoscopy|Quality diagnostic upper gastrointestinal endoscopy will be performed without intervention in patients assigned to this treatment arm.
224192534|NCT05216016|OTHER|RETAIN Program|Facilitates early intervention strategies to support workers in staying-at or returning-to-work (SAW/RTW) after injury or illness and preventing unnecessary disability. This is done by incorporating a Return-to-Work Case Manager as a member of the healthcare clinical team who acts as a liaison for the patient and assists in coordination of referrals between healthcare and Workforce Development services. Return-to-Work Case Managers will interact with treating providers of Minnesota RETAIN intervention group participants to ensure functionally based work restrictions are documented and shared with the patient's employer.
224192535|NCT06300580|DRUG|ABBV-932|Oral Capsule
223591813|NCT03596684|DIETARY_SUPPLEMENT|placebo supplementation|2.5 g of the product in the morning and in the evening during 4 weeks.
224309916|NCT01274676|DEVICE|carotid stenting with MOMA|The MOMA system is an endovascular catheter for proximal protection during carotid stenting. The system allows a concomitant balloon occlusion of both external and common carotid arteries leading to blood flow reversal within the internal carotid artery.
224309917|NCT01274676|DEVICE|Carotid stenting with filter wire EZ|The filter wire EZ a distal protection system that is placed in he distal internal carotid artery before carotid stenting. The filter should entrap almost all the debries that are generated during endovascular procedure. At the end of the procedure the filter is retrieved throught a dedicated retrieval catheter.
224309918|NCT02105974|DRUG|Fluticasone Furoate/Vilanterol|100 mcg FF micronized drug blended with lactose per blister in one strip and 25 mcg VI micronized drug blended with lactose and magnesium stearate per blister in another strip, administered together by ELLIPTA™ inhaler
224309919|NCT02105974|DRUG|Vilanterol|25 mcg of Vilanterol micronized drug (as the 'M' salt triphenylacetate) blended with lactose and magnesium stearate per blister in one strip and lactose in another strip, administered together by ELLIPTA™ inhaler
223512090|NCT00127543|BEHAVIORAL|Medication Education for Children|
224074726|NCT06101615|OTHER|Foam Rolling|Group-B participants would receive Foam Rolling (FR). Treatment sessions will be carried out three times per week for eight weeks after an initial warm-up session. All the sessions will be performed at the same time of day (i.e., between 4-6 pm) to avoid possible confounding circadian effects. The Foam Roller group will receive 2x1 min of FR on the quadriceps and the hamstrings on the dominant leg with the opposite leg crossed over the dominant one. During each minute the muscle will be rolled out 4-5 times, with a break of 30s in between sets. They will be instructed to utilize short, kneading like movements in one direction and a quick motion in the other direction. A grid foam roller will be utilized with a length of 33cm, diameter of 14 cm and with a hard hollow core, wrapped in ethylene vinyl acetate foam.
223512091|NCT03494842|DEVICE|Transcutaneous nerve stimulation (TENS)|The active TENS unit (delivers electrical stimulation) with indicator light
224074727|NCT03055975|DIAGNOSTIC_TEST|Detection of residual vital bacteria in the root canal space|Detection of residual vital bacteria in the root canal space. No intervention, as it is an observational study. Vital bacteria are looked for in the samples taken from the root canal space.
224074728|NCT04087525|DRUG|HIP1701|Vildagliptin
224074729|NCT04087525|DRUG|HGP1809|Vildagliptin
224074730|NCT06352294|OTHER|Core stability training|Before starting core stabilization exercises, hotpack will be given for 15 minutes in the warm-up phase, TENS application, then craniocervical flexion training will be given. Core stabilization exercises consist of three stages: easy, medium and difficult
224074731|NCT06352294|OTHER|Core stability training and myofascial relase|Before starting core stabilization exercises, hotpack will be given for 15 minutes in the warm-up phase, TENS application, then craniocervical flexion training will be given. Core stabilization exercises consist of three stages: easy, medium and difficult. In addition, myofascial relaxation will be applied with roller bar along the superficial back line.
224074732|NCT01511770|DRUG|Fluconazole|Fluconazole Tablets, 200 mg
224074733|NCT01511770|DRUG|Fluconazole|Fluconazole 200 mg tablets
224074734|NCT00993031|DRUG|Lopinavir/ritonavir|LPV 200mg/r 50mg
224074735|NCT00993031|DRUG|Efavirenz|600mg
224074736|NCT00993031|DRUG|Zidovudine|Zidovudine 300 mg
224074737|NCT00993031|DRUG|Lamivudine|Lamivudine 150 mg
224074738|NCT04011865|PROCEDURE|Radical prostatectomy|The patients diagnosed with prostate cancer (local or locally advanced stages) will be allocated to the study for performing radical prostatectomy surgery.
224074739|NCT00598416|BEHAVIORAL|Family-Responsive Psychoeducation Program (PERF)|Group psychoeducation for HCV patients and their primary caregiver.
224074740|NCT00270530|DRUG|Sulfadoxine-pyrimethamine (Fansidar)|
224074741|NCT00875355|DRUG|temozolomide|Given orally
224074742|NCT00875355|RADIATION|radiation therapy|Patients undergo radiotherapy
224074743|NCT03115151|DRUG|Bupivacaine|Bupivacaine (0.0625%) will be combined with fentanyl for postoperative epidural analgesia via a lumbar epidural catheter
223512092|NCT03494842|DEVICE|Placebo Transcutaneous nerve stimulation (TENS)|the placebo TENS unit (delivers no electrical stimulation) with indicator light
223512093|NCT04188626|BEHAVIORAL|Driving simulator sessions|The volunteers will be placed in a driving simulator that will simulate autonomous highway driving. This autonomous driving will be interrupted by take-over requests related to events that disrupt autonomous driving. During autonomous driving, the driver will have to disengage from driving by performing non-related driving tasks. During each non-related driving tasks, a take-over request will be sent. Electrophysiological (EEG, ECG, EDA, EMG, respiration) and behavioural data will be recorded before, during and after the take-over control.
223512094|NCT01609387|DIETARY_SUPPLEMENT|Fit For me|
223512095|NCT01609387|DIETARY_SUPPLEMENT|Davitamon|
223512096|NCT06041828|DEVICE|Lumoral Treatment|Photodynamic antibacterial dual-light device with a marker substance
223512097|NCT06041828|OTHER|Standard oral hygiene|Standard oral hygiene instructions
223512098|NCT05392660|OTHER|assumed upright position during first stage of labor|The study group assumed one of upright positions during first stage of labor, defined as walking , sitting, standing, kneeling \& squatting positions )
224074744|NCT03115151|DRUG|Hydromorphone|Hydromorphone will be given continuous infusion for intravenous patient controlled analgesia (syringe 25 mg/50 mL).
224074745|NCT03115151|DRUG|Fentanyl|Fentanyl (2 mcg/ml) will be given via epidural route together with bupivacaine.
224074746|NCT00005059|DRUG|carboplatin|
224074747|NCT00005059|DRUG|paclitaxel|
224074748|NCT04471727|BIOLOGICAL|Gocatamig|IV infusion
224074749|NCT04471727|BIOLOGICAL|Atezolizumab|IV infusion
224309920|NCT02804711|BIOLOGICAL|Low dosage of Staphylococcus aureus vaccine (15µg/0.6ml)|
224309921|NCT02804711|BIOLOGICAL|Middle dosage of Staphylococcus aureus vaccine (30µg/0.6ml)|
224309922|NCT02804711|BIOLOGICAL|High dosage of Staphylococcus aureus vaccine (60µg/0.6ml)|
224309923|NCT02804711|BIOLOGICAL|Placebo|
224309924|NCT04632160|DEVICE|IASD System II|The implant is placed across the interatrial septum using a percutaneous transcatheter approach.
224309925|NCT04186351|BEHAVIORAL|Encounter notification service|The caring support and services provided by SCHSA will consist of multiple components, including standard call \& care center support, medical appointment reminder, assistance to reschedule appointment, follow-up calls with either nurse or health workers to monitor health situation of service recipients, assessing needs of service recipient for elderly home care and/or rehabilitation services, providing elderly home care and/or rehabilitation services based on assessment, assessing needs of service recipient for emotional and community support, providing additional emotional support via either social calls by volunteers or counseling by social workers, and making referrals for community support services.
224309926|NCT02832180|DRUG|OC containing EE and NET|
224309927|NCT02832180|DRUG|BMS-986142|
224309928|NCT02254161|DRUG|Matching placebo|Tablet
224309929|NCT02254161|DRUG|BI 1181181 healthy elderly|Tablet
224309930|NCT02254161|DRUG|BI 1181181 Healthy young|Tablet
224309931|NCT02125162|DRUG|BCX4161|Each subject will receive Treatments A, B, and C in an open-label, randomized sequence with a washout period of at least 7 days between each dose
224309932|NCT06232473|BEHAVIORAL|Patient Education|Please see arm desciption
223501410|NCT06278805|OTHER|The reliability and validity study of the T-LUNS|To test the reliability and validity of the T-LUNS, 110 chronic stroke survivors fulfilling the inclusion / exclusion criteria at the 3 study sites will be assessed. The assessment of each patient will include recording of the demographic and clinical characteristics and administration of the T-LUNS as well as the Turkish version of the Stroke Impact Scale 3.0 (SIS). For the assessment of test-retest reliability of the T-LUNS, half of the participants (n= 55) will fill in the T-LUNS again, 2 weeks after the first administration.
223501411|NCT03197155|DRUG|Direct Acting Antivirals against hepatitis C virus infection|The cohort includes cirrhotic patients infected with HCV and successfully treated for their first history of hepatocellular carcinoma. Some of these patients were treated with direct-acting antivirals for their HCV infection while the others did not receive any direct-acting antivirals treatment during the follow-up period.
223501412|NCT04981054|PROCEDURE|Cystocele repair|Repair of endopelvic fascia and anterior colporrhaphy
223591814|NCT03596684|PROCEDURE|glucose tolerance test|2 exploration mornings distant from 28 days (before and after citrulline) will allow carrying out an oral glucose tolerance test of 2 hours (75 g glucose per os)
223591815|NCT02540668|DRUG|Lanabecestat|Administered orally
223591816|NCT02540668|DRUG|Warfarin|Administered orally
223591817|NCT05589675|OTHER|Dispatch of the screening test along the invitation letter to the national colorectal cancer screening program|The individuals eligible for the colorectal cancer screening program will receive at home an invitation letter to participate to the program along with a FIT test. The follow-up will be similar to the standard of care, i.e. reminder letters at 5 and 10 months if there is no participation, and reminders if no coloscopy after a positive FIT test
224074750|NCT04471727|BIOLOGICAL|Ifinatamab Deruxtecan (I-DXd)|IV infusion
224074751|NCT00465595|DRUG|psilocybin|The dose of psilocybin received in the two sessions will range anywhere from low to high.
224309933|NCT06232473|DRUG|Duloxetine|Please see arm description
224074752|NCT04515732|DRUG|Apremilast Oral Tablet|As in description
224074753|NCT00027339|DRUG|lopinavir/ritonavir|
224309934|NCT06232473|DRUG|Benztropine Mesylate 0.5 MG and passive placebo RAP|Please see arm description
224309935|NCT06232473|BEHAVIORAL|Enhanced usual care|Please see arm description
224309936|NCT04037774|DRUG|Dexmedetomidine|comparision of different doses of dexmedetomidine used intrathecally
224309937|NCT04037774|OTHER|placebo|addition of placebo with local anesthetic to create a control group
224309938|NCT01462773|DRUG|Bortezomib|VELCADE (1.0 mg/m2, 1.3 mg/m2, or 1.6 mg/m2 IV based on patient cohort). After three patients have received 5 weeks of therapy (1 cycle) at the initial dose of VELCADE (1.0 mg/m2, Cohort 1) with no dose limiting toxicity, the dose will be raised to 1.3 mg/m2 for the next cohort of three patients. If this dose level is well-tolerated in three consecutive patients, the dose of VELCADE will be raised to 1.6 mg/m2.
224309939|NCT01462773|DRUG|Interferon Alfa-2b|I = IFN-α-2b (INTRON A): 5 million units (MU)/m2 SC. INTRON A (5MU/m2) will be administered subcutaneously on Days 1, 3 and 5 of Week 0. During Cycle I, INTRON A will be administered on Days 1, 3 and 5 of Weeks 1-3 of and on Days 1 and 3 of Week 4 to allow for surgical biopsy on Day 5. During Cycles II-V, IFN-α will be administered on Days 1, 3 and 5 of Weeks 1-4. To assess the toxicity profile of IFN-α-2b alone, no VELCADE will be administered during Week 0.
224309940|NCT06632431|OTHER|Endometrial cancer (EC)|"Endometrial cancer (EC) who underwent surgical staging (total hysterectomy and bilateral salpingo-oophorectomy) Histopathological slides for these cases will be reexamined and staged according to both the Federation of Gynecology and Obestetrics (FIGO) 2009 and updated Federation of Gynecology and Obestetrics (FIGO) 2023 endometrial staging systems. Upstaging refers to reclassification to a higher stage in the FIGO 2023 system compared to Federation of Gynecology and Obestetrics (FIGO)2009, while downstaging is the opposite.~All patients underwent lymph node dissection except those with Stage IA-Grades I and II endometrioid endometrial cancer and tumor size \<2 cm."
224309941|NCT01181362|PROCEDURE|Endoscopy|All patients will meet the physician at the Head and Neck centre at PMH, where they will have a topical anesthetic (lidocaine endotracheal aerosol, 10 mg/dose) sprayed into both nostrils. After allowing 5-10 minutes to let the anesthetic take effect, they will have an endoscopy procedure using a flexible scope inserted through the nostrils. The procedure will first be performed while patients are sitting up. During the procedure, patients will be asked to rate their discomfort on a 10-point scale. The endoscope will then be removed. After a short rest (15 minutes), the endoscopy procedure will be repeated with patients lying down. They will again be asked to rate their level of discomfort. After another short rest for recovery, they will meet with the physician to discuss both endoscopic procedures and to complete a questionnaire on discomfort, tolerance and acceptability
224074754|NCT00027339|DRUG|indinavir sulfate|
224074755|NCT00027339|DRUG|tenofovir disoproxil fumarate|
224074756|NCT00027339|DRUG|ritonavir|
224074757|NCT00027339|DRUG|fosamprenavir|
224074758|NCT01075555|DRUG|pravastatin sodium|
224074759|NCT01075555|DRUG|sorafenib tosylate|
224074760|NCT05547178|OTHER|Qualitative interview - eurythmy group|Participants will be interviewed about self-perceived changes in everyday life during participation in the eurythmy intervention of the ENTAiER study.
224192536|NCT03729830|DEVICE|Boston Scientific Open Irrigated Ablation Catheters|The BSC Open-Irrigated catheters are designed to deliver RF energy to catheter tip electrode for cardiac ablation. The BSC OI catheters incorporate an open-irrigated cooling mechanism through a tip that is partitioned into two chambers. The proximal chamber circulates normal saline (0.9 %) within the tip to cool the proximal electrode and mitigate overheating while the distal chamber allows the fluid to flow through six irrigation holes into the patient's vasculature, thereby cooling the tip/tissue interface.
224192537|NCT05070624|BEHAVIORAL|The Virtual Peer Support Program|Training: We have previously developed and beta-tested a virtual peer mentor training program adapted from the St. Jude's Research Hospital's (Memphis, USA) program for FCs of children with cancer for adults using HMV. Content \& Design of the Virtual Peer-Support Program: The program will be delivered by the aTouchAway™ App used for the LIVE program. Participants will be requested to access peer mentors ≥1 time/week. Participants can choose to interact with a peer mentor which will be assigned as well as other peer participants. Onboarding: Participants and mentors will create a personal profile of their caregiving situation (e.g., duration of care, family member age and diagnosis), to enable selection of mentors by the research team believed to be well suited to address support needs, questions, and concerns based on similar lived experience.
224192538|NCT04148313|OTHER|No Intervention|There is no intervention for this study.
224192539|NCT04552769|DRUG|Abemaciclib|200 mg orally
224309942|NCT00902317|PROCEDURE|Cryoplasty (PolarCath peripheral balloon catheter)|Cryoplasty involves advancing the balloon catheter to the site of the lesion and delivering liquid nitrous oxide into the balloon, where it expands into gas and inflates the balloon.
224192540|NCT04211467|OTHER|No Intervention|There is no intervention for this study
224192541|NCT05216419|DRUG|Cholecalciferol|"Since the concentration of D-mac 30,000 IU in the body reaches the maximum in the body around 1 to 3 weeks after administration, the drug is taken once 15 days before the surgery so that the vitamin D3 concentration is maximized at the time of surgery.~In the case of the control group, there is no drug to be taken."
224192542|NCT05011760|RADIATION|Baseline [C-11]NPA PET Scan|Radiotracer
224192543|NCT05011760|DRUG|d-amphetamine|Oral, 0.5 mg/Kg
224192544|NCT05011760|RADIATION|Post-amphetamine [C-11]NPA PET Scan|Radiotracer
224192545|NCT01711736|BIOLOGICAL|Quadrivalent influenza GSK2282512A vaccine|1 or 2 doses administered intramuscularly (IM) in deltoid muscle or anterolateral thigh on Day 0 (primed subjects) and on Day 0 and Day 28 (unprimed subjects) respectively.
224192546|NCT01711736|BIOLOGICAL|Fluarix|1 or 2 doses administered IM in deltoid muscle or anterolateral thigh, on Day 0 (primed subjects) and on Day 0 and Day 28 (unprimed subjects) respectively.
224309943|NCT00902317|PROCEDURE|Laser Angioplasty (Spectranetics)|The basic concept of laser angioplasty is to apply light energy directly to the arterial plaque, thereby altering the plaque in some helpful way, without damaging the surrounding artery.
224309944|NCT00902317|PROCEDURE|SilverHawk Atherectomy|Once the catheter is connected to the cutter driver, by retracting the positioning lever this simultaneously turns on the motor and caused the distal portion of the cutter housing to deflect, forcing the device against the target lesion.
224309945|NCT00902317|DEVICE|Viabahn Endograft|The Gore-Viabahn should be positioned across the target lesion using the radiopaque hub and tip markers on the catheter. These markers identify the proximal and distal ends of the device, respectively.
223591818|NCT05589675|OTHER|Sending of a prior notification to the new entrants of the national program|Dispatch of a notification, one month prior the dispatch of the screening test along the invitation letter. This intervention is among the new entrants to the national program
224309946|NCT00902317|PROCEDURE|"Angioplasty/Stent (Guidant Absolute stent)"|A Stent is a metal scaffold that is also delivered by a catheter and positioned through the narrowing in the artery. The stent is then expanded against the wall of the blood vessel to provide a wider channel for blood flow. The stent remains implanted in the blood vessel, and after a few weeks, the inner lining of the blood vessel will grow over the stent surface.
224309947|NCT05367050|BEHAVIORAL|Lucid Lane Therapy Program|This intervention is designed to aid participants with pre-surgery anxiety management and surgery prep and pain management post-surgery. Participants will be assigned a Lucid Lane pain coach who will utilize mindfulness, cognitive behavioral therapy, group therapy, and mind-body therapies, to accomplish those goals.
224309948|NCT05367050|BEHAVIORAL|Surgical Preparedness Course|This intervention is designed to help the participant prepare for their upcoming surgery. Classes will include discussions around managing chronic pain before surgery, building mental resilience, dealing with the uncertainty of a new diagnosis or treatment plan, questions to ask their anesthesiologist before and on the day of surgery, what to expect during their potential stay at the hospital, and how to optimize their recovery after surgery. Sessions will often include expert doctors who focus on surgery and medical management around it.
224309949|NCT02819700|BEHAVIORAL|prevalence of behavioural dysexecutive syndrome|Behavioural Dysexecutive Syndrome Inventory (ISDC)
224309950|NCT03123432|DIETARY_SUPPLEMENT|immunomodulating nutrients enriched diet|
224309951|NCT03123432|DIETARY_SUPPLEMENT|standard diet|
224309952|NCT06884514|DRUG|Psilocybin|A moderate dose of 20 mg psilocybin will be administered.
223501413|NCT01850940|DRUG|Tolvaptan|Tolvaptan (OPC-41061) is a benzazepine derivative synthesized by Otsuka Pharmaceutical Company, Ltd. Tolvaptan was approved for the treatment of specific forms of hyponatremia by the United States (US) Food and Drug Administration (FDA) in May 2009, the European Medicines Agency on Aug 2009, Japan (Oct 2010), China (Sep 2011) and Korea (Sep 2011). Tolvaptan was approved for the adjunct treatment of volume overload in heart failure by the Japanese Ministry of Health, Labour, and Welfare (MHLW) in Oct 2010. It is also being developed for the treatment of autosomal dominant polycystic kidney disease (ADPKD), and for the treatment of hepatic edema.
223501414|NCT01850940|OTHER|conventional thearpy|conventional therapy with salt limitation ,et al
224192547|NCT04416009|DEVICE|NİCaS|whole body bioimpedence method
224192548|NCT01342445|DRUG|lisdexamfetamine dimesylate|30-mg, 50-mg, 70-mg administered for one week in context of double-blind, placebo-controlled crossover design
224192549|NCT01342445|DRUG|Placebo|
224192550|NCT05299359|BIOLOGICAL|TAK-019|TAK-019 intramuscular injection
224192551|NCT04515979|DRUG|Vactosertib 300 mg BID and pembrolizumab 200 mg IV|Vactosertib 300 mg orally (PO) BID(5 days on/2days off) and pembrolizumab 200 mg IV (Q3W).
224192552|NCT04208178|DRUG|Alpelisib|Alpelisib orally taken - continuous once daily, in a 21-day cycle.
224192553|NCT04208178|DRUG|Alpelisib matching Placebo|Alpelisib matching placebo orally taken - continuous once daily, in a 21-day cycle
224192554|NCT04208178|DRUG|Trastuzumab|Trastuzumab 6mg/kg given intravenously - Day 1 of Cycle 1, and on Day 1 of every cycle thereafter (Cycle=21 days)
224192555|NCT04208178|DRUG|Pertuzumab|Pertuzumab 420 mg given intravenously - Day 1 of Cycle 1, and on Day 1 of every cycle thereafter (Cycle=21 days)
224192556|NCT05141266|BEHAVIORAL|Patient Navigation|PN involves 8 weekly telephonic sessions lasting 30-45 minutes (telephonic to support lower-costs/sustainability). In session 1, the navigator reviews with the participant a report of scores from the baseline assessment to understand the participant's current health needs/challenges; session 1 also involves development of therapeutic alliance/rapport and goal setting. Sessions 2-4 focus on goal setting and identifying barriers and problem resolutions. The navigator elicits motivation and discusses this in context of readiness to change heath behavior and self-management skills. Sessions 2-4 also involve navigators supporting/assisting patients to fill out paperwork and enroll in needed social services and/or mental/behavioral/physical healthcare, including but not limited to primary care. Sessions 5-7 focus on encouraging and reinforcing treatment adherence, review-ing and identifying other care needs, and offering linkages to service providers as applicable
224192557|NCT05141266|OTHER|Standard Medication Counseling (SMC)|SMC participants receive a single medication information/counseling session delivered by a University of Utah pharmacist to: (1) offer counseling, (2) document counseling was offered, (3) offer a counseling process for patients not present (not applicable to this study given all patients must screen in person), and (4) discuss generic substitution.
224192558|NCT06341972|BEHAVIORAL|Cognitive behavioral therapy based self-management for anxiety|Evidenced based approach for educating patients about how to manage anxiety after respiratory failure.
224309953|NCT06884514|DRUG|3,4-Methylenedioxymethamphetamine|A moderate dose of 100 mg MDMA will be administered.
223591819|NCT05282433|DRUG|Surufatinib|Surufatinib Alone or Combined With Anti-PD-1 mAb in the Treatment of Advanced Hepatocellular Carcinoma
223591820|NCT05799417|OTHER|Acoustic stimuli|During different states of sedation/anaesthesia and sleep, acoustic stimuli will be presented and compared to a within-subject baseline.
223591821|NCT02716181|DEVICE|"Атопик Soothing Cream"|Topical application of a study cream to involved skin areas twice a day.
223591822|NCT02716181|DEVICE|Placebo|Topical application of a study placebo cream to involved skin areas twice a day.
223591823|NCT00407017|DRUG|Gatifloxacin|
223591824|NCT00407017|DRUG|Ketorolac LS|
223591825|NCT00407017|DRUG|Pred Forte|
224074761|NCT05547178|OTHER|Qualitative interview - tai chi group|Participants will be interviewed about self-perceived changes in everyday life during participation in the tai chi intervention of the ENTAiER study.
223591826|NCT00407017|DRUG|Moxifloxacin|
223591827|NCT00407017|DRUG|Nepafenac|
223591828|NCT00407017|DRUG|EconoPred Plus|
223591829|NCT02251938|DRUG|DE-109 440 μg|Medium Dose
223591830|NCT04456192|BEHAVIORAL|Indoor Cycling Interval Exercise Training|"The 3-month intervention consisted of a physical exercise program involving three indoor cycling sessions per week, with a total of 36 training sessions. Subjects exercised on cycle ergometers Schwinn® Evolution® (Schwinn Bicycle Company, Boulder, Colorado, USA). Each session lasted approximately 55 minutes. Training sessions consisted of a 5-min low-intensity warm-up (cycling at 50-65% of maximum heart rate (HRmax)), 40 min of main training at an intensity of 65-95% of HRmax, 5 min of non-weight-bearing cycling, finishing with 5 min of low-intensity cool-down stretching and breathing exercises.~Main part of the training was interval. Each exercise session consisted of 3 to 4 high intensity intervals with intensity exceeding 80% of HRmax, often reaching anaerobic threshold. High intensity intervals lasted approximately 4-minutes and were interspersed by recovery periods at 65-80% of HRmax."
224074762|NCT05547178|OTHER|Qualitative interview - standard care group|Participants will be interviewed about self-perceived changes in everyday life during participation in the standard care group of the ENTAiER study.
224074763|NCT02767648|OTHER|proteomic urine analysis|proteomic urine analysis
224074764|NCT04600895|DRUG|Favipiravir|Favipiravir
224074765|NCT04600895|DRUG|Placebo|Placebo
224074766|NCT03506295|DEVICE|Radial Endobronchial Ultrasound Probe|The radial EBUS procedure is performed by inserting a miniature ultrasound probe (radial EBUS probe) through the working channel of a flexible bronchoscope or catheter (guide sheath). Real-time imaging of the surrounding tissue enables the clinician to determine the lesion's exact location and size.
224074767|NCT03506295|DEVICE|Flouroscopy|Real-time fluoroscopy will be used in all cases to guide the radial probe ultrasound and/or cryobiopsy probe placement.
224074768|NCT00868283|DRUG|Cerebrolysin|30 ml study drug will be given once daily by intravenous infusion for 10 consecutive days.
224074769|NCT00868283|DRUG|0.9% Saline Solution|30 ml will be given once daily by intravenous infusion for 10 consecutive days.
224074770|NCT03823469|BEHAVIORAL|CCTP|Twelve weekly one-on-one 30-minute tele-sessions through video conference. At the first session, subjects identify their vision regarding home cooking and 3-month goals. During each subsequent meeting, subjects will review their progress towards reaching the prior week's culinary goals and identify goals for the coming week, using a self-discovery process. When patients detect a new culinary skill that is necessary for their progress, s/he will either be taught through discussions or referred to active learning from a Culinary Resource Center.
223591831|NCT05612334|BEHAVIORAL|exercise (5 minutes warm-up-30 minutes walking-5 minutes cooling down)|the breathing exercise group, which constituted the placebo control group, were first informed by the researcher about the correct breathing techniques and was given an informative training brochure prepared by the researcher containing the correct breathing exercise information.
223746310|NCT07181395|BEHAVIORAL|Conventional Physiotherapy|Conventional physiotherapy including transcutaneous electrical nerve stimulation (20 minutes), massage, lumbar stretching and strengthening exercises, postural training, and patient education. Delivered twice weekly for 4 weeks.
224074771|NCT03823469|BEHAVIORAL|Nutritional counseling|Two 30-minute nutritional counseling sessions
224074772|NCT01622881|DRUG|Normal saline|Normal saline 200mL : the infusion of 4mL/hr for post-operative 48 hours
224074773|NCT01622881|DRUG|Nefopam|Nefopam 160mg (16 mL) mixed to normal saline 184 mL : the infusion of 4mL/hr for post-operative 48 hours
223501415|NCT00768859|DRUG|paclitaxel, trastuzumab and carboplatin|paclitaxel; 70 mg/m2 trastuzumab; 2 mg/kg (loading dose 4 mg/kg) carboplatin; AUC = 3
223501416|NCT03940677|PROCEDURE|Brain MRI|3 Tesla brain MRI for structural and perfusion evaluation, resting state analysis and functional MRI
223501417|NCT03940677|PROCEDURE|TMS-EEG|Transcranial magnetic stimulation (TMS) coupled with electroencephalogram (EEG) study
223501418|NCT03940677|BEHAVIORAL|Behavioral and cognitive battery|Emotional, attentional and behavioral assessment using predefine scales and measures
223501419|NCT03940677|OTHER|Clinical evaluation and clinical scales|Neurological evaluation, ophthalmologic assessement, Montreal cognitive assessment (MoCA), movement disorder society (MDS)- UPDRS
224074774|NCT02762474|DRUG|nab-paclitaxel group|Weekly Regimens of Nab-paclitaxel Plus Cispaltin Combined With Concurrent IMRT
224074775|NCT05779826|OTHER|Play dough|In the play dough group, play dough was used during the treatment of children receiving nebulizer therapy.
224074776|NCT05764486|DEVICE|Hitachi's Heavy Ion Beam Therapy System HyBEAT|treating patients with solid tumor
224074777|NCT04481776|OTHER|Breakfast consumption|Standardised breakfast consumption across seven days
224074778|NCT04481776|OTHER|Breakfast omission|No breakfast consumed across seven days
224074779|NCT03188237|BEHAVIORAL|AfyaJamii|AfyaJamii is a group antenatal and well-child care program developed in Kenya for use in Kenyan health centers
224074780|NCT04776590|DRUG|Tislelizumab|neoadjuvant immunotherapy
224074781|NCT00373035|GENETIC|proteomic profiling|
224074782|NCT00373035|OTHER|immunological diagnostic method|
224074783|NCT00373035|OTHER|laboratory biomarker analysis|
224074784|NCT00373035|OTHER|mass spectrometry|
224074785|NCT00373035|PROCEDURE|biopsy|
224074786|NCT00373035|PROCEDURE|ultrasound imaging|
224074787|NCT03996915|DEVICE|Pdt Photodynamic Therapy|device irradiation with low intensity laser (wave length = 660 nm) 9 J (Joules) per point(6 points) and radiant 90 seconds PS will be applied in sufficient quantity to cover the middle third and back of the tongue and wait for 5 minutes.six points with the distances of 1 cm between them will be irradiated.
224074788|NCT03996915|OTHER|tongue scrapper|Tongue scrapping will be performed by the same operator in all patients. Posterior -anterior movements will be performed with the scrapper over the lingual dorsum. in order to promote the mechanical removal of tongue coating
224074789|NCT00005112|DRUG|Human recombinant growth hormone|
224074790|NCT00791271|DRUG|Decitabine|Starting dose of 10mg/m\^2 given daily via intravenous infusion on days 1-5 of 28 day cycle.
224074791|NCT00791271|DRUG|Pegylated Interferon Alpha-2b|Starting dose of 3 µg/kg injection under the skin once a week on days 1, 8, 15, and 21 of 28 day cycle.
224074792|NCT03006939|PROCEDURE|Cytoreductive surgery|Cytoreductive surgery in terms of tumor debulking is performed in order to promote survival
224074793|NCT03640871|DEVICE|URGO AWC_019 dressing (AWC=Advanced Wound Care)|URGO AWC\_019 dressing 10x10 cm (AWC=Advanced Wound Care)
224074794|NCT06099587|DIAGNOSTIC_TEST|high-resolution diffusion MRI|The study will combine multi-compartment models (e.g. Archer et al., 2020; Parker et al., 2020) of high-resolution diffusion MRI within medial temporal lobes regions of interest defined through the ASHS algorithm (Yushkevich et al., 2015), with theoretically driven cognitive assessment medial temporal lobes functions. The '4 mountains test' and the 'Memory entities' test will allow specific probing of hippocampal and rhinal cortices functions, respectively (Hartley et al., 2007; Besson et al., 2020).
224192559|NCT06367764|BEHAVIORAL|Cognitive Processing Therapy|Cognitive Processing Therapy teaches cognitive restructuring skills to help clients change beliefs and process emotions related to a traumatic event or events.
224192560|NCT06367764|BEHAVIORAL|STAIR Narrative Therapy|STAIR Narrative Therapy teaches coping skills (e.g., for emotional regulation, interpersonal relationships, everyday stress) and includes a narrative trauma-focused component.
224192561|NCT05512533|DEVICE|Linear Ultrasound Bronchoscope BF-UC290F (Olympus)|A thin Olympus EBUS bronchoscope BF-UC290F will be used for all endobronchial ultrasound examinations, and biopsies will be conducted with EBUS needles - the ViziShot 2 22G (Olympus).
224192562|NCT05881031|OTHER|Home Initiation of NiPPV|Initiation of NiPPV in the home environment through the utilization of an awake NiPPV titration, oximetries, and telemonitoring.
224192563|NCT04319939|OTHER|Assist Control Mode and Pressure Support Mode Mechanical Ventilation|Diaphragm ultrasound measurements (end expiration and peak inspiration thickness) will be performed in assist control mode and pressure support mode mechanical ventilation in each participant. The participant will thus serve as his/her own control for these interventions.
224192564|NCT06009523|DEVICE|Transcranial direct current stimulation|1 stimulation per day during 15 days.
224192565|NCT06209060|BEHAVIORAL|Hammock Position|Researchers will make a hammock by using a soft rectangular cotton cloth with ropes that pass through the circular openings of the incubator and are tied on the upper part of it. Babies will be placed in this hammock in a supine position with their extremities in the midline. The spine of the preterm neonate will support while arms and knees are flexed. Additionally, a small rectangular roller will be placed between the cervical and scapular region of the newborn in the hammock position to ensure that no hyperflexion or hyperextension position of the head occurs, which may impair respiratory function.
224192566|NCT06209060|BEHAVIORAL|Nesting|In the nesting group, a nest will be made using rolls prepared with materials such as towels and blankets, and the baby will be placed in this nest. The baby's head and body will be positioned on the same axis, its extremities will be positioned in the midline, and its hands will be positioned close to its face.
224192567|NCT04961645|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|TMS is a safe and noninvasive method for affecting brain function relying on the properties of electromagnetic induction. Action potentials are triggered in neurons, along with a subsequent period of deactivation. Normal ongoing brain activity is disrupted providing a way for investigators to produce a transient and reversible period of brain disruption.
224192568|NCT04961645|BEHAVIORAL|Computer-based Test|Participants will be seated comfortably in a chair and asked to complete a simple computer-based task where they imagine walking through a room and press a button indicating if they can leave through a door on the left, center, or right wall. During or just before each of these tasks, participants will receive rTMS. In rTMS, a small plastic coil is placed next to the participant's head. The coil will be placed over the relevant brain region identified during the participant's fMRI scan. The coil will then generate a magnetic pulse, and stimulation will occur.
224309954|NCT06884514|DRUG|Psilocybin placebo|Mannitol capsules instead of capsules containing psilocybin.
224309955|NCT06884514|DRUG|3,4-Methylenedioxymethamphetamine placebo|Mannitol capsules instead of capsules containing MDMA.
223501420|NCT03684057|BEHAVIORAL|App-Delivered Mindfulness Training (MT)|Unwinding Anxiety is an app-delivered mindfulness training program which includes a progression through 30+ daily modules. Each module's training is delivered via short video tutorials and animations (\~10 min/day). Each training builds on the previous one; modules are 'locked' so that they can only be viewed at a pace of 1/day (previous modules can be reviewed at any time). A built-in self-assessment is taken after every seven modules to ensure key concepts are learned before moving on with automated suggestions on which modules to repeat based on the self-assessment results. User-initiated guided practices range from short exercises (30 seconds) to manage anxiety the moment it arises to formal guided meditations (up to 15 minutes), and can be accessed at any time
223501421|NCT04937530|DRUG|RT001|RT001 8.64 g/d (3 capsules TID) for 1 month followed by 5.76 g/d (3 capsules BID) for an additional 11 months
223501422|NCT04937530|DRUG|Placebo|Placebo Comparator: Placebo Inactive comparator capsule 960 mg/capsule: 3 capsules TID for 4 weeks, followed by 3 capsules BID for the remaining 44 weeks.
224074795|NCT03046355|PROCEDURE|Labor induction at 37.0 to 37.6 weeks of gestation|Diagnosis of FGR with induction at 37 weeks 0 days of gestation to 37 weeks and 6 days
224074796|NCT03046355|PROCEDURE|Expectant monitoring until delivery|Diagnosis of FGR managed with expectant monitoring and delivery as indicated
224074797|NCT03087006|OTHER|Automatic Self Transcending Meditation (ASTM)|Automatic Self Transcending Meditation (ASTM) is a class of meditation that helps quiet the mind. Research suggests that ASTM helps reduce depression, anxiety, stress, and may improve health related quality of life. Further, ASTM is easier to learn and to teach.
224074798|NCT03087006|OTHER|Treatment as Usual|Usual Care includes usual care of the participants including dry eye disease medications
224074799|NCT03870555|DRUG|TAK-954|TAK-954 infusion administered intravenously.
224074800|NCT03870555|DRUG|TAK-954 Placebo|TAK-954 placebo-matching infusion intravenous.
224074801|NCT01924208|BIOLOGICAL|Timothy, Phleum pretense|Allergen. Grazax® sublingual 75.000 SQ-T tablet (extracted from timothy, Phleum pretense), once daily until operation (ALK-Abelló, Hørsholm, Denmark) (n=30) .
224074802|NCT01924208|BIOLOGICAL|Live attenuated influenza virus|Virus. Fluenz®, nasal live attenuated influenza vaccine, one 0.2 mL dose (MedImmune, Gaithersburg, USA) (n=60, 50:50 atopic:non-atopic).
224074803|NCT01924208|PROCEDURE|Timothy + attenuated influenza virus|Allergen. Grazax® sublingual 75.000 SQ-T tablet (extracted from timothy, Phleum pretense), once daily until operation (ALK-Abelló, Hørsholm, Denmark) + Virus. Fluenz®, nasal live attenuated influenza vaccine, one 0.2 mL dose (MedImmune, Gaithersburg, USA) (n=30).
224074804|NCT01309035|PROCEDURE|Total Knee Arthroplasty|Surgery for OA knee pains
224074805|NCT04279015|PROCEDURE|Kinesio tape procedure|"Conventional rehabilitation treatment: Hotpack, ultrasound, conventional TENS and exercise for neck pain.~Kinesio taping procedure: Inhibition technique with 15-25% tension to the upper trapezius muscle with I tape to reduce pain and muscle spasm, to support the weak muscles, Facilitation technique with Y-band with 15-35% tension to the cervical paravertebral muscles, and X-band with 15-35% tension to the rhomboideus major muscle technique and the correction technique was applied to the region where the individual defined the most pain and tenderness in palpation by using the star application."
224074806|NCT05730400|DRUG|BMAC loaded on bovine graft|Bone marrow aspirate concentrate loaded on bovine graft for sinus floor augmentation
224074807|NCT05730400|DRUG|Bovine graft only|Bovine graft only for sinus floor augmentation
224074808|NCT01570673|BEHAVIORAL|Group urotherapy|Children in this arm will receive group urotherapy in small groups with other children.
224074809|NCT01570673|BEHAVIORAL|Individual Urotherapy|Children will receive standard individual urotherapy in regular pediatric urology clinic.
224074810|NCT01828931|BEHAVIORAL|Lifestyle Intervention|A lifestyle intervention (LI) aimed at reducing caloric intake and increasing physical activity
224074811|NCT01828931|OTHER|Usual Care|Care as usual
224074812|NCT02693587|DRUG|Misodel and Angusta|
224074813|NCT04313907|COMBINATION_PRODUCT|low level laser therapy plus topical clonazepam|combination of treatment, low level laser therapy (15 joules, 6 sesions, 14 days) plus topical clonazepam (1 mg,3 times per day, 14 days)
224309956|NCT06882811|BIOLOGICAL|CD83-positive MSC|90 patients are infused with 1×10⁸ stem cells per session and receive regulatory treatment
224309957|NCT06882811|BIOLOGICAL|regulatory MSC|45 patients are infused with 1×10⁸ stem cells per session and receive regulatory treatment
224309958|NCT06882811|OTHER|control solution|45 patients are infused with equal volume of control solution and receive regulatory treatment
223501423|NCT00688779|DRUG|AZD8848|Concentrate for nasal spray,solution 60 mg/g
224074814|NCT04313907|DRUG|Sham laser plus topical clonazepam|Sham laser therapy (0 joules, 6 sesions, 14 days) plus topical clonazepam(1 mg,3 times per day, 14 days)
224074815|NCT04313907|RADIATION|Active laser plus placebo of topical clonazepam|low level laser therapy (15 joules, 6 sesions, 14 days) plus placebo topical clonazepam(lactose,3 times per day, 14 days)
224074816|NCT00280007|DRUG|bevacizumab|bevacizumab 5 mg/kg i.v. every 14 days for 52 weeks
224074817|NCT01230957|BIOLOGICAL|Clostridium difficile toxoids A and B (Low-dose with adjuvant)|0.5 mL, Intramuscular on Days 0, 7, and 30
224074818|NCT01230957|BIOLOGICAL|Clostridium difficile toxoids A and B (Low-dose without adjuvant)|0.5 mL, Intramuscular on Days 0, 7, and 30
224074819|NCT01230957|BIOLOGICAL|Clostridium difficile toxoids A and B (high-dose with adjuvant)|0.5 mL, Intramuscular on Days 0, 7, and 30
224309959|NCT03209557|OTHER|SmartWatch SmokeBeat Application|The SmokeBeat app is a digital health app that allows for the user to monitor their smoking behavior in real time, set smoking cessation goals, and allows investigators, doctors and others using the app with participants to send messages directly related to smoking behavior. The SmokeBeat app, developed by Somatix Inc., will collects time-stamped on hand movements associated with smoking behavior. Participants will receive notifications on their phone and smartwatch when a smoking bout has been detected. In addition this app will deliver daily text messages aimed at improving quit rates among participants. We will be able to create the types of messaging we want to send and to modify when these messages will be sent to all participants. http://somatixinc.com/smokebeat/
224309960|NCT01919788|DRUG|Insulin (Insuman Rapid)|
224309961|NCT01919788|DRUG|Glucose|
224192569|NCT04961645|BEHAVIORAL|Behavioral-based Test|Participants will be asked to complete a simple behavioral task that will require them to walk around in a small room and search for hidden objects. During or just before each of these tasks, participants will receive rTMS. In rTMS, a small plastic coil is placed next to the participant's head. The coil will be placed over the relevant brain region identified during the participant's fMRI scan. The coil will then generate a magnetic pulse, and stimulation will occur.
224192570|NCT03396445|DRUG|Boserolimab|IV infusion
224192571|NCT03396445|BIOLOGICAL|Pembrolizumab|IV infusion
224192572|NCT03396445|DRUG|Pemetrexed|IV infusion
224192573|NCT03396445|DRUG|Carboplatin|IV infusion
224192574|NCT03396445|DRUG|Nab-paclitaxel|IV infusion
224192575|NCT01892397|DEVICE|Optune (NovoTTF-100A)|
224192576|NCT06583993|DRUG|HNF4α srRNA|"HNF4α srRNA will be administered intravenously for the treatment of ICC. The dosing regimen is planned for a second dose 14 ± 3 days post-initial treatment, followed by subsequent treatments every 28 ± 7 days, with adjustments made based on patient tolerance and therapeutic response.~According to Amendment 1, patients who have received at least 4 cycles of HNF4α srRNA therapy and have a tumor assessment of SD (stable disease) or PD (progressive disease) per RECIST v1.1 criteria may, after a comprehensive evaluation by the investigator considering the patient's treatment history and the current safety and efficacy data of HNF4α srRNA, continue HNF4α srRNA at the same dose, or have their dose adjusted, in combination with immunotherapy, targeted therapy, or chemotherapy."
224192577|NCT03707769|DEVICE|TIPS microspheres|TIPS microspheres manufactured from GMP grade poly(lactide-co-glycolide) (PLGA) prepared as a paste with GranuGel.
224192578|NCT05216575|DRUG|Administration of Almitrine|Administration of Almitrine (intravenous bolus of 0.5 mg/kg over 30 minutes followed by a continuous perfusion of 16 mg/kg/min in responders)
224192579|NCT02177370|DRUG|Fenoterol MDI|
224192580|NCT02177370|DRUG|DSCG MDI|
224309962|NCT01919788|OTHER|Saline|
223501424|NCT00688779|DRUG|Placebo|
223501425|NCT04027387|BIOLOGICAL|TMB-365|An IgG1 monoclonal antibody targeting domain 2 of the CD4 receptor for treatment of HIV-1 infection
224309963|NCT01177059|GENETIC|OZ1 transduced cells|Long term follow up of previously infused OZ1 transduced cells
224309964|NCT06955091|OTHER|contrast strength training|For eight weeks players performed Contrast strength training included bench press, pull-over, half squat, and forward lunge. Each session began with a 10-minute warm-up (jogging, dynamic stretching, and basic weightlifting exercises) and ended with a 5-minute cool-down. Training was performed twice a week for 8 weeks on non-consecutive days (Tuesday and Thursday). Exercises were done using free weights at 40-80% of 1-repetition maximum, in 3-4 sets of 2-4 repetitions
224309965|NCT06955429|DEVICE|Dental restorative or endodontic treatment requiring Biodentine XP use|In this observational and prospective study, the patients are included since this intervention is schedulded as part of their routine care.
224309966|NCT00839553|PROCEDURE|Intrapleural Minocycline application|
224309967|NCT05158088|DEVICE|Borescope|Endotracheal intubation using borescope
223501426|NCT05957341|DEVICE|active rTMS: 20min inter-session interval|Participants will receive active TMS, with 3 sessions per day, 1800 pulses/session, and 20 min inter-session intervals, lasting for 21 days. Individualized targets will be generated using the pBFS method.
223501427|NCT05957341|DEVICE|active rTMS: 50min inter-session interval|Participants will receive active TMS, with 3 sessions per day, 1800 pulses/session, and 50 min inter-session intervals, lasting for 21 days. Individualized targets will be generated using the pBFS method.
223501428|NCT05957341|DEVICE|sham rTMS: 20min inter-session interval|The parameters in this group are the same as in the active rTMS: 20min inter-session interval group. Stimulation was delivered by the same device as the active group fitted with a sham coil.
223501429|NCT05957341|DEVICE|sham rTMS: 50min inter-session interval|The parameters in this group are the same as in the active rTMS: 50min inter-session interval group. Stimulation was delivered by the same device as the active group fitted with a sham coil.
223501430|NCT00611156|DIETARY_SUPPLEMENT|ginger|added to a brunch meal
223501431|NCT00611156|DIETARY_SUPPLEMENT|black pepper|Added to a brunch meal
223501432|NCT00611156|DIETARY_SUPPLEMENT|horseradish|Added to a brunch meal
224309968|NCT05158088|DEVICE|Video laryngoscope|Endotracheal intubation using video laryngoscope
224309969|NCT04556071|DRUG|Niraparib|Niraparib will be administered orally once a day continuously throughout each 21-days cycle. The initial dose will be based on the participant's basal body weight or platelet count. Participants with basal body weight≥77 kg and basal platelet count of≥150,000/microliter (μL) will take 300 mg daily. While participants with basal body weight\<77 kg and/or basal platelet count \<150,000/μL will take 200 mg daily.
224309970|NCT04556071|DRUG|Bevacizumab|The dose of Bevacizumab will be 15 mg/kg that administered via a 30-minute intravenous infusion on day 1 of every 21-day cycle in the absence of progressive disease (PD), unacceptable toxicity, participant withdrawal, Investigator's decision, or death.
223501433|NCT00611156|DIETARY_SUPPLEMENT|mustard|Added to a brunch meal
223501434|NCT00611156|DIETARY_SUPPLEMENT|placebo|Added to a bruch meal
223501435|NCT02737059|DRUG|Naloxegol|25mg daily
223501436|NCT02737059|DRUG|Codeine|30mg 4 times daily
223501437|NCT02737059|DRUG|codeine placebo|4 times daily (placebo will be made to match the codeine)
223501438|NCT02737059|DRUG|naloxegol placebo|placebo will match naloxegol, given daily
224192581|NCT04353570|OTHER|clinical interview|This interview can be carried out face to face or remotely. In the latter case, it is part of telemedicine, which is recognised by the health authorities in France.
224192582|NCT06262867|DIETARY_SUPPLEMENT|Ready. Set. Food! Stage 1 Mix ins|These supplements contain cow's milk, eggs, and peanuts.
224192583|NCT05268367|BEHAVIORAL|Written Exposure Therapy|A brief exposure-based psychotherapy for posttraumatic stress disorder
224192584|NCT06095557|DEVICE|Sponsor MCG device|unshielded device measuring cardiac magnetic fields
224309971|NCT01704274|OTHER|Low Dose GTN 0.0285 mg/hr|Low Dose GTN
224309972|NCT01704274|OTHER|High Dose GTN 0.057 mg/hr|High Dose GTN
224309973|NCT01704274|OTHER|Placebo|Placebo
224309974|NCT06490679|PROCEDURE|Hand and ultrasonic scalers and curettes|Combination of ultrasonic and hand instrumentation only. Pockets ≥7 mm will be subgingivally debrided using the piezo device according to manufacturer's instructions, and hand curettes will be used until the operator considers the surfaces to be sufficiently clean and free of deposits.
224309975|NCT06490679|DEVICE|Electro Medical Systems AIRFLOW® Prophylaxis Master Device|"(a) Disclosure of biofilm with erythrosine, (b) Removal of supragingival and subgingival (up to 10 mm) biofilm and stains with the use of AIRFLOW® Master Piezon® with AIRFLOW® PLUS powder (EMS-Dental, Nyon Switzerland).~(c) Supra- and sub-gingival debridement by using the AIRFLOW® Master Piezon® device with Piezon NO PAIN® (EMS-Dental) technology."
224309976|NCT06626464|DRUG|[14C]MK-8189|Oral administration
224192585|NCT06570031|DRUG|ONO-4578|Specified dose on specified days
224192586|NCT06570031|DRUG|letrozole|Specified dose on specified days
224192587|NCT06570031|DRUG|Palbociclib|Specified dose on specified days
224192588|NCT06570031|DRUG|abemaciclib|Specified dose on specified days
224192589|NCT04359836|OTHER|There is no intervention in this study|There is no intervention in this study
224192590|NCT05611892|COMBINATION_PRODUCT|18F-FDS PET/CT|20 millicurie (mCi) of 18F-FDS in adult patient age group and 2.5 mCi in children (age 12-18 years old) followed by a PET/CT scan.
224192591|NCT06487390|BEHAVIORAL|PrEP Pro training intervention|Training intervention adapted from evidence-based HIV epidemiology, sexual history taking, and PrEP prescription curricula.
224192592|NCT06534580|DEVICE|Virtual Reality|"A range of virtual reality software, delivered through the DR.VR (TM) device."
224192593|NCT03234023|BEHAVIORAL|INTERVENTION GROUP|Offer recommendations of healthy living habits and control of pharmacy administration
224192594|NCT04148248|OTHER|No intervention|There is no intervention for this study
224192595|NCT04800029|OTHER|Telehealth in preventing suicide (TIPS)|The TIPS synchronous telehealth protocol will consist of (a) two-way televideo evaluation with enhanced suicide risk components, performed by a Masters-level evaluator from Community HealthLink, and (b) telephone consultation and, in some cases, televideo evaluation by a psychiatrist for patients the evaluator judges should be admitted. The primary evaluation will gather data form the ED providers, patient, and any other collateral sources available. The core of the evaluation itself will consist of Community HealthLink's existing standard adult emergency mental health evaluation, which is a semi-structured evaluation focused primarily on informing a disposition decision on whether to admit the patient to a psychiatric unit. The evaluators will use this same evaluation to guide the telehealth evaluation.
224192596|NCT04800029|OTHER|Modified ED-SAFE|"Half of the ED discharged patients with suicide risk will be invited to receive post-discharge telephone counseling originally developed during the Emergency Department Safety Assessment and Follow-up Evaluation (ED-SAFE) study. The participant will receive three coaching/counseling calls, clustered within three months of the index visit, with some flexibility to continue beyond that if desired. These coaching calls will still follow the original structure and content from ED-SAFE, with modifications guided by study investigators."
224309977|NCT06633705|DRUG|Vaginal Cream with Applicator|Vaginal Cream that contains estriol (1mg estriol in 1 g cream)
223501439|NCT03343574|OTHER|Abdominal Strengthening Exercise|Abdominal strengthening exercises involve the muscles of the abdomen. These exercises are to be done in different positions like lying down (recumbent) position, sitting and standing positions. The person performing the exercise contracts the abdominal muscles for a predetermined number of times (up to 10 times), holds the contracted position for up to 10 seconds and then releases the contraction to relax and return to the original state. These exercises are done for three times everyday.
223501440|NCT05979597|PROCEDURE|Suprainguinal fascia iliaca block|After the operation is completed, the fascia iliaca will be separated from the iliacus muscle. With ultrasound guidance, the local anesthetic injection will be made between the fascia and the muscle.
223501441|NCT05979597|PROCEDURE|Suprainguinal fascia iliaca block+dexamethasone|After the operation is completed, the fascia iliaca will be separated from the iliacus muscle. With ultrasound guidance, the local anesthetic+dexamethasone injection will be made between the fascia and the muscle.
223501442|NCT03474835|DIAGNOSTIC_TEST|ISCHEMIC HEART DISEASE diagnostic|ISCHEMIC HEART DISEASE diagnostic
224192597|NCT04800029|OTHER|Treatment as Usual (TAU)|No study related intervention, just monitoring of current practices used to provide suicide-related care in the non-intervention EDs.
224192598|NCT03338257|BEHAVIORAL|Husky Reads Intervention|The Husky Reads curriculum now includes a series of 10 lessons designed to introduce preschool-age children to MyPlate while improving fruit and vegetable literacy. Each lesson includes reading at least one children's book, an activity or game, and food tasting to complement learning objectives related to MyPlate and fruit/vegetable literacy. Undergraduate students enrolled in the Husky Reads service- learning course at UConn or college students participating in the paid summer internship program deliver the preschool lessons. Each team of 2-3 undergraduate students is assigned 2-3 early care classrooms to visit and deliver Husky Reads lessons to on a weekly basis.
224192599|NCT06445179|PROCEDURE|Total Laparoscopic Hysterectomy|"The standard procedure for performing total hysterectomy will also follow the Querleu and Morrow classification system, which divides the procedure into four types based on the extent of resection:~* Type A: minimum resection of paracervix.~* Type B: transection of the paracervix and the ureter.~* Type C: Transection of paracervix at the junction with the internal iliac vascular system~* Type D: Laterally extended resection. Furthermore, bilateral ureterolysis will be performed with the option of bilateral concomitant salpingo-oophorectomy."
224192600|NCT06445179|DEVICE|Ureterolysis|unilateral or bilateral ureterolysis with or without bilateral adnexectomy
224192601|NCT02866747|RADIATION|Hypofractionated stereotactic radiation therapy|
224192602|NCT02866747|DRUG|Durvalumab|
224192603|NCT04884594|DRUG|AAV8-hCocH|2e12 vg/kg single infusion intravenous
224192604|NCT04884594|DRUG|AAV8-hCocH|6e12 vg/kg single infusion intravenous
224309978|NCT06550739|OTHER|Randomization|Randomly divide the data into a training set and a validation set in a 7:3 ratio
224309979|NCT06159244|OTHER|stool withdrawal|stool withdrawal at day 0 and day 7
223501443|NCT01078428|OTHER|Topical silicone gel|Topical silicone gel will be applied to the scar twice daily for a period of 8 weeks
223501444|NCT01078428|OTHER|Vaseline|Topical petrolatum gel will be applied to the scar twice daily for a period of 8 weeks
224192605|NCT04884594|DRUG|AAV8-hCocH|4e12 vg/kg single infusion intravenous
223501445|NCT03924297|DEVICE|chilipad|Chilipad is a commercially available pad designed to be placed between the top of a mattress and bed sheets. It allows for precise temperature regulation in one's bed.
223501446|NCT05308693|OTHER|Education material - Patient Compatible Stoma Educational Material|It is an educational material made of rubber, similar to a stoma, that can be placed on the patient.
223501447|NCT01105130|OTHER|Placebo|Given orally
224074820|NCT01230957|BIOLOGICAL|Clostridium difficile toxoids A and B (high-dose without adjuvant)|0.5 mL, Intramuscular on Days 0, 7, and 30
224074821|NCT01230957|BIOLOGICAL|Placebo: 0.9% normal saline|0.5 mL, Intramuscular on Days 0, 7, and 30
223501448|NCT01105130|DRUG|Oral L-Arginine|Given orally 3 capsules ArginMax and 3 Placebo capsules
223501449|NCT01105130|DRUG|Oral L-Arginine|Patients will take 6 capsules of ArginMax twice daily
223501450|NCT01546298|OTHER|Patch tests|Patch tests for allergic reaction
223501451|NCT00729001|BIOLOGICAL|Human Rotavirus Vaccine - two different formulations|Two oral doses
223501452|NCT00729001|BIOLOGICAL|Prevnar|Three-dose intramuscular injection (US subjects only)
223501453|NCT00729001|BIOLOGICAL|IPOL|Two-dose intramuscular injection (US subjects only)
224074822|NCT01230957|BIOLOGICAL|Clostridium difficile toxoids A and B (high-dose with adjuvant)|0.5 mL, Intramuscular on Days 0, 7, and 180
224074823|NCT01230957|BIOLOGICAL|Clostridium difficile toxoids A and B (high-dose with adjuvant)|0.5 mL, Intramuscular on Days 0, 30, and 180
224074824|NCT02989519|DRUG|dydrogesterone|
224074825|NCT02989519|DRUG|Micronized progesterone|
224074826|NCT01337076|DEVICE|cochlear implant|Cochlear implant surgery
224074827|NCT05042310|DRUG|LY3541860|Administered either IV or SC.
224074828|NCT05042310|DRUG|Placebo|Administered either IV or SC.
224074829|NCT00941460|DRUG|Temozolomide in both arms|initial dose 120 mg/m2 in arm A
224074830|NCT00941460|DRUG|Temozolomide in both arms|initial dose 80 mg/m2 in arm B
224074831|NCT03395379|PROCEDURE|RFA|Radiofrequency ablation (RFA) is a medical procedure in which part of the electrical conduction system of the tumor is ablated using the heat generated from medium frequency alternating current.
224074832|NCT03694925|DIAGNOSTIC_TEST|Calprotectin test|Calprotectin will be measured both by ELISA and point of care test.
224074833|NCT03104725|DRUG|N-Acetylcysteine|Oral
224074834|NCT03104725|PROCEDURE|Lumbar Puncture|Each participant undergoes a baseline lumbar puncture (LP 1) as an inpatient at the NIH Clinical Center to obtain cerebrospinal fluid (CSF) for assays of Cys-DA, 3,4-dihydroxyphenylacetic acid (DOPAC), and related biochemicals. The second LP (LP 2) is completed after the PD participant has taken at least 5 doses of NAC (2 grams orally twice per day) and approximately 2 hours after the last NAC dose. For the HV participant, LP 2 occurs approximately 48 hours after LP 1 (no NAC administered).
224074835|NCT03104725|RADIATION|Fluoroscopy|If needed for lumbar puncture
224074836|NCT01639872|DRUG|Clozapine|Clozapine: target dose of 400mg per day with a maximum dose of 550mg per day
224074837|NCT01639872|DRUG|Risperidone|Clozapine: target dose of 4mg per day with a maximum dose of 6mg per day
224074838|NCT00717600|DIETARY_SUPPLEMENT|Lactobacillus reuteri RC-14 and Lactobacillus rhamnosus GR-1|2x10\^9 cfu of Lactobacillus reuteri RC-14 and Lactobacillus rhamnosus GR-1 administered daily via a single orally ingested freeze-dried capsule.
224074839|NCT04511728|DRUG|HSK3486|The initial Induction dose of HSK3486 is 0.4 mg/kg. The initial maintenance dose of HSK3486 is 0.8 mg/kg/h
224074840|NCT04511728|DRUG|Propofol|The initial Induction dose of propofol is 2.0 mg/kg. The initial maintenance dose of propofol is 5.0 mg/kg/h
224074841|NCT00423163|DRUG|micafungin|
224074842|NCT00423163|DRUG|voriconazole|
224074843|NCT01532531|DEVICE|"GEMORE Multi-Function Electrotherapy Stimulator"|"The Collateral Meridian Therapy (CMT) group patients received, according to the CMT protocol described previously (5), CMT at the selected points with the CMT Electrotherapy Stimulator (GEMORE Multi-Function Electrotherapy Stimulator; GM390TE, GEMORE Co Ltd, Taiwan) to treat the affected OA knee. The 6-minute treatment (electrotherapy was set at 40 Hz biphasic and 30 mA) comprises reduction and enhancement procedures on the specific points. Each patient received CMT twice per week for three weeks during the study."
224074844|NCT02050269|DRUG|Iohexol|Iohexol, 300 mg/mL
224074845|NCT03227705|DRUG|Prometrium|Intravaginal use, off label, of Prometrium
224074846|NCT03227705|DEVICE|Dr. Arabin, cerclage pessary perforated|A Dr. Arabin, cerclage pessary perforated will be inserted participants diagnosed with a short cervix
224074847|NCT06488157|OTHER|I-HoME|Video visits with a nurse practitioner for up to six visits every 2 weeks to address symptom management and care needs
224074848|NCT01732887|OTHER|Cognitive fitness training|"Computer-based training of basic cognitive functions. It has activities under two headings,~1. General training applications~2. Memory training applications~Each individual session in both groups will include playing specific computer games for at least 1/2 hour a day, 3 days per week, throughout the 10 week interval."
224074849|NCT00837785|DRUG|BG00012|240 mg (two 120 mg capsules) orally three times a day
224074850|NCT00837785|DRUG|BG00012|240 mg (two 120 mg capsules) orally twice a day
224074851|NCT05818657|BIOLOGICAL|levels of CKD markers, Oral health status, apical periodontitis|To observe levels of CKD markers :Levels of serum keratinise ,urea, eGFR, and assessment of Oral health status, apical periodontitis
224074852|NCT05818657|BIOLOGICAL|systemic inflammatory marker, Oral health status, apical periodontitis|estimation of hs-CRP levels, and assessment of Oral health status, apical periodontitis
224074853|NCT03959722|DIETARY_SUPPLEMENT|Ecologic® PERFORMANCE|"Ecologic® PERFORMANCE is a probiotic formulation consisting of different probiotic bacterial strains, namely:~Bifidobacterium bifidum W23 Bifidobacterium lactis W51 Enterococcus faecium W54 Lactobacillus acidophilus W22 Lactobacillus brevis W63 Lactococcus lactis W58~Except for the bacterial strains, Ecologic® PERFORMANCE contains the following other ingredients:~* maize starch and maltodextrins~* fructo-oligosaccharides (FOS) P6 and Polydextrose P4 (strain specific prebiotics)~* vegetable protein~* mineral mix (Potassium chloride, Magnesium sulphate, Manganese sulphate)"
224192606|NCT02422641|DRUG|High-dose Methotrexate (8 gm/m2; HD-MTX)|Enrolled patients will undergo treatment with HD-MTX (8 g/m2) as per current standard practice on an every 2 week schedule until disease progression or death from any cause. Treatment will be performed according to standard clinical practice. Surveillance imaging with or without cytologic evaluation will be performed as per standard clinical practice after every 2 cycles (\~28 days). Treatment will continue until there is unequivocal evidence of clinical or radiographic CNS or systemic disease progression, death from any cause, or intolerance.
224192607|NCT03913936|OTHER|YES portal|The YES portal is designed to collect and assess participants' toxicities and symptoms, as well as informational needs in between visits with their clinician
224192608|NCT05168930|DRUG|Venetoclax|C4-15
224192609|NCT05168930|DRUG|Zanubrutinib|C1-15
224192610|NCT05290129|DRUG|Oxytocin|Oxytocin will be prepared in a 1L bag of Ringer's lactate, to be infused at a rate of 125 ml/h.
224192611|NCT03868410|DEVICE|New Repetitive Magnetic Stimulation (rTMS) Approach|Participants in this arm will receive rTMS-based facilitation of the contralesional dorsal premotor cortex (cPMd) located in the non-stroke hemisphere before start of each session. High-frequency rTMS (5-Hz) will be delivered using 42 10-sec trains of 50 pulses each (total 2100 pulses) for a period of 24 minutes. Immediately after the completion of rTMS, participants will undergo upper limb training for a total of one hour. Participants will receive these interventions 2 days a week for 6 weeks, i.e., for a total of 12 sessions.
224192612|NCT03868410|DEVICE|Conventional Repetitive Magnetic Stimulation (rTMS) Approach|Participants in this arm will receive rTMS-based facilitation of the ipsilesional primary motor cortex (iM1) before the start of each session. iM1 will be stimulated with high-frequency rTMS (5-Hz) using 42 10-sec trains of 50 pulses each (total 2100 pulses) for a period of 24 minutes. Immediately after the completion of rTMS, participants will undergo upper limb training for a total of one hour. Participants will receive these interventions 2 days a week for 6 weeks, i.e., for a total of 12 sessions.
224192613|NCT01059175|DEVICE|Additional Endocardial or Epicardial LV Lead|Addition of a second left ventricular endocardial or epicardial lead
224192614|NCT01059175|DEVICE|CRT-P or CRT-D|Implantable Cardiac Resynchronization Therapy Pacemaker (CRT-P) or Defibrillator (CRT-D) Device
224192615|NCT06389214|DRUG|Reproxalap Ophthalmic Solution (0.25%)|Reproxalap Ophthalmic Solution (0.25%) administered six times over two consecutive days
224192616|NCT06389214|DRUG|Vehicle Ophthalmic Solution|Vehicle Ophthalmic Solution administered six times over two consecutive days
224192617|NCT06580145|DRUG|L-leucine|"L-leucine is an essential amino acid used to competitively inhibit kynurenine uptake into the brain via the large neutral amino acid transporter (LAT1).~The proposed dose for L-leucine is 4.31 g/day, administered orally."
224192618|NCT06580145|DRUG|L-lysine|"L-lysine monohydrochloride is also an essential amino acid. It serves as an active comparator to control for general effects on brain protein synthesis and enters the brain through separate cationic amino acid transporters.~The proposed dose for L-lysine is 6 g/day, administered orally"
224192619|NCT00478504|DRUG|Letrozole|Starting daily dose 2.5 mg on menstrual cycles days 2 to 6, to be increased to 5 mg daily if there is no response to 2.5 mg
224192620|NCT00478504|DRUG|Clomifene citrate|Starting daily dose 50 mg on menstrual cycles days 2 to 6, to be increased to 100 mg daily if there is no response to 50 mg
224192621|NCT04322929|DRUG|Roflumilast Oral Tablet|Roflumilast, a phosphodiesterase 4 (PDE4) inhibitor is approved worldwide (including Hong Kong) for treatment of severe chronic obstructive pulmonary disease (COPD) with frequent exacerbations. Roflumilast has been shown to have anti-inflammatory effect in patients with COPD, with significant reduction of sputum absolute neutrophil count, IL-8 and neutrophil elastase compared with placebo treatment. Roflumilast can also improve the lung function parameters in patients with COPD and reduce the rate of moderate-to-severe exacerbations.
224192622|NCT06123481|PROCEDURE|Core Decompression|Standard core decompression procedure is performed by drilling into the necrotic bone of the femoral head. A sham bone marrow aspiration involves advancing a needle to the iliac crest (no bone penetration, no bone marrow aspiration) through a small skin incision.
224192623|NCT06123481|PROCEDURE|Core Decompression Procedure with Autologous Bone Marrow Aspirate Concentrate|This involves bone marrow aspiration, concentrating the bone marrow aspirate, and injecting 6 milliliters of bone marrow aspirate concentrate into the necrotic femoral head through an opening created by the core decompression.
223501454|NCT00729001|BIOLOGICAL|Infanrix|Three-dose intramuscular injection (US subjects only)
223501455|NCT00729001|BIOLOGICAL|OmniHIB|Three-dose intramuscular injection (US subjects only)
223501456|NCT00729001|BIOLOGICAL|Pentacel|Three-dose intramuscular injection (Canada only)
223501457|NCT06423027|BEHAVIORAL|Nature-Oriented Chatbots|Nature-oriented chatbots are an intervention with nature-based video delivered by self-developed chatbots
223501458|NCT00943904|DEVICE|Interstim implant for SNS|stimulates third sacral nerve root
223501459|NCT05061355|PROCEDURE|Heart valve surgery|Heart valve surgery will be performed as soon as possible and preferably within 48 hours
223591832|NCT06245252|OTHER|passive stretching for group A|A description of stretch is performed 3 times per week for 12 weeks. The stretches included (in the order they were applied): Seated knee flexor (bilateral); Seated knee flexor-hip adductor (bilateral); Seated shoulder lateral flexor (bilateral); Supine hip flexor- knee extensor (unilateral). Seated hip external rotators, extensor (unilateral); Seated shoulder extensors, adductors, retractors (unilateral). Supine knee flexor-plantar flexor (unilateral); Prone hip flexor (unilateral); Seated shoulder flexors, depressors (bilateral); Seated shoulder and elbow flexors (unilateral).
224192624|NCT03372564|PROCEDURE|Hip Capsule Repair|In the central compartment, significant and obvious pathologies will be addressed accordingly. Following addressing central compartment pathologies, cam impingement type lesions in the peripheral compartment will be treated. Once all pathologies are addressed, the interportal capsulotomy10 will be repaired by using simple interrupted sutures with absorbable suture (Number 1 Vicryl).
223501460|NCT02927145|BIOLOGICAL|RH5.1/ ASO1|"The RH5.1 protein consists of the entire full-length ectodomain of the PfRH5 antigen (amino acids E26 - Q526) with the sequence based on the 3D7 clone of P. falciparum.~The AS01 adjuvant system has been developed and manufactured by GlaxoSmithKline (GSK) Biologicals and is presented as a liquid solution in a monodose glass vial. AS01 is a liposome-based Adjuvant System with a specific aim to improve cell-mediated immunity."
223501461|NCT03451032|OTHER|Non Interventional Study|Non Interventional Study
224192625|NCT06198023|BEHAVIORAL|Educational|The educational intervention is an 8-session series of informational presentations about brain function and altered social processing related to eating disorders. Participants will receive a reflective prompt to complete as homework and will have an opportunity to discuss their responses during the following session.
224192626|NCT06198023|BEHAVIORAL|Interactive|The interactive intervention is an 8-session series of experiential art therapy tasks followed by education about social processing. Participants will complete the tasks as a group or in small teams. Afterward, they will be encouraged to discuss their thoughts and feelings related to their experience. The educational component will include a homework assignment that participants will have the opportunity to discuss at the following session.
224192627|NCT06579027|DEVICE|SPEED Training|Children will use ride-on toys controlled using their affected arm to navigate through their environment and complete playful theme-based challenges. Children will use their affected UE during navigation to start and stop the toy, move steadily forward and backward, turn to the right and left, perform 180° and 360° turns to either side, and avoid obstacles. Children will complete object-based UE tasks requiring gross and fine motor control at intermediate stops during navigation. Navigational tasks will be progressed by increasing complexity of paths (straight to slalom paths needing more directional changes), spaces (wide to narrow spaces), and precision (obstacle courses and mazes requiring skillful navigation, motor planning, and route finding). Object-based tasks will be progressed in terms of force requirements (small to large forces), range of motion (near to far reaches), precision (manipulation of large to small objects), and speed of movements (slow to fast).
224192628|NCT06579027|BEHAVIORAL|CRAFT Training|Children will engage in predominantly seated activities based on conventional occupational therapy to promote unimanual and bimanual UE function. Training sessions will be based on playful child-friendly themes (e.g., dinosaurs, space exploration, aquatic theme, etc.) and all training activities will incorporate the session theme. Activities will involve practice of functional gross and fine motor UE movement patterns that children typically use during daily life. Training will emphasize the use of the affected UE in different roles (i.e., stabilizer, mobilizer, and active and passive assist) during warm-up, building, and art-craft activities. The training will be progressed in terms of forces needed, range of motion, precision, and movement speed.
224192629|NCT06477588|BEHAVIORAL|Health Navigation|Participants meet with Health Navigator twice in-person and receive 7 check-ins from the Health Navigator over a 6 month period. The health navigator provides participants with referrals and support to HIV, mental health, substance use, and other supportive services
224192630|NCT06477588|BEHAVIORAL|Health Navigation, Employment Navigation plus Contingency Management Intervention|Participants meet with health navigator twice in-person and receive 7 check-ins from the health navigator over a 6 month period. The health navigator provides participants with referrals and support to HIV, mental health, substance use, and other supportive services. Participants meeting with the employment navigator twice in-person and receive 10 check-ins from the employment navigator over 12 months. The employment navigator provides participants with referrals to employment and career development opportunities in the community and up to $200 for employment and career development support (e.g., transportation to interview, GED preparation course). Participants also receive up to $140 for HIV/STI care, treatment, and prevention milestones as part of the contingency management interview over a period of 12 months.
224192631|NCT06232616|PROCEDURE|vitrectomy combined with intravitreal dexamethasone implant|The dexamethasone implant will be injected into the vitreous cavity at the end of the surgery.
224192632|NCT04579666|DRUG|Pegcetacoplan (APL-2)|Complement (C3) Inhibitor
224192633|NCT04579666|OTHER|Placebo|Sterile solution of equal volume to active arm
224309980|NCT02171871|OTHER|exposed to a smoking environment|Then the subjects will be exposed to a smoking environment for 20 minutes, under a continuous measurement of emitted particles using the SIDEPAK AM510 in Pm level 2,5=250, in a closed space of 20 m3. The passive smoking environment will be achieved via a smoking machine. Afterwards, the subject will again undergo IOS in four positions (standing, sitting, right and left lateral decubitus) and nitrogen washout test in two positions (sitting and decubitus). Thanks to the above mentioned techniques, changes in measured parameters will be evaluated.
224309981|NCT01047514|BEHAVIORAL|Chronic Disease Self-Management Online Workshop|6 week, online, small group self-management workshop
224309982|NCT00309725|DRUG|galantamine|
224309983|NCT00775905|DRUG|amlodipine 10 mg tablet|
224309984|NCT02585934|DRUG|RVT-101|once daily, oral, 35 mg tablets
224309985|NCT02585934|DRUG|Placebo|once daily, oral, pill manufactured to match RVT-101 35 mg tablet
224309986|NCT00599378|BEHAVIORAL|Implementation Intentions-based telephone counseling|Implementation Intentions-based telephone counseling
224309987|NCT01344278|BEHAVIORAL|Lifestyle Counseling|A lifestyle curriculum of individualized telephone counseling calls, augmented with e-mails and an interactive study Web site.
224309988|NCT01458730|DRUG|Immunochemotherapy|Rituximab, HD-MTX, HD-Ara C, Cyclophosphamide, Iphosphamide, Vincristin, Vindesin, Temozolomide, Depocyte
224309989|NCT03972163|BEHAVIORAL|NIA Medication Management - Active Comparator|"As the attention control, we will refer staff in control offices to the National Institution on Aging (NIA)'s website on Medicines and Medication Management to review content and materials for use in Family Care Giver (FCG) support."
224309990|NCT03972163|BEHAVIORAL|STOPPFrail (Screening Tool of Older Persons Prescriptions)|A screening tool used by clinicians with frail older adults with life-limiting illness to review medications
224309991|NCT03972163|BEHAVIORAL|"Discontinuing Medication Appropriately and Understanding the Art of Communication about Deprescribing"|Education resoruce used by clinicians to simplify and align medications with goals of care
224309992|NCT03972163|BEHAVIORAL|"Key Approaches to Support Informal Family Caregivers in Managing Medications"|Education resource used by clinicians to support Family Care Givers (FCGs)
224309993|NCT01260519|DRUG|Heparin|unfractionated heparin 2000 unites
224309994|NCT04062474|PROCEDURE|Epidural Intervention with TNF-α inhibitor|Epidural administration with TNF-α inhibitor
224309995|NCT03322618|BIOLOGICAL|blood samples|7 tubes of 6 ml (42 ml of blood )
223501462|NCT05599425|BEHAVIORAL|Enhanced Healthy Living Education|24-session healthy living education program, with enhanced content about health beliefs and mechanisms of behavior change
223501463|NCT05599425|BEHAVIORAL|Basic Healthy Living Education|24-session healthy living education program
223591833|NCT06245252|OTHER|electrical stimulation for group b|reated by 30 minutes electrical stimulation three times per week for 12 weeks
224192634|NCT06190249|BIOLOGICAL|LN-144|A tumor sample is resected from each patient and cultured ex vivo to expand the population of tumor infiltrating lymphocytes. After lymphodepleting chemotherapy including cyclophosphamide and fludarabine, patient is infused with autologous TIL (LN-144), followed by IL-2.
223591834|NCT03270384|DEVICE|Urotronic Drug Coated Balloon (DCB)|The Urotronic Drug Coated Balloon (DCB) is a guidewire compatible catheter with a tapered atraumatic tip. The distal end of the catheter has an inflatable balloon coated with a proprietary coating containing the drug paclitaxel that facilitates the drug's transfer to the urethral wall upon inflation.
223591835|NCT06067737|DRUG|Psilocybin|High-dose psilocybin (30 mg) session will be administered following standard-of-care outpatient buprenorphine induction to evaluate its effect on drug abstinence, quality of life, craving, tobacco use, and treatment retention in healthy participants with an active OUD diagnosis.
223591836|NCT06067737|DRUG|Psilocybin|A very low dose (1 mg) psilocybin session following standard-of-care outpatient buprenorphine induction will be used as a comparator arm to the high-dose psilocybin arm in evaluating psilocybin's effect on drug abstinence, quality of life, craving, tobacco use, and treatment retention in healthy participants with an active OUD diagnosis.
223591837|NCT06561932|DEVICE|WiSE CRT System|The WiSE CRT System is an implantable cardiac system to provide left ventricular (LV) pacing stimulation in conjunction with a co-implanted system that provides right ventricular (RV) stimulation. In combination, the devices deliver biventricular (BiV) pacing.
223591838|NCT03301038|DRUG|Rifampin|Rifampin 5 mg/kg (max 300 mg) daily for 8 weeks, followed by rifampin 10 mg/kg (max 600 mg) daily for 8 weeks.
223591839|NCT05977049|BEHAVIORAL|Takotsubo Support Group|Participants will undergo virtual group therapy/education. Participants will meet once every other week (at minimum), for 1 - 1.5 hours (on average). The frequency and/or length of the support group sessions may be adjusted according to participants' needs.
223591840|NCT06969872|DIETARY_SUPPLEMENT|Placebo|Take a capsule of placebo within 30 minutes after breakfast, and once a day.
224192635|NCT06190249|DRUG|Cyclophosphamide|Given by IV.
224192636|NCT06190249|DRUG|Mesna|Given by IV.
224192637|NCT06190249|DRUG|Fludarabine|Given by IV.
224192638|NCT06190249|BIOLOGICAL|Interleukin-2 (IL-2)|Given by IV.
224192639|NCT06190249|DRUG|Pembrolizumab|Given by IV.
224192640|NCT06511479|BEHAVIORAL|MIND-BP|8-week program delivered to small groups by a trained facilitator using Zoom/Webex. Each session is one hour long and includes a check-in period, teaching on the week's topic, group discussion, a skill-building exercise and home practice assignment. Participants receive a workbook of all session content, audio guides for home practice, and practice logs. At the start of the program, the stress response and its importance for hypertension and cardiovascular disease is discussed, and the rationale for the mindfulness and cognitive skills to be taught are explained. Weekly sessions focus on learning and practicing skills.
224192641|NCT06511479|BEHAVIORAL|BOOST|The BOOST program is designed to control for attention, credibility, and expectation of benefit. To parallel MIND-BP, the BOOST program will be delivered in 8 weekly group sessions via Zoom/Webex and led by a trained facilitator. Each weekly BOOST session will be 1 hour long and comprised of a check-in period, introduction of the week's topic, and group discussion. Didactic information, skill-building instruction and home practice are not included. Weekly BOOST session topics include: (1) personal experience of hypertension; (2) personal experience of stress; (3) personal experience of mood-related challenges; (4) personal experience of social relationships; (5) concerns related to hypertension treatment; (6) concerns about other health problems; (7) personal experience related to healthcare; and (8) review of the BOOST experience.
224192642|NCT02741986|OTHER|Risk estimation|"Physicians will be asked to provide their risk scores (ranging from 0 to 100) for postoperative complications prior to surgery and immediately after the surgery for the same patients that IPS is producing the scores. Physicians will provide scores both before and after reviewing the risk scores produced by the IPS.~The IPS system will generate risk scores (ranging from 0 to 100) for postoperative complications prior to surgery and immediately after the surgery for patients taken care by the physicians enrolled in the study."
224192643|NCT05763667|DRUG|Liposomal bupivacaine|"Liposomal bupivacaine is FDA-approved for use single-dose infiltration in adults to produce postsurgical local analgesia and as an interscalene brachial plexus nerve block to produce postsurgical regional analgesia.~The solution will be placed into 20 mL syringes on 18-gauge needles for injection. The injections will be performed percutaneously by the surgeon along the midaxillary line at 4 equidistant points from the anterior superior iliac spine to the costal margin, as well as a single injection subcostally at the anterior axillary line. 20 mL will be injected at each site, 5 sites per side bilaterally, total of 10 sites. The depth of injection will be judged by laparoscopic visualization of a diffuse bulge during injection, indicating injection in the correct plane, just superficial to the transversus abdominis muscle."
224192644|NCT05763667|DRUG|Bupivacain|"Bupivacaine is FDA-approved for use as a local or regional anesthetic for surgery. It is widely used in TAP blocks.~The solution will be placed into 20 mL syringes on 18-gauge needles for injection. The injections will be performed percutaneously by the surgeon along the midaxillary line at 4 equidistant points from the anterior superior iliac spine to the costal margin, as well as a single injection subcostally at the anterior axillary line. 20 mL will be injected at each site, 5 sites per side bilaterally, total of 10 sites. The depth of injection will be judged by laparoscopic visualization of a diffuse bulge during injection, indicating injection in the correct plane, just superficial to the transversus abdominis muscle."
224309996|NCT00799448|DRUG|repaglinide|
224309997|NCT00799448|DRUG|biphasic human insulin 30|
224309998|NCT00799448|DRUG|insulin NPH|
224309999|NCT01119183|BEHAVIORAL|ACOG education pamphlet on preeclampsia|The ACOG pamphlet on preeclampsia will be offered to this group
224310000|NCT01119183|BEHAVIORAL|Preeclampsia education tool|The newly created preeclampsia educational tool will be offered to this group
223591841|NCT06969872|DIETARY_SUPPLEMENT|Probiotics (ABKefir)|Take a capsule of ABKefir within 30 minutes after breakfast, and once a day.
223591842|NCT06362187|DEVICE|Gut Directed VR|The VR experiences follow a protocolized gut-directed therapy
223591843|NCT06362187|DEVICE|Sham Control VR|The same Oculus Quest 2 device as the active treatment group but will use distractive therapy
223591844|NCT05958290|OTHER|Discontinuation of antibiotics|Discontinuation of antibiotic treatment after at least 10 days iv antibiotic therapy and then per oral treatment to at least 6 weeks total.
224192645|NCT06296628|DEVICE|Miraπ|"This device has tiny sensors that measure the movement of the healthy fingers and tiny motors that move the affected fingers of the patient.~The device is connected to a specially designed finger mechanism that moves the affected fingers of the patient. This opening mechanism is designed in a way that it prevents the fingers from being forced into any hurting position. If the patient moves the healthy fingers during training, also the fingers of the affected hand are moved by the device at the same time. This creates the effect of mirror therapy for the brain as the patient can see both hands moving."
224192646|NCT06296628|BEHAVIORAL|Mirror Therapy|Current standard of care using MT.
224192647|NCT04951206|DEVICE|Fractionated CO2-laser|All women will be undergoing FxCO2-laser therapy as this treatment is a criterion for enrollment.
224192648|NCT04951206|DRUG|Clobetasol Propionate 0.05% Ointment|Clobetasol propionate 0.05% ointment obtained from a commercial manufacturer
223501464|NCT04079725|PROCEDURE|Combined trabeculotomy-trabeculectomy with mitomycin c|Combined trabeculotomy-trabeculectomy with mitomycin C Will be done in all cases then histopathological examination of iris tissue to detect the nature of the disease
223501465|NCT00133354|DRUG|Arimidex (Anastrozole)|Subjects will be randomized in a 1:1 ratio to be given either Arimidex 1 mg or placebo orally. Subjects will receive trial treatment for 36 months while continued on GH.
223501466|NCT00133354|DRUG|Placebo|Subjects will be randomized in a 1:1 ratio to be given either Arimidex 1 mg or placebo orally. Subjects will receive trial treatment for 36 months while continued on GH.
223501467|NCT00133354|DRUG|Growth Hormone|GH (Nutropin®, Genentech, So. San Francisco, CA) will be administered throughout the trial at a dose of \~0.3mg/kg.w (no more than 0.4mg/kg.w) given subcutaneously (SC) at bedtime daily. Dose adjustments on the GH dose will be made by the investigator at least every 6mo.
223501468|NCT00169403|PROCEDURE|Deep brain stimulation|
223512099|NCT01428141|DRUG|E7050|Drug: E7050 The starting dose of E7050 will be 400 mg given orally, once-daily, in patients with advanced tumor that have progressed following effective therapy. The study consists of 2 parts: a Tolerability Confirmation Component to confirm the tolerable dose in subjects with solid tumor and an Expansion Component to confirm the safety and to preliminarily assess the anti-tumor activity in subjects with gastric cancer.
224074854|NCT03959722|DIETARY_SUPPLEMENT|Placebo|"The placebo contains no bacterial strains, but the following ingredients:~* maize starch and maltodextrins~* fructo-oligosaccharides (FOS) P6 and Polydextrose P4 (strain specific prebiotics)~* vegetable protein~* mineral mix (Potassium chloride, Magnesium sulphate, Manganese sulphate)"
224074855|NCT03881397|BEHAVIORAL|Family Media Use Plan|A tool developed by the American Academy of Pediatrics that engages teens and parent to discuss internet safety ideas and develop rules around technology use together.
224074856|NCT03881397|BEHAVIORAL|Media Use Resources Awareness|Resources offered to parents and teens that include tools and publicly available resources for safe technology use among teens
224074857|NCT00972673|DRUG|Placebo|comparator
224074858|NCT00972673|DRUG|GW685698X|Inhaled steroid
224074859|NCT05207007|PROCEDURE|Phacomulsification lens removal cataract surgery with Intraocular lens(IOL) implantation|Phacomulsification lens removal cataract surgery with IOL implantation in both two groups
224074860|NCT03173833|OTHER|CAGO questionnaire outcome|Every time when cancer patients fulfill the following questionnaires, SDS, PTGI, CNS, PedsQL, the outcome of the questionnaires will be provided to the experimental group of the participants by using a computer assessment with graphic outcome.
224074861|NCT00372502|PROCEDURE|Modified EGDT|Early goal directed therapy with lactate clearance
224074862|NCT00372502|PROCEDURE|Standard EGDT|Early goal directed therapy
224074863|NCT03659019|OTHER|Quality of life questionnaires|During 10 years, the study will be conduct to obtain the quality of life evolution and medical complications in patients candidates but not implanted, and in patients candidates then implanted with the phrenic nerve stimulator.
224074864|NCT03536871|DIETARY_SUPPLEMENT|multi-nutrient supplement|Compare the effects of a multi-nutrient supplement following a healthy lifestyles program in healthy young men and women, healthy older men, and sarcopenic older men.
224074865|NCT03536871|OTHER|Exercise|We will evaluate the effect of 12 weeks of combined endurance and resistance home-based exercise in younger and older adults.
224074866|NCT01112098|BEHAVIORAL|Patient Pamphlet|letter informs patient of opportunity to self-schedule a DXA scan; pamphlet includes information about receiving a DXA scan
224074867|NCT02035995|OTHER|Pregnant volunteers with GDM|
224074868|NCT01383837|BEHAVIORAL|STYLEnS|Multifamily group HIV/STI Prevention Intervention or Single Family Dyad (youth and a parent)
224074869|NCT01383837|BEHAVIORAL|Health Promotion|Health Promotion Intervention
224074870|NCT01533376|DRUG|Timolol|0.5% timolol maleate ophthalmic gel-forming solution applied once
224074871|NCT01533376|DRUG|Preservative free artificial tear gel.|Preservative free artificial tear gel applied topically twice a day.
224074872|NCT00653822|DRUG|alefacept|IC and SC
224074873|NCT00653822|DRUG|placebo|IV and SC
224074874|NCT04993404|DRUG|Jaktinib Hydrochloride Tablets|A single oral dose of 100 mg Jaktinib Hydrochloride Tablets will be administered.
224074875|NCT02178488|DRUG|Cholecalciferol|Cholecalciferol 4000 IU/day for 12 months
224074876|NCT02178488|OTHER|Placebo|Placebo (mimic of cholecalciferol) in the same amount and same time frame as Cholecalciferol for 12 months
224074877|NCT04000685|OTHER|Yoga exercise program|Yoga exercise program will be applied two sessions per week, totally eight week.
224074878|NCT04000685|OTHER|Spinal stabilization exercise program|Spinal stabilization exercise program will be applied two sessions per week, totally eight week.
224074879|NCT04000685|OTHER|Aerobic walking program|Aerobic walking program will be applied two sessions per week, totally eight week.
224074880|NCT02065154|DRUG|Cyclophosphamide|
224074881|NCT02841969|OTHER|Electrolysed water|Irrigation of wound using electrolysed water
224074882|NCT02841969|OTHER|Prontosan|Irrigation of wound using Prontosan
224074883|NCT02271503|DRUG|CD-LD IR|CD-LD IR containing 25 mg carbidopa and 100 mg levodopa
224074884|NCT02271503|DRUG|IPX203 180 mg|IPX203 containing 45 mg carbidopa and180 mg levodopa
224074885|NCT02271503|DRUG|IPX203 270 mg|IPX203 containing 67.5 mg carbidopa and 270 mg levodopa
224074886|NCT02271503|DRUG|Rytary 195 mg|Rytary 48.75Mg-195Mg Extended-Release Capsule
224074887|NCT02271503|DRUG|Rytary 145 mg|Rytary 36.25Mg-145Mg Extended-Release Capsule
224310001|NCT04177784|OTHER|Online Educational Videos|The videos were developed by the researchers based on a prior study to test if specific information about obesity and weight control influence weight bias.
224310002|NCT00513279|DRUG|GSK618334|GSK618334 will be available as white to off-white coated tablets. GSK618334 will be swallowed with 250 milliliters (mL) of water.
224310003|NCT00513279|DRUG|GSK618334 matching placebo tablets|GSK618334 placebo tablets visually match the active GSK618334 tablets and contain the same excipients except for the omission of the active ingredient. GSK618334 matching placebo will be swallowed with 250 mL of water.
224310004|NCT05430984|PROCEDURE|Laparoscopic TAPP inguinal hernia repair|"Isolation of preperitoneal space will be accomplished to guarantee the mesh flattening with the medial border at the pubic symphysis, the lateral border at the psoas major and anterior superior iliac spine, superior border at least 3 cm above the conjoined tendon, medial inferior border 3 cm below the pectineal ligament, and lateral inferior border to permit perietalization of the spermatic cord (6-8 cm isolation of the hernia sac and spermatic cord).~For the mesh fixation group, the mesh will be fixed to the abdominal wall using suture, spiral tacks, whereas for the non-fixation group it will be left as it is and the operation will be concluded. A mesh measuring 15x10cm is placed in the preperitoneal space and fixed using limited numbers of tacks or suture. In some cases, based on body habitus, a slightly smaller mesh could be used. The peritoneum will be closed over the mesh."
224310005|NCT04701086|DEVICE|Cationorm Pro|Eye Drops
224310006|NCT04701086|DEVICE|Vismed|Eye Drops
224310007|NCT00093873|DRUG|Anti-angiogenesis|Anti-angiogenesis
223591845|NCT06278883|BEHAVIORAL|Disease Risk Assessment|Undergo personal and family history-based risk assessment and make recommendations for managing risk.
223591846|NCT05633979|DRUG|Trastuzumab deruxtecan|Given by IV (vein)
223591847|NCT05633979|DRUG|Valemetostat|Given by PO
223591848|NCT04199767|DRUG|20 IU Humulin® R U-100 (NDC: 0002-8215, Eli Lilly & Company)|Participants will be assigned to receive regular insulin either 20 or 40 IU administered through an intranasal nebulizer-like device.
223591849|NCT04199767|DRUG|40 IU Humulin® R U-100 (NDC: 0002-8215, Eli Lilly & Company)|Participants will be assigned to receive regular insulin either 40 or 20 IU administered through an intranasal nebulizer-like device.
223591850|NCT06574997|DRUG|OCU400|Participants will receive a subretinal injection of OCU400 modifier gene therapy product.
223591851|NCT05498272|DRUG|Olaparib|300 mg orally twice a day (D1-D30) for 6 Cycles (30 day Cycles)
223591852|NCT05498272|DRUG|LHRH agonist|Total duration of therapy will be for 180 days with use of agent as per institutional standards
223591853|NCT06524960|DRUG|Denosumab|Denosumab is a sterile, preservative-free, clear, colorless to pale yellow solution. Each 1 mL single-dose prefilled syringe of denosumab contains 60 mg denosumab (60 mg/mL solution), 4.7% sorbitol, 17 mM acetate, 0.01% polysorbate 20, Water for Injection (USP), and sodium hydroxide to a pH of 5.2.
223591854|NCT06524960|OTHER|Placebo|Placebo is 1 mL of normal saline drawn up in a commercially available syringe.
223591855|NCT05162469|DRUG|SHR-1909 injection|SHR-1909 for intravenous injection;Strength:6ml:0.3g/vial. Dose escalation (non randomized, 6 dose-levels); Dose-expansion and efficacy-expansion(non-randomized,1-3 dose-level(s)).
224074888|NCT00630955|DRUG|memantine|Memantine 20 mg once per day for 7 days
224074889|NCT00630955|DRUG|Memantine|Memantine 40 mg once per day for 7 days
224074890|NCT00630955|DRUG|Placebo|Placebo once per day for 7 days
224074891|NCT04897464|OTHER|BGaze therapy Alzheimer|BGaze Therapy is an interactive eye tracking game
224074892|NCT03655964|DRUG|Olmesartan|At Day 4 of stroke onset, patients with clinic BP \>160/100 mmHg will receive olmesartan 20 mg once daily until Day 7 of stroke onset
224074893|NCT03655964|DRUG|Nebivolol|At Day 4 of stroke onset, patients with clinic BP \>160/100 mmHg will receive nebivolol 5mg once daily until Day 7 of stroke onset
224074894|NCT03655964|OTHER|No antihypertensive treatment|Patients will be left without treatment
224074895|NCT04223934|OTHER|optima4BP|"optima4BP establishes a no gaps computational framework in determining the most effective treatment change that can optimize a patient's HTN management towards BP Target. All possible drug combination options available through the 16 anti-HTN drug classes and subclasses are quantitatively evaluated in the context of 5 actions: add a drug, remove a drug, replace a drug, increase a drug dose, and decrease a drug dose. The pharmacological intervention efficacy ranking is computed and the highest ranked treatment recommendation is selected for consideration by the treating physician."
224074896|NCT04427631|DEVICE|Bone conduction headphones|Children will be offered hearing support with bone conduction headphones that can either be paired to a microphone or to a tablet/ phone/ computer to help children to hear. The Hear Glue Ear app is available for free to provide speech and language enrichment.
224074897|NCT02018731|DRUG|Metformin and Metformin & L-Citrulline|
224074898|NCT02018731|DRUG|L-Citrulline and Metformin & L-Citrulline|
224074899|NCT02519166|BIOLOGICAL|1 clinical examination of the wound, 1 sample taken with the curette, 1 sample by swabbing|
224074900|NCT04086550|DEVICE|LIQOSEAL|Adjunctive bioresorbable patch
224074901|NCT04086550|DEVICE|DuraSeal, Adherus|synthetic absorbable sealants
224074902|NCT01819909|PROCEDURE|Postoperative Jackins Exercise Protocol|Jackin's exercises were initially designed for patients with difficulty performing forward elevation. The patient initially is positioned supine to perform shoulder flexion. When the patient can actively elevate in the supine position, one to two pounds of weight is placed in the patients hand and the patient is asked to repeat the maneuver of supine active elevation. When the patient can do this with little difficulty, the head of the bed is elevated approximately 20 degrees from the supine position and the sequence is repeated. Once the patient is able to perform flexion in this elevated head position, the inclination of the patient is increased in 20 degree increments until the patient is able to perform upright sitting shoulder flexion.
224074903|NCT01819909|PROCEDURE|Postoperative Pulleys Exercise Protocol|Pulleys have been used in postoperative shoulder rehabilitation to improve passive as well as active range of motion and develop strength.
224074904|NCT02611986|DEVICE|the McGrath MAC|in a randomised order we evaluate the success rate with the first attempt of the tracheal tube into the trachea.
224074905|NCT02611986|DEVICE|the Macintosh Laryngoscope|in a randomised order we evaluate the success rate with the first attempt of the tracheal tube into the trachea.
224074906|NCT03186235|OTHER|Flow cytometry|Isolation of T regulatory cells from blood
224310008|NCT00093873|DRUG|AMG 706|Anti-angiogenesis
224310009|NCT01944176|DRUG|simvastatin, placebo|
224310010|NCT05119348|OTHER|STOPCOV|Fieldworkers delivered an infection mitigation intervention which consisted of personal protective equipment and messaging on managing COVID19 and reducing onward transmission of SARS-CoV-2 infection.
224192649|NCT04076657|BEHAVIORAL|Brock String Therapy|Oculomotor exercise to improve binocular vision function
224310011|NCT05658458|DRUG|Vericiguat (Verquvo, BAY1021189)|The recommended starting dose of vericiguat is 2.5 mg once daily, taken with food. The dose of vericiguat would be doubled approximately every 2 weeks to reach the target maintenance dose of 10 mg once daily, as tolerated by the participant.
224310012|NCT00562237|BIOLOGICAL|S205 placebo|2 i.m. injections per subject (0.5 mL each)
224310013|NCT00562237|BIOLOGICAL|S205 10ugHA|2 i.m. injections per subject (0.5 mL each)
224310014|NCT00562237|BIOLOGICAL|S205 30ugHA|2 i.m. injections per subject (0.5 mL each)
224310015|NCT00562237|BIOLOGICAL|S205 10ugHA+500ugAlOH|2 i.m. injections per subject (0.5 mL each)
224192650|NCT04076657|BEHAVIORAL|Standard of Care|patient engages in normal behavior to manage vision issues, such as breaks with reading and screen use
224192651|NCT04673760|BEHAVIORAL|Specialized palliative home care|"Specialist palliative home care teams will initiate care as usual, including managing a systematic and collaborative process of advance care planning with patients, family caregivers, GPs and SPITEX nurses using the Betreuungsplan, information packages and regular case meetings. The GP was additionally provided with educational palliative care information by the study team."
224192652|NCT04384120|DEVICE|Blood Flow Restriction Therapy|Blood flow restriction cuffs which are FDA approved will be provided to patients randomized into the BFR group. Patients will be provided video instruction and training on how to conduct the traditional therapy exercises with the use of BFR.
224192653|NCT04384120|PROCEDURE|Traditional Therapy|Patients will be provided video instruction and training on how to conduct the traditional therapy exercises.
224192654|NCT05571982|PROCEDURE|Tidal volume breathing technique|High-flow nasal oxygen will be applied to the patients through nasal openings using Optiflow system before anesthetic induction. Tidal volume breathing will be applied. Pulse oximetry, end-tidal O2, and oxygen reserve index will be monitored continuously.
224192655|NCT05571982|PROCEDURE|Vital capacity breathing technique|High-flow nasal oxygen will be applied to the patients through nasal openings using Optiflow system before anesthetic induction. Vital capacity breathing will be applied. Pulse oximetry, end-tidal O2, and oxygen reserve index will be monitored continuously.
224192656|NCT02478853|OTHER|Implementation of a new regional care framework|Integrated care framework for the prevention and management of cardio-metabolic chronic diseases in primary care
224192657|NCT00185146|DRUG|Pactimibe|
224310016|NCT00562237|BIOLOGICAL|S205 30ugHA+500ugAlOH|2 i.m. injections per subject (0.5 mL each)
223746311|NCT05191446|BEHAVIORAL|Stepped alcohol intervention (SAT) to reduce unhealthy alcohol use|"Step 1 includes three sessions of motivational interviewing (MI). MI will consist of three video (Zoom) or telephone sessions: an initial 45-minute session, followed by two 20-minute sessions. Treatment is based on Motivational Interviewing by Miller and Rollnick, and includes exploring ambivalence about change, reflective listening, expressing empathy, and discussion about change. To support increased motivation to reduce drinking, discussion will center on effects of hazardous drinking on liver disease.~Step 2 includes referral to addiction medicine for participants who do not reduce unhealthy alcohol use or requested by patient. Specialty addiction services include both direct treatment and coordination of addiction care. After an evaluation, the addiction medicine physician may recommend pharmacotherapy (in consultation with hepatology provider if indicated), and/or referral to intensive outpatient, or residential level of care depending on clinical judgement."
224310017|NCT00562237|BIOLOGICAL|S205 10ugHA+1250ugAlOH|2 i.m. injections per subject (0.5 mL each)
224310018|NCT00562237|BIOLOGICAL|S205 30ugHA+1250ugAlOH|2 i.m. injections per subject (0.5 mL each)
224310019|NCT06426615|DEVICE|Intracranial electrodes|Placement of intracranial electrodes in the cortico-subcortical system
224310020|NCT00534807|DRUG|Vinflunine|
224310021|NCT00534807|DRUG|Rifampin|
224310022|NCT01345487|OTHER|Vegetable Protein|Vegetable protein in the form of fava beans/split peas
224310023|NCT01345487|OTHER|Animal protein|Protein in the form of minced pork/beef
224310024|NCT04359511|DRUG|Prednisone|prednisone 0.7 mg/kg/d (PO)
224310025|NCT04359511|DRUG|Hydrocortisone|hémisuccinate d'hydrocortisone 3,5 mg/kg/jour (IV)
224310026|NCT05744180|OTHER|Interventional|The FitScore is a machine learning algorithm embedded within the electronic health record that identifies patients most likely to benefit from remote patient monitoring.
224310027|NCT03157648|OTHER|observing for shivering symptom|In the PACU investigators measure body temperature of all patients at tympanic membrane, forehead, and dorsal of hand. Investigators calculate the difference between body temperature measure at tympanic membrane and forehead/dorsal of hand. Investigators observe the shivering symptom and grading for severity.
224310028|NCT05255848|DRUG|Unfractionated heparin|Patients will be given the same standard of care treatment plus nebulized heparin 5000IU every 8 hours started 24 hours after randomization, using a compressed air nebulizer, and will be continued for one week. In case of any complication, if the attending physician feels it necessary intervention treatment will be stopped
224310029|NCT05811806|DEVICE|Treatment using the MyHand System|Participants will undergo three weeks of 1-hour hand therapy with the MyHand System. The MyHand System provides a highly unique and targeted approach to hand function rehabilitation with the help of the aforementioned protocols delivered with gamified training techniques. The gamified format of the protocols allows for better patient engagement, thus allowing for more effective and efficient therapy.
224310030|NCT06450795|BEHAVIORAL|Participants in both groups will then receive PTKE treatment for 8 weeks, 3 days a week for 30-45 minutes, under the supervision of specialist physiotherapists.|HIFEM treatment for 6 weeks, 2 days a week for 28 minutes. The evaluations will be repeated at the end of the treatment.
224310031|NCT01161407|DIETARY_SUPPLEMENT|1500 mg/d elemental calcium as calcium carbonate|500 mg elemental calcium as calcium carbonate given 3 times per day with meals for a total of 1500 mg/d elemental calcium. Given for 21 days in conjunction with a controlled diet.
224310032|NCT01161407|DIETARY_SUPPLEMENT|Placebo|Placebo for calcium carbonate in same capsule form. Given 3 times per day with meals for 21 days in conjunction with a controlled diet.
224310033|NCT03910387|DRUG|Gemcitabine|Given gemcitabine/nab-paclitaxel combination therapy
224310034|NCT03910387|DRUG|Nab-paclitaxel|Given gemcitabine/nab-paclitaxel combination therapy
224192658|NCT05173714|BEHAVIORAL|SLIMM|Increase in light walking activity, replacing 1 hour/day of sedentary duration with casual walking duration. Increase in sedentary breaks, from sitting/lying position to standing position, at least once every hour as independent of the total time spent on sedentary activities.
224192659|NCT05173714|BEHAVIORAL|Standard Resistance Training|Participants will be provided a standard resistance training regimen to follow during the course of the study. Participants will not receive individualized instruction, guidance or modification to the resistance training regimen.
224310035|NCT03910387|DRUG|Telotristat Ethyl|Given PO
224310036|NCT04914455|DIAGNOSTIC_TEST|Echocardiography and transhepatic inferior vena cava assessment using ultrasound.|"For all participant :~* Inferior vena cava diameter will be measure before and after fluid expansion 'which administration will be decided by a physician other that the investigator).~* Stroke volume using primarily VTI in TTE or a cardiac output monitoring device (Swan ganz catheter (Edwards life science), EV 1000 (edwards life science), PiCCO(Getinge))~* Absence of significant pericardial effusion of hematoma~Whenever possible:~Subcostal measurement of IVC, ejection fraction, cardiac outcput, mitral E, A and E' waves, TAPSE, tricupid S' wave, Right ventricle fractional area change.~venous congestion assesment : hepatic vein, portal vein and renal vein Doppler to define the VEXUS Score;"
224192660|NCT05173714|BEHAVIORAL|Guided Resistance Training|Supervised resistance training sessions are individualized for a low-resistance, high-repetition regimen of lower body major muscle groups with established guidelines. Instructions and resistance training bands will be provided for home use. Study participants will record compliance to the resistance training regimen for further guidance and potential modification.
224192661|NCT05173714|DRUG|Placebo|Oral placebo tablets (matching the experimental semaglutide) will be administered from the first through ninth months of the drug intervention period.
224192662|NCT05173714|DRUG|Semaglutide|Oral semaglutide 3 mg/day will be administered for the first month of study drug intervention period, if tolerated, the dose will increase to 7 mg/day for the second month and to a maximum dose of 14 mg/day from the third through ninth months of the drug intervention period.
224192663|NCT05843604|OTHER|Functional MRI|Three cognitive tests will be performed in the MRI, namely a stroop task, an N-back task and a switching task
224192664|NCT06641245|DIETARY_SUPPLEMENT|Folic Acid|folic acid (0.6 mg)
224310037|NCT00421395|BIOLOGICAL|90Y-hLL2|weekly dosing for either 2 or 3 weeks
224310038|NCT06396767|DIAGNOSTIC_TEST|DIA measured via Ultrasonography|Ultrasound will be used to measure Diaphragmatic Inspiratory Amplitude (DIA) of patients before and after elective cardiac surgery to determine if there is a correlation between changes in DIA and postoperative pulmonary complications.
224310039|NCT03012984|DRUG|Dexmedetomidine supplemented morphine analgesia|Patients in this group will receive patient-controlled intravenous analgesia for 3 days after surgery. The formula is a mixture of dexmedetomidine (1.25 ug/ml) and morphine (0.5 mg/ml), diluted with normal saline to 160 ml. 5-HT3 receptor antagonist is added when necessary. The analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with a bolus dose of 2 ml each time and a lockout time from 6 to 8 minutes according to patients' condition.
224192665|NCT06641245|DIETARY_SUPPLEMENT|5-MTHF (5-methyltetrahydrofolate)|0.625 mg/d (6S)-5-MTHF
224192666|NCT06585670|OTHER|Calm Health - smartphone application|Participants randomized to the intervention arm of the study will be given free access to a mobile phone application called Calm Health, which they will use to engage in guided meditation and mindfulness modules for at least 10 minutes per day for 8 weeks.
224192669|NCT04997512|DEVICE|Freestyle libre|A glucose sensor (flash) which measures interstitial blood glucose every 15 minutes or on demand.
224192670|NCT04997512|OTHER|Nurse led structured intervention - hypoglycaemia education and diabetes treatment modification modification|An education programme surrounding avoidance of hypoglycaemia at baseline. Regular review (weeks 2, 4, 12 and 24) and adjustment of diabetes medications based on freestyle libre data.
224192671|NCT06227819|DIAGNOSTIC_TEST|BVA-200|Blood samples collected for measurement with the BVA-100 will also be tested with the BVA-200. The BVA-200 uses whole blood collection cartridges which allow for a precise amount of blood to be measured without the need to first centrifuge and then pipette plasma aliquots. A small amount of whole blood from each sample will be set aside for BVA-200 use, while the remainder of the blood sample is used for BVA-100 measurement. The BVA-200 device was developed with the support of the Department of Defense through Phase I (W81XWH19C0048) and Phase II (W81XWH20C0025) SBIR contracts.
224192672|NCT01363999|DRUG|atorvastatin|single dose of atorvastatin on day 1
224192673|NCT01363999|DRUG|dalcetrapib|single dose of dalcetrapib on day 1
224192674|NCT04614142|DRUG|Glecaprevir / Pibrentasvir Oral Tablet [Mavyret]|The subject will begin an 8 week course of therapy with glecaprevir (100mg) / pibrentasvir (40mg) starting on day 3 (+/- 2 days) post-kidney transplantation from a hepatitis C positive donor.
224192675|NCT00643006|BEHAVIORAL|Physical exercise|Supervised walks with poles twice a week at moderate-high intensity
224192676|NCT00643006|BEHAVIORAL|Active comparator: low intensive exercise|Supervised walks once a week at low-intensity.
224192677|NCT06269562|PROCEDURE|Serratus posterior superior intercostal plane block and clavipectoral plane block|The analgesic effectiveness achieved by the concurrent application of these two techniques was investigated.
224192678|NCT02506101|DEVICE|narrow-band ultraviolet B phototherapy|There are two types of UVB: broad band and narrow band, with the major difference being that narrow band emits a smaller range of ultraviolet light, typically 311-312 nm. NB-UVB is a clinically indicated treatment for vitiligo lesions and treatments are usually administered in an outpatient setting 3 times a week.
224310040|NCT03012984|DRUG|Morphine analgesia|Patients in this group will receive patient-controlled intravenous analgesia for 3 days after surgery. The formula is morphine (0.5 mg/ml) diluted with normal saline to 160 ml. 5-HT3 receptor antagonist is added when necessary. The analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with a bolus dose of 2 ml each time and a lockout time from 6 to 8 minutes according to patients' condition.
224192679|NCT04271423|PROCEDURE|Ridge Preservation|Ridge Preservation using demineralized bone matrix and mineralized particulate allograft and covered with calcium sulfate barrier.
224192680|NCT03714139|PROCEDURE|immediate loading|"The participants will be assigned to immediate or delayed functional loading groups. In each participant, edentulous areas with adequate thickness of the alveolar bone crest will be identified and at least two sites will be identified for implant installation. All implant recipient sites will be sub-prepared to allow good stability of the implants. Experimental mini-implants (Sweden \& Martina, Due Carrare, Padova, Italy), 3.5 mm in diameter and with an intraosseous portion of 4 mm in length will be installed.~Immediate loading group - A prosthetic component will be applied over the trial implants. Impressions will be taken and a crown / bridge will be provided to patients in one day."
224192681|NCT03714139|PROCEDURE|non implant loading|Control implants will receive a healing screw and will remain unloaded
224192682|NCT00005803|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous transplantation
224192683|NCT00005803|PROCEDURE|Autologous-Allogeneic Tandem Hematopoietic Stem Cell Transplantation|Undergo autologous-allogeneic tandem hematopoietic stem cell transplantation
224192684|NCT00005803|DRUG|Carmustine|Given IV
224192685|NCT00005803|DRUG|Cyclophosphamide|Given IV
224192686|NCT00005803|DRUG|Cyclosporine|Given PO
224192687|NCT00005803|DRUG|Cytarabine|Given IV
224192688|NCT00005803|DRUG|Etoposide|Given IV
224192689|NCT00005803|DRUG|Fludarabine Phosphate|Given IV
224192690|NCT00005803|OTHER|Laboratory Biomarker Analysis|Correlative studies
224192691|NCT00005803|DRUG|Melphalan|Given IV
224192692|NCT00005803|DRUG|Mycophenolate Mofetil|Given PO
224192693|NCT00005803|PROCEDURE|Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic transplantation
224192694|NCT00005803|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo allogeneic transplantation
223501469|NCT02971189|DEVICE|Librata Endometrial Ablation|The treatment procedure will be performed in accordance with the physician's routine endometrial ablation practice and in accordance with the requirements of the LibrataTM IFU. The uterine cavity will be systematically inspected using hysteroscopy prior the ablative procedure (after any blind cervical dilatation) and post the ablative procedure to estimate the completeness of endometrial destruction and to exclude uterine trauma including uterine perforation. The patient will undergo standard post-operative monitoring and recovery according to usual hospital practices. An assessment will be made for any ablation procedure or device related serious adverse events.
223501470|NCT01328626|DRUG|ABT-199|Arm A (Cohorts 1-8) and Arm B (Cohort 1-6): Subjects in dose escalation phase will receive 1 dose of ABT-199, followed by 6 days off drug, followed by continuous once daily dosing with ABT-199. Arm B (Cohorts 7+): Subjects in dose escalation phase will receive continuous once daily dosing with ABT-199. Arm A and Arm B: Subjects in expanded safety cohort will receive continuous once daily dosing with ABT-199.
223501471|NCT01305343|PROCEDURE|Routinely performed surgical correction of spinal deformity|Routinely performed surgical correction of spinal deformity
223501472|NCT01363440|DRUG|Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321)|
223501473|NCT01363440|PROCEDURE|Macular Laser Photocoagulation|Laser therapy
223501474|NCT04426162|OTHER|Multi-domain Intervention|Intervention includes neurofeedback, heart rate variability biofeedback, memory and cognitive training, and one-on-one coaching to encourage behavior change in diet, sleep, physical fitness, and stress reduction.
223501475|NCT00126217|BIOLOGICAL|Bacille Calmette Guerin (BCG)|0,1 ml, revaccination at 19 months of age
223501476|NCT02981251|BEHAVIORAL|Health education with support by trained female health volunteer|Along with usual care four sessions of interactive health education will be provided to the participants by medical officer and/or registered nurse based on a syllabus for six months. Trained female female health volunteer will motivate the participants through their home visit twice a month where they will monitor blood pressure and counsel the family members to support the patient.
223501477|NCT03017261|DEVICE|TSolution One®|Total knee arthroplasty with the TSolution One® System for the preparation of the femoral and tibial cuts.
223512100|NCT01798823|PROCEDURE|History, physical, LF, SPT, blood sample, FeNO, EBC.|Medical history and physical examination, (LF) lung function (spirometry, (SETC) standardized exercise treadmill challenge, (BRT) bronchial reversibility test,(MBP) metacholine bronchial provocation), (SPT) skin prick tests, blood sample, (FeNO) fractional exhaled nitric oxide measurements, (EBC) exhaled breath condensate.
224192695|NCT00005803|BIOLOGICAL|Therapeutic Autologous Lymphocytes|IV donor lymphocyte infusion
224192696|NCT00005803|RADIATION|Total-Body Irradiation|Undergo radiotherapy
224192697|NCT00232128|PROCEDURE|Radiofrequency Ablation of pulmonary neoplasms|
224192698|NCT01151085|DRUG|Voriconazole|"Voriconazole Intravenous Solution 200 mg:~Voriconazole is administered by intravenous drip infusion at the dose of 6 mg/kg twice daily on day 1 and 3 mg/kg or 4 mg/kg twice daily from day 2 onward in adults.~Voriconazole Tablet 50 mg/ Voriconazole Tablet 200 mg:~administration for an adult (weighing 40 kg or more) is voriconazole 300mg orally twice daily between meals for day 1 and then 150 mg or 200 mg twice daily between meals from day 2 onward.~Depending on the symptoms or in cases where the effect is insufficient, the dosage may be increased.~However, the maximum dose on day 1 must be 400 mg twice daily, and the maximum dose from day 2 onward must be 300 mg twice daily.~In patients weighing less than 40 kg, voriconazole 150 mg shall be administered twice daily on day 1, and voriconazole 100 mg shall be administered twice daily from day 2 onward.~Depending on the symptoms, the maintenance dose from day 2 onward may be increased to 150 mg twice daily."
224192699|NCT04173520|DRUG|DDA|Follow up after SVR
224192700|NCT02653131|DRUG|Dipeptidyl peptidase-4 inhibitor|
224192701|NCT04100616|OTHER|No intervention|There is no intervention for this study
224192702|NCT00157638|BEHAVIORAL|integration of pharmacist into primary care|
224192703|NCT00157638|DRUG|optimizing therapeutic treatments|
224192704|NCT00157638|BEHAVIORAL|optimizing processes of care|
224192705|NCT03730064|DRUG|N-acetyl cysteine (NAC)|Experimental medication with N-acetyl cysteine (NAC) for six weeks
224192706|NCT01308476|PROCEDURE|SMS reminder|daily SMS in the SMS group to remind of treatment with tiotropium
224192707|NCT01308476|PROCEDURE|control group|no daily SMS to remind of treatment with tiotropium
224192708|NCT01006785|DRUG|DLBS1425|3 X 150 mg daily for 12 - 16 weeks of treatment
224192709|NCT01006785|DRUG|DLBS1425|3 X 300 mg daily for 12 - 16 weeks of treatment
224205850|NCT03050528|BEHAVIORAL|Acceptance and Commitment Therapy|Participants will attend weekly group psychology sessions for an eight-week period. Each session will be two hours in duration and will delivered by a Senior Psychologist trained in Acceptance and Commitment Therapy (ACT). The sessions will feature an ACT treatment process that is designed to promote psychological flexibility through various methods including acceptance and values awareness. The overall aim is to promote behaviour change, enhancing patient engagement in meaningful activities and reducing pain-avoidant behaviours. There is an emphasis on mindfulness, experiential learning and the use of metaphor which is unique to ACT.
223501478|NCT00818272|BIOLOGICAL|Remicade (infliximab)|Participants with confirmed diagnosis of severe active Crohn's disease (CD) and participants suffering from fistulae who do not respond sufficiently to a complete and adequate therapy with a conventional treatment received infliximab administration as intravenous (IV) infusion over a period of two hours. Dosage and infusion intervals were employed in accordance to the Summary of Product Characteristics (SmPC): 5 mg/kg body weight at week 0 of infliximab therapy with additional infusions of 5 mg/kg at week 2 and week 6 after the initial dose, followed by infusions every 8 weeks (maintenance) or if signs and symptoms of the disease recur (readministration).
223501479|NCT02513082|PROCEDURE|Sono guided nerve block|Sono guided nerve block is effectively and safely performed for pain relief after total knee arthroplasty
223501480|NCT02323334|DRUG|LY3202626|administered orally
223501481|NCT02323334|DRUG|Placebo (Part A, B, C)|administered orally
223501482|NCT02323334|DRUG|Itraconazole|administered orally
223501483|NCT01597232|OTHER|Transfusion trigger based on WCPTS|Determination of whether a patient needs red blood cell transfusion or which hemoglobin level should be maintained is based on WCPTS
223501484|NCT01597232|OTHER|Maintenance of hemoglobin level more than 10g/dL|The patient's hemoglobin level is maintained more than 10g/dL perioperatively
223501485|NCT01597232|OTHER|Transfusion trigger based on experience|Determination of whether the patient need red blood cell transfusion or which hemoglobin level should be maintained is based on the physician's experience
223501486|NCT02470572|OTHER|Omnyx™ IDP system|Omnyx™ IDP system for Whole Slide Images (WSI)
223501487|NCT02470572|OTHER|Conventional light microscope|Conventional light microscope
223501488|NCT00327535|DRUG|Darbepoetin alfa|According to the approved local label (6.75 micrograms/kg every 3 weeks, or 2.25 micrograms/kg every week)
224205851|NCT05872451|DRUG|Rocuronium Bromide|After measuring the initial current intensity, quantitative neuromuscular blockade monitoring is applied, and rocuronium (0.6 mg/kg) is administered.
223501489|NCT00327535|DRUG|methoxy polyethylene glycol-epoetin beta [Mircera]|6.3 micrograms/kg every 3 weeks
223501490|NCT00327535|DRUG|methoxy polyethylene glycol-epoetin beta [Mircera]|9 micrograms/kg every 3 weeks
223501491|NCT00327535|DRUG|methoxy polyethylene glycol-epoetin beta [Mircera]|12 micrograms/kg every 3 weeks
223501492|NCT05019053|BEHAVIORAL|Coping Crew|Coping Crew consists of five 60-minute virtual intervention sessions coinciding with five weeks of EMI. Participants will receive psychoeducation, challenge cognitive biases or mythbust, and participate in behavioral exposure and behavioral experiments. An EMI component of this treatment will be included for the purpose of treatment monitoring and homework tracking. Participation in this EMI component involves the daily report of levels of anxiety, depression, stress, and loneliness. When participants endorse elevated levels on any of these constructs, they will receive a targeted message reminding them of the topics covered in COPING CREW. One month after the intervention session, COPING CREW participants will complete follow-up questionnaires and interview. Participants will also participate in a feedback session 3 months after the intervention.
223501493|NCT04723368|DEVICE|Automated flying Drone carrying an Automated external defibrillator (AED)|Totally n=5 drones are equipped with automated external defibrillators (AEDs). These drones are deployed by the dispatch centre to cases of suspected out-of-hospital cardiac (OHCA) as a complement to standard care (ambulance/EMS) over up to 14 months during daytime Monday to Sunday 08:00-22:00. The bystander onsite receives instructions from the dispatcher to retrieve the AED outside the house when it has been delivered by the drone. The bystander attaches the AED to the patients chest to facilitate early defibrillation.
223501494|NCT04132180|OTHER|Early Mobilization|Range of motion exercises of the upper extremity will be performed under the guidance of the physical therapy team starting on post-operative day 1.
223501495|NCT04132180|OTHER|Late Mobilization|The patient's grafted upper extremity will be immobilized using an elbow flexion blocking splint until post-operative day 5.
223501496|NCT05380596|BEHAVIORAL|Telepharmaceutical Care|The intervention will be carried out through three teleconsultations, one per month, with a pharmacist (Times 0, 1, 2 and 3). In the opportunities, aspects related to pharmacotherapy and health status, non-pharmacological approaches, treatment adherence and evaluation of problems related to pharmacotherapy (PRM) will be discussed.
223501497|NCT02506036|OTHER|Brain HQ|Brain HQ is a web application that will be used to provide patients with a training intervention that addresses deficits in social-emotional functions. These include areas such as identifying facial expression, understanding tone of voice, and predicting how people may react in certain situations. The training will take about 30 hours over the course of 4-6 weeks and is done at home.
224205852|NCT05872451|DIAGNOSTIC_TEST|Nerve stimulator|Measuring the minimum current intensity for the stimulation of the obturator nerve to show the contraction of the adductor longus muscle.
224205853|NCT02612649|DRUG|Ramosetron|Oral
224205854|NCT02304302|DRUG|Memantine|Encapsulated Namenda 10 mg bid (after four-week standard dose titration protocol)
224205855|NCT02304302|DRUG|Placebo|Identically looking placebo capsules bid (after a four-week regimen designed to mimic standard dose titration protocol)
224205856|NCT01016431|OTHER|Rate-adaptive pacemaker programming|The ICD will be programmed in a AAI-R mode, with peak atrial stimulation rate set at 85% of maximal predicted heart rate, and ongoing protection VVI backup at 40 bpm
224205857|NCT01016431|OTHER|VVI at 40 bpm|ICDs will be programmed in VVI mode at 40 bpm
224205858|NCT00391118|DRUG|enzastaurin|
224205859|NCT00391118|DRUG|carboplatin|
224205860|NCT00391118|DRUG|paclitaxel|
224205861|NCT00391118|DRUG|placebo|
224205862|NCT02591017|DRUG|Morphine|
224205863|NCT02591017|DRUG|Ketamine|
224205864|NCT02591017|DRUG|Placebo|
224192710|NCT05936801|OTHER|Anterior Chest Compression technique|"Baseline treatment given is percussion and vibration in side lying position. The therapist puts one arm across the patient's pectoral region to stabilize or compress the upper chest while the other arm is placed either parallel on the lower chest or abdomen below the xiphoid process. Inspiration is facilitated by the pressure on anterior chest, followed by a hold.~Just as the patient is instructed to cough, the therapist applies a quick force with both arms:~down and back on the upper chest and up and back on the lower chest or abdomen. 3 sessions in a wk would be given on alternate days Baseline treatment given is percussion and vibration in side lying position. It Can be used in both the supine and side lying positions. With the patient in the supine position, the therapist places the heel of one hand inferior to the patient's xiphoid process and below the patient's lower ribs."
224192711|NCT05936801|OTHER|Abdominal Thrust Technique|Baseline treatment given is percussion and vibration in side lying position. It Can be used in both the supine and side lying positions. With the patient in the supine position, the therapist places the heel of one hand inferior to the patient's xiphoid process and below the patient's lower ribs.
224192712|NCT01955291|DEVICE|Reinforced Feedback in Virtual Environment (RFVE)|"The patients allocated to RFVE group, will be treated using the Virtual Reality Rehabilitation System (VRRS). During the virtual therapy the subject will be seated in front of the wall screen grasping a sensorized real object with the affected hand. If the grasp is not possible the sensors will be fixed on a glove worn by the patient. The real object held by the subject, equipped with electromagnetic sensors, is matched to the virtual handling object. Thereafter, the patient moved the real object (e.g. ball) following the trajectory of the corresponding virtual object displayed on the computer screen in accordance with the requested virtual task."
224192713|NCT01955291|OTHER|Traditional Neuromotor Rehabilitation|The patients randomized to the Traditional Neuromotor Rehabilitation group will be asked to perform exercises for postural control, exercises for hand pre-configuration, exercises for the stimulation of manipulation and functional skills, exercises for proximal-distal coordination. All the exercises will be performed with or without the assistance of a physiotherapist. The upper limb motricity will be trained with progressive complexity. To achieve the requested goal (in a horizontal or vertical plane) patients will be asked to perform various movements, for example: shoulder flexion and extension, shoulder abduction and adduction, shoulder internal and external rotation and shoulder circumduction, elbow flexion and extension, forearm pronation and supination, hand grasping-release and clenching into a fist.
224192714|NCT01406548|DRUG|BPS804 20mg/Kg|
224192715|NCT01406548|DRUG|Placebo to 20mg/Kg BPS804|
224192716|NCT01821001|DRUG|Vaginal Bromocriptine|Patients will receive 2.5 mg of vaginal bromocriptine tablet twice a day for the intervention. This will be administered for 6 months.
223501498|NCT05921500|DRUG|sodium peborate|Internal bleaching of discolored primary anterior teeth by using sodium peborate
223501499|NCT04015687|DRUG|AG-881|Supplied as uncoated tablets.
223501500|NCT04015687|DRUG|Lamotrigine|Supplied as tablets of LAMICTAL® or generic equivalent.
223501501|NCT00319891|PROCEDURE|Computer-based Cognitive Training|
223501502|NCT01371760|PROCEDURE|Venous PTA|PTA of the internal jugular and/or azygous vein
223501503|NCT01371760|OTHER|Catheter Venography|The patients will undergo catheter venography but not PTA
223501504|NCT06103682|DEVICE|Ablative local therapy|Stereotactic ablative radiotherapy (SABR) or interventional radiology (IR) ablation therapy
223501505|NCT04073576|DEVICE|AHCL|Closed loop algorithm contained in the MiniMed™ 670G 4.0 pump to be used in the study; includes a modified proportional integrative derivative (PID) model, with insulin feedback, an auto correction bolus feature and additional safety features.
223501506|NCT04073576|DEVICE|SAP+PLGM|Sensor Augmented Pump (SAP) Therapy Mode with Predictive Low Glucose Management (PLGM), contained in the the MiniMed™ 670G 4.0 pump to be used in the study.
224074907|NCT04729777|PROCEDURE|Combined Cardiovascular Magnetic Resonance and Cardiopulmonary Exercise Testing|Clinical Cardiac MRI scan at rest with routine administration of gadolinium contrast agent. Participants then undergo the research component of the test which requires them to perform exercise, using a recumbent, MRI-compatible cycle ergometer, whilst their breathing is simultaneously analysed using a mask connected to a CPET machine, until they are limited by symptoms and they stop pedalling. Most participants will undergo only one scan. Some participants will be asked to have two or three such scans over 3 months to assess changes over time, and in response to standard treatment of pulmonary hypertension.
224074908|NCT03434977|DRUG|TAK-536|TAK-536 granule formulation
224074909|NCT02055066|DRUG|ARGX-111|
223501507|NCT04715100|OTHER|Observational group|The study dependent variables will be: pain (vas scale), joint status (Hemophilia Joint Health Score), perception of quality of life (SF-36 questionnaire), list of roles (Oakley questionnaire), performance of basic activities of daily life (Barthel index) and the performance of instrumental activities of daily living (Lawton and Brody scale).
223501508|NCT04234542|OTHER|Low Level Laser Therapy|Each stage will follow this sequence of applications: (1) spine application (DUO-240 red and infrared array in a horizontal placement and 2 oblique placements bilaterally + LDR-100 laser probe + LDI-200 laser probe), (2) perineum application (DUO-240 red and infrared array in the surface of the perineum + LDR-100 probe) and (3) overlying branches of the pudendal nerve at the lateral perineum (LDI-200 probe). Parameters of frequency and duty cycle will be increased along with intensity as the stages progress.
223591856|NCT05383872|DEVICE|Focused Ultrasound (Exablate Model 4000)|BBB opening via Exablate Type 2 system with microbubble resonators and drawing blood before and after opening
223591857|NCT02883062|DRUG|Atezolizumab|Given IV
223591858|NCT02883062|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
224074910|NCT03920670|DEVICE|TetraGraph (TG)|TetraGraph device is a neuromuscular transmission monitor capable of estimating the depth of neuromuscular block in anesthetized patients who received neuromuscular blocking agents. TetraGraph uses EMG to measure the muscle action potentials that are generated in response to percutaneous electrical neurostimulation. Following simultaneous ulnar nerve stimulation on each arm, the response of the adductor pollicis will be measured.
224192717|NCT04337463|DRUG|ATG-008|Tablet
224192718|NCT04337463|DRUG|Toripalimab|IV infusion
224205865|NCT02591017|DRUG|Chitosan|
224205866|NCT03054168|DRUG|Sustanon 250|The frequency of the injection will be every 2 weeks, 250mg of testosterone, intramuscular injection.
224192719|NCT02400658|DEVICE|IORT with CT-Guided HDR Brachytherapy|This therapy targets the cancer cells directly, reducing the volume of breast tissue exposed to the radiation and the risks involved with the radiation. CT imaging will be used via a multichannel/multi-dwell balloon catheter to better sculpt the cancer away from the heart, skin, and ribs.
224192720|NCT06175052|OTHER|Dietary Intervention|Four nutrition counselling sessions conducted over eight weeks, in conjunction with food items to assist in meal preparation and with weekly educational information messages sent via email.
224192721|NCT04893174|BIOLOGICAL|UMC119-06-05|"Subjects will receive a single-dose IA injection of UMC119-06-05 followed by an IA injection of hyaluronic acid.~Cohort 1: Low does UMC119-06-05 Cohort 2: High does UMC119-06-05"
224192722|NCT04893174|DEVICE|Hyaluronic acid|IA injection of hyaluronic acid.
224310041|NCT06353568|DEVICE|Photobiomodulation|The PBM Group will use a boot with 1344 LEDs, including 504 LEDs of 660 nm located on the sides of the boot (28.5 mW, 10 J per LED); 504 LEDs of 850 nm also located on the sides of the boot (23 mW, 8 J per LED); 168 LEDs of 660 nm located at the base of the boot (28.5 mW, 10 J per LED); and 168 LEDs of 850 nm also located at the base of the boot (23 mW, 8 J per LED) once daily for 6 minutes, over 60 days.
224310042|NCT06353568|DEVICE|Simulation of Photobiomodulation|The Control Group will use a non-therapeutic LED boot (sham procedure) for 6 minutes once daily for 60 days. The boot used is identical to the active boot, but there is no light emission.
224310043|NCT06353568|BEHAVIORAL|Therapeutic education|Participants will receive therapeutic education regarding nutrition, foot examination, self-care, and guidance on physical activity.
224310044|NCT05860205|BEHAVIORAL|Multiple Component Mobile-Aid Pain Reduction Intervention|1.Posture training through the wearable device, UPRIGHT GO. The participant wears the device on their neck. The device provides biofeedback to poor posture with vibrations and tracks posture. 2. A daily core muscle training and stretching exercise program including trunk rotation, lumbar rotation, hip flexor stretch, side plank, glute bridge, suitcase carry, and palloff press. 3. Participants will practice stress reduction through breath focus which will help them to concentrate on deep breathing to help them ignore distracting thoughts and sensations. 4. Strategies to improve daily level of activity including wearing a Garmin device that tracks their daily physical activity and reminds them to walk and the use of the communication principle to assist participants in overcoming barriers to physical activity.
224310045|NCT05860205|OTHER|Osteopathic Manipulation Treatment|Osteopathic Manipulation Treatment (OMT) will be conducted by putting pressure on certain muscles in the back and performing OMT exercises on the patient. The physician will treat participants with OMT twice during month 1 and once during month 2 and 3.
223501509|NCT04234542|OTHER|Sham Low Level Laser Therapy|Each stage will follow this sequence of applications: (1) spine application (DUO-240 red and infrared array in a horizontal placement and 2 oblique placements bilaterally + LDR-100 laser probe + LDI-200 laser probe), (2) perineum application (DUO-240 red and infrared array in the surface of the perineum + LDR-100 probe) and (3) overlying branches of the pudendal nerve at the lateral perineum (LDI-200 probe). Parameters of frequency and duty cycle will be progressed, but power will always be set to 1%..
223501510|NCT04370600|DRUG|beta hydroxybutyrate (BHB) ester|Ketone supplementation given 3x/day (60mL per dose, or 22g BHB)
223591859|NCT02883062|DRUG|Carboplatin|Given IV
223591860|NCT02883062|PROCEDURE|Lumpectomy|Undergo lumpectomy
224192723|NCT05710367|DRUG|Dapagliflozin 10mg Tab|Forxiga® as an add-on treatment in patients with renal and/or cardiac association FD in an exploratory framework.
224310046|NCT05860205|OTHER|Sham Osteopathic Manipulation|The sham osteopathic manipulation treatment (OMT) will be performed by the medical team. Hands will be placed on the patient as if the OMT is being performed. The physician will treat participants with sham OMT twice during month 1 and once during month 2 and 3.
224310047|NCT05180357|OTHER|FASENRA(benralizumab)|This is a retrospective, observational study with secondary data collection utilizing medical chart review in hospitals or clinical centres that treated SEA + NP patients with benralizumab. Patient data including demographics, clinical characteristics, medication history, biologic treatment, and NP and asthma clinical outcomes will be abstracted from patient medical charts onto a pre-approved electronic case report form. No personal identifiable data will be collected. Data from all participating centres will be combined into a single anonymised dataset for analysis.
223501511|NCT04370600|DRUG|Placebo|Denatonium benzoate + HVMN ketone placebo flavor mix + Stevia
223512101|NCT02169999|OTHER|Personalized Diabetes Care Website|Subjects enrolled in the intervention view the Personalized Diabetes Care website and enter their self-reported medical history and personal preferences into the website. A model runs and creates a 2 page print out with risk estimates for the subject to review with their physician.
223512102|NCT05734807|DRUG|Nucleoside/nucleotide reverse transcriptase inhibitors (NrtIs)|Subjects will receive NrtIs therapy for 24 weeks.
224192724|NCT05710367|DRUG|Placebo|matched oral drug. Placebo tablet will have the same color, taste, smell and package as the verum tablet
224192725|NCT00812968|DRUG|Lenalidomide|Oral 10mg daily on Days 1-21 days every 28 days until disease progression/relapse or CC-5013 is permanently discontinued for any reason for up to 156 weeks (3 years).
224192726|NCT03504501|DRUG|Lovastatin|oral application prior to transcranial magnetic stimulation intervention
224192727|NCT03504501|DRUG|Lamotrigine|oral application prior to transcranial magnetic stimulation intervention
224192728|NCT01388036|DRUG|esmolol|consecutive infusions of esmolol and normal saline (placebo)
224310048|NCT03803930|DEVICE|Using 22G FNB, the first pass is SP|Using 22G FNB, the first pass is SP and the pass sequence is SP-MWST-SP-MWST.
223512103|NCT05734807|DRUG|HH-003 and NrtIs|Subjects will receive HH-003 20 mg/kg intravenously Q2W and NrtIs therapy for 24 weeks.
223512104|NCT05734807|DRUG|HH-003, NrtIs and PEG-IFN-α|Subjects will receive HH-003 20 mg/kg intravenously Q2W, NrtIs therapy and PEG-IFN-α 180μg SC QW for 24 weeks.
223512105|NCT01452789|DRUG|sublingual buprenorphine|Initial daily dose: 15.9 mcg/kg/day; Initial unit dose: 5.3 mcg/kg q8 hours; Maximum daily dose: 60 mcg/kg/day; Up-titration rate: 25%; Weaning rate: 10%; Cessation Dose: Within 10 or 20% of starting dose
223512106|NCT01452789|DRUG|oral morphine|Initial daily dose: 0.4 mg/kg/day; Initial unit dose: 0.07 mg/kg q 4 hours; Maximum daily dose: 1.25 mg/kg/day; Up-titration rate: 20%; Weaning rate: 10%; Cessation Dose: 0.025 mg/kg q 4 hours
223512107|NCT01340170|DEVICE|OsseoSpeed TX|OsseoSpeed TX dental implants, 6-17 mm
224310049|NCT03803930|DEVICE|Using 22G FNB, the first pass is MWST|Using 22G FNB, the first pass is MWST and the pass sequence is MWST-SP-MWST-SP.
224192729|NCT03851536|PROCEDURE|Transvaginal Ultrasound Guided ET|Use of TVUS to guide ET
224192730|NCT03851536|PROCEDURE|Transabdominal Ultrasound Guided ET|Use of TAUS to guide ET
224192731|NCT04123951|OTHER|Home-based Exercise|Patients in the home-based exercise arm will complete a 12 week home-based aerobic and resistance exercise training programme. There will be a 2 week period prior to this in which patients will complete up to 6 supervised sessions in order to learn about the home-based exercise training. There will be a 4 week return visit and an optional 8 week return visit in order to reassess fitness and aid the patients with any questions or queries they may have and to aid them in progressing their exercise.
224192732|NCT03148509|DRUG|risperidone|DA receptor-mediated drugs
224192733|NCT03148509|DRUG|aripiprazole|DA receptor-mediated drugs
224192734|NCT03148509|DRUG|bupropion|DA receptor-mediated drugs
224192735|NCT05959174|DEVICE|3D printed mitchigen appliance|the process of appliance construction done by intra-oral scanning of the arch and 3d printing
224192736|NCT05959174|DEVICE|side chair appliance|the impresion will be taken to make a cast to reconstruct the appliance
224192737|NCT05390060|DEVICE|Neuromonitoring|Multimodal neuromonitoring encompassing intracranial pressure, brain tissue oxygenation, microdialysis and cerebral blood flow monitoring
224192738|NCT03986216|DEVICE|ReIn-Hand device assisted home-based practice|Practice reach-grasp-retrieve-release at home with the aid of ReIn-hand device
224192739|NCT05877508|DRUG|AER002|Intravenous infusion of AER002
224192740|NCT05877508|OTHER|Placebo|Placebo infusion
224310050|NCT03803930|DEVICE|Using 20G FNB, the first pass is SP|Using 20G FNB, the first pass is SP and the pass sequence is SP-MWST-SP-MWST.
224310051|NCT03803930|DEVICE|Using 20G FNB, the first pass is MWST|Using 20G FNB, the first pass is MWST and the pass sequence is MWST-SP-MWST-SP.technique-slow pull.
224310052|NCT01708148|DIETARY_SUPPLEMENT|Probiotics|lyophilised L. rhamnosus, L. jensenii, L. crispatus, L. gasseri and sodium alginate
223501512|NCT05018559|BEHAVIORAL|BuG lesson|Participants of the intervention group in nursing care received a co-created setting-specific intervention to promote physical activity called BuG lesson. The BuG lesson comprises a weekly 90-minute lesson for apprentices of nursing care during regular school hours, covering physical activity and health in theory and practice. Previously, the nursing teachers voluntarily underwent a qualification process as physical activity instructors, enabling them to conduct the BuG lessons independently.
223501513|NCT05018559|BEHAVIORAL|Tutoring system|Participants of the intervention group in automotive mechatronics received a co-created setting-specific intervention to promote physical activity called tutoring system. In the tutoring system, automotive mechatronics apprentices act as physical activity promotors for their fellow apprentices. In the sense of a peer-to-peer approach, apprentices voluntarily participate in a workshop to be qualified as tutors. Subsequently, the tutoring system takes place every two weeks for about ten to fifteen minutes during regular working hours, allowing the tutors to discuss the issues of physical activity and health among their peers.
223591861|NCT02883062|PROCEDURE|Mastectomy|Undergo mastectomy
223591862|NCT02883062|DRUG|Paclitaxel|Given IV
223591863|NCT06445361|DIAGNOSTIC_TEST|FibroScan|Performance of a FibroScan measurement to determine steatosis and fibrosis.
224192741|NCT03413618|DRUG|Rivaroxaban|15 mg b.i.d. for 3 weeks and then 20 mg q.d. up to 6 month
224192742|NCT03413618|DRUG|Diosmin|600 mg q.d. for 12 month
224192743|NCT03413618|OTHER|compression stockings|above knee stocking for 12 month
224192744|NCT01636596|DRUG|Insulin LISPRO|Insulin is delivered in a pulsatile fashion. One treatment is approximately 10-15 units of insulin (exact dose based on weight) split into ten pulses delivered over one hour. Three treatments will be administered per session with one session per week for six month duration.
223591864|NCT02888743|BIOLOGICAL|Durvalumab|Given IV
223591865|NCT02888743|RADIATION|Radiation Therapy|Undergo radiation therapy
223591866|NCT02888743|BIOLOGICAL|Tremelimumab|Given IV
224192745|NCT04435431|DRUG|Mesdopetam|Oral use
224192746|NCT04435431|DRUG|Placebo|Oral use
224192747|NCT01243762|DRUG|dalotuzumab|Administered intravenously (IV) once weekly in 28-day cycles for a maximum of 6 months of study therapy
224192748|NCT01243762|DRUG|MK-0752|Administered orally (PO) weekly in 28-day cycles for a maximum of 6 months of study therapy
224192749|NCT01243762|DRUG|ridaforolimus|Administered PO daily for 5 consecutive days per week in 28-day cycles for a maximum of 6 months of study therapy
224192750|NCT01243762|DRUG|MK-2206|Administered PO weekly in 28-day cycles for a maximum of 6 months of study therapy
224192751|NCT00433368|DRUG|L-Ornithine L-Aspartate|
224192752|NCT04196023|DIETARY_SUPPLEMENT|Magnesium glycinate|Oral administration of magnesium glycinate daily for 12 weeks
224192753|NCT04196023|DIETARY_SUPPLEMENT|Placebo|Oral administration of identical-appearing placebo daily for 12 weeks
224192754|NCT00874718|BEHAVIORAL|educational program|6-week educational program for prevention of occupational musculoskeletal diseases.
224192755|NCT00874718|BEHAVIORAL|General education|Non-specific educational program for general health.
224192756|NCT00036621|DRUG|BMS-275291|
224310053|NCT01708148|OTHER|Placebo|control group would receive a oral lactose placebo
224310054|NCT04314648|BEHAVIORAL|Substance Use Treatment and Recovery Team (START)|Embedding of a collaborative care team, called the Substance Use Treatment and Recovery Team (START), for inpatients with OAUDs within an existing hospital consultation liaison psychiatry service.
224310055|NCT01415102|DRUG|PF-05212372|Inhaled. Dose Level 1: 50 ug
224310056|NCT01415102|DRUG|PF-05212372|Inhaled. Dose Level 2 - Dose to be selected based upon safety/tolerability/PK at preceding dose
224310057|NCT01415102|DRUG|PF-05212372|Inhaled. Dose Level 3 - Dose to be selected based upon safety/tolerability/PK at preceding dose
224310058|NCT01415102|DRUG|PF-05212372|Inhaled. Dose Level 4 - Dose to be selected based upon safety/tolerability/PK at preceding dose
224310059|NCT01415102|DRUG|Placebo|Inhaled
224310060|NCT01415102|DRUG|PF-05212372|Inhaled. Dose Level 5 - Dose to be selected based upon safety/tolerability/PK at preceding dose
224310061|NCT01415102|DRUG|PF-05212372|Inhaled. Dose Level 6 - Dose to be selected based upon safety/tolerability/PK at preceding dose
224192757|NCT00681434|BEHAVIORAL|bilateral upper extremity training|Bilateral symmetrical upper extremity training for proximal control for three hours per week for eight weeks.
224192758|NCT00681434|BEHAVIORAL|Unilateral upper extremity training|Unilateral upper extremity training for proximal extremity for three hours a week for eight weeks.
224192759|NCT04233606|OTHER|Hypertonic Saline|Infusion of hypertonic saline to induce an osmotic secretion of the hormone vasopressin
224192760|NCT04233606|OTHER|Normal Saline|Infusion of normal saline to inhibit the secretion of the hormone vasopressin
224192761|NCT01322061|DRUG|Ascorbic Acid|Effervescent,1000mg/tablet, 2000 mg dissolved in 50ml water, the drug will be given once, one hour prior to surgery
224192762|NCT05643807|DEVICE|Flexible cystoscopy|Urinary cytology will be collected through the flexible cystoscope itself at the end the cystoscopy. Before starting the urinary collection, the cystoscope will either be placed in front of a suspected intravesical lesion (if present) or at the bladder neck (if no lesion present).
224192763|NCT05643807|DEVICE|Urinary catheter|Urinary cytology will be collected through a Ch14 urinary catheter after the cystoscopy
224192764|NCT05371262|DRUG|Levothyroxin|Congenital hypothyroidism children received two different doses of levothyroxin within the recommended range to evaluate any differences in long-term outcomes.
224192765|NCT04861688|COMBINATION_PRODUCT|Traditional Chinese Medicine (NeuroAiD II™ (MLC901)|NeuroAiD II™ (MLC901) contains the extracts of 9 botanical active ingredients blended with commonly used excipients. The 9 botanical active ingredients are traditional herbs well documented in the Pharmacopoeia of the People's Republic of China.
224192766|NCT04861688|OTHER|Placebo|Placebo with same appearance as active intervention
224192767|NCT02443558|OTHER|Brain-Computer Interface control of robotic arms.|The patients will be trained to modulate self-paced Visual Motor Imagery (VMI) and Kinesthetic Motor Imagery (KMI) under EEG recording in order to achieve BCI-control of a custom-built bimanual arms robot (MERCURY v2.0). In KMI they will be asked to modulate brain waves in order to learn to control the BCI and in VMI they will additionally be projected a visual cue (representation of the intended movement).
224192768|NCT02443558|DEVICE|MERCURY v2.0 robotic arms|MERCURY v2.0 robotic arms is a non-commercial 6-degree-of-freedom anthropomorphic bimanual robotic arms device that was built and developed by the research team of the Medical Physics Lab.
224310062|NCT01415102|DRUG|PF-05212372|Inhaled. Dose Level 7 - Dose to be selected based upon safety/tolerability/PK at preceding dose
224310063|NCT01415102|DRUG|Placebo|Inhaled
223501514|NCT05713370|DIETARY_SUPPLEMENT|high fat meal|A high fat meal (milkshake) will be administered on the morning after the intervention of no exercise and no SR the night before.
223501515|NCT02619656|PROCEDURE|CO2 insufflation|Patients were randomized to insufflation with CO2.
223501516|NCT02619656|PROCEDURE|Ambient air insufflation|Patients were randomized to insufflation with ambient air.
223501517|NCT03516500|DRUG|Iron Sucrose Injection|The investigators inject Iron Sucrose (100 mg dissolved in 50 mL saline) into the segmental bronchus.
223501518|NCT02237274|OTHER|High altitude exposition|High altitude exposition
223501519|NCT03688737|OTHER|low level laser|LLLT with wavelength (λ) of (600 nm to 700nm), The laser will be held 1 cm away from the surface of the target tissue, the irradiated area is 0,5 cm2.The area of impact is the surgical wound zone and the neighboring 0,5-1,0 cm of the adjacent oral mucosa for 1min and 22sec, at day of surgery, 1st day and 3rd day and come for follow up visits at 5th day ,2 weeks, month and 3 months postoperative
223591867|NCT02686502|BEHAVIORAL|Lifestyle|As part of the intervention Mode 2 and 3 subjects will use various mobile health applications including heart rate monitor, global positioning system, diet diary, and weight, sleep and mood monitors. They will also be offered music streaming service for e.g. motivation and relaxation.
223591868|NCT06225466|DRUG|Rocuronium|After induction of anesthesia and placement of an IV, rocuronium 0.6 mg/kg (maximum dose 50mg) will be administered. Additional doses of rocuronium 0.2 mg/kg (maximum dose 15 mg) will be administered when the neuromuscular transmission monitor indicates a train of four count of 2 or greater.
223591869|NCT06225466|DRUG|Sugammadex|When the surgery is completed, sugammadex 2 mg/kg will be administered if the neuromuscular transmission monitor indicates the train of four count is 2 or greater. Sugammadex 4 mg/kg will be administered if 1) the train of four count is 1, or 2) if the train of four count is 0 and the post tetanic count is at least 1. There is no maximum dose of sugammadex.
223501520|NCT03688737|OTHER|placebo|placebo like device as it like low level laser device shape but with no effect to blind the intervention
223591870|NCT06225466|OTHER|Anesthesia without neuromuscular blockade|Anesthesia without rocuronium or sugammadex
223591871|NCT04909229|DEVICE|PEAR-003b PDT Intervention|The PEAR-003b digital therapeutic delivers CBT-I via mobile devices as 6 treatment core modules over 9 weeks.
223591872|NCT04909229|DEVICE|Fitbit|Patients will receive a Fitbit and receive standard of care
224192769|NCT02315651|DIETARY_SUPPLEMENT|Coenzyme Q10|A snack containing 60 mg of Coenzyme Q10. The snack contains also dried fruits and nuts, and their content are identical to this of placebo.
224192770|NCT02315651|DIETARY_SUPPLEMENT|Placebo|A snack identical to the trial snack, but without Coenzyme Q10. The snack contains also dried fruits and nuts.
224192771|NCT00528125|PROCEDURE|active laser acupuncture|low level laser acupuncture, 830 nm, 30 mW, 0,3 J per acupoint, 2 points per neonate (Hegu and Shen Men). Overall 30 seconds of treatment
224192772|NCT00528125|PROCEDURE|placebo laser acupuncture|placebo laser acupuncture at two acupoints (Hegu, Shen Men). Overall treatment time 30 seconds.
224192773|NCT01905891|PROCEDURE|Superficial shave biopsy|Sample will be obtained from random dorsal forearm skin sites without evidence of keratotic lesions. The site will be selected by the investigator. Skin will first be wiped with an alcohol pad and 1% lidocaine will be superficially infiltrated per standard skin surgical procedures. 30% trichloroacetic acid (TCA, standard chemical peel) will then be applied for five minutes. TCA will be neutralized using bicarbonate. Using a cytology brush (a small brush which is used to collect cells during the course of a biopsy) cells will be collected by gentle scraping surface of the skin. Then, a superficial shave biopsy specimen, obtained by using a dermablade (a flexible, one piece blade specifically designed for shave biopsy and excision of skin lesions) will be obtained.
224192774|NCT02985996|DRUG|Truvada|Truvada is intended for the treatment of HIV-1 infection. Truvada is a combination of emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg in one tablet.
224192775|NCT02985996|DRUG|Genvoya|Genvoya is a 1-pill, once-a-day prescription medicine used to treat HIV-1. Genvoya is a combination of 150 mg of elvitegravir, 150 mg of cobicistat, 200 mg of emtricitabine, and 10 mg of tenofovir alafenamid in one tablet.
224192776|NCT00401726|DRUG|Venlafaxine ER|
224192777|NCT00401726|BEHAVIORAL|Dialogues Time to Talk Program|
224192778|NCT00242840|DRUG|No intervention; Observational study|
224192779|NCT03113773|DRUG|Proleukin|Patients will be treated with subcutaneous injections of IL-2 (range 0.3 X 10\^6 - 3.0 X 10\^6 IU) or placebo once daily for five consecutive days during the trial.A maximum dose of 3.0 X 10\^6 IU will be allowed per day.
224192780|NCT03113773|DRUG|Placebo Injection|Dextrose 5%
224310064|NCT02784041|DRUG|single adductor-canal-block|Single adductor-canal-block is performed before the surgery. A 12Hz linear ultrasound transducer is placed on the medial part of the thigh with the leg slightly externally rotated. The femoral artery was identified in short axis in the adductor canal, underneath the sartorius muscle. After skin disinfection , an 18-gauge needle (B.Braun Medical, Melsungen, Germany) is inserted in-plane from the lateral side of the transducer. The needle tip was placed underneath the sartorius muscle, just lateral to the artery and saphenous nerve, using 2-3 ml of saline to ensure correct placement. 25 ml of 0.35% ropivacaine is slowly injected with repeated aspiration.
224310065|NCT02784041|DRUG|periarticular infiltration|The periarticular infiltration of multimodal agents will involve the preparation of a mixture of 100 ml solution. The mixture contains 30ml (300mg) ropivacaine, 0.5ml (5 mg) morphine, 2 ml (50 mg) flurbiprofen and 0.5 ml of 1:1000 epinephrine, and then is diluted with 0.9% normal saline to a total volume of 100ml. 50 ml of mixture will be injected into the anterior, medial and lateral soft tissues after the implantation of the joint prostheses. The remaining 50 ml of mixture will be injected into intraarticular space after the closure of articular capsule.
224310066|NCT03518801|BEHAVIORAL|Prolonged Exposure|psychotherapy
224310067|NCT03518801|DRUG|Cannabidiol|active medication
224310068|NCT03518801|DRUG|placebo|non-active medication
224310069|NCT04939220|PROCEDURE|TEE with SGA|SGA Placement and maintenance with inhalational anesthetic or propofol
223501521|NCT05015179|PROCEDURE|mixed reality technology in laparoscopic partial nephrectomy|All patients undergo contrast-enhanced computed tomography before surgery. DICOM files are converted to a 3D model. This model is then sent to HoloLens 2 smart glasses using HLOIA software
223501522|NCT00516854|DRUG|chlordiazepoxide 5 mg, clidinium 2.5 mg, twice daily|
223512108|NCT05912725|PROCEDURE|Implant placement|"4 implants were placed , 2 implants in each side of the patient mouth opposite lower second premolar and second molar~4 implants were placed , 2 implants in each side of the patient mouth opposite lower second premolar and second molar"
224192781|NCT02016638|OTHER|Polysomnography and ambulatory blood pressure recording|
224192782|NCT03051152|PROCEDURE|D1 gastrectomy|Gastrectomy with limited lymph node dissection
224192783|NCT03051152|PROCEDURE|D2 gastrectomy|Gastrectomy with extended lymph node dissection
224192784|NCT04186637|DRUG|ALPN-202|Multiple dose levels and dose regimens of ALPN-202 will be administered
224192785|NCT00442572|DRUG|PEGASYS [peginterferon alfa-2a]|There were 4 treatment cycles of continuous intermittent treatment with Peginterferon alfa-2a. Each cycle consisted of 12 weeks injection treatment with Peginterferon alfa-2a 135 micrograms in 0.5 ml solution in prefilled syringes, applied once weekly subcutaneously and followed by 12 weeks period without treatment.
224192786|NCT03132610|DRUG|andrographolide sulfonate|Conventional Therapy+Xiyanping injection
224192787|NCT03132610|DRUG|andrographolide sulfonate simulation|Conventional Therapy+Xiyanping injection simulation
224192788|NCT01167699|DRUG|Oxycodone and naloxone|Oxycodone hydrochloride and naloxone hydrochloride combination, prolonged release
224192789|NCT01901393|DRUG|IV ibuprofen|
224192790|NCT01901393|DRUG|Ketorolac|
224192791|NCT01113073|OTHER|ventilatory protocol|Ventilatory protocol for short period with four different tidal volumes (12 min)
224192792|NCT01113073|OTHER|Elastic band|Placement of an elastic band around thorax to reduce thorax compliance
224192793|NCT01113073|OTHER|passive leg raising test|performing the passive leg raising test
224192794|NCT00843739|DEVICE|EMST - Active Treatment|Hand held device used for strengthening expiratory muscles
224310070|NCT04939220|PROCEDURE|TEE with Deep Sedation|Deep sedation with propofol and natural airway
223512109|NCT03878602|PROCEDURE|Delayed umbilical cord clamping|Umbilical cord will be clamped after 1 min after the birth of the newborn
223512110|NCT03878602|PROCEDURE|Immediate umbilical cord clamping|Umbilical cord will be clamped immediately after the birth of the newborn
223512111|NCT01289587|BEHAVIORAL|Physical activity intervention|36 sessions of physical activity offered at different frequencies
223512112|NCT03901209|DEVICE|Mid-face osteotomy|The mid-face osteotomy - typically according to LeFort I - is performed using a pulsed erbium-doped yttrium aluminium garnet (Er:YAG) laser driven by the CARLO robot arm.
223512113|NCT02285244|DRUG|sotrastaurin acetate|Given PO
223512114|NCT02285244|OTHER|pharmacological study|Correlative studies
223512115|NCT02285244|OTHER|laboratory biomarker analysis|Correlative studies
223512116|NCT04419350|PROCEDURE|Microneedling|One session of microneedling will be performed by using dermaroller 1.5 mm. The microneedling done from the edge of the normal skin towards the center of the hypopigmented lesion in all the directions (horizontal, vertical. diagonal).
224192795|NCT00843739|DEVICE|sham EMST|Four week sham device training program
224192796|NCT00622752|DRUG|EVT 302, 10 mg|2 X EVT 302, 5 mg tablets
224192797|NCT00622752|DRUG|placebo|2 X placebo tablets to match EVT 302 5 mg
224192798|NCT00622752|DRUG|Nicotine replacement therapy (NRT)|NRT patch containing 21 mg of nicotine
224192799|NCT00622752|DEVICE|NRT placebo|Medically inert plaster cut to match the NRT plaster
224192800|NCT06484387|BEHAVIORAL|Social interaction|Participants are required to speak to one another. Participants are given various topics of conversation.
224192801|NCT02868294|DEVICE|Fassier-Duval Nail|Implementation of a telescopic system intramedullary
223501523|NCT02347007|DIETARY_SUPPLEMENT|Almond|Participants will be randomized to consume approximately 17.5% of their estimated energy requirements from almonds daily for 24 weeks. Prescribed energy requirements will be determined for each participant individually using the Mifflin St Jeor Equation equation with an activity factor of 1.3. Participants will be asked to consume half of their daily almond supplement as a mid-afternoon snack and the rest at a meal of their choice.
223501524|NCT02347007|DIETARY_SUPPLEMENT|Cereal Bar|Participants will be randomized to consume approximately 17.5% of their estimated energy requirements from cereal bars daily for 24 weeks. Prescribed energy requirements will be determined for each participant individually using the Mifflin St Jeor Equation equation with an activity factor of 1.3. Participants will be asked to consume half of their daily cereal bar supplement as a mid-afternoon snack and the rest at a meal of their choice.
223501525|NCT00552058|BIOLOGICAL|certolizumab pegol (CDP870, CZP)|Certolizumab Pegol 400 mg CZP sc injection 2 x 1 mL CZP (200 mg/mL) at Week 0, 2, and 4
223501526|NCT00552058|OTHER|Placebo|Saline 0.9% sc injection 2 x 1 mL Placebo at Week 0, 2 and 4
223501527|NCT04172064|DIAGNOSTIC_TEST|Myocardial perfusion scintigraphy|
223501528|NCT00295776|DRUG|Lamictal in the treatment of Post-Herpetic Neuralgia|
223501529|NCT02126202|PROCEDURE|Coronary angiography and revascularization if feasible|Coronary angiography and revascularization with PCI or CABG (coronary artery bypass grafting) if feasible
223501530|NCT03521336|DRUG|Umbilical Cord Mesenchymal Stem Cells|Intrathecal Transplantation of Umbilical Cord Mesenchymal Stem Cells
223501531|NCT03521336|DRUG|Placebo|Saline，Sham operation
223501532|NCT04162483|DEVICE|Neuroform Atlas Stent System|Stenting Assisted coiling procedure
223501533|NCT00325585|BEHAVIORAL|Couples HIV counseling and testing|
223501534|NCT00325585|BEHAVIORAL|Women's relationship-focused HIV counseling and testing|
223501535|NCT04383015|OTHER|Exercise strategies|Strategies for exercise in type 1 diabetes to maintain glucose control
223501536|NCT01559623|PROCEDURE|retrospective data analysis|retrospective data analysis
223501537|NCT05130697|OTHER|eMPowEr App|A mobile app to support participants in the management of malignant pleural effusions at home
223501538|NCT01952678|OTHER|DaTscan™ - Non-Caucasian Participants|Participants who previously administered DaTscan™ and had undergone SPECT imaging of the brain per local practice at each institution.
223501539|NCT01952678|OTHER|DaTscan™ - Caucasian Participants|Participants who previously administered DaTscan™ and had undergone SPECT imaging of the brain per local practice at each institution.
223746312|NCT05191446|OTHER|Usual Care (UC)|UC participants will receive their usual services in hepatology. They will also be given publicly available patient education materials regarding risk associated with unhealthy drinking (mail/email or in-person if desired) and will be asked to follow up with their physician should they have questions about information provided in the handouts. UC participants' hepatology provider will be notified if AUDIT-C scores are greater than 3 at baseline. All UC participants will have access to alcohol and other substance use treatment available to patients at their respective sites.
223746313|NCT05311488|DIAGNOSTIC_TEST|neurofilament light chain|Blood test
223746314|NCT05311488|DIAGNOSTIC_TEST|In-vivo Meissner Corpuscle imaging|Imaging
223746315|NCT05311488|DIAGNOSTIC_TEST|Nerve conduction study|Nerve conduction study
223746316|NCT04273776|DRUG|Suvorexant 10 mg|10 mg of suvorexant
223501540|NCT03604627|OTHER|Coronal calcium score measurement|"A medical interview with clinical examination by a cardiologist for screening cardiovascular risk factors, including smoking, and looking for symptoms of heart disease as part of routine care.~In accordance with routine care, a fasting and fasting blood test will be performed performed on exam day at Bichat Hospital or at another time, close to the patient's home according to his availability. The biological blood test will include the measurement of plasma triglyceride concentrations, total cholesterol and its HDL and LDL fractions, blood glucose, glycated hemoglobin and serum creatinine with estimated glomerular filtration rate according to the CKD-EPI formula. Sample urinalysis will include measurement of creatinine, proteinuria, and microalbuminuria.~An electrocardiogram (ECG) rest, a cardiac ultrasound, a test and respiratory function tests (EFR) will be performed as part of routine care. Coronal calcium score measurement will be performed as part of the research."
223501541|NCT03422718|BEHAVIORAL|Healthy Behavior Texts|Participants receive motivational health behavior texts
223501542|NCT03422718|BEHAVIORAL|No healthy behavior texts|Participants do not receive healthy behavior texts
223501543|NCT03422718|BEHAVIORAL|BP Monitoring Daily Via Text Messaging|Daily text messages will prompt participants for BP by home cuff
223501544|NCT03422718|BEHAVIORAL|BP Monitoring Weekly Via Text Messaging|Weekly text messages will prompt participants for BP by home cuff
223501545|NCT03422718|BEHAVIORAL|Physician appointment and transportation scheduling|Participants receive assistance scheduling physician appointment and transportation to those appointments
223501546|NCT03422718|BEHAVIORAL|No physician appointment and transportation scheduling|Participants do not receive assistance scheduling physician appointment or transportation
223501547|NCT00143351|DRUG|Ziprasidone|
223501548|NCT03295916|RADIATION|Stereotactic Body Radiotherapy|Five fraction SBRT (or two fraction in case of spine) to any sites of breast cancer oligometastasis using robotic radio surgery or linear accelerator based SBRT
223501549|NCT01129284|DRUG|ACTHAR gel|Patients will be treated with ACTHAR gel starting with 40 units given twice weekly subcutaneously for two weeks, then 80 units given twice weekly subcutaneously afterwards for a period of up to six months.
223501550|NCT02216877|DRUG|Mablet 360 mg|
223501551|NCT02216877|DRUG|Placebo|
223501552|NCT00771602|DRUG|Rituximab|375 mg/m\^2 by standard IV (intravenous) infusion on days 1, 8, 15, and 22 of weeks 1-4.
223746317|NCT04273776|DRUG|Zolpidem|5 mg of zolpidem
223746318|NCT04273776|DRUG|Placebos|Avicel
223746319|NCT05906082|BEHAVIORAL|E-cigarette cessation text-messaging intervention|This is the intervention for e-cigarette cessation using text messages targeting young adults in rural areas.
223746320|NCT05906082|BEHAVIORAL|Standard care control using standard national resources|This is the standard care with national resources from smokefree.gov.
223746321|NCT05831761|DRUG|Comparison of analgesic efficacy protocol|Comparison of 4 possible analgesic protocols
223746322|NCT00561756|BIOLOGICAL|plasmid DNA vaccine therapy|
223746323|NCT00561756|OTHER|flow cytometry|
224192802|NCT04405115|BEHAVIORAL|Geriatric Assessment|Geriatric Assessment Visit
224192803|NCT03729752|DRUG|[89]Zr-DFO-VRC-HIVMAB060-00-AB|Radiolabeled monoclonal antibody that targets the envelope protein of HIV-1.
224192804|NCT04578600|DRUG|Lenalidomide|Given PO
224192805|NCT04578600|BIOLOGICAL|Obinutuzumab|Given IV
224192806|NCT04578600|DRUG|Oral Azacitidine|Given PO
224310071|NCT01919021|OTHER|Magnetic Resonance Imaging MRI|400ml of milkshake and 12 agar beads are ingested and gamma scintigraphy scanning completed to document gastric emptying and outcome measures listed earlier.
224310072|NCT01919021|OTHER|Gamma Scintigraphy|400ml of milkshake and 12 agar beads are ingested and gamma scintigraphy scanning completed to document gastric emptying and outcome measures listed earlier.
224310073|NCT01919021|PROCEDURE|Assessment of Gastric motor and sensory function|
224310074|NCT04447339|PROCEDURE|Nipple Sparing Mastectomy|Prophylactic open NSM procedures
224192807|NCT03061916|DIETARY_SUPPLEMENT|Cinnamon|Cinnamon 20% will be given to participants after baseline collection of saliva
224310075|NCT00849186|DRUG|sunitinib malate|oral
224310076|NCT00849186|PROCEDURE|neoadjuvant therapy|IV
223501553|NCT00771602|DRUG|Alemtuzumab|Dose escalation of 3, 10 and 30 mg subcutaneously (SQ) during week 1, followed by dose of 30 mg subcutaneously three times weekly (e.g. Monday-Wednesday - Friday) starting on week 2 for a total of 12 weeks (2-13).
223501554|NCT01629862|DEVICE|Continuous positive airway pressure|CPAP at therapeutic pressure; ResMed S9 device in fixed pressure mode (Sydney, Australia).
223501555|NCT01629862|DEVICE|Sham continuous positive airway pressure|CPAP at non-therapeutic pressure; ResMed S9 device using a ResMed sham mask (Sydney, Australia).
223501556|NCT02510482|OTHER|No intervention|
223501557|NCT02345343|DRUG|Apixaban|
223591873|NCT04909229|BEHAVIORAL|Sleep education materials|Patients will receive sleep hygiene and healthy sleep tips.
223591874|NCT06665997|DRUG|Depot medroxyprogesterone acetate (DMPA)|150mg dose intramuscular administration of depot medroxyprogesterone acetate (DMPA) injectable suspension
224192808|NCT03061916|DIETARY_SUPPLEMENT|Ginger|Ginger 20% will be given to participants after baseline collection of saliva
223501558|NCT01973400|DIETARY_SUPPLEMENT|Tocotrienol|Palm-Oil derived Vitamin E, tocotrienol
223501559|NCT01973400|DIETARY_SUPPLEMENT|Placebo|Placebo
223501560|NCT02985710|DEVICE|Sudoscan|The Sudoscan is a non invasive procedure and similar to standing on a scale to be weighed. Sudoscan measurements are made in compliance with the manufacturer's recommended procedures. The measurement is rapid and non-invasive, and requires no advance preparation.
223501561|NCT02985710|PROCEDURE|Skin biopsy|For subjects that give additional consent, skin biopsy will be done in standard fashion under sterile conditions. Assessment of nerve fiber density typically involves a 3-mm punch biopsy of skin from the leg (10 cm above the external malleolus).
223591875|NCT05559853|DIAGNOSTIC_TEST|CEST-MRF|CEST-MRF enables accurate quantification of both proton exchange rates and volume fractions in a fraction of the time required by conventional pulse sequences will be developed and optimized.
223591876|NCT04298424|OTHER|PLSM|The program was designed for implementation over 4 consecutive weeks, with groups of 6-8 people each attending one 60-90-minute class per week. Peer leaders lead the groups to promote interaction, sharing, and support, and assist in goal setting to address behavior-related health problems, and thereby the development and implementation of strategies to achieve suitable, sustainable, and feasible self-management behavior.
223591877|NCT02885974|DRUG|Celecoxib|Celecoxib (100 mg daily)
223591878|NCT02885974|DRUG|Gemcitabine|1,000 mg/m2 (IV), on Days 1 and 8 of each 21-day cycle. Up to 4 cycles.
223591879|NCT02885974|DRUG|Cisplatin|70 mg/m2 (IV), on Day 1 of each 21-day cycle. Up to 4 cycles.
223591880|NCT04816721|DRUG|EDP-938|Oral suspension
223591881|NCT04816721|DRUG|Placebo|Placebo oral suspension to match EDP-938
223591882|NCT06687434|BEHAVIORAL|accurate carb counting|Participants will use precise carb counting to manage their meals
223591883|NCT06687434|BEHAVIORAL|Simplified qualitative meal size estimation|participants will use a simplified meal announcement based on three presets for each meal, small, medium, or large, which will be personalized based on the dietitian's assessment.
224192809|NCT03061916|DRUG|Chlorhexidine Gluconate|Chlorhexidine Gluconate will be given to participants after baseline collection of saliva
224192810|NCT03053531|DEVICE|"PockeTalker Hearing Assistive Device (HAD)"|Investigators will test impacts of the provision of the HAD on hearing and understanding, and preparation for discharge. Just prior to going home, consented subjects will answer a set of survey questions, using an electronic tablet to support impaired hearing.
224192811|NCT04246593|OTHER|Mobile Market program implementation|"Mobile Market program implementation includes utilizing a Veggie Van model which sells reduced cost locally-grown produce in communities with barriers to accessing fresh F\&Vs because of availability, cost, or lack of produce preparation skills.The Veggie Van visits sites that already serve the target market (e.g., lower-income housing communities, community health centers, community colleges). While Mobile Market programs vary in their model and operation, we believe that the three components of Veggie Van's success are it's share model, price reductions (incentives), and educational component"
224192812|NCT01713374|PROCEDURE|Mental stress|Subjects will be asked to perform complex mathematic operations at a very fast pace
223746324|NCT00561756|OTHER|immunoenzyme technique|
224192813|NCT01713374|OTHER|no intervention|control visit
224310077|NCT00849186|PROCEDURE|therapeutic conventional surgery|Surgery
224310078|NCT01926574|BEHAVIORAL|long rehabilitation program|
224310079|NCT01926574|BEHAVIORAL|short rehabilitation program|
224310080|NCT01926574|BEHAVIORAL|Acceptance and commitment therapy (ACT)|
224310081|NCT05738317|DRUG|Adebrelimab Combined With Bevacizumab and Albumin Paclitaxel|Adebrelimab is recommended to be administered with an infusion pump. The infusion pipeline is equipped with a 0.22-micron online filter membrane. Intravenous injection or bolus injection is not allowed. At the end of infusion, flush the infusion tube with sufficient 5% glucose or physiological saline, and do not share the same infusion tube with other drugs. In each treatment cycle, Adebrelimab should be given intravenously first.
224310082|NCT00492024|DRUG|Moxifloxacin (Avelox, BAY12-8039)|Moxifloxacin - 400 mg once a day for 5 days
224310083|NCT00492024|DRUG|Placebo|Placebo - 380 mg Microcrystalline Cellulose
223501562|NCT02985710|PROCEDURE|QSART|QSRT (quantitative sudomotor axon reflex test) testing involves having a technician wipe the subject's arms and leg with alcohol, then tissue to wipe it dry. Electrodes filled with acetylcholine are put on three areas of the leg and one on the wrist, stimulators are turned on and sweat responses are measured.
223501563|NCT04954443|PROCEDURE|Removing urinary catheter|Removing urinary catheter after vaginal surgery of pelvic organ prolapse
223501564|NCT04871438|DEVICE|Flash glucose monitoring|Group A will use FreeStyle Libre for two weeks of FGM-based titration of medications at two time-points: 1) At recruitment and 2) At 6 weeks. Outside of these time points, they will use SMBG (standard care) for monitoring of blood glucose.
223501565|NCT02859012|DRUG|Axitinib|Dosing schedule: 5mg twice per day orally (4 weeks is considered as 1 cycle)
223501566|NCT02859012|OTHER|Observation|this group is observational ones.
223501567|NCT00894920|DIETARY_SUPPLEMENT|biotin|capsule approximately 30 mcg daily 21 days
223501568|NCT00894920|DIETARY_SUPPLEMENT|biotin|capsule 300 mcg daily 21 days
223501569|NCT02102828|DEVICE|extended compression|Home use of extended compression therapy and aspirin
223501570|NCT02102828|OTHER|Aspirin|standard therapy of aspirin
223501571|NCT00629213|DRUG|acarbose|
223501572|NCT00629213|DRUG|placebo|
223501573|NCT00845182|DRUG|Pioglitazone|Pioglitazone 15 mg/day for 1 month and then 45 mg/day for 5 months
223501574|NCT00845182|DRUG|Exenatide|Exenatide 5mcg twice daily for 1 month, then 10mcg twice daily for 5 months
223501575|NCT00845182|DRUG|Pioglitazone and Exenatide|Pioglitazone 30mg daily for 1 month and then 45mg daily for 5 months and Exenatide 5mcg twice daily for one month then 10mcg twice daily for 5 months
223501576|NCT03213236|DIAGNOSTIC_TEST|Homemonitoring diagnostic system|"In addition to the standard full-night diagnostic polysomnography, patients will be evaluated during the same night with a homemonitoring diagnostic system that consists out of a pulse oximeter, accelerometer, smartphone for audio recording and a mattress that measures the ballistocardiogram."
223501577|NCT04039269|OTHER|Preoperative video information|
223501578|NCT02927314|DRUG|CF102|orally q12h
223501579|NCT02927314|DRUG|Placebo|orally q12h
223501580|NCT03380572|DEVICE|Senhance Assisted Cholecystectomy|Cholecystectomy performed using Senhance surgical robotic system
223501581|NCT03380572|PROCEDURE|Laparoscopic Cholecystectomy|Standard laparoscopic cholecystectomy
223501582|NCT01433874|PROCEDURE|Pulmonary recruitment maneuver|A pulmonary recruitment maneuver consisting of five manual pulmonary inflations was performed with a maximum pressure of 60 cmH2O. The anesthesiologist held the fifth positive pressure inflation for approximately 5 seconds.
223501583|NCT01433874|PROCEDURE|Intraperitoneal normal saline infusion|The upper part of the abdominal cavity was evenly and bilaterally filled with the 0.9% normal saline in the amount of 500cc. We will leave the fluid in the abdominal cavity
223501584|NCT01433874|PROCEDURE|combined group|The upper part of the abdominal cavity was evenly and bilaterally filled with the 0.9% normal saline in the amount of 500cc. Later, a pulmonary recruitment maneuver consisting of five manual pulmonary inflations was performed with a maximum pressure oof 60 cmH2O.
223501585|NCT01433874|PROCEDURE|Control group|Co2 was removed by passive exsufflation through the port site.
223501586|NCT04783727|DIAGNOSTIC_TEST|Individualised treatment duration based on RNA transcriptomic model|Anti-MDR-TB treatment with standard drugs and individual treatment duration guided by the RNA transcriptomic model; may be shorter or longer than standard WHO-recommended treatment duration of 20 months.
223501587|NCT01625182|DRUG|Fingolimod|Fingolimod 0.5 mg capsules
223501588|NCT01625182|DRUG|Placebo Comparator|Matching placebo capsules
223501589|NCT05737498|DEVICE|Transcranial direct current stimulation (tDCS)|Transcranial direct current stimulation will use to deliver a constant direct current through two surface electrodes, Anodal stimulation was applied according to the 10-20 international system for EEG electrode placement, over F3 of the dorsolateral prefrontal cortex (DLPFC), while the cathode was placed over the contralateral supraorbital area for 20 min, on alternate days for 2 weeks 6 sessions with working memory training task. the anode (positive) and the cathode (negative). To reduce resistance and minimize discomfort during application (the electrodes were covered in 35 cm2, saline-soaked sponges
223501590|NCT00354211|DEVICE|minimally invasive cardiac output system consisting of arterial line sensor and cardiac output bedside monitor (device)|
223501591|NCT01235819|DRUG|Insulin|Exenatide Sitagliptin
223501592|NCT01235819|DRUG|Sitagliptin|Sitagliptin 100 mg per day oral
223501593|NCT01235819|DRUG|Exenatide|Exenatide 10 micrograms daily twice
223501594|NCT02575625|DEVICE|Fibroscan|Three series oh independent measures Measure done with Fibroscan will be preceded by tracking ultrasonography.
223501595|NCT02575625|BIOLOGICAL|Blood test for biological assessment of liver function|Blood test for biological assessment of liver function
223501596|NCT02575625|DEVICE|MRI|Liver MRI
223501597|NCT02920554|PROCEDURE|wedge resection|The extent of hepatic resection is wedge resection of liver including gallbladder fossa
223501598|NCT02920554|PROCEDURE|bisegmentectomy|The extent of hepatic resection is 4b/5 bisegmentectomy of liver
223501599|NCT00447278|DRUG|Atomoxetine|0.5 mg/kg/day once a day (QD) or twice a day (BID) for 1 week then 1.2-1.8 mg/kg/day QD or BID for 6 months, up to an additional 6 months optional extension
223501600|NCT00447278|DRUG|Other standard therapy for ADHD|Any treatment for ADHD as prescribed by investigator, 6 months, up to an additional 6 months extension
223501601|NCT04821011|DEVICE|electronic stethoscope|Record of maternal heart sounds (heartbeats) with an electronic stethoscope during 10 minutes.
223501602|NCT04821011|DEVICE|acoustic listening of mother's heartbeats|Each newborn included will have 20 minutes of an acoustic listening of their mother heartbeats previously recorded.
223501603|NCT04821011|DEVICE|Recording of the newborn's heart rate|"Recording of the newborn's heart rate: one hour before the acoustic listening, during the acoustic listening and one hour after the acoustic listening .~The variations of the autonomic nervous system will be analyzed.~An coupled Heart rate variability recording (ECG signal obtained from a Philips® IntelliVue MX700 monitor) and NIPΣ index of comfort (MDMS® NIPΣ monitor) will be used."
223501604|NCT01348698|PROCEDURE|Tumor tissue biopsy|Participants whose tumor does not secrete hormones will have a tumor biopsy to collect tissue for the study.
223746325|NCT02423616|OTHER|Healthy individuals|INSPIRATORY PRESSURE AND HAND GRIP FORCE CORRELATION
224192814|NCT01713374|PROCEDURE|Myogenic activation|A pneumatic cuff will be inflated to suprasystolic pressure around both thighs and the subjects will be asked to perform plantar flexion exercises.
224192815|NCT01713374|PROCEDURE|Cold pressure test|A hand will be placed in ice-cold water.
224192816|NCT04095494|BEHAVIORAL|Nitrous oxide use|In order to evaluate the perception of the Nantes health students we wish to place an anonymous survey concerning their training, their knowledge of the legislative framework governing the use of EMONO and their personal and professional experience around nitrous oxide.
224192817|NCT03571568|BIOLOGICAL|BI-1206|"BI-1206 150 mg / 225 mg Subcutaneous injection~BI-1206 50 mg /100 mg Intravenous infusion"
224192818|NCT03571568|BIOLOGICAL|Rituximab|Rituximab 375 mg/m2, as per SmPC
224192819|NCT03571568|BIOLOGICAL|Acalabrutinib|Acalabrutinib 100 mg orally as per SmPC
224192820|NCT03455556|BIOLOGICAL|Anetumab Ravtansine|Given IV
223746326|NCT02293226|DEVICE|CoopDech|Video-laryngoscopy 1
224192821|NCT03455556|BIOLOGICAL|Atezolizumab|Given IV
224192822|NCT03455556|OTHER|Laboratory Biomarker Analysis|Correlative studies
224192823|NCT02369874|DRUG|MEDI4736|MEDI4736 Monotherapy
224192824|NCT02369874|DRUG|MEDI4736 + Tremelimumab|MEDI4736 + Tremelimumab combination therapy
224192825|NCT02369874|DRUG|Standard of Care|Standard of Care
224192826|NCT00914472|BIOLOGICAL|heparin sodium - APP|Heparin 5000 IU / mL
223501605|NCT01348698|PROCEDURE|Surgery|Participants who have a large tumor or one that secretes hormones will have standard surgery to remove the tumor. Tissue will be collected for study.
223501606|NCT03943992|DRUG|YYD601 40mg|Patients should take druges 30 minutes before breakfast.
223501607|NCT03943992|DRUG|Nexium 40mg|Patients should take druges 30 minutes before breakfast.
223501608|NCT03943992|DRUG|Placebos|The placebo YYD601 is made from microcrystalline cellulose covered with hard shell. The placebo Nexium is made from microcrystalline cellulose, Crospovidone, Magnesiumstearat and other ingredients.
223501609|NCT02595749|DRUG|Oxytocin|
223501610|NCT02595749|DRUG|Placebo|
223501611|NCT06420583|PROCEDURE|MTA pulpotomy|"1. Application of rubber dam for isolation, then a standardized access cavity procedure will be performed using a large sterile round end bur in a high-speed handpiece with copious irrigation, a sharp spoon excavator will remove pulpal tissues to the orifice level, bleeding control in the pulp chamber will be achieved by using 5% sodium hypochlorite.~2. gentle condensation of MTA mix in the pulp chamber will be done by a wet sterile cotton pellet and then the rest of the pulp chamber will be filled with Glass Ionomer restoration.~3. The tooth will be restored with a stainless steel crown."
223501612|NCT06420583|PROCEDURE|Extraction|After complete Anesthetic application in the affected area, non-surgical extraction will be done.
223501613|NCT00263562|DRUG|Steroid arm|Day 1: Solumedrol 15 mg/kg (maximum 1 gram) Day 2: Prednisone 2mg/kg PO BID Day 3: Prednisone 2mg/kg PO daily Day 4: Prednisone 1mg/kg PO daily Day 5: Prednisone 1mg/kg PO daily
224192827|NCT00914472|BIOLOGICAL|Heparin sodium - Hipolabor|Heparin 5000 IU / mL
224192828|NCT03260699|DEVICE|OCSI Rehabilitator brace|Guardian Brace features the innovative Rehabilitator™ line of gait correcting, leg strengthening braces. Rehabilitator™ Knee Braces are clinically proven to reduce UNBRACED pain, strengthen the affected leg, and significantly improve function after only 90 days of brace wear.
224205867|NCT03054168|DRUG|Zoladex|The frequency of the injection will be just one injection, 3.6 mg of Zoladex, Subcutaneous injection (abdomen).
223512117|NCT05257044|DRUG|Cannabigerol|Participants will ingest CBG and placebo in a double-blind randomized cross-over design
223512118|NCT05257044|OTHER|Placebo|Placebo
223512119|NCT00066170|DRUG|Xyrem|Xyrem oral solution at 6 g/day for 4 weeks and 9 g/day for another 4 weeks.
223512120|NCT00066170|DRUG|Xyrem Placebo|Xyrem Placebo oral solution 12 ml per day for 4 weeks and 18 ml per day for another 4 weeks.
223512121|NCT00066170|DRUG|Modafinil at established dose|Modafinil oral capsules at 200 to 600 mg per day for 8 weeks.
223512122|NCT00066170|DRUG|Modafinil (Placebo)|Modafinil Placebo oral capsules 1 to 3 capsules per day for 8 weeks.
223512123|NCT01297114|DRUG|Florbetaben|This is a purely observational study. Results of the Florbetaben PET scan will be correlated with other observations.
223512124|NCT00552500|DRUG|Depakote (valproate)|500 mg -2000 mg QD based on individual tolerance and VPA levels
223512125|NCT00098293|DRUG|Maraviroc + Zidovudine/Lamivudine|maraviroc (UK-427,857) 300 mg once daily added to zidovudine/lamivudine (300 mg/150 mg twice daily)
223512126|NCT00098293|DRUG|Efavirenz + Zidovudine/Lamivudine|efavirenz (600 mg once daily) added to zidovudine/lamivudine (300 mg/150 mg twice daily)
224205868|NCT03054168|OTHER|Placebo|
224205869|NCT05473247|BEHAVIORAL|Ring-Fit Adventure Group|Participants will be asked to play the exergame software, Ring-Fit Adventure, and attend weekly virtual health coaching sessions.
224205870|NCT05243134|OTHER|Collect the clinical data|We analyze the influence of the anatomic deformity on the clinical efficacy at the follow-up.
224205871|NCT02392559|DRUG|Evolocumab|Dose of subcutaneous evolocumab every 4 weeks
224205872|NCT02392559|DRUG|Placebo|Dose of subcutaneous placebo treatment every 4 weeks
224205873|NCT02034500|BIOLOGICAL|S. sonnei 1790GAHB|
224205874|NCT02034500|BIOLOGICAL|Placebo|
224205875|NCT04770194|DRUG|SP-8008 Prototype Capsule A|Oral
224205876|NCT04770194|DRUG|SP-8008 Prototype Capsule B|Oral
224205877|NCT04770194|DRUG|Placebo|Oral
224205878|NCT03434808|OTHER|Whole Blood Donation|Study subjects will provide 250ml whole blood donation for the manufacture and banking of iPS cells.
224205879|NCT04831502|DRUG|TAK-906|TAK-906 Tablets.
224205880|NCT04831502|DRUG|TAK-906|TAK-906 Capsules.
224205881|NCT03370627|BIOLOGICAL|Monoclonal anti-cd303 antibody|Addition of monoclonal anti CD303 antibodies or not (control) on 2 blood samples of the same patient, to which 10 μl of CpG (20 μg / ml) are added in order to activate plasmacytoid Dendritic Cells and to induce the secretion of Type I interferons.
224205882|NCT05844644|DIETARY_SUPPLEMENT|Release|One capsule of Release will be taken three times per day for 180 days in combination with the G4LP.
224205883|NCT02208388|DEVICE|computed tomography perfusion guided treatment|
224205884|NCT02208388|DEVICE|Fractional flow reserve guided treatment|
224192829|NCT04737226|DIAGNOSTIC_TEST|myotonometric assessment|The measurement method of the device is based on the free oscillation technique. Firstly, the probe of the device is placed perpendicular to the skin and a pre-pressure is applied to compress the subcutaneous tissue. Then, a short mechanical impulse is applied, causing damped oscillation on the tissue and the co-oscillation is recorded by an accelerometer.
224192830|NCT04737226|DIAGNOSTIC_TEST|Ankle mobility assessment|The knee to wall lunge test will use in a standing position while the heel in contact with the ground and the knee was in line with second toe. Athletes will do lunge forward and inclinometer will be place at the middle anterior tibial crista and measurement will be record.
224192831|NCT02557269|DRUG|Xylometazoline - intranasal application|Applied as needed up to 5 consecutive days when prominent congestion
224192832|NCT02557269|DRUG|Azelastine - intranasal application|Applied as needed when prominent symptom is rhinorrhea
224192833|NCT02557269|DRUG|Mometasone furoate - intranasal application|Applied once daily (2 puffs) when no satisfactory therapeutic control from other intranasal treatment
224192834|NCT02557269|DRUG|Hydroxyl-propyl-methyl cellulose powder - intranasal application|Applied intranasally immediately after every application other intranasal formulation
224192835|NCT02557269|OTHER|Placebo - Lactose powder|Applied intranasally immediately after every application other intranasal formulation
224192836|NCT02557269|DRUG|Bilastine 20 mg|1 tablet per os - as needed
224192837|NCT02557269|DRUG|Prednisolone 5 mg|Per os - if needed (only in case of broncial obstruction)
224192838|NCT01848769|DRUG|CHF1535 pMDI + AC Plus|Four inhalations for a total dose of BDP/FF 200/24 mcg
224192839|NCT01848769|DRUG|BDP + AC Plus|Four inhalations for a total dose of BDP 200 mcg
224192840|NCT01848769|DRUG|Formoterol + AC Plus|Four inhalations for a total dose of Formoterol 24 mcg
224192841|NCT01049360|DRUG|Aclidinium 400 μg / Formoterol 12 μg|Aclidinium bromide 400 μg / formoterol fumarate 12 μg fixed dose combination administered twice-daily (BID) for a 14 day period within four different treatment periods.
224192842|NCT01049360|DRUG|Aclidinium 400 μg / Formoterol 6 μg|Aclidinium bromide 400 μg / formoterol fumarate 6 μg fixed dose combination administered twice-daily (BID) for a 14 day period within four different treatment periods.
224192843|NCT01049360|DRUG|Aclidinium 400 μg|Aclidinium bromide 400 μg administered twice-daily (BID) for a 14 day period within four different treatment periods.
224192844|NCT01049360|DRUG|Formoterol 12 μg|Formoterol fumarate 12 μg twice-daily for a 14 day period within four different treatment periods.
224192845|NCT01049360|DRUG|Placebo|Placebo twice-daily delivered by inhalation for a 14 day period within four different treatment periods.
224192846|NCT04522128|BEHAVIORAL|Behaviour Change Technique Intervention to Improve Quality of Life|"The intervention targets each facet of the five domains of WHOQOL COMBI. The intervention is based on the COM-B Framework (Michie et al., 2012) and utilises behaviour change techniques to help participants change their behaviour to improve their quality of life.~The intervention will be compared to an active comparator 'feedback intervention' and a waitlist control group."
224192847|NCT04419220|OTHER|Doppler Ultrasound|Flow measurements using Doppler ultrasound
224192848|NCT04479774|OTHER|Compelled Body Weight Shift Technique|"Routine Physical Therapy with 0.6 cm thickness insole inserted in shoe of unaffected side and following exercises were performed by patients~* Muscle re-education~* Sit to stand exercise , 4 to 10 repetitions~* Supported heel raise to 10 repetitions with 3 sets~* Supported squat exercise tibialis anterior and quads muscles to 10 repetitions with 3 sets~* Gait training~* Forward walk in parallel bars with number of 10 rounds.~* Task oriented training balance training~* A. Stepping exercise on 15 cm height step and number of repetitions 10.~* B. Tandem standing for 10 seconds.~* C. Reaching exercise in which patient performed reaching for object in therapists hand and the number of repetitions was 10."
224192849|NCT04479774|OTHER|Compelled Body Weight Shift Technique without insole|"Routine Physical Therapy without 0.6 cm thickness insole inserted in shoe of unaffected side and following exercises were performed by patients~* Muscle re-education~* Sit to stand exercise , 4 to 10 repetitions~* Supported heel raise to 10 repetitions with 3 sets~* Supported squat exercise tibialis anterior and quads muscles to 10 repetitions with 3 sets~* Gait training~* Forward walk in parallel bars with number of 10 rounds.~* Task oriented training balance training~* A. Stepping exercise on 15 cm height step and number of repetitions 10.~* B. Tandem standing for 10 seconds.~* C. Reaching exercise in which patient performed reaching for object in therapists hand and the number of repetitions was 10."
224192850|NCT04621474|DIAGNOSTIC_TEST|Narrow band imaging (NBI)|Narrow-band imaging uses specific light wavelengths of 415 nm (blue) and 540 nm (green) due to a special filter which is electronically activated by a switch in the endoscope.
224192851|NCT04956068|COMBINATION_PRODUCT|PIPAC|A novel drug delivery system using the CapnoPen device which allows the aerolisation of chemotherapeutic agents within the peritoneal cavity. PIPAC procedure will be carried out with either oxaliplatin or doxorubicin/ cisplatin.
224192852|NCT01012765|DRUG|Indacaterol|Indacaterol 150µg once daily (o.d.) delivered via single-dose dry powder inhaler (SDDPI)
223501614|NCT00263562|OTHER|Placebo|Patients received normal saline in lieu of intravenously-administered methylprednisolone and placebo pills equal in number to the steroid pills received in the steroid arm
224192853|NCT01012765|DRUG|Tiotropium|Tiotropium 18µg o.d. delivered via a proprietary inhalation device.
224192854|NCT01012765|DRUG|Placebo|Placebo to indacaterol o.d. delivered via SDDPI
224192855|NCT01326312|DRUG|GTx-758 1000mg|comparison of different dosages of GTx-758 with leuprolide acetate for depot suspension
224192856|NCT01326312|DRUG|Lupron Depot|comparison of different dosages of GTx-758 with leuprolide acetate for depot suspension
224192857|NCT01326312|DRUG|GTx-758 2000mg|comparison of different dosages of GTx-758 with leuprolide acetate for depot suspension
223501615|NCT02024009|DRUG|nab-paclitaxel|Abraxane is a proprietary solvent-free, protein-stabilized formulation of paclitaxel comprised of paclitaxel and human albumin in a noncrystalline amorphous state
223501616|NCT02024009|RADIATION|60Gy in 30#|
223501617|NCT02024009|RADIATION|50.4Gy in 28#|
223501618|NCT02024009|DRUG|Nelfinavir|VIRACEPT® (nelfinavir mesylate) is an inhibitor of the human immunodeficiency virus (HIV) protease.
223501619|NCT02024009|DRUG|Capecitabine|Given in combination with gemcitabine, known as GemCap.
224192858|NCT04503655|OTHER|Training|"Training dedicated on implementation of organizational and therapeutic measures (for prevention and management of complications) to reduce lenght-of-stay after TF TAVI."
224192859|NCT02885831|DEVICE|Abduction splintage|Treatment by abduction splintage 24 hours a day and 7 days a week, for 2 months.
224192860|NCT00499694|BIOLOGICAL|bevacizumab|10mg/kg,Intravenous, Day 1 of each Cycle (every 35 days) 15mg/kg,Intravenous, Day 15 of each Cycle (every 35 days)
224192861|NCT00499694|DRUG|satraplatin|80 mg/m(2), Orally, Days 1-5, every 35 days
224192862|NCT03142282|DRUG|maintenance chemotherapy|National Comprehensive Cancer Network (NCCN) or European Society for Medical Oncology (ESMO) suggested maintenance chemotherapy regimens: xeloda, bevacizumab
224192863|NCT03142282|RADIATION|Consolidative Radiotherapy|Stereotacticbodyradiationtherapy (SBRT) or intensity modulated radiation therapy (IMRT) for metastatic sites (less than 5)
224192864|NCT00620191|DRUG|Metformin|Metformin 1000 mg twice a day titrated from 500 mg once a day
224192865|NCT00620191|DRUG|Placebo|Placebo identical to metformin 2 tablets twice a day titrated from one table once a day
224192866|NCT03948321|PROCEDURE|Aminolevulinic acid photodynamic therapy|Aminolevulinic acid photodynamic therapy
224192867|NCT00375024|PROCEDURE|Patient Navigation|Inclusion of Patient Navigator in treatment plan.
224192868|NCT00375024|PROCEDURE|Clinic Staff|Specific Patient Navigator will not be included in treatment plan. Existing clinical staff will work with the patients.
224192869|NCT03320980|PROCEDURE|RALPPS|RALPPS: split-in-situ resection with radio-frequency ablation (RFA) instead of liver partition on the first stage and major liver resection on the second stage
224192870|NCT03320980|PROCEDURE|portal vein embolization + major liver resection|PVE on the first stage and major liver resection on the second stage
224192871|NCT04395625|PROCEDURE|Direct bonding of Orthodontic brackets|Patients in group 1 had their upper right and lower left quadrants bonded with indirect bonding, and their upper left and lower right quadrants with direct bonding
224192872|NCT04395625|PROCEDURE|Indirect bonding of Orthodontic brackets|Patients in group 2 had their upper left and lower right quadrants bonded with indirect bonding, and their upper right and lower left quadrants with direct bonding.
224192873|NCT00917904|DRUG|dapivirine|"dosage form: vaginal gel~dosage: 1.25mg dapivirine/day~frequency: once daily~duration: 6 weeks"
224192874|NCT00917904|DRUG|placebo|"dosage form: vaginal gel~frequency: once daily~duration: 6 weeks"
224192875|NCT03417648|OTHER|Plant-based diet|Weekly instructions will be given to the participants in the intervention group about following vegan diet.
224192876|NCT03417648|OTHER|Supplement|unrestricted diet with clinically insignificant amount of omega- 3 oils and vitamin E
224192877|NCT00394498|DRUG|Granulocyte Colony Stimulating Factor|
224192878|NCT03907111|DEVICE|Chitosan Gauze|Gauze made by chitosan material
224192879|NCT03907111|DEVICE|placebo|traditional gauze
224192880|NCT00685074|BEHAVIORAL|Computer-based Motivational Interviewing|The software includes three intervention components - pros and cons, feedback, and optional goal-setting in a fixed order.
224192881|NCT00685074|BEHAVIORAL|Time control|A series of therapeutically inactive videos and questions to (a) maintain RA blind, and (b) serve as a time control.
224192882|NCT01961765|DRUG|cabozantinib|
224192883|NCT02980484|PROCEDURE|Active|Repetitive transcranial magnetic stimulation (rTMS) will be applied to the left dorsolateral prefrontal cortex (DLPFC) (4000 pulses, 10 Hz, 5-sec trains, 25-sec inter-train interval) followed by the right DLPFC (1000 pulses, 1 Hz frequency, single train). The DLPFC will be identified using individual subject-level resting-state network estimation (Hacker et al, 2013). Each treatment will be completed over the course of 1 hour, and each subject will receive a total of 20 treatments over the course of 20 consecutive weekdays.
224192884|NCT02980484|PROCEDURE|Sham|Treatment that looks and feels similar to active rTMS will be administered as a sham treatment.
224192885|NCT03155061|DRUG|ONO-4578|ONO-4578 specified dose on specified days
224192886|NCT03155061|DRUG|ONO-4538|ONO-4538 specified dose on specified days
224192887|NCT04218903|BEHAVIORAL|Combined training performed four times per week (CT4)|CT4 will perform four combined training sessions per week throughout 12 weeks. Each session will be composed 10-15 minutes of resistance exercise (1-4 sets of 10-15 repetitions, using an intensity corresponding to 50-70%1RM in 3 exercises) followed by 20-25 minutes of aerobic exercise (walking or running at an intensity corresponding to 60-70% of VO2peak).
224192888|NCT04218903|BEHAVIORAL|Combined training performed two times per week (CT2)|CT2 will perform two combined training sessions per week throughout 12 weeks. Each session will be composed 20-30 minutes of resistance exercise (1-4 sets of 10-15 repetitions, using an intensity corresponding to 50-70%1RM in 6 exercises) followed by 40-50 minutes of aerobic exercise (walking or running at an intensity corresponding to 60-70% of VO2peak).
224192889|NCT06070298|DIAGNOSTIC_TEST|Computer algorithms|Collection of lightweight computer algorithms called ausculto™ that is designed to perform real-time heart sound analysis to detect heart murmur.
224192890|NCT06464198|PROCEDURE|simultaneous postoperative radiochemotherapy|The efficacy and tolerability of simultaneous postoperative radiochemotherapy is being investigated.
224192891|NCT04456816|DRUG|100 mg AP1189|100 mg AP1189 tablet
224192892|NCT04456816|DRUG|Placebo|Matching placebo tablet
224192893|NCT04936646|DEVICE|RepetitiveTranscranial Magnetic Stimulation (rTMS)|The rTMS protocol consist of one session per day for five days during the first week, then three sessions the second week and then one session the third week, followed by two monthly sessions.
224192894|NCT06018376|DRUG|Systemic oncological treatment|Oncological systemic treatment for at least 3 months or being in oncological follow-up after having received systemic treatment for a minimum of 3 months
224192895|NCT06040905|DIETARY_SUPPLEMENT|Coenzyme Q10|300 mg/day (150mg/b.i.d)
224192896|NCT06040905|OTHER|Placebo|Starch, dextrin
224205885|NCT00486577|PROCEDURE|significant chronic primary auditory cortex stimulation during the first two weeks|significant chronic primary auditory cortex stimulation during the first two weeks of the follow up than wash out period followed by two weeks of non significant stimulation
224205886|NCT00486577|PROCEDURE|non significant chronic primary auditory cortex stimulation during the first two weeks|non significant stimulation during the first two weeks of the follow up than wash out period followed by two weeks of significant chronic primary auditory cortex stimulation
223746327|NCT02293226|DEVICE|CoPilot|video-laryngoscopy 2
224192897|NCT01333046|BIOLOGICAL|Antigen-Escalation Stage|"Antigen-Escalation Stage~Each patient will receive 2 injections at the same dose (5 x 10\^6 cells/m2), 28 days apart, according to the following schedules:~Schedule One:~* Day 0: PRAME-specific T cells~* Day 28: PRAME- and SSX-specific T cells~Schedule Two:~* Day 0: PRAME- and SSX-specific T cells~* Day 28: PRAME/SSX/MAGE-specific T cells~Schedule Three:~* Day 0: PRAME/SSX/MAGE-specific T cells~* Day 28: PRAME/SSX/MAGE/NY-ESO specific T cells~Schedule Four:~* Day 0: PRAME/SSX/MAGE/NY-ESO specific T cells~* Day 28: PRAME/SSX/MAGE/NY-ESO/Survivin-specific T cells"
224192898|NCT01333046|BIOLOGICAL|Dose-Escalation Stage|"Dose-Escalation Stage~Three different dosing schedules will be evaluated. Each patient will receive 2 injections at the same dose, 14 days apart, according to the following dosing schedules:~DL1: Day 0 and Day 14: 5 x 10\^6 cells/m\^2~DL2: Day 0 and Day 14: 1 x 10\^7 cells/m\^2~DL3: Day 0 and Day 14: 2 x 10\^7 cells/m\^2"
224192899|NCT01333046|BIOLOGICAL|azacytidine and multiTAA T cells Stage|"Up to 15 patients will be treated with 3 cycles of aza at a dose of 75 mg/m2 I.V. administered for 5 days/cycle followed, within 28 days of the last aza dose, by two infusions (on Day 0 and Day 14) of multi-TAA specific CTLs at a fixed dose of 1x10\^7 cells/m2. If drug-related myelosuppression occurs aza dosing will be modified, according to the following:~1. ANC \>1,000 or Platelets \>50,000 (or any other grade I AE attributable to aza)~   Adjustment: None~2. ANC 500-1000 or Platelets 25,000-50,000 (or any other grade II-III AE attributable to aza)~   Adjustment: 50% dose reduction~3. ANC \<500 or any episode of febrile neutropenia or platelets \<25,000 or any episode of bleeding attributed to thrombocytopenia (or any other grade IV or higher AE attributable to aza)~Adjustment: Discontinue drug, can proceed with CTL infusion if eligible within 28 days of last aza infusion"
224192900|NCT01333046|BIOLOGICAL|Pediatric multiTAA T cells Stage|Patients \< 18 years old will receive two infusions (on Day 0 and Day 14) of multi-TAA specific T cells at a fixed dose of 1x10\^7 cells/m2. We will enroll and infuse at least 5 adolescents on the pediatric arm before opening to all patients.
224192901|NCT01692990|DIETARY_SUPPLEMENT|Fish oil|For 3 weeks 5 g/d in 10 capsules, providing 3.5 g long-chain n-3 fatty acids in the fish oil period. Cross-over between arms with 1 week of wash out
223591884|NCT06743529|PROCEDURE|control group|immediate empiric Antibiotic Therapy (started within 1 hour after randomization) with antibiotic(s) chosen by the bedside physician based on time of ventilator-associated pneumoniaoccurrence, risk of antimicrobial resistance, local ecology, and local protocol. If the respiratory samples are negative, Antibiotic Therapy will be stopped. If ventilator-associated pneumonia is confirmed by positive samples, Antibiotic Therapy active against the recovered bacterial specie(s) will be given for a total of 7 days.
223591885|NCT06743529|PROCEDURE|Conservative strategy|No Antibiotic Therapy until receipt of the respiratory sample culture and/or polymerase chain reaction results. If these results are negative, no Antibiotic Therapy is given. If they are positive (confirmed ventilator-associated pneumonia), Antibiotic Therapy is started as appropriate for the bacterial specie(s) detected by culture and/or polymerase chain reaction, without considering gram-stain results and without waiting for antimicrobial susceptibility testing results, and continued for a total of 7 days of Antibiotic Therapy active against the identified bacterial specie(s).
223591886|NCT06762080|DRUG|Cadonilimab (AK104)|Intrathecal injection of PD-1/CTLA-4 bispecific antibody was administered every two weeks for six weeks during the induction phase, followed by monthly injections during the maintenance phase, until recurrence or death.
224192902|NCT01258751|DRUG|PF-05212377|Single dose of up to 70 mg PF-05212377, delivered as .25 mg, 5 mg and/or 15 mg on study day 1
224192903|NCT01667523|DIETARY_SUPPLEMENT|Capsaicin|1.5 mg capsaicin administered intraduodenally
224192904|NCT01667523|DIETARY_SUPPLEMENT|Cinnamaldehyde|70 mg per intervention administered intraduodenally
224192905|NCT01667523|DIETARY_SUPPLEMENT|Placebo|Physiological saline
223746328|NCT02293226|DEVICE|Intubrite|Video-laryngoscopy 3
223746329|NCT02293226|DEVICE|Vividtrack|video-laryngoscopy 4
224192906|NCT05934409|PROCEDURE|Bariatric surgery|Laparoscopic Sleeve Gastrectomy
224192907|NCT05934409|DRUG|Nicotinic Acid|Only during A1. 150mg every half hour for 6 hours. A total dose of 1800mg will be ingested.
224192908|NCT05510297|DEVICE|FitSitt Prototype|FitSitt merges features of a posture chair, exercise machine, and tracking means. It provides seated stepping, postural support, and semi-recline capabilities. A digital interface and app will allow users to set goals and track performance.
223591887|NCT06762080|DRUG|Pemetrexed (Alimta)|Pemetrexed was administrated by intrathecal injection, first as induction therapy, twice per week for 2 weeks, followed by consolidation therapy, once per week for 4 weeks, then maintenance therapy, once per month until the patient's death, leptomeningeal metastasis progresses, or intolerable severe adverse events occurred.
223591888|NCT06430164|OTHER|Gait Training|Gait training: One or multiple short bouts of stepping practice on a treadmill at self-selected or fast speeds will be delivered without FES.
224192909|NCT02184234|DRUG|Antistax film coated tablets|
224192910|NCT05303428|OTHER|Neuromodulation with low-intensity focused ultrasound|application of LIFU to induce temporary neuromodulation, effects tested with resting state and task based fMRI scanning.
224192911|NCT01302366|DRUG|TBL12|
224192912|NCT03626337|DRUG|Thiamine 100 MG/ML|100 mg thiamine provided as intramuscular injection
224192913|NCT00934661|DRUG|Extended Release Epidural Morphine (EREM)|A single Four mg (0.4 ml)dose of EREM will be administered into the epidural space and flushed with 1 ml of saline
224192914|NCT00934661|DRUG|Placebo|A single epidural injection will be a placebo consisting of 0.4 ml of saline followed by 1 ml saline flush
224192915|NCT03890133|BEHAVIORAL|Ba-Duan-Jin|"Ba-Duan-Jin is a common form of self-healthcare Qigong exercise that has been practiced by Chinese people for at least eight hundred years.It consists of eight sets of simple movements. By combining meditation with slow, graceful movements,deep breathing, and relaxation, Ba-Duan-Jin practitioners believe it has the ability to move vital energy (Qi) throughout the body. Ba-Duan-Jin is also considered to be a multicomponent intervention that integrates physical, psychosocial, emotional, spiritual, and behavioral elements. While the biological mechanisms remain unclear."
224192916|NCT03890133|DRUG|Pregabalin capsule|Pregabalin is one of the three medications (pregabalin, duloxetine, and milnacipran) that have been approved by the Food and Drug Administration (FDA) to treat fibromyalgia in US, and the only medicine that has been approved in China.
224192917|NCT00467051|DRUG|Carboplatin|Given IV
224192918|NCT00467051|BIOLOGICAL|Filgrastim|Given IV or subcutaneously
224192919|NCT00467051|DRUG|Ifosfamide|Given IV
223746330|NCT04900064|BEHAVIORAL|Brief interventions|'Brief Interventions' (BI) is a generic term for a multitude of tools and interventions used in patient visits within PCBH. BI start immediately at the initial consultation, which ends with a personally tailored and evidence-informed plan adjusted to the patient's context. As such, there is no separation between assessment and intervention. The interventions within BI often have their foundation in CBT, ACT or Motivational Interviewing (MI). The common theme is that they are principle-based rather than manual-based and focus on behavioural change in relation to a problem, rather than focusing on a specific diagnosis. Follow-up appointments are scheduled flexibly depending on the patient's perceived need. A BI treatment usually consists of 1-4 appointments with several weeks apart and has an open ending, where the patient easily can schedule a new appointment. Clinicians delivering brief interventions will have had 3 days of training as well as regular supervision.
223746331|NCT04900064|BEHAVIORAL|Self-help CBT|The patient receives a previously scientifically evaluated CBT-based self-help book for one of the following conditions: depression, generalized anxiety disorder, panic disorder, social anxiety, health anxiety, insomnia, or stress/burnout. The therapist support consists of 3-6 contacts throughout the 6-12 weeks long intervention period as decided by the clinician and patient together, as long as at least one and not more than three are physical visits at the center and the rest via phone, video conferencing, or secure internet messages. Clinicians delivering self-help CBT will need four days of reading and two days of training as well as regular supervision to be able to make initial assessments and problem profiling and use the self-help books.
224192920|NCT00467051|OTHER|Laboratory Biomarker Analysis|Optional correlative studies
224192921|NCT00467051|DRUG|Paclitaxel|Given IV
224192922|NCT02688751|RADIATION|time-resolved CT Angiography|A multi-phase contrast CT
224192923|NCT02688751|PROCEDURE|Contrast Enhanced Ultrasound|A ultrasound scan with micro bubble contrast injection
224192924|NCT03030131|DRUG|Durvalumab|durvalumab 750 mg IV Day1, 15, 29
224192925|NCT05959564|BEHAVIORAL|Personalized Chatbot Intervention|In this intervention, participants will first see a standard CDC HPV vaccine message. After that they will be invited to interact with a chatbot designed to deliver additional HPV vaccine messages, which are tailored to their personalities.
224192926|NCT05959564|BEHAVIORAL|Non-Personalized Chatbot Intervention|In this intervention, participants will first see a standard CDC HPV vaccine message. After that they will be invited to interact with a chatbot designed to deliver additional HPV vaccine messages, which are not tailored to their personalities.
224192927|NCT05959564|BEHAVIORAL|No Chatbot Control|In this intervention, participants will see a standard CDC HPV vaccine message only and will not interact with any chatbot.
223501620|NCT02024009|DRUG|Gemcitabine|Gemcitabine is indicated for treatment of patients with locally advanced or metastatic adenocarcinoma of the pancreas. It is administered as an infusion
223501621|NCT00947466|DRUG|Buprenorphine|Transdermal patch
223501622|NCT02072044|DRUG|Anlotinib|Anlotinib p.o. qd
223501623|NCT02314429|DEVICE|Vaginal ring releasing lactic acid (racemic mixture)|
223501624|NCT06432426|BEHAVIORAL|Virtual reality training group|Participants will be given virtual reality games on Nintendo Wii Fit® and its peripheral Balance Board system. This equipment offers safe and engaging training protocols. Additionally, it ensures physical exercise in the three planes of movement (sagittal, frontal, and transverse) and with three difficulty levels, thus providing a linear progressive demand.
223501625|NCT06432426|BEHAVIORAL|Standard physical exercise group|Participants will be submitted to a standard physical exercise program based on the ACSM guidelines. Resistance training will involve exercises for arms and legs, using bodyweight self-loading and external weights. Balance exercises will include the three planes of movement.
223501626|NCT01286324|DIETARY_SUPPLEMENT|Chamomile High Grade Extract|three tablets each (equivalent to 7.5 g of dried herb) p.o. twice daily for 28 days
223591889|NCT06430164|DEVICE|Functional electrical stimulation (FES)|"Electrical stimulation involving the parameters and settings proposed here is commonly used in clinical practice and research for pain relief and other applications also referred to as neuromuscular or transcutaneous electrical nerve stimulation. The FES will be delivered using the UDel Stimulator, a custom-designed FES system from the University of Delaware FES lab.~Researchers will use a customized, real-time system to control the stimulator and deliver stimulation during appropriate phases of the gait cycle. Stimulation will be delivered to the ankle dorsiflexors when the subject's foot is in the air (swing phase). Stimulation will be delivered to the ankle plantarflexors during the terminal stance phase of gait. 30-Hz variable frequency stimulation trains will be delivered during gait."
223591890|NCT06430164|DEVICE|Peripheral electrical stimulation paired with cortical magnetic stimulation pulses|The paired associative stimulation (PAS) will be conducted in a static posture (seated or standing), to evaluate effects on somatosensory, spinal-reflex, and/or corticospinal neurophysiology delivered with different stimulation parameters. One or multiple short bouts of stepping practice on a treadmill at self-selected or fast speeds may be completed before and/or after PAS to evaluate gait performance
223746332|NCT03971695|DRUG|BI 706321|Capsule or Oral Solution
223746333|NCT03971695|DRUG|Placebo|Capsule or Oral solution
224192928|NCT00961727|OTHER|Bedside Paediatric Early Warning System (Bedside PEWS)|The Bedside PEWS is comprised of 4 components; \[1\] an expert derived, multi-centre validated severity of illness score, \[2\] an inter-professionally developed documentation record into which the severity of illness score is embedded, \[3\] a series of score-matched care recommendations based on the opinions of over 280 paediatric health care professionals, and \[4\] an educator-developed education-implementation program.
224205887|NCT01445873|DRUG|Sitaxentan sodium|Sitaxentan sodium 100 mg / day
224205888|NCT04479488|OTHER|Hospital admission|Usual care.
224205889|NCT04479488|OTHER|Non-hospitalization procedures|Usual care.
223501627|NCT01286324|DRUG|Placebo Tablet|
223501628|NCT00886236|DRUG|Gabapentin|Gabapentin 1200 mg (24 cc) by mouth 1 hour prior to surgery AND Gabapentin 300 mg (6cc) by mouth x 6 doses after surgery (0800PM the evening of surgery, 0800AM postoperative day 1, 0200PM postoperative day 1, 0800PM postoperative day 1, 0800AM postoperative day 2, 1200PM postoperative day 2)
223501629|NCT00886236|DRUG|Placebo|Placebo 1200 mg (24 cc) by mouth 1 hour prior to surgery AND Placebo 300 mg (6cc) by mouth x 6 doses after surgery (0800PM the evening of surgery, 0800AM postoperative day 1, 0200PM postoperative day 1, 0800PM postoperative day 1, 0800AM postoperative day 2, 1200PM postoperative day 2)
224192929|NCT02531282|BEHAVIORAL|Patient education|Self-management patient education in groups once a week for 6 weeks. Each session include pain-related theory, group discussions and physical exercises focusing on posture and relaxation. Instructors with education in health promotion and behavioural change in addition to psychomotor physiotherapy.
224192930|NCT02531282|BEHAVIORAL|Physical activity|Physical activity once a week for a period of 6 weeks in form of walking and simple strength exercises outdoor in groups led by an instructor. Each session has a duration of one hour. The instructor has education in physical activity.
224192931|NCT00761462|DRUG|Ciprofloxacin|Either as oral suspension, oral tablets or sequential intravenous (IV) - oral therapy or purely IV therapy according to label
224192932|NCT00761462|DRUG|Non-quinolone antibiotic|Common used dose and route
224192933|NCT00936468|BIOLOGICAL|Fluzone® vaccine with JVRS-100 adjuvant or Fluzone alone|One vaccination on Day 0 of Fluzone® vaccine at 45ug mixed with one of three doses (3.75ug, 7.5ug, 25ug) of JVRS-100 adjuvant versus Fluzone® vaccine at 45ug alone.
224205890|NCT03989037|DRUG|SIBP-01|IBP-01: injection; strength: 150mg; first dose 8mg/kg (intravenous infusion, not less than 90 minutes, on the 1st day of each cycle), then 6mg/kg once every 3 weeks, totaling 6 cycles
224205891|NCT03989037|DRUG|Herceptin|Herceptin: injection; strength: 440mg; first dose 8mg/kg (intravenous infusion, not less than 90 minutes, on the 1st day of each cycle), then 6mg/kg once every 3 weeks, totaling 6 cycles
224205892|NCT03989037|DRUG|Docetaxel|Docetaxel: injection; dose 75mg/m2, 75mg/m2 once every 3 weeks (intravenous infusion, not less than 60 minutes, on the 1st day of each cycle), totaling 6 cycles;
223501630|NCT00886236|DRUG|Gabapentin|Gabapentin 1200 mg (24 cc) by mouth 1 hour prior to surgery AND Placebo 300 mg (6cc) by mouth x 6 doses after surgery (0800PM the evening of surgery, 0800AM postoperative day 1, 0200PM postoperative day 1, 0800PM postoperative day 1, 0800AM postoperative day 2, 1200PM postoperative day 2)
223501631|NCT04767516|OTHER|no intervention|no intervention
223501632|NCT01770730|DEVICE|Urine LAM strip test|This is a point-of-care lateral flow strip test to detect the presence of lipoarabinomannan (LAM) in patient urine samples. Only patients with a grade 2-5 visual band intensity will be considered positive and commenced on treatment
223501633|NCT04165902|DRUG|compare the effects of steroid plus hyaluronic acid and destrose plus hyaluronic acid on knee osteroarthritis|compare the immediate effect (one week after 3 times of injections), short-term effects (one month and three months after 3 times of injections), and midterm effect (6 months after 3 times of injections).
223501634|NCT05427916|DEVICE|Avance Solo|Avance® Solo will include the collective description for a complete device capable of delivering negative pressure to the incision site and managing exudate generated by the incision.
223501635|NCT05427916|OTHER|Optifoam|Optifoam is a silicone backed foam that is conformable, with a border that is waterproof, flexible and breathable for increased comfort, with a wear time of up to seven days. It is a standard of care product that is given to patients for surgical wounds.
223501636|NCT00055107|DRUG|Nitazoxanide|
223501637|NCT06476821|DRUG|BMS-986435|Specified dose on specified days
223501638|NCT03195530|DRUG|Propofol|Induction of anesthesia using propofol, and recording the BIS values and EEG patterns during the induction
223501639|NCT03466372|BEHAVIORAL|biofeedback|treadmill walking with biofeedback regarding propulsion and other gait parameters
223501640|NCT00623376|DRUG|nabilone then placebo|The subjects were first on Nabilone, then crossed over to placebo
223501641|NCT00623376|DRUG|placebo then nabilone|the subjects were first on placebo then crossed over to nabilone
223501642|NCT06502080|RADIATION|Consolidative radiotherapy|Consolidative radiotherapy: total dose and number of fractions will depend on the site of disease. Treatment will be given daily, or every other day, over 1 -3 weeks. Physicians should try to give the highest BED whenever possible while respecting normal tissue tolerance. All lesions are recommended to receive a biologically effective dose (BED) of 60 Gy or higher (BED10≥70), assuming α/β ratio of 10 and using the linear-quadratic model: BED = nd x \[1 + d/(α/β)\] where n is number of fractions and d is dose per fraction. Sometimes BED ≥80 Gy is preferred, with lower doses ≥50 Gy allowed at the discretion of the treating physician for concerns about normal tissue toxicity.
223501643|NCT06502080|DRUG|Standard-of-care systemic therapy: Gemcitabine + cisplatin/oxaliplatin + Durvalumab/Pembrolizumab/Sintilimab/Toripalimab|Standard-of-care systemic therapy as decided by the treating medical oncologist: Gemcitabine + cisplatin/oxaliplatin + Durvalumab/Pembrolizumab/Sintilimab/Toripalimab
223501644|NCT05558410|DRUG|Suzetrigine (SUZ)|Tablets for oral administration.
223501645|NCT05558410|DRUG|HB/APAP|Capsules for oral administration.
223501646|NCT05558410|DRUG|Placebo (matched to SUZ)|Placebo matched to SUZ for oral administration.
223501647|NCT05558410|DRUG|Placebo (matched to HB/APAP)|Placebo matched to HB/APAP for oral administration.
223501648|NCT04565288|DRUG|Atomoxetine|Participants randomized to receive the study medication, atomoxetine (brand name: Straterra) for 6-weeks (40 mg/day for 3 days then 80 mg/day thereafter). A comparator group will receive placebo (sugar pills).
223501649|NCT04565288|DRUG|Placebo|Matching placebo (sugar pill)
223501650|NCT04049084|BIOLOGICAL|autologous ex vivo gene therapy products based on the EFS LV encoding for the human adenosine deaminase (ADA) gene (EFS-ADA LV)|ADA-SCID patients previously treated with autologous ex vivo gene therapy products based on the EFS LV encoding for the human adenosine deaminase (ADA) gene (EFS-ADA LV)
223501651|NCT05202496|DRUG|Calcitriol 0.25Mcg Cap|After orthodontic levelling and alignment, experimental group subjects are administered one capsule of calcitriol 0.25 mcg on a daily basis during the study period. Also, serum vitamin D levels are monitored at monthly intervals and rate of canine retraction is measured at monthly intervals
223501652|NCT05202496|PROCEDURE|orthodontic treatment|experimental group subjects undergo orthodontic treatment after extraction of premolars
223501653|NCT03560596|BEHAVIORAL|Adherence Intervention|9 sessions with bilingual health coaches who will utilize a culturally tailored adherence checklist to identify patients specific medication adherence barriers.
223501654|NCT03560596|BEHAVIORAL|Usual Care|standard hypertension treatment recommendations as determined by PCP
223512127|NCT00098293|DRUG|Maraviroc (UK-427,857) + Zidovudine/Lamivudine|maraviroc (UK-427,857) 300 mg twice daily added to zidovudine/lamivudine (300 mg/150 mg twice daily)
224192934|NCT02592369|DEVICE|Medtronic CoreValve™ Evolut R™ System|The Evolut R System is intended for relief of aortic stenosis in patients with symptomatic heart disease due to severe native calcific aortic stenosis who are judged by a heart team, to be at high or extreme risk for open heart surgery. The Evolut R TAV treats aortic stenosis by displacing and functionally replacing the dysfunctional native valve with a bioprosthetic valve delivered on a catheter while the heart is still beating, thus avoiding the risks of cardiopulmonary bypass. Its intended performance is to relieve aortic valve stenosis without inducing significant regurgitation, thereby restoring effective aortic valve function.
224192935|NCT05764629|DIAGNOSTIC_TEST|blood test|Testing the peripheral blood for PPDM-C, including blood glucose, glycated hemoglobin A1c, fasting insulin and C-peptide, etc.
224192936|NCT05764629|DRUG|pharmacologic approaches to glycemic treatment|documenting the change of glycemic treatment during the follow-up period
224192937|NCT01419834|BIOLOGICAL|Humanized 3F8 Monoclonal Antibody (Hu3F8)|Hu3F8 is infused IV over \~30 minutes
224192938|NCT05783011|PROCEDURE|Electroacupuncture|Electroacupuncture was applied bilaterally to the LI4, ST5 and ST6 acupuncture points before and after periodontal flap surgery
224192939|NCT05783011|PROCEDURE|periodontal flap surgery|periodontal flap surgery
224192940|NCT05825911|DIAGNOSTIC_TEST|Rest/Stress MCG scan|All patients enrolled and receiving standard screening tests for CAD will undergo rest/stress MCG scan before CAG.
224192941|NCT05825911|DIAGNOSTIC_TEST|Rest MCG scan|This is an normal adult population with age-, and sex-matched control group. All participants enrolled will undergo rest MCG scan.
224192942|NCT01479777|DEVICE|FES Stepping (RT600 from Restorative Therapies, INC.)|You will be transferred to the RT600 device and secured in a support harness. We will place your legs onto the RT600 device and secure them with straps. Electrodes (pads that stick to the skin) will be placed on your skin on your legs, buttock, stomach, and back. The pads will be connected to a stimulator box through a wire. We will then start the stepping motor and stimulate your muscles with electric current. This will cause your legs to step. You will do this for 1 hour.
224192943|NCT03563729|DRUG|Pembrolizumab Injection [Keytruda]|Alone
224192944|NCT03563729|DRUG|Ipilimumab Injection [Yervoy]|In combination with nivolumab.
224192945|NCT03563729|DRUG|Nivolumab Injection [Opdivo]|In combination with ipilimumab.
224192946|NCT03563729|DRUG|Encorafenib|In combination with binimetinib
224192947|NCT03563729|DRUG|Binimetinib|In combination with encorafenib
224192948|NCT03563729|DRUG|Dabrafenib|In combination with dabrafenib
224192949|NCT03563729|DRUG|Trametinib|In combination with trametinib
224192950|NCT05950529|OTHER|Experimental lozenge with the enzyme Polyphenol oxidase and green coffee extract|Subjects will be instructed to allow their assigned lozenge to dissolve in the mouth while placed on the dorsal surface of the tongue. Subjects can suck on the lozenge and press the lozenge against the palate; however, the lozenge should not be moved around in the mouth or placed on the buccal mucosa. Subjects should avoid biting or chewing the lozenge and talking while dissolving the lozenge. After the lozenge has dissolved, the subject will be instructed to swallow the remaining solution.
223501655|NCT04717180|BEHAVIORAL|aphasia rehabilitation using software program or conventional therapy|Patients were randomized into two groups: group I who received therapy using the software aphasia rehabilitation program and group II who received conventional (traditional) language therapy
223501656|NCT03161847|OTHER|Non-interventional study|Non-interventional study
223501657|NCT04120675|DIETARY_SUPPLEMENT|Early Harvest Extra Virgin Olive Oil|Participants will take 3 tablespoons on a daily basis
223501658|NCT00532857|DRUG|Paclitaxel/Gemcitabine/Trastuzumab|80 mg/m2 of paclitaxel 1,200 mg/m2 of gemcitabine, day 1, day 8 every 3-week. trastuzumab at a dose of 4 mg/kg IV on D1 of first treatment cycle subsequently given weekly at a dose of 2 mg/kg
223501659|NCT02277860|BEHAVIORAL|Exercise|Aerobic and strength training using the Wii Fit for ≥ 30 min, ≥3 days/week, for 12 weeks, at a moderate intensity (Borg CR10 3-5).
223512128|NCT03451305|OTHER|Pillow|A soft pillow was placed under the segment of the collapsed vertebrae, which resulted in a hyperextension position
223512129|NCT01370642|DRUG|vaniprevir|Capsules containing 150 mg vaniprevir, orally, two in the morning and two in the evening for 12 or 24 weeks
224192951|NCT05950529|OTHER|Experimental lozenge with the enzyme Polyphenol oxidase, green coffee extract and flavor|Subjects will be instructed to allow their assigned lozenge to dissolve in the mouth while placed on the dorsal surface of the tongue. Subjects can suck on the lozenge and press the lozenge against the palate; however, the lozenge should not be moved around in the mouth or placed on the buccal mucosa. Subjects should avoid biting or chewing the lozenge and talking while dissolving the lozenge. After the lozenge has dissolved, the subject will be instructed to swallow the remaining solution.
224192952|NCT05950529|OTHER|Placebo lozenge control (sorbitol only)|Subjects will be instructed to allow their assigned lozenge to dissolve in the mouth while placed on the dorsal surface of the tongue. Subjects can suck on the lozenge and press the lozenge against the palate; however, the lozenge should not be moved around in the mouth or placed on the buccal mucosa. Subjects should avoid biting or chewing the lozenge and talking while dissolving the lozenge. After the lozenge has dissolved, the subject will be instructed to swallow the remaining solution.
224192953|NCT05950529|OTHER|No product|no product
224192954|NCT03652129|PROCEDURE|Disinfection|Disinfection maneuver using LASER and nano irrigant
224192955|NCT05946096|OTHER|Dynamic surface exercise training|Dynamic surface exercise training involves a set of exercises that are performed on various dynamic surfaces like gym ball and vestibular swing. All these exercise provide optimal arousal as they provide proprioceptive and vestibular stimulus. This group received a set of exercises on various dynamic surfaces.These exercises were implemented for 60 minutes for four days a week for two months.And it was observed how these exercises impacted gross motor function and trunk control of children with diplegic cerebral palsy of GMFCS level 3 and 4
224192956|NCT05946096|OTHER|conventional physical therapy|conventional physical therapy based on NDT involves a set of exercises that mostly include positioning exercises such as quadruped, side sitting, reaching sideways and overhead in sitting and catch and throw activities.
224192957|NCT03446846|DRUG|MIN-117 5.0 mg|5.0 mg MIN-117 administered as two MIN-117 2.5 mg capsules as a single dose once daily
224192958|NCT03446846|DRUG|MIN-117 2.5 mg|2.5 mg MIN-117 administered as one MIN-117 2.5 mg capsule and one Placebo capsule as a single dose once daily
223746334|NCT05705284|OTHER|Structured multidisciplinary medication review|Multidisciplinary process for medication review/deprescribing: The intervention will be a structured process for performing a shared-decision, person-centred medication review among those living with frailty involving GPs, PCN-pharmacist and ANPs.
223746335|NCT02109614|DRUG|Extended release Niacin|Arm will be taking 1500-2000mg of niacin daily to see if lipoprotein(a) levels are lowered and aortic stenosis does not increase.
223746336|NCT02109614|DRUG|Placebo Comparator|Placebo Comparator arm will be taking 1500mg of the placebo daily
223746337|NCT03609515|OTHER|Patient-controlled admission|The patients with a contract for patient-controlled admissions may refer themselves to short inpatient stays when they feel the need, without needing an approval from a clinician. They will be accepted for admission if a patient-controlled bed is available in the ward. Patient-controlled admissions are limited to a length of 5 days and at least three weeks between such stays.
223746338|NCT04733742|DRUG|rhTNK-tPA|intravenous thrombolysis with rhTNK-tPA followed by endovascular treatment
223746339|NCT04733742|OTHER|Endovascular treatment|endovascular treatment
223746340|NCT04749953|PROCEDURE|Maxillary sinus floor augmentation|The sinus membrane of the maxillary sinus is elevated to create a space for the grafting material and placement of dental implants in the posterior maxilla
223501660|NCT04953260|OTHER|APRF|20ml venous blood was collected from the elbow before operation and centrifuged with a special centrifuge. One piece of APRF gel was chopped and mixed with Bio-oss, and the other piece was pressed into a thin film; the mixture of APRF and Bio-oss was filled into the bone defect, covered with a properly trimmed Bio-gide film, and then covered with APRF film
223501661|NCT04953260|OTHER|CGF|20ml venous blood was collected from the elbow before operation and centrifuged with a special centrifuge. One piece of CGF gel was chopped and mixed with Bio-oss, and the other piece was pressed into a thin film; the mixture of CGF and Bio-oss was filled into the bone defect, covered with a properly trimmed Bio-gide film, and then covered with CGF film
223501662|NCT03246854|DRUG|DBPR112|DBPR112 hard gelatin capsule solid dosage formulation; strength: 25 mg, 100 mg.
223501663|NCT05409612|BIOLOGICAL|Supemtek®|"Quadrivalent recombinant high-dose influenza vaccine containing 45 µg of hemagglutinin (HA) for each of the 4 strains included (2 strains A and 2 strains B).~Solution for injection is sterile liquid supplied in 0.5mL single dose pre-filled syringe. Vaccine is injected intra-muscularly in the non-dominant arm at Day 0."
223501664|NCT05409612|BIOLOGICAL|Vaxigriptetra®|Quadrivalent inactivated influenza vaccine containing 15 µg of hemagglutinin (HA) for each of the 4 strains included. Suspension for injection is sterile liquid supplied in 0.5mL single dose pre-filled syringe. Vaccine is injected intra-muscularly in the non-dominant arm at Day 0.
223501665|NCT02866266|OTHER|Retrospective database review|
223501666|NCT00746161|PROCEDURE|Reconstruction after total gastrectomy|Roux-en-Y
223746341|NCT01802957|OTHER|Training of health workers in Basic Obstetric Emergency Care|Health workers at the eight health centers will be trained in maternal, newborn, and child health (MNCH) care, including all basic emergency obstetric and neonatal care (BEmONC) signal functions and other essential MNCH services. The training is a three week competency-based curriculum developed recently by the Ethiopian Federal Ministry of Health (FMoH).
223746342|NCT01802957|OTHER|Hospital-health center networking system|A key intervention will be the creation of an effective, formalized networking system between Saint Paul Millennium Hospital and its eight satellite health centers in Addis Ababa. The networking system will create a conducive environment for the transfer of knowledge and skills between health care providers working at the hospital and in the health centers. Monthly review meetings will bring together staff from the hospital and health centers, and dedicated cell phones will be distributed to improve communication between the networked facilities.
223746343|NCT01802957|OTHER|Post Basic Emergency Obstetric Training Mentorship|At Saint Paul Millennium Hospital and the health centers, providers who have undergone BEmONC training will undergo regular monthly mentorship visits for the first six months post training. The frequency of visits after six months will be adjusted based on the retention of BEmONC skills and provider performance
223501667|NCT00746161|PROCEDURE|Reconstruction after total gastrectomy|double tract reconstruction
223501668|NCT04169412|DIAGNOSTIC_TEST|Blood Collection|Blood Gas Analysis using Stat Profile pHOx® Series (nova biomedical, Waltham, U.S.) and Enzym-linked Immunosorbent Assay (ELISA) using Bio-Rad (Bio-Rad Laboratories, California, U.S.)
223501669|NCT03319121|DRUG|Empirical therapy group|Receive extended release lansoprazole (Dexlansoprazole, Takeda Pharmaceuticals, Japan) 60 mg daily for 2 weeks.
223501670|NCT03319121|DRUG|Guided therapy group|Receive Dexlansoprazole 30 mg daily for GERD, 60 mg daily for GERD with erosive esophagitis for 8 weeks and Theophylline SR 250 mg daily for functional chest pain for 4 weeks.
223746344|NCT01802957|OTHER|Team-Based Supportive supervision|Saint Paul Hospital will use team-based models to provide supportive supervision to health centers in its network. Representatives of the supportive supervision teams may, in addition to Saint Paul Hospital employees, include representatives from the Addis Ababa Regional Health Bureau.
223746345|NCT01802957|OTHER|Midwives exchange program|Saint Paul Millennium Hospital's maternity wards are often over-crowded and have to turn patients away. Health professionals incorrectly refer non-complicated deliveries, resulting in the occupation of beds that should be used for emergency deliveries. This action is attributed to inexperienced midwives at the health center level who are uncomfortable performing normal labor and delivery duties. In order to address this challenge, this project will establish an exchange program in which well-trained, experienced midwives from the hospitals will temporarily exchange places with less-experienced midwives in the health centers. This exchange would allow less-experienced midwives to work in the hospital environment, gaining the experience and confidence necessary to attend normal deliveries and identify appropriate referrals.
223746346|NCT01802957|OTHER|Strengthening the referral network|Mechanisms and protocols for smooth communication between the health centers and the hospital have been developed, allowing health centers to utilize the hospital's ambulance, and implementing mechanisms for back referrals and feedback. To facilitate this work, we will support the use of dedicated cell phones in each of the eight networked facilities and at Saint Paul Millennium Hospital, and institute referral log books at both the referring and receiving institutions.
223746347|NCT01802957|OTHER|Facility Checklists|Facility checklists will be used daily in each of the facilities to assess readiness for obstetric emergencies. Formally, the checklists will be used at the quarterly supportive supervision visits, to assess improvements over time.
224192959|NCT03446846|DRUG|Placebo|Placebo administered as two Placebo capsules as a single dose once daily
224192960|NCT04796168|PROCEDURE|Splinting (plaster of paris)|Placing stockinette followed by cotton rolls and 10-12 layer of posterior ankle splint made of plaster of paris
224192961|NCT04299126|DEVICE|high absorption pad for blood and pus|High absorption pad for blood and pus will be covered on half of split-thickness skin graft donor site wound until the wound has healed.
224192962|NCT04299126|DEVICE|commercial wound dressing|Commercial wound dressing will be covered on half of split-thickness skin graft donor site wound until the wound has healed.
224192963|NCT05863780|OTHER|Carpal bone mobilization|"Carpal bone mobilization 5 repetition/1 set lasted for 15 secs followed by 10 secs of rest- 3 sessions on alternate days per week for 04 weeks.~Total of 12 sessions will be given, each consisting of 45 mins."
224192964|NCT05863780|OTHER|Flexor retinaculum stretch|"Flexor retinaculum stretch 5 repetitions/ 1 set held for 60 secs at a time,-3 sessions on alternate days per week for 04 weeks.~Total of 12 sessions will be given, each consisting of 45 mins."
224192965|NCT05863780|OTHER|Carpal bone mobilization and flexor retinaculum stretch|"1. Carpal bone mobilization 5 repetition/1 set lasted for 15 secs followed by 10 secs of rest.3 sessions on alternate days per week for 04 weeks.~2. Flexor retinaculum stretch 5 repetitions/ 1 set held for 60 secs at a time-3 sessions on alternate days per week for 04 weeks.~Total of 12 sessions will be given, each consisting of 45 mins."
224192966|NCT02500173|RADIATION|Radiation|Radiation therapy
223501671|NCT05469061|DRUG|Tislelizumab|The 1st to 3rd doses were administered concurrently with FP regimen chemotherapy, 200 mg Tislelizumab each, on D1, D22 and D43 by intravenous infusion. In patients with successful conversion, one dose of 200 mg was administered 21 days after surgery in concurrent with the 4th to 6th cycles of 5-Fu, then 6 cycles of 200 mg Tislelizumab as adjuvant therapy; in patients with failed conversion, chemotherapy combined with tislelizumab were administered, with or without radiation therapy.
223501672|NCT05469061|DRUG|5-FU|A FP regimen with 5-Fu 850mg/m\^2 d1-4 + cis-platinum 850mg/m\^2 d1-4 was used, on D1, D22 and D43 infused intravenously. 3 cycles of 5-Fu 850mg/m\^2 d1-4 adjuvant chemotherapy were started at 21 days after surgery in patients with a successful conversion. In patients with failed conversion, chemotherapy combined with tislelizumab were administered, with or without radiation therapy.
223501673|NCT05469061|DRUG|cis Platinum|A FP regimen with 5-Fu 850mg/m\^2 d1-4 + cis-platinum 850mg/m\^2 d1-4 was used, on D1, D22 and D43 infused intravenously. In patients with failed conversion, chemotherapy combined with tislelizumab were administered, with or without radiation therapy.
223501674|NCT01691807|DRUG|ofatumumab|treatment for NHL
223501675|NCT01691807|DRUG|bendamustine|treatment for NHL
223501676|NCT03519607|BEHAVIORAL|FertiStrong App|The FertiStrong mobile app is similar to FertiCalm, which is designed for women with infertility. FertiCalm (www.FertiCalm.com) can be downloaded for free anywhere in the US, for both Apple and Android phones. Each app contains twelve main categories and each main category contains up to five tailored situations. For each situation, there are six options. Three of the options are the same for all situations (humor, self-nurture, relaxation) and three are unique (cognitive solutions, behavioral solutions, social solutions).
223501677|NCT05012969|DEVICE|Hipstop bandage|12 weeks use of a bandage to prevent hip dislocations in patients with previous dislocations
223501678|NCT03049800|DEVICE|Magnetic Resonance Imaging|Functional, structural, and diffusion weighted imaging conducted with a 7T-PS scanner and a Prisma 3T scanner.
223501679|NCT05213351|OTHER|Graded Motor Imagery|"Graded Motor Imagery program will be performed two times a week for six consecutive weeks and will include the following three steps: laterality training, imagined movements, and mirror therapy.~1. Right-left discrimination training (lateralization training)~2. Imagination of hand movements (motor imagery):~3. Mirror therapy Treatments including traditional physiotherapy approaches; joint mobilizations, stretching, scapula focused exercises etc."
223746348|NCT01802957|OTHER|Emergency Drills|Non-punitive obstetric drills will provide multiple measurable indicators of quality maternal care, will illustrate opportunities for improving facility capabilities and provider care, and will allow providers to assess appropriate referral mechanisms and facility readiness. Incorporating emergency drills into current training and at all levels of health facilities will also give providers hands-on experience
224192967|NCT00000172|DRUG|Galantamine|
224192968|NCT06118216|PROCEDURE|rectus abdominis(RAM) and external oblique muscle(EOM) infiltration analgesia|After suturing the muscular fascia, an indwelling catheter was placed above the RAM and EOM and under the subcutaneous tissue and then sutured to the skin for fixation. Approximately 30 min before surgery completion, 1 mg/kg of 0.2% ropivacaine was infused through the indwelling catheter for IA. Additionally, 1 mg/kg of 0.2% ropivacaine was infused through the indwelling catheter every 12 h, starting 8 h postoperatively, injected four times.
224192969|NCT06118216|PROCEDURE|intravenous patient-controlled anesthesia|After completion of the operation, the anesthesiologist used the IPCA device; it was programmed with a background infusion rate of 2 mL/h, a bolus volume of 2 mL, and a lockout interval of 15 minutes. The 100 mL total volume of the PCA consisted of normal saline, 2.0 ug/kg sufentanil, and adjuvant antiemetic (tropisetron).
224192970|NCT00048438|DRUG|paricalcitol|
224192971|NCT01013207|DEVICE|CPAP Pre Nexus (S9)|This is the patient's own CPAP prior to trialling the Nexus (S9). 4 weeks of data will be downloaded from this device and compared to 4 weeks using Nexus (S9), and 4 weeks usage post trialling Nexus (S9)
224205893|NCT03989037|DRUG|Carboplatin|Carboplatin: injection; dose AUC6, AUC6 once every 3 weeks (intravenous infusion, not less than 30 minutes, on the 1st day of each cycle), totaling 6 cycles;
224205894|NCT03078192|DRUG|GE-141, Hyperpolarized 129Xenon gas|XeMRI scans will provide 3D images of ventilation and gas exchange. Subjects will inhale HP 129Xe from the dose delivery bags. Then the subject will be moved into the scanner and they will undergo basic 1H localizer and anatomical scans. Once localization is complete, subjects will under-go several MRI scans after inhalation of HPXe
224205895|NCT03078192|DEVICE|MRI|Perform MRI scans with administration of GE-141, Hyperpolarized 129Xenon
224205896|NCT00000754|DRUG|Interferon alfa-2a|
224205897|NCT00000754|DRUG|Zidovudine|
224205898|NCT00000754|DRUG|Zalcitabine|
224205899|NCT00383929|DRUG|Candesartan cilexetil|32mg oral
224205900|NCT00383929|DRUG|Hydrochlorothiazide|12.5 mg oral
224205901|NCT00383929|DRUG|Hydrochlorothiazide|25 mg oral
223501680|NCT05213351|OTHER|Exercise|Treatments including traditional physiotherapy approaches; joint mobilizations, stretching, scapula focused exercises etc.
223501681|NCT01279187|DRUG|Teriparatide|20ug per day,via subcutaneous injection, for 7 weeks
223501682|NCT01279187|DRUG|Placebo|20ug per day, self administered injection, for 7 weeks
223501683|NCT00046943|DRUG|atrasentan hydrochloride|
223501684|NCT02558569|DRUG|Levobupivacaine|L form of bupivacaine with less cardiotoxicity.
223501685|NCT02558569|OTHER|NSS|Clear intravenous fluid looks alike local anesthetic.
223501686|NCT00731536|OTHER|No intervention|This is an observational study. Medical records of patients with the diagnosis of HSTCL in the PALGA database will be analyzed.
223501687|NCT02786511|DRUG|Safety and efficacy assessments|Vector copy number (VCN) measurement, safety evaluations, disease-specific assessments, and assessments to monitor for long-term implications of autologous transplant
223501688|NCT03597555|DRUG|Sodium Oxybate Oral Solution 500 MG/ML|"First night after V1: Dose prescribed at 4.5 g per night (2.25 g x 2) for 2 weeks First night after V2: Dose increased to 6 g per night (3 g x 2) for 2 weeks, according to investigator's opinion, tolerance of drug and CGI-S First night after V3: Dose either maintained stable at 6 g or increased to 9 g per night (4.5 g x 2) with dose increments of 1.5 g per night (0.75 g x 2) every week, based on benefit-risk ratio, for 2 weeks.~First night after V4: Dose maintained at 9 g or reduced at 6 g per night according to benefit-risk ratio for 2 weeks. No dose adjustment during the Maintenance period.~First night after V5: Taper period. Dose decrease by 2.25 g x 2 every two days until complete withdrawal"
223591891|NCT04680949|DRUG|Anakinra|Standard-of-care and anakinra. Anakinra is injected subcutaneously as 100 mg once daily for 10 days
223591892|NCT04680949|DRUG|Placebo|Standard-of-care and placebo. Placebo is injected subcutaneously once daily for 10 days
223591893|NCT06385327|DRUG|ABI-5366|Once daily tablet dosing (SAD) or weekly or monthly tablet dosing over the 29-day treatment period (MAD)
223501689|NCT03597555|DRUG|Placebos|Xyrem Placebo: sodium citrate solution in equimolar concentration of sodium in the 500 mg/mL Xyrem oral solution, PH adjusted with malic acid
223501690|NCT04941911|DRUG|Octreotide Acetate|Octreotide syringes will contain 50ml of octreotide acetate at 20mcg/ml in 0.9% w/v sodium chloride in water.
223501691|NCT04941911|OTHER|Placebo|Sodium chloride 0.9% w/v
223501692|NCT05516095|DEVICE|Transcranial magnet stimulation|Theta burst stimulation, which is a form of Transcranial magnet stimulation, works by inducing focused magnetic field pulses to make durable changes in the activity of brain regions. The magnetic pulses are transferred to the brain through an electromagnetic coil.
223512130|NCT01370642|DRUG|Placebo to vaniprevir|Placebo to vaniprevir, capsules, orally, twice daily for 12 weeks or 24 weeks
223512131|NCT01370642|BIOLOGICAL|Peg-IFN|Peg-IFN 1.5 μg/kg once per week, subcutaneously (SC) for 24 or 48 weeks
223512132|NCT01370642|DRUG|ribavirin|Capsules containing 200 mg RBV orally, 3 to 5 capsules, dosage based on the participant's weight (600 mg/day to 1000 mg/day), for 24 or 48 weeks
223512133|NCT05253235|BEHAVIORAL|SAAF|A 7 session online intervention designed to augment protective processes associated with deterrence of substance use
223512134|NCT05253235|OTHER|Receipt of parenting book|Parents will receive a copy of the book, Parenting for Liberation: A Guide for Raising Black Children
223512135|NCT02071654|DEVICE|Venus P-valve transcatheter implantation|Percutaneous implantation of Venus-P valve to treat RVOT stenosis patients
223512136|NCT01796470|DRUG|Entospletinib|Entospletinib tablets administered orally twice daily
223512137|NCT01796470|DRUG|Idelalisib|Idelalisib tablets administered orally twice daily
223512138|NCT00370604|DEVICE|19g Tuohy-type epidural needle, 23g catheter|Patients in the experimental group will receive a 23g 90cm adult length epidural catheter placed via a 19g Tuohy epidural needle (SIMS Portex, Hythe, UK). The 19g Tuohy needle is a standard 3½ inch length.
223512139|NCT00370604|DEVICE|=> 18g Tuohy-type needle|Patients in the control arm will receive a traditional large gauge (16g, 17g or 18g Tuohy or Hustead) epidural needle and a traditional epidural catheter. Two control needles and two control catheters will be designated apriori by each institution for use in the study.
223512140|NCT03810794|OTHER|Acupuncture|The main acupoints are DU 24, EX-HN 3, DU 20, EX-HN 1, GB 12, HT 7, KI 6, GB39, and then selecting other acupoints according to TCM syndrome. The electric stimulator will be applied to DU 24, GB 12, HT 7, and LR 3 or SP 6 with a disperse-dense wave of 2/50 Hz, 0.5-1.0 mA. There are three sessions per week with each session lasting for 30 min. There will be 12 weeks of treatment for each participant in total.
223512141|NCT03810794|DRUG|Donepezil|Donepezil 5 mg will be given once daily before bed-time for 12 weeks. After the clinical trial, participants will be given conventional treatment clinically.
223512142|NCT03480516|DEVICE|SDF|38% silver diamine fluoride solution
223512143|NCT03480516|DEVICE|Fluoride varnish|5% sodium fluoride varnish
223512144|NCT03785132|PROCEDURE|Cardiac surgery|The relationship between performance measurement of blood pressure during cardiac surgery (before, during and after cardiopulmonary bypass) and postoperative mortality
223512145|NCT05863364|DRUG|Low-dose of Rifaximin|The patients in group B were given rifaximin with the dose of 600mg/d (600mg, qd) for 24 weeks
223512146|NCT05863364|DRUG|Conventional dose of Rifaximin|the patients in group C were delivered 1200mg/d (600mg, bid) for 24 weeks
223512147|NCT01927861|DRUG|somatropin|Administered subcutaneously (s.c., under the skin) in a daily regimen for at least 104 weeks. Subject will be offered to continue treatment for another 104 weeks.
223512148|NCT00987935|DRUG|Sorafenib|400 mg twice daily
223512149|NCT00987935|DRUG|BIBF 1120|Twice daily
223512150|NCT03077308|PROCEDURE|Auditory and Visual Event-related Potentials and EEG|Specifically, through up to three standardized sessions (i.e., annual \[every 10-14 months\]), we will assess AEP and VEP. ERP recordings will also provide data for specific rhythms/band (gamma and alpha) pattern analyses as secondary measures as well as technical control data, which will help to exclude those with co-current seizures.
223512151|NCT05136521|DRUG|Trazodone HCl - new polymer|A single 300 mg dose of the test (T) and of the reference (R) products will be administered to the study subjects in two consecutive periods, according to a randomised 2-sequence cross-over design. A wash-out interval of at least 10 days will elapse between the two administrations. The two investigational products will be administered with 240 mL of still mineral water on day 1 of the two study periods, at 08:00±1 h after an overnight fasting.
223501693|NCT05516095|DEVICE|Sham Transcranial magnet stimulation|Similar in appearance and give the same sound as the active device, but deliver no magnetic pulse that reach the brain
223501694|NCT04591132|DEVICE|kinematic analysis|motor tasks appropriate for each diagnosis will be recorder with wearable inertial sensors
223501695|NCT06156267|DRUG|Adebrelimab|Adebrelimab is a programmed death-ligand 1 antibody.
223501696|NCT06156267|DRUG|mRNA tumor vaccines|neoantigen personalized mRNA vaccines
223501697|NCT00933166|DEVICE|Lotrafilcon A contact lens|Investigational silicone hydrogel, single vision, soft contact lens worn on a daily wear basis, flexible wear basis, or extended wear basis for three months
223501698|NCT05831046|OTHER|ED management software|Patients utilize software after being screened, but prior to being re-evaluated by physician
223501699|NCT01558570|PROCEDURE|Blood Draw|One time blood draw
223501700|NCT06183567|PROCEDURE|Sedoanalgesia|In Acute Ischemic Stroke Patients Undergoing Endovascular Thrombectomy, the procedure was performed under sedoanalgesia. The procedure was continued with mean arterial pressure, heart rate, pulse oximetry and BIS monitoring.
223501701|NCT06183567|PROCEDURE|general anesthesia|In Acute Ischemic Stroke Patients Undergoing Endovascular Thrombectomy, the procedure was performed under general anesthesia. The procedure was continued with mean arterial pressure, heart rate, pulse oximetry and BIS monitoring.
223501702|NCT03278782|BIOLOGICAL|Pembrolizumab|Given IV
223501703|NCT03278782|DRUG|Romidepsin|Given IV
223501704|NCT04402957|DRUG|LSALT peptide|LSALT, a peptide drug with the sequence NH3-LSALTPSPSWLKYKAL-COOH, binds to dipeptidase-1 (DPEP-1) but does not inhibit its biologic enzymatic activity. LSALT peptide inhibits leukocyte recruitment in multiple experimental disease models through the direct inhibition of leukocyte adhesion to DPEP-1 present in lungs, kidney, and liver.
223501705|NCT04402957|DRUG|Placebo|0.9% saline solution
223501706|NCT05641363|DRUG|Ketorolac Tromethamine|ketorolac tromethamine, an NSAID belonging to a group of non-opioid analgesics that inhibit the synthesis of prostaglandins and thromboxanes with strong analgesic and anti-inflammatory properties. It is the only non-opioid parenteral non-sedating analgesic available for use to treat acute pain in the emergency department.
223501707|NCT04195347|DRUG|CM4620|IV
223501708|NCT00837447|DEVICE|Total knee replacement with NexGen CR knee prosthesis|comparison of functional outcome in patients receiving either NexGen posterior cruciate-retaining or a high-flexion posterior cruciate-retaining total knee prosthesis
223501709|NCT00837447|DEVICE|Total knee replacement(TKR) with Nexgen CR-flex|TKR using Nexgen CR-flex implant
223501710|NCT01527981|BEHAVIORAL|Cognitive behavioral therapy for adherence and depression|Cognitive-behavioral therapy for adherence and depression (CBT-AD) is a weekly, psychosocial treatment focusing on depression and patients' adherence to diabetes self-care. Treatment consists of weekly one-hour sessions for approximately 10 sessions.
223501711|NCT04700462|BEHAVIORAL|Sm-EMA|Self-monitoring ecological momentary assessment behavior change tool to promote adherence to a desired behavior (i.e. COVID-19 preventative behaviors).
223501712|NCT05354947|DEVICE|Ultrasound Delivery|A General Electric LOGIQ E10 ultrasound machine with a C1-6-XD clear probe, will be used to selectively deliver pulsed ultrasound to both, the portal region of the liver and the superior mesenteric plexus.
223501713|NCT01102283|DEVICE|Evolution(R) Colonic Stent|Palliative treatment of colonic obstruction or strictures caused by malignant neoplasms and to relieve acute large bowel obstruction prior to colectomy in patients with malignant strictures.
223501714|NCT03959319|OTHER|Movement Pattern Training|Treatment will include 10 supervised sessions over 12 weeks and instruction in a home exercise program After randomization, participants will be scheduled with a physical therapist trained in standard procedures. Treatment will include assessment of patient goals, patient education and instruction in a home program. Patient education will focus on patient-specific tasks, identified by the participant to be symptom-producing.
223501715|NCT03959319|OTHER|Manual Therapy|Treatment will include 10 supervised sessions over 12 weeks and instruction in a home exercise program After randomization, participants will be scheduled with a physical therapist trained in standard procedures. Treatment will include assessment of patient goals, patient education and instruction in a home program. Patient education will focus on patient-specific tasks, identified by the participant to be symptom-producing.
223501716|NCT05930470|OTHER|Magnetic Mitohormesis Therapy|The MMT device that will be used in the trial will be the QuantumTx BIXEPS Fitness and Wellness. The apparatus will provide pulsed electromagnetic fields at flux densities 1.5 mT. During the treatment period, participants will receive PEMF therapy during two ten-minute sessions each week for a total of 12 weeks. The treatment period will be preceded or followed by 12 weeks of twice-weekly sham treatments depending on randomization.
223501717|NCT02286674|OTHER|Tablet (Audio/Visual Device)|Subjects will be given a tablet to use before surgery
223501718|NCT03501277|DRUG|Alogliptin|Alogliptin tablets.
223501719|NCT03501277|DRUG|Pioglitazone|Pioglitazone tablets.
223501720|NCT03501277|DRUG|SYR-322-4833 BL|SYR-322-4833 BL FDC tablets.
223501721|NCT01015196|DRUG|Zavedos|
223501722|NCT01015196|DRUG|Cerubidine|
223501723|NCT02198131|PROCEDURE|laser therapy|Undergo pulsed dye laser
223501724|NCT02198131|OTHER|questionnaire administration|Ancillary studies
223501725|NCT01008787|BEHAVIORAL|Training|In-person 8-hour group physical activity training session (either over 1 or 2 days) and receive workbook and pedometer.
223501726|NCT01008787|BEHAVIORAL|Questionnaire|Weekly during Weeks 2-7, complete question form given at training course about conversations with study partner, 5 minutes to complete.
223501727|NCT01008787|BEHAVIORAL|Interview|Weeks 4 and 8, 30 minute phone interview about mood and physical activity.
223501728|NCT01008787|BEHAVIORAL|PA Newsletter|At Weeks 5 and 9, receive a physical activity (PA) newsletter.
223501729|NCT04056468|DRUG|Mobocertinib|Mobocertinib capsule.
223501730|NCT06319196|DRUG|Opdualag|Opdualag vial IV every 4 weeks (Q4W)
223501731|NCT06319196|DRUG|Nivolumab|Nivolumab 480mg IV Q4W
223501732|NCT00009555|DRUG|Testosterone|
223501733|NCT05906004|DEVICE|Pitch-Patch|Pitch-Patch device used for rotator cuff augmentation/ reinforcement.
223501734|NCT00401115|DRUG|MS-R001 (rapamycin)|Subconjunctival injection in various dosages
223501735|NCT00401115|DRUG|MS-R001 (rapamycin)|Intraocular injection in various dosages
223591894|NCT06385327|DRUG|ABI-5366 Placebo|Once daily tablet dosing (SAD) or weekly or monthly tablet dosing over the 29-day treatment period (MAD)
223591895|NCT07077226|DIAGNOSTIC_TEST|Polysomnography|Sleep studies (polysomnography and polygraphy) will be performed and reported according to current American Academy of Sleep Medicine guidelines
223591896|NCT07077707|OTHER|Prenatal GENEie Chatbot|Patient Educational Phone Chatbot Application for Prenatal Genetics in English \& Spanish
223591897|NCT07077707|OTHER|In-person genetic counseling|Standard in-person genetic counseling for prenatal genetics education
224192972|NCT01013207|DEVICE|Nexus (S9)|The patient will use the new Nexus (S9) CPAP for four weeks in place of their usual CPAP every night when they sleep to treat their OSA. Compliance data will be compared between four weeks on this device to the last four weeks on their current device (CPAP Pre S9). After using the Nexus (S9) CPAP for four weeks, participants will return to their current device for four weeks. Data from this post-trial period will be compared with both the Nexus (S9) four weeks, and the four weeks pre Nexus (S9) usage.
224192973|NCT01013207|DEVICE|CPAP Post Nexus (S9)|After trialling the Nexus (S9) for four weeks, patients will return to their usual CPAP. Data from the patient's usual CPAP for four weeks will be compared to data while using the Nexus (S9), and data from the patient's usual device pre trialling S9 (CPAP Pre Nexus)
224192974|NCT00835861|DRUG|Metformin|Women randomized to the Experimental arm will receive standard diet and glucose self-monitoring education. They will be initiated on Metformin 500 BID if they were medication naïve, or will be continued on their current dosage of Metformin if they were taking it prior to pregnancy. At each clinic visit fasting and one hour post prandial glucose values will be reviewed, and dosage will be titrated to a maximum of 2250mg/day to achieve target glycemic control. If glycemic control can not be achieved with Metformin as a single agent insulin will be added.
224192975|NCT00835861|DRUG|Insulin|Women randomized to the Insulin group will receive standard diet and glycemic monitoring education. They will be initiated on weight based Regular and NPH insulin at a total dosage of 0.7units/kg in the first trimester or 0.8units/kg in the second trimester divided as 2/3 of the total dosage (with 2/3 given as NPH and 1/3 given as Regular) administered before breakfast and 1/3 of the total dosage (with 1/2 given as NPH and 1/2 given as Regular)administered with dinner. At each clinic visit fasting and one hour post prandial glucose values will be reviewed, and dosage will be titrated to achieve optimal glycemic control with fasting values \<90 and one hour post prandial values \<130.
224192976|NCT06615245|BEHAVIORAL|No VR vs. immersive high tech VR|No VR vs. immersive High Tech VR
224192977|NCT06615245|BEHAVIORAL|Plausible control vs immersive High Tech VR|plausible control condition vs. immersive high tech VR
224192978|NCT00181051|DEVICE|Alaris AEP monitor|
224192979|NCT02865616|DRUG|MET-2|Microbial Ecosystem Therapeutics (MET) is a new treatment approach for debilitating recurrent Clostridium difficile infection that has been developed as an alternative to fecal transplantation.
224192980|NCT02865616|DRUG|Vancomycin|Patients will be on vancomycin to control symptoms up until the time of the treatment. Patient must hold their p.o. vancomycin for 24 hours prior to receiving the first dose.
224192981|NCT06022666|OTHER|Geriatric assessment|Geriatric assessment through PATH clinic which includes an evaluation of comorbidities, health trajectory and baseline frailty as well as conducting an in-depth discussion with the patient on how frailty stage impacts decision-making about surgery in order to co-develop a care plan.
224192982|NCT05199714|DRUG|Fiasp|Fiasp Insulin delivered in a basal-bolus manner.
224192983|NCT05199714|DEVICE|Artificial Pancreas|Medtronic insulin pump, Dexcom G6 continuous glucose sensor, tablet running the Artificial Pancreas Algorithm.
224192984|NCT05199714|DRUG|Pramlintide|Pramlintide delivered in a basal-bolus manner.
224192985|NCT05199714|DRUG|Aspart|Aspart insulin delivered in a basal-bolus manner.
224192986|NCT00608127|DEVICE|LupusorbTM|Single treatment
224205902|NCT06646003|OTHER|Evaluation of 6-minute walking distance and related factors in patients with chronic stroke|Evaluation of 6-minute walking distance and related factors in patients with chronic stroke.
223501736|NCT03084484|DIETARY_SUPPLEMENT|Kiwifruit addition to the diet|Subjects were instructed to eat two kiwifruit per day during the whole study period. No recommendation on the type of kiwifruit, brand or origin was delivered. Kiwifruit was suggested to be taken as a whole and not mixed with sugar or other ingredients. No changes to their routinely dietary habits were suggested.
223501737|NCT03084484|PROCEDURE|Non Surgical periodontal treatment|Non-surgical treatment of periodontal pockets with hand and ultrasonic instrumentation
223501738|NCT06549543|OTHER|High Intensity Laser Therapy|HILT is applied per session, with a maximum of 10.0 W, a mean of 5.7 W, a dose of 99 J/cm², and a total energy flux of 2079 J were applied over 6 minutes and 5 seconds on a 21 cm² field on the medial aspect of the knee joint.
223501739|NCT06549543|OTHER|Transcutaneous Electrical Nerve Stimulation|TENS is an analgesic modality of physical therapy
223501740|NCT06549543|OTHER|Hotpacks|Hotpacks is a thermoanalgesia modality of physical therapy
223501741|NCT06549543|OTHER|SHAM - High Intensity Laser Therapy|for control group, sham HILT was applied, with lights on but no laser beam
223501742|NCT03062839|DRUG|Melatonin 5 mg|Melatonin 5 mg taken 30 minutes before bed time
223501743|NCT05638984|DRUG|Decitabine Injection|Injection site citabine, 10 mg/ bottle, 10 mg/d, Q3W, D1-D5 intravenous infusion; Tirelizumab injection 200mg D5 intravenous infusion
223591898|NCT07078591|DRUG|Venetoclax|Given PO
223591899|NCT07078591|DRUG|Azacitidine (AZA)|Given SC
223591900|NCT07078591|DRUG|Daunorubicin|Given IV
223591901|NCT07078591|DRUG|Idarubicin（IDA）|Given IV
223591902|NCT07078591|DRUG|Cytarabine (Ara-C)|Given IV
224205903|NCT06043518|DIAGNOSTIC_TEST|MRI|Use of functional and structural MRI in both the brain and the spinal cord as well as questionnaires and clinical measures of motor function
223501744|NCT05638984|DRUG|tirelizumab|10ml: 100mg / 1 bottle, 200mg, Q3W, D1 i. v. infusion.
223501745|NCT01704859|DIETARY_SUPPLEMENT|Vitamin D3 placebo|Vitamin D placebo
223501746|NCT01704859|DIETARY_SUPPLEMENT|Fish oil placebo|Fish oil placebo
223501747|NCT01704859|DRUG|omega-3 fatty acids (fish oil)|Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid \[EPA\] and 375 mg of docosahexaenoic acid \[DHA\]).
223591903|NCT07078591|BIOLOGICAL|GPBMC infusion|HLA-mismatched donor GPBMC infusion
224192987|NCT06648408|PROCEDURE|Balett Training|The ballet training will happen twice a week for six weeks, with each session lasting 60 minutes, for a total of 12 sessions. These sessions will be held in groups of 10 to 12 children and led by experienced ballet teachers. The classes will follow a beginner-level ballet routine, introducing the kids to ballet techniques in a fun and playful way, making sure they learn the movements step by step. Each lesson will follow the same structure, allowing the children to improve their skills week after week. In addition to the group sessions, the children will be given a 10-minute daily home exercise program. This will include simple ballet exercises they learned in their first class, which they should practice on the five days when they don't have ballet sessions. The children will track their practice in a child-friendly diary designed just for them.
224192988|NCT06427382|DEVICE|Perfusion index|Perfusion index determination using non-invasive pulse oximetry
224192989|NCT05184491|DRUG|Naïve patients - ACO therapy|Naïve patients will receive classic triple therapy (amoxicillin, clarithromycin and lansoprazole) for 14 days
224192990|NCT05184491|DRUG|Naïve patients - LNDL therapy|Naïve patients will receive Levofloxacin, nitazoxanide, doxycycline and Lansoprazole for 14 days
224192991|NCT05184491|DRUG|Naïve patients - MNDL therapy|Naïve patients will receive Moxifloxacin, nitazoxanide, doxycycline and Lansoprazole for 14 days
224192992|NCT05184491|DRUG|Treatment-experienced patients- LNDL therapy|Experienced patients will receive Levofloxacin, nitazoxanide, doxycycline and Lansoprazole for 14 days
224192993|NCT05184491|DRUG|Treatment-experienced patients- MNDL therapy|Experienced patients will receive Moxifloxacin, nitazoxanide, doxycycline and Lansoprazole for 14 days
224192994|NCT00808769|DRUG|Zegerid®|capsule(20 mg omeprazole/sodium bicarbonate), single dose
224192995|NCT00808769|DRUG|Prilosec OTC®|Omeprazole-magnesium 20.6 mg, tablet, single dose
224192996|NCT03742869|COMBINATION_PRODUCT|A multi-omics analysis|A multi-omics analysis including genome-wide association study, whole exome sequencing, transcriptomics and metabolomics.
223501748|NCT01704859|DIETARY_SUPPLEMENT|Vitamin D3|Vitamin D3 (cholecalciferol), 2000 IU per day.
223501749|NCT02154659|DEVICE|24hr pH monitoring|
223501750|NCT04755478|PROCEDURE|Thoracotomy|Participants will undergo lobectomy via open thoracotomy at the discretion of the surgical team.
223501751|NCT04755478|PROCEDURE|VATS|Participants will undergo lobectomy via VATS at the discretion of the surgical team.
223501752|NCT04266977|DRUG|Dexamethasone|restrictive use of DEX, based on standardized clinical and radiological criteria.
223501753|NCT06038643|BEHAVIORAL|Motivational behavioural intervention and daily activities monitoring|Social motivation manipulation, self-transcendence daily messaging, and daily activities monitoring through accelerometry. Participants in this arm will have a study partner who receives daily feedback on the main participant's daily step count.
223501754|NCT06038643|BEHAVIORAL|Active Control|Daily activities monitored through accelerometry.
223501755|NCT02825459|BEHAVIORAL|Abstinence from e-cigarettes|Abrupt cessation for 6 days
223501756|NCT05876312|DRUG|ADX-038|siRNA duplex oligonucleotide
223501757|NCT05876312|DRUG|Placebo|Saline
223501758|NCT04136366|DRUG|ADX-2191 (intravitreal methotrexate 0.8%)|ADX-2191 (intravitreal methotrexate 0.8%) injected 13 times over 16 weeks upon completion of pars plana vitrectomy
223501759|NCT04136366|OTHER|Standard surgical care procedure|Standard surgical care performed upon completion of pars plana vitrectomy
223501760|NCT00892255|DEVICE|Microwave Ablation|Tumor tissue from the liver is inter-operatively treated with the microwave ablation device to measure the destruction of tissue.
223501761|NCT06188806|OTHER|ADDUKTOR CANAL BLOCK|All patients who will undergo adductor canal block are sedated with midazolam 0.03 mg/kg in the preoperative preparation room, after standard monitoring. After 2-3 ml skin infiltration with 2% lidocaine under sterile conditions, a block is applied under USG guidance.To verify block success, sensory function is assessed by pinprick testing along the saphenous nerve distribution by comparing the pinprick sensation to the unaffected limb.All patients are monitored in the operating room and in a sitting position, 10-20 mg (2-4 ml) of heavy marcaine (0.5% bupivacaine hydrochloride and dextrose monohydrate) is applied to the subarachnoid space by entering the L3-4 or L4-5 space with a 25-gauge Whitrace needle.For postoperative multimodal analgesia, which is routinely applied to all patients, intravenous PCA (patient controlled analgesia )tramadol and paracetamol 10 mg / kg iv (8 hours apart) will be given.
223501762|NCT06188806|OTHER|CONTROL GROUP|No nerve block procedure is applied to patients.All patients are monitored in the operating room and in a sitting position, 10-20 mg (2-4 ml) of heavy marcaine (0.5% bupivacaine hydrochloride and dextrose monohydrate) is applied to the subarachnoid space by entering the L3-4 or L4-5 space with a 25-gauge Whitrace needle.For postoperative multimodal analgesia, which is routinely applied to all patients, intravenous PCA (patient controlled analgesia) tramadol 50 mg at 10 mg / hour basal rate after loading (20 mg bolus dose + 30 minutes lock time) and paracetamol 10 mg / kg iv (8 hours apart) will be given.
223501763|NCT03496675|BEHAVIORAL|Group Music Therapy|The core intention of GMT is to meet the psychosocial needs of each person living with dementia, which in turn is thought to reduce depressive symptoms and anxiety and to stimulate overall social and emotional wellbeing. It includes active, reciprocal music making with the use of singing and musical instruments. GMT is provided by a trained music therapist, highly skilled as a musician, and registered with the appropriate professional association in his or her country.
223501764|NCT03496675|BEHAVIORAL|Recreational Choir Singing|RCS is intended to foster connectedness in a group, wellbeing, and enjoyment of music making in a group. It includes singing familiar songs and providing a familiar musical environment for participants. RCS is provided by a musician with choir leading skills.
223501765|NCT03496675|OTHER|Standard care|May include pharmacological and non-pharmacological interventions as locally available
223512152|NCT05136521|DRUG|Trazodone HCl - Contramid®|A single 300 mg dose of the test (T) and of the reference (R) products will be administered to the study subjects in two consecutive periods, according to a randomised 2-sequence cross-over design. A wash-out interval of at least 10 days will elapse between the two administrations. The two investigational products will be administered with 240 mL of still mineral water on day 1 of the two study periods, at 08:00±1 h after an overnight fasting.
223512153|NCT00005596|DRUG|cyclophosphamide|
223512154|NCT00005596|DRUG|cytarabine|
224310084|NCT03303196|DEVICE|Bihormonal Bionic Pancreas|A 4-day inpatient admission in which subjects will wear the bihormonal pancreas. The bihormonal pancreas will be placed upon admission and there will be 1 day of run-in. This will be followed by 3 days of data collection for comparison with the data obtained from the standard of care during the control admission.
223746349|NCT01277354|BEHAVIORAL|Cognitive Processing Therapy|"CPT utilizes a combination of a) exposure therapy aimed at extinguishing fear and distress induced by memories and external cues associated with the trauma, and b) cognitive behavioral techniques that address faulty thinking patterns developed to promote a sense of control over possible future traumas, but that instead perpetuate PTSD symptoms. In CPT, exposure to the traumatic memory occurs through writing and reading for periods of time determined by the client and is confined to the week of the 4th and 5th sessions. These sessions are otherwise used to identify stuck-points, i.e., distorted interpretations regarding the trauma and unrealistic beliefs regarding self and others."
223501766|NCT06527703|OTHER|no intervention|"Patients have to answer a questionnaire. The following data will be recorded:~Patient Number:~Informed Consent: ☐ yes ☐ no~Screening for eligibility Age \>/= 18 years: ☐ yes ☐ no Gender: ☐ M ☐ F Patient undergoing elective procedure: ☐ yes ☐ no~Time of arrival in the operating room \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_~Procedure:~General surgery ☐ Orthopaedic surgery ☐ Neurosurgery ☐ Cardiac surgery ☐ Vascular ☐ Urology ☐ ENT/ dental/ maxillo-facial ☐ Obstetrics and Gynaecology surgery ☐ Ophthalmic surgery ☐ Non-operating room anaesthesia ☐ Endoscopy ☐ Other \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_~Type of Anaesthesia (choose 1):~GA ☐ Sedation ☐ Regional ☐~Date and Time at which clear fluids were last consumed:\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_"
223501767|NCT04873583|DRUG|Methylprednisolone|At the time of inclusion, intravenous Methylprednisolone for 3 days. Dose: 30 mg/kg/day (max. 1000 mg/dose)
223501768|NCT04873583|DRUG|Prednisolone|"Intravenous treatment will be immediately followed by oral tapering with Prednisolone.~Oral Prednisolone, 2 weeks (week 1 and 2) Dose: 1 mg/kg/day (max 40 mg/day) Oral Prednisolone, 2 weeks (week 3 and 4) Dose: 0.5 mg/kg/day (max 20 mg/day)"
223501769|NCT05721742|OTHER|virtually administered dietitian consults for IBS patients.|Participants will receive virtual one on one consults with a dietitian who has training in the dietary management of IBS.
223501770|NCT05721742|OTHER|IBS Group Online Session|IBS online group session run by Happy Bellies Nutrition
223501771|NCT05502783|DRUG|fostamatinib|Participants will receive fostamatinib 100 mg BID for 4 weeks. On the 4-week evaluation, a) if cytopenia improves (hemoglobin =10 g/dL, platelets = 50 x 109/L), patients will continue the same dose for a total of 12 weeks, b) if refractory cytopenias persist (hemoglobin \< 10 g/dL, platelets \< 50 x 109/L), the dose will be increased to 150 mg BID. Subjects with persistent (=2 readings, 2 weeks apart) loss of hematologic response after week 5 can increase their dose to 150 mg BID until at end of the study on week 12.
223501772|NCT05813977|DEVICE|tritube|The patient is intubated with Tritube® after the removal of the conventional endotracheal tube (ETT) and Tritube® was advanced until proximal to the carina. Before starting the PDT, measurements with ATP bioluminescence-based method (3M Clean-trace®) were made by taking sample from a sterile PVC surface (10 cm2) which is held 50 cm over the operation site. After PDT with Griggs method (Portex), the measurements were repeated by taking sample from surface.
223591904|NCT07081945|DEVICE|hAM|The hAM stands for human amniotic membrane, which was used to seal inferior retinal breaks after complete vitrectomy.
223591905|NCT07081191|BEHAVIORAL|Dance|CDP was designed based on a 12-week dance curriculum, which involves 3 separate blocks of choreography of increasing complexity and intensity. According to World Health Organization, a minimum of 150 minutes of moderate intensity exercise would result in improvement in physical health, therefore, the intervention arm would involve 2 sessions of CDP, 75 minutes per session each week.
223501773|NCT00963508|DRUG|Malathion gel 0.5%|Malathion gel 0.5% applied to scalp for 30 minutes. May be repeated in 1 week if head lice are still present.
223501774|NCT00963508|DRUG|Permethrin 1% rinse (Nix Crème)|Permethrin 1% shampooed into scalp for 10 minutes. May be repeated in 1 week if head head lice are still present.
223501775|NCT03104023|PROCEDURE|Staple line inversion|A staple line inversion will be performed with a running suture of Polypropylene 2/0
223501776|NCT03104023|COMBINATION_PRODUCT|Staple line buttressing|The gastric section will be performed with a stapler with preloaded buttress material
223501777|NCT00699127|BEHAVIORAL|Lecture|Lecture of information regarding prematurity, NICU hospitalization, etc.
223501778|NCT04739709|DRUG|APP13007, 0.05%|APP13007 eye drop, 0.05%
223501779|NCT04739709|DRUG|Matching Vehicle Placebo for APP13007, 0.05%|Matching vehicle placebo eye drop
223591906|NCT07081191|BEHAVIORAL|Active Control|CDP was designed based on a 12-week dance curriculum, which involves 3 separate blocks of choreography of increasing complexity and intensity. According to World Health Organization, a minimum of 150 minutes of moderate intensity exercise would result in improvement in physical health, therefore, the active control arm would only include 60 minutes of CDP (1 session) per week to assess the effect of CDP on the cognitive and physical health of older adults.
223591907|NCT07086053|DEVICE|MyotonPRO|The MyotonPRO is a non-invasive handheld device that assesses the mechanical and viscoelastic properties of soft tissue (e.g., skin stiffness, elasticity, and relaxation time). In this study, it is used in patients with breast cancer-related lymphedema (BCRL). Each participant is evaluated by two blinded raters to determine intra- and inter-rater reliability.
223591908|NCT02708485|OTHER|Physical exercise|A 3-month walking program (3 times a week for 12 weeks) on treadmill supervised by a physiotherapist. Duration of the exercise is progressively increased from 15 min to 45 min over a 6-week period and the intensity of the exercise is moderate (a 12-13 score on Borg scale).
223501780|NCT02779296|OTHER|2-Octyl Cyanoacrylate Glue|topical
223501781|NCT05462678|BEHAVIORAL|Cognitive Rehabilitation|Each patient performed two weekly sessions of 45 minutes each, for 12 weeks
223501782|NCT05462678|BEHAVIORAL|Combined Rehabilitation|Each patient performed one session per week (45 minutes) of CR and one session per week of traditional MR training for 12 weeks.
223501783|NCT05462678|BEHAVIORAL|Motor Rehabilitation|Each patient performed two weekly sessions45 minutes each, for a total of 12 weeks.
223746350|NCT01277354|BEHAVIORAL|Waitlist Placebo|Behavioral ratings are conducted by a blind rater.
224310085|NCT05446012|DIAGNOSTIC_TEST|thyroid function tests|blood sample for thyroid function tests (TSH,T3,T3,Anti peroxidase antibody, anti thyroglobulin antibody)
224192997|NCT01855594|DRUG|Lithium Carbonate|250 mg/tablet, 6 weeks course of oral administration
224192998|NCT01855594|DRUG|Placebo|placebo tablet, 6 week course of oral administration
224192999|NCT04547829|DRUG|pegylated recombinant human granulocyte-colony stimulating factor|The dosage was determined according to the patient's weight, 100 UG / kg each time; The method of administration: subcutaneous injection; The time of administration: 24-48 hours after the end of chemotherapy, once in each chemotherapy cycle.
224193000|NCT03444129|BEHAVIORAL|Healthy eating workshop and interactive health game|The intervention sessions will be weekly for 6 weeks and will involve participation in health education workshop and interactive health game. Sessions may last up to 2 hours and will be held at designated times/days at a Chicago Church.
224193001|NCT03444129|BEHAVIORAL|Healthy eating workshop|The intervention sessions will be weekly for 6 weeks and will involve participation in health education workshop. Sessions may last up to 2 hours and will be held at designated times/days at a Chicago Church.
224193002|NCT04766346|OTHER|Fortified Cow's Milk-Based Oral Nutritional Supplement|The NS is a fortified cow's milk-based product provided in powdered form that provides the appropriate amount of energy and protein to promote growth in children.
224193003|NCT03638648|DRUG|Capecitabine|Capecitabine 2500mg/m2/day, d1-d14, every 3 weeks a cycle for 8 cycles
224193004|NCT01541644|DEVICE|Acupuncture|Participants will receive acupuncture treatment twice weekly for 2 weeks, then once per week for 4 weeks, and then biweekly for 4 weeks.
224193005|NCT01551238|DIETARY_SUPPLEMENT|Differences in protein content of meals|Differences in protein content (energy percent) of meals
224193006|NCT01551238|DIETARY_SUPPLEMENT|Differences in protein content of meals|Differences in protein content (energy percent) of meals
224193007|NCT02389621|DRUG|Lusutrombopag|Tablets for oral administration
223501784|NCT01276652|BEHAVIORAL|Environmental modification|Environmental modification consists of nursing-related efforts to optimize daytime light exposure, to minimize nighttime light and noise exposure, and to batch nursing care at night.
223501785|NCT00334919|BEHAVIORAL|Diet (Anti-Inflammatory or standard diabetic diet)|6 weeks standard ADA diet, then randomized to either ADA or antiinflammatory (AI) diet for 6 weeks
223501786|NCT02226900|PROCEDURE|Hybrid Revascularization|Off-pump LIMA connected to the left anterior descending artery followed by percutaneous coronary intervention with drug eluting stents to the other territories.
223501787|NCT02226900|PROCEDURE|Conventional Coronary Artery Bypass Surgery|On pump coronary artery by-pass surgery
223501788|NCT06241443|OTHER|hybrid simulation|"During the hybrid simulation, a student and a standardized patient participated. The patient wore a wearable pregnancy model. Before the start of the Natural Birth Approach Scenario, a pre-briefing session was conducted. The student's performance during the simulation was recorded on video, and each simulation lasted approximately 30 minutes. After the simulation, a debriefing session was held with the student, and feedback was given. Scales were used to evaluate the implementation of the practices."
223501789|NCT06241443|OTHER|video-modeling|"The students in the group had the opportunity to learn through an educational video that followed the Natural Birth Approach Scenario. Afterward, they put their knowledge into practice and were evaluated using the Birth Approach Clinical Skills Guide. A feedback session followed the practice session. Finally, they were assessed using scales to measure their performance."
223501790|NCT05151614|DRUG|Colchicine 0.5 MG|Colchicine 0.5 mg tab 1x2 for 1 week then o.5mg tab. 1x1 for another week + the standard therapy ( total duration of colchicine 14 days).
223501791|NCT03237754|DEVICE|tDCS device from neuroConn|weak electrical direct current stimulation
223501792|NCT02373072|DRUG|PF-06649751|Subjects completing all three treatment periods will be administered two doses. Doses: 0.75mg, 1.5mg, 3mg, 6mg, 9mg. Tablets in the form of 0.25mg or 1 mg.
223501793|NCT02373072|DRUG|Trimethobenzamide Hydrochloride|300mg TID, Capsules. Optional in both Cohorts.
223501794|NCT02373072|DRUG|Placebo|Subjects completing all three treatment periods will be receiving placebo once.
223501795|NCT03233217|BIOLOGICAL|QIV-HD by IM|IM, injected into the upper arm (deltoid area)
223501796|NCT03233217|BIOLOGICAL|QIV-SD by SC|SC, injected into the upper arm (posterior region)
223501797|NCT03233217|BIOLOGICAL|QIV-HD by SC|SC, injection into the upper arm (posterior region)
223501798|NCT05920226|DEVICE|pacemakers implantation and assessment of cardiac function and cardiac fibrosis|"150 patients will be implanted with pacemakers. In addition to the echocardiography, contrast-enhanced cardiac MRI and peripheral venous blood sampling for myocardial fibrosis markers, the tests described above will be repeated at 1 (V1), 12 (V2), 24 (V3) months after inclusion. Echocardiography and peripheral venous blood sampling for myocardial fibrosis markers detection will be repeated to all patients before pacemakers implantation and after 6,12 and 24 months of observation period. Contrast-enhanced cardiac magnetic resonance imaging (MRI) will be performed before pacemaker implantation and 6 months after surgery.~In addition, pacemakers programming data will be evaluated after 1, 12, 24 months after inclusion in the study (atrioventricular delay, percentage of ventricular stimulation, episodes of high atrial frequency, fibrillation/atrial flutter, ventricular tachycardia)."
223501799|NCT05920226|DIAGNOSTIC_TEST|assessment of cardiac function and cardiac fibrosis|The patients who do not require a pacemaker placement will undergo diagnostic testing such as echocardiography, contrast-enhanced cardiac MRI and peripheral venous blood sampling for myocardial fibrosis markers.
223501800|NCT02530242|DEVICE|End-tidal Carbon Monoxide Subjects|ETCO monitor will be used to measure CO levels in subjects and controls.
223501801|NCT02530242|DEVICE|End-tidal Carbon Monoxide Controls|ETCO monitor will be used to measure CO levels in subjects and controls.
223501802|NCT03436927|OTHER|Nintendo Wii Fit Balance exercises|Nintendo Wii Fit' training protocol consisted of 'Penguin Slide', 'Table Tilt', 'Ski Slalom', 'Heading' and 'Balance Bubble' games that selected from the Wii Fit Plus balance games section
223501803|NCT03436927|OTHER|Balance Trainer Balance Exercises|Balance Trainer' training protocol consisted of 'Collect Apples', 'Outline', 'Paddle War' and 'Evaluation of Movement' games which were included in the device software and allowed the patients to done balance exercises in different directions.
224193008|NCT02389621|DRUG|Placebo|Tablets for oral administration
224205904|NCT06043518|DIAGNOSTIC_TEST|MRI|Use of functional and structural MRI in both the brain and the spinal cord and questionnaires.
224310086|NCT06453135|DRUG|Eculizumab|On the Day 0, participants received a single dose of eculizumab before the transplant surgery: 900 mg (blood type antibody titer ≥ 1:64 and/or body weight ≥ 60 kg) or 600 mg (blood type antibody titer \< 1:64 and body weight \< 60 kg). Plasmapheresis was not planned. When participants developed AMR, they may receive additional dose of eculizumab.
224193009|NCT02471794|BEHAVIORAL|Personalized Health Planning Shared Medical Appointment|The PHP SMA group will combine personalized health planning with a modified version of the standard shared diabetes medical appointment. Modifications include: a self-assessment of health status, greater emphasis on a collaborative patient-provider health goal-setting process, a plan to meet goals, a mindfulness practice included in each session, and the creation of a 'personalized health plan' participant notebook for each individual to document health goals and track progress to review at each session. The participant notebook also includes educational handouts and worksheets to complement the educational curriculum
224193010|NCT04158466|DEVICE|Kalifilcon A Daily Disposable Contact Lenses|Contact lens
224193011|NCT04158466|DEVICE|Biotrue ONEday Daily Disposable Contact Lenses|Contact lens
223501804|NCT00283959|DRUG|migalastat HCl|
223501805|NCT05993143|DRUG|Ivermectin|Round and white tablets
223501806|NCT05993143|DRUG|Placebo|Round and white tablets
223501807|NCT05225831|BIOLOGICAL|Autologous CD19/CD22 Chimeric Antigen Receptor T-cells|A single infusion of CD19 and CD22 CAR-T cells.
223501808|NCT05225831|DRUG|Cyclophosphamide,Fludarabine|Given
223501809|NCT03275922|DRUG|Placebo ZNS|Placebo Zolmitriptan Nasal Spray
223501810|NCT03275922|DRUG|ZNS|Zolmitriptan Nasal Spray
224193012|NCT05072431|OTHER|SVVR training program|The SVVR training program is consisted of five scenarios with tasks. Before the SVVR training implementation, the research team provided 10-minute orientation session to introduce the purpose of the training. The 3D VR professional taught the participants how to wear the 3D VR helmets and select the VR scenes, so that the participants could practice multiple times.
223501811|NCT05591755|DRUG|Brimonidine Tartrate 0.025%/ Ketotifen Fumarate 0.035% Ophthalmic Solution|Brimonidine Tartrate 0.025%/ Ketotifen Fumarate 0.035% Ophthalmic Solution
223501812|NCT05591755|DRUG|Ketotifen fumarate ophthalmic solution 0.035%|Ketotifen fumarate ophthalmic solution 0.035%
223501813|NCT05591755|DRUG|Brimonidine tartrate ophthalmic solution 0.025%|Brimonidine tartrate ophthalmic solution 0.025%
223501814|NCT05591755|DRUG|Experimental: Vehicle ophthalmic solution|Experimental: Vehicle ophthalmic solution
223501815|NCT04441398|DRUG|Nitazoxanide|Subjects will receive nitazonanide 600 mg TID for 7 days. Treatment can be extended for another 7 days at Investigators discretion.
223501816|NCT04441398|DRUG|Placebo|Subjects will receive placebo TID for 7 days. Treatment can be extended for another 7 days at Investigators discretion.
223501817|NCT03535688|DRUG|D-cycloserine|200 mg twice daily
223501818|NCT03535688|DRUG|Placebo|twice daily
223501819|NCT05175365|BEHAVIORAL|Dance|Each session consists of a 60-minute dance class taught by a professional dancer. Dance classes begin with a seated warm-up with various coordination, rhythm, range of motion, memorization and coordination exercises. The level of difficulty of the exercises increases as the sessions progress. Balance is also an important part of training as well as the feeling of being part of a group, of interacting with each other. The hour ends with stretching in a sitting position.
223501820|NCT01922193|DRUG|Highly Purified Urofollitropin|for injection
223501821|NCT01922193|DRUG|Recombinant Human Follitropin Alfa|for injection
223501822|NCT00433290|DRUG|Duloxetine|duloxetine 30 mg every day (QD), by mouth (PO) for 1 week, then duloxetine 60 mg QD, PO for 6 weeks, followed by duloxetine 60 mg QD, PO for 6 weeks for responders or duloxetine 120 mg QD, PO for 6 weeks for non-responders
224193013|NCT06133465|PROCEDURE|Surgical wide local excision|Surgical excision of breast carcinoma
224193014|NCT06133465|PROCEDURE|Cavity shaving|Cavity shaving of resection margins to guarantee oncological safety
223501823|NCT00433290|DRUG|Placebo|placebo every day (QD), by mouth (PO) for 13 weeks
223501824|NCT00583544|DRUG|TC-2216|Multiple ascending dose groups will be explored.
223501825|NCT01060956|OTHER|reporting of two different bacteria in urine culture|reporting of two different bacteria in urine culture
223501826|NCT01060956|OTHER|"reporting mixed growth on urine culture"|"reporting mixed growth on urine culture"
223501827|NCT00308347|DRUG|MK0954, losartan / Duration of Treatment: mean 3.4 years|
223501828|NCT00308347|DRUG|Placebo / Duration of Treatment: mean 3.4 years|
223501829|NCT00554723|DRUG|NeuroAid|4 capsules 3 times daily, for three months
223501830|NCT00554723|DRUG|NeuroAid matched Placebo|NeuroAid matched Placebo, 4 capsules 3 times daily, for three months
223501831|NCT03217097|DRUG|Oxaliplatin-based chemotherapy|"The oxaliplatin-based group will receive gemox (gemcitabine-oxaliplatin, 1x/2 week); alternatively folfox (5 fluorouracil-leucovorin-oxaliplatin, 1x/2 week) or capox (capecitabine-oxaliplatin, 1x/3 week)."
223501832|NCT03217097|DRUG|Alkylating-based chemotherapy|"The alkylating-based group will receive CapTem regimen (capecitabine and temozolomide, /4 week), alternatively LV5FU2 (folinic acid-5 fluorouracil)-dacarbazine (1x/2 week) or LV5FU2 (folinic acid-5-fluorouracil)-streptozotocine (1x/2 week)."
223501833|NCT00004055|BIOLOGICAL|filgrastim|
223501834|NCT00004055|DRUG|paclitaxel|
223501835|NCT00004055|DRUG|topotecan hydrochloride|
223501836|NCT03875417|PROCEDURE|liver resection|resection of one or more HCC nodules within the liver
223501837|NCT03875417|PROCEDURE|Thermic ablation|ablation of HCC nodule through a percutaneous needle, by using radiofrequency or microwaves
223501838|NCT03875417|PROCEDURE|Transcatheter arterial chemoembolization|embolization of HCC nodule via drug-eluted microbeads.
223512155|NCT00005596|DRUG|daunorubicin hydrochloride|30 mg/m2 IV Day 1 of weeks 16, 17, and 18. Give Week 16 dose if ANC ≥ 500/μL and platelets ≥ 75,000/μL. Continue to give during Weeks 17 and 18, even in the face of uncomplicated myelosuppression
223512156|NCT00005596|DRUG|dexamethasone|6 mg/m2/day divided BID for 7 days during weeks 8 and 17.
223512157|NCT00005596|DRUG|leucovorin calcium|5 mg/m2/dose of leucovorin will be given PO q12h x 2 doses beginning 48 hours after the start of the MTX.
223512158|NCT00005596|DRUG|mercaptopurine|50 mg/m2 dose po qhs Weeks 5 through 13 (total 9 wks) and from Week 24 until the end of consolidation. Only hold for uncomplicated myelosuppression, only if IV MTX course is delayed, until ANC \> 500/μL and platelets \> 75,000/uL
224193015|NCT06133465|PROCEDURE|Excision margin surgical clearance|Surgical clearance of involved and/or closed excision margins
223746351|NCT03160833|DRUG|HMPL-453|oral administrative
224193016|NCT06133465|RADIATION|Adjuvant Radiotherapy|Adjuvant radiotherapy
224193017|NCT06133465|BIOLOGICAL|Adjuvant Hormone Therapy|Adjuvant hormone therapy
223746352|NCT05282550|DRUG|Trazodone|50mg of trazodone administered for 4 weeks.
223746353|NCT05282550|DRUG|Placebo|Placebo administered for 4 weeks.
223746354|NCT00234195|DRUG|bupropion extended release (Wellbutrin XL)|
223746355|NCT02356783|DEVICE|Pedometer|Wireless pedometer
223746356|NCT01365507|DRUG|insulin degludec/insulin aspart|Insulin degludec/insulin aspart injected subcutaneously (under the skin) once daily. Dose individually adjusted.
223746357|NCT01291056|OTHER|Placebo|Each participant will take assigned medication (clomiphene citrate 50mg or placebo) on days 3-7 of her menstrual cycle.
223746358|NCT01291056|DRUG|Clomiphene|Each participant will take assigned medication (clomiphene citrate 50mg or placebo) on days 3-7 of her menstrual cycle.
224193018|NCT02999646|OTHER|MVX-ONCO-1|Autologous cells: 1 vial containing 4x10\^6 irradiated tumor cells Capsules: 2 biocompatible capsules loaded with 8x10\^5 MVX-1 cells
223512159|NCT00005596|DRUG|methotrexate|"IV: 1 gm/m2 given as a 200 mg/m2 bolus over 20 min followed by 800 mg/m2 over 23.6 hours given during Weeks 7, 10, 13, 16, 19, and 22.~IT: Doses by age, Weeks 7, 10, 13, 16, 19 and 22."
223512160|NCT00005596|DRUG|pegaspargase|2,500 IU/m2 will be given IM x 1 on Days 2,3,or 4 of Week 16; \> or = 1 day after the IT MTX
224193019|NCT05416034|DEVICE|Use of the ATLAS 2025 exoskeleton at home|Each participant will use the ATLAS 2025 exoskeleton at their homes, 5 days a week during a period of two months, for walking with the device and performing motor activities in 60 minutes duration sessions..
224193020|NCT02246855|BIOLOGICAL|Gammaplex® (Human Normal Immunoglobulin)|
224193021|NCT02469402|DIETARY_SUPPLEMENT|Standard infant formula|
224193022|NCT02469402|DIETARY_SUPPLEMENT|Protein reduced alpha-lactalbumin formula, with higher levels of alpha-lactalbumin|
224193023|NCT05367895|BIOLOGICAL|COVID-19 Vaccine (Vero Cell), Inactivated|"Form: CoronaVac® is a milky-white suspension. Stratified precipitate may form that can be dispersed by shaking.~Presentation: Each vial contains 0.5 mL (a single dose) and contains 600SU of inactivated SARS-CoV-2 virus antigen.~Administration and schedule: Two doses with an interval of 21 days should be administered for primary immunization. 0.5 mL per dose.~Route: IM in the deltoid region of the upper arm after shaking the vial well before use."
224193024|NCT06346743|DRUG|Fenofibrate|Single dose of Fenofibrate will be given at dose of 10mg/Kg along with phototherapy for 24 hours before next blood sampling
224193025|NCT06346743|DEVICE|Phototherapy|only phototherapy will be given for 24 hours before next blood sampling
224193026|NCT01002118|DRUG|Omega-3 Acid Ethyl Esters|1 gram capsules Omega-3 Acid Ethyl Esters for a total of 4 grams (4 capsules) per day for 16 weeks
223512161|NCT00005596|DRUG|thioguanine|60 mg/m2 po qhs during Weeks 20 and 21 (total 14 days). Start week 20 when ANC \> or = 500/ul and platelets \> or = 75,000/uL. Continue to give all 14 doses despite uncomplicated myelosuppression.
224193027|NCT01002118|DRUG|Placebo|4 capsules each day for 16 weeks
223512162|NCT00005596|DRUG|vincristine sulfate|1.5 mg/m2 IV on Day 1 of Weeks 8, 9, 17 and 18 (max 2 mg)
223512163|NCT03958487|BEHAVIORAL|Video feedback, Feedback online|The treatment phase have 3 timepoints, 1 the patient is asked to perform an ADL alone, 2. Video feedback is administrated. This requires the participant to watch its own videotaped performance with the therapist while the therapist encourage the participant to identify errors, areas of strength, and to suggest strategies to solve errors in future sessions. 3. feedback online will be provided by the therapist on participant performance. The therapist will wait for the patient to detect and correct their error spontaneously. If the patient does not detect it, the therapist provides unspecified/specific help. This strategy is based on previous work (Schmidt, et al 2013, Ownstorth et al. 2010). The novelty of our procedure is the inclusion of distracting and conflicting/problem solving situations to be inhibited, detected and solved. Feedback will focus on these situations. The level of monitoring requirements will be adjusted to participants performance using a changing criterion design.
223512164|NCT05999851|DEVICE|Arterial applanation tonometry|Arterial applanation tonometry will be performed at the carotid and femoral level by the PulsePen device (Software WPulsePen version 2.3.1, DiaTecne, Milan, Italy), while the subject is lying in the horizontal position and after 5 minutes of rest.
223512165|NCT05999851|DEVICE|In vivo endothelial glycocalyx measurement|The in vivo microscopy (GlycoCheck system) is performed in the sublingual capillaries during the morning, with the participant sitting on a chair. The sublingual capillaries are visualized using an SDF video microscope (Capiscope handheld, KK Research technology Ltd).
223512166|NCT05999851|DIAGNOSTIC_TEST|Serum markers of angiogenesis and endothelial dysfunction|ELISA assays to measure serum circulating markers of angiogenesis and endothelial dysfunction (ANG-1, ANG-2, ET-1, ICAM-1 and VCAM-1).
223512167|NCT05999851|DIAGNOSTIC_TEST|Blood chemistry test|Immunochemistry analysis of serum levels of uric acid, total cholesterol, LDL-cholesterol, HDL-cholesterol, Triglycerides, Lipoprotein (a)
223512168|NCT05999851|DIAGNOSTIC_TEST|Serum xanthine oxidase activity|Serum xanthine oxidase (XO) activity will be assessed in blood samples measuring the ability of XO to produce uric acid
223512169|NCT06238700|DIETARY_SUPPLEMENT|pregnenolone|Pregnenolone is an endogenous steroid available in the US and elsewhere as an orally administered over-the-counter supplement.
223512170|NCT06238700|OTHER|placebo|Placebo pills are identical-appearing capsules containing cellulose
223512171|NCT03768674|OTHER|Assessment of diagnoses, functioning and health services|Systematic differential diagnostics, assessment of psychosocial and personality functioning and treatment/ health services
223512172|NCT04338620|DRUG|camrelizumab、albumin-bound paclitaxel and platinum|Experimental Group：camrelizumab、albumin-bound paclitaxel and platinum. Camrelizumab will be administered as a 30-minute IV infusion Q3W at a dose of 200mg on day1 of each cycle. Albumin-bound paclitaxel will be administered as a 30-minute IV infusion Q3W at a dose of 130 mg/m2 on day1 and day8 of each cycle. Platinum included Cisplatin/carboplatin/Nedaplatin
223512173|NCT04338620|DRUG|albumin-bound paclitaxel and platinum|"Control group：albumin-bound paclitaxel and platinum. Albumin-bound paclitaxel will be administered as a 30-minute IV infusion Q3W at a dose of 130 mg/m2 on day1 and day8 of each cycle.~Platinum included Cisplatin/carboplatin/Nedaplatin"
224074911|NCT03920670|DEVICE|ToFscan (TS)|ToFscan is a nerve stimulator module used for the measurement of neuromuscular transmission via accelerometry. ToFscan was developed by Drager Technologies, Canada, and it uses a three-dimensional piezoelectric sensor that attaches to the thumb via a hand adapter to measure acceleration in multiple planes (Murphy et al, 2018). Following simultaneous ulnar nerve stimulation on each arm, the response of the adductor pollicis will be measured.
223501839|NCT01483651|DRUG|Glucagon|The first dose of glucagon will be delivered approximately one hour after infusion of IV insulin has started. The subsequent three doses will be delivered every two hours. The dosage will depend on the IV insulin infusion (50 units regular insulin in 499.5 mL 0.9% saline): Study 1) insulin 0.01 units/kg/hour and glucagon doses (ug): 10,25,45,70; Study 2) insulin 0.02 units/kg/hr and glucagon doses (ug): 25,45,70,100; Study 3) insulin 0.04 units/kg/hr and glucagon doses (ug): 45,70,100,135; Study 4) insulin 0.08 units/kg/hr and glucagon doses (ug): 70,100,135,175. Insulin levels and glucagon doses will be randomized. Glucagon will be reconstituted with 10 mL of sterile water and administered subcutaneously.
223501840|NCT01483651|DRUG|Insulin|Insulin was administered at a low, medium or high infusion rate. The intervention sequence was randomly pre-determined for all participants.
223591909|NCT07077915|OTHER|Osseodensification burs|Densah burs are osseodensification burs used to condense bone and prepare dental implant site, unlike conventional technique which cuts and removes the bone
223591910|NCT07077915|OTHER|Conventional burs|Preparation of dental implant site by the Conventional technique using Conventional burs that are subtractive
223591911|NCT06027346|BIOLOGICAL|Bio-008|The subjects in each dose group received the corresponding dose of BIO-008 monotherapy, administered intravenously (ivd) for a duration of 0.5 to 3 hours (the researchers can adjust the administration time according to the patient's tolerance). If there is an infusion reaction, the infusion can be suspended and completed within 12 hours. Administer on the first day of each cycle, once every 3 weeks (1 cycle, i.e. 21 days) (Q3W) until the criteria for termination of treatment or withdrawal from the study are met, whichever occurs first.
223591912|NCT07088146|DRUG|Dexamethasone|Immediately after sub-arachnoid block 8mg of Dexamethasone will be administered intravenously
223591913|NCT07088146|DRUG|Placebo|2ml of Normal saline will be given intravenously immediately after administration of spinal anesthesia
224074912|NCT03436615|DRUG|SB206 4%|Twice daily
224074913|NCT03436615|DRUG|SB206 8%|Twice daily
224074914|NCT03436615|DRUG|SB206 12%|Once or twice daily
224074915|NCT03436615|DRUG|Placebo|Once or twice daily
224074916|NCT02271412|DRUG|LY03005|LY03005 is a new investigational pro-drug of desvenlafaxine formulated as extended-release oral tablets for the treatment of major depressive disorder.
224074917|NCT02271412|DRUG|Placebo|Placebo
224074918|NCT03341169|DRUG|N(2)-L-Alanine L-Glutamine dipeptide|:Intravenous infusion of N (2) -L-alanyl-L-glutamine(mixed with normal saline, ratio 1:1) at the dose of 0.25g/kg(body weight) for 8 hours before induction of anesthesia(rate=2.5\*weight/8 ml/h) and administration another 0.25g/kg(body weight) of N (2) -L-alanyl-L-glutamine(mixed with 8.5% amino acid solution, ratio 1:5) into the central vein for 10 hours after induction of anesthesia(rate=0.75\*weight ml/h)
224074919|NCT03341169|DRUG|placebo (0.9% NaCl (normal saline))|Intravenous infusion of 0.9% NaCl for 8 hours before induction of anesthesia(rate=2.5\*weight/8 ml/h) and administration 0.9% NaCl into the central vein for 10 hours after induction of anesthesia(rate=0.75\*weight ml/h)
224074920|NCT03436186|OTHER||no intervention
224074921|NCT00401063|DEVICE|Acupuncture|Acupuncture treatment twice a day for eight weeks
224074922|NCT03797469|DIETARY_SUPPLEMENT|Vitamin B3|3 tablets of 1000 mg each will be administered orally.
224074923|NCT03797469|DIETARY_SUPPLEMENT|Pyruvate|2 tablets of 1500 mg each will be administered orally.
224074924|NCT03797469|DIETARY_SUPPLEMENT|Placebo|Tablets will look identical to the supplements and the number of tablets will equal the amount of supplements provided.
224074925|NCT04610528|DRUG|U3 1402|6.4 mg/kg dose
224074926|NCT04610528|DRUG|U3 1402|5.6 mg/kg dose
224074927|NCT06186141|DRUG|Morphine|Intravenous (IV) delivery via Patient Controlled Analgesia device (PCA) 20mcg/kg bolus to a maximum of 1mg with a 5-minute lockout
224074928|NCT06186141|DRUG|Oxycodone|Intravenous (IV) delivery via Patient Controlled Analgesia device (PCA) 20mcg/kg bolus to a maximum of 1mg with a 5-minute lockout
224074929|NCT04445883|BEHAVIORAL|Feeding Assistance|Patients will be receiving assistance during mealtimes. This includes assistance by opening packages, listing/explaining the food products on the tray, providing encouragement and companionship during mealtimes and directly feed patients.
224074930|NCT06282575|DRUG|Zanidatamab|Administered intravenously (IV)
224074931|NCT06282575|DRUG|Cisplatin|Administered intravenously (IV)
223501841|NCT00571090|PROCEDURE|Thyroid ultrasonography|Ultrasound-guided thyroid fine-needle aspiration biopsy
224074932|NCT06282575|DRUG|Gemcitabine|Administered intravenously (IV)
224074933|NCT06282575|DRUG|Pembrolizumab|Administered intravenously (IV)
224074934|NCT06282575|DRUG|Durvalumab|Administered intravenously (IV)
224074935|NCT06839287|OTHER|Interpersonal psychotherapy-based counseling|The first data from the individuals in the experimental and control groups will be collected after the first interview. Data will be collected from the individuals to whom interpersonal relationship therapy techniques are applied after the 8th session by face-to-face interviews. In addition, if the individuals in the experimental group have questions about psychotherapy, they will be answered. The control group will be verbally informed with the data collection form and chronic disease adaptation and depression scales and will continue to receive routine care. Data will be collected by face-to-face interviews with the control group after the first interview and 8 weeks later when they come to the dialysis center. Follow-up data of the participants will be collected again at the 3rd month after the last interview.
224074936|NCT06263491|DRUG|Rituximab|Given by PO
224074937|NCT06263491|DRUG|Pirtobrutinib|Given by PO
224074938|NCT05832008|BEHAVIORAL|Patient Nudge|Brief persuasive messaging to increase awareness about the importance of annual lung cancer screening and completion of recommended follow-up sent to patients via text message.
224074939|NCT05832008|BEHAVIORAL|Clinician Nudge|EHR-based Prompts - an pended order and message that alerts a clinician if a patient is due for screening or diagnostic follow-up.
224074940|NCT05226624|BEHAVIORAL|Rooming-in care|Implementation of Rooming-in model of care
224310087|NCT03167268|DRUG|Lycopene|
224193028|NCT00661037|DEVICE|Implantable defibrillator|Implantable defibrillator to reduce ventricular arrhythmias via shock.
224193029|NCT00661037|DEVICE|Implantable defibrillator|Implantable defibrillator to reduce ventricular arrhythmias via shock.
224193030|NCT01564680|OTHER|placebo|normal saline
224193031|NCT01564680|DRUG|Paracetamol|IV paracetamol infusion
224193032|NCT01564680|DRUG|Lornoxicam|16 mg at skin closure and 8 mg 12 hours postoperative
224310088|NCT03167268|OTHER|Placebo|
223746359|NCT03047642|DIAGNOSTIC_TEST|Biomarker assay|There is no intervention on the patients but biomarker assays are being evaluated for their performance to distinguish bacterial infection from non-bacterial infections in febrile patients
224074941|NCT05226624|BEHAVIORAL|Baseline standard of care|Baseline standard of care
223501842|NCT00335075|DRUG|Temozolomide|Temozolomide orally for 5 consecutive days (Day 1 through Day 5) every 28 days, at a dose of 150 mg/m2/day for subjects previously treated with chemotherapy, or 200 mg/m2/day for subjects who have not received previous chemotherapy.
223501843|NCT00335075|DRUG|Semustine|Semustine orally once every 28 days at a dose of 150 mg/m2/day.
223501844|NCT04248179|DRUG|Ropivacaine injection|Ropivacaine 5mg/ml
223501845|NCT04248179|DRUG|Saline 0.9%|Saline 0.9%
223501846|NCT04248179|DRUG|Sufentanil and PONV prophylaxis|30 minutes prior to emergence 0.2 μg/kg total body weight Sufentanil IV and 1 gram of paracetamol IV (if 6hrs since preoperative medicine) and 4 mg ondansetron IV (PONV prophylaxis) will be administered.
223501847|NCT03876353|OTHER|Floss|All participants will have half of their mouth flossed. Each participant will act as their own control.
223501848|NCT01989273|DEVICE|Ultrasound of inferior vena cava|
223501849|NCT00500890|DRUG|Carboplatin|350 mg/m\^2 by vein, Over 2 Hours x 2 Days
223501850|NCT00500890|DRUG|Cyclophosphamide|1 g/m\^2 by vein, Over 1 Hour x 2 Days
223501851|NCT00500890|DRUG|Etoposide|100 mg/m\^2 by vein, Over 1 Hour x 5 Days
223501852|NCT00500890|DRUG|Vincristine|1.5 mg/m\^2 (by vein)IV Push Over 15 Minutes On Day 5
224074942|NCT06428357|DIETARY_SUPPLEMENT|Recombinant Bovine Lactoferrin|Participants will take a single dose equal to 3 capsules daily before a meal for 4 weeks. Meal timing is not controlled.
224074943|NCT06428357|DIETARY_SUPPLEMENT|Bovine Milk-Derived Lactoferrin|Participants will take a single dose equal to 3 capsules daily before a meal for 4 weeks. Meal timing is not controlled.
224074944|NCT06428357|DIETARY_SUPPLEMENT|Placebo|Participants will take a single dose equal to 3 capsules daily before a meal for 4 weeks. Meal timing is not controlled.
224074945|NCT04938661|OTHER|Center-Based Cardiac Rehab|36 center-Based Cardiac Rehab Sessions
224074946|NCT04938661|OTHER|mHealth|Mobile Health Platform
224074947|NCT04938661|OTHER|Home-Based Cardiac Rehab|Encouraged to exercise 3 times per week at home
224074948|NCT05621564|DRUG|pre-operative therapy|pre-operative therapy includes pre-operative chemotherapy, radiation, endocrine therapy, target therapy and other anti-tumor therapy
224074949|NCT04507737|OTHER|Rapid Response Team Composition_ ICU Nurse|In case of deterioration a Rapid Response Team may be activated. We will be examining the composition of the teams alternating between a MET or a CCOT.
224074950|NCT04253483|RADIATION|High-Dose Rate Brachytherapy|Undergo HDR
224074951|NCT04253483|OTHER|Quality-of-Life Assessment|Ancillary studies
224074952|NCT04253483|OTHER|Questionnaire Administration|Ancillary studies
224074953|NCT04253483|PROCEDURE|Stereotactic Ablative Radiotherapy|Undergo SABR
224074954|NCT05838729|DRUG|RiMO-301|"A single dose of RiMO-301 will be administered via an intratumoral injection.~PD-1 inhibitor (pembrolizumab or nivolumab) will be administered via a 30-minute intravenous infusion until disease progression or unacceptable toxicity.~Patients will receive hypofractionated radiation in 5 fractions."
224074955|NCT06660225|DEVICE|Medtronic Percept Deep Brain Stimulation Therapy [Sham Control Stimulation]|Deep brain stimulation is a surgery where bilateral electrodes are precisely inserted to specific brain targets affected by a disease state, and electrical stimulation is applied to achieve symptom relief. DBS is a reversible and adjustable treatment option and is now a preferred alternative to neurosurgical ablation. Sham Stimulation=DBS OFF
224074956|NCT06660225|DEVICE|Medtronic Percept Deep Brain Stimulation Therapy [Therapeutic stimulation]|Deep brain stimulation is a surgery where bilateral electrodes are precisely inserted to specific brain targets affected by a disease state, and electrical stimulation is applied to achieve symptom relief. DBS is a reversible and adjustable treatment option and is now a preferred alternative to neurosurgical ablation. Therapeutic Stimulation= DBS ON
224074957|NCT04820309|DRUG|Xanomeline and Trospium Chloride Capsules|Oral xanomeline 50 mg/trospium 20 mg BID on days 1-2 followed by xanomeline 100 mg/trospium 20 mg BID on days 3-7. The dose is increased to xanomeline 125 mg/trospium 30 mg BID on days 8-364 unless the subject is experiencing adverse events from the xanomeline 100 mg/ trospium 20 mg dose. Subjects who were increased to xanomeline 125 mg/trospium 30 mg will have the option to return to xanomeline 100 mg/ trospium 20 mg depending on clinical response and tolerability. Re-escalation to 125/30 BID or re-titration in cases in which the subject has been off KarXT for a longer period of time (at least a week) is allowed and will require a discussion between the principal investigator and the medical monitor.
224074959|NCT00223899|GENETIC|VCL-IM01 (encoding IL-2) with Electroporation|IL-2-encoding plasmid formulated in phosphate-buffered saline at 0.5 mg/mL, 1.5 mg/mL, and 5.0 mg/mL (VCL-IM01) intratumorally injected and followed by electroporation with Inovio MedPulser® 1.0 cm array with needles up to 3 cm long (one 6-pulse cycle per tumor).
224074960|NCT05632770|BEHAVIORAL|Stepped Collaborative Care|Case management, behavioral intervention elements, psychopharmacologic medication recommendations and 24/7 cell phone coverage for 6 months post-injury.
224193033|NCT01694927|PROCEDURE|Autologous Mesenchymal Stem Cells|Expanded Intralesional Autologous Mesenchymal Stem Cells Transplantation
224193034|NCT05651373|DRUG|Prednisone|5-30mg, po, once per day(Qd) prescribed if needed and adjusted due to patient response
224193035|NCT05651373|DRUG|Hydroxychloroquine|200mg, po, twice per day (Bid) prescribed if needed and adjusted due to patient response.
224193036|NCT05651373|DRUG|CertolizumabPegol injection|200mg, iH,q2w, once two weeks (q2w) prescribed from the beginning and adjusted due to patient response.
224193037|NCT02753582|DIETARY_SUPPLEMENT|SOD+Gliadin Capsule|
224193038|NCT02753582|DIETARY_SUPPLEMENT|Placebo|
224193039|NCT00616304|DRUG|L-arginine hydrochloride|Patients will be randomized in two blocks of 18. The first block of 18 patients will receive either 12 g L-arginine or saline placebo. If safety is demonstrated in the first block, a further 18 patients will be enrolled in the second block and randomized to receive either 24g arginine or saline placebo Block 1: Standard RSMM artesunate regimen for severe falciparum malaria plus 12g of L-arginine diluted to a 10% solution and given over 8 hours (n=12); Block 2: Standard RSMM artesunate regimen for severe falciparum malaria plus a 24g dose of L-arginine diluted to a 10% solution given over 8 hours (n=12) Phase 2b: To evaluate any additional benefits of a longer infusion, a further 24 patients will receive L-arginine infusion 1.5g/hour for 24 hours
224193040|NCT00616304|OTHER|Normal saline|Patients with severe malaria will be randomized in two blocks of 18. The first block of 18 patients will receive either 12 g L-arginine or saline placebo. If safety is demonstrated in the first block, a further 18 patients will be enrolled in the second block and randomized to receive either 24g arginine or saline placebo. Blocks 1 and 2: Standard RSMM antimalarial artesunate regimen for severe falciparum malaria plus saline placebo, 240 ml given over 8 hours (n=12).
224193041|NCT06566976|OTHER|Exercise Intervention|Aerobic and resistance exercise will be components of the prehabiliation and rehabilitation programs. Given the presence of PAD, a particular emphasis will be placed on volume of walking and improving walking performance.
224193042|NCT06566976|OTHER|VAPAHCS Rehabilitation Core Components|The prehabilitation and rehabilitation programs include all Core Components of rehabilitation as outlined in guidelines. The current clinical VAPAHCS program includes smoking cessation, nutrition, risk factor management and psychosocial counseling referrals as appropriate, and these services will be available for the current proposal.
224193043|NCT00395395|DRUG|Oral salmon calcitonin, salmon calcitonin nasal spray|
224193044|NCT05292248|BEHAVIORAL|Confidently Navigating Financial Decisions and Enhancing Financial Wellbeing in Dementia Caregiving|Multicomponent psychoeducational intervention focused on financial wellbeing
224193045|NCT00201630|DRUG|Uroxatrol (drug)|
224193046|NCT03541356|COMBINATION_PRODUCT|Placebo|Delivered via the I231 POD (Precision Olfactory Delivery) device
224193047|NCT03541356|COMBINATION_PRODUCT|L-dopa 35 mg|Delivered via the I231 POD (Precision Olfactory Delivery) device via one puff to one nostril
224193048|NCT03541356|COMBINATION_PRODUCT|L-dopa 70mg|Delivered via the I231 POD (Precision Olfactory Delivery) device with two puffs, one to each nostril
224193049|NCT03541356|COMBINATION_PRODUCT|L-dopa 140 mg|Delivered via the I231 POD (Precision Olfactory Delivery) device with four puffs, two to each nostril
224193050|NCT03541356|COMBINATION_PRODUCT|L-dopa 70mg/carbidopa 7mg|Delivered via the I231 POD (Precision Olfactory Delivery) device with two puffs, one to each nostril
224193051|NCT02957149|OTHER|Autologous Platelet-Rich Plasma|Platelets that are collected from the subject during the radical prostatectomy, for prostate cancer. The platelets are concentrated in a device to 1,000,000 platelets/mL and applied topically once to the neurovascular bundle during the surgery.
224193052|NCT02957149|DEVICE|Angel Concentrated Platelet Rich Plasma System|
223501853|NCT00500890|RADIATION|Radiation Therapy|Radiation treatment over a period of about 6 weeks.
224193053|NCT06827678|OTHER|No Intervention: Observational Cohort|No intervention
224205905|NCT06126185|DIETARY_SUPPLEMENT|12-week course of synbiotic|A 12-week-course of synbiotic, which contains containing 5 billion colony-forming unit (CFU) of a combination of 4 probiotic species belonging to the genus of Lactobacillus, Bifidobacterium and Streptococcus, and 3 prebiotics, will be given to participants to take daily through oral route.
224205906|NCT00006001|DRUG|semaxanib|
224205907|NCT06123897|OTHER|Regular follow-up assessments without intervention.|Participants will undergo follow-up for a minimum of one year, with regular clinical data collection at baseline, half a month, 1st month, 3rd months, 6th months, 9th months and 12th months. Baseline assessments will include demographic information, medical history, and previous medication use. For participants on antipsychotics at baseline, the Simpson-Angus Scale for extrapyramidal symptoms(SAS) will also be administered. At baseline and each follow-up, data on current medication, physical examination, anthropometry, ECG, EEG, psychiatric scales (PANSS, CGI, GAF, PSP, SAS, TESS, MMAS-8), the MATRICS Consensus Cognitive Battery, and laboratory tests (blood routine, liver and renal function, lipids, fasting glucose, fasting insulin, HbA1c) will be obtained, alongside fMRI, eye movement, and fNIRS measures. Blood samples will be collected and stored for mechanistic investigations.
224205908|NCT06123897|OTHER|Cross-sectional assessment|Volunteers will undergo assessments, including SCID scale, SCL-90, Chinese Perceived Stress Scale(CPSS), the Measurement and Treatment Research to Improve Cognition in Schizophrenia(MATRICS) Consensus Cognitive Battery, blood test(blood routine, liver function, renal function, blood lipids, fasting blood glucose, fasting serum insulin, fasting blood glycosylated hemoglobin), as well as functional MRI, eye movement, functional near-infrared spectroscope and electroencephalogram. Blood samples for exploring difference between patients and healthy people will be collected and stored.
223501854|NCT00315575|PROCEDURE|BOLD and Perfusion brain MRI|Blood oxygenation and perfusion functional MRI performed twice, two weeks apart; each scan lasts 1 hour
223501855|NCT03837938|DRUG|Levopront® syrup 30 mg/5 ml|The first study drug administration was performed at the clinical site on the day of randomization; the last study drug administration was performed in the evening before Day 8 (±1).
223501856|NCT03837938|DRUG|Libexin®|The first study drug administration was performed at the clinical site on the day of randomization; the last study drug administration was performed in the evening before Day 8 (±1). No chewing.
223501857|NCT00064454|DRUG|OPC-6535 Tablets (drug)|
223501858|NCT00005850|DRUG|cisplatin|80 mg/m2 administered by intravenous (IV) over 30 minutes on Day 1 following the gemcitabine infusion. Treatment repeated every 21 days for a total of 6 cycles.
224193054|NCT05392465|OTHER|Fascial mobilization group|Fascial mobilization+ conventional treatment (3 sessions per week). MFR is thought to work directly on restricted fascia; practitioners use knuckles or elbow to slowly sink into the fascia, and the pressure applied to contact the restricted fascia, apply tension, or stretch the fascia. MFR involves application of gentle stretch the pressure applied is a few grams of force, and the hands tend to follow the direction of fascial restriction, hold the stretch, and allow the fascia to release itself + hot pack (10 min) + neck isometrics (neck flexion, extension, side bending) + neck stretches (neck flexors, extensors, side benders and rotation).A total of 40-45 min session three times a week on alternate days for three weeks.
224193055|NCT05392465|OTHER|Conventional physical therapy|Conventional Therapy (3 sessions per week). In this treatment group conventional treatment for chronic neck pain will be given which includes hot pack, Neck Isometrics and Neck Stretches. Hot pack (10 min) + neck isometrics (neck flexion, extension, side bending) + neck stretches (neck flexors, extensors, side benders and rotators).A total of 40-45 min session three times a week on alternate days for three weeks On eligible participants baseline assessment was done,3 session were given per week.
224193056|NCT00671645|DRUG|capecitabine, bevacizumab|Capecitabine 825 mg/m2 bid (on each therapy day of first 4 Therapy weeks) Bevacizumab 5 mg/kg weight; day 1, 15, 29
224193057|NCT01689922|OTHER|AlterG|All patients will begin an early postoperative rehabilitation program and standard PT no later than 4 weeks following surgery and continue for at least 6 weeks. The duration of standard PT program could be extended depending on the patient needs. The patients randomized to undergo (LBPP) treadmill training will have an additional 7-week 3 times a week training on the antigravity
224193058|NCT03796897|DIETARY_SUPPLEMENT|Leucine-enriched protein|Supplement contains 16g of protein given twice per exercise session (4 total exercise sessions)
224193059|NCT03796897|BEHAVIORAL|Habitual diet only|Habitual diet only (no supplementation) for 4 exercise sessions
224310089|NCT01837524|BEHAVIORAL|KP Personal Shopper Visits|Testing co-shopping visits conducted in the grocery store (1:1 visits with dietitian while grocery shopping) versus in-office visits which are the current standard of care.
223501859|NCT00005850|DRUG|fluoxetine|10 mg PO QD (by mouth once daily) starting on week 2 (day 8) and continuing for 7 weeks (days 8-57). After 7 weeks of fluoxetine treatment (day 57), further use of fluoxetine is at the discretion of the patient and physician.
223501860|NCT00005850|DRUG|gemcitabine hydrochloride|1000 mg/m2 intravenous (IV) administered by IV over 30 minutes on days 1 and 8. Repeat treatment every 21 days for a total of 6 cycles.
223501861|NCT06188546|DRUG|Propofol|trying different dosages of propofol 10mg/ml IV to determine the prophylactic dose for morphine induced pruritis
223746360|NCT04738773|DRUG|Naltrexone|On the active drug group, naltrexone will be prescribed on flexible dose mode, receiving 50mg per day on the first week, with an increase of 25mg each week until a maximum of 200 mg per day or as much as tolerated by the patient.
223746361|NCT04738773|DRUG|Placebo|Placebo
223746362|NCT01218074|DEVICE|Aggregometry+Thromboelastography|Patients undergo standard thromboelastography and subsequent aggregometry to test effectiveness of residual antiaggregation drugs. Patients found to have altered value undergo optimization with desmopressin.
223746363|NCT01218074|DEVICE|Thromboelastography Alone|Patients undergo standard of care Thromboelastography to evaluate overall coagulation performance.
223746364|NCT01932827|BEHAVIORAL|Mock Package Questionnaire|Within a online questionnaire we exposed participants randomly to 4 mock cereal packages differing only by the nutrition claim it carried and asked participants to answer several questions on attitudes and understanding after each mock package.
224193060|NCT06635408|DIAGNOSTIC_TEST|cystatin c|a biomarker to assess renal function
224193061|NCT05814380|RADIATION|99mTc-DPD scintigraphy|99mTc-DPD scintigraphy
224193062|NCT05814380|DIAGNOSTIC_TEST|Collection of blood samples and echocardiography|Collection of blood samples from a peripheral vein and TTR sequencing. Transthoracic echocardiography.
223501862|NCT01789775|DRUG|Drug: CD07805/47 gel|
223501863|NCT01789775|DRUG|CD07805/47 gel Placebo|
223501864|NCT01481025|DRUG|Cimicifuga + Hiperico|"1 tablet, 80+450mg/tablet, twice a day for 1-3 months~1 tablet, 80+450mg/tablet, once a day for 3-6 months"
223501865|NCT01481025|DRUG|Cimicifuga Herbarium|"2 caps, 80mg/caps, once a day for 1-3 months~1 caps, 80mg/caps, once a day for 3-6 months"
223501866|NCT01481025|DRUG|Aplause®|4 tablets, 20mg/tablet, twice a day for 1-3 months 2 tablets, 20mg/tablet, twice a day for 3-6 months
223501867|NCT04737694|DIETARY_SUPPLEMENT|Ketone ester|Oral ketone ester + glucose supplement
223501868|NCT04737694|DIETARY_SUPPLEMENT|Glucose|Glucose supplement
223501869|NCT03743818|DEVICE|dry needling|dry needling on the trigger point of the vastus medialis of the quadriceps
223501870|NCT03743818|OTHER|ultrasound|aply ultrasound on the knee
223501871|NCT03743818|DEVICE|hyauluronic acid|aply hyaluronic acid on the knee
223501872|NCT02596672|BEHAVIORAL|The friendly walking group|A 12 week peer led walking group for adults and older adults (\> 55 years) living in independent living communities in Northern Ireland. Designed to increase physical activity levels of inactive older adults and measure sustained changes in physical behaviour 6 months after the intervention ends.
223501873|NCT05360446|DRUG|Inclisiran sodium 300 mg|Subcutaneously administered on Days 1, Month 3 (Day 90), and every 6 months thereafter.
223501874|NCT05360446|DRUG|Placebo|Subcutaneously administered on Day 1, Month 3 (Day 90), and every 6 months thereafter.
223501875|NCT06011226|OTHER|focus groups|A dozen patients with Chiari malformation and syringomyelia (n = 4) or isolated Chiari malformation (n = 4) or isolated syringomyelia (n = 4) will be brought together in at least two focus groups. Each focus group will include 5 to 8 patients and will last approximately 1 to 2 hours. The focus groups will be recorded (audio only, no personal data will be collected during these sessions) and will be conducted in the presence of a neurosurgeon and a psychologist, who will moderate the session.
223501876|NCT06011226|OTHER|questionnaire|developed questionnaire will be proposed to the patients in phase 2 and 3
223501877|NCT01917773|DRUG|Octreotide|Average MI for all patients was calculated over 15-minutes, 30-minutes and 45- minutes before and after administration of octreotide
223501878|NCT01917773|DRUG|Bisacodyl|
224193063|NCT00003526|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Cancer of Unknown Primary Origin will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
224193064|NCT01644968|DRUG|Cohort 1 anti-OX40|0.1 mg/kg anti-OX40 on days 1, 3, and 5
224193065|NCT01644968|DRUG|Cohort 2 anti-OX40|.4 mg/kg anti-OX40 on days 1, 3, and 5
224193066|NCT01644968|DRUG|Cohort 3 anti-OX40|2.0 mg/kg anti-OX40 on days 1, 3, and 5
224193067|NCT01644968|BIOLOGICAL|Tetanus Day 29|Tetanus toxoid vaccine 0.5ml (5 LF/ml tetanus toxoid)on Day 29
224193068|NCT01644968|BIOLOGICAL|Tetanus Day 1|Tetanus toxoid vaccine 0.5ml (5 LF/ml tetanus toxoid)on Day 1.
224193069|NCT01644968|BIOLOGICAL|KLH Day 1|1 mg KLH in 1 cc diluent subcutaneously on Day 1.
224193070|NCT01644968|BIOLOGICAL|KLH Day 29|1 mg KLC in 1 cc diluent by subcutaneous injection on Day 29.
224193071|NCT01005810|DRUG|N-Acetylcysteine|1200 mg twice daily for 8 weeks
224193072|NCT01005810|DRUG|placebo|2 capsules twice daily for 8 weeks
224193073|NCT01005810|BEHAVIORAL|Contingency Management|rewarding biologically verified marijuana abstinence during study visits, with an escalating reward schedule
223501879|NCT04867148|DEVICE|Inertial measurement unit sensor-based gait analysis system|Gait analysis was performed on 20-m long corridor to collect gait data on more than 23 strides. The gait protocol was performed with an IMU sensor-based gait analysis system (DynaStab™, JEIOS, South Korea) consisting of a shoe-type data logger (Smart Balance1 SB-1, JEIOS, South Korea) and a data acquisition system (DynaStab-Spotfire1, Tibco Spotfire 7.10). The shoe-type data logger included an IMU sensor (IMU-3000™, InvenSense, USA) that measured tri-axial acceleration (up to ± 6 g) and tri-axial angular 136 velocity (up to ± 500˚ s-1) along three orthogonal axes.12,16 The IMU sensors were installed in both shoe outsoles, and the data were transmitted wirelessly to a data acquisition system via Bluetooth®. Shoe sizes were adapted to each participant, with available sizes ranging from 225 mm to 280 mm. The local coordinate system for the IMU sensors included the 140 anteroposterior, mediolateral, and vertical directions.
223501880|NCT02260622|DRUG|rivaroxaban plus aspirin|Rivaroxaban 2.5 mg twice daily for 90 days (rivaroxaban will be started 6 to 8 hours after the finalization of the procedure) and 81 mg of ASA daily for 90 days
223501881|NCT02260622|DRUG|clopidogrel plus aspirin|Clopidogrel 75 mg daily for 90 days (with a loading dose of 300 mg clopidogrel following PTA) and 81 mg of ASA daily for 90 days
223501882|NCT00800514|DRUG|amantadine|amantadine twice daily
223501883|NCT00800514|DRUG|amantadine|amantadine 100 mg twice daily
223501884|NCT00504309|DRUG|4/day of 4g P-OM3 capsules|4/day of 4g P-OM3 capsules for 8 weeks
224193074|NCT01499498|DRUG|Sildenafil and Boceprevir|25mg once/800mg three times a day
224193075|NCT00912431|DRUG|ABT-126|ABT-126 administered on Day 1 of Period 1
224193076|NCT00912431|DRUG|Placebo|Placebo for ABT-126 administered on Day 1 of Period 2
224193077|NCT00396357|DRUG|Vildagliptin|
224193078|NCT00396357|DRUG|metformin|
224193079|NCT05223504|DEVICE|Continuously monitoring|Included patients are monitored with WARD equipment during the last part of hospitalization and the first days after discharge. Monitoring will last for a maximum of eight days.
224193080|NCT05782504|BEHAVIORAL|Patient-centered teleprehabilitation|"Education about the consequences of stress and low physical activity levels with examples of how improving stress tolerance and physical activity can influence QoL and oncological treatment outcomes.~Exercise therapy based on shared-decision making and using a patient-centered approach. The goal will be to strive for 150-220 min. of moderate physical activity/week, including a home exercise program (at least 1 session/week) of 30-45 min. moderate aerobic exercise, 20 min. of strength training and 10 min. cool down. The latter is guided by Physitrack software.~Stress management, including questioning personal stress experiences and perceptions, relevant stressors, and stress coping strategies. Next, 3 different relaxation strategies will be explained. Also, cognitive-emotional approaches to stress management and identification of uplifts will be introduced.~Motivational interviewing will be used during the whole intervention."
224193081|NCT01725204|DRUG|Dasatinib + PegIFN|
224193082|NCT05056363|OTHER|Home Based Traditional Scoliosis Exercises|Patients in this group will receive posture exercises, strengthening exercises, diaphragmatic breathing exercises and stretching exercises.
224193083|NCT05056363|OTHER|Core Stability Training|Patients in this group will receive traditional scoliosis exercises. In addition, the training group will receive core stabilization exercises for multifidus, diaphragm,erector spines, rectus abdominis, internal and external obliques, quadratus lumborum, iliopsoas, gluteus maximus, and pelvic floor muscles.
223501885|NCT00504309|DRUG|4/day of 1g P-OM3 capsules|4/day of 1g P-OM3 capsules for 8 weeks
223501886|NCT00504309|DRUG|Corn Oil Placebo, 4 capsules/day for 8 weeks|4 capsules per day of corn oil placebo for 8 weeks
223501887|NCT02301091|PROCEDURE|TACE|TACE will be done according to the current method in our center. We use intra-injection of lipiodol mixed with pirarubicin,mitomycin and lobaplatin when the catheter was placed in the superselective location very close to the tumor. Gelfoam sponge was then injected to temporarily occlude the arterial blood flow.
224193084|NCT06230822|DRUG|VUM02 Injection|VUM02 Injection will be administered intravenously every 3 days for a total of 3 doses.
224193085|NCT03303144|DRUG|Triferic|ferric pyrophosphate citrate
224193086|NCT06479850|BEHAVIORAL|KF-STRIDE®|Treatment group will receive 12 web based sessions of a strength-based training tool (once or twice a week). Sessions are approximately 60 minutes long.
224193087|NCT04359758|BEHAVIORAL|Proactive Streamlined Genetic Education and Testing|This intervention consists of the proactive delivery of genetic education print materials followed by streamlined and facilitated access to genetic testing.
224193088|NCT04359758|BEHAVIORAL|Usual Care|This intervention consists of a standard genetic referral letter that notified the participant that he qualified for genetic referral, recommends the scheduling of a genetic counseling session and provides a telephone number for scheduling.
224205909|NCT03913429|PROCEDURE|Infiltration|"Infiltration performed by the surgeon at the intraoral and intranasal submucosal level in the maxilla (blockage of terminal branches of the maxillary nerve) after intubation and previous to surgical incision.~A total of 50ml of the following preincisional mixture is infiltrated: ½ amp Adrenaline + 1amp Lidocaine 2% in physiological saline (SF) 100ml"
224193089|NCT00883766|OTHER|Controlled ovarian hyperstimulation for IVF with a long agonist protocol|"Day 1 of 1st menstruation: OC for 18-21 days (Microdiol ®) + Metformin (Dianben ®) 850 x 2/day if: BMI\>30, HOMA \>3.8, G/I ratio \<4.5~Day 18-24 of cycle: Leuprorelin (Procrin ®) 0.1 s.c. for 14-21 days~Day 1 of 2nd menstruation (=Day 1 COH cycle): Hormonal profile (FSH, LH, E2, Pg, T, SHBG), Ultrasonography to exclude cyst \>10 mm~Day 2of COH cycle: rFSH (Gonal F ®) 150 IU/day for 4 days; Leuprorelin (Procrin ®) 0.1 s.c. (and following days)~Day 7 of COH (and following): Measure FSH, LH, E2, Pg + Ultrasound~Day before HCG: stop rFSH~Day HCG: measure FSH, LH, E2, Pg, administer 250 mcg Choriogonadotropin-alfa ( Ovitrelle®)~Day of pick-up: Follicular fluid from 1st follicle to be centrifuged and stored at -20°C~Day 7 after pick-up: ultrasound, patient evaluation.~Day 14 after pick-up: HCG in blood~Day 28 after pick-up: Ultrasound to visualize heart beat if pregnancy test positive~(OC= oral contraceptive; COH= Controlled Ovarian Hyperstimulation)"
224310090|NCT01837524|BEHAVIORAL|In-Office Dietitian Visits|Participants will have 3, 1 hour in-office sessions with the dietitian during which targeted curriculum on nutritional knowledge, weight management, healthier eating, menu and label reading, will be delivered. These visits will take place monthly over a three month period.
224310091|NCT05396521|OTHER|Blood Flow Restriction|Group 2 (experimental) will receive standard of care physical therapy to be done with blood flow restriction therapy (BFR). This method includes standard of care physical therapy while occluding blood flow.
224310092|NCT05396521|OTHER|Standard of Care Physical Therapy|Group 1 (Control) will receive standard of care physical therapy.
224310093|NCT02530658|OTHER|Study Introduction Visit|Within 5±3 weeks following arrival at SJCRH, or at the participant/family's convenience, participants will meet with a genetic counselor and clinician, provide information for a family pedigree, undergo a physical and discuss germline testing options. Study introduction materials will be provided. Families interested in the G4K study will be referred to the study nurse or other G4K member and an Informed consent visit will be scheduled.
223591914|NCT07087704|DIETARY_SUPPLEMENT|High-fat diet|The group follows a Chilean diet (adapted from the Mediterranean Diet using Chilean ingredients) supplemented with 30 g/day of Gevuina avellana and providing 40% of total energy value from fat. To promote adherence to the diet, individual motivational interviews and group sessions (with approximately 25 participants) are conducted once per month. Each participant is provided once a month with individually packaged Chilean hazelnuts to reach a daily intake of 30 g.
223591915|NCT07087704|DIETARY_SUPPLEMENT|Low-fat diet|The group maintains a low-fat diet (\<30% of total energy value) based on the Chilean Ministry of Health (MINSAL) technical guidelines for dyslipidemia management. To promote adherence to the diet, individual motivational interviews and group sessions (with approximately 25 participants) are conducted once per month.
223591916|NCT07089017|DEVICE|medstrom仪器|In addition to conventional monitoring methods, such as electrocardiography (ECG), bispectral index (BIS), and train-of-four (TOF) monitoring, Medstrom instruments were utilized to assess and monitor the patient's pain, sedation, and muscle relaxation status.
223591917|NCT07088614|OTHER|Remote respiratory physiotherapy|"Remote respiratory physiotherapy protocol supervised 3 times a week via digital video conferencing, based on Chilean national guidelines for cystic fibrosis.~Each 1-hour session (3×/week for 6 months) includes:~Evaluation: respiratory assessment, teaching and reinforcement of airway clearance techniques, inhaled medication use, physical activity, and adherence to non-physiotherapy care. Six checklists are used to guide and monitor weekly patient activities.~Respiratory physiotherapy: conducted on-screen by the patient or caregiver, guided remotely. Includes: short-acting bronchodilator (if indicated), 7% hypertonic saline nebulization (10 min), 5-min Flutter/Acapella, ELTGOL or ELPr (2×5 min), and assisted coughing.~Re-evaluation: reassessment with the initial checklist, Q\&A, and scheduling the next session.~Participants continue their usual hospital-based care and receive baseline and post-intervention measurements."
223591918|NCT07089719|DRUG|Bevacizumab Injection|Participants will receive Bevacizumab at a dose of 10mg/kg via intravenous infusion. They will receive a total of 5 injections, administered every two weeks.
223591919|NCT07087483|BEHAVIORAL|The fathers who receive training|We will provide training to fathers on how they can improve and support their fatherhood skills with their newborns, and the control group will only receive the brochure about the basic fatherhood skills.
223746365|NCT00877695|BEHAVIORAL|Entre Culturas: Navigating Culture, Identity, and HIV Risk|A pilot test of a culturally and developmentally tailored MEI to reduce risky sex (unprotected anal sex and multiple partners) among young Hispanic men who have sex with men (YHMSM) to be delivered face-to-face (FtF) and through the Internet using a real-time implementation approach. A tailored MEI for two delivery modalities, and a health education control (HEALTH) comparable in time and number of sessions. We will test the MEI's acceptability and feasibility, obtain effect size estimates of the intervention's strength to reduce risky sex, and determine if it is ready for efficacy testing.
223746366|NCT00164346|BEHAVIORAL|neurocognitive habilitation|
223746367|NCT03676322|DRUG|M5049|Participants will receive single ascending oral dose of M5049 in Part A. Participants will receive multiple ascending oral dose of M5049 once daily for 14 days or twice daily for 13 days followed by a single dose on Day 14 in the morning in Part B. Participants will receive a single oral dose of M5049 under fed conditions in Part C.
224310094|NCT02530658|OTHER|Informed Consent Visit|Within 1±3 weeks following the Study Introduction Visit, or at the participant/family's convenience, the research nurse or other study team member will consent the family and collect demographic and medical information. Participants will complete assessment questionnaires.
224310095|NCT02530658|OTHER|Informed Consent Follow-Up Visit|At or after enrollment but before the release of the gerline results, or at the participant/family's convenience, a subset of participants (30-40) will participate in semi-structured interviews.
223501888|NCT02301091|PROCEDURE|RFA|For RFA, we used two commercially available system (Cool-Tip, Valleylab，USA) and (Octopus RF Systema，Starmed,Korea）with needle electrode with a 17-gauge internally cooled electrode.
223501889|NCT02301091|DRUG|pirarubicin,mitomycin and lobaplatin|They were cytotoxic drugs used in the TACE procedure.
223501890|NCT02997670|OTHER|Algorithmic Cardiac Resynchronisation Therapy Optimisation|Use of a computer algorithm to run through multiple combinations of pacing options in patients who have a Cardiac resynchronisation pacemaker with defibrillator where a quadripolar lead has been implanted. These quadripolar leads offer extra options for pacing locations across the heart, as well as for different combinations and sequences of pacing stimuli.
223501891|NCT03345095|DRUG|Marizomib|Intravenous administration of Marizomib
223591920|NCT07087483|BEHAVIORAL|Fatherhood Skill Training|"FATHERHOOD TRANSITION TRAINING PROGRAM • Explanation of the goals and objectives of the training~* Introduction to the training program~* Newborn's physiological characteristics (weight, height, head circumference, fontanelles, body temperature, sleep, feeding, urination, meconium, genital organs, reflexes, sleeping position, safety, hygiene)~* Infant feeding and burping the baby~* Changing baby's clothes, giving a bath, diapering, and general care of the eyes, ears, mouth, umbilical cord, and skin~* Importance and benefits of breast milk~* Breastfeeding positions and techniques~* Methods of expressing, storing, and increasing breast milk~* Information about vaccinations, hearing and heel-prick screening, developmental hip dysplasia, and jaundice~* General information on gender roles~* Importance of father-infant bonding and its short- and long-term outcomes"
223591921|NCT07087925|DRUG|Haloperidol|A single dose of haloperidol (1-2 mg) was administered intravenously during the intraoperative period to patients undergoing surgery under subarachnoid block (RA-SAB). This intervention was designed to evaluate its effectiveness in preventing postoperative nausea and vomiting (PONV). Both patients and providers were blinded to the assignment.
223591922|NCT07087925|DRUG|Ondansetron 4mg|A single dose of ondansetron (4 mg) was administered intravenously during the intraoperative period to patients undergoing surgery under subarachnoid block (RA-SAB). This intervention served as the active comparator to haloperidol in evaluating the prevention of postoperative nausea and vomiting (PONV). The study was conducted in a double-blind manner.
223591923|NCT07088536|OTHER|Occupational Status Survey and Telephone Follow-up and Quality-of-Life Assessment in a subset of patients|Collection of demographic, employment, and clinical data at hospital admission, with additional EQ-5D-5L quality-of-life questionnaire and telephone follow-up for occupationally active patients undergoing major uro-oncological surgeries or urinary tract stone procedures.
223591924|NCT05771038|PROCEDURE|socket preservation using sodium alendronate gel|"sockets will be preserved by sodium alendronate gel before then Patients will be evaluated after 3 days and weekly thereafter for the first month and then once monthly for signs of soft tissue irritation.~After 3 months post-operative CBCT scans will be done to evaluate the bone density, alveolar crest bone height will be measured and core biopsy will be taken for Histomorphological study at the same visit where implant will be placed"
223591925|NCT05771038|PROCEDURE|socket preservation using sticky bone|"sockets will be preserved by sticky bone as mentioned before then Patients will be evaluated after 3 days and weekly thereafter for the first month and then once monthly for signs of soft tissue irritation.~After 3 months post-operative CBCT scans will be done to evaluate the bone density, alveolar crest bone height will be measured and core biopsy will be taken for Histomorphological study at the same visit where implant will be placed"
223501892|NCT03345095|DRUG|Temozolomide|Oral Administration of Temozolomide
223501893|NCT03345095|RADIATION|radiotherapy|60 Gy in 30 fractions over 6 weeks
223501894|NCT01121575|DRUG|PF-02341066|Arm 1: The starting dose will be 200 mg by mouth, twice a day of PF 02341066 in tablet form The dose of each drug in the combination \[PF-02341066 and PF-00299804\] will be escalated or de-escalated until the maximum tolerated combined dose is reached. Patients will then be treated with the maximum tolerated combined dose.
223501895|NCT01121575|DRUG|PF-00299804|Arm 1: The starting dose will be 30 mg by mouth once a day of PF-0029804 in tablet form. The dose of each drug in the combination \[PF-02341066 and PF-00299804\] will be escalated or de-escalated until the maximum tolerated combined dose is reached. Patients will then be treated with the maximum tolerated combined dose.
223501896|NCT01121575|DRUG|PF-02341066|Arm 2: With progressive disease the maximum tolerated combined dose of PF-02341066 (given by mouth twice a day in tablet form) and PF-00299804 (given by mouth once a day in tablet form).
223501897|NCT01121575|DRUG|PF-00299804|Arm 2: The dose of 45 mg by mouth once a day of PF-00299804 in tablet form until progressive disease and then the maximum tolerated combined dose of PF-02341066 (given by mouth twice a day in tablet form) and PF-00299804 (given by mouth once a day in tablet form).
223501898|NCT05539287|DRUG|Lactobacillus-Based Capsule|25 patients will receive Lactobacillus species 5 billion colonies forming unit (CFU) 2 capsules daily together with their standard antiepileptic drug for 6 months.
223501899|NCT04375592|DIETARY_SUPPLEMENT|Phenylalanine-free protein substitute in tablet form (XPhe minis)|Intervention is a Phenylalanine-free protein substitute in tablet form. Subjects who currently take a concentrated second stage phenylalanine-free protein substitute will be recruited. Subjects will take the study product for 7 days and daily questionnaires will be completed. Subjects will replace some or all of their usual protein substitute with the new product. The amount of study product prescribed will be calculated to provide the same amount of protein as their usual protein substitute. Daily acceptability and tolerance questionnaires will record information on ease of preparation and administration; how it is taken; and any problems or gastrointestinal effects. Additional questions at the beginning and end of the study will record information on taste, appearance, smell, presentation and packaging of the product. Routine weekly finger prick blood spots will be collected and analysed for phenylalanine and tyrosine as usual.
223501900|NCT04216004|BEHAVIORAL|Controlled-Feeding Intervention|All energy-containing food and beverages will be provided for 1-week as a controlled-feeding study.
223501901|NCT04216004|DIETARY_SUPPLEMENT|Non-dairy beverage|Isolated amino acid, fatty acid, and monosaccharide beverage matched to the macronutrient content of 8 fl oz whole milk.
223501902|NCT04216004|OTHER|Full-fat milk|3 daily servings (cup-eq) of full-fat (3.25%) commercial cow's milk.
223501903|NCT04216004|OTHER|Fat-free milk|3 daily servings (cup-eq) of fat-free (0%) commercial cow's milk.
223501904|NCT01799278|DRUG|MLN8237|MLN8237 will be administered orally. The study drug will be administered on an empty stomach with the patient remaining nothing by mouth (NPO), except for water and prescribed medications, for 2 hours before and 1 hour after each dose. Patients will be instructed to take each oral dose of MLN8237 with 8 ounces (1 cup, 240 mL) of water.
223512174|NCT03801109|OTHER|Hyperbaric group|Participants in this group performed 5 sessions per week for 8 weeks (40 sessions in total) . The time of each session is 90 minutes and the chamber pressure is 1.4 ATA with a 100% oxygen mask.
223512175|NCT03801109|OTHER|Magnetic group|There will be 5 sessions per week for 2 consecutive weeks (10 sessions in total), stimulating the left motor cortex at high frequencies, 10 Hz, for 30 minutes.
223512176|NCT03801109|OTHER|Physical group|A protocol of low-impact physical exercise will be performed twice a week for 8 weeks, with a total of 16 sessions.
223591926|NCT04797871|BEHAVIORAL|Resistance training|Participants will complete a 2-days-a-week training routine: Resistance training (RT, 50-75% 1RM (one-repetition maximum), 4 sets, 8-12 repetitions, 4 exercises). The warn up include Light Intensity Continuous Training (8-10 min, 65-70% HRR). Progressions will be individualized and consistent with patient tolerance. Sessions will be supervised by Physiotherapists and Graduated in Sports Sciences.
223591927|NCT04797871|BEHAVIORAL|Standard care|This group will be allocated to standard care and therefore no supervised exercise regimen according to scientific guidelines for general physical activity and return to sport provided by the ACSM guidelines for Chronic Obstructive Pulmonary Disease and Cardiovascular Disease.
223591928|NCT03266172|DRUG|GSK2982772 Modified Release|GSK2982772 MR will be available as prototype MR minitablet in capsules with unit dose strength of 60 mg in Part A. In Part B, GSK2982772 MR minitablet in capsules with unit dose strength of 15, 30 or 60 mg will be administered by subjects for Days 1 to 3. In Part C, GSK2982772 MR tablet with unit dose strength of 240, 360 or 480 mg will be administered by subjects. GSK2982772 MR will be administered orally with 240 mL of water.
223591929|NCT03266172|DRUG|GSK2982772 Immediate Release|In part A, GSK2982772 IR tablet will be available with unit dose strength of 30 mg and the total dose administered by subjects will be 120 mg (4 tablets of dose strength 30 mg) orally with 240 mL of water. In part C, GSK2982772 IR tablet will be available with unit dose strength of 30 mg and the total dose administered by subjects will be 240 mg (8 tablets of dose strength 30 mg) orally with 240 mL of water.
223591930|NCT06766357|DRUG|Cyclosporine ophthalmic gel|Administer to eyes
223591931|NCT06766357|DRUG|Cyclosporine ophthalmic gel vehicle|Administer to eyes
223746368|NCT03676322|DRUG|Placebo|Participants will receive placebo matched to M5049.
223746369|NCT03020823|DRUG|SCB01A|intra-subject dose escalation, 12, 18, 24 mg/m2, 24h-IV infusion (in the vein) on day 1 and 8 of each 21 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
224074961|NCT05632770|BEHAVIORAL|American College of Surgeons (ACS) Required Screening and Referral (Usual Care)|The study will contribute to usual care with the study 10-domain electronic health record (EHR) screen and the posttraumatic stress disorder (PTSD) evaluation. The study team may also collaborate with hospital providers on the referral process and/or inform a member of the patient's care team of distress patients are experiencing as identified by a DSM-5 PTSD Checklist (PCL) score of ≥ 30 or a DSM-IV PTSD Checklist (PCL) score of ≥ 35.
224074962|NCT06261294|DIAGNOSTIC_TEST|OncoSweep Lung Spotligh|This study is to develop and validate the performance of OncoSweep Lung Spotlight for detecting circulating miRNA expression, ctDNA methylation status, platelet RNA, and tumor marker expressions by utilizing real-time polymerase chain reaction (qPCR). The method is to collect venous blood from subjects during their routine visit to the healthcare facilities.
224074963|NCT04969081|BEHAVIORAL|referral to work focused program|referral to Incentive Therapy or to Other Therapeutic and Supported Employment Services
224074964|NCT04969081|OTHER|treatment as usual|usual treatment
224074965|NCT06232317|OTHER|Virtual Reality Software|The ReCognitionVR virtual reality software is delivered via an Oculus Quest 2 device. This three-dimensional simulated software was designed to improve attention and executive functions.
224074966|NCT06232317|OTHER|Traditional Orientation Methods|Standard-of-care methods to orient patients after surgery
223746370|NCT04149951|DEVICE|Vestal Device|Vestibular nerve stimulator
223746371|NCT04149951|DEVICE|Placebo device|Sham nerve stimulator
224074967|NCT02967289|DRUG|Irinotecan|every 14 days, 12 cycles, 24 weeks, new cycle beginning on day 15: irinotecan (Campto®) 180 mg/m² on D1, IV infusion over 90 minutes to begin 30 min after folinic acid infusion is started
224074968|NCT02967289|DRUG|Folfox Protocol|every 14 days, 12 cycles, 24 weeks, new cycle beginning on day 15: oxaliplatin (Eloxatin®) 85 mg/m² on D1, IV infusion over 2 hours, followed by folinic acid 400 mg/m² (racemic mixture) (or 200 mg/m² if L-folinic acid) IV infusion over 2 hours 5-FU 2400 mg/m²/h IV continuous infusion over 46 hours starting at the end of folinic acid infusion
224074969|NCT04547504|DRUG|Pembrolizumab|Pembrolizumab 200 mg once every 3 weeks for a maximum of 35 cycles or until disease progression, death, unacceptable toxicity, or the Investigator's or the patient's decision to stop.
224074970|NCT04547504|DRUG|Pembrolizumab and Chemotherapy drugs|"An induction therapy followed by a maintenance therapy.~4 induction cycles every 3 weeks associating, on the first day of each cycle:~* Cisplatin 75mg/m² or carboplatin AUC 5mg/mL/min, pemetrexed 500mg/m² and pembrolizumab 200mg for non squamous NSCLC.~* Carboplatin AUC 6mg/mL/min, paclitaxel 200mg/m² and pembrolizumab 200mg for squamous NSCLC.~After the 4 induction cycles, a maintenance therapy will be possible for patients who are responding or stable:~* Non squamous NSCLC: pembrolizumab and pemetrexed combination or either drug as monotherapy.~* Squamous NSCLC: pembrolizumab monotherapy.~For pembrolizumab: treatment may be continued for a maximum of 35 cycles or until disease progression, death, unacceptable toxicity, or following the Investigator's or the patient's decision to stop.~For pemetrexed, treatment may be continued until disease progression, death, unacceptable toxicity, or following the Investigator's or the patient's decision to stop."
224074971|NCT05853497|BEHAVIORAL|Multi-Component Weight Loss Intervention|The intervention group will receive weekly 1-on-1 health coaching with a very-low calorie nutrition plan prior to total knee replacement and a conventional weight maintenance nutrition plan after surgery.
224074972|NCT04951778|DRUG|CC-91633|Administered orally according to the assigned treatment schedule
224074973|NCT05245500|DRUG|MRTX1719|"MRTX1719 is a potent PRMT5-MTA inhibitor~Specified dose on specified days"
224074974|NCT05165654|DEVICE|Transcranial Electrical Stimulation|Transcranial electrical stimulation
224074975|NCT04955808|PROCEDURE|Biospecimen Collection|Undergo collection of tissue and blood samples
224074976|NCT04955808|OTHER|Laboratory Biomarker Analysis|Correlative studies
224074977|NCT04342975|DRUG|Nicotinamide Riboside + Pterostilbene|It will be administered a total of 1000 mg/day of NR and 200 mg/day of Ptero in a regimen of 2 capsules of Basis™ (each capsule 250 mg of NR and 50 mg of Ptero) 2 times a day by mouth for 2 weeks before surgery and 6 weeks after surgery. Each intake has to be apart from each other by, at least, 6 hours of interval.
224074978|NCT04342975|DRUG|Placebo|The correspondent placebo will be administered in a regimen of 2 capsules 2 times a day by mouth for 2 weeks before surgery and 6 weeks after surgery. Each intake has to be apart from each other by, at least, 6 hours of interval.
224193090|NCT00883766|OTHER|Controlled ovarian hyperstimulation for IVF with an antagonist protocol|"Day 1 of pre COH-cycle: OC for 18-21 days (Microdiol ®) + Metformin (Dianben ®) 850 x 2/day if: BMI\>30, HOMA \>3.8, G/I ratio \<4.5~Day 3 of free-pill interval: Hormonal profile (FSH, LH, E2, Pg, T, SHBG), Ultrasonography to exclude cyst \>10 mm~Day 5 of free-pill interval (=Day 1 COH cycle): Cetrorelix acetate (Cetrotide®) 0.25 mg s.c. + rFSH (Gonal F ®) 150 IU/day (and following days)~Day 3-4-10 of COH cycle: measure FSH, LH, E2, Pg + ECO~Day before HCG: stop rFSH + cetrorelix~Day HCG: measure FSH, LH, E2, Pg, administer 250 mcg Choriogonadotropin-alfa ( Ovitrelle®)~Day of pick-up: Follicular fluid from 1st follicle to be centrifuged and stored at -20°C~Day 7 after pick-up: ultrasound, patient evaluation.~Day 14 after pick-up: HCG in blood~Day 28 after pick-up: Ultrasound to visualize heart beat if pregnancy test positive (OC= oral contraceptive; COH= Controlled Ovarian Hyperstimulation)"
224310096|NCT02530658|OTHER|Return of Results Conversation|Participants will complete the assessment questionnaires.
223746372|NCT02034786|PROCEDURE|Adipose tissue collection|"Only the patients selected for the Test Group will go through the procedure. The adipose tissue collection will occur in an elective surgery liposuction, in patients who meet the inclusion criteria, after signing the informed consent form. Thus, the material that would be disposed after surgery will be donated to the study.~The material for the study will be collected by the tumescent liposuction technique, which involves the removal of subcutaneous fat under local anesthesia."
223746373|NCT02034786|BIOLOGICAL|Transdermal injection|Transdermal injection of the filler agent composed of mesenchymal stem cells derived from autologous adipose tissue associated with hyaluronic acid.
223501905|NCT00724503|DEVICE|SIR-Spheres yttrium-90 microspheres|"SIR-Spheres microspheres (yttrium-90 \[Y-90\] labelled resin microspheres), hepatic artery injection administered on Day 3 or 4 of cycle 1.~mFOLFOX6 administered on Day 1 and at the start of each cycle every 14 days: 85 or 60 mg/m2 oxaliplatin by 2-hour intravenous (IV) infusion + 200 mg/m2 leucovorin by 2-hour IV infusion + 400 mg/m2 5-fluorouracil (5-FU) by IV bolus + 2.4 g/m2 5-FU by 46-hour continuous IV infusion.~Treatment with the biologic agent bevacizumab, if part of standard practice at the participating institution, was permitted at the discretion of the treating Investigator.~In the event that leucovorin was not available, use of levofolinic acid (the active S enantiomer) was acceptable at half the dose of the racemic leucovorin i.e. 100 mg/m2."
223501906|NCT00724503|DRUG|Systemic chemotherapy (FOLFOX)|"mFOLFOX6 administered on Day 1 and at the start of each cycle every 14 days: 85 or 60 mg/m2 oxaliplatin by 2-hour intravenous (IV) infusion + 200 mg/m2 leucovorin by 2-hour IV infusion + 400 mg/m2 5-fluorouracil (5-FU) by IV bolus + 2.4 g/m2 5-FU by 46-hour continuous IV infusion.~Treatment with the biologic agent bevacizumab, if part of standard practice at the participating institution, was permitted at the discretion of the treating Investigator.~In the event that leucovorin was not available, use of levofolinic acid (the active S enantiomer) was acceptable at half the dose of the racemic leucovorin i.e. 100 mg/m2."
223501907|NCT03927716|DRUG|SB206 12%|Topically once daily
223501908|NCT03927716|DRUG|Placebo|Topically once daily
223501909|NCT02633657|DRUG|HORIZANT 300 mg|HORIZANT 300 mg once daily
223501910|NCT06810531|DRUG|Ondanesterone plus dexamethasone combination|"Group D: Ondanesterone 4mg plus dexamethasone 8mg All the drugs will be prepared and diluted by normal saline in 10 ml syringe by an anesthesiologist who is not included in the study.~The drugs will be slowly injected intravenous 15 minute from spinal anesthesia."
223501911|NCT06810531|DRUG|ondanesterone plus metoclopramide combination|"Group M: ondanesterone 4mg plus metoclopramide 10 mg All the drugs will be prepared and diluted by normal saline in 10 ml syringe by an anesthesiologist who is not included in the study.~The drugs will be slowly injected intravenous 15 minute from spinal anesthesia."
223501912|NCT05785715|DRUG|NX-13 250mg|NX-13 250mg tablet, plus 2 placebo tablets
223501913|NCT05785715|DRUG|NX-13 750mg|NX-13 250mg tablets times 3 to equal 750mg
223501914|NCT05785715|DRUG|NX-13 Placebo|NX-13 Placebo tablets times 3 for blinding purposes
223501915|NCT00627107|DEVICE|ReWalk - a motorized exoskeleton suit|The subject will wear the ReWalk suit and have training sessions for walking with the device.
223501916|NCT01186419|DRUG|SPD602 (FBS0701, SSP-004184)|Oral FBS0701 taken one time daily for up to 96 weeks.
223501917|NCT04565223|BEHAVIORAL|Cognitive behavioral therapy for insomnia|is a multicomponent intervention which focuses on cognitive and behavioral factors that contribute to sleep disorders , The CBT-i included sleep hygiene counseling, stimulus control, cognitive restructuring, relaxation techniques, and benzodiazepine therapy or withdrawal (when needed). To conduct the intervention, guidelines for GPs and nurses and graphic and written materials for patients (sleep diary, registry of behavior habits, and cognitive problems) were developed
223501918|NCT05907759|DRUG|Daratumumab SC|Daratumumab SC (daratumumab and hyaluronidase) is administered subcutaneously (SC) as 1800 mg/30,000 units weekly for a total of 8 weeks (8 doses) followed by every 2 weeks for a total of 16 weeks (8 doses) followed by every 4 weeks for up to 96 weeks (24 doses)
223501919|NCT06232083|RADIATION|PLDR+Cardunizumab|Application of PLDR external irradiation combined with Cardunizumab in recurrent lung cancer, esophageal cancer and cervical cancer.
223501920|NCT01218178|DRUG|Sodium bicarbonate plus NAC|154 mEq/L sodium bicarbonate (infusion rate of 3 ml/Kg for 1 hour followed by 1 ml/Kg for 6 hours) plus NAC (1200 mg bid for 48 hours)
223501921|NCT01218178|DRUG|Saline hydration plus NAC|0.9% saline (1 ml/Kg for 12 hours) plus NAC (1200 mg bid for 48 hours)
223501922|NCT00931424|PROCEDURE|valve reconstruction|reconstruct valve at the same time of superficial vein surgery
223501923|NCT04325347|OTHER|Virtual Reality application|Virtual Reality application with a VR goggle
223501924|NCT04970108|DRUG|Egito|EGITO Egito coated tablet. EMPAGLIFLOZIN PLACEBO Empagliflozin placebo coated tablet. TELMISARTAN PLACEBO Telmisartan coated tablet.
223501925|NCT04970108|DRUG|Empagliflozin + telmisartan|Drug: EMPAGLIFLOZIN Empagliflozin 25 mg coated tablet. Drug: TELMISARTAN Telmisartan 40/80 mg coated tablet. EGITO PLACEBO Egito placebo coated tablet.
223512177|NCT03801109|OTHER|Baseline group|This group will be the control group that did not take any action, perform the activities of daily life
223746374|NCT02034786|PROCEDURE|Transdermal injection|Transdermal injection of hyaluronic acid only.
223591932|NCT07087821|BEHAVIORAL|UPLIFT|"UPLIFT is an 8-week epilepsy self-management programs delivered to small groups of people with epilepsy (PWE) by Webex. UPLIFT is focused on self-management of depressive symptoms.~Each weekly session is 1 hour long and is comprised of a check-in period, teaching on the week's topic, group discussion, a skill-building exercise and a home practice assignment."
223591933|NCT07087821|BEHAVIORAL|PACES|"PACES is an 8-week epilepsy self-management programs delivered to small groups of people with epilepsy (PWE) by Webex. PACES focuses on general epilepsy self-management.~Each weekly session is 1 hour long and is comprised of a check-in period, teaching on the week's topic, group discussion, a skill-building exercise and a home practice assignment."
223591934|NCT07087821|BEHAVIORAL|Enhanced Usual Care|Participants receive referrals to local epilepsy support groups.
223591935|NCT04366375|DIAGNOSTIC_TEST|PTX-3|Pentraxin-3 ng/mL PTX-3 levels were measured using human PTX3 ELISA Kit 96 Tests/Box (Cat. No: CK-E90303) (Hangzhou Eastbiopharm Co.,Ltd., PRC) read by a ELISA device matching with the kit. For the purpose of measurement, microplate washer RT 2600 device and Rayto microplate reader RT 2100C device were used.
223591936|NCT00238459|DRUG|Patients elected to take licensed drugs. The vaccine was not provided for evaluation|Note:In August 2007 we were notified by the manufacturer that the experimental vaccine was no longer being made and would no longer be available for this study. Too few participants have received the vaccine or placebo to conclude anything about potential efficacy
223591937|NCT00238459|DRUG|multiple licensed drugs not randomized|
223591938|NCT00238459|DRUG|multiple licensed antiretroviral drugs; not randomized|
223591939|NCT00238459|OTHER|Intended vaccine not provided, Licensed drugs provided, but were not investigated|
223591940|NCT00997620|DRUG|Fluticasone furoate Nasal Spray 110 mcg|Fluticasone fuorate nasal spray 110 mcg 2 sprays each nostril am will be compared to similar appearing placebo given 2 sprays each nostril am. The subjects will receive one week placebo nasal spray to establish a baseline then they will then be switched to a nasal spray of fluticasone furoate 110 mcg once daily and continue the evaluations.
224193091|NCT04366011|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|CBT teaches a set of cognitive and somatic coping skills to manage panic and anxiety as patients conduct repeated exposure to feared situations and sensations.
224193092|NCT04366011|BEHAVIORAL|Capnometry Assisted Respiratory Training (CART)|CART has four major treatment components: educating patients about the etiology and maintenance of PD according to a hyperventilation centered rationale, directing patients' attention to potentially aberrant respiratory patterns, instructing patients in respiratory control techniques, and instructing patients in home breathing exercises.
224193093|NCT04392791|OTHER|balneotherapy|Balneotherapy, a medical remedy, with medically and legally recognized mineral waters for therapeutic and rehabilitation purposes
224193094|NCT03358407|DRUG|GSK2983559|GSK2983559 will be available as oral capsules with dose strength of 2-45 milligram (mg), 100 and 114 mg.
223591941|NCT00997620|DRUG|Placebo|Fluticasone nasal spray 2 sprays each nostril will be compared to similar appearing placebo. The subjects will receive one week placebo nasal spray to establish a baseline then they will then be switched to a nasal spray of Placebo once daily and continue the evaluations.
223591942|NCT01554514|BIOLOGICAL|rituximab|rituximab intravenously 100 mg every week for four doses
223591943|NCT00300365|DRUG|Pioglitazone|Pioglitazone, initially 30 mg, then titrated to 45 mg/day
223591944|NCT00300365|OTHER|Placebo|Pioglitazone placebo
223591945|NCT00300365|DRUG|Niacin ER|Niacin ER 2.0 g/day
223591946|NCT00300365|DRUG|Aspirin|asprin 325 mg/day
223591947|NCT03067376|DRUG|[14C]-CORT125134|
223591948|NCT04777266|BEHAVIORAL|Music therapy and treatment as usual|The session-based intervention programme was designed with an integrated and multimodal perspective of music therapy \[37\], which allows the combination of active and passive activities together with focuses and perspectives based on empirical evidence \[38\]. It was implemented using a process-based approach, adapting content to different phases in the process: initial contact, managing resistance, confidence building, relationships, awareness, and closure. The central focus is on the patient and to adapt and remain flexible in the sessions in accordance with the capabilities and needs of the group members. Different perspectives are integrated via nonverbal communication. The layout and any changes to the setting are made in a gradual way in keeping with the process to foster feelings of security and belonging. Sessions begin with a brief period of breathing which then moves into warming-up and free-expression using instruments, followed by the central activity and the closure.
223591949|NCT04361305|DRUG|Dapoxetine|30 mg tablets 1 to 3 hours before sexual activity prn (as needed) not to be taken more than once every 24 hours for 8 weeks Tadalafil 5 mg tablets every day for 8 weeks
223591950|NCT04361305|DRUG|Tadalafil|5 mg tablets every day for 8 weeks
223591951|NCT04361305|DRUG|Tadalafil|5 mg tablets every day for 8 weeks
224193095|NCT03358407|DRUG|Placebo|Placebo oral capsules matching GSK2983559 will be available for subjects.
224193096|NCT03195946|DRUG|Lu AF35700|tablets for oral use, 10 mg/day
224193097|NCT03195946|DRUG|Midazolam|syrup for oral use, 4mg/day
224193098|NCT03195946|DRUG|Cocktail of CYP450 substrates|Caffeine tablets for oral use, 200 mg/day. Omeprazole tablets for oral use, 40 mg/day. Dextromethorphan tablets for oral use, 30 mg/day. Midazolam IV solution for Intravenous use, 0.025 mg/kg/day
224193099|NCT00094146|DRUG|Sandostatin LAR Depot|
224193100|NCT03605758|DRUG|Ivermectin|Ivermectin is an anti-parasitic
224193101|NCT00082134|DRUG|ILX651|
224193102|NCT04753606|DRUG|Obicetrapib|tablets
224193103|NCT00489411|DRUG|duloxetine hydrochloride|Given orally
224193104|NCT00489411|OTHER|placebo|Given orally
224193105|NCT03686085|DRUG|Dinoprostone 3 mg|1 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia \& Upjohn, Puurs, Belgium) inserted by the study nurse 6 hours before IUD insertion.
224193106|NCT03686085|DRUG|placebo vaginal tablet|1 vaginal tablet of placebo inserted by the study nurse 6 hours before IUD insertion.
224310097|NCT02530658|OTHER|Return of Results Follow-Up Visits|Return of Results Follow-Up Visits will be conducted twice: the first within 8±4 weeks of the Return of Results Conversation, or at the participant/family's convenience, and the second within 28 ± 4 weeks of the Return of Results Conversation or at the participant/family's convenience. At each visit, participants will complete assessment questionnaires. Semi-structured interviews with parents and adolescents will be conducted.
224193107|NCT05809999|PROCEDURE|Standard colonoscopy with targeted biopsies|Participants will undergo standard colonoscopy as part of their routine IBD surveillance. During this colonoscopy targeted biopsies (biopsies of any pre-cancerous lesions observed by the doctor) and/or removal of any polyps will be undertaken.
223746375|NCT05891678|RADIATION|doppler study of central retinal artery|pulsed wave Doppler after decreasing the sample volume to fit inside the center of CRA. We will measure the peak systolic velocity (PSV), end diastolic velocity (EDV), and the resistivity index which equal PSV-EDV/PSV, we will measure 3 times and the expected normal value is less than 0.7.
223746376|NCT03739112|BIOLOGICAL|Quadrivalent VLP Vaccine|Single dose of a 30 µg/strain of Quadrivalent VLP Vaccine
223746377|NCT03739112|BIOLOGICAL|Fluarix Quadrivalent® Comparator Vaccine|Single dose of a 15 μg/strain of Fluarix Quadrivalent® Comparator Vaccine
223746378|NCT03451877|GENETIC|TGFB1 AND LAMA1 GENE POLYMORPHISMS|we evaluated polymorphisms in the LAMA1 (rs2089760) and TGFB1 (rs4803455) genes in children younger than 13 years of age with ≥6 D myopia in an attempt to further elucidate the genetic basis of high myopia.
223746379|NCT03217227|OTHER|Cardiovascular Magnetic Resonance Imaging with Exercise Bike|A rest scan is performed and a gadolinium contrast may be administered during the scan (depending on the kidney function). After the rest scan is completed, images of the subject's heart during exercise via cycling in the supine position, will be scanned.
223746380|NCT03217227|PROCEDURE|Cardiac Catheterization|"It is a procedure to diagnose and treat cardiovascular diseases by inserting a long and thin tube known as a catheter into the artery or vein in the neck, groin or arm and threaded through the blood vessels to the heart.~A coronary angiogram is also performed during the procedure where an invisible contrast dye (only visible in the X-rays) is injected through the catheter and X-ray images scanned will show the flow of the dye through the heart arteries to determine any blockages in the arteries.~In the case where there is severe narrowings, fractional flow reserve (FFR) may be performed to measure the pressure in the coronary arteries.~If there is no significant narrowing lesions, the interventionist may perform additional flow resistance measurements of the small vessels to further investigate the cause of angina"
224193108|NCT04148274|OTHER|No intervention|There is no intervention for this study.
224193109|NCT02382107|OTHER|Observational|TB suspects, who present themselves to the pulmonary ambulance at the Marius Nasta Instiute
223501926|NCT03982654|DEVICE|Bloomlife|Women use the Bloomlife sensor to collect data throughout their pregnancy. The collected data is stored locally in the device, but it is not used to provide any feedback to the patients or to the clinical team. Therefore the use of the device doesn't have an impact on clinical decision making and patients' care.
223501927|NCT03812328|DRUG|SelK2|I.V., single-dose
223501928|NCT03812328|BIOLOGICAL|Enoxaparin|SC, QD for up to 10 ± 2 days
223501929|NCT03693677|DRUG|Irinotecan Liposomal Injection|Nal-IRI at 80 mg/m2 IV over 90 minutes
223501930|NCT03693677|DRUG|5-FU/LV|5-FU 2400 mg/m2 IV over 46-hours, every 2 weeks.
223501931|NCT03693677|DRUG|Nab-Paclitaxel|Nab-Paclitaxel: 125 mg/m2 This treatment is administered at D1, D8, D15 and at D29, D36, D43.
223501932|NCT03693677|DRUG|Gemcitabine|1000 mg/m² in 500 ml normal saline infusion at a fixed dose rate of 10 mg/m²/min (i.e. 100 min). This treatment is administered at D1, D8, D15 and at D29, D36, D43.
223501933|NCT06811415|PROCEDURE|virtual temporomandibular joint reconstruction with costochondral graft|All patients were placed in preoperative occlusion in CASS. The planned rib was harvested in the standard manner through an inframammary incision. The length of the rib was equal to the prefabricated template as calculated in the cranial-maxillofacial 3D reconstruction, and comprised at most 5 mm of cartilage. The cartilage was trimmed and contoured to facilitate the setting of the cartilage side properly into the center of the TMJ fossa. A 4-hole titanium plate was fixed with four bicortical screws as previously planned
223501934|NCT06179940|OTHER|Pairwise food selectivity protocol|Overall, the intervention aims to gradually expose the child to various foods, starting with familiarization, progressing to exposure without pressure, and finally, shaping positive behaviors using reinforcement and observing reactions to different food items. The experimental group will conduct the protocol activity in pairs.
223501935|NCT06179940|OTHER|Individual food selectivity protocol|Overall, the intervention aims to gradually expose the child to various foods, starting with familiarization, progressing to exposure without pressure, and finally, shaping positive behaviors using reinforcement and observing reactions to different food items. The control group will conduct the activity individually.
223501936|NCT00932711|BEHAVIORAL|Educational brochures|A locally developed educational brochure containing information about smoking cessation, influenza and pneumococcal vaccination, regular exercise, compliance with prescribed COPD therapy and recognition of symptoms, along with a goal setting questionnaire
223501937|NCT04374552|DRUG|Hydroxychloroquine sulfate &Azithromycin|Drug - Hydroxychloroquine sulfate \&Azithromycin
223501938|NCT04374552|DRUG|Placebo|Drug - placebo
223501939|NCT01607008|OTHER|MRI imaging|"3 total MRI imaging studies:~1. pre standard radiation treatment~2. during standard radiation treatment~3. post standard radiation treatment"
223501940|NCT06654999|DEVICE|Deep Ensemble for the Recognition of Malignancy (DERM)|"DERM variants + and DS"
223501941|NCT03827798|DRUG|CFZ533|s.c.
223501942|NCT03827798|DRUG|Placebo to CFZ533|s.c.
223501943|NCT03827798|DRUG|LYS006|p.o.
223501944|NCT03827798|DRUG|Placebo to LYS006|p.o.
223501945|NCT03827798|DRUG|MAS825|s.c.
223501946|NCT03827798|DRUG|Placebo to MAS825|s.c.
223501947|NCT03827798|DRUG|LOU064 25mg|p.o.
223501948|NCT03827798|DRUG|LOU064 100mg|p.o.
223501949|NCT03827798|DRUG|Placebo to LOU064|p.o.
223501950|NCT03827798|DRUG|VAY736|s.c.
223501951|NCT03827798|DRUG|Placebo to VAY736|s.c.
223512178|NCT06249477|DEVICE|Wrist activity tracker and scale|Wrist activity tracker used to evaluate number of steps, heart rate, and frequency of usage of the devices to monitor activity. Scale used to record a patient's weight value.
223512179|NCT06249477|BEHAVIORAL|Nutritional Coaching group sessions|Nutritional coaching group sessions held via zoom and performed by a certified clinical nutritionist regarding nutrition, and physical activity specific for weight loss.
223512180|NCT00917020|DRUG|Nasal CO2|As-Needed during the 14 day Treatment Period
223512181|NCT00917020|DRUG|Inactive Placebo Gas|Placebo
224193110|NCT06717256|BEHAVIORAL|training|The diabetes education booklet is a collection of information designed by the researcher. These interventions will continue for 1.5 months, with a total of 6 sessions for each type 2 DM individual, lasting approximately 120 minutes (2 hours per week and 12 hours in total after 6 weeks), and will be carried out as reminders afterwards. In these sessions, agendas will be created appropriately on regular eating habits, physical activity, regular monitoring of blood sugar, compliance with treatment, problem-solving ability, coping strategies and minimizing risks, conflicts regarding self-management and skin care behaviors of the patient will be tried to be resolved, the patient's suitability and adaptation to the change phase will be determined, their willingness to change will be questioned, and the change plan will be helped in the matters of care and self-management.
224310098|NCT02530658|PROCEDURE|Blood Sample|For patients who have not previously provided a blood sample, a sample of blood will be obtained as a source of germline DNA.
223746381|NCT03217227|OTHER|Retinal Photography (Optional)|The test studies the structure and function of the eye vessels. It involves using eye drops to dilate the pupils, allowing the retinal photographer to have a better view of the back of the eye.
223746382|NCT03217227|DIAGNOSTIC_TEST|I123 MIBG Scintigraphy (Optional)|"The test studies the cardiac sympathetic signalling that may help to identify patients with high risks of adverse events. The scan consists of 2 acquisitions of images 3-4 hours apart.~For this study, only patients without clinically significant lesions (diagnosed via the cardiac catetherisation and have normal FFR results) will undergo this test."
223746383|NCT05805761|PROCEDURE|Conventional Treatment|A bicarbonate jet will be used to remove the biofilm from the surface of the teeth.
223501952|NCT06856759|GENETIC|Intrathecal injection of AAV-MECP2 for the treatment of Rett syndrome|"For Dose 1, the first 5 subjects will be enrolled in the trial in sequence, with one patient completing the administration and no significant dose limiting toxicity (DLT) observed during a one month follow-up. The latter subject will be enrolled in the trial medication.~Once the fifth subject in Dose 1 completes the administration and no significant DLT is observed after a follow-up period of at least two weeks, the study dose can be escalated to a higher level.~For Dose 2, the 3 subjects will be enrolled in the trial in sequence, with one patient completing the administration and no significant DLT observed during a one month follow-up. The latter subject will be enrolled in the trial medication.~DLT definition: see Study Description."
223501953|NCT00469729|DRUG|StemEx®|The stem/progenitor cell based product composed of ex vivo expanded allogeneic umbilical cord blood cells, which is infused to subject at a rate of 1-3 ml/min in combination with non-manipulated cells derived from the same cord blood unit.
223501954|NCT01426646|DRUG|S-1|S-1 was administered at 40mg/m2 orally twice daily (days 1-28) every 42 days. Patients received a maximum of eight cycles.
224310099|NCT02530658|PROCEDURE|Skin Biopsy|After consent, for participants with a diagnosis where peripheral blood is likely to be contaminated by tumor cells, skin biopsies may be done as a source of germline DNA.
223501955|NCT01426646|DRUG|S-1 plus cisplatin|"S-1 plus cisplatin every 3 weeks, a total of eight cycles~* S-1: 40mg/m2 orally twice daily (days 1-14)~* Cisplatin: 60mg/m2 IV on day 1"
223501956|NCT04377568|BIOLOGICAL|Convalescent plasma (CP)|Participants will receive one infusion of convalescent plasma proportional to their weight (10 mL/kg), up to a maximum of 500 mL
223501957|NCT07006467|DEVICE|Implantation of RFS|Percutaneous transluminal implantation of the RFS in the infrapopliteal lesion
223501958|NCT07011368|BEHAVIORAL|Intervention Group|"Healthy Lifestyle Recommender Solution (HLRS) will be developed as intervention tool for the trials. It integrates tools (mostly digital): a meal recommender to propose balanced and individually adapted meal plans, physical activity and sleep pattern measures and recommendations, assessment of behavioural/psychological aspects, and motivational features for sustained engagement and adherence.~Within our multi-disciplinary portfolio approach, a set of predominantly eHealth solutions applied during the intervention trials for overweight/obesity prevention, developed in a participatory design approach with relevant stakeholders. This will include the HLRS, thus combining motivational features (nudging, gamification), targeted psychological support, dietary and physical activity advice, though also additional recommendations (healthy eating guidelines...) or education materials will be provided.~Intervention trials/studies."
223501959|NCT07021313|DEVICE|Pulmonary vein isolation by percutaneous endocardial catheter ablation using the FARAPULSE pulsed high voltage electrical field system in patients with atrial fibrillation|Standard of care 4 pulsed electrical field applications in basket shape and 4 applications in flower shape
223512182|NCT02176525|DRUG|BI 207127 NA|
223512183|NCT02176525|DRUG|Placebo|
223512184|NCT00544726|BEHAVIORAL|Physical training|
223512185|NCT00544726|BEHAVIORAL|No training|
223512186|NCT06525454|BEHAVIORAL|Personalized coaching messages for blood glucose and emotions|For six weeks, the intervention group will receive weekly personalized coaching messages for glycemic management based on blood data from continuous glucose monitors and bi-weekly personalized coaching messages for depression management based on depression questionnaires.
223512187|NCT03240445|DRUG|ODM-203 (Period 1)|ODM-203 400mg as tablets taken 30 minutes after food
223512188|NCT03240445|DRUG|ODM-203 (Period 2)|ODM-203 400mg as tablets taken 1 hour before a light breakfast
223512189|NCT03240445|DRUG|ODM-203 (Periods 3-6)|ODM- 203 400mg as tablets for oral administration or 400mg as oral dispersion either before/after food
223512190|NCT01905267|BEHAVIORAL|Rumination-Focused Cognitive Behavior Therapy|This intervention targets rumination and other maladaptive forms of emotion regulation such as suppression and avoidance and provides skills training in effective coping strategies. Mindfulness is a key component of this intervention as a strategy for disengaging from one's thoughts. Strategies from Dialectical Behavior Therapy (DBT), such as the use of effective interpersonal skills, are also included as methods for regulating strong emotion. Rumination-Focused Cognitive Behavior Therapy is a structured, manual based program designed to be delivered weekly over eight weeks. Sessions are 60-90 minutes in length.
223512191|NCT03272165|DRUG|MEDI1341|Participants will receive IV infusion of MEDI1341 doses as stated in the arms' description.
223512192|NCT03272165|DRUG|Placebo|Participants will receive IV infusion of placebo matched to MEDI1341.
223512193|NCT03535519|DRUG|Methotrexate|standard of care treatment with methotrexate
223512194|NCT03686722|DRUG|Metformin|Metformin is used primarly in treatment of diabetes type II
223512195|NCT03686722|DRUG|Daclatasvir|Daclatsvir is a direct acting antiviral drug
223746384|NCT05805761|PROCEDURE|Antimicrobial Photodynamic Therapy|aPDT will be performed before each cleaning/prophylaxis session, only in one of the groups. Participants will swish with the photosensitizer erythrosine for 1 min of pre-irradiation time, so that the drug can stain all the bacterial biofilm. The D-2000 LED (DMC) will be applied, emitting at a wavelength of ʎ = 430-490 nm and 900-1100 mW/cm2. Irradiation will be performed until the biofilm of the cervical region is illuminated for 2 min per point. Each irradiation point will be approximately 0.4 cm2.
223746385|NCT02933242|RADIATION|Stereotactic Ablative Body Radiotherapy|The total dose and number of fractions will depend on the site of disease. Treatment will be given daily, or every other day, over 1 -3 weeks
223746386|NCT06274541|GENETIC|Somatic and Germline BRCA1/2 Testing|Germline BRCA1/2 mutation testing will be undertaken by NGS using blood samples. Somatic BRCA1/2 mutation testing will be undertaken by NGS using tumour tissue.
223746387|NCT01145768|DRUG|TC-5214|4 mg tablet, oral, BID, group 1
223746388|NCT01145768|DRUG|TC-5214|TBD tablet, oral, BID, groups 2-6
223746389|NCT01145768|DRUG|Placebo|
223746390|NCT00046332|DRUG|GW810781|
224193111|NCT01283009|DRUG|Inactive Substance|Inactive Substance will be given in a double-blind fashion for 20 full days. The treatment course includes a bolus dose on the day of randomization, 7 days of full dose (40 mg/day), 7 days of half dose (20 mg/day), and 6 days of tapering doses (12 mg/day and 4 mg/day).
224193112|NCT01283009|DRUG|Methylprednisolone|Methylprednisolone will be given in a double-blind fashion for 20 full days. The treatment course includes a bolus dose on the day of randomization, 7 days of full dose (40 mg/day), 7 days of half dose (20 mg/day), and 6 days of tapering doses (12 mg/day and 4 mg/day).
224193113|NCT04436497|DRUG|Zilucoplan|"Drug: Zilucoplan Administration: Subcutaneous injection~Dosage: 0.3mg/kg administered daily"
223501960|NCT07021313|DEVICE|Pulmonary vein isolation by percutaneous endocardial catheter ablation using a pentaspline pulsed high voltage electrical field system in patients with atrial fibrillation|Experimental treatment delivering 2 pulsed electrical field applications in olive shape, 4 in basket shape and 6 applications in flower shape
223501961|NCT06870149|OTHER|Dance Rehabilitation Intervention|Cognitive Groove (GERAS DANCE) presents a novel approach to increasing or maintaining independence and quality of life by improving physical performance and mobility using reminiscent music and rhythmic movement in a fun, safe environment. Cognitive Groove was designed to meet the complex needs of older adults with frailty. Our pilot quasi-experimental studies have demonstrated Cognitive Groove results in clinically significant improvements in walking speed by 0.1 m/s with enhanced temporal-spatial walking parameters and improved lower extremity function, including balance and chair stands.
223501962|NCT07020546|PROCEDURE|Ovarian Platelet-rich plasma (PRP) injections|This is a procedure that our patients receive at our clinic. We want to use the AI software to evaluate embryo development before and after treatment to see if there is a difference in embryo quality after PRP treatment within the same patient.
223501963|NCT06453460|DRUG|Letermovir|Subjects will receive 14 weeks of letermovir prophylaxis at standard recommended dose follow by CMV-TCIP-directed extended prophylaxis.
223501964|NCT06453460|DEVICE|CMV T Cell Immunity Panel (CMV-TCIP)|Viracor CMV-TCIP assay to measure how a person's immune system responds to CMV. Viracor CMV-TCIP will be measured monthly, starting at week 14, until positive, then at week 30 and 52.
223501965|NCT06453460|DIAGNOSTIC_TEST|CMV DNA PCR|Plasma level of CMV DNA PCR will be measured at enrollment and at least weekly through week 30, then at least every 2 weeks through week 52 of transplant if no GVHD or CMV reactivation.
223501966|NCT01560416|DRUG|Fulvestrant|
223501967|NCT01560416|DRUG|Ganetespib|
223501968|NCT07039734|OTHER|collection of data from medical records|collection of data from medical records
223501969|NCT07040475|OTHER|Inpatient TCIM therapy|This multicenter, prospective, uncontrolled observational study is evaluating the effects and safety of inpatient TCIM therapy (German: naturheilkundliche Komplextherapie) at three German clinics: Immanuel Hospital Berlin, Klinikum Bamberg, and Evangelical Clinics Essen-Mitte. This therapy, reimbursed by statutory health insurance under certain conditions, combines evidence-informed TCIM approaches such as hyperthermia, exercise therapy, phytotherapy, and dietary interventions including fasting i.a.
223501970|NCT06724198|DIETARY_SUPPLEMENT|Psyllium husk|3.66 gram Psyllium husk twice daily for 8 weeks
223501971|NCT07043361|DRUG|semaglutide|testing the effect of baseline vitamin D on metabolic effects of semaglutide
223501972|NCT07044999|OTHER|no intervention|no intervention
223512196|NCT01885234|OTHER|Aerobic exercise|Pregnant women with Gestational Diabetes and pregnant women with chronic hypertension will perform 50 minutes of aerobic exercise in a bicycle, 3 times a week
223512197|NCT01885234|OTHER|Stretch exercise|Pregnant women with Gestational Diabetes and pregnant women with chronic hypertension will perform 50 minutes of stretch exercise, once a week
223512198|NCT06514729|PROCEDURE|Adopting different ventilation modes during the operation|The ventilation side adopts different ventilation modes combined with continuous positive pressure ventilation on the surgical side.
223512199|NCT01608308|DRUG|IV Acetaminophen|1000mg IV acetaminophen over 15 minutes every 4 hours for up to 2 doses.
223746391|NCT05930730|BIOLOGICAL|Comvigen (Bivalent, ChulaCov19 BNA159.2)|single dose of COMVIGEN at 50 ug, as a booster dose, given at 3 months and above after receipt of a previous booster dose of any approved mRNA COVID-19 vaccine
223746392|NCT05930730|BIOLOGICAL|BIVALENT Pfizer/BNT vaccine|single dose of BIVALENT of Pfizer/BNT Bivalent vaccine at 30 ug, as a booster dose, given at 3 months and above after receipt of a previous booster dose of any approved mRNA COVID-19 vaccine
223746393|NCT04588987|BIOLOGICAL|PD-1|Neoadjuvant PD-1 and Apatinib for rHGG. Adjuvant PD-1 and Apatinib for rHGG
223746394|NCT04779684|OTHER|Advance care planning by proxy for health care proxies of people without medical decision making capacity|Two discussions between a trained health professional and a health care proxy of an RACF resident who no longer has decision making capacity. First discussion focuses on life story, values, previous experiences with medical treatments, illness and death. Second discussion also includes treating physician and focuses on establishing general goals of care and medical orders in case of emergency.
223746395|NCT03877627|PROCEDURE|Pelvic and Peritoneal Lymphadenectomy|Patients in arm 2 will be randomized to undergo pelvic and peritoneal lymphadenectomy to treat their endometrial carcinoma.
224193114|NCT04436497|DRUG|Matching Placebo|"Drug: Matching Placebo~Administration: Subcutaneous injection~Dosage: Daily subcutaneous injection"
223501973|NCT07045779|BEHAVIORAL|Orofacial myofunctional therapy - traditional|Behavioral interventions, like orofacial myofunctional therapy (OMT), target brain reorganization and plasticity by establishing new motor patterns or re-establishing old ones. The aim of OMT is to correct pathological function and resting positions based on the equilibrium theory. A service model that is often used in OMT is the model provided by Garliner, which includes a 10 week OMT program with a frequency of one session of 45 minutes per week together with home practice. Treatment sessions will be used to introduce and practice new exercises, to monitor home practice and motivation of the patients. Additionally, the participant will be instructed to perform the same exercises from the treatment session at home daily. This intervention will consist of (1) creating awareness, (2) establishing nasal breathing, (3) labial seal and lip closure exercises, (4) tongue posture exercises, (5) lip and tongue strengthening, (6) practicing a physiological swallowing act.
223501974|NCT07045779|BEHAVIORAL|Orofacial myofunctional therapy - reduced|Behavioral interventions, like orofacial myofunctional therapy (OMT), target brain reorganization and plasticity by establishing new motor patterns or re-establishing old ones. The aim of OMT is to correct pathological function and resting positions based on the equilibrium theory. A service model that is often used in OMT is the model provided by Garliner, which includes a 10 week OMT program with a frequency of one session of 45 minutes per week together with home practice. Treatment sessions will be used to introduce and practice new exercises, to monitor home practice and motivation of the patients. Additionally, the participant will be instructed to perform the same exercises from the treatment session at home daily. This intervention will consist of (1) creating awareness, (2) establishing nasal breathing, (3) labial seal and lip closure exercises, (4) tongue posture exercises.
223501975|NCT07045779|BEHAVIORAL|Vocal warm up|The sham treatment program will include exercises from an evidence-based vocal warm up program, with exclusion of the exercises that include active involvement of the tongue or lips. Exercises that will be included are: open mouth approach, glottal fry, producing ascending and descending tones and the hand-over-mouth technique. These exercises aim to improve the dynamics of the extrinsic and intrinsic laryngeal muscles and therefore are expected not to interfere with the content of the OMT program. Furthermore, exercises regarding body posture (no focus on articulators), relaxation and voice onset will be included. This sham treatment program will be provided by the same speech-language pathologist with comparable motivation techniques as those applied in the real OMT programs.
223501976|NCT07045090|DEVICE|Transcutaneous electrical acupoint stimulation|Before induction of anaesthesia, electrodes were attached to selected acupoints and energised for 30 min, with the electrical stimulation parameter of dispersed dense wave (2/100 Hz), and the current intensity was based on the maximum current intensity that could be tolerated by the patient.
223501977|NCT07045090|DEVICE|Transcutaneous electrical acupoint stimulation combined with auricular vagus nerve stimulation|Before anaesthesia induction, the electrodes were attached to the selected acupoints and energized for 30 min, with the electrical stimulation parameters of dispersed dense wave (2/100Hz), and the current intensity was based on the maximum current intensity that the patient could tolerate. At the same time, the left ear auricular region was stimulated with a fasciculus nerve stimulator, the electrical stimulation parameters were: pulse width of 250 μs, pulse frequency of 20Hz, every 30s on, 30s off, and then 30s on again, the current intensity was based on the maximum current intensity that the patient could tolerate, for 30min.
223746396|NCT03145896|DIETARY_SUPPLEMENT|vitamin D|After the gastroscopy all patients will be taught to take 4000 unit of vitamin D (25(OH)D) daily (not a specific brand) , for the next 2 week. All patients will be invited for follow-up in 2 weeks to get the histopathology result. In this encounter we will take again blood sample for 25(OH)D, calcium, phosphate, CRP and complete blood count including hemoglobin. a control group will not take the Vitamin D supplements.
223746397|NCT03179150|DIAGNOSTIC_TEST|Computed Tomography|CT scans were performed on a 128 detector rows CT scanner (Somatom Definition Flash Siemens Medical Systems, Erlangen, Germany) as in routine clinical practice in the centre
223746398|NCT03929848|PROCEDURE|Cuff pressure|observe and record the required cuff pressure to prevent gas leakage during mechanical ventilation for laryngomicrosurgery
223746399|NCT04577937|DIAGNOSTIC_TEST|LAM patients underwent PSG|Patients with confirmed diagnosis of LAM underwent a whole-night polysomnography. The presence of either acute or chronic respiratory failure or the use of long-term oxygen therapy are considered exclusion criteria
223746400|NCT02984033|RADIATION|Head and Neck patients|Treatment consists of Intensity Modulated Radiation Therapy (until 2.2 Gy) with a total dose of 50-66 Gy in post-operative setting and 66-72 Gy in radical setting.
224074979|NCT05343312|DRUG|AL (Coartem)|"Eligible patients will be consecutively assigned to the four cohorts. Rescue therapy according to national malaria treatment guidelines will be also administered in cases of early or late treatment failure.~Follow-up visits will take place on days 1, 2, 3, 7, 14,21 and 28 after enrolment or at any time point whenever the child is sick. Adverse events will be recorded and assessed for severity and association with study medication.~Thick and thin Giemsa-stained blood slides will be prepared before each dose to be administered and at every follow-up visit of days 2, 3, 7, 14, 21, 28, 35 and 42. Blood samples for PCR analysis will be collected from every patient at baseline and at days 7, 14, 28, and 42 day of treatment failure or at any other unscheduled visit. The Molecular markers associated with suboptimal response to ACTs will be investigated."
224193115|NCT04800991|DEVICE|Rhexium Onco Nutrition|"The research devices in this study are classified into subject mobile application and investigator web portal with no invasive action on the human body"
224193116|NCT04099589|DRUG|Toripalimab|Gemcitabine/Cisplatin plus Toripalimab
223746401|NCT00175721|PROCEDURE|The Combined Cardiac Kidney Diabetes Care Clinic|See Detailed Description.
223746402|NCT05511142|OTHER|Classic Peyton's Four-Step Approach|Instructor demonstrated endotracheal intubation and mask ventilation procedural skills directly to the preclinical students, followed by direct hands-on practice using manequin, ended with giving feedback to the students
224193117|NCT06566729|OTHER|Peripheral blood sample collection|In this study, peripheral blood samples would be collected before adjuvant chemotherapy, after adjuvant chemotherapy and every 3 months thereafter until 2 years after surgery.
224193118|NCT06568289|DRUG|Lignocaine|A perineal infiltration of a 5-ml of the drug (100 mg of lignocaine) in the margins of the episiotomy. Careful aspiration before and during injection of the product should be performed to prevent intravascular injection. The entire contents will then be injected slowly at several points of infiltration. All planes will be infiltrated (vagina, muscle, and skin) before episiotomy repair.
223746403|NCT05511142|OTHER|Modified Peyton's Four-Step Approach|Video tutorial of endotracheal intubation and mask ventilation were given to the students without explanation, followed by video tutorial making using manequin (without instructor) by the students which will be uploaded to Youtube
223746404|NCT01049321|DIETARY_SUPPLEMENT|DASH diet|
224193119|NCT06568289|DRUG|Bupivacaine|A perineal infiltration of a 5-ml of the study drug (20 mg of Bupivacaine) in the margins of the episiotomy. Careful aspiration before and during injection of the product should be performed to prevent intravascular injection. The entire contents will then be injected slowly at several points of infiltration. All planes will be infiltrated (vagina, muscle, and skin) before episiotomy repair.
223501978|NCT06726876|DIETARY_SUPPLEMENT|Manuka honey oral rinse.|"Name: Manuka Honey Oral Rinse~Description:~Dosage: Patients will use 20 ml of Manuka honey diluted in 100 ml of purified water.~Administration: Oral rinse, performed 3 times per day.~Instructions: Patients are instructed to rinse their mouths with the solution for a specified duration and avoid swallowing it.~Unique Elements:~Active Ingredient: Manuka honey, known for its unique antibacterial properties due to high levels of methylglyoxal (MGO).~Mechanism of Action: MGO and Non-Peroxide Activity (NPA) contribute to antibacterial potency, effective against antibiotic-resistant bacteria, and potential immunomodulatory effects that aid wound healing and tissue regeneration.~Additional Procedures: Scaling and root debridement, along with the local application of 0.5 ml non-diluted Thyme honey on sites with Probing Pocket Depth (PPD) ≥ 5 mm.~Supplementary Care: Patients receive motivation and detailed oral hygiene instructions (proper tooth brushing technique, flossing, use of inte"
223501979|NCT06726876|DRUG|Normal saline rinses.|"Dosage: Patients will use 20 ml of normal saline.~Administration: Oral rinse, performed 3 times per day.~Instructions: Patients are instructed to rinse their mouths with the saline solution for a specified duration and avoid swallowing it.~Unique Elements:~Control Comparison: Provides a placebo comparison to evaluate the efficacy of the Manuka honey intervention.~Additional Procedures: Scaling and root debridement, along with the local application of 0.5 ml non-diluted Thyme honey on sites with Probing Pocket Depth (PPD) ≥ 5 mm."
223501980|NCT07050693|DIETARY_SUPPLEMENT|Vitamin + Zinc + micronutrient mixture|a dietary supplement containing Vitamin D, Zinc, Beta glucan WELLMUNE WGP, 2'Fucosyllactose.
223501981|NCT07050693|DIETARY_SUPPLEMENT|Placebo|Placebo is identical to intervention product
223512200|NCT01608308|DRUG|Placebo|100 mL of 0.9% normal saline over 15 minutes in place of IV acetaminophen.
223746405|NCT01049321|DIETARY_SUPPLEMENT|a usual diabetic diet|
223746406|NCT05159895|DRUG|[14C]-DZD9008|Each subject will receive a total of 100 mg DZD9008 oral suspension containing approximately 1 μCi of \[14C\] as a single administration
223746407|NCT04307446|DEVICE|Immersive Virtual Reality|Immersive Virtual Reality
223746408|NCT02817165|DIETARY_SUPPLEMENT|Probiotic (BioK+)|Probiotic (BioK+) with 3 stains of Lactobacillus
223746409|NCT02817165|OTHER|Placebo|Strawberry flavored tub of milk, identical (taste, color, odor) to the active Bio-K+ treatment.
223746410|NCT03506750|DRUG|IVC|Patients with PDR will receive intravitreal injection of conbercept (0.5 mg/0.05 mL; Chengdu Kanghong Biotech, Inc., Chengdu, Sichuan, China) in the inferior-temporal sector 4 mm from the sclerocorneal limbus before pars plana vitrectomy (PPV) surgery.
223512201|NCT06437366|BEHAVIORAL|Nurse-Led Heart Math Training Program|"he nurse-led HeartMath training program consists of several key components designed to enhance resilience, sense of coherence, and emotional adjustment:~Heart-Focused Breathing Techniques: Patients are taught specific breathing techniques that help synchronize heart and brain activity, leading to a state of physiological coherence.~Emotional Regulation Skills: The training includes exercises that help individuals recognize and shift from negative to positive emotional states, thereby improving emotional stability and reducing stress."
223591952|NCT05517798|PROCEDURE|Alveolar ridge preservation|Alveolar ridge preservation is a method of decreasing bone resorption following tooth extraction and facilitating prosthetically-driven implant placement
223591953|NCT04955418|DEVICE|Epi-No®|evaluation, 10 sessions (twice a week for 5 weeks) of perineal preparation with the Epi-No device and revaluation six months after delivery.
223591954|NCT04955418|DIAGNOSTIC_TEST|Evaluation|evaluation (anamnesis, childbirth data, perineometry, International Consultation on Incontinence Questionnaire - Short Form, Female Sexual Function Index) six months after vaginal delivery.
223591955|NCT00910169|OTHER|inpatient treatment|Hospitalisation modalities are described but are naturalistic
223591956|NCT01395407|RADIATION|Radiosurgery dose escalation|"Cohort A: resection cavity volume up to 4.2 cc (corresponds to 0 - 2 cm diameter).~Cohort B: resection cavity volume \> 4.2 cc and ≤ 14.1 cc (2 - 3 cm diameter) Cohort C: resection cavity volume \> 14.1 cc and ≤ 35 cc (3 - 4 cm diameter)~Dose level Cohort A (Gy) Cohort B (Gy) Cohort C (Gy)~1. 21 18 15~2. 23 20 17~3. 25 22 19"
223591957|NCT03897842|DEVICE|Reprieve Cardiovascular System|The Reprieve Cardiovascular System (RCS) shall be utilized to maximize fluid removal over a maximum duration of 72 hours.
223746411|NCT03506750|PROCEDURE|Blood and aqueous humor at the time of IVC|Initial blood and aqueous humor will be harvested at the time of IVC.
223746412|NCT03506750|PROCEDURE|Collect blood, aqueous humor, and initial vitreous at the time of surgery.|Blood, aqueous humor, and vitreous will be collected at the time of surgery.
223746413|NCT03506750|PROCEDURE|IVC-sham|Patients with PDR will receive sham intravitreal injection of conbercept in the inferior-temporal sector 4 mm from the sclerocorneal limbus 4 days before PPV surgery.
223746414|NCT02206425|DRUG|Melphalan|Melphalan will be administered at the same schedule and dose intensity as those of the last PI-containing treatment the patient failed (it varies with each patient).
224193120|NCT04818866|DIAGNOSTIC_TEST|SuPAR, C-reactive protein, Ferritin, D-Dimer, Procalcitonin, Interleukin-6, Lactate Dehydrogenase|Biomarkers of inflammation
224193121|NCT00931866|DRUG|Diclofenac Sodium|Topical diclofenac patch applied once daily to area of pain
223746415|NCT02206425|DRUG|Prednisone|Prednisone will be administered at the same schedule and dose intensity as those of the last PI-containing treatment the patient failed (it varies with each patient).
224193122|NCT00931866|DRUG|Matching Placebo Patch|Matching placebo patch, containing identical constituents to the active comparator except for diclofenac sodium; applied once daily
224193123|NCT02160223|DRUG|Sugammadex|Group S patients will receive 2 mg kg -1 sugammadex at he end of surgery
224193124|NCT02160223|DRUG|Neostigmine|Patient in Gropu N will receive 50 µg kg-1 neostigmin and 05 mg atropin at the end of surgery
224193125|NCT05477927|BIOLOGICAL|Dual-targeting VEGFR1 and PD-L1 CAR-T cells|"In the dose escalation part, the dose levels will be escalated following a traditional escalation scheme for 3+3 design.~In the dose expansion part, patients will be assigned to different groups based on pleural or peritoneal metastases condition."
224193126|NCT02822027|DRUG|human gamma globulin|human gamma globulin for preterm infants with encephalopathy of prematurities
224193127|NCT02822027|DRUG|non-human gamma globulin|Non-human gamma globulin for preterm infants with encephalopathy of prematurities
224193128|NCT03383276|DRUG|IL-1Ra|custom eye drop to be applied to the left eye.
224193129|NCT01028859|DRUG|CKD-516 inj|5.0 mg/2ml; 1.0, 2.0, 3.3, 5, 7, 9 \~ mg/m2; Day 1, Day 8 every 3 weeks
224193130|NCT01132027|DRUG|Tacrolimus Capsules|Tacrolimus Capsules, 5 mg of Dr. Reddy's Laboratories Limited
224193131|NCT01748162|DRUG|Fluticasone|Daily inhaled steroids. Fluticasone 2 puffs inhaled orally twice daily for six months.
224193132|NCT01748162|DRUG|Prednisolone IF needed|
224193133|NCT01073176|OTHER|TEAMS (Training Attention Executive and Motor Skills)|Training Executive, Attention and Motor Skills (TEAMS) is a new research program for preschool children with Attention-Deficit/Hyperactivity Disorder (ADHD) that attempts to use game-like activities and physical exercise to promote the growth of neural processes that underlie the core features of the disorder (e.g., hyperactivity, impulsivity) as well as associated areas of difficulty (e.g., socialization, motor skills). These activities are implemented at home and in supervised playgroups at no cost to families and are coupled with extensive parental education about ADHD symptoms and associated impairments.
224193134|NCT01813760|DEVICE|Illuiminage ® Diode Laser|Diode laser for treatment of peri-orbital and peri-oral wrinkles
224193135|NCT00505765|DRUG|AL-108|AL-108, 5 mg/day- one spray in each nostril once per day
224193136|NCT00505765|DRUG|AL-108|AL-108, 30 mg/day- 3 sprays in each nostril, twice per day
224193137|NCT00505765|DRUG|Placebo|Placebo- 3 sprays in each nostril, twice per day
224193138|NCT00505765|DRUG|Placebo|Placebo- one spray in each nostril, once per day
224193139|NCT01172860|DEVICE|EndoVe endoscopic electroporation|The EndoVe device enables the endoscopic treatment of gastrointestinal tumor tissues. The device is placed on the tumor tissue and an electrical pulse of less than 1msec is delivered. The tumor tissue becomes permeabilised and absorbs much greater concentrations of the drug than the surrounding healthy tissue
224193140|NCT01737463|PROCEDURE|Endoscopic snare papillectomy|Endoscopic snare papillectomy (ESP) was performed by using diagnostic or therapeutic duodenoscope. A pancreatic duct stent was or was not inserted immediately after the excision.
224193141|NCT05364164|DRUG|CT-L01 12.5/1,000 mg|FDC tablet, 2 tablets at a time, oral administration, dosing under fasting condition
224193142|NCT05364164|DRUG|CT-L01 12.5/1,000 mg|FDC tablet, 2 tablets at a time, oral administration, dosing after high-fat meal
223501982|NCT07045064|OTHER|Aerobic exercise without medication|"twenty patients will participate in moderate intensity intradialytic aerobic training for 12 weeks. (3 times per week). Using Horizontal electromagnetically braked cycle ergometer during the first half of the dialysis session.~(1) Frequency: received intradialytic, lower-limb, cycling exercise three times per week on alternative days (2) Intensity: the intensity of exercise will be at 12-14 (moderate-intensity: somewhat hard or reports of feeling a little bit tired but still ok to continue) based on the Borg's Perceived Exertion Rating Scale Appendix III (a rating of 6 perceiving no exertion at all to 20 perceiving a maximal exertion of effort) ,Appropriate speed and grade of resistance were adjusted to achieve the required intensity. (3) Time: the duration of each exercise session consisted of a 5-min warm-up in form of circulatory exercise."
223501983|NCT07045064|OTHER|resistive exercise without medication|"Twenty patients will participate in moderate intensity intradialytic resistive training for 12 weeks. (3 sessions per week) using ankle weights.~During session: The warming up phase for 5-minute in form of circulatory exercises, then the main exercise phase and then cooling down phase for 5 minutes. in form of circulatory exercises.~The training protocol consisted of five lower-body resistance exercises using ankle weights 3 days/week, The intensity of the program will be moderate, starting with two sets of each exercise at 60% of each patient's three repetition max (3-RM) strength, progressing to three sets per session, with additional weight added as tolerated"
223501984|NCT07045064|OTHER|circulatory exercise without medication|this group will include 20 patients will participate in circulatory exercises and will be evaluated at the beginning and at the end of the study.
223512202|NCT05128448|OTHER|Cross-body stretch (CBS)|CBS is a self administered stretch that aims to stretch posterior shoulder structures
223512203|NCT05128448|OTHER|Mobilisation with movement (MWM)|WMW is a musculoskeletal procedure that aims to improve restricted and/or painful range of movement
223512204|NCT00787488|DEVICE|Hyperthermia|Every 3 weeks
223591958|NCT05885802|OTHER|No specific intervention other than routine anesthesia protocol|No specific intervention other than routine anesthesia protocol
223591959|NCT00733941|BEHAVIORAL|High frequency training|24 training sessions, 8x weekly, followed by detraining phase 8 weeks, and retraining
223591960|NCT00733941|BEHAVIORAL|normal frequence training|24 training sessions, 3x weekly, followed by detraining phase 8 weeks, and retraining
224193143|NCT03841331|DRUG|5 mg Serlopitant Tablets|Serlopitant Tablets
224193144|NCT03841331|DRUG|Matching Placebo Tablets|Placebo Tablets
223591961|NCT01088022|DRUG|Aprepitant, Palonosetron, Dexamethasone|Aprepitant 125-mg capsule 80-mg capsule 80-mg capsule Palonosetron 0.25 mg i.v. Dexamethasone 8 mg i.v. 8 mg os 8 mg os
223591962|NCT01088022|DRUG|Placebo, Palonosetron, Dexamethasone|Aprepitant 125-mg placebo capsule 80-mg placebo capsule 80-mg placebo capsule Palonosetron 0.25 mg i.v. Dexamethasone 8 mg i.v. 8 mg os 8 mg os
223591963|NCT00909597|DRUG|pioglitazone|30mg po once daily for 4 weeks, followed by 45mg once daily
223591964|NCT00909597|DRUG|taspoglutide|10mg sc once weekly
223591965|NCT00909597|DRUG|taspoglutide|10mg sc once weekly for 4 weeks, followed by 20 mg sc once weekly
224193145|NCT05359289|BEHAVIORAL|Forest therapy training|Participants will experience nature-based interventions including forest hiking, horticultural therapy and green wellness activities for their mental health and physical conditions.
224193146|NCT05359289|BEHAVIORAL|Senior fitness training|The fitness program includes physics fitness of stamina, coordination and aerobic exercise in 12 weeks. Participants will join the senior fitness program including physical fitness, aerobic exercise and exercise prescription during the 12 weeks program.
224193147|NCT05359289|BEHAVIORAL|Board Games|Participants will play board games with each other.
224193148|NCT02743117|BIOLOGICAL|Monovalent Influenza Vaccine|A single dose of 10\^(7.0 ± 0.5) FFU strain of monovalent influenza vaccine will be administered as intranasal spray on Day 1.
224193149|NCT02743117|OTHER|Placebo|A single dose of placebo matched to monovalent influenza vaccine will be administered as intranasal spray on Day 1.
224193150|NCT02120690|DEVICE|Trigeminal nerve stimulation|10-day TNS interventional protocol over an 10-day follow-up. Subjects will have electrodes (Superior Silver 1.25-in. diameter) placed on their foreheads to stimulate the V1 branches of the trigeminal nerve bilaterally for approximately 30 minutes each day. Current was adjusted to maintain comfortable but perceptible levels of stimulation
224193151|NCT01219179|OTHER|Sterile water feedings|"Control group- no intervention~Prophylactic group will receive sterile water feeds starting at 24 hours of life if/or when their serum sodium value is ≥ 145 mEq/L. The volume of sterile water is 10mls/Kg/day based on birth weight, given via continuous infusion feed.~The feeding will be stopped when the serum sodium value is ≤ 140 mEq/L.~The hypernatremia group will receive sterile water feeds when their serum sodium value is ≥ 150 meq/L. The volume of sterile water is 10 mls/Kg/day based on birth weight,given via continuous infusion feed. The feeding will be stopped when the serum sodium value is ≤ 140 mEq/L."
224193152|NCT06360159|OTHER|Intervention|As an intervention, the newborn will be massaged.
224193153|NCT06165575|DEVICE|Press needle|Press needle is a very small needles (1-3 mm long) that are 'pressed' onto acupuncture point and are held in place with a small, sterile surgical adhesive patch.
224193154|NCT06165575|DEVICE|Sham press needle|Sham press needle is a surgical adhesive patch placed on acupuncture points
224193155|NCT04228718|BEHAVIORAL|Zarit Burden Interview Scale|It is a questionnaire consisting of 22 items. A minimum score of 0 and a maximum score of 88 can be obtained. The higher the scale score, the higher the difficulty experienced.
224310100|NCT03067597|DRUG|Dinoprostone|The DVI contains 10 mg dinoprostone
224310101|NCT04126590|BIOLOGICAL|KN044|"The modified phase I 3 + 3 study design was used in dose escalation from low dose to high dose to determine the MTD.Sequential assignment of Patient cohorts to one of five dose levels of KN044: 0.03mg/kg,0.3 mg/kg,1 mg/kg,3 mg/kg,6 mg/kg,10 mg/kg."
223501985|NCT07046416|OTHER|Occupation-Based Exercise Program|"In the occupation-based exercise program, while trying to improve the range of motion and muscle strength of the hand, it is aimed to successfully return to daily life activities. For this reason daily activities are used instead of memorized range movements. In this way, the occupation-based exercise program provides a physical recovery in patients with hand injuries, while providing positive improvements in parameters related to the mind and spirit. Patients' participation, motivation and compliance with the treatment are increased in the hand rehabilitation process, which can be challenging for patients.~In addition to the conventional treatment program, the study/experimental group, will be given occupation-based exercises for a total of 4 weeks between the 6th and 10th weeks postoperatively, 2 days a week with a physiotherapist and the other days with a home program."
223512205|NCT06525870|DRUG|85%TCA topical application|85%TCA topical application is done at cervical lesion and transformation zone. Application of TCA will be guided by colposcopy using a small cotton-tipped applicators and wooden end of the applicators. A thin film of TCA will be applied to cover the lesion and transformation zone.
223746416|NCT02206425|DRUG|Cyclophosphamide|Cyclophosphamide will be administered at the same schedule and dose intensity as those of the last PI-containing treatment the patient failed (it varies with each patient).
223746417|NCT02206425|DRUG|Dexamethasone|Dexamethasone will be administered at the same schedule and dose intensity as those of the last PI-containing treatment the patient failed (it varies with each patient).
223746418|NCT02206425|DIETARY_SUPPLEMENT|Ascorbic acid|Vitamin C will be administered at the same schedule and dose intensity as those of the last PI-containing treatment the patient failed (it varies with each patient).
224193156|NCT04228718|BEHAVIORAL|Family Needs Survey (FNS)|It is a questionnaire consisting of 35 items prepared to determine the requirements. In the FNS survey; The points given to the items can be directly collected and the amount of family needs can be determined over the total score. The lowest score that can be obtained from FNS is 29 and the highest score is 87. As the scores obtained from the scale and subscales increase, it can be said that the families' level of necessity increases.
224310102|NCT04241926|DIAGNOSTIC_TEST|transpolmonary thermodilution|Thermodilution was attempted via PICC and via CICC in the same patient
224310103|NCT00111826|DEVICE|Celacade™ system|
224310104|NCT00002960|BIOLOGICAL|recombinant adenovirus-p53 SCH-58500|
224310105|NCT02991326|OTHER|Osteopathic Manipulative Treatment|"The Osteopathic manipulative treatment will follow the approach bellow (using latex gloves for intra oral techniques):~* Compression of the fourth ventricle;~* inhibitory intra-oral pressure technique (IPT) of the temporal muscle;~* inhibition of the inferior head of the lateral pterygoid muscle;~* intra-oral inhibition of the masseter muscle;~* Balanced ligamentous tension (BLT) of the accessory ligaments - sphenopalatine;~* BLT of the accessory ligaments - pterygomandibular raphe;~* sphenopalatine ganglion technique;~* Craniosacral rebalancing;"
224310106|NCT02991326|OTHER|Sham intervention|The sham intervention will be made in the same examination table and the same position, with the use of the latex gloves, to simulate the Osteopathic Manipulative Treatment, only doing simple touches without therapeutic effect intention.
223512206|NCT06525870|DRUG|3% acetic acid|3% acetic acid topical application is done at cervical lesion and transformation zone. Application will be guided by colposcopy using a small cotton-tipped applicators and wooden end of the applicators. A thin film of acetic acid will be applied to cover the lesion and transformation zone.
223512207|NCT00180453|DEVICE|Coronary artery drug eluting stent placement|Coronary artery drug eluting stent placement
223512208|NCT00180453|DEVICE|Coronary artery stent placement|Coronary artery stent placement
223512209|NCT06122493|DRUG|Tirelizumab|immunotherapy, 200 mg on day 1 per 3 weeks
223512210|NCT06122493|DRUG|Nab paclitaxel|chemotherapy, 175 mg/m² on day 1 per 3 weeks
223512211|NCT06122493|DRUG|Carboplatin|chemotherapy, AUC=5 on day 1 per 3 weeks
223512212|NCT06122493|RADIATION|Radiotherapy|Patients without disease progression after four cycles of chemoimmunotherapy receive radiotherapy targeting esophageal lesions and positive lymph nodes, with a total dose of 50.4 Gy delivered over 28 fractions.
223512213|NCT03849612|DEVICE|AID System|AID system
224193157|NCT04228718|OTHER|Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND)|CHOP-INTEND uses a scale of 0-64 points. Higher scores indicate better motor function. It is used to reliably measure natural motor function decline in infants with SMA Type 1.
224193158|NCT04228718|OTHER|Hammersmith Functional Motor Scale Expanded (HMFSE)|It is an extended version of the 20-item HFMS. Based on another scale known as GMFM, 13 items were added and expanded HFMS to include these elements. Therefore, HFMSE is a scale used to evaluate motor functions in types 2 and 3 SMA. It contains 33 items with a total score of 66 on a scale of 0, 1, 2.
224193159|NCT03301168|BIOLOGICAL|BPX-501 T cells|T cells transduced with CaspaCIDe® safety switch
224193160|NCT03301168|DRUG|Rimiducid|administered to inactivate BPX-501 cells in the event of GVHD
224193161|NCT04353427|BEHAVIORAL|The Seven Pathways to Healing, Health and Wellness curriculum|"The curriculum seeks to increase civic engagement by fostering a sense of community and a sense of social and personal responsibility in community. There will be 7 monthly session that will be approximately 1 hour in duration. Session topics include:~1. Education and Information (including mental health awareness, and a one-day certificate program in Mental Health First Aid)~2. Connection with Others~3. The Body as Temple~4. Emotional Healing~5. The Nature of Mind~6. Life Assessment~7. The Nature of Spirit"
224193162|NCT04890691|DEVICE|Feel Bright Light|During the first waking hour, the participants will be required to wear the light visor (either therapeutic or placebo light) for 30 minutes/day for 4 weeks.
224193163|NCT04411030|DRUG|ASTX660|Form: capsule; Route of administration: oral
224193164|NCT04411030|DRUG|Midazolam|Form: syrup; Route of administration: oral
224193165|NCT04411030|DRUG|Itraconazole|Form: capsule; Route of administration: oral
224193166|NCT05053594|DRUG|Neostigmine 10 mcg/kg|Once the third response to TOF is obtained, neostigmine 10 mcg/kg will be administered
224193167|NCT05053594|DRUG|Neostigmine 20 mcg/kg|Once the third response to TOF is obtained, neostigmine 20 mcg/kg will be administered
224193168|NCT05053594|DRUG|Neostigmine 30 mcg/kg|Once the third response to TOF is obtained, neostigmine 30 mcg/kg will be administered
224193169|NCT05053594|OTHER|Placebo|Once the third response to TOF is obtained, saline will be administered
223501986|NCT07046416|OTHER|Conventional therapy group|Conventional group treatment will be according the early passive hand rehabilitation program. Conventional group will be followed with a cast-splint made by the surgical team for the first 4 weeks within the scope of the conventional treatment program. From the 4th week onwards, the duration of splint use is gradually reduced and is completely discontinued from the 6th week onwards. At the end of the 4th week, depending on the wound condition, contrast bath, scar massage, retrograde massage, active and passive flexion, active extension and tendon shifting exercises are applied as tolerated. After the 6th week, isolated block exercises and stretching exercises are added if there is contracture. Strengthening exercises are started from the 8th-10th week.
224193170|NCT03637101|DIAGNOSTIC_TEST|Ischemia modified albumin (IMA)|Ischemia modified albumin is a biomarker for cardiac ischemia and acute stroke whether ischemic or hemorrhagic
224193171|NCT03324373|DRUG|Lenvatinib|Lenvatinib is a receptor tyrosine kinase (RTK) inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). Lenvatinib also inhibits other RTKs that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progression in addition to their normal cellular functions, including fibroblast growth factor (FGF) receptors FGFR1, 2, 3, and 4; the platelet derived growth factor receptor alpha (PDGFRα), KIT, and RET.
224193172|NCT03324373|DRUG|Everolimus|Everolimus is an inhibitor of mammalian target of rapamycin (mTOR), a serine-threonine kinase, downstream of the PI3K/AKT pathway. The mTOR pathway is dysregulated in several human cancers. Everolimus binds to an intracellular protein, FKBP-12, resulting in an inhibitory complex formation (mTORC1) and thus inhibition of mTOR kinase activity. Everolimus reduced the activity of S6 ribosomal protein kinase (S6K1) and eukaryotic elongation factor 4E-binding protein (4E-BP1), downstream effectors of mTOR, involved in protein synthesis. In addition, everolimus inhibited the expression of hypoxia-inducible factor (e.g., HIF-1) and reduced the expression of vascular endothelial growth factor (VEGF). Inhibition of mTOR by everolimus has been shown to reduce cell proliferation, angiogenesis, and glucose uptake in in vitro and/or in vivo studies.
223501987|NCT07044856|BEHAVIORAL|distraction with virtual reality|Before the procedure, the patient's vital signs will be checked and pain and anxiety will be assessed. This group will be shown a video using virtual reality glasses during the lumbar puncture procedure. After the intervention, the patient's vital signs will be checked again and pain and anxiety will be assessed.
223501988|NCT06734897|OTHER|music therapy after Cochlear Implantation|The music therapy is specially designed for the rehabilitation of CI-patients. It focuses on learning to distinguish different sound sources, especially when they occur at the same time. Training involves familiarization with different aspects of music such as rhythm, melody, and pitch while at the same time also getting to know the sound of different musical instruments, including singing. The training is also aimed at learning to concentrate on spoken instructions while the music is going on. This latter aim is fundamental to the goal of this study and plays a central role in the therapy.
223501989|NCT06734897|OTHER|no music therapy after Cochlear Implantation|Group C consists of persons who do not receive any music therapy after Cochlear Implantation.
223501990|NCT07055490|PROCEDURE|Interdisciplinary Practice Bundle|interdisciplinary practices were combined in a bundle framework called (5-Ps) to maintain normal process during labor and prevent unnecessary routine interventions, which are (patience, positioning, physiological resuscitation, progress, and preventing urinary harm). These practices implemented from the beginning of the second stage of labor which is started from onset of complete cervical dilatation (10 cm) until delivery with a duration of 2 hours period.
223501991|NCT07056127|OTHER|manual dynamic agitaion|5 mL of 2.5% NaOCl solution will be activated with a well-fitting gutta-percha cone that will be placed to full working length and then will be moved in push-pull strokes of 2 mm amplitude at a frequency of 100 strokes in about 1 min
224193173|NCT03324373|PROCEDURE|Partial or Radical Cytoreductive Nephrectomy|"Surgical removal of a kidney.~After completion of 8 weeks of therapy and restaging, investigators will require 2 weeks wash out period. The patients will be evaluated by urology oncology team and appropriate surgery will be planned. This includes partial nephrectomy and radical nephrectomy."
224193174|NCT02679716|OTHER|MRI of the cerebral arteries|MRI of the cerebral arteries is performed
224193175|NCT02433522|DRUG|rituximab|500 mg rituximab infusion at the randomization visit and every 6 months for 18 months. Each infusion will be preceded by an infusion of 1000 mg paracetamol, 100 mg methylprednisolone and 5 mg dexchlorpheniramine.
224193176|NCT02433522|DRUG|Placebo|
224193177|NCT00267917|DEVICE|Berodual Respimat|
224193178|NCT00267917|DEVICE|Berodual HFA-MDI|
224193179|NCT01207219|BEHAVIORAL|Yoga therapy|3 sessions per week for 12 weeks, total 36 sessions. Each session lasts around one hour.
224193180|NCT01207219|BEHAVIORAL|Aerobic exercise|3 session per week for 12 weeks, total 36 sessions. Each session lasts around one hour.
224193181|NCT01829659|DRUG|Ticagrelor|
224193182|NCT03554759|DRUG|Avatrombopag|Avatrombopag dosing will be determined by the treating physician in conjunction with the FDA-approved package insert.
224193183|NCT03315442|OTHER|Caffeine versus Energy Drink|Caffeine group consumed 200mg of caffeine one time, while the energy drink group consumed 1 16 ounces of energy drink.
224193184|NCT05498545|BIOLOGICAL|LUCAR-B68 cells product|Before treatment with LUCAR-B68 cells, subjects will receive a conditioning regimen
223501992|NCT07056127|OTHER|ultrasonic activation|5 mL of 5.25% NaOCl solution will be activated with PUI using a #20 endosonic ﬁle that will be driven by an ultrasonic device on medium power setting for 1 minute and inserted 1 mm short of the working length
223501993|NCT07056127|OTHER|xp-endo finisher|5 mL of 5.25% NaOCl solution will be activated with XP-Endo Finisher which will be used in the canal for 1 minute at 800 rpm and 1 Ncm up to the working length and in slow up-and-down movements at 7-8mm length according to the manufacturer's recommendations
223501994|NCT07056127|OTHER|laser|First, root canals will be filled with 0.5 mL of 0.05% ICG dye and left in place for 1 minute as preirradiation time. A #20 laser fiber will be inserted into the root canals to the working length. Then infrared diode laser with a wave length of 810 nm will be used to activate the dye for 30 seconds. For activation, circular movements will be performed along with the fiber removal movement . After the first activation, dye will be reintroduced, the laser fiber will be inserted again, and a new activation cycle of 30 seconds will be performed similarly to the previous one
223501995|NCT07056855|DRUG|nano hydroxy apatite varnish Intervention (1)|Fygg's professional strength, Fygg, USA
223501996|NCT07056855|DRUG|Potassium Nitrate Gel|Ultradent UltraEZ Desensitizing Gel, Ultradent Inc., USA
223501997|NCT07056855|DRUG|Varnishes, Fluorid|DentKist Charm Varnish 5% Sodium Fluoride Varnish
223501998|NCT07055633|DEVICE|CCT+MBLT|Compensatory Cognitive Training + Morning Bright Light Therapy (Aurora LightPad)
223501999|NCT07055633|DEVICE|CCT+ION|Compensatory Cognitive Training + Negative Ion Generator (SphereOne)
223502000|NCT07057011|DRUG|Paroxetine 20 Mg Oral Tablet|to compare the safety and efficacy of paroxetine alone versus the combination of paroxetine and sildenafil in Premature Ejaculation Patients with genetic polymorphism in the serotonin transporter gene-linked polymorphic region.
223502001|NCT07057375|DEVICE|Pulsed electromagnetic fields Thearpy|Pulsed electromagnetic fields (PEMF) is a non-invasive and non-thermal treatment used to stimulate muscle regeneration, resulting in increased muscle mass and strength.
223502002|NCT07057375|DEVICE|Sham Therapy|Sham Therapy
223502003|NCT07056374|DEVICE|C-REX RectoAid Cath|Adaptive anastomotis
223502004|NCT07056088|DRUG|Insulin Drip Therapy|"Simple randomization will be used for randomization. The participants will be randomized into two groups based on methods of insulin delivery.~* Group A: Insulin drip will be administered at a starting rate of 2 units/hour and titrated to maintain blood glucose levels between 80-180 mg/dL.~* Group B: Insulin boluses will be administered every 30 minutes to maintain blood glucose levels between 80-180 mg/dL.~Insulin boluses will be considered as a control group."
223591966|NCT03305393|DEVICE|Adaptiv CRT|Adaptiv CRT algorithm to be programmed to ON in CRT devices of study patients at 6 month follow-up visit
223591967|NCT03469024|OTHER|Home Rehabilitation Program|It consists in a home rehabilitation program performing electroanalgesia and an exercise program following the Mckenzie method. Patients will be instructed in the use of the TENS device using 5x9cm electrodes at the bilateral paravertebral level, the patients that present radicular pain, the electrodes will be placed in the path of the affected nerve. The realization of exercises will be through the application of an Mckezie protocol. The duration will be the same as that used to carry out the Mckenzie protocol. Mckenzie exercises are designed to make changes in the internal components periarticular of the spine.
223591968|NCT03469024|OTHER|e-Health program|It consists in an e-Health rehabilitation program through a web platform performing electroanalgesia and an exercise program following the Mckenzie method. Patients will be instructed in the use of the TENS device using 5x9cm electrodes at the bilateral paravertebral level, the patients that present radicular pain, the electrodes will be placed in the path of the affected nerve. The realization of exercises will be through the application of an Mckezie protocol. The duration will be the same as that used to carry out the Mckenzie protocol. Mckenzie exercises are designed to make changes in the internal components periarticular of the spine.
224193185|NCT05681676|OTHER|Blood samples before and after standard of care of polymyalgia rheumatica|Blood samples were taken before glucocorticoid treatment and three months after.
224193186|NCT05695456|OTHER|personalized exclusion diet based on CLE|personalized exclusion diet based on CLE
224193187|NCT05695456|OTHER|empiric exclusion diet|exclusion diet with milk or gluten-containing grains
224193188|NCT03018756|DRUG|Fentanyl Citrate|100 mcg fentanyl citrate will be inhaled via nebulizer.
224193189|NCT03018756|DRUG|Placebo|0.9% saline solution will be inhaled via nebulizer
224193190|NCT06006026|DRUG|Ropivacaine Hydrochloride 10 MG/ML [Naropin]|According to the specified dosage, dilute 1% ropivacaine to 0.2% and inject 1/2 of the total amount on each side.
224193191|NCT04494191|DRUG|Flibanserin 100Mg Tab|One tablet contains 100 mg Flibanserin
224193192|NCT04494191|DRUG|Flibanserin 100 MG [Addyi]|One tablet contains 100 mg Flibanserin
224193193|NCT03427320|DRUG|[131]I-IAZA|Injection of a single dose of 185MBq ( range 150-220MBq) of \[131\]I-IAZA prior to whole body imaging acquisition at 0-1 hrs,1-3 hrs , 4-8 hrs,19-36 hrs,41-72 hrs and 6-8 days post-injection. SPECT CT of target lesion(s) will be acquired at 19-36 hrs post injection.
224193194|NCT03583801|OTHER|Olfactory aromatherapy|2 drops of the essential oil choosed by the patient are applied on a compress placed next to his head from his arrival in the recovery room to his leaving from the operating theatre. The method of administration is the respiratory tract..
224193195|NCT03583801|OTHER|without aromatherapy|no intervention
224193196|NCT01076140|DRUG|Nebivolol|Nebivolol 5 or 10 mg tablets daily for 4 weeks. Lisinopril 20 or 40 mg daily for 4 weeks
224193197|NCT01076140|DRUG|Lisinopril|Nebivolol 5 or 10 mg tablets daily for 4 weeks. Lisinopril 20 or 40 mg daily for 4 weeks
224193198|NCT02332044|DRUG|Erdos|capsule, 300mg
224193199|NCT02332044|DRUG|Talion|tablet, 10mg
224193200|NCT02332044|DRUG|Erdos, Talion|capsule 300mg and tablet 10mg
224193201|NCT05354401|OTHER|HHF|HHF is an integrated flow generator that delivers heated and humidified air or oxygen at high flow rates via a soft nasal cannula using an open circuit. HHF via the Fisher and Paykel myAIRVO 2 device will be initiated as per The Hospital for Sick Children's sleep laboratory standard protocol by a sleep technician or respiratory therapist (RT) during an overnight polysomnography. Nasal prongs will be selected that are less than fifty percent of the subject's nares. The lowest flow rate of HHF will be selected and titrated upwards until clinical effect is achieved, to a maximum flow of 60L/minute, as per standard clinical care.
224193202|NCT05588401|BIOLOGICAL|GenPHSat injection (Safety)|Participants receive gene edited primary human muscle stem cells (GenPHsat) injection in the left biceps muscle.
223502005|NCT07056088|DRUG|Insulin boluses|"Insulin boluses will be administered every 30 minutes to maintain blood glucose levels between 80-180 mg/dL.~Insulin boluses will be considered as a control group"
223591969|NCT04767152|DIAGNOSTIC_TEST|MRI|The quantitative assessment of MRI parameters, The macromolecular proton fraction (MPF) (%) in brain tissue. Before the start of therapy - the starting point. Point 2. 36 ± 3 days after the start of the therapy. Point 3. After completing three courses of consolidation chemotherapy. Point 4. After confirmation of remission status, optionally provided.
223591970|NCT04956458|PROCEDURE|Lumbar motion style acupuncture treatment|Motion Style Acupuncture Treatment(MSAT) is a therapeutic technique using acupuncture needle created in Jaseng Hospital. This treatment involves patients with musculoskeletal pain to move the part of their body actively during acupuncture treatment under physicians' observation
223591971|NCT04956458|PROCEDURE|Korean medical treatment|acupuncture treatment, chuna, pharmacoacupuncture, Korean herbal medicine
223591972|NCT03891368|OTHER|Virtual Learning Collaborative|InSHAPE teams consisting of health mentors, supervisors, and senior leaders from each mental health agency randomized to the VLC will be invited to attend an in-person initial kick-off meeting followed by once per month 90-minute VLC sessions. The VLC is organized into three stages: Prework, Action, and Continuous Improvement. VLC faculty, including interventionists with expertise in implementation science, quality improvement, and subject matter (i.e., InSHAPE) experts, will facilitate VLC sessions following a structured protocol to standardize the planning and execution of the VLC across three cohorts enrolled in the study.
223591973|NCT03891368|OTHER|Technical Assistance|Scheduled calls will occur at 1 month, 2 months, 8 months, and 14 months following their participation in initial InSHAPE training following randomization and follow a structured protocol. At the end of each scheduled conference call, the coach will schedule the next call with the site.
223591974|NCT04326088|OTHER|Reconstruction group|Patients with primary tumor which underwent free flap reconstruction group.
223591975|NCT04326088|OTHER|Recurrent group|Patients with recurrent tumor which underwent free flap reconstruction group.
223591976|NCT02501200|DRUG|CKD-391|Investigational product is prescribed to all of randomized subjects for two times.
223591977|NCT02501200|DRUG|Atrovastatin and Ezetimibe combination therapy|Investigational products are prescribed to all of radomized subjects for two times.
223591978|NCT03339973|BIOLOGICAL|allo-APZ2-PAOD|Suspension of ABCB5-positive mesenchymal stem cells in pre-filled syringe
223591979|NCT03339973|DRUG|Placebo|Solution for injection in pre-filled syringe
223591980|NCT02161107|BIOLOGICAL|Grass-SPIRE|Intradermal injection
223746419|NCT02206425|DRUG|PLD|Pegylated liposomal doxorubicin will be administered at the same schedule and dose intensity as those of the last PI-containing treatment the patient failed (it varies with each patient).
224193203|NCT05588401|BIOLOGICAL|GenPHSat injection (Efficacy)|Participants receive gene edited primary human muscle stem cells (GenPHsat) injection in the right biceps muscle.
224193204|NCT05588401|OTHER|Muscle Biopsy (Safety)|Participants undergo muscle biopsy 3 month after safety GenPHSat injection.
224193205|NCT02539329|OTHER|Neurological assessment and Blood sample|Neurological assessment (physical examination, electroneuromyography , International Prognostic Score (ISS), Overall Disability Scale (ODS), Rankin score) and 2 blood collection tubes for antibody screening
224193206|NCT03619512|GENETIC|Whole exome sequencing.|Retrospective biological exploration of the samples, including tumoral DNA exploration.
224193207|NCT03619512|GENETIC|RNA sequencing|Characterization of tumor transcriptomic profile.
224193208|NCT03619512|OTHER|Mass spectrometry|Characterization of tumor proteomic profiles.
223502006|NCT03150212|DIETARY_SUPPLEMENT|Saccharomyces cerevisiae CNCM I-3856|2 capsules daily, just before the breakfast with a glass of water, during 8 weeks.
223502007|NCT03150212|DIETARY_SUPPLEMENT|Placebo|2 capsules daily, just before the breakfast with a glass of water, during 8 weeks.
223502008|NCT06767722|BEHAVIORAL|Lifestyle intervention and self-monitoring of blood glucose|The intervention will consist of a lifestyle intervention that comprises advice on diet, exercise, weight management, and self-monitoring of blood glucose (SMBG) with feedback from healthcare professionals on results and insulin treatment if indicated.
223591981|NCT02161107|BIOLOGICAL|Placebo|Intradermal injection
223591982|NCT00973492|OTHER|functional insulinotherapy class|"The functional insulinotherapy class lasts for 4 days. It is taught by 2 nurses, 2 dieticians and 2 physicians to 6 to 10 patients.~On day 1, patients describe their difficulties with diabetes. Fast-acting insulin scales are elaborated from preprandial and postprandial blood glucose levels. At dinner, patients start a 24-hour glucose-fasting period to evaluate their need for basal insulin. Meals contain virtually no carbohydrates. Correcting doses of insulin are administered if preprandial glycemia is over 1.50 g/l or postprandial glycemia is over 2 g/l. Blood glucose levels must stay within normal values during the whole 24-hour period.~Carbohydrate management is taught during meals and every afternoon through workshops about dietetics. Patients also learn how to deal with hypoglycaemia, hyperglycaemia and physical activity.~A one-day follow-up takes place 3 months later."
223591983|NCT01662947|DEVICE|Blood pressure Transtek Wrist Blood Pressure Monitor, TMB-1117|Systolic, Diastolic pressure.
224193209|NCT02378870|DRUG|Osteodex|Osteodex 3.0 mg/kg given every two week, maximum 13 times.
224310107|NCT02021357|BEHAVIORAL|hyperbolid combined with tongue exercises on the palate|
224310108|NCT02021357|OTHER|hyperbolid|
224193210|NCT02378870|DRUG|Placebo|
224193211|NCT04911569|DEVICE|Cryoneurolysis|Cryoneurolysis
224193212|NCT03396601|DRUG|Ketamine Hydrochloride|Ketamine HCl will be infused intravenously at a dose of 0.5 mg/kg over 40 minutes
224310109|NCT01366950|BEHAVIORAL|Intelligent physical activity|30 minutes of moderate activity 6 days a week and 45 minutes of high intensity training 1 day a week. Moderate activity is monitored in diaries and high intensity training is monitored by a trainer.
224310110|NCT01303770|BEHAVIORAL|Self-management cognitive rehabilitation group intervention|8-week cognitive rehabilitation program facilitated by an occupational therapist. Program goals include increased knowledge of cognitive impairments in multiple sclerosis, increased self-efficacy to manage cognitive changes and increased use of cognitive compensatory strategies.
223502009|NCT00853047|DRUG|Telotristat etiprate|Telotristat etiprate capsules; orally 3 times daily.
224310111|NCT01303770|BEHAVIORAL|Control intervention|8-week group program that is not specifically directed to management of cognitive impairments.
224310112|NCT01496300|PROCEDURE|Manual Intervention|Implantation of acetabular component without the use of the navigation system information
224310113|NCT01496300|PROCEDURE|Navigated Intervention|Navigated implantation of acetabular component using OrthoPilot image free navigation system
223502010|NCT00853047|DRUG|Octreotide LAR Depot|A stable-dose octreotide LAR depot therapy; administered subcutaneously once per month.
223502011|NCT00853047|DRUG|Placebo|Placebo-matching telotristat etiprate capsules; orally 3 times daily.
223502012|NCT04792268|OTHER|Access to eCDSS on wards|"Electronic clinical decision support (eCDSS) will be available to clinicians on wards recruited to this arm.~An eCDSS is a health information technology system designed to assist clinicians and other health care professionals in clinical decision-making.~The key digital tool to be used for eCDSS in this study is CogStack. This eCDSS has been developed to alert clinicians automatically regarding patients admitted under their care, triggered by the presence of new, old or absent HbA1c pathology reports on the electronic health record (EHR)."
223502013|NCT05208190|DRUG|Clozapine|treatment will occur naturalistically, as per standard clinical guidelines
223502014|NCT05208190|DRUG|treatment as usual|naturalistic treatment with any other antipsychotic medication except clozapine
223502015|NCT04925401|BEHAVIORAL|The Information brochure will be created on the basis of information given by the French pediatric network Courlygone and the French National Authority for Health.|An information brochure on fever in children and how to deal with a paediatric febrile episode and usual medical management.
223502016|NCT03208452|DRUG|Magnesium Sulfate|Comparing the effect of continuous infusion magnesium sulfate and normal saline in the occurrence of emergence agitation
223502017|NCT03208452|DRUG|Normal saline|Comparing the effect of continuous infusion magnesium sulfate and normal saline in the occurrence of emergence agitation
223502018|NCT04094480|DEVICE|polymeric non absorbable clips|a method to secure appendicular stump
223502019|NCT04094480|OTHER|endoloops|a method to secure appendicular stump
223502020|NCT01824004|DRUG|S-1|
224310114|NCT06079346|DRUG|OT-101|OT-101: antisense oligodeoxynucleotide complementary to the messenger ribonucleic acid (mRNA) of the human TGF-β2 gene
224310115|NCT06079346|DRUG|mFOLFIRINOX|Folinic acid, 5-FU, Irinotecan, Oxaliplatin
224310116|NCT06338761|BEHAVIORAL|Smoking cessation|Stop smoking
223502021|NCT01424852|DIETARY_SUPPLEMENT|Probiotics in infant milk formula|Probiotic infgant milk formula administered during the forst year of life
223502022|NCT06142552|DRUG|FRSW117|once a week, 50 weeks and as needed
223502023|NCT04439409|DEVICE|Holter electrocardiogram|Holter electrocardiogram will be carried during 7 days to measure heart's electrical activity continuously.
223502024|NCT00004859|DRUG|carboplatin|Induction Chemotherapy dosing: AUC=6.0, 15-30 min IV infusion immediately following paclitaxel, Day 1 and Day 22. Concurrent Chemotherapy / Radiotherapy dosing, AUC=2; 15- 30 minutes IV infusion immediately following paclitaxel; administered weekly during radiotherapy
223502025|NCT00004859|DRUG|paclitaxel|Induction chemotherapy dosing: 225 mg/m² (3 hour infusion) Day 1 and Day 22. Concurrent Chemotherapy / Radiotherapy dosing: 45 mg/m2; administered weekly during radiotherapy over one hour
223502026|NCT00004859|DRUG|thalidomide|Induction Chemotherapy dosing: oral daily, starting Day 1 for 24 months or until disease progression. Concurrent Chemotherapy / Radiotherapy dosing: oral daily, begin with 200 mg thalidomide as a single dose at bedtime. The dose is then increased by 100 mg every week as tolerated up to a total dose of 1000 mg.
224193213|NCT03396601|DRUG|Placebo|Normal Saline placebo will be infused IV over 40 minutes
224193214|NCT05059366|DEVICE|Manual Ventilation Grip Device|Manual Ventilation Grip Device is an add-on device placed on a standard valve mask to assist ventilation.
224193215|NCT05059366|OTHER|2VE|the standard 2VE technique for ventilation
224193216|NCT03788239|OTHER|Staples versus sutures|"Prolene suture: non-absorbable, sterile surgical suture composed of an isotactic crystalline steroisomer of polypropylene, a synthetic linear polyolefin. After completion of the procedure, deep tissues will closed with subcuticular prolene suture. Compared to the absorbable sutures, prolene is known to cause less infection since it is a monofilament material.~Staples: specialized staples used in surgery in place of sutures to close skin wounds. After completion of the procedure, deep tissues were closed with absorbable braided suture, then the skin will be closed by staples."
224193217|NCT01453296|DRUG|GW642444|GW642444 25 μg; Novel dry powder inhaler
224193218|NCT01453296|DRUG|Placebo|Matching placebo; Novel dry powder inhaler
224193219|NCT01254695|DEVICE|Medtronic InterStim / InterStim II|Standard stimulation (Amplitude: sensory threshold, frequency 14 Hz, Pulsewidth 210 microsec.) will be compared wiht experimental setting 1,2,3,4
224193220|NCT05628818|DEVICE|Transcranial Direct Current Stimulation (tDCS)|Real anodal tDCS over the left dorsolateral prefrontal cortex in acute stroke patients to improve dysexecutive syndrome. Intensity: 2 mA. Stimulation period: 20 minutes.
224193221|NCT05628818|DEVICE|Sham Transcranial Direct current Stimulation|Sham anodal tDCS over the left dorsolateral prefrontal cortex: anodal tDCS. Intensity: 2 mA. Stimulation period: 1 minute. Afterwards, the device will automatically shut down but the sham stimulation period will last a total of 20 minutes.
224193222|NCT04121832|DEVICE|Biofeedback training treatment in Fibromyalgia, a pilot study|The selected sample will undergo 10 total Biofeedback Training sessions, once a week. Each session will last 45 minutes. The total duration of the treatment will be 10 weeks
224193223|NCT04121832|OTHER|Control (treatment as usual)|The sample will be treated only with standard therapies without the use of biofeedback training for 10 weeks
224193224|NCT02806206|DRUG|Prucalopride|A single 2 mg oral dose of prucalopride will be given to each study participant just before the ingestion of the capsule endoscopy pill.
224193225|NCT02806206|DRUG|Placebo|A single dose of a placebo pill will be given to each study participant just before the ingestion of the capsule endoscopy pill.
224205910|NCT03913429|PROCEDURE|Maxillary nerve blockade|"Bilateral ultrasound-guided maxillary nerve block by suprazygomatic route after intubation and previous to surgical incision performed by the anesthesiologist.~A total of 5ml of Ropivacaine 0.37% infiltrated on each side. Together with adrenaline infiltration performed by the surgeon at the intraoral and intranasal submucosal level in the maxilla.~A total of 50ml of the following preincisional mixture is infiltrated: ½ amp Adrenaline + 110ml SF."
224205911|NCT04649437|DIAGNOSTIC_TEST|Quantitative sensory testing|Quantitative sensory testing recordings will be collected by pressure algometry Assessment of temporal summation of pressure pain and conditioning pain modulation will be used to investigate the involvement of pain sensitization.
224205912|NCT00002037|DRUG|Trifluridine|
224205913|NCT02424357|DRUG|5%povidone iodine ophthalmic solution|one drop of 5% povidone iodine instilled into the conjunctival fornix.
224205914|NCT02424357|DRUG|routine post-operative ophthalmic ointment|patient received a routine antibiotic/steroid ointment to operated eye at surgery completion
224310117|NCT06338761|BEHAVIORAL|Switching to E-cigarette|Switching to E-cigarette
224310118|NCT01866046|BEHAVIORAL|RESPECT-IPV|rapid HIV testing intervention and behavioral counseling session where identify risks and develop a risk reduction plan
223502027|NCT00004859|RADIATION|radiation therapy|Radiation therapy started between days 43-50 from day 1 of cycle 1. The primary tumor and areas of known nodal disease received 60 Gy at 2.0 Gy fractions, 5 fractions/week for 30 fractions over 6 weeks to the post chemotherapy tumor volume as seen on computed tomography (CT). The initial 50 Gy was delivered to target volume (TV). The final 10 Gy was delivered to a reduced volume targeting defined by TV
223502028|NCT05601973|DRUG|Amivantamab|Amivantamab is given at a fixed dose of 1750 mg (if baseline body weight is \<80 kg) or 2100 mg (if baseline body weight is ≥80 kg), i.v. every 3 weeks, until disease progression, or intolerable toxicity.
223502029|NCT05601973|DRUG|Lazertinib|Lazertinib is given at a dose of 240 mg, orally, once daily. Treatment with lazertinib continues until disease progression or intolerable toxicities.
223502030|NCT05601973|DRUG|Zirabev|Bevacizumab (Zirabev®) is administered at a dose of 15mg/kg, i.v. every 3 weeks, until disease progression, or intolerable toxicity.
223502031|NCT07124910|COMBINATION_PRODUCT|Epi-ON corneal cross-linking|"Corneal cross-linking involves the following steps:~* applying riboflavin (Vitamin B2 eye drops) to the eye, then~* exposing the eye to ultraviolet (UV-A) light"
223502032|NCT07124559|DRUG|Rifapentine|Dispersible Tablet administered orally
223502033|NCT07124559|DRUG|Isoniazid|Dispersible Tablet administered orally
223502034|NCT07124559|DRUG|Dolutegravir|Tablets and Tablets for oral suspension administered orally
223502035|NCT07124247|DEVICE|Activity registration for one week with an activity monitor (MOX1)|"The participants will be equipped with the MOX activity monitor, which will be attached to the thigh. The device is waterproof, allowing participants to shower and swim, and does not require recharging during the study period.~The MOX will be attached on the same day as the BBS and Handgrip strength measurements, which will take place on a Friday. The following Monday, the 10mWT will be conducted, thus within the same week that the MOX is attached.~The MOX monitor will be worn for one week."
223502036|NCT06168812|DRUG|Glipizide|The therapeutic intervention in this study involves the sulfonylurea glipizide in ER formulation.
223502037|NCT07124845|OTHER|Focusing on the mind|8 times of multimedia cases videos and focused conversation
223502038|NCT06519097|DRUG|Vitamin E Delta Tocotrienol|"Tocotrienols are natural vitamin E compounds that are known to have a neuroprotective effect at nanomolar concentration and anti-carcinogenic effect at micromolar concentration.~400 mg orally, twice daily"
223502039|NCT06519097|OTHER|Placebo|"Placebo contains no active ingredients.~465 mg pure olive oil orally, twice daily"
223502040|NCT06544655|DRUG|BMS-986484|Specified dose on specified days
223502041|NCT06544655|BIOLOGICAL|Nivolumab|Specified dose on specified days
223502042|NCT06544655|DRUG|Oxaliplatin|Specified dose on specified days
223502043|NCT06544655|DRUG|Capecitabine|Specified dose on specified days
223502044|NCT06544655|DRUG|Fluorouracil|Specified dose on specified days
223502045|NCT06544655|DRUG|Calcium folinate|Specified dose on specified days
223502046|NCT06544694|DRUG|0.003% AR-15512|Ophthalmic solution administered via topical ocular instillation
223502047|NCT06544694|OTHER|Artificial Tears|Commercially available, preservative-free lubricant eye drops
223591984|NCT01662947|DEVICE|Blood pressure Reference Device: Yuyue Medical Blood Pressure Meter, YYBP-2|Systolic, Diastolic pressure
223591985|NCT00290498|DRUG|Rituximab|Arm A: Rituximab 375 mg/m² by vein on day 1, Cycle 1 and alternating cycles. Arm B: Rituximab 375 mg/m² on day 1, Cycle 2 and alternating cycles.
223591986|NCT00290498|DRUG|Cyclophosphamide|"Arm A: Cyclophosphamide 300 mg/m\^2 by vein (IVPB) over 3 hours every 12 hours x 6 doses on Days 2-4, Cycle 1 and alternating cycles.~Arm B: Cyclophosphamide 750 mg/m² by vein day 1"
223591987|NCT00290498|DRUG|Doxorubicin|Arm A: Doxorubicin 50 mg/m\^2/day by vein over 15 minutes (12 hours after last dose of cyclophosphamide) on Day 5, Cycle 1 and alternating cycles.
223591988|NCT00290498|DRUG|Vincristine|"Arm A: Vincristine 1.4 mg/m\^2 (maximum 2 mg) by vein (IVPB) on Days 5 (1-24 hours after last cyclophosphamide) and on day 12, Cycle 1 and alternating cycles.~Arm B: Vincristine 1.4 mg/m\^2 (maximum 2 mg) by vein (IVPB) on Days 5 (1-24 hours after last cyclophosphamide) and on day 12 of each cycle."
223591989|NCT00290498|DRUG|Dexamethasone|Arm A: Dexamethasone 40 mg by vein or by mouth daily x 4 on Days 2-5 and on days 12-15 of cycle 1 and alternating cycles.
223591990|NCT00290498|DRUG|Methotrexate|Arm A: Methotrexate after finishing Rituximab, 200 mg/m2 by vein over 2 hours, then 800 mg/m2 by vein over 22 hours day 1 cycle 2.
224193226|NCT05081115|DIAGNOSTIC_TEST|ABCDE-Stress Echo|Each laboratory will adopt the preferred Echo stress among physical pharmacologic or pacing stress according to guidelines recommendations. Pharmacologic testing will be with dobutamine or vasodilators (dipyridamole, adenosine or regadenoson) according to physician preferences, patients' contraindications, local availability and cost. Pacing stress can be performed with transesophageal or with external permanent pacemaker. A standardized format with the ABCDE protocol will be followedl. Step D is easy with vasodilator, less easy with dobutamine, not easy and less feasible - impossible with (peak or post) treadmill exercise. Our recommendation is to use semi-supine exercise, capturing coronary flow signal in early or intermediate stages when most flow increases and feasibility is still high. When treadmill is used, step D is skipped; if information is deemed important, a vasodilator test can be performed at 30' after the end of exercise focused on CFVR and heart rate response.
224205915|NCT04532086|DIAGNOSTIC_TEST|Uterocervical angle|Transvaginal ultrasound examination will be performed at 18-28 weeks gestation in (197) pregnant women with live singleton fetuses, attending routine prenatal care services. Measuring length of uterine cervix at (18-28) weeks \& evaluation of dilatation of internal os \& measurement of uterocervical angle between(18-28)weeks gestational age.
224310119|NCT04623086|DRUG|Insulin Degludec|Insulin Degludec injection
223502048|NCT03496636|PROCEDURE|Ovarian tissue transplant|Pieces of previously frozen ovarian cortex will be put in the abdomen laparoscopically, or with mini laparotomy
223502049|NCT04886791|PROCEDURE|Vaginal NOTES hysterectomy|Vaginal assited NOTES hysterectomy
223502050|NCT04886791|PROCEDURE|Vaginal hysterectomy|Vaginal hysterectomy
223502051|NCT05534984|DRUG|Tecovirimat Oral Capsule|"Drug: Tecovirimat Oral capsules~* Participants weighing 25 kg to less than 40 kg - Tecovirimat 400 mg every 12 hours for 14 days~* Participants weighing 40 kg to less than 120 kg - Tecovirimat 600 mg every 12 hours for 14 days~* Participants weighing 120 kg and over - Tecovirimat 600 mg every 8 hours for 14 days"
223502052|NCT05534984|DRUG|Placebo|"Drug: Placebo Oral capsules~* Participants weighing 25 kg to less than 40 kg - Placebo for Tecovirimat 400 mg every 12 hours for 14 days~* Participants weighing 40 kg to less than 120 kg - Placebo for Tecovirimat 600 mg every 12 hours for 14 days~* Participants weighing 120 kg and over - Placebo for Tecovirimat 600 mg every 8 hours for 14 days"
223502053|NCT05534984|DRUG|Tecovirimat Oral Capsule (Open Label)|"* Participants weighing \<3kg - Tecovirimat 533.3mg every 12 hours for 14 days~* Participants weighing 3 kg to less than 6kg- Tecovirimat 50 mg every 12 hours for 14 days~* Participants weighing 6 kg to less than 13 kg - Tecovirimat 100 mg every 12 hours for 14 days~* Participants weighing 13 kg to less than 25 kg - Tecovirimat 200 mg every 12 hours for 14 days~* Participants weighing 25 kg to less than 40 kg - Tecovirimat 400 mg (2 capsules) every 12 hours for 14 days~* Participants weighing 40 kg to less than 120 kg - Tecovirimat 600 mg every 12 hours for 14 days~* Participants weighing 120 kg and over - Tecovirimat 600 mg every 8 hours for 14 days"
223502054|NCT03651609|PROCEDURE|Simple decompression of the ulnar nerve|Surgical release 2-3 cm distal to medial epicondyle with minimal-incision technique .
223502055|NCT03651609|BEHAVIORAL|Conservative treatment|Patients will be given pictured recommendations with descriptions, which limb positions should be avoided.
223502056|NCT04020263|DRUG|Levosimendan 2.5 MG/ML Injectable Solution|Levosimendan will be diluted with Glucose G5%. The reconstitution of levosimendan will be performed, as close as possible to the start of the infusion. A continuous infusion of levosimendan will be administered over 24 h without bolus, started at a rate of 0.1 μg per kilogram of body weight per minute and, in both the persistence of hypoperfusion signs and in the absence of rate-limiting side effects, will be increased after 2 to 4 hours to a maximum of 0.2 μg per kilogram per minute for a further 20 to 22 hours.
223502057|NCT04020263|DRUG|Placebo|Placebo will be diluted with Glucose G5%. The reconstitution of Placebo will be performed, as close as possible to the start of the infusion. A continuous infusion of Placebo will be administered over 24 h without bolus, started at a rate of 0.1 μg per kilogram of body weight per minute and, in both the persistence of hypoperfusion signs and in the absence of rate-limiting side effects, will be increased after 2 to 4 hours to a maximum of 0.2 μg per kilogram per minute for a further 20 to 22 hours.
223502058|NCT06040762|OTHER|Best Practice|Receive SOC educational materials
223502059|NCT06040762|OTHER|Exercise Intervention|Receive (P)REHAB exercise program
223502060|NCT06040762|OTHER|App-Based Intervention|Use ExerciseRx app
223502061|NCT06040762|OTHER|App-Based Intervention|Use FitBit app
223502062|NCT06040762|OTHER|Interview|Ancillary studies
223502063|NCT06040762|OTHER|Wearable Activity Tracker|Wear FitBit
223502064|NCT06040762|OTHER|Physical Performance Testing|Ancillary studies
223502065|NCT06040762|OTHER|Questionnaire Administration|Ancillary studies
223502066|NCT06164704|DRUG|Verekitug (UPB-101)|Verekitug (UPB-101) 0.5 mL of formulated solution (100 mg verekitug \[UPB-101\])
223502067|NCT06164704|DRUG|Placebo|Verekitug (UPB-101) matching placebo
223502068|NCT04210089|DEVICE|Total Contact Soft Cast|"The total contact soft cast will consist of wound dressing of choice to the ulcer and a plantar foot accommodative offloading felt pad for all foot ulcers, with 4x4 gauze pads added to the arch to create a rocker bottom for metarsophalangeal joint (MPJj) and plantar heel ulcers. The next layers will be:~* Unna boot from MPJs to just below the knee,~* Sterile Kerlix from MPJs to just below the knee~* Sterile 4 inch Kling wrap from the MPJs to just below the knee,~* Four inch coban from MPJs to just below the knee, and~* Ace wraps from MPJs to just below the knee"
223502069|NCT04210089|DEVICE|Cam Boot|Removable Diabetic cam boot will be used in patients willing and capable of using it. If patient does not want to use Diabetic cam boot then surgical shoe or regular shoe would be options.
223502070|NCT06210711|BEHAVIORAL|Treatment as Usual|Standard clinical treatment received by all patients admitted to BUMC, BSWMC Temple or FH/MCW trauma centers. At BUMC and FH/MCW, this may include an evaluation by a licensed psychologist or psychiatrist and continued follow-up psychotherapy and/or medication as needed. At BSWMC Temple this may include an evaluation by a licensed psychiatrist and follow up treatment as needed. In all locations this therapy does not consist of trauma-focused therapy and will be summarized in the analysis as a part of standard of care.
223591991|NCT00290498|DRUG|Cytarabine|Arm B: Cytarabine 3 g/m\^2 by vein over 2 hours every 12 hours X 4 doses on days 3 \& 4, cycle 2 and alternating cycles.
224310120|NCT04623086|DRUG|Insulin Glargine|Insulin Glargine injection
224310121|NCT04623086|DRUG|Placebo|9g/L sodium chloride (normal saline) subcutaneous injection manufactured to mimic insulin glargine injection
224310122|NCT06402760|OTHER|TCM comprehensive treatment|"1. Taodan Granules (TCM formulation for promoting blood circulation and removing blood stasis): The granules consist of the following herbal components: milkvetch, licorice, angelica, rhizoma chuanxiong, peach seed, Salvia miltiorrhiza, Curcuma zedoaria, Achyranthes bidentata, and sarsaparilla. Patients will take it orally in two divided doses after breakfast and dinner.~2. Fish Oil: Patients will take 1g of fish oil orally twice daily. Patients will be instructed to purchase fish oil under the guidance of the researchers.~3. Exercise Plan: Researchers will design an exercise plan for patients, who will be required to engage in at least 150 minutes of moderate-intensity aerobic exercise per week.~Patients will undergo a 16-week treatment period followed by a 24-week follow-up period. During the follow-up, patients will continue taking fish oil and adhering to the exercise regimen, while other treatment modalities will be unrestricted."
224205916|NCT05206279|DRUG|Ureteral injection of Indocyanine Green Powder (diluted)|The intervention we study is the intraureteral injection of ICG during a laparoscopic deep infiltrative endometriosis resection procedure. Cystoscopy with intraureteral administration of ICG will be performed, after which intervention the ureters will be examined by laparoscopy. ICG is injected cystoscopy-guided into the ureters (cystoscopy-guided) in a dosage of 5 or 10ml (25mg ICG in 5 or 10ml NaCl) per ureter as a bolus injection.
224310123|NCT06402760|DRUG|Western medicine|The treatment methods prescribed in the guidelines.
224310124|NCT04928092|PROCEDURE|Standard of care Ultra Low Contrast PCI|PCI using low amounts of contrast media which is standard of care at VCU Medical Center
224310125|NCT02006225|DRUG|Plerixafor|
224310126|NCT03108378|PROCEDURE|Surgery|hip, shoulder or knee replacement surgery, limb amputations or other orthopedic surgical procedures
224310127|NCT05775198|BIOLOGICAL|PBMC immunomodulated with IFNt|Autologous peripheral blood mononuclear cells (PBMC) isolated using a standard protocol will be cultured in the presence of interferon tau (IFNt) for 24 hours at 37 ˚C and administered in the uterine cavity of patients 1 day prior to embryo transfer.
223502071|NCT06210711|BEHAVIORAL|Brief Prolonged Exposure Therapy|Brief PE will include 3 therapy sessions, each lasting approximately 60 minutes. The treatment is manualized and has been successfully implemented and evaluated in other challenging environments (i.e., Emergency Department. Trauma center). Brief PE includes education about common reactions to trauma, breathing retraining, prolonged (repeated) imaginal exposure to trauma memories, repeated in vivo/behavioral exposure to situations that participants are avoiding due to trauma-related fear, and discussion of thoughts and feelings related to exposure exercises. This discussion addresses patients' unrealistic beliefs about themselves and the world. In addition, patients are given homework to complete between each session (breathing practice, listening to the session recording, and completing behavioral exposures).
223502072|NCT04653064|BEHAVIORAL|Placebo Cream|Approximately 1 teaspoon of exfoliating skin scrub delivered approximately 5 minutes prior to pain tasks will coincide with verbal descriptors of the cream as being analgesic.
223502073|NCT04653064|BEHAVIORAL|Control Cream|Approximately 1 teaspoon of exfoliating skin scrub delivered approximately 5 minutes prior to pain tasks will coincide with verbal descriptors of the cream as one of no effect.
223502074|NCT04268511|PROCEDURE|Caudal epidural block group|The linear probe of ultrasound was then rotated 90 degrees and placed longitudinally in the midline to evaluate the sacral cornus, sacrococcygeal ligament and sacral bone. A 22 Gauge 50 mm echogenic block needle was advanced
223502075|NCT04268511|PROCEDURE|Pudendal nerve block group|A 22 Gauge 50 mm insulated needle was then introduced in the anterior-posterior direction at the middle of the ultrasound probe's superior edge with an out-of-plane approach and using an inclination of 15° in the sagittal plane. The needle tip's position was identified by direct visualization using the movement of adjacent anatomical structures.
223502076|NCT04520906|DEVICE|microwave ablation|ultrasound-guided microwave ablation is performed to treat hepatocellular carcinoma patients
223502077|NCT00184509|BEHAVIORAL|integrated psychosocial treatment (behavior)|
223502078|NCT02887352|OTHER|assessment of problem-solving ability|
223502079|NCT00268398|DRUG|oxaliplatin, folinic acid, fluorouracil|folinic acid 200 mg/m² (day 1\&2) oxaliplatin 85 mg/m² (day 1) bolus 5FU 400 mg/m² (day 1\&2) continuous 5FU 600mg/m² (day 1 to 2)
223502080|NCT00268398|DRUG|oxaliplatin, irinotecan, folinic acid, fluorouracil|"FOLFOX7 folinic acid 400 mg/m² (day 1) oxaliplatin 130 mg/m² (day 1) continuous 5FU 3000mg/m² (day 1 to 2)~FOLFIRI folinic acid 400 mg/m² (day 1) irinotecan 180 mg/m² (day 1) bolus 5FU 400 mg/m² (day 1) continuous 5FU 2400mg/m² (day 1 to 2)"
223502081|NCT02209909|DRUG|aspirin continuation|Patients are randomized to continue aspirin before OPCAB surgery.
223502082|NCT02209909|DRUG|aspirin discontinuation|Patients are randomized to discontinue aspirin more than 4 days before OPCAB surgery.
223502083|NCT05542537|BEHAVIORAL|Brighter Bites (BB) Produce Distribution|For 16 weeks in the school year, teachers in participating program schools will receive distributions of 8-10 different types of produce items.
223502084|NCT05542537|BEHAVIORAL|Brighter Bites (BB) Nutrition Education|Brighter Bites Nutrition Education will consist of recipes, food preparation and storage ideas, and tips and tools to budget and plan meals. Teachers will be trained in a nutrition education curriculum, which will be implemented in the program schools as part of the BB program.
223502085|NCT05542537|BEHAVIORAL|Create Healthy Futures (CHF) Weekly Wellness Groups|Peer-facilitators will lead virtual weekly group discussions. Penn State Better Kid Care will train the wellness facilitators.
223502086|NCT05542537|BEHAVIORAL|Create Healthy Futures (CHF) Web-Based Module|Create Healthy Futures Web-Based Module is self-paced and focuses on the following topics: 1) Introduction, 2) Challenges of the food environment, 3) Nutrition and your health, 4) Food culture reform, and 5) Providers' role in creating healthy futures. The Create Healthy Futures module utilizes several educational methods to increase interactivity and engagement, including video footage of content experts, reflection activities, downloadable handouts, and action planning. Each chapter takes approximately 30-40 minutes to complete. The program is delivered on the Better Kid Care On Demand platform, an asynchronous learning management system that provides professional development training for teachers in all 50 states and 69 countries.
223502087|NCT00504231|BIOLOGICAL|Fluzone Influenza Vaccine (2007-2008)|Manufactured by Sanofi Pasteur
223591992|NCT00290498|DRUG|Prednisone|Arm B: Prednisone 100 mg by mouth (as a pill, capsule, or tablet) once a day on Days 1-5, each cycle.
223591993|NCT00294255|DRUG|Risperidone|risperidone will be administered 1-3mg pills, each night, for up to 20 weeks
224193227|NCT05081115|DIAGNOSTIC_TEST|SE diastolic assessment|The diastolic assessment should be included into all exercise SE tests by measuring standard Doppler-derived mitral inflow velocity, pulsed Tissue Doppler of mitral annulus, and retrograde tricuspid gradient of tricuspid regurgitation, at intermediate load of exercise and/or 1- 2 min after the end of the exercise. We will also assess, at baseline, intermediate load (50 watts) and peak-post stress: end-diastolic left ventricular volume index; end-systolic left ventricular volume index; ejection fraction and both stroke volume and cardiac output (to assess conventional contractile reserve); mitral regurgitation and left ventricular outflow tract obstruction; pulmonary artery systolic pressure; B-lines; right ventricular free wall strain to assess the presence of right ventricular dysfunction; left atrial volume index; peak atrial longitudinal strain; and mitral inflow E velocity and mitral annulus e' tissue Doppler velocity; global longitudinal strain (GLS).
224310128|NCT02976285|PROCEDURE|arthroscopic rotator cuff repair with a polyester patch|Patients were operated under general anesthesia and a supraclavicular nerve block, in a beach-chair position with 80° forward shoulder flexion and traction between 3-5 kg. After washing and draping a standard viewing portal was placed at the dorsal softspot. Further portals included, a lateral, a dorso-lateral, an antero-lateral and an anterior portal. If additional pathologies were present, they were treated simultaneously and mostly involved the long head of the biceps tendon, treated with tenodesis or tenotomy respectively. After a thorough bursectomy, the rupture was fully visualized and thereafter its size was estimated. Following debridement of the footprint, we used a triple row repair and implanted the patch.
224310129|NCT00709488|DRUG|Talaporfin sodium|LS11 (Talaporfin Sodium) dose is 1mg/kg administered intravenously slow push (3-5 minutes).
223591994|NCT02846012|OTHER|CSCM2|
223591995|NCT03957876|DRUG|CPX-351|CPX-351 is a liposomal formulation of a fixed combination of the antineoplastic drugs cytarabine and daunorubicin.
224310130|NCT00709488|PROCEDURE|Placement of device in prostate urethra|Placement of device in prostate urethra
224310131|NCT00709488|DEVICE|Transurethral illumination with light emitting diodes (Litx™ BPH Device)|Patients in Cohort A will receive 50 J of light treatment with 1 mg/kg LS11 administration; patients in Cohort B will receive 70 J of light treatment with 1 mg/kg LS11 administration; patients in Cohort C will receive 100 J of light treatment with 1 mg/kg LS11 administration; patients in Cohort D will receive 100 J of light treatment (with the active light emitting length increased from 10mm to 20 mm) with 1 mg/kg LS11 administration.
223591996|NCT01826435|BEHAVIORAL|Electronic Intervention|Patients will be able to receive the intervention notifications over the electronic/multimedia mode they prefer; selecting either text messaging/mobile web and/or email/online web. Text message or email alerts with an included uniform resource locator (URL) link to the specified mobile or online web site will be utilized to notify patients of a pending encounter available on mobile. Topics that will be addressed in the intervention include medication and side effects, social support, hypertension knowledge, memory and smoking. All intervention encounters that are designed to collect responses from the patient will require the patient to supply credentials before responding to the encounter; thus, ensuring privacy of the patient session, as well as patient-specific tracking of responses.
223591997|NCT01716104|DRUG|Afalaza|Safety and Efficacy
223591998|NCT01716104|DRUG|Placebo|Safety and Efficacy
223591999|NCT06243120|DRUG|Lidocaine IV|The study group will receive lidocaine (2%) 1mg/ kg iv diluted by normal saline to a volume of 100 ml. The VAS will be assessed every 10 minutes for 60minutes after the treatment. A regression of more than 4 points of VAS score is considered a success and if less than 4 points , it will be considered as a failure.
223592000|NCT06362122|OTHER|identification anatomo-clinico-biological profiles|to determine an anatomo-clinico-biological correlation associating the anatomopathological profile, the clinical characteristics and the cytokine signature
223592001|NCT01753401|DRUG|Acthar|Acthar is given by subcutaneous (SC) injection (shot under the skin), at a dose of 40 units daily or 80 units every other day
223592002|NCT01753401|DRUG|Placebo|Placebo contains the same inactive ingredients as Acthar, and is given by SC injection
223592003|NCT01753401|DRUG|Steroid Drug|The patient's steroid regimen 7.5 to 30 mg/day of prednisone or equivalent, chronic/stable within the 4 weeks prior to screening.
223592004|NCT05026853|BEHAVIORAL|PRO Integration into Clinical Practice|HCPs will document their discussion and recommendations/referrals in MiChart (Epic EMR)
223592005|NCT04928560|DIAGNOSTIC_TEST|SMI|ULTRASOUND
223592006|NCT03832608|OTHER|No intervention|There is not intervention to be administered, only collection of data through various tests and questionnaires.
223592007|NCT06087900|OTHER|Moderate continuous training (MICT)|The participants received a moderate continuous training (MICT) program of walking or running a treadmill 3 days/week, 12 weeks. This training comprises 5 minutes of warm up at 50-55% of maximal heart rate, following by 50 minutes of exercise at 65-70% of maximal heart rate, and 5 minutes of cool down at 50-55% of maximal heart rate. The intensity of exercise increases to 70-75% of maximal heart rate at week 7-12.
223746420|NCT02206425|DRUG|Lenalidomide|Lenalidomide will be administered at the same schedule and dose intensity as those of the last PI-containing treatment the patient failed (it varies with each patient).
223746421|NCT02206425|DRUG|Pomalidomide|Pomalidomide will be administered at the same schedule and dose intensity as those of the last PI-containing treatment the patient failed (it varies with each patient).
224310132|NCT04833530|DIAGNOSTIC_TEST|Gastric Ultrasound|"In the operating room, a gastric ultrasound will be performed in the supine position and the antral cross sectional area will be measured. Anesthesia will be induced in standard procedure and positive pressure will be instituted according to the standard protocol accepted in our hospital.~At the end of the procedure, the gastric ultrasound circumference will be measured again."
223746422|NCT04187560|DRUG|LB-102|(N-Methyl amisulpride)
223746423|NCT00775931|PROCEDURE|umbilical cord blood transplantation|Umbilical cord blood will be collected, processed and shipped according to existing protocols. 2 cord blood units will be utilized if available. The choice of units will be based on the HLA typing standards of the University of Minnesota Blood and Marrow Program. If 2 units are not available, a single unit may be used. If a single unit is used, the unit should provide at least 10 x 107 nucleated cells/kg recipient body weight.
223746424|NCT00775931|DRUG|Campath-1H|Campath-1H will be administered 0.3 mg/kg subcutaneously per day for three days starting on Day -21 through Day -19.
224193228|NCT05081115|DIAGNOSTIC_TEST|SE Right ventricular function assessment|Right ventricular function will be assessed at baseline and peak stress with variations of tricuspid annular plane systolic excursion, an index of right ventricular longitudinal function, and right ventricular fractional area change (a load-dependent index of right ventricular inlet function). To distinguish between genuine right ventricular dysfunction and/or pathological increases in pulmonary vascular load, we will combine systolic pulmonary artery pressure and right ventricular end-systolic area to calculate right ventricular end-systolic pressure-area relation. Peak systolic tricuspid annulus velocity and conventional indices of left ventricular systolic and diastolic function will also be measured at baseline and peak stress according to the standard ABCDE-FGLPR protocol. Right ventricular free wall strain combined with interventricular septum strain will be assessed. Left ventricular function, wall motion score index and E/e' at baseline and peak stress.
224193229|NCT05081115|DIAGNOSTIC_TEST|SE in heart donors|The examination of the heart starts with a resting transthoracic echocardiography. Exclusion criteria are: resting wall motion score index\>1.0; ejection fraction \<45%; diastolic dysfunction of grade 2 or more; hemodynamically significant (moderate or higher) valve regurgitation or stenosis; severe left ventricular hypertrophy (left ventricular mass index \>175 g/m2). A pharmacological SE with dipyridamole (0.84 mg/kg over 6 minutes) is recommended. The diagnostic end-points are stress-induced RWMA and abnormalities in global LVCR. All images will be analyzed as per guidelines similarly to the other projects, with emphasis on wall motion score index and LVCR based on ejection fraction and force. The hearts excluded from donation for RWMA or abnormal LVCR could however be collected for heart valve preparation and evaluated by coronary angiography and by pathological examination according to local facilities.
224193230|NCT00766727|DEVICE|GLYDe Dressing|Wound dressing intended to minimize scar formation
224193231|NCT06250660|DIETARY_SUPPLEMENT|Strawberry Intervention|"This is an intervention based on the intake of strawberry, specifically the Fortuna variety. This intervention is based on the intake of 250 g of fresh strawberries per day for a month. The amount and duration of strawberry intake has been consulted in other studies carried out with strawberries."
224310133|NCT06010186|OTHER|Ultrasound measurement of the diaphragm and intercostals|"The specific research procedures correspond to the addition of :~* Two additional ultrasound examinations, i.e. at discharge from intensive care and 3 months after hospital discharge: non-invasive examination (duration 20 minutes). Ultrasound is a risk-free, painless procedure involving the placement of an ultrasound probe on the body part under investigation, without the need for a radius or puncture.~* Questionnaires to assess quality of life (SF-36) and functional impact (LCADL) of dyspnea, carried out at discharge from hospital and at 3 months (duration 15 minutes)."
223502088|NCT06557369|DEVICE|reSEES|"The treatment consists of combining SMPL and PBM light therapies to exploit the full advantage of their action. The combination will result in an additive or synergetic effect.~* Treatment sessions are scheduled for three weeks after enrolment (Loading-Phase).~* Two visits per week are needed.~* At the first visit of every treatment week, two treatment sessions will follow each other; PBM is applied at least 15' after SMPL (treatment pairs).~* Only PBM will be administered during the second visit of every treatment week.~Patients will receive:~* 1x SMPL treatment at days 0, 7, and 14 (3 in total),~* 1x PBM treatment at days 0, 3, 7, 10, 14, and 17 (6 in total)~Nine treatments will be delivered within three weeks. The study will be concluded with three follow-up visits at 18, 24, and 54 weeks."
223502089|NCT05123105|OTHER|1) cupping therapy|The participant lay on his front on a couch. The examiner applied a plastic cup on a pre-marked trigger point, suctioned it with a mechanical pump and left it for 2 minutes. This was a stationary application with medium suction force. Therapy was performed on both sides. Measurements were taken before and 2 minutes after the therapy.
223502090|NCT05123105|OTHER|2) control test (no intervention)|The participant lay on his front on a couch for 4 minutes without any activity and without anyy intervention. Measurements were taken before and after the session.
223502091|NCT05123105|OTHER|3) ischemic compression|The participant lay on his front on a couch. The researcher applied pressure to a pre-marked trigger point using the thumb for 2 minutes until tissue resistance was felt. This included 60-second compression and after a break of a few seconds, another 60 seconds of compression. Therapies were performed on each side. Measurements were taken before and 2 minutes after the therapy.
223502092|NCT01382407|DRUG|Cetuximab|Once a week:Loading dose-400 mg/m2;subsequent-250 mg/m2 on days 8,15, 22,29,36 if administered as a single agent, or together with Irinotecan 125 mg/m2 on days 1,8,15,29 followed by administration every 42 days.
223502093|NCT04836910|OTHER|Dietary recommendations|"Fruit, vegetables, legumes (e.g. lentils and beans), nuts and whole grains (e.g. unprocessed maize, millet, oats, wheat and brown rice).~At least 400 g (i.e. five portions) of fruit and vegetables per day excluding potatoes, sweet potatoes, cassava and other starchy roots.~Less than 10% of total energy intake from free sugars Less than 30% of total energy intake from fats. Unsaturated fats (found in fish, avocado and nuts, and in sunflower, soybean, canola and olive oils) are preferable to saturated fats.~Less than 5 g of salt (equivalent to about one teaspoon) per day."
223502094|NCT04836910|DRUG|Oral contraceptive pills|Hormonal treatment
223502095|NCT04836910|DRUG|Metformin|Insulin resistance treatment
223502096|NCT05556187|OTHER|Individualized automated oxygen titration|Automated oxygen titration based on the oxygen saturation during the entire day.
223502097|NCT01793454|OTHER|Fraction of inspired oxygen 40%|
223502098|NCT01793454|OTHER|Fraction of inspired oxygen 80%|
223502099|NCT00101738|DRUG|Myfortic|
223502100|NCT04290676|DRUG|DEXYCU (dexamethasone intraocular suspension) 9%.|DEXYCU contains dexamethasone 9% w/w (103.4 mg/mL) as a sterile suspension for intraocular ophthalmic administration. DEXYCU is provided as a kit for administration of a single dose of 0.005 mL of 9% dexamethasone (equivalent to 517 micrograms of dexamethasone).
223502101|NCT02405208|DEVICE|PyroTITAN HRA|Humeral resurfacing using the PyroTITAN HRA device
223512214|NCT03849612|DRUG|Insulin Lispro|Individualized doses of insulin lispro administered via the AID system to maintain glycemic control, except during procedures designed to induce hyperglycemia and hypoglycemia.
223512215|NCT00558493|DRUG|Clevudine|clevudine 30 mg qd for 24 seeks
223512216|NCT00725231|BIOLOGICAL|alemtuzumab|Addition of 30 mg Alemtuzumab by subcutaneous application for the first 4 cycles
223512217|NCT00725231|DRUG|chemotherapy|dose dense chemotherapy with CHOP-14, 6 cycles, + G-CSF
224193232|NCT03532048|BEHAVIORAL|The Papás Saludables, Niños Saludables Program|Papás Saludables, Niños Saludables is a 10 week program for fathers and their children that meets weekly. Each session is 90 minutes long: 15 min introduction, 30 min pull-out sessions for fathers and children, and 45 min active play sessions together. Fathers are encouraged to improve their eating and physical behaviors to lose weight and to be healthy role models for their child. Children are encouraged to help their fathers lose weight and improve their health. The program has been adapted to contextualize the information for low-income Hispanic families and changed to US food and physical activity guidelines. Mothers will be provided a Handbook and will be sent short videos, recipe links, and short motivational messages every week covering the same topics as in the sessions.
224193233|NCT03532048|BEHAVIORAL|The Papás Saludables, Niños Saludables Wait-list Control|The same program as above delivered to the wait-list control after the T1 follow-up data has been collected.
224193234|NCT02078141|DRUG|18F-deoxyglucose (FDG)|18F-deoxyglucose (FDG) One injection of 3.5 MBq/kg of 18FDG with a minimum of 220 MBq and a maximum of 400 MBq
223502102|NCT06169423|OTHER|Educative intervention|"an activity for simulation-based learning First, a theoretical session was carried out in order to acquire theoretical knowledge, skills to provide support for perinatal grief, and improve self-awareness. Prior to this, a pre-questionnaire was carried out in order to previously evaluate these aspects.~Subsequently, a first session was held to make contact with the simulation, teach the scenarios, material, etc. After this, two questionnaires were passed: one related to the acquisition of knowledge, skills to provide support, self-awareness and another on the students' satisfaction with the simulation."
223502103|NCT05072041|DEVICE|Nexsphere™|Nexsphere™ is a yellow powder, made of 100% hydrophilic gelatin. It is used to make a suspension by mixing a contrast agent and physiological saline. The indications are hepatic artery chemoembolization, uterine artery embolization, prostate artery embolization, and treatment of various hemorrhagic diseases. It physically embolizes blood vessels and is decomposed within 4-8 weeks after intravascular injection.
223502104|NCT04995003|GENETIC|T cells or CAR T cells|"There are 2 dose levels:~Dose Level 1 (1x10\^8 cells/m2) and Dose Level -1 (5x10\^7 cells/m2). In the event that Dose Level 1 is not tolerable, de-escalation to Dose Level -1 will occur."
223502105|NCT04995003|DRUG|Pembrolizumab Injectable Product|2 mg/kg/dose (max 200 mg/dose) every 3 weeks
223502106|NCT04995003|DRUG|Nivolumab Injectable Product|3 mg/kg/dose (\<40kg) or 124 mg (≥40 kg) every 2 weeks
223502107|NCT05129709|BEHAVIORAL|"My Health Priorities Identification Program"|"The web-based My Health Priorities Identification Program may improve values solicitation and operationalization skills in primary care, but has not been optimized for AAs with MCCs and their FCGs. The Program is a facilitator-led evidence- and values-based care communication model for patients, clinicians, and caregivers that has reduced patient-reported treatment burden by aligning value-based priorities with treatment. The web-based program assists patients in identifying their health priorities as they complete t four online modules that help them to identify specific and actionable health goals and preferences. The final result can be printed and brought to the clinic or uploaded to the Electronic Medical Record to inform subsequent healthcare decision making. Unrecognized cultural preferences of AAs, including the important role of R/S beliefs and family-centered values, can interfere with adequate healthcare communication resulting in healthcare disparities and inequities."
223502108|NCT00095771|DRUG|arsenic trioxide|
223502109|NCT00095771|RADIATION|radiation therapy|
223502110|NCT03170440|DEVICE|Transcutaneous nerve stimulation location 1|Non-invasive stimulation by transcutaneous electrical nerve stimulation device in test location
223502111|NCT06252935|DEVICE|FormaAid|FormaAid is mainly composed of pure collagen extracted from bovine tendon, it is fabricated in the form of highly dense collagen matrix without chemical cross-linking to act as a barrier excluding epithelium.
223502112|NCT06252935|DEVICE|Bio-Gide|Bio-Gide is a bilayer collagen membrane made of porcine collagen, permits prompt and homogeneous vascularization and so brings about optimal tissue integration and wound stabilization.
223502113|NCT05413460|DEVICE|transcutaneous electrical acupoint stimulation|Electrodes are placed at acupoints and connected to the stimulator. Electrical stimulation is given during surgery.
223502114|NCT02015715|DRUG|RO6864018|A single oral ascending dose of RO6864018 capsules on Day 1.
223502115|NCT02015715|DRUG|Placebo|A single oral dose of placebo matching RO6864018 capsules on Day 1.
223502116|NCT05557682|OTHER|composite restorative treatment|Restorative treatment using dental materials
223502117|NCT02035293|OTHER|PEP|
223502118|NCT04786925|OTHER|Control diet|Control diet: A Mediterranean conventional diet based on the current dietary guidelines of the Spanish Society of Community Nutrition (SENC). Participants were strongly advised to use the Healthy Eating Plate (Harvard) to structure and prepare the main meals (lunch and dinner). In this way, at least ½ of the plate should be composed of vegetables, ¼ of lean protein, and ¼ of low glycemic index carbohydrates. The diet encourages participants to eat 5 times/day (breakfast, lunch, dinner, and two snacks). Overall, the control diet was based on high consumption of vegetables and fruits, whole grains, healthy fats (olive oil), and healthy proteins (legumes, fish, and lean meat). There was not energy restriction in the control diet.
223502119|NCT04786925|OTHER|Nutriprecision diet|Nutriprecision diet: a Mediterranean balanced diet based on the inclusion of precision foods designed according to the particularities of the senior population. The selected precision foods were a) fruit compote, b) smoothie, c) extruded meat product, d) wholemeal bread, e) wholemeal biscuit and f) microwaveable deep-frozen vegetable products. The diet encourages participants to eat 5 times/day with a conventionally balanced distribution of macronutrients (50% of the total caloric value from carbohydrates, 20% from proteins, and 30% from lipids). There was not energy restriction, although the energy requirements of the participants were adjusted to a BMI of 25 kg/m2 to avoid an overestimate of calorie intake. A mobile application designed and developed to provide volunteers with information about follow-up visits, the assigned diet, recommendations, and messages to motivate them during the intervention. A digital tool for cognitive stimulation.
223502120|NCT05027282|DEVICE|CLEAR + BRILLIANT TOUCH(R) 1440-nm and 1927-nm handpieces.|CLEAR + BRILLIANT TOUCH(R) diode laser 1440-nm and 1927-nm Combination Wavelength Treatment.
223502121|NCT00932854|PROCEDURE|EBUS|Endobronchial ultrasound guided transbronchial needle aspiration will be performed under conscious sedation and as an outpatient procedure. Additional bronchoscopy, transbronchial biopsies and bronchoalveolar lavage will be performed at the investigator's discretion.
224193235|NCT01001091|DRUG|AL-38583 ophthalmic solution|
223746425|NCT00775931|RADIATION|Total Lymphoid Irradiation|Dose 500 cGy via anteroposterior (AP) and posteroanterior(PA) fields (250 cGy AP and 250 cGy PA).
223746426|NCT00775931|DRUG|Cyclophosphamide|Cyclophosphamide (50 mg/kg/dose) will be given IV on day -4, -3, -2 and -1 over 2 hours. The total dose to be given over 4 days is 200 mg/kg for cord blood grafts-receiving patients only.
224193236|NCT01001091|DRUG|AL-38583 ophthalmic solution vehicle|Inactive ingredients used as a placebo comparator
224193237|NCT01001091|DRUG|Dexamethasone ophthalmic suspension, 0.1%|
224193238|NCT04366258|DEVICE|Transcranial Photobiomodulator|Delivers laser-generated Near-Infrared Radiation (NIR) to forehead at 3 doses of irradiance - High (770 mW/cm2), Middle (300 mW/cm2), and Low (50 mW/cm2).
224193239|NCT04366258|DEVICE|Sham|Transcranial Photobiomodulator delivers sham irradiance dose of 0 mW/cm2.
224193240|NCT00314847|DEVICE|Extra-Corporeal Life Support -Impella 2.5|Percutaneous implantation of Impella pump for a duration of 3 days as a minimum and up to 7 days (recommended)
224193241|NCT05866159|OTHER|Kinesiotape using Rocktape®|Kinesiotape using Rocktape® on day one by a physiotherapist who has experienced more than five years. If possible, the taping will be left for seven days.
224193242|NCT05866159|OTHER|Sham taping|sham taping with Rocktape®, with no tension.
224193243|NCT02401217|OTHER|Phase 1- Arm 1 Infant Formula|Powder infant formula
224193244|NCT02401217|OTHER|Phase 2- Arm 2 Infant Formula|Powder infant formula
224193245|NCT02401217|OTHER|Phase 2- Arm 3 Infant Formula|Powder infant formula
224193246|NCT03330340|PROCEDURE|Percutaneous Vertebroplasty|The procedure takes place under sterile conditions. Local anesthesia is administered from skin to the periosteum of the targeted pedicle. Polymethylmethacrylate bone cement (Mendec Spine; Tecres SPA, Sommacampagna, Italy) is injected under continuous fluoroscopic imaging guidance using 1.0 ml syringes and 13 Gauge bone biopsy needles by bilateral procedures. The amount of injected cement in each treated vertebral body and any cement leakage is recorded.
224193247|NCT01092312|PROCEDURE|Vanguard Knee System with Signature Knee Guide|Use of Signature Knee Guide
224193248|NCT01092312|PROCEDURE|Vanguard Knee System with conventional Instruments|Vanguard Knee System with conventional Instruments
224193249|NCT03551457|DIAGNOSTIC_TEST|Biopsy|Patient-derived xenograft treatment response phenotype.
223502122|NCT00456612|PROCEDURE|CyberKnife|Radiosurgery to enhancing high grade glioma in 5 fractions with escalating doses.
223502123|NCT00266812|DRUG|Temozolomide and radiotherapy|Oral temozolomide 75mg/m2/day for 14 days, during radiation treatment, and later on temozolomide 100 mg/m2/day at 14 days on/14 days off, until unacceptable toxicity or evidence of disease progression for up to 6 cycles from initial treatment. Radiotherapy (as in Intervention 2).
223502124|NCT00266812|PROCEDURE|Whole brain radiotherapy|2 regimens are allowed: a) 20 fractions of 2 Gray each, administered on days 1 to 5, 8 to 12, 15 to 19, and 22 to 26; b) 10 fractions of 3 Gray each, administered on days 1 to 5 and 8 to 12.
223502125|NCT03695094|DRUG|Padsevonil|Padsevonil (PSL) will be dosed to steady state and the effect of background therapies on pharmacokinetics will be assessed
223502126|NCT03695094|DRUG|Oxcarbazepine|Concomitant administration of oxcarbazepine (OXC) at therapeutic dosage
223502127|NCT03695094|DRUG|Levetiracetam|Concomitant administration of levetiracetam (LEV) at therapeutic dosage
223502128|NCT03695094|DRUG|Lamotrigine|Concomitant administration of lamotrigine (LTG) at therapeutic dosage
223502129|NCT03695094|DRUG|Brivaracetam|Concomitant administration of brivaracetam (BRV) at therapeutic dosage
223502130|NCT03986541|DIAGNOSTIC_TEST|Immunohistochemistry|Assessment of tumour amphiregulin, epiregulin and EGFR expression by immunohistochemistry.
223502131|NCT04038398|PROCEDURE|Non-invasive ventilation with different FiO2 settings|CPAP therapy applied with different order of FiO2 settings.
223502132|NCT00205608|DEVICE|Positron Emission Tomography|camera is new
223502133|NCT05000437|OTHER|HIIT|3x/week high intensity interval training for 12 weeks
223502134|NCT01834261|DRUG|Syntocinon Nasal Spray, 40IU|Subjects will be scanned twice. Prior to first brain scanning session, they will be randomly assigned to receive either Syntocinon or Placebo. Prior to second scanning session, they will receive what they have not received in the first session; i.e., same subjects will be receiving both Syntocinon and placebo on two different days.
223502135|NCT01834261|DRUG|Syntocinon Placebo Formulation, 40IU|Subjects will be scanned twice. Prior to first brain scanning session, they will be randomly assigned to receive either Syntocinon or Placebo. Prior to second scanning session, they will receive what they have not received in the first session; i.e., same subjects will be receiving both Syntocinon and placebo on two different days.
223502136|NCT00530075|DRUG|Gusperimus|SC, 0.5mg/kg/day, consecutive 21 days administration, 1 to 2 weeks rest, 6 cycles
223502137|NCT02316613|DRUG|Rituximab|
223746427|NCT00775931|DRUG|Busulfan|patients\<12 kg: 1.1 mg/kg/dose IV every 6 hours for 8 doses total; patients \>12 kg: 0.8 mg/kg/dose IV every 6 hours for 8 doses. on Day -8 to -7 for donor grafts-receiving patients, and on Day -9 to -6 for cord blood grafts-receiving patients.
223746428|NCT00775931|DRUG|Fludarabine monophosphate|Fludarabine (35 mg/m2 daily for 5 days, 175 mg/m2 total) will be administered IV over 30 minutes on days -6, -5, -4, -3, and -2 for donor grafts-receiving patients only.
224193250|NCT04389008|OTHER|no interventions|no interventions
224193251|NCT02264925|DEVICE|Deep Brain Stimulation with Medtronic Activa PC+S systems|Deep Brain Stimulation of VIM.
224193252|NCT03784755|RADIATION|Ablative Radiation Therapy|Undergo stereotactic radiotherapy and/or surgery to all sites of disease (oligometastases and primary prostate if previously untreated).
224193253|NCT03784755|OTHER|Standard of care|Patients continue to receive their current planned systemic therapy at the discretion of the treating physician
224193254|NCT05234073|BEHAVIORAL|SEE Learning Online Training|This intervention includes classes about socioemotional learning theory and practice, topics related to ethics and well-being practices
224193255|NCT05234073|BEHAVIORAL|Waiting list|This group will wait for one month to receive SEE Learning Online Training
223502138|NCT03426007|PROCEDURE|Uterine lavage|embryo recovery from the uterus following either natural cycle (NC)/intrauterine insemination (IUI), or controlled ovarian hyperstimulation (COH)/intrauterine insemination (IUI).
223512218|NCT05652140|OTHER|Data collections|Data collections of cognitive function, neuroelectrical activities, ApoE genotype, and physical fitness.
224193256|NCT06404294|DEVICE|External Diaphragm Pacemaker treatment|On the basis of conventional treatment, the patients in this group were treated with external diaphragm pacemaker for 2 weeks or until extubation.The treatment process of external diaphragm pacemaker is as follows: Set parameters: pacing frequency: 5-9 times /min, generally starting from 5 times /min, and adjusted according to the tolerance of the child; Pulse frequency 30 hertz; The stimulation intensity generally starts from 2-3. If the respiratory waveform of the child on the machine is not disturbed, it indicates that the child can tolerate it and the intensity can be appropriately increased. Treatment time: generally starts from 5 minutes, the longest is not more than 20 minutes, the frequency of treatment: 1 time/day in the first week, 2 times/day in the second week.
224193257|NCT05493059|OTHER|Data collection|o Retrospective data collection in database from medical records (clinical, parasitological and therapeutic data)
224193258|NCT05493059|OTHER|Questionnaires|"o Administration of two standardized questionnaires by telephone in prospective:~* Dermatology Life Quality Index (DLQI)~* Treatment Satisfaction Questionnaire for Medication (TSQM)"
224193259|NCT05577975|DEVICE|The Aspara @ smart grower|The program will consist of three face-to-face (F-T-F) horticultural activity training session for a group of 6-8 participants and then biweekly telephone follow-up for 8-week home-based horticultural intervention. The home-based program contains different horticultural, cognitive and multisensory stimulation activities such asking the PWD and the family caregiver to record the sense of touch and odor when taking care of the plant and the various changes of the plants by using the smart grower. Program evaluation will be conducted through focus groups with 15 participants with different levels of stress reduction after the intervention.
224193260|NCT01737359|DRUG|amdoxovir 300 mg bid|2 x 150 mg capsules bid
224193261|NCT01737359|DRUG|amdoxovir 500 mg bid|2 x 250 mg capsules bid
224193262|NCT01737359|DRUG|tenofovir DF 300 mg qd|1 x 300 mg tablet once daily
224193263|NCT04588740|DRUG|concentrated beet root juice|On average, we will expect subjects to ingest the supplement for approximately 5 days minimum depending on their testing schedule. On each testing day subjects will be asked to consume the two bottles of either beetroot juice (BRJ) or Placebo 2.5 hours before testing time. Specifically, for female subjects, they will be asked to start their supplementation on day 1 of menses. On day 3-4 they will take the last 2 shots. Female subjects' wash-out period will go according to their menstrual cycle as we will be controlling for hormone fluctuation (low vs high estrogen phase) know to interact with nitric oxide physiology.
224193264|NCT04588740|DRUG|Placebo beet root juice|This will follow the same supplementation regime as explained above but this supplement taste and looks exactly the same as the nitrate-rich beet root juice. It is provided by the same company that produces the concentrated beet root juice shots (Beet It, UK)
224193265|NCT04833816|DRUG|Administration of drug|Administration of ketamin during the 48h after trauma
223592008|NCT06087900|OTHER|High intensity interval training (HIIT)|The participants received a 7x2 high intensity interval training (HIIT) program of walking or running a treadmill 3 days/week, 12 weeks. This training comprises training comprises 5 minutes of warm up at 50-55% of maximal heart rate, following by 28 minutes of exercise (2 minutes of high intensity at 85-90% of maximal heart rate interval with 2 minutes of low intensity at 50-55% of maximal heart rate 7 times), and 5 minutes of cool down at 50-55% of maximal heart rate. The intensity of exercise at high intensity increases to 90-95% of maximal heart rate at week 7-12.
223592009|NCT06087900|OTHER|Inspiratory muscle training (IMT)|The participants received Powerbreathe ® ClassicLight in this training program. The IMT group demonstrated the training 8 cycles of 30 breath, 5 days/week with progressive load 50% of maximal inspiratory pressure (MIP) at week 1-3, 60% of MIP at week 4-6, 70% of MIP at week 7-9, and 80% of MIP at week 10-12. Every first day of the week participants had to undergoing load adjustment at laboratory
223592010|NCT06087900|OTHER|Control|The CON group did not have any intervention but usual care.
223592011|NCT02499042|DRUG|Oxygen|oxygen delivery by ETT/ SGA connected to bag/valve/oxygen reservoir
224193266|NCT03948646|DRUG|Sofpironium Bromide, 15%|Active
223502139|NCT05838872|DEVICE|Minuteful - Kidney Urine Analysis Test System|Urine samples were collected and tested by a lay user, using the Minuteful - Kidney test device. The lay user test results were compared to the results obtained by testing the same urine sample on the comparison device, the URiSCAN Optima.
223502140|NCT03057327|BEHAVIORAL|Improve awareness of checking moles|"Intervention:~1. Improve awareness Each of the eight changing rooms will have a large mirror that can be used to see the face and chest. Each room will be equipped with a poster, brochures and the SSE kit consisting of the laminated card with a ruler on one edge and the magnifying lens will be fastened to the wall on a cord.~2. Provide education The subject may chose to read the poster and a brochure. c) A woman research assistant will perform in-person exit interviews with participants to ascertain if women noticed the poster, and found the information relevant."
223502141|NCT03057327|OTHER|Comparator|Prior to placing the intervention materials into the changing rooms, 100 eligible subjects will be asked if they regularly check their moles for concerning features. If the response is yes, then they will be asked if they have found concerning moles and what they did next.
223502142|NCT00442689|DRUG|flutamide|250 mg twice daily
223502143|NCT00442689|DRUG|ethinyl estradiol 35 mcg and drospirenone 3 mg|one active pill per day for three weeks and then 1 sugar pill per day for one week
223502144|NCT00442689|OTHER|placebo|
223502145|NCT00758043|DRUG|telaprevir|750 mg every 8 hours (q8h) for 12 weeks
223502146|NCT00758043|DRUG|ribavirin|1000 - 1200 mg/day based on body weight for either 24 or 48 weeks
223592012|NCT05896813|DRUG|CMOP+Chidamide|Cyclophosphamide: 750 mg/m2, d1; Mitoxantrone Hydrochloride Liposome: 20 mg/m2, d1; Vincristine: 1.4 g/m2, d1 (maximum dose of 2 mg), or vindesine 3 mg/m2, d1; Prednisone: 60 mg/m2, d1-d5; Chidamide:20 mg, biw. The treatment is administered every 3 weeks as a cycle and lasts for a total of 6 cycles.
223502147|NCT00758043|BIOLOGICAL|peginterferon alfa-2a|180 mcg/week for either 24 or 48 weeks
223502148|NCT00875459|DRUG|VIAject™|Subcutaneous injection 25 IU/mL
224193267|NCT03948646|DRUG|Vehicle|Vehicle gel
224193268|NCT01725217|BIOLOGICAL|MenACWY-CRM|1 vaccination at visit 1, conjugate vaccine, Intramuscular (IM) injection
224193269|NCT00852267|OTHER|High Carbohydrate, High Saturated Fat Diet|50% Carbohydrate; 12% Protein; 38% Fat (15% Saturated Fat; 15% Monounsaturated Fat)
224193270|NCT00852267|OTHER|Low Carbohydrate, High Saturated Fat Diet|31% Carbohydrate; 31% Protein; 38% Fat (15% Saturated Fat; 14% Monounsaturated Fat)
224193271|NCT00852267|OTHER|Low Carbohydrate, Low Saturated Fat Diet|31% Carbohydrate; 31% Protein; 38% Fat (8% Saturated Fat; 21% Monounsaturated Fat)
224310134|NCT05190692|DEVICE|Use simulators in Obstetrics vaginal examination|"Two simulators will be used in the study:~(1st ) : PROMPT Flex Birthing Simulator Advanced - Light (PRODUCT NO. 80106).UK, 2020 .~2nd): PROMPT Flex Cervical Dilatation \& Effacement Module -Light (PRODUCT NO. 80102),Uk,2020.~Both will be used to perform obstetric vaginal examination before examination of patients"
224310135|NCT01233739|DRUG|Chondroitin sulfate|Administration of 2 capsules of 400 mg of chondroitin sulfate orally.
224193272|NCT01398540|BIOLOGICAL|IXIARO|2 immunizations (0,5ml) with a 28 day interval
224193273|NCT05601414|DEVICE|BIO-Z|a novel cuffless continuous BP wrist monitor
224193274|NCT05601414|DEVICE|Finapres Nova|a cuffless continuous BP monitor
224310136|NCT01233739|DRUG|Placebo|Administration of 2 capsules of placebo orally.
224310137|NCT04621019|DEVICE|BTL-785F|Treatment with study device.
224310138|NCT03844256|COMBINATION_PRODUCT|nivolumab 480mg|Immuno-chemoradiotherapy
224310139|NCT03844256|COMBINATION_PRODUCT|nivolumab 3mg/kg, ipilimumab 1mg/kg|Immuno-chemoradiotherapy
224310140|NCT03844256|COMBINATION_PRODUCT|nivolumab 1mg/kg, ipilimumab 3mg/kg|Immuno-chemoradiotherapy
224310141|NCT05015283|PROCEDURE|The laparoscopic One-anastomosis gastric bypass will consist of:|gastrointestinal anastomosis: anterior colon and posterior stomach gastrointestinal anastomosis size: diameter \< 1.5cm, linear anastomosis length 2.5cm biliary and pancreatic branches 200cm, food branches 100cm exact relationship with mesangial defect
224310142|NCT05015283|PROCEDURE|The laparoscopic Roux-en-Y gastric bypass will consist of:|the laparoscopic Roux-en-Y gastric bypass gastric sac size \< 30ml gastrointestinal anastomosis: anterior colon and posterior stomach gastrointestinal anastomosis size: diameter \< 1.5cm, linear anastomosis length 2.5cm biliary and pancreatic branches 50cm, food branches 150cm exact relationship with mesangial defect
224310143|NCT04546724|BIOLOGICAL|VLA1553|Single intramuscular vaccination on Day 1 with VLA1553, a lyophilized live-attenuated Chikungunya vaccine candidate; 1x10E4 TCID50 per dose
224310144|NCT04546724|BIOLOGICAL|Placebo|Single intramuscular vaccination on Day 1 with Phosphate-Buffered Saline (PBS) as placebo
224310145|NCT04238260|BEHAVIORAL|Enhancing Physical Therapy Usual Care|The protocol is focused on the completion of a minimum of 30 minutes of weight-bearing, walking-related activities that progressively increase in intensity informed by heart rate and step counters over 4 weeks.
224310146|NCT04238260|BEHAVIORAL|Physical Therapy Usual Care|Usual physical therapy
224310147|NCT04996914|PROCEDURE|TACE|1-2 session TACE before SBRT according to the preference of the interventional radiologist. Goal of TACE is the complete emnbolization of the HCC-nodules. It is allowed to use both conventional TACE (cTACE) and drug-eluting beads TACE (DEB-TACE) according to the interventional radiologist preference.
223502149|NCT02027571|BEHAVIORAL|Intensive Lifestyle Intervention (ILI)|ILI consists of weight loss ( \> 10%); caloric reduction; physical activity (180 min/week); monthly visits for group counseling for 6 months, followed by quarterly visits; and meal replacements.
223502150|NCT05669066|BEHAVIORAL|Mindful meditation|Adding mindful meditation to pre- and post-operative care for patients who are having a TKA
223502151|NCT02313597|PROCEDURE|SETON|In seton treatment, initially Hydrogen peroxide will be applied to the external opening with a 10-cc syringe, and the internal opening will be located by direct visualization of the anal canal via proctoscope. A probe will be inserted into the external opening and carefully maneuvered through the internal opening. Silk 1/0 suture will be then tied to the tip of the probe, which will be then squeezed out of the external opening. The suture will be then tied around the sphincter and through fistula tract. Later, the seton will be tightened at four-week intervals under local anesthesia until the suture cut through the sphincter.
223502152|NCT02313597|PROCEDURE|VAAFT|Patients assigned to the VAAFT group will receive the following procedure. The external opening will be widened with a probe, and a fistulascope will be inserted to delineate the primary and secondary tracts and locate the internal opening. The internal opening will be then stitched with Vicryl™ (Polyglactin 910) 2-0 suture through the anal route with the help of a proctoscope. The tract of the fistula will be washed and debrided through the scope and cauterized. Finally, the external opening will be excised and will be sent for biopsy.
223502153|NCT02328729|PROCEDURE|mandibular block with Epinephrine|Delivery of mandibular block anesthesia for dental treatment with Lidocaine HCl 2% with 1:100,000 Epineprine
224193275|NCT00308555|DRUG|Cannabis|
224193276|NCT03304132|OTHER|Classification of Oral Microbiome Using 16S rRNA gene sequence-based approach|The sequence-based approach is selected because it classifies samples by considering the entire difference (genetic distance) in 16S rRNA gene sequences among samples analyzed, unbiased by artificial details such as taxonomies, sequence length, or even quality scores.
224193277|NCT03304132|OTHER|Classification of Oral Microbiome Using taxonomic approach|The taxonomic approach is a complement to the sequence-based approach in that it will further identify specific taxonomic groups or species that can explain the difference found by overall analyses.
224193278|NCT05112224|BEHAVIORAL|Education program based on health belief model to improve oral health|Five weekly sessions each one lasted for one hour to encourage participants to follow healthy behaviors on oral health.
224193279|NCT01736982|BEHAVIORAL|Contingency Management|Participants earn reinforcement in the form of prizes for breath samples that test negative for cigarette smoking.
223502154|NCT02328729|PROCEDURE|C-CLAD-IL with Epinephrine|Delivery of C-CLAD-ILanesthesia for dental treatment with Lidocaine HCl 2% with 1:100,000 Epineprine
223592013|NCT00304005|DRUG|laromustine|
223592014|NCT00616694|DRUG|Actonel|Actonel 5 mg orally once daily (OD), calcium 500 mg + vitamin D 200 units twice daily (BID)
223592015|NCT00136669|PROCEDURE|Acupuncture|
223592016|NCT03437824|DRUG|Cyanocobalamin|1,000 mg, Once
223592017|NCT03437824|DRUG|Placebo|0.9% Sodium Chloride, Once
223592018|NCT00594594|OTHER|Probiotic Lactobacillus GR-1 and RC-14|Two capsules of Lactobacillus GR-1 and RC-14 daily for 12 months
223592019|NCT03841136|DRUG|anlotinib|anlotinib 12mg PO QD CBP(AUC 5mg/mL/min，or DDP（75mg/m2）D1 etoposide（100mg/m2）D1\~D3
223592020|NCT03683888|BEHAVIORAL|HealthSnap|HealthSnap provides personalized lifestyle reports and track progress over time using an electronic lifestyle record (ELR). HealthSnap Assessment is a simple, quick and not invasive tool that uses an algorithm that includes a questionnaire, physical measurements, dietary data and body fat indices
223592021|NCT03683888|BEHAVIORAL|dietary counseling|Dietary counseling by RD. Low Calorie and/or Low Carb dietary plans will be discussed and provided to the study participant
223592022|NCT00556270|DRUG|Matrifen|as defined in the Summary of Product Characteristics (Fachinformation Chapter 4.2)
223592023|NCT04077931|OTHER|exercises|Walking on treadmill with fixed 0% grade inclination
223502155|NCT02328729|PROCEDURE|Infiltration with Epinephrine|Delivery of infiltration anesthesia for dental treatment with Lidocaine HCl 2% with 1:100,000 Epineprine
223502156|NCT02328729|PROCEDURE|Mandibular block without Epinephrine|Delivery of mandibular block anesthesia for dental treatment with Mepivacaine 3% without Epineprine
223502157|NCT02328729|PROCEDURE|C-CLAD-IL without Epinephrine|Delivery of C-CLAD-ILanesthesia for dental treatment with Mepivacaine 3% without Epineprine
223502158|NCT02328729|PROCEDURE|nfiltration without Epinephrine|Delivery of infiltration anesthesia for dental treatment with Mepivacaine 3% without Epineprine
223502159|NCT05331937|COMBINATION_PRODUCT|repetitive transcranial magnetic stimulation (rTMS)|rTMS (real versus sham) is used as adjuvant to ERP
223502160|NCT05649774|PROCEDURE|Therapy|Only Myofascial Release will be provided
223502161|NCT05649774|PROCEDURE|Taping technique|Only Kinesiotaping will be provided
223502162|NCT05649774|PROCEDURE|Therapy with taping|Myofascial release will be provided followed by Kinesiotaping
223502163|NCT05649774|PROCEDURE|SHAM|Placebo Treatment will be given
223502164|NCT06358989|OTHER|HOMA IR|Homa ir
223502165|NCT04678310|OTHER|Support from the hospital palliative and end of life care volunteer service (developed for this study).|Hospital palliative and end of life care volunteer service: a volunteer service to provide support to patients dying in the hospital and their families. The volunteer service has been designed to provide presence and companionship to dying patients at the end of life, and their families.
223502166|NCT01701648|OTHER|Laser CO2|Transplantation of autologous melanocytes using amniotic membrane as a substrate. Transplantation of suspension of autologous melanocytes.
223502167|NCT03418207|PROCEDURE|trans-perineal template-guided mapping biopsy|new super saturation of prostate biopsy technique
223502168|NCT01067235|DRUG|BF2.649|BF2.649 oral capsules at 10, 20 or 40 mg/day associated with Modafinil Placebo capsules for 8 weeks
223502169|NCT01067235|DRUG|BF2.649 add on Modafinil|BF2.649 oral capsules at 10, 20 or 40 mg/day associated with Modafinil capsules at 200 mg per day for 8 weeks
223502170|NCT06494813|DIAGNOSTIC_TEST|conventional pcr|conventional pcr to study matrix metalloproteinase -9 gene polymorphismin rheumatoid arthritis
223502171|NCT02201082|PROCEDURE|Airway clearance technique|
223502172|NCT02201082|DRUG|Amikacin nebulization|
223502173|NCT03990688|DRUG|AK3280|Active Substance: AK3280, Pharmaceutical Form: Tablet, Route of Administration: Oral
223502174|NCT03990688|DRUG|Placebo|Active Substance: Placebo, Pharmaceutical Form: Tablet, Route of Administration: Oral
223592024|NCT01627028|PROCEDURE|Thai traditional massage|two hours of Thai traditional massage twice a week for 4 weeks
223592025|NCT04511065|OTHER|Newsletter using a virtual mode of delivery|Newsletter creation where topics in the newsletter are chosen by participants in the intervention group.
223592026|NCT03474783|BEHAVIORAL|Health education|Stages of change of intentions to cease smoking of participants at the baseline were determined, and a personal-tailored health education was accordingly delivered.
223592027|NCT00154128|DEVICE|occlusal appliance|
223592028|NCT05592132|OTHER|Virtual reality headset|Each patient in this treatment group will use a virtual reality headset during 3 procedures. During each procedure, the pain level will be assessed and compared with the assessed group.
223592029|NCT03615066|DRUG|Placebo|Tablet(s) administered orally every 7 days for 24 doses in fasted state
223592030|NCT03615066|DRUG|Selgantolimod|Tablet(s) administered orally every 7 days for 24 doses in fasted state
223592031|NCT03615066|DRUG|TAF|Tablet(s) administered orally once daily with food
224193280|NCT01736982|OTHER|Standard of Care|Standard smoking cessation counseling
224193281|NCT01736982|OTHER|Standard of Care|transdermal nicotine replacement \[21 mg patches (4 wks), 14 mg (2 wks), 7 mg (2 wks)\]
224193282|NCT01736982|OTHER|Standard of Care|Breath sample monitoring
224193283|NCT00276458|DRUG|Comparator: atorvastatin|Atorvastatin 40mg tablet po qd (by mouth, once a day) for 6 weeks
224193284|NCT00276458|DRUG|Comparator: Placebo|Atorvastatin 20mg Pbo and ezetimibe 10mg Pbo tablets po qd (by mouth, once a day). for 6 weeks
224193285|NCT00276458|DRUG|Comparator: ezetimibe|Atorvastatin 20mg and ezetimibe 10mg tablets po qd (by mouth, once a day). for 6 weeks.
224193286|NCT00276458|DRUG|Comparator: Placebo.|Atorvastatin 40mg Pbo tablets po qd (by mouth, once a day). for 6 weeks.
224193287|NCT04111666|BIOLOGICAL|AL101|Active dose of AL101
224193288|NCT04111666|OTHER|Placebo|Saline solution administered as a single and multiple infusion as placebo.
224193289|NCT06106217|OTHER|bapne|An exercise program was created in the form of a movement sequence consisting of nine movement combinations.
224193290|NCT06106217|OTHER|qi gong|The exercise program, which was prepared in a 40-minute sequence, was arranged as 10 minutes of warm-up, 20 minutes of Qi Gong exercises, and 10 minutes of cool-down.
224193291|NCT06385275|DRUG|Vitamin K1 500 µg|One pill daily for 4 weeks.
224193292|NCT06385275|DRUG|K1 1000 µg|One pill daily for 4 weeks.
224193293|NCT06385275|DRUG|Vitamin K2 (MK-7) 300 µg|One pill daily for 4 weeks.
224193294|NCT06385275|OTHER|Placebo|Placebo pill daily for 4 weeks.
224193295|NCT01595399|DRUG|atropine|Atropine 0.02 mg/kg IV
224193296|NCT01595399|DRUG|Placebo|an equivalent volume of normal saline to atropine IV
224193297|NCT05355506|DEVICE|Application|Knowledge \& record
224310148|NCT04996914|RADIATION|SBRT|"SBRT should be 1 month after last TACE. This can be extended till 2 months if indicated. However, prolongation of the gap between TACE and SBRT is not encouraged.~Treatment center should choose one of fractionation schedule mentioned allowed in the study, in order to achieve a balance between dose applied for tumor control and constraints for OAR PTV Dose in 5 / 8 fractions (Gy) EQD2 (α/β 10Gy) 5x 8-6 Gy @ 83% isodose = 40-30 Gy (60-40 Gy) 8 x 6-4.5 Gy @ 83% isodose = 48-36 Gy (64-43.5 Gy)"
224193298|NCT01056458|OTHER|auricular acupressure|use the tape of ear adhesive beads on shenmen and subcortical area of both ears after three meals and before bed for three minutes each area with alternating ears, twice a week to replace paste.
224193299|NCT01056458|OTHER|sham acupressure|use only tape without ear adhesive beads under the same ways
224310149|NCT02143973|DRUG|nalbuphine HCl ER|nalbuphine HCl ER
224310150|NCT00351884|DRUG|Vildagliptin AM|
223502175|NCT04725643|DEVICE|Track bleeding patterns before and after implant|Participants will report if they had bleeding and the amount based on the Pictorial Blood Assessment Chart. Participants will also complete weekly surveys regarding their satisfaction with their bleeding. We will also ask participants to complete a survey regarding their satisfaction with their bleeding at end of month 2 and at the end of month 3 after replacement of their contraceptive implant.
223746429|NCT00775931|PROCEDURE|marrow graft transplantation|Related donor marrow will be collected, processed and shipped according to existing protocols of the National Marrow Donor Program or other URD registry, with the goal of achieving a cell dose of ≥ 6.0 x 108 nucleated cells/kg. The proportion of cells that are CD34+ will be determined prior to the administration of the graft. This will allow a portion of the graft (2 x 106 CD34+ cells) to be frozen for a subsequent infusion on day +42.
223502176|NCT01037465|DRUG|N-acetylcysteine|N-acetylcysteine
223502177|NCT01037465|DRUG|Placebo|Placebo
223502178|NCT01290250|OTHER|Orange juice based beverage enriched in polyphenols|2 daily doses (250 ml each) during 3 months
223746430|NCT02433236|DRUG|Fostamatinib Disodium tablet 100 mg|
223746431|NCT02433236|DRUG|Fostamatinib Disodium tablet 150 mg|
223746432|NCT06546904|DEVICE|Artificial intelligence empowers anesthesia with ultrasound assistance|Artificial intelligence empowers anesthesia with ultrasound assistance
223746433|NCT04200807|DEVICE|Ultrasound Cardiac Output Monitor (USCOM 1A)|doplerometry with USCOM and echocardiograph is made for assessing central blood flow and spectroscopy with NONIN- for the blood flow in individual peripheral organs (brain and kidney)
223746434|NCT02717988|DRUG|SKI-O-703 capsule|SKI-O-703 25 mg capsule or 200 mg capsule without excipient
223746435|NCT02717988|DRUG|Placebo capsule|Placebo 180 mg capsule filled with microcrystalline cellulose
224193300|NCT03546270|BEHAVIORAL|Swimming|This group completed 20-weeks of swimming
224193301|NCT03751852|BEHAVIORAL|Exercise Coaching|28 classes in 16 weeks
224193302|NCT03751852|BEHAVIORAL|Psychoeducation|28 classes in 16 weeks
224193303|NCT01995604|OTHER|Application of Sterile 0.9% Saline Solution|Application of Sterile 0.9% Saline Solution to half of face after UltraPulse laser therapy.
224193304|NCT01995604|OTHER|Application of dHACM|Application of dHACM to half of face after UltraPulse laser therapy.
224193305|NCT00750373|PROCEDURE|Valve surgery with removal of vegetations|Early valve repair or replacement with removal of vegetations within 48 hours of randomization
224310151|NCT00351884|DRUG|vildagliptin pm|
224310152|NCT00351884|DRUG|placebo|
224310153|NCT05229003|DRUG|Anlotinib|Anlotinib 8mg or 10mg, d1-9，q2w
224310154|NCT05229003|DRUG|Penpulimab|Penpulimab 200mg, d6, q2w
224310155|NCT05229003|DRUG|Irinotecan|Irinotecan 180mg/m2, d6, q2w
223502179|NCT01549509|BIOLOGICAL|VRC-HIVADV014-00-VP Vaccine|All participants will receive one injection in their upper arm of 1 x 10\^10 particle units (PU)/mL of VRC-HIVADV014-00-VP at study entry.
223502180|NCT04689243|PROCEDURE|ALA-PDT|Low concentration ALA-PDT, 3 times a week.
223502181|NCT04689243|PROCEDURE|red light|red light, 3 times a week.
223502182|NCT02263313|OTHER|EGO-COMBO group|Assess the safety and effectiveness of Combo stent
223512219|NCT01064284|DRUG|PLASMA DERIVED Factor VIII|Maximum dosage : 50IU per kilo. 2-3 times per week or on demand during acute episode of bleeding
223512220|NCT01064284|DRUG|Recombinant FVIII|Maximum dosage : 50IU per kilo. 2-3 times per week or on demand during acute episode of bleeding
223512221|NCT04642066|OTHER|Cold water immersion|Full body CWI in open standing, except the head (same location, timing), frequency three times a week in the duration of 7-10 minutes. Swimming was permitted. Volunteers must not use neoprene aids (gloves, shoes), caps were allowed. Volunteers should be in the final phase submerged in water, above which there should only be the head and neck. The upper limbs were below the water surface. Non-neoprene footwear was permitted. Volunteers entered the water continuously without stopping. The time of stay in water was calculated from the first contact of the foot with water. On average, the whole body needed to be immersed in water within 30 seconds.
223512222|NCT04642066|OTHER|No cold water immersion|People without cold water immersion
223512223|NCT01311011|PROCEDURE|SCT|SCT
223512224|NCT05783349|BIOLOGICAL|Unique blod sample|sampling of 4mL of blood on lithium heparin tube, the day of frozen embryo implantation
223512225|NCT04011189|PROCEDURE|Videotaping|Before the videotaping, patients will be asked on their baseline pain scores. Their face and body pose from a frontal view will be videotaped via a mobile phone with no internet access. The collected videos will be further processed to extract key points, which will be the primary input for modelling algorithms and will further ensure anonymity of the patients in the video sequences.
223512226|NCT04011189|OTHER|Questionnaires|"Patients will be asked to fill in 1-2 questionnaires before surgery/procedure/consultation (Hospital Anxiety and Depression Scale (HADS) and/or EQ-5D-3L). After surgery/procedure/consultation, patients will be again asked to fill in HADS questionnaire (optional).~For pediatrics patient, only Child Pain Anxiety Symptoms Scale (CPASS) will be administered before the surgery."
223512227|NCT04011189|DEVICE|Empatica E4 wristband|A medical grade wearable device, Empatica E4 wristband, will be used in phase 3 for pediatrics patients to monitor real-time physiological data on heart rate and body temperature.
223512232|NCT03121274|PROCEDURE|vaginal delivery|vaginal delivery is carried by an expert obstetrician and the need for forceps or ventose is recorded
224193306|NCT04335760|COMBINATION_PRODUCT|Modified Bruce protocol on treadmill|"Fear of activity scale in CAD (FactCAD) was used to assess fear of activity and exercise in subjects with CAD. FactCAD is a novel scale developed specifically for patients with heart disease. Mean time to complete this self-administered scale is 4-7 minutes. The final score of the questionnaire ranges between 0 and 84. High scores indicate higher levels of fear regarding activity or exercise.~Functional capacity was assessed by 6MWT and exercise test. The 6MWT was performed to all participants according to the American Thoracic Society guidelines in a 30-m corridor10. The subjects were asked to walk as long distance as they could within 6 minutes. The 6MWT distance was recorded in meters.~Exercise test was performed using modified Bruce protocol on treadmill in institutions where technical equipment and experience was available."
224193307|NCT02353273|DRUG|WH-1 ointment|Each subject will be applied the one dose of WH-1 ointment on Day 1, and twice a day of WH-1 application from Day 2 to Day 13, then one dose for Day 14.
224193308|NCT05158075|BEHAVIORAL|Approach-Avoidance Bias Modification|In this task participants must zoom in or zoom out a food image according to its format (vertical or horizontal) using their smartphone device. 90% of healthy food images will appear in the format to be approached (for example, vertical), while only 10% of unhealthy images will appear in that format (to ensure concentration on the task). The format to be approached will be counterbalanced. Participants will practice the task at home at least once a day (about 5 minutes) for one week, and will receive daily reminders to practice via instant messaging on their mobile phones.
224193309|NCT05158075|BEHAVIORAL|Inhibition Training|In this App participants are instructed to touch green circle items as quickly as possible, but to withhold their response and not to press on the red circle items, using their smartphone device. Some images are food, some non-foods. Participants can choose which food categories they would like to train to resist. The food-specific inhibition training condition included pictures of high-calorie foods always paired with the no-go signal. Participants will practice the task at least once a day (about 5 minutes) for one week, and will receive daily reminders to practice via instant messaging on their mobile phones.
224193310|NCT05158075|BEHAVIORAL|Implementation of Intentions|"Participants establish one intention related to food and one related to exercise, and write when, where and how they will implement each one, possible inconveniences to do it, and how they will overcome them. Furthermore, motivational cues (why I eat) will be considered (negative emotions -I'm bored; social motives -eat a piece of cake you are offered in a party; politeness/conformity with others' expectations; pleasure). The implementation of intentions related to food will be written in format: if… then…. This format allows for the consideration of the health goals and medium and long-term objectives for each of the participants. The intention related to food will focus on unhealthy snacking habits whenever possible. Participants will read and visualized their implementation of intentions at least twice a day (about 5 minutes) for one week, and will receive two daily reminders to practice via instant messaging on their mobile phones."
224193311|NCT05158075|BEHAVIORAL|Episodic Future Thinking|Participants will decide health-related goals and anticipate positive future personal events at various time points (next month, 2-3 months and 4-6 months), from which contextual, temporal and emotional cues should be obtained. Goals and future events will be matched to generate episodic future thinking cues that include the necessary keys to facilitate their effectiveness. Participants will read and visualized their three cues at least twice a day (about 5 minutes) for one week, and will receive two daily reminders to practice via instant messaging on their mobile phones.
224193312|NCT05158075|BEHAVIORAL|Sham Approach-Avoidance Bias Modification|Participants must zoom in or zoom out a food image according to the format (vertical or horizontal) using their smartphone device. 50% of healthy food images and 50% of unhealthy food images will appear in the format to be approached (for example, vertical). The format to be approached will be counterbalanced. Participants will practice the task at least once a day (about 5 minutes) for one week, and will receive daily reminders to practice via instant messaging on their mobile phones.
224193313|NCT05158075|BEHAVIORAL|Sham Inhibition Treatment|In this App participants are instructed to touch green circle items as quickly as possible, but to withhold their response and not to press on the red circle items, using their smartphone devices. Some images are food, some non-foods. Participants can choose which food categories they would like to resist. High-calorie and low-calorie foods will be paired with the go signal on 50% of trials and with the no-go signal on 50% of trials. Participants will practice the task at least once a day (about 5 minutes) for one week, and will receive daily reminders to practice via instant messaging on their mobile phones.
224310156|NCT06552572|DRUG|Glofitamab|Glofitamab is administered to patients who have residual disease after CD19 CAR T-cell therapy for their relapsed or refractory diffuse large B-cell lymphoma
223746436|NCT03314727|OTHER|High salt (NaCl) intake|Participants are asked to consume two high sodium-containing soups while monitoring their serum osmolarity levels
223502183|NCT03376009|DIAGNOSTIC_TEST|Blood sample for serum and plasma biomarkers:|Serum/plasma biomarkers: Approximately 10ml (3 teaspoons) of blood will be extracted to measure pre-specified biomarkers of renal injury including kidney injury molecule-1 (KIM-1), cystatin C and neutrophil gelatinase-associated lipocalin (NGAL). Samples will then be stored to facilitate measurement of additional biomarkers in the future.
223502184|NCT03376009|DIAGNOSTIC_TEST|Urine sample for biomarkers|Urinary biomarkers: A random urine sample will be obtained to measure urinary protein to creatinine ratio (uPCR), KIM-1 and liver-type fatty acid binding protein (L-FABP)
223512233|NCT06048705|DRUG|GSK3901961|GSK3901961 was administered.
223512234|NCT06048705|DRUG|Cyclophosphamide|Cyclophosphamide was administered as lymphodepleting chemotherapy.
223512235|NCT06048705|DRUG|Fludarabine|Fludarabine was administered as lymphodepleting chemotherapy.
223512236|NCT06838988|DIAGNOSTIC_TEST|Transcutaneous ultrasound|"The ultrasonographic characteristics of the subcutaneous nodules were evaluated using an ultrasound machine (Venue Go™, wide-band linear array ultrasound probe (hockey stick shape), frequency range between 6.7 MHz and 18.0 MHz, from GE HealthCare Illinois, United States).~The procedure for capturing images at the location of the lesion of interest is as follows:~* Brightness mode (B-mode): Record at least 4 images using a depth of 2 cm.~* Color Doppler mode: Record images along the vertical axis (1 image) and along the horizontal axis (1 image). The two axes mentioned above must be perpendicular to each other.~* Video recording: Capture at least 10 seconds of video in both Brightness mode and Color Doppler mode."
223512237|NCT05478707|DRUG|Dulaglutide|GLP1-RA
223746437|NCT04724954|DEVICE|Rehabilitation Therapy on Experimental Robotic Table and standard of care|Experimental group will receive VR game-based rehabilitation therapy through Bright Cloud's proprietary device, called BrightArm Compact (BAC). They will also receive Standard of Care rehabilitation
223746438|NCT04724954|GENETIC|Rehabilitation Therapy as part of Standard of Care (Control)|Control group will receive Standard of Care training only
224193314|NCT05158075|BEHAVIORAL|Setting Intentions|Participants will choose 10 items of healthy foods to eat whenever they want to eat unhealthy food. They will also order a list of physical activities that they could do to lose weight. Participants will read their lists (food and exercise) at least twice a day (about 5 minutes) for one week, and will receive two daily reminders to practice via instant messaging on their mobile phones.
224193315|NCT05158075|BEHAVIORAL|Recent Episodic Thinking|Participants will match habits and positive recent past events (1 day ago, 2 days ago, 1 week ago), both unrelated to food or physical activity, to establish their cues. Participants will read and visualized their three cues at least twice a day (about 5 minutes) for one week, and will receive two daily reminders to practice via instant messaging on their mobile phones.
224193316|NCT05158075|BEHAVIORAL|Motivational Interviewing|Participants will assist a 90-minute group Motivational Interviewing session to maximize motivation and adherence to the program. The session will be guided through open questions and empathic reflections and affirmations to promote change talk. Participants will share their personal aims to reduce weight, improve their diet and increase their level of physical activity. Further, participants will talk about obstacles they have had on previous occasions, their expectations, and their motivations in regards to weight loss. When needed, information will be provided with the elicit-provide-elicit format. Sessions will end with an individual empathic summary for each participant's interventions.
224193317|NCT05158075|BEHAVIORAL|Nutritional intervention|Participants will maintain a 60-minute group session with a nutritionist and will watch a 20-minute video to match and complete relevant information on nutrition. The nutritionist will design a 6-week individualized diet that participants will receive after the initial assessment. When the 6-week diet ends, participants will assist another 60-minute group session with the nutritionist and will watch another video intended to teach them how to design their own healthy diet and maintain long-term healthy eating habits.
224193318|NCT05158075|BEHAVIORAL|Physical exercise intervention|Participants will maintain a 60-minute group session with a physical exercise professional and will watch a 20-minute video to match and complete relevant information on exercise. The physical exercise professional will design a 6-week physical exercise planning that participants will receive after the initial assessment. After those 6-weeks, participants will assist another 60-minute group session with the physical exercise professional and will watch another video intended to teach them how to design their own physical activity planning and maintain long-term healthy exercise habits.
224193319|NCT03305926|OTHER|Conventional CVR programme|Programme in a CVR centre involving 20 sessions of reconditioning to effort, 3 times per week for roughly 7 weeks, as well as 14 sessions of therapeutic education in groups.
224193320|NCT03305926|OTHER|Connected CVR programme|First week in the CVR centre with 3 sessions combining reconditioning to effort, individual interviews and targeted therapeutic education, so as to define the objectives and methods of the connected CVR at home for the 6 following weeks.
224193321|NCT03305926|OTHER|Follow-up visit M2|Effort test and evaluation at the end of the CVR programme
224193322|NCT03305926|OTHER|Follow-up vsit M8|Evaluation at 8 months following the CVR programme
224310157|NCT06173947|DEVICE|FibroScan® Expert 630|The SSM by FibroScan 630 was first performed after admission, repeated at the day 5±2 as soon as feasible, and finally evaluated before discharge.
223502185|NCT03376009|DIAGNOSTIC_TEST|Cardiac bio-impedance (Cardioscreen Medis)|Cardiac bio-impedance - a non-invasive assessment of cardiac output, cardiac index and systemic vascular resistance index using the bio-impedence technique (Cardioscreen 1000 Medis) Cardiac bio-impedance is performed by attaching sticky electrodes to the participant's neck and thorax. These electrodes pass a very low, constant and alternating current (1.5 mA, 86 kHz) across the thorax, which is imperceptible to the patient. This provides beat by beat data on cardiac output and haemodynamic measurements.
223746439|NCT01126996|PROCEDURE|Venepuncture|"1. Venepuncture and blood sample collection in 2010 in a sample of children who received a single dose of a MenC conjugate vaccine at age 1-3 years 10 years earlier.~2. A booster dose of a MenC conjugate vaccine (optional)."
223746440|NCT01652664|DRUG|Travoprost 0.004% PQ ophthalmic solution|
223746441|NCT01652664|DRUG|Timolol, 0.5% or 0.25% ophthalmic solution|Patients 2 months to \< 3 years of age received 0.25%
223746442|NCT01652664|DRUG|Travoprost Vehicle|Inactive ingredients used to maintain masking
223746443|NCT02357069|DRUG|Enbrel|Etanercept
223746444|NCT02357069|DRUG|LBEC0101|Etanercept
223746445|NCT01980043|PROCEDURE|endoluminal rectal prolapse repair under sedation|endoluminal rectal prolapse repair under sedation
223512238|NCT05478707|DRUG|Placebo|Saline placebo
223512239|NCT05478707|BEHAVIORAL|exercise training|supervised high intensity interval training
223512240|NCT05063383|OTHER|This study does not involve any interventions|This study does not involve any interventions
223512241|NCT05940246|BEHAVIORAL|Motivational Interviewing|"MI was introduced by William Miller in 1983 as a strategy to promote behavioral changes that would make people drink less. It is well established that MI can be successfully applied to many areas across the medical disciplines. Although the aim of MI is behavioral changes toward a specific goal it is necessary to understand the essence of MI with the four key interrelated elements of the spirits of MI. These are partnership, acceptance, compassion, and evocation. Together they form an equal and respectful collaboration between the MI practitioner and the patient wherein empathy and acknowledgment are important pillars. Moreover, an important message derived from the spirit of MI is the belief that patients in themselves have and know what is needed and get support from the MI practitioner to find it."
223746446|NCT00297037|DRUG|Pimecrolimus 1% cream|pimecrolimus cream or matching placebo BID for 6 weeks
223746447|NCT02155140|DIETARY_SUPPLEMENT|Jejunal feeding|A feeding jejunostomy tube is inserted at the time of surgery to provide enteral nutritional support.
223746448|NCT04322318|PROCEDURE|Biopsy Procedure|Undergo a biopsy
223512242|NCT03072849|PROCEDURE|Pulmonary function testing|Each enrolled patient will receive pulmonary function testing every three months. Pulmonary function testing includes spirometry, plethysmography, and diffusion capacity measurements.
224193323|NCT01226992|DRUG|Vancomycin|"Oral Vancomycin:~Dose: 125 mg po qid x 2 weeks then 125 mg po bid x 1 week then 125 mg po od x 1 week then 125 mg po q every other day x 1 week then 125 mg po q every third day x 1 week then discontinue Route: oral"
224193324|NCT01226992|BIOLOGICAL|Fecal Transplant|Fecal slurry 50 grams stool in 500ml normal saline
224193325|NCT01042288|DRUG|Carboplatin|Carboplatin AUC=6IV, Day 1 of Cycles 1-6 (Cycles are 3 weeks / 21 days in length)
224193326|NCT01042288|DRUG|Pemetrexed|Pemetrexed 500mg/m² IV, Day 1 of Cycles 1-6 (Cycles are 3 weeks / 21 days in length)
224193327|NCT01042288|DRUG|Panitumumab|Panitumumab 9mg/kg IV, Day 1 of Cycles 1-6 (Cycles are 3 weeks / 21 days in length)
224193328|NCT03205046|DRUG|acalabrutinib|Acalabrutinib is a selective, irreversible small molecule Bruton's tyrosine kinase (BTK) inhibitor.
224193329|NCT03205046|DRUG|vistusertib|Vistusertib is an inhibitor of mechanistic target of rapamycin (mTOR) kinase
224193330|NCT03676439|DEVICE|Magnetic Spinal Stimulation|"Spinal Magnetic Stimulation (TMS) on Lateral Cord Stimulation (LCS), in the search of the improvement of the tone, motor function and speech, in patients with spastic cerebral Palsy.~Due to its non-invasiveness and possible efficacy, the use of Magnetic Spinal Stimulation is proposed to try to prove its therapeutic usefulness.~This is the phase 2/3 clinical test of the method, in the future, and as its use could be extended, if the results were positive, its indications could be extended to other pathological conditions, giving a greater spectrum of spastic patients, potentially benefited."
224193331|NCT01112969|BEHAVIORAL|Internet-based supportive coaching OSCAR|The Internet-based supportive coaching (OSCAR) is an scientifically based multicomponent intervention
224193332|NCT01112969|OTHER|Waiting-list control group (TAU)|Waiting-list control group (treatment as usual, TAU, no specific intervention)
224193333|NCT06225401|OTHER|Simcapture PRE|Practice with the SimCapture for Skills interface before the traditional teaching with the teacher in the classroom
224193334|NCT06225401|OTHER|Simcapture POST|Practice with the SimCapture for Skills interface after the traditional teaching with the teacher in the classroom
224193335|NCT01656109|DRUG|boosted atazanavir (ATV/r)|ATV/r will be taken orally once daily with food plus standard dose of 2 NRTIs according to Thai National HIV treatment guideline
224193336|NCT03172715|PROCEDURE|Locking plate|Osteosynthesis
224193337|NCT03172715|PROCEDURE|TKR|Total knee arthroplasty
224193338|NCT03253809|DEVICE|Biotronik Vision Guidewire|The apical, mid ventricular and basal sites within the anterior,posterior and lateral coronary sinus branch veins will be paced.
224193339|NCT05070507|DIETARY_SUPPLEMENT|Enzyme containing lozenge|Subjects are instructed to take one lozenge three times daily, at least 30 minutes after a meal, for seven days. No oral health care procedures are allowed during the intervention period.
224193340|NCT05070507|DIETARY_SUPPLEMENT|Placebo lozenge|Subjects are instructed to take one lozenge three times daily, at least 30 minutes after a meal, for seven days. No oral health care procedures are allowed during the intervention period.
224193341|NCT02772341|DEVICE|Salt room with halogenerator|Patients were assigned to 14 sessions (7 weeks, twice weekly, 45 minutes each treatment) sitting in a salt room with salt aerosol produced by a halogenerator (study group) or halotherapy without salt aerosol (placebo). Both the walls and the ceiling of the salt room are completely covered with ESCO-(European Salt Company) type certified-origin rock salt. The temperature (20-24°C) and humidity (44-60%) are at constant values. The halogenerator is located outside the salt room.
224193342|NCT02772341|OTHER|Salt room without halogenerator|Patients were assigned to 14 sessions (7 weeks, twice weekly, 45 minutes each treatment) sitting in a salt room without salt aerosol (placebo). Both the walls and the ceiling of the salt room are completely covered with ESCO-(European Salt Company) type certified-origin rock salt. The temperature (20-24°C) and humidity (44-60%) are at constant values.
223592032|NCT05985096|DIAGNOSTIC_TEST|Virtual reality group|Participants in this group will be expected to meet their physical activity levels using the Oculus Quest 2 VR Goggles platform with Racket, Climb, Acron, Skiing, Cycling games.
223592033|NCT03759106|OTHER|home written exercise program|exercises such as picking up objects, placing objects, frequently prescribed at discharge
223592034|NCT03759106|OTHER|telerehabilitation/exergame system|Video games using the Kinect camera that are carried out using the impaired arm and monitored by a therapist by videoconferencing
223592035|NCT06508229|DRUG|Adebrelimab|adebrelimab, IV
224193343|NCT05518409|BIOLOGICAL|Detection of cytof in peripheral PBMC|Each subject needs to take 5ml of peripheral venous blood to extract PBMC cells, and then conduct cytof detection. This is a mass spectrometry flow cytometry method based on single cell level. It has the ability to analyze all immune cells with high resolution.
224193344|NCT05518409|DRUG|Donepezil for patients with AD and DLB|The subjects in AD and DLB groups were given donepezil at an initial dose of 5mg and then increased to 10mg one month later. Lasting for 1 year.
224193345|NCT00926809|DRUG|Lansoprazole (proton pump inhibitor), amoxicillin, clarythromycin|Lansoprazole, Amoxicillin 1000 mg, Clarithromycin 500 mg
224193346|NCT00926809|DRUG|Lansoprazole (proton pump inhibitor), placebo|Lansoprazole, Amoxicillin placebo, Clarythromycin placebo
224193347|NCT05885711|OTHER|self-management|self-managing a pessary: removing, cleaning and inserting
224193348|NCT00443573|DRUG|recombinant nematode anticoagulant protein c2 (rNAPc2)|escalating dose administered 2x/week sq.
224193349|NCT05624515|DEVICE|dry needling|Active trigger point puncture of the angularis scapulae muscle
224193350|NCT05624515|OTHER|Ischaemic compression|Ischaemic compression at the active trigger point of the angularis scapulae muscle
224193351|NCT00052507|DRUG|bortezomib|
224193352|NCT03874507|OTHER|Virtual Reality/Augmented Reality Headset|"A virtual reality (VR) headset is a device the participant will wear over his/her head and eyes like a pair of goggles. It blocks out all external light and shows him/her an image on high-definition screens in front of his/hers eyes. It implies a complete immersion experience that shuts out the physical world.~Augmented reality (AR) headset is a device that the participant will wear over his/hers head and eyes and it adds digital elements to a live view."
224193353|NCT02974270|DRUG|Leuprolide|
224193354|NCT05036876|DRUG|Degludec|Treatment with insulin degludec when compared to insulin glargine U-300 will result in similar blood glucose control in hospitalized patients with type 2 diabetes.
224193355|NCT05036876|DRUG|Glargine U300|Treatment with insulin glargine U300 when compared to insulin degludec will result in similar blood glucose control in hospitalized patients with type 2 diabetes.
224193356|NCT06294327|DEVICE|Reactive static air support surfaces|"* Repose® Mattress~* Repose® Cushion~* Repose® Wedge~* Repose® Foot Protectors"
224193357|NCT04897724|OTHER|dental composite|clinical performance of composite restorations used for posterior teeth in patients with Amelogenesis Imperfecta
224193358|NCT03715816|BEHAVIORAL|Work break schedule|Participants will receive 2.5-min breaks during a 90-min simulated laparoscopic surgery in the laboratory. The breaks will be either passive (simple rest) or active (selected mobilization exercises).
224193359|NCT05416567|PROCEDURE|Endovascular embolization|Therapeutic endovascular embolization in general anesthesia
224193360|NCT05797142|OTHER|Virtual reality glasses|"Beginning 1-2 minute before the start of the procedure, the patients will be watched (30 minutes) with an android mobile phone inserted into the Cardboard Super Flex Binoculars Glasses, with a music background, licensed product Secret Garden, during the procedure (30 minutes)."
223746449|NCT04322318|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
224193361|NCT01224769|DRUG|bendamustine +/- rituximab|
224193362|NCT02823782|OTHER|MRI|MRI and neuropsychological assessment planned for the study for patient and volunteers
224193363|NCT02823782|OTHER|neuropsychological assessment|
224193364|NCT04113746|BEHAVIORAL|Better asthma self-management and incorporation of physical activity|Participants in the asthma and exercise lifestyle change arm will participate in 4 sessions focused on behavioral change and goal-setting education to teach them how to better incorporate exercise into their daily lives and better manage their asthma. Following sessions 1 and 4, these participants will use the accelerometer to track activity, but will be blinded to the data.
223502186|NCT03376009|DIAGNOSTIC_TEST|Aortic pulse wave velocity (APWV) (TensioMed and SphygmoCor)|"Aortic pulse wave velocity (APWV) a non-invasive measure of arterial function using oscillometric recordings to detail peripheral and central haemodynamics. This will be measured using two different techniques:~TensioMed Arteriograph: After a rest period a blood pressure cuff inflates and deflates twice on the arm. This takes \~3 minutes and should cause only mild, temporary discomfort. The test will routinely be performed in duplicate to ensure accuracy of results.~SphygmoCor: A pressure sensor is held over the radial pulse at the wrist to analyse the pulse wave. Then held over the carotid artery and/or femoral artery to assess the speed of the pulse wave through the body. The probe is similar to an ultrasound probe and should not cause any discomfort."
223502187|NCT03376009|DIAGNOSTIC_TEST|Optical Coherence Tomography (Spectralis OCT)|"OCT is a non-invasive imaging test which uses light waves to take cross sectional images of the back of the eye. Examination of the retinal and retinal nerve fibre layer thickness, macular volume, and choroidal thickness provides an assessment of generalised systemic microvascular injury. A strong correlation between choroidal thickness and renal dysfunction has previously been shown in patients with chronic kidney disease (Balmforth C et al, JCI Insight 2016).~The participant is asked to sit in front of the OCT machine and rest their chin on a support to keep it motionless. The equipment will then scan the eye without touching it. Scanning takes about 5 - 10 minutes."
223512243|NCT03072849|DRUG|FAM Therapy|All patients who have evidence of early airflow obstruction on pulmonary function testing will be started on FAM therapy. Early airflow obstruction is defined by a FEV1 decline of ≥10% predicted in addition to a FVC \<0.8.
223512244|NCT03512158|OTHER|Non-invasive respiratory support mode|A mode of providing respiratory support via nasal masks or prongs
223512245|NCT03954730|OTHER|Eccentric Training|First session will be performed 24 hours after pre-training tests i.e. on 4th post- operative day and subsequent sessions will be performed with lapse of 48 hours. During pre-testing, weight for the eccentric training will be determined using Standardized Brzycki formulas for lower limb. Participants will perform one set of 10 repetitions with selected weight. Intensity will be increased every week by decreasing the time of performance. Volume will be increased by increasing one set after two weeks. Eccentric training will be performed in sitting position on dynamic constant external resistance equipment.After session, patient will perform strengthening of quadriceps muscle as per clinical practice guidelines of National Health Service (UK).
223746450|NCT04322318|PROCEDURE|Bone Scan|Undergo a bone scan
224193365|NCT04113746|BEHAVIORAL|Asthma Education|General asthma education, but no discussion of the role of exercise and other lifestyle habits in asthma self-management. Following sessions 1 and 4, these participants will use the accelerometer to track activity, but will be blinded to the data.
224193366|NCT06075927|BIOLOGICAL|Virus specific T cells|"Subjects will receive partial HLA-matched viral-specific T cells (VSTs) against both CMV and EBV on one of the following dose levels:~Level One: 1 x 10\^7 cells/m2 Level Two: 2 x 10\^7cells/m2 Level Three: 5x 10\^7 cellss/m2"
224193367|NCT02594384|DRUG|LAM-002A|25 mg capsules or 50 mg capsules
224193368|NCT02594384|DRUG|Rituximab|375 mg/m2 by vein
224193369|NCT02594384|DRUG|Atezolizumab|1200 mg by vein
223512246|NCT03954730|OTHER|Active Release Technique|Isometric Quadriceps' contractions against therapist's resistance lasting for 10 seconds will be performed by the patient in inner range of knee extension and after relaxing; actively perform maximum full knee flexion. Patient will perform extension at knee joint again; when reaches the innermost range, therapist will apply pressure on deep fascia either through knuckles/fingers or forearm in the direction towards the hip joint and patient is asked to perform knee flexion simultaneously. The procedure is applied onto vastus lateralis, rectus femoris and vastus intermedialis thrice in a session. After session, patient will perform strengthening of quadriceps muscle as per clinical practice guidelines of National Health Service (UK).
224193370|NCT02427568|DRUG|Midomafetamine HCl|Two sessions of MDMA-assisted therapy lasting six to eight hours, scheduled two to four weeks apart.
224193371|NCT02427568|DRUG|Placebo|Two sessions of placebo with therapy lasting six to eight hours, scheduled two to four weeks apart.
224193372|NCT02427568|BEHAVIORAL|Therapy|Manualized therapy
224193373|NCT04034524|DRUG|GLP-1 receptor agonist|any GLP-1 receptor agonist (other than Saxenda or liraglutide 3.0mg)
224193374|NCT04034524|DRUG|Insulin|glargine, detemir, neutral protamine Hagedorn (NPH), degludec
224193375|NCT02705664|DRUG|Loceryl Nail Lacquer|Topical over entire toenail plates of affected toenails once weekly in the evening (at bed time) after having filled down affected toenails to gently remove as much as affected nails and having cleaned toenails surfaces with the provided cleansing swab
224310158|NCT06509893|DRUG|aspirin 80 mg and clopidogrel 75 mg daily|post PCI patients received these two drugs as dual antiplatelet regimen
224193376|NCT02705664|DRUG|Urea Ointment|Topical over the infected part of the toenails only once daily under occlusion in the evening (at bed time) after having soaked toenails in warm water and having removed the soften infected toenail plates and dried the toenails
224193377|NCT02705664|DRUG|Bifonazole Cream|Topical, to be rubbed sparingly over the affected toenail skin (nail bed) once daily in the evening (at bed time) after having cleaned and dried thoroughly toenails
224310159|NCT06509893|DRUG|Ticagrelor 90 MG|Post PCI patients receive Ticagrelor 90 mg two times daily as single potent antiplatelet
224310160|NCT04997226|DEVICE|tDCS or tACS over the left DLPFC with adaptive memory game|This intervention is described in arms 1 and 3.
223502188|NCT03376009|DIAGNOSTIC_TEST|Arterial Spin Labelling Magnetic Resonance Imaging|"Magnetic resonance imaging using arterial spin labelling (ASL-MRI) This promising quantitative technique has the potential to identify dysregulated renal perfusion, stratify risk of AKI in pre-OLT patients, and to monitor alterations in renal haemodynamics in the post transplantation setting.~* We aim to recruit 5 participants with 'normal' renal function (eGFR≥60ml/min/1.73m2) and a further 5 participants with 'abnormal' renal function (eGFR\<60ml/min/1.73m2)~* ASL-MRI will be performed in this subgroup during the week of OLT assessment and then repeated at 6-weeks post transplantation in those participants who undergo OLT during the study period."
223502189|NCT03461809|OTHER|Ocular acupuncture|Patient's skin located in the extraocular muscles projection area is routinely disinfected. A diameter of 0.20 mm and length of 25 mm needle is inserted slowly. Piercing depth is about 20mm. The electropuncture apparatus is used, each group of electrodes are distinguished with different colors of wires to generate current stimulations of current 1.0\~1.5 milliampere (mA), voltage 9 volt(V), frequency 1.5 hertz (Hz), and duration of 40 minutes.
223502190|NCT02412319|DRUG|Anti-HBV placenta transfer factor injection|Anti-HBV Placenta Transfer Factor Injection: 2mg/4ml, intramuscular injection, the 0-24 week, once every other day; week 24-48, 2 times / week; entecavir tablets: 0.5mg/ tablet / time, daily bedtime fasting oral once, treatment course 96 weeks
223592036|NCT06508229|DRUG|albumin paclitaxel|albumin paclitaxel, iv
224193378|NCT04964960|DRUG|Pembrolizumab|Pembrolizumab is an immunotherapy that can help fight certain cancers.
224310161|NCT04997226|DEVICE|Sham tDCS or tACS over the left DLPFC with adaptive memory game|This intervention is described in arms 2 and 4.
224310162|NCT02543619|OTHER|Injection technique|One group received Gow-Gates technique and the other group received Infra Alveolar Nerve Block technique for their failed first one anesthesia
223502191|NCT02412319|OTHER|Placebo|Physiological saline injection: 2mg/4ml, intramuscular injection,the 0-24 week, once every other day, week 24-48, 2 times / week; entecavir tablets: 0.5mg/ tablet / time, daily bedtime fasting oral once, treatment course 96 weeks
223502192|NCT02869139|OTHER|Mentholated lip moisturizer and ice popsicle|Mentholated package of measures
223502193|NCT02869139|OTHER|Non-mentholated lip moisturizer and ice popsicle|Non-mentholated package of measures
224310163|NCT05532371|OTHER|Aerobic exercise training combined with lower limb strengthening|The participants performed aerobic exercise training and lower limb strengthening during this intervention.
224310164|NCT05532371|OTHER|Dual-task training combined with lower limb strengthening group (DG)|The participants performed dual-task training combined with lower limb strengthening during this intervention.
223502194|NCT02585492|OTHER|Head-of-bed elevated 15°|Head-of-bed elevated 15° during 2 hours after delivery.
223502195|NCT02585492|OTHER|Head-of-bed elevated 45°|Head-of-bed elevated 45° during 2 hours after delivery.
223502196|NCT05830747|DRUG|Prednisone|Pre-operative drug administration before third molar surgery
223502197|NCT05830747|DRUG|Placebo|Pre-operative Placebo administration before third molar surgery
223502198|NCT03309111|BIOLOGICAL|ISB 1342|ISB-1342 is CD38 x CD3 BEAT® 1.0 bispecific antibody. ISB 1342 is administered by intravenous (IV) infusion or subcutaneous injection (SC)
223502199|NCT02043067|OTHER|Comprehensive TB screening|All enrollees will receive a comprehensive TB screening regardless of symptom presentation.
223502200|NCT04688996|DIAGNOSTIC_TEST|Lateral Flow Assay for Pathogens of the Plague|A dipstick type of rapid test for antigens of the plague bacterium Yersinia pestis in samples from enrolled participants from both a known geography of plague activity (Madagascar) as well as samples from a geographically separated population of likely plague free status (US Naval Health Research Center, San Diego, CA).
223502201|NCT00472381|DRUG|Insulin|Insulin
223592037|NCT06508229|DRUG|Nedaplatin|Nedaplatin，IV
223592038|NCT03783494|DRUG|Target control infusion with propofol|Target control infusion with propofol for patients with indications of sustaining very painful orthopedic emergency emergent procedures
223592039|NCT00683969|DRUG|mycophenolate mofetil (CellCept)|1g bid for 36 weeks
223592040|NCT00683969|DRUG|placebo|po bid for 36 weeks
223592041|NCT01180517|PROCEDURE|Percutaneous coronary intervention (PCI)|balloon angioplasty
223592042|NCT01180517|PROCEDURE|PCI|balloon angioplasty
223592043|NCT03948919|DRUG|Fecal microbiota|Lyophilized encapsulated fecal microbiota given daily for 8 weeks.
223592044|NCT03948919|DRUG|Placebo|Placebo capsules identical in appearance to fecal microbiota capsules to be taken daily for 8 weeks.
223746451|NCT04322318|DRUG|Carboplatin|Given IV
224193379|NCT04964960|DRUG|Nab paclitaxel|Nab-paclitaxel is a taxane derivative that is an albumin-bound paclitaxel nanoparticle formulation that promotes microtubule assembly.
224310165|NCT05532371|OTHER|Aerobic exercise training combined with dual-task training and lower limb strengthening|The participants performed aerobic exercise training combined with dual-task training and lower limb strengthening during this intervention.
224310166|NCT05532371|OTHER|Only lower limb strengthening group (CG)|The participants performed only lower limb strengthening group during this intervention.
224310167|NCT03728855|BEHAVIORAL|Self-administration of medication (SAM)|Patients use medication from their own stock, self-administered.
224310168|NCT02069483|BEHAVIORAL|Motivational Interviewing|Subjects will engage in motivational interviewing in order to generate motivating messages related to quitting smoking.
224310169|NCT02069483|BEHAVIORAL|Tailored Feedback|Subjects will self-generate reasons they want to quit smoking during the baseline survey and record these reasons during the in-person activity.
224310170|NCT04058249|DEVICE|Accelerated intermittent theta-burst stimulation over right DLPFC|"All participants will receive accelerated intermittent theta-burst stimulation to the right DLPFC. Stimulation intensity will be standardized at 90% of resting motor threshold adjust to the skull to cortical surface distance.~Stimulation will be delivered to right-DLPFC using the Brainsway stimulator."
224310171|NCT03953989|DRUG|Ranolazine PR (prolonged-release) 500 mg 1 tablet bis in die and 750 mg 1 tablet bis in die|Patients enrolled in the study, at the end of the titration phase will be treated with ranolazine 750 mg or 500 mg, 1 oral tablet twice a day for 4 months on top of standard of care treatment
224310172|NCT00785460|DRUG|Benfotiamine|
224193380|NCT04964960|DRUG|Paclitaxel|Paclitaxel is a taxane derivative that promotes microtubule assembly by enhancing the action of tubulin dimers, stabilizing existing microtubules, and inhibiting their disassembly, interfering with the late G2 mitotic phase, and inhibiting cell replication.
224310173|NCT01648660|DIETARY_SUPPLEMENT|Lutein/ Zeaxanthin + Omega- 3- Fatty Acids|capsule with Lutein, Zeaxanthin, Omega-3-FA for two years
224310174|NCT01064050|DEVICE|silicone trachea-bronchial stent Dumon (Novatech)|Bronchial desobstruction under interventional bronchoscopy, for inclusion, with the insertion of silicone stent trachea-bronchial covering the entire tumor area
224310175|NCT05387850|OTHER|no intervention|no intervention
224310176|NCT02373033|OTHER|Natural food folate|Consumed folate-rich foods (providing additional 250 μg/d folate).
223502202|NCT01841853|BEHAVIORAL|Senior meetings|The intervention will be led by professionals such as a registered occupational therapist, a nurse, a physical therapist, and a social worker. The intervention will comprise four weekly meetings in small groups (4-6 participants) in addition to an individual follow-up home visit two to three weeks after the last senior meeting. To use groups involve the possibility of peer education where participants in a person-centeredness perspective are seen as experts on their own situation and learn from each other. The relationship between the personnel and the participants in the senior meetings can be described as a partnership. Respect for the participant and his/her values, and that the participant gets an opportunity to maintain and develop their own power over their own everyday activities will be essential in the meeting.
223502203|NCT03363438|OTHER|no intervention survey|there was no intervention this was a survey
223502204|NCT05381636|PROCEDURE|Esophageal arterial infusion chemotherapy|Percutaneous femoral artery puncture was performed to search for feeding arterial vessels corresponding to the lesion, and chemotherapeutic drugs were directly injected into the tumor vessels via targeted blood vessels.
224310177|NCT02373033|OTHER|Folic acid|Received a folic acid supplement (providing additional 500 μg/d folic acid).
224193381|NCT04964960|DRUG|Pemetrexed|Pemetrexed is an antifolate agent that disrupts folate-dependent metabolic processes essential for cell replication.
224193382|NCT04964960|DRUG|Carboplatin|Carboplatin is a platinum compound alkylating agent which covalently binds to DNA and interferes with the function of DNA by producing interstrand DNA cross-links.
224193383|NCT02686749|DEVICE|Catheter Ablation|"During ablation, a doctor inserts a catheter through blood vessels into the heart. The doctor looks at the electrical activity of the heart. The catheter is used to determine which areas of the heart are causing AF. After the area is identified, the doctor uses a special machine delivers energy through the catheter to tiny areas of the heart muscle that is causing AF. This energy causes a scar in the tissue which disconnects the pathway of the AF."
224193384|NCT02686749|DRUG|FDA approved anti arrhythmic drug|Anti arrhythmic drug medical treatment will be based on treating physicians discretion following standard clinical guidelines
224193385|NCT01678586|OTHER|Acupuncture|In true acupuncture the needles penetrate the skin.
224310178|NCT02373033|OTHER|Apple juice|Received apple juice containing no folate or folic acid.
223502205|NCT05381636|DRUG|Systemic intravenous chemotherapy|Albumin paclitaxel 125 mg / m2, D1, D8 + cisplatin 75 mg / m2, D1, every 3 weeks for 1 cycle
223502206|NCT06243159|GENETIC|JY231|Infusion of JY231 Injection by dose of 1-10×10\^6 TU/kg、 1-5×10\^7 TU/kg、5-10 ×10\^7 TU/kg Administration method: intravenous infusion、Splenic artery infusion、Lymph node infusion; Subjects will be treated with Fludarabine and Cyclophosphamide before cell infusion (PI evaluation is required)
223502207|NCT00062959|BEHAVIORAL|Going Places: School program to prevent problem behavior|
223502208|NCT02528136|DRUG|Carbetocin|
223502209|NCT02528136|DRUG|Oxytocin|
223502210|NCT03938870|OTHER|L-Leucine 13C6|
223592045|NCT05014113|DEVICE|DELTA-ST cup in combination with MINIMA stem|Advance articular destruction generated by primary degenerative or post-traumatic arthrosis or reumatoid arthritis; fracture or avascular necrosis; congenital or acquired deformity.
223592046|NCT02653716|BEHAVIORAL|New Orleans Intervention Method|An attachment based assessment, then a tailored intervention aimed at maximising the chances of the maltreated child being returned to the birth family
223592047|NCT02653716|BEHAVIORAL|Case Management|A social work assessment of family functioning that makes future recommendations regarding the future placement of a maltreated child.
224193386|NCT01678586|OTHER|Sham Acupuncture|In sham acupuncture the needles do not penetrate the skin.
224193387|NCT01678586|DRUG|Gabapentin|Gabapentin is a commonly prescribed drug used to treat neuropathic pain.
224310179|NCT00899041|PROCEDURE|Total Knee Arthroplasty (TKA)|28 subjects will receive the standard Sigma FB knee prosthesis. 28 subjects will receive the high flexion Sigma RP-F knee prosthesis.
224310180|NCT01337258|DRUG|Dutasteride|dutasteride 0.5mg daily.
224310181|NCT01337258|DRUG|Placebo|Men taking placebo daily
224310182|NCT03179215|DIAGNOSTIC_TEST|fluid challange|A set of hemodynamic measurements will be obtained at baseline and after infusing a fluid challenge (FC) of 150-250 ml normal saline over 5-10 minutes.Fluid-responders are patients with a SV increase ≥10% after fluid challenge
224310183|NCT05578456|DRUG|Prednisone and Aspirin|prednisone 10 mg and aspirin 75-100mg per day per os
224310184|NCT05578456|DRUG|Placebo|placebo 2 starch tablets per day per os
223502211|NCT01603914|DEVICE|central venous catheter replacement (Arrowgard Blue plus Quad-Lumen CVC )|"Routine practices for the type of catheter of each participating Unit will be respected. Multilumen central venous catheter will be used (i.e Arrowgard Blue plus Quad-Lumen CVC set). Impregnated Catheter with antiseptics or with antibiotics will be allowed.The anatomical locations selected for the replacement of central venous catheter are: subclavian vein, internal jugular vein, femoral vein and the change will be addressed according to the randomization.~The dressing and maintenance of the catheter will be guided according with the Guides of The Centers for Disease Control and Prevention (CDCs) and a check-in lists will be fill in for each catheter.~A pre-defined stratified analysis will be performed according with: type of catheter, participating unit, and insertion site."
223502212|NCT00709800|BIOLOGICAL|VCL-IPT1|IM, 0.1 mg/mL, 2 injections, 0 and 21 days
223502213|NCT00709800|BIOLOGICAL|VCL-IPT1|IM, 0.5 mg/mL, 2 injections, 0 and 21 days
223502214|NCT00709800|BIOLOGICAL|VCL-IPT1|IM, 1 mg/mL, 2 injections, 0 and 21 days
223502215|NCT00709800|BIOLOGICAL|VCL-IPM1|IM, 1 mg/mL, 2 injections, 0 and 21 days
223502216|NCT00709800|BIOLOGICAL|PBS|IM, 1 mL, 2 injections, 0 and 21 days
223592048|NCT05484323|OTHER|Glucose as reference food|Thirteen healthy participants (male: 4, female: 9) after 10-14h fast, consumed 50 g available carbohydrates from D-glucose, in different visits as reference food, tested two times; and 50 g available carbohydrates from white bread, tested two times; and 50 g available carbohydrates from cookies containing 0 and 2.5g spirulina, tested once, in different visits, along with 250 mL water. There was a washout period of at least two days between visits. Fingertip capillary blood glucose and salivary insulin samples were taken at 0, 15, 30, 45, 60, 90 and 120 min postmeal. The first glucose and salivary insulin sample were taken exactly 15 min after the first bite of food or drink.
223592049|NCT05484323|OTHER|White bread|Thirteen healthy participants (male: 4, female: 9) after 10-14h fast, consumed 50 g available carbohydrates from D-glucose, in different visits as reference food, tested two times; and 50 g available carbohydrates from white bread, tested two times; and 50 g available carbohydrates from cookies containing 0 and 2.5g spirulina, tested once, in different visits, along with 250 mL water. There was a washout period of at least two days between visits. Fingertip capillary blood glucose and salivary insulin samples were taken at 0, 15, 30, 45, 60, 90 and 120 min postmeal. The first glucose and salivary insulin sample were taken exactly 15 min after the first bite of food or drink.
223592050|NCT05484323|DIAGNOSTIC_TEST|Cookie containing 0 g spirulina|Thirteen healthy participants (male: 4, female: 9) after 10-14h fast, consumed 50 g available carbohydrates from D-glucose, in different visits as reference food, tested two times; and 50 g available carbohydrates from white bread, tested two times; and 50 g available carbohydrates from cookies containing 0 and 2.5g spirulina, tested once, in different visits, along with 250 mL water. There was a washout period of at least two days between visits. Fingertip capillary blood glucose and salivary insulin samples were taken at 0, 15, 30, 45, 60, 90 and 120 min postmeal. The first glucose and salivary insulin sample were taken exactly 15 min after the first bite of food or drink.
223746452|NCT04322318|PROCEDURE|Computed Tomography|Undergo a CT scan
223502217|NCT01579305|DEVICE|Juvéderm® Volbella with Lidocaine|Up to 4.0 mL at the discretion of the Investigator to achieve optimal results
223502218|NCT01579305|DEVICE|Restylane-L®|Up to 4.0 mL at the discretion of the Investigator to achieve optimal results
223502219|NCT02400580|DRUG|IV acetaminophen|The patients in the treatment arm will receive 1000mg of IV acetaminophen.
223502220|NCT02400580|DRUG|placebo|The patients in the placebo arm will receive normal saline.
223502221|NCT00965094|DRUG|Everolimus|One tablet containing 0.25, 0.5mg or 0.75 mg. Initially 2 mg/day. Afterwards based on blood level (target 6-10 ng/mL)
223502222|NCT00965094|DRUG|Tacrolimus (FK506)|Capsules 0.5 mg, 1 mg. Dosing according to blood level.
223502223|NCT00965094|DRUG|Basiliximab|One vial containing 20 mg lyophilisate. 2 x 20 mg \[day 0 (2 hrs prior to Tx) and day 4 post Tx\] to be applied as 10 sec. bolus injection, i.v.
224074980|NCT05343312|DRUG|AS-AQ (Carsucam)|"Eligible patients will be consecutively assigned to the four cohorts. Rescue therapy according to national malaria treatment guidelines will be also administered in cases of early or late treatment failure.~Follow-up visits will take place on days 1, 2, 3, 7, 14,21, 28, 35 and 42 after enrolment or at any time point whenever the child is sick. Adverse events will be recorded and assessed for severity and association with study medication.~Thick and thin Giemsa-stained blood slides will be prepared before each dose to be administered and at every follow-up visit of days 2, 3, 7, 14, 21, 28, 35 and 42. Blood samples for PCR analysis will be collected from every patient at baseline and at days 7, 14, and 28 day of treatment failure or at any other unscheduled visit. The Molecular markers associated with suboptimal response to ACTs will be investigated."
224074981|NCT05343312|DRUG|DHP|"Eligible patients will be consecutively assigned to the four cohorts. Rescue therapy according to national malaria treatment guidelines will be also administered in cases of early or late treatment failure.~Follow-up visits will take place on days 1, 2, 3, 7, 14,21, 28, 35 and 42 after enrolment or at any time point whenever the child is sick. Adverse events will be recorded and assessed for severity and association with study medication.~Thick and thin Giemsa-stained blood slides will be prepared before each dose to be administered and at every follow-up visit of days 2, 3, 7, 14, 21, 28, 35 and 42. Blood samples for PCR analysis will be collected from every patient at baseline and at days 7, 14, 28, and 42 day of treatment failure or at any other unscheduled visit. The Molecular markers associated with suboptimal response to ACTs will be investigated."
224074982|NCT05343312|DRUG|PA|"Eligible patients will be consecutively assigned to the four cohorts. Rescue therapy according to national malaria treatment guidelines will be also administered in cases of early or late treatment failure.~Follow-up visits will take place on days 1, 2, 3, 7, 14,21, 28, 35 and 42 after enrolment or at any time point whenever the child is sick. Adverse events will be recorded and assessed for severity and association with study medication.~Thick and thin Giemsa-stained blood slides will be prepared before each dose to be administered and at every follow-up visit of days 2, 3, 7, 14, 21, 28, 35 and 42. Blood samples for PCR analysis will be collected from every patient at baseline and at days 7, 14, 28, and 42 day of treatment failure or at any other unscheduled visit. The Molecular markers associated with suboptimal response to ACTs will be investigated."
224193388|NCT01678586|DRUG|Sham Gabapentin|Benadryl or diphenhydramine is used as a placebo as it could mimic some common side effects of gabapentin (i.e. sedation, drowsiness, lightheadedness)
224193389|NCT00800085|DRUG|glucose 20%|maintain glycemia at 180 mg/dL till 150 min. after start glucose infusion: with a maintenance dose computed at 5- to 10-minute intervals
224193390|NCT02411032|BEHAVIORAL|Reminder|Customer gets mailing that reminds them to take their medication.
224193391|NCT02411032|BEHAVIORAL|Fresh start|Customers receive a mailing around a fresh start event: New Year's or birthday
224193392|NCT02411032|BEHAVIORAL|Fresh start framing|The fresh start event will be highlighted in the mailings.
224193393|NCT01752244|DIETARY_SUPPLEMENT|Placebo|corn oil Capsules 1 gram: were given to the placebo group once a day for 8 weeks
224193394|NCT01752244|DIETARY_SUPPLEMENT|Alfacalcidol|Alfacalcidol
224193395|NCT01052220|BEHAVIORAL|BP education and BP self-regulation|"The intervention will consist of 3 phases: 1) BP education sessions, 2) 12 week intervention and 3) 30 day post intervention follow-up period. The participants in the treatment group will be asked to monitor and record home BP daily, 24 hour fluid intake and complete a salt intake check-lists twice weekly for 12 weeks.~The PI will visit weekly with the intervention participants in the HD unit. to review BP and fluid logs and salt check lists with the participant to determine if predetermined goals for BP control were attained. When goals related to BP control are met, positive verbal reinforcement will be given to the participant. When goals related to BP control are not met, further exploration and problem solving will be done."
224193396|NCT01052220|BEHAVIORAL|Supportive Educative Nursing Intervention|BP Education, BP, salt and fluid monitoring, BP goal-setting, and reinforcement
223502224|NCT00965094|DRUG|Enteric Coated Mycophenolate Sodium (EC-MPS)|One tablet containing 180 mg or 360 mg. 1440 mg/day (2x720 mg). If tolerated, dose reduction due to side effectis were possible (min. dose at BL@: 720 mg/day)
223502225|NCT00965094|DRUG|Corticosteroids|Used according to Israeli standards. A minimum dose of 5mg \[prednisone, or equivalent, was used throughout the study period.
223502226|NCT03280680|OTHER|Female+male group sessions|Female and male group member received separate group session on sexual and reproductive health and rights, gender, violence against women and girls, consent and choice, conflict resolution etc. Each group received 13 sessions of 2 hours over 20 months. Community mobilization and service provision for sexual and reproductive and violence against women were also provided.
223502227|NCT03280680|OTHER|Female group sessions|Only female group member received separate group session on sexual and reproductive health and rights, gender, violence against women and girls, consent and choice, conflict resolution etc. Each group received 13 sessions of 2 hours over 20 months. Community mobilization and service provision for sexual and reproductive and violence against women were also provided.
223502228|NCT03280680|OTHER|No group sessions|Community mobilization and service provision for sexual and reproductive and violence against women were also provided.
223502229|NCT02227966|DEVICE|Yband (YDT-201N)|transcranial Direct Current Stimulation (tDCS) 2mA for 30 min; 20 sec of ramp-up and -down; left (anode) and right (cathode) Dorsolateral prefrontal cortex (DLPFC)
223502230|NCT02227966|DEVICE|Sham-Yband (YDT-201N)|tDCS 2mA for 20 sec; left (anode) and right (cathode) Dorsolateral prefrontal cortex
223502231|NCT04129801|OTHER|Isokinetic Dynamometer|Participants then executed two series of four uninterrupted repetitions of Ext and Flex of both legs, first with the dominant member and subsequently with the non-dominant member, at an angular velocity of 60o/s, with a 60-second interval between series.
223502232|NCT04129801|OTHER|Bioimpedance|Bioimpedance The BC measurements as FM (% and kg), FFM (% and kg), will be obtained by the indirect noninvasive method of electrical bioimpedance (BIA) 230, 2.0, (Biospace Seoul, Korea). Those evaluated will be standing and positioned on the platform electrodes, barefoot and with their arms extended with their hands on the two supports (electrodes).
223502233|NCT02313272|RADIATION|Hypofractionated Stereotactic Irradiation (HFSRT)|Radiation therapy treatment (FSRT) which will be given to participants over 5 days.
223502234|NCT02313272|DRUG|Pembrolizumab|"Dose Escalation: The dose of pembrolizumab will be escalated per schema in a 3+3 fashion. The starting dose (i.e., dose level 1) will be 100 mg.~Dose Expansion: The pembrolizumab dose used in the dose expansion cohort will be maximum tolerated dose (MTD) determined from the dose escalation phase."
223592051|NCT05484323|OTHER|Cookie containing 2.5 g spirulina|TThirteen healthy participants (male: 4, female: 9) after 10-14h fast, consumed 50 g available carbohydrates from D-glucose, in different visits as reference food, tested two times; and 50 g available carbohydrates from white bread, tested two times; and 50 g available carbohydrates from cookies containing 0 and 2.5g spirulina, tested once, in different visits, along with 250 mL water. There was a washout period of at least two days between visits. Fingertip capillary blood glucose and salivary insulin samples were taken at 0, 15, 30, 45, 60, 90 and 120 min postmeal. The first glucose and salivary insulin sample were taken exactly 15 min after the first bite of food or drink.
223592052|NCT02029794|PROCEDURE|HPV self-colleciton|Women will self-collect a cervical sample that will be provided to an outreach worker and then labelled and sent to laboratories in Kampala for HPV testing. Women who test positive for HPV will be contacted by phone and provided with follow-up instructions.
223592053|NCT02029794|PROCEDURE|visual inspection with acetic acid (VIA)|
223592054|NCT02029794|DRUG|3-5% acetic acid|
223746453|NCT04322318|DRUG|Cyclophosphamide|Given IV
223746454|NCT04322318|DRUG|Doxorubicin|Given IV
223746455|NCT04322318|DRUG|Etoposide|Given IV
224193397|NCT02276274|DRUG|SYR-322-MET|Oral administration of SYR-322-MET
224193398|NCT02504099|DRUG|ombitasvir/paritaprevir/ritonavir and dasabuvir|Tablet; ombitasvir coformulated with paritaprevir and ritonavir, dasabuvir tablet
224193399|NCT02504099|DRUG|ombitasvir/paritaprevir/ritonavir|Tablet; ombitasvir coformulated with paritaprevir and ritonavir
224193400|NCT02504099|DRUG|ribavirin|Tablet
224193401|NCT02730975|DRUG|AA Reduced dose-normal diet (A)|Cycles of 28 days length of AA at reduced doses (250 mg) administered with a pre-defined normal diet, described with specific caloric and fat content.
224193402|NCT02730975|DRUG|AA reduced dose-fat diet (B)|Cycles of 28 days length of AA at reduced doses (250 mg) administered with a pre-defined fat diet, described with specific caloric and fat content.
224193403|NCT02730975|DRUG|AA normal dose-fasting conditions (C)|Cycles of 28 days length of AA at approved doses (1000 mg) administered in fasting conditions.
224193404|NCT00596466|DRUG|pregabalin|pregabalin
224193405|NCT05921851|OTHER|no intervention|no intervention
224193406|NCT01391260|OTHER|Gefitinib|Radiation Therapy: 3D-CRT/IMRT 95%PTV 60-66Gy, 1.8-2.0Gy/f,5f/w; Gefitinib: 250 mg, Qd, p.o;
224310185|NCT01205984|DRUG|methylprednisolone|Patients enrolled in the study were given either oral amoxicillin/clavulanate (AMX/C) or metylprednisolone (MP) (group MP) or AMX/C and placebo (group P) twice daily using a random allocation chart based on a table of random numbers. Oral AMX/C was administered 45/6.4 mg/kg/d (maximum 2000/285 mg/d) for 30 days for both groups. Oral MP was administered for the first 15 days: 1 mg/kg/d (maximum 40 mg/d) for 10 days, 0.75 mg/kg/d for 2 days, 0.5 mg/kg/d for 2 days, and 0.25 mg/kg/d for 1 day. Placebo tablets contained lactose and were of same size and color as MP tablets.
224310186|NCT04251520|DIAGNOSTIC_TEST|Pharmacogenomics testing|Participants will undergo pharmacogenomics testing and will be asked to provide a one-time buccal scraping. These results will be utilized for clinical treatment decisions.
223502235|NCT02313272|DRUG|Bevacizumab|Initial cycle of bevacizumab must start within 10 days of registering to the trial. It will be given concurrent with radiation therapy. Bevacizumab will be administered intravenously at a dose of 10 mg/kg every 2 weeks. Doses will be adjusted if there is a \> 10% change in weight.
223502236|NCT01336972|DRUG|Tolvaptan|Tolvaptan was supplied as 15 and 30 mg tablets.
223502237|NCT01997255|DRUG|Everolimus|Afinitor tablets will be administered at a starting dosage of 5 mg/ m2/ day, dosed once per day in the morning. To achieve appropriate doses for all subjects 2mg, 3mg, 5mg of everolimus Disperz tablets will be used. Subjects will take one or more of these tablets in combination to achieve the required dose. Dosages will be rounded to the nearest 2 mg when calculating doses for individual subjects.
223502238|NCT03865680|DRUG|CPP-ACP|The fluoride varnish applications will be applied with identical intensive protocols every 2 weeks for 6 weeks. The application of will be according to manufacturer's instructions.
223502239|NCT03865680|DRUG|Duraphat|The fluoride varnish applications will be applied with identical intensive protocols every 2 weeks for 6 weeks. The application of will be according to manufacturer's instructions.
223502240|NCT05026385|BEHAVIORAL|Intervention|Targeted nutrition advice, progressive resistance training exercise, and self-management support
223502241|NCT00576394|DRUG|IV Insulin drip|IV insulin drip at 100units insulin in 100ml saline designed to keep blood glucose between 120-180mg/dl
223502242|NCT00576394|DRUG|Insulin|IV insulin drip to keep serum glucose between 80-120mg/dl.
223592055|NCT02003937|BEHAVIORAL|Aerobic conditioning|Subjects performed 12 weeks of aerobic training on a stationary cycle ergometer. Subjects compleeted a total of 42 training sessions of 30min. exercise at an individually adjusted moderate workload.
223592056|NCT00514462|DEVICE|diode laser|wavelength at 830nm, 9.7J/cm2 for 10 min
223592057|NCT00129961|DRUG|sirolimus|
223592058|NCT00129961|DRUG|cyclosporine or tacrolimus|
223592059|NCT06394453|OTHER|enteral feeding with mother milk or human donor breast milk|The experimental group will start enteral feeding with mother milk or human donor breast milk if mother milk is not accesible during the first day of therapeutic hypothermia.
223592060|NCT04502368|PROCEDURE|Fiberoptic Bronchoscopy (FOB)|FOB under full sedation (RASS sedation scale -5) and full paralysis.
223592061|NCT04502368|PROCEDURE|Bronchoalveolar Lavage (BAL)|BAL under full sedation (RASS sedation scale -5) and full paralysis. Lavage: NaCl 0,9% 50ml x 3 in lung region targetted according to RX/CT scan.
223746456|NCT04322318|DRUG|Ifosfamide|Given IV
224193407|NCT03529539|DRUG|PSV|
224193408|NCT00117975|BIOLOGICAL|galiximab|given IV
224193409|NCT00117975|BIOLOGICAL|rituximab|Given IV
224193410|NCT01040806|BEHAVIORAL|Usual care|Patients will receive their usual medical care
224193411|NCT01040806|BEHAVIORAL|Health coaching|Peer health coaches will counsel patients with diabetes
224193412|NCT04380662|OTHER|Risk factors|"The studied potential risk factors will be the following:~* Socio-demographic: age, sex, place of residence, CSP and income.~* Comorbidities or aggravation: COPD, asthma, immunosuppression, or heart failure, diabetes imbalance, etc.~* Clinical signs: asthenia, dyspnea (kinetics), blood sugar, nutritional status, weight gain…~* Drugs other than those related to the infection and potential self-medication (anti-inflammatory, CEI, ARA…)"
224193413|NCT00353392|DEVICE|Laser Therapy|
224193414|NCT04401046|OTHER|Survey to assess Post traumatic stress and anxiety at inclusion and 6 months later|The first survey will include questions relative to sociodemographic characteristics, existence of psychological troubles; living conditions in the Covid19 pandemic context; IES-R, Stait Trait Anxiety, and the fear of a cancer recurrence scales, satisfaction with cancer care and medical status of patients (diagnosis, ongoing treatment, follow-up of the disease).
224193415|NCT02152930|DRUG|Omega-3 fatty acids|1000 mg of omega-3 fatty acid ethylesters, 2 times daily, for 4 weeks, followed by 12 weeks of supervised exercise therapy in combination with 2 times daily omega-3 fatty acid supplementation.
224193416|NCT06312917|BEHAVIORAL|Physical activity|Exercise intervention According to the guidelines of the American Sports Medicine Association (ACSM) and the National Fitness guidelines of the General Administration of Sport of China, the FITT-VP principle of ACSM is adopted. The patients were given the intervention guidance of aerobic exercise, resistance training and flexibility training. During the training, the patients filled in the weekly training records, including the feeling after each training, physical dimension and other relevant information, and the nurses gave personalized exercise guidance according to the patients' conditions.The diet is to maintain a balanced diet.
224193417|NCT02237885|DEVICE|NeuroSky MindWave Mobile|
224193418|NCT02736734|DRUG|CRH|CRH injection: 100 µg CRH powder for injection (CRH Ferring) dissolved in 1ml NaCl 0.9%, administration intravenously over the course of 1 minute to avoid side effects.
224193419|NCT06224504|BEHAVIORAL|routine health education|guided the diet of patients, and introduced the knowledge of the disease in detail
224193420|NCT06224504|BEHAVIORAL|psychological nursing|hen the patient has negative emotions, patiently listen to the patient's expression, and timely provide language comfort and guidance to the negative psychological emotions
224193421|NCT06224504|BEHAVIORAL|MBSR therapy|Conducted in small groups once a week for 8 weeks, with each session lasting approximately 1-1.5 hours, encompassed mindfulness-based breathing exercises, dietary interventions, and body scans
224193422|NCT06224504|BEHAVIORAL|exercise therapy|Participants were assigned daily tasks for each session, requiring approximately 35-45 minutes per day
224193423|NCT06115707|OTHER|The lying flat (0°-10°) head position for 72 hours|The lying flat (0°-10°) head position for 72 hours after endovascular therapy.
224193424|NCT06115707|OTHER|The The head elevation (30°-40°) position for 72 hours|The head elevoatin (30°-40°) position for 72 hours after endovascular therapy.
224193425|NCT05021315|DRUG|10% povidone iodine|50 women who received preoperative vaginal cleansing with 10% povidone iodine.
224310187|NCT04251520|OTHER|Pharmacist review|Participants will have their medical information, including patient demographics, problem list, medication list, allergies, and relevant lab work reviewed by a One Point pharmacist. The pharmacist will work with the Palliative Medicine team to make medication related recommendations to improve individual patient care. The pharmacist will call the patient roughly 48 hours following their outpatient consultation or hospital discharge to review the medication list and address any medication-related questions. The pharmacy will send refill reminders to the patients.
224310188|NCT04874155|DEVICE|NTX100 Neuromodulation System - Active|Noninvasive peripheral nerve stimulation device programmed to active mode.
223502243|NCT05945758|PROCEDURE|Injectable resin composite technique.|A metal impression tray was filled with transparent vinyl polysiloxane (EXACLEAR, GC) and used to copy the stone model with the wax-up. Then, the replica will be separated from metal tray and a needle-shaped bur will be used to drill holes through the silicone key ending in the middle of the incisal edge. It will be checked whether the holes were large enough to enable the tip of the composite syringe to pass easily and completely. Neighbouring teeth (mesial and distal one) isolated using Teflon tape, as each tooth will individually be restored for establishment of satisfactory contact points. Following etching and rinsing, the tooth dried, and a dental cord (Ultrampak, Ultradent) will be packed into sulcus for mechanical prevention of subgingival composite flow. Then, the transparent silicone index will be placed in the correct intraoral position, and a syringe filled with flowable composite will be inserted through the hole on the incisal edge.
223502244|NCT05945758|PROCEDURE|Conventional layering technique|the palatal surface will be restored by enamel shade; adapted on the index in the spacing area then The Unica matrix (Polydentia) will be used to restore the proximal wall, and to achieve a good seal with the palatal wall. The matrix can be stabilized with a wedge if necessary. Building the proximal wall using the enamel shade, and the incisal halo by using a dentin shade, the frame to layer the core of the restoration will be ready.
223502245|NCT06391515|DIAGNOSTIC_TEST|Blood sample, CRF, thyroid ultrasound|Five visits were planned: at diagnosis (V0) and after 1, 3, 6 and 12 months (V1, V2, V3 and V4, respectively). At each visit, subjects were evaluated with anamnesis, physical examination, thyroid US and blood tests.
223502246|NCT04729426|OTHER|Peanut Ball Position|The group of healthy pregnant women who meet the inclusion criteria will be determined by randomization according to the order of application to the delivery room. A group (intervention group) will be given positions using the peanut ball tool in active phase and transition phase and the positions will be changed every 30 minutes.
223502247|NCT01777529|BIOLOGICAL|MMR Vaccine|Administration of MMR Vaccine by Bio-Manguinhos or MMR Vaccine by GlaxoSmithKline
223502248|NCT05759455|DIETARY_SUPPLEMENT|vitamin d|Assessment of Vitamin D level in Children with Autism in assiut university children hospital
223502249|NCT02746380|DRUG|LBAL|Adalimumab
223502250|NCT02746380|DRUG|Humira®|Adalimumab
223502251|NCT06244251|PROCEDURE|TU-LESS|TU-LESS group will receive TU-LESS for myomectomy; MPLS group will receive MPLS for myomectomy
223502252|NCT06244251|PROCEDURE|MPLS|Patients with uterine who plan to receive MPLS for myomectomy
223502253|NCT02781194|DEVICE|3M™ Bair Hugger™|forced-air warming blanket
223502254|NCT02781194|DEVICE|F&P HumiGard™ Surgical Humidification System|warmed, humidified insufflation
223502255|NCT02441114|DRUG|HCP0910 and HGP1011|Inhalation of HCP0910 (Seretide 250 diskus (Fluticasone Propionate 250 mcg/Salmeterol Xinafoate 72.5 mcg)) and HGP1011 (Spiriva capsule for inhalation (Micronized Tiotropium Bromide Monohydrate 22.5 mcg))
223502256|NCT00593645|DRUG|Clofarabine|
223502257|NCT00593645|DRUG|Cytarabine|
223502258|NCT00593645|DRUG|Thymoglobulin|
223502259|NCT00593645|PROCEDURE|Stem cell infusion|
223502260|NCT01029483|OTHER|Low carbohydrate diet|Ad libitum low carbohydrate diet (\<28g carbohydrate/day). Participants provided with research diet at 120% of estimated energy needs for weight maintenance and allowed to eat as much or as little of the food desired.
223502261|NCT01029483|OTHER|High-carbohydrate ad libitum intervention|Participants provided with a high complex carbohydrate diet (55% carbohydrate, 18% protein, and 27% fat) at 120% of estimated energy needs for weight maintenance and allowed to eat as much or as little of the foods provided as desired
223502262|NCT01029483|OTHER|High carbohydrate diet-energy matched intervention|Participants provided a high complex carbohydrate diet (55% carbohydrate, 18% protein, and 27% fat) at \~70% of estimated energy needs to maintain weight. Participants required to eat all food provided and nothing else.
223502263|NCT05338580|DRUG|TJ271 Injection in Combination with Pembrolizumab|TJ271 Injection: 0.9% sodium chloride solution Pembrolizumab: 0.9% sodium chloride solution or 5% glucose solution
223502264|NCT02344095|DRUG|weekly paclitaxel|Patients are treated with weekly paclitaxel 70mg/m2 (IV) on day 1, 8, and 15 at an intervals of 4 weeks
223502265|NCT02344095|DRUG|weekly cisplatin|Patients are treated with weekly cisplatin 40mg/m2 (IV) on day 1, 8, and 15 at an intervals of 4 weeks.
223502266|NCT02344095|DEVICE|oncothermia|"Thermotherapy is performed by applying oncothermia (EHY 2000) probe on the part of body where tumor is located and delivering energy. It is performed on day 1, 4, 8, 11, 15, 18, 21, and 24 (8 times in total every cycle). Oncothermia can be performed a day earlier than scheduled day or a day later than scheduled day. With tumors at multiple sites, oncothermia is performed several times changing sites that apply probe and type of probes.~\- It takes 60 minutes to treat a site for oncothermia. Energy is gradually increased from 60W to 140W."
223502267|NCT03364010|BEHAVIORAL|Evaluation of proprioception|Velocity perception and Position perception
223502268|NCT03364010|BEHAVIORAL|Evaluation of motor learning|Motor accurancy and State Estimation with visual perturbations
223502269|NCT03364010|BEHAVIORAL|Evaluation of written language|Text reading, Identifying words and Phonological awareness: phonemic blending and phonemic elision
223592062|NCT04502368|DIAGNOSTIC_TEST|Electrical Impedance Tomography (EIT)|Realtime thoracic impedance coupled with ventilation parameters recording.
224193426|NCT04366518|DRUG|Rivastigmine Transdermal System|Rivastigmine doses will be administered transdermally using 9.5 mg/24 hr transdermal patches. Participants will be randomized to two treatments with oral rivastigmine vs. placebo separated by a 15-hour washout period (\>5 half-lives to eliminate any residual effects). This will require three separate visits: a baseline visit, a visit for the first transdermal treatment and a visit for the second transdermal treatment. All visits include fMRI scans. The first transdermal patch will be administered 8-14 hours before the scan. After the washout period, the second transdermal patch will be administered 8-14 hours before the scan. No study team member except for the unblinded team member will know which capsule the participant receives first. Because we are interested in rivastigmine as a probe for a pre-identified computational/physiological abnormality, we will median-split groups post-hoc for the purposes of analysis.
224193427|NCT04366518|DRUG|Scopolamine|The authors have chosen to use scopolamine to determine the effects of cholinergic antagonism, as treatment with scopolamine demonstrates a dose-related increase in propensity toward conditioned hallucinations and in doses much higher than those proposed here, can cause spontaneous hallucinations. At the proposed dose, scopolamine has an excellent safety profile and has been used routinely for nearly 20 years for treatment of nausea due to surgery or motion sickness in adults and children. Scopolamine is available in the US only as a 1mg / 72 hours transdermal patch, and peak plasma levels are reached within 24 hours. This standard dosage level is very well tolerated in the general population.
224193428|NCT04366518|DRUG|Placebo Patch|Participants in Aim 2 will receive a placebo patch versus rivastigmine patch.
224193429|NCT04366518|DRUG|Placebo Patch|Participants in Aim 1 will receive a placebo patch versus scopolamine patch.
224193430|NCT05312658|PROCEDURE|External aortic compression|External aortic compression by assistant in cesarean section.
224193431|NCT05363878|BEHAVIORAL|Native HEALTH|This application proposes the development and initial test of a culturally grounded, trauma informed intervention for alcohol use.
224193432|NCT06357299|BEHAVIORAL|Small Bottle Size|Small sized bottle
224193433|NCT06357299|BEHAVIORAL|Standard Bottle Size|Standard sized bottle
224193434|NCT06357299|BEHAVIORAL|Clear Bottle|Clear bottle
224193435|NCT06357299|BEHAVIORAL|Opaque Bottle|Opaque bottle
224193436|NCT06281665|DRUG|Low-dose aspirin|The intervention group will receive low-dose \[81 mg\] aspirin pill daily for 6 months.
223502270|NCT03446573|DRUG|DTG + 3TC|DTG+3TC is supplied as white, oval, film-coated, fixed dose combination tablet. The tablets will be available in packed high density polyethylene (HDPE) bottles with induction seals and child-resistant closures.
223502271|NCT03446573|DRUG|TAF based regimen (TBR)|Participants will continue to receive their TBR.
223502272|NCT05525715|DRUG|2mg QY201 tablets or 2mg QY201 placebo,BID|2mg QY201 tablets or 2mg QY201 placebo,BID
223502273|NCT05525715|DRUG|5mg QY201 tablets or 5mg QY201 placebo,BID|5mg QY201 tablets or 5mg QY201 placebo,BID
223502274|NCT05525715|DRUG|10mg QY201 tablets or 10mg QY201 placebo,QD|10mg QY201 tablets or 10mg QY201 placebo,QD
223502275|NCT05525715|DRUG|10mg QY201 tablets or 10mg QY201 placebo,BID|10mg QY201 tablets or 10mg QY201 placebo,BID
223502276|NCT05525715|DRUG|15mg QY201 tablets or 15mg QY201 placebo,BID|15mg QY201 tablets or 15mg QY201 placebo,BID
223502277|NCT05525715|DRUG|20mg QY201 tablets or 20mg QY201 placebo,BID|20mg QY201 tablets or 20mg QY201 placebo,BID
223502278|NCT05525715|DRUG|5mg QY201 tablets，BID|5mg QY201 tablets，BID
223746457|NCT04322318|DRUG|Irinotecan|Given IV
223502279|NCT05525715|DRUG|10mg QY201 tablets，BID|10mg QY201 tablets，BID
223502280|NCT05525715|DRUG|20mg QY201 tablets，BID|20mg QY201 tablets，BID
223502281|NCT05525715|DRUG|QY201 placebo，BID|QY201placebo，BID
223502282|NCT04837742|DRUG|ESPB group|ESPB injection at T10 region with Chirocaine 100mg(20 cc)+ Omnipaque 10cc
223502283|NCT04837742|DRUG|Control group|ESPB injection at T10 region with Normal saline 20cc + Omnipaque 10cc
223502284|NCT04784403|DIAGNOSTIC_TEST|SARS-CoV-2 PCR and serology tests|Once the informed consent has been signed, the selected subjects must complete an epidemiological survey and go to a UB sample collection center to perform a PCR and serology test for SARS-CoV-2.
223502285|NCT01793909|OTHER|Single Leg Exercise Training|Following the completion of baseline testing, all 3 subject groups will undergo supervised single leg, exercise training of the index (dominant) calf muscle 5 days per week for two weeks - alternating weight-bearing single leg calf raises and single leg calf extensions by endurance resistance training (weight machine apparatus).
223592063|NCT04502368|DIAGNOSTIC_TEST|Arterial Blood Gas test (ABG)|Multiples Arterial Blood Gas test (ABG) via arterial catheter.
223592064|NCT03074682|DEVICE|Lifeflow|Following a 5-minute training video where instructions on device are presented to participants, participants are given the device, a 1L NS bag, tubing and a 22g IV. Prior to beginning the simulation, they will demonstrate ability to set up the device and fill an empty container with fluid.
224193437|NCT06281665|DRUG|Placebo|The control group will receive similar appearing placebo daily for 6 months.
224193438|NCT06798389|BEHAVIORAL|Nurse Nudge|Nurses will be nudged to call the patients, which may increase the likelihood that the patient receives a post-appointment follow-up call.
224193439|NCT00480077|DEVICE|Programming (CRT-D, ICD OptiVol® and Cardiac Compass® )|OptiVol® Fluid status Monitoring with Cardiac Compass
224193440|NCT04214015|OTHER|No intervention|There is no intervention for this study
224193441|NCT06510894|DRUG|Sotagliflozin|Sodium-glucose cotransporter-1/2 inhibitor
224193442|NCT05879614|DRUG|NNZ-2591|NNZ-2591 oral solution (50mg/mL) to be administered twice daily for 13 weeks.
224310189|NCT04874155|DEVICE|NTX100 Neuromodulation System - Sham|Noninvasive peripheral nerve stimulation device programmed to sham mode.
224310190|NCT04874155|DEVICE|NTX100 Neuromodulation System - Open-Label|Noninvasive peripheral nerve stimulation device programmed to active mode.
224310191|NCT03620968|OTHER|cognitive training|15 minutes day of brain training by an APP
224310192|NCT03735316|DRUG|Hydroxocobalamin|5g, IV, Infused once over 15 minutes. The drug comes in a 250ml glass vial with 5g of lyophilized hydroxocobalamin to be reconstituted in 200ml of Normal Saline, Dextrose or Lactated Ringers.
223746458|NCT04322318|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223746459|NCT04322318|PROCEDURE|Positron Emission Tomography|Undergo a PET scan
223746460|NCT04322318|RADIATION|Radiation Therapy|Undergo RT
224193443|NCT04810377|PROCEDURE|EUS-guided gastroenterostomy|First after an upper endoscopy is performed, a catheters passed throughout the endoscope channel and with x-ray verification, a guide wire is passed up to the third portion of duodenal loop. then small intestinal is filled with saline solution up to 1500cc and contrast solution. Then an endoscopic ultrasound examination will be carried out where a loop of the small intestine that is located less than 2 cm apart from the gastric wall will be looked for. Once the intestinal loop is identified a direct antegrade puncture will be performed with a luminal apposition prosthesis release system . Finally, correct position is verified with x-ray and we will look for any misplacement or leakage during this process or the presence of bleeding. Endoscopic treatment will be performed if necessary. Subsequently, the participants will go to monthly follow-up with clinical evaluation, laboratory and radiological test will be carried out until the participants dies.
224193444|NCT05969678|BEHAVIORAL|breathing training|receive the breathing training of abdominal diaphragmatic breathing method combined with incentive spiromete
224310193|NCT03735316|PROCEDURE|Cardiopulmonary Bypass|Technique that temporarily takes over the function of the heart and lungs during surgery, maintaining the circulation of blood and the oxygen content of the patient's body.
223502286|NCT03096990|DRUG|apremilast|Psoriatic arthritis patients treated with Otezla® (apremilast) in Belgium
223502287|NCT02690740|OTHER|(diagnostic) conjunctival provocation test with solution: ALK 100, 1.000, 10.000, 20.000, 50.000 and 100.000 SQ-U/ml|"see information in arm/group descriptions"
223502288|NCT00000665|DRUG|Foscarnet sodium|
223746461|NCT04322318|PROCEDURE|Surgical Procedure|Undergo surgery
223746462|NCT04322318|DRUG|Topotecan|Given IV
223746463|NCT04322318|PROCEDURE|Transabdominal Ultrasound|Undergo abdominal ultrasound
223746464|NCT04322318|DRUG|Vincristine|Given IV
223746465|NCT04322318|PROCEDURE|X-Ray Imaging|Undergo a chest x-ray
223746466|NCT06154447|DRUG|VX-828|Suspension for Oral Administration
223746467|NCT06154447|DRUG|Placebo|Suspension for Oral Administration
223746468|NCT06154447|DRUG|Itraconazole|Solution for Oral Administration
223746469|NCT06154447|DRUG|Midazolam|Syrup for Oral Administration
223746470|NCT06154447|DRUG|Tezacaftor|Tablets for Oral Administration
223746471|NCT06154447|DRUG|VX-118|Tablets for Oral Administration
223746472|NCT06154447|DRUG|Placebo|Suspension and Tablets for Oral Administration
223746473|NCT06154447|DRUG|Deutivacaftor|Tablets for Oral Administration
223502289|NCT00000665|DRUG|Ganciclovir|
223502290|NCT01371565|DRUG|Mifepristone|mifepristone at doses from 300mg/day up to 1200mg/day
223502291|NCT04270760|DRUG|Olpasiran|Dose 1 Dose 2 Dose 3 Dose 4
223502292|NCT04270760|DRUG|Placebo|Dose 5
223502293|NCT04765072|BEHAVIORAL|Survivorship Patient Navigation Intervention|Patient navigator assistance for navigating the healthcare system and locating and utilizing beneficial resources
223502294|NCT04765072|BEHAVIORAL|Telehealth Survivorship Visit Intervention|Individualized survivorship care plan
223502295|NCT02070991|DRUG|Macitentan|oral tablet, 10 mg once daily
223502296|NCT02070991|DRUG|Placebo|matching placebo
223502297|NCT00563212|DRUG|aerosol interferon-gamma|aerosol interferon-gamma-1b 100mcg given via nebulizer three times weekly for one year
223502298|NCT05296590|DIAGNOSTIC_TEST|Monocyte Distribution Width (MDW) , observation|Observation of MDW performance blinded to treating clinical teams
223502299|NCT00407667|DEVICE|transcranial galvanic stimulation|for tDCS: Siemens Universal-Neuroton 826 for arm training: Bi-Manu-Track, Reha-Stim, Berlin
223502300|NCT05930951|DRUG|OBT076|OBT076 is an ADC constituted by a fully human immunoglobulin 1 (IgG1) antibody directed against the CD205/Ly75 antigen (MBH1309), inducing potent cytotoxic and anti-tumor activity
223502301|NCT05930951|DRUG|Balstilimab|Balstilimab is a human monoclonal antibody that targets programmed cell death protein 1 (PD-1).
223502302|NCT04664387|DIAGNOSTIC_TEST|coronary angiography|A coronary angiography is a test to find out if there is stenosis in coronary artery.
223502303|NCT04731116|DRUG|Cannabidiol|Oral Cannabidiol 150 mg twice daily during 14 days
223502304|NCT00940173|DEVICE|DIABECELL(R)|10,000 IEQ/kg injected into the peritoneal cavity via laparoscopy
223746474|NCT06154447|DRUG|VX-828|Tablets for Oral Administration
223746475|NCT02364544|BEHAVIORAL|Relapse Prevention Plan|brief, in-person, relapse prevention counseling with supplemental web-based learning modules,
223746476|NCT02364544|BEHAVIORAL|Daily Support Website|web-based program for patients and families that provides psychoeducation about schizophrenia and its treatments to improve knowledge, increase problem-solving skills and offer social support through the use of web-based therapist facilitated sessions
223746477|NCT02364544|BEHAVIORAL|Computer CBT for voices and paranoia|A ten-session CBT programs, one to address voices and the other for paranoia. The web-based programs incorporate the essential elements of CBT for psychosis such as normalizing behavior and offering behavioral coping strategies
223746478|NCT02364544|BEHAVIORAL|FOCUS|an interactive smart phone text-messaging application to support medication adherence, facilitate coping with symptoms and improve daily functioning in individuals with schizophrenia
223746479|NCT02364544|OTHER|Prescriber Decision Assistant|is a web-based prescriber decision support system that includes a brief patient-completed assessment describing symptoms and adverse events which prompts the prescriber to conduct a detailed clinical assessment. Embedded in the program are decision supports for medication choices based on best evidence-based practices regarding symptoms, side effects, information from laboratory tests and history of prior treatment response
224193445|NCT03104491|DRUG|Inotuzumab Ozogamicin|"Inotuzumab ozogamicin, IV, 28 day cycles~Phase 1 dosages:~Dose Level -2 (0.1 mg/m\^2)~Dose Level -1 (0.2 mg/m\^2)~Dose Level 0 (0.3 mg/m\^2)~Dose Level 1 (0.4 mg/m\^2)~Dose Level 2 (0.5 mg/m\^2)~Dose Level 3 (0.6 mg/m\^2)"
224193446|NCT04211428|OTHER|No intervention|There is no intervention for this study
224193447|NCT06801054|DRUG|Tenecteplase (TNK) (0.25 mg/kg, to maximum of 25mg)|All patients will receive a second dose of tenecteplase.
224310194|NCT03735316|DRUG|Placebos|Placebo is a Normal Saline, 5g, IV, Infused once over 15 minutes. The placebo comes in a 250ml glass vial.
223746480|NCT00668941|DRUG|Teriparatide|Teriparatide will be given subcutaneously in 20-mcg doses either continuously or cyclically.
224193448|NCT06248216|DEVICE|Relievrx|The RelieVRx program is a prescription-use immersive virtual reality system intended to provide adjunctive treatment based on cognitive behavioral therapy skills and other evidence-based behavioral methods for patients (age 18 and older) with a diagnosis of chronic lower back pain (defined as moderate to severe pain lasting longer than three months). The device is intended for in-home use for the reduction of pain and pain interference associated with chronic lower back pain.
224193449|NCT06248216|OTHER|Audio Mp4|Audio Mp4 modules ranging from 3-15 minutes with guided meditation.
224193450|NCT04899206|DRUG|With an Antidepressant Drug|Current users of an antidepressant drug.
224193451|NCT04899206|DRUG|Without an Antidepressant Drug|Non-current users of an antidepressant drug.
224193452|NCT03196518|PROCEDURE|PET Imaging|PET/CT study immediately after injection
224193453|NCT03196518|OTHER|18F-tetrafluoroborate (18F-TFB)|administration of a single dose of approximately 5-10 mCi 18F-TFB (mass \<= 50 μg) for imaging purposes
224310195|NCT04733703|OTHER|questionnaire|assessment of postoperative quality of recovery with the QoR-15
224310196|NCT01798316|DRUG|IV Acetaminophen|Single dose, 1000g mg infusion over 15 minutes plus standard of care pain management regimen
223502305|NCT00940173|DEVICE|DIABECELL(R)|15,000 IEQ/kg injected into the peritoneal cavity via laparoscopy
223502306|NCT00940173|DEVICE|DIABECELL(R)|20,000 IEQ/kg injected into the peritoneal cavity via laparoscopy
223502307|NCT00940173|DEVICE|DIABECELL(R)|5,000 IEQ/kg injected into the peritoneal cavity via laparoscopy
223502308|NCT04225143|PROCEDURE|urostim bilateral|Treatment by bilateral neurostimulation of the tibial nerve
223502309|NCT04225143|PROCEDURE|urostim unilateral|Treatment by unilateral neurostimulation of the tibial nerve
223502310|NCT02385357|DIETARY_SUPPLEMENT|Protein-enriched drink|Participants will drink 330 ml of a protein-enriched drink (6 g/ml of protein) after a high intensity exercise that induce muscle damage (30 min running downhill with a slope of -10º)
223502311|NCT00001903|DRUG|RSV Polyclonal Immunoglobulin|
223502312|NCT00827242|DRUG|Placebo|Following a 4-week placebo lead-in period, subjects received placebo tablet by mouth once daily over a 12-week period.
223502313|NCT00827242|DRUG|tadalafil|Following a 4-week placebo lead-in period, subjects received tadalafil 5 mg tablet by mouth once daily over a 12-week period.
223502314|NCT04022694|BEHAVIORAL|Exposure to beverage health information|Red stop sign and avoidance message for sugar-sweetened beverages and green check mark and promotion message for non-sugar-sweetened beverage nutrition information
223502315|NCT04022694|BEHAVIORAL|Exposure to beverage calorie information|Calories for sugar-sweetened and non-sugar-sweetened beverages
223502316|NCT01843881|DRUG|Exendin 9, 39|Exendin 9,39 is a competitive antagonist of endogenous GLP-1.
223502317|NCT01843881|DRUG|Placebo|A saline infusion will be given to match the study drug infusion.
223502318|NCT02609633|DEVICE|Accu-Chek® CONNECT DMS|SMBG will be performed during the 6-month study using the Accu-Chek® Aviva CONNECT monitoring device, and corresponding Smartphone app and online tracking tool.
223502319|NCT02609633|DEVICE|DMS|SMBG will be performed during the 6-month study according to usual care, using the participant's current DMS (other than Accu-Chek® CONNECT DMS).
223502320|NCT04186585|DRUG|BP-C2|Oral daily intake
223502321|NCT02557893|BEHAVIORAL|Resistance exercise|Resistance exercise involved 12-weeks of strength training twice per week
223502322|NCT02557893|OTHER|Education|Bimonthly pregnancy education classes
223502323|NCT02557893|OTHER|Wait list|Wait list participants were tested on the outcomes during their pregnancy and were eligible to participate in a post-partum supervised exercise program. The wait list participants formed a no treatment control group.
223502324|NCT02919605|DRUG|Single dose of Pentamidine|The patients will come to the hospital to take a single dose of the Pentamidine.
223502325|NCT02919605|DRUG|Two doses of Pentamidine|The patients will come to the hospital to take two doses of the Pentamidine, in interval of one week between them.
223502326|NCT02919605|DRUG|Three doses of Pentamidine|The patients will come to the hospital to take three doses of the Pentamidine, in interval of one week between them.
223502327|NCT01192477|OTHER|Ozone|All subjects will have a 3-hour exposure to clean air, a 3-hour exposure to clean air with lower ozone (0.1 ppm), and a 3-hour exposure to clean air with higher ozone (0.2 ppm). Exposures will take place at least 3 weeks apart. Order of exposure will be randomized for each subject.
223592065|NCT03074682|DEVICE|Push/Pull|Following a 5-minute training video where instructions on device are presented to participants, participants are given the device, a 1L NS bag, tubing and a 22g IV. Prior to beginning the simulation, they will demonstrate ability to set up the device and fill an empty container with fluid.
223592066|NCT03074682|DEVICE|Pressure Bag|Following a 5-minute training video where instructions on device are presented to participants, participants are given the device, a 1L NS bag, tubing and a 22g IV. Prior to beginning the simulation, they will demonstrate ability to set up the device and fill an empty container with fluid.
223592067|NCT00694304|DRUG|Vortioxetine (Lu AA21004)|2.5, 5, or 10 mg/day; tablets; orally
223592068|NCT05401318|PROCEDURE|Tumor tissue sampling for organoid development|Fresh tissue from colorectal tumors will be sampled and cultivated in 3D cultures for drug testing.
223592069|NCT00034736|DRUG|Levofloxacin|
223592070|NCT04877769|DRUG|AT-527|administered twice daily (BID) for 2.5 days (5 doses in total)
223592071|NCT04595162|BIOLOGICAL|GC019F|GC019F is the CAR-T cell immunotherapy targeted CD19. The subjects will receive one single infusion of GC019F.
223592072|NCT03377933|OTHER|Compound Lactobacillus acidophilus|Compound Lactobacillus acidophilus Tablet
223592073|NCT04004013|DIETARY_SUPPLEMENT|Lifenol®|"Lifenol®, powdered extract obtained from female hops flowers (Humulus lupulus L.) standardized in 8-PN content (100 µg /day) + maltodextrin = 500 mg/capsule~\+ 1000 mg of calcium and 800 IU of vitamin D per day"
223592074|NCT04004013|DIETARY_SUPPLEMENT|Placebo|"Maltodextrin = 500 mg/capsule~\+ 1000 mg of calcium and 800 IU of vitamin D per day"
223592075|NCT01270256|DRUG|Budesonide|Pulmicort Respules at a dose of 0.25 mg. delivered intranasally via NasoNeb nebulizer once daily
223592076|NCT01270256|DRUG|Placebo|Placebo delivered intranasally via NasoNeb nebulizer once daily
223502328|NCT04574700|OTHER|knee joint mobilization and traction|"Grade 3 traction (Kaltenborn)from knee fully flexed to end of available Range of motion(ROM). Traction 30 sec, 10 sec rest period, 4reps, total 2 min of traction.3 sets for a total of 6 min of traction mobilization.Grade3 keltonborn tibiofemoral and tibiofibular anterior, posterior mobilization 3 sets10glides/set, 3 times/week on alternative days for 4 weeks.~TENS for 20 mins in sitting and strengthening exercises i.e. Quadriceps Setting10 reps, air Cycling 2 min for a bout, straight leg raise (SLR) with weight , Full arc extension 10 reps of each exercise will be carried per session except for full-arc extension and air cycling. Air cycling cont. for 2 min for 1 bout of exercise. Measurement will be taken at base level, after first and last session. Treatment will be given for 3 times/week on alternative days for 4 weeks"
223502329|NCT04574700|OTHER|Post isometric relaxation|"Control group include Post isometric relaxation technique on hamstring muscle will be performed in supine lying, hip flexed to 90 degrees knee extended until the point of resistance 20% of maximum effort will be used by patient to create isometric contraction. Patient will be asked to breathe in and hold for 5 to 8 seconds and release both breath and effort then move to new barrier point and process was repeated three times per session~TENS and strengthening exercises as mentioned above.~This treatment regime will be given for 3 times/week on alternative days for 4 weeks."
223502330|NCT03565653|OTHER|High dietary salt|\~4,000 mg Na+/day
223502331|NCT03565653|OTHER|Placebo|dextrose
223502332|NCT04688944|OTHER|observation|observation the difference between two groups
223502333|NCT05987540|DEVICE|Non-invasive brainstem stimulation|Study participants will self-administer \~19-minute treatments twice daily in the home setting over 12 weeks using a non-invasive brainstem modulation device.
223502334|NCT00471107|DEVICE|DC brain polarization|0.08 mA/cm2
223502335|NCT01494974|DEVICE|FP7 Ahmed Glaucoma Drainage Implant|Ahmed Glaucoma Valve model FP7
223502336|NCT01494974|DEVICE|FP8 Glaucoma Drainage Implant|Ahmed Glaucoma Valve model FP8
223502337|NCT01176994|DEVICE|Formulations for in-vivo fixation|Formulations are comprised of non-toxic ingredients used in dermatology.
223502338|NCT02232321|OTHER|PsA MDA|
223502339|NCT01769443|DRUG|bortezomib|Bortezomib dosed at 1.3 mg/m\^2 as a 3 to 5 second bolus administered by intravenous injection on treatment days 0, 3, 7 and 10. The first dose of bortezomib is administered between 4-8 hours after the first plasmapheresis session is completed and there must be at least 96 hours between the second and third dose of bortezomib.
223502340|NCT01769443|PROCEDURE|plasmapheresis|Plasmapheresis for 3 consecutive days (treatment days 0, 1 and 2) followed by concomitant bortezomib dosed at 1.3 mg/m\^2 as a 3 to 5 second bolus administered by intravenous injection on treatment days 0, 3, 7 and 10. The first dose of bortezomib is administered between 4-8 hours after the first plasmapheresis session is completed and there must be at least 96 hours between the second and third dose of bortezomib.
223502341|NCT05169944|DRUG|Magrolimab|Anti-cancer therapeutic agent targeting the CD47-signal receptor protein-alpha (SIRP-alpha) axis
223502342|NCT05625971|OTHER|MRD Assessment|MRD assessment includes liquid biopsy and functional imaging. Liquid biopsy will be performed by the Adaptive ClonoSEQ® assay in peripheral blood. Functional imaging will be performed by whole body diffusion-weighted magnetic resonance imaging (WB-DWI).
223502343|NCT03401294|DRUG|FOLFOXIRI and Bevacizumab|Every 2 week for a total of 12 cycles
223502344|NCT06640647|DRUG|HDM1005 injection or placebo|HDM1005 injection or placebo isubcutaneous injection once
223502345|NCT04996264|DRUG|Varespladib Methyl|Varespladib-methyl (LY333013) is an IR, oval, white, film-coated tablet at a dosage strength of 250 mg for oral administration. Scaled pediatric doses of varespladib-methyl (LY333013) are supplied as 50 mg IR capsules for oral administration.
223502346|NCT04996264|DRUG|Placebo|"The oral placebo is supplied as a white film-coated oval tablet to match the appearance of the varespladib-methyl 250 mg tablet and contains a subset of the excipients present in the active tablet formulation: lactose monohydrate, microcrystalline cellulose, and magnesium stearate.~Placebo for scaled pediatric dosing is supplied as an IR capsule to match the varespladib-methyl 50 mg capsule, and contains the excipients lactose monohydrate, microcrystalline cellulose, and magnesium stearate."
223502347|NCT04996264|DRUG|Standard of care (SOC)|SOC (including antivenom) will continue to be administered throughout the subject's participation in the study according to the protocol and the judgment of the Investigator.
223502348|NCT02574208|PROCEDURE|HIV testing by ELISA|HIV testing randomized between ELISA or rapid test
223502349|NCT02574208|PROCEDURE|HIV testing by rapid test|HIV testing randomized between ELISA or rapid test
223502350|NCT04433975|BEHAVIORAL|Psychosocial Pain Management (PPMI)|The main theme of the treatment is to provide participants with new ways of thinking and coping skills related to managing pain and opioid use in order to increase the likelihood the participant may remain in buprenorphine treatment.
223502351|NCT04433975|BEHAVIORAL|Enhanced Usual Care (EUC)|The EUC condition is designed to match the PPMI condition in terms of the non-specific aspects of receiving support for pain, substance use, and receiving monitoring of buprenorphine adherence.
223746481|NCT00668941|DRUG|Alendronate|Participants will take 70 mg per week of alendronate for 48 months.
223746482|NCT00668941|DIETARY_SUPPLEMENT|Calcium|Calcium supplements will be administered in varied amounts for all participants, but each participant will take enough to bring her total daily calcium intake to 1,200 mg.
223746483|NCT00668941|DIETARY_SUPPLEMENT|Vitamin D3|Vitamin D3 supplements will be administered in varied amounts for all participants, but each participant will take enough to bring her total daily intake to 1,200 mg.
223502352|NCT00232154|DRUG|Zithromax&#153; (azithromycin) 500mg tablets|
223502353|NCT00232154|PROCEDURE|Endoscopic Sinus Surgery|
223502354|NCT00232154|PROCEDURE|Blood sampling for hematology|
223502355|NCT00232154|PROCEDURE|Blood sampling for plasma chemistry profile|
223502356|NCT00232154|PROCEDURE|Serum pregnancy test (for women of child-bearing potential)|
223502357|NCT04606771|DRUG|Osimertinib + Savolitinib|"Osimertinib 80 mg oral QD~Savolitinib 300mg oral QD"
223502358|NCT04606771|DRUG|Savolitinib + Placebo|"Savolitinib 300mg Oral QD~Placebo to Osimertinib 80mg oral QD"
223502359|NCT06479720|DRUG|Combined pharmacotherapy with Solifenacin and Mirabegron|Solifenacin (5mg) is anticholinergic and Mirabegron (25mg) is a beta-3 adrenergic agonist.
223502360|NCT06479720|DRUG|Solifenacin with vaginal estrogen cream|Solifenacin (5mg) is anticholinergic. Premarin, vaginal conjugated equine estrogen vaginal cream (0.625 mg).
224193454|NCT05119283|OTHER|Scraping and straightening of the crown and root and rinsing with mouthwashes|Patients will answer a questionnaire about their socioeconomic conditions, and soon after undergoing the examination for bleeding, probing, clinical attachment level, probing depth and plaque index for initial clinical evaluation. Basic periodontal treatment will be carried out with the same operator (blind to the treatments performed), with complete removal of plaque and calculi, prophylaxis with pumice and prophylactic paste and oral hygiene instructions. After basic periodontal treatment, patients will be randomly divided based on a draw with closed, opaque and non-translucent envelopes, into 3 groups according to the supporting treatments: G1 - patients who will receive mouthwashes with saline solution; G2 - patients who will be rinsed with 0.12% chlorhexidine and G3 - patients who will be treated with PHTALOX®.
224193455|NCT04920968|DRUG|Obinutuzumab|Chemotherapy will be conducted according to PALG ALL7 protocol, which is considered a standard of care in Poland. Patients in experimental arm will receive obinutuzumab .Obinutuzumab: 1000 mg i.v. (first infusion divided into 100 mg on d. 1 and 900 mg on d. 2).
224193456|NCT04920968|DRUG|Rituximab|Chemotherapy will be conducted according to PALG ALL7 protocol, which is considered a standard of care in Poland.The protocol includes the use of rituximab in combination chemotherapy. Rituximab: 375 mg/m2 intravenously (i.v.)
224193457|NCT03050723|DEVICE|Princess® FILLER|Princess® FILLER injections up to 10 ml applied to the eligible subjects at the baseline visit, and the touch-up visit, if applicable.
224193458|NCT06308952|DRUG|Atorvastatin 20mg|Eligible subjects screened will enter the pretreatment period (at least 24 hours) and be randomly assigned to the trial group (oral atorvastatin) or the control group (placebo) to start receiving the trial drug (20mg, qd). Additionally, the patient was started on basic dual anti-platelet (aspirin 75mg qd + clopidogrel 75mg qd/ticagrelor 45mg bid).
224310197|NCT01798316|DRUG|Standard of Care|Standard of care pain management regimen, no IV Acetaminophen,
224310198|NCT03467139|OTHER|Abdominal breathing exercise|Deep Breathing Exercise
224310199|NCT00210990|DRUG|doripenem|
224310200|NCT05864963|PROCEDURE|Medial tab-type fasciocutaneous flap|"The flap can be taken in different ways depending on the defect. Once the base of the flap is identified, the posterior edge of the tibia is taken as reference; marking of the tab is performed considering that the posterior incision is located 5 cm from the posterior edge of the tibia, and the anterior incision is located longitudinally of the medial region of the tibial diaphysis, the length of the incision depends on the base of the flap and the defect's size.~The posterior incision is made first in the skin, subcutaneous cellular tissue until the fascia is identified; the subfascial flap is dissected to avoid injuring perforators, dissection is completed up to the anterior edge of the flap, if needed direct cutaneous perforators are ligated; once the subfascial plane has been identified and dissected, the tab is completed in its proximal or distal part according to the previous surgical planning. Later, the tab is rotated to the anterior region of the tibia to cover the defect."
224310201|NCT03541980|DRUG|Acetaminophen|Administration of 15 mg/kg (1000 mg max dose) of IV acetaminophen
224310202|NCT03541980|DRUG|Normal saline|Normal saline volume equivalent
224310203|NCT06050889|OTHER|Positive Expectations Instructional Set|"Participants randomly assigned to this instructional set will be told, You will be completing an intervention known to be effective for some people with shoulder pain. We expect this will make you less sensitive to the pressure applied to your shoulder and thigh and you will require more pressure than what was previously necessary to experience pain."
223592077|NCT04896372|OTHER|ACT comprehensive of standard care|"The proposed intervention was designed by the authors of the study. It was developed following the main ACT-based manuals, with adjustments according to the users and the context of the study implementation.~Specifically, we developed a practical and interactive intervention, which comprises practical activities such as roleplay and writing activities and imaginative activities supported by metaphors. The sessions are based on the use of age-appropriate language to convey the most complex therapeutic processes easily. According to Strosahl and colleagues' model, sessions will respectively target the components of openness, awareness, and engagement."
223592078|NCT04896372|OTHER|TAU only|adolescents will be assessed by a staff dietician and placed on an individualized hy-pocaloric balanced Mediterranean diet. They will also follow a nutritional counselling aimed at promoting the adoption of a healthy lifestyle. Moreover, they will attend a physical activity program consisting of five training sessions per week lasting one hour each with trainers; In addition, they will be involved in psychological counselling pro-vided once a week by a clinical psychologist, aimed to address psychological factors related to dysfunctional lifestyle habits.
223746484|NCT05867628|OTHER|Activities-based locomotor training (physical therapy)|AB-LT is implemented through a combination of partial body weight supported treadmill training, overground walking, and play-based activities.
224193459|NCT03465683|OTHER|ESBL-producing Enterobacteriaceae|Data and biological sample collection
224193460|NCT06405750|PROCEDURE|left atrial appendage closure|systematic closure of the left atrial appendage in addition to the planned heart surgery
224310204|NCT06050889|OTHER|Negative Expectations Instructional Set|"Participants randomly assigned to this instructional set will be told, You will be completing an intervention which is not effective for some people with shoulder pain. We expect this will make you more sensitive to the pressure applied to your shoulder and thigh and you will require less pressure than what was previously necessary to experience pain."
224310205|NCT00541879|BEHAVIORAL|Program ENERGY|Weekly or biweekly classroom and gym based science enrichment focused on how the body works including blood glucose regulation, healthy eating and physical activity, diabetes abd how it can be prevented
224310206|NCT00541879|OTHER|comparison|
224310207|NCT02345837|DEVICE|endometrial sampling|injury to the endometrium
224310208|NCT02345837|DRUG|clomiphene citrate|ovulation induction by 100mg clomiphene citrate
224310209|NCT05850806|DEVICE|The KmAsthma self-management smart phone app intervention|KmAsthma is a free app which enables users to track their symptoms, access their action plan, learn about asthma and set goals to make change
224310210|NCT01147107|DRUG|Raltegravir|Emtricitabine/tenofovir DF\* 200 mg/300 mg po daily + Raltegravir 400 mg twice daily
224310211|NCT01147107|DRUG|Efavirenz|Emtricitabine/tenofovir DF\* 200 mg/300 mg po daily + Efavirenz 600 mg po daily
224310212|NCT05513846|DEVICE|DREEM EEG Device|The DREEM EEG device will be used to measure brain age.
224310213|NCT05513846|DEVICE|SleepImage Ring|The SleepImage ring uses plethysmography to analyze sleep architecture and cardiopulmonary coupling.
224310214|NCT03573778|BEHAVIORAL|iHEAL|Women work with a Registered Nurse in 10-18 visits (over 6 months) that focus on 6 inter-related 6 components (areas): Safeguarding, Managing Symptoms, Getting Basics, Cautiously Connecting, Regenerating Family, Renewing Self. Using a standard 3 phase process, and guided by 5 principles, the nurse discusses each of these components with the woman in order to identify the woman's needs, experiences and priorities. The nurse then provides personalized support to assist the woman in address the concerns that she sees as most important for her health and well-being; this support includes linking women to existing services if she chooses.
224310215|NCT03573778|BEHAVIORAL|Information about Community Services|Women are provided with information about community services appropriate for women experiencing intimate partner violence and consistent with what service providers might recommend (usual care). Women are encouraged to use this information as they see fit.
224310216|NCT02475330|DIETARY_SUPPLEMENT|Flaxseed|Whole grain flaxseed diet consisting of 40g flaxseed ingested per day
224310217|NCT03833401|PROCEDURE|Autologous tissue transplantation|Root canal disinfection and revascularization with patient's own minced pulp tissues
224310218|NCT03833401|PROCEDURE|Root canal revascularization|Root canal disinfection and revascularization without tissue transplantation
223502361|NCT06479720|DRUG|Mirabegron with vaginal estrogen cream|Mirabegron (25mg) is a beta-3 adrenergic agonist. Premarin, vaginal conjugated equine estrogen vaginal cream (0.625 mg).
223502362|NCT04549207|DRUG|Bone modifying agent|Use of bone modifying agent
223502363|NCT04253964|DRUG|Pembrolizumab|ALL PARTICIPANTS: Pembrolizumab 200 mg intravenously (IV) on day 1 of each 3-week cycle for 4 cycles. Participants with predictive biomarker PD-L1 greater than or equal to 50% will not receive any other drugs besides pembrolizumab.
223502364|NCT04253964|DRUG|Carboplatin|FOR PARTICIPANTS IN EITHER ARM with non-squamous OR squamous subtype, predictive biomarker PD-L1 less than 50%: Carboplatin area under the curve (AUC) 5 IV on day 1 of each 3-week cycle for 4 cycles.
223502365|NCT04253964|DRUG|Paclitaxel|FOR PARTICIPANTS IN EITHER ARM with squamous subtype, predictive biomarker PD-L1 less than 50%: Paclitaxel 200 mg/m2 IV on day 1 of each 3-week cycle for 4 cycles.
223592079|NCT03645512|BEHAVIORAL|Corporate Athlete Resilience (CAR) Training Program|A 1-day training program developed by the J\&J Human Performance Institute (HPI), which uses a holistic approach that focuses on moving between stress and strategic recovery to help build resilience and enable higher performance.
223592080|NCT06530719|DRUG|Osimertinib mesylate|Osimertinib mesylate , 80mg QD，until the duration of treatment reaches 3 years, the disease progresses, or other treatment termination criteria are met
223746485|NCT06416618|PROCEDURE|Surgical|Surgical group: After osteosynthesis, they will be provided with a sling and swathe immediately after the surgery. From the first postoperative day, only the sling will be used. Two weeks postoperatively, patients will undergo clinical and radiological follow-up in the outpatient clinic. They will be referred to post-operative rehabilitation in the municipalities. At 12 weeks postoperatively, patients will have another clinical and radiological follow-up. This is the current standard care for surgical treatment with a plate or intramedullary nail.
223502366|NCT04253964|DRUG|Nab paclitaxel|FOR PARTICIPANTS IN EITHER ARM with squamous subtype, predictive biomarker PD-L1 less than 50%: Nab-paclitaxel 100 mg/m2 on day 1, 8, 15 of 3-week cycle for 4 cycles.
223502367|NCT04253964|OTHER|Quality of Life Questionnaire, lung cancer-specific (QLQ-LC13)|The QLQ-C30 is composed of both multi-item scales and single-item measures. These include five functional scales, three symptom scales, a global health status / QoL scale, and six single items.
223592081|NCT03004755|OTHER|Tissue Harvest|
223592082|NCT00791596|OTHER|Ergonomic Intervention|The intervention used in this investigation was an ergonomic adjustment of the VDT workstation design
223746486|NCT06416618|PROCEDURE|Non surgical|Non-surgical group: Patients in the non-surgical group will be offered an optional sling for comfort for an additional 1-2 weeks at their first visit, 10-14 days post-injury. Patients will be referred to rehabilitation in the municipalities. At week 6 post-injury, all patients will undergo clinical and radiological follow-up. This represents the current standard care for non-surgical treatment of displaced PHF at the departments.
223746487|NCT06490029|DIAGNOSTIC_TEST|Auditory, vestibular and electrophysiological investigations|otoacoustic emissions, electrocochleography, vocal audiometry in noise and high-frequency tonal audiometry, impedancemetry
223746488|NCT06490029|DIAGNOSTIC_TEST|Biologic investigations; seric proteins|seric proteins
223746489|NCT04829565|DRUG|Botulinum toxin|echo-guided injection into the trapezo-medial-phalangeal jointof 0.5 ml of botulinum toxin 50 IU
223746490|NCT04829565|DRUG|Placebo|echo-guided injection into the trapezo-medial-phalangeal jointof 0.5 ml of placebo
223746491|NCT04878523|DIETARY_SUPPLEMENT|multi berries juice|Testing product
223502368|NCT04253964|OTHER|QLQ-C30 Global Health/Quality of Life Questionnaire|30 item questionnaire - Functional scales (physical, role, cognitive, emotional, social), symptom scales (fatigue, pain, and nausea and vomiting), global health status and quality of life scale, also several single-item symptom measures
223502369|NCT04253964|OTHER|COPD Assessment Test and modified Medical Research Council Dyspnea Patient Reported Outcomes|Dyspnea scale scores in patients with respiratory disease (particularly COPD) to establish baseline functional dyspnea burden (taken pre-study at Week 0 and Post Treatment at week 13)
223502370|NCT04253964|DRUG|Pemetrexed|FOR PARTICIPANTS IN EITHER ARM with nonsquamous subtype, predictive biomarker PD-L1 less than 50%: Pemetrexed 500 mg/m2 IV on day 1 of each 3-week cycle for 4 cycles.
223502371|NCT03440437|DRUG|FS118|Dosing of participants will occur intravenously (IV) weekly in 3-week treatment cycles until iCPD (i.e., immune confirmed progressive disease), unacceptable toxicity, or discontinuation.
223502372|NCT03440437|DRUG|Paclitaxel|Dosing on Days 1, 8 and 15 of each 28 day cycle in combination with FS118 given on days 1, 8, 15 and 22 of each 28 day cycle.
223502373|NCT04392635|DEVICE|TauTona Pneumoperitoneum Assist Device (TPAD)|The TPAD is an experimental device used to assist with placement of Veress needle during laparoscopic surgery.
223746492|NCT04878523|DIETARY_SUPPLEMENT|Placebo drink|Blank
223746493|NCT02494427|DEVICE|CAD/CAM manufactured fixed unitary dental prostheses|
223746494|NCT02494427|DEVICE|Conventionally manufactured unitary dental prostheses|
223746495|NCT00464568|DRUG|GSK256066|
223746496|NCT05181449|BEHAVIORAL|Twin Precision Treatment|Combination of Artificial Intelligence algorithms based on daily sensor input and live nutrition, exercise, sleep and breath coaching to help treat type 2 diabetes
224310219|NCT05090488|BEHAVIORAL|Personal Health Coaching and Diabetes Education in Group|Health coaching was given as face to face with a trained coach from primary health care. Diabetes education in group, with trained educator team from primary health care
223502374|NCT04392635|PROCEDURE|Standard of Care (SOC)|Standard of Care was used for Veress needle insertion.
223502375|NCT06128226|GENETIC|Blood Sampling|For Tripeptidyl Peptidase 1 enzyme level measurement, blood will be taken from the patient into a 5 mL EDTA tube at Gazi University Faculty of Medicine, Metabolism Laboratory, and for patients with low enzyme activity, the genetic evaluation test will be performed with whole blood at the Gene2Info Laboratory.
223502376|NCT02030418|DEVICE|Leadless Pacemaker|Patients will undergo an attempted leadless pacemaker implant
223502377|NCT03483662|BEHAVIORAL|Multicomponent Intervention|The core component of the intervention is protocol-based treatment using the SPRINT BP management algorithm. The following implementation strategies are adaptable components that will be modified to fit specific federally-qualified health center (FQHC) settings: dissemination of SPRINT study findings among provider-teams, patients, and administrators, team-based collaborative care, BP audit and feedback, home BP monitoring, and health coaching on antihypertensive medication adherence and lifestyle modification.
223502378|NCT03483662|BEHAVIORAL|Enhanced Usual Care|The investigators will provide an up-to-date clinical guideline for hypertension management to providers. A webinar education session on the new American College of Cardiology (ACC)/American Heart Association (AHA) hypertension guideline and findings from the SPRINT trial will be conducted. Otherwise, the investigators will not conduct any active intervention and all control clinics will follow their routine clinic practice in the management of hypertensive patients
223502379|NCT06637020|DRUG|HDM1005 injection or placebo|Within each cohort, subjects are randomized in a 4:1 ratio to receive either HDM1005 injection or placebo subcutaneously.
223502380|NCT04915027|OTHER|a usual follow-up with Rehabkompassen®|Rehabkompassen® is a patient-centered digital graphic tool for capturing the patient's rehabilitation needs in the follow-up after stroke.
223502381|NCT04915027|OTHER|a usual follow-up with Post-Stroke Checklist, i.e. without Rehabkompassen®|Post-Stroke Checklist consists of eleven questions concerning common and treatable post-stroke problems affecting quality of life.
223502382|NCT05844124|OTHER|Exercise for Knee Osteoarthritis Recommendations (Control group)|Patients in this group will receive available exercise recommendations of 150 minutes of moderate intensity exercise per week (30 minutes per day).
223502383|NCT05844124|OTHER|Exercise for Knee Osteoarthritis -(LBPP supported low-load treadmill Walking)|Lower-body positive-pressure (LBPP) supported low-load treadmill walking exercise
223502384|NCT05844124|OTHER|Exercise for Knee Osteoarthritis - (Aquatic Walking)|Aquatic Walking exercise
223592083|NCT05979168|BEHAVIORAL|Phone call and text Messages|The intervention consists of recommended lifestyle counselling (on a healthy diet, physical activity, smoking, alcohol intake, medication adherence and continuity of care). This counselling will be provided through the research nurse at baseline and for six months (tentative plan phone call once a month; frequency and duration will be finalized based on formative study) by calling on participants' given mobile numbers. In addition, text message reminders on the same topics will be delivered regularly (2-3 times a week) for six months. The counselling and message will focus on three domains of COM-B; capabilities needed, opportunities and practical tools, and motivation strategies informed by behaviour change techniques.
223592084|NCT00000466|DRUG|estrogens, conjugated|
223592085|NCT00000466|DRUG|medroxyprogesterone|
223592086|NCT00000466|DRUG|progesterone|
223592087|NCT00000466|DRUG|estrogen replacement therapy|
223592088|NCT06002568|PROCEDURE|Silent|Apply wave file created in silence.
223592089|NCT06002568|PROCEDURE|Binaural beats|Apply wave file which is intended to generate binaural beats by applying waves of different frequency (1Hz difference) in each ear.
223592090|NCT02854254|DEVICE|peripherally inserted central catheter|peripherally inserted central catheter
223592091|NCT02854254|DEVICE|peripherally venous access|standard over-the-needle intravenous catheter
223592092|NCT01671631|OTHER|Measurement of intracoronary pressure|
223592093|NCT06191107|DEVICE|Removable Partial Denture|Integration of removable partial dentures made of PEEK for the treatment of tooth loss.
223592094|NCT05136261|DEVICE|Ceradan ® Advanced Cream|Ceradan ® Advanced Cream
223592095|NCT05136261|DEVICE|Basic cream|Basic cream
223592096|NCT03537313|PROCEDURE|Vagina douching|Vaginal douches with 1000 ml of 1% povidone-iodine solution on the night before surgery and again on the morning of surgery
223592097|NCT03537313|PROCEDURE|Vagina painting|Vaginal painting of vagina stump after hysterectomy with 10% povidone-iodine solution 30 ml
223592098|NCT05583149|DRUG|ACALABRUTINIB|Oral, twice daily, timing and dosage per protocol
223746497|NCT02981628|DRUG|Asparaginase Erwinia chrysanthemi|Given Asparaginase Erwinia chrysanthemi
224310220|NCT05232266|DRUG|Caralluma Fimbriata|Caralluma fimbriata in capsule form - taken as a 500mg dose (two 250mg capsules) twice daily, morning and evening with food.
224310221|NCT05232266|DRUG|Placebo comparator - Microcrystalline cellulose|Placebo comparator in capsule form - taken as a 500mg dose (two 250mg capsules) twice daily, morning and evening with food.
223502385|NCT05621798|OTHER|Hearing Aid Manufacturer's Software|"When using hearing aid manufacturer's software (s.c. first-fit or initial fit) the fitting will follow the guided fitting procedure in the fitting software."
223746498|NCT02981628|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223746499|NCT02981628|PROCEDURE|Bone Marrow Aspiration and Biopsy|Undergo a bone marrow aspiration and biopsy
223746500|NCT02981628|DRUG|Calaspargase Pegol|Given IV
223592099|NCT05583149|DRUG|LISOCABTAGENE MARALEUCEL|via IV timings and dosage per protocol
223592100|NCT05583149|DRUG|Lymphodepleting chemotherapy|lymphodepleting chemotherapy with cyclophosphamide and fludarabine once a day for 3 days via IV about 2-4 hours. This will occur only once prior to lisocabtagene maraleucel infusion.
223592101|NCT00815828|OTHER|Resistance exercises|Resistance exercises program consisting of 08 different exercises.
223592102|NCT02880150|OTHER|Stress test|
223746501|NCT02981628|DRUG|Cyclophosphamide|Given IV
223746502|NCT02981628|DRUG|Cytarabine|Given IV or SC
223746503|NCT02981628|PROCEDURE|Diagnostic Imaging|Undergo imaging
223746504|NCT02981628|BIOLOGICAL|Inotuzumab Ozogamicin|Given IV
223502386|NCT05621798|OTHER|REM (Real Ear Measurements)|Participants' hearing aids are fitted by using REM. In this method REM measurement tube is placed inside participant's ear canal near the tympanic membrane and the Real Ear Unaided Gain (REUG) is measured. REUG is used to measure the ear canal without any hearing device and shows the patients ear acoustics. Next the hearing aid is placed on the patients ear together with the REM measurement tube. In REM measurements the Real-Ear Occluded Gain (REOG) is measured with the hearing aid off. REOG allows consideration of the attenuation caused by the earpiece and its obstructing effect of external sounds. Next Real Ear Aided Response (REAR) is measured with the hearing device on. REAR allows measurement of the hearing device's amplification effect within the patients' ear and includes the effect of the patient's ear acoustics.
224193461|NCT05923203|OTHER|Electric and acoustic stimulation (EAS) technology in the implanted ear(s)-this is the combination of a cochlear implant (CI) and hearing aid (HA) in the implanted ear(s)|This is a clinical fitting of an FDA approved EAS system for study participants that have received or who are scheduled to receive a CI based on clinical recommendations (i.e. not study related). The investigators will activate the CI sound processor's integrated HA circuit to allow for low-frequency acoustic amplification and mid-to-high frequency electric stimulation in the implanted ear(s) using recommended and accepted clinical practices and audiologic verification. EAS fitting will be completed using FDA approved clinical software and thereby is within the electrical and clinical specifications of the FDA approved device and accompanying software.
224193462|NCT03550989|OTHER|Non-Exposure Event|Non-Exposure event of 4h duration for the individual participants, where no use of any tobacco or nicotine-containing product is allowed, designed to establish background measurements in the absence of exposure to IQOS.
224193463|NCT03550989|OTHER|Exposure Event|Exposure Event designed to measure urinary BoExp to selected HPHCs representative of ETS in all participant groups, with up to 5h of exposure to IQOS tobacco environmental aerosol for non-smokers, cigarette smokers (not using any tobacco or nicotine-containing product, including cigarettes), and IQOS passive users (not using IQOS). Additionally, this event includes up to 8h of exposure for IQOS active users (using IQOS).
224193464|NCT04601389|BIOLOGICAL|"Omalizumab (JSC GENERIUM, the Russian Federation)"|150 mg of omalizumab was subcutaneously injected once in the deltoid muscle area
224193465|NCT04601389|BIOLOGICAL|Xolair® (Novartis Pharma AG, Switzerland)|150 mg of omalizumab was subcutaneously injected once in the deltoid muscle area
224193466|NCT06487637|BEHAVIORAL|CardioCare Quest|CardioCare Quest will be the first telehealth game designed to enhance High Blood Pressure (HBP) treatment compliance and education about HBP, featuring a telemetry system that provides physicians and researchers data about sustainable healthy heart lifestyles beyond the clinic. The novelty of CardioCare Quest lies in its ability to compel HBP patients to playfully celebrate the mundane everyday practices that lead to sustainable habits and improved health outcomes using culturally sensitive and community-based design practices.
224193467|NCT03029572|DRUG|Diet supplementation|Micronutriment supplementation therapy
224193468|NCT03029572|PROCEDURE|Bariatric surgery|Roux-en-Y gastric bypass provided in both arms.
224193469|NCT04881149|DEVICE|TempSure treatment|Self-controlled, single-arm study using the TempSure device.
224193470|NCT00262119|DEVICE|Pacemaker Medtronic EnRhythm|Pacemaker specific programming
224193471|NCT03986658|DEVICE|Linear Asymmetric rTMS System|Linear Asymmetric rTMS System
223502387|NCT06467344|DRUG|ACDN-01|ACDN-01 is an AAV-based vector carrying a DNA construct encoding for an ABCA4 RNA exon editor. One time administration is via subretinal injection.
223502388|NCT04095845|DEVICE|CO THA|Replacement of arthritic hip with artificial implant using CT-based navigation and conventional technique
223502389|NCT04095845|DEVICE|Mako THA|Replacement of arthritic hip with artificial implant using mako robotic-arm assist
223502390|NCT03287063|OTHER|Tumor Biopsy|Stereotactic biopsies will be performed prior to resection.
223502391|NCT04595019|RADIATION|SBRT|Stereotactic Body Radiotherapy. Ultrahypofractionated radiotherapy.
223502392|NCT02216851|DEVICE|Restylane Perlane|Intradermal injection
223502393|NCT01149538|DRUG|Choline bitartrate|Choline bitartrate 500 mg. daily, administered in fruit-flavored drink mix.
223502394|NCT01149538|DIETARY_SUPPLEMENT|Placebo for choline bitartrate|Placebo for choline bitartrate, administered daily in fruit-flavored drink mix.
223592103|NCT06946238|RADIATION|Adjuvant single-fraction accelerated partial breast irradiation|Experimental arm (arm 1-single-fraction APBI) patients will be treated to a total dose (TD) of 15.5 Gy to the PTV with a simultaneous integrated boost (SIB) to a TD of 21 Gy to the tumor bed, while arm 2-five-fractions APBI patients with 30 Gy/ 5 fractions to PTV.
223592104|NCT04231916|DEVICE|Thermal imaging device|
224193472|NCT01723358|DEVICE|Neuromuscular electrical stimulation (NMES)|The intervention will consist of a period of treatment with NMES. This treatment will involve 20-45 minute feeding therapy sessions during which NMES will be administered by an Occupational Therapist. Frequency of therapy sessions will be 4 times per week for the first 2 weeks (as in inpatient, if hospitalized) and then biweekly for 14 weeks for a total of 36 sessions (over 16 weeks). For patients who are discharged prior to the first 2 weeks of treatment, outpatient sessions will be biweekly.
224193473|NCT05913921|DRUG|Amphotericin B liposome for injection|IV infusion, 2.0 mg/kg
224193474|NCT05913921|DRUG|AmBisome|IV infusion, 2.0 mg/kg
224193475|NCT01683565|DRUG|LCPUFA oil supplement|"2.5mL per day for 90 days~Daily Dose: EPA (338mg) + DHA (225mg) + GLA (83mg) + OA (200mg)"
224193476|NCT01683565|OTHER|Canola Oil Placebo|2.5mL per day for 90 days
224193477|NCT03730623|BEHAVIORAL|Supervised exercise training|Supervised exercise training as a conservative management of intermittent claudication in a community setting based on cardiac rehabilitation program
224193478|NCT01680757|DEVICE|LARIAT Suture Delivery Device and Accessories|
224193479|NCT05774080|OTHER|Observational|Observational
224193480|NCT05551585|DEVICE|Transcranial pulse stimulation|TPS will be performed in three treatment sessions per week, applying 1000 pulses per session (single ultrashort (3 μs) ultrasound pulses, 0.2-0.25 mJ mm-2, \~5 Hz pulse frequency,
223592105|NCT00630227|BIOLOGICAL|Biologic Lung Volume Reduction|20 mL Hydrogel
223746505|NCT02981628|DRUG|Leucovorin Calcium|Given PO or IV
224193481|NCT06537661|OTHER|Virtual reality|Virtual reality (VR): is the artificial construction of a 3D environment viaThe VR glasses which were the source of visual and auditory feedback, were connected by Bluetooth to a mobile phone and all the videos of selected tasks.
224193482|NCT06537661|OTHER|Traditional exercises|"Active mobility exercises (jaw opening 6 times of 30 s; lateralization 10 times of 5 s; protrusion 10 times Of 5 s). Self-massage masticatory Muscles, After each session.~* Isometric contraction exercises Were included (3 times of 10 s)"
224193483|NCT02427620|DRUG|Cyclophosphamide|Given IV
224193484|NCT02427620|DRUG|Cytarabine|Given IV
224193485|NCT02427620|DRUG|Dexamethasone|Given PO or IV
224193486|NCT02427620|DRUG|Doxorubicin|Given IV
224193487|NCT02427620|DRUG|Doxorubicin Hydrochloride|Given IV
223502395|NCT01614119|OTHER|Hypoxic exposure|Subjects breath either normoxic or hypoxic (FiO2 = 12%) gas mixture
223502396|NCT04021355|OTHER|Oral sodium supplementation|Participants will receive dietary sodium supplementation in the form of tablets to be taken either with breakfast or dinner.
223502397|NCT04076137|OTHER|Targeted T-cell armed with bispecific antibody (Decitabine)|In this study, 10 patients eligible for the study were clinically screened for intravenous infusion of targeted activated T cells,every participant has a unique identification number and emergency letter which have the information of group.
223502398|NCT05574049|DRUG|Tetrahydrocannabivarin|The subjects will take once daily oromucosal strip with intervention drug for 90 days.
223502399|NCT05574049|OTHER|Placebo|The subjects will take once daily oromucosal strip with no drug on it for 90 days
224193488|NCT02427620|DRUG|Ibrutinib|Given PO
223502400|NCT06259500|OTHER|observational|Profiling the function of iPSC derived Arcuate neurons and PBMC derived microglia
223502401|NCT05469204|DRUG|Midazolam oral solution|2 mg single-dose before and during estradiol treatment.
223592106|NCT02520739|DIETARY_SUPPLEMENT|Virgin Olive Oil (VOO)|VOO was sequentially administered over 3 periods of 3 weeks preceded by 2-week washout periods in which participants were requested to avoid olives and olive oil consumption. During intervention periods, they were requested to ingest a raw daily dose of 30 mL of VOO distributed over 3 meals. Daily doses of VOO were blindly prepared in special containers, with the corresponding 30 mL VOO daily dose were delivered at the beginning of each intervention period to the participants. The participants were instructed to return the containers when collecting the next daily doses for the amount of unconsumed VOO to be registered. During washout periods participants were provided of sunflower oil for raw and cooking purposes.
223746506|NCT02981628|PROCEDURE|Lumbar Puncture|Undergo lumbar puncture
224193489|NCT02427620|OTHER|Laboratory Biomarker Analysis|Correlative studies
223746507|NCT02981628|DRUG|Methotrexate|Given IT
223502402|NCT05469204|DRUG|Digoxin Oral Tablet|0.25 mg single-dose before and during estradiol treatment.
223502403|NCT05469204|DRUG|Acetaminophen Oral Tablet|500 mg single-dose before and during estradiol treatment.
223502404|NCT05469204|DRUG|Midazolam Injectable Solution|1 mg intravenous single-dose before and during estradiol treatment.
223502405|NCT06533904|PROCEDURE|Percutaneous Cryoablation of Intercostal Nerves|Percutaneous Cryoablation of Intercostal Nerves
223502406|NCT06533904|OTHER|Multi-modal pain regimen|Standard rib fracture protocol including cyclooxygenase inhibitors, anti-neuropathic, muscle relaxers, short term anesthesia interventions (percutaneous block, epidural)
223746508|NCT02981628|DRUG|Pegaspargase|Given IV or IM
223502407|NCT06376409|DIETARY_SUPPLEMENT|Nutrafol Women's Hair Growth Supplement|Hair growth supplement for women ages 18 - 44
223502408|NCT06376409|DIETARY_SUPPLEMENT|Nutrafol Women's Balance Hair Growth Supplement|Hair growth supplement for women ages 45 - 70
223502409|NCT06376409|DIETARY_SUPPLEMENT|Nutrafol Women's Vegan Hair Growth Supplement|Hair growth supplement for women ages 18 - 44. This treatment group may also include subjects who do not follow a plant-based diet for purposes of extending the product claims beyond the initially studied demographic of women primarily adhering to a plant-based diet
223502410|NCT06376409|DIETARY_SUPPLEMENT|Nutrafol Women's Postpartum Hair Growth Supplement|Hair growth supplement for women ages 18 - 44. This product will be studied in the general women population and not postpartum women.
223746509|NCT02981628|DRUG|Vincristine|Given IV
223746510|NCT00163475|DRUG|Roflumilast|
223746511|NCT04692428|PROCEDURE|Locoregional analgesia|the supra-inguinal fascia iliaca block versus the femoral nerve block
223746512|NCT02062333|DRUG|Dexmedetomidine|1 mcg/kg dexmedetomidine is applied bolus and 0.2 mcg/kg/h dexmedetomidine is applied iv infusion
224193490|NCT02427620|DRUG|Methotrexate|Given IV
224193491|NCT02427620|BIOLOGICAL|Rituximab|Given IV
224193492|NCT02427620|DRUG|Vincristine|Given IV
224193493|NCT02427620|DRUG|Vincristine Sulfate|Given IV
224193494|NCT06309602|OTHER|Free Water Protocol|Intake of plain, un-thickened water is allowed even when a patient has orders for thickened liquids. Risks of pulmonary complications are decreased with use of a strict oral care regimen and timed intake of water related to meals. Patient satisfaction and comfort is increased with ingestion of plain water.
224193495|NCT06309602|OTHER|Control / Standard Care|Standard care will be given to patients with orders for thickened liquids. This will include oral care twice a day and implementation of swallowing strategies and precautions as prescribed by the treating speech-language pathologist. Only fluids thickened to the recommended viscosity will be available to the patient.
224193496|NCT05261126|DRUG|Enclitide Chloride|Enclitide Chloride administered orally
224193497|NCT05261126|DRUG|Placebo|Placebo matching enclitide chloride administered orally
224193498|NCT05060549|DRUG|Cariprazine|Participants will receive 6 weeks of cariprazine treatment
224193499|NCT05570604|BEHAVIORAL|Sweep Seeker|The person is asked to clear the rows of blocks presented on the screen, either by moving them into horizontal or vertical blocks that have identical color. The goal is to refine and increase the response of primary visual cortex neurons and to enable the person to increase speed and accuracy of visual processing (executive function) and visual memory.
224193500|NCT05570604|BEHAVIORAL|Bird Safari|The user is first presented with a target bird. Subsequently, a group of birds is presented in the peripheral vision and then disappears when the trial begins. The user selects the section of the screen where the target bird appeared. The presentation speed adapts with user performance (i.e. better performance = faster presentation). The goal is to improve speed and accuracy of object identification in peripheral vision and improve visual precision important for improving memory.
224193501|NCT05570604|BEHAVIORAL|Jewel Diver|The person is first presented objects (jewels) on the screen. The objects are then covered with occluders (bubbles) and then identical distracters are presented. The objects move around in screen and when the movement stops, the user chooses the occluders that cover the jewels. The number of jewels adapts to performance (more jewels = better performance). The goal is to improve divided visual attention, sustained visual attention, visual working memory, and visual precision.
223746513|NCT02062333|DRUG|esmolol|500 mcg/kg brevibloc is applied bolus and 100 mcg/kg/h iv infusion
223746514|NCT02397421|DRUG|Dapagliflozin|Sodium Glucose Linked Transporter Type 2 (SGLT-2) Inhibitor
223502411|NCT02741817|DRUG|Aspirin|The intervention has been described previously in both arms individually. Group A will receive 20mg of soluble Aspirin and group B with 75mg of soluble Aspirin. As this is a crossover study, all patients will fall under both groups throughout the duration and be un-blinded.
223502412|NCT00448149|DRUG|RAD001|RAD001 will be administered orally once a day, daily, without interruption per 4 wk cycle for 2 cycles. MTD is established in Phase I portion of trial (2.5, 5 or 10mg). If responding, additional therapy will be given.
223502413|NCT00448149|DRUG|Sorafenib|A dose of 400mg of Nexavar® will be administered orally twice a day, daily, without an interruption per 4 week cycle for 2 cycles. If responding, additional therapy will be given.
223502414|NCT02802722|DIETARY_SUPPLEMENT|Vitamin D3 supplementation|Capsules to be dispensed using an electronic dispenser to allow real time logging of adherence.
223502415|NCT02802722|BIOLOGICAL|Peripheral blood and induced sputum sampling|To attain samples for immunological testing
223502416|NCT02802722|RADIATION|Chest computerised tomography (CT) scans|For volumetric quantification of lung abnormalities
223502417|NCT02802722|OTHER|Symptom questionnaire|Symptom questionnaire for recent symptom history
223502418|NCT02802722|OTHER|Placebo|To be dispensed using an electronic dispenser to allow real time logging of adherence.
223502419|NCT01870037|DRUG|Placebo (PBS-20% sucrose)|
223502420|NCT01870037|DRUG|hMaxi-K|Single treatment/2 escalating dose levels (16000 µg and 24000 µg by intramuscular injection)
223502421|NCT06235957|OTHER|Cast 3 weeks|patients will be treated either in a cast or a brace, patients in group A are treated by cast immobilization for 3 weeks
223502422|NCT06235957|OTHER|Brace 1 week|patients will be treated either in a cast or a brace, patients in group B are treated in a brace for 1 week
223502423|NCT00250718|DRUG|Vincristine|Vincristine should be administered intravenously through a freely-running IV.
223502424|NCT00250718|DRUG|VP-16|The VP-16 is optional for the first cycle if the patient has delays in obtaining the drug.
224193502|NCT05570604|BEHAVIORAL|Master Gardener|The person is presented a series of target stimuli and distracters which are presented at one time and then disappear. The locations of the stimuli are marked by icons, and the user chooses the icons where the target stimuli were once located. The goal is to increase speed and accuracy as well as the ability to extract information accurately.
224193503|NCT05570604|BEHAVIORAL|Road Tour|The person is presented with a target vehicle briefly in both the center of the screen and in one of eight locations in the periphery. Two vehicles are then presented briefly in the center of the screen, one of which is the target vehicle. The user must identify the location of the target vehicle in the periphery as well as identify which was the target vehicle that appeared in the center. The goal of this activity is to improve divided attention and ability to extract information and discard irrelevant information from peripheral vision.
223502425|NCT00250718|DRUG|Rituximab|"The total amount of rituximab needed for a patient's entire infusions (one course) will be determined at study entry. A single dose of 375 mg/m2 will be based upon the patient's actual body surface area calculated during the baseline evaluation. The dose level of rituximab will not be adjusted.~Patients will only receive rituximab if their tumors are CD20 positive CLL or NHL.~Rituximab will only be administered to patients if they have previously had less than 8 doses. If a patient is treated with rituxan they should have at least 4 doses"
223502426|NCT00250718|DRUG|Dexamethasone|Dexamethasone will be administered at 200mg q 14 days. Dexamethasone should be administered over a 1 hour infusion.
223502427|NCT00250718|DRUG|Levofloxacin|Levofloxacin will be administered at 500 mg PO qd.
223746515|NCT02397421|DRUG|Placebo|Capsules containing microcrystalline cellulose Ph Eur overencapsulated in a hard gelatine capsule shell to match the active comparator
223502428|NCT03573089|DRUG|Liberal phosphate target|All phosphate-lowering medications in use at baseline will be discontinued. Phosphate-lowering medications will be prescribed only if serum phosphate concentration exceeds 2.50 mmol/L. The choice and dosages of phosphate-lowering medications will be at the discretion of treating physicians and/or participants.
223502429|NCT03573089|DRUG|Intensive phosphate target|This will be achieved by prescribing phosphate-lowering medications aimed to intensively lower serum phosphate concentration towards normal level (≤1.50 mmol/L). The choice and dosages of phosphate-lowering medications will be at the discretion of treating physicians and/or participants.
223502430|NCT06482983|PROCEDURE|Mechanical Ventilation Mode|after intubation different ventilation mode (VC,PC,PC-VG)
223502431|NCT06415487|DRUG|Cyclophosphamide|Lymphodepleting agent
223502432|NCT06415487|DRUG|Fludarabine|Lymphodepleting agent
223502433|NCT06415487|DRUG|ACE2016|Allogeneic gamma delta T (gdT) cell therapy
223502434|NCT06415487|DRUG|Pembrolizumab|Immune checkpoint anti-PD-1 antibody
223502435|NCT02359253|OTHER|Passive stretching|Prior to active training, subjects will be passively move their arm or hand by IntelliArm or the hand robot within preset ranges of motion.
223502436|NCT02359253|OTHER|Passive movement|Prior to active training, subjects will be passively move their arm or hand by IntelliArm or the hand robot only within ranges that produce no to very minimal forces.
223746516|NCT01688258|PROCEDURE|Diagnostic swab|
224193504|NCT05570604|BEHAVIORAL|Computerized Crossword Puzzles|The program offers a pre-determined set of computerized crossword puzzles. The site has over 100,000 puzzles and can be accessed easily via the web and are free to users. The computerized crossword puzzles do not provide for progressive challenges of increasing speed, visual field size, number of distractors or degree of difficulty of targeted stimulus differentiation.
224193505|NCT04774991|DRUG|Azithromycin for Oral Suspension|"Azithromycin will be administered as a single dose in oral suspension form for children as follows:~* Single-dose of 20mg/kg in children (up to the maximum adult dose of 1g)~* For children 1 to \<12 months of age, weight-based dosing will be used~* For children 12 to 59 months of age, height-based dosing will be used via height-stick approximation as currently performed by Niger's trachoma program."
224193506|NCT05739682|PROCEDURE|Local anaesthetic injection of 4% articaine with 1:100000 epinephrine|Buccal infiltration injection using a side loading aspirating syringe and a 30-gauge needle
224193507|NCT05739682|PROCEDURE|Tooth isolation|Rubber dam application to the affected tooth
224193508|NCT05739682|PROCEDURE|Access cavity preparation|Complete removal of caries, undermined tooth structure, and defective restoration. Access cavity preparation with complete removal of the pulp chamber roof using a sterile bur other than the ones used for caries removal.
224193509|NCT05739682|PROCEDURE|Root canal shaping and cleaning|Working length determination using an electronic apex locator and then canal instrumentation using Hyflex CM rotary files up to size 40.04 with irrigation using 2.5% NaOCl between files.
224193510|NCT05739682|PROCEDURE|Final irrigation with antimicrobial-corticosteroid mixture|1 ml of levofloxacin will be withdrawn in a 3ml plastic syringe followed by 1 ml of fluconazole and 1 ml of dexamethasone sodium phosphate, the whole solution is then passively delivered into the canal using a 30-gauge side vented needle reaching 1 mm shorter than the working length. The solution will be left inside the canal for 5 minutes
224193511|NCT05739682|PROCEDURE|Final irrigation with cold saline|Frozen sterile saline will be brought at room temperature and monitored using a digital liquid thermometer till the temperature reaches 2.5°c. 4ml are then withdrawn in a 5ml plastic syringe and delivered inside the canal in 1 minute. The process is then repeated 5 times so that the canal receives 20 ml of 2.5°c cold saline for 5 minutes.
224193512|NCT05739682|PROCEDURE|Temporary restoration and patient's instructions|The canals are dried using paper points and the access cavity is sealed using a non-eugenol temporary filling.
224193513|NCT05739682|PROCEDURE|Root canal obturation|After the 1st visit by 3 days to 1 week, the patient is scheduled for a second appointment for root canal obturation.
224193514|NCT06230393|DEVICE|STREAMLINE® SURGICAL SYSTEM|STREAMLINE® SURGICAL SYSTEM
224193515|NCT06548113|DEVICE|TMS|transcranial magnetic brain stimulation
224193516|NCT06324864|BEHAVIORAL|START NOW Adapted|"The START NOW skills-training combines aspects of cognitive behavioral therapy (CBT), motivational interviewing (MI), dialectical behavior therapy (DBT), Acceptance and Commitment Therapy (ACT) and trauma-sensitive care. Studies in different contexts have shown START NOW's effectiveness in terms of reducing behavioral problems, reducing hospitalization rates, improving mental health functioning and increasing satisfaction rates. The culturally adapted version will be contextually adapted to different cultural backgrounds and the experience of migration. In ten sessions, participants learn about emotions and are introduced to the START NOW skills. These skills, called SLOW DOWN, TAKE A STEP BACK, ACCEPT, RESPECT and TAKE ACTION, are strategies or techniques that can be used to better manage stress and difficult emotions."
224193517|NCT06241768|OTHER|mPATH-CRC Web app|Cloud-based web application that informs individuals of colorectal cancer screening and helps them receive screening
224193518|NCT05241249|DRUG|Bethanechol|Study Drug: Bethanechol (generic), supplied as 50mg oral tablets. Subjects will take 2 tablets (100mg) twice daily. Medication should be taken 1 hour before meals in AM and PM. Medication will be purchased commercially and dispensed at the research pharmacy.
224193519|NCT05241249|DRUG|Gemcitabine|Non-experimental. Chemotherapy will be administered on a day 1, 8 and 15 schedule with gemcitabine at a dose of 1000 mg/m2
224193520|NCT05241249|DRUG|nab-paclitaxel|Non-experimental. Chemotherapy will be administered on a day 1, 8 and 15 schedule with nab-paclitaxel dose at 125 mg/m2
224193521|NCT03671746|DRUG|Ketorolac|Participants will receive Ketorolac at 15 mg IV every 6 hours for their first 5 days of hospitalization
224193522|NCT03671746|DRUG|Saline Solution|Participants will receive 1 ml of saline solution IV every 6 hours for their first 5 days of hospitalization
223502437|NCT02359253|OTHER|IntelliArm|During the active training, subjects will be asked to actively move their arm while supported with IntelliArm robot to interact with virtual targets and objects. The IntelliArm may provide resistance or assistance.
223502438|NCT02359253|OTHER|Hand robot|During the active training, subjects will be asked to actively open and close their hand with the hand robot on while participating in task oriented occupational therapy focused on grasp and release tasks. The hand robot may provide resistance or assistance.
223502439|NCT04359615|DRUG|Favipiravir|This will be drug only used in the intervention arm of our study, designed mainly to assess the additional efficacy and safety of Favipiravir in COVID-19 patients.
223502440|NCT04359615|DRUG|Hydroxychloroquine|This Drug will be used in all arms as mandated by our governmental guidelines.
223502441|NCT06100250|BEHAVIORAL|Motivational interviewing and specimen self-collection|Participants will be asked to attend a pre-test live AV conferencing session, collect and return a urine sample, a throat swab, a rectal swab, and a blood sample for bacterial STI testing, and attend a post-test live AV conferencing session.
223502442|NCT02021318|DRUG|Roxadustat|Oral tablet.
223502443|NCT02021318|DRUG|Darbepoetin alfa|Subcutaneous or intravenous injection.
223502444|NCT06560320|BEHAVIORAL|Virtual Reality Glasses|Virtual Reality(VR) Glasses were introduced to the children pre-procedure. The children were made to watch a video with VR glasses before starting the application and it continued until the end of the vaccination procedure.
223502445|NCT05636124|DEVICE|Kaneka i-ED coil|The study device is the Kaneka i-ED coil T, FDA cleared under 510K number K192068. The coil is indicated for use in the endovascular embolization of intracranial aneurysms and other neurovascular abnormalities such as arteriovenous malformations and arteriovenous fistulae.
223502446|NCT06973304|DRUG|Teduglutide|Teduglutide 0.05 mg/kg SC injection.
224193523|NCT04100889|OTHER|No Intervention|There is no intervention for this study.
224193524|NCT06500819|DRUG|B7-H3CART Dose (Intravenous)|"Subjects who meet cell infusion eligibility will receive IV B7-H3CART cells on Day 0.~Dose level -1 (DL-1) 0.3 x 106 transduced T cells/kg~Subjects who meet cell infusion eligibility will receive IV B7-H3CART cells on Day 0.~Dose level 1 (DL1) 1 x 106 transduced T cells/kg~Subjects who meet cell infusion eligibility will receive IV B7-H3CART cells on Day 0.~Dose level 2 (DL2) 3 x 106 transduced T cells/kg~Subjects who meet cell infusion eligibility will receive IV B7-H3CART cells on Day 0.~Dose level 2 (DL2) 3 x 106 transduced T cells/kg~Subjects who meet cell infusion eligibility will receive IV B7-H3CART cells on Day 0.~Dose level 3 (DL3) 9 x 106 transduced T cells/kg"
224193525|NCT05721976|BEHAVIORAL|"With Love, Grandma (Con Cariño, Abuelita)"|"Cancer survivor-Daughter dyads will log in to a secured website to access intervention content over a period of 10-12 weeks. The intervention will be delivered primarily through smartphones and will include 8 modules with didactic content on healthy lifestyle behaviors for cancer prevention and control, family behavior change content for setting weekly goals and self-monitoring health behaviors, and family communication and positive parenting/grandparenting content, all of which were developed in accordance with participant feedback based on formative intervention development work. In addition, and to increase participant compliance/reduce attrition often observed in digital health interventions, human support (supportive accountability) will be provided. Specifically, each family will be assigned a coach who will use video conferencing software to engage in weekly 15-30 minute sessions regarding the family's progress throughout the intervention period."
224193526|NCT05866107|DEVICE|"Effectiveness and Feasibility of Self-Monitoring for Weight Management in Individuals with Mental Disorders Using Digital Intervention (SWIM trial)"|"Participants receive a digital-behavioral intervention via Huawei Health App and smart scale:~1. Weekly weigh-ins (auto-synced)~2. Dietary logging (≥3x/week) with calorie-deficit targets~3. Biweekly exercise plans (150-300 min/week)~4. Weekly motivational messages~Implementation:~Staggered rollout: Batch 1 (Month 3-6), Batch 2 (Month 5-6). Includes 2-week training. Effectiveness monitored via app metrics and adherence. Routine care maintained."
224193527|NCT02566304|DRUG|Fludarabine|Given IV
224193528|NCT02566304|RADIATION|Total-Body Irradiation|Undergo TBI
224193529|NCT02566304|BIOLOGICAL|T Cell-Depleted Donor Lymphocyte Infusion|Undergo DLI
224193530|NCT02566304|DRUG|Cyclophosphamide|Given IV
223502447|NCT04892303|COMBINATION_PRODUCT|Combination treatment (CXRPT) of external beam radiation (XRT) plus radioactive iodine (RAI)|To safely administer a minimum cumulative dose of external beam radiation to up 3 index tumors per patient, supplemented radiation dose delivered by radioactive iodine (RAI)
223502448|NCT05356611|BEHAVIORAL|Engage|Engage is a 9-week, behavioral-based, psychotherapy treatment protocol for late-life depression.
223502449|NCT05253469|PROCEDURE|Cryopreserved Aortic Homograft|CAH is used for aortic root reconstruction and for repair of mitro-aortic curtain (emicommando procedure) and it is inserted as miniroot . In cases of PVE the infected prosthesis is removed with aggressive debridement of all infected and necrotic tissue. (7)The coronary ostia are prepared for reconstruction of aortic root. In complex valve endocarditis involving aortic and mitral valve a double homograft may be used.Mitro-aortic endocarditis intervalvular fibrosa is largely involved.The abscess cavity is precisely bounded and debrided. and a double homograft is used for the reconstruction (commando procedure
223502450|NCT05253469|PROCEDURE|Stented/Non stented xenograft|The insertion of stented/non stented xenograft may be performed using separate or continuos stich with or without teflon pledget. Biological valves may be implated alone or combined with polyester or pericardial patch when reconstruction of annulus is required. In cases of aggressive lesions requiring root and /or intervalvular fibrosa reconstruction the choice of prosthetic bioroot using bioprosthetic valve is considered acceptable alternatives to CAH although it should be guided by the surgeon's experience
223502451|NCT05253469|PROCEDURE|Mechanical prostheses|The insertion of conventional mechanical valves may be performed using separate or continuos stich with or without teflon pledget. Mechanical prostheses may be implated alone or combined with polyester or pericardial patch when reconstruction of annulus is required. In cases of aggressive lesions requiring root and /or intervalvular fibrosa reconstruction the choice of prosthetic valved conduit with a mechanical valve is considered acceptable alternatives to CAH although it should be guided by the surgeon's experience
223502452|NCT03585543|BEHAVIORAL|Voice Crisis Alert V2|Intervention consists of a mHealth app delivered via smartphone
223502453|NCT04516876|OTHER|Camp-based bimanual intensive training(BIT)|The day-camp BIT model will be delivered in a group-based design. In day-camp model, each child is assigned to a trained therapist to maintain at least a 1:1 to 1:2 ratios of therapy and child. The therapist will monitor and modify the activities to fit each individual's ability and need to make sure the intervention quality is equivalence to the individualized treatment method. The chosen tasks of each intervention session have to be considering the child's preference, age-appropriated, and at the right level of difficulty. Target movements are embedded in the functional activities, whereby the environment is manipulated to vary task requirement and the difficulty is graded to match the child's capacity.
223502454|NCT02430233|DRUG|micronized progesterone 400 mg (Utrogestan)|participants receive vaginal micronized progesterone (Utrogestan- 200mg×2 PV(per vagina) per day)
223502455|NCT01660542|DRUG|Neoadjuvant Chemotherapy with Docetaxel|Doxorubicin 60 mg/m2 plus cyclophosphamide 600 mg/m2 (day 1), IV (in the vein), every 21 days, a total of 4 cycles -\> Docetaxel 100 mg/m2 (day 1) IV, every 21 days, a total of 4 cycles
223502456|NCT03343028|OTHER|Psychotherapy|
224193531|NCT02566304|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo PBSC transplant
224193532|NCT02566304|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo PBSC transplant
224193533|NCT02566304|DRUG|Tacrolimus|Given PO
224193534|NCT02566304|DRUG|Mycophenolate mofetil|Given IV
224193535|NCT02566304|OTHER|Laboratory Biomarker Analysis|Correlative studies
224193536|NCT04715451|OTHER|Novel Swaddle|A novel swaddling method.
224193537|NCT04210817|OTHER|No Intervention|There is no intervention for this study
224193538|NCT04100005|OTHER|No intervention|There is no intervention for this study.
224193539|NCT05545007|RADIATION|Hypofractionated Radiosurgery (HSRS)|HSRS converges multiple radiation beams to deliver a single, large dose of radiation to a discrete tumor target with high precision, thereby minimizing radiation dose to the surrounding normal tissue.
224193540|NCT05545007|PROCEDURE|Brain metastases surgical resection|Complete surgical resection of brain lesions with adeguate margins.
224193541|NCT06167096|OTHER|Lavender essential oil|Lavender Oil; blend of two (2) pure lavender oil - Lavandula angustifolia from Bulgaria and Lavandula hybrida from France
224193542|NCT06167096|OTHER|Water|Water
224193543|NCT06638801|BEHAVIORAL|Coach-led caregiver-implemented early literacy and developmental programming|Caregivers will receive training about child brain development in the first 3 years of life. The training will emphasize the areas of spoken words, physical education, pointer-finger concept, focus and label, reading lessons, and mathematics.
224193544|NCT06638801|BEHAVIORAL|Reach Out and Read Training|Reach Out and Read parent training
224193545|NCT04208217|BEHAVIORAL|Modeling to Learn (MTL)|Modeling to Learn is a facilitated health care quality improvement or evidence-based practice implementation strategy that includes frontline addiction and mental health staff running simulations of clinic improvement strategies to find the best approaches for improving the reach of evidence-based psychotherapy and evidence-based pharmacotherapy.
224193546|NCT04208217|BEHAVIORAL|Usual quality improvement (QI)|Usual quality improvement is a health care quality improvement or evidence-based practice implementation strategy that includes frontline addiction and mental health staff reviewing data to find the best approaches for improving the reach of evidence-based psychotherapy and evidence-based pharmacotherapy.
223502457|NCT00238290|DRUG|Trastuzumab + Letrozole|Patients receive trastuzumab (Herceptin®) IV over 30-90 minutes once in weeks 1-3 OR once in week 1. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity. Patients experiencing disease progression after 9 weeks receive trastuzumab as before and oral letrozole once daily in the absence of further disease progression or unacceptable toxicity.
223502458|NCT06520280|OTHER|polyamide and 3D printed complete denture|pts. receive 2 sets of complete dentures made from polyamide and 3d printed to use
223502459|NCT04092764|DEVICE|Electroacupuncture|Participants will receive electroacupuncture for 30 minutes once per week for a total of 3 weeks. The acupoints will be stimulated by the electroacupuncture machine with alternating frequencies in order to induce endorphins at different points in the nervous system. Frequencies between 2 Hz and 100 Hz will be utilized. Sterile single-use needles will be placed at Ba Feng, four points on the dorsum of each foot between the digits. KI2 (Rang Gu), a point located at the soles of the feet and SP-4 (Gongsun) will also be needled per recommendation of our acupuncturist. A total of 12 needles will be used per participant.
223502460|NCT04092764|DEVICE|NeuroMetrix|The NeuroMetrix is a point-of-care conduction device that will be used to measure peripheral neuropathy
223502461|NCT04092764|DEVICE|Rydel-Seiffer tuning fork|The level of periphal neuropathy will be measured by vibration detection using a Rydel-Seiffer graduated tuning fork placed on the dorsum of the right great toe between the nail and the distal interphalangeal joint. The two arms of the 128 Hz tuning fork are fitted with calibrated weights at the ends, and as the amplitude decreases, the intersection of the triangles moves upward on the weight. This test will be performed three times and a mean of the scores calculated. Vibration sensation is lost sooner in CIPN, which means that lower scores are associated with increased CIPN
223502462|NCT02213575|DRUG|Minocycline|Subjects will receive the dose of Minocycline determined to best lower BP and will undergo baseline and 26 week follow-up MRI and PET scans for changes in the paraventricular nucleus.
223502463|NCT00189670|PROCEDURE|6 TEC q 3 weeks|
223502464|NCT00189670|PROCEDURE|4 EC q 2 weeks followed by 4 TXT q 2 weeks|
223502465|NCT00189670|PROCEDURE|4 TXT q 2 weeks followed by 4 EC q 2 weeks|
223502466|NCT06214390|PROCEDURE|Single strategy|In the single strategy, RRT weaning will be achieved when urine output exceeds 500ml/24h without diuretics or 2000ml/24h with diuretics use
223502467|NCT06214390|PROCEDURE|Combined strategy|In the combined strategy, when urine output exceeds 500ml/day with or without diuretic use, RRT will be stopped during 48h to assess urinary indices (urinary creatinine and urea). Soon as urinary indices are higher than thresholds values (urinary creatinine \> 5.2mmol/day \[5\] and 3) urinary urea \> 1.35mmol/kg/day (using the patient's body weight at ICU admission) \[6\], RRT will be weaned. If they are lower, a RRT session will be perform after which the weaning process will be resume.
223502468|NCT01935804|DRUG|Pioglitazone|30 mg/daily for 12 months
223502469|NCT01935804|DRUG|Metformin|850 mg/daily for 12 months
223502470|NCT03603704|DRUG|LY3209590|Administered SC
223502471|NCT03603704|DRUG|Placebo|Administered SC
223502472|NCT06071988|DRUG|Adezunap (AP707)|Sublingual spray with maximum application of 16 actuations per day or a maximum daily dose of 17,6mg THC distributed over 4 daily intakes.
223502473|NCT06071988|DRUG|Placebo|Sublingual spray with maximum application of 16 actuations per day distributed over 4 daily intakes.
224193547|NCT05959421|BIOLOGICAL|ERVEBO® (rVSV∆G-ZEBOV-GP)|intramuscular vaccination
224193548|NCT05959421|BIOLOGICAL|ERVEBO® (rVSV∆G-ZEBOV-GP)|intramuscular vaccination
224193549|NCT05535738|DRUG|Squaric Acid Dibutyl Ester|Sensitization dose: 2% Elicitation doses: {0.0001%, 0.00025%, 0.00075%, 0.001%, 0.0025%, 0.005%, 0.0075%, 0.01%, 0.025%, 0.05%, 0.06%, 0.07%, 0.08%, 0.09%, 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6% 0.7%, 0.8%, 0.9%, 1.0%, 1.2%, 1.4%, 1.6%, 1.8%, 2.0%}
224193550|NCT05535738|OTHER|Known patch test allergens|Positive patch test allergens during the course of clinical patch testing will be re-applied on the back followed by skin sampling
224193551|NCT05535738|DRUG|Dupilumab|300mg
224193552|NCT05535738|DRUG|Adalimumab|40mg
224193553|NCT05535738|DRUG|Ustekinumab|45mg
224193554|NCT05535738|DRUG|Guselkumab|100mg
224193555|NCT05535738|DRUG|Canakinumab|150mg
224193556|NCT05535738|DRUG|Sarilumab|200mg
224193557|NCT05535738|DRUG|Triamcinolone Acetonide|0.1% ointment
224193558|NCT05535738|DRUG|Betamethasone Valerate|0.1% ointment
224193559|NCT05535738|DRUG|Fluticasone Propionate|0.005% ointment
224193560|NCT05535738|DEVICE|Microneedle|Painless and non-scarring skin sampling with a 7mm x 7mm patch of hydrogel-coated poly-l-lactide microneedles (\<2mm length) will be used to collect interstitial fluid
224193561|NCT05535738|DEVICE|Suction blistering|Suction blistering is a technique to induce and collect blister fluid using a negative pressure instrument (Electronic Diversities Finksburg, MD). It does not require local anesthetic, stitches or pain medication following the procedure. The blisters will be no greater than 1cm in diameter and no deeper than the epidermis (\<1mm deep). This process of inducing blisters is typically less than 1 hour. After the formation of blisters, the blister fluid will be extracted using a syringe. The blister roofs will be left attached to the skin and covered with petrolatum and a bandage.
224193562|NCT05535738|PROCEDURE|Skin punch biopsy|A skin biopsy is the removal of a small piece of tissue, under local anesthetic.
223502474|NCT05984459|DIETARY_SUPPLEMENT|VLCKD|The analysis will focus on the observation of the evolution of anthropometric and clinical parameters,such as the improvement or normalization of HbA1c, as well as on the evolution of the hypoglycemic medication between patients who accept VLCKD method
223502475|NCT02679105|DRUG|ALK Alutard birch or 5-grasses|3 injections with 4-5 weeks interval.
223502476|NCT02679105|DRUG|ALK diluent|0,3% human albumin
223592107|NCT02520739|DIETARY_SUPPLEMENT|Optimized High Phenolic Content Oil (OHPCO)|OHPCO was sequentially administered over 3 periods of 3 weeks preceded by 2-week washout periods in which participants were requested to avoid olives and olive oil consumption. During intervention periods, they were requested to ingest a raw daily dose of 30 mL of OHPCO distributed over 3 meals. Daily doses of OHPCO were blindly prepared in special containers, with the corresponding 30 mL OHPCO daily dose were delivered at the beginning of each intervention period to the participants. The participants were instructed to return the containers when collecting the next daily doses for the amount of unconsumed OHPCO to be registered. During washout periods participants were provided of sunflower oil for raw and cooking purposes.
223592108|NCT02520739|DIETARY_SUPPLEMENT|Functional Olive Oil (FOO)|FOO was sequentially administered over 3 periods of 3 weeks preceded by 2-week washout periods in which participants were requested to avoid olives and olive oil consumption. During intervention periods, they were requested to ingest a raw daily dose of 30 mL of FOO distributed over 3 meals. Daily doses of FOO were blindly prepared in special containers, with the corresponding 30 mL FOO daily dose were delivered at the beginning of each intervention period to the participants. The participants were instructed to return the containers when collecting the next daily doses for the amount of unconsumed FOO to be registered. During washout periods participants were provided of sunflower oil for raw and cooking purposes.
223592109|NCT02784769|OTHER|measurement of skin autofluorescence|
223592110|NCT02784769|OTHER|skin biopsy collection|
223592111|NCT01416428|DRUG|oprozomib|Patients enrolled will receive Oprozomib Tablets once daily either on Days 1-5 (QDx5 schedule) or on Days 1, 2, 8, and 9 (QDx2 weekly schedule) of the 14-day treatment cycle.
223592112|NCT03628274|DEVICE|Magnetic Resonance Imaging (MRI) 7 Tesla|An MRI performed as part of the project
223592113|NCT03628274|DEVICE|Magnetic Resonance Imaging (MRI) 1,5 Tesla|An MRI performed as part of the care
223592114|NCT05242094|PROCEDURE|Pulmonary Rehabilitation Program|An in-patients 3-week high intensity rehabilitation program, five times a week, was used as the intervention treatment. The author's pulmonary rehabilitation program was programmed based on previous experience in patients with COPD. A holistic pulmonary rehabilitation program with combined treatment focused on increasing exercise capacity, restoring lung function, and supporting mental health, developed by a multidisciplinary team, was introduced. Based on the patient's submaximal exercise tolerance test results, the qualification for one of the respiratory physiotherapy models differing in therapy intensity was performed. Rehabilitation models included exercise capacity training on a cycle ergometer, breathing exercises, general fitness exercises, resistance training, and relaxation.
223592115|NCT00135109|DRUG|SPM 927|
223592116|NCT01720238|DRUG|Entecavir|0.5mg qd
223592117|NCT01720238|DRUG|Lamivudine plus Adefovir Dipivoxil|Lamivudine:100mg qd Adefovir Dipivoxil:10mg qd
223592118|NCT06102109|PROCEDURE|Pars plana vitrectomy|25gauge pars plana vitrectomy: to remove the vitreous if present
223592119|NCT06102109|PROCEDURE|IOL explantation|Removing if present a subluxated IOL from the anterior chamber or the vitreous cavity
224193563|NCT04082234|BEHAVIORAL|Partnering to Achieve School Success (PASS)|Individualized parent training program delivered at child's primary care provider office. Providers use engagement and motivation strategies during each session to reinforce help-seeking behavior and family empowerment, and encourage family adherence to recommended strategies. Also includes regular communication between pass provider and PCP and development of a problem-solving partnership between parents and teachers to address school problems. Families are supported in between sessions by a Community Health Partner who contacts families to promote attendance and implementation of strategies and assist in resolving barriers to treatment. The intervention is up to 12 sessions over the course of 16 weeks depending on caregiver goals.
224193564|NCT04082234|OTHER|Treatment as Usual (TAU)|Caregivers will work with their primary care physician to address their child's ADHD. Primary care physicians have been trained in and informed of American Academy of Pediatrics guidelines for treating ADHD. Treatment may include strategies to educate families about ADHD and evidence-based treatments, refer families to community mental health agencies that deliver evidence-based behavioral programming (other than PASS), engage families in shared decision making, titrate medication, and monitor treatment effects. In addition, families will have access to integrated behavioral health services that are typically offered at their child's primary care office.
224193565|NCT05746572|DRUG|MDMA|Participants will receive MDMA HCl (100 mg, 84 mg MDMA) in combination with massed exposure therapy for PTSD.
224193566|NCT00810654|DIETARY_SUPPLEMENT|Aspergillus niger prolyl endoprotease|160 PPU daily for 2 weeks
224193567|NCT00810654|DIETARY_SUPPLEMENT|Placebo|Placebo
224193568|NCT00413322|DRUG|belinostat|300, 600, or 1000 mg/m2 belinostat IV for 5 days every 21 days starting with cycle 1
223592120|NCT06102109|PROCEDURE|Scleral IOL fixation Yamane Technique|Scleral IOL fixation using the Yamane technique. A 3 piece IOL (Kowa Avansee Preset) gets fixated in the sclera using only its haptics, which are externalised 2.5mm behind the blue line. The haptic ends are flanged using a thermo cautery to prevent slipping back in.
223592121|NCT06102109|PROCEDURE|"Scleral IOL fixation 4-flanged Technique"|Scleral IOL fixation using the 4 flanged technique. A 4 loop haptic IOL (Physical Micropure 123) gets fixated in the sclera using one 6.0 polypropylene suture per 2 haptic loops, which are put trough the loops in a W shape. The suture ends are externalised 2.5mm behind the blue line and its ends are flanged using a thermo cautery to prevent slipping back in.
224193569|NCT00413322|DRUG|5-Fluorouracil (5-FU)|250, 500, 750, or 1000 mg/m2/d of 5-FU starting with cycle 2 onwards in combination with belinostat. Starting on day 2, 5-FU is administered as a continuous 96 hour infusion.
224193570|NCT00953173|DEVICE|LAP-BAND AP® Adjustable Gastric Banding System|The LAP-BAND AP® is a device surgically implanted via a laparoscopic procedure. It is designed to induce weight loss in severely obese patients by limiting food consumption.
224193571|NCT04943601|OTHER|action observation therapy|The participants will be three meters from the screen onto which the videos will be projected. The initial posture will vary depending on each movement, lying down, sitting, or standing and ensuring a clear field of vision. The sessions will be performed in groups of three to four patients
224193572|NCT04943601|OTHER|conventional physical therapy|Verbal instructions will be given to perform and correct the movements requested. The sessions will be conducted in groups of three to four patients and all participants will have 3 to 4 assistants in the session, they will help them achieve their active-assisted range of motion requested in the exercises, when necessary.
224193573|NCT03364699|DIETARY_SUPPLEMENT|dietary supplementation|The volunteers ingested 3 g daily of Soybean lecithin or fish oil rich in docosa-hexanoic acid (DHA) containing 1.5 g DHA and 0.3 g EPA (DHA:EPA = 5:1) or fish oil rich in eicosapentaenoic acid (EPA) containing 1.6 g EPA and 0.3 g DHA (EPA:DHA = 5.4:1) during 60 days.
224193574|NCT03364699|OTHER|Exercise|All volunteers performed two half-marathons. In the first half-marathon, all participants were not supplemented. In the second half-marathon, all participants were supplemented. Blood samples were collected before and after both half-marathon race.
224193575|NCT03611452|PROCEDURE|Episiotomy|repair of perineal muscles and skin
224193576|NCT01991600|DIETARY_SUPPLEMENT|ferrous sulphate|
224193577|NCT01991600|DIETARY_SUPPLEMENT|ferric iron oxide-organic acid (Fe-OA)|
224193578|NCT00911560|BIOLOGICAL|adjuvant OPT-821 in a vaccine containing two antigens (GD2L and GD3L) covalently linked to KLH|Pts receive a total of 7 subcutaneous injections, at weeks 1, 2, 3, 8, 20, 32, \& 52. Minor schedule adjustments are permitted, as needed. Vaccines must occur a minimum of 6 days apart. Induction of antibody response against the target antigens will be assessed. A fixed dose of oral β-glucan (40 mg/kg/day) is started at week 6 or 7(to allow time for generation of antibodies), \& continued as approximately 2 weeks on, 2 weeks off, up to 1 cycle after the last vaccination. Neutrophils will be tested for glucan effects on cytotoxicity. Antineuroblastoma activity will be monitored using standard radiographic \& bone marrow studies, as well as RT-PCR for measurement of minimal residual disease in blood \& bone marrow. Phase II treatment schema for patients in 1st CR/VGPR or \>2nd CR/VGPR will be the same for the vaccine as in phase I except OPT-821 will be given at a fixed dose of 150 mcg/m2.
224193579|NCT00911560|BIOLOGICAL|oral β-glucan|Phase II Patients will be randomized to starting oral β-glucan (40 mg/kg/day) in week 1 or in week 6.
224193580|NCT06150183|BIOLOGICAL|BNT314|Intravenous infusion
223502477|NCT03731143|PROCEDURE|insertion of self retaining bicanalicular stent|"The pigtail probe was passed through the canalicular system from the normal punctum to the occluded aspect. When the tip of the pigtail probe was positioned near the occluded punctal area, the surgeon pushed the area to be tented with the pigtail probe. After they advanced the pigtail probe back and forth several times until they could locate the correct position of the occluded punctum, the authors incised the tented area with a scalpel No. 11 to make a new punctal opening.~To ensure punctal and canalicular patency, syringing was repeated through the perforated punctum. To prevent re-occlusion of punctal opening, a self retaining bicanalicular tube (FCI®; Paris, France) was inserted through the normal and perforated puncti"
224193581|NCT01211405|DRUG|Low dose MDMA-assisted therapy|30 mg midomafetamine HCl administered p.o. once at start of an experimental session. Upon mutual agreement, this may be followed by a supplemental dose of 15 mg 1.5 to 2 hours later
224193582|NCT01211405|DRUG|Medium dose MDMA-assisted therapy|75 mg midomafetamine HCl administered p.o. once at start of an experimental session. Upon mutual agreement, this may be followed by a supplemental dose of 37.5 mg 1.5 to 2 hours later
224193583|NCT01211405|DRUG|Full dose MDMA-assisted therapy|125 mg midomafetamine HCl administered p.o. once at start of an experimental session. Upon mutual agreement, this may be followed by a supplemental dose of 62.5 mg 1.5 to 2 hours later
224193584|NCT01211405|BEHAVIORAL|Therapy|Non-directive therapy during each session
224193585|NCT02643121|OTHER|therapy sepsis|Treatment of sepsis varies depending on the site and cause of the initial infection, the organs affected and the extent of any damage
224193586|NCT01085331|DRUG|Pimasertib|Subjects will be administered with pimasertib orally once daily on Days 1-5, 8-12, 15-19, and 22-26 of a 28 day cycle.
224193587|NCT01085331|DRUG|Placebo|Subjects will be administered with placebo orally once daily on days 1-5, 8-12, 15-19, and 22-26 of a 28 day cycle.
223502478|NCT06098547|PROCEDURE|Liver transplantation|"Patients will undergo liver transplantation according to the standard procedures of the institutional Center's protocol (cadaveric or living donor transplantation, whole or partial liver).~Liver transplantation is preceded by an exploratory laparotomy with clinical evaluation and frozen section examination of lymph nodes in the hepatoduodenal ligament and along the common hepatic artery/celiac axis."
223502479|NCT03868371|DIETARY_SUPPLEMENT|High phosphorous containing meal|A meal with a high phosphorous content
223502480|NCT03868371|DIETARY_SUPPLEMENT|Low phosphorous containing meal|A meal with a low phosphorous content
223592122|NCT03628729|OTHER|Embrace™ WetBond™ Pit & Fissure Sealant|pit and fissure sealant that contain the precursor in the formation of hydroxyapatite which is Amorphous Calcium Phosphate (ACP) ,which has anti-cariogenic effect as well as remineralization potential as it contain bioactive material which stimulate crystal growth within the lesion by increasing the concentration of calcium and phosphate ions
223592123|NCT03628729|OTHER|Seal-Rite™ Pit & Fissure Sealant, Pulpdent Corportation, USA|Fluoride releasing resin based pits and fissures sealant
223592124|NCT03903939|DRUG|Iloprost|continuously infusion for 72 hours 1 ng/kg/min
223592125|NCT03903939|DRUG|Isotonic saline|continuously infusion for 72 hours equal volume to Iloprost
223592126|NCT02356679|DRUG|Eupasidin-s Tab|three times per day, 1 tab for each time, PO, during 2weeks
224193588|NCT01085331|DRUG|FOLFIRI|Subjects will be administered with FOLFIRI (laevoleucovorin 200 milligram per square meter \[mg/m\^2\] intravenous \[i.v\] infusion over 90 minutes or leucovorin \[dl-leucovorin\] 400 mg/m\^2 i.v. infusion over 90 minutes; followed by irinotecan 180 mg/m\^2 given as a 90-minute infusion in 500 milliliter \[mL\] dextrose 5%; followed by a bolus 5-fluorouracil \[FU\] 400 mg/m\^2 and a 46-hour infusion 5-FU 2400 mg/m\^2) at conventional doses on days 1 and 15 of the same 28 day cycle.
224193589|NCT02551900|OTHER|Warm water exercise|Warm water based cycling exercise training program will be based on cycling in warm water (temperature 34◦C ). Warm water exercise will be conducted at moderate intensity (60-70% maximum heart rate). The three groups were exercise 15 minutes on the first month, second month will be increased to 20 minutes and the last month will be increased to 30 minutes. The training program will be performed 3 times per week for 12 weeks.
224310222|NCT03750292|DEVICE|HEPAirX air filter|It is a trademarked, patented (U.S. Patent # 7,802,443), U.S. FDA approved Class II medical re-circulating air cleaner, built by Air Innovations, Inc. (North Syracuse, NY) to provide improved indoor air quality in the bedrooms of asthmatic children. Units to be used in the proposed study have a 99.97% efficient filter for particles 0.3 µm in size. The device provides a clean air delivery rate (CADR) of 9 per hour with 1.8 of them being outdoor air.
223502481|NCT03514797|DRUG|Bleaching Agents|In-office tooth bleaching with 35% hydrogen peroxide in a single application of 45 minutes.
223502482|NCT03514797|DRUG|Bleaching Agents|At-home tooth bleaching with 10% carbamide peroxide for 1 hour per day.
223502483|NCT00421993|DRUG|Adapalene/Benzoyl Peroxide|Topical Gel, One application daily in the evening for 12 weeks
223502484|NCT00421993|DRUG|Adapalene|Topical Gel,One application daily in the evening for 12 weeks
224193590|NCT02551900|OTHER|Cold water exercise|Cold water based cycling exercise training will be based on cycling in cold water (temperature 20◦C ). Cold water exercise will be conducted at moderate intensity (60-70% maximum heart rate). The three groups were exercise 15 minutes on the first month, second month will be increased to 20 minutes and the last month will be increased to 30 minutes. The training program will be performed 3 times per week for 12 weeks.
224310223|NCT03750292|DEVICE|control air filter|A placebo mode was added to the HEPAirX to provide only recirculation (without filtration or ventilation using outdoor air) and temperature control of the room air. The placebo filter is made of metal.
224310224|NCT03961490|OTHER|No interventional study|No interventional study
224310225|NCT03845803|OTHER|Reducing sedentary behaviour|Implementing sit/stand workstations at work
224310226|NCT00683579|DRUG|Early Treatment with HAART|HAART with possibility of de-intensification
223502485|NCT00421993|DRUG|Benzoyl Peroxide|Topical Gel, one application daily in the evening for 12 weeks
223502486|NCT00421993|DRUG|Topical Gel Vehicle|Topical Gel Vehicle,one application daily in the evening for 12 weeks
223502487|NCT03630601|PROCEDURE|Photoacoustic Imaging|Undergo PAI
223502488|NCT06323993|PROCEDURE|Piezoelectric osteotomy|The piezoelectric technique, another window preparation procedure that does not use a round bur, was first introduced to LSFE in 2001 for its high accuracy of osteotomy and low rate of membrane perforation. Later studies demonstrated that the operation time, postoperative reactions, and perforation rate of this procedure are considered to be acceptable compared with rotary bur. Moreover, the piezoelectric technique allows for the lateral bone window to be cut and preserved relatively completely.
223502489|NCT03569462|BEHAVIORAL|"Mobile WeChat intervention"|Participants watch a demonstration of HIV self-testing, receive HIV self-testing kits, and receive access to a mobile application that delivers content to promote HIV self-testing and reduce HIV risk behavior
223502490|NCT03569462|BEHAVIORAL|Control condition|Participants watch a demonstration of HIV self-testing and receive HIV self-testing kits.
223502491|NCT00589264|DIETARY_SUPPLEMENT|zinc|10 mg elemental zinc + 10 mg elemental iron + 0.5 mg copper syrup taken daily for 1 year, from 6 to 18 months of age
223502492|NCT00589264|DIETARY_SUPPLEMENT|iron + copper|10 mg elemental iron + 0.5 mg copper in syrup given daily for one year from 6 months to 18 months of age
223502493|NCT04079959|PROCEDURE|endometrial biopsy|. Endometrial samples are obtained using a biopsy catheter as follows: the Pipette is inserted through the cervical os and advanced gently until resistance is felt. The inner piton of the device is then withdrawn to create suction, and the endometrial sample is obtained by moving the pipette up and down approximately 2-3 cm within the uterine cavity. The device is rotated 360° to ensure adequate coverage of the area.
223502494|NCT03033628|DEVICE|injection using DentalVibe comfort system|giving maxillary infiltration injection of dental local anesthesia using DentalVibe comfort system.
223502495|NCT03033628|DEVICE|traditional dental injection|giving maxillary infiltration injection of dental local anesthesia without using DentalVibe comfort system.
223502496|NCT01980888|DRUG|Idelalisib|150 mg tablet administered orally twice daily
223592127|NCT02356679|DRUG|Stillen Tab.|three times per day, 1 tab for each time, PO, during 2weeks
223592128|NCT04042727|DRUG|Dexmedetomidine Hydrochloride|Six vials of Dexmedetomidine hydrochloride 100mcg/ml (2ml per vial) will be added to a 250mL bag of normal saline by the investigational pharmacy to prepare for infusion by patient's bedside nurse. Infusion rate will be 1mcg/kg/hr.
223502497|NCT01980888|DRUG|Bendamustine|Administered intravenously at a starting dose of 90 mg/m\^2 for up to 6 cycles. Dosing will be based on mg/m\^2 of body surface area.
223502498|NCT01980888|DRUG|Rituximab|Single-use vials administered intravenously weekly starting at 375 mg/m\^2 on Day 1 (Week 0) and 500 mg/m\^2 thereafter for a total of 6 infusions
223502499|NCT01980888|DRUG|Placebo|Placebo to match idelalisib administered orally twice daily
223502500|NCT02761538|BEHAVIORAL|AVIITAM|"The purpose of the project is to test the medico economic impact related to the utilization of the Aviitam online platform in primary care.~.~."
223502501|NCT02193152|DRUG|Pazopanib|
223502502|NCT03990753|DIAGNOSTIC_TEST|esophagogastroduodenoscopy|standard esophagogastroduodenoscopy
223502503|NCT02990962|DRUG|5% dextrose|Ultrasound-guided perineural injection with 5% dextrose (5cc) between carpal tunnel and surrounding median nerve with hydrodissection.
223502504|NCT02990962|DRUG|1cc 2% Xylocaine+4cc Triamcinolone (40mg)|Ultrasound-guided perineural injection with1cc 2% Xylocaine+4cc Triamcinolone (40mg) between carpal tunnel and surrounding median nerve with hydrodissection.
224193591|NCT02551900|OTHER|Land based cycling exercise|Land based cycling exercise training will be based on ride a bicycle ergometer (Monark 894e, Sweden). Land based cycling exercise training will be conducted at moderate intensity (60-70% maximum heart rate). The three groups were exercise 15 minutes on the first month, second month will be increased to 20 minutes and the last month will be increased to 30 minutes. The training program will be performed 3 times per week for 12 weeks.
224193592|NCT04374331|OTHER|video-assisted training|The patients in the VAT group watch a training video in the patient rooms before RCR. The VAT prepared by the researchers consisted of information about things to pay attention to in the hospital in the early period after RCR (nursing care on post-operative day 1, early mobilization, pain control, shoulder protection, and wearing/removing the shoulder sling), maintaining ADL at home (bathing, nutrition, eating, sleeping position, driving, doing household chores, sexual life, worship, and safety measures to be taken at home) and gradual exercise programs (for the first 90 days after discharge).
224193593|NCT01560806|OTHER|Commune Hypertension Management|"People with high blood pressure will be invited to join the management programme, with monthly check-up, delivery of multi anti-hypertensive drugs and lifestyle consultation.~Antihypertensive drugs delivered to local patients included (1) low-dose hypothiazide diuresis, (2) calcium channel blocker and (3) ACEI"
224310227|NCT00683579|OTHER|No treatment|No treatment. For group 2, participants do not yet meet DHHS guidelines. For group 4, treatment is not initiated due to unwillingness or providers' expectation of poor adherence.
224310228|NCT00683579|DRUG|HAART Treatment - standard care|Initiation of HAART per DHHS guidelines, i.e. starting treatment and CD4+ T cells less than 350 cells/mm3 or HIV RNA \>100,000 copies/ml
223502505|NCT00665639|DRUG|micafungin|IV
223502506|NCT00665639|DRUG|caspofungin|IV
223592129|NCT04042727|OTHER|Normal Saline|0.5% sodium chloride (NaCl). The investigational pharmacy will prepare the normal saline placebo 250mL bag for infusion by patient's bedside nurse. Infusion will be 1mcg/kg/hr.
223592130|NCT05460156|BEHAVIORAL|Bridges Self-management Support|Self-management support intervention tailored for people with neuromuscular diseases
223592131|NCT00565799|PROCEDURE|Omentectomy|Removing the omentum
223592132|NCT00565799|OTHER|No intervention|Only LAGB without Omentectomy
223592133|NCT06523257|DIAGNOSTIC_TEST|Spirometry|"Spirometry is a simple test used to diagnose and monitor lung diseases by measuring how much air a person can breathe out in one forced breath.~After the baseline spirometry, and only if there is clear evidence of an airflow limitation/obstruction, i.e., if the FEV1/FVC (forced expiratory volume in the first second/forced vital capacity) ratio is less than 70% or less than the 5th percentile of the distribution of values measured in the reference population, a bronchodilator test will be performed using standardised post-bronchodilator spirometry (200 µg salbutamol), in order to identify persistent airflow limitation/obstruction."
223592134|NCT01257035|OTHER|18F-FAZA-PET/CT|Contrast fluid injected prior to scan
223592135|NCT04203420|OTHER|screening and confirmatory tests|screening test is a blood test of the ratio of plasma aldosterone concentration(PAC) and direct renin concentration(DRC), confirmatory test is Captopril Challenge test
223592136|NCT03570320|OTHER|Modification of opioid prescription method|Patients in the interventional arm of the study will receive post-op opioid medications in three small prescriptions as opposed to one large prescription. They may fill these prescriptions as needed.
224193594|NCT01657773|OTHER|Ultrasound examination and Colonoscopy examination|
224310229|NCT03201965|DRUG|Cyclophosphamide|Participants will receive 300 mg/m\^2 of cyclophosphamide as an oral or IV dose.
223502507|NCT04569370|PROCEDURE|Laparoscopic Cholecystectomy|Surgical removal of Gall bladder using laparoscopy
224310230|NCT03201965|DRUG|Bortezomib|Participants will receive 1.3 mg/m\^2 of bortezomib as an subcutaneous (SC) injection.
224310231|NCT03201965|DRUG|Dexamethasone, 40 mg|Participants of CyBorD alone arm will receive 40 mg dexamethasone orally or IV dose. Participants of CyBorD plus daratumumab arm will receive dexamethasone 20 mg orally or IV dose as premedication and 20 mg on the day after daratumumab dosing to make a total of 40 mg.
224310232|NCT03201965|DRUG|Daratumumab|Participants will receive 1800 mg of daratumumab subcutaneously.
223502508|NCT03969420|DRUG|Alvocidib (flavopiridol) and cytarabine (Ara-C)|Alvocidib (flavopiridol), administered intravenously, + cytarabine (Ara-C), administered by subcutaneous injection
224310233|NCT03813810|OTHER|Non|There would be no interventions. Only measurements will be performed.
224310234|NCT02329847|DRUG|Ibrutinib|Participants will receive oral capsule of ibrutinib once daily as either 420 mg or 560 mg or at recommended Phase 2 dose in any of the cohort.
224310235|NCT02329847|DRUG|Nivolumab|Participants will receive nivolumab intravenously as 3 mg/kg on Day 1 every cycle of 14 days.
224310236|NCT06061068|PROCEDURE|Hernia belt compression|Use the hernia belt to compress the inguinal region
224310237|NCT05293639|DEVICE|Pulse Field Ablation|PFA ablation using a circular multi-electrode pulsed electrical field catheter and multichannel generator
224310238|NCT02143648|DRUG|nalbuphine HCl ER tablets 60 mg BID|nalbuphine HCl ER tablets 60 mg BID administered for 6 weeks
223502509|NCT03969420|DRUG|Alvocidib (flavopiridol)|Administered intravenously
223502510|NCT03878459|DRUG|Pioglitazone 45 mg|patients will be started on 15 mg and the dose escalated to the maximal tolerated dose
223502511|NCT03878459|DRUG|Placebo|PATIENTS WILL RECEIVE PLACEBO
223592137|NCT05378074|DRUG|Maxipost|Study participants will be allocated to receive continuous intravenous infusion of 0.05 mg/min MaxiPost.
223592138|NCT05378074|DRUG|Placebo|Study participants will be allocated to receive continuous intravenous infusion of 20 mL placebo (isotonic saline).
223592139|NCT01274910|DIETARY_SUPPLEMENT|EPAX 6000 EE 1000mg (0.6 gr DHA+EPA)|"Patient will receive Fish Oil capsules (EPAX 6000 EE) .~Treatment: 5 capsules per day"
223592140|NCT01274910|DIETARY_SUPPLEMENT|Capsules (Placebo)|"Patient will receive capsules which not contain fish oil.~Treatment: 5 capsules per day"
223592141|NCT04692142|OTHER|Flipped classroom teaching method|Participants will have 7 -day monitored remote access to a recorded lecture about orthodontic topic. At the expiry of remote access to the recorded lecture, participants from FG will be invited to attend post-lecture discussion sessions. To enhance the effectiveness of flipped classroom teaching method, the cohort of FG will be randomly, using computer generated randomisation, subdivided to two smaller groups in which each group will be consisted of half of the FG cohort. The same lecturer will moderate the discussions for each group separately.
224193595|NCT05031156|PROCEDURE|Splinting of OT Bridge system|splinting of implant abutment using titanium wire followed by pick up using the patient's denture
223502512|NCT05835700|OTHER|Gasdermin-d|Maternal serum Gasdermin-D levels in preterm labor and healthy pregnant women.
223502513|NCT01550185|DRUG|eltrombopag olamine|Given PO
223502514|NCT01550185|PROCEDURE|standard follow-up care|Receive standard care
223502515|NCT01003626|PROCEDURE|Tumor Interstitial Fluid Pressure (IFP) assessments|The tip of a needle will be inserted in a skin lesion (similar to a biopsy needle) for up to 3 tumors. The needle is connected to a machine that reads the pressure inside the tumor. The whole process, including cleaning and numbing the lesion, will take about 3-4 minutes.
223502516|NCT01003626|DEVICE|Transducer-catheter SPC-320 + Amplifier|Transducer-tipped catheter Mikro-Tip SPC-320 and transducer Millar with Power Lab used to assess the interstitial fluid pressure in a malignant melanona nodule
223502517|NCT03537677|BEHAVIORAL|Reduction in Sedentary Behavior|This 12-week intervention targets a reduction in prolonged sitting and includes provision of a wrist-worn activity prompter and in-person group sessions with behavioral counseling.
223502518|NCT00222274|BEHAVIORAL|RSA Biofeedback|RSA Biofeedback Condition. The biofeedback will consist of 10 weekly sessions of training, at the same time of day for each subject. The details of the procedure for RSA biofeedback are described in Appendix A. One single practitioner, a certified biofeedback technician, will provide the biofeedback following the aforementioned protocol. In each session, 20 minutes of biofeedback will be delivered using a J\&J C-2+ Physiograph. The participant will be taught to breathe at her resonant frequency, as a first step to training the individual how to produce maximal increases in amplitude of RSA.
224193596|NCT00243620|DEVICE|Vacuum therapy (device)|
223502519|NCT00222274|BEHAVIORAL|EEG Biofeedback Condition|EEG Biofeedback Condition. Participants assigned to this condition will receive 10 sessions of EEG alpha biofeedback. In each session, 20 minutes of biofeedback will be delivered using a J\&J I-330-C2+ physiograph. The participant will learn how to modify specific brainwave activity known as alpha. In particular, participants will be taught to increase amplitude of alpha in the range of 8-12 Hz. Increased amplitude is this range is associated with relaxation and reduction of anxiety, but not baroreflex gain. Participants will also practice for two 20-minute periods daily using the same methods used to increase alpha found in lab sessions.
223502520|NCT06470724|BEHAVIORAL|Structural visual approach|"The intervention comprised seven behavior approaches in this research defined as follows:~A successive approach: An approach to familiarization with the unfamiliar environment of the simulated dental office.~Tell-Feel-Show-Do (T-F-S-D): A dental approach explained to the patient's treatment by telling the patient what would happen, what he felt or did, and what had been done.~Visual pedagogy: Introduced dentistry to autistic children through visual media, such as pictures and photographs.~Audiovisual modeling: A learning process through audiovisual media, such as video and animation.~In-vivo modeling: Learning new activities by watching them in front of the model.~Behavioral trials: A learning strategy conducted through practicing the recent activity by him/herself.~Auto-modeling: A learning process following the activity of editing pictures during the prior visit of the patient."
223502521|NCT01197027|BEHAVIORAL|Standard counseling|Standard HIV counseling
223502522|NCT05788926|DRUG|TG6050|Oncolytic Vaccinia virus containing genes encoding the human interleukin 12 (IL-12) and an anti-CTLA4 antibody administered at different dose.
223502523|NCT05086692|DRUG|MDNA11|MDNA11 will be administered, IV on a once every 2 weeks (Q2W) dosing schedule. Provisional dose cohorts for monotherapy dose escalation doses ranging from 0.003 to 0.6 (mg/kg): until determining the monotherapy Recommended Dose for Expansion (mRDE).
224193597|NCT04252196|DEVICE|usability evaluation of medical device|participants interact with medical device and rate it for usability
224193598|NCT04155567|DRUG|TAK-123|TAK-123 infusion
224193599|NCT00003266|DRUG|methylphenidate hydrochloride|
224193600|NCT00003266|PROCEDURE|quality-of-life assessment|
224193601|NCT03439319|DEVICE|MyndMove®|This FES therapy can be used as a short-term therapeutic intervention to help improve voluntary grasping function
224193602|NCT03439319|OTHER|Conventional Therapy|Conventional training involves repetitive practice of upper extremity movements with manual assistance provided by a therapist as needed.
224193603|NCT06221111|DRUG|Rimegepant 75 MG [Nurtec]|placebo controlled trial
224193604|NCT00000968|BIOLOGICAL|gp160 Vaccine (Immuno-AG)|
224193605|NCT02596074|DRUG|Omiganan (CLS001) topical gel|
224193606|NCT02596074|DRUG|Vehicle topical gel|
224193607|NCT00138866|DRUG|Risedronate|
224193608|NCT01463631|DRUG|LY3007113|Administered orally
224193609|NCT06004518|OTHER|sexual counselling with PLISSIT model|sexual counselling with PLISSIT model
224193610|NCT05847023|BEHAVIORAL|LUNA|see description above
224193611|NCT04689334|OTHER|Outcome|The number of surgeries
224193612|NCT03741530|DRUG|Glibenclamide Tablets|Giving glibenclamide tablets, 1.25 mg 3 times daily, orally or through gastric tube, for 7 consecutive days after enrollment.
224193613|NCT03741530|OTHER|Standard management for ICH|Usual care and drug in hospital
224193614|NCT04136509|PROCEDURE|sinus floor elevation|sinus floor elevation with the lateral technique
224193615|NCT04136509|PROCEDURE|bone core biopsy|After 6 month healing time reentry took place and bone core biopsy samples were collected from the augmented bone of the maxillary sinuses with a trephine drill. Biopsy samples were collected from the sites where the dental implants were to be placed.
224193616|NCT04136509|DEVICE|dental implant placement|During reentry after bone biopsy dental implants were placed.
224193617|NCT04136509|DIAGNOSTIC_TEST|Cone Beam Computed Tomography scans (CBCT)|Preoperative CBCT scans are carried out before dental implant placement, 6 months after sinus floor elevations. Postoperative CBCT scans are taken 3 years after sinus floor augmentations.
224193618|NCT03441828|PROCEDURE|Quality of surgical field conditions|evaluation of the intraoperative surgical conditions assessed by the surgeon as a 5 points scale (Optimal= 5 points/ Good= 4 points / Adequate= 3 points / Poor = 2 points / Inadequate = 1 point) given by deep vs moderate neuromuscular block
224193619|NCT03441828|DRUG|Deep Neuromuscular Block|maintenance of a deep neuromuscular block by infusion of rocuronium
224193620|NCT03441828|DRUG|Moderate Neuromuscular Block|maintenance of a moderate neuromuscular block.
224310239|NCT02143648|DRUG|nalbuphine HCl ER tablets 120mg BID|nalbuphine HCl ER tablets 120mg BID administered for 6 weeks
224193621|NCT01102881|DIETARY_SUPPLEMENT|Glucose polymer fiber|20 grams of fiber per day split into two 10 gram doses administered as a breakfast cereal and a muffin or no-fiber breakfast cereal and muffin
224193622|NCT01102881|DIETARY_SUPPLEMENT|Fiber made from corn starch|20 grams of fiber per day split into two 10 gram doses administered as a breakfast cereal and a muffin or no-fiber breakfast cereal and muffin
224193623|NCT01102881|DIETARY_SUPPLEMENT|placebo|low fiber breakfast cereal and muffin
224193624|NCT05798325|OTHER|2MWT|Two minutes walk tests.
224193625|NCT05798325|OTHER|MFM32|Motor Function Measurement (MFM) is a quantitative scale created to measure global motor functional abilities in a person with neuromuscular disease.
224193626|NCT05798325|OTHER|MyoGrip|The MyoGrip is a dynamometer for measuring grip strength.
224193627|NCT05798325|OTHER|QOL-gNMD|"The Quality of Life in genetic Neuromuscular Disease questionnaire (QoL-gNMD) is a patient reported outcome measure (PROM) tool specifically designed for patients with a lowly progressive neuromuscular disease with genetically predominant muscular damage"
224193628|NCT05798325|DIAGNOSTIC_TEST|Spirometry|Forced vital capacity (FVC), peak expiratory flow (PEF) and forced expiratory volume in 1 second (FEV1) will be measured in the hospital with the local hospital device (e.g. Vitalograph) under the supervision of the clinical evaluator, and at home with a portable device.
224193629|NCT05798325|DEVICE|Acceleromerty|The Links sensor system is a measuring device and consists of the Links Pods and the Links Hub. The Links pods contain an accelerometer, gyroscope and magnetometer to measure position relative to a global reference frame.
224193630|NCT05798325|OTHER|10mWT|10 meters walking Test.
224193631|NCT05798325|OTHER|PUL|The Performance of the Upper Limb (PUL) is a functional scale specifically designed for assessing upper limb function in Duchenne muscular dystrophy.
224193632|NCT05798325|OTHER|NSAA|The North Star Ambulatory Assessment (NSAA) is a 17-item rating scale that is used to measure functional motor abilities in ambulant children with Duchenne Muscular Dystrophy.
224193633|NCT05798325|OTHER|NSAD|The NSAD was developed to measure motor performance in ambulant and non-ambulant subjects as part of the clinical outcome study of dysferlinopathy.
224193634|NCT05798325|OTHER|TANS|This scale is derived from the North Star Ambulatory Assessment and several items from the Egan Klassifikation Scale (EK2).
224193635|NCT05798325|OTHER|MyoPinch|The MyoPinch is a high-precision dynamometer that allows the evaluation of key pinch strength.
224193636|NCT05798325|OTHER|MyoQuad|The MyoQuad is a high-precision dynamometer that allows the evaluation of knee extension strength.
224193637|NCT05798325|OTHER|ACTIVLIM|Activity limitations, as measured by ACTIVLIM, is defined as the difficulties a patient may have in executing daily activities, whatever the strategies involved.
224193638|NCT05798325|OTHER|PREM|This questionnaire is made up of simple questions relating to the assessments and assessment tools that were used during the study.
223502524|NCT05086692|DRUG|Pembrolizumab (KEYTRUDA®)|MDNA11 will be administered in combination with pembrolizumab, IV. MDNA11 dose range to be evaluated in combination with pembrolizumab until determining the combination Recommended Dose for Expansion (cRDE).
223502525|NCT03033433|DRUG|DCB-DM101|determination of optimal dose for Stage 2
223502526|NCT01922297|OTHER|Day Treatment MDFT-HIV|MDFT-HIV is a specialized intervention aimed at reducing risk factors for HIV-associated sexual behaviors. It builds protective behaviors in the adolescent's intrapersonal and interpersonal functioning, as well as those aspects of family functioning to reduce youths' high-risk sexual behavior. For instance, interventions target inadequate monitoring, parent-adolescent conflict, and parental disengagement - behaviors consistently associated with elevated HIV/STD risk. It facilitates positive and supportive family relationships, processes that can significantly reduce HIV/STD risk. Additionally, it aims to promote effective family communication about sexuality and safer sexual behaviors, among the most important protective factors against sexual risk taking behavior.
223502527|NCT01922297|OTHER|Day Treatment SAU|Substance abuse treatment and HIV prevention services are routinely provided to youth in the day treatment programs. The day treatment programs contract to local substance abuse and mental health providers for these services that are provided both within and outside of the day treatment setting. The intervention's specific features are similar to those found in the literature on outpatient peer-based group treatment for adolescent alcohol abusers (CSAT 1998). Specifically, it is based on a cognitive-behavioral group treatment model (Kaminer et al 1998; Marshall \& Marshall 1993), with a comprehensive treatment package including individual counseling and treatment planning.
223502528|NCT06021496|BEHAVIORAL|face to face health education|Face-to-face health education with home visit
223502529|NCT06021496|BEHAVIORAL|online health education|online health education with video call
223502530|NCT00411541|DRUG|vincristine|
223502531|NCT00411541|DRUG|dexamethasone|
223502532|NCT05571488|OTHER|Electronic surveys|Online questionnaires will be used to collect data, at recruitment and follow-up once a year
223502533|NCT05571488|OTHER|Qualitative Interviews|Remote focus groups or semi-structured interviews will be proposed to a subsample of the participants, first the year after recruitment and then every two years
223502534|NCT05068115|PROCEDURE|Clinical characteristics, diagnosis and treatment, survival status|Describe the clinical characteristics, diagnosis and treatment, survival status and the trends of young breast cancer
223502535|NCT05363800|DRUG|HRS-3738|HRS-3738 will be administrated per dose level in which the patients are assigned.
223502536|NCT02469909|OTHER|Overnight observation|patients in the immediate decannulation group would be admitted for an overnight in intensive care unit or the otolaryngology department. they would be monitored for any respiratory or airway complications.
223502537|NCT02469909|OTHER|Pre-discharge evaluation|After an overnight observation, patients in the immediate decannulation group would would undergo clinical and laboratory evaluation including vital signs and blood gases.
223592142|NCT02597140|DRUG|lidocaine|Patients in lidocaine group will be received an intravenous bolus injection of 1.5 mg/kg lidocaine followed by a continuous infusion of 2 mg/kg/hr lidocaine.
224193639|NCT05798325|OTHER|SF-MPQ|The main component of the SF-MPQ consists of 15 descriptors (11 sensories; 4 affective) which are rated on an intensity scale as 0 = none, 1 = mild, 2 = moderate or 3 = severe.
224193640|NCT05798325|OTHER|FSS|The Fatigue Severity Scale is used to assess the severity of fatigue and its impact on daily living. The patient responds on a Likert-type scale ranging from 1 to 7.
223746517|NCT03503903|PROCEDURE|Wet Cupping|CT was applied using plastic disposable vacuum cups on the back in the 5 areas of C7 cervical spine (DU14 acupoint), T2-4 lateral spine bilaterally (BL41-42 acupoint) and T6-8 lateral spine bilaterally (BL44-46), which are the recommended sites for headache (12). The cupping technique procedure was conducted in five phases:Primary suction,Area disinfection,Scarification,Secondary suction and bloodletting,Removing and dressing.
223746518|NCT02327858|OTHER|Supportive text messages|Patients in all the intervention groups will receive twice daily supportive SMS text messages for 3 months. The messages will be tailored towards improving mood, compliance with medication or targeting abstinence from alcohol in accordance with the primary aims of our study. As far as possible, the majority of the text messages will reflect lessons patients usually learn during CBT and addiction counselling sessions.
224193641|NCT05798325|OTHER|IPAQ|This questionnaire assesses overall physical activity and the level of sedentary lifestyle during the last seven days.
224193642|NCT05798325|OTHER|Rang of motion|The EasyAngle® is a digital goniometer improving long established goniometric functionality with rotation, inclination, and scoliosis measurement capabilities.
224193643|NCT05798325|DEVICE|Goniometry|The Links sensor system is a measuring device and consists of the Links Pods and the Links Hub. The Links pods contain an accelerometer, gyroscope and magnetometer to measure position relative to a global reference frame.
224193644|NCT05798325|OTHER|Video captured monitoring|"Once every four weeks, while wearing the Yumen electronic goniometers (Links Sensor System), the patients will be asked to record on video three tasks related to:~1. Upper limbs: hands to head~2. Lower limbs: Sit to stand with or without the help of a person~3. Self-defined important task: A task of the patient's choice, from a list of tasks, representative of his/her motor difficulties or hindrance to autonomy."
224193645|NCT05798325|DEVICE|Activity monitoring|Wearable devices (connected watch) will collect health-related data on a 24/7 basis remotely as patients go through their daily routines at home and work.
224193646|NCT02823223|DEVICE|Zephyr endobronchial valve placement|Patients will have ELVR (Endoscopic Lung Volume Reduction) with Zephyr valve inserted into the target lobe of the lung with the aim of complete lobar exclusion.
224193647|NCT01997060|BEHAVIORAL|Intensive Lifestyle Intervention|
224193648|NCT00667069|DRUG|triptorelin|
224193649|NCT00667069|PROCEDURE|adjuvant therapy|
224193650|NCT00667069|RADIATION|3-dimensional conformal radiation therapy|
224193651|NCT06502002|DRUG|Dexmedetomidine Hydrochloride|Initial dexmedetomidine bolus of 1 mcg/kg over 30 min after induction, followed by an infusion rate of 0.3 mcg/kg/hr that will be stopped 30-45 minutes before the end of the surgery or once a maximum dose of 2mcg/kg has been achieved, whichever comes first.
224310240|NCT02143648|DRUG|Placebo tablets BID|Placebo tablets BID administered for 8 weeks
224310241|NCT05067621|DRUG|Semaglutide Pen Injector|Semaglutide (Wegovy) pen is a subcutaneous injection that contains 2.4mg/0.75mL of active ingredient. The injection pen can deliver doses of 0.24mg, 0.5mg, 1.0mg, 1.7mg, and 2.4mg.
224310242|NCT05067621|DRUG|Placebo|Injection pen contains excipients.
223502538|NCT02469909|OTHER|outpatient clinic follow ups|all patients would visit the otolaryngology outpatient clinic in 7, 30 and 90 days following decannulation for an evaluation of any respiratory complications following decannulation
223502539|NCT02469909|PROCEDURE|immediate decannulation|the tracheostomy tube is removed at once
223502540|NCT02469909|PROCEDURE|Gradual tracheostomy tube decrease|The tracheostomy tube will be reduced in 2 sizes compared with the initial inner diameter of the tube. The patients will remain with the reduced tube for 48 hours, and the tube will be removed if the patients would meet pre-decannulation evaluation
223502541|NCT06596486|OTHER|CoolStick|Assessment of block using CoolStick.
223502542|NCT06596486|OTHER|Ethyl Chloride|Assessment of block using ethyl chloride spray
223502543|NCT06596486|OTHER|Question|Participant will be asked if they felt pain or not.
223502544|NCT04333459|BIOLOGICAL|Hataan DNA Vaccine/Puumala DNA Vaccine|Vaccine compared in High and Lose Doses.
223502545|NCT01801605|PROCEDURE|rTMS|Active session with stimulation and placebo session with fictive stimulation
223502546|NCT06985875|DEVICE|Multidose mosturizing solution DROP 0.4%|Ophthalmic mosturizing solution to be administered 1-4 times per day in both eyes
223502547|NCT06985875|DEVICE|Multidose mosturizing solution Avizor Eye Drops 0.2% Preserved|Ophthalmic mosturizing solution to be administered 1-4 times per day in both eyes
223502548|NCT06990854|DEVICE|Electroacupuncture (Hans-100A, Nanjing Jisheng Medical Technology, China)|"Acupoint prescription: The therapeutic protocol utilized Ashi points (localized to herpetic lesion areas) and Jiaji points (EX-B2, ipsilateral to affected dermatomes).~Acupuncture procedure: For Ashi points, sterile disposable needles (0.25 mm diameter, 40 mm length) were inserted at a 15° angle to a depth of 15-20 mm, without deqi sensation or manual manipulation. For Jiaji points (EX-B2), needles (0.30 mm diameter, 50 mm length) were inserted perpendicularly to a depth of 40-45 mm, with twisting manipulation (90° rotation at 90 cycles/min) until patients felt soreness, numbness, or distension. Electroacupuncture was applied using the Hans-100A device, with dense-disperse wave mode (2/100 Hz) and intensity adjusted to patient tolerance, for 30 minutes."
223592143|NCT02597140|DRUG|normal saline|Patients in control group will be received an intravenous bolus injection of 1.5 mg/kg normal saline followed by a continuous infusion of 2 mg/kg/hr normal saline.
223592144|NCT02597140|DRUG|propofol|Propofol will be administered using target controlled infusion during monitored anesthesia care to adjust 60 to 80 of bispectral index.
223592145|NCT06258096|DEVICE|LX2.3 Laser and LED Photobiomodulation System|The LX2.3 Laser and LED Photobiomodulation system by THOR Photomedicine Ltd is a CE marked product and has a long track record of safety, usability, and effectiveness.
223746519|NCT00206453|DRUG|Taxotere|Chemotherapy IV
223746520|NCT02761707|OTHER|Electrical Brainstem Responses|Eye blink responses will be induced using standard stimulating electrodes employed in surface electromyography (EMG). The subjects will recline with their eyes gently closed. Sticky electrodes will be placed to the left and below the left eye. 6 different facial regions will be stimulated. The electrical stimulation will be kept constant during the test sessions. To prevent habituation, the stimuli will be delivered randomly at intervals of 45-60 sec. Four 0.2 msec pulses will be presented. In some cases, paired pulse stimulation will be performed, and a conditioning stimulus will be applied to the target facial regions at the following intervals: 10, 200, 400, 600 and 800 msec. 4 pulses will be presented at each stimulus interval with randomized interval and pulse sequences.
224193652|NCT06502002|DRUG|Placebo|normal saline infusion
224193653|NCT05966129|OTHER|Pharmacogenetic testing|Genetic testing of CYP2D6 and CYP2C19
224193654|NCT05966129|OTHER|Clinical decisions support|Prescribing recommendations to the provider based on the pharmacogenetic testing results
224193655|NCT04394858|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
224193656|NCT04394858|PROCEDURE|Computed Tomography with Contrast|Undergo CT with contrast
224193657|NCT04394858|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
224193658|NCT04394858|DRUG|Olaparib|Given PO
224193659|NCT04394858|OTHER|Quality-of-Life Assessment|Ancillary studies
224193660|NCT04394858|DRUG|Temozolomide|Given PO
224193661|NCT05891834|DRUG|INV-202|tablet, once daily, oral
224193662|NCT05891834|DRUG|Placebo|tablet, once daily, oral
224193663|NCT04963777|DIETARY_SUPPLEMENT|Prebiotic|Chicory root derived inulin-type fructan (13.2 kcal/day for ages 8-13 years; 26.4 kcal/day for ages ≥14 years)
224193664|NCT04963777|DIETARY_SUPPLEMENT|Placebo|Maltodextrin (isocaloric; 13.2 kcal/day for ages 8-13 years; 26.4 kcal/day for ≥14 years)
224193665|NCT05354349|DRUG|PRA023 IV Low Dose|Drug
224193666|NCT05354349|DRUG|PRA023 SC|Drug
224193667|NCT05354349|DRUG|Placebo IV|Placebo
224193668|NCT05354349|DRUG|Placebo SC|Placebo
224193669|NCT05354349|DRUG|PRA023 IV High Dose|Drug
224193670|NCT04516798|OTHER|vibration|local and whole-body vibration were applied
224193671|NCT02440490|BEHAVIORAL|Computerised cognitive training|
223502549|NCT06990854|DRUG|Pharmacotherapy：① Pregabalin ( Lyrica™ ，Pfizer Inc. America) ② Methylcobalamin ( Mecobalamin tablets， Weicai (China) Pharmaceutical Co., Ltd， China）|Patients received protocol-guided therapy consisting of: ① Pregabalin: Initial dose 75 mg twice daily. Dose may be titrated upward to 150 mg twice daily within one week based on therapeutic response and tolerability. Gradual discontinuation is recommended when clinically appropriate, tapered by 100 mg decrements every 3-7 days. ② Methylcobalamin: 5 mg three times daily.
223502550|NCT06990854|PROCEDURE|Streitberger Placebo Needle Set ( Asiamed )|The Streitberger needle, a widely reported placebo needle device in acupuncture RCTs, was applied for sham intervention. This telescoping blunt-tip needle achieves non-penetrating placebo stimulation through its retractable design. Its key advantage lies in evoking a skin-penetrating sensation akin to true needling through tissue compression, while avoiding actual dermal perforation to minimize specific therapeutic effects. Following the perception of needle insertion reported by patients, the device is retracted by approximately 1 mm and connected to electroacupuncture apparatus without electrical stimulation activation.
224193672|NCT02440490|BEHAVIORAL|Video watching|
224193673|NCT03666494|DRUG|Ketamine Hydrochloride|As part of anesthetic induction, the addition of ketamine hydrochloride 0.5mg/kg.
224193674|NCT03666494|DRUG|Propofol|As part of the patient's anesthetic induction, they will receive propofol.
224193675|NCT03666494|DRUG|Fentanyl|As part of the patient's anesthetic induction, they will receive fentanyl.
224193676|NCT05508308|DEVICE|OxyMate|Automated Oxygen Control algorithm (VDL 1.1) coupled with Diamedica Baby CPAP device
224193677|NCT05508308|OTHER|Manual oxygen control|Guidelines and training in FiO2 titration to achieve a target range of SpO2. Health workers instructed in responding to continuous pulse oximetry readings and alarms
224193678|NCT03122899|DEVICE|SIJ fusion with iFuse-3D|Minimally invasive SIJ fusion with iFuse-3D titanium implant (usually 3 implants per SIJ).
224193679|NCT06380075|DEVICE|Spectralis FAF imaging|Spectralis is a scanning laser ophthalmoscope which uses a blue light excitation wavelength of 488nm and a 500nm barrier filter to produce FAF images. Spectralis images 20-55 degrees of the retina.
224193680|NCT06380075|DEVICE|Optos imaging|Optos is an ultrawide field imaging platform which images up to 200 degrees of the retina. It uses both a green-light excitation wavelength of 532nm and a red-light excitation wavelength of 633nm with an emission filter of greater than 540nm to produce FAF images.
224193681|NCT06380075|DEVICE|Clarus imaging|Clarus 700 is an ultrawide field imaging system with similar retinal coverage to that of Optos. It uses Broad Line Fundus Imaging to produce blue FAF images at excitation wavelengths of 435-500nm and green FAF images at wavelengths of 500-585nm
224193682|NCT05053334|DRUG|Omalizumab Prefilled Syringe|150mg/ml of Omalizumab prefilled syringe
224193683|NCT00045136|DRUG|melphalan|
224193684|NCT00045136|PROCEDURE|peripheral blood stem cell transplantation|
224193685|NCT00045136|RADIATION|holmium Ho 166 DOTMP|
224193686|NCT00555711|DEVICE|Modulated Imaging|Modulated Imaging
224193687|NCT06011668|DEVICE|video game playing, kaleidoscope and virtual reality glasses|This thesis study was conducted with randomized controlled methods for control in order to analyze the effect of drawing attention to different directions during intramuscular use in countries to what extent the methods of drawing attention to pain and anxiety.
224193688|NCT05195242|DRUG|Dexamethasone|ATC code H02AB02
224193689|NCT00657176|DRUG|OPB-31121|"* 100mg tablet~* oral administration, Qd"
224193690|NCT06999486|OTHER|CAT well-being test|Evaluate the psychometric properties (e.g., reliability, validity) of the Computerized Adaptive Testing (CAT) system for assessing the well-being of caregivers of children with Type 1 Diabetes (T1D).
224193691|NCT07007455|BEHAVIORAL|wrist extensor strength training with BFR.|Wrist extensor strength training without BFR.
224193692|NCT06653725|DIETARY_SUPPLEMENT|1,3-butanediol|1,3-butanediol (Ketone-IQ®) 118 mL (33 g) servings trice daily
224193693|NCT06653725|DIETARY_SUPPLEMENT|Placebo|Taste-matched placebo (isovolumic, isoviscous water with stevia) 118 mL servings trice daily
224193694|NCT03151928|DIAGNOSTIC_TEST|BDMax Vaginal Panel|The tests will be used to compare results between clinician diagnosis/routine care testing and the above interventions
224193695|NCT03137212|COMBINATION_PRODUCT|thrombolysis and PCI of A type|STEMI patients first are given thrombolysis and then transfer to PCI centers to be treated by PCI 3-6 hours after thrombolysis.
224193696|NCT03137212|COMBINATION_PRODUCT|thrombolysis and PCI of B type|STEMI patients first are given thrombolysis and then transfer to PCI centers to be treated by PCI 6-24 hours after thrombolysis.
224193697|NCT05810415|DIAGNOSTIC_TEST|Renin levels and lactic acid levels|Sampling of blood for measuring renin and lactate
224193698|NCT05818215|OTHER|NO intervention|NO intervention
224193699|NCT05978063|DRUG|difelikefalin 2.0 mg tablets|Oral difelikefalin 2.0 mg administered twice daily
224193700|NCT05978063|DRUG|difelikefalin 1.0 mg tablets|Oral difelikefalin 1.0 mg administered twice daily
223502551|NCT06612203|DRUG|Debio 0123 and Sacituzumab govitecan|Debio 0123 will be administered orally during 6 days of each 21-day cycle in combination with 10 mg/kg of Sacituzumab govitecan administered intravenously on D1 and D8 of each 21-day cycle until documented disease progression, death, unacceptable toxicity, or discontinuation from the study treatment for any other reason, whichever occurs first.
223502552|NCT02429440|BIOLOGICAL|peptide vaccine|subcutaneous
223502553|NCT02429440|DRUG|Granulocyte Macrophage Colony Stimulating Factor|intradermal
223502554|NCT02429440|DRUG|Montanide ISA-51|subcutaneous
223502555|NCT06989099|PROCEDURE|Immediate Lymphatic Reconstruction (ILR)/|Given by Procedure
223502556|NCT06989099|PROCEDURE|Prophylactic Lymphovenous Bypass (pLVB)|Given by Procedure
223502557|NCT06989762|DEVICE|Conventional Foley Catheter(Medline)|The Conventional Foley Catheter is a standard urinary catheter used in ICU care to monitor urine output. It does not have intra-abdominal pressure (IAP) monitoring capabilities.
223502558|NCT06989762|DEVICE|Accuryn Foley Catheter|The Accuryn Foley Catheter is an FDA-approved urinary catheter with continuous intra-abdominal pressure (IAP) monitoring capability.
223502559|NCT06307080|DEVICE|Multi-mode thermal ablation device|The tumor tissue was rapidly frozen until the ice ball exceeded 5mm of the lesion tissue, kept for 5 minutes, then thawed and warmed. Then, complete ablation was performed according to the radiofrequency temperature control mode of multimodal tumor therapy to ensure that the ablation area included a safe range of 5\~10mm around the tumor.
223502560|NCT06307080|DRUG|Intravenous anti-PD-1 and chemotherapy|intravenous anti-PD-1 and chemotherapy
223502561|NCT06993389|OTHER|Inapplicable|Inapplicable
223502562|NCT00995878|PROCEDURE|Focused ultrasound (MRgFUS)|MRgFUS treatment will take place in a MRI machine and powerful ultrasound waves go through the abdominal wall to destroy the fibroid or fibroids. No incision is made during this treatment and light sedation is required. There are certain fibroids that may not be treated with this technique and there is no treatment of normal uterine tissue.ough the abdominal wall to destroy the fibroid.
223502563|NCT00995878|PROCEDURE|Uterine artery embolization (UAE)|UAE treatment takes place on a regular x-ray machine. A small incision is made where the leg meets the trunk and a small tube is used to use very small pellets to block off the blood supply to the entire uterus. Sedation is used. Most fibroids are treated with this technique and normal uterine tissue is also affected.
223502564|NCT04978779|DRUG|VIP152|Weekly IV infusion for 28 day cycles.
223502565|NCT04978779|DRUG|BTKi|Taken per local prescribing information
223502566|NCT03691532|BEHAVIORAL|Seated control (CON)|Seated rest
223502567|NCT03691532|BEHAVIORAL|Arm cycle exercise (ACE)|Arm cycling at a continuous power output
223502568|NCT03691532|BEHAVIORAL|Liquid meal|Liquid meal of 0.5 L volume containing 20 kcal/kg fat free mass (FFM) and 5 mg/kg FFM of uniformly 13-carbon labeled palmitate (\[U-13C\]palmitate) at a macronutrient distribution of 50% carbohydrate, 35% fat, and 15% protein (by kcal).
223502569|NCT06675578|DRUG|Tulsi gel|After scaling and root debridement, 4% of Tulsi gel will be injected in to the sulcus until it over flooded, at base line, then after one month.
223502570|NCT06675578|DRUG|Chlorhexidine gel|After scaling and root debridement, 1% of Chlorhexidine gel will be injected in to the sulcus until it over flooded, at base line, then after one month.
223502571|NCT05339438|RADIATION|functional MRI|Functional MRI scanning (around 1h30 min): SMS + multi-band (with FPVS paradigms for both)
223502572|NCT05965895|PROCEDURE|Ultrasound-guided continuous serratus anterior plane block|Patients will receive US-guided SAP block with a bolus of 2 mg/kg levobupivacaine made up to a volume of 40 ml followed by an infusion of 0.125% levobupivacaine will be commenced at rate of 8 ml/hr for 48 hr.
223502573|NCT05965895|DRUG|intravenous dexmedetomidine infusion|Patients will receive initial loading dose of dexmedetomidine of 1 µg/kg over 30 min followed by a continuous infusion at a rate of 0.5 µg/kg/hr for 48 hr.
223502574|NCT04851717|DRUG|Remimazolam|Remimazolam for intravenous sedation
223502575|NCT03928431|OTHER|Maternal microbiota|See arm descriptions
223502576|NCT06676722|DRUG|SBRT combined with Nimotuzumab followed by Tislelizumab|BRT combined with 3 cycles of Nimotuzumab 400mg qw followed by maintain Tislelizumab for 2 years or until disease progression
223502577|NCT07000955|DRUG|Tirzepatide|Tirzepatide administered subcutaneously (SC) once a week.
223502578|NCT07000955|DRUG|Placebo|Placebo administered subcutaneously (SC) once a week.
223502579|NCT07000955|DRUG|IBI362|IBI362 administered subcutaneously (SC) once a week.
223502580|NCT05762744|DRUG|Exenatide Injection (before the first FSIGT)|"Nurses administered exenatide (5 mcg) subcutaneously 15 minutes prior to conducting the first frequently sampled intravenous glucose tolerance test.~In this crossover study, participants will also be crossed over to receive saline rather than exenatide: Nurses administered saline (0.2 mL) subcutaneously 15 minutes prior to conducting a frequently sampled intravenous glucose tolerance test."
223502581|NCT05762744|DRUG|Exenatide injection before the second FSIGT)|Nurses administered exenatide (5 mcg) subcutaneously 15 minutes prior to conducting the second frequently sampled intravenous glucose tolerance test.
223502582|NCT00789165|DRUG|quinidine|quinidine at highest tolerated dose. Expected doses are hydroquinidine 600 - 900 mg daily.
223502583|NCT00789165|DRUG|no therapy|No therapy; this is not a placebo-controlled trial
224193701|NCT05978063|DRUG|difelikefalin 0.25 mg tablets|Oral difelikefalin 0.25 mg administered twice daily
223502584|NCT04817072|OTHER|Blood sample|Blood sample (20mL) for pro-inflammatory cytokines assay
223502585|NCT07009860|DRUG|Pemvidutide|Pemvidutide 2.4 mg
223502586|NCT07009860|OTHER|Placebo|Subcutaneous injection
223502587|NCT07012694|DEVICE|22G Franseen Needle Group|Fine-needle-biopsy (22G Franseen, Boston Scientific, Winston-Salem, USA)
223502588|NCT07012694|DEVICE|22G Adapt Needle Group|Fine-needle-biopsy (22G Adapt, Micro.Tech Endoscopy, Nanjing, China)
223502589|NCT07008534|PROCEDURE|Patients receiving computer-guided immediate implant placement and inferior alveolar nerve (IAN) lateralization only.|Standard procedure without Sticky Bone application.
224193702|NCT05978063|DRUG|Placebo tablets|Oral Placebo administered twice daily
224193703|NCT07031193|PROCEDURE|Foam roller instructions for pain reduction|Foam rolling procedure with pain reduction instructions over hamstring muscle group
224193704|NCT07031193|PROCEDURE|Foam rolling for range of motion improvement|Foam rolling over hamstring muscle group with range of motion improvement instructions.
224193705|NCT02186548|PROCEDURE|Closed surgical technique|"* Surgically uncovering of the impacted canine with a mucoperiosteal flap dissected off the bone~* The bone covering the canine is being removed~* Attachment with a chain is bonded to the exposed tooth~* The palatal flap is repositioned and sutured back with the chain above the mucosa. Shortly after the surgery~* The canine is orthodontically moved beneath the palatal mucosa"
224193706|NCT02186548|PROCEDURE|Open surgical technique|"* Surgically uncovering of the impacted canine, removing a window of tissue from around the tooth~* Pack/filling material is applied on the tooth~* Spontaneous eruption of the palatally impacted canine is allowed expected~* The canine is orthodontically moved above the mucosa"
224193707|NCT05240573|OTHER|SKI App|"The intervention for the SKI App digital service will include the visualization of real-time kidney data, the kidney care recommendation, and innovative artificial intelligence-based services for kidney health prediction and suggestion.~The intervention for the CMUH Dialysis Care App digital service will include simple records of blood pressure, medication records, and routine health education information."
224193708|NCT01375491|DRUG|Doxycycline|generic doxycycline 100mg twice daily
224193709|NCT01375491|OTHER|Placebo|Placebo comparator to doxycycline
224193710|NCT01156636|DRUG|Sildenafil|50 mg 3 times/day for 1 year
224193711|NCT01156636|DRUG|Placebo|
224193712|NCT06204003|DRUG|Cannabis/Hemp Isolate Extract|Formulation: CBD (99%; 0.1% THC isolate)
224193713|NCT03145207|DRUG|Lidocaine patch|lidocaine patch
223502590|NCT07008534|PROCEDURE|IAN lateralization with computer-guided immediate implant placement using Sticky Bone|The same as the control with additional application of Sticky Bone as an insulator for enhanced neurosensory disfunction
223502591|NCT06627582|BEHAVIORAL|PROMIS Scale v2.0 - Pain Intensity 3a|PROMIS Scale v2.0 - Pain Intensity 3a is a 3-question short form in which patients rate their worst, average, and current level of pain during the past 7 days.
223502592|NCT06627582|BEHAVIORAL|PROMIS 29+2|PROMIS 29+2 (PROMIS-Preference, PROPr) is a compilation of item banks to assess pain intensity
223502593|NCT06627582|BEHAVIORAL|PROMIS Scale v2.0 - Nociceptive Pain Quality 5a|5-question short form that identifies patients who have experienced nociceptive pain during the past 7 days
223502594|NCT06627582|BEHAVIORAL|PROMIS Scale v2.0 - Neuropathic Pain Quality 5a|5-question short form that identifies patients who have experienced neuropathic pain during the past 7 days
223502595|NCT05482165|BEHAVIORAL|Multi-faceted health promotion programme|"This intervention programme will target the influencing factors of childhood obesity to influence the knowledge, attitude and behaviours of school children. Students in the intervention group will receive the following interventions:~* Develop and implement school policies related to weight loss~* Distribute health education materials on diet and exercise to students~* Carry out student health education courses"
223502596|NCT03630354|BEHAVIORAL|Exercise Intervention (supervised)|Complete supervised exercise
223502597|NCT03630354|BEHAVIORAL|Exercise Intervention (unsupervised)|Complete unsupervised exercise
223502598|NCT03630354|OTHER|Informational Intervention|Receive instructional DVD
223502599|NCT03630354|OTHER|Questionnaire Administration|Ancillary studies
223502600|NCT02988609|DEVICE|fMRI|fMRI at 3 different times after concussion: just after concussion (V1), once players have clinically recovered (V2) and 3 months after V2 (V3).
223502601|NCT06687928|BIOLOGICAL|CT-P6 SC|A single fixed dose (600 mg) of CT-P6 subcutaneous
223502602|NCT06687928|BIOLOGICAL|EU-Approved Herceptin SC|A single fixed dose (600 mg) of EU-approved Herceptin subcutaneous
223502603|NCT07022938|DIETARY_SUPPLEMENT|Epineuron|Palmitoylethanolamide (PEA, 300 mg), Superoxide Dismutase (SOD, 70 UI), Alpha Lipoic Acid (ALA, 300 mg), vitamins B6 (1.5 mg), B1 (1.1 mg), B12 (2.5 mcg), E (7.5 mg), Nicotinamide (9 mg) and minerals (Mg 30 mg, Zn 2.5 mg) in one tablet
223502604|NCT07022938|DIETARY_SUPPLEMENT|Placebo Tablets|placebo tablet without active ingredients
223502605|NCT01537367|BEHAVIORAL|Enhanced contact plus behavioral skills|The enhanced contact plus behavioral skills arm is the longer experimental arm.
223502606|NCT01537367|BEHAVIORAL|Enhanced contact only|The enhanced contact only arm is the shorter experimental arm.
223502607|NCT01537367|BEHAVIORAL|Standard of Care|The standard of care arm is the comparison group arm that receives only standard clinical services.
223502608|NCT05604313|DEVICE|Ergonomic chinrest used with low shoulder rest (EC)|Participants will play the violin using the ergonomic chinrest with a low Kun Super shoulder rest (EC) for two weeks before the test day (crossover study), measuring upper body kinematic and muscle activity. The novel ergonomic chinrest (Kréddle®, Wyoming, US) is fully adjustable to accommodate each violinist's body type and performance style: regarding height, rotation and tilting. The low Super Kun shoulder rest has been adjusted to be in the lowest position for all legs attached to the violin before the violinists received it. All participants was told not to adjust the shoulder rest but adjust the chinrest.
223502609|NCT07028710|DRUG|hCG|Subcutaneous injection of 250 µg of recombinant hCG (Ovitrelle®)
223502610|NCT07040956|DRUG|Tislelizumab|200mg IV Q3W
223502611|NCT07040956|DRUG|Afatinib|Targeted therapy
223502612|NCT07040956|RADIATION|Low dose radiotherapy|Radiotherapy
223502613|NCT07040150|DEVICE|Spinal bracing|The semi-rigid spinal brace was developed to enhance patient compliance while maintaining effective curve correction. Patients were instructed to wear the brace for 18-20 h daily.
223502614|NCT07044973|PROCEDURE|Transcranial focused ultrasound thalamotomy|Thalamotomy Using Exblate
223502615|NCT07046013|DIAGNOSTIC_TEST|Lactate dehydrogenase|It's elevation at the time of diagnosis
223592146|NCT06258096|DEVICE|LX2.3 Laser and LED Photobiomodulation System Sham-PBMT Setting|The sham setting consists of light of the same colour (white light with a red filter), applied in the same way as in the experimental group.
224193714|NCT00028015|DRUG|SarCNU|
224193715|NCT05539378|BEHAVIORAL|Auditory Stimulation|enhancement of sleep slow wave activity through acoustic stimulation
224193716|NCT05539378|BEHAVIORAL|Sham (no stimulation)|Playing no tones during sleep but still recording brain activity
224310243|NCT05066334|DRUG|Autologous BM-MSC|intradiscal injection of autologous bone marrow mesenchymal stromal cells
224310244|NCT05066334|PROCEDURE|Sham|local anaesthesia, no disc injection, no placebo injection
223746521|NCT02761707|OTHER|Olfactory Tests|Olfactory testing will be performed using standard tests. The University of Pennsylvania Smell Identification Test (UPSIT) assesses a subjects ability to identify odors in a forced choice format. The Snap and Sniff Threshold Test provides a threshold measure of phenyl ethyl alcohol. Short-term odor memory will be assessed using a standardized 12-item four-alternative forced-choice Odor Memory Test. This non-lexical test employs 10-, 30-, and 60-second delay intervals between the presentation of the target odorant and the first of four successively presented odors from which the target is to be selected.
223746522|NCT02761707|OTHER|Visual Deprivation|During a 2-hour visual deprivation period, subjects will wear comfortable light-tight goggles with lenses that have been blackened by flat black paint. Subjects will be given the opportunity to recline comfortable in a padded reclining chair during this time.
223746523|NCT02761707|OTHER|Peripheral Nerve Stimulation|Electrical stimulation will be applied to a nerve of your arm. Sticky electrode pads will also be placed on a hand muscle. You will receive electrical stimulations that lasts less than a second. The stimulations will make your muscle twitch.
224193717|NCT06493617|OTHER|Cervical Mobilization|The technique is used to mobilize a specific cervical or upper thoracic segment (C2-C3 through T3-T4) in a posterior to anterior direction. The therapist gently applies pressure in an anteroposterior direction in the plane of the facet joint to assess mobility, resistance, end feel, and pain provocation. Gentle oscillations can be used to either inhibit pain (grades I and II) or restore motion (grades III and IV). Slight variations in depth and direction of force can be used to optimize the therapeutic effects of this technique.
223746524|NCT05565911|OTHER|no intervention|this is an observational study, there is no intervention.
223746525|NCT04985851|DRUG|durvalumab + anlotinib|Approximately 64 patients who complete the 4 cycles of durvalumab + EP treatment and don't have progressive diseases (Non-PD patients) will be randomized in a 1:1 ratio to receive maintenance treatment durvalumab + anlotinib (Arm 1) or durvalumab (Arm 2) until confirmed progressive disease.
223746526|NCT04985851|DRUG|Durvalumab|durvalumab
224193718|NCT06493617|OTHER|Traditional physical therapy treatment|tendon gliding exercises, median nerve gliding exercise, strengthening exercises for 60 minutes
224193719|NCT04275024|DRUG|Calcipotriol ointment|The topical treatment in the study was calcipotriol ointment(Dovonex;LEO Laboratories Ltd, Ireland) twice daily for 12 weeks.
224193720|NCT04275024|DRUG|PSORI-CM01 Granule|PSORI-CM01#YXBCM01# granule 5.5g os once a day for 12weeks.
224193721|NCT04275024|BIOLOGICAL|adipose-derived multipotent mesenchymal stem cells|AD-MSCs(adipose-derived multipotent mesenchymal stem cells) were infused intravenously at a dose of 2 million cells/kg
224193722|NCT04390711|OTHER|High density lipoprotein isolation, detection and in-vitro study.|All blood samples were taken on the day of cardiac catheterization after overnight fasting.High density lipoprotein from each participants was isolated and further collected for carbamylation level detection and in-vitro study.
224193723|NCT06723730|PROCEDURE|Upper Quadrant Core Strengthening protocol|"Upper Quadrant Core Strengthening protocol Core strengthening protocol will comprise of following four week protocol.~1. Week one Scapular postural correction and shoulder shrugging exercises~2. Week two External rotation at 0 degree~3. Week three Internal rotation at 0 degree~4. Week four Standing row at 45 and 90 degree , Anterior shoulder stretch and Thoracic exercise in sitting"
223502616|NCT07044713|OTHER|Hand Puppet|Children who come to the hospital's blood collection unit and meet the research criteria will be randomly assigned to the hand puppet group. The scales will be filled out by the nurse and the child five minutes before the blood collection. The researcher will benefit from the experiences of the child development specialist and preschool teacher before the research on puppet scenarios. In the interview room outside the blood collection unit, the child's parent will be asked to tell the researcher about the things the child enjoys and likes. The researcher will show the child puppet characters on various themes and the child will be asked to choose the puppet character he/she wants before the blood collection. The puppet scenarios will be improvised in light of the information received from the child's mother and father during the demonstration and will be shaped according to the child's wishes. In this way, the child will turn the scary hospital environment into an entertaining environm
223746527|NCT03240679|DEVICE|Acell MatriStem® Surgical Matrix|Extracellular matrix (ECM) product that is composed of collagen and natural proteins that provide a re-absorbable scaffold for tissue remodeling to facilitate constructive healing following endoscopic submucosal resection (EMR). Covers the defect site following mucosal resection using endoscopy clips or X-tac. The device will remain attached to the esophagus and integrate with native tissue over time.
223746528|NCT03442621|DRUG|Relacorilant Fasted|Relacorilant, presented as 7 x 50-mg white, hard gelatin capsules for oral administration, given following a 10.5 h fast
223746529|NCT03442621|DRUG|Relacorilant with a high fat breakfast|Relacorilant presented as 7 x 50-mg white, hard gelatin capsules for oral administration, given following a 10 h fast and 0.5 h after the start of a high fat breakfast
223746530|NCT03442621|DRUG|Relacorilant with a moderate breakfast|Relacorilant, presented as 7 x 50-mg white, hard gelatin capsules for oral administration, given following a 10 h fast and 0.5 h after the start of a moderate breakfast
223746531|NCT02618174|BEHAVIORAL|Neutral Control Condition|Message about age of University of Birmingham
224193724|NCT06723730|PROCEDURE|Mobilization with movement|"In addition to upper quadrant core strengthening protocol participants will also perform mobilization with movement.~Mobilization with movement protocol will comprise of following forms.~1. Acromioclavicular joint glides~2. Scapular glides~3. Glenohumeral joint glides ( inferior glides, postero-lateral glides, postero-inferior)"
224193725|NCT01396434|BIOLOGICAL|Prevenar 13|Prevenar 13 vaccine as prescribed by the physician based on approved product indication
224193726|NCT04678557|COMBINATION_PRODUCT|VC-01 Combination Product|PEC-01 cells loaded into an Encaptra Drug Delivery System
224193727|NCT03149731|DEVICE|NIRS|The recent technological advancement of tissue NIRS enables continuous, real time and bedside monitoring of hemoglobin oxygen saturation in mixed arterial, venous, and primarily capillary blood in the tissue bed being probed.
224193728|NCT06892834|DRUG|Stannous Fluoride Dentifrice|Each subject will be randomly assigned to one of four treatment products and will be asked to brush 2x a day (1 minute per brushing) for 3 months.
224193729|NCT06892834|DRUG|Sodium Fluoride Dentifrice|Each subject will be randomly assigned to one of four treatment products and will be asked to brush 2x a day (1 minute per brushing) for 3 months.
223746532|NCT02618174|BEHAVIORAL|Food-based Control Condition|Message about variety of vegetables in the world
223746533|NCT02618174|BEHAVIORAL|Health Condition|Message about the health benefits of eating vegetables
223746534|NCT02618174|BEHAVIORAL|Descriptive Social Norm|Message suggesting most people eat plenty of vegetables
223746535|NCT02618174|BEHAVIORAL|Liking Social Norm|Message suggesting most people like eating vegetables
223746536|NCT02763033|DRUG|Bob's Red Mill®|Standard bone marrow transplant (BMT) diet + potato-based starch
224193730|NCT06892834|DRUG|Sodium monofluorophosphate dentifrice|Each subject will be randomly assigned to one of four treatment products and will be asked to brush 2x a day (1 minute per brushing) for 3 months.
224193731|NCT05644145|BIOLOGICAL|Serological study after yellow fever vaccination|It is a serological survey of the cohort of children who participated in the preliminary investigation and seroconverted after vaccination against yellow fever.
223592147|NCT00375167|BEHAVIORAL|Recovery Workbook Training (psychoeducational training)|The Recovery Workbook uses an educational process to increase awareness of recovery, increase knowledge and control of the illness, increase awareness of the importance and nature of stress, enhance personal meaning, build personal support, and develop goals and plans of action. The intervention period of 30 weekly sessions recommended by Spaniol and colleagues was shortened to 12 weekly sessions to accommodate for clinical and participant commitment. No workbook content was excluded, and all practice exercises were covered.
223592148|NCT00375167|BEHAVIORAL|ACT as usual|Assertive Community Treatment services provided as per established and evidence-based fidelity standards.
223592149|NCT00175448|PROCEDURE|physiotherapy|See Detailed Description.
223592150|NCT03218930|BEHAVIORAL|Delayed antibiotic prescription|Delayed antibiotic prescription pads will be disseminated to all participating general practitioners in both hard and soft copies.
223592151|NCT03218930|BEHAVIORAL|Antibiotic prescribing guidelines|Antibiotic prescribing guidelines will be disseminated to all participating general practitioners in both hard and soft copies.
223746537|NCT02763033|OTHER|Starch Placebo|Standard bone marrow transplant (BMT) diet + corn-based starch
223746538|NCT00405587|DRUG|PLX4032|Oral capsules administered BID
223746539|NCT05061979|DRUG|BAY1747846|Solution for intravenous (IV) injection, single dose
223746540|NCT01057420|DRUG|oxygen inhalation|Inhalation of 80% oxygen via face mask
223746541|NCT05175417|OTHER|MRI|3 tesla (T) MRI to provide higher resolution and quality brain images.
223746542|NCT06027866|DEVICE|SRAVI (Speech Recognition Application for the Voice Impaired)|Speech Recognition Application for the Voice Impaired (SRAVI) is a novel communication aid developed by Liopa (a company formed by Queen's University Belfast (QUB) and the Centre for Security Information Technologies (CSIT), QUB). SRAVI is an application-based lip-reading system, and the application ('app') can be downloaded onto any device with a standard forward facing camera (e.g., smartphone, tablet). When the device is held in front of a patient, it will track lip movement and identify phrases being mouthed.
224193732|NCT00988910|DRUG|EE30-DRSP (Yasmin, BAY86-5131)|DRSP-containing combined oral contraceptives according to the normal routine praxis
224193733|NCT00988910|DRUG|Other combined oral contraceptives|Other combined oral contraceptives according to the normal routine praxis
223592152|NCT03218930|BEHAVIORAL|Education|General practitioners will receive a package of educational sessions tailored towards their specific needs.
223592153|NCT03218930|BEHAVIORAL|Educational materials|Educational materials for patients, namely posters and leaflets, will be disseminated to all participating general practitioners.
223592154|NCT03327194|DEVICE|ADHEAR Audio Processor|"ADHEAR Audio Processoris a non-invasive bone conduction hearing device which is retained on the patient's head with an adhesive adapter that is placed behind the auricle.~The ADHEAR Audio Processor transmits sounds to the mastoid by vibrating on the skull and stimulates the inner ear without any previous surgery.~ADHEAR Audio Processor is classified as a Class lla medical device and ADHEAR Adhesive Adapter is classified as a Class I medical device.~The ADHEAR Audio Processor has the CE mark."
223592155|NCT01912534|DRUG|Valsartan|40, 80 and 160 mg tablets of Valsartan
223592156|NCT01912534|DRUG|Placebo|During Active Run-In, all patients take Valsartan. During maintenance, all patients are randomized to valsartan or placebo
223746543|NCT02829463|RADIATION|Magnetic resonance imaging|3.0 T Magnetic resonance imaging of knee joints. It does not harm the subjects.
223746544|NCT02382458|BEHAVIORAL|Newsletters on cancer prevention and control|E-mailed or mailed newsletters that provide information on how to prevent cancer
223746545|NCT02382458|BEHAVIORAL|Behavioral program to reduce inflammation|Group classes which will provide participants with information on achieving a healthy diet, increase physical activity, and manage stress
223746546|NCT06496776|PROCEDURE|Choukroun's technique|Suturing will be done using the method described by Choukroun.
223746547|NCT03721341|RADIATION|Palliative Radiation|Investigators should follow the principles of palliative radiotherapy as per the individual institution in order to alleviate symptoms or prevent complications. If radiotherapy is indicated, recommended doses are 8 Gy in 1 fraction, 20 Gy in 5 fractions, and 30 Gy in 10 fractions.
223746548|NCT03721341|DRUG|Chemotherapy|Chemotherapy may be given as indicated.
223746549|NCT03721341|DRUG|Immunotherapy|Immunotherapy may be given as indicated.
223746550|NCT03721341|DRUG|Hormones|Hormones may be given as indicated.
224193734|NCT04686396|DEVICE|Demineralized bone matrix|Demineralized bone matrix
224193735|NCT01663246|PROCEDURE|Saliva Sample|Small plastic cups will be placed on the inside of subject cheeks, and held in place with gentle suction. These cups are attached to tubes which will allow the collection of saliva into a test tube. Saliva will also be collected from the glands underneath the tongue using a small gentle suction device, similar to the one used by a dentist. Saliva production will be stimulated by dabbing a mild citric acid solution that tastes like lemon onto the tongue using a Q-Tip. After this test, subjects will also be asked to chew wax to simulate saliva, and the saliva that accumulates in their mouth will be collected by spitting into a test tube.
224193736|NCT06911957|DIETARY_SUPPLEMENT|Prebiotic blend|10g of prebiotic fibre blend powder
224193737|NCT06911957|DIETARY_SUPPLEMENT|Placebo|10g of matched placebo powder
224193738|NCT06915259|OTHER|Doula Model of Care|Doula model of care is defined as emotional support, prenatal support, intrapartum support, and postpartum support provided to the birthing individual by a certified doula.
223502617|NCT07044713|OTHER|The Visual Viewing and Coloring Book|Children who come to the hospital's blood collection unit and meet the research criteria will be randomly assigned to the coloring group. The scales will be filled out by the nurse and the child five minutes before the blood is drawn. The Visual Viewing and Coloring Book consists of pictures that require coloring. The children will be given a book before the blood is drawn and will be asked to draw or color a picture as they prefer during the procedure. The fear scale will be assessed by the nurse and the child five minutes before, during, and five minutes after the procedure. The pain scale will be assessed by the nurse and the child during and five minutes after the procedure. The child will be shown the facial expressions on both the fear scale and the pain scale and asked which one it is, and the score corresponding to the facial expression he/she indicates will be recorded. Mothers will stay with their children during the treatment proce
223746551|NCT03721341|OTHER|Observation|Observation only is acceptable if this is the standard practice.
223502618|NCT07046442|OTHER|Pulmonary Rehabilitation|The Active Cycle of Breathing Technique (ACBT), is a structured method aimed at restoring normal breathing patterns, improving respiratory muscle efficiency, and reducing airway irritation.
223502619|NCT07046156|DRUG|Oxybutynin Cl|Oxybutynin in a dose of 0.5 mg/kg will be used in the treatment of overactive bladder
223502620|NCT07046156|DRUG|propiverine|Propiverine in a dose of 0.8 mg/kg will be used in the treatment of overactive bladder
223502621|NCT07046156|DRUG|Tolterodine|Tolterodine in a dose of 0.1 mg/kg will be used in the treatment of overactive bladder
223502622|NCT07040111|OTHER|oral food challenge (OFC)|oral food challenges with subsequent steps of a 4-step egg ladder (muffin \[1.5 g of hen's egg protein per portion\], pancake, hard-boiled egg, soft-boiled egg)
223502623|NCT07040111|OTHER|oral food challenge (OFC)|oral food challenges with subsequent steps of a 5-step egg ladder (muffin \[0.75 g of hen's egg protein per portion\], muffin \[1.5 g of hen's egg protein per portion\], pancake, hard-boiled egg, soft-boiled egg)
223502624|NCT07047001|DRUG|Vorolanib Tablets|200mg PO QD
223502625|NCT07047001|DRUG|Vorolanib + Toripalimab|"Vorolanib: 100mg PO QD~Toripalimab: 240mg IV infusion Q3W"
223502626|NCT07046507|DIAGNOSTIC_TEST|Diagnostic procedures|Diagnostic ability of optical coherence tomography in kayser fleischer rings
223502627|NCT07050836|COMBINATION_PRODUCT|Definity contrast during ultrasound|Definity contrast injection given just prior to brain tumor surgery. Contrast enhanced ultrasound during brain tumor surgical resection to aid in brain tumor visualization.
223502628|NCT07045701|COMBINATION_PRODUCT|Epinephrine 4mg nasal powder spray|Epinephrine nasal powder spray in a unidose nasal applicator device. Will be administered together with a placebo saline IM injection
223502629|NCT07045701|COMBINATION_PRODUCT|Adrenalin 0.5mg Injectable Product|Epinephrine 0.5mg for IM injection. Will be administered together with a placebo nasal powder spray.
223502630|NCT07048834|OTHER|lidocaine local anesthetic drug|Lidocaine Nerve Block technique
223502631|NCT07048834|OTHER|articaine local anesthetic drug|Articaine Local Infusion technique
223502632|NCT06732388|PROCEDURE|Biopsy Procedure|Undergo tissue biopsy
223502633|NCT06732388|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223502634|NCT06732388|PROCEDURE|Endoscopic Procedure|Undergo endoscopy
223502635|NCT06732388|DRUG|Itraconazole|Given PO
223502636|NCT06732388|DRUG|Placebo Administration|Given PO
223502637|NCT06732388|OTHER|Questionnaire Administration|Ancillary studies
223502638|NCT06732388|PROCEDURE|Radiofrequency Ablation|Undergo radiofrequency ablation
223502639|NCT07047157|BEHAVIORAL|Video-Based Virtual Reality Education|Participants receive VR-based video training using a headset. The content includes step-by-step instruction on peripheral venous catheterization.
223502640|NCT07047157|BEHAVIORAL|Traditional Education with Demonstration|Participants receive traditional face-to-face instruction and live demonstration of peripheral venous catheterization (PVC).
223502641|NCT07047547|DRUG|Vericiguat|Under the premise of ensuring safety, treat with a stable dose of Vericiguat 2.5mg PO QD for 2 weeks. After 2 weeks, increase the dose to 5mg PO QD. If blood pressure elevation occurs during the operation phase, the researchers suggest titrating or starting additional antihypertensive drugs, with a follow-up of 12 months. If the patient has tolerability issues (symptomatic hypotension or SBP\<90 mmHg), the dose should be reduced or discontinued.
223502642|NCT06733493|BEHAVIORAL|integrated psychosocial care|Employment of a psychologist in psychotherapeutic training as a member of the multiprofessional team at the ICU ward for the duration of one year. Tasks: Psychosocial Support for staff, patients and their relatives.
223502643|NCT07049731|DIETARY_SUPPLEMENT|Protein powder intervention|On the basis of a balanced diet, 2 sachets of Aiben Leap Protein Nutritional Powder (each sachet containing 6g of milk protein) were supplemented daily.
223502644|NCT07049731|BEHAVIORAL|Resistance exercise intervention|Low-intensity resistance training was conducted 3 times a week.
223502645|NCT07049731|DIETARY_SUPPLEMENT|Placebo control|placebo was given and an individualized balanced dietary plan based on the Dietary Guidelines for Chinese Residents was provided.
223502646|NCT07055646|DIAGNOSTIC_TEST|Traditional Assistive Technology|Participants in Group 1 utilize traditional, non-digital assistive devices designed to enhance mobility and spatial orientation
223502647|NCT07055646|DIAGNOSTIC_TEST|Digital Assistive Technology|Participants in Group 2 use modern, digital assistive technologies specifically designed to improve navigation, orientation, and real-time decision-making for visually impaired individuals
223502648|NCT07055646|COMBINATION_PRODUCT|Combined Technology Users|Participants in Group 3 use a combination of traditional tools (e.g., cane, magnifiers) alongside modern digital aids (e.g., smart canes, GPS apps). This group is important to examine how integrated usage of both types of technologies
223746552|NCT03721341|RADIATION|Stereotactic Ablative Radiotherapy|Total dose of radiation and number of fractions will depend on the site of disease. Doses are 20 Gy in 1 fraction, 30 Gy in 3 fractions (every 2 days), or 35 Gy in 5 fractions (daily).
223746553|NCT05299749|OTHER|stg-rt-fMRI-Neurofeeback|the patients will receive real-time feedback from the brain activity of the superior temporal gyrus
223746554|NCT05299749|OTHER|sham-rt-fMRI-Neurofeedback|the patients will receive real-time feedback from the brain activity of the somato-motor cortex
224193739|NCT01761682|OTHER|Diagnosed as ALL|All patients who will be enrolled in this prospective registry are confined to those who are diagnosed as acute lymphoblastic leukemia at Asan Medical Center, Seoul, Korea, from Jan 2013 till Dec 2047
224310245|NCT06323525|BIOLOGICAL|TCR reserved and Power3 (SPPL3) gene knock-out allogeneic CD19-targeting CAR-T cell (ATHENA-2 CAR-T)|Phase 1 dose escalation (3+3): dose 1 (1 × 10\^6 cells/kg), dose 2 (3 × 10\^6 cells/kg), dose 3 (6 × 10\^6 cells/kg); Phase 2: dose of RP2D.
224310246|NCT06323525|DRUG|Fludarabine|Intravenous fludarabine 30\~50 mg/m\^2/day on days -5, -4, and -3.
224310247|NCT06323525|DRUG|Cyclophosphamide|Intravenous cyclophosphamide 500\~1000 mg/m\^2/day on days -5, -4, and -3.
223502649|NCT07056673|DEVICE|Active CAP therapy|"The patients in the CAP group will receive six sessions of CAP treatment, administered once weekly for six consecutive weeks. If complete clearance of facial acne is achieved before all six sessions, CAP treatment will be discontinued early.~For device selection, the CAP patch trauma therapy device (CAP-PTTD) will be used for lesions located on relatively flat areas of the face. In cases of lesions on areas with greater anatomical curvature (eg, the mandibular angle or near the tragus), the CAP jet trauma therapy device (CAP-JTTD) will be used in combination."
223502650|NCT07056673|DEVICE|sham CAP therapy|the device will be operated with the plasma-generating field disabled, so that no plasma will be produced. Only environmental cues such as sound will be simulated to ensure blinding.
223502651|NCT07056673|OTHER|standard care based on the JAAD acne guidelines|the group will receive standard care based on the JAAD acne guidelines
223502652|NCT07055971|BEHAVIORAL|Experimental: Pain Neuoescience Education Group|The experimental group will receive a pain neuroscience education (PNE) intervention delivered through an in-person, didactic educational model in small groups of 5 to 10 patients. PNE sessions will be conducted once per week for 6 weeks, each lasting approximately 45 to 60 minutes, by a physiotherapist with extensive clinical experience and specialized training in PNE. The content of the sessions will be based on models described in previous studies. Patients will receive detailed information on the neurophysiology and neurobiology of chronic pain and its relationship to fibromyalgia (FM). Pre-prepared PowerPoint presentations will be used to deliver the material in an accessible and engaging manner, employing images, metaphors, anecdotes, and stories to facilitate understanding. All variables will be recorded at baseline (prior to the intervention), at 6 weeks (end of the intervention), at 12 weeks and at 18 weeks.
223502653|NCT07055971|BEHAVIORAL|Active Comparator: Biomedical Education Group|The control group will receive two sessions of biomedical education and general guidance on chronic pain and its management, delivered in small groups of 5 to 10 patients with a duration about 45-60 minute. These sessions will also be conducted by the same physiotherapist who delivers the intervention sessions. Both groups will be instructed to continue their usual care and will be encouraged to engage in therapeutic exercise tailored to their physical limitations. All variables will be recorded at baseline (prior to the intervention), at 6 weeks (end of the intervention), at 12 weeks and at 18 weeks
223502654|NCT07055789|OTHER|Combined respiratory muscle training, incorporating both inspiratory and expiratory muscle training|IMT: Inspiratory Muscle Training EMST: Expiratory Muscle Strength Training RMST: Respiratory Muscle Strength Training In this trial we are combining both IMT and EMST in the intervention group.
223502655|NCT07055997|DEVICE|Robotic-assisted needle localization|Robot-assisted needle localization involves the use of a robotic system to assist with the percutaneous localization of pulmonary nodules under CT guidance. The robotic system provides real-time navigation and increased precision during needle placement, reducing the variability in positioning and improving the accuracy of localization. The system offers automatic adjustments to the needle's trajectory, minimizing the need for manual corrections, and potentially reducing the number of CT scans required. This method is designed to enhance the overall localization success rate and reduce complications associated with traditional manual techniques.
223502656|NCT07055997|PROCEDURE|Manual needle localization|Manual needle localization involves the traditional technique of percutaneous localization of pulmonary nodules under CT guidance without the assistance of robotic systems. The procedure is performed by the physician manually guiding the needle based on real-time CT imaging. The physician adjusts the needle position based on visual cues from the CT scan, which may require multiple attempts for accurate localization.
223502657|NCT07056647|DIETARY_SUPPLEMENT|Staircase Nutritional Intervention|"Fourteen days before admission, different nutritional supplements will be provided according to whether the patient has diabetes and their nutritional status. Patients without diabetes who are malnourished should take enteral nutrition powder mixture three times a day, with each dose providing 265 kCal of energy. Patients without diabetes but at risk of malnutrition should take enteral nutrition powder mixture twice a day. Patients with diabetes who are malnourished should take low - sugar whole - protein enteral nutrition powder three times a day, with each dose providing 250 kCal of energy. Patients with diabetes and at risk of malnutrition should take low - sugar whole - protein enteral nutrition powder twice a day.~During the peri - operative period, a strict 6 - hour fasting of solid food and 2 - hour fasting of clear liquid before surgery is implemented. Two hours after surgery, all patients should take multi - dimensional carbohydrates, which provide 115 kCal of energy. Four ho"
223502658|NCT07056647|DIETARY_SUPPLEMENT|Standard ERAS Diet Management Group|Only nutritional education is provided to patients before admission, without any specific nutritional supplements. During the peri - operative period, patients are required to fast from food and water for 8 hours before surgery. Six hours after surgery, patients are allowed to drink water. They can start consuming liquid food after passing gas from the anus. No specific energy - containing nutritional supplements are given during this period. A nutritional guidance manual is distributed to patients upon discharge, and there are no targeted nutritional interventions or follow - up measures related to energy intake subsequently.
223592157|NCT01816802|DEVICE|In-vitro fertilization using Eeva|Eeva will image embryos through cleavage stage (Day 3). Embryologists will use Eeva results along with traditional morphological grading to assist in selecting embryo(s) for transfer or freezing.
223592158|NCT01441466|OTHER|Isolation|Patients in this arm are nursed together (in the same room) independent of viral agent
223746555|NCT05898581|PROCEDURE|PENG Block|Participants will receive a PENG block with local anesthetics (which is a freezing medication, in this case, 0.5% ropivacaine) before receiving spinal anesthesia. Patients in this group will also receive a sham ILAI procedure with 60 mL of saline (performed by the operating surgeon).
223592159|NCT02212158|BEHAVIORAL|motivational interviewing group|Group therapy sessions will include 8 teen sessions that cover the following topics: acceptance of diabetes, family issues, division of diabetes management, communication and facilitating motivation and skill development to improve diabetes care. Motivational interviewing and cognitive behavioral techniques will be the therapeutic modalities used in sessions. Parents will be involved in 3 therapy sessions that cover topics regarding family functioning, division of responsibility and parenting strategies.
223592160|NCT05060965|DRUG|Nicotine lozenge|Nicotine replacement therapy
223592161|NCT05060965|DRUG|Nicotine gum|Nicotine replacement therapy
223592162|NCT05060965|DRUG|Nicotine patch|Nicotine replacement therapy
223502659|NCT07056998|PROCEDURE|root canal retreatment|if Retreatment was needed, local anesthesia using 1.8 ml (one cartridge) of 4% articaine with 1:100,000 epinephrine local anesthetic solution, administered with end -loading cartridge aspirating syringe and a 27-gauge long needle. Under rubber dam isolation, All carious tissue and existing coronal restorations were thoroughly removed using a round bur, an endodontic access cavity, canal preparation and removal of existing root canal filling, irrigation with 2.6% NAOCL and saline, determining the working length using apex locator and PA radiograph, to be 0.5 to 1 mm shorter than radiographic apex, Drying the canal with paper point and obturation to achieve a dense, well adapted Monoblock obturation. A post-obturation periapical radiograph was taken to confirm the quality of the fill in terms of length, density, then sealed by a temporary restorative material.
223502660|NCT07057427|DRUG|Nab paclitaxel|Nab-paclitaxel (on days 1 and 8 of a 21-day cycle)
223502661|NCT07057427|DRUG|Docetaxel and Carboplatin|Docetaxel 75 mg/m2(day 1) + Carboplatin (AUC=6) (day 1)
223502662|NCT07057427|DRUG|Trastuzumab + Pertuzumab|Trastuzumab (8mg/kg first dose, 6mg/kg sequential) and pertuzumab (840mg first dose, 420mg/kg sequential) were administered intravenously every 3 weeks, or fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection (1200 mg pertuzumab plus 600 mg trastuzumab loading dose in 15 mL, followed by 600 mg pertuzumab plus 600 mg trastuzumab maintenance doses in 10 mL), both administered every 3 weeks.
223502663|NCT07055711|DIAGNOSTIC_TEST|Peripheral Neuropathic Pain|to find out the association between work-related stress and peripheral neuropathic pain in female breast cancer survivors post-chemotherapy.
223502664|NCT07055828|DRUG|Ketamine|Patients received IV ketamine 0.25 mg/kg before Spinal anesthesia as a prophylactic drug
223502665|NCT07055828|DRUG|Intranasal ketamine|Patients received nebulized ketamine at a dose of 0.75 mg/kg adjusted to 5 ml by adding normal saline to be inhaled through a breath-actuated nebulizer
223502666|NCT07055828|DRUG|Normal Saline|Patients received Intravenous Normal saline
223502667|NCT07055828|DRUG|Saline Inhalants|Patients received nebulized Saline
223502668|NCT00677222|BIOLOGICAL|AMI MultiStem®|AMI MultiStem® administered via catheter into peri-vascular space of the target vessel, 2-5 days post PCI. There will be 3 dose escalation cohorts, 6 patients per cohort.
223502669|NCT07056790|DRUG|68Ga-PSMA-CYC|Each prostate cancer patient underwent a 68Ga-PSMA-CYC (3-4 mCi) PET/CT scan, as well as a 68Ga-PSMA-617 (3-4 mCi) or 68Ga-PSMA-11 (3-4 mCi) PET/CT scan, with the time interval between the two scans not exceeding one week.
223502670|NCT07056790|DRUG|CYC|The dose will be 3-4mCi given intravenously.
223502671|NCT07055568|DRUG|iNKT|iNKT: Intravenous infusion, 0.5×10\^8cell-3.0×10\^8 cell
223502672|NCT07057401|DEVICE|CAD-CAM Manufactured Crowns|Single crowns produced using computer-aided design and milling technology applied to permanent molars.
223502673|NCT07057401|DEVICE|3D Printed Crowns|Single crowns produced using 3D printing technology applied to permanent molars.
223502674|NCT07055802|COMBINATION_PRODUCT|Inversion Table|Inversion Table group will receive flexion biased exercises in supine position with 05 repetitions every session and in addition will be given an inversion table therapy as a treatment at the angle of 60' for 5 minutes in every session. Two follow ups in a week were taken for total of 04 weeks. Measurements were taken for NPRS, Oswestry low back disability questionnaire and sit and reach test respectively
223502675|NCT07055802|COMBINATION_PRODUCT|Mulligan flexion biased exercises|experimental group named as Mulligan group will receive flexion biased exercises in supine position with 05 repetitions every session and in addition will be given mulligan technique. It was done at level just below ASIS (at level of L4-L5 spinous process), ten times/session, for 12 sessions three/week every other day for 4 weeks. . Measurements were taken for NPRS, Oswestry low back disability questionnaire and sit and reach test respectively
223502676|NCT07057362|OTHER|Intraoperative Hemodynamic Monitoring|Continuous intraoperative monitoring of systolic blood pressure and heart rate following spinal anesthesia. Vasopressor usage and total fluid administration will be recorded.
223592163|NCT05060965|OTHER|Maryland Quitline|Telephone-based tobacco cessation service
223592164|NCT05060965|OTHER|John Hopkins Tobacco Treatment Clinic|Clinic-based tobacco cessation service
223592165|NCT06297473|BEHAVIORAL|Telephone-/video follow-up|"The yearly routine review of patients takes place by using a telephone or video interview rather than in-person interview in the endocrine outpatient department.~All other assessments, e.g. biochemical, MRI, is conducted as usual."
223592166|NCT06297473|BEHAVIORAL|In-person follow-up|The yearly routine review on patients takes place at the endocrine outpatient department
223592167|NCT00122044|DRUG|trihexyphenidyl|
223592168|NCT02727491|DRUG|Dextromethorphan|Dextromethorphan is a drug of the morphinan class with sedative, dissociative, and stimulant properties (at higher doses). Dextromethorphan has been explored for a number other uses in medicine, including pain relief (as either the primary analgesic, or an opioid potentiator).
223592169|NCT02727491|DRUG|Placebo|Placebo syrup identical to active comparator in taste, appearance and volume but is inactive. Placebo comparator will be used in the placebo arm of the trial.
223592170|NCT03936972|PROCEDURE|ilizarov circular frame and uni-planarexternal fixator|both are types of external fixators, but one is circular frame and other is uni-planar frame
223746556|NCT05898581|PROCEDURE|Control Group|Participants will receive a sham PENG block performed with 20ml of normal saline solution before spinal anesthesia. After, patients will receive ILAI (performed by the operating surgeon) with a plain solution of ropivacaine 0.25% 60ml.
223746557|NCT03102294|OTHER|inspiratory muscle training|inspiratory muscle training with 50% of MIP
223746558|NCT03102294|OTHER|"Placebo training"|placebo training with PowerBreathe (without inspiratory load)
224193740|NCT06222138|OTHER|The samples described below will be collected:|"For each included patient, blood samples will be collected during baseline visit (before initiation of radio-chemotherapy), then before initiation of TTFields and every 3 months during TTFields treatment. Additional blood samples will be scheduled at recurrence (if applicable).~Moreover, tumor samples (formalin paraffin embedded (FFPE) tumor block and fresh samples) will be collected from surgery specimen on primary tumor by the sponsor for analysis. In case of recurrence, and if a second surgery is possible, tumor samples will also be collected.~Tumor samples will be collected from biopsies taken in the course of routine practice and from surgical specimens collected during surgical procedure."
224193741|NCT06942065|PROCEDURE|Sham-BFR|The exercise protocol for the operated leg (with sham pressure of 20mmHg) consisted of four sets with 75 repetitions (reps) in total (1. Set: 30 reps, 2.-4. Set: 15 reps) with 30% of the individual one-repetition maximum for each exercise and were performed five times per week during the three-week outpatient rehabilitation.
224193742|NCT06942065|PROCEDURE|Blood Flow Restriction Training|The exercise protocol for the operated leg (with a BFR pressure of 60% of the LOP) consisted of four sets with 75 repetitions (reps) in total (1. Set: 30 reps, 2.-4. Set: 15 reps) with 30% of the individual one-repetition maximum for each exercise and were performed five times per week during the three-week outpatient rehabilitation.
224193743|NCT06942273|RADIATION|hyperthermia|hyperthermia over the carpal tunnel area and adjacent areas
224193744|NCT06942273|OTHER|physical exercise|Performing therapeutic physical exercise focused on the flexor muscles of the hand and neural stretching
224193745|NCT06942273|OTHER|splint|imposition of a night splint
224193746|NCT06943300|OTHER|Aerboic Training|Group A will perform Aerobic training exercises will be conducted 2 times per 12 weeks in which the warm up phase for 10 minutes. 30 minutes of aerobic exercise like walking, jogging, cycling, calisthenics, rhythmic exercises, continuous slow running, sit ups and cool down phase for stretching Phase 1: stretching of upper limb, trunk, lower limb muscles for 10 minutes. Phase 2: Individualized walking, jogging, cycling, rhythmic exercises, continuous slow running, sit ups Phase 3: Cool down exercise for 10 minutes.
224193747|NCT06943300|OTHER|Circuit Training|The training program will consist of 10 types of resistance and aerobic exercise and will be done 2 times per week for 12 weeks. Specifically, the resistance exercise program comprises of push-up, squat, crunches, lunge and superman exercise. An aerobic exercise program comprises of light jumping, running on the spot, foot stamping, stepping and jumping jack. Phase 1: In Warm up period, dynamic stretching for 10 minutes. Phase 2: Resistance and aerobic exercise (push-up, squat, crunches, lunge and superman exercise, light jumping, running on the spot, foot stamping, stepping and jumping jack) Phase 3: In cool down period, static stretching for 10 minutes.
224193748|NCT02207413|BIOLOGICAL|Influsplit Tetra™ vaccine produced by investigational process (IP)|Influsplit Tetra™ vaccine using a new manufacturing process administered intramuscularly (IM) in the deltoid region of non-dominant arm (Dose 1) in Adults Group and in non-dominant deltoid or left anterolateral thigh (Dose 1) and dominant deltoid or right anterolateral (Dose 2 - unprimed subjects) in 6-35m and 3-17y Groups.
223502677|NCT07057336|DRUG|Conventional Calcium Hydroxide (CH)|Following completion of canal shaping with rotary instrumentation and irrigation using 5 mL of 2.5% sodium hypochlorite (NaOCl), canals were flushed sequentially with 5 mL distilled water, 5 mL of 17% ethylenediaminetetraacetic acid (EDTA), another 5 mL of distilled water, 5 mL of 2.5% NaOCl, and finally 5 mL of distilled water. The cavity was sealed temporarily with a sterile cotton pellet and glass ionomer cement. Conventional calcium hydroxide was retained for 7 days before final obturation.
223502678|NCT07057336|DRUG|Nanocalcium Hydroxide (NCH)|Following completion of canal shaping with rotary instrumentation and irrigation using 5 mL of 2.5% sodium hypochlorite (NaOCl), canals were flushed sequentially with 5 mL distilled water, 5 mL of 17% ethylenediaminetetraacetic acid (EDTA), another 5 mL of distilled water, 5 mL of 2.5% NaOCl, and finally 5 mL of distilled water. The cavity was sealed temporarily with a sterile cotton pellet and glass ionomer cement. Nanocalcium hydroxide was retained for 7 days before final obturation.
223502679|NCT07055906|BEHAVIORAL|Video-feedback Intervention to Promote Racial-Ethnic Socialization CompEtency (VIP-RACE)|VIP-RACE is a brief, strengths-based, video-feedback intervention that targets parental racial-ethnic socialization (RES) motivation and competency in parents of 10-to-14-year-old Latino/a/x/e youth. Intervention sessions include: (1) Youth and parent assessment including videotaped parent-adolescent RES conversations; (2) Parent interview; and (3) Video feedback session during which parents and RES coaches review clips from the RES interaction tasks. Video feedback highlights parents' RES strengths and when sensitively applied, encourages parents to examine missed opportunities for engaging in RES. RES coaches emphasize that through the provision of cultural socialization and preparation for bias messages, parents can help protect their children from the damaging effects of discrimination and support positive racial-ethnic identity development. Parents develop a personalized action plan with goals and have the opportunity to receive up to 3-5 follow-up sessions to strengthen RES skill
223502680|NCT07056257|PROCEDURE|Scaling-root planning (SRP)|Thirteen sites \[scaling-root planning (SRP)\] were used as a control group.
223502681|NCT07056257|PROCEDURE|Scaling-root planning (SRP)+ laser therapy|Thirteen sites \[scaling-root planning (SRP)+ laser therapy with application of methyl cellulose gel at repeated times weekly for one month\].
223502682|NCT07056257|PROCEDURE|Scaling-root planning (SRP)+ omega 3 gel|Thirteen sites \[scaling-root planning (SRP) + omega 3 gel repeated time weekly for one month\].
223502683|NCT07056257|PROCEDURE|Scaling-root planning (SRP)+ laser therapy+ omega 3 gel|Thirteen sites \[combination therapy between scaling-root planning (SRP) + laser + omega 3 gel in repeated time weekly for one month\].
223502684|NCT06756308|DRUG|Enasidenib|Enasidenib 100 mg daily on 28-day cycles.
223502685|NCT06756308|DRUG|Rituximab|IV rituximab 375 mg/m² weekly for the first month, and monthly thereafter on 28-day cycles, for a total of four months of rituximab.
223502686|NCT07056322|DIETARY_SUPPLEMENT|200 ml dairy|Participants consume the meal after a fasting baseline bloodsample. Bloodsamples are collected over a six-hour period to evaluate postpandrial changes in bone turnover markers.
223502687|NCT07056322|DIETARY_SUPPLEMENT|100 ml milk|Participants consume the meal after a fasting baseline bloodsample. Bloodsamples are collected over a six-hour period to evaluate postpandrial changes in bone turnover markers.
223502688|NCT07056322|DIETARY_SUPPLEMENT|100 g banana|Participants consume the meal after a fasting baseline bloodsample. Bloodsamples are collected over a six-hour period to evaluate postpandrial changes in bone turnover markers.
223502689|NCT07056322|DIETARY_SUPPLEMENT|100 ml dairy and fibers|Participants consume the meal after a fasting baseline bloodsample. Bloodsamples are collected over a six-hour period to evaluate postpandrial changes in bone turnover markers.
224193749|NCT02207413|BIOLOGICAL|Influsplit Tetra™ vaccine produced by licensed process (LP)|Influsplit Tetra™ vaccine using a licensed manufacturing process administered IM in the deltoid region of non-dominant arm (Dose 1) in Adults Group and in non-dominant deltoid or left anterolateral thigh (Dose 1) and dominant deltoid or right anterolateral (Dose 2 - unprimed subjects) in 6-35m and 3-17y Groups.
224193750|NCT06540690|PROCEDURE|Palatal Wound|With the goal to harvest the free gingival graft (FGG), an 8mm diameter scalpel will be used to ensure standardized wounds. Thereafter, a 2-mm thick FGG will be removed. The wound area will receive 4.0 silk sutures.
224193751|NCT04130165|OTHER|Matched donor human milk|Milk from donor mothers will be sorted according to their secretor status. This milk will be provided to infants in the intervention (experimental) arm.
224193752|NCT00869726|DRUG|dirucotide|500mg, intravenous, dosed once every six months for 18 months
224193753|NCT00869726|DRUG|Placebo|intravenous, once every six months for 18 months
224193754|NCT01683331|DRUG|Insulin treatment for hyperglycemia|
223502690|NCT07056322|OTHER|Fasting (control)|Participants consume the meal after a fasting baseline bloodsample. Bloodsamples are collected over a six-hour period to evaluate postpandrial changes in bone turnover markers.
223502691|NCT07056322|DIETARY_SUPPLEMENT|100 ml dairy|Participants consume the meal after a fasting baseline bloodsample. Bloodsamples are collected over a six-hour period to evaluate postpandrial changes in bone turnover markers.
223502692|NCT07056010|PROCEDURE|curative minimally invasive gastrectomy with D2+PAND lymphadenectomy|Thirty patients with HER2-negative gastric adenocarcinoma or gastroesophageal junction (GEJ) cancer, presenting with PAN metastasis (No. 16 lymph nodes ≥10 mm), will be enrolled. Participants will receive four cycles of conversion immunochemotherapy with a PD-1 inhibitor (Serplulimab) combined with the SOX chemotherapy regimen (oxaliplatin and S-1). After completion of conversion therapy, patients will undergo curative minimally invasive (laparoscopic or robotic) gastrectomy with D2+PAND lymphadenectomy.
223502693|NCT07056660|DEVICE|Active CAP therapy|The CAP group will additionally undergo atmospheric pressure cold plasma (CAP) treatment (plasma-activated gas form, CAP-Activated Gas; patent number: ZL202110209052.X, provided by Xi'an Jiaotong University), once daily for the first five days and every other day thereafter, for a total of 13 sessions. Each session will involve enclosing the target area in a treatment bag sealed with medical adhesive tape; plasma-activated gas rich in ozone (O₃) will be delivered and recirculated for 20 minutes, followed by plasma-activated gas rich in nitric oxide (NO) for an additional 5 minutes, in strict accordance with the standard operating procedures provided by the manufacturer.
223502694|NCT07056660|DEVICE|Sham CAP therapy|In the placebo group, the electric field for plasma generation will remain off, so no plasma will be produced; only operational sounds will be simulated to maintain procedural blinding.
223502695|NCT07056660|OTHER|standard care|The group will receive standard care according to current clinical guidelines
223502696|NCT07057479|DRUG|Fixed-dose combination of SGLT2 inhibitor and thiazolidinedione|Oral fixed-dose combination tablet containing an SGLT2 inhibitor and a thiazolidinedione, administered once daily. Participants also receive matching placebos for both comparator drugs to maintain blinding. All participants continue background metformin therapy (≥1000mg/day).
223502697|NCT07057479|DRUG|Control Group 1 Intervention - SGLT2 inhibitor monotherapy|Oral tablet containing an SGLT2 inhibitor, administered once daily. Participants also receive matching placebos for both the fixed-dose combination and the thiazolidinedione comparator to maintain blinding. All participants continue background metformin therapy (≥1000mg/day). This represents standard monotherapy for comparison against the combination approach.
223502698|NCT07057479|DRUG|Control Group 2 Intervention - Thiazolidinedione monotherapy|Oral tablet containing a thiazolidinedione, administered once daily. Participants also receive matching placebos for both the fixed-dose combination and the SGLT2 inhibitor comparator to maintain blinding. All participants continue background metformin therapy (≥1000mg/day). This represents standard monotherapy for comparison against the combination approach.
223502699|NCT07057479|DRUG|Background Therapy (All Groups) - Metformin|Extended-release metformin tablets (≥1000mg daily) continued as background therapy for all participants throughout the study duration.
223502700|NCT07057284|RADIATION|Orthopantomogram (or a set of Lateral Oblique Radiographs)|A dental assessment will be conducted on eligible participants who still attend annual review appointments in the Oncology Departments at the Royal Manchester Children's Hospital or at The Christie NHS Foundation Trust (approximately 10% of eligible study population). The dental assessment will include the following: a tooth chart, a basic periodontal examination (BPE), a brief orthodontic assessment (incisor, molar and skeletal classification including any asymmetry), caries assessment and an assessment of any dental development disturbances. Clinical photographs of the teeth and face will be taken with a patient's consent. If clinically justified, an OPT will be taken. If cooperation for an OPT proves challenging, lateral obliques as an alternative radiographic image modality will be considered.
223502701|NCT01822743|PROCEDURE|Osteopathic manipulative treatment|Osteopathic compression of pterygopalatine node
223502702|NCT01822743|PROCEDURE|sham comparator|
223502703|NCT07056218|DEVICE|neck ultrasound|ultrasound scan
223502704|NCT07056218|DIAGNOSTIC_TEST|thyroglobulin|blood test
223502705|NCT07055659|DIAGNOSTIC_TEST|Oral hygiene assessment|experimental group will be given a plant to water it during 2-minute brushing habit. number of decayed teeth and and status of gingiva with the amount of plaque will be compared between the groups
223502706|NCT07051239|OTHER|Closed-loop acoustic stimulation|At-home sleep will be monitored using an EEG headband. Non-awakening auditory stimuli will be delivered during non-rapid eye movement sleep (NREM), timed to the ascending phase of slow waves, using either active or control (sham) conditions.
223502707|NCT07052513|DRUG|Placebo|Intravenous infusion of normal saline.
223502708|NCT07052513|DRUG|M2RLAB 001|Intravenous infusion of M2RLAB 001
223502709|NCT01030900|BIOLOGICAL|Campath|campath plus etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin (EPOCH) and rituximab every 3 weeks for up to 6 cycles
223502710|NCT01030900|BIOLOGICAL|Rituximab|rituximab plus etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin (EPOCH) and campath every 3 weeks for up to 6 cycles
223502711|NCT01030900|DRUG|EPOCH|Etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin (EPOCH) plus rituximab and campath every 3 weeks for up to 6 cycles
223502712|NCT07056270|OTHER|static CT scans|Patients with chronic liver disease and liver cancer received static CT scans before hepatectomy to establish a high-definition CT database.
223502713|NCT05497323|DRUG|Combination Cream|The combination cream consists of Salicylic Acid, Aqua Posae Filiformis, Niacinamide, Lipohydroxy Acid, Procerad and Zinc PCA, were applied every morning by group 2 and group 3.
223502714|NCT05497323|DRUG|Adapalene 0,1% cream|Adapalene 0,1 % cream were given to subjects to be applied every night in group 1 and group 3, and intermittently every two nights in group 2.
223592171|NCT04161001|DRUG|Amlodipine/Olmesartan 10/40mg (Combination drug), Ezetimibe/Rosuvastatin 10/20mg(Combination drug)|co-administration of Sevikar tab. 10/40mg(Amlodipine/Olmesartan 10/40mg), Rosuzet Tab. 10/20mg(Ezetimibe/Rosuvastatin 10/20mg) and placebo of Olmetec Tab. 40mg(Olmesartan 40mg)
223592172|NCT04161001|DRUG|Olmesartan 40mg, Ezetimibe/Rosuvastatin 10/20mg(Combination drug)|co-administration of Olmetec tab. 40mg(Olmesartan 40mg), Rosuzet Tab. 10/20mg(Ezetimibe/Rosuvastatin 10/20mg) and placebo of Sevikar tab. 10/40mg (Amlodipine/Olmesartan 10/40mg)
223592173|NCT04161001|DRUG|Amlodipine/Olmesartan 10/40mg (Combination drug)|co-administration of Sevikar tab. 10/40mg(Amlodipine/Olmesartan 10/40mg, and placebo of Rosuzet Tab. 10/20mg(Ezetimibe/Rosuvastatin 10/20mg), Olmetec Tab. 40mg(Olmesartan 40mg)
223502715|NCT02485769|DRUG|PF-06650833|Suspension
223502716|NCT02485769|DRUG|Placebo|Suspension
223502717|NCT02485769|DRUG|PF-06650833|Tablet (Modified Release)
223502718|NCT02485769|DRUG|Placebo|Tablet (Modified Release)
223502719|NCT01179399|DRUG|TAK-960|TAK-960 administered orally once a day for 21-days of a 28-day treatment cycle. A 3 + 3 dose escalation scheme will be employed.
223502720|NCT07056114|OTHER|The patients with active or inactive TED|The patients were categorized into either the active or inactive TED group based on the Clinical Activity Score
223502721|NCT07055685|COMBINATION_PRODUCT|Progressive Resistance Training + Core Stability Exercises|"Participants in Group A will engage in a combined program focusing on upper limb strengthening and trunk stabilization. The core stability component aims to improve neuromuscular control and trunk endurance, while the resistance training targets upper limb muscle strength and shoulder stability.~Core Stability Exercises:~Exercise Description Duration/Repetitions Planks Holding a straight-body position on elbows and toes. 30-60 seconds Bird-Dog Extending one arm and opposite leg, maintaining neutral spine. 5-10 sec/rep, 10-12 reps per side Dead Bug Supine position, extending opposite arm and leg. 3-5 sec/rep, 12-15 reps Bridging Lifting hips off ground, maintaining spinal alignment. 10-15 sec/rep, 12-15 reps Swiss Ball Stability Balance in sitting or leg lift positions using a Swiss ball. 20-30 sec/position, 10-12 reps Progression in core exercises will occur by increasing repetitions, duration, or complexity based on individual capability."
223502722|NCT07055685|COMBINATION_PRODUCT|Progressive Resistance Training|will perform only the upper limb progressive resistance training protocol as outlined below. This regimen focuses on strengthening the shoulder complex, upper back, and arm muscles to improve muscular performance, endurance, and control. Progressive Resistance Training
223502723|NCT07056348|DEVICE|Deep Brain Stimulation (DBS) of the Motor Thalamus|All participants enrolled will undergo stimulation parameters tuning of deep brain stimulation electrode leads. All subjects will participate in a series of experiments to evaluate the stimulation effects on movement of face and upper extremities, swallowing, and speech abilities.
223502724|NCT07057050|OTHER|The designed physiotherapy program|"* Scapular and thoracic mobilization, active assisted and passive exercises, and positioning such as weight bearing on the affected upper limb.~* Strengthening of the shoulder flexors and elbow and wrist extensors.~* Stretching exercises of the spastic muscles (shoulder extensors, elbow and wrist flexors.)"
223502725|NCT07057050|DRUG|The Botulinum toxin injection|The injection of 1000 units per upper extremity will be done into the biceps brachii muscle at 2 sites, and 150 units into the flexor carpi radialis muscle at 1 site per muscle, using anatomical landmarks similar to routine electromyography.
223502726|NCT07057050|OTHER|Task oriented training|The training involves 30 minutes of bilateral functional tasks like carrying a block, grabbing and folding a towel, staking cups upright, holding a glass and drinking water, throwing a ball into a basket, and moving pegs.
223502727|NCT07057050|OTHER|Constrained induced movement therapy|The therapy session focuses on enhancing the affected arm's functional tasks, such as throwing a ball, holding a glass, combing hair, turning on and off a light switch, grasping and releasing blocks, pouring from glass to another, moving cups, and moving pegs. Participants are instructed to wear a restrictive mitt on their non-paretic hand for 6 hours a day for 4 days, 7 weeks, and 12 weeks, with the mitt removed for safety, hygiene, or agreed-on activities.
223502728|NCT07045636|OTHER|PEMF abd Sham (control)|Dental implants receive MED that could (test) or could not (control/SHAM) be activated to emit PEMF
223502729|NCT07045636|DIAGNOSTIC_TEST|Teeth wih gingivits|Comparison with dental implants
223502730|NCT02803541|BEHAVIORAL|12 day mainstream summer camp experience|see arm description
223592174|NCT02518191|DRUG|GnRHa|3.6mg subcutaneous injection every 28 days.Initiated 1-2 weeks before chemotherapy and ended 4-8 weeks after chemotherapy.
223592175|NCT04407234|DRUG|Tirzepatide|Tirzepatide administered SC.
223592176|NCT04407234|DRUG|Acetaminophen|Acetaminophen administered orally.
223592177|NCT05323097|OTHER|Drowning-related OHCA|Drowning-related out-of-hospital cardiac arrest (OHCA): YES
223592178|NCT02146027|DIETARY_SUPPLEMENT|Fermented Milk Drink Yakult 40|Lactobacillus casei Shirota, with 40 billion bacteria per 80 g (concentration of 5 x 10\^8 CFU/g). Intervention will be used for 12 weeks.
223592179|NCT02146027|DIETARY_SUPPLEMENT|Fermented Milk Drink Yakult 40|Ingredients: Skimmed milk and/or Reconstituted Skimmed Milk, Sugar, Glucose, Live Lactic Bacteria (Lactobacillus casei Shirota) 40 billions per 80 g - concentration of 5 x 108 CFU/g), Flavour. Gluten Free.
224310248|NCT05039866|BIOLOGICAL|ST-920|No study drug is administered in this study. Subjects who received ST-920 in a separate parent trial will be evaluated in this trial for long-term safety.
224310249|NCT06105801|PROCEDURE|Endobronchial ultrasound with transbronchial needle aspiration|Participants will undergo Endobronchial ultrasound with transbronchial needle aspiration
224310250|NCT06105801|PROCEDURE|Bronchoscopy|Participants will undergo Bronchoscopy
224310251|NCT06105801|PROCEDURE|Cryobiopsy|Participants will undergo Cryobiopsy
223592180|NCT01705912|OTHER|Complete intervention|The basic intervention, an occupational therapist assessed the home environment and gave advice, if necessary. Then participants were assessed by a physiotherapist concerning health and function pre and post intervention. The intervention consisted of an individually designed home exercise program aiming at improving balance, muscle strength and walking ability. The program, which was made by the physiotherapist, should be performed three times a week. A minimum of 30 minutes of walking per week was recommended, encouring further walking on an individual basis. An assistant nurse made eight home visits to supervise, help and encourage performance of activities.
223592181|NCT01705912|OTHER|Basic intervention|The basic interventions was an occupational therapist assessed the home environment and gave advice, if necessary. Then participants were assessed by a physiotherapist concerning health and function pre and post intervention.
223592182|NCT00727558|DEVICE|nelfilcon A|spherical soft contact lens
223592183|NCT00727558|DEVICE|narafilcon A|spherical soft contact lens
223592184|NCT04736615|DEVICE|SAFEWATER systems for drinking water disinfection|A domestic water purification technology, consisting of a raw water storage tank, a pump, a filtration unit (2 cartridge filters), a UVC disinfection unit (UV lamp), a storage tank for drinking water (treated and safe water), and a distribution network inside the house for drinking water.
223592185|NCT04736615|BEHAVIORAL|Behavior change interventions|Targeting behaviors around the use of the technology and water more generally. Behavioral interventions will be data-driven (i.e., dependent on the problems that arise) but are likely to include household and community-level activities.
223592186|NCT01949610|DRUG|14C-JNJ26489112|Participants will receive single dose of oral suspension of 1000 mg (10 mL) of 14C-JNJ26489112 on Day 1.
223592187|NCT03678168|OTHER|Throat Pack|Post rhinology surgery throat packs will be used as a control to compare against the intervention (Pharyngeal tampons)
223592188|NCT03678168|OTHER|Pharyngeal Tampons|Post rhinology surgery Pharyngeal Tampons will be used as an intervention to compare against the throat pack (control)
223592189|NCT01106274|RADIATION|ultraviolet-A|Corneal cross linking (C3R) with riboflavin and ultraviolet-A (UVA, 370 nm, 3mW/cm2) for 30 min
223592190|NCT01605721|DEVICE|XIENCE PRIMETM everolimus-eluting coronary stent|"Active prospective registration of patients receiving the following stent~: XIENCE PRIMETM"
223592191|NCT05069753|PROCEDURE|Immediate sequential bilateral cataract surgery (ISBCS)|Surgery on both eyes will be performed on the same day as separate procedures: Once surgery on the first eye is completed, a new sterile procedure on the second eye will commence.
223592192|NCT05069753|PROCEDURE|Delayed sequential bilateral cataract surgery (DSBCS)|The group will undergo bilateral cataract surgery on two separate days with a time period of one week between the two procedures.
223592193|NCT05735249|DRUG|ARN-75039 oral capsules|SAD: Up to 5 single escalating doses MAD: Up to 3 escalating doses Food-effect: Selected single dose
223592194|NCT05735249|DRUG|Placebo|Given at frequency and amounts matching ARN- 75039 dosing regimen
223592195|NCT01085370|OTHER|Early psychological intervention|3 modules: psychoeducation, reconstruction of the trauma, coping skills
223592196|NCT02624427|DEVICE|Measurement of intraocular pressure (IOP)|Measurement of IOP with the following devices: (1) Goldmann tonometer, (2) Dynamic Contour tonometer, and (3) Corvis ST tonometer
223592197|NCT03981068|RADIATION|Re-irradiation|Cisplatin for all eligible patients, nimorazole for all SCC
223592198|NCT06464263|DRUG|Dexmedetomidine|to investigate the postoperative analgesic-sedative effect of dexmedetomidine versus fentanyl-midazolam to achieve fast-track extubation after adult valvular cardiac surgeries.
223592199|NCT03394586|DRUG|Exposure to golimumab|retrospective chart review to assess patient related outcomes and objective measures of inflammation at baseline, 6-10 weeks, 6 months, 12 months.
223592200|NCT05228483|DEVICE|CO2 fractional laser|CO2 fraction laser
223592201|NCT05228483|COMBINATION_PRODUCT|5-aminolevulinic acid (5-ALA) with red light illumination|5-aminolevulinic acid (5-ALA) is a photosensitizing agent which can induce photochemical reactions in tissues in response to an appropriate wavelength of light (red light 630-635nm).
223592202|NCT05228483|DRUG|Mometasone furoate (MMF) 0.1% ointment|0.1% Mometasone furoate ointment is a potent steroid and has been proven to result as efficacious and well tolerated as clobetasol propionate which represent the recomended first-line treatment of vulvar lichen sclerosus.
223592203|NCT01754493|DRUG|Duloxetine|This study is a 12-week open trial to assess the efficacy of duloxetine (Cymbalta) for the treatment of Irritable Bowel Syndrome (IBS) symptoms and comorbid Major Depressive Disorder (MDD). Participants will visit the clinic 8 times to meet with the psychiatrist. They will receive duloxetine to see if it helps their major depression and Irritable Bowel symptoms.
223592204|NCT05575193|OTHER|Acupressure|The patients will receive 4 acupuncture points, including Quchi acupoint, Xuehai acupoint, Sanyinjiao acupoint, and Zusanli acupoint. Each acupoint will be pressed for 3 minutes, and totally 4 acupuncture points are 12 minutes.
223592205|NCT03172156|GENETIC|ctDNA detection|To detect ctDNA in Patients With Stage I Non-small Cell Lung Cancer (NSCLC) Using Secondary Gene Sequencing (NGS)
223592206|NCT05865912|COMBINATION_PRODUCT|Mindfulness training + real tDCS|"The MT is an established app-based programme delivered by Headspace®. During MT, participants complete guided meditation sessions which focus on mindful eating and on coping with cravings. Each MT session lasts 15 min. Participants in the MT+ real tDCS and MT+ sham tDCS groups will be given instructions to practice daily mindfulness for 3 weeks. During 10 of these sessions, MT and real/sham tDCS will be delivered concurrently.~TDCS: During tDCS, a constant weak direct current is applied via electrodes (anode and cathode) placed on the scalp. In this study, the anode will be placed over the right dorsolateral prefrontal cortex (dlPFC) and the cathode will be placed over the left dlPFC. In the real tDCS condition, stimulation will be delivered at a constant current of 2 mA with a 10 second fade in/fade out for 20 minutes. In sham tDCS, the stimulator will deliver 60 seconds of active stimulation at the start (ramping up) and end (ramping down) of the 20 minute period."
223592207|NCT05865912|COMBINATION_PRODUCT|Mindfulness training + sham tDCS|Mindfulness training + sham tDCS
223592208|NCT01543776|DRUG|abiraterone acetate|Given PO
223592209|NCT05508919|DEVICE|Biofeedback|EMG, RESP, and TEMP Biofeedback Training
223592210|NCT05508919|OTHER|Writing Sessions|The subjects will be asked to take three 20-minute writing sessions and write about the given control topic about their daily events of the past week
223592211|NCT00254670|DRUG|Naltrexone|
224193755|NCT01655173|BEHAVIORAL|Cognitive behaviour therapy|"The CBT intervention consisted of five elements: (a) structure, (b) group setting, (c) psycho-education, (d) social training and (e) CBT.~The participants were presented with the session plan for the whole year and given a binder in which they kept all materials. In addition, each session followed a strict agenda: (1) introduction and presentation of the agenda of the day, (2) resume of homework assignments from the previous session, (3) psycho-educative lecture and discussions on the session topic, (4) coffee break with buns or sandwiches, and social interaction, (5) relaxation or mindfulness exercise, (6) discussions and exercises on the session topic, (7) distribution of homework and (8) evaluation and end of session."
224193756|NCT01655173|BEHAVIORAL|Recreational activity intervention|The therapists did not provide any deliberate interventions, such as psychoeducation, social training or CBT. Instead, the intervention relied on structure and group setting only. During the first session the participants were asked to write down group activities they would like to engage in. The therapists created a list of the suggested activities, such as visiting museums, board game playing, cooking, restaurant visits, boating, cinema and taking walks. The participants voted for the activity of the next session.
224193757|NCT04749173|DRUG|DWRX2003, 96mg|Drug: Placebo Intramuscularly injection at predefined injection sites
224193758|NCT04749173|DRUG|DWRX2003, 432mg|Drug: Placebo Intramuscularly injection at predefined injection sites
224193759|NCT04749173|DRUG|DWRX2003, 144mg|Drug: Placebo Intramuscularly injection at predefined injection sites
224193760|NCT04749173|DRUG|DWRX2003, 144mg|Drug: Placebo Intramuscularly injection at predefined injection sites
224310252|NCT05002777|DRUG|rilzabrutinib|Pharmaceutical form: Tablet Route of administration: Oral
224193761|NCT01145573|DIETARY_SUPPLEMENT|Calcium or Placebo|Participants are randomized to take either 1000mg of calcium or placebo from week 16 of pregnancy until delivery.
224193762|NCT04167839|OTHER|Sensory diet|Sensory diets are one of the interventions occupational therapists use in school-based settings to manage manifestations of sensory processing disorder. Sensory diets are composed of exercises and multisensory activities that are tailored for children and provide them sensorimotor experiences to facilitate their participation in daily activities.
224310253|NCT06595303|DRUG|Nitrous oxide for labour analgesia|Any woman may choose to have nitrous oxide inhalation as a standard protocol for labour analgesia
223502731|NCT06349278|PROCEDURE|Pancreatic resection and non-anatomic liver resections.|Pancreatic resection and non-anatomic liver resections.
223502732|NCT02859116|PROCEDURE|Collection of digestive tissues|The surgeon will resect a sample (approximately 1-5 cm x 1-5 cm) of healthy tissue from the distal margins of the segment and at least 4 cm from the diseased area. The specimen for research will be obtained from the tissue that would ordinarily be removed during surgery.The tissue collected for our research purposes will be only remnant tissue which is discarded by the surgeon during the surgical intervention and has no diagnostic clinical value.
223502733|NCT00375297|DRUG|sildenafil|
223502734|NCT01631253|PROCEDURE|Laparoscopic ovarian cyst enucleation|
223502735|NCT02387112|DEVICE|Early VAD implantation|Implantation of a left ventricular assist device
223502736|NCT03622840|BEHAVIORAL|Cognitive Remediation|Weekly 30-45mins Cognitive Remediation Sessions over 11 weeks
223502737|NCT03533933|DEVICE|Collagen matrix|Mucograft collagen matrix combined with coronal advanced flap
223502738|NCT03533933|OTHER|autologous connective tissue graft|Soft tissue harvesting from patient palate with coronal advanced flap
223502739|NCT06015100|DRUG|Inetetamab plus pyrotiniband and capecitabine|Inetetamab plus pyrotiniband and capecitabine
223502740|NCT05556018|DEVICE|Electrical Activation Mapping Guided Cardiac resynchronization therapy|To study the feasibility to optimize configuration of CRT delivery for acute correction of electrical dyssynchrony using a noninvasive mapping of global electrical activation
223502741|NCT06686459|RADIATION|ALL-in-one radiotherapy|ALL-in-one radiotherapy (breast + supraclavicular + internal mammary lymph node drainage area)
223502742|NCT06686459|RADIATION|IMRT|IMRT (breast + supraclavicular + internal mammary lymph node drainage area)
223502743|NCT00441896|DRUG|Ganaxolone|
223502744|NCT00441896|OTHER|Placebo|
223502745|NCT03630900|OTHER|Sequential O2 Culture|We investigate the effect of sequential O2 levels on human embryo culture after Intracytoplasmic sperm injection (ICSI)
223502746|NCT01392937|DEVICE|All-in-One Light multipurpose|The study was conducted over two months of wear. Subjects were examined initially, and at three follow-up visits after two weeks, one month and two months.
223502747|NCT01392937|DEVICE|Aquify care|The study was conducted over two months of wear. Subjects were examined initially, and at three follow-up visits after two weeks, one month and two months.
223502748|NCT05355220|DEVICE|Silver Spike Point Therapy (SSPT)|Silver Spike Point Therapy (SSPT) means passing an electric current through the skin surface with the triangle spike silver coated metal electrode. SSPT was reported by Hyoto and Kitade in Edinburg, Scotland. 3rd World Congress on Pain in 1981; It has a number of advantages over traditional narcotic medication in pelvic girdle pain management. It does not depress the cardiovascular, respiratory, or the metabolic systems and has no apparent effect on the sensorium
223502749|NCT05355220|OTHER|Conservative Managment|2 sets of 10 repetitions Bridging, Cat \& cow exercises, Back press exercises, stretching of hip external rotators and extensors 20 sec / stretch
223502750|NCT04475510|OTHER|Antiplatelet treatment discontinuation|All patients will undergo a clinical evaluation and cerebral MRI at 12 months (before antiplatelet treatment cessation) and at 24 months post-PFO closure.
223502751|NCT02744456|DRUG|Losartan|An angiotensin II receptor antagonist drug used mainly to treat high blood pressure.
223502752|NCT02744456|DRUG|Amlodipine|A calcium channel blocker and may be used alone or in combination with other antihypertensive and antianginal agents for the treatment of hypertension.
223502753|NCT02744456|DRUG|Hydrochlorothiazide|A diuretic medication often used to treat high blood pressure and swelling due to fluid build up.
223502754|NCT01955018|DEVICE|New algorithm called VeoTM (General Electric Healthcare, Milwaukee, MI, USA)|The objective of the present study is to compare Veo with the gold standard FBP for detecting pulmonary asbestos-related conditions among workers previously exposed to asbestos. Comparisons included radiation delivered and image quality.
224193763|NCT00421369|DRUG|sertraline|
223502755|NCT05370118|BEHAVIORAL|Telerehabilitation physical activity behavioral (TPAB) intervention|The intervention includes the behavior change techniques of self-monitoring of behavior, action planning, graded tasks, restructuring the physical and social environment, problem-solving, and prompts/cues.
223502756|NCT01301092|BIOLOGICAL|LY2189265|administered intravenous, subcutaneous or intramuscular
223502757|NCT06305325|BEHAVIORAL|eHealth Antenatal Coparenting Intervention|This intervention focuses on developing conflict management, problem solving, communication, and mutual support to foster positive joint parenting of an infant. A modification in the delivery of this intervention was made in the current study in order to make it deliver online. The eACoP intervention included eight antenatal videos from Feinberg's Family Foundation intervention. A website for the eACoP intervention was developed, and all the videos were uploaded to the website. These videos were 30-40 minutes each. The videos were in English and subtitles in Urdu were added to the videos. These videos were accompanied by an activity-based coparenting workbook. The coparenting workbook includes a worksheet and homework for each video and was also translated into Urdu
223502758|NCT06750185|BIOLOGICAL|BNT317 DL1|Intravenous infusion
223502759|NCT06750185|BIOLOGICAL|BNT317 DL2|Intravenous infusion
223502760|NCT06750185|BIOLOGICAL|BNT317 DL3|Intravenous infusion
223502761|NCT06750185|BIOLOGICAL|BNT317 DL4|Intravenous infusion
223502762|NCT06750185|BIOLOGICAL|BNT317 DL5 (intermediate)|Intravenous infusion
223502763|NCT06750185|BIOLOGICAL|BNT317 DL6 (intermediate)|Intravenous infusion
223502764|NCT06750185|BIOLOGICAL|BNT317 DL7 (additional)|Intravenous infusion
223502765|NCT01603160|BEHAVIORAL|Quality Improvement|"There are no interventions for the individual patient. The changes in processes developed by the quality improvement team will be made for all adults with sickle cell disease, not just adults who consent to interviews.~A proactive risk assessment methodology, Failure Modes, Effects, and Criticality Analysis (FMECA), will be used in two EDs to identify the vulnerabilities, risks, and weak points (failures) in the systems and processes involved in four key decisions of the ED-SCANS. Based on the aggregated results of the FMECA's, generalizable quality improvement interventions (QII's) will be developed and implemented with the purpose of changing the way emergency care for adults with SCD is delivered and organized."
223502766|NCT03334175|DRUG|Walnuts|1 ounce of individually wrapped, raw walnuts to be consumed daily replacing a high-refined carbohydrate food.
223502767|NCT03366584|DIETARY_SUPPLEMENT|Beta carotene|Beta carotene 25,000 IU
223502768|NCT03366584|DIETARY_SUPPLEMENT|Vitamin D3|Vitamin D3 50,000 IU
223502769|NCT03366584|DIETARY_SUPPLEMENT|Zinc|Zinc 50 mg
223502770|NCT03366584|DRUG|Dexamethasone|Dexamethasone 6 mg
223502771|NCT04015063|OTHER|Anti-Aging Skin Care product|Primary Subjects will use P29429-01 as an anti-aging skin care product on full face twice a day for 12-week.
223502772|NCT01271738|PROCEDURE|Remove tumor only|No additional margins (tissue) removed at the initial surgery
223502773|NCT01271738|PROCEDURE|Removal of tumor and tissue|5 additional margins (tissue) removed at the time of surgery
223502774|NCT03827642|DRUG|Treatment A: Naloxone Nasal Spray|Participants received naloxone nasal spray following a 10 hour fast.
224193764|NCT00421369|DRUG|triiodothyronine (T3)|
224193765|NCT00421369|DRUG|reboxetine|
224193766|NCT04756167|OTHER|Conventional Treatment|Hotpack, TENS, ultrasound and exercise
223502775|NCT03827642|DRUG|Treatment B: Naloxone Nasal Spray|Participants received naloxone nasal spray following a 10 hour fast.
223502776|NCT03827642|DRUG|Treatment C: Naloxone HCl Intravenous (IV) Injection|Participants received naloxone HCl IV injection following a 10 hour fast.
223502777|NCT03827642|DRUG|Treatment D: Naloxone HCl Intramuscular (IM) Injection|Participants received naloxone HCl IM injection following a 10 hour fast.
223502778|NCT01088893|DRUG|Everolimus|10mg/d) for three weeks 1 week after completion of neoadjvuant treatment and before surgery
223502779|NCT05870436|DIAGNOSTIC_TEST|Methacholine Choline Provocation Test|Perform methacholine choline provocation test according to the protocol
223502780|NCT03546543|PROCEDURE|Position change|Each subject will serve as his or her own control. Half of the infants will be placed supine for 3 hours, followed by 3 hours of prone positioning and back to supine for 3 hours and the other half will be start in prone position with consecutive periods of supine and then prone
223502781|NCT01350973|DRUG|Omega-3-acid ethyl esters 90 (TAK-085)|Omega-3-acid ethyl esters 90 (TAK-085) capsules. Each one gram of fatty acid in TAK-085 contains approximately 465 mg of EPA plus 375 mg of docosahexaenoic acid-ethyl as ethyl esters.
223502782|NCT01350973|DRUG|Eicosapentaenoic acid-ethyl (EPA-E)|EPA-E, 0.6 g, orally, three-times daily for up to 12 weeks.
223502783|NCT00566033|BEHAVIORAL|Audit-driven intervention|Patients included in this arm will undergo to the multi-method quality improvement intervention (intensive intervention) that adds practice visits, telephone and e-mail contacts (for quality improvement facilitation) and audits to the approach of periodic guideline dissemination and feedback on demand used in the less intensive intervention.
223502784|NCT02507284|DRUG|SRX246|
223502785|NCT02507284|DRUG|Placebo|
223502786|NCT03738215|DRUG|Cariprazine|Cariprazine supplied in capsules
223502787|NCT03738215|DRUG|Placebo|Placebo supplied in capsules
223502788|NCT06516432|PROCEDURE|Parasternal block|In the case-control groups, patients with elevated serum lactate levels above 2 mmol/L and those who remained below this limit will be identified.
223502789|NCT06516432|PROCEDURE|Requirement of total dose regarding fentanyl|In case-control groups, obtain measurement of total postoperative fentanyl requirement.
223502790|NCT03672825|DRUG|REcycled CartiLage Auto/Allo IMplantation|Treating cartilage defects with autologous (your own) cartilage cells mixed with allogeneic (from someone else) adipose-derived mesenchymal stem cells (AMSCs).
223502791|NCT04849832|DIETARY_SUPPLEMENT|SIC|Sodium Iron Chlorophyllin as prepared by the human nutrition laboratory, ETH Zurich
224193767|NCT04756167|OTHER|Myofascial Release Treatment|Hotpack, TENS, ultrasound, exercise and myofascial release therapy for subscapularis and serratus anterior muscles
224193768|NCT00002767|BIOLOGICAL|Detox-B adjuvant|
224193769|NCT00002767|BIOLOGICAL|recombinant interferon alfa|
224193770|NCT02996604|OTHER|acupuncture|Manual acupuncture treatment will be conducted. thirty minutes duration every time, five times per week for one course, a total four courses.
223502792|NCT04849832|DIETARY_SUPPLEMENT|SIC + tea|Sodium Iron Chlorophyllin as prepared by the human nutrition laboratory, ETH Zurich with 2g of tea brewed for 5 minutes
223746559|NCT01906710|OTHER|integrated medicines management|"PITH includes the following interventions:~A) MR on admission to obtain an up-to-date medication list, B) Intermediate medication review during hospitalization C) MR at discharge to maintain an up-to-date medication overview, counseling of the patient at hospital discharge and preparation of the patient to manage their medication at home., Written material is provided for oral support, which includes an overview of the current medication, a summary of potentially important side effects, advices on medication use and hospital pharmacy contact information in order to answer any possible questions, D) Information transfer to GP/community pharmacist at discharge"
224193771|NCT04463771|DRUG|retifanlimab|INCMGA00012 administered intravenously on Day 1 of each 28-day cycle for up to 26 cycles.
224193772|NCT04463771|DRUG|epacadostat|epacadostat will be administered orally BID.
224193773|NCT04463771|DRUG|pemigatinib|pemigatinib will be administered orally QD.
224193774|NCT04463771|DRUG|INCAGN02385|INCAGN2385 will be administered every 2 weeks
224193775|NCT04463771|DRUG|INCAGN02390|INCAGN2390 will be administered every 2 weeks
224193776|NCT04238624|DRUG|Dabrafenib|Participants will receive dabrafenib 150 mg orally twice a day
224193777|NCT04238624|DRUG|Trametinib|Participants will receive trametinib 2 mg orally once a day
224193778|NCT02096406|DRUG|ACE/ARB continuation|ACE/ARB will be taken the morning of surgery with a sip of water
224193779|NCT02096406|DRUG|ACE/ARB withdrawal|ACE/ARB will be stopped 48 hours prior to surgery
224193780|NCT03526549|BIOLOGICAL|CCH-aaes|Administered to participants who qualified for, and opted for, retreatment.
224193781|NCT03526549|OTHER|Observation|No treatment administered during 180 days of observation.
224193782|NCT05317949|OTHER|Integrated neuromuscular training program group|Integrated neuromuscular training program group will do plyometric training, speed and sensitivity training, resistance training for 3 days in a week and total for eight weeks.
223502793|NCT04849832|DIETARY_SUPPLEMENT|FeSO4|Ferrous sulfate solution serves as a positive control - and whose absorption is well known.
223502794|NCT04849832|DIETARY_SUPPLEMENT|FeSO4 + tea|Ferrous sulfate solution given with 2g of tea brewed for 5 minutes - expected iron absorption inhibition
224193783|NCT05317949|OTHER|General fitness exercises program group|General fitness exercises program group will do general fitness exercise for 3 days in a week and total for eight weeks.
224193784|NCT00006049|DRUG|carboplatin|
224193785|NCT00006049|DRUG|gefitinib|
224193786|NCT00006049|DRUG|paclitaxel|
223502795|NCT03421457|PROCEDURE|Uterus-preserving laparoscopic lateral suspension with mesh|V-shaped 2cm wide and 25cm length mesh strip is prepared from a 30x30cm Prolene mesh (Ethicon J\&J).Deep dissection of the uterovesical space is performed.Cutaneous incisions are bilaterally made 3-4 cm superoposterior to the anterosuperior iliac spine.A grasper is introduced retroperitoneally through the sub-peritoneum holding the beginning part of mesh until reaching the vesicovaginal space in an oblique route rather than transverse.Round ligament is lifted upward and tunnel is practiced horizontally.Assistant grasper catches the distal mesh and pulls out through the opposite subperitoneal tunnel.Corner of mesh is fixed to the pubocervical fascia,uterine cervix and isthmus with Absorba-Tack™(Covidien, Mansfield,USA).Tension-free lateral mesh suspension is achieved at the desired level.
223502796|NCT03421457|PROCEDURE|Uterus-preserving laparoscopic sacrocervicopexy with mesh|The peritoneum over the sacral promontory is incised until the anterior longitudinal ligament is reached and ureters are identified. Peritoneal relaxing incision is made medial to the right ureter, down into the pelvis, posterior to the cervix and rectovaginal fascia, laterally to the rectum. The arm of the mesh is sutured to the posterior cervix by 2.0 prolene and fixated to the sacral promontory by either Tacker (Covidien) and/or 2.0 prolene as tension-free. Complete peritonisation of the mesh is performed.
223502797|NCT02290093|DRUG|Standard full-volume PEG|Subjects will be asked to take 4L of PEG-3350 solution the day prior to procedure.
223502798|NCT02290093|DRUG|Split-dose full-volume PEG|Subjects will be asked to take 2L of PEG-3350 solution the day prior to procedure, followed by another 2L of PEG-3350 solution on the day of the procedure.
223502799|NCT02290093|DRUG|Split-dose low-volume PEG|Subjects will be asked to take 1L of PEG-3350 containing ascorbic acid solution the day prior to procedure, followed by another 1L of PEG-3350 containing ascorbic acid solution on the day of the procedure.
223502800|NCT00744198|PROCEDURE|Autologous transobturator tape procedure|A strip of rectus fascia is harvested. Small incision sites in the vagina and in the femoral/pelvic fold. Bilateral transobturator insertion of the autologous strip by means of reusable needles
223502801|NCT00744198|PROCEDURE|Synthetic transobturator tape procedure|Small incision sites in the vagina and in the femoral/pelvic fold. Bilateral transobturator insertion of synthetic mesh by means of mono-use needles.
223502802|NCT00744198|PROCEDURE|Biological transobturator tape procedure|Small incision sites in the vagina and in the femoral/pelvic fold. Bilateral transobturator insertion of biological mesh by means of mono-use needle
223502803|NCT03695588|PROCEDURE|Quadratus lumborum block|Ultrasound guided Quadratus Lumborum block using a posterior approach. (QLB 2)
223502804|NCT03695588|PROCEDURE|Sham QLB|Sham QLB - Ultrasound identification of QLB followed by skin pressure with blunt needle.
223502805|NCT00667966|DRUG|Vardenafil (Levitra, BAY 38-9456), 10 mg|10 mg vardenafil was administered with a glass of water 1 h before starting the test with the stimulator.
223502806|NCT00667966|DRUG|Placebo|10/20 mg placebo in sequence in respective arm
223502807|NCT00667966|DRUG|Vardenafil (Levitra, BAY 38-9456), 20 mg|20 mg vardenafil was administered with a glass of water 1 h before starting the test with the stimulator.
223502808|NCT04002895|DRUG|Foliglurax|Single oral dose of 80 mg \[14C\]-foliglurax(93µCi/3.44 MBq), 1mg/mL oral solution (prepared from \[14C\]-foliglurax powder for oral solution)
223502809|NCT00369018|DRUG|methyl aminolevulinate (MAL) and hexaminolevulinate (HAL)|MAL 1.2M, HAL 10mM and HAL 40mM solutions for 3 and 12 hours application
223502810|NCT02557997|OTHER|Blood tube bottom analyses|
223502811|NCT06061419|OTHER|Huel Powder|Huel Powder v3.0 white, vanilla flavour
223502812|NCT06773481|BIOLOGICAL|BC008-1A|Biological: 900 mg BC008-1A will be intravenously injected once every 3 weeks.
223502813|NCT06773481|BIOLOGICAL|BC008-1A|Biological: 1200 mg BC008-1A will be intravenously injected once every 3 weeks.
224193787|NCT03988049|DEVICE|1,550 fracionated photothermolysis laser|All subjects will have one side of their face treated with one laser, and the other side with the other laser.
224193788|NCT03988049|DEVICE|755 picosecond laser|All subjects will have one side of their face treated with one laser, and the other side with the other laser.
224193789|NCT00070070|BIOLOGICAL|TICE®-strain BCG|
224193790|NCT00070070|BIOLOGICAL|NY-ESO-1 protein|
224193791|NCT00070070|BIOLOGICAL|sargramostim|
224193792|NCT05857501|DEVICE|abdominopelvic computerized tomography (CT) without contrast|scan combines a series of X-ray images taken from different angles around your body and uses computer processing to create cross-sectional images (slices) of the bones, blood vessels and soft tissues inside your body. CT scan images provide more-detailed information than plain X-rays do.
224193793|NCT02052206|PROCEDURE|Shoulder replacement surgery|
224193794|NCT06519799|OTHER|Menstrual hygiene products|The influence on the intimate health of each product will be evaluated. As you can't not use a menstrual product during menstruation, no control group is included
224193795|NCT05981365|DRUG|Voxelotor|Drug drug interaction
224193796|NCT05981365|DRUG|Bupropion|Drug drug interaction
224193797|NCT05981365|DRUG|Repaglinide|Drug drug interaction
224193798|NCT05981365|DRUG|Flurbiprofen|Drug drug interaction
224193799|NCT05981365|DRUG|Omeprazole|Drug drug interaction
224193800|NCT05981365|DRUG|Midazolam|Drug drug interaction
224193801|NCT05981365|DRUG|Metformin|Drug drug interaction
224193802|NCT05981365|DRUG|Furosemide|Drug drug interaction
223592212|NCT05041270|DRUG|normal saline|"Surgery will be started under spinal anesthesia. When sensory block regress to T12 dermatome Epidural bolus dose will be given epidural bolus dose of 12ml (10ml 0.25% bupivacaine + 2ml normal saline) The onset of sensory blockade injected epiduraly with maximal cephalic spread will be assessed by bilateral pinprick method along the midclavicular line, every 5 min for 30 min and then every 30 min.~top up dose of 8ml will be given postoperative (6ml 0.25% bupivacaine + 2ml normal saline)."
224193803|NCT05981365|DRUG|Rosuvastatin|Drug drug interaction
224193804|NCT04780776|DEVICE|UVB treatment|5 weeks of UVB titration to determine individual's UVB sensitivity followed by 16 weeks of UVB exposure intervention
224193805|NCT04780776|DEVICE|Sham comparator|5+16 weeks of visible light exposure
224193806|NCT05053581|OTHER|Survey|Patients will complete 7 questionnaires at inclusion (T0) and 1,3 and 6 months after start of CPAP treatment
223502814|NCT05548855|PROCEDURE|Heart Transplant|Patients who have undergone a heart transplant as standard of care (SOC) procedure
224193807|NCT03113760|DRUG|Tadekinig alfa|Tadekinig alfa is a soluble glycoprotein of 164 amino acids produced from Chinese Hamster Ovary cell line. Tadekinig alfa is supplied as a colorless to slightly yellow, sterile solution for injection in glass vials containing sodium chloride, and 0.02M sodium phosphate buffer as excipients. It is available in a concentration of 20mg/0.5mL.
224193808|NCT03113760|OTHER|0.9% sodium chloride|To ensure that the treatment remains blinded for the entire study period, the placebo solutions will be supplied in identical vials and similar labelling as the active drug and will be indistinguishable in terms of their texture, color, and smell.
224193809|NCT00736216|OTHER|survey administration|Participants complete the Young Adult Survey online documenting demographic data; sexual history (i.e., whether they ever had sex, age of first sexual encounter, number of life time partners, condom use, sexually transmitted diseases \[STDs\], and pregnancy history); cigarette use; current and past drug use; knowledge of human papillomavirus (HPV) and cervical cancer; past history of Pap tests and STD screenings; attitudes towards HPV testing; vaccine knowledge and acceptability; sources of information about HPV; source of information about cervical cancer; identification of common STDs; perceived risk of acquiring STDs; perceived risk of acquiring HPV; social support; and religion.
224193810|NCT03927989|BEHAVIORAL|Text messaging plus nicotine replacement therapy|Brief advice to quit smoking prior to lung cancer screening (LCS), 8 weeks of gain-framed, LCS-tailored text messages, and nicotine replacement therapy.
224193811|NCT03927989|OTHER|Standard Care at Lung Cancer Screening|Brief advice to quit smoking prior to lung cancer screening
224310254|NCT06062043|BEHAVIORAL|Brief ACT with CPP Education Treatment|The Brief ACT with CPP Education treatment provides women veterans with new ways of responding to difficult thoughts and emotions related to pain while also encouraging them to engage in meaningful life activities. The CPP educational component includes information about pathology, risk factors, health outcomes, and treatment that are specific to women's biological and reproductive functioning. Treatment content has been further tailored to reflect the cultural experiences of women veterans (including discussions on the interplay between military culture, perceived social norms, and gender role expectations).
223502815|NCT05548855|DEVICE|Cardiac Assistive Device|Patients who have undergone a placement of a cardiac assistive device
223502816|NCT02571231|DEVICE|HFV + and - VG|High frequency ventilation with and without volume guarantuee
223502817|NCT02302456|DRUG|Tranexamic Acid|Intravenous administration of a 10 mL solution containing 1g of tranexamic acid within 2 minutes of birth and routine prophylactic IV injection of oxytocin
223502818|NCT02302456|DRUG|Placebo|Intravenous administration of 10 mL of 0.9% sodium chloride solution within 2 minutes of birth and routine prophylactic IV injection of oxytocin
223502819|NCT00302471|DRUG|Comparator: MK0429|"Part 1 - MK3328 of 1600 mg twice a day for 4 weeks given to men with hormone refractory prostate cancer and metastatic bone.~Disease."
223502820|NCT00302471|DRUG|Comparator: MK0429|Part 2- MK3328 of 200 mg twice a day for 4 weeks to men with hormone refractory prostate cancer and metastatic bone disease.
223502821|NCT00302471|DRUG|Comparator: MK0429|Part 1- MK3328 of 800mg twice a day for 8 weeks to men with hormone refractory prostate cancer and metastatic bone disease.
223502822|NCT00302471|DRUG|Comparator: MK0429|Part 2 - MK3328 of 400 mg twice a day for 8 weeks to men with hormone refractory prostate cancer and metastatic bone disease.
223502823|NCT01033071|DRUG|Azilsartan medoxomil and chlorthalidone|"Azilsartan medoxomil 20 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily and olmesartan and hydrochlorothiazide placebo-matching tablets, orally, once daily for up to 4 weeks.~Participants will be force titrated at Week 4 to azilsartan medoxomil 40 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily for the next 4 weeks.~Participants will then be force titrated at Week 8 to azilsartan medoxomil 40 mg and chlorthalidone 25 mg combination tablets, orally, once daily for the next 4 weeks."
224193812|NCT05960461|BEHAVIORAL|FMF (Families Moving Forward) Connect Pro|"FMF Connect Pro is a program supported by mental health providers to increase access to care for children (ages 3 to 12) with fetal alcohol spectrum disorders (FASD) and their families. FMF Connect Pro teaches and supports providers in 3 main activities:~1. Routine screening of prenatal alcohol exposure (PAE)~2. Apply DSM-5 diagnostic criteria for Neurodevelopmental Disorder Associated with Prenatal Alcohol Exposure (ND-PAE)~3. Support caregivers using the FMF Connect app~FMF Connect Pro involves a Provider Dashboard with several main sections:~* Learning - includes content and additional resources to support providers in learning how to screen PAE, diagnose ND-PAE, and support families using the FMF Connect app.~* Tools and Resources - includes: screening, diagnostic, and documentation templates; app tip sheets; workbooks; supporting articles, websites, and other resources~* Clients - providers can track clients' progress using the FMF Connect app"
224193813|NCT05960461|BEHAVIORAL|ECHO (Extension of Community Healthcare Outcomes) implementation.|Mental health providers participate in a 13-session tele-mentoring training program using the ECHO (Extension of Community Healthcare Outcomes) approach. Each session involves a brief didactic presentation and case-based learning using de-identified cases shared by participants. The curriculum teaches providers how to do FMF Connect Pro.
224193814|NCT05960461|BEHAVIORAL|Self-Directed Learning implementation.|Mental health providers complete 13 learning modules asynchronously on the FMF Connect Pro Dashboard. These modules include pre-recorded didactic content, brief exercises to assess learning, and additional resources. The curriculum teaches providers how to do FMF Connect Pro.
224193815|NCT04632485|DEVICE|Ultrasound imaging|Carotid artery ultrasound exam. US imaging will include complete clinical carotid ultrasound examination (B-mode, Doppler and color-flow modes), clinical strain and shear wave imaging study, backscattered and beam-steered radiofrequency (RF) data acquisition using research mode, and reference phantom RF data acquisition.
224193816|NCT04632485|DEVICE|Magnetic Resonance Imaging (MRI)|Head and Neck MRI exam with contrast
224193817|NCT04632485|OTHER|Neurocognitive testing|Harmonization battery to assess executive function/attention, speeded psychomotor, verbal, and nonverbal memory, language, and visuospatial skills
224193818|NCT04632485|DEVICE|Transcranial Doppler (TCD)|Use of a TCD system to monitor right and left middle cerebral artery Doppler waveforms in the volunteer for 60 minutes
224193819|NCT04632485|DEVICE|Pulse Wave Doppler|Pulse wave Doppler will be used to acquire a Doppler waveform in the right common carotid artery and the right femoral artery
224193820|NCT06237855|OTHER|Self-drain removal|Subjects will be trained to self-remove drain at home following ventral hernia repair.
224193821|NCT06256900|OTHER|Flow-controlled ventilation|FCV mode during robot-assisted laparoscopic surgery
224193822|NCT06256900|OTHER|Pressure-controlled ventilation|PCVmode during robot-assisted laparoscopic surgery
224193823|NCT00204568|DRUG|Adriamycin|60 mg/m2, d1, W d22
224193824|NCT00204568|DRUG|Trofosfamide|300 mg absolute d1-7, followed by 150 mg absolute continuously
224193825|NCT01940731|DRUG|Colistimethate sodium|3-5mg/(kg.d)(if CLcr≥80 mL/min),The maximum dose≤300mg/d 2.5-3.8mg/(kg.d)（if CLcr=50-79mL/min），The maximum dose≤230mg/d twice a day
223502824|NCT01033071|DRUG|Azilsartan medoxomil and chlorthalidone|"Azilsartan medoxomil 40 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily and olmesartan and hydrochlorothiazide placebo-matching tablets, orally, once daily for up to 4 weeks.~Participants will be force titrated at Week 4 to azilsartan medoxomil 80 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily for the next 4 weeks.~Participants will then be force titrated at Week 8 to azilsartan medoxomil 80 mg and chlorthalidone 25 mg combination tablets, orally, once daily for the next 4 weeks."
223592213|NCT05041270|DRUG|Dexmedetomidine|"Surgery will be started under spinal anesthesia. When sensory block regress to T12 dermatome Epidural bolus dose will be given epidural bolus dose of 12ml (10ml 0.25% bupivacaine + 100µg dexmedetomidine in 2ml volume) The onset of sensory blockade injected epiduraly with maximal cephalic spread will be assessed by bilateral pinprick method along the midclavicular line, every 5 min for 30 min and then every 30 min.~top up dose of 8ml will be given postoperative (6ml 0.25% bupivacaine + 20µg dexmedetomidine in 2ml volume)."
223746560|NCT00930579|DRUG|Metformin|1500 mg per day, divided 500 mg in the morning and 1000 mg in the evening, for at least two weeks prior to surgery
223746561|NCT00507442|DRUG|VELCADE (bortezomib)|bortezomib 1.3 mg/m\^2 given via IV on days 1, 4, 8, and 11 of a 3-week cycle for 8 cycles, then on days 1, 8, 15 and 22 of a 6-week cycle for 4 cycles (maintenance).
224193826|NCT02988830|DEVICE|Subcutaneous Electric Lumbar Stimulation|
224193827|NCT02140996|DRUG|Ad-sig-hMUC-1/ecdCD40L vector vaccine|
224193828|NCT00007735|DRUG|Doxycycline (200mg/day) or Placebo|
224193829|NCT05489016|DRUG|Yuekang Huoxin Pills (concentrated pills)|Huoxin Pill (concentrated pill) is composed of Radix Ginseng, Radix Aconiti Lateralis Preparata, Ganoderma, Flos Carthami, artificial Moschus, cultured calculus bovis in vitro, Fel Ursi, Margarita, Venenum Bufonis, and Borneolum Syntheticum. It has the effect of invigorating qi and promoting blood circulation. It has been marketed in China for more than 30 years. Clinical studies have shown that Huoxin Pill (concentrated pill) has significant clinical efficacy in improving the symptoms and prognosis of coronary heart disease and angina pectoris. Basic studies have also confirmed that Huoxin Pill (concentrated pill) can play a role in myocardial protection by dilating coronary arteries and promoting angiogenesis. It produced by Guangzhou yuekang biopharmaceuticals co., ltd.
223502825|NCT01033071|DRUG|Olmesartan medoxomil and hydrochlorothiazide|"Olmesartan medoxomil 20 mg and hydrochlorothiazide 12.5 mg combination tablets, orally, once daily and azilsartan medoxomil and chlorthalidone placebo-matching tablets, orally, once daily for up to 4 weeks.~Participants will be force titrated at Week 4 to olmesartan medoxomil 40 mg and hydrochlorothiazide 12.5 mg combination tablets, orally, once daily for the next 4 weeks.~Participants will then be force titrated at Week 8 to olmesartan medoxomil 40 mg and hydrochlorothiazide 25 mg combination tablets, orally, once daily for the next 4 weeks."
223746562|NCT00507442|DRUG|dexamethasone|dexamethasone 40 mg orally on days 1, 8, and 15 of a 3-week cycle for 8 cycles, then stop
223746563|NCT00507442|DRUG|cyclophosphamide|cyclophosphamide 500 mg/m\^2 orally on days 1 and 8 of a 3-week cycle for 8 cycles, then stop
224193830|NCT05489016|DRUG|Yuekang Huoxin Pills (concentrated pills)simulant|Huoxin Pill (concentrated pill) simulant, a placebo-like simulation have no therapeutic effect. The shape, packaging and taste are the same as Huoxin Pill (concentrated pill), produced by Guangzhou yuekang biopharmaceuticals co., ltd.
223746564|NCT00507442|DRUG|Revlimid (lenalidomide)|"lenalidomide 25 mg orally on days 1 to 14 of a 3-week cycle for 8 cycles then stop (VDR arm)~lenalidomide 15 mg orally on days 1 to 14 of a 3-week cycle for 8 cycles then stop (VDCR arm)"
223746565|NCT05494242|OTHER|Surgical intervention|Pars-plana vitrectomy.
223746566|NCT05017363|PROCEDURE|ENGAGE|Goal-setting approach and strategies including the Perceived Efficacy and Goal Setting Tool (PEGS), which is established goal setting tools for children aged 5-9. Administration of the Canadian Occupational Performance Measure (COPM), the most widely used goal-setting tool in paediatric rehabilitation that has been used with children as young as seven years. Introducing simple strategies to assist children in identifying goals and to ensure ongoing focus on goals using principles of motivational interviewing, strategies to assess and nurture perceived competence (self-efficacy), and child-friendly feedback strategies on goal-related performance.
223746567|NCT02806310|OTHER|Blood draw|blood sampling for biomarker levels
223746568|NCT04291651|OTHER|Survey|There are no study-specific interventions, as this is a prospective registry. However, patients will be asked to complete approximately 1-2 hours worth of surveys on things such as demographics, medical and surgical history, and pancreatic cyst-specific questionnaires.
223746569|NCT05266807|DRUG|oral capsulized Fecal Microbiota Transplantation|FMT will be administered per os in the form of capsules containing faeces from a healthy donor. Capsules are manufactured at the CHUV pharmacy (University Hospital of Lausanne, Switzerland)
223746570|NCT05266807|DRUG|Vancomycin or Fidaxomicin|Vancomycin or Fidaxomicin per os as initially prescribed per SoC
223746571|NCT05264623|DEVICE|TENEO 317 Model 2 excimer laser|TENEO 317 Model 2 excimer laser use for refractive surgery
223746572|NCT05704738|DRUG|Rocatinlimab|Subcutaneous (SC) injection
223746573|NCT05704738|DRUG|Placebo|SC injection
223746574|NCT00739544|OTHER|1|Testing with thermal sensor testing device, von Frey filaments, cotton wisp, turning fork, pressure gauge device
223746575|NCT06093009|PROCEDURE|pancreatectomy|
223746576|NCT02672423|DRUG|Abemaciclib Capsules (Reference Formulation)|Administered orally
224193831|NCT06016296|OTHER|Combined Movement and Storytelling Intervention|The 40-minute sessions will include three moments: (i) warm-up (5 minutes), which consists of joint mobility exercises and introduction to the motor story of the week; (ii) main part (25 minutes), which incorporates the narration of the motor story by the educator initially, as well as the participation of the children, through their own corporeality with movements based mainly on FMS (locomotion skills and object control) and two way verbal interaction based on questions allusive to the narration delivered by the educator or direct verbal participation cast by each child and; (iii) cool down (10 minutes), where space is provided for the children to gradually return to calm, together with feedback on the contents addressed during the session.
224193832|NCT05040282|DEVICE|Implanon NXT|women will be subjected to etonogestrel 68 mg implant insertion. Participants will be trained on how to fill the menstrual diary. The menstrual diary includes information about days of bleeding and spotting days.
224193833|NCT04314115|OTHER|Mindfulness|Brief intervention in mindfulness, of individual type, of four sessions of sixty minutes per week, in addition to individual tasks, according to protocol of brief intervention in developed mindfulness.
224193834|NCT04314115|OTHER|Systemic therapy|Brief systemic therapy intervention, of four weekly sessions of sixty minutes, with individual tasks and assignments, according to the protocol designed.
224193835|NCT04314115|OTHER|Cognitive behavioral therapy and positive psychology|Brief intervention of traditional cognitive behavioral therapy with elements of positive psychology, of four weekly sessions of sixty minutes, with individual assignments and assignments, according to the protocol designed.
224193836|NCT01716546|DRUG|Pazopanib|
223502826|NCT03018730|BIOLOGICAL|PRX-102 (pegunigalsidase alfa)|PRX-102 1 mg/kg every 2 weeks
223746577|NCT02672423|DRUG|Abemaciclib Tablet (Test Formulation)|Administered orally
223746578|NCT06544265|BIOLOGICAL|SynKIR-310|Autologous T Cells transduced with CD19 KIR-CAR
223746579|NCT04484454|DIETARY_SUPPLEMENT|ProdromeNeuro Omega 3 Oil Nutritional Supplement|ProdromeNeuro is an algae-derived Omega 3 oil nutritional supplement product comprised of naturally occurring alkylglycerol and natural fatty acids. ProdromeNeuro functions as a natural plasmalogen precursor which can be administered orally.
223746580|NCT00912990|DRUG|Cisatracurium|One intravenous dose: 0.2mg/kg/dose
223746581|NCT00912990|DRUG|Normal saline|One Intravenous dose
223746582|NCT03533452|DRUG|Ropivacaine|Local anesthetic injection
223746583|NCT03533452|DRUG|Normal saline|Sham injection
224193837|NCT05901376|DIAGNOSTIC_TEST|MicroRNA|MiR-20a, MiR-21, MiR-106b, MiR-199a, MiR-223
224193838|NCT00219362|BIOLOGICAL|one injection of vCP1452 at W0, W4, W8 and W20|
224193839|NCT00219362|BIOLOGICAL|one injection of vCP1452 at W4, W8 and W20|
224193840|NCT00219362|BIOLOGICAL|one injection of placebo at W0, W4, W8, W20 or at W4, W8,W20|
223502827|NCT00312416|DRUG|Clonidin|
223502828|NCT00312416|DRUG|Brimonidine|
223502829|NCT03022448|OTHER|No Intervention|This is a NIS. No intervention.
223502830|NCT06392087|DRUG|Methoxyflurane|Patients ≥ 18 years of age (using a waiver of consent process) Pain score ≥ 4 on the verbal numeric pain rating scale (NPRS) traumatic injury (defined as: physical injuries of sudden onset and severity which requires immediate medical attention) Unaltered (Glasgow Coma Scale (GCS) ≥ 14) Normotensive (systolic blood pressure ≥100) Treated and transported
223746584|NCT06167109|RADIATION|CTV optimized IMRT|The contralateral CTV1 was defined as a subclinical disease consisting of 5mm margin surrounding GTVnx.The CTV2 was defined as a potentially involved regions consisting of 5mm margin surrounding CTV1, and contralateral CTV2 only included the pharyngeal recess.
223746585|NCT00006202|DRUG|Lutein|
223746586|NCT00284479|BEHAVIORAL|Walking 45 mins 2x p.w.|
223746587|NCT03469479|DRUG|FOLFOX|Hepatic intra-arterial infusion via the tumor feeding arteries of Oxaliplatin , fluorouracil, and leucovorin
223746588|NCT03469479|PROCEDURE|Hepatic resection|R0 resection
223746589|NCT05541627|GENETIC|AB-1001 Gene Therapy|One-time intracerebral bilateral injections of AB-1001 (AAVrh10.CAG.hCYP46A1), an adeno-associated viral vector serotype Rh10 containing the human cholesterol 24-hydroxylase gene
223746590|NCT04019314|PROCEDURE|Blood Collection|Samples for proEnkephalin PENK will be obtained daily and aliquots of these samples will be stored for later batch assays.
223502831|NCT06392087|OTHER|Standard Care|Patients ≥ 18 years of age (using a waiver of consent process) Pain score ≥ 4 on the verbal numeric pain rating scale (NPRS) traumatic injury (defined as: physical injuries of sudden onset and severity which requires immediate medical attention) Unaltered (Glasgow Coma Scale (GCS) ≥ 14) Normotensive (systolic blood pressure ≥100) Treated and transported
223592214|NCT05041270|DRUG|Nalbuphine|"Surgery will be started under spinal anesthesia. When sensory block regress to T12 dermatome Epidural bolus dose will be given epidural bolus dose of 12ml (10ml 0.25% bupivacaine + 10mg nalbuphine in 2ml volume) The onset of sensory blockade injected epiduraly with maximal cephalic spread will be assessed by bilateral pinprick method along the midclavicular line, every 5 min for 30 min and then every 30 min.~top up dose of 8ml will be given postoperative (6ml 0.25% bupivacaine + 2mg nalbuphine in 2ml volume)."
223592215|NCT03646474|DRUG|tranexamic Acid infusion|The tranexamic Acid group will receive an intravenous bolus of (10 mg/kg) in 100 ml of normal saline over 20 minutes after induction of anesthesia and before surgical incision.
223592216|NCT03646474|DRUG|saline infusion|In the placebogroup, patients will receive a placebo of 100 mL 0.9% normal saline.
223592217|NCT04885413|DRUG|Niraparib in Combination With Anti-PD1 Antibody|Sintilimab： 200mg i.v., d1, 21days one cycle Niraparib： 200mg p.o qd，d1-d21, 21days one cycle
223592218|NCT02301026|DRUG|5% Iron Isomaltoside 1000|Administered according to local routines and product labeling in doses at the doctors discretion
223592219|NCT04785924|DRUG|Imipenem+Relebactam|Antibiotic treatment for KPC producing CRE-containing gram-negative infections
223592220|NCT05148078|OTHER|PROMISE (Pediatric Radiation Oncology with Movie Induced Sedation Effect)|Pediatric Radiation Oncology with Movie Induced Sedation Effect (PROMISE) is an interactive, incentive-based movie system that integrates with a video surveillance gating module (VisionRT) to help keep a child's attention and prevent him or her from moving during radiation treatment. This technology is being studied as an alternative sedation solution for pediatric patients needing radiation treatment. As part of the trial, patients will be attempted to have CT simulation scan and first radiation treatment(s) using PROMISE, with general anesthesia on standby should PROMISE be unsuccessful. If PROMISE is unsuccessful for a given patient, then standard of care general anesthesia will be used for that patient's radiation treatment and PROMISE will be reattempted at physician discretion with anesthesia on standby.
223592221|NCT05245188|OTHER|Chocolate milk shakes - Product 1|11.3 glucose
223746591|NCT04019314|PROCEDURE|Blood Volume Analysis|A small amount of a radioactive isotope or tracer is injected and blood samples are taken at 6 time points during the test and analyzed.
223746592|NCT04977076|OTHER|Uninterrupted NOAC use|Continuing NOAC use in advance of elective CAG or PCI.
224193841|NCT01311531|PROCEDURE|Open reduction and fixation with TriMed fragment-specific system|Anatomical reduction, achieved by the open technique.
224193842|NCT01311531|PROCEDURE|Open reduction and fixation with TriMed volar locking plate|Anatomical reduction, achieved by the open technique.
223502832|NCT00254072|PROCEDURE|3.5 mm vs 4.8 mm Stapler During Laparoscopic Gastric Bypass|The procedure consists of a creation of a small gastric pouch and rerouting the small bowel to bypass the stomach and duodenum. There are two anastomoses in this procedure: the gastrojejunostomy and the jejunojejunostomy.
223502833|NCT01695772|DRUG|5-FU based doublet chemotherapy|Standard 5-FU based doublet chemotherapy. Protocol did not specify any particular chemotherapy regimen. The choice of 5-FU based doublet chemotherapy was as per standard of practice and the dosage of 5-FU based doublet chemotherapy was as per product labels.
223502834|NCT01695772|DRUG|bevacizumab|5 mg/kg every 2 weeks, up to 12 cycles pre- and postoperatively
223502835|NCT05047380|BEHAVIORAL|Owstery Disability Scale for disability Beck Depression Scale, Beck Anxiety Scale for psychological evaluation, VAS for pain, Pittsburgh Sleep Quality Scale for sleep quality|All assessments will be made using questionairres. The Oswestry Disability Index scale will be filled in to assess the severity of disability resulting from pain in the patient. Pain severity will be evaluated with the Visual Analog Scale (VAS). Depression and anxiety assessment will be made with Beck Depression Scale and Beck Anxiety Scale, respectively. Sleep quality will be evaluated with the Pittsburg Sleep Quality Index.
223502836|NCT03277274|DRUG|TAK-954|TAK-954 intravenous infusion.
223502837|NCT03819699|DRUG|Lu AF20513|Lu AF20513 suspension for injection
223502838|NCT03819699|BIOLOGICAL|booster vaccine|booster vaccine (Cohort 2) - to be administered as per national recommendations
223502839|NCT02492386|DEVICE|Bioabsorbable everolimus-eluting stent deployment|Bioabsorbable everolimus-eluting stent deployment
223502840|NCT01675700|DRUG|Nitroglycerin patch|Nitroglycerin 0.1 mg/hr patch
223502841|NCT05752864|BEHAVIORAL|spine manual therapy|The manual treatment method applied to the sacroiliac joint used high-velocity, low amplitude (HVLA).
223592222|NCT05245188|OTHER|Chocolate milk shakes - Product 2|8.84 glucose
223592223|NCT05245188|OTHER|Chocolate milk shakes - Product 3|4.24 glucose
223502842|NCT05752864|DEVICE|Superficial heat therapy|In the physical therapy used in this study, it was applied for 20 minutes using conventionally used superficial heat therapy.
223592224|NCT05245188|OTHER|Chocolate milk shakes - Product 4|4.36 glucose
223592225|NCT05311267|OTHER|Action observation training|Subject is asked to observe videos with motor contents
223592226|NCT00568126|DRUG|Maca Root|3g/day of Maca Root for 12 weeks.
223592227|NCT00568126|DRUG|Placebo|Placebo provided by research pharmacy daily for 12 weeks.
223592228|NCT04681963|OTHER|Clinical Assessment within 4 hours of admission|Demographics, Symptoms, Severity scores (Triage at admission, confusion, urea, respiration, blood pressure, age (CURB 65) and pneumonia severity score (PSI), clinical parameters, blood testing, chest x-rays, comorbidities, electro-cardiogram
224193843|NCT02208427|DRUG|Rifapentine and Isoniazid for 3 months|weekly oral Rifapentine 15 mg/kg plus Isoniazid 15 mg/kg for 12 doses
224193844|NCT02208427|DRUG|Isoniazid for 9 months|daily oral Isoniazid 5 mg/kg for 9 months under supervision (conventional IPT)
223502843|NCT06777979|DRUG|Fludarabine|IV
223502844|NCT06777979|DRUG|Cyclophosphamide|IV
223502845|NCT06777979|DRUG|Mesna|IV
223502846|NCT06777979|DEVICE|CD19-CD22 CAR T cell infusion|CAR T cell infusion will be given intravenously, either centrally or peripherally.
223502847|NCT04073407|DIETARY_SUPPLEMENT|AXA1957|Amino acids, food study
223502848|NCT04073407|DIETARY_SUPPLEMENT|Placebo|placebo
224193845|NCT02613559|BIOLOGICAL|TK001|Intravitreal Injection
224310255|NCT04171206|OTHER|Free From Abuse|Participants in the treatment arm will watch a 15-minute talk given by an adult female survivor of IPV who tells the story of her abusive relationship. After watching the video, participants will read information on 10 signs of an unhealthy relationship. The intervention will take approximately 25 minutes to complete.
224310256|NCT04171206|OTHER|Technology and crime|Participants in the placebo control arm will watch a 19-minute talk on technology development and crime. After watching the video, participants will read 10 facts about cyber security. The intervention will take approximately 25 minutes to complete.
223592229|NCT04395690|PROCEDURE|Dental Implant Placement in the posterior mandible|Surgery done in the posterior mandible with missing teeth for placing dental implants.
223592230|NCT01836302|OTHER|Observation|
223592231|NCT02689115|OTHER|Genetic relative expression|The genetic expression of NF-KB1 and IKK epsilon were quantified in both groups.
224193846|NCT03788785|BEHAVIORAL|Experimental arm|The specific tobacco cessation intervention will be based on meeting with trained nurses : three 1/2 hour session of assessment of current addictive behaviors and motivation to change smoking habits occurring within five days tops.
224193847|NCT03788785|OTHER|Control arm|In the control arm, patients will receive the current standard of care for these patients, namely referral to external care after general advice on tobacco cessation (self-help tools).
224193848|NCT02010671|OTHER|Survey|Survey
224193849|NCT02393404|OTHER|PT-FMT|Physiotherapeutic functional movement-power training
224310257|NCT01308905|DEVICE|FLT-PET|PET scan will be conducted at diagnosis, at the end of the first cycle of treatment and prior to the surgical procedure (resection).
224310258|NCT06581055|DRUG|Luspatercept|As per COMMANDS Trial (NCT03682536) study protocol
224310259|NCT06581055|DRUG|Epoetin Alfa|As per COMMANDS Trial (NCT03682536) study protocol
223502849|NCT03739554|DRUG|CYC065|intravenous infusion
223502850|NCT03739554|DRUG|Venetoclax|oral capsule
223502851|NCT06755216|BEHAVIORAL|Experimantal group|"In order to identify students who meet the criteria for the study, the PIF and SSSCL will be administered as a pre-test to female students studying in the relevant departments of Karabük University Faculty of Health Sciences.~After providing theoretical information to the students, the cardinal movements of the fetal head within the pelvis during the second stage of labor will be demonstrated in a laboratory setting. Students will be divided into groups of five, and after the demonstration, each student will be asked to perform all stages individually. Approximately 15 minutes will be allocated for each student. Two weeks later, the same students will be brought into the laboratory environment and asked to perform all procedural steps. While performing the steps, a researcher will mark the completed and missing actions on the learner's guide, and any missing steps will be explained to the student and corrected. For the post-test, the Learner's Guide (LG) and SSSCL will be administered"
223502852|NCT06577558|DRUG|SR1375 capsule 3mg+regular treatments|SR1375 capsule 3mg QD orally+CAP regular treatments
223502853|NCT06577558|DRUG|SR1375 capsule 1mg+regular treatments|SR1375 capsule 1mg QD orally+CAP regular treatments
223502854|NCT06577558|DRUG|SR1375 capsule 0.3mg+regular treatments|SR1375 capsule 0.3mg QD orally+CAP regular treatments
223592232|NCT00321815|DRUG|PF-3512676 + Erlotinib|"PF-3512676 0.2 mg/kg subcutaneously on days 1, 8 and 15 of each 21 day cycle until disease progression or unacceptable toxicity.~Erlotinib 150 mg orally daily (21 day cycles) until disease progression or unacceptable toxicity"
223592233|NCT00321815|DRUG|Erlotinib|Erlotinib 150 mg orally daily (21 day cycles) until disease progression or unacceptable toxicity
223746593|NCT04977076|OTHER|Interrupted NOAC use|Usual care, interruption of NOAC prior to procedure.
224193850|NCT02393404|OTHER|FMT alone|Physiotherapeutic power training
224310260|NCT06982560|DEVICE|electrical cardiometry|use of cardiometry parameters as cardiac output, thoracic fluid content, systemic vascular resistance
224310261|NCT06982560|OTHER|traditonal methods|clinical examination, lung ultrasound, inferior vena cava
224310262|NCT06982729|DRUG|YK012|YK012 is a bispecific antibody targeting CD19 on B cells and CD3 on T cells leading to T cell-mediated cytotoxicity of malignant B cells
223502855|NCT06577558|DRUG|Placebo capsule+regular treatments|Placebo capsule QD orally+CAP regular treatments
223502856|NCT07056777|DRUG|DR30206|Subjects receive DR30206 intravenously
223502857|NCT07056777|DRUG|Oxaliplatin|Subjects receive Oxaliplatin intravenously
223502858|NCT07056777|DRUG|Capecitabine|Subjects take Capecitabine orally
223502859|NCT07056777|DRUG|Calcium Folinate|Subjects receive Calcium Folinate intravenously
223502860|NCT07056777|DRUG|5-FU|Subjects receive 5-FU by Intravenous Bolus
223502861|NCT07056777|DRUG|Irinotecan (CPT-11)|Subjects receive Irinotecan intravenously
223592234|NCT06486896|OTHER|Pelvic floor training|It will be in the form of pelvic floor relaxation with biofeedback, as well as stretching exercises for the pelvic floor and the adjacent muscles. The patient will be asked to lie in a comfortable crock lying position. She will be instructed to do diaphragmatic breathing exercises. The vaginal electrode of the biofeedback will be gently introduced into the vagina to start pelvic floor relaxation training. Then, the patient will be asked to perform pelvic floor relaxation by slightly contracting the pubococcygeus muscle. After 10 minutes of pelvic floor relaxation training, the patient will then be instructed to return to the active state gradually, the treatment procedure will be performed 3 times/ week for 8 weeks. Stretching exercises for the pelvic floor and the adjacent muscles: Levator ani \& perineal muscles stretch, hip adductor muscles stretch, piriform muscle stretch, hip flexor muscles stretch, and obturator internus muscle stretch.
223592235|NCT06486896|DEVICE|Interferential current|Each female in the experimental group will receive interferential current, 3o minutes per session, 2 sessions per week, for 8 weeks. The applied parameters will be a frequency of 2000Hz, a modulated amplitude of frequency of 80Hz, pulse width of 200μs, and the intensity is modulated according to the sensory level of each participant. While the participant is in a comfortable crock lying position with abducted hips, the position of the electrodes will be maintained in all sessions
223746594|NCT06850636|PROCEDURE|Epidural Analgesia|Labour epidural analgesia
224310263|NCT06982313|DRUG|Tamoxifen (Nolvadex)|5 mg per day for 3 years during TAM-01 phase III trial
224310264|NCT06982313|DRUG|Tamoxifen (Nolvadex) placebo|Tamoxifen (Nolvadex) placebo per day for 3 years during TAM-01 phase III trial.
223592236|NCT06486896|BEHAVIORAL|General advice|The patients in both groups will follow general advice to help vaginismus for 8 weeks
223592237|NCT03112655|DIAGNOSTIC_TEST|RNA and neopterin detection|Detection of spliced leader RNA will be performed on blood and cerebrospinal fluid taken before treatment, 11 days after treatment, 6, 12 and 18 months after treatment. Neopterin and 5-hydroxytryptophan will be quantified in cerebrospinal fluid taken at the same time points.
223592238|NCT02120391|OTHER|iPhone Application|All subjects will receive the iPhone App on their phone however not all subjects will have the intervention (medication notifications) turned on.
223592239|NCT05572164|PROCEDURE|TRADITIONAL EPIDURAL|epidural technique used for intraoperative analgesia (the EPL group; local anesthetics will be delivered via epidural catheter guided by SPI to provide intraoperative analgesia)
223592240|NCT05572164|PROCEDURE|DURAL PUNCTURE EPIDURAL|group on whom dural puncture epidural technique used for intraoperative analgesia ( the DPL group; local anesthetics will be delivered via an epidural catheter placed after a dural pucture performed with the SPI guidance to provide intraoperative analgesia)
223592241|NCT04623229|PROCEDURE|MCS|Manual Cataract Surgery
223592242|NCT04623229|PROCEDURE|ReLACS Early|ReLACS with early administration of anesthesia
223592243|NCT04623229|PROCEDURE|ReLACS Standard|ReLACS with standard time administration of anesthesia
223592244|NCT01750359|DRUG|curcumin|500 mg/day for 6 week
223592245|NCT02877498|OTHER|Adaptive support ventilation|Adaptive support ventilation during invasive mechanical ventilation
223592246|NCT02877498|OTHER|Volume controlled ventilation|Volume controlled ventilation during invasive mechanical ventilation
223746595|NCT04846803|BIOLOGICAL|ABU bladder lavage|Clinical effect of preventive treatment (prophylactic treatment) - bladder lavage with the non-pathogenic bacterial strain (ABU)
224193851|NCT04640168|DRUG|Baricitinib|Baricitinib is a Janus kinase (JAK) inhibitor with the chemical name \[1-(ethylsulfonyl)-3-(4-(7Hpyrrolo(2,3-d)pyrimidin-4-yl)-1H-pyrazol-1-yl)azetidin-3-yl\]acetonitrile. Each tablet contains 2 mg of baricitinib and the following inactive ingredients: croscarmellose sodium, magnesium stearate, mannitol, microcrystalline cellulose, ferric oxide, lecithin (soya), polyethylene glycol, polyvinyl alcohol, talc and titanium dioxide.
224193852|NCT04640168|DRUG|Dexamethasone|Dexamethasone Sodium Phosphate Injection, USP, is an adrenocortical steroid anti-inflammatory drug. It is a water-soluble inorganic ester of dexamethasone. Each mL contains dexamethasone sodium phosphate equivalent to dexamethasone phosphate 4 mg or dexamethasone 3.33 mg; benzyl alcohol 10 mg added as preservative; sodium citrate dihydrate 11 mg; sodium sulfite 1 mg as an antioxidant.
224193853|NCT04640168|OTHER|Placebo|Placebo matching oral baricitinib or intravenous dexamethasone.
224193854|NCT04640168|DRUG|Remdesivir|Drug remdesivir is a single diastereomer monophosphoramidate prodrug designed for the intracellular delivery of a modified adenine nucleoside analog GS-441524. In addition to the active ingredient, the lyophilized formulation of remdesivir contains the following inactive ingredients: water for injection, sulfobutylether beta-cyclodextrin sodium (SBECD), and hydrochloric acid and/or sodium hydroxide.
223502862|NCT07057453|OTHER|Motivation Engagement for Movement and Interactive Nutrition Development|The intervention includes using of fitness bracelets, a gamified mobile app, a web portal, and regular pediatric check-ups to support healthy habits in overweight children (6-11 years). The bracelets track physical activity, while the mobile app monitors energy balance, encouraging movement and healthy eating through challenges and rewards. The web portal provides family education, and pediatric check-ups track progress and overall health outcomes.
223502863|NCT07056725|OTHER|Manual Therapy and Therapeutic Exercises Programs|A treatment based on the combination of Manual Therapy targeting the orofacial region and a therapeutic exercise program focused on either the cervical or orofacial region
223502864|NCT07056062|DRUG|Calcium carbonate|2,000 mg PO calcium carbonate as a single dose
223502865|NCT06771700|DIAGNOSTIC_TEST|Intraoperative PRAETORIAN Score|The intraoperative PRAETORIAN Score is calculated based on the additional measurements.
223502866|NCT06847165|DEVICE|Trigeminal Nerve Stimulation (TNS)|In TNS, a weak electric current is applied to the child's forehead overnight while sleeping to gently stimulate the brain. TNS treatment is typically administered at home at bedtime by the parent to the child. The TNS device is small (size of a cell phone) and easy to use. Two thin wires go from the device to a pair of small electrodes that tape onto the forehead like a band-aid. The parent presses three keys on the device and it is ready to go.
223502867|NCT06895148|DEVICE|New ventilator|"The new ventilator order (intervention) was developed using economic behavior theory to decrease the cognitive burden on the ordering provider while enhancing the operability of the order itself. The strategy resulted in a new ventilator order that includes the following changes:~1. Automatic calculation of the PBW based on the most recent height~2. If the height is not available, an order to obtain a height will be generated and the choice of tidal volume will be based on cc/kg PBW~3. Simplify ventilator modes to accurately reflect the standard of care~4. Reduce duplicative information in the monitoring and comments portion of the order~5. Cascade ventilator orders based on mode to enhance visualization."
223502868|NCT06895148|DEVICE|control ventilator|Current ventilator order used by control hospitals
223502869|NCT06895447|DRUG|Pre-operative chemotherapy|Patients will undergo pre-operative drug treatment (any chemotherapy drug or immunotherapy drug are accepted).
223592247|NCT03230565|DRUG|Ropivacaine|Patient will be given a continuous infusion of local anesthetic.
223592248|NCT03230565|DRUG|Ropivacaine|Patient will be given a scheduled intermittent bolus of local anesthetic.
223592249|NCT05298800|BIOLOGICAL|Vaccine|Different arms were administrated different vaccines
223592250|NCT04494126|DRUG|Tranexamic acid|Drug: Tranexamic Acid Injectable Solution the drug will be given to patients intravenously at a dose of 10mg/kg pre-operatively after induction on general anesthesia before incision.
223746596|NCT04846803|BIOLOGICAL|Saline bladder lavage|Clinical effect of preventive treatment (prophylactic treatment) - bladder lavage with saline
223746597|NCT06849986|DRUG|Tislelizumab+liposomal doxorubicin+ifosfamide|Liposomal Doxorubicin (PLD) 30mg/m2 on day 1 Ifosfamide (IFO) 3 g/m2/day on days 1 to 3 Tislelizumab 200mg on day 1, administered by intravenous infusion, every 3 weeks
223746598|NCT05416437|DEVICE|PneumoCool|Device to channel medical air to the patient to alleviate dyspnea
223746599|NCT05416437|OTHER|Current supportive measures that are used in the hospital for standard of care|a room fan, or any other currently used supportive measures can be used for patients in the control arm
224193855|NCT05448469|PROCEDURE|ultrasound guided erector spinae plane block|patients will receive combined general anesthesia and ultrasound guided erector spinae plane block with 20 ml of bupivacaine 0.2 % at T9 level bilaterally.
224193856|NCT05448469|PROCEDURE|ultrasound guided paravertebral block|patients will receive combined general anesthesia and ultrasound guided paravertebral block with 7 ml of bupivacaine 0.2 % at T8 and T10 bilaterally.
224193857|NCT05448469|DRUG|conventional analgesia|patients will receive combined general anesthesia and conventional analgesia
224193858|NCT00779857|DEVICE|AtriCure LAA Exclusion System|Exclusion of the left atrial appendage using the AtriCure LAA Exclusion System
223746600|NCT04577287|DEVICE|Transcranial direct current stimulation|Cathodal/Anodal tDCS will be applied in 1.5 mA, 20 mins before conventional physical therapy for 5 days. All experiments will be performed in random order for each subject.
224193859|NCT04425876|DRUG|Fluzoparib|Fluzoparib combined with mFOLFIRINOX followed by maintenance Fluzoparib monotherapy
224193860|NCT00620776|BEHAVIORAL|Cognitive Behavioral Therapy|This cognitive behavioral therapy for GAD has a cognitive restructuring component and an applied relaxation component. Patients will be educated about the nature of anxiety and be trained in the recognition and monitoring of situational, physiological, cognitive, and behavioral cues associated with anxious responding. They will be guided through copings skill rehearsals in addition to imaginal and in vivo exposure to anxiety cues. This cognitive behavioral treatment will consist of 1 to 1.5 hour sessions of psychotherapy, which will be held once weekly over a period of 12 weeks.
224193861|NCT00620776|DRUG|Venlafaxine XR|Venlafaxine XR, 75-225 mg/d, oral administration. 14 days at 75 mg/d, 150 mg/d for the remaining 6 months, 225 mg/3 for patients unimproved at week 6, tapered at 75 mg/week (this intervention is provided by protocol 709012).
224193862|NCT06519201|DEVICE|SRT with SpineCare|Korean medicine doctors performed the treatment regimens.The TG underwent SRT with SpineCare. Treat-ment was administered for six consecutive weeks, with sessions held twice per week dur-ing the first four weeks and once per week during the final two weeks. No additional treatments (e.g., procedures or surgeries) were allowed during the six-week period. To an-alyze pain according to the number of treatment sessions, a counselor assessed patients using the NRS after each of the ten treatment sessions. To compare the differences in Cobb's angle between the groups, X-rays were performed after the first and tenth treatment sessions. Detailed records of adverse events were maintained before and after each treat-ment session.
223592251|NCT04494126|DRUG|Placebo|Other: Placebo (normal saline 0.9%) An equivalent amount of normal saline (0.9%) will be given to the patient pre-operatively after induction of general anesthesia. The amount of saline given will correspond to the same amount of fluid which would have been given had the patient been in the intervention group.
223746601|NCT05315518|DIAGNOSTIC_TEST|single-shade universal resin composite (omnichroma) with blocker( omnichroma blocker)|(OMNICHROMA BLOCKER) is indicated for preventing shade-matching interference in Class IV restorations, Masking dark dentition and dentin. In cases where there is a lack of tooth structure to bond to, (BLOCKER) works as a supplementary product to provide a lingual wall to the restoration, prevent shade-match obstruction and mask staining.
223746602|NCT05815121|OTHER|Acupressing|Acupuncture with placement of 4 vaccaria seeds covered with stickers on the ears and 2 on the wrists.
223746603|NCT05815121|OTHER|Control|with stickers only on the points, and the points should not be massaged.
223502870|NCT06895447|PROCEDURE|Robotic radical gastrectomy after neoadjuvant therapy|"Eligible participants must have stage III resectable gastric or gastroesophageal junction (GEJ) adenocarcinoma based on imaging studies such as ultrasound endoscopy, CT, or MRI.~Patients will receive 3-4 cycles of neoadjuvant therapy, followed by imaging evaluations to assess the treatment response and determine eligibility for radical D2 gastrectomy. Within 2-6 weeks of the final neoadjuvant treatment cycle, eligible patients will undergo robotic radical gastrectomy."
223502871|NCT06931002|BIOLOGICAL|Rhinovirus A-16 Infection|All participants will be deliberately infected with Rhinovirus A-16
223592252|NCT02421588|DRUG|Lurbinectedin (PM01183)|
223592253|NCT02421588|DRUG|Pegylated liposomal doxorubicin (PLD)|
223592254|NCT02421588|DRUG|Topotecan|
224074983|NCT02886143|PROCEDURE|Active Voiding Trial|"Nursing protocol:~1. Instill 250-400 cc of STERILE SALINE via the lumen of the Foley catheter into the bladder via gravity drainage or slow push~2. Clamp the Foley~3. Deflate the catheter balloon and remove the catheter from the bladder.~4. Record the amount of saline that was instilled into the bladder.~5. Immediately assist the patient to void. Report the amount instilled and the amount voided to the physician within one hour a. Unless the patient reports extreme bladder fullness or pain, give the patient one hour to urinate~7\. If the patient fails the voiding trial, the physician will decide to do in and out catheterization or place a new Foley catheter"
224074984|NCT02886143|PROCEDURE|Passive Voiding Trial|"Nursing protocol:~1. Deflate the catheter balloon and remove the catheter from the bladder.~2. Record the time that the catheter was removed and the time the patient is due to void (approximately 6 hours).~3. 5\. If the patient has not voided within 5 hours, assist the patient to try to void.~6\. If the patient is unable to void, is only voiding in small amounts, or reports fullness or abdominal pain, perform a bladder scan.~7\. If the patient has not voided after 6 hours, report this to the physician along with the results of the bladder scan 8. The physician will decide to do in and out catheterization or place a new Foley catheter"
224074985|NCT05326542|PROCEDURE|ESWL and ERCP|First, ESWL will be used for lithotripsy, and then ERCP will be performed to clear the stones after lithotripsy.
224074986|NCT05326542|PROCEDURE|LL and ERCP|After establishing the working channel under ERCP, the stone will be crushed with a laser lithotripter, and then ERCP will clear the stones after lithotripsy.
224074987|NCT02270242|DRUG|Aspirin|
224074988|NCT02270242|DRUG|Placebo|
224074989|NCT02270242|DRUG|ticagrelor|
224074990|NCT04800289|OTHER|questionnaires|questionnaires about disease and satisfaction of patient
224074991|NCT02294240|DIETARY_SUPPLEMENT|Energy dense biscuits|Energy dense biscuits will be provided
224074992|NCT02294240|OTHER|Wheat Flour, oil, iron & Folic acid|Wheat flour, oil, iron and folic acid will be provided
223592255|NCT06584500|OTHER|Dry needling|"Dry needling will be performed on the pelvitrochanteric musculature, targeting those muscles where the patient reports mechanical hyperalgesia points upon palpation that reproduce familiar and recognizable pain. No more than 3 different muscles will be treated, and no more than 2 needles will be used per muscle to reduce irritability. The Gluteus Medius muscle will be needled in all patients, and the Gluteus Minimus, Tensor Fasciae Latae (TFL), Piriformis, and obturator muscles will also be examined.~Dry needling will be performed using monofilament needles of different sizes, 0.30mm x 7.5mm, 6mm, and 4mm (AGUPUNT, APS®), depending on the muscle being treated.\&#34;~During the dry needling procedure, an attempt will be made to provoke a local twitch response (LTR). Once achieved, the needle will be manipulated with rapid in-and-out movements in different directions until 4 to 6 LTRs are obtained, or if the participant verbally requests the intervention to stop."
224193863|NCT06519201|DEVICE|SRT without SpineCare|Korean medicine doctors performed the treatment regimens. The CG underwent SRT without SpineCare. Treat-ment was administered for six consecutive weeks, with sessions held twice per week dur-ing the first four weeks and once per week during the final two weeks. No additional treatments (e.g., procedures or surgeries) were allowed during the six-week period. To an-alyze pain according to the number of treatment sessions, a counselor assessed patients using the NRS after each of the ten treatment sessions. To compare the differences in Cobb's angle between the groups, X-rays were performed after the first and tenth treatment sessions. Detailed records of adverse events were maintained before and after each treat-ment session.
224193864|NCT01327066|DRUG|Droxidopa|600 mg, single oral dose
224193865|NCT01327066|DRUG|Droxidopa|2000 mg, single oral dose
224193866|NCT01327066|DRUG|Moxifloxacin|400 mg, single oral dose
224193867|NCT01327066|DRUG|Placebo|Placebo matching Droxidopa or Moxifloxacin
224193868|NCT02866721|BIOLOGICAL|Mesenchymal Stem Cells|"A single dose, one time infusion (in the vein) of one of the following doses of human mesenchymal stem cells (hMSCs): 1 x 10\^6, 3 x 10\^6 or 5 x 10\^6 human mesenchymal stem cells per kilogram body weight (hMSCs/kg) during Visit 2. A traditional 3+3 design will be utilized.~Allogeneic mesenchymal stem cells (MSCs) will be derived from bone marrow aspirates from a healthy donor whose serum tests negative for cytomegalovirus (CMV) antibodies. Healthy donors will undergo tests for infectious disease and screening for 41 common cystic fibrosis transmembrane conductance regulator (CFTR) mutations. In addition, the MSCs will be validated for in vitro and in vivo efficacy and potency using the in vivo murine pre-clinical model of cystic fibrosis lung infection and inflammation."
224193869|NCT05038085|BEHAVIORAL|progressive muscle relaxation exercise|"36-37 with pregnant women in the experimental group. There will be two online interviews starting from week one. Before the first interview, the PMRE video will be sent to the women, explained by the researcher. In the first meeting, basic information about postpartum depression and what to do to prevent postpartum depression and its treatment will be explained. The women will then be asked to describe the PKGE. Relaxation Exercises CD Audio Recordings belonging to the Turkish Psychological Association will be sent to women, and they will be asked to perform PMRE at least 3 days a week until delivery, accompanied by the instructions on the CD. In the second meeting; maternal attachment will be explained. In this interview, women will be asked to continue to do PMRE at least 3 days a week from the day they feel ready, starting at the latest 1 week after delivery."
224193870|NCT03273816|BEHAVIORAL|sessions of sophrology|10 sessions of sophrology in preparation for the intervention 5 weeks before this one.
223592256|NCT06584500|OTHER|Sham Dry Needling|The intervention protocol for sham dry needlig will be just as to the real dry needling procedure, but instead of inserting the needle into the muscle, the needle is manipulated to touch the skin without penetrating it. This may involve the use of retractable needles or simply making contact with the skin
223592257|NCT06584214|DIAGNOSTIC_TEST|Diagnostic test: Determine™ Syphilis Advanced test|The Determine™ Syphilis Advanced test is intended as an aid in detecting antibodies to Treponema pallidum in individuals with current or past infection.
223592258|NCT02085278|DEVICE|Apollo Micro Catheter device|Detachable Tip Micro catheter
223592259|NCT04040829|BEHAVIORAL|Cognitive remediation therapy (CR)|Cognitive remediation therapy is a behavioral intervention that aims to improve cognition. This intervention has the goal to produce long-term improvements in cognition as well as to generalize these improvements in daily functioning.
223592260|NCT04040829|BEHAVIORAL|Supported education (SE)|Supported education (SE) is a behavioral intervention that aims to help people return to school and/or succeed in school. SE offers a wide range of services that are personalized to the needs of each patients.
223502872|NCT06912269|OTHER|Exercise|A progressive calf strength training program lasting 12 weeks (twice weekly sessions), with a total of 25 visits to the gym. Specific exercises for ankle flexors: standing unilateral plantar flexion (on the machine) and seated unilateral plantar flexion (adapted on the Smith machine) will be performed. Participants will use progressive load from 55% of one repetition maximum load for the specific plantar flexion exercises.
223502873|NCT06912269|OTHER|Exercise|A progressive calf strength training program lasting 12 weeks (twice weekly sessions), with a total of 25 visits to the gym. Specific exercises for ankle flexors: standing unilateral plantar flexion (on the machine) and seated unilateral plantar flexion (adapted on the Smith machine) will be performed. Participants will use progressive load from 70% of one repetition maximum load for the specific plantar flexion exercises.
223502874|NCT06906848|DIETARY_SUPPLEMENT|Placebo|Oral
223502875|NCT06906848|DIETARY_SUPPLEMENT|Cognizin®|Oral
223502876|NCT01939457|DRUG|Misoprostol|
223502877|NCT05947006|OTHER|Standard care|Patients in this arm will receive the standard care stablished in the emergency room after a febrile seizure, consisting of a medical assessment of the child, followed by 6 hours of supervision of the child and his parent in the waiting room, a reassessment of the child by the doctor, and finally they can return home
223502878|NCT05947006|OTHER|CONSULFE consultation|In addition to the standard care, patients in this arm will receive a consultation managed by the pediatric nurse (CONSULFE) during the 6 hour supervision time in the waiting room
223502879|NCT01009697|DRUG|Codeine Sulfate|15 mg, 30 mg, and 60 mg tablets
223502880|NCT04022980|DRUG|Nivolumab|HD-MTX containing induction chemotherapy (per standard of care) followed by Nivolumab consolidation.
223592261|NCT04040829|OTHER|Treatment as usual (TAU)|Treatment as usual (TAU) consists of medication and routine contact with the clinical team.
224193871|NCT04739202|DRUG|Atezolizumab + Ipatasertib|Atezolizumab IV (1200 mg on day 1 of each 21-day cycle) and Ipatasertib PO (400 mg per day continuously, starting on cycle 1 day 1). Treatment given until disease progression or unacceptable toxicity.
224193872|NCT04739202|DRUG|Atezolizumab + Bevacizumab|Atezolizumab IV (1200 mg on day 1 of each 21-day cycle) and Bevacizumab IV (15 mg/kg on day 1 of each 21-day cycle). Treatment given until disease progression or unacceptable toxicity.
224193873|NCT00869700|DRUG|Artemether/Lumefantrine|"80mg artemether/480mg lumefantrine~Trade name: Coartem~Indication: for management of non-severe malaria"
224193874|NCT00235300|BIOLOGICAL|Thymoglobulin [Anti-thymocyte Globulin (rabbit)]|1.5 mg/kg per day, for a maximum of 5 doses
223592262|NCT05462418|PROCEDURE|electrosurgery|incisions completed using use the unipolar diathermy from Whiteline till we reach the parietal peritoneum (cutting the Whiteline then coagulation till reaching the peritoneum). The used diathermy frequency was 50-70 MHz.
223592263|NCT05462418|PROCEDURE|scalpel|patients had their incisions completed using the surgical scalpel till we reach the parietal peritoneum.
223592264|NCT03487497|PROCEDURE|Lateral column lengthening osteotomy|Lengthening osteotomy of the lateral column of the foot
223592265|NCT00612560|DRUG|Anastrozole|1 mg per day
223592266|NCT00612560|DIETARY_SUPPLEMENT|flaxseed|25 g per day ground
223592267|NCT00612560|DRUG|Placebo|Placebo pill 1 per day
223592268|NCT05489367|BIOLOGICAL|sars cov 2 biontec vaccine|volunteers will be expected to receive 2 doses of vaccine
223592269|NCT03123328|DEVICE|Radical-7 Pulse CO-Oximeter and sensor|Noninvasive device that measures hemoglobin.
223592270|NCT06000865|BEHAVIORAL|Action video game training|20 sessions of AVG over 10 weeks (45 minutes per session, 2 sessions per week)
223502881|NCT05556837|OTHER|Control Cereal|A portion of cereal (25g available carbohydrate), served with 125ml of 2% milk and 250ml water, will be fed to participants and postprandial glucose and insulin will be measured
223502882|NCT05556837|OTHER|OBG Cereal|A portion of cereal (25g available carbohydrate) containing OBG, served with 125ml of 2% milk and 250ml of water, will be fed to participants and postprandial glucose and insulin will be measured
223502883|NCT05556837|OTHER|BBG Cereal|A portion of cereal (25g available carbohydrate) containing BBG, served with 125ml of 2% milk and 250ml of water, will be fed to participants and postprandial glucose and insulin will be measured
223502884|NCT06946927|DRUG|JMKX001899|JMKX001899 tablet administered orally daily.
223502885|NCT06946927|DRUG|IN10018|IN10018 tablet administered orally daily.
223502886|NCT06946927|DRUG|Chemotherapy: Pemetrexed|IV infusion once every 3 weeks
223502887|NCT06946927|DRUG|Carboplatin|IV infusion once every 3 weeks, 4 Cycles
223592271|NCT06000865|BEHAVIORAL|Conventional physical training|20 sessions of physical training over 10 weeks (45 minutes per session, 2 sessions per week)
223592272|NCT05693506|OTHER|Cooking workshops|Cooking workshop in classic form, i.e. with recipes imposed by the dietician on the participants, or cooking workshops in the form of culinary challenges, i.e. without imposed recipes but according to the creativity of the participants
223592273|NCT03749278|BEHAVIORAL|Latina Friends Motivating the Soul (ALMA)|In a series of 8 weekly sessions, the program uses a group format to teach and encourage women to use coping strategies to reduce depression and anxiety. Over the course of the eight ALMA sessions, 25 women are (1) engaged in activities to identify coping strategies they are currently using and encouraged to continue to use them; (2) introduced to new coping strategies (e.g. mindfulness techniques, increased social ties and social support); and, (3) provided resources for seeking additional help if needed
223592274|NCT06173908|PROCEDURE|cell treatment|Autologous epidermal basal cells were used to repair nonhealing postoperative wound
223592275|NCT06173908|PROCEDURE|control treatment|anyother treatments except autologous epidermal basal cells were used to repair nonhealing postoperative wound
223592276|NCT02649894|DEVICE|Active Comparator: Approved Uncoated PleurX Indwelling Pleural Catheter|
223592277|NCT02649894|DEVICE|Experimental: Silver Nitrate Coated Indwelling Pleural Catheter (SNCIPC)|
223592278|NCT01436474|DRUG|Varenicline|Patients will be randomly assigned to receive either varenicline or placebo for 45 days. Patients assigned to varenicline and are current smokers will receive 0.5mg by the oral route once a day for 3 days, followed by 0.5mg twice a day for 4 days. After the first week the dose will be increased to 1mg twice daily for the remainder of the active treatment period of the study. Patients assigned to varenicline and are non-smokers will receive 0.5mg by the oral route once a day for 6 days, followed by 0.5mg twice a day for 6 days. After the first 12 days the dose will be increased to 1mg twice daily for the remainder of the active treatment period of the study. Patients assigned to placebo will receive identical looking capsules in a dosage schedule similar to varenicline.
224074993|NCT04876014|OTHER|Guided Mobile-Based Perinatal Mindfulness Intervention|GMBPMI includes 6 EBMI lessons in 6 weeks, and it will require the participants to do mindfulness practice for about 30-60 minutes daily. The project RA will send prompt and guidance for daily mindfulness practice to each participant through social media platform. The RA will be available online to support, and will initiate chat every week throughout the whole intervention period. The chats will focus on participants' experiences or difficulties of mindfulness practice.
224074994|NCT06062186|DIETARY_SUPPLEMENT|Placebo|650 mg of placebo, given as two capsules containing maltodextrin
224074995|NCT06062186|DIETARY_SUPPLEMENT|AmaTea Guayusa Extract|650 mg of AmaTea Guayusa Extract, given as two capsules
224074996|NCT06062186|DIETARY_SUPPLEMENT|Lion's Mane|1000 mg of Lion's Mane, given as two capsules
224074997|NCT02321436|BIOLOGICAL|Botulinum toxin type A|Subjects to receive Dysport® 500U administered intramuscularly in the targeted upper limb.
224074998|NCT02321436|DRUG|Placebo|Placebo administered intramuscularly in the targeted upper limb.
224074999|NCT04926272|DRUG|18F-92|Intravenous injection of one dose of 0.10mCi/kg(±5%) 18F-92. Each subject receive a single intravenous injection of 18F-92, and undergo PET/CT imaging within the specificed time.
224075000|NCT03801655|DIETARY_SUPPLEMENT|Bio-Kult|4 capsules/day
224075001|NCT03801655|OTHER|Placebo|4 capsules/day
224075002|NCT00664833|BEHAVIORAL|Levitra (Vardenafil, BAY38-9456)|The Primary Care Physician (PCP) received the educational intervention
224193875|NCT00235300|DRUG|Simulect (basliximab)|20 mg per day on 2 days
224193876|NCT01987570|DRUG|Allopurinol|
224075003|NCT00664833|BEHAVIORAL|Levitra (Vardenafil, BAY38-9456)|The Subject received the educational intervention
224193877|NCT01987570|DRUG|Placebo|
224193878|NCT01224600|OTHER|patients with newly diagnosed PAD (<1year)|patients with newly diagnosed PAD (\<1year) symptomatic or asymptomatic, without any history of previous coronary nor cerebrovascular event, and with no previous investigation of the aorta and cervical arteries were eligible
224193879|NCT02705534|DRUG|Sofosbuvir|400 mg, included in a combination pill with 90 mg ledipasvir
223502888|NCT05571254|OTHER|Data collection|All patients will have a focussed Case Report Form completed collecting routine data describing the prevalence, clinical presentation, assessment, management and ESC risk category of patients, at the time or shortly after the patients ED attendance.
224075004|NCT00664833|BEHAVIORAL|Levitra (Vardenafil, BAY38-9456)|Both the Primary Care Physician (PCP) and the subject received the educational intervention
224075005|NCT00664833|OTHER|No Education|No education provided to either the Primary Care Physician (PCP) or the subject.
224193880|NCT02705534|DRUG|Ledipasvir|90 mg, included in a combination pill with 400 mg sofosbuvir
224193881|NCT02705534|DRUG|Ribavirin|1000 mg/day if \<75 kg, 1200 mg/day for \>75 kg. Divided into two daily doses
224193882|NCT02254629|DRUG|Probiotic Clostridium Butyricum|probiotic:2 tablets/ times, 3 times / day for 2 weeks
224193883|NCT02254629|DRUG|Laxative Polyethylene Glycol|laxative：2000 ml.
224193884|NCT03493477|OTHER|exposure will be abnormal skeletal jaw relations|Class II skeletal jaw relation or class III skeletal jaw relation based on lateral cephalometric radiograph
224193885|NCT02402608|DIETARY_SUPPLEMENT|dietary supplement|oral essential amino acid (EAA), whey protein and vitamin D mixture
224193886|NCT02402608|DIETARY_SUPPLEMENT|placebo|placebo consisting of an equicaloric amount of maltodextrin with the same flavour and appearance as for the intervention product
223502889|NCT06505642|DEVICE|needle-based confocal laser endomicroscopy|needle-based confocal laser endomicroscopy at the tip of the TBNA needle for two punctures, combined with confirmatory CBCT spin for tool-in-lesion confirmation
223502890|NCT01281072|OTHER|vaccine|
223502891|NCT06478563|DRUG|NNC0487-0111 (formulation D)|Participants will receive NNC0487-0111 (formulation D) tablet once daily.
223502892|NCT06478563|DRUG|NNC0487-0111 (formulation C)|Participants will receive NNC0487-0111 (formulation C) tablet once daily.
223502893|NCT01773902|DIETARY_SUPPLEMENT|High Dose Protein (Individualized)|Protein supplementation according to breast milk content aiming for 4.5g/kg/d of enteral protein if \<1500g b.w. or 4.0g/kg/d of enteral protein if \>1500g b.w. until 1 week before discharge
223502894|NCT01773902|DIETARY_SUPPLEMENT|High Dose Protein (Standardized)|Protein supplementation independent of individual breast milk content using a new high-dose-protein breast milk fortifier until 1 week before discharge
223502895|NCT01773902|DIETARY_SUPPLEMENT|Standard Protein Supplementation|Protein supplementation independent of individual breast milk content using a standard-dose-protein breast milk fortifier until 1 week before discharge
223502896|NCT00959452|BEHAVIORAL|Cognitive behavioural therapy|16 sessions vs 5 sessions of cognitive behavioural therapy
223502897|NCT04212065|DRUG|buprenorphine|To improve compliance with medication assisted therapy, decrease relapse and neonatal abstinence syndrome, we propose a randomized control trial of long acting subcutaneous buprenorphine compared to short acting sublingual buprenorphine/naloxone administration in pregnant and lactating women.
223502898|NCT03004131|DRUG|Azelastine hydrochloride + fluticasone propionate nasal spray|
223502899|NCT03004131|DRUG|Placebos|
223502900|NCT03004131|DRUG|fluticasone propionate nasal spray + loratadine|
223502901|NCT04941898|BIOLOGICAL|PEGylated Recombinant Factor VIII|Polyethylene glycol (PEG)-ylated full-length recombinant FVIII (rFVIII)
223502902|NCT02439411|DRUG|Trametinib|
223502903|NCT04840771|PROCEDURE|Endoscopic Endonasal Pituitary Surgery|Surgical treatment consisted of an endoscopic endonasal approach using a rigid 0-degree endoscope, 18 cm in length and 4 mm in diameter.
223502904|NCT04630886|DRUG|Tranexamic acid injection|subcutaneous injection of 50mg/ml TXA
223502905|NCT04630886|DRUG|Lidocaine Epinephrine|subcutaneous injection of 1% lidocaine mixed with 1:200,000 epinephrine
224075006|NCT02369614|OTHER|Active Comparator: 1 Hz rTMS|1 Hz rTMS
224075007|NCT02369614|OTHER|Active Comparator: 10 Hz rTMS|10 Hz rTMS
224075008|NCT02369614|OTHER|Sham Comparator:|Sham rTMS
224075009|NCT03225053|DEVICE|MEP® technique|G1 (n = 15), referred to as LMF, will be submitted to the myofascial release technique consisting of: classic massage (superficial sliding, deep sliding, pumping-kneading, pulse and four-finger smear and sliding) Minutes. G2 (n = 15) will be applied to the MEP® technique, in which the needles will be introduced in three occasions during each session, in different points of the musculature of the most painful region, for a total of 3 minutes. The G3 (n = 15) will execute the two techniques above, being applied the first version Myofascial and later to the MEP®. G4 (n = 15) will be the control group, not performing any of the interventions. The reevaluations will occur immediately and after 48 hours of the intervention.
224075010|NCT03355300|DRUG|Cannabidiol Oral Solution|An oral solution containing pharmaceutical grade cannabidiol (nonplant-based).
224075011|NCT05056532|DIAGNOSTIC_TEST|patient assessment|subjective and objective measurement will be performed in patients with PAH
224075012|NCT03048422|DRUG|Dolutegravir|One 50 mg DTG tablet was administered orally once daily
224075013|NCT03048422|DRUG|Emtricitabine/tenofovir alafenamide|One fixed-dose combination tablet (FTC 200 mg/TAF 25 mg) was administered orally once daily
224075014|NCT03048422|DRUG|Emtricitabine/tenofovir disoproxil fumarate|One fixed-dose combination tablet (FTC 200 mg/TDF 300 mg) was administered orally once daily
224075015|NCT03048422|DRUG|Efavirenz/emtricitabine/tenofovir disoproxil fumarate|One fixed-dose combination tablet (EFV 600 mg/FTC 200 mg/TDF 300 mg) was administered orally once daily
224075016|NCT01051427|DEVICE|Surgiflo|Before to put a nasal catheter to stop nasal bleeding when anterior packing fails, we'll try to stop bleeding with Surgiflo.
224075017|NCT01051427|DEVICE|Nasal catheter|In patients randomized not to put Surgiflo, we use a nasal catheter to try to stop nasal bleeding.
224193887|NCT05874609|OTHER|Teaching with VR spine simulator|The participants spent 30 minutes with the VR spine simulator after receiving the didactic teaching session. The learning objective with the VR simulator is to review the 3D lumbar spine anatomic model，learn the sonoanatomy presented by a dynamic ultrasound scan of the sagittal and transverse plane, and practice a preprocedural ultrasound scan.
224193888|NCT05874609|OTHER|Traditional didactic teaching|A 30-min traditional didactic teaching session of spine ultrasonography. This session was consisted of general spine anatomy, sonographic technique and sonoanatomy, description of five key spine ultrasonographic views (transverse spinous process view, transverse interlaminar view, parasagittal oblique interlaminar view, parasagittal articular process view, parasagittal transverse process view), and a stepwise technique of preprocedural lumbar spine scan
224193889|NCT00268775|BEHAVIORAL|training and follow-up of pharmacists|
223592279|NCT01436474|DRUG|Placebo|Patients will be randomly assigned to receive either varenicline or placebo for 45 days. Patients assigned to varenicline and are current smokers will receive 0.5mg by the oral route once a day for 3 days, followed by 0.5mg twice a day for 4 days. After the first week the dose will be increased to 1mg twice daily for the remainder of the active treatment period of the study. Patients assigned to varenicline and are non-smokers will receive 0.5mg by the oral route once a day for 6 days, followed by 0.5mg twice a day for 6 days. After the first 12 days the dose will be increased to 1mg twice daily for the remainder of the active treatment period of the study. Patients assigned to placebo will receive identical looking capsules in a dosage schedule similar to varenicline.
223592280|NCT04189549|DIAGNOSTIC_TEST|CNA Rapid Sepsis Dx|Novel biomarker based on circulating cell-free DNA (cfDNA) in the human blood stream
223592281|NCT06490042|BEHAVIORAL|Questionnaire|A questionnaire about helmet use and attitude towards helmet use.
224193890|NCT00268775|BEHAVIORAL|patient-directed discontinuation letter|
224193891|NCT05487677|DEVICE|BioBrace Augmentation|During shoulder replacement surgery, the subscapularis (rotator cuff muscle) is sometimes repaired back again. This will be stitched and augmented with a BioBrace. The Biobrace is a biocomposite scaffold meaning both synthetic and biologic, compared to other traditional implants that are either synthetic or biologic. The stitch in the BioBrace group will be anchored to and reinforced by this material.
224193892|NCT05487677|PROCEDURE|Standard Repair with Sutures|During shoulder replacement surgery, the Subscapularis (rotator cuff muscle) is sometimes repaired back again. This is usually repaired with stitches per standard of care treatment.
224193893|NCT04000958|DRUG|PIRF measured by InCheck DIAL|Peak inspiratory flow rates(PIFR) will be measured using the InCheck DIAL(Clement Clarke International Ltd, Harlow, UK and Alliance Tech Medical). The InCheck DIAL is accurate to +/- 10% or 10 L/min, whichever is greater, and can measure flows in the range of 15 to 120 L/min. Dry powder inhaler(DPI) is to be prescribed if PIFRr is over 60L/min, otherwise pressure metered dose inhaler(pMDI) with spacer is given. All the patients will be given inhaled corticosteroid（ICS）/long-acting β agonist（LABA）. For symptomatic patients, long-acting anticholinergic agents(LAMA) will also be used.
223502906|NCT05850312|DEVICE|Gamified Digital Intervention - Feasibility Analysis on MoM|In first round we aim to clinically analyze the game Militant of the Maze (MoM) as a vehicle for Exposure Theory, including, play, observation, and feedback from five clinicians.
223502907|NCT05850312|DEVICE|Gamified Digital Intervention|In the first phase of round 2 of the study, 5 clinicians will play the game to evaluate the revised game MoMG. In the next phase, 5 carefully-selected non-clinician participants will play the game. under real-time observation of clinicians, to ensure that subjects experience no harm, and that the gameplay is interesting and enjoyable.
223502908|NCT06426888|OTHER|Experimental interventional group 1(scapular stabilization exercise therapy)|"Ball stabilization exercise: While standing close to the wall, the participant will be asked to position her affected hand on the ball and keep the ball from moving as disturbance will be applied in different directions.~Wall push up: While facing wall patient will be asked to place both hands on wall, shoulder width apart. He will be instruct to breath in, bend his elbows, lean into wall and hold this position for one second then breath out slowly push back until arms are straight again Wall slides~• Patient will be asked to lean his head, upper thorax and butts against the wall, place his hands and arms against the wall in high five position."
223502909|NCT06426888|OTHER|Experimental :interventional group II (scapular mobilizations)|"Patient lies on unaffected side close to the edge of the treatment bench with hips and knees bent for stability.~Therapist will start by supporting the patient arm on his/her forearm so that shoulder is in maximally loose pack position.~Then he/she will grab on the scapula with both hands. One hand supports the scapula from cranial around the acromion and scapular spine and other hand from the caudal at the inferior angle of scapula.~Then both hands move the scapula cranially over the thorax into elevation and caudally into the depression, upward/downward rotation as well as retraction and protraction."
223502910|NCT06963723|OTHER|Financial Hardship Screening|Financial Hardship Screening and Financial Needs Assessment
223502911|NCT06963723|OTHER|Enhanced Usual Care|Enhanced Usual Care
223502912|NCT06963918|DEVICE|Expiratory muscle strength training|After the 4-week wait-to-start period during which they will not receive any intervention, will participants undergo a 4-week respiratory training program using the EMST150™ device (Expiratory Muscle Strength Trainer). EMST therapy sessions will be completed at home on 5 days (of the patients choosing) per week, performing five sets of five forceful exhalations through the EMST150™. The resistance of the device will be set to 75% of the patient's individual maximum expiratory pressure (MEP). The daily training will take approximately 15 minutes. Following the training period, patients will be observed for an additional 4 weeks to assess the sustainability of the potential training effects.
223502913|NCT06964243|DEVICE|transcranial magnetic stimulation (TMS)|A brief, short, and repeated magnetic field is generated by 2 copper coils inducing an electric current that will propagate within the targeted cortical areas.
223592282|NCT00381147|DRUG|Clarithromycin|
223592283|NCT00722956|DRUG|AZD5672|100 mg once daily, 10 days
223592284|NCT00722956|DRUG|atorvastatin|one single dose of 40 mg on day 10
223592285|NCT00719680|BIOLOGICAL|IgPro20|
223592286|NCT04071158|BIOLOGICAL|RSV Vaccine|RSV vaccine
223592287|NCT04071158|BIOLOGICAL|Tdap|Tetanus, Diphtheria, and Acellular Pertussis Vaccine
223592288|NCT04071158|BIOLOGICAL|Placebo|Normal saline solution for injection (0.9% sodium chloride injection)
223592289|NCT04651491|DRUG|Kagocel|"The researchers prescribed antiviral medications, including Kagocel, according to routine clinical practice. Patients who were assigned Kagocel were invited to participate in the study.~Kagocel administration:~1. for children from 3 to 6 years old (n=41): In the first 2 days - 1 tablet 2 times a day, in the next 2 days - 1 tablet once a day. Total for the course of administration 6 tablets within the period of 4 days.~2. for children from 6 years old (n=39) - administered in the first 2 days - 1 tablet 3 times a day, in the next 2 days - 1 tablet 2 times a day. Total for the course of administration 10 tablets within the period of 4 days."
224193894|NCT04000958|DRUG|Regular treament|The choice of inhalers depends on physician's evaluation. The medication is the same as experimental group.
224193895|NCT00934518|RADIATION|Radiation|Radiation Therapy 60 Gy total dose in 30 fractions: 2.0 Gy/fraction once daily five fractions per week
223592290|NCT05652712|DRUG|Toripalimab|"Toripalimab injection, recommended dose is 3 mg/kg, intravenous infusion every 2 weeks or 240 mg fixed dose, intravenous infusion every 3 weeks.~Other treatment options are individualized according to the diagnosis and treatment experience of doctors in each center, diagnosis and treatment specifications and individual conditions of patients."
223592291|NCT06854458|DIAGNOSTIC_TEST|Quantitative Myocardial Blood Flow Evaluation|The perfusion sequence will produce on-the-fly additional quantitative perfusion maps with segmental myocardial blood flow values.
223592292|NCT06854458|DIAGNOSTIC_TEST|Qualitative Myocardial Blood Flow Evaluation|The perfusion sequence will not produce additional quantitative perfusion maps.
223592293|NCT06854458|DRUG|Gadavist|Participants will receive Gadavist 0.05 mmol/kg dose for each stress and rest perfusion imaging (total dose of 0.1 mmol/kg).
223592294|NCT06854458|DRUG|Vasodilator|All participants will receive vasodilator (regadenoson or adenosine depending on local site practice).
223592295|NCT06854458|DIAGNOSTIC_TEST|Blood draw for the laboratory assessment|A single (7-10 ml tube) whole blood sample will be collected from each patient for processing of blood biomarkers.
223592296|NCT05269550|RADIATION|High-Intermediate Risk Patients-cohort 1|Patients will receive 35Gy/5 fractions to the whole prostate (25 Gy to proximal Seminal Vesicles) with a simultaneous boost to PET/MRI defined intra-prostatic foci to a target maximum dose of 50Gy/5 fractions. Six months of androgen deprivation therapy will commence with the end of radiotherapy (concurrent plus adjuvant)
223592297|NCT05269550|RADIATION|High Risk or Very High-Risk Patients-cohort 1|Patients will receive 35Gy/5 fractions to the whole prostate (25Gy to whole Seminal Vesicles) with a simultaneous boost to PET/MRI defined intra-prostatic foci to a target maximum dose of 50Gy/5 fractions. Pelvic lymph nodes will receive 25Gy/5 fractions synchronous with prostate treatment with a simultaneous boost to imaging involved nodes to a maximum of 35Gy/5 fractions. Eighteen months of androgen deprivation therapy will commence with the end of radiotherapy (concurrent plus adjuvant)
223592298|NCT05269550|RADIATION|High-Intermediate Risk Patients-cohort 2|Patients will receive 35Gy/5 fractions to the whole prostate (25 Gy to proximal Seminal Vesicles) with a simultaneous boost to PET/MRI defined intra-prostatic foci to a target maximum dose of 50Gy/5 fractions. Androgen deprivation therapy will commence 3 months before radiotherapy (concurrent plus adjuvant) and will continue for a total of 6 months.
223592299|NCT05269550|RADIATION|High Risk or Very High-Risk Patients-cohort 2|Patients will receive 35Gy/5 fractions to the whole prostate (25 Gy to proximal Seminal Vesicles) with a simultaneous boost to PET/MRI defined intra-prostatic foci to a target maximum dose of 50Gy/5 fractions. Androgen deprivation therapy will commence 3 months before radiotherapy (concurrent plus adjuvant) and will continue for a total of 18 months.
223592300|NCT01389037|BEHAVIORAL|Health Literacy-focused Self-help|Weekly 2-hour sessions over 6 weeks followed by 12 month follow-up with home blood pressure self monitoring with telephone counseling by community health workers.
223592301|NCT01389037|BEHAVIORAL|Delayed Intervention Control|Given pamphlets on the importance of high blood pressure control and offered weekly workshops. This group will be offered the intervention at the conclusion of data collection.
223592302|NCT06172725|OTHER|Dietary and exercise intervention|"The healthy older adults will follow a twelve-week high-protein vegetarian diet or high-protein omnivorous diet both in combination with a resistance exercise program.~All participants will receive blended dietary counselling. Blended dietary counselling is based on tele-coaching and face-to-face coaching performed by dieticians."
223592303|NCT01359228|DRUG|Rifaximin (XIFAXAN)|Rifaximin (XIFAXAN®) 1650 mg/day (550 mg tablet three times a day) for 14 days
223592304|NCT01359228|DRUG|Placebo|Placebo 1 tablet three times a day for 14 days.
223592305|NCT03592563|BEHAVIORAL|Neuro-QoL questionnaire|Follow-up over time will continue (either in-person or over the phone) using the same questionnaires (depending on which group they are belongs to) at approximately 6-month intervals. During each follow-up, participants will be screened for any new signs, symptoms and diagnoses of neurological and/or psychiatric disorders, in order to correlate these outcomes with risk factors captured using the procedures described above.
224075018|NCT01348997|BEHAVIORAL|Project Onward website + 16 person social network|The website will include 8 weeks of Internet-based cognitive behavioral therapy combined with discussion and support from a group of up to 16 other cancer survivors.
224075019|NCT01348997|BEHAVIORAL|Project Onward website + 8 person social network|The website will include 8 weeks of Internet-based cognitive behavioral therapy combined with discussion and support from a group of up to 8 other cancer survivors.
224075020|NCT05583266|DRUG|Pentoxifylline sustained-release tablets|a dose of 1 tablet twice a day of Pentoxifylline sustained-release tablets
224193896|NCT00934518|DRUG|Cetuximab|"Radiation Therapy 60 Gy total dose in 30 fractions: 2.0 Gy/fraction once daily five fractions per week~Cetuximab 400 mg/m2 of body surface area over a period of 120 minutes day 1 250 mg/m2 of body surface area over a period of 60 minutes weekly during radiation"
224075021|NCT05583266|DRUG|Pentoxifylline sustained-release tablets placebo|Pentoxifylline sustained-release tablets placebo will be administrated at the same dosage and frequency as the experimental group
223746604|NCT06518187|OTHER|Assessing the impact of three different catheter advancement techniques on needle tip movement during intravenous insertion|Each participant will perform 3 simulated IV catheter insertions using each of the specified techniques. Participants will use the instrumented 16ga IV catheter to insert into the peripheral vascular access simulator. Needle tip movement (from intent of catheter advancement to 5mm of advancement off the needle) will be measured with 0.2mm accuracy using the electromagnetic tracking technology of the simulator. Data collected will include needle movement after simulated vein punction and during initial catheter advancement off the needle (in mm) which will be recorded within the simulation program and output as a de-identified Excel file
224193897|NCT03187639|DIAGNOSTIC_TEST|FFRct|In the test group all patients who are eligible for CTA will undergo CTA as their default test. Those patients with any coronary stenosis of equal or \> 40% data in at least one major epicardial vessel of stentable/graftable diameter will be referred for FFRct. (NB Lesions in distal vessels or vessels of a diameter not suitable for stenting/grafting will not qualify for FFRct if there are no other more significant lesions). In patients in whom FFRct analysis is performed, FFR will be derived for all vessels. The data derived from this test will determine their management strategy. The patients in this arm will not follow the NICE guideline algorithm. Those patients randomised to FFRct with contraindications for CTA will be asked to take part in a trial registry.
223746605|NCT03134560|DEVICE|Vein Display Instrument|
224075022|NCT03922698|OTHER|No interventions|No interventions - observational study
224310265|NCT06983600|OTHER|alternative therapy:sujok therapy|As of the first day of the menstrual period for a total of 10 days, the researcher will provide sensitization of the points and painful point detection with the ring and in-hand spiral in the hand macro insect and mini system. Then, moxa will be applied to the uterus and ovary reflection point between 2 minutes and 5 minutes. Moxa is a method that burns wormwood and treats it with the heat emitted to the skin by the smoke with perforated apparatus. It is one of the oldest treatment methods based on heat and plant healing. After the Moxa application, the black pepper seed will be fixed to the painful spot with the help of an air-tight plaster. The black pepper seed will be kept for at least 4 hours and maximum 8-10 hours.
224310266|NCT06983756|DRUG|Erythropoietin|EPO resistance
223502914|NCT06964399|OTHER|Reminiscence therapy|Reminiscence Therapy can be applied as 1 or 2 sessions per week and the longest is 1.5 hours, so it will be applied for 5 weeks, 3 days a week (Monday, Wednesday, Friday) with 2 sessions per day. Each session is planned to last an average of 1.5 hours according to the answers from the elderly. The elderly individuals in the experimental group will be divided into 3 groups. Each group will consist of 15 people. The sessions will include, respectively, getting to know each other, childhood, places lived, holidays-festivals, foods-cooking, unforgettable historical periods, favorite music, movies specific to the period, family life-values in life-achievements, evaluation and closing topics.
223502915|NCT06964178|DEVICE|Experimental: antimicrobial photodynamic therapy (aPDT) after extraction of third molar|In the test, a photoactive substance activated with laser light (20 mW, 660 nm) was applied to the post-extraction site for 60 seconds before suturing, to promote healing and disinfection
223502916|NCT02724644|BIOLOGICAL|COLLAGENASE CLOSTRIDIUM HISTOLYTICUM|Injectable intervention
223502917|NCT02724644|BIOLOGICAL|Placebo Comparator|
223502918|NCT04676776|DRUG|Levonorgestrel|All participants receive 1.5 mg levonorgestrel on day 1
223502919|NCT04676776|DRUG|Mifepristone|All participants receive 200 mg mifepristone on day 3
223502920|NCT00228852|DRUG|Busulfan, Fludarabine and ATG|
223502921|NCT02073617|RADIATION|Real-time 3-dimensional DynaCT|After coronary angiography is performed, a 6Fr pigtail catheter will be placed in the aorta and 40cc of 50% contrast media diluted normal saline will be delivered using standard automated injection during dynaCT cardiac image acquisition. Intravenous delivery of contrast as alternative.
223502922|NCT00884949|DRUG|BMN 110|"Subjects will receive a weekly 4- to 5-hour intravenous infusion of BMN 110 in 3 consecutive 12-week dosing intervals, using the following regimen:~* Weeks 1-12: 0.1 mg/kg/week~* Weeks 13-24: 1.0 mg/kg/week~* Weeks 25-36: 2.0 mg/kg/week~Subjects who complete the 36-week Dose-Escalation Period will have the option to continue drug treatment for an additional 36 to 48 weeks. Subjects continuing on treatment after the Dose-Escalation period will receive weekly 4- to 5-hour intravenous infusions of BMN 110 at a dose of 1.0 mg/kg/week."
223502923|NCT03022630|OTHER|Comprehensive Palliative Care services|Participants who are randomly assigned to the intervention arm will receive informational materials, comprehensive inpatient palliative care consultations with a palliative care physician or nurse practitioner, in addition to standard hepatic care. If the patient is discharged, follow-up consults will be provided by a palliative care nurse via telephone contact. Telephone contacts will occur on a flexible schedule (e.g., weekly, bi-weekly, monthly) based on the needs and wishes of the patient, at a minimum frequency of once a month. If a need for further care is identified from a telephone contact, appropriate follow-up (referral, appointment, clinical communication, etc.) will occur per standard procedures. If the participant is readmitted, the consultation schedule will restart.
223502924|NCT03022630|OTHER|Usual hepatic care|Participants randomized to the usual care arm will not be scheduled to meet with the palliative care service unless a consult is requested by the patient, the family, or treating physician. These consultations would include the same palliative care services as the intervention arm, excluding the informational patient materials and telephone consultations.
223502925|NCT04807296|PROCEDURE|TFLEP|"Thulium fiber laser (TFL) is a novel laser technology that delivers a pulsed laser at a more optimal wavelength and a shallower depth of tissue penetration leading to better hemostatic properties. Patients will undergo thulium fiber laser enucleation of the prostate (TFLEP) at the Centre Hospitalier de l'Université de Montréal (CHUM) as a treatment for benign prostate hyperplasia. The surgeon performing TFLEP is experienced in TFLEP procedures.~Fifty (50) patients will undergo TFLEP."
224075023|NCT02796248|OTHER|cross-sectional survey|This is an observation study. Participants will complete a survey at one occasion. Participants are also invited to do a A1c mail-in capillary test.
224075024|NCT06235099|DRUG|Copper Cu 64 PSMA I&T|Radiopharmaceutical PET imaging tracer injected intravenously for the detection of PSMA expression.
224075025|NCT02975544|BEHAVIORAL|CRECES programme|The first unit of CRECES programme was implemented in 8 sessions. Each session was 40-50 minutes long and delivered during four weeks. Parents were provided with home-extension activities.
224075026|NCT00653003|DRUG|Leflunomide|tablets, 20mg, single-dose
224075027|NCT00653003|DRUG|ARAVA|Tablets, 20mg, single-dose
223746606|NCT03333954|DEVICE|PRIMA|"The PRIMA Bionic Vision System is a device for treatment of patients who have lost their sight through outer retinal degenerative conditions of the eye such as atrophic dry age related macular degeneration.~The PRIMA System is designed to provide partial restoration of the patient's visual function through electrical stimulation of the retinal neurons by a sub-retinally implanted stimulator that replace part of the degenerate photoreceptors"
223746607|NCT06505824|DRUG|BL-M14D1|Administration by intravenous infusion for a cycle of 3 weeks.
224310267|NCT06981845|DRUG|Immunosuppressive therapy|prednisone + sirolimus
224310268|NCT06981845|DRUG|Placebo|Placebo
223502926|NCT04807296|PROCEDURE|m-HoLEP|"The holmium: yttrium-aluminum-garnet (Ho: YAG) laser is the longest running and most studied laser used to perform this minimally invasive procedure. Holmium laser enucleation of the prostate reduces hospital stay and hemoglobin drop while improving IPSS and quality of life, as well as other positive postoperative outcomes compared to the historical gold standard, transurethral resection of the prostate (TURP). HoLEP has been found to have a better enucleation efficiency rate and may have better hemostatic properties when combined with the modulated pulsed laser energy featured associated with Moses technology (m-HoLEP). Patients will undergo m-HoLEP at the Centre intégré universitaire de santé et de services sociaux (CIUSSS) du Nord-de-l'Île-de-Montréal as a treatment for benign prostate hyperplasia. The surgeon performing m-HoLEP is experienced in m-HoLEP procedures.~Fifty (50) patients will undergo m-HoLEP"
223502927|NCT06783946|BEHAVIORAL|Meditation|The meditation technique will be comprised of breathing techniques, full body relaxation, color meditation, visualization, and positive affirmations. A physician researcher trained in teaching meditation will conduct virtual meditation sessions with patients enrolled in the study. Participants will practice a daily 20-minute meditation for 2-4 weeks before scheduled surgery (whichever is the maximum length of time from enrollment) to 2 weeks post-operatively using the provided audio guided meditation recordings. Participants will also log completion of daily meditation practice electronically.
223502928|NCT03126734|OTHER|Infant Massage course|"Infant massage courses consist of 5 sessions. Investigators explain parents how to make an infant massage technique to their babies and which should be the general conditions of the environment.~This massage is based on the methodology of the International Association of infant massage (IAIM) created by Vimala Schnneider. The courses will make individually."
223502929|NCT01258855|BIOLOGICAL|Aldesleukin|Given IV
223502930|NCT01258855|OTHER|Laboratory Biomarker Analysis|Correlative studies
223502931|NCT01258855|BIOLOGICAL|Ziv-Aflibercept|Given IV
223502932|NCT04330898|DEVICE|Biotronik peacemakers, implantable cardioverter-defibrillators and cardiac resynchronizers|Any of these Biotronik cardiac stimulation devices with the Home Monitoring function activated for the remote control of patients
223502933|NCT01958684|DRUG|Levonorgestrel IUS (Mirena, BAY86-5028)|LNG-IUS once inserted will be effective for 5 years.
223502934|NCT01958684|DEVICE|Copper-IUD|Copper-IUD once inserted will be effective for more than 10 years.
223502935|NCT01567085|DRUG|Eculizumab|
223502936|NCT04231006|RADIATION|High dose rate brachytherapy|High dose rate brachytherapy will be delivered to the site of recurrence within the prostate gland based on MRI and PSMA PET/CT
223502937|NCT03899493|OTHER|Observation|Patients will be dispositioned to usual obstetric care which may include minimal intervention if spontaneous labor, induction of labor or augmentation of labor as indicated and dictated by the participants obstetrical provider. This study is observational only.
223502938|NCT05719389|DRUG|CT-P13|CT-P13 is a biosimilar of infliximab approved by EMA since 2015, and it is administered intravenously (i.v.) at a standard dose of 5 mg/kg at week 0, 2, 6 and then every 8 weeks, although the scheduled maintenance regimen can be optimized by administering the drug every 4-6 weeks or increasing the dose up to 10 mg/kg2.The safety profile of CT-P13 SC was comparable to that of CT-P13 i.v.; There were also fewer patients with positive anti-drug antibodies with CT-P13 SC than with CT-P13 i.v.3 At the moment, no data are available on the effectiveness, safety and immunogenicity in a real-world population of patients who have been switched from i.v. to s.c. infliximab.
223502939|NCT00449969|DEVICE|Zoll AED pro|Arm one (Extended feedback) offers full feedback guidance during CPR
223502940|NCT00449969|DEVICE|Zoll AED pro|In arm two (limited feedback) feedback is modified lacking several elements of feedback
223502941|NCT06413771|DRUG|Letrozole 2.5mg|Letrozole pretreatment during ovarian stimulation with gonadotropins, in intrauterine insemination cycles.
223502942|NCT06413771|DRUG|Gonadotropin|Ovarian stimulation with gonadotropins, in intrauterine insemination cycles.
223502943|NCT04762199|DRUG|Flt3/MerTK Inhibitor MRX-2843|Given PO
223502944|NCT04762199|DRUG|Osimertinib|Given PO
223502945|NCT03421080|BEHAVIORAL|MoodGYM|The MoodGYM Internet intervention will employ the latest version of MoodGYM (Mark 4) which has been updated to support mobile devices. The core design and function of the program has not been altered. A major focus of this intervention is to provide individuals with behavioral and cognitive strategies to improve depression symptoms.
223502946|NCT03421080|BEHAVIORAL|Check Your Drinking|Internet intervention designed to assess and provide feedback on hazardous alcohol use. The CYD has been subjected to seven randomized trials from two independent research groups, all of which displayed a significant impact of the CYD to reduce hazardous alcohol consumption compared to controls.
223502947|NCT00115531|BIOLOGICAL|Trivalent inactivated influenza vaccine|Standard Dose Influenza Vaccine Fluzone® (15 µg HA / viral strain; 45 µg/0.5 mL dose) will be administered to Arm 1: 200 subjects intramuscularly on day 0.
224193898|NCT03187639|DIAGNOSTIC_TEST|Standard care|All patients in the standard care group will be assessed according to their current conventional pathways that are based upon NICE guidelines for Chest Pain of Recent Onset. The trial will encourage the routine and standard assessment and management of all patients at these sites… (anticipated outcomes include ETT, stress echo, stress MR, nuclear perfusion, CTA, CT calcium, invasive CA, reassurance), in accordance with the local application of the NICE guideline for chest pain of recent onset.
224193899|NCT01205139|DRUG|TMC435|150 mg capsule once daily for 7 days
224193900|NCT01205139|DRUG|TDF|300 mg tablet once daily for 7 days
224193901|NCT01205139|DRUG|TMC435 + TDF|150 mg TMC435 capsule + 300 mg TDF tablet, once daily for 7 days
224193902|NCT01205139|DRUG|TMC435 + TMC278|150 mg TMC435 capsule + 25 mg TMC278 tablet, once daily for 11 days
224193903|NCT01205139|DRUG|TMC278|25 mg tablet once daily for 11 days
224193904|NCT01205139|DRUG|TMC435|150 mg capsule once daily for 11 days
223746608|NCT06127992|DEVICE|Cold stimulation tests / critical temperature threshold|ICT was performed following a standard protocol. Briefly, a melting ice cube in thin plastic bag was placed on the volar surface of the patient forearm for 5 min, with macroscopic assessment of the test site 10 min later. TempTest® CSTs were done with TempTest® 4.0 (Courage \& Khazaka, Cologne, Germany), which has a single Peltier element (length: 350 mm, width: 2 mm) that provides a continuous temperature gradient from 4°C to 44°C. The use of TempTest® allows for reproducible and standardized cold (and heat) provocation tests and the identification of CTTs. TempTest® CST results were also assessed 10 min after the end of cold exposure.
223746609|NCT01192282|PROCEDURE|Medical / Surgical Treatment|All participants received treatment based on the morphology and distributions of lesions. For the treatment with Trichloroacetic Acid (TCA), patients were advised to attend the clinic weekly until no visible lesions seen. For electrosurgery or laser, patients were given a date for admission a day prior to surgery. Post-operatively, she remained in the ward for at least five days.
223746610|NCT02905682|DRUG|Desmopressin|
223746611|NCT02905682|DRUG|Placebo|
223746612|NCT03441841|DRUG|Lidocaine + Prilocaine|Single topical dose of 2g lidocaine + prilocaine 2.5 % formulation.
223502948|NCT00115531|BIOLOGICAL|Trivalent inactivated influenza vaccine|High Dose Influenza Fluzone® Vaccine (60 µg HA / viral strain; 180 µg/0.5 mL dose) will be administered to Arm 2: 200 subjects intramuscularly on Day 0.
223502949|NCT04597333|DRUG|Dinoprostone|Dinoprostone vaginal insert.
223502950|NCT04597333|DEVICE|Cervical ripening balloon.|Double lumen cervical ripening balloon.
223502951|NCT04029038|BIOLOGICAL|Autologous CD19/CD22 Chimeric Antigen Receptor T-cells|Given IV
223502952|NCT04029038|DRUG|Cyclophosphamide|Given IV
223502953|NCT04029038|DRUG|Fludarabine|Given IV
223592306|NCT03922178|DEVICE|Pressure/Volume Combination Catheter|Hemodynamic data routinely collected and data collected by means of the placement of a Pressure/Volume Combination Catheter (Pressure/Volume Combination Catheter,Leycom,The Netherlands) will be collected simultaneously. The catheter will be placed and held in place as long as the patient is in a position to be assisted by extracorporeal circulation. This means that the placement of the catheter will follow the heparinization of the patient and the placement of the cannulas necessary for the realization of extracorporal circulation. It will be removed from the left ventricular cavity before removal of extra-corporal cannulas.
223592307|NCT03922178|DEVICE|Transthoracic echocardiography|A complete transthoracic echocardiography will be performed the day before the surgical procedure, as per standard of care. It will establish the presence of the inclusion and exclusion criteria and evaluate the contractile function of the left ventricle. This will be done using a Philips IE33 echocardiograph (Koninklijke Philips Electronics N.V., Netherlands).
223592308|NCT03922178|DEVICE|Transesophageal echocardiogram|A transesophageal echocardiogram will be performed during the cardiac surgery, as per standard of care, using an Acuson Sequoia system (Siemens AG, Germany). It will facilitate the placement of the pressure/volume combination catheter and collect echographic data.
223592309|NCT00815594|DRUG|bevacizumab|0.05ml, 1.25mg
223592310|NCT01286740|DRUG|FTC/RPV/TDF|Emtricitabine (FTC) 200 mg/rilpivirine (RPV) 25 mg/tenofovir disoproxil fumarate (tenofovir DF; TDF) 300 mg single-tablet regimen (STR) administered orally with a meal once daily
223592311|NCT00510744|DRUG|pancreatic enzyme supplement|4 caps with meals, 2 with snacks
223592312|NCT06893939|OTHER|Limited Trophic Feeds (1 day of trophic feeds)|Advancing enteral feeds after 1 day of trophic feeds of 20-25 mL/kg birthweight/day. Advancement of enteral feeds will be by approximately 30 mL/kg birthweight/day until achieving at least 140 mL/kg birthweight/day of enteral feeds. Enteral feeds will consist of parent's own milk or donor human milk.
223592313|NCT06893939|OTHER|Extended Trophic Feeds (3 days of trophics)|Advancing enteral feeds after 3 days of trophic feeds of 20-25 mL/kg birthweight/day. Advancement of enteral feeds will be by approximately 30 mL/kg birthweight/day after 3 days of trophic feeds. Advancement will occur until achieving at least 140 mL/kg birthweight/day of enteral feeds. Enteral feeds will consist of parent's own milk or donor human milk.
223592314|NCT06886997|DIAGNOSTIC_TEST|Pelvic Floor Ultrasound|Pelvic Floor Ultrasound will be carried out by a sonographer expert in the technique and who will be blinded from the data of clinical examination as well as the UDS results. The 3D/4D abdominal ultrasound probe will be used to perform a transperineal scan to capture midsagittal pelvic floor views. The test will be conducted both at resting state and during the maximum Valsalva maneuver.
223746613|NCT03441841|DRUG|Lidocaine|Single topical dose of 2g lidocaine 2.5 % formulation.
223746614|NCT03441841|DRUG|Prilocaine|Single topical dose of 2g prilocaine 2.5 % formulation.
223746615|NCT02555332|OTHER|75g oral glucose tolerance test (OGTT)|All these women underwent the 75g oral glucose tolerance test (OGTT) at 24-28 weeks of gestation.
223746616|NCT04460820|DRUG|Doxorubicin Hydrochloride Liposome Injection|50mg/m2,IV on Day 1 of each cycle
223746617|NCT01561820|BEHAVIORAL|5-month aerobic exercise intervention|The 5-month aerobic exercise intervention is in accordance with the American Heart Association and American College of Sports Medicine physical activity recommendation for optimizing cardiovascular fitness in older adults.Exercise will consist primarily of walking on the treadmill.The goal of the program will be for participants to exercise at a moderate- to high-intensity, defined as 65-80% (ACSM guidelines) of heart rate reserve (HRR), for 30 minutes, 4 days per week.The duration of exercise will progress from 15-20 mins at 50% HRR the 1st week to 30 mins at 65-80% HRR by the end of the 6th week and thereafter.At the start of each session, exercise intensity will be gradually increased to 50% HRR(0.5\[HRmax-HRrest\]+HRrest)during a 10minute warmup period,and then to the individualized target heart rate training zone for the next 25-30 minutes.Participants will wear a digital heart rate monitoring device for the duration of the training session.
223746618|NCT00536107|DRUG|Gefitinib|250 mg oral
223746619|NCT00536107|PROCEDURE|CT or MRI|performed at screening and every 6 weeks
223746620|NCT00536107|DRUG|Docetaxel|60mg/m2 intravenous infusion
223746621|NCT01761214|DRUG|Fluroquinolones|All antibiotics are administered based on British Thoracic Society guideline for bronchiectasis
223502954|NCT02360501|DRUG|Docetaxel|75mg/㎡,d1
223502955|NCT02360501|DRUG|Cisplatin|25mg/㎡,d1-3
223502956|NCT02360501|DRUG|Capecitabine|2000mg/㎡,d1-14
223502957|NCT04331171|DEVICE|Web application users|questionnaire of comorbidity and symptoms completed by the patient on his smartphone
224310269|NCT06981728|PROCEDURE|Mid point transverse to pleura block|"TPVB and MTPB was performed at a spinal level midway between the uppermost and the lowest fractured rib, with the patient in a sitting position, and under complete aseptic conditions, a linear ultrasound probe (GE Healthcare-Logiq F6) will be placed oblique parasagittally 3 cm lateral to spinous process used to identify the transverse process, pleura, superior costotransverse ligament, and the paravertebral space at the target vertebral level.~After skin and subcutaneous tissue infiltration with 2-3 mL of 2% lignocaine, an 18-gauge Touhy needle was inserted under ultrasound guidance until the needle tip reaches :~* the midpoint between the transverse process and the pleura (group M).~* the paravertebral space (group P). A bolus dose (0.3mL/kg) of plain bupivacaine 0.5% plus 8 mg of dexamethasone was injected after negative aspiration to blood and air."
224310270|NCT06983054|DRUG|ertugliflozine|SGLT2i versus placebo
224310271|NCT06983054|BEHAVIORAL|low salt diet|comparing low salt versus high salt diet
224193905|NCT02570399|RADIATION|Oligometastatic patients with abdominal-pelvic lymph nodes|Hypofractionated ablative radiation therapy for oligometastatic patients with lymph node metastases
224193906|NCT00612300|BEHAVIORAL|Lokomat - Physical therapy|A: Lokomat training, 30 minutes per day for 3 weeks, 5 days per week. B: Categorized gait training by physical therapist, 30 minutes per day for 3 weeks, 5 days per week
224310272|NCT06983054|DRUG|placebo|placebo tablet
224310273|NCT06983054|BEHAVIORAL|high salt diet|high salt diet
224310274|NCT06982547|BIOLOGICAL|UTAA91 injection|After signing the informed consent form, eligible subjects will receive an infusion of UTAA91 injection. Blood samples will be collected from the subjects before and after the infusion for the evaluation of pharmacokinetics, pharmacodynamics, immunogenicity, and safety.
223592315|NCT06886997|DIAGNOSTIC_TEST|Urodynamic studies|Urodynamic studies (UDS) will be carried out according to the usual protocol and will include: cystometry, Valsalva leak point pressure, urethral pressure profile, and uroflowmetry.
223592316|NCT06760754|DIETARY_SUPPLEMENT|Digital culinary medicine intervention|Participants will receive 30lbs of healthy foods through an on-site hospital-base food pantry
223592317|NCT07073378|DEVICE|Brain computer interface|"Families will first complete an in-person visit to review available activities, set their first goals, and learn to use BCI independently. A BCI kit will be given to each family, with a headset and the equipment and software required to pursue their identified goals. Following this, families will participate in 12 virtual sessions over 3-6 months. Scheduling will be flexible to accommodate complex family needs. Daily online support will be provided via a messaging application. Participants who choose to continue using BCI beyond 12 sessions will be provided kits and supported."
224193907|NCT00612300|BEHAVIORAL|Physical therapy - Lokomat|"B: Daily 30 minutes of gait training with a physical therapist, 5 days per week for 3 weeks.~A: Daily 30 minutes of Lokomat training, 5 days per week for 3 weeks."
223502958|NCT04348578|OTHER|QMix 2in1|In QMix 2in1 group root canals were irrigated with Mix as a final irrigation.
223592318|NCT07080996|COMBINATION_PRODUCT|Strengthening training with biofeedback|Participants in this group trained their tongue strength with the Iowa Oral Performance Instrument (IOPI), completing 3 sets of 10 repetitions at 80% of their maximum.
224310275|NCT06438263|DRUG|Rocatinlimab|Vial supplied as a single-use preservative free solution for SC injection.
224310276|NCT06438263|DRUG|Rocatinlimab|Autoinjector for SC injection.
224310277|NCT02032095|DRUG|GB-0998|
224310278|NCT02768714|DRUG|Eurofarma's pegfilgrastim|Eurofarma's pegfilgrastim is a clear, colourless solution for injection (6 mg/0.6 mL) provided in a single use prefilled syringe. Subjects randomised to Eurofarma's pegfilgrastim will receive 6 mg administered as a single SC injection in the abdomen, upper arm, or thigh on Day 2 of each CTX cycle, approximately 24 hours after
224310279|NCT02768714|DRUG|Neulastim|Eurofarma's pegfilgrastim is a clear, colourless solution for injection (6 mg/0.6 mL) provided in a single use prefilled syringe. Subjects randomised to Eurofarma's pegfilgrastim will receive 6 mg administered as a single SC injection in the abdomen, upper arm, or thigh on Day 2 of each CTX cycle, approximately 24 hours after
224310280|NCT00426712|BIOLOGICAL|1018 ISS immunostimulatory oligonucleotide with HBV surface antigen|Intramuscular (IM) injections on Day 0, Week 4 and Week 24, plus a placebo (salt solution) injection at Week 8
224310281|NCT00426712|BIOLOGICAL|Hepatitis B Vaccine (Recombinant)|IM (in the muscle) injections on Day 0, Week 4, Week 8 and Week 24
224310282|NCT02365558|DRUG|Evacetrapib|Administered orally
224310283|NCT02365558|DRUG|Omeprazole|Administered orally
224310284|NCT00369317|DRUG|asparaginase|Given IM
224310285|NCT00369317|DRUG|daunorubicin hydrochloride|Given IV
224310286|NCT00369317|DRUG|cytarabine|Given IV or IT
224310287|NCT00369317|DRUG|thioguanine|Given orally
224310288|NCT00369317|DRUG|etoposide|Given IV
223592319|NCT07080996|COMBINATION_PRODUCT|Endurance training with biofeedback|Participants in this group trained their tongue endurance with the Iowa Oral Performance Instrument (IOPI), completing 3 sets of 20 repetitions at 60% of their maximum.
223746622|NCT01761214|DRUG|Beta-lactamase inhibitor|All antibiotics are administered based on British Thoracic Society guideline for bronchiectasis.
223746623|NCT02278107|DEVICE|Tidal Assist Ventilator System|Tidal volume augmentation with supplemental oxygen. Source gas options: cylinder, concentrator, wall.
224310289|NCT00369317|OTHER|laboratory biomarker analysis|Correlative studies
224310290|NCT01004094|BEHAVIORAL|simple goal setting|This group will set goals only
224310291|NCT01004094|BEHAVIORAL|goal setting plus action intentions|This group will set goals and form action intentions (plans)
224310292|NCT01004094|BEHAVIORAL|goal setting plus coping intentions|This group will set goals and form coping intentions (plans)
224310293|NCT01004094|BEHAVIORAL|goal setting plus action intentions plus coping intentions|This group will set goals and form action intentions and coping intentions
223502959|NCT03150797|DRUG|Melatonin|Melatonin
223502960|NCT03150797|DRUG|Placebo oral capsule|Placebo
223502961|NCT00652613|RADIATION|3 Dimensional Radiation Therapy|Radiation with 6 MV photons to dose of 70Gy/ 35#/ 7 weeks
223502962|NCT00652613|RADIATION|Intensity Modulated Radiation Therapy|IMRT with 6 MV photons to a dose of 66Gy/30#/ 6 weeks
223502963|NCT05180656|BEHAVIORAL|Yoga Intervention|The yoga intervention will consist of two 60-minute yoga classes each week, taught by a certified yoga instructor and delivered remotely through videoconferencing. Participants will be asked to participate in the intervention for 8 weeks.
224193908|NCT02940392|DEVICE|Rezum System|"The Rezūm System is designed to treat patients with bothersome urinary symptoms associated with benign prostatic hyperplasia (BPH). The Rezūm System utilizes radiofrequency current to generate wet thermal energy in the form of water vapor, which is then injected into the transition zone and/or median lobe of the prostate tissue in controlled 9-second doses. The vapor that is injected into the prostate tissue rapidly disperses through the interstitial space between the tissue cells. As the vapor cools, it condenses immediately on contact with tissue and the stored thermal energy is released, denaturing the cell membranes and causing cell death.~The denatured cells are absorbed by the body, which reduces the volume of prostate tissue adjacent to the urethra. The vapor condensation process also causes a rapid collapse of vasculature in the treatment zone, resulting in a bloodless procedure."
224193909|NCT03869905|DRUG|Aquamin®|4 capsules per day; 2 to be taken in the morning and 2 in the evening (containing approximately 800 mg calcium/day)
224193910|NCT03869905|DRUG|Placebo first then Aquamin®|4 capsules per day; 2 to be taken in the morning and 2 in the evening
224193911|NCT04707833|DIAGNOSTIC_TEST|Serological testing for COVID-19 infection|"The tests used will be the following:~EUROIMMUN SARS-CoV-2(IgA) ELISA ELISA SARS-CoV-2 (IgG) EUROIMMUN WANTAI SARS-CoV-2 Ab ELISA WANTAI SARS-CoV-2 IgM ELISA Abbott Architect SARS-CoV-2 IgG Diasorin SARS LINK CoV-2 S1/S2 IgG Roche ECL anti-SARS-Cov-2 (combined IgG IgM IgA)"
224193912|NCT01023815|DRUG|everolimus|Everolimus (Certican®) was provided in blisters containing tablets of 0.25 mg and 0.75 mg. Everolimus was initiated within 48 hours after graft reperfusion and it was administered orally.
224193913|NCT01023815|DRUG|cyclosporine|Cyclosporine for microemulsion (CsA, Sandimmun® Neoral®) was coadministered with everolimus at the same time of the day. CsA was available in alu-alu blisters containing soft gelatine capsules of 100 mg, 50 mg, 25 mg and 10 mg. Oral solution, as bottles containing 50 mL of solution (100 mg/mL) has been provided and used in case the drug had been administered to patients by nasogastric tube immediately after transplant.
224193914|NCT01023815|DRUG|Prednison (continuous steroids)|continuous steroids
224193915|NCT01383759|DRUG|Bortezomib/Dexamethasone (BD), Followed By Autologous STC & Maintenance Bortezomib/Dexamethasone|"The treatment has three phases:~1\) Initial treatment phase: This phase consists of 1-3 21-day-cycles of a combination regimen that includes bortezomib 1.3 mg/m2, IV or Subcutaneous Injection (SQ), on days 1, 4, 8, and 11; and dexamethasone 40 mg PO or IV, on days 1, 4, 8, and 11. Stem cell mobilization and HDM/ASCT. Post-ASCT consolidation/maintenance treatment phase: This phase consists of six cycles of bortezomib 1.3 mg/m2, IV or (SQ) with dexamethasone 20 mg PO or IV administered on days 1, 8, 15, and 22 every 12 weeks +/- 2 weeks. Long Term Follow Up will cease when all patients on study have fulfilled the requirements for at least five follow up appointments."
224193916|NCT00007332|BIOLOGICAL|ALVAC(2)120(B,MN)GNP (vCP1452)|
224193917|NCT00007332|BIOLOGICAL|MN rgp120/HIV-1 and GNE8 rgp120/HIV-1|
224193918|NCT03642158|DEVICE|repetitive Transcranial Magnetic Stimulation|repetitive Transcranial Magnetic Stimulation (rTMS) utilizes a magnetic coil of wire to non-invasively and painlessly activate small sections of the brain through the skull.
224193919|NCT03992456|BIOLOGICAL|Panitumumab|Given IV
224193920|NCT03992456|OTHER|Quality-of-Life Assessment|Ancillary studies
223746624|NCT02278107|DEVICE|Nasal Cannula Oxygen|Standard oxygen therapy delivered by nasal cannula at 2-5 lpm based on patient requirements. Source gas options: cylinder, concentrator, wall.
224193921|NCT03992456|OTHER|Questionnaire Administration|Ancillary studies
224193922|NCT03992456|DRUG|Regorafenib|Given PO
224193923|NCT03992456|DRUG|Trifluridine and Tipiracil Hydrochloride|Given PO
224193924|NCT02003248|DEVICE|transcranial magnetic resonance guided focused ultrasound pallidotomy|Focused ultrasound is an attractive method for non-invasive thermal ablation of soft tissue, including functional brain targets. Treatment begins by acquiring a series of MR images of the target organ. The physician then identifies a target volume in the MR images, and delineates the treatment contours on the images. Therapy planning software calculates the parameters required to effectively treat the defined target volume. During the treatment, an ultrasound transducer generates a point of focused ultrasound energy, called a sonication. The sonication raises the tissue temperature within a well-defined region, enabling neurophysiological assessment in the low range, and thermal coagulation at higher ranges. MR images acquired during sonication provide a quantitative, real-time temperature map of the target area to confirm the location of the sonication and the size of the affected region.
224193925|NCT02556112|BEHAVIORAL|Group Lifestyle Balance|The content of the GLB program consists of educating participants about the association between high calorie and fat intake with excessive weight, how to determine the fat and calorie content of foods they eat, and how to make changes in their diet to reduce the fat and calorie content. Participants are also given information about increasing activity in their daily routines. In addition, they are given information about negative behaviors that lead to overeating and decreased activity and are taught ways to develop positive behaviors to facilitate weight loss and increased activity. GLB instructors function as lifestyle coaches for class participants. They provide individual feedback and encouragement on documented eating and activity habits. The instructors make themselves available to be contacted by participants outside of class to address participant concerns and issues as needed
224193926|NCT02556112|BEHAVIORAL|Better Body Better Life|The BBBL program is an Air Force weight management program.). It was created based on the Adult Learning Model and consists of 5 independent modules that are taught in-person to groups of up to 15-20 individuals. Each module is done in a classroom and is 2 hours long. One module per week is offered. Individuals can attend the modules in any order but they are required to complete a pre-survey and 3-day food record prior to attending their first class
224193927|NCT02556112|BEHAVIORAL|Fitness Improvement Program|The FIP is a standardized course that can be accessed on-line through the Advanced Distributed Learning Service (ADLS) and takes approximately 90 minutes to view all of the course material. The on-line FIP can be done all in one sitting or in segments. There is no restriction on the frequency with which the FIP is viewed however, because it is accessed through ADLS, it may be difficult to view at a non-military computer. The FIP consists of an introduction, three core components (nutrition, physical training, and spiritual well-being), and a summary. Each section has a short video presentation. The core components have short quizzes at the end to assess knowledge and the training asks participants to set goals. Participants are then responsible for using the information for their own self-directed program.
224310294|NCT00000717|DRUG|Primaquine|
224310295|NCT00000717|DRUG|Clindamycin|
224193928|NCT03237000|DRUG|MgSO4|"Magnesium sulphate was administered by continuous intravenous infusion according to our hospital protocol as follows:~* Loading dose: 4-6 gm of magnesium sulphate diluted in 100 mL of IV fluid administered over 15-20 min.~* Maintenance dose: 2 gm/hr in 100 mL of IV infusion to be continued for 24 hours after delivery."
224193929|NCT03733379|PROCEDURE|Scaling and root planing|SRP will be performed in four to six appointments lasting approximately 1 h each, using manual curettes (Hu-Friedy, Chicago, IL, USA) and ultrasonic device (Cavitron Select SPC, Dentsply professional, York, PA, USA) under local anesthesia. The deep sites will be scaled throughout the first week and treatment of the entire oral cavity will be completed in 14 days.
223502964|NCT01232907|DRUG|L-Carnitine|L-Carnitine, a pharmaceutical product, for the treatment of fatigue in persons with spinal cord injury will be used for this study. L-Carnitine is a nutrient normally obtained in the fat from meat. It promotes fatty acid oxidation of muscle, thereby promoting efficient energy production. Treatment with L-Carnitine has been shown to produce clinically significant improvement in fatigue in persons with multiple sclerosis (MS), cancer, and in aging populations. While the causes of fatigue in persons with SCI may be multifactorial, successful use of L-Carnitine in MS-related fatigue suggests it may have a role in SCI. Standard treatment will entail daily dosages of 1980 milligrams of L-Carnitine (three 330 mg tablets in the morning and three 330 mg tablets in the evening) for 4 weeks.
223502965|NCT05948982|BIOLOGICAL|Human Umbilical Cord Mesenchymal Stem Cells|The stem cell infusion route is peripheral intravenous infusion, once every 4 weeks for a total of 3 infusions. All subjects received experimental drugs and conventional treatment during the study period.
223502966|NCT02388100|PROCEDURE|Capillary HbA1c collection|
223502967|NCT05362175|DEVICE|Obstetric ultrasound|ultrasound measurement of the cross sectional area of umbilical cord within 1 cm from the cord insertion in to fetal abdomen and the standard Hadlock's formula
223502968|NCT04148755|PROCEDURE|Endoscopic ultrasound guided fine needle aspirate|All patients are going to have an EUS guided elastography with FNA of solid pancreatic lesions
224193930|NCT03733379|DRUG|Metronidazole and Amoxicillin placebos|Amoxicillin and metronidazole placebos thrice a day for 14 days (beginning with the first SRP session).
223502969|NCT03928704|DRUG|Bimekizumab|Subjects will receive bimekizumab at pre-specified time-points.
223502970|NCT03928704|OTHER|Placebo|Subjects will receive placebo at pre-specified time-points during the Double-Blind Treatment Period.
223502971|NCT05411549|BEHAVIORAL|Diet Modification to Adopt Mediterranean Diet|Participants enrolled in group 1 will be counselled by a dietician and asked to adopt a Mediterranean diet for a 12-week period from counselling. Participants will complete a series of Mediterranean Diet Adherence Score, pain questionnaires as well as quality of life questionnaires (EPH-30, SF-36, GIQLI) which have been previously validated. Participants in this group will give a baseline and final visit blood sample and stool samples to assess inflammation biomarkers as well as gut microflora.
223502972|NCT06472765|DIAGNOSTIC_TEST|Vaginal Swab Collection|Vaginal Swab Collection
223502973|NCT03597867|OTHER|Placebo|Artificial tears for 3 days preoperatively
223592320|NCT07087652|OTHER|Onco Move multicomponent face-to-face training program|The Onco Move intervention will include three training sessions per week (each lasting 60 minutes), held in the fitness rooms and the gym at Gdansk University of Physical Education and Sport in Poland for 16 weeks. The intervention will include aerobic and strength exercises but also coordination/balance and flexibility, with warm-up and cool-down elements.
223592321|NCT07088341|DIAGNOSTIC_TEST|elisa|enzyme- linked immunesorbent assay ( ELISA ) was used to measure soluble programmed death ligand-1 level
223592322|NCT07088185|OTHER|Routine medical care|Routine medical care
223592323|NCT07088185|OTHER|Pulmonary rehabilitation|Pulmonary rehabilitation ( breathing exercises, posture drainage, additive techniques with postural drainage like vibration,shaking and percussion, active cycle of breathing techniques, autogenic drainage) plus routine care.
224193931|NCT03733379|DRUG|Metronidazole|Metronidazole 400 mg thrice a day for 14 days (beginning with the first SRP session).
224193932|NCT03733379|DRUG|Amoxicillin|Amoxicillin 500 mg thrice a day for 14 days (beginning with the first SRP session).
224193933|NCT03733379|DIETARY_SUPPLEMENT|Probiotic|The probiotic contains 2 different strains of Lactobacillus reuteri: L.reuteri DSM 17938 and L. reuteri ATCC PTA 5289 each at a concentration of 1 x 108 CFU per tablet. It will be used 2 times per day by 90 days.
224193934|NCT03733379|DIETARY_SUPPLEMENT|Probiotic placebo|The placebo is identical to the active but without L. reuteri. The two Study Products are identical in taste, texture and shape. It will be used 2 times per day by 90 days.
224193935|NCT05630989|OTHER|combination therapy with no MEKi|This cohort will receive combination therapy with no MEKi.
224193936|NCT05630989|DRUG|combination therapy with MEKi-HCQ|This cohort will receive combination therapy with MEKi-HCQ.
224193937|NCT05630989|DRUG|combination therapy with MEKi-EGFRi|This cohort will receive combination therapy with MEKi-EGFRi.
224193938|NCT05630989|DRUG|combination therapy with MEKi.|This cohort will receive combination therapy with MEKi.
224193939|NCT00910000|DRUG|Vorinostat|
224193940|NCT00910000|DRUG|Carboplatin|
224193941|NCT00910000|DRUG|Gemcitabine|
224193942|NCT05872282|DEVICE|ZIPPER aortic arch stentgraft system|The ZIPPER aortic arch stentgraft system consists of the arch mainbody stentgraft system, the branch artery stentgraft system and the thoracic extension stentgraft system.
224193943|NCT06565585|PROCEDURE|Glans-sparing surgery|Patients who underwent glans-sparing surgery
224193944|NCT06409325|DEVICE|MST|MST was delivered with NS 7000 (Wuhan Yiruide Medical Equipment New Technology Co., Ltd.) using a round coil (125-mm diameter) positioned on the vertex.
224193945|NCT06409325|DEVICE|ECT|The bitemporal ECT procedure utilized the Thymatron System IV device (Somatics, USA).
224310296|NCT03240237|DEVICE|Optimizer SMART|Cardiac Contractility Modulation
223502974|NCT03597867|DRUG|Dicloftil|Dosing of drug 3 days prior to surgery
223502975|NCT03597867|DRUG|Nevanac|Dosing of drug 3 days prior to surgery
223502976|NCT03597867|DRUG|Indom|Dosing of drug 3 days prior to surgery
223502977|NCT03597867|DRUG|Yellox|Dosing of drug 3 days prior to surgery
223502978|NCT04822415|DRUG|Mepivacaine|IANB using 3.6 ml of 2% mepivacaine hydrochloride with 1:100,000 epinephrine.
223502979|NCT04822415|DRUG|Articaine|IANB using 3.4 ml of 4% articaine hydrochloride with 1:100,000 epinephrine.
223592324|NCT07087561|DIETARY_SUPPLEMENT|Personalized Oral Nutritional Supplementation|Participants receive individualized oral nutritional supplementation based on energy and protein requirements, calculated using the Harris-Benedict equation and body weight (1.2-1.5 g protein/kg/day). The supplement may include complete nutrition powder, whey protein powder, and compound multivitamins. The intervention is prescribed and monitored by a clinical nutrition team and adjusted every 3 days during the 14-day intervention phase. The goal is to ensure both energy and protein intake targets are met. Supplements are administered in addition to standard meals.
224193946|NCT01977625|DRUG|Lisdexamfetamine|The overall objective of this study is to assess the effects of LDX on brain activation patterns during tasks of sustained attention and working memory in menopausal women.
224193947|NCT01977625|OTHER|Placebo|To assess the effects of a placebo pill on brain activation patterns during tasks of sustained attention and working memory in menopausal women.
224193948|NCT04925622|DIAGNOSTIC_TEST|Complex eye movement exam|"Subjects will undergo a complex eye exam which will capture fixation, optokinetic nystagmus, guided saccades, microsaccades, smooth pursuit, and pupillometry.~Eye tracking equipment will be set and calibrated to the participant who will then perform the full 10 minute testing protocol with instructions from the investigator. After this, they will take a five minute break. The oculomotor testing protocol will be repeated twice."
224193949|NCT04517630|DIAGNOSTIC_TEST|urinary NGAL, TIMP-2, IGFBP7, IL-6, viral load and metabolomic|Determine the evolution of NGAL, TIMP-2, IGFBP7, IL-6, viral load and metabolomic at basal, and the 3 , 5 and 7 days after recruitment
224193950|NCT01210625|DIETARY_SUPPLEMENT|Nutrabiotix|Fiber supplement: 9mg or 12mg
224193951|NCT01210625|DIETARY_SUPPLEMENT|Psyllium|12g total per day (4 capsules containing 1 gram psyllium fiber 3 times a day)
224193952|NCT05288621|DEVICE|electroacupuncture|"For'four sacral points'group, Hua Tuo brand disposable acupuncture needles (size 0.40 × 100mm) and electronic needle therapy instrument SDZ-IIB will be used.Bilateral BL30 and BL35, were selected as acupoints protocol.~'Four sacral points'group consists of 8 sessions over an 4-week period after baseline(2 sessions in each week), each for 30minutes. The electroacupuncture will be set at a frequency of 2.0 Hz, continuous wave, a moderate intensity the patient can tolerate and 30 min during each treatment."
224193953|NCT06568835|BEHAVIORAL|exercise|such as walking, jogging, swimming, Tai Chi, etc. It needs to be at a certain frequency and intensity
224193954|NCT00003452|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Stage IV Bladder Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
224193955|NCT06568380|OTHER|Oyster consumption|Volunteers consume one of the four panel of oysters (Noro+Phage+, Noro+Phage-, Noro-Phage+ and Noro-Phage-).
224193956|NCT02073591|OTHER|Ceradan Cream|
224310297|NCT06659965|DRUG|Intravenous Methocarbamol|At least 500 mg of intravenous methocarbamol administered within 2 hours after the end of elective spine surgery for acute postoperative pain management
224193957|NCT02073591|OTHER|Ceradan Wash|
224193958|NCT06318975|BEHAVIORAL|Brief Alcohol Intervention|All Airmen will receive a standard BAI during the 4th week of Technical Training, the last week of enforced abstinence. The BAI is a group-based, one-hour session which includes the following components: Interactive discussion of the positives and negatives of drinking during training and heavy vs. moderate drinking; Discussion of USAF rules on alcohol use and penalties for violations; Discussion of impact of alcohol on military readiness; effects of alcohol and hangover on performance; Review of standard drinks, blood alcohol levels and tolerance; and normative feedback on the Airmen's drinking level compared to others. We will engage in a conversation about whether they have observed concerning patterns of alcohol misuse among other USAF personnel, and how to handle this, along with harm reduction and alcohol refusal strategies.
224310298|NCT01330420|BEHAVIORAL|Relaxation Response Resiliency Program for Depression|"The program combines lecture, skills training, symptom monitoring, and group sharing aimed at preparing patients to take active roles in managing their own health. Elements of the program include:~* Elicitation of the relaxation response through techniques such as diaphragmatic breathing and mindfulness.~* Examination and reversal of negative thought patterns.~* Physical movement, including stretching and yoga.~* Healthy eating and other positive lifestyle behaviors.~* Goal setting."
224310299|NCT03322930|DIAGNOSTIC_TEST|Rod sensitivity|diagnostic test for rod loss in central retina
224310300|NCT01687244|DRUG|INSTILADRIN|The INSTILADRIN components will be mixed with a diluent. The total dose will be given as a single, one-hour intravesical administration which may, depending on clinical response, be repeated every 3 months up to a maximum of 4 instillations.
223502980|NCT01309880|DEVICE|Test lens|Investigational silicone hydrogel contact lens worn on a daily wear basis
223502981|NCT01309880|DEVICE|Air Optix Aqua|Air Optix Aqua contact lens worn on a daily wear basis
223502982|NCT03149419|DRUG|Paroxetine|
223502983|NCT03149419|DRUG|Placebo oral capsule|
223502984|NCT04415918|DRUG|Bezlotoxumab Injection|A single dose of Bezlotoxumab (Zinplava) 10mg/kg (actual body weight) 60-minute intravenous infusion during active CDI treatments.
223502985|NCT02871362|DIETARY_SUPPLEMENT|IQP-AS-118|Take one a day
223502986|NCT02871362|DIETARY_SUPPLEMENT|Placebo|Take one a day
223502987|NCT04575324|BEHAVIORAL|Telemedicine Linkage Intervention|Participants will be immediately linked to telemedicine care provided by an FQHC provider waivered to prescribe buprenorphine and naltrexone or able to refer patients to methadone treatment. Participants will have their vitals checked and be virtually connected to the provider. The research assistant will share the vitals with the provider, and the provider will provide personalized care during which they discuss treatment options with the participant. If a medication for opioid use disorder is prescribed or if a methadone referral is made, transportation assistance will be provided to the participant as part of the intervention. Transportation to pick up the prescription or complete the first appointment will be provided via a HIPAA compliant ride-share company, and a bus pass will be provided to the participant for the return trip.
224193959|NCT06318975|BEHAVIORAL|Automated and Targeted Text Messages|All messages are pre-written, and their timing is pre-planned - All Airmen will start receiving 3-5 text messages per week starting the Monday after they received the Brief Alcohol Intervention and lasting for six weeks. The intervention is also targeted to age, with some messaging differing for Airmen less than 21 years and those already 21 years old or who will turn 21 during the intervention period. All Airmen randomized to the text message arm will be enroll into the supplemental program, and may opt out at any time. Messages reinforce content of the BAI and provide additional, actionable advice on reducing or avoiding alcohol in more detail and specificity than time typically allows for during the BAI. Messages are sent on days and at times that were indicated as being preferred during formative development of the intervention. Messages are designed to maintain or enhance skill building. No drinking behavior is collected as part of the text messaging intervention
223746625|NCT05196841|BEHAVIORAL|Anastatica Hierochuntica|During the sampling process, the researcher inquired through women who apply for pregnancy follow-up and contacted the mothers who had some inclusion criteria. Also, the researcher outlined the research plan and objectives. The participants were assessed based on the eligibility criteria and, if they were eligible and willing to participate in the study.
223592325|NCT07087561|DRUG|Personalized Parenteral Nutritional Supplementation|For participants unable to meet nutritional goals through oral intake, parenteral nutrition is administered intravenously. The formulation includes amino acids, glucose, lipids, electrolytes, trace elements, and vitamins. Dosages are aligned with those of the enteral nutrition group, ensuring a consistent intake of energy and protein (1.2-1.5 g/kg/day protein). Formulation and administration follow standardized hospital protocols and are supervised by the nutrition support team.
223746626|NCT00105703|BEHAVIORAL|Case management using advanced nurse practitioners|
224193960|NCT04404192|DRUG|PH94B|Intranasal administration of 100 microliters to each nostril 4 times a day
224193961|NCT04404192|DRUG|Placebo|Intranasal administration of 100 microliters to each nostril 4 times a day.
224193962|NCT03919669|DRUG|All Subjects|All subjects will be given the experimental tau PET radioligand \[18F\]MK-6240
224193963|NCT06520839|DRUG|Tadalafil 5mg|We will include in the study 90 patients with diabetes and erectile dysfunction. We will use the IIEF-5 questionnaire to confirm the diagnosis of erectile dysfunction. Patients between the ages of 40 and 65 who score 21 points or less on the IIEF-5 scale will be included in the study. Each patient will receive drug tadalafil 5 mg every day for three months.
224193964|NCT00000868|BIOLOGICAL|Salmonella typhi CVD 908-HIV-1 LAI gp 120 (VVG 203)|
224193965|NCT00000868|BIOLOGICAL|Aluminum hydroxide|
224193966|NCT00000868|BIOLOGICAL|MF59|
224193967|NCT00000868|BIOLOGICAL|rgp120/HIV-1MN|
224193968|NCT04773314|OTHER|PROPESS Cohort|Non-intervention
224193969|NCT03125382|DEVICE|Carelink System|Patients start to perform device data transmission through Carelink system
223746627|NCT02229942|DRUG|Rituximab|"Induction with two infusions two weeks apart, rituximab 500 mg/m2 (max 1000 mg).~Maintenance with rituximab infusions (500 mg fixed dose) at 3, 6, 9 and 12 months."
223592326|NCT07087561|BEHAVIORAL|Structured Nutrition-Focused Health Education|"Participants receive structured health education focused on nutrition, physical activity, and psychological well-being. The education is delivered over 14 days using a digital Internet Plus platform, featuring weekly videos, interactive Q\&A sessions, and guidance from a multidisciplinary nutrition support team. Educational content covers dietary recommendations, exercise safety, stress management, and post-treatment recovery strategies. Materials are updated weekly, and participants may access them remotely via smartphone or tablet. This intervention aims to improve nutrition knowledge, adherence, and health behavior change."
223746628|NCT02229942|DRUG|Placebo|Saline (NaCl 0,9%) added human albumin (Flexbumin) 0,4 mg/ml, two infusions two weeks apart. Maintenance infusions after 3,6, 9 and 12 months.
223746629|NCT04165083|BIOLOGICAL|Pembrolizumab|IV infusion
223746630|NCT04165083|BIOLOGICAL|MK-4830|IV infusion
223746631|NCT04165083|BIOLOGICAL|MK-0482|IV infusion
224193970|NCT03125382|DEVICE|In office standard visit|Patients start or maintain in office standard visits
224193971|NCT00310869|BEHAVIORAL|Individualized Developmental Care in the NICU|Newborn Individualized Developmental Care and Assessment Program (NIDCAP) utilizes close observation of each infant's thresholds of moving from organization to disorganization and stress, as exhibited by the infant's behavior. Care and environment are then continuously and dynamically adjusted to increase the infant's self-regulation and organization and decrease the infant's stress. This individualized model of NICU care provides an opportunity to investigate the modifiability of very early born infants' brain function and structure and the possibility of reducing or altogether eliminating the disruption and disturbance of fetal brain development in the NICU.
224193972|NCT06522360|DRUG|Brigatinib|Given by mouth
224193973|NCT06522360|DRUG|Carboplatin|Given by mouth
224193974|NCT06522360|DRUG|Pemetrexed|Given by vein
224193975|NCT05572814|BEHAVIORAL|Decision Support|Prompts will be provided to clinicians signaling gaps in guideline-directed care
224193976|NCT05572814|BEHAVIORAL|Referral|Patients will be referred to an interdisciplinary, expert guideline-directed medical therapy team
224193977|NCT04196959|DIETARY_SUPPLEMENT|TYR sphere|TYR sphere is a powdered protein substitute for patients with tyrosinaemia.
224193978|NCT02319642|DRUG|Certolizumab Pegol|Active Substance: Certolizumab Pegol Pharmaceutical form: Prefilled syringes Concentration: 200 mg/ ml Route of Administration: Subcutaneous injection
224193979|NCT02854202|OTHER|Arm1: Whey protein|Arm1: Whey protein:The participants will consume 42 g protein, namely from Whey protein in the breakfast
224193980|NCT02854202|OTHER|Arm 2 Breakfast- other proteins|Arm 2 Breakfast- other proteins: The participants will be assigned to 42 g protein of other protein sources at breakfast
224193981|NCT02854202|OTHER|Arm 3 Breakfast- low protein|Arm 3: Low protein' :The participants will consume 22 g protein at breakfast
224193982|NCT05462990|DRUG|QUC398|QUC398 150 mg/mL, solution for s.c. injection (1 mL)
224193983|NCT05462990|DRUG|Placebo|Placebo 0 mg/mL, solution for s.c. injection (1 mL)
224193984|NCT06960460|OTHER|Dental implant surgery with ZygoFixU implants|Adult patients who have had dental implant surgery.
224193985|NCT06959004|DRUG|Substance P|The participants will receive a continuous intravenous infusion of 20 mL of substance P (4.0 pmol/kg/min) over 20 minutes.
224193986|NCT06959004|DRUG|Placebo|The participants will receive a continuous intravenous infusion of 20 mL of placebo (isotonic saline) over 20 minutes.
224193987|NCT05971329|DEVICE|Cervical Fusion (ZetaFuse™ Bone Graft)|Fusion of the C3-C7 cervical vertebral bodies
224193988|NCT06474325|BEHAVIORAL|Intervention via mobile application|Intervention via mobile application include psychoeducational videos, reminders, and virtual rewards and badges for completing the challenges to encourage adherence of medications
224193989|NCT05720039|DEVICE|Robotic NSM|Robotic-assisted Nipple sparing mastectomy procedures
224193990|NCT05720039|PROCEDURE|Open NSM|open nipple-sparing mastectomy procedures
224193991|NCT04546126|DRUG|Dexamethasone (Group 2)|Participants will take 1 mg dexamethasone 2x a day for 3 days to suppress cortisol production.
224193992|NCT04546126|DRUG|Cosyntropin (Group 3)|Cosyntropin, 250 micro-gm will be administered IV. Five minutes following administration FNP-59 will be given. Following uptake of FNP-59 imaging will occur.
224193993|NCT04546126|COMBINATION_PRODUCT|PET/CT Scan with FNP-59|FNP-59, a radiotracer, is administered for PET/CT scans.
224193994|NCT06243731|OTHER|No Intervention|This is a non-interventional study.
224193995|NCT02628197|DIETARY_SUPPLEMENT|calcium (500mg) and vitamin D (250I.U.)|calcium (500mg) and vitamin D (250I.U.) was given twice a day for 6 months
224193996|NCT02628197|PROCEDURE|Scaling and root planing|scaling and root planing was done in the test group along with calcium (500mg) and vitamin D (250I.U.)
224193997|NCT02459470|PROCEDURE|Fluid loading|fluid loading was performed by using 7ml/kg of 6% hydroxyethyl starch within 10 min to all patients
224193998|NCT05979987|BEHAVIORAL|Reminder of preventive care measures|"The investigators will send randomized participants an SMS reminder encouraging them to click the provided link and close their outstanding, overdue preventive care measures.~The provided link will take them to their MyChart login page; after logging in, they would see their personalized My Action Plan Letter detailing their personalized, overdue preventive care measures."
224193999|NCT05979987|BEHAVIORAL|Persuasion via anecdote|The message will contain an anecdote of a patient whose cancer was caught early through similar, recommended preventive screenings. The message prompts patients to click on a link to read the story about the patient.
224194000|NCT05979987|BEHAVIORAL|Persuasion via anecdote without link|The message will contain a link to an anecdote of a patient whose cancer was caught early through similar, recommended preventive screenings. The message won't contain a link to the story, but it will briefly describe the story.
224194001|NCT05979987|BEHAVIORAL|Persuasion via research|This message will mention that research has shown promptly closing health gaps saves lives.The message will contain a link to an official website that supports the statement.
223592327|NCT07089498|OTHER|Dietary Intervention (Low Fodmap Gluten Free Diet)|The intervention provides the administration of a Low Fodmap Diet to celiac or non celiac patients with functional gastrointestinal disorders
223592328|NCT07089108|BEHAVIORAL|Arabic NODA Video-Based Diagnostic Assessment|NODA (Naturalistic Observation Diagnostic Assessment) is a telehealth-based diagnostic tool for Autism Spectrum Disorder (ASD) that guides caregivers to record structured home videos of their child's behavior using a smartphone app. In this study, a culturally adapted Arabic version of NODA was used to capture four standardized behavioral scenarios, which were later reviewed by licensed clinicians for diagnostic evaluation.
224194002|NCT03241511|OTHER|Test|Briefly, treatment sessions will include oral hygiene behavioral modification and scaling and root planning (removing the bacterial biofilm and calculus below the gum line) in order to eliminate etiologic factors and control periodontal inflammation. Once the treatment sessions are completed, the patients will enter the maintenance phase and will be followed for 6 months. In this phase, the patients will receive systematic supportive periodontal treatment (tooth cleanings above the gum line with re-enforcement of oral hygiene).
224194003|NCT02317796|DRUG|MLR-1023|Each subject will receive an oral dose of placebo or MLR-1023 once before breakfast and either placebo (placebo and q.d. dose groups) or a second dose of MLR-1023 (b.i.d. dose groups) before dinner for 4 weeks.
224194004|NCT04668066|DRUG|PF-07242813|PF-07242813 given intravenously or subcutaneous
224194005|NCT04668066|DRUG|Placebo|Placebo given intravenously or subcutaneous
224194006|NCT06430268|PROCEDURE|implant decontamination with titanium curette|Titanium curettes (Hu-Friedy, Chicago, Illinois, USA) will be used for supra and submucosal around the implant, with and without flap elevation.
224194007|NCT06430268|DEVICE|implant decontamination with Air-Flow device|Air-polishing (Airflow Prophylaxis Master, EMS, Nyon, Switzerland) will be carried out with AIR-FLOW powder PLUS (EMS) containing erythritol (sugar alcohol, 14 μm), amorphous silica and 0.3% chlorhexidine to decontaminate implants with and without flap elevation. The device will be adjusted to a power setting of 5 bar static pressure and a maximum level of irrigation with water.
224194008|NCT04624204|BIOLOGICAL|Pembrolizumab 200 mg|Pembrolizumab 200 mg Q3W
224194009|NCT04624204|BIOLOGICAL|Pembrolizumab 400 mg|Pembrolizumab 400 mg Q6W
224194010|NCT04624204|DRUG|Pembrolizumab placebo (saline)|Pembrolizumab placebo (saline) Q3W
224194011|NCT04624204|DRUG|Pembrolizumab placebo (saline)|Pembrolizumab placebo (saline) Q6W
224194012|NCT04624204|DRUG|Olaparib 300 mg BID|Olaparib 300 mg twice daily (BID)
224194013|NCT04624204|DRUG|Olaparib matching placebo|Olaparib matching placebo BID
224194014|NCT04624204|DRUG|Etoposide 100 mg/m^2|Etoposide 100 mg/m\^2 intravenous (IV) Q3W, Day 1-3
224194015|NCT04624204|DRUG|Platinum, investigator's choice|Carboplatin titrated to an area under the plasma drug concentration time curve (AUC) of 5 mg/mL/min IV Q3W OR Cisplatin 75 mg/m\^2 IV Q3W on Day 1 of each cycle
223592329|NCT07088042|DRUG|Limitless Allzyme|Received Limitless Allzyme Max® Trypsin/Chymotrypsin/Bromelain(15 microkatal/42microkatal/240 GDU)
223592330|NCT07088042|DRUG|Oral tablets of Alphintern®|received (Trypsin/Chymotrypsin 5 micro Katals/14 micro Katals)
223592331|NCT07088042|DRUG|Cataflam® 50 coated tablet|of Cataflam 50 mg as part of their treatment protocol
223592332|NCT07087717|DEVICE|Split-Mouth Placement of an implant with a moderately rough surface (DCC).|Surgical placement of a dental implant in canine area (left or right, assigned by flipping a coin) of the mandibular bone of the patient.
223592333|NCT07087717|DEVICE|Split-Mouth Placement of an implant with a hybrid surface (MSC).|Surgical placement of a dental implant in canine area (left or right, assigned by flipping a coin) of the mandibular bone of the patient.
223502988|NCT03083379|DEVICE|Volumetric Incentive Spirometry|"A study investigator will provide instruction on Incentive Spirometry procedure performance before supervised therapy and monitoring begins.~* Five minutes of eupneic ventilation EIT monitoring will occur before I.S. therapy commences.~* Study participants will be asked to take 10 deep breaths through the incentive spirometer's mouthpiece, followed by a 60 second pause.~* The 10-breath cycle will be repeated three times with respiratory therapist coaching.~* Five minutes of eupneic ventilation EIT monitoring will occur following the last I.S. lung expansion therapy breath cycle.~* Incentive Spirometry therapy and monitoring session will last about 15 minutes"
223502989|NCT03083379|DEVICE|EzPAP® POSITIVE AIRWAY PRESSURE|"* A study investigator will provide instruction on EzPAP® procedure performance before supervised therapy and monitoring begins. A second study investigator will perform EIT device set-up and monitoring only.~* Five minutes of eupneic ventilation EIT monitoring will occur before EzPAP® therapy commences.~* Study participants will be asked to breathe normally through the EzPAP® device's mouthpiece for 10 breaths, followed by a 60 second pause.~* The 10-breath cycle will be repeated three times with respiratory therapist coaching.~* Five minutes of eupneic ventilation EIT monitoring will occur following the last EzPAP® lung expansion therapy breath cycle.~* EzPAP® therapy and monitoring sessions will last about 15 minutes"
223502990|NCT00906581|BEHAVIORAL|Computer-based Problem-Solving Treatment|6 sessions of problem-solving treatment delivered via computer
224194016|NCT04624204|RADIATION|Standard Thoracic Radiotherapy|Standard Thoracic Radiotherapy
224194017|NCT04624204|RADIATION|Prophylactic Cranial Irradiation (PCI)|PCI will be strongly recommended for participants who achieve CR or PR after completion of chemoradiation treatment.
224194018|NCT06163768|PROCEDURE|Insulin resistance|Steps to conduct testing and treatment according to the approved regimen at Ho Chi Minh City University of Medicine and Pharmacy Hospital. The researcher did not intervene in the treatment process.
224194019|NCT05791955|BEHAVIORAL|Reminder of preventive care measures|"The investigators will send randomized participants an SMS reminder encouraging them to click the provided link and close their outstanding, overdue preventive care measures.~The provided link will take them to their MyChart login page; after logging in, they would see their personalized My Action Plan Letter detailing their personalized, overdue preventive care measures."
224194020|NCT05791955|BEHAVIORAL|Acknowledgement of personal responsibility|"The message will contain a request for the participant to take personal responsibility for their health by either clicking on the link to make an appointment or replying noted to the text message."
224194021|NCT05791955|BEHAVIORAL|Planning prompt|The message will prompt people to either click on the link to make an appointment now or text back when they plan to close their health gap
224194022|NCT05978492|DRUG|TXN10128|TXN10128: Oral administration once daily everyday
224194023|NCT05978492|DRUG|Irinotecan|Intravenous (IV) administration at 150 mg/m2 twice (Day 1 and Day 15) at intervals of 2 weeks in one cycle
224194024|NCT05978492|DRUG|Paclitaxel|IV administration at 80 mg/m2 three times (Day 1, Day 8, and Day 15) at intervals of 1 week in one cycle (IV administration at 90 mg/m2 for patients with breast cancer)
224194025|NCT05258968|OTHER|Education on the Injeti Model of Self-Esteem|1 hour educational session
224194026|NCT05147311|BEHAVIORAL|Positive Psychology Intervention|Weekly phone calls with the study interventionist and positive psychology exercises over an 9-week period. The positive psychology program exercises include three modules: gratitude-based activities, strength-based activities, and meaning-based activities.
224194027|NCT02844231|OTHER|Single-photon emission computed tomography|
224194028|NCT06509880|DIETARY_SUPPLEMENT|Adenorine|"The immunostimulating effect of the drug is associated with its ability to activate the cells of the monocyte-macrophage system, thus increasing the functional activity of all parts of the body, stimulating the repair and regeneration of cells and tissues. It reduces the symptoms of the iflammatory process, stimulates the development of granulations and growth of epithelial tissues, accelerates the process of cleansing and healing of infected wounds. While with healthy people, it can be used as a phylactic drug that improves immunity protection. It was proved that when the drug is used externally, activation of macrophages occurs, thus accelerating wound cleansing process and stimulating reparative processes. In cases when thermal injury to the skin is more than 15-20% of the surface, there is a stress syndrome that suppresses the immune system. When exposed to DNA-Na, lymphocyte activation occurs, wound cleansing processes are accelerated."
224194029|NCT06509880|BIOLOGICAL|Placebo|Placebo
224194030|NCT06509880|DRUG|FOLFOX regimen|(Day 1-2: Oxaliplatin 100 mg/m2 IV infusion, given as a 120 minutes IV infusion in 500 mL D5W, concurrent with leucovorin 400 mg/m2 (or levoleucovorin 200 mg/m2) IV infusion, followed by 5-FU 400 mg/m2 IV bolus, followed by 46-hour 5-FU infusion (2400 mg/m2 for first two cycles, and may be increased to 3000 mg/m2 if tolerated by patient (no toxicity \> grade 1 during the first two cycles), days 3-14: Rest days)
224194031|NCT01917149|DRUG|Benazepril|
224194032|NCT01917149|DRUG|Valsartan|
224194033|NCT01917149|DRUG|Metoprolol|
224194034|NCT06125847|GENETIC|NGGT006|Single intravenous infusion of NGGT006 at dose 1 (7.5e12vg/kg), dose 2 (1.5e13vg/kg) , dose 3 (3e13vg/kg) and dose 4 (4e13vg/kg).
224194035|NCT03166891|DRUG|Chiauranib|Take 50mg orally once daily
224194036|NCT05507346|DEVICE|Cross over Device (PCD or Dayspring - alternate to first group)|Cross over after three month of use and a month of washout period
224194037|NCT02223624|OTHER|walking and light weights|
224194038|NCT02223624|OTHER|eccentric aerobic exercise|
224194039|NCT02223624|OTHER|concentric aerobic exercise|
224194040|NCT01641731|OTHER|Cow's milk|"Group I: Increase 2 mL until 10 mL, 10 mL until 50 mL, 20 mL until 100 mL and 50 mL until 200 mL was reached.~Groups II and III: Doubling dose until 1 mL, increase 2 mL until 20 mL, 5 mL until 50 mL, 10 mL until 100 mL and 20 mL until 200 mL was reached."
224194041|NCT06498570|DEVICE|Intracorneal rings|The (ICRS), intracorneal rings segments implantation surgery
224194042|NCT02821975|OTHER|Cognitive computer training|COGNIFIT is cognitive computer training. Its purpose is to improve cognitive function and is designed to accommodate each individual's cognitive strengths and weaknesses. The cognitive computer training last three months and must be done three times a week, in session lasting 10-20 minutes.
224194043|NCT06302075|OTHER|One Day Rehabilitation|Patient discharged at home the day after the operation and carrying out outpatient rehabilitation according to the clinical standard
224194044|NCT06302075|OTHER|Fast Rehabilitation|Patient discharged to the rehabilitation department of the Institute 48 hours after surgery which carries out rehabilitation during the hospital stay according to the clinical standard
224194045|NCT02635906|OTHER|2 hours|BED REST FOR TWO HOURS AFTER CORONARY ARTERIOGRAPHY OR CORONARY ANGIOPLASTY
224194046|NCT02635906|OTHER|4 hours|BED REST FOR FOUR HOURS AFTER CORONARY ARTERIOGRAPHY OR CORONARY ANGIOPLASTY
224194047|NCT04556149|DEVICE|imPulse™ Una e-stethoscope|The imPulse™ System is an every/anywhere-point-of-care cardiopulmonary functional state assessment platform designed to capture normal and abnormal, audible and inaudible cardiopulmonary sounds, rhythms and patterns, via a real-time, intelligent, full-spectrum phonocardiogram obtained from direct to skin coupling or through a layer of clothing.
224194048|NCT04556149|DEVICE|Philips Lumify Ultrasound System|Point-of-care ultrasound
224194049|NCT02835794|DRUG|Omacetaxine|Comparison of different doses of omacetaxine in combination with azacitidine and G-CSF
224194050|NCT02835794|DRUG|Azacitidine|Comparison of different doses of omacetaxine in combination with azacitidine and G-CSF
224194051|NCT02835794|DRUG|G-CSF|Comparison of different doses of omacetaxine in combination with azacitidine and G-CSF
224194052|NCT01285726|OTHER|Non-interventional study|This is a purely non-interventional, observational study, where treatment decisions are completely guided by the discretion of the attending nephrologists.
224194053|NCT04505592|DRUG|Tenecteplase|First 20 patients randomized to treatment arm will receive 0.25 mg/kg of tenecteplase. Next 20 patients randomized to treatment arm will receive 0.50 mg/kg of tenecteplase. Both will receive concomitant heparin to maintain activated partial thromboplastin time between 2.0 and 2.5 upper limit of normal.
224194054|NCT04505592|DRUG|Placebo|Patients will receive placebo with concomitant heparin to maintain activated partial thromboplastin time between 2.0 and 2.5 upper limit of normal.
224194055|NCT03312504|OTHER|Neuromuscular training program|This is a 15-minute warm-up program designed to be implemented at the beginning of junior high school physical education classes. This warm-up is comprised of 15 components; nine of which are aerobic exercises (forward running, forward run with skipping, forward run with knee lifts, forward run with heel kicks, sideways shuffles, zigzag running, forward running with intermittent stops, speed runs, and squat/skate jumps), and six of which are balance/strengthening exercises (front plank, side plank, nordic hamstring exercise, lunges, balancing on the wobble board, and balancing on foam balance pads).
224194056|NCT03312504|OTHER|Standard-of-practice Warm-up (Control)|This is a 15-minute warm-up program designed to be implemented at the beginning of junior high school physical education classes. This warm-up is comprised of 16 components; seven of which are aerobic exercises (forward running, forward running with arm swings, side shuffling, lunging, skipping, arm running with arm swings, and cool-down running), and nine of which are static stretching exercises (standing quadriceps, standing hamstrings, standing calf, standing groin, rotating ankle, lunges, standing shoulder, standing triceps, standing neck).
224194057|NCT05240313|BEHAVIORAL|kiR venezolano|A multi-week intervention focused on drug refusal skills and self-regulation.
224194058|NCT06325072|DIAGNOSTIC_TEST|Conclusive genetic testing|Patients will be referred for genetic counseling at the study coordinating center. This will lead to a conclusive genetic diagnosis.
223502991|NCT06389162|DEVICE|transcranial direct current stimulation|Transcranial direct current stimulation is a type of non-invasive brain stimulation that involves passing a weak current between two electrodes placed on the scalp.
223502992|NCT01756001|DEVICE|GlowCap|The main research instrument is an electronic pill bottle called GlowCaps (by Vitality) that has the ability to transmit adherence data to the Way to Health (WTH) web portal. The investigators will measure adherence by counting the number of properly taken doses during the final four weeks of the study. Each time the pill bottle is opened, a date- and time-stamped wireless signal is sent to the Vitality server via the AT\&T cellular network which will then be uploaded to the Way to Health portal for aggregation.
223502993|NCT01756001|BEHAVIORAL|Daily email, text message, or phone call reminders|
223502994|NCT01756001|BEHAVIORAL|Paid for adherence|
223502995|NCT05548504|RADIATION|Photon|50-66Gy/ 24 fractions, inhomogeneous dose distribution photon therapy
223502996|NCT05548504|RADIATION|Proton|50-66Gy/ 24 fractions, inhomogeneous dose distribution proton therapy
223502997|NCT03664141|DRUG|Cannabis oil|Treatment with cannabis oil
223502998|NCT03664141|DRUG|Placebo/ Regular Oil|Treatment with placebo (Regular Oil)
223502999|NCT03404167|DRUG|AZD0914|Zoliflodacin (also known as AZD0914 and ETX0914), is a spiropyrimidinetrione antibacterial agent
223503000|NCT02847767|PROCEDURE|Perfusion Imaging|IV contrast perfusion CT will be performed at baseline and at 1 week after completing treatment. Perfusion imaging is similar to a diagnostic CT except a smaller region is serially imaged post contrast injection with multiple data acquisitions and high temporal resolution
223503001|NCT02264041|DRUG|Cilobradine, low dose|
223503002|NCT02264041|DRUG|Cilobradine, high dose|
223503003|NCT02264041|DRUG|Itraconazole|
223503004|NCT05904366|DIAGNOSTIC_TEST|MR Spectroscopy (MRS)|MR Spectroscopy (MRS)
223503005|NCT05904366|DIAGNOSTIC_TEST|MR Elastography (MRE)|MR Elastography (MRE) with a device that induces shear waves in the body. This device is placed upon the abdomen of the subject and is hold in place by straps. The device will produce low-frequency vibrations (e.g. 30-60 Hz) which are not painful to the participant. A declaration of conformity and a safety document are provided in the study dossier.
223503006|NCT01002105|DRUG|Baclofen|Baclofen 50mg per day for 12 weeks and psychosocial intervention
223503007|NCT01002105|OTHER|Control group|psychosocial intervention and placebo for 12 weeks
223503008|NCT04894240|DRUG|Monepantel|Monepantel is provided to individuals living with ALS/MND as a white oval tablet to be administered once a day following meals
224194059|NCT06325072|DIAGNOSTIC_TEST|Genotype-phenotype correlation for personalized diagnosis|Patients and their family members will undergo a thorough clinical reassessment at the study coordinating center to identify diagnostic handles of the suspected disease based on the genetic test result (reverse phenotyping). The clinical reassessment could include the performance of additional clinical and instrumental tests, as well as other specialized consultations. This will lead to a conclusive genetic diagnosis in a substantial proportion of cases, cases, who will then be provided with genetic counselling.
224194060|NCT06325072|DIAGNOSTIC_TEST|Personalized study of variants of uncertain clinical significance (VUS) through functional studies on 3D organ-on-a-chip|The investigators will perform functional assessment trough urine derived Renal Progenitor Cells (u-RPC) to establish the role of variants in determining the clinical phenotype.
224194061|NCT01882101|PROCEDURE|Posterior tibial nerve stimulation|34G needle is introduced percutaneously three finger-breadths superior to the medial malleolus and an electrode is attached to the ipsilateral foot. Electrical stimulation is applied monitoring motor and sensory response. The treatment lasts for 30 minutes, and will be repeated twice a week for 6 weeks.
224194062|NCT01882101|PROCEDURE|Biofeedback|Electrodes are attached to the lower abdomen and acryl plug is inserted into the anal canal. The patients perform pelvic muscle exercise watching EMG activity of themselves. The treatment lasts over 30 minutes, and will be repeated twice a week for 6 weeks.
223503009|NCT02826499|DEVICE|Pediguard|It is a guide for the perforation of the pedicular channel, with a probe at its extremity. This probe allows a real time measurement of the electric conductivity of the tissues that are being crossed. The conductivity measure is translated in a sound signal. Because the cortical bone has a low conductivity, the probe will emit a low intensity sound signal. The cancellous bone has a medium conductivity. Therefore, the probe will emit a medium sound signal. However, in the event of a breach in the pedicular cortical, as blood and periost have a high conductibility, the probe will emit a intense, rapid pace, sound signal.The Pediguard technique helps thus to anticipate a cortical effraction, by detecting the proximity of the cortical wall.
223503010|NCT02826499|OTHER|Fluoroscopy|The placing of pedicular screws under fluoroscopic control is the most common technique as it is both reproducible and accessible. It is a two dimensional imaging technique. The profile incidence at the level of the spine is mostly used to spot the vertebral pedicle and the direction of the screw in the sagittal plane. However, there is no real control of the direction of the pedicular screw in the horizontal or frontal plane and it is an irradiating imaging technique.
223503011|NCT00281801|PROCEDURE|psychosocial assessment and care|psychosocial assessment and care
223503012|NCT00281801|PROCEDURE|Quality of Life Assessments|PACT Scale, Brief COPE, POMS Short Form and FACT BMT
223503013|NCT03974009|OTHER|Calcaneal taping|Calcaneal taping will be given in long sitting position foot out of the edge.BSN Medical Leukotape P Sports Tape (3.8cm×137m,1.5inch× 15yds) on focusing the calcaneus with the aim of choosing dorsiflexion with eversion. First strap of tape will be applied below the medial malleolus,stretch towards lateral malleolus on affected side. Second strap of tape will be applied repetitively placing the first strap,another will be applied to fix the small tapes.
223503014|NCT03974009|OTHER|Sham taping|Sham taping will be given to the control group patients.Simple clinical tape will be applied on calcaneus without stretch.It will be applied for 3 days/week for 4 weeks.
223503015|NCT03974009|OTHER|Conventional therapy|Balance activities (Forward, backward and sideways walking in between 2 parallel lines;Ball kicking against wall(reducing upper limb support)to raising the distance from the wall, kicking to the fixed target; Obstacle walking and Strengthening exercises (Sit to Stand from several heights of chair, Forward \& backward and sideward stepping onto blocks of several heights. Each acitivity will be given for 5 minutes.
223503016|NCT03403517|DRUG|Methylprednisolone|10 mg/kg methylprednisolone mixed in 100 ml NaCl (sodium chloride), infusion over 30 minutes, prior to surgery
223503017|NCT03403517|DRUG|Dexamethasone|Dexamethasone mixed in 100 ml NaCl, infusion over 30 minutes, prior to surgery
223503018|NCT02665936|DRUG|Levobupivacaine|Levobupivacaine will be given epidurally and the duration of analgesia will be calculated
223503019|NCT02665936|DRUG|Dexamethasone and levobupivacaine|dexamethasone 4 mg epidurally with levobupivacaine and duration of analgesia is measured
223503020|NCT02665936|DRUG|Levobupivacaine and Dexamethasone|dexamethasone 8 mg epidurally with levobupivacaine and duration of analgesia is measured
223592334|NCT07089160|BEHAVIORAL|Online Survey (Decision Fatigue Scale and Emotional Exhaustion Scale)|Participants will complete an online survey including demographic questions, the Decision Fatigue Scale (DFS), and the Emotional Exhaustion subscale of the Maslach Burnout Inventory.
223592335|NCT05425680|OTHER|Core muscle training|Combining virtual reality technology and waist wearable sensors, training the pelvis and lumbar spine movements as the main training goal, it is estimated that two 1-hour training sessions per week, a total of 6 weeks of training, to improve the core muscle of patients with lumbar degenerative diseases muscle strength.
223592336|NCT07088029|PROCEDURE|Indirect occlusal veneer (Occlusal veneer of lithium disilicate)|Split-mouth design, (right/left posterior tooth) will be restored with an Indirect occlusal veneer (Occlusal veneer of lithium disilicate). Indirectly fabricated occlusal veneers of lithium disilicate allow better control and design of the occlusal anatomy and proximal contacts, in addition to possessing better mechanical properties and fracture strength when compared to direct occlusal veneers. However, indirect occlusal veneers are lab fabricated, consequently, more clinical visits are required.
223592337|NCT07088029|PROCEDURE|Direct occlusal veneer ( Occlusal Veneer of Composite resin)|Split-mouth design, (right/left posterior tooth) will be restored with an occlusal veneer composite resin (Direct occlusal veneer). Directly fabricated occlusal veneers are a conservative approach, however, it requires a great skill from the operator to assure good margins and occlusal anatomy. Direct veneers are fabricated from composite resin and can be finished in a single visit, but longer chair time is required, in addition to the low wear resistance compared to ceramics. However, direct occlusal veneers have the benefit of resiliency close to that of natural dental tissue.
223592338|NCT07088484|DRUG|ICI-chemotherapy and LIMT|gemcitabine, docetaxel, paclitaxel, cisplatin, platinum, capecitabine, S1; Tislelizumab.
223592339|NCT01110382|DRUG|Doripenem|Type=once every 8 hours infused over 60 minutes, Unit=mg, Number=20mg/kg up to 500mg/dose, Form=solution for infusion, Route-intravenous use. At least 3 days of iv doripenem administered every 8 hours immediately after meropenem placebo for up to 14 days
223746632|NCT05852587|DRUG|Xylitol|Xylitol is a sugar alcohol and considered a GRAS substance by the FDA. Xylitol is also an FDA approved as a food additive. Xylitol will be used as a treatment for the decolonization of C. difficile and will be given in gel capsules. The xylitol provided will be prepared by the BWH investigational drug service and ordered from MEDISCA suppliers. It will be 100% pure. Xylitol has a distinct taste and therefore it will be administered in gel capsules as opposed to an oral solution to maintain blinding.
223746633|NCT05852587|DRUG|Placebo|The placebo will be administered by the BWH investigational drug services. The placebo will be composed of cellulose microcrystal.
224194063|NCT06344650|PROCEDURE|Blood sample|Collection of blood serum for molecular and biochemical tests
224194064|NCT06344650|DIAGNOSTIC_TEST|Radiological tests|Performance of radiological tests (DXA, VFA, TBS, BSi, HR-pQCT) and DXA morphometry
224194065|NCT06344650|OTHER|Questionnaires|Compilation of questionnaires (AcroQol, SF-36)
224194066|NCT02020356|BEHAVIORAL|Music therapy|"U sequence: the musical sequence lasts 20 minutes and is made up of several phases that progressively induce a relaxed state in the patient. The phase of maximum relaxation is followed by a stimulating phase."
224194067|NCT02020356|BEHAVIORAL|Placebo|Interview with an occupational activity (such as discussion of personal pictures or news) with the caregiver in charge of music therapy sessions with the same period.
223503021|NCT00327171|DRUG|Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)|"Aflibercept 4.0 mg/kg administered intravenously (IV) over 1 hour once every 2 weeks.~Aflibercept could be reduced by 1 dose level ( to 2.0 mg/kg) or 2 dose levels (to 1.0 mg/kg) in case of uncontrolled hypertension or urinary protein \>3.5 g/24 hours. Intrapatient dose escalation was not to be permitted. Participants requiring more than 2 dose level reductions would be withdrawn from study treatment."
223503022|NCT00327171|DRUG|Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)|"Aflibercept 2.0 mg/kg administered intravenously (IV) over 1 hour once every 2 weeks.~Aflibercept could be reduced by 1 dose level (to 1.0 mg/kg) or 2 dose levels (to 0.5 mg/kg) in case of uncontrolled hypertension or urinary protein \>3.5 g/24 hours. Intrapatient dose escalation was not to be permitted. Participants requiring more than 2 dose level reductions would be withdrawn from study treatment."
223503023|NCT00167570|DEVICE|Prosthetic socket fabricated using selective laser sintering|
223592340|NCT01110382|DRUG|Meropenem placebo|Form=solution for infusion, Route=intravenous use, administered once every 8 hours infused over 30 minutes immediately before each iv infusion of doripenem for up to 14 days.
223592341|NCT01110382|DRUG|Meropenem|Type=once every 8 hours infused over 30 minutes, Unit=mg, Number=20 mg/kg to 1 gram per dose, Form=solution for infusion, Route=intravenous use. At least 3 days of iv meropenem administered every 8 hours immediately before doripenem placebo for up to 14 days
223592342|NCT01110382|DRUG|Doripenem placebo|Form=solution for infusion, Route=intravenous use, administered once every 8 hours infused over 60 minutes immediately after each iv infusion of meropenem for up to 14 days
223592343|NCT01110382|DRUG|Amoxicillin/clavulanate potassium|Form=suspension or tablets, Route=oral (by mouth), may be administered at the discretion of the investigator once every 12 hours for up to 14 days following IV therapy with doripenem or meropenem.
223592344|NCT05153213|PROCEDURE|Finger lengths|Vernier caliper was used to measure finger length
223592345|NCT05153213|PROCEDURE|Conventional method|Gillis gauge was used to measure occlusal vertical dimension
223592346|NCT05222555|DRUG|Tafasitamab|tafasitamab will be administered intravenously at protocol defined timepoints
223592347|NCT05222555|DRUG|Lenalidomide|lenalidomide will be administered orally at protocol defined timepoints
224194068|NCT00516698|GENETIC|polymorphism analysis|
224194069|NCT00516698|OTHER|high performance liquid chromatography|
224194070|NCT00516698|OTHER|laboratory biomarker analysis|
224194071|NCT00516698|PROCEDURE|radiomammography|
223503024|NCT04139525|BIOLOGICAL|unfractionated heparin|A bolus of 30 I.U./kg at the start of hemodialysis, followed by 18 I.U./kg per every hour of hemodialysis.
223503025|NCT04139525|BIOLOGICAL|8% trisodium citrate|8% trisodium citrate in the dose of 150 ml/h.
223592348|NCT03134781|BEHAVIORAL|DoIT workout|A hybrid small-group (5-10 women/session) training modality, that combines interval training, resistance exercise and functional training and performed according to a periodized model of exercise prescription as an alternative approach for weight management. FFIT was performed 3 times/week with 48 hours recovery between sessions for 40 weeks.
223592349|NCT03134781|BEHAVIORAL|DoIT workout - Detraining|A hybrid small-group (5-10 women/session) training modality, that combines interval training, resistance exercise and functional training, performed according to a periodized model of exercise prescription for a 20-week period (3 times/week). Immediately after a 20-week detraining period (no training was performed) was followed.
223592350|NCT03134781|BEHAVIORAL|Control - No training|No training was performed during a 40-week period. Participation only in measurements.
223592351|NCT04487457|OTHER|Blood samples|Blood samples
223592352|NCT04977219|BEHAVIORAL|Prism Adaptation Training|Therapists administering PAT followed the protocol developed by the Kessler Foundation (2014).PAT sessions lasted approximately 30 minutes during which patients with left sided neglect don 20 diopter prism goggles deviating their visual field to the right while aiming their finger at a series of visual targets.
223592353|NCT01211314|DRUG|Lercanidipine/enalapril fixed combination|Lercanidipine 10 mg + enalapril 20 mg, once a day, used as a fixed combination drug. Unique dose during the study
223592354|NCT02238834|DRUG|FP-025|Subjects will receive single doses of 200 to up to 800 mg of FP-025 (API-in-capsule) in a dose escalation format (cohorts 1-3). Subjects will receive single doses of 50 to up to 450 mg of FP-025 (ASD-in-capsule) in a dose escalation format (cohorts 4-8).
223592355|NCT02238834|DRUG|Placebo|Subjects will receive single doses of FP-025 matching placebo (capsule) in a dose escalation format.
223746634|NCT06536257|OTHER|Predictive model|Patient who have not had immunotherapy will have tumour tested using the predictive model. This determines whether patients are likely to respond, or not to respond to immunotherapy. Results of the predictive model will be compared with the actual response to immunotherapy when this has been completed.
223746635|NCT06570473|DRUG|Empagliflozin|Tablet
223746636|NCT06570473|DRUG|Ranolazine|Tablet
223503026|NCT01166945|DRUG|Amoxicillin-Potassium Clavulanate Combination|All subjects will be started on treatment with 5 days of high dose amoxicillin (90mg/kg) with potassium clavulanate (6.4 mg/kg) twice daily in bottle A. The allocation to group B1 or B2 will be concealed until after the family and subject has signed the assent and consent, respectively. The maximum dose will be 2 gms twice daily. After 5 days the subjects will be randomized to either continue to receive the same dose of amoxicillin clavulanate or a look-a-like and taste-a-like placebo for the next 9 days.
223503027|NCT01166945|DRUG|Placebo|After 5 days the subjects will be randomized to either continue to receive the same dose of amoxicillin clavulanate or a look-a-like and taste-a-like placebo for the next 9 days.
223503028|NCT04568772|DRUG|Atovaquone / Proguanil 250/100 mg|Atovaquone / Proguanil 250/100 mg tablet
223503029|NCT04568772|DRUG|Tegoprazan 50 mg|Tegoprazan 50 mg tablet
223503030|NCT04568772|DRUG|Esomeprazole 40 mg|Esomeprazole 40 mg tablet
223503031|NCT04568772|DRUG|Vonoprazan 20 mg|Vonoprazan 20 mg tablet
223503032|NCT01160900|PROCEDURE|Coronary angioplasty all lesions|treatment by coronary angioplasty and drug eluting stent of all lesions, adjunctive use of prasugrel and bivalirudin
223503033|NCT02410876|PROCEDURE|Bladder biopsy|Small biopsy of the bladder is taken with cold-cup tongs.
223503034|NCT02410876|PROCEDURE|Urodynamic study|Assessment of bladder function through intravesical and intrabdominal pressure measurements according to International Continence Society standards.
223503035|NCT04869930|OTHER|specimen collection|participants will submit at minimum two of four required samples: fecal, urine, finger/toe-prick blood, and cheek swab, collected at home via commercially available kits
223503036|NCT05438420|DRUG|Q702|The study drug Q702 will be administered once daily by mouth on Days 1 through 7, Days 15 through 21 and Days 29 through 35 of every treatment cycle.
223503037|NCT05438420|BIOLOGICAL|Pembrolizumab|Pembrolizumab will be administered using IV infusion on Day 1 of each 3-week treatment cycle
223503038|NCT06025461|OTHER|no intervention|no intervention
223503039|NCT01263379|BIOLOGICAL|LZRSE-Col7A1 Engineered Autologous Epidermal Sheets|"This trial will create a graft, which we call LEAES, of the patient's own skin that has been genetically engineered in our lab to express this missing protein."
223503040|NCT06355687|DRUG|Melatonin|Obese patients undergoing laparoscopic cholecystectomy will receive melatonin oral (0.2 mg /kg) 45 minutes before general anesthesia.
223503041|NCT06355687|DIETARY_SUPPLEMENT|Vitamin Supplement|Obese patients undergoing laparoscopic cholecystectomy will receive placebo medication (Vitamin Supplement) 45 minutes before general anesthesia.
223503042|NCT01135056|DEVICE|SIR-Spheres|One time treatment. Dose administered based on tumour volume. Each vial is 3.0GBq.
223503043|NCT01135056|DRUG|Sorafenib tosylate|Oral Tablet, 400mg B.i.d, until progression or unacceptable toxicity develops
223503044|NCT00496327|BIOLOGICAL|Varicella Virus Vaccine Live (Oka-Merck)|VARIVAX(TM) (Refrigerated) \[Varicella Virus Vaccine Live (Oka/Merck), Refrigerator-Stable Formulation.\] Subjects enrolled in the study received one 0.5 mL subcutaneous dose of VARIVAX(TM). Frequency is single dose.
223503045|NCT01192360|PROCEDURE|Phase contrast flow velocity mapping (PC)|An MRI is done using the phase contrast flow velocity mapping (PC)technique. Using PC, an imaging slice is prescribed perpendicular to the vessel's course. Within the pulmonary circulation, PC can quantify total pulmonary blood flow and the right / left distribution of the lung blood flow volume.
223592356|NCT02238834|DRUG|FP-025|Subjects will receive doses of FP-025 (capsule) twice daily for 5 days.
223592357|NCT02238834|DRUG|Placebo|Subjects will receive FP-025 matching placebo (capsule) twice daily for 5 days
223592358|NCT05400421|DEVICE|System & Method for Monitoring Aortic Pulse Wave Velocity & Blood Pressure|Carotid-femoral aortic pulse wave velocity will be compared against values collected from the oximeter system. The former is assessed by placing piezoelectric pressure sensors at three locations: the right common carotid artery, the right common femoral artery (groin), and the right superficial femoral artery (thigh). The oximeter will be secured on the right index finger. Simultaneous data collection will occur for both methods, with each trail lasting 60 seconds.
223592359|NCT00485966|DRUG|CX-3543|360 mg/m2 daily x 5 q 21 days
223503046|NCT01192360|PROCEDURE|Dynamic contrast-enhanced magnetic resonance imaging|Dynamic contrast-enhanced magnetic resonance (DCE MR) perfusion imaging imaging is a non-invasive method to quantify regional pulmonary blood flow. A bolus of gadolinium-containing contrast medium is injected and its passage through the pulmonary circulation traced using a repetitive rapid three-dimensional (3D) T1 weighted angiography sequence.
223503047|NCT06579248|DEVICE|Intraoral Device|Device that circulates cooled water through the oral cavity.
223503048|NCT05509374|DRUG|Carfilzomib 56 MG [Kyprolis]|Carfilzomib 56 mg/m2 (Day1, 8, 15) (Cycle1 Day1, 20 mg/m2)
223503049|NCT05509374|DRUG|Pomalidomide|Pomalidomide 4 mg per os (Day1-21)
223503050|NCT05509374|DRUG|Dexamethasone|Dexamethasone 40 mg (D1, 8, 15, 22) (20 mg for patients ≥ 75 years old)
223592360|NCT00464659|DEVICE|Effective CPAP|Auto-titrating CPAP machines (Remstar Auto; Philips Respironics, Murrysville, PA) provided by a home care company (Bastide Medical, France). Pressure was set between 6 and 14 cm of water
223592361|NCT00464659|DEVICE|Sham CPAP|Similar CPAP machine delivering a 4 cm of water pressure that was too low to suppress sleep respiratory events.
223592362|NCT00038779|PROCEDURE|Megadose T-cell Depleted HLA-nonidentical Blood Progenitor Cell Transplantation|
223746637|NCT04266197|COMBINATION_PRODUCT|Drug: RT234 - vardenafil inhalation powder; Device: Axially Oscillating Sphere dry powder inhaler (AOS DPI)|RT234 capsules of a dry powder formulation containing vardenafil administered via oral inhalation with a non-invasive AOS DPI.
224194072|NCT04762706|BEHAVIORAL|CRUTCH Pathway|Patients will be offered referral to a behavioral medicine specialist in the novel Combined Rehabilitation Using Team Centered Help (CRUTCH) Pathway. Once enrolled, these patients will meet virtually with a psychiatrist. The psychiatrist will complete a 30-minute intake visit where he will review the patient's DT scoring, discuss contributing factors to current distress level, and assess for psychiatric comorbidities. Following this assessment, psychotherapy, psychotropic medication, and referral for social work/financial services will be offered to the patient as indicated. If more frequent behavioral health follow-up is clinically indicated, it will be provided to the patients.
224194073|NCT01144858|OTHER|a complete transesophageal echocardiography|All patients were evaluated by a complete transesophageal echocardiography with multiplane probes with a 7-MHz transducer before catheter ablation .LA appendage flow was obtained by placing the pulsed Doppler sample volume at the orifice of the LA appendage, after which peak flow velocities were measured and averaged within each RR interval of 10 consecutive cardiac cycles
223503051|NCT04398914|DRUG|Pyrotinib|Pyrotinib 400 mg taken orally everyday, every 3 weeks, for 4 cycles.
223503052|NCT04398914|DRUG|Trastuzumab|"Trastuzumab IV infusion in 3-week cycles.~Neoadjuvant treatment: 8 milligrams per kilogram (mg/kg) loading dose for Cycle 1, followed by 6 mg/kg for Cycles 2-4.~Adjuvant treatment: 8 mg/kg loading dose, followed by 6 mg/kg for remaining cycles till completion of 1 year trastuzumab"
223503053|NCT04398914|DRUG|Pertuzumab|"Pertuzumab IV infusion in 3-week cycles.~Neoadjuvant treatment: 840 milligrams (mg) loading dose for Cycle 1, followed by 420 mg for Cycles 2-4.~Adjuvant treatment: 840 mg loading dose, followed by 420mg for remaining cycles till completion of 1 year pertuzumab"
223503054|NCT04398914|DRUG|Nab-paclitaxel|Nab-paclitaxel 100mg/m2 by intravenous (IV) infusion on day1, day8 and day15, every 3 weeks, for 4 cycles.
223503055|NCT04398914|DRUG|EC chemotherapy|Epirubicin 90 mg/m2, and cyclophosphamide 600 mg/m2 by intravenous (IV) infusion every 3 weeks for 4 cycles (Cycles 5-8)
223503056|NCT04398914|DRUG|Physician's choice|Physician decided chemotherapy for 0-4 cycles.
223503057|NCT04398914|DRUG|T-DM1|T-DM1 IV infusion in 3-week cycles. 3.6 mg/kg by intravenous (IV) infusion every 3 weeks for 14 cycles
223503058|NCT04398914|PROCEDURE|Surgery|All participants who are eligible for surgery will undergo surgery and have their pathologic response evaluated.
223503059|NCT01726686|DRUG|Ropivacaine|100 ml Ropivacaine 10mg/ml in a continuous infusion pump set at 2 ml/hour
223503060|NCT01726686|DRUG|Placebo|
223503061|NCT02444377|BEHAVIORAL|Interval training|
223503062|NCT05915169|OTHER|Topical haemoglobin wound care spray|It is a wound care spray used in the care of chronic wounds.
223503063|NCT00000987|DRUG|Bleomycin sulfate|
223503064|NCT00000987|DRUG|Vincristine sulfate|
223503065|NCT00000987|DRUG|Doxorubicin hydrochloride|
223503066|NCT00000987|DRUG|Zidovudine|
223503067|NCT03202550|DRUG|Oxycodone and Lorazepam (Active Comparator)|Oxycodone and Lorazepam
223503068|NCT03202550|DRUG|Placebo Comparator|Placebo oral pills
223503069|NCT05031130|OTHER|Empowered program integrated with family support|The empowered program integrated with family support is an intervention consisted of five steps that will be given when pregnant adolescents on gestational age 32 or 33 weeks the second meeting will be when the pregnant adolescents on gestational age 34 or 35 weeks.
223592363|NCT04161170|DEVICE|Digital integrated healthcare platform|Digital Integrated Healthcare Platform Utilizing AI-based Dietary Management Solution and Real-time Continuous Glucose Monitoring system
223503070|NCT05343507|DRUG|Ketalar 50 MG/ML Injectable Solution|Intravenous solution (other info already provided)
223503071|NCT05343507|DRUG|Placebo|Saline Solution
223503072|NCT04522791|BEHAVIORAL|RFB|The RFB protocol entails a combination of 8 weekly, in-lab training sessions using HRV biofeedback software (Physiocom, Seattle, WA) and daily paced breathing homework using a mobile-based HRV biofeedback app (Inner Balance, HeartMath, LLC, CA).
223503073|NCT04522791|BEHAVIORAL|VSOP|The investigators will use the INSIGHT online program (Posit Science). The platform will be built for our study, including 5 tasks (Eye for detail, Peripheral challenge, Visual sweep, Double decision, Target tracker) that practice different cognitive processes with PS/A as the shared domain.
223503074|NCT04522791|BEHAVIORAL|IR|Guided imagery relaxation, equal in dose and frequency to RF practice, will be used to control for relaxation effects that may occur via RFB (which could provide an alternative explanation for outcomes). IR activities will be facilitated using the Insight Timer mobile-based app, which emphasizes the use of visualization and imagery strategies to help the body relax.
223503075|NCT06310109|OTHER|PICU diary|.The PICU diary is a notebook with lined sheets located at the patient's bedside. In this diary parents, other caregivers, family members, healthcare professionals or other visitors can write thoughts, report events related to the child/adolescent's admission, attach drawings or photographs for the patient or related to the PICU admission.
223503076|NCT00784927|BIOLOGICAL|rituximab|
223503077|NCT00784927|DRUG|cyclophosphamide|
223503078|NCT00784927|DRUG|dexamethasone|
223503079|NCT00784927|DRUG|lenalidomide|
223503080|NCT01779362|DRUG|Metformin|Titrated to 1000 mg BID
223503081|NCT01779362|DRUG|Liraglutide|Titrated to 1.8 mg/day
223503082|NCT01779362|DRUG|Glargine|Titrated to target fasting glucose \<90 mg/dl
223503083|NCT01779362|DRUG|Placebo|Matching to metformin 1000 mg BI
223503084|NCT05649371|OTHER|Prehabilitation|A multiphasic exercise prehabilitation program for alloHSCT candidates across each treatment phase, that includes behaviour change support
223503085|NCT00714272|DEVICE|Treatment with a Granulocyte Adsorber, Medica Adsorber 1.1|6 treatments. One per week during the first six consecutive weeks.
223503086|NCT00714272|DEVICE|Treatment with a sham device, EXcorLab box 1.2|6 sham treatments. One treatment per week during the first six consecutive weeks.
223503087|NCT01922661|DRUG|REGN1908-1909|
223503088|NCT01922661|OTHER|placebo|
223503089|NCT00422461|DRUG|placebo|placebo, oral, tablets, once daily, for 28 days
223746638|NCT04546165|PROCEDURE|manipulation plus exercise|HLVA manipulation was performed for 8 sessions (twice a week for four weeks) using a segment-specific technique for segmental dysfunctions of the upper cervical spine. . By bringing the cervical spine to light flexion and about 15-20º lateral flexion without any rotational motion, the middle finger of the manipulating hand provided deep contact, and an HVLA thrust was applied out of the rotational slack by applying a deep force from the dorsal to the ventral direction
223746639|NCT04546165|PROCEDURE|suboccipital inhibition plus exercise|Suboccipital inhibition was performed for 8 sessions (twice a week for four weeks) as a combined muscle and soft tissue inhibition technique. While the patient was in the supine position, the physician sitting at the top end of the table placed the fingers of both hands on the patient's suboccipital region
223592364|NCT02110797|OTHER|biological markers and evaluation of the mineral density at the lumber spine using DEXA|
223592365|NCT00902174|DRUG|imatinib mesylate|Two or 4 imatinib mesylate (QTI571) 100 mg film coated tablets once daily.
223746640|NCT04546165|PROCEDURE|exercise|Patients were asked to exercise at least three days a week during treatment. The exercise program, which lasted 20 to 30 minutes, included cervical range of motion (ROM) exercises to warm-up and cool-down, and then stretching exercises of cervical and upper thoracic spine muscles (trapezius, levator scapula, sternocleidomastoid) and strengthening exercises (cervical isometric contraction and concentric contraction of the deep cervical flexor muscles).
223746641|NCT05533931|OTHER|Resistive Breathing Training group|The patients performed two sessions each of 15 minutes session of resistive breathing for four days a week for six weeks using an inspiratory resistive device. Ask patient to take long slow inspirations while breathing through the resistive device
223746642|NCT05533931|OTHER|inspiratory hold technique|With the patient in a comfortable position such as side lying or reclined, the therapist may assist the patient by placing both hands on abdominal area to provide proprioceptive feedback. Then in a relaxed tone of voice therapist instructs the patient to sniff quickly through the nose three times with slow, relaxed exhalations
223746643|NCT05759468|DRUG|Investigational Product - MIB 626|The eligible participants will be assigned to receive either NMN or placebo using concealed block randomization in a 1:1 ratio, stratified by sex (male, female), age (60 to 75, \>75 years) and trial site. The randomization list will be generated by the unblinded biostatistician using the software R (www.r-project.org), and deployed in a secure, centralized web-based application accessible to study staff following confirmation of a participant's eligibility.
223746644|NCT05759468|DRUG|Placebo|Placebo - Participants randomized to placebo will receive Matching placebo tablets will be provided by Metro International Biotech, LLC.
224194074|NCT05344391|OTHER|BFR cycling|Cycling with BFR followed by shoulder exercises
224194075|NCT05344391|OTHER|Cycling without BFR|Cycling without BFR followed by shoulder exercises
224194076|NCT06240468|OTHER|not have|not have
224194077|NCT04651569|OTHER|Observational study|none, Observational study
223592366|NCT00902174|DRUG|Placebo|Placebo to imatinib 100 mg film coated tablets
223592367|NCT06097546|DIAGNOSTIC_TEST|laboratory test (RAI14 and MACC-1 )|Measurement of serum RAI14 and serum MACC-1 levels by immunochemical assays
223746645|NCT00846937|DIETARY_SUPPLEMENT|Plant stanolester and fatty acid|Plant stanol ester 2gr/day and fatty acid in a beverage compared to plant stanol ester 2gr /day and placebo
223746646|NCT01508780|DEVICE|St Jude Medical C7 Dragonfly Optical Coherence Tomography (OCT)|All subjects will have OCT and IVUS imaging during their right heart catheterization.
223746647|NCT01508780|DEVICE|Boston Scientific Intravascular Ultrasound|All subjects will have OCT and IVUS imaging during their right heart catheterization.
224194078|NCT04864704|OTHER|dry needling|Physical therapy
224194079|NCT02648646|OTHER|Otago Exercise Programme and Walk with Ease|The Otago Exercise Programme is a falls prevention program that is successful at reducing falls in adults 65+ years of age. Briefly, this program includes flexibility, progressive lower extremity strengthening with ankle weights, and balance exercises. The investigators are replacing the Otago walking program with the evidence-based Arthritis Foundation's Walk With Ease program.
224194080|NCT00819923|DEVICE|Percutaneous coronary intervention|Intra-coronary stenting
224194081|NCT00819923|DEVICE|Percutaneous coronary intervention|Intra-coronary stenting
224194082|NCT03962426|DEVICE|SocialVille Social Cognitive Training|"SocialVille exercises in this study include 4 exercises:~* Recognition: a speeded face matching task~* Face to Face: a speeded facial emotion matching task~* Gaze Match: a speeded gaze matching task~* Face Poke: a continuous performance task with facial expressions"
223592368|NCT01195493|OTHER|Essential Oils solution|(Essential oils solution, Listerine®, Johnson \& Johnson) to use twice a day (2 x 20 ml) following daily mechanical oral hygiene practices
223592369|NCT01195493|OTHER|negative control solution|this solution would be used twice per day (2 x 20 ml) following daily home care.
223592370|NCT01587092|BEHAVIORAL|WorkStation|Participants will be asked to attend 2 scheduled sessions per day of treadmill walking, which will replace their sitting desk time. Participants will complete 2 sessions per day for 6 months.
223592371|NCT01587092|BEHAVIORAL|Usual Working Condition|Participants will be asked to continue working at their desk in their usual manner.
223592372|NCT00143377|DRUG|tolterodine SR, overactive bladder|
224194083|NCT02209220|DEVICE|Positive airway pressure for the treatment of OSA|
224194084|NCT05056909|DEVICE|Kidney ACTion|AI-supported software for chronic kidney disease care
224194085|NCT05056909|OTHER|Standard of care|Standard of care
224194086|NCT04347174|DRUG|Suspension of heat killed (autoclaved) Mycobacterium w|Patients will be randomized to receive either Mycobacterium w in combination with standard care as per hospital practice or standard care alone in COVID-19 as per hospital practice.
224194087|NCT04347174|DRUG|Placebo|All patients will continue to receive standard therapy as per hospital practice till considered requisite by the treating physician
223592373|NCT03529279|DRUG|CNG Chemotherapy|"CNG I, IMRT plus oral adjuvant chemotherapy, if EBV-DNA \> 0,according to CNG II. CNG II, IMRT + concurrent chemotherapy + oral adjuvant chemotherapy. CNG III, systemic chemotherapy, plus IMRT.~Chemotherapy strategy: Concurrent chemotherapy, 5-Fu + nedaplatin (cisplatin), every 28 days; 5-Fu 500mg/m2. D, civ d1-d5, nedaplatin (cisplatin) 80mg (70mg) /m2. D, D1. Systemic chemotherapy, 5-Fu + nedaplatin (cisplatin), every 60 days; 5-Fu (100 - 200 mg/m2. D) civ for 30 days, nedaplatin (cisplatin) 80mg (70mg) /m2. D, D1,D28. Aim to achieve CR in imaging.Oral adjuvant chemotherapy, tegafon (400 mg, QID) and Calcium Folinate Tablets (30 mg, QID). Oral 10 days and stop 20 days, 3 months/course. After 6 courses, oral 10 days and stop 50 days, half year/course, 6-7 courses, lasted for 5 years."
223592374|NCT03529279|DRUG|NCCN Chemotherapy|"UICC I, IMRT. UICC II-IVA, concurrent chemoradiotherapy ± adjuvant chemotherapy, or induced chemotherapy plus concurrent chemoradiotherapy. UICC IVB, platinum based combined chemotherapy, followed by IMRT or concurrent chemoradiotherapy, or concurrent chemoradiotherapy.~Chemotherapy strategy: Concurrent cisplatin with or without cisplatin plus 5-Fu or carboplatin combined with 5-Fu adjuvant chemotherapy; The combined chemotherapy regimen of IVB stage patients may choose cisplatin or carboplatin plus docetaxel or paclitaxel, cisplatin plus 5-Fu, carboplatin and cetuximab, cisplatin plus gemcitabine, and gemcitabine. The combination of vinorelbine and cisplatin, carboplatin, paclitaxel, docetaxel, 5-Fu, methotrexate, gemcitabine and capecitabine can be used in combination with radiotherapy."
223592375|NCT03529279|RADIATION|CNG Radiation|"IMRT technique. GTV was given to 6810cGy, CTV1 was given to 6000cGy, and CTV2 was given to 4800-5400cGy. 30 fractions, daily, QW1-5.~CT-SIM or MR-CIM was evaluated every 10 fractions. If CR for CNG I and II patients at 10 fractions, radiotherapy were given 25 fractions, that was, GTV was given to 5675cGy, CTV1 was given 5000cGy, and CTV2 was given 4000-4500cGy, 25 fractions, daily, QW1-5.~If tumor reduced less than 50% at 20 fractions, GTV was modified according to tumor size at 20 fractions. The modified GTV was given 300cGy/F×5 after 25 fractions; the original CTV1 and CTV2 were unchanged, that is, GTV was given to 5675cGy/25Fr+1500cGy/5Fr and CTV1 was given to 6000cGy/30Fr, CTV2 was given 4800-5400cGy/30Fr."
223592376|NCT03529279|RADIATION|NCCN Radiation|"IMRT technique. When IMRT alone, GTV were given (1) 66Gy (2.2Gy/Fr) to 70-70.2 Gy (1.8-2.0 Gy/Fr), QW1-5, 6-7 weeks; (2) 69.96 Gy (2.12 Gy/Fr), 6-7 weeks; CTV1-2 were given 44-50 (2.0 Gy/Fr) to 54-63 (1.8 Gy/Fr).~When combined with chemotherapy, GTV were given 70-70.2 Gy (1.8-2.0 Gy/Fr), QW1-5, 7 weeks; CTV1-2 were given 44-50 Gy (2 Gy/Fr) to 54-63 Gy (1.8 Gy/Fr).~When palliative radiotherapy, 50Gy/20Fr; 37.5 Gy/15Fr (if tolerable, increases 5 fractions to 50Gy); 30Gy/10Fr, 30Gy/5Fr, 2 fractions per week, interval more than 3 days; 44.4Gy/12Fr was divided into 3 cycles, 2 fractions a day, 6 hours of interval, 2 consecutive days and 3-4 weeks between two cycles. After second cycles, the treatment plan must completely avoid the irradiation of the spinal cord."
223592377|NCT00899158|OTHER|immunologic technique|
223592378|NCT00899158|OTHER|laboratory biomarker analysis|
223592379|NCT00899158|PROCEDURE|biopsy|
223592380|NCT01581619|RADIATION|External Beam Partial-Breast Irradiation|40 Gy in ten daily fractions over two weeks
223592381|NCT02641717|OTHER|vaginal swab|
223592382|NCT04294771|DRUG|ICI|Immune checkpoint inhibitor targeting either PD-1, PD-L1 or CTLA-4, and included in the ATC following list (ATC classification): Ipilimumab (L01XC11), Nivolumab (L01XC17), Pembrolizumab (L01XC18), Durvalumab (L01XC28), Avelumab (L01XC31), Atezolizumab (L01XC3)
223592383|NCT06142006|OTHER|Diabetes Staging System (DSS) use among Primary Care Teams|Evaluate the feasibility of using the DSS in PACT clinics to increase SGLT2i and/or GLP-1 agonist use in Veteran DM2 patients with cardiovascular disease
224194088|NCT04188613|DEVICE|Percutaneous tracheostomy|Age, gender, height, BMI, ASA scores, presence and type of additional diseases, tracheostomy day, pre- and post-procedure blood gas analysis, duration of procedure, duration of anesthesia, complications during the procedure (bleeding , desaturation, accidental extubation, malposition, bradycardia, hypotension, etc.) will be recorded from intensive care follow-up. Patients will be observed for mortality in the first 30 days after the procedure. Mortality results will be recorded.
224194089|NCT02235207|BEHAVIORAL|Neuromuscular exercise|"Fustra20 Neck \& Back is individually guided, graded neuromuscular exercise program which is conducted twice a week for 20 times. Each session lasts one hour. After 20 sessions participants are encouraged to continue exercising at home with a help of an individual home exercise plan including diary of compliance.~The main targets are to~* improve movement control in different posture and movements of the neck and back~* improve flexibility with active functional movements~* improve pelvic, spine and shoulder-neck stability using co-contraction of several muscle groups, and thus enhancing gross movement of the whole kinetic chain~* improve muscular endurance of shoulder neck area, trunk, pelvis and lower extremities"
223592384|NCT00665769|OTHER|Hypercapnia|transcutaenous CO2 50-60 mm Hg
223592385|NCT00665769|OTHER|Normocapnia|transcutaneous CO2 35-45 mm Hg
223592386|NCT05047146|OTHER|Morphological classifications of HCC|Morphological classifications of Hepatocellular carcinoma
223592387|NCT01364701|DRUG|Sildenafil 100 mg|4 tablets for on demand use
223592388|NCT01364701|DRUG|Tadalafil 20 mg|4 tablets on demand
223746648|NCT02637778|DIETARY_SUPPLEMENT|Cardioprotective diet|The 'cardioprotective diet' is characterized by (i) adequate energy intake, (ii) intake of carbohydrates, protein, fat according to the guidelines of the German Society of Nutrition (DGE e. V.), (iii) desirable intake of saturated fatty acids (SFA, 7 En%), monounsaturated fatty acids (MUFA, \> 10 En%), polyunsaturated fatty acids (PUFA, approx. 10 En%) and in particular n-3 LC-PUFA, (iv) encouraged consumption of vegetables, fruits, cereals, (v) salt and sugar reduction, (vi) avoiding of highly processed, calorie-dense, nutrient-poor food as well as (vii) encouraged physical activity.
224194090|NCT00390338|BIOLOGICAL|polarized dendritic cells|
224194091|NCT00390338|BIOLOGICAL|non-polarized dendritic cells|
224194092|NCT01015118|DRUG|Placebo|comparator to BIBF 1120
224194093|NCT01015118|DRUG|Paclitaxel|Paclitaxel (standard chemo-therapy)
224194094|NCT01015118|DRUG|BIBF 1120|comparison of BIBF 1120 in combination with chemotherapy and placebo in combination with chemotherapy (paclitaxel/carboplatin)
224194095|NCT01015118|DRUG|Carboplatin|Carboplatin (standard chemo-therapy)
224194096|NCT01015118|DRUG|Paclitaxel|Paclitaxel (standard chemo-therapy)
224194097|NCT01015118|DRUG|Carboplatin|Carboplatin (standard chemo-therapy)
224194098|NCT03522506|DRUG|TAK-925|TAK-925 intravenous infusion.
224194099|NCT03522506|DRUG|TAK-925 Placebo|TAK-925 placebo-matching given as saline intravenous infusion.
224194100|NCT03522506|DRUG|Modafinil|Modafinil tablets.
224194101|NCT03522506|DRUG|Modafinil Placebo|Modafinil placebo-matching tablet.
224194102|NCT05672277|OTHER|TENS 1|Parasacral TENS will be applied for 30 minutes 3 days a week during 6 weeks.
224194103|NCT05672277|OTHER|TENS 2|Parasacral TENS will be applied for 30 minutes one day a week during 6 weeks.
224194104|NCT06565845|PROCEDURE|Surgery|patients underwent complete excision of the inflammatory breast tissue and some surrounding normal tissue under combined intravenous with inhalation anesthesia. Damaged skin was also removed.
224194105|NCT06565845|DRUG|triple anti-tuberculosis drug|Patients took oral rifampin (450 mg/day), isoniazid (300 mg/day), and ethambutol (15 mg/kg/day).
224194106|NCT05990725|BIOLOGICAL|Lebrikizumab|Lebrikizumab solution for injection administered subcutaneously.
223592389|NCT01364701|DRUG|Combination half of maximal dose for sildenafil & tadalafil|4 tablets on demand
223592390|NCT02522442|DEVICE|CPAP|Continuous positive airway pressure
223592391|NCT02522442|DEVICE|Auto BiLevel|Auto Bilevel positive airway pressure with Flex
223592392|NCT02896270|DRUG|Valproic Acid|The concomitant immunosuppressive regimen is to be reduced at the discretion of the investigators. It is suggested to lower immunosuppressive therapy only in valproic acid target trough levels have been attained.
223592393|NCT03129360|DRUG|Levetiracetam|Levetiracetam is an atypical anticonvulsant that is frequently used in children and adults due to its superior tolerability, ease of use and excellent safety profile.
223592394|NCT03129360|DRUG|Placebo|Prepared in capsules to appear identical to levetiracetam.
223592395|NCT04516551|BIOLOGICAL|anti-CD19 allo-CAR-T cells|The T cells collected from haploidentical donors have been manufactured to express CAR to binding CD19 on B-cell leukemia.
223592396|NCT02209623|BIOLOGICAL|TDAP|
223592397|NCT04491851|DIAGNOSTIC_TEST|68Ga-NODAGA-LM3 and 68Ga-DOTA-LM3 PET/CT|Patients will undergo PET/CT using 68Ga-NODAGA-LM3 (40ug peptide/150-200MBq) and 68Ga-DOTA-LM3 (40ug peptide/150-200MBq) on two consecutive days. The scan will be acquired at 1hour post-injection.
224194107|NCT05429749|DRUG|Ferinject|Intravenous ferinject 1000mg is administered between the admission day and the surgery day.
224194108|NCT05429749|DRUG|Normal saline|Normal saline 250ml is administered between the admission day and the surgery day.
224194109|NCT03480243|DRUG|Padsevonil (UCB0942)|"* Pharmaceutical Form: film-coated tablet~* Route of Administration: Oral use"
224194110|NCT03480243|DRUG|Erythromycin|"* Pharmaceutical Form: film-coated tablet~* Route of Administration: Oral use"
224194111|NCT00761085|DRUG|Morphine|Standard of care for pain management of acute episode of pain
224194112|NCT00761085|DRUG|Methadone|Compare to standard of care for pain management of acute episode of pain
224194113|NCT00083356|PROCEDURE|Wisdom tooth extraction|
224194114|NCT04670510|OTHER|On-site AE|"Participants will attend on-site supervised AE sessions 3 times per week for the first 6 weeks, twice weekly for weeks 7-12; once weekly for weeks 13-18.~All supervised sessions will start and end with 5-minute warm-up and cool-down and will involve exercise on the treadmill, elliptical, and/or bike. During AE sessions, participants will exercise so that their heart rate is approximately 65% of their peak heart rate and gradually increase the intensity of exercise so that their heart rate is between 70 and 85% of their peak heart rate. All participants will wear heart rate monitors and encouraged to exercise in their target heart rate zone. Supervised AE sessions will gradually increase to 50-minutes per session"
224194115|NCT04670510|OTHER|At-home AE|Participants will increase at-home AE during the 6-month intervention period with weeks 19-26 occurring entirely at-home. As participants transition to home-based exercise, they will be equipped with a polar heart rate monitor and will be instructed to use this to record average heart rate during each exercise session. On a log sheet, they will record both average heart rate during exercise and average subjective rating of perceived exertion (RPE) during each exercise session.
224194116|NCT04670510|OTHER|Social Engagement (SE)|To control for the social component of the AE intervention participants in the SE group will be invited to attend at total of 25 group meetings over the course of the 6-month study period.
223592398|NCT04491851|DIAGNOSTIC_TEST|68Ga-NODAGA-LM3 and 68Ga-NODAGA-JR11 PET/CT|Patients will undergo PET/CT using 68Ga-NODAGA-LM3 (40ug peptide/150-200MBq) and 68Ga-NODAGA-JR11 (40ug peptide/150-200MBq) on two consecutive days. The scan will be acquired at 1hour post-injection.
223592399|NCT03006887|DRUG|lenvatinib|lenvatinib capsules
223592400|NCT03006887|DRUG|pembrolizumab|pembrolizumab intravenous infusion
223592401|NCT00001909|DRUG|Soluble recombinantly produced IL-4R|
223592402|NCT04467970|PROCEDURE|Unicompartmental Knee Replacement|Unicompartmental Knee Replacement involves replacement of the medial compartment of the knee in patients with anteromedial osteoarthritis.
223592403|NCT04467970|PROCEDURE|High Tibial Osteotomy|High Tibial Osteotomy involves medial wedge opening high tibial osteotomy in cases of anteromedial osteoarthritis.
223592404|NCT03381313|BEHAVIORAL|Conditioned word repetition training|In the classical conditioning training the onset of the visual stimulus preceded that of the auditory stimulus with a short onset asynchrony, and both stimuli co-terminated. By contrast, in the training without conditioning the auditory stimulus was administered first and the visual stimulus appeared short after the off-set of the auditory one.
223592405|NCT03836677|COMBINATION_PRODUCT|BGF|Treatment with Budesonide/Glycopyrronium/FormoterolFumarate
223592406|NCT03836677|COMBINATION_PRODUCT|GFF|Treatment with Glycopyrronium/Formoterol Fumarate
223592407|NCT05338203|OTHER|tandem breastfeedıng|mother mılk wıll collected from mothers and they wıll be analyzed in laboratuar.
223592408|NCT01606033|OTHER|questionnaires|Anxiety and depression questionnaire, life quality questionnaire, adjustment strategy questionnaire, emotional regulation questionnaire, satisfaction survey
223592409|NCT01606033|OTHER|questionnaire|understanding of the implications of participating in a clinical trial
223746649|NCT02637778|DIETARY_SUPPLEMENT|Cardioprotective diet + 3 g EPA + DHA/d|The 'cardioprotective diet' is characterized by (i) adequate energy intake, (ii) intake of carbohydrates, protein, fat according to the guidelines of the German Society of Nutrition (DGE e. V.), (iii) desirable intake of saturated fatty acids (SFA, 7 En%), monounsaturated fatty acids (MUFA, \> 10 En%), polyunsaturated fatty acids (PUFA, approx. 10 En%) and in particular n-3 LC-PUFA, (iv) encouraged consumption of vegetables, fruits, cereals, (v) salt and sugar reduction, (vi) avoiding of highly processed, calorie-dense, nutrient-poor food as well as (vii) encouraged physical activity.The participants will consume additional n-3 LC-PUFA (3 g EPA+DHA/d)
223746650|NCT03581656|DEVICE|ChordArt System|The ChordArt System is intended for chordal replacement in mitral valve insufficiency due to leaflet prolapse or flail. One or more ChordArt System may be utilized within the same intervention for optimal mitral valve treatment.
223746651|NCT04318236|BEHAVIORAL|HERMES (Online Self-Help Intervention based on problem-solving therapy)|"The Online Self-Help Intervention is an online program based on the problem-solving therapy (an evidence based approach of psychotherapy). All participants will receive the exact same intervention.~However, what will be experimentally varied are the four listed interventions."
223746652|NCT04361162|DRUG|Nivolumab|Nivolumab is a type of immunotherapy. Immunotherapy works by encouraging the body's own immune system to attack the cancer cells. Nivolumab work by stopping various molecules on cancer cells and body cells from working against the immune system's natural fight against cancer
223746653|NCT04361162|DRUG|Ipilimumab|Ipilimumab is a type of immunotherapy. Immunotherapy works by encouraging the body's own immune system to attack the cancer cells. Ipilimumab work by stopping various molecules on cancer cells and body cells from working against the immune system's natural fight against cancer
223592410|NCT03233126|DRUG|KRN23|Subjects will receive subcutaneous injections of KRN23 every 2 weeks from Week 0 through Week 86
223592411|NCT05760534|DRUG|Remimazolam|0.075 mg/kg Remimazolam will be loaded over 1 min, then continuously infused at 0.2-1.0 mg/kg/h based on ideal or total body weight
223746654|NCT04361162|RADIATION|Radiation|3D Conformal Radiotherapy to shrink or kill tumors
223746655|NCT03491683|BIOLOGICAL|INO-5401|INO-5401 is a combination of 3 separate DNA plasmids targeting Wilms tumor gene-1 (WT1) antigen, prostate-specific membrane antigen (PSMA) and human telomerase reverse transcriptase (hTERT) genes. Starting on Day 0 three milligrams (mg) of each plasmid will be delivered IM followed by EP using the CELLECTRA® 2000 EP device every three weeks for four doses, and then every 9 weeks until disease progression as defined by immunotherapy Response Assessment in Neuro-Oncology (iRANO), unacceptable toxicity, withdrawal of consent, or death.
223746656|NCT03491683|BIOLOGICAL|INO-9012|INO-9012 is a DNA plasmid for expression of human interleukin-12 (IL-12). Starting on Day 0 one mg plasmid will be delivered IM followed by EP using the CELLECTRA® 2000 EP device every three weeks for four doses, and then every 9 weeks until disease progression as defined by iRANO, unacceptable toxicity, withdrawal of consent, or death.
224194117|NCT05016219|DEVICE|Circadian-Effective Light|Narrowband blue light
224194118|NCT05016219|DEVICE|Rhythmic Light|40 hertz (Hz) flicker
224194119|NCT05016219|DEVICE|Placebo Light|Narrowband red light
224194120|NCT05016219|DEVICE|Placebo Rhythmic Light|Random flicker for placebo rhythmic effect
224194121|NCT01823250|BEHAVIORAL|Family Therapy based on Structural Family Therapy|Once per week family therapy based on Structural Family Therapy. Sees to improve parenting practices, communication, and problem solving skills. It also seeks to increase the attachment/bond between parents and adolescents.
224194122|NCT01823250|BEHAVIORAL|Group Therapy|Group Therapy is provided once per week and is designed to share information on HIV and STI risk and protection. There are typically 8-10 adolescents in a group.
224194123|NCT01823250|BEHAVIORAL|Psychoeducational Sessions|Psycho-educational sessions are used to provide didactic in formation to parents alone, adolescents alone, or both together. Content may focus on parenting, drug use risks, depression, HIV/STI risk or other major issues that adolescents and families confront. There are also modules that focus on culture-related stressors and processes that can be provided to families for whom this is a prominent issue.
224194124|NCT01823250|BEHAVIORAL|Individual Adolescent Therapy Sessions|Individual sessions with the adolescent focus on Motivational Interviewing, coaching for family sessions, and monitoring of unhealthy behaviors.
224194125|NCT02317523|BEHAVIORAL|Behavioral Activation|Six face-to-face sessions (60 minutes each) of Behavioral Activation (BA) therapy
224194126|NCT02317523|BEHAVIORAL|Information and Support|Six face-to-face sessions (60 minutes each) of Supportive Therapy
224194127|NCT01522755|DEVICE|Pacing system implant with the CapsureFix MRI pacing lead model 5086|Pacing system implant with the CapsureFix MRI pacing lead model 5086
223592412|NCT01092962|DRUG|Cyclophosphamide|2mg/kg/day during 12 weeks (cumulative dose 148mg/kg)
223592413|NCT01092962|DRUG|Mycophenolate mofetil|1200mg/m²/jour in two divided doses during 18 months
223592414|NCT05629910|DEVICE|O2Matic|During the interventional period the O2Matic will operate in automatic mode using the Neonatal Study Profile. O2Matic will continuously adjust the O2 flow to adjust SpO2 within range based on readings from the pulse oximeter connected to O2Matic, while AIRVO-2 will adjust the flow of ambient air to keep the total gas flow constant.
224194128|NCT03414658|DRUG|Vinorelbine|work by interfering with cell division, which leaves the tumor unable to grow and spread
224194129|NCT03414658|DRUG|Trastuzumab|trastuzumab induces an antibody-dependent cell-mediated cytotoxicity against tumor cells that overexpress HER2.
224194130|NCT03414658|DRUG|Avelumab|monoclonal antibody directed against the human immunosuppressive ligand programmed death-ligand 1 (PD-L1) protein
224194131|NCT03414658|DRUG|Utomilumab|Utomilumab is an antibody designed to stimulate the body's immune system to fight cancer cells
223592415|NCT06221748|DRUG|Disitamab Vedotin Injection|Phase II and III study ：2.5mg/kg, intravenous infusion，D1, every 2 weeks
223592416|NCT06221748|DRUG|Cadonilimab Injection|Phase II and III study ：6.0mg/kg, intravenous infusion，D1, every 2 weeks.
223592417|NCT06221748|DRUG|Paclitaxel Injection|Phase II and III study ：Calculate dosage based on body surface are,160mg/m2,intravenous infusion，D1,D8 every 3 weeks
223592418|NCT06475040|DEVICE|transcranial magnetic stimulation|non-invasive form of brain stimulation accelerated intermittent theta burst stimulation (aiTBS)
223592419|NCT01300988|DRUG|Aprepitant|Aprepitant (Emend®) 375 mg daily for 14 days
223592420|NCT01300988|DRUG|Aprepitant placebo|Aprepitant(Emend®) placebo for 14 days
223592421|NCT03668405|DRUG|Lu AF20513|Injection
223592422|NCT06934382|BIOLOGICAL|Allogeneic anti-CD7 CAR-T cells (BEAM-201)|The investigational agent in this protocol is allogeneic anti-CD7 CART cells (BEAM-201). BEAM-201 is comprised of allogeneic anti-CD7 CAR-T cells edited by 4 gRNAs and a single mRNA encoding a CBE, then transduced with a lentiviral vector (LVV) encoding the anti-CD7 chimeric antigen receptor (CAR) molecule.
223592423|NCT04080323|DRUG|Dinoprostone 3 mg|1 vaginal tablet of 3mg dinoprostone 60 minutes before surgery
223592424|NCT04080323|DRUG|placebo|1 vaginal tablet of placebo 60 minutes before surgery
223592425|NCT01232985|DEVICE|RD047-26|RD047-26 emollient gel
223592426|NCT05406869|DEVICE|Pulsed Sonic Balloon Dilatation Catheter and Pulsed Sonic Generater|Deliver Pulsed Sonic Balloon Dilatation Catheter to the target vessel prior to placing a coronary stent or others
223592427|NCT00069355|DRUG|Propranolol|
223592428|NCT03329261|DRUG|Clopidogrel|COPIGREL® - clopidogrel dosed at 75 mg per tablet
223592429|NCT03960723|OTHER|Questionnaire|A questionnaire asking the patients for several questions related to the Informed Consent Form they have signed before surgery, will be administered.
223592430|NCT04622813|DRUG|nefopam, ketoprofen, paracetamol|Patients in this group will receive Nefopam and Ketoprofen in addition to the paracetamol intraoperatively prior to the anticipated end of the surgery
223592431|NCT04622813|DRUG|saline infusion, ketoprofen, paracetamol|Patients in this group will receive one placebo infusion (saline infusion) in addition to the ketoprofen and paracetamol intraoperatively prior to the anticipated end of the surgery
223592432|NCT00005014|DRUG|Risperidone|
223592433|NCT01353911|DRUG|Grazoprevir|Orally once daily in AM. Blinded or open-label depending on treatment arm.
223592434|NCT01353911|DRUG|Boceprevir|Four 200 mg capsules orally three times daily.
223592435|NCT01353911|DRUG|Placebo for Grazoprevir|Orally once daily in AM.
223592436|NCT01353911|DRUG|Placebo for Boceprevir|Four capsules orally three times daily.
223592437|NCT01353911|DRUG|Peg-interferon alfa-2b|1.5 μg/kg/week subcutaneous injection.
223592438|NCT01353911|DRUG|Ribavirin|300 mg to 700 mg orally twice daily.
223592439|NCT05647785|DEVICE|Long-term follow-up of cerena™|Long term follow-up for eligible participants from the RESTORE study
223592440|NCT05647785|DEVICE|Long-term follow-up of attune™|Long term follow-up for eligible participants from the RESTORE study
223592441|NCT02152774|DRUG|Rho-Kinase Inhibitor|
223592442|NCT04003987|DRUG|Liposomal bupivacaine|20ml
223592443|NCT04003987|DRUG|bupivacaine, 0.125%|60ml
223592444|NCT01946126|OTHER|No Intervention|There is no intervention in this study.
223592445|NCT02706587|DEVICE|Neuromuscular electrical stimulation|NEMS is delivered bilaterally to the quadriceps femoris muscle using a portable battery-powered stimulator (Rehab 400, Cefar Compex, France). The electrodes are placed on the motor points of vastus medialis and vastus lateralis muscles. Electrical stimuli of 45Hz (pulse width: 380 µseconds; 6 seconds on with 1.5 second rise time; and 0.75 seconds fall time.; 5 seconds off). The current is adjusted to ensure maximum tolerable muscle contraction The protocol is applied twice daily for 25 minutes, five days a week.
223592446|NCT02706587|DEVICE|Sham control|No electrostimulation
223746657|NCT03491683|BIOLOGICAL|Cemiplimab|Cemiplimab is an antibody to programmed death-1 (PD-1) protein. Starting on Day 0 cemiplimab will be administered intravenously (IV) every three weeks at a dose of 350 mg per dose in the absence of dose holding, until disease progression as defined by iRANO, unacceptable toxicity, withdrawal of consent, or death.
223592447|NCT00462748|DRUG|ezetimibe (+) simvastatin|ezetimibe (+) simvastatin 10/40mg. once daily tablet formulation, all tablet form, taken orally, cholesterol lowering medication.
223592448|NCT00462748|DRUG|Comparator: atorvastatin|atorvastatin 40mg. once daily tablet formulation, all tablet form, taken orally
223592449|NCT00462748|DRUG|Comparator: rosuvastatin|rosuvastatin 10 mg. once daily tablet formulation, all tablet form, taken orally.
223592450|NCT06379282|BEHAVIORAL|HIT|Exercise training only
223592451|NCT06379282|BEHAVIORAL|EXE+ Nutritional Guidance|Exercise Training + Nutritional Guidance
223592452|NCT04110080|PROCEDURE|multimodal pain management|Regional anesthesia techniques, specifically rectus sheath and transabdominal plane blocks, for pain management will be performed.
223592453|NCT04110080|OTHER|goal directed fluid management|Intraoperatively fluids will be administered based on hemodynamic parameters, in addition to clinical judgement.
223592454|NCT04110080|OTHER|preoperative carbohydrate loading|Patient's nutrition will be optimized preoperatively by administering carbohydrate drinks, and limiting fasting time.
223592455|NCT04110080|PROCEDURE|Donor nephrectomy|All patient will have laparoscopic nephrectomy procedure with transplant surgery.
223592456|NCT04110080|PROCEDURE|regional anesthesia|transabdominal plane and rectus sheath nerve block
223592457|NCT03778385|OTHER|Exercise|Submaximal exercise is performed in randomized order with the participant seated and the arm supported in an adjustable hand-arm orthosis.
223746658|NCT03491683|RADIATION|Radiation Therapy|Radiation therapy (RT) will begin no later than 42 days after surgical intervention, and should start approximately 2 weeks after Day 0. RT will be given for three weeks.
224194132|NCT03532399|DRUG|Bivalirudin|"CPB: Per hospital protocol, bivalirudin 1 mg/kg IV will be administered to the patient 10 minutes prior to the start of CPB along with an infusion of bivalirudin at 2.5 mg/kg/hr. Additional bolus doses of 0.5 to 1 mg/kg will be administered for ACTs less than the specified target (either 2 times baseline ACT or \> 400 seconds per the discretion of the patient's providers). 50mg of bivalirudin will be administered to the bypass circuit.~Cardiac Catheterization: Bivalirudin will be administered to the patient as 0.75mg/kg IV bolus followed by a 1.75mg/kg/hr infusion for the length of the procedure. Changes in infusion rate or bolus dosing during the procedure and post-procedure will be at the discretion of the patient's care providers.~ECMO/VAD: Dosing will be informed by the hospital's formulary recommendations(http://online.lexi.com/lco/action/doc/retrieve/docid/chibos\_f/6317841), but will ultimately be determined by patient's primary provider."
224314216|NCT05082792|DIAGNOSTIC_TEST|doppler ultrasound|"Doppler ultrasound evaluation of AVF:~* pre-operative evaluation: venous system (patency of central veins and deep venous system, patency of superficial veins, the latter diameter, depth form skin surface, distance from nearby artery, any sizable adjacent tributaries), and arterial system including morphological evaluation (course, diameter, wall alterations, any stenoocclusive disorders) and functional evaluation (flow volume and ability to dilate)~* post-operative evaluation: anastomotic site (type of anastomosis, patency, diameter, PSV and any other morphologic alterations), inflow afferent artery (diameter, PSV and flow volume), outflow efferent vein (patency, diameter, color flow, spectral waveform)~* the first post-operative sonographic evaluation will be done after removal of stiches from the wound and periodic monitoring every one week up until completion of 6 weeks"
223503090|NCT00422461|DRUG|PF-00489791|PF-00489791 20 mg titrated to 40 mg, oral, tablets, once daily, for 28 days
223503091|NCT00422461|DRUG|PF-00489791|PF-00489791 4 mg, oral, tablets, once daily, for 28 days
223503092|NCT00422461|DRUG|PF-00489791|PF-00489791 10 mg, oral, tablets, once daily, for 28 days
223503093|NCT05406895|DRUG|2% Lidocaine with 1:100,000 epinephrine|2% Lidocaine with 1:100,000 epinephrine will be used for administering the lower jaw anesthesia (inferior alveolar nerve block).
223503094|NCT01471574|DRUG|Daclatasvir|Tablets; oral; 30, 60, or 90 mg; once daily; up to 24 weeks
223503095|NCT01471574|DRUG|Ribavirin|Tablets; oral; for patients weighing \<75 kg, the total dose is 1000 mg per day (2 200-mg tablets in the morning and 3 200-mg tablets in the evening); for patients weighing \>75 kg, the total dose is 1200 mg per day (3 200-mg tablets in morning and 3 200-mg tablets in evening); twice daily with food; 24 or 48 weeks depending on response
223503096|NCT01471574|DRUG|PEG-Interferon alfa 2a|Syringe, subcutaneous injection, 180 μg, once weekly, 24 or 48 weeks depending on response
223503097|NCT02590510|DRUG|methotrexate|The quantity of methotrexate is different in the two groups.
223503098|NCT04568512|DIAGNOSTIC_TEST|Control|Brushed biliary samples from a known case of benign biliary stricture were sent for DNA Methylation Biomarker test and cell cytology
223503099|NCT04568512|DIAGNOSTIC_TEST|Cholangiocarcinoma|Brushed biliary samples from a known case of cholangiocarcinoma were sent for DNA Methylation Biomarker test and cell cytology
223503100|NCT01795937|DRUG|Itraconazole|twice daily
223503101|NCT01795937|DRUG|Atorvastatin|single dose
223503102|NCT01795937|DRUG|Faldaprevir|once daily
223503103|NCT01795937|DRUG|Rosuvastatin|single dose
223503104|NCT01795937|DRUG|Faldaprevir|once daily
223503105|NCT00635180|BEHAVIORAL|isometric exercise|
223503106|NCT01459159|DRUG|ezatiostat hydrochloride (Telintra®)|Three weeks of treatment with ezatiostat at 2000 mg per day in divided doses followed by a one week rest period in four-week treatment cycles.
223503107|NCT00673829|BIOLOGICAL|Gene Modified T Cells|Gene Modified T Cells Phase Ia: One time infusion Modified TCells given through a vein in the arm or a catheter over a 30-60 minute period
223503108|NCT00673829|BIOLOGICAL|Gene Modified T Cells and Interleukin 2|One time infusion Modified T Cells without or with (randomized) continuous infusion outpatient interleukin 2 (IL2) for two weeks
223503109|NCT04261595|OTHER|Dates fruit as functional Food|Two groups will receive Dates; The number per group is dependant on the child age. For children aged 3-6 years; they will receive the minimum numbers of dates (3 pieces). For children aged more than 6-12 years will receive 5 pieces of Dates the choice of the minimum numbers of dates (3 pieces) in this current trial is based on a study that was done by Al Jaouni and his colleagues, 2019 which proved the effects of three pieces of Ajwa on infection, hospitalization, and survival among 26 pediatric cancer patients in a university hospital; for which their treatment outcome was improved due to their intake of this amount of Ajwa during their standard treatment
223503110|NCT04261595|BEHAVIORAL|behavioral modification and stimulation|Behavioral modification applied to the autistic children that is based on applied behavior analysis (ABA), a widely accepted approach that tracks a child's progress in improving his or her skills. We use Positive Behavioral and Support (PBS)
223503111|NCT04261595|OTHER|nutritional Guidance|The nutritional education sessions are based on educating parents on providing their autistic children with a nutritious, balanced diet. Because children with ASD often have restricted diets as well as difficulty sitting through meal times, they may not be getting all the nutrients they need, particularly calcium and protein
223503112|NCT05634928|OTHER|collection data|collection data
223503113|NCT04027946|DRUG|LMB-100|Participants will receive LMB-100 on days 1, 3 and 5 of a 21-day cycle for up to 2 cycles.
223503114|NCT04027946|DRUG|pembrolizumab|Participants will receive pembrolizumab on day 1 of each subsequent 21-day cycle.
223503115|NCT04027946|DIAGNOSTIC_TEST|Mesothelin Expression|Testing for mesothelin expression performed at screening
223503116|NCT04027946|DIAGNOSTIC_TEST|TrueSight Oncology 500|Testing for ROS oncogene 1 (ROS1) gene, anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR) variations performed at screening.
223503117|NCT03593629|COMBINATION_PRODUCT|6-month PrEP + blood-based HIV self-test|Participants receive 6-month PrEP supply plus two blood-based HIV self-tests (Atomo Diagnostics Blood-Based HIV-1 Self-Testing Kit) for quarterly HIV testing.
223503118|NCT03593629|COMBINATION_PRODUCT|6-month PrEP + oral fluid HIV self-test|Participants receive 6-month PrEP supply plus two oral fluid HIV self-tests (OraQuick Oral Fluid-based HIV-1 Self-Testing Kit) for quarterly HIV testing.
223503119|NCT01028053|DRUG|Flutemetamol (18F) Injection|All subjects will receive an i.v. dose of (18F) flutemetamol (less than 10 mg flutemetamol). The nominal activity of a single administration of (18F) flutemetamol will be 185 MBq.
223746659|NCT03491683|DRUG|Temozolomide|Temozolomide (TMZ) will be given daily during radiation therapy (RT) at a dose of 75 milligrams per square meter (mg/m\^2).
223746660|NCT03211949|PROCEDURE|axillary block|2 ml of scandicaine 1.5 % is deposited in an inplane technique around the medial antebrachial cutaneous nerve with a 22 G sonoplex needle as a surplus to an axillary block
223746661|NCT03211949|DRUG|Scandicaine|2 ml of scandicaine 1.5 % is deposited in an inplane technique around the medial antebrachial cutaneous nerve with a 22 G sonoplex needle as a surplus to an axillary block
223746662|NCT01343563|PROCEDURE|Trigeminal Nerve Stimulation|External trigeminal nerve stimulation (TNS) as an adjunctive treatment added onto antidepressant medications.
223503120|NCT04097912|DRUG|Acetylsalicylic Acid (Aspirin, BAYE4465)|75-100mg
223746663|NCT00630968|DRUG|Levetiracetam (Keppra)|
224194133|NCT01162993|PROCEDURE|Spinal Cord Stimulation|The intervention is spinal cord stimulation and will be used for 2 weeks trial stimulation. After clinical successful pain relief (≥50% relief of pain intensity on a weighted numeric rating scale (NRS) or a score of ≥6 on a seven-point Likert scale (1=very much worse; 7=very much improved) of the PGIC scale for pain and sleep) a definite spinal cord system will be implanted.
224194134|NCT06251765|OTHER|Clinical scores|Clinical scores will be administered to patients
224194135|NCT06251765|OTHER|Range of Motion|Evalutation of knee mobility
224194136|NCT02388906|DRUG|Ipilimumab|Specified dose on specified days
224194137|NCT02388906|DRUG|Nivolumab|Specified dose on specified days
224194138|NCT02388906|OTHER|Placebo matching Ipilimumab|Specified dose on specified days
224194139|NCT02388906|OTHER|Placebo matching Nivolumab|Specified dose on specified days
224194140|NCT04008121|COMBINATION_PRODUCT|Fluorescein sodium and Zeiss FF450 fundus camera|Fluorescein sodium administered as a bolus intravenous injection; Zeiss FF450 fundus camera used for imaging of the eye of all participants
223503121|NCT01763957|BEHAVIORAL|Paula Method|All subjects allocated to this group will receive one group lesson, 45 minute sessions once a week for twelve weeks. All will be encouraged to practice daily for 15-45 minutes at home. The teachers will be followed a set exercise list.
223503122|NCT01763957|BEHAVIORAL|Pelvic Floor Muscle Training (PFMT)|All subjects allocated to this group will receive one group lesson, 45 minute sessions once a week for twelve weeks. All will be encouraged to practice daily for 15-45 minutes at home. The teachers will be followed a set exercise list .
223503123|NCT03383939|DRUG|Group A|one nebulization with 250mg alpha-1-antitrypsine diluted in 10ml injectable solution once a day during 1 month. A CR-60 high flow compressor and Ventstream nebulizer were used for nebulization.
223503124|NCT03383939|DRUG|Group B|10ml of 0.9% NaCl saline solution nebulised once daily for 1 month. A CR-60 high flow compressor and Ventstream nebulizer were used for nebulization.
223503125|NCT03347539|DEVICE|Nexplaon|This study is an exploratory study of user reasons for Nexplanon implant and removal, and NOT a study on the efficacy or safety of Nexplanon. Nexplanon has already been FDA approved and its efficacy and safety studied.
223503126|NCT02346916|DRUG|Capsaicin|1 inch ribbon of Capzasin-HP 0.1% will be applied to the forearm for 30 minutes
223503127|NCT00003107|BIOLOGICAL|recombinant interleukin-12|
223503128|NCT00284648|PROCEDURE|Surgical repair Achilles tendon rupture|
223503129|NCT00284648|PROCEDURE|Non-surgical repair Achilles tendon rupture|
223503130|NCT02549378|DEVICE|confocal microscopy|microvessel diameter measured by confocal microscopy
223503131|NCT02296697|DEVICE|Low-level laser therapy AlGaInP|Pressure ulcers will be treated with AlGaInP 660 nm laser, wich will be used once a day, five days per week, dosed with 6 J/cm2. Laser therapy is applied punctually in each 1cm2 of the ulcer.
223503132|NCT02296697|DEVICE|High-frequency therapy with O3 formation|High-frequency laser therapy will be applied with spherical electrode, wich contains neon gas inside, from a short distance from the pressure ulcer. The application will last 15 minutes, with increasing intensity from 80 to 100% for ozone formation, once a day, five days per week.
223503133|NCT02296697|OTHER|Wound dressing with saline solution|Wound dressing will be done daily on patients from the three groups during the study period. On patients who will receive laser therapy and high frequency, the pressure ulcer will be sanitized with worm saline solution in order to clean the wound. This cleaning will be done before and after the interventions.
223503134|NCT03591419|DEVICE|polymer clip|polymer clips will be used to ligate the stump of appendix during appendectomy and time for application and cost of clips will be calculated
223503135|NCT03591419|DEVICE|endoloop|endoloop will be used to ligate the stump of appendix during appendectomy and time for application and cost of clips will be calculated
223503136|NCT01439334|BEHAVIORAL|MB-SBIRT (multiple behavior screening, brief intervention and referral to treatment) Online Program Brief|Online prevention program using positive images
223503137|NCT01439334|BEHAVIORAL|MB-SBIRT (multiple behavior screening, brief intervention and referral to treatment) Online Program Extended Length|Online Program Extended Length
223503138|NCT01439334|BEHAVIORAL|MB-SBIRT (multiple behavior screening, brief intervention and referral to treatment) Control|Control
223503139|NCT02083263|DEVICE|Bilevel|3 months
223503140|NCT02083263|DEVICE|PEP mask|3 months
223503141|NCT05373966|OTHER|Delphi Questionnaire|"An invitation email, including a link to the survey, will be sent to the panel of experts in the field of robotic RNU. The Delphi questionnaire will be administered via Welphi.com.~In the first survey, panel members will outline the training program for robotic RNU.~In subsequent surveys, the expert panel will evaluate the modified criteria using a 1 to 5-point Likert scale with space provided for suggested edits and comments. Multiple rounds will be conducted until consensus is reached. After each round of Likert responses, the study team will calculate the agreement and distribution of responses. Likert responses will be dichotomized with positive values indicating agreement and neutral or negative values indicating disagreement.~For the questions that do not reach a consensus of more than 80% in the first round or need further explanation, additional rounds of the survey may be performed."
223503142|NCT06218784|DRUG|iN1011-N17 HCl Suspension (Part 1)|Dose: 100 mg b.i.d for 7 days (Multiple Ascending Dose)
223503143|NCT06218784|DRUG|iN1011-N17 HCl Capsule (Part 1)|Dose: 200, 400, 800 mg b.i.d for 7 days (Multiple Ascending Dose)
223503144|NCT06218784|DRUG|Placebo Capsule (Part 1)|Dose: b.i.d for 7 days
224194141|NCT04008121|COMBINATION_PRODUCT|MB-102 and Zeiss FF450 fundus camera|MB-102 administered 3 days after fluorescein sodium as a bolus intravenous injection; Zeiss FF450 fundus camera used for imaging of the eye of all participants
224194142|NCT04008121|COMBINATION_PRODUCT|Fluorescein sodium and commercially available optical angiography imaging system|Following Zeiss FF450 imaging, one of two systems (Heidelberg Spectralis or Optos California or 200Tx) will be used for imaging of the eye in a subset of participants
224194143|NCT04008121|COMBINATION_PRODUCT|MB-102 and commercially available optical angiography imaging system|Following Zeiss FF450 imaging, one of two systems (Heidelberg Spectralis or Optos California or 200Tx) will be used for imaging of the eye in a subset of participants
223592458|NCT04059432|DIAGNOSTIC_TEST|Tooth Wear and Musculoskeletal Disorders evaluation|"Evaluation of dental wear by BEWE (Basic Erosive Wear Examination: score 0-3) examination and Musculoskeletal disorders are listed by the NORDIC questionnaire developed by Kuorinka et al. (2001)"
223592459|NCT03233438|DRUG|Dalbavancin|Dalbavancin administered as a single IV dose of 1500 mg over 30 minutes.
223592460|NCT03233438|DRUG|Usual Care|Usual care as prescribed by the physician as standard of care in clinical practice for the treatment of ABSSSI.
223592461|NCT03429543|DRUG|Metformin|At least 1000 mg/day or up to a maximal tolerated dose.
223592462|NCT03429543|DRUG|Insulin|Basal or multiple dose injection.
223592463|NCT03429543|DRUG|Placebo|1 film-coated tablet of either Linagliptin or Empagliflozin matched placebo once daily.
223592464|NCT03429543|DRUG|Linagliptin|1 film-coated tablet Linagliptin once daily, until end of treatment.
223592465|NCT03429543|DRUG|Empagliflozin|1 film-coated tablet of Empagliflozin once daily, until end of treatment.
223592466|NCT00036257|DRUG|CP-461|
223592467|NCT00100594|DRUG|Efavirenz|
223592468|NCT00100594|DRUG|Lamivudine/zidovudine|
223592469|NCT01818492|BIOLOGICAL|NI-0501|
223592470|NCT05890482|BEHAVIORAL|Islamic Trauma Healing|Manualized, lay-led psychosocial intervention
223592471|NCT03974295|BEHAVIORAL|Vaginal unprotected intercourse|Patients will allowed to engage in vaginal unprotected intercourse as many times as desired after 24 hours of pelvic rest after a frozen embryo transfer.
223592472|NCT05684185|BIOLOGICAL|Intramuscular (IM) rabies post-exposure prophylaxis|one-site, 0.5 mL at Day 0, D3, D7 and D14
223592473|NCT05684185|BIOLOGICAL|Intradermal (ID) rabies post-exposure prophylaxis|two-site, 0.1 mL at Day 0, D3 and D7
224194144|NCT02510417|BIOLOGICAL|VSTs|most closely HLA-matched multivirus-specific T cell lines obtained from a bank of allogeneic virus-specific T cell lines (VSTs) have antiviral activity against three viruses: EBV, CMV and adenovirus
224194145|NCT06636526|GENETIC|The i4i PRODICT™ test.|The i4i PRODICT™ test combining both common and rare genetic variants into one saliva-based DNA test to estimate a person's future risk of prostate cancer. This test will be offered to all participants in Part 1 of the study. Participants will be classified into high-risk or population risk based on the results of the i4i PRODICT™ test. Those classified as high-risk due to either falling within the high polygenic risk score category, and/or having a rare variant in a gene in the test will be offered targeted prostate cancer screening.
224194146|NCT06636526|OTHER|Prostate cancer screening|Prostate cancer screening in the form of PSA testing will be offered to all participants identified as high risk from the i4i PRODICT™ test for three years in order to track development of cancer in the future.
224194147|NCT06636526|PROCEDURE|MRI Scan|MRI scan will be offered to participants identified in the high-risk category of the i4i PRODICT™ test depending on their PSA test results. Where PSA is above age-specific threshold (\&gt;2.5ug/L for people with prostates (PwPs) aged 40-50 years and \&gt;3.5ug/L for PwPs aged 50-55 years), those with raised PSA levels will be referred for multiparametric MRI at The Royal Marsden Hospital.
224194148|NCT06636526|PROCEDURE|Prostate Biopsy|Transperineal prostate biopsy under local anaesthetic will be offered to to participants identified in the high-risk category of the i4i PRODICT™ test depending on their MRI results. Where a lesion is visible on MRI (defined as a PIRAD score ≥3) onward referral will be made for a transperineal targeted prostate biopsy (or current gold standard NHS practice).
223592474|NCT02945813|DRUG|Metformin|850mg PO BID; 48 weeks
223592475|NCT02945813|RADIATION|Salvage Radiotherapy SRT|SRT 35 x 2Gy; 7 weeks
223592476|NCT03298399|BIOLOGICAL|Autologous MSCs|Participants at dose level 1 receive four infusions of MSCs, given once per week. The first MSC infusion will be given no sooner than 4 hours after the bone marrow transplant. The total number of cells delivered to each patient will depend on their weight and assigned dose level. The maximal individual dose of MSCs any patient will receive is 2 x 10\^6 cells/kg, which will be delivered via intravenous infusion. The infusion can be administered to patients in the inpatient or outpatient setting.
223592477|NCT03298399|BIOLOGICAL|Autologous MSCs|Participants at dose level 2 receive four infusions of MSCs, given twice per week. The first MSC infusion will be given no sooner than 4 hours after the bone marrow transplant. The total number of cells delivered to each patient will depend on their weight and assigned dose level. The maximal individual dose of MSCs any patient will receive is 2 x 10\^6 cells/kg, which will be delivered via intravenous infusion. The infusion can be administered to patients in the inpatient or outpatient setting.
223592478|NCT03298399|BIOLOGICAL|Autologous MSCs|Participants at dose level 3 receive six infusions of MSCs, given twice per week. The first MSC infusion will be given no sooner than 4 hours after the bone marrow transplant. The total number of cells delivered to each patient will depend on their weight and assigned dose level. The maximal individual dose of MSCs any patient will receive is 2 x 10\^6 cells/kg, which will be delivered via intravenous infusion. The infusion can be administered to patients in the inpatient or outpatient setting.
223592479|NCT02702687|BEHAVIORAL|PEF Feedback|Intervention group will receive PEF feedback and verbal feedback sessions across 3 feedback visits and asthma education.
223592480|NCT02702687|BEHAVIORAL|Control Feedback|Control feedback group will receive feedback consisting of standardized messages and have 3 control feedback visits and asthma education.
223592481|NCT04940884|BEHAVIORAL|Supervised exercise training|SET Participants underwent 24 sessions of moderate-intensity exercise training (MICT) at 70% maximum predicted heart rate for 30 min in each session
223746664|NCT03525015|OTHER|A decision aid booklet about cataract surgery choice|Potential participants receive a decision aid booklet with information about cataract surgery choice, and outcome data will be gathered using standardized questions in a structured interview after 2 weeks and 1 year.
224194149|NCT05081531|RADIATION|Adaptive Radiotherapy|All the patients will be treated with VMAT technique in its RapidArc form. A simultaneous integrated boost (SIB) technique will be used. The GTV will encompass the tumor delineated on CT scan, adjusted for MRI and PET scans. Patients will be treated with a total dose of 66 Gy, 60 Gy and 54 Gy on PTV1, PTV2 and PTV3, respectively, delivered in 30 fractions, 5 fractions per week.
224194150|NCT05934591|BEHAVIORAL|Community Wise|The intervention received by each group will be Community Wise, a multi-level manualized behavioral intervention to decrease alcohol and substance misuse frequency
224194151|NCT04365387|DRUG|Nemolizumab|Nemolizumab was administered by 2 SC injections as 60-mg loading dose at baseline and a single 30-mg dose at Weeks 4, 8, and 12.
224314217|NCT05574608|BIOLOGICAL|CD123-CAR-NK cells|CD123-CAR-NK is an allogenic CD123-Targeted chimeric antigen receptor NK-cell (CAR-NK) therapy.
224194152|NCT04365387|DRUG|Placebo|Placebo was administered by 2 SC injections at baseline and a single dose at Weeks 4, 8, and 12.
224194153|NCT05770401|BEHAVIORAL|Internet-Behavioral Cough Suppression Therapy|Participants will access training modules to learn behavioral techniques and will implement them in daily life over a four-week period.
224194154|NCT05770401|BEHAVIORAL|Sham Treatment|Participants will access training modules to learn behavioral techniques and will implement them in daily life over a four-week period.
224194155|NCT05440942|DRUG|Trametinib|Trametinib will be administered orally once daily via tablet.
224314218|NCT00094861|DRUG|Palifermin|
224314219|NCT00094861|DRUG|Placebo|
224314220|NCT00094861|RADIATION|Radiotherapy|
224314221|NCT00094861|DRUG|Paclitaxel|
224314222|NCT00094861|DRUG|Carboplatin|
223503145|NCT06218784|DRUG|iN1011-N17 HCl Capsule (Part 2)|Dose: 400 mg QD
223503146|NCT06218784|DRUG|iN1011-N17 Mesylate Capsule (Part 2)|Dose: 400 mg QD
223503147|NCT06218784|DRUG|iN1011-N17 HCl Capsule (Part 3)|Dose: 400 mg b.i.d for 14 days
223503148|NCT06218784|DRUG|iN1011-N17 Mesylate Capsule (Part 3)|Dose: 400 mg b.i.d for 14 days
223503149|NCT06218784|DRUG|Placebo Capsule (Part 3)|Dose: b.i.d for 14 days
223503150|NCT01897389|DRUG|Treatment A|1000 mg abiraterone acetate (4 250-mg tablets - current commercial formulation, reference drug) administered as a single oral dose under fasted conditions
223503151|NCT01897389|DRUG|Treatment B|1000 mg abiraterone acetate (4 250-mg tablets - new formulation) administered as a single oral dose under fasted conditions
223503152|NCT01897389|DRUG|Treatment C|1000 mg abiraterone acetate (2 500-mg tablets - new formulation) administered as a single oral dose under fasted conditions
223503153|NCT01897389|DRUG|Treatment D|1000 mg abiraterone acetate (4 250-mg tablets - same composition as current commercial formulation) administered as a single oral dose under fasted conditions
223503154|NCT01897389|DRUG|Treatment E|1000 mg abiraterone acetate (2 500-mg tablets - same composition as current commercial formulation) administered as a single oral dose under fasted conditions
223503155|NCT02022527|DRUG|Acetyl Salicylic Acid|
223503156|NCT02022527|DRUG|Warfarin|
223503157|NCT02022527|DRUG|Placebo (for Aspirin)|Sugar pill manufactured to mimic 75 mg Aspirin
223503158|NCT03880890|PROCEDURE|sphenoidotomy versus sphenoid nasalisation|sphenoidotomy opening of sphenoid sinus ostum and cleaning of the sinus sphenoid nasalization in which bilateral extended sphenoidotomy, the posterior aspect of the nasal septum is resected, along with the sphenoid rostrum, the intersinus septum, and other intrasphenoid partitions, creating a common cavity with a broad drainage pathway .
223503159|NCT03736369|DRUG|DWP14012 40mg|DWP14012 40mg, tablet, orally, once daily for up to 8 weeks
223503160|NCT03736369|DRUG|DWP14012 40mg placebo|DWP14012 40mg placebo-matching tablet, orally, once daily for up to 8 weeks
223503161|NCT03736369|DRUG|Esomeprazole 40mg|Esomeprazole 40mg tablet, orally, once daily for up to 8 weeks
223503162|NCT03736369|DRUG|Esomeprazole 40mg placebo|Esomeprazole 40mg placebo-matching tablet, orally, once daily for up to 8 weeks
223503163|NCT01509924|OTHER|Physical activation on Prescription|The advice on physical activity is patient oriented and based on FYSS (FYSS is a information bank that summarizes the up-to-date scientific knowledge on how to prevent and treat various diseases and conditions using physical activity). An individual prescription on physical activity is issued. The prescription form reminds of an ordinary drug prescription and provides specified types of physical activities including intensity, frequency and duration of the respective activities. The prescribed physical activity could be either self-monitored or organized by public physical activity organizations.
223503164|NCT04094805|DRUG|Rocaltrol|Rocaltrol 0.25 μg daily for 1 month; HD-DXM (orally at 40 mg daily for 4d )
223503165|NCT04094805|DRUG|Dexamethasone|HD-DXM (orally at 40 mg daily for 4d )
223503166|NCT04393844|OTHER|turbo-ject PICC set|The turbo-ject PICC set, which will be used in this study, is the set for peripherally inserted central catheterization. In this study, we will see the difference according to the presence or absence of the hydrophilic coated stiffening obturator included in this turbo-ject PICC set.
223503167|NCT05137613|OTHER|One visit root canal retreatment|The teeth were treated in one-visit (OV) root canal retreatment. Final root canal irrigation was performed with 5% EDTA, followed by 2.5% NaOCl and received an additional final rinse with 2% CHX before obturation
223503168|NCT05137613|OTHER|Two visit root canal retreatment|The teeth were treated in two visit (TV) root canal retreatment. After completion of root canal instrumentation, calcium hydroxide (CH) paste was placed into the root canal. In second visit, all root canals were irrigated with 5% EDTA followed by 2.5% NaOCl before obturation.
223503169|NCT00983957|DRUG|BMS-790052|Tablets, Oral, 60 mg, once daily, 10 days
223503170|NCT00983957|DRUG|Ortho Tri-Cyclen®|Tablets, Oral, once daily, 78 days
223503171|NCT04553536|DRUG|Esketamine, Sulfentanil or/and Remifentanil|The esketamine or the opioids will be intravenously injected or infused to the patients with propofol and one of the muscle relaxants to induce and maitain general anesthesia.
223503172|NCT00986232|BIOLOGICAL|Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live|a single 0.5 mL subcutaneous injection of ProQuad (low, middle, or high dose) at Day 0 and Day 90
223503173|NCT00986232|BIOLOGICAL|Comparator: M-M-R II|A single 0.5 mL subcutaneous injection at Day 0
223503174|NCT00986232|BIOLOGICAL|Comparator: PUVV|A single 0.5 mL subcutaneous injection at Day 0
223503175|NCT03004092|PROCEDURE|blood sample|Twice weekly blood sample, and at every outpatient visit
223592482|NCT04940884|BEHAVIORAL|Aerobic exercise training|All recruited subjects were instructed to walk \>=8000 steps per day in the community. Part of the participants were randomly assigned to underwent additional 24 sessions of supervised aerobic exercise training (SET) with the intensity at 70% of maximum predicted heart rate and the remaining participants follow the above home exercise training (HET) instruction without additional supervised exercise training.
223592483|NCT03370562|DRUG|Dexmedetomidine|Administration of 10 mcg intravenous dexmedetomidine
223592484|NCT03370562|DRUG|Placebo|Administration of normal saline
223592485|NCT02625714|DRUG|Renexin®|Cilostazol 100mg/ginko biloba leaf extract 80mg, Immediate release, bid
223592486|NCT02625714|DRUG|SID142|Cilostazol 200mg/ginko biloba leaf extract 160mg, Controlled release, qd
223592487|NCT03028935|BEHAVIORAL|Exercise Intervention|Undergo instructor-led exercise program
223592488|NCT03028935|BEHAVIORAL|Nutritional Intervention|Undergo instructor-led nutritional education program
223592489|NCT04383275|DRUG|capecitabine and trastuzumab|In IRIS-A cohort, patients who met the inclusion criteria(ER，PR\<10%, T≤2cm or ER,PR ≥10% 1cm\<T≤2cm）would be given capecitabine for 6 cycles with standard trastuzumab for 1 year, in which HR+ patients would be given endocrine therapy for 5 years.
223592490|NCT04383275|DRUG|endocrine therapy and trastuzumab|In IRIS-B cohort, patients who met the inclusion criteria(ER,PR ≥10% T≤1cm) would be given endocrine therapy (premenopausal: tamoxifen or toremifene; postmenopausal: letrozole or anastrozole or exemestane) combined with standard trastuzumab for 1 year and complete endocrine therapy for 5 years.
223592491|NCT03125460|DEVICE|Xpert Bladder Cancer Monitor|in vitro diagnostic test for the recurrence of bladder cancer in patients that have been previously diagnosed with bladder cancer
223592492|NCT02325297|OTHER|Letter of condolence|
223592493|NCT01729208|DEVICE|Dual Focus Soft Contact Lens|
223592494|NCT01729208|DEVICE|Single Vision Soft Contact Lens|
223592495|NCT00828789|DRUG|Efavirenz; Tenofovir disoproxil fumarate; Telaprevir|
223592496|NCT01008124|OTHER|Liberatory Maneuver|3 cycles of the liberatory maneuver initial session.
223592497|NCT01008124|OTHER|Placebo maneuver|3 cycles placebo maneuver initial session.
224194156|NCT05440942|DRUG|Ruxolitinib|Ruxolitinib will be administered orally twice daily (BID) via tablet.
224194157|NCT05440942|DRUG|Retifanlimab|Retifanlimab will be administered intravenously (IV) on Day 8 of a 28-day cycle..
224194158|NCT06414148|DRUG|Epcoritamab|Epcoritamab will be administered as a 28-day cycle. In Cycle 1 and 2, epcoritamab will be given with step up dosing in Cycle 1. From Cycle 3 onwards dosing will be on Day 1 and 15 of each cycle.
224194159|NCT06414148|DRUG|Epcoritamab, lenalidomide and rituximab|"Treatment with epcoritamab will be administered following the same dosing schedule as Arm A. On days where rituximab and/or lenalidomide are also due, epcoritamab should be administered last.~Patients will receive lenalidomide once daily on Day 1-21 of each 28-day cycle, starting at Cycle 1 through to Cycle 6.~Patients will receive rituximab administered by intravenous (IV) infusion on Day 1, 8, 15 and 22 of Cycle 1 and on Day 1 only of Cycles 2-6."
224194160|NCT04884256|DRUG|CBT-004|Dose response study
224194161|NCT03804853|OTHER|Rehabilitiation|This study will be a non-blinded randomized controlled outcomes study evaluating outcomes at baseline, 2 weeks, 6 weeks, 3 months, 6 months, and 1 year post-operatively from a primary reverse total shoulder arthroplasty with two different post-operative physical rehabilitation protocols. There will be 2 groups, one undergoing the immediate active shoulder physical therapy protocol consisting of four quadrant stretches and full active motion of the shoulder from post op day 1 in the hospital. The second group will follow the traditional TRIA physical therapy protocol consisting of PT (standard of care) followed by a gradual return to active range of motion of the shoulder beginning by week 6, calling for 18 physical therapy visits. The physical therapy will occur where the patient is most comfortable receiving it.
223592498|NCT03821116|OTHER|Milk|Swedish milk from cow.
223592499|NCT03821116|OTHER|Soured milk (filmjölk)|Swedish soured milk (from cow milk).
223592500|NCT06307236|BEHAVIORAL|Emotional Freedom Techniques|Emotional Freedom Technique (EFT), which is included in the energy psychotherapy similar to the cognitive behavioral therapy method, is an easily applicable method that is used to relieve mental problems such as anxiety and stress and has positive results, which has just started to be used in the world and in our country. EFT can be applied safely to all ages and groups.
223592501|NCT03358134|DRUG|Secukinumab|anti IL17 therapy (subcutaneous)
223592502|NCT02424682|OTHER|No intervention|No intervention administered in this study
223592503|NCT05574465|DEVICE|High resolution solid state manometry|The use of esophageal manometry device during removal of endotracheal tube by anesthesia
223592504|NCT00317590|DEVICE|Rapid Diagnostic Test for Malaria (Paracheck®)|
223592505|NCT03249103|DRUG|NYX-2925|NYX-2925 is a novel small molecule that modulates the N-methyl-D-aspartate receptor (NMDAR).
223592506|NCT03249103|DRUG|Placebo oral capsule|Matching placebo capsules.
223592507|NCT01951313|OTHER|Egg consumption|Subjects will participate in 3 testing days (randomized, crossover design). Each day, the subject will consume a carefully portioned mix-vegetable salad without eggs (C, control); 75g (about 1½ eggs) scrambled whole egg (LE, low egg), and 150g (about 3 eggs) scrambled whole egg (HE, high egg). Prior to each testing day, subjects will consume a low-carotenoid diet for 7 days to reduce blood carotenoid concentration. In the testing day, blood collected every 60 minutes for 10 hours will be processed to analyze carotenoid and vitamin E concentrations. At the 5-h time point, subjects will be fed a low fat (\< 2g) and low carotenoid (\< 2000µg) meal as the 2nd meal.
223592508|NCT02428413|DEVICE|ISO-Gard Mask|to scavenge waste anesthetic gases from patients and provide supplemental oxygen
223592509|NCT02428413|DEVICE|Standard oxygen mask|Provide supplemental oxygen
223592510|NCT01469403|BEHAVIORAL|8 weeks weight loss program, Cambridge.|Fast weight losses improve the prognosis for the sustained weight loss. During the first week a dietitian will tutor the participants in formula food diet (The Cambridge Health and Weight plan UK.), followed by seven weeks with control guidance and instruction in healthy eating habits once a week. The guidance by the dietitian will be carried out both on an individual basis and in groups. The goal of the intervention is to achieve a preoperative weight loss of at least 5 to 10% of the patient's body weight, thus improving patient's health before surgery.
223592511|NCT05898230|DEVICE|Mitral Valve Replacement|Mitral Valve Replacement with Carbomedics OptiForm Mitral Heart Valve
223503176|NCT02245373|DRUG|Antidepressants|
223746665|NCT03525015|OTHER|An usual booklet about cataract and cataract surgery|Potential participants receive an usual booklet with information about cataract and cataract surgery, and outcome data will be gathered using standardized questions in a structured interview after 2 weeks and 1 year.
223746666|NCT05820932|GENETIC|Blood-based assay|Blood samples will be collected
223746667|NCT05820932|DIAGNOSTIC_TEST|Cognitive assessments|Cognitive assessments will be both participant- and partner-reported
223746668|NCT05820932|OTHER|Quality of Life Surveys|Participant-reported Quality of Life Surveys
223746669|NCT02296385|DIETARY_SUPPLEMENT|Triple Strength Fish Oil|Triple Strength Fish Oil
223746670|NCT06046729|DRUG|Eltrekibart|Administered SC
223746671|NCT06046729|DRUG|Placebo|Administered SC
223746672|NCT06285695|DEVICE|Clareon Toric IOL|Aspheric hydrophobic acrylic IOL placed in the capsular bag in the posterior chamber of the eye during cataract surgery for the visual correction of aphakia and preexisting corneal astigmatism
224194162|NCT00402298|DRUG|Full Dose Midomafetamine HCl|Participants will receive an initial dose of 125 mg midomafetamine HCl orally followed 2.5 hours later by 62.5 mg midomafetamine HCl orally during the course of a day-long therapy session.
224194163|NCT00402298|DRUG|Low Dose Midomafetamine HCl|Participants will receive an initial dose of 25 mg midomafetamine HCl orally followed 2.5 hours later by a supplemental dose of 12.5 mg midomafetamine HCl orally during the course of each of two day-long therapy sessions.
223746673|NCT06285695|PROCEDURE|Cataract surgery|Cataract extraction by phacoemulsification, followed by implantation with a Clareon Toric IOL
223746674|NCT02410954|DEVICE|NeuroConn Direct Current stimulator Multiple Channel -4|(tDCS) will be administered with a multichannel tDCS device that can be programmed so that the operator doesn't know the combination of electrodes being used for stimulation, and, thereby allow double-blinding. The active tDCS electrode configuration to be used will be determined with the 3 round iterative procedure described above; based on electric field modeling and personalized electrical dose titration to find the lowest dose that is well-tolerated and engages the target in terms of inhibiting the AOT pupillary response.
224194164|NCT05868135|BEHAVIORAL|eMeistring|Initial face-to-face visit, eight/nine sessions/modules of therapist guided ICBT, final face-to-face visit
224194165|NCT05043857|RADIATION|Stereotactic Body Radiotherapy (SBRT)|"Postoperative Stereotactic Body Radiation Therapy (SBRT) after tumor resection targeting 2 volumes~* CTV1 (clips+isotropic 5mm expansion, edited on anatomic barriers): receiving 40 Gy in 5 fractions of 8 Gy~* CTV2 (CTV1+ anisotropic 10-15 mm expansion including corresponding vessels, retroperitoneum posterior to the SMV/SMA or celiac axis, edited on anatomic barriers): receiving 30 Gy in 5 fractions of 6 Gy."
224194166|NCT04594772|DRUG|Folfirinox|Chemotherapy will begin with FOLFIRINOX - a standard regimen used in pancreatic cancer treatment, consisting of 5-fluorouracil (2400 mg/m2), irinotecan (180 mg/m2) and oxaliplatin (85 mg/m2). Treatment will continue for 2 cycles (4 doses), and then re-evaluation will be performed. If a decision to continue with FOLFIRINOX is made, it will be administered for another 4 cycles (8 doses).
223746675|NCT06544395|DEVICE|Non invasive neuromodulation therapy|"In the 4 studies, the intervention consisted of 15 sessions spread over 5 weeks.~Each intervention lasted 60 minutes. The intensity will be programmed in all sessions at Low, following the Arndt-Schulz law. The treatment was distributed in 3 phases: phase 1 of preparation, phase 2 to reduce fatigue and phase 3 to enhance autonomic improvement."
223746676|NCT06544395|OTHER|Manual therapy|Common manual therapy administered for said pathology by traditional physiotherapy and therapeutic exercise.
223746677|NCT06544395|DEVICE|Placebo with non invasive neuromodulation|"In the 4 studies, the intervention consisted of 15 sessions spread over 5 weeks.~Each intervention lasted 60 minutes. The treatment was carried out with the machine turned off."
224194167|NCT04594772|DRUG|Gemcitabine|At the first planned analysis, if a switch is indicated based on prespecified criteria , gemcitabine (1000 mg/m2) and nab-paclitaxel (125 mg/m2) - another standard regimen in this setting - will be used. It will be administered for 4 cycles (12 doses).
223503177|NCT02245373|OTHER|Active Monitoring|
223503178|NCT00113685|DRUG|Hypertonic Saline-Dextran Solution|
223503179|NCT00113685|DRUG|Lactated Ringer's Solution|
223503180|NCT00790933|DRUG|Vedolizumab|Vedolizumab intravenous infusion
223503181|NCT00349076|DRUG|5-FU and oxaliplatin|"Preoperative radiochemotherapy:~Oxaliplatin: 50 mg/m² i.v., days 1, 8, 22 und 29; 5-Fluorouracil: 250 mg/m²/d continuous infusion, days 1-14 and 22-35~Adjuvant Chemotherapy:~Oxaliplatin: 100 mg/m² i.v. on day 1; Calciumfolinate: 400 mg/m² on day 1; 5-Fluorouracil: 2400 mg/m² continuous infusion for 46 hours repeat day 15, 8 cycles"
223503182|NCT00349076|DRUG|5-FU|"Preoperative radiochemotherapy:~5-Fluorouracil: Days 1-5 and 29-33: 120h-continuous infusion 1000 mg/m²/d~Adjuvant Chemotherapy: 5-Fluorouracil: 500 mg/m² on 5 consecutive days (day 1-5) i.v. bolus fot 2-5 minutes; repeat day 29, 4 cycles"
223503183|NCT01155609|PROCEDURE|quality-of-life assessment|Ancillary studies
223503184|NCT01155609|PROCEDURE|management of therapy complications|Discontinue supplement; treat symptomatically
223503185|NCT01155609|DIETARY_SUPPLEMENT|L-lysine|Given PO
223503186|NCT04280861|OTHER|Multicomponent Intervention|Multicomponent intervention conducted by and expert psychologist that target different aspects of the caregiving experience (affective responses, communication skills, burden experience, social support and loneliness, cognitive performance, the practice of mindfulness and health-related behaviours). The number of sessions will be 8, 1 session of 90 minutes a week, and the number of participants will be 12-14 per group. In some sessions other collaborators will be invited to participate (social workers, physiotherapist).
223503187|NCT04080934|BEHAVIORAL|Swimming|Patients will participate in 8 weeks of the swimming program, which involves three weekly swimming sessions of 30 minutes minimum.
223503188|NCT00999206|BIOLOGICAL|Influenza Vaccine|surface antigen, inactivated, prepared in cell cultures
223503189|NCT00999206|BIOLOGICAL|Influenza Vaccine|surface antigen, inactivated, prepared in egg (influvac ®)
223503190|NCT00999206|BIOLOGICAL|Influenza Vaccine|surface antigen, inactivated, prepared in cell cultures
223503191|NCT00999206|BIOLOGICAL|Influenza Vaccine|surface antigen, inactivated, prepared in cell cultures
223503192|NCT03395990|PROCEDURE|Active comparator: chloroprocaine|15 ml of 2% chloroprocaine was placed under ultrasound guidance adjacent to the femoral nerve in the operative limb.
223746678|NCT00949325|DRUG|temsirolimus plus liposomal doxorubicin|Patients were treated with temsirolimus (Torisel) weekly by IV and with liposomal doxorubicin (Doxil) (standard dose) by IV once every 28 days. Cohorts of patients receive sequentially increasing dose of temsirolimus until dose limiting toxicity (DLT) occurred and the maximally tolerated dose (MTD) was identified. The MTD dose was the standard dose of temsirolimus used for the remainder of the study. Dose modifications were based on protocol parameters for toxicities.
223746679|NCT03273881|DRUG|glucose solution and Insulin|"Women in group 1, will receive intravenous saline solution boosted with 5% glucose combined with 8 units of insulin at a rate of 125mL/h. The desirable intrapartum glucose level will be 70 to 100 mg/dL. Glucose levels will be checked hourly.~Glucose level between 100-140 mg/dL will be treated with additional intravenous insulin, 1 units/hour.~Glucose level between 141-160 mg/dL will be treated with intravenous insulin, 2 units/hour. Additionally, the 5% glucose solution will be substitute with lactated Ringer's solution.~Glucose level between 161-200 mg/dL will be treated with intravenous insulin, 4 units/hour.~Glucose level above 200 mg/dL will be treated with intravenous insulin, 6 units/hour."
223746680|NCT03273881|DRUG|glucose solution only|Women in group 2, will receive intravenous saline solution boosted with 5% glucose only, at a rate of 125mL/h. Women in this group will be treated similar to group 1 if glucose levels crossed over 100 mg/dL.
223746681|NCT00574054|RADIATION|Far Infrared|Far infrared radiation (5 μm to 20 μm wavelength) for 30 to 40 minutes per treatment session.
224194168|NCT04594772|RADIATION|radiation therapy|Radiation therapy may be used prior to surgery, based on findings on the final pre-operative scan per standard of care. Radiation therapy will be delivered in patients with artery and venous involvement meeting the Intergroup definition for borderline resectable disease. Radiotherapy will be delivered via a hypofractionated approach over 10 fractions and will include target volumes to the primary tumor and elective coverage of vascular structures at risk. Radiation will be delivered with concurrent chemotherapy.
223746682|NCT02003131|BIOLOGICAL|Trophic factors from umbilical cord mesenchymal stem cells|
223746683|NCT00210821|DRUG|topiramate|
223746684|NCT01758653|OTHER|No study intervention|There is no study-related intervention.
223746685|NCT06468826|DRUG|Avacopan|Oral capsules
223746686|NCT00791518|DRUG|No intervention|No intervention
223746687|NCT00798109|BEHAVIORAL|Motivational therapy|One hour of motivational therapy each weak during 4 weeks
223746688|NCT00798109|BEHAVIORAL|Usual care|Patients received at least six hour of usual therapy, as in the experimental group
223746689|NCT04739007|PROCEDURE|Veno-arterial extracorporeal membrane oxygenation (VA-ECMO)|VA-ECMO used for resuscitation after cardiac arrest
223746690|NCT04739007|DEVICE|Electrical Impedance Tomography (EIT)|EIT used to demonstrate ventilation and perfusion distribution in intubated patients on VA-ECMO
223503193|NCT03395990|PROCEDURE|Sham comparator: saline|15 ml of normal saline was placed under ultrasound guidance adjacent to the femoral nerve in the operative limb.
223746691|NCT00387478|BIOLOGICAL|Tree MATA MPL or Tree MATA|"4 injections of increasing dose strength for Tree MATA MPL or Tree MATA:~1. 600 SU/0.5 ml~2. 1600 SU/0.5 ml~3. 4000 SU/0.5 ml~4. 4000 SU/0.6 ml~4 injections of 0.5 mL of 2% w/v L-tyrosine for Placebo"
223746692|NCT04898465|OTHER|Social Paediatric Intervention|Family will meet the hospital's social-paediatrician and social worker. Together they will evaluate the need for social support, risk for neglect and refer families for local social services if needed. The visit will contain primary and secondary prophylaxis of child abuse and neglect.
223503194|NCT00245570|DRUG|Comparator: Montelukast|1 dose montelukast 10 mg tablet given orally in one of three treatment periods
223503195|NCT00245570|DRUG|Comparator: Salmeterol|1 dose of 50 ug salmeterol given by inhalation in one of three treatment periods
223503196|NCT00245570|DRUG|Comparator: Placebo (montelukast)|1 dose matching-image placebo to montelukast tablet in two of three treatment periods
223503197|NCT00245570|DRUG|Comparator: Placebo (salmeterol)|1 dose matching-image placebo of salmeterol 50 ug inhalation in two of three treatment periods
223503198|NCT01829165|DEVICE|rTMS Treatment|MRI-compatible TMS stimulator
223503199|NCT01829165|DEVICE|Sham rTMS Treatment|
223503200|NCT06343883|DEVICE|low-intensity focused ultrasound - low pressure|low-intensity focused ultrasound applied to the S1.
223503201|NCT06343883|DEVICE|low-intensity focused ultrasound - medium pressure|low-intensity focused ultrasound applied to the S1.
223503202|NCT06343883|DEVICE|low-intensity focused ultrasound - high pressure|low-intensity focused ultrasound applied to the S1.
223503203|NCT05417256|DEVICE|Tappa Endobronchial Blocker|After intubation, the Tappa bronchial blocker will be advanced either through the intubation tube or outside the tube using a fiberoptic broncoscope. Once the position of the blocker is confirmed, the cuff of the blocker will be inflated with 1-3 mL of air. Since Tappa blocker has an autoinflation system, the anaesthetist can both inflate the cuff with one hand and operate the fiberoptic broncoscope at the same time.
223503204|NCT05417256|DEVICE|Arndt Endobronchial Blocker|After intubation, the endobronchial blocker will be passed through a multiport airway adapter that is placed at the proximal end of the tracheal tube.The fiberoptic broncoscope will be passed through the port and then through the guidewire loop at the end of the blocker. The bronchial blocker and the broncoscope will be advanced as a single unit into the target part of a right or left lung. The broncoscope will be withdrawn into the trachea and the blocker cuff will be inflated and the position of the blocker will be confirmed using the fiberoptic broncoscope. The wire loop will be removed after correct placement of the blocker. Once the guide wire is removed, the blocker can't be replaced.
223503205|NCT00937911|DRUG|YM150|oral
223503206|NCT03290729|PROCEDURE|wedge shape implants insertion|Narrow dental implants inserted in narrow ridges
223503207|NCT01272622|RADIATION|Radiation|Immediate irradiation after incomplete resection (fractionated, percutaneous irradiation, 54 gy)
223503208|NCT01272622|OTHER|wait and watch|wait ans watch, MRI controls, irradiation at the time of progression of residual tumor
223503209|NCT01033227|DRUG|sodium nitrite injection, usp|Sodium nitrite injection, USP will be administered in blocks of six subjects (3 sodium nitrite and 3 no drug). A total of five dose levels are planned, pending safety starting. Drug will be given by continuous infusion infusion for 48 hours starting at 6 nmol/min/kg (10% of the maximal tolerated dose).
223503210|NCT05509673|OTHER|Lipofilling (sublesional fat grafting)|
223746693|NCT01520363|DRUG|dextromethorphan|The DM group will take 5mg/kg/day orally in 2 divided doses 12 hours apart for the 3 month period of the study. The pharmacists will dispense the DM to the study participants.
223746694|NCT01520363|DRUG|placebo|The placebo will be dispensed to equal the volume of DM of 5mg/kg/day. It is taken orally in 2 divided doses 12 hours apart during the study period of 3 months. The Research pharmacist will dispense the placebo to the participants.
223746695|NCT04940299|BIOLOGICAL|Ipilimumab|Given IV
223746696|NCT04940299|BIOLOGICAL|Nivolumab|Given IV
224194169|NCT04594772|PROCEDURE|Pancreatectomy|Pancreatectomy should occur within 4 to 8 weeks after the last dose of preoperative chemotherapy. Staging laparoscopy may be performed at the time of planned laparotomy but is not required. Either standard or pylorus-preserving pancreaticoduodenectomy, distal subtotal pancreatectomy, or total pancreatectomy may be performed. Surgical drains and enteral tubes (e.g. gastrostomy and/or jejunostomy tubes) may be placed at the discretion of the operating surgeon.
223746697|NCT04940299|BIOLOGICAL|Tocilizumab|Given SC
223746698|NCT02889874|RADIATION|Omission of radiation therapy|Omission of radiation therapy (adjuvant endocrine therapy only).
223746699|NCT05268588|BEHAVIORAL|MESSSSAGE intervention|group mHealth education and social support intervention
223746700|NCT05334784|DEVICE|Impella ECP|Subjects will receive the Impella ECP prior to high-risk percutaneous intervention. Device escalation or early termination of the study will be allowed for subjects as deemed necessary by the treating physician. Subjects will be followed until 30-days post-intervention.
223746701|NCT06508333|BEHAVIORAL|alarm therapy|These patients will receive alarm therapy for 8 weeks.
224194170|NCT04486573|DIAGNOSTIC_TEST|Cardiac Magnetic Resonance Imaging|A cardiac MRI is a painless imaging test that uses radiowaves, magnets, and a computer to create detailed pictures of the heart.
224194171|NCT04785287|BIOLOGICAL|Anti-CTLA4 Monoclonal Antibody BMS-986218|Given IV
224310301|NCT02373189|DEVICE|Bright light|The purpose of this R34 Pilot and Feasibility study is to develop a morning bright light treatment to help manage chronic pain and improve PTSD symptoms, mood, and sleep in US veterans. Veterans will have 7 baseline days at home, followed by a baseline pain sensitivity assessment and baseline home circadian phase assessment (dim light melatonin onset). Following an instructional home visit, patients will then self-administer morning bright light treatment for 6 days, followed by reassessments of pain sensitivity and home circadian phase. This will be repeated after a further 7 days of morning bright light treatment. The Patient Reported Outcomes Measurement Information System (PROMIS) will also be administered at every lab visit. Additionally, pain and mood (electronic diaries) and sleep (wrist actigraphy) will be assessed daily throughout baseline and treatment. Pain, mood and sleep will also be self-reported daily during a 1 month follow up after cessation of light treatment.
224310302|NCT03596892|DRUG|Decitabine|Decitabine was administered at 20mg/m2/day on days -14 and -10.
223503211|NCT01881295|DIETARY_SUPPLEMENT|Placebo control|
223746702|NCT06508333|DRUG|Vitamin D3|These patients will receive high-dose vitamin D supplementation (more than 2000IU daily) (combined with alarm therapy) for 8 weeks.
223746703|NCT03353584|OTHER|Virtual Reality Therapy|The VR intervention consists of an interactive audio and visual underwater experience designed to serve as a calming distraction activity. The VR software (Kind VR® Aqua) was developed by KindVR specifically for the purpose of pain distraction in a hospital setting.
223746704|NCT05260463|DEVICE|Implantation|Fractures of the distal fibula are treated with a trauma implant.
223746705|NCT03962153|DIAGNOSTIC_TEST|Obstetric Ultrasonography|Obstetric Ultrasonography
223746706|NCT05729607|PROCEDURE|Vertical soft tissue augmentation|Vertical soft tissue augmentation with autogenous connective tissue graft (CTG)
224194172|NCT04785287|BIOLOGICAL|Nivolumab|Given IV
224194173|NCT04785287|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
224194174|NCT04214548|OTHER|No Intervention|There is no intervention for this study
224310303|NCT03596892|DRUG|Busulfan (BU)|Busulfan was administered at 3.2 mg/kg/day on days -7 to -4.
223503212|NCT01881295|DIETARY_SUPPLEMENT|Low dose potassium gluconate|
223503213|NCT01881295|DIETARY_SUPPLEMENT|Medium dose potassium gluconate|
223503214|NCT01881295|DIETARY_SUPPLEMENT|High dose potassium gluconate|
223503215|NCT01881295|DIETARY_SUPPLEMENT|Low dose potato|
223503216|NCT01881295|DIETARY_SUPPLEMENT|Medium dose potato|
223503217|NCT01881295|DIETARY_SUPPLEMENT|High dose potato|
223503218|NCT01881295|DIETARY_SUPPLEMENT|High dose French fries|
223503219|NCT01881295|DIETARY_SUPPLEMENT|Basal diet control|
223503220|NCT02142621|OTHER|transpyloric feeding|
223503221|NCT02142621|OTHER|gastric feeding|
223503222|NCT02740010|DEVICE|EDOF Mini WELL Ready IOL|implant
223503223|NCT03191201|DRUG|Ferric Carboxymaltose|Ferric Carboxymaltose 1000 mg iron element will be diluted in 250 mL of a commercially available sterile 0.9% sodium chloride solution.
223503224|NCT03191201|DRUG|0.9% sodium chloride solution|250 mL of a commercially available sterile 0.9% sodium chloride solution.
223503225|NCT02548364|DRUG|Calcifediol|calcifediol treatment
223503226|NCT02548364|DRUG|Placebo|placebo control group
223503227|NCT03648970|DRUG|Pravastatin|The participant will be given pravastatin 2 x 20 mg per oral daily
223503228|NCT01805570|DRUG|Prasugrel|25 patients with STEMI undergoing PPCI with bivalirudin (GP IIb/IIIa not allowed) will be randomized to receive Prasugrel before PPCI. The loading dose of Prasugrel will be 60 mg. The loading dose will be performed as soon as possible in the Emergency Room or in the Cath Lab. In the case of vomit in the first hour after drug loading dose a new reduced loading dose will be administered .
223503229|NCT01805570|DRUG|Ticagrelor|25 patients with STEMI undergoing PPCI with bivalirudin (GP IIb/IIIa not allowed) will be randomized to receive Ticagrelor before PPCI. The loading dose of Ticagrelor will be 360 mg. The loading dose will be performed as soon as possible in the Emergency Room or in the Cath Lab. In the case of vomit in the first hour after drug loading dose a new reduced loading dose will be administered .
223503230|NCT02002208|DRUG|OC000459|Oral CRTH2 antagonist
223503231|NCT03676725|DRUG|Lidocaine gel|Lidocaine gel (0.75 g premeasured dose of Septodont 5% oral gel NDC 0362-0221-10)
223503232|NCT01030575|DRUG|Inositol lower volume|5 mg/kg/dose inositol every 12 hours, given intravenously over 20 minutes
223503233|NCT01030575|DRUG|Inositol mid-level volume|20 mg/kg/dose inositol every 12 hours, given intravenously over 20 minutes
223592512|NCT04190797|DEVICE|Photobiomodulation + patiente controled anaethesia (PCA)|Patients in the immediate postoperateve of knee arthroplasty surgery treated with the Photobiomodulation device connected, 24h and 48h after the peripheral nerve block (femoral nerve and obturator nerve). With conventional analgesia and with the device of PCA.
223592513|NCT04190797|DEVICE|Placebo + patiente controled anaethesia (PCA)|Patients in the immediate postoperateve of knee arthroplasty surgery treated with the Photobiomodulation device switched off, in 24h and 48h after peripheral nerve bloc (femoral nerve and obturator nerve). With conventional analgesia and with the device of PCA.
223592514|NCT05490108|BIOLOGICAL|ZR202-CoV|SARS-CoV-2 adjuvanted recombinant protein vaccine (prototype)
223592515|NCT05490108|BIOLOGICAL|ZR202a-CoV|SARS-CoV-2 adjuvanted recombinant protein vaccine (variant)
223592516|NCT05490108|BIOLOGICAL|Comirnaty®|Comirnaty® (Pfizer-BioNTech)
223592517|NCT05755555|BEHAVIORAL|Visit a doctor|Test messages based on concepts from behavioural economics that aim to make information on screening more salient by using the concept of social proof (person like you) and an authoritative source (a diabetes specialist)
223592518|NCT05019391|DEVICE|transcranial doppler|it provides an accurate, noninvasive, and simple method for the diagnosis of VBI. Through the diagnosis results, it will be clear about the blood flow status of single vessel and vascular compliance, which is helpful for accurate reflection of the subtle changes of VBI
223592519|NCT05503888|DRUG|Almonertinib combined with SHR-1701|"Phase Ⅰb/Phase Ⅱ：~SHR-1701: injection, intravenous infusion~Almonertinib: tablets, oral"
223592520|NCT05503888|DRUG|Almonertinib|"Phase Ⅱ:~Almonertinib: tablets, oral"
223592521|NCT01286103|DRUG|Canagliflozin 300 mg once daily and 150 mg twice daily|Treatment A (one 300-mg tablet once daily for 5 days) followed 10 days later by Treatment B (one 50-mg and one 100-mg tablet twice daily for 5 days) or Treatment B followed by Treatment A.
223592522|NCT01286103|DRUG|Canagliflozin 100 mg once daily and 50 mg twice daily|Treatment C (one 100-mg tablet once daily for 5 days) followed 10 days later by Treatment D (one 50-mg tablet twice daily for 5 days) or Treatment D followed by Treatment C.
223592523|NCT02025439|DEVICE|rTMS|
223592524|NCT02025439|DRUG|Amantadine|
223592525|NCT04129385|PROCEDURE|20 degree Trendelenburg position|The patients in the intervention group will be placed in trendelenburg position postoperatively.
223592526|NCT01869660|BEHAVIORAL|Shared Decision Making|The focus of the SDM is to empower patients to discuss their attitudes and preferences toward treatments.
223592527|NCT00468975|DRUG|PF-610,355|
223592528|NCT00468975|DRUG|Salmeterol|
223592529|NCT00461461|PROCEDURE|meeting nurses / physicians, quality improvement sessions|"For each iatrogenic indicator, the interventions are:~1. Meeting with the ICU staff to discuss the epidemiology of patients on each theme.~2. Pocket card with guidelines on the theme and ICU protocol in each study ICU.~3. Feedback meeting twice a month on errors in the unit, preventability, and appropriate changes in procedures on the subject."
223592530|NCT01257607|DRUG|MIM-D3 Ophthalmic Solution|28 Days, BID
223592531|NCT01257607|DRUG|Placebo Ophthalmic Solution|28 Days, BID
223592532|NCT02073669|PROCEDURE|Answering the study Questionnaire and blood sampling for Interferon gamma release assay (IGRA)|
224194175|NCT06770049|BEHAVIORAL|Standard Lifestyle Intervention (SLI) program|Subjects will receive recommendations for calorie and macronutrient intake, physical activity, and behavioral skills to be followed for 12 months and will be delivered by a multidisciplinary team of obesity experts in a 12-month structured follow up. Participants will meet with a registered dietician as well as member of the study team to learn more about their intervention. Diets will be prescribed for each participant with a 30% calorie deficit calculated from measured REE. Macronutrient composition will be guided based on the patient preference. Participants will be prescribed 150 minutes of physical activity per week (spread across 4-5 days) and recommendations to reach 10,000 steps daily. During the first 12 weeks, participants will be scheduled a 12-week behavioral program focusing on self-monitoring and stimulus control using cognitive-behavioral approaches to promote adherence to diet and exercise prescriptions.
224310304|NCT03596892|DRUG|Cyclophosphamide (CY)|Cyclophosphamide was administered at 60 mg/kg/day on days -3 to -2.
223592533|NCT00559676|DRUG|capecitabine|
223592534|NCT00559676|DRUG|fluorouracil|
223592535|NCT00559676|DRUG|irinotecan hydrochloride|
223592536|NCT00559676|DRUG|leucovorin calcium|
223592537|NCT00559676|DRUG|oxaliplatin|
223592538|NCT00559676|OTHER|laboratory biomarker analysis|
223592539|NCT00559676|OTHER|pharmacological study|
223592540|NCT04288700|DRUG|oral propranolol|oral propranolol therapy at a dose of 1 mg/kg/d (Inderal 20 mg/5 mL) in three divided doses. If the child will tolerate the treatment with no side effects, therapy will continue in an outpatient clinic. Blood glucose level will be also measured in a periodic manner during therapy. The dose will be increased gradually to 2 mg/kg/d in three divided doses if there will be no adverse effects from the initial therapy.
223592541|NCT04288700|DRUG|Oral Captopril|A test dose of 0.1 mg kg) will be administered orally with pulse rate and blood pressure monitored at 0.5, 1 and 2 h and at each follow up. If the test dose is tolerated, captopril administration will start at 0.15 mg kg) per dose 8-hourly. Pulse rate and blood pressure will be monitored 4-hourly and doses will be withheld if hypotension is documented. After 24 h, the dose will be increased to 0.3 mg kg) per dose 8-hourly .
223592542|NCT04288700|DRUG|intralesional propranolol injection|intralesional propranolol injection 1 mg/mL
223592543|NCT04288700|DRUG|topical Timolol maleate 0.5% eye drops|To be Applied on the surface of the lesions three times daily
223592544|NCT01816555|DIETARY_SUPPLEMENT|Vitamin D|Subjects will be assigned to a dosage level between 600IU daily and 10,000IU daily depending on their age, weight and current vitamin D level
223592545|NCT01093066|DRUG|optimal TURB|The TURB will always try to be optically complete.
223592546|NCT00673283|DEVICE|bi-plane chest radiography|Bi-plane radiography of the thorax
223592547|NCT02195167|DRUG|Dasotraline 1 mg, 2 mg, 4 mg, 8 mg, 12 mg, 16 mg, 20 mg, 24 mg, 28 mg, 32 mg once daily|"Dasotraline 1 mg, 2 mg, 4 mg, 8 mg, 12 mg, 16 mg, 20 mg, 24 mg, 28 mg, 32 mg once daily. The planned dose for the first cohort is 1mg. There will be no more than a 2-fold increase in dose increase in dose between consecutive dose cohorts up to 8 mg, and dose cohorts beyond the 8 mg level will increment no more than 4mg. The maximum dose will not exceed 32mg. The language should precede the text that is currently there"
224194176|NCT06770049|BEHAVIORAL|Phenotype-tailored Lifestyle Intervention (PLI) program|Subjects will receive recommendations for calorie and macronutrient intake, physical activity, and behavioral skills to be followed for 12 months and will be delivered by a multidisciplinary team of obesity experts. The recommendations will be determined a priori to tailor for each obesity phenotype
224194177|NCT05637879|DRUG|Glecaprevir/pibrentasvir|Direct-acting antiviral, Food \& Drug Administration (FDA) approved for the treatment of hepatitis C viral infection
224194178|NCT05637879|OTHER|Placebo|Compounded, inactive pill equal in appearance to active study drug
224194179|NCT06806865|PROCEDURE|Periarticular nerve group block (PENG)|The pericapsular nerve group (PENG) block targets the nerves that supply the hip capsule. The continuous PENG block will be applied immediately after general anesthesia is given to the participants under ultrasound guidance. 30 ml of 0.25% bupivacaine will be used.
224194180|NCT06806865|PROCEDURE|Continuous supra-inguinal fascia iliaca compartment block (SIFICB)|The supra-inguinal fascia iliaca compartment block (SIFICB) targets the femoral, lateral femoral cutaneous, and obturator nerves. Under ultrasound guidance, 30 mL of 0.25% bupivacaine is administered, followed by catheter placement for continuous infusion at 5 mL/h.
224194181|NCT04119440|BIOLOGICAL|MVA-MERS-S_DF1 - Low Dose|Administrations of the low dose via the intramuscular route
224194182|NCT04119440|BIOLOGICAL|MVA-MERS-S_DF1 - High Dose|Administrations of the high dose via the intramuscular route
224194183|NCT04119440|OTHER|Placebo|Administrations of placebo via the intramuscular route
224194184|NCT05356182|OTHER|Diet|Control diet consisting of 20% protein, intervention diet consisting of 10% protein
224194185|NCT04741256|BEHAVIORAL|Education booklet & standardized discharge training|Tracheostomy education booklet and tracheostomy teaching performed by nurses during hospitalization as dictated by the booklet.
224194186|NCT00393783|BIOLOGICAL|MAB HER 2 (HERCEPTIN)|Rat HER2 DNA will be delivered intramuscularly at four different dose levels (0.5mg, 1mg, 3mg, or 6mg) during weeks 1, 4, 7, 10 and 13 for five injections.
224194187|NCT03328078|DRUG|Emavusertib|Emavusertib will be provided as a tablet dosage form to be taken BID.
224194188|NCT03328078|DRUG|Ibrutinib|Ibrutinib will be provided as a tablet or capsule dosage form to be taken QD.
224194189|NCT05658432|OTHER|Exercise via telehealth|Same as arm/group description
224194190|NCT05658432|OTHER|Exercise unsupervised|Same as arm/group description
224194191|NCT04469790|BEHAVIORAL|SIT+WALK|Participants will interrupt their sitting for one week
224194192|NCT04469790|BEHAVIORAL|EX|Participants will perform a single bout of exercise and then sit for the remaining time for one week
224194193|NCT04708717|BEHAVIORAL|Stimulation Rate|Psychophysical training listening to stimulation rate as a cue for auditory pitch perception. The intervention is the listening rehabilitative exercises. Exercises are completed daily as 30-minute sessions for 2 weeks.
224194194|NCT04708717|BEHAVIORAL|Electrode Location|Psychophysical training listening to electrode location as a cue for auditory pitch perception. The intervention is the listening rehabilitative exercises. Exercises are completed daily as 30-minute sessions for 2 weeks.
224310305|NCT02819050|DEVICE|NCPAP|Nasal Continuous Positive Airway Pressure
224310306|NCT01449448|DRUG|Ketorolac|Subacromial injection
223503234|NCT01030575|DRUG|Inositol high volume|40 mg/kg/dose inositol every 12 hours, given intravenously over 20 minutes
223503235|NCT01030575|DRUG|Placebo low volume|Glucose 5% given in volumes equal to that of the comparator drug
223503236|NCT03662971|DRUG|Germinal peptide eye drops|Germinal peptide eye drops of 0.0005%, 0.001%, 0.002%, 0.004% and 0.008%
223503237|NCT05696158|DEVICE|MHNA-003|MHNA-003 is a self-guided digital program for people living with tinnitus
223503238|NCT06531473|PROCEDURE|HoLEP|Patients will be randomized to one of the laser energy groups day of surgery.
223503239|NCT00489268|DEVICE|HALO Ablation System|"Phase I: 1-2 ablation visits; Phase II 1 to 12 months: 1-2 ablation visits; Phase II 12 to 30 months: 1-3 ablation visits Phase II 55-60 months: 0-1 ablation visit~\*\*\*\*\*\*Phase I was a dosimetry study and Phase II used the preferred dose. The same intervention was used for each dose."
223503240|NCT05560633|OTHER|No intervention|No intervention
223503241|NCT00283582|DRUG|rhTPO|
223503242|NCT02457286|DRUG|Metformin|Although metformin is FDA approved to treat type 2 diabetes, it is not FDA approved for the treatment of NAFLD and is considered investigational for the purpose of this study.
223503243|NCT02457286|BEHAVIORAL|Lifestyle modifications|Recommendations for lifestyle modification will be based on the Diabetes Prevention Program 2002 (26) and will include recommendations for greater than 150 minutes of physical activity weekly, referrals to group and/or individualized sessions with nutritionists and/or lifestyle coaches as well as educational materials
223503244|NCT02457286|DEVICE|Fibroscan device (Echosens)|This study will be incorporating the use of a Fibroscan device (Echosens) at the initial visit and upon completion of the study, which works by measuring shear wave velocity.
223503245|NCT05470725|DRUG|CIN-107|A single 10 mg CIN-107 oral dose (2 X 5 mg tablets).
223503246|NCT06237907|OTHER|Patients underwent lymphedema surgery|Patients who have developed lymphedema and undergone lymphedema surgery.
223503247|NCT06237907|OTHER|Patients underwent surgery without LVA|For patients who have not experienced lymphedema but require surgery due to other disease such as cancer, trauma, chronic wounds, skin defects, etc.
223503248|NCT04233580|DEVICE|Amnio Excel + weekly|Amnio Excel + weekly
223503249|NCT04233580|DEVICE|Amnio Excel + max every 2 weeks|Amnio Excel + max every 2 weeks
223503250|NCT02929121|DRUG|Doxycycline|Once daily tablet for 6 weeks: Doxycycline hyclate 200 mg per day x 6 weeks for patients \>50 kg or 100 mg per day for patients \<50 kg)
223503251|NCT02929121|DRUG|Placebo|Once daily tablet for 6 weeks: matching tablets containing no active ingredients
223503252|NCT01694394|DEVICE|Implantable Cardiac Monitor (Confirm ICM model 2102)|Patients who meet the study criteria will be implanted with a St. Jude Medical Confirm Implantable Cardiac Monitor (Confirm ICM) model 2102 or other St. Jude Medical ICM with the same capabilities.
223503253|NCT01492803|DIETARY_SUPPLEMENT|Probiotics|"Probiotic is a live microorganism that when administered in adequate amounts confer a health benefit on the host. It is classified by the FDA as generally recognized as safe (GRAS)"
223503254|NCT01492803|DIETARY_SUPPLEMENT|Placebo|The placebo sticks will contain approximately 1 g maltodextrin
223592548|NCT01026740|DRUG|Ceftobiprole|single intravenous (i.v.) infusion, 500 mg ceftobiprole administered over 2 hours.
223592549|NCT01009866|BIOLOGICAL|MR1-1|Based on preclinical toxicity studies, the starting total drug dose will be 0.5μg (500ng) which represents 1/20th of the MTD in rats. The infusion flow rate will be fixed at 0.5 mL/h from each of two catheters. A total of 96 mLs of drug solution will be delivered over 96 hours. MR1-1KDEL dose escalation will be accomplished by increasing drug concentration allowing flow rate and infusion volume to remain unchanged. Drug dose will be doubled in successive cohorts so long as DLTs are not observed as follows: 25 ng/mL (2.4 μg)(starting dose); 50ng/mL (4.8μg); 100 ng/mL (9.6μg); 200ng/mL (19.2μg); 400 ng/mL (38.4μg); 800 ng/mL (76.8μg); and 1600 ng/mL (153.6μg).
224194195|NCT05085236|PROCEDURE|Fu's subcutaneous needling (FSN)|physician will use a disposable Fu's subcutaneous needling (FSN) to penetrate the subject's skin in the middle from elbow lateral epicondyle to radial styloid process. Then physician will push forward the needle parallel to the skin surface. the physician will sway the needle 100 times in a minute. After procedure of swaying needle, the physician will instruct subject to do several movements, and each movement will perform 10 seconds and rest 10 seconds for 3 repetitions. The movements are active isometric elbow flexion, active isometric shoulder internal rotation, passive shoulder external and internal rotation. After above re-perfusion approach of muscles, the physician will take out the needle to finish the treatment.
224194196|NCT05085236|PROCEDURE|Rehabilitation|Rehabilitation mentioned here is the regular rehabilitation programs for treating post-stroke hemiplegic shoulder pain prescribed by the rehabilitation physician.
223503255|NCT01296113|DRUG|Chemotherapy|"Pemetrexed + Carboplatin~On D1 of a 21-day cycle:~* Pemetrexed 500 mg/m² IV in 10 minutes followed 30 minutes later by:~* Carboplatin AUC 5 in 30 minutes in 100 ml sterile water or 5% glucose or physiological serum. The carboplatin dose will be calculated by the Calvert formula with a target AUC of 5 mg/mL.min as follows:~Carboplatin dose in mg = 5 x (GFR + 25) GFR is estimated according to the MDRD equation for creatinine clearance~• 4 cycles total"
223503256|NCT02902315|OTHER|Cryotherapy|The intervention will consist of the application of hypothermia by immersion of the lower limbs of water on individuals to 15ºC for a period of 10 minutes immediately after the exercise protocol.
223503257|NCT02902315|OTHER|Vitamins C and E|The session of resistance exercises with intervention will be based on the supplementation with vitamin C (1000 mg) and vitamin E (800 IU) by oral intake (100mL of water) 40 minutes before basal blood collection.
223503258|NCT02902315|OTHER|Vitamins C and E associated with cryotherapy|The session of resistance exercises with intervention will be based on the supplementation with vitamin C (1000 mg) and vitamin E (800 IU) by oral intake (100mL of water) 40 minutes before basal blood collection. The intervention will consist of the application of hypothermia by immersion of the lower limbs of water on individuals to 15ºC for a period of 10 minutes immediately after the exercise protocol.
223503259|NCT02902315|OTHER|Placebo|The volunteers from placebo exercise session will receive two pills (containing wheat flour) and the remaining procedures were conserved.
223503260|NCT03954938|BEHAVIORAL|Craving Manipulation|Craving will be manipulated based on instructions about cocaine associated images shown to subjects.
223503261|NCT03954938|DRUG|Cocaine|The pharmacodynamic effects of cocaine will be determined based on the craving manipulation condition.
223503262|NCT03954938|DRUG|Placebo|The pharmacodynamic effects of placebo will be determined based on the craving manipulation condition.
223503263|NCT05099211|PROCEDURE|Muscle biopsies|"Optional~In pre-training:~Biopsy performed during the digestive surgery procedure~Final evaluation (minimum 1 day and maximum 7 days after the last training session): biopsy performed in the digestive surgery department."
223503264|NCT05099211|OTHER|Muscle Strengthening|3 sessions per week for 18 weeks. Duration: 1 hour Training on different strength training machines for the main muscle groups of the lower and upper limbs. The training load will be gradually increased over the sessions.
223592550|NCT04237246|DRUG|Tacrolimus|"24 hour long acting advegraf"
223592551|NCT03108508|DIETARY_SUPPLEMENT|Prod1|60 mL of product (water, silicic acid, Equisetum Arvense, Rosmarinus officinalis) (Silicic acid) equivalent to 21.6 mg of elemental silicon.
223592552|NCT03108508|DIETARY_SUPPLEMENT|Prod2|1.4 g of product (Orthosalicic acid) equivalent to 21.6 mg of elemental silicon
223503265|NCT05099211|BIOLOGICAL|Blood and urine samples|fasting blood sample taken at assessments 1, 2, 3 and 4 for patients and assessment 1 for controls
224194197|NCT06160414|DRUG|Metformin|Participants will receive Metformin orally, after fasting.
224194198|NCT06160414|DRUG|Rosuvastatin|Participants will receive Rosuvastatin orally, after fasting.
224194199|NCT06160414|DRUG|ALXN2080|Participants will receive ALXN2080 orally, after fasting.
223503266|NCT05099211|OTHER|Aerobic Training|"3 sessions per week for 18 weeks. Duration: 1 hour Training on a classic pedal bicycle (called an ergocycle). The intensity and duration of the training will be gradually increased over the sessions and according to the patient's abilities."
224310307|NCT01449448|DRUG|Triamcinolone|Subacromial Injection
223503267|NCT05099211|OTHER|Evaluation 1 pre-surgery|"Carried out at least 15 days before surgery~1. st visit:~   * Nutritional assessment~  * Body composition~  * Psychometric tests of quality of life + IPAQ Test~  * VO2pic~2. nd visit:~   * Neuromuscular tests~  * Functional tests"
223503268|NCT05099211|OTHER|Evaluation 2 post-surgery|"1. st visit:~   * Body composition~  * Nutritional assessment~  * Psychometric tests of quality of life~2. nd visit:~   * neuromuscular tests~  * Functional tests~  * Familiarization with training equipment if patient participates in re-training"
223503269|NCT05099211|OTHER|Intermediate Evaluation 3|performed 9 weeks after the beginning of training Identical tests to evaluation 1 + TM6
223592553|NCT03108508|DIETARY_SUPPLEMENT|Prod3|120 mL of product (Aloe barbadensis Miller, organic silicon, potassium sorbate, cítric acid) (Organic silicon) equivalent to 21.6 mg of elemental silicon
223592554|NCT03688100|BEHAVIORAL|Behavioral Activation Therapy|The therapy group will consist of an introductory in person 50-minute treatment session, followed by 12 weekly telephone 50-minute outpatient treatment sessions, then 3 monthly telephone 50-minute outpatient maintenance sessions. A typical BA session will last 50 minutes and include a review of the previous session and completed daily monitoring record forms, an in-depth discussion of life areas and value, and verbal reinforcement of activity engagement.
224310308|NCT03599492|DIAGNOSTIC_TEST|SMART Pill Pre-TIPS|Assessment of motility with Smart Pill, which will be read and confirmed by gastroenterologist trained to interpret motility studies
224194200|NCT05842122|BEHAVIORAL|Client-sustained delivery of pharmacy PrEP/PEP|"* Services delivered: 1) behavioral HIV risk assessment (+ counseling), 2) PrEP/PEP medical safety assessment, 3) HIV testing, and 4) PrEP (30-day supply at initiation; 90-day supply at refill visits) or PEP dispensing (28-day supply) among those determined eligible.~* Service provider(s): pharmacists or pharmaceutical technologist trained on PrEP/PEP service delivery~* Cost to client: 250 KES per pharmacy PrEP/PEP visit~* Payment to pharmacy:\* 0 KES per pharmacy PrEP/PEP visit \*Pharmacies paid by the research team (i.e., the implementer in this trial)"
224194201|NCT05842122|BEHAVIORAL|Implementor-sustained delivery of pharmacy PrEP/PEP|"* Services delivered: 1) behavioral HIV risk assessment (+ counseling), 2) PrEP/PEP medical safety assessment, 3) HIV testing, and 4) PrEP (30-day supply at initiation; 90-day supply at refill visits) or PEP dispensing (28-day supply) among those determined eligible.~* Service provider(s): pharmacists or pharmaceutical technologist trained on PrEP/PEP service delivery~* Cost to client: 0 KES per pharmacy PrEP/PEP visit~* Payment to pharmacy:\* 250 KES per pharmacy PrEP/PEP visit \*Pharmacies paid by the research team (i.e., the implementer in this trial)"
224194202|NCT05842122|BEHAVIORAL|Counselor-supported delivery of pharmacy PrEP/PEP|"* Services delivered: 1) behavioral HIV risk assessment (+ counseling), 2) PrEP/PEP medical safety assessment, 3) HIV testing, and 4) PrEP (30-day supply at initiation; 90-day supply at refill visits) or PEP dispensing (28-day supply) among those determined eligible.~* Service provider(s): pharmacists or pharmaceutical technologist trained on PrEP/PEP service delivery with support from a HTS counselor (to assist with screening and HIV testing)~* Cost to client: 0 KES per pharmacy PrEP/PEP visit~* Payment to pharmacy:\* 100 KES per pharmacy PrEP/PEP visit \*Pharmacies paid by the research team (i.e., the implementer in this trial)"
224194203|NCT05842122|BEHAVIORAL|Referral to clinic-based PrEP/PEP|"* Services delivered: 1) behavioral HIV risk assessment (+ counseling), 2) PrEP/PEP medical safety assessment, 3) referral to clinic-based PrEP/PEP services~* Service provider(s): pharmacists or pharmaceutical technologist trained on PrEP/PEP service delivery~* Cost to client: 0 KES per pharmacy PrEP/PEP referral~* Payment to pharmacy:\* 100 KES per pharmacy PrEP/PEP referral \*Pharmacies paid by the research team (i.e., the implementer in this trial)"
223503270|NCT05099211|OTHER|Final post-training evaluation 4|Tests identical to evaluation 1 + TM6
223503271|NCT04120324|OTHER|Eligible for Same Day Discharge|Preoperative Physiotherapy and Anesthesia Criteria met.
223503272|NCT04120324|PROCEDURE|Primary Single Joint Total Hip Arthroplasty|Total Hip Replacement Surgery
223503273|NCT04120324|OTHER|Discharge Same Day|Postoperative criteria for Same Day Discharge met.
223503274|NCT03514225|OTHER|Metacognitive Therapy for Social Anxiety|The transdiagnostic Metacognitive model posits that psychological disorder stems from the activation of a perseverative thinking style called the CAS (Cognitive Attentional Syndrome). This has 3 key elements: worry/rumination, threat-focussed attention and unhelpful coping behaviours. Each of these elements results in extended cognitive responses to negative thoughts, prolonging negative emotions and maintaining an individual's sense of threat. The CAS arises from an individual's positive and negative metacognitive beliefs (beliefs about cognition). Metacognitive Therapy (MCT) aims to bring the CAS under control by modifying metacognitive beliefs and enabling individuals to develop new reactions to negative thoughts.
223503275|NCT04151498|BEHAVIORAL|Reengagement and Assessment Mobile Program|Participants will participate in mobile clinic visit that will include an educational interview, adherence counseling, and standard blood draws for HIV reengagement. The goal of this intervention is to motivate participants to become reengaged in traditional HIV care by making an in person clinic appointment.
223503276|NCT04151498|OTHER|Qualitative Interview|Qualitative interview about barriers and facilitators to HIV care, and experience at most recent clinic visit.
223503277|NCT06012695|DRUG|NBM-BMX Capsule|Each capsule contains 100 mg of the active ingredient.
223503278|NCT06012695|DRUG|Temozolomide|TMZ will be administered orally at a 75 mg/m2 dose daily during concomitant therapy. In the maintenance period, days 1-5 of each cycle will be administered 150-200 mg/m2.
223503279|NCT06012695|RADIATION|Standard radiotherapy|A total dose of 60 Gy will be administered in 6 weeks.
223503280|NCT02421510|DRUG|Sotagliflozin|High dose Sotagliflozin, once daily, before the first meal of the day
223503281|NCT02421510|DRUG|Sotagliflozin|Low dose Sotagliflozin,once daily, before the first meal of the day
223503282|NCT02421510|DRUG|Placebo|Placebo, once daily, before the first meal of the day
223503283|NCT03752931|DRUG|Celiprolol|receiving 1 tablet per day of Celiprolol 200 mg in the morning from the first postoperative day after pneumonectomy or bi lobecomty for 2 weeks.
223503284|NCT03752931|DRUG|Diltiazem|receiving 1 tablet per day of Diltiazem 200 mg in the morning from the first postoperative day after pneumonectomy or bi lobecomty for 2 weeks.
223503285|NCT04406831|PROCEDURE|Blood draw|Individuals in the unresectable pancreatic cancer group will receive monthly blood draws. Individuals in the control group will receive one blood draw
223503286|NCT02489201|DRUG|donafenib tosilate tablets|200mg,bid
223503287|NCT00139516|BEHAVIORAL|self-help|
223503288|NCT00139516|DRUG|nicotine replacement therapy|
223503289|NCT00139516|BEHAVIORAL|smoking cessation|
223503290|NCT04126668|DRUG|CM082 with fed or fasting|The two groups of subjects were given an equal dose of CM082 tablet (200 mg) after a single cross-over fasting or high-fat high-calorie diet in two different test cycles to examine the effect of food on the pharmacokinetics of CM082.
223503291|NCT02845388|DRUG|Sildenafil citrate|
223503292|NCT02845388|DRUG|estradiol valerate|
223503293|NCT01381588|OTHER|Fracture evaluation|DEXA(Dual-energy X-ray absorptiometry), X-ray
223503294|NCT05970211|DEVICE|Phonak Audeo Lumity Receiver in Canal Hearing Aid|bilateral receiver in canal hearing aids provided as part of a best practices hearing loss intervention including devices, hearing centered counseling, and self management skills training for hearing loss
223503295|NCT00899847|PROCEDURE|Autologous peripheral blood stem cells (auto-PBSC) transplantation|"Auto-PBSC ≥ 2 to 3 x 10e6 CD34+ cells/kg are intravenously (IV) infused as part of the combination stem cell therapy.~and allogeneic stem cells are administered intravenous (IV) infusion to reestablish hematopoietic function in patients whose bone marrow or immune system is damaged or defective"
223503296|NCT00899847|PROCEDURE|Allogeneic peripheral blood stem cells (allo-PBSC) transplantation|Allo-PBSC (target collection ≥ 5 x 10e6 CD34+ cells/kg) are intravenously (IV) infused as part of the combination stem cell therapy.
223592555|NCT03688100|DRUG|Medication Management|Collaborative care model will be used. The medication management group will meet with the patient in a one 50 minute in person introductory antidepressant medication treatment session to educate the patient about depression and medication options. Patients will get prescribed a standard of care anti-depressant medication by treating physician, followed by 12 weekly follow up telephone visits, then on a monthly basis for 3 months, and then as needed thereafter.
224194204|NCT05743166|PROCEDURE|Bariatric surgery|JDF11 JDF41 JDF97
223503297|NCT00899847|DRUG|Filgrastim|"Filgrastim is administered subcutaneously (SC) at 10 µg/kg/day for auto-PBSC mobilization starting day 2 of mobilization until the last day of apheresis.~Filgrastim is administered SC at 5 µg/kg/day from Day 6 after auto-PBSC infusion to hematologic recovery.~Filgrastim is administered SC at 16 µg/kg/day for donor allo-PBSC mobilization at from Day - 4 to Day 0, prior to allo-PBSC collection."
223503298|NCT00899847|DRUG|Cyclophosphamide|Cyclophosphamide is administered intravenously (IV) at 4 g/m2 on Day 1 of the auto-PBSC mobilization regimen.
223503299|NCT00899847|DRUG|Melphalan|Melphalan is administered after CSP at 200 mg/m2 intravenously (IV) on Day -2 before auto-PBSC infusion.
223503300|NCT00899847|DRUG|Cyclosporine|Cyclosporine is administered by mouth (PO) for allo-PBSC graft vs host disease (GvHD) prophylaxis at 5 mg/kg from Day -3 through Bay +56. Tacrolimus may substituted.
223503301|NCT00899847|RADIATION|Total lymphoid irradiation|Total lymphoid irradiation is administered at 80 centigrey (cGy) on Day -11 to -7; and Day -4 to -2 before alllo-PBSC infusion. TLI is also administered at 80 centigrey (cGy) x 2 on Day -1 before alllo-PBSC infusion.
223503302|NCT00899847|BIOLOGICAL|Rabbit anti-thymocyte globulin|ATG 1.5 mg/kg is administered intravenously (IV) on Day -11 to -7 before allo-PBSC infusion.
223592556|NCT01786252|DRUG|human chorionic gonadotropin (hCG)|"500IU of hCG diluted to a final volume of 50ul in IVF media (Global-trademark)"
223592557|NCT01786252|DRUG|Placebo Comparator (for hCG)|"50ul of IVF medium (Global-trademark) to mimic hCG infusion"
223592558|NCT02345330|BIOLOGICAL|Tavokinogene Telseplasmid (tavo)|Patients received intratumoral injection(s) of tavo.
223592559|NCT02345330|DEVICE|OncoSec Medical System (OMS)|Electroporation via OMS was performed immediately following intratumoral injection of tavo. A sterile applicator containing 6 stainless steel electrodes arranged in a circle were placed around the tumor. The applicator was connected to the OMS power supply and six pulses were administered to each tumor lesion at the approximate point of tavo injection.
223592560|NCT00547027|BEHAVIORAL|print-based physical activity intervention|individually-based, print-based physical activity intervention
223592561|NCT00547027|BEHAVIORAL|usual care|print-based materials of nutritional information
223592562|NCT00005994|DRUG|ondansetron|
223503303|NCT00899847|DRUG|Mycophenolate Mofetil 250mg|MMF is administered at 15 mg/kg 3x/day by mouth (PO) after allo-PBSC through Day 40, followed by 10% dose reduction weekly (dose taper) through day 96, and adjusted if there is evidence of MMF-related GI toxicity or excessive myelosuppression
223503304|NCT00899847|DRUG|Solumedrol|Solumedrol 1 mg/kg is administered intravenously (IV) on Day -11 to -7 as a premedication for ATG and allo-PBSC infusion
223503305|NCT00899847|DRUG|Diphenhydramine|Diphenhydramine 25 to 50 mg is administered as a premedication for the ATG; allo-PBSC; and DLI infusions.
223592563|NCT00494507|DRUG|Dichlorphenamide (double-blind)|50mg tablet; maximum dosage 400mg/day
223592564|NCT00494507|DRUG|Placebo (double-blind)|Inactive substance manufactured to look like Dichlorphenamide 50mg tablet
223592565|NCT00494507|DRUG|Dichlorphenamide (open-label)|50mg tablet; maximum dosage 400mg/day
223592566|NCT03077204|BIOLOGICAL|1 or 2-Level ACDF utilizing BIO4 with Bio AVS Cervical Allograft (with graft window).|The study will utilize the BIO4 on label as a 361 HCT/P (human cell, tissue and cellular and tissue-based product) for homologous use for the repair, replacement or reconstruction of bone defects. Interbody fusion (1 or 2-level fusion) in conjunction with an allograft (hct/p) interbody spacer (anterior approach in the cervical spine with hardware). Investigators will also use the Aviator Anterior Cervical Plating System for anterior intervertebral screw fixation of the cervical spine at levels C2-T1. The Aviator Anterior Cervical Plating System is intended for use as an aid in cervical spinal fusion and is intended for unilateral fixation. The Aviator plates are intended to be used with the Aviator bone screws.
223592567|NCT03077204|DEVICE|Aviator Anterior Cervical Plating System|The study will utilize the BIO4 on label as a 361 HCT/P (human cell, tissue and cellular and tissue-based product) for homologous use for the repair, replacement or reconstruction of bone defects. Interbody fusion (1 or 2-level fusion) in conjunction with an allograft (hct/p) interbody spacer (anterior approach in the cervical spine with hardware). Investigators will also use the Aviator Anterior Cervical Plating System for anterior intervertebral screw fixation of the cervical spine at levels C2-T1. The Aviator Anterior Cervical Plating System is intended for use as an aid in cervical spinal fusion and is intended for unilateral fixation. The Aviator plates are intended to be used with the Aviator bone screws.
223592568|NCT04953624|DIAGNOSTIC_TEST|Appetite rating scale CNAQ|Chinese version of Appetite rating scale CNAQ
223592569|NCT03649204|BEHAVIORAL|HY-PAD|Hybrid intervention that includes supervised on-site and home-based components in people with PAD
223592570|NCT02437084|DRUG|Atorvastatin|Study subjects will receive atorvastatin 40 mg for 10 weeks.
223592571|NCT04738630|DRUG|HX008|200 mg administered as IV infusion on Day 1 of each 21-day cycle.
223503306|NCT00899847|DRUG|Acetaminophen|Acetaminophen 650 mg is administered as a premedication for the ATG and allo-PBSC infusions.
223592572|NCT03389737|BEHAVIORAL|Counseling|Counseling on healthy behaviors with in person meetings.
223592573|NCT03389737|BEHAVIORAL|Counseling|Counseling on healthy behaviors with emails.
224194205|NCT04784455|DRUG|nomacopan (rVA576)|The study population will consist of paediatric patients who have undergone allogeneic or autologous HSCT and develop HSCT-TMA within a year of HSCT
224194206|NCT03572283|DRUG|Bethanechol|Supplied as 50mg oral tablets. Take 2 tablets (total 100mg) twice daily from day 1 for a minimum of 1 week and a maximum of 4 weeks (or 2 days prior to scheduled surgery). Medication should be taken 1 hour before meals in the morning and the evening. Although bethanechol is FDA approved, in this study its use is experimental.
224194207|NCT04631510|DRUG|Gabapentin 300 mg PO at 8 PM|Administer gabapentin 300 mg PO at 8 PM for sleep
224194208|NCT05324449|DRUG|Cannabidiol 100 MG/ML|pharmaceutical grade cannabidiol
224194209|NCT05245292|DRUG|3BNC117-LS|Intravenous infusion of 3BNC117-LS at 30 mg/kg
224194210|NCT05245292|DRUG|10-1074-LS|Intravenous infusion of 10-1074-LS at 10 mg/kg
224194211|NCT05245292|DRUG|N803|Subcutaneous injections of N803 at 6 mcg/kg
224194212|NCT04150809|OTHER|No intervention|There is no intervention for this study
224194213|NCT05987891|DIAGNOSTIC_TEST|Treadmill exercise stress test|Ellestad protocol will be applied in all subjects up to fatigue and recovery will be monitored.
224194214|NCT04905589|DIETARY_SUPPLEMENT|BetaQuik™|MCT (Medium chain triglycerides)
224194215|NCT04905589|DIETARY_SUPPLEMENT|WheyBasics|Whey Protein Isolate
223503307|NCT00899847|DRUG|Hydrocortisone|Hydrocortisone 100 mg is administered intravenously (IV) is a premedication for the allo-PBSC and DLI infusions.
223503308|NCT06466772|BEHAVIORAL|Hyper-personalized feedback (HPF intervention)|For lower limb motor rehabilitation, the investigator will employ real-time continuous feedback for movement aspects that are specific to each participant's motor deficit. The feedback will be adapted and tailored to each participant.
223503309|NCT06466772|BEHAVIORAL|Targeted auditory stimulation during sleep (TASS verum intervention)|The investigator aim to reactivate rehabilitation- related memories through the presentation of auditory stimuli during sleep with the goal of promoting motor memory consolidation into stable motor commands
223503310|NCT06466772|BEHAVIORAL|Control targeted auditory stimulation during sleep (TASS sham intervention)|Identical auditory presentation during the motor rehabilitation training, but not during the night (sham promotion memory reactivation)
223503311|NCT03632330|DRUG|Dexmedetomidine|Dexmedetomidine group
223503312|NCT03632330|DRUG|Midazolam|Midazolam group
223592574|NCT00587847|DRUG|Campath|Campath 30 mg administered subcutaneously at varying intervals for up to 1 year
223592575|NCT06507384|OTHER|AI-Based Risk Assessment Model|Bukret AI Risk Assessment Model is a sophisticated decision support system that evaluates clinical data and patient history to generate personalized risk scores and classify patients into risk group categories for those undergoing plastic surgery. This AI model analyzes various risk factors, including BMI, age, smoking habits, and medical history, to identify potential complications. Based on the AI-generated risk group and specific risk factors, the model provides tailored recommendations for preoperative management, such as weight management, smoking cessation, blood pressure monitoring, and specialist consultations, to minimize surgical risks and improve outcomes. This intervention aims to enhance surgical planning and patient safety by offering personalized, actionable recommendations.
223592576|NCT04607460|DEVICE|JOGO Digital Therapeutics EMG Biofeedback for Lower Back Pain|Use of the JOGO Digital Therapeutics EMG Biofeedback device for 8 weeks with specific exercises to target low back pain.
223592577|NCT04607460|DEVICE|JOGO Digital Therapeutics EMG Biofeedback for Persistent Post Mastectomy Pain|Use of the JOGO Digital Therapeutics EMG Biofeedback device for 4 weeks with specific exercises to mitigate persistent post mastectomy pain ahead of the surgery.
223592578|NCT04607460|DEVICE|JOGO Digital Therapeutics EMG Biofeedback for Migraine|Use of the JOGO Digital Therapeutics EMG Biofeedback device for 6 weeks with specific exercises to target migraine pain.
223592579|NCT00487370|PROCEDURE|Implantation of gold beads around a knee through needles|
223592580|NCT00487370|PROCEDURE|Sham implantation: Insertion of needles around a knee|
223592581|NCT03324919|BEHAVIORAL|HRQL|Intervention of patient centered care situation and health-related quality of life of patients with Psoriasis, Urticaria or Lupus erythematodes from non-urban practices vs urban practises. Identification of relevant health-related quality of life parameters of these patients.
223592582|NCT04542720|PROCEDURE|Observational: Decompression|Patients will undergo decompression alone of the supradjacent level. The surgical technique will be surgeon dependent. All surgeons will be encouraged to avoid damaging facet joints above the fusion mass, retaining 50% of the pars of the decompressed level and performing as minimal of a medial facetectomy as necessary.
223592583|NCT04542720|PROCEDURE|Observational: Extension Fusion|Patients will undergo decompression and extension of posterior instrumentation and fusion. This may or may not include exchange of pre-existing instrumentation. The use of interbody cages will be left to the discretion of the treating surgeon. The purpose of introducing this heterogeneity is to increase the generalizability of the trial results. The fusion cohort will not utilize bone morphogenetic protein products.
223592584|NCT03729245|BIOLOGICAL|bempegaldesleukin|Specified dose on specified days
223592585|NCT03729245|DRUG|sunitinib|Specified dose on specified days
223592586|NCT03729245|BIOLOGICAL|nivolumab|Specified dose on specified days
223592587|NCT03729245|DRUG|cabozantinib|Specified dose on specified days
223746707|NCT05729607|PROCEDURE|Vertical soft tissue augmentation|Vertical soft tissue augmentation with acellular dermal matrix (ADM) and enamel matrix derivative (EMD)
223746708|NCT05874752|DIAGNOSTIC_TEST|Transthoracic echocardiography|noninvasive myocardial work
224194216|NCT04905589|OTHER|Iso-voluminous water|Iso-voluminous Water as comparitor to Betaquik or WheyBasics
224194217|NCT06279910|DRUG|Calcifediol|Calcifediol added as a treatment to the rest of the prescribed drugs of the protocol
224194218|NCT06433557|DRUG|Combination of Navepegritide and Lonapegsomatropin administered as two separate s.c. injections|For navepegritide, a once weekly s.c. dose of 100 μg CNP/kg. For lonapegsomatropin, a once weekly s.c. dose of lonapegsomatropin 0.30 mg hGH/kg as starting dose. Treatment duration of up to 156 weeks.
223503313|NCT03632330|DRUG|Propofol|Propofol group
223503314|NCT03632330|DRUG|Midazolam/Propofol|Midazolam/Propofol group
223503315|NCT02082093|DEVICE|Telemedicine System|
223503316|NCT01545466|BEHAVIORAL|Mindfulness Based Stress Reduction (MBSR)|MBSR involves 8 weekly 2 hour classes and one 4-6 hour retreat after the 6th class
223503317|NCT01926535|PROCEDURE|Implant of amniotic membrane grafts|Amniotic membrane grafts were implanted in the affected eyes using topical anesthesia. Each graft was sutured to the bulbar conjunctive tissue using 10-0 nylon sutures and a reinforcement stitch was applied at the cornea
224194219|NCT05265975|DRUG|ATG-010|Tablets,20mg, once a week: dosage group 1:40mg/time, dosage group 2:60mg/time, dosage group 3:80mg/time The treatment period was 28 days. The drug was administered on day 1,8 and 15 of each cycle
224194220|NCT05265975|DRUG|Lenalidomide|Oral administration,QD, Days 1-21 of each cycle
224194221|NCT05265975|DRUG|Rituximab|Intravenous injection Days 1 of each cycle, Cycles 1-6
224194222|NCT06545552|DIETARY_SUPPLEMENT|An oral formulation of green tea extract, bamboo shoot extract and selenium-enriched yeast|Hard shell capsule containing 280mg of the oral formulation
224194223|NCT06545552|DIETARY_SUPPLEMENT|Placebo|Hard shell capsule containing maltodextrine
224194224|NCT05970848|DEVICE|Washing Pipe With a Spray Nozzle|Administration of topical airway anesthesia via a washing pipe with a spray nozzle using the spray-as-you-go technique
224194225|NCT05479708|DEVICE|ctDNA-based MRD detection|Postoperative circulating tumor DNA (ctDNA)-based minimal residual disease (MRD) detection for predicting relapse and survival benefit
224194226|NCT05517122|DIETARY_SUPPLEMENT|Nicotinamide (NAM)|500 mg a day
224310309|NCT03599492|DIAGNOSTIC_TEST|SMART Pill Post TIPS|Assessment of motility with Smart Pill, which will be read and confirmed by gastroenterologist trained to interpret motility studies
224310310|NCT02828241|DRUG|DFD-04 Ointment|
224310311|NCT02828241|OTHER|Placebo Ointment|
224310312|NCT06634251|OTHER|No intervention|This study is purely observational and does not involve any direct intervention. It utilizes retrospective analysis of computed tomography (CT) scans to simulate the fluoroscopic visualization and screw placement technique in the anterior column fixation corridor (ACFC) of the acetabulum. The objective is to define the optimal antegrade entry point and assess anatomical parameters without performing any physical intervention on the participants.
224310313|NCT03849183|DRUG|Nitroglycerin|Subcutaneous nitroglycerin injection to increase the first attempt success rate of radial artery cannulation in pediatric patients
224310314|NCT03849183|DRUG|Normal saline|Subcutaneous normal saline injection to increase the first attempt success rate of radial artery cannulation in pediatric patients
223503318|NCT01926535|DEVICE|Therapeutic contact lenses|Therapeutic contact lenses were applied in all patients included in the control group and the lenses were replaced every two months according to the pre-established gold standard for this procedure.
223503319|NCT05852210|OTHER|Infrared Imaging|This study will use thermal forward looking infrared (FLIR) imaging to assess the severity of Complex Regional Pain Syndrome in newly diagnosed patients.
223503320|NCT03896217|DRUG|Simvastatin|Simvastatin 40mg for first 4 weeks and 80mg (if tolerated) thereafter up to 17 weeks
223503321|NCT05498207|BEHAVIORAL|Maya App|Participants will utilize the Maya App for at least 20 minutes per day, 2 days per week, for 6 weeks. Additionally, participants will complete assessments at baseline, 3 months, 6 months, 9 months and 12 months (this includes specimen collections, interviews, and surveys). Participants will also be asked to wear a Fitbit for 12 months.
224194227|NCT05517122|DIETARY_SUPPLEMENT|Nicotinamide Riboside (NR)|1000 mg a day
224194228|NCT05517122|DIETARY_SUPPLEMENT|Nicotinamide Mono Nucleotide (NMN)|1000 mg a day
224194229|NCT05517122|DIETARY_SUPPLEMENT|Microcrystalline cellulose|500 mg a day
224194230|NCT05295888|DEVICE|Temporal Interference stimulation|TI involves simultaneous delivery of independent currents to the brain at slightly different kHz frequencies, which are individually too high to recruit neural firing. However, the difference ('beat') frequency where the currents overlap (i.e., temporally interfered) is low enough to drive neural activity. The interferometrically derived low frequencies have been demonstrated to activate neurons at a selected focus without activation of surrounding regions in awake mice. The safety of the TI paradigm has been demonstrated in over 60 healthy human volunteers, and finite element modeling of simulations of TI fields in human anatomical models suggests that large subcortical structures such as the hippocampus or SCC could be selectively targeted. However, the precise TI parameters for selective engagement of SCC in healthy participants and in MDD is currently unknown.
224194231|NCT05295888|DEVICE|Sham stimulation|Electrodes will be placed in the same location on the head as that for the TI intervention; 0 mA of electrical current will be delivered to the brain (compared to 2 mA in the active intervention arm), therefore it is expected to elicit no changes in neural activity.
224194232|NCT00147290|DEVICE|Implantable Cardiac Defibrillator|Implantable cardiac defibrillator with programmable Fast Ventricular tachycardia detection (FVT) window
224194233|NCT06446765|BEHAVIORAL|mindfulness-based Neurofeedback|Participants will complete one session of mindfulness-based fMRI neurofeedback prior to 20 weeks of remote online weekly DBT skills group.
224194234|NCT06446765|OTHER|control Neurofeedback|Participants will complete one session of control fMRI neurofeedback prior to 20 weeks of remote online weekly DBT skills group.
224310315|NCT02542553|PROCEDURE|Bilateral BAL|
224310316|NCT06016491|BEHAVIORAL|acupressure|Depending on the preparation and compression time on each point, an average of 10 minutes was applied to each woman, and then the person were asked to apply it to themselves. After making sure that the women learned, they were asked to apply acupressure on their own. They applied a total of 12 sessions, three times a week for a total of four weeks.
224310317|NCT06016491|BEHAVIORAL|Sham acupressure|Compression was applied on the bone region where the meridians did not pass, parallel to the KD1 and SP6 points (approximately 1-1.5 cm away). Similar to the acupressure group, the sham group was treated with symmetrical extremities and for similar durati
223503322|NCT06284304|RADIATION|De-escalated radiotherapy|5 fraction de-escalated dose SBRT protocol
223503323|NCT05114798|BEHAVIORAL|Time restricted eating|daily ad libitum food intake, 8-h 12pm - 8pm, 6 m active weight loss phase; 10-h 10am-8pm, 6 m maintenance phase
223503324|NCT05114798|BEHAVIORAL|Calorie Restriction|daily 25% calorie restriction, 6 m active weight loss phase; 100% energy needs, 6 m maintenance phase
223503325|NCT05169268|DRUG|ARIPiprazole Injection [Abilify]|subject already receiving the combination of Abilify Maintena and Rexulti
223503326|NCT05169268|DRUG|Brexpiprazole|subject already receiving the combination of Abilify Maintena and Rexulti
223503327|NCT05821829|DEVICE|Intravascular litothripsy (IVL)|endovascular treatment of primary common femoral artery atherosclerotic disease with intravascular litothripsy
223503328|NCT05452226|DEVICE|neuromuscular electrical stimulation (NMES)|Electrical stimulation will be applied using two adhesive pads affixed to the front of both of the thighs. The intensity will be progressively increased to a level that provokes a strong contraction. The stimulation intensity will be increased until the stimulation is uncomfortable, but does not hurt. Care will be taken to make sure that the level of stimulation will be adjusted such that the intensity does not cause pain. Contractions will last 10 seconds, with 30 seconds of rest between. NMES will occur 6 days per week for 60 minutes per day. Patients will self-administer NMES 6 days per week after discharge for up to 6 weeks.
223503329|NCT00724893|BIOLOGICAL|PegIFN-2b|PegIFN-2b powder for solution adminstered subcutaneously using the newly approved Redipen. Dosing per approved labeling
224194235|NCT03210545|DRUG|Betamethasone|A cross-over study where patients with Addison´s disease will undergo two treatment periods where their usual hydrocortisone replacement therapy will be replaced by the glucocorticoid betamethasone in physiological and supra physiological doses. A wash-out period of 2-5 weeks in-between the treatment periods will be carried out where participants intake their usual hydrocortisone replacement therapy.
224194236|NCT05792852|BEHAVIORAL|ENGAGE|ENGAGE is a group intervention designed to improve social participation within the context of the COVID-19 pandemic.
224194237|NCT05363397|DRUG|TBO-309|TBO-309 is a potent, selective and ATP competitive PI3Kβ inhibitor which blocks platelet activation adhesion/aggregation and promotes platelet disaggregation, thereby specifically inhibiting thrombosis without interfering with normal haemostasis.
224194238|NCT04114955|BEHAVIORAL|Manas por Manas|Manas for Manas works at both the group- and individual-levels to increase self-care and reduce the negative health impacts of stigma, including: 1) a group-level, peer-led intervention, which first demonstrated efficacy with trans women in the US as 'Sheroes' and has been successfully adapted for Brazil, and 2) an individual-level peer navigation program.
223503330|NCT00724893|DRUG|Ribavirin|Ribavirin capsules administered orally. Dosing in accordance with approved labelling.
223503331|NCT03489525|BIOLOGICAL|Dose Escalation, MEDI2228, ADC (antibody drug conjugate)|Single agent MEDI2228 will be administered to adult subjects with R/R MM. The study aims to evaluate up to 9 planned, sequentially ascending main dose levels
223503332|NCT03489525|BIOLOGICAL|Dose Expansion, MEDI2228, ADC (antibody drug conjugate)|Adult subjects with R/R MM with measurable disease will be enrolled in the dose-expansion cohort at the dose selected for evaluation in the dose-expansion phase.
223503333|NCT04694885|BEHAVIORAL|Structured Hypnotherapy|"The Intervention includes 10 structured hypnotherapy sessions lasting 45 to 60 minutes. During hypnosis, patients reach a trance-like state comparable to a deep relaxation. The therapist guides the patient verbally and also communicates with the patient.~Patients will be supported to use their own imagination without suggesting any imagery. By repeatedly asking what the patient is perceiving, and by verbally repeating what the patient is saying, the therapist can help the patient to go deeper into trance. In these trance states the patient learns to reduce negative side effects of the chemotherapy and increase the quality of life by activating both physical and mental resources using imagination and focusing on positive memories and feelings."
223503334|NCT02147080|BEHAVIORAL|UV4me|Tailored website includes: personalized responses to quizzes, information on skin type and burn risk, UV damage photo of similar individual, avatar activity, age progression images, personal risk calculator, SPF (sun protection factor) calculator
223503335|NCT02147080|BEHAVIORAL|Skin Cancer Foundation website|Current best practice website for skin cancer and prevention. Includes information, images, news, and opportunities for advocacy.
223503336|NCT01104337|DRUG|paracetamol|Treatment consisted of two paracetamol 500mg (Doliprane® 500mg, Sanofi-aventis, Paris, France) tablets twice a day along with two matching placebo tablets once daily
223503337|NCT01104337|DRUG|paracetamol|Treatment consisted of two paracetamol 500mg (Doliprane® 500mg, Sanofi-aventis, Paris, France) tablets three times a day
223503338|NCT01104337|DRUG|Placebo|Treatment consisted of two matching placebo tablets three times a day.
223503339|NCT06495944|DRUG|Dazucorilant|75 mg soft gelatin capsules formulation for oral administration
223503340|NCT06495944|DRUG|Itraconazole|100 mg capsules for oral administration
223503341|NCT05066217|DRUG|Clemizole HCl|Clemizole HCl will be administered as an oral solution.
223746709|NCT05400928|DEVICE|Pulsed Field Ablation|pulmonary vein isolation will be performed with ring-shaped pulsed field ablation catheter directed by integrated three-dimensional mapping system
223746710|NCT06212219|BEHAVIORAL|Neurofeedback procedure|Personalized NF will consist of adding to these motor imagery tasks, personalized aspects depending on the patient's profile, for example in terms of level of support and emotional support (addition of a relaxation exercise using an audio recording at the start of training - and in the middle of training if necessary, adding the presence of a companion is to provide social presence and emotional support, depending on the user's performance and progress.), of the virtual environment.
224194239|NCT05733520|BEHAVIORAL|Brain CareNotes|The Brain CareNotes mobile telehealth app is used by unpaid caregivers for BPSD management. It includes remote communication with an external human support person-a care coach-as well as features for users to independently perform health-related activities.
224194240|NCT05733520|BEHAVIORAL|Dementia Guide Expert|"Dementia Guide Expert provides education only and no interactive BPSD management support, coaching, assessment, or external response. It contains evidence-based expert information on what dementia is, types, contributing factors, risks, symptoms, stages, diagnosis, tests, treatment, management, communication techniques, and links to resources and support services."
224194241|NCT05793489|OTHER|Silibinin|"WBRT will be concomitant to Silibinin. Silibinin at dose of 500 mg must be administrated twice a day for the first month, after once a day continuously.~Total dose and fractionation of WBRT: 30 Gy in 10 fractions."
223503342|NCT05066217|DRUG|Placebo|Placebo will be administered as an oral solution.
223503343|NCT04246476|BEHAVIORAL|Mentally singing|All participants (people with PD and age-matched controls) sing their song in their head and match their footfalls or finger tapping to the beat.
223503344|NCT04246476|BEHAVIORAL|Listening to music|All participants (people with PD and age-matched controls) listen to their song and match their footfalls or finger tapping to the beat.
224194242|NCT04099979|OTHER|No Intervention|There is no intervention for this study
224194243|NCT06339203|DEVICE|Irrisept|450ml low concentration (0.05%) Chlorhexidine Gluconate (CHG) in 99.95% Sterile Water
224194244|NCT06339203|DRUG|Normal Saline|450mL
223503345|NCT06306183|DIETARY_SUPPLEMENT|Acetaminophen and Vitamin C with Naproxen rescue|"900 mg vitamin C taken orally twice a day (one in the morning and one in the evening) for a 7-day period after ED discharge for the treatment arm used in combination with extended-release acetaminophen 650 mg two pills every eight hours regularly.~Naproxen 500mg as rescue medication if still in pain 60 minutes after treatment with acetaminophen."
223503346|NCT06306183|OTHER|Acetaminophen and Placebo with Naproxen rescue|"Placebo taken orally twice a day (one in the morning and one in the evening) for a 7-day period after ED discharge for the treatment arm used in combination with extended-release acetaminophen 650 mg two pills every eight hours regularly.~Naproxen 500mg as rescue medication if still in pain 60 minutes after treatment with acetaminophen."
224194245|NCT06017713|BEHAVIORAL|tDCS + symptoms provocation|The treatment consists of 10 sessions of tDCS. Each tDCS session lasts 30 minutes at an intensity of 2mA and is preceded by a provocation of symptoms.
224194246|NCT05660070|BEHAVIORAL|mobile Social Interaction Therapy by Exposure (mSITE)|mSITE is a blended intervention that integrates brief in-person psychotherapy with context-triggered mobile smartphone intervention and remote telephone coaching.
224194247|NCT05762276|DRUG|VXX-401|A synthetic PCSK9 peptide-based immunotherapy
224194248|NCT05762276|BIOLOGICAL|Placebo|Normal saline
224194249|NCT04298229|DRUG|Dapagliflozin 10 MG|SGLT2 inhibitors being investigated for its diuretic and natriuretic effects on top of protocolized diuretic therapy.
224194250|NCT04298229|OTHER|Protocolized Diuretic Therapy|Structured usual care arm with protocolized diuretic therapy based on urine output.
224194251|NCT00618046|DRUG|Oxcarbazepine|
224310318|NCT02990780|RADIATION|Conventionally fractionated concurrent chemo-radiotherapy|5Fx/W,2Gy/Fx,Dt:PTV-G:60Gy/30F/6W.
223503347|NCT03713580|DRUG|Venetoclax|"Adding Venetoclax, a BCL-2 inhibitor, to standard high dose therapy prior to autologous stem cell transplant (ASCT).~Venetoclax is a novel, orally bioavailable, small-molecule B-cell lymphoma-2 (Bcl-2) family inhibitor."
223503348|NCT01279200|OTHER|Midcycle ultrasound + hCG injection|Mid-cycle ultrasound with administration of hCG (single dose of standardized pre-filled injection, 250 mcg, at time of ultrasound) when appropriate.
223503349|NCT01279200|OTHER|Urinary LH kits|Subjects randomized to monitoring with LH kits at home will keep a monthly calendar documenting when LH testing begins, day LH surge occurs and day(s) of intercourse/insemination.
223503350|NCT05277766|DRUG|PIPAC with Nal-IRI|Nanoliposomal irinotecan (Nal-IRI, Onivyde) will be administered intraperitoneally using the PIPAC technique. The administered dose will escalate ranging from 30 to 90 mg/m². PIPAC will be performed every 4 to 6 weeks for 3 cycles.
223503351|NCT06406595|OTHER|Observation|This study is observational, therefore, there is no intervention included.
223503352|NCT06635161|DEVICE|Trancranial pulse stimulation (without a stand-off device)|A single session of TPS will be performed, applying 1000 pulses in the session (single ultrashort (3 μs) ultrasound pulses, 0.2 mJ mm-2, 4 Hz pulse frequency). No stand-off device will be used to target dorsal anteior cingulate cortex.
223503353|NCT06635161|DEVICE|Transcranial pulse stimulation (with Neurology stand-off device)|A single session of TPS will be performed, applying 1000 pulses in the session (single ultrashort (3 μs) ultrasound pulses, 0.2 mJ mm-2, 4 Hz pulse frequency). A Neurology stand-off device will be used to target the anterior insula cortex.
223503354|NCT06635161|DEVICE|Transcranial pulse stimulation (with a sham stand-off device)|A single session of TPS will be performed, applying 1000 pulses in the session (single ultrashort (3 μs) ultrasound pulses, 0.2 mJ mm-2, 4 Hz pulse frequency). A sham stand-off device will be used to target vertex.
223503355|NCT04999124|OTHER|Screening and studying characteristics|Type 2 diabetes patients have a high risk of developing NAFLD. This was confirmed during previous research, a high prevalence of NAFLD among type 2 diabetes mellitus patients was found. Now we want to determine the characteristics of this population.
223503356|NCT05323045|DRUG|BYON3521|BYON3521 (in the vein) infusion every three weeks. Number of cycles: until cancer progression or unacceptable toxicity develops. Different doses.
223746711|NCT06212219|OTHER|Fugl-Meyer test|419 / 5 000 Résultats de traduction Résultat de traduction This questionnaire assesses the motor selectivity of the upper limb. Several questions are asked about the movements that the patient can perform and to each question, the patient can answer either 0 (minimum) and 2 (maximum)
224194252|NCT03142230|OTHER|the laying of the gastric tube and a group using the holed baby bottle nipple, the feeding tube ideally positioned at the center of the intersection pharyngeal|The newborn then receives the care with the introduction of the gastric tube after randomization with holed baby bottle nipple
224194253|NCT03142230|OTHER|the laying of the gastric tube and a group with simple non-nutritive suction, the feeding tube passing next to the newborn's personal pacifier|The newborn then receives the care with the introduction of the gastric tube after randomization with the newborn's personal pacifier
224194254|NCT00028496|BIOLOGICAL|recombinant fowlpox-CEA(6D)/TRICOM vaccine|Given intradermally
224194255|NCT00028496|BIOLOGICAL|sargramostim|Given subcutaneously
224194256|NCT00028496|BIOLOGICAL|recombinant fowlpox GM-CSF vaccine adjuvant|Given intradermally
224194257|NCT01481064|BEHAVIORAL|Multifaceted approach|Audit and feedback, educational outreach visits, and patient-mediated interventions.
224194258|NCT01642472|DRUG|Ulipristal Acetate - open label|Ulipristal Acetate (PGL4001) tablets 10mg orally daily for 3 months (84 days) for each treatment course. There are four 3-month treatment courses in this study.
224194259|NCT04284046|OTHER|CT score|CT score = normal lung tissue (%) ×1 + GGO (%) ×2 + consolidation (%) ×3
224194260|NCT02116374|OTHER|Physiopathology study|
224194261|NCT03816969|DEVICE|Self-pressurized air-Q with blocker|"It has a drain tube through which a suction tube is passed like the Air-QILA blocker, and Instead of the pilot balloon and inflating cuff, the air-Q SP with blocker incorporates a self-regulating periglottic cuff at the end of this tube , a communication orifice at the junction of the peri-glottic cuff and the airway tube.~This communication between two spaces enables the cuff to dynamically regulate intra-cuff pressure depending on airway pressure. This distinguishing feature of the air-Q SP may result in reduced risk for airway morbidities related to cuff hyperinflation"
224194262|NCT03816969|DEVICE|Air-Q ILA blocker|A good seal will provide good ventilation, will guarantee the desired depth of anesthesia at lower gas flows and with lesser leaks to the esophagus, it will not cause rise in intragastric pressure thus preventing regurgitation However, When the cuff pressure is more than the mucosal perfusion pressure, it is likely to either cause postoperative pharyngo-laryngeal symptoms (sore throat, dysphagia, dysphonia) or cause local mucosal trauma and nerve injuries
224194263|NCT00071006|DRUG|AG-013736 (Axitinib)|patients were treated with axitinib at starting dose of 5 mg BID continuous dosing.
224194264|NCT04865536|DRUG|TBI-223 1800 mg|3 x 600 mg SR1 tablets
224194265|NCT04865536|DRUG|TBI-223 2400mg|3 x 600 mg SR1 tablets and 1 x 600 mg IR tablets
224194266|NCT04865536|DRUG|TBI-223 Placebo|Placebo SR and IR tablets for TBI-223
224310319|NCT02990780|RADIATION|Accelerated hypofractionated concurrent chemo-radiotherapy|5Fx/W,2.5Gy/Fx,Dt:PTV-G:55Gy/22F/4.4W.
224310320|NCT02977897|DRUG|Octreotide Acetate|Octreotide 100mcg SC q12h for 5 days
224194267|NCT00859313|DRUG|Sufentanil NanoTab PCA System/15 mcg|15 mcg Sufentanil NanoTab taken sublingually q 20 minutes as needed for pain for 12 hours
224194268|NCT05557526|OTHER|Expectation optimization|A short (2-5 min) verbal intervention will be createad individually based on the expectation of the patient towards the procedure.
224194269|NCT03283033|BEHAVIORAL|New salad bar|New salad bar placed in school
224194270|NCT03283033|BEHAVIORAL|Marketing|Marketing conditions (printed material, displays, verbal announcements, prompts and taste tests)
224194271|NCT01369836|DRUG|Tafamidis meglumin|A single oral dose of 20 mg capsule
224194272|NCT01369836|DRUG|Tafamidis meglumin|A single oral dose of 40 mg capsule.
224194273|NCT01369836|DRUG|Placebo|A single oral dose of matched placebo.
223503357|NCT05701085|OTHER|Educational Intervention|The intervention will occur at a separate dedicated in-person visit with the patient navigator estimated to last 30-45 minutes. The Pre-Intervention Survey will be scored to generate a list of barriers identified for each patient. This list of barriers will be reviewed by the patient navigator prior to the intervention date. The patient will be asked to view educational videos on an iPad that correspond with each identified barrier. Afterwards, the patient navigator will lead a discussion based on the topics discussed.
223746712|NCT06212219|OTHER|Intrinsic Motivation Inventory questionnaire|This psychometric motivation questionnaire offers the patient words representative of their motivation to carry out the neurofeedback session and for each proposition they can respond between rather positive (maximum) or rather negative (minimum)
224194274|NCT06455670|DRUG|Sanhan Huayin recipe, Qingre Huatan recipe or Zaoshi Huatan recipe|On the basis of conventional treatment of western medicine,the experimental group will be given Sanhan Huayin granule , Qingre Huatan granule or Zaoshi Huatan granule based on CM syndrome differentiation.Take 1 dose daily for 10 days.
224194275|NCT06455670|DRUG|Sanhan Huayin recipe placebo, Qingre Huatan recipe placebo or Zaoshi Huatan recipe placebo|On the basis of conventional treatment of western medicine, in the experimental group 5% of the placebo drug, color, smell, taste, appearance, weight, similar to the experimental drug, drug packaging and test group. One dose was given daily for 10 days.
224194276|NCT04688034|DRUG|OP-724|Twice a week for 4 hours continuous intravenous administration of OP-724.
224194277|NCT00005607|DRUG|FOLFIRI regimen|
224310321|NCT02917070|OTHER|Patients|In this study we aimed to investigate effect of family history and consanguineous marriage in the development of CKD in the adult Turkish population.
223503358|NCT04242745|BEHAVIORAL|Intervention group|"The elderly in this group were trained using the For Your Health For Fluid training booklet and a projection device, and after training, all individuals were given a training booklet. The training was carried out individually in a room reserved for training and took an average of 25-30 minutes.~A Beyid wristwatch was used. This spoke the time in Turkish, every hour on the hour. In this way, the old people were reminded to drink a glass of liquid each hour. The watch had an alarm capability, and could be taken on to sleep mode at night in order not to wake the old people."
223503359|NCT04242745|BEHAVIORAL|Control group|"The elderly in this group were trained using the For Your Health For Fluid training booklet and a projection device, and after training, all individuals were given a training booklet. The training was carried out individually in a room reserved for training and took an average of 25-30 minutes."
223503360|NCT04046653|DIETARY_SUPPLEMENT|Allin|Dietary supplement
223503361|NCT04046653|DIETARY_SUPPLEMENT|Sulforaphane|Dietary supplement
224194278|NCT00005607|DRUG|fluorouracil|
224194279|NCT00005607|DRUG|irinotecan hydrochloride|
224194280|NCT00005607|DRUG|leucovorin calcium|
224194281|NCT05100693|OTHER|Fetoscopic Endoluminal Tracheal Occlusion with the Smart-TO Balloon|Fetal Endoscopic Tracheal Occlusion using the Smart-TO balloon and non-invasive balloon removal by the peripheral magnetic field of an magnetic resonance scanner.
224194282|NCT05570721|BEHAVIORAL|Trier Social Stress Test|The TSST has both social-evaluative and arithmetic components. During the social-evaluative component, the participant is asked to prepare and then deliver a brief speech to the research team. After this component there is a surprise arithmetic problem. This challenge paradigm has been well-established to rapidly and robustly induce psychological stress as well as physiological indices of stress (e.g., cortisol response, heart rate response). This task takes approximately 15 minutes to complete.
224194283|NCT04999969|DRUG|AZD0171|AZD0171
224194284|NCT04999969|DRUG|Durvalumab|Durvalumab
224194285|NCT04999969|DRUG|Gemcitabine|Chemotherapy (Standard-of-Care)
224194286|NCT04999969|DRUG|Nab-paclitaxel|Chemotherapy (Standard-of-Care)
224194287|NCT04647916|BIOLOGICAL|Sacituzumab Govitecan|Given IV
224194288|NCT03901274|BEHAVIORAL|Wellness|The Wellness framework packages together evidence-based practices of family engagement, modular evidence-based practice, quality assurance, and implementation support. Depending on their time of enrollment, participants can be involved in this condition for one to three years. They will be asked to complete assessments during their therapy sessions periodically throughout the trial.
224194289|NCT03901274|BEHAVIORAL|Partnership|The two patient-centered enhancements are: enhancing mental health literacy and stigma reduction, and improving family-school-mental health partnerships. Depending on their time of enrollment, participants can be involved in this condition for one to three years. They will be asked to complete assessments during their therapy sessions periodically throughout the trial.
224194290|NCT04348747|BIOLOGICAL|Anti-HER2/HER3 Dendritic Cell Vaccine|Given ID
224194291|NCT04348747|BIOLOGICAL|Pembrolizumab|Given IV
224194292|NCT06354686|DEVICE|TMS Tolerability|The primary objective is to characterize the tolerability of TMS by scalp location (over parietal, motor, modified Beam F3 prefrontal, THREE-D prefrontal, orbitofrontal, and medial prefrontal) and stimulation parameters (single pulse, 10 Hz, theta burst). The secondary objective is to evaluate the feasibility of the knee as a surrogate location to safely trial TMS parameters.
224194293|NCT04880083|DIETARY_SUPPLEMENT|Commercially Available Starter Infant Formula|Study formula is provided in powder form and will be administered orally, ad libitum, via an infant feeding bottle and the volume of formula offered to the infant will be guided by the recommended feeding table for the age group or by physician recommendation. The amount consumed by the infant will vary by each infant's weight and appetite.
224310322|NCT01177475|OTHER|blood samples , feces samples|After the 32nd week until the 36th week or the end of hospitalization,infants received mother's native milk or substitute.
223503362|NCT04046653|DIETARY_SUPPLEMENT|Placebo|Dietary supplement
223503363|NCT04111783|DEVICE|POU protocol ultrasound|The evaluation method performed a preoperative examination of the patient within 10 minutes by a heart scan and a standard scan of the face, a large vascular scan under the xiphoid, a body cavity scan, and a standard scan of the face and a lung scan. Preparation, providing anesthesia and surgeons with a fast, comprehensive and accurate preoperative judgment with important clinical and social significance.
223503364|NCT03724344|OTHER|Cross section resaerch|Assessment of cognitive (MoCA), mental behavioral symptoms (NPI） the Self-rating Depression Scale (SDS) and the Self-rating Anxiety Scale (SAS).
223503365|NCT04730375|DRUG|Dexmedetomidine Injection [Precedex]|two different doses dexmedetomidine bolus then maintenance infusion till end of surgeries and evaluation of lung mechanics and oxygenation
223592588|NCT04032080|COMBINATION_PRODUCT|Drug 1: LY3023414; Drug 2: Prexasertib|"Metastatic TNBC patients will consent to and undergo core needle biopsies of a metastatic lesion for NGS, RPPA, and other molecular analyses at study entry.~Patients will then be treated with 150 mg LY3023414 PO BID and prexasertib 80 mg/m\^2 IV administered every 2 weeks until disease progression or unacceptable toxicity. Any time after the completion of Cycle 2 of the treatment combination, or at the physician's discretion, a second core needle biopsy of the same metastatic lesion (or different metastases if the initial metastasis has regressed) will be performed for RPPA and other molecular analyses. If a research biopsy from a patient's metastatic disease cannot be safely obtained, a skin biopsy is permitted.~Treatment will be discontinued in patients who achieve a confirmed clinical complete response, and these patients will be followed to document the durability of the complete responses."
223592589|NCT00647660|DRUG|Nadolol/Bendroflumethiazide Tablets 80 mg/5 mg|80/5mg, single dose fasting
223592590|NCT00647660|DRUG|Corzide® Tablets 80 mg/5 mg|80/5mg, single dose fasting
223592591|NCT00996060|DRUG|Hydralazine and Valproic Acid: Cohort -1|"Initially, 3 patients will be enrolled into each cohort, beginning with the hydralazine 25 mg PO daily, with the valproic acid dosing beginning two weeks earlier to achieve a steady state level of valproic acid in the blood.~In this cohort, Hydralazine is administered at 10 mg/day."
223592592|NCT00996060|DRUG|Hydralazine and Valproic Acid: Cohort 0|"Initially, 3 patients will be enrolled into each cohort, beginning with the hydralazine 25 mg PO daily, with the valproic acid dosing beginning two weeks earlier to achieve a steady state level of valproic acid in the blood.~Hydralazine is administered at 25 mg/day in this cohort."
223592593|NCT00996060|DRUG|Hydralazine and Valproic Acid: Cohort 1|"Initially, 3 patients will be enrolled into each cohort, beginning with the hydralazine 25 mg PO daily, with the valproic acid dosing beginning two weeks earlier to achieve a steady state level of valproic acid in the blood.~Hydralazine is administered at 50 mg/day in this cohort."
223592594|NCT00996060|DRUG|Hydralazine and Valproic Acid: Cohort 2|"Initially, 3 patients will be enrolled into each cohort, beginning with the hydralazine 25 mg PO daily, with the valproic acid dosing beginning two weeks earlier to achieve a steady state level of valproic acid in the blood.~Hydralazine is administered at 100 mg/day in this cohort as 25 mg four times per day."
223592595|NCT00996060|DRUG|Hydralazine and Valproic Acid: Cohort 3|"Initially, 3 patients will be enrolled into each cohort, beginning with the hydralazine 25 mg PO daily, with the valproic acid dosing beginning two weeks earlier to achieve a steady state level of valproic acid in the blood.~Hydralazine is administered at 200 mg/day in this cohort as 50 mg four times per day."
223592596|NCT00996060|DRUG|Hydralazine and Valproic Acid: Cohort 4|"Initially, 3 patients will be enrolled into each cohort, beginning with the hydralazine 25 mg PO daily, with the valproic acid dosing beginning two weeks earlier to achieve a steady state level of valproic acid in the blood.~Hydralazine is administered at 300 mg/day in this cohort as 75 mg four times per day."
223592597|NCT00996060|DRUG|Hydralazine and Valproic Acid: Cohort 5|"Initially, 3 patients will be enrolled into each cohort, beginning with the hydralazine 25 mg PO daily, with the valproic acid dosing beginning two weeks earlier to achieve a steady state level of valproic acid in the blood.~Hydralazine is administered at 400 mg/day in this cohort as 100 mg four times per day."
224194294|NCT06210321|OTHER|Prescription of escitalopram using pharmacogenetic testing|Adjustment of escitalopram treatment according to pharmacogenetic results obtained by genetic testing for cytochrome CYP 2C19 (alleles \*2, \*3 and \*17)
224194295|NCT04708223|DEVICE|Direct restorative treatment with fast-curing composites (Tetric PowerFill/ Tetric PowerFlow)|Tooth (teeth) affected by dental caries or with an existing defective filling will be restored. Adhese Universal in self-etch mode, was used to prepare the surfaces for the composite fillings. Tetric PowerFill/ Tetric PowerFlow (test group) was cured for 3 s.
224194296|NCT04708223|DEVICE|Direct restorative treatment with conventionally applied composites (Tetric EvoCeram Bulk Fill/ Tetric EvoFlow Bulk Fill)|Tooth (teeth) affected by dental caries or with an existing defective filling will be restored. Adhese Universal in self-etch mode, was used to prepare the surfaces for the composite fillings. Tetric EvoCeram Bulk Fill/ Tetric EvoFlow Bulk Fill (control group) were conventionally cured for 10 s per increment.
224194297|NCT04691674|PROCEDURE|Endoscopy|Endoscopic removal of the pancreatic stent
224194298|NCT06037603|BEHAVIORAL|Brain & Walk Exercise Every Day (BraW-Day)|The Brain \& Walk Exercise Every Day (BraW-Day) program comprises 15-minute-long daily cognitive-walking tasks for 14 consecutive days. The program will be delivered on the Uplode mobile app. Each participant will be asked to perform three different 5-minute-long cognitive tasks (e.g., subtracting numbers or remembering long phrases) and one physical task (tandem walking or 8-shape walking) either indoors or outdoors at the same time for 15 minutes every day, which they will repeat daily for the next 13 days (2 weeks in total).
224194299|NCT03716349|DIAGNOSTIC_TEST|Pulp vitality testing|each tooth will be tested to determine if the pulp of the tooth responds to cold
224194300|NCT03716349|OTHER|Photos|Photos of teeth (Photos will be taken with a DSLR camera settings will be determined with optimal settings) and captured periodically throughout the study. Photographs will be made of the cavity preparation. Photographs will be made post-operatively
223503366|NCT02346422|GENETIC|MYDICAR Phase 1|Single dose of MYDICAR
223503367|NCT02346422|GENETIC|MYDICAR Phase 2|Single dose of MYDICAR
223503368|NCT02346422|GENETIC|Placebo Phase 2 only|Single dose of placebo
223503369|NCT06345820|DEVICE|Evolux|Evolux, enhanced monofocal IOL
223503370|NCT06345820|DEVICE|Tecnis Eyhance|Tecnis Eyhance, enhanced monofocal IOL
223503371|NCT00102167|DRUG|gaboxadol|Duration of Treatment -1 day
223592598|NCT00875940|OTHER|Diagnostic imaging procedures.|
223503372|NCT01968317|DRUG|Megestrol acetate and metformin|Patients will receive metformin 500 mg by mouth third daily and megestrol acetate 160 mg by mouth daily for 3 months.
223503373|NCT01968317|DRUG|Megestrol acetate|Patients will receive megestrol acetate 160 mg by mouth daily for 3 months.
223503374|NCT03237091|OTHER|bihemispheric transcranial pulsed current stimulation (tPCS)|Two sets of sponge electrodes (one set placed on each side of the head) will be placed on the participant's head. The transcranial electrical stimulator will apply unidirectional, positive pulses of current separated by brief interpulse intervals to the scalp via the sponges for 30 minutes.
223503375|NCT03237091|OTHER|unihemispheric transcranial pulsed current stimulation (tPCS)|One set of sponge electrodes will be placed on the participant's head. The transcranial electrical stimulator will apply unidirectional, positive pulses of current separated by brief interpulse intervals to the scalp via the sponges for 30 minutes.
223503376|NCT03237091|OTHER|bihemispheric transcranial direct current stimulation (tDCS)|Two sets of sponge electrodes (one set placed on each side of the head) will be placed on the participant's head. The transcranial electrical stimulator will apply continuous, direct current to the scalp via the sponges for 30 minutes.
223503377|NCT03237091|OTHER|unihemispheric transcranial direct current stimulation (tDCS)|One set of sponge electrodes will be placed on the participant's head. The transcranial electrical stimulator will apply continuous, direct current to the scalp via the sponges for 30 minutes.
223503378|NCT03237091|OTHER|sham-control|Sponge electrodes will be placed on the participant's head. The transcranial electrical stimulator will apply stimulation to the scalp via the sponges for 1-2 minutes. The stimulator will then be turned off.
223503379|NCT02310347|DRUG|dronabinol|
223503380|NCT02310347|DRUG|Placebo|
223503381|NCT04832061|OTHER|Respiratory supports|The respiratory supports used in this patient population included conventional oxygen therapy (COT) via nasal cannula or face mask, non-invasive ventilation (NIV), and invasive mechanical ventilation (IMV). NIV has three different methods, including high-flow nasal cannula (HFNC), bilevel positive airway pressure (BiPAP), and continuous positive airway pressure (CPAP).
223503382|NCT04073277|DEVICE|SCF-N-treated needles|The SCF-N-treated needles were used for acupuncture at LI 4 (Hegu) and LI 11 (Quchi) acupoints in the experimental groups..
223503383|NCT04073277|DEVICE|Untreated needles|he untreated needles were used for acupuncture at LI 4 (Hegu) and LI 11 (Quchi) acupoints in the control groups.
223503384|NCT04321499|GENETIC|lung cancer|PCR for SHOX2 and PTGER4
223503385|NCT05165043|PROCEDURE|position change|The patients who conducted position change due to massive EGVB resulting in poor visualization in the stomach were included,patients changed from the left lateral position to the right lateral position.
223503386|NCT02747225|DEVICE|network analyzer|The dielectric properties of the tissues were measured using the open-ended coaxial line method. The measurement system consisted of a network analyzer (Model 4395A, Agilent Corp., Santa Clara, CA) associated with an S-parameter test set (Model 87511A, Agilent Corp., Santa Clara, CA). A semi-rigid coaxial line with a diameter of 3.58 mm was connected to the network analyzer system by using a Bayonet Neill-Concelman connector. The other tip of the coaxial line (probe) was placed on the flat bare surface of the tissue.
223503387|NCT02492919|DEVICE|Medixair®|Medixair system uses C-ultraviolet rays, which are the strongest ultraviolet kind of rays to kill microorganisms. The intervention consist consists of adding the Medixair® device, to be various beds of Cardiac Reanimation Units, or not.
223503388|NCT01873885|DRUG|Placebo Single IV (Intravenous) Infusion|0.9% Sodium Chloride - 30 minute IV infusion
223503389|NCT01873885|DRUG|Experimental: Single IV Infusion Vasomera (PB1046)|
223503390|NCT04342585|DRUG|Micronised vaginal progesterone|A diary will be given to participants to ensure compliance.
223503391|NCT04342585|DEVICE|Vaginal pessary|The internal diameter size will be decided based on the clinical assessment of the cervix.
224194301|NCT03716349|DRUG|local and/or topical anesthetic|Local and/or topical anesthetic will be applied as necessary to the teeth or gingiva
223503392|NCT01227811|DRUG|Darifenacin|Single oral dose Darisec(R) 15.0 mg
223503393|NCT01227811|DRUG|Darifenacin|Single oral dose Enablex(R) 15 mg
223503394|NCT00106561|DRUG|Spironolactone|
223503395|NCT00106561|DRUG|Irbesartan|
223503396|NCT00888849|PROCEDURE|Advant 55 Linear Cutter/Stapler|Advant 55 Linear Cutter/Stapler
223503397|NCT00888849|PROCEDURE|Suturing|Suturing
223503398|NCT01939392|DEVICE|Renal Denervation (OneShot™ Renal Denervation System)|
223503399|NCT05992038|PROCEDURE|Osteotomy with putty|Synthetic ceramic putty
223503400|NCT05992038|PROCEDURE|Conventional osteotomy|conventional osteotomy
223503401|NCT02663167|BEHAVIORAL|Internet-delivered Cognitive Behavioral Therapy|The treatment consists of a standard cognitive behavioral therapy for obsessive-compulsive disorder. The treatment is delivered through an Internet platform. The child and his/her parent(s) work through the treatment with regular therapist contact several times per week.
223503402|NCT02508207|DRUG|Tezacaftor/Ivacaftor|Tezacaftor/Ivacaftor FDC
223503403|NCT02508207|DRUG|Ivacaftor|
223503404|NCT02508207|DRUG|Tezacaftor/Ivacaftor matching placebo|
223503405|NCT02508207|DRUG|Ivacaftor matching placebo|
223503406|NCT02122952|BIOLOGICAL|AVXS-101|Self-complementary AAV9 carrying the SMN gene under the control of a hybrid CMV enhancer/chicken-β-actin promoter
223503407|NCT01400633|DRUG|decitabine injection|decitabine intravenous injection 20mg/m2 once a day for 5 consecutive days every 4 weeks
223503408|NCT01284764|DRUG|Mosapride|Mosapride 10mg, one dosage, once evening of the day before the endoscopy
223503409|NCT06530095|OTHER|prone positioning|prone positioning
223503410|NCT03707730|DIETARY_SUPPLEMENT|AGY|oral AGY taken prior to meals
223503411|NCT03707730|OTHER|placebo|oral placebo taken prior to meals
223503412|NCT00662701|PROCEDURE|Catheter Ablation|RF ablation with complete circumferential ablation around the right and PVs, optional additional lines between the lower and upper PVs, and towards the mitral valve ring.
223503413|NCT00662701|PROCEDURE|Surgical Ablation|Minimal invasive thoracoscopic surgery including isolation of the PVs by AtriCure and removal of the LAA.
224194302|NCT03716349|DEVICE|rubber dam|The area will be isolated with rubber dam isolation
224194303|NCT03716349|OTHER|tooth surface cleaned|The tooth surface will be cleaned with flour of pumice on a prophy cup only, cavity preparation will be performed as usual for caries removal.
223746713|NCT06212219|OTHER|Hospital Anxiety and Depression Scale|This questionnaire assesses the patient's state of anxiety and depression. Concerning anxiety, to each proposition, the patient can answer a number between 0 at minimum (never/not at all) and 3 at maximum (very often) and about depression, the patient can answer a number between 0 at minimum (often, always) and 3 at maximum (never/not at all) The patient can calculate his score at the end
223746714|NCT06212219|OTHER|State Anxiety Inventory scores|"This questionnaire measures the patient's anxiety at a given time. It features a number of statements that people have previously used to describe themselves. For each statement, choose a grade from 1 (not at all) to 4 (Very much)"
223746715|NCT06212219|OTHER|Acceptability questionnaire (BCI-ACCEPT)|This questionnaire asks the patient about their level of acceptability of NF training using words representative of their motivation to carry out the neurofeedback session and for each proposal they can respond on their feelings regarding the proposals.
223746716|NCT06212219|OTHER|System Usability Scale questionnaire|This questionnaire evaluates the usability of personalized NF procedures compared to standard procedures. To each statement, the patient can respond between a minimum of 1 (strongly disagree) and a maximum of 5 (totally agree).
223746717|NCT06212219|OTHER|NASA Task Load Index questionnaire|"This scale assesses psychological validity from the perspective of mental workload. 6 words are offered to the patient about his mental load and he can respond at least little and at maximum A lot"
223746718|NCT06212219|OTHER|Agency test|Questionnaire in which statements referring to the patient's general feeling and/or beliefs are presented. the patient has the choice between completely disagree (minimum) and totally agree (maximum)
223746719|NCT06212219|OTHER|Visual and Kinesthetic Imagery Questionnaire|"The aim of this questionnaire is to obtain an index of individuals' ability to mentally represent different movements. Different movements to imagine are indicated and the patient responds based on their ability to imagine the movement.~He has the choice between as clear as a film (maximum) and no image (minimum)"
223746720|NCT06212219|OTHER|Technology Locus of Control Assessment Questionnaire|"The questionnaire focuses on patients' opinions on problems related to the use of technical devices. It presents twelve statements that the patient can affirm or deny, depending on their personal point of view. The patient can respond at least disagree at all and at maximum agree completely"
223746721|NCT06212219|OTHER|POSITIVE AFFECTIVITY AND NEGATIVE AFFECTIVITY SCALE|"This scale is made up of a list of words that indicate certain emotions or feelings. The patient must carefully read each of these words and spontaneously indicate at what level he feels this way at the time he responds to this scale. To do this, he can answer at least Very little or not at all and at maximum A lot"
223746722|NCT06212219|OTHER|Self-questionnaire: OCEAN of the five major factors of per- sound (or Big Five model)|"The model for measuring personality factors is the Anglo-Saxon model known as the Big Five or OCEAN in French. It measures 5 major personality traits: openness to experiences, conscientiousness, extroversion, agreeableness and neuroticism. The OCEAN questionnaire is a self-administered questionnaire to be given to a person who wishes to evaluate themselves. It includes 45 items presented in the table below. For each item, patients have 5 response possibilities numbered from 1 to 5: 1 for strongly disapproves and 5 for strongly approves. The patient can calculate his score at the end"
223746723|NCT06212219|OTHER|Feeling VAS scores|"The EVA scale relates to the patient's personal feelings: perceived difficulty, perceived fatigue, perceived ease of learning, level of embodiment, Relevance, Demonstrability of results, Fun aspect, Benefit/risk ratio, Self-efficacy.~For each statement, the patient can respond on a scale ranging from strongly disagree (minimum) to totally agree (maximum)."
223746724|NCT06212219|OTHER|Reaching Performance Scale|This scale analyzes the evolution of speed, precision and range of movement using motion capture tools. For each statement, the patient has a rating between 0 (corresponds to not possible) and 3 (corresponds to entirely possible)
223746725|NCT04779008|OTHER|remote ischemic preconditioning （RIPC）|Four five-minute cycles of upper limb ischaemia and Four five-minute pauses using a blood pressure cuff inflated to 200 mmHg.
223746726|NCT00916474|DRUG|telaprevir|
224194304|NCT03716349|PROCEDURE|enamel margins|Enamel margins will be beveled with a long flame diamond bur (8863.314.012 Komet) at 45 degrees to the external tooth surface to achieve the desired bevel length. Along with the use of the diamond bur, infinite invisible margins will be created by contouring and smoothing with a dark orange Sof-LexTM extra-thin contouring and polishing disc (3M).
224194305|NCT03716349|PROCEDURE|Adhesive Systems|Adhesive systems will be applied according to manufacturer's instructions and selective etching of the enamel will be performed. The dental composite will be incrementally placed using a two- layer or one-layer technique based on the cavity size and light-cured (detailed adhesive instruction sheet will be chairside for reference)
224194306|NCT03716349|PROCEDURE|cavity preparation|The technique to be used will be determined by the size of the final cavity preparation. For small preparations a one-layer technique will be used. No backing material is necessary for the Tokuyama system, Filtek Supreme Ultra will be determined by manufacturer's wheel. A two-layer technique will be used for a large cavity preparation. Large cavity preparation is defined as being 4mm in length or more and/or at least 2mm in depth.
224194307|NCT03716349|OTHER|Shade selection using Easy Shade 5|A1 (shade determined by Easy Shade 5), ECM-001/Backing material, A1E/A2D (shade will be selected by shade wheel) A4 (shade determined by Easy shade5), ECM-001/Backing material, A3E/A6D (shade will be selected by shade wheel
224194308|NCT03716349|PROCEDURE|Light Curing|A Valo Grand curing unit (Ultradent) with an exitant irradiance with no less than 500 and no greater than 1500 mW/cm2 as measured with MARC Light Collector will be used in standard mode to deliver the required radiant exposure J/cm2 for adhesive and dental composite increments.
224194309|NCT03716349|PROCEDURE|Contoured and polished|The restoration will be contoured and polished with - Long flame diamond bur (8863.314.012 Komet), Sof-Lex Medium (orange) Contouring and Polishing Discs (3M), Green Jiffy cup pre-polisher (Ultradent Products, Inc.), Blue and grey silicone points composite polisher gloss plus finisher (Kerr Hawe)
224194310|NCT03716349|OTHER|Consent|The consent form will be signed, copy will be provided to the patient
224194311|NCT03716349|OTHER|Health Questionnaire|The health questionnaire will be completed at initial visit and updated at each follow-up visit
224194312|NCT03716349|RADIATION|xray|When necessary a radiograph (xray) will be obtained
224194313|NCT03716349|OTHER|Release of medical information signed|The release of medical information form will be signed
224194314|NCT03716349|OTHER|Oral Exam|An Oral Exam will be completed
223503414|NCT03997201|PROCEDURE|Ripple Mapping guided ischaemic VT ablation|"Endocardial mapping of the ventricle performed with Ripple Mapping (CARTO3v6, Biosense Webster Inc). Ablation (SmarTouch Thermocool Catheter, Biosense Webster Inc) delivered to areas of abnormal late electrical activity within ventricular scar tissue."
223503415|NCT05687565|DIETARY_SUPPLEMENT|Control group placebo|Dietary suplementation
223503416|NCT05687565|DIETARY_SUPPLEMENT|Experimental group 1 lauric acid|Lauric acid 1.5 grams once daily
223503417|NCT05687565|DIETARY_SUPPLEMENT|Experimental group 2 lauric acid|Lauric acid 3 grams once daily
223503418|NCT00104260|DRUG|sapropterin dihydrochloride|
223592599|NCT03273660|DEVICE|Aliaxin (new trademark - IBSA Farmaceutici Italia S.r.l.)|"First treatment was performed during baseline visit, after the basal evaluations planned by the study procedure.~0.5-1.1 ml of Aliaxin (new trademark) for emi-face was injected by needle (25-27 G) and/or cannula (25 G, 40 mm).~A touch-up treatment (0.5-1.1 ml of Aliaxin new trademark for subject) was performed after 3-4 weeks (T1) in order to treat possible asymmetry."
223592600|NCT02180477|DRUG|UHAC 62 XX - TF1 tablet|
223592601|NCT02180477|DRUG|UHAC 62 XX - TF2 tablet|
223592602|NCT02180477|DRUG|UHAC 62 XX - capsules|
223746727|NCT05442944|PROCEDURE|Physiotherapeutic procedures|As part of the rehabilitation program, the patients performed two exercises in the Universal Therapeutic Rehabilitation Room (UTRR) system. The patient's task was to perform simultaneous abduction and adduction of the upper and lower limbs. The duration of the procedure was 10 minutes, the patient performed the exercises at a comfortable pace. In the second exercise - the patient's task was to alternately bend and straighten the opposite lower and upper limbs. The duration of the exercise was 10 minutes. The combined duration of both procedures used was 20 minutes. In addition, each patient underwent three physical therapy treatments. The procedures were carried out 5 days a week (Monday to Friday) for three weeks.
223746728|NCT03997656|BEHAVIORAL|MyDiPP (Malaysia Diabetes Prevention Program)|The participants will go through 16-weekly core lessons that need to be completed within the first 24 weeks after randomisation focusing on changing dietary habits, increase physical activity and relapse prevention and 6-monthly post-core lessons focusing on maintenance of lifestyle habits and weight loss achieved during the core program.
223746729|NCT03997656|OTHER|usual care|standard health education from primary care providers in the clinic
223746730|NCT05976802|DRUG|High dose budesonide rectal foam|Twice a day for 2 weeks, then once a day for 4 weeks
223746731|NCT05976802|DRUG|Low dose budesonide rectal foam|Twice a day for 2 weeks, then once a day for 4 weeks
224194315|NCT03716349|OTHER|Teeth Assessment|The teeth assessment by subject will be completed using the Visual Analog Scale (VAS) and Verbal Rating Scale (VRS) at the follow-up visits 1 month after restoration, 1 year, 2 years and 3 years post restoration.
224194316|NCT03716349|OTHER|Clinical Assessment|A clinical assessment will be completed by the evaluators
224194317|NCT03716349|DEVICE|Tokuyama Universal Bond|Tokuyama Universal Bond (TUB) single component self-etching 1-step adhesive system with Tokyuama supra-nanofilled dental composite (ECM) (Tokuyama Dental Corp., Japan)
223503419|NCT01447472|DRUG|MDMA|One single dose of MDMA ( 1.5 mg/kg; range: 75-100 mg)
223503420|NCT01475500|PROCEDURE|Sputum sample|This is a collection of sputum (mucous) you cough up. Three morning samples will be collected at one time. Sputum will be collected at baseline, year 1, year 2 and year 5.
223503421|NCT01475500|PROCEDURE|Pulmonary function tests|A series of different breathing tests designed to measure lung function and to determine the presence or absence of chronic obstructive pulmonary disease will be performed at baseline.
223503422|NCT01475500|RADIATION|Computerized tomography (CT) scan of the chest|A CT scan uses x-rays to take detailed pictures of the chest. Performed at baseline, year 2 and year 5. If nodules are present, CT scans will be performed every 3 months for the first year of the study.
223503423|NCT01475500|OTHER|Buccal epithelium collection|Collect cells from the inside of the cheek. Samples will be collected at baseline and yearly to year 5.
223503424|NCT01475500|PROCEDURE|Nasal brushings|A cytobrush is used to remove cells on the surface of the inside of the nose. Samples will be collected at baseline and yearly to year 5.
223592603|NCT01605318|DRUG|Labetuzumab Govitecan (LG)|Administered as a slow intravenous (IV) infusion.
223592604|NCT03441503|OTHER|Child HCAHPS: Automated day-of-discharge survey|Child HCAHPS surveys will be administered on the day of discharge via an electronic interactive patient care system on inpatient televisions.
223592605|NCT01433094|BEHAVIORAL|Falloon et al. Psychoeducation Program|The intervention aims to improve communication and problem-solving abilities in patients and their families by sessions focused on: assessment of the individual's and the family's strengths, weaknesses, and goals; education about schizophrenia and treatment; communication skills training; problem-solving training; and special problems (Falloon et al. 1985). Treatment sessions are provided on a weekly basis for months (1 hour for each session) (groups of about 8-9 persons - patients and caregivers).
223592606|NCT01433094|BEHAVIORAL|Generic Treatment|The comparator is a treatment with generic informative prospect on the disorders and with the same frequencies as the Intervention. Treatment sessions are provided on a weekly basis for 6 months (1 hour for each session) (groups of about 8-9 persons - patients and caregivers).
223592607|NCT05949489|DIAGNOSTIC_TEST|WOMAC pain subscale|"The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale is a self-reported questionnaire that is used to measure pain in people with osteoarthritis (OA). The subscale consists of five items that ask about the intensity, frequency, and duration of pain in the hip and knee joints.~The WOMAC Pain Subscale has been shown to be a reliable and valid measure of pain in people with OA. It has been used in a number of clinical trials and is considered to be a standard measure of pain in OA.~The WOMAC Pain Subscale is scored on a scale of 0 to 4, with 0 indicating no pain and 4 indicating severe pain. The total score for the subscale is the sum of the scores for the five items. A higher score indicates more pain."
223592608|NCT05246813|OTHER|Blood and bone marrow cell collection|Collection of blood and bone marrow
224194318|NCT03716349|DEVICE|ScotchBond|Scotch Bond Universal one-step adhesive system with Filtek Supreme Ultra™, nanofilled dental composite (3M)
224194319|NCT06071767|BIOLOGICAL|ChAdOx1.tHIVconsv1|Administered as 0.4 mL intramuscularly (IM) at Week 0
224194320|NCT06071767|BIOLOGICAL|ChAdOx1.HIVconsv62|Administered as 0.3 mL IM at Week 0
224194321|NCT06071767|BIOLOGICAL|MVA.tHIVconsv3|Administered as 0.3 mL IM at Week 4
223503425|NCT01475500|PROCEDURE|Bronchoscopy|A flexible tube with a light and a camera will be inserted through the nose or mouth, and into the lungs to look at the airway. Bronchial tissue will be obtained.
223503426|NCT01475500|PROCEDURE|Bronchoalveolar lavage|During a bronchoscopy, a flexible tube with a light and a camera is passed through the mouth or nose into the lungs and fluid is squirted into a small part of the lung and collected for examination. Bronchoscopies will be performed at baseline and at year 5.
223503427|NCT01475500|PROCEDURE|Blood sample collection|A venous blood sample will be collected for testing of biomarkers and other relevant tests. Blood will be taken at baseline and yearly to year 5.
223503428|NCT01475500|PROCEDURE|Urine sample|Urine will be collected for routine urine tests at baseline and yearly to year 5.
223503429|NCT01475500|PROCEDURE|Questionnaire-data collection|A questionnaire about the patient's health, medical, and smoking history. Administered at baseline and yearly to year 5. Data will be taken from patient interviews and from the medical record.
223503430|NCT00940459|DEVICE|Senofilcon A contact lens (Acuvue Oasys)|Silicone hydrogel contact lens CE-marked for the intended usage.
223503431|NCT00940459|DEVICE|Comfilcon A contact lens (Biofinity)|Silicone hydrogel contact lens CE-marked for the intended usage.
223503432|NCT00940459|DEVICE|Lotrafilcon B contact lens (Air Optix)|Silicone hydrogel contact lens CE-marked for the intended usage.
223503433|NCT00940459|DEVICE|Balafilcon A contact lens (PureVision)|Silicone hydrogel contact lens CE-marked for the intended usage.
223503434|NCT00940459|DEVICE|Etafilcon A contact lens (Acuvue 2)|Hydrogel contact lens CE-marked for the intended usage.
223503435|NCT00940459|DEVICE|Contact lens care system (EasySept)|Contact lens care system CE-marked for the intended usage.
223503436|NCT06214715|DEVICE|Philips ultrasonography system|RRI will be measured by renal ultrasonography with a C5-1 convex probe using a Philips ultrasonography model device.
223503437|NCT01566825|DRUG|Amitriptyline|amitriptyline 25 mg at 9:30 pm, day 10, and 50 mg at 1:30 am, day 11
223503438|NCT01566825|DRUG|Placebo|placebo(white 8 mm Lichtenstein®) at 9:30 pm, day 10, and at 1:30 am, day 11
223503439|NCT06501937|OTHER|Influencer marketing|Participants watched online survey-imbedded promotional videos featuring influencers
223503440|NCT00179179|DRUG|nutritional supplementation|2 oral ingestions per study visit of protein supplement containing a total of 960 kilocalories: 132.8 kilocalories from protein, 412.8 kilocalories from carbohydrates, and 412.8 kilocalories from fat; 6 study visits over a 12-month period
223503441|NCT00179179|BEHAVIORAL|exercise|resistance training on a duel leg press consisting of 3 sets of 8-12 repetitions; the first 5 study visits over a 12-month period
223503442|NCT03423693|OTHER|No any intervention|No any intervention is applied to any groups in this study
223503443|NCT04017468|DRUG|Vancomycin|Patients randomized into the treatment arm will receive 1-2 g of vancomycin powder (Vancocin® i.v.) which will be administered above the closed muscle fascia (suprafascially) before closing the subcutaneous tissue and skin. The dose of the drug will depend on the length of the skin incision: 1 g for incisions ≤ 20 cm, 2 g for incisions ≥ 20 cm.
223592609|NCT01054625|BIOLOGICAL|zalutumumab|Zalutumumab is a clear to opalescent liquid. It is intended for intravenous infusion following dilution in sterile, pyrogen free, 0.9% NaCl. Patients will be treated at a specified dose of Zalutumumab over a period of 7 weeks. The dose will be 4mg/kg, 8mg/kg or 16mg/kg depending on when they enter the study. The study will begin with 6 patients on 4mg/kg, then 10 patients on 8mg/kg and lastly 10 patients on 16mg/kg.
223592610|NCT05849519|DRUG|Coenzyme I for Injection + conventional treatment|The intervention group used Coenzyme I for injection and conventional treatment for 7 consecutive days
224194322|NCT06071767|BIOLOGICAL|MVA.tHIVconsv4|Administered as 0.5 mL IM at week 4
223503444|NCT05087303|OTHER|Types of Telemedicine Delivery Models|Each arm delivers standard sickle cell care using a different model based on patient location.
223503445|NCT01857154|DIETARY_SUPPLEMENT|Micronized Calcium Carbonate|"Subjects currently being treated with bisphosphonates will be administered 500 mg micronized calcium carbonate.~Subjects not currently being treated with bisphosphonates will be administered 500 mg micronized calcium carbonate."
223503446|NCT01857154|DIETARY_SUPPLEMENT|Non-Micronized Calcium Carbonate|"Subjects currently being treated with bisphosphonates will be administered 1000 mg non-micronized calcium carbonate.~Subjects not currently being treated with bisphosphonates will be administered 1000 mg non- micronized calcium carbonate."
223503447|NCT01857154|DIETARY_SUPPLEMENT|Vitamin D3|All subjects in the study cohort will be administered 800 IU Vitamin D3.
223503448|NCT00896233|PROCEDURE|MRE|"Part 1: Participants will have a screening visit, followed \~1 month later by two imaging visits over \~14 days. Each imaging visit will consist of two liver MRE scans.~Part 2: Participants will have a screening visit, followed \~1~month later by one imaging visit. The imaging visit will consist~of two liver MRE scans."
223503449|NCT04280562|DEVICE|Sana Pain Reliever|Participants will receive the SPR device and a tablet with instructions of how to use the device and how to answer the questionnaires on the tablet mobile application. Each session with the device will last 16 minutes and run under the device's normal settings. The session consists of periods of light and sounds (beeps). Participants will be instructed to use the device each day at the end of the day prior to going to sleep and whenever they experience heightened pain during the day.
223503450|NCT04280562|DEVICE|Sham SPR|Participants will receive the SPR device and a tablet with instructions of how to use the device and how to answer the questionnaires on the tablet mobile application. Each session with the device will last 16 minutes and run under the device's sham settings. The session consists of periods of light and sounds (beeps). Participants will be instructed to use the device each day at the end of the day prior to going to sleep and whenever they experience heightened pain during the day.
223503451|NCT00083109|DRUG|Fluorouracil|Given IV
223503452|NCT00083109|OTHER|Pharmacological Study|Correlative studies
223503453|NCT00083109|DRUG|Suramin|Given IV
223503454|NCT01497093|DRUG|Pomalidomide|Pomalidomide 1, 2, 3, or 4 mg will be taken orally on Days 1-14 of a 21-day cycle
223503455|NCT01497093|DRUG|Bortezomib|Bortezomib 1 or 1.3 mg/m2 will be administered intravenously or subcutaneously on Days 1, 4, 8 and 11 of 21 days for cycles 1 -8 and on days 1, 8 of 21 days for cycle 9 and onward until disease progression
223592611|NCT05849519|DRUG|Conventional treatment|The control group was treated with conventional treatment
224194323|NCT06071767|DRUG|Vesatolimod (VES)|VES 6 mg administered orally once every 2 weeks for two doses, then VES 8 mg once every 2 weeks for 8 doses. Dose escalation may be held or the 8 mg dose may be reduced for intolerability for weeks 6 through 24.
224194324|NCT06071767|DRUG|GS-5423|Administered via intravenous (IV) infusion at week 7
224194325|NCT06071767|DRUG|GS-2872|Administered via IV infusion at week 7
224194326|NCT06071767|BIOLOGICAL|MVA.tHIVconsv4|Administered 0.5 mL IM at week 60
224194327|NCT06071767|BIOLOGICAL|Placebo|Placebos for vaccines, VES, and bnAbs
224194328|NCT06053307|BEHAVIORAL|Acceptance commitment therapy|The baseline intervention will use ACT, a psychological intervention based on modern behavioral psychology, including relational frame theory, that uses acceptance and mindfulness strategies, along with commitment and behavior-change strategies to increase psychological flexibility. The proposed intervention will be delivered over a 6-week period, with each week including content related to one of the six tenets of ACT: cognitive defusion, acceptance, contact with the present moment, the observing self, values, and committed action. Each week will include educational material, skills work, and homework. The intervention will be delivered via a mobile application.
224194329|NCT05434754|OTHER|eHealth Tool|text messaging algorithm
224194330|NCT04527380|DRUG|Ixekizumab|Administered SC
224194331|NCT04527380|DRUG|Adalimumab|Administered SC
224194332|NCT06467981|OTHER|Retrospective study|The data from the PET request form will be collected in each center for this population of patients who have had an amyloid PET scan with flutemetamol and the results of the PET examination reports will also be provided, all data will be made anonymous.
224194333|NCT05410418|DRUG|Mosunetuzumab|"Mosunetuzumab is administered subcutaneously using a step-up dosing strategy. The initial dose on C1D1 will be 5 mg, and doses thereafter will be 45 mg."
224194334|NCT05410418|DRUG|Polatuzumab vedotin|Polatuzumab vedotin is administered intravenously over 90 minutes for the initial dose, and over 30 minutes thereafter.
224194335|NCT05329961|DRUG|Gardasil9|The Gardasil 9 vaccine is a recombinant L 1 VLP vaccine containing HPV types 6, 11,16,18, 31, 33, 45, 52 and 58 VLP. The vaccine is not currently licensed for children under 9 years of age but it is licensed in the USA for males and females ages 9 to 45 years old.
224194336|NCT05355545|BEHAVIORAL|Virtually supervised exercise|Participants will participate twice weekly in an live exercise program that they will access through a computer connected to the Internet.
224194337|NCT05355545|BEHAVIORAL|Health education|Participants will first participate in a once weekly live health education class that they will access through a computer connected to the Internet. During the second half of the study, participants will participate twice weekly in an live exercise program that they will access through a computer connected to the Internet.
224194338|NCT05048875|DRUG|Cohort 1 - Group 1 JNJ High Dose|High dose: 600-mg loading dose for 5 days/200-mg maintenance dose for 21 days
224194339|NCT05048875|DRUG|Cohort 1 - Group 2 JNJ Medium Dose|Medium dose: 200-mg loading dose for 5 days/50-mg maintenance dose for 21 days
224194340|NCT05048875|DRUG|Cohort 1 - Group 2 JNJ Low Dose|Low dose: 40-mg loading dose for 5 days/10-mg maintenance dose for 21 days
224194341|NCT05048875|DRUG|Cohort 1 - Group 1/2 Placebo|Matching placebo. Note Group 1 placebo and group 2 placebo are combined per sponsor data analysis.
224194342|NCT06798922|RADIATION|Standard post-operative radiotherapy without flap sparing (current practice)|Standard post-operative radiotherapy without flap sparing (current practice)
224194343|NCT06798922|RADIATION|Post-operative radiotherapy with flap sparing|Post-operative radiotherapy with flap sparing
223503456|NCT01497093|DRUG|Dexamethasone|Dexamethasone 20 mg/day \[≤ 75 years old\] or 10 mg/day \[\> 75 years old\] will be taken orally on days 1, 2, 4, 5, 8, 9, 11, 12 of 21 days for cycles 1-8 and on days 1, 2, 8, 9 of 21 days for cycles 9 and onward until disease progression
223503457|NCT05381168|DIETARY_SUPPLEMENT|Calcium from fish bone|Calcium from fish bone contained calcium 312 mg and vitamin D 100 IU per capsule.
223503458|NCT05381168|DIETARY_SUPPLEMENT|Calcium carbonate|Calcium carbonate contained calcium 600 mg and vitamin D 200 IU per capsule.
223746732|NCT05976802|DRUG|Matching placebo rectal foam|Twice a day for 2 weeks, then once a day for 4 weeks
224194344|NCT05127837|BEHAVIORAL|CBTpro|CBTpro is a novel spoken language technology tool to support high-quality skills training in CBT for psychosis.
224194345|NCT04957979|OTHER|Nursing/Medical Model of Care Coordination|"No social worker on the clinic's care coordination team.~Services provided:~* Coordinated medical care for patients~* Patient education~* Assistance in developing care plan~* Support for patient self-management~* Referrals for continuing care~* Referral to community resources~* Referral to mental health services if needed or requested~* Referral to interventional counseling for behavioral health issues"
224194346|NCT04957979|OTHER|Medical/Social Model of Care Coordination|"Social worker is part of the clinic's care coordination team.~* Need not be licensed as a social worker~* Must have time dedicated to care coordination for a specific clinic or clinics~* Must interact with individual patients to provide them with services~* Must interact with individual clinicians about their individual patients in care coordination~Services provided:~* Coordinated medical care for patients~* Patient education~* Assistance in developing care plan~* Support for patient self-management~* Assistance with referrals for continuing care~* Assessment and plan to address social and resource needs including housing, transportation or financial needs; Assist patient in locating and obtaining needed community resources~* Assistance with identifying and addressing psychological/emotional issues and referrals as needed~* Interventional counseling for behavioral health issues or referrals to interventional counseling, depending on licensure"
224194347|NCT01550237|RADIATION|radiotherapy daily verification reduced safety margins|curative radiotherapy to 78 Gy in 39 fractions with daily CT position verification and reduced safety margins (7mm)
224194348|NCT01550237|RADIATION|radiotherapy weekly verification standard safety margins|curative radiotherapy to 78 Gy in 39 fractions with weekly orthogonal position verification and standard safety margins (10-15 mm)
224314223|NCT05856630|DRUG|Goserelin Acetate Sustained-Release Microspheres for Injection|10.8mg, Single dose, subcutaneously（SC）
223503459|NCT03139253|DRUG|amoxicillin|amoxicillin 1000 mg bid. for 14 days
223503460|NCT03139253|DRUG|clarithromycin|clarithromycin 500 mg bid. for 14 days.
223503461|NCT03139253|DRUG|tinidazole|tinidazole 500 mg bid. for 14 days.
223746733|NCT02869594|OTHER|Data collection|
223746734|NCT01361438|OTHER|Total therapy approach|Total therapy approach
223503462|NCT03139253|DRUG|levofloxacin|levofloxacin 500 mg qd. for 14 days.
223503463|NCT03139253|DRUG|furazolidone|furazolidone 100 mg bid. for 14 days.
224194349|NCT06521320|DIAGNOSTIC_TEST|speaking valve combined with airway pressure|All patients were given speaking valves and airway pressure was measured to assess upper airway patency.
224194350|NCT06521320|DIAGNOSTIC_TEST|Bronchoscopy|The same examiner performed bronchoscopy on all patients to assess upper airway patency.
224194351|NCT03978988|DEVICE|Carotid Stenting|emergent carotid stenting will be performed if the patient is randomized in the intervention arm. The order to treat (head first or neck first), and the choice of a previous angioplasty of the extracranial carotid artery lesion will be left to the interventionist discretion.
224194352|NCT03978988|DRUG|Procedural Aspirin|After carotid stenting, an intravenous bolus of 250mg of Aspirin will be given at the end of the procedure in case of absence of complication.
224310323|NCT01177475|OTHER|blood samples, feces samples|After the 32nd week until the 36th week or the end of hospitalization,infants continued mother's native milk or received substitute.
223503464|NCT03139253|DRUG|tetracycline|tetracycline 750 mg bid. for 14 days.
223503465|NCT03139253|DRUG|Ilaprazole|Ilaprazole 5 mg bid. for 14 days.
223503466|NCT01254877|DRUG|ondansetron|ondansetron 0.2 mg bid, oral preparation, 16 weeks
223503467|NCT01254877|DRUG|placebo ondansetron|Matching placebo will be prepared using a colorless strawberry syrup, simple syrup and flat Schweppes tonic water.
223503468|NCT01254877|DRUG|Ondansetron|Ondansetron 0.8 mg bid, oral preparation, 16 weeks duration
223503469|NCT03406052|BEHAVIORAL|Smartphone-Assisted MB-CBT|Experimental subjects will receive a mindfulness-based CBT online software program workbook (in collaboration with Nex J Systems, Inc.) accessible online. Exposure to and interaction with the online workbook is combined with health coaching (duration of 24 total hours) primarily delivered in phone and software interactions. In addition, each participant will be given a Fitbit-HR Charge, a wearable bracelet that assesses physical steps and 24 hour heart rate in 5 second (averaged) durations (with related access to software that permits daily tracking).
223503470|NCT06281613|DEVICE|AMCOP group|Patients were treated with AMCOP for 18 months.
223503471|NCT06281613|DEVICE|High-pull headgear|Patients were treated with high-pull headgear for 18 months.
223503472|NCT05507450|BIOLOGICAL|V181 High-Potency Level|0.5 mL SC dose of V181 High-Potency vaccine
223503473|NCT05507450|BIOLOGICAL|V181 Mid-Potency Level|0.5 mL SC dose of V181 Mid-Potency vaccine
223503474|NCT05507450|BIOLOGICAL|V181 Low-Potency Level|0.5 mL SC dose of V181 Low-Potency vaccine
223503475|NCT05507450|BIOLOGICAL|Placebo|0.5 mL SC dose of placebo
223503476|NCT01746875|DRUG|Aflibercept|2.0 mg monthly x 3 doses, then as needed based on recurrence of activity on OCT. If no effect after the initial 3 doses; 2.0 mg monthly x 3 doses is repeated.
223503477|NCT01746875|DRUG|Verteporfin|given if aflibercept does not have any effect. Verteporfin photodynamic therapy is given in combination with aflibercept and triamcinolone. The treatment can be repeated after 3 month.
223503478|NCT02904356|DEVICE|Repetitive transcranial magnetic stimulation|High-frequency, brainsway H-coil for repetitive transcranial magnetic stimulation will be administered to the medial prefrontal cortex for 3 weeks. The intensity of stimulation will be based on resting-motor threshold (RMT).
223503479|NCT01118091|BIOLOGICAL|Aldesleukin|Aldesleukin 720,000 IU/kg IV over 15 minute every eight hours and continuing for up to 5 days (maximum of 15 doses). Patients will receive one additional cycle of aldesleukin approximately 10-14 days after completion of the first cycle of aldesleukin.
223503480|NCT01118091|BIOLOGICAL|CD8 enriched Young TIL|Adoptive Cell Therapy consisting of the lymphocyte depleting preparative regimen consisting of fludarabine and cyclophosphamide, followed by infusion of between 1x10\^9 to 2x10\^11 CD8+ enriched tumor infiltrating lymphocytes (minimum of 5 x 10\^8) and the administration of high-dose aldesleukin.
223503481|NCT00034385|DRUG|Valganciclovir|
223503482|NCT00514917|DRUG|Docetaxel|75 mg/m\^2 intravenous infusion over 1 hour every 3 weeks up to 10 cycles.
223503483|NCT00514917|DRUG|Leuprolide|22.5 mg injection subcutaneously every 12 weeks up to 18 months.
223503484|NCT00514917|DRUG|Bicalutamide|50 mg tablet orally once daily for first 4 weeks of treatment.
223503485|NCT01877954|DRUG|Extra-fine hydrofluoroalkane beclometasone dipropionate|
223503486|NCT01877954|DRUG|Fluticasone propionate|
223503487|NCT05319405|DEVICE|Sana Device|Externally worn mask that physically contacts the skin of the face. The Sana Device delivers Audio Visual Stimulation (AVS) in the form of coordinated pulses of light (through closed eyelids) and sound at various frequencies.
223503488|NCT02697422|OTHER|Community-based peer health coach intervention|The focus of the peer health coach intervention will be to deliver brief health messages, discuss goal setting, and action planning around health behavior changes shown to decrease CVD risk (for instance, healthy diet, regular to moderate-intensity physical activity, and quitting smoking).
223503489|NCT00444249|PROCEDURE|White Alcon IOL|Implantation of white Alcon IOL
223503490|NCT00444249|PROCEDURE|Yellow Alcon IOL|Implantation of yellow Alcon IOL
223503491|NCT00444249|PROCEDURE|White Hoya IOL|Implantation of white Hoya IOL
223503492|NCT00444249|PROCEDURE|Yellow Hoya IOL|Implantation of yellow Hoya IOL
223503493|NCT00016302|DRUG|prednisone|Given orally
223503494|NCT00016302|DRUG|vincristine sulfate|Given IV
223503495|NCT00016302|DRUG|daunorubicin hydrochloride|Given IV
223503496|NCT00016302|DRUG|asparaginase|Given IM
223503497|NCT00016302|DRUG|methotrexate|Given IT and orally
224194353|NCT03978988|DRUG|Dual dual antiplatelet therapy after 24-hours imaging follow-up|A dual antiplatelet therapy is administered after 24-hours imaging follow-up excluding intracranial hemorrhagic complications (the type and the dose of the dual antiplatelet therapy are left to the discretion of the local practice)
224194354|NCT03978988|PROCEDURE|Intracranial thrombectomy|Intracranial thrombectomy is the endovascular procedure. In the experimental group, thrombectomy will be completed with a extracranial carotid stenting.
224310324|NCT04614415|DEVICE|Autocrosslinked Hyaluronic aid|IAL-SYSTEM ACP gel is an auto-cross-linked HA derivative in the form of highly viscous gel. In this direct formation of ester linkages no foreign substances are introduced into the molecule, thus catabolism of ACP leads only to HA
224310325|NCT04614415|OTHER|placebo|The placebo consists in an isotonic saline solution (NaCl 0.9%)
224194355|NCT05311878|DEVICE|EEG-based perceptual training|Electroencephalography (EEG) signals will be recorded from subjects as they perform rotation-based perceptual tasks. The neural correlates of conscious perception of rotations will be processed and decoded in real-time using machine learning algorithms to provide feedback. Subjects are instructed to assume a mental state/find a strategy to maximise the accuracy of feedback. In total, each subject will complete 5 sessions of perceptual training with this intervention.
224194356|NCT05311878|DEVICE|Behavior based perceptual training|Subjects complete the rotation-based perceptual tasks, and ground truth visual feedback is provided indicating whether subjects have spotted the rotations correctly. Subjects are instructed to spot as many rotation as possible to maximise the accuracy of feedback. In total, each subject will complete 5 sessions of perceptual training with this intervention.
224194357|NCT06137040|DRUG|Magnesium Sulfate within the first hour|"The experimental group will receive 40-50 mg/kg of IV magnesium sulfate will be given to the experimental group alongside the first line asthma therapies (ie inhaled beta agonists, IV steroids). This will be given with a 20 mL/kg normal saline bolus (max 1000 mL) to avoid possible hypotension.~15-19 kg: 750 mg~20-29 kg: 1000 mg~30-39 kg: 1500 mg~\>40 kg: 2000 mg"
224194358|NCT06137040|OTHER|No Magnesium sulfate within the first hour|The control group will not receive IV magnesium sulfate within the first hour of treatment.
224194359|NCT04213651|OTHER|No intervention|There is no intervention for this study
224194360|NCT05688943|PROCEDURE|Spinal Anesthesia|Fentanyl (1µg/kg) and midazolam are administered intravenously prior to puncture. Using an aseptic technique, the subarachnoid space is punctured with a 25/27 gauge needle in the intervertebral space, and a standard dose of chloroprocaine 45-60mg is injected. Alternative spinal anesthetics include bupivacaine 6-15mg and mepivacaine 50-70mg. The participant is then placed in the supine position in 10-degree Trendelenburg until the lack of sensitivity is adequate at spinal level T4.
223503498|NCT00016302|DRUG|cyclophosphamide|Given IV
223503499|NCT00016302|DRUG|cytarabine|Given IV or SC
223503500|NCT00016302|DRUG|mercaptopurine|Given orally
223503501|NCT00016302|DRUG|leucovorin calcium|Given IV or orally
223503502|NCT00016302|DRUG|dexamethasone|Given orally
223503503|NCT00016302|DRUG|doxorubicin hydrochloride|Given IV
223503504|NCT00016302|DRUG|thioguanine|Given orally
223503505|NCT00016302|RADIATION|radiation therapy|Undergo cranial irradiation
223503506|NCT00016302|DRUG|nelarabine|Given IV
223503507|NCT00016302|DRUG|pegaspargase|Given IM
223503508|NCT00016302|RADIATION|radiation therapy|Undergo craniocervical radiotherapy
223592612|NCT04827303|OTHER|Kinesio taping|A 10-15 cm sized I band was applied to the trapezius muscles of the first group patients with the patient's neck in lateral flexion. Then, while the patient's neck is flexed, a Y-shaped 15-20 cm tape will be affixed between C1-7 with the arms of the Y up, and I tape of 5-10 cm is attached on the arms. In group 2 patients, 1 cc lidocaine diluted with 4 cc saline (SF) was applied to the trigger points palpated manually in the trapezius muscles. After the trigger point was squeezed between the thumb and index finger, a few cc of local anesthetic mixture was applied into the trigger point with the injector and exited. In the 3rd group patients, a few cc local anesthetic mixture will be applied intradermally over the trigger point without entering into the trigger points palpated manually in the trapezius muscles. Patients were checked 72 hours and 1 week after the first applications.
223592613|NCT02461082|DEVICE|Expiratory muscle strength training (EMST)|The EMST is performed 4 weeks, 5 days per week, for 20 minutes per day, using a calibrated or sham, handheld device (EMST 150, Aspire Products, Gainesville, FL).
223592614|NCT02461082|OTHER|Transcranial magnetic stimulation (TMS)|A sham or active transcranial magnetic stimulation is performed at the last 5 days of EMST training.
223592615|NCT02666612|PROCEDURE|Blood samples|
223592616|NCT01767623|DRUG|Vemurafenib|Vemurafenib orally BID 960 or 720 mg.
223592617|NCT01391988|PROCEDURE|Electric scalpel|Radical mastectomy with electric scalpel. Electric scalpels were calibrated at 40 watts of cutting and coagulation power.
223592618|NCT01391988|PROCEDURE|Harmonic scalpel|Radical mastectomy with harmonic scalpel. Harmonic GEN04 generator calibrated at power leve 3 and 5, using the HP054 handpiece and HF 105 curved blade
223592619|NCT03876665|OTHER|No intervention|No intervention
223746735|NCT01874496|DIETARY_SUPPLEMENT|GDS, no meal|GDS, no meal
223746736|NCT01874496|DIETARY_SUPPLEMENT|GDS, meal|GDS, meal
224194361|NCT05688943|PROCEDURE|General Anesthesia|General anesthesia is a state of controlled unconsciousness. During a general anesthetic, medicines are used to send the participant to sleep making the participant unaware of surgery and so that the participant does not move or feel pain while the surgery is carried out. Induction of general anesthesia includes the use intravenous sedative-hypnotic agents such as propofol, etomidate, or ketamine, along with adjuvant agents such as fentanyl, lidocaine, or midazolam. A neuromuscular blocking agent such as succinylcholine or rocuronium is used to facilitate endotracheal intubation.
224194362|NCT04525755|DRUG|Varenicline 0.5 MG|varenicline comes in bottles of 56 - 0.5 mg pills
224194363|NCT04525755|DRUG|Nicotine Replacement Therapy (NRT)|28 day supply of nicotine patch (1 patch x 28 days @ 14 mg) and lozenge (14 per day x 28 days @ 4 mg)
224310326|NCT01758588|DRUG|Peginterferon alfa-2a|50 mcg subcutaneous injection once per week
224314224|NCT05856630|DRUG|Zoladex 10.8 MG Drug Implant|10.8mg, Single dose, subcutaneously（SC）
223503509|NCT00016302|OTHER|pharmacological study|Correlative studies
223503510|NCT00016302|OTHER|laboratory biomarker analysis|Correlative studies
223503511|NCT00235313|PROCEDURE|Dose adjustment of nicotine replacement therapies|Dose adjustment of nicotine replacement therapies
223503512|NCT00235313|DRUG|nicotine patch|normal following with a nicotine patch
223503513|NCT01708525|DEVICE|Ulthera® System Treatment|Focused ultrasound energy delivered below the surface of the skin
223503514|NCT01708525|OTHER|Heavy Water|A tissue labeling model via the consumption of the stable isotope, deuterated water (heavy water). Heavy water consumed over the course of the 6-week study period for a direct kinetic measure of in vivo collagen synthesis. 60 ml (about 12 teaspoons) of heavy water (also called deuterated water or 2H2O), was consumed three times a day for the first five days. Starting on Day 6, two 60 ml doses of heavy water were consumed per day for the remaining 37 days.
223503515|NCT02815956|DEVICE|percutaneous tibial nerve stimulation|
223503516|NCT02815956|DEVICE|Placebo|
223592620|NCT00614484|RADIATION|Proton Radiation Therapy|A five week coarse of proton radiotherapy begins on day 28 and is given once daily for the first two weeks and twice daily for the final 3 weeks. The total dose given with proton beam is 76 Gy. Weekly chemotherapy with carboplatin and taxol is given during proton therapy.
223592621|NCT00614484|DRUG|Taxol|200 mg/m2, IV, for 2 cycles followed by 50 mg/m2 weekly for 5 weeks during radiotherapy.
223592622|NCT00614484|DRUG|Carboplatin|AUC 6, IV, for two cycles followed by AUC 2 weekly for 5 weeks during radiotherapy.
223592623|NCT05945160|DRUG|Alpha Lipoic Acid 300mg|A naturally occuring mitochondrial antioxidant
223592624|NCT05945160|DRUG|Coenzyme Q10 200mg|A naturally occuring mitochondrial antioxidant
223592625|NCT03590951|OTHER|Retrospective chart review|A retrospective chart review was conducted to evaluate the effect of body mass index on obstetric, anesthetic and neonatal complications in patients who underwent cesarean section at our institution
223592626|NCT02058394|PROCEDURE|Phacoemulsification|Subjects will be recruited serially from eligible candidates on the basis of presentation for cataract evaluation and subsequent cataract surgery with phacoemulsification.
223592627|NCT04462939|DIETARY_SUPPLEMENT|Elevit Breastfeeding & Postnatal Care|Multi-micronutrients, lutein and DHA soft gel capsules; one capsule daily, oral
223592628|NCT04462939|DRUG|Placebo|No active ingredients except of 225 μg iodine; One capsule daily, oral
223592629|NCT03085186|DRUG|Crizotinib|
223592630|NCT01143194|DIETARY_SUPPLEMENT|oréVida™|1 capsule 30 mg oréVida™ twice a day (one in the morning, one in the afternoon, so in total 60 mg/day)
223592631|NCT01143194|DIETARY_SUPPLEMENT|oréVida™|1 capsule 60 mg oréVida™ twice a day (one in the morning, one in the afternoon, so in total 120mg/day)
223592632|NCT01143194|DIETARY_SUPPLEMENT|oréVida™|1 capsule 120 mg oréVida™ in the morning, one placebo capsule in the afternoon (si in total 120 mg/day)
223592633|NCT01143194|DIETARY_SUPPLEMENT|Placebo|1 capsule of placebo twice a day
223592634|NCT01218399|DRUG|Symbicort|
223592635|NCT06120894|DIAGNOSTIC_TEST|Central visual acuity|Measurement of central visual acuity using Snellen optotype chart.
223746737|NCT01874496|DIETARY_SUPPLEMENT|control, no meal|control, no meal
224194364|NCT03569956|OTHER|556 Razor|In the Razor group, subjects will use the 556 Razor with their regular shaving products, and shave at least 5 or more times per week. In the Regimen group, subjects will use the 556 Razor, Pre-Shave Gel, Cleansing brush and Shaving Gel, and shave at least 5 or more times per week. All subjects will be given the 556 Razors during the 12-week study. The Regimen group will also be given the Pre-Shave Gel, Cleansing Brush, and Shaving Gel.
224314225|NCT03339167|DIETARY_SUPPLEMENT|Metabolic availability of lysine in millet|Four levels of lysine intakes will be provided by the reference protein drinks, 3 levels of lysine from millet and 1 level from millet with lentils.
224314226|NCT01250886|DRUG|Lactated Ringer's solution|Lactated Ringer's solution is administered. The volume of fluid administration is calculated by means of Holliday and Segar formula.
223592636|NCT06120894|DIAGNOSTIC_TEST|Intraocular pressure measurement|Measurement of intraocular pressure using non-contact Canon TX-20P tonometer.
223592637|NCT06120894|DIAGNOSTIC_TEST|Slit lamp examination|Slit lamp examination of the anterior and posterior segment of the eye after pharmacological dilation of the pupil using application of short-time mydriatics (1% tropicamide and 10% phenylephrine).
223592638|NCT06120894|DIAGNOSTIC_TEST|Refraction and keratometry|Measurement of refraction and keratometry using refractometer Nidek ARK-1a.
223592639|NCT06120894|DIAGNOSTIC_TEST|Optical biometry|Measurement of optical biometry using biometer Argos (Barrett or SRK/T formula).
223592640|NCT06120894|DIAGNOSTIC_TEST|Strip meniscometry (SM)|Strip meniscometry examination using strip meniscometry tube.
223592641|NCT06120894|DIAGNOSTIC_TEST|Lid Parallel Conjunctival Folds test (LIPCOF)|Evaluation of lid parallel conjunctival folds using slit lamp examination.
223592642|NCT06120894|DIAGNOSTIC_TEST|Staining of the ocular surface with fluorescein|Evaluation of ocular surface fluorescein staining using Oxford scheme.
223746738|NCT01874496|DIETARY_SUPPLEMENT|control, meal|control, meal
223746739|NCT04640545|DRUG|LBL-007|LBL-007 will be administered intravenously every two weeks (Q2W) .
223746740|NCT04640545|DRUG|Toripalimab|Toripalimab Injection will be administered by intravenously (Q2W) .
223746741|NCT04640545|DRUG|Axitinib Tablets|Axitinib Tablets On-demand administration
223746742|NCT00358085|PROCEDURE|Endovascular Repair of Abdominal Aortic Aneurysm|
223746743|NCT00358085|PROCEDURE|Conventional open repair of Abdominal Aortic Aneurysm|
223592643|NCT06120894|DIAGNOSTIC_TEST|Tear break up time test (TBUT)|Evaluation of tear break up time using slit lamp examination.
223592644|NCT06120894|OTHER|Ocular Surface Disease Index questionnaire (OSDI)|Evaluation of Ocular Surface Disease Index using Ocular Surface Disease Index questionnaire.
223592645|NCT03009318|OTHER|tumors are confirmed by surgery and pathology|Each patient undergoes both MRS and MET PET scan before surgery. The lesion will be considered as a glioma when either MRS or MET PET results indicated the diagnosis. Pathologic diagnosis will be performed to confirm the final diagnosis.
223592646|NCT00989781|RADIATION|3-D Ultrasound|One time pelvic ultrasound
223592647|NCT00989781|DRUG|recombinant human chorionic gonadotropin|Recombinant human chorionic gonadotropin will be given iv and blood samples obtained before and 24 hr afterwards
223592648|NCT00989781|DRUG|Recombinant human follicle stimulating hormone|Recombinant human follicle stimulating hormone will be given iv and blood samples obtained before and 24 hr later.
223592649|NCT00989781|DRUG|Adrenocorticotropin|Each subject will receive a 7 hr dose-response infusion of Adrenocorticotropin.
223592650|NCT00989781|DRUG|Dexamethasone|Dexamethasone will be given prior to ACTH infusion test.
223592651|NCT00989781|DRUG|Glucose|Each subject will undergo 3 oral glcuose tolerance tests.
223592652|NCT05967949|DRUG|chidamide|This subset of patients received chidamide as first-line maintenance therapy.
223592653|NCT00410306|DRUG|Testosterone Undecanoate (Nebido, BAY86-5037)|Patients from routine practice
223746744|NCT04295148|PROCEDURE|ACL Reconstruction with Semitendinosus graft|Participants will undergo Anterior Cruciate Ligament Reconstruction with Semitendinosus graft
223746745|NCT04295148|PROCEDURE|ACL Reconstruction with Quadriceps tendon-bone graft|Participants will undergo Anterior Cruciate Ligament Reconstruction with Quadriceps tendon-bone graft
224194365|NCT06374381|BEHAVIORAL|PEACE Online Resources|The PEACE online resource includes self-paced training modules that cover the foundations of caregiver coaching, caregiver perspectives towards coaching, strategies for aligning with caregivers and gaining buy-in for coaching, evidence-based strategies to empower caregivers from marginalized backgrounds, and strategies to improve collaboration and cohesion among providers working with the same child. Each module includes brief example videos, easy-to read infographics, tip sheets, and checklists to guide implementation. A virtual communication application, Slack, facilitates frequent communication, enhances social networks among providers, and creates social norms related to the use of caregiver coaching. Providers can post questions or suggestions, share resources, and receive updates about other providers' accomplishments. Consultants frequently post encouraging messages and progress updates to increase motivation and shared norms for coaching.
224194366|NCT06374381|BEHAVIORAL|PEACE Weekly Group Facilitation|Facilitation comprises interactive problem solving and support, a shared understanding of need for improvement, and a supportive interpersonal relationship. Providers participate in 12 weekly group facilitation meetings for one hour virtually with an expert consultant focused on auditing providers' fidelity to caregiver coaching through role-play and performance feedback. Each group meeting aligns with content from the PEACE online resource library modules.
224194367|NCT06374381|BEHAVIORAL|PEACE Weekly Individual Facilitation|Individual facilitation is delivered virtually for one hour each week for eight weeks with a consultant focused on reflection and problem solving any identified implementation barriers, as well as practice and performance feedback.
224194368|NCT04211402|OTHER|No Intervention|There is no intervention for this study
224194369|NCT04081805|PROCEDURE|LASER|The patient will use intravaginal estriol, daily for 2 weeks and them twice a week for 3 months . Each 30 days, the patients will have an appointment when will be checked the weight of the estriol tube to verify the correct use.vulvar application of LASER, to postmenopausal genitourinary syndrome. The patient will be in gynecological position, after remove of vaginal secretion, with gauze and under topic anesthesia, the LASER will be applied, according to the protocol of the manufactured.
224194370|NCT04081805|PROCEDURE|Micro Ablative Radiofrequency|Use of Linly™ equipment to perform ambulatory intravaginal and vulvar application of fractionated microablative radiofrequency, to postmenopausal genitourinary syndrome. The patient will be in gynecological position, after remove of vaginal secretion, with gauze and under topic anesthesia, the radiofrequency will be applied, according to the protocol of the manufactured
224194371|NCT04081805|DRUG|Promestriene|The patient will perform self application of this vaginal promestriene daily for 2 weeks and after that the applications will occur twice a week.
224194372|NCT06127121|BEHAVIORAL|Digital Art Activity|"* complete a symptom questionnaire~* complete another activity such as listening to meditative music for 10 minutes~* fill out the symptom questionnaire and engage in the digital art activity again"
224194373|NCT04591093|DEVICE|FineHearing Strategy with 10 more apical electrodes or with 10 more basal electrodes activated|Cochlear implant with FineHearing Strategy with 10 more apical electrodes activated or with 10 more basal electrodes activated
224194374|NCT05740956|DRUG|HS-10502|HS-10502 will be administered once per day on a continuous dosing schedule starting on Cycle 1 Day 1 (C1D1) in a 28-day treatment cycle.
224194375|NCT06535347|BEHAVIORAL|Information about scheduling a follow-up appointment|Text message(s) will be sent following discharge from the emergency department, along with an after visit summary.
224194376|NCT01860937|PROCEDURE|leukapheresis or collection of PBMCs|
224194377|NCT01860937|DRUG|cyclophosphamide based chemotherapy regimens|
224194378|NCT01860937|BIOLOGICAL|modified T cells|
224194379|NCT05065554|DRUG|Acalabrutinib|Dose per protocol, oral twice daily per cycle
224194380|NCT05065554|DRUG|Rituximab|Premedications (including acetaminophen, an antihistamine, and a steroid) will be given per institutional guideline Dosage determined per protocol and cycle timepoint, Route IV or SQ per protocol and cycle timepoint, schedule per protocol and cycle timepoint
224194381|NCT02780310|DRUG|Lenvatinib|
224194382|NCT06647849|PROCEDURE|centers whose interns receive simulation training in the announcement of early spontaneous miscarriage between the 2 inclusion phases|"The simulation training sessions for the announcement consultation are set up directly in the centers participating in the with training arm of the study, after the first phase of patient inclusion. These sessions will take place in situ in the center's maternity ward, and will be run by a single team trained in simulation and announcement.~This team of trainers is identical for all centers randomized in the with training arm, and is made up of two trainers: an obstetrician-gynecologist and a psychologist."
224194383|NCT06647849|OTHER|centers with standard in-house management of spontaneous miscarriage/pregnancy arrested in the emergency department|"In the participating centers included in the no training arm, interns will have no specific training in announcement. Patients will receive information concerning the diagnosis of a terminated pregnancy or miscarriage from interns not trained in simulation.~During the course of the study, training in the announcement of a miscarriage will be offered to interns from centers in the no training group."
224314227|NCT01250886|DRUG|Normal saline solution|Normal saline solution is administered. The volume of fluid administration is calculated by means of Holliday and Segar formula.
223592654|NCT05339230|DIETARY_SUPPLEMENT|Salovum and SPC-flakes active or placebo|Foods for specific medical purposes or corresponding placebo
223592655|NCT00189501|DRUG|Sensipar®|
224314228|NCT01250886|DRUG|Acetate Ringer's solution|Acetate Ringer's solution is administered. The volume of fluid administration is calculated by means of Holliday and Segar formula.
223592656|NCT06219395|PROCEDURE|Endoscopy|Patients will be examined with gastroscopy, colonoscopy and WCE and the diagnostic yield of combined gastroscopy/colonoscopy will be compared to WCE
223592657|NCT00651625|DEVICE|Reciprocating Procedure Device (RPD) - AVANCA Re No. 1091001|The RPD is a safety syringe device that is hypothesized to be safer, less painful, and more effective for patients undergoing a syringe and needle procedure (please see arm #1).
223592658|NCT00651625|DEVICE|conventional syringe - BD Ref 309604|the conventional syringe or the RPD will be used for syringe and needle procedures performed by physicians.
223592659|NCT00257972|DRUG|aripiprazole|
223592660|NCT04841369|BIOLOGICAL|13-Valent Pneumococcal Polysaccharide Conjugate Vaccine（CRM197,TT）|0.5mL,Intramuscular
223592661|NCT04841369|BIOLOGICAL|13-Valent Pneumococcal Polysaccharide Conjugate Vaccine|0.5mL,Intramuscular
224194384|NCT02318342|DRUG|Warfarin|Patients with prosthetic valve abnormalities suggestive of thrombus will be administered anticoagulation therapy with Vitamin K antagonists (Warfarin) for 3 months with goal INR 2-3, followed by repeat contrast CT of the chest and transthoracic imaging. Repeat imaging following 3 months of anticoagulation therapy is performed to evaluate the response to anticoagulation therapy.
224194385|NCT03914547|BEHAVIORAL|REDCHiP|REDCHiP includes 10 telehealth sessions. REDCHiP uses a three-pronged approach to reduce parents' FH. It uses T1D education and problem-solving to enhance parents' knowledge and skills. It uses child age-appropriate behavioral parent training to promote parents' skills and confidence in managing disruptive child behaviors and reducing their reliance on hypoglycemia avoidance behaviors. It uses cognitive-behavioral therapy strategies to help parents reduce maladaptive thinking/coping related to hypoglycemia fear.
224194386|NCT03914547|BEHAVIORAL|ATTN|Provides a similar attention control. ATTN includes 10 telehealth sessions.
224194387|NCT06058988|DRUG|Trastuzumab deruxtecan|All participants will receive T-DXd prior to indicated brain tumor resection/biopsy
224194388|NCT05525663|BEHAVIORAL|Rehabilitation Intervention|progressive, multi-domain rehabilitation and exercise training intervention
223592662|NCT03288363|DEVICE|tDCS|20 sessions of tDCS stimulation on dorsolateral prefrontal cortex with the apparatus DC-Stimulator Plus (Neuroconn)
223746746|NCT04037319|DIAGNOSTIC_TEST|24 Hour Holter Monitor|24 hour holter monitor to be performed pre-operatively, and at day 30 and 90 post-operatively.
223746747|NCT04380610|DIAGNOSTIC_TEST|iohexol GFR|We will perform mGFR in 400 SCA patients
223746748|NCT04387227|DRUG|Carboplatin|Given IV
223592663|NCT05957614|PROCEDURE|Traditional rehabilitation protocol|Rehabilitation protocol after open surgery for Achilles tendon rupture, including immobilization, early weightbearing ankle motion exercise and isolated early ankle motion exercises.
223592664|NCT05957614|PROCEDURE|Acupuncture-assisted Rehabilitation Protocol|Add acupuncture treatment on the basis of traditional rehabilitation protocol.The acupuncture procedure is as follows, acupuncture treatment is carried out for half an hour every day in two weeks after surgery. The acupoints on the affected side are ST36(ZuSanLi), GB34(YangLingQuan) and SP9(YinLingQuan), and the acupoints on the healthy side are Ki3(TaiXi), bl60(KunLun) and PC7(DaLing).
223592665|NCT04232436|OTHER|Survival at discharge|Survival at discharge
223592666|NCT04232436|OTHER|Survival without severe morbidity|Survival without severe morbidity (IVH, severe BPD, NEC, ROP)
223592667|NCT03650790|DIAGNOSTIC_TEST|Blood test|For serum analysis, approximately 2 cc antecubital vein venous blood serum will be taken from each patient to be studied for CTRP9 Level analysis. Adult blood will be centrifuged at 4000 rpm for 10 minutes to separate greenhouses. The obtained serum samples will be stored at -80 ° C until analysis.
223592668|NCT00230152|DEVICE|Imaging|
223592669|NCT00576576|DRUG|Atorvastatin|Atorvastatin 80 mg a day
223592670|NCT00712803|BIOLOGICAL|rDEN3-3'D4delta30|Live attenuated 10\^3 dose of rDEN3-3'D4delta30 vaccine.
223592671|NCT00712803|BIOLOGICAL|rDEN3-3'D4delta30|Live attenuated 10\^5 dose of rDEN3-3'D4delta30 vaccine.
223592672|NCT00712803|BIOLOGICAL|rDEN3-3'D4delta30|Live attenuated 10\^1 dose of rDEN3-3'D4delta30 vaccine.
223746749|NCT04387227|BIOLOGICAL|Pembrolizumab|Given IV
223746750|NCT04387227|PROCEDURE|Computed Tomography|Undergo CT
223746751|NCT04387227|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223746752|NCT04387227|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
224194389|NCT04996173|DEVICE|Spray cryotherapy|A novel FDA cleared technique that allows for Liquid nitrogen (LN2) to be delivered in a metered fashion via a catheter through a flexible bronchoscope.
224194390|NCT04996173|DEVICE|Ballon Dilation|An endoscopic balloon that is inflated with water to pressures between 45 and 131 psi (3 to 9 atm) using a syringe and pressure manometer.
224194391|NCT04996173|DEVICE|Radial Incision|Carbon dioxide (CO2) laser or Monopolar electrocautery knife
223592673|NCT01432990|DEVICE|Robot gait training|Robotic gait training for 20 minute include preparing and rest time for 10 minute plus conventional physical therapy program for 30 minute, totally 60 minute per day for 5 working day per week.
223592674|NCT01432990|OTHER|control|Conventional physical therapy program for 60 minute per day for 5 working day per week.
223592675|NCT05976009|DEVICE|active rTMS stimulating|Two sessions of active rTMS would be delivered, with 1800 pulse/session and 50 min inter-session intervals.
223592676|NCT05932368|OTHER|evaluation|examining files and taking records
223592677|NCT00016549|BIOLOGICAL|Bevacizumab|
223746753|NCT04280510|GENETIC|Blood sample collection; gastrointestinal biopsy|Targeted Next generation sequencing and whole exome sequencing Phenotyping of intestinal lymphocytes, single cell analyses, cytokines dosage...
223746754|NCT06325150|DEVICE|Light emitting glasses|Assess the capacity of 20 min use of AYO light emitting glasses on different outcomes
223746755|NCT04251026|DRUG|tividenofusp alfa|Intravenous repeating dose
223746756|NCT04098354|DIAGNOSTIC_TEST|home BP telemonitoring system .|Patients will receive a Bluetooth-enabled and validated electronic upper arm oscillometric BP device (A\&D Ltd. UA-651BLE; San Jose, CA) that will be paired to their smartphone. Patients will be required to sit with their back rested for at least 5 minutes with the BP cuff around their arm. They will then be required to push the start button on the HBPT device to initiate BP measurement. HBPT values will be based on a series comprised of the mean of duplicate measures, for morning and evening, for a 7-day period and the first day home BP values will not be considered. The BP data will be auto transmitted via Bluetooth to their smartphone and relayed to a secure web portal for review.
223746757|NCT02097355|OTHER|TriVox for clinical care|Use TriVox disease modules to manage patients
223746758|NCT05207995|BIOLOGICAL|Autologous tolerogenic dendritic cells|Autologous tolerogenic dendritic cells treated with Vitamin-D3, co-cultivated with mesenchymal stem cell and primed peptides (MSC-tolDC) injected subcutaneous.
223746759|NCT05207995|OTHER|Standard treatment according to the clinical protocols|Standard treatment of type 1 diabetes mellitus according to the clinical protocols
223746760|NCT05811442|DRUG|50561 high dose|study drug
223746761|NCT05811442|DRUG|50561 low dose|study drug
223746762|NCT05811442|DRUG|Placebo|Non-active study drug
224310327|NCT06456905|BEHAVIORAL|Contingency Management|Participants in the contingent group will be rewarded on an incrementally increasing scale for submitting consecutive breathalyzer samples that are 0.00%. For every day this target is met, the participant will receive an increase in reward until a daily cap is reached. If a day contains at least one sample where the target is not met, the participant will not be paid for that day, and the amount will reset. The participant will have the opportunity to earn on this scale throughout the duration of the study.
224310328|NCT00185445|DRUG|Fludarabine Phosphate (Fludara)|All patients will receive fludarabine phosphate orally for 3 consecutive days per cycle and mitoxantrone on day 1. Each patient will receive up to six treatment cycles. Treatment cycles will be given at 4 weeks intervals.
224310329|NCT02838121|DRUG|Aclasta|Aclasta once annually for 2 years
224310330|NCT02838121|DRUG|Placebo|No IV aclasta
224310331|NCT04504305|OTHER|NeuropAWAY|2 capsules thrice daily to be taken half an hour prior to meal.
223503517|NCT03170921|OTHER|Angola|The rhythm performance (Angola) had duration of 90 seconds. During recovery period (post- intervention) in the moments 1, 3, 5, 7, and 9 minutes was measured the physiological and the perceptual variables of the study.
224194392|NCT06340503|DEVICE|Research-grade accelerometer|Participants will be instructed to wear device for 7 days prior to each visit and to bring the device to each visit. Study staff will extract data from the device within 14 days after each appointment and return the device to patients by mail.
224194393|NCT06340503|OTHER|National Comprehensive Cancer Network (NCCN) Education Materials|The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) are comprised of recommendations for the prevention, diagnosis, and management of malignancies across the continuum of care.
224194394|NCT06340503|DEVICE|Garmin Vivofit activity tracker|This device can automatically capture and classify different physical activities such as walking, running, biking, swimming and using an elliptical.
224194395|NCT06340503|OTHER|Exercise Consultation Calls|The intervention group will receive five monthly exercise consultation calls with an exercise coach in between clinical visits and be provided with an exercise log for their personal use
224194396|NCT06340503|OTHER|Interview|The interviews will be conducted by a trained Q-PRO interviewer and audio recorded. Interviews are expected to last approximately 30 minutes. Discussion will include acceptability of the PAI intervention, related tools, and clinical experiences and will help shape/inform refinements need for a larger efficacy trial
224194397|NCT06340503|OTHER|Physical Activity Index Assessment (Intervention Arm)|Assessment will capture frequency and time spent in strenuous, moderate, and mild PA over the past 7 days. Survivors also report hours of TV or similar sedentary screen time per week as a measure of sedentary behavior. Completed at months 1, 3, 6, 9 and 12 while on study
224194398|NCT06340503|OTHER|Physical Activity Index Assessment (Control Arm)|Assessment will capture frequency and time spent in strenuous, moderate, and mild PA over the past 7 days. Survivors also report hours of TV or similar sedentary screen time per week as a measure of sedentary behavior. Completed at months 6, 9 and 12 while on study.
224194399|NCT06340503|OTHER|Health Surveys|Various health surveys will be completed to assess participant health and physical activities.
224194400|NCT00568490|PROCEDURE|Tumor biopsy|For patients who undergo tumor biopsy or resection at Stanford, approximately 500 mg of the tumor will be removed from the resection specimen
224194401|NCT00568490|PROCEDURE|Phlebotomy|Blood draw (approximately 20 cc) prior to any anticancer therapy Weekly blood draw (approximately 20cc) only for patients who are undergoing radiation treatment at Stanford University
224194402|NCT06542614|DRUG|TQH3906 capsules|To assess the efficacy and safety of TQH3906 in subjects with moderate to severe plaque psoriasis.
224194403|NCT06542614|DRUG|Placebo of TQH3906 capsules|Placebo without drug substance.
224194404|NCT06137742|DRUG|PF-07868489|Experimental Treatment
224194405|NCT06137742|DRUG|Placebo for PF-07868489|Placebo
224310332|NCT04504305|OTHER|Microcystalline cellulose|2 capsules thrice daily to be taken half an hour prior to meal.
224310333|NCT02151877|DRUG|Inhaled Nitric Oxide|delivering inhaled Nitric Oxide into the cardiopulmonary bypass circuit during neonatal cardiac surgery
224310334|NCT02151877|DRUG|placebo|inhaled Nitric Oxide not delivered to the cardiopulmonary bypass circuit during neonatal cardiac surgery
224310335|NCT02505087|DRUG|N-Acetylcysteine followed by Placebo|"Arm receiving N-Acetylcysteine (NAC) for 6 months and then placebo for 6 months.~Treatment periods are separated by a 2 month washout."
224310336|NCT02505087|DRUG|Placebo followed by N-Acetylcysteine|Arm receiving placebo for 6 months then N-acetylcysteine (NAC) for 6 months. Treatment periods are separated by a 2 month washout.
224310337|NCT00224471|BIOLOGICAL|GSK208141 vaccine|3 IM doses
224310338|NCT00217555|DRUG|gemcitabine hydrochloride|
224310339|NCT00217555|DRUG|topotecan hydrochloride|
223503518|NCT03170921|OTHER|Benguela|The rhythm performance (Benguela) had duration of 90 seconds. During recovery period (post- intervention) in the moments 1, 3, 5, 7, and 9 minutes was measured the physiological and the perceptual variables of the study.
223503519|NCT03170921|OTHER|São Bento|The rhythm performance (São Bento) had duration of 90 seconds. During recovery period (post- intervention) in the moments 1, 3, 5, 7, and 9 minutes was measured the physiological and the perceptual variables of the study.
223503520|NCT00143143|DRUG|Pregabalin|
224194406|NCT05437211|DEVICE|Virtual-reality (VR) Based Solution|VR-based solution comprises a mobile phone application including explanation on the different steps to be followed to perform infusions in satisfactory conditions, notably as regards safety, as well as VAS for pain and anxiety to be completed at each Factor VIII or Factor IX infusion between inclusion and the Week 4 visit. It also comprises a 3D mask (to be used before or during infusions) including simulation of the infusions themselves (before infusion) and a relaxing and distracting content (during and after infusions).
224194407|NCT03261492|BEHAVIORAL|Physical Activity|SAGE curriculum is a garden-based PA and nutrition educational program for early care and education centers.
224194408|NCT03261492|BEHAVIORAL|Child Safety Attention Comparison|The goal of this comparison group is to provide centers with an engaging, useful, carefully sequenced, and easy-to-deliver curriculum so that randomization to this group does not influence attrition or reach and serves as a placebo (unlikely to affect outcomes of interest).
224194409|NCT04411641|DRUG|Tolebrutinib|Pharmaceutical form: Film-coated tablet Route of administration: Oral
223503521|NCT01659541|DEVICE|Expiratory muscle stimulator|The expiratory muscle stimulator consists of two small electrodes (wire leads) implanted on the surface of the spinal cord on the lower back to stimulate the expiratory muscles and restore cough. These electrodes are connected to an implanted receiver in the abdomen or chest wall. The device is activated through an external antenna connected to an external control box.
223746763|NCT05603273|BEHAVIORAL|non-weight bearing exercise|exercise on a non-weight bearing device at 50% of peak capacity, 3 days per week for 6 weeks
223503522|NCT01659541|PROCEDURE|Implantation of device|The expiratory muscle stimulator consists of two wire leads(each with two metal contacts) inserted onto the surface of their spinal cord on the lower back using a needle. The procedure to implant these wire leads is commonly used today for other purposes. This is a minimally invasive surgical technique with minimal risks. The wire leads are connected to an implanted receiver in the abdomen or chest wall. The device is activated through an external antenna connected to an external control box to stimulate the expiratory muscles and restore cough.
223503523|NCT04825977|OTHER|RISK STRATIFICATION USING AIMS65 SCORE AND RDW|Risk Statification of patients presenting with upper gastrointestinal bleeding to the emergency department using AIMS65 score and Red cell Distribution Width.
223503524|NCT05298839|DIAGNOSTIC_TEST|Evaluation of core muscle endurance, hand grip strength, upper extremity functional performance, reaction time, agility performance and 3 minutes step test|"Core muscle endurance was evaluated with extensor muscle endurance test, flexor muscle endurance test and lateral muscle endurance test.~Hand Grip Strength was evaluated with Jamar hand dynamometer. Upper extremity functional performance was evaluated with health ball throwing test.~Reaction time was evaluated with Fitlight Trainer. Agility performance was evaluated with Pro-agility test. Cardiovascular endurance was evaluated with the 3-minute step test."
223503525|NCT03080714|DEVICE|Topcon DRI OCT Triton (plus)|The Topcon DRI OCT Triton (plus) is an OCT machine used for diagnostic purposes
223503526|NCT03080714|DEVICE|3D OCT-1 Maestro|The 3D OCT-1 Maestro is an OCT machine used for diagnostic purposes
223503527|NCT01804335|DRUG|CD5789 0.01% Cream|CD5789 0.01% cream applied on the lesions once daily for twelve weeks.
223503528|NCT01272856|DRUG|Abatacept|125 mg pre-filled syringe for sub-q injection weekly.
223503529|NCT06153238|DRUG|GME751|400 mg Q6W, i.v. infusion, over 24 weeks period
223503530|NCT06153238|DRUG|Keytruda - EU|400 mg Q6W, i.v. infusion, over 24 weeks period
223503531|NCT06153238|DRUG|Keytruda - US|400 mg Q6W, i.v. infusion, over 24 weeks period
223503532|NCT03983109|DEVICE|EpiFaith loss of resistance detect syringe|An EpiFaith syringe will be used to detect the loss of resistance and facilitate the needle localization.
223503533|NCT03428204|PROCEDURE|Balloon dilation during 180 seconds|Percutaneous angioplasty with balloon dilation during 180 seconds as a method for percutaneous treatment of femoropopliteal artery lesions
223503534|NCT03428204|PROCEDURE|Balloon dilation during 300 seconds|Percutaneous angioplasty with balloon dilation during 300 seconds as a method for percutaneous treatment of femoropopliteal artery lesions
223503535|NCT02326688|OTHER|Kinematic analysis of trunk compensation|
223503536|NCT02105857|OTHER|grade A+ knee mobilization|grade A+ knee mobilization using the joint active systems knee device, 20minutes twice a day in knee extension and knee flexion
223503537|NCT04134312|BIOLOGICAL|MVA-BN-Brachyury|MVA-BN-Brachyury will be administered intravenously every three weeks with three administrations in total at the dose indicated by the enrolled cohort.
223503538|NCT02723331|DRUG|Nab paclitaxel|Nab-paclitaxel and gemcitabine, for R-PDAC patients, will be given in combination as neoadjuvant and adjuvant chemotherapy. Nab-paclitaxel will be administered by IV infusion at a dose of 125 mg/m2 over 30 minutes on Days 1, 8, and 15 of every 28-day cycle. Gemcitabine will be administered by IV infusion, immediately after the administration of nab-paclitaxel, at a dose of 1000 mg/m2 over 30 minutes on Days 1, 8 and 15 of every 28-day cycle.
224194410|NCT04411641|DRUG|Placebo to match Tolebrutinib|Pharmaceutical form: Film-coated tablet Route of administration: Oral
224194411|NCT06176989|DRUG|Enasidenib|100mg PO (orally) once daily, on days 1-28 of a 28-day cycle
224194412|NCT05155423|OTHER|mask for immobilization|mask for immobilization
223503539|NCT02723331|DRUG|Gemcitabine|Nab-paclitaxel and gemcitabine, for BR-PDAC patients, will be given in combination as neoadjuvant and adjuvant chemotherapy. Nab-paclitaxel will be administered by IV infusion at a dose of 125 mg/m2 over 30 minutes on Days 1, 8, and 15 of every 28-day cycle. Gemcitabine will be administered by IV infusion, immediately after the administration of nab-paclitaxel, at a dose of 1000 mg/m2 over 30 minutes on Days 1, 8 and 15 of every 28-day cycle.
223503540|NCT04225520|DEVICE|Cardiac resynchronization therapy ON|Implantation of a CRT device. Bi-ventricular pacing will be turned ON.
223503541|NCT04225520|DEVICE|Cardiac resynchronization therapy OFF|Implantation of a CRT device. Bi-ventricular pacing will be turned OFF.
223503542|NCT06239597|BEHAVIORAL|occupation-based lifestyle intervention|9 week lifestyle course
223503543|NCT06239597|OTHER|Other courses|Other courses in the same university, during the same academic years.
223503544|NCT05962905|OTHER|Blood sample|During the standard of care interventional or diagnostic cardiac catheterization, paired arterial and venous blood samples will be obtained. The venous sample will be obtained from 2 cm superior to the clavicle, which is beyond standard of care during the routine cardiac catheterization
223503545|NCT05962905|DEVICE|INVOS monitoring|During the standard of care interventional or diagnostic cardiac catheterization, INVOS monitoring will be used. INVOS™ regional oxygen saturation (rSO2) values will be compared to the calculated global field saturation of cerebral tissue determined from blood sample co-oximetry.
223503546|NCT04578054|OTHER|Flying transport|Patient care who requires flying transport
223503547|NCT04556825|DRUG|PRP|After the arthroscopic operation was completed, a local PRP with 4ml was injected
223503548|NCT04556825|DRUG|normal saline|After the arthroscopic operation was completed, a local normal saline injection with same ml was performed
223746764|NCT05172544|BIOLOGICAL|HydroVax-002 YFV|Inactivated YFV vaccine
223746765|NCT05172544|OTHER|Placebo|NaCl 0.9%, Normal Saline
224194413|NCT05155423|OTHER|Elekta BodyFix|Elekta BodyFix
224194414|NCT04855253|DRUG|E7777|E7777 is a recombinant fusion toxin consisting of full-length human IL-2 fused to the catalytic domains of diphtheria toxin. E7777 is preferentially bound to and internalized by cells expressing the high affinity form (CD25+) of the IL-2 receptor.
224194415|NCT04855253|DRUG|Fludarabine|Fludarabine 25 mg/m2 IV daily for 3 days. Days -5, -4 and -3. Taken in combination with Cyclophosphamide
223503549|NCT06633510|DEVICE|massimo group|masimo is a device for the continuous noninvasive measurement of arterial hemoglobin functional oxygen saturation (SpO2), pulse rate (PR), pleth variability index (PVi) and pleth respiratory rate (Rrp) PI (perfusion index).
223503550|NCT06633510|OTHER|standart group|intraoperative fluid deficit is calculated according to the 4-2-1 rule by summing up the hourly basal fasting level, intraoperative losses depending on the degree of tissue trauma (1-2mlt/kg/h in small-sized surgeries, 2-4mlt/kg/h in medium-sized surgeries, 4-8mlt/kg/h in large-sized surgeries), blood losses, urine and losses from the nasogastric tube. Fluid is given in this way.
223503551|NCT05592626|DRUG|STAR0602|solution, intravenous infusion
224194416|NCT04855253|DRUG|Cyclophosphamide|Cyclophosphamide 250 mg/m2 IV daily for 3 days starting with the first dose of fludarabine. Days -5, -4 and -3.
224194417|NCT04855253|DRUG|Tisagenlecleucel|Patient will receive one FDA approved CAR-T product - Tisagenlecleucel/Kymriah, Axicabtagene Ciloleucel/Yescarta, or lisocabtagene maraleucel/Breyanzi) for the treatment of relapsed/refractory diffuse large B-cell lymphoma
224194418|NCT04855253|DRUG|Axicabtagene Ciloleucel|Patient will receive one FDA approved CAR-T product - Tisagenlecleucel/Kymriah, Axicabtagene Ciloleucel/Yescarta, or lisocabtagene maraleucel/Breyanzi) for the treatment of relapsed/refractory diffuse large B-cell lymphoma
224310340|NCT06665204|OTHER|Clinical Practice Guideline-adherent Care|Clinical examination procedures will be used to identify all appropriate impairment subcategories (Overuse/Overload without Other Impairment, PFP with Movement Coordination Deficits, PFP with Muscle Performance Deficits, PFP with Mobility Impairments) and create a subcategory-specific or multimodal (for patients classified to \>1 subcategory) plan of care. Research physical therapists will target all applicable impairment subcategories using the corresponding CPG-recommended interventions, all of which are recommended for use as part of standard-of-care physical therapy practice. The duration and length of care will not be prespecified or standardized across participants to allow flexibility pending participant's care needs and schedule (e.g., vacation, short-term TDY status); however, research PTs will be trained to target providing no more than 10-12 visits over no more than 6-8 weeks to promote generalizability of the CPG-adherent intervention.
224310341|NCT06665204|OTHER|Usual Care|Usual physical therapy care will be provided by a licensed outpatient staff physical therapist who is not associated with the research team. The outpatient physical therapists will not treat participants in the CPG-adherent group and will be free to treat their participants based on their current personal and organizational clinical practice standards. The research team will neither influence nor restrict the evaluations conducted or interventions provided.
224310342|NCT03148106|DEVICE|Somatosensory Electrical Stimulation|The investigators will put adhesive electrodes on the affected arm and connect it to a device that will deliver a gentle electrical stimulation to the hand and arm. The stimulation will last for different amounts of time, depending on the stimulation condition. This can be 30 minutes twice a day (1 hour apart), 1 hour continuously, 2 hours continuously, or 3 hours continuously. The stimulation conditions will also vary in stimulation strength. It is normal that some people may feel a tingling sensation, while others may feel nothing.
224310343|NCT06985368|DRUG|SIBP-A18|"SIBP-A18 formulation for injection, Claudin18.2-ADC. Strength: 1.0, 2.0, 3.2, 4.0, 4.8, 5.6, 6.4 and 8.0 mg/kg. Intravenous infusion administration, with a treatment cycle of every 21 days, administered once on the first day of each cycle. The dose escalation stage, 1mg/kg and 2mg/ kg were subjected to accelerated titration, where the safety was evaluated within 21 days after the first administration to one participant. If dose-limiting toxicity (DLT) occurred, the traditional 3+3 dose escalation method was immediately switched. If DLT does not occur, the next dose group will be explored. The third stage will use RP2D for further exploration."
224310344|NCT06982586|DEVICE|Repetitive transcranial magentic stimulation|Low frequencey repetitive transcranial magentic stimulation
224314229|NCT05682651|PROCEDURE|tracheal stenosis follow-up file|Patients' age, gender, American Society of Anesthesiologists (ASA) classification, comorbidities, etiologic cause, intubation time, type of surgery, length of hospital stay, and morbidity/mortality information will be recorded.
223503552|NCT02502448|PROCEDURE|Acute normovolemic hemodilution (ANH)|applying acute normovolemic hemodilution (ANH) by using HES 130/0.4 of 5 ml/kg before the initiation of cardiopulmonary bypass
223746766|NCT04090567|DRUG|Cediranib|Given PO
223746767|NCT04090567|DRUG|Ceralasertib|Given PO
223503553|NCT02502448|DRUG|hydroxyethyl starch (HES 130/0.6)|
223503554|NCT03778333|BIOLOGICAL|Autologous mesenchymal stem cells|IV therapy with autologous bone-marrow derived mesenchymal stem cells
223746768|NCT04090567|DRUG|Olaparib|Given PO
223746769|NCT04716387|OTHER|Standard LLIN|Long-lasting insecticidal net containing alphacypermethrin, a pyrethroid insecticide, and manufactured by Shobikaa Impex Private Limited.
224194419|NCT04855253|DRUG|Lisocabtagene Maraleucel Intravenous Suspension|Patient will receive one FDA approved CAR-T product - Tisagenlecleucel/Kymriah, Axicabtagene Ciloleucel/Yescarta, or lisocabtagene maraleucel/Breyanzi) for the treatment of relapsed/refractory diffuse large B-cell lymphoma
224194420|NCT05917210|BEHAVIORAL|Standard TB-EC|Standard TB-EC by healthcare workers
224194421|NCT05917210|BEHAVIORAL|Peer navigation strategy for TB-EC|multi-component, peer-navigation strategy for TB-EC
224194422|NCT05658354|OTHER|Computerized cognitive program|BrainHQ was developed by Posit Science and includes computer-based brain-training exercises organized into six categories: Attention, Brain Speed, Memory, People Skills, Intelligence, and Navigation. Participants were instructed to perform a total of 24 sessions of computerized cognitive training at home, consisting of 45 minutes of training, twice per week, over a 3-month period.
224194423|NCT05861284|DEVICE|Transcranial Magnetic Stimulation (TMS)|Transcranial magnetic stimulation (TMS) is a non-invasive brain stimulation method that can induce long-term changes in connections between neuronal networks.
224194424|NCT05482282|BIOLOGICAL|Recombinant Hepatitis B new Bulk vaccine|"1 dose of Recombinant Hepatitis B vaccine using new Hepatitis B bulk (Bio Farma)~1 dose of 0.5 ml Recombinant Hepatitis B new Bulk vaccine dose of DTP-HB-Hib using new Hepatitis B Bulk vaccine injected intramuscularly into the left external antero-lateral thigh region."
224194425|NCT05482282|BIOLOGICAL|DTP-HB-Hib with Recombinant Hepatitis B new Bulk vaccine|3 doses of DTP-HB-Hib with Recombinant Hepatitis B new Bulk vaccine
223503555|NCT05965934|DRUG|Direct Sodium Removal Infusate 2.0|Direct Sodium Removal via peritoneal ultrafiltration using Infusate 2.0 (30% icodextrin, 10% dextrose). Patients (if not yet on SGLT-2 inhibitors) will receive SGLT-2 inhibitors.
223503556|NCT00739219|DEVICE|Apieron Insight eNO monitor|The Apieron Insight(tm) eNO monitor is used to measure exhaled nitric oxide, and asthma is managed to keep eNO below an individualized target.
223503557|NCT05635760|BEHAVIORAL|Group-based Parent-implemented Social Communication Training|The intervention will be taught by a speech therapist online (approximately 25 hours distributed over 6 months), with up to 8 parents in a group.
223503558|NCT05635760|BEHAVIORAL|Self-learning-based Parent-implemented Social Communication Training|Self-learning families will learn the same materials without the guidance of a therapist.
223503559|NCT00424164|DRUG|lapatinib ditosylate|
223503560|NCT00424164|DRUG|tamoxifen citrate|
223503561|NCT00424164|OTHER|pharmacological study|
223503562|NCT05024942|PROCEDURE|Transfemoral TAVR (Transcatheter aortic valve replacement)|Transfemoral transcatheter aortic valve replacement (TAVR) is a minimally invasive heart procedure to replace a narrowed aortic valve that fails to open properly (aortic valve stenosis) through an incision in the groin. All FDA approved transcatheter aortic prosthesys are allowed.
223503563|NCT04534946|OTHER|This is not an intervention study|This is not an intervention study
223503564|NCT03653078|DEVICE|Three dimensional printed digital guide|A CAD/CAM printed plate with a channel for mini-screw insertion
223503565|NCT03334097|OTHER|Prenatal education|"Education intervention will consist of a total of six sessions one week apart, with two hours of duration each one. The sessions that are exclusively oriented towards preparation for childbirth are session 1 and session 2. The content of each session is:~1. St. Birth: Start of childbirth, Symptoms and Signs, Delivery schedules, Phases of childbirth, Normal childbirth, Other circumstances (Obstetrical pathology / previous pathology, Induction of labor, Instrumental birth, Caesarean section).~2. nd:methods for relieving birth pain: Alternative Methods of Pain Relief, Pharmacological analgesia, Regional analgesia. Local and regional anesthesia, General anesthesia, breathing training and accompaniment during childbirth-~3. rd: Puerperium.~4. rd :Breastfeeding~5. rd : Newborn care~6. rd :Positive parenting."
223503566|NCT03341429|DRUG|Liraglutide Pen Injector [Saxenda]|Daily injection of GLP-1 agonist (liraglutide 3.0 mg) for obese patients presenting poor weight loss (\<20%) after bariatric surgery and suboptimal GLP-1 levels.
223503567|NCT03341429|DRUG|Placebo|Daily subcutaneous injection
223503568|NCT00195793|DRUG|fenofibrate|
223503569|NCT00195793|DRUG|ezetimibe|
223503570|NCT00195793|DRUG|atorvastatin|
223503571|NCT06512233|DRUG|LMW Heparin 5000 U/ML-Aspirin 75 MG|Arm 1
223503572|NCT06512233|DRUG|LMW Heparin 5000 U/ML|Arm 2
223503573|NCT03182712|DIETARY_SUPPLEMENT|n-3 PUFA Group|Participants received n-3 PUFA capsules (capsules containing 180 mg of eicosapentaenoic acid, 120 mg of docosahexaenoic acid and 2 mg of vitamin E). Three capsules were ingested daily for eight weeks, distributed between breakfast, lunch and dinner.
223503574|NCT03182712|DIETARY_SUPPLEMENT|Placebo Group|Participants received capsules containing 500 mg of gelatin.Three capsules were ingested daily for eight weeks, distributed between breakfast, lunch and dinner.
223503575|NCT00769405|DRUG|fluorouracil|Given IV
224194426|NCT05482282|BIOLOGICAL|Recombinant Hepatitis B vaccine (Registered BioFarma)|1 dose of Recombinant Hepatitis B vaccine (Registered Bio Farma)
224194427|NCT05482282|BIOLOGICAL|Pentabio|3 doses of Pentabio
223746770|NCT04716387|OTHER|Piperonyl butoxide ITN|Insecticide treated net containing permethrin, a pyrethroid, and piperonyl butoxide, an insecticide synergist, manufactured by Sumitomo Chemical.
224194428|NCT04501562|OTHER|Examinations|Participants will undergo focused examinations that include measurement of height, weight, waist circumference, body composition analysis, baseline data collection and blood pressure examinations. Resting electrocardiography will be performed to ascertain sinus rhythm.
224194429|NCT04501562|OTHER|Cardiovascular Tests|Specific quantitative cardiac ageing-related outcome parameters will be examined by multimodal techniques including two-dimensional transthoracic echocardiogram, and/or non-contrast magnetic resonance imaging/magnetic resonance spectroscopy.
223503576|NCT00769405|DRUG|leucovorin calcium|Given IV
224194430|NCT04501562|OTHER|Bio-specimen collection|Bio-specimens collected will include fresh blood, urine and/or stool specimens.
224194431|NCT04501562|OTHER|Clinical/health outcome collection|Health status will be tracked by telephone follow-up and/or matching at national disease registries at periodic intervals within one to five years, up to three decades.
223503577|NCT00769405|DRUG|oxaliplatin|Given during surgery
224194432|NCT03172195|PROCEDURE|rectosigmoidoscopy|A rectosigmoidoscopy will be realized and two fragments will be collected.
224194433|NCT03172195|BIOLOGICAL|biopsies|For this study, two biopsies in healthy area and two biopsies in ulcer will be collected.
223503578|NCT00769405|PROCEDURE|hyperthermia treatment|Given intraperitoneally during surgery
223503579|NCT02867826|DEVICE|Cap|Cap-assisted endoscopy
223503580|NCT01993368|OTHER|flow cytometry|"These populations will be identified by different combinations of antibodies to identify:~* T cell subsets (CD45, CD3, CD4, CD8, CD45RA, CD69, CD28, TCRαβ, TCRγδ, CD197, CD25, FoxP3), B cells (CD45, CD19, HLA-DR, IgA), cells NK (CD45, CD3, CD56).~* Monocyte subsets (CD45, CD11b, CD14, CD16, CD1c, HLA-DR)~* Mesenchymal stromal cells (CD45, HLA-ABC, CD105, CD90, CD73)"
223503581|NCT04149353|DIAGNOSTIC_TEST|PET/MR|Patient will be scheduled for a pre-treatment PET/MR and proceed to neoadjuvant chemotherapy per the direction of the medical oncologist. Within four weeks after completion of chemotherapy the patient will undergo a post-treatment PET/MR, and proceed for curative intent surgery if they are still surgical candidates.
224194434|NCT03172195|BIOLOGICAL|blood sample|Blood sample will be collected in more.
224194435|NCT03810417|DRUG|Digoxin Antibodies Fab Fragments|Digoxin antibodies
224194436|NCT03810417|OTHER|Placebo|Saline
224194437|NCT03810417|DIAGNOSTIC_TEST|Baseline EO > 360 pM|Baseline ouabain concentration \> 360 pM
224194438|NCT03810417|DIAGNOSTIC_TEST|EO < 360 pM|Baseline ouabain concentration \< 360 pM
224194439|NCT05751473|BEHAVIORAL|Prolonged Exposure for Primary Care (PE-PC)|"Treatment will be given by telehealth or in person, depending on the participant preference.~Content is drawn from the Full Prolonged Exposure model and condensed so as to deliver the most efficacious components in a brief format. There will be 4-6 weekly 30-minute sessions. Treatment follows the standardized PE-PC manual and workbook. At the end of the final session, the counselor and participant will review treatment progress and either conclude treatment or refer the participant to outside mental healthcare for more intensive treatment.~Participants will complete surveys and complete homework during and following the study."
224194440|NCT05751473|BEHAVIORAL|EAP Treatment as Usual (TAU)|"Treatment will be given by telehealth or in person, depending on the participant preference and current EAP practices (4-6 weeks). This will be the standard of care practice at each EAP site. Usually, this includes up to six sessions of solution focused therapy, and referrals to an established network of community providers who specialize in PTSD treatment. All PTSD care received during the study will be collected and monitored as TAU. The type of TAU used will reflect the current practice in EAPs and will not be constrained in the study design. EAP staff will monitor and record all EAP care received, including tracking no shows and cancellations. Study team members will document care received outside of the EAP (including psychiatric medications) by self-report.~Participants will complete surveys and complete homework during and following the study."
223503582|NCT04583826|DEVICE|CAVA|CAVA is a medical device containing 5 face-mounted ECG electrodes which are used to record the movement of the eyes.
223503583|NCT00632970|DRUG|Raltegravir|1, 400mg tablet twice a day, with Truvada 1 tablet once a day
223503584|NCT00632970|DRUG|Lopinavir/Ritonavir|2 tablets twice a day, with Truvada 1 tablet once a day
223503585|NCT00632970|DRUG|Truvada|1 tablet, once a day, with either Raltegravir (Isentress) or Lopinavir/Ritonavir(Kaletra)
223592678|NCT05833451|OTHER|Reiki|Reiki, one of integrative practices, is an energy therapy involving the use of energy that flows naturally from the hands of the practitioner to strengthen the body's ability to heal itself in order to increase well-being. Reiki improves well-being in many areas, ensures that blood and lymph circulation is maintained properly, regulates blood pressure and pulse rate by stimulating the autonomic nervous system, increases comfort, reduces depression and anxiety levels. In this way, Reiki facilitates physical and mental relaxation and promotes health
223592679|NCT04018313|BIOLOGICAL|CT-P39|150 mg/mL, Solution for injection in PFS
223592680|NCT04018313|BIOLOGICAL|EU-approved Xolair|150 mg/mL, Solution for injection in PFS
223746771|NCT04716387|OTHER|Pyriproxyfen ITN|Insecticide treated net containing alpha-cypermethrin, a pyrethroid, and pyriproxyfen, an insect growth regulator, manufactured by Disease Control Technologies.
224194441|NCT04410991|DRUG|Tolebrutinib|"Pharmaceutical form: Tablet~Route of administration: Oral"
224194442|NCT04410991|DRUG|Teriflunomide HMR1726|"Pharmaceutical form: Tablet~Route of administration: Oral"
224194443|NCT04410991|DRUG|Placebo to match Tolebrutinib|"Pharmaceutical form: Tablet~Route of administration: Oral"
223503586|NCT04041128|DRUG|Lynparza|Lynparza taken orally at a dose of 300mg twice daily for 7 days
223503587|NCT06468475|DRUG|Magnesium Sulphate infusion|Magnesium sulphate 24 hours apart by intravenous infusion at 250 mg/kg/dose (0.5 mL/kg/dose of injection magnesium sulphate 50% w/v diluted in 5 mL/kg of 5% glucose) over a duration of half an hour by an infusion pump
223503588|NCT01204372|DRUG|Gemcitabine - Trastuzumab - Erlotinib|"Treatment will be administered until disease progression, patient's refusal, unacceptable toxicity or investigator's decision.~* Gemcitabine: IV 1000 mg/m2 on D1, D8, D15, D22, D29, D36 and D43 followed by one week of rest. Subsequently on D1, D8 and D15 followed by one week of rest.~* Trastuzumab: IV once a week; 4 mg/kg over 90 min. at D1, and 2 mg/kg over 30 min. for the subsequent infusions.~* Erlotinib: oral route 100 mg/day from C1D1."
223503589|NCT00309244|DRUG|Technosphere® Insulin Inhalation Powder|Inhalation, 15U/30U
223503590|NCT00309244|DRUG|70% insulin aspart protamine suspension and 30% insulin aspart injection (rDNA origin)|BPR 70/30, which is a premix of intermediate acting and rapid acting insulin given sc
223592681|NCT04018313|BIOLOGICAL|CT-P39|150 mg/mL, Solution for injection in PFS
223592682|NCT04018313|BIOLOGICAL|EU-approved Xolair|150 mg/mL, Solution for injection in PFS
223592683|NCT04018313|BIOLOGICAL|US-licensed Xolair|150 mg/mL, Solution for injection in PFS
223592684|NCT04798209|DRUG|ACT-777991 (SAD)|ACT-777991 administered as hard capsules for oral use.
223592685|NCT04798209|DRUG|ACT-777991 (MAD)|ACT-777991 administered as hard capsules for oral use, once daily.
223592686|NCT04798209|DRUG|Placebo (SAD)|ACT-777991 matching placebo administered as hard capsules for oral use.
223592687|NCT04798209|DRUG|Placebo (MAD)|Matching placebo administered as hard capsules for oral use, once daily.
223746772|NCT04716387|OTHER|Chlorfenapyr ITN|Insecticide-treated nets containing two active ingredients: alpha-cypermethrin, a pyrethroid insecticide, and chlorfenapyr, a pyrrole insecticide, manufactured by BASF.
224194444|NCT04410991|DRUG|Placebo to match Teriflunomide|"Pharmaceutical form: Tablet~Route of administration: Oral"
224194445|NCT01245712|RADIATION|Accelerated Partial Breast Irradiation|Undergo APBI delivered with proton radiation
224194446|NCT01245712|RADIATION|Proton Beam Radiation Therapy|Undergo APBI delivered with proton radiation
224194447|NCT01245712|OTHER|Quality-of-Life Assessment|Ancillary studies
224194448|NCT06579079|OTHER|Implementation Mapping|Implementation mapping is a stakeholder-driven process whereby researchers and practitioners work together to develop an implementation strategy.
224194449|NCT06579079|OTHER|Waitlist Comparison - Implementation Mapping|Implementation mapping is a stakeholder-driven process whereby researchers and practitioners work together to develop an implementation strategy. Participating schools receiving this treatment will wait one year before developing an implementation strategy for testing.
224194450|NCT05102929|DEVICE|active intermittent Theta Burst Stimulation (iTBS)|iTBS is a brief stimulation of a part of the brain with a magnetic field that passes through the scalp and skull safely. It is FDA-approved as a treatment for psychological conditions including depression; however, this device is not approved for the treatment of adults with patients with schizophrenia. This research study is using iTBS off label in SCZ patients to examine research questions.
224194451|NCT05102929|DEVICE|sham intermittent Theta Burst Stimulation (iTBS)|"Sham TBS over the left DLPFC will be performed using a Cool-B65 A/P TMS coil, designed to support blinded clinical trials. Specifically, when the coil is placed in the P position (i.e. the placebo position), only a very small amount of current is induced in tissue, thus preventing the activation of cortical neurons."
224194452|NCT05870202|OTHER|screening tool|The screening tool identifies areas of treatment burden in patients with type 2 diabetes. The tool is in the form of a brief questionnaire that the patient completes prior to a clinical appointment. The patient's responses to the questionnaire are then included in the discussion with the patient's primary care clinician during the clinical visit.
224194453|NCT05776225|PROCEDURE|Right heart catheterization (RHC)|RHC to evaluate pulmonary hemodynamics
224194454|NCT04256018|DRUG|Mogamulizumab|Administered 1 mg/kg as an intravenous infusion over at least 60 minutes on Days 1, 8, 15, and 22 of the first 28 day cycle and on Days 1 and 15 of each subsequent cycle.
224194455|NCT04256018|RADIATION|LD TSEBT|Patients will receive total skin dose of 12 Gy fractionated at 4 to 6 Gy per week, for 2-3 weeks
224194456|NCT03282123|DRUG|Midomafetamine|80 to 120 mg MDMA
224194457|NCT03282123|BEHAVIORAL|Manualized therapy|Non-directive therapy conducted during MDMA-assisted therapy session
223503591|NCT01263028|DRUG|Ergocalciferol supplementation|Vitamin D in the form of ergocalciferol will be the drug utilized in the study. This medication is a Vitamin D analog and is normally used in the current study population to help augment those who are deficient in Vitamin D.
223503592|NCT03941886|OTHER|Low-dose aspirin in women with high risk of preeclampsia|Low-dose aspirin 150-162 mg/night or 100 mg/night if body weight \<40 Kg, from \<15 weeks till 36 weeks or, in the event of early delivery, at the onset of labor
223503593|NCT03019588|BIOLOGICAL|Pembrolizumab|IV infusion
223503594|NCT03019588|DRUG|Paclitaxel|IV infusion
223503595|NCT05504421|OTHER|Sustainability education in nursing to be given with two different teaching methods|Sustainability education in nursing to be given with two different teaching methods (cooperative learning versus traditional learning) and the effects of two different teaching methods on the sustainability knowledge, attitude and skill acquisition of nursing students will be compared.
223503596|NCT00558883|DRUG|acarbose|oral application
224194458|NCT06421311|DRUG|nivolumab|According to approved product label (France)
224194459|NCT05707273|DRUG|Autologous Anti-CD19 CAR-expressing T Lymphocytes|Given IV
224194460|NCT05707273|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
224194461|NCT05707273|PROCEDURE|Bone Marrow Aspiration and Biopsy|Undergo bone marrow aspirate
224194462|NCT05707273|DRUG|Cyclophosphamide|Given IV
224194463|NCT05707273|DRUG|Fludarabine|Given IV
223503597|NCT03849456|DRUG|GWP42006|Oral solution containing cannabidivarin 50 milligrams per milliliter (mg/mL) in sesame oil with anhydrous ethanol, sucralose, strawberry flavoring, and β-carotene.
223503598|NCT00430859|DRUG|Alkaline Phosphatase|Intravenous over a period of 24 hours
223503599|NCT00430859|DRUG|Placebo|Saline over a period of 24h
223503600|NCT00887588|DRUG|LCZ696|50 mg, 100 mg and 200 mg tablets
223503601|NCT00887588|DRUG|Valsartan|40 mg, 80 mg and 160 mg tablets
223503602|NCT00887588|DRUG|Placebo|matching placebo to LCZ696 and Valsartan
223503603|NCT00562107|DEVICE|Symphony DR 2550 and REPLY DR cardiac pacemakers|AAISafeR/SafeR ON
223503604|NCT00562107|DEVICE|Symphony DR 2550 and REPLY DR cardiac pacemakers|DDD(R) (SafeR OFF)
223503605|NCT00366535|DRUG|Placebo|4 tabs b.i.d.
223503606|NCT00366535|DRUG|Neurotropin|4 tabs b.i.d.
223503607|NCT00290420|DRUG|Chloroquine profilaxis|"Prevention:~Give a profilaxis with chloroquine once a week to prevent Plasmodium vivax malaria attacks and to prevent harmfull effect on birth outcomes"
223503608|NCT06507865|DEVICE|GORE® TAG® Thoracic Branch Endoprosthesis|Patients presenting with thoracic vascular disease that may benefit from the placement of TBE device. The target registry population is patients who are treated with TBE at participating sites. TBE treatment is qualified as receiving the TBE aortic component, at a minimum.
223503609|NCT00106535|DRUG|tocilizumab [RoActemra/Actemra]|4 mg/kg or 8 mg/kg IV/month every 4 weeks.
223503610|NCT00106535|DRUG|Placebo|IV/month
223503611|NCT00106535|DRUG|Methotrexate|10-25 mg/week
223503612|NCT03468946|OTHER|salty taste perception|"salty taste perception in high caries risk, medium caries risk, low caries risk.~The aim of this study was to evaluate salty taste perceptions of school children and compare them with demographic, clinical, microbiologic and biochemical caries-risk factors(high caries risk, medium caries risk, low risk )."
224194464|NCT05707273|PROCEDURE|Leukapheresis|Undergo T-cell leukapheresis
224194465|NCT05707273|OTHER|Questionnaire Administration|Complete questionnaires
224194466|NCT06022159|RADIATION|Hypofractionated Radiation Therapy|The Hypofractionated Intensity-Modulated Radiation Therapy will be delivered in 5 fractions of 6 Gy each on the Planning Target Volume (PTV). The total dose of 30 Gy will be administered in approximately 1 week.
224194467|NCT06022159|PROCEDURE|Conservative treatment|A wide en bloc resection is required (amputation is excluded) while ensuring the best functional preservation. The surgical procedure will take place about 1,5 to 2 months after the end of the radiation therapy.
224194468|NCT03862222|OTHER|Retinal Imaging|Retinal imaging will be conducted on the Heidelberg SPECTRALIS (FDA 510k cleared) device, routinely used in clinical care in ophthalmology. Optical Coherence Tomography (OCT) and Angiography (OCT-A) sequences will be conducted, as well as a sequence examining macular pigment (MPOD).
224194469|NCT03862222|OTHER|Pupillometry|Participants will complete a task studying pupillary response to light
224194470|NCT03862222|OTHER|Contrast Sensitivity|Participants will complete a task evaluating contrast sensitivity
224194471|NCT03862222|DIAGNOSTIC_TEST|Neuropsychological Evaluation|Neuropsychological evaluation will be completed, including testing in domains of memory, executive function, visuospatial ability, language, processing speed. Results will be used for research purposes only.
223503613|NCT03468946|OTHER|bitter taste perception|"bitter taste perception in high caries risk, medium caries risk, low caries risk.~The aim of this study was to evaluate bitter taste perceptions of school children and compare them with demographic, clinical, microbiologic and biochemical caries-risk factors (high caries risk, medium caries risk, low risk )."
223503614|NCT03468946|OTHER|sour taste perception|sour taste perception in high caries risk, medium caries risk, low caries risk. The aim of this study was to evaluate sour taste perceptions of school children and compare them with demographic, clinical, microbiologic and biochemical caries-risk factors (high caries risk, medium caries risk, low risk ).
223503615|NCT03468946|OTHER|sweet taste perception|"sweet taste perception in high caries risk, medium caries risk, low caries risk.~The aim of this study was to evaluate sweet taste perceptions of school children and compare them with demographic, clinical, microbiologic and biochemical caries-risk factors (high caries risk, medium caries risk, low risk )."
223503616|NCT02575183|DRUG|Varinecline (Chantix)|A randomized double-blind placebo-controlled trial that will evaluate the effect of Varenicline (Chantix), in 2 parallel groups of habitual waterpipe smokers who are willing to quit (n=152). 76 subjects will be randomized to receive varenicline (Chantix). The participants, study investigators and personnel who will be interviewing the participants and collecting the clinical data, will be blinded to the assigned treatment.
223503617|NCT02575183|DRUG|Placebo (for Varenicline)|A randomized double-blind placebo-controlled trial that will evaluate the effect of Varenicline (Chantix), in 2 parallel groups of habitual waterpipe smokers who are willing to quit (n=152). 76 subjects will be randomized to receive a varenicline-matched. The participants, study investigators and personnel who will be interviewing the participants and collecting the clinical data, will be blinded to the assigned treatment.
223503618|NCT02575183|BEHAVIORAL|Behavioral Therapy|This intervention is for all study participants and it involves 4 visits to the hospital. Each visit include a 30-min one-on-one individual session with the specialized therapist during which participants will be taught how to manage any withdrawal symptoms they experience, how to anticipate high-risk situations, deal with smoking triggers, achieve and maintain their goal to stop waterpipe smoking.
223503619|NCT06133504|PROCEDURE|Early Multimodal Therapy|Early multimodal therapy is defined as the collection of therapeutic maneuvers performed by the physiotherapy, speech therapy, respiratory therapy, and occupational therapy team at the time of study inclusion.
223503620|NCT06133504|PROCEDURE|Late Multimodal Therapy|Late multimodal therapy is characterized by the same set of maneuvers carried out by the same disciplinary team, but it is initiated once indicated by the attending physician.
223503623|NCT01194700|DRUG|Seretide 250(8puffs) via Evohaler actuator|8 puffs of Seretide250/Placebo via Evohaler actuator
223503624|NCT01194700|DRUG|Seretide 250 (8 puffs)/placebo via Volumatic spacer|8 puffs of Seretide 250/placebo via volumatic spacer
223503625|NCT01194700|DRUG|Seretide 250/placebo 8 puffs via Aerochamber Plus spacer|Seretide 250/placebo 8 puffs via Aerochamber Plus
223503626|NCT01194700|DRUG|Seretide 250/placebo via Synchro-Breathe|Seretide 250/placebo 8puffs via breath actuated Synchro-Breathe device
223503627|NCT01890005|DRUG|Aspirin|Low dose aspirin (100 mg) starting between 13 and 16 weeks of pregnancy until 36 weeks of pregnancy, taken at night.
223503628|NCT01890005|DRUG|Placebo|Placebo starting between 13 and 16 weeks of pregnancy until 36 weeks of pregnancy, taken at night.
223503629|NCT03923842|DRUG|Denosumab Inj 120 MG/1.7ML|Denosumab 120 mg sc on day -15, -8 and day 1, followed by Denosumab 120 mg sc q4wks + platinum based drugs q3wks + Gemcitabine 1250 mg/sm day 1,8 q3wks for 6 cycles. Denosumab 120 mg sc q4wks will continue for 12 months since chemotherapy end.
223503630|NCT03923842|DRUG|Chemotherapy as clinical standard of care|platinum based drugs q3wks + Gemcitabine 1250 mg/sm day 1,8 q3wks for 6 cycles. Gemcitabine will continue for 12 months if the patient will not shown disease progression
223503631|NCT02685865|DEVICE|FCSEM Stent|Hot Axios Fully covered self-expandable metal stent - Boston Scientific
223503632|NCT02685865|DEVICE|Plastic Stent|7 French 4 cm double pigtail plastic stent - Cook 7 French 4 cm double pigtail plastic stent - Boston Scientific
223503633|NCT03753542|OTHER|Multimedia education, booklet Providence and tele-nursing follow-up|Multimedia education, booklet and weekly tele-nursing follow-up is about chemotherapy and side effects management
223503634|NCT04690647|OTHER|Opioid and non opioid postoperative analgesia.|Postoperative analgesia will be based on opioid and non opioid analgesics according to standardised protocol.
223503635|NCT04690647|OTHER|Fascia iliaca compartment block|Ultrasound guided suprainguinal fascia iliaca compartment block will be performed using 0.375% ropivacaine and 5ug/ml adrenaline according to standardised protocol.
223503636|NCT04690647|DRUG|Dexamethasone|Dexamethasone will be administered preoperatively in a dose of 0,1 mg/kg.
224194472|NCT03862222|GENETIC|APOE genotyping|APOE genotyping will be completed during screening to assign participants to the correct group. Results will not be shared with participants as part of the study.
223503637|NCT05395780|DRUG|MAX-40279|MAX-40279 capsule will be administered orally
223503638|NCT04864067|DRUG|Oxaliplatin|Consolidation Chemotherapy
223503639|NCT04864067|DRUG|5-Fluoracil|Consolidation Chemotherapy
223503640|NCT04864067|DRUG|Leucovorin|Consolidation Chemotherapy
223503641|NCT04864067|DRUG|Capecitabine|Consolidation Chemotherapy
223503642|NCT04864067|RADIATION|5x5 Gy|Neoadjuvant Radiotherapy
223503643|NCT04864067|BEHAVIORAL|Quality of Life Questionnaires|Quality of Life Evaluation (LARS Score, IIEF, FSFI, I-PSS and EORTC QLQ-C30)
223503644|NCT04864067|PROCEDURE|DRE/ Endoscopy|Flexible Sigmoidoscopy and Digital Rectal Exam
223503645|NCT07045246|PROCEDURE|Coenzyme Q 10|Patients received Coenzyme Q 10 as a graft material in unilateral maxillary alveolar cleft
223503646|NCT07045246|PROCEDURE|iliac bone graft|iliac bone used as a graft for alveolar cleft reconstruction
223592688|NCT04798209|DRUG|14C-ACT-777991 microtracer (SAD - Absolute Bioavailability)|Single dose of 14C-ACT-777991 microtracer, administered intravenously.
223746773|NCT05224973|BEHAVIORAL|speech therapy|speech therapy during 2 months
224194473|NCT03862222|OTHER|blood draw|Blood will be drawn and banked for proteomic, biomarker, and GWAS analysis
224194474|NCT03862222|OTHER|Gait Assessment|Gait assessment will be conducted by trained researcher
223746774|NCT06533332|DRUG|ERX-315|Drug administered intravenously twice a week at increasing dose levels, with starting dose of 0.4mg/kg.
223746775|NCT00814086|DRUG|Paclitaxel|Given IV or intraperitoneally
223746776|NCT00814086|DRUG|Cisplatin|Given intraperitoneally
223746777|NCT06393712|DRUG|Placebo|Placebo will be administered intrathecally
224194475|NCT03862222|OTHER|Actigraphy|Actigraphy monitors will be worn by all participants for 2 weeks after each visit to examine physical activity, movement, and sleep patterns.
224194476|NCT04050761|BIOLOGICAL|Nivolumab|Specified dose on Specific Days
224194477|NCT01587716|DRUG|GSK2339345 (Inhaled) Single Dose|250, 1000 and 2000 microgram (proposed doses)
224194478|NCT01587716|OTHER|Placebo (Inhaled) Single Dose|Inhaled 0.9% sodium chloride solution
224194479|NCT01587716|DRUG|GSK2339345 (Inhaled) Repeat Dose|2000 microgram (proposed dose) administered 4 times a day for two consecutive days
224194480|NCT01587716|OTHER|Placebo (Inhaled) Repeat Dose|Inhaled 0.9% sodium cholride solution
224194481|NCT01195662|DRUG|Dapagliflozin|Tablets, Oral, 10 mg, once daily, Up to 12 weeks
224194482|NCT01195662|DRUG|Placebo matching Dapagliflozin|Tablets, Oral, 0 mg, once daily, Up to 12 weeks
224194483|NCT00762281|DEVICE|MEL 80 Hyperopic LASIK Treatment|Treatment of Hyperopic corrections ≤ +6.0 D with or without Astigmatism of +0.50 to +3.50 D and MRSE ≤ +6.50 D.
224194484|NCT01367626|DRUG|letrozole|2.5 mg tablet
224194485|NCT01367626|DRUG|letrozole|2.5 mg tablet
224194486|NCT02249546|DRUG|N-acetylcysteine + PPI-amoxicillin-clarithromycin|
224194487|NCT02249546|DRUG|PPI-amoxicillin-clarithromycin|Triple therapy
224194488|NCT05011357|DRUG|Phenylephrine|Phenylephrine will be administered as an infusion
224194489|NCT05011357|DRUG|Saline Control|Saline infusion
224194490|NCT06967259|DRUG|ENA-001|Concentration for ENA-001 IV formulation is 10 mg/mL. Concentration for ENA 001 IM formulation is 30 mg/mL.
224194491|NCT06967259|DRUG|Placebo Comparator|Placebo comes in 5 mL/vial. Placebo matches ENA-001 injection; however, no ENA-001 is included.
224194492|NCT01215968|BIOLOGICAL|LY2189265|1.5 mg administered subcutaneously
224194493|NCT01215968|DRUG|Placebo|Administered subcutaneously
224194494|NCT04839627|OTHER|serum progesterone measurement|progesterone levels measurement on the day of the embryo transfer on all AMP cycles
224194495|NCT05939440|OTHER|Proactive Cost of Care (P-COC) intervention|As in Arm description
224194496|NCT05939440|OTHER|Usual Care|As in Arm description
223503647|NCT07046364|DRUG|Remimazolam|After anesthesia induction, a loading investigational drug at a rate of \[3.6\*kg\] ml/h (lasting for 5 minutes, equivalent to 0.3 mg/kg of remimazolam), and then adjust the infusion rate to \[1\*kg\] ml/h (equivalent to 1 mg/kg of remimazolam). The infusion is expected to stop 10 minutes before the end of the surgery.
223503648|NCT07046364|DRUG|Normal Saline|After anesthesia induction, a loading investigational drug at a rate of \[3.6\*kg\] ml/h (lasting for 5 minutes, equivalent to 0.3 mg/kg of normal saline), and then adjust the infusion rate to \[1\*kg\] ml/h (equivalent to 1 mg/kg of normal saline). The infusion is expected to stop 10 minutes before the end of the surgery.
223503649|NCT07044765|DRUG|Comparator 1|Dapagliflozin 10mg + Linagliptin 5mg
223503650|NCT07044765|DRUG|Comparator 2|Metformin 1000mg
223503651|NCT07044765|DRUG|Test Drug|Fixed-dose combination tablet (AJU-A53)
223746778|NCT06393712|DRUG|ALN-APP|ALN-APP will be administered intrathecally
223746779|NCT04829318|DRUG|Esketamine|Esketamine will be self-administered as nasal spray.
223746780|NCT04829318|DRUG|SSRI/SNRI|Participants will continue to take SSRI/SNRI that is approved for use in depression in their country of participation; off-label use of any SSRI/SNRI is not permitted. The continuing SSRI/SNRI dosage may be optimized throughout the study, at the investigator's discretion and based on the summary of product characteristics (SmPC) (or local equivalent, if applicable). During this LTE study, investigators will be allowed to switch individual participant's SSRI/SNRI for tolerability issues.
223746781|NCT00728130|PROCEDURE|neck dissection of at least the ipsilateral sub-level 1B|neck dissection of at least the ipsilateral sub-level 1B
224194497|NCT04828993|DRUG|tafamidis meglumine|Tafamidis meglumine 20 mg, once daily, oral administration, for 72 weeks (18 months).
224194498|NCT02632773|BEHAVIORAL|Responsive Intervention|Mothers assigned to the responsive experimental condition will learn how to talk about what is in their child's focus of attention and to respond to all child communicative attempts by either: (a) assigning a presumed meaning to preverbal communication or vocalizations or (b) by repeating the child's verbal communication and adding words.
224194499|NCT02632773|BEHAVIORAL|Directive Intervention|Mothers assigned to the directive experimental condition will learn how to: (a) set up a prompting trial through management of toys or by responding to a child request, (b) recruit the child's attention, (c) provide a discriminative stimulus (cue), (d) wait for the child's response for 5 seconds, (e) reinforce the child for correct production of the target or provide additional prompts after incorrect productions. Parents will perform one prompting trial per minute for a total of 20 trials per parent session.
224194500|NCT04131452|OTHER|Filling out the forms including IDAS-II, BAI, SF-36 and FSFI|Participants will fill out certain validated forms including the expanded version of the inventory of depression and anxiety symptoms (IDAS-II), Beck Anxiety inventory (BAI), Short Form Survey (SF-36) and Female Sexual Function Index (FSFI).
224194501|NCT06288607|DEVICE|High intensity focused ultrasound (MFUS One, Hunan Peninsula Medical Technology Co., Ltd., China)|Before treatment, a 2-3mm thick medical condensation gel is evenly applied on the face. Patients are to be treated with two macro-focused handpieces with focal depths at 3.0 mm (D3.0) and 4.5 mm (D4.5) on both side. Following the treatment, local cooling with an ice pack was performed for 10 min to reduce redness and swelling. Patients were followed up at 2, 4, 6, and 8 weeks. Clinical images and non-invasive skin assessments were collected at baseline and during each visit.
224194502|NCT05552183|DRUG|oral dose of 200 mg pacritinib twice daily (BID)|Subjects will receive 200 mg BID pacritinib for 14 days.
224194503|NCT05935046|BEHAVIORAL|Walk test and meal test|"The subjects will perform a treadmill walking test at increasing speed from 2 to 6km.h-1 in 5min increments.~During the second experimental visit, subjects will be required to consume a test meal containing 590kcal (12% protein, 35% fat, 53% carbohydrate) (Duhita et al 2017).~The composition of the test meal will be developed based on the food preferences and habits questionnaires completed during the inclusion visit. Foods indicated as preferred by participants will not be offered during these sessions to avoid any influence of their palatable nature on participants' consumption."
224194504|NCT05163353|DEVICE|Treatment with diluted Radiesse|Injection of Décolleté Wrinkles with diluted Radiesse
224194505|NCT03643133|DRUG|Mifamurtide|48 doses overall over 36 weeks
224194506|NCT03643133|COMBINATION_PRODUCT|EI or M-API regimen depending on patient age|"M-API regimen:~One course of high-dose Methotrexate (optional) followed by 5 courses of API, every 21 days~EI regimen :~5 course of EI, every 21 days"
224194507|NCT05151484|DRUG|Teriparatide|Participants will receive 20 μg teriparatide per day via subcutaneous injections. Participants, and if needed a caregiver, will be trained in the subcutaneous administration of teriparatide according to the manufacturer's guidelines. The investigators will measure serum calcium, BSAP and TRAP-5b levels via blood draws at quarterly monitoring visits. If BSAP or TRAP-5b do not increase compared to baseline or decrease after any quarter, participants will be contacted and correct administration will be reviewed. Serum calcium is measured for safety to avoid hypo- and hypercalcemia. Participants will also be given a daily dose of Vitamin D of 800 IUs to prevent development of Vitamin D deficiency.
224194508|NCT05151484|DRUG|Alendronate|Participants will receive 70 mg alendronate p.o. once per week. Participants will be carefully instructed to follow the manufacturer's recommendations for administration. Compliance will be assessed by measurement of the bone turnover markers BSAP and TRAP-5b from blood drawn at quarterly monitoring visits. These markers have been shown to be useful for assessment of turnover changes with treatment. If these markers do not decrease compared to baseline or rise after any quarter, participants will be contacted and correct administration will be reviewed. Participants will also be given a daily dose of Vitamin D of 800 IUs to prevent development of Vitamin D deficiency.
224194509|NCT05892159|BEHAVIORAL|HRV biofeedback|An HRV biofeedback tool will be employed and utilized by individuals each day for the first 5 weeks during the intervention period.
224194510|NCT06199531|GENETIC|GS-100|A single intracerebroventricular (ICV) dose of the study treatment will be administered to patients with confirmed mutations in the NGLY1 gene.
223503652|NCT07045025|OTHER|No Clinical Intervention - Analysis of Previously Acquired CBCT Scans|This study does not involve any clinical or therapeutic intervention. It is solely based on the retrospective analysis of previously acquired CBCT scans from patients who have undergone root canal treatment. No drugs, devices, or procedures are administered or applied to participants as part of this study.
223503653|NCT07045506|OTHER|UVC insertion|"UVC insertion was performed under sterile conditions according to the unit protocol by a senior NICU physician. For preterm deliveries, written informed consent was obtained from a parent before enrollment in the study. In emergency cases, where the neonate required immediate UVC insertion upon admission to the NICU, a waiver of informed consent was applied. In such instances, parents were informed as soon as possible about their infant's participation in the study, provided with written information, and asked for their consent to include their infant's data in the analysis, with the option to give consent via telephone if they were unable to be present in person.~After UVC insertion, anteroposterior and lateral thoracoabdominal radiographs were performed to verify the position of the UVC tip."
223503654|NCT07046728|OTHER|Efficay and Safety of DAROMUN on patient treated by intralesionnal injection: DAROMEL|Observationnal study with clincal data collection to evaluate the efficiency and the tolerability of DAROMUN
223503655|NCT07044427|OTHER|Strength and balance training in combination with a treadmill-based pertubation intervention|Patients receive a personalized home-based training plan with strength and balance exercises to be carried out three times a week for six months. In addition, treadmill-based pertubation training is carried out at 2 timepoints.
223503656|NCT07044492|BEHAVIORAL|Virtual Reality (VR) with Debriefing|Participants will receive a weekly 5-minute VR session featuring immersive experiences of residents' lives within the facility, followed by a 25-minute debriefing discussion in small groups of 5\~6 participants. This will continue for three weeks.
223503657|NCT07046117|DRUG|Tezepelumab|injection with Tezepelumab every 4 weeks
223503658|NCT07045454|DRUG|MHB118C for Injection|IV administration by Q3W; Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and confirmed disease progression.
223503659|NCT07044661|PROCEDURE|Unilateral ARM|ARM is performed to the dependent lung only. During ARM, mechanical ventilation is set to a pressure-controlled ventilation mode with a driving pressure of 20 cmH₂O and an inspiratory-to-expiratory ratio of 1:1. The positive end-expiratory pressure (PEEP) is increased by 5 cmH₂O every five respiratory cycles, reaching a final PEEP of 20 cmH₂O and a peak airway pressure of 40 cmH₂O, which is then maintained for ten respiratory cycles.
223503660|NCT07044661|PROCEDURE|Bilateral ARM|ARM is performed to both lungs. During ARM, mechanical ventilation is set to a pressure-controlled ventilation mode with a driving pressure of 20 cmH₂O and an inspiratory-to-expiratory ratio of 1:1. The positive end-expiratory pressure (PEEP) is increased by 5 cmH₂O every five respiratory cycles, reaching a final PEEP of 20 cmH₂O and a peak airway pressure of 40 cmH₂O, which is then maintained for ten respiratory cycles.
223503663|NCT07044453|DRUG|Gem/Nabpaclitaxel infusion|Downstaging and pathological response is empirically define as T1-2/N0/R0 status. If the anatomopathological analysis shows a lesion classified as T3-4 or N+ or R1, an adjuvant chemotherapy based on Gemcitabine with Nab Paclitaxel will be proposed for a period of 3 months.
223503664|NCT07044453|DRUG|mFOLFIRINOX infusion|Downstaging and pathological response is empirically define as T1-2/N0/R0 status. In that setting the patients will receive mFOLFIRINOX adjuvant chemotherapy 3 months.
223503665|NCT06726174|DRUG|ECCEC|0.5-1x10\^6 cells/300 uL, intracameral injection.
223503666|NCT07044752|BEHAVIORAL|Anxiety Prevention Intervention|community and school based, delivered by peers from the community to educate and lower anxiety symptoms among youth
223503667|NCT07044752|BEHAVIORAL|Anxiety Intervention|5-session social and behavioral intervention about managing anxiety symptoms
224194511|NCT06087822|DEVICE|IMD SiPore21®|The intended use/purpose to improve blood glucose control, as measured by a reduction in HbA1c
224194512|NCT06080490|DRUG|TAC C/D ratio|Pharmacokinetics of TAC according to possible influencing factors
224194513|NCT06472934|OTHER|Transcatheter aortic valve replacement in the absence of B-blocker treatment|Transcatheter aortic valve replacement (TAVR) is performed in patients that temporarily pause B-blocker treatment.
224194514|NCT06472934|OTHER|Transcatheter aortic valve replacement|Transcatheter aortic valve replacement (TAVR) is performed in patients that do not temporarily pause B-blocker treatment.
224310345|NCT06983574|OTHER|MIA|"Through a collaborative co-creation process, MIA, a mHealth app was developed and refined over multiple iterations with the goal of promoting physical activity and fostering a lifestyle centred around an active and healthy approach. Content and design were derived from both the co-creative workshops and based on the theoretical framework of the intervention functions of the BCW. The final mHealth app is composed by five major features:~* Tailor-made tips~* Literacy aiming to improve awareness about PA and an active healthy lifestyle~* Exercise workouts~* Community calendar aiming to enhance social connections~* A diary consisting of daily activities (MIA workouts and self-registration) To customize the user experience, a brief personal description was created as the start screen, which prompts older adults to answer questions related to their baseline physical activity level, motivation, and medical history."
224310346|NCT06374862|OTHER|mobilization|specific mobilization on neuromuscular functioning, thanks to surface EMG, before and after a specific mobilization of the spine
224310347|NCT06374862|OTHER|no effect|"a mobilization identified as no effect could modulate neuromuscular activity by a placebo effect."
223503668|NCT07046481|OTHER|Physical activity|One or two physical activities according to the participant´s preferences will be selected and prescribed and specified for frequence and intensity. The selected activity/-ies could be of any type, as long as they increase the heart rate. The activity/-ies should be performed regularly during 12 weeks, A training diary will be used to monitor and register the activities.
223503669|NCT07047196|DEVICE|HS-20116|Innovative chitosan-based biomaterial intended for intra-articular injection
223503670|NCT07047196|DEVICE|Medical Chitosan (for intra-articular injection)|Medical chitosan for intra-articular injection
223503671|NCT06741670|BEHAVIORAL|Breastfeeding|The routine practice of the Breastfeeding Group is to place the infants in their mother's arms and start breastfeeding 1 minute before the procedure. Then, the nurse will take the heel blood.
223503672|NCT06741670|DEVICE|Vibration|The vibration device was placed on the infant's left extremity in the mid/lateral region just below the knee where the sural nerve passes. The device was secured to the extremity with a gauze bandage. The infants in the Vibration Group will be placed in their mother's arms and vibration will be applied 30 seconds before the routine application, and vibration will be applied during the 10-second waiting phase while the nurse performs the heel prick blood collection procedure.
223503673|NCT06741670|OTHER|Breastfeeding+Vibration|"The vibration device was placed on the infant's left extremity in the mid/lateral region just below the knee where the sural nerve passes. The device was secured to the extremity with a gauze bandage.~The routine practice for the Breastfeeding+Vibration Group babies will be started by holding them in their mother's arms and breastfeeding will be started 1 minute before the application. At the same time, vibration will be applied 30 seconds before the application and vibration will be applied in a 10-second waiting phase while the nurse performs the heel prick procedure."
223503674|NCT06734104|OTHER|Interactive Video Education|After participants are informed about the study, eligible individuals (based on inclusion and exclusion criteria) will be identified. From the students deemed eligible for the study group, 60 students will be selected using a simple random sampling method by an independent statistician. Informed consent will be obtained from students who agree to participate in the study. Initially, a pre-test will be administered to the 60 selected students. Following the pre-test, the students will be randomly assigned to the experimental and active control groups using a simple randomization method. The researcher will provide the interactive video to the students in the experimental group. After one week of interactive video training for the experimental group, a post-test will be administered to all students.
223503675|NCT06734104|OTHER|Non-Interactive Video Education|After participants are informed about the study, eligible individuals (based on inclusion and exclusion criteria) will be identified. From the students deemed eligible for the study group, 60 students will be selected using a simple random sampling method by an independent statistician. Informed consent will be obtained from the students who agree to participate in the study. Initially, a pre-test will be administered to the 60 selected students. After the pre-test, the 60 students will be randomly assigned to the experimental and active control groups using a simple randomization method. The researcher will provide the non-interactive video to the students in the active control group. After one week of watching the non-interactive video, a post-test will be administered to all students.
223512247|NCT04867590|DEVICE|Endorotor|"The treatment itself is preceded by a sub-mucosa saline and adrenalin solution injection administered by an endoscopic sclerotherapy needle lifting the submucosa and thus reducing the risk of perforation and hemorrhage.~The interventional tool is then applied tangentially to be brought into contact with the lifted mucosa, visual monitored by endoscope. The aspiration and sectioning system is activated by use of a pedal and a generator specially made for the system, used in every procedure. The entire surface area of the targeted mucosa must be covered by the probe. The residual tissue is then removed via the aspiration system and caught by a filter. The specimens are then easily retrievable at the end of the procedure and can be stored in formalin fixing solution for histological analysis."
224194515|NCT05965947|BEHAVIORAL|Medical Nutrition Therapy|One-on-one nutrition assessment, education, and counseling with a Registered Dietitian.
224194516|NCT05182840|DRUG|BI 690517|Film-coated tablets
224194517|NCT05182840|DRUG|Placebo to BI 690517|Film-coated tablets
224194518|NCT05182840|DRUG|Empagliflozin|Empagliflozin
224194519|NCT05182840|DRUG|Placebo to empagliflozin|Placebo to empagliflozin
224194520|NCT05718336|OTHER|Integrated care|multi-discipline care program
223592689|NCT04798209|DRUG|Microtracer matching placebo (SAD - Absolute Bioavailability)|Single dose of 14C-ACT-777991 microtracer matching placebo, administered intravenously.
224194521|NCT04946994|BEHAVIORAL|HIIT|The participant will walk/jog for 50 continuous minutes at 55% VO2peak. For resistance exercise, the initial goal will be to complete 3 sets of 8-10 repetitions of 4 exercises at low intensity (50% 1-RM) and then progress to moderate intensity (70-80% 1-RM). Exercise intensity will increase every 4 weeks or when participants can complete more than 8 repetitions with proper form at the prescribed weight.
224194522|NCT04946994|BEHAVIORAL|CME|The participant will walk/jog for 50 continuous minutes at 55% VO2peak. For resistance exercise, the initial goal will be to complete 3 sets of 8-10 repetitions of 4 exercises at low intensity (50% 1-RM) and then progress to moderate intensity (70-80% 1-RM). Exercise intensity will increase every 4 weeks or when participants can complete more than 8 repetitions with proper form at the prescribed weight.
224194523|NCT06108947|DRUG|Aspirin|Aspirin discontinuation
224194524|NCT03583255|DRUG|Dexamethasone|Given PO
224194525|NCT03583255|BEHAVIORAL|Exercise Intervention|Complete resistance training and moderate intensity walking
224194526|NCT03583255|OTHER|Placebo Administration|Given PO
224194527|NCT02161380|DRUG|injection of scAAV2-P1ND4v2 1.18x10e9 vg (Low),|injection of Total Volume of each intravitreal injection is 200 µL
224194528|NCT02161380|DRUG|injection of scAAV2-P1ND4v2 5.81 X10e9 vg (Med)|injection of Total Volume of each intravitreal injection is 200 µL
224194529|NCT02161380|DRUG|injection of scAAV2-P1ND4v2 2.4 X10e10vg (High)|injection of Total Volume of each intravitreal injection is 100 µL
224194530|NCT02161380|DRUG|injection of scAAV2-P1ND4v2 1.0 X10e11vg (Higher)|injection of Total Volume of each intravitreal injection is 100 µL
224194531|NCT01832272|PROCEDURE|Reinflation after early tourniquet deflation|The tourniquet is released after cement implant fixation, and then reinflated, once arterial bleeding was controlled
224194532|NCT00863265|DRUG|Ezetimibe|Subjects will undergo three diet periods of 21 days each separated by 7 day washouts. Food will be supplied by a metabolic kitchen and will consist of a phytosterol-deficient baseline diet. During each period subjects will receive either phytosterol esters or placebo and ezetimibe or placebo.
223503676|NCT07045298|DEVICE|Libre 2 rt-CGM|Freestyle Libre 2 consists of a sensor applied to the back of the upper arm. The sensor is a penny-sized flexible filament placed beneath the skin's surface to measure interstitial fluid. This sensor is applied utilizing a sensor applicator provided in the packaging. The sensor continuously reads interstitial glucose readings every minute and syncs with the Freestyle View app. The hypoglycemia alarm will be set to \< 80 mg/dl (for prevention of low blood glucose levels). Participants will be instructed to provide 15 grams of carbohydrates in response to a hypoglycemia alarm. The hyperglycemia alarm will be set at 300 mg/dl. Participants will call the research team if they experience repeated episodes \> 300 mg/dl (more than 2 episodes in a single day or 2 or more episodes in consecutive days). The research team will instruct the participant to check with their physician for a possible new insulin regimen, but they will be allowed to remain in the study.
223503677|NCT07045298|DIAGNOSTIC_TEST|POC BG + Blinded CGM|Standard of care point-of-care (POC) capillary blood glucose (BG) monitoring will be done before meals and bedtime daily during the study participation for up to 3 months.
223503678|NCT07055620|OTHER|Mediterranean diet|The group that will be applied the Mediterranean diet will be prepared with diet lists that include 35-40% carbohydrate, 15-20% protein and 35-45% fat (\>50% Monounsaturated Fatty Acid (MUFA)) of daily energy. The Mediterranean diet pyramid will be explained to the participants who will be applied the Mediterranean diet, and the portions and frequency of olive oil, nuts, olives, fish, yogurt, fruits and vegetables that they should consume will be planned by the dietitian. The Mediterranean diet pyramid recommends the frequency of foods that should be consumed daily, weekly and monthly. It recommends consuming fish and seafood at least twice a week, 2 portions of white meat, 2-4 portions of eggs, less than 2 portions of red meat, 1 portion or less of processed meat and less than 3 portions of dessert. It is recommended to consume 2 portions of dairy products, 1-2 portions of oil seeds and nuts, more spices, herbs, garlic and onions on a daily basis.
223592690|NCT04798209|DRUG|14C-ACT-777991 microtracer (MAD - ADME)|Single dose of 14C-ACT-777991 microtracer, oral solution..
223592691|NCT04798209|DRUG|Microtracer matching placebo (MAD - ADME)|Single dose of 14C-ACT-777991 microtracer matching placebo, oral solution.
223592692|NCT00708760|BEHAVIORAL|paper based training|read selected material, test skills learned in simulator lab
223592693|NCT00708760|BEHAVIORAL|web based training|read and view selected web based material, test skills learned in simulator lab
223592694|NCT01230138|DRUG|Placebo|Placebo tablets
223592695|NCT01230138|DRUG|FP187|High daily dose of 750mg administered as 250mg TID
223592696|NCT01230138|DRUG|FP187|High daily dose of 750mg administered as 375mg BID
223592697|NCT01230138|DRUG|FP187|Low daily dose of 500mg FP187 administered as 250mg BID
223592698|NCT01230138|DRUG|FP187|Oral tablets, up to 3 times daily for 20 weeks.
223592699|NCT03936751|DEVICE|CPAP|This is the standard treatment for OSA.
224194533|NCT00863265|OTHER|Phytosterols + ezetimibe|Subjects will undergo three diet periods of 21 days each separated by 7 day washouts. Food will be supplied by a metabolic kitchen and will consist of a phytosterol-deficient baseline diet. During each period subjects will receive either phytosterol esters or placebo and ezetimibe or placebo.
224194534|NCT00863265|OTHER|Placebo|
224194535|NCT04230746|DRUG|Bactrim DS 800Mg-160Mg Tablet|To study effect on urinary microbiome
224194536|NCT04230746|DRUG|Placebo oral tablet|To study effect on urinary microbiome
224194537|NCT03679117|BEHAVIORAL|Mindfulness Training|Phone-delivered mindfulness training. 8 weeks of 30 minute phone sessions with an instructor, plus 15 minutes of self-guided practice.
224194538|NCT03833908|DEVICE|MAF-1217|Patients will be enrolled at screening (2 weeks before surgery), then will be randomized with a 1:1 ratio to 2 groups of 23 patients each: A. patients receiving MAF-1217 B. patients receiving just standard antibiotic therapy
224194539|NCT00382499|DRUG|Lidocaine Intravenous Infusion|1.5 mg/kg IV bolus on induction, 3 mg/kg/hr infusion from inducation until fascia closure
224194540|NCT06620744|DEVICE|Sponsor MCG deivce|Unshielded device measuring cardiac magnetic fields.
224194541|NCT06395649|DEVICE|Classical rTMS to M1|The rTMS intervention consists of 10-Hz rTMS. Thirty trains of ten seconds with an interval of twenty seconds between trains will be delivered, as traditionally performed. Each train includes 100 pulses, and the total number of pulses will be 3,000 given in 15 minutes.
224194542|NCT06395649|DEVICE|rTMS to the High connectivity target|The rTMS intervention consists of 10-Hz rTMS. Thirty trains of ten seconds will be delivered with an interval of twenty seconds between trains. Each train includes 100 pulses, and the total number of pulses will be 3,000 given in 15 minutes. The rTMS will be delivered to the target, showing the highest connectivity.
224194543|NCT06395649|DEVICE|rTMS to the low connectivity target|The rTMS intervention consists of 10-Hz rTMS. Thirty trains of ten seconds with an interval of twenty seconds between trains will be delivered. Each train includes 100 pulses, and the total number of pulses will be 3,000 given in 15 minutes. The rTMS will be delivered to the target, showing the lowest connectivity.
224194544|NCT06395649|DEVICE|Sham rTMS|Sham stimulation was carried out with a sham coil of identical size, color, and shape, emitting a sound similar to that emitted by the active coil.
224194545|NCT06051474|DRUG|Nicotine Replacement Product|Adults will receive a 2-week supply of nicotine patches to place on skin (14mg or 21mg; dosing depending on tobacco use per package insert) and oral nicotine mini-lozenges (2mg, 4mg, dosing depending on tobacco use per package insert). All participants will also receive a single smoking cessation counseling session with a physician. Surveys will be completed pre-intervention, within 24 hours of hospital discharge, and 2-weeks after hospital discharge.
224194546|NCT04768881|DRUG|Selinexor|Dose and formulation: 80 mg (4 tablets of 20 mg)
224194547|NCT04768881|DRUG|Pembrolizumab|Dose and formulation: 400 mg (25 milligrams per milliliter \[mg/mL\]) Solution
224194548|NCT06056505|PROCEDURE|partial kidney nephrectomy|surgery for partial nephrectomy
224194549|NCT06056505|DEVICE|DaVinci Robot|device to perform the surgery for partial nephrectomy (not the intervention of interest)
224194550|NCT06056505|DEVICE|Innersight 3D software|investigational product to generate the 3D model
224194551|NCT05921604|DRUG|Baclofen 10mg|which will include 50 patients scheduled for sleeve gastrectomy and will receive 10 mg oral baclofen 1 h before anesthesia.
224194552|NCT05921604|DRUG|Gabapentin|which include 50 patients scheduled for sleeve gastrectomy and will receive 600 mg oral gabapentin 1 h before anesthesia.
224194553|NCT04550260|DRUG|Durvalumab|Durvalumab intravenous infusion
224194554|NCT04550260|DRUG|Placebo|Durvalumab matching placebo for intravenous infusion
224194555|NCT04550260|DRUG|cisplatin + fluorouracil|cisplatin + fluorouracil, as per Standard of Care
224194556|NCT04550260|DRUG|cisplatin + capecitabine|cisplatin + capecitabine, as per Standard of Care
224194557|NCT04550260|RADIATION|Radiation|50-64Gy in total
224194558|NCT06651034|OTHER|Platelet Rich Plasma|Under aseptic measures, a phlebotomist obtained the blood in vacutainers. Vacutainers was centrifuged and middle zone containing platelet rich plasma was aspirated in a 5 ml disposable syringe. The patient received intralesional injection
224194559|NCT03547661|OTHER|P-Dragees rosa Lichtenstein|Placebo dragées
223503679|NCT07055620|OTHER|Standard diet|When writing the weight loss diets applied to the individuals in the standard diet group, it will be taken into account that 45-60% of the energy comes from carbohydrates, 10-20% from protein and 20-35% from fat, as specified in the Turkish Nutrition Guide (TUBER). It will be planned that 10% (preferably 7-8%) of the total energy from fat will come from saturated fats (fat found in animal foods, butter, tallow, tail fat), 12-15% from monounsaturated fats (olive oil, hazelnut oil, rapeseed oil) and 7-10% from polyunsaturated fats (corn, soy, sunflower and cottonseed oils containing n-6 fatty acids and fish, fish oil, walnut, flaxseed containing n-3 fatty acids). It will be stated that this ratio is 1 part solid oil, 1 part any vegetable oil and 1.5 or 2 parts olive oil among the oil types.
223503680|NCT07055620|OTHER|standard diet and time-restricted feeding|In time-restricted nutrition, the focus is on when the food is consumed rather than the type of food. However, in medical nutrition treatment of obesity, the content of the meals is also important along with the time (Soran and Öney 2022). As stated in the Turkish Nutrition Guide (TÜBER), it will be taken into account that 45-60% of the energy comes from carbohydrates, 10-20% from protein and 20-35% from fat (Ministry of Health, 2022). A time-restricted nutrition model will be implemented from intermittent fasting diet models. The time restriction will be planned as 8 hours of eating and 16 hours of fasting, suitable for the lifestyle of the individuals. The feeding time for individuals who agree to participate in the study will be determined as 11.00-12.00 and 19.00-20.00. Individuals will be given 2 main meals and the first meal will start with breakfast or lunch according to their wishes.
223503681|NCT07056868|PROCEDURE|extraperitoneal colostomy|Patients in this group will undergo extraperitoneal stoma creation using the arcuate line approach. This technique involves creating a stoma through the extraperitoneal space by accessing the posterior sheath at or below the arcuate line, thereby avoiding direct peritoneal entry. The goal is to reduce the risk of parastomal hernia by maintaining abdominal wall integrity and preventing intra-abdominal content herniation around the stoma.
224194560|NCT06502821|OTHER|questtionnaire|questionnaire regarding workplace preferences and the factors influencing choosing a career in physiotherapy
224194561|NCT06805383|BEHAVIORAL|Phone call|Phone call to patients randomized to experimental arm.
224194562|NCT06805383|OTHER|Mailed FIT Kit|FIT Kit mailed to patient address in EMR.
224194563|NCT04498975|OTHER|Rurality; Ethnicity; Exercise; Hopelessness|Observational study exploring rurality, ethnicity, exercise and hopelessness patterns cross-sectionally and longitudinally
224194564|NCT02278042|OTHER|Beverage Consumption|
224194565|NCT04535921|OTHER|FCR7 questionnaire|A 7 item questionnaire about fear of cancer recurrence
224194566|NCT01958619|DRUG|1440mg PQP tablets|Piperaquine phosphate tablets (1440mg)
224194567|NCT01958619|DRUG|960mg PQP tablets|Piperaquine phosphate tablets (960mg)
224194568|NCT01958619|DRUG|800mg OZ439 + TPGS|OZ439 (800mg) + TPGS granules for oral suspension
224194569|NCT01958619|DRUG|960mg PQP granules|Piperaquine phosphate granules for oral solution (960mg)
224194570|NCT06560658|DRUG|Psilocybin|Participants will receive four 2-hour sessions of supervised microdosing of psilocybin in a two week period.
223592700|NCT03936751|DEVICE|Nasal Strips|Nasal strips were commercially available in the market for supposing treat snoring and sleep apnea but no proof that this is true. Our group previously validated nasal strips as an interesting placebo.
224194571|NCT06560658|BEHAVIORAL|Meditation|Participants will receive four 2-hour sessions of supervised microdosing of psilocybin in a two week period. In addition to meditating during their sessions, participants will also meet online five days a week for meditation instruction and practice.
224194572|NCT04804306|DEVICE|Diagnostic Test: CBC-DIFF Monocyte Volume Width Distribution (MDW)|MDW measurement used to detect sepsis. Results will not be used to manage patients.
224194573|NCT05362773|DRUG|MGD024|MGD024 is a CD123 x CD3 bispecific DART® molecule designed to target CD123-expressing leukemic cells for elimination by CD3-expressing T lymphocytes.
224194574|NCT03677440|BEHAVIORAL|Treadmill Walking Exercise Training|12-weeks of supervised, progressive treadmill walking exercise training
224194575|NCT03677440|BEHAVIORAL|Stretching-and-Toning Exercise Training|12-weeks of supervised, progressive stretching-and-toning exercise training
224194576|NCT01710839|DRUG|0.5mg Ranibizumab|intravitreal injections
224194577|NCT01710839|PROCEDURE|Targeted Pan Retinal Photocoagulation|Targeted Pan Retinal Photocoagulation based on wide field angiography
224194578|NCT00038571|DRUG|PS341 (Bortezomib)|1.5 mg/m2 intravenous (IV) bolus push over 3 to 5 seconds on days 1, 4, 8, and 11, followed by a 10-day rest for a 21-day cycle.
223503682|NCT07056868|PROCEDURE|transperitoneal colostomy|Patients in this group will receive a conventional transperitoneal stoma. In this approach, the stoma is brought out through the abdominal wall via a peritoneal opening, which is the standard method used in colorectal surgery. This technique serves as the control for evaluating whether the arcuate line approach offers improved outcomes, particularly in reducing parastomal hernia incidence.
223503683|NCT07056972|OTHER|Discontinuation of surveillance|The intervention is discontinuation of current surveillance policies which consist of annual imaging with MRI/MRCP and clinical assessment.
223503684|NCT00525356|DEVICE|Medtronic Talent Stent-Graft-System|
223592701|NCT03461094|DEVICE|Preload assessment and volume expansion|Fluid therapy perform
223592702|NCT00488904|DIETARY_SUPPLEMENT|supportan|2 sip feed pr. day
223592703|NCT00488904|DIETARY_SUPPLEMENT|supportan placebo|2 sip feed pr. day
223592704|NCT04491760|OTHER|Inspiratory Muscle Training|The inspiratory muscle training (IMT) will be carried out with a load of 30% of maximal inspiratory pressure (MIP) using a threshold inspiratory muscle trainer (c-type, Shengchang medical equipment factory, Yuyao city, China) at the beginning. During the hospital period, the resistance will increase incrementally, based on the rate of perceived exertion scored on the Borg scale (Borg, 1982). If the rate of perceived exertion less than 5, the resistance of the inspiratory threshold trainer will then be increase incrementally by 5%. The load for home-based IMT training will be set as the highest training load in the hospital. All patients will be required in sitting position during training, wearing nose-clips.
223592705|NCT01846650|DRUG|Capecitabine tablets|Single oral Capecitabine tablets 2000mg qd
223592706|NCT01846650|DRUG|XELODA|Single oral XELODA 2000mg qd
223592707|NCT05920772|BEHAVIORAL|KickAsh! intervention|The general aim of the KickAsh! intervention is to prevent smoking initiation in adolescents living in vulnerable socioeconomic situations. The intervention exists of different components concerning smoking prevention. Most components have a direct influence on smoking initiation by affecting several determinants of the adolescents. These components include smoke-free games, mood boards, a smoke-free camp, the Kick some Ash!-challenge and exercises concerning self-efficacy and skills. Yet, some of the components target adolescents by influencing their environment, i.e. smoking policy in the organisation and youth workers as role models. All components are developed using a combination of theoretical methods to change or influence these determinants or environmental factors.
223592708|NCT01805037|DRUG|brentuximab vedotin|Given IV
223592709|NCT01805037|BIOLOGICAL|rituximab|Given IV
223592710|NCT01805037|OTHER|laboratory biomarker analysis|Correlative studies
223592711|NCT00085332|DRUG|docetaxel|
223592712|NCT05832749|DEVICE|Ophtesis Bio 3% ophthalmic viscosurgical device|Intraocular surgery of the anterior segment, including cataract extraction and intraocular lens (IOL) implantation. The viscoelastic properties of OphtesisBio 3.0% allow lubrication, support and protection of ocular tissues during ophthalmic surgery. Maintains the depth of the anterior chamber during surgery, allows for efficient manipulation with reduced trauma to the corneal endothelium and other surrounding tissues.
223592713|NCT05832749|DEVICE|Healon Endocoat 3% ophthalmic viscosurgical device|"Healon@ EndoCoat OVD is an ophthalmic viscoelastic containing 3% sodium hyaluronate indicated for use as a surgical aid in patients undergoing ophthalmic anterior segment procedures including:~* Cataract surgery with an intraocular lens~* Cataract surgery without an intraocular lens~* Secondary intraocular lens implantation~Healon@ EndoCoat maintains a deep chamber during anterior segment surgery, aids in tissue manipulation during surgery, enhances visualization during the surgical procedure and protects the corneal endothelium and other ocular tissue. The viscoelasticity of the solution maintains the normal position of the vitreous face and prevents formation of a flat chamber during surgery. It may also be used to coat intraocular lenses and insertion instruments prior to intraocular lens implantation."
223592714|NCT03974373|PROCEDURE|BFP removal|The surgical procedure was performed using the technique with intrabuccal access, already consecrated in the literature (Materasso 2006). The Bichat fat ball access was made by means of a small incision no more than 3 mm in length in the soft tissue located in the lower aspect of the zygomatic counterfoot, taking care to visualize and protect with the retractor the Stensen's conduit. With the aid of blunt-tipped or hemostatic scissors dissection was performed, taking care to preserve the membrane surrounding the ball of fat. After removal of one side, pressure was removed to remove air and the procedure was started on the opposite side, after the removal of the two sides was realized simple suture with silk thread. There were no formal indications for sending the samples for anatomic and / or histological examination.
223592715|NCT00868907|DRUG|35 mg risedronate DR tablet|35 mg risedronate DR oral tablet administered within 5 minutes after completing a standard breakfast and taking one Caltrate® 600+D tablet
224194579|NCT05852301|OTHER|no intervention|no intervention, observational study only
224194580|NCT00854776|DRUG|lansoprazole|30 mg once daily
224194581|NCT00854776|DRUG|aluminum hydroxide 334 mg and Mg hydroxide 166 mg|1 tablet once daily
223746782|NCT04521972|DEVICE|Room light/light bulb|Room light will be ON/OFF or red light used in the room. Reducing/eliminating light in the room in the evening and night is expected to allow the natural release of melatonin, which is thought to promote uterine contractions in late pregnancy.
223746783|NCT02132325|BEHAVIORAL|Dignity Therapy|Dignity Therapy/Life Plan will be provided by an advanced practice nurse or chaplain (APN/Chap), who has undergone training in provision of Dignity Therapy (offered through a 3-day group workshop by Dr. Harvey Chochinov).
223746784|NCT05102383|DEVICE|Comfilcon A Toric contact lenses|Monthly replacement contact lenses
223746785|NCT05102383|DEVICE|Verofilcon A for Astigmatism Daily Disposable contact lenses|Daily disposable contact lenses
223746786|NCT06964464|DRUG|Metoprolol Succinate|Metoprolol succinate is a beta-blocker used for the management of heart failure with reduced ejection fraction (HFrEF). In this study, participants in the metoprolol succinate group will remain on their current treatment regimen with metoprolol succinate. The dose will be titrated to the recommended target dose as per the study protocol. The intervention aims to evaluate the effectiveness of continued use of metoprolol succinate in patients with heart failure and an implantable cardioverter defibrillator (ICD).
223746787|NCT06964464|DRUG|Carvedilol|Carvedilol is a non-selective beta-blocker with alpha-blocking activity used in the treatment of heart failure. In this study, participants assigned to the carvedilol group will switch from metoprolol succinate to carvedilol at an equivalent dose. The carvedilol dose will be titrated to recommended target doses according to the study protocol. This intervention aims to compare the effectiveness of carvedilol versus metoprolol succinate in improving clinical outcomes in patients with heart failure and ICDs.
223746788|NCT06054555|DRUG|ABP 206|ABP 206 will be given intravenously over a period of 30 or 60 minutes, every 4 weeks (Q4W) for a total of 24 months.
223746789|NCT06054555|DRUG|Nivolumab|Nivolumab will be given intravenously over a period of 30 or 60 minutes, Q4W for a total of 24 months.
224194582|NCT05023499|DRUG|SYMPT-X Glutamine, Oral Powder for Reconstitution|erioperative glutamine supplementation (PGS) was defined as the subjects with five-day parenteral plus one-month oral use.
224194583|NCT00609934|DRUG|Sorafenib|Dose level 1: sorafenib 200mg PO OD on Days 1-84 Dose level 2: sorafenib 400mg PO OD on Days 1-84
224194584|NCT00609934|RADIATION|external beam radiotherapy|3000cGy in 10 fractions
224194585|NCT01003691|BIOLOGICAL|RN6G|Intravenous, multiple dose, dose ranging from 5 mg/kg up to a maximum of 15 mg/kg
224194586|NCT01003691|BIOLOGICAL|Placebo|Intravenous, multiple dose with experimental dose
224194587|NCT02989701|DRUG|Plerixafor|Dose escalation of Plerixafor for Hematopoietic stem cell mobilization in patients with Sickle Cell Disease
224194588|NCT06107465|DRUG|Nitroglycerin|high dose Nitroglycerin
224194589|NCT04226209|OTHER|PSSE|Physiotherapeutic Scoliosis-Specific Exercises (PSSE) group will receive exercise for 30-40 mins in a day, twice in a week, totally 8 weeks and 16 hours. Control group will be taught the basic elements of corrective exercises and want them to do the practising during 8 weeks at home.
224310348|NCT04661891|OTHER|Isometric contractions|HD-EMG grids will be applied to the lower limb muscles of interest. Isometric contractions will consist of applying joint torque to reach a pre-defined torque level based on the subject's maximal voluntary contraction (i.e., 25%, 60%, 70%, 80%, 90%). The participant will control torque intensity by responding to a biofeedback displayed on a screen. The joint will be secured with non-compliant bands to prevent any movement of the participant. The order of the joints tested (i.e., dominant ankle, knee, or hip joint) will be randomized.
224310349|NCT04661891|OTHER|Isokinetic contractions|HD-EMG grids will be applied to the lower limb muscles of interest. Isometric contractions will consist of moving a joint to completing a set of contractions (10-20 contractions) at various velocities (i.e., 10 degrees per second, 30 degrees per second, 60 degrees per second). The joint will be secured with non-compliant bands to prevent any movement of the participant. The order of the joints tested (i.e., dominant ankle, knee, or hip joint) will be randomized.
224310350|NCT04661891|DEVICE|Dynamic contractions|HD-EMG grids will be applied to the lower limb muscles of interest. Multi-joint tasks (i.e. walking, squatting, cycling) will be performed at a given frequency. A motion capture system will be used to record the joint angles and ground reaction forces simultaneously.
223746790|NCT00004323|DRUG|anti-thymocyte globulin|
224310351|NCT04661891|DEVICE|Isometric contraction with muscle fatigue|"An identical experiment will be performed as stated in Isometric contraction with the addition of induced muscle fatigue by repeatedly maintaining 40% of muscle torque until failure to maintain a contraction for 5 seconds."
224310352|NCT04661891|DEVICE|Multi-joint functional activities while wearing exoskeleton|Participants will be measured and fitted with the bilateral exoskeleton, and sufficient range of motion to used exoskeleton will be confirmed. HD-EMG grids will be applied to the lower limb muscles of interest. The participant will perform single-joint movements to calibrate the decoder parameters. The participant will then perform multi-joint activities (e.g., standing, squatting, walking overground or on a treadmill, cycling, or stair climbing) in a movement analysis laboratory
224310353|NCT04661891|OTHER|Clinical Assessments|Subjects may complete a 10 meter walk test (10MWT) overground or over a pressure-sensitive walkway, 6 minute walk test (6MWT), Berg Balance scale (BBS), and/or Functional Gait Assessment (FGA). They may also complete step ups or squats.
223746791|NCT00004323|DRUG|cyclophosphamide|
223746792|NCT00004323|DRUG|cyclosporine|
223746793|NCT00004323|DRUG|mesna|
224194590|NCT07007468|OTHER|Abdominal Massage|Abdominal massage is a massage technique performed with soft and rhythmic movements applied to the abdomen. Abdominal massage is an inexpensive, non-invasive, non-harmful, non-invasive method that can be applied by nurses for the treatment of constipation or by teaching the patient and his/her family. During the application of abdominal massage, effleurage (patting), abdominal effleurage , petrissage (kneading), abdominal petrissage maneuvers are applied.
223746794|NCT00004323|DRUG|methotrexate|
223746795|NCT00004323|DRUG|methylprednisolone|
223746796|NCT04317456|DEVICE|Hearing Aids and Hearing Implants|Hearing Aids and Hearing Implants (age at first fitting and implantation and aided audibility)
223746797|NCT04317456|BEHAVIORAL|Family Centred Early Intervention|Family Centred Early Intervention
223746798|NCT00044395|DRUG|Ruboxistaurin mesylate|
223746799|NCT01096810|DRUG|TBL 12|TBL 12 will be administered orally at a dose of 2 units (20 mL each) twice a day until disease progression.
223592716|NCT00868907|DRUG|35 mg risedronate DR tablet|35 mg risedronate DR oral tablet administered within 5 minutes after completing a standard dinner
223592717|NCT00868907|DRUG|35 mg risedronate DR tablet|35 mg risedronate DR oral tablet administered within 5 minutes after completing a standard breakfast
223592718|NCT03972956|OTHER|No intervention will be given to patients.|Samples are collected at the time of a scheduled surgery that is part of normal treatment. This study will not have any impact on the care or treatment the patient receives.
223592719|NCT04734587|DIAGNOSTIC_TEST|Blood serum Neuron-specific Enolase measurement|The Silent Brain Injury ratio was compared by measuring the Neuron-specific enzyme level with venous blood sampling from both patient groups before and after percutaneous coronary intervention.
223592720|NCT02964585|DRUG|Canagliflozin|100 mg
223592721|NCT02964585|DRUG|Placebo|1 tablet daily for 16 weeks
223592722|NCT03251950|BEHAVIORAL|healthy eating and gardening|15 week healthy eating and gardening intervention for children aged 3-5 years; 15 week online parenting intervention to promote healthy eating; Menu change in early childhood center to promote healthy eating
223592723|NCT00935441|BEHAVIORAL|case management with telemonitoring|telephone contact with a case manager, home telemonitoring equipment for blood sugar and blood pressure, home HbA1c measurement
223592724|NCT00935441|BEHAVIORAL|usual case management|telephone contact with a case manager
223592725|NCT04409093|PROCEDURE|Nail bed repair with eponychial sent|The nail bed repair will be performed with 6-0 chromic suture material. After the nail bed repair, an eponychial stent will be secured under the eponychial fold with suture. The stent can be the native nail plate, suture container foil, or nonadherent gauze (i.e. Xeroform). If the injury avulsed the nail plate and the patient presents without it, either the foil from the suture wrapper/container or a piece of nonadherent gauze (i.e. Xeroform) will be used as a stent. A nonadherent sterile dressing will be applied to the digit, and each patient will be discharged with a 5-day course of cephalexin for prophylaxis against infection.
223592726|NCT04409093|PROCEDURE|Nail bed repair without eponychial stent|The nail bed repair will be performed with 6-0 chromic suture material. After the nail bed repair, an eponychial stent will not be secured under the eponychial fold. A nonadherent sterile dressing will be applied to the digit, and each patient will be discharged with a 5-day course of cephalexin for prophylaxis against infection.
223592727|NCT02177838|BIOLOGICAL|cetuximab|Given IV
223592728|NCT02177838|DRUG|cisplatin|Given IV
223592729|NCT02177838|RADIATION|external beam radiation therapy|Undergo EBRT
223592730|NCT02177838|OTHER|laboratory biomarker analysis|Correlative studies
223592731|NCT03040115|OTHER|Non-Interventional Study|
223592732|NCT03517566|DRUG|Placebo|once daily from baseline until week 16
223592733|NCT03517566|DRUG|ZPL389 3mg|ZPL389 3 mg oral powder; once daily from baseline to week 16
223592734|NCT03517566|DRUG|ZPL389 10mg|ZPL389 10 mg oral powder; once daily from baseline to week 16
224310354|NCT06988865|OTHER|Clinical evaluation|treatment methods, associated symptoms, evolution and clinical presentation
223592735|NCT03517566|DRUG|ZPL389 30mg|ZPL389 30 mg oral powder; once daily from baseline to week 16
223592736|NCT03517566|DRUG|ZPL389 50mg|ZPL389 50 mg oral powder; once daily from baseline to week 16
223592737|NCT05172804|BEHAVIORAL|Progressive muscle relaxation|PMR (Smith Version) involves a tense-let go exercise of 11 muscle groups including hand, arm, arm and sides, back, shoulder, face, front of neck, stomach, chest, leg, and foot. This tense-let go exercise is performed twice for each muscle group. The tensing up phase for each muscle group should last for 5 to 10 seconds and the letting go phase for 20-30 seconds. Simultaneously, the subjects will be asked to pay attention to the sensations of muscle tension and relaxation. After the tense-let go exercise, subjects are asked to systematically scan the muscle groups to notice and let go any remaining muscle tension. The entire exercise should take around 30 minutes, not counting instructions and times of measurement \[11\].
223592738|NCT05172804|BEHAVIORAL|Guided Imagery|Guided imagery (Smith Version) involves creating in one's mind or imagining a passive relaxing places or activities. In sense imagery, one simply imagines sensations associated with a relaxing setting or activity. The relaxation approach involves the sense of sight, sound, touch, and smell. The categories of stimuli consist of: (1) Travel such as boats, plains, trains, balloons, horses, (2) outdoor nature settings such as mountains, gardens, and forest, (3) water such as rivers, lakes, ocean, beach, rain, and (4) indoor settings such as childhood home, castle, religious institution, and cabin \[11\].
223592739|NCT05172804|BEHAVIORAL|Mindfulness Meditation|"Smith version of the mindfulness meditation will be used in the current study. The mindful mediators are neutral observers who view the world as it is, without reactions, judgments, and evaluations. They quietly attend to, note, and let go of every internal external stimulus such as thought, feeing, sensation, sound, idea that enters awareness. They do not try to think about, push away, and do anything with these stimuli experienced and do not have to figure out the connections between each stimulus. They simply let each stimulus come and go and wait for the next stimulus. They do not have to be concerned about distractions. Each time they are distracted, they note it as yet another passing stimulus (Ah, a distraction… how interesting) \[11\]."
223592740|NCT05172804|OTHER|Control group|Participants in the control condition will be instructed to sit with their eyes closed and relax during the intervention periods. Participants in the control group will follow an identical procedure and time periods as the experimental groups. For instance, when the experimental groups will practice for 30 minutes, the participants in the control group will be asked to sit with eyes closed and relax for 30 minutes.
224310355|NCT06989827|DRUG|Preservative free artificial tear|After diagnosing patients with dry eye disease we prescribed them preservative free artificial tears and scheduled them for a follow-up keratometry.
224310356|NCT06988982|DRUG|Intravenous Lipid Emulsion 20%|patients will receive 1.5 ml/kg bolus of intravenous lipid emulsion 20 % followed by 0.25 ml/kg/hr infusion over 30 minutes at the end of surgery
224310357|NCT06988982|DRUG|Control (placebo) group|patients will receive equal volume of normal saline at the end of surgery
224310358|NCT06990035|BEHAVIORAL|Mediterranean diet lessons program|Participants will attend five one-hour lessons delivered by qualified professionals to learn about foods that have a positive impact on cognitive function and how to incorporate them into their dietary regimen.
224310359|NCT06990035|BEHAVIORAL|Physical activity|Participants will undergo a 12-week physical exercise program guided by specified personal trainers.
224194591|NCT00852657|PROCEDURE|Tendon repair with acromioplasty|Open or mini-open tendon repair in combination with an acromioplasty and eventually a tenodesis of the long head of the biceps
224194592|NCT00852657|PROCEDURE|Physiotherapy|According to a rehabilitation program which was established prior to study start.
224194593|NCT07006168|DRUG|Ketorolac 15mg|An intra-articular cocktail injection ( Ketoralac 15mg, Ropivacaine 1% 15ml, 0.9% Normal Saline 35ml, Adrenaline 1:1000 0.5ml, Stacort-A Triamcinolone Acetonide 40mg) will be injected into the surgical site after fracture fixation surgery.
224194594|NCT07006168|DRUG|Triamcinolone Acetonide 40mg|An intra-articular cocktail injection ( Ketoralac 15mg, Ropivacaine 1% 15ml, 0.9% Normal Saline 35ml, Adrenaline 1:1000 0.5ml, Stacort-A Triamcinolone Acetonide 40mg) will be injected into the surgical site after fracture fixation surgery.
223503685|NCT07056426|OTHER|Exercises|"Joint mobilization exercises:~-Active ankle range of motion exercises~Ankle strengthening with resistance band (Thera-band®):~* Resisted dorsiflexion~* Resisted plantar flexion~* Resisted inversion~* Resisted eversion~* Leg muscle strengthening exercises:~* Heel raises (standing)~* Heel raises (sitting)~* Toe raises (standing)~* Toe raises (sitting)~Hip and pelvis stabilizer muscle strengthening exercises:~* Pelvic bridge~* Side leg lifts with hip and knee at 0°~* Side leg lifts with hip and knee at 90°~Stretching exercises:~* Calf stretch with towel~* Gastrocnemius stretch (standing)~* Soleus stretch (standing)~* Anterior compartment leg stretch~These exercises will be applied three times a week in 40-minute sessions, for a total of 12 sessions."
223503686|NCT07056426|OTHER|ESWT|"The Extracorporeal Shock Wave Therapy (ESWT) will be administered once a week for a total of four sessions. Each session will deliver 2000 pulses at a pressure of 2.5 bar and a frequency of 8 Hz using radial shock wave technology. The total energy flux density per session is planned to be approximately 200 mJ/mm².~Patients will be positioned in a supine lying position during the treatment. A generous amount of ultrasound gel will be applied to the medial tibial border and surrounding tissues to ensure effective transmission of shock waves and patient comfort.~The application of shock waves will follow the clinical focusing principle: treatment will start from the point of greatest tenderness and maximal pain on the medial tibial border, progressing in a circular motion from medial to lateral. The treatment area will typically cover a region approximately 2-4 cm in width and 4-8 cm in length."
223503687|NCT07056426|OTHER|Deep Tissue Massage|The deep tissue massage begins with the patient lying on their side, the affected leg on top, knee flexed at about 45 degrees, and the medial surface of the tibia facing upward. The sensitive line along the medial tibia is identified by palpation, and the area is prepared with petroleum jelly. The massage starts with 4-5 superficial strokes along the medial calf using the palm, followed by 2-3 deep strokes to assess muscle tone and patient tolerance. Moderate pressure is applied with the thumb perpendicular to the tibial line, moving slowly from just above the medial malleolus toward the medial tibial plateau. Then, the thumb shifts one finger width posteriorly and moves upward along the soleus muscle with similar pressure. These two steps are repeated 6-8 times, each lasting 10-15 seconds, with pain adjusted to 7-8 on the VAS scale. A 10-second rest is given between applications, and the massage ends with 4-5 superficial strokes.
223503688|NCT07055841|DRUG|Adebrelimab|1200mg, intravenous infusion, D1， Every three weeks, there are two cycles in total.
223503689|NCT07055841|DRUG|TP regimen|TP regimen: Docetaxel 75 mg/m2, intravenous infusion, D1， Cisplatin 75 mg/m2, intravenous infusion, D1， Every three weeks, there are two cycles in total.
223503690|NCT07055841|PROCEDURE|Surgery or radiotherapy|Surgery or radiotherapy should be performed 1-4 weeks after the completion of neoadjuvant therapy.
223503691|NCT07056296|DEVICE|3D Maxillary Expansion with 3 expansion screws|In patients requiring maxillary expansion, after randomization and allocation for each to receive which expander, appliance will be cemented. In the 3-way group (A), 3 screw activations will be delivered by the care giver to expand the maxillary arch in 3D manner correcting the collapsed arch anteriorly.
223503692|NCT07056296|DEVICE|3D Maxillary Expansion using modified Fan expander with springs|For the fan expander with palatal springs (B) , spring activation will be done by the operator after cemenation intraorally, then the care giver too will just activate one fan screw. Also 3D expansion evaluation was done.
223503693|NCT01225302|DRUG|Linifanib|Low dose linifanib (once a day)
223503694|NCT01225302|DRUG|Linifanib|High dose linifanib (once a day)
223503695|NCT01225302|DRUG|Carboplatin|Given on Day 1 of every 21-day cycle
223503696|NCT01225302|DRUG|Paclitaxel|Given on Day 1 of every 21-day cycle
223503697|NCT01981252|DEVICE|Ulthera® System Treatment|Focused ultrasound energy delivered below the surface of the skin
223503698|NCT04179630|BIOLOGICAL|Aldafermin (NGM282)|Single 3 mg dose
223503699|NCT02137811|OTHER|MICK Assay|An automated microculture kinetic (MiCK) assay for measuring drug induced apoptosis in tumor cells; the MiCK assay for apoptosis provides a mechanism-based approach to studying effects of cytotoxic agents on tumor cells.
223503700|NCT00314106|BIOLOGICAL|Melanoma Reactive TIL|
223503701|NCT00314106|DRUG|Cyclophosphamide|60 mg/kg/ day x 2 days intravenous
223503702|NCT00314106|BIOLOGICAL|IL-2|720,000 IU/kg/dose every 8 hours for up to 15 doses
223746800|NCT03070574|DRUG|mesalamine 2400 MG (5-ASA)|For this study IMP will be supplied as film-coated tablets packed in containers. Each patient will receive two different containers, each 1200mg of IMP (= 2400 mg), every 3 months (± 1 week), 100 tablets per container. The containers will be marked in different colours, to prevent the patients from taking two tablets from one container accidentally.
224194595|NCT07006168|DRUG|Ropivacaine HCL 1% 15ml|An intra-articular cocktail injection ( Ketoralac 15mg, Ropivacaine 1% 15ml, 0.9% Normal Saline 35ml, Adrenaline 1:1000 0.5ml, Stacort-A Triamcinolone Acetonide 40mg) will be injected into the surgical site after fracture fixation surgery.
224194596|NCT07006168|DRUG|0.9 % Normal Saline 35ml|An intra-articular cocktail injection ( Ketoralac 15mg, Ropivacaine 1% 15ml, 0.9% Normal Saline 35ml, Adrenaline 1:1000 0.5ml, Stacort-A Triamcinolone Acetonide 40mg) will be injected into the surgical site after fracture fixation surgery.
224194597|NCT07006168|DRUG|Adrenaline 1:1000 0.5ml|An intra-articular cocktail injection ( Ketoralac 15mg, Ropivacaine 1% 15ml, 0.9% Normal Saline 35ml, Adrenaline 1:1000 0.5ml, Stacort-A Triamcinolone Acetonide 40mg) will be injected into the surgical site after fracture fixation surgery.
223503703|NCT00314106|DRUG|Fludarabine|25 mg/m\^2/day intravenous x 5 days
223503704|NCT00314106|RADIATION|1200 total body irradiation (TBI)|1200 cGY total body radiation
224194598|NCT06869330|BEHAVIORAL|psychosocial|Measure changes in mental health indicators like depression, anxiety, and stress levels using validated scales (e.g. DASS 21).
224194599|NCT06308523|DRUG|AP303 150 μg|AP303 Tablet 150 μg QD
224194600|NCT06308523|DRUG|Placebo 150 μg|Placebo Tablet 150 μg QD
224194601|NCT06308523|DRUG|AP303 300 μg|AP303 Tablet 300 μg QD
224194602|NCT06308523|DRUG|Placebo 300 μg|Placebo Tablet 300 μg QD
224194603|NCT00001658|DRUG|Amoxicillin|
224194604|NCT03917576|OTHER|Behavioral|The resting heart rate (HRrest), maximum HR (HRmax), HR recovery (HRRTEST), delta HR recovery (ΔHRRTEST) were measured by continuous telemetric heart rate sensor (Polar FT4, PolarTM, Finland) during an incremental exercise test designed to obtain maximum oxygen consumption (VO2max) on a cycle ergometer (Lode Corival, Groningen, The Netherlands) similar with previous studies using similar cohort. An indirect calorimetry/ergospirometry system (Ultima CPXTM metabolic system, Medgraphics, Minnesota, USA) was used to measure VO2max until volitional exhaustion. Thus, the modified Astrand volitional protocol was applied in the participants of all NG, Pre-T2D and T2D groups increasing the load (i.e., Watts) 25 W each 2 min to women, and 50 W each 2 min to men.
224194605|NCT03917576|OTHER|Exercise training intervention|Subjects also participated in a single HIIT session composed of 10-cycling intervals, using a Lode Corival cycle ergometer. The exercise session consisted of 1-minute cycling at high intensity (workload during each interval was set at \~80-100 % maximal power achieved during the incremental exercise test with a workload that allowed to work until the volitional muscle failure in 1-minute), followed by 2-minutes of inactive resting period (sitting still on the cycle ergometer), and was repeated 10 times (1x2x10 protocol; 1:2:10 to work:rest:repetitions respectively).
224194606|NCT04408716|PROCEDURE|Ablation Index Guided High-Power Short-Duration Strategy|Point-by-point circumferential pulmonary vein ablation will be performed using the advanced STSF catheter under ablation index guided high power short duration strategy (Radiofrequency energy is set up at a power of 50 W, temperature of 43 °C, contact force of 5-20 gram, and flow rate of 20 mL/min; Target ablation index is set to 500 at the anterior wall and 350 at the posterior wall of left atrium).
224194607|NCT04408716|PROCEDURE|Standard Radiofrequency Ablation Technique|Point-by-point circumferential pulmonary vein ablation will be performed using the ST catheter under standard radiofrequency ablation settings (Radiofrequency energy is set up at a power of 30 to 35 W, temperature of 43 °C, contact force of 5-20 gram, and flow rate of 17 to 30 mL/min. Target ablation index is set to 500 at the anterior wall and 350 at the posterior wall of left atrium).
224194608|NCT05032391|BIOLOGICAL|The pentavalent rotavirus vaccine (live attenuated oral, freeze-dried)|Three times orally in a volume of 2.5 ml (1 dose)
224194609|NCT05032391|DRUG|Placebo|Three times orally in a volume of 2.5 ml (1 dose)
224194610|NCT01796795|DRUG|Vehicle gel|Topical application on the target lesion(s)once daily with occlusive dressing; a maximum of 3 times of administration of gel without exceeding 0.2 g per administration.
224194611|NCT01796795|DRUG|SR-T100 gel with 1.0% of SM|Topical application on the target lesion(s)once daily with occlusive dressing; a maximum of 3 times of administration of gel without exceeding 0.2 g per administration.
224194612|NCT01796795|DRUG|SR-T100 gel with 2.3% of SM|Topical application on the target lesion(s)once daily with occlusive dressing; a maximum of 3 times of administration of gel without exceeding 0.2 g per administration.
224194613|NCT04046029|DRUG|Bivalirudin|Bivalirudin will be given as a bolus of 0.75 mg/kg followed by infusion of 1.75 mg/kg/h during the PCI procedure and for at least 30 minutes but no more than 4 hours afterwards. Following this mandatory infusion,a reduced-dose infusion (0.2 mg/kg/h) for up to 20 hours could be administered at physician discretion. An additional bivalirudin bolus of 0.3 mg/kg was given if the activated clotting time 5 minutes after the initial bolus was less than 225 seconds.
224194614|NCT04046029|DRUG|Heparin|Heparin will be administered at a dose of 70 to 100 units per kilogram in patients not receiving glycoprotein IIb/IIIa inhibitors and at a dose of 50 to 70 units per kilogram in patients receiving glycoprotein IIb/IIIa inhibitors. Subsequent adjustment of the heparin dose on the basis of the activated clotting time will be left to the discretion of the treating physicians.
224194615|NCT03783312|DRUG|placebo|250 ml saline will be administered 60 minutes before the onset of Electroconvulsive therapy procedure. All administrations will be applied through IV infusion over 60 minutes.
224194616|NCT03783312|DRUG|paracetamol|1 g paracetamol will be administered 60 minutes before the onset of Electroconvulsive therapy procedure. All administrations will be applied through IV infusion over 60 minutes.
224194617|NCT03783312|DRUG|ibuprofen|800 mg ibuprofen will be administered 60 minutes before the onset of Electroconvulsive therapy procedure. All administrations will be applied through IV infusion over 60 minutes.
224194618|NCT00000721|DRUG|CD4 Antigens|
224310360|NCT06988930|DIAGNOSTIC_TEST|Control group|The non-operation group was treated with rehabilitation therapy for 6 weeks, and the operation group was treated with arthroscopic surgery and the pathological tissue of cartilage and subchondral bone was taken. Assessment was performed at three months, one year, and two years after treatment and recorded in the database.
223592741|NCT00328250|BEHAVIORAL|Cognitive behavioral treatment (CBT) delivered over the Internet|CBT delivered over the Internet for insomnia targets maladaptive behaviors and dysfunctional thoughts that perpetuate sleep problems. Treatment includes through educational, behavioral, and cognitive strategies.
223592742|NCT02722265|DRUG|CS-3150|CS-3150 2.5mg to 5mg, orally, once daily for 28 or 52 weeks
223592743|NCT04777292|DEVICE|Use of a mobile health application until app completion|Participants are asked to use esTOCma app approximately during 10 days, until app completion. This app has been designed to increase knowledge about obsessive-compulsive disorder (OCD), help seeking attitudes, and reduce stigmatizing attitudes. It consists in a game in which participants are asked to fight against the OCD stigma monster through ten missions. Participants have to liberate 10 characters who are prisoners of EsTOCma monster.
223592744|NCT04040621|DRUG|Ceftazidime-avibactam|Single intravenous infusion of ceftazidime-avibactam over 2 hours. Dosage will vary depending upon age, weight and renal function.
223592745|NCT00506168|DRUG|Irinotecan, Capecitabine|
223592746|NCT05423392|PROCEDURE|Tooth extraction of deciduous and permanent molars in children aged 5-18 years and mandibular premolars in children aged 10-18 years|Tooth extraction will be following up with the methodological procedures in order to define the effectiveness of anesthetics during indicated dental procedure.
223503705|NCT07056816|OTHER|Interactive Doll|"Interactive Doll: Their hearts beat and they say hello as soon as you put it on your finger because they know it's really yours! They also have a different personality and reactions when they open and close your finger. With sensors in their head, mouth and belly, Fingerlings respond to your touch and will respond to you. You can also shake them and turn them upside down for even more reactions because they love to monkey around. And their positive tail can hang down or flip up so they can sit on your table or shelf. Kids will play with the Interactive Doll during the inhalation treatment."
223592747|NCT05423392|PROCEDURE|Endodontic dental treatment of deciduous and permanent molars in children aged 5-18 years and mandibular premolars in children aged 10-18 years|Endodontic dental treatment will be following up with the methodological procedures in order to define the effectiveness of anesthetics during dental treatment.
223592748|NCT05423392|PROCEDURE|Conservative tooth restoration of deciduous and permanent molars in children aged 5-18 years and mandibular premolars in children aged 10-18 years|Conservative tooth restoration will be following up with the methodological procedures in order to define the effectiveness of anesthetics during conservative tooth restoration.
223592749|NCT04566692|BIOLOGICAL|IGSC 20%|SC infusion pump.
223592750|NCT03254355|PROCEDURE|Multimodal physiotherapy|12 weeks of weekly physiotherapy treatments including education segment, electrical stimulation and PFM exercises consisting of strength, endurance and coordination exercises accompanied by biofeedback
223592751|NCT02336542|BIOLOGICAL|5μg/ml ESAT6-CFP10 in left arm and TB-PPD in right arm|TB subjects and non-TB subjects with lung disease inject 5μg/ml ESAT6-CFP10 in left arm and TB-PPD in right arm respectively. Two drug must use at the same person and different arm.
223592752|NCT02336542|BIOLOGICAL|5μg/ml ESAT6-CFP10 in right arm and TB-PPD in left arm|TB subjects and non-TB subjects with lung disease inject 5μg/ml ESAT6-CFP10 in right arm and TB-PPD in left arm respectively. Two drug must use at the same person and different arm.
223592753|NCT02336542|BIOLOGICAL|10μg/ml ESAT6-CFP10 in left arm and TB-PPD in right arm|TB subjects and non-TB subjects with lung disease inject 10μg/ml ESAT6-CFP10 in left arm and TB-PPD in right arm respectively. Two drug must use at the same person and different arm.
223592754|NCT02336542|BIOLOGICAL|10μg/ml ESAT6-CFP10 in right arm and TB-PPD in left arm|TB subjects and non-TB subjects with lung disease inject 10μg/ml ESAT6-CFP10 in right arm and TB-PPD in left arm respectively. Two drug must use at the same person and different arm.
223592755|NCT01879046|PROCEDURE|arthroplasty|Blood, bone marrow, synovial fluid and Hoffa's fat pad samplings
223592756|NCT02547168|DEVICE|iRhythm ZIO XT patch|The iRhythm ZIO XT patch is an ECG monitor that has to be worn by study participants. It will be used to track any incidence of atrial fibrillation.
223592757|NCT01426776|PROCEDURE|heart valve replacement|The patients with heart valve disease and CSR will be received heart valve replacement
223592758|NCT01496755|DRUG|Placebo|Single/multiple doses
223592759|NCT01496755|DRUG|RG7667|Single/multiple ascending doses
223592760|NCT05808413|BEHAVIORAL|Informational Video|This video emphasizes that vaccination against COVID-19 continues to be important, highlights the importance of seeking accurate information, and provides statistics about the estimated number of lives saved by vaccination and reported adverse events following vaccination in Canada.
223592761|NCT05808413|BEHAVIORAL|Altruistic Video|This video presents a vignette about a young adult woman who has many social interactions during her daily life. It shows that her decision to stay up-to-date on COVID-19 vaccination could help to protect those people she comes into contact with, who may be at greater risk from COVID-19 infection. Statistics are used to show that up to one-in-four people in Canada have underlying conditions that make them more vulnerable to COVID-19, and to quantify the number of surgeries that were delayed by pandemic-related disruptions.
223592762|NCT05808413|BEHAVIORAL|Individualistic Video|This video presents a vignette about a young adult man who is very health-conscious. He is unsure about staying up-to-date on COVID-19 vaccination until he learns that COVID-19 infection can have serious and disruptive consequences even if someone is younger. Statistics are used to quantify the increased risk of severe symptoms in young adults who are not up-to-date on vaccination.
223746801|NCT03070574|DRUG|mesalamine 1200 MG|For this study IMP will be supplied as film-coated tablets packed in containers. Each patient will receive two different containers of IMP (1200 mg/placebo) every 3 months (± 1 week), 100 tablets per container. The containers will be marked in different colours, to prevent the patients from taking two tablets from one container accidentally.
224310361|NCT06988839|PROCEDURE|Microneedling followed by coronally advanced flap|Microneedling will be performed using a 30 gauge lancet needles, inserted until hard tissue is felt. It will be performed in 4 sessions at 10 day intervals, followed by coronally advanced flap procedure, 2 months post microneedling.
223503706|NCT07056816|OTHER|Interactive Robot|Interactive Robot: It has an interactive design that improves children's music listening and learning skills. It attracts children's attention with its vibrant colors and cute design, and teaches them while having fun. It has a voice imitation feature and a response feature that makes different sounds when its head is touched. Children will play with the Interactive Robot during inhalation treatment.
223503707|NCT01065441|BIOLOGICAL|AlloStim|Patients meeting eligibility criteria will be primed with at least three and up to nine intradermal AlloStim-TM injections at a frequency of every 2-8 days at doses between 1-4 x 10\^7 cells
223503708|NCT01065441|PROCEDURE|Cryoablation|Percutaneous cryoablation of selected tumor lesion under CT or US guidance
223503709|NCT01065441|BIOLOGICAL|AlloStim|intratumoral injection of AlloStim-TM into cryoablated tumor lesion at a dose of 1-6 x 10\^7 cells
223503710|NCT01065441|BIOLOGICAL|AlloStim|intravenous AlloStim-TM at doses between 1 x 10\^7 to 1 x 10\^9 cells
223503711|NCT01065441|BIOLOGICAL|AlloStim|Intraperitoneal AlloStim-TM infusion in patients with peritoneal carcinomatosis and/or ascites
223503712|NCT01065441|BIOLOGICAL|AlloStim|Patients with malignant pleural effusion may receive intrapleural AlloStim-TM infusion at a dose of 5-10 x 10\^7 cells.
223503713|NCT01065441|BIOLOGICAL|AlloStim|Patients with palpable tumors may receive alcohol ablation and intratumoral AlloStim-TM
223503714|NCT01845857|BEHAVIORAL|Chronic Disease Self-Management Workshop|6 week, small group self-management workshop
223503715|NCT03795909|DRUG|Ruxolitinib|Ruxolitinib （2.5 mg twice daily for patients if the age\<14 years and the weight \<25kg，5 mg twice daily for patients if the age\<14 years and the weight≥25kg, 10mg twice daily for patients if the age ≥14 years and\<18 years）
223746802|NCT03070574|OTHER|Placebo|For this study IMP will be supplied as film-coated tablets packed in containers. Each patient will receive two different containers of IMP (placebo/placebo) every 3 months (± 1 week), 100 tablets per container. The containers will be marked in different colours, to prevent the patients from taking two tablets from one container accidentally.
223746803|NCT00509782|DRUG|ZIO-101|Starting Dose 78 mg/m\^2 intravenously daily for 5 consecutive days repeated every 4 weeks.
223746804|NCT02970279|BEHAVIORAL|Behavioural Activation Group (BAG) Psychotherapy|Behavioural activation (BA) is a psychotherapy intervention based on behaviour theory and operant conditioning. It teaches patients to reduce avoidant depressive behaviours and in turn increase the positive reinforcement they receive from their environment for non-depressive behaviours through the use of activity scheduling and pleasant events. For the trial, BA will be delivered in a group format (BAG) and facilitated by two therapists. BAG treatment will consist of eight weekly sessions, lasting two hours and will follow a manualised treatment protocol. Each session will be based on a different topic relevant to the principles of BA and patients will be given between session work to complete to encourage increased participation in rewarding personally meaningful activities.
223746805|NCT05542875|PROCEDURE|Thrust Manipulation|Prone thoracic extension manipulation technique will be applied from T2 - T6 to participants of Group A (Experimental group). Intervention will be applied on alternate days with a total of 4 treatment sessions
224194619|NCT01979029|PROCEDURE|preserving the left colic artery|The root of the inferior mesenteric artery(IMA) was carefully dissected and the artery wall was exposed all the way to the bifurcation of the left colic artery(LCA) and the superior rectal artery (SRA), exposing the LCA from its root until the inferior mesenteric vein (IMV) was recognized. Subsequently, dissection was continued along the IMV up to the level of the root of the IMA. Then the sigmoid mesentery was transected from the root of the IMA to the IMV, and the IMV and the root of the SRA were ligated. Finally, the adipose tissue with the lymph nodes in the area surrounded by the IMA, IMV, and LCA was dissected, with preservation of the LCA .
224194620|NCT01979029|PROCEDURE|not preserving the left colic artery|The root of the IMA was exposed and the fatty tissue around the root of the IMA was swept in order to maximize the lymph node retrieval rate. Subsequently, the IMA was ligated 1 cm from the aorta to avoid damaging the nerves.
224194621|NCT03196401|DRUG|Durvalumab|durvalumab 1500mg administered intravenously every 28 days, for a total of six doses
224194622|NCT03196401|RADIATION|Radiation therapy|concurrent definitive radiation therapy to the bone plasmacytoma initiated within two weeks of starting
224194623|NCT02850666|BEHAVIORAL|Interdisciplinary process drama|Process drama program (5 days/week, 1 week, 25-3 hour sessions) of movement-based activities combining music, art, and drama. Activities have been planned by a collaborative team of drama teachers, occupational therapists, and speech language pathologists.
223503716|NCT03795909|DRUG|Dexamethasone|Dexamethasone (10mg/m2.d) delayes for the first 2 weeks（form week 1 to 2),(5mg/m2.d) from week 3 to 4，(2.5mg/m2.d) from week 5 to 6），1.25mg/m2.d for week 7，and dropped off on week 8.
223503717|NCT00168532|DRUG|Sulfamethoxazole-Trimethoprim|
223503718|NCT03217825|DRUG|Rostafuroxin|This is a potent, selective and safe inhibitor of this altered mechanism and has been proved to be effective in reducing blood pressure levels in Adducin mutated rat strains and in chronic Ouabain infused rat model.
223503719|NCT03217825|DRUG|Losartan|COZAAR (losartan potassium) is an angiotensin II receptor (type AT1) antagonist. Losartan potassium, a nonpeptide molecule, is chemically described as 2-butyl-4-chloro-1-\[p-(o-1H-tetrazol-5-ylphenyl)benzyl\]imidazole- 5-methanol monopotassium salt.
223503720|NCT03321032|DEVICE|Polymer-free amphilimus-eluting stents|Cre8 Evo coronary stent system (CID, Saluggia, Italy)
223503721|NCT03321032|DEVICE|Biolinx Polymer-based zotarolimus-eluting stents|Resolute Onyx coronary stent system (Medtronic, Minneapolis, Minnesota, US)
223503722|NCT05850507|BIOLOGICAL|Omicron BA.4/5-Delta strain recombinant novel coronavirus protein vaccine (CHO cells)|Intramuscular injection of deltoid muscle of upper arm of 25μg/0.5ml/person dose Omicron BA.4/5-Delta strain recombinant novel coronavirus protein vaccine (CHO cells).
223503723|NCT05850507|BIOLOGICAL|Recombinant novel coronavirus protein vaccine (CHO cells)|Intramuscular injection of deltoid muscle of upper arm of 25μg/0.5ml/person dose Recombinant new coronavirus vaccine (CHO cells) .
223503724|NCT06050772|BEHAVIORAL|Immersive Virtual Reality Reminiscence|a computer-generated environment using head-mounted displays (HMDs) that provide a fully immersive, completely engaging, and realistic experience so that users feel like they are a part of the virtual world
223503725|NCT06050772|BEHAVIORAL|Traditional Reminiscence Therapy|RT is a technique that encourages older adults' positive emotions and coping mechanisms by using the recall of earlier memories and the sharing of life experiences.
223503726|NCT04344093|DEVICE|Patch validation|Use of connected patch to collect blood pressure, heart rate, respiratory rate, arterial oxygen saturation and temperature
223503727|NCT02687737|PROCEDURE|Electromyography|During the fine wire electromyography (EMG), the participant will be asked to complete breathing exercises at 50% and 75% of their maximum capacity (determined prior to fine wire EMG using manometry) to determine activation and recruitment of genioglossus muscle.
223503728|NCT02687737|PROCEDURE|Maximum expiratory pressure|The participants' maximum expiratory pressure (MEP) will be assessed using a hand-held digital manometer (MP01, Micro Direct Inc.). The subject will be standing and while wearing a nose clip be asked to blow out as hard and fast as they can to determine their MEP. This will be completed a maximum of three times to obtain values within close range of one another.
223503729|NCT02687737|PROCEDURE|Videofluoroscopy|Videofluoroscopy allows for time-synced, frame-by-frame data analysis for the specific measures taken during swallowing tasks.
223503730|NCT02687737|BEHAVIORAL|Swallowing Tasks|"These include: an anterior tongue press to the alveolar ridge (behind the front molars), a saliva swallow, a 10 mL barium swallow, a 10 mL barium hard swallow (i.e. swallowing with extra effort), and two breathing exercise trials at 50% MEP and 75% MEP."
224194624|NCT03563807|OTHER|Golf Instruction|Subjects will participate in two weekly hour-long golf classes. Classes will be led by professional golf instructors that will work with individuals to teach participants how to play golf. This will include stretching, individual coaching, and working with participants to maximize their golf swing.
224310362|NCT06988839|PROCEDURE|Coronally advanced flap with connective tissue graft|Coronally advanced flap operation will be performed with connective tissue graft harvested from palate after phase 1 therapy.
224194625|NCT03563807|OTHER|Tai Chi Class|Tai Chi is an ancient martial art that uses meditative movement to improve strength, flexibility, and balance. Subjects will participate in two weekly hour-long Tai Chi classes.The class will be led by a certified Tai Chi instructor and consist of approximately 12 people.
224194626|NCT06875986|DRUG|Brexpiprazole (Rexulti)|In general, for adults, start with taking 0.5 mg of brexpirazole at a time, once a day. Then the dose will be increased with an interval of at least one week to 1 mg at a time, once a day. If you have no problem with tolerability and do not show an adequate response, the dose may be increased to 2 mg at a time, once a day, but the increase should be made at intervals of at least one week.
224194627|NCT01645449|DRUG|Atorvastatin Calcium Tablets, 80 mg|Atorvastatin Calcium Tablets, 80 of Dr. Reddy's Laboratories Limited
224194628|NCT07034755|OTHER|autologous hematopoietic stem cell transplantation (ASCT) followed by CAR-T therapy|The efficacy of autologous hematopoietic stem cell transplantation (ASCT) followed by CAR-T therapy was evaluated in patients with multiple myeloma who either achieved partial response (PR) or better (but not complete response \[CR\]) after four cycles of first-line chemotherapy, or those who achieved CR but had high-risk factors.
224194629|NCT06722495|RADIATION|SBRT|Patient will receive SBRT (8Gy\*3F) in combination with the original regimen of neoadjuvant immunochemotherapy in course 3. Gross tumor target volume (GTV) based on the primary foci clearly identified by clinical and imaging examinations. The GTV was discharged 3 mm to generate a Planning target volume (PTV). the target area (PTV) was dosed accordingly to the PTV.
224194630|NCT06723093|BEHAVIORAL|Social Medicine Housing Initiative|"Through the Social Medicine Housing Initiative, patients will receive access to permanent supportive housing and support services based on a social medicine model. The Housing Initiative provides a housing-first approach which offers housing to individuals without prerequisites (e.g., requiring cessation of substance use, adherence to treatment). Housing will be provided through a rent-geared-to-income model, with participants paying up to 30 percent of their income towards rent.~Participants will also be provided with customized social and medical support within and beyond the University Health Network, tailored to their specific needs and preferences. Patient care will be a collaborative effort involving the housing provider, the Social Medicine team, and community agencies."
224194631|NCT06723223|DIAGNOSTIC_TEST|Traditional Peritoneal Equilibrium Test|The first day started with a traditional PET consisting of a 240-minutes dwell with 2.3% glucose PD solutions. The intervention includes sampling of blood plasma (Na, K, glucose, creatinine, urea and albumin) and dialysate (Na, K, glucose, creatinine, urea and albumin).
224194632|NCT06723223|DIAGNOSTIC_TEST|Combined Peritoneal Equilibrium Test|The PET test on the first day (Day 1) was followed by a short (60 min) combined PET with 4.25% glucose solution. On the second day (Day 2), the combined PET was repeated. The intervention includes sampling of blood plasma (Na, K, glucose, creatinine, urea and albumin) and dialysate (Na, K, glucose, creatinine, urea and albumin).
224194633|NCT06723067|DEVICE|Wearable wireless breast pump|As above
224194634|NCT06723769|DEVICE|rTMS treatment|Repetitive transcranial magnetic stimulation (rTMS) is a new physiotherapy technique for the treatment of PSD Compared to other strategies, it has the advantages of simple operation, non-invasive, painless, and safe. Studies have comprehensively shown that rTMS can effectively improve depressive symptoms in PSD patients
224194635|NCT06723769|OTHER|conventional treatment|general treatment of stabilizing vital signs (such as antidepressants, stabilizing blood pressure, stabilizing blood sugar, etc. ) and conventional rehabilitation treatment (hemiplegic limb comprehensive training, swallowing speech training, cognitive perception training, etc. ).
224194636|NCT06724770|OTHER|Resilience training intervention|Training intervention on tools and strategies to strengthen the resilience of work teams in healthcare centres.
224194637|NCT04489511|DRUG|STG-001|Dose 1 or Dose 2 of STG-001 will be administered daily for 28 days to compare safety, pharmacokinetics and pharmacodynamics in Stargardt disease subjects.
224194638|NCT06893484|DIAGNOSTIC_TEST|Weekly high-sensitivity urine pregnancy tests|Participants will take a high-sensitivity urine pregnancy test at home weekly for up to 4 weeks compared to the taking just one home urine pregnancy test at 4-5 weeks. Participants will also complete short weekly questionnaires on their pregnancy symptoms and follow-up care.
224194639|NCT00157820|DEVICE|Single Chamber Implantable Cardioverter Defibrillator|Single chamber ICD implantation: Medtronic GEM, Medtronic Marquis family of SC ICD
223503731|NCT06244901|DEVICE|Ankle Exoskeleton|Walking for twenty minutes with a wearable powered robotic ankle exoskeleton on real-world terrain every day for a week.
223503732|NCT06244901|OTHER|Normal walking|Normal walking for twenty minutes on real-world terrain every day for a week.
223503733|NCT02863042|PROCEDURE|Repair Deltoid Tendon|
223503734|NCT02863042|OTHER|Ankle Fracture Without Deltoid Tendon Repair|Standard of care
223503735|NCT04999397|OTHER|standards clinical management|outcomes seen in cardiac injuries post clincal care
223503736|NCT00302666|DRUG|Valette (Dienogest/EE30, BAY86-5038)|Oral contraceptive extended cycles
223503737|NCT00302666|DRUG|Valette (Dienogest/EE30, BAY86-5038)|Oral contraceptive conventional cycles
223503738|NCT02324595|PROCEDURE|Laparoscopic interval debulking surgery|"Diagnostic laparoscopy with a careful exploration of peritoneal cavity: if available a 5 mm flexible tip videolaparoscope will be used to explore all peritoneal recesses.For eligible patients,will be placed 3 5mm trocar in standard position for pelvic surgery:cytoreduction will consist in total/radical hysterectomy,bilateral salpingo-oophorectomy,radical omentectomy.If needed pelvic/upper peritonectomy will be performed:in these cases additional trocar can be placed in right or left subcostal spaces. All surgical procedure requested will have be carried out by laparoscopy/robotic or by laparotomy,in case of increased surgical risk or technical impossibility:the case will be registered as laparotomic conversion.At the end of surgical procedures residual tumor will be registered"
223503739|NCT03451968|OTHER|amino acid tracer injection for metabolism analysis|"the intervention includes injecting stable amino acid tracers in order to evaluate differences in processing of amino acid in critically ill patients compared to a normal population.~after injection 5 ml of blood will be drawn at time 0, 2, 5, 10, 15, 20, 30, 40, 50, 60, 90, 120, 150, 180 minutes from the start of the study, a total of 14 blood samples (70 cc)."
223503740|NCT06097572|DIAGNOSTIC_TEST|Intranasal food challenge|Subjects will undergo an incremental intranasal challenge to initially 0.9% NaCl saline solution, and then increasing doses of the food protein
223746806|NCT05542875|PROCEDURE|Non-Thrust manipulation|Maitland grade III or IV thoracic 0manipulation will be given to participants of Control group from T1 to T6. Posterior to anterior glide over spinous process will be maintained for 30 seconds. Intervention will be applied on alternate days with a total of 4 treatment sessions
224194640|NCT00157820|DEVICE|Dual Chamber implantable cardioverter defibrilator|Dual chamber ICD implantation: Jewel AF \& GemIII AT as DC ICDs (DC true and SC sim arms)
224194641|NCT05275946|DRUG|Targeted alpha therapy|Single intravenous administration
223503741|NCT06097572|DIAGNOSTIC_TEST|Mast cell activation test|Blood will be processed for mast cell activation as previously described (https://doi.org/10.1016/j.jaci.2018.01.043)
223503742|NCT00727064|DRUG|Desvenlafaxine Succinate Sustained-Release (DVS SR)|
223503743|NCT00727064|DRUG|Venlafaxine Extended Release (VEN ER)|
223503744|NCT06461559|DEVICE|antegrade infusion of ileostomy content|infusing the contents of ileostomy output back into intestine of the patient
223503745|NCT00346528|DRUG|Next Generation Ophthalmic Irrigating Solution (NGOIS)|Volume sufficient to irrigate adequately during cataract surgery
223503746|NCT00346528|DRUG|BSS Plus|Volume sufficient to irrigate adequately during cataract surgery
223503747|NCT00151515|DRUG|minoxidil|Topical 5% minoxidil foam, BID, for sixteen weeks
223503748|NCT00126737|OTHER|Weight Control Nutritional Program|a week of food diary and information about dietary fat intake and proper proportions of vegetables.
223503749|NCT00126737|OTHER|Home-based exercise program|24 week home-based exercise program encompassed aerobic exercises, isometric and isotonic exercises, and stretching exercises.
223503750|NCT01926392|DRUG|water-soluble therapy|The patient acted as their own control and the experimental and comparison arms (water-soluble therapy and silver sulfadiazine) were alternated on a daily basis
223503751|NCT01926392|DRUG|silver sulfadiazine|The patient acted as their own control and the experimental and comparison arms (water-soluble therapy and silver sulfadiazine) were alternated on a daily basis
223503752|NCT07055724|BIOLOGICAL|Eque-cel CAR-T Therapy|Participants in this arm receive a single infusion of Eque-cel at a dose of 1.0 x 10\^6 CAR-T cells/kg following lymphodepletion preconditioning with fludarabine and cyclophosphamide. Eque-cel is a fully human BCMA-targeted CAR-T cell therapy designed to recognize and eliminate BCMA-expressing cells.
223503753|NCT04539366|PROCEDURE|Biopsy Procedure|Undergo biopsy
223503754|NCT04539366|PROCEDURE|Biospecimen Collection|Undergo collection of blood
223503755|NCT04539366|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
223503756|NCT04539366|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
223503757|NCT04539366|DRUG|Cyclophosphamide|Given IV
223503758|NCT04539366|PROCEDURE|Echocardiography Test|Undergo ECHO
223503759|NCT04539366|DRUG|Fludarabine Phosphate|Given IV
223503760|NCT04539366|BIOLOGICAL|GD2-CAR-expressing Autologous T-lymphocytes|Given IV
223503761|NCT04539366|PROCEDURE|Imaging Procedure|Undergo standard imaging scans
223503762|NCT04539366|PROCEDURE|Magnetic Resonance Imaging of the Heart|Undergo cardiac MRI
223503763|NCT04539366|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
223503764|NCT04539366|OTHER|Questionnaire Administration|Ancillary studies
223503765|NCT06684002|OTHER|Pilates training|Participants in the Pilates group attended supervised 60-minute sessions twice weekly for eight weeks, led by a certified physiotherapist trained by the Australian Institute of Pilates and Physiotherapy.
223503766|NCT06684002|OTHER|Standard prenatal care and ergonomic advice|The control group received standard prenatal care and ergonomic advice, and did not participate in any exercise training.
223503767|NCT06706102|BIOLOGICAL|Biological tests|Biological tests : cell quantification et characterization
223503768|NCT06706102|DIAGNOSTIC_TEST|MRI|MRI
223503769|NCT06706102|DIAGNOSTIC_TEST|Neuropsychological tests|Neuropsychological tests
223503770|NCT06145516|BEHAVIORAL|Cognitive behavioral therapy for insomnia (CBT-I)|Hybrid CBT-I (self-guided digital format focusing on sleep restriction therapy and stimulus control + telehealth video-consultations with psychologist)
223503771|NCT06145516|BEHAVIORAL|Sleep education therapy (SET)|Self-guided digital sleep education (sleep hygiene, sleep physiology, sleep disturbances etc) + telehealth video-consultations with research nurse
223503772|NCT06914869|DRUG|Mavorixafor|Mavorixafor will be administered per schedule specified in the arm description.
223503773|NCT06914869|DRUG|Carbamazepine|Carbamazepine will be administered per schedule specified in the arm description.
223503774|NCT06914869|DRUG|Efavirenz|Efavirenz will be administered per schedule specified in the arm description.
223503775|NCT06773507|BIOLOGICAL|BC008-1A 900mg|BC008-1A 900mg will be administered once every 3 weeks until disease progression occurs, or intolerable toxicity develops, or they are lost to follow-up, or withdraw their informed consent, or start a new anti-tumor treatment, or the investigator decides to withdraw them based on the subject's benefit situation.
223503776|NCT06773507|BIOLOGICAL|BC008-1A 1200mg|BC008-1A 1200mg will be administered once every 3 weeks until disease progression occurs, or intolerable toxicity develops, or they are lost to follow-up, or withdraw their informed consent, or start a new anti-tumor treatment, or the investigator decides to withdraw them based on the subject's benefit situation.
223503777|NCT05257707|DIAGNOSTIC_TEST|Molecular biology|"Samples will be taken as part of routine care consultations. These include~* Smears taken with cytobrushes adapted to the anatomical site (cervix, vulva, vagina, penis, anus, upper aerodigestive tract...).~* Blood samples taken to isolate plasma, cells or serum.~* CSF and effusion samples taken with a suitable puncture needle (lumbar puncture, ascites puncture, pleural puncture, etc.).~* Urine samples collected in sterile ECBU jars.~* Biopsies taken according to the recommendations of good clinical practice using specific forceps adapted to the anatomical site.~* Surgical parts.~* Eyebrows.~* Saliva samples or gargle samples."
223503778|NCT06735014|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|Participants will undergo 3T MRI scanning of the brain and cervical spine MRIs
223503779|NCT06735014|DIAGNOSTIC_TEST|Plasma neurofilament light chain (NfL) quantification|Participants will undergo a blood draw for the quantification of plasma neurofilament light chain
223503780|NCT03213704|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
224194642|NCT06518616|BEHAVIORAL|10-day meditation intervention|prerecorded meditation units delivered by smartphone app
223746807|NCT05542875|PROCEDURE|Standard Treatment|"Standard treatment protocol includes moist heat, TENS and Post isometric relaxation technique. Standard treatment will be given to both groups on every session. Standard treatment consists of:~Superficial Moist Heat (Device): Superficial moist heat will me applied for 10 minutes on Upper Trapezius TENS (Device): TENS will be applied for 10 minutes at 80-100Hz, the electrodes will be placed at upper trapezius.~Post-isometric Relaxation (procedure/surgery): 5-10 repetions of Post Isometric relaxation technique will be applied on various muscle groups which include Upper trapezius, levator scapulae, sternocleidomastoid and scalenes."
224194643|NCT06518616|BEHAVIORAL|10-day health education intervention|prerecorded health education units delivered by smartphone app
223746808|NCT03365310|DRUG|C. longa, curcuminoids , Z. officianale, O. sanctum along with 200 ml of Milk|Polyherbal formulation along with standard of care
224194644|NCT06768658|DRUG|TAK-951|TAK-951 subcutaneous injection.
224194645|NCT06768658|DRUG|TAK-951 Placebo|TAK-951 placebo-matching subcutaneous injection.
224310363|NCT06989619|BEHAVIORAL|Sleep health and mindfulness intervention|This educational, healthy lifestyle intervention will include several modules detailing sleep health and mindfulness strategies. In addition, opinion leaders will be identified in the population to help diffuse messages through each housing facility.
223503781|NCT03213704|PROCEDURE|Bone Marrow Aspiration and Biopsy|Undergo a bone marrow aspiration and/or biopsy
223503782|NCT03213704|PROCEDURE|Bone Scan|Undergo a bone scan
223503783|NCT03213704|PROCEDURE|Computed Tomography|Undergo a CT scan
223503784|NCT03213704|DRUG|Larotrectinib Sulfate|Given PO or via nasogastric- or gastric-tube
223503785|NCT03213704|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223503786|NCT03213704|PROCEDURE|Radionuclide Imaging|Undergo a MIBG scintigraphy
223503787|NCT03213704|PROCEDURE|X-Ray Imaging|Undergo an x-ray
223503788|NCT03597594|DRUG|Anti-thymocyte globulin (rabbit)|given intravenously
223503789|NCT03597594|DRUG|Busulfan|given intravenously
223503790|NCT03597594|DRUG|Fludarabine|given intravenously
223503791|NCT03597594|DRUG|Thiotepa|given intravenous infusion
223503792|NCT03597594|DEVICE|CliniMACS|The mechanism of action of the CliniMACS Cell Selection System is based on magnetic-activated cell sorting (MACS). The CliniMACS device is a powerful tool for the isolation of many cell types from heterogeneous cell mixtures, (e.g. apheresis products). These can then be separated in a magnetic field using an immunomagnetic label specific for the cell type of interest, such as CD3+ human T cells.
223503793|NCT03597594|OTHER|Donor Lymphocyte Infusion|given intravenous infusion
223746809|NCT03365310|OTHER|Standard of Care|Usual standard of care for consist of exercise, caloric and protein support, vitamin D, reduction of polypharmacy along with medical management of health condition, assessment of care needs and provision of care. These will be determined on case by case basis by research clinician.
224194646|NCT05657457|DRUG|Tenecteplase|intra-arterial tenecteplase
224194647|NCT05044039|DRUG|Duvelisib|Patients should take duvelisib at approximately the same time every day, with or without food.
224194648|NCT06929507|DRUG|Intravitreal injection of Faricimab or Aflibercept 2 mg|Anti-VEGF agents Faricimab (Vabysmo) or Aflibercept 2 mg (Eylea) will be delivered intravitreally
224194649|NCT06943430|OTHER|laughter yoga|Participants in the intervention group received laughter yoga sessions twice a week for a total of four weeks.
224194650|NCT01441882|DRUG|Dasatinib|Given PO
224194651|NCT01441882|OTHER|Laboratory Biomarker Analysis|Correlative studies
224194652|NCT01441882|OTHER|Pharmacological Study|Correlative studies
224194653|NCT02010359|DRUG|Lovaza|Lovaza 4 grams per day
224310364|NCT06990568|DRUG|Lacidofil|1 capsule twice daily.
223503794|NCT02860000|DRUG|Alisertib|Given PO
223503795|NCT02860000|DRUG|Fulvestrant|Given IM
223503796|NCT02860000|OTHER|Laboratory Biomarker Analysis|Correlative studies
223503797|NCT06932666|OTHER|Diet A group|Diet high in fiber (\> 40g/10MJ), high in resistant starch (\> 10g/10MJ), and containing large food particles. Diet is provided for 3 full days, consists of three meals per day (breakfast, lunch, and dinner) and in-between meals, and covers 100% of the participants' energy requirements.
223503798|NCT06932666|OTHER|Diet B group|Diet low in fiber (\< 10g/10MJ), low in resistant starch (\< 3g/10MJ) and containing small food particles. Diet is provided for 3 full days, consists of three meals per day (breakfast, lunch, and dinner) and in-between meals, and covers 100% of the participants' energy requirements.
223503799|NCT06935812|OTHER|Bimanual Exercise|The bimanual exercise group consists of exercises that involve movements in which both hands are used simultaneously. The bimanual exercise group will have 40 minutes of training for 3 sessions per week for 8 weeks.
223503800|NCT06935812|OTHER|Finger Exercise|The finger exercise group consists of exercises that involve finger movements. The bimanual exercise group will have 40 minutes of training for 3 sessions per week for 8 weeks.
223503801|NCT06935812|OTHER|Virtual Reality|The virtual reality exercise group consists of hand-tracking game exercises that involve finger movements. The bimanual exercise group will have 40 minutes of training for 3 sessions per week for 8 weeks.
224194654|NCT02010359|DRUG|Placebo|Placebo pill
224194655|NCT05754242|DRUG|Ascorbic acid|1.5 gr of ascorbic acid
224194656|NCT05754242|DRUG|0.9% Saline solution|100 ml of 0.9% saline solution
224194657|NCT04976205|RADIATION|Total Marrow (Lymph-node) Irradiation|To the standard procedure for TMI/TMLI target definition, based on simulation WB-CT acquired 10/15 days before BMT, we acquire: WB- magnetic resonance imaging (MRI) the same day of the simulation WB-CT. A verification WB-CT will be performed 3/4 days before the delivery. Plans will be optimized with Volumetric Modulated Arc Therapy (VMAT) technique.
224194658|NCT01388322|DRUG|Enoxaparin|40 mg (4000 IU) women \<80 kg at the time of randomization or 60 mg (6000 IU) women\> 80 kg at the time of randomization One dose daily. Subcutaneous administration. Treatment periods: the same day of the Initiation visit (from 9 to 13.6 weeks of gestation) until 36 weeks gestation.
224310365|NCT06990568|DRUG|Placebo|1 capsule twice daily.
224310366|NCT06988956|DRUG|Nimotuzumab|Nimotuzumab 400mg
224310367|NCT06988956|DRUG|Tegafur|S-1 60mg/m2
224310368|NCT06988956|RADIATION|radiotherapy|PTV 50Gy/2Gy
224310369|NCT06988709|OTHER|Real-time Visual Feedback|Runners will visualize their real-time ground contact time (GCT) measured by the RunScribe on a TV screen. They will be instructed to run with a goal of matching their target GCT. Their target GCT will be 5% less than their baseline.
224310370|NCT06988709|OTHER|Real-time Auditory Feedback|Runners will be instructed to match their step rate to a target step rate, 10% above their baseline step rate. A metronome will be played over a speaker to provide real-time auditory feedback of the target step rate.
224310371|NCT06988709|OTHER|Real-time Verbal Feedback|"The clinician will provide real-time verbal feedback to runner to pull your foot off the ground as quickly as you can, every 15 seconds during the retraining condition."
223503802|NCT06943144|OTHER|Dual task Training|In dual-task training, participants walk while performing cognitive tasks such as object identification, counting backward, or solving math problems. These exercises aim to improve coordination, attentional control, and dual-task performance by simultaneously engaging cognitive and motor functions. Training sessions are held twice a week, each lasting 30 minutes with breaks for rest and reflection. Tasks vary in complexity to progressively challenge participants and enhance both cognitive processing and gait stability.
223592763|NCT01890668|OTHER|Osteopathic Manipulative Treatment|"Visit 1 between H60 and discharge :~Interview (pregnancy step, initiation of breastfeeding, baby posture…) Osteopathic Clinical exam (osteopathic specific diagnosis, mobility…) Osteopathic Manipulative Treatment by sweet osteopathic mobilization Time of intervention = 30 to 45 min Visit 2 : 7 days after visit 1 (+/- 24H) with the same procedure~To keep the blinded procedure the interventions will be realized behind a screen, allowing interactions with parents but depriving their visibility.~A telephone contact will be perform at M1 (one month of life) to assess breastfeeding persistence and collect questionnaire data.~Two others telephone contacts will be perform at 3 months and 6 months to precise breastfeeding interruption date.~The follow-up for each patient is 6 months"
224194659|NCT04913584|BEHAVIORAL|Cognitive Behavioural Therapy|Cognitive Behavioral Therapy 9 weekly 2-hour online group CBT sessions delivered by trained lay peers.
224194660|NCT00509223|DEVICE|Positive Airway Pressure therapy|Positive Airway Pressure (PAP) therapy initiated at Randomization and continued through the entire study duration (6 months), with instructions for use on a daily basis, during periods of sleep.
224194661|NCT00509223|BEHAVIORAL|Lifestyle counseling|Lifestyle counseling: All subjects were counseled regarding adopting a healthy lifestyle and advised on the Heart Foundation, National Health and Medical Research Council, and American Diabetes Association nutrition and exercise recommendations.
224194662|NCT03050749|DEVICE|Princess® VOLUME|Princess® VOLUME injections up to 10 ml applied to the eligible subjects at the baseline visit, and the touch-up visit, if applicable.
224194663|NCT02516449|OTHER|Patient decision aid|"The patient decision aid is a 12-page A3 size color-printed booklet entitled Should I take asthma inhaled controller medication to optimize asthma control?"
224194664|NCT04116307|DIETARY_SUPPLEMENT|Polymethylsiloxane|
224194665|NCT04116307|DIETARY_SUPPLEMENT|Lactobacillus reuteri|
224194666|NCT03087227|DEVICE|NEUTROSIS|evaluate a shared health information system (NEUTROSIS) for home-hospital management of febrile neutropenia after anti-tumor chemotherapy
224194667|NCT04959266|DRUG|Adavosertib|Patients will receive a single dose of Adavosertib orally in arm A, B, and C.
224194668|NCT04959266|DRUG|Itraconazole|Patients will receive Itraconazole orally once daily for 7 days in arm A.
224194669|NCT04959266|DRUG|Rifampicin|Patients will receive Rifampicin orally once daily for 13 days in arm B.
224194670|NCT04959266|DRUG|Omeprazole|Patients will receive Omeprazole orally once daily for 5 days in arm C.
223503803|NCT06943144|OTHER|Embodied Learning|Participants in the embodied learning group engage in activities such as yoga, painting, sensory play, physical storytelling, gesture-based learning, and creative storytelling. These exercises use full-body movement to support learning and cognitive development. Examples include using gestures to reinforce concepts, acting out stories to blend movement with narrative, and engaging in yoga for focus and calmness. Art and sensory activities further promote creativity and tactile exploration. Sessions are held twice a week, lasting 45 to 60 minutes, and are tailored to individual needs and progress.
223503804|NCT05479045|BIOLOGICAL|NY-ESO-1 Peptide vaccine|300 mcg of NY-ESO-1 peptide, 100 micrograms (mcg) granulocyte-macrophage colony-stimulating factor (GM-CSF) and 1 milliliter (mL) of Montanide ISA-51 adjuvant. The first two doses will be administered subcutaneously in a 2 week interval and thereafter, remaining three doses will be administered every 3 weeks.
224194671|NCT02525367|BEHAVIORAL|Online cognitive training|The intervention is a computerized, online training programme which aims to train several cognitive abilities; especially the executive functions, attention, working memory and processing speed. The mental processes that are appealed to by the intervention are similar to processes that are trained in classic face-to-face training methods. Both the intervention protocol and the active control condition will contain several games that have the participant train cognitive functions/perform cognitive activities for 8 weeks, 3 times a week, 45-60 minutes each session.
224310372|NCT06990178|RADIATION|Neoadjuvant concurrent chemoradiotherapy|Non-cCR group will continue with neoadjuvant concurrent chemoradiotherapy (2Gy\*20f) followed by radical surgery
224310373|NCT06990893|DRUG|Oliceridine|a loading dose of 1.5 mg of oliceridine was intravenously injected. Ten minutes later, an intravenous analgesic pump of 0.01 mg.kg-1.h-1 oliceridine was connected with normal saline to 100 ml at a rate of 2 ml per hour
224310374|NCT06990893|DRUG|Morphine|a loading dose of 4 mg of morphine was intravenously injected. Ten minutes later, an intravenous analgesic pump of 0.03 mg.kg-1.h-1 morphine was connected with normal saline to 100 ml at a rate of 2 ml per hour
224310375|NCT06990893|DRUG|Sufentanil|A 4 ug loading dose of sufentanil was intravenously injected. Ten minutes later, an intravenous analgesic pump of 0.03 ug.kg-1 h-1 was connected. sufentanil was mixed with normal saline to 100 ml at a rate of 2 ml per hour
224310376|NCT06990438|DRUG|TDF (Tenofovir)|ANTIVIRAL TREATMENT FOR CHRONIC HEPATITIS B VIRUS INFECTION
224310377|NCT06989723|DRUG|Pioglitazone 15 MG [Actos]|Participants will receive pioglitazone 15 mg, administered orally once daily. The tablet may be taken with or without food.
224310378|NCT06989723|DRUG|Empagliflozin 10 MG [Jardiance]|Participants will receive empagliflozin 10 mg, administered orally once daily. The tablet may be taken with or without food.
223592764|NCT01890668|OTHER|No Osteopathic manipulative Treatment|"Visit 1 between H60 and discharge :~Interview (pregnancy steps, initiation of breastfeeding, baby posture…) Osteopathic Clinical exam and Treatment will not be realized. Newborn will be undressed, lying naked (covered with polar sheet) on the exam table, dissimulated to parents by adequate screen. The osteopathic procedure will take place on a dolly to mimic from an indiscernible manner, osteopathic management.~Time of intervention = 30 to 45 min Visit 2: 7 days after visit 1 (+/- 24H) with the same procedure.~To keep the blinded procedure the interventions will be realized behind a screen, allowing interactions with parents but depriving their visibility.~A telephone contact will be perform at M1 (one month of life) to assess breastfeeding persistence and collect questionnaire data.~Two others telephone contacts will be perform at 3 months and 6 months to precise breastfeeding interruption date.~The follow-up for each patient is 6 months"
223592765|NCT03147638|DRUG|Warfarin, NOAC|duration of treatment
223592766|NCT01722656|DRUG|Aflibercept|
223592767|NCT02208349|DEVICE|King Video Laryngoscope|We will outfit ½ of the ambulance crews with the King Video Laryngoscope (KVL) for 6 months while the other ½ of the ambulances will use traditional direct laryngoscopy (DL). After 6 months, the groups will switch devices. We will randomly assign those ambulances that first use the KVL. After one year (12 months) we will compare the outcomes between the two methods.
223592768|NCT02208349|DEVICE|traditional direct laryngoscopy (DL)|
223592769|NCT00634790|DRUG|alprazolam XR|Alprazolam XR oral tablet 1 mg daily for 7 days; thereafter the daily dose will be titrated at a maximum rate of 1 mg every 7 days up to a maximum dose of 6 mg; dose adjustments up or down may be made, at a rate not to exceed 1 mg every 7 days; alprazolam XR will be administered for a total of 6 months followed by a gradual taper at a rate of 1 mg every 7 days.
223592770|NCT00768482|DRUG|Probuphine (buprenorphine implant)|Implantable formulation of buprenorphine made of buprenorphine HCl/ethylene vinyl acetate, considered a drug. (4 implants)
223592771|NCT00768482|DRUG|Sublingual Buprenorphine|16 mg/day, QD
223592772|NCT01017445|OTHER|Boonme stick exercise|individual exercise daily
223592773|NCT04311463|DRUG|Paroxetine hydrochloride|Paroxetine hydrochloride will be administered.
223592774|NCT04311463|DRUG|PAXIL (Paroxetine hydrochloride )|PAXIL will be administered.
223592775|NCT02392936|PROCEDURE|Sternotomy for coronary artery bypass graft, valvuloplasty, aortic surgery or combined procedures, under extracorporeal circulation or not, in emergency or scheduled.|
223592776|NCT03104257|DRUG|[11-C]OMAR|The radiotracer, \[11-C\]OMAR will be administered at no more than 10 micrograms at the beginning of each PET scan.
223592777|NCT00209794|DRUG|Sulfadoxine-Pyrimethamine (Fansidar)|
223592778|NCT02307162|DRUG|RPL554|Phosphodiesterase 3 and 4 Inhibitor
224194672|NCT02525367|BEHAVIORAL|Active control condition|The active control condition consists of cognitive activities that do not intend to train cognitive functions based on 'cristallized intelligence', such as trivia. Both the intervention protocol and the active control condition will contain several games that have the participant train cognitive functions/perform cognitive activities for 8 weeks, 3 times a week, 45-60 minutes each session.
224194673|NCT04812886|OTHER|Epidemiological study|Questionnaires (quality of life, gout, life habit, comorbidities) anthropometrics and health measures DNA analysis RNA analysis Metabolomic analysis
224194674|NCT05338749|BEHAVIORAL|Cognitive Training|Gamified cognitive training intervention to improve mental speed and attention.
224194675|NCT02070952|RADIATION|CyberKnife Stereotactic Ablative Body Radiation Therapy|The prescribed planned tumor volume (PTV) dose of 36.25 Gy shall be given in 5 fractions using CyberKnife Hypofractionated Stereotactic Ablative Body Radiation Therapy. PTV will be defined per parameters outlined in the protocol and will at minimum include the entire prostate gland.
224194676|NCT02696837|DEVICE|ETT|
224310379|NCT06989723|DRUG|Empagliflozin 10 MG [Jardiance] + Pioglitazone 15 MG [Actos]|Participants will receive one tablet of pioglitazone 15 mg and one tablet of empagliflozin 10 mg, administered orally once daily. Both tablets may be taken with or without food.
223592779|NCT02307162|DRUG|Placebo|Dummy solution
223592780|NCT00756210|OTHER|Whole body vibration|Frequence: 35 Hz Amplitude: 'high' (approx. 4 mm)
223592781|NCT05544149|RADIATION|Thoracic radiotherapy|Thoracic radiotherapy for ES-SCLC after first line immunecheckpoint inhibitors
223592782|NCT01599741|RADIATION|Low-dose DSA (83% reduction compared to normal dose) with novel X-ray imaging technology.|Digital Subtraction Angiography (DSA) of iliac artery with reduced dose settings (83% dose reduction expected) in combination with novel X-ray imaging technology.
223592783|NCT01599741|RADIATION|Normal dose DSA with conventional X-ray imaging technology|Digital Subtraction Angiography (DSA) of iliac artery with normal dose settings in combination with conventional X-ray imaging technology.
223592784|NCT02195804|DRUG|Ranitidine hydrochloride ODT|Ranitidine hydrochloride ODT#1 150 mg (Vanilla-Mint)
223592785|NCT02195804|DRUG|Ranitidine hydrochloride ODT RM|Ranitidine hydrochloride ODT Reduced Mannitol (RM) 150 mg Vanilla-Mint (ODT#2)
223592786|NCT02195804|DRUG|Ranitidine hydrochloride|
223592787|NCT04524624|DEVICE|AI-based CDSS|"1. Automatically identifying acute ischemic stroke lesions on DWI.~2. Classification of stroke subtypes and mechanisms.~3. Evidence-based alerts and guidelines for early stroke management.~4. Guideline-recommended secondary stroke prevention strategies."
223592788|NCT00498121|DEVICE|PROCALCITONIN LEVEL|measuring PROCALCITONIN LEVEL
223592789|NCT00737633|DRUG|VI-0521|Phentermine 15 mg/Topiramate controlled release (CR) 92 mg, oral capsule, once daily, 58 weeks
223592790|NCT00440830|DRUG|nicotine patch|nicotine patch (0,5,10 or 15mg/day) applied to smokers
223592791|NCT00440830|DRUG|nicotine patch|nicotine patch (0,5,10,or 15mg/day) applied to nonsmokers
223592792|NCT00440830|DRUG|placebo|placebo patch applied to smokers
224194677|NCT02696837|DEVICE|Proseal LMA|
224194678|NCT02696837|DRUG|Rocuronium|
224194679|NCT02696837|OTHER|No Muscle Relaxant|
224194680|NCT02696837|DRUG|Rocuronium|
224194681|NCT04429776|DIAGNOSTIC_TEST|Drug level testing with feedback provided|Feedback about drug levels in blood provided to participant's site
223592793|NCT00440830|DRUG|placebo|placebo patch applied to nonsmokers
224194682|NCT04429776|DIAGNOSTIC_TEST|Drug level testing with no feedback provided|Testing drug levels in blood but feedback not provided to participant's site
224194683|NCT00478218|DRUG|cyclophosphamide|300 mg/m2 administrated by PO (with food)on Days 1, 8, 15 (up to 12 cycles) OR 300 mg administrated by PO (with food)on Days 1, 8, 15 (up to 12 cycles)
224194684|NCT00478218|DRUG|dexamethasone|40 mg administrated by PO (with food)on Days 1, 8, 15 \& 22
224194685|NCT00478218|DRUG|lenalidomide|25 mg administrated by PO (with food)on Days 1-21
224194686|NCT03854799|DRUG|Avelumab|"Eligible patients will receive:~CHEMORADIOTHERAPY PLUS AVELUMAB:~* CAPECITABINE 825 mg/sqm/bid p.o. 5 days/week~* EXTERNAL-BEAM IRRADIATION 50.4 GY in 28 fractions over 5.5 weeks~* AVELUMAB 10 mg/Kg ev over 1 hour every 2 weeks at days 1, 14, 28, 42, 56, 70~Surgery with TME must be performed at week 8-10 after the end of CTRT. The final choice of surgical procedure (ie, abdominoperineal surgery or anterior resection) is at the surgeon's discretion."
224194687|NCT03854799|DRUG|Capecitabine|"Eligible patients will receive:~CHEMORADIOTHERAPY PLUS AVELUMAB:~* CAPECITABINE 825 mg/sqm/bid p.o. 5 days/week~* EXTERNAL-BEAM IRRADIATION 50.4 GY in 28 fractions over 5.5 weeks~* AVELUMAB 10 mg/Kg ev over 1 hour every 2 weeks at days 1, 14, 28, 42, 56, 70~Surgery with TME must be performed at week 8-10 after the end of CTRT. The final choice of surgical procedure (ie, abdominoperineal surgery or anterior resection) is at the surgeon's discretion."
224194688|NCT03854799|RADIATION|EXTERNAL---BEAM IRRADIATION 50.4 GY|Surgery with TME must be performed at week 8-10 after the end of CTRT. The final choice of surgical procedure (ie, abdominoperineal surgery or anterior resection) is at the surgeon's discretion.
224194689|NCT02304770|DRUG|Aminolaevulinic acid photodynamic therapy|Aminolaevulinic acid mediated photodynamic therapy
224194690|NCT04572737|BEHAVIORAL|Activity plan to break up sitting time|This research study aims to prove efficacy of a home-based physical activity intervention targeted at reducing periods of prolonged sitting and improving physical function in patients with intermittent claudication.
224194691|NCT06374693|DEVICE|Transcutaneous Vagus Nerve Stimulation|"* Pulse width - 25ms~* Frequency - device default (20 or 25Hz)~* Intensity - below pain threshold.~* Frequency - 45 minutes twice daily. On the basis of similarity to other studies, practicalities on the ward and clinical scenario~We have chosen a duration of 5 days based on the usual clinical pathway of inpatient management at the Royal Hallamshire Hospital, and have chosen to deliver the treatment twice daily to optimise the dose. This is a pilot study with feasibility outcomes and as such we will be exploring the feasibility of this treatment regimen.~The Parasym Device will be applied to the left tragus (figure 1) as this is the most common site for tVNS delivery in neurological studies and is associated with few afferents to the heart."
224194692|NCT06374693|DEVICE|Sham Transcutaneous Vagus Nerve Stimulation|The active intervention will be compared to sham tVNS where the vagal nerve stimulator will be attached to the earlobe instead of the tragus, in keeping with evidence that this does not cause vagus nerve stimulation and is in line with sham methods used in other studies. We do not anticipate that patients will have the intervention long enough to become familiar with the common sensations associated with true tVNS intervention. At the end of the intervention period, participants will be asked if they thought they had received true of sham tVNS to understand the blinding ability of the sham.
224194693|NCT05649709|DRUG|L-VA dual therapy|1000mg amoxicillin capsules twice times daily and 20mg vonoprazan Fumarate Tablets twice daily for 14 days
223592794|NCT03765827|DRUG|Vitamine E Acetate|Vitamin E acetate ointment will be applied over the staple lines and anastomoses in Roux-en-Y gastric bypass
224194694|NCT05649709|DRUG|H-VA dual therapy|1000mg amoxicillin capsules three times daily and 20mg vonoprazan Fumarate Tablets twice daily for 14 days
224194695|NCT01619709|OTHER|Pet AV-45|AV-45 (Florbetapir F 18) : Bolus of 5 MBq/kg IV ; A 10-minutes Pet scan acquisition Starts at 50 minutes after injection.
224194696|NCT00006354|DIETARY_SUPPLEMENT|mistletoe extract|
224194697|NCT03174457|DRUG|Micafungin|Intravenous
224194698|NCT04901520|OTHER|High Intensity Training|High Intensity Training group performed resistance training with the intensity of 80 - 90 % of 1RM with 4 - 6 repetition
224194699|NCT04901520|OTHER|Moderate Intensity Training|Moderate Intensity Training group performed resistance training with the intensity of 65 - 75 % of 1RM with 8 - 10 repetition
224194700|NCT04901520|OTHER|Low Intensity Training|Low Intensity Training group performed resistance training with the intensity of 50 - 60 % of 1RM with 12 - 14 repetition
223503805|NCT05479045|DRUG|Toripalimab-tpzi|240 milligrams (mg), intravenously, every 3 weeks starting with the second dose of NY-ESO-1 Peptide vaccine
223592795|NCT03765827|DRUG|No application of vitamin E acetate|Vitamin E acetate ointment will not be applied in this group
223592796|NCT00188006|DEVICE|heparin-coated cardiopulmonary bypass|
223746810|NCT01353417|OTHER|In this observational study no study specific intervention is planned|Patients with stable kidney function who already receive Tacrolimus Sandoz© capsules before being included in this non-interventional study, are being observed for 6 months by their attending physicians. Routine medical treatment is provided.
223503806|NCT06944223|OTHER|Kidney stone formers|"Consuming a special drink (potassium citrate) during an all-day visit to the University of Chicago research clinic~Subjects in both groups will be asked to partake in the same activities, as follows: The day before presenting to the research clinic, subjects will collect urine at home. Subjects will then come to the research clinic at the University of Chicago in Hyde Park, where they will spend most of the day. We will give them a special liquid that contains potassium citrate. After this, we will collect urine and blood samples throughout the day. While at the clinic, subjects will also receive a boxed lunch at the end of the visit."
223592797|NCT00212706|DRUG|ONO-8025 (KRP-197)|
223592798|NCT04683120|DIAGNOSTIC_TEST|Zenith FLIM Diagnostics|In-vitro
223592799|NCT01300260|BIOLOGICAL|LY2189265|Administered subcutaneously
223592800|NCT01300260|DRUG|Placebo|Administered subcutaneously
223592801|NCT01300260|DRUG|Insulin|Administered intravenously
223592802|NCT01300260|DRUG|Glucose|Administered intravenously
223592803|NCT01300260|DRUG|Glucagon|Administered intravenously
223592804|NCT04651829|OTHER|oral food challenge 1|First oral food challenge after a short period of several weeks of avoidance of CMP to confirm diagnosis of CMPA
223592805|NCT04651829|OTHER|oral food challenge 2|Second oral food challenge to test tolerance after 4 months of age if confirmed CMPA
223746811|NCT02073279|DRUG|Satralizumab|Satralizumab will be administered subcutaneously (SC) at Weeks 0, 2, and 4, and thereafter once every 4 weeks (Q4W).
223746812|NCT02073279|DRUG|Placebo|Placebo will be administered subcutaneously (SC) at Weeks 0, 2, and 4, and thereafter once every 4 weeks (Q4W).
223746813|NCT02206555|DRUG|emtricitabine/tenofovir disoproxil fumarate|
223746814|NCT03837561|DRUG|Cunox|Inject 4 Units (0.1 mL) of reconstituted investigational product or the comparator intramuscularly into each of 5 sites, 2 in each corrugator muscle and 1 in the procerus muscle for a total dose of 20 Units.
223746815|NCT03837561|DRUG|Botox|Inject 4 Units (0.1 mL) of reconstituted investigational product or the comparator intramuscularly into each of 5 sites, 2 in each corrugator muscle and 1 in the procerus muscle for a total dose of 20 Units.
223746816|NCT02492529|OTHER|Neuropsychological tests|"Scales and tests to evaluate:~* Global cognitive performance~* Handedness~* Memory functions performance~* Gestural praxis functions performance~* Lexical and semantic functions performance~* Executive functions performance~* Memory disorders~* Way of life~* Mood"
224194701|NCT02335229|DEVICE|Axium DRG Neurostimulator|Implantation with Axium DRG Neurostimulator
224194702|NCT00040001|DRUG|DTI-0009|
224194703|NCT02808559|DEVICE|Bodystudio ATBM (Automatic Total Body Mapping)|The mapping of the entire body is automatically done using a high-resolution apparatus (20 photographs of the patient in 8 positions (face, back, lateral left and right, specific extremities) The photographs will be done with a standardized procedure established by FotoFinder. Every lesion is completely evaluated and the PASI score can be calculated.
224194704|NCT00644527|OTHER|Purpose designed music and sound listening program|Listening to one of two different specific music programs (Group A and B), which is composed for the treatment of depressive symptoms. The music is listened to during a period of 30 minutes in the morning and 30 minutes in the evening over 5 - 15 weeks.
224194705|NCT00644527|OTHER|Sham music for depression|Listening 30 min in the morning and 30 min in the evening to selection of Mozart compositions over 5 weeks.
224194706|NCT00437294|DRUG|enzastaurin|1125 milligrams (mg) loading dose then 500 mg, oral, daily, 21-day cycles until progressive disease
224194707|NCT00437294|DRUG|placebo|oral, daily, 21-day cycles until progressive disease
223503807|NCT06944223|OTHER|Control cohort|"Consuming a special drink (potassium citrate) during an all-day visit to the University of Chicago research clinic~Subjects in both groups will be asked to partake in the same activities, as follows: The day before presenting to the research clinic, subjects will collect urine at home. Subjects will then come to the research clinic at the University of Chicago in Hyde Park, where they will spend most of the day. We will give them a special liquid that contains potassium citrate. After this, we will collect urine and blood samples throughout the day. While at the clinic, subjects will also receive a boxed lunch at the end of the visit."
223503808|NCT06951490|DEVICE|PillSense™|The PillSense™ System is a prescription only device consisting of a reusable receiver and single-use ingestible capsule, intended to be used for the detection of blood in the upper gastrointestinal tract.
223503809|NCT06259890|OTHER|measurement of salt intake|measurement of salt intake without intervention
223503810|NCT06404268|DEVICE|Motor relearning training|Ankle motor control relearning training under real-time feedback
223503811|NCT06404268|DEVICE|Passive stretching|Passive stretching under intelligent robotic control
223503812|NCT06404268|DEVICE|Gamed-based active movement training|Active movement training through movement games with robotic assistance
223503813|NCT06404268|DEVICE|Passive movement|Passive movement in the joint middle range of motion
223503814|NCT06404268|DEVICE|Active movement training|Active movement training without robotic assistance
223503815|NCT06404268|DEVICE|Ankle torque and motion measurement|Ankle torque and motion measurement with no real-time feedback
223503816|NCT05086224|DRUG|Hematoma Local Anesthetic Block Procedure with 1% Lidocaine|Inject anesthetic into the hematoma site, 20 mL of 1% lidocaine without epinephrine.
223503817|NCT05086224|DRUG|Bier Anesthetic Block Procedure with 1% Lidocaine|Intravenous anesthetic infusion, a maximum lidocaine dosing of 3 mg/kg.
223503818|NCT01729091|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous stem cell transplant
223503819|NCT01729091|BIOLOGICAL|Elotuzumab|Given IV
223503820|NCT01729091|OTHER|Laboratory Biomarker Analysis|Correlative studies
223503821|NCT01729091|DRUG|Lenalidomide|Given PO
223503822|NCT01729091|DRUG|Melphalan|Given IV
223503823|NCT01729091|BIOLOGICAL|Natural Killer Cell Therapy|Given IV
223503824|NCT01729091|BIOLOGICAL|Umbilical Cord Blood-Derived Lymphocyte Therapy|Given IV
223503825|NCT04464083|DIAGNOSTIC_TEST|IOP Measurment|To determine IOP readings before and after accelerated corneal collagen crosslinking (CXL)
223503826|NCT04514549|DEVICE|Emerald|The Emerald is a wireless sensor that can track the motion, breathing, and sleep of subjects without touching or requiring any interaction with the subjects, allowing them to go about their normal lives. The physical device is roughly a 30 x 35 x 5 cm box that contains directional antennas and a motherboard to process these signals. In typical operation, the device is mounted onto a wall within a clinic or home setting using peel-away (reversible) mount strips.
223503827|NCT05618626|OTHER|Physical exercise and dietary intervention for NAFLD|Investigators will assess the efficiency of the intervention by measuring adherence to physical exercise and nutritional diet.
223503828|NCT04825587|PROCEDURE|Patients will be randomized into one of two study arms: (1) concomitant ACL and ALL reconstruction or (2) ACL reconstruction alone.|By randomizing patients into one of two study arms: (1) concomitant ACL and ALL reconstruction or (2) ACL reconstruction alone, following statistical analysis, we hope to determine whether concomitant ALL reconstruction in children undergoing and ACL reconstruction will longitudinally result in a lower rate of graft failure than ACL reconstruction alone.
223746817|NCT02492529|DEVICE|A cranial MRI|
223746818|NCT02492529|OTHER|Experimental procedure|
223746819|NCT01311193|OTHER|light therapy|early morning exposures to bright light, 8000lux for 40min, daily during 3 weeks
223746820|NCT00199784|DRUG|Phenylephrine|
223746821|NCT05927714|OTHER|Amnion-chorion Membrane|Amnio-chorion membranes specifically for palatal wound healing following free soft tissue autografts (FTSA) procedures.
224194708|NCT00437294|DRUG|capecitabine|1250 mg/m\^2, BID, days 1-14 of each 21-day cycle until progressive disease
224194709|NCT01782638|BEHAVIORAL|deep brain stimulation|
224194710|NCT01977131|OTHER|Cells|
224194711|NCT02457780|BEHAVIORAL|Relaxation Response Resiliency Program (3RP)|The 3RP is designed to decrease psychiatric and physical health symptoms and build resiliency by teaching skills to (1) elicit the relaxation response, (2) decrease stress reactivity and (3) increase social connectedness. Eliciting the relaxation response involves sustained mental focus with an attitude of receptive awareness with strategies aimed at reducing muscle tension, breathing rate, heart rate, and blood pressure. Decreasing stress reactivity involves increasing awareness of the stress response and learning skills to proactively address stress. Increasing connectedness involves skills to promote positive growth, self-efficacy and social support. Other skills and experiential exercises focus on increasing acceptance, optimism, empathy, and appreciation to promote resiliency.
224194712|NCT02457780|BEHAVIORAL|Health Enhancement Program (HEP)|The HEP is designed to address comorbid physical and mental health symptoms via psychoeducation, self-monitoring and goal setting techniques. It is an 8 session manualized group intervention which addresses topics including sleep hygiene, nutrition, exercise, working with a healthcare team, and substance use. The program uses a variety of in-session activities to engage participants in discussion related to self-care and wellness principles. Relapse prevention and long-term goal setting are addressed. The program is designed to be implemented by professionals with a background in mental health.
224194713|NCT00001080|BIOLOGICAL|Influenza Virus Vaccine|
223503829|NCT05228015|DRUG|IK-930|tablets for oral administration
223503830|NCT05228015|DRUG|Osimertinib|tablets for oral administration
223503831|NCT03554473|DRUG|M7824|Arm A \& B: 2400mg intravenous (IV) over up to 120 minutes every 3 weeks on a 3-week cycle. Arm C: 1200 mg IV over 1 hour every 2 weeks on a 4-week cycle.
223503832|NCT03554473|DRUG|Topotecan|Arm B: 1 mg/m(2) intravenous (IV) over 30 minutes days 1-5 on a 3-week cycle.
223503833|NCT03554473|DRUG|Temozolomide|Arm C and progressive disease patients on Arm A: 200 mg/m(2) by mouth (PO) days 1-5 on a 4-week cycle.
223503834|NCT03554473|DIAGNOSTIC_TEST|EKG|Screening and baseline.
223503835|NCT03554473|DIAGNOSTIC_TEST|CT scan|Computed tomography (CT) scan performed at Screening and after every 2 cycles (6 weeks) per Study Calendar for Arm B 3.5.2, Arm B 3.5.2, and/or Arm C 3.5.3 as applicable.
223503836|NCT03554473|DIAGNOSTIC_TEST|PET scan|Positron emission tomography (PET) not mandatory - If a computed tomography (CT) scan is not sufficient to assess response, a PET scan may be added per Study Calendar for Arm A 3.5.1, Arm B 3.5.2, and/or Arm C 3.5.3 as applicable.
223503837|NCT03554473|DRUG|Acetaminophen|For infusion related reaction, 500-1000 mg by mouth (PO) prior to infusion.
223503838|NCT03554473|DRUG|Antihistamines|As medically indicated.
223503839|NCT03554473|DRUG|Diphenhydramine|For infusion related reaction, 50 mg by mouth (PO) prior to infusion.
223503840|NCT03554473|DRUG|Dexamethasone|As medically indicated.
223503841|NCT03554473|DRUG|Epinephrine|As medically indicated.
223503842|NCT05893030|PROCEDURE|anesthesia guided by sedation and analgesia monitoring|"Anesthesia guided by sedation and analgesia monitoring The level of sedation will be monitored by~* Monitoring System BIS™ : Bispectral index (BIS) between 45 and 60 AND Suppression Ratio (SR) at 0;~* or SedLine® Sedation Monitor : Patient State Index (PSi) between 25 and 50;~* or Entropy Sensor™: State entropy (SE) between 45 and 60 AND Burst Suppression Ratio (BSR) at 0;~and the level of nociception by :~* Nociception monitor PMD-200® : Nociception Level (NoL) between 10 and 25."
223503843|NCT05893030|PROCEDURE|anesthesia performed according only to the clinical judgment of the anesthetist as usual practice|Administration of anesthesia will be performed according to the clinical judgment of the anesthetist as usual practice without sedation and analgesia monitoring
223503844|NCT02704832|OTHER|Geriatrician Intervention|Arm B : The duration of the geriatric intervention will be 12 months. The quality of life will be assessed every 3 months during the first year and at 18 months. The study's follow-up will last until 3 years after the enrollment of the last patient and data on vital status of the patient, weight, place of life and the status of the disease will be collected every 6 months.
223503845|NCT04423367|DRUG|bortezomib/dexamethasone|Enrolled patients would receive the combination therapy of bortezomib and dexamethasone.
223503846|NCT05399134|DIETARY_SUPPLEMENT|Modified Functional Foods|"Subjects will be provided with ABREP-fortified bread, microfluidic co-flow noodles, and 5ibrePlus™-fortified white rice served in a mixed meal.~ABREP-fortified bread: Anthocyanins are known to exert anti-diabetic effects through modulating digestion, glucose uptake, insulin secretion and sensitivity. Moreover, inhibitory effects of anthocyanins on various carbohydrases, including a-glucosidase and a-amylase have been widely reported.~Microfluidic co-flow noodles: Microfluidic technology is employed to design noodle-food structures consisting of a mix of soy protein isolate and alginate as gelling agents to offer a type of novel noodles with proteins and negligible carbohydrate content.~5ibrePlus™-fortified white rice: 5ibrePlus™ is a patented novel fibre grain product by Alchemy Foodtech Pte. Ltd (WO 2017/142477) with reduced GI. Its main constituents are insoluble resistant starch and soluble fibre."
223503847|NCT05399134|DIETARY_SUPPLEMENT|Control Functional Foods|Subjects will be provided with control function foods including white bread, beehoon noodles, and jasmine white rice served in a mixed meal.
223503848|NCT01501513|DRUG|PEG-3350 based bowel preparation|solution for oral administration prior to colonoscopy
223503849|NCT01501513|DRUG|BLI800 approved preparation regimen|solution for oral administration prior to colonoscopy
223503850|NCT01501513|DRUG|BLI800 investigational preparation regimen|solution for oral administration prior to colonoscopy
223503851|NCT06469125|PROCEDURE|Endoscopic Prostate Interventions for Anatomic Enucleation|The intervention in this study involves performing anatomic endoscopic enucleation of the prostate (AEEP) using different energy sources. Following the enucleation, the resected prostate tissue will be morcellated within the bladder using various morcellators to remove the enlarged prostate tissue minimally invasively. The process will also involve evaluating and categorizing any resulting bladder injuries using the BICEP classification system.
223503852|NCT03834116|DEVICE|Inspiratory muscle training|A pressure threshold device will be used to deliver IMT, which is commercially available by Phillips Respironics.
223503853|NCT04971837|DIETARY_SUPPLEMENT|Cannabidiol (CBD) powder formulation|T-P-S-10 Caliper powder - 30 mg CBD in the form of 300 mg of 10% CBD isolate (Formulation 725: Water soluble.Contains sorbitol)
223503854|NCT04971837|DIETARY_SUPPLEMENT|Cannabidiol (CBD) Oil based tincture formulation|30 mg CBD isolate in MCT oil,1:1 ratio of CBD to Medium Chain Triglycerides oil. (Formulation 088: Not water soluble. Contains medium chain triglyceride coconut oil.)
224194714|NCT00001080|BIOLOGICAL|Pneumococcal Vaccine, Polyvalent (23-valent)|
224194715|NCT00001080|DRUG|Lamivudine|
224194716|NCT00470301|DRUG|tipifarnib|Given orally
224194717|NCT00470301|DRUG|paclitaxel|Given IV
224194718|NCT00470301|DRUG|doxorubicin|Given IV
224194719|NCT00470301|DRUG|cyclophosphamide|Given IV
224194720|NCT04960137|DEVICE|button plates fixation system|The button plates fixation system consists of fixing plate, prefabricated mix, button and fuse. In the process of use, the fuse plays the role of guiding the fixed plate through, pulling the button and shortening the distance between the button and the fixed plate. The prefabricated mix is pre-worn between the button and the fixed plate, and the lead pulls the distance between the fixed plate and the button after tightening and fixing. Prefabricated mix, make mix tight and knot. Finish the preliminary work of fixing.
224194721|NCT04960137|DEVICE|Non-absorbable Suture Anchor|A conventional device used in surgery for shoulder dislocation.
224194722|NCT04480554|DRUG|Methadone|Participants will receive a 48-week integrated treatment program for opiate use disorder with daily directly observed oral methadone syrup (MET), structured counseling sessions (BDRC-based) weekly for the first 3 months and monthly thereafter, and antiretroviral therapy.
224194723|NCT04480554|DRUG|Buprenorphine/naloxone|Participants will receive a 48-week integrated treatment program for opiate use disorder with daily directly observed oral buprenorphine/naloxone tablets (Suboxone(R)), structured counseling sessions (BDRC-based) weekly for the first 3 months and monthly thereafter, and antiretroviral therapy.
224194724|NCT04480554|DRUG|XR-Naltrexone|Participants will receive a 48-week integrated treatment program for opiate use disorder with monthly extended-release naltrexone (Vivitrol(R)), structured counseling sessions (BDRC-based) weekly for the first 3 months and monthly thereafter, and antiretroviral therapy.
224194725|NCT02464176|DRUG|Dexamethasone|A lumbar plexus nerve block will be performed for patients undergoing hip arthroplasty. A total of 25cc's of 0.25% bupivacaine with 1:400,000 epinephrine will be administered for postoperative analgesia. Surgical anesthesia will be provided either by an intrathecal spinal block or general anesthesia. Successful blockade will be assumed if the patient has a decrease or loss of pinprick sensation in the femoral nerve distribution, which innervates the anterior thigh. If no evidence of blockade is present, testing will occur again at 30 minutes post block. Testing will be performed with a 25 gauge Whitacre needle and once present the area of testing will be marked with a surgical marking pen so that repeat sensory testing can be undertaken at that same site over the course of the study. The subjects will then receive dexamethasone (4 or 8 mg) or placebo (saline) based on arm placement.
224310380|NCT06990503|DRUG|SHR-A1811|"Injection SHR - A1811 (hereinafter referred to as SHR - A1811) is an antibody - drug conjugate (ADC) targeting the HER2 protein, independently developed by Suzhou Shengdeya Biopharmaceutical Co., Ltd. (hereinafter referred to as the sponsor). It is composed of a recombinant humanized anti - HER2 IgG1 monoclonal antibody (SHR - 1805) conjugated with a small molecule component, SHR169106."
224310381|NCT06990503|DRUG|Chemotherapy|"The treatment regimens for the control group are as follows:~Liposomal doxorubicin: Administered intravenously on Day 1 of each 4 - week treatment cycle at a dose of 40 mg/m².~Paclitaxel: Given intravenously on Days 1, 8, 15, and 22 of each 4 - week treatment cycle at a dose of 80 mg/m² per administration.~Topotecan: Intravenously infused on Days 1, 8, and 15 of each 4 - week treatment cycle at a daily dose of 4 mg/m².~Gemcitabine: Infused intravenously on Days 1 and 8 of each 3 - week treatment cycle at a daily dose of 1000 mg/m²."
224310382|NCT06990802|BEHAVIORAL|Learning Through Play plus Culturally adapted Cognitive Behaviour Therapy (LTP+CaCBT)|LTP+CaCBT has two components. LTP is underpinned by Piaget's theory of cognitive development and Bowlby's theory of attachment. The CBT component uses active listening techniques, changing negative thinking, and guided discovery (i.e., Socratic questioning style to gently probe for cultural beliefs on mental health and stimulate alternative positive thinking). This includes a culturally adapted pictorial calendar devised for women, depicting successive stages of child well-being from 0-3 years, with illustrations of mother-child play and other culturally relevant activities that promote healthy parenting and mother-child attachment.
224310383|NCT06990802|DRUG|Treatment as Usual (TAU)|TAU is the routine care currently available for the treatment of postnatal depression at the health care sites of intervention (e.g. diagnosis, management, antidepressant prescription and/or other forms of mental health care).
223746822|NCT05927714|OTHER|ActCel Cellulose Gauze|When these products come in contact with blood, they convert to a gel that expands to cause direct pressure on blood vessels and control bleeding. ActCel is water-soluble and dissolves over a short time period. It can be removed easily when water, saline or hydrogen peroxide is applied.
224194726|NCT02464176|DRUG|Bupivacaine|Bupivacaine will be used in lumbar plexus nerve block mixture.
224194727|NCT02464176|DRUG|Epinephrine|Epinephrine will be used in lumbar plexus nerve block mixture.
224194728|NCT02464176|PROCEDURE|Lumbar Plexus Nerve Block|This is the procedure that will be performed.
224194729|NCT02464176|DRUG|Saline|Patients randomized to the placebo group will receive normal saline intravenously.
224194730|NCT00058994|DRUG|anecortave acetate|
224194731|NCT02277665|BEHAVIORAL|CUD Treatment|
224194732|NCT02277665|BEHAVIORAL|Tobacco Treatment|
224310384|NCT06990659|OTHER|Ambulatory care|Patients with Hepato cellular carcinoma (HCC) treated by chemo-embolization (CEH) or radioembolization (REH) are managed on an outpatient basis: hospitalization in an outpatient unit, followed by systematic telephone and on-demand nursing follow-up for 48 hours for REH and 72 hours for CEH. A dedicated re-hospitalization circuit has also been set up in the event of complications.
223503855|NCT04971837|DIETARY_SUPPLEMENT|Cannabidiol (CBD) Gum Arabic, maltodextrin base formulation|10% CBD Gum Arabic, maltodextrin base(Formulation 126: Water soluble. Contains gum arabic and maltodextrin)
223503856|NCT04971837|DIETARY_SUPPLEMENT|Cannabidiol (CBD) Gum Arabic, sorbitol base formulation|10% CBD Gum Arabic, sorbitol base (Formulation 213: Water soluble. Contains gum arabic and sorbitol)
223503857|NCT04971837|DIETARY_SUPPLEMENT|Cannabidiol (CBD) Isolate in water formulation|Pure CBD as crystalline powder (\>99% purity) (Formulation 625 Not water soluble)
223503858|NCT04971837|DIETARY_SUPPLEMENT|CBD matching Placebo|Matching Placebo
224194733|NCT05588765|OTHER|Neck stretching exercises|Neck stretching exercises towards lateral flexion, ipsilateral flexion and rotation and towards flexion each for 30 sec and repeated 2-3 times
224194734|NCT05859594|OTHER|Laughter yoga|Although the history of laughter yoga dates back to ancient times, its use in medicine has become widespread in the 21st century, while it is used to reduce pain, anxiety, stress, depression and fatigue, it is also a method that can be used to accelerate immunity, quality of life, happiness, sleep quality and recovery.
224194735|NCT00694330|BIOLOGICAL|GM-K562 Vaccination|Lethally irradiated autologous glioma cells combined with GM-K562 cells as vaccine therapy given once a week for three weeks then every other week.
224194736|NCT01075126|DRUG|Depakote|
224194737|NCT01075126|DRUG|Lithium|
224194738|NCT04961944|OTHER|Disease assessment|"A comprehensive evaluation of the disease's extension, its impact on function, quality of life, and the search for phenotype/endotypes will be performed.~The association between endotypes and disease progression will be tested."
224194739|NCT06135272|DRUG|Resin infiltration|Icon Resin Infiltration as minimally invasive technique
224194740|NCT06135272|DRUG|Resin modified glass ionomer varnish|Resin modified glass ionomer varnish as minimally invasive technique
224194741|NCT06135272|DRUG|Light cured giomer varnish|Light cured giomer varnish as minimally invasive technique
224194742|NCT06372392|DEVICE|Universal meal coefficient utilization|Usage of universal fixed meal bolus coefficients for the control of postprandial hyperglycemia compared to individualized coefficients n the users of Medtronic Minimed 780G pumps
224310385|NCT06990659|OTHER|Conventional inpatient care|Patients with Hepato cellular carcinoma (HCC) treated by chemo-embolization (CEH) or radioembolization (REH) are managed on an inpatient basis: conventional hospitalization.
224310386|NCT06991075|DEVICE|High frequency transcutaneous electrical nerve stimulation|TENS 7000 digital TENS unit will be used.
224310387|NCT06981949|DRUG|Dexmedetomidine|"Dexmedetomidine added to ropivacaine in the bilateral single-shot Ultrasound-guided erector spinae plane block that will be applied to each side (bilateral):~20ml/side of 0.375% ropivacaine+0.5 μg/kg/side of dexmedetomidine (lean body weight if BMI \>30)"
224310388|NCT06981949|DRUG|Ropivacaine|"Ropivacaine only in the Bilateral single-shot Ultrasound-guided Erector Spinae Plane Block:~20ml/side of 0.375% ropivacaine"
224310389|NCT04769687|BIOLOGICAL|probiotic Vivomixx®|Vivomixx® is in powder form packaged in sachets of 4.5.1011 bacteria. The dose used is 2 sachets per day (morning and evening) for 8 weeks (56 days). For the study, the symbiotics will be packaged in the same sachet at the same doses as mentioned above.
224310390|NCT04769687|BIOLOGICAL|prebiotic Orafti®Synergy1|Orafti®Synergy1 is a slightly sweet white powder packaged in 5 g sachets. The dose used is 2 sachets per day (morning and evening) for 8 weeks (56 days).
224310391|NCT04769687|OTHER|Placebo|Placebo
224310392|NCT06429579|PROCEDURE|Comprehensive therapy combined Potts-shunt procedure and conventional drug therapy|Potts-shunt procedure is the surgery that connect the descending aorta and the left/main pulmonary artery by direct anastomosis, a Gore-tex tube or a Gore-tex tube with flap.
224310393|NCT06429579|DRUG|Only conventional drug therapy|Only conventional drug therapy (i.e., Prostacyclin analogues, PDE-5 inhibitors, and Endothelin receptor antagonists)
224310394|NCT06988501|BEHAVIORAL|Goal setting with mobile-based self-management tool|In addition to the nutrition education provided to both groups, the participants of the intervention group will work with the dietitian to make behavior-change goals based on SMART goal setting strategy. They will also have access to diet tracking function and weekly report on smart phone application. The dietitian will also meet with the participants virtually to track their progress and provide suggestions.
224310395|NCT06988501|OTHER|Nutrition education|The control group will receive nutrition education about blood pressure management by the dietitian
224310396|NCT06989476|OTHER|CARELOOP Intervention|"CARELOOP Intervention (Clinics cAtch needs, REfer, Link to services, and close the lOOp using an equitable family-centered Process).~CARELOOP is a way of enhancing psychosocial screenings through PSM methodology and Implementation Science, and grounded in the Clinical-Community Relationships Evaluation framework"
224310397|NCT06989736|DIAGNOSTIC_TEST|Taste Test|Participants received nine solutions (tasteless, sweet, salty, sour, and bitter; each in two concentrations) before treatment and six weeks later.
224310398|NCT06991062|PROCEDURE|Repetitive Transcranial Magnetic Stimulation (rTMS)|TMS is a non-invasive procedure in which a coil is placed over the scalp, and focused magnetic pulses are applied to parts of the brain through the coil.
224310399|NCT06990347|DRUG|Inetetamab and Pyrotinib Combined with Chemotherapy|Inetetamab and Pyrotinib Combined with Chemotherapy
224310400|NCT06989047|PROCEDURE|Pericapsular Nerve Group (PENG) Block|"Assigned Interventions:~Procedure/Surgery: Pericapsular Nerve Group (PENG) Block An ultrasound-guided nerve block targeting articular branches of the femoral, obturator, and accessory obturator nerves. Performed under aseptic technique using a curved low-frequency ultrasound probe to visualize the iliopsoas plane and pubic ramus.~Drug: Bupivacaine (0.25%, 30 ml) Local anesthetic used to provide analgesia in nerve block. Drug: Magnesium sulfate (10%, 5 ml = 500 mg) Adjunct used to enhance analgesic efficacy of the block."
224310401|NCT06989047|PROCEDURE|Femoral Nerve Block (FNB)|An ultrasound-guided nerve block targeting the femoral nerve to provide analgesia before spinal anesthesia in proximal femur fracture surgery. Administered using 30 ml of 0.25% bupivacaine and 5 ml of 10% magnesium sulfate (500 mg). The block is performed with an in-plane ultrasound approach, identifying the femoral nerve lateral to the femoral artery under sterile conditions.
224310402|NCT06981637|DRUG|Pegylated liposomal doxorubicin|pegylated liposomal doxorubicin 40mg / m2 every 4 weeks for a maximum of 12 cycles.
224194743|NCT02713724|BEHAVIORAL|physical exercise|DAPS-group will follow a personal adjusted training program including instructions from a personal trainer Standard-group will receive a membership at a gym but limited instructions
224194744|NCT02713724|BEHAVIORAL|limited physical exercise|The standard group will receive a membership at a gym but limited instructions and no access to a personal trainer
224194745|NCT04766658|OTHER|Gargle Phonation|Subjects will gargle water while making sound
224194746|NCT04766658|OTHER|Water swallow|Subjects will hold water in their mouth for 5 seconds and swallow
224194747|NCT03361839|DIAGNOSTIC_TEST|endometrial biopsy|endometrial biopsy for genetic study of endometrial receptivity
224194748|NCT04027634|OTHER|Baduanjin program|This exercise program aimed to increase patient participation and control their BW through Baduanjin program. The entire program continued for 3 months (mid-September to mid-December 2014), and the intervention was performed for 60 min 3 times per week; particular attention was paid to the disease characteristics of the patients with chronic schizophrenia and to preventing excessive fatigue. Every session began with a 20-min warm-up, followed by 20 min of Baduanjin program, and ended with a cool-down session. The participants were instructed, with the assistance of a video, to practice Baduanjin program in a group by two authors who are experienced in the psychiatric nurses and had been trained in this program.
224194749|NCT05309317|OTHER|Virtual Simulation Game for the Prevention of Catheter-Associated Urinary Tract Infections|"A training on Prevention of CAUTI will be held for the experimental and control groups. The experimental group will be able to play a seven-day virtual simulation game devised by the researcher to prevent CAUTI."
224194750|NCT05309317|OTHER|Ongoing education|"Only a course on Prevention of CAUTI will be given to the control group."
224194751|NCT00322517|DRUG|SU014813|100 mg capsule/day for 6 cycle of 21 days
224194752|NCT04047316|DEVICE|Digital dermoscopy|Acquire skin images with a new digital dermatoscope
224194753|NCT00008034|DRUG|capecitabine|
224310403|NCT06983509|DRUG|Regiocit|"Regiocit can be used as a replacement fluid for CRRT with RCA. It will be used in pre-dilution mode only.~At least 200 mL of post-replacement solution is recommended to minimize clotting in the de-aeration chamber. A replacement/dialysate solution with 22 to 26 mEq/L bicarbonate buffer is advised as the first choice. A higher concentration of bicarbonate may be required in severe cases of acidosis. The use of a non-calcium-containing dialysate or replacement fluid is advised. The rate of administration depends on the targeted citrate dose and the prescribed flow rate. The pre-filter infusion rate of Regiocit will be indexed to the blood flow rate (BFR) to achieve a target blood citrate concentration of 3 to 4 mmol/L. A BFR between 100 to 180 mL/min will be advised; a lower BFR can minimize patient citrate exposure, particularly in patients with lower body weight."
224310404|NCT06983509|DRUG|Biphozyl|"Biphozyl is used as a replacement fluid during CRRT. It is injected into the extracorporeal circuit before (pre-dilution) or after (post-dilution) the filter. After the initiation of RRT, Biphozyl is used for late treatment of the acute condition when pH, potassium, and phosphate concentrations return to normal. Biphozyl can also be used if any other buffer is in use or during RCA.~The volume and rate of administration of Biphozyl depend on the blood concentration of phosphate and other electrolytes, acid-base balance, body fluid balance, and overall clinical condition of the patient. The volume of replacement fluid given also depends on the expected intensity (dosage) of treatment."
224310405|NCT06983509|DRUG|Prismasol 2|"Prismasol 2 is used as a replacement fluid during CRRT. It is injected into the extracorporeal circuit before (pre-dilution) or after (post-dilution) the filter.~The volume and rate of administration of Prismasol 2 depend on the blood concentration of electrolytes, acid-base balance, fluid balance, and overall clinical condition of the patient. The volume of replacement fluid administered also depends on the required intensity (dosage) of the treatment."
224310406|NCT06990906|DEVICE|BAIBYS Sperm selection|Software based decision support device for sperm selction based on morphology and motility
224310407|NCT06990906|PROCEDURE|Intra cytoplasmatic sperm injection|Sperm injection into oocytes for ferilization
224310408|NCT06990906|PROCEDURE|Conventional manual sperm selection|selection beased on motility at low magnification
224310409|NCT06498739|DRUG|Erector spinae plane block(15 ml bupivacaine 0.5%)|Patients will preoperatively receive high concentration-low volume ultrasound guided Erector Spinae Plane block, and then the patient will be transferred to the operating room (one syringe of 15 ml bupivacaine 0.5% {15 ml bupivacaine 0.5% }, for each patient).
224194754|NCT00008034|DRUG|cyclophosphamide|
224310410|NCT06498739|DRUG|Erector spinae plane block (15 ml bupivacaine 0.5% and 15ml normal saline)|Patients will preoperatively receive low concentration-high volume ultrasound guided Erector Spinae Plane block, and then the patient will be transferred to the operating room ) one syringe of 30ml bupivacaine 0.25% {15 ml bupivacaine 0.5% and 15ml normal saline}, for each patient.
224310411|NCT05775952|BIOLOGICAL|HRV-39|We will use a US Food and Drug Administration (FDA) approved Good Manufacturing Practices (GMP)-grade HRV-39 for our proposed study. Use of this GMP-grade HRV-39 viral stock ensures compliance with recent regulatory agency requirements which, beginning in 2001, have mandated that HRV preparations used for human inoculation be made under Good Manufacturing Practices (GMP). This proposed clinical study will allow us to address fundamental questions regarding the nature, kinetics and potential mechanisms of upper and lower airway inflammatory responses in subjects with well-controlled mild-moderate asthma and in healthy, non-asthmatic control subjects; a better understanding of these mechanisms may lead to new paradigms in the treatment of virally-induced airway remodeling and asthma exacerbations.
224310412|NCT00987753|DRUG|L-377202|For each cycle, L-377202 will be administered as a 30-minute infusion every 3 weeks. The starting dose will be 20 mg/m2/week. Doses will be doubled until a patient experiences a greater than or equal to Grade 2 toxicity.
224310413|NCT01438528|DEVICE|easypod ™|Saizen (Somatotropin) as per Summary of Product Characteristics administered by easypod™
224194755|NCT00008034|DRUG|epirubicin hydrochloride|
224194756|NCT01300741|DEVICE|Lotrafilcon B contact lens (AIR OPTIX® AQUA)|Silicone hydrogel, single vision contact lens worn in one eye in a daily wear modality for approximately 5 days or more per week, at least 10 hours per day, for up to 4 weeks.
224194757|NCT01300741|DEVICE|Galyfilcon A contact lens (ACUVUE® ADVANCE® Plus)|Silicone hydrogel, single vision contact lens worn in one eye in a daily wear modality for approximately 5 days or more per week, at least 10 hours per day, for up to 4 weeks.
224194758|NCT01300741|DEVICE|Contact lens solution (Clear Care®)|Hydrogen peroxide-based system used for cleaning, disinfection and overnight storage of the study contact lenses.
224194759|NCT01473602|DRUG|Teriparatide|Administered by SC injection
224310414|NCT05854823|RADIATION|dose-reduced radiotherapy|Patients receive 50Gy/25F, 2Gy/F QD, five days a week for 5 weeks
224194760|NCT01473602|DRUG|Placebo|Administered by SC injection
224194761|NCT01473602|DIETARY_SUPPLEMENT|Calcium supplementation|Administered orally
224194762|NCT01473602|DIETARY_SUPPLEMENT|Vitamin D supplementation|Administered orally
224194763|NCT01754012|DIETARY_SUPPLEMENT|Dietary Intervention|nutrient-rich diet and 10micrograms per day of Vitamin D (cholecalciferol) supplement from MCOHealth
224194764|NCT00160719|PROCEDURE|retrieve blood samples|blood samples obtain pre-op, 6 and 12 months post-op
224194765|NCT03148912|DIAGNOSTIC_TEST|Diagnostic algorithm|The treating physician will complete an enrollment assessment including the 4T score pretest probability assessment14. All patients will have laboratory testing for HIT anti-PF4 as well as SRA testing. Results of the anti-PF4 assay (OD value) will be available to the treating physician who will be instructed to follow the study diagnostic algorithm
223503859|NCT06482424|OTHER|intervention group|"Actions to be taken to the Intervention Group The researcher will record the state-trait anxiety scale and Pittsburg Sleep Quality Index score on the patient follow-up chart-researcher form at the patient's home at the beginning of the first week and at the end of the fourth week. The aromatic oil given to patients in the intervention group will be placed in 10ml dark glass bottles with droppers and a numbered label will be attached to the bottle.~Procedures to be Performed on the Placebo Group The researcher will record the state-trait anxiety scale and Pittsburg Sleep Quality Index score on the patient follow-up chart-researcher form at the patient's home at the beginning of the first week and at the end of the fourth week. Sesame oil given to patients in the placebo group will be placed in 10 ml dark glass bottles with droppers and a number two label will be attached to the bottle."
223592806|NCT06256653|DIETARY_SUPPLEMENT|Freeze-dried blueberries|"* Participants will be supplied with an 8-week supply of Study Product and instructions of dosing.~* Participants will be instructed to mix one sachet of the Study Product either to breakfast, or dessert, or mixed with yoghurt daily for the next 56 days, starting on the same day, Day 1.~* Additional product will be supplied in case of delay of study visit or loss of Study Product.~* Participants will be provided with a stool collection kit and instructions for collecting and storing. Participants will collect stool samples at home, within 48 hours prior to their visit but preferably the morning, of their scheduled visit and bring it to the clinic.~* Participants will be provided with a urine collection kit and instructions for collecting and storing."
224194766|NCT02503696|DEVICE|Stool Collection Kit|Stool Collection Kit.
224194767|NCT06274281|DEVICE|Digital Telerehabilitation|"The 5-day rehabilitation program will consist of exercises to re-establish standard movement patterns within a multidisciplinary etiological framework, according to a validated rehabilitation protocol for FMDs. Treatment will be tailored to the needs of each patient, following general treatment principles in physiotherapy for FMDs.~Telemedicine sessions: the patient will perform specific exercises under the supervision of a qualified physiotherapist to provide feedback on the execution and adapt the treatment according to clinical changes/improvements.~Wearable devices: each patient in the experimental group will receive 2 wearable sensors (Axivity AX3,) for monitoring of movement data (i.e., activity level, number of steps, distance travelled) during daylife activities and rehabilitation sessions. The subjective assessment of the patient's motor activity will be collected by clinical diaries focusing on gait and activity level."
224310415|NCT06624709|DRUG|Iron Supplement|The interventional group will receive 2-3mg/kg/day of iron supplementation 4 times per week and the sham comparator will receive 2-3mg/kg/day of iron supplementation 7 times per week
224314230|NCT04855578|OTHER|In-Hopsital Patient Educational Brochure|The participant's medication list will be identified from the pharmacy database and validated with the participant's best possible medication history taken at time of admission by a pharmacist. Eligibility will be confirmed by the participant's treating medical team with support from the study investigators. Participants who are enrolled during the intervention phase will receive an educational brochure about the risks of chronic gabapentinoid use, and about how to safely discontinue use. The brochure is written using a sixth-grade vocabulary and has been validated in both English and French for comprehension and readability, including for people with mild cognitive impairment.
223503860|NCT04618965|DRUG|control group|Each patient will receive intrathecal hyperbaric bupivacaine 10 mg in 2.5 ml and 0.5 ml saline with 3 mL total volume. Continous 50 ml saline infusion for 10 min followed by 200 ml saline infusion till the end of surgery.
223503861|NCT04618965|DRUG|Intrathecal dexmedetomidine|Each patient will receive dexmedetomidine 5 μg diluted in 0.5ml saline and hyperbaric Bupivacaine 10 mg in 2.5 ml with 3 mL total volume. Continous 50 ml saline infusion for 10 min followed by 200 ml saline infusion till the end of surgery.
223503862|NCT04618965|DRUG|Intravenous dexmedetomidine|Each patient will receive intravenous dexmedetomidine started at a loading dose of 1 μg/kg diluted in 50 ml saline and administered within 10 min as a loading dose, followed by maintenance at a dose of 0.4 μg/kg/h diluted in 200 ml saline till the end of surgery and hyperbaric Bupivacaine 10 mg in 2.5 ml total volume.
223503863|NCT02563210|OTHER|airway resistance measurement|assessment of airway resistance
223503864|NCT04113486|OTHER|Blood test|About 4 ml of blood draw
223503865|NCT05095792|OTHER|Observational - no intervention|This is an observational study with no intervention.
223503866|NCT06694623|PROCEDURE|Apically positioned flap|The split thickness flap was apically positioned as much as possible and sutured to the periosteum utilizing T-mattress sutures.
223503867|NCT06694623|PROCEDURE|Apically positioned flap with FGG strip|The split thickness flap was apically positioned as much as possible and sutured to the periosteum utilizing T-mattress sutures. FGG strip was sutured to the apical end of recipient bed.
223503868|NCT06002074|BEHAVIORAL|Stress Management and Resilience Training Program|One-on-one stress management and resilience consultation by a certified SMART trainer followed by self-guided on-line training consisting of 4 modules.
223503869|NCT04527731|DEVICE|Accelerometry|Participants are asked to wear an accelerometer during the day for a period of seven days.
223503870|NCT05192785|PROCEDURE|Incentive Spirometry Group|"The inspiration and expiration applications of incentive spirometry (IS) involved 10-20 breaths every one to two hours, depending on the tolerance of the patients.~During the inspiration application of IS, the head of the bed was elevated to a 45° angle, and the patient was placed in a long sitting position. The patient was requested to surround and fix the IS mouthpiece well, ensuring no gap was left between the lips. The patient was told to breathe slowly and deeply, and was asked to hold their breath for 2-3 seconds, and then to breathe normally with the IS mouthpiece in his/her mouth. The patient was advised to repeat the exercise 5-10 times, and to try to cough after every 5 exercises.~For the applied IS expiration technique applied in the study, which had not been previously encountered in literature, the patient was requested to turn the IS upside down (clockwise,180°) and to place the mouthpiece in his/her mouth and expiration application it."
223503871|NCT01229670|OTHER|exercise|"* 1.exercise(Aerobic interval training (AIT)): training with 90% of VO2 peak and 40% of VO2 peak cycle for total 30 minutes exercise time~* 2.exercise(moderate continuous training (MCT)):training with 60% of VO2peak for 30 min"
224194768|NCT06274281|OTHER|Usual care|The 5-day rehabilitation program will be the same as the telemedicine group. A self-management paper log will be given to the patient at the end of the 5-day rehabilitation program. It will include goals, activity plans, and strategies to be used for retraining movements and redirecting attention. Videos stored on the patients' digital device (i.e., tablet, mobile) will include exercises demonstration and execution and strategies to retrain movements. Patients will be encouraged to perform the self-management plan at home on their own (or with their caregivers' help) which will be reported in a paper log and video recorded. The subjective assessment of the patient's motor activity will be collected by clinical diaries focusing on gait and activity level.
224310416|NCT02442583|OTHER|Brochure regarding sedentary behavior|This pilot will occur in two phases. Phase 1 will occur in two steps. In Step 1, we will conduct one-on-one telephone interviews with 15 early stage CRC (colorectal cancer) survivors to obtain their knowledge and insights about sedentary behaviors and ways to reduce them. Their input will be used to help create a brochure on sedentary behaviors. In Step 2, we will conduct one-on-one telephone interviews with 5 early stage CRC survivors to provide feedback about the brochure. In Phase 2, we will recruit 15 CRC survivors. After completing a baseline survey, they will be asked to both wear an ActiGraph and self-report their daily sedentary behaviors for one week. They will receive tailored feedback as to their average weakly levels of sedentary behaviors and receive the brochure. One month post-intervention, they will be asked to take part in telephone survey assessing sedentary behaviors, PA (physical activity), and use of brochure.
223592807|NCT06256653|DIETARY_SUPPLEMENT|Placebo|"* Participants will be supplied with an 8-week supply of Placebo Product and instructions of dosing.~* Participants will be instructed to mix one sachet of the Placebo Product either to breakfast, or dessert, or mixed with yoghurt daily for the next 56 days, starting on the same day, Day 1.~* Additional product will be supplied in case of delay of study visit or loss of Placebo Product.~* Participants will be provided with a stool collection kit and instructions for collecting and storing. Participants will collect stool samples at home, within 48 hours prior to their visit but preferably the morning, of their scheduled visit and bring it to the clinic.~* Participants will be provided with a urine collection kit and instructions for collecting and storing."
224310417|NCT03061682|DEVICE|"Scharioth macula lens A45sml/A45smy"|Implantation of an add on intraocular lens to low vision patients
224310418|NCT00000734|DRUG|Sulfamethoxazole-Trimethoprim|
224310419|NCT00000734|DRUG|Zidovudine|
223592808|NCT03048877|DRUG|Apatinib Oral Tablet|Apatinib Mesylate Tablets
223592809|NCT03048877|DRUG|Placebo Oral Tablet|Placebo Oral Tablet
223592810|NCT02145351|DEVICE|Rate adaptive atrial pacing using a dual-chamber pacemaker|The Azure XT DR is a permanent, dual-chamber cardiac pacemaker with the ability to continuously monitor and record patient activity, and respond to activity by pacing faster and increasing the heart rate (rate adaptive atrial pacing). It will be programmed in AAIR mode to pace the right atrium. The leads will be placed in the right atrium and right ventricle using CapSureFix model 5086.
223592811|NCT02145351|DEVICE|Pacemaker system will be implanted but set to Pacing Off.|The identical pacing system will be implanted, but will be set to Pacing Off.
224194769|NCT04559802|PROCEDURE|Transmucosal Technique|Dental implant will be placed in transmucosal manner (Healing abutment is exposed in the mouth).
224310420|NCT06048627|DRUG|Amine/zinc lactate/fluoride system|Amine/zinc lactate/fluoride system (250 ppm F), meridol®, Colgate-Palmolive
223503872|NCT00160615|DRUG|Levetiracetam|"* Pharmaceutical form: Film-coating tablets~* Concentration: 250 mg/ 500 mg~* Route of administration: oral use"
223503873|NCT03166631|DRUG|BI 891065|Part A, Part B
223503874|NCT03166631|DRUG|BI 754091|Part B
223503875|NCT00060385|DRUG|CHOP regimen|
223503876|NCT00060385|DRUG|EPOCH regimen|
223503877|NCT00060385|DRUG|cyclophosphamide|
223503878|NCT00060385|DRUG|doxorubicin hydrochloride|
223503879|NCT00060385|DRUG|etoposide|
223503880|NCT00060385|DRUG|prednisone|
223503881|NCT00060385|DRUG|vincristine sulfate|
223503882|NCT00060385|RADIATION|radiation therapy|
223503883|NCT06455280|DRUG|Siplizumab|Siplizumab is an anti-CD2 monoclonal antibody that has demonstrated a favorable safety profile of siplizumab in over 779 human subjects and has been shown to target memory T cells-a key driver in the immune processes surrounding rejection and autoimmunity post LT in AILD.
223503884|NCT01579877|DIETARY_SUPPLEMENT|Herbal extract granule|The herbal extract granule, Yukmijihwang-tang granule, consists of 6 herbs. Ingredients: Rehmanniae Radix, Deoscoreae Radix, Corni Fructus, Hoelen, Alismatis Radix, Paeoniae Radicis Cortex. Dosage and frequency: 1 pack (3g), 3 packs per day (2 hours after morning, afternoon and evening meal)
223503885|NCT01579877|DIETARY_SUPPLEMENT|Placebo herbal extract granule|The Yukmijihwang-tang\_Placebo has the same form, color and flavor as experimental intervention (Yukmijihwang-tang). The dosage, frequency and duration is also the same as experimental intervention (Yukmijihwang-tang).
223503886|NCT02740582|DRUG|Tolcapone|
224310421|NCT06048627|DRUG|negative control|Sodium fluoride mouthwash 250 ppm
224310422|NCT04546893|BIOLOGICAL|CD19 CAR-T|Biological: CD19 CAR-T; Drug: Cyclophosphamide,Fludarabine; Procedure: Leukapheresis;
224310423|NCT00168597|DRUG|Vitamin A|
224310424|NCT05966220|DEVICE|Hip surgery with FH Ortho devices|"This study is a real-life observatory designed to collect long-term clinical data on patients who have undergone hip joint replacement or repair following hip trauma.~In this type of intervention, one or more medical devices distributed by FH ORTHO Company may be used by surgeons."
224314231|NCT04855578|OTHER|Physician Education about Gabapentinoid Prescription|An educational session about the purpose of the study and risks of gabapentinoid prescription will be delivered to physicians (staff and medical residents) on each study unit at both sites during the intervention period. The educational session will include a presentation by the chief of the medical service at the monthly teaching rounds, and an electronic message will be sent to all physicians on the medical service. Physicians will also be presented a brief overview of the educational brochure.
223503887|NCT02740582|DRUG|Placebo|
223503888|NCT06580769|OTHER|Physical activity|Implementation of a physical activity program, executed through immersive virtual reality
223503889|NCT03983369|DEVICE|Low-Level Laser Therapy|The LLL used is the K-Laser Cube 3. The LLL is an athermal laser beam of low power, equipped with a placebo function (dummy imitating beam laser light, emitted by the same device but without physiological effect).
223503890|NCT03983369|OTHER|Placebo|Placebo
223592812|NCT03230682|DRUG|antidepressant|regular one-drups treatment of selective serotonin reuptake inhibitor(SSRIs)
223592813|NCT00003658|BIOLOGICAL|filgrastim|
223592814|NCT00003658|BIOLOGICAL|rituximab|
224194770|NCT04559802|PROCEDURE|Submerged Technique|Dental implant will be installed in submerged manner (implant is completed covered by soft tissue).
224194771|NCT04592666|DRUG|Almonertinib|the standard therapy of single agent almonertinib
224194772|NCT04592666|DRUG|Pemetrexed|standard dose
224194773|NCT04592666|DRUG|Carboplatin|AUC=5
224194774|NCT02793258|DEVICE|transcranial direct current stimulation|"Subjects will receive 10 30-minutes sessions of two milliamps transcranial direct current stimulation , twice a day for 5 consecutive day.~Facial emotion recognition task and attentional task with measurement of eye-tracking, heartrate, respiratory frequency and skin conductance will be conducted before and after the first session, and after the last session."
224194775|NCT03302221|DRUG|0.5% ropivacaine paravertebral block|The investigators designed a study to assess whether there were any blood flow indexes change during induction with doppler ultrasonography after 0.5% ropivacaine paravertebral block
224194776|NCT03302221|DRUG|0.25% ropivacaine epidural block|A 4-5 ml bolus of 0.25% ropivacaine was administered 1 h after the initiation of TEB.
224194777|NCT03302221|DRUG|0.5% ropivacaine local anaesthesia|local anaesthesia at the incision was induced by 0.5% ropivacaine by the surgeon just before the surgery.
224194778|NCT01377207|PROCEDURE|Primary PCI|Thrombus aspiration and hystopathological analysis, Optical Coherence Tomography assessment of STEMI culprit vessel, Primary PCI with Drug Eluting Stent implantation; Repeat OCT assessment of culprit vessel at 9 monts follow-up
224194779|NCT02058459|DEVICE|Holaira™ Lung Denervation System with energy delivery|
224194780|NCT02058459|DEVICE|Holaira™ Lung Denervation System without energy delivery|
224194781|NCT02544607|DRUG|Ketamine|Ketamine 0.5mg/kg over 40 minutes IV
224194782|NCT02544607|OTHER|Magnetic Resonance Imaging (MRI)|MRI technology will be used before and after ketamine for patients with depression
224194783|NCT00592137|DIETARY_SUPPLEMENT|C (smoothies based on soy protein containing no additional calcium)|Two smoothies per day based on soy protein containing no additional calcium
224194784|NCT00592137|DIETARY_SUPPLEMENT|B (smoothies based on soy protein containing calcium)|Two smoothies daily based on soy protein containing 650 mg calcium as calcium carbonate
224310425|NCT06085768|BEHAVIORAL|VRE intervention|Virtual reality exposure therapy is a new treatment technology developed in recent years. This technology combines virtual reality technology with traditional exposure therapy, and uses virtual reality technology to present the exposure scenes required for exposure therapy. Therefore, it can break through the limitations of time and space and more intuitively display some things that are difficult to simulate in the treatment room. Scenes do not require the client to undergo treatment through imaginary exposure, thereby increasing the immersion and reality of the treatment. Over the past two decades, numerous studies have explored and proven the effectiveness of virtual exposure therapy.
223592815|NCT00003658|DRUG|cyclophosphamide|
223592816|NCT00003658|DRUG|pentostatin|
223592817|NCT00785174|DEVICE|continuous positive airway pressure|respiratory assistance using face mask and positive expiratory pressure apllied by a Boussignac valve
223592818|NCT00785174|DEVICE|noninvasive pressure support ventilation|noninvasive pressure support ventilation can provide inspiratory pressure support and expiratory positive pressure
223592819|NCT00785174|DEVICE|noninvasive pressure support ventilation|noninvasive pressure support ventilation provides an inspiratory aid and positive expiratory pressure using ventilator through face mask
223592820|NCT04059107|DEVICE|3D Printed Myoelectric Prosthetic Device|3D Printed Myoelectric Prosthetic Device
223592821|NCT02437370|DRUG|Pembrolizumab|Given IV
223592822|NCT02437370|DRUG|Docetaxel|Given IV
224194785|NCT00592137|DIETARY_SUPPLEMENT|A (smoothies based on dairy protein containing calcium)|Two smoothies daily based on dairy protein containing 650 mg calcium
224194786|NCT05260528|DRUG|Cytarabine and Idarubicin|"Induction 1: Cytarabine 200 mg/m2 i.v. (continuously) d1-7 + Idarubicin 12mg/m2 d1, 2, 3 i.v (60 min)~Induction 2: Cytarabine 1500 mg/m2 i.v. q12h d1-3~Consolidation: Cytarabine 1500 mg/m2 i.v. q12h d1-3"
223592823|NCT02437370|DRUG|Gemcitabine Hydrochloride|Given IV
223592824|NCT02667470|DRUG|Solifenacin|Oral
224194787|NCT05260528|DRUG|CPX-315|"Induction 1:CPX-351 44 mg/m2 daunorubicin / 100 mg/m2 cytarabine i.v. (90 min) d1,3,5~Induction 2: CPX-351 44 mg/m2 daunorubicin / 100 mg/m2 cytarabine i.v. (90 min) d1,3~Consolidation therapy:CPX-351 29 mg/m2 daunorubicin / 65 mg/m2 cytarabine i.v. (90 min) d1,3"
224194788|NCT02189928|DEVICE|Lower limb tourniquet|"Lower limb tourniquet will be put on half thigh. The protocol will include 4 cycles of inflation cuff 110 mm Hg above systolic blood pressure followed by 4 cycles of deflation in between.~The total duration of per-CID protocol will be 40 minutes (4 phases of 5 minutes inflations' of and 4 phases of 5 minutes deflations')."
224194789|NCT02189928|OTHER|Usual care|
224194790|NCT02594254|DRUG|C16G2 Gel|Antimicrobial peptide
223592825|NCT01204762|DRUG|pegIFN|Syringe, Subcutaneous, 180 μg, Once Weekly, 48 weeks
223592826|NCT01204762|DRUG|pegIFNα-2a|Syringe, Subcutaneous 180 μg, Once Weekly, 48 Weeks
223592827|NCT01204762|DRUG|PegIFN lambda|Syringe, Subcutaneous, 180 µg, Once weekly, 48 weeks
223592828|NCT01204762|DRUG|Entecavir|Tablet, Oral, 0.5 mg, Once daily, 12 weeks initial monotherapy followed by 48 weeks of combination therapy with PegIFN lambda
224194791|NCT02594254|OTHER|Placebo|Placebo
224194792|NCT06651138|RADIATION|Fluoroscopy|Pulsed or Continuous fluoroscopy during MILD procedure
224194793|NCT06650293|DRUG|Vitamin D|Vitamin D supplementation as vitamin D, 2 drops i.e., 800 IU daily for 5 days.
224310426|NCT01781520|BIOLOGICAL|DC-CIK Treatment|The DC-CIK cells were infused on days 15, 17, and 19 of 21-day cycles.
224314232|NCT06353542|DIAGNOSTIC_TEST|Software analysis|The tested AI software analyzes the optic disc retinography to determine if the patient is healthy, a glaucoma suspect, or a glaucoma case
223592829|NCT00439374|DRUG|17 alpha-hydroxyprogesterone caproate|Coded study medication is sterile solution containing 250 mg/mL of 17 alpha-hydroxyprogesterone caproate in castor oil with benzyl benzoate and benzyl alcohol as a preservative; placebo is same without the active ingredient. Study drug is administered as weekly 1 ml intramuscular injections until 36 week 6 days of gestation or delivery, whichever occurs first.
223592830|NCT00439374|OTHER|Placebo Oil|Placebo oil is a 250 mg/mL solution of castor oil with benzyl benzoate and benzyl alcohol as a preservative
223592831|NCT02169856|BEHAVIORAL|EFTs (emotional freedom techniques)|The Emotional Freedom Techniques (EFTs) which has been pioneered by Gary Craig is a form of alternate medicine which works by tapping on body energy meridian points. Unlike drugs the EFTs has no side effects too
224194794|NCT06651125|OTHER|Adapted Physical Activity|Patients in the Adapted Physical Activity arm realized a 12-weeks supervised exercise program. The supervised PA intervention consisted of two sessions per week. Each session lasted one hour and was divided into 30 minutes of aerobic exercise using an ergometer (treadmill and/or bicycle), followed by 30 minutes of resistance exercises involving major muscle groups, with or without small equipment such as dumbbells, resistance bands, and balls. The exercise regimen was carried out at an intensity ranging from 50% to 70% of the heart rate reserve, with a rate of perceived exertion (RPE) set at 4 on a Borg scale of 0 to 10. A total of 24 sessions were planned. There was also the option to incorporate a 45-minute session of moderate-intensity water aerobics into the weekly routine.
224194795|NCT01958502|GENETIC|surgical treatment of non union with mesenchymal stem cells with BMP2 within a 3-D tissue engineered scaffold|
223503891|NCT05855551|OTHER|Base cash transfer|Program beneficiaries will receive a monthly transfer of 800 BDT. A government-to-person (G2P) payment system will be used, which will transfer cash on a monthly basis. Under this new system, beneficiaries will select one of the following payment channels based on convenience: mobile financial services or through a bank transfer (which women in remote areas could access through agent banking). Each month, women will receive a text message from the government informing her that the money has been credited to her account.
223503892|NCT05855551|BEHAVIORAL|Behavior change communication (BCC)|"The BCC strategy has two different components:~* Monthly courtyard meetings: Courtyard sessions (12 to 15 women) will be organized at a place no more than 15 to 20 minutes walking distance from the beneficiary's home. Family members (husband, mother-in-law, …) are invited to join the meeting. Sessions are part of a continuous 4-session cycle. Each session will lasts 1.5 hours and will use different didactic methods. Topics include pregnancy nutrition and care, breastfeeding, importance of different micronutrients, and nutrition and care during lactation. The importance of a healthy diet during pregnancy is repeated in each session. Pregnant women receive a take-home poster that summarizes how to eat a healthy diet during pregnancy.~* Home visits: Visits will cover the content of any sessions missed by pregnant women and will reinforce the messages regarding maternal diet on the take-home poster."
223503893|NCT05855551|OTHER|Food basket|"The monthly food basket will provide 10 kg micronutrient fortified rice , 3.5 kg of lentils, and 1000 ml of oil, valued at 800 BDT . Assuming a the ration is split equally among the 5 members of an average-sized household in rural Bangladesh and using food composition data for Bangladesh, the food basket is estimated to provide 354 kcal and 11 g of protein per person per day. The food basket will be provided once every month.~The individually packaged foods will be distributed at the Union parishad office, community clinic, or another government facility in the first week of each month. The UDW will inform the beneficiaries of the place and time of the food distribution. Recipients will only receive the food when they present their food card. The card will also be used to record receipt of each ration. If beneficiaries cannot attend the food distribution themselves, a designated nominee can pick up the ration on their behalf."
223503894|NCT05855551|OTHER|Top-up cash|"The monthly top-up cash of 1,000 BDT will be added to the base amount that is part of the standard program. For the top-up cash transfer, a person-to-person payment system is used. WFP will contract with one popular mobile banking service (either bKash or Rockets) for the monthly top-up cash transfers. About two weeks after receiving the base cash transfer, women will receive the top-up cash through a mobile account (which can also be used to receive the base cash transfer). A text message will be sent to the beneficiary to inform her that the top-up transfer has been made into her account."
223503895|NCT01558505|DEVICE|PEB|paclitaxel-eluting balloon angioplasty
223503896|NCT01558505|DEVICE|POBA|conventional balloon angioplasty
223503897|NCT03683537|DIAGNOSTIC_TEST|Glial fibrillary acidic protein|3 samples of serum are drawn from patients. The 1st Sample of patient serum is drawn before induction into anesthesia. The 2nd is drawn 24 hours after the 1st one. The 3rd sample is drawn on 3 or 4 postoperative day. All samples collected and preserved in the same temperature as required for ELISA.
223503898|NCT04731662|BEHAVIORAL|Short sleep|6-hours time-in-bed during weeknights
223503899|NCT04731662|BEHAVIORAL|Variable short sleep|Variable hours of time-in bed during weeknights
223503900|NCT06329622|COMBINATION_PRODUCT|low-protein diet + Ketosteril|low-protein diet (0.6-0.8g protein/kg body weight/day) and Ketosteril 0.12 g/kg body weight/day will be prescribed with the target energy intake of 25-30kcal/kg body weight/day.
223503901|NCT06329622|DIETARY_SUPPLEMENT|low-protein diet|low-protein diet (0.6-0.8g protein/kg body weight/day) with the target energy intake of 25-30kcal/kg body weight/day.
223503902|NCT05397405|DRUG|PCSK9 inhibitor|The aim is to improve blood lipid management by using atorvastatin 20-40mg or rosuvastatin 10-20mg or simvastatin 20-40mg and PCSK9 inhibitors for 6-12 months
223503903|NCT04160221|OTHER|12 hours interval|Time interval between treatments
223503904|NCT04160221|OTHER|24 hours interval|Time interval between treatments
223592832|NCT02169856|DRUG|Tab. Midazolam 7.5 mg|Tab. Midazolam 7.5 mg will be given to all patients at night before surgery.
223592833|NCT02169856|DRUG|Inj. Midazolam 0.7mg/kg|Inj . Midazolam 0.7 mg/kg given as premedication 45 min before surgery.
223592834|NCT02169856|DRUG|Inj. Propofol 2.5mg/kg|It was given to induce anesthesia after 3 min of pre oxygenation.
223592835|NCT02169856|DRUG|Inj. Atracurium 0.5 mg/kg|It was given to induce muscle relaxation during anesthesia
223592836|NCT02169856|DRUG|Sevoflurane 2.5 vol %|It was given to maintain anesthesia during surgery alongwith oxygen in air mixture
223592837|NCT02169856|DRUG|Inj. Cefuroxime 1.5 g IV|It was given as prophylactic antibiotic. 2 doses given. 1st 30-60 min before surgery. 2nd 6 hours after surgery
223592838|NCT02169856|DRUG|Drug: Inj. Ketorolac 30 mg IV|3 doses for analgesia. 1st immediate postoperative, 2nd at 8 hours postoperative and 3 rd at 16 hours postoperative period
223592839|NCT02169856|DRUG|Inj. Zantac 50mg IV|2 doses. 1st at immediate postoperative and 2nd 12 hours after surgery
223592840|NCT05011526|BIOLOGICAL|MVC-COV1901|Approximately 471 participants will receive 2 doses of MVC-COV1901(S-2P protein with adjuvant) at Day 1 and Day 29 via intramuscular (IM) injection in the deltoid region
224194796|NCT00078273|BEHAVIORAL|Personalized Feedback Intervention|Sessions lasted for 60-90 minutes and used Motivational Interviewing (MI) to facilitate discussion of feedback from participants' survey responses. Sessions began with open-ended questions about contextual factors associated with participants' gambling, then review of each feedback section: gambling pattern; perceived gambling norms; positive expectancies and negative consequences of gambling; beliefs about control over gambling; and situational self-efficacy to avoid gambling. Participants were encouraged to consider the feedback in light of their personal goals. All participants received a copy of their feedback, a list of skills for limiting gambling and a resource/referral list.
224194797|NCT00078273|BEHAVIORAL|Cognitive Behavioral Intervention|Participants completed either six weekly 1-hour sessions or attend four sessions containing the same content. Sessions covered functional analysis and gambling triggers; challenging cognitive distortions, with emphasis on illusions of control; coping with triggers; assertiveness; and relapse prevention. Participants received a pamphlet covering each week's topic (which was reviewed with the participant if a session was missed), as well as homework sheets and gambling diaries. CBI participants were asked to refrain from gambling for the duration of the group to provide an opportunity to practice and develop skills applicable to gambling and other behavior change situations.
224194798|NCT04129866|BEHAVIORAL|M-IBM|"In this paradigm, an ambiguous word or two-word phrase related to ASCC is followed by a sentence that resolves the word-sentence meaning as threatening or benign. For example, participants are presented with an ambiguous word or two-word phrase for 1 second. On half the trials the combination of the word/phrase and sentence creates a benign meaning (as in the previous example). On the other half of trials this combination creates an anxious-threat meaning Participants are required to judge the relatedness of the word/phrase and the sentence. Participants are given feedback during training such that judging the anxious-threat combinations to be unrelated and the benign combinations as being related would produce a correct response. In contrast, if participants produce an incorrect response they see incorrect."
224194799|NCT04129866|BEHAVIORAL|Control-IBM|Placebo IBM where sentences are not related to anxious threat meaning of cue word.
224194800|NCT06008470|OTHER|observational tests|"Respiratory Muscle Strength Measurement In our study, respiratory muscle strength will be measured using a portable, electronic mouth pressure measuring device (MEC Pocket Spiro MPM100, Belgium). Maximal inspiratory pressure (MIP) and maximal expiratory pressure (MEP) measurement is one of the most commonly used non-invasive methods to evaluate respiratory muscles.~6 Minute Walk Test (6MWT): It has been used to assess physical activity and functional capacity in many pulmonary rehabilitation programs for patients with chronic pulmonary disease and limited respiratory capacity"
224194801|NCT00560573|DRUG|CP-751,871|CP-751,871 at doses ranging from 6 to 20 mg/Kg on Day 1 of each 21-day cycle. CP-751,871 may be administered even after active comparators discontinuation, for a total number of 17 cycles (1 year).
224194802|NCT00560573|DRUG|Cisplatin|"Cisplatin 75\* mg/m2 or 80\* mg/m2, IV on Day 1 of each 21-day cycle up to 6 cycles.~\* 75 mg/m2 when in combination with pemetrexed, 80 mg/m2 when in combination with gemcitabine"
224310427|NCT01781520|DRUG|S1|The dose of S-1 is determined according to the body surface area as follows: \<1.25 m2, 40 mg; 1.25-\<1.5 m2, 50 mg; and \>1.5 m2, 60 mg, given twice daily after meals for 14 days followed by a 7-day rest. Cycles is repeated every 21 days. Treatment is continued until disease progression, unacceptable toxic effects, or the withdrawal of consent.
224310428|NCT01781520|OTHER|Best supportive care|Best supportive care
224310429|NCT00140660|DRUG|rituximab|375 mg/m2 on D1
223592841|NCT05011526|BIOLOGICAL|AZD1222|Approximately 471 participants will receive 2 doses of AZD1222 at Day 1 and Day 29 via intramuscular (IM) injection in the deltoid region
224194803|NCT00560573|DRUG|Gemcitabine|Gemcitabine 1250 mg/m2, IV on Days 1 and 8 of each 21-day cycle up to 6 cycles
224194804|NCT00560573|DRUG|Pemetrexed|Pemetrexed 500 mg/m2, IV on Day 1 of each 21-day cycle up to 6 cycle
224194805|NCT00726882|PROCEDURE|Blood sample collection only|Approximately monthly collection of blood samples.
224194806|NCT00726882|DRUG|ABT-333|Previous treatment in prior ABT-333 studies.
224194807|NCT01339273|PROCEDURE|Ultrasound guided Transversus Abdominis Plane (TAP) bock|Ultrasound guided TAP bock with Bupivacaine 0.25% 20ml per side or to a maximum 1mg/kg per side and the skin puncture will be covered with a small plaster
224194808|NCT01339273|PROCEDURE|Local anaesthetic infiltration of laparoscopic port sites|Laparoscopic port sites and specimen extraction site will be infiltrated with a total of 40 mls 0.25% bupivacaine subcutaneously at the end of the procedure in the control group and plasters will be stuck on either side approximately where a skin puncture for tap block would be made.
224310430|NCT01833091|OTHER|artificial night|Infants in the intervention group received light cyclic with pattern 12 hours. Light period was from 7 to 19 during which the infants were put in the normal environmental light and dark period was from 19 to 7 during which was the infants' incubator was covered with linen cloth. The vital signsand \& arterial oxygen saturation of the infants in the intervention group were controlled before covering the incubator i.e. at 19. Also, the infant's vital signs were again monitored at 7 am.The infant weighed in every day at 7 am during the 10 days of study. Feeding tolerance was daily determined at 8 am, using nasogastric tube or orogastric tube to control residue as well as to review the presence or absence of abdominal distention, vomiting.
224310431|NCT03483168|BEHAVIORAL|Culturally sensitive pain education|The content of the PNE program include the characteristics of acute and chronic pain, purpose of acute pain, formation process of acute pain from the nervous system, the formation process of chronic pain, and potential sustaining factors for central sensitization.
224314233|NCT06353542|DIAGNOSTIC_TEST|Ophthalmologist examination|The ophthalmologist (a glaucoma specialist) will analyze the tests and will examine the patient to determine if the patient is healthy, a glaucoma suspect or a glaucoma case
224314234|NCT02376400|BIOLOGICAL|MVA-BN-Filo|One 0.5 milliliter (ml) intramuscular (IM) injection of 1\*10\^8, (50%Tissue Culture Infectious Dose \[TCID50\]) on Day 1, 29 or 57.
223592842|NCT03289117|DEVICE|Novel gel installation device procedure|Catheter change with novel device Each subject will undergo catheter change with novel gel instillation device
223592843|NCT03289117|DEVICE|Standard procedure|Catheter change with standard procedure Each subject will undergo catheter change with standard procedure
223592844|NCT00293020|DRUG|BEMA Fentanyl|buccal soluble film; 200, 400, 600, 800, 1200 mcg fentanyl; up to 4 times daily
223592845|NCT05254873|OTHER|Long term follow-up|Long term follow-up for patient who completed the EYE-TAR(MA) study.
224194809|NCT06653920|OTHER|Chiropractic|SM used by the practitioner was the chiropractic side posture pisiform contact push move with a P-A thrust isolated to the lumbosacral joints and applied to the side of primary back and/or leg pain. Patients presenting with spondylolisthesis received a side posture distraction type maneuver instead of a P-A thrust. As pain began to subside during subsequent visits patients were transitioned to bilateral application of SM, rather than continuing treatment only on the side of back pain or radiculopathy.
224194810|NCT06653920|OTHER|Exercise|Core spine stretch and strength training throughout the course of care.
223503905|NCT03606590|DEVICE|NovoTTF-100L(P) device|Patients will be treated continuously with the NovoTTF-100L(P) device. NovoTTF-100L(P) treatment will consist of wearing four electrically insulated electrode arrays on the abdomen. The treatment enables the patient to maintain regular daily routine.
223503906|NCT03606590|DRUG|Sorafenib|Sorafenib 400 mg (2 x 200 mg tablets) taken twice daily without food (at least 1 hour before or 2 hours after a meal).
223503907|NCT05503732|OTHER|Energy Drink|Two 16-oz energy drinks consumed orally to be finished approximately 4 hours prior to bed
223503908|NCT05503732|OTHER|Placebo Drink|Two 16-oz identical looking placebo drink without caffeine consumed orally to be finished approximately 4 hours prior to bed
223503909|NCT03456297|OTHER|Web-based clinical pedagogy program (WCP)|The nurse preceptors in the experimental cluster will be given access to download the WCP on mobile devices. The unique interactive features provide continuous support and allow preceptors to discuss the clinical encounters with their peers and consult experts for advice.
224194811|NCT06653920|OTHER|Cryotherapy|Therefore, during each treatment session when patients reported pain they received pretreatment with cryotherapy using a reusable ice pack (Polar Ice, Pelton/Shepherd Industries, Stockton, California) wrapped in 2 layers of headrest paper, but otherwise applied directly to the skin vertically along the lumbosacral spine, for 5 minutes.
224194812|NCT06653920|DEVICE|Spinalator|When patients no longer reported leg pain, spinalator intersegmental traction at \~10 lb/F, while the patient was lying supine with an ice pack between the traction table and the lumbar spine, was permitted as a pretreatment to side posture lumbar manipulation.
224194813|NCT02350114|PROCEDURE|6 Minute Walk Test|Evaluation of walking distance on standardized 6 minute walk test
224194814|NCT04973917|PROCEDURE|respiratory support|respirators for invasive mechanical ventilation
224194815|NCT02526017|BIOLOGICAL|Cabiralizumab|Solution for IV administration
224194816|NCT02526017|BIOLOGICAL|Nivolumab|Solution for IV administration
224194817|NCT02514434|RADIATION|Ultrasonography|Subjects will be randomly allocated to either Ultrasonography arm or Non-contrast MRI arm for their surveillance method.
224194818|NCT02514434|RADIATION|non-contrast MRI|Subjects will be randomly allocated to either Ultrasonography arm or Non-contrast MRI arm for their surveillance method.
224194819|NCT06006416|DRUG|Fenugreek Fibre|Daily dose of 2 x 10g per day with/in food
224194820|NCT01001286|BEHAVIORAL|Questscope Non-Formal Education|"Participation in two-hour classes for three to five days per week. Duration involves 24 months of programming (three, eight-month learning cycles), but this randomized controlled trial will only assess impacts of participation in the first four months.~Regular presence of trained, supportive adults. Educational topics and class activities determined by the youth as a group with the support of the adult teachers (facilitators)."
224194821|NCT01977924|DIETARY_SUPPLEMENT|one month polyphenols supplementation (600mg)|
224194822|NCT01977924|DIETARY_SUPPLEMENT|placebo (microcrystalline cellulose)|
223503910|NCT00567580|RADIATION|PBRT|1.8 Gy per fraction once daily, 5 days a week totaling 64.8-70.2 Gy. 3D-CRT or IMRT required.
223503911|NCT00567580|RADIATION|PLNRT|1.8 Gy per fraction once daily, 5 days a week, totaling 45 Gy. 3D-CRT or IMRT required.
224194823|NCT02288234|DRUG|Vibativ|This is an observational study for patients who were already prescribed Vibativ.
224194824|NCT03041818|BEHAVIORAL|Horseback riding therapy|Apply 30 minutes/session, twice a week for 8 weeks of horseback riding therapy (provided with 1 horse rider, 2 side walkers)
224194825|NCT04540315|BEHAVIORAL|MobiMD|MobiMD is a mobile app. This is an app available to IOS and Android devices only. The app provides a digitized version of the discharge instructions and provides push notifications to remind the participant of important instructions. In addition, the app allows participants (and their care teams) to record and track relevant clinical data.
224194826|NCT01800500|BEHAVIORAL|smoking cessation intervention|Purchase ST products using a fixed rate of product prices
224194827|NCT01800500|BEHAVIORAL|smoking cessation intervention|Purchase ST products using escalating product prices
224194828|NCT01800500|OTHER|questionnaire administration|Ancillary studies
224194829|NCT01800500|OTHER|quality-of-life assessment|Ancillary studies
224194830|NCT01800500|OTHER|laboratory biomarker analysis|Correlative studies
224194831|NCT01800500|OTHER|ecigarettes|Purchase ST products using escalating product prices nicotine replacement therapy
223503912|NCT00567580|DRUG|AA|Antiandrogen (AA) therapy can be either 250 mg flutamide by mouth three times a day or 50 mg bicalutamide by mouth once a day.
223503913|NCT00567580|DRUG|LHRH agonist|Luteinizing hormone-releasing hormone (LHRH) agonist can be any analog approved by the FDA (or by Health Canada for Canadian institutions) and may be given in any possible combination such that the total LHRH treatment time is 4-6 months. LHRH analogs are administered with a variety of techniques, including subcutaneous insertion of a solid plug in the abdominal wall, intramuscular injection, and subcutaneous injection.
223503914|NCT05501717|DRUG|ALXN2030|ALXN2030 will be administered subcutaneously as a single dose either as a manual SC injection or as an SC infusion via a syringe pump.
223503915|NCT05501717|DRUG|Placebo|Placebo will be administered subcutaneously as a single dose either as a manual SC injection or as an SC infusion via a syringe pump.
223503916|NCT04524923|OTHER|visual motor integration|investigate the relation between touch screen usage and visual motor integration in preschoolers
224194832|NCT01800500|OTHER|ecigarettes|Purchase ST products using a fixed rate of product prices nicotine replacement therapy
224194833|NCT01578109|PROCEDURE|Bone Marrow Transplantation|Undergo BMT
224194834|NCT01578109|DRUG|Sorafenib|Given PO
224194835|NCT01578109|DRUG|Sorafenib Tosylate|Given PO
224194836|NCT02742415|BEHAVIORAL|Caring Hand Massage|Caring Hand Massage is a hand massage therapy program with several steps and techniques.
224194837|NCT03488537|DEVICE|AeonoseTM|Breath test
224194838|NCT00153751|DRUG|Traditional Chinese Medicine|They are Common peony root, Rhizoma Atractylodis Macrocephalae, Radix Paeoniae Lactiflorae, Cortex Magnoliae Officinalis, Rhizoma Curcumae Longae, Fructus Schisandrae Chinensis, Pericarpium Citri Reticulatae, and Rhizoma Corydalis Yanhusuo.
224194839|NCT00153751|DRUG|Holopon|holopon
224194840|NCT00153751|OTHER|placebo|placebo
224310432|NCT03483168|BEHAVIORAL|Standard pain education program|"For the standard translated PNE, The English translation of Pain Neuroscience Education: slides for supporting and illustrating your explanation at the Pain in Motion Group web page (http://www.paininmotion.be/education/tools-for-clinical-practice) and English translation of the Patient Information Leaflet will be used. The education materials will be translated using the forward/backward translation process. The English version of PNE presentation and information leaflet will be translated to Turkish by two independent translators."
224310433|NCT04208074|OTHER|Exercise Intervention|Participants will exercise under the supervision of expert personal trainers and follow an optimized exercise program tailored to the strength and fitness level of each participant. Participants will exercise for 16 weeks; 2 days a week at the gym for an hour and 2 days of the week at home for 45 minutes.
223503917|NCT04524923|OTHER|Quality of life assessment|investigate the relation between touch screen usage and Quality of life assessment in preschoolers
223503918|NCT04524923|OTHER|Cognitive Functioning|investigate the relation between touch screen usage and Cognitive Functioning assessment in preschoolers
223503919|NCT06957782|DRUG|⁶⁸Ga-FAPI-46|All patients will be administered with 1.5 MBq/kg ⁶⁸Ga-FAPI-46. ⁶⁸Ga-FAPI-46 will be injected intravenously followed by a flush injection of 10 mL of saline following routine procedures.
223503920|NCT06964581|BEHAVIORAL|Cognitive treatment delivered via telerehabilitation.|Three hours of cognitive rehabilitation per week, carried out independently and remotely using a computerized device, which is pre-programmed according to the patient's specific needs.
223503921|NCT06964581|BEHAVIORAL|In-person cognitive treatment.|Three hours of in-person cognitive rehabilitation per week using a computerized device. The participant will perform cognitive exercises on the computerized device in the presence of the therapist, who will activate the device (using credentials specifically created for them) and select the appropriate activity to administer at each session.
223503922|NCT06964659|DIETARY_SUPPLEMENT|Sulforaphan-Smart® formula|Volunteers will intake a daily dose of Sulforaphan-Smart® pill for 12 weeks (84 days)
223503923|NCT06964659|OTHER|Control (placebo) group|Volunteers will intake a daily dose of placebo pill for 12 weeks (84 days)
223503924|NCT06963515|PROCEDURE|Magnetic Resonance Imaging|3T Magnetic Resonance Imaging
223503925|NCT06964607|DRUG|Sodium-glucose cotransporter-2 Inhibitors|Patients received conventional management of acute myocardial infarction and reperfusion therapy as indicated, plus one of the available sodium-glucose co-transporter-2 Inhibitors in Egypt (Empagliflozin or Dapagliflozin), irrespective of the presence or absence of diabetes mellitus or type of heart failure(HFrEF, HFmEF, HFpEF).
223503926|NCT06964607|DRUG|Conventional treatment|Patients received conventional management of acute myocardial infarction and reperfusion therapy as indicated without adding sodium-glucose co-transporter-2 inhibitors.
223503927|NCT06963788|DRUG|Chlorhexidine 0,12%|Rinse mouth with 10ml for 30 seconds after brushing teeth for 30 minutes
223503928|NCT06963788|DRUG|0,9% Chloride Sodium|Rinse mouth with 10ml for 30 seconds after brushing teeth for 30 minutes
223503929|NCT06963788|DRUG|Silver nanoparticles mouthwash|Rinse mouth with 10ml for 30 seconds after brushing teeth for 30 minutes
223503930|NCT06963645|DEVICE|AR rehabilitation app|The intervention will consist of an 8-week home rehabilitation program during which the participant will have 1) a total of 7 weekly remote video visits with a therapist and 2) daily at-home exercises using the AR headset with rehabilitation app, done independently.
223503931|NCT06119412|OTHER|blood pressure measurement starting with standard technique or alternative new technique. manual sphygmomanometer will be used.|Each participant will have their blood pressure measured with two different techniques.
223503932|NCT06964373|DEVICE|Cervical Ripening Balloon|30 milliliter Foley balloon
223503933|NCT06964373|DEVICE|Osmotic Dilators|Dilapan-S
223503934|NCT06963762|BEHAVIORAL|Conventional rehabilitation will be applied|Conventional rehabilitation will be applied for 30 minutes, 4 times a week for 4 weeks.
223503935|NCT06963762|BEHAVIORAL|Mirror therapy will be applied along with conventional rehabilitation|In addition to conventional rehabilitation, patients in the experimental group will receive mirror therapy for 30 minutes, 4 times a week for 4 weeks.
223503936|NCT06964529|BIOLOGICAL|Concentrated PRF|Injectable platelet-rich fibrin was prepared using low-speed centrifugation and injected using the same protocol as C-PRF (1 surgical + 3 injection sessions at 10-day intervals).
223503937|NCT06964529|BIOLOGICAL|Injectable PRF|Injectable platelet-rich fibrin was prepared using low-speed centrifugation and injected using the same protocol as C-PRF (1 surgical + 3 injection sessions at 10-day intervals).
223503938|NCT06963424|PROCEDURE|Erector Spinae Plane Block|lumbar erectro spinae block
223503939|NCT06964204|BEHAVIORAL|Kangaroo Care|"Kangaroo care practice will be carried out in 3 stages: preparation, implementation and recording stage. Vital signs of the baby such as body temperature, heart rate, respiratory rate will be evaluated and necessary materials such as hats and covers will be prepared. In the implementation phase; the general condition of the baby will be checked, clothing and position will be adjusted, and then the baby will be transferred to the mother. After the baby is placed, his/her back will be covered with a blanket and the mother will be asked to support the baby's back with one hand and the hips with the other. When 60 minutes are completed, kangaroo care will be terminated. After the baby is placed, vital signs and general condition will be evaluated and all nursing observations will be recorded. For the babies in the other group, their mothers will sing lullabies along with kangaroo care and inclusion in the groups will be done by randomization."
223503940|NCT06964204|BEHAVIORAL|Kangaroo Care+lullabies|For the babies in the other group, their mothers will sing lullabies along with kangaroo care and inclusion in the groups will be done by randomization.
223503941|NCT06964321|PROCEDURE|intercostal tube drainage|intercostal tube drainage in managing massive malignant pleural effusion (MPE).
223503942|NCT06964321|PROCEDURE|big tail catheter drainage|big tail catheter drainage in managing massive malignant pleural effusion (MPE).
223503943|NCT06964321|PROCEDURE|ultrasound-guided aspiration|ultrasound-guided aspiration in managing massive malignant pleural effusion (MPE).
224194841|NCT06652061|DIAGNOSTIC_TEST|Dual Energy X-Ray Absorptiometry Scan (DEXA Scan)|"A DEXA scan, or Dual-Energy X-ray Absorptiometry, is a specialized imaging technique used to measure Bone Mineral Density (BMD). It is commonly employed to diagnose osteoporosis and assess the risk of fractures, especially in areas prone to bone density loss, such as the spine, hip, and forearm. The scan works by using two low-energy X-ray beams that pass through the bone, allowing it to differentiate between bone and soft tissue and calculate the bone's density. DEXA is considered the gold standard for osteoporosis diagnosis due to its high accuracy and precision.~The DEXA scan is a non-invasive, out-patient and painless procedure. Patients lie on an examination table while the scanner passes over the targeted area, typically the hip and spine. The entire procedure is straightforward, taking around 10 to 30 minutes depending on the areas being scanned."
224310434|NCT06205329|DRUG|WPV01 Dose 1-4|WPV01 Dose 1-4 or Placebo on day 1
224310435|NCT06205329|DRUG|WPV01 Dose 5-8 and Ritonavir|WPV01 Dose 5-8 and Ritonavir or Placebo on day 1
224310436|NCT06205329|DRUG|WPV01 Dose 9-12|WPV01 Dose 9-12 or Placebo from day 1 to day 6
224310437|NCT06205329|DRUG|WPV01 Dose 13-15 and Ritonavir|WPV01 Dose 13-15 and Ritonavir or Placebo from day 1 to day 6
224310438|NCT06205329|DRUG|WPV01 Dose 16|Cohort 1:WPV01 Dose 16 or Placebo (with high fat meal) Cohort 2:WPV01 Dose 16 or Placebo (fasted)
223503944|NCT04274465|DIAGNOSTIC_TEST|digital PCR (dPCR) assay|It is a highly sensitive and specific droplet digital PCR assay for absolute quantification of circulating tumor HPV DNA for the most prevalent HPV types that will determine if a woman has cHPVDNA
223503945|NCT06964152|DIAGNOSTIC_TEST|Computational electrocardiography and cardiac computed tomography mapping|Use of non-invasive computational ECG and cardiac CT models to localize arrhythmia origins
223503946|NCT06963970|OTHER|Remote Community Health Worker support|trained/certified community health worker supporting care partner remotely
223503947|NCT05064670|BEHAVIORAL|Exercise|A twice weekly, 3-month supervised exercise program of whole body resistance training using body weight and a resistance band, and moderate to high intensity aerobic activities, consisting of a consecutive series of timed exercises performed one after the other (14-18 on the Borg scale). Classes are conducted live in groups through Microsoft Teams. Participants will not receive any contact or exercise support in the 3-month follow-up period following the initial 3-month intervention
223503948|NCT06322862|OTHER|Indocyanine green|Intraoperative perfusion assessment with ICG Fluorescence Angiography (ICG-FA) in standard approved doses
223503949|NCT01658878|BIOLOGICAL|Nivolumab|
223503950|NCT01658878|DRUG|Sorafenib|
223503951|NCT01658878|DRUG|Ipilimumab|
223503952|NCT01658878|DRUG|Cabozantinib|
223503953|NCT01562691|PROCEDURE|Nasopore|Bilateral nasal packing using Nasopore without airway integrated
223592846|NCT04566406|PROCEDURE|Laparoscopic adrenalectomy|Preoperative staging in all cases consisted of computed tomography or/and magnetic resonance imaging. Prior to surgery, a routine panel of laboratory tests was carried out. The catecholamines metabolites (metanephrine, normetanephrine, and methoxytyramine) were measured from 24-hour urine collection. All patients were preoperatively treated with phenoxybenzamine or alternative doxazosin.Additionally, beta-blockers in case of coexisting tachycardia were given. In the morning of the operation, preinduction blood pressure was measured. Pneumoperitoneum was achieved by insufflating CO2 gas to an intraperitoneal pressure of 12 mmHg. The operative method in our department was laparoscopic transperitoneal lateral total adrenalectomy. Intraoperatively SBP and diastolic blood pressure (DBP) were measured and recorded every 10 minutes. To treat hypertensive and hypotensive episodes, intravenous doses of urapidil, ephedrine, nitrates, MgSO4, norepinephrine, or ß-blockers were administered.
224310439|NCT04473521|DEVICE|Investigational denture adhesive cream|The denture adhesive application will be controlled by weight (1.00g +/-0.05g) applied to the maxillary denture only.
224310440|NCT04473521|DEVICE|Super Poligrip Free|The denture adhesive application will be controlled by weight (1.00g +/- 0.05g) applied to the maxillary denture only.
224310441|NCT01664221|DRUG|Epoetin Alfa|Intravenous administration of the drug, test or comparator, for 4 weeks, 3 times a week (monday, wednesday and friday).
223503954|NCT01562691|PROCEDURE|airway integrated Nasopore|post nasoseptoplasty with nasal packing using airway integrated Nasopore
223503955|NCT01562691|PROCEDURE|airway-integrated Vaseline gauze|post nasal septoplasty with packing using airway-integrated Vaseline gauze
223503956|NCT04901052|DIETARY_SUPPLEMENT|n-3 supplementation group|n-3 supplementation group (1.5g of omega 3)
223503957|NCT04901052|DIETARY_SUPPLEMENT|Placebo group|Placebo group (sunflower oil)
223503958|NCT05348694|DIETARY_SUPPLEMENT|Pendulum WBF-038|"All bacteria contained in Pendulum WBF-038 are commensal organisms that have been repeatedly documented to inhabit the human gastrointestinal tract under normal circumstances. Pendulum's WBF-038 is a proprietary formulation of the following strains: Akkermansia muciniphila, Clostridium butyricum, Clostridium beijerinckii, Anaerobutyricum hallii, Bifidobacterium infantis, plus chicory inulin and magnesium stearate. The organisms were grown under controlled conditions consistent with Good Manufacturing Practices (GMP) and employ no animal-derived products. All ingredients utilized during manufacturing were food grade and qualified as generally recognized as safe (GRAS).~The product is provided as acid-resistant capsules in bottles that are to be stored refrigerated at 4℃."
223503959|NCT05348694|DIETARY_SUPPLEMENT|Pendulum Placebo|Pendulum placebo capsules containing magnesium stearate
223503960|NCT05291481|BEHAVIORAL|CAPAS-yOUTH|11-week parent training intervention exclusively delivered to parents
223503961|NCT05691439|BEHAVIORAL|Sleep extension and advance|"Participants in the sleep extension and advance condition will maintain a stable sleep schedule that extends sleep duration and advances bedtime by 90 min relative to weekday bedtime. This chronotherapeutic manipulation will include blocking phase-delaying light in the evening using goggles with orange lenses (blue blockers) beginning 2 h prior to bedtime, and 30 min of 506 lux blue-green light exposure in the morning beginning at rise time using bright light goggles (ReTimer Pty Ltd., Australia). Schedule and chronotherapy adherence will be reinforced using motivational techniques (e.g., securing motivation, preplanning, problem-solving), requiring participants to text the study coordinator and complete morning assessments at rise time, and monetary incentives."
224310442|NCT04461366|DEVICE|Monopolar radiofrequency|The RF electrode was moved randomly for 30 seconds over each scar. The total duration of the treatment session is only 5 minutes for each cheek. It takes 15 minutes if the forehead and 2 cheeks are affected.
223503962|NCT05691439|BEHAVIORAL|Regular sleep duration and timing|Participants in the regular sleep duration and timing condition will keep a stable sleep schedule that matches their typical weekday sleep opportunity and timing. Schedule adherence will be reinforced using motivational techniques (e.g., securing motivation, preplanning, problem-solving), requiring participants to text the study coordinator and complete morning assessments at rise time, and monetary incentives.
223503963|NCT04060745|OTHER|cooling using a water-perfused vest|"BAT is activated by cold exposure. Each participant will have a shivering threshold test performed before entering the cooling arm. Participants will be gradually cooled (decreasing the temperature in the cooling vest by 0.6C every 15 min. until 3.8C) using a perfused cooling vest until they start to shiver. The temperature in which they start to shiver will be noted. If shivering has not occurred at 3.8C after 15 min. they will stay at the temperature for 45 min. in total or until shivering occurs. Shivering is defined by subjective perception of shivering by the participant in a numeric scale (NRS) where 0 refers to I'm not shivering and 10 refers to I'm shivering a lot and visual inspection by the investigator. The temperature used in the cooling arm will be set a few degrees above the shivering threshold test or at 3.8C if shivering did not occur.~During cooling indirect calorimetry and OGTT will be performed and finally the DMI scan will be performed"
223503964|NCT04060745|OTHER|thermoneutrality|In the thermoneutrality arm participants will rest in thermoneutrality (22C) for one hour. Before the DMI scan indirect calorimetry will be performed
224194842|NCT06652061|DIAGNOSTIC_TEST|X-Ray (Hip and Spine)|Hip and spine X-rays are specific types of radiographic imaging used primarily to evaluate bone health, joint integrity, and alignment in these crucial areas. In the context of osteoporosis assessment, hip and spine X-rays can reveal signs of bone thinning or fractures, serving as an initial screening tool before more detailed imaging like a DEXA scan. During a hip X-ray, the patient typically lies on an examination table with the hip positioned for a clear view of the pelvis and femur. In a spine X-ray, the patient's posture may vary, often lying on the table in either a supine or lateral position to capture views of the vertebrae in the lower back (lumbar spine). Patients may be asked to remain very still, or even hold their breath momentarily, to prevent motion blur, which can obscure important details. Both hip and spine X-rays are quick and painless, generally taking only a few minutes, with the X-ray exposure itself lasting less than a second.
224194843|NCT04675489|OTHER|Procedure: Vivity Toric IOL|The U.S. Food and Drug Administration (FDA) has granted approval of Alcon's Vivity Toric Extended Vision intraocular lens (IOL) for cataract patients. This innovative lens is an extended depth of focus IOL that has been reported to result in fewer visual disturbances than diffractive IOLs.
224194844|NCT01502267|DRUG|High dose IVIG and B cell depleting agents|"1. IVIG(2g/kg two times on day 1, 30)~2. Rituximab(375mg/m2 on day 3)~3. Bortezomib(1.3mg/m2 four times on day 31, 34, 38, 41)"
224194845|NCT00583427|DRUG|Sulodexide|200 mg per day in an oral gelcap form
224194846|NCT01038076|BEHAVIORAL|MedCHEC Tablet Computer & Adherence Care|Patients answer questions about their medication, medication-taking behavior and risks for non-adherence on the MedCHEC tablet touch-screen computer, which generates patient and provider reports. Patients may be referred to an Adherence Care Manager on the basis of the reports.
224194847|NCT03226782|OTHER|Short intervention protocol|Will be offered an instructional material that will consist of a routine of 12 exercises to be performed autonomously for range of motion and muscular fitness, using the environmental resources of the home. It will be suggested a daily frequency in the execution of this exercise routine. Also, stimuli and guidelines will be given for the practice of active movement (walking) so that they accumulate at least 10 to 20 minutes of this activity daily. All control and training guidelines for using the manual will be offered through an introductory lecture and subsequent weekly telephone contacts (twice a week). Participants should complete their respective program for a total period of 12 weeks and mark in the manual how often they performed the exercises.
224194848|NCT03226782|OTHER|Long intervention protocol|This Manual guides its implementation in a progressive way and at the end it totals about 30 to 45 min of physical exercises per day. All control and training guidelines for use of the manual will be offered through an introductory lecture and subsequent weekly telephone contacts (twice a week). Participants should complete their respective program for a total period of 12 weeks and mark in the manual how often they performed the exercises. Therefore, it guides the implementation of daily walks with cumulative effect.
223503965|NCT04310228|DRUG|Favipiravir Combined With Tocilizumab|"Favipiravir: On the 1st day, 1600mg each time, twice a day; from the 2nd to the 7th day, 600mg each time, twice a day. Oral administration, the maximum number of days taken is not more than 7 days.~Tocilizumab:The first dose is 4 \~ 8mg/kg and the recommended dose is 400mg. For fever patients, an additional application (the same dose as before) is given if there is still fever within 24 hours after the first dose and the interval between two medications ≥ 12 hours.Intravenous infusion, The maximum of cumulative number is two, and the maximum single dose does not exceed 800mg."
223503966|NCT04310228|DRUG|Favipiravir|On the 1st day, 1600mg each time, twice a day; from the 2nd to the 7th day, 600mg each time, twice a day. Oral administration, the maximum number of days taken is not more than 7 days.
223503967|NCT04310228|DRUG|Tocilizumab|The first dose is 4 \~ 8mg/kg and the recommended dose is 400mg. For fever patients, an additional application (the same dose as before) is given if there is still fever within 24 hours after the first dose and the interval between two medications ≥ 12 hours.Intravenous infusion, The maximum of cumulative number is two, and the maximum single dose does not exceed 800mg.
223592847|NCT05314959|OTHER|Physician Awareness|The patients' pre-visit Control Preference Scale responses are shared with their physician.
223592848|NCT05314959|OTHER|Usual Care|The patients' pre-visit Control Preference Scale responses are not shared with their physician.
223503968|NCT00382070|DRUG|Letrozole|Letrozole 2.5 mg taken orally once daily for 5 years
223503969|NCT00382070|OTHER|Placebo|Placebo tablet taken orally once daily for 5 years
223503970|NCT06114550|OTHER|High intensity resistance training|The HIRT protocol comprised five exercises (bench press, barbell back squat, deadlift, seated leg flexion, and reverse arm curl) at 80% of 1RM, and 4-5 sets of 12 repetitions with 1-2 minutes of rest period between sets for approximately 60 minutes.
223592849|NCT04903366|DRUG|Timolol Maleate|timolol maleate 0.5% gel-forming solution
223592850|NCT01147848|DRUG|Fluticasone furoate/Vilanterol Inhalation Powder|Fluticasone furoate/Vilanterol Inhalation Powder inhaled orally once daily for 24 weeks
224194849|NCT03382691|DEVICE|blood pressure check|Check blood pressure using new device and conventional device alternatively. Compare blood pressure measured with new device and conventional device.
224194850|NCT03309072|DEVICE|tDCS|active tDCS
224194851|NCT03309072|DEVICE|sham tDCS|sham tDCS
224194852|NCT04143568|OTHER|Observation|Evaluation of endothelial progenitor cells level and correlation of endothelial progenitor cells level with periodontal and cardiovascular disease
224194853|NCT03861689|DIAGNOSTIC_TEST|MRI pelvis|MRI pelvis monitoring every 6 months; FiLAC to treat fistula tract within 24 months if the anatomy of the fistula is favourable
224194854|NCT03047889|DRUG|standard therapy|standard therapy for advanced/metastatic breast cancer
224194855|NCT00018343|DRUG|estrogen|
224194856|NCT04114474|DIAGNOSTIC_TEST|TRANSTHORACIC ECHOCARDIOGRAPY|TTE (Vivid I echocardiography machine General Electric Healthcare, Milwaukee, WI, USA) with a 3S-RS (1.5-3.6 MHz) transthoracic probe). was done by professional anesthesiologist following the :Hemodynamic Echocardiography Assessment in Real Time ( HEART) protocol. According to the clinical findings of TTE patients may be either free or have one or more of the following haemodynamic states normal, empty, vasodilated ,left ventricular systolic or diastolic failure, left ventricular systolic and diastolic failure, and right ventricular failure, valve stenosis or regurgitation of at least moderate severity
224194857|NCT03459066|DIAGNOSTIC_TEST|Institution-Group|"The study includes three measurement times:~* Time 1 (T1): corresponds to the first measurement, which will take place between the 3rd and 10th day of hospitalization.~* Time 2 (T2): corresponds to the second measurement, which will be carried out 3 months after the first measurement.~* Time 3 (T3): corresponds to the third measurement, which will be carried out 12 months after the first measurement.~The evaluations will be tone, functionality and quality of life."
224194858|NCT02837666|DIETARY_SUPPLEMENT|Supplementation with Spirulina maxima|Supplementation with Spirulina maxima (4.5 g/d) in capsules during 6 weeks.
224194859|NCT02837666|OTHER|Washout|2 weeks washout period to each study subject to avoid any possible carryover effect.
224194860|NCT02837666|OTHER|Supplementation with placebo|Supplementation with placebo (4.5 g/d) in capsules during 6 weeks.
224194861|NCT02837666|OTHER|Isoenergetic diet|All participants will have a personal isoenergetic diet according to their height, weight, body composition and daily physical activity during 14 weeks
224194862|NCT02837666|OTHER|Exercise program|Participants are going to exercise five days a week with the following protocol: Between 5 and 10 min of heating exercise, Between 20-30 min anaerobic exercise and 20-30 min of aerobic exercise (cardiovascular exercise): walking, jogging, running and/or cycling, Three days a week aerobic intensities will be between 60% and 80% and two days between 70% and 90% of the maximum heart rate reserve, and five final minutes of stretching.
224194863|NCT02484131|BEHAVIORAL|Educational materials/mail|Participants in this group will receive any educational materials by mail during hte follow-up period.
224310443|NCT04461366|DEVICE|Pulsed dye laser|PDL was applied for the affected areas with no pre-treatment regimens or topical anaesthetics. There was no requirement for skin cooling.
224194864|NCT02484131|BEHAVIORAL|Educational materials/participant choice|Participants in this group will not receive any educational materials by participant choice during hte follow-up period.
224194865|NCT00632138|BEHAVIORAL|exercise intervention|
224310444|NCT02365259|DEVICE|Phototherapy|Participants will be exposed to phototherapy according to the 2014 Guidelines issued by the American Academy of Dermatology 3 days per week over an 8-week period.
223503971|NCT06114550|OTHER|Low intensity resistance training|For LIRT protocol, which performed same training exercises as HIRT. The repetitions in the LIRT protocol were assessed using the following equation: 80% of 1RM lifting load (kg) ×repetitions (HIRT)/40% of 1RM to volition fatigue, with 1-2 minutes of rest period between sets. Therefore, the LIRT protocol completed 4-5 sets of 24 repetitions at 40% of 1RM for a total of 60 minutes.
223503972|NCT04947267|DRUG|3% Mepivacaine Hydrochloride|1.8 ml of 3% mepivacaine (3% Scandonest, Septodont) was administered to Group B patients. Inferior alveolar nerve block was administered to both the groups. Rubber dam was then placed in the desired quadrant. Selected carious mandibular was restored and seven pulpal oxygen saturation spot readings were taken for an hour.
223592851|NCT01147848|DRUG|Fluticasone propionate/salmeterol Inhalation Powder|Fluticasone propionate/salmeterol Inhalation Powder inhaled orally twice daily for 24 weeks
224194866|NCT00632138|OTHER|questionnaire administration|
224194867|NCT00632138|PROCEDURE|biofeedback|
224194868|NCT00632138|PROCEDURE|management of therapy complications|
224194869|NCT00632138|PROCEDURE|psychosocial assessment and care|
224194870|NCT00632138|PROCEDURE|quality-of-life assessment|
224194871|NCT00622622|BIOLOGICAL|VEGFR2-169 and gemcitabine|Escalating doses of VEGFR2-169 will be administered by subcutaneous injection on days 1,8,15 and 22 of each 28-day treatment cycles(doses of 0.5,1.0,2.0mg/body are planned). Gemcitabine will be administered intravenously at a fixed dose of 1000mg/m2 on days 1,8 and 15. Repeated cycles of VEGFR2-169 and gemcitabine will be administered until patients develop progressive disease or unacceptable toxicity,or for maximum 2 cycles, whichever occurs first.
224194872|NCT03269565|BIOLOGICAL|BCD-100|Anti-PD-1 monoclonal antibody
224310445|NCT02121275|DEVICE|Ultrasound of the lungs|Ultrasound examination of the lungs
224310446|NCT02121275|DEVICE|Electric impedance tomography|Electric impedance tomography (EIT) is a noninvasive tool based on the measurement of electrical impedance changes within the thorax and lung tissue during ventilation and depicts the regional changes in ventilation in real time. To use electric impedance tomography 16 electrodes are applied in a circular fashion around the patient's chest, typically at the level of the 7th intercostal space.
224310447|NCT03786133|DIAGNOSTIC_TEST|Analysis of microbiological tests|Collection and comparison of microbiological data
224310448|NCT02610387|DEVICE|Transcranial direct current stimulation (tDCS)|Participants underwent tDCS(2mA) brain stimulation for 20 minutes plus balance training for 20 minutes for 5 consecutive days.
224310449|NCT02610387|DEVICE|Sham tDCS|During sham stimulation, the current ramped up for 30 seconds, ramped back down for 30 seconds, and then remained off for the duration of the stimulation plus balance training for 20 minutes for 5 consecutive days.
224310450|NCT00500175|DEVICE|TempTouchRM|
224310451|NCT00500175|DEVICE|Offloading|
224310452|NCT04128475|OTHER|N/A - observational study.|N/A - observational study.
224310453|NCT03457649|BIOLOGICAL|ARGX-113|
224194873|NCT04301401|OTHER|Vaginal swabs|On the day of the surgical intervention, vaginal swabs will be taken at various stages of surgery: before vaginal disinfection/draping, directly after disinfection/draping, 1 hour after disinfection, 6 weeks after surgery and 12 months after surgery.
224194874|NCT04301401|OTHER|Stool samples|Stool samples will also be taken (and collected in a pot devoted to coproculture with an airtight opaque bag given to the patient) at the inclusion visit on the day before surgery and also 6 weeks after surgery (in a second pot with an airtight opaque bag given to the patient at the time of being discharged).
224194875|NCT04301401|OTHER|Urine samples|Urine samples will also be taken before surgery and 6 weeks after surgery.
223503973|NCT04947267|DRUG|2% Mepivacaine with 1:100,000 epinephrine|1.8 ml of 2% mepivacaine with 1:100,000 epinephrine (2% Scandonest Special, Septodont) was administered to Group A patients. Inferior alveolar nerve block was administered to both the groups. Rubber dam was then placed in the desired quadrant. Selected carious mandibular was restored and seven pulpal oxygen saturation spot readings were taken for an hour.
223503974|NCT05465876|BIOLOGICAL|EVUSHELD|EVUSHELD is a combination of 2 monoclonal antibodies (mAbs), Tixagevimab and Cilgavimab. The single dose, is to be administered intramuscular, each mAb sequentially into the deltoid
223503975|NCT04908527|BEHAVIORAL|Walking to OR|Patients, after being prepared for the OR, walk to the operating room
223503976|NCT00358800|DEVICE|REMStar Auto with C-Flex|
223503977|NCT03382171|OTHER|FoodforCare at home|Five small protein rich meals that will be delivered twice a week for 3 weeks.
223503978|NCT04557345|DIAGNOSTIC_TEST|Determination of cytokines|Subsequently, a blood sample will be taken from which the processing will be as follows: 6 ml of peripheral blood will be taken in tubes with a yellow cap and inert gel and clot retractor, immediately afterward it will be placed on ice, it will be transported to the laboratory where it will be centrifuged at 2500 rpm for 15 minutes at 4 degrees centigrade, immediately afterward 500 µl of serum will be aliquoted and stored at minus 75 ° C until later analysis. The general methodology for sandwich ELISA will be used.
223503979|NCT04557345|DIAGNOSTIC_TEST|Two-dimensional transthoracic echocardiogram|With prior informed consent, a two-dimensional transthoracic echocardiogram will be obtained by an echocardiographer certified by the Mexican Council of Cardiology (CMC) with a Phillips EPIC 7 echocardiography, 2D Arrary 3D Convex (1-6 Mhz) transducer.
223503980|NCT02465047|OTHER|Self-help booklet|See Arm/Group Description
223503981|NCT01533220|DRUG|naphazoline hydrocloride|02 drops into each nostril, 04 times a day for 03 days
223503982|NCT01533220|DRUG|Naphazoline hydrocloride + Pheniramine Maleate + Panthenol|02 drops into each nostril each 12 hours for 03 days
223503983|NCT05431790|DEVICE|Absorbable interface screws manufactured by Natong Biotechnology|Anterior cruciate ligament reconstruction uses absorbable interface screws manufactured by Natong Biotechnology.
223503984|NCT05431790|DEVICE|Absorbable interface screws manufactured by INION.|Reconstruction of anterior cruciate ligament using Inion Oy absorbable interface scews from INION, Finland
223503985|NCT00284934|DRUG|Enteric-coated mycophenolate sodium (EC-MPS)|
223503986|NCT00284934|DRUG|Tacrolimus|
224194876|NCT05423639|DEVICE|palodent|innovative sectional matrix system with Nickel-Titanium rings, anatomically shaped matrix bands and adaptive self-guiding wedges that provides predictable, tight contacts and restorations that accurately replicate the natural tooth anatomy.
224194877|NCT05423639|DEVICE|optracontact|The instrument is used to achieve large and tight proximal contacts in posterior teeth.
224194878|NCT00968539|BIOLOGICAL|GSK investigational vaccine GSK2340272A|Two intramuscular injections
224194879|NCT00968539|BIOLOGICAL|GSK investigational vaccine GSK2340269A|Two intramuscular injections
224194880|NCT00219024|DRUG|aliskiren|
223503987|NCT00284934|DRUG|Corticosteroids|At a dose of at least 5 mg/day.
223503988|NCT06024161|OTHER|Weight gain|≥5% weight gain
223503989|NCT06024161|OTHER|Weight loss|≥5% weight loss after arthroplasty
223503990|NCT06024161|OTHER|Weight unchanged|\<5% weight change after arthroplasty
223503991|NCT00358579|DRUG|Adrenaline|1 mg
223503992|NCT00358579|DRUG|Vasopressin|40 IU
223503993|NCT03309605|DRUG|ELX-02|ELX-02 is a synthetic, designer eukaryotic ribosomal specific glycoside (ERSG) optimized as a translational read-through drug
223503994|NCT03309605|DRUG|Placebo|Placebo
223503995|NCT04981561|DRUG|GATE-251|Single dose of GATE-251
223503996|NCT04981561|DRUG|Placebo|Placebo
223503997|NCT05328895|OTHER|Transcutaneous Auricular Vagus Nerve Stimulation with Betahistine|"Transcutaneous Auricular Vagus Nerve Stimulation (taVNS) on the left ear was selected and stimulated with electronic acupuncture apparatus (Hwato, SDZ-IIB), with continuous wave, 25 Hz in frequency, 4 to 8 mA in intensity depending on patient's tolerance. The first 3 treatments were conducted in hospital, during which, the patients were trained to use the apparatus under the instruction of research staff. Afterwards, the rest treatments were exerted at home, twice a day, after every breakfast and dinner respectively, 30 min each time. The treatment was given from Monday to Friday a week, totally for 12 weeks.~Participants received betahistine mesylate tablet (Merislon, Eisai Co., Ltd., China) with the treatment of 6 mg 3 times a day."
223592852|NCT01147848|DRUG|Placebo (1)|Inhalation powder inhaled orally once daily for 24 weeks
223592853|NCT01147848|DRUG|Placebo (2)|Inhalation powder inhaled orally twice daily for 24 weeks
223592854|NCT00685737|DRUG|1-MNA|Capsule
223592855|NCT00685737|DRUG|Placebo|Capsule
223592856|NCT02886559|DRUG|Chidamide plus DCAG regimen|chidamide, decitabine, aclarubicin, cytarabine and G-CSF
223592857|NCT04538079|DEVICE|Multimodal objective non-invasive Monitoring|Multimodal objective non-invasive monitoring including cerebral oxygenation (NIRS), pulse oximetry with Pulsatility Index (PI) and non-invasive Cardiac Output Monitoring will be recorded but not used for clinical decision making. 2 ECHOs will be performed (one within the first 24h, one in the 2nd 24 hours after birth)
223592858|NCT05231707|BEHAVIORAL|A couples-focused intervention for HIV prevention and care in South Africa|From a sample of 272 male-female couples (544 individuals, 272 men and 272 women) recruited from rural KaZulu-Natal, South Africa, couples will be randomized to receive either individual a package of dyadic counseling and testing (intervention arm) or an attention matched control.
224194881|NCT04130555|DEVICE|CELLIS Rectopexy (Porcine Acellular Dermal Matrix, PADM)|Biological membrane used in Laparoscopic Ventral Rectopexy (LVR) or robotic assisted rectopexy
224310454|NCT03457649|BIOLOGICAL|Placebo|
223592859|NCT01909765|OTHER|Dorsal slit|Skin and mucosa incision made together
223592860|NCT01909765|OTHER|Double incision|Skin and mucosa incision made separately
223592861|NCT04279665|DEVICE|Virtual Reality (VR)|20 minutes of wearing a virtual reality headset with a choice of 4 environments based on their preference and another 20 minutes with a less immersive condition
223592862|NCT01181258|DRUG|Rituximab|375 mg/m\^2 administered intravenously (IV) weekly \* 4, (day -7, -1, +6, +13) pre-infusion with natural killer cells (NK)
223592863|NCT01181258|BIOLOGICAL|Interleukin-2|subcutaneously administered 9 million international units (IU) every other day \* 6 doses over 2 weeks begin 1 to 24 hours after NK cell infusion. If weight \< 45 kilograms, give IL-2 at 5 million units/m2 on same schedule.
223592864|NCT01181258|BIOLOGICAL|Natural killer cells|administered intravenously 1.5 to 8 \* 10\^7 cells/kg on Day 0 (day of NK cell infusion)
223592865|NCT01181258|DRUG|Cyclophosphamide|60 mg/kg administered intravenously (IV) for 2 hours on day -5 after Fludarabine.
223592866|NCT01181258|DRUG|Methylprednisolone|1 mg/kg on Days -2 through +9 as an intravenous (IV) infusion.
223592867|NCT01181258|DRUG|Fludarabine|25 mg/m\^2/day administered as a 1 hour IV infusion once a day for 5 doses (day -6 through day -2).
224194882|NCT03192917|PROCEDURE|Low intensity extracorporeal shock wave treatment (LI-ESWT)|Shock wave treatment with 3000 Hz for 10 min on the penile shaft. This will be done one time a week for five weeks.
224194883|NCT03192917|PROCEDURE|Low intensity extracorporeal shock wave treatment (LI-ESWT) sham|A specialized cap can be applied to the chock wave device, which disallow shock waves to transmit through the unit.
224194884|NCT00326118|BIOLOGICAL|Haemophilus influenzae type b and meningococcal serogroup C (vaccine)|One intramuscular dose at 12-18 months of age
224194885|NCT00326118|BIOLOGICAL|Priorix™|One subcutaneous dose at 12-18 months of age
224194886|NCT00326118|BIOLOGICAL|Hiberix™|One intramuscular dose at 12-18 months of age.
224194887|NCT00326118|BIOLOGICAL|Meningitec™|One intramuscular dose at 12-18 months of age
224194888|NCT05846503|BEHAVIORAL|1. Quality and info management system|"1. The intervention package prioritizes information and quality management with a focus on HTN screening, diagnosis, and treatment. From the point-of-care, flow charts placed in the patient file will ensure that vitals are performed in accordance with national guidelines.~2. The care coordinator will present data to clinic staff in multi-disciplinary meetings, providing an opportunity for programmatic feedback and discussion.~3. Patients will be encouraged to complete the vital signs measurements at each clinic visit. They will be provided with their BP readings and given info about what their reading means. They will be issued with pocket sized color coded booklets providing info on the measurement and what to do to control their BP.~4. Task shifting: A care coordinator will be the champion of the intervention package for the clinic.~5. All staff will receive apt training on how to use the patient flow chart, info management system and how to respond to abnormal BP values."
224194889|NCT05636475|OTHER|Manual hand massage after laparoscopic cholecystectomy surgery|Manual hand massage is applied to a group of patients at 0, 4 and 8 hours after the patient returns from laparoscopic cholecystectomy surgery. It is applied to each hand for ten minutes.
224194890|NCT05636475|OTHER|Machine-based hand massage after laparoscopic cholecystectomy surgery|Machine-based hand massage is applied to a group of patients at 0, 4 and 8 hours after the patient returns from laparoscopic cholecystectomy surgery. It is applied to each hand for ten minutes.
224194891|NCT04185259|OTHER|Acupuncture|The investigators will apply two Ashi points (the two most severe tender points in the most sensitive area over the anteromedial aspect of the heels), Chengshan (BL57), Taixi (KI3) and Kunlun (BL60) in this trial. With the patient in a prone position, the local skin will be routinely sterilized followed by a 10mm diameter and 5mm thick sterile adhesive pad pasting onto each selected acupoint. Ashi points will be perpendicularly inserted through the pad to the plantar fascia layer with a depth of approximately 15-20mm depending on the location. BL57, KI3 and BL60 will be punched perpendicularly 10-15mm deep into the skin through the pad. All needles except Ashi points will be manually stimulated by small, equal manipulations of lifting, thrusting, twirling and rotating to achieve De qi. Needles will be retained for 30 minutes per treatment. During each treatment, every needle will be manipulated three times every 10 minutes.
223503998|NCT04644757|OTHER|Music Listening|The study will employ an individual receptive relaxation music method with participants selecting music based on their preference from a selection of various styles from the MUSIC CARE© app. The music intervention will last 20 minutes per session and will be administered twice daily for 4 consecutive days. Participants will be given an electronic tablet with the MUSIC CARE© app loaded on it and trained on how to access the app to select their preferred style of music.Participants will be instructed to use the provided headphone during all interventions and to sit in a quiet area while wearing an ocular mask to avoid distractions.The PI will remotely monitor each of the music intervention sessions in real-time monitoring via a secured video conferencing interface to ensure adherence to study protocol.
223503999|NCT03197935|DRUG|Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody|Atezolizumab was administered as per schedule described in respective arm.
223504000|NCT03197935|DRUG|Placebo|Placebo matched to atezolizumab was administered as per schedule described in respective arm.
223592868|NCT00642317|BEHAVIORAL|Questionnaire|Questionnaire about tobacco and alcohol use, acculturation, and other related topics.
223592869|NCT01179165|OTHER|Diagnostic|Diagnostic non-invasive tests:Dopplerechocardiography, cardiac MRI
223504001|NCT03197935|DRUG|Nab-paclitaxel|Nab-paclitaxel was administered as per schedule described in the arms.
223504002|NCT03197935|DRUG|Doxorubicin|Doxorubicin was administered as per schedule described in the arms.
223592870|NCT06515262|BIOLOGICAL|Anti-BCMA-GPRC5D CAR-T cells infusion|Subiects who meet the enrollment conditions will receive intravenous infusion of anti-BCMA-GPRC5D CAR-T Cells after lymphodepleting therapy.
223592871|NCT01626417|DEVICE|Tibion Bionic Leg|The device is a lightweight, wearable, portable, battery-powered, robotic leg orthosis that provides active assistance and resistance to lower limb movement according to the patient's intent to move.
223592872|NCT02540265|DRUG|N1539|
223592873|NCT02540265|DRUG|Intravenous Placebo|
223592874|NCT04132674|DRUG|Bictegravir/emtricitabine/tenofovir alafenamide|Taking one oral tablet of B/F/TAF once-daily for 72 weeks
223592875|NCT00945230|PROCEDURE|Re-section of a large left anterior cranial fossa meningioma|Neurosurgical re-section of an incidental large left anterior cranial fossa meningioma
224194892|NCT04185259|OTHER|Sham acupuncture|Sham Ashi (0.5 cun away from Ashi, one 'cun' is equivalent to the greatest width of the individual patients' thumb, \~1.5 cm), sham BL57 (0.5 cun lateral to true BL57 horizontally), sham KI3 (midway between true KI3 and heel tendon) and sham BL60 (midway between true BL60 and heel tendon) will be used. Treatment protocol will be similar to that of the acupuncture group. The Hwato-brand disposable blunt-tipped needles (size 0.30 × 25 mm) will be inserted at sham points through adhesive pads to the skin without skin penetration. The needles will then be lifted, thrusted, twirled, and rotated evenly three times every ten minutes. No specific de qi response will be elicited.
224194893|NCT06257459|PROCEDURE|subinguinal varicocelectomy|exision or preservation of spermatic cord lipoma during subinguinal varicocelectomy
224194894|NCT05489952|DRUG|iron sucrose and ferrous lactate|The experimental group added to the intravenous iron sucrose during perioperative period according to the degree of iron deficiency. If there is still a iron deficiency or anemia at discharge, oral ferrous lactate is added after discharge.
224194895|NCT00938392|BIOLOGICAL|GSK investigational FluNG vaccine GSK2186877A, aged lot|Single dose, intramuscular injection
224194896|NCT00938392|BIOLOGICAL|GSK investigational FluNG vaccine GSK2186877A, fresh lot|Single dose, intramuscular injection
223592876|NCT00510978|BIOLOGICAL|Bifidobacterium infantis 35624|1 sachet/day for one year
223504003|NCT03197935|DRUG|Cyclophosphamide|Cyclophosphamide was administered as per schedule described in the arms.
223504004|NCT03197935|DRUG|Filgrastim|Filgrastim was administered according to local prescribing information as determined by the Investigator for 4 doses after completion of initial 12 weeks.
223504005|NCT03197935|DRUG|Pegfilgrastim|Pegfilgrastim was administered according to local prescribing information as determined by the Investigator for 4 doses after completion of initial 12 weeks.
223504006|NCT05082155|DRUG|Bupivacaine 0.25%|Bupivacaine 0.25% will be delivered as a basal infusion of 1 mL/h and an automatic intermittent bolus of 20 mL every 4 hours.
223504007|NCT05082155|DRUG|Normal Saline|Normal saline will be delivered as a basal infusion of 1 mL/h and an automatic intermittent bolus of 20 mL every 4 hours.
223504008|NCT05014230|DIETARY_SUPPLEMENT|Open Placebo|Zeebo
223504009|NCT05014230|OTHER|Opioid medication as part of standard care|Opioid medication as prescribed by prescriber. This is not impacted by being in the research study.
223504010|NCT02082483|OTHER|Selective Screening|Patients randomized to selective-use of screening tests will not routinely undergo Myocardial Perfusion Scintography or Dobutamine Stress Echocardiography. If patients develop symptoms of CAD at any time, they will undergo investigations as per the usual standard of care.
223504011|NCT04545138|OTHER|cognitive training combine treadmill training|Treadmill training includes warming up for 3 minutes, training for 25 minutes, and relaxing for 2 minutes. The speed of the treadmill during the warm-up and relaxation period is based on the participant's Borg's rating of perceived exertion (RPE) 7-9 points (very slight to very slight), and the RPE during the training period does not exceed 10\~12 points (slight), and ensures that patients can be cognitively trained at the same time. The cognitive training tasks will be projected on the screen and the participant have to answer the task orders during treadmill training simultaneously.
223504012|NCT04545138|OTHER|Treadmill training|Treadmill training includes warming up for 3 minutes, training for 25 minutes, and relaxing for 2 minutes. The speed of the treadmill during the warm-up and relaxation period is based on the participant's Borg's rating of perceived exertion (RPE) 7-9 points (very slight to very slight), and the RPE during the training period does not exceed 10\~12 points (slight).
223504013|NCT03159949|OTHER|REHIIT|REHIIT participants will come into the lab one time per training days (3 training days per week), each session lasting 10 minutes. Training sessions involve a two-minute warm-up, 3 X 20-second cycling sprints on an exercise bike with three minutes rest in between, and a one-minute cool-down.
224194897|NCT06537973|OTHER|İndividualized care education|A single session of training will be given to the mothers in the experimental group. In addition, the mother will be provided with counseling by the researcher at any time she wishes. The aim is to increase the mother-infant bonding levels and self-efficacy of the mothers, who will be supported by the care plans that will be created based on Swanson\&#39;s Theory of Care, and to adapt more easily to the role of motherhood, by evaluating them with the help of check-lists after the observations.
224310455|NCT01467206|BEHAVIORAL|Long term follow up by a coordinating physiotherapist|Monthly meetings with an coordinating physiotherapist who motivate and encourage the patient to do 60 minutes of weekly exercise and 30 minutes of daily physical activity
223504014|NCT03159949|OTHER|PR-REHIIT|"PR-REHIIT participants will come into the lab on 3 separate occasions on the training days, which occur 3 days per week (i.e., 9 sessions per week). Each session lasts 3 minutes and 20 seconds and consists of a two-minute warm-up, a 20-second all-out sprint on a cycle ergometer, and a one-minute cool-down. There will be 1-4 hours of rest in between training sessions where participants are free to leave the lab and go about their normal day."
223592877|NCT00510978|BIOLOGICAL|Lactobacillus salivarius UCC118|1 sachet per day for 1 year
223504015|NCT04058912|GENETIC|PTEN-AKT-FOXO3 Gene Expression|In the patient and patient control groups, 0.5 mm tissue strip will be removed for pathology from the cyst wall removed during surgery. and tissue samples will be stored in phosphate buffered saline at -80 C and PTEN-AKT-FOXO3 gene expression level will be evaluated by RT-PCR analysis.
223504016|NCT02357485|BIOLOGICAL|ADSC|Single injection of ADSC
223504017|NCT02797535|PROCEDURE|Endoscopy procedures|GI fluids samples will be collected from: (i) fluids suctioned during standard endoscopy procedures / pouchoscopy, (ii) from ileostomy/colostomy bags removed for bag replacement and (iii) from stool samples collected by patients after pouch surgery.
223504018|NCT04209842|DEVICE|gastric balloon|non surgical weight loss via placement of gastric balloon
223504019|NCT02455089|OTHER|GADD34 RNA level measurement.|"Blood analysis including GADD34 RNA level measurement is performed every 3 months up to 1 year for SLE patients.~A modal including physical exam, standard biological results and GADD34 RNA level is correlated to a SLE flare occurence in the next 3 months."
223504020|NCT05332795|DRUG|Metformin|gouty patients, will receive metformin tablets (1000 mg) once daily for about 3 months.
223504021|NCT05332795|DRUG|Placebo|gouty patients, will receive placebo tablets once daily for about 3 months.
223504022|NCT04122495|DIETARY_SUPPLEMENT|Probiotic|Oral administration of B. lactis M8 at 10 log CFU/day for 4-weeks
223504023|NCT04122495|DIETARY_SUPPLEMENT|Placebo|Oral administration of maltodextrin daily for 4-weeks
224194898|NCT04402580|DRUG|Rituximab Biosimilar|for dosage between 100 and 250 mg Rituximab will be diluted in 100 ml of normal saline and administered at 2 ml/h for the first 30'; 3 ml/h for the second 30'; 6 ml/h for the third 30'; 15 ml/h until the end. For dosage between 260 and 500 mg Rituximab will be diluted in 250 ml of normal saline and administered at 6 ml/h for the first 30'; 9 ml/h for the second 30'; 18 ml/h for the third 30'; 36 ml/h until the end. For dosage between 510 and 1000 mg Rituximab will be diluted in 500 ml of normal saline and administered at 9 ml/h for the first 30'; thereafter, the infusion rate can be doubled every 30 minutes up to a maximum of 72 ml/h.
224194899|NCT04402580|DRUG|Mycophenolate Mofetil|1,200 mg/1,73 sqm orally divided in 2 daily doses
223504024|NCT03638271|DIAGNOSTIC_TEST|Cardiac magnetic resonance imaging|Patients in different sex and age groups diagnosed with any type of nonischemic cardiomyopathy clinically or with echocardiography will undergo cardiac magnetic resonance imaging and compare their results.
223504025|NCT01768273|DRUG|Midazolam|
224310456|NCT01467206|BEHAVIORAL|Standard care|Standard care as it is given to all stoke patients after stroke
224310457|NCT06150456|PROCEDURE|extraction|extraction: in all groups, extraction will be performed
223504026|NCT01768273|DRUG|PA-824|
223504027|NCT00494884|DRUG|vildagliptin|
223504028|NCT01801527|BEHAVIORAL|Telerehabilitation group|Interventions will be based on to provide cardiovascular, mobility, strength and stretching exercises through telerehabilitation system
223504029|NCT02131493|DRUG|S-1, Gemcitabine|
223504030|NCT05076123|OTHER|Modified Constraint Induced Therapy and Threshold Electrical Stimulation|M-CIMT emphasizes massed practice with the affected upper limb with restraining unaffected limb by a mitt. Threshold electrical stimulation is based on low-intensity (\<100 Hz) and long-duration current and is applied with superficial electrodes.
223504031|NCT00864513|DRUG|pemetrexed|pemetrexed 500 mg/m2 IV day 1 of each 21 day cycle until disease progression or unacceptable toxicity for a maximum of 8 cycles
223504032|NCT03160807|DRUG|Levofloxacin|Levolet 500 mg OD for 5 days
223504033|NCT03160807|DRUG|Levofloxacin|Levolet 500 OD for 10 days
223504034|NCT05938010|DEVICE|Dailies Total1® contact lenses for astigmatism (T30fA)|Dailies Total1® contact lenses for astigmatism (T30fA)
223504035|NCT05403515|OTHER|foot massage|foot massage
223504036|NCT05403515|OTHER|Foot massage +Aromatherapy group|foot massage and lavender oil inhalation
223504037|NCT04832308|BEHAVIORAL|Exercise Therapy|This is a health coach driven exercise prescription for patients recommending 30 minutes or more of moderate effort walking 3-5 days a week with expected walk-rest-walk-rest intervals.
223504038|NCT02834897|RADIATION|EOS and CT Exam|EOS and CT Examen for pregnant women in the 8th month of pregnancy
223504039|NCT02603029|OTHER|Placebo cream|Subjects will use placebo cream twice per day for 12 weeks on one half of the face and of the gluteal area.
223504040|NCT02603029|OTHER|Belinal cream|Subjects will use Belinal cream twice per day for 12 weeks on the other half of the face and of the gluteal area.
223592878|NCT00510978|BIOLOGICAL|Placebo|1 sachet per day for 1 year
223592879|NCT00908466|DRUG|Sirolimus (rapamycin)|Will receive intravitreal injections of sirolimus (rapamycin) 352 µg in study eye on Days 0, 60, and 120.
223592880|NCT00908466|DRUG|Sirolimus (rapamycin)|Will receive subconjunctival injections of sirolimus 1320 µg in the study eye on Days 0, 60, and 120.
223592881|NCT05563831|OTHER|national registry|The investigators will collect demographic, clinical, biological and imaging characteristics of patients with PROS.
223504041|NCT04472208|DEVICE|Ambulatory monitoring solution|Subjects participating in this study will be monitored with the site's standard of care primary monitor and the evaluable device as the secondary monitor.
223504042|NCT03091491|DRUG|Ipilimumab|Ipilimumab 1 mg/kg administered every 6 weeks as a 30 min IV infusion
223504043|NCT03091491|DRUG|Nivolumab|Nivolumab 3 mg/kg administered every 2 weeks as a 30 min IV infusion
223504044|NCT00069329|DRUG|anakinra|daily injection of subcutaneous injection
223504045|NCT02331407|DEVICE|Robotic arm therapy|Training with the ReoGo device
223504046|NCT01562444|OTHER|Blood draw|Annual blood draw at years 6 (Visit 18), 7 (Visit 19), 8 (Visit 20), 9 (Visit 21) and 10 (Visit 22)
223504047|NCT02201576|DRUG|Bortezomib|"1. Five plasma exchanges +0.1 g/kg of intravenous immunoglobulins at the end of each course~2. two cycles of bortezomib (1.3 mg/m2 IV at day-1, day-4, day-8, day-11) + oral dexamethasone (20 mg po at day-1, day-4, day-8, day-11)~3. four courses of polyclonal intravenous immunoglobulins every three weeks (2g/kg, the first two courses are performed simultaneously with the two bortezomib cycles)"
223504048|NCT02201576|DRUG|Plasma exchanges and intravenous immunoglobulins|"1. Five plasma exchanges +0.1 g/kg of intravenous immunoglobulins at the end of each course~2. four courses of polyclonal intravenous immunoglobulins every three weeks (2g/kg)~3. oral dexamethasone (20 mg po at day-1, day-3, day-5, day-7 of the two first intravenous immunoglobulins courses)"
223504049|NCT00546273|BIOLOGICAL|RUTI|dose: 5 micrograms of FCMtb; given subcutaneously twice, on days 0 and 28
223504050|NCT00546273|BIOLOGICAL|RUTI|dose: 25 micrograms of FCMtb; given subcutaneously twice, on days 0 and 28
223504051|NCT00546273|BIOLOGICAL|RUTI|dose: 100 micrograms of FCMtb; given subcutaneously twice, on days 0 and 28
223504052|NCT00546273|BIOLOGICAL|RUTI|dose: 200 micrograms of FCMtb; given subcutaneously twice, on days 0 and 28
223504053|NCT00546273|BIOLOGICAL|placebo of the vaccine RUTI|placebo of the vaccine RUTI given subcutaneously twice, on days 0 and 28
223504054|NCT00227955|DRUG|Imipramine|
223504055|NCT00227955|BEHAVIORAL|Interpersonal Psychotherapy|
223504056|NCT01795755|BEHAVIORAL|Mentalization based inpatient treatment.|1-3 month of inpatient treatment
223592882|NCT03157037|BIOLOGICAL|Imlifidase|One dose of 0.25 mg/kg body weight imlifidase on study day 1
223592883|NCT01919216|DRUG|Citalopram|
223592884|NCT05224037|DIAGNOSTIC_TEST|iLivTouch|Eligible subjects will undergo liver stiffness and controlled attenuation parameters examination with two devices on the same day
223592885|NCT02346513|DEVICE|Ceramic on Metal Articulation|Patients have THA with ceramic on metal articulation
223592886|NCT02346513|DEVICE|Non-Ceramic on Metal Articulation|Patients have THA with non-ceramic on metal articulation
223592887|NCT02102399|BEHAVIORAL|Vocal Warm-up|Vocal Warm-up group performed 13 minutes of vocal warm-up exercises everyday before teaching over a course of 6 weeks, with one session exercise per day.
224194900|NCT03458039|BEHAVIORAL|In-person CETA|The Common Elements Treatment Approach (CETA) is a transdiagnostic, multi-problem intervention designed to address adult and youth trauma, depression, anxiety, safety, and substance use. It is comprised of a small set of common elements found to be efficacious and prevalent across a range of EBTs to treat common mental health problems. CETA was designed to be flexible in the elements utilized, their order, and their dose (number of sessions) to allow counselors to address heterogeneity, comorbidity, and symptom fluctuations in and across clients. Treatment typically consists of 6 to 12 weekly, approximately 60-minute sessions delivered by lay workers.
224194901|NCT03458039|BEHAVIORAL|Telephone CETA|"For adaptation of the CETA manual for telephone delivery, the Applied Mental Health Research (AMHR) Group at Johns Hopkins University (JHU) reviewed evidence-based telehealth strategies and recommendations, telehealth ethical and legal guidelines, and clinical recommendations from telehealth providers. In addition, local TTTs in multiple contexts reviewed telehealth modifications and provided input that was incorporated into the final T-CETA manual used in this study. No changes were made to the structure, duration, and dose of CETA sessions, treatment components, or measurement-based clinical decision-making processes. Telehealth modifications, additions, and strategies were incorporated throughout the manual in delineated telehealth boxes. This way, the original manual was maintained outside of the telehealth boxes, allowing for clear identification and training of telehealth modifications for both new and existing CETA counselors."
224194902|NCT03458039|BEHAVIORAL|Treatment as Usual (TAU)|The control condition is defined as 'treatment as usual'. In Zambia, there are no formal services or standard of care treatments for mental and behavioral health problems among AYA. There are, however, organizations (such as non-governmental organizations) operating in Lusaka that provide intermittent services for these types of problems. Some AYA receive informal counseling from parish priests or other leaders in their communities. In this study we are therefore defining these types of informal services as 'treatment-as-usual.' We will closely track the type, number, and degree of these kinds of services that all participants receive and access. Following the conclusion of the study, we will offer the CETA intervention to control participants if it has been found to be safe and effective
223592888|NCT02102399|BEHAVIORAL|Respiratory Muscle Training|Respiratory Muscle Training group performed 13 minutes of Respiratory Muscle Training everyday before teaching over a course of 6 weeks, with one session exercise per day.
223592889|NCT06325319|OTHER|Community engagement using M-MAMA Champions to improve awareness on obstetric danger signs, bith preparedness and complication readiness among pregnant women|Community engagement using M-MAMA Champions to improve awareness of obstetric danger signs, birth preparedness, and complication readiness among pregnant women. The empowered M-MAMA Champions will deliver the intervention to pregnant women in their communities. A total of three (3) sessions will be held, whereby each will take two (2) hours. The sensitization will take place at one of the study participant's residential area, where women will gather up and be sensitized on the subject by the M-MAMA Champion as a facilitator using a well-prepared brochure (package).
223592890|NCT04591236|DEVICE|Brain stimulation|tDCS brain stimulation on leg motor areas was applied to Parkinson patients.
223504057|NCT01795755|BEHAVIORAL|Horse assisted Therapy (HAT)|A structured program of 12 X 90 minute HAT sessions (horse care, ground and mounted work) conducted by two clinically qualified therapists who are also Level I Riding Instructors.
223592891|NCT04591236|DEVICE|Treadmill gait training|Treadmill gait training was applied to Parkinson patients.
223592892|NCT02644382|OTHER|qualitative data collection|qualitative data collection
223504058|NCT01163565|DEVICE|Ligasure Device|Ligasure device used to seal blood vessels during left or right side of a total thyroidectomy. Traditional method of hand ties/clips on contralateral side.
223504059|NCT05244837|DRUG|Tislelizumab 200 mg|Tislelizumab 200mg IV Q3W + Followed by adjuvant treatment for 1 year (Tislelizumab 200 mg IV Q3W for 2 cycles and Tislelizumab 200 mg Q4W for 12 cycles)
223504060|NCT05244837|DRUG|Carboplatin AUC 5|Carboplatin AUC 5 IV Q3W
223504061|NCT05244837|DRUG|pemetrexed 500mg/m2|Pemetrexed 500mg/m2 IV Q3W if non-squamous lung cancer
223504062|NCT05244837|DRUG|Paclitaxel 175mg/m2|Paclitaxel 175mg/m2 IV Q3W if squamous lung cancer
223504063|NCT05244837|DRUG|Nab-paclitaxel 260 mg/m2|nab-paclitaxel 260 mg/m2 Q3W if squamous lung cancer
223504064|NCT05415787|OTHER|Blood sample|2 tubes Cell free DNA are taken during a blood sample already planned in the patient's care.
223504065|NCT05415787|OTHER|Urine sample|Urine sample is taken during the consultation carried out for the patient's care
223504066|NCT04761354|PROCEDURE|Unilateral adrenalectomy|
223504067|NCT05552495|DRUG|CKD-386(4) F1|1 Tablet
223504068|NCT05552495|DRUG|CKD-386(4) F2|1 Tablet
223504069|NCT05552495|DRUG|D013, D326, D337|D013 1 Tablet, D326 1Tablet, D337 1 Tablet
223504070|NCT06434779|DEVICE|JETi 6F and 8F Thrombectomy system|To demonstrate the efficacy and safety of the mechanical thrombectomy device (JETi 6F and 8F) for treatment of patients with symptomatic peripheral artery disease (PAD) due to acute or acute on chronic occlusions of the femoral and/or popliteal arteries and the first 10 cm of the below-the -knee arteries.
223504071|NCT05050838|OTHER|Transcranial Doppler (TCD)|"TCD ultrasonography is based on the principle of the Doppler effect. According to this principle, ultrasound waves emitted from the Doppler probe are transmitted through the skull and reflected by moving red blood cells within the intracerebral vessels. The difference in the frequency between the emitted and reflected waves, referred to as the Doppler shift frequency, is directly proportional to the speed of the moving red blood cells (blood flow).~Cerebral blood flow (in cm/s) of the middle cerebral artery will be measured with TCD in blood-injured ARDS patients before and one hour after prone positioning (normal ranges: 48 to 72 cm/s)."
223504072|NCT01769118|DRUG|Caffeine|Caffeine will be given according to departmental protocol
223504073|NCT02620111|DIETARY_SUPPLEMENT|Whey protein high in leucin|This Group is analysed for muscle protein synthesis and breakdown, mTor pathway signaling and Amino acid metabolism while supplemented first water then whey protein high in leucin
223592893|NCT02644382|OTHER|survey|survey pre and post-surgical consult
223592894|NCT02644382|OTHER|decision aid|web-based decision aid post-surgical consult
223592895|NCT00456651|DEVICE|CPAP (Continuous Positive Airway Pressure)|
223592896|NCT03101085|DRUG|S-equol and Placebo|S-equol is an estrogen receptor β (ERβ) agonist. Provided in capsules. The placebo is a matched pill that cannot be distinguished from the active S-equol.
223592897|NCT03101085|DRUG|Placebo and S-equol|S-equol is an estrogen receptor β (ERβ) agonist. Provided in capsules. The placebo is a matched pill that cannot be distinguished from the active S-equol.
223592898|NCT05602077|DEVICE|POCUS|"POCUS: The ultrasound examination of the injured elbow includes seven standard settings. The probe is placed on the joint in four ventral and in three posterior positions. If hemarthrosis is detected, this is always suspicious of a possible intra-articular fracture. Even the smallest amounts of blood can be detected sonographically. The surfaces of the bones involved in the joint (humerus, ulna, radius) are accurately displayed in all seven sonography settings. Disrupted bone surface indicates a fracture.~XR: The conventional radiograph of the injured elbow consists of three standard views: ap, lateral and Norman oblique.~CBCT: The injured elbow is placed in an almost most extended position in the CBCT tube."
223592899|NCT00472966|DRUG|Fluocinolone acetonide 0.1%/hydroquinone 4%/tretinoin 0.05% Cream in sequence with glycolic acid peels|Apply cream once daily at night. Subjects will be asked to discontinue use of Fluocinolone acetonide/hydroquinone/tretinoin Cream 2 days prior to the peel and restart 2 days after the peel; Glycolic Acid Peels - In office treatment at weeks 2, 4, 6, 8 and 10
223592900|NCT04057885|DEVICE|Orthosensor™ VERASENSE™ Knee System|A group of patients will receive a total knee arthroplasty using the Orthosensor device
223592901|NCT00518193|DRUG|ERBITUX|400 mg/m² 2h injection at week 1, then 250 mg/m² in one hour injection the following weeks
223592902|NCT03323190|BEHAVIORAL|Inpatient COPD education|
224194903|NCT02763007|DRUG|alogliptin+pioglitazone|alogliptin and pioglitazone add on metformin
224194904|NCT02763007|DRUG|alogliptin|nesina add on metformin
224194905|NCT02763007|DRUG|pioglitazone|actos add on metformin
224194906|NCT01652807|BEHAVIORAL|Hatha Yoga|The yoga intervention will last eight weeks and include two 90-minute sessions each week. Each yoga session will consist of the same series of 26 Hatha yoga postures, two breathing exercise, and two savasanas (i.e., a resting/relaxation posture), in a room heated to 104 degrees Fahrenheit, which aids in safe muscle stretching. Each participant will be given a yoga studio scan card valid for two months, and, like all yoga studio members, they will be required to scan their card prior to their yoga class.
224194907|NCT00290511|DRUG|Fludarabine|25 mg/m\^2 intravenous (IV) over 5-30 minutes on Days 2-4.
224194908|NCT00290511|DRUG|Mitoxantrone|10 mg/m\^2 IV over 5-30 minutes on Day 2.
224194909|NCT00290511|DRUG|Rituximab|375 mg/m\^2 IV over 4-6 hours on Day 1 and 8; maintenance Rituximab = 375 mg/m\^2 IV over 4-6 hours on Day 1 only, a single dose every other month for 12 months (6 doses total).
224194910|NCT00290511|DRUG|Zevalin|0.3 mCi/kg IV after 4 cycles of R-FND.
224194911|NCT00290511|DRUG|Dexamethasone|20 mg by mouth (PO) or IV daily on Days 2-6.
224194912|NCT01469845|DEVICE|3% hypertonic saline|4 ml dose to be administered every 6 hours
224194913|NCT02536625|OTHER|prospective study|
223504074|NCT02620111|DIETARY_SUPPLEMENT|Whey protein normal in leucin|This Group is analysed for muscle protein synthesis and breakdown, mTor pathway signaling and Amino acid metabolism while supplemented first water then whey protein normal in leucin.
223504075|NCT00666978|BEHAVIORAL|smoking cessation intervention|
223504076|NCT00666978|DRUG|bupropion hydrochloride|
223504077|NCT00666978|GENETIC|gene expression analysis|
223504078|NCT00666978|GENETIC|polymerase chain reaction|
223504079|NCT00666978|OTHER|counseling intervention|
223504080|NCT00666978|OTHER|educational intervention|
223504081|NCT00666978|PROCEDURE|psychosocial assessment and care|
223504082|NCT04561609|OTHER|Transcutaneous CO2 application|"Patients lie on examination tables. Lower extremities of the patients are isolated in a therapeutic wrap (single use, low-density, made from biocompatible polyethylene), sealed at the waist. After this, air is first pumped out of the therapeutic wrap, then the wrap was filled with 99.9% CO2 gas. The therapy lasts for 45 minutes.~Each patient from the study group will receive CO2 therapies - four weeks (meaning 20 CO2 therapies that were performed on workdays only)."
223504083|NCT04561609|OTHER|Placebo treatment|Each patient from control group will have therapeutic wrap filled with air instead of CO2. Patients from control group will also receive 20 therapies (4 weeks on workdays only), that will also last 45 minutes.
223592903|NCT01458028|DRUG|BAY85-3934|Single doses of 20 mg BAY85-3934 as tablet
223592904|NCT01458028|DRUG|Placebo|Single dose of placebo tablet matching the 20 mg BAY85-3934 tablet
223592905|NCT00067782|DRUG|Atazanavir (immediate switch)|Capsules, Oral, 400mg, Once daily, 48 weeks.
223592906|NCT00067782|DRUG|Atazanavir (Week 24 switch)|Capsules, Oral, 400mg, Once daily, 48 weeks.
223592907|NCT00861328|DRUG|ON 01910.Na and irinotecan|"ON 01910.Na will be administered by IV infusion over 24 hours once per week in a 6-week cycle (6 doses per cycle). The dose of ON 01910.Na will start at 250 mg/m2 and will proceed to higher dose levels after safety evaluation.~The suggested starting dose of Irinotecan is 180 mg/m2 administered by intravenous (IV) infusion over 90 minutes every 2 weeks of a 6-week cycle (3 doses per cycle). Reductions in the starting doses according to recommendations of current approved prescribing information may be considered after review of patients' medical histories and potential tolerances to treatment with the chemotherapy agent."
224194914|NCT01638260|DRUG|Liraglutide|Liraglutide once daily 1.8 mg injection subcutaneously, 26 weeks
224194915|NCT01638260|BEHAVIORAL|NEAT|Increasing NEAT by activating lifestyle interventions, combined with liraglutide once daily 1.8mg injections subcutaneously
224194916|NCT05032573|DIETARY_SUPPLEMENT|Olive oil and Dietary Guideline recommendations|60 mL of olive oil and healthy diet recommendations
224194917|NCT05032573|OTHER|Dietary Guideline recommendations|healthy diet recommendations
224194918|NCT00611780|RADIATION|tube voltage|standard 120 kV
224194919|NCT00611780|RADIATION|tube voltage|reduced voltage of 100 kV
224194920|NCT03456401|DRUG|Sorafenib or Sunitinib|After two lines of TKIs, patients received a third line with sunitinib or sorafenib, according to previous treatments
224194921|NCT02191969|BEHAVIORAL|Walk With Ease|A self-directed walking intervention developed by the Arthritis Foundation. The intervention is a workbook that coaches participants through walking regularly at a safe, comfortable pace with the ultimate goal of walking at least 30 minutes a day five days a week.
224194922|NCT01028274|DIETARY_SUPPLEMENT|Placebo|Two capsules, twice daily with meals for 12 weeks.
224194923|NCT01028274|DIETARY_SUPPLEMENT|Investigational Product 1|Two capsules, twice daily with meals for 12 weeks.
224194924|NCT01028274|DIETARY_SUPPLEMENT|Investigational Product 2|Two capsules, twice daily with meals for 12 weeks.
224194925|NCT05542173|DRUG|BALI association|BALI association oral suspension, 25 mg + 25 mg + 15 mg, oral. Three applications per day or more in case of pain, not exceeding six applications per day.
224194926|NCT05542173|DRUG|Placebo|Placebo. Three applications per day or more in case of pain, not exceeding six applications per day.
224194927|NCT04151316|PROCEDURE|crown preparation|includes tooth preparation
224194928|NCT04151316|PROCEDURE|vertical preparation|type of vertical preparation on the tooth that accepts the crown
224194929|NCT04151316|PROCEDURE|horizontal preparation|type of horizontal preparation on the tooth that accepts the crown
224194930|NCT03891602|BEHAVIORAL|Cataldo Lung Cancer Stigma Scale (Smoking-Related Subscale)|Perceived Smoking-Related Stigma will be measured using the 5-item Cataldo Lung Cancer Stigma Scale (Smoking-Related Subscale). The response scale is 1 = strongly disagree, to 4 = strongly agree, and scores range from 5 to 25 (high stigma). Cronbach's alphas were 0.75 to 0.89 in prior studies.
224194931|NCT03891602|BEHAVIORAL|Patient Trust in the Medical|"Medical Mistrust will be measured using the 5-item Patient Trust in the Medical Profession Scale.80 The five-point Likert responses measure the extent to which patients perceive their clinician to be honest, caring more about convenience, thorough and careful, and trusted. The range of scores is 5 to 25 (higher mistrust). Reliability and validity have been well established with a Cronbachs alpha of 0.84."
224194932|NCT03891602|BEHAVIORAL|Decision Conflict Scale (DCS) - Lung Cancer Screening|"The DCS is a 16-item Likert-response item scale that has been modified for the lung cancer screening and smoking cessation contexts. The DCS was developed by OConnor,74-75 and validated in many health decisions including breast cancer screening with Cronbachs alphas ranging from 0.78 to 0.81. 74-75 Despite its name, the DCS measures more than decision conflict to encompass personal perceptions of perceived decision-making quality such as feeling the choice is informed, values based, and likely to be implemented as well as expressing satisfaction with the decision. 74-75 The DCS is comprised of items with response options ranging from 1 (strongly disagree) to 5 (strongly agree). The items are summed to total scale score with lower scores reflective of higher decision conflict and higher scores reflective of lower decision conflict."
224310458|NCT06150456|RADIATION|low level laser therapy|extraction: in all groups, extraction will be performed Treatment with low-intensity infrared 808 nm laser therapy will be applied in 2 stages: one in the immediate postoperative period and 10 days after surgery.
224310459|NCT06150456|BIOLOGICAL|Plenum® OSShp and Plenum® Guide|extraction: in all groups, extraction will be performed Immediately after tooth extraction, the biomaterials Plenum® OSShp and Plenum® Guide (Brazil) will be added to the dental socket, serving as a bone substitute and maintaining alveolar dimensions.
224310460|NCT00438477|DRUG|Isosulfan Blue|At time of surgery, breast injected with 3-5 cc of isosulfan blue in subareolar or peritumoral position.
224310461|NCT00438477|PROCEDURE|Lymphangiography|2 lymphoscintigraphy images performed following peritumoral and subareolar injection of breast
224310462|NCT00438477|RADIATION|Technetium Tc 99m sulfur colloid|"At least 2 days before scheduled surgery, receive technetium Tc 99m sulfur colloid by peritumoral injection; and again the day before surgery by subareolar injection.~At the time of surgery, patients receive isosulfan blue by subareolar injection."
224310463|NCT01678053|DRUG|onabotulinumtoxinA|Botulinum toxin A is injected into the larynx in order to treat vocal fold granulomas.
224310464|NCT01678053|DRUG|omeprazole (proton pump inhibitor)|Standard therapy of anti-reflux medications using omeprazole or equivalent PPI.
224310465|NCT02451098|DRUG|Atorvastatin10mg, Ezetimibe10mg|Atorvastatin10mg, Ezetimibe 10mg (Duration: 8weeks)
224310466|NCT02451098|DRUG|Atorvastatin10mg, Ezetimibe placebo|Atorvastatin10mg, Ezetimibe placebo(Duration: 8 weeks)
224310467|NCT02451098|DRUG|Atorvastatin20mg, Ezetimibe10mg|Atorvastatin20mg, Ezetimibe 10mg (Duration: 8weeks)
224310468|NCT02451098|DRUG|Atorvastatin20mg, Ezetimibe placebo|Atorvastatin20mg, Ezetimibe placebo(Duration: 8weeks)
224310469|NCT02451098|DRUG|Atorvastatin40mg, Ezetimibe10mg|Atorvastatin40mg, Ezetimibe 10mg (Duration: 8weeks)
224310470|NCT02451098|DRUG|Atorvastatin40mg, Ezetimibe placebo|Atorvastatin40mg, Ezetimibe placebo(Duration: 8weeks)
223504084|NCT05039593|OTHER|chlorhexidine|The population of the research is the patients hospitalized in the Internal Medicine intensive care unit of Aydın Adnan Menderes University Practice and Research Hospital between 01.06.2021 and 01.06.2022, and the sample is; Patients who are older than 18 years of age, who are in the first 24 hours of mechanical ventilation, who are 18 years of age and older, and whose relatives have consented.Oral care of the patients will be done with 0.12% chlorhexidine solution, and the frequency of oral care will be in three groups. Oral care will be done twice a day for the patients in the first group, 3 times a day for the patients in the second group, and 4 times a day for the patients in the third group. Oral care of the patients will be applied according to the guide used in the training given to the nurses.
224310471|NCT00943462|RADIATION|External-beam radiation therapy|60 Gy of external beam radiotherapy using a standard technique will be administered in 2-Gy fractions, for a total of 30 fractions
224310472|NCT00943462|DRUG|Temozolomide|The chemotherapy will have to be administered in accordance with the protocol used in the CAN-NCIC-CE3 study, which established the current standard for treatment of GBM with the administration of temozolomide as adjuvant therapy at the same time as radiotherapy (clinicaltrials.gov ID NCT00006353).
224310473|NCT01689662|DRUG|Tc 99m EC20|
224310474|NCT05865080|DRUG|Ketamine|0.3 mg/kg of ketamine IV diluted to 10 ml followed by infusion 0.1 mg/kg/hr. as 20 ml solution before spinal anesthesia
224310475|NCT05865080|DRUG|Placebo|Normal saline
224310476|NCT03729076|OTHER|Crystalloid|Patients will receive the rapid co-loading with plasma solution A (PSA) 10ml/kg, from the initiation of spinal anesthesia, within 10 minutes.
224310477|NCT03729076|OTHER|Colloid|Patients will receive the rapid co-loading with 6% volulyte (HES in acetated electrolyte) 10ml/kg, from the initiation of spinal anesthesia, within 10 minutes.
224310478|NCT00000569|DRUG|triamcinolone|1200 micrograms of triamcinolone in daily divided doses
224310479|NCT00000569|OTHER|Placebo|Placebo
224314235|NCT02376400|BIOLOGICAL|Ad26.ZEBOV|One 0.5 mL IM injection of 5\*10\^10 viral particles (vp) on Day 1, 29 or 57.
224314236|NCT02376400|BIOLOGICAL|Placebo|One 0.5 mL IM injection of 0.9% saline on Day 1 and 29 or on Day 1 and 57.
224194933|NCT03891602|BEHAVIORAL|Shared Decision Making Questionnaire (SDM-Q)- Patient|"Shared Decision Making Process will be measured from the patient perspective using the 9-item Shared Decision Making Questionnaire (SDM-Q-9),77 which has been validated with a Cronbachs alpha of 0.94."
224194934|NCT03891602|BEHAVIORAL|Stage of Readiness for Smoking Cessation - Contemplation Ladder|Among current smokers
224194935|NCT03891602|BEHAVIORAL|Primary Care Clinicians' Lung Cancer Screening Survey|Includes items to assess attitudes, barriers, and knowledge of lung cancer screening guidelines.
224194936|NCT00470249|DRUG|Carboplatin|At a dose equivalent to an area under the concentration-time curve of 4.5 mg/ml.min on day 1 of every 2-week cycle
224194937|NCT00470249|DRUG|Gemcitabine Hydrochloride|1500 mg/m2 on day 2 of every 2-week cycle
224194938|NCT05196802|COMBINATION_PRODUCT|mHeart.4u|The mHeart.4U is a multiple-components intervention entailing the adoption and use of technological devices and self-management recommendations tailored to behavioural modifications (e.g. physical exercise and dietary patterns)
224194939|NCT04400175|DEVICE|Valved ergonomic teat|Administration of milk with a feeding system with a valved ergonomic teat in late preterm newborns.
224194940|NCT04400175|DEVICE|Standard silicon teat|Administration of milk with a feeding system with a standard silicon teat
224194941|NCT00696059|DRUG|Adalimumab (Humira)|Adalimumab (Humira) 40 mg subcutaneously every other week
224194942|NCT03500237|BEHAVIORAL|Team-Guided ICBT|An 8-week transdiagnostic internet-delivered cognitive behavioural therapy (ICBT) for persons with chronic conditions course will be delivered to participants. In addition to the online program, a guide from the Online Therapy Unit team will respond within one business day of the client's email. The team of guides consist of registered social workers, psychologists or supervised graduate students, with experience delivering ICBT. Amount of contact will be personalized to participants' needs.
224194943|NCT03500237|BEHAVIORAL|Self-Guided ICBT|An 8-week transdiagnostic internet-delivered cognitive behavioural therapy (ICBT) for persons with chronic conditions course will be delivered to participants. Participants are able to contact the Online Therapy Unit regarding any technical issues with logging onto the site. However, no psychoeducational support will be provided. A team member from the Unit will contact the participant only if there is a significant clinical issue requiring attention (e.g., sudden increase in symptoms).
224194944|NCT06651671|PROCEDURE|Myofascial release|THe treatment group was instructed to lay prone on the treatment table such that the skin on their upper back was visible. Participants then received direct and indirect myofascial release for 30 seconds each, performed by the same osteopathic physician.
224194945|NCT06651671|PROCEDURE|Sham (No Treatment)|The medical student gently placed their hands on the patients back for 60 seconds without manipulating the tissue in any way.
224194946|NCT02303977|DRUG|Abraxane|
224194947|NCT02303977|DRUG|Gemcitabine|
224194948|NCT01256086|DRUG|Formatris 24µg|12µg Formoterol Novolizer#1 + 12µg Formoterol Novolizer#2 + Placebo Aerolizer#1 + Placebo Aerolizer #2
224194949|NCT01256086|DRUG|Formatris 12µg|12µg Formoterol Novolizer#1 + Placebo Novolizer#2 + Placebo Aerolizer#1 + Placebo Aerolizer #2
224194950|NCT01256086|DRUG|Foradil P 24µg|Placebo Novolizer#1 + Placebo Novolizer#2 + 12µg Formoterol Aerolizer#1 + 12µg Formoterol Aerolizer #2
224310480|NCT01775436|BEHAVIORAL|FAmily-CEntered Advance Care Planning|"Two-60 to 90 minute sessions scheduled one week apart.~Session 1: Respecting Choices Interview (R)to facilitate conversations and shared decision-making between the patient and surrogate about palliative care \& prepare the surrogate to be able to fully represent the patient's wishes.~Session 2: Five Wishes (C). Patient selects which person the patient wants to make health care decisions for him/her; the kind of medical treatment the patient wants; how comfortable the patient wants to be; how the patient wants people to treat him/her; what patient wants loved ones to know; and any spiritual or religious concerns the patient may have."
224310481|NCT01775436|BEHAVIORAL|Healthy Living Control|"Session 1: Developmental History: Goal: To take a non-medical developmental history. The RA-Control will conduct the session in a structured interview format. Administered with all medical questions removed to prevent any risk of contamination with the experimental condition.~Session 2: Nutrition and Exercise: Assess nutritional status and provide advice for maintaining optimal nutrition to boost immune functioning. Administered by the RA Control and will be videotaped to control for what occurs in the FACE intervention."
224310482|NCT03185013|BIOLOGICAL|VGX-3100|1 mL VGX-3100 will be injected IM and delivered by EP using CELLECTRA™-5PSP on Day 0, Week 4 and Week 12.
224310483|NCT03185013|BIOLOGICAL|Placebo|1 mL of Placebo will be injected IM and delivered by EP using CELLECTRA™-5PSP on Day 0, Week 4 and Week 12.
224310484|NCT03185013|DEVICE|Electroporation (EP)|Intramuscular injection followed by EP with the CELLECTRA™ 5PSP device.
224194951|NCT01256086|DRUG|Foradil P 12µg|Placebo Novolizer#1 + Placebo Novolizer#2 + 12µg Formoterol Aerolizer#1 + Placebo Aerolizer #2
224194952|NCT06466057|BEHAVIORAL|Metacognitive Therapy|A one-on-one face-to-face dialogue format will be used to conduct psychotherapy with each participant, and the treatment protocol will be based on the treatment manual for metacognitive therapy.
224194953|NCT06466057|OTHER|General mental health promotion|A general mental health mission will be conducted, not covering any metacognitive therapy related content, set for 8-15 weeks, 1 time per week
224194954|NCT03001427|BEHAVIORAL|Structured center-based lifestyle intervention|
224194955|NCT03001427|BEHAVIORAL|Standard education and physician advice|
224194956|NCT06566573|OTHER|Pain|The relationship between the degree of stenosis and pain in patients with lumbar spinal stenosis will be evaluated with a visual analogue scale.
224194957|NCT06566573|OTHER|Normal Range of Motion|CROM will be used for normal range of motion (ROM) of the cervical region. Measurements will be made separately for flexion, extension, right rotation, left rotation, right and left lateral flexion.
224194958|NCT06566573|OTHER|Proprioceptive Sense|CROM will be used for cervical proprioception. Measurements will be made separately for flexion, extension, right rotation, left rotation, right and left lateral flexion.
224194959|NCT04341727|DRUG|Hydroxychloroquine Sulfate|anti-rheumatic drug (DMARD)
224194960|NCT04341727|DRUG|Azithromycin|Antibiotic
224194961|NCT04341727|DRUG|Chloroquine Sulfate|Antimalarial
223746823|NCT05823571|DRUG|Itacitinib|A standard 3+3 design will be used to evaluate the safety of itacitinib plus different immunosuppression regimens. This study has four predefined Regimens that will be explored in the optimal Regimen-finding phase and are listed in Table 2 of the protocol. Itacitinib will be given in conjunction with each of four different regimens for immunosuppression. Regimen 1 is the current standard for our BMT patients, with a duration of MMF from day 5-35. Regimen 2 will decrease the duration of MMF from 35 to day 25. Regimen 3 will decrease the duration of MMF from 35 to day 15. Regimen 4 will eliminate MMF altogether. We will start with Regimen 1, which combines itacitinib with the current standard of immunosuppression. Progression through cohorts (Regimens) will be based on a standard 3+3 design to find the optimal regimen.
223746824|NCT01983527|PROCEDURE|Arthrographic distention|Arthrographic distention of the glenohumeral joint with injection of 5 ml contrast, 15 ml local anaesthetic (Prilocaine) and up to 15 ml saline.
224194962|NCT06556576|DEVICE|IMPROVA Platform|"Adolescents, teachers, school staff, and parents will have access to a variety of content aimed at promoting the mental health and well-being of adolescents that can be accessed through the IMPROVA platform, an innovative eHealth solution that can be accessed via app and website.~Students: around 20 modules that can be grouped in five categories: Me and My Emotions, Me and My Body, Me and My Relationships, School and Free time, and Finding my Strengths.~Teachers and other school staff: 1) pedagogical and health-related modules to support their students and teaching practices; 2) modules to manage their own health; 3) tutoring sessions: resources (lessons plans) for tutors (teachers or other school staff) for carrying out a discussion with students in topics related to the students' health and wellbeing.~Parents: contents on promoting positive relationships, emotional and social skills, positive behaviour, behaviours to support wellbeing, and family-school collaboration."
224194963|NCT00265460|DRUG|Oliwer Twist smokeless tobacco (tobacco)|
224194964|NCT00088504|DRUG|Merimepodib|
224310485|NCT04842136|OTHER|Scales and indexes|Patients with TMD regardless of diagnosis with sleep bruxism were assessed with the Jaw Function Limitations Scale (JFLS), Neck Disability Index (NDI), Pittsburgh Sleep Quality Index (PSQI), Fatigue Severity Scale (FSS), and Headache Impact Test-6 (HIT-6) scales.
224310486|NCT03343613|DRUG|LY3381916|IDO-1 inhibitor administered orally
224310487|NCT03343613|DRUG|LY3300054|PD-L1 inhibitor administered IV
224310488|NCT06233084|DRUG|Desogestrel-Test product|Desogestrel Tablets 0.075 mg Manufactured by: POND'S CHEMICAL THAILAND R.O.P., Thailand
224310489|NCT06233084|DRUG|Desogestrel-Reference product|Desogestrel Tablets 0.075 mg Manufactured by: N.V. Organon, The Netherlands
224310490|NCT03248453|OTHER|CoPS|The COPS is an automated and objective computer-based program which generate a score/number after the colonoscope has reached the cecum. The participants are able to compare the score with experts.
223504085|NCT02386579|PROCEDURE|Blood sample measurements|Blood samples are drawn in the feet and arms (a/v) before and after cooling the feet with ice water
223504086|NCT05166928|DEVICE|carriere motion appliance|after finished treatment with carrirere motion appliance in the two group (group 1 have upper wisdom teeth ,group 2 have not upper wisdom teeth ) the pre and post casts will be scanned and superimposed to determine amount upper molar distalization
223504087|NCT00860431|DRUG|AST-120|6g/day (3 times a day)
223504088|NCT01496443|DRUG|TAK-875 and Glimepiride|
223504089|NCT04578977|BEHAVIORAL|Functional assessment of surgical treatment of terrible triade injury of the elbow|Functional assessment of surgical treatment of terrible triade injury of the elbow
223504090|NCT03751748|DEVICE|AFR implantation|Implantation of atrial flow regulator (AFR) device
223504091|NCT03751748|DEVICE|Sham procedure|Sham procedure to include cardiac catheterization and hemodynamic. Ongoing management at the discretion of the treating physician. Patient to undergo
223504092|NCT00076609|DRUG|PHY906|
223504093|NCT00076609|DRUG|capecitabine|
223504094|NCT05829733|DEVICE|SYNOLIS VA 80/160|SYNOLIS VA 80/160 (hyaluronic acid 80 mg, sorbitol 160 mg)
223504095|NCT05113602|DEVICE|URGOnight|EEG dry electrodes portable device
223504096|NCT05113602|DEVICE|Enobio|EEG wet electrodes portable device
223504097|NCT00559117|DRUG|VB-111|A single intravenously infusion of diluted VB-111 should be administered 1 ml/minute
223504098|NCT03458091|DEVICE|THRIVE|Oxygenation during apnea using transversal humidified oxygen
223504099|NCT03458091|DEVICE|Endotracheal intubation|Ventilation during the procedure is governed by an endotracheal tube in the trachea and mechanical ventilation
223504100|NCT04847921|DRUG|Dalbavancin|long-acting lipoglycopeptide antibacterial agent
223504101|NCT06130202|DEVICE|Echocardiographic findings|Echocardiographic findings as Markers of Subclinical Cardiac dysfunction in Patients with Non-Alcoholic Fatty Liver Disease
223504102|NCT04094636|BEHAVIORAL|In-bed cycling|Patients will daily perform 30 min of supervised in-bed cycling
223504103|NCT04094636|BEHAVIORAL|Exercise booklet|Patients will daily perform 30 min of supervised physical training with exercises from the exercise booklet
223504104|NCT00574951|DRUG|motesanib diphosphate|
223504105|NCT01567020|OTHER|Diagnostic|All participants will be evaluated with a battery of behavioral and electrophysiological measures to assess central auditory processing abilities.
223504106|NCT02580344|DRUG|Ibuprofen|The women will receive 400mg ibuprofen 3 times per day from the first day of the cycle for 5 days
223504107|NCT01160744|BIOLOGICAL|IMC-1121B (ramucirumab)|10 milligrams/kilogram (mg/kg) once every 3 weeks beginning Day 1, Cycle 1
223504108|NCT01160744|DRUG|Pemetrexed|500 milligrams/square meter (mg/m²) on Day 1 of every 21-day cycle
223504109|NCT01160744|DRUG|Carboplatin (AUC 6)|Day 1 of every 21-day cycle
223504110|NCT01160744|DRUG|Cisplatin|75 mg/m² intravenous (IV) on Day 1 of each 21-day cycle
223504111|NCT01160744|DRUG|Gemcitabine|1000 mg/m² on Days 1 and 8 of every 21-day cycle
223504112|NCT01160744|DRUG|Carboplatin (AUC 5)|Day 1 of every 21-day cycle
223504113|NCT01557816|DRUG|Naproxen|Naproxen for 7 days (3 days at 250 mg BID followed by 4 days at 500 mg BID) during either of the 2 treatment periods.
223504114|NCT01557816|DRUG|Placebo|Placebo for seven days given BID during either of the 2 treatment periods.
223504115|NCT02301429|DEVICE|Model 20105|implant and follow-up of study device
223504116|NCT02080728|DRUG|Ropivacaine 500mg/100ml Naropeine|
223504117|NCT02080728|DRUG|0.9% sodium chloride BAXTER|
223746825|NCT01983527|DRUG|Intra-articular corticosteroid Depo Medrol|Intra-articular injection of 1 ml (40 mg) Depo Medrol(Methylprednisolone Acetate Injectable Suspension)
223746826|NCT03342547|PROCEDURE|Duodenal biopsy|Two duodenal biopsy samples will be collected from each participant
224194965|NCT00088504|DRUG|PEG-Interferon-alpha 2a (Pegasys®)|
224194966|NCT00088504|DRUG|Ribavirin (Copegus®)|
224194967|NCT06653868|PROCEDURE|dental implant with bone augmentation|gap distance augmentation with bone graft
224194968|NCT01438346|BEHAVIORAL|Substance Abuse Education|10 weeks of usual care for substance abuse.
224194969|NCT01438346|BEHAVIORAL|Mind-body Bridging|Two sessions per week for 10 weeks, besides usual care treatment for substance abuse.
224194970|NCT06214780|DEVICE|advanced hybrid closed-loop|"An advanced hybrid closed-loop system is a type of insulin delivery system that uses an algorithm to automatically adjust insulin delivery based on glucose levels. It combines an insulin pump with a continuous glucose monitor (CGM) and uses a closed-loop algorithm to adjust insulin doses based on real-time glucose readings. The hybrid aspect refers to the fact that the system still requires some user input, such as entering meal information, but the algorithm takes over the majority of insulin dosing decisions."
224194971|NCT02014194|BEHAVIORAL|attentional bias modification treatment|The attentional bias modification treatment is a behavioral computerized program (software e-prime)
224194972|NCT06496360|DIAGNOSTIC_TEST|Artificial Intelligence|The model employs machine learning algorithms to analyze CT imaging data of patients with non-small cell lung cancer. It focuses on the identification and assessment of features of the mediastinal fourth group lymph nodes, including size, shape, margins, and density. By extracting features related to lymph node metastasis, the model assists doctors in making more accurate diagnoses.
224310491|NCT05072197|DEVICE|Mobile device as a support tool for the treatment of women with breast cancer undergoing chemotherapy|This study will develop a Mobile device application providing medical care information and social support for breast cancer women during their chemotherapy treatment to help them receive individually tailored information related to chemotherapy and support from healthcare professionals and peers.
224310492|NCT06713382|COMBINATION_PRODUCT|Pleural Saline Irrigation|This intervention, Pleural Saline Irrigation, involves the administration of up to 250 mL of sterile saline solution into the pleural cavity through a chest tube immediately following each intrapleural tPA/DNase (IPFT) therapy session. The saline irrigation is intended to aid in clearing infected pleural fluid and reducing pleural effusion volume. This maneuver is repeated based on the treating physician's criteria, differentiating it from standard care, which includes only antibiotics, chest tube placement, and IPFT without saline irrigation. The irrigation is expected to enhance infection resolution and may impact chest tube duration and the frequency of pleural interventions.
224194973|NCT03908229|PROCEDURE|Trainee colonoscopy|Colonoscopy performed by trainee
224194974|NCT03908229|PROCEDURE|Experienced physician colonoscopy|Experienced physician colonoscopy
224194975|NCT00136565|DRUG|Velcade|1.5 mg/m², D1, D5, 4 cycles
224194976|NCT00136565|DRUG|Doxorubicin|75 mg/m², D1, 4 cycles
223504118|NCT05086172|BEHAVIORAL|Ultrabrief Behavioral Activation|The ultrabrief behavior activation (UBA) intervention is a condensed version of the LETS ACT intervention. The main treatment elements include: (1) explanation of treatment rationale to facilitate behavior change via increased engagement in values-related activities, (2) identification of participant-specific values via detailed assessment of life areas, values and activities, (3) values-based activity planning and scheduling, and (4) post-treatment planning. The overall goal of behavioral activation (BA) is to shift from values-incongruent behavior (including alcohol use) to behaviors that provide positive reinforcement and environmental reward with the overall goal of increasing the number of engaged-in, value-based activities. This intervention will take 90 minutes.
223504119|NCT00800150|DRUG|fludarabine phosphate|
223504120|NCT00800150|DRUG|melphalan|
223504121|NCT00800150|PROCEDURE|nonmyeloablative allogeneic hematopoietic stem cell transplantation|
223504122|NCT00800150|RADIATION|intensity-modulated radiation therapy|
223504123|NCT00800150|RADIATION|tomotherapy|
223504124|NCT00800150|RADIATION|total marrow irradiation|
223504125|NCT00800150|RADIATION|total nodal irradiation|
223504126|NCT05066139|OTHER|EPODIG-G program (coordination of supportive care)|EPODIG-G program includes: a nutritional evaluation (laboratory tests: albumin, pre-albumin, C reactive protein and vitamin D dosage, nutritional status, Handgrip test, Simple Evaluation of Food Intake (SEFI), spontaneous food intake evaluation) ; a medication reconciliation ; physical therapy (Six Minute Walk Test)
223504127|NCT05363085|OTHER|Mechanically ventilated neurosurgical patients|Observational study where respiratory variables and intracranial pressure will be measured during mechanical ventilation and during specific respiratory manoeuvres. No intervention is planned.
223504128|NCT02207179|DEVICE|LumaScan Image Guided Surgery|
223504129|NCT00151073|DRUG|Zoledronic acid|
223504130|NCT00151073|DRUG|Estramustine|
223504131|NCT00151073|DRUG|Docetaxel|
223504132|NCT06499909|OTHER|Hypnosis|The patient will receive a course of hypnosis
223504133|NCT02217982|DRUG|Simethicone|
223504134|NCT02217982|DRUG|Loperamide|
223504135|NCT02217982|OTHER|Peanut Butter|
223504136|NCT05412901|OTHER|discrimination task|Participants perform a discrimination task while their brain activity is recorded with EEG. Beta power will be estimated using spectral decomposition techniques, zooming in on subject specific bands in temporospatial windows of interest, and correlated with (1) WM content, (2) decision outcome, and (3) behavioral performance (i.e., accuracy and RT).
223504137|NCT05615441|DEVICE|Analgesia Nociception Index monitor|Patients will receive remimazolam-based total intravenous general anesthesia with nociception monitoring with the ANI monitor
224194977|NCT00136565|DRUG|Prednisone|60 mg/m², D1-D5, 4 cycles
224194978|NCT00136565|DRUG|Cyclophosphamide|1200 mg/m², D1, 4 cycles
224194979|NCT00136565|DRUG|Vindesine|2 mg/m², D1, D5, 4 cycles
224194980|NCT00136565|DRUG|Bleomycin|10 mg, D1, D5, 4 cycles
224194981|NCT01861730|BIOLOGICAL|AERAS-404|AERAS-404 has two components: the H4 antigen and the IC31 adjuvant. The reconstitution of the vaccine components, H4 antigen (manufactured at SP) and IC31 adjuvant (supplied by SSI), will take place at the clinical research site (CRS) prior to injection.
224194982|NCT01861730|BIOLOGICAL|Placebo|Tris buffered saline (10mM Tris, pH 7.4, 150nm sodium chloride).
224194983|NCT06702150|BEHAVIORAL|Changing the nursing care model to the primary nursing model|The nurses received training in primary nursing care before the start of the intervention. The model was tested and implemented in early April 2022. Since then, all patients admitted to the unit have been assigned to a primary nurse within the first 48 hours. This nurse is responsible for developing and monitoring the patient's care plan, assessing care needs, implementing the care plan and evaluating the outcomes. This nurse is also responsible for coordinating care needs and discharge planning with other healthcare professionals. When the primary nurse is not working, another nurse from his or her team continues the care plan that he or she has defined. All patients admitted to the unit who met the selection criteria were informed about the study and, if they agreed to take part, completed a self-care competence questionnaire at admission (baseline), at discharge and one month after discharge. They also completed a questionnaire on satisfaction with nursing care at discharge.
224194984|NCT04707014|BEHAVIORAL|Hypnosis|Rapid conversational hypnosis
224194985|NCT04707014|BEHAVIORAL|Attention-distracting techniques|i-pad with movies, games and music
224194986|NCT03390010|DRUG|Misoprostol + syntocinon and using extra uterotonic drugs when needed ; methergine|medical prophylaxis against postpartum atony and postpartum hemorage by giving misoprostol plus syntocinon and using extra uterotonic drugs when needed ; methergine, carboprost
224194987|NCT03390010|DRUG|Syntocinon and using extra uterotonic drugs when needed ; methergine carboprost|medical prophylaxis against postpartum atony and postpartum hemorage by giving syntocinon and using extra uterotonic drugs when needed ; methergine, carboprost
224194988|NCT02516917|BEHAVIORAL|Attention Training Technique|
223504138|NCT05615441|DEVICE|Standard monitoring|Patients will receive remimazolam-based total intravenous general anesthesia based on hemodynamic monitoring and without nociception monitoring
223504139|NCT06523946|BEHAVIORAL|Diabetes Prevention Program (DPP) (shortened)|The investigators will adapt the protocol of the 'Ohana project. The 'Ohana protocol was developed based on CDC's Diabetes Prevention Program (DPP) curriculum and designed to fit PcI's cultural background. It includes a 8-lesson curriculum delivered in 8 weeks (shortened from the original 16-lesson, 24-week core curriculum of DPP while retaining all original foci and behavior change strategies). Specifically, the first four lessons, delivered every week, focus on getting the participants started on increasing PA and improving diet (e.g., introduction; getting started on PA and diet; utilizing goal setting; making the process fun). The second four classes will be taught every other week and will focus on how to handle various challenges involved in maintaining healthy lifestyle behaviors. The investigators will deliver the curriculum in group settings of 15 people in a separate room in the National Tongan American Society.
224194989|NCT05604521|BIOLOGICAL|PfSPZ Vaccine|PfSPZ vaccine consists of radiation-attenuated, aseptic, purified Plasmodium falciparum (NF54) sporozoites (SPZ) cryopreserved in liquid nitrogen vapor phase (LNVP) at -150C to - 196C. PfSPZ Vaccine is composed of PfSPZ derived from the NF54 strain of Pf, which is thought to be from West Africa. PfSPZ Vaccine is diluted in phosphate buffered saline (PBS) with human serum albumin (HSA) to achieve the correct dosage and is administered by DVI.
224194990|NCT05604521|BIOLOGICAL|PfSPZ Challenge (7G8)|PfSPZ Challenge (7G8) is similar to PfSPZ Vaccine but has not been attenuated by radiation and is therefore infectious.PfSPZ Challenge (7G8) is composed of PfSPZ derived from the 7G8 clone of Pf, which is from Brazil.
224194991|NCT05604521|OTHER|Normal Saline|0.9% sodium chloride
224194992|NCT01530152|PROCEDURE|Truwiev PCD laryngoscope|"The aim of the method evaluation study is a comparing study of Truview PCD™ laryngoscope vs. Macintosh laryngoscope. The result of this study will form a basis for a possible recommendation of the Truview PCD™ laryngoscope in our organisation.~The laryngoscopes are compared according to their ability to visualize the glottis area measured by the Cormack Lehane (CL) grade and the time used to get the best CL grade. (See figure 1.) A registration of any damage of tissue/teeths caused by the laryngoscopes, and a possible decrease of the saturation will also be made."
224194993|NCT04352907|DEVICE|Continuous Glucose Sensor|Continuous glucose sensor results will be compared with arterial glucose samples
224194994|NCT06180993|BIOLOGICAL|Nirsevimab|Nirsevimab will be administered administered in a single dose at birth for birth cohort and at the beginning of the campaign for the other cohorts under study
224194995|NCT04669756|PROCEDURE|ovariopexy|if endometriosis was removed from the pelvic side wall or the ovary or both leading to an open wound adjacent to the ovary, ovariopexy was performed on both sides using a transabdominal-transovarian suture being tied extracorporeally on the patients Skin leading to uplifting of the ovary to the abdominal wall
224194996|NCT04669756|PROCEDURE|placebo operation|in arm D sutures are transabdominal only
224194997|NCT03877276|DIETARY_SUPPLEMENT|Breakfast|a prepared meal consisting of pastry and 2 cooked egg whites
224310493|NCT03530176|RADIATION|18Fluoride-Sodium Fluoride radio-isotope|The investigators will be using 18F-NaF to image premature atherosclerosis in the coronary arteries of diabetic patients.
223504140|NCT00004032|BIOLOGICAL|ALVAC-hB7.1|Given IP
223504141|NCT00004032|BIOLOGICAL|recombinant interferon gamma|Given IP
223504142|NCT00004032|OTHER|laboratory biomarker analysis|Correlative studies
223504143|NCT02117817|DRUG|BKM120|
223504144|NCT02117817|DRUG|Nabpaclitaxel|Given IV
223504145|NCT02993302|DRUG|1α-D3|patients were given PTU and 1α-D3
223504146|NCT02993302|DRUG|Placebos|patients were given PTU and placebos
223504147|NCT03279965|DIAGNOSTIC_TEST|MRI|MRI of lungs, paranasal sinuses and liver in addition to established clinical examinations (lung CT, pulmonary function testing)
223504148|NCT00508300|PROCEDURE|Epidural analgesia|Thoracic epidural analgesia until day 2
223504149|NCT00508300|PROCEDURE|Patient controlled analgesia|Patient controlled analgesia (morphine-based)
223504150|NCT05406999|DRUG|ADT|The ADT regimen will be determined by the investigators at separate centers. The dose and frequency of administration will be consistent with the prescribing information. Available drugs include triptorelin, goserelin, leuprolide, digareke ect.
223504151|NCT05406999|DRUG|Abiraterone Acetate|1000 mg (250 mg×4 tablets) once daily, orally
223504152|NCT05406999|DRUG|Prednisolone tablets|5 mg once daily, orally.
223504153|NCT05406999|DRUG|Enzalutamide|160 mg (40 mg× 4 tablets) once daily, orally.
224194998|NCT03877276|DIETARY_SUPPLEMENT|Spinach smoothie|a prepared blended spinach smoothie, consisting of banana, avocado, orange juice, and spinach
224194999|NCT03877276|DIETARY_SUPPLEMENT|Kale smoothie|prepared blended kale smoothie, consisting of banana, avocado, orange juice, and kale
224195000|NCT03877276|DIETARY_SUPPLEMENT|Blended smoothie|a prepared blended smoothie, consisting of banana, avocado, and orange juice
224195001|NCT03877276|DIETARY_SUPPLEMENT|V spinach smoothie|a prepared blended spinach smoothie, consisting of banana, avocado, orange juice, and a varying amount (low, medium, high) of spinach
223592908|NCT00861328|DRUG|ON 01910.Na and oxaliplatin|"ON 01910.Na will be administered by IV infusion over 24 hours once per week in a 6-week cycle (6 doses per cycle). The dose of ON 01910.Na will start at 250 mg/m2 and will proceed to higher dose levels after safety review of the combination regimen in the previous cohort.~The suggested starting dose of Oxaliplatin is 85 mg/m2 administered by IV infusion over 120 minutes every 2 weeks of a 6-week cycle (3 doses per cycle). Reductions in the starting doses according to recommendations of current approved prescribing information may be considered after review of patients' medical histories and potential tolerances to treatment with the chemotherapy agent."
223592909|NCT05238805|RADIATION|Observational heart and kidney on siemens TEP scan|Same as arm description
223592910|NCT03009084|BEHAVIORAL|Lifestyle counseling|Lifestyle counseling of modifiable risk factors of chronic kidney disease: telemonitoring of blood pressure, counseling for smoking cessation, losing weight and increasing the physical activity.
223592911|NCT03753399|PROCEDURE|acupuncture|Acupuncture at back-shu points according to heat-pain threshold measurement at 24 well-points, combining with electro-acupuncture at fixted acupoints.
223592912|NCT03549559|DRUG|11C-Martinostat|Imaging probe for evaluating the activity of histone deacetylase in the heart
223592913|NCT03549559|DEVICE|PET-MRI|Siemens PET-MR Scanner (Biograph MMR)
223592914|NCT01085032|DRUG|Transdermal Nicotine|Subjects in the experimental group receive six weeks of nicotine patch treatment, 24 hour dose, using a step-down algorithm. Participants who smoke greater than 10 cigarettes/day receive two weeks of 21 mg patch, followed by two weeks of 14 mg patch, and then two weeks of 7 mg patch. Participants who smoke 5-9 cigarettes per day receive four weeks of 14 mg patch, followed by two weeks of 7 mg.
223592915|NCT01085032|DRUG|Placebo nicotine patch|"Subjects in the placebo condition receive an inert placebo patch matched for size, shape, color, and packaging.~The same step-down dosing algorithm as in the experimental condition is used."
223592916|NCT04651127|DRUG|Toripalimab + Chidamide|In combination dose finding phase, phase 1b will begin with Dose Level 1: chidamide 30 mg/day orally (twice a week) and toripalimab (240mg q3w, intravenously) will be administered to eligible subjects on a 21-day treatment cycle. Two dose de-escalation steps are included: Dose Level 2 (chidamide 25 mg/day orally, twice a week and toripalimab 240mg q3w, intravenously) and Dose Level 3 (chidamide 20 mg/day orally, twice a week and toripalimab 240mg q3w, intravenously). If RP2D was reached in Part A, eligible patients would be enrolled and receive toripalimab (240mg q3w, intravenously) plus chidamide (RP2D, twice a week).
223592917|NCT00115895|DRUG|Radioactive iodine|Radioiodine is radionuclear treatment given in oral capsules in two activies 1,1 and 3,7 GBq
223592918|NCT02441556|DEVICE|endovascular treatment|The endovascular treatment is comprised of thrombolysis, mechanical thrombectomy, stenting, or a combination of all these approaches. Generally, Solitaire FR is preferred, other devices such as Trevo or future advanced devices can also be considered which will be decided by the executive committee.
224195002|NCT03877276|DIETARY_SUPPLEMENT|Sodium oxalate drink|a prepared sodium oxalate drink
224195003|NCT03981315|DIAGNOSTIC_TEST|Bile test|Analyze bile components related to gall stones synthesis (cholesterol, bile acids, phospholypids, etc.)
224195004|NCT03981315|DIAGNOSTIC_TEST|Blood test|Analyze blood components related to gall stones synthesis (cholesterol, bile acids, phospholypids, etc.)
224195005|NCT03981315|DIAGNOSTIC_TEST|Gall stone study|Study of the extracted gall stones, analyzing their composition, type, etc.
224195006|NCT03981315|DIAGNOSTIC_TEST|Microbiological bile test|Determination of the microbiological composition of the bile
224195007|NCT03381898|BEHAVIORAL|Telehealth Exercise, speech therapy, medication management|Telehealth exercise once per week, speech therapy 4 times per week, medication management once per week
224195008|NCT04651582|BEHAVIORAL|Cognitive Training|20 hours of computerized activities designed to improve processing speed and divided attention
224195009|NCT04651582|BEHAVIORAL|Cognitive Stimulating Activities|20 hours of traditional computer games
223504154|NCT05406999|DRUG|Apalutamide|240 mg (60 mg×4 tablets) once daily, orally.
223504155|NCT05406999|DRUG|Darotamide|600 mg (300 mg × 2 tablets) twice daily, orally.
223504156|NCT05406999|DRUG|Rezvilutamide|240 mg (80 mg × 3 tablets) once daily orally
223504157|NCT05406999|DRUG|PARP inhibitor|The PARP inhibitors will be determined by the investigators at separate centers. The dosage and frequency of administration will be consistent with the prescribing information. Available drugs include olaparib, fluzoparib, pamiparib, talazoparib ect.
223504158|NCT05406999|PROCEDURE|Robot-assisted radical prostatectomy|Robot-assisted radical prostatectomy was performed within 2 weeks after the end of the therapy.
223504159|NCT02324322|DEVICE|Exoskeleton Training|Exoskeleton Training (100 sessions - 1 hour, 4 - 5 sessions per week for 20 weeks) to enhance functional ambulation for persons with a spinal cord injury. To examine the effectiveness of exoskeleton assisted overground walking to induce positive changes in muscle volume and structure of the lower limbs for non-ambulatory persons with SCI.
223504160|NCT02324322|OTHER|Muscle Biopsies|"Needle Biopsies for Quadricep Muscles will be performed to define changes in BMD and Bone structure with intensive exoskeleton assisted walking. This procedure includes having a trained physician make a small skin incision, after numbing the area over the muscle, and then removing a tiny sliver of muscle to study under the microscope. Three separate biopsies for one incision will be obtained. The biopsies will be performed at baseline, 7 days, and after the intervention.~To define changes in biochemical markers of bone metabolism with intensive exoskeleton-assisted walking."
223504161|NCT02324322|OTHER|MRI|MRI's will provide accurate assessments of muscle CSA of each lower limb (from above the origin of the iliopsoas to the insertion of the achilles tendon) to determine individual's muscle thigh and shank volume.
223746827|NCT03342547|PROCEDURE|Saliva|Saliva (1-2 mL) will be collected from each participant for secretor status testing
223746828|NCT03357692|PROCEDURE|all on four implant rehabilitation|implant insertion after piezoelectric site preparation for trans-sinusal implants
223746829|NCT03054584|OTHER|Collecting Nevi|Will be collecting Nevi and completing a DNA analysis, no intervention will be made.
223746830|NCT01807897|DEVICE|Continuous positive airway pressure|Nocturnal continuous positive airway pressure, titrated to minimize apnea-hypopnea index
223746831|NCT01807897|DEVICE|Nocturnal supplemental oxygen|Nocturnal supplemental oxygen, titrated to 2-4 liters/minute with target of eliminating nocturnal hypoxemia
223746832|NCT01807897|BEHAVIORAL|Healthy Lifestyle and Sleep Education|A 60-minute educational intervention with slide show and printed materials, educating the patient in healthy sleep habits and heart-healthy lifestyle
223746833|NCT02951338|BEHAVIORAL|PROPEL program|The PROPEL program involves both group aerobic exercise and group discussion aimed at enabling participation in exercise after discharge. Components of the PROPEL program were developed according to the Transtheoretical Model of health behaviour change and Social Cognitive Theory. In addition to group exercise participants will attend 1-hour small group discussion sessions once weekly to learn self-management skills for exercise in preparation for discharge from rehabilitation. These discussions include: identifying and solving problems around barriers to exercise; understanding personal and general benefits of exercise; exploring appropriate community resources for exercise; and finding individualized and realistic strategies for incorporating exercise in a regular routine. Participants will become comfortable with progressing their exercise and will set short- and long-term exercise goals.
224195010|NCT06452862|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|Both Diabetics and Healthy Volunteers will undergo MRI protocols including Blood Oxygen Level Dependence (BOLD), Intravoxel Incoherent Motion (IVIM), Arterial Spin Labeling (ASL), T1\&T2-mapping imaging and Magnetic Resonance Elastography (MRE). For Diabetics, blood tests for creatinine and cystatin C, along with blood pressure measurements, will be taken within a three-day window surrounding the MRE test. Additionally, Diabetics will undergo a renal biopsy to assess the extent of kidney damage.
224195011|NCT06048198|OTHER|No intervention|No intervention
224310494|NCT05211076|OTHER|Music Group|"The Introductory Information Form will be filled in by researcher using face-to-face interview technique.It will be ensured that the mother fills the State Anxiety Scale with her own statement.On the 1st day of the post-op,mothers will be able to listen to Classical Turkish Music works in the forms of Saz Semaisi,Peşrev,Medhal in Rast,Uşşak,Kürdi,Muhayyer makams for 30 minutes via their phone at 11:00am.~While the mother continues to listen to the music,at the 16th minute,the researcher will manually milk the mother for at least 15 minutes until milk comes out.At the end of the milking process,the milk accumulated in the container will be measured by the researcher with injector,recorded in the Breast Milk Follow-up Form.At the end of the music session,it will be ensured that the mother fills in the State Anxiety Scale with her own statement.~The same procedure will be applied to the mother atb05:00pm.This process will be carried out 8 times in total,at 11:00am and 05:00pm for 4days."
224195012|NCT00672308|OTHER|Benefiber|
224195013|NCT00672308|OTHER|Benefiber with ORS|Benefiber (50 g/L)-supplemented, reduced-osmolarity WHO-ORS
224195014|NCT00672308|OTHER|Benefiber with ORS|
224195015|NCT00672308|OTHER|Benefiber with ORS|
223504162|NCT01755637|DRUG|Albendazole|Albendazole tablets 400 mg
223504163|NCT00668564|PROCEDURE|Stem Cell Transplantation|The purpose of hematopoietic stem cell transplantation is to introduce blood producing cells from a normal donor. These cells can either provide what is missing in the body to the other cells, or can change the body's immune response to the substances that have accumulated in the body. These normal hematopoietic stem cells can come from bone marrow, peripheral blood (i.e., the blood circulating in our body's blood vessels) or umbilical cord blood (i.e., blood taken from the umbilical cord after a baby is born and umbilical cord is cut). The new donor cells repopulate the blood and bone marrow system and enter the organs of the body, including the brain. Wherever these cells go, they will produce the needed enzyme.
223504164|NCT00668564|DRUG|Cyclophosphamide|"Days before Transplant Drug Frequency~* 4 Cyclophosphamide Once, given over 2 hours~* 3 Cyclophosphamide Once, given over 2 hours~* 2 Cyclophosphamide Once, given over 2 hours~* 1 Cyclophosphamide Once, given over 2 hours"
223504165|NCT00668564|DRUG|Campath-1H|"Days before Transplant Drug Frequency~12 Campath-1H Once, given over 2 hours~11 Campath-1H Once, given over 2 hours~10 Campath-1H Once, given over 2 hours"
223504166|NCT00668564|DRUG|Busulfan|"Days before Transplant Drug Frequency~9 Busulfan Four times per day~8 Busulfan Four times per day~7 Busulfan Four times per day~6 Busulfan Four times per day"
223504167|NCT01814332|DRUG|GSK561679|GSK561679, oral administration, 350mg/day, 6 week administration
223504168|NCT01814332|DRUG|Placebo|Placebo compound treatment for comparison with IP
223504169|NCT05551897|DRUG|Camizestrant|Subjects will be administered a single oral dose of Camizestrant on Day 1 of treatment period 1 and treatment period 3.
223504170|NCT05551897|DRUG|Itraconazole|Subjects will be administered Itraconazole twice a day on Day 1 and once daily on Day 2 and Day 3 of treatment period 2, and once daily on Day 1, 2 and 3 of treatment period 3.
223504171|NCT04048083|BEHAVIORAL|Mental trainings|Patients will receive 36 trainings (12 weeks with 3 trainings a week) of mental, kinesthetic reaching-to-grasp movement. During each training session they will perform 3 practice trials by following the instructions, after practicing 3 trials, the instructions will be discontinued, and subjects will perform 30 mental movements by following auditory cues.
224195016|NCT00672308|OTHER|the reduced-osmolarity WHO-ORS without added Benefiber|
224195017|NCT00672308|OTHER|the reduced-osmolarity WHO-ORS without added Benefiber|
224195018|NCT03350880|OTHER|Flexibility training|Flexibility training was carried out over a period of six weeks, with two sessions per week, totaling 12 sessions.
224195019|NCT03835312|PROCEDURE|Sequential transplantation|After successful matching of umbilical cord blood stem cells, patients will receive pretreatment and chemotherapy under protective isolation, followed by thawing and reinfusion of umbilical cord blood stem cells. Immunosuppressive agents will be used for GVHD prevention and anti-infection support will be provided after reinfusion. The status of umbilical cord blood stem cell implantation, immune reconstruction and therapeutic effect will be evaluated. Islet transplantation will be performed in those who meet the conditions. The long-term prognosis will be observed by long-term follow-up.
223746834|NCT02951338|OTHER|Group aerobic exercise|"Supervised group exercise up to 3-times/week for 6 weeks. A typical exercise session will involve a 3-5 minute 'warm-up', 20-30 minutes of aerobic exercise at a target heart rate determined from a sub-maximal test, and a 3-5 minute 'cool-down' of low-intensity exercise. The choice of exercise modality for the submaximal test and for training (e.g., recumbent stepper, cycle ergometer, or treadmill) will be individually prescribed based on patients' sensori-motor recovery, postural control, functional abilities, and safety. Heart rate, blood pressure, rate of perceived exertion, workload, and duration of training will be documented for each session. These data will be reviewed by the physiotherapist with appropriate progression of the intensity and/or duration of exercise as necessary.~Participants may receive general advice to keep physically active after discharge, and may receive an individualized home exercise program, as is currently routine care at all sites."
224195020|NCT02135276|DRUG|eravacycline|All subjects will receive s single dose of intravenous eravacycline (1.5 mg/kg) administered over 60 minutes on Day 1. This study includes an up to 21-day Screening Period, a 5-day Treatment Period, and an End of Study Visit occurring approximately 2 weeks (±2 days) after study drug administration. Approximately 12 subjects will be enrolled: 6 subjects with ESRD and 6 healthy subjects with normal renal function. Healthy subjects will be matched to renally impaired subjects in gender, age, and body mass index (BMI).
224195021|NCT06698263|DRUG|Isotretinoin|ARESPERM is a multicenter, randomized, double-blind, placebo-controlled study that assesses whether a weekly dose of isotretinoin can stimulate spermatogenesis in men with oligozoospermia. The study hypothesizes that isotretinoin can trigger the differentiation of spermatogonial cells, leading to improved sperm production.
224195022|NCT06698263|DRUG|Control group (placebo)|placebo administration
224195023|NCT02599610|OTHER|Digital vaginal examination|Patients will be subject to digital vaginal examinations every four hours during latent phase of first stage, hourly during active phase of first stage and as needed during second stage.
224195024|NCT02599610|DEVICE|Transperineal ultrasound examination|Patients will be subject to transperineal ultrasound examinations every four hours during latent phase of first stage, hourly during active phase of first stage and as needed during second stage.
223592919|NCT02441556|OTHER|standard medical therapy|If the patient meets the criteria for IV rt-PA within 4.5 h of stroke onset, he/she will receive a single alteplase dose of 0.9 mg/kg IV(maximum dose: 90mg), with 10% given as a bolus, followed by continuous IV infusion of the other dose within 1h. All patients will receive standard medical therapy. The standard medical therapy conforms with the current American Heart Association/American Stroke Association guidelines.
223592920|NCT03131882|DRUG|Hyaluronic Acid|1 ml of Low molecular weight hyaluronic acid injection under ultrasound guidance after subcutaneous 0.5ml of 1%lidocaine injection
223592921|NCT03131882|DRUG|Triamcinolone Acetonide|1ml of 10 mg of triamcinolone injection under ultrasound guidance after subcutaneous 0.5 ml 1%lidocaine injection
223592922|NCT05895539|OTHER|An automated patient-reported outcome data collection and adverse event surveillance tool|Patients received a short prompt to provide information on treatment satisfaction and side effects
223592923|NCT06543329|PROCEDURE|polyglactin 910|75 PARTICIPANT, Vicryl suture was used in subcuticular suture
223592924|NCT06543329|PROCEDURE|poliglecaprone 25|75 PARTICIPANT, monocryl suture was used in subcuticular suture
223592925|NCT06543329|PROCEDURE|polypropylene|75 PARTICIPANT, Prolene suture was used in subcuticular suture
223592926|NCT06543329|PROCEDURE|polyester|75 PARTICIPANT, Polyester suture was used in subcuticular suture
223592927|NCT06543927|DIAGNOSTIC_TEST|serum creatinine|Detection of renal impairment in patients receiving anticoagulants
223592928|NCT06543927|DIAGNOSTIC_TEST|INR|Detection of bleeding in patients with choronic kidney disease receiving anticoagulants
223592929|NCT00992823|DRUG|iron supplementation|40 doses of 30 mg of ferrous sulfate during a 10-month intervention period
223592930|NCT00992823|BIOLOGICAL|iron supplementation|supplementation in two 5-month cycles, each cycle consisting of one month of supplementation (20 workdays) and four months without supplementation.
223592931|NCT00607399|DRUG|SGX523 Capsules|This is a dose escalation study
223746835|NCT04431479|PROCEDURE|Biospecimen Collection|Undergo collection of blood sample
223592932|NCT00240383|DRUG|Muraglitazar|
223592933|NCT01364909|OTHER|Exercise|"The subjects will be given 2 x 30 minute sessions of exercise per day consisting of either passive, active, active assisted depending on level of sedation and stability of condition.~According to level of sedation and stability they may also perform sitting exercises"
223592934|NCT01364909|OTHER|Usual practice|These patients will not receive exercise early in their intensive care admission
223746836|NCT04431479|OTHER|Medical Chart Review|Review of medical chart
223746837|NCT04431479|OTHER|Quality-of-Life Assessment|Ancillary studies
223746838|NCT04431479|OTHER|Questionnaire Administration|Complete questionnaire
224195025|NCT03681769|DEVICE|iTBS to the left dlPFC|This will be delivered with the Magventure Magpro system; 600 pulses with the active sham coil (double blinded using the Universal Serial Bus (USB) key).
224195026|NCT03681769|DEVICE|Sham iTBS to the left dlPFC|This will be delivered with the Magventure Magpro system; 600 pulses with the active sham coil (double blinded using the USB key). The MagVenture MagPro system has an integrated active sham that passes current through two surface electrodes placed on the skin beneath the B60 coil.
224195027|NCT03681769|DEVICE|cTBS to the mPFC|This will be delivered with the Magventure Magpro system; 600 pulses with the active sham coil (double blinded using the USB key)
224314237|NCT01551030|DRUG|Buparlisib|Buparlisib will be administered at a dose of 100 mg orally once daily (two 50 mg capsules) continuously. Intra-patient dose reduction may be required depending on the type and severity of the individual toxicity encountered. Re-staging imaging studies will be performed after every two cycles of treatment (one cycle = 4 weeks). Patients may continue on study as long as they are tolerating therapy and are free of disease progression.
224314238|NCT00219817|DRUG|RC-1291 HCl|
223592935|NCT04496011|OTHER|Aerobic training with cycle ergometer|Patients start with an initial warm-up of 2 minutes, with rotations per minute free, without load. Progressively, the load of the exercise cycle increases every minute up to the supported limit or up to 60% - 70% of maximum heart rate (HRmax). The training will be carried out for 20 continuous minutes, being interrupted whenever the heart rate (HR) reaches 90% of the maximum expected for the age and / or the loss of effort perceived in the BORG scale, above 8 on a scale of 0 to 10.
224195028|NCT03681769|DEVICE|Sham cTBS to the mPFC|This will be delivered with the Magventure Magpro system; 600 pulses with the active sham coil (double blinded using the USB key). The MagVenture MagPro system has an integrated active sham that passes current through two surface electrodes placed on the skin beneath the B60 coil.
224195029|NCT02705417|PROCEDURE|preoperative color Doppler ultrasonographic vascular mapping|Preoperative color Doppler ultrasonographic vascular mapping was performed with linear probe. The patient extremity under scrutiny was placed under support, with tourniquet augmentation. Vessels were examined in both short (transverse) and long (longitudinal) axis. Anatomical variations, wall morphology and internal diameters at the antecubital fossa, the proximal (cranial), mid and distal (caudal) third of the arm and forearm were assessed in both extremities. Veins were evaluated for compressibility and adequate drainage to deep venous system. The presence of sclerotic, thrombosed and fibrosed segments were noted. Doppler waveforms were obtained in the long axis and volume flow (VF) calculated for arteries selected for potential access construction.
224195030|NCT02705417|PROCEDURE|physical examination|Arterial pulse examination, differential blood pressure measurements and the Allen test in both extremities. Inspection of the superficial venous system with tourniquet enhancement in the arm was performed during venous assessment.
224195031|NCT02705417|PROCEDURE|medical history|medical history with respects to diabetes mellitus, coronary heart disease, peripheral vascular disease
224314239|NCT02256423|DRUG|REFERENCE 1: Nurofen® 200 mg tablet|
223504172|NCT04048083|BEHAVIORAL|Computer-aided trainings|Patients will receive 36 trainings (12 weeks with 3 trainings a week) of visual feedback of reaching-to-grasp movement. During each training session they will be sitting on a chair, in front of a computer screen observing simple tasks of reaching and precision fine grasping of a small object with 4 fingers of virtual upper extremity using the visualization software that will be coded specifically for the purpose of this experiment.
224195032|NCT02705417|PROCEDURE|native arteriovenous fistula construction|surgigal creation of native arterial and venous anastomoses
224314240|NCT02256423|DRUG|REFERENCE 2: Ibuprofen 200 mg soft gel capsule|
224314241|NCT02256423|DRUG|ibuprofen 200 mg soft gel capsule|
224314242|NCT06280521|OTHER|fGQ-ASC|French version of the Girl Questionnaire for Autism Spectrum Conditions (fGQ-ASC)
223504173|NCT04048083|BEHAVIORAL|Computer-aided and mental trainings|Patients will receive 36 trainings (12 weeks with 3 trainings a week) of mental, kinesthetic reaching-to-grasp movement that will be supplemented by visual feedback of this task by the visualization software that will be coded specifically for the purpose of this experiment (they will receive trainings that link the features of the two mentioned above types of training (MT and CAT).
223504174|NCT04048083|OTHER|No trainings|Healthy controls without any kind of training
223504175|NCT00027443|DRUG|Muromonab-CD3|
223504176|NCT00027443|DRUG|Cyclosporine|
223504177|NCT03356561|BIOLOGICAL|Ad26.ZIKV.001 5*10^10 vp|Participants will receive Ad26.ZIKV.001 at a dose of 5\*10\^10 vp via IM route.
223504178|NCT03356561|BIOLOGICAL|Ad26.ZIKV.001 1*10^11 vp|Participants will receive Ad26.ZIKV.001 at a dose of 1\*10\^11 vp via IM route.
223504179|NCT03356561|BIOLOGICAL|Placebo|Participants will receive placebo via IM route.
223504180|NCT01283425|DEVICE|InsuPatch|Heaters for single use and a permanent control unit.
223504181|NCT05349266|BIOLOGICAL|ThisCART19A|each patient will receive a dose level per body weight(kg) for only once.
223504182|NCT03701087|DRUG|Vitamin D|2800 IU daily till 26 weeks of pregnancy
223504183|NCT06195215|OTHER|Peer Counselling|7 weeks peer counselling process will be carried out.
223504184|NCT02141724|OTHER|Positioning consultation|Assessment of pain,bedsores and postural troubles
223504185|NCT03316560|BIOLOGICAL|rAAV2tYF-GRK1-RPGR|Adeno-associated virus vector expressing a human RPGR gene
223504186|NCT02468375|DRUG|mirabegron 50mg|434 OAB patient intake mirabegron 50mg/day for 12 weeks.
223504187|NCT01096186|DRUG|IPX066 95 mg|23.75 - 95 mg CD-LD capsules
223504188|NCT01096186|DRUG|IPX066 145 mg|36.25 - 145 mg CD-LD capsules
223504189|NCT01096186|DRUG|IPX066 195 mg|48.75 - 195 mg CD-LD capsules
223504190|NCT01096186|DRUG|IPX066 245 mg|61.25 - 245 mg CD-LD capsules
223504191|NCT00884000|DRUG|Genotropin|
223504192|NCT00884000|DRUG|Zomacton|
223504193|NCT06259838|OTHER|no intervention|no intervention
223504194|NCT04037956|PROCEDURE|Tubeless NOSES|The whole procedures undergo by total laparoscopic surgery with no specimen extraction incision in the abdominal wall. The specimen then will be removed through natural orifice such (anal).
223504195|NCT04037956|PROCEDURE|traditional laparoscopic radical resection|The traditional laparoscopic operation undergo and then a small incision(5-8cm) is made in the middle of the lower abdominal wall to remove the specimen.
223504196|NCT01367756|DRUG|RO4995819|multiple oral doses, Days 10-16
223504197|NCT01367756|DRUG|citalopram|multiple oral doses, Days 1-16
223504198|NCT01367756|DRUG|placebo|multiple oral doses, Days 10-16
223504199|NCT01123564|DRUG|ranibizumab|applied monthly in the first 3 months period, and after this only if visual acuity (VA) decreases with more than 5 letters at any monthly visits
223504200|NCT01123564|RADIATION|Argon laser treatment|Conventional grid pattern argon laser treatment and panretinal argon laser photocoagulation in an as needed basis.
223504201|NCT06107673|DRUG|Dalpiciclib|Dalpiciclib: Take 125 mg once daily for 3 weeks, then stop for 1 week. Each cycle is completed in 4 weeks. It is recommended to take the medication approximately at the same time each day, with warm water, preferably on an empty stomach. Fasting for at least 1 hour before and after medication is advised.
223504202|NCT06107673|DRUG|Aromatase inhibitor|AI: Take according to the instructions provided.
224195033|NCT02705417|PROCEDURE|arteriovenous graft placement|surgical placement of arteriovenous graft
224195034|NCT04476459|DRUG|Camrelizumab|Camrelizumab will be administered every 3 weeks up to 6 cycles during induction phase, and then every 4 weeks up to 12 cycles in maintenance phase if patients get CR or PR after induction phase.
224195035|NCT04476459|DRUG|Apatinib|"Phase I: dose escalation phase. Patients will oral dosage as 250mg, 500mg or 750mg,qd, per day. Aim to evaluate MTD and DLT, RP2D.~Phase II：Patients continuous oral apatinib as RP2D up to 6 cycles during induction phase, and then 250mg/d up to 1 year in maintenance phase if patients get CR or PR after induction phase."
224195036|NCT04296071|OTHER|Research study|Blood and tracheal aspirates will be collected
224195037|NCT00000254|DRUG|40% Nitrous oxide|Used as pain assay positive control
224195038|NCT00000254|OTHER|Sham comparator|0% isoflurane in oxygen
224195039|NCT00000254|DRUG|0.2% isoflurane|
224195040|NCT00000254|DRUG|0.4% isoflurane|
224195041|NCT00000254|DRUG|0.6% isoflurane|
224195042|NCT04377516|OTHER|pelvic floor muscle training|pelvic floor muscle training
224195043|NCT04377516|OTHER|pelvic floor muscle combined global muscle exercise training|pelvic floor muscle combined global muscle exercise training
224195044|NCT04377516|OTHER|education of pelvic girdle|education of pelvic girdle
224195045|NCT04177472|BEHAVIORAL|Obesity Prevention Group|Parents will be provided with responsive feeding coaching to help them recognize hunger and satiety cues and nutrition coaching that involves recommending a sequence of introducing complementary foods that corresponds with food textures and feeding styles, breast/bottle weaning, healthy snacking and hands on demonstrations for healthy food options.
224195046|NCT04177472|BEHAVIORAL|Obesity Prevention Group + Food Boxes|Parents will be provided with responsive feeding coaching to help them recognize hunger and satiety cues and nutrition coaching that involves recommending a sequence of introducing complementary foods that corresponds with food textures and feeding styles, breast/bottle weaning, healthy snacking and hands on demonstrations for healthy food options. Parents will also be provided with grocery items (fruits, vegetables, meat) prior to each intervention visit to facilitate a healthy family diet.
224195047|NCT04177472|BEHAVIORAL|Infant Safety and Injury Prevention Group|Parents will be provided with information about safe sleeping, car seats, baby-proofing, etc., delivered during home visits, newsletters, and reinforcing text messages.
224195048|NCT04390100|DRUG|hyaluronic acid (Gengiegel 0.2% oral gel )|coverage of the free gingival graft area in the palate
223504203|NCT06107673|DRUG|Docetaxel injection|Administered as a 75 mg/m2 intravenous infusion over approximately 30 minutes. It is given every three weeks and dose reduction or treatment delay is allowed, up to a maximum delay of 3 weeks from the previous dose calculation. Treatment will be terminated if the delay exceeds this limit.
224195049|NCT04390100|OTHER|Platelet rich fibrin|coverage of the free gingival graft area in the palate
224195050|NCT04390100|OTHER|Gel foam|coverage of the free gingival graft area in the palate
224195051|NCT01277107|DRUG|Zaleplon AP formulation|Gastric retentive dual release Zaleplon
224195052|NCT01277107|DRUG|Placebo capsule|Identical placebo capsule
224195053|NCT01637207|OTHER|Palpation|Group A: Palpation Group
224195054|NCT01637207|OTHER|Ultrasound|Group B: Ultrasound Group
224195055|NCT02406937|DIETARY_SUPPLEMENT|Oral intake of Feihe New Formula|Oral intake of Feihe New Formula
224195056|NCT02406937|DIETARY_SUPPLEMENT|Oral intake of Feihe Stage 1 Formula|Oral intake of Feihe Stage 1 Formula
224195057|NCT02406937|DIETARY_SUPPLEMENT|Breast Feeding|Oral intake of breast milk
224195058|NCT01491737|DRUG|Pertuzumab|Participants will receive a loading dose of 840 milligrams (mg) as an intravenous infusion on Day 1 of first treatment cycle, followed by 420 mg on Day 1 or Day 2 of each subsequent 3-week cycle until disease progression or unacceptable toxicity.
224195059|NCT01491737|DRUG|Trastuzumab|Participants will receive a loading dose of 8 milligrams per kilogram (mg/kg) as an intravenous infusion on Day 1 or 2 of first treatment cycle, followed by 6 mg/kg on Day 1 or Day 2 of each subsequent treatment 3-week cycles until disease progression or unacceptable toxicity.
224195060|NCT01491737|DRUG|Aromatase Inhibitor|Participants will receive 1 mg anastrozole or 2.5 mg letrozole orally once daily.
224195061|NCT01491737|DRUG|Induction Chemotherapy|Participants receiving induction chemotherapy up to the first 18-24 weeks of the treatment period will receive a taxane (docetaxel every 3 weeks or paclitaxel weekly), administered in line with the respective pertuzumab and/or trastuzumab infusions at the investigator's discretion.
224195062|NCT06278532|DIAGNOSTIC_TEST|Brief Negative Symptoms Scale|The Lithuanian Brief Negative Symptoms scale (BNSS) version will be used and validated. BNSS is used as a modern tool for the evaluation of negative symptoms of schizophrenia. Older tools used for negative symptoms evaluation often include symptoms from other dimensions of symptoms of schizophrenia, and BNSS evaluates negative symptoms specifically. BNSS is a semi-structured interview made of 13 items. There are six subscales: anhedonia (3 items), lack of normal distress (1 item), asociality (2 items), avolition (2 items), blunted affect (3 items) and alogia (2 items).
223504204|NCT06107673|DRUG|Epirubicin Hydrochloride Injection|Administered as a 75 mg/m2 intravenous infusion. It is given every three weeks and dose reduction or treatment delay is allowed, up to a maximum delay of 3 weeks from the previous dose calculation. Treatment will be terminated if the delay exceeds this limit.
223504205|NCT06107673|DRUG|Cyclophosphamide injection|Administered as a 500 mg/m2 intravenous infusion. It is given every three weeks and dose reduction or treatment delay is allowed, up to a maximum delay of 3 weeks from the previous dose calculation. Treatment will be terminated if the delay exceeds this limit.
223504206|NCT00947388|DRUG|Bendamustine Hydrochloride|Bendamustine 70 mg/m2 IV Day 8 and 9 every 28 days for 6 courses of therapy
223504207|NCT00947388|BIOLOGICAL|Alemtuzumab|Given subcutaneously (SC)on days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, and 26.
224195063|NCT06278532|DIAGNOSTIC_TEST|The Calgary Depression Scale for Schizophrenia|The Lithuanian version of the CDSS will be used and validated. CDSS is a tool used to evaluate depressive symptoms, specifically for patients with schizophrenia. Often, distinguishing between depressive and negative symptoms of schizophrenia is difficult. Therefore, it is recommended to use tools designed specifically for patients with schizophrenia. CDSS is the only depression scale designed to assess depression in people with a schizophrenia syndrome disorder. It is a semi-structured interview consisting of 9 items.
224195064|NCT06278532|DIAGNOSTIC_TEST|The Schizophrenia Cognition Rating Scale|The Lithuanian version of the SCoRS will be used and validated. SCoRS is a 20-item interview-based assessment tool that evaluates cognitive deficits and the degree to which these deficits impair specifically in patients with schizophrenia.
224195065|NCT04500054|OTHER|Music Listening|The music type was chosen by the patients and researchers did not have any influence on their choices.
224195066|NCT04732884|DEVICE|Smartsens, Gelenic AG; with biofeedback|The Smartsens is a CE certified 4-cell load sensor integrated in an insole that can be placed in any orthosis or cast. A threshold (10-50kg) can be defined at which - if higher loads are measured - an audio signal warns the patient of overloading (biofeedback). The device additionally registers loads from 0-100kg continuously.
224195067|NCT04732884|DEVICE|Smartsens, Gelenic AG; without biofeedback|Patients will not be warned by an audio signal in case of overloading. The device registers loads from 0-100kg continuously.
224195068|NCT03212443|PROCEDURE|Suprascapular nerve- axillary nerve block combination|In Group B, suprascapular (10 ml of 0.250% bupivacaine ) and axillary block (10 ml of 0.250% bupivacaine) will be performed with ultrasound and nerve stimulator guidance before induction of anesthesia
224195069|NCT03212443|PROCEDURE|Subacromial infiltration|In group A, the surgeon will apply 20 ml of 0.250% bupivacaine to the subacromial region at the end of the procedure
224195070|NCT01976663|DEVICE|JUVEDERM VOLIFT® XC|Up to 4 mLs JUVEDERM VOLIFT® XC injected intradermally in one NLF (total; including initial and touch-up treatments) and up to 4 mLs JUVEDERM VOLIFT XC is allowed for repeat treatment. For asymmetric correction, only the more severe NLF is eligible for asymmetric correction.
224195071|NCT01976663|DEVICE|Control|Up to 4 mLs Control injected intradermally in opposite NLF (total; including initial and touch-up treatments). Up to 4 mLs JUVEDERM VOLIFT XC is allowed for asymmetry correction and up to 4 mLs JUVEDERM VOLIFT XC is allowed for repeat treatment. Only the more severe NLF is eligible for asymmetric correction.
224195072|NCT06604949|DRUG|LP-003 200mg|Subcutaneous injection of 200 mg LP-003
224195073|NCT06604949|DRUG|Placebo|Subcutaneous injection of placebo
224195074|NCT01817764|DRUG|Umeclidinium/vilanterol|Dry white powder delivered via NDPI (2 strips with 30 blisters each, first containing UMEC 62.5 mcg per blister and second containing VI 25 mcg per blister), administered as one inhalation of UMEC/VI 62.5/25 mcg once-daily in the morning
224195075|NCT01817764|DRUG|Fluticasone propionate/salmeterol|Dry white powder delivered via ACCUHALER/DISKUS (1 strip with 60 blisters, containing 250 mcg fluticasone propionate and 50 mcg salmeterol per blister), administered as one inhalation of FSC 250/50 mcg each morning and evening
224195076|NCT01817764|DRUG|Placebo|Placebo will be administered via ACCUHALER/DISKUS or NDPI. Dry white powder administered as one inhalation each morning and evening via ACCUHALER/DISKUS (1 strip with 60 blisters containing placebo) OR once-daily in the morning via NDPI (2 strips with 30 blisters each, containing placebo)
223504208|NCT02203786|DRUG|Haloperidol|"Dose/maximum dose = 3-mg; route = oral. Participants assigned to the haloperidol antagonist group will receive 2 doses (@ 3 mg) on alternate sessions (with minimum of 2 weeks between individual doses).~Dose 1: 3 visually identical capsules, each containing 1 mg haloperidol."
223504209|NCT02203786|DRUG|Fluphenazine|"Dose/maximum dose = 3-mg; route = oral. Participants assigned to the fluphenazine antagonist group will receive 2 doses (@ 3 mg) on alternate sessions (with minimum of 2 weeks between individual doses).~Dose 1: 3 visually identical capsules, each containing 1 mg fluphenazine."
223504210|NCT02203786|DRUG|Dexedrine|"Dose/maximum dose = 20-mg; route = oral. All participants will receive 2 doses (@ 20 mg) during Phase II - sessions 3, 4, with minimum 1 week between individual doses.~Dose 2: when participants reach expected peak blood levels for dose 1, they will receive their second dose. On sessions 3 and 4 (Phase II), the dose will consist of 2 visually identical capsules each containing 10 mg D-amphetamine."
223504211|NCT02203786|DRUG|Placebo|"Dose 1: On alternate sessions (1 and 3 or 2 and 4, depending on counterbalancing) participants will receive 3 visually identical placebo (lactose) capsules.~Dose 2: when participants reach expected peak blood levels for dose 1, they will receive their second dose. On sessions 1 and 2 (Phase I), this will consist of 2 dummy capsules, visually identical to those administered for dose 1."
223504212|NCT02203786|BEHAVIORAL|Slot Machine|15 minute play of a commercial slot machine game in bar-simulated laboratory setting.
223504213|NCT04673695|DRUG|Lixiana(D006)|NOAC(Factor Xa inhibitor)
223504214|NCT04673695|DRUG|CKD-344|NOAC(Factor Xa inhibitor)
223504215|NCT02011763|BIOLOGICAL|Avaxim 80U Pediatric: Inactivated Hepatitis A Virus|0.5 mL, Intramuscular (2 injection 6 months apart)
223504216|NCT02765971|OTHER|gums|Group A, 180 women will receive sugarless gum after their operating room discharge by 3 hours for at least half an hour at two hours interval.
223504217|NCT02765971|DRUG|picolax drops|Group B, 180 women will receive laxatives after their operating room discharge by 3 hours.
223504218|NCT02765971|DRUG|normal saline|Group C received 500 cc of normal saline, Intravenous fluid
223504219|NCT05611424|GENETIC|FT-003|Administered via intraocular injection.
223504220|NCT00047632|DRUG|Interferon gamma-1b|100 mcg, SQ, 3x per week
223504221|NCT00122187|DEVICE|Electronic Consult System|Consult system is an event notification system programmed to function within the VA electronic medical record system.
223504222|NCT02061592|DEVICE|etafilcon A|
223504223|NCT02061592|DEVICE|etafilcon A|
223504224|NCT05877664|DRUG|ZG0895 Hydrochloride for Injection|The dose escalation of ZG0895.HCl is set as 0.06, 0.12, 0.18, 0.37, 0.75, 1.50, 2.25, 3.00, and 3.75 mg/m\^2 groups, subcutaneous (SC) injection once a week (QW)
223504225|NCT03338023|DRUG|LY2963016|Administered SC
223504226|NCT03338023|DRUG|Lantus®|Administered SC
223504227|NCT03338023|DRUG|Insulin Lispro|Administered SC
223504228|NCT05733533|DRUG|HRS-2261 oral tablet|HRS-2261 oral tablet, oral, BID
223504229|NCT05733533|DRUG|Matching placebo to HRS-2261|Matching placebo to HRS-2261, oral, BID
223504230|NCT01491932|DRUG|AFQ056|AFQ056 will be supplied as oral capsules.
223592936|NCT01202058|DEVICE|NEVO™ Sirolimus-eluting Coronary Stent System|"Design Original Protocol~Intervention will consist of percutaneous coronary intervention for treatment of a single or multiple coronary lesion(s) using standard coronary intervention techniques. Intervention in this arm will include treatment with the NEVO™ Sirolimus-eluting Coronary Stent System. Subjects assigned to the IVUS sub-study population will undergo intravascular ultrasound evaluation immediately post-stenting."
223746839|NCT05225272|OTHER|Enhanced Recovery Program for on-pump cardiac surgery|Implementation of a Enhanced Recovery Program for on-pump cardiac surgery patients
224195077|NCT05383703|DRUG|Treatment of MNC-168 enteric-coated capsules as a single oral drug|Treatment of live bacterium MNC-168 as a single oral agent as a single oral drug in subjects with advanced malignant solid tumors. First, live fungi can directly or indirectly inhibit tumor growth or induce tumor cell apoptosis through their metabolites or surface proteins, and can also regulate the immune system, especially the tumor microenvironment, to play an antitumor function. Second, tumor immunotherapies exhibit different response levels in different populations, and live bacterial analogs derived from gut microbes may enhance the response to immunotherapy in weakly responding patients.
224195078|NCT05868187|BEHAVIORAL|Exercise, Problem-Solving Session and Education|Complete assigned exercises three times a week Complete Action plan co-developed Complete part or all of one of the four interactive educational modules
224195079|NCT06297642|DRUG|TQB2928 injection|Anti-CD47 monoclonal antibody
224195080|NCT06297642|DRUG|Penpulimab|Humanized Monoclonal Antibody to Programmed Cell Death Protein 1 (PD-1)
224195081|NCT06180655|BEHAVIORAL|Diabetes Self-Management Education and Support (DSMES) plus Tai Chi Easy (TCE)™|Participants will be asked to attend 45 minutes of DSMES and 45 min of TCE twice a week for 6 weeks. All classes will be recorded and available online and can viewed at a time when it is most convenient to accommodate working adults.
224195082|NCT03841591|DRUG|Insulin|Women with GDM will receive insulin and tailored according to their blood glucose levels to achieve glycemic control. Starting dose will be 30unit (20 unit intermediate dose + 10 unit rapid acting insulin) in the morning and before breakfast). In the 2nd trimester, we will start with half of the previous dose and if post dinner glucose level remain elevated additional injection of rapid acting insulin will be given just prior to dinner. If fasting glucose is elevated, intermediate acting insulin can be given along with the dinner dose of rapid acting insulin.
224195083|NCT03841591|DRUG|Metformin|Women with GDM will receive metformin and tailored according to their blood glucose levels to achieve glycemic control. They will receive an initial metformin dose of 500 mg once or twice daily (according to initial blood glucose level) with food and increased 500 mg every one or two weeks toward targets or up to a maximum daily dose of 2500 mg divided doses with each meal.
224195084|NCT03841591|OTHER|Assessment of weight gain|Body weight will be measured monthly from the start of treatment till delivery.
224195085|NCT06636136|DEVICE|OPRA|Surgery
224195086|NCT02392312|DRUG|ATF-Fresenius S|intravenous
224195087|NCT06626737|DRUG|Dapagliflozin (DAPA)|Participants will take Dapagliflozin 10mg every day in -1 to 14 days
224195088|NCT05690282|DRUG|Multimodal Pain Management (Ibuprofen/Acetaminophen/GABAPentin/0.25%Bupivacaine)|Multimodal Pain Management to minimize patients' reliance on opioids.
224195089|NCT02255422|DRUG|Omaveloxolone capsules, 2.5 mg|
224195090|NCT02255422|DRUG|omaveloxolone capsules, 5 mg|
223504231|NCT05371223|DRUG|Combined Nabpaclitaxel Pressurized IntraPeritoneal Aerosol Chemotherapy With Systemic Nabpaclitaxel-Gemcitabine|"Each combined course is constituted by two consecutive 28-day cycles of systemic chemotherapy (three adminstrations per cycle: days 1,8 and 15) and one cycle of PIPAC administered within 10-13 days from the last administration of systemic chemotherapy. Between each combined course a 7-10 days pause is observed.~The recommended dose of Nabpaclitaxel in combination with Gemcitabine is 125 mg/m2 administered endovenous over 30 minutes on Days 1, 8 and 15 of each 28-day cycle. The concurrent recommended dose of Gemcitabine is 1000 mg/m2 administered intravenously over 30 minutes immediately after the completion of Nabpaclitaxel administration on Days 1, 8 and 15 of each 28-day cycle.~A pressurized aerosol containing Nabpaclitaxel at the dose of 112,5 mg/m2 diluted in a total volume of 200 ml of NaCl 0.9% is applied through the nebulizer inside the abdominal cavity during laparoscopy."
223504232|NCT05335265|OTHER|Treatment training|"Face-to-face:Metered-DoseInhalerTraining gave 3 times on the 1st day, 2 times on the 2nd day, once on the 3rd day.During discharge, inhaler technical evaluation were done according to the Application Steps of Inhalation Techniques Evaluation Form checklist prepared by using the Patient's Booklet of the Turkish Thoracic Society (TTS).The people who is evaluate the patient's inhaler technique (IT) on the day of discharge was someone different from the health personnel who provided the training. In IT control, the patient's performance was evaluated simultaneously by 2 observers.~Video training:Training gave 3 times on the 1st day, 2 times on the 2nd day,once on the 3rd day.The TTS-Virtual Training Video were used.During discharge,inhaler technical evaluation was done same with face-to-face training.The person who is evaluate the patient's IT was someone different from the training personnel.In IT observation,it was used same method with face-to-face training."
223504233|NCT00387309|DRUG|Methylnaltrexone (MOA-728)|
223504234|NCT00005684|DRUG|warfarin|
223504235|NCT00005684|DRUG|heparin|
223504236|NCT00382473|BEHAVIORAL|Aerobic exercise program - 8 weeks|No drugs. Regular aerobic exercise in structured prescription format
223504237|NCT03398382|DIETARY_SUPPLEMENT|Magnesium tablet group|Before the anaesthesia, all principles of surgical sterility and asepsis with oral cavity flushing for 1 min. ( 15 ml. 0.12% CHX.) will be performed. Operative side will be anaesthetized with the same anaesthetic 3M ESPE, Ubistesin-artikain. The surgeon, assistant, surgical approach, surgery technique and instruments will be the same in all subjects. For one side which will be randomly selected, the patient will receive magnesium citrate tablets. The same analgesics will also be prescribed: Ibuprofen tbl 400 mg which will be taken as needed, and magnesium citrate tablets. 200 mg. After the surgery, all patients will be given the same written and oral instructions for postoperative care.
223746840|NCT05370313|BEHAVIORAL|Market Price Condition (control)|Nicotine/tobacco products available in the Experimental Tobacco Marketplace at market price. Cigarette taxes increased across trials at the same magnitudes used in the tax conditions.
224195091|NCT02255422|DRUG|omaveloxolone capsules, 10 mg|
224195092|NCT02255422|DRUG|Placebo capsules|
224195093|NCT02255422|DRUG|omaveloxolone capsules, 20 mg|
224195094|NCT02255422|DRUG|omaveloxolone capsules, 40 mg|
224195095|NCT02255422|DRUG|omaveloxolone capsules, 80 mg|
224195096|NCT02255422|DRUG|omaveloxolone capsules, 160 mg|
224195097|NCT04755101|PROCEDURE|EPS, electro-anatomical mapping, ARGP ablation, and pharmacological evaluation.|EPS and electro-anatomical mapping of the right atrium and the surrounding veins. A target line (TL) is traced at the posteroseptal side of the junction, between the right atrium and superior vena cava, facing the mid and caudal parts of the right superior pulmonary vein antrum on the right heart cavities on a CT image imported into the CARTO system. This map will be carefully merged with the CT image and the TL will be visible. Sequential ablations will be delivered along theTL until the procedure endpoint is reached. Pharmacological evaluation.
224195098|NCT04755101|PROCEDURE|EPS, electro-anatomical mapping, and pharmacological evaluation.|EPS and electro-anatomical mapping of the right atrium and the surrounding veins. A target line (TL) is traced at the posteroseptal side of the junction, between the right atrium and superior vena cava, facing the mid and caudal parts of the right superior pulmonary vein antrum on the right heart cavities on a CT image imported into the CARTO system. This map will be carefully merged with the CT image and the TL will be visible. No ablation is performed (sham). Pharmacological evaluation.
223592937|NCT01202058|DEVICE|XIENCE V®/XIENCE PRIME™/PROMUS® Everolimus-eluting Coronary Stent System)|Intervention will consist of percutaneous coronary intervention for treatment of a single or multiple coronary lesion(s) using standard coronary intervention techniques. Intervention in this arm will include treatment with the XIENCE V®/XIENCE PRIME™/PROMUS® Everolimus-eluting Coronary Stent System. Subjects assigned to the IVUS sub-study population will undergo intravascular ultrasound evaluation immediately post-stenting.
223592938|NCT03271905|DRUG|salbutamol sulfate and ipratropium bromide|Nebulization with salbutamol sulfate and ipratropium bromide during mechanical ventilation.
223592939|NCT03271905|DEVICE|Mesh nebulization|Nebulization with Mesh device.
223592940|NCT00718770|DRUG|Bexarotene|Bexarotene will be given by mouth once a day every day for 1 year. The dose to be used will be 300 mg/m2.
223592941|NCT00695864|DRUG|Ondansetron and Placebo crossover|
223592942|NCT01704456|BEHAVIORAL|Mindfulness-based Cognitive Therapy|The MBCT intervention will be administered in small group format (8-9 women). Each session will be 2.25 hours in duration and there will be eight, weekly sessions over the course of 2 months. Session content includes education about chronic pain, PVD, stress and sexual response, mindfulness practices, and cognitive techniques to notice thought patterns that contribute to increased pain.
223592943|NCT01704456|BEHAVIORAL|Cognitive Behavioural Therapy|The CBT intervention will be administered to women in small group format (8-9 women). Each session will be 2.25-hrs in duration and there will be eight, weekly sessions over the course of 2 months. Session content includes education about chronic pain, PVD, stress and sexual response, behavioural techniques such as progressive muscle relaxation, cognitive techniques to challenge unhealthy thinking patterns, and communication skills training.
223592944|NCT00898456|GENETIC|gene expression analysis|
224195099|NCT04148326|OTHER|No Intervention|There is no intervention for this study.
223592945|NCT00898456|GENETIC|molecular genetic technique|
223592946|NCT00898456|GENETIC|polymorphism analysis|
224195100|NCT02265874|DRUG|Habitrol|Patch used daily for 28 weeks
224195101|NCT02265874|DRUG|Placebo to Habitrol|
224195102|NCT06216132|COMBINATION_PRODUCT|BIOPIN-6 Active Implant with Naltrexone|An extended release formulation of naltrexone implanted in the subcutaneous space.
224195103|NCT06216132|DEVICE|BIOPIN-6 Placebo Implant|The placebo will be an implant consisting of the poly-d-l Lactic Acid and polycaprolactone contained in BIOPIN 6 without naltrexone.
224195104|NCT03449238|DRUG|Pembrolizumab|Pembrolizumab infusion will be given on Day 4 (+/-1) after SRS treatment at the standard dose of 200mg IV over 30 minutes and repeated every 3 weeks until disease progression or unacceptable toxicity.
224195105|NCT06418659|DRUG|CD-801|"CD-801 will be administered intravenously for the treatment of HCC. The dosing regimen is planned for a second dose 14 ± 3 days post-initial treatment, followed by subsequent treatments every 28 ± 7 days, with adjustments made based on patient tolerance and therapeutic response.~According to Amendment 1, patients who have received at least 4 cycles of HNF4α srRNA (CD-801 or CD-GA-102) therapy and have a tumor assessment of SD (stable disease) or PD (progressive disease) per mRECIST criteria may, after a comprehensive evaluation by the investigator considering the patient's treatment history and the current safety and efficacy data of HNF4α srRNA, continue HNF4α srRNA at the same dose, or have their dose adjusted, in combination with immunotherapy, targeted therapy, or chemotherapy."
224195106|NCT03589729|DRUG|Cladribine|Given IV
223592947|NCT00898456|GENETIC|protein expression analysis|
224195107|NCT03589729|DRUG|Cytarabine|Given IV
224195108|NCT03589729|DRUG|Dexrazoxane Hydrochloride|Given IV
223592948|NCT00898456|OTHER|diagnostic laboratory biomarker analysis|
223592949|NCT06459336|OTHER|Intensive constraint-induced movement therapy|Intensive protocol of CIMT will be given for 6hrs for 6 days to make total of 36 hours
223592950|NCT06459336|OTHER|Distributed constraint-induced movement therapy|Distributed protocol of CIMT will be given for 2.25hrs two times a week for 8 weeks making total of 36 hours
223592951|NCT00005107|DRUG|N-monomethyl-L-arginine|
223592952|NCT00498355|DRUG|Ranibizumab|0.5 mg of ranibizumab by intravitreal injection at baseline and at monthly intervals for the following two months for a total of 3 injections. Afterwards, PRN injections for 9 months.
223746841|NCT05370313|BEHAVIORAL|Tobacco Parity Tax Condition|Tobacco products in the Experimental Tobacco Marketplace are placed into three tax tiers: high-, medium-, and no-tax. In this condition, all tobacco products are placed in the high-tax tier while products that do not contain tobacco (e.g., herbal cigarettes and nicotine-free ENDS) are placed in the medium-tax tier. Nicotine Replacement Therapy products are placed in the no-tax tier.
224195109|NCT03589729|DRUG|Gemtuzumab Ozogamicin|Given IV
224195110|NCT03589729|DRUG|Idarubicin|Given IV
224195111|NCT04100980|OTHER|No Intervention|There is no intervention for this study
224195112|NCT04686773|BIOLOGICAL|AZD1222|"AZD1222 (0.5 ml per dose) contains:~Active substance: ChAdOx1 nCoV-19, a replicant-deficient simian adenoviral vector in the amount of 5 х 10\^10 particles per dose.~Solution for intramuscular injection, supplied in vials (5 mL, up to 10 doses per vial) in a carton box."
224195113|NCT04686773|BIOLOGICAL|rAd26-S|"Component I (0.5 ml per dose) contains:~Active substance: recombinant adenovirus serotype 26 particles containing the SARS-CoV-2 protein S gene, in the amount of (1.0±0.5) х 10\^11 particles per dose.~Solution for intramuscular injection, supplied in vials (3 mL, 5 doses per vial) in a carton box"
223592953|NCT05210426|OTHER|Pilates exercises|The Pilates Group completed a 10-week Pilates program. The intervention was performed in 20 sessions. In the first session, introduction and explanations regarding the principles and benefits of Pilates was made in a language that preschool children can understand. Exercises were supervised, and they were taught via gamification. In addition, the participation of the children was encouraged and stickers were given to increase their motivation at the end of the sessions. No adverse events occurred during intervention. The exercise program was created based on books and from the booklet acquired in the APPI Pilates Method training courses. Since the study was in preschool children, the basic level of Pilates was performed. Each exercise was performed 5 times for 30 minutes each twice a week.
223592954|NCT02481609|DRUG|N-acetyl cysteine (NAC)|
223592955|NCT04958226|DRUG|Capivasertib|Capivasertib (tablet) will be given as an intermittent schedule (4 days on/3 days off) from Cycle 1 Day 2 until discontinuation. Capivasertib will be administrated in both Part A and Part B.
223592956|NCT04958226|DRUG|Midazolam|Single doses of midazolam (syrup, 1 mg) will be given on cycle 1 Days 1, 8, and 12.
223592957|NCT04816058|BEHAVIORAL|Determining the level of ankle instability|Ankle instability
223592958|NCT02758327|DRUG|TheraTears Lubricating Eye Drops|Sodium Carboxy-methylcellulose 0.25% eye Lubricant
223592959|NCT03881904|DRUG|0.075mg gestodene/0.03mg ethinylestradiol|OCPs will be started from day 2 of the cycle preceding COH and continued for 21 days, then induction of ovulation using antagonist protocol will be started.
223592960|NCT05481047|DEVICE|HPI|based on HPI values, clinicians will administer drugs or fluids in order to avoid arterial hypotension
223592961|NCT04583956|OTHER|Placebo|Risankizumab placebo will be given at an equal volume at the same schedule.
223592962|NCT04583956|DRUG|Remdesivir|Remdesivir is a single diastereomer monophosphoramidate prodrug for the intracellular delivery of a modified adenine nucleoside analog GS-441524.
223592963|NCT04583956|BIOLOGICAL|Risankizumab|Risankizumab is a humanized immunoglobulin (Ig) G1 antagonistic monoclonal antibody (mAb) directed against the p19 subunit of the human cytokine interleukin-23. Risankizumab is formulated in a buffer of 4.4 mM disodium succinate hexahydrate/succinic acid, 225 mM sorbitol, 0.2 mg/mL polysorbate 20, and WFI in a 6R vial.
223592964|NCT02924909|DRUG|carboplatin paclitaxel|induction carboplatin paclitaxel for 2 cycles
223592965|NCT04883814|DIAGNOSTIC_TEST|18F-fluoroestradiol PET/CT|Estrogen receptor targeted imaging
223592966|NCT01143584|DRUG|Cabergoline|"In the Conventional escalation group Cabergoline 0.5 mg once a week for 4 weeks and further will be incrementally dose adjusted on the basis of individual PRL values until amelioration of hyper prolactinemia @ 0.5 mg/wk every 4 weeks, till 24 weeks or until primary endpoint.~Cabergoline will be maintained at the dose at which PRL will be first normalized till primary end point."
223592967|NCT01143584|DRUG|cabergoline|"In the Rapid escalation group schedule of cabergoline dosing will be as follows:~Begin with 0.5 mg twice a week~1. mg twice a week - second week 1.5 mg twice a week - third week~2. mg twice a week - fourth week~4mg/wk would be continued for next 4 weeks. If prolactin does not normalize by 8 weeks, a repeat hike in dose of 1mg/wk will be done every 4 weekly until normalization of prolactin levels and also \>50% decrease in tumor volume. Ceiling dose of Cabergoline will be 12mg/wk."
223746842|NCT05370313|BEHAVIORAL|Nicotine-Content Tax Condition|Tobacco products in the Experimental Tobacco Marketplace are placed into three tax tiers: high-, medium-, and no-tax. In this condition, products with greater than 3 mg nicotine per single unit are placed in the high-tax tier, products with 0.6-3.0 mg/unit in the medium-tax tier, and those with 0.5 mg/unit or less in the no-tax tier.
223592968|NCT03461081|DRUG|telmisartan/amlodipine and atorvastatin|Telmisartan/Amlodipine(40/5 mg) 2 Tab for 10 days Telmisartan/Amlodipine(40/5 mg) 2 Tab with Atorvastatin 40 mg 1 Tab for 4 days Atorvastatin 40 mg 1 Tab for 4 days
223746843|NCT05370313|BEHAVIORAL|Harm-Reduction Tax Condition|Tobacco products in the Experimental Tobacco Marketplace are placed into three tax tiers: high-, medium-, and no-tax. In this condition, all combustible products with high abuse liability are placed in the high-tax tier. All non-combustible products or combustible products with low abuse liability are placed in the medium-tax tier. Nicotine Replacement Therapy products are placed in the no-tax tier.
224195114|NCT04275999|DRUG|ivermectin|Subjects will be given the ivermectin with an electronic monitoring device attached with a return appointment at month 3 for end of study visit. Subjects will be instructed to use the ivermectin once daily.
224195115|NCT04275999|BEHAVIORAL|digital interaction|Subjects will receive weekly digital interaction; an electronic survey asking about their use of the ivermectin which will have the electronic monitoring device attached. Subjects will be instructed to use the ivermectin once daily. They will have a 3 month return appointment for end of study visit.
223592969|NCT05262647|DIAGNOSTIC_TEST|18F-FAPI|Patients with chronic liver disease underwent 18F-FAPI-04 PET/CT and percutaneous liver biopsy.
223592970|NCT03310385|DRUG|GHX02|Herbal medicine originating from gualouhengryunhwan
223592971|NCT03310385|DRUG|Placebo|Placebo tablets
223592972|NCT04016077|DRUG|PF-06651600 30 mg|PF-06651600 in 10 mg oral tablets will be administered on days 1 to 10.
223592973|NCT04894890|DRUG|secukinumab|There is no treatment allocation. Patients administered secukinumab by prescription that have started before inclusion of the patient into the study will be enrolled.
223592974|NCT05318911|DIETARY_SUPPLEMENT|Novel yogurt drink|Novel ovine yogurt drink containing polar lipids
223592975|NCT05318911|OTHER|Placebo Drink|Placebo drink (skimmed milk)
223592976|NCT04928118|OTHER|Evaluate the blood flow and pressure into kidneys|"Renal artery pressure and flow measures will be obtained using dedicated equipment positioned into the renal artery under fluoroscopic guidance.~A pulmonary artery catheter will be used to measure the pressure inside participant's renal vein and to collect small blood samples to measure oxygen content."
223592977|NCT00154882|DRUG|Paclitaxel (Phyxol) , Cisplatin|
223592978|NCT02181114|BEHAVIORAL|Expert System Coaching|Patients will receive coaching and feedback over the phone and stag-appropriate educational materials (i.e. paphlets, brochures, personalized feedback report) based on their answers to the survey questions and where they are in their kidney transplant evaluation process.
223592979|NCT01433562|DRUG|DLBS1425|DLBS1425 capsule 150 mg thrice daily for 3 cycles @ 21 days. CAF (Cyclophosphamide (500 mg/m2 iv), Doxorubicin 50 mg/m2 iv, Fluorouracil 500 mg/m2 iv) or CEF (Cyclophosphamide 500 mg/m2 iv, Epirubicin 70 mg/m2 iv, Fluorouracil 500 mg/m2 iv) regimens on Day-1 of every cycle for the total of 3 cycles.
224195116|NCT04275999|DEVICE|GPSkin|Subjects in the GPSkin group will receive the GPSkin Barrier® to measure their moisture level of their face daily. Subjects will be instructed to use the ivermectin with the electronic monitoring device once daily. They will be scheduled for a 3 month end of study visit.
224195117|NCT02534428|OTHER|wool clothing|superfine merino wool ensembles for baby wear
224195118|NCT05437731|OTHER|Coated titanium mesh|patients will undergo repairing of defects or reconstruction using the titanium mesh coated with hydroxyapatite nanocrystals.
224195119|NCT05437731|OTHER|Uncoated titanium mesh|patients will undergo reconstruction using the conventional uncoated titanium mesh.
224195120|NCT01970020|DRUG|JNJ-38518168|Following an at least 10-hour overnight fast, participants will receive a single dose containing 30 mg of 14C JNJ-38518168 given as an oral solution on Day 1
224195121|NCT05665946|DIAGNOSTIC_TEST|Blood sample analysis|Analysis of proposed biomarkers.
224195122|NCT00938366|DRUG|Cladribine|Subjects will receive two single doses of 10 mg cladribine orally in either first or second intervention period followed by a washout period of 10-25 days.
224195123|NCT00938366|DRUG|Pantoprazole|Subjects will receive a pantoprazole 40 mg orally for 2 consecutive days either in first or second intervention period.
224195124|NCT01955824|DRUG|1% lignocaine|
224195125|NCT01955824|DRUG|2% lignocaine|
224195126|NCT02715843|DRUG|MT-3724|Intravenous dosing M-W-F X 2 weeks; MT-3724 infusion over 2 hours on each dosing day over 4 week initial cycle and then 3 week repeat cycles for up to 5 total cycles.
224195127|NCT00343148|DRUG|AVI-4126 Injection (RESTEN-NG®)|
224195128|NCT03710681|BIOLOGICAL|SHR-1314|Pharmaceutical form: Injection solution. Route of administration: subcutaneous injection.
224195129|NCT01574976|BEHAVIORAL|probabilistic choice|subjects should choose between low-certain outcome and high-uncertain outcome
223504238|NCT03398382|DIETARY_SUPPLEMENT|Placebo tablets group|Before the anaesthesia, all principles of surgical sterility and asepsis with oral cavity flushing for 1 min. ( 15 ml. 0.12% CHX.) will be performed. Operative side will be anaesthetized with the same anaesthetic 3M ESPE, Ubistesin-articain. The surgeon, assistant, surgical approach, surgery technique and instruments will be the same in all subjects. For one side which will be randomly selected , the patient will receive placebo tablets which will be identical to the right drug. The same analgesics will also be prescribed: Ibuprofen tbl 400 mg which will be taken as needed, and placebo tablets. 200 mg. After the surgery, all patients will be given the same written and oral instructions for postoperative care.
223504239|NCT03398382|DIETARY_SUPPLEMENT|Magnesium lozenge group|Before the anaesthesia, all principles of surgical sterility and asepsis with oral cavity flushing for 1 min. ( 15 ml. 0.12% CHX..) will be performed. Operative side will be anaesthetized with the same anaesthetic 3M ESPE, Ubistesin-articain. The surgeon, assistant, surgical approach, surgery technique and instruments will be the same in all subjects. For one side which will be randomly selected patient will receive magnesium citrate lozenge.The same analgesics will also be prescribed: Ibuprofen tbl 400 mg which will be taken as needed, and magnesium citrate lozenges. 100 mg. After the surgery, all patients will be given the same written and oral instructions for postoperative care.
223504240|NCT03398382|DIETARY_SUPPLEMENT|Placebo lozenges group|Before the anaesthesia, all principles of surgical sterility and asepsis with oral cavity flushing for 1 min. ( 15 ml. 0.12% CHX.) will be performed. Operative side will be anaesthetized with the same anaesthetic 3M ESPE, Ubistesin-articain. The surgeon, assistant, surgical approach, surgery technique and instruments will be the same in all subjects. For one side which will be randomly selected patient will receive placebo lozenges which will be identical to the right drug. The same analgesics will also be prescribed: Ibuprofen tbl 400 mg which will be taken as needed, and placebo lozenges 100 mg. After the surgery, all patients will be given the same written and oral instructions for postoperative care.
223504241|NCT01642849|DIETARY_SUPPLEMENT|high protein diet|6 months on HP diet
223504242|NCT01642849|DIETARY_SUPPLEMENT|high carbohydrate diet|12 subjects will be placed on a hig carbohydrate diet for 6 months
223504243|NCT03041337|DIAGNOSTIC_TEST|stress echocardiography|"stress echocardiography will be performed in accordance with the current guidelines on a variable load 45° cycle ergometer with an incremental workload of 25 W every 2 minutes up to the symptom-limited maximal tolerated workload. Echocardiographic measurements will be acquired at baseline, at peak exercise and during recovery of 5 minutes.~The electrocardiogram and blood pressure will be monitored at each workload. Termination criteria and / or positive test criteria for inducible myocardial ischemia will follow the current recommendations"
223504244|NCT04055298|DEVICE|SMASS-Triage|SMASS-Triage is a web-based symptom checker developed by In4medicine Ltd. SMASS-Triage is based on a computerized transparent neural network, which was trained with the evidence of more than 1200 studies and the expertise of various panels of specialists in the field of preclinical medical triage. SMASS-Triage provides digitalized questionnaires of 87 frequent reasons of encounters (e.g. fever, cough, abdominal pain) and their associated red flags. The triage-result of SMASS-Triage encompasses the appropriate time-to-treat (T2T) and the adequate point-of-care (PoC).
223504245|NCT02907957|DEVICE|FLIR ONE|Thermographic assessment of the lower extremities is obtained using the FLIR ONE smartphone camera and software.
223504246|NCT02907957|PROCEDURE|Regional Anesthesia - Caudal Nerve Block|Nerve block placement as a pain management strategy indicated for certain urological and lower extremity surgeries.
224195130|NCT03063931|DRUG|Magnesium: Magnésium UPSA Action Continue®|This clinical trial compares magnesium and placebo for the prevention of neuropathic pain induced by mastectomy assessed with a (0-10) numerical pain rating scale
224195131|NCT03063931|DRUG|Placebo: Lactose|This clinical trial compares magnesium and placebo for the prevention of neuropathic pain induced by mastectomy assessed with a (0-10) numerical pain rating scale
224195132|NCT00636857|PROCEDURE|Fluid administration|Preoperative: bolus of 10 ml/kg body weight. During operation: 5 ml/kg body weight/hr. Postoperative: 3 ml/kg body weight/hr
224195133|NCT00636857|PROCEDURE|Perioperative fluid management based on Lean Body Mass|Preoperative: bolus of 12 ml/kg LBM. During operation: 6 ml/kg LBM/hr. Postoperative: 3.5 ml/kg LBM/hr
224195134|NCT04174443|PROCEDURE|High-voltage pulsed radiofrequency|2 Hz of pulsed radiofrequency will be administered at a voltage of 70 V, temperature of 42 °C, pulse width of 20 ms, and treatment time of 600 s.
224195135|NCT04174443|PROCEDURE|Low-temperature continuous radiofrequency|Low-temperature continuous radiofrequency will be performed at 60 °C, with a treatment time of 270 s.
224310495|NCT05211076|OTHER|Marmet Technique Group|"Consent will be obtained from those who agree to participate in the study. The Introductory Information Form will be filled by the researcher using face-to-face interview technique.~It will be ensured that the mother fills the State Anxiety Scale with her own statement.~The Marmet Technique will be applied to the mothers at 11:00am for 20-30 minutes by the researcher.~At the end of the milking process performed in accordance with the technique, the milk accumulated in the container will be measured with an injector and recorded in the Breast Milk Follow-up Form.~Then, it will be ensured that the mother fills in the State Anxiety Scale with her own statement.~At 05:00pm, the same procedure will be applied to the mother. At the end of the 4th day, the satisfaction of the mother will be evaluated on the Mother Satisfaction Evaluation Scale.This process will be carried out 8 times in total,at 11:00am and 05:00pm for 4days."
223592980|NCT01433562|DRUG|Placebo DLBS1425|Placebo DLBS1425 capsule thrice daily for 3 cycles @ 21 days. CAF (Cyclophosphamide (500 mg/m2 iv), Doxorubicin 50 mg/m2 iv, Fluorouracil 500 mg/m2 iv) or CEF (Cyclophosphamide 500 mg/m2 iv, Epirubicin 70 mg/m2 iv, Fluorouracil 500 mg/m2 iv) regimens on Day-1 of every cycle for the total of 3 cycles.
223592981|NCT03772262|DIETARY_SUPPLEMENT|goldenseal|Oral 500 mg capsules
223592982|NCT03772262|DRUG|Metformin|Oral solution
223592983|NCT03772262|DRUG|Furosemide|Oral solution
223592984|NCT03772262|DRUG|Midazolam oral solution|Oral syrup
223592985|NCT03772262|DRUG|Rosuvastatin Oral Tablet|Oral tablet
223592986|NCT00033488|OTHER|cytology specimen collection procedure|
223592987|NCT00033488|PROCEDURE|annual screening|
224195136|NCT03693482|DIAGNOSTIC_TEST|the Four Square Step test|A square will be formed by using four 90 cm long canes placed on the ground. The sequence will be explained and demonstrated to the participants. They will be allowed one practice trial and subsequently two trials. Instructions will be given and encouraged to complete the sequence as fast as possible without touching the canes. The sequence of trial was 1,2,3,4,1,4,3,2,1. If a participant touch the canes, or perform the test sequence inaccurately, or both feet of the participant do not make contact with the floor in each square, the trial will be considered as unsuccessful and the test will be repeated. One unsuccessful trial will be allowed. The best time will be taken as the score of FSST which are completed successfully.
224195137|NCT04214470|OTHER|No intervention|There is no intervention for this study
224195138|NCT00005658|DRUG|Glycine|
224195139|NCT05280886|PROCEDURE|therapeutic drug monitoring(TDM)|Based on this data, population pharmacokinetic models of antibiotics drugs that can be applicable to TDM will be developed.
224195140|NCT01197846|DRUG|Quetiapine|quetiapine 300 mg or 600 mg
224195141|NCT01197846|DRUG|Placebo|Placebo
224195142|NCT03222570|BEHAVIORAL|Interpersonal Psychotherapy for Depressed Adolescents|IPT-A is an evidence-based intervention that aims to decrease depressive symptoms by helping adolescents improve their relationships and interpersonal interactions. It addresses one or more of four interpersonal problem areas: grief, role disputes, role transitions, and interpersonal deficits. The primary treatment techniques in IPT-A include emotion identification/expression, linking interpersonal events to mood, communication analysis, communication skill building, decision analysis, role playing, and assignment of interpersonal experiments (i.e. homework). In clinical trials, depressed adolescents treated with IPT-A demonstrated fewer depressive symptoms and better psychosocial functioning post-treatment than adolescents in control conditions.
224195143|NCT03222570|DRUG|Selective Serotonin Reuptake Inhibitor|Fluoxetine, escitalopram, citalopram, fluvoxamine, or sertraline
224195144|NCT03222570|OTHER|Usual Care|Therapists will implement therapy procedures that they usually use and believe to be effective in clinical practice. Therapists will use whatever methods they usually use to make decisions regarding the frequency of therapy sessions and whether to refer the adolescent to start an SSRI
223592988|NCT00033488|PROCEDURE|comparison of screening methods|
224195145|NCT05932979|DRUG|L-arginine|L-arginine 2-amino-5-guanidino-pentanoic acid is a proteinogenic amino acid that is a natural constituent of the protein diet.
223592989|NCT05629130|DEVICE|embolization with spherical microparticles embosphere|embolization of affected joints with spherical microparticles embosphere
223592990|NCT03800238|BEHAVIORAL|Telehealth Delivery Format|Participants will engage in a 6-week Powerful Tools for Caregivers program delivered via telehealth.
223592991|NCT03800238|BEHAVIORAL|Standard Delivery Format|Participants will engage in a 6-week Powerful Tools for Caregivers program delivered in the traditional in-person format.
223592992|NCT05342272|DRUG|Betaine taurine PVP gel|At the beginning of the trial (t0) each patient received a print-out summarizing the instructions for use of the products: they were instructed to apply during a 28 days treatment period 1 to 2 cm of GUM Hydral® gel to gums, oral mucosa membrane and tongue, repeating as many times as necessary, and to brush their teeth with GUM® Technique® Pro soft compact toothbrush (Sunstar Europe S.A., Etoy, Switzerland) using GUM® Hydral® Toothpaste (Sunstar Europe S.A., Etoy, Switzerland) at least twice a day. The first application was done by the participants themselves under the supervision of the same operator that provided them both oral and written usage instructions. They had to refrain from using any other commercial mouthrinse, toothpaste or saliva supplements during the trial.
223592993|NCT05342272|DRUG|Xylitol, Lactoperoxidase, Lysozyme, Lactoferrin|At the beginning of the trial (t0) each patient received a print-out summarizing the instructions for use of the products: they were instructed to apply during a 28 days treatment period 1 to 2 cm of Biotene® Oral Balance gel to gums, oral mucosa membrane and tongue, repeating as many times as necessary, and to brush their teeth with GUM® Technique® Pro soft compact toothbrush (Sunstar Europe S.A., Etoy, Switzerland) using GUM® Hydral® Toothpaste (Sunstar Europe S.A., Etoy, Switzerland) at least twice a day. The first application was done by the participants themselves under the supervision of the same operator that provided them both oral and written usage instructions. They had to refrain from using any other commercial mouthrinse, toothpaste or saliva supplements during the trial.
224195146|NCT05932979|OTHER|Placebo|Starch
224195147|NCT02384590|BEHAVIORAL|Computerized cognitive behavioral therapy|"The Beating the Blues computerized cognitive behavioral therapy (CCBT) program is eight 50-minute online sessions that teach the participant how to better manage stress using cognitive behavioral therapy techniques. Cognitive behavioral therapy involves helping people change their thoughts and behaviors so they can limit the negative impact stress will have on their mood and pain experience."
223592994|NCT04241484|DEVICE|Piezowave 2|Piezowave Myofascial Acoustic Compression Therapy (MyACT), which provides mechanical stimuli delivery to improve circulation and provide relief of pain. The focused sound waves produced by the Piezowave MyACT device are classified by a pressure surge, which is followed by a drop in pressure and a brief negative pressure phase low energy/low pressure application. It is this transformation of mechanical stimuli into biochemical signals, or mechanotransduction, which yields the treatment of myofascial and musculoskeletal pain
223592995|NCT05307042|DIAGNOSTIC_TEST|Deamino Arginine Vasopressin (dDAVP)|After voiding, 40 μg 1-desamino-8-D arginine vasopressin (dDAVP) will be administered intranasally. Throughout the day, urine volume and maximal renal concentrating ability will be determined by measuring osmolality in urine collected at 4 and 6 hours after administration of dDAVP. In addition, water intake, body weight, blood pressure and heart rate will be determined at baseline and 6 hours after administration of dDAVP.
223592996|NCT00464503|DRUG|Rosuvastatin-Crestor|
223592997|NCT00464503|DRUG|Pravastatin-Pravasine|
223592998|NCT05479240|DRUG|Tislelizumab|Participants will receive Tislelizumab, 200mg, intravenously over 30 - 60 minutes, day 1 of every 3 weeks for 6 cycles.
223592999|NCT05479240|DRUG|Capecitabine|Participants will receive Capecitabine, 1000mg/m2, day 1-14 of every 3 weeks for 6 cycles
223593000|NCT05479240|DRUG|oxaliplatin|Participants will receive oxaliplatin, 130mg/m2, day 1 of every 3 weeks for 6 cycles.
223593001|NCT05479240|RADIATION|short-range radiotherapy|5\*5Gy，d1-d5
223593002|NCT02184923|OTHER|presentation of visual vertical|
223593003|NCT05584280|DEVICE|Orsiro stent on shelf|Cluster randomization to Orsiro stent on shelf vs. control
223593004|NCT05584280|DEVICE|Promus stent on shelf|Cluster randomization to Promus stent on shelf vs. treatment
223593005|NCT05967650|BIOLOGICAL|standard hepatitis B vaccine|IBD patients with negative HBV will be diveded in to two arms first arm vaccinated with standard HBV vaccine regemin( dose 0.2.6)
223746844|NCT05370313|BEHAVIORAL|Modified Risk Tobacco Product (MRTP) Tax Condition|Tobacco products in the Experimental Tobacco Marketplace are placed into three tax tiers: high-, medium-, and no-tax. In this condition, all non-MRTP tobacco products are placed in the high-tax tier, MRTPs are placed in the medium-tax tier, and Nicotine Replacement Therapy products are placed in the no-tax tier.
223746845|NCT05382338|PROCEDURE|Audiometric Test|Ancillary studies
224195148|NCT04920838|DRUG|Nitazoxanide and Ciclésonide|Inhaled Ciclésonide: 320 mcg BID per day and Oral Nitazoxanide:2000 mg tablets daily (divided into two daily intakes of two tablets of nitazoxanide 500 mg) during 14 days.
224195149|NCT04920838|DRUG|Telmisartan 20Mg Oral Tablet|20 mg tablet daily
223593006|NCT05967650|BIOLOGICAL|accelerated HBV Vaccine|IBD patients with negative HBV will be diveded in to two arms second arm vaccinated with accelerated HBV vaccine regemin( dose 1.2.3)
223593007|NCT05317065|BEHAVIORAL|Mindfullness Based Stress Reduction (MBSR) intervention|Mindfullness Based Stress Reduction (MBSR) intervention: Monitoring stress and anxiety levels with mindfulness program
223593008|NCT03634163|BEHAVIORAL|Neighbourhood exchange|Facilitated coaching support to identify needs and priorities and link with resources - personal, community, friend and family, or from professional service providers; plan and implement a personalized care pathway through community exchange
224195150|NCT04920838|DRUG|Paracetamol|"Tablets containing 500 mg of paracetamol. One to two tablets every 4-6 hours as required, to a maximum of 6 tablets (3 grams) daily in divided doses.~Duration of treatment: up to 14 days"
223593009|NCT03634163|BEHAVIORAL|Quality of Life Assessment|Completion of baseline measures
223593010|NCT04519463|DRUG|Xylocaine Mucosal Product|Xylocaine 10% Nasal Spray
223593011|NCT04519463|DRUG|Placebo|Sodium Chloride 0.9%
223593012|NCT04142294|DIETARY_SUPPLEMENT|Histidine|ingestion of encapsulated high quality histidine for four continuous weeks followed by a washout period of 3 weeks
223593013|NCT02566590|DEVICE|NMES|device is used to stimulate muscle contraction in the legs of the patient. The intervention will be used 3 times a day during bed rest.
224195151|NCT04920838|DRUG|Fluoxétine and Budésonide|Inhaled Budésonide: 400mcg BID per day and oral Fluoxétine : 80mg tablets daily (divided into two daily intakes of two tablets of Fluoxétine 40 mg) during 7 days.
224195152|NCT03445663|DRUG|AMG 424|Subjects will receive IV infusions of AMG 424
224195153|NCT01906762|DRUG|Acetaminophen|This protocol prepared by a nurse and labeled as Drug A. Since the rapid injection of Acetaminophen can result in hypotension, therefore based on the Apotel Injection Instruction, it must be infused slowly within 15 minutes.
224195154|NCT01906762|DRUG|Morphine|This protocol was prepared by a nurse and labeled as Drug B. Since the rapid injection of Morphine can result in histamine release, therefore it must be infused slowly within 15 minutes. The nurse, who was in charge of infusing pain reliever, was unaware of the type of injected drug.
223593014|NCT02566590|DIETARY_SUPPLEMENT|Protein|supplement will used to enhance muscle anabolism. The intervention will be provided 3 times a day during bed rest.
223746846|NCT05382338|PROCEDURE|Auditory Brainstem Response|Ancillary studies
223746847|NCT05382338|PROCEDURE|Biospecimen Collection|Undergo CSF and blood sample collection
223746848|NCT05382338|DRUG|Cisplatin|Given IV
223746849|NCT05382338|DRUG|Cyclophosphamide|Given IV
223746850|NCT05382338|DRUG|Lomustine|Given PO
223746851|NCT05382338|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223746852|NCT05382338|OTHER|Quality-of-Life Assessment|Ancillary studies
223746853|NCT05382338|RADIATION|Radiation Therapy|Undergo radiation therapy
223593015|NCT02566590|DIETARY_SUPPLEMENT|non-protein placebo supplement|supplement will be used as a placebo to control participants. The supplement will be provided 3x a day during bed rest.
223593016|NCT03605446|DIETARY_SUPPLEMENT|Biscuit acceptance|Acceptance of high protein biscuits
223593017|NCT06090084|OTHER|Evaluation|Functional capacity, balance, core muscle strength, trunk muscle structure, lower extremity muscle strength, upper extremity functions, fatigue and respiratory muscle strength will be evaluated.
223593018|NCT05691114|BIOLOGICAL|hAESCs|human Amniotic Epithelial Stem Cells
223746854|NCT05382338|DRUG|Sodium Thiosulfate|Given IV
223746855|NCT05382338|OTHER|Survey Administration|Ancillary studies
223746856|NCT05382338|DRUG|Vincristine|Given IV
223593019|NCT00903435|OTHER|Quantitative Sensory Testing and Stimulus|No therapeutic intervention will be given. Quantitative Sensory Testing, thermal/mechanical/ischemic stimulus will be performed.
223593020|NCT05742607|DRUG|IPH5201 + durvalumab + standard chemotherapy|"Patients will receive Neoadjuvant therapy with IPH5201 and durvalumab in addition to standard chemotherapy.~Following surgery, patients will receive adjuvant treatment with IPH5201 and durvalumab."
223593021|NCT05665296|OTHER|cervicothoracic mobilization|Each participant in study group will receive cervicothoracic mobilization (central PA and transverse Grade III or grade IV) with comprehensive corrective exercise. The duration will eight weeks three sessions per week.
223593022|NCT05665296|OTHER|CCE|"Each participant will receive comprehensive corrective exercise include three phases: Initial phase -Improvement phase and Maintenance phase.~The initial phase exercises progress in frequency and intensity during this phase, as long as participants are able to demonstrate good quality movement. The initial phase duration is 2 weeks and the exercises will be performed for seven sets of 10-s hold .~Improvement phase exercises are progressed by considering individual characteristics of each participant and by observing the overload principle and the progression in the number of repetitions of each set during the 4 weeks of the improvement phase. The exercises will be performed from five sets of ten repetitions to six sets of 15 repetitions .~Maintenance phase exercises:The exercises are the same as in the improvement phase without any progression in intensity and frequency. The maintenance phase duration is 2 weeks"
223593023|NCT05692102|OTHER|Evaluate quality of life after gynaecological malignancies diagnosis and treatment|diagnosis and treatment
223504247|NCT05448547|RADIATION|Radiotherapy or surgery|see arm/ group description
224195155|NCT04437732|DEVICE|Apioc-P and Apioc-PT Contact Lens Design|Novel soft contact lens design
224195156|NCT00458133|BEHAVIORAL|exercise|compared effects on HbA1C on aerobic only, resistance only, combination of aerobic and resistance, and a stretching \& relaxing groups.
224195157|NCT05692570|DRUG|PBI-200 Tablet|PBI-200 is a TRK inhibitor
223504248|NCT05448547|OTHER|initial observation|see arm/ group description
224195158|NCT05692570|DRUG|Ritonavir Oral Tablet|Ritonavir is a potent CYP3A inhibitor
224195159|NCT05692570|DRUG|Cobicistat Oral Tablet|Cobicistat is a potent CYP3A inhibitor
224195160|NCT02339246|DRUG|Prograf vs Envarsus XR vs Astagraf XL|prograf vs Envarsus XR vs Astagraf XL
224195161|NCT02339246|DRUG|Prograf vs Astagraf XL vs Envarsus XR|Prograf vs Astagraf XL vs Envarsus XR
224195162|NCT03461393|DEVICE|Medical-Eye-Trainer (MET)|In order to provide a high contrast, dynamic visual stimulus to the patients, we developed an app that allowed the patients to regularly train with this stimulus. The app runs on Android (version 4.2 or later). The display of the screen is divided into 4 rows. In each row, a pattern of black and white squares is moving in one direction. The directions in subsequent rows are opposite to each other. Through the movement in the opposite direction a changing pattern is achieved in vertical and horizontal extension, the pattern alternates between continuous beams and a checkered pattern. The speed of the display on the monitor is 2 cm per second. In a comfortable viewing distance (ca. 40 cm), this leads to an angular velocity of approximately 3°/sec.
224195163|NCT06059508|DRUG|SHR-5495 for injection|SHR-5495 for injection
224195164|NCT02847078|DEVICE|smart phone app|App for this study is provided with real time updating educational materials, reminder, and consultation for improving secondary prevention, and the related information is pushed to a patient in chronological order after his or her PCI operation.
224195165|NCT02847078|DEVICE|A guideline booklet|A guideline booklet with general advice on secondary prevention of coronary artery disease.
224195166|NCT04980599|DIETARY_SUPPLEMENT|probiotic drink with Lactobacillus paracasei K56|Probiotic drink (K56 10\^11CFU) 350ml/d for 60days
224195167|NCT04980599|DIETARY_SUPPLEMENT|maltodextrin|maltodextrin ,for 60days
224195168|NCT04980599|DIETARY_SUPPLEMENT|Probiotic powder E3|Probiotic powder 3.0g/d (K56 10\^10cfu) 60days;
224195169|NCT04980599|DIETARY_SUPPLEMENT|Probiotic powder E5|probiotic powder 8g/day for 60days
224195170|NCT04980599|DIETARY_SUPPLEMENT|probiotic capsule E7|probiotic k56 capsule, 2capsules/d (10\^7cfu) for 60days
223504249|NCT05448547|DRUG|Hormone therapy|androgen depression therapy (ADT) by either LHRH agonist or antagonist or androgen monotherapy
223504250|NCT03507283|PROCEDURE|Double head pterygia excision and repair|Complete excision of the pterygia was done. A free conjunctival autograft was obtained. The graft was divided vertically into two parts then secured into conjunctival defects.
223504251|NCT00685698|DRUG|TG-873870 (Nemonoxacin)|750 mg
223504252|NCT02213107|DRUG|Enzalutamide and Dutasteride or finasteride|"Use of either two oral drugs together~1. Enzalutamide by mouth daily and dutasteride by mouth daily or~2. Enzalutamide by mouth daily and finasteride by mouth daily"
223504253|NCT05061706|DRUG|Lumateperone|Lumateperone 42 mg capsules administered orally, once daily.
223504254|NCT05061706|DRUG|Placebo|Matching capsules administered orally, once daily.
223504255|NCT06787144|DRUG|ELVN-001|Orally once or twice daily
224195171|NCT04980599|DIETARY_SUPPLEMENT|probiotic capsule E9|probiotic k56 capsule, 2capsules/d (10\^9cfu) for 60days
224195172|NCT04980599|DIETARY_SUPPLEMENT|probiotic capsule E10|probiotic k56 capsule, 2capsules/d (10\^10cfu) for 60days
224195173|NCT04980599|DIETARY_SUPPLEMENT|probiotic capsule E11|probiotic k56 capsule, 4capsules/d (10\^11cfu) for 60days
224195174|NCT02575261|BIOLOGICAL|CAR-T cell immunotherapy|This CAR-T cell immunotherapy with a novel specific Chimeric antigen receptor aiming at EphA2 antigen.
224195175|NCT03930901|OTHER|Health education learning package|Health education learning package (HELP) was introduced to children in the selected schools. The package involved different items and activities during the study period, e.g. comic booklet on the intestinal parasitic infections, stand banners, posters, lectures, songs, drawing competition, puppet show, lectures, with a toolkit that involved soap, slipper (plastic clogs shoes), \& nail clipper).
224195176|NCT00260949|PROCEDURE|Arthroscopic repair of rotator cuff tear|Patients will undergo arthroscopic shoulder surgery in the standard fashion
224195177|NCT01250418|DRUG|Ketamine group|ketamine bolus of 0.25mg/kg followed by an infusion set at 1.5 mcg /kg/min.
223593024|NCT02990039|BEHAVIORAL|Counseling letter|The intervention is based on the Health Action Process Approach. The first letter provides information on knowledge regarding sedentary time and physical activity as well as intervenes on self-efficacy depending on the mindset of participants (non-intender, intender, actor). The second letter focuses on benefits and barriers of physical activity as well as the role of social support for physical activity. In case of actional stage, the third letter intervenes on self-efficacy again and suggests action and coping planning. Otherwise, the letter includes ipsative feedback according to the second letter.
223746857|NCT05919940|DIETARY_SUPPLEMENT|Dietary Supplement: additional substitution of protein|"Day one (admission) no nutrition is applied.~Protein target is increased as follows:~* to a level of 1,2g/kg/d on day 1 after ICU admission~* to a level of 1,4g/kg/d on day 2 after ICU admission~* to a level of 1,6g/kg/d on day 3 after ICU admission~* to a level of 1,8g/kg/d on day 4 after ICU admission~* to a level of 2,0g/kg/d from day 5 onwoards~Additional protein is given within 2 hours after mobilization respectively:~* to 0,125g/kg/d on day 1 after ICU admission~* to 0,2g/kg/d on day 2 after ICU admission~* to 0,25g/kg/d on day 3 after ICU admission~* to 0,3g/kg/d from day 4 after ICU admission onwoards"
224195178|NCT02673827|OTHER|Progressive muscle relaxation|Intervention group: 20 patients with relapsing-remitting multiple sclerosis receive five sessions of Progressive Muscle Relaxation under the supervision of a researcher in neurology clinic. Before and after each session of the Progressive Muscle Relaxation They will be measured heart rate, respiratory rate and blood pressure. Participants will be guided to realize the Progressive Muscle Relaxation daily for 8 weeks, the time of day you feel more comfortable. the same receive education and training as the technical as well as a audio and a leaflet with the description the stages of the Progressive Muscle Relaxation. Control group: 20 patients with relapsing-remitting multiple sclerosis only receive traditional treatment.
224195179|NCT05277909|OTHER|The expert assessment of shoulder impairments and individualised treatment plan|The participant's diagnosis based on the history, symptoms and clinical findings will be used to guide the individualised treatment plan.
224195180|NCT05277909|OTHER|A minimal physiotherapeutic rehabilitation program delivered in a pamphlet|This pamphlet contains a program with minimal exercise recommendations for the shoulder consisting of mobility, stretching, strength exercises and tissue treatment.
224195181|NCT03804554|OTHER|Non-Interventional|Non-Interventional
224195182|NCT04056650|DRUG|L-theanine|up to 250 mg
224195183|NCT04056650|DIETARY_SUPPLEMENT|Caffeine supplement|50-400mg
224195184|NCT04056650|DEVICE|N1 app|N1 App on mobile device
224195185|NCT05936775|OTHER|nano-hydroxy apatite coated titanium implants|titanium implants with surface treatment of nano-hydroxy apatite
223504256|NCT05472909|OTHER|Standardized Relaxation Music|Participants listen to standardized relaxation music during surgery.
223504257|NCT05472909|OTHER|Personal Choice of Music|Participants listen to their preferred music during surgery.
223504258|NCT05455398|PROCEDURE|Surgical treatment of round window niche enlargement via round window for inner ear drug delivery|The round window niche is surgically removed and the hormone is slowly released into the inner ear using a gelatin sponge that has absorbed the hormone in the round window
223504259|NCT05455398|PROCEDURE|Drum chamber drug injection|Injection of drugs into the tympanic chamber through the tympanic membrane
223504260|NCT01640106|DIETARY_SUPPLEMENT|Omega-3|800 mg Omega 3 daily (600 mg DHA/200 mg EPA)
223504261|NCT01640106|DIETARY_SUPPLEMENT|Placebo|Placebo is a combination of dietary plant-based oils in a paste containing no Omega-3 (EPA or DHA)
223504262|NCT04251494|DIAGNOSTIC_TEST|Carotid intima media thickness measurement (CIMT)|CIMT is a measurement of the thickness of the two inner layers of the common carotid artery wall. Using ultrasound, a linear array transducer is placed on the surface of the skin at the neck. Electrocardiogram(ECG) electrodes are placed on each wrist and one on the ankle. An image of the common carotid artery (CCA) is then produced in anterior, posterior and lateral views, and saved along with the ECG recording. The wall thickness can then be measured at the same point in the cardiac cycle using semi-automated detection software (Philips QLAB), which can reduce observer variability. The CIMT will be averaged across left and right CIMTs, as the control reference values use an average of both sides.
223504263|NCT04251494|DIAGNOSTIC_TEST|Pulse Wave Velocity measurement|The PWV measures the speed of a pulse wave travelling between two points in the vascular systems of known distance between them. PWV will be measured by the gold standard carotid-femoral PWV method which is a direct measurement of aortic stiffness. A 3-Lead ECG is connected alongside measurements of the blood velocity trace for the left CCA 2cm proximal to the bifurcation, and for the left common femoral artery origin.
224195186|NCT05936775|OTHER|sandblasted large acid itched coated titanium implant|titanium implants with SLA surface treatment
224195187|NCT00710008|OTHER|exercise training|3 bouts of exercise at 90%RCP during one week
224195188|NCT01761565|DRUG|Single dose of SUF NT 15 mcg|
224195189|NCT01761565|DRUG|40 consecutive doses of SUF NT 15 mcg taken every 20 minutes|
224195190|NCT01559584|RADIATION|ultraviolet A (UVA)|"0.5% solution of 8-methoxypsoralen (MOP) will be applied 20 minutes before UVA exposure (315-400nm).~UVA sessions will be carried out twice weekly aiming to achieve a phototoxic reaction, in the form of erythema and vesiculation. Once a phototoxic reaction will be achieved, the patient will be asked to rest until the reaction subsides and then resume the phototherapy sessions."
224195191|NCT01559584|DRUG|Triamcinolone Acetonide|One monthly injections of intralesional triamcinolone acetonide
224195192|NCT00104858|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo HSCT
224195193|NCT00104858|DRUG|Cyclosporine|Given PO
224195194|NCT00104858|DRUG|Fludarabine Phosphate|Given IV
224195195|NCT00104858|OTHER|Laboratory Biomarker Analysis|Correlative studies
224195196|NCT00104858|DRUG|Mycophenolate Mofetil|Given PO
224195197|NCT00104858|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo HSCT
224195198|NCT00104858|OTHER|Pharmacological Study|Correlative studies
224195199|NCT00104858|BIOLOGICAL|Rituximab|Given IV
224195200|NCT00104858|RADIATION|Total-Body Irradiation|Undergo TBI
223593025|NCT04402723|DRUG|Donafenib|In first 28-days-cycle, eligible subjects will be given Donafenib 0.2/0.3g, bid, for first 14 days, combination with Daunorubicin 60mg/m2/d, for first 3 days, and Cytarabine 100mg/m2/d, for first 7 days. If CR or CRi is observed, subjects will be given Donafenib 0.2/0.3g, bid, for first 14 days, combination Cytarabine 2g/m2/q12h, for first 3 days, in next 28-day-cycle.
223746858|NCT05919940|DEVICE|Neuromuscular electrical stimulation|twice daily 60 minutes till day 28 or ICU discharge
224195201|NCT00581334|PROCEDURE|Robotic-assisted laparoscopic sacrocolpopexy|4 abdominal incisions will be made: 1 infraumbilical port and 3 lateral ports. The peritoneum overlaying the sacrum is entered and the anterior longitudinal ligament is exposed. 3 permanent sutures are placed through the ligament at the S2-S3. Then a vaginal obturator is placed transvaginally and the apex of vagina is elevated into the operative field. The peritoneum overlying the anterior and posterior vaginal epithelium is reflected and the bladder is dissected off the underlying vagina to expose 4cm of apical vagina. 2 segments of polypropylene mesh are prepared and one segment is anchored along the anterior vagina with a series of interrupted permanent suture and the second segment is anchored along the posterior vagina. These 2 segments are brought together to the previously placed sutures within the anterior longitudinal ligament of the sacrum. The peritoneum is then closed over the graft complex and the pelvis irrigated. The 4 robotic ports are removed and the abdomen closed.
224195202|NCT00581334|PROCEDURE|Open sacrocolpopexy|mesh augmented repair for post-hysterectomy prolapse performed via open laparotomy
224195203|NCT00423501|DRUG|Placebo|sc weekly
224195204|NCT00423501|DRUG|taspoglutide|20mg sc weekly
224195205|NCT00423501|DRUG|taspoglutide|10mg sc every 2 weeks
223504264|NCT04251494|DIAGNOSTIC_TEST|Ankle-brachial pressure index (ABPI)|A blood pressure cuff is placed around the ankle and upper arm of the participant. A continuous wave Doppler probe is used over the surface of the skin to locate the artery distal to the cuff (such as the brachial artery in the arm, or the anterior tibial and posterior tibial arteries in the ankle). The cuff is then inflated, and the systolic pressure identified by listening cessation of the sounds produced by the probe corresponding to blood flow in the artery. The ABPI is then the ratio of the highest systolic ankle pressure divided by the highest systolic brachial pressure for the left and right sides of the body.
223593026|NCT06279832|OTHER|trascriptomic profiling|The mutational and copy number analyses will be complemented by transcriptomic profiling. RNA will be extracted from FFPE samples using miRNAeasy FFPE kit (Qiagen) and checked for quality and quantify by 2100 Bioanalyzer instrument (Agilent) and Qubit Fluorometer (ThermoFisher), respectively. Transcriptome analyses will be performed by RNA-seq. We will apply total RNAseq using the Illumina® TruSeq Stranded Total RNA workflow that provides a solution allowing the detection of whole transcriptome, splicing variants, and transcript fusions of human RNA isolated from FFPE samples. Libraries will be run using the Illumina's Novaseq6000 system, with a least 50 millions of reads/sample, the minimum read depth for the correct evaluation of low expressed transcripts.
223593027|NCT04599465|DRUG|ELX/TEZ/IVA|Fixed dose combination (FDC) tablets for oral administration.
223593028|NCT04599465|DRUG|IVA|Tablets for oral administration.
223593029|NCT04079998|DEVICE|Procellera®|Application of Procellera® dressing.
223593030|NCT04079998|OTHER|Standard of Care|Application of standard of care dressings as prescribed.
223593031|NCT04345315|OTHER|serological test|serological test assessing IgM and IgG directed against SARS-CoV-2
223593032|NCT04345315|OTHER|Rapid molecular test|Molecular test to detect SARS-CoV-2 in oro/rhinopharyngeal swab
223593033|NCT04345315|GENETIC|Next generation Sequencing (NGS) analysis|analysis of genetic variability of virus and host
223593034|NCT04345315|OTHER|serum chemistry analysis|Analysis of serum chemistry factors and coagulation panel in blood samples
223746859|NCT05919940|OTHER|Early Mobilization|at least 20 minutes a day following the SOMS concept. Duration: till 28 day or ICU discharge
224195206|NCT00423501|DRUG|taspoglutide|5mg sc weekly
224195207|NCT00423501|DRUG|taspoglutide|10mg sc weekly
224195208|NCT00423501|DRUG|taspoglutide|20mg sc every 2 weeks
224195209|NCT05688800|DEVICE|conventional therapy|Participants in control group will receive conventional physical therapy treatment including Conventional TENS high frequency (90-130hz) low intensity according to the patient sensation for 30-45 min(Gozani, 2019) , continuous ultrasound with frequency 1 MHz and intensity 0.8 W/cm 2 will be applied by slow circular perpendicular movements with slightly deep pressure. Application time was 5 minutes at each side of the level of C7\_T4 along the medial borders of the scapulae width, infra-red radiation will be four 15 minutes and directed perpendicular to the inter-scapular area, centered at the level of C7\_T4 long and between the 2 medial borders of the scapulae width . Also combined stretching and strengthening exercise will be added due to its greater pain-relieving effect
224195210|NCT05688800|OTHER|Experimental group 1 : pressure release technique|Participants who are assigned to this group will receive conventionalphysical therapy treatment in addition to pressure release technique. the participant will be positioned either sitting or prone position according to his preferred position, the researcher will apply the pressure release procedure by a pressure below the PPT dependent onsoft tissue release. When the researcher detected a reduction in soft tissue resistance, the amount of compression will be increased. The pressure should -33- be nonpainful, applied at slow rate, and will maintained until release of tissue barrier. Further pressure was increased to reach a new barrier. The pressure will last 60 seconds. With the thumb or the second and third fingers, the non-painful manual therapy approach was applied to the active MTrPs of therhomboid muscle
224195211|NCT05688800|OTHER|Experimental group 2: thoracic spine manipulation|Thoracic spine manipulation will be performed as screw thrust manipulation technique; the vertebral transverse processes will beforced from posterior to anterior direction. The direction of the manipulation should be identified by applying springing test to the adjacent spinous process to determine the painful and stiff segment. Patient will be prone and researcher hand placement will be positioned as the following one pisiform on the right facet of the above, and the other pisiform on the left facet of the below vertebrae.A slack will be taken up. The thrust applied directly toward the patient once
224195212|NCT05156164|DEVICE|Kinesio Tape Group|The application of the KT consists of 6 strips of I-shaped tape adhered to the skin areas of the shoulder
224195213|NCT05156164|DEVICE|Control Group|KT application on the deltoid but without support function
224195214|NCT03125707|OTHER|Registry study|
223593035|NCT02056327|DEVICE|A novel monitoring suite of sensors will be inserted into the standard oral device.|
224195215|NCT03621566|OTHER|No intervention|Routine care (registry)
224195216|NCT03133208|PROCEDURE|Blood draws|Blood draws will be collected via venipuncture or IV at hours 0, 6, 12, 18, 24, 48, 72 (7 draws total). Each draw would be up to 20 mL of blood (but no less than 10 mL).
224195217|NCT06264830|DEVICE|Alcon-NGENUITY®(NG)-system|During operation, the Alcon NGENUITY® (NG) System is mounted on microscope, while the surgeon will wear 3D glasses, watch 3D screen, and perform operation
224195218|NCT06264830|PROCEDURE|Standard cataract operation|Standard, modern cataract extraction with standard phacoemulsification technique, and posterior chamber intraocular lens implantation.
224195219|NCT05754632|DEVICE|Blood Flow Restriction using Delfi Personalized Tourniquet System|The Delfi Tourniquet System is designed to be used in conjunction with exercise. The system automatically determines the degree of occlusion and allows for safe regulation of pressure. Patients will then complete exercises with the use of this device.
224195220|NCT06279273|DEVICE|Transcranial direct current stimulation|Participants were treated for a total of 20 sessions with active or sham stimulation at 2 mA. Each session lasted 20 min at a fixed daytime interval.
224195221|NCT06021431|DEVICE|MORE-VR|"An 8-session version of Mindfulness-Oriented Recovery Enhancement (MORE) delivered by virtual reality. The treatment involves training in mindfulness,reappraisal, and savoring techniques to address OUD.~Combination Product: Participants in this arm will also receive Treatment as usual (TAU) with medications for opioid use disorder (MOUD). Usual addictions treatment with medications such as buprenorphine or methadone plus psychological counseling."
224195222|NCT06021431|OTHER|Treatment as Usual|Participants will receive their usual treatment for OUD, including medications such as buprenorphine or methadone and any counseling they might already be receiving
224195223|NCT04988724|BEHAVIORAL|Exercise training|Exercise training with aerobic and strength training, 30 min per session
224195224|NCT04474171|BEHAVIORAL|SCI&U online health coaching program|Online secure videoconferencing health coaching platform with resource library to promote self-management. Maximum number of sessions is 14 over 6 months and covers health related topics to reduce secondary complications
224195225|NCT04723264|BEHAVIORAL|Food protocols|"Participants will engage in several activities (i.e. offering a variety of foods and age appropriate games, etc.) regarding eating behaviors.~Participants will be asked to videotape interactions using a secure system. An alternative option may be provided if this videotaping is not acceptable."
224195226|NCT06971094|GENETIC|GC101 adeno-associated virus injection|Self-complementary recombinant adeno-associated viral vector (scAAV) containing a single-stranded transgene encoding a codon-optimized human SMN1 gene
224195227|NCT05042128|DRUG|LSTA1|LSTA1 is a novel cyclic tumour-penetrating peptide iRGD (internalizing Arginylglycylaspartic acid) which may overcome poor drug delivery by activation of a complex trans-tissue transport pathway, providing an opportunity to overcome this mechanism of resistance in PDAC
224195228|NCT05042128|DRUG|Gemcitabine Injection|Chemotherapy drug provided as solution to be administered via IV infusion.
224195229|NCT05042128|DRUG|Nab paclitaxel|Chemotherapy drug provided as solution to be administered via IV infusion.
224195230|NCT06116890|DRUG|KHK4951|KHK4951 eye drop for 44 weeks until end of the trial
224195231|NCT06116890|DRUG|Aflibercept Injection|Intravitreal injection (IVT) of aflibercept will be given as specified in the protocol
224195232|NCT05477901|OTHER|Supplemental cash transfer|Supplemental cash transfer ($40/month)
223504265|NCT04251494|OTHER|Diet questionnaire and diet diary|Dietary information will be collected in two formats. One will be a 14-item questionnaire (Martínez-González et al., 2012), which is a simplified version of a comprehensive food frequency questionnaire. This provides a quick measure of compliance to a Mediterranean dietary pattern and a rough measure of protective and adverse dietary factors that could affect individual CVD risk. The second will be a 3-day diet diary (3DDD). This will consist of participants recording the foods that they consume and the quantities, which will then be analysed for macro- and micronutrient composition once completed.
223593036|NCT03009617|BEHAVIORAL|the educational program and counseling|to examine the effectiveness of web-based health education and consultation on health promotion behaviors of adolescents, their e-health literacy, and their information levels.
223593037|NCT01354925|DRUG|Insulin treatment during Ramadan|Insulin analogs will be used: Levemir and NovoMix70. The daily insulin dose will be calculated as follows: Sixty percent of the total daily dose will be used as the beginning daily dose at the first day of fasting. Sixty percent of the daily dose will be given as NovoMix70 before the Eftar (the main meal in the evening that breaks the fast). Forty percent of the amount will be given as Levemir (Early in the morning before the beginning of fasting.
223593038|NCT01354925|DRUG|Standard of care|Standard of care during Ramadan according to physicians decision
223593039|NCT01835665|DRUG|Nimodipine|Nimodipine is an FDA-approved drug for subarachnoid hemorrhage indication
224195233|NCT04840979|DRUG|11C-ER176|11C-ER176 is a novel TSPO radioligand that was developed because of its relative insensitivity to the rs6971 polymorphism. Increased TSPO signal on PET is associated with activation of microglia in the brain. The radioligand will be administered in tracer doses at activity of up to 20 mCi (740 MBq), IV, total of one injection. A single dose of radioligand will be injected over 1 minute.
224195234|NCT04840979|DRUG|18F-florbetaben|Florbetaben has been approved by the FDA to help diagnose Alzheimer's disease. Florbetaben measures amyloid in the brain.
224195235|NCT05643573|DRUG|Asundexian (BAY2433334)|Once a day
224195236|NCT05643573|DRUG|Apixaban|5 mg or 2.5 mg, twice a day, according to product label.
224195237|NCT05643573|DRUG|Asundexian matching placebo|Placebo to asundexian, once a day
224195238|NCT05643573|DRUG|Apixaban matching placebo|Placebo to apixaban, twice a day
224195239|NCT02308085|OTHER|Endocrine therapy interruption|"3 months wash-out between treatment interruption and pregnancy attempt. Up to 2 years interruption to allow pregnancy, delivery, breastfeeding or failure to conceive.~Endocrine therapy resumption. Completion of full duration of endocrine therapy according to individual risk, institutional policy or patient's preference."
224195240|NCT04026867|OTHER|Linkage Navigation|The Linkage Navigation arm will consist of an additional service layered onto clinician referral and will incorporate protocols from Antiretroviral Treatment and Access Studies (ARTAS), the most influential studies of HIV linkage-to-care to date.
223593040|NCT03680443|OTHER|assembly in THA revision|A single-center continuous series of 62 patients receiving such an assembly in THA revision was assessed retrospectively at a minimum 5 years' follow-up. Failure due to aseptic loosening or instability and implant survival at last follow-up were analyzed.
223593041|NCT04427020|DIETARY_SUPPLEMENT|Milk protein + GBI-30|Both conditions matched flavor, color, and serving size
223593042|NCT04427020|DIETARY_SUPPLEMENT|Milk protein|Both conditions matched flavor, color, and serving size
223504266|NCT04251494|OTHER|Routine blood samples|Blood samples will be taken from participants during their outpatient appointment. Patients routinely have blood samples taken during this clinic. The study will use the results from the routine blood tests, and also extra blood samples to collect data on other biomarkers. The laboratory facilities at Guy's and St Thomas Hospitals will be used to conduct analysis, no other laboratories will be used. Data will be collected on Phenylalanine levels, lipids, vitamin B12 and related biomarkers.
223504267|NCT02331121|BEHAVIORAL|Family First Aid Online Training|Web-based interactive multimedia program comprised of videos, interactive animations and text information designed to teach parents of children aged birth to 12 years old basic first-aid and CPR skills, including the option to practice skills as needed.
224195241|NCT04026867|OTHER|Clinician Referral|"The Clinician Referral arm will serve as an active control and baseline standard of care."
224195242|NCT06503224|DRUG|Anti-BCMA and CD19 CART cells will be injected intravenously on a one-time basis.|A single intravenous infusion of anti-BCMA and CD19 CART cells (dose-escalating infusion of 0.5-3 x10\^6 CART cells/kg）.
224195243|NCT05768880|BIOLOGICAL|SC-CAR4BRAIN|Courses of weekly intraventricular CNS administered SC-CAR4BRAIN infusions for 3 weeks, then 1 week off
224195244|NCT06120231|DIAGNOSTIC_TEST|Pulse width modulation|Will be stimulating the pedicle screws utilizing three different pulse-width settings, 0.4 milliseconds, 0.2 milliseconds, and 0.05 milliseconds.
224195245|NCT06244212|OTHER|Demonstration of applying triamcinolone cream|Live demonstration of applying 1 fingertip unit of triamcinolone cream
224195246|NCT06244212|BEHAVIORAL|Mobile App Use|Additional mobile application that provides amount dispensed and adherence data.
223504268|NCT02331121|BEHAVIORAL|Text-only Online Training|Online text created from the American Heart Association's 2010 guidelines for CPR training via a computer, depicting infant, child and adult CPR skills and choking relief.
223504269|NCT05159011|BEHAVIORAL|AGILITY (Access to Genetic Information Leveraging Innovative TechnologY)|information about genetic testing through technology
223504270|NCT01937338|DRUG|AZD7624|nebuliser solution; 20 mg/mL for inhalation
223504271|NCT01937338|DRUG|Placebo|nebuliser solution for inhalation
223504272|NCT04183478|DRUG|K-001|K-001 is an antitumor active substance (peptidoglycan) which is prepared from the fermentation product of marine microorganism. K-001 is the Chinese first class new drug and get patent licensing in China, America and Japan.
223504273|NCT04183478|OTHER|placebo|Placebo which looks the same as K-001 in apparence
223504274|NCT02749929|OTHER|Low level laser therapy|The laser is an infrared (invisible) 60 mW 904 nm Irradia Midlaser
223504275|NCT02749929|OTHER|Placebo Low Level Laser Therapy|The placebo laser is an identical device to the active laser, made by Irradia Midlaser
223593043|NCT00487071|DEVICE|Anal fistula plug|
223593044|NCT04705246|BEHAVIORAL|Psychoeducation|The goal of the psychoeducation session is to provide insight in the hyperacusis symptoms, take away the fear of external noises, and encourage exposure to noise.
223593045|NCT05706571|OTHER|control group (skill laboratory), experimental group 1 (Banner model) and experimental group2 (augmented reality mobile application)|In the research, the control group will form the control group of both experiment one and experiment two. In the creation of quantitative and qualitative data, it will be formed in three groups, two of which are the experimental group and one is the control group. While forming the experimental and control groups of the research, it is planned to ensure homogeneity between the groups by making random and unbiased selection. It is planned to do a pre-test before applying the child patient end-of-life care module of nursing students of teaching with augmented reality and Benner model to the experimental and control groups.
223593046|NCT01756118|DRUG|BEZ235|A minimum of 3 dose levels
223593047|NCT03765203|DIAGNOSTIC_TEST|Natera KidneyScan|Online educational materials on Natera Kidneyscan (dd-cfDNA) and sample test results for simulated patients
223593048|NCT03765203|OTHER|Clinical Performance and Value Vignettes|Online renal allograft simulated patients
223504276|NCT03051009|DRUG|Desmopressin ODT 25 μg|
223593049|NCT01162811|BEHAVIORAL|visualization together with structured behavioural attention.|visualization and relaxation exercises together with structured behavioural attention.
224195247|NCT06244212|OTHER|Standard of Care|Written/verbal instructions only
224195248|NCT04935164|OTHER|Psychiatric evaluations|At different time points, several psychiatric evaluations will be performed on patients and volunteers for study purposes
224195249|NCT05855382|OTHER|Persistent COVID-19|To determine the prevalence of persistent COVID-19 diagnosis in the current study, we will identify adults between 18 and 100 years of age who have had at least one positive SARS-CoV-2 RT-qPCR test from the COVID-19 database maintained by the SEREMI of Health in Punta Arenas between July 2022 and July 2023.
224195250|NCT03754400|BIOLOGICAL|Albumin|All patients will receive a daily intravenous infusion of 20% Human Albumin Solution (HAS) 40 gram at day 0 (loading dose), Day-1 to day 7, 20 gm daily, then from day 8 to day 28, 20 gm every alternate day.
224195251|NCT03754400|OTHER|Standard Medical Treatment|Antibiotics, nutrition and supportive treatment
223504277|NCT03051009|DRUG|Desmopressin ODT 50 μg|
223504278|NCT04077398|DRUG|Ropivacaine 0.5% Injectable Solution|There will be two groups, in order to compare two different sets of volumes with the same amount of drug. we will try to identify if it is better one volume over the other in terms of pain control and consume of opioids, as well the presence or absence of motor weakness.
224195252|NCT06235034|OTHER|Diagnostic CT|radiotherapy will be designed on diagnostic CT. If plan is of sufficient quality, RT will be delivered to patient
224195253|NCT04567849|BEHAVIORAL|message|patient portal message
224195254|NCT04567849|BEHAVIORAL|provider|nudging calling the patient's provider
224195255|NCT04567849|BEHAVIORAL|tele-nurse|nudging calling the tele-nurse
224195256|NCT03362411|DRUG|BMS-986205|Single 100 mg dose on Day 1 and Day 15
224195257|NCT03547921|DEVICE|iu22 ultrasound system - phillips|iu22 ultrasound system - phillips
224195258|NCT04684979|BIOLOGICAL|Hematopoietic Stem Cells from HLA-compatible Related|NMA PBSCT (Non-Myeloablative peripheral blood stem cell transplantation) incorporating rituximab and utilizing PBSC (Peripheral blood stem cells) to increase graft cell dose in patients with selected B lymphoid malignancies.
224195259|NCT04684979|BIOLOGICAL|Hematopoietic Stem Cells from HLA Unrelated|NMA PBSCT (Non-Myeloablative peripheral blood stem cell transplantation) incorporating rituximab and utilizing PBSC (Peripheral blood stem cells) to increase graft cell dose in patients with selected B lymphoid malignancies.
224195260|NCT02268214|DRUG|Dapagliflozin|Tablets
224195261|NCT02268214|DRUG|Placebo for dapagliflozin|Tablets
224195262|NCT04342390|OTHER|High-Intensity Interval Training (HIIT)|The exercise we are studying is called high-intensity interval training, or HIIT. Participants in the exercise group will participate in the exercise program. Each exercise session will last up to 1 hour. All exercise sessions will be directed and monitored by an experienced exercise trainer or exercise physiologist.
224195263|NCT01795534|DIETARY_SUPPLEMENT|Beetroot shot then placebo shot|Beetroot shot, four day wash out, then placebo shot
224195264|NCT01795534|DIETARY_SUPPLEMENT|Placebo shot then beetroot shot|Placebo shot, four day wash out, then beetroot shot
224195265|NCT06539611|OTHER|Observational|This study is observationnal: Questionnaires to assess the endpoint
224195266|NCT01620749|RADIATION|18F MEL050|Diagnostic intervention to establish the safety and biodistribution of MEL050 in participants with melanoma.
224195267|NCT03741335|OTHER|Resistance Training|Participants attend supervised, group-based moderate-intensity strength training program 3 times per week for 60 minutes per session.
224195268|NCT03741335|OTHER|Stretching|Participants attend a supervised, group-based supervised flexibility program 3 times per week for 60 minutes per session
224195269|NCT03741335|OTHER|Tai Chi|Participants attend a supervised, group-based tai ji quan program where they perform an integrated exercise routine consisting of 8 purposeful movement forms and a set of therapeutic movements 3 times per week for 60 minutes per session.
224195270|NCT05339139|COMBINATION_PRODUCT|Dialysis|In this study critically ill adult patients requiring Continuous Renal Replacement Therapy (CRRT) will receive Regional Citrate Anticoagulation (CRA) which will be delivered by multiFiltratePRO system.
224195271|NCT06639711|DRUG|Taurine|Taurine-containing eye drops (VIZILOTON) are applied 4 times daily for a period of one year
224195272|NCT04036942|PROCEDURE|Ablation of the gastroesophageal junction with hybrid argon plasma|In the management group with argon plasma hybrid after marking 270 degrees of the esophagogastric junction, submucosal elevation and argon plasma burn of the marked and elevated area is performed.
224195273|NCT04036942|PROCEDURE|mucosectomy with band of the gastroesophageal junction|In the management group with mucosectomy after marking 270 degrees of the esophagogastric junction, a submucosal elevation of the marked area is performed to subsequently perform ligation and resection with a hot snare below the ligation area.
224195274|NCT04563039|DEVICE|Ureteroscopy Laser Lithotripsy (URS-LL) with Acoustic Enhancer|Applaud's Acoustic Enhancer is provided in a lyophilized form. After reconstitution, it is a liquid, containing micron-scale particles that are made of a perfluoroalkane gas core with a lipid shell. The device is intended to be used with cleared/approved pulsed laser systems in fragmenting urinary stones (calculi) in the upper (superior) pole, lower (inferior) pole, and interpolar region of the kidney, pelvis of the kidney, and proximal ureter.
224195275|NCT04563039|DEVICE|Standard Ureteroscopic Laser Lithotripsy|Standard of care Ureteroscopic Laser Lithotripsy
224195276|NCT05035394|PROCEDURE|Cataract surgery|Cataract Surgery in a standardized fashion
223504279|NCT04377386|DIETARY_SUPPLEMENT|1000 IU D vitamin|Participants in the intervention group will receive 105 DV doses of 1000 IU. The supplementation will be given by the Farma de Colombia laboratory, known commercially as Farma D, whose presentation is in soft gelatin capsules. It is recommended to take one dose per day at the same time and participants should record the daily intake time of the supplement for 15 weeks on a calendar.
223504280|NCT04377386|DIETARY_SUPPLEMENT|200 IU D vitamin|Participants in the control group will receive 105 DV doses of 200 IU. The supplementation will be given by the same laboratory; it will have the same characteristics and recommendations for the intake as for the intervention group.
224195277|NCT05035394|PROCEDURE|KDB|Goniotomy with KDB glide will be performed at the end of Cataract Surgery
224195278|NCT05035394|PROCEDURE|Istent|Two iStent inject W will be injected into Schlemms Canal at the end of Cataract Surgery
224195279|NCT03447015|OTHER|ambulation|"Ambulation during labour here will refer to moving from place to place during the first stage of labour that reduces the amount of time a woman spends laying down during this stage (measured by recording the number of minutes spend on walking)."
224195280|NCT06019793|DEVICE|DBS for Chronic Pain|Participants ill receive deep brain stimulation to relieve their chronic pain symptoms.
224195281|NCT06103734|COMBINATION_PRODUCT|Zavegepant 10 mg|4 doses of zavegpant 10 mg intranasal spray device
224195282|NCT06103734|COMBINATION_PRODUCT|Placebo - Control 1|3 doses of placebo intranasal spray device and 1 dose of zavegepant 10 mg intranasal spray device
224195283|NCT06103734|COMBINATION_PRODUCT|Placebo - Control 2|3 doses of placebo intranasal spray device and 1 dose of zavegepant 10 mg intranasal spray device
224195284|NCT04868188|OTHER|5 blood samples|5 blood samples across 3 occasions/sampling windows (Day 1-4, Day 6-9 and Day 11-14) to determine plasma concentrations of voriconazole
223504281|NCT06152354|DEVICE|rotary system|crown down technique using Kedo-SG file rotary system using endodontic motor
223504282|NCT06152354|DEVICE|Manual files|instrumentation were done by step back technique using K- file (Mani ) from size 15 to size 35 in quarter pull turn motion apically
223504283|NCT01294072|DIETARY_SUPPLEMENT|curcumin|tablets-3.6 gram (gm) taken daily for 7 days - 15 subjects
223504284|NCT01294072|DIETARY_SUPPLEMENT|Curcumin conjugated with plant exosomes|tablets-taken daily for 7 days - 15 subjects
223504285|NCT01294072|OTHER|No intervention|no treatment
223504286|NCT01708837|DRUG|Propofol|Propofol infusion rate is titrated to maintain the target BIS values
223504287|NCT01222351|DRUG|BAY 94-9172 (Florbetaben)|Measure of brain amyloid load using BAY 94-9172 PET/CT
223504288|NCT04251936|BEHAVIORAL|Exercise training|The moderate-intense aerobic exercise training will involve supervised aerobicycle ergometer training for 30 min with 60-80% HRmax three times per week for 12 weeks.
223593050|NCT04533867|PROCEDURE|Laparoscopic sleeve gastrectomy|Sleeve gastrectomy, also called a vertical sleeve gastrectomy, is a surgical weight-loss procedure. This procedure is typically performed laparoscopically, which involves inserting small instruments through multiple small incisions in the upper abdomen. During sleeve gastrectomy, about 80 percent of the stomach is removed, leaving a tube-shaped stomach about the size and shape
223593051|NCT04533867|DRUG|Palonosetron 1mcg/kg|Injectable Palonosetron 1 mcg/kg diluted up to 5 mL with normal saline solution and injected intravenously at the end of the bariatric surgery.
223593052|NCT04533867|DRUG|Ondansetron 1 mg/kg, max dose 8 mg|Injectable ondansetron 0.1 mg/kg, maximum of 8 mg was injected intravenously at the end of the bariatric surgery.
223593053|NCT01916343|PROCEDURE|Study Laparoscopic Curriculum|
224195285|NCT04868188|GENETIC|Determination of CYP2C19 genotype|A single buccal swab to determine the CYP2C19 genotype will be undertaken during the course of ICU stay.
224195286|NCT05412225|DIAGNOSTIC_TEST|Pre-neoadjuvant radiotherapy (NART) biopsy|Participants will undergo pre-NART core biopsy guided by post-NAC MRI to the area of residual enhancement or to the previously biopsied cancer if no residual enhancement remains
224195287|NCT05412225|RADIATION|Neoadjuvant radiotherapy|After biopsy, participants will undergo neoadjuvant radiotherapy/NART
224195288|NCT05412225|PROCEDURE|Unilateral total mastectomy with axillary lymph node dissection|At 2-6 weeks after completion of NART, participants will undergo unilateral MRM (total mastectomy with axillary lymph node dissection), with resection of all involved breast skin. Skin-sparing mastectomy will not be permitted. All patients will also undergo simultaneous unilateral autologous-based breast reconstruction with DIEP, ms-TRAM, or latissimus dorsi flap.
224195289|NCT06578624|DRUG|SA53-OS (phase 1)|Dose escalation phase in which participants receive SA53-OS on 3 consecutive days every 3 weeks for a maximum of 2 years. Single participant cohorts will be enrolled until a Grade 2 or greater toxicity is observed and then 3+3 multi-participant cohorts will be enrolled until the MTD is identified.
224195290|NCT06578624|DRUG|SA53-OS (phase 2)|Dose expansion phase in which participants receive SA53-OS on 3 consecutive days every 3 weeks for a maximum of 2 years at the MTD identified in phase 1.
224195291|NCT06805370|BEHAVIORAL|Mailed Additional FIT Kit|Mailed additional FIT Kits in November 2024.
224195292|NCT06805370|OTHER|Usual Care|This group was sent an annual FIT Kit per usual care.
224195293|NCT04950426|DRUG|Propranolol|One administration of propranolol, once a week during six weeks. Reading by the participant of his/her traumatic story, 75 minutes (+/- 15 min) after propranolol intake.
224195294|NCT06192108|DRUG|Orforglipron|Administered orally
224195295|NCT06192108|DRUG|Dapagliflozin|Administered orally
224195296|NCT04419909|DRUG|CD19 redirected autologous T cells (CTL019 or CTL119 cells)|Retreatment with CD19-directed Chimeric Antigen Receptor-modified T Cells (CART19 cells) or huCD19-directed Chimeric Antigen Receptor-modified T Cells (huCART19 cells) in subjects with late relapse of B-cell lymphomas.
223593054|NCT02222376|DRUG|Pirfenidone|Twice a day topical application
223593055|NCT02222376|PROCEDURE|Debridement|Weekly ulcer debridement
223593056|NCT00133666|BEHAVIORAL|Asthma Communication Education|
223593057|NCT00133666|BEHAVIORAL|Standard Asthma Education|
223593058|NCT01890408|DRUG|wound infusion ropivacaine|"Laparotomy Hepatic surgery :~Bolu of 10 ml de ropivacaine 0,2% + infusion with elastomeric pump with ropivacaine 0,2% at a 10ml/h during 48 hours."
223593059|NCT02202343|BEHAVIORAL|school based health and nutrition education|
223593060|NCT03416127|DRUG|Propolis|Propolis capsules, 300 mg, two times per day before break-fast and dinner during 12 weeks.
223746860|NCT01622361|DRUG|Adriamycin+Cyclophosphamide>Docetaxel|"1. Adriamycin 60mg/m2 + Cyclophosphamide 600mg/m2~   * Route: by slow intravenous bolus~  * Schedule: every 3weeks for 4 cycle~2. Docetaxel 75mg/m2~   * Route: intravenous as per local practice~  * Schedule: every 3weeks for 4 cycle"
224195297|NCT01891318|RADIATION|radiosurgery|Undergo radiosurgery
224195298|NCT01891318|PROCEDURE|therapeutic conventional surgery|Undergo surgical resection
224195299|NCT01891318|PROCEDURE|quality-of-life assessment|Ancillary studies
224195300|NCT06523725|DRUG|PO BRC-003 (High Cannabidiol Cannabis Extract)|The research is divided into two phases: an open-label dose-finding phase (Part A) and a subsequent randomized controlled phase (Part B).
224195301|NCT06523725|DRUG|Placebo|Placebo
224195302|NCT06650345|OTHER|supervised aerobic exercise|In this training program, the participants exercised for 45-60 minutes through intervals on a treadmill, bike, or stair climber, three times a week for 12 weeks.
224195303|NCT05959551|DEVICE|high definition transcranial direct current stimulation (HD-tDCS)|HD-tDCS will be provided for 20 minutes for each stimulation with peak intensity of 2mA.
224195304|NCT06350630|DRUG|Hydroxychloroquine Oral Tablet|Active hydroxychloroquine once daily by oral route at 6.5 mg/kg of ideal weight/day, with maximal dose of 400mg/day for 3 years
224195305|NCT06350630|DRUG|Placebo oral tablet|placebo once daily by oral route (no active drug - same dosage as hydroxychloroquine )
223593061|NCT03416127|DRUG|Metformin|Metformin capsules, 850 mg, two times per day before break-fast and dinner during 12 weeks.
223593062|NCT03416127|DRUG|Placebo|Calcined magnesium, two times per day before break-fast and dinner during 12 weeks.
223593063|NCT01971008|DEVICE|Elastic abdominal binder|
223593064|NCT01971008|DEVICE|Placebo binder|
223746861|NCT01622361|DRUG|GnRHa with Tamoxifen|"1. Goserelin(GnRHa) 3.6mg~   * Route: subcutaneously under the abdominal skin~  * Schedule: every 4weeks for 6cycles (period of 34 days between 2 administrations must not be exceeded)~2. Tamoxifen 20mg/day~   * Route: Oral~  * Schedule: everyday"
223746862|NCT04540757|PROCEDURE|Surgery|Participants will be randomised to receive surgery as part of multi-modality treatment
223746863|NCT04540757|PROCEDURE|No surgery|Participants will be randomised to receive no surgery as part of multi-modality treatment
223746864|NCT02663609|OTHER|No intervention|No treatment (intervention) was administered.
223593065|NCT05223049|OTHER|painDETECT questionnaire|The painDETECT questionnaire was specifically developed to detect neuropathic pain components in adult patients with low back pain. It is also used in detecting the neuropathic pain in rheumatic diseases. A score between ≤12 represents a nonneuropathic pain, ≥13 and ≤18 represents a possible neuropathic pain, while a score of ≥19 represents a neuropathic pain.
223593066|NCT05223049|OTHER|Douleur Neuropathique 4 questionnaire (DN4)|DN4 is a clinician-administered questionnaire consisting of 10 items. Seven items related to pain quality (i.e. sensory and pain descriptors) are based on an interview with the patient and 3 items based on the clinical examination. A score of ≥4 represents a neuropathic pain.
223593067|NCT05223049|OTHER|Short form-36|The 36-Item Short Form Survey (SF-36) is a self-reported measure of health. It comprises 36 questions which cover eight domains of health. 1) Limitations in physical activities because of health problems. 2) Limitations in social activities because of physical or emotional problems 3) Limitations in usual role activities because of physical health problems 4) Bodily pain 5) General mental health (psychological distress and well-being) 6) Limitations in usual role activities because of emotional problems 7) Vitality (energy and fatigue) 8) General health perceptions. Each domain is scored between 0 and 100 and a higher score represents a better outcome.
223593068|NCT05223049|OTHER|Spondyloarthritis Research Consortium of Canada Enthesitis Index (SPARCC)|SPARCC was created as a measure for enthesitis in spondyloarthritis in general. It assesses 16 enthesial sites. Total number of the enthesitis is the total score of the evaluation. Total score is between 0 and 16, and higher scores represent a worse outcome.
223593069|NCT05223049|OTHER|Numeric Rating Scale|Self reported pain scored between 0 (minimum)-10 (maximum). Higher scores represent a worse outcome.
223593070|NCT05223049|OTHER|Disease activity in psoriatic arthritis (DAPSA)|DAPSA includes a 68/66 joint count summed with a patient global, patient pain score, and C- reactive protein level. The DAPSA provides a continuous score of arthritis activity and has validated cut points for remission (\< 4) and low disease activity (\< 14).
223593071|NCT01905449|BEHAVIORAL|Ultrasound visual feedback|Real-time visual displays of the tongue are used to cue participants to modify the tongue position/shape as they articulate speech sounds
223593072|NCT02270554|DEVICE|Endo GIA Reinforced Reload with Tri-Staple technology|Device:Endo GIA Reinforced Reload with Tri-Staple technology
223593073|NCT01963845|DRUG|Sitagliptin|
223593074|NCT01963845|DRUG|Placebo|
223593075|NCT02298400|DEVICE|Acuvue® Oasys® Lenses (senofilcon A)|Contact lenses placed in each eye during the day for about 8 hours
223593076|NCT02298400|DEVICE|30-Day Bausch + Lomb PureVision (balafilcon A)|Contact lenses placed in each eye during the day for about 8 hours
223593077|NCT02298400|DEVICE|Clariti® 1-Day (Somofilcon A)|Contact lenses placed in each eye during the day for about 8 hours
223593078|NCT04472455|DIAGNOSTIC_TEST|HRME|
223593079|NCT02489942|DRUG|Jardiance|Empagliflozin
223593080|NCT00858208|DRUG|pegaptanib sodium|pegaptanib sodium intravitreal injection every 6 weeks for 2 years
223593081|NCT01517464|GENETIC|SGT-94|SGT-94 will be given at doses of 0.6, 1.2, 2.4, 3.6 and 4.8 mgDNA/infusion(Doses 0-5, respectively)twice weekly for 3 weeks out of 4 in dose levels 0 to 4, and for 5 weeks out of 6 for dose level 5 (also 4.8mg DNA). Intravenous infusion will occur over 1 to 2.5 hours in 5% dextrose,with a final volume of SGT-94 and dextrose of 100 mL to 250 mL, depending on dose level.
223746865|NCT01265849|BIOLOGICAL|LI|LI 400 IU (2.0mL total daily) 1.0 mL peritumoral, 1.0 mL perilymphatic 5x weekly x3 consecutive weeks administered as neoadjuvant therapy prior to SOC, (surgery followed by radiation or concurrent radiochemotherapy with cisplatin 100 mg/m\^2 intravenously x3) to determine if LI plus CIZ affects the 3-5 year overall survival.
223746866|NCT01265849|DRUG|Cyclophosphamide|Cyclophosphamide was administered IV bolus (one time only) at a dose of 300mg/m\^2 three days prior to beginning treatment with LI. Standard of care (SOC) for previously untreated squamous cell carcinoma of the head and neck is currently surgery followed by radiotherapy (60-70Gy in 30 to 35 fractions over 6 to 7 weeks) for higher risk subjects (subjects determined at surgery to have adverse features per the National Comprehensive Cancer Network (NCCN) guidelines, such as, positive surgical margins, 2 or more clinically positive nodes or extracapsular nodal spread, etc. that would pre-dispose them for higher risk of recurrence) radiotherapy is combined with concurrent chemotherapy (cisplatin 100mg/m\^2 intravenously on day 1 of weeks 1, 4 and 7 of radiotherapy.
223746867|NCT01265849|DRUG|Indomethacin|One 25mg capsule of indomethacin was self administered orally (BID) beginning on day one of LI treatment daily until the day before surgery.
223746868|NCT01265849|DIETARY_SUPPLEMENT|Zinc|One capsule daily self administered beginning on day one of treatment with LI until one day before surgery
223504289|NCT04251936|BEHAVIORAL|Smoking cessation group program|Participants of both groups will receive a 6-week standard cognitive behavioral therapy-oriented smoking cessation group program (SCP, one 60 min session per week).
223504290|NCT05343169|BEHAVIORAL|Overdose Education and Naloxone Distribution|"Education on OD risk behaviors and methods for responding to an OD, including naloxone use.~Duration and dose: Single 20-minute training at time of enrollment, provided to all participants in both arms"
223746869|NCT01265849|PROCEDURE|Surgery|Excise tumor and nodes
223746870|NCT01265849|DRUG|Cisplatin|Cisplatin was administered 100mg/m\^2 IV concurrent with radiotherapy. The chemotherapy agent (cisplatin 100mg/m\^2) was administered intravenously on day 1 of weeks 1, 4 and 7 of radiotherapy.
224195306|NCT04049474|DEVICE|ERBOKRYO® CA - Cryosurgical Unit with Flexible ERBECRYO Probe, 1.9 mm outer diameter (ERBE Inc., Tubingen, Germany)|See BCI description.
224195307|NCT05685355|DIAGNOSTIC_TEST|Standardized intraoral photography|Mouth photos will be taken with a plastic retractor to retract the subject's cheek and lips. This is a standard clinical procedure that is non-invasive and does not cause any harm or adverse effect on subjects.
224195308|NCT00318357|DEVICE|Continuation of CRT|Implantation of CRT device and medical treatment according normal hospital routine.
223504291|NCT05343169|BEHAVIORAL|Advanced Education in Safer Substance Use, Treatment, and Self-Care|Education about misinformation about OAT, self-care, SEP services, HIV/HCV treatment Duration/dose: 9 mos., monthly \~2 hr. group sessions + ongoing access to video archive of recorded trainings.
223593082|NCT02484352|DRUG|saline|different dosage of IV oxycodone was given before intubation
223593083|NCT02484352|DRUG|0.05 mg/kg of oxycodone|different dosage of IV oxycodone was given before intubation
224195309|NCT00318357|DEVICE|Upgrade to CRT|Recommended implantation of a Medtronic CRT InSync® family devices. Implantation of CRT device and medical treatment according normal hospital routine.
224195310|NCT02643992|OTHER|DOAC concentration measurement|
224195311|NCT03086252|PROCEDURE|Red Blood Cell Transfusions (RBCT)|Undergo patient-driven RBCT
224195312|NCT03982381|DRUG|Metformin|Active comparator
224195313|NCT03982381|DRUG|Dapagliflozin 10 MG|Experimental treatment
224195314|NCT06560723|DIAGNOSTIC_TEST|Quality of life test|The results of the various quality-of-life scores used to compile the study statistics (ADL, iADL, MMS, GDS, MNA, EPICES, SPPB, SF-36) will be provided to the doctor, but without any specific comments or recommendations, and then presented to the patient. Number of emergency room visits and hospitalization days, drug untake evalautions and thepareutic compliance (GIRERD score) will be also collected.
224195315|NCT04832009|DRUG|Dextrose 20 % in 500 ML Injection|Dextrose (20% intravenous solution) will be obtained from the Investigational Pharmacy located in the KU Clinical Research Center where studies take place. After fasting for at least 8 hours, dextrose will be administered via antecubital vein at a standard rate of 4 mg/kg/min for 2 hours.
224195316|NCT04832009|DRUG|Intralipid|Intralipid ® 20% will be obtained from the Investigational Pharmacy located in the KU Clinical Research Center where studies take place. After fasting for at least 8 hours, Intralipid ® 20% will be administered via antecubital vein at 0.75 mL/min for 2 hours Increases in circulating markers of oxidative stress peak within 2 hours of Intralipid ® 20% infusion in healthy adults (42). An initial heparin bolus of 1000 UL followed by 200 U/hr infusion will be included to activate endothelial lipoprotein lipase and accelerate hydrolysis of fatty acids.
224195317|NCT04832009|DRUG|Saline|Saline will be obtained from the Investigational Pharmacy located in the KU Clinical Research Center where studies take place. Will be administered via antecubital vein at 75 to 150 mL/hour for 2 hours.
224195318|NCT04832009|DRUG|Ascorbic acid|"(ASCOR) will be obtained from the KU Investigational Pharmacy located in the KU Clinical Research Center where studies will take place. A priming bolus of 0.06 g ascorbic acid/kg fat free mass (FFM) dissolved in 100 mL of saline will be infused intravenously at 5 mL/min for 20 minutes, followed immediately by a drip-infusion of 0.02 g/kg FFM dissolved in 30 mL of saline administered over 2 hours at 0.5 mL/min. The KU Investigational Pharmacy will randomize ascorbic acid or placebo (saline) for each participant."
224310496|NCT05211076|OTHER|Control group|"The Introductory Information Form will be filled by the researcher using face-to-face interview technique.It will be ensured that the mother fills the State Anxiety Scale with her own statement.The mothers will milk the mother manually by the researcher at 11:00am for at least 15 minutes until the milk does not come.~At the end of the milking process, the milk accumulated in the container will be measured with an injector and recorded in the Breast Milk Follow-up Form in ml.~Then, it will be ensured that the mother fills in the State Anxiety Scale with her own statement. At 05:00pm, the same procedure will be applied to the mother.~At the end of the 4th day, the satisfaction of the mother will be evaluated on the Mother Satisfaction Evaluation Scale.This process will be carried out 8 times in total,at 11:00am and 05:00pm for 4days."
224310497|NCT04599127|OTHER|Mobilization with movement|The physical therapist will adjust the active movement of the shoulder joint during the arm elevation or abduction and shoulder external rotation
224310498|NCT04599127|OTHER|Conventional physical therapy|The exercise is tailor-made and each participant will be performing some of the exercises based on the list that physical therapist prescription
223504292|NCT05343169|BEHAVIORAL|Social Service and Health Navigation|Help navigate access and barriers to healthcare, motivation and health goals Duration/dose: 9 mos., monthly face-to-face sessions to set goals and schedule appts, phone calls between sessions \> 1x/wk.
223504293|NCT05343169|BEHAVIORAL|Peer Social Support|Support with social (re)integration, isolation, relationship building Duration/dose: 9 mos., monthly face-to-face events and phone calls/texts between sessions \> 1x/wk.
223504294|NCT03770975|PROCEDURE|delayed implant with immediate provisionaliztion and soft tissue graft|delayed implant placement in the esthetic zone with immediate provisinalization and placement of a connective tissue graft buccal
223504295|NCT03770975|PROCEDURE|delayed implant placement with immediate provisionalization|delayed implant placement with immediate provisionalization
223504296|NCT03889262|OTHER|Hippotherapy|Hippotherapy is a therapeutic method in which a mechanical horse is used for therapeutic purposes.
223504297|NCT03889262|OTHER|Neurodevelopmental Therapy|Neurodevelopmental therapy (NDT) is a hands-on treatment approach used by physical therapists, occupational therapists, and speech-language pathologists. NDT was developed to enhance the function of children who have difficulty controlling movement as a result of neurological challenges, such as cerebral palsy and head injury. During treatment interventions, repeated experience in movement ensures that a particular pattern is readily accessible for motor performance. The more a patient performs certain movements, the easier these movements becomes.
223504298|NCT00088101|DRUG|STA-5312|
223504299|NCT01873833|DRUG|capecitabine|Given PO
223504300|NCT01873833|DRUG|cyclophosphamide|Given PO
223504301|NCT01873833|DRUG|lapatinib ditosylate|Given PO
223504302|NCT01873833|BIOLOGICAL|trastuzumab|Given IV
223504303|NCT01873833|OTHER|laboratory biomarker analysis|Correlative studies
223504304|NCT03055507|DRUG|Ibuprofen 400 mg|Addition of ibuprofen to standard pain regimen.
223504305|NCT03055507|DRUG|Acetaminophen 650 mg|Standard analgesic provided post-operatively to patients undergoing sinus surgery
223504306|NCT03055507|DRUG|OxyCODONE 5 Mg Oral Tablet|Standard PRN medication offered post-operatively for breakthrough pain
223504307|NCT03398109|DEVICE|Customized toric IOL for post-DALK atigmatism|
223504308|NCT05219786|BEHAVIORAL|Appendicitis Decision Support Tool|Viewing of a decision support tool.
223504309|NCT05219786|BEHAVIORAL|Control Infographic|Viewing of a standardized infographic
223504310|NCT03545581|OTHER|Experimental diet Fru rich diet|7 days (day 1 to day 7) with fructose enriched drinks 3x/d. Test meal at day 7 with fructose (0.7 g/body weight) and glucose (0.7 g/body weight)
223504311|NCT03545581|OTHER|Experimental low Fru diet|7 days (day 1 to day 7) with low-fructose diet (\<10g/d). Test meal at day 7 with fructose (0.7 g/body weight) and glucose (0.7 g/body weight)
223504312|NCT04805788|RADIATION|Proton Stereotactic Body Radiation Therapy|Undergo SBPT
223504313|NCT04805788|OTHER|Quality-of-Life Assessment|Ancillary studies
224195319|NCT04513015|DIETARY_SUPPLEMENT|Antioxidant diet|"The antioxidant diet will include the principal antioxidant molecules/nutrients previously shown to be beneficial in IBD: Flavonoids, particularly resveratrol and curcumin; Olive oil; Glutathione, Vitamins A, C, E; Carotenoids; Selenium and Omega 3 Fatty Acids (PUFAs). The daily amount of these substances will be calculated following the published evidence, whether these amounts will not be achievable by a standard diet, a supplementary formulation will be proposed."
224195320|NCT04513015|DIETARY_SUPPLEMENT|Normal dietetic scheme|Isocaloric, normolipidic diet for age and sex
224195321|NCT05124886|OTHER|Moderately High Oxalate (MOx) Diet|Diets will contain 16% protein, 30% fat, and 54% carbohydrate, and are controlled in the amounts of calcium (400mg), oxalate (250mg), ascorbic acid (50mg), fiber (30 grams) and, other nutrients. Each controlled diet will be consumed for four days. On days of controlled diets, subjects will be provided with 2 liters of bottled water per day to ensure adequate hydration. After the controlled diet period, there will be a three-day washout period, where participants will consume Ad-lib diets supplemented with a daily intake of oxalate in the form of cooked spinach to be taken with breakfast daily for a total of 2 weeks.
224195322|NCT05266144|PROCEDURE|radiofrequency ablation|Bilateral pulmonary vein isolation, a kind of radiofrequency ablation, is performed in atrial fibrillation patients for atrial arrhythmia therapy.
224195323|NCT05932875|OTHER|Exercise Training|4 day per week concurrent exercise training program
224195324|NCT02981979|DRUG|Leflunomide(LEF)|"Leflunomide:~For LEF arm, 20mg per day, p.o. through the whole study. For placebo group, 20mg per day, p.o. from week 25 to week 52."
223504314|NCT01467804|DRUG|Sertraline plus placebo of JWXYJN|oral sertraline (start with 50 mg/day for one week then continue with 100 mg/day plus placebo of JWXYJN
223504315|NCT01467804|DRUG|JWXYJN plus placebo of Sertraline|JWXYJN 3.6g/d plus placebo of sertraline
223504316|NCT05509621|OTHER|The Effect of Supine Position on Physiological Parameters in Mechanically Ventilated Preterm Newborns|Preterm neonates who receive mechanical ventilation support and meet the study criteria will be provided with daily routine nursing care. Afterward, when it is time for positioning, the infant will be randomly placed in positions assigned according to the randomization. After positioning, data will not be collected for the first 30 minutes of each positioning in order to ensure the stability of the neonate. Starting from the 30th minute, the heart rate and oxygen saturation of the preterm neonate will be checked on the monitor at 15-minute intervals over the course of 90 minutes, and the respiratory rate will be counted and recorded for 1 minute by the researcher. For each position, the procedures will be repeated in the same way and the values will be recorded.
223504317|NCT05509621|OTHER|The Effect of Prone Position on Physiological Parameters in Mechanically Ventilated Preterm Newborns|Preterm neonates who receive mechanical ventilation support and meet the study criteria will be provided with daily routine nursing care. Afterward, when it is time for positioning, the infant will be randomly placed in positions assigned according to the randomization. After positioning, data will not be collected for the first 30 minutes of each positioning in order to ensure the stability of the neonate. Starting from the 30th minute, the heart rate and oxygen saturation of the preterm neonate will be checked on the monitor at 15-minute intervals over the course of 90 minutes, and the respiratory rate will be counted and recorded for 1 minute by the researcher. For each position, the procedures will be repeated in the same way and the values will be recorded.
223504318|NCT05509621|OTHER|The Effect of left lateral Position on Physiological Parameters in Mechanically Ventilated Preterm Newborns|Preterm neonates who receive mechanical ventilation support and meet the study criteria will be provided with daily routine nursing care. Afterward, when it is time for positioning, the infant will be randomly placed in positions assigned according to the randomization. After positioning, data will not be collected for the first 30 minutes of each positioning in order to ensure the stability of the neonate. Starting from the 30th minute, the heart rate and oxygen saturation of the preterm neonate will be checked on the monitor at 15-minute intervals over the course of 90 minutes, and the respiratory rate will be counted and recorded for 1 minute by the researcher. For each position, the procedures will be repeated in the same way and the values will be recorded.
223504319|NCT05509621|OTHER|The Effect of right lateral Position on Physiological Parameters in Mechanically Ventilated Preterm Newborns|Preterm neonates who receive mechanical ventilation support and meet the study criteria will be provided with daily routine nursing care. Afterward, when it is time for positioning, the infant will be randomly placed in positions assigned according to the randomization. After positioning, data will not be collected for the first 30 minutes of each positioning in order to ensure the stability of the neonate. Starting from the 30th minute, the heart rate and oxygen saturation of the preterm neonate will be checked on the monitor at 15-minute intervals over the course of 90 minutes, and the respiratory rate will be counted and recorded for 1 minute by the researcher. For each position, the procedures will be repeated in the same way and the values will be recorded.
223504320|NCT05509621|OTHER|The Effect of Quarter prone Position on Physiological Parameters in Mechanically Ventilated Preterm Newborns|Preterm neonates who receive mechanical ventilation support and meet the study criteria will be provided with daily routine nursing care. Afterward, when it is time for positioning, the infant will be randomly placed in positions assigned according to the randomization. After positioning, data will not be collected for the first 30 minutes of each positioning in order to ensure the stability of the neonate. Starting from the 30th minute, the heart rate and oxygen saturation of the preterm neonate will be checked on the monitor at 15-minute intervals over the course of 90 minutes, and the respiratory rate will be counted and recorded for 1 minute by the researcher. For each position, the procedures will be repeated in the same way and the values will be recorded.
223593084|NCT02484352|DRUG|0.1 mg/kg of oxycodone|different dosage of IV oxycodone was given before intubation
223593085|NCT02484352|DRUG|0.15 mg/kg of oxycodone|different dosage of IV oxycodone was given before intubation
223593086|NCT02484352|DRUG|0.2 mg/kg of oxycodone|different dosage of IV oxycodone was given before intubation
223593087|NCT05917990|BEHAVIORAL|Dyadic Text-Messaging Micro-Intervention|Participants receive text-messages consisting of information and skills relevant to improving couples' communication and relationship functioning.
223593088|NCT02702180|DRUG|Molgramostim|300 mcg molgramostim (rhGM-CSF) nebulizer solution for inhalation
223593089|NCT02702180|DRUG|Placebo|Placebo nebulizer solution for inhalation
223593090|NCT02702180|DEVICE|PARI eFlow nebulizer system|PARI eFlow nebulizer system
223746871|NCT01265849|RADIATION|Radiotherapy|Total 60 to 70 Gy (2Gy per day) in 30 to 35 fractions over 6 to 7 weeks to subjects determined at surgery to be at lower risk for recurrence (per NCCN guidelines). For subjects determined at surgery to be at higher risk for recurrence due to having positive surgical margins, 2 or more clinically positive nodes or extracapsular nodal spread etc. (per NCCN guidelines), radiotherapy (as above) is combined with concurrent chemotherapy (cisplatin 100 mg/m\^2) intravenously on day 1 of weeks 1, 4 and 7 of radiotherapy.
223746872|NCT01794052|OTHER|Evidence based, DSS enabled, health care delivery model|"The study focus on preliminary work before a definitive randomised controlled trial. In this phase, we are developing an intervention for the evidence based management of hypertension and diabetes at primary care setting in India.~The components of the interventions that we are developing are:~1. A structured training of the health care staff for identifying people at risk of developing diabetes or hypertension~2. Treating patients as per a standard clinical guidelines~3. Giving health education to patients on lifestyle changes for better self-care~4. Optimizing the care pathways at the health facilities to enable better delivery of the intervention and~5. Development and implementation of a smartphone based decision support system (DSS) with inbuilt diagnostic and treatment algorithm"
223746873|NCT00674453|DRUG|Lasofoxifene|Oral tablet, 0.25 mg, daily, 2 years
223746874|NCT00674453|OTHER|Placebo|Matching placebo tablet given once daily for 2 years
223746875|NCT04396431|BEHAVIORAL|education|"The intervention group was offered a six-hour training program based on the transtheoretical model in order to promote sun protection behavior and to reinforce self-efficacy. The program was prepared by the researchers in consideration of the SunSmart Program implemented in Australia, the SunWise School Program developed by the United States Environmental Protection Agency. The program included various educational tools such as a sun protection story, activity book, PowerPoint presentations, cartoons, and puzzles.~Refresher training was conducted 15 days, 1 month, and 2 months after the initial training. Sun protection behavior and self-efficacy of the children were evaluated at the beginning of the study and six months after the program. As gifts to support their sun protection behavior, the children were given an FDA-approved sunscreen with 50+ SPF, a white cotton short-sleeved T-shirt as protective clothing, sunglasses with 100% UV protection, and a wide-brimmed hat."
223746876|NCT01172184|PROCEDURE|Cardiac catheterization|Before surgical intervention for severe mitral regurgitation, cardiac catheterization will be performed and left ventricular filling pressure will be assessed. Simultaneously, echocardiography, including left atrial distensibility, will be performed.
223746877|NCT02440477|OTHER|clinical shoulder tests|Three clinical shoulder tests (Neer impingement sign,Hawkins-kennedy, empty can) performed in three different sitting positions: normal resting posture, slouched posture, and upright posture with scapular retraction and shoulder. and in addition shoulder muscle strength test with handheld dynamometer
223746878|NCT06403735|DRUG|QLC1101|QLC1101 is an innovative small molecule inhibitor targeting KRAS G12D with independent intellectual property rights developed by Qilu Pharmaceutical Co., Ltd.QLC1101 can prevent GTP/GDP nucleotide exchange and/or the formation of KRAS G12D/GTP/RAF1 complex and inhibit mutant KRAS-dependent signal transduction by specifically binding to the KRAS G12D target, thereby inhibiting the generation of KRAS G12D mutant tumors.
223746879|NCT04843748|DEVICE|cataract surgery and intraocular lens implantation - both eyes|cataract surgery and intraocular lens implantation for both eyes
224195325|NCT02981979|DRUG|Prednisone Acetate Tablets|Prednisone (5mg/tab): basic therapy, start with 0.6mg/kg/d and maintained for 4 weeks, then reducing 5mg every 2 weeks until 10mg per day.
224195326|NCT02981979|DRUG|Placebos|2 tabs/d used in placebo arm for the first 24 weeks.
224195327|NCT00696592|DRUG|Bevacizumab (Avastin), Verteporfin (Visudyne)|
224195328|NCT05237570|PROCEDURE|Interradicular septum window|In this group, the maxillary sinus will be accessed through a window in the interradicular septum and the membrane will be elevated, carrying out the regeneration of the area to facilitate subsequent implant placement.
223746880|NCT02139527|DEVICE|Total Disc Replacement|
223746881|NCT06110780|OTHER|acupuncture|"The insertion of the needles will be applied to a depth of 1-2 cm according to the thickness of the local tissues according to the standards of Traditional Chinese Medicine. The EA parameter will be set to a frequency of 2 HZ/100 HZ at a current that the patients' tolerance is best between 0.5 mA and 1.2 mA.~The patient will be electrically stimulated for 30 minutes until the patient feels Teh Chi - heaviness, numbness and swelling."
223746882|NCT02857478|DRUG|BAY 987519, SPF 50, Y51-002|Sufficient amount to cover all exposed skin liberally two times - approximately 240 min.
224310499|NCT02575976|BEHAVIORAL|comprehensive CR|In the comprehensive CR arm, 24 sessions education will be offered, of 30 minutes duration beyond the exercises already performed in the cardiac rehabilitation program (The main program is 6 months in duration, with 36 1-hour exercise sessions)
223504321|NCT06373939|DEVICE|Digital lung auscultation|"Two 30-second recordings will be made using CE-marked Littmann® CORE digital stethoscopes and the Pneumoscope at two bilateral lung positions on the posterior chest wall, focusing on the lower lobes. Spectral comparison and audio quality indices will be assessed between the Pneumoscope and the Littmann® CORE digital stethoscope.~Comparator: The Gold Standard Littmann® CORE picks up sounds, such as heart and lung sounds, from a patient's body. After amplification and filtering, the sounds are sent to the user through a binaural headset. The stethoscope chest piece is designed for use with adult, pediatric, and infant patients."
223593091|NCT01260597|BEHAVIORAL|IVR intervention|If individuals report having any smoking in the previous 30 days, the IVR will deliver questions to identify barriers to quit line re-enrollment and motivational messages to promote the re-enrollment
223593092|NCT01260597|BEHAVIORAL|IVR control|If individuals report any smoking in the last 30 days the IVR will thank them for their time and the call will end
223593093|NCT00567359|DRUG|Erlotinib|Oral drug taken daily around the same time. Starting dose is 150mg once daily.
223593094|NCT01974011|PROCEDURE|Performing dorsal penile nerve block (DPNB)|
223593095|NCT02352623|RADIATION|DXA scan|DXA scan
223746883|NCT02857478|DRUG|BAY 987519, SPF 50, P04-147|Sufficient amount to cover all exposed skin liberally two times - approximately 240 min.
224195329|NCT02605720|DRUG|Dihydroartemisinin-piperaquine|DHA/PPQ dose 2.1/17.1 mg/Kg daily for 3 days (PNG National Malaria Treatment Protocol) monthly for 3 months
224310500|NCT02575976|OTHER|exercise-based CR|The main program is 6 months in duration, with 36 1-hour exercise sessions.
223593096|NCT02352623|PROCEDURE|Clinical examination|Clinical examination
224195330|NCT04477239|BEHAVIORAL|Gluten (behaviour)|Gluten is a protein normally present in the daily diet of healthy volunteers not suffering from gluten related disorders, in far greater quantities (10-20 g/day) than those used in this study (10 mg-1 g/day).
224195331|NCT04477239|BEHAVIORAL|Placebo (behaviour)|Placebo is composed of pregelatinized maize starch Ph.Eur. 97.5%; magnesium stearate Ph.Eur. 1.5%; micronized silica Ph.Eur. 0.5%; Micronized talc Ph.Eur. 0.5% (NOT containing preservatives, colorings, or gluten).
224195332|NCT04096716|DRUG|Tc-99m tilmanocept|Tc-99m tilmanocept is a radioactive diagnostic agent.
224195333|NCT02259777|DRUG|Telmisartan/Amlodipine|Fixed dose combination tablet
224195334|NCT02259777|OTHER|high fat, high caloric meal|
223504322|NCT06373939|DEVICE|Pulse oximetry measurement|"Pulse oximetry and heart rate will be measured using the CE-marked Masimo Rad-G® and iHealth® Air oximeters, as well as the Pneumoscope's built-in oximeter. Agreement between the Pneumoscope's oximeter and the reference oximeters will be evaluated. Measurement will take 30 second on the right index finger.~Comparators:~1. The Gold Standard Masimo Rad-G® sensor is indicated for the continuous noninvasive peripheral monitoring of arterial oxygen saturation (SpO2) and pulse rate. Its use consists in positioning the emitting window of the sensor attachment envelope on the top of the finger nail bed, while the detector is placed opposite the emitter on the other side of the same finger.~2. The Gold Standard iHealth® Air works by projecting two beams of light through a clip with a transmitter and a detector that is placed around a finger, nail side down and screen side up."
223504323|NCT06373939|DEVICE|Non invasive body temperature measurement|"Comparison of body temperature measurements between the Pneumoscope's built-in thermometer and Gold Standard thermometers (Terumo® C205 and VisioFocus Pro 06480).~Comparators:~1. The Gold Standard Terumo® C205 is an axillary thermometer. Its use consists in placing the probe in the armpit, then lowering the arm and holding the device firmly until the temperature is stabilised and the temperature is read and displayed on the thermometer screen.~2. The Gold Standard VisioFocus Pro 06480 is an infrared thermometer that detects the infrared radiation naturally emitted by the body and in particular from the human forehead. Its use consists in holding the thermometer close to the forehead but without direct contact with the skin. The temperature reading is then projected on the patient's forehead using a symbol system."
223504324|NCT03899090|BEHAVIORAL|Float pool|Subject floats supine in a pool of water saturated with Epsom salt in an environment which minimizes stimulation of the nervous system, including reduced light, sound, and pressure on the spinal cord.
223504325|NCT03899090|BEHAVIORAL|Float chair|Subject floats supine in a zero-gravity chair in an environment which minimizes stimulation of the nervous system, including reduced light, sound, and pressure on the spinal cord.
223504326|NCT04588272|DEVICE|DualGuard|DualGuard device (FlexiCare) which incorporate an endoscopy bite block with oxygen delivery and CO2 monitoring from both the mouth and nose simultaneously.
223504327|NCT03934307|DRUG|ALN-AGT01|ALN-AGT01 will be administered by subcutaneous (SC) injection.
223504328|NCT03934307|DRUG|ALN-AGT01-Matching Placebo|Normal saline (0.9% NaCl) matching volume of ALN-AGT01 doses will be administered SC.
223504329|NCT03934307|DRUG|Irbesartan|Irbesartan will be administered orally.
223504330|NCT03934307|DRUG|Irbesartan-Matching Placebo|Irbesartan-matching placebo will be administered orally.
223504331|NCT03296345|DRUG|Ketamine|The intervention is IV low-dose bolus ketamine as an adjuvant to standard therapy (IV opiates and NSAIDs).
223504332|NCT03977688|DEVICE|Cytokin Adsorption|Haemadsorption with Cytokin Adsorber (Cytosorb)
223504333|NCT02524678|DRUG|Placebo|
223504334|NCT02524678|DRUG|URC102|
223504335|NCT02487485|DRUG|Ketamine|. Subjects will receive an infusion of ketamine (0.5 mg/kg infusion over approximately 40 minutes). All subjects will receive two ketamine infusions-once with a placebo and once with a single dose of sirolimus (6 mg, oral administration).
223504336|NCT02487485|DRUG|sirolimus|Subjects will receive a single 6 mg oral dose via oral solution of sirolimus or a dose of placebo approximately two hours prior to the infusions. As above, the order of placebo and sirolimus is randomized. The sirolimus dose as well as the placebo solution will be given in 6 ounces of orange juice.
223504337|NCT02487485|DRUG|Placebo|Placebo oral dose
223504338|NCT03893708|BEHAVIORAL|Prenatal yoga|The prenatal yoga classes will be offered at Urban Wellness (2024 N. 7th St., Phoenix, AZ 85006). Classes will be offered Tuesdays's from 4:15-5:30 pm and Saturday's from 9:00-10:15 am. Participants will be able to attend both classes if they so choose but are only asked to attend 1/week. Participants will be asked to arrive to class at least 10 minutes early in order for the research team to collect their weight in a private room. Additionally, if participants have attended at least 70% of classes (1 per week for 8/12 weeks), participants will be able to attend sessions up until birth (beyond the 12-week intervention) if they so choose. If participants decide to attend classes beyond the 12-week intervention the investigators will continue to collect their weight at each session.
223746884|NCT05728346|DRUG|Allogeneic human pulp mesenchymal stem cells mixed with hyaluronic acid polymers|stem cells from human exfoliated deciduous teeth (SHED) mixed with hyaluronic acid polymers
223746885|NCT04265781|DRUG|BAY1817080|Three different doses over the course of study
223746886|NCT04265781|DRUG|Matching Placebo|Matching Placebo to BAY1817080
224195335|NCT05646706|DRUG|Semaglutide|Participants will receive once-weekly s.c. injections of semaglutide in escalating doses (0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, 2.4 mg and 7.2 mg) every fourth week. Treatment was continued on the maintenance dose of 7.2 mg once-weekly for an additional 52 weeks. Injections may be administered in the thigh, abdomen, or upper arm, at any time of day irrespective of meals.
224195336|NCT05646706|DRUG|Semaglutide|Participants will receive once-weekly s.c. injections of semaglutide in escalating doses (0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, and 2.4 mg) every fourth week. Treatment was continued on the maintenance dose of 2.4 mg once-weekly for an additional 52 weeks. Injections may be administered in the thigh, abdomen, or upper arm, at any time of day irrespective of meals.
224195337|NCT05646706|DRUG|Placebo|Participants will receive once-weekly s.c. injection of placebo matched to semaglutide for 72 weeks. Injections may be administered in the thigh, abdomen, or upper arm, at any time of day irrespective of meals.
224195338|NCT04792489|BIOLOGICAL|zamtocabtagene autoleucel (MB-CART2019.1)|Chimeric antigen receptor (CAR) T cell therapy
224195339|NCT04792489|DRUG|Cyclophosphamide|Lymphodepleting chemotherapy
224195340|NCT04792489|DRUG|Fludarabine|Lymphodepleting chemotherapy
224195341|NCT04792489|DRUG|Bendamustine|Lymphodepleting chemotherapy
224195342|NCT05340465|DRUG|Darbepoetin Alfa|Infants in groups 2-5 will be started on Darbe 10 mcg/kg/week between 72 and 84 hours after birth.
224195343|NCT05340465|DRUG|Low Molecular Weight Iron Dextran|Infants in groups 2 and 3 will be given LMW-ID IV, 10 or 20 mg/kg/dose. They will be re-dosed if ferritin falls below 76. Iron parameters will be checked biweekly.
224195344|NCT05340465|DRUG|Ferumoxytol injection|Infants in groups 4 and 5 will be given FMX IV, 10 or 20 mg/kg/dose. They will be re-dosed if ferritin falls below 76. Iron parameters will be checked biweekly.
224195345|NCT05340465|DRUG|Oral iron supplements|Infants in group 1 will receive standard care in the UW NICU with iron started on day 7 if tolerating 100 mL/kg/day enteral feeding. Iron supplements are adjusted every 2 weeks based on ferritin, zinc protoporphyrin to heme ratio and complete blood count (CBC).
224195346|NCT01754610|BEHAVIORAL|Strengthening Family Coping Resources (SFCR)|"Trauma Version (15 weeks) and High Risk Version (10 weeks) are 2 hour sessions. Dinner will be provided at the start of group for all participants.~Activities will be conducted at each group to encourage family involvement. The treatment modules focus on family rituals and routine, strengthening families' collaborative coping, and resolution of the trauma(s) bringing the families to treatment. Activities will be both family-based and age-based."
224195347|NCT04089566|DRUG|Nusinersen|Administered as specified in the treatment arm
224195348|NCT04100603|OTHER|No Intervention|There is no intervention for this study
224195349|NCT02478281|DRUG|Methylene Blue|
224195350|NCT00003230|DRUG|paclitaxel|
224195351|NCT00056472|DRUG|Olanzapine|10-20mg/day
224195352|NCT00056472|DRUG|Sertraline|150-200mg/day
224195353|NCT00056472|OTHER|placebo|tablet that ressembles sertraline but contains no medication
224195354|NCT06417658|PROCEDURE|Endoscopic Supraorbital Eyebrow Craniotomy|The Endoscopic Supraorbital Eyebrow Craniotomy is a minimally invasive neurosurgical procedure used to access and remove brain tumors located in the anterior skull base region. In this approach, surgeons make a small incision within the eyebrow area to gain access to the underlying pathology, avoiding larger incisions and more extensive tissue disruption associated with traditional open craniotomies.
224195355|NCT06417658|PROCEDURE|Conventional Frontal Craniotomy|The Conventional Frontal Craniotomy is a traditional surgical approach used to access and treat lesions located in the frontal region of the skull base. In this procedure, surgeons make a single or multiple large incisions in the scalp overlying the frontal bone to gain access to the underlying pathology.
224195356|NCT05205642|DEVICE|Cardiopulmonary exercise test (CPET)|Cardiopulmonary exercise testing (CPET) using a Quark CPET metabolic cart (Rome, Italy) according to American Thoracic Society (ATS) guidelines. A symptom-limited test on a treadmill will be performed, using incremental ramp Bruce protocol up to exhaustion. Patients who will not be able to perform the test on a treadmill will be tested on a cycle ergometer beginning with a no-resistance warm-up lasting 2-3 minutes, followed by incrementing resistance (8-30 Watts/minute) adapted to the patient's functional capacities according to the examiner's free judgment, up to exhaustion.
224195357|NCT05205642|DEVICE|Peripheral Arterial Tonography (PAT) using the EndoPAT™ device|A volume sensor measuring reactive hyperemia is placed on the second fingertip of both hands. First the device evaluates the baseline volume of the pulse. Then, we will apply pressure that is 50 mmHg higher than the baseline systolic pressure of the examinee on the evaluated hand for five minutes, using a sphygmomanometer cuff. After the pressure is released on the evaluated hand, the new pulse volume is tested. To neutralize the effects of the autonomous systemic response, the program divides the difference of the pulse volume in the examined hand by the difference in the untested hand and we get the Reactive Hyperemic Index (RHI) which represents the endothelial function in the tested hand. During the examination, the calculated arterial tonometry graph is generated, and out of it the RHI will be automatically calculated, using the EndoPAT2000™ program.
224195358|NCT05205642|DIAGNOSTIC_TEST|Endothelin|For Endothelin levels we will use the Endothelin ELISA kit from R\&D company, and for measurement 1 cc of serum will be needed.
224195359|NCT04798560|PROCEDURE|Pancreaticoduodenectomy|Patients udergo pancreaticoduodenectomy for periampullary tumors. All of them are observed for developing POPF
224195360|NCT02730832|OTHER|Questionnaires completed at D0|
224195361|NCT02730832|OTHER|Questionnaires completed at D15 (test-retest for 30 patients)|
224195362|NCT03378921|BIOLOGICAL|Fecal microbiota transplantation|Follow up of the patients include a telephone call after 12 and 26 weeks after the FMT, and a clinical control visit 52 weeks after the transplantation. The clinical part of the Pouchitis Disease Activity Index score is assessed during each call and clinical visit. Fecal stool samples for phylogenetic analysis are collected before FMT and on weeks 4, 12, 26, and 52.
224195363|NCT03378921|BIOLOGICAL|Placebo|Follow up of the patients include a telephone call after 12 and 26 weeks after the FMT, and a clinical control visit 52 weeks after the transplantation. The clinical part of the Pouchitis Disease Activity Index score is assessed during each call and clinical visit. Fecal stool samples for phylogenetic analysis are collected before FMT and on weeks 4, 12, 26, and 52.
224195364|NCT01364506|OTHER|Water aerobic exercise|"The hydrotherapy program of Prevedel et al.14 was used. One-hour sessions, led by a physiotherapist under the supervision of an obstetrician, were held three times a week in an indoor swimming-pool heated at 28oC-32oC, and consisted of exercises of moderate intensity (60-70% of maximum heart rate). Subgroups of up to 10 subjects participated in each session. Sessions were offered at different times of the day (morning, afternoon, and evening).~The exercises included 5 phases: stretching, warm up, endurance training, strength training and relaxation with breathing exercises, in accordance with the recommendations of ACOG11."
224195365|NCT02908594|DEVICE|Medical Exercise Peddler 3000, Medi-Bike, Taiwan|"A horizontal electromagnetic cycle ergometer (Medical Exercise Peddler 3000, Medi-Bike, Taiwan) was used for the exercise program. The cycling equipment includes the resistance of 6 Levels, from Level 1 the lightest to Level 6 the heaviest. Other indicators examined are RPM (rotary per minute), DICT (The distance for this exercise), TIME (The time of exercise). This is the simplest way to use this Motion Exercise Machine. Press the ST / SP (Start/ Stop) button to start an exercise program for 30 minutes."
224310501|NCT02575976|OTHER|wait list control|No cardiac rehabilitation.
223593097|NCT02533492|DEVICE|vicryl|wound closure with vicryl suture
223593098|NCT02533492|DEVICE|Vicryl plus|wound closure with vicryl plus suture
223593099|NCT04120272|PROCEDURE|Spine surgery|Eligible Surgeries: lumbar spine fusion surgery, posterior cervical spine fusion surgery, or anterior cervical spine fusion surgery
224195366|NCT05933278|BIOLOGICAL|SARS-CoV-2 Subunit Recombinant Protein Vaccine|SARS-CoV-2 RBD subunit recombinant protein, manufactured by PT Bio Farma
224195367|NCT03324282|DRUG|Avelumab|Combination of Gemcitabin-Cisplatin and avelumab given for 6 cycles (each cycle is 21 days)
223593100|NCT05433922|DRUG|Avatrombopag|cyclosporine in combination with Avatrombopag to treat
223593101|NCT04312347|DRUG|Tamoxifen dose adjustment|Patients with low endoxifen level and poor/intermediate metabolizer CYP2D6 phenotype will receive tamoxifen dose escalation into 40 mg/day.
223593102|NCT00679172|BIOLOGICAL|Dose of 5.0 x 10^9 CFU (Cohort 1)|S. typhi (Ty2 aroC-ssaV-) ZH9 live attenuated typhoid vaccine, single dose, oral administration
223593103|NCT00679172|BIOLOGICAL|Dose of 7.5 x 10^9 CFU (Cohort 2)|S. typhi (Ty2 aroC-ssaV-) ZH9 live attenuated typhoid vaccine, single dose, oral administration
223593104|NCT00679172|BIOLOGICAL|Dose of 1.1 x 10^10 CFU (Cohort 3)|S. typhi (Ty2 aroC-ssaV-) ZH9 live attenuated typhoid vaccine, single dose, oral administration
223593105|NCT00679172|BIOLOGICAL|Dose of of 1.7 x 10^10 CFU (Cohort 4)|S. typhi (Ty2 aroC-ssaV-) ZH9 live attenuated typhoid vaccine, single dose, oral administration
223593106|NCT00679172|OTHER|Placebo (Cohorts 1-4 pooled)|Excipients only, single dose, oral administration
223593107|NCT04359979|DRUG|Tamsulosin|selective alpha1 receptor antagonist
223593108|NCT00793325|DRUG|Somatropin|"Genotropin® 5.3mg, Genotropin®inj.12mg, Genotropin®MiniQuick s.c. inj.0.6mg・1.0mg・1.4mg, depending on the Investigator prescription.~Frequency and duration are according to Package Insert as follows.  Normally, the dosage is 0.021 mg/kg/week as somatropin (genetical recombination) in 6-7 divided doses by s.c. route. If efficacy is insufficient, the dose may be increased up to 0.47 mg/kg/week in 6-7 divided doses in a week by s.c. route."
223593109|NCT02751476|OTHER|Point of Use (PoU) water treatment flocculent disinfectant.|A household level point of use water treatment of a flocculent disinfectant will be tested.
223746887|NCT06484244|OTHER|5 Sessions of Split-belt Treadmill-based Locomotor Adaptation|Participants will complete 5 sessions of split-belt treadmill-based locomotor adaptation. The split-belt instrumented treadmill allows the two belt speeds to be operated independently, enabling different belt speeds for each leg. The split-belt walking assessment will consist of 3 phases: baseline phase in which the belts operated at the same speed (Pre-tied, 2-minutes), a phase in which the belts operated at different speeds (Split-belt, 15-minutes), and a final phase in which the belts operated at the same speed (Post-tied, 4-minutes).
223746888|NCT05748756|OTHER|Enucleation and filling by Bone marrow aspirate|"The iliac crest is palpated along its widest part forming the iliac tubercle ( 5-6 cm posterior to the anterior superior iliac spine), then a 5 mm incision is made 3-4 cm posterior to the ASIS directly on the crest.~The needle is advanced between the outer and inner plates of the ileum for a 4-6 cm into the cancellous bone and 10 ml of bone marrow is aspirated.~Bone marrow aspirate is processed by a dual centrifugation technique."
224195368|NCT03324282|DRUG|GC|Combination of Gemcitabin-Cisplatin given for 6 cycles (each cycle is 21 days)
224195369|NCT03083795|BEHAVIORAL|Social relationships intervention|Participants randomized to the social interaction cohort will meet on a monthly basis for a two hour group session designed to build social connections. In addition, participants will be paired with another study participant in this group, and will be asked to meet on a monthly basis for a minimum of 45 minutes. All participants in the social support cohort will continue to receive best standard diabetes management.
224195370|NCT02976909|DRUG|Paclitaxel+Cisplatin+5fluorouracil|Patients will receive the following chemotherapy: Paclitaxel 135mg/m2 IV over 3 hours on Day 1; Cisplatin 75mg/m2 IV over 1 hours on Day 1; 5-FU 4g/m2 for 5 days continuous infusion from Day 1 to Day 5.
224195371|NCT02463500|OTHER|DFU|Standard care.
224195372|NCT05403502|DEVICE|t:slim X2 insulin pump with Control-IQ technology 1.5|t:slim X2 insulin pump with Control-IQ technology 1.5, and wearing the Dexcom G6 sensor, used with Lyumjev® insulin.
224195373|NCT03230760|DEVICE|acupuncture|Device: acupuncture Acupuncture is the treatment which balances qi and blood by inserting needles into the acupoints of the meridians in human body.
224310502|NCT00510289|DRUG|Sorafenib|400 mg twice a day until progression or unacceptable toxicity develops.
223593110|NCT02751476|OTHER|Point of Use (PoU) water treatment chlorine disinfectant|A household level point of use water treatment of a chlorine disinfectant will be tested.
223593111|NCT02751476|DEVICE|Point of Use (PoU) ceramic water filter|A household level point of use water treatment of a ceramic water filter will be tested.
223593112|NCT02751476|OTHER|Standard Severe Acute Malnutrition Treatment|Standard CMAM treatment.
223593113|NCT05627024|DRUG|30% Oxygen|Before anesthesia induction, the participants inhaled pure oxygen through the mask for 5 mins. After successful anesthesia induction, Fio2 will be adjusted to 30%, and the total gas flow rate will be set at 2L/min. All patients will be performed via the lung protective ventilation strategy. The respiratory parameters are VT: 6-8ml/kg, PEEP: 6-8 cmh2O, RR: 1:2, and respiratory rate will be adjusted by maintaining a partial pressure of carbon dioxide at 35-45 mmHg. Manual lung recruitment maneuvers will be performed after tracheal intubation and before tracheal extubation, however when intraoperative oxygen saturation is less than 92% the manual lung recruitment maneuver will be done too. Arterial blood will be collected twice for blood gas analysis, the first once is in the non-oxygen inhalation state before anesthesia induction and the second is 30min before the end of surgery. Patients in both groups will be extubated in the operating room and then sent to the PACU.
223593114|NCT05627024|DRUG|60% Oxygen|Before anesthesia induction, the participants inhaled pure oxygen through the mask for 5 mins. After successful anesthesia induction, Fio2 will be adjusted to 60%, and the total gas flow rate will be set at 2L/min. All patients will be performed via the lung protective ventilation strategy. The respiratory parameters are VT: 6-8ml/kg, PEEP: 6-8 cmh2O, RR: 1:2, and respiratory rate will be adjusted by maintaining a partial pressure of carbon dioxide at 35-45 mmHg. Arterial blood will be collected twice for blood gas analysis, the first once is in the non-oxygen inhalation state before anesthesia induction and the second is 30min before the end of surgery. Patients in both groups will be extubated in the operating room and then sent to the PACU.
223593115|NCT05880498|BEHAVIORAL|Mindfulness Intervention|Self-guided mindfulness training using a customized version of the Healthy Minds app
223593116|NCT00372697|DRUG|Octreotide acetate 30 mg suspension|Each vial of study medication contained octreotide acetate 30 mg in a microencapsulated biodegradable polymer, poly (DL-lactide-co-glycolide) (D-(+)glucose), with 17% w/w mannitol in an approximate octreotide:polymer ratio of 1:20. The vehicle contained 0.5% sodium carboxymethylcellulose.
223504339|NCT03893708|BEHAVIORAL|Pregnancy education|Pregnancy education classes will be offered at the Arizona Biomedical Collaborative Building on ASU Phoenix Campus. Classes will be offered on Tuesday's from 5:30-6:45 pm and Saturday's from 9:00-10:15 am. Participants will be able to attend both classes if they so choose but are only asked to attend 1/week. Participants will be asked to arrive to class at least 10 minutes early in order for the research team to collect their weight in a private room. Additionally, if participants have attended at least 70% of classes (1 per week for 8/12 weeks), participants will be able to attend sessions up until birth (beyond the 12-week intervention) if they so choose. If participants decide to attend classes beyond the 12-week intervention the investigators will continue to collect their weight at each session.
223504340|NCT01613833|PROCEDURE|Blood Draw|Blood drawn for A2M levels to be assayed at Cytonics
223504341|NCT01613833|PROCEDURE|Joint Aspirate Harvest|Joint aspirate harvested for A2M levels to be assayed at Cytonics
223504342|NCT01613833|PROCEDURE|Blood Draw|Blood drawn for A2M levels to be assayed at Cytonics
223504343|NCT01613833|PROCEDURE|Joint Aspirate Harvest|Joint aspirate harvested for A2M levels to be assayed at Cytonics
223504344|NCT02322515|OTHER|Intervention taping|A rigid patellar taping will be used for the correction in lateralization of the patella and more stabilization of the knee.
223504345|NCT02322515|OTHER|Placebo Taping|A rigid patellar taping will be used in the vertical position and without no correction in lateralization of the patella and/or stabilization of the knee.
223504346|NCT03630887|DEVICE|WarmTouch Model 5900, Covidien Ltd, Mansfield, USA|Forced-air warming will be applied in the preanesthetic room during different time periods.
223504347|NCT02867488|OTHER|Soybean oil in salad dressing|
223504348|NCT00476541|DRUG|Gemtuzumab ozogamicin|Two courses of Gemtuzumab vs. no further therapy
223504349|NCT04967703|PROCEDURE|Group A|Patients received ultrasound therapy protocol with the following parameters (1 MHz frequency, intensity of 1.5 W/cm2 and use of continuous mode of ultrasound for 5 minutes), in addition to a conventional physiotherapy program consisting of calf muscles stretching, plantar fascia stretch, strengthening exercises and manual massage for 3 sessions per week, for 4 weeks
223504350|NCT04967703|PROCEDURE|Group B|Patients received radial shock wave therapy protocol with the following parameters (1) the energy level was 0.12 mJ/mm2 equivalent to 2.5 bar intensity, (2) the number of shoots was 2000, (3) the frequency was 8 Hz, in addition to the same conventional physiotherapy program given for group A
223504351|NCT04967703|PROCEDURE|Group C|Patients received both ultrasound and radial shock wave therapy, in addition to the same conventional physiotherapy program given for group A
223504352|NCT00907114|DRUG|Ketorolac tromethamine|Presentation 5 mg/ml; Dosage: one drop (0.25 mg) four times a day during one week after panphotocoagulation
223504353|NCT00907114|DRUG|Polivynilic alcohol|Presentation: alcohol polivinilico 14 mg/ml; Dosage: one drop (0.7 mg alcohol polivinilico) four times a day during one week after panphotocoagulation
223504354|NCT02068599|DRUG|TV-45070|TV-45070 ointment administered twice a day (morning and evening) to target knee. Participants were provided with a laminated instruction sheet including pictures that both described and illustrated how the ointment was to be spread over the entire knee anteriorly, medially, and laterally in a thin layer that fully covered the area. The ointment was gently massaged into the skin.
223504355|NCT02068599|DRUG|Placebo|Placebo ointment matching active intervention administered twice a day (morning and evening) to target knee. Participants were provided with a laminated instruction sheet including pictures that both described and illustrated how the ointment was to be spread over the entire knee anteriorly, medially, and laterally in a thin layer that fully covered the area. The ointment was gently massaged into the skin.
223504356|NCT02282384|DRUG|oseltamivir|They will be assessed for eligibility at the clinics and those randomized to the intervention will receive oseltamivir 75 mg orally twice daily for 5 days within 72 hours of symptom onset. Participants randomized to the control group will receive calcium carbonate placebo pills twice daily for five days within 72 hours of symptom onset. For patients with a known creatinine clearance \< 10 ml/min, the recommended dose of 75mg orally daily for 5 days of either intervention or placebo will be administered.
223504357|NCT02282384|OTHER|Placebo|
223504358|NCT01784536|DRUG|Single-Dose IV Oritavancin Diphosphate|Oritavancin will be administered as a single IV infusion. The infusion will last approximately 3 hours.
223504359|NCT02959606|DRUG|Sarpogrelate SR 300mg|
223504360|NCT02959606|DRUG|Clopidogrel|
223504361|NCT01871727|DRUG|E7777 9 mcg/kg|administered by intravenous (i.v.) infusion over 60 minutes (+/-10 minutes) on 5 consecutive days during every cycle of 21 days
223504362|NCT03650608|DRUG|Cohort 1: HL217 Ophathalmic Solution QD|Cohort 1 (Once a day)
223504363|NCT03650608|DRUG|Cohort 2: HL217 Ophathalmic Solution BID|Cohort 2 (Twice a day)
223504364|NCT03650608|DRUG|Cohort 3: HL217 Ophthalmic Solution QID|Cohort 3 (Four times a day)
223504365|NCT03650608|DRUG|Placebo Ophthalmic solution|Placebo
223504366|NCT01106950|BIOLOGICAL|Natural Killer Cells|Given by infusion on Day 0. The product is T cell-depleted (CD3-) and B cell-depleted (CD19). Target dose for infusion is \< or = 8 x 10\^7 nucleated cells/kilogram.
223504367|NCT01106950|DRUG|Fludarabine|Administered as a 1 hour intravenous infusion once a day for 5 doses beginning on day -6.
223504368|NCT01106950|DRUG|Cyclophosphamide|Administered as a 2 hour intravenous infusion with high volume fluid flush and mesna per institutional guidelines on day -5 and -4 one hour after fludarabine infusion. (Day -4 administration may be omitted if patient has had a transplant in the previous 4 months.)
223504369|NCT01106950|DRUG|Denileukin diftitox|12 ug/kg/day will be administered on day -1 and day -2 intravenously.
223746889|NCT05748756|OTHER|Conventional enucleation only|patients were treated conventionally by enucleation and plain collagen sponge only.
223746890|NCT05871827|PROCEDURE|Intraoperative Fluoroscopic Computer Navigation|Computer technology used during surgery
224310503|NCT00658931|DRUG|Drug treatment with Cymbalta|Drug treatment with Cymbalta
223504370|NCT01106950|PROCEDURE|Donor lymphapheresis|Day -1 before planned NK cell infusion, the donor will undergo lymphapheresis (Removal of lymphocytes from donated blood, with the remainder of the blood retransfused into the donor).
223746891|NCT05543525|OTHER|Echocardiography|Transthoracic echocardiography
223746892|NCT05543525|OTHER|Cardiopulmonary exercise testing|Cardiopulmonary exercise testing
223746893|NCT00814398|PROCEDURE|Double Embryo Transfer (DET)|Two embryos are transferred during an IVF treatment
223746894|NCT00814398|PROCEDURE|Single Embryo Transfer (SET)|A single embryo is transferred during an IVF treatment
224195374|NCT04745052|OTHER|Clinical observation index|The first is to verify the application effect of intravenous thrombolytic hemorrhage prediction models (HAT, SIT-sICH, THRIVE) in the population of acute ischemic stroke in Guangdong Province, and verify the clinical application effects of existing prediction models. Secondly, analyze the predictive value of clinical indicators, optimize HAT, SIT-sICH, and THRIVE scores, construct an improved HT prediction model, and optimize and improve the existing prediction model. The third is to apply the improved HT prediction model to the clinic, collect clinical data prospectively, evaluate the prediction effect of the model, and evaluate the clinical application effect of the improved prediction model.
223593117|NCT06409143|DEVICE|HD-tES|The intensity of HD-tES is set at 2 mA, the current intensity ramps up to 2 mA within 5 seconds, remains at 2 mA for 10 minutes, and then ramps down to zero within 5 seconds. For the sham stimulation, the current intensity ramps up and down at the first and last 10 seconds, with the remaining 10 minutes set at 0 mA. The inhibitory and excitatory waveform will be selected based on results of sub-project 1.
223593118|NCT06409143|DEVICE|Sham HD-tES|The intensity of HD-tES is set at 2 mA, the current intensity ramps up to 2 mA within 5 seconds, remains at 2 mA for 10 minutes, and then ramps down to zero within 5 seconds. For the sham stimulation, the current intensity ramps up and down at the first and last 10 seconds, with the remaining 10 minutes set at 0 mA. The inhibitory and excitatory waveform will be selected based on results of sub-project 1.
223593119|NCT06409143|OTHER|UE rehabilitation|Upper extremity rehabilitation programs will be selected and graded in accordance with each patient's upper extremity function and specific aims of activities of daily living. Upper extremity rehabilitation will be provided for 60 minutes each time, 5 times a week, lasting for 3 weeks.
223593120|NCT06409143|DEVICE|HD-tES (Bilateral)|The intensity of HD-tES is set at 2 mA, the current intensity ramps up to 2 mA within 5 seconds, remains at 2 mA for 10 minutes, and then ramps down to zero within 5 seconds.
223593121|NCT01815840|DRUG|Vismodegib|Vismodegib 150 mg hard gelatin capsule orally once daily
223593122|NCT01815840|DRUG|Placebo|Vismodegib placebo orally once daily
223593123|NCT06297382|BEHAVIORAL|ChatGPT Based Nursing Process Training|"ChatGPT Based Nursing Process Training topics:~Lesson 1: Use of artificial intelligence and ChatGPT in healthcare Lesson 2: Using ChatGPT in determining nursing diagnoses and goals Lesson 3: Using ChatGPT to determine nursing interventions Lesson 4: Things to consider and ethical principles when using ChatGPT when creating a nursing process."
223593124|NCT02144025|DRUG|Cyclosporine|Use of topical cyclosporine (one drop of cyclosporine in each eye, twice a day for 12 months)
223746895|NCT05147493|DRUG|Isatuximab|Route of administration: Intravenous (IV). Dose regimen: Isatuximab will be given at a dose of 10 mg/kg once weekly (QW) on Days 1, 8, 15, and 22 in Cycle 1, on Days 1 and 15 during Cycles 2-6 and on Day 1 from Cycle 7 onwards.
223746896|NCT05147493|DRUG|Bortezomib|Route of administration: Subcutaneous (SC). Dose regimen: Bortezomib will be given at 1.3 mg/m2 on Days 1, 4, 8, 11 of Cycle 1 and days 1, 8, 15, 22 of Cycles 2-6.
223746897|NCT05147493|DRUG|Cyclophosphamide|Route of administration: Intravenous (IV). Dose regimen: Cyclophosphamide will be given at 300 mg/m2on Days 1, 8, 15 of Cycle 1 and days 1, 8, 15, 22 of Cycles 2-6.
223746898|NCT05147493|DRUG|Dexamethasone|Route of administration: per os (PO)/Intravenous (IV). Dose regimen: Dexamethasone will be given at 40 mg (20 mg for ≥75 years old) on Days 1-4 and 9-12 of Cycle 1 and Days 1, 8, 15 and 22 of Cycles 2-6.
224195375|NCT01180452|PROCEDURE|enteroscopy|endoscopic enteroscopy to do biopsies on jejunum
224195376|NCT06991387|OTHER|Myofascial Release|A single session of myofascial release techniques including Single Arm Pull, Lateral Neck Shoulder Release, Thoracic Transverse Release, and Anterior Cervical Release applied by a physiotherapist trained in manual therapy.
224195377|NCT00943566|DRUG|Sufentanil|Transdermal Delivery System; Apply up to six 3 cm2 sufentanil TDS patches every 3 days for 12 days of observation. The 12 days of observation begin after a 7 day conversion to sustained release morphine sulfate. If the subject continues on the pharmacokinetic portion of the study, an additional 6 days of intervention will be evaluated (at the same dose as the primary efficacy study).
224310504|NCT03602963|DEVICE|Dexcom G5 Mobile CGM system|The accuracy and usability ot the Dexcom G5 mobile CGM system will be evaluated
223593125|NCT05496569|DRUG|TQB3616 capsule|TQB3616 capsule is a cyclin-dependent kinase 4/6 kinase inhibitor
223593126|NCT05496569|DRUG|TQB3616 placebo|Placebo
223593127|NCT03221842|DRUG|C1-esterase inhibitor|C1-esterase inhibitor is a human plasma-derived lyophilised powder for reconstitution
223593128|NCT03221842|DRUG|Placebo|Excipients of C1-INH plus albumin
223593129|NCT00901199|DRUG|Combo Chelation with Deferasirox (Exjade) and Deferoxamine (DFO)|All subjects will be given Deferasirox 20-30 mg/kg for 7 days per week. All subject will be given Deferoxamine 50 mg/kg for 3-7 days per week. The number of days for Deferoxamine will be determined by liver iron concentration at baseline.
223593130|NCT01181869|DEVICE|oxygen|oxygen therapy, ventilation for respiratory failure CPAP for sleep apnoea
223593131|NCT05809492|OTHER|step test|"The step speed of 18 steps/min was chosen for the first level because it is suitable for all subjects and prevents them from being too fast at the end of the test.~the slow standardized initial tempo at Level 1 of 72 beats/min allowed familiarity with the coordinated cascading technology of the tests (step up and down in time with the metronome beat). Regular replacement of the leading leg was encouraged to prevent unilateral leg fatigue and November muscle pain.~pwCF selected 1-minute stage times for each level in accordance with the maximum exercise test (CPET) recommendations in 18; at each new level, the test speed was increased by two steps / minute to ensure a progressive change in exercise parameters; a suitable end test time of 16 minutes was achieved along with an initial speed of 18 steps/min. The fast pace of 194 beats/min (48 steps/min at Level 16), which was eventually reached, it was physically possible to perform safely."
223593132|NCT00003883|DRUG|fluconazole|
223593133|NCT00003883|DRUG|itraconazole|
223746899|NCT05147493|DRUG|Lenalidomide|Route of administration: per os (PO). Dose regimen: Lenalidomide will be given at 10 mg (or according to renal function) daily from Cycle 7 onwards.
223746900|NCT03194321|DRUG|Tacrolimus Extended-Release Oral Capsule|Maintenance immunosuppression will consist of tacrolimus extended-release, mycophenolate mofetil 500mg twice daily or mycophenolate sodium 360mg twice daily, and prednisone.
223593134|NCT00334984|DRUG|glutamine|
223593135|NCT00334984|PROCEDURE|chemoprotection|
223593136|NCT00334984|PROCEDURE|management of therapy complications|
224195378|NCT00943566|DRUG|Sustained Release Morphine Sulfate|Sustained Release Morphine Sulfate tablets every 12 hours; up to 400 mg every day for 19 days (7 days of conversion to sustained release morphine sulfate and 12 days of observation)
224195379|NCT01054443|DRUG|Placebo|Tablet
224195380|NCT01054443|DRUG|Lusutrombopag|Tablet
224195381|NCT06992596|DEVICE|N1 Implant|The N1 Implant is a type of implantable brain-computer interface.
224195382|NCT06992596|DEVICE|R1 Robot|The R1 Robot is a robotic electrode thread inserter that implants the N1 Implant.
224195383|NCT01265927|DRUG|GRN163L in combination with trastuzumab|GRN163L will be administered in escalating dose cohorts on Day 1 of each 21-day cycle prior to trastuzumab infusion. Trastuzumab will be a administered day 1 of each 21-day cycle after GRN163L. There will be a 30 minute observation period between the end of the GRN163L infusion and the beginning of the trastuzumab infusion.
223593137|NCT00334984|PROCEDURE|therapeutic nutritional supplementation|
223593138|NCT00704288|DRUG|XL184|Gelatin capsules supplied in 25-mg and 100-mg strengths; continuous daily dosing
223593139|NCT03520907|DRUG|Transversalis Fascia Plane Block|block will be performed under real-time ultrasound guidance
223593140|NCT03520907|DRUG|Ilioinguinal/iliohypogastric Nerve Block|block will be performed under real-time ultrasound guidance
223593141|NCT02396563|PROCEDURE|epidural analgesia|
223593142|NCT02396563|DRUG|Ropivacaine|
223593143|NCT02435927|DRUG|ASLAN001+ CAPOX (Oxaliplatin, capecitabine)|ASLAN001 in combination with oxaliplatin and capecitabine
223593144|NCT02435927|DRUG|ASLAN001 + mFolfox6 (5-FU, leucovorin)|ASLAN001 in combination with 5-FU and leucovorin
223593145|NCT00625781|DRUG|Insulin aspart and Insulin human (isophane)|Insulin treatment if fasting p-glucose \>5.0 mmol/l or post meal value \>6.5 mmol/l according to study protocol.
223504371|NCT01106950|DRUG|IL-2|Administered after NK cell infusion, 10 million units every other day for a total of 6 doses. (Patients weighing less than 45 kilograms will receive a dose of 5 million units/m\^2 every other day for 6 doses).
223504372|NCT04769401|OTHER|Normal Progesterone group|Progesteron supplementation was initiated by the use of 100 mg of a vaginal progesterone tablet two times daily (Lutinus, Ferring Pharmaceuticals) plus 250 mg of intramuscular hydroxyprogesterone caproate in oil twice a week (IMHPC) as luteal phase support (referred to as day 0 of progesterone administration).
223504373|NCT04769401|OTHER|Low Progesterone group|Progesterone level \<10 ng/mL on ET day. If serum progesterone levels were \<10 ng/ml at ET day, 25 mg/d of SC progesterone daily (Prolutex) was given to patients and ET was performed on the same day and the blood sample was taken 2 days later to check serum progesterone levels.
223504374|NCT00356421|DRUG|Inhaled Human Insulin (Exubera®)|Preprandial inhaled insulin regimen and administration of insulin glargine QD
223504375|NCT00356421|DRUG|Insulin lispro (Humalog)|Subcutaneous insulin regimen of pre-prandial insulin lispro and administration of insulin glargine QD.
223593146|NCT04489082|DEVICE|Near Infrared Laser Stimulation|10 minutes of transcranial near infrared laser stimulation
224195384|NCT06140407|DRUG|Cisplatin|Receive Cisplatin
224195385|NCT06140407|DRUG|Carboplatin|Receive Carboplatin
224195386|NCT06140407|DRUG|Etoposide|Receive Etoposide
224195387|NCT06140407|BIOLOGICAL|Pembrolizumab|Receive Pembrolizumab by IV
224195388|NCT06140407|PROCEDURE|Computed Tomography|Undergo Computed Tomography
224195389|NCT06140407|PROCEDURE|Positron Emission Tomography|Undergo Positron Emission Tomography
224195390|NCT06140407|PROCEDURE|Magnetic Resonance Imaging|Undergo Magnetic Resonance Imaging
223504376|NCT04291833|BEHAVIORAL|Intervention group 1|Protein supplementation BID, Vitamin D and calcium supplementation Vitamin D 2000 IU / d, calcium 1000mg/d, exercise 6 months
223504377|NCT04291833|BEHAVIORAL|Intervention group 2|Protein supplementation QD, Vitamin D and calcium supplementation Vitamin D 1000 IU / d, calcium 500mg/d, exercise 3 months
223504378|NCT04291833|BEHAVIORAL|Control group 0|no protein supplementation , no Vitamin D and calcium supplementation , no exercise
223504379|NCT02694250|DEVICE|DTRAX® Cervical Cage with DTRAX Bone Screw|DTRAX Cervical Cage is an intervertebral fusion device that provides mechanical support to the spine. DTRAX Cervical Cage is intended to be used in cervical spine fusion surgery. DTRAX Bone Screw is indicated for use in arthrodesis and provides supplemental fixation. .
223504380|NCT04958590|RADIATION|whole spine X-ray|Group 1 underwent whole spine X-ray in standing and sitting positions.
223504381|NCT05950126|OTHER|pain catastrophizing scala|"The PCS, a 13-item self-report inventory used to determine the extent to which individuals catastrophize in response to pain, was developed. Total possible scores range from 0 to 52, with higher scores indicating negative results.~The Turkish version was tested for reliability and validity and the Cronbach alpha coefficient was measured at 0.90. PCS scores of 16 or lower are regarded as normal, and scores of 17 or above as high."
223504382|NCT00501085|DEVICE|LAP-BAND AP Adjustable Gastric Banding System|Reduction of food intake due to creation of smaller stomach pouch.
223504383|NCT04449809|BEHAVIORAL|Exercise program|3x per week group monitored group exercise sessions
223504384|NCT06479057|OTHER|Supportive Care Pathway|All pathways include a medical consultation with comprehensive needs assesment and evidence-based coordinated supportive care referrals at institutional and community-based level.
223504385|NCT04026516|DEVICE|CAVA Device|The CAVA device will be worn continuously for thirty days, during which time it will record eye and head movements
223504386|NCT03898609|OTHER|Dietary intervention|3 weeks
223504387|NCT01468961|BEHAVIORAL|Internet-based CBT|10 weeks of internet-based CBT with online therapist contact
223504388|NCT00004083|DRUG|cisplatin liposomal|
223504389|NCT02958527|DRUG|venlafaxine|The usual adult starting dosage for oral use is 37.5 mg of venlafaxine once daily, which is increased to 75 mg once daily after a meal from 1 week later. The dose may be adjusted within a range not exceeding 225 mg/day according to the patient's age and symptoms. However, the dose should be increased by 75 mg/day at intervals of not less than 1 week.
224195391|NCT06140407|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
224195392|NCT06140407|RADIATION|Radiation Therapy|Undergo Radiation Therapy
224195393|NCT00848302|DRUG|L-arginine|30 patients will receive either 50, 100 or 500mg L-arginine supplementation infused via a end-hole catheter
224195394|NCT00287261|DRUG|zoledronic acid|4 mg IV every 3 weeks for 36 weeks
224195395|NCT00985114|DEVICE|EndoBarrier|EndoBarrier implant
224195396|NCT00985114|BEHAVIORAL|Diet + Lifestyle Counseling|Multidisciplinary lifestyle and nutritional counseling
224195397|NCT01616992|DRUG|Bupivacaine|20 ML dose of 0.75% Bupivacaine Instillation (into bladder) 1 time during second study visit.
224195398|NCT03252652|RADIATION|vascular duplex ultrasound imaging|Duplex ultrasound is a non-invasive evaluation of blood flow through cranial arteries and veins.
224195399|NCT02258893|OTHER|NO2 Scrubber|an NO2 scrubber that removes NO2 and particles
224195400|NCT02258893|OTHER|HEPA filter|a HEPA filter that removes 95% of suspended particles ≥ 0.003 μm in size (but does not remove NO2)
224195401|NCT02258893|OTHER|Control|"a control filter designed to be the same size and weight as the other two filters, but filters neither NO2 nor particles"
224195402|NCT04696601|DIAGNOSTIC_TEST|Olfactory test|The olfactory test (Olfascan) is in the form of a paper stick, previously impregnated with an odorant (non-liquid). It is placed a few centimetres from the participant's nose at the time of the test. It is a single-use test, without contact with the participant.
223593147|NCT06388603|DEVICE|Bioactive Glass|Bonalive Granules and Bonalive Putty will be used (according to their IFU and CE certification) to fill the bone void after the debridment of infected tissue as they have osteoconductive and osteostimulative properties that allow bone rigeneration. Moreover, Bonalive Granules also present some bacteria growth inhibiting properties to combact bone infection propoer of Ostemyelitis.
223593148|NCT06388603|OTHER|Standard of Care|The investigators are left free to proceed according to the normal standar procedure they normally use. The procedures can vary according to investigator judgment also depending on the state of Osteomylitis.
223593149|NCT00000228|DRUG|Buprenorphine|
223593150|NCT05248880|DRUG|AGN-151586|Intramuscular Injection
223593151|NCT05248880|DRUG|Placebo|Intramuscular Injection
223593152|NCT05942443|PROCEDURE|Pre-treatment|The custom MCP blocking orthosis was made of a 1.6-mm-thick thermoplastic material that extends from the palm over the MCP joint and includes a ring around the proximal phalanx. It is designed to block the MCP joint in flexion of 10°-20° while allowing full range of motion of the proximal and distal interphalangeal joints.
223593153|NCT05942443|PROCEDURE|Post-treatment|The RME orthosis was fabricated from 3.2-mm-thick thermoplastic material with the affected finger positioned at an extension of approximately 10°-20° relative to the adjacent fingers.
223593154|NCT03306511|OTHER|Repeated-sprint test|6x30-meter sprint interspersed with 90-s rest
223593155|NCT03405649|BEHAVIORAL|Group A|Muscle conditioning exercise for postpartum women and infants less than 20 weeks of age.
223593156|NCT03405649|BEHAVIORAL|Group B|Muscle conditioning exercise for postpartum women and infants more than 20 weeks of age.
223593157|NCT05739461|OTHER|Dental implant|Dental implants with triangular cross-section neck design
224195403|NCT01621763|DRUG|Clopidogrel|Clopidogrel Tablets 300 mg
224195404|NCT01287260|DRUG|Nifedipine (Adalat, BAYA1040)|BAYA1040\_Nifedipine 40mg twice daily (BID)
224195405|NCT01287260|DRUG|Nifedipine (Adalat, BAYA1040)|BAYA1040\_Nifedipine 40mg once daily (OD)
224195406|NCT01119118|DRUG|ZD4054|All patients will be treated with ZD4054 at 10 mg PO daily, repeated in four week cycles (1 cycle = 28 days). All patients will initially undergo NaF and FDG PET/CT and MRI imaging at baseline (scan#1), and then again after 4 weeks (scan#2) of ZD4054 exposure. Subsequently, ZD4054 will be held for 2 weeks followed by the final NaF and FDG-PET/CT and MRI acquisition (scan#3). After the final PET/MRI is obtained, patients will resume ZD4054 and be assessed for safety prior to each new cycle of therapy. Standard disease evaluation assessments will be conducted after cycle#3, and repeated after every third cycle (sooner if clinically indicated). Therapy will continue until radiographical/clinical disease progression or unacceptable toxicity
224195407|NCT02977052|DRUG|Ipilimumab|
224195408|NCT02977052|DRUG|Nivolumab|
224195409|NCT02977052|PROCEDURE|Surgery|Surgery will be done at 6 weeks
224195410|NCT02977052|PROCEDURE|Blood for PBMCs|Blood will be taken for translational research on PBMCs
224195411|NCT02977052|PROCEDURE|Biopsies|Biopsies will be taken during screening and at relapse.
224195412|NCT05416086|DEVICE|cryoablation procedure using the iCLAS Cryoablation System|all subjects will receive a cryoablation procedure using the iCLAS Cryoablation System (catheter, stylets, and console) and warming balloon
224195413|NCT00984386|DRUG|Zesteem|Intradermal Zesteem, 0.02μg/100μl administered once before punch biopsy
224195414|NCT00984386|DRUG|Zesteem|Intradermal Zesteem, 0.1μg/100μl administered once before punch biopsy
224195415|NCT00984386|DRUG|Zesteem|Intradermal Zesteem, 0.2μg/100μl administered once before punch biopsy
224195416|NCT00984386|DRUG|Zesteem|Intradermal Zesteem, 0.4μg/100μl administered once before punch biopsy
224195417|NCT00984386|DRUG|Placebo|Intradermal placebo, 100μl administered once before punch biopsy
224195418|NCT00517517|BIOLOGICAL|Whole virion, Vero cell-derived influenza vaccine containing either 3.75 µg or 7.5 µg H5N1 hemagglutinin (HA) antigen in a non-adjuvanted formulation|Subjects will be randomized 1:1 to receive two intramuscular injections of the whole virion, Vero cell-derived influenza vaccine containing either 3.75 mg or 7.5 mg H5N1 hemagglutinin (HA) antigen in a non-adjuvanted formulation on Day 0 and Day 21.
224195419|NCT06854952|DRUG|TERN-601|Investigational drug
224195420|NCT06854952|OTHER|Matching Placebo|Matching placebo
223593158|NCT04610398|DRUG|Dexamethasone 4mg|s. arm/group description
223593159|NCT04610398|DRUG|NaCl 0.9%|s. arm/group description
223593160|NCT00197899|DRUG|E. Coli endotoxin|
223593161|NCT04086095|DEVICE|Neofact application aid|The Neofact application aid is a specifically for the LISA procedure designed guide of a soft catheter and replaces the Magill forceps. Catheter (3.5 Fr.) and guide are already combined and packed together sterile. The catheter tip is marked in black (1cm).
223593162|NCT01186055|BEHAVIORAL|Smoking Cessation Counseling|Participants shall all receive 8 weeks (6 weeks) of group or individual counseling during their quit attempt.
224195421|NCT04885582|OTHER|HLA antigen results|HLA-A, HLA-B, HLA-DR tissue matching results in both groups will be compared.
224195422|NCT02687724|DRUG|Golimumab (GLM)|GLM is a human IgG1κ monoclonal antibody produced by a murine hybridoma cell line with recombinant DNA technology
224195423|NCT03416166|DEVICE|Transcatheter Tricuspid Intervention|Any available transcatheter tricuspid valve intervention
224195424|NCT03950934|OTHER|no intervention, observational study, perioperative survey|no intervention
224195425|NCT00167414|PROCEDURE|Hypofractionated Stereotactic Body Radiation Therapy|Hypofractionated Stereotactic Body Radiation Therapy
224310505|NCT04039386|DEVICE|Cell Phone Based Cognitive Based Therapy (Pacifica App)|Cell phone application that provides support for individuals with psychosocial conditions.
224195426|NCT00167414|RADIATION|Hypofractionated Stereotactic Body Radiation Therapy|Hypofractionated Stereotactic Body Radiation Therapy for treatment of limited metastases from breast cancer primary.
224195427|NCT02852239|DRUG|dabrafenib|Single dose dabrafenib 100 mg
224195428|NCT05765994|DIAGNOSTIC_TEST|Modified hydrogen breath test|A modified technique to obtain expired hydrogen from the ventilator tubes is performed. A connection with a valve attached to a collecting bag is inserted at the end of the expiratory limb of the breathing circuit for exhaled air collection.
224195429|NCT06863168|BEHAVIORAL|Cigarillo Health Harm and Nicotine Addiction Messaging|Participants in the harm messaging arm will receive messages about the 1) long-term health risks, 2) short-term health risks, 3) social health risks, and 4) nicotine addiction of cigarillo smoking.
223504390|NCT02706548|BEHAVIORAL|Integrative Medication Self Management (IMedS) Intervention|Half of participants received a manualized 30-minute occupational therapy intervention, Integrative Medication Self-Management Intervention (IMedS). During IMedS, the interventionist and client progress through three steps in which the pair: 1) reflect on past performance of medication management, 2) set a medication goal, and 3) generate strategies to reach the goal. During strategy generation, the interventionist uses therapeutic use of self and motivational interviewing to help the client self-generate new medication management strategies, specifically addressing 1) altering the activity, 2) advocacy, 3) education, 4) assistive technology, 5) environmental modifications, and 6) securing timely refills.
223504391|NCT02706548|BEHAVIORAL|Standard Care Educational Intervention|The standard care educational intervention was a 30-minute pamphlet based educational session. In the standard care intervention group, participants and interventionist first reviewed the pamphlet, Managing Your Medicines: Our Guide to Effective Medication Management (American Heart Association \& American Stroke Association, 2013). Then, the interventionist engaged in active listening, where she asked open-ended questions about the participant's medication routines and provided simple reflections. For the standard care procedures, the interventionist was prohibited from providing affirmations, complex reflections, summaries, problem-solving, or suggesting any specific interventions.
223504392|NCT02072993|DRUG|AZD1979|Single dose, oral solution administration
223504393|NCT02072993|DRUG|Placebo to match|Single dose, oral solution administration
223504394|NCT06304727|OTHER|clinical data review|Medical records review to gather and analyze demographic, clinical, care and virological data
223504395|NCT02321150|PROCEDURE|Cautery|"* Pterygium dissected off, corneal bed burred smooth and autograft harvested as per usual technique.~* Conjunctiva undermined at the recipient site.~* Relaxing incisions placed at the corners of the recipient site.~* Graft is slid into place~* Graft / host interface is gently dried with a Qtip~* Bipolar cautery is applied after grasping the graft and host conjunctiva gently between cautery forceps.~  * Power setting: 25.~ * Duration of cautery: 4 -5 seconds; the tissue should whiten and contract as desiccation and coagulation take place. Some charring may occur.~* Counter traction is applied to the conjunctiva as the cautery forceps are gently teased off~* Cautery is applied at the 4 apices of the graft then in between these points."
223504396|NCT02321150|PROCEDURE|Sutures|"* Pterygium dissected off, corneal bed burred smooth and autograft harvested as per usual technique.~* Conjunctiva undermined at the recipient site.~* Graft is slid into place The graft is secured to host conjunctiva using 7 interrupted sutures"
223504397|NCT03092037|PROCEDURE|Blood draw|The Investigators will collect serum and whole blood from participants.
223504398|NCT04076215|BEHAVIORAL|Stressogenic stimulus|Participants will be exposed to an anxiety-provoking stimulus for 15-20 minutes, in a controlled setting
223504399|NCT04076215|DEVICE|Biobeat smart watch and adhesive biosensor patches.|Physiological and biochemical measures will be obtained using the Biobeat smart watch and adhesive biosensor patches.
223504400|NCT03033212|OTHER|Therapist-Guided Rehabilitation|Rehabilitation consists of exercises guided by a certified physical therapist. These exercises include: aerobics, walking tests, stability exercises, and strengthening exercises.
223504401|NCT03033212|OTHER|Self-Guided Rehabilitation|Rehabilitation consists of self-guided exercises with provided instructions. These exercises include: aerobics, walking tests, stability exercises, and strengthening exercises.
223504402|NCT04773977|DRUG|IBI362 liquid formulation|Administered by subcutaneous injection
223504403|NCT04773977|DRUG|IBI362 lyophilized powder|Administered by subcutaneous injection
223504404|NCT03472677|OTHER|Ice Pack and Cooling Device|A comparison of two cooling methodologies in healthy volunteers after single intra-articular (IA) injection (15 mL) of 2% lidocaine (without epinephrine).
223504405|NCT03472677|DRUG|CNTX-4975-05 (trans-capsaicin)|Controlled cooling wrap vs ice pack cooling after single IA injection of 1 mg CNTX-4975-05 in each arm after single IA (15 mL) injection of 2% lidocaine (without epinephrine).
223504406|NCT03472677|DRUG|CNTX-4975-05 (trans-capsaicin)|Controlled cooling parameters will be determined after evaluation of data from prior Cohort(s) after single IA injection (15 mL) of 2% lidocaine (without epinephrine) and single IA injection of 1 mg CNTX-4975-05.
223504407|NCT03472677|DRUG|CNTX-4975-05 (trans-capsaicin)|Controlled cooling with knee device vs no cooling (determined after evaluation of data from previous cohorts) after single IA injection (15 mL) of 2% lidocaine (without epinephrine) and single IA injection of 1 mg CNTX-4975-05.
223504408|NCT03472677|DRUG|Capsaicin|Four intradermal injections of capsaicin, two on each forearm.
223504409|NCT04607616|BEHAVIORAL|Baseline sessions TAU|TAU consists of sessions lasting around one/one and a half hour ; the consultant is practicing as usual. The interventions focus on child's behavior, parent infant relationship, with moments of play with the child, advices, informations about child development and Autism.
224310506|NCT04039386|OTHER|Control|Subjects in the control group will receive standard care.
224310507|NCT00141986|DIETARY_SUPPLEMENT|vitamin D3|2000 IU per day
224310508|NCT00141986|DIETARY_SUPPLEMENT|vitamin D3|400 IU per os once daily
224310509|NCT04161014|DRUG|Nintedanib 150 MG [Ofev]|Nintedanib 150mg twice daily for 3 years
224195430|NCT06863168|BEHAVIORAL|Cigarillo Health Harm and Nicotine Addiction Messaging Contextualized to Outcome Expectancies|Participants in the harm messaging contextualized to outcome expectancies arm will receive messages about the health harm and nicotine addiction risks of cigarillo smoking (i.e., 1) long-term health risks, 2) short-term health risks, 3) social health risks, and 4) nicotine addiction of cigarillo smoking) contextualized to one of the following themes: 1) smoking sensory experience, 2) anticipated pleasure, relaxation, and satisfaction from smoking, 3) social persona/admiration related to smoking, and 4) that smoking does not align with personal values and authenticity.
224195431|NCT06861673|DEVICE|Pulmonary vein isolation|concomitant PVI and LAAC
224195432|NCT07000526|DRUG|Isoflurane|Inhaled sedation with isoflurane via Sedaconda ACD-S
224195433|NCT07000526|DRUG|Propofol|Intravenous sedation with Propofol 20 mg/ml
224195434|NCT07007039|OTHER|Datos Health App|Tracking participants step activity, workout frequency, minutes in target heart rate zone, and/or strength bouts completed over 3 month period. Individualized goals will be selected and set with a customized amount by a rehabilitation provider with at least monthly follow up contact to modify goals.
224195435|NCT05775718|DRUG|Zoster Vaccine Recombinant|Injection
224195436|NCT07005349|OTHER|Quality improvement program|The intervention comprises two mandatory risk assessments (preoperatively in theatre and postoperatively prior to discharge from the recovery area) which are linked to hospital-specific responses. Assessments for bleeding will occur intraoperatively (through direct vision, haemodynamic changes and/or measurement of blood loss) and postoperatively (with the use of the rapid assessment tool). If bleeding is diagnosed at any point, the THUMB checklist will be used to activate bundled care. On discharge from recovery, high-risk patients will be scheduled to receive a postoperative ward visit within four hours, when a further assessment for bleeding will occur.
224195437|NCT07007481|DEVICE|Purrble|"The intervention takes the form of an interactive plush toy, which was co-designed with children to support in-the-moment soothing. The device is framed as an anxious creature, in need of care and attention when it feels distressed. This distress is indicated by a simulated heartbeat using embedded electronics to produce vibration patterns of i) frantic and anxious, to ii) slow, steady and relaxed. When held, the device emits a frantic heartbeat which can be slowed by stroking movements registered by embedded sensors. Once the device has been soothed for long enough, the heartbeat transitions into a purring vibration indicating a relaxed state. This transition can be achieved in under 1 minute but is dependent on the device-human interaction."
224195438|NCT06690164|DRUG|Atorvastatin 40mg Tablet|once a day for 30 days
224195439|NCT06690164|DRUG|Omeprazole 20mg Capsule|once a day for 30 days
224195440|NCT05947084|OTHER|Infant Formula|Growth Monitoring Study of Infant Formula fed to Healthy Term Infants over a 16 week period
224195441|NCT01875731|BEHAVIORAL|BPS|In this study a strategy based on BPS guided antibiotic use in children with community acquired pneumonia implementation will be compared with enforced guideline.
224195442|NCT01875731|BEHAVIORAL|Guideline|Strategy based on enforced guideline guided antibiotic use
224195443|NCT06597747|DEVICE|Audio processor|MED-EL SONNET 3 (EAS) audio processor
224195444|NCT02319798|OTHER|telephone consultations|Those randomized to telephone consultation will be told to expect a call from the gastroenterology doctor at the time of their appointment.
224195445|NCT02319798|OTHER|face-to-face consultations|Those randomized to face-to-face follow up will attend their appointments in hospital
224195446|NCT00412555|DRUG|oseltamivir [Tamiflu]|30-75mg po daily for 6 weeks
224195447|NCT05964933|PROCEDURE|Complete Pulpotomy|"Complete caries removal and excision of the entire coronal pulp to the level of the root canal orifices will be performed. After haemostasis, the pulp chamber will be filled with Biodentine® and a final direct restoration placed in 1 or 2 visits.~If there is no bleeding from the exposed pulp, pulpectomy and root canal treatment will be performed instead, and the patient will be excluded from the study."
223746901|NCT03792308|DRUG|SPR206|"SAD Cohorts: Double-blind dosing will occur in Cohorts 1 - 8. Six participants will receive single doses of SPR206. The dose escalation steps may be altered following review of the safety data upon completion of each cohort.~MAD Cohorts: Double blind dosing will occur in Cohorts 9 - 13. Six participants in each cohort will receive multiple doses of SPR206. The dose escalation steps may be altered following review of the safety data upon completion of each cohort. Dosing will commence on the morning of Day 1. Three doses will be administered per day at approximately 8 hours apart. Daily dosing will continue for a total of 7 consecutive days for Cohorts 9 - 12 and for a total of 14 consecutive days for Cohort 13."
223746902|NCT03792308|DRUG|Placebo|0.9% sodium chloride for injection. SAD Cohorts: Two participants in each cohort will receive matching placebo. MAD Cohorts: Two participants in each cohort will receive matching placebo.
223746903|NCT01204164|DRUG|TG02 citrate|TG02 citrate capsules given orally.
223746904|NCT01204164|DRUG|Carfilzomib|Carfilzomib per PI
223746905|NCT01204164|DRUG|Dexamethasone|Dexamethasone (Oral or IV)
223746906|NCT03803774|PROCEDURE|Biopsy Procedure|Undergo biopsy
223746907|NCT03803774|DRUG|Birinapant|Given IV
224195448|NCT05964933|PROCEDURE|Pulpectomy and Root Canal Treatment|After complete caries removal and pulp exposure, Pulpectomy will be performed to remove all pulp tissues. Conventional root canal treatment will be performed using rotary instrumentation followed by obturation with gutta percha and traditional sealers in 1 or 2 visits. A final restoration will be placed to ensure a good coronal seal, and this may include full coronal coverage restorations if clinically indicated.
224195449|NCT04146259|DRUG|calcium carbonate and alphacalcidol|treatment for hypocalcemia
224195450|NCT00783055|OTHER|Individually tailored programmes|Individualised intervention programmes based on individual wishes for daily activities
224195451|NCT02566629|OTHER|collect faeces from participants|analyze the fecal microbiota community using 16S rDNA detection technique
224195452|NCT01042431|OTHER|No Intervention|No intervention
224195453|NCT02944604|DRUG|PEG-rhG-CSF|
224195454|NCT00719511|DRUG|Purified allergen dose 1 integrated in a Patch system|Epicutaneous application of a patch
223746908|NCT03803774|PROCEDURE|Computed Tomography|Undergo CT scan
223746909|NCT03803774|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRRT
223746910|NCT03803774|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223746911|NCT03803774|PROCEDURE|Positron Emission Tomography|Undergo PET scan
224195455|NCT00719511|DRUG|Purified allergen dose 2 integrated in a Patch system|Epicutaneous application of a patch
224195456|NCT00719511|DRUG|Purified allergen dose 3 integrated in a Patch system|Epicutaneous application of a patch
224195457|NCT00719511|DRUG|Purified allergen integrated in a Patch system|Epicutaneous application of a patch
224195458|NCT06712433|DRUG|2% intranasal mupirocin ointment|Mupirocin nasal ointment is used to treat or prevent infections in the nose due to certain strains of Staphylococcus aureus bacteria. This medicine works by killing bacteria or preventing their growth.
224195459|NCT06712433|DRUG|4% chlorhexidine gluconate body cleanser|Chlorhexidine Gluconate (CHG) Solution Antiseptic Skin Cleanser solution is a topical skin cleanser that keeps working after it is used. CHG is a strong antiseptic (liquid used to kill germs and bacteria) that lowers the risk of infection.
224195460|NCT06278571|BEHAVIORAL|Educational intervention with App and web site education|This group will only receive intervention with access to the educational website from home, where they will review the different modules focused on diabetes care, nutrition and exercise. in addition to the usual medical care by your treating physician.
224195461|NCT06278571|BEHAVIORAL|Educational interventión with web site education|This group will receive, in addition to nutritional therapy, diabetes education through an educational site, to learn more about the most important aspects of diabetes care. In addition to the usual medical care by your treating physician.
224195462|NCT06278571|OTHER|Control group with nutritional therapy|This group will receive only the usual medical care by your treating physician.
224195463|NCT02327949|DEVICE|W-Shaped Angular Plate|Treatment of posterior wall fracture of the acetabulum with a W-Shaped Angular Plate
223504410|NCT04607616|BEHAVIORAL|Interactive guidance therapy|"The objective is to reinforce the identification, deciphering, interpretation, and answer to child's signals by the parent, in order to to promote a synchronous and attuned response to the child's needs.~Sessions last around one/one and a half hour. Parent plays 7-10 minutes with the child, in the presence of the therapist, with toys chosen according to the child's developmental stage. Then therapist proposes an immediate viewing of the play session. The therapist selects short moments of positive interaction. He has determined a  focus , depending on the play, previous sessions, the child's difficulties and parent's interventions. He accompanies, guides and supports the parent to describe the interaction, the alternance in play, joint attention, shared affect, in a co-construction: the parent discovers the child's and his own skills."
223504411|NCT04607616|DIAGNOSTIC_TEST|Developmental and diagnostic assessments|MSEL, CARS, ECAR, CIM10, DMS5, ADOS, ADIR
223504412|NCT04607616|BEHAVIORAL|Developmental assessment -Parental scales|Vineland II, IFDC, IDE
223593163|NCT05731479|OTHER|Diathermy + exercise group|The Diathermy + Exercise group will receive diathermy for 15 minutes, of which 5 minutes will be applied in the capacitive method and 10 minutes in the resistive method. You will then perform 20 minutes of the following exercises: 1) Bird-Dog, 2) Crunch, 3) Obliques, 4) Drawing, 5) Half plank and 6) Side-plank. You will perform 8-12 repetitions and 3 sets of each exercise. 3 sessions of 35 minutes per week for 8 weeks.
223593164|NCT05731479|OTHER|Diathermy placebo + exercise group|The Placebo + Exercise group will receive 15 minutes of application of the diathermy device without energy emission. It will then perform the same therapeutic exercise protocol described in the GDE. 3 sessions of 35 minutes per week for 8 weeks.
223593165|NCT02692755|DRUG|Palbociclib + Letrozole or Fulvestrant|Palbociclib x 21 days with a 7 day rest plus 2.5 mg Letrozole QD (no break) or Fulvestrant 500mg IM every 2 weeks for 3 doses and then every 4 weeks until progression or maximum of 12 months
223593166|NCT03387020|DRUG|Everolimus|Given PO
223593167|NCT03387020|OTHER|Laboratory Biomarker Analysis|Correlative studies
223593168|NCT03387020|OTHER|Pharmacological Study|Correlative studies
223593169|NCT03387020|DRUG|Ribociclib|Given PO
223593170|NCT02139488|OTHER|Fiducial markers|
223593171|NCT02139488|OTHER|Fiducial markers, Pet and MRI|Insertion of Fiducial markers in esophageal wall.
223593172|NCT00077324|GENETIC|proteomic profiling|
223593173|NCT00077324|OTHER|surface-enhanced laser desorption/ionization-time of flight mass spectrometry|
223593174|NCT00077324|PROCEDURE|biopsy|
223593175|NCT00077324|PROCEDURE|surgery|
223593176|NCT02496299|DRUG|Dexamethasone|Comparison of analgesic effects of dexamethasone with plain bupivacaine during caudal blocks in children
223593177|NCT02496299|DRUG|Bupivacaine|Comparison of analgesic effects of dexamethasone with plain bupivacaine during caudal blocks in children
223746912|NCT04648345|PROCEDURE|Erector spinal plane block|After induction of general anesthesia, pre-operative ultrasound-guided bilateral erector spinae plane block/ vertebral side block will be performed in the ESPB/VSB group. Local block will be performed at the surgical incisions after the surgery under general anesthesia. All the intervention will be performed without patients' awareness.
223746913|NCT02436551|OTHER|Observation|
224195464|NCT02327949|DEVICE|Reconstruction Plate|Treatment of posterior wall fracture of the acetabulum with a Reconstruction Plate
224195465|NCT06722898|DIETARY_SUPPLEMENT|Supplement|Contains ingredients believed to reduce Blood Alcohol Concentration and symptoms of alcohol impairment.
224195466|NCT06722898|DIETARY_SUPPLEMENT|Placebo|Placebo
224195467|NCT06722066|DEVICE|Transcatheter aortic valve replacement with ballon-expandable or self-expandable valves|Device: Edwards SAPIEN 3 valve, Medtronic Evolut valve, Boston Acurate Neo valve, or Abbott Navitor Access route: transfemorak, subclavian, transapical, transcarotid, or transcaval The use of balloon dilation will be left to the discretion of the operator.
224195468|NCT06724536|OTHER|non interventional study with the use of biological samples.|"Patients will undergo to the follow evaluations:~Gut microbiome on stool samples by NGS (16S rRNA gene amplicon sequencing); Markers of impaired intestinal permeability \[diaminoxidase (DAO), serum zonulin\], and markers of inflammation of the GI tract (fecal calprotectin); Plasma inflammatory indices, cytokines (by Luminex), markers of autoimmunity, and metabolic profile; Acquired and adaptive immunity by multiparametric flow cytometry on PB samples."
224195469|NCT06722287|BEHAVIORAL|Caregiver Mental Health Mobile Application Intervention|The mobile application includes self-care tools, caregiving management tools, and online support groups
224310510|NCT00725114|BIOLOGICAL|Tetrodotoxin|30 µg twice daily for 4 days
224310511|NCT00725114|BIOLOGICAL|Placebo|2 mL subcutaneous injection twice daily for 4 days
224310512|NCT02158286|OTHER|Measuring emptying rate from the gastric tube|
223746914|NCT01425957|PROCEDURE|Lumbar puncture|"All the patients will be divided in two groups based on their Aβ 1-42 levels measured in the cerebro-spinal fluid obtained form a lumbar puncture: in low Aβ1-42 (positive aMCI patients CSFP) and high Aβ1-42 (Negative aMCI patients CSFN). The threshold of Aβ1-42 used to divide the patient will be 500 (ng/L) based on Sjogren criteria (2001).~Timeframe of lumbar punctures: every 18 months during 2 years (T0 and T18) or 3 years (T0, T18 and T36)."
224310513|NCT03150823|PROCEDURE|Upward Direct Current (Ascending Effect)|Application of direct current (Galvanic) in milliamperes current which varies according to the positioning of the electrodes. In the ascending stream direct current (Ascending effect) the proximal cathode and distal anode are placed, a excitatory effect on the nervous system being described in theory.
223504413|NCT04607616|BEHAVIORAL|Qualitative analysis|Interpretative Phenomenological Analysis. Parents' semi structured interview about the Interactive Guidance experience. Qualitative analysis of transcripts (recurrent themes, meta themes).
223504414|NCT04317846|OTHER|Intravenous administration of vasodilatory drugs|Administration of the vasodilatory drugs in a different pattern than intra-arterially
223504415|NCT02945046|DRUG|Fremanezumab|Fremanezumab will be administered per dose and schedule specified in the arm.
223504416|NCT02945046|DRUG|Placebo|Placebo matching to fremanezumab will be administered per schedule specified in the arm.
223504417|NCT00086463|DRUG|Iloprost or placebo|
223504418|NCT00962455|OTHER|e-learning & performance feedback|Initial e-learning by studying CD-Rom 'Spirometry Fundamentals', followed by repeated periodic performance feedback on spirometry test quality
223504419|NCT00962455|OTHER|usual practice|Usual practice regarding spirometry execution in family practice
223504420|NCT04433026|DIAGNOSTIC_TEST|N terminal pro B type natriuretic peptide (NTproBNP), D-Dimer, and serum Tropinin - I|Biomarkers detected in the serum of patients
223504421|NCT02245386|RADIATION|transperineal pelvic floor ultrasound|"Transperineal pelvic floor ultrasound applied for the submitted 120 women primiparae (40 women after normal vaginal delivery), (40 women after urgent cesarean section), (40 women after elective cesarean section), in early postpartum period (48 to 72) hours postpartum, to evaluate levator ani morphology."
223504422|NCT02722135|DRUG|Volasertib|
223504423|NCT01619449|PROCEDURE|Renal replacement therapy|Liver transplant recipients receiving continuous renal replacement therapy for duration of liver transplant surgery.
223504424|NCT05812989|BEHAVIORAL|Social Engage Coaching|"Participants will complete up to 8 weekly individual Social Engage psychotherapy sessions. Participants will be allotted up to 3 months to complete all sessions, a time-frame that allows for two weeks without meeting to address life stressors such as illnesses that may pop up. All sessions are provided via phone or videocall (Zoom). The first and last session are longer - up to 60 minutes if needed. Middle sessions are shorter (20-45 minutes). Engage is a stepped care psychotherapy in that the simplest strategy is taught first-action planning (a derivative of problem solving therapy)-and barrier strategies are added only if needed. Action plans are designed to address loneliness and social isolation in the context of caregiving demands."
223504425|NCT05812989|BEHAVIORAL|Connect for Caregivers|Participants will complete an individual session with a coach who will use a digitized prioritization tool to help identify goals and an action plan for social connectedness.
223504426|NCT03113136|BEHAVIORAL|Low wattage E cigarette device|The low wattage E cigarette device will be provided to the participant and they will be instructed to vape ad libitum for 12 weeks and then be assessed at 6 months and 12 months for continued use of device.
223504427|NCT03113136|BEHAVIORAL|High wattage E cigarette device|The high wattage E cigarette device will be provided to the participant and they will be instructed to vape ad libitum for 12 weeks and then be assessed at 6 months and 12 months for continued use of device.
223504428|NCT03113136|BEHAVIORAL|Usual brand cigarette|The usual brand of cigarettes will be provided to the participant and they will be instructed to smoke ad libitum for the duration of the study.
223504429|NCT05009771|DRUG|Intravenous patient-control analgesia|At the two trial sites, IV-PCA is commonly used with morphine. The device is installed after delivery and removed within 3 days.
223504430|NCT05009771|DRUG|Dinalbuphine sebacate|Dinalbuphine sebacate is a prodrug of nalbuphine. With oil-based formulation, the active ingredient releases slowly and the effect lasts longer than nalbuphine. After delivery, a single 150 mg dose of dinalbuphine sebacate is administered intramuscularly.
223504431|NCT03587857|OTHER|Mobile Health Application|This mobile health app is a modular, adaptive, and personalized intervention delivered via a mobile phone. It is grounded in the Information Motivation Behavioral Skills (IMB) model. It was created in collaboration with YLWH (18-29 years-old) using a Human-Centered Design approach to help improve engagement in HIV care among this age group.
223504432|NCT04460235|BIOLOGICAL|Prevenar 13 + Pneumovax 23|Cohort study A before modification of vaccination national guidelines
223504433|NCT04460235|BIOLOGICAL|PREVENAR20|"Health authorities changed guidelines to recommend one injection of PREVENAR20 instead of the 2-vaccine scheme general practitioners are usually in charge of this vaccination.~Cohort study B"
223504434|NCT06129890|DEVICE|Repetitive transcranial magnetic stimulation (rTMS) - M1/DLPFC|Repetitive transcranial magnetic stimulation (rTMS) is a treatment technique involving the induction of an electrical current on the surface of the cortex by applying a magnetic field to the scalp. This field is generated using a stimulation loop controlled by a robotic arm linked to a neuronavigation system. rTMS of M1 then rTMS of DLPFC.
223504435|NCT06129890|DEVICE|Repetitive transcranial magnetic stimulation (rTMS) - DLPFC/M1|Repetitive transcranial magnetic stimulation (rTMS) is a treatment technique involving the induction of an electrical current on the surface of the cortex by applying a magnetic field to the scalp. This field is generated using a stimulation loop controlled by a robotic arm linked to a neuronavigation system. rTMS of DLPFC then rTMS of M1.
223504436|NCT01571986|PROCEDURE|Non-invasive ventilation|Non-invasive ventilation
223504437|NCT02177578|DRUG|Temozolomide|Patients will be scheduled to receive continuous daily temozolomide (75 mg per square meter of body surface area per day, 7 days per week from the first to the last day of radiation therapy), followed by 6 cycles of adjuvant temozolomide (150 to 200 mg per square meter for 5 days during each 28 day cycle).
223504438|NCT02177578|RADIATION|Subventricular Zone radiation|"Patients will receive 60 Gy in 30 fractions, 5 days per week using IMRT. The target delineation and treatment volumes will be as follows:~Initial treatment plan:~Will be prescribed to 46 Gy in 2 Gy fractions~Cone down treatment plan:~Will be prescribed to 14 Gy in 2 Gy fractions"
223593178|NCT05045300|PROCEDURE|Ultrasound guided Selective trunk block|High definition ultrasound images that were acquired during USG SeTB are routinely stored in the hard disk of ultrasound machine in DICOM (Digital Imaging and Communications in Medicine) format will be used for this review. The images of principal investigator's previous research studies with Clinical trial registration: NCT04752410 and NCT04773405 will also be retrieved. The ultrasound imaging was performed before (scout scan), during and immediately after the USG SeTB. As is the principal investigator's standard practice, all ultrasound scan was performed in a sequential manner (SUIT: Sequential Ultrasound Imaging Technique) with the orientation marker of the transducer directed laterally so as to obtain a transverse oblique view of the brachial plexus block at the supraclavicular fossa. Approximate 50 cases who had undergone USG SeTB for surgical anesthesia during upper extremity surgery since January 1 2020 to June 30, 2021 will be evaluated by two anesthesiologists.
223593179|NCT00434642|DRUG|Carboplatin|Carboplatin was provided as commercially available drug.
223593180|NCT00434642|DRUG|Gemcitabine|Gemcitabine was provided as commercially available drug.
223593181|NCT00434642|DRUG|Bevacizumab|Bevacizumab was supplied as a clear to slightly opalescent, sterile liquid in glass vials (400 mg in 8 mL \[25 mg/mL\]) with a vehicle consisting of sodium phosphate, trehalose, polysorbate 20, and Sterile Water for Injection, USP.
223593182|NCT00434642|DRUG|Placebo|Placebo consisted of the vehicle for bevacizumab without the antibody and contained sodium phosphate, trehalose, polysorbate 20, and Sterile Water for Injection, USP.
223593183|NCT04139356|PROCEDURE|Deep breaths|Patients will undergo a 6 minutes protocol. Baseline: 1 minute normal breaths. Intervention: 1 minute with 10 deep breaths, 1 each 6 secs. Pulse-oxymetry will be continuously recorded.
223593184|NCT03424356|DRUG|Rocuronium Bromide|0.15 mg/kg rocuronium bromide
223593185|NCT03424356|DRUG|Saline Solution|1-2 ml saline solution
223593186|NCT03424356|DRUG|Fentanyl|1mcg/kg for induction
223593187|NCT03424356|DRUG|Propofol|2-3mg/kg for anaesthetic induction
223593188|NCT03424356|PROCEDURE|cystoscopy|patients will treated with this surgical procedure
223593189|NCT04120363|DRUG|Testosterone Undecanoate|single intramuscular injection of 750 mg testosterone undecanoate
223593190|NCT04120363|DRUG|Sesame Oil|single intramuscular injection of 750 mg sesame oil solution
223593191|NCT04680429|DRUG|RP7214|Participants will receive single and multiple ascending doses of RP7214
223593192|NCT04680429|DRUG|Placebo|Participants will receive single and multiple ascending doses of matching placebo
223593193|NCT02265718|DRUG|Ritalin|1 - 20 mg tablet taken once on Day 0 and taken once on Day 28
223593194|NCT02265718|DRUG|Placebo|1 - matching tablet taken once on Day 0 and once on Day 28
223593195|NCT02265718|DRUG|Ritalin|1 - 20 mg tablet taken once on Day 0 and taken once on Day 28
223593196|NCT02265718|DRUG|Placebo|1 - matching tablet taken once on Day 0 and once on Day 28
223593197|NCT02354872|DRUG|Nicotine Mini-Lozenge|If randomized to only the Nicotine Mini-Lozenge condition: Participants randomized to this condition will receive up to a 12 month supply of 2 mg or 4 mg nicotine mini-lozenges. Mini-Lozenges will be given at the initial visit and over the course of the whole study. Participants will be instructed to use 9 pieces daily for the 12 months.
223746915|NCT02558712|OTHER|Technology-based Eye Care Services (TECS) Protocol|Extensive History will be taken. Distance auto-refraction measurements will be made on both eyes. Eye pressure using the iCare tonometer and central corneal thickness (CCT) using the corneal pachymeter will be taken for each eye. Participants will have fundus photos taken following the standard VA diabetic teleretinal protocol. Then participants will have OCT Macula and Nerve performed. After protocol complete, then patients will see an ophthalmologist for standard eye exam.
223746916|NCT02721927|OTHER|Syrian Refugees|Adult Syrian patients who visited the Emergency Department
223593198|NCT02354872|BEHAVIORAL|Behavioral Reduction Counseling|We will deliver BR in 10 (10-15 minute) sessions over a 52-week period, with an in-person session at Visit 1 followed by nine phone counseling sessions. Sessions are front-loaded to enhance acquisition of new behaviors. BR Counseling will emphasize the development of smoking control skills via feasible, specific, and graded assignments of smoking reduction activities that will be tracked over time. BR will also emphasize competence and self-efficacy, both which will be directly linked to the practice of smoking reduction skills and success in smoking control. The health counselor will provide rationales for the reduction intervention, why reduction (e.g., eliminating smoking contexts) should help the smoker, and provide the participant with specific exercises and goals. The health counselor will explicitly address pragmatic issues such as work contexts, smoking policies, and habits that interfere with smoking reduction efforts.
223593199|NCT02354872|BEHAVIORAL|5Rs Motivation Counseling|"The 5Rs Motivation Counseling will be delivered in four (10-15 min) sessions over a 52-week period. Participants in the on condition will receive three brief phone sessions over the year to prompt processing of motives for smoking reduction or cessation. The health counselor and smoker will discuss: 1) Relevance of smoking to the individual; 2) Risks of continued heavy smoking; 3) Rewards of quitting and significant reduction; and 4) Roadblocks to success; and will do so on a 5) Repeated basis. The discussion will follow the general principles of MI: counselors will use strategies that are nonauthoritarian, nonconfrontational, supportive, and use open-ended questions."
223593200|NCT02354872|BEHAVIORAL|Behavioral Activation Counseling|The BA treatment will be delivered in 10 (10-15 minute) sessions over a 52-week period starting with Visit 1 followed by nine phone counseling sessions. This BA treatment will be modeled after Behavioral Activation for quitting smoking, but made relevant for smoking reduction. Treatment goals focus on helping participants engage in positively reinforcing activities while not smoking. The treatment includes: 1) a rationale for the BA exercises as they relate to smoking (e.g., engaging in non-smoking reinforcers will provide other sources of pleasure and assist with cutting down); 2) assessment of the participant's goals, values, and reinforcing value of current nonsmoking activities; 3) training in self-monitoring using an activity log; 4) ongoing assignments of activities that should significantly increase the participant's nonsmoking reinforcement and create broader lifestyle and cue exposure changes; and 5) problem-solving to address obstacles to goal attainment.
223593201|NCT02354872|OTHER|No Treatment|No Treatment
223593202|NCT00288236|DRUG|Rimonabant (SR141716)|
223593203|NCT00288236|DRUG|Placebo|
223746917|NCT00841529|DEVICE|Medtronic LAA Occlusion Device|Placement of the occlusion band on the LAA
224195470|NCT06722508|BEHAVIORAL|exercise and nutritional prehabilitation|The study involves a behavioral intervention (exercise and nutritional prehabilitation) designed to assess outcomes related to feasibility, acceptability, and safety in head and neck cancer patients. Outcomes are being measured following the intervention over a defined period (from diagnosis through 1-month post-surgery).
224195471|NCT06722638|OTHER|Use of Virtual Reality Headset|Virtual Reality Headsets will be used to augment pain and anxiety management during therapeutic LPs in children with acute lymphoblastic leukemia
224195472|NCT05794334|OTHER|Low Dye Taping|This second group also contains 20 participents.French functional method is similar to the Ponseti method. In this technique, the patient undergoes 30-minute daily session for 2 weeks and then twice a week until achieving foot correction. It consists of stretching of triceps surae to improve tibio-talar joint function. daily manipulations of the newborn's foot, stimulation and strenghtening of the muscles around the foot (particularly the peroneal muscles) and temporary immobilization of the foot with elastic and nonelastic adhesive taping so that the reduction achieved by.The average time of this method ranges between 6 to 8 weeks, with all the deformities being corrected apart from equinus. This method reports a 93% success rate
224195473|NCT03644966|DIETARY_SUPPLEMENT|Bifidobacterium infantis|Probiotics
224195474|NCT03644966|OTHER|Placebo|Sugar pill manufactured to mimic probiotic tablet
224195475|NCT03644966|DRUG|Antibiotics|Per Infectious Disease Society guidelines for Antimicrobial treatment of uncomplicated cystitis and pyelonephritis in women
224195478|NCT05507879|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
224195479|NCT05507879|OTHER|Electronic Medical Record|Review of medical records
224195480|NCT06868589|DRUG|Methadone|Participants in this group will receive one bolus dose of intravenous Methadone and Ketamine at the start of operation
224195481|NCT06868589|DRUG|ketamine|Participants in this group will receive one bolus dose of intravenous Methadone and Ketamine at the start of operation
224195482|NCT06868589|DRUG|Hydromorphone|Participants in this group will receive standard of care for pain with either intravenous fentanyl and/or hydromorphone boluses during the procedure
224195483|NCT06868589|DRUG|fentanyl|Participants in this group will receive standard of care for pain with either intravenous fentanyl and/or hydromorphone boluses during the procedure
224195484|NCT06747338|DRUG|KN026|KN026
224195485|NCT06747338|DRUG|HB1801|HB1801
224195486|NCT06747338|DRUG|Pertuzumab|Pertuzumab
224195487|NCT06747338|DRUG|Trastuzumab|Trastuzumab
224195488|NCT06747338|DRUG|Docetaxel|Docetaxel
224195489|NCT06747338|DRUG|Carboplatin|Carboplatin
223504439|NCT02177578|RADIATION|Neural Progenitor Cell Sparing radiation|"Patients will receive 60 Gy in 30 fractions, 5 days per week using IMRT. The target delineation and treatment volumes will be as follows:~Initial treatment plan:~Will be prescribed to 46 Gy in 2 Gy fractions~Cone down treatment plan:~Will be prescribed to 14 Gy in 2 Gy fractions"
223504440|NCT06964503|OTHER|Exposure: psychological stress status|The assessment of depressive and anxiety symptoms was conducted using Patient Health Questionnaire-9 (PHQ-9) and Generalized Anxiety Disorder Assessment 7 (GAD-7). Patients with a PHQ-9 score ≥ 5 or a GAD-7 score ≥ 5 were categorized as the stressed group.
223504441|NCT06963697|BIOLOGICAL|Personalized Synthetic Long Peptide Vaccine|Neoantigen synthetic long peptide vaccines are composed of synthetic long peptides which are 8-35 amino acids in length and designed to induce immune responses to cancer neoantigens identified by exome sequencing. Neoantigen synthetic long peptide vaccines will be co-administered with poly-ICLC, an innate immune adjuvant capable of activating TLR3 and other pathways.
223504442|NCT06964594|PROCEDURE|vNOTES adnexal surgery|New minimalinvasive technique
223504443|NCT06959303|BEHAVIORAL|Teach Back Education|Discharge training will be given to patients who underwent coronary angiography with the Teach-Back method.
223504444|NCT00999570|OTHER|Specialty training for knee surgeons|
223504445|NCT02325453|PROCEDURE|Robotic Surgery|Surgical procedure performed with a robotic system.
223504446|NCT02325453|PROCEDURE|Laparoscopic Surgery|Surgical procedure performed with laparoscopic techniques.
223504447|NCT02325453|PROCEDURE|Open Surgery|Traditional approach for gastric cancer.
223504448|NCT02919345|DRUG|Dapagliflozin 10 mg|Dapagliflozin 10 mg in addition to Metformin 1500 mg/day
223504449|NCT02919345|DRUG|Glibenclamide 5 mg|Glibenclamide 5 mg in addition to Metformin 1500 mg/day
223504450|NCT06388226|DEVICE|Leg heat therapy|A sous vide heating immersion circulator heats up the water inside the water tank to 42ºC. A water pump circulates temperature-regulated water through the trousers.
224195490|NCT06449326|DEVICE|Active Intermittent theta burst stimulation|Intermittent theta burst stimulation (iTBS) is an efficient form of transcranial magnetic stimulation that allows up to 10x more pulses to be delivered in a given timeframe compared to conventional stimulation patterns.
224195491|NCT06449326|DEVICE|Sham Intermittent theta burst stimulation|Intermittent theta burst stimulation (iTBS) is an efficient form of transcranial magnetic stimulation that allows up to 10x more pulses to be delivered in a given timeframe compared to conventional stimulation patterns.
224195492|NCT06219733|DRUG|Vactosertib|200 mg PO BID 5 days on / 2 days off
224195493|NCT06219733|DRUG|Imatinib|Imatinib 400 mg PO QD daily
224195495|NCT06910306|DEVICE|Device :DaRT seeds|The sources are impregnated with a layer containing Ra-224 which is well fixated to the surface of the source. Ra-224 undergoes a series of decay events with each daughter product producing an alpha particle
224195496|NCT05469893|DRUG|Teclistamab|Intravenous (IV) dosage and timing per protocol design
224195497|NCT05469893|DRUG|Lenalidomide|Oral, dosage and timing per protocol design
224195498|NCT05469893|DRUG|Dexamethasone|Oral, dosage and timing per protocol design
224195499|NCT00223990|BIOLOGICAL|FMP1/AS02A|FMP1/AS02A candidate malaria vaccine
224195500|NCT00223990|BIOLOGICAL|RabAvert|RabAvert rabies vaccine
224195501|NCT04998058|PROCEDURE|Maxillary sinus floor elevation grafting with synthetic bone substitute.|Bone augmentation at the floor of the maxillary sinus with bone substitutes.
224195502|NCT06934200|DRUG|Omalizumab|omalizumab injections
224195503|NCT06936982|OTHER|Sports Exercise|The exercise intervention program used a combination of moderate-intensity aerobic exercise and resistance exercise in the form of exercise day time: 9:00 a.m. to 10:30 a.m., in which 10min warm-up exercise after 45min aerobic exercise, each aerobic exercise 10-12min, with a rest in the middle of the rest 3-5min. resistance exercise was placed in the aerobic exercise after the resistance exercise, resistance exercise using 3 movements, 2 groups, each group 10 times. Each movement was performed 10 times, with a 3-min break between each movement in each group and a 5-min break between groups. 15-min stretching exercises were performed after the exercise. The RPE scale was examined during the exercise, and the subjects were asked about the RPE scale level at the end of every 10 min during the exercise.
224195504|NCT06936982|OTHER|control group|No intervention
224195505|NCT06943482|DRUG|Prednisolone|20mg of prednisolone will be prescribed, taken orally, and daily for first month followed by tapering doses of 15mg over one month, then 12.5mg for one month, proceeding to 10mg for one month, subsequently taking 7.5mg for one month, and lastly 5mg for one month.
224195506|NCT06943482|DRUG|Methotrexate|10mg of methotrexate will be prescribed to be taken once a week for one month. The dosage will be increased to 15mg of methotrexate taken once a week on the 1st (T1) month clinical visit and will be further increased to 20mg of methotrexate taken once a week on the 2nd (T2) month clinical visit. There will be no further escalation of dosage after this visit.
224195507|NCT06943482|DRUG|Folic Acid 5 MG|5mg of folic acid is to be taken together with methotrexate once a week.
224195508|NCT06943482|DRUG|Omeprazole 20 mg|Omeprazole will be prescribed at 20mg to protect the stomach lining.
224195509|NCT06942182|DRUG|Isomyosamine 250mg|Isomyosamine 250 mg capsules dosed 4 times daily
224195510|NCT06942182|DRUG|Placebo 250 mg|Placebo 250 mg capsule 4 times daily
224195511|NCT06943703|DRUG|Sclerotherapy with intralesional bleomycin injection|The intervention studied is intralesional Bleomycin injection, which involves the direct injection of Bleomycin, a chemotherapeutic agent, into the lymphangioma lesions. This minimally invasive procedure is aimed at reducing the size of the lymphangioma by disrupting the abnormal growth of lymphatic vessels. The dosage of Bleomycin is tailored based on the patient's body weight, typically ranging from 1 to 3 mg per kg of body weight per injection. The intervention is distinct from other treatments, such as surgical excision or other sclerotherapy agents, as it specifically utilizes Bleomycin's mechanism of action to induce tissue sclerosis and promote lesion regression without the need for invasive surgery. This intervention may require multiple treatment sessions, depending on the size, location of the lymphangioma, and individual's response to therapy, with the goal of achieving long-term effectiveness and improving cosmetic outcomes.
224195512|NCT06943092|DRUG|Piroxicam group|Experimental drug
224195513|NCT06943092|DRUG|Diclofenac group|Active drug
224195514|NCT06942845|OTHER|non-intervention|non-intervention
224195515|NCT06203067|BEHAVIORAL|Standard of Care|Quarterly clinic visits with endocrinology provider.
224195516|NCT06203067|BEHAVIORAL|Type 1 Together|In Type 1 Together, families will work with other families who have experience using CGM (Peer Mentors) to overcome common barriers to CGM use. Families in the Type 1 Together program will also have access to CGM-specific educational materials, a digital journal to facilitate patient-provider communication around issues with CGM, and social determinant of health screening and intervention with a diabetes community health worker.
223504451|NCT06388226|DEVICE|Leg sham therapy|A sous vide heating immersion circulator heats up the water inside the water tank to 33ºC. A water pump circulates temperature-regulated water through the trousers.
223504452|NCT00840853|GENETIC|CD19CAR/virus specific T cells|CD19CAR/virus specific T cells will be thawed and given by intravenous injection from day +30 post transplant.
223504453|NCT00840853|DRUG|Benadryl and Tylenol|Patients may be premedicated with Benadryl and Tylenol before receiving the injection of cells.
223504454|NCT02821793|OTHER|Consultation, evaluation questionnaire|Consultation, evaluation questionnaire
223504455|NCT02821793|OTHER|Geriatric consultation, evaluation questionnaire|Geriatric consultation, evaluation questionnaire
223504456|NCT02814019|DRUG|Idebenone 150 mg film-coated tablets|
223504457|NCT02814019|DRUG|placebo|
223504458|NCT01486394|OTHER|Focused Sonography of the heart, lungs and deep veins|The patient is randomised to either a control group where usual treatment and diagnostic work-up is performed or to an intervention group where usual treatment and diagnostic workup are supplemented by a sonographic examination of the heart, lungs and deep veins are performed within one hour after the primary evaluation. The primary evaluation is defined as the first evaluation of the patient by a physician in the Acute Medical Admission Department.
223504459|NCT00785941|BIOLOGICAL|IMC-A12|"Cohort 1~6 mg/kg I.V., once every other week for 4 weeks"
224195517|NCT06060314|PROCEDURE|Conservative Approach|Patients in Group A were treated conservatively i.e Splinting in neutral position of wrist for 6 wks min at night and during the day as preferred
224195518|NCT06060314|PROCEDURE|Surgical Approach|Patients in Group B were managed through surgical intervention i.e open carpal tunnel release (OCTR)
224195519|NCT02263118|OTHER|Uni-directional SMS|Exposure to breastfeeding promoting SMSs
224195520|NCT02263118|DEVICE|Feature phone|Participants were given a feature phone.
224195521|NCT02263118|OTHER|Virtual communities|Exposure to virtual community communication via SMS
224195522|NCT02263118|OTHER|Hybrid setup|Exposure to virtual community and access to communications with health professional via SMS
224195523|NCT06270537|DEVICE|Stent-Graft Dominus® Endoprosthesis|Placement of the Dominus® Stent-Graft for endovascular repair of diseases of the Thoracic Aorta
224195524|NCT05878600|OTHER|kendall's exercise|comparative effect of targeted cervical spine strengthening versus kendalls exercise will be analyzed
224195525|NCT05878600|OTHER|cervical spine strengthening|sole effect of cervical spine strengthening will be analyzed
224195526|NCT02204709|OTHER|2N Trout|Diploid/2N trout source
224195527|NCT02204709|OTHER|3N Trout|Triploid/3N trout source
224195528|NCT02204709|OTHER|Tilapia|Tilapia/control fish source
224195529|NCT05996601|BEHAVIORAL|Educational intervention|Educational materials would be given to all the participants. They would also be followed up by pharmacist.
224195530|NCT05732012|BEHAVIORAL|Sexual Health Psychoeducation Program|"62 adolescents were included in the study. Adolescents were assigned to intervention and control groups by randomization using simple numbers table. The intervention group was divided into 3 groups of 10 and included in a six-week psychoeducation program that lasted for one hour once a week, and 55 adolescents completed the program. The data on the sociodemographic characteristics of the adolescents constituting the sample were collected with the Participant Information Form. Data on the effectiveness of the psychoeducation program on sexual health knowledge and attitudes were collected with the Sexual Health Knowledge and Attitude Inventory before the psychoeducation, at the end of the training and at the 3rd month of follow-up."
224195531|NCT00887965|DRUG|Previous denosumab|Participants who had previously received denosumab received a transiliac crest bone biopsy performed following standard labeling procedures with tetracycline or tetracycline derivative.
224195532|NCT01726426|DIETARY_SUPPLEMENT|Probiotic|Each capsule Probiotics (Lactobacillus- 2 billion, Bifidobacterium- 1 billion, fructo-oligosaccharide): 1 capsule twice daily orally for 12 weeks
224195533|NCT04324957|OTHER|Neonatal cardio-pulmonary outcome measure used to assess cardio-pulmonary status|Neonatal cardio-pulmonary outcome measure will be used to assess overall status of pulmonaryand cardio-vascular system
224195534|NCT00928629|PROCEDURE|Ankle-brachial index (ABI) Screening Test|Patients will undergo an ABI measurement
224195535|NCT02130648|OTHER|A sampling of blood|A sampling of blood de 14 ml
224195536|NCT03352804|OTHER|Screening of MDR Bacteriae|questionnaire will be filled by every patient
224195537|NCT02674568|DRUG|Rovalpituzumab tesirine|Rovalpituzumab tesirine is a DLL3 targeted antibody drug conjugate (ADC).
224195538|NCT01077167|DRUG|Omecamtiv mecarbil|Oral dosing twice each day or three times each day, depending on the cohort assignment, of Omecamtiv mecarbil for 8 days. Omecamtiv mecarbil comes in 2 formulations: modified release and immediate release, and the formulation given will depend on the cohort assignment.
224195539|NCT01790139|DRUG|Oral simethicone|10 mL of simethicone is administered as an agent to prevent colonic bubbles
224195540|NCT06445517|DRUG|ISM8207|Pharmaceutical formulation: Capsules Mode of Administration: Oral
224195541|NCT03893279|BEHAVIORAL|Smell and Taste and questionnaire|The questionnaire must be completed before the antibiotic is taken, if a change of antibiotic is planned (stop of a treatment or addition of another treatment) and at the end of the antibiotic treatment.
224195542|NCT01655810|DIETARY_SUPPLEMENT|Vitamin D3|Multivitamin containing cholecalciferol 4000 units orally daily
224195543|NCT01655810|DIETARY_SUPPLEMENT|Vitamin D3|Multivitamin containing cholecalciferol 600 units orally daily
224195544|NCT01655810|DIETARY_SUPPLEMENT|Calcium carbonate|500 mg orally twice daily
224195545|NCT01019746|DRUG|propofol|propofol administration
223504460|NCT00785941|BIOLOGICAL|IMC-A12|"Cohort 2~10 mg/kg I.V., once every other week for 4 weeks"
223504461|NCT00785941|BIOLOGICAL|IMC-A12|"Cohort 3~15 mg/kg I.V., once every other week for 4 weeks"
224195546|NCT00457249|BIOLOGICAL|ADACEL®: Tetanus, Reduced Diphtheria and Acellular Pertussis Adsorbed|0.5 mL, IM
224195547|NCT00457249|BIOLOGICAL|DECAVAC®: Tetanus and Diphtheria Toxoids Adsorbed|0.5 mL, IM
224195548|NCT00396318|DRUG|tenecteplase|"2 mL of reconstituted lyophilized tenecteplase instilled into lumen of dysfunctional CVC.~Patients weighing ≥ 30 kg received 2-mL instillations of tenecteplase (i.e., 2 mg of tenecteplase). Patients weighing \< 30 kg received instillations of tenecteplase equal to 110% of the internal lumen volume of the dysfunctional CVC. This dose was rounded to the nearest 0.1 mL and should not have exceeded 2 mL (2 mg)."
223504462|NCT00785941|BIOLOGICAL|IMC-A12|"Cohort 4~21 mg/kg I.V., once every other week for 4 weeks"
223504463|NCT00785941|BIOLOGICAL|IMC-A12|"Cohort 5~27 mg/kg I.V., once every other week for 4 weeks"
223504464|NCT06245707|DRUG|prednisone,methylprednisone and cyclophosphamide|In the first month, methylprednisolone 500mg/d was given intravenously for 3 days, and then prednisone 0.5 mg/(kg d) \* for 27 days. Oral cyclophosphamide 2.0 mg/(kg d) \* 30 days in the second month. After that, the first month and the second month plan were repeated twice.
223504465|NCT06245707|DRUG|Rituximab|The dosage of rituximab depends on peripheral blood B cells. After the treatment of rituximab, the peripheral blood B cells were in a clear state and then stopped. After monitoring the recovery of B cells, additional doses were given.
223504466|NCT01666314|DRUG|Orteronel|Orteronel tablets
223593204|NCT00629811|DRUG|Avotermin (Juvista)|"Intradermal avotermin administered to four wound sites per subject, one wound site per anatomically matched pair, according to the subject's assigned dose group:~* Group 1: avotermin concentrations of 5, 50, 200 and 500ng per 100μL per linear cm of wound site (pre-wounding, Day 0) and 100μL per linear cm of wound margin (post-wounding, Day 1)~* Group 2: avotermin concentrations of 5, 50, 200 and 500ng per 100μL per linear cm of wound site (pre-wounding, Day 0) and 100μL per linear cm of wound margin (post-wounding, Day 0)~Each subject received four doses of active drug at concentrations of 5, 50, 200 and 500ng per 100μL per linear cm of wound site, one dose to one wound site per anatomically matched pair of wounds."
223593205|NCT00629811|DRUG|Placebo|"Reference therapy was Placebo (vehicle). On Day 0, the four sites randomised to receive Placebo were administered with a 100μL intradermal injection of Placebo.~Subjects in Group 2 were dosed again on Day 0 at 10 to 30 minutes after wound closure.~Subjects in Group 1 were dosed again on Day 1 at 24 (+/-4) hours after initial administration of drug."
224195549|NCT01735136|DIETARY_SUPPLEMENT|InSan Bamboo Salt|InSan Bamboo Salt (10g/day)
224195550|NCT01735136|DIETARY_SUPPLEMENT|Placebo|Placebo (10g/day)
224195551|NCT03693235|PROCEDURE|bending angle of a lightwand|For tracheal intubation, investigators will bend the tracheal tube combined a lightwand by assigned angles (70, 80, or 90 degrees) for each patient. Next a practitioner will perform tracheal intubation with the bent tube.
224195552|NCT04598815|DRUG|Sirolimus|"Group Sirolimus: Patients will receive a first dose of Sirolimus of one 2 mg tablet on the first day, given approximately at 10 am, followed by 0.5 mg tablet per day for 12 weeks.~Group Methylprednisolone: Methylprednisolone pulse therapy will be administered for 12 weeks as follows: 500 mg iv once weekly for 6 weeks, then 250 mg iv once weekly for a further 6 weeks, for a cumulative dose 4.5 g."
224195553|NCT00000847|BIOLOGICAL|ALVAC-HIV MN120TMG (vCP205)|
223593206|NCT04924517|BEHAVIORAL|Extended Evening Fasting|Participants will undertake 4 days of extended evening fasting (feeding between 8am-4pm). The participants will visit the laboratory on day 1, following a 16 h fast, where baseline measures will be taken and the response to a standardised meal will take place. The participant will also have an opportunity to feed ad-libitum before they leave the laboratory. The participant will continue to adhere to the feeding window on day 2 and day 3, although this will be in free-living conditions. On day 4, the participant will arrive back to the lab for post-intervention assessment, identical in format to day 1 with a metabolic assessment and energy intake assessment via a ad-libitum meal.
223593207|NCT04924517|BEHAVIORAL|Control|Participants will undertake 4 days of a standard western feeding pattern (feeding between 8am-8pm). The participants will visit the laboratory on day 1, following a 12 h fast, where baseline measures will be taken and the response to a standardised meal will take place. The participant will also have an opportunity to feed ad-libitum before they leave the laboratory. The participant will continue to adhere to the feeding window on day 2 and day 3, although this will be in free-living conditions. On day 4, the participant will arrive back to the lab for post-intervention assessment, identical in format to day 1 with a metabolic assessment and energy intake assessment via a ad-libitum meal.
223593208|NCT03876119|DRUG|Intraarterial alteplase|See arm/group descriptions.
223593209|NCT03876119|DRUG|Placebo|See arm/group descriptions.
223593210|NCT05979922|BEHAVIORAL|Mindfulness-based Cognitive Coping|Participants will receive the Caring Mind mobile app containing the Mindfulness-based Cognitive Coping program.
223593211|NCT05979922|BEHAVIORAL|Traditional Educational/Resources Program|Participants will receive a traditional educational/resources program, containing a downloadable workbook and online resources.
223593212|NCT02191332|DRUG|Viramune|
223593213|NCT05307809|OTHER|Blood sample collection|Blood sample collection
223593214|NCT05307809|OTHER|Skin sample collection|Skin sample collection
223593215|NCT04512976|OTHER|Control (no cooling modalities)|Subjects will exercise for 60 minutes in the indicated environmental condition while being exposed to no cooling modality.
223593216|NCT04512976|OTHER|Water Spray Only|"Subjects will exercise for 60 minutes in the indicated environmental condition while being exposed to the skin wetting modality.~Skin wetting will be performed by spraying water onto the skin throughout the exercise bout."
223593217|NCT04512976|OTHER|Fan Only|"Subjects will exercise for 60 minutes in the indicated environmental condition while being exposed to the fan cooling modality.~The fan will be a commercially available fan will be directed to the research subject throughout the exercise bout."
223593218|NCT04512976|OTHER|Water Spray and Fan|"Subjects will exercise for 60 minutes in the indicated environmental condition while being exposed to both the skin wetting and fan cooling modalities.~The fan will be a commercially available fan will be directed to the research subject throughout the exercise bout.~Skin wetting will be performed by spraying water onto the skin throughout the exercise bout."
224195554|NCT00000847|BIOLOGICAL|ALVAC-RG Rabies Glycoprotein (vCP65)|
224195555|NCT00000847|BIOLOGICAL|rgp120/HIV-1 SF-2|
224195556|NCT00152594|DRUG|voriconazole|
224195557|NCT01802762|DEVICE|NeMo Patch and NeMo Probe|A plaster based patch (NeMo Patch) and a combined probe for ICP monitoring and near infrared spectroscopy (NIRS) are applied as sensors. Data are collected by a NIRS instrument (NeMo Control Unit)
224195558|NCT05653648|DIETARY_SUPPLEMENT|Potato starch|Participants will consume 24 grams (days 1-15) and 48 grams (days 16-30) of potato starch. Potato starch is a type 2 resistant starch that is available over the counter.
224195559|NCT03833531|BEHAVIORAL|ImRS|ImRs is a PTSD treatment that specifically addresses the troubling memories of the traumatic event and the personal meaning of the event and consist of 12 to 18 sessions in maximum 6 months.
224195560|NCT03833531|BEHAVIORAL|SFT|SFT is a treatment for personality disorders that takes at least one group-session per week, for the duration of one year.
224195561|NCT03879759|DRUG|NAC 2400mg/day|2400mg/day 2 x 600mg b.d
224195562|NCT03879759|DRUG|Placebo|4 matched placebo tablets/day
224195563|NCT00036556|DRUG|Atrasentan|
224195564|NCT00144859|DRUG|SB681323|
223593219|NCT00527982|DRUG|Celecoxib|600 mg by mouth daily for a total of 12 months.
223593220|NCT00771524|DRUG|Ceftobiprole|Ceftobiprole, 500 mg single 2 hour infusion prior to hip replacement surgery
223593221|NCT00003711|DRUG|irinotecan hydrochloride|
223593222|NCT00003711|DRUG|pemetrexed disodium|
223593223|NCT00789672|DRUG|levodopa/carbidopa|Oral levodopa 0.76 mg/kg tid with carbidopa 0.17 mg/kg tid (approximately 4.5 to 1 formulation)
223593224|NCT00789672|DEVICE|patching|2 hours daily patching
223593225|NCT00789672|DRUG|levodopa/carbidopa|Oral levodopa 0.51mg/kg tid with carbidopa 0.17 mg/kg tid (3 to 1 formulation)
223593226|NCT04473664|DRUG|Quizartinib|Single oral dose, 30 mg tablet
224195565|NCT02916056|DRUG|Azeliragon 5mg|
224195566|NCT00124709|DRUG|Pimecrolimus|Pimecrolimus cream 1 %
224195567|NCT00124709|DRUG|Corticosteroid|conventional corticosteroid-based treatment
224195568|NCT00122954|DRUG|Fish oil concentrate|fish oil concentrate at a daily dose of 6 grams (2.1 gram EPA and 1.5 gram DHA).
224195569|NCT00122954|DRUG|Placebo|soybean oil with 1% fish oil at a daily dose of 6 grams
224195570|NCT03299439|OTHER|acupuncture|a stimulation of the body or auricular points
224195571|NCT04014413|PROCEDURE|Fecal Microbiota Transplantation|Fecal microbiota transplantation
224195572|NCT05879692|PROCEDURE|focused ultrasound|"focused ultra sound cavitation using a device of Mabel6 DUO Ultra Cavitation Technology system produced by DAEYANG MEDICAL COMPANY, KOREA will be applied on the abdominal region which extending bilaterally from the line extending from mid axilla to iliac crest, and above from center of diaphragm to the line extending between two iliac crest below.~the session of Focused Ultra Sound will take 25- 30 minutes, twice/week and with about three day intervals for 12 weeks."
224195573|NCT05879692|BEHAVIORAL|Low Caloric Diet (LCD) and a low (FODMAPs) diet|"The Low caloric diet (LCD) diet will be an equilibrated diet that had a caloric value 10% below the total metabolic expenditure (total energy expenditure) of each individual.~The low FODMAPs diet (LFD) is a diet low in fermentable oligo-, di-, mono- saccharides and polyols (FODMAPs)."
224195574|NCT05879692|OTHER|aerobic exercise|aerobic exercise program under direct supervision at a frequency of 3 times/week for 12 weeks, in the form of walking on a treadmill for 30 minutes with moderate intensity (12-14) according to The Borg Rating of Perceived Exertion (RPE) scale.
223593227|NCT05216471|RADIATION|chest X-ray|Chest Xray : postero-anterior view ,digital high resolution X-ray or ,full inspiratory
223593228|NCT05977829|DIAGNOSTIC_TEST|Ultrasound|Transvaginal ultrasound to carry out uterine surveillance
223593229|NCT05977829|DIAGNOSTIC_TEST|Hysteroscopy|Outpatient hysteroscopy to carry out uterine surveillance
223593230|NCT03392649|DEVICE|Parasym|Tragus stimulation was done using the Parasym device.
223593231|NCT01289054|DRUG|Tasigna|
223593232|NCT01289054|DRUG|Gleevec|
223593233|NCT03118089|DIETARY_SUPPLEMENT|Biscuit style oral nutritional supplement|
223593234|NCT03636646|DEVICE|X.ray|Surgical treatement of posterior acetabular wall fractures
223593235|NCT00437411|BEHAVIORAL|Affective Self-Awareness workshop|Affective Self Awareness intervention: 90 minute face-to-face consultation with the treating physician, then three 2-hour weekly small-group workshops involving education regarding Mind-Body connections, written emotional expression, meditation, and self-affirmation practices.
223593236|NCT01320592|DRUG|PD0332991|
223593237|NCT01320592|DRUG|Paclitaxel|
223593238|NCT03408184|DRUG|Lumbar paravertebral group|A mixture of 0.5 ml /kg bupivacaine (0.25%), and 0.5µg/Kg dexmedetomidine and Epinephrine 5 microgram/ ml.
223593239|NCT03408184|DRUG|The field block group|A mixture of 0.5 ml /kg bupivacaine (0.25%), and 0.5µg/Kg dexmedetomidine and Epinephrine 5 microgram/ ml.
223593240|NCT00122174|BEHAVIORAL|Stress Busting Program for family caregivers|
223593241|NCT05025878|DIETARY_SUPPLEMENT|[U-13C]Glucose|Patients are intravenously infused with 28g of \[U-13C\]glucose over a 5 hour period. Briefly, \[U-13C\]glucose will be provided by intravenous line containing 8g of \[U-13C\]glucose in 60 mL over 10 min. After 10 minutes, 4g of \[U-13C\]glucose will be administered over an hour. This process will continue until the patient's ascites is drained, or after 5 hours. We will monitor blood glucose levels during infusions using a continuous glucose monitor.
223593242|NCT00753454|DRUG|Certolizumab pegol|Liquid certolizumab pegol administered every two weeks as a single injection (400 mg at Entry, Week 2 \& Week 4, followed by 200 mg every 2 weeks).
223593243|NCT00614848|DEVICE|Endeavor drug eluting coronary stent|Zotarolimus coated coronary stent (10ug/mm)
223593244|NCT06321770|DIETARY_SUPPLEMENT|Bioactive collagen peptides|2,5 g collagen peptides
223593245|NCT06321770|DIETARY_SUPPLEMENT|Placebo|Placebo sachet daily
223593246|NCT06346522|DRUG|Gabapentin (Gaptin ®) 400mg oral capsule once|After the patient will regain feeding, the patients will take with sips of water Gabapentin (Gaptin ®) 400mg oral capsule once in the first 24 hour after icu admission
224195575|NCT00817427|OTHER|Controls Short sleep|Healthy control subject's bedtime will be decreased by 2 hours/night with acoustic sleep disruption
223593247|NCT06346522|DRUG|Trospium chloride slow release (Trospikan ® SR) 60mg oral capsule|After the patient will regain feeding, the patients will take with sips of water Trospium chloride slow release (Trospikan ® SR) 60mg oral capsule once in the first 24 hour after icu admission
223593248|NCT01982461|DRUG|Rosuvastatin|10mg,once daily
224195576|NCT00817427|OTHER|CKD- sleep extension|Sleep will be increased by 2 hours each night for 3 nights
223593249|NCT01982461|DRUG|Crestor®|10mg,once daily
223593250|NCT03927144|DRUG|AMG334|Subcutaneous Injection
223593251|NCT03927144|DRUG|Oral Prophylactic|SOC Oral Tablet/Capsule
223593252|NCT04084847|DIETARY_SUPPLEMENT|berberis vulgaris=barberry|10 grams of barberry powder will be consumed daily for 8 weeks.
223593253|NCT04084847|DIETARY_SUPPLEMENT|Placebo|Placebo powder
223593254|NCT06339931|OTHER|SMWLM combined Spinal traction with belt|Group A, therapist 1 will stand at the participant's ventral side and apply a transverse glide with the thumb on the involved lumbar spinous process. Therapist 2 will then abduct the affected leg by 10° and take the limb gently into hip flexion with the knee extended, while the glide will be sustained continuously by Therapist. Wrap the traction belt around both your hips and the proximal aspect of the patient's thighs.Apply traction by leaning backward and shifting your body weight onto your posterior leg.
223593255|NCT06339931|OTHER|SMWLM combined spinal traction without belt|Group B, therapist 1 will stand at the participant's ventral side and apply a transverse glide with the thumb on the involved lumbar spinous process. Therapist 2 will then abduct the affected leg by 10° and take the limb gently into hip flexion with the knee extended, while the glide will be sustained continuously by Therapist. Manual traction is applied by placing the patient over a rolled pillow while lying sideways. The roll should be 6-8 inches in diameter and should be placed at the level of the spine where the traction or separation is to occur. Pull the patient's legs toward you as you lean your body backward to apply a traction force.
223593256|NCT03858530|DIAGNOSTIC_TEST|Ultrasound Examination|Grayscale ultrasound, Doppler ultrasound, ultrasound elastography with or without ultrasound intravenous contrast will be performed.
223593257|NCT01463072|OTHER|Laboratory Biomarker Analysis|Correlative studies
223593258|NCT01463072|DRUG|Nab-paclitaxel|Given IV
223593259|NCT01463072|OTHER|Questionnaire Administration|Ancillary studies
223593260|NCT06962800|DRUG|Felzartamab|Administered intravenously
223593261|NCT06962800|DRUG|Tacrolimus|Administered orally
223593262|NCT06962800|DRUG|Standard of Care IST|Administered intravenously and orally
223593263|NCT00756782|DRUG|TAC-101|Patients will receive TAC-101 20 mg (2 x 10-mg formulated tablets) administered orally every day with approximately 8 oz. water within 1 hour following a morning meal for 14 days followed by a 7-day recovery period, repeated every 21 days.
223593264|NCT00756782|DRUG|Placebo|Patients will receive placebo (two matching tablets) at same frequency and duration of active treatment
223593265|NCT03829722|DRUG|Nivolumab|Given intravenously (IV), 240 mg every 2 weeks for 4 doses concurrent with radiation therapy (RT). Following completion of RT, 480 mg given every 4 weeks for 4 doses.
223593266|NCT03829722|DRUG|Carboplatin|Given IV once per week during radiation therapy (AUC=1).
223593267|NCT03829722|DRUG|Paclitaxel|Given IV once per week during radiation therapy (30mg/m\^2)
223593268|NCT03829722|RADIATION|Radiation Therapy|Given 5 days/week for a total of 35 doses (70 gray total).
223593269|NCT01836328|DRUG|Parenteral /oral methadone ratio 1:2|"See arm/group descriptions"
224195577|NCT01728376|DRUG|Daptomycin|Intravenous daptomycin given at 7 mg/kg (ages 12-17 years); 9 mg/kg (ages 7-11 years); 12 mg/kg (ages 1-6 years) infused once daily, intravenously, over 30 or 60 minutes. Participants may be switched to oral therapy following completion of IV study drug administration provided they showed clear clinical improvement and the pathogen was susceptible to an oral agent.
224195578|NCT01728376|DRUG|Comparator|Vancomycin, Semi-synthetic penicillin, First-generation cephalosporins, Clindamycin: administered per standard of care. Participants may be switched to oral therapy following completion of IV study drug administration provided they showed clear clinical improvement and the pathogen was susceptible to an oral agent.
224195579|NCT00626574|DRUG|Epoetin alfa|Intravenous administration of epoetin alfa (40,000 IU) immediately before clipping surgery. Successive doses will be given 24 and 48 hours after the first dose.
224195580|NCT00626574|DRUG|Saline|3ml of saline will be administered via an IV push immediately before clipping surgery. Successive doses will be given 24 and 48 hours after the first dose.
224195581|NCT03302130|BEHAVIORAL|Mood induction (using own memories)|Subjects deliver three positive, three negative and three neutral memories 30 seconds reliving a memory - answering questions about the memory - reliving memory for 2 minutes during ASL-MRI
223504467|NCT01666314|DRUG|Orteronel Placebo|Orteronel placebo-matching tablets
223504468|NCT01666314|DRUG|Prednisone|Prednisone 5 mg
223504469|NCT00513630|DRUG|Glipizide|
223504470|NCT00513630|DRUG|Metformin|
223504471|NCT01386177|DRUG|3,4-Methylenedioxymethamphetamine|125 mg per os, single dose
223504472|NCT01386177|DRUG|Doxazosin|"3 days (-64h) before MDMA: 4 mg doxazosin per os. 2 days (-40h) before MDMA: 8 mg doxazosin per os.~1 day (-16h) before MDMA: 8 mg doxazosin per os."
223504473|NCT01386177|DRUG|placebo|capsules identical to MDMA or doxazosin
223504474|NCT00167947|DRUG|Cyclosporine|"Arm 1= Rapamune+ low dose Cyclosporine+steroids Arm 2= 1° day rapamune 15 mg/die + steroids 2°-7° day Rapamune 5mg/die + steroids In both arms, Cylcoporine is stopped "
223504475|NCT00167947|DRUG|Steroids|"Arm 1= Rapamune+ low dose Cyclosporine+steroids Arm 2= 1° day rapamune 15 mg/die + steroids 2°-7° day Rapamune 5mg/die + steroids In both arms, Cylcoporine is stopped "
223504476|NCT00167947|DRUG|Rapamune (Sirolimus)|"Arm 1= Rapamune+ low dose Cyclosporine+steroids Arm 2= 1° day rapamune 15 mg/die + steroids 2°-7° day Rapamune 5mg/die + steroids In both arms, Cylcoporine is stopped "
223504477|NCT05879172|DEVICE|electric tubular anastomotic device|"The electric tubular anastomotic device developed by Suzhou Yingtukang Medical Technology Co., Ltd. is used for colorectal end-to-end and end-to-side anastomosis. This product is suitable for open or minimally invasive colorectal cancer surgery.~Before firing the device, tissue thickness should be carefully assessed to prevent poor staling leading to leakage, inadequate hemostasis, or poor treatment."
223504478|NCT05879172|DEVICE|traditional anastomotic device|Traditional anastomosis is used in this group. Staplers of the same brand are uniformly adopted to avoid differences between groups caused by different brands.
223504479|NCT06183528|PROCEDURE|Pericapsular Nerve Group (PENG) Block|With ultrasonography-guided PENG block, the femoral, obturator and accessory obturator nerve branches that provide sensory innervation of the anterior surface of the hip joint capsule are blocked .
223504480|NCT00309179|DRUG|E7820 plus cetuximab|Escalating doses from 40 mg/m\^2 irinotecan plus E7820 in combination with cetuximab.
223504481|NCT00652041|DRUG|Bortezomib|Bortezomib, 1,3 mg/ m2 iv twice a week in combination with Melfalán 9 mg/m2 oral, days 1 to 4 and Prednisone, 60 mg/m2 oral, days 1 to 4
223504482|NCT00652041|DRUG|Thalidomide|Thalidomide, day 1 cycle 1, 100 mg/24 h. oral, in combination with cyclophosphamide and dexamethasone. If toxicity is \<Grade 2, dose should be increased to 200 mg/24 h. in day 15
223504483|NCT00652041|DRUG|Bortezomib|Bortezomib, 1,3 mg/ m2 iv twice a week in combination with Melfalán 9 mg/m2 oral, days 1 to 4, Prednisone, 60 mg/m2 oral, days 1 to 4 and Adriamicine, 40 mg/m2 IV day 1 or Caelyx 30 mg/m2 IV day 1.
223504484|NCT01076933|PROCEDURE|repetitive Transcranial Stimulation Magnetic (rTMS)|The motor threshold was determined in each subject once, before treatment. This was defined as the lowest stimulation intensity capable of inducing a visible movement at least five times out of 10 stimulations. The position of the right dorsolateral prefrontal cortex was defined as 5 cm anterior (in a parasagittal line) to the motor cortex. The stimulus intensity was 80% of the patient's motor threshold intensity. Treatments were given for 20 minutes per day over 10 working days.
223504485|NCT01076933|PROCEDURE|sham rTMS|sham rTMS
223504486|NCT04279600|DIETARY_SUPPLEMENT|Taurine|Taurine supplementation in capsules of 1 gram of taurine powder, total dosage: 3 grams/day
223504487|NCT04279600|DIETARY_SUPPLEMENT|Placebo|Placebo supplementation in capsules of 1 gram of starch powder, total dosage: 3 grams/day
223504488|NCT04279600|OTHER|Exercise training|4 weeks of combined exercise training (alternating strength and aerobic exercise), with a frequency of 3 times/week with 55 min/day.
223504489|NCT06128239|BEHAVIORAL|Caring Contacts|Text message version of Motto's Caring Contacts intervention. The study will compare two versions of text-based Caring Contacts: two-way messages, to which participants can respond to receive text-based support from follow-up specialists, and one-way text messages, to which participants cannot respond.
223504490|NCT05423600|PROCEDURE|BES + TS|Blood Flow Restriction Enhanced Neuromuscular Electrical Stimulation (BES) treatment plus transspinal stimulation (TS) plus repetitive practice of task-specific activities, also known as massed practice (MP)
223504491|NCT05423600|PROCEDURE|Experimental: BES+sham TS|Blood Flow Restriction Enhanced Neuromuscular Electrical Stimulation (BES) sham treatment plus transspinal stimulation (TS) plus repetitive practice of task-specific activities, also known as massed practice (MP)
223504492|NCT04230304|BIOLOGICAL|Daratumumab|Given IV
223504493|NCT04230304|DRUG|Ibrutinib|Given PO
223504494|NCT06230770|BEHAVIORAL|Bleeding data|Participants will report their daily bleeding patterns
223504495|NCT05230407|OTHER|Visual analog scale (VAS) assesment of pain|Post operation VAS score will be assessed before discharge from hospital and 24 hours post operation
223504496|NCT05521698|DRUG|Apalutamide|Given PO
223504497|NCT05521698|PROCEDURE|Biopsy Procedure|Undergo tumor biopsy
223504498|NCT05521698|PROCEDURE|Biospecimen Collection|Undergo blood and urine sample collection
223504499|NCT05521698|DRUG|Placebo Administration|Given PO
223504500|NCT05521698|OTHER|Questionnaire Administration|Ancillary studies
224195582|NCT03302130|DEVICE|Arterial spin labeling MRI|Single PLD PCASL
224195583|NCT03302130|DEVICE|Physiological monitoring|During MRI: heart rate, end-tidal CO2, respiratory rate and skin conductance
224195584|NCT05726110|DRUG|Selinexor|Given PO
224195585|NCT05726110|DRUG|Homoharringtonine|Given per standard of care
224195586|NCT05726110|DRUG|Daunorubicin|Given per standard of care
224195587|NCT05726110|DRUG|Cytarabine|Given per standard of care
224195588|NCT05726110|DRUG|Granulocyte Colony-Stimulating Factor|Given per standard of care
224195589|NCT05726110|DRUG|Aclacinomycin|Given per standard of care
224195590|NCT04462354|PROCEDURE|Blumgart Anastomosis|Patients undergoing cephalic duodenopancreatectomy, reconstructing pancreatic-enteric communication by Blumgart anastomosis
224195591|NCT04462354|PROCEDURE|Pancreatogastric anastomosis.|Patients undergoing cephalic duodenopancreatectomy, reconstructing pancreatic-enteric communication by Pancreatogastric anastomosis.
224310514|NCT03150823|PROCEDURE|Downward Direct Current (Descending Effect)|Application of direct current (Galvanic) in milliamperes current which varies according to the positioning of the electrodes. In the descending stream direct current (Descending effect) the proximal anode and distal cathode are placed, a sedative and analgesic effect on the nervous system being described in theory.
223593270|NCT01836328|DRUG|Parenteral /oral methadone ratio 1:1.2|"See arm/group descriptions"
224195594|NCT06214065|DIAGNOSTIC_TEST|fMRI|fMRI will be performed pre- and post-rTMS
224195595|NCT06214065|DEVICE|rTMS|TMS procedures are scheduled during study sessions 2-4 between the two MRI scans on those days. Because rTMS induces neural changes that last about 1 hour, rTMS will be applied immediately before the second MRI scan on each day. Prior to the TMS visits, target coordinates and orientation vectors will be generated from the MRI data and the e-field models and loaded into Localite along with the participant's reconstructed T1 image. During the visits, the participant's head will be co-registered to the T1 using fiducial points at the Nasion and Tragi. TMS pulses will be delivered, using the Localite software to target and track the optimal orientation calculated with e-field modeling.
224195596|NCT00526162|DEVICE|Bi-ventricular Implantable Cardioverter Defibrillator|Implantation of a Bi-ventricular Implantable Cardioverter Defibrillator
224195597|NCT05842330|DRUG|Concerta|"Dosages of Concerta® will be defined according to the Swiss Compendium (from 18 to 72 mg/d).~The psychiatrist will start with the smallest dosage (18 mg) and will adapt it on a weekly basis or on need, depending on tolerance (side effects measured at each visit), clinical response (subjective improvement felt by the patient in terms of attention, impulsivity, and hyperactivity), and according to the observations made by the professionals or patient's entourage in term of attention, impulsivity, hyperactivity, and for this project, behavioral problems. In general, the dose can be increased in 18 mg at weekly intervals.~The treatment will be monitored weekly the first month, and then monthly, except for side effects which will be monitored daily in prison and every two weeks after release."
224195598|NCT05842330|DRUG|Placebo|"The placebo will be strictly identical (same packaging, size no. 2 and color according to dosage, with no label).~Procedure for adjustment of dosage will be the same as in the Concerta arm."
224195599|NCT05465330|DRUG|Desflurane|After induction, anesthesia will be maintained with 0.7-1.0 MAC desflurane and remifentanil 0.05-0.2 μg/kg/min
224195600|NCT05465330|DRUG|Desflurane, Propofol|After induction, anesthesia will be maintained with 0.5 MAC desflurane, propofol 1.5-2.5 μg/ml and remifentanil 0.05-0.2 μg/kg/min
224310515|NCT03150823|PROCEDURE|Sham Direct Current|Installation of electrotherapy equipment off (Sham tratment).
223504501|NCT05521698|PROCEDURE|Transurethral Resection of Bladder Tumor|Undergo TURBT
223504502|NCT06585072|DIAGNOSTIC_TEST|All enrolled subjects completed dynamic blood glucose monitoring to obtain continuous peripheral blood glucose data.|All enrolled subjects completed dynamic blood glucose monitoring to obtain continuous peripheral blood glucose data.
223504503|NCT06028230|DRUG|SAR444656 (KT-474)|Oral Tablet
224310516|NCT05534308|PROCEDURE|Transoperative taping|The intervention group (IG) will be composed of patients undergoing phleboextraction with saphenectomy and intervention with contensive taping, on intraoperative period associated with compression with elastic stockings.
224310517|NCT05534308|OTHER|No trasoperative taping|Patients will received only compression stockings after surgery
223504504|NCT06028230|DRUG|Placebo|Oral Tablet
223504505|NCT06347588|OTHER|Observational: Blood sample of HVB-specific Elispot assay, HBSAg, HBV-DNA|Blood sample at baseline, week 4, month 3, 6, 9,12.
223504506|NCT00435721|BEHAVIORAL|Psychoeducation|
223504507|NCT06470906|DIETARY_SUPPLEMENT|Probiotic Group|The intervention is a mixture of two probiotics: 1) Lactobacillus acidophilus GLA-14 and 2) Lactobacillus rhamnosus HN001. These products will be combined into a single capsule/sachet with a dose of approximately 10\^10 colony forming units (CFUs) of GLA-14 (ATCC SD5212) and HN001 (ATCC SD5675) in a 4:1 ratio, using similar doses as recent studies using this product.
223504508|NCT06470906|DIETARY_SUPPLEMENT|Placebo Group|The placebo will of be Maltodextrin, a carbohydrate, packaged similarly to the intervention and having the same weight.
223504509|NCT06462573|DRUG|locally infilterating anaethesia like lidocaine|which patients will undergo ESWL under locally infiltrated anaesthetic. Using ultrasound guidance, the quadratus lumborum muscle will be identified. Then a mixture of 0.5 % bupivacaine (10 ml) and 2 % lidocaine (10 ml) will be injected into the muscle as a single shot 20 minutes before the procedure.
223504510|NCT06462573|DRUG|general anaethesia|"which patients will undergo ESWL under systemic analgesia. The latter will be achieved using one gram of paracetamol IV infusion at the beginning of the procedure.~In case of unsatisfactory pain control in either group, systemic analgesia using IV Ketorolac injection will be used on demand or the required dose will be recorded at the end of the session."
223504511|NCT06786234|DRUG|STP938|At enrolment all patients will be assigned to a single dose level of STP938 for 4 weeks. After 4 weeks the dose level may be adjusted as needed by the Investigator.
223593271|NCT03240159|DRUG|Degarelix|"Degarelix 24mg Degarelix 16mg Degarelix 12mg~Active Comparator:~Down regulation of LH, during exposing in three different doses of Degarelix"
224195601|NCT04461678|DIAGNOSTIC_TEST|HPV Genotyping Nucleic Acid Assay Kit|The total sample size of screening population is approximately 12,000 cases (all females ≥ 21 years of age). Two cervical cytology samples will be collected from each subject with a tube of SurePath sample followed by a tube of PreservCyt sample. The 1st tube of SurePath liquid-based cytology sample is used for cytology test and BD Onclarity Assay HPV detection. Subjects with cytology test results ≥ ASCUS or positive HPV test results will be suggested to return for baseline colposcopy within approximately 12 weeks.
224195602|NCT05344417|PROCEDURE|Pneumoperitoneum Pressure|"Low Pneumoperitoneum Pressure: defined as an intrabdominal pressure between 8-12 mmHg during the laparoscopic procedure.~High Pneumoperitoneum pressure: defined as an intrabdominal pressure of 15 mmHg or more during the laparoscopic procedure.~Note: surgeons will set the pneumoperitoneum at the lowest value they are comfortable with based on their surgical criteria"
224195603|NCT05344417|PROCEDURE|Neuromuscular blockade|"Moderate neuromuscular blockade: defined as the presence of 1 or 2 responses after train-of-four stimulation.~Deep neuromuscular blockade: defined as no response to train-of-four stimulation and 1 or less responses after post-tetanic count stimulation."
224195604|NCT05344417|DEVICE|Pneumoperitoneum insufflation device|"AirSeal® device or Olympus standard of care insufflation device. Both devices are approved for use in laparoscopic gastrointestinal surgeries."
224195605|NCT05344417|DRUG|Neuromuscular blockade reversal|"Neostigmine: for Arm 1 only (standard use).~Sugammadex: will be used for the other arms in the study.~All drugs used in our randomized trial (neuromuscular blockade with rocuronium and reversal with neostigmine or sugammadex) are standard of care and approved for use by our institutional Institutional Review Board (IRB) Ethics Committee for this trial."
224195606|NCT05443659|DEVICE|Nerivio|Remote electrical neuromodulation (REN) device for the acute treatment of migraines. The device delivers transcutaneous electrical stimulation to the upper arm to induce conditioned pain modulation(CPM) that activates a descending endogenous analgesic mechanism. The treatment is self-administered and controlled by a smartphone application.
224195607|NCT05283226|DRUG|NRC-2694-A|300 mg orally once daily
224195608|NCT05283226|DRUG|Paclitaxel|175 mg/m² IV infusion over approximately 3 hours
224195609|NCT04211376|OTHER|No Intervention|There is no intervention for this study
224195610|NCT04695210|BEHAVIORAL|Virtual peer-to-peer support|See arm description
224195611|NCT06164301|DIETARY_SUPPLEMENT|Elemental amino-acids|mono peptide oral protein formula
224195612|NCT05963217|BIOLOGICAL|TBI-2001|"Phase-I portion:~cohort 1: 3×10\^5 cells/kg, cohort 2: 1×10\^6 cells/kg, cohort 3: 3×10\^6 cells/kg). Phase-Ib portion: The dose of Phase-Ib will be determined during the phase I portion."
223504512|NCT05573035|BIOLOGICAL|LYL845|LYL845 is an autologous tumor infiltrating lymphocyte (TIL) enhanced via Epi-R, a proprietary epigenetic reprogramming technology
223504513|NCT04761120|DEVICE|Abbott SJM Rigid Saddle Ring|The Abbott SJM Rigid Saddle Ring is a rigid, polyester-velour-covered, titanium alloy mitral annuloplasty ring with a saddle shape intended to mimic the shape of a healthy mitral annulus during systole.
223504514|NCT04761120|DEVICE|Abbott SJM Séguin Ring|The Abbott SJM Séguin Ring is a semi-rigid, polyester-velour-covered, polyethylene mitral annuloplasty ring that varies in thickness and flexibility over its circumference, with the posterior portion of the ring having greater flexibility than the anterior portion.
223504515|NCT04761120|DEVICE|Abbott SJM Tailor Ring|The Abbott SJM Tailor Ring is a flexible, polyester-velour-covered, silicone annuloplasty ring indicated for use in surgical repair of the mitral or tricuspid valve. The Tailor Ring can be implanted as a full annuloplasty ring, or the surgeon can remove the ring's cut zone with a scalpel and use the partial Tailor Ring as a posterior annuloplasty band.
224195613|NCT05963217|DRUG|Cyclophosphamide|IV Cyclophosphamide (for 3 days) will be administered as conditioning before cell infusion with TBI-2001.
224195614|NCT05963217|DRUG|Fludarabine|IV Fludarabine (for 3 days) will be administered as conditioning before cell infusion with TBI-2001.
224195615|NCT01617343|BEHAVIORAL|hemifield eye patching (HEP) + optokinetic stimulation (OKS)|"Patients in this arm will wear standard spectacle frames containing noncorrective lenses to which right half-field patches are attached (hemifield eye patching, HEP). In case of patients already wearing prescribed glasses, the patches will be attached to their own glasses. The glasses will be worn all-day for the duration of the treatment phase (seven days) and only be removed for sleeping and face cleaning as well as for the duration of the daily OKS treatment sessions.~Furthermore these patients will receive daily sessions (20 minutes) of optokinetic stimulation (OKS). Therefore patients will be seated in front of a widescreen monitor, watching a black background with a pattern of various objects (size 1°), which coherently and continuously move to the left at a velocity of 10 °/s."
223504516|NCT04761120|DEVICE|Abbott SJM Tailor Band|The Abbott SJM Tailor Band is a flexible, polyester-velour-covered, silicone band for posterior annuloplasty indicated for use in surgical repair of mitral or tricuspid valve. The Tailor Band is identical to the Tailor Ring with the cut zone removed, save that the polyester covering is sewn closed at the ends of the band during manufacturing.
223746918|NCT05077592|DRUG|10% Povidone Iodine|Povidone-iodine is a topical antiseptic agent used for the treatment and prevention of infection in wounds.
223504518|NCT00901498|DRUG|BMS-708163|Oral, 25 mg Hard Gelatin Capsule, Size #2, 150 mg, Once per period of 3, 7 days between dosings. Will be compared with any 2 comparators.
223746919|NCT00227162|BEHAVIORAL|Group 1|Patients set a physical activity goal and were assigned to one of four groups. Patients were assigned to receive positive affect intervention.
223504519|NCT00901498|DRUG|BMS-708163|Oral, 75 mg Tablet Formulation 1, 150 mg, Once per period of 3, 7 days between dosings
223504520|NCT00901498|DRUG|BMS-708163|Oral, 50 mg Hard Gelatin Capsule, Size #0, 150 mg, Once per period of 3, 7 days between dosings
223746920|NCT00227162|BEHAVIORAL|Group 2|Patients set a physical activity goal and were assigned to one of four groups. Patients were assigned to receive the self-affirmation intervention.
223746921|NCT00227162|BEHAVIORAL|Group 3|Patients set a physical activity goal and were assigned to one of four groups. Patients were assigned to receive both positive affect and self-affirmation intervention.
223746922|NCT02692781|DRUG|MOD-6031|
223746923|NCT02692781|OTHER|Placebo control|
224195616|NCT02089022|OTHER|Physiotherapy resources|The application of ice has been accomplished by means of a plastic bag containing 1.5 kg of crushed ice. The duration of the application was 30 minutes. The use of shortwave diathermy was performed by means of rectangular electrodes having a duration of 20 minutes.
224195617|NCT06020378|DRUG|Hydroxychloroquine|Hydroxychloroquine was administered during pregnancy
223593272|NCT03287037|DEVICE|tDCS over DLPFC|We applied tDCS over dorsolateral prefrontal cortex (DLPFC) for these depressed patients. Direct current (DC) generated by a DC stimulator (Eldith DC stimulator: www. neuroconn.de/dc-stimulator\_plus\_en/) was bilaterally delivered through a pair of saline-soaked surface sponge electrodes (35 cm2). The anodal electrode was placed over the left dorsolateral prefrontal cortex (F3, International EEG System 10-20) and cathode electrode over F4. Stimulation was applied at an intensity of 2 mA for 20 min, twice-daily on 5 consecutive weekdays. The twice daily sessions were separated by at least 3 hours. All patients were maintained on their treatment throughout the study period.
223593273|NCT06551259|DRUG|Dexmedetomidine|Intravenous infusion of 0.6μg/kg load dose of dexmedetomidine within 10 minutes after intubation, followed by continuous infusion at a rate of 0.4 μg/kg/h until 30 minutes before the end of surgery
223593274|NCT06551259|DRUG|physiological saline|physiological saline
223593275|NCT05714644|OTHER|FIT kit Screening Test|FIT kit mailed to the patient's home
223593276|NCT05714644|OTHER|Cologuard Screening Test|Cologuard test mailed to the patient's home
223593277|NCT06338592|BEHAVIORAL|MyLungHealth|MyLungHealth is a patient-centered, EHR-integrated smoking data-quality improvement and education intervention. A key component of the MyLungHealth intervention is a pre-visit LCS eligibility questionnaire asked through the Epic EHR patient portal for individuals with unclear LCS eligibility due to missing or potentially inaccurate data in the EHR. Another key component of the MyLungHealth intervention is an interoperable, patient-centered educational app delivered through the EHR patient portal.
223593278|NCT06338592|BEHAVIORAL|DecisionPrecision+|DecisionPrecision+ is a multi-faceted intervention which includes provider-facing EHR preventive care reminders, a provider-facing EHR SDM tool, and simple patient-facing preventive care reminders.
223593279|NCT06578065|DEVICE|Echelon Circular™ Powered Stapler|Echelon Circular™ Powered Stapler will be used in colorectal anastomosis.
223593280|NCT06578065|DEVICE|2-row circular staplers manual|2-row circular staplers manual will be used in colorectal anastomosis.
223593281|NCT04541628|COMBINATION_PRODUCT|SIG-001|Laparoscopic administration of SIG-001 spheres, an encapsulated allogeneic cell therapy genetically modified with a non-viral vector to produce BDD-hFVIII.
223593282|NCT04951466|BEHAVIORAL|Mindfulness-based therapy for insomnia (MBTI)|Participants randomly assigned to either the MBTI or healthy lifestyle intervention will receive 2 hours weekly session of mindfulness meditation and behavioral sleep strategies for 8 weeks.
223593283|NCT04951466|BEHAVIORAL|Healthy lifestyle intervention|Participants randomly assigned to either the MBTI or healthy lifestyle intervention will receive 2 hours weekly session of mindfulness meditation and behavioral sleep strategies for 8 weeks.
223593284|NCT03538366|OTHER|Donor FMT|Fecal transplant from unrelated, healthy donors using enemas
224195618|NCT04638439|DRUG|P1101 + Nivolumab + Entecavir|P1101 (Ropeginterferon alfa-2b) 450 µg subcutaneously (SC) Q2W for 6 doses (12 weeks), followed by 0.3 mg/kg Nivolumab for 6 doses (12 weeks), with a follow up of 24 weeks. All patients will also receive Entecavir 0.5 mg QD from Day 1 to Follow-up 24.
224195619|NCT06505694|DIETARY_SUPPLEMENT|Alcohol Alternative Herbal Tincture (Test Product)|The test product contains organic vegetable glycerin, distilled water, organic elderberries, organic bilberries, organic beetroot juice powder, organic California poppy (whole plant), organic tart cherry, organic hawthorn berries, organic blue vervain (aerial parts), organic ceylon cinnamon bark, organic black pepper fruit, and L-theanine.
224310518|NCT06163599|BEHAVIORAL|Transdiagnostic Telenovela Intervention|The intervention constitutes nine videos depicting the main character, Esperanza, who is struggling with anxiety and depression, undergoing therapy involving the a trandiagnostic treatment, and completing worksheets relating to the weekly therapy sessions.
224310519|NCT04158700|DRUG|LY3200882|LY3200882 administered orally
224310520|NCT04158700|DRUG|Pembrolizumab|Pembrolizumab administered IV
224310521|NCT01684163|DRUG|GLYX-13 5 mg/kg|Intravenous administration of 5 mg/kg into arm.
224310522|NCT01684163|DRUG|GLYX-13 10 mg/kg|Intravenous administration of 10 mg/kg into arm.
224310523|NCT01684163|DRUG|Placebo|Intravenous administration of normal saline into arm.
224310524|NCT01881113|DRUG|AC-170 0.24%|1 drop in each eye at 2 separate times during a 14 day period
224310525|NCT01881113|DRUG|AC-170 0%|1 drop in each eye at 2 separate times during a 14 day period
224310526|NCT01458821|BEHAVIORAL|Brain Fitness Program - Tinnitus|Brain Fitness Program-Tinnitus was developed to improve cognitive function by engaging the brain's neuroplasticity; the program is novel, non-invasive, and inexpensive.
223593285|NCT00003515|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|"Patients With Metastatic, Recurrent, or Refractory Primitive Neuroectodermal Tumors will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
223593286|NCT02781480|BIOLOGICAL|AAV RPE65|Comparison of different dosages of AAV RPE65
223593287|NCT04119128|DEVICE|Active Transcranial Direct Current Stimulation|Subjects will undergo 5 sessions of tDCS of up to 2mA, at 20 minutes per session, 1x per day. During active stimulation, the current will be active for the full 20 minutes.
223593288|NCT04119128|DEVICE|Sham Transcranial Direct Current Stimulation|Subjects will undergo 5 sessions of tDCS, at 20 minutes per session, 1x per day. For sham tDCS, electrodes will be placed the same way as in the intervention group, for 20 minutes. However, the stimulator will deliver 2mA of current for only 30s. The current will not be active for the rest of the 20 minutes.
223593289|NCT03312842|DRUG|CS1001|"In the dose escalation part, the dose levels will be escalated following a modified 3+3 dose escalation scheme.~In the dose expansion part, patients will be assigned to different groups based on their tumor type."
223593290|NCT03842059|DEVICE|Computer-aided detection|We developed an artificial intelligent computer system with a deep neural network (PX-1) to analyze real-time video signals from the endoscopy station
224310527|NCT06877819|OTHER|Motor Imaginary Technique alongwith task-oriented training|Motor imaginary technique followed by task oriented trunk control training alongwith conventional physiotherapy.Frequency: 10- 15 reps 4 times/week for 8 consecutive weeks. Time for each session will be 60 mins. First of all task based exercises will be assumed by patient. To make imaginations more strong an audio demonstration of each exercise will be recorded by therapist and will be administered to patients hearing via headphones. This will make it easy for patients to assume as they are performing theses exercises in their head. Motor imagination will be followed by practical performance of same tasks. The experimental group will receive motor imagery technique for 15 minutes followed by task-specific training for 45minutes along with conventional physiotherapy to improve postural control and balance in stroke patients. .
224195620|NCT06505694|DIETARY_SUPPLEMENT|Placebo|The placebo is designed to match the test product in appearance and taste but does not contain the active herbal ingredients. Participants will take 2 ml of the placebo directly onto the tongue every evening, 1-2 hours before bedtime, for a duration of 8 weeks. The placebo contains organic vegetable glycerin, distilled water, organic beet juice powder, organic tart cherries, organic ceylon cinnamon chips, and natural green food coloring (derived from spirulina and turmeric).
224195621|NCT03110107|BIOLOGICAL|Ipilimumab|Specified dose on specified days
224310528|NCT06877819|OTHER|Task Oriented Training|Control group will receive task oriented trunk control training exercises followed by conventional physiotherapy. .Frequency: 10- 15 reps 4 times/week for 8 consecutive weeks. Time for each session will be 60 mins.
224310529|NCT00673387|DRUG|pramlintide acetate|subcutaneous injection, twice a day
224310530|NCT00673387|DRUG|metreleptin|subcutaneous injection, twice a day
224310531|NCT00673387|DRUG|placebo-P|subcutaneous injection, twice a day
223504521|NCT00901498|DRUG|BMS-708163|Oral, 75 mg Soft Gelatin Capsule, 150 mg, Once per period of 3, 7 days between dosings
223504522|NCT00901498|DRUG|BMS-708163|Oral, 75 mg Tablet Formulation 2, 150 mg, Once per period of 3, 7 days between dosings
223504523|NCT05805605|BIOLOGICAL|Peripheral Blood Stem Cell Transplant|On day 0, a target dose of 5 x 106 CD34 cells/kg will be infused.
223504524|NCT05805605|DRUG|Allopurinol 300 MG|300 mg/day from day -7 to day 0. Allopurinol 150mg/m2/day for pediatric participants.
223504525|NCT05805605|DRUG|Fludarabine|30 mg/m2 IV over 1 hour. Administered on day -6 to day -2.
223504526|NCT05805605|DRUG|Cyclophosphamide|Administered as a 2 hour IV infusion on day -6, +3, and +4.
223504527|NCT05805605|BIOLOGICAL|Bone Marrow Cell Transplant|On day 0, a target dose of 3 x 108 nucleated cells/kg recipient weight will be infused.
223504528|NCT05805605|RADIATION|Total Body Irradiation|The dose of TBI will be 200 cGy given in a single fraction on day -1.
223504529|NCT05805605|DRUG|Sirolimus Pill|"All participants begin +5 to day +60.~Loading dose on day +5 of 5 mg/m2/day orally once (max dose of 8 mg).~Maintenance dose 2.5 mg/m2 orally daily to maintain a level of 8-12 ng/ml (max dose of 4 mg)."
223504530|NCT05805605|DRUG|Mycophenolate Mofetil|"All patients begin day +5 through day +35.~3 gram/day IV/PO for patients who are ≥ 40 kg divided in 2 doses. In obese patients (\>125% IBW) 15 mg/kg every 12 hours may be considered. Pediatric patients will receive MMF at the dose of 15 mg/kg/dose (maximum of 1 gram per dose) every 8 hours."
223504531|NCT05089916|DRUG|Osimertinib|Osimertinib: according to its marketing authorization, i.e. at daily doses of 80 mg, for a maximum of 12 months within the study.
223504532|NCT05089916|RADIATION|Radiotherapy|"Radiotherapy: according to standard of care~The target population will comprise 3 parallel cohorts, for cohort 1 and 3 a minimum of 10 subjects is planned to be enrolled:~1. Irradiation of bone, solid organ (non-lung, non-brain) or soft-tissue metastases~2. Irradiation of brain metastases (initial lesion size \< 3 cm)~3. Irradiation of lung lesions (primary tumor or metastases, lesion size \< 5 cm)"
224195622|NCT03110107|BIOLOGICAL|BMS-986218|Specified dose on specified days
224195623|NCT03110107|BIOLOGICAL|Nivolumab|Specified dose on specified days
224195624|NCT04691570|DRUG|ANX005|ANX005 is provided as a solution for IV infusion
224195625|NCT06839872|DRUG|Pirtobrutinib|Patients will receive pirtobrutinib orally with dosing schedule as prescribed
224195626|NCT06839872|DRUG|Acalabrutinib|Patients will receive acalabrutinib orally with dosing schedule as prescribed.
224310532|NCT00673387|DRUG|placebo-M|subcutaneous injection, twice a day
224310533|NCT05553899|RADIATION|PET-MRI|magnetic resonance imaging with positron emission tomography scanning using the tracer 18F-FDG
224310534|NCT02127775|DRUG|Lesinurad 400 mg (manufactured at Site 1)|
224310535|NCT02127775|DRUG|Lesinurad 400 mg (manufactured at Site 2)|
224310536|NCT01882075|DRUG|Open loop|
224310537|NCT01882075|DEVICE|Closed-loop|
224310538|NCT00406042|DRUG|prednisolone acetate 1%|
224310539|NCT01436799|DRUG|propofol|anaesthesia was induced with the effect-site concentration of propofol 5.0 μg ml-1 mainly.
223504533|NCT00689143|DRUG|sargramostim|
223504534|NCT04043026|DRUG|Statin|Any statin therapy
223504535|NCT03081169|DRUG|Enoxaparin Sodium 150 MG/ML Prefilled Syringe|The same drugs and dosages will be used in both groups, with only the timing being different
223504536|NCT03081169|DRUG|Heparin|The same drugs and dosages will be used in both groups, with only the timing being different
223504537|NCT01737086|DIETARY_SUPPLEMENT|Lactobacillus reuteri DSM 17938 and zinc sulphate|
223504538|NCT01737086|DIETARY_SUPPLEMENT|placebo|
223504539|NCT01410253|OTHER|Combination of four techniques of physiotherapy|The patients receive conventional physiotherapy, expiratory positive airway pressure, inspiratory muscle training and physical exercise. Twice daily for seven days
223504540|NCT01410253|OTHER|Combination of three techniques of physiotherapy|Patients receive conventional physiotherapy, expiratory positive airway pressure and physical exercise. Twice daily for seven days
224310540|NCT01436799|DRUG|Desflurane|anaesthesia was maintained by desflurane 4-7vol%
224310541|NCT01436799|DRUG|alfentanil|administration of alfentanil 10 μg kg-1 for anesthetic induction
224310542|NCT01436799|DRUG|Rocuronium|administration of rocuronium 0.6 mg kg-1 for anesthetic induction
224195627|NCT06630663|BEHAVIORAL|A Wearable Device and AI-Supported Diet and Exercise intervention|The standard dietary education encompasses instruction on the calculation of total caloric intake and emphasizes the principles of the Mediterranean diet. Tailored dietary concepts are developed based on individual patient habits to give practical advice. Each participant who chose an extra wearable device downloaded the APP to connect with the health management platform. User interface of the health management platform collected data on the number of steps walked, distance, and heart rate spontaneously. Participants recorded a dietary diary every day with a smartphone APP. All collected information was uploaded to the health management platform, too. The well-trained case managers offered a platform to coach the participants to set-up a better self-managed lifestyle modification through strategies of emphasize reminders, tracking / monitoring/ feedback and goals / rewards.
224195628|NCT06630663|BEHAVIORAL|standard care|The standard dietary education encompasses instruction on the calculation of total caloric intake and emphasizes the principles of the Mediterranean diet. Tailored dietary concepts are developed based on individual patient habits to give practical advice. Each participant who chose an extra wearable device downloaded the APP to connect with the health management platform. User interface of the health management platform collected data on the number of steps walked, distance, and heart rate spontaneously. Participants recorded a dietary diary every day with a smartphone APP. All collected information was uploaded to the health management platform, too. The well-trained case managers offered a platform to coach the participants to set-up a better self-managed lifestyle modification through strategies of emphasize reminders, tracking / monitoring/ feedback and goals / rewards.
224195629|NCT06161038|DEVICE|LASER|LLLT with a 685-nm wavelength and an output of 30 mW (BTL-5000 Laser, BTL, Stevenage, UK) at energy densities of 8 J/cm2 at trigger point of upper trapezius muscle.
224195630|NCT06161038|DEVICE|Ultrasound|1 MHz therapeutic ultrasound for 5 min at a frequency of 4-6 times two week at the painful upper trapezius muscle.
224195631|NCT06161038|DRUG|Prolotherapy|Hypertonic prolotherapy at perimysium of upper trapezius muscle. The injectant is 5ml 5% dextrose solution.
224195632|NCT02989623|RADIATION|Copper Cu 64 TP3805|Given Intravenously
224195633|NCT02989623|PROCEDURE|Positron Emission Tomography and Computed Tomography Scan|Undergo copper Cu 64 TP3805 PET/CT scan
224195634|NCT00501072|DEVICE|Real-Time Continuous Glucose monitoring System (RT-CGMS)|
224195635|NCT01757873|DRUG|Z160|
224195636|NCT01757873|DRUG|Placebo|
224195637|NCT02675660|DIETARY_SUPPLEMENT|L-Homoarginine|125 mg L-homoarginine once daily
224195638|NCT02675660|DRUG|Placebo|placebo capsules once daily
224195639|NCT06145945|DRUG|0.5% Ropivacaine|20ml 0.5% ropivacaine is sprayed intraperitoneally
224195640|NCT06145945|DRUG|Saline|20ml saline is sprayed intraperitoneally
224195641|NCT02455960|DIETARY_SUPPLEMENT|L-arginine|Comparison of the efficacy of L-arginine 3 grams for days versus placebo in contrast induced AKI prevention
224195642|NCT02455960|DIETARY_SUPPLEMENT|Placebo|
224195643|NCT04983927|DEVICE|cASPECTS|Clinical decision support system for scoring ASPECTS score
224195644|NCT04446182|DRUG|Itacitinib|All eligible patients will begin study therapy with approximately a week lead-in of itacitinib monotherapy at scheduled dose. Itacitinib will be taken daily at scheduled dose for a total of six cycles. Itacitinib may be tapered as deemed appropriate by the treating investigator. Patients will remain on study therapy as long as treatment discontinuation criteria are not met. Patients with Partial Response (PR) or better may continue itacitinib for up to 1 year.
224195645|NCT04446182|DEVICE|Extracorporeal Photopheresis (ECP)|ECP will begin after itacitinib lead in period. At the end of 8 weeks of combination therapy, patients will start a standard ECP taper schedule. Patients achieving PR or better after 6 cycles of itacitinib may continue treatment with itacitinib for up to 1 year. Thereafter, itacitinib may be tapered at the treating investigator's discretion.
223504541|NCT01410253|OTHER|Combination of two techniques of physiotherapy|Patients receive conventional physiotherapy,expiratory positive airway pressure respiratory muscle training. Twice daily for seven days
223504542|NCT01410253|OTHER|standard therapy|Patients receive conventional physiotherapy and expiratory positive airway pressure. Twice daily for seven days
223504543|NCT01158677|PROCEDURE|Meniscectomy|patients undergoing meniscectomy will be asked to complete the KOOS-scale,Vas-scale, Tegner questionnaire, SF-36 questionnaire pre-operatively and at 3, 6 and 12 months post-operatively
223504544|NCT00513539|DRUG|porfimer sodium|
223504545|NCT00513539|PROCEDURE|biliary stenting|
223504546|NCT02860078|DEVICE|Ultrasound|Location and function of sacral epidural space with ultrasound
223504547|NCT02860078|DEVICE|Radioscopy|Location and puncture of the sacral epidural space only with fluoroscopy
223504548|NCT02542527|PROCEDURE|Fluid filled breast pump|breast milk pumping with a fluid filled breast pump
223504549|NCT04849013|DRUG|Placebo|Drug: Placebo Capsules containing mannitol looking identical to the other drugs Other: Placebo Capsules containing mannitol looking identical to the other drugs
223504550|NCT04849013|DRUG|Mescaline 100mg|"Drug: 100mg Mescaline per os, single dose~Other: Placebo (Capsules containing mannitol looking identical to the other drugs)"
223504551|NCT04849013|DRUG|Mescaline 200mg|"Drug: 200mg Mescaline per os, single dose~Other: Placebo (Capsules containing mannitol looking identical to the other drugs)"
223504552|NCT04849013|DRUG|Mescaline 400mg|"Drug: 400mg Mescaline per os, single dose~Other: Placebo (Capsules containing mannitol looking identical to the other drugs)"
223593291|NCT03842059|DEVICE|Standard colonoscopy|Standard colonoscopy
223593292|NCT05011058|DRUG|Nanatinostat in combination with valganciclovir|"Drug: Nanatinostat, 20 mg orally once daily, 4 days per week in 28 day cycles~Drug: Valganciclovir, 900 mg orally once daily in 28 day cycles"
223593293|NCT01950312|DRUG|gevokizumab|
223593294|NCT01452919|DRUG|LY2140023|Administered orally
223593295|NCT01452919|DRUG|Placebo|Administered orally
223593296|NCT01635803|DRUG|Bevacizumab|1.25 mg bevacizumab administered by monthly interval for six months (6 injections).
223593297|NCT01635803|DRUG|Ranibizumab|0.5mg ranibizumab administered by monthly interval for six months (6 injections).
223593298|NCT03964688|DRUG|Vitamin C|vitamin C intravenous during hospitalization, after oral, total 6 weeks.
223593299|NCT03964688|DRUG|Placebos|placebo intravenous during hospitalization, after oral, total 6 weeks
223504553|NCT04849013|DRUG|Mescaline 800mg|"Drug: 800mg Mescaline per os, single dose~Other: Placebo (Capsules containing mannitol looking identical to the other drugs)"
223746924|NCT00166088|DIETARY_SUPPLEMENT|Mediterranean Diet|The Mediterranean diet group will receive all meals as a prototypical Mediterranean diet for 4 consecutive weeks prepared by the GCRC metabolic kitchen with dietary instruction. During the second month of the study they will be asked to follow a Mediterranean diet using their own home-cooked meals
224195646|NCT03023358|DRUG|chidamide|30mg po twice a week
224195647|NCT03023358|DRUG|cyclophosphamide|750mg/m2 iv on day 1
224195648|NCT03023358|DRUG|liposomal doxorubicin|30mg/m2 iv on day 1
224195649|NCT03023358|DRUG|vincristine|1.4mg/m2 iv on day 1
224195650|NCT03023358|DRUG|prednisone|100mg/d po on day 1-5
224195651|NCT01471197|BIOLOGICAL|Ipilimumab|Intravenous (IV) solution, IV, 10mg/kg, Once every 3 weeks for 4 doses, then once every 12 weeks during Treatment Phase, 90 minute infusion
224195652|NCT01471197|BIOLOGICAL|Pemetrexed|IV solution, IV, 500 mg/m2, Once every 3 weeks during Treatment Phase, 10 minute infusion.
224195653|NCT03374709|DRUG|Oxtellar XR 150Mg Extended Release Tablet|Oxtellar XR
224195654|NCT01683786|DRUG|Pegintron + Riba|Pegylated IFN-α2b at 1.5 µg/kg of body weight/week and ribavirin 800\~1400 mg/day
223504554|NCT04849013|DRUG|Mescaline 800mg + Ketanserin 40mg|"Drug: 800mg Mescaline per os, single dose~Other: 40mg Ketanserin per os, single dose"
223504555|NCT02596087|OTHER|Problem List Suggestion|Sites will configure their EHR systems so that alerts for these conditions will be triggered for providers in the intervention arm if the patient does not have the condition on her/his problem list. each alert will be actionable and allow the provider to add the problem to her or his patient's problem list with a single click. The provider will also be able to override the rule of the patient does not have the condition (in which case the alert will not be displayed again unless new information that would trigger the alert is added to the patient's record), or defer the alert until later.
223504556|NCT03304288|DRUG|Rituximab|Low-dose rituximab was used in combination with ATRA or as the monotherapy
223504557|NCT03304288|DRUG|All-trans retinoic acid|ATRA was used in combination with low-dose rituximab
223504558|NCT02512562|DRUG|AL-335|AL-335 is a prodrug being developed as an orally administered anti-HCV therapeutic.
223504559|NCT02512562|DRUG|ACH-3102|ACH-3102 is an NS5A inhibitor being developed as an orally administered anti-HCV therapeutic.
223504560|NCT02512562|DRUG|Simeprevir|Simeprevir is an orally active, small molecule inhibitor of the NS3/4A protease of HCV and indicated for the treatment of chronic HCV infection as a component of a combination antiviral treatment regimen.
223504561|NCT00610519|DIETARY_SUPPLEMENT|mixture of aromatic essential oils.|3% of mixture containing aromatic essential oils of Eucalyptus citriodora, Eucalyptus globulus, Mentha piperita, Origanum syriacum, and Rosmarinus Officinalis, spraying to the throat.
223504562|NCT00610519|DIETARY_SUPPLEMENT|placebo|0:1% of Lemon VIP (Florasynth,Israel), spraying to the throat.
223504563|NCT02069314|DIETARY_SUPPLEMENT|Whey protein supplementation|subjects are asked to consume a smoothie with whey protein added
223504564|NCT02069314|DIETARY_SUPPLEMENT|Carbohydrate (polycose) supplementation|Subjects are asked to consume a beverage with polycose added
223504565|NCT06364527|DEVICE|Aptar Digital Health respiratory disease management platform|The Aptar Digital Health respiratory disease management platform is a digital health tool that combines a Healthcare Professional portal (BreatheSmart Connect) and an associated patient mobile application (BreatheSmart mobile application). The Aptar Digital Health respiratory disease management platform is intended to be used in conjunction with compatible connected sensor devices that track medication adherence and for some, technique.
223504566|NCT00623129|OTHER|questionnaire administration|
223504567|NCT00623129|PROCEDURE|electroacupuncture therapy|
223504568|NCT00623129|PROCEDURE|management of therapy complications|
223504569|NCT00623129|PROCEDURE|quality-of-life assessment|
223504570|NCT00013325|PROCEDURE|Cardiac Disease|
223504571|NCT04100057|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia (CBT-I)|CBT-I improves sleep through a combination of behavioral interventions (stimulus control (SC), sleep restriction (SR)), cognitive therapy (CT) as well as additional components such as mindfulness training and sleep hygiene education. SC is an intervention that re-establishes the connection between the bed/bedroom with sleep to help develop a more consistent sleep/wake pattern. SR leads to higher quality sleep by reducing excessive time spent in bed to the actual amount of sleep, thereby creating mild sleep deprivation and increasing the homeostatic sleep drive. Like CT for other disorders, CT for insomnia targets maladaptive thoughts and cognitions that may interfere with sleep.
223504572|NCT04100057|BEHAVIORAL|Desensitization Therapy for insomnia (DT-I)|"DT-I is a quasidesensitization treatment presented as a means of eliminating the conditioned arousal, which prolongs nocturnal awakenings. DT-I has been validated as an active-placebo control condition. Therapists help each DT-I recipient develop a chronological 12-item hierarchy of common activities he/she does on awakening at night (e.g., opening eyes, clock watching). Therapists also help them develop 6 imaginal scenes of themselves engaged in neutral activities (e.g., reading the newspaper). Each session, DT-I recipients are taught to pair neutral scenes with items on the 12-item hierarchy so, by the end of the sixth session, all hierarchy items have been practiced with therapist assistance. Each session, the exercise is tape recorded and the patient is given this tape locked in a player. The patients are told to practice their exercises at home once each day, no less than 2 hours before bedtime, but to avoid using the tape or exercise during sleep periods."
223593300|NCT01192412|PROCEDURE|Intervention is blood pressure management approach|1\) 'Less tight' control. The dBP treatment goal is 100 mmHg. For safety, if dBP is \>105 mmHg, then antihypertensive medication must be started or increased in dose. For dBP \<100 mmHg, antihypertensive therapy should be decreased in dose or stopped, as appropriate. The intervention will be applied until delivery.
223593301|NCT01192412|PROCEDURE|Intervention is blood pressure management approach.|'Tight' control. The dBP treatment goal is 85 mmHg. For safety, if dBP is \<80 mmHg, then antihypertensive medication must be decreased in dose or discontinued. If dBP is \>85 mmHg, then antihypertensive therapy should be started or increased in dose. The intervention will be applied until delivery.
223593302|NCT02750839|PROCEDURE|proximal humerus fracture fixation|Mini-invasive proximal humerus fixation with plate, patient in beach chair position, general anesthesia, a small incision lateral to shoulder is made to insert the plate under scope control
223746925|NCT00166088|DIETARY_SUPPLEMENT|Mediterranean Dietary Supplement|The subjects randomized to the typical diet + targeted Mediterranean dietary supplement group will not receive dietary counseling. They will be given a one-month supply of specific supplements by the GCRC nutritionists and advised to consume these daily, in addition to their usual diet.
224195655|NCT01797458|PROCEDURE|Hall Technique|"Technique:~* Removal of dental plaque and rest of aliments from the cavity~* Selection of the SSC~* If the contact points are very tight, orthodontic separator elastics could be placed through the mesial and distal contacts and the SSC has to be fitted at a subsequent appointment~* Dry the crown and fill with glass-ionomer luting cement~* Place the crown over the tooth~* Removal of cement excesses from the crown margins~* The child should be asked to keep biting on the crown until the cement has set"
224195656|NCT01797458|PROCEDURE|Non-Restorative Caries Treatment|"Technique:~* A high-speed bur should be used to remove the undermined enamel and make the cavity accessible for plaque removal. Do not remove the contact area~* Clean, dry the cavity and apply Duraphat® varnish fluoride (50/mg/ml)~* Show the cavity to patient/parents and give them tooth-brushing instructions~* Tell to parents that good plaque control is the key for this treatment~* The recall interval for these patients is every 3 months."
224195657|NCT01797458|PROCEDURE|Conventional Restoration|"Technique:~* Local anesthesia should be used when needed~* Perform complete caries removal and cavity preparation~* Use a matrix band and a wedge to tightly hold the band against the tooth~* Place the material (Compomer)~* Check contacts and occlusion, and polish the restoration"
224195658|NCT02352831|DRUG|Tosedostat|
224195659|NCT02352831|DRUG|Capecitabine|
224195660|NCT02352831|PROCEDURE|Fresh tissue biopsy|Patients who have a partial response at the end of cycle 2 will be required to undergo biopsy if deemed safe for the patient and tissue is feasible to obtain.
224195661|NCT04711642|DRUG|The study will include three arms, one non interventional and 2 interventions. The intervention arms will include two commercially available sodium hyaluronate 0.1% (Systane ultra plus and Hylo-comod)|All groups will receive a topical steroid-antibiotic for 3 weeks. The study groups will be also prescribed eye drops containing sodium hyaluronate 0.1% from the postoperative day 7 for 4 weeks.
224195662|NCT03557775|DEVICE|Inspiratory Muscle Strength Training (IMST)|IMST will be conducted using an inspiratory pressure threshold trainer (Philips Respironics® Threshold IMT or POWERbreathe® Medic Plus), which consists of a mouthpiece with a spring-loaded valve. The valve blocks the airflow until the threshold pressure is achieved by breathing in forcefully into the device. This allows airflow as long as the sufficient pressure is maintained.
224195663|NCT03557775|DEVICE|Expiratory Muscle Strength Training (EMST)|EMST will be conducted using an expiratory pressure threshold trainer (EMST150®), which consists of a mouthpiece with a spring-loaded valve. The valve blocks the airflow until the threshold pressure is achieved by breathing out forcefully into the device. This allows airflow as long as the sufficient pressure is maintained.
223504573|NCT02098551|OTHER|SPT and APT|"All patients will be tested by skin prick testing (SPT: Histamine, buffer, commercial birch pollen extract, rBet v 1 (20 and 40 μg/ml), rBet v 1 fragment 1 (20 and 40 μg/ml), rBet v 1 fragment 2 (20 and 40 μg/ml), equimolar rBet v 1 fragment mix (20 and 40 μg/ml) in duplets.~Atopy patch testing (APT: birch pollen extract, rBet v 1:160 μg/application, rBet v 1 fragment 1: 160 μg/application, rBet v 1 fragment 2: 160 μg/ml, equimolar mix of rBet v 1 fragments: 160 μg/application; negative control with vaseline alone."
223504574|NCT04344444|DRUG|Hydroxychloroquine|tablets provided as described in Arm B
223504575|NCT04344444|DRUG|Azithromycin|tablets provided as described in Arm C
223504576|NCT01560702|DRUG|Epinephrine|10-30 cc of 1/10000 diluted epinephrine will be injected at edges of an actively bleeding ulcer.
223504577|NCT01560702|BIOLOGICAL|Blood|5-20 cc autologous blood immediately withdrawn from the patient will be injected at edges of the actively bleeding ulcer.
223746926|NCT02084147|DEVICE|positron emission tomography|Undergo PET
223746927|NCT02084147|DEVICE|computed tomography|Undergo CT
223746928|NCT02084147|DEVICE|magnetic resonance imaging|Undergo MRI
223504578|NCT01384409|DRUG|KW-3357|Intravenous infusion once a day
223504579|NCT02114684|DRUG|moxifloxacin|\[isoniazid (H), rifampicin (R), pyrazinamide (Z), moxifloxacin (M)\]
223504580|NCT02195323|BIOLOGICAL|Intravenous injection|Intravenous injection of bone marrow derived MSC in patients with CKD.
223504581|NCT00990769|OTHER|Depth of anesthesia|The intervention in this study is the titration of the depth of anesthesia according to the BIS monitor, as maintained by a combination of routine anesthetic agents (nitrous oxide, sevoflurane, and fentanyl).
223504582|NCT00136474|DRUG|Amifostine|Given 30-60 minutes prior to daily radiation therapy
223504583|NCT00136474|RADIATION|Radiation Therapy|Daily radiation therapy
223504584|NCT01320449|DRUG|recombinant human erythropoietin|rHuEpo (5000 IU)is administered using a small syringe under the skin every other day for the first 2 weeks, on 3 consecutive days during week 3, and once a week from week 4-10.
223504585|NCT01320449|BEHAVIORAL|Training|For ten weeks participants will receive supervised endurance training on a bike three times a week. Physical effect will be examined with VO2-max tests before during and after the training period.
223504586|NCT01320449|OTHER|Placebo|placebo (saline) is administered using a small syringe under the skin every other day for the first 2 weeks, on 3 consecutive days during week 3, and once a week from week 4-12.
223504587|NCT05391152|DEVICE|robotic assisted total knee replacement|the study group used robotic-arm assisted total knee replacement.
223504588|NCT05391152|DEVICE|traditional total knee replacement|the control group used traditional total knee replacement
223504589|NCT04625972|DRUG|AZD7442|Single dose (× 2 IM injections) of 300 mg of AZD7442 on Day 1.
223504590|NCT04625972|DRUG|Placebo|Single dose (× 2 IM injections) of saline placebo on Day 1.
223504591|NCT03457584|PROCEDURE|air arm|epiretinal membranes are excised during membrane peeling and air-tamponade is left in the eye
223504592|NCT03457584|PROCEDURE|BSS arm|epiretinal membranes are excised during membrane Peeling and BSS is left in the eye
223504593|NCT01794416|PROCEDURE|Thoracoscopic epicardial ablation|
223504594|NCT01794416|PROCEDURE|Endocardial catheter ablation|
223504595|NCT01794416|DEVICE|Implantable loop recorder|
223746929|NCT06258655|OTHER|Close Collaboration with Parents|"The Close Collaboration with Parents intervention is an educational program for the neonatal staff to improve their skills to collaborate with parents and provide support to parenting during an infant's hospitalization. First, experienced nurses and doctors from the units will undergo a 14-day to become unit mentors. Then these unit mentors will train other members of staff. The training of the units is based on bedside practices, a reflection of the practices, and the application of the knowledge in everyday work. Theoretical learning, preceding clinical bedside mentoring, will occur through an e-learning module. Staff members will spend about 4 working days in training alongside their routine work. The unit mentors will function as facilitators for the staff, and they have dedicated time for this. The content of the bedside practices is guided by a manual. The training team will provide frequent remote and contact support for the implementation."
223593303|NCT02396368|DRUG|Tasquinimod|Tasquinimod is a quinoline-3-carboxamide analog that has demonstrated significant improvements in progression-free survival and overall survival in men with CRPC in a phase II trial.Tasquinimod will be administered at three dose levels (dose levels 1, 2, and -1). During dose level 1, tasquinimod will start at 0.25mg/day orally with a goal of 0.5mg/day. Dose level 2 will start at 0.25mg/day with a goal of 1mg/day. Dose level -1 will be 0.25mg/day without dose titration.
223593304|NCT02396368|RADIATION|Radium 223|Radium Ra 223 dichloride, an alpha particle-emitting pharmaceutical, is a radiotherapeutic drug. Radium 223 is supplied as a clear, colorless, isotonic, and sterile solution to be administered intravenously with pH between 6 and 8. Each milliliter of solution contains 1,000 kBq radium-223 dichloride (27 microcurie), corresponding to 0.53 ng radium-223, at the reference date. Radium is present in the solution as a free divalent cation.Radium-223 will be administered per FDA-approved dosing (six IV injections at a dose of 50kBq/kg of body weight, administered every 4 weeks).
223593305|NCT03390309|OTHER|Partially Hydrolyzed Formula|Partially Hydrolyzed Whey Protein Infant Formula
223593306|NCT03390309|OTHER|Normal Formula|Normal Formula
223593307|NCT05131230|DEVICE|CytoSorb® treatment|Patients with Acute on Chronic Liver Failure (ACLF) due to Severe Alcoholic Hepatitis in combination with systemic inflammation and ACLF grade ≥2 will be enrolled in this study. Every patient that is screened, fulfills the inclusion/exclusion criteria, and consents to the study, will be allowed to enter the study. Patients will receive Standard of Care treatment for alcoholic hepatitis plus treatment with the CytoSorb® 300 mL device.
223593308|NCT05157139|DRUG|Oral Capsule|Oral Capsule of vanillin \& wheat germ oil
223593309|NCT03792568|OTHER|ALK Inhibitor|Any ALK inhibitor like crizotinib, alectinib and so on.
223593310|NCT06583694|BEHAVIORAL|Health promotion campaigns to correct the health problems|
223746930|NCT06435533|DEVICE|low energy argonplasma coagulation|see above
223746931|NCT06420479|PROCEDURE|Bariatric surgery|A well-known intervention known to induce substantial weight loss
223746932|NCT00000976|DRUG|CD4-IgG|
223746933|NCT00000976|DRUG|Zidovudine|
223746934|NCT05023525|DRUG|HSK31858, tablet|Starting dose in single ascending dose: 5 mg
223746935|NCT05023525|DRUG|Placebo, tablet|Matching placebo
223746936|NCT00758030|DRUG|Paliperidone ER OROS|
224310543|NCT00960115|BIOLOGICAL|Tecemotide (L-BLP25)|After receiving a single low-dose cyclophosphamide, participants will receive weekly subcutaneous vaccinations with tecemotide (L-BLP25) (930 microgram \[mcg\]) for 8 weeks, followed by a maintenance treatment phase starting at Week 14, in which subcutaneous vaccinations with tecemotide (L-BLP25) (930 mcg) will be administered every 6 weeks until progressive disease (PD).
223746937|NCT06294964|BEHAVIORAL|sleep education, behavioral education|Provide health education materials which covering sleep education, behavioral education, chronic diseases such as cardiovascular diseases. Topics touch on such as why you need healthy sleep? What methods can be used to regulate insomnia, and how to regulate sleep breathing problems? How do the elderly maintain a good sleep? What are the risk factors for cardiovascular and cerebrovascular diseases? How to reduce the risk of developing sleep disorders or chronic diseases through changing everyday life?
223593311|NCT06583603|BEHAVIORAL|Barriers to Implementing Sensory Strategies Survey|Survey, see arm description
223593312|NCT06584058|DRUG|HPP737|\[14C\]HPP737 oral preparation, 20mg（150μCi）, once
223746938|NCT04156776|OTHER|Muscle Energy Technique|Muscle energy technique was repeated 4 times per session every day for 3 days a week for 4 weeks after the application of moist heating pad for 30 minutes before each session.
223746939|NCT04156776|OTHER|Active Isolated Stretching|"The patient was asked to sit in an upright seated position and flex his/her knees 12 to 18 inches. Patient was asked to tuck the chin, exhale, and firmly contract the abdominal muscles as he/she curls their body forward. He/she was also guided not to bounce or make rapid movements at the end range of the active motion. Then, he was asked to move back to the starting position and repeat the same procedure for 8 to 10 times. Stretch on the end range was not more than 2 seconds.~This technique was repeated 10 times per session every day for 3 days a week for 4 weeks after the application of moist heating pad for 30 minutes before each session."
223746940|NCT04156776|OTHER|Conventional Treatment|Conventional physical therapy treatment includes the application of moist heating pad for 30 minutes on lower back/ lumbar region prior to the intervention to both groups.
223746941|NCT05436847|OTHER|Proprioceptive Training|Proprioceptive Training using increased joint to joint approximation through ankle weights and joint splints.
223593313|NCT06584227|DRUG|Adebrelimab and Chidamide Combined with Gemcitabine and S1|Chidamide：20mg，po，biw，（d8、11、15、18）； Adebrelimab: 1200mg，d8，q3w； Gemcitabine：800-1000mg/m2，bid，d1、d8，q3w； S1：40mg/50mg，bid，d1-14，q3w.
223746942|NCT05436847|OTHER|Routine Physical Therapy|Neurodevelopmental treatment- age appropriate
223746943|NCT02786628|OTHER|Physical performance testing and patient-generated health data|All patients will complete cardiopulmonary exercise testing and 6 minute walk distance performance testing prior to a cycle of chemotherapy (or transplant) and wear a Fitbit Charge HR for the duration of one cycle of chemotherapy.
223746944|NCT02512432|DEVICE|INTACS|asymmetrical corneal inserts to reduce, or eliminate myopia and astigmatism in patients with keratoconus to decrease dependence on contact lenses and spectacle correction, while potentially deferring need for corneal transplantation.
224310544|NCT00960115|DRUG|Single low dose cyclophosphamide|A single intravenous (IV) infusion of 300 milligram per square meter (mg/m\^2) (to a maximum 600 mg/m\^2) of cyclophosphamide will be administered 3 days prior to tecemotide (L-BLP25), the first vaccine treatment.
223746945|NCT04474860|DIAGNOSTIC_TEST|gene sequencing|Gene fragment analysis, Sanger sequencing method and/or high-throughput whole-genome sequencing will be performed to find the pathogenic gene and mutation site of MH in Chinese population.
223746946|NCT04826770|DRUG|BNT162b2|vaccination against COVID-19
223746947|NCT04826770|DRUG|AZD 1222|vaccination against COVID-19
224195664|NCT03557775|BEHAVIORAL|Voice Exercises|Voice exercises will consist of the Vocal Function Exercises (VFE) protocol, developed by Stemple (2005). It contains 4 steps: (a) sustain the vowel /i/ on the musical note F for as long as possible. Repeat as judged by the SLP. (b) Glide from the lowest note to the highest note. Repeat as judged by the SLP. (c) Glide from the highest note to the lowest note. Repeat as judged by the SLP. (d) Sustain the notes C-D-E-F-G for as long as possible. Each note will be repeated until the participant finds the right placement (forward-focused voice), as judged by the SLP. Humming will be used to facilitate placement.
224195665|NCT06281522|OTHER|Operated patients with hydatid cyst of the lung|File screening and blood test results will be evaluated
224195666|NCT06652620|OTHER|Cola|regular Coca-Cola (Coca-Cola company, Atlanta, GA) or Pesi-cola (PepsiCo, Inc.New York, NY)
224195667|NCT03426995|DRUG|Placebo|Placebo will be administered as a matching oral solution or matching capsule to study drug GSK3358699, during Part A and C once daily
224195668|NCT03426995|DRUG|GSK3358699|GSK3358699, will be administered from 1 mg to 45 mg as an oral solution (1 to 10 mg) or as a capsule (3 to 45 mg), in Part A, B and Part C once daily.
224195669|NCT03426995|BIOLOGICAL|GM-CSF|The GM-CSF will be administered as an intravenous infusion to subjects as 60 microgram per meter\^2 in Part A (Day 1) and Part C (Day 14).This will be administered for 2 hours approximately, no later than 24 hours post -dose of the GSK3358699 or placebo in Part C
224195670|NCT03426995|BIOLOGICAL|LPS|LPS will be administered as an intravenous injection to subjects not exceeding 0.75 nanogram per kilogram in Part A (Day 1) and Part C (Day 14). This will be administered no later than 24 hours post -dose of the GSK3358699 or placebo in Part C.
224195671|NCT03426995|OTHER|Cantharidin|This will be applied as a topical application with 0.7% cantharidin liquid which will be diluted with acetone to 0.2%.
224195672|NCT05485506|OTHER|Multimodal exercise program|"Running technical drills: pogo, askip, dribble, scissor, etc. Exercises for lumbopelvic stabilization: mobility exercises, hip thrust, dead lift, lunge to skip.~Resisted sprints by using a sled: resistance leading to a 60% and 30% of optimal load (previously calculated)"
224195673|NCT02405624|PROCEDURE|continuous positive airway pressure|CPAP training for muscle strength
224195674|NCT04477343|DRUG|SX-682|Allosteric inhibitor to human CXCR1 and CXCR2 receptor
224195675|NCT04477343|DRUG|Nivolumab Injectable Product|humanized monoclonal antibody to program cell death receptor 1 (PD1)
224310545|NCT00960115|BIOLOGICAL|Placebo|After receiving single dose of saline, participants will receive weekly subcutaneous vaccinations with placebo that matches with tecemotide (L-BLP25) for 8 weeks, followed by a maintenance treatment phase starting at Week 14, in which subcutaneous vaccinations with placebo will be administered every 6 weeks until PD.
223504596|NCT03723954|DEVICE|ECG Holter SpiderFlash-t|"Record at visit V0 (day without match) and the competition days (Visit V1, V2 et V3) during the matches the heart rate of the golf fans.~SpiderFlash-t™ from MicroPort is a long-lasting event recorder set in walking position by the investigator the day of the record and it is activated by detecting rhythm anomalies. This recorder is a Class IIA medical device (according to European Economic Community Directive 93/42). It benefits from European Economic marking."
223504597|NCT03723954|DEVICE|Actigraph GT3Xp|"Record the study participant's physical activity while we record his heart rate.~The GT3Xp based activity monitors provide objective measurements of human activity and are used in many research and clinical applications. It includes a micro-electro-mechanical system (MEMS) based accelerometer and an ambient light sensor. It benefits from CE marking and FDA agreement (Class II medical device)."
223504598|NCT06390215|BEHAVIORAL|School Readiness Coaching Intervention|Two 1-hr School Readiness Coaching Session
223504599|NCT05312112|DRUG|Venetoclax|Observational study of venetoclax in AML
223504600|NCT05312112|DRUG|Gilteritinib|Observational study of gilteritinib in AML
223746948|NCT04826770|DRUG|mRNA-1273|vaccination against COVID-19
223504601|NCT00694122|DRUG|Lantus (glargine)|Described in Arm Description
223504602|NCT00466219|DRUG|Ribavirin|
223504603|NCT00466219|DRUG|Pegylated interferon alpha2a|
223593314|NCT06583369|DRUG|Liangxue ointment（Traditional Chinese Ointment）|"The main ingredients of Liangxue Ointment include: Lithospermum sibiricum, Sanguisorba Sanguis, Rehmannia glutinosa, Gardenia, rhubarb, skullcap, borneol, dragon's blood, olibanum and myrrh.~Apply 2 times a day, 14 days is a course of treatment, and the treatment is 2 courses."
223593315|NCT06583369|DRUG|Urea cream|Apply 2 times a day, 14 days is a course of treatment, and the treatment is 2 courses.
223593316|NCT06584201|PROCEDURE|Erector Spinae Plane Block (ESP)|The ESP block will be administered before the VATS procedure, aiming to manage postoperative pain and minimize the impact on early lung function test (SFT) parameters. The block will be performed using standard techniques under ultrasound guidance to ensure accurate placement.
223746949|NCT02653287|BEHAVIORAL|Experimental|The experimental intervention includes 4 individual coaching sessions (initial 1 hour in-person and remaining 10-15 minutes per telephone) designed to identify barriers and supports for physical activity and nutrition using motivational interviewing. They occur shortly after randomization, 1.5, 3, and 6 months. Daily participants monitor their physical activity via the Fitbit Flex and their dietary behavior on a paper diary.
224195676|NCT06566768|DRUG|Deucravacitinib|Specified dose on specified days
224195677|NCT01961310|BIOLOGICAL|Plasma analysis for bacterial translocation|1 ml of plasma will be obtained (blood sample). DNA will be extracted and amplified, and real-time quantitative PCR (polymerase chain reaction) performed.
224195678|NCT01961310|BIOLOGICAL|Stool analysis|DNA from stool samples will be extracted, amplified, and used to identify the bacteria species present.
224195679|NCT00929552|DIETARY_SUPPLEMENT|Dietary oils (fish, vegetable oil)|6g pr day.
224310546|NCT00960115|OTHER|Saline|A single dose of saline (sodium chloride, 9 grams per liter \[g/L\]) will be administered intravenously, 3 days prior to the start of placebo.
224310547|NCT01516307|BIOLOGICAL|OPT-822/OPT-821(30 μg/100 μg)|Subcutaneously on week 1, 2, 3, 5, 9, 13, 17, 25, and 37. OPT-822 and OPT-821 are combined at time of injection.
224310548|NCT01516307|BIOLOGICAL|Phosphate Buffer Saline (PBS)|Subcutaneously on week 1, 2, 3, 5, 9, 13, 17, 25, and 37.
224195680|NCT05311111|PROCEDURE|distal radial artery approach|Procedure: Use of radial artery for access for a coronary angiography or intervention After preparation and local anesthesia, the operator will puncture the distal radial artery in the dorsum of the hand or the anatomical snuff-box. Then a sheath will be placed. A cocktail combining Risordan®, Loxen® and unfractionated heparin will be injected through the sheath. a wire will be introduced. At the end of the procedure, the sheath will be removed immediately and hemostasis by compression will be carried out with an elastic band for 12 hours. The choice of limb side, sheath, catheters will be chosen according to the operator's discretion.
224195681|NCT05311111|PROCEDURE|conventional radial artery approach|Procedure: conventional radial access for a percutaneous coronary intervention After preparation and local anesthesia, the operator will puncture the proximal radial artery at the conventional site in distal forearm. Then a sheath will be placed. A cocktail combining Risordan®, Loxen® and unfractionated heparin will be injected through the sheath. a wire will be introduced. At the end of the procedure, the sheath will be removed immediately and hemostasis by compression will be carried out with an elastic band for 12 hours. The choice of limb side, sheath, catheters will be chosen according to the operator's discretion.
224195682|NCT04387487|BEHAVIORAL|Multimedia video information|"During pre anesthesia visit after regular pre anesthesia check up patient will be asked to fill the Hamilton scoring questionnaire about anxiety.~After this a multimedia video information about spinal anesthesia of around 6 minutes will be shown to the intervention group during pre anesthesia visit. This video will contain explanation about how spinal anesthesia procedure is conducted. Patient will be allowed to ask questions.~On the day of surgery in the pre surgical area again Hamilton scoring questionnaire will be asked with the patients to check the level of anxiety."
224195683|NCT06422949|DEVICE|Hilotherm® Cooling treatment|Patient will receive cooling treatment with Hilotherm® at hands and feet level from half an hour before taxol treatment start until half an hour after treatment end
224195684|NCT05524805|DEVICE|BTL-785-7 Treatment|Treatment of wrinkles with the BTL-785-7 applicator to the BTL-785F system.
224195685|NCT05273060|PROCEDURE|3D Nasal Reconstruction Planning|3D molds or models to use in the reconstruction of nasal cartilage
224195686|NCT05038228|DRUG|Apixaban|Anticoagulant
224195687|NCT05038228|DRUG|Rivaroxaban|Anticoagulant
224195688|NCT05038228|DRUG|Dabigatran|Anticoagulant
224195689|NCT05038228|DRUG|Vitamin K antagonist (VKA)|Anticoagulant
224195690|NCT06209268|DRUG|Paricalcitol injection|5 μg intravenous paricalcitol (1 mL) per day in five consecutive days
224195691|NCT06209268|DRUG|Placebo|0.9% NaCl 1 ml per day in five consecutive days
224195692|NCT06649617|OTHER|Control Group (Standard Procedure)|Before the application of nursing interventions ( Intramuscular , Intravenous , Subcutaneous Injection) to the patients, the patients' physiological parameters (fever, pulse, blood pressure, respiration and oxygen saturation ), pain levels with VAS and anxiety levels with State- Trait Anxiety Scale were evaluated. Then , information was given about the nursing intervention to be performed as a standard procedure . The nursing intervention was applied. After the application, the patients' physiological parameters (fever, pulse, blood pressure, respiration and oxygen saturation ), pain levels with VAS and anxiety levels with State- Trait Anxiety Scale were evaluated. Whichever nursing intervention was necessary for the patients ( Intramuscular , Intravenous , Subcutaneous Injection), that application was applied. No unnecessary procedure was applied. .
224310549|NCT01516307|DRUG|Cyclophosphamide|Subcutaneously on week 1, 2, 3, 5, 9, 13, 17, 25, and 37.
223593317|NCT06584201|PROCEDURE|Paravertebral Block (PVB)|The PVB will be administered prior to the VATS procedure, with the objective of managing postoperative pain and assessing its impact on early postoperative lung function (SFT) parameters. This block will also be performed using standard techniques and ultrasound guidance for precision.
223593318|NCT02103777|DRUG|Caffeine citrate|Caffeine will be given by either high dose in Arm 1 or low dose in Arm 2
223593319|NCT01743820|DRUG|dihydroartemisinin-piperaquine|
223593320|NCT01743820|DRUG|0.125 mg/kg Primaquine|
223593321|NCT01743820|DRUG|0.5 mg/kg Primaquine|
223593322|NCT01743820|DRUG|0.25 mg/kg Primaquine|
223593323|NCT01743820|DRUG|0.0625 mg/kg Primaquine|
223593324|NCT00950898|OTHER|decaff|2 mugs of decaffeinated coffee
223593325|NCT00950898|OTHER|caffcoff|2 mugs of caffeinated coffee
223593326|NCT00950898|OTHER|caffeine|2 mugs of hot water containing caffeine
223593327|NCT00950898|OTHER|placebo|2 mugs of hot water
223593328|NCT05013203|DIAGNOSTIC_TEST|Tissue culture|Discarded tissue collected during surgery will be sent to the hospital microbiological lab for aerobic and anaerobic
223593329|NCT05013203|DIAGNOSTIC_TEST|Next Generation Sequencing|Discarded tissue collected during surgery will be sent to an outside lab for testing using next generation sequencing (NGS)
223593330|NCT05670158|BIOLOGICAL|Blood sampling|Blood will be collected into 2 EDTA and 1 heparin tube. The 2 EDTA tubes (4ml of blood in each) will be transported on ice to the proteomics platform in the next three hours, centrifuged and stored on -80 degrees Celcius in low-binding tubes for further molecular analysis. 1 heparin tube (5mL) will be sent to the Bacteriology-Virology Department for the active PBMC counting.
223593331|NCT05670158|PROCEDURE|Perilymph sampling|The perilymph collection will be performed during the cochlear implantation surgery at the same time as the round window opening. 5 to 15 microliters will be aspirated using an atraumatic spinal needle mounted onto 1 ml insulin syringe.
223593332|NCT00038233|DRUG|Thalidomide|200 mg at bedtime daily for 14 days (days 1-14), followed by an increase to 400 mg daily for 14 days (days 15-28), 600 mg daily for 14 days (days 29-42), up to a maximum 800 mg (days 43-completion)
223593333|NCT06168682|DEVICE|SuperNO2VA™ Et by Vyaire Medical, Inc.|SuperNO2VA™ Et provides a nCPAP between 3 to 10 cmH20 using a oxygenflowrate of 6l/O2
223593334|NCT06168682|DEVICE|nasal oxygen cannula|Standard Operating Procedure (SOP) for endoscopy: Using a nasal oxygen cannula with oxygenflowrate of 6l/O2
223593335|NCT00383942|DRUG|Misoprostol|Misoprostol,25 micrograms every 4 hours.
223593336|NCT00383942|DEVICE|Catheter|A catheter with extra amniotic saline infusion (EASI) is placed in the uterus and applies pressure to the cervix to cause it to ripen
223593337|NCT03219632|DRUG|Fimasartan|Fimasartan is a non-peptide angiotensin II receptor antagonist (ARB) used for the treatment of hypertension and heart failure.
223593338|NCT01145339|DRUG|Lactase|1 chewable tablet of the test drug or comparative drug 30 minutes before the standard lactose dose (25 g).
223593339|NCT01359943|BIOLOGICAL|secukinumab (AIN457)|"Secukinumab is a human monoclonal antibody. Monoclonal antibodies are proteins that recognize and bind to unique proteins that your body produces. Secukinumab binds and reduces the activity of a cytokine (a messenger protein in the body) called Interleukin 17 (IL-17)."
223593340|NCT01359943|DRUG|placebo|Matching placebo to AIN457 i.v. and to AIN457 s.c..
223593341|NCT05310981|BEHAVIORAL|iCanChange|iCC is a psychological app based intervention that will be delivered in form of up to 24 brief (10-15 minutes) interactive modules developed based on the principles of Motivational Interviewing (MI) and Cognitive Behavioural Therapy (CBT). During the intervention, participants will be offered MI and CBT-based activities (i.e., modules and strategies) aiming at facilitating change in cannabis use. At any point during the intervention, participants can reference modules that had been completed. Due to the frequency of behavioral stage changes in this population (e.g., regression in behavioral stage of change), stage of change will be monitored regularly throughout the intervention. During the follow-up period (i.e., Week 12-24), participants will have continuous access to the smart phone application and all built-in add-ons as described above. During this period, they will have access to 3 booster session.
223593342|NCT00217568|BIOLOGICAL|pegfilgrastim|
223593343|NCT00217568|DRUG|carboplatin|
223593344|NCT00217568|DRUG|docetaxel|
223593345|NCT02357121|DEVICE|Focal Laser Ablation|Focal laser ablation of prostate tissue using laser interstitial thermal therapy (LITT) under MR/ultrasound fusion guidance
223593346|NCT00006249|BIOLOGICAL|pegylated interferon alfa|
223593347|NCT00006249|PROCEDURE|adjuvant therapy|
223593348|NCT03433417|DEVICE|Cutera truSculpt|One truSculpt treatment delivered 0 to 90 days before scheduled Abdominoplasty to one side of the tissue to be removed during abdominoplasty
223593349|NCT03781505|DRUG|Paracetamol +caudal ropivacaine|Paracetamol + Ropivacaine
224195693|NCT06649617|OTHER|Music Therapy Group|Before the application of nursing interventions ( intramuscular , intravenous , subcutaneous injection) to the patients, the patients' physiological parameters (fever, pulse, blood pressure, respiration and oxygen saturation ), pain levels with VAS and anxiety levels with State -Trait Anxiety Scale were evaluated. During the nursing intervention, the patients were made to listen to Büzürk makam, a Turkish musical makam. After the application, the patients' physiological parameters (fever, pulse, blood pressure, respiration and oxygen saturation ), pain levels with VAS and anxiety levels with State -Trait Anxiety Scale were evaluated. Whichever nursing intervention was necessary ( intramuscular , intravenous , subcutaneous injection), that application was performed on the patients . No unnecessary procedure was performed.
224195694|NCT06649617|OTHER|Virtual Reality Group|Before the application of nursing interventions ( Intamuscular , Intravenous , Subcutaneous Injection) to the patients, the patients' physiological parameters (fever, pulse, blood pressure, respiration and oxygen saturation ), pain levels with VAS and anxiety levels with State -Trait Anxiety Scale were evaluated. During the nursing intervention, the patients watched 3D videos with relaxation effect with virtual glasses. After the application, the patients' physiological parameters (fever, pulse, blood pressure, respiration and oxygen saturation ), pain levels with VAS and anxiety levels with State -Trait Anxiety Scale were evaluated. Whichever nursing intervention was necessary ( Intamuscular , Intravenous , Subcutaneous Injection), that application was performed on the patients . No unnecessary procedure was performed.
224195695|NCT06509048|OTHER|STN-DBS Theta Gamma Stimulation|Standard STN-DBS stimulation with addiction of bilateral theta frequency stimulation of ventral contacts
223504604|NCT01767285|DRUG|Etonogestrel implant|This will be placed in subjects in both arms. Those in Arm 1 will receive the implant in the hospital postpartum. Those in Arm 2 will receive the implant at the 6 week postpartum visit.
223504605|NCT01095770|PROCEDURE|AF Ablation with Ablation Frontiers Technology|AF Ablation with Ablation Frontiers Technology - PVAC, TVAC and MASC.
223504606|NCT01095770|PROCEDURE|AF Ablation with LASSO catheter|AF Ablation with traditional LASSO catheter
223504607|NCT01095770|DEVICE|Reveal XT|Reveal XT implantable loop recorder monitored group
223504608|NCT01095770|DEVICE|Permanent Dual Chamber Pacemaker|This group will be monitored with a dual chamber pacemaker with advanced AF monitoring capabilities.
223504609|NCT02517229|OTHER|Parabolic flight|
223504610|NCT02517229|OTHER|balance control measurements|
223504611|NCT02517229|DEVICE|electromagnetic maneuverable postural platform|
223504612|NCT00436709|BIOLOGICAL|bevacizumab|
223504613|NCT00436709|BIOLOGICAL|pegfilgrastim|
223504614|NCT00436709|DRUG|cyclophosphamide|
223504615|NCT00436709|DRUG|doxorubicin hydrochloride|
223504616|NCT00436709|DRUG|paclitaxel albumin-stabilized nanoparticle formulation|
223504617|NCT00436709|OTHER|flow cytometry|
223504618|NCT00436709|OTHER|immunoenzyme technique|
223504619|NCT00436709|OTHER|immunologic technique|
223504620|NCT00436709|OTHER|laboratory biomarker analysis|
223504621|NCT00436709|PROCEDURE|adjuvant therapy|
223504622|NCT00436709|PROCEDURE|immunoscintigraphy|
223504623|NCT03549195|PROCEDURE|ICG|The ICG powder was diluted and injected into the cervix, divided into 3 and 9 o'clock position, 4 hours before surgery.
223504624|NCT03549195|PROCEDURE|ICG-CP|The ICG-CP powder was diluted and injected into the cervix, divided into 3 and 9 o'clock position, 4 hours before surgery.
223504625|NCT03549195|PROCEDURE|ICG-TMTP1|The ICG-TMTP1 powder was diluted and injected into the cervix, divided into 3 and 9 o'clock position, 4 hours before surgery.
223504626|NCT00003090|BIOLOGICAL|aldesleukin|
223504627|NCT01053052|DEVICE|Sonography with FemVue, and HSG|Sono HSG for FDA 510(k) cleared indication for use
223504628|NCT00368485|DEVICE|Neurally Controlled Mechanical Ventilation|A new mode of mechanical ventilation controlled by the electrical activity of the diaphragm (NAVA) will be used before and after extubation.
223504629|NCT05742750|DRUG|Camrelizumab and Apatinib Plus GP|"Patients received apatinib orally at 250 mg once a day irrespective of the patient weight.~Camrelizumab 200 mg was administered intravenously over 30 minutes every 3 weeks.~GP chemotherapy: Gemcitabine/Cisplatin (gemcitabine 1000mg/m2 + cisplatin 25mg/m2) will be administered on D1/D8 in every three weeks cycle and up to 8 cycles.~All patients continued combination treatment until disease progression, unacceptable toxicity, or discontinuation for any reason."
224195696|NCT04103645|DRUG|Vactosertib|50 mg BID This drug is a TGF-Beta receptor type 1 inhibitor, by inhibiting phosphorylation of the ALK5 substrates SMAD2 and SMAD3. This inhibition could promote regeneration of normal human stem cells and proliferation of erythroid progenitors to treat the underlying hypoproliferative anemia in advanced MPNs.
224195697|NCT04103645|DRUG|Vactosertib|100 mg BID This drug is a TGF-Beta receptor type 1 inhibitor, by inhibiting phosphorylation of the ALK5 substrates SMAD2 and SMAD3. This inhibition could promote regeneration of normal human stem cells and proliferation of erythroid progenitors to treat the underlying hypoproliferative anemia in advanced MPNs.
224195698|NCT04103645|DRUG|Vactosertib|150 mg BID This drug is a TGF-Beta receptor type 1 inhibitor, by inhibiting phosphorylation of the ALK5 substrates SMAD2 and SMAD3. This inhibition could promote regeneration of normal human stem cells and proliferation of erythroid progenitors to treat the underlying hypoproliferative anemia in advanced MPNs.
224195699|NCT04103645|DRUG|Vactosertib|200 mg BID This drug is a TGF-Beta receptor type 1 inhibitor, by inhibiting phosphorylation of the ALK5 substrates SMAD2 and SMAD3. This inhibition could promote regeneration of normal human stem cells and proliferation of erythroid progenitors to treat the underlying hypoproliferative anemia in advanced MPNs.
224195700|NCT04103645|DRUG|Vactosertib|The lowest dose level of vactosertib for which no DLT was observed in Tier 1 AND The lowest dose level for which at least one of the 12 subjects enrolled on Tier 1 met Criteria for Clinical Benefit. Or, if a single dose level does not fulfil both Criterion 1 and Criterion 2, the starting dose level for Tier 2 will lowest dose from Tier 1 for which no DLT was identified.
224195701|NCT05198323|DRUG|LT3001 Drug Product|LT3001 Drug Product administered once by intravenous infusion
224195702|NCT05198323|DRUG|Placebo|Placebo administered once by intravenous infusion
224195703|NCT06975605|DRUG|Radiprodil + co-administered drugs|"Study drug radiprodil will be administered asbelow in a sequential manner.~\- Radiprodil 7.5 mg, 15 mg and 30 mg will be administered in a sequential manner.~Co-administered drugs include: - Warfarin - 10 mg tablets, midazolam 1 mg, digoxin 0.25 mg, rosuvastatin 10 mg, omeprazole 20 mg, Vitamin K - 10 mg."
223504630|NCT00809146|DRUG|Intramuscular route of active treatment|IM administration by autoinjector of midazolam 5 mg for subjects under estimated weight of 40 kg or midazolam 10 mg for subjects with estimated weight of 40 kg or above, IV administration of matching volume of IV flush.
223504631|NCT00809146|DRUG|Intravenous route of active treatment|IV administration of lorazepam 2 mg for subjects under estimated weight of 40 kg or midazolam 4 mg for subjects with estimated weight of 40 kg or above, IM administration by autoinjector of matching volume of saline.
223504632|NCT06471166|DIAGNOSTIC_TEST|Amh hormone|Ovarian reserve
223504633|NCT02663440|RADIATION|Hypofractionated IMRT|Hypofractionated IMRT
223504634|NCT02663440|BIOLOGICAL|Granulocyte-macrophage Colony-stimulating Factor|Granulocyte-macrophage Colony-stimulating Factor
223504635|NCT02663440|DRUG|Temozolomide|Temozolomide
223504636|NCT03020888|DEVICE|Magseed and Sentimag|Magseed marker and Sentimag probe for lesion localization
223504637|NCT00908687|BIOLOGICAL|A/H5N1|A/H5N1 Low Dose
223504638|NCT00908687|BIOLOGICAL|A/H5N1|A/H5N1 High Dose
223504639|NCT00908687|BIOLOGICAL|LT Adjuvant Patch|LT Adjuvant Patch Low Dose
223504640|NCT00908687|BIOLOGICAL|LT Adjuvant Patch|LT Adjuvant Patch High Dose
223504641|NCT05212142|BEHAVIORAL|verbal education|Participants will receive oral health anticipatory guidance in the form of verbal and written education alongside the same preventive follow up and recall appointment schedule.
223504642|NCT05212142|BEHAVIORAL|verbal education, visual aids, and motivational interviewing|Participants will receive oral health anticipatory guidance through a combination preventive strategy using motivational interviewing, individualized goal setting, visual aids, and verbal education alongside a preventive follow up and recall appointment schedule
223504643|NCT01198548|DRUG|leucovorin calcium|Given IV
223504644|NCT01198548|BIOLOGICAL|bevacizumab|Given IV
223504645|NCT01198548|DIETARY_SUPPLEMENT|cholecalciferol|Given PO
223504646|NCT01198548|DRUG|fluorouracil|Given IV
223504647|NCT01198548|DRUG|oxaliplatin|Given IV
223504648|NCT01198548|OTHER|pharmacological study|Correlative studies
223504649|NCT05926193|DIETARY_SUPPLEMENT|Tailor Food Bags|The treatment group will participate in 6 nutrition workshops over the course of 6 months as well as receive weekly food bags that have been tailored for a DASH diet.
223504650|NCT04464902|DEVICE|brace1|The brace1 can provide resistance when patients want to extend their knee.
223504651|NCT04464902|DEVICE|brace2|The brace1 can't provide resistance when patients want to extend their knee.
223504652|NCT04464902|OTHER|No Intervention|Control Group don't have any brace.
223504653|NCT04899128|DRUG|Pyrotinib|Pyrotinib-based therapy
223504654|NCT02539693|DRUG|Clonidine 75 µg/mL in sacrococcygeal block|Sacrococcygeal block will be performed using 75 µg/mL clonidine in the anesthetic mixture
223504655|NCT02539693|DRUG|Clonidine 150 µg/mL in sacrococcygeal block|Sacrococcygeal block will be performed using 150 µg/mL clonidine in the anesthetic mixture
223504656|NCT02539693|DRUG|Lidocaine|3 ml lidocaine 1% is injected at each block site
223504657|NCT02539693|PROCEDURE|Pilonidal sinus|Removal of pilonidal sinus
223504658|NCT02679092|DRUG|Misoprostol|400 mcg buccal 60-90 minutes prior to procedure
223504659|NCT02679092|DRUG|Mifepristone|200 mg PO on the day prior to D\&E
223504660|NCT02679092|DEVICE|Hygroscopic cervical dilators|osmotic cervical dilators inserted through the internal os
223504661|NCT02269488|DRUG|MEDI3250|MEDI3250
223504662|NCT01351558|OTHER|Knee muscle strengthening exercises|Muscle strengthening exercises of the quadriceps and hamstring muscles will be performed based on a standard muscle strengthening exercise paradigm: 3 sets with 6-8 repetitions (corresponding to approximately 80% repetition maximum (RM)) will be performed. The training load will be progressed by means of weekly estimates of muscle strength to ensure a constant load of 80% RM. The exercises will be supervised
223593350|NCT03781505|DRUG|Placebo|Caudal ropivacaine
224195704|NCT02159742|OTHER|Data Collection|
224195705|NCT04410978|DRUG|Tolebrutinib|"Pharmaceutical form: Tablet~Route of administration: Oral"
224195706|NCT04410978|DRUG|Teriflunomide|"Pharmaceutical form: Tablet~Route of administration: Oral"
224195707|NCT04410978|DRUG|Placebo to match Tolebrutinib|"Pharmaceutical form: Tablet~Route of administration: Oral"
224195708|NCT04410978|DRUG|Placebo to match Teriflunomide|"Pharmaceutical form: Tablet~Route of administration: Oral"
224195709|NCT06062953|DRUG|Melatonin|3-9 mg flexible dosing before bed time
224195710|NCT06062953|DRUG|Quetiapine|50-150 mg flexible dosing before bed time
224195711|NCT06062953|DRUG|Placebo|1-3 capsules flexible dosing before bed time
224310550|NCT04298645|OTHER|Glycaemic response to high GI carbohydrates consumed at morning versus evening meals.|Controlled nutrition trial on the glycaemic response to morning and evening meals with high glycemic index carbohydrates among students with early and late chronotypes.
223504663|NCT01351558|OTHER|Upper extremity strengthening exercises|Muscle strengthening exercises of the upper amrs and shoulder girdle will be performed based on a standard muscle strengthening exercise paradigm: 3 sets with 6-8 repetitions (corresponding to approximately 80% repetition maximum (RM)) will be performed. The training load will be progressed by means of weekly estimates of muscle strength to ensure a constant load of 80% RM. The exercises will be supervised
223504664|NCT01351558|OTHER|Cardiovascular fitness exercises|Cardiovascular fitness exercises encompass circuit training including exercises on (but not limited to): ergometer cycles, treadmills (running), and cross-trainers. The exercise intensity is aiming at exercises within 60-85% of maximum heart rate (defined as 220 - age). The heart rate is monitored using a standard heart rate monitor. The exercises will be supervised
223504665|NCT06818708|DEVICE|Experimental Treatment|Percutaneous peripheral nerve stimulation with a frequency between 1-250 Hz, a pulse duration of 1-200 µs, and a current of 0.001-10 mA (1-10,000 µA). If the same pattern holds for the RELAY device as for previously tested peripheral nerve stimulators, we will maximize frequency, minimize pulse duration, and have participants adjust the amplitude, as needed.
223504666|NCT06219122|BEHAVIORAL|Creative arts and psychomotor therapies intervention for people with personality disorders|a Group (max of 9 participants) Creative arts and psychomotor therapies (CAPTS) intervention for people with personality disorders. Consisting of 10 sessions, where two CAPTS disciplines and therapists are represented each session. Each session lasts 90 minutes. Sessions are aimed at psychological adativity thru=ough the CAPTS. The sessions cover warming up in one of the CAPTS, short psycho education and a longer assigment focusing on the session goal. The first half of the interventions focusses mainly on listening to body signals, emotions and emotional needs and dealing in a healthy way with these. The second half will be more complex when dealing with challenges and adapting tot he context in a healthy way are goals of the sessions.
223504667|NCT01245062|DRUG|GSK1120212|MEK inhibitor
223504668|NCT01245062|DRUG|Chemotherapy|Investigator Choice of DTIC or paclitaxel
223504669|NCT03401333|BEHAVIORAL|Text Messaging and Brief Negotiation Interview|An in-person brief motivational intervention coupled with 4 weeks of motivational text messages
223504670|NCT06825559|DRUG|Saroglitazar Magnesium 1 mg|Saroglitazar Magnesium 1 mg will be assigned to all participants enrolled in this open label study
223504671|NCT02015104|BIOLOGICAL|BCG intravesical live (TICE Bacillus Calmette-Guerin (BCG))|TICE BCG for intravesical use, is an attenuated, live culture preparation of the Bacillus of Calmette and Guerin (BCG) strain of Mycobacterium bovis
223504672|NCT02015104|BIOLOGICAL|PANVAC|A recombinant virus vector vaccine containing genes for human carcinoembryonic antigen (CEA), mucin-1 (MUC-1) and three co-stimulatory molecules (designated Triad of costimulatory molecules (TRICOM): B7.1, intercellular adhesion molecule-1 (ICAM-1), and leukocyte function-associated antigen-3 (LFA-3).
223504673|NCT06079918|DIETARY_SUPPLEMENT|Multiple Micronutrient Supplements with 30 mg of elemental iron|MMS with 30 mg iron is the active comparator group. The standard UNIMMAP MMS formulation includes 30 mg of iron which will be taken orally once daily from the time of randomization until delivery.
223504674|NCT06079918|DIETARY_SUPPLEMENT|Multiple Micronutrient Supplements with 45 mg of elemental iron|MMS with 45 mg iron is an intervention group. MMS with 45 mg of iron plus standard UNIMMAP formulation for other 14 micronutrients will be taken orally once daily from the time of randomization until delivery.
223504675|NCT06079918|DIETARY_SUPPLEMENT|Multiple Micronutrient Supplements with 60 mg of elemental iron|MMS with 60 mg iron is an intervention group. MMS with 60 mg of iron plus standard UNIMMAP formulation for other 14 micronutrients will be taken orally once daily from the time of randomization until delivery.
223504676|NCT06855875|PROCEDURE|autogenous tooth graft combined with bovine bone|unilateral alveolar cleft which will be repaired using autogenous tooth graft combined with bovine bone .
223504677|NCT06855875|PROCEDURE|bovine bone|unilateral alveolar cleft which will be repaired using bovine bone .
223504678|NCT06092151|DEVICE|Silver diamine fluoride|silver diamine fluoride - maximum 1 drop to be applied per visit (manufacturer advises this would treat up to 5 teeth)
223504679|NCT06092151|PROCEDURE|Usual dental care|Usual restorative or preventative care determined by the child's dentist - for examples fillings or crowns
223504680|NCT06859593|DIAGNOSTIC_TEST|Upper Extremity Exercise Capacity, 6-Minute Pegboard And Ring Test|Upper Extremity Exercise Capacity
223504681|NCT02837653|BEHAVIORAL|Physical Activity Counselling|
223504682|NCT02837653|OTHER|Therapeutic Exercise for LBP|
223504683|NCT02837653|OTHER|Superficial Thermotherapy|
224195712|NCT04820179|DRUG|Cabozantinib + Atezolizumab|All the subjects will be treated with the combination of cabozantinib and atezolizumab until disease progression, unacceptable toxicity or patient consent withdrawal (whichever occurs first).
224195713|NCT05864326|DEVICE|Warm group|The operator will introduce a 14Fr or 18Fr Balloon catheter through the cervical canal, up above the internal orifice using a long Pean clamp and inflate the internal balloon with 30 to 80ml of Heated saline water (NaCl 0.9%) at 40°C - according to the mechanic resistance with a graduated syringe.
224195714|NCT05864326|DEVICE|Room temperature group|The operator will introduce a 14Fr or 18Fr Balloon catheter through the cervical canal, up above the internal orifice using a long Pean clamp and inflate the internal balloon with 30 to 80ml of unheated saline water (NaCl 0.9%) - according to the mechanic resistance with a graduated syringe.
224195715|NCT05603572|DRUG|KAT-101|oral dosage form
224195716|NCT05603572|DRUG|KAT-201|IT dosage form
224195717|NCT04871282|DRUG|AL102|AL102 is an inhibitor of gamma secretase-mediated Notch signaling.
224195718|NCT04871282|OTHER|Placebo|Placebo to match AL102
224195719|NCT05761574|DRUG|Acetaminophen/Naproxen Sodium Fixed Combination|Fixed combination of Acetaminophen/Naproxen Sodium will be administered orally.
224195720|NCT05761574|DRUG|Naproxen Sodium|Naproxen Sodium will be administered orally.
223746950|NCT02653287|OTHER|Control|The control group will receive four individual phone calls focusing on education for SLE disease management, as well as answering any questions the participants have about the study. Topics include: what is lupus, laboratory tests, medications, taking charge of your health care and managing stress (2 sessions). Each call will last about 10-15 minutes, and occur shortly after randomization, then at 1.5, 3, and 6 months.
224195721|NCT05761574|DRUG|Acetaminophen|Acetaminophen will be administered orally.
224195722|NCT05761574|DRUG|Placebo|Placebo will be administered orally.
224195723|NCT06240117|PROCEDURE|Intraoperative cellular salvage|When the patient is randomized to this intervention the cell salvage machine will be set up for intraoperative use. The surgical team will collect blood from the surgical field into the cell salvage machine, which will process the blood for reinfusion. The volume of blood available for reinfusion is determined by the amount of blood lost which can be collected into the cell salvage system. The blood collected into the salvage system will be collected and processed per standard operating room procedure. At least 100mL of blood collected in the system are necessary for processing. If \>100mLs are collected, they will be processed and reinfused. The need for additional blood products and medications will be determined by the anesthesiology team based on the patient's hemodynamic status and will proceed per standard of care.
224195724|NCT06212011|OTHER|Functional Neuromuscular Electrical Stimulation|The functional NMES technique involves the application of electrical stimulation during functional activity. In our study, in the functional neuromuscular electrical simulation group, neuromuscular electrical stimulation will be applied to the lumbar multifidus muscle while individuals perform the activity of standing up from sitting.
224195725|NCT06212011|OTHER|Conventional Neuromuscular Electrical Stimulation|The conventional neuromuscular electrical simulation technique, electrical stimulation is applied without the individual performing voluntary contractions. In our study, conventional NMES will be applied to the lumbar multifidus muscle with the individual lying in the prone position and the individual will not elicit any voluntary contractions during the simulation.
224195726|NCT04515940|DIETARY_SUPPLEMENT|acceptability, tolerance and palatability study|prospective acceptability study
224195727|NCT04813484|BEHAVIORAL|Kickin it with the Gulz|The intervention is a multicomponent intervention, including a screening, groups, and individual sessions.
224195728|NCT05396950|DEVICE|CPAP|CPAP in conjunction with radiotherapy
224195729|NCT05105126|DEVICE|Transcranial Direct Current Stimulation (tDCS)|"The anodal electrode will be placed over F3 using the international 10-20 EEG electrode placement system to target the left dorsolateral prefrontal cortex (DLPFC).~The cathode electrode will be placed on the right dorsolateral prefrontal cortex.~40 stimulation sessions will be completed (20 active, 20 sham), each lasting 20 minutes per session at 1.0mA."
224195730|NCT05105126|DEVICE|Sham tDCS|Sham tDCS
224195731|NCT05058677|DRUG|aerosolized 2% lidocaine (20mg/ml)|The aerosolized solution to be used is 2% lidocaine (20 mg/ml) at a dose of 1.5 mg/kg with a maximum volume of 3 ml or adjusted to a volume of 3 ml with addition of NS solution.The aerosolized solution will be administered with an Aerogen ultrasonic nebulizer, which is standard of care for administering aerosolized solutions in our pediatric intensive care unit (PICU).After each treatment a 3-minute interval will be allowed prior to ETS and there will be a 4-6 hour wash out period between each treatment.
224195732|NCT05058677|DRUG|instilled 0.9% sodium chloride (NS)|The instilled solution will be given with a standard 3-5 ml syringe.After each treatment a 3-minute interval will be allowed prior to ETS and there will be a 4-6 hour wash out period between each treatment.
224195733|NCT05058677|DRUG|instilled 2% lidocaine solution|The instilled 2 % lidocaine solution used will be 1.5 mg/kg, with a max volume of 3 ml or adjusted to a volume of 3 ml with addition of NS solution.The instilled solution will be given with a standard 3-5 ml syringe.After each treatment a 3-minute interval will be allowed prior to ETS and there will be a 4-6 hour wash out period between each treatment.
224195734|NCT05058677|PROCEDURE|Endotracheal Suctioning (ETS)|ETS will be performed in a single pass using a closed-system suctioning. Suction will be applied only on withdrawal of the catheter and fraction of inspired oxygen (FIO2) will remain at 100% for 60 seconds following suctioning and then returned to the preprocedural level (baseline).
224195735|NCT05862246|OTHER|Clinical examination|No intervention, only clinical examination
223593351|NCT06303219|OTHER|RADITIONAL MODERATE INTENSITY TRAINING|"It consists of patients who will receive High-intensity interval training, including running as well as walking at 80% to 95% HR peak. Which is monitored by a smart watch. Before starting treatment, it follows a 10-minute warm-up exercise which includes basic stretches (Quads, Hams, and calf muscles) with a 30-second hold of both legs and same exercise will be pursued for the cool-down period. This intervention will be performed 5 days per week for 4 weeks.~The total duration of this session will be 50 minutes"
223746951|NCT03866343|OTHER|Diet low or high in advanced glycation endproducts|All subjects will undergo an intervention consisting of a prescribed diet containing either a low or high quantity of AGEs during 4 continuous weeks.
224195736|NCT02662621|OTHER|blood samples|
224195737|NCT02662621|OTHER|Urine samples|
224195738|NCT05153629|DEVICE|TENS|TENS device used four times a day for 60 minutes each time
224195739|NCT04133675|DEVICE|BTL Emsella|The Emsella Chair is a novel high-intensity focused electromagnetic (HIFEM) technology for the treatment of SUI, in addition to other pelvic floor related disorders. HIFEM technology induces deep pelvic floor muscle contractions designed to deliver the equivalent of 11,200 Kegel exercises over 28 minutes. The treatment paradigm consists of 3 different phases. The phases consist of an intense stimulation of the pelvic floor muscles (PFM), which consists of stimlulation and relaxation. The repetition of the phases and focused electromagnetic energy delivery leads to pelvic floor stimulation, adaptation, and remodelation.
224310551|NCT00861198|OTHER|ERCP as per medical indication|ERCP as per medical indication
223746952|NCT05829486|PROCEDURE|gastroscopy|anaesthetic management of ambulatory endoscopic procedures
223746953|NCT00345137|DRUG|Ng-monomethyl-L-arginine (drug)|
223746954|NCT02838680|DEVICE|HLT Transcatheter Aortic Valve System|Transcatheter aortic valve replacement with HLT Transcatheter Aortic Valve System
223746955|NCT05133518|DRUG|MELT-300|Sublingual tablet
223746956|NCT05133518|DRUG|Midazolam alone|Sublingual tablet
223746957|NCT05133518|DRUG|Ketamine alone|Sublingual tablet
223746958|NCT05133518|DRUG|Placebo|Sublingual tablet
224310552|NCT03137927|BIOLOGICAL|Vaccine GamLPV|live intranasal vaccine for whooping cough prevention
224195740|NCT04133675|DEVICE|Sham BTL Emsella|Sham subjects will be positioned on the device in the same manner as the active treatment group. The sham treatment will be provide some sensation without active HIFEM technology. The programming for the sham treatment will have an amplitude limitation, with the setting below therapeutic level (\<10% power).
224195741|NCT00102011|PROCEDURE|annual screening|Participants with negative baseline FOBT undergo FOBT annually for up to 4 years in the absence of a positive FOBT
224195742|NCT00102011|PROCEDURE|fecal occult blood test|Participants undergo a baseline fecal occult blood test (FOBT)
224195743|NCT00102011|PROCEDURE|screening colonoscopy|Patients undergo baseline screening colonoscopy
224195744|NCT00102011|PROCEDURE|standard follow-up care|Standard care
224195745|NCT02100215|OTHER|Common readings and educational handouts|Participants in all groups have common readings related to policies for nursing care in acute care facilities. There will be additional handouts related to performing safety checks and a focused physical assessment.
223504684|NCT05960656|DRUG|Empagliflozin 25 MG|A medication used in the management and treatment of type 2 diabetes mellitus. It is in the sodium-glucose co-transporter (SGLT-2) class of medications.
223504685|NCT05960656|OTHER|Placebo|Inert tablet
223504686|NCT03289000|DEVICE|iTotal Posterior Stabilized (PS) Knee Replacement System|Patient-specific posterior stabilized total knee replacement and patient specific surgical jigs
223504687|NCT06996626|DEVICE|Revealed Alerts|Bedside reveal of alerts generated by the alerting system
223504688|NCT06996626|DEVICE|Unrevealed Alerts|Alerts will be generated but not revealed.
223504689|NCT01398527|OTHER|Educ sessions & LTC Osteoporosis toolkit|Three points of contact to be made. The first being a 1-hour personal visit at each intervention LTC home from an osteoporosis expert with the homes professional or health advisory committee (PAC or HAC). The second and third contact points will be made through webinars between the osteoporosis expert and the group from the first meeting.
223504690|NCT07019051|DIAGNOSTIC_TEST|Transthoracic Echocardiographic Evaluation|Non-invasive transthoracic echocardiography will be performed prior to the initiation of continuous veno-venous hemodiafiltration (CVVHDF) in ICU patients. The evaluation includes measurements of LVOT VTI, MAPSE, TAPSE, S' wave velocity, and E/e' ratio to assess cardiac function and estimate the risk of hemodynamic instability. The procedure will be conducted at the bedside using standard parasternal and apical windows by trained intensive care physicians or cardiologists. No contrast, sedation, or invasive monitoring will be used.
223504691|NCT07030309|OTHER|Gastroschisis|"Gastroschisis (GS) is a congenital abdominal wall defect in which the intestine is located outside the abdominal cavity. The prevalence of the GS classifies it as a rare disease (ORPHA:2368) Pregnancy complicated by gastroschisis is associated with an increased risk of serious perinatal complications.~The presence of accompanying intestinal anomalies (atresia, necrosis, perforation, and volvulus), which qualifies the defect in the cGS (complex gastroschisis) group, as opposed to sGS (simple gastroschisis), where these anomalies are absent.~cGS is associated with significantly increased neonatal morbidity and mortality when compared to sGS."
223504692|NCT05407896|OTHER|myKIDNEY decision aid|Patients and caregivers will be counselled using myKIDNEY decision aid which includes a video. Patients will be asked to complete a values clarification exercise (VCE). If a caregiver is recruited without their patient, he/she will be asked to complete the VCE on patient's behalf (i.e., surrogate). At the end of VCE, the participant will be given real-time feedback on which treatment might be the best fit for the patient. With the patient's consent, this information will be shared with the treating physician who can then make recommendations based on the patient's preferences.
223504693|NCT07036562|BEHAVIORAL|Time-restricted eating and high-intensity interval training|1-month intense periods of maximal daily eating window of 10 hours and high-intensity interval training (three weekly, unsupervised, aerobic exercise sessions performed at \> 90 % heart rate maximum), separated by 3-month maintenance periods of time-restricted eating on 5 days per week and minimum 1 HIIT session per week. Each exercise session will last for 33-38 minutes. Participants will receive digital follow-up once weekly during intense periods, and once monthly during maintenance periods. The intervention period will be 12 months in total.
223593352|NCT06303219|OTHER|HIGH INTENSITY INTERVAL TRAINING|"It consists of patients who will receive Moderate-intensity interval training, including running as well as walking at 60% HR peak. Which is monitored by a smart watch. Before starting treatment, it follows a 10-minute warm-up exercise which includes basic stretches (Quads, Hams, and calf muscles) with a 30-second hold of both legs and same exercise will be pursued for the cool-down period. This intervention will be performed 5 days per week for 4 weeks.~The total duration of this session will be 50 minutes ("
223593353|NCT06429774|OTHER|Neurological function|Neurological function will be examined using Glasgow Coma Scale (GCS) and Extended Glasgow Outcome Scale (GOSE).The GOSE was created as an advancement from the original GOS. The GOSE score categorizes the prognosis of patients with traumatic brain injury into eight categories.The 8 categories are: Dead, Vegetative State, Lower Severe Disability, Upper Severe Disability, Lower Moderate Disability, Upper Moderate Disability, Lower Good Recovery, and Upper Good Recovery.
223593354|NCT06429774|OTHER|Mental State, cognitive function, and life quality assessment|Mental State, cognitive function, and life quality will be examined using the Generalized Anxiety Disorder-7 (GAD-7), Patient Health Questionnaire-9(PHQ-9), Rivermead post-concussion symptoms questionnaire(RPQ), PTSD Checklist-5 Version(PCL-5)，Six-Item Screener（SIS） and 12-Item Short-Form Health Survey version 2(SF-12v2).
223593355|NCT06429774|OTHER|Peripheral blood test|Collect peripheral blood samples from patients.
224195746|NCT02100215|OTHER|Expert Modeling|70 minutes of expert modeling videos
224195747|NCT02100215|OTHER|Voice Over Power Point|60 minutes of Voice Over PowerPoint presentations
224195748|NCT05818046|DIAGNOSTIC_TEST|transcutaneous oxygen pressure|External proxe fixed to the skin and ultrasound examination.
224195749|NCT05818046|PROCEDURE|Supervised Exercise therapy|Supervised exercise therapy consists of three exercise sessions per week for 3 months, combining treadmill walking, lower limb muscle strengthening and stretching exercises. It is considered highly effective for people with leg pain related to peripheral arterial disease and has shown statistically significant improvements in maximum walking distance and quality of life parameters.
224310553|NCT03137927|OTHER|Placebo|Placebo
223593356|NCT06429774|OTHER|Hematoma test|Collect hematoma fluid, dura mater, and hematoma outer membrane samples from patients.
224195750|NCT04560088|BEHAVIORAL|Mindfulness|Mindfulness-based mobile health intervention.
224195751|NCT04560088|BEHAVIORAL|Breathing|Breathing mobile health intervention.
224195752|NCT04402125|BEHAVIORAL|TargEted MAnageMent Intervention (TEAM)|"TEAM targets acquisition of self-management expertise and use of healthy behaviors that are intended to reduce stroke risk and burden. TEAM participants will continue in their regular medical care, supplemented by the TEAM intervention. Components are as follows:~1. A 60 minute initial session in which the nurse and the PED meet with the patient who has experienced stroke or TIA. The initial session will cover introductions, orientation, and logistic planning.~2. Five 60-minute group sessions with 6-10 stroke survivors (and their care partners as applicable) held approximately 4 weeks, 6 weeks, 8 weeks, 10 weeks, and 12 week after enrollment. Sessions are co-lead by a nurse and a PED.~3. Six brief telephone sessions implemented after the conclusion of the 5 TEAM group sessions. Calls will be conducted every 2 weeks for 12 weeks. Calls will reinforce group session content, provide social support and facilitate linkage with other care providers."
224195753|NCT05182476|DRUG|Placebo|Oral tablets
224195754|NCT05182476|DRUG|Luvadaxistat|Oral tablets
224195755|NCT05366842|DRUG|Stravix lyopreserved placental tissue (LPT)|Participants will undergo surgical implantation of Stravix lyopreserved placental tissue (LPT) during a standard of care radical prostatectomy.
224195756|NCT05366842|PROCEDURE|Radical prostatectomy|Standard care (no placement of tissue)
224195757|NCT05097261|DRUG|Ketamine|Racemic ketamine® will be administered by continuous infusion in a prefilled 50 ml syringe at a concentration of 50 mg/ml, undiluted. The ketamine dose is 1 mg/kg/h, to a maximum dose of 120 mg/hour, which corresponds to an infusion rate of 0.02 ml/kg/h to a maximum rate of 2.4 ml/h.
224195758|NCT05097261|DRUG|Placebo|Placebo (NaCl 0.9%) will be provided in the same type syringes and administered at the same infusion rate as the IMP (0.02 ml/kg/h to a maximum rate of 2.4 ml/h).
224195759|NCT00798122|PROCEDURE|Intravascular ultrasound|intravascular ultrasound
224195760|NCT00798122|PROCEDURE|MRI|cardiac MRI
224195761|NCT04100915|OTHER|No Intervention|There is no intervention for this study
224195762|NCT06808802|DRUG|Retatrutide|Administered subcutaneously (SC)
224195763|NCT06808802|DRUG|Metoprolol|Administered orally
224195764|NCT03968055|OTHER|Integration with Epic|Participants will have CGM data connected to our medical record through an already established pathway (Dexcom app on iOS device to Apple HealthKit to Epic MyChart to Epic)
223504694|NCT07039331|DIETARY_SUPPLEMENT|Short Term Fasting|Short Term Fasting during the first three cycles of NACT (36h before and 24h after the end of each cycle of CT).
223504695|NCT07039331|OTHER|Free Diet|Ordinary diet during the first three cycles of NACT without any change.
223504696|NCT07037862|DRUG|ENTR-601-44|intravenous infusion
224195765|NCT06650449|OTHER|Mobile App-Based Mental Health Support|This intervention uses a mobile application designed to deliver Cognitive Behavioral Therapy (CBT) techniques. The app provides 12 weekly tasks aimed at reducing emotional distress and depressive symptoms in healthcare workers. Tasks include exercises on emotional regulation, coping strategies, and mindfulness. Participants receive notifications to encourage task completion, and the app tracks progress over the 3-month period. At the start and end of the study, participants will complete the PHQ-9 and GHQ-12 questionnaires to assess their mental health status.
224195766|NCT04853914|DEVICE|HIFU treatment|HIFU treatment of Benign Prostatic Hyperplasia
224195767|NCT02665273|PROCEDURE|Greater occipital nerve block|Bilateral greater occipital nerve block
224195768|NCT02665273|DRUG|Bupivacaine|0.5 cc of 0.5% bupivacaine injected intradermally
224195769|NCT02133716|OTHER|expressed breast milk|"The administration will be by direct instillation feeding syringe (maximum capacity 1ml) in the front of the mouth of the infant and accompanied throughout the administration of non-nutritive sucking (pacifier) and manual containing both sucrose treatment oral, as in the oral expressed breastmilk.~A single dose prior to venipuncture of expressed breast milk given two minutes in the sequence and then will proceed to the venipuncture care nurse responsible for the child, accompanied at all times provided the technical permitted with non-nutritive sucking and containment."
224195770|NCT02133716|BEHAVIORAL|sucrose 24% oral|"The administration will be by direct instillation feeding syringe (maximum capacity 1ml) in the front of the mouth of the infant and accompanied throughout the administration of non-nutritive sucking (pacifier) and manual containing both sucrose treatment oral, as in the oral expressed breastmilk.~A single dose prior to venipuncture of oral sucrose 24% given two minutes in the sequence and then will proceed to the venipuncture care nurse responsible for the child, accompanied at all times provided the technical permitted with non-nutritive sucking and containment."
224310554|NCT03332927|OTHER|Egg based breakfast foods|Two eggs/day, 6 days per week provided as breakfast foods such as burrito-type roll-up, egg sandwich and omelet.
224310555|NCT03332927|OTHER|Non-egg based breakfast foods|Non-egg based control foods provided as breakfast foods 6 days per week such as waffles, ready-to-eat cereal, fruits and cheeses.
223504697|NCT07037862|DRUG|ENTR-601-44 - matching placebo|intravenous infusion
223504698|NCT06710288|DRUG|Gemcitabine|Dose: 800 mg/m2 intravenously (IV) Frequency: administered on Day 1, Day 8, and Day 15 of each cycle (every 4 weeks)
223504699|NCT06710288|BIOLOGICAL|N-803|Dose: fixed dose of 1.2 mg subcutaneously (SC) Frequency: administered on Day 1 and Day 15 of each cycle starting at Cycle 2 (every 4 weeks) and when the last dose of M-CENK is administered, N-803 will be administered on Days 1 and 15 of the same cycle followed by 3 additional doses, 2 weeks apart (total of 5 N-803 doses).
223504700|NCT06710288|BIOLOGICAL|M-CENK|Dose: 0.15 to 0.75 × 109 cells per infusion intravenously (IV) Frequency: administered on Day 1 of each cycle as long as M-CENK cells are available.
223504701|NCT07043907|DRUG|PANK-003 cell injection combined with standard postoperative adjuvant chemotherapy|PANK-003 cell injection combined with standard postoperative adjuvant chemotherapy
223504702|NCT07046533|PROCEDURE|(pulpotomy)|non invasive technique depends on remove only the coronal pulp tissue instead of remove all pulp tissue
223504703|NCT07046533|PROCEDURE|root canal treatment|invasive technique depends on remove all radicular and coronal pulp tissue
223504704|NCT07045051|OTHER|Low-Glycemic Breakfast Containing Oats and Mango|Low-glycemic breakfast of 80 grams of oats prepared with 473mL water and sweetened with 146 grams of mango.
223593357|NCT06017791|OTHER|tunnel technique with a 3D printed PEEK shell to fill the skeletal subnasal depression|"The area will be anesthetized using infiltration technique with 1.5ml of anesthetic solution containing Articaine Hydrochloride 68 mg/1.7 ml with Adrenaline 0.017 mg/1.7 ml~Two bilateral full thickness vertical incisions will be created using a #15 blade. One on each side of the frenum~A subperiosteal tunnel connecting the two vertical incisions will be created using a periosteal elevator/tunneling knife until the complete communication between the two ends is established~The custom made PEEK framework will be inserted from the incision on one side and eased through until it sits in the subnasal concavity.~Once fitted in place the shell will be fixed in place using two mini screws bilaterally, one on each side.~The two vertical incisions will be closed by interrupted sutures 6-0 Polyglycolic acid suture material"
223593358|NCT06303323|OTHER|Qigong Exercise|"Baduanjin Exercise will be performed which consists of 8 standing postures. At least 30 minutes per time. 10-13 min for a set of Badaunjin.~In the first 2 weeks, two sets of Baduanjin will be performed. Total Duration: 6 weeks Frequency: for 3 days/week. (alternative days) Intensity: low-intensity exercise Total Time: 50 Minutes Type: aerobic training"
223593359|NCT06303323|OTHER|Wu Dang Tai Chi|"Wu Dang 13 form postures will be performed. Initially, each posture will be performed 3 times then progressively increase to more according to the patient's discomfort.~Total Duration: 6 weeks Frequency: 3 times/ week (alternative day ) Intensity: Low to Moderate Intensity Time: 50 Minutes Type: aerobic training"
223593360|NCT00773240|DRUG|Grazax|1 tablet, 75,000 SQ-T, daily during the trial period
223593361|NCT00773240|DRUG|placebo|1 placebo tablet, matching the active treatment, daily during the trial period
223504705|NCT07045051|OTHER|High-Glycemic Breakfast Containing Cereal and Mango|High-glycemic breakfast of 84 grams of corn flakes prepared with 355mL of 2% milk and sweetened with 262 grams of mango.
223504706|NCT07045051|OTHER|Low-Glycemic Breakfast Containing Oats and Table Sugar|Low-glycemic breakfast of 80 grams of oats prepared with 473mL of water and sweetened with 20 grams of table sugar.
223504707|NCT07045051|OTHER|High-Glycemic Breakfast Containing Cereal and Table Sugar|High-glycemic breakfast of 84 grams of corn flakes prepared with 355mL of 2% milk and sweetened with 36 grams of table sugar.
223504710|NCT07055919|DEVICE|Structural Heart Surgery Assist System|Following femoral venous access and transseptal puncture, the steerable guide catheter and transcatheter mitral valve clip system are inserted and mounted onto the Structural Heart Surgery Assist System. The surgeon manipulates the joystick and controls on the operator console, guided by real-time animations on the human-machine interface that confirm the direction and range of device motion. Under fluoroscopic (DSA) and echocardiographic guidance, the system assists in performing edge-to-edge mitral valve repair. The procedure achieves regurgitation reduction by either creating a double-orifice configuration (A2/P2 segments) or approximating the opposing leaflets at the A1/P1 or A3/P3 regions.
223504711|NCT07055919|DEVICE|Manual MitraClip G4|Manual MitraClip G4
223504712|NCT07057245|DIETARY_SUPPLEMENT|Protein supplementation with an animal-based protein isolate|Study participants will consume, in random order, twice daily (2 x \~20 g) a plant protein (fava bean protein isolate), animal protein (milk protein isolate) or control (cornstarch providing no extra protein)
223504713|NCT07057245|DIETARY_SUPPLEMENT|Protein supplementation with a plant-based protein isolate|Study participants will consume, in random order, twice daily (2 x \~20 g) a plant protein (fava bean protein isolate), animal protein (milk protein isolate) or control (cornstarch providing no extra protein)
223504714|NCT07057245|OTHER|Control arm - cornstarch|Study participants will consume, in random order, twice daily (2 x \~20 g) a plant protein (fava bean protein isolate), animal protein (milk protein isolate) or control (cornstarch providing no extra protein)
223504715|NCT07057271|DRUG|CJC-1134-PC Injection|Double-blind Treatment Period: 0.2ml (2mg) once weekly ×24 weeks (Week 1 to Week 24); Open-label Treatment Period: 0.2ml (2mg) once weekly ×28 weeks (Week 25 to Week 52)
223504716|NCT07057271|DRUG|Placebo|Double-blind Treatment Period: 0.2ml (0mg) once weekly ×24 weeks (Week 1 to Week 24); Open-label Treatment Period: 0.2ml (2mg) once weekly ×28 weeks (Week 25 to Week 52)
223504717|NCT07055932|BEHAVIORAL|"Interactive Oral Health Education Program"|"The interactive program in this study is distinguished by its multi-modal, hands-on approach and its sustained, bi-weekly delivery over two months, whereas most other school-based interventions rely on a single lecture or short-term animation. Specifically, our program:~Combines interactive lectures with live demonstrations (brushing/flossing on models), group discussions, and educational puzzles to reinforce learning through active participation rather than passive listening.~Uses anatomical tooth-and-gum replicas alongside PowerPoint slides and photographs to bridge theory and practice within each 30-45-minute session.~Addresses periodontal risk factors (e.g., smoking, diet) in dedicated sessions, integrating behavioural change techniques (e.g., problem-solving brainstorming, personalized feedback) rather than focusing solely on plaque removal.~Is delivered in six sessions (one every 10 days) to maximize retention and allow for iterative skill practice, unlike brief brush-along"
223504718|NCT06794411|BEHAVIORAL|Intervention group: Food habits and physical activity program|"5 dynamic face-to-face sessions to promote healthy eating and regular physical activity. The 5 sessions are structured based on the pedagogical approach of Seeing, Judging and Acting (Gibson, 1999; Rodríguez-Bailón, et al., 2016). This methodology provides a logical structure to achieve nutritional and physical activity self-analysis. It is applied based on 3 stages:~* 1st reflective stage: to raise awareness about the importance of following healthy eating and physical activity habits and identify to what extent families are close to the healthy recommendations in relation to these two habits (first two sessions).~* 2nd: more active stage, to acquire strategies and learn to put these recommendations into practice in their day-to-day lives (session 3th and 4th session).~* 3th: to plan specific actions to address and transform some aspects of improvement by freely assuming one's own commitment proposals with the aim of modifying the presented reality, if deemed appropriate (last session)."
223504719|NCT06794411|BEHAVIORAL|Usual Care Group|They will be evaluated on baseline, final and follow up, and they will recieved basic nutritional and physical activity information.
223593362|NCT00308074|DRUG|Aripiprazole|open-label, flexible-dosing
224195771|NCT02013726|DEVICE|MBI Scan: The LumaGEM®|The LumaGEM Scanner is a dual-head, MBI scanner that has previously been cleared for medical marketing (510(k) number K111791), and has been used to image more than 5,000 patients to date. The LumaGEM MBI scanner is used as a diagnostic adjunct to mammography screening for problem cases The efficacy of MBI has been well documented in clinical trials. The LumaGEM MBI scanner is a dual-head, small field-of-view (FOV) device for developing an MBI image of Tc99m-Sestamibi uptake within the breast. The device consists of solid-state detectors, a data acquisition system, and a computer. The detectors are also used to immobilize the breast during image acquisition by mild compression. The detectors are housed in two heads that are positioned on both sides of a compressed breast.
224195772|NCT02013726|DEVICE|3D Mammogram/Breast Tomosynthesis Scan: Selenia® Dimensions®|The breast tomosynthesis procedure involves x-ray imaging of the breast using a moving x-ray source and digital detectors composed of cesium iodide crystals on an amorphous silicon layer or of solely selenium in order to produce an image of the breast. This procedure is considered to basically be a modification of mammography and also is used as a diagnostic adjunct to mammography screening for problem cases.
224195773|NCT03818334|DRUG|Cyclophosphamide|Cyclophosphamide 1000 mg/flask
224195774|NCT03818334|DRUG|ATG|Antihuman T-Lymphocyte Immune Globulin 25 mg/flask
223504720|NCT06473805|PROCEDURE|VISTA technique and 3D printed PMMA implant|Intraoral scanning and radiographic examination (CBCT) will be performed to assess the anatomy of the sub nasal area and plan the position, size and thickness of PMMA implant The data will be transferred to 3D planning software to create digital model that fit in the defect followed by 3D printing of the implant using VISTA technique
223504721|NCT06473805|PROCEDURE|VISTA technique and 3D printed PEEK implant|Intraoral scanning and radiographic examination (CBCT) will be performed to assess the anatomy of the subnasal area and plan the position, size and thickness of PEEK implant The data will be transferred to 3D planning software to create digital model that fit in the defect followed by 3D printing of the implant using VISTA technique
223504722|NCT04075656|BEHAVIORAL|Standard of Care|Participants will be provided a folder of educational material on NS, including general information on symptoms, treatments, and possible complications; healthy diet for children taking corticosteroids; and low sodium diet. Site research staff will demonstrate how to check urine for protein with test strips, and educate patients on the definitions of disease relapse and remission. Urine test strips and urine protein logs will be provided to ensure that each participant can check their urine daily for protein. Participants will be instructed to check their urine daily for protein and call their provider within 1 business day for relapses and remissions.
223504723|NCT04075656|BEHAVIORAL|UrApp|Caregivers/parents will download UrApp at the baseline visit. UrApp contains instructional videos to guide users. The telephone number of the patient's provider will be entered into UrApp and participants will be able to call their providers directly through UrApp. The email address of the Emory study staff will also be entered. UrApp will automatically e-mail test results to the research staff when elected by the users. Participants will be asked by study staff, and reminded by the app, to call their providers and send urine testing results to the study staff whenever there is a relapse or remission. When the study staff receives alerts of a relapse/remission via UrApp, the information will be communicated to the treating physician within 1 business day.
223504724|NCT03297060|OTHER|SSL Implementation Strategy|Science to Service Laboratory (SSL) is an approach developed by the SAMHSA-funded Addiction Technology Transfer Centers (ATTCs) that consists of didactic training + performance feedback + leadership coaching to improve SBIRT adherence within the pediatric trauma center
223504725|NCT06240143|DRUG|Ipilimumab|intradermal
223504726|NCT06240143|DRUG|Nivolumab|intradermal
223504727|NCT06240143|DRUG|Nivolumab|intravenous
223504728|NCT01552889|BEHAVIORAL|Collaborative Care|No direct treatment will be offered. We will make treatment recommendations to the patient, PCP and cardiologist. Referral to mental health specialist is also possible, depending on need. The nurse case manager will monitor treatment progress and patient status for duration of the intervention period.
223504729|NCT05197621|BIOLOGICAL|mRNA COVID-19 vaccine (Pfizer or Moderna)|mRNA vaccine received at any time during pregnancy course
223504730|NCT00312962|BEHAVIORAL|Targeted cognitive training (TCT)|TCT includes cognitive remediation exercises that participants practice 1 hour per day, 5 days per week, for 20 weeks. TCT exercises are specifically designed to improve speed and accuracy in the perception of and response to verbal and visuo-spatial targets.
223504731|NCT00312962|BEHAVIORAL|Computer games|The control treatment involves commercially available computer games that participants practice 1 hour per day, 5 days per week, for 20 weeks.
223504732|NCT03083730|OTHER|Narrow band UVB treatment (NB-UVB)|NB-UVB light treatment NB-UVB light treatment for 3x/week for 12 weeks (36 visits)
223504733|NCT01517776|DRUG|Cilengitide|Cilengitide 1800 mg/m² i.v. twice weekly with a mandatory platelet-count dependent dose adaptation rule
223504734|NCT01517776|DRUG|Temozolomide|Temozolomide 75 mg/m²/d p.o. for 6 weeks, followed by 1 week rest with a mandatory platelet-count dependent dose adaptation rule
223593363|NCT04706728|OTHER|Listening to playlists with music prior to-, during and after the ECT procedure|Patients choose between two expert-curated playlists with music one day prior to ECT procedures for the first four weeks of their ECT treatment.
223593364|NCT04706728|OTHER|Listening to playlists with music prior to-, during and after the ECT procedure|Patients choose between two expert-curated playlists with music one day prior to ECT procedures for the first two weeks of their ECT treatment.
224195775|NCT00594009|DEVICE|Venovenous CO2 Removal (VVCO2R) in COPD|Patients who meet criteria will be placed on an extracorporeal circuit consisting of an oxygenator, centrifugal pump, tubing and indwelling double lumen venous catheter for CO2 removal for up to 96 hours for treatment of COPD exacerbation requiring hospitalization and intensive care
224195776|NCT01573988|OTHER|Increasing eating frequency|"The subjects receive the same breakfast with two sequences :~* breakfast in one intake at 8:00~* breakfast in four isocaloric intakes (8:00, 9:00, 10:00, 11:00) The sequence made twice : one for metabolic study and one for the study of eating behavior~The lunch during metabolic study is a standard meal The lunch during behavioural study is an ad libitum buffet test meal.~The administration order is determined by randomized allocation. The wash-out period is one to three weeks.~There are not diet or exercise interventions."
223746959|NCT00984243|PROCEDURE|PHOTODYNAMIC THERAPY (PDT)|"Photodynamic Procedure:~Photofrin II will be injected at a dosage of 2 mm/Kg intravenously. Laser treatment will take place 40-50 hours later. An argon-dye or an excimer-dye laser tuned to 620-630 nm will be used.~It is anticipated that a microlens fiber will be used in almost all cases, but a cylinder-diffusing fiber can be used to treat lesions in segmental bronchi if needed.~Argon-dye laser: Power settings 200 milliwatt (mW) microlens and 400 mW for cylinder Excimer laser: 4 milliJoules (mJoules)/pulse at 30 hertz for the microlens~Energy density:~Argon-dye laser: 200-300 Joules/cm\^2 Excimer-dye laser: 100-200 Joules/cm\^2"
224195777|NCT04179929|DRUG|Pediatric-type of chemotherapy|Pediatric type chemotherapy (induction, early and delayed consolidation, reinduction, maintenance). Induction (VCR,PDN,PegASP,DNR). Early and delayed consolidation (high-dose Methotrexate, high-dose Cytarabine, PegASP). Reinduction (VCR, PDN, PegASP, DNR). Maintenance (Methotrexate, Mercaptopurine)
224195778|NCT04179929|PROCEDURE|allogeneic HSCT|allogeneic HSCT
224195779|NCT02507531|DEVICE|NeXsys Embolization System|Woven metallic mesh placed in aneurysm fundus
224195780|NCT00062829|BEHAVIORAL|Teen Driving: Program for parents|A behavioral intervention targeting driving risks unique to young drivers, including completing a behavioral contract, was administered to the intervention group. The control group received safety information appropriate for new drivers.
224195781|NCT02333175|OTHER|Specialist review|Specialist review with individually tailored treatment strategies suggested by specialist
224195782|NCT00256256|DRUG|glucagon-like-peptide-1|Dose: 1.2pmol/kg/min for 6 hours
223593365|NCT04706728|OTHER|Listening to playlists with sound from nature (rain, waves) prior to-, during and after the ECT procedure|Patients choose between two expert-curated playlists with sounds from nature one day prior to ECT procedures for the first two weeks of their ECT treatment
223593366|NCT03103035|OTHER|Blog|Participants randomised to the experimental group are exposed to one blog post each week for a period of 6 months. Blog posts focus on the improvement of fruits and vegetables consumption targeting four main determinants of the behavior: (1) knowledge; (2) attitude; (3) self-efficacy; and (4) motivation/goals. Each post included a step-by-step recipe developed by the research team and featuring fruits and vegetables. Recipes were described textually and also using pictures and/or video. Twenty-six posts were created over the six-month intervention.
223746960|NCT05950789|OTHER|Virtual reality application|"During the preparation stage of the port catheter injection attempt, the intervention group was given a calming video and music concert using virtual reality glasses.~With virtual reality glasses, patients watch three-dimensional video nature images, which we determined according to the patient's preference, accompanied by music. They put on the virtual reality glasses before the process started and removed them after the process was over."
223746961|NCT04324060|DRUG|Danazol + rhTPO (recombinant human thrombopoietin injection)|subcutaneous injection, 300U/kg/d×14d every month，stop if the PLT≥100×10e9/L or increased \>50×10e9/L, total course is 6 months
224195783|NCT03743571|DEVICE|transcranial direct current stimulation|tDCS will be applied over EEG coordinate FpZ to target mPFC activation during exposure therapy
224195784|NCT03743571|BEHAVIORAL|exposure therapy|participants will complete one session of exposure therapy for fear of public speaking, which will involve providing speeches to audiences in virtual reality
224195785|NCT05726383|DRUG|Iscador*P|Iscador P given for 2 cycles with follow up imaging done every 2 cycles. If imaging is negative patient remains on study for 13 cycles. If new lesion is found, then patient is off study.
224195786|NCT03287154|DEVICE|Active tDCS stimulations|20 min, 2mA
224195787|NCT03287154|DEVICE|Sham tDCS|20 min, Sham
224195788|NCT06253195|DRUG|BGB-43395|Administered orally.
224195789|NCT06253195|DRUG|Fulvestrant|Administered via intramuscular injection.
224195790|NCT06253195|DRUG|Letrozole|Administered orally.
224195791|NCT06811090|OTHER|Tele-rehabilitation|Rehabilitation service provided remotely through information and communication technologies.
224195792|NCT06811090|OTHER|Hospital rehabilitation|Rehabilitation program that will be carried out in person at the North Physical Medicine and Rehabilitation Unit. The program will be carried out by a physiotherapist and the patient will be taught: Information about the disease and self-care, Exercise module (Stretching, strengthening and proprioception), and phased gait re-education.
223593367|NCT02092311|PROCEDURE|Combined Microscopic Varicocelectomy|After making a mini-incision at inguinal level, veins are evaluated, and if the including criteria (Complexity and tortuosity of the veins and/or existence of veins that are contiguous with arteries so that separating and ligation of the veins could jeopardize the artery) are existed, only external spermatic vein, if dilated, is ligated at the depth of the inguinal canal, and other veins are left alone for prevention of damage to the artery. Subsequently, another mini-incision is made at high inguinal level and the rest of surgery is conducted by retroperitoneal approach, which is also done microscopically
223746962|NCT04324060|DRUG|Danazol + sodium chloride|Danazol 0.2g tid po+ control (sodium chloride)
224195793|NCT06588296|DRUG|Ixekizumab|Administered SC
224195794|NCT06588296|DRUG|Tirzepatide|Administered SC
224195795|NCT05146726|OTHER|BARMER anemia treatment|BARMER insured patients are informed about the machine autotransfusion directly by the patient blood management (PBM) service and its intraoperative use is organized. The aim of these measures is to ensure that the intraoperative transfusion trigger does not fall below the intraoperative transfusion trigger by integrating the PBM into standard care and to avoid a perioperative transfusion. In addition, a postoperative treatment recommendation is made for the cause-related anemia treatment, e.g. in order to reduce the risk of a renewed anemia-related perioperative transfusion risk in the event of a possible follow-up operation or other elective operations.
224195796|NCT05146726|OTHER|NON-BARMER anemia treatment|Patients not insured with BARMER also receive early anemia detection, selection according to indication intervention (transfusion probability\> 10%) and evaluation for machine autotransfusion through the above-mentioned patient blood management (PBM) restructuring of standard care. In the case of preoperative anemia before an indication intervention and / or an intervention with machine autotransfusion application, the operating clinic will be given a recommendation by the PBM service for the diagnosis and treatment of the preoperative anemia and / or the use of the machine autotransfusion (implementation is the responsibility of the operating clinic)
224195797|NCT02435615|DEVICE|SaniSal Oral Fluid Collector|SaniSal is an oral fluid collector used to collect oral fluid from the mouth with an absorbant sponge.
223593368|NCT02092311|PROCEDURE|Inguinal and Subinguinal varicocelectomy|Microscopic Inguinal and Sub inguinal varicocelectomy, recommended by Goldstein and associates, are currently popular approaches. In this approach the spermatic cord structures are pulled up and out of the wound so that the testicular artery, lymphatics, and small periarterial veins may be more easily identified. In addition, an inguinal or subinguinal approach allows access to external spermatic and even gubernacular veins.
223593369|NCT00733681|DEVICE|PFC Sigma RP TC3 Revision knee system|Orthopaedic implant system for revision total knee replacement
223593370|NCT00741403|DRUG|CPI-613|CPI-613, the investigational drug, is a novel anti-tumor compound believed to operate via a novel mechanism of action that does not belong to any existing pharmacological class of anticancer agents currently being used in the clinics. Specifically, CPI-613 is Cornerstone Pharmaceutical Inc.'s lead drug from its Altered Energy Metabolism-Directed (AEMD) technology platform. It is selective against tumor cells (but not normal cells)according to preclinical studies
223593371|NCT00652080|DRUG|API 31510|Topical Cream; 3% active; AM \& PM application
223593372|NCT02408263|PROCEDURE|Total Hip Replacement (THR) and Total Knee Replacement (TKR)|Total Hip Replacement is a surgical procedure where the cartilage and bone of the hip joint is replaced with artificial materials. Total Knee Replacement involves replacement of all three compartments of the knee the medial, the lateral and patellofemoral compartment.
223593373|NCT00759408|DRUG|BQ-123|6-120 µg/min
223593374|NCT04269356|DRUG|BMS-986256|Specified dose on specified days
223593375|NCT04269356|DRUG|Milk of magnesia|Specified dose on specified days
223593376|NCT04808739|BIOLOGICAL|Adalimumab|Analysis of survival of adalimumab biosimilar in clinical practice
223593377|NCT01529034|DRUG|USL261|
223593378|NCT06426836|OTHER|Amoxicillin-clavulanate|blood sampling in patients receiving amoxicillin-clavulanate as part of routine clinical care
223593379|NCT06426836|OTHER|Piperacillin-tazobactam|blood sampling in patients receiving piperacillin-tazobactam as part of routine clinical care.
223593380|NCT06426836|OTHER|Meropenem|blood sampling in patients receiving meropenem as part of routine clinical care.
223593381|NCT06426836|OTHER|Cefazolin|blood sampling in patients receiving cefazolin as part of routine clinical care.
223593382|NCT06426836|OTHER|Vancomycin|blood sampling in patients receiving vancomycin as part of routine clinical care.
223593383|NCT06426836|OTHER|Teicoplanin|blood sampling in patients receiving teicoplanin as part of routine clinical care.
223593384|NCT06426836|OTHER|Ciprofloxacin|blood sampling and urine sampling in patients receiving ciprofloxacin as part of routine clinical care.
224195798|NCT06978062|DRUG|Bemarituzumab|• Bemarituzumab will be given as a IV infusion
223593385|NCT06426836|OTHER|Amikacin|blood sampling in patients receiving amikacin as part of routine clinical care.
223593386|NCT01991522|BEHAVIORAL|Curriculum Group|
223593387|NCT01991522|BEHAVIORAL|Self-directed learning group|
223593388|NCT04985318|DRUG|Cablivi®|Intervention with Cablivi® take place outside of the study
223593389|NCT03422497|OTHER|Male sex|Male sex-as listed in the discharge abstract database
223593390|NCT03422497|OTHER|Female sex|Male sex-as listed in the discharge abstract database
223593391|NCT03319004|DEVICE|apply phase lag entropy sensor|apply phase lag entropy sensor as well as bispectral index sensor on forehead during the sedation using propofol
223593392|NCT05830071|DRUG|CHF5993|BDP/FF/GB 100/6/12.5 μg pMDI
223593393|NCT05830071|DRUG|CHF5259|GB 12.5 μg pMDI
223593394|NCT05830071|DRUG|Moxifloxacin 400mg|400 mg Oral Tablets
223593395|NCT05830071|DRUG|CHF5993 Placebo|placebo pMDI
223593396|NCT03063281|OTHER|BIological analysis|Biological analysis : ficolin-2 et anti-ficolin-2 antibodies
223593397|NCT03194646|DRUG|Vilaprisan (BAY1002670)|2 mg of Vilaprisan once daily for 12 weeks, 4 treatment periods of 12 weeks, each separated by 1 bleeding episode (3/1 regimen).
223593398|NCT03194646|DRUG|Vilaprisan (BAY1002670)|2 mg of Vilaprisan once daily for 24 weeks, 2 treatment periods of 24 weeks, each separated by 2 bleeding episodes (6/2 regimen).
223593399|NCT03194646|DRUG|Vilaprisan (BAY1002670)|2 mg of Vilaprisan once daily for 12 weeks, 4 treatment periods of 12 weeks, each separated by 2 bleeding episodes (3/2 regimen).
223593400|NCT03194646|OTHER|Standard of care|Standard of care as determined by the investigators (including watch and wait, symptomatic nonhormonal)
223593401|NCT03194646|DRUG|Vilaprisan (BAY1002670)|2 mg of Vilaprisan once daily for 12 weeks, 8 treatment periods of 12 weeks, each separated by 1 bleeding episode (3/1 regimen)
223593402|NCT03194646|DRUG|Vilaprisan (BAY1002670)|2 mg of Vilaprisan once daily for 24 weeks, 4 treatment periods of 24 weeks, each separated by 2 bleeding episodes (6/2 regimen)
223593403|NCT03194646|DRUG|Vilaprisan (BAY1002670)|2 mg of Vilaprisan once daily for 12 weeks, 6 treatment periods of 12 weeks, each separated by 2 bleeding episodes (3/2 regimen)
223593404|NCT00002230|DRUG|Hydroxyurea|
223593405|NCT00002230|DRUG|Efavirenz|
223593406|NCT00002230|DRUG|Stavudine|
223593407|NCT00002230|DRUG|Didanosine|
223593408|NCT02949063|BEHAVIORAL|Comfortable Cafeteria Program|6-week program integrated into the cafeteria lunchtime to build capacity of supervisors and students to create a positive social and emotional atmosphere so that students can enjoy eating their lunch and socializing with peers.
223593409|NCT03954613|COMBINATION_PRODUCT|Ebicomb|Combination product and combination product plus cognitive exercises will primarily be evaluated in this study
223593410|NCT02578056|DEVICE|Midurethral sling|Anti-urinary incontinence procedure, in a prophylactic way.
223593411|NCT02578056|PROCEDURE|Genital prolapse surgery|Surgical correction of genital prolapse
223593412|NCT05854342|OTHER|bicarbonate-calcium water|water with high content of bicarbonate and calcium, low sodium
223593413|NCT04313270|DRUG|Evolocumab|12 weeks of treatment with Evolocumab
223593414|NCT00663403|DRUG|Daptomycin|Daptomcyin 8 mg/kg infused intravenously every 48 hours
224195799|NCT06978062|DRUG|FLOT|FLOT will be given as a IV infusion
224195800|NCT06653491|OTHER|high-speed, low-amplitude talocrural decompression technique and changes at the level of mobility and plantar pressure|high-speed, low-amplitude talocrural decompression technique and changes at the level of mobility and plantar pressure in a supine position
224195801|NCT06653491|OTHER|simulated ankle technique|simulated ankle technique in a supine position
223746963|NCT02722850|BEHAVIORAL|ALIVE|ALIVE is an email-based platform designed to help participants increase their physical activity, increase fruit and vegetable consumption, and decrease their intake of saturated and trans fats and added sugars. This automated system contains content and tailoring that is delivered in the form of emails obtained directly from cancer patients. Additional information they will receive included: tips for achieving those goals, health information, and opportunities for interaction and engagement.
224195802|NCT06984419|DEVICE|Cross-linked hyaluronic acid dermal filler|Alexa Volume is a CE-marked, cross-linked hyaluronic acid dermal filler used for aesthetic correction of midface volume loss. It was administered subcutaneously or to the upper periosteum in adult female participants according to standardized procedures.
224195803|NCT06605118|DRUG|Azithromycin Injection|500mg azithromycin in 250 mL of normal saline
224195804|NCT06605118|DRUG|Placebo|250 mL of normal saline
224195805|NCT06605118|DRUG|Standard of Care Preoperative antibiotics|standard of care preoperative antibiotics (excluding azithromycin) prior to incision
224195806|NCT04115488|BIOLOGICAL|Intravenous (IV) infusions|Intravenous (IV) infusions of a dose of 300mg, every 4 weeks with a total of 12 doses
224195807|NCT06106633|DEVICE|TriNaV|Assess Pain Reduction and Ovarian Perfusion Following Uterine Fibroid Embolization Via Pressure-Enabled Drug Delivery With the TriNav Infusion System
224195808|NCT00885677|DEVICE|Medtronic CareLink® Network|"Continuous monitoring via a disease remote management system.~Patients of the Study group will receive a remote monitor and their device will be programmed to have wireless telemetry, Care Alerts, and the ability to transmit over the Medtronic CareLink® network. Clinical and device conditions will be then monitored continuously and alarms for the physician will be generated if a set of pre-defined potentially harming conditions should occur."
224195809|NCT06650358|DEVICE|Light Adjustable Lens+|The Light Adjustable Lens+ (LAL+) is a posterior chamber, UV absorbing, three-piece, foldable, photo reactive silicone intraocular lens with a squared-posterior optic edge intended to be implanted in the capsular bag following phacoemulsification. Selective exposure to the implanted LAL+ using the Light Delivery Device (LDD) to deliver a spatially profiled UV light produces modifications in the lens curvature resulting in a spherical or spherocylindrical power change postoperatively. A subsequent lock-in exposure is delivered to the implanted LAL+ to stabilize the lens power. The LAL+ has a modified aspheric anterior surface that creates a small continuous increase in central lens power, which is designed to slightly extend the depth of focus.
224195810|NCT04071769|DRUG|Hyperpolarized 129 Xenon Gas Comparing Idiopathic Pulmonary Fibrosis (IPF) Treatment|Whether magnetic resonance imaging (MRI) using inhaled hyper-polarized 129 Xenon gas can help visualize impaired lung function to detect changes over time in Idiopathic Pulmonary Fibrosis (IPF) patients receiving approved IPF treatments
224195811|NCT06821074|DEVICE|Defocus-enhanced spectacles|Vision function training while wearing defocus-enhanced spectacles
223593415|NCT00975949|OTHER|Survey|Parents of subjects were interviewed and two surveys were obtained, the Child Health Questionnaire and the Vineland-II.
223593416|NCT06491784|OTHER|Exercise Therapy|12 week personalised exercise, nutrition and wellbeing programme
224195812|NCT06821074|DEVICE|Single vision spectacles|Vision function training while wearing single vision spectacles
224195813|NCT06537583|DEVICE|Parasym Neuromodulation Device (Treatment Group)|Participant will undergo stimulation in their left tragus for 60 minutes by using Parasym device
223593417|NCT05762406|DEVICE|Respiratory protective mask|"Subjects will perform a cardiopulmonary exercise test (CPET) and a series of standardized daily activities while wearing a protective mask.~During the exercises, oxygen consumption, ventilation and other cardiorespiratory parameters will be assessed using a portable device (K5, Cosmed)"
223593418|NCT01375023|RADIATION|Radiotherapy|daily radiation therapy for 10 days, total dose of 80 cGY
223593419|NCT01375023|BIOLOGICAL|Anti-Thymocyte Globulin|1.5 mg/kg/day, IV from day -11 through day -7 before transplantation
224195814|NCT06537583|DEVICE|Parasym Neuromodulation Device (Sham Group)|Participant will undergo implantation of Parasym device lead in their left tragus but without any stimulation for 60 minutes
224195815|NCT05774756|DRUG|Setmelanotide|Solution for daily subcutaneous injection
224195816|NCT05774756|DRUG|Placebo|Placebo matched to setmelanotide for daily subcutaneous injection
224195817|NCT03277638|DRUG|Pembrolizumab at 7 days prior|Pembrolizumab injections 7 days before surgery
224195818|NCT03277638|DRUG|Pembrolizumab at 14 days post|Pembrolizumab injections 14 days after surgery
224195819|NCT03277638|DRUG|Pembrolizumab at 35 days post|Pembrolizumab injections 35 days after surgery
224195820|NCT03277638|PROCEDURE|Laser Interstitial Thermotherapy|surgical procedure to heat hard to reach tumors with a laser beam
224195821|NCT06603948|DEVICE|Spectral Focused Imaging|Use of SFI for colon inspection during both insertion and withdrawal phase of colonoscopy
224195822|NCT06603948|DEVICE|White Light Imaging|Use of WLI for colon inspection during both insertion and withdrawal phase of colonoscopy
224195823|NCT06588725|BEHAVIORAL|Play Nicely|Multimedia tool and handbook designed to educate parents about healthy discipline strategies.
224195824|NCT06588725|BEHAVIORAL|Cavity Prevention Handout|Two page handout with information about how to prevent cavities.
224195825|NCT06589908|BEHAVIORAL|RELAX glasses|Glasses which are a solution of audiovisual sedation by positiv distraction for hospital medical use
224195826|NCT05868408|OTHER|Control Formula|Infant formula made with intact protein - minimum 1.8g protein/100kcal
224195827|NCT05868408|OTHER|Experimental Formula 1|Infant formula made with hydrolyzed protein - minimum 1.9g protein/100kcal
224195828|NCT05868408|OTHER|Experimental Formula 2|Infant formula made with hydrolyzed protein - minimum 1.9g protein/100kcal
224195829|NCT00972309|BIOLOGICAL|T-cell receptor alternate reading frame protein (TARP) peptide vaccine|Will receive an admixture of the wildtype and epitope enhanced TARP peptides emulsified with Montanide ISA 51 VG and granulocyte-macrophage colony-stimulating factor (GM-CSF). TARP peptide will be administered subcutaneously at weeks 3, 6, 9, 12 and 15 for a total of five vaccinations with a booster dose of vaccine at Weeks 48 and 96
223746964|NCT01002950|DRUG|ACU-4429|ACU-4429 tablets (2, 5, 7, or 10 mg) taken orally once daily for 90 days
223746965|NCT01002950|DRUG|Matching placebo|Matching placebo tablets taken orally once daily for 90 days
224195830|NCT00972309|BIOLOGICAL|T-cell receptor alternate reading frame protein (TARP) dendritic cell vaccine|Will receive peptide pulsed dendritic cells administered intradermally in two vaccination sites. TARP pulsed dendritic cells will be administered at weeks 3, 6, 9, 12 and 15 for a total of five vaccinations with a booster dose of vaccine at Weeks 48 and 96.
224195831|NCT01721668|BEHAVIORAL|Music Supported Rehabilitation|Music Supported Rehabilitation -using musical exercises to improve hand and arm motor functioning.
224195832|NCT01721668|BEHAVIORAL|Conventional Upper Extremity Therapy|-GRASP (Graded Repetitive Arm Supplementary Program-developed Janice Eng, PhD, PT/OT Jocelyn Harris, PhD, OT, Andrew Dawson, MD, FRCP, Bill Miller, PhD, OT) protocol will be used to improve arm and hand function in people living with stroke.
224195833|NCT02604134|PROCEDURE|Prophylaxis|A dental prophylaxis is a cleaning procedure performed to thoroughly clean the teeth. Prophylaxis is an important dental treatment for halting the progression of periodontal disease and gingivitis.
224195834|NCT02604134|DRUG|Fluoride varnish|Fluoride varnish is a highly concentrated form of fluoride which is applied to the tooth's surface, by a dentist, dental hygienist or other health care professional, as a type of topical fluoride therapy.
224195835|NCT02604134|DRUG|Silver Nitrate|a small amount will be applied to the tooth via a cotton applicator. Silver nitrate is a colorless, odorless, transparent solution used as an escharotic, dehydrating and sclerosing agent.
224195836|NCT05129644|DRUG|P1101 (24 mcg)|P1101 solution for injection, 180 mcg/mL, 1.2 mL/vial;Dose/subject: 24 mcg subcutaneously.
224195837|NCT05129644|DRUG|P1101 (48 mcg)|P1101 solution for injection, 180 mcg/mL, 1.2 mL/vial;Dose/subject: 48 mcg subcutaneously.
224195838|NCT05129644|DRUG|P1101 (90 mcg)|P1101 solution for injection, 180 mcg/mL, 1.2 mL/vial;Dose/subject: 90 mcg subcutaneously.
224195839|NCT05129644|DRUG|P1101 (180 mcg)|P1101 solution for injection, 180 mcg/mL, 1.2 mL/vial;Dose/subject: 180 mcg subcutaneously.
224195840|NCT05129644|DRUG|P1101 (225 mcg)|P1101 solution for injection, 180 mcg/mL, 1.2 mL/vial;Dose/subject: 225 mcg subcutaneously.
223593420|NCT01248637|DRUG|Pimonidazole hydrochloride|Pimonidazole is a 2-nitroimidazole that is selectively reduced and covalently binds to intracellular macromolecules in areas of hypoxia (by definition, p02 \<= 10mm Hg) within normal and tumour tissue. Pimonidazole adducts can then be detected by immunolabelling techniques (microscopy, ELISA, flow cytometry etc). In this study, pimonidazole will be administered orally as a one time dose of 0.5gm/m2 24hrs prior to surgery. Since the drug has a half-life of approximately 5 hrs, this time-frame ensures low circulating levels at the time of surgery and therefore reduces the confounding effects of surgical hypoxia on tumour analysis.
223593421|NCT00158691|DRUG|Ethyol|
223593422|NCT04872660|DRUG|Gushen Antai Pill|The Gushen Antai Pill (GSATP, Z20030144) is composed of 10 herbs including radix-polygoni multiflori, radix rehmanniae praeparata, cistanche salsa, radix dipsaci, uncaria, semen cuscutae, rhizoma atractylodis macrocephalae, radix scutellariae, radix paeoniae lactiflorae. Its production follows GMP standards and takes the form of water honey pills, each bag of 6g.
223593423|NCT04872660|DRUG|Placebo pill|The placebo pill is produced by Beijing boran Pharmaceutical Co., Ltd. It can simulate the appearance, color and smell of GSATP formula, but it has no clinical effect because it has no active ingredients.
223593424|NCT04979494|OTHER|ultrasound examination|We conduct abdominal ultrasound examinations for each patient.
223593425|NCT01083589|DRUG|Imatinib Mesylate|Oral 400 mg daily
223746966|NCT03498625|DIAGNOSTIC_TEST|Colonoscopy|Colonoscopy for CD patients in clinical remission
224195841|NCT05129644|DRUG|P1101 (270 mcg)|P1101 solution for injection, 180 mcg/mL, 1.2 mL/vial;Dose/subject: 270 mcg subcutaneously.
224195842|NCT05129644|DRUG|Pegasys|Pegasys for injection, 180 mcg/mL, 1.0 mL/vial, Dose/subject: 180 mcg subcutaneously.
224195843|NCT01331525|BIOLOGICAL|Ipilimumab|This trial will investigate the addition of the anti-CTLA4 antibody ipilimumab to conventional carboplatin and etoposide chemotherapy in extensive stage small cell lung cancer.
224195844|NCT05984628|PROCEDURE|human umbilical cord mesenchymal stem cells|After the completion of the donor site harvesting in the experimental group, allogeneic umbilical cord mesenchymal stem cells are injected into the deep layer of the de-epithelialized area and the surrounding 0.5cm subcutaneous region. After the injection, the wound is covered and dressed with conventional dressings.
224195845|NCT05984628|PROCEDURE|blank solvent|After the completion of the donor site harvesting in the experimental group, the de-epithelialized area and the surrounding 0.5cm subcutaneous region is injected an equal volume of blank solvent for stem cell suspension in the control group. After the injection, the wound is covered and dressed with conventional dressings.
224195846|NCT00352794|DRUG|Lenalidomide|Oral 10 mg daily/days 1-21 of 28 day cycle
224195847|NCT00352794|DRUG|Prednisone|Starting dose oral 30 mg/day during cycle 1, 15 mg/day during cycle 2, and 15 mg every other day during cycle 3, and then it will be discontinued.
224195848|NCT04854356|OTHER|Exercise with blood flow restriction (BFR)|All participants completed high-intensity interval exercise plus (1) BFR applied during exercise phase, or (2) BFR applied during interval phase, or (3) no BFR applied.
223593426|NCT01083589|DRUG|Docetaxel|60 mg/m2 over 1 hour intravenous infusion repeated every 21 days.
223593427|NCT02406404|BEHAVIORAL|Incentive spirometer training|The incentive spirometer, a device that can help improve breathing and strengthen inspiratory muscles. First, the subjects exhaled normally, then placed the mouthpiece in their mouth and sealed their lips around the mouthpiece. Then they inhaled slowly and deeply with their lips sealed tightly on the mouthpiece. After they inhaled as deeply as possible, held their breath for at least 3 seconds, and then removed the mouthpiece from their mouth and breathed out normally. Subjects repeated this technique 10-15 times. When they finished 10-15 exercises, they took a deep breath and coughed. The training was performed ten sessions daily, for 4 weeks.
223746967|NCT04962009|COMBINATION_PRODUCT|Travoprost Evolute® (Travoprost Punctal Plug Delivery System), 166 ug|Each subject will have his/her lower puncta of each eye inserted with a Travoprost Evolute®. Each study subject will be instructed to return to the investigator's office the next day, 7, 28, 60 and 90-days after the insertion of their plugs for follow-up examinations.
223746968|NCT00003641|BIOLOGICAL|interferon alfa-2b|Given IV
223746969|NCT00003641|OTHER|observation|Patients undergo observation for 4 weeks.
223746970|NCT04814758|DIAGNOSTIC_TEST|MRI DWI sequence (ADC values)|Initially and after pre-operative chemotherapy To evaluate the differences in ADC values according to the malignancy degree of nephroblastoma in children
224195849|NCT05502406|PROCEDURE|Instrument Assisted Soft tissue Mobilization|Using a C shaped IASTM tool gentle horizontal stroking at an angle of 45 degree will be given over the cervicodorsal fascia
224195850|NCT05502406|PROCEDURE|Manual Myofascial Release|"Participants will receive myofascial release through velvet glove technique on upper trapezius and sternocleidomastoid muscle using four strokes in the following fashion:~* Begin superior to the clavicle with a loose fist and move the back of the hand over the upper trapezius, fastening the tissue and bringing it over the table.~* The next stroke addresses the curve of the neck, again hooking the tissue while moving the bak of your fist towards the table.~The last stroke goes over the entire cervical spine hooking over the sternocleidomastoid muscle bringing it into myofascial release. Stay away from the carotid pulse, and incase a pulse is felt, do not apply pressure and reposition your hand"
224195851|NCT03733704|DIAGNOSTIC_TEST|Heart rate variability analysis|Heart rate variability analysis extracted from ECG during normal and obstructed breathing
224195852|NCT02662075|DEVICE|E-cigarette/tobacco Smoking Exposure|Subjects will be asked to smoke an e-cigarette containing the equivalence of nicotine in one tobacco cigarette (15 puffs) in the presence of research staff. Each puff will be timed at 4 seconds and there should be a 20-30 seconds interpuff interval as previously recommended.
224195853|NCT02931357|DEVICE|Hyaluronic Acid 0.54%|Administration: application of the gel on the gingival tissue, massage it in gently, five to six times a day
224195854|NCT02931357|DRUG|Calgel®|Administration: application of the gel on the gingival tissue, massage it in gently, three/four times a day (away from meals). In any case the interval between gel applications must be at least 3 hours.
224195855|NCT00783822|OTHER|RGCT|rapid genetic counseling and testing
224195856|NCT01103661|DEVICE|Numeris®-AF Guided Coagulation System with VisiTrax®|Combined epicardial / endocardial procedure using the nContact Numeris®-AF Guided Coagulation System with VisiTrax® epicardially and the St. Jude Medical Therapy™ Cool Path™ Ablation Catheter endocardially.
224195857|NCT05687266|DRUG|Datopotamab deruxtecan|Intravenous (IV) infusion every 3 weeks (Q3W) on Day 1 of each 21-day cycle.
224195858|NCT05687266|DRUG|Durvalumab|Intravenous (IV) infusion every 3 weeks (Q3W) on Day 1 of each 21-day cycle.
224195859|NCT05687266|DRUG|Carboplatin|Intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle for up to 4 cycles.
224195860|NCT05687266|DRUG|Pembrolizumab|Intravenous (IV) infusion every 3 weeks (Q3W) on Day 1 of each 21-day cycle for a maximum of 35 cycles or 2 years (whichever occurs first).
224195861|NCT05687266|DRUG|Cisplatin|Intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle for up to 4 cycles.
224195862|NCT05687266|DRUG|Pemetrexed|Intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle.
224195863|NCT05687266|DRUG|Paclitaxel|Intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle for up to 4 cycles.
224195864|NCT06015269|DRUG|DC cells|At a single arm, 1x107cells dose
224195865|NCT01867996|DRUG|Retosiban|Retosiban will be supplied as clear colorless solution for infusion (300 mg in 20 mL via). Subject will receive loading dose of 6 mg over 5 min infusion followed by 6 mg/hour infusion for 12 hrs on Day 1 and Day 18.
223504735|NCT06633406|OTHER|Age-appropriate Wechsler Intelligence Test|"2.5-6 years: Wechsler Preschool and Primary Scale of Intelligence for children (WPPSI IV)~7-16 years: Wechsler Intelligence Scale for Children (WISC V)~\>17 years: Wechsler Adult Intelligence Scale (WAIS IV)"
223593428|NCT06124391|OTHER|Long-term follow-up|Participants diagnosed with PCOS were not subjected to any specific intervention post-diagnosis. Instead, they were followed up after 6.5 years to assess various outcomes related to PCOS and associated conditions.
223746971|NCT05476341|DRUG|Bevacizumab injection|Recombinant humanized monoclonal antibody injection against human vascular endothelial growth factor
223746972|NCT05476341|DRUG|Bevacizumab injection（Avastin）|Recombinant humanized monoclonal antibody injection against human vascular endothelial growth factor
223504736|NCT06633406|OTHER|Disruptive Behavior Disorders Rating Scale|Dutch version of the Disruptive Behavior Disorders Rating Scale
223504737|NCT06633406|OTHER|Social Responsiveness Scale|"3-18 years: social responsiveness scale 2 (SRS-2)~\>19 years: Social Responsiveness Scale - Adult version (SRS-A)"
223504738|NCT04088357|DRUG|TolaSure Topical Gel|TolaSure topical gel is applied to skin punch biopsies daily for the first seven consecutive days, then three times a week, defined as every two to three days, until closure.
223593429|NCT05838092|DRUG|allo-APZ2-OTS|Allogeneic dermal ABCB5-positive Mesenchymal Stromal Cells (ABCB5+ MSCs)
223593430|NCT05838092|DRUG|Placebo|Placebo
223746973|NCT00955942|DIETARY_SUPPLEMENT|flaxseed|Given orally
224195866|NCT01867996|DRUG|EFZ 600 mg|EZF 600 mg will be supplied as a yellow, capsular-shaped, film-coated tablet. Subjects will receive EFZ 600mg OD in the evening from Day 3 till Day 18.
223593431|NCT06205082|DRUG|LIT-00814|LIT-00814 is an oral tablet.
223593432|NCT04625764|PROCEDURE|Blood sampling and analysis|Blood sampling for pharmacokinetics (Plasma ticagrelor concentrations and its metabolite) and MEA platform testing (ADPtest, TRAPtest)
223593433|NCT02141360|DEVICE|MRI Diagnostic|Commercially available MRI scanner using investigational or standard of care MR coils and a series of investigational Application Packs containing a predetermined set of MRI pulse sequences
223746974|NCT00955942|OTHER|placebo|Given orally
223746975|NCT00116532|DRUG|Escitalopram|
224195867|NCT04400773|OTHER|Plyometric exercises|Types of exercises include resistance tubing 90-90 external rotation, plyometric push-up, reverse overhead throws, rotational wall throw, overhead medicine ball, chest passes.
224195868|NCT04400773|OTHER|Strength training exercises|Types of exercise include push-ups, resisted external rotation, overhead presses, biceps curl, bench presses and triceps kick backs.
224195869|NCT04217941|PROCEDURE|Health education with practical demonstration of nasal ointment|Health education with practical demonstration of medicine was compared to health education without practical demonstration
224195870|NCT04217941|DRUG|Health Education and practical demonstration of Nasal spray and intranasal ointment|We compared the effect of Health education and practical demonstration for using nasal spray and apply intranasal ointment compared to health education without practical demonstration
224195871|NCT02862366|OTHER|Blood sampling|Blood sampling every 6 month following the routine calendar of visit
224195872|NCT05210959|OTHER|The Affordances in the Home Environment for Motor Development-Infant Scale (AHEMD-IS)|The Affordances in the Home Environment for Motor Development-Infant Scale (AHEMD-IS) is an instrument that assesses the quality and quantity of motor development opportunities available in the home for infants aged 3 to 18 months. In this study, the Turkish version of the AHEMD-IS were constructed. Also, the validity and reliability of this version were examined.
224195873|NCT00948896|DRUG|trimethoprim-sulfamethoxazole (TS; TMP/SMX)|daily dosing, 20mgTMP/100mgSMX tabs, 80mgTMP/400mgSMX tabs
224195874|NCT00948896|DRUG|sulfadoxine-pyrimethamine (SP)|monthly dosing given as a single dose, 500mg/25mg tabs
224195875|NCT00948896|DRUG|dihydroartemisinin-piperaquine (DP)|monthly dosing given once a day for 3 consecutive days, 40mg/320mg tabs
224195876|NCT05280691|OTHER|Family Support Intervention (FSI)|In addition to usual care, families in the intervention group will receive (1) specialist nurse support along the patient pathway at defined time-points, from admission to discharge including follow-up care, and (2) nurse-coordinated liaison and structured, interprofessional communication by the ICU team. The intervention is grounded in a family systems approach and guideline-based strategies for family engagement in the ICU and has been pilot-tested in one ICU.
224195877|NCT03795233|BIOLOGICAL|Fecal microbiota transplant G3 capsules|After standard of care therapy with oral vancomycin, frozen oral FMT capsules will be provided in a formulation designed to deliver the product to the large intestine. 30 FMT capsules will be administered over a 2 hour period under direct observation
224195878|NCT03795233|OTHER|Oral Vancomycin alone|Standard of care will be provided with oral vancomycin therapy.
224195879|NCT06514508|DRUG|Motixafortide+G-CSF|Patients will receive the first dose of motixafortide (1.25 mg/kg) by subcutaneous (SC) injection on the evening of Day 4 (10 to 14 hours) prior to initiation of the first apheresis. A second dose of motixafortide can be administered 10 to 14 hours before a third apheresis, if necessary for patients who did not reach the goal of collection. Injections of G-CSF per standard of care.
224195880|NCT06514508|DRUG|Placebo+G-CSF|Patients will receive the first dose of placebo by subcutaneous (SC) injection on the evening of Day 4 (10 to 14 hours) prior to initiation of the first apheresis. A second dose of placebo can be administered 10 to 14 hours before a third apheresis, if necessary for patients who did not reach the goal of collection. Injections of G-CSF per standard of care.
224195881|NCT02630992|DRUG|Amoxicillin-Clavulanate potassium|
224195882|NCT06519903|BEHAVIORAL|BREATH technique|The BREATH techniques include deep breathing, rapid breathing, and alternate nostril breathing exercises. Participants were first instructed on the breathing exercises (at the lowest point of breathing, close the left nostril with the right index finger and exhale through the right nostril): Breathe in through the right nostril, then close it with your thumb and breathe out through the left nostril. This cycle was repeated at least three more times.
224195883|NCT00409565|DRUG|Cetuximab|"* Cetuximab 400 mg/m2 IV over 120 minutes on day 1 of cycle 1 ONLY~* Cetuximab dose will be 250 mg/m2 IV over 60 minutes weekly on ALL subsequent administrations"
224195884|NCT00409565|DRUG|Bevacizumab|Once every 3 weeks, 15 mg/kg of bevacizumab will be given by IV infusion after cetuximab has been given
223504739|NCT04088357|DRUG|Topical Vehicle Gel|TolaSure Vehicle Gel is applied topically to skin punch biopsies daily for the first seven consecutive days, then three times a week, defined as every two to three days, until closure.
223504740|NCT05080543|DRUG|Albumin 20% and terlipressin|Evaluation the effect of adding 20% HSA and terlipressin on microvascular ﬂow index (MFI), flow heterogeneity index, total vessel density (TVD), and perfused vessel density (PVD) in comparison to the standard care in patient with septic shock.
223504741|NCT05715346|DRUG|LEV102 1.0%|Oxymetazoline ophthalmic gel
223504742|NCT05715346|DRUG|LEV102 2.0%|Oxymetazoline ophthalmic gel
223504743|NCT05715346|DRUG|Vehicle|Vehicle ophthalmic gel
223504744|NCT03843216|OTHER|observation|patients not treated
223504745|NCT03843216|OTHER|Physiotherapic scoliosis specific exercise|Specific exercise according to the SEAS (Scientific Exercises Approach to Scoliosis) protocol
223504746|NCT03843216|DEVICE|brace|different kind of braces being elastic, rigid or very rigid. All devices are custom made. The hours of application per day varied from 18 to 24h.
223504747|NCT01838811|BEHAVIORAL|Speed of Process Training|SPT involves trainer-guided practice of computer-based exercises, including Target Detection (indicating presence or absence of targets, identifying targets, etc.) and Discrimination and Localization (performing same/ different discriminations of targets presented very quickly and followed by a masking pattern) 10, 19, 84. Display speed, ranging from 17 to 500 ms, is the primary manipulation during training, which increases task demands and thus demands on PS itself. These training tasks are tailored to each individual's ability by the trainer.
223504748|NCT04685122|PROCEDURE|Phacoemulsification and intraocular lens implantation for cataract|Phacoemulsification and intraocular lens implantation for cataract
223504749|NCT01063582|OTHER|exposure to occupational noise|We performed the measurement of occupational noise exposure through sound level meter and Dosimeter during flight operations of F-16 fighter plane.
223504750|NCT01063582|PROCEDURE|cardiovascular valuation|Cardiovascular valuation was performed via electrocardiogram and echocardiographic techniques to correlate the changes observed during exposure to occupational noise
223504751|NCT02569905|DRUG|parecoxib sodium|parecoxib sodium 40mg
223504752|NCT02569905|DRUG|flurbiprofen|flurbiprofen 50mg
223504753|NCT02569905|DRUG|saline|normal saline
223504754|NCT02560415|DEVICE|Experimental|Gaming Open Library for Intervention in Autism at Home plus Treatment as usual
223504755|NCT02560415|BEHAVIORAL|Comparator|Treatment as usual
223504756|NCT00071331|DRUG|Tolvaptan|
223504757|NCT01291875|PROCEDURE|non-surgical periodontal treatment|Patients in this group will receive a non surgical periodontal therapy: scaling and root planing of the root surfaces under local analgesia (depending on the severity in one session or two sessions within 2 days). Any tooth that from the baseline examination is defined as hopeless or irrationale to treat will be extracted. After to 2 months re-assessment presenting at least one periodontal site with pocket depth of 6 mm will have additional corrective periodontal therapy.
223504758|NCT01291875|PROCEDURE|Supragingival biofilm control|Control group patients will receive a standard cycle of supra-gingival mechanical instrumentation and polishing in one appointment performed as appropriate by a single clinician using a combination of hand and machine driven (piezoelectric) instrumentation.
223746976|NCT05546047|DRUG|Acthar Gel 80 UNT/ML Injectable Solution|Follow up and observation for 12 months off Acthar gel or Acthar gel and Tacrolimus
223504759|NCT01599676|DIETARY_SUPPLEMENT|Citrulline|The subject will receive citrulline 10 g/day orally in the morning for 12 weeks.
223504760|NCT01599676|DIETARY_SUPPLEMENT|Non essential amino acid|Non essential amino acid supplementation
223504761|NCT03957057|DRUG|Iron Carboxymaltose|Intravenous iron carboxymaltose application
223504762|NCT03957057|DRUG|Iron Isomaltoside|Inravenous iron isomaltoside application
223504763|NCT03957057|DRUG|Ferrous sulphate|Oral ferrous sulphate application
223504764|NCT00795405|BEHAVIORAL|Exposure to sporting events|Exposure to sporting events
223504765|NCT00795405|BEHAVIORAL|No exposure to sporting events|No exposure to sporting events
223504766|NCT00004485|DRUG|cyclosporine|
223504767|NCT00004485|DRUG|fludarabine|
223504768|NCT00004485|DRUG|mycophenolate mofetil|
223504769|NCT00004485|PROCEDURE|Bone Marrow Transplantation|
223504770|NCT03989570|PROCEDURE|transversus abdominis plane block|The TAP block will be performed laterally behind the midaxillary line between the iliac crest and the most inferior extent of the ribs. The plane between the internal oblique and transversus abdominis muscle will be located around the midaxillary line with the probe transverse to the abdomen. Anteriorly,The needle will be passed to come in plane with the ultrasound beam and placed between transversus and internal oblique posterior to the midaxillary line then, the local anesthetic will be injected
223504771|NCT03989570|PROCEDURE|erector spinae plane block|The ESP block will be performed into a fascial plane between the deep surface of erector spinae muscle and the transverse processes
223504772|NCT03989570|OTHER|control group|placebo
223504773|NCT05520177|DRUG|601 1.25mg|loading phase (6 months): 601 1.25mg/eye/time, Intravitreal injection, administered once every 4 weeks for 6 consecutive doses
223504774|NCT05520177|DRUG|ranibizumab 0.5mg|loading phase (6 months): ranibizumab 0.5mg/eye/time, Intravitreal injection, administered once every 4 weeks for 6 consecutive doses
223504775|NCT04654052|DRUG|Clopidogrel|Clopidogrel during 11 months
223504776|NCT04654052|DRUG|Previous treatment|non-intervention
223504777|NCT03611465|OTHER|Pace-mapping|Acquire pace-mapping on three distinct populations to better understand the influence of heart disease on electrical conduction.
223504778|NCT03611465|OTHER|Standard pace-mapping examination|Acquire pace-mapping on three distinct populations to better understand the influence of heart disease on electrical conduction.
223504779|NCT03008330|BIOLOGICAL|High-activity natural killer|Each treatment: 8-10 billion cells in all, transfuion in 3 times, i.v.
223504780|NCT01142687|DIETARY_SUPPLEMENT|dihydrocapsiate capsule|"* Group 1: 1 dihydrocapsiate capsule and 2 placebo capsules three times a day within 30 minutes before breakfast, lunch and dinner.~* Group 2: 3 dihydrocapsiate capsules three times per day within 30 minutes before breakfast, lunch and dinner~* Group 3: Placebo 3 capsules three times per day within 30 minutes before breakfast, lunch and dinner"
223504781|NCT02415803|DRUG|low-dose ticagrelor|90 mg loading dose, then 45 mg twice daily for 5 days
223504782|NCT02415803|DRUG|conventional-dose ticagrelor|180 mg loading dose, then 90 mg twice daily for 5 days
223504783|NCT02415803|DRUG|Clopidogrel|300 mg loading dose, then 75 mg once daily for 5 days
223504784|NCT01172301|DIETARY_SUPPLEMENT|Essential amino acid intake + Leucine vs total AA supplement|7 g as bolus
223504785|NCT04743596|DEVICE|High-Definition Videobronchoscopy|Endoscopic inspection and endobronchial biopsy with standard forceps during high-definition videobronchoscopy.
223504786|NCT02454764|DRUG|Tenofovir + Interferon alpha 2b|
223504787|NCT02454764|DRUG|Tenofovir disoproxil Fumarate|
223504788|NCT06042660|OTHER|the prevalence of comorbid conditions|analysis of history of comorbidities at the time of CML diagnosis
223504789|NCT02196909|OTHER|motor function and strength assessment|
223504790|NCT02196909|OTHER|NMR assessment|
223504791|NCT02196909|OTHER|24h urine and serum collection|
223504792|NCT04686409|BIOLOGICAL|COVID-19 vaccines|Participants will be vaccinated with one of the approved COVID-19 vaccines
223504793|NCT05788328|DRUG|Dabigatran etexilate (DE)|Dabigatran etexilate (DE) as oral capsule
223504794|NCT05788328|DRUG|Rosuvastatin|Rosuvastatin as oral tablet
223504795|NCT05788328|DRUG|PF-07081532|PF-07081532 as oral tablets
223504796|NCT02459925|BEHAVIORAL|CBT- Mental Health Program|Manualized Stress Management class; brief individual behavioral counseling.
223504797|NCT02459925|BEHAVIORAL|MOMS GROW|MOMS GROW (Generating Real Opportunities for Work) Teaching, coaching, and supportive services for participants as they navigate their journeys to sustainable employment that pays a family-supporting wage.
223504798|NCT03874403|PROCEDURE|DSA|The changes on DSA on NIVATS and VATS
223504799|NCT00145327|DRUG|Zoledronic Acid|Zoledronic Acid 5 mg in 100 mL physiologic 0.9% normal saline for intravenous infusion.
223504800|NCT00145327|DRUG|Placebo|100 mL physiologic 0.9% normal saline for intravenous infusion.
223504801|NCT00661154|DRUG|Bevacizumab|2-12microCi IV injection
223504802|NCT05931900|DEVICE|moderate-severe or greater (MR ≥ 3+) functional mitral regurgitation (FMR) patients|Functional mitral regurgitation (FMR) is common in patients with myocardial infarction or dilated cardiomyopathy, and portends a poor prognosis despite guideline-directed medical therapy (GDMT).
223504803|NCT03315689|DRUG|Vehicle|Vehicle Topical Solution
223504804|NCT03315689|DRUG|ATI-50002|ATI-50002 Topical Solution
223746977|NCT02441608|DEVICE|KL029 Intimate Lubricant Gel|All the volunteers will receive the application of four dressings (3 placebos and 1 containing the tested product). After a certain period of time, photoirritation and photosensitization will be measured through the evaluation of tested region.
223504805|NCT04624997|OTHER|biological sample|biological sample
223746978|NCT05461651|PROCEDURE|Knee arthroplasty|total or unilateral knee arthroplasty
223746979|NCT00451386|DRUG|MK0826, ertapenem sodium /Duration of Treatment: 14 Days|
223746980|NCT00451386|DRUG|Comparator: ceftriaxone sodium /Duration of Treatment: 14 Days|
223746981|NCT05844189|PROCEDURE|Physical therapy modalities on pelvic floor (manual therapy)|Intravaginal treatment (perineal massage)
224195885|NCT00371748|DEVICE|TAXUS Liberté-SR|Paclitaxel-Eluting Coronary Stent, 2.25 mm
224195886|NCT00371748|DEVICE|TAXUS™ Express2|Paclitaxel-Eluting Coronary Stent System
223504806|NCT06458166|OTHER|Assessment of low frequency fatigue using low frequency eletrical stimulation|Pre-programmed muscle electrical stimuli will be applied via Myocene® software using 3 electrodes: 1 cathode (5 x 10 cm) placed transversely over the proximal quadriceps femoris, and 2 anodes (5 x 5 cm) over the distal vastus medialis and vastus lateralis. Sixteen sets of stimuli will be administered with 5 seconds between sets. Each set consists of a single pulse, a train of 5 stimuli at 20 Hz, and a train of 18 stimuli at 120 Hz, with 1-second intervals between. The stimulation intensity starts at 25 mA and increases by 1 mA per set, reaching 40 mA in the final set. The Myocene® software calculates the ratio of low- to high-frequency evoked forces within each set. The outcome (Powerdex) is the median value of these 16 ratios for each leg. This evaluation will be conducted on both legs, taking 2 minutes per leg.
223504807|NCT05051358|PROCEDURE|Therapeutic Endoscopic Ultrasound|Therapeutic Endoscopic Ultrasound or Interventional Endoscopy for Gastrointestinal Indications
223504808|NCT06366958|PROCEDURE|excision of dorsal wrist ganglion|open and arthroscopic excision of dorsal wrist ganglion
223504809|NCT06314035|OTHER|COPD Patient Decision Aid|Participants in this group will receive two 60-minute intervention sessions in one month. The COPD PDA consists of three main parts: The first component, clinical counselling, guides the participants in reviewing the common EOL scenarios. The second component, an evidence-based decision aid, is presented as an option grid in a booklet and a video to provide information about outcome probabilities of various treatment options and survival estimates in a balanced and unbiased manner. The information is presented in plain language for laypersons. The third component, decision coaching, introduces the concept of ACP and guides deliberation through value clarification.
223504810|NCT06314035|OTHER|General Health Coaching Intervention|The participants in the control group will receive two 60-minute health coaching sessions developed by the PI for another project as an attention placebo control. Trained research personnel will use the same amount of interaction time and similar formats to avoid threats to the study's internal validity. This intervention will focus on lifestyle modification and self-care management unrelated to the tested intervention content or outcomes. The trained research personnel will give the guidebook consisting of general self-management advice to participants in this group.
223504811|NCT04102644|OTHER|Observation|Documentation of course and outcome of hospitalization, labor, delivery, and postpartum period
223504812|NCT06165653|BEHAVIORAL|5-Minute, Audio-Recorded Guided Mediation Practice|"Five different meditation practices will be provided, all of which have been validated in prior research.~* The Body Scan practice consists of instruction in how to direct non-judgmental attention to different regions of the body~* The Mindful Breathing practice consists of focused attention on the breath and metacognitive monitoring and acceptance of discursive thoughts, negative emotions, and body sensations~* The Mindfulness of Discomfort practice consists of instruction in how to zoom in to deconstruct discomfort and map each feelings' spatial location, use mindful breathing to zoom out and broaden the field of awareness to include neglected sensory elements, and shift attention from unpleasant feelings to neutral/pleasant sensations or experiences~* The Savoring practice consists of instruction in identifying and amplifying pleasant memories~* The Loving-Kindness practice consists of instruction in cultivating feeling of warmth and compassion toward the self and others"
223504813|NCT00762788|DEVICE|senofilcon A|1 week extended wear contact lens
223504814|NCT00762788|DEVICE|lotrafilcon A|1 week extended wear contact lens
223504815|NCT00762788|DEVICE|lotrafilcon B|1 week extended wear contact lens
223504816|NCT00762788|DEVICE|balafilcon A|1 week extended wear contact lens
223504817|NCT00762788|DEVICE|comfilcon A|1 week extended wear contact lens
223504818|NCT00762788|DEVICE|etafilcon A|1 week extended wear contact lens
223504819|NCT01728961|DRUG|Artemether/Lumefantrine (AL)|
223504820|NCT04416685|PROCEDURE|primary repair|For Level I-II tumors, in case of segmental resection of PV/SMV, the reconstruction was performed by an end-to-end anastomosis either by direct suture (for defect under 2 cm) or by using an interposition venous or prosthetic graft. For this purpose, autologous grafting we used internal jugular vein and cadaveric iliac vein and alternatively, synthetic PTFE graft was also used.
223504821|NCT04416685|PROCEDURE|segmental resection|For Level I-II tumors, in case of segmental resection of PV/SMV, the reconstruction was performed by an end-to-end anastomosis either by direct suture (for defect under 2 cm) or by using an interposition venous or prosthetic graft. For this purpose, autologous grafting we used internal jugular vein and cadaveric iliac vein and alternatively, synthetic PTFE graft was also used.
223504822|NCT04416685|PROCEDURE|graft reconstruction|Regarding Level III tumors, complete resection of the tumor was done either by tangential excision or by partial venous excision and subsequent reconstruction. To maintain a secure anastomosis, the mesenteric root was mobilized completely or/and splenic vein was divided.
223504823|NCT02197104|DRUG|citocoline|Ten subjects will receive 1,000mg once daily of citicoline. Each subject will stay on the study drug for 12 months. The outcome measures will be assessed at baseline and then again at the end of month 3, month 6, and month 12. The subjects will continue taking the same study drug at the same dose throughout the entire trial.
223504824|NCT02992431|BEHAVIORAL|Participatory patient care planning|Intervention includes the patient activation questionnaire form, a visit to the nurse who conducts the measurements (blood pressure, waist measurement, weight and length) and a visit to the general practitioner who discusses and agrees with the patient about the treatment goals and follow-up resulting in the written PPCP.
223504825|NCT02992431|OTHER|Usual care|Usual care including standard disease specific follow-up with visit to general practitioner.
223504826|NCT04096885|DIAGNOSTIC_TEST|Blood and urine samples, skin and stool swabs|Blood samples will be collected before surgery, on the first postoperative day and after 3-8 weeks. Urine samples will be collected after surgery and after 3-8 weeks. Stool and skin swabs will be collected before surgery.
223504827|NCT01498666|DIETARY_SUPPLEMENT|L. reuteri protectis|1 tablet once daily for 4 weeks
223504828|NCT01498666|DIETARY_SUPPLEMENT|Placebo tablet|1 tablet once daily for 4 weeks
223504829|NCT02296359|BIOLOGICAL|Influenza Vaccination|The individuals will be followed to observe their immune system activation, following their vaccination with the standard influenza vaccine approved for the year by the FDA.
223504830|NCT00365963|DEVICE|Comprehensive Health Enhancement Support System|computer based support and education
223504831|NCT04124510|DRUG|Brand Name: Flutiform K-haler|Brand Name: Flutiform K-haler Generic name: Fluticasone/formoterol dosage form: oral inhalation
224310556|NCT04638075|DEVICE|Supplemental Nursing System|The SNS is a device designed to deliver supplemental milk by suckling at the mother's nipple. A specially designed bottle attaches to the mother's breast and serves as the reservoir for milk. Attached to the bottle is a small tube which runs down to and is placed on the tip of the mother's nipple. With an adequate latch the neonate obtains supplementation by suckling. Additionally, this suckling stimulates milk production (Lawrence \& Lawrence, 2016).
224310557|NCT06718790|OTHER|Using menstrual cup|"In the prospective, randomized controlled study, two groups (Case = Menstrual cup, Control = Menstrual pad) will be randomly formed from individuals who volunteer to participate in the study and meet the inclusion criteria. All participants will be asked to answer the questions in the first interview questionnaire.~Women who will use menstrual cups will be trained on the use of the product and a menstrual cup will be provided for them to use. In the next stage, participants will be called by phone in the 1st, 2nd, 3rd and 6th menstrual cycles and asked to answer questions about their menstrual cup use by sharing an online form."
224310558|NCT06718790|OTHER|Using menstrual pads|In the prospective, randomized controlled study, two groups (Case = Menstrual cup, Control = Menstrual pad) will be randomly formed from individuals who volunteer to participate in the study and meet the inclusion criteria. All participants will be asked to answer the questions in the first interview questionnaire. For women in the group who will use menstrual pads, the average number of pads they have used in their previous menstrual cycles will be asked and an appropriate number of menstrual pads will be provided. In the next stage, participants will be called by phone in the 1st, 2nd, 3rd, and 6th menstrual cycles and asked to answer questions about their menstrual pad use by sharing an online form.
224310559|NCT00537927|PROCEDURE|laparoscopic correction of hernia with mesh|Correction of hernia with mesh and fixation of mesh using one of the arms.
224310560|NCT00485680|DRUG|Olanzapine Hydrochloride|
224310561|NCT00485680|DRUG|Lithium Carbonate|
224310562|NCT00260169|BEHAVIORAL|Collaborative care treatment|Patients receiving collaborative care treatment choose 12 weeks of CBT and/or medication management (antidepressants prescribed by patients' primary care provider) from the study depression care specialist (DCS).
223504832|NCT00669331|DRUG|Inhaled mannitol|400mg dose of Mannitol BD (twice a day) for 52 weeks
223504833|NCT00669331|DRUG|Matched control|50mg dose of Mannitol BD (twice a day) for 52 weeks
223504834|NCT01454063|DRUG|OMS302|OMS302 drug product will be supplied as a sterile, clear colorless liquid, free from particulates of foreign matter. Each vial contains a nominal 4.5 mL solution containing 60.75 millimolar (mM) phenylephrine hydrochloride (HCl) and 11.25 mM ketorolac tromethamine formulated in a 20 mM sodium citrate buffer (pH 6.3 +/- 0.5). For administration to patients, 4.4 mL of the drug product is added to a 500 mL bottle of commercially available balanced salt solution (BSS) through a syringe filter. This will achieve 4.0 mL of the drug product in a 500 mL bottle of BSS.
223504835|NCT01454063|DRUG|Placebo|Placebo drug product will be supplied as a sterile, clear colorless liquid, free from particulates of foreign matter. Each vial contains a nominal 4.5 mL solution containing 20 mM sodium citrate buffer (pH 6.3 +/- 0.5). For administration to patients, 4.4 mL of the drug product is added to a 500 mL bottle of commercially available BSS through a syringe filter. This will achieve 4.0 mL of the drug product in a 500 mL bottle of BSS.
223504836|NCT06066931|PROCEDURE|Plastic surgery of the pelvic floor and perineal wound with counter-displaced skin-subcutaneous fascial flaps after extralevatory abdominal-perineal extirpation of the rectum|Skin-subcutaneous fascial flap on the leg is cut out from one side of the perineal wound, and deepithelized, forming a diamond-shaped perineal wound. The cut flap is immersed in the aperture of the pelvis and fixed with single sutures to the remains of levators of the opposite side. The flap width should be 3-4 cm, sufficient to fill the pelvic aperture. On the opposite side of the wound, a skin-subcutaneous fascial flap is cut out on a triangular leg equal to the width of the previously formed diamond-shaped wound. The flap is moved to the center of the wound, additionally filling wound cavity with it, combining the vertex of the triangle with the vertex of the rhombus. The perineal wound is drained through the contraperture. The flap is fixed with separate nodal seams.
223504837|NCT06066931|PROCEDURE|Plastic surgery of the pelvic floor and perineal wound with local tissues|Simple layer-by-layer suturing of the sciatic-anal and subcutaneous adipose tissue is performed using nodular sutures. The skin was sewn up with nodular sutures at the discretion of surgeons. The installation of abdominal drainage and/or perineal drainage was left to the discretion of the surgeon.
223504838|NCT06066931|PROCEDURE|Plastic surgery of the pelvic floor and perineal wound with mesh endoprosthesis|A mesh allograft with an adhesive coating is inserted into the bottom of the wound, positioned horizontally between the inner surfaces of the ischial bones and vertically between the sacrum and the vagina in women or between the sacrum and the prostate gland in men. The mesh was sewn from behind on both sides of the coccyx or sacrum. From the side, the mesh was attached to the remainder of the levator muscle and from the front to the transverse muscles of the perineum. The installation of abdominal drainage and/or perineal drainage was left to the discretion of the surgeon. The sciatic-anal and subcutaneous fat are sutured using nodular sutures.
223504839|NCT03929055|DEVICE|Physiological assesment|"1. Arterial blood gas analysis.~2. esophageal pressure variation during inspiration and expiration~3. Arterial blood pressure, central venous pressure (CVP), heart rate.~4. diaphragmatic contraction detected by ultrasound"
223504840|NCT04337073|DRUG|Propofol|Before anesthesia induction, M group received intravenous injection of 0.3mg/kg Propofol, while N group received corresponding intravenous normal saline of the same volume. After 1 min, both groups received intravenous injection of dexamethasone sodium phosphate injection of 10mg.
223504841|NCT04337073|DRUG|normal saline|Before anesthesia induction, M group received intravenous injection of 0.3mg/kg Propofol, while N group received corresponding intravenous normal saline of the same volume. After 1 min, both groups received intravenous injection of dexamethasone sodium phosphate injection of 10mg.
223504842|NCT05125627|DRUG|"Progesterone 200 mg Soft Capsule (JSC Farmak, Ukraine)"|Each dose was administered Intravaginally, the capsule introduced deeply into the vagina while lying down, after at least 10 hrs of fasting, under the direct supervision of the Principal and/ or clinical Investigator
223504843|NCT05125627|DRUG|Utrogestan® 200 mg Soft Capsule (Manufacturer: Cyndea Pharma, S.L., Spain, MAH: Laboratoires Besins International, France)|Each dose was administered Intravaginally, the capsule introduced deeply into the vagina while lying down, after at least 10 hrs of fasting, under the direct supervision of the Principal and/ or clinical Investigator
223593434|NCT02692001|OTHER|Intervention MealTrain menu|"Nutrition education was incorporated using an interpretive traffic light system menu labeling. Dietitians categorized current menu items as green, yellow and red based on fiber, added sugar, saturated fats, and sodium content. A section entitled Eat like a superhero was created to prime children to consider what their potential role models choose, and incorporates descriptive names, suggest sample breakfast, lunch and dinner meals with photographs of portion sizes. Original cartoon female grapes and male broccoli superhero characters were created to employ promotional techniques specifically to promote fruits and vegetable selection for boys and girls."
223746982|NCT05844189|DEVICE|CRMRF|"CRMRF application on pelvic floor:~* Externally over the urogenital triangle of the patient,~* Intracavitary application (intravaginal)~* Externally over the urogenital triangle of the patient while the physical therapist performs the intracavitary manual therapy (intravaginal),~The device used is named Intradermik and it is the portable CRMRF device of the brand RÖS'S Estética SL.~It has these features:~* Frequency: 448kHz~* Capacitive power: 450 voltamperes~* Resistive power: 200 watts"
223746983|NCT05844189|DEVICE|Sham CRMRF|The physical therapist applies the same treatment as the Treatment Group but the device is switched off.
223746984|NCT02154581|DEVICE|SLActive implant|
224195887|NCT00371748|DEVICE|Express2|Coronary Stent System
224195888|NCT04487886|DRUG|Duvelisib|Duvelisib will be taken orally at an initial dose of 25 milligrams (mg) twice per day for 14 days. The dose will be de-escalated to 15 mg, twice per day, under certain clinical circumstances.
224195889|NCT04487886|DRUG|Placebo|A placebo to match duvelisib will be taken orally twice per day for 14 days.
224195890|NCT04501874|DRUG|EMB-001|720 mg metyrapone/24 mg oxazepam mg BID
224195891|NCT04501874|DRUG|EMB-001 Placebo|Inactive comparator
224195892|NCT05326958|DEVICE|HRT RCM|Imaging with HRT RCM done only at site 1 (on normal eyes of subjects without DM).
224195893|NCT05326958|DEVICE|HRT RCM-E|imaging done on eyes of all enrolled subjects at site 1 and site 2.
224195894|NCT03899038|PROCEDURE|spinal anesthesia|Patients will receive real-time ultrasound guided spinal anesthesia using Taylor's approach. Various doses of bupivacaine 0.5% (Bupivacaine hydrochloride injection, Harvest Pharmaceutical CO., LTD., Shanghai, China) will be administered.
223504844|NCT04402814|DIAGNOSTIC_TEST|Clungene rapid test cassette|Blood will be tested for the presence of IgG and IgM antibodies using the Clungene rapid test cassette.
223504845|NCT01610401|DRUG|Metformin|metformin 500 mg three times a day, for 3 days
223504846|NCT01610401|DRUG|Pretreatment with metformin in combination of infusion of caffeine.|Pretreatment with metformin 500 mg three times a day for 3 days, in combination with pretreatment with caffeine (4 mg/kg intravenously over 10 minutes) prior to FMD measurement
223504847|NCT01610401|DRUG|No pretreatment with metformin in combination with infusion of caffeine|No pretreatment with metformin in combination with pretreatment with caffeine (4 mg/kg intravenously over 10 minutes).
223504848|NCT06088628|DIAGNOSTIC_TEST|Facial expression; Electroencephalogram; MRI|Recording facial expressions of participants, EEG recordings, and MRI scans.
223504849|NCT04332185|PROCEDURE|vestibular socket therapy|(VST) included the following steps. a-traumatic tooth extraction, the socket curetted and rinsed with normal saline thoroughly . One-cm long vestibular access incision was made using a 15c blade 3-4 mm apical to the mucogingival junction at the related socket. A subperiosteal tunnel was created connecting the socket orifice and the vestibular access incision using periotomes and micro periosteal elevators A flexible cortical membrane shield that is made of cortical bone of heterologous origin of 0.6 mm thickness was hydrated and then trimmed and introduced from the vestibular access incision reaching 1 mm below the socket orifice through the tunnel then stabilized using a micro screw to the alveolar bone apical to the base of the socket .
223504850|NCT01341548|DRUG|Civamide nasal solution 0.01%|20ug/dose, BID for 7 days 0.1 ml to each nostril
223593435|NCT06167707|DRUG|SCP-111|Furosemide injection 80 mg/mL, 80 mg SC via autoinjector x 1 dose
223746985|NCT03659981|OTHER|MRI 7T|The imaging parameters will come from the 7 Tesla Siemens MRI
223746986|NCT02070835|DEVICE|autologous skin cell|autologous skin cell and skin graft
224195895|NCT00100282|DRUG|PPI-1019 (APAN)|
224195896|NCT01046617|DIETARY_SUPPLEMENT|Lactobacillus reuteri (DSM 17938)|5 drops once daily (10(8) CFU) for 21 days
223504851|NCT03005574|BEHAVIORAL|TSW-HP|TSW-HP involves home practice of cognitive exercises along with the training sessions facilitated by the cognitive specialist at the agency.
223504852|NCT03005574|BEHAVIORAL|TSW-T|Participants assigned to traditional TSW will receive the usual TSW program which includes a one hour session per week at BCS for 6 months. This group will not receive home based cognitive practice exercises
223504853|NCT02487706|DRUG|Dolutegravir|Dolutegravir 50mg/day per 5 days
223593436|NCT06167707|DRUG|Furosemide USP|Furosemide injection, USP 10 mg/mL, 40 mg IV over 2 minutes followed by 40 mg 2 hours later
223746987|NCT02070835|PROCEDURE|skin graft|split-thickness skin graft
223746988|NCT00817115|DEVICE|Region-of-Interest Imaging (X-ray Fovea Imaging)|Use of an experimental fluoroscopy system fitted with a region-of-interest attenuator (fovea) to evaluate or treat lesions during cardiac interventional procedures.
224195897|NCT06315634|DRUG|Dexmedetomidine|5 micrograms intrathecal dexmedetomidine
224195898|NCT06315634|DRUG|Midazolam|2 milligrams intrathecal midazolam
224195899|NCT06315634|DRUG|Bupivacain|12.5 milligrams 0.5% intrathecal hyperbaric bupivacaine
223746989|NCT01039233|DRUG|Bicalutamide 50 mg Tablet vs Casodex® 50 mg Tablet|
224195900|NCT02159872|DRUG|Omacetaxine|1.25 mg/m2 subcutaneously every 12 hours on Days 1-3 of every 28-day study cycle.
224195901|NCT00855634|PROCEDURE|Resection of metastases|resection of the primary tumor, followed by resection of the liver metastasis/metastases
224195902|NCT00855634|PROCEDURE|Resection of infiltrated veins|resection of the primary tumor with resection of the portal vein (and/or superior mesenteric vein/splenic
224195903|NCT04936126|DRUG|Quetiapine|Quetiapine XR 100 mg/day augmentation to the ongoing Sertraline treatment for the study period
224195904|NCT04936126|DRUG|Amantadine|Amantadine 200 mg/day (in two divided doses) augmentation to the ongoing Sertraline treatment for the study period
224195905|NCT04936126|DRUG|Pramipexole|Pramipexole 0.375 mg/day (in three divided doses) augmentation to the ongoing Sertraline treatment for the study period
224195906|NCT02409017|PROCEDURE|Insulin drip|
223593437|NCT01891474|DEVICE|U-health care|voice inception technique based U-healthcare service
223593438|NCT05641415|OTHER|Imaging|MRI and x-ray of both shoulders
223746990|NCT06210490|DRUG|Disitamab Vedotin|Disitamab vedotin (RC48-ADC) is a novel humanized anti-human epidermal growth factor receptor 2 (HER2) antibody conjugated with monomethyl auristatin E via a cleavable linker. Two phase II studies, RC48-C005 (NCT03507166) and RC48-C009 (NCT03809013), have shown its significant antitumor potential in patients with la/mUC with HER2 overexpression (immunohistochemistry (IHC) 3+ or 2+). In 2022, RC48-ADC was approved for patients with HER2 overexpressing la/mUC who had received prior chemotherapy in China.
223746991|NCT06210490|RADIATION|Radiotherapy|Radiotherapy dose: 45-50 Gy/25f/5w to lymph node drainage area; 62.5 Gy/25f/5w to metastatic or suspected metastatic lymph nodes.
223746992|NCT06210490|OTHER|Standard of Care|Standard of Care
223746993|NCT01680718|DRUG|Intranasal oxytocin|Through the use of 1oz bottles attached with metered nasal pumps (1 puff = .1ml), participants will self-administer 24 IU oxytocin (Syntocinon, Novartis Pharmaceuticals). 5 puffs per nostril (1 puff = 2.4 IU oxytocin).
223746994|NCT01680718|DRUG|Intranasal vasopressin|Through the use of 1oz bottles attached with metered nasal pumps (1 puff = .1ml), participants will self-administer 20 IU vasopressin (American Regent Pharmaceuticals). 5 puffs per nostril (1 puff = 2 IU vasopressin).
224195907|NCT05131139|DEVICE|Continuous Glucose Monitoring System|Eversense 524 CGM System and ROME CGM System.
224195908|NCT00516217|BIOLOGICAL|galiximab|
224195909|NCT02960191|DEVICE|Magnetic resonance imaging (MRI)|
224195910|NCT02410057|DIETARY_SUPPLEMENT|Protein-reduced α-lactalbumin formula|Protein-reduced formula with levels of α-lactalbumin more similar to breast milk and higher than in whey formula and in standard infant formula
224195911|NCT02410057|DIETARY_SUPPLEMENT|Protein-reduced whey formula|Protein-reduced whey formula with higher levels of α-lactalbumin than in standard infant formula
224195912|NCT02410057|DIETARY_SUPPLEMENT|Standard infant formula|Standard infant formula
223504854|NCT01590966|DRUG|administration of Cimzia®|Patients will be treated with prefilled syringes containing each 200 mg/ml Cimzia® every 2 weeks which will be administered subcutaneously (The first 3 injections, a dosage of 400mg Cimzia® subcutaneously will be administered).
223504855|NCT01590966|DRUG|Immunoscintigraphy with radiolabeled Cimzia®.|All 20 patients will undergo an immunoscintigraphy with radiolabeled Cimzia®. Certolizumab pegol (Cimzia®) is an engineered humanized monoclonal antibody Fab' fragment with specificity for human TNF-α, manufactured in E. coli. The antibody fragment is subsequently purified and conjugated with high molecular weight polyethylene glycol (PEG) (40kDa). Lyophilized Cimzia® will be conjugated with S-HYNIC (a bifunctional chelator). The conjugate will be radiolabeled with Tc-99m by adding 0.1 mg Tricine, 0.01 mg SnSO4 and 750 MBq Tc-99m pertechnetate. A dose of 750 MBq Tc-99m Cimzia® will be injected intravenously.
223504856|NCT01124539|DRUG|AR-67 (7-t-butyldimethylsiltyl-10-hydroxy-camptothecin)|IV AR-67 administered once daily for 5 days on an every 21-day cycle
223504857|NCT04240847|PROCEDURE|Skin incision|Skin incision on medial or lateral to tibial tubercle
223504858|NCT06359522|DEVICE|NIRS monitor|NIRS monitoring data will be collected to determine organ perfusion.
223504859|NCT03055195|DRUG|Mepolizumab 100 mg|Mepolizumab is available as lyophilized powder in sterile vials for injection. The content is reconstituted with 1.2 milliliter (mL) Sterile Water just prior to use. Subjects will receive 1mL (100 mg/mL) bolus subcutaneous injections.
223504860|NCT03055195|DRUG|Placebo matching mepolizumab|Placebo is available as 0.9% sodium chloride solution. Subjects will receive 1mL bolus subcutaneous injections.
223504861|NCT03615898|OTHER|Medication errors analysis|TEN YEAR ANALYSIS OF MEDICATION ERRORS IN THE SPANISH INCIDENTS REPORTING SYSTEM IN ANAESTHESIA
223504862|NCT01665378|DIETARY_SUPPLEMENT|Multiple Micronutrient|"There is no current recommendation for weekly MM supplements for WRA. Therefore, we propose a supplement that contains: The same amounts of iron and folic acid as the weekly, pre-natal IFA supplement; An amount of vitamin D based on the Food and Nutrition Board's Recommended Daily Allowances (RDA); UNICEF/WHO/UNU recommended amounts of remaining nutrients (UNIMMAP recommendations). The supplement is taken weekly during pre-pregnancy.~Vitamin A (μg) 800 Vitamin D (IU) 600 Vitamin E (mg) 10 Vitamin C (mg) 70 Thiamine (mg) 1.4 Riboflavin (mg) 1.4 Niacin (mg) 18 Vitamin B6 (mg) 1.9 Vitamin B12 (μg) 2.6 Folic acid (μg)\* 2800 Iron (mg)\* 60 Zinc (mg) 15 Copper (mg) 2 Selenium (μg) 65 Iodine (μg) 150"
223504863|NCT01665378|DIETARY_SUPPLEMENT|Iron and Folic Acid|The doses of weekly and daily iron (60mg) and folic acid (2800μg) are based on current WHO recommendations for WRA.
223504864|NCT01665378|DIETARY_SUPPLEMENT|Folic Acid|It is unethical to have a placebo group as FA is universally recommended for WRA to prevent neural tube defects. Therefore, the control group will receive 2800 μg FA once a week during the pre-pregnancy period. This dosage is safe and meets the minimum recommended intake of 400 μg/d for Women of Reproductive Age (WRA). Recent studies have shown that a weekly dose of 2800 μg FA is as effective as a daily dose of 400 μg in improving folic acid and reducing homocysteine levels among WRA.
223504865|NCT01908842|DRUG|BNX sublingual tablets|Buprenorphine/naloxone sublingual tablets
223504866|NCT01908842|DRUG|BNX sublingual film|Buprenorphine/naloxone sublingual film
223504867|NCT01908842|DRUG|Buprenorphine|Buprenorphine sublingual tablets
223504868|NCT02568423|DRUG|Mirikizumab - IV|Administered IV
223504869|NCT02568423|DRUG|Mirikizumab - SC|Administered SC
223504870|NCT02568423|DRUG|Placebo - IV|Administered IV
223504871|NCT02568423|DRUG|Placebo - SC|Administered SC
223504872|NCT00197483|DRUG|Pergolide (drug)|
223504873|NCT00249041|DRUG|50 mg Etanercept|50 mg Etanercept liquid injected SC once weekly using prefilled syringes
223504874|NCT00249041|DRUG|Enbrel liquid|50 mg Etanercept liquid injected SC once weekly using prefilled syringes
223504875|NCT00211939|DRUG|calcium acetate|667 mg gelcap, 2-4 t.i.d titrated to serum phosphorus level
223504876|NCT00211939|DRUG|sevelamer|1-3 tablets t.i.d, titrated to serum phosphorus level
223504877|NCT00211939|DRUG|atorvastatin|20 mg PO qD (in PhosLo group), or held until D60 (sevelamer group); titrate by LDL levels and liver function tests
224195913|NCT00000362|BEHAVIORAL|Chin-down position|
224195914|NCT00000362|BEHAVIORAL|Thickened liquid administration|
224195915|NCT05058599|DIAGNOSTIC_TEST|DM|A new technology based on 3D reconstruction and deep learning algorithm to irreversibly erase the biometric attributes whilst retaining the clinical attributes needed for diagnosis and management
224195916|NCT03860038|DRUG|TJ202 and Dexamethasone|one dose of TJ202 16 mg/kg or an adjusted dose will be administered on Day 1 and Day 4 of Week 1, then every week from Week 2 to Week 12, then every 2 weeks from Week 13 to Week 24 and then every 4 weeks thereafter, until the subjects experience an onset of endpoint events like intolerance or PD. DEX 40 mg will be administered on Day 1 and Day 4 of Week 1, respectively and then 40mg weekly thereafter.
224195917|NCT05915780|DEVICE|Cycling|The experimental group will be administered with the cycling exercises in addition to the complete plan of care that is being administered to the control group. The cycling intervention will be performed 3 times per week, for 30 minutes, within a 8-week period
224195918|NCT05915780|DEVICE|Balance Board|Control group will be given with the standard physical therapy intervention that includes progressive resistance training that will be performed using weights, two sets of 10 repetitions will be given for each muscle group, resistance will be increased by ½ Kg as children are able to complete without undue stresses); balance exercises (stand on a balance board, one-leg stance, heal-to-toes stance, walking on balance board, walking on a balance beam, walking on a line, and walking on the inclined surface); flexibility exercises (if required);
224310563|NCT00260169|BEHAVIORAL|Enhanced usual care|Usual care participants are assigned to a 16-week wait-list for the study treatment, during which they are free to receive treatment elsewhere. A letter is given to participants' primary care providers (PCP) that indicates they screened positive for depression. In addition, patients receive an information booklet about depression and a community resource list.
224310564|NCT02011386|DRUG|Treatment|
223504878|NCT00390351|DEVICE|optical coherence tomography|
223504879|NCT00038610|DRUG|Imatinib Mesylate|600 mg by mouth on days 1 - 14 for course 1, and 600 mg by mouth daily days 1-14 (or daily if tolerated with course 1) for courses 2, 4, 6, 8.
224195919|NCT01652040|DEVICE|Resistance Training and Testosterone Patches|We are going to activate the knee extensor muscle group to lift ankle weights over 16 weeks and we are going to provide Tp to improve anabolic profile.
224195920|NCT01652040|DRUG|Testosterone Patches|The investigators will provide Tp patches for 16 weeks for patients with Spinal Cord Injury.
224310565|NCT04588714|BEHAVIORAL|Resilience-based, Energy Management to Enhance Wellbeing (RENEW)|The program includes unlimited website access and 10 scheduled phone calls with an assigned peer mentor.
223504880|NCT00038610|DRUG|Cyclophosphamide|300 mg/m\^2 by vein every 12 hours for 6 doses days 1, 2, 3 (total dose 1800 mg/m\^2) for courses 1, 3, 5, 7.
223504881|NCT00038610|DRUG|Doxorubicin|50 mg/m\^2 by vein on day 4 after last dose of CTX for courses 1, 3, 5, 7.
223504882|NCT00038610|DRUG|Vincristine|2 mg by vein on day 4 and day 11 for courses 1, 3, 5, 7.
223504883|NCT00038610|DRUG|Dexamethasone|40 mg by vein or by mouth daily on days 1 - 4 and days 11 - 14 for courses 1, 3, 5, 7.
223504884|NCT00038610|DRUG|Methotrexate|"12 mg intrathecally (6 mg if via Ommaya reservoir) day 2 for courses 1, 3, 5, 7.~200 mg/m\^2 by vein over 2 hours followed by 800 mg/m\^2 over 22 hours on day 1 of courses 2, 4, 6, 8."
223504885|NCT00038610|DRUG|Cytarabine|"100 mg intrathecally day 7 for courses 1, 3, 5, 7.~3 gm/m2 by vein over 2 hrs every 12 hrs for 4 doses on days 2 and 3 for courses 2, 4, 6, 8."
223504886|NCT00038610|DRUG|Mesna|600 mg/m\^2 by vein daily for 24 hours for courses 1, 3, 5, 7.
223504887|NCT00038610|DRUG|G-CSF|10 mcg/kg/day after completion of chemotherapy until neutrophil recovery to 1 x 109/L or higher for all courses.
223504888|NCT02550210|DEVICE|Breast Cancer Locator (BCL)|This locator is constructed pre-operatively, sterilized and provided to the surgeon at the time of the procedure. The outline of the breast cancer on the breast surface at the point where the cancer is closest to the skin is built into the locator, so that the surgeon can simply apply the locator to the patient's breast and trace the tumor outline on the skin.
223504889|NCT01027416|DRUG|Tamoxifen|Drug: Tamoxifen 20 mg orally 1x/day for 4 weeks
223504890|NCT01058824|DRUG|Lincomycin|Single Dose Hard Gelatin Capsule - oral - 500 mg
223504891|NCT01058824|DRUG|Lincomycin|Single Dose Hard Gelatin Capsule - oral - 500 mg
223504892|NCT05362019|DRUG|Compound Norethisterone Enanthate Injection|Combined injectable contraceptive use
223504893|NCT05362019|OTHER|One-to-one Service|"A mobile phone based service system will be used to pushing contraceptive knowledges, reminding injection, providing consultation on adverse reactions and ect."
223504894|NCT05362019|OTHER|Family Planning Service|routine family planning service and contraceptive service.
223504895|NCT05099445|DRUG|INCB000928|INCB000928 200 mg will be administered on Day 1 of each treatment period.
223504896|NCT03722628|DIAGNOSTIC_TEST|MMP1 genotypes polymorphism|Determination of MMP-1 gene polymorphism By PCR amplification followed by restriction Fragment length polymorphism (RFLP) and gel electrophoresis
223504897|NCT05160285|DRUG|Nivolumab 100 MG in 10 ML Injection|If you meet all the conditions to participate in the trial, you will receive the following treatments: Your physician will give you 360 mg of Nivolumab as an intravenous infusion every 3 weeks for about 30 minutes. For safety reasons, we recommend that you stay in the hospital for 60 minutes after the initial infusion of nivolumab. There will be a total of 3 cycles of Nivolumab treatments during the study period. You will need to return every 3 weeks. Each return will collect about 50 ml (10 tsp) of blood samples, depending on local standards.
223504898|NCT01277731|DRUG|Methylprednisolone|Run-in period: dexamethasone 10-20mg q day iv during chemotherapy Treatment period: methylprednisolone 60-125mg iv during chemotherapy
224195921|NCT03225313|DRUG|Bupivacaine Hydrochloride 0.5% Injection Solution_#4|ultra sound guided injection into the rectus sheath
224195922|NCT03225313|DRUG|Normal Saline Flush, 0.9% Injectable Solution_#5|injected into rectus sheath using ultrasound \& locally surrounding the hernia
224195923|NCT03225313|DRUG|Bupivacaine Hydrochloride 0.5% Injection Solution_#4|locally surrounding the hernia
224195924|NCT01593761|DRUG|CG400549|960mg QD at fed state approx 1 hour after meal
224195925|NCT05732025|DEVICE|Electrohydraulic shock wave lithotripsy|Pre-treatment of severe calcified coronary lesions with electrohydraulic shock wave lithotripsy
224195926|NCT05732025|DEVICE|Rotary atherectomy|Pre-treatment of severe calcified coronary lesions with rotary atherectomy
224310566|NCT01197755|DRUG|fostamatinib|fostamatinib 100 mg twice daily
224195927|NCT02267174|BEHAVIORAL|Standardized handoff|A standardized handoff will be implemented that consists of choreographed handoffs utilizing a structured handoff tool to facilitate information exchange.
224195928|NCT02839213|DRUG|Hyoscine Butyl bromide|
224195929|NCT02839213|DRUG|Saline|
224195930|NCT06670482|DEVICE|Non-invasive ventilation (NIV)|Delivery of positive airway pressure to the lungs via an interface, such as a mask.
224195931|NCT06670261|OTHER|Data collection|Retrospective pseudo-anonymized clinical and scannographic data from the routine management of patients in rhino-sinusology consultations.
224195932|NCT00308230|PROCEDURE|Six minute walk test|
223504899|NCT02129881|BIOLOGICAL|Autologous regulatory T Cell Product|Autologous regulatory T Cell Product (1-10 million cells/kg) infused intravenously 5 days post renal transplantation. Recipients also receive prednisolone, mycophenolate mofetil, and tacrolimus as detailed in the arm description.
224195933|NCT00308230|BEHAVIORAL|Minnesota Living with Heart Failure Questionnaire|
224195934|NCT03722459|DEVICE|MR Fingerprinting|The MR fingerprinting technique requires less than 15 minutes and will be added following the standard MRI sequence.
224195935|NCT01869959|DRUG|LY2405319|Administered SC
224195936|NCT01869959|DRUG|Placebo|Administered SC
224195937|NCT02903849|BEHAVIORAL|Drafting Motivational Messages|Write down three motivating messages
224195938|NCT02903849|BEHAVIORAL|Control Reminders|Receive standard reminders at three points during the challenge
224195939|NCT02903849|BEHAVIORAL|Treatment Reminders|Receive reminders containing the messages they leave themselves at three points during the challenge
223504900|NCT03886324|COMBINATION_PRODUCT|GIE Medical Drug Coated Balloon|Stricture patients treated by DCB
223504901|NCT04557137|DRUG|Somatostatin analog|120 mg ipstyl every 28 days
223504902|NCT03173508|DRUG|ACETAZOLAMIDE oral capsule|Administration of 125mg acetazolamide in the morning, 250mg in the evening, starting 24 hours before departure to 3200m
223746995|NCT01680718|DRUG|Intranasal placebo|Through the use of 1oz bottles attached with metered nasal pumps (1 puff = .1ml), participants will self-administer 5 puffs per nostril. Placebo consists of: 2 mls Glycerine and 3 mls purified water (methylparaben and propylparaben mixed according to purified water formula) for a total of 5 ml, which will be filtered with a 5mu filter (used previously; Bartz et al., 2010).
224310567|NCT01197755|DRUG|fostamatinib|fostamatinib 100 mg twice daily/150 mg once daily
223504903|NCT03173508|DRUG|Placebo oral capsule|Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3200m
223504904|NCT06539650|OTHER|Fractal Paced|The intervention consists in a single session of metronome paced strength training composed by 4 sets of 15 repetitions at 65% of the one-repetition maximal (1RM) in single leg extension machine, synchronizing each repetition with fractal external cues presented by a visual metronome. The rest between sets will be set at 2 minutes of rest between sets.
223504905|NCT06539650|OTHER|Isochronus Paced|The intervention consists in a single session of metronome paced strength training composed by 4 sets of 15 repetitions at 65% of the one-repetition maximal (1RM) in single leg extension machine, synchronizing each repetition with isochronus external cues presented by a visual metronome. The rest between sets will be set at 2 minutes of rest between sets.
223504906|NCT06539650|OTHER|Self Paced|The intervention consists in a single session of strength training composed by 4 sets of 15 repetitions at 65% of the one-repetition maximal (1RM) in single leg extension machine, at at participants' own self pace (with no metronome). The rest between sets will be set at 2 minutes of rest between sets.
223504907|NCT00443287|DRUG|ataciguat (HMR1766)|oral administration
223504908|NCT00443287|DRUG|placebo|oral administration
223504909|NCT00443287|DRUG|cilostazol|oral administration
223746996|NCT01256554|PROCEDURE|Stereotactic Radiosurgery (SSRS)|Target dose of 18 or 24 Gy to spine in single session of radiation.
224195940|NCT00626067|DEVICE|Fully functional monitoring device|Pt received fully functional monitoring dispenser for use with their Travatan eye drops
224195941|NCT00626067|DEVICE|Partially functional monitoring device|Patient received a particually functional Travatan Compliance Monitoring Dispenser
224195942|NCT00626067|DEVICE|Non-functional monitoring device|Patient received a non functioning Travatan Compliance Monitoring Dispenser
224195943|NCT02984904|OTHER|survey|survey
224195944|NCT04187937|DEVICE|Stereotactic image-guided resection|Stereotactic image-guided resection with an ultrasound-based image-guidance system.
224195945|NCT06452420|OTHER|Traumatic dental injuries|The Degree of knowledge and Attitude of Medical Residents and Interns in Egypt regarding Emergency treatment of traumatic dental injuries.
224195946|NCT00828009|BIOLOGICAL|bevacizumab|IV
224195947|NCT00828009|BIOLOGICAL|Tecemotide|
224195948|NCT00828009|DRUG|carboplatin|IV
224195949|NCT00828009|DRUG|cyclophosphamide|IV
224310568|NCT01197755|DRUG|placebo|Placebo twice daily
224310569|NCT00888823|RADIATION|Stereotactic Radiotherapy|Stereotactic Radiotherapy
224195950|NCT00828009|DRUG|paclitaxel|IV
224195951|NCT00828009|RADIATION|radiotherapy|radiotherapy is given 5 days a week for 6½ weeks during concomitant chemoradiotherapy
224195952|NCT04853953|OTHER|Incidence of bleeding complications in ARDS patients on veno-venous ECMO|All bleeding complications (especially cerebral bleedings) will be analyzed in the study groups. At the bleeding event, laboratory parameters of coagulation will be collected and the intensity of the ECMO treatment
224195953|NCT05377541|PROCEDURE|Surgical treatment of femur fracture|Definitive surgical treatment of femur fracture.
224195954|NCT04520633|OTHER|biologic initiation|introduction or modification of biotherapy at M0
224310570|NCT05795738|BEHAVIORAL|Chinese character-based visuomotor training program|this program includes visual-perceptual-motor play, paper-pencil activities, and ipad games using Chinese character as activity materials
224310571|NCT05795738|BEHAVIORAL|traditional visuomotor training program|this program includes play and paper-and-pencil activities, ipad games using commercial or self-designed stuffs as activity materials
224310572|NCT00796679|DRUG|paricalcitol|oral paricalcitol capsule 1 microgram once daily if iPTH \<500pg/mL or 2 microgram once daily if iPTH \>=500pg/mL. Thereafter, dose titration in 1 microgram decrement will be done based on safety reasons (that is, for low PTH or high calcium and phosphorus level). The duration of treatment will be for 1 year.
223746997|NCT01256554|BEHAVIORAL|Questionnaires|Questionnaire completion about health symptoms and pain at baseline, 3 months, 6 months, 9 months, 12 months, 24 months, then every 6 months.
223746998|NCT01817933|BEHAVIORAL|physical therapy|
223746999|NCT03942354|DRUG|Bedaquiline|Bedaquiline is a diarylquinoline class antimicrobial which blocks the proton pump for ATP synthase of mycobacteria. This in turn blocks the ATP production required for cellular energy production and leading to cell death.
223747000|NCT03942354|DRUG|Pretomanid|Pretomanid is a nitroimidazole class antimicrobial which interferes with cell wall biosynthesis in mycobacteria. It may have other mechanisms of action as well in non-replicating mycobacteria.
223747001|NCT03942354|DRUG|Moxifloxacin|Moxifloxacin is an 8-methoxyquinolone class antimicrobial that is a potent inhibitor of DNA gyrase and topoisomerase IV in bacteria
223747002|NCT03942354|DRUG|Linezolid|Linezolid, an oxazolidinone class antimicrobial which works by inhibiting ribosomal protein synthesis. It is approved for Gram-positive bacterial infections, and is increasingly being used for drug resistant TB disease.
223747003|NCT03942354|DRUG|Clofazimine|Clofazimine is a lipophilic riminophenazine licensed for treatment of leprosy. Its mechanism(s) of action remains unclear, but existing evidence suggests production of reactive oxygen species within Mycobacterium tuberculosis is one mechanism.
223747004|NCT03942354|DRUG|Directly observed therapy (DOT)|Standard therapy
223747005|NCT00001758|DRUG|Abacavir|
224195955|NCT02729727|DEVICE|CryoBalloon Ablation System|Tissue Ablation using CryoBalloon Ablation System
223504910|NCT02661373|DRUG|SJ733|SJ733 is an oral, novel inhibitor of Plasmodium Falciparum plasma membrane protein PFATP4. It will be administered as a single, multi, or boosted oral dose.
223504911|NCT02661373|DRUG|Cobicistat|Commercially available cobicistat 150 mg tablets will be used. It will be administered as a single oral dose together with SJ733.
223504912|NCT00727337|BEHAVIORAL|LACE-computer|Computerized Auditory Training
223504913|NCT00727337|BEHAVIORAL|PLACEBO-Directed listening|Subjects will be asked to listen to books on tape for 20 minutes a day and answer questions as they go along
223504914|NCT00727337|BEHAVIORAL|CONTROL|No specialized treatment will be provided in addition to standard of care audiology treatment provided with the provision of hearing aids
223504915|NCT00727337|BEHAVIORAL|Lace-DVD|DVD based Auditory Training
223504916|NCT04322045|DIAGNOSTIC_TEST|multi-parametric MRI|Multi-parametric MRI will be suggested for those PSA ≥4 ng/mL, PI-RADS v2 score will be used to evaluate images.
223504917|NCT01901588|DRUG|Dexmedetomidine|intravenous dose of dexmedetomidine 0.3 mcg/kg over 5 minutes
223504918|NCT01901588|OTHER|Placebo|intraoperative dose of intravenous placebo
223504919|NCT03708289|RADIATION|DXA scan|total and hip and spine dual energy x-ray absorptiometry
223504920|NCT03708289|OTHER|Achilles bone US|
223504921|NCT03708289|OTHER|Medical body composition measurements|
223504922|NCT03708289|OTHER|Resting energy expenditure measurement|
223747006|NCT00001758|DRUG|Amprenavir|
223504923|NCT01197235|DRUG|darbepoetin-α|Infusion of darbepoetin-α 1.5 μg/kg will be performed 1 hour before angiography
223504924|NCT01197235|DRUG|isotonic saline|Infusion of isotonic saline will be performed 1 hour before angiography
223504925|NCT03588000|OTHER|Strengthen self-monitoring of blood glucose|Strengthen self-monitoring of blood glucose by Internet mobile terminal（APP）.
223504926|NCT01390935|OTHER|guideline adherence|guideline adherence of physician
223504927|NCT03896360|BEHAVIORAL|Food order behavioral intervention plus standard care|Subjects in the Food order behavioral intervention plus standard care will receive standard counseling by a registered dietitian and additional carbohydrate last food order behavioral counseling by a member of the research team at baseline and Weeks 4, 8 and 12.
223504928|NCT03896360|BEHAVIORAL|Standard Care|Subjects will receive standard counseling by a registered dietitian at the baseline visit. Standard counseling will be similarly reinforced at weeks 4, 8 and 12.
223504929|NCT00754039|DRUG|colesevelam HCl tablets and fenofibrate tablets|Colesevelam 625 mg tablets - 6 tablets/day Fenofibrate 160 mg tablet - 1/day
223504930|NCT00754039|DRUG|fenofibrate tablets and Welchol placebo tablets|fenofibrate tablets 160 mg - 1/day + Welchol placebo tablets - 6/day
223504931|NCT00754039|DRUG|fenofibrate tablets and Welchol placebo tablets|fenofibrate 160 mg tablet - 1/day and Welchol placebo tablets - 6/day
223504932|NCT05991479|OTHER|Pilates exercises|"Pilates exercises:~The subjects will receive Pilates training (3 sessions/week) for 8 weeks. The Pilates training protocol will take 60 min per session, including 10 min of warm up prior to initiating the Pilates technique, 40 min for Pilates exercises and 10 min for cool down. The number of repetitions will be 10 times. The patient will perform the following Pilates exercises: (Hundred exercises, spine stretch, single leg stretch , double leg stretch, criss cross, swimming, one leg kick, side kick, clam, one leg circle, shoulder bridge, hip twist, roll up and down and standing footwork)."
223747007|NCT00001758|DRUG|Efavirenz|
223747008|NCT03659916|DRUG|A4250 (odevixibat)|A4250 is a small molecule and selective inhibitor of IBAT
223747009|NCT03456596|OTHER|ENABLE|This is an implementation science study in which an evidence-based early palliative care intervention, ENABLE (Educate, Nurture, Advise, Before Life Ends), is being implemented in rural community cancer centers that did not have a palliative care program.
224075028|NCT04314440|BEHAVIORAL|Music therapy|"An accredited music therapist will deliver 15-20 minutes of music therapy every day, 4-5 days in week one and remaining in week two to all MT participants. All participants in music therapy group will get a total of nine sessions. The lullaby twinkle twinkle little star will be sung for \~5 minutes, followed by the same songs played on acoustic guitar for \~5 minutes and another \~5 minutes of the same song sung in voice. This protocol will be followed in all 9 sessions for all infants in the experimental arm. The sound levels will be maintained at 55-65 decibels (dB) using appropriate meters. If MT is interrupted within 10 minutes then a make-up session will be delivered, assuming no discharge. In case of missed sessions and interrupted session infants will receive a maximum of 12 session."
224075029|NCT06649942|DRUG|KP-001|KP-001 100 mg + placebo
224195956|NCT05071235|DEVICE|LG1 (LLLT group 1)|Application of LLLT (low-level laser therapy) AsGa 904 nm 10 J/cm².
224195957|NCT05071235|DEVICE|LG2 (LLLT group 2)|Application of LLLT (low-level laser therapy) AsGa 904 nm 8 J/cm².
224195958|NCT05071235|DEVICE|LG3 (LLLT group 3)|Application of LLLT (low-level laser therapy) AsGa 904 nm 4 J/cm².
223504933|NCT05991479|OTHER|Traditional physical therapy programme:|"All patients will receive a traditional physical therapy programme consisting of 45 minutes per session of a supervised and individualized exercise programme for three sessions per week for eight weeks which will include:~Stretching exercises for calf and hamstring muscles. Strengthening exercises for hip, knee, ankle, and foot muscles. Deep friction massage for scar management."
223747010|NCT06054087|PROCEDURE|Basal therapy+EA|"1. Participants are not set up with uniform medication. High blood sugar is controlled by hypoglycaemic drugs, patients with hypertension and hyperlipidaemia can take antihypertensive and lipid-lowering drugs, while other drugs are based on the patient's current medication.~2. Main acupoints: Qihai (RN6), Guanyuan (RN4), Xuehai (SP10), Yanglingquan (GB34), Zusanli (T36), Yinlingquan (SP9), Sanyinjiao (SP6), Xuanzhong (GB39), Jiexi (ST41), Zulinqi (GB41), Taichong (SP41). Supporting acupoints: for pain in the upper limbs, add Baxie, Quchi (LI11), Shousanli (LI10), Hegu (LI4), and Ashixue; for pain in the lower limbs, add Bafeng, Neiting (ST44),Kunlun (BL60). Operation: Acupuncture needles of size 25\*40mm will be used. The electrode will be connected Yanglingquan (GB34) and Sanyinjiao (SP6), electrode wire will be connected to the electro-acupuncture apparatus using continuous wave with a frequency of 2Hz at an intensity suitable for the comfort of the subject."
223747011|NCT06054087|OTHER|Basal therapy|Participants are not set up with uniform medication. High blood sugar is controlled by hypoglycaemic drugs, patients with hypertension and hyperlipidaemia can take antihypertensive and lipid-lowering drugs, while other drugs are based on the patient's current medication.
223747012|NCT03886220|DRUG|Elagolix|Oral; Tablet
223504934|NCT01368770|OTHER|Coronary CTA|Coronary CTA using standard protocols
223504935|NCT01368770|OTHER|Stress MPI SPECT|Stress MPI using standard protocols
223504936|NCT00045955|DRUG|Fexofenadine, Comparator = Montelukast|
223504937|NCT01960842|DRUG|Levodopa-carbidopa intestinal gel|Dose levels will be individually optimized. Infusion should be kept within a range of 0.5-10 mL/hour (10-200 mg levodopa/hour) and is usually 2-6 mL/hour (40-120 mg levodopa/hour)
223504938|NCT01960842|DEVICE|CADD-Legacy® 1400 ambulatory infusion pump|
223504939|NCT01960842|DEVICE|PEG tube|percutaneous endoscopic gastrostomy tube
223504940|NCT01960842|DEVICE|J-tube|jejunal tube
223504941|NCT00397930|PROCEDURE|Standard Care Control Condition|Cancer survivors assigned to this condition continued with the standard follow-up care provided by their treating oncologists as appropriate for individual diagnoses. Participants in the control condition were offered the 4-week YOCAS program gratis after completing all study requirements.
223504942|NCT00397930|PROCEDURE|Yoga Intervention (YOCAS)|The Yoga for Cancer Survivors (YOCAS) intervention uses two forms of yoga: Gentle Hatha yoga and Restorative yoga. The YOCAS sessions are standardized, and each session includes physical alignment postures, breathing and mindfulness exercises. The intervention is delivered in an instructor taught, group format, twice a week for 75 minutes each time over 4 weeks for a total of eight sessions of yoga. All sessions were taught in community-based sites (eg. yoga studios, community centers, community oncology practices) with an average group size of 12 (range, 10-15) in the late afternoon or evening after 4pm.
223504943|NCT02021604|DRUG|Fluorodopa F 18|A dose of Fluorodopa F 18, 3-6 MBq/Kg (0.08-0.16 mCi/kg), will be injected intravenously into the subject under the direct supervision of the radiology sub-investigator. Then, the PET imaging procedure will begin and proceed for up to 70 minutes after injection. An abdominal CT image will be made using intravenous contrast. Both images, PET and CT, will be co-localized by the radiologist for interpretation.
223504944|NCT02391584|DEVICE|XprESS|Balloon dilation of the Eustachian tube
223504945|NCT02391584|OTHER|Control|Continued medical management
223504946|NCT04619030|OTHER|Augmented Reality|The patient leaflet has an Augmented Reality model that appears out of the leaflet when viewed with a smartphone
223504947|NCT04619030|OTHER|Traditional leaflet|Traditional leaflet with no Augmented Reality capability
223504948|NCT05992740|DEVICE|bronchoscope|bronchoscpe with broncial brush and biopsy or bronchial wash and biopsy
223504949|NCT01215240|DEVICE|Peritoneal dialysis|Prophylactic peritoneal dialysis
223504950|NCT03843970|DRUG|Levobupivacaine Hydrochloride 0.5%|The solution is called L solution, which contains a combination of 0.5% isobaric levobupivacaine with fentanyl. Injectable Solution.
223504951|NCT03843970|DRUG|Isobaric bupivacaine 0.5%|The solution is called B solution, which contains a combination of 0.5% isobaric bupivacaine with fentanyl. Injectable Solution.
223504952|NCT02396797|BEHAVIORAL|The new atWork intervention|"atWork is a cognitive intervention, and uses a nondirective delivery approach. It does not prescribe any change in lifestyle, but aims at establishing an understanding of common complaints and what to do when pain and health complaints occur. All information is based on the non-injury model, where pain and complaints are not signs of injury caused by wrongdoing or inappropriate behavior. The consistent take home message from all parts of the intervention is that keeping up usual activities, including going to work, is beneficial for health and recovery. This group will receive one management course, two workplace courses for all employees targeting mild mental disorders and nonspecific musculoskeletal complaints, and one reflection and review meeting."
223747013|NCT03886220|DRUG|Placebo|Oral; Tablet
224075030|NCT06649942|DRUG|KP-001|KP-001 400 mg
224075031|NCT06649942|DRUG|Moxifloxacin 400 mg|moxifloxacin 400 mg tablet
224075032|NCT06649942|DRUG|Placebo|Placebo
224075033|NCT07121894|BEHAVIORAL|Ketogenic Diet|Participants will initiate a modified ketogenic diet under structured, intensive guidance. Simultaneously, participants will attend weekly behavioral support interviews with a psychiatrist to monitor mental health and mood stability.
224075034|NCT06564207|DRUG|Placebo|Placebo to be given twice daily for 14 days
224075035|NCT06564207|DRUG|Fostamatinib|Fostamatinib 150mg to be given twice daily for 14 days
224075036|NCT06130293|DEVICE|VR game intervention|Using self-paced VR game to train.
224075037|NCT06856473|OTHER|Traditional Physical Therapy|Traditional Physical Therapy based on neurodevelopmental technique
224075038|NCT06856473|OTHER|Dry Needling|Dry Needling in addition to the same traditional physical therapy program
224075039|NCT07006714|DRUG|Vitamin D3|Patients with a Vitamin D3 level of less than 30 nanograms per milliliter will receive a single oral (pill) dose of 300,000 international units of vitamin D3.
224075040|NCT06869447|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
224075041|NCT06869447|OTHER|Electronic Health Record Review|Ancillary studies
224195959|NCT05071235|DEVICE|CG (control group)|Application of placebo LLLT (low-level laser therapy), that is, with the device turned off.
224195960|NCT05071235|PROCEDURE|Dressing|Application of Helianthus annuus oil dressing.
224195961|NCT01717300|DRUG|Anacetrapib 100 mg|100 mg tablet, oral, once daily for 24 weeks
224195962|NCT01717300|DRUG|Placebo for anacetrapib 100 mg|Placebo tablet, orally, once daily for 24 weeks
224195963|NCT01717300|DRUG|Anacetrapib 25 mg|25 mg tablet, oral, once daily for 24 weeks
224195964|NCT01717300|DRUG|Placebo for anacetrapib 25 mg|Placebo tablet, orally, once daily for 24 weeks
224195965|NCT06994871|OTHER|Aerobic exercise|"Intensity of exercise：Subjects conduct an aerobic exercise at 40-59% heart rate reserve(HRR).~Time of aerobic exercise：from 30 to 45 minutes each day, five days a week."
224195966|NCT06994871|OTHER|Resistance exercise|"The resistance exercise was consisted of equipment trainings and body weight trainings. Participants are required to exercise 3 times a week.~Intensity of equipment trainings: 70% 1-RM. Exercise volume: 15-20 repetitions for a set, from 2 sets to 4 sets gradually.~Body weight trainings: 15-30 repetitions for a set, from 2 sets to 4 sets gradually."
224195967|NCT06994871|OTHER|combined exercise|"Subjects conduct both aerobic and resistance trainings. Details of aerobic training session: Subjects conduct an aerobic exercise at 40-59% heart rate reserve(HRR) from 50-55 minutes each day, 3-4 days a week.~Details of resistance training session: The resistance exercise was consisted of equipment trainings and body weight trainings. Participants are required to exercise 2 times a week."
224195968|NCT06854406|DRUG|Varenicline|Initial, 0.5 mg orally once daily for 3 days, then 0.5 mg every 12 hours on days 4 through 7, and then 1 mg in morning of day 8. Medication is taken after eating and with a full glass of water.
223593439|NCT01491997|BEHAVIORAL|Mind/Body Medicine Course 1|The subject of the course is Mind/Body medicine. This course is learning about the mind and the body through experiences. The course will meet once every week, for a total of 8 weeks, for roughly 2 hours per class. You will be provided with a schedule of the weekly classes, which will occur on the same day every week, at the same time. Weekly sessions will be run by a teacher and will include other participants in the class. You will also be given homework assignments that are intended to reinforce what you learn in the program. The assignments will require up to 45 minutes, 6 days/week. Following the 6th class, and before the 7th class, there is a voluntary all day Saturday program. Participation in this program is optional. You are expected to continue to incorporate what you learned in the class in your daily routine after you are done with the classes.
223593440|NCT01491997|BEHAVIORAL|Mind/Body Medicine Course 2|The subject of the course is Mind/Body medicine. This course is learning about the mind and the body through lectures. The course will meet once every week, for a total of 8 weeks, for roughly 2 hours per class. You will be provided with a schedule of the weekly classes, which will occur on the same day every week, at the same time. Weekly sessions will be run by a teacher and will include other participants in the class. You will also be given homework assignments that are intended to reinforce what you learn in the program. The assignments will require up to 45 minutes, 6 days/week. Following the 6th class, and before the 7th class, there is a voluntary all day Saturday program. Participation in this program is optional. You are expected to continue to incorporate what you learned in the class in your daily routine after you are done with the classes.
223593441|NCT03439930|OTHER|Balance training|6 weeks lasting balance training program
223593442|NCT03288636|DRUG|Danoprevir|Danoprevir tablet administered orally 100mg QD on day 7 and 13, 100mg BID on day 14-22, 100mg QD on day 23
223593443|NCT03288636|DRUG|Ritonavir|Ritonavir tablet administered orally 100mg QD on day 7 and 13, 100mg BID on day 14-22, 100mg QD on day 23
223593444|NCT03288636|DRUG|Ravidasvir|Ravidasvir tablet administered orally 200mg QD on day 1, 13 - 23
223593445|NCT03288636|DRUG|Placebo|Placebo
223593446|NCT01178099|DRUG|Prasugrel|Oral, daily for 12 days
223593447|NCT01149720|DRUG|Tivantinib (ARQ 197) Capsule|Oral BID 360 mg dose (Capsule C: 6 X 60 mg) of ARQ 197 at least 1 hour before or 2 hours after a meal for 7 days
224075042|NCT06869447|OTHER|Medical Device Usage and Evaluation|Use Power Lung breathing device
223593448|NCT01149720|DRUG|Tivantinib (ARQ 197) Tablet|Oral BID 360 mg dose (Tablet: 3 x 120 mg) of ARQ 197 under fed conditions for 7 days
223593449|NCT01149720|DRUG|Tivantinib (ARQ 197) Capsule D, oral|Oral BID 360 mg dose (Capsule D: 3 x 120 mg) of ARQ 197 under fed conditions in the extension phase
224075043|NCT06869447|OTHER|Questionnaire Administration|Ancillary studies
224075044|NCT06869447|PROCEDURE|Respiratory Muscle Training|Participate in RMT sessions
224075045|NCT06869447|PROCEDURE|Sham Intervention|Participate in sham sessions
224075046|NCT06860724|OTHER|NG-nitro-L-arginine methyl ester (L-NAME)|Acute local perfusion of L-NAME (15 mM) directly to the microvasculature will be used to inhibit NO synthase.
224075047|NCT07028788|OTHER|Health Education Material|Weekly electronic health education handbooks covering nutrition, sleep, shift work, stress awareness, and digital device use.
224075048|NCT07028788|BEHAVIORAL|Mobile-Based Mindfulness|Guided mindfulness practice via mobile app using pre-recorded 360° natural environment video.
224075049|NCT07028788|BEHAVIORAL|Mobile-Based Mindfulness combined with Breathing|Mindfulness training combined with brief structured breathing exercises via mobile app using 360° nature video.
224075050|NCT07028788|BEHAVIORAL|VR-Based Mindfulness combined with Breathing|Virtual reality-delivered mindfulness and structured breathing training using immersive 360° natural environment video.
224075051|NCT07029633|OTHER|storytelling|to distract telling a story
224075052|NCT07029633|OTHER|cartoon|to distract watching a cartoon
224075053|NCT07037641|OTHER|Lumbar Spine Manipulation|Painful lumbar segments will be identified through palpation of the spinous and transverse processes. Patients will be positioned side-lying with head supported by a pillow. The lower arm will rest across the chest, and the lower leg will be extended while the upper leg will be flexed, with the foot placed in the popliteal space. The practitioner will assume a 45-degree angled stance, stabilizing the patient's pelvis between their thighs. The hypothenar eminence will contact the mammillary process of the dysfunctional vertebra, while the opposite hand stabilizes the upper shoulder. A high-velocity, low-amplitude (HVLA) thrust will be applied in a rotational direction toward the patient's umbilicus. This technique will be performed twice per week for two weeks (4 sessions total), alongside conventional physiotherapy (hot pack, TENS, ultrasound, and exercise).
224195969|NCT06861881|DEVICE|Dexcom G7 Continuous Glucose Monitor|Dexcom G7 continuous glucose monitor will be placed prior to cardiac surgery. It will be worn continuously throughout the perioperative period and during the time admitted to the Cardiovascular Intensive Care Unit.
224195970|NCT05784467|BEHAVIORAL|Methamphetamine, PrEP, and Intersectional Stigma (eMPrISe) study|Group behavioral intervention with 12 weekly sessions lasting 2 hours focusing on coping, resistance, and resilience.
224195971|NCT03954054|BEHAVIORAL|"Choizitaconso - therapeutic patient education programme"|"Choizitaconso is a therapeutic patient education programme that teaches psychosocial skills to people with alcohol use disorder (PWAUD), to help them (re)establish controlled drinking and reduce harms.~It lasts for 10 weeks for each participant and consists of the following 5 modules, including one optional module focusing on the family environment:~1. Understand the mechanisms that trigger and/or maintain alcohol-related difficulties~2. Plan and evaluate personalized controlled drinking strategies~3. Understand and identify external and internal influences (e.g., thoughts and emotions), identify and manage risk situations~4. Identify alcohol effects and alcohol-related expectations (by developing self-observation skills)~5. Family environment: learning how to evaluate and take care of oneself (e.g., how to express feelings)~Each module consists of 2 to 4 collective workshops that each last 120 minutes and involve 5 to 10 persons."
224195972|NCT07004309|PROCEDURE|Microfluidic sperm sorting|Sperm selection using the ZyMot Microfluidic Sperm Separation Device. Process involves loading semen into microfluidic channels to isolate motile sperm with low DNA fragmentation.
224195973|NCT07004309|PROCEDURE|Density Gradient Centrifugation|Sperm preparation using a discontinuous density gradient technique with SpermGrad and SpermRinse media. Centrifugation separates motile sperm for use in ICSI.
224195974|NCT03168347|BEHAVIORAL|Anecdotal Evidence|Communicate basic information on the therapeutic effect of a drug using only anecdotal evidence.
224195975|NCT03168347|BEHAVIORAL|Research Study Evidence|Communicate basic information on the therapeutic effect of a drug using only research study evidence.
224310573|NCT03365011|DRUG|Nitrous oxide gas for inhalation|Nitrous oxide gaseous mixture (50% nitrous oxide and 50% oxygen) for 40 minutes duration under anesthesia supervision with monitoring according to standards set by the American Society of Anesthesiologists.
224310574|NCT03365011|DRUG|Placebo gas for inhalation|Placebo gaseous mixture (50% nitrogen and 50% oxygen) for 40 minutes duration under anesthesia supervision with monitoring according to standards set by the American Society of Anesthesiologists.
224310575|NCT05364060|OTHER|Questionnaires|Different questionnaires detailed in the objectives part
223593450|NCT03688464|DRUG|Melatonin|Drug to be administered for 4 weeks. Subjects will complete surveys prior to initiation and at the end of the study that will assess severity of eczema, quality of life, severity of itch, and sleep quality.
223593451|NCT03688464|DRUG|Diphenhydramine|Drug to be administered for 4 weeks. Subjects will complete surveys prior to initiation and at the end of the study that will assess severity of eczema, quality of life, severity of itch, and sleep quality.
223593452|NCT03688464|DRUG|Placebos|Drug to be administered for 4 weeks. Subjects will complete surveys prior to initiation and at the end of the study that will assess severity of eczema, quality of life, severity of itch, and sleep quality.
223593453|NCT05748457|BEHAVIORAL|Non-manualised family therapy.|Family therapy provided by qualified therapists without reference to a specific therapy manual.
223593454|NCT05748457|BEHAVIORAL|Family Based Treatment|"Family therapy implemented according to the published Treatment manual for anorexia nervosa: A family-based approach by Lock \& Le Grange (2nd edition, 2015)."
224195976|NCT03168347|BEHAVIORAL|Anecdotal + Research Study Evidence|Communicate basic information on the therapeutic effect of a drug using only anecdotal and research study evidence.
224195977|NCT03168347|BEHAVIORAL|No Evidence|Communicate basic information on the therapeutic effect of a drug using neither anecdotal evidence nor research study evidence.
224195978|NCT06598397|BEHAVIORAL|Motivational Interviewing (MI) Counseling|Six sessions of phone counseling over 10-12 weeks with MI counselor trained in motivational interviewing and tobacco use treatment.
223593455|NCT06574516|DRUG|Ibuprofen 200 mg|Ibuprofen every 8 hours for three days post operatively
223593456|NCT06574516|DRUG|paracetamol|Paracetamol PRN for three days
223593457|NCT06041152|DRUG|Psilocybin|2 macrodoses of 25mg separated by one week.
223593458|NCT06041152|DRUG|Placebo|2 doses of placebo separated by one week.
223593459|NCT00307788|PROCEDURE|acupuncture|acupuncture
223593460|NCT02703480|BIOLOGICAL|d-PTFE|high-density polytetrafluoroethylene (d-PTFE) membrane
223593461|NCT02703480|BIOLOGICAL|Ti-mesh|Titanium mesh
223593462|NCT02516592|DRUG|QVA149 110/50 micrograms|QVA149 110/50 micrograms o.d. capsules for inhalation, supplied in blisters via a single dose dry powder inhalater (SDDPI)
223593463|NCT02516592|DRUG|Salmeterol/fluticasone 50/500 microgrammes|Salmeterol/fluticasone 50/500 microgrammes b.i.d.dry inhalation powder delivered via Accuhaler / Diskus device
224195979|NCT06598397|BEHAVIORAL|Peer Mentoring|Eight sessions of informal counseling with an experienced peer former smoker living with HIV to model healthy behavior and provide practical advice and tips for quitting based on their lived experience.
224195980|NCT06598397|BEHAVIORAL|Skills-based Text Messaging|NCI's 8-week text messaging smoking cessation program, smokefreeTXT.gov.
224310576|NCT00440544|BIOLOGICAL|Ag85B-ESAT6 fusion protein H1|100 ug H1 antigen in BCG naive subjects
224310577|NCT00440544|BIOLOGICAL|Ag85B-ESAT6 fusion protein H1|100 ug H1 antigen + LTK63 adjuvant 30 ug in BCG naive subjects
224310578|NCT00440544|BIOLOGICAL|Ag85B-ESAT6 fusion protein H1|50 ug H1 antigen in BCG immunized subjects
224310579|NCT00440544|BIOLOGICAL|Ag85B-ESAT6 fusion protein H1|50 ug H1 antigen + LTK63 adjuvant 30 ug in BCG immunized subjects
224310580|NCT00440544|BIOLOGICAL|Ag85B-ESAT6 fusion protein H1|100 ug H1 antigen in BCG immunized subjects
224310581|NCT00440544|BIOLOGICAL|Ag85B-ESAT6 fusion protein H1|100 ug H1 antigen + LTK63 adjuvant 30 ug in BCG immunized subjects
224310582|NCT00499174|PROCEDURE|conventional surgery|Radical prostatectomy
224310583|NCT00499174|RADIATION|brachytherapy|high dose rate temporary seed implant; permanent seed implant.
224310584|NCT00499174|RADIATION|external beam radiation therapy|3D conformal radiation therapy; intensity modulated radiation therapy.
224310585|NCT00499174|PROCEDURE|Biopsies|Periodic repeat biopsies
224310586|NCT00370357|DRUG|3% w/w SPL7013 Gel (VivaGel™)|
223593464|NCT04068116|PROCEDURE|Primary per-cutaneous coronary intervention|Patients presenting with ST-elevation myocardial infarction will undergo primary per-cutaneous coronary intervention including balloon angioplasty \& coronary stent deployment as needed +/- post-conditioning (for post-conditioning arm) making 4 cycles of repeated occlusion \& reperfusion 30-second each by inflation/deflation of an appropriately sized PTCA (percutaneous transluminal coronary angioplasty) balloon
224310587|NCT03131674|OTHER|Cervical physical therapy|Patients receive a multimodal cervical physical therapy treatment
224310588|NCT00039520|DRUG|docetaxel|
223504953|NCT02396797|BEHAVIORAL|The original atWork intervention|This group will receive three workplace courses for all employees targeting nonspecific musculoskeletal complaints, and peer support. Peer support involves selecting a peer advisor at the workplace. A peer advisor is a fellow worker without former medical training who as part of the atWork intervention receive more in-depth medical knowledge and training about nonspecific musculoskeletal complaints. The peer advisors role is to give social support and to use their local knowledge of the work place to facilitate staying at work for colleagues with health complaints.
223504954|NCT02475057|DRUG|Degarelix (LHRH antagonist)|Two initial loading doses of 120mg Degarelix for 1 month followed by 80mg monthly for eleven additional months.
223504955|NCT02475057|DRUG|LHRH agonist|LHRH agonist at the discretion of the treating Urologist/Oncologist for 1 year.
223504956|NCT02475057|DEVICE|EndoPAT2000|Peripheral arterial plethysmography using an EndoPAT2000 device
223504957|NCT02202720|DRUG|Sevoflurane|Short term sedation with sevoflurane in ICU
223504958|NCT05034978|OTHER|no intervention|evaluating the performance of a novel point-of-care test
223504959|NCT05017948|OTHER|Risk score based intervention|Targeted interventions based off of risk score software
223504960|NCT01795131|DIETARY_SUPPLEMENT|Vitamin B12|
223504961|NCT01795131|DIETARY_SUPPLEMENT|Placebo|
223504962|NCT02056288|DRUG|Fentanyl|Patients randomized to the systemic analgesia group will receive 1mcg/kg of fentanyl IV after induction.
223504963|NCT02056288|DRUG|Ropivacaine|Patients randomized to the systemic analgesia group will receive 1mcg/kg of fentanyl IV after induction. Patients randomized to the supraclavicular block group will receive an ultrasound guided nerve block with 0.2 ml/kg ropivacaine 0.5% (maximum 10 ml).
223504964|NCT05898880|OTHER|Self-acupressure|In the self-acupressure group, before the application, the tissue sensitivity will be reduced by heating and rubbing for 20 seconds without direct pressure on the acupressure points, and the points will be made ready for acupressure application. Afterwards, sequential (breathing rhythm) compressions will be applied to the determined acupressure points by the researcher for a total of two minutes for each point without raising the finger, taking into account the pain threshold of the individual who is applied with the thumb, with 10 seconds of pressure for two seconds of relief. Two of the three different points (LI4 and P6) selected for the application will be applied symmetrically on the other extremity. Therefore, the session duration of each patient will be approximately 12 minutes, depending on the preparation and compression time on each point. Afterwards, acupressure will be applied to themselves by participants
223504965|NCT05898880|OTHER|Acupressure by therapists|In the acupressure group applied by therapist, before the application, the tissue sensitivity will be reduced by heating and rubbing for about 20 seconds without direct pressure on the acupressure points, and the points will be ready for acupressure application. Afterwards, sequential (breathing rhythm) compressions will be applied to the determined acupressure points by the researcher for a total of two minutes for each point without raising the finger, taking into account the pain threshold of the individual who is applied with the thumb, with 10 seconds of pressure for two seconds of relief. Two of the three different points (LI4 and P6) selected for the application will be applied symmetrically on the other extremity. Therefore, the session duration of each patient will be approximately 12 minutes, depending on the preparation and compression time on each point.
223504966|NCT05898880|OTHER|Control group|No intervention will be made in the control group.
223504967|NCT01881633|DRUG|ISU302|
223504968|NCT01881633|DRUG|Placebo|
223504969|NCT05573737|OTHER|education|education about ubilical cord care
223504970|NCT01377311|PROCEDURE|Transplant of cultured limbal stem cells on cornea|Remove the abnormal surface tissue on the lesion cornea, transplant the amniotic membrane with cultured limbal stem cells on the denuded cornea. Cover with contact lens after operation, and apply topical antibiotics and steroids.
223504971|NCT06110182|DIETARY_SUPPLEMENT|enteral or parenteral nutritional support|Parents will be classified based on whether they received enteral or parenteral nutritional support during treatment.
223504972|NCT03737032|DEVICE|Intermittent Theta Burst Stimulation|Theta Burst Stimulation, a form of Transcranial Magnetic Stimulation, will be applied to the dorsomedial prefrontal cortex. will include 600 pulses delivered in brief bursts of three pulses with a frequency of 50 Hz, at an intensity of 110% of resting motor threshold, and administered every 200 ms (5 Hz). Bursts will be delivered without interruption for a total duration of 40 seconds.
223504973|NCT03737032|DEVICE|Continuous Theta Burst Stimulation|Theta Burst Stimulation, a form of Transcranial Magnetic Stimulation, will be applied to the dorsomedial prefrontal cortex. will include 600 pulses delivered in brief bursts of three pulses with a frequency of 50 Hz, at an intensity of 110% of resting motor threshold, and administered every 200 ms (5 Hz). Bursts will be delivered during 2 second periods (10 bursts/period) interleaved with 8-second stimulation-free intervals, for a total duration of 190 seconds.
223504974|NCT03737032|DEVICE|Sham Theta Burst Stimulation|For the sham of theta burst stimulation, the device providing Theta Burst Stimulation can be placed in the same position and turned on, creating a similar experience for the participant, without providing any neural stimulation. Sham TBS will be delivered with a Cool-B65 Active/Placebo Coil, which includes a sham setting, and MagLink research software.
223504975|NCT04286503|DRUG|Carrimycin|Carrimycin
223504976|NCT04286503|DRUG|lopinavir/ritonavir tablets or Arbidol or chloroquine phosphate|lopinavir/ritonavir tablets or Arbidol or chloroquine phosphate
223504977|NCT04286503|DRUG|basic treatment|basic treatment
223504978|NCT05181631|OTHER|Biobanking|"Collection of blood (One tube of blood 4-5 ml + One EDTA tube of blood 5 ml) will be attempted for each participant at baseline. Availability of these samples will be indicated in the e-CRF.~Samples will be collected by hospital staff and stored following regulatory conditions of conservation in CRB of Hospital Avicenne under the responsibility of Pr Marianne ZIOL. "
223504979|NCT01141868|BEHAVIORAL|Internet Intervention|online treatment for insomnia
224195981|NCT06598397|DRUG|Combination NRT|If they smoke 10 or more cigarettes per day (CPD), participants will receive 2 weeks of 21 mg patches, 2 weeks of 14 mg patches and 2 weeks of 7 mg patches; if they smoke less than 10 CPD, participants will receive 4 weeks of 14 mg patches and 2 weeks of 7 mg patches. Participants will receive either 2 or 4 mg of nicotine lozenges for a total of up to 20 lozenges per day.
224195982|NCT07006922|PROCEDURE|hypospadias repair using the STAR technique with PRP as protective layer|"the STAR technique involves anatomical reassembly of penile tissues guided by the topography of the glans and corpus spongiosum (the exclusive zipping-up of the unfolded spongiosal plate). A fine-tipped tenotomy scissor used for dissection, starting at the apex of the hypoplastic V and extending into the ventral edges of the hooded prepuce on each side, following the demarcation lines. Then, a midline cutting back of the ventral hypoplastic urothelial sheet from the hypospadias meatus to the point of spongiosal bifurcation was made . Excision of the hypoplastic skin ridge all the way from the point of bifurcation till each ipsilateral ventral endpoint of the glanular meatal marks to maximize the epithelialized endoluminal surface of the newly zipped-up spongiosal plate. An interrupted single -layedred spongioplasty ( zipper closure) using 6/0 Vicryl Absorbable sutures (13mm needle, Ethicon Inc, Somerville, New Jersey) is applied over a naeleton catheter . Lastly, the glansplasty is d"
224310589|NCT00039520|DRUG|sulindac|
224310590|NCT02866526|OTHER|Patient questionnaire|quantitative and qualitative data collection will be proposed.
224310591|NCT03891966|PROCEDURE|Rigid Splint|50 patients undergoing operative fixation of isolated bothbone forearm, radial head, olecranon, distal humerus, or humeral shaft fractures will either receive a splint.
223504980|NCT04955093|DEVICE|Biofeedback|Technology to provide Heart Rate Variability Biofeedback
223504981|NCT03749174|PROCEDURE|Long acting Supraclivicular block vs Short acting Supraclavicular block|"Patients are randomized to receive; long-acting Supraclavicular plexus block or short-acting Supraclavicular plexus block or general anesthesia~Sub group randomized to plaster/cast or orthosis/brace, both having short-acting block"
223504982|NCT05655572|OTHER|Action Observation Theraoy|After initial baseline assessment patients allocated in AOT group will undergo treatment protocol of 6 weeks having 4 stages of duration 1.5 weeks each performed 3 days per week. . Assessment will be perform at baseline after 2, 4 and 6 weeks
223593465|NCT05916469|DRUG|Levonorgestrel Intrauterine System|52 mg levonorgestrel intrauterine system
223593466|NCT05916469|DRUG|Norethindrone Acetate|norethindrone acetate 5 mg daily
223747014|NCT02146573|BEHAVIORAL|Continuity Care Intensivist Communication Training|Physicians enrolled in the intervention arm will complete a two to three part communication training. Survey measures of communication competency and burnout will be administered at baseline, after training, and at the end of the study. After the communication training, physicians will undergo an OSCE assessment with a simulated patient to evaluate communication skills. At the end of the study, CCI providers will receive surveys that assess the experience and challenges of the role, repeat surveys assessing competency with communication and frequency of engaging families in goals of care conversations, in addition to a follow-up focus group that will assess their experience with the intervention, the time required and the potential tradeoffs in other duties required by them to participate as a CCI.
223747015|NCT02146573|BEHAVIORAL|Continuity Care Intensivist (CCI) Provider Program|"After undergoing CCI training, CCI providers will fulfill a standardized role with parent-patient dyads:~* CCI will meet with families on a regular basis and at change of physician of record throughout their entire PICU hospitalization.~* Help patients/families navigate decisions in concert with preferences and beliefs~* Help patients/families and other care providers look at bigger picture; trajectory of illness, goals, and hopes for the patient.~* Serve as point person for active intensivists on service and other specialists~* Help resolve conflict when multiple providers have different opinions on course of action"
223593467|NCT02395523|RADIATION|Proton Beam Therapy|"Definition of target volume:~* Gross tumor volume (GTV) = gross tumor defined using a treatment planning CT scan~* Clinical target volume (CTV) = GTV + internal target volume~* Planning target volume (PTV) = CTV + 5 - 7 mm of lateral, craniocaudal, and anteroposterior margins.~Radiation dose and planning~* Prescription dose to PTV: 70 GyE /10 fx, 7GyE fraction dose, 5 days/week~* Dose prescription : 95% isodose volume of prescribed dose encompassed PTV"
223747016|NCT04002596|DEVICE|ExAblate Neuro Thalamotomy Treatment|Non-invasive Focused Ultrasound Ablation of Thalamus Vim nucleus using ExAblate MRgFUS system for treatment Tremor Dominant Parkinson Disease
223747017|NCT03332576|BIOLOGICAL|DPX-Survivac|SubQ injection
223747018|NCT03332576|BIOLOGICAL|DPX-Survivac(Aqueous)|SubQ injection
224310592|NCT03891966|PROCEDURE|Soft Dressing|50 patients undergoing operative fixation of isolated both bone forearm, radial head, olecranon, distal humerus, or humeral shaft fractures will either receive a soft dressing post-operatively.
223593468|NCT02110862|OTHER|Transittime. Defecography|
223593469|NCT06094790|DRUG|CORT125134 150 mg|CORT125134 150 mg (3 X 50 mg current capsule formulation)
224310593|NCT02788682|GENETIC|WT+ Diplotype|3 or 4 vitamin D binding protein major alleles
224310594|NCT01133886|DRUG|Decitabine|Patients will receive decitabine as a 20mg/m2 one hour intravenous infusion once daily on days 1 to 5 of a 4 week cycle.
224310595|NCT01072955|BIOLOGICAL|Bovine Heparin|5.000UI/mL bottle with 5mL
224310596|NCT01072955|BIOLOGICAL|Porcine heparin|5000 USP Heparin Units / mL vial with 10 mL vial
224310597|NCT01523223|BIOLOGICAL|therapeutic allogeneic lymphocytes|Undergo CD8 memory T-cell infusion
223593470|NCT06094790|DRUG|CORT125134 250 mg|CORT125134 250 mg (5 X 50 mg current capsule formulation)
223593471|NCT06094790|DRUG|CORT125134 dose to be determined|CORT125134 current capsule formulation, dose to be determined
223593472|NCT02473367|DRUG|Raltegravir 1200 mg|Two tablets of 600 mg raltegravir administered orally, once daily, over 5 days of Pre-treatment, and once at the start of Periods 1-4.
223747019|NCT03332576|DRUG|Cyclophosphamide|PO BID
223747020|NCT00495833|BEHAVIORAL|Personalized brochure|either photo personalization, blood pressure personalization, both, or no personalization
223747021|NCT00495833|BEHAVIORAL|Promotional gift|half of participants who go to a fire station will receive a gift card.
223747022|NCT01599871|DRUG|theophylline|theophylline 100 mg, twice at day
223747023|NCT01599871|OTHER|placebo|Placebo
223747024|NCT00003814|DRUG|eflornithine|
224310598|NCT03542955|DEVICE|ActiPatch|A Pulsed Shortwave Therapy Device
224195983|NCT07006922|PROCEDURE|hypospadias repair using the STAR technique|"the STAR technique involves anatomical reassembly of penile tissues guided by the topography of the glans and corpus spongiosum (the exclusive zipping-up of the unfolded spongiosal plate). A fine-tipped tenotomy scissor used for dissection, starting at the apex of the hypoplastic V and extending into the ventral edges of the hooded prepuce on each side, following the demarcation lines. Then, a midline cutting back of the ventral hypoplastic urothelial sheet from the hypospadias meatus to the point of spongiosal bifurcation was made . Excision of the hypoplastic skin ridge all the way from the point of bifurcation till each ipsilateral ventral endpoint of the glanular meatal marks to maximize the epithelialized endoluminal surface of the newly zipped-up spongiosal plate. An interrupted single -layedred spongioplasty ( zipper closure) using 6/0 Vicryl Absorbable sutures (13mm needle, Ethicon Inc, Somerville, New Jersey) is applied over a naeleton catheter . Lastly, the glansplasty is d"
224195984|NCT07005167|PROCEDURE|endocrowns|endocrowns made of HC hard blocks or cerasmart blocks to restore endo treated molars
224195985|NCT07005167|PROCEDURE|endocrowns|endocrowns made of Cerasmart blocks to restore endo treated molars
224195986|NCT07006155|DEVICE|Images|PET/CT images
224195987|NCT07006012|DRUG|RGL-305|RGL-305 is administered intravenously with a recommended rate of 3-5 mL /min. The interval after the first administration was 3 weeks, and then every 2 weeks was a cycle, each cycle was given d1, and up to 5 cycles of cell transfusion were received.
224195988|NCT07005310|DEVICE|Powerglide pro™|A long peripheral catheter will be placed under ultrasound guidance. This catheter will be placed by using the Accelerated seldinger technique.
224195989|NCT07005310|DEVICE|Introcan safety deep access|The catheter will be placed using ultrasound guidance and by using the 'catheter-over-the needle' approach.
224195990|NCT07005492|DIAGNOSTIC_TEST|radiological and clinical examination|Standard radiological (periapical radiography) and clinical (inspection, percussion, palpation tests etc.) examinations were performed.
224195991|NCT07006740|PROCEDURE|MR-guided Focused Ultrasound Thalamotomy|This intervention involves a unilateral magnetic resonance-guided focused ultrasound (MRgFUS) thalamotomy targeting the ventral intermediate nucleus (VIM) of the thalamus. The procedure is non-invasive and uses MRI guidance to deliver focused ultrasound energy to ablate the target area. It is performed without surgical incisions or implanted devices. The intervention is intended for patients with medication-refractory essential tremor. Participants receiving this intervention will be followed for 12 months to assess efficacy and safety.
224195992|NCT07007338|BIOLOGICAL|Supplementary blood samples and urines samples|Supplementary blood and urines samples realised during routine visits
224195993|NCT07005323|PROCEDURE|Pars plana vitrectomy|One sheet of PAL-222 is implanted into the subretinal space of either of eyes through pars plana vitrectomy.
224310599|NCT03542955|DRUG|Etoricoxib 60 mg|nonsteroidal anti-inflammatory drug used as standard therapy
224310600|NCT03802955|DRUG|ADG106|IV infusion over 60 minutes on Day 1 of each cycle, at 7 doses depending on cohort at enrollment.
224310601|NCT01413516|BEHAVIORAL|Smoking cessation counseling|Counseling sessions provided by a trained smoking counselor
223504983|NCT05655572|OTHER|Functional Training|after baseline assessment participants including in this group will perform the tasks for 6 weeks (3 days per week) s and after that again assessment will be made for examining the improvements.Assessment will be perform at baseline after 2 ,4 and 6 weeks
223504984|NCT00732459|DEVICE|Electro-acupuncture preconditioning|electro-acupuncture
223504985|NCT01359280|BEHAVIORAL|Adherence Counseling|5 Sessions of theory-based medication adherence counseling
223504986|NCT01359280|BEHAVIORAL|General Health Counseling|5 sessions of health improvement counseling
223504987|NCT01359280|BEHAVIORAL|Text Messages|Daily medication regimen tailored adherence reminders delivered by cell phone
223504988|NCT01818648|DRUG|Exenatide|Qualifying participants will be assigned to 2 different treatment arms consisting of placebo or exenatide 5 mcg administered subcutaneously twice: the first dose during fasting and the second four hours later. Subsequently, participants will switch over to the alternate treatment arm. In both arms participants will undergo a series of measurements including 24 hour GI transit, permeability measurements by using mannitol and lactulose, and 24 hour urine and stool collections.
223504989|NCT01818648|DRUG|Placebo|Qualifying participants will be assigned to 2 different treatment arms consisting of placebo or exenatide 5 mcg administered subcutaneously twice: the first dose during fasting and the second four hours later. Subsequently, participants will switch over to the alternate treatment arm. In both arms participants will undergo a series of measurements including 24 hour GI transit, permeability measurements by using mannitol and lactulose, and 24 hour urine and stool collections.
223504990|NCT01038895|DRUG|Ramipril|tablet; 10 mg; od; 3 months
223504991|NCT01038895|DRUG|Experimental|tablet; 300 mg; od; 3 months
223504992|NCT03391154|DRUG|levothyroxin|90 female received levothroxine
223504993|NCT00500110|DRUG|Docetaxel|30 mg/m\^2 by vein (IV) Weekly Over 60 Minutes on Days 1, 8, 15, and 22. This will be followed by 2 weeks with no docetaxel.
223504994|NCT00500110|DRUG|Imatinib Mesylate|600 mg by mouth (PO) Daily x 42 Days.
223504995|NCT00500110|DRUG|Leuprolide|Hormone injections given every other month or every 3 months, as determined by the doctor.
223504996|NCT00500110|DRUG|Goserelin Acetate|Hormone injections given every other month or every 3 months, as determined by the doctor.
223504997|NCT03473158|DEVICE|Transvaginal ultrasound|using the 6.5mHz intra-cavitary probe (65EC10EA) of ultrasound machine DP-50 (Shenzhen Mindray Bio-Medical Electronics Co., Ltd., P.R.China) to determine the number, site, size and cardiac activity of the fetuses, and monitor the fetal reduction procedure
223504998|NCT03473158|PROCEDURE|Mechanical fetal reduction|under transvaginal ultrasound guidance, fetal reduction will be achieved by mechanical disruption of the fetal heart till asystole is achieved, and may be aided by partial or total suction of the fetus, using suction device attached to the embryo reduction needle (Cook® Ireland Ltd., Limerick, Ireland)
223504999|NCT03473158|PROCEDURE|Chemical fetal reduction|under transvaginal ultrasound guidance, fetal reduction will be achieved by injecting 0.5 mL of potassium chloride (Potassium Chloride® 15% , EIPICO, Egypt) into the cardiac region through the embryo reduction needle (Cook® Ireland Ltd., Limerick, Ireland)
223505000|NCT01502072|DRUG|Ribavirin|Modified schedule of 60 milligrams/milliliter for 3-hour period 3 times/day for at least 5 days by aerosolization via a SPAG-2 generator via a face mask.
224075054|NCT07037641|OTHER|Sacroiliac Joint Manipulation|The side for sacroiliac joint manipulation will be determined using the Derifield leg length test. Based on functional leg length differences, a PI (posterior-inferior) ilium will be identified. Patients will be positioned side-lying with appropriate limb and trunk alignment. The practitioner's hypothenar eminence will be placed on the PSIS of the dysfunctional side. A high-velocity, low-amplitude (HVLA) thrust will be applied in a rotational direction from the PSIS toward the patient's umbilicus to correct the joint dysfunction. The manipulation will be performed twice a week over two weeks (4 sessions in total), combined with conventional physiotherapy (hot pack, TENS, ultrasound, and exercise).
224195994|NCT07005232|DEVICE|defibrillation lead|This is a device registry for the OmniaSecure™ defibrillation lead. The OmniaSecure lead is a steroid eluting, integrated bipolar, nonretractable screw-in, catheter delivered, transvenous ventricular lead with a Right Ventricular (RV) defibrillation coil electrode. The lead is designed for pacing, sensing, cardioversion, and defibrillation therapies, and has application for patients whom transvenous ICDs and cardiac resynchronization therapy defibrillators (CRT-Ds) are indicated.
224195995|NCT07005908|OTHER|Physical evaluations of post-COVID-19 individuals|In this study, pain, posture and musculoskeletal disorders were evaluated in post-COVID-19 individuals. The data to be obtained from all these evaluations were collected from the individuals at one time and over a period of approximately 1 hour at the most.
224310602|NCT01413516|DRUG|Placebo|Sugar pill without any active medication
223505001|NCT01502072|DRUG|Ribavirin|One time loading dose of 10 mg/kg oral dose then 20 mg/kg orally (rounded to the nearest 200 mg dose) divided into three doses per day (max 1800 mg/day).
223505002|NCT00000538|BEHAVIORAL|diet, fat-restricted|
223505003|NCT01121458|DRUG|Clevidipine|The clevidipine infusion is to be administered via IV infusion at a starting dose of 0.5 mg/hour. The dose may be doubled every three (3) minutes to a maximum dose of 32 mg/hr as tolerated, until a 20% reduction in PVR is achieved or until the patient experiences hypotension (SBP\< 80 mmHg), hypertension (SBP\>150 mmHg), tachycardia (120 beats per minute), bradycardia (\<50 beats per minute), or symptoms of hypotension or ischemia (chest pain, anxiety, nausea, vomiting), allergic reaction (hives, urticaria) or other adverse event. Clevidipine infusion may be terminated at any time for a safety reason or at the investigator's discretion.
223505004|NCT02363127|DRUG|subcutaneous progesterone|subcutaneous progesterone 25 mg/day
223505005|NCT02363127|DRUG|vaginal progesterone|vaginal progesterone in capsules 200 mg/3 times a day
223505006|NCT02266862|RADIATION|Study group|Patients will receive an additional CT sequence (end-expiration) at the time of their standard CT imaging before and after the repair.
223505007|NCT05267002|PROCEDURE|Suture removal timing|Cutaneous nylon suture removal of each half of the split-scar at one and two weeks.
223505008|NCT00337961|PROCEDURE|Optic Nerve Sheath Fenestration|
223505009|NCT03646188|DRUG|Placebo-containing MNA|A 15 x 15 mm array containing 400 tip-loaded, dissolvable microneedles delivering a placebo.
223505010|NCT03646188|DRUG|25 µg doxorubicin-containing MNA|A 15 x 15 mm array containing 400 tip-loaded, dissolvable microneedles delivering 25 µg of doxorubicin hydrochloride.
223505011|NCT03646188|DRUG|50 µg doxorubicin-containing MNA|A 15 x 15 mm array containing 400 tip-loaded, dissolvable microneedles delivering 50 µg of doxorubicin hydrochloride.
223505012|NCT03646188|DRUG|100 µg doxorubicin-containing MNA|A 15 x 15 mm array containing 400 tip-loaded, dissolvable microneedles delivering 100 µg of doxorubicin hydrochloride.
223505013|NCT03646188|DRUG|200 µg doxorubicin-containing MNA|A 15 x 15 mm array containing 400 tip-loaded, dissolvable microneedles delivering 200 µg of doxorubicin hydrochloride.
223505014|NCT01271829|DIETARY_SUPPLEMENT|Avocado supplement|Calories from avocados replace calories of the control lunch
223505015|NCT01271829|DIETARY_SUPPLEMENT|Avocado included|Calories from avocados will be added to calories from the control lunch
223505016|NCT05001412|DRUG|Camrelizumab; apatinib; carboplatin; etoposide|2 cycle chemotherapy (carboplatin and etoposide), and then 2 cycle chemotherapy (carboplatin and etoposide) combine with Camrelizumab and apatinib, finally maintenance therapy with Camrelizumab and apatinib
223505017|NCT01451788|DEVICE|Gelatin matrix with human derived thrombin (Floseal, Baxter)|Floseal will be used to stop cancellous bone bleeding, pedicle channel bleeding or epidural space bleeding by injecting suitable amount of this matrix and irrigating it away after few minutes.
223505018|NCT00617903|DRUG|Azelaic acid|15% foam to be applied topically twice daily
223505019|NCT00617903|DRUG|Vehicle foam|Active-ingredient-free vehicle to be applied topically twice daily
223505020|NCT01544075|BEHAVIORAL|Pain neurophysiology education (PNE) and psychologic inoculation (PI)|3 sessions of PNE+PI are given which include education on pain neurophysiology and applying the PI technique for which subjects are asked to refute sentences which are read by the therapist.
223505021|NCT01544075|BEHAVIORAL|Neck school (NS)|3 sessions of NS which includes advice on posture, ergonomics and on performing activities.
223505022|NCT00281853|PROCEDURE|management of therapy complications|Patients undergo a 1-hour peripheral nerve function assessment, including hearing, vibratory sensation, and blood pressure testing, at baseline and then at 4, 8, and 12 weeks during treatment with chemotherapy or biologic therapy.
223505023|NCT04676646|DRUG|Sodium zirconium cyclosilicate|Investigational medicinal product
223505024|NCT04676646|DRUG|Placebo|Placebo comparator
223505025|NCT04676646|OTHER|Spironolactone|"Background intervention.~During the run-in phase, spironolactone will be initiated/uptitrated up to a maximum of 50 mg per day. During the randomized withdrawal phase the spironolactone dose at the end of the run-in phase will be maintained."
223505026|NCT02773823|BEHAVIORAL|Intervention group|Diet instruction for 3-4 times/semester,exercise 60min/day for 5d/week for 8 months.
223505027|NCT04378049|PROCEDURE|Total knee arthroplasty|Surgeon will perform a total knee arthroplasty procedure according to local standard of care
223505028|NCT04378049|PROCEDURE|Robot-assisted partial knee arthroplasty|Surgeon will perform a robot-assisted unicompartmental or bicompartmental knee arthroplasty procedure
223505029|NCT04863807|PROCEDURE|Regional Anaesthesia|Thoracic epidural/Erector Spinae block/Serratus Anterior block
223505030|NCT02867852|DRUG|Abiraterone acetate|Abiraterone acetate is a prodrug of abiraterone, an irreversible inhibitor of 17α hydroxylase/C17, 20-lyase (cytochrome P450c17 \[CYP17\]), a key enzyme required for testosterone synthesis. This enzyme is found in the testes, adrenals, prostate tumors
223593473|NCT02473367|DRUG|TUMS|Three tablets of TUMS Ultra Strength (US) 1000, taken orally, concomitantly with raltegravir in Period 2, and 12 hours after raltegravir in Period 4
223593474|NCT02473367|DRUG|Leader Antacid|20 mL Leader Antacid Maximum Strength (MS) taken orally 12 hours after raltegravir, in Period 3
223593475|NCT03682692|DRUG|ACEI/CCB|benazepril 10 mg / amlodipine besylate 5 mg fixed-dose combination
223593476|NCT03682692|DRUG|ACEI/DIU|benazepril 10 mg / hydrochlorothiazide 12.5 mg fixed-dose combination
223593477|NCT02225834|DRUG|Atorvastatin|treatment with atorvastatin 80 mg (once-daily) from admission day until discharge
223593478|NCT02486965|DEVICE|thermode (TSA-II model)|thermal stimulation with test thermode
223593479|NCT02486965|OTHER|Adapted Physical Activity|
223593480|NCT02486965|OTHER|Physical activity|
223593481|NCT06980623|DRUG|Tirzepatide|Exposure group
223593482|NCT06980623|DRUG|Semaglutide|Referent group
223593483|NCT04384939|DEVICE|magnetic-end Double-J ureteral stent|"* Inserting the ureteral stent with magnet (same process as classic ureteral stent)~* Removing the ureteral stent with magnet without general anaesthesia. Usually, the classic ureteral stent removed during a general anaesthesia."
223593484|NCT01691040|DRUG|NOX-H94|intravenous injection
223593485|NCT01691040|DRUG|Placebo solution|intravenous injection
223593486|NCT00771771|OTHER|Early supported discharge with day unit rehabilitation|Treatment by physiotherapist and occupational therapist up to 4 hours a day for up to 5 weeks in a day unit
223593487|NCT00771771|OTHER|Early supported discharge with home rehabilitation|Treatment by physiotherapist and occupational therapist up to 4 hours a day for up to 5 weeks in the patient's home
224195996|NCT07005843|DEVICE|The Elana Anastomotic System|The Elana Anastomotic System is a medical device and is intended to create a suture less blood vessel anastomosis in Coronary Artery Bypass Grafting (CABG) procedures on the beating heart, without blo
224195997|NCT07005388|BEHAVIORAL|Cognitive behavioral therapy for psychosis|Cognitive behavioral therapy for psychosis is a group protocol design specially for psychotic patients to treat their positive and negative symptoms
224195998|NCT07005271|BEHAVIORAL|virtual reality|The exercises in this group consist of four different games, including: (1) MasterChef, which involves performing daily living tasks in a virtual kitchen environment such as slicing tomatoes and cheese, adding salt, cracking and adding eggs, and stirring with a fork to prepare an omelet; (2) PinchPeg, where participants use a pinch grip to grasp rods generated in the center of a virtual environment and place them into holes on a pegboard, followed by removing and returning them to their original location; (3) Hold and Put, which requires the use of a standard palmar grasp to pick up virtual cups or cans and place them onto designated shelves; and (4) bPuzzle, a task that integrates cognitive and fine motor exercises by requiring participants to change the color of a puzzle using finger movements and place the pieces into the correct positions using hand gestures.
223593488|NCT06682494|BEHAVIORAL|Traditional Education|Participants will receive traditional educational handouts focusing on increasing awareness of oral cancer risks, preventive strategies, and the importance of regular dental check-ups. Participants will be provided time to read the handouts based on calculated reading time.
223593489|NCT06682494|BEHAVIORAL|AI-powered Chatbox|The chatbot interaction will be initiated through a provided link, allowing participants to access information and ask questions related to oral health and cancer prevention. The chatbot is programmed to provide accurate information on oral cancer risks, symptoms, preventive measures, and the importance of regular dental check-ups. Participants will be encouraged to interact with the chatbot for a specified duration
223593490|NCT04735991|BEHAVIORAL|Kapok Initiative|"The detailed process is:~1. After randomization, the Kapok assistant will contact the patient's family~2. The family of the patient joins the Kapok Initiative. They will participate in a 60-minute training program for 27 days, which is taught online by experts; The contents of the lectures are as follows: 1) Doctors are also mortal; 2) New medicines and new therapies; 3) Alternative therapies; 4) Don't panic during the operation; 5) Pain relief; 6) Side effects of treatment; 8) About the truth; 9) New topics; 10) Anti-cancer cost-effectiveness; 11) Medical insurance; 12) Commercial medical insurance; 13) Exercise and rehabilitation; 14) Nutrition and Foods to increase leukocytes level; 15) Long-term persistence; 16) Acceptance Change; 17) Two new roles; 18) Future expectation."
223593491|NCT06127628|PROCEDURE|Ultrasound-guided scalp block with ropivacaine 0.375%|Scalp block will be performed under USG guidance, using the technique described by Tsan et al. The block needle used will be an echogenic block needle, with a length of 50 mm, and a diameter of 22 G. Trained personnel comprising of the investigators in this study will perform the scalp block. Using ultrasound to identify landmarks, ropivacaine 0.375% will be administered in volumes of 1.5 ml to 3 ml. The nerves targeted will be the supraorbital, supratrochlear, zygomaticotemporal, auriculotemporal, greater auricular, lesser occipital, greater occipital and third occipital nerves.
223593492|NCT06726187|OTHER|Structured Clinical Interview for DSM-5 Screening Personality Questionnaire (SCID-5-SPQ).|Screening questionnaire
224195999|NCT07005271|BEHAVIORAL|Conventional treatment|Participants will be asked to complete puzzles consisting of 30 to 50 pieces, with 3 to 4 different puzzles used to eliminate the learning effect. They will perform the Nine-Hole Peg Test, which is similar to the PinchPeg game in the virtual reality group, by picking up pegs one by one from a container and placing them into holes on the board as quickly as possible using only the evaluated hand; this will be used for training purposes. Additionally, participants will be instructed to cut out geometric shapes with dotted outlines using scissors, aiming to follow the lines accurately. Finally, they will sort objects by placing the correct number and color of items into designated locations according to a predetermined pattern, and use a magnetic fishing rod to catch wooden fish, promoting both fine motor skills and task-oriented hand function.
223593493|NCT06750484|DRUG|Trastuzumab Deruxtecan|Participants will receive the study drug trastuzumab deruxtecan (T-DXd) by IV infusion every 21 days. The number of treatment cycles will depend on how participants respond to treatment.
223593494|NCT06894654|PROCEDURE|Skin punch biopsy|Skin punch biopsies are 5mm for this study. Participants with SSc will undergo 4 biopsies (2 in diseased area, 2 in non-diseased area if available). Healthy Volunteers will undergo 2 biopsies.
223593495|NCT06894654|OTHER|blood sampling|10mls blood will be taken for analysis and DNA sequencing
223593496|NCT06894654|BEHAVIORAL|Questionnaire|All participants are required to complete a questionnaire with information on demographics, lifestyle, medical and medication history.
224196000|NCT07006688|DRUG|Ivosidenib Oral Tablet|500mg Ivosidenib taken orally once daily for continuous 28-day cycles
223593497|NCT07058207|BEHAVIORAL|Multimodal weight management program|"This intervention consists of three components:~* Nutritional Counseling:~  * A personalized hypocaloric and high-protein diet is prescribed, based on individual energy requirements with a 20% caloric reduction.~ * The protein intake target is 1.5 g/kg/day to promote fat loss while maintaining muscle mass.~* Exercise Program~  * Home-based, supervised aerobic and resistance training sessions conducted 3 times per week.~ * Each 60-minute session includes: 5 minutes flexibility, 25 minutes aerobic training, 25 minutes resistance training, and 5 minutes balance exercises.~* Behavioral Support~  * Patients receive training in problem-solving strategies, motivation, and emotional self-regulation to improve adherence to both dietary and exercise goals.~ * Health professionals delivering the intervention are trained in behavior change techniques by a clinical psychologist."
223593498|NCT07060339|BEHAVIORAL|Exercise Programme|Midwifery care, breathing exercises, massage and exercise applications were performed on pregnant women in this group during the active phase of labour. Following breathing exercises, massage was applied for 10 minutes using different techniques according to rest and contraction intervals. Pain levels were assessed using the VAS before and after massage. After the massage, the exercise session began; the pregnant woman was first walked along a 50-metre corridor, followed by squatting, squat, four-legged positions, wall stretching movements, and pelvic tilt, swaying, and leg stretching exercises using a Pilates ball. Pain levels were measured using the VAS before and after all exercise applications.
223593499|NCT07060339|BEHAVIORAL|Hot Shower Programme|In addition to midwifery care, breathing exercises, massage, and hot showers were administered in this group. Massage was administered for 10 minutes after the breathing exercises, and pain levels were measured using the VAS before and after the massage. After the massage, considering the risk of the pregnant woman falling, she was seated on a stool in the shower, and warm water at a temperature of 36.5-37.8 °C was applied to the lower abdomen and sacrum region during contractions for 15 minutes. To prevent chills, the application was repeated at 10-minute intervals, and pain levels before and after were again assessed using the VAS.
223593500|NCT07060339|BEHAVIORAL|Combined Application (Exercise + Hot Shower)|In addition to midwifery care, breathing exercises, massage, exercise and hot shower treatments were performed for this group. As in Groups 1 and 2, the application began with breathing exercises, followed by massage, exercise, and hot showers in sequence. Pain levels were assessed using the VAS before and after each application, and measurements were taken again during the massage. Ten-minute breaks were given between applications to allow the pregnant women to rest, and the applications were continued alternately.
223593501|NCT07060339|BEHAVIORAL|Pharmacological Intervention|In this study, the fourth group was evaluated as the intervention 4 group and was followed up in accordance with standard interventions frequently applied during the birth process. Pregnant women in this group received routine midwifery care, massage treatments to promote relaxation, and breathing exercises in accordance with hospital protocols. In addition, pharmacological pain management methods commonly used in the clinic were also applied in this group.
223593502|NCT01002274|DRUG|MCS-2|2 soft-gel capsules Qd for 40 weeks
223593503|NCT02169765|OTHER|Hepatic resection|Adequate remnant liver volume was 30% for HCC patients without cirrhosis, and \>50% for HCC patients with chronic hepatitis, cirrhosis, or severe fatty liver.
223593504|NCT02169765|OTHER|Radiofrequency ablation|Radiofrequency ablation is performed in less than one week after clinical diagnosis.
223593505|NCT04029571|DRUG|TCM-FMD|"Apply fastening-mimicking diet combined with a dispelling dampness meal replacement. For the convenience of implementation, a cycle of 4 weeks. The first 5 days of each cycle is the calorie restriction stage (daily calorie about 800kcal). The traditional Chinese medicine with dampness effect is used as the main source of calories in this stage. The normal diet is carried out under the guidance of a professional dietitian for the next 23 days. Study for 12 weeks."
223593506|NCT04029571|OTHER|FMD|"A grain package is used to replace the dispelling dampness meal replacement, and the other thing is the same as the proposal in TCM-FMD."
223593507|NCT04921332|DEVICE|Bright Light Therapy (BLT) Lamp|With its built in automatic timer shut-off function, the bedside registered nurse (RN) would not need to return to the room to turn off this lamp after 30 minutes because the lamp will automatically shut off on its own.
223593508|NCT02092766|DRUG|artesunate|
223593509|NCT02092766|DRUG|quinine|
223593510|NCT01636349|OTHER|soccer exercise or continued daily lifestyle|Recreational soccer or continued unchanged lifestyle
223593511|NCT01587365|BIOLOGICAL|BMS-962476|
223593512|NCT01587365|BIOLOGICAL|Placebo matching with BMS-962476|
223593513|NCT02904148|PROCEDURE|Shoulder mobilisation|early shoulder mobilisation
223593514|NCT02134288|DRUG|Belatacept|
223593515|NCT02134288|DRUG|Everolimus|
223593516|NCT01280578|DEVICE|Transcatheter PFO Closure|Transcatheter PFO Closure
223593517|NCT03191253|OTHER|Medically-appropriate meals and groceries|Full nutrition Intervention Components: (1) 7 pre-packaged frozen meals; (2) Groceries or another 7-pack of meals; (3) Nutritional supplement bag to round out the nutrition in terms of nutrients, or dietary reference intakes (DRIs), and number of servings from fruits/vegetables, whole grains, legumes, nuts/seeds and dairy. The nutritional supplemental bag will also contain bulk ingredients to aid in cooking e.g., cooking oil, spices, and herbs as well as bulk items e.g., jar of peanut butter, quart of milk; (4) Individual nutritional counseling (x2 sessions); and (5) Group nutrition education classes (X3 classes) by POH registered dietitian (RD) team.
223593518|NCT00454584|DRUG|CNTO 1275 45 mg|Type=exact number, number=45, unit=mg, form=injection, route=subcutaneous
223593519|NCT00454584|DRUG|CNTO 1275 90 mg|Type=exact number, number=90, unit=mg, form=injection, route=subcutaneous
223593520|NCT00454584|DRUG|Etanercept 50 mg|Type=exact number, number=50, unit=mg, form=injection, route=subcutaneous
223593521|NCT03381417|DRUG|pegcyte|Eligible patients are scheduled to receive three cycles of chemotherapy every two weeks. During each chemotherapy cycle pegfilgrastim is injected s.c. post chemotherapy application.
224196001|NCT07005609|DIETARY_SUPPLEMENT|Snakehead fish meal|Subjects in the treatment group received snakehead fish meal daily for about 3 months until delivery. The meal contained carbohydrate, protein, vegetables and fruits. Snakehead fish was given +- 100 g per serving.
224310603|NCT01413516|DRUG|Varenicline|Varenicline (an approved medication for smoking cessation)
224310604|NCT01806818|DRUG|Epirisone 50mg or placebo TID|3 times a day after meals for 1 week
223593522|NCT03381417|DRUG|Neulastim|Eligible patients are scheduled to receive three cycles of chemotherapy every two weeks. During each chemotherapy cycle pegfilgrastim is injected s.c. post chemotherapy application.
223593523|NCT02303106|DRUG|Lamotrigine|
223593524|NCT01501552|OTHER|Training and support (T&S)|Two face-to-face educational meetings of at least one hour and a maximum of 2 hours, and one telephone support call of at least ten minutes and a maximum of 30 minutes. The telephone call will be offered to one of the GPs ('leader'). Depending on the needs of the PHCU, one additional face to face training (1 to 2 hours) may be offered. The time interval between meetings will be on average 2 weeks. The training sessions will address improving knowledge, skills, attitudes, and perceived barriers and facilitators by combining theory and practice-based training.
224196002|NCT07005453|DEVICE|SCALE-EYE (1)|Participants will undergo the colonoscopy and once a colorectal polyp is identified, the polyp will first be measured by optical assessment by the endoscopist, then with SCALE-EYE and lastly by biopsy-forceps assisted measurement.
223593525|NCT01501552|OTHER|Financial incentive|Groups will receive a financial incentive depending on their screening and brief intervention activities. They will be paid for the performance, with the country dependent system of pay (fee for item or fee for achieving set rates) and based on normal practices and financial rates for financial incentives for clinical preventive activities.
223593526|NCT01501552|OTHER|E-SBI (online screening and brief intervention)|Referring identified at-risk patients to an approved e-SBI programme, which will be either country specific (where these exist) or based on the WHO e-SBI programme (Poland).
223593527|NCT03222947|GENETIC|Deoxyribonucleic acid analysis|This study consists in the high throughput exome sequencing and subsequent genetic bio-analysis of 19 deoxyribonucleic acid samples from 6 families, already collected and consented, including patients diagnosed with a Taybi-Linder syndrome and their relatives (parents and/or siblings).
223593528|NCT02825212|DRUG|Harvoni|12 weeks for naïve subjects or non-cirrhotic treatment experienced subjects; or 24 weeks for treatment experienced subjects with cirrhosis
223593529|NCT02825212|DRUG|Epclusa|once daily for 12 weeks (naïve subjects, non-cirrhotic treatment experienced or treatment experienced subjects with compensated cirrhosis) for genotype 1-6 subjects.
224196003|NCT07005453|DEVICE|SCALE-EYE (2)|Participants will undergo the colonoscopy and once a colorectal polyp is identified, the polyp will first be measured by optical assessment by the endoscopist, then by biopsy-forceps assisted measurement and lastly with SCALE-EYE.
224196004|NCT07007351|DEVICE|Intradermal injection|The product is the first solution with free hyaluronic acid boosted with silicium the administration mode is same as any other intradermal multi-injection procedure
223593530|NCT04713501|BEHAVIORAL|PARTS Program|The PARTS Program is a 16-week group intervention model, with 8 individual clinical sessions on a biweekly basis, developed to resolve and alleviate trauma and stress for individuals diagnosed with PTSD.
223593531|NCT02706379|OTHER|Local cerebral oxygen saturation|take blood culture before antibiotic use;measure the blood lactate;liquid rescisutation as 20ml/kg
223593532|NCT01071824|PROCEDURE|Transverse coloplasty pouch (Long limb)|Transverse coloplasty pouch with long limb
223593533|NCT01071824|PROCEDURE|Transverse coloplasty pouch (Short limb)|Transverse coloplasty pouch with short limb
224196005|NCT07007377|OTHER|Follow-up|Follow-up
224196006|NCT06999590|OTHER|ACApatch™|Participants will receive weekly applications of ACApatch™ and Standard of Care until ulcer closure, or a maximum of 20 weeks, whichever occurs first.
223593534|NCT03211013|DRUG|Oxytocin|single-dose administration of OT nasal spray, complete computer-based tasks post-dose for approximately 1 hour
223593535|NCT03211013|DRUG|Placebos|single-dose administration of placebo nasal spray, complete computer-based tasks post-dose for approximately 1 hour
223593536|NCT05670509|DRUG|administration of Nasal midazolam in home group as a rescue medication for seizure control.|Children from home group assigned to receive treatment with intranasal midazolam with doses of 0.2 mg/kg (maximum, 10 mg) body weight of the standard IV formulation of midazolam (5mg/mL) via a metered dose sprayer at 0.1 mL/spray (i.e. 0.5 mg/spray). If the volume to be administered exceeded 1 mL, the dose was divided between both nostrils to avoid runoff and swallowing
223593537|NCT05670509|DRUG|administration of Buccal midazolam in home group as a rescue medication for seizure control.|Children from home group randomly assigned to receive treatment with buccal midazolam with doses of 0.2 mg/kg (maximum, 10 mg) body weight of the standard IV formulation of midazolam (5mg/mL) via dripping between the cheek and the gum per side using insulin syringe
223593538|NCT05670509|DRUG|administration of intramuscular midazolam in homegroup as a rescue medication for seizure control.|Children from home group randomly assigned to receive treatment with intramuscular midazolam with doses of 0.2 mg/kg (maximum, 10 mg) body weight of the standard IV formulation of midazolam (5mg/mL) using 3 mm syringe in the front aspect of thigh
224196007|NCT06999590|OTHER|caregraFT™|Participants will receive weekly applications of caregraFT™ and Standard of Care until ulcer closure, or a maximum of 20 weeks, whichever occurs first.
224196008|NCT06999590|OTHER|Standard of Care|Beginning at the screening visit, participants will receive weekly treatment with standard of care (cleaning, debridement, ulcer moisture balance) until ulcer closure, or a maximum of 20 weeks, whichever occurs first.
224196009|NCT07005544|DEVICE|RealityCare|Participants utilized a Virtual Reality scenario that simulated a complete handwashing sequence with water and soap, including an instructional display demonstrating the correct hand hygiene technique.
224196010|NCT07006766|OTHER|Microsurgical Training Models|"Four models will be compared: Japanese shirataki konjac noodle, Dragon skin silicone vessel, standard silicone vessel from Microsurgery and Regenerative Medicine (MSRM) lab, and the blue-blood chicken thigh model."
224196011|NCT07007130|DRUG|Actrapid insulin|0.1 IU/kg of short-acting human insulin diluted in 100 mL of normal saline, instilled intraperitoneally before closure
224196012|NCT07007130|DRUG|Normal saline|100 mL normal saline intraperitoneally
224196014|NCT07005596|DEVICE|Passy-Muir Speaking Valve|This intervention group receives early speaking valve intervention during ventilator weaning.
223747025|NCT04380259|BEHAVIORAL|Mindfulness-Based Trauma Recovery for Refugees (MBTR-R)|"MBTR-R is a mindfulness-based group intervention of nine 2.5-hour weekly sessions. MBTR-R format and structure parallel MBSR (mindfulness-based stress reduction) and MBCT (mindfulness-based cognitive therapy). MBTR-R includes systematic training in formal and informal mindfulness practices with trauma-sensitive adaptations and home practice. Trauma-sensitive adaptations include a safe place practice, psychoeducation about posttraumatic stress, stress reactivity, as well as self-compassion practices to cope with fear, self-judgement, guilt and shame. Socio-cultural adaptations include real-time linguistic translation of each session by a cultural mediator from the refugee community and use of socio-culturally specific metaphors. MBTR-R groups were conducted for men and women separately and delivered in an accessible, safe space in the local refugee community. Group meetings included a shared meal of traditional Eritrean food and female participants were offered free child care."
223747026|NCT04011501|PROCEDURE|Continuous Erector spinae block|Erector spine block and catheter placement will be performed for continuous analgesia prior to the surgical procedure.A initial bolus of 20 ml of Levobupivacaine 0.25% will be administered. Subsequently a 22G catheter will be introduced. At the end of the surgery, an elastomeric pump will be installed at a flow rate of 7 ml / hr with a 1.3% Ropivacaine solution.
223747027|NCT03410355|PROCEDURE|BMAC/PRP Injection|Patients will be placed on an office procedure under local anesthesia. The investigators will harvest 60 cm3 of bone marrow from posterior iliac crest and centrifuged obtaining approximately 3 cm3 of autologous bone marrow-mesenchymal stem cells concentrate. At the same time, 60cm3 of peripheral blood will be taken and centrifugated once, to obtain approximately 3 cm3 of PRP. After activation of platelet rich plasma cells they will be mixed in one syringe with the concentrated BMaC and both will be injected in the hip joint under ultrasound.
223747028|NCT03410355|PROCEDURE|Cortisone Injection|An intraarticular injection of 1cm3 with 80mg of methylprednisolone combined with 3cm3 of 0.25% bupivacaine will be injected in the hip joint under ultrasound.
224196015|NCT07005596|BEHAVIORAL|Standard Non-Verbal Communication Methods|This control group continues using conventional non-verbal communication methods such as gestures and lip-reading.
224196016|NCT07006870|OTHER|Virtual Reality plus Balance Exercise Training|Virtual reality balance training will be completed using the BRU system's preloaded programs for postural training and rehabilitation. Rehabilitation exercises will include tasks performed standing with virtual reality headset on whereby the visual and vestibular systems will be stressed and will be customized according to the participant's needs and ability to tolerate the training stimulus. Postural training exercises will be used to develop limits of stability, with 3 exercises performed requiring participants to move their center of mass to collect rings/blocks through a course within a given amount of time. Each of the 3 postural training exercises contained 15 levels of varying difficulty. Sessions will be tailored to everyone, with progression of increasing the level of difficulty or time of exposure for each exercise. Participants at this group will be also participate in a Balance exercise training program for 40 min/3 times per week for 8 weeks.
224196017|NCT07006870|OTHER|Balance Exercise Training|Each session of balance exercises will be composed of three phases, including warm-up, balance training and cool down. The warm-up phase will involve gentle stretching for calf, hamstring, quadriceps, iliopsoas muscles, as well as anterior, posterior and lateral step-ups for 5-10 minutes. The active phase will be performed on a balance training for 20 minutes. It included heel and toe raises, one-legged stance for each extremity, shifting weight anteriorly, posteriorly, laterally and diagonally, step-ups, narrow walking, backward walking, sideward walking, stepping over obstacles, passing balls arranged on the training mat in a circle, and throwing and catching a ball on the training mat. A rest period of 1 minute will be given between each component. The program will be ended with 5-10 minutes of cool down. During the cool-down phase, patients will perform deep breathing exercises and static exercises for back extensors in a recumbent position.
224196018|NCT05896670|DRUG|licaminlimab|ophthalmic solution 60 mg/mL Subjects will be randomized to receive licaminlimab eye drops three times daily (TID) for 6 weeks.
224196019|NCT05896670|OTHER|vehicle of OCS-02|inert ophthalmic solution vehicle of OCS-02 Subjects will be randomized to receive vehicle eye drops three times daily (TID) for 6 weeks.
223505031|NCT03110276|DRUG|EYP001a|10 mg and 100 mg capsules. Number of capsules to be ingested will depend on the dose cohort. Administered orally once daily. Single dose (SAD) or 14 days treatment (MAD).
223505032|NCT03110276|DRUG|Placebo|Placebo capsules, identical in appearance to the EYP001a 10 mg and 100 mg capsules.
223505033|NCT05145036|BEHAVIORAL|Tai-Chi|Tai Chi exercise could improve muscle performance, balance and have the benefit for fall down prevention in the elders and patients with frailty.
223505034|NCT05145036|BEHAVIORAL|Comprehensive training|There are 3 exercises. Each session consisted of 10 minutes of warm-up, 40 minutes of Tai Chi, and 10 minutes of cool down.
223505035|NCT01332162|DEVICE|Biventricular pacing|All patients will be pacing during two years
223505036|NCT01332162|DEVICE|No Pacing|No Pacing during the first year. In the second year all patients will be pacing
223505037|NCT05993325|BIOLOGICAL|AdCLD-CoV19-1 OMI|3000 participants will receive investigational product (AdCLD-CoV19-1 OMI) via intramuscular administration in the deltoid muscle
223505038|NCT05993325|BIOLOGICAL|Comirnaty Bivalent 0.1mg/mL (tozinameran and riltozinameran)|1000 participants will receive investigational product (Comirnaty Bivalent) via intramuscular administration in the deltoid muscle
223505039|NCT05075772|DRUG|BI 765080|BI 765080
223505040|NCT01685554|DEVICE|hypothermic CPB|maintenance of mild hypothermia during cardiopulmonary bypass
223505041|NCT01685554|DEVICE|normothermic CPB|maintenance of normal body temperature during cardiopulmonary bypass
223505042|NCT03537456|DEVICE|mRDX-02-17|"mRDX -02-17 is a dermal filler recommended for the correction and treatment of wrinkles and dermal depressions.~It is a sterile and viscous aqueous solution of hyaluronic acid in a concentration of 1.5% (p/v) with acetyl tetrapeptide-9 and palmitoyl tripeptide-5, as auxiliary ingredients which is administrated by intradermal injections.~This medical device encourages repair and restructuring of skin tissue and reduces the signs of aging.~mRDX -02-17 is indicated for patients with hypotrophic tissues, Crow's feet, Glogau III-IV, all skin photo types (Fitzpatrick I - VI) and a WSRS score (Wrinkle Severity Ranking Scale) from 2 to 5."
224196020|NCT05896670|OTHER|Artificial tears|Subjects who quality after an initial screening were entered into a run-in phase where they received artificial tears to use three times daily (TID) for approximately 14 days.
223593539|NCT05670509|DRUG|administration of Nasal midazolam in ER group as a rescue medication for seizure control.|Children from the ER group assigned to receive treatment with intranasal midazolam with doses of 0.2 mg/kg (maximum, 10 mg) body weight of the standard IV formulation of midazolam (5mg/mL) via a metered dose sprayer at 0.1 mL/spray (i.e. 0.5 mg/spray). If the volume to be administered exceeded 1 mL, the dose was divided between both nostrils to avoid runoff and swallowing
223593540|NCT05670509|DRUG|administration of Buccal midazolam in ER group as a rescue medication for seizure control.|Children from ER group randomly assigned to receive treatment with buccal midazolam with doses of 0.2 mg/kg (maximum, 10 mg) body weight of the standard IV formulation of midazolam (5mg/mL) via dripping between the cheek and the gum per side using insulin syringe
223593541|NCT05670509|DRUG|administration of intramuscular midazolam in ER group as a rescue medication for seizure control.|Children from ER group randomly assigned to receive treatment with intramuscular midazolam with doses of 0.2 mg/kg (maximum, 10 mg) body weight of the standard IV formulation of midazolam (5mg/mL) using 3 mm syringe in the front aspect of thigh
223593542|NCT00454181|DRUG|Interferon-alpha|500 IU interferon-alpha lozenges taken 3 times per day for 24 weeks
223593543|NCT00454181|OTHER|placebo|200 mg lozenges containing anhydrous crystalline maltose taken three times per day for 24 weeks
223593544|NCT02961491|DRUG|Ultratrace Iobenguane I131|Subjects will receive a dosimetry dose of AZEDRA and will undergo 3 whole body scans. If the scans indicate tumor avidity for AZEDRA, the subjects will receive up to 2 therapeutic doses of AZEDRA each at 500 mCi (or 8 mCi/kg, for subjects weighing 62.5 kg or less) approximately 90 days apart.
223593545|NCT00000572|PROCEDURE|positive-pressure ventilation|Detailed computer protocol controlled positive pressure ventilation
223593546|NCT00000572|PROCEDURE|extracorporeal membrane oxygenation (CO2 removal)|Detailed computer protocol controlled Extracorporeal CO2 Removal with reduced positive pressure ventilation
223593547|NCT01262664|DRUG|Prohibitin-TP01|Starting dose of 0.03 mg/kg as an injection under the skin 1 time each day for 28 days.
223593548|NCT04783077|BEHAVIORAL|WhatsApp|Participants assigned to the WhatsApp group will receive weekly messages developed by communication specialists aimed to motivate blood donation, be encouraged to discuss their blood donation experiences, and share their own motivations for donating blood in a moderated, closed group over a six-month duration. The moderator will provide guidelines on acceptable use of WhatsApp in the group, including images they can or cannot share. Participants will also receive standard NBSG communications for first-time donors.
223593549|NCT04783077|BEHAVIORAL|Control|Participants in this group will receive the standard NBSG communications for first-time donors: 1) a thank you phone call and 2) and a reminder phone call two-weeks prior to the second blood donation eligibility. The second blood donation eligibility is four months after the first donation.
223593550|NCT04783077|BEHAVIORAL|Docudrama|Participants will be exposed to a document-drama related to blood donation.
223593551|NCT05583994|OTHER|Optim Park Intervention|For participants receiving the Optim-Park II intervention, the aim is to enhance the process of living with Parkinson's Disease for the person with PD and the family-carer by building a multisectoral care pathway, with a special focus on how to optimize the use of resources and systems of support in the community in disadvantaged populations in UK.
223593552|NCT01141491|BIOLOGICAL|Trivalent ganglioside vaccine|Patients will be given 10 injections of ganglioside vaccine plus adjuvant OPT-821 as a 1.0 ml subcutaneous injection in an outpatient setting at Visit Weeks 1, 2, 3, 8, 16, 28, 40, 52, 68 and 84
223593553|NCT01141491|BIOLOGICAL|OPT-821|Patients will be given 10 injections of adjuvant OPT-821 as a 1.0 ml subcutaneous injection in an outpatient setting at Visit Weeks 1, 2, 3, 8, 16, 28, 40, 52, 68 and 84
223593554|NCT00147004|DRUG|hydrocortisone sodium succinate|50 mg intravenous bolus every six hours for 5 days, then tapered to 50 mg intravenously every 12 hours for days 6-8, 50 mg every 24 hours for days 9-11 and then stopped
223593555|NCT00147004|DRUG|Placebo|
223593556|NCT04870918|BEHAVIORAL|self-care intervention|Health education will be carried out by the nurse.
223593557|NCT02954666|DEVICE|radio-frequency ablation|"Patients will undergo a tailored 'radio-frequency ablation' of the ARGP with the Smart Touch™ catheter or with the nMARQ™ catheter. Radiofrequency applications will be interrupted if no significant P-P interval shortening is observed after 30 seconds or if P-P interval is ≤ 550 ms during ablation.~The ablation procedure is considered complete when one of the following conditions is fulfilled:~P-P interval \< 70% baseline procedural P-P interval after 5minute of waiting time; P-P interval \< 600 ms after 5 minute of waiting time; 5 radiofrequency applications \> 30 seconds have been delivered with the nMARQ™ catheter or 10 applications with the Smart Touch catheter."
223593558|NCT06083818|OTHER|Application of an anterior cruciate ligament injury prevention protocol for female football players with dynamic knee valgus for 12 weeks.|12-week ACL Injury Prevention Protocol
223593559|NCT06083818|OTHER|Placebo - Conventional fitness programme|Conventional training and physical preparation programme
223593560|NCT00307866|PROCEDURE|Resovist (BAY86-4884, SH U 555 A)|Single bolus injection, followed by MRI
223593561|NCT03045341|DRUG|NB medication (Naltrexone Bupropion combination)|NB medication
223593562|NCT03045341|BEHAVIORAL|Behavioral Weight Loss (BWL) counseling|BWL counseling
223593563|NCT03045341|OTHER|Placebo|Placebo
224196021|NCT04900506|PROCEDURE|Posterior SPAIRE approach, anterior approach|Based on power calculation a sub-group analysis of 50 patients will be examined with DXA, all patients for biochemical and clinical muscle damage (CK, CRP, TUG-test, Trendelenburg, strenght test)
224196022|NCT03809962|DEVICE|Ostenil® Plus|Ostenil® Plus is a CE-certified viscoelastic solution for injection into the Joint cavity, containing 2.0 % Sodium hyaluronate from fermentation
224196023|NCT06613685|DRUG|GS-1720|Tablets administered orally without regard to food
224196024|NCT06613685|DRUG|GS-4182|Tablets administered orally without regard to food
224196025|NCT06613685|DRUG|Bictegravir/emtricitabine/tenofovir alafenamide|Tablets administered orally without regard to food
224196026|NCT06613685|DRUG|GS-1720/GS-4182 FDC|Tablets administered orally without regard to food
224196027|NCT06613685|DRUG|Placebo to Match BVY|Tablets administered orally without regard to food
224196028|NCT06613685|DRUG|Placebo to Match GS1720/GS-4182 FDC|Tablets administered orally without regard to food
223593564|NCT03689855|DRUG|Ramucirumab|Ramucirumab is an investigational agent for this trial and will be supplied by Lilly Oncology, free of charge to the patient.
223593565|NCT03689855|DRUG|Atezolizumab|The initial dose will be administered over 60 minutes (+/- 15 minutes). If the first infusion is tolerated without infusion-associated events, the second infusion may be delivered over 30 minutes (+/- 10 minutes).
223593566|NCT03689855|PROCEDURE|Peripheral blood draw|-Baseline and Cycle 2 Day 1
223593567|NCT03689855|PROCEDURE|Biopsy|"* If archival biopsy tissue not available, participant will undergo biopsy at baseline~* When feasible, a repeated tumor biopsy will be obtained between Cycles 2 and 3 after the scheduled CT scan."
223593568|NCT06195189|DRUG|Sunvozertinib|Sunvozertinib 200mg Quaquedie (QD)
223593569|NCT06195189|DRUG|Chemotherapy|Pemetrexed +platinum
223747029|NCT06611072|PROCEDURE|Bone marrow aspiration|Bone marrow samples (40 ml) will be obtained from the sternum or the iliac crest according to standard practice by experienced operators during the surgery patients will undergo as part of their medical treatment. BM mononuclear cells will be isolated using Ficoll-Paque and progenitor cells will be enriched using positive selection with CD34 beads by MACS. Progenitor cell composition will be identified using flow cytometry. HSPC proliferation assays (standard CFU assays) to assess myeloid colony-forming potential will be performed. In addition, single-cell RNA- sequencing and epigenetic assessment (ATAC-seq, ChIP-seq, DNA methylation) will be performed.
223747030|NCT06611072|PROCEDURE|Vena puncture|Whole blood (60 ml) will be collected and peripheral blood mononuclear cells (PBMC) will be isolated using Ficoll-Paque. Cellular subpopulations will be purified using negative selection of monocytes with PanMonocyte beads by MACS.
223747031|NCT06611072|PROCEDURE|Peritoneal fluid|Peritoneal fluid will be collected during the surgery.
223747032|NCT06611072|PROCEDURE|Spleen biopsy|Spleen samples will be obtained by experienced surgeons during the debulking surgery. Spleen mononuclear cells will be isolated using Ficoll-Paque and progenitor cells will be enriched using positive selection with CD34 beads by MACS. Cellular subpopulations will be further purified using negative selection of monocytes with PanMonocyte beads by MACS. Progenitor cell composition will be identified using flow cytometry. HSPC proliferation assays (standard CFU assays) to assess myeloid colony-forming potential will be performed. In addition, single- cell RNA-sequencing and epigenetic assessment (ATAC-seq, ChIP-seq, DNA methylation) will be performed.
223747033|NCT06611072|PROCEDURE|Tumor biopsy|During debulking surgery, all visible tumor tissue will be removed by experienced surgeons.
223747034|NCT06611072|PROCEDURE|Omental biopsy|During debulking surgery, an omental biopsy will be done.
223747035|NCT03615105|RADIATION|Hyperfractionated total body irradiation|Hyperfractionated TBI is administered by a linear accelerator at a dose rate of \<20 cGy/minute. Doses of 125 cGy/fraction are administered at a minimum interval of 4 hours between fractions, three times/day for a total of 11 or 12 doses (1,375 or 1,500 cGy) over 4 days (days -9 through -6).
224196029|NCT05590624|OTHER|Lower-Carbohydrate Med-t-Diet|"Diet will focus on including:~* Lean protein sources~* High-quality fat~* High-quality carbohydrate sources that are rich in fiber~* Nuts and seeds~Diet will focus on limiting:~* Refined sugars~* High glycemic carbohydrates~* Seed oils that may cause inflammation~Diet Composition: 45% fats, 35% carbs, 20% protein"
224196030|NCT05590624|OTHER|Low-Fat Med-t-Diet|"Diet will focus on including:~* Lean protein sources~* High-quality fat~* High-quality carbohydrate sources that are rich in fiber~* Nuts and seeds~Diet will focus on limiting:~* Refined sugars~* High glycemic carbohydrates~* Seed oils that may cause inflammation~Diet Composition: 70% carbs, 20% protein, 10% fat"
224310605|NCT02632513|DEVICE|Proultra PiezoFlow (Dentsply Tulsa Dental Specialties)|In continuous ultrasonic irrigation group, Proultra PiezoFlow (Dentsply Tulsa Dental Specialties, Tulsa,OK) was used for the activation of the irrigating solution according to manufacturer's recommendations.
223593570|NCT02409719|OTHER|Schedule|Illustrative daily planner to point the day that the exercise was performed
223593571|NCT02409719|OTHER|Verbal Information and Booklet|Verbal information will be provided in order to explain how the patient should perform physical rehabilitation exercises. Furthermore, an illustrative booklet with representative exercises will be given. Also, an illustrative daily schedule to mark on the exact day in which the exercise was performed
223593572|NCT02218944|BEHAVIORAL|Response Inhibition Training|The primary purpose of this research is to examine the feasibility and efficacy of a smoking specific response inhibition training program in the context of a quit attempt. The task is based on a modified stop-signal task. The study utilizes a one-way nested design with three conditions.
223593573|NCT05325385|OTHER|There are no interventions - this is a database study only|There are no interventions - this is a database study only
223593574|NCT05548985|DRUG|Midodrine Oral Tablet|oral midodrine tablet (5 mg) 90 min before performing spinal block
223747036|NCT03615105|DRUG|Thiotepa|Thiotepa 5 mg/kg IV
223747037|NCT03615105|DRUG|Cyclophosphamide|Cyclophosphamide 60 mg/kg IV
223747038|NCT03615105|DRUG|Busulfan|Busulfan (adult/ped dose)
223747039|NCT03615105|DRUG|Fludarabine|Fludarabine 25 mg/m2 IV
223747040|NCT03615105|DRUG|Melphalan|Melphalan 70 mg/m2 IV
224196031|NCT07006779|BEHAVIORAL|Music intervention|Engaging into conversation during procedure
224196032|NCT07006779|BEHAVIORAL|Conversation|Engaging patients into conversation
224196033|NCT07002632|DRUG|Dexpanthenol 5 % Topical Ointment|Dexpanthenol is a topical agent, a derivative of pantothenic acid (a B-complex vitamin), used for its moisturizing and skin regenerative properties. The formulation studied was a 5% dexpanthenol in a water-in-oil emulsion.
224310606|NCT05295238|BEHAVIORAL|Compass Course|An 8-session group intervention that integrates education, support, self-reflection, and action-expectation to help people reaffirm or reconstruct self-grounded purpose after significant life events/transitions. The 8 sessions extend over 2-3 months, with 7 weekly sessions and the final session 1 month after Session 7. The intervention, called the Compass Course is structured around the 6 dimensions of flourishing (autonomy, self-acceptance, personal growth, relationships, purpose in life, external mastery), the goal of which is to help people enact behaviors that move them forward in reframing a sense of self and reaffirming or reconstructing a sense of purpose in their daily lives.
223593575|NCT05548985|DRUG|Metoclopramide|oral placebo (metoclopramide 10 mg tablet). 90 min before performing spinal block
223593576|NCT00343707|DRUG|vestipitant|
223593577|NCT00343707|DRUG|paroxetine|
223593578|NCT03615014|OTHER|Filling questionnaires|Questionnaires will be submitted to patients during their visit to emergency service and 3 months later to evaluate the prevalence of Post Traumatic Stress Disorder and to identify predictive biopsychosocial factors
223593579|NCT05201950|OTHER|Virtual simulation|Virtual simulation using Full-Code, a virtual simulation software with a bank of emergency medicine cases
223593580|NCT05201950|OTHER|Team based in situ simulation|In situ simulation, using a high fidelity manikin in the critical care area of the emergency department, with team members consisting of multiple junior doctors and nurses, facilitated by senior emergency medicine doctors and nurses.
223593581|NCT00764673|DEVICE|3DKnee|Subjects with knee osteoarthritis and willing to participate in the study
223593582|NCT05392036|OTHER|baseline physical therapy treatment along with shockwave therapy|Group A, this group will receive conventional therapies along with shockwave therapy. Basic treatment includes icing (15-20 min) to control inflammation, rest, cessation of pain causing activity, anti-inflammatory (NSAIDs) and basic stretching and strengthening exercises. Shockwave therapy is a non-invasive therapeutic modality with convenience, effectiveness and safety. It is used to treat various musculoskeletal disorders without surgery. A session of 30-45 min will include icing 15 min and 5-10 min of shock wave therapy session will be commenced with strengthening and stretching exercises.
223593583|NCT05392036|OTHER|baseline physical therapy treatment along with therapeutic ultrasound|"This group will receive therapeutic ultrasound along with conventional treatment. Conventional therapy includes icing, rest, anti-inflammatory drugs, and basic strengthening and stretching exercises. A session of 30-45 min will include icing for 10-15 min therapeutic ultrasound 15min with a frequency 1-3MHz and the session will be ended with strengthening and stretching exercises.~Only eligible patients who have fulfilled the inclusion criteria will be included. A daily session of 30-45min for 2 consecutive weeks will be given. A baseline assessment will be done and the patient will be allocated randomly to both groups for two weeks. Re-assessment will be done after 2 weeks. For long term, effects re-assessment will be done after 6 weeks"
223593584|NCT05457088|OTHER|1.5 protein|dietary plan having dietary protein of 1.5 gr/kg/day
223593585|NCT05457088|OTHER|0.8 protein|dietary plan having dietary protein of 0.8 gr/kg/day
223593586|NCT03570346|DRUG|Hemay005|Subjects will be randomized into 3 dose groups orally twice daily.
223593587|NCT03570346|DRUG|Placebo|Subjects will be randomized into 3 dose groups orally twice daily.
223593588|NCT02193412|PROCEDURE|noxious stimulus|standardized noxious stimulus with tetanic stimulation
223593589|NCT02193412|PROCEDURE|change in operating table slope: head-down tilt position|-30°
223593590|NCT02193412|PROCEDURE|change in operating table slope: head-up tilt position|+30°
223593591|NCT01438177|DRUG|Velcade|
223593592|NCT01438177|DRUG|Cyclophosphamide|
223593593|NCT01438177|DRUG|Chloroquine|
223593594|NCT00849862|DRUG|Levetiracetam|750 mg Tablet
223593595|NCT00849862|DRUG|Keppra®|750 mg Tablet
223593596|NCT01727336|DRUG|Dalantercept and axitinib|
223593597|NCT01727336|DRUG|Placebo and axitinib|
223593598|NCT01014039|PROCEDURE|Flexible Sigmoidoscopy Screening arm|sigmoidoscopy screening
223747041|NCT03615105|DRUG|Clofarabine|Clofarabine 20-30 mg/m2 IV
223747042|NCT03615105|PROCEDURE|HPC(A) stem cell allograft|All patients will receive anti-thymocyte globulin based conditioning followed by a G-CSF mobilized, peripheral blood hematopoietic progenitor cell HPC(A) product depleted of TCR-α/β+ Tlymphocytes using the CliniMACS system.
224196034|NCT07006402|PROCEDURE|Reverse NAGS(experimental)|"All participants will receive 2 weeks of intervention with a frequency of 3-4 days/week with a period of rest in between. 20 minutes of TENS+ hot pack will be given followed by Reverse NAGs on hypomobile segments at level T1-T4.~In these type of mobilization, the inferior facet glides up on the superior. The mobilizations are repeated \<6 times and then movements are reassessed. If no change occurs, the process will be repeated upto 10 minutes with resting period."
224196035|NCT07006402|PROCEDURE|Grade III Ventro-Cranial Translatoric Glides(standard protocol)|"All participants will receive 2 weeks of intervention with a frequency of 3-4 days/week with a period of rest in between. 20 minutes of TENS+ hot pack will be given followed by Grade III Ventro-Cranial Translatoric Glides on hypomobile segments at level T1-T4.~The mobilization will be applied and sustained for 30-40 seconds and will be continued for 10-15 minutes in a cyclic manner.~The grades of mobilization will be tapered as per individual needs."
224196036|NCT07005076|OTHER|Experimental Group|Participants in the experimental group will participate in a conventional exercise program similar to the control group, but with the addition of a technology-assisted exercise program. The intervention group will receive training with a reaction time measurement set using lights and an exercise set. The reaction time measurement and exercise set will be used, where light pods are placed in different positions, such as on a table, mirror, and floor, and patients will be instructed to extinguish the lit light as quickly as possible. The difficulty level of the sessions will be progressively increased by adjusting factors such as the duration of light activation, colors, the number of illuminated pods, their placement locations, and the distance between them.
223593599|NCT05701046|PROCEDURE|Interbody fusion surgery|Interbody fusion surgery
223593600|NCT01410188|DRUG|OPA-6566|OPA-6566, 2 dosing schedules (one drop once per day for 2 weeks and twice per day for 2 weeks)
223593601|NCT01410188|DRUG|Placebo|Placebo, 2 dosing schedules (one drop once per day for 2 weeks and twice per day for 2 weeks)
223593602|NCT01410188|DRUG|Latanoprost|Latanoprost (one drop once per day for 4 weeks)
223747043|NCT03615105|DRUG|Rituximab|Rituximab 200 mg IV flat dose
223593603|NCT04506203|DIAGNOSTIC_TEST|Air test|Patients will breathe 0.21 \< FiO2 \< 0.25 during 5 min and have a lung ultrasound perfomed at the end of the 5 min trial.
223593604|NCT00619099|DRUG|decitabine|Schedule A: decitabine will be administered subcutaneously (SQ) daily for 3 consecutive days (Days 1 to 3) every 28 days. The dose will be 20 mg/m\^2/day. One course will be considered 28 days.
223593605|NCT00619099|DRUG|decitabine|Schedule B: decitabine will be administered SQ every 7 days for 21 days (Days 1, 8, and 15) followed by 7 days without an administration of decitabine. The dose will be 20 mg/m\^2/day. One course will be considered 28 days.
223593606|NCT05701566|DEVICE|virtual reality headset|use of virtual reality headset during colonoscopy as a substitute to sedation.
223593607|NCT05701566|OTHER|colonoscopy with standard sedation.|use of standard sedation during colonoscopy.
223593608|NCT06129929|BEHAVIORAL|Hospital Jujutsu Group, HJJ Group|The aim of this study, procedures, methodology, and the subject's rights were well explained to the eligible nursing staff according to the informed consent form. Written informed consent was obtained from each participant before data collection.
223593609|NCT01170078|DRUG|Epoetin Hospira|IV dose 3 times a week.
223593610|NCT01170078|DRUG|Epogen|IV dose 3 times a week
223593611|NCT00875862|PROCEDURE|Interscalene catheter with Ropivicaine or normal saline|Patients will be randomized to one of two groups: 0.2% Ropiviciane or normal saline in the infusion pump, following a shoulder manipulation for adhesive capsulitis. The patients will be followed by doctors and study staff to assess pain, range-of-motion and quality-of-life.
223593612|NCT05902481|OTHER|Education|education about breastfeeding with mixed reality technology.
223505043|NCT03611062|BEHAVIORAL|VR Executive Functions Training|"The Windows 10-based VICT program invites children to rescue an animated character named Lubdub from a castle. The program consists of three challenging and child-friendly tasks that correspond to the three core EFs."
223593613|NCT03505736|BIOLOGICAL|Adenosine|Given IV
223593614|NCT03505736|PROCEDURE|Magnetic Resonance Imaging|Undergo CMR imaging
223593615|NCT03505736|DRUG|Regadenoson|Given IV
223747044|NCT03615105|DEVICE|Rabbit antithymocyte globulin|Rabbit antithymocyte globulin dosing per nomogram. This dynamic nomogram is based on absolute lymphocyte count at the start of conditioning and can result in either 2 or 3 day ATG administration. If a patient requires 2 day administration the subjequent chemotherapies may be moved forward by one day at the treating physician's discretion.
224196037|NCT07005804|GENETIC|transcriptomic and metabolomic analysis|Venous blood samples for transcriptomic and metabolomic analysis will be taken in 3 x 4 mL ethylenediaminetetraacetic acid (EDTA) tubes and stored immediately at 4°C, before being cryopreserved at -80°C in 500 μL aliquots of plasma. In addition, for transcriptomic analysis, a sample will also be taken in a Paxgen RNA tube cryopreserved at -80°C.
224196038|NCT07005557|DRUG|Chemotherapy|Chemotherapy options at physician's discretion: TC, EC-T(wP), or capecitabine.
224310607|NCT04822233|DEVICE|Hall Technique (HT)|Prior to each restoration, a bacterial sample of the lesion will be obtained with a cotton swap and dispensed in a transport medium for microbial analyses.The preformed metal crown (PMC) will placed without local anesthetic and without crimping or trimming. When the contact points are tight, an orthodontic elastic separator will be placed for 2 hours prior to PMC placement. The PMCs will be cemented with glass ionomer Ketac cem.
224310608|NCT04822233|DEVICE|Modified Hall Technique (MHT)|Prior to each restoration, a bacterial sample of the lesion will be obtained with a cotton swab and dispensed in a transport medium for microbial analyses.This group will in addition to all the procedures for the Hall will have the Caries lesions treated with 30% Silver Diamine Fluoride (SDF) before cementation of the stainless-steel crowns.
224310609|NCT04822233|DEVICE|Conventional Technique (CT)|Prior to each restoration, a bacterial sample of the lesion will be obtained with a cotton swab and dispensed in a transport medium for microbial analyses. Conventional occlusal, proximal slicing and when necessary buccal and lingual surfaces will be carried out under local anesthesia and dental dam isolation local anesthesia.The PMC will be trimmed and crimped at the gingival margin to improve the fit, and cemented with Ketac cem.
223505044|NCT03611062|BEHAVIORAL|VR Placebo Game|In this game, children in the control group will use the VR hand controller to cast different types of spells (bees, bouncy balls, sparkler spells) to objects in the virtual world. Objects in the VR world will all react differently to a spell being cast so as to provide children a relaxing and EF-free gaming experience.
223747045|NCT06595238|DRUG|AZD6234|IMP injected subcutaneously, once a week. Unit dose strength as per CSP
223747046|NCT06595238|DRUG|Placebo comparator|Placebo matching IMP dose injected subcutaneously, once a week.
224196039|NCT07005557|DRUG|CDK4/6 Inhibitor|All patients will receive CDK4/6 inhibitor (abemaciclib/ribociclib/dalpiciclib/palbociclib)
224310610|NCT00164151|DRUG|HalfLytely|
224310611|NCT00164151|DRUG|Visicol|
223505045|NCT03061019|PROCEDURE|Oral Myofunctional Therapy with exercices|Oral-Motor training of oral muscles (tongue, lips) associated with nasal hygiene with daily repetition of exercices and parental support.
223505046|NCT03061019|PROCEDURE|Oral Myofunctional Therapy with soft oral appliance|Ora-Motor training of oral muscles (tongue, lips) associated with nasal hygiene, with reduced parental support.
223505047|NCT01684800|DRUG|A. Desmopressin 10 microgram|1 orally disintegrating tablet every night during study period
223593616|NCT03505736|PROCEDURE|Stress Management Therapy|Undergo stress test
223593617|NCT02178267|DIETARY_SUPPLEMENT|Lactobacillus reuteri (biogai AB, Sweden)|Lactobacillus reuteri (biogai AB, Sweden) was given to probiotic group, same way to all newborn newborn preterm infants, directly oral feeding and without any along with a mixture, admission following the in nicu, as a daily dose 1x108 cfu / day (1x5 drops / day) during hospitalization
223593618|NCT04123613|DRUG|DM199|A pharmaceutical formulation comprised of recombinant human tissue kallikrein-1 (rhKLK-1) that is being developed as an injectable protein drug
223747047|NCT06759935|DEVICE|Sham Laser therapy|sham laser therapy for 4 consecutive weeks with a minimum of 3 sessions per week.
223747048|NCT06759935|DEVICE|Laser therapy|laser therapy for 4 consecutive weeks with a minimum of 3 sessions per week.
224196040|NCT07005557|DRUG|Endocrine therapy|Endocrine therapy (letrozole/anastrozole/exemestane)
224196041|NCT07007143|DRUG|Experimental: Aspirin monotherapy|Aspirin monotherapy
224196042|NCT07007143|DRUG|Active Comparator: Aspirin+Clopidogrel|Aspirin+Clopidogrel
224196043|NCT07005531|PROCEDURE|Ultrasound-Guided Microbubble Clearance During Circuit Priming|CRRT circuits will be primed under real-time ultrasound monitoring. A portable ultrasound probe will be used to scan key points in the circuit and filter to detect and guide the removal of residual microbubbles before treatment. The process is considered complete when three consecutive scans (at 2-minute intervals) show no detectable microbubbles.
224196044|NCT07007208|DRUG|a positon emission tomography (PET) exam|TEP exam using tau-specific tracer ( Flortaucipir, unique dose 360 MBq)
223593619|NCT04183088|DRUG|Tislelizumab+regorafenib for part 1;Tislelizumab+regorafenib for group 1 of part 2; Regorafenib for group 2 of part 2.|"There will be no dose reduction for tislelizumab in this study. In the part 1(safety cohort), if the subjects do not experience grade 2 or greater regorafenib-related adverse events after 2 cycles (6 weeks) of treatment, the dosage of regorafenib may be escalated. For subjects who escalate the regorafenib dosage to Level 2, if the subjects do not experience grade 2 or greater regorafenib-related adverse events after 2 cycles of study drug treatment, the dosage of regorafenib may be further escalated to Level 3.~During study drug treatment, dose delay/ interruption of regorafenib will be done depending on the occurrence and severity of regorafenib-related adverse events. After dose reduction of regorafenib, if the subjects tolerate the reduced dose of regorafenib well, the investigators may consider re-escalation of regorafenib to the previous dose level, depending on the types and severity of adverse events that led to dose reduction."
223593620|NCT00129467|DRUG|Methylphenidate|"Subjects will take methylphenidate 5 mg twice daily (bid) for 3 days, then 10 mg bid for the remainder of the study. Should a subject have a 50% decrease in their depressive symptoms as measured by the Montgomery Asberg Depression Rating Scale (MADRS) at the initial dose of methylphenidate, they will be maintained at that lower dose as long as their MADRS score remains reduced by 50%. During the 18-day blinded treatment period the total daily dose will not exceed 20 mg.~If subjects have side effects when increasing to 10 mg bid, they will drop back to 5 mg bid. If the participant develops psychosis or cardiac events, they will be discontinued from methylphenidate.~Subjects who receive methylphenidate and respond with a 50% reduction in MADRS score will have the option to continue in the open label portion of the study for up to 6 weeks. For patients taking methylphenidate 10 mg bid whose MADRS score is \> 10 at day 18, the dose may be increased to 15 mg bid."
223593621|NCT00129467|DRUG|Placebo|"Subjects assigned to placebo will receive 1 capsule of placebo twice per day (bid) for 3 days and then 2 capsules bid for the remainder of the study. Should a subject have a 50% decrease in their depressive symptoms as measured by the Montgomery Asberg Depression Rating Scale (MADRS) at the initial dose of placebo, they will be maintained at that lower dose as long as their MADRS score remains reduced by 50%.~If subjects have side effects when increasing the dose to 2 capsules bid, they will drop back to 1 capsule bid. If the participant develops psychosis or cardiac events, they will be discontinued from the intervention."
223593622|NCT00129467|DRUG|Selective Serotonin Uptake Inhibitor (SSRI)|"Each subject will be treated with a SSRI. Patients who are taking an SSRI at the time of enrollment will continue on the same medication during the 18-day blind treatment period. The prescribed dose will only be adjusted if it is more than the highest dose in the recommended range (fluoxetine to 40 mg, paroxetine to 40 mg, citalopram to 40 mg, sertraline to 150 mg). Patients who are not on a SSRI at the time of enrollment will be prescribed citalopram 10 mg per day for 2 weeks, then 20 mg per day.~A subject's SSRI may be discontinued if the subject experiences moderate to severe side effects likely attributable to a SSRI. If subjects experience similar symptoms when increasing their citalopram dose to 20 mg per day, they will drop back to 10 mg per day. During the open label extension, the SSRI may be increased, decreased, or changed to a different SSRI or other antidepressant with the exception of venlafaxine and bupropion"
223593623|NCT03322670|OTHER|Signs of CAP and a positive chest X-Ray|"* collection of clinical examination data~* biological and bacteriological examinations (blood, urine, sputum, nasopharyngeal)~* self-reported questionnaires on duration of symptoms and restriction of activity~* telephone contact on day 28 and day 90 if hospitalized before day 28"
223593624|NCT03322670|OTHER|Patients directly hospitalized|"* collection of clinical examination data~* telephone contact on day 28 and retrieval of hospitalization report~* telephone contact on day 90"
223593625|NCT03322670|DIAGNOSTIC_TEST|Control patients|\- bacteriological examinations (urine)
223593626|NCT03322670|OTHER|Patients with partial participation|\- collection of clinical examination data
223747049|NCT06759935|OTHER|physiotherapy/exercise protocol|physiotherapy/exercise protocol represents the standard of care (SOC) and the program includes Codman's pendulum exercise, range of motion (ROM) exercises, stretching and isometric strengthening exercises, for 4 consecutive weeks with a minimum of 3 sessions per week.
223747050|NCT07082998|BEHAVIORAL|heated yoga|12-weeks of twice weekly 90-min heated yoga classes in the community
223747051|NCT07082998|BEHAVIORAL|sauna|12-weeks of twice weekly 40-min sauna sessions in the community
224196045|NCT07007208|OTHER|MRI Contrast|"Data acquisition will include different sequences (anatomical MRI, resting fMRI). The MRI sequences performed will be anatomical imaging (i.e. T1 imaging, FLAIR), a diffusion sequence, a neuromelanin-sensitive sequence and functional imaging at rest (i.e. the resting state, which allows the functional connectivity within the so-called default network to be assessed)."
224196046|NCT07007208|OTHER|oculometry assessment|Pupillometry and oculometry will be conducted using an EyeBrain medical device (class IIa). Several cognitive tasks will be submitted to the participant, during which the same measurements will be taken. Different stimuli will be presented on the computer screen (visual scenes, text, geometric shapes) during the eye tracking measurement, and an instruction (cognitive task, such as semantic categorization, free exploration of the gaze, reading, saccade execution) will be associated with each type of stimulus. The successive stimuli will be spaced more than 7 secondes apart in order to allow the pupillary response to the first stimulus to be recorded and then to return to the basal diameter before presentation of the next stimulus.
224196047|NCT07007208|OTHER|cognitive exams|Cognitive measures will be acquired during an evaluation session through 6 interactive cognitive exercises. These exercises are developed using tools offered by Covirtua Healthcare.
224196048|NCT04008108|OTHER|Activity sensor|Activity sensor worn on the wrist during 7 days, 24h/24 to evaluate physical activity of patient (measured by the number of step per day) before and after Artificial Urinary Sphincter Implantation.
224196049|NCT07006506|DRUG|Belumosudil|Belumosudil is an oral selective inhibitor of Rho-GTPase-associated coiled-coil kinase 2 (ROCK2)
224310612|NCT06719011|DRUG|NNC0174-1213 A|"Participants will be randomized to receive NNC0174-1213 A administered as subcutaneous (s.c. under the skin) injection.~Single ascending dose (SAD) will be injected for Part A cohorts and multiple ascending doses (MAD) will be injected for Part B cohorts."
224310613|NCT06719011|DRUG|Cagrilintide B|"Participants will be randomized to receive Cagrilintide B administered as subcutaneous (s.c. under the skin) injection.~Single ascending dose (SAD) will be injected for Part A cohorts and multiple ascending doses (MAD) will be injected for Part B cohorts."
223505048|NCT01684800|DRUG|B: Desmopressin 25 microgram|1 orally disintegrating tablet every night during study period
223505049|NCT01684800|DRUG|C: Placebo|1 orally disintegrating tablet every night during study period
224310614|NCT06719011|DRUG|Placebo A (NNC0174 1213 A)|"Participants will be randomized to receive Placebo administered as subcutaneous (s.c. under the skin) injection.~Single ascending dose (SAD) will be injected for Part A cohorts and multiple ascending doses (MAD) will be injected for Part B cohorts."
224310615|NCT02351960|DRUG|Dexlansoprazole|Dexlansoprazole capsules
224310616|NCT00472862|BEHAVIORAL|Cognitive training|Cognitive training for 16 weeks integrated in OPUS psychosocial treatment
224310617|NCT03158974|DRUG|East Indian Sandalwood Oil Cream|Cream containing 10% East Indian Sandalwood Oil (EISO)/Albuterpenoids
223505050|NCT01225744|DRUG|Cetuximab|"Cetuximab will be prepared under Good Manufacturing practice (GMP) and supplied by Merck KGaA (Darmstadt, Germany) as a solution for intravenous infusion. It will be made up into 250ml with N/Saline.~Dose administered is 400mg/m2 and will be given on day 1 and day 15 of a 28 day cycle.Cetuximab will always be administered first, i.e. the cetuximab infusion should be completed one hour before any chemotherapy begins. The cetuximab dose must always be based on the body surface area(BSA). There is no restriction for cetuximab in patients with a BSA \> 2 m2 ."
223505051|NCT01225744|DRUG|Irinotecan|Dose is 180mg/m2 made up into 250ml with 5% dextrose or 0.9% saline. It will be administered as a short infusion over 60-90 minutes after a 60 minute gap left after cetuximab administration. Irinotecan is administered on day 1 of the 28 day cycle.
223505052|NCT01225744|DRUG|Oxaliplatin|Dose is 100mg/m2 and will be made up into 250ml with 5% dextrose. It will be administered as a short infusion over 120 minutes after the 60 minute gap left after cetuximab administration. Oxaliplatin is administered on day 15 of the 28 day cycle.
223505053|NCT01225744|DRUG|UFT|UFT dose is 250mg/m2 and is given in three divided doses with calcium folate 30mg p.o. tds on days 1-21 of the 28 day cycle. The highest dose of UFT should be given in the morning if the dose cannot be divided equally.
223505054|NCT02909595|DEVICE|Balloon catheter|Balloon stone extraction was carried out with a balloon catheter \[Extractor Pro RX \[M00547000, M00547010, or M00547020\]; Boston Scientific,Shang hai,China). The Extractor Pro has multiple sizes (9-12, 12-15, and 15-18mm), the choice being made on the basis of the CBD diameter. It has a contrast-injection hole above the balloon for the performance of balloon occlusion cholangiography (BOC).
223505055|NCT02909595|DEVICE|Basket catheter|Basket stone extraction was performed with a basket catheter (Flower Basket V \[FG-V435P or FG-V425PR\]; Olympus Corp., Shang hai,China).
223505056|NCT02843386|DRUG|Adjuvant chemotherapy by Fotemustin|"Fotemustin is given for 6 cycles :~* One Induction cycle: Fotemustin 100 mg/m², 1 hour IV infusion, D1D8D15, 5 week rest period, restart on D50.~* Five Maintenance cycles: Fotemustin 100 mg/m², 1 hour IV infusion, D1-D21."
223505057|NCT02843386|OTHER|Intensive surveillance|"Intensive surveillance~* Total duration: 3 years.~* liver functional tests/3 months, - liver MRI or CT-scan/6 months, - whole body CT-scan/12 months."
223505058|NCT05189197|DRUG|Zanubrutinib + R-CHOP|"Zanubrutinib 160 mg BID administered by oral every day of each 21-day cycle. Rituximab 375 mg/m2, Cyclophosphamide 750 mg/m2, Doxorubicin 50 mg/m2 and Vincristine 1.4 mg/m2 (maximum total 2 mg) administered by IV infusion on Day 1 of each 21-day cycle.~Prednisone 100 mg administered by oral on Day 1-5 of each 21-day cycle. After 6 cycles of zanubrutinib and R-CHOP combination therapy, patients achieved CR will continue to receive zanubrutinib 160mg BID for 1 year."
223505059|NCT00158457|DRUG|Tenofovir (TDF)|
223505060|NCT00158457|DRUG|Emtricitabine (FTC)|
223505061|NCT00158457|DRUG|Efavirenz (EFV)|
223505062|NCT03123588|DRUG|Ruxolitinib|Ruxolitinib administered orally twice daily (BID) at the protocol-defined starting dose.
223505063|NCT03123588|DRUG|Anagrelide|Anagrelide administered orally at a starting dose of 1 mg BID.
223505064|NCT03123588|DRUG|Placebo|Anagrelide-placebo administered orally BID
223505065|NCT03123588|DRUG|Placebo|Ruxolitinib-placebo administered orally BID.
223505066|NCT01127360|DRUG|Bevacizumab|Intravitreal injections
223505067|NCT01127360|DRUG|Ranibizumab|Intravitreal injections
223505068|NCT01677065|DRUG|Oxycodone controlled-release test formulation|single dose administration of test formulation under fasted conditions
223505069|NCT01677065|DRUG|Immediate-release reference drug|single dose administration of reference drug under fasted conditions
223505070|NCT05430295|PROCEDURE|phacoemulsification|cataract extraction followed by bilateral implantation of Eyhance intraocular lens in 10 patients and bilateral implantation of Tecnis 1 piece IOL in 10 patients
223505071|NCT05430295|PROCEDURE|monofocal intraocular lens implantation|implantation of monofocal intraocular lens in the capsular bag at the end of phacoemulsification surgery
223505072|NCT00910390|OTHER|Slow freezing|Embryos at different developmental stages will be frozen using a solution that contains propanediol and sucrose, individually placed in high security straws, cooled with a programmator and stored in liquid nitrogen.
223505073|NCT00910390|OTHER|VIT-Irvine|Embryos at different developmental stages will be frozen using the vitrification solution according to the manufacturer's instructions, individually placed in high security vitrification devices and plunged directly in liquid nitrogen for storing.
223505074|NCT00910390|OTHER|Vit-Vitrolife|Embryos at different developmental stages will be frozen using the vitrification solution according to the manufacturer's instructions, individually placed in high security vitrification devices and plunged directly in liquid nitrogen for storing.
223505075|NCT05848375|PROCEDURE|Arthroscopic rotator cuff repair|The operation involves systematic acromioplasty during the supra +/- infraspinatus repair and sometimes requires a tenotomy of the long biceps if it is pathological.
223505076|NCT05848375|DRUG|naropeine or chirocaine (Arthroscopic rotator cuff repair under LRA associated to GA)|Loco Regional Anesthesia is performed by injecting anesthetic (between 10 and 20 ml of naropeine or chirocaine) into the interscalene nerve block under ultrasound guidance associated to General Anesthesia performed by injection of diprivan and ultiva.
223505077|NCT05848375|DRUG|naropeine or chirocaine (Arthroscopic rotator cuff repair under LRA)|Loco Regional Anesthesia is performed by injecting anesthetic (between 10 and 20 ml of naropeine or chirocaine) into the interscalene nerve block under ultrasound guidance
223505078|NCT01058005|DRUG|BG00002 (natalizumab)|300 mg intravenous injection every 4 weeks
224196050|NCT07007000|DEVICE|Temporary cardio-neural pacing|After routine ventricular lead implantation, a coronary sinus sheath will be delivered to RA septum, posterior to CS ostium, at the expected location of parasympathetic ganglion plexus. Pace mapping will be performed with a pacing lead at 30Hz, variable amplitude (20, 10, 5V) at 1ms pulse width. An electrophysiology catheter may be used where necessary for pace-mapping the response. At the site where lowest output can generate 30% prolongation of ventricular CL, the lead is fixed for 2-5mm depth. The output is tested again to achieve 50% prolongation of ventricular CL (at 20, 10, 5, 2, 1V). Fluoroscopic image will be collected with contrast injection at the sheath. Repositioning of lead can be performed if the rate suppression cannot be achieved with 3V@0.4ms. Implanted lead will serve as an atrial sensing and pacing lead and will not be removed at the end of procedure. Patient will be connected to a dual to a dual chamber pacemaker with device programming per usual clinical care.
224196051|NCT07007065|DRUG|Surabgene Lomparvovec (ABBV-RGX-314)|subretinal injection
224196052|NCT07007065|DRUG|Ranibizumab Control|intravitreal injection
223505079|NCT01058005|DRUG|interferon beta-1a|44 mcg subcutaneous injection 3 times per week
223505080|NCT01058005|DRUG|glatiramer acetate|20 mg subcutaneous injection once daily
223505081|NCT02298283|DRUG|brentuximab vedotin|is 1.8 mg/kg administrated by IV infusion
223505082|NCT02298283|DRUG|Cyclophosphamide|1250 mg/m², IV, part of the BEACOPP chemiotherapy, D1 of 2 BEACOPP cycles, every 3 weeks
223505083|NCT02298283|DRUG|Adriamycin|35mg/m², IV, part of the BEACOPP chemiotherapy, D1 of 2 BEACOPP cycles, every 3 weeks
223505084|NCT02298283|DRUG|Oncovin|1.4 mg/m², IV, part of the BEACOPP chemiotherapy, D8 of 2 BEACOPP cycles, every 3 weeks
223505085|NCT02298283|DRUG|Bleomycin|10 mg/m², IV, part of the BEACOPP chemiotherapy, D8 of 2 BEACOPP cycles, every 3 weeks
223505086|NCT02298283|DRUG|Etoposide|200 mg/m², IV, part of the BEACOPP chemiotherapy, D1 to D3 of 2 BEACOPP cycles, every 3 weeks
223505087|NCT02298283|DRUG|Procarbazine|100 mg/m², IV, part of the BEACOPP chemiotherapy, D1 to D7 of 2 BEACOPP cycles, every 3 weeks
223505088|NCT02298283|DRUG|Prednisone|40 mg/m², IV, part of the BEACOPP chemiotherapy, D1 to D7 of 2 BEACOPP cycles, every 3 weeks
223505089|NCT02298283|DRUG|G-CSF|5 µg/kg/j, SC, D9 until GB 1.0x109/L
223505090|NCT02298283|RADIATION|30 Grays|30 Gy radiation of sites initially diagnoses + 6Gy for residual sites, 3 to 4 weeks after D1 of BEACOPP cycle 2.
223505091|NCT03968627|OTHER|Rehabilitative intervention|intensive multidisciplinar rehabilitation
223505092|NCT01436292|DRUG|5% human albumin solution (HAS)|"Patient will receive 5% HAS daily for the first 7 days of stay in ICU according to their albumin level:~≥ 30 gr/L: albumin will not be administered; 25 - 29.9 gr/L: 25 g of 5% HAS; 20 - 24.9 gr/L: 50 g 5% HAS; 15 - 19.9 gr/L: 75 g of 5% HAS; 10 - 14.9 gr/L: 100 g of 5% HAS; \< 10 gr/L: 150 g of 5% HAS."
223505093|NCT00332098|BEHAVIORAL|Family-Focused Treatment Plus Pharmacotherapy|Participants assigned to FFT will take part in weekly treatment sessions with their families for 12 weeks, biweekly for 12 weeks, monthly for 3 months, and then trimonthly until Month 24. Medications used for the pharmacotherapy portion of the study will include mood stabilizers, such as lithium or divalproex sodium, and atypical antipsychotics, such as quetiapine. Participants will also receive anti-anxiety medications, psychostimulants, or antidepressants as needed.
223747052|NCT07082998|BEHAVIORAL|mindfulness app|12-weeks of 80-mins a week of a mindfulness app
223505094|NCT00332098|BEHAVIORAL|Enhanced Care Plus Pharmacotherapy|Participants assigned to Enhanced Care will take part in weekly brief psychoeducation sessions for 3 weeks. The pharmacotherapy treatment will be the same as for the FFT participants.
223505095|NCT02287025|DRUG|Regorafenib (Stivarga, BAY73-4506)|Dose(s) 160 mg tablet (4 tablets per day at 40 mg) daily for 3 weeks on / 1 week off
223505096|NCT02287025|OTHER|iPAD application|Investigators were supported with enhanced drug-specific information via an iPad application (SMART).
223505097|NCT02287025|OTHER|Bayer specialist|The treating investigator will have access to the prescribing information and have ability to consult a Bayer specialist, should questions arise.
223505098|NCT00385229|DRUG|induction of labor|Misoprostol, Dinoprostone, amniotomy, Oxytocin
223505099|NCT04053452|DIAGNOSTIC_TEST|Peripheral nerve ultrasound|Ultrasound of the bilateral ulnar nerves, median nerves, vagus nerves, and C6 and C7 nerve roots will be performed.
223505100|NCT04053452|DIAGNOSTIC_TEST|Measurement of strength|Strength will be assessed by physical examination and recorded using Medical Research Council (MRC) scale, and a hand dynamometer will be used to measure grip strength.
223505101|NCT05690191|DRUG|Chidamide|Chidamide tablets: 20mg orally, twice a week (at least 3 days between doses
223505102|NCT05690191|DRUG|Lenalidomide|Lenalidomide capsule: 25mg orally, once before going to bed every night, from day 1 to day 21 of each cycle
223505103|NCT05690191|DRUG|Rituximab|Rituximab injection: 375mg/m2 intravenously, once every 4 weeks (Q4w), on the first day of each cycle
223505104|NCT01421134|DRUG|Lurasidone|20, 40, 60 mg, flexible dose, once daily PM 6 weeks
223505105|NCT01421134|DRUG|Placebo|Placebo
224196053|NCT07006974|OTHER|SMCs|patients with SMCs
224196054|NCT03653052|DRUG|Durvalumab|Durvalumab will be administered via an infusion in the arm, over a duration of up to 1 hour.
224310618|NCT03806712|OTHER|multi method questionary (developped by De Rosa, in 1995 and 2014)|questions from an association network according to the subject and the grounded theorise (Glasser and Strauss)
224310619|NCT04748523|DRUG|Mirtazapine|arm to receive 15 to 30 mg of Mirtazapine for a period of 8 weeks.
223505106|NCT06422858|DRUG|Serplulimab|Serplulimab will be administered as a fixed dose of 300 mg via intravenous infusion every three weeks, continuing for up to 12 months or until disease progression, unacceptable toxicity, or withdrawal of consent
223593627|NCT03322670|OTHER|Signs of CAP and a negative chest X-Ray|"* collection of clinical examination data~* telephone contact on day 28"
223747053|NCT06898957|DRUG|YL201|YL201 will be administered as an IV infusion.
223747054|NCT06898957|DRUG|Tarlatamab|Tarlatamab will be administered as an IV infusion.
224310620|NCT04748523|DRUG|Placebo Oral Tablet|arm to receive 15 to 30 mg of Placebo for a period of 8 weeks.
223505107|NCT06422858|DRUG|Tegafur-gimeracil-oteracil potassium capsule(S1)|S1 will be administered at a dose of 60 mg/m2 per day, taken orally in two divided doses on day 1 concurrent with radiotherapy, repeated every 28 days; and from day 1 to day 14 of each 21-day cycle, for up to 12 months or until disease progression, unacceptable toxicity, or withdrawal of consent
223505108|NCT06422858|RADIATION|Radiotherapy|Radiotherapy will be delivered as a total dose of 50.4 Gy in 28 fractions over six weeks using techniques such as IGRT, IMRT, VMAT, or TOMO, targeting the primary tumor and associated lymph nodes
223505109|NCT06422858|DRUG|Cisplatin|Cisplatin will be administered at a dose of 75 mg/m\^2 on day 1 concurrent with radiotherapy, repeated every 28 days
223505110|NCT03536377|OTHER|very low calorie liquid diet|Phase 1: very low calorie liquid formulation Phase 2: Nutritionally balanced solid diet Phase 3: Educational material
224196055|NCT03335189|DEVICE|ASyMS-Can|Data reported by the participants will be sent to a secure, encrypted clinical central server hosting the risk-alerting algorithms. The web interfaces will provide a clinical portal for the nurses to screen and follow any alerts being triggered, as well as review patient-specific information. Based on these back-end computations, participants will receive automated self-care notifications on their mobile phones. If incoming symptom reports indicate severe adverse effects a designated clinic nurse will receive an 'amber alert', or 'red alert', that will require response within 30 minutes. Nurses will handle alerts during business hours (9 am to 5 pm). After-hour alerts will be sent to the oncologist or nursing supervisor on call as per usual care. Patients will be instructed that clinicians will not receive alerts during the evening hours or night and instructed to follow usual practice of contacting their family physician, or oncologist on call, or call 911, as required.
224196056|NCT03189706|DRUG|Irinotecan|50mg/m\^2/day IV will be administered from day 1-5
224196057|NCT03189706|DRUG|temozolomide|(given concurrently with Irinotecan) 150mg/m\^2/day orally
224196058|NCT03189706|BIOLOGICAL|Hu3F8|2.25mg/kg IV will be administered on days 2, 4, 8 and 10
224196059|NCT03189706|DRUG|GM-CSF|250mcg/m2/day SC will be administered on days 6-10
224196060|NCT07005895|OTHER|Hydration assessment via mobile app|Open the Gatorade Sports Science Institute (GSSI) branded mobile application and click on 'Complete Hydration Assessment'
224196061|NCT07006675|DRUG|600 mg Ibuprofen|Treatment patients will receive oral ibuprofen 600 mg three times a day (tid) for up to six weeks. Clinicians in this group may use whatever further analgesia they desire, excluding NSAIDs. For patients who have a clinical concern regarding NSAID and prophylactic anticoagulation, the treating physician may consider prescribing misoprostol.
224196062|NCT07005856|OTHER|Soft tissue mobilization|Soft tissue mobilization: mobilization participants' soft tissue by using hands
224196063|NCT07005856|OTHER|Stretching|Stretching: help patients do the movement that they're limited to stretch their soft tissue
224196064|NCT07005856|OTHER|Hot pack|Add an hot pack on participants' shoulder
224196065|NCT07006415|DEVICE|Brain-computer interface rehabilitation|10 sessions of motor imagery rehearsal rehabilitation using a brain-computer interface with functional electrical stimulation and a virtual avatar
224196066|NCT07005700|DIAGNOSTIC_TEST|Targeted genomic sequencing|Single 0.5 mL venous or capillary blood sample.
224196067|NCT07006259|OTHER|Bobath Therapy|Treatment with bobath therapy
224196068|NCT07006259|OTHER|Bobath therapy plus virtual reality|Treatment with bobath therapy plus virtual reality
224196069|NCT07006259|OTHER|Home exercises|Treatment with home exercises
223505111|NCT00910741|DRUG|Nanoplatin (NC-6004) and Gemcitabine|
224196070|NCT06867666|BEHAVIORAL|In Person CBT-I|6-week CBT-I delivered in-person at the TBI Clinic at NMCSD or via telehealth on a secure, Health Insurance Portability and Accountability Act (HIPAA) compliant platform by a doctoral-level clinician.
224196071|NCT06867666|BEHAVIORAL|CBT-I via COAST|6-week CBT-I delivered remotely via a clinician supervised digital platform by a doctoral-level clinician.
224196072|NCT05595499|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
224196073|NCT05595499|DRUG|Fisetin|Given PO
224196074|NCT05595499|DRUG|Placebo Administration|Given PO
223505112|NCT02200575|DRUG|Telmisartan|
223505113|NCT02734147|DRUG|Ascorbic Acid|
224196075|NCT05595499|OTHER|Quality-of-Life Assessment|Ancillary studies
223505114|NCT02734147|OTHER|Normal Saline|
223505115|NCT02346370|DRUG|PEGylated recombinant human hyaluronidase PH20|
223505116|NCT02346370|DRUG|Docetaxel|
223505117|NCT06009497|DRUG|Romiplostim|Romiplostim 10 µg/kg, subcutaneous injection, once a week.
223505118|NCT06009497|DRUG|Ciclosporin|Ciclosporin 3-5mg/kg/d, adjust the dose to keep trough ciclosporin plasma concentration 100-200ng/ml.
223505119|NCT03024164|OTHER|Treatment following current guidelines|Treatment following current guidelines
223505120|NCT05931601|DRUG|Noradrenaline|See arm description
223593628|NCT02953886|DEVICE|Silver Diamine Fluoride (SDF)|No caries removal will take place. Bacterial samples will be collected using Gracey curettes at the initial visit before application of SDF and one month after. The tooth will be dried and SDF will be placed on the carious dentin until saturated. Excess will be blotted dry with a cotton pellet
223747055|NCT06898957|DRUG|Atezolizumab|Atezolizumab will be administered as an IV infusion.
223747056|NCT06898957|DRUG|Durvalumab|Durvalumab will be administered as an IV infusion.
224196076|NCT05595499|OTHER|Questionnaire Administration|Ancillary studies
224196077|NCT07011589|BIOLOGICAL|Efgartigimod|Dosage: 10mg/kg Frequency: Once a week Duration: 25 weeks
224196078|NCT07007078|DRUG|dihydroartemisinin|DHA 40mg tid for 90 days
224196079|NCT07006207|OTHER|olfactory stimulation|the patients have a sniff-test
224196080|NCT07006207|OTHER|functional MRI|patients have a an f MRI
224196081|NCT07006428|DEVICE|Clareon PanOptix or PanOptix Toric IOLs|Bilateral implantation of the Clareon PanOptix or PanOptix Toric IOLs.
224196082|NCT07006428|DEVICE|Comparable multifocal IOL|Bilateral implantation of a comparable multifocal IOL
224196083|NCT07005193|DEVICE|Using rang hood during cooking|Cooking ventilation facilities
223593629|NCT03031067|DEVICE|Machine perfusion|"The graft preservation will be performed perfusing with a oxygenated solution of preservation at 4°C for two hours with Exiper, Bologna Machine Perfusion, developed by Medica s.p.a and our research group.~Flow and pressure values will be set up for the kidney and liver perfusion, differently. The oxygenation of solution will be performed by an oxygenator and a filter for decapneization / oxygenation. During the perfusion the oxygen pressure will be required between 600-750 mmHg (pO2 80-100 Kpa), as reported in the scientific literature. The pH, lactate concentration, and oxygen (PO2) and carbon dioxide (PCO2) partial pressure were measured in the preservation solution at T0 and T1 by means of a standard haemogasanalyzer."
223593630|NCT05158790|OTHER|Questionnaire|Administration of a questionnaire
223593631|NCT02163421|DRUG|Vedolizumab SC|Vedolizumab injection, for subcutaneous use (vedolizumab SC)
223593632|NCT02163421|DRUG|Vedolizumab IV|Vedolizumab injection, for intravenous use (vedolizumab IV)
223593633|NCT05735756|DRUG|Citalopram 20mg|Citalopram 20mg once a day for 12 weeks
223593634|NCT05735756|DRUG|Placebo|Placebo once a day for 12 weeks
223747057|NCT06797453|BEHAVIORAL|Shared Medical Visits|Shared group medical visits over eight weeks and two cooking classes.
224196084|NCT07005193|BEHAVIORAL|Using liquefied gas for cooking|Using liquefied gas instead of solid fuels for cooking
224196085|NCT07006545|OTHER|Return to Activity Battery|The main target parameters are muscle mass (sonography), muscle strength (isometric maximum strength measurement), neuromuscular activation (surface EMG), functionality (e.g. 6MWT, chair rising test), knee swelling and subjective assessment of everyday and leisure activities, quality of life (e.g. SF-36) and return to work
224196086|NCT07005661|BIOLOGICAL|Autologous Platelet Rich Plasma|Platelet apheresis was initiated immediately after central venous catheterization and completed before systemic heparinization using the XTRA system (LivaNova, UK). Whole blood was collected at \~60 mL/min via central venous access, \~300 mL per cycle, anticoagulated with sodium citrate. After separation, autologous platelet rich plasma and concentrated RBCs were obtained. The process was repeated for 4-6 cycles, collecting plasma equal to \~20-30% of estimated blood volume (Nadler formula). Crystalloids or colloids were infused during the procedure, and RBCs from the prior cycle were reinfused to maintain hemodynamic stability. Platelet rich plasma was stored in collection bags, agitated at room temperature, and reinfused after heparin neutralization .
223593635|NCT05850923|OTHER|speech competition training|Speech competition training include voice competition training twice a day in adjunction with drug treatment, and the patients will be required to perform voice-related tasks according to the instruction.
223593636|NCT05850923|OTHER|the soothing music|the soothing music
223593637|NCT01010152|DRUG|Codeine Sulfate|30 mg Tablet
223747058|NCT06797453|BEHAVIORAL|Full Plate Living|Online modules teaching how a high-fiber diet can lead to more energy, lower cholesterol, better blood sugar, and easier weight loss.
224196087|NCT07005661|PROCEDURE|Standard Blood Management|Perioperative transfusion is based on intraoperative hemodynamics and internal environment. Routine blood salvage is performed, with tranexamic acid given throughout (30 mg/kg IV loading dose, 16 mg/kg/h IV maintenance, 2 mg/kg for CPB priming). CPB is primed with 1500 ml using an integrated oxygenator, without ultrafiltration emphasis. At surgery's end, heparin-protamine neutralization is guided by a decision-making system, with point-of-care coagulation monitoring to selectively transfuse blood products based on coagulation abnormalities.
224196088|NCT06872151|DEVICE|Gel containing a Propionibacterium extract|Patients will apply 1 ml of gel (equal to one phalanx) twice a day for 20 days, manually at the anal level and in the perianal area. In the morning, after defecation and in the evening before going to bed.
224196089|NCT06872151|DRUG|Hyaluronic acid and silver sulfadiazine|Patients will apply 1ml of gel (equal to a phalanx) twice a day for 20 days, manually at the anal level and in the perianal area. In the morning, after defecation and in the evening before going to bed.
224196090|NCT05078047|DRUG|Reduced dose intensity of IO|After 6 months of treatment with standard IO, IO will be administered every 3 months (at the same dose levels) until disease progression, unacceptable toxicity, death or patient's choice or investigator's decision
224310621|NCT01080664|DRUG|AS703569|"Dose Escalation~Regimen 1 - 3-47 mg/m2/day, orally once daily on days 1, 2,3 and 8, 9, 10 of a 21 day cycle:~Number of cycles: until progression or unacceptable toxicity develops.~Cohort Expansion~Regimen 1 - Maximum tolerated dose from dose-escalation part or a lower dose in mg/m2/day, orally once daily on days 1, 2,3 and 8, 9, 10 of a 21 day cycle:~Number of cycles: until progression or unacceptable toxicity develops"
223593638|NCT04942990|OTHER|calisthenic exercises|these exercises are a kind of exercise for increasing cardiovascular endurance
223593639|NCT00002299|DRUG|Interferon beta-1b|
223593640|NCT00002299|DRUG|Ganciclovir|
223593641|NCT05322330|DRUG|Selinexor|40-60mg QW,w-3～d-3,PO
223593642|NCT05322330|DRUG|Flu|25-30 mg/m2，d-5 ～d-3，qd，ivgtt
223593643|NCT05322330|DRUG|CTX|250-500 mg/m2，d-5 ～d-3，qd，ivgtt
223747059|NCT05658510|DRUG|BXCL501|Sublingual Film
223747060|NCT05658510|DRUG|Matching Placebo|Sublingual Placebo Film
223747061|NCT06152250|OTHER|Liver Fine-Needle Aspiration|"At the time of inclusion, when liver biopsy will be performed as part of routine medical management, fine-needle aspiration will also be made in all patients.~The procedure will be performed in the Day Hospital, immediately after the liver biopsy."
223593644|NCT05322330|DRUG|CAR-T|2-5×10\^6 CAR-T/kg，ivgtt。
223593645|NCT03870425|OTHER|Distribution pattern of dietary proteins (minced meat)|Study effect of an even or skewed distribution pattern of dietary protein
223593646|NCT00158912|DEVICE|Implantable Cardioverter Defibrillator|
223593647|NCT03201159|DRUG|VLX103|150mg tablets
223593648|NCT01424228|DRUG|placebo|Placebo matching tablet 2 mg once daily before breakfast for 24 weeks
223593649|NCT01424228|DRUG|prucalopride|"Prucalopride 2 mg daily before breakfast~1 mg for subjects \>65 years; in case of insufficient response 2 mg at week 2 or week 4"
223747062|NCT04927156|DEVICE|BALT medical devices|"Includes, but is not limited to, the following:~* Access devices~* Aneurysm treatment devices~* Ischemic Stroke and peripheral occlusive diseases treatment devices~* Arterio-Venous Malformations/fistulas treatment devices"
223593650|NCT02562807|DRUG|TAS-303 18mg single-dose|
223505121|NCT06179680|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|"MRI Protocol: Uses advanced MRI sequences to examine brain structures and detect white matter issues.~WMH Assessment: Evaluates white matter health using various methods, including manual and automated tools.~Neuropsychological Testing: Subjects undergo comprehensive cognitive testing administered by IRCCS Policlinico San Donato's Clinical Psychology Service.~Follow-up: Patients are monitored for cognitive changes semiannually, with additional assessments for those showing signs of progression. After two years, all patients undergo examination and tests to assess their condition."
223593651|NCT02562807|DRUG|Placebo 18mg single-dose|
223593652|NCT02562807|DRUG|TAS-303 9mg single-dose|
223505122|NCT05611905|COMBINATION_PRODUCT|11C-para-aminobenzoic acid PET/CT|A bolus of 20 mCi of 11C-PABA followed by PET/CT
223505123|NCT05611905|DRUG|Probenecid|Oral dose of 500 mg (tablet) 2 hours before IV dose of 11C-PABA will be administered.
223505124|NCT04080232|DEVICE|lung MRI|lung MRI (1.5T Siemens Aera) using the following sequences: 3D Fast gradient-echo pulse sequences with ultra-short echo time (UTE), acquisitions at end-inspiration breath hold, end-expiration breath hold, and free-breathing using an echonavigator positioned on the diaphragm, acquisitions using routine pulse sequences (SSFP, T2FSE) and the administration of oxygen during the MRI: O2 will be administered at 15L/min during 6 minutes.
223505125|NCT06150014|DRUG|Placebo|TQA3605 placebo tablets were orally administered on an empty stomach (at least 2 hours before or after meals) with warm.
223505126|NCT06150014|DRUG|TQA3605 tablets|TQA3605 inhibits viral replication.
223505127|NCT06150014|DRUG|Entecavir dispersible tablets|Entecavir inhibits viral replication and indicated for chronic hepatitis B treatment.
223505128|NCT06150014|DRUG|Tenofovir disoproxil fumarate tablet|Tenofovir disoproxil fumarate is a Nucleotide reverse transcriptase inhibitor.
223505129|NCT06150014|DRUG|Tenofovir alafenamide fumarate tablet|Tenofovir alafenamide fumarate inhibits hepatitis B virus replication.
223505130|NCT06960616|OTHER|Changes in traditional follow-up|Traditional follow-up includes the following visits after activation: 1-week, 1-month, 3-months, 6-months and 1 year. With the intervention used, the 1-week follow-up is removed.
223505131|NCT06960616|OTHER|Population mean mapping|Traditional mapping at activation involves the measurement of at least 5 electrodes (both T-levels and C-levels). The intervention uses a population mean mapping strategy where there is a pre-set dynamic range of 46 CL with a spot check of C-levels.
223505132|NCT05098236|OTHER|Training in the Blind Field|A computer software and chin-rest necessary to perform visual training will be loaned to each subject to be used at home. Subjects will perform one to two daily training sessions in their home, consisting of 200-300 trials each. The visual task performed repetitively will involve discriminating the direction of motion, the presence of motion, or the orientation of a visual stimulus (either a small cloud of dots or bars) located at a predetermined location in the blind field. The computer program will automatically create a record of patient performance during each home training session. Subjects will train daily (about 40-60 minutes total), 5 to 7 days per week for at least 3 and up to 12 months at a time.
223505133|NCT05098236|OTHER|Training in the Sighted Field|This training will take place in lab at the University of Rochester Medical Center. Subject will perform one daily training session, consisting of 200-300 trials each. The visual task performed repetitively will involve discriminating the direction of motion, the presence of motion, or the orientation of a visual stimulus (either a small cloud of dots or bars) located at a predetermined location in the visual field. The computer program will automatically create a record of patient performance during each training session. Subjects will train daily (about 30-40 minutes total), 5 to 7 days per week for at 7 - 14 days.
223505134|NCT06290024|DEVICE|A multi-center clinical longitudinal study of neuropathic pain by collecting data on patients' brain physiology and cognitive function|Using the use of pain visual analog scale (VAS), digital pain grading method (NRS), neuropathic pain assessment scale (DN4), sleep quality (Pittsburgh sleep quality index, Ascens insomnia scale), social support assessment scale (SSQ), Montreal cognitive assessment scale (MoCA), Barrett impulse scale (BIS), anxiety and depression score (GAD-7, PHQ-9), emotional tasks, cognitive function (N-back, time perception, delay-discount), electroencephalogram (EEG), near-infrared brain function imaging (fNIRS) and other indicators to study the dynamic changes of various factors in the process of acute pain.
223505135|NCT05561933|BEHAVIORAL|Healthy Minds Program Foundations Training|"The HMP was developed by Healthy Minds Innovations at the UW Center for Healthy Minds, and is based on decades of research on well-being. The program is delivered through a smartphone application and consists of didactic (learns) and experiential (practice) components. Practice components involve contemplative practices such as mindfulness, loving-kindness, and gratitude practices. Each practice allows participants to choose duration (between 5-30 minutes). In addition to sitting style practices common in other meditation apps/programs, the HMP also provides instruction in active practices. Active practices engage the same skills as sitting practice, but focus on strengthening skills during daily routines. Learn components provide psycho-educational content about the science of well-being. HMP learns and practices are based on a four pillar model of well-being skills consisting of Awareness, Connection, Insight, and Purpose."
223505136|NCT06236997|DRUG|Adebrelimab|Etoposide 100mg/m2 day1-3+carboplatin AUC 5 day 1(EC) combined with Adebrelimab（ PD-L1 inhibitor）1200mg day1 Q3w for 2 cycles, and the efficacy is evaluated 3 weeks after the treatment. If the efficacy evaluation is SD/PR/CR, concurrent radiotherapy(45Gy /3Gy/qd/3w) with EC(2 cycles) + Adebrelimab will be initiated. After concurrent chemoradiotherapy+ Adebrelimab, Adebrelimab was maintained until PD or intolerance or for at most 2 years.
223505137|NCT06236997|RADIATION|Radiation Therapy|Etoposide 100mg/m2 day1-3+carboplatin AUC 5 day 1(EC) combined with Adebrelimab（ PD-L1 inhibitor）1200mg day1 Q3w for 2 cycles, and the efficacy is evaluated 3 weeks after the treatment. If the efficacy evaluation is SD/PR/CR, concurrent radiotherapy(45Gy /3Gy/qd/3w) with EC(2 cycles) + Adebrelimab will be initiated. After concurrent chemoradiotherapy+ Adebrelimab, Adebrelimab was maintained until PD or intolerance or for at most 2 years.
223593653|NCT02562807|DRUG|Placebo 9mg single-dose|
223593654|NCT05173701|DIETARY_SUPPLEMENT|Probiotics|Selected probiotics mixture, in powder form, will be administered once daily for three months in the morning.
223593655|NCT05173701|DIETARY_SUPPLEMENT|Placebo|A placebo (2,7g maltodextrin) will be administered once daily for three months in the morning.
224196091|NCT07011563|BEHAVIORAL|Intervention|"Youth: interventionist-facilitated 1:1 conversation with the youth via videoconference that includes a) brief sexual health assessment, b) individualized information about HIV risk reduction including PrEP, and c) use of motivational interviewing strategies to discuss barriers to PrEP.~Parents: brief (\~20-30 min) web-based, interactive learning module (module) designed to provide information about sexual health communication (SHC) best practices, HIV prevention strategies (e.g., condoms, STI testing, PrEP), as well as build practical skills around SHC using evidence-based behavior change methods (e.g., building confidence, aligning values with actions)."
224196092|NCT07011563|BEHAVIORAL|Control|"Youth: interventionist-facilitated 1:1 conversation with the youth via videoconference that includes a) brief sexual health assessment, and b) didactic information about condom use, STI testing (including HIV), and PrEP (but not motivational interviewing or individualized information on HIV risk reduction).~Parent: brief written information on a digital platform (i.e., website) with advice about talking to youth about sexual health with web-links to resources about STI/HIV prevention and PrEP. This information will not be interactive or use behavior change methods."
224196093|NCT07013877|BEHAVIORAL|RELAX glasses|Glasses which are a solution of audiovisual sedation by positiv distraction for hospital medical use
224310622|NCT01080664|DRUG|AS703569|"Dose Escalation Regimen 2 - 3-47 mg/m2/day, orally once daily on days 1, 2, 3, 4, 5, 6 of a 21 day cycle Number of cycles: until progression or unacceptable toxicity develops.~Cohort Expansion Regimen 2 - Maximum tolerated dose from dose-escalation part or a lower dose in mg/m2/day, orally once daily on days 1, 2, 3, 4, 5, 6 of a 21 day cycle Number of cycles: until progression or unacceptable toxicity develops."
223505138|NCT06236997|DRUG|etoposide, carboplatin(EC)|Etoposide 100mg/m2 day1-3+carboplatin AUC 5 day 1(EC) combined with Adebrelimab（ PD-L1 inhibitor）1200mg day1 Q3w for 2 cycles, and the efficacy is evaluated 3 weeks after the treatment. If the efficacy evaluation is SD/PR/CR, concurrent radiotherapy(45Gy /3Gy/qd/3w) with EC(2 cycles) + Adebrelimab will be initiated. After concurrent chemoradiotherapy+ Adebrelimab, Adebrelimab was maintained until PD or intolerance or for at most 2 years.
223505139|NCT03528577|DRUG|Zero-dose|Treatment A
223505140|NCT03528577|DRUG|90 mcg of PROAIR® HFA|Treatment B
223505141|NCT03528577|DRUG|180 mcg of 90 mcg of PROAIR® HFA|Treatment C
223505142|NCT03528577|DRUG|90 mcg of albuterol sulfate inhalation aerosol|Treatment D
223505143|NCT02407977|OTHER|Novel nano-scintillatorfiber-optic dosimeter ( nanoFOD)|This is an observational study whose purpose is to determine the feasibility of using a novel nano-scintillator fiber-optic dosimeter ( nanoFOD) for real time dosimetric monitoring of external beam radiotherapy.
223593656|NCT00881465|BEHAVIORAL|Cognitive-behavioral therapy|Cognitive-Behavioral Therapy. The psychotherapy protocol will include 14 90-minute sessions of videophone administered CBT over 12 weeks.
223593657|NCT00881465|BEHAVIORAL|Wait-list control|Waitlist Control. The participant and his/her parents will be instructed to not obtain treatment outside of the protocol or make medication changes/additions. This will be assessed through interview at the Post-Waitlist assessment.
223593658|NCT04495725|OTHER|Discounted Vouchers for Medical Cannabis Soft-Gel Capsule Products|We will randomize participants to one of the following four conditions for discounted vouchers: 1) a discounted voucher for a placebo soft-gel capsule product, 2) a discounted voucher for a high THC:low CBD soft-gel capsule product, 3) a discounted voucher for an equal THC:CBD soft-gel capsule product, or 4) a discounted voucher for a low THC:high CBD soft-gel capsule product. We will stratify randomization by history of cannabis use (no use in the past year, used in the past year and not near-daily or daily (used in the past year and \<20 days out of the last 30 days), near-daily or daily (\>= 20 days out of the last 30 days) baseline opioid analgesic prescription (chronic opioid treatment vs. not chronic opioid use), and primary pain condition (neuropathy, not neuropathy). Chronic opioid treatment is defined as prescribed opioids ≥90 non-overlapping days in the past 182 days. Randomization will occur in blocks to ensure equal randomization over time.
223593659|NCT05277038|DRUG|Clonidine 0.1mg pill|Routine prescription for insomnia
223593660|NCT05277038|DRUG|Clonidine 0.2mg pill|Routine prescription for insomnia
223593661|NCT05277038|DRUG|Zopiclone 3.75mg pill|Routine prescription for insomnia
223593662|NCT05277038|DRUG|Zopiclone 7.5mg pill|Routine prescription for insomnia
223593663|NCT01288547|DIETARY_SUPPLEMENT|theobromine|700 mg theobromine in gelatin capsules given one time only
223593664|NCT01288547|DIETARY_SUPPLEMENT|Caffeine|120 mg caffeine in capsules given one time only
223593665|NCT01288547|DIETARY_SUPPLEMENT|caffeine + theobromine|120 mg caffeine and 700 mg theobromine in capsules given one time only
223593666|NCT01288547|DIETARY_SUPPLEMENT|placebo|cellulose in capsules given one time only
223593667|NCT00169091|DRUG|Clozapine|Medication will be divided into twice daily dosing and administered in a blinded fashion. The medication will be tapered from 12.5 mg on Day 1 to up to 300 mg on Day 12.
223593668|NCT00169091|DRUG|Haloperidol|Medication will be divided into twice daily dosing and administered in a blinded fashion. The medication will be tapered from 2 mg on Day 1 to up to 12 mg on Day 12.
223593669|NCT05067738|OTHER|same day discharge|same day discharge
223593670|NCT05673525|DEVICE|Transcatheter Aortic Valve Implantation (KOKA-VALVE)|Transcatheter Aortic Valve Implantation
223593671|NCT00671437|PROCEDURE|FDG-PET/CT|
223593672|NCT00671437|DRUG|Cetuximab|
223593673|NCT05115916|BEHAVIORAL|MyChart Priming Message|In addition to the standard FIT mailer protocol, we will send randomized participants a message via their personal health portal. Patients receive the primer approximately 1-2 weeks prior to arrival of the FIT kit, which informed patients about the incoming FIT Kit and instructed patients to complete and return the kit promptly.
223593674|NCT06430515|PROCEDURE|Intratumoral Injection of Chemotherapy|This project intends to investigate the clinical efficacy of intra-tumoural injection of chemotherapeutic agents (e.g. cisplatin, oxaliplatin, etc.)via fine needle aspiration guided by CT or ultrasound in patients with advanced solid cancers to validate the safety and efficacy.
223593675|NCT03927404|DEVICE|Active vacuum test prosthesis|The adaptive vacuum prosthesis is sold as a commercial device by the company Willow Wood with suggested U.S. L-Code L5781. The device is designated as a Class 1 Medical Device and 510(K) Exempt. This category is part of a low or moderate risk to patient safety and health. The Prosthetic socket system uses an active vacuum pump to push air out of the socket. The level of vacuum is controlled by hardware that automatically detects the socket fit based on in-socket motion and adjusts vacuum as needed to eliminate this motion.
223593676|NCT03754829|BEHAVIORAL|Her Sey Kontrol Altinda (HSKA)|HSKA consists of 5 sessions over 5 weeks and is based on Problem-Solving therapy. Participants receive feedback on their homework assignments in brief weekly online messages from a clinical psychologist.
223747063|NCT03482791|RADIATION|Proton beam therapy|"* The daily prescription dose will be 1.8 or 2 Gy RBE (Relative Biologic Equivalence) to be delivered to the periphery of the planning target volume (PTV).~* The Mevion S-250 Proton Radiation Beam Therapy System will be used."
223747064|NCT03482791|OTHER|Patient-Reported Outcome Measures|-Prior to start of therapy, end of chemoradiation (day of end of treatment or up to 1 week after), 8 weeks, 4, 6, 9, and 12-months following end of chemoradiation
223593677|NCT01229449|DRUG|Ibuprofen/acetaminophen|One tablet of ibuprofen 200 mg plus acetaminophen 500 mg and one placebo tablet, single dose taken orally with 300 ml water
223593678|NCT01229449|DRUG|Ibuprofen/acetaminophen (higher dose)|Two tablets of ibuprofen 200 mg plus acetaminophen 500 mg, single dose taken orally with 300 ml water
224196094|NCT06125483|PROCEDURE|Umbilical Cord Blood Transplantation|Compared with peripheral blood stem cell transplantation (PBST), UCBT has a higher transplantation rate, as cord blood stem cells are more primitive. Since the first successful umbilical cord blood transplantation (UCBT) in a child with severe Fanconi anemia reported by Gluckman et al. in France in 1988, cord blood has been widely used as a graft source of hematopoietic stem cells for the treatment of hematological diseases. The first sibling UCBT for leukemia was performed successfully by Professor Yongping Song in China, who played a pioneering role in the development of UCBT for leukemia in China. On the basis of previous research, TBI/Flu/Bu/Mel combined with UCBT is safe and feasible for the treatment of patients with malignant hematological diseases who experienced post-transplant relapse, which has enormous potential to improve patient outcomes.
224196095|NCT06372197|DRUG|Psilocybin|Following Oregon Psilocybin Services (OPS) rules, participants will be placed in cohorts of five to six, which whom they will do two 90-minute preparation session, two psilocybin sessions, and two 90-minute integration sessions. All sessions will be guided by two licensed facilitators.
224196096|NCT07007286|DRUG|ETV,TDF,TAF,TMF combination with PEG IFNα-2b|The study will not involve any additional interventions, nor will it interfere with any related clinical decision-making.
224196097|NCT07007286|DRUG|ETV,TDF,TAF or TMF|The study will not involve any additional interventions, nor will it interfere with any related clinical decision-making.
224196098|NCT07006363|OTHER|IASTM|IASTM: For the application, the participant is seated on a chair, puts his hands together on the bed in front of him and puts his head on his hands (Figure 4). Vaseline cream is applied to the area to be applied to ensure that the Graston Technique instruments slide more easily in the tissue. The application area is the area between the mastoid processes proximally, the acromial processes laterally, and the T2 vertebra level distally. The researcher who will perform the application stands behind the participant. Application is performed for 10 minutes at a 45o angle with 3 different Graston instruments.
223593679|NCT01229449|DRUG|Nurofen Plus®|Two tablets ibuprofen 200mg plus codeine 12.8mg (Nurofen Plus®), single dose taken orally with 300 ml water
223593680|NCT01229449|DRUG|Panadeine® Extra|Two tablets acetaminophen 500 mg plus codeine 15 mg (Panadeine® Extra), single dose taken orally with 300 ml water
223593681|NCT01229449|DRUG|Placebo|Two placebo tablets, single dose taken orally with 300 ml water
223593682|NCT01943240|DRUG|Paravertebral nerve block: 4 mL ropivacaine 0.5% at each of six levels|
223593683|NCT01943240|DRUG|10 cc of 0.375% ropivacaine pectoral nerve block|
223747065|NCT06911424|DRUG|Fusidic Acid 1%|Fusidic acid 1%
223747066|NCT06911424|DRUG|Placebo|Placebo ophthalmic solution
224196099|NCT07007169|DIETARY_SUPPLEMENT|The goal is daily consumption of a minimum of 30 grams of dietary fiber and weekly consumption of a minimum of 30 different plant foods; minimizing the amount of ultra-processed food.|The intervention group will receive personalized education and guidance from a nutrition therapist.
224196100|NCT07007169|OTHER|Standard Diet|The control group will continue their normal diet, and not receive guidance or participate in group sessions.
224196101|NCT05962463|PROCEDURE|Canal adductor blockade|The same experienced anesthesiologist has performed all blocks. Always after surgical cleaning of the anteromedial thigh, all participants in this group received single shot ultrasound guided canal adductor blockade. After the blockade, all participants were monitored in our ambulance for the next hour.
224196102|NCT05962463|PROCEDURE|Canal adductor pulsed radio-frequency therapy|The same experienced anesthesiologist has performed all PRF therapy After surgical cleaning of the anteromedial thigh, all participants in this group received ultrasound-guided pulsed radiofrequency therapy. We've previously scanned the adductor canal and chose the middle of the canal as the entry point of the RF 10 cm needle with a 1 cm free tip. After sensory and motor checking all patients have gotten 6 minutes of therapy divided into 3 sequences of 2 minutes of 50 V current and 42ºC. After the treatment, all participants were monitored in our ambulance for the next hour.
223593684|NCT04505579|DEVICE|Anterior Vertebral Body Tethering|Anterior Vertebral Body Tethering (AVBT) is a technique that utilizes growth modulation to remodel the shape of the vertebra and straighten scoliotic curves in skeletally immature individuals. In this technique, screws are inserted at each vertebral level for the length of the convex side of the curve. A strong cord is connected through the screw tulip heads and used to initially straighten the curve as each level is fixed with a set screw. Following surgery and during the growth period the spine begins to remodel according to the Hueter-Volkmann Law, bone growth is relatively inhibited in areas of increased pressure (convex or tethered side) and relatively stimulated in areas of decreased pressure or tension (concave side).
223593685|NCT05583032|DEVICE|ScanNav Anatomy PNB|AI-powered device that highlights anatomy of interest during ultrasound scans.
223593686|NCT06481085|DRUG|HDM1002 50 mg|HDM1002 tablets, 50 mg once daily, 12 weeks
223593687|NCT06481085|DRUG|HDM1002 100 mg|HDM1002 tablets, 100 mg once daily, 12 weeks
223593688|NCT06481085|DRUG|HDM1002 200 mg|HDM1002 tablets, 200 mg once daily, 12 weeks
223593689|NCT06481085|DRUG|HDM1002 400 mg|HDM1002 tablets, 400 mg once daily, 12 weeks
223593690|NCT06481085|DRUG|HDM1002 200 mg BID|HDM1002 tablets, 200 mg twice daily, 12 weeks
223593691|NCT06481085|DRUG|Placebo|Matching placebo will be provided
223593692|NCT00002580|DRUG|cyclophosphamide|
223593693|NCT00002580|DRUG|fluorouracil|
223747067|NCT06909968|OTHER|palliative care|"As this study is intended to be observational (not interventional), the patient's medical record will be the source of all data to be recorded.~No additional procedures/patient visits should be planned in the study with respect to clinical practice.~Two tools will be used to to analyze appropriateness and timeliness of progressive palliative care approach: NECPAL CCOMS-ICO(©), specific for the assessment of needs in palliative care, and the PaP score, for the assessment of prognosis."
223747068|NCT06911034|DRUG|Iron Carboxymaltose|In ferrous carboxymaltose treatment maximum dose per sitting was 1000 mg, diluted in 200 ml 0.9% normal saline and administered as an IV infusion over 30 min. Parenteral iron therapy was administered under doctor's supervision. The women were then followed up after 3 weeks of completion of therapy. On follow up, hemoglobin and serum ferritin were measured again.
223747069|NCT06911034|DRUG|Iron Sucrose Injection|Iron sucrose infusion was administered as 300 mg in 200 ml NS over 15-20 min twice weekly till dosage was completed, not exceeding 600 mg per week. Parenteral iron therapy was administered under doctor's supervision. The women were then followed up after 3 weeks of completion of therapy. On follow up, hemoglobin and serum ferritin were measured again.
224196103|NCT05405218|DEVICE|CTR with Ultrasound Guidance using the UltraGuideCTR device|Carpal Tunnel Release with Ultrasound Guidance using UltraGuideCTR device
224196104|NCT05405218|PROCEDURE|mOCTR|Mini Open Carpal Tunnel Release
224196105|NCT06686862|DRUG|ibuprofen|Ibuprofen tapering schedule during 3 weeks. First week: Ibuprofen 600 mg every 8 hours. Second week: Ibuprofen 600 mg every 12 hours. Third week: Ibuprofen 600 mg every 24 hours.
224196106|NCT07006246|DRUG|Tenofovir disoproxil fumarate + lamivudine/emtricitabine (TDF+3TC /FTC)|Tenofovir disoproxil fumarate + emtricitabine/ lamivudine Dosage Formulation: 300 mg / 200 mg (300mg) fixed dose combination tablet Route of Administration: Oral Dosing Instructions: 1 tablet (300/200/ TDF/FTC) daily or (300/300/TDF/3TC) daily
223505144|NCT04882215|BEHAVIORAL|GMT combined with WMU Training|"GMT teaches the use of mental strategies to support sustained attention during complex (multi-step) task performance following an interactive programme. GMT is structured into nine modules, with interactive discussions and homework assignments. It will be conducted on a group basis.~WMU training consists of computerised working memory updating tasks in which trial accuracy and response time are recorded. Two tasks will be trained: 1. a visuo-spatial Matrix Updating (MU) and 2. a verbal Keep Track (KT). For both training tasks, level of difficulty can be modulated by increasing or decreasing the update level, i.e., the number of updates on each trial."
223505145|NCT04263532|DEVICE|Modified BiPAP A40 with Vector Algorithm (Vector)|The Modified BiPAP A40 with Vector Algorithm (Vector) is intended to provide non-invasive ventilatory support to treat patients weighing over 10 kg (22 lbs) with Obstructive Sleep Apnea (OSA) or Respiratory Insufficiency. It is intended to be used within the home, institutional/ hospital, and diagnostic laboratory environments. This device is not intended for life support. The BiPAP A40 EFL screening and therapy is intended for patients weighing over 30 kg (66 lbs) with Obstructive Sleep Apnea (OSA), or Respiratory Insufficiency with primary cause being Chronic Obstructive Pulmonary Disease (COPD) to screen for the presence, and abolishment of Expiratory Flow Limitation (EFL).
223505146|NCT04263532|DEVICE|Modified BiPAP A40 with Standard of Care Settings|The Modified BiPAP A40 with Standard of Care settings is intended to provide non-invasive ventilatory support to treat patients weighing over 10 kg (22 lbs) with Obstructive Sleep Apnea (OSA) or Respiratory Insufficiency. It is intended to be used within the home, institutional/ hospital, and diagnostic laboratory environments. This device is not intended for life support. The BiPAP A40 EFL screening and therapy is intended for patients weighing over 30 kg (66 lbs) with Obstructive Sleep Apnea (OSA), or Respiratory Insufficiency with primary cause being Chronic Obstructive Pulmonary Disease (COPD) to screen for the presence, and abolishment of Expiratory Flow Limitation (EFL).
223505147|NCT03911687|BEHAVIORAL|CONCERN CDS system notification|"The CONCERN CDS will trigger based on analytics of nursing documentation that indicates recognition and concern of patient changes. The CONCERN CDS will alert the care team of the patients risky state to increase team-based situational awareness (i.e., shared understanding of the patient situation) of patients predicted to be at risk for patient decompensating in need of rapid intervention to prevent mortality and associated harm.~Version 1: Burn in phase to evaluate adoption and adaptation to the algorithm being studied. Expected time frame - 3 months~Version 2: Version 2 refined based on continuous monitoring of data. Expected time frame - 3 months~Version 3: Version 3 refined based on continuous monitoring of data. Expected time frame - 3 months"
223505148|NCT01931631|BEHAVIORAL|Low-fat, low-Glycemic Index, vegan diet|Low-fat, low-Glycemic Index, vegan diet
223505149|NCT01931631|BEHAVIORAL|ADA diet|Diet in accordance with the American Diabetes Association
223505150|NCT03110432|DRUG|PCSK9 Inhibitor [EPC]|drug use according to the respective product labelling
223505151|NCT03110432|DRUG|Standard lipid lowering therapy|drug use according to the respective product labelling
223505152|NCT04098302|DRUG|Dutasteride Capsules|1 mg/day oral dutasteride (2 x 0.5 mg capsules)
223505153|NCT04098302|DRUG|Placebo Capsules|Placebo capsules with matching appearance as Dutasteride Capsules
223505154|NCT05123417|DIAGNOSTIC_TEST|Follow up|Each group participants will be tested with questionnaire before the training and two weeks after the training they will get post test with the same questionnaire.
223505155|NCT03067415|DRUG|D565H(Latanoprost 25㎍/㎖)|D565H twice daily
223505156|NCT03067415|DRUG|D565(Latanoprost 50㎍/㎖)|D565 once daily
223505157|NCT06359561|DEVICE|cervical lead placement|implant of cervical lead neurostimulation, using saluda medical devices
223505158|NCT04998110|OTHER|Ambulatory Supportive Care|Ambulatory supportive care visits monthly for six months - a monthly visit with an ambulatory palliative care provider educated in kidney disease
223505159|NCT01810952|DRUG|Glargine insulin|In both protocols glargine dose was increased by 10% if the FSG value was 141-200 mg/dL and by 20% if the FSG value was more than 200 mg/dL, and decreased by 10% if the FSG was 70-89 mg/dL and by 20% if the FSG was less than 70 mg/dL.
223505160|NCT01810952|DRUG|Lispro insulin|In both protocols lispro insulin was given to cover meals. Additional lispro insulin was Lispro insulin was administered before meals to cover the prednisone or glucocorticoid equivalent in the Glargine/Lispro Insulin Arm.
223505161|NCT01810952|DRUG|NPH Insulin|NPH insulin was given once or twice a day to cover the prednisone or glucocorticoid equivalent in the Glargine/Lispro/NPH Insulin Arm
223505162|NCT01290731|DRUG|TMC435|100-mg capsule once daily for 12 weeks
223593694|NCT00002580|DRUG|goserelin acetate|
223593695|NCT00002580|DRUG|leuprolide acetate|
223593696|NCT00002580|DRUG|methotrexate|
223593697|NCT00002580|DRUG|tamoxifen citrate|
223593698|NCT00002580|PROCEDURE|conventional surgery|
223593699|NCT00002580|PROCEDURE|laparoscopic surgery|
223593700|NCT00002580|PROCEDURE|oophorectomy|
223593701|NCT00002580|RADIATION|radiation therapy|
223593702|NCT04082780|DRUG|Rifamycin SV MMX|Intervention arm
223593703|NCT04082780|OTHER|Placebo|Placebo arm
223593704|NCT06349668|DRUG|spinal analgesia with morphine and bupivacaine|single shot spinal analgesia with 0.2-0.3 mg morphine and 10-20 mg bupivacaine before surgery
223593705|NCT06349668|DRUG|lidocaine infusion|intraoperative intravenous infusion of lidocaine at a rate of 2 mg/kg/t (Ideal Body Weight)
223593706|NCT00377364|DRUG|Drug: Acetaminophen, Drug: Placebo|Acetaminophen: Participants will be given acetaminophen (two 500 mg tablets) four times daily for 7 days, not exceeding 4,000 mg/day. Placebo: Participants will be given placebo(two 500 mg tablets) four times daily for 7 days
223593707|NCT04194073|DEVICE|Pulse oximeter calibration population (NightOwl)|The NightOwl is a finger and/or forehead mounted device with, among other functions, the capability to acquire double-wavelength PPG, from which SpO2 can be derived
223593708|NCT02800265|DIETARY_SUPPLEMENT|Avmacol|Avmacol is an over-the-counter mixture of broccoli seed and sprout extracts in tablet form to promote detoxification. These tablets contain natural substances that stimulate the body's own defense mechanisms against toxic substances commonly encountered in the environment, such as air pollution and tobacco smoke.
223593709|NCT02528682|BIOLOGICAL|MiHA-loaded PD-L-silenced DC Vaccination|Eligible patients will receive one cycle of donor DC vaccination consisting of maximal 3 immunizations, given at 2 week intervals. PD-L1/L2-silenced, MiHA mRNA-electroporated donor DC will be infused intravenously (2.5x105/kg body weight).
223593710|NCT04678791|DRUG|Nimotuzumab|Patients receive Nimotuzumab 400 mg each time, once a week, slow intravenous drip, for a total of 6 weeks.
223593711|NCT04678791|DRUG|Cisplatin|Patients receive 40 mg/m2, d1, 7 days as 1 treatment cycle, 6 treatment cycles in total
223593712|NCT04678791|RADIATION|External-beam radiation|Patients undergo IMRT/VMAT radiotherapy with pelvic and/or extended field irradiation at a total dose of 45 - 50.4 Gy; 1.8 - 2.0 Gy/f, 25 - 28 f.
224196107|NCT06116292|DEVICE|The mobile application ESTOI for Asthmatic patients|"The mobile application ESTOI have various sections that can be managed and customized by the researchers to meet each patient's needs:~1. SYMPTOM CONTROL, it will record the ACT, TAI, the number of exacerbations, weight, and, depending on the case, symptom control for comorbidities.~2. RECOMMENDATIONS, it will provide patients with information needed to understand their condition, how to control it, and what to do in case of worsening symptoms.~3. YOUR TREATMENT, it will display personalized and update information about the patient's current asthma medication, including dosages and frequencies. There will be explanatory videos on how to administer the therapy and includes an action plan.~4. PEAK FLOW, the patient can record measurements using a Peak Flow Meter at home.~5. NUTRITIONAL PLAN, it will provide a daily dietary guide to enable individuals to adapt these tools and recommendations to their specific needs.~6. MESSAGING, it is a bidirectional contact area."
224196108|NCT04416451|DRUG|Rituximab|Induction:Rituximab will be administered per institutional guidelines once per week for 4 weeks at a dose of 375 mg/m\^2. Maintenance: In addition, patients will receive rituximab 375 mg/m2 starting on day 1 of the maintenance phase and repeated once every 3 months for 12 months (for a total of 4 infusions). On days when venetoclax and rituximab will both be administered, patients will take venetoclax prior to administration of rituximab.
223505163|NCT01290731|DRUG|Pegylated interferon (pegIFN alpha-2a)|180 mcg injected subcutaneously (by a syringe under the skin) once weekly for 12 to 36 weeks (or until Week 48).
223593713|NCT04678791|RADIATION|Brachytherapy|Patient undergo Brachytherapy with high dose rate, with a total dose of 30-40 Gy and a cumulative dose of 80 \~ 85 Gy at point A/HRCTV D90; if the tumor diameter is ≥ 4 cm, the cumulative dose of ≥ 87 Gy at point A/HRCTV D90.
223505164|NCT01290731|DRUG|Ribavirin (RBV)|200-mg tablets (daily dose: 600-1000 mg) taken orally (by mouth) two times a day for 12 to 36 weeks (or until Week 48).
223593714|NCT02128074|DRUG|KRX-0502|1g tablets of KRX-0502
223505165|NCT03390192|DEVICE|Dual-mode stimulation|1Hz rTMS over contralesional primary motor cortex and anodal tDCS over ipsilesional primary motor cortex are simultaneously simulated.
223505166|NCT03390192|DEVICE|Single sham stimulation|1Hz rTMS over contralesional primary motor cortex and sham tDCS (no stimulation) over ipsilesional primary motor cortex are simultaneously simulated.
223505167|NCT00285675|DRUG|DN-101 (calcitriol) - Drug|
223505168|NCT04027621|DEVICE|remote ischemic conditioning|Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min re-perfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 200 mm Hg.
223505169|NCT04027621|DEVICE|sham remote ischemic conditioning|Sham remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min re-perfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 60 mm Hg.
223505170|NCT00143520|DRUG|Rivoglitazone|
223505171|NCT00143520|DRUG|Pioglitazone|
223505172|NCT00143520|DRUG|Placebo|
223505173|NCT05821595|DRUG|JYB1907|for injection
223505174|NCT00560638|DRUG|loteprednol etabonate ophthalmic suspension, 0.5%|TID
223505175|NCT00560638|DRUG|loteprednol etabonate ophthalmic suspension, 0.5%|QID
223505176|NCT00560638|DRUG|vehicle of loteprednol etabonate|TID or BID according to the randomization
223505177|NCT03057301|DEVICE|iCare home tonometer|All subjects will be taught to use the home care tonometer.
223505178|NCT04619082|DRUG|Tenofovir alafenamide|Tenofovir alafenamide 25 mg once per day for one year
223505179|NCT05571592|DRUG|Cannabidiol|Oral Capsule Formulation of CBD dissolved in a self-emulsifying drug technology called nanodomains, encapsulated within 1-ml softgel capsules, with a CBD purity ≥98%. Imported from Ananda Scientific
223505180|NCT05571592|DRUG|Placebo|"Drug: Placebo~Placebo softgel capsule formulation."
224310623|NCT06137690|DEVICE|other antifungal agents,breathing machine|If treatment failure for patients in group A and group B，change other antifungal agents (Amphotericin B for Injection, 25mg, North China Pharmaceutical Co., Ltd or Caspofungin Acetate for lnjection,50mg and 70mg Cancidas®). Mechanical ventilation (EVITA 4, Dräger Medical Equipment (Shanghai) Co.,Ltd) was adopte.Treatment failure was defined as no improvement or worse of clinical symptoms, laboratory data, requiring change of antifungal agents therapy.
223505181|NCT05970406|OTHER|high intensity dysphagia therapy|Intensive swallowing interventions with Speech Language Pathologists to begin within 24 hours of video swallow study results. Daily treatment will include two 30-minute sessions, 5-6 days a week which will include the evidence-based dysphagia exercises focusing on tongue resistance, head lift/chin tuck against resistance and expiratory muscle strength training tasks
223505182|NCT01399099|DEVICE|embrace device|Adhesive bandage/dressing intended to minimize scar formation.
223505183|NCT05396170|PROCEDURE|phlebotomy|500ml of blood phlebotomized per standard of care to reduce symptoms from polycythemia
223505184|NCT06140641|DIETARY_SUPPLEMENT|Probiotics|Bifidobacterium Longum BL21 or placebo for 8 weeks.
223505185|NCT05232526|OTHER|Mental imagery (MI) and exercise program|Mental imagery and exercise program will be used to improve balance, functional status, cognitive ability, depression and quality of life of the sample
223505186|NCT05232526|DEVICE|Mental Imagery and Exercise program|Questionnaires and functional tests are going to be used to evaluate balance, functional status, cognitive ability, depression and quality of life of the sample.
223505187|NCT05235607|BIOLOGICAL|Tumor antigen-sensitized DC vaccine and their sensitized T cells subcutaneous administration|subcutaneous administration
223505188|NCT03248804|BEHAVIORAL|Soy group|
223505189|NCT03248804|BEHAVIORAL|Non-soy group|
223505190|NCT01668537|BIOLOGICAL|LF formulation of IMVAMUNE®|
223505191|NCT01668537|BIOLOGICAL|FD formulation of IMVAMUNE®|
223505192|NCT04772235|DRUG|Repotrectinib|"Repotrectinib will be taken orally once daily with or without food Part A: Dose escalation phase, with 3 dose levels for repotrectinib: (1) 80 mg QD, (2) 160 mg QD and (3) 160 mg QD for 14 days followed by 160 mg BID; in combination with 80 mg QD of osimertinib~Part B: at the RP2D for all patients in combination with osimertinib."
223505193|NCT04772235|DRUG|Osimertinib|"Osimertinib will be taken orally at 80 mg once daily with or without food. Part A: lead in dose in monotherapy at 80 mg QD during 14 days. In combination with repotrectinib afterwards. Depending on the safety and PK/ dose dependent interactions (DDIs) readout during the DLT assessment period, osimertinib dose may be adjusted.~Part B: at the RP2D level in combination with repotrectinib"
223505194|NCT03848468|PROCEDURE|Hemorrhoidectomy|excision of 3rd and 4th degree hemorrhoids
223505195|NCT02083211|DRUG|mAb Nimotuzumab|This group will receive a dose of 200 mg mAb hR3 (weekly over 18 weeks) plus chemotherapy (6 cycles every 21 days of Cisplatin (CDDP) 50 mg/m2 on day 1/, Vinorelbine 30 mg/m2 on day 1 and day 8)
223505196|NCT02083211|DEVICE|Placebo|This group will receive a placebo in addition to chemotherapy in a similar regimen. Once the chemotherapy is completed a maintenance dose will be administered with 200 mg/dose of mAb hR3 every 14 days until progression.
223505197|NCT00183898|DRUG|oxaliplatin, capecitabine|cetuximab 400 mg/m2, followed by weekly cetuximab 250 mg/m2 with oxaliplatin 130 mg/m2 on day 1 (every 3 weeks) with capecitabine 850 mg/m2 bid, daily on days 1-14, every 3 weeks.
223505198|NCT03506126|OTHER|Leucine|There are 8 different leucine test levels ranging from 20 to 120 mg of leucine per kilogram body weight per day (20-120 mg/kg/d)
223505199|NCT01828684|OTHER|Therapeutic Lens Coating|Subjects will wear a therapeutic lens coating for 2 weeks.
223505200|NCT01828684|OTHER|Sham Lens Coating|Each subject will wear a sham lens coating for 2 weeks.
223505201|NCT03331406|OTHER|Physical Activity Program|12-weeks in length, and includes moderate-intensity aerobic, strength, flexibility, and balance training.
223505202|NCT02580552|DRUG|Cobomarsen|
223505203|NCT00601237|BEHAVIORAL|HIV-related text messaging|Participants will receive up to 90 text messages related to abstinence, monogamy, and condom use over 3 months.
223505204|NCT00601237|BEHAVIORAL|Nutrition-related text messaging|Participants will receive up to 30 text messages about nutrition and healthy eating over 3 months.
223505205|NCT01838889|BEHAVIORAL|Culturally adapted psychological intervention (Positive Health Programme)|This study will evaluate the efficacy of a group psychological intervention (PHP) based on the principles of Cognitive Behaviour Therapy in treating depression in postpartum women.
223505206|NCT00051727|BEHAVIORAL|Bridges to High School Project|
223505207|NCT05025917|DIETARY_SUPPLEMENT|Shatavari|Shatavari root powder
223505208|NCT05025917|DIETARY_SUPPLEMENT|Magnesium stearate|Magnesium stearate powder
223505209|NCT02974426|RADIATION|PORT-first|PORT administered at the first day of adjuvant therapy, using 3- dimensional conformal or intensity-modulated radiation, total dose of 50.4 Gy, 1.8 Gy once daily over 5.5 weeks.
223505210|NCT02974426|RADIATION|PORT-last|PORT administered sequentially after participants received adjuvant chemotherapy for four cycles, using 3- dimensional conformal or intensity-modulated radiation, total dose of 50.4 Gy, 1.8 Gy once daily over 5.5 weeks.
223505211|NCT02974426|DRUG|Platinum-based two drug chemotherapy (cisplatin/carboplatin + vinorelbine or cisplatin/carboplatin + pemetrexed regimen)|Cisplatin/ carboplatin + vinorelbine regimen for squamous cell lung carcinoma Cisplatin/carboplatin + pemetrexed regimen for lung adenocarcinoma
223505212|NCT02417181|OTHER|Care provided by Physician Assistants|Patients will receive care at the out-of-hours primary care service by a Physician Assistant instead of a General Practitioner (substitution of care from physicians to nurses).
223505213|NCT00897845|GENETIC|RNA analysis|
223505214|NCT00897845|GENETIC|microarray analysis|
223505215|NCT00897845|OTHER|immunohistochemistry staining method|
223505216|NCT00897845|OTHER|laboratory biomarker analysis|
223505217|NCT05064800|DRUG|Dabigatran|A single dose of Dabigatran on Day 1
223505218|NCT05064800|DRUG|PF-07321332/ritonavir + Dabigatran|PF-07321332/ritonavir twice daily (BID) for Days 1 and 2 Single dose of Dabigatran on Day 2
223505219|NCT05064800|DRUG|Ritonavir + Dabigatran|Ritonavir BID on Days 1 and 2 Single dose of Dabigatran on Day 2
223505220|NCT04909255|DRUG|mirabegron|use beta-3 agonist for sjogren syndrome patient
223505221|NCT04909255|DRUG|oxybutynin, tolterodine, solifenacin|use anti-muscarinic agent for patient with overactive bladder syndrome
223747070|NCT06913426|COMBINATION_PRODUCT|Pelvic Tilt, Hip and Knee Focused Exercises (Intervention Group)|The treatment program is between one to six weeks with strictly 18 sessions with at least thrice in a week to give room to recuperate from muscle fatigue. This protocol is set in a 45 minutes session that involves a series of exercises and stretches. The quadriceps muscles strengthening exercises, hamstring and the calf raising workouts such as the hamstring curls and heel raise are done in 3 sets of 10-15 reps. Patellofemoral joint mobilization which should not last more than 2-3 minutes due to possible patient discomfort is performed and its primary goal is increasing joint mobility. After that the patient is to perform exercises for pelvic tilt in three approaches, each made in 10 to 15 repetitions.
223747071|NCT06913426|DIAGNOSTIC_TEST|Hip and Knee Focused Exercises(Control Group)|The treatment program covers a time frame of one to six weeks, three sessions a week, total of 18 sessions, over six weeks. Each session takes 45 minutes and contains a schedule of activities. The quadriceps muscles strengthening exercises, hamstring and the calf raising workouts such as the hamstring curls and heel raise are done in 3 sets of 10-15 reps. Patellofemoral joint mobilization which should not last more than 2-3 minutes due to possible patient discomfort is performed and its primary goal is increasing joint mobility. Then Patient performs hip exercises; hip abductor as well as hip extension, which are done in three sets of 10 to 15 repetitions each. Likewise, the knee-focused workouts such as quad sets, straight leg raises and step-up are conducted in the same 3 sets of 10-15 repetitions style. Static flexibility exercises includes Hip Flexor Stretch, IT Band Stretch and these exercises are performed with 5 sets of 30 seconds.
224196109|NCT04416451|DRUG|Venetoclax|"Induction: Starting one week after the last induction dose of rituximab (approximately week 5), venetoclax will be administered orally at a flat dose of 100 mg daily and escalating each week to a target dose of 800 mg daily on the following schedule:~* Week 1: 100 mg~* Week 2: 200 mg~* Week 3: 400 mg~* Week 4: 800 mg Maintenance: Following the 4-week induction phase ramp-up of venetoclax, patients will begin their target dose of 800 mg venetoclax daily and continue this dose during the 24- month maintenance treatment phase. On days when venetoclax and rituximab will both be administered, patients will take venetoclax prior to administration of rituximab."
224196110|NCT03405155|BIOLOGICAL|Nivolumab|Given IV
224196111|NCT06316557|DEVICE|iTBS group|iTBS on the contralesional cerebellum, twice a day for seven days
224196112|NCT06316557|DEVICE|control group|shame stimulation on the contralesional cerebellum, twice a day for seven days
224196113|NCT06870279|DRUG|CGC738|CAR-NKT Cells treatment
224196114|NCT04479241|BIOLOGICAL|lerapolturev|Lerapolturev (5x10\^7 TCID50) delivered intratumorally via convection enhanced delivery (CED).
224196115|NCT04479241|BIOLOGICAL|pembrolizumab|Pembrolizumab (200 mg IV) given every 3 weeks.
224196116|NCT04571658|OTHER|Communication|The NEPTUNE Match study includes an interdisciplinary Communication Team that will translate findings from the Molecular Nephrology Board (MNB) to inform patients of the matching assessment with ongoing clinical trials. This team has considerable experience with conveying complex biomedical research information to patients and families and includes experts in precision nephrology, nephrology patient \[adult and pediatric\] communication, and health education.
224196117|NCT07028983|BEHAVIORAL|Active Music Group (AMG)|Active music group is a music therapy intervention where participants actively make/play music in groups. The sessions will be conducted by an appropriately qualified music therapist.
223505222|NCT00854854|BIOLOGICAL|TKCell|"TKCell 150ml IV for 7times after each FOLFOX-4 regimen :~From the second cycle of FOLFOX4(start Day1),TKCell is administered in Day3 and Day8.In the third cycle of FOLFOX4(Day1),TKCell is administered in Day3 and Day8.In the fourth cycle of FOLFOX4(Day1),TKCell is administered in Day8.In the fifth cycle of FOLFOX4(Day1),TKCell is administered in Day8.In the sixth cycle of FOLFOX4(Day1),TKCell is administered in Day8"
223505223|NCT01158586|DRUG|Levobupivacaine|patient control epidural analgesia using 0.2% levobupivacaine with 2ug/ml fentanyl
223505224|NCT03307070|BEHAVIORAL|Cognitive Behavioral Therapy for individuals with TBI|Cognitive Behavioral Therapy for depression that has been adapted for a population who has experienced a moderate to severe Traumatic Brain Injury. This is a 12 week long treatment for depression with weekly visits that challenges negative thoughts and behaviors. This version has been specifically developed for the study to account for specific cognitive needs of individuals who have experienced a moderate to severe TBI.
224196118|NCT07028983|BEHAVIORAL|Music Listening Group (MLG)|Music listening group is a music therapy intervention where participants partake in music listening in groups. The sessions will be conducted by an appropriately qualified music therapist.
223505225|NCT03307070|OTHER|Waitlist Control|Participants will be randomized to a waitlist. They will attend biweekly study sessions for 12 weeks to track progress, but will receive their treatment as usual.
223505226|NCT02411955|DRUG|Tazarotene Cream 0.1%|Tazarotene Cream 0.1% applied to lightly cover the entire face once daily for 84 consecutive days.
223505227|NCT02411955|DRUG|Tazorac®|Tazorac® applied to lightly cover the entire face once daily for 84 consecutive days.
223505228|NCT02411955|DRUG|Placebo|Placebo (vehicle of the test product) applied to lightly cover the entire face once daily for 84 consecutive days.
223505229|NCT00629642|DRUG|Solifenacin Succinate|Oral, 10mg
223505230|NCT00629642|DRUG|Solifenacin Succinate|Oral, 5mg
223505231|NCT00629642|DRUG|Oxybutynin Hydrochloride|Oral, 15mg
223505232|NCT00629642|DRUG|Placebo|Oral
223505233|NCT04294238|BEHAVIORAL|Aerobic exercise|The aerobic exercise intervention consisted of 12 weeks of aerobic exercise training of moderate intensity (about 75 percentage peak heart rate) of 40-60 min per time, 3-5 times per week, at least 150 min per week.
223505234|NCT04867070|DIAGNOSTIC_TEST|NAS score|Participants will be recorded according to the NAS and W-BAS pain scores
223505235|NCT03044561|DRUG|Sildenafil Citrate|25 mg orally, 4 times per day for 21 days
223505236|NCT03044561|DRUG|matching placebo|orally, 4 times per day for 21 days
223505237|NCT00663143|PROCEDURE|Stromal Cells Sample|Human Bone Marrow Stromal Cells will be obtained from 5 patients. Stromal cells will be obtained from subjects undergoing bone graft procedure to repair traumatic mandible fractures. Bone graft specimens will be obtained from the ileac crest. This will allow easy access to bone marrow specimen without additional pain or complications. A total of 5 ml of bone marrow will be obtained from each patient.
223505238|NCT04477486|DRUG|Ibrutinib|Capsule; Oral
223505239|NCT04477486|DRUG|Venetoclax|Tablet; Oral
224196119|NCT07028983|BEHAVIORAL|Treatment as Usual (TAU)|Treatment as usual as provided locally, which may include pharmacological and/or non-pharmacological interventions (e.g. mindfulness-based intervention, structured physical activity).
224196120|NCT06871306|DEVICE|Transcutaneous Auricular Vagus Nerve Stimulation|taVNS was performed using the Vagustim device (Vagustim Health Technologies, Teknokent, Istanbul, Türkiye) at the tragus and concha regions for 30 minutes, with a frequency of 25 Hz and a pulse width of 300 µs in both groups. The difference in stimulation between the groups depends only on to which ear it was applied. Electrical stimulation was increased in 0.1 mA steps until the detection threshold was reached.
224196121|NCT06699394|DRUG|Teclistamab (Tec)|Teclistamab is administered subcutaneously with higher step-up doses (SUDs). Patients receive teclistamab with SUDs: 0.2 and 0.7 mg/kg and 1.5 mg/kg in Cycle 1 (2-4 days between doses). 3 mg/kg every 4 weeks will be used in subsequent cycles.
224196122|NCT04710628|DRUG|Pembrolizumab|Pembrolizumab 200 mg will be administered to patients as 30-minute intravenous infusion (a window of -5 minutes and +10 minutes is permitted) every 3 weeks.
224196123|NCT04710628|DRUG|Lenvatinib 10 mg|Lenvatinib 20 mg (2 capsules of 10 mg) will be administered daily at the same time, with or without food. At the day 1 of each cycle, lenvatinib will be administered within 4 hours after finishing pembrolizumab (lenvatinib after pembrolizumab)
224196124|NCT04244227|DEVICE|Empower Neuromodulation System|Peripheral nerve stimulation with the Empower device. The active and sham treatments only differ by the location of application on the body.
224196125|NCT05692427|DEVICE|Cryopen - Cryotherapy|Cryotherapy with N20
224196126|NCT05493579|OTHER|Implant supported overdenture|Implant supported overdenture compared to complete denture
224196127|NCT00069654|PROCEDURE|Forearm blood flow study|
224196128|NCT00069654|PROCEDURE|Brachial artery reactivity study|
224196129|NCT00069654|PROCEDURE|Treadmill exercise test|
224196130|NCT02576951|DRUG|Galcanezumab|Administered SC
224196131|NCT02576951|DRUG|Placebo|Administered SC
224196132|NCT03471494|OTHER|Exposure: human development index of country|Primary comparison: Between country groups defined by human development index.
224196133|NCT02307331|DEVICE|Optivac|A vacuum mixing system for cement with mixing and collection under vacuum but open initial mixture of powder and monomer. Has been used since 1993 with excellent results
224310624|NCT01501864|BEHAVIORAL|School Support Intervention|Comprehensive school support is provided that includes payment of school fees, school uniform, and a nurse researcher who monitors attendance and addresses problems that may lead to school absence and dropout.
223593715|NCT05339282|PROCEDURE|Laparoscopic cholecystectomy|"Method of operation~1. Surgery was started under general anesthesia~2. A trocar of 10 mm was placed on the navel, 5 mm under the blade, and a 5 mm trocar was placed on the right upper abdomen.~3. Pneumoperitoneum was performed using CO2 gas in the abdominal cavity.~4. Dissection started from Calot's triangle, and the operation was performed by retrograde cholecystectomy.~5. The excised gallbladder was placed in a laparoscopic pocket and extracted through the umbilicus.~6. The trocar was removed, and the skin was sutured~On the 1st day after surgery, hematology, blood chemistry, urine, blood clotting, and chest x-rays were performed. (Inspection and treatment were performed according to the current clinical pathway of gallbladder surgery)"
223593716|NCT02533726|OTHER|Optimal Turning|Patients within this arm will receive optimal turning practices. Nurses caring for these patients will receive real-time quantitative measures of patient turning procedures from the User Dashboard and provide a visual advisory to the nurse for the time to next turn.
223593717|NCT02533726|OTHER|Standard Care Practices|Patients within this arm will receive standard preventative care practices - that is, nurses will provide standard care as necessary, without the aid of visual advisories from a patient sensor.
224196134|NCT02307331|DEVICE|Optipac|A vacuum mixing system for cement with mixing and collection under vacuum but with a pre-packed mixing system allowing for an all closed system minimizing exposure for monomer fumes. This is a relatively new mixing system
224196135|NCT02307331|DEVICE|Arcom (Exceed cup)|The Exceed cup is available in two type of advanced bearing polyethylene material: The first is the 'classic', long term proven ArCom, a conventional polyethylene
224196136|NCT02307331|DEVICE|E1 (Exceed cup)|The Exceed cup is available in two type of advanced bearing polyethylene material: The new is a highly cross linked polyethylene with infusion of vitamin E1 to remove free radicals in order to reduce wear.
224196137|NCT02307331|DEVICE|Sirius stem|A polished tapered stem
224196138|NCT01272349|OTHER|Acute intermittent hypoxia|30 minutes of intermittent breathing low oxygen followed by walking on a body-weight support treadmill
224196139|NCT01272349|OTHER|Room air|30 minutes of breathing room air followed by walking on a body-weight support treadmill
224196140|NCT02143427|BEHAVIORAL|Social Skills Training|"Behavioral: computer-based Treatment Program for Children with Aggressive Behavior 16 sessions with the child aiming at the reduction of peer related aggressive behavior via social skills training. Additionally up to 2 sessions with relatives of the child in most cases with the parents and subsequent Treatment Program for Children with Aggressive Behavior 16 sessions with the child aiming at the reduction of peer related aggressive behavior via social skills training. Additionally up to 6 sessions with relatives of the child in most cases with the parents.~Arms: Social Skills Training"
224196141|NCT02143427|BEHAVIORAL|Treatment Program with techniques to activate resources|"Behavioral: Treatment Program with techniques to activate resources 16 sessions with the child aiming at the reduction of peer related aggressive behavior via activate resources. Additionally up to 2 sessions with relatives of the child in most cases with the parents and subsequent computer based Treatment Program for Children with Aggressive Behavior 16 sessions with the child aiming at the reduction of peer related aggressive behavior via social skills training.~Arms: Treatment Program with techniques to activate resources of the child and subsequent Social Skills Training"
224196142|NCT01968473|DEVICE|NMES Device comfort|NMES device, establishing Sensory, Motor and Pain thresholds and Pain tolerance.
224196143|NCT05440227|DRUG|PG2 Lyo. Injection 500mg|PG2 Lyo. Injection 500mg (reconstituted with 0.9% normal saline 500ml) will be administered weekly for 8 weeks.
224310625|NCT00362479|DRUG|DR-1021|1 tablet daily
224310626|NCT02320760|BEHAVIORAL|Physical activity on prescription|
224310627|NCT02733926|OTHER|Adding of vegetation into the backyards of kindergarten|Living plants are transferred into the backyards of kindergartens. This is assumed to affect the measured variables of children.
224310628|NCT00210873|DRUG|topiramate|
223593718|NCT02533726|OTHER|Patient Sensor|A small sensor with adhesive backing is applied to the upper chest (midline) of the patient. Sensor tracks and records body movement and position, and displays this on a User Dashboard located on a computer at the bedside.
223747072|NCT06913309|DEVICE|Bright light therapy（High light intensity）|"In this study, we will utilize the optocoupler-controllable light source, a product jointly developed by the School of Physics at Peking University and Peking University Sixth Hospital, which granted a national patent in China, for the purpose of intervention.~Participants randomly assigned to the high light density intervention group will receive bright white light therapy interventions with light intensities of 10000 lux, and the main wavelength of light source is 476.4nm. The intervention plan is to receive 40 minutes of light therapy from 7:00-9:30 in the morning for 4 consecutive weeks, 6 days a week. The subject sits at a distance of 60cm from the light source."
224196144|NCT05440227|DRUG|Placebo 0.9% normal saline|0.9% normal saline 500ml will be administered weekly for 8 weeks.
223593719|NCT03180307|DRUG|OTL38|0.025 mg/kg of OTL38 in 250ml dextrose 5% in water (D5W) infused intravenously over 60 minutes
223593720|NCT03180307|DEVICE|near infrared camera imaging system|Infrared imaging used to excite OTL38 for fluorescence
223593721|NCT03180307|PROCEDURE|laparotomy|primary surgical cytoreduction, interval debulking, or recurrent ovarian cancer surgery
223593722|NCT03599479|DEVICE|Virtual reality group|Virtual reality group The study intervention is to provide acute pain management for the subject undergoing fluoroscopic pain intervention by using the virtual reality program provided by the collaborator through virtual reality device (headset, headphone, and smartphone) that are commercialized on the market.
223593723|NCT01057563|DEVICE|drug (paclitaxel)-eluting balloon (DEB)|BMS implantation after lesion predilation with DEB
223747073|NCT06913309|DEVICE|Bright light therapy（Low light intensity）|In this study, we will utilize the optocoupler-controllable light source, a product jointly developed by the School of Physics at Peking University and Peking University Sixth Hospital, which granted a national patent in China, for the purpose of intervention. Participants randomly assigned to the low light density intervention group will receive bright white light therapy interventions with light intensities of 5,000 lux,and the main wavelength of light source is 476.4nm. The intervention plan is to receive 40 minutes of light therapy from 7:00-9:30 in the morning for 4 consecutive weeks, 6 days a week. The subject sits at a distance of 60cm from the light source.
223747074|NCT06913309|DEVICE|Dim red light placebo-controlled intervention|In this study, participants randomly assigned to the placebo-controlled group will receive dim red light therapy interventions with light intensities of 100 lux, and the main wavelength of light source is 690.4nm. The placebo-controlled intervention plan is to receive 40 minutes of red light therapy from 7:00-9:30 in the morning for 4 consecutive weeks, 6 days a week. The subject sits at a distance of 60cm from the light source.
223747075|NCT06913881|DRUG|GLP-1|We will compare people who have picked up GLP1 to those who have picked up insulin at any Swedish pharmacy
223747076|NCT06914843|BEHAVIORAL|OptimalWork|An online intervention that teaches concepts of cognitive restructuring, mindfulness, and behavioral activation as they apply in one's daily life and work. Users are given personalized content recommendations based on their inventory results and instructed to complete 15-25 minutes of content per day, 5 days/week for 4 weeks. (optimalwork.com)
224196145|NCT04327245|OTHER|Intervention ingest a 5000 mg of D-tagatose|"Woman with resistance insulin who ingest a 5000 mg of D-tagatose. D-tagatose is a sweetener of natural origin, low in calories (1.5 kcal / g) and with a sweetness power of 0.9.~About 20 to 25% of the ingested D-tagatose is absorbed and metabolized in the liver, the rest is fermented by the microbiota producing short chain fatty acids."
224310629|NCT00378404|DRUG|Docetaxel|30 mg/m2 IV on days 1, 8, 15 every 28 days for 6 cycles
224310630|NCT00378404|RADIATION|Radiation|50 - 80 cGy on days 1, 8, 15 every 28 days for 6 cycles
224310631|NCT02519738|DRUG|Silver Nitrate|Silver nitrate to be applied 3 times weekly for a period of 3 weeks.
224310632|NCT02519738|DRUG|Kenalog (Triamcinolone)|Triamcinolone will be applied as an ointment to the granulation tissue site three times daily for a total of three weeks.
224310633|NCT02519738|OTHER|Washcloth Abrasion|Gentle wash and abrasion with washcloth done once daily for a total of 3 weeks.
224310634|NCT04063436|DEVICE|New nasal pillows mask with PAP therapy|Participants will be placed in the experimental arm for 14±5 days, during which they will be using the new nasal pillows mask for PAP therapy.
223505240|NCT06100835|OTHER|Complex intervention involving physical activity and behaviour change techniques|"The intervention protocol derives from a previous, extensive, co-creation phase involving end-users as well as relatives, experts, professionals working working with older adults, university students and researchers.~It will be based on a structured group-based PA programme supervised by trained professionals, tailored to participants' needs to include joyful components combined with self-management strategies to encourage behaviour change also beyond the sessions. All participants (including end-users but not only) will also be encouraged to join virtual communities of practice (VCoP) for further support and knowledge exchange."
223505241|NCT04813874|DRUG|Nitrous Oxide|Nitrous Oxide Inhalational Agent
223593724|NCT01057563|DEVICE|bare-metal stent (BMS)|BMS implantation
223593725|NCT01057563|DEVICE|Drug (paclitaxel)-eluting balloon (DEB)|BMS implantation followed by post-dilation with DEB
223593726|NCT01005927|DIETARY_SUPPLEMENT|Fructooligosaccharide|Zero or 3 g of a fructooligosaccharide will be administered in a beverage containing 300 mg total calcium as well as 15 mg 44Ca (calcium carbonate). Participants will be given one of the above beverages in addition to intravenously receiving 5 mg 43Ca (calcium chloride)in 10 ml saline.
223593727|NCT00997360|DRUG|PKI-179|
223593728|NCT01150968|BEHAVIORAL|End of life education|Residents will participate in one hour, case-based, interactive teaching sessions on end of life communication.
223593729|NCT04563013|DEVICE|Transcutaneous vagus nerve stimulation|the transcutaneous vagus nerve stimulation was conducted by ear clip with cathode and anode placed at the tragus for 30 min.
223593730|NCT00006656|DRUG|carmustine in ethanol|
223593731|NCT00006656|PROCEDURE|conventional surgery|
223593732|NCT03596450|DRUG|Semaglutide|Participants will be prescribed commercially available semaglutide s.c. and will be instructed to initiate treatment with semaglutide s.c. according to the approved label. The study doctor will determine the intended maintenance dose of semaglutide, as well as changes to the maintenance dose thereafter.
223593733|NCT03596450|DRUG|Standard of care|Participants will receive standard of care, defined as commercially available oral or injectable antidiabetic medication other than semaglutide. Participants will be prescribed and instructed to initiate commercially available antidiabetic medication according to the approved label and, if relevant for the specific antidiabetic medication, adjusted at the discretion of the study doctor.
223593734|NCT04484207|OTHER|A short video intervention|Three minutes video of a veteran that shares his personal story
223593735|NCT04484207|OTHER|A vignette intervention|A written description of the content of the video
223593736|NCT05032339|DIAGNOSTIC_TEST|IUO Plasma Cell Disorders Panel|This Investigational Panel , comprised of 2 reagents , is intended for in vitro diagnostic use for qualitative flow-cytometric immunophenotyping of plasma cell populations. These reagents are used as an aid in the differential diagnosis of hematologically abnormal patients having, or suspected of having, plasma cell disorders.
223593737|NCT03173768|PROCEDURE|ID specialist approval|Appropriateness of intravenous antibiotics ordered by the primary team was assessed by ID specialist. ID fellow modified the intravenous antibiotics ordered by the primary team if those intravenous antibiotics were judged as inappropriate by ID fellow as follows: 1) discontinue intravenous antibiotics (treatment was complete), 2) switch to oral antibiotics, 3) change intravenous antibiotics to cover isolated pathogens, 4) adjust the dose of intravenous antibiotics, and 5) change the duration of intravenous antibiotics. Finally, ID specialist retrospectively assessed the appropriateness of intravenous antibiotics at hospital discharge managed by ID fellow in post-intervention period.
223593738|NCT04499222|DEVICE|Portex|nasotracheal intubation with PORTEX POLAR \[Smiths Medical International, Hythe, United Kingdom\] nasotracheal tube.
223747077|NCT06914843|BEHAVIORAL|Podcast Listening|A curated series of podcasts on topics unrelated to cognitive behavioral therapy or mindfulness, modeled after a similar control from a study of a mindfulness based intervention (Basso et al. 2019). Users are instructed to complete one podcast per day on a digital platform (\~15 minutes/day), 5 days/week for 4 weeks.
224075055|NCT07037641|OTHER|Conventional Physiotherapy|Conventional physiotherapy will consist of hot pack, TENS, therapeutic ultrasound, and supervised exercises applied over two weeks (6 sessions/week). Hot packs filled with silicate gel will be wrapped in four towel layers and applied for 20 minutes with the patient prone and a pillow under the abdomen. TENS will be delivered via Chattanooga Intelect device with a symmetrical biphasic program for 30 minutes using four electrodes placed on the treatment area. Ultrasound will be applied continuously for 3 minutes with the same device. Patients will be instructed on lumbar mobility and strengthening exercises, performed twice daily with 15 repetitions each. No spinal or sacroiliac manipulation will be performed in this group.
223505242|NCT04813874|PROCEDURE|Neuraxial analgesia|Epidural Labor Analgesia Placement
223505243|NCT00512083|DRUG|AS1411|AS1411 IV administration continuously over 7 days. Dose either 10mg/kg/day or 40 mg/kg/day.
223505244|NCT06493565|DEVICE|Routine endoscopic anastomosis inspection|"The routine care pathway for early detection of anastomotic leakage includes:~* C-reactive protein guided imaging~* Rectoscopy of the anastomosis three to six days after surgery~* Rectoscopy of the anastomosis two to three weeks after surgery"
223505245|NCT02130011|OTHER|with feeding/fluid instruction|No additional intervention besides standard treatment prescription will be added. Investigators foresee daily kV cone beam CT matching (already standard in house). this subgroup of 10 patients will be asked not to eat or drink carbonated fluids three hours before CT simulation and daily treatment
223505246|NCT05451888|BEHAVIORAL|Spa treatment|A 40 minute period of lying in the spa treatment pool
223505247|NCT04724200|DIAGNOSTIC_TEST|Echocardiogram|Echocardiography plays a crucial role in the diagnosis of HF; it is the standard of care imaging modality used to confirm the diagnosis, it permits real-time imaging of the heart and quantitative assessment of cardiac structure and function, crucial for diagnosis.
223505248|NCT02966925|DEVICE|Cellular Matrix BCT-HA Kit|Submucosal injections in the vulva, in the posterior vaginal wall and in the perineum of a combination product made of PRP and HA prepared using the Cellular Matrix BCT-HA medical device
223505249|NCT05797090|DRUG|Crystalloid Cardioplegic solution|To compare between conventional crystalloid cardioplegia with modified del Nido cardioplegia in mitral valve regurge replacement surgery.
223505250|NCT04869917|BEHAVIORAL|Decision Aid intervention|"* Displays information about the benefits and risks of ILI and metformin~* Asks open-ended questions: What am I willing to do to prevent T2D? and What do I need to prevent T2D?~* Prompts patients to commit to immediate next steps~* Health educator schedules interested patients for first ILI session or sends message to provider about patients' interest in starting metformin, if chosen"
223505251|NCT04869917|BEHAVIORAL|Text Messaging intervention|"* Defines prediabetes and includes individualized A1c values~* Present benefits and risks of intensive lifestyle intervention and metformin~* States that other prediabetic Erie patients are adopting intensive lifestyle intervention and metformin~* Encourages initiating intensive lifestyle intervention or discussing metformin with provider~* Include selected behavioral content from diabetes prevention program~* Initial message with automatic opt-in, allows opt-out for messages~* Subsequent messages include: information about T2D risk and treatments; prompts to directly schedule intensive lifestyle intervention or office visit to discuss metformin; selected behavioral content from diabetes prevention programming"
223505252|NCT04869917|BEHAVIORAL|Usual Care|Patients receiving care at non-intervention clinic sites will not be exposed to treatment intervention.
223505253|NCT04107363|PROCEDURE|Oropharyngeal aspiration before changing the position of the patient|"Patients in the experimental group underwent oropharyngeal aspiration prior to each position change in addition to routine nursing care (Endotracheal aspiration in case of indication and oropharyngeal aspiration in the follow-up; routine and non-routine position changes every 2 hours during the day and 4 hours during the night; oral care).~Patients in this group underwent oropharyngeal aspiration at least 9 times in 24 hours with a pressure of 100-120 mmHg for 10 seconds prior to routine (2 hours a day, 4 hours a night) and non-routine position changes. After the oropharyngeal aspiration was completed, the patient's position was changed."
223505254|NCT04107363|OTHER|Control group:|The patients in the control group received routine nursing care in the unit. (Endotracheal aspiration in case of indication and oropharyngeal aspiration in the follow-up; routine and non-routine position changes every 2 hours during the day and 4 hours during the night; oral care).
223593739|NCT04499222|DEVICE|Mallinckrodt|nasotracheal intubation with Mallinckrodt TaperGuard \[Covidien, Ireland\] nasotracheal tube.
224310635|NCT03220347|DRUG|CC-90010|CC-90010 is an oral, potent and reversible inhibitor of the epigenetic target bromodomain and extra-terminal (BET) proteins.
223593740|NCT00001410|DRUG|Lysodase|
223593741|NCT04608422|OTHER|Electrical stimulation|A protocol of neuromuscular electrical stimulation will be applied on the quadriceps muscle (symmetric biphasic pulsed current, 80 Hz, 400 µs, 10 s contraction time, 50s/30s/20s rest time, the reciprocal mode, 20 min. After, a protocol of sensory stimulation will be applied on the anatomical region of the kidneys (First: 50 pps, 300 µs, continuous mode for 5 min; Second: 30 pps, 100 µs, continuous mode for 10 min; Third: 20 pps, 1000 µs for 30 min).
223747078|NCT06913439|DIAGNOSTIC_TEST|Exercise Group|technique was implemented with three sets of ten repetitions on each treatment occasion for a period of 3 days/ week for 8 weeks. In this group, the adjustable couch was used to treat the patients effectively. During MWM, position of the patients was prone lying and high sitting position with swinging bilateral leg out of the couch at available various range of motion of affected knee joint. In prone lying position, the therapist was stand just behind the patient towards the affected knee joint. The mulligan belt placed at proximal tibia ends which already wrapped with the lower back of the therapist. In high or couch sitting position, the therapist was sitting on rest chair. The method using of mulligan belt was same as in prone lying position. After stabilization, the mobilization with movement (MWM) started in order with the therapist mobilized the knee joint followed by active movement of knee joint performed by the patients
224075056|NCT04049045|DRUG|Empagliflozin 25 mg|Empagliflozin 25 mg film-coated tablets, for oral use administered once daily for 5 days in addition to routinely administered (weight adjusted) intravenous furosemide
224075057|NCT04049045|DRUG|Placebo|matching Placebo, film-coated tablets, for oral use, matching to investigational product Jardiance® administered once daily for 5 days in addition to routinely administered (weight adjusted) intravenous furosemide
223593742|NCT05082415|DRUG|Brolucizumab|Participants received brolucizumab injection during the index period
223593743|NCT00410605|BIOLOGICAL|bevacizumab|Given IV
223593744|NCT00410605|DRUG|lenalidomide|Given orally
223593745|NCT00410605|DRUG|dexamethasone|Given orally
223593746|NCT01289366|DEVICE|Endocytoscopy|Patients with Crohn's disease and ulcerative colitis who underwent colonoscopy are prospectively included in this study. Methylene blue or toluidine blue is topically applied to enable EC (XEC-120-U, Olympus, Tokyo, Japan). Data are digitally saved and analyzed independently from each other by two gastroenterologists and one pathologist who are blinded to clinical and endoscopic data.
223593747|NCT00164411|BIOLOGICAL|Tetanus-diphtheria toxoids (Td)|
224075058|NCT06888960|BIOLOGICAL|CC312|After a 28-day screening period, subjects who meet the inclusion and exclusion criteria will be enrolled for baseline assessments and biological sample collection prior to the guided administration period. The guided dose of CC312 will be administered via IV infusion on Day -3, followed by safety and tolerability assessments on the third day after the initial administration (i.e., Day -1). The therapeutic dose of CC312 will be administered via IV infusion on Day 1, with subsequent infusions scheduled on Day 4, Day 8, Day 11, Day 15, Day 18, Day 22, and Day 25. Comprehensive safety and tolerability assessments will be conducted at each of these time points.
224075059|NCT07042243|BEHAVIORAL|MyCarePulse and ASCENT PN|The combination of a digital platform and patient navigators assisting the process. Also, taking a multi-level approach engaging community members, patients, and providers in phase one through qualitative interviews. Then using the findings to adapt MyCarePulse for the clincial trial in phase two.
223593748|NCT00164411|BIOLOGICAL|7-valent pneumococcal conjugate vaccine|
223593749|NCT00164411|BIOLOGICAL|23-valent polysaccharide vaccine|
223593750|NCT03468647|OTHER|soles|Volunteer must walk this this connected seamless to measure different walking parameters
223593751|NCT03468647|OTHER|weighting machine|This weighting machine measure weight evolution and equilibrate of volunteers
223593752|NCT03468647|OTHER|gripping force|this machine measure the gripping force of volunteer
224075060|NCT06746415|OTHER|Conventional Gait Training|onventional walking training group will be given 20 minutes of NMES, 20 minutes of weight transfer, stretching, mobilization, bobath exercises and 20 minutes of parallel bar walking exercises. Patients in both groups will be treated 3 days a week, 1 hour a day for 6 weeks.
224075061|NCT06746415|OTHER|Robotic Gait Training|The robot-assisted walking group will receive 20 minutes of NMES, 20 minutes of weight transfer, stretching,mobilization, bobath exercises and 20 minutes of robot-assisted walking exercises. Patients in both groups will be treated 3 days a week, 1 hour a day for 6 weeks
224075062|NCT03505021|DRUG|Levosimendan|Levosimendan 1 mg capsule for oral administration
224075063|NCT03505021|DRUG|Placebo for levosimendan|Placebo capsule for oral administration
224075064|NCT06864143|BIOLOGICAL|mRNA-1083 Composition 1 Dose A Lot A|Sterile liquid for injection
224075065|NCT06864143|BIOLOGICAL|mRNA-1083 Composition 1 Dose A Lot B|Sterile liquid for injection
224075066|NCT06864143|BIOLOGICAL|mRNA-1083 Composition 1 Dose B|Sterile liquid for injection
224075067|NCT06864143|BIOLOGICAL|mRNA-1083 Composition 1 Dose C|Sterile liquid for injection
224075068|NCT06864143|BIOLOGICAL|mRNA-1083 Composition 2 Dose A|Sterile liquid for injection
224075069|NCT06864143|BIOLOGICAL|mRNA-1083 Composition 2 Dose B|Sterile liquid for injection
224075070|NCT06864143|BIOLOGICAL|mRNA-1083 Composition 3 Dose A|Sterile liquid for injection
224075071|NCT06864143|BIOLOGICAL|mRNA-1083 Composition 3 Dose B|Sterile liquid for injection
224075072|NCT06864143|BIOLOGICAL|Influenza Vaccine|Sterile liquid for injection
224075073|NCT06864143|BIOLOGICAL|COVID-19 Vaccine|Sterile liquid for injection
224075074|NCT06864143|BIOLOGICAL|Investigational Influenza Vaccine|Sterile liquid for injection
224075075|NCT06864143|BIOLOGICAL|Investigational COVID-19 Vaccine Lot A|Sterile liquid for injection
224075076|NCT06864143|BIOLOGICAL|Investigational COVID-19 Vaccine Lot B|Sterile liquid for injection
224075077|NCT07062887|BEHAVIORAL|Mindfulness app|Mindfulness app called Calm Health. It has mindfulness guidance modules related to different aspects of physical and mental health, including type 1 diabetes. It also provides a final report to help you track the relationship between mindfulness and your blood sugar, stress, and sleep.
223747079|NCT06913439|COMBINATION_PRODUCT|Parafin Wax Bath|Group B will receive Paraffin Wax Bath Therapy in combination with standard care exercises. In this treatment, the affected knee joint will be immersed in warm paraffin wax to deliver thermotherapy, which helps reduce joint stiffness, improve circulation, and enhance joint mobility. Each paraffin wax session will last 15-20 minutes. Following the thermotherapy, participants will perform standard care exercises targeting knee mobility, flexibility, and strength. These sessions will also occur 3 times per week over a period of 8 weeks.
223747080|NCT06914622|BEHAVIORAL|Mental Health Recovery Star (MHRS)|"The personal recovery-oriented treatment is the Mental Health Recovery Star (MHRS), a recovery-oriented tool developed in England to support and monitor personal recovery. It features a 10-point star representing life dimensions grouped into four areas: health, functioning, self-image, and social networks. Residents assess their progress on each point using a Scale of Change  with five recovery stages, from feeling stuck to self-reliance.~After assessment, residents and professionals set recovery goals (up to three at a time) and create a shared care plan.~The MHRS shows good psychometric properties, with strong validity, consistency, and ease of use, despite some inter-rater reliability issues. It is best suited for shared rehabilitation plans rather than clinical monitoring.~Peer review meetings will be provided. The personal recovery-oriented treatment will last six months and will be considered complete upon follow-up evaluation."
223747081|NCT06914830|OTHER|Musical video demonstration with virtual reality glasses|The research was explained to the patient before the operation. The patient was started to watch a video with music with virtual glasses at the 5th minute of the operation and watched it throughout the operation. Two hours after the surgery, the patient who underwent ureteroscopy completed the Data Collection Form, Surgery Specific Anxiety Scale and Perianesthesia Comfort Scale.
223747082|NCT06913725|DRUG|FCN-159|An investigational oral MEK inhibitor
223747083|NCT06914466|PROCEDURE|Deep Brain Stimulation|Deep Brain Stimulation
223747084|NCT06913816|DIAGNOSTIC_TEST|Grouyp 1 (without blinking exercises).|Group B (Control Group) The control group will continue receiving only the routine rehabilitation (without blinking exercises). Routine rehabilitation included the 20-20-20 rule, blue light-blocking glasses, and polyvinyl alcohol eye drops.
223747085|NCT06913816|COMBINATION_PRODUCT|EXP group (Routine CVS treatment)|"Group A (Experimental Group): Individuals in the Experimental group will receive Routine CVS treatment with optimized blinking exercise.~Routine rehabilitation includes the 20-20-20 rule, blue light-blocking glasses, and polyvinyl eye drops.~The blinking exercise involved the individuals looking at an object 6 meters away for 5 seconds, followed by complete eyelid closure for 5 seconds. This cycle was repeated for 5 minutes, twice a day."
223747086|NCT06913582|BEHAVIORAL|Yoga|A 12-week pregnancy yoga program was delivered to experimental group (n=30) including one weekly 60-minute remote online yoga class and followed by 2 times of DVD yoga exercise.
223505255|NCT06494982|PROCEDURE|Sacrospinous hysteropexy with the synthetic mesh, vaginal flap and anterior colporrhaphy|Sacrospinous hysteropexy with the synthetic mesh, vaginal flap and anterior colporrhaphy
223505256|NCT06494982|PROCEDURE|Sacrospinous hysteropexy with the synthetic mesh and anterior colporrhaphy|Sacrospinous hysteropexy with the synthetic mesh and anterior colporrhaphy
223505257|NCT05632900|PROCEDURE|Endoscopic ultrasound guided drainage of walled off pancreatic necrosis|It is Therapeutic procedure to treat walled off pancreatic necrosis.
223505258|NCT00779883|BIOLOGICAL|ISF35|Subjects participating in this study will receive a single dose of 1x10\^8, 3x10\^8, or 1x10\^9 autologous Ad-ISF35-transduced CLL B cells.
223505259|NCT05565404|BEHAVIORAL|mobile health|Scaling and root planing, interdental brushing demonstration and regular text messages in type 2 embrasure patients.
223505260|NCT05565404|PROCEDURE|Scaling and root planing+Interdental aid|Scaling and root planing, interdental brushing demonstration in type 2 embrasure patients.
223505261|NCT00513864|DRUG|Dextromethorphan|one time dose - 0.3mg/kg PO
223505262|NCT00513864|DRUG|Codeine|one time dose - 2mg/kg PO
223505263|NCT00513864|DRUG|Morphine|one time dose - 0.15mg/kg IV
223505264|NCT04915066|OTHER|Medical data collection|Collection of medical data from patients'medical records
223505265|NCT03745456|DIAGNOSTIC_TEST|Blood samples for ROTEM and platelet function.|Thormoboelastometry is based on the measurement of elasticity of blood by continuous graphical logging of the firmness of a blood clot during clot formation and subsequent fibrinolysis
223505266|NCT01524458|PROCEDURE|Per-Oral Endoscopic Myotomy|To perform myotomy for lower esophageal sphincter using endoscope through a long submucosal tunnel
223505267|NCT04038658|BEHAVIORAL|Move-It|
223505268|NCT00372515|DRUG|Gefitinib|On days 1-14 gefitinib will be taken orally daily at either 750, 1000, or 1250mg (depends upon when subject entered trial). If medication is tolerated well, subject will take 500mg daily on days 15-28 of each 28-day cycle. Cycles (higher dose followed by lower dose) will be repeated as long as subject's cancer does not worsen and they do not experience any serious side effects.
223505269|NCT03335267|DRUG|CPX-351|Cytarabine:Daunorubicin Liposome Injection
223505270|NCT02923622|OTHER|Traditional Chinese medicine herbals|TCM herbal treatment based on TCM syndrome differentiation，without any anti tumor therapy in Western Medicine
223505271|NCT02923622|OTHER|Integrated traditional Chinese and Western medicine|TCM herbal treatment combine with anti tumor therapy in Western Medicine ( including non recommended chemotherapy, radiotherapy and targeted therapy in clinical guidelines)
223505272|NCT02923622|OTHER|Western medicine|Anti tumor therapy in Western Medicine ( including non recommended chemotherapy, radiotherapy and targeted therapy in clinical guidelines)
223505273|NCT05022862|BEHAVIORAL|Usual Care|Medication is dispensed to participant at each visit in 30-60 day supplies by Baltimore City Health Department (BCHD) nurses. For study participants, medication dispensation will occur in medication bottles with MEMS Caps, supplied by the study.
223505274|NCT05022862|BEHAVIORAL|Video Directly Observed Therapy alone|Usual care plus Video-DOT using the emocha platform, a HIPAA compliant commercial platform for video based DOT. The app allows a secure/encrypted video recording to be taken as the participant ingests the medication. Electronic text reminders will be sent to the participant on the smart phone when it is time to take the medication. The participant will record a video of the pill ingestion process. Study staff will verify each video to confirm the video shows the correct person and that the pill was ingested appropriately (according to standardized approach involving visualization of the pills, ingestion and observation of an empty mouth after ingestion).
224196146|NCT04327245|OTHER|Intervention ingest a 15,3 mg of stevia|"Woman with resistance insulin who ingest a 15,3 mg of stevia (steviol glycosides). The word stevia refers to the whole plant of Stevia rebaudiana Bertoni (SRB), only some of the components of the stevia leaf are sweet. Steviol glycosides are up to 300 times sweeter than sucrose, do not provide calories and can be used as a substitute for sucrose or as a non-nutritive sweetener alternative. Your allowable daily intake is 4 mg / kg / body weight (expressed as steviol)"
224196147|NCT03489460|BEHAVIORAL|Specialized sleep-related message interventions|Over the course of 2 weeks' participants will receive specialized sleep-related message interventions to encourage sleep awareness via the smartphone application.
224196148|NCT03489460|BEHAVIORAL|GAD|Survey responses will be merged with objective GAD data (sleep time, time in deep sleep, physical activity) which will assist in developing message design formats for message testing.
224196149|NCT04430491|DIAGNOSTIC_TEST|radiomics|The high-throughput extraction of large amounts of quantitative image features from medical images
224196150|NCT02218619|DRUG|Tauroursodeoxycholic Acid (TUDCA)|TUDCA at 1750 mg/day x 12 months
224196151|NCT02218619|DRUG|Sugar Pill (placebo)|Placebo
224196152|NCT04369443|PROCEDURE|Large volume Acute Normovolemic Hemodilution|Following induction of anesthesia, the volume of blood to be removed during Acute Normovolemic Hemodilution was calculated using an established formula:V=Weight（Kg）×12-15（mL/Kg）;Blood to be removed was capped at： Vmax=EVB×(Hi-Hf)/Hav（EBV= estimated blood volume （male:70mL/Kg，female:65mL/Kg）；Hi= initial hemoglobin ；Hf=target Hb（ 10g/dL ）；Hav= the average of the initial and minimal allowable hemoglobin）.Ensure the volume of removed blood does not exceed the upper limit and Hb ≥10g/dL after blood removed.
224196153|NCT02215915|PROCEDURE|Angiography|The size and number of stents and post-dilation will be determined on physician's discrete within the range allowed in this study protocol. All procedure will be performed according to current standard technique. Additional stent implantation or post dilation will be allowed according to attending physician's discrete. IVUS will be not used in this arm.
224196154|NCT02215915|PROCEDURE|IVUS|The size and number of stents and post-dilation will be determined on physician's discrete within the range allowed in this study protocol. All procedure will be performed according to current standard technique. IVUS will be used to assess the anatomic characteristics of lesion and determine appropriate stent size and length. Additional stent implantation or post dilation will be allowed according to attending physician's discrete based on IVUS results.
224196155|NCT02215915|PROCEDURE|DES implantation|
224196156|NCT04600115|DRUG|Adenosine|Adenosine: 0.14mg/kg/min for 6 min. IV injection for MRI perfusion
224196157|NCT04600115|DRUG|Regadenoson|0.4mg in 5ml, given as a rapid (10 seconds) IV injection for MRI perfusion.
224196158|NCT04600115|DRUG|O-15 labeled radioactive water|O-15 labeled radioactive water: Up to 50mCi IV injection at rest and again at hyperemia for PET Imaging
224196159|NCT04600115|DEVICE|MRI|Pass dynamic contrast enhanced MRI scans will be performed at rest and during hyperemia caused by either adenosine infusion or regadenoson
223593753|NCT04836247|BEHAVIORAL|Disclosing Recovery: A Decision Aid and Toolkit|Participants will be guided through a workbook and accompanying worksheet designed to help them: (1) decide whether or not they want to share information about their substance use with others, and (2) build skills for disclosing (e.g., planning what to say). Importantly, the intervention is not designed to encourage participants to disclose or not disclose, but rather to help participants decide whether they want to disclose based on their own goals and values.
223593754|NCT04836247|BEHAVIORAL|Mindfulness|Participants will be able to choose from several guided meditations to promote mindfulness
224196160|NCT04600115|DEVICE|PET Imaging|Quantitative PET imaging with O-15 labeled radioactive water will be given at a different day
224196161|NCT02917369|OTHER|Normal lung tissue|The investigators will extract total protein, DNA and RNA from LCLC patients.
224196162|NCT04229342|PROCEDURE|Per-oral endoscopic myotomy|"Per-oral endoscopic myotomy (POEM) is an endoscopic modality for the management of achalasia cardia. In this study, we will evaluate the impact of two different techniques of posterior POEM on the incidence of gastroesophageal reflux disease (GERD).~Posterior POEM will be performed using the standard technique. The myotomy beyond the GEJ will be different in the two groups. In one group, the sling fibers will not be spared from dissection and in the second group, the sling fibers will be selectively spared from myotomy."
224196163|NCT06709612|DRUG|AMT-143 hydrogel containing containing ropivacaine|AMT-143 is provided as a hydrogel containing 385 mg/mL ropivacaine (on a ropivacaine HCl equivalence basis). AMT-143 hydrogel will be provided as pre-filled syringes for administration via instillation into the surgical site after surgery and prior to suture.
224196164|NCT06709612|DRUG|Ropivacaine|5 mL Ropivacaine 10 mg/mL (1%) solution
223593755|NCT02968147|DEVICE|High frequency jet ventilation|General anaesthesia and ventilation with the Acutronic Monsoon III Jet ventilator system
223747087|NCT06913296|PROCEDURE|parathyroidectomy|typical open parathyroidectomy
223747088|NCT06912958|DIETARY_SUPPLEMENT|Drinking of matcha tea|Japanese tea that will take twice daily for one month
223747089|NCT06912958|DIETARY_SUPPLEMENT|Organic Japanese Matcha, Jade Leaf, Japan|dietary intake
224196165|NCT06709612|OTHER|Placebo|Saline Placebo
224310636|NCT02433054|DEVICE|CE-certified dedicated venous stents|Implantation of self-expanding nitinol venous stents in the iliofemoral veins and/or inferior vena cava.
223747090|NCT06913621|DRUG|amino acid formula|amino acid formula for 6 months
224196166|NCT06716008|OTHER|Aerobic training|For twelve weeks, the women in the study group will participate in aerobic training on cycle ergometer. Each session will consist of 30-45 minutes of cycling at a moderate intensity, accompanied by a workout heart rate ranging from 65% to 75% of the maximal heart rate and ranging between 12 and 14 on the Borg rating of perceived exertion 20-point scale. After ten minutes of warm-up, every session will end with a brief 3-minute period of cool-down.
224310637|NCT05009680|DRUG|GB1211|GB1211 is a galectin-3 inhibitor an orally available small molecule anti-fibrotic. It is administered orally twice a day
224310638|NCT05009680|DRUG|Placebo|Placebo is administered orally twice a day
224310639|NCT04695145|BEHAVIORAL|Aerobic exercise in group|"Progression~The goal with every new week should be making every workout a little bit harder than the week before.~Strength sessions~* Week 1-6: 12-18 reps x 2 set per exercise and muscle 30 s rest between exercises~* Week 7-12: 10-12 reps x 3 set per exercise and muscle 20 s rest between exercises~Adding weight with gym equipment or changing body position in the exercises to succeed with the rep scheme and making it harder as the group develop their physical and mental ability.~Conditioning sessions~* Week 1-6: 75 seconds work time x 1 set per exercise 30 seconds of rest between exercises~* Week 7-12: 50 seconds work time x 2 set per exercise 20 seconds of rest between exercises~Mixed sessions~* Week 1-6: 35 s work time per exercise 25 s rest between exercises x 2 rounds~* Week 7-12: 45 s work time per exercise 15 s rest between exercises x 2 rounds"
224310640|NCT04695145|BEHAVIORAL|Group sessions with leisure activities|The control group will receive leisure activity in a group setting for one hour three times a week for 12 weeks. The sessions will be held at the same weekdays and about the same hours as the exercise group sessions. The same group leaders as in the exercise sessions will participate in leisure sessions and will support the adolescents through reminders and reassurance before and during the sessions to enhance adherence. The sessions will start with a check in on feelings, recent events and difficulties (i.e. supportive listening but not any interventions) followed by non heart rate increasing activities, such as playing games or watching movies together.
224310641|NCT03433898|DRUG|BI 754091|Solution for infusion
224310642|NCT03433898|DRUG|BI 754111|Solution for infusion
224310643|NCT05226546|DRUG|Platelet rich plasma (PRP)|PRP injections were performed in each olfactory cleft by nasal endoscopy and under local anesthesia, a sniffing stick test was performed before the injection and one month after
224310644|NCT05226546|OTHER|olfactory training|"The investigators compare the result of the PRP group to a control group how underwent simple olfactive training for one month.~The control group matched for age, gender and olfactory score at baseline. The patients had a sniffing stick test at the beginning and also after one month of olfactory training."
223505275|NCT05022862|BEHAVIORAL|Video Directly Observed Therapy plus Financial Incentives|Usual care plus video-DOT and financial incentives contingent on adherence verified by video DOT. The amount of the financial incentive that can be earned for future verified doses decreases after a missed dose (video). The amount of the financial incentives increases incrementally back to baseline amount after verification of medication ingestion according to the prescribed schedule for several consecutive doses.
223747091|NCT06913621|DRUG|low bile acid binding blenderized diet|low bile acid binding blenderized diet for 6 months
224196167|NCT06716008|OTHER|Manual Diaphragm Release|The participant will assume a supine position with relaxed limbs. The therapist should position themselves at the head of the participant and make manual contact with the pisiform, hypothenar region, and the last three fingers on both sides, underneath the seventh to tenth rib costal cartilages. The therapist's forearms should be aligned towards the participant's shoulders. During the inspiratory phase, the therapist gently pulled the points of contact with both hands in the direction of the head and slightly laterally, accompanying the elevation of the ribs. Therapist progressively increases the depth of their contact within the costal margin.
224196168|NCT01882036|PROCEDURE|Gastric Bypass w/ matched hypocaloric diet|Roux en Y Gastric Bypass with Hypocaloric liquid diet for 10 days
224196169|NCT01882036|OTHER|Hypocaloric diet|Hypocaloric liquid diet for 10 days
224196170|NCT04129736|DRUG|Teriflunomide 14 MG|Blood and cerebrospinal fluid is obtained from teriflunomide treated patients with multiple sclerosis
224196171|NCT06722469|OTHER|WCI|The WCI group will receive automated messages based on the Health Belief Model (HBM) and Protection Motivation Theory (PMT), including personalized risk assessments, educational videos featuring medical professionals and relatable scenarios, and tailored prompts to encourage mammographic screening.
223505276|NCT01853085|DRUG|Bimatoprost Ophthalmic Solution|Patients with primary open angle glaucoma (POAG) or ocular hypertension (OHT) treated with Lumigan® UD (bimatoprost ophthalmic solution) administered in accordance with physician standard practice for up to 12 weeks.
224196172|NCT06724653|DRUG|RAS blocker tapering group|RAS blocker tapering out
224196173|NCT06724653|DRUG|Beta blocker tapering out|Beta blocker tapering out group
223505277|NCT00502879|DRUG|Enbrel (etanercept)|
223747092|NCT06913621|DRUG|high bile acid binding blenderized diet|high bile acid binding blenderized diet for 6 months
223747093|NCT06913803|DIAGNOSTIC_TEST|Stretching|The group A contains 34 patients and received STM for twice a week for three weeks with each session lasting approximately 20 min.focusing on mobilizing soft tissue to enhance circulation, reduce scar tissue and improve tissue flexibility.
223747094|NCT06913803|COMBINATION_PRODUCT|Soft Tissue Mobilization|Group B received both STM and stretching twice a week for three weeks with each session lasting approximately 20 min.encourage the patient to breathe deeply and slowly to promote relaxation.The stretching of tight muscles 1 set of 10 repetitions hold of 5 second of each exercise,then breathing for 1 min
224196174|NCT07043855|DRUG|single dose preoperative antibiotic|Arm A is a single preoperative dose of cefazolin administered immediately before surgery
224310645|NCT02817945|DRUG|68Ga-NOTA-3P-TATE-RGD|68Ga-NOTA-3P-TATE-RGD were injected into the patients before the PET/CT scans
224310646|NCT03478527|DIETARY_SUPPLEMENT|Vivomixx® powder|Participants will take in a daily dose of 4.4g for 28 consecutive days
224310647|NCT03478527|OTHER|Placebo powder|Participants will take in a daily dose of 4.4g for 28 consecutive days
224310648|NCT00977886|DRUG|Placebo|Oral, 10 days
224310649|NCT00977886|DRUG|ELB353|Oral, 10 days
224310650|NCT03384082|PROCEDURE|hysteroscopic treatment|treatment
224310651|NCT02968849|BIOLOGICAL|ALVAC-HIV (vCP2438)|Expresses the gene products ZM96 gp120 (clade C strain) linked to the sequences encoding the HIV-1 transmembrane anchor (TM) sequence of gp41 (28 amino acids clade B LAI strain) and gag and pro (clade B LAI strain). It is formulated as a lyophilized vaccine for injection at a dose \> 10\^6 cell culture infectious dose 50% (CCIDv50) and \< 1 × 10\^8 CCIDv50 (nominal dose of 10\^7 CCIDv50) and is reconstituted with 1 mL of sterile sodium chloride solution (NaCl 0.4%) delivered IM
224310652|NCT02968849|BIOLOGICAL|Bivalent Subtype C gp120/MF59|Subtype C TV1.C gp120 Env and 1086.C gp120 Env proteins, each at a dose of 100 mcg, mixed with MF59 adjuvant (an oil-in-water emulsion) and delivered IM
224310653|NCT02968849|BIOLOGICAL|Placebo|Sodium Chloride for injection, 0.9% delivered IM
224196175|NCT07043855|DRUG|Prolonged perioperative antibiotics|Preoperative Single-Dose Cefoxitin followed by Three-Day Cefotaxime and Metronidazole Prophylaxis
224310654|NCT03510780|PROCEDURE|Periodontal surgery with Enamel Matrix Derivative|Patients will be treated by periodontal surgical flaps with the addition of EMD + bone graft
223505278|NCT01078545|DRUG|Leuprolide acetate Depot Susp. 11.25 mg (Poland), 3.75 mg (Ukraine)|Leuprolide acetate 11.25 mg every 3 months sc or im, number of injections during the trial - 5 in Poland, Leuprolide acetate 3.75 mg every 1 month sc or im, number of injections during the trial - 12 in Ukraine.
223593756|NCT02968147|DEVICE|Conventional ventilation|General anaesthesia and ventilation with a conventional Phillips intermittent positive pressure ventilator system
223593757|NCT03589222|DRUG|Selinexor|Selinexor will be administered via oral at flat dose of 100 mg weekly in 4 out of each 4-week cycle
224196176|NCT06878612|BIOLOGICAL|Polyphenol whole tumor cell vaccine|3 patients enrolled in each dose group, and planned dose groups of 5 x 10\*6, 2 x 10\*7, and 5 x 10\*7 cells/dose. The dosing regimen consisted of 5 doses of basal immunization and subsequent individualized treatment. In the basal immunization, the administration times were D0, D14, D28, D42, and D56. After completion of the 5 doses of basal immunization, the subsequent individualized treatment was decided by the investigator based on the subject's tumor assessment, i.e., 1 vaccination per month for a total of 4 doses.
224196177|NCT07042880|OTHER|No intervention|No intervention
224196178|NCT06724250|DEVICE|Biofeedback therapy|Biofeedback therapy involves the use of specialized equipment to provide real-time feedback on pelvic floor muscle activity. Participants are trained to improve muscle coordination and relaxation through guided exercises, targeting the resolution of dyssynergic defecation.
224196179|NCT06724250|DRUG|Botulinum Toxin A (Botox )|Botulinum toxin is injected into the pelvic floor muscles to reduce muscle overactivity and improve coordination, aiming to relieve symptoms of dyssynergic defecation.
224196180|NCT06724744|OTHER|Aerobic training|For twelve weeks, the women participate in aerobic training on cycle ergometer. Each session consists of 30-45 minutes of cycling at a moderate intensity, accompanied by a workout heart rate ranging from 65% to 75% of the maximal heart rate and ranging between 12 and 14 on the Borg rating of perceived exertion 20-point scale. After ten minutes of warm-up, every session ends with a brief 3-minute period of cool-down.
224310655|NCT03510780|PROCEDURE|Periodontal surgery with Platlet Rich fibrin|Patients will be treated by periodontal surgical flaps with the addition of PRF + bone graft
224310656|NCT03877991|DRUG|CBD-sesame oil capsule|A capsule containing cannabidiol dissolved in sesame oil and surfactant vehicle.
224310657|NCT03877991|DRUG|CBD-LNL capsule|A capsule containing Cannabidiol dissolved in self nano emulsifying formulation
223505279|NCT02497755|BEHAVIORAL|App for smartphone|A smartphone app will send psychoeducation and reminders to patients to complete self-report data, will collect passive data, and will provide aggregated information to a provider dashboard.
223505280|NCT02497755|DEVICE|smartphone|
223593758|NCT03589222|DRUG|Daratumumab|daratumumab at dose of 16 mg/Kg iv weekly on days 1, 8, 15 and 22 during the first two cycles; on days 1 and 15 (Q2W) during the cycles 3 to 6; and on day 1 (Q4W) thereafter
223593759|NCT03589222|DRUG|Bortezomib|bortezomib will be given via subcutaneous at dose of 1.3 mg/m2 on days 1, 8, 15 and 22 starting from the first cycle and on days 1 and 15 (Q2W) since cycle 9
223593760|NCT03589222|DRUG|Dexamethasone|dexamethasone is 20mg (IV) when given on days that daratumumab is administered (as pre-infusion medication) plus 20 mg of dexamethasone (VO) the day after and the dose of dexamethasone is 40mg (VO) on days when daratumumab is not administered
223593761|NCT03085745|OTHER|Transcranial Magnetic Stimulation (TMS)|TMS is a non invasive brain stimulation technique which allows to measure corticospinal excitability from peripheral muscles.
223593762|NCT05228561|OTHER|Mobile Application Supported Nutrition and Diabetes Education|With this intervention, the difference between the mobile application supported nutrition diabetes education created with written and visual (video) and face-to-face nutrition and diabetes education will be found.
223593763|NCT04855383|DRUG|The effect of intramuscular injection of triple doses of human chorionic gonadotropin in frozen embryo transfer cycles|Patients receive 5,000 IU of human chorionic gonadotropin by intramuscular injection, 72 hours before embryo transfer, on the day of embryo transfer, and 72 hours after embryo transfer.
223593764|NCT04751877|DRUG|Isatuximab|Isatuximab by IV route, per 28 days cycle - Cycle1: 10 mg/kg on days 1, 8, 15, and 22. Cycles 2 to 12: 10 mg/kg on days 1 and 15. From cycle 13: 10 mg/kg on day 1.
223593765|NCT04751877|DRUG|Lenalidomide|Lenalidomide by oral route, per 28 days cycle - 25 mg daily on days 1-21.
223593766|NCT04751877|DRUG|Bortezomib|Bortezomib sub-cutaneous, per 28 days cycle - Cycles 1 to 12: 1.3 mg/m2 on days 1, 8, 15. Cycles 13-18: 1.3 mg/m2 on days 1, 15.
224310658|NCT03877991|DRUG|CBD powder form capsule|Powder of Cannabidiol filled in a hard gelatin capsule, without formulation.
224310659|NCT00801580|DRUG|doxorubicin liposomal|"* Cyclophosphamide~* Mesna~* Methotrexate~* Doxorubicin liposomal~* Vincristine~* Dexamethasone~* Rituximab~* Cytarabine"
224310660|NCT00506584|DIETARY_SUPPLEMENT|Pasteurized human milk and pasteurized human milk fortifier|Human milk fortifier is initiated when nutrition volume reaches 100 mL/kg/day
224310661|NCT00506584|DIETARY_SUPPLEMENT|Pasteurized human milk and pasteurized human milk fortifier|Human milk fortifier is initiated when nutrition volume reaches 40 mL/kg/day
223505281|NCT05230927|OTHER|Multidisciplinary Rehabilitation|All patients admitted to an inpatient rehabilitation program will undergo medical history collection, physical, clinical, and functional examination, exercise testing, educational sessions, exercise training (cycle ergometer/treadmill, arm ergometer, breathing, and strength exercises where indicated, calisthenics exercises), psychological counseling, and metabolic evaluation with a personalized diet when needed.
223505282|NCT01303497|DRUG|Paclitaxel|Day 1, 8 and 15 : Paclitaxel 90 mg/m², IV over 1h, during 6 cycles (1 cycle = 28 days)
223505283|NCT01303497|DRUG|Bevacizumab|"Bevacizumab until progression or inacceptable toxicity :~* During the cycles of chemotherapy : Day 1 and D15 : 10 mg/kg,IV~* After 6 cycles of chemotherapy : 15 mg/kg, IV"
223505284|NCT02864914|DRUG|Empagliflozin|drug
223505285|NCT02864914|DRUG|DPP-4 inhibitors|drug
223505286|NCT03695835|DRUG|Immunotherapeutic Agents|Antigen exposure immediately followed by in situ injection of combination of immunotherapeutic agents
223593767|NCT04751877|DRUG|Dexamethasone|Dexamethasone by oral route, per 28 days cycle - 20 mg daily on days 1, 8, 15 and 22.
223593768|NCT00988364|DRUG|Simvastatin|Simvastatin 20mg daily for 3 months.
223593769|NCT00988364|DRUG|Vytorin|Vytorin 20/10mg daily for 3 months.
223593770|NCT00988364|DRUG|Placebo|Placebo one tablet daily times 3 months.
223593771|NCT00988364|DRUG|Ezetimibe|Ezetimibe 10mg daily for 3 months.
223593772|NCT03821194|OTHER|Gua sha|Scrape the skin around the knee joint
223593773|NCT03821194|OTHER|hot pack|hot pack
223593774|NCT02474407|DRUG|diazepam nasal spray|
223505287|NCT03695835|DEVICE|Ablation|Antigen exposure immediately followed by in situ injection of combination of immunotherapeutic agents
223505288|NCT00561327|DRUG|losartan|Daily treated with losartan 100mg for at least the past 2 months (retrospective, no new drug treatment/ intervention)
223505289|NCT01774370|DRUG|Pradaxa (Dabigatran etexilate mesilate)|110 mg or 150 mg b.i.d.
223505290|NCT05436288|DRUG|KIO-201, a Crosslinked Thiolated Carboxymethyl Hyaluronic Acid 0.75% (CMHA-S)|KIO-201 is a stand-alone drug therapy that acts as a barrier that minimizes mechanical lid friction and mechanically protects the ocular surface thereby reducing repeat injury and providing an environment that enables the body to repair the ocular surface whether the corneal epithelial defects are large or small.
223505291|NCT02736214|BEHAVIORAL|Reproductive Life Plan (RLP)|A structured discussion based on the RLP, including information about reproduction and a brochure with the same information.
223505292|NCT03948386|DRUG|isobaric bupivacaine|The anesthesiologist and CRNA or resident performing the spinal will perform spinal anesthesia according to standard operating procedures with the randomly assigned local anesthetic.
223505293|NCT03948386|DRUG|hyperbaric bupivacaine|TThe anesthesiologist and CRNA or resident performing the spinal will perform spinal anesthesia according to standard operating procedures with the randomly assigned local anesthetic.
223505294|NCT03948386|DRUG|isobaric mepivacaine|The anesthesiologist and CRNA or resident performing the spinal will perform spinal anesthesia according to standard operating procedures with the randomly assigned local anesthetic.
223505295|NCT02128750|OTHER|contrast echographie with hexafluorur of sulfur|Echography of contrast after injection of product of contrast (sonovue (r))
223593775|NCT02474407|DRUG|diazepam rectal gel|
223593776|NCT05477797|DRUG|Ixazomib DX/Lenalidomide DX|After assessment of risk stratification，patients will be assigned to Id or Rd group randomly for maintenance therapy. Then they will be reviewed the efficacy monthly.
223593777|NCT04078984|OTHER|Experimental|"* Daily measures of End Inspiratory Pressure with respiratory synchronisation optimised by use of EAdi~* Daily spontaneous breathing trial using low levels of pressure support~* Pplat, Respiratory System Compliance, Driving Pressure, PEEP, Tidal Volume will be monitored daily as well as clinical and other routine ventilatory data. Data concerning initial severity of ARDS, and duration of ARDS, controlled mechanical ventilation, sedation and neuromuscular blockade and date of first spontaneous breathing trial will be collected. A weaning test will be conducted daily."
223593778|NCT01505439|DRUG|solifenacin|oral
223593779|NCT01407445|DRUG|Placebo|1 tablet/ oral/ 3 times a day for 90 days
223593780|NCT01407445|DRUG|Tribulus terrestris|1 tablet of 250mg/ oral/ 3 times a day for 90 days
223593781|NCT02854748|DRUG|Empagliflozin 25mg|Empagliflozin 25 mg QD for 5 days
223593782|NCT02854748|DRUG|Lobeglitazone 0.5mg|Lobeglitazone 0.5mg QD for 5 days
223593783|NCT02854748|DRUG|Empagliflozin 25mg/Lobeglitazone 0.5mg|Empagliflozin 25 mg + Lobeglitazone 0.5mg QD for 5 days
223593784|NCT06334068|OTHER|Short-term glycemic control group|Patients will be admitted to the hospital for 2-3 days before surgery. During this pilot study, patients will be admitted to the intermediate care unit to monitor and control preoperative blood glucose. We aim to maintain moderate glucose control (140-180 mg/dl) using the basal-bolus insulin protocol, plus correctional doses as needed.
223593785|NCT06334068|OTHER|Standard-of-care group|Patients will be admitted the day before surgery with the usual patient treatment.
223593786|NCT00609739|DRUG|cyclosporine|Patients will receive CSA therapy beginning on day -3, with a taper commencing on day +60 (unless GVHD) and ending on day +90. For patients \>40 kg with normal renal function (creatinine \<1.3 mg/dL), the initial dose will be 2.5 mg/kg intravenously (IV) over 2 hours every 12 hours. For children \<40 kg, the initial dose will be 2.5 mg/kg IV over 2 hours every 8 hours.
223593787|NCT00609739|DRUG|cytarabine|3000 mg/m\^2 intravenously (IV) over 2 hours x 2 (i.e. total 6000 mg/m\^2/day) on days -9 through -4.
224310662|NCT00506584|DIETARY_SUPPLEMENT|Human milk fortifier (bovine-based), pre-term formula|Bovine-based human milk fortifier is initiated when nutrition volume reaches 100 mL/kg/day
223505296|NCT02763358|DEVICE|Bite Counter|This study is a 15-week assessment of the possible utility of a wrist-worn device, the Bite Counter, in assisting the weight loss behavior change efforts of overweight and obese individuals. The Bite Counter tracks and analyzes wrist motions to identify those associated with taking bites of food and drinking beverages. It also has a step-counter feature. This study is designed to determine if using the Bite Counter with specific goals to reduce the numbers of bites and increase the numbers of steps will result in those changes.
223505297|NCT02804646|DRUG|recombinant human endostatin|endostar was continuous intravenous transfusion for 7 days，with the dose of 15mg/m2 for one day
223505298|NCT02804646|DRUG|pemetrexed plus cisplatin or carboplatin|the dose of pemetrexed was 500mg/m2 on day 1 of every 21 days,plus cisplatin or carboplatin.
223505299|NCT03645447|DIAGNOSTIC_TEST|Taste test|A pseudo-randomised series of taste solutions are presented to the participant for identification as sugar or water, in order to establish their taste threshold.
223505300|NCT01937442|DRUG|Thalidomide Celgene™|200mg once daily and by mouth
223505301|NCT03886623|PROCEDURE|4-day systematic oral hygiene|he intervention proposed would include a 4-5 day systematic oral hygiene program. Using a pea-sized amount of Colgate Total Clean Mint Toothpaste with a Battery-operated Oral-B Pro-Health Type 3744 toothbrush, all surfaces, tongue-side, check-side, and biting surfaces of the participants teeth will be brushed. The tongue will be brushed with a GUM Dual Action Tongue Cleaner and flossing will be done with GUM Flossmate handle and Oral B Guide Floss in between the contacts of each tooth. The mouth will then be rinsed with Crest Pro-Health mouthwash rinse for 30 seconds twice daily. A Medline Remedy Phytoplex lip balm will then be applied.
223747095|NCT06913829|COMBINATION_PRODUCT|base-out exercising prisms|"Participants in the experimental group will use base-out exercising prisms as their primary intervention. This involves:~1. Procedure:~   * Wearing customized prism glasses designed to increase the convergence demand during near tasks.~  * Performing near vision activities such as reading or viewing objects while wearing the prisms.~2. Schedule:~   * Prisms will be prescribed based on individual clinical measurements.~  * Participants will use the prisms during near tasks for 15-20 minutes daily, 5 days a week, for a total duration of 6 weeks.~3. Monitoring:~   * Initial training will be provided to ensure proper use of the prisms.~  * Adherence will be checked during weekly follow-up visits, where adjustments to the prism strength will be made if necessary."
224196181|NCT06724744|OTHER|Manual Diaphragm Release|The participant is asked assume a supine position with relaxed limbs. The therapist should position themselves at the head of the participant and make manual contact with the pisiform, hypothenar region, and the last three fingers on both sides, underneath the seventh to tenth rib costal cartilages. The therapist's forearms should be aligned towards the participant's shoulders. During the inspiratory phase, the therapist gently pulled the points of contact with both hands in the direction of the head and slightly laterally, accompanying the elevation of the ribs. Therapist progressively increases the depth of their contact within the costal margin.
224196182|NCT06722820|DRUG|LPH-5|LPH-5
224196183|NCT06722820|DRUG|Placebo|Placebo
224196184|NCT06723977|OTHER|Auditory Hallucination Based Voice Hearing Simulation|"1. st stage: Preparation of the environment, introduction, providing information about the purpose, duration and content of the application, application of data collection tools and distribution of the information brochure were provided.~2. nd stage: Introducing the recording devices and headphones, performing the first task simultaneously while listening to the prepared three-dimensional sound recording (watching a city promotional film and answering verbal questions about this film), performing the second task simultaneously while listening to the prepared three-dimensional voice recording (telling a story). (reading the text and answering the questions about this story text in writing) were applied.~3. rd stage: Information about the next application time of the measurement tools was provided.~Additional stage: Data collection tools were reapplied."
223593788|NCT00609739|DRUG|filgrastim|Patients with absolute neutrophil count (ANC) \<0.2 x 10\^8/L on day 21 may receive G-CSF at 5 mcg/kg/day. G-CSF will be continued until ANC ≥2.5 x 10\^8/L for two consecutive days. As the malignant cell population of JMML is known to be hypersensitive to GM-CSF, this cytokine will not be given to these patients.
223593789|NCT00609739|DRUG|methotrexate|MTX will be administered to recipients of non-genotypically identical BMT. MTX will be administered at a dose of 15 mg/m\^2 (based on adjusted ideal body weight) intravenously (IV) on day +1 and at a dose of 10 mg/m\^2 IV on days +3, +6, and +11.
223593790|NCT00609739|DRUG|methylprednisolone|Recipients of UCB will receive methylprednisolone 2 mg/kg/day from day +5 to +19 at a dose of 1 mg/kg twice a day (bid) with a 10% taper every week thereafter.
223593791|NCT00609739|DRUG|mitoxantrone hydrochloride|10 mg/m\^2 over 30 minutes intravenously (IV) on days -9 through -7.
224196185|NCT06724367|DEVICE|Transspinal direct current stimulation|Direct current electrical stimulation applied non-invasively to the spinal cord.
224196186|NCT06724367|DEVICE|Sham Comparator|transspinal direct current stimulation simulated
224196187|NCT06722937|OTHER|Observation|Observe the clinical natural changes of eye parameters of the subjects.
224196188|NCT06724393|OTHER|Blood flow restrictions in combination with low-intensity resistance training|Blood flow restrictions in combination with low-intensity resistance training to test if an online intervention (telehealth) can improve functional capacity and balance in older adults
224196189|NCT07047768|OTHER|No intervention : data-based study|No intervention : data-based study
224310663|NCT00506584|DIETARY_SUPPLEMENT|Pasteurized human milk and pasteurized human milk fortifier|Human milk fortifier initiated when nutrition volume reaches 100 mL/kg/day
223593792|NCT00609739|PROCEDURE|allogeneic bone marrow transplantation|Donor marrow will be collected in the usual sterile manner with a collection goal of 2.0 \>10\^8/kg recipient weight. Infused on Day 0.
224196190|NCT07048444|OTHER|N/A as observational study|N/A as observational study design
224196191|NCT07048691|DIAGNOSTIC_TEST|G.E HEALTHCARE ultrasound machine with high-resolution convex probe|After approval from the institutional ethical committee, a total number of patients presenting to the Radiology and Peads Neurosurgery department of Allied Hospital, Faisalabad, that met the inclusion criteria was selected. After obtaining informed consent from each patient and attendant of the patient, transabdominal ultrasound was examined longitudinal, transverse and oblique plans, ultrasound with a high- resolution convex probe was used by the radiologist
224196192|NCT07047729|OTHER|Early oral feeding|Liquid diet will be initiated within 24 hours after surgery and, if well-tolerated without vomiting, will transition to a regular diet over the subsequent 24 hours
224196193|NCT07047729|OTHER|Standard oral feeding|Standard diet (late feeding), including liquid filtrates, will only be introduced after the resolution of the ileus, during which these patients will remain NPO (nothing by mouth).
224196194|NCT06922877|DIAGNOSTIC_TEST|endoscopic evaluation of colorectal polyps and adenomas using 2D imaging colonoscope|endoscopic diagnostic evaluation of colorectal polyps and adenomas before polypectomy using 2D imaging colonoscope
224196195|NCT06922877|DIAGNOSTIC_TEST|endoscopic evaluation of colorectal polyps and adenomas using 3D imaging colonoscope|endoscopic diagnostic evaluation of colorectal polyps and adenomas before polypectomy using 3D imaging colonoscope
224196196|NCT07047664|DEVICE|KERMIT dermal patch|The KERMIT patch is a non-invasive, wearable device designed to collect sweat and measure concentrations of kidney function biomarkers, including creatinine, urea, and cystatin C. The patch integrates printed biosensors and a microfluidic system for electrochemical detection. It is applied to the skin for a short duration (typically \<1 hour), with pilocarpine stimulation. This study evaluates the patch's performance in differentiating between CKD patients with reduced versus preserved renal function.
224310664|NCT00506584|DIETARY_SUPPLEMENT|Pre-term/term formula|Bovine milk-derived nutrition formulated for very low birth weight infants
224310665|NCT02529891|OTHER|Measurement of VOC in exhaled air|Measurement of VOC in exhaled air during 10 min (tidal breathing) with a portable mass spectrometer
223593793|NCT00609739|PROCEDURE|umbilical cord blood transplantation|Umbilical cord blood (UCB) will be cryopreserved prior to transplantation. Cord blood units will be selected for transplantation according to current University of Minnesota Department of Blood and Marrow Transplantation Guidelines.
223593794|NCT00609739|DRUG|Cis-Retinoic acid|Post-Transplant Cis-Retinoic Acid (CRA) Therapy - CRA will be given at a dosage of 100 mg/m\^2/day by mouth in a single daily dose starting on day +60 and continuing until 1 year after transplant.
223593795|NCT05321251|DRUG|Insulin|see arm description
223593796|NCT05321251|PROCEDURE|Tarsorrhaphy|see arm description
223593797|NCT01178424|BEHAVIORAL|Mindfulness Based Cognitive Therapy|Mindfulness-Based Cognitive Therapy, a manualized, group skills training program (Segal et al., 2013) that is based on an integration of aspects of cognitive therapy for depression (Beck, 1979) with components of the mindfulness-based stress reduction program (Kabat-Zinn, 1990). Patients participate in 8 weekly sessions, each of which incorporates didactic and experiential learning, along with home practice of skills taught in the program.
223593798|NCT01178424|BEHAVIORAL|Cognitive Behaviour Therapy|CBT is an evidence based depression-specific psychotherapy that examines the relationship between thinking styles and the perpetuation of mood symptoms in major depression. Patients use thought records and activity scheduling, among other tools, to record and reappraise their thinking during situations where negative affect is present, both in session and for homework.
223593799|NCT06217003|DRUG|Trilaciclib|Preoperative application of trilaciclib during perioperative chemotherapy
223593800|NCT00332891|DRUG|SR58611A|
223593801|NCT00826670|DRUG|Decolonization|"Colistin sulphate (50mg 4x/d PO) + Neomycin (250mg 4x/day PO) for 10 days~plus In the presence of urinary tract colonization choice of one of the following agents (according to susceptibility profile, creatinine clearance and individual contraindications) Nitrofurantoin (100mg 3x/day PO) or Norfloxacin (400mg 2x/day PO) for 5 days"
223593802|NCT00826670|DRUG|Placebo (Decolonization)|Placebo
223593803|NCT06402032|OTHER|Hesperidin|Hesperidin is a natural flavonoid with well-known of its anti-inflammatory properties in many disease. Hesperidin in previous studies has been documented to reduce inflammation as well as pain through suppression of cytokine production, NF-κB activity, and oxidative stress. Hesperidin, as a natural product, have been considered as a promising pulp capping material in several invitro and animal studies. However, the regenerative effect of hesperidin as pulp capping material in human teeth has not yet been reported.
223593804|NCT06402032|OTHER|Mineral Trioxide Aggregate (MTA)|Mineral trioxide aggregate is a cementitious material having various advantages as it is biocompatible, bioactive, osteo-inductive, non-resorbable material with exciting clinical applications, stimulating reparative continuous dentin formation along with maintaining the integrity of the pulp. Moreover, mineral trioxide aggregate provides seal to tooth structure and is of high strength. It is considered the gold standard material for direct pulp capping.
223593805|NCT04739579|DIAGNOSTIC_TEST|C-Reactive Protein|C-Reactive Protein trend in post-operative course
223593806|NCT05894447|DRUG|Naptumomab Estafenatox|5 or 10 µg/kg IV naptumomab estafenatox will be given on the first four days of every 21-day treatment cycle for 6 cycles
223593807|NCT05894447|DRUG|Pembrolizumab|200 mg IV pembrolizumab will be given on day 2 of each 21 day cycle for up to 24 cycles
223593808|NCT05894447|DRUG|Obinutuzumab|Two doses of 1,000 mg IV obinutuzumab given prior to starting pembrolizumab and naptumomab estafenatox
223593809|NCT02100475|DRUG|insulin degludec/liraglutide|"Insulin degludec/liraglutide will be given subcutaneously (s.c., under the skin) once daily in combination with metformin.~Dose individually adjusted."
223593810|NCT02100475|DRUG|insulin aspart|Dose titration of insulin aspart will be based on the respective pre-meal(s) and bedtime SMPG measured daily.
223593811|NCT03066414|PROCEDURE|echography|The inferior vena cava and the internal jugular vein diameters were measured by echography before and after blood withdrawal during a standardized respiratory maneuver
223593812|NCT02484755|DRUG|Gefitinib|See Arm Description
223593813|NCT00002503|RADIATION|strontium chloride Sr 89|
223593814|NCT00007358|DRUG|Dexamethasone or other corticosteroid|Administered during the third trimester of pregnancy
223593815|NCT02246907|OTHER|Exercise|All intervention patients will participate in an individualized prescriptive exercise intervention 2 to 4 times per week for a period of the induction chemotherapy/in-hospital recovery. The exercise intervention will begin on week 1 of the study, the day after the first batteries of initial assessments are concluded. Each exercise session will be divided into two parts. One part will be administered in the morning and the second one late in the afternoon. There will be a period of rest of at least 36 hours between each exercise session.
223593816|NCT00649428|BIOLOGICAL|Autologous Human Fibroblast (azficel-T)|"1. Collection of 3 mm post auricular skin punch biopsies.~2. Three injection treatments administered 5 ± 1 weeks apart on each side of the face."
223593817|NCT00649428|BIOLOGICAL|Placebo|"1. Collection of 3 mm post auricular skin punch biopsies.~2. Three injection visits administered 5 ± 1 weeks apart on each side of the face."
223593818|NCT01548508|OTHER|Functionnal ElectroStimulation (FES)|Functionnal ElectroStimulation on lower limbs, 1h per day, 5 days per 7, during 6 weeks
223593819|NCT01548508|OTHER|SHAM|SHAM on lower limbs, 1h per day, 5 days per 7, during 6 weeks
223593820|NCT03179397|DEVICE|Model SC9|Experimental
223593821|NCT03179397|DEVICE|Model LI61SE|Active Comparator
223593822|NCT02745808|BIOLOGICAL|HUC-MSCs|The subjects will receive intracavernous injection of HUCMSC.
223593823|NCT02745808|BIOLOGICAL|Injectable Collagen Scaffold + HUC-MSCs|The subjects will receive intracavernous injection of the mixture of injectable collagen scaffold and HUC-MSCs.
223593824|NCT05177367|OTHER|Sequential Variety|3 courses each consisting of a different food
223593825|NCT05177367|OTHER|Simultaneous Variety|3 courses each consisting of 3 foods
223593826|NCT05177367|OTHER|Single Food|3 courses each consisting of the same food
223593827|NCT05177367|OTHER|Small portion|Small meal portion size
223593828|NCT05177367|OTHER|Large Portion|Large meal portion size
223593829|NCT00939458|DRUG|Lamotrigine|
223593830|NCT00438165|BEHAVIORAL|home visitation|Home visitation by nurses from midway through pregnancy until child age 12
223593831|NCT00742417|BIOLOGICAL|Albutein 5%|"18 Plasma Exchanges using Albutein 5%:~* three weeks of intensive treatment with two plasma exchanges per week~* six weeks of maintenance treatment with one weekly plasma exchange~* three months of maintenance treatment with one plasma exchange every two weeks"
223593832|NCT00742417|OTHER|Control|Control group followed the same schedule; however, they did not undergo plasma replacement (it was subjected to simulated plasma replacements)
224196197|NCT07047664|DEVICE|KERMIT dermal patch|The KERMIT patch is a non-invasive, wearable device designed to collect sweat and measure concentrations of kidney function biomarkers, including creatinine, urea, and cystatin C. The patch integrates printed biosensors and a microfluidic system for electrochemical detection. It is applied to the skin for a short duration (typically \<1 hour), with pilocarpine stimulation. This study evaluates the patch's performance in differentiating between CKD patients with reduced versus preserved renal function.
224196198|NCT07048600|BEHAVIORAL|Acceptance and Commitment Therapy for Insomnia|"Monotherapy ACT-i, with no behavioral components, is a brief and low-intensity treatment that has recently been detailed by experts in the field in a session-by-session guideline, intending to help people affected by chronic insomnia. The key components of the sessions are psychoeducation, mindfulness, values and actions derived from chosen values, and defusion.~An adapted, brief and online version of the intervention was developed by the authors of this study. Both interventions were matched in terms of overall duration and delivery format. Each session was tailored to follow a comparable format. Therapeutic alliance, psychoeducation, sleep hygiene, relaxation training and homework was targeted in the first session. In the second session, ACT-i focused on values, acceptance strategies and psychological flexibility. This version will be published online upon request. Each session will last 120 min. They will be delivered once per week, for two consecutive weeks."
224196199|NCT07048600|BEHAVIORAL|Attentional Control Group|The focus of the sessions will be on participants, on general topics. It will not include any active, psychological intervention components, such as cognitive restructuring or ACT processes. No recommendations or psychological guidance will be given. Each session will last 120 minutes. It will be held once per week, for two weeks.
224196200|NCT07047417|DIAGNOSTIC_TEST|CLE and ROSE|All patients undergo white light bronchoscopy after general anesthesia to rule out abnormalities in the lumen and clear the airways. After locating the target lymph node using convex probe endobronchial ultrasound (CP-EBUS), the target lymph node is routinely explored using the grayscale, blood flow and elastography modes CP-EBUS. Puncture is performed using a puncture needle under the guidance of CP-EBUS, and then the CLE probe is inserted into the target lymph node through the puncture needle. Sodium fluorescein is intravenously injected before CLE imaging. Under the guidance of CP-EBUS, the CLE probe is slowly moved to examine the target lesion. According to the real-time CLE images, the ideal biopsy location is identified. After the CLE examination is completed, cryobiopsy is performed at the ideal biopsy location confirmed by CLE under the guidance of CP-EBUS. After sampling, ROSE of the samples is performed.
224196201|NCT07046975|DRUG|Torsemide and Spironolactone tablet|Fixed Dose Combination (FDC): (12 mg Extended Release (ER) Torsemide and 15 mg Spironolactone) tablet
224196202|NCT07046975|DRUG|Torsemide Tablets and Spironolactone Tablets|10 mg Torsemide tablet and 25 mg Spironolactone tablet given together
224196203|NCT07048119|BEHAVIORAL|Japi 1.0|The intervention has ten sessions, and two sessions of 30 minutes were delivered each week for 5 weeks. Sessions numbers 1 to 5 were focused on emotional recognition and inhibitory control. Sessions numbers 6 to 10 worked on working memory and social competence. Each session had eight activities and five tasks per activity with increasing difficulty levels.
224196204|NCT02082743|BEHAVIORAL|Outdoor activity in recess time|Outdoor activity in recess time
224196205|NCT01114191|DRUG|ABT-869|2.5mg \[5 mg days 1, 8 and 12. 17.5 mg on days 13 and after\]
224196206|NCT01114191|DRUG|ketoconazole|400 mg days 6-11
224196207|NCT07048249|DRUG|Romiplostim (AMG-531)|Romiplostim may be started as supportive care, as early as cycle 1 day 1; all patients MUST initiate romiplostim no later than 2 weeks from the start of the 5th cycle of chemotherapy (see exception below for patients with platelet count of 200,000 or greater). If plt count \< 200,000/mm3, patients will start romiplostim based on their weight
224196208|NCT07046806|DRUG|Deucrictibant XR tablet|Deucrictibant 40 mg XR tablet for prophylaxis
224196209|NCT07046806|DRUG|Placebo comparator to XR tablet|Placebo comparator to deucrictibant 40 mg XR tablet, prophylaxis
224196210|NCT07046806|DRUG|Deucrictibant 20 mg capsule|Deucrictibant active drug for on-demand treatment of angioedma attacks
224196211|NCT07046806|DRUG|Placebo comparator to 20 mg capsule|Placebo comparator to Deucrictibant 20 mg capsule for on-demand treatment of angioedema attacks
224196212|NCT07047287|OTHER|global postural reeducation exercise|The global postural reeducation exercise involves a sequence of active, moderate postures as well as exercises that are designed to realign joints, stretch shortened muscles, in addition, strengthen the contraction of the antagonist's muscles to prevent postural asymmetry. There are eight different therapeutic postures in the GPR approach that should be held for 15 to 20 min while lying, sitting, or standing. Only two or three postures have been proposed to encourage treatment standardization+ conventional therapy
224310666|NCT00704847|DRUG|Oral Salmon Calcitonin|0.8mg SMC021, twice daily
223505302|NCT03886623|OTHER|Standard of Care oral care|Standard of Care oral care. Currently, the intensive care units utilize a commercially available pre-package oral hygiene kit. This includes mouthwash swabbing every 2 hours with Careline Alcohol-Free mouthwash or Sage Alcohol Free mouthwash, teeth brushing (with Sage Toothette Oral Care, Sodium Bicarbonate Toothpaste and Sage Suction Toothbrush) every 12 hours, deep oral suctioning every 8 hours and prior to oral Endotracheal tube (ET) retaping, and Paroex Oral Rinse chlorohexidine gluconate (15ml) swabbed onto oral surfaces every 12 hours (SICU patients only). Mouth care is documented every two hours.
223505303|NCT00350506|DEVICE|64 Channel VCT|
223505304|NCT03794063|OTHER|Robson 10 group classification system|WHO proposed the Robson classification system as a global standard for assessing, monitoring and comparing caesarean section rates within healthcare facilities over time, and between facilities. It classifies women in 10 groups based on their obstetric characteristics (parity, previous CS, gestational age, onset of labour, fetal presentation and number of fetuses) without needing the indication for CS.
223505305|NCT03510702|DIAGNOSTIC_TEST|Levels of epigenetic biomarkers present in the gingival fluid and its possible relationship with bone metabolism.|"Once the anamnesis has been done, all the records corresponding to the Gingival Index and Plaque Index, in both groups are taken.~Subsequently, samples of gingival crevicular fluid are taken for the screening of epigenetic biomarkers."
223505306|NCT01436500|DRUG|Ifetroban Injection|Ifetroban sodium injectable, diluted in sterile water with 5% dextrose
223505307|NCT01436500|DRUG|Placebo|Sterile water with 5% Dextrose
223505308|NCT00500929|DRUG|CMI X-11S|
223593833|NCT02255994|DEVICE|UGYTEX|Patients in this arm received the UGYTEX mesh in the pro-cure 1 study (see NCT00153257)
224196213|NCT07047287|OTHER|pilates exercises|the patients will receive pilates in the form of single leg stretch + Pelvic press + Swimming + Opposite arm and leg reach + Side to side), 3 sets of 10 repetitions
224196214|NCT07047287|OTHER|conventional therapy|the patients will receive conventional physiotherapy treatment which consists of routine physical therapy eg. (Back, hamstring, calf and hip flexors stretches, Abdominal curl up exercises etc along with ultrasound and Transcutaneous electrical nerve stimulation (TENS).
224196215|NCT07048613|DIAGNOSTIC_TEST|MRI (mpMRI)|: Combines T2-weighted imaging, Diffusion-weighted imaging (DWI), and Dynamic contrast-enhanced MRI (DCE-MRI) to provide detailed anatomical images and assess tissue characteristics.
224196216|NCT02996266|DEVICE|Targeted Temperature Management|Prophylactic normothermia
224196217|NCT02996266|OTHER|Standard Care|No intervention to control temperature unless fever occurs
224196218|NCT07048522|DRUG|Nimodipine|A continuous dose of 4 mg/h (20 ml/h) of nimodipine solution will be administered continuously 1 h prior to start of operation until 1 h after start of the procedure. • The nimodipine dose will be then reduced to 2 mg/h (10 ml/h) until 24 hrs after the end of the procedure.
224196219|NCT07048522|DRUG|Isotonic Saline|A continuous dose of 20 ml/h of normal saline solution will be administered continuously one (1) h prior to start of operation until 1 h after start of the procedure. The normal saline dose will be then reduced to 10 ml/h until 24 h after the end of the procedure.
224196220|NCT07047313|OTHER|jones and mulligan therapy|for jones technique in upper trapezius and suboccipital muscles, the participants supine , the therapist used manual palpation to locate the tender area in the UT and sub-ossipital muscles. Once detected, pressure to the tender area was progressively increased . The participant was then repositioned passively to decrease the stress under palpation, resulting in a 70% subjective decrement in pain. That position was maintained for 90 s. eventually, the participant returned to the neutral position slowly and passively. for mulligan SNAGS,The therapist held the patient with his trunk, and wrapped the patient's head lightly with his arm on the patient's side, and placed the ring finger on the trouble spot right above the small vertebral joint. The therapist placed the thenar eminence of his opposite hand on the ring finger, which was touching the lesion site. On the site, the therapist performed gliding in the upward direction of the front pupil (45 degrees) exercises
224310667|NCT00704847|DRUG|Oral Salmon Calcitonin (Placebo)|0.8mg Placebo, twice daily
224310668|NCT02075177|DRUG|Fenretinide Lym-X-Sorb Oral Powder|Fenretinide Lym-X-Sorb 1500 mg/m2/day, daily for 7 days every 3 weeks
224310669|NCT02075177|DRUG|Ketoconazole|Ketoconazole 6 mg/kg/day, daily for 7 days every 3 weeks.
224310670|NCT04778553|DIAGNOSTIC_TEST|iMOST X-1 Hematology Analyzer|The X-1 is a point of care automated hematology analyzer
223505309|NCT01910532|DRUG|Clevidipine|Clevidipine for the treatment of acute hypertension defined SBP \> 160 mmHg in patients who require an Intracranial Pressure Monitoring Device
223505310|NCT05444127|OTHER|Saliva samples|A saliva sample is added by research for all patients, as well as an oral quality of life questionnaire. For the witnesses, participation also entails the completion of the standardized oral examination (potentially longer than the assessment that would have been carried out as part of the treatment) and the administration of the oral quality of life questionnaire.
223505311|NCT05444127|OTHER|Questionnaire OHIP-14|A saliva sample is added by research for all patients, as well as an oral quality of life questionnaire. For the witnesses, participation also entails the completion of the standardized oral examination (potentially longer than the assessment that would have been carried out as part of the treatment) and the administration of the oral quality of life questionnaire.
223505312|NCT05444127|OTHER|Thorough dental examination|A saliva sample is added by research for all patients, as well as an oral quality of life questionnaire. For the witnesses, participation also entails the completion of the standardized oral examination (potentially longer than the assessment that would have been carried out as part of the treatment) and the administration of the oral quality of life questionnaire.
223505313|NCT00222261|DRUG|aspirin|Aspirin 160 mg once daily for two years
223505314|NCT00222261|DRUG|clopidogrel|clopidogrel 75 mg once daily for two years
223505315|NCT01604200|BEHAVIORAL|focus group|key informant review
223505316|NCT06093503|DRUG|Telisotuzumab Vedotin|Intravenous (IV) Infusion
223505317|NCT06093503|DRUG|Osimertinib|Oral: Tablet
223505318|NCT06093503|DRUG|Cisplatin|IV Infusion
223505319|NCT06093503|DRUG|Carboplatin|IV Infusion
223505320|NCT06093503|DRUG|Pemetrexed|IV Infusion
223505321|NCT01109381|DRUG|GT08|GT08 is the combination of omeprazole 40mg daily, lauric acid 150-300mg daily, NAC 1.2 - 2g daily
223505322|NCT00331149|DRUG|Ropinirole prolonged release|
223505323|NCT00331149|DRUG|ropinirole immediate release|
223505324|NCT00581997|DRUG|QAX576|
223505325|NCT00581997|DRUG|Placebo|
223505326|NCT03967665|DRUG|N-acetyl-L-cysteine|NAC 400 mg three times per day from -14D pre-HSCT to +2 months post-HSCT
223505327|NCT04253678|DRUG|Vortioxetine|Flexible dosing from 5mg to 20mg based on attending psychiatrist's discretion
223505328|NCT01196234|DRUG|Paclitaxel/Carboplatin/Gefitinib|paclitaxel (175mg/m2 on day 1)/carboplatin (AUC 5 on day 1)/daily gefitinib 250mg/day during day 2-15
223505329|NCT01196234|DRUG|Paclitaxel/Carboplatin|paclitaxel (175mg/m2 on day 1)/carboplatin (AUC 5 on day 1)
223505330|NCT01761227|DRUG|Fufangdanshen Tablets|1 tablets contains contains tanshinoneⅡA 0.67mg , salvianolic acid B 8.2mg, Panax Notoginsenosides R1 0.53mg, ginsenoside Rb1 3.03mg, ginsenoside Rg1 2.73mg, 3 tablets per time, 3 times per day for 24 weeks
223505331|NCT01761227|DRUG|Placebo|Placebo for 3 tablets per time, 3 times per day for 24 weeks
223505332|NCT03949114|BEHAVIORAL|Evaluation|Evaluate a weak debilitating phenotype screening on the patients before surgery;
223505333|NCT03949114|BEHAVIORAL|nursing care|Traditional post-operative nursing care
223505334|NCT03949114|BEHAVIORAL|rehabilitation|"1. Postoperative vital signs were stabilized for 2 hours and then assisted to turn over; 2 to 3 hours to change position, awake without swallowing dysfunction, to fluid diet; 6 hours later, raise the bed 15 to 30 °, eat a half-flow diet.~2. On the first day after surgery, raise the bed 45 °, row and position training; catheter clamping training; assessment of pain, preventive analgesia. Early rehabilitation training was performed for 60 minutes each time for 5 consecutive days."
223505335|NCT01487161|DRUG|FX006|Single 3 mL intra-articular injection
223505336|NCT01487161|DRUG|TCA IR|Single 1 mL intra-articular injection
223505337|NCT04759092|DEVICE|transcranial direct current stimulation (tDCS)|Apply 30min low dose (2mA) transcranial current stimulation on the scalp every day for four months.
223505338|NCT06196827|GENETIC|LX101|Subretinal Administration
223505339|NCT06377540|DRUG|Pembrolizumab|"Patients will receive 200 mg Pembrolizumab on Day -28 and Day -6 by IV infusion.~Pembrolizumab 200 mg IV will resume at day 30+ after ASCT every 3 weeks for 1 year."
223505340|NCT06377540|PROCEDURE|Autologous stem cell transplant|On day 0 the stem cells will be infused immediately after thawing over 15-60 minutes per institutional guidelines.
223505341|NCT06377540|DRUG|Carmustine|Patient will receive a single dose of BCNU on day -6, dose of 300 mg/m2 by IV infusion.
223505342|NCT06377540|DRUG|Etoposide|Etoposide will be given at dose 100 mg/m2 BID intravenously on days -5, - 4, -3, and -2.
223505343|NCT06377540|DRUG|Cytarabine|Cytarabine will be given at dose 100 mg/m2 BID intravenously on days -5, -4, - 3, and -2.
223505344|NCT06377540|DRUG|Melphalan|Melphalan will be given at dose of 140 mg/m2 intravenously on day -1 in a single 20 minute infusion; dose will be based on actual body weight but capped at 3.6 mg/kg as part of BEAM conditioning.
223505345|NCT06091345|DRUG|Midodrine|• Midodrine starting at 0.25mg/kg/day in divided doses, increased to 0.5mg/kg/day after 7 days if MAP does not increase by \>10%
223505346|NCT06091345|BIOLOGICAL|albumin|• Albumin infusion 1g/kg/day (max 20g) every two weeks (if pre-infusion serum albumin is \< 3.5 gm/dl
223505347|NCT06091345|OTHER|Standard Medical Treatment|Standard Medical Treatment
223505348|NCT04786600|DEVICE|Signatera ctDNA assay|Subjects will be tested with the Signatera ctDNA assay every 2 weeks.
223505349|NCT04786600|DRUG|pre-specified sequence of FDA-approved drugs and drug combinations|Subjects will receive treatment with a pre-specified sequence of FDA-approved drugs and drug combinations
223505350|NCT05071898|DRUG|Semaglutide Pen Injector [Ozempic]|Participants will receive subcutaneously injected semaglutide (0.25 mg/wk) for 4 weeks followed by semaglutide (0.5 mg/wk) for an additional two weeks.
223505351|NCT02675452|DRUG|AMG 176|Study Drug
223505352|NCT02675452|DRUG|Azacitidine|Non-investigational product
223505353|NCT02675452|DRUG|Itraconazole|Non-investigational product
223505354|NCT06121050|OTHER|Pet visit|Intensive care patients visited by their pets for 20 minutes
223505355|NCT04907240|DEVICE|GORE® VIABAHN® Endoprosthesis with PROPATEN Bioactive Surface (VSX)|Intent to treat with the GORE® VIABAHN® Endoprosthesis with PROPATEN Bioactive Surface (VSX) in the treatment of Peripheral Artery Disease as part of routine clinical practice.
223505356|NCT06963372|DEVICE|True filter (4w) → Washout (2w) → Sham filter (4w)|Used a true filter for 4 weeks, followed by a 2-week washout, then used a sham filter for 4 weeks.
223505357|NCT06963372|DEVICE|Sham filter (4w) → Washout (2w) → True filter (4w)|Used a sham filter for 4 weeks, followed by a 2-week washout, then used a true filter for 4 weeks.
223505358|NCT03853837|DIAGNOSTIC_TEST|rest-exercise echocardiography|an echocardiogram performed during rest and exercise
223505359|NCT02164188|BEHAVIORAL|Flourishing protocol|This intervention is based on relaxation, well-being promotion, meditation practices, positive psychology principles. The format is 1hour and half meetings during 8 weeks, and daily practices. MP3 audios are presented for daily practices.
223505360|NCT06411808|BEHAVIORAL|Sensory-Adapted Dental Environment|The Sensory-Adapted Dental Environment (SADE) involves altering the dental setting to reduce sensory stimuli that can cause discomfort or anxiety in children with sensory processing disorders. This includes the use of controlled lighting, ambient sounds, and non-threatening tools to create a calming atmosphere conducive to positive dental experiences.
223505361|NCT01320098|BEHAVIORAL|Home-Based Parenting Program|"The Home-Based Parenting Program aims to improve impulsive and oppositional behaviors in 3 and 4 year-olds. The program involves 8 home visits with a therapist. The visits focus on the skills listed below as a means of improving your child's behavior.~1. Helping you set developmentally appropriate goals for your child. One way we do this is by focusing on situations that occur naturally in your home. Another way is by having you engage in activities with your child that focus on improving attention and the ability to delay.~2. Increasing the quality and quantity of positive interactions between you and your child~3. Changing the way you respond to your child's inappropriate behaviors so as to reduce the frequency of negative interactions.~4. Improving your parenting skills. This program also includes between-session homework tasks so that you can practice the skills you have learned throughout the week."
223505362|NCT01320098|BEHAVIORAL|Clinic-Based Parenting Program|"The Clinic-Based Parenting Program aims to improve ADHD symptoms by reducing noncompliance, which is common in children with ADHD. Parents learn how to help their child attend to and comply with requests and directions so as to improve compliance and attention.~The program involves 8 clinic visits with a therapist. Parents learn various parenting skills to help improve their child's behaviors.~Parents learn techniques and skills to promote positive interactions with their child, including:~1. Increasing the positive attention you give to your child.~2. Reducing the inappropriate use of commands, questions and criticisms.~3. Appropriate use of praise and physical attention (e.g., hugs) as rewards.~4. Actively ignoring minor, inappropriate behaviors. Parents also learn how to: increase compliance via clear instruction; respond to compliant and noncompliant behaviors; and create and use clear rules about appropriate and inappropriate child behaviors."
223505363|NCT01320098|BEHAVIORAL|Wait-List Control Group|If your child is randomized to the 8-week Wait-List group, you and your child will be asked to attend 2 assessment visits -1 screening/baseline visit and one 8 weeks later. These assessment visits will take place at our clinic. After completing the second assessment, you will receive your choice of either the home-based or clinic-based parenting program.
223505364|NCT04498117|BIOLOGICAL|Oregovomab|2 mg, dissolved in 2 mL of 0.9% Sodium Chloride Injection USP, then added to 50 mL of Sodium Chloride Injection USP infused over 20 ± 5 minutes
223505365|NCT04498117|DRUG|Paclitaxel|175 mg/m\^2, every 3 weeks
223593834|NCT02255994|PROCEDURE|No mesh.|Patients in this arm had subvesical plication without reinforcement.
223593835|NCT04566601|DRUG|BI 1358894|Film-coated tablet
223593836|NCT04566601|DRUG|Placebo|Film-coated tablet
223505366|NCT04498117|DRUG|Carboplatin|AUC 6 IV Day 1 x 6 cycles (every 21 days)
223505367|NCT04498117|BIOLOGICAL|Placebo|2 mg, dissolved in 2 mL of 0.9% Sodium Chloride Injection USP, then added to 50 mL of Sodium Chloride Injection USP infused over 20 ± 5 minutes
223593837|NCT03833466|DRUG|metformin and chemotherapy|"Drug: Metformin Metformin is orally administered as 500mg bid for 7 days and escaladed to 500mg tid if adverse events are tolerated.~Drug: Cisplatin Cisplatin is given at 75mg/m2 intravenously on day 1 of each 21 day cycle.~Drug: Paclitaxel Paclitaxel is given at 175mg/m2 intravenously on day 1 of each 21 day cycle."
223593838|NCT00954499|BEHAVIORAL|Tactile stimulation added to Standard care|"* Parent rubs the infant's skin near the injection site just before, during and after the injection.~* Fast injection technique without aspiration.~* Oral sucrose 2 minutes before first injection.~* Parent holds infant close."
223593839|NCT00954499|BEHAVIORAL|Standard care|"* Fast injection technique without aspiration.~* Oral sucrose 2 minutes before first injection.~* Parent holds infant close."
223593840|NCT05835180|DRUG|TVB-2640 - 50 mg|TVB-2640 -50 mg administered orally once daily
224075078|NCT07071350|OTHER|HRV Coherence Ratio|Evaluates autonomic function and the intervention process's efficacy, specifically resonance frequency breathing. The HRV Coherence Ratio will be quantified using a non-invasive procedure during resonance frequency breathing conditions and a standardized definition.
224075079|NCT07071350|BEHAVIORAL|NSI|This inventory assesses the overall symptom burden, including post-concussion symptoms, on a 5-point scale. It is a well-established measure used by the Department of Defense (DoD) and VA and in mTBI outcome research at large, and includes 27 items that capture vestibular, somatosensory, cognitive, and affective symptoms.
224075080|NCT07071350|BEHAVIORAL|Pittsburgh Sleep Quality Index (PSQI)|It includes seven components: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleeping medication, and daytime dysfunction. Higher PSQI scores indicate poorer sleep quality.
224075081|NCT07071350|BEHAVIORAL|Quantitative Sleep Measures|Measured using wrist actigraphy, which provides objective data on sleep parameters such as sleep latency, duration, efficiency, fragmentation, and wake time after sleep onset (WASO). Participants will wear the actigraphy monitors at baseline, post-training, and follow-up assessments.
224310671|NCT04274231|GENETIC|different effection|Analysis of the reasons for treatment
223505368|NCT04498117|DRUG|Carboplatin|AUC 5-6 IV Day 1 x 6 cycles (every 21 days)
223505369|NCT02836106|OTHER|Butter|Butter with jam and three slices of bread
223505370|NCT02836106|OTHER|Cheese|Cheese with jam and three slices of bread
223505371|NCT02836106|OTHER|Whipped cream|Whipped cream with jam and three slices of bread
223505372|NCT02836106|OTHER|Sour cream|Sour cream with jam and three slices of bread
223505373|NCT02939781|DEVICE|Indirect calorimetry|Indirect calorimetry measurement at baseline (stable state), at onset of fever and continued till fever dehiscence
223505374|NCT00541775|DRUG|Sitagliptin|Sitagliptin 100 mg administered as one oral tablet once daily in the morning for up to 18 weeks.
223505375|NCT00541775|DRUG|Comparator: Rosiglitazone|Rosiglitazone 8 mg administered as two 4 mg capsules once daily in the morning for up to 18 weeks.
223505376|NCT00541775|DRUG|Comparator: Placebo|placebo - administered as one placebo tablet to match Sitagliptin 100 mg and two placebo capsules to match rosiglitazone 4 mg once daily in the morning for up to 18 weeks.
223505377|NCT00541775|DRUG|Comparator: Metformin|Open-label metformin was supplied by the Sponsor as 500, 850, or 1000 mg oral tablets administered at a daily dose of \>= 1500 mg.
223505378|NCT00270166|DRUG|epoetin alfa|
223505379|NCT02323061|PROCEDURE|BCI using EEG signals|A robot hand will be used and controlled by the system in real time based on EEG pattern for identification of motion intention for hand movements in the cortex.
223505380|NCT00032487|DRUG|Insulin|Insulin (intermediate or long-lasting) in a.m. 1 unit 9 lbs Arm 1 Insulin (intermediate or long-lasting) in a.m. 1 unit 9 lbs, add one injection of insulin Arm 2
223505381|NCT00032487|DRUG|Glimepiride|Glimepiride 2 mg Arm 1 Glimepiride 8 mg Arm 2
223505382|NCT00032487|DRUG|Rosiglitazone|Rosiglitazone 4 mg Arm 1 Rosiglitazone 4 mg bid Arm 2
223505383|NCT00032487|DRUG|Metformin|Metformin 500 mg (go up to 1000 mg) Arm 1 Metformin 500 mg (go up to 2000 mg) Arm
223505384|NCT04267328|PROCEDURE|Elective Orthopedic Surgery|Patients having knee (unilateral primary osteoarthritis or bilateral primary osteoarthritis) surgery, hip (unilateral primary osteoarthritis or bilateral primary osteoarthritis) or shoulder (primary osteoarthritis) elective surgery.
223505385|NCT04309448|BEHAVIORAL|Perturbation-based balance training with functional electrical stimulation|The PBT program will consist of repetitive practice of reactive stepping for one hour. The participants will be equipped with the Odstock 2-Channel stimulator on one or both sides depending on their deficits. One channel of stimulation may be applied to the common fibular nerve to elicit a flexor withdraw reflex and elicit a step. The second channel of stimulation may be applied to the quadriceps muscles to assist with the supporting phase of the reactive step, as required. Participants will experience about 60 perturbations per session during balance exercises. To create a perturbation, the researcher will apply unexpected pushes or pulls to a safety harness around the participant's trunk. Throughout the hour-long session, participants will complete challenging balance tasks, customized to their ability level, during standing and walking. The training will be supervised by a licensed physiotherapist and administered by a licensed physiotherapist or registered kinesiologist.
223505386|NCT02465970|DEVICE|STARSTIM|"Multifocal transcranial direct current stimulation.~* CE-marked device, comprising a cap with 2 to 8 electrodes, connected with a programmable mobile stimulator.~* The stimulation is applied during a 60 min session"
223505387|NCT02465970|DEVICE|sham TDCS|
223505388|NCT01624207|DRUG|generic formulation of atorvastatin (Atorva®)|Treatment with generic formulation of atorvastatin (Atorva®) once daily, for 8 weeks
223505389|NCT01624207|DRUG|branded formulation of atorvastatin (Lipitor®)|Treatment with branded formulation of atorvastatin (Lipitor®)once daily, for 8 weeks
223505390|NCT01117545|BEHAVIORAL|EFT (Emotional Freedom Techniques)|Six sessions of EFT
223505391|NCT02650349|OTHER|fMRI|
224075082|NCT07071350|BEHAVIORAL|Patient Global Impression of Change (PGIC)|It evaluates patients' perceptions of clinically meaningful changes in their condition following the intervention. It is considered the gold standard for such assessments.
224075083|NCT07071350|BEHAVIORAL|Cognitive Performance/NIH Toolbox Cognitive Battery|Assessed using the NIH Toolbox Cognitive Battery, which measures executive function, episodic memory, working memory, processing speed, language, attention, and reading through a brief, computer-based test
224196221|NCT07047313|OTHER|mulligan therapy|mulligan SNAGS,The therapist held the patient with his trunk, and wrapped the patient's head lightly with his arm on the patient's side, and placed the ring finger on the trouble spot right above the small vertebral joint. The therapist placed the thenar eminence of his opposite hand on the ring finger, which was touching the lesion site. On the site, the therapist performed gliding in the upward direction of the front pupil (45 degrees). The hand, which was touching the spinous process, should be relaxed in order not to squeeze too hard. The source of the power of gliding on the joint surface must come from the opposite hand of the patient-contacting hand. Gliding was applied rhythmically (three times per second) and the width of gliding starts from the middle to the end+ exercises
224196222|NCT07047313|OTHER|exercises program|The exercise program will be in the form of stretching exercises for the sternocleidomastoids (SCM), the scalenes, and upper fibers of trapezius; strengthening isometric exercises for the neck flexors, extensors, lateral flexors, and neck rotators; and postural correction exercises.
224196223|NCT07047339|DRUG|Probiotics 6600|"As the core commensal bacteria of human body, probiotic 6600 has a unique ability to synthesize adhesins and exopolysaccharides. The intestinal protective effect is mediated by the following mechanisms: (1) regulation of Treg/Th17 balance by producing short-chain fatty acids (SCFAs); (2) activation of TLR2/MyD88 pathway inhibits NF-κB inflammatory cascade; (3) Upregulation of zonula occludens-1 enhances intestinal barrier function. Notably, this strain specifically metabolized arabinoxylan to produce the anti-inflammatory metabolite indole lactate, which has important therapeutic value in the colitis microenvironment.~Probiotic 6600 capsules are enteric capsules (containing probiotic 6600 10\^11 CFU/ capsule), taken orally twice a day (after meals in the morning and evening), one capsule each time, and taken with warm water. The drug was stored at 2-8℃."
224196224|NCT07047339|DRUG|Placebo|The placebo capsules were also enteric-coated capsules, and were taken orally twice a day (morning and evening after meals), one capsule each time, with warm water.
224196225|NCT07047963|DIAGNOSTIC_TEST|ENDI (Neuropsychological Evaluation in Intellectual Disability)|This neuropsychological battery comprises 15 subtests designed to assess language, memory, attention and executive skills. By analyzing changes in Trisomy 21 patients performance over time, the neuropsychologist can detect early signs of Alzheimer's disease.
224196226|NCT07048509|OTHER|Control-no treatment|30 minutes of rest
224196227|NCT07048509|OTHER|Exercise|30 minutes of Moderate-Intensity Continuous Exercise
224196228|NCT07048509|OTHER|Exercise|30 minutes of High-Intensity Interval Exercise
224196229|NCT07048704|DRUG|Intravenous Bacteriophage Cocktail plus Standard IV Antibiotics|"Participants will receive a seven-day course of intravenous (IV) bacteriophage therapy in combination with standard IV antibiotics. The bacteriophage therapy consists of a pathogen-specific cocktail containing four purified, lytic bacteriophages selected based on pre-treatment sensitivity testing of the participant's bacterial isolate. Each phage cocktail targets one of the following antibiotic-resistant pathogens: Pseudomonas aeruginosa, Klebsiella spp., Stenotrophomonas maltophilia, Escherichia coli, Staphylococcus aureus, or Achromobacter xylosoxidans.~Phage cocktails are administered IV twice daily at a concentration of 1x10⁹ PFU/mL, following antibiotic infusion. The first three doses are observed in clinic; remaining doses are self-administered at home via PICC line. All phages are produced under GMP conditions and screened to be lytic-only, free of known toxin, resistance, or lysogeny genes."
224196230|NCT06722040|OTHER|Implementation of a pediatric triage track|In 2023, a pediatric triage track was implemented at MH1813 to route calls concerning children to specialists in pediatrics, ensuring better expertise.
224310672|NCT02013674|BIOLOGICAL|Allogeneic hMSCs|Allogeneic Adult Human Mesenchymal Stem Cells (MSCs) delivered via injection
224310673|NCT02334592|RADIATION|Sunbed tanning|Invention groups undergo a 12-week tanning protocol that follows Health Canada's RED Act
224310674|NCT00416884|DRUG|Campath|30 mg on day -8 over 5-6 hours
224310675|NCT00416884|DRUG|Fludarabine|Fludarabine 30 mg/m\^2 on day -4 through day -2
224310676|NCT00416884|RADIATION|Total Body Irradiation (TBI)|Total body irradiation single fraction 200 cGy at 7 cGy per minute on day 0
224310677|NCT00416884|OTHER|T-Cell Deplete|Stem cells will be T cell depleted and given on day 0
224310678|NCT04332965|PROCEDURE|Non-Surgical Periodontal Treatment|Scaling and root planing and polishing with specific curettes were performed to patients and oral hygiene education was provided to each patient.
224310679|NCT00960635|DRUG|1,25-dihydroxy-vitamin D3 (calcitriol)|
223505392|NCT04425395|BEHAVIORAL|Cold pressor task (CPT)|"The cold pressor test is among the most common and established methods for studying human reactions to pain and pain tolerance. Participants submerge a hand in cold water (approx. 5°C) and are asked to keep their hand submerged for as long as can (until the sensation is intolerable), up to a maximum of 5 min. The procedure is safe because the hand is removed before adverse effects can occur. The participant will be given a break of 5 min in between trials, and will interchange hands between trials. During this break hand may to be place in warm water (25-35°C) for up to 4 min to normalise hand temperature, which will be measured before and after each trial using a digital thermometer held firmly in the palm of the hand.~Each participant will complete no more than three trials (conditions) in a randomised order."
223593841|NCT02736435|DEVICE|Magnetic Resonance Guided High Intensity Focused Ultrasound|Direct treatment of uterine fibroids with MR-HIFU
223505393|NCT04425395|BEHAVIORAL|Acoustic Recordings|During the experiment, the vocalizations produced will be systematically recorded for each participant and an analysis of the acoustic structure of these vocalizations will be carried out.
223505394|NCT04425395|DIAGNOSTIC_TEST|Index measurement NOL™|Four sensors placed non-invasively on one finger. of the participants will be able to calculate a dozen physiological parameters converts in real time into a pain index called NOL (for Nociception Level Index).
223593842|NCT02736435|DRUG|leuprolide acetate for depot suspension|Treatment of uterine fibroids with leuprolide acetate prior to MR-HIFU
223593843|NCT01542710|DRUG|Ganfort|Bimatoprost/Timolol fixed combination
223593844|NCT01542710|DRUG|Duotrav|Fixed combination of Travoprost and Timolol
224310680|NCT00960635|DRUG|placebo|pill without agent
224310681|NCT02203331|DRUG|Placebo|Placebo intravaginal ring (treatment for 84 days, 28 days wearing period for each ring) and Placebo 3-months depot intramuscular injection
223505395|NCT04425395|DIAGNOSTIC_TEST|Video pupillometry|This technique is based on the observation of the dilatation of the pupil during the perception of a nociceptive stimulus in test persons.
224196231|NCT06722794|PROCEDURE|Novel Technique for Fixating the Plate of Ahmed Valve to the Sclera Using a Single Flanged Prolene Suture|This novel technique of fixating the plate of Ahmed glaucoma valve to the sclera using a single flanged prolene suture is an efficient, safe, fast, and reproducible technique that combines the benefits of both fixing the plate providing excellent stability without the complications of free plate techniques and at the same time, minimizing both the risks of conventional old valve plate fixation techniques and the concerns of the relative technical difficulty of suturing due to the difficult access to the posterior globe
224310682|NCT02203331|DRUG|Levonorgestrel|Levonorgestrel 40 µg/d intravaginal ring (treatment for 84 days, 28 days wearing period for each ring) and Placebo 3-months depot intramuscular injection
224310683|NCT02203331|DRUG|Anastrozole|Participants received Anastrozole 300 µg/d or 600 µg/d or 1050 µg/d + Levonorgestrel 40 µg/d intravaginal ring (treatment for 84 days, 28 days wearing period for each ring) and Placebo 3-months depot intramuscular injection
224310684|NCT02203331|DRUG|Lupron / Leuprolide acetate|Placebo intravaginal ring (treatment for 84 days, 28 days wearing period for each ring) and Lupron / Leuprolide acetate 11.25 mg 3-months depot intramuscular injection
223505396|NCT02569242|DRUG|Nivolumab|
223505397|NCT02569242|DRUG|Docetaxel/Paclitaxel|
223505398|NCT00689052|DRUG|pramipexole ER|
223505399|NCT00689052|DRUG|placebo|
223505400|NCT06731244|OTHER|Usual Care Group|Patients will be managed as regards their anticoagulant treatment according to usual practice and in accordance with international guidelines.
223505401|NCT06731244|OTHER|shared decision-making process|"The intervention is based on a strategy based on a shared decision-making process which is a collaborative process that involves a patient and their healthcare professional working together to reach a joint decision about care (anticoagulant treatment).~The shared decision-making process will be conducted as follows:~* Step 1: prepare the risk estimates (risk of recurrent VTE, risk of bleeding) for the patient, based on time-dependent multicomponent risk prediction scores and socio-anthropological scales (TDMI) and other validated risk prediction scores and evidence-based medicine;~* Step 2: Communicating risks, benefits and consequences to the patient;~* Step 3: Make a joint decision about treatment and care, and agree together when this will be reviewed."
223505402|NCT04838028|PROCEDURE|TEP|Laparoendoscopic totally extraperitoneal mesh repair of groin hernia
223747096|NCT06913829|DIAGNOSTIC_TEST|pencil pushup exercises|Participants in the control group will perform pencil pushup exercises as their primary intervention. This involves: 1. Procedure: o Holding a pencil or similar object vertically at arm's length and focusing on a letter or small mark on it. o Gradually moving the pencil closer to the nose until the participant experiences visual blur or sees double. o Returning the pencil to the starting position and repeating the process. 2. Schedule: o Exercises will be prescribed for 15-20 minutes daily, 5 days a week, for a total duration of 6 weeks. 3. Monitoring: o Participants will receive instructions during the initial session and periodic supervision at follow-up visits to ensure proper technique and adherence. o Progress will be monitored weekly through symptom reporting and clinical measurements.
223747097|NCT06914505|BEHAVIORAL|visual restoration therapy|In this study, we used a reversing checkerboard pattern as a stimulus and acted on the relatively dark spots area of the patient's visual field.
223747098|NCT03627533|PROCEDURE|Electroacupuncture|Electroacupuncture therapy is done at the point of CV3 Zhongji, CV4 Guanyuan, and EXCA-1 Zigong with continuous wave, 2 Hz frequency for 30 minutes. Acupuncture manuals on endocrine ear points, GV20 Baihui, ST36 Zusanli, SP6 Sanyinjiao, BL57 Chengsan and KI3 Taixi for 30 minutes.
223747099|NCT07123467|DRUG|Low-Dose Cannabidiol|Oral cannabidiol solution (EPIDIOLEX®) administered as an adjunct to cognitive behavioral therapy. Low-dose participants receive 5 milligram/kilogram/day throughout. The intervention targets emotion regulation circuitry and symptom improvement.
224196232|NCT06722144|BEHAVIORAL|Animal-assisted Therapy|By the professor leader makes social interaction, and helping residents with rehabilitation through the Doctor dogs.
224310685|NCT02091466|DEVICE|pre-warming|warming patients 30 minutes prior to anesthesia
224310686|NCT03560180|DIAGNOSTIC_TEST|Dutch score|leakage score (DUtch LeaKage, DULK), that consider several items (fever, heart rate, respiratory rate, urinary production, mental status, clinical conditions, signs of ileus, gastric retention, fascial dehiscence, abdominal pain, wound pain, leukocytosis, CRP, increase of urea or creatinine and nutrition status), to give a score
224310687|NCT03560180|DIAGNOSTIC_TEST|Serum C-reactive Protein|see study protocol
224310688|NCT03560180|DIAGNOSTIC_TEST|serum Procalcitonin|see study protocol
224310689|NCT06341829|OTHER|Prismatic adaptation|Participants will fit with prismatic goggles that deviate their visual field by 13° either leftward or rightward. They will seat in front of a white horizontal board on which three target dots (5 mm diameter) were positioned at 0, -10 and +10° from their body midline at a distance of 57 cm from their eyes. They will perform a total of 150 verbally instructed pointing movements with their right index finger towards the right (+10°) and left (-10°) targets in a pseudorandom order.
224310690|NCT05258448|OTHER|Chemoradiotherapy|Cardiac Magnetic Resonance scan and ECG
223505403|NCT04838028|PROCEDURE|TAPP|Laparoscopic transabdominal mesh repair of groin hernia
223505404|NCT04838028|PROCEDURE|Other or unspecified laparoendoscopic groin hernia repair|"Other refers to any laparoendoscopic mesh repair specified as not being either TEP or TAPP, eg, intraperitoneal onlay mesh (IPOM)."
224310691|NCT03749083|OTHER|The Functional Assessment of Cancer Therapy- Colorectal|The Functional Assessment of Cancer Therapy- Colorectal (FACT-C) questionnaire measures health-related quality of life for people with chronic illnesses.
224310692|NCT03558061|DRUG|ALK4290|ALK4290 400 mg tablet twice a day
224310693|NCT06733142|DIETARY_SUPPLEMENT|Test Product: Yoghurt|High protein spoonable yoghurt
224310694|NCT06733142|DIETARY_SUPPLEMENT|Micellar casein drink|Micellar casein drink made from water, casein powder and fruit syrup
224310695|NCT06733142|DIETARY_SUPPLEMENT|Placebo|Placebo sugar free jelly
224310696|NCT00497913|DRUG|NaCl 0.9%|
224310697|NCT00497913|DRUG|Botulinum Toxin A|
224310698|NCT04335318|DEVICE|AI-assisted colonoscopy|Colonoscopies performed with assistance of an AI tool that highlights the areas that are susceptible to be a polyp.
224310699|NCT03134118|DRUG|Nivolumab|Patients will be centrally registered and will receive nivolumab 240 mg IV every 2 weeks
224310700|NCT05260580|OTHER|No Intervention: Routine care|
224196233|NCT06727266|DIAGNOSTIC_TEST|Shoulder ultrasound|The ultrasound examination is performed according to the protocols of the European Society of Musculoskeletal Radiology (ESSR). The tendons of the muscles forming the rotator cuff, the enthesis regions, the tendon of the long head of the biceps muscle, the subacromial-subdeltoid bursa, the acromioclavicular and glenohumeral joints are examined.
224196234|NCT05436067|DEVICE|Vestibular rehabilitation app|Delivery of vestibular rehabilitation through an app on a tablet or other portable device. The app takes patients through their rehabilitation session that has been prescribed by a clinician. Exercises are presented in the forms of games that are controlled by head or torso motion via a motion sensor that is placed on that body part. Data on the motion of the patient are calculated from sensor data and sent over the cloud for the clinician to access remotely.
224196235|NCT05436067|OTHER|Traditional Physical Therapy|Delivery of vestibular rehabilitation through traditional physical therapy.
224196236|NCT07047833|BEHAVIORAL|Plyometric Training with Hamstring Strengthening|This intervention consisted of a six-week training protocol involving both plyometric exercises and targeted hamstring strengthening. Sessions were conducted twice per week, lasting 60 minutes each. Plyometric drills included squat jumps, depth jumps, and lateral jumps, while hamstring exercises included Nordic hamstring curls and machine-based leg curls. All sessions included a standardized 15-minute warm-up and a 5-minute cool-down. The program was designed to enhance lower limb strength, balance, and neuromuscular control for ACL injury prevention in female amateur athletes.
224196237|NCT07047833|BEHAVIORAL|Plyometric Training Only|This intervention involved a six-week plyometric-only training program delivered twice weekly for 40-minute sessions. Exercises included squat jumps, depth jumps, and lateral jumps, performed with progressive intensity and control. Each session included a standardized 15-minute warm-up and a 5-minute cool-down. The program aimed to improve lower limb power, balance, and functional mobility to reduce the risk of ACL injuries in female amateur athletes.
224310701|NCT03483363|DRUG|topical irrigation with gentamicin (80mg diluted in 1L 0.9% normal saline)|Fractures will be irrigated with the topical antibiotic gentamicin (80mg diluted in 1L 0.9% normal saline) prior to closure.
223505405|NCT06975865|DRUG|Rilzabrutinib|Pharmaceutical form:Tablet -Route of administration:Oral
223505406|NCT06975865|DRUG|Placebo|Pharmaceutical form:Tablet -Route of administration:Oral
223505407|NCT04257253|OTHER|Targeted exercise program|Participants in this experimental intervention group will perform a combination of motor control and isolated lumbar extensor strenghtening exercises. The level of difficulty of the exercises will be progressed gradually. The intervention will last 12 weeks, and each participant will have 2 supervised exercise sessions per week.
223505408|NCT04257253|OTHER|General exercise program|Participants in this active intervention group will perform a generalized exercise program comprising upper-body and lower-body and hip strengthening exercises, as well as flexibility. The level of difficulty of the exercises will be progressed gradually. The intervention will last 12 weeks, and each participant will have 2 supervised exercise sessions per week.
224196238|NCT06724458|OTHER|Resistance exercise|All arms will involve participants performing resistance exercise bouts of the described exercises. at the given loads, and with the stated flow condition
224196239|NCT06723496|BEHAVIORAL|Child Behavioral Checklist (CBCL):is a checklist parents complete to detect emotional and behavioral problems in children and adolescent, it consists of 113 questions for both groups.|is a checklist parents complete to detect emotional and behavioral problems in children and adolescent, it consists of 113 questions.
223505409|NCT05424211|DEVICE|Music Therapy Mobile Application|The authorities determined by taking consultancy from TÜMATA (Turkish Music Research and Promotion Group) will be uploaded to the mobile application developed by the software specialist. The maqams (Rast, Nihavent and Neva) to be used in the application will be played to the patients 3 times in half an hour at different times of the day via the mobile application. Rast tonality will be played in the morning, nihavent tune will be played at noon and neva tune will be played in the afternoon.
223505410|NCT05685004|BIOLOGICAL|TVI-Brain-1|Attenuated autologous cancer cells and activated autologous blood-derived t cells
223505411|NCT05685004|PROCEDURE|Standard of Care|Surgery for tumor removal or debulking to minimize tumor burden
223505412|NCT05685004|RADIATION|Radiotherapy|Conformal radiotherapy consists of fractionated focal irradiation at a dose of 2 Gy per fraction given once daily five days per week (Monday through Friday) over a period of six weeks.
223505413|NCT05685004|DRUG|Temozolomide|All Subjects receive 75 mg/m2 of temozolomide daily beginning on the first day of radiotherapy and continuing until the completion of radiotherapy. Standard of care Subjects will also receive adjuvant temozolomide .
223505414|NCT01459549|PROCEDURE|Roux-en-Y hepaticojejunostomy|All participants received routine perioperative care and followed the same surgical principles: removing affected liver segments, clearing stones, correcting strictures, and then restoring bile drainage. The primary indications for hepatectomy were unilobar or segmental diseases and the presence of the following lesions in the affected liver segment or lobe: 1) multiple stones with biliary strictures that cannot be cured via choledochoscopy, 2) atrophy, fibrosis, and multiple abscesses, and 3) suspicious neoplasia. Biliary exploration was routinely conducted to facilitate stone removal, rectify strictures, and assess the functionality of the Oddi sphincter. Following this, patients would be evaluated for eligibility and assigned accordingly. The sole distinction between the two arms was performing RYHJ or maintaining the common bile duct for bile drainage.
223505415|NCT04894708|PROCEDURE|colonoscopy|addition of polyp detection algorithm by Fujifilm
223593845|NCT04070417|BEHAVIORAL|Lifestyle Medicine|Lifestyle intervention with components including physical activity, diet, relaxation/mindfulness, sleep and socialisation
223593846|NCT04979117|DEVICE|Superb Microvascular Imaging (SMI) (Toshiba)|to determine whether there is a diagnostic value of SMI in Plantar Fasciitis and whether there is a superiority when compared Power Doppler and Color Doppler modalities.
224196240|NCT06723496|BEHAVIORAL|parent report on child's responses to stress (PCT):is a questionnaire which is used to obtain mothers' and fathers' reports of their children's coping with cancer|It includes a list of 12 cancer -related stressors (e.g., missing school, frequent hospital or clinic visits, changes in personal appearance), and 57 items reflecting voluntary (coping) and involuntary (automatic) stress responses of children /adolescents in response to cancer-related stressors
224310702|NCT03483363|DRUG|topical irrigation with sterile normal saline (NS)|Fractures will be irrigated with sterile normal saline prior to closure.
224196241|NCT06723496|BEHAVIORAL|Symptom Checklist -90- Revised (SCL-90-R) for parents|It is a method to evaluate psychological problems and identify symptoms, it includes 90 symptoms and evaluate nine symptomatic dimensions
224196242|NCT06723496|BEHAVIORAL|posttraumatic stress disorders by posttraumatic check list -5 (PCL-5) for parents|It is a 20 -item measure that assess the 20 DSM-5 symptoms of PTSD.
223505416|NCT03753906|DEVICE|Osmed® hydrogel expander implantation|Under local anaesthesia, a small vertical incision, adapted to the diameter of the Osmed® sself-inflating hydrogel expander, was made with #15 scalpel blade at the mesial line angle of the adjacent tooth which started below the gingival margin extending from the keratinized tissue above the MGJ to the non-keratinized tissue beyond the MGJ. A minimally invasive preparation of a subperiosteal pouch was performed with KPA tunnelling knife. Size of the pouch was controlled with the specific surgical template to ensure the device easily fits into the prepared pouch without tension. Expanders were secured in the correct position with a bone fixation screw, at the flat end, which does not possess an expansion capability. The wound was closed with 3-0 silk suture using simple interrupted sutures.
223505417|NCT02001883|DRUG|Association low-dose statin and nutraceuticals|
223505418|NCT02221414|DRUG|Linagliptin/Metformin FDC|
223505419|NCT02221414|DRUG|Linagliptin|
223505420|NCT02221414|DRUG|Metformin|
223505421|NCT04718753|BEHAVIORAL|Mindful breathing intervention|Mindful breathing intervention audio, which is used in mindfulness-based interventions, will be sent to the participants once per day.
223505422|NCT05869409|BEHAVIORAL|Physical activity and sedentary behavior education|Enrolled patients will participate in an individual face-to-face education session, addressing: definitions and examples of sedentary and physical activity behaviors; physical health-related and mental health-related consequences of these behaviors; ways to break sedentary behaviors; age-adjusted physical activity recommendations (based on the guidelines of the World Health Organization).
223505423|NCT02846428|DRUG|5-Fluorouracil|5-FU will be administered at 500 mg/m\^2 by short IV infusion on Day 1 of each 21-day cycle during neoadjuvant treatment period for 4 cycles.
223505424|NCT02846428|DRUG|Capecitabine|Capecitabine will be administered at 900 mg/m\^2 orally twice daily on Days 1-14 of each 21-day cycle for 4 cycles during neoadjuvant treatment period.
223505425|NCT02846428|DRUG|Cyclophosphamide|Cyclophosphamide will be administered at 500 mg/m\^2 by short IV infusion on Day 1 of each 21-day cycle for 4 cycles during neoadjuvant treatment period.
223505426|NCT02846428|DRUG|Docetaxel|Docetaxel will be administered at 100 mg/m\^2 by IV infusion on Day 1 of each 21-day cycle for 4 cycles during adjuvant treatment period.
223505427|NCT02846428|DRUG|Epirubicin|Epirubicin will be administered at 100 mg/m\^2 by short IV infusion on Day 1 of each 21-day cycle for 4 cycles during neoadjuvant treatment period.
223505428|NCT04810156|DRUG|Mycophenolate Mofetil|Day 1: MMF 500 mg twice a day Day 2: MMF 1000 mg twice a day
223505429|NCT04810156|DRUG|Solu-Medrol|2 mg/kg/day
223505430|NCT04810156|DRUG|Ursodeoxycholic acid|Patients with mixed or cholestatic liver injury pattern will also be administrated peroral UDCA according to weight
223505431|NCT04810156|DRUG|Prednisone tablet|Shift from solu-medrol IV to peroral prednisolon. A tapering plan will be performed.
223593847|NCT04195217|BEHAVIORAL|Art therapy|"When the patient is placed in a treatment room, a nurse or the ARC proposes to complete the questionnaires corresponding to his visit in accordance with the diagram of the investigations, then retrieve the questionnaire and forward it to the art therapist Then, the art therapist intervenes ans propose different Artistic supports : paint, watercolor pencils, pastels, pencils, clay , origami, music in as an accompaniment to artistic creation.~The workshop runs from 30 minutes to 2:30. It can be cut by doctors and nurses interventions during medical care. The limit of care is set at 2:30 for reasons of concentration of the patient, organization of the service but the patient is an actor of his care, and chooses when the session ends.~At the end of intervention, the nurse or the ARC proposes at patient to complete the end questionnaire. Theses last are retrieve it and to forward it to the art therapist."
223593848|NCT04820413|OTHER|Faecal microbiota transplantation|FMT by daily enema with donor faeces
223593849|NCT04492111|PROCEDURE|post-extraction dental implant|Insertion of a dental implant immediately after tooth extraction.
223593850|NCT00644488|DRUG|BMS-641988 (AR#2)|Tablets, Oral, 20 mg, 40 mg, 60 mg, 100 mg, once daily, 24 weeks
223593851|NCT00610311|DRUG|cyclophosphamide|60 mg/kg day x 2 days intravenous in 250 ml dextrose 5% in water (D5W) with Mesna 15 mg/kg day x 2 days over 1 hour
223593852|NCT00610311|DRUG|fludarabine phosphate|25 mg/m\^2 day intravenous piggy back over 30 minutes for 5 days
223593853|NCT00610311|BIOLOGICAL|Aldesleukin|720,000 IU/kg intravenously over 15 minutes every 8 hours (+/- 1 hour) for up to 5 days.
223593854|NCT00610311|BIOLOGICAL|ALVAC gp100 Vaccine|0.5 ml containing a target dose of 10\^7 CCID50 (with a range of approximately 10\^6,4 to 10\^7,9/mL) of the gp100 ALVAC virus subcutaneously in each extremity (total of 4 x 10\^7 CCID50/2mL)
223593855|NCT00610311|BIOLOGICAL|anti-gp100:154-162 Tcell receptor (TCR) peripheral blood lymphocyte (PBL)|3 x 10\^11 anti-gp100:154-162 TCR engineered PBL by intravenous infusion. A minimum of approximately 5 x 10\^8 cells will be given.
223593856|NCT00966212|BEHAVIORAL|parent education|Especially for Daughters audio-cd parent education
223593857|NCT06106919|OTHER|surveys (Fertiqol and WHOQOL-BREF)|surveys (Fertiqol and WHOQOL-BREF)
223593858|NCT03332836|BIOLOGICAL|HM12460A|HM12460A is a long-acting insulin
223593859|NCT01363661|DRUG|Coruno|Molsidomine 16 mg tablet, per os, once a day
223593860|NCT01363661|DRUG|Placebo|Placebo (16 mg tablet, per os; once-daily)
223593861|NCT05706441|OTHER|Point-of-Care Ultrasound|Ultrasonographic scans of the lung and right hemidiaphragm were acquired after 30 min from the beginning of the SBT, or immediately before reconnecting the patient to the ventilator in the case of SBT failure occurring before
223593862|NCT02470481|OTHER|No Intervention|This is an obervational study
224196243|NCT06722625|OTHER|Evaluation of a blood pressure monitoring system with an integrated algorithm that supports the doctor's decision-making process|Receiving remote care facilitated by a specialized informatic system to support the physician
224196244|NCT06599684|DRUG|INV-102|0.7% Ophthalmic Solution
224196245|NCT07047352|OTHER|Empirical treatment|Empirical treatment to cover carbapenem-resistant enterobacterales
224310703|NCT03483363|DRUG|intravenous (IV) prophylactic antibiotic|All arms with receive standard parenteral (IV) prophylactic antibiotic.
223593863|NCT05873972|DRUG|Cetuximab|"AEM A：The specialist's decision to add cetuximab to chemotherapy will be based on their own judgment~ARM B：The patient's CT imaging,genetic mutation information were input into the signature, and the FOLFOX+cetuximab regimen was selected when the output label was 1. FOLFOX+bevacizumab chemotherapy regimen was selected when the output label was 0"
223747100|NCT07123467|DRUG|Placebo Matched to Moderate-Dose Cannabidiol|The placebo mimics the appearance, smell, and taste of EPIDIOLEX®. For blinding the moderate-dose cannabidiol arm, dosing starts at 5 mg/kg/day and titrates to 10 milligram/kilogram/day (divided twice a day) after 6 days.
223747101|NCT07123467|DRUG|Moderate-Dose Cannabidiol|Oral cannabidiol solution (EPIDIOLEX®) administered as an adjunct to cognitive behavioral therapy. Moderate-dose participants receive 5 milligram/kilogram/day for 6 days, then titrate to 10 milligram/kilogram/day. The intervention targets emotion regulation circuitry and symptom improvement.
223747102|NCT07123467|DRUG|Placebo Matched to Low-Dose Cannabidiol|The placebo mimics the appearance, smell, and taste of EPIDIOLEX®. For blinding the low-dose cannabidiol arm, dosing is maintained at 5 milligram/kilogram/day (divided twice a day) throughout the treatment period. No titration is required.
224196246|NCT07048353|DRUG|chimeric antigen receptor gene modified T cells|The rate of intravenous infusion of CD30 CAR T cells was 10 mL to 20 mL/min, and the infusion was performed using a blood transfusion apparatus with a filter screen. Use saline rinsing tube prior to infusion; Rinse the infusion bag with 10 mL\~30 mL normal saline.
224196247|NCT07047430|DEVICE|Portable air cleaner with HEPA filter|The Winix 9800 is a true HEPA air cleaner that has been AHAM (Association of Home Appliance Manufacturers) Verifide® for rooms that are 500 square feet in size. The air cleaner has a washable fine mesh pre-filter that captures large airborne particles, an activated carbon filter that reduces volatile organic compounds and odors, and a true HEPA filter that captures 99.99% of airborne allergens as small as 0.003 microns in size.
224196248|NCT07047430|DEVICE|Less effective portable air cleaner (no HEPA)|Winix 9800 air cleaner, with data logging energy use monitor is installed in the child's bedroom. In the sham group, the Winix 9800 true HEPA filter and activated carbon filter were removed. This was an internal modification and not visible to the user. The air cleaner still included a washable fine mesh pre-filter that captures large airborne particles.
224196249|NCT04468984|DRUG|Navitoclax|Tablet; Oral
223593864|NCT03775512|DEVICE|RF Ablation with QDOT Micro|Subjects will be ablated using QDOT Micro catheter
223593865|NCT03704259|OTHER|Ceramic coating|coating the laparoscope lens with commercial brand ceramic coating, bought from car service centers specialized in such applications
223593866|NCT02277925|OTHER|Polytetrafluoroethylene|Suture used to attach mesh during sacral colpopexy surgery
223593867|NCT02277925|OTHER|Polydioxanone|Suture used to attach mesh during sacral colpopexy surgery
223593868|NCT00746434|DRUG|Roflumilast cream|Roflumilast cream 0.5%
223593869|NCT00746434|DRUG|Placebo cream|Placebo cream
223593870|NCT01712425|BIOLOGICAL|0-24 week prime/boost regimen|ChAdV63.HIVcons (5x10\^10 vp) and MVA.HIVconsv (2x10\^8 pfu) HIV-1 vaccines, delivered intramuscularly
223593871|NCT01712425|BIOLOGICAL|0-8 week prime/boost regimen|ChAdV63.HIVcons (5x10\^10 vp) and MVA.HIVconsv (2x10\^8 pfu) HIV-1 vaccines, delivered intramuscularly
223593872|NCT01378325|DRUG|Phenylephrine|Prophylactic variable rate of phenylephrine infusion started at 0.75 µg/kg/min vs saline
223593873|NCT01378325|DRUG|saline|Prophylactic variable rate of saline infusion where we adjusted the pump at a starting rate of 0.75 µg/kg/min, equivalent to 0.0075 mL/kg/min of saline
224310704|NCT01987310|DRUG|atorvastatin|atorvastatin 20 mg per day for 6 months
224310705|NCT01987310|BEHAVIORAL|lifestyle counseling|lifestyle modification by dietician counseling and follow up
224310706|NCT06658535|DRUG|dodecafluoropentane (0.025 mL/kg)|dodecafluoropentane (0.025 mL/kg)
224310707|NCT06658535|DRUG|dodecafluoropentane (0.032 mL/kg)|dodecafluoropentane (0.032 mL/kg)
224310708|NCT06658535|DRUG|dodecafluoropentane (0.050 mL/kg)|dodecafluoropentane (0.050 mL/kg)
223505432|NCT04331405|BIOLOGICAL|Human Allogeneic Umbilical Cord Blood Mononuclear Cells (hUCBMCs) systemic (i.v.) infusions|"HUCBMCs samples were prepared for infusion in the specialized laboratory of Cord Blood Bank (CryoCenter Ltd) and transported to the clinic immediately within 2 hours in the Dry Shipper. All samples were chosen according to patients blood group and rhesus-factor.~All samples were examined for hemotransmissive infections and cell viability prior to the preparation.~Obtained samples were infused through the blood transfusion systems with additional filter after 3 tests for biological and individual compatibility and tolerance.~Each patient of the pilot group received 4 cell infusions (1 infusion per week) with 1 week interval during the in-hospital treatment."
223505433|NCT00761800|DRUG|Lactic acid|
223505434|NCT04058691|DEVICE|Surgical repair|Open surgery
223505435|NCT04955925|DIAGNOSTIC_TEST|Ultrasound examination of the optic nerve sheath diameter|The optic nerve sheath diameter is examined using ultrasonography.
223505436|NCT05625464|OTHER|SCTP|Real-time automated monitoring of the electronic medical record to identify suspected sepsis patients without completion of sepsis bundle measures within 1-hour of the completion deadline and generated reminder pages. Clinicians responsible for patients randomized to the intervention receive reminder pages whereas no pages are sent for control arm patients.
223505437|NCT00080106|BIOLOGICAL|MRK Ad5 HIV-1 gag vaccine|MRK Ad5 HIV-1 gag vaccine injected into the upper arm muscle.
223505438|NCT00080106|OTHER|Vaccine placebo|MRK Ad5 HIV-1 gag placebo vaccine injected into the upper arm muscle.
223505439|NCT02981641|RADIATION|Intraoperative radiotherapy (IORT)|Total dose: 18\~22 Gy; Single dose: 18\~22 Gy; Frequency: 1
223505440|NCT02981641|DRUG|Sequential chemotherapy|Sequential chemotherapy
223505441|NCT02981641|RADIATION|Three dimensional conformal radiation therapy (3D-CRT)|Total dose: 60 Gy; Single dose: 2 Gy; Frequency: 30
223593874|NCT00988273|DEVICE|Confocal endomicroscopy|Patients will undergo confocal endomicroscopy during their endoscopy, and findings of the confocal endomicroscopy in the control group will be compared to the diseased group.
223593875|NCT00988273|DEVICE|Confocal endomicroscopy|Patients will undergo confocal endomicroscopy during their endoscopy, and findings of the confocal endomicroscopy in the diseased group will be compared to the control.
223593876|NCT00280085|PROCEDURE|MR imaging|
223593877|NCT00280085|PROCEDURE|Glucose clamp|
223593878|NCT00280085|DRUG|Arginine|
223747103|NCT06932640|DEVICE|- Non-Invasive Near-infrared Spectroscopy (NIRS) device (HEM1 with Foresight Elite Sensor)|Near-Infrared Spectroscopy (NIRS) monitors, provided by Edwards Lifesciences, is a monitoring technique. It will be connected to consented patients, automatically capturing brain oxygen as waveform output, and stored in Sickbay system. The NIRS is a non-invasive monitoring method, in which adhesive pads will be applied to forehead. 4 hours continuous monitoring will be recorded on day 1 after SAH (or on presence to NICU), then every three days from day 3 to day 14 (within the DCI window), to 1 to 2 recordings from day 15 to day 21.
223593879|NCT06201286|OTHER|Mulligan Concept|"Mulligan Concept was applied by the physiotherapist who received A-B module trainings. Mulligan techniques were performed with 3 sets of 10 repetitions and 15-20 seconds rest between sets. Mobilisations were applied to the spinous process of each vertebra of the lumbar region with 3 sets of 10 repetitions of SNAG and 3 sets of 10 repetitions of NAGS techniques. In the standing position, the physiotherapist took a position next to the patient and stabilised the patient by grasping the abdomen with one arm.~Strengthening exercises were applied to the rectus abdominis, internal and external obliquus, transversus abdominis muscles from flexor muscle groups in 3 sets of 10 repetitions. Stretching exercises were applied to the erector spinae and intertransversarii lumborum muscles from extensor muscle groups as 3 sets of 10 repetitions for 15-30 seconds."
224196250|NCT04468984|DRUG|Ruxolitinib|Tablet; Oral
224196251|NCT04468984|DRUG|Best Available Therapy (BAT)|Tablet/Capsule; Oral or Solution for Subcutaneous Injection
223593880|NCT06201286|OTHER|Stretching and strengthening exercises|Strengthening exercises were applied to the rectus abdominis, internal and external obliquus, transversus abdominis muscles from flexor muscle groups in 3 sets of 10 repetitions. Stretching exercises were applied to the erector spinae and intertransversarii lumborum muscles from extensor muscle groups as 3 sets of 10 repetitions for 15-30 seconds.
223593881|NCT03587441|DRUG|Neostigmine Methylsulfate|20 µg Neostigmine Methylsulfate intrathecal in 0.2 ml of Dextrose 5% solution
223593882|NCT03587441|DRUG|Dextrose 5% in water|intrathecal
223593883|NCT01616680|DRUG|brentuximab vedotin|Given IV
223593884|NCT01616680|OTHER|laboratory biomarker analysis|Correlative studies
223593885|NCT01616680|OTHER|pharmacological study|Correlative studies
223593886|NCT00767806|DRUG|Duloxetine|60 mg orally once daily for 12 weeks
223593887|NCT00767806|DRUG|Placebo|Placebo once daily orally for 12 weeks
223593888|NCT03749811|DEVICE|Pupillometry|After induction of anesthesia and determination of the loss of consciousness of the participant, baseline diameter of pupil is measured by electronic pupillometry device. During anesthesia, participant's pupil diameter is repeatedly measured with 5-minute interval. Pupil dilation of 30% or more compared to baseline is indicative of insufficient analgesia.
223593889|NCT04807335|DRUG|CT001|nasal spray
223593890|NCT04807335|DRUG|Ketamine|iv single dose
223593891|NCT04807335|DRUG|sufentanil|iv single dose
223593892|NCT03482037|DRUG|Rec 0/0438 1 mg or Rec 0/0438 2 mg|Each vial content will be administered via the catheter used for the self-catheterization
223593893|NCT03482037|DRUG|placebo|Each vial content will be administered via the catheter used for the self-catheterization
223593894|NCT02630511|DRUG|Mannitol|Mannitol consists of inhaling 0 (empty capsule acting as a placebo), 5, 10, 20, 40, 80, 160, 160, and 160 mg mannitol, resulting in a maximum cumulative dose of 635 mg
223593895|NCT02630511|DRUG|Methacholine|Methacholine consists of inhaling 0.0625 mg/mL, 0.25 mg/mL, 1 mg/mL, 4 mg/mL, and 16 mg/mL
223593896|NCT02630511|DRUG|Placebo|Placebo consists of inhaling humidified air
223593897|NCT02630511|OTHER|Rest|
223593898|NCT02630511|OTHER|Exercise|
223593899|NCT05990361|DIAGNOSTIC_TEST|clinical diagnostic test|"The clinical diagnosis tests are Active Straight Leg Rise ASLR, Posterior Pelvic Pain Provocation, Long Dorsal Sacroiliac Ligament Palpation (LDSLP), Pelvic Compression, Pelvic Distraction, Patrick-Faber Test (PF), and Gaenslen Test (GT).~The subjects who had at least one positive result from ASLR and P4 Tests; and at least two positive results from the Pelvic Compression and Distraction, PF, GT and LDSLP tests are classified as with PGP group."
223593900|NCT01986608|DRUG|Lacosamide infusion|"Strength: 10 mg/mL for infusion~Form: solution for infusion~Dosage: 200 mg, single dose~Duration: 30-minute infusion or 60-minute infusion"
223593901|NCT01986608|DRUG|Lacosamide oral|"Strength: 200 mg~Form: film-coated tablet~Dosage: 200 mg, single dose~Duration: single oral intake"
223593902|NCT00532688|DRUG|N-acetylcysteine|28 days of oral n-acetylcysteine (500mg bd)(in addition to standard therapy) and then repeat serum creatinine and vascular study then crossover to placebo for 28 days after one week washout period with tests repeated again at 4 weeks and 9 weeks.
223593903|NCT01272635|DRUG|Azithromycin|Suspension, 12 mg/kg once daily for 5 days, maximum dose 500mg/day
223747104|NCT07134127|DRUG|placebo|Placebo (without active ingredients) (cohort1, 2,4) Method of administration: oral, fasted administration. Placebo (without active ingredients) (cohort3) Method of administration: oral, administration after meal.
223747105|NCT07134127|DRUG|IBI3032|IBI3032: (cohort1, 2,4) Method of administration: oral, fasted administration. IBI3032: (cohort3) Method of administration: oral, administration after meal.
224196252|NCT07047950|BEHAVIORAL|Individual Education and Counseling Program|"The educational programme entitled HBM Approach to Prevent CHD was designed by the researcher and delivered as a presentation. The educational sessions were conducted face-to-face at the Cardiology Outpatient Clinic of Van Yüzüncü Yıl University Dursun Odabaş Medical Center and lasted approximately 35-45 minutes. In addition, follow-up telephone calls were made to individuals in the intervention group twice at two-month intervals.~The content of the educational programme was developed based on a comprehensive literature review using resources from the Turkish Society of Cardiology, the WHO, the Ministry of Health, the Turkish Public Health Institution, evidence-based research and previous studies. The programme covered topics such as the definition of CHD, risk factors, treatment, complications, perceived susceptibility and severity of CHD, perceived benefits, barriers and strategies to overcome them, self-efficacy, and rules for engaging in physical activity and maintaining a health"
224196253|NCT07048301|OTHER|BUHOS app|In this study, the BUHOS app initiative will be implemented among participants in the intervention group. BUHOS will be a two-weeks nursing intervention that includes monitoring KAB, employing Education, Guidance and Counseling (education videos), and Surveillance (reminder messages), and assessing the outcomes.
224310709|NCT04726176|BIOLOGICAL|Exposure to COVID-19|To study the exposure of COVID-19 on the brain and executive functioning
223593904|NCT01272635|DRUG|Prednisolone|Syrup, 1 mg/kg/dose twice daily for 5 days, maximum dose 60mg/day
223593905|NCT01272635|OTHER|Placebo Azithromycin|Suspension, 12 mg/kg once daily for 5 days, maximum dose 500mg/day
223593906|NCT01272635|DRUG|Placebo Prednisolone|Syrup, 1 mg/kg/dose twice daily for 5 days, maximum dose 60mg/day
223593907|NCT02196155|DRUG|Botulinum toxin A|"Researchers discovered in the 1950s that injecting overactive muscles with minute quantities of botulinum toxin type-A would result in decreased muscle activity. Botulinum toxin type-A has this effect because it prevents the vesicle where the acetylcholine is stored from binding to the membrane where the neurotransmitter can be released. Botulinum toxin type-A thus blocks the release of acetylcholine by the neuron. This will effectively weaken the muscle for a period of three to four months.~In addition to its cosmetic applications, Botox is currently used in the treatment of spasms and dystonias, by weakening involved muscles, for the 60-70 day effective period of the drug. The main conditions treated with botulinum toxin are: Cervical dystonia (spasmodic torticollis) (a neuromuscular disorder involving the head and neck), Blepharospasm (excessive blinking) etc.."
223593908|NCT02196155|DRUG|cortisone|
223593909|NCT02196155|DRUG|Saline|
223593910|NCT04996251|DRUG|Bupivacaine Injection|0.25% Bupivacaine being used as local anesthetic to inject into incision sites of tracer sites during a laparoscopic/robotic-assisted sacrocolpopexy
223593911|NCT02374567|DRUG|Phenobarbital|
224196254|NCT07048301|OTHER|Control Group|No intervention will be made to the patients in the control group, and the training videos prepared after the study is completed will be shared.
224196255|NCT07045285|DEVICE|Antibacterial Vicryl Plus 2/0|antibacterial Vicryl Plus 2/0 sutures are multifilament absorbable synthetic sutures that are coated with triclosan, a purified antimicrobial.
223593912|NCT02374567|DRUG|Phenytoin|
223593913|NCT02374567|DRUG|Carbamazepine|
223593914|NCT02374567|DRUG|Oxcarbazepine|
223593915|NCT02374567|DRUG|Valproic Acid|
223593916|NCT02374567|DRUG|Lamotrigine|
223593917|NCT02374567|DRUG|Topiramate|
223593918|NCT02374567|DRUG|Gabapentin|
223593919|NCT02374567|DRUG|Levetiracetam|
223593920|NCT02374567|DRUG|Pregabalin|
223593921|NCT02374567|DRUG|Lacosamide|
223593922|NCT02374567|DRUG|Clonazepam|
223593923|NCT02374567|DRUG|Biperiden|
223593924|NCT02374567|DRUG|Levomepromazine|
223593925|NCT02374567|DRUG|Fluphenazine|
223593926|NCT02374567|DRUG|Perphenazine|
223593927|NCT02374567|DRUG|Perazine|
223593928|NCT02374567|DRUG|Thioridazine|
223593929|NCT02374567|DRUG|Haloperidol|
223593930|NCT02374567|DRUG|Melperone|
224196256|NCT07045285|DEVICE|Standard Vicryl 2/0|Vicryl rapid coated 2/0 sutures are multifilament absorbable synthetic sutures not treated with any antimicrobial.
224196257|NCT07047521|BIOLOGICAL|Tetravalent Dengue Vaccine (TDV)|TDV subcutaneous injection
223593931|NCT02374567|DRUG|Pipamperone|
223593932|NCT02374567|DRUG|Bromperidol|
223593933|NCT02374567|DRUG|Benperidol|
223593934|NCT02374567|DRUG|Sertindole|
223593935|NCT02374567|DRUG|Ziprasidone|
223593936|NCT02374567|DRUG|Flupentixol|
223593937|NCT02374567|DRUG|Chlorprothixene|
223593938|NCT02374567|DRUG|Zuclopenthixol|
224196258|NCT07048171|PROCEDURE|Endodontic Micro-Surgery|Surgery performed using bone graft(DFDBA) and iPRF with collagen membrane in test group and bone graft and iPRF without collagen membrane in control group
224196259|NCT07048678|COMBINATION_PRODUCT|preoperative respiratory exercises|Participants in Group 1 will receive a combination of preoperative respiratory exercises designed to improve lung function and reduce the risk of postoperative pulmonary complications. The intervention includes:
224196260|NCT07048678|COMBINATION_PRODUCT|Standard Care (Control Group)|Participants in Group 2 will receive standard preoperative care provided by the hospital, which includes routine instructions related to surgery such as fasting guidelines, medication administration, and anesthesia protocols. No preoperative respiratory exercises (incentive spirometry, chest physiotherapy, or deep breathing exercises) will be provided to this group. This group serves as a control to compare the outcomes with the intervention group.
224196261|NCT07048821|DIETARY_SUPPLEMENT|Dietary modification|3-month dietary plan
223593939|NCT02374567|DRUG|Fluspirilene|
223593940|NCT02374567|DRUG|Pimozide|
223593941|NCT02374567|DRUG|Clozapine|
223593942|NCT02374567|DRUG|Olanzapine|
223593943|NCT02374567|DRUG|Quetiapine|
223593944|NCT02374567|DRUG|Sulpiride|
223593945|NCT02374567|DRUG|Tiapride|
223593946|NCT02374567|DRUG|Amisulpride|
223593947|NCT02374567|DRUG|Prothipendyl|
223593948|NCT02374567|DRUG|Risperidone|
223593949|NCT02374567|DRUG|Aripiprazole|
223593950|NCT02374567|DRUG|Paliperidone|
223593951|NCT02374567|DRUG|Diazepam|
223593952|NCT02374567|DRUG|Oxazepam|
223593953|NCT02374567|DRUG|Lorazepam|
223593954|NCT02374567|DRUG|Bromazepam|
223593955|NCT02374567|DRUG|Clobazam|
223593956|NCT02374567|DRUG|Alprazolam|
223593957|NCT02374567|DRUG|Hydroxyzine|
223593958|NCT02374567|DRUG|Buspirone|
223593959|NCT02374567|DRUG|Chloral Hydrate|
223593960|NCT02374567|DRUG|Flurazepam|
223593961|NCT02374567|DRUG|Nitrazepam|
223593962|NCT02374567|DRUG|Triazolam|
223593963|NCT02374567|DRUG|Lormetazepam|
223593964|NCT02374567|DRUG|Temazepam|
223593965|NCT02374567|DRUG|Midazolam|
223593966|NCT02374567|DRUG|Brotizolam|
223593967|NCT02374567|DRUG|Zopiclone|
223593968|NCT02374567|DRUG|Zolpidem|
223593969|NCT02374567|DRUG|Zaleplon|
223593970|NCT02374567|DRUG|Melatonin|
223593971|NCT02374567|DRUG|Clomethiazole|
223593972|NCT02374567|DRUG|Diphenhydramine|
223593973|NCT02374567|DRUG|Promethazine|
223593974|NCT02374567|DRUG|Imipramine|
223593975|NCT02374567|DRUG|Clomipramine|
224196262|NCT07043816|BEHAVIORAL|PharmaTE Trial|In addition to standard care, patients in the PharmaTE trial interventional group will receive tele-education led by a clinical pharmacist who has completed a training course and is certified as a diabetes educator. The tele-education program is comprised of five individualized educational sessions, each lasting approximately 20-30minutes and held at two-month intervals. These sessions are conducted via Zoom or telephone based on patient preference. Before the beginning of each session, participants will receive a reminder message along with the Zoom meeting invitation link about the session, covering various educational topics related to diabetes management. Additionally, after each session, patients will receive a brochure summarizing what has been discussed.
224196263|NCT07048652|DIAGNOSTIC_TEST|High-Resolution Computed Tomography|High-resolution computed tomography (HRCT) plays a crucial role in diagnosing and managing Idiopathic Pulmonary Fibrosis (IPF). It helps identify the characteristic pattern of IPF, known as Usual Interstitial Pneumonia (UIP), and can sometimes obviate the need for lung biopsy.
224196264|NCT07048275|BEHAVIORAL|Virtual Reality Chest Percussion Teaching Program|Participants will be assessed at two time points: on the day of hospital admission or transfer, and on the fourth day after the teaching intervention.
224196265|NCT07047092|DEVICE|Non-invasive Ventilation (NIV)|Patients will receive a dedicated training for the use of their NIV in the home setting. The training is the same provided in the usual care of patients established on NIV. They will choose a home care provider for the delivery of NIV as per standard care in France. A telemonitoring of adherence to NIV will be performed.
224196266|NCT07047092|DEVICE|Continous Positive Airway Pressure (CPAP)|Patients will receive a dedicated training the use of their CPAP in the home setting. The training is the same provided in the usual care of patients established on CPAP. They will choose a home care provider for the delivery of CPAP as per standard care in France. Follow-up of CPAP will be performed according to standard care in France and will therefore include a telemonitoring of adherence to CPAP.
224196267|NCT06893887|DRUG|FOLFOX4|FOLFOX4 was administered by oxaliplatin 85 mg/m² d1+ leucovorin 200 mg/m² d1-2+ fluorouracil 400 mg/m² 2 h→ 600 mg/m² 24 h d1-2 q2w, with a total of 4 cycles
223505442|NCT02981641|DRUG|Concurrent chemotherapy|Gemcitabine (GEM), 800 mg/m2 weekly on Day 1-21, Q28d; or S-1 orally, 400 mg/d, bid on Day 1-21, Q28d
223505443|NCT05542602|BEHAVIORAL|Social intervention|The social intervention consists of four 90-minute sessions per week delivered over eight weeks by paraprofessional staff as part of the children's existing after-school program. The sessions follow a schedule and include social skills groups, social recreational games, and a reinforcement system to teach, practice, and reinforce targeted social knowledge and social skills. The sessions are manualized and include a specific instructional sequence and treatment (lesson) plan for the paraprofessional staff to implement. The children also earn points for use of the targeted skills (frequency of use) and each can earn a home or site-based reinforcer for reaching her/his targeted number of points each session. Each group is facilitated by two paraprofessionals, and includes 12-15 children including two with hfASD (the remaining will be typically-developing peers).
223505444|NCT03355456|PROCEDURE|Radiofrequency ablation|Ablation procedure to eliminate atrial fibrillation
223505445|NCT02310607|OTHER|Not an interventional study|Not an interventional study
224196268|NCT06893887|DRUG|Adebrelimab|Adebrelimab 1200mg, intravenous infusion, every 3 weeks
224196269|NCT06893887|DRUG|Apatinib|Apatinib 250mg, oral, once daily.
224196270|NCT06893887|DRUG|Icaritin|Epimedium extract soft capsules 2.4g, oral, 2 times daily.
224196271|NCT06893887|DRUG|SHR-1701|SHR1701，30mg/kg, intravenous infusion, every 3 weeks, use for up to 2 years at most.
224196272|NCT06893887|DRUG|QL1706|QL1706，5mg/kg, intravenous infusion, every 3 weeks, use for up to 2 years at most.
224196273|NCT06893887|DRUG|Bevacizumab|Bevacizumab 7.5mg, intravenous infusion, once every 3 weeks.
224196274|NCT06893887|PROCEDURE|HAIC|Hepatic Arterial Infusion Chemotherapy
224196275|NCT06893887|PROCEDURE|Local treatment|Local treatment of oligo-metastases.
224196276|NCT06893887|DRUG|The original treatment regimen|Continue the original targeted therapy combined with immunotherapy. dosage, dosage form,frequency of administration was the same as before.
223505446|NCT01938937|DEVICE|Transcranial bright light device|
223505447|NCT01938937|DEVICE|Transcranial sham device|
223505448|NCT01249196|DRUG|SK-PC-B70M|for dosage
223505449|NCT01055327|DRUG|Lamotrigine monotherapy|Exposure to lamotrigine monotherapy in the first trimester of pregnancy (time period from first day of menstrual period to 12th week of gestation).
223505450|NCT01055327|DRUG|No anti-epileptic drug exposure|No exposure to anti-epileptic drugs in the first trimester of pregnancy (time period from first day of menstrual period to 12th week of gestation).
223593976|NCT02374567|DRUG|Opipramol|
223593977|NCT02374567|DRUG|Trimipramine|
223593978|NCT02374567|DRUG|Amitriptyline|
223593979|NCT02374567|DRUG|Nortriptyline|
223593980|NCT02374567|DRUG|Doxepin|
223593981|NCT02374567|DRUG|Maprotiline|
223593982|NCT02374567|DRUG|Amitriptyline oxide|
223593983|NCT02374567|DRUG|Fluoxetine|
223593984|NCT02374567|DRUG|Citalopram|
223593985|NCT02374567|DRUG|Paroxetine|
223593986|NCT02374567|DRUG|Sertraline|
223593987|NCT02374567|DRUG|Fluvoxamine|
223593988|NCT02374567|DRUG|Escitalopram|
223593989|NCT02374567|DRUG|Tranylcypromine|
223593990|NCT02374567|DRUG|Moclobemide|
223593991|NCT02374567|DRUG|Mianserin|
223593992|NCT02374567|DRUG|Trazodone|
223593993|NCT02374567|DRUG|Mirtazapine|
223593994|NCT02374567|DRUG|Bupropion|
223593995|NCT02374567|DRUG|Venlafaxine|
223593996|NCT02374567|DRUG|Reboxetine|
223593997|NCT02374567|DRUG|Duloxetine|
223593998|NCT02374567|DRUG|Agomelatine|
223593999|NCT02374567|DRUG|Pyritinol|
223594000|NCT02374567|DRUG|Piracetam|
223594001|NCT02374567|DRUG|Donepezil|
223594002|NCT02374567|DRUG|Rivastigmine|
223594003|NCT02374567|DRUG|Galantamine|
223594004|NCT02374567|DRUG|Memantine|
223594005|NCT02374567|DRUG|Nicergoline|
223594006|NCT02374567|DRUG|Acamprosate|
223594007|NCT02374567|DRUG|Lithium|
224196277|NCT04170244|OTHER|AD subject visit sampling procedures|Skin swabs for microbial analysis, Tape stripping and transepidermal water loss measurements (TEWL) with tape stripping (all patients) to assess skin barrier function, blood serum (adults \& optional for adolescents), and optional biopsy (adults only)
224196278|NCT04170244|OTHER|PS subject visit sampling procedures|Skin swabs for microbial analysis, Tape stripping and transepidermal water loss measurements (TEWL) with tape stripping (all patients) to assess skin barrier function, and blood serum (optional for all PS subjects)
224196279|NCT04170244|OTHER|Healthy control visit sampling procedures|Skin swabs for microbial analysis, Tape stripping and transepidermal water loss measurements (TEWL) with tape stripping (all patients) to assess skin barrier function, blood serum (adults \& optional for adolescents), and optional biopsy (adults only)
223505451|NCT01055327|DRUG|Non lamotrigine anti-epileptic drug monotherapy|Exposure to non lamotrigine monotherapy (with or without valproate) during the first trimester of pregnancy (time period from the first day of the menstrual period to the 12th week of gestation)
223505452|NCT02468453|DEVICE|velos|VELOS combines 595nm pulsed dye laser energy with bipolar RF energy. The study device can deliver 0.45 to 40 ms laser pulses at a maximum of 25 J/cm2
223594008|NCT06583499|BEHAVIORAL|Sustainable nutrition education based on the transtheoretical model|"Before the intervention begins, the Sustainable Nutrition Behaviour Change Stage Survey will be administered to determine participants' training stage. In addition, the Transtheoretical Model (TTM) Based Sustainable Nutrition Scales will be administered to evaluate the effectiveness of the training programme.~TTM Based Nutrition Training Programme consists of 11 modules developed according to the stages of the model.The methodology and tools used are aligned with the objectives of the training programme.The training modules are offered twice a week, with each session lasting a maximum of 40 minutes and continues for a total of 5 weeks. Participants may attend more than one training session in order to develop behaviours that increase adherence to a sustainable diet. At the end of the training programme, data from the Transtheoretical Model-Based Sustainable Nutrition Behaviour Scale will be collected again and evaluated by comparison with the baseline data set.."
223594009|NCT02314832|PROCEDURE|adductor canal block|ultrasound guided saphenous nerve block in the adductor canal
223594010|NCT02314832|PROCEDURE|femoral nerve block|ultrasound guided femoral nerve block
223594011|NCT04240158|DRUG|IW-6463|IW-6463 Tablet
223594012|NCT04240158|DRUG|Matching Placebo|Matching Placebo Tablet
223505453|NCT06237491|DRUG|177Lu-LNC1003 Injection group 1|The treatment regimen will consist of a single dose 30 mCi intravenous administration of 177Lu-LNC1004 Injection per 6-week cycle, for a total of 2 cycles, the dose per cycle will be fixed.
223505454|NCT06237491|DRUG|177Lu-LNC1003 Injection group 2|The treatment regimen will consist of a single dose 50 mCi intravenous administration of 177Lu-LNC1004 Injection per 6-week cycle, for a total of 2 cycles, the dose per cycle will be fixed.
223505455|NCT06237491|DRUG|177Lu-LNC1003 Injection group 3|The treatment regimen will consist of a single dose 70 mCi intravenous administration of 177Lu-LNC1004 Injection per 6-week cycle, for a total of 2 cycles, the dose per cycle will be fixed.
223505456|NCT03821597|PROCEDURE|Sequential compression devices (SCDs)|Application of sequential compression devices in surgery.
223505457|NCT03821597|PROCEDURE|No sequential compression.|No sequential compression devices are applied.
223505458|NCT05661968|OTHER|Online educational program|The intervention group will receive an online educational program, containing current information on low back pain management according to international clinical practice guidelines. Program content includes recommendations on assessment, diagnosis, and treatment of low back pain. The online program has 6 units of studies, with the content offered in the formats of video classes, infographics, texts, websites and clinical cases. The participant must complete the course within 6 weeks and will be able to set their own pace. Participants in the intervention group will receive their login and access password via email.
223505459|NCT03003468|DRUG|Imprime PGG|Arm A: Phase Ib Cohort 1: 2mg/kg IV; Arm A: Phase Ib Cohort 2: 4mg/kg IV
223505460|NCT03003468|DRUG|MK-3475|200mg IV
223505461|NCT03003468|DRUG|Imprime PGG|Arm B: Phase II treatment: administered at the maximum safe dose of 2mg or 4 mg as established in the Phase Ib cohort study.
223505462|NCT00150553|DRUG|Extended-release carbamazepine|
223505463|NCT01076517|DEVICE|Therasphere|Beta-emitting 90yttrium encapsulated in glass microspheres for intraarterial administration to the liver.
223505464|NCT01717508|BEHAVIORAL|Cognitive Behavioral Therapy|12 sessions of cognitive behavioral therapy
223505465|NCT00997529|DRUG|nonmyeloablative stem cell transplant|Conditioning includes cytoxan 60mg/kg/d on Days 6 \& 5, total dose 120mg/kg, Fludarabine 25mg/m2/d on days -5 to -1, total dose 125mg/m2. Patients with decreased cardiac or liver function pre-transplant will have their dose of cytoxan reduced by 25% - 45 mg/kg/d for 2 days or total dose of 90mg/kg. Patients will receive G-CSF (5ug/kg) to foster engraftment. PBSC progenitors will be mobilized from donor with G-CSF 5ug/kg 2x daily starting 4 days prior to stem cell collection until a target of 5-10 x106 CD34+ cells/kg is reached. Peripheral blood progenitors will be isolated from leukaphereses obtained on Days 5 \& 6 with additional collections dependent on cell yields. Peripheral blood from donors will be given to patients 1 day after cytoreduction \& immunosuppression. Immunosuppression will be tapered Day +60 if no signs of GVHD. Patients with residual non-regressing disease or mixed chimerism after day 100, who are off immunosuppression \& do not have signs of GVHD, will receive a DLI
223505466|NCT03362320|PROCEDURE|double layer fixation|
223505467|NCT03362320|PROCEDURE|single layer fixation|
223505468|NCT05419258|DEVICE|UPLUG Hemodialysis Connection Device|use of the device UPLUG during 1 month
223594013|NCT00356343|DEVICE|NMES Strength Training|Subjects will complete 12 weeks of NMES isometric strength training using implanted electrodes in bilateral quadriceps and triceps surae muscles.
223594014|NCT00356343|OTHER|Volitional Strength Training|Subjects will complete 12 weeks of volitional isometric strength training of bilateral quadriceps and triceps surae muscles.
223594015|NCT06423924|OTHER|no intervention|no intervention
223594016|NCT03277027|OTHER|interventional study|The participants wear a monitoring equipment (Actigraph) for a week. And parents do Child Health Questionnaire Parent Form 50 (CHQ-PF50), and Korean Parenting Stress Index-Short Form (K-PSI-SF)
223594017|NCT05347706|DIETARY_SUPPLEMENT|formula|Enteral feeding is started with in the first 24 hours of life. Human milk is encouraged, and preterm formula is fed when human milk is not available due to mother's or family's condition. Patients with feeding intolerance are temporarily fed with AAF or EHF instead of human milk or preterm formula. Once the patients with feeding intolerance show clinical improvement, AAF or EHF feeding is discontinued, and the previous feeding, either human milk or preterm formula is resumed
223594018|NCT02435420|DEVICE|EMPERION Modular Primary Stem|Primary total hip arthroplasty using the EMPERION Modular Primary Stem
223594019|NCT04602442|DRUG|EXO 1 inhalation|Twice a day during 10 days inhalation of 3 ml special solution contained 0.5-2x10\^10 of nanoparticles (exosomes) of the first type.
223594020|NCT04602442|DRUG|EXO 2 inhalation|Twice a day during 10 days inhalation of 3 ml special solution contained 0.5-2x10\^10 of nanoparticles (exosomes) of the second type.
223594021|NCT04602442|DRUG|Placebo inhalation|Twice a day during 10 days inhalation of 3 ml special solution free of nanoparticles (exosomes).
223594022|NCT03853863|BEHAVIORAL|in-school walking training with minimalist shoes|Participants in the MSW group will be given a pair of minimalist shoes for all in-school activities (i.e., 5 days/week and 7 hours/day) for 12 weeks. Similar to previous minimalist footwear studies, the intervention duration will be gradually increased over the 12-week training. In brief, subjects will wear the minimalist shoes for 1 out of 5 school days at the first week; 2 days at the second week, and so on until fully use of the minimalist shoes at the fifth week.
223747106|NCT00483223|DRUG|Cisplatin|Given intravenously on the first day of each 3-week treatment cycle at 75mg/m2. Participants may continue to receive study treatment as long as their disease does not worsen and they do not experience serious side effects.
223747107|NCT00483223|DRUG|carboplatin|Given intravenously on the first day of each 3-week treatment cycle at AUC 6. Participants may continue to receive study treatment as long as their disease does not worsen and they do not experience serious side effects.
223747108|NCT05078866|BIOLOGICAL|Adenoviral Tumor-specific Neoantigen Priming Vaccine GAd-209-FSP|Given IM
223747109|NCT05078866|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
224196280|NCT07047066|DRUG|Fluzoparib with Temozolomide|"Fluzoparib: 100mg, po.bid. Q4W, d1-28, for a total of 6 cycles~Temozolomide (TMZ): 150-200 mg/m2, po. Q4W, d1-5, for a total of 6 cycles~If unacceptable toxicity occurs and a dose reduction is required, it is recommended to first reduce the dose from 100 mg (2 tablets) to 50 mg (1 tablet) twice a day. If further dose reduction is required, it is recommended to reduce the dose from 50 mg (1 tablet) twice a day to 50 mg (1 tablet) once a day. If it is still intolerable, the patient should withdraw from the clinical study.~The TMZ dose is adjusted by the investigator according to standard chemotherapy requirements. Adjuvant TMZ treatment of less than 6 cycles is allowed depending on the subject's condition (e.g. confirmed disease progression, intolerable toxicity, etc.). Tumor assessment is performed during two cycles of TMZ (q8w±7 days) during the study or when clinically indicated"
224196281|NCT06267989|PROCEDURE|Extraction of the primary canine teeth|Extraction of the primary teeth has show to be successful in some cases.
224196282|NCT06267989|PROCEDURE|Expansion|Expansion of the maxilla with rapid maxillary expander with no extractions
223594023|NCT03853863|BEHAVIORAL|in-school walking training with protective shoes|Participants in the TSW group will be given a pair of given a pair of protective shoes with arch support for all in-school activities (i.e., 5 days/week and 7 hours/day) for 12 weeks,while follow the same wearing pattern as the MSW group.
223747110|NCT05078866|PROCEDURE|Endoscopic Biopsy|Undergo endoscopy with biopsy
223747111|NCT05078866|BIOLOGICAL|MVA Tumor-specific Neoantigen Boosting Vaccine MVA-209-FSP|Given IM
223747112|NCT05078866|OTHER|Questionnaire Administration|Ancillary studies
223747113|NCT06935474|BIOLOGICAL|C-CAR168|This is a multi-center, Phase 1/2, open-label, dose-escalation and dose-expansion study evaluating C-CAR168 for the treatment of autoimmune diseases refractory to standard therapy. A traditional 3+3 design is used to identify the Maximum Tolerated Dose (MTD) and/or Recommended Dose (RD) in disease-specific cohorts.
224196283|NCT06895460|DRUG|Budesonide Formoterol|Investigator Selection
224196284|NCT06895460|DRUG|Placebo|Placebo: 0.3 mg/tablet, 4 tablets per dose, 3 times per day, for a course of 3 months
223594024|NCT05055817|OTHER|bloody stool group|bloody stool appear in the hospitalized neonate
223594025|NCT05055817|OTHER|non-bloody stool group|bloody stool do not appear in the hospitalized neonate
223594026|NCT02397057|DRUG|Injectafer|
223594027|NCT02397057|OTHER|Placebo|
223594028|NCT00099658|BIOLOGICAL|Pneumococcal polysaccharide-protein conjugate vaccine|Injection administered three times before the age of 24 weeks
223594029|NCT02235896|BEHAVIORAL|Education/Behavior Modification|Education, lifestyle counseling, experiential cooking, exercise classes.
223594030|NCT06069947|PROCEDURE|sequential adult left lateral lobe liver transplantation (SALT)|Hemihepatectomy combined with left lateral lobe liver transplantation was performed first, and residual liver resection was performed after the graft grew to a sufficient functional liver volume.
223747114|NCT06933498|PROCEDURE|PREOPERATIVE ESPB|After 0.03 mg/kg IV midazolam sedation is applied to patients who will undergo preoperative ESPB, bilateral ultrasound-guided ESPB (in-plane approach) will be applied over the vertebral level that is equidistant from the highest and lowest vertebral levels planned for surgery in the prone position. ESPB will be performed by experienced anesthesiologists. After sterilization of the skin with povidone iodine, the probe with a sterile sheath is placed 3 cm lateral to the spinous process and the trapezius, rhomboid major, erector spinae muscles and the transverse process of the vertebrae are visualized. The needle is placed in the fascial plane on the deep surface of the erector spinae muscle on the bone shadow of the transverse process of the vertebra. A total of 40 mL of 0.25% bupivacaine is administered bilaterally after the LA spread is seen. After waiting for the effect of the block for 30 minutes, the patients will be taken to the operating room.
224196285|NCT06895460|DRUG|Immune Modulators (Staphylococcus and Neisseria Tablets)|Staphylococcus and Neisseria Tablets: 0.3 mg/tablet, 4 tablets per dose, 3 times per day, for a course of 3 months
224196286|NCT06746623|DIAGNOSTIC_TEST|Enrolled participants will complete Esocheck/Esoguard and diagnostic upper endoscopy.|"Esocheck (EC)/Esoguard (EG): EC is a encapsulated balloon device available commercially from Lucid Diagnostics (New York, NY). EG assay uses bisulfite sequencing for detection of aberrant methylation in the vimentin and cyclin A1 genomic loci, respectively.~EGD (upper endoscopy): EGD will be performed by gastroenterologists practicing in the Louis Stokes Cleveland VA Medical Center Endoscopy laboratories on the same day when EC/EG is performed."
224196287|NCT05689554|BEHAVIORAL|STOP Falls Educational Intervention|This is a pragmatic, cluster-randomized, parallel-group, controlled clinical trial. The unit of randomization is the clinic, to avoid the risk of contamination if healthcare providers within a clinic were randomized (i.e., reducing the potential for intervention providers to communicate with control providers about the intervention and share materials). Eighteen clinics were identified for the trial, of which 9 were randomized to the intervention and 9 to usual care.
224196288|NCT00551629|BIOLOGICAL|AR51 (12, 10)|vaccine formulation containing 12 mcg of PRP-T and 10 mcg of HBsAg
224196289|NCT00551629|BIOLOGICAL|PR51 (3, 10)|vaccine formulation containing 3 mcg of PRP-OMPC and 10 mcg of HBsAg
224196290|NCT00551629|BIOLOGICAL|PR51 (6, 10)|vaccine formulation containing 6 mcg of PRP-OMPC and 10 mcg of HBsAg
224196291|NCT00551629|BIOLOGICAL|PR51 (6, 15)|vaccine formulation containing 6 mcg of PRP-OMPC and 15 mcg of HBsAg
223594031|NCT01632436|DRUG|Pixantrone|Experimental Drug
223594032|NCT03781453|BEHAVIORAL|POWERPLAY|"Employees from participating worksites will be invited to completed surveys prior to and following implementation of a workplace wellness program (called POWERPLAY)"
223594033|NCT00966251|DRUG|CT-011|CT-011
223594034|NCT05359835|DRUG|Calcium DTPA and Zinc DTPA|Intravenous administration of 2.5 mL (500 mg) of Ca-DTPA over one minute, followed by 900 mL of normal saline infusion over about 90 minutes, followed by 2.5 mL (500 mg) of Ca-DTPA over one minute, followed by infusion of the remaining 100 mL of normal saline over about 10 minutes. Procedure repeated with Zn-DTPA the following day. Two-day procedure repeated at an interval of one week or more for a total of six 2-day treatment sessions.
223594035|NCT01393639|DRUG|PF-04171327|1 mg tablet once daily (QD) for 8 weeks
223594036|NCT01393639|DRUG|PF-04171327|5 mg tablet once daily (QD) for 8 weeks
223594037|NCT01393639|DRUG|PF-04171327|10 mg tablet once daily (QD) for 8 weeks
223594038|NCT01393639|DRUG|PF-04171327|15 mg tablet once daily (QD) for 8 weeks
223594039|NCT01393639|DRUG|prednisone|5 mg capsule once daily for 8 weeks
223594040|NCT01393639|OTHER|prednisone|10 mg capsule once daily for 8 weeks
223747115|NCT06933498|PROCEDURE|INTRAOPERATIVE ESPB|Intraoperative ESPB will be performed by the neurosurgeon after LDH repair, starting from the level of the operated vertebra and covering all surgical segments. This procedure will be repeated for the other side (right/left). A total of 40 mL of 0.25% bupivacaine will be used for both sides.
223747116|NCT00508807|DRUG|RTA 402|5 mg by mouth (PO) daily for 21 days
223747117|NCT00640445|BEHAVIORAL|Expressive Writing|In EW, people are asked to write about their deepest thoughts and feelings surrounding a significant life event for 20 minutes a day for 4 days
224196292|NCT05613075|PROCEDURE|tooth extraction and socket preservation with demineralized tooth graft|tooth extraction and socket preservation with demineralized tooth graft
224196293|NCT05613075|PROCEDURE|tooth extraction and socket preservation with demineralized tooth graft with hyaluronic acid|tooth extraction and socket preservation with demineralized tooth graft with hyaluronic acid
224196294|NCT06822413|OTHER|No Interventions|All blood samples from participating patients were obtained from routine clinical blood tests conducted during hospital admission or other necessary medical evaluations, followed by serum extraction.
224196295|NCT06742502|DRUG|Sintlimab+Rituximab follwed by R-CHOP(Cyclophosphamide, doxorubicin, vincristine, prednisone)|First strategy of targeted immunotherapy followed by chemotherapy for PMBL. Participants will first receive sintilimab(200mg) plus rituximab(375mg/m2) for 2 cycles. If patients achieve CR or CMR, they will continue to receive 2 courses of sintilimab plus rituximab, followed by 4 cycles of R-CHOP. Patients will receive 6 courses of R-CHOP if they do not achieve CR or CMR after 2 cycles of sintilimab plus rituximab. Patients will undergo PET-CT assessment and will receive 6 cycles of maintenance treatment with nintedanib if CR/CMR/PR is achieved and will be withdrawn from the study if SD/PD occurs. Total treatment cycles will not exceed 14 cycles.
224196296|NCT06373432|OTHER|Fingerstick|Fingerstick to check glucose value during labor.
223594041|NCT01393639|OTHER|placebo|placebo (tablet or capsule) once daily (QD) for 8 weeks
223594042|NCT04473248|DEVICE|Spartan COVID-19 System|PCR analysis of patient samples using the Spartan COVID-19 System
223594043|NCT01657734|OTHER|MR imaging|MR imaging
223594044|NCT02282280|DRUG|Prilocaine Chlorhydrate|Use of prilocaine in spinal anesthesia
223594045|NCT04183608|DRUG|Adalimumab|Patients will all receive Adalimumab 160/80/40mg EOW until V1 (W14) followed by 40mg EOW until V2 (W26)
223594046|NCT04183608|DIAGNOSTIC_TEST|Calprotectin|Fecal calprotectin dosing at home with IBDoc
223594047|NCT04183608|OTHER|e-Monitoring|"e-Monitoring at Week 6, Week 10, Week 14, Week 18, Week 22, Week 26, Week 34, Week 38, Week 42 and Week 48~The patient must complete the first 2 questions of the Mayo score:~* Stool frequency~* The frequency of bleeding~He must also complete the information on his injections"
223594048|NCT04183608|OTHER|Therapy Education|Patient Education at W0, W2, W14, W26 and W38.
223594049|NCT03127423|PROCEDURE|Hybrid ablation|This intervention includes totally thoracoscopic surgical ablation and percutaneous catheter ablation simultaneously.
223594050|NCT03127423|PROCEDURE|Thoracoscopic surgical ablation|This intervention only includes totally thoracoscopic surgical ablation without percutaneous catheter ablation.
223594051|NCT00450645|DRUG|low molecular weight heparin|LMWH were continued for additional 6 months after detection of residual vein thrombosis (6 months after the index deep vein thrombosis) in patients randomized to group A. LMWH are stopped in patients randomized to group B or in those patients without residual vein thrombosis after 6 months from the index DVT. Dosage of LMWH are 75% of the therapeutic dosage (almost 1 mg/Kg every 12 hours)
223594052|NCT03300921|DRUG|Paricalcitol|"Product: Paricalcitol~Dose/Route/Regimen:~Arm A: 50mcg IV weekly Arm B: 12mcg PO daily"
223747118|NCT00640445|BEHAVIORAL|Control Writing|Those assigned to control writing conditions are asked to describe factual information for 20 minutes a day for 4 days.
223747119|NCT01344161|DIETARY_SUPPLEMENT|Placebo|dosage form:lactose dosage: 25 micrograms frequency: every day duration: 12weeks
223505469|NCT04679246|BEHAVIORAL|Participatory intervention|Surveillance in compliance with the regulation of the sale of food in school buildings, according to official guidelines Training for the preparation of hygienic and healthy food for the personnel in charge of food sale Promotion of the consumption of simple water and healthy foods Reconditioning of the infrastructure for the consumption of simple water, free and healthy food, and the realization of physical activity Organization of events and support in the coordination of groups that promote physical activity at the community level Optimization of physical education classes at school sites Implementation of health promotion and care actions in the school context Development of skills in the school community for health care and generation of healthy school environments Creation and strengthening of health and nutrition committees in schools, with the participation of directors, teachers and parents to generate necessary and permanent conditions that favor healthy environments
223747120|NCT01344161|DIETARY_SUPPLEMENT|vitamin D|dosage form:cholecalciferol dosage: 25 micrograms (1000 International Unit) frequency: every day duration: 12weeks
224196297|NCT04810858|OTHER|Multimodal, multi-parametric MRI|The investigators will use multimodal, multi-parametric sequences to investigate neuroinflammatory and neurodegenerative processes in vivo. Participants will be assessed three times over 2 years.
224196298|NCT04810858|OTHER|Immune and cytokine profiling|Blood samples will be collected for immune and cytokine profiling. Participants will be assessed three times over 2 years.
224196299|NCT04810858|BEHAVIORAL|Neuropsychological testing|Participants will have neuropsychological testing three times over 2 years.
224196300|NCT06761716|BEHAVIORAL|Ericksonian Hypnotherapy|Participants in this group will receive 12 weekly sessions of 50 minutes each. The therapy will focus on tailored hypnotic suggestions, subconscious communication techniques, and trauma-focused interventions specifically designed to address PTSD symptoms. Sessions will be conducted by a certified hypnotherapist under clinical supervision.
224196301|NCT06761716|BEHAVIORAL|Cognitive Behavioral Therapy|Participants in this group will receive 12 weekly sessions of 50 minutes each. The therapy will utilize cognitive restructuring techniques, exposure exercises, and behavioral interventions aimed at reducing PTSD symptoms. Sessions will be led by a licensed psychotherapist trained in trauma-focused CBT.
223505470|NCT06255548|OTHER|Immersive virtual reality group|The children in the IVR group were offered two video games from the Oculus Quest gallery. These games were Ocean Rift and Epic Roller Coaster-T-Rex Kingdom. Ocean Rift is the world's first VR water safari park. It has 12 different marine animals such as dolphins, sharks, and turtles and a habitat. Here one can visit a vibrant underwater world that extends all the way to the Arctic and Atlantis. Epic Roller Coaster-T-Rex Kingdom takes one on a roller coaster ride through the Age of Dinosaurs. There are more than 10 species of dinosaurs such as terrestrial, flying, herbivorous and carnivorous.
223505471|NCT06255548|OTHER|Music group|In musical interventions, it is recommended to play music chosen by individuals. Disposable ear pads were used for each child and the headphones were cleaned after each intervention.
223505472|NCT04373733|DRUG|Favipiravir|Anti-viral
223505473|NCT04373733|OTHER|Standard of care management|Standard of care management for COVID-19
223505474|NCT02516436|DRUG|BEMA Buprenorphine NX|Buprenorphine with naloxone
223505475|NCT02516436|DRUG|Buprenorphine|Buprenorphine
223505476|NCT00929032|RADIATION|Nanocoll®|To determine reticuloendothelial system (RES) phagocytosis activity and liver phagocytic function respectively we will measure plasma clearance of 99mTc labelled micro-aggregated human albumin without any imaging studies.
223505477|NCT04557644|OTHER|7-items-questionnaires addressing CI, disgust and empathy|7-items-questionnaire including numerical rating scales (NRS) ranging from 0 (no itch/disgust/empathy) to 10 (worst itch/disgust/most empathy imaginable) to rate itch, disgust and empathy they experience when treating the infested families.
223505478|NCT04557644|OTHER|Saarbrucken Personality questionnaire (SPQ) addressing empathy.|Empathy is additionally assessed by the Saarbrucken Personality Questionnaire (SPQ) ,a 16-item tool.
223505479|NCT04557644|OTHER|10-items-questionnaire addressing previous dermatological conditions, intensity of itch|10-items-questionnaire (completed by the hospitalised family) regarding demographic information (gender, age, profession), previous dermatological conditions, intensity of itch a.) on the first day of the hospitalisation, b.) when seeing the skin lesions of the other family members c.) when talking about the scabies/itch with the other family members, d.) when seeing other family members scratching themselves, and questions regarding their intensity of disgust of the scabies and empathy for the other family members (0-10 NRS).
223505480|NCT04557644|OTHER|ItchyQol-questionnaire composed of 22 items addressing itch-related symptoms, functions and emotions|ItchyQol-questionnaire to assess the itch-related quality of life impairment. The ItchyQoL is composed of 22 items addressing itch-related symptoms, functions and emotions.
223505481|NCT00498732|DEVICE|CPAP|CPAP treatment for 4 weeks
223505482|NCT02919332|PROCEDURE|Computed Tomography|Undergo 18F-FDG PET/CT
223505483|NCT02919332|RADIATION|Fludeoxyglucose F-18|Given IV
223505484|NCT02919332|PROCEDURE|Positron Emission Tomography|Undergo 18F-FDG PET/CT
223505485|NCT03319888|DEVICE|CPAP|continuous positive pressure in the airway
223505486|NCT03319888|OTHER|conservative treatment|conservative treatment group with lifestyle modifications
223505487|NCT01346683|DEVICE|OsseoSpeed TX|OsseoSpeed TX implants of lengths 8-17 mm
223505488|NCT03228407|PROCEDURE|Confocal endomicroscopy|Confocal laser endomicroscopy (CLE) permits real-time in-vivo histologic analysis of esophageal mucosa at the time of upper endoscopy. The technology is based on the principle of illuminating a tissue with a low-power laser and then detecting fluorescent light reflected from the tissue. Because CLE relies upon tissue fluorescence, intravenous fluorescein is generally used to highlight the vasculature and intercellular spaces of the tissue being examined.
223505489|NCT03228407|DIAGNOSTIC_TEST|Endoscopic biopsies|Additional biopsies will be obtained of the esophageal mucosa.These will be obtained with a standard biopsy forceps inserted through the channel in gastroscope.
223747121|NCT06913049|OTHER|Social Engagement Support System|In this protocol, we will develop and deploy a set of machine learning models that use multiple individual- and community-level data sources to predict which members use the emergency department to fulfill social or non-urgent needs as opposed to treatment for urgent medical conditions. These models will identify individuals whose social needs are driving inappropriate utilization so that high-risk individuals will be given enhanced outreach services to facilitate completion of a comprehensive social needs assessment. We will also develop and deploy an engagement support system that identifies and displays the characteristics of members that prevent them from engaging with a Community Based Organization (CBO). This system will use artificial intelligence techniques to identify characteristics of individuals who have historically disengaged from the social service pipeline before receiving social services and suggest potential strategies for increasing engagement.
223747122|NCT07143370|DEVICE|Thermoformed clear aligner|All participants will receive a thermoformed aligner fabricated from polyethylene terephthalate glycol (PETG) material. This aligner is made from using an intraoral scan to print a 3D model of their maxillary dentition, that is then used for the thermoforming process. This aligner will be worn 20-22 hrs/day for 1 week.
223505490|NCT03228407|DIAGNOSTIC_TEST|Mucosal impedance (MI)|MI balloon measures epithelial impedance along a 10 cm length of esophagus. The gastroscope will be withdrawn and the MI balloon will be advanced into the esophagus through the mouth. The balloon will be inflated so that the sensors contact the esophageal mucosa. After MI measurements are obtained, the balloon will be deflated and withdrawn.
223505491|NCT06522802|DIAGNOSTIC_TEST|balance tests, reaction time evaluation|Only 3 tests were applied to participants
223505492|NCT02641353|DRUG|Apremilast Tablet|30 mg tablet
223505493|NCT02641353|DRUG|Apremilast Oral Suspension|30 mg oral suspension
223505494|NCT01741818|OTHER|Measuring IVC collapsibility index by bedside ultrasonography|
223505495|NCT03259308|DRUG|Ontamalimab|Participants will receive 1 mL of ontamalimab sterile aqueous buffered solution at an appropriate concentration to provide the intended dose of drug (25 or 75 mg).
223505496|NCT03259308|DRUG|Placebo|Participants will receive 1 mL of sterile aqueous buffered solution.
223505497|NCT00893295|OTHER|informational intervention|
223505498|NCT00893295|OTHER|medical chart review|
223505499|NCT00893295|OTHER|screening questionnaire administration|
223505500|NCT00893295|OTHER|study of socioeconomic and demographic variables|
223505501|NCT00893295|PROCEDURE|barium enema injection|
223505502|NCT00893295|PROCEDURE|colon imaging study|
223505503|NCT00893295|PROCEDURE|screening colonoscopy|
223505504|NCT00893295|PROCEDURE|sigmoidoscopy|
223505505|NCT03812250|PROCEDURE|ERCP assisted trans-papillary drainage for malignant biliary obstruction|ERCP assisted trans-papillary drainage for malignant biliary obstruction
223505506|NCT03812250|PROCEDURE|EUS-guide biliary drainage for malignant biliary obstruction|EUS-guide biliary drainage for malignant biliary obstruction
223505507|NCT01609140|DRUG|MPSK3169A|Dose regimen A, repeating subcutaneous injections every 4 weeks
223505508|NCT01609140|DRUG|MPSK3169A|Dose regimen E, repeating subcutaneous injections every 4 weeks
223505509|NCT01609140|DRUG|MPSK3169A|Dose regimen D, repeating subcutaneous injections every 4 weeks
223505510|NCT01609140|DRUG|MPSK3169A|Dose regimen C, repeating subcutaneous injections every 4 weeks
223505511|NCT01609140|DRUG|MPSK3169A|Dose regimen B, repeating subcutaneous injections every 4 weeks
223505512|NCT01609140|DRUG|Placebo|Repeating subcutaneous injections of placebo every 4 weeks
223505513|NCT01456338|BEHAVIORAL|Cognitive Behavioral Therapy for PTSD|Individual CBT, approx. 12 sessions, one session per week
223505514|NCT01456338|BEHAVIORAL|Individual Addiction Counseling|Individual therapy, approx. 12 sessions, one session per week
223505515|NCT05563974|OTHER|Family led postnatal care|"Family-led Postnatal Care-FPNC A midwife involves families and uses a visual checklist to assess and counsel. The midwife then gives families the checklist and guides them how to retrieve a home care kit that has a blood pressure machine, infrared thermometer, and health education booklet.~At home, families assess the health of postnatal mothers and newborns for 6 days, and then return the completed checklist and home care kit to the community location."
223505516|NCT04992286|OTHER|questionnaire|questionnaire to evaluate fragility
223505517|NCT04992286|OTHER|accelerometer|To evaluate physical activity level
223505518|NCT01727154|BIOLOGICAL|Sipuleucel-T|Each dose of sipuleucel-T contains a minimum of 50 million autologous CD54+ cells activated with PAP-GM-CSF. The recommended course of therapy for sipuleucel-T is 3 complete doses, given at approximately 2-week intervals.
223505519|NCT02819375|DRUG|Propofol|1 mg/kg propofol
223505520|NCT02819375|DRUG|Propofol+Remifentanil|0.5 mg/kg propofol+0.5 mg/kg remifentanil
223505521|NCT02819375|DRUG|Propofol+Ketamine|0.5 mg/kg propofol and 0.5 mg/kg ketamine
223505522|NCT03650270|DRUG|Phenobarbital|Three repeated doses of pareneteral phenobarbital was compared to a single parenteral infusion of phenytoin followed by an infusion of parenteral midazolam
223505523|NCT05135325|BEHAVIORAL|Patient portal message|Portal message encourages patients to donate blood
223505524|NCT05135325|BEHAVIORAL|Social responsibility|Message specifies that there is a shortage of the patient's blood type
223505525|NCT00003474|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|"Adults with a residual/recurrent/progressive Glioblastoma Multiforme will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
223505526|NCT01532375|DIETARY_SUPPLEMENT|Kochujang|Kochujang (32g/day) for 12weeks.
223505527|NCT01532375|DIETARY_SUPPLEMENT|placebo|placebo(32g/day) for 12weeks
223505528|NCT03237663|BIOLOGICAL|The oral O1 / O139 cholera vaccine (enteric capsules)|
223505529|NCT00194090|DRUG|celecoxib|
223505530|NCT04505111|OTHER|Prehabilitation Program + Enhanced Recovery After Surgery|Prehabilitation Program (nutrition + exercise + psychological counseling) + ERAS protocol
223505531|NCT04505111|OTHER|Enhanced Recovery After Surgery|ERAS protocol
223505532|NCT06122051|RADIATION|Dynamic chest x-ray|Group A and Group B- posterior-anterior dynamic chest x-ray film (Group A, This will represent an additional intervention not part of standard clinical care) (Group B, People with CF, already have this as part of their annual review process)
224196302|NCT05345392|BEHAVIORAL|Mindfulness-Based Intervention (MBI)|The mindfulness-based intervention is based on mindfulness-based stress reduction and mindfulness-based cognitive therapy, borrowing publicly available materials from the Mindfulness in Schools Program and Acceptance and Commitment Therapy. The MBI consists of 8 weekly groups, 45-60 minutes in length, and include 3-8 youth.
224310710|NCT06988904|OTHER|Energy2MOB|"Intervention: The Energy2MOB programme will take place at three primary healthcare centres in Berguedà:~Baix Berguedà (Puig-Reig CAP) Berga Centre (Berga CAP) Alt Berguedà (Guardiola de Berguedà CAP)~The programme will include:~One pre-intervention visit 8 weekly group sessions One post-intervention visit One-month telephone follow-up In-person follow-ups at three and six months~The control group will continue with standard care at their usual primary healthcare centre and will only attend pre-intervention, post-intervention, and six-month follow-up visits. They will not receive group sessions or telephone follow-ups. If the Energy2MOB programme proves effective, control group participants will be invited to participate in the intervention sessions."
224310711|NCT02613702|PROCEDURE|Free Gingival Graft|Surgical technique (autologous graft): Free gingival graft technique, harvested from palate.
224310712|NCT02613702|PROCEDURE|Original Free Gingival Graft technique|Surgical technique (autologous graft): Original technique of free gingival graft, positioned at the inferior incisors area at the donor area
224310713|NCT02613702|PROCEDURE|Modified Free Gingival Graft technique|Surgical technique (autologous graft): Free gingival graft. positioned at the inferior incisors area and covered by a flap at the donor area
224310714|NCT06219278|DEVICE|Profound Matrix|The source study consisted of up to three treatment visits with treatment intervals 6 weeks ± 2 weeks
224196303|NCT05345392|BEHAVIORAL|Health and Wellness Intervention (HWI)|The control intervention is inspired by the Health Enhancement Program that has been adapted for youth 11-14 years old, using brief, engaging, and age-appropriate activities to address topics related to physical and mental health. HWI consists of 8 weekly groups, 45-60 minutes in length, and include 3-8 youth.
224196304|NCT06787742|PROCEDURE|full pulpotomy|access to dental pulp chamber under aseptic condition, collect blood sample using a micropipette for ELIZA test, stop bleeding using sodium hypochlorite 2.5%, pulpotomy dressing material over pulp stump and final restoration with resign modified glass ionomer and composite resign
224196305|NCT03422848|DIETARY_SUPPLEMENT|Water|Increased daily water intake with 1.5 L of water on top of habitual water intake.
224196306|NCT03422848|BEHAVIORAL|general life style advice|oral and written advice on diet and physical activity
224196307|NCT06481397|DEVICE|ONCObind (Onco-Seraph) 100 Filter|"The ONCObind (Onco-Seraph) 100 Microbind® Affinity Blood Filter (Onco-Seraph 100) manufactured by ExThera Medical Corporation in Martinez, CA. The Onco-Seraph 100 filter has been designed and manufactured to reduce residual risks as much as possible to ensure safe usage. Literature search results concluded that heparin coated medical devices are safe and decrease platelet adhesion without affecting the adsorption of major adhesive proteins.~Literature search yielded over 45 publications and 370 treated patients with Seraph platform technology for pathogen removals without significant safety concern. The achieved results from the above-mentioned testing and studies support the performance and safety of Onco-Seraph 100 consistent with the intended use. ExThera Medical concludes that the known and potential benefits of Onco-Seraph 100, when used to treat patients with PDAC, outweigh the known and potential risks when used according to the intended use."
224310715|NCT06144164|PROCEDURE|Immediate Lymphatic Reconstruction|Immediate Lymphatic Reconstruction will happen at the time of Axillary Lymph Node Dissection
223505533|NCT06122051|DIAGNOSTIC_TEST|Spirometry|Group A and Group B- Spirometry lung function test (Group A, This will represent an additional intervention not part of standard clinical care) (Group B, People with CF, already have this as part of their annual review process)
224196308|NCT06887972|DRUG|Suzetrigine|Tablets for oral administration.
224196309|NCT05844176|OTHER|Routine clinical treatment|Routine clinical treatment is based on the latest international and local guidelines
224196310|NCT04132817|BIOLOGICAL|Nivolumab|specified dose on specified days
223505534|NCT03639051|DEVICE|Targeted Lung Denervation (TLD)|Targeted Lung Denervation (TLD) Therapy is a bronchoscopically guided, minimally invasive procedure using the Nuvaira™ Lung Denervation System.
223505535|NCT03639051|OTHER|Optimal Medical Care|Taking regular maintenance medication that minimally includes a long-acting muscarinic antagonist (LAMA) and a long-acting beta2-agonist (LABA).
223594053|NCT02339194|PROCEDURE|Denture fabrication technique|"Both arm groups are composed by patients present severely resorbed mandibular alveolar bones who will receive complete dentures fabricated by means of a simpler techinique previously proved to be effective. Although for the traditional protocol group a second more complex impression step will be performed in order to evaluate if the simpler approach for this anatomical condition could be safely applied."
223594054|NCT00854035|DRUG|MK-0431/ONO-5435|Double-blind period (16 wk); 50 mg QD. The double-blind period will be followed by a 36 wk open-label extension period where MK-0431/ONO-5435 could be titrated from 50mg QD to 100mg QD
224196311|NCT04132817|BIOLOGICAL|Ipilimumab|specified dose on specified days
224196312|NCT04132817|DRUG|Nab-paclitaxel|specified dose on specified days
224196313|NCT05111652|OTHER|observational|observational electromiographic musculature activation
224196314|NCT03984968|BIOLOGICAL|ssCART-19 cells combined with CD19+ feeding T cells (FTCs) infusion|Phase 1: Optimal biological doses of feeding T cells (FTCs) identification. ssCART-19 cells combined with CD19+ FTCs were administered to Philadelphia chromosome-positive B-ALL patients with remission. ssCART-19 was infused at the dose of 5×10\^6/kg on days 1 to 3 of the first cycle and on day 1 of the second to fourth cycle. CD19+ FTCs (5×10\^6 cells/kg) were infused two hours after the infusion of ssCART-19 cells on day 1 and at the same dose alone on day 8 of the second to fourth cycle. Five patients were enrolled in this arm, and all the patients received four cycles of ssCART-19 consolidation.
224310716|NCT06144164|DIAGNOSTIC_TEST|Volumetric arm measurements|Volumetric arm measurements will occur at each in-person postoperative visit time points.
224310717|NCT06144164|OTHER|Lymphatic massage|Participants will begin self-directed lymphatic massage 24 to 48 h after surgery and will continue to do lymphatic massage 3 times a week for 3 months after surgery or until 3 months after any adjuvant treatments (chemotherapy, radiation, etc.) are completed
223747123|NCT07143370|DEVICE|3D printed clear aligner TC-85|All participants will receive a 3D printed aligner fabricated from TC-85 resin. This aligner will be made using an Stereolithography (STL) file from their intraoral scan to design the clear aligner and then will be fabricated using the SprintRay Pro 95 S printer. This aligner will be worn 20-22 hrs/day for 1 week.
224196315|NCT03984968|BIOLOGICAL|ssCART-19 cells combined with CD19+ feeding T cells (FTCs) infusion|Phase 1: Optimal biological doses of feeding T cells (FTCs) identification. ssCART-19 cells combined with CD19+ FTCs were administered to Philadelphia chromosome-positive B-ALL patients with remission. ssCART-19 was infused at the dose of 5×10\^6/kg on days 1 to 3 of the first cycle and on day 1 of the second to fourth cycle. CD19+ FTCs (3.25×10\^6 cells/kg) were infused two hours after the infusion of ssCART-19 cells on day 1 and at the same dose alone on day 8 of the second to fourth cycle. Four patients were enrolled in this arm, and all the patients received four cycles of ssCART-19 consolidation.
224196316|NCT03984968|BIOLOGICAL|ssCART-19 cells combined with CD19+ feeding T cells (FTCs) infusion|Phase 1: Optimal biological doses of feeding T cells (FTCs) identification. ssCART-19 cells combined with CD19+ FTCs were administered to Philadelphia chromosome-positive B-ALL patients with remission. ssCART-19 was infused at the dose of 5×10\^6/kg on days 1 to 3 of the first cycle and on day 1 of the second to fourth cycle. CD19+ FTCs (2×10\^6 cells/kg) were infused two hours after the infusion of ssCART-19 cells on day 1 and at the same dose alone on day 8 of the second to fourth cycle. Four patients were enrolled in this arm, and all the patients received four cycles of ssCART-19 consolidation.
224310718|NCT06144164|OTHER|Range of motion exercises|Participants will begin self-directed lymphatic massage 24 to 48 h after surgery and will continue to do lymphatic massage 3 times a week for 3 months after surgery or until 3 months after any adjuvant treatments (chemotherapy, radiation, etc.) are completed
224310719|NCT06144164|OTHER|Compression garment use|Participants will use compression garments 24 to 48 h after surgery and will continue daily use for at least 8 h a day for 3 months or until 3 months after any adjuvant treatments are completed
224310720|NCT01910974|PROCEDURE|endoscopic sub-mucosal dissection|endoscopic sub mucosal dissection of oesophagus stomach intestine or rectum lesions
224310721|NCT01723579|DRUG|Nomegestrol acetate (NOMAC)|Oral tablet with daily release of 2.5 mg
224310722|NCT01723579|DRUG|Estradiol (E2)|Daily release of 1.5 mg
223594055|NCT00854035|DRUG|MK-0431/ONO-5435|Double-blind period (16 wk); placebo QD. The double-blind period will be followed by a 36 wk open-label extension period where MK-0431/ONO-5435 could be titrated from 50 mg QD to 100 mg QD
223594056|NCT00785343|DEVICE|Reo Go robotic arm trainer|Robotic training with the Reo Go is included with conventional treatment during daily OT sessions
223594057|NCT00785343|PROCEDURE|Conventional Therapy|Occupational therapy that is the current standard of care
223594058|NCT03472144|DRUG|gel loaded with steroids (momentasone)|One of the purpose of this study is to evaluate the efficacy of a gel that actively releases local corticosteroids (momentasone) after balloon sinuplasty for chronic sinusitis patients.
223594059|NCT03472144|DRUG|gel loaded with antibiotic (Levofloxacin)|One of the purpose of this study is to evaluate the efficacy of a gel that actively releases local antibiotic(levofloxacin) after balloon sinuplasty for chronic sinusitis patients.
223594060|NCT03472144|DRUG|gel loaded with both steroids and antibiotic|One of the purpose of this study is to evaluate the efficacy of a gel that actively releases local both steroids (momentasone)and antibiotic(levofloxacin) after balloon sinuplasty for chronic sinusitis patients.
223594061|NCT05336149|PROCEDURE|Alveolar ridge preservation using whole-tooth dentin graft|Minimally-traumatic extraction of non-restorable teeth then grafting with whole-tooth dentin graft
223594062|NCT05336149|PROCEDURE|Alveolar ridge preservation using particulate dentin graft|Minimally-traumatic extraction of non-restorable teeth then grafting with particulate dentin graft
223747124|NCT07143370|DEVICE|3D printed clear aligner TA-28|All participants will receive a 3D printed aligner fabricated from TA-28 resin. This aligner will be made using an STL file from their intraoral scan to design the clear aligner and then will be fabricated using the SprintRay Pro 95 S printer. This aligner will be worn 20-22 hrs/day for 1 week.
224310723|NCT05233930|PROCEDURE|TKR with augmented reality-based navigation system|Surgery
224310724|NCT05233930|PROCEDURE|TKR with traditional mechanically aligned technique|As per local practice and standard guidelines.
224310725|NCT03481218|OTHER|The World Health Organization Quality of Life (WHOQOL) -BREF|The WHOQOL-BREF instrument comprises 26 items, which measure the following broad domains: physical health, psychological health, social relationships, and environment.
223594063|NCT01483911|BIOLOGICAL|ALX-0171|Single or multiple ascending doses (2.1-210 mg), administered via pulmonary inhalation. Multiple dosing will consist of twice daily dosing on 5 consecutive days.
223594064|NCT01483911|BIOLOGICAL|Placebo|Single or multiple doses, administered via pulmonary inhalation. Multiple dosing will consist of twice daily dosing on 5 consecutive days.
223594065|NCT01620814|DRUG|Dinoprostone|
223594066|NCT01620814|DRUG|misoprostol|
223594067|NCT01620814|DRUG|control|
223594068|NCT03162081|DIAGNOSTIC_TEST|Substance misuse screening|Diagnostic and Statistical manual of mental disorders, version 4 (DSM-IV)/MINI-international Neuropsychiatric interview (MINI interview) for Diagnostics of dependence, additional questions for DSM-V classification, severity of dependence scale (SDS)
223594069|NCT03162081|DIAGNOSTIC_TEST|EQ-5D|Health related Quality of life
223594070|NCT03162081|DIAGNOSTIC_TEST|Impulsivity screening|Barratts impulsivity test v. 11, Behavioural inhibition/behavioural activation test
223594071|NCT03162081|DIAGNOSTIC_TEST|Cognitive screening|Minimental state examination (MMSE), Hospital anxiety and depression scale (HADS), Trail-making test, clock drawing test
223594072|NCT03162081|DIAGNOSTIC_TEST|Functional tests|Timed up and go (TUG), Single leg balancing test (SLB)
223594073|NCT03162081|DIAGNOSTIC_TEST|Cognistat|Assessment of cognitive domains
223594074|NCT03162081|DIAGNOSTIC_TEST|Neuropsychological profiling|Controlled Oral Word Association Test, Categorical fluency tests, Wechsler Adult Intelligence Scale, Color-Word Interference Test (CWIT) from the Delis-Kaplan Executive Function test
223594075|NCT03162081|OTHER|Clinical interview|Interview for sociodemographics, utilisation of health care, economic varables, The De Jong Gierveld Loneliness Scale
223747125|NCT06942754|DEVICE|post-surgical functional bracing|Quadriceps Autograft ACL Reconstruction with the use of post-surgical functional bracing, using the DonJoy Defiance Pro brace
223594076|NCT03162081|OTHER|Medication use|Detailed screen of used medications, interactions, side effects in electronic patient registry
223594077|NCT03162081|OTHER|Comorbidity|Charlson comorbidity index and Cumulated illness rating scale (CIRS) based on electronic patient registry
223594078|NCT05006027|PROCEDURE|Percutaneous coronary intervention via the distal radial approach|Percutaneous coronary intervention using a 7-Fr thin walled sheath (Prelude IDeal, MERIT MEDICAL, South Jordan, UT, USA) via the distal radial approach
223594079|NCT01359189|DEVICE|ProxiScan (scintigraphic rectal probe)|"ProxiScanTM is a compact, high-resolution gamma camera which has been developed for the detection of cancer and other abnormalities in the body by imaging the distribution of radionuclides in the human body using planar imaging techniques. This camera is capable of high-performance imaging of radiopharmaceuticals distributed within anatomical regions of interest located close to the camera head. The ProxiScan compact scintigraphic detector was approved by the FDA to market the device for the following indication: The ProxiScanTM is indicated for use in imaging the distribution of radionuclides in the human body using planar imaging techniques. ProxiScanTM may also be used intraoperatively, on pathological specimens and for endocavity applications if a protective sheath is used."
223594080|NCT01286025|BEHAVIORAL|video case modality|Patients whose case histories are pathophysiologically illustrative will be recruited, and interviewed on video. Their stories will be edited and divided into sections, and combined with the patient's laboratory, imaging, and pathological reports when appropriate
223747126|NCT06950385|DRUG|eRapa (encapsulated rapamycin)|0.5 mg capsules for oral use; white opaque capsule filled with off-white powder; Trial intervention will be provided in 28-count round high-density polyethylene bottles with a polypropylene child-resistant screw cap and foil induction seal.
224196317|NCT03984968|BIOLOGICAL|ssCART-19 cells combined with CD19+ feeding T cells (FTCs) infusion|Phase 2: Expansion Study. ssCART-19 cells combined with FTCs at the optimal biological dosage determined in the Phase 1 study were given to expanded Philadelphia chromosome-positive B-ALL patients with remission. The 5×10\^6 cells/kg of CD19+ FTCs was the optimal biological dose determined in phase I. Therefore, CD19+ FTCs at 5×10\^6 cells/kg were infused two hours after the infusion of ssCART-19 cells on day 1 and at the same dose alone on day 8 of the second to fourth cycle, while ssCART-19 was infused at the dose of 5×10\^6/kg on days 1 to 3 of the first cycle and on day 1 of the second to fourth cycle. The Bayesian optimal design was applied to perform the futility assessment at the specified interim analyses. Thirty-four evaluable subjects were recruited, and all the patients received at least two cycles of ssCART-19 consolidation.
223594081|NCT01286025|BEHAVIORAL|Text case modality|Patients whose case histories are pathophysiologically illustrative will be recruited, and interviewed on video. Their stories will be edited and divided into sections, and combined with the patient's laboratory, imaging, and pathological reports when appropriate. The transcript of these video-recordings will form the basis of the text-based case presentation modality.
223594082|NCT03400163|DRUG|BMS-986036|BMS-986036 20 mg QD
223594083|NCT03400163|DRUG|Placebo|Placebo QD
223594084|NCT02241343|DEVICE|Venous occlusion (leg tourniquet, made in-house)|Leg occlusion applied via a blood pressure cuff. Venous occlusion checked using duplex ultrasound
223594085|NCT04800237|DRUG|VQW-765|oral capsule
223747127|NCT06950385|DRUG|Placebo|Capsules in 28-count round high-density polyethylene bottles with a polypropylene child-resistant screw cap and foil induction seal.
223747128|NCT00709774|DEVICE|Pacemaker Implantation|Implantation of right ventricular lead at septal or apex.
223747129|NCT07151261|DIETARY_SUPPLEMENT|Ashwagandha|Sustained-Release, lower-dosage (150mg) Ashwagandha Supplement, 1 capsule 1 time per day.
223747130|NCT07151261|OTHER|Placebo|This placebo does not contain any of the interventional dietary supplement. The placebo consists of microcrystalline cellulose and is matched for shape, color, and smell. 1 capsule, 1 time per day.
223747131|NCT05932602|DEVICE|Aveir DR Leadless Pacemaker System|This study will utilize real-world data from patients implanted with the Aveir DR Leadless Pacemaker System. No device intervention is required in this study.
223747132|NCT05932602|DEVICE|Dual Chamber Transvenous Pacemaker|This study will utilize real-world data from patients implanted with a dual-chamber transvenous pacemaker as a comparator to the Aveir DR LP system study arm. No device intervention is required in this study.
224196318|NCT06941909|OTHER|Mindfulness-Based Self-Compassion|The intervention consisted of weekly online group training and counseling sessions over an 8-week period. Following each session, participants were provided with a practice guide and audio recordings to support home-based practice.
224196319|NCT06943508|OTHER|Conventional Therapy|Conventional Therapy group: Group A will be control group which will recieve conventional physical therapy program like curl up, lateral step up and sit to stand for 6 weeks( 5 sessions per week)
224196320|NCT06943508|OTHER|Nordic Walk|Nordic Walk group: Group B will recieve Nordic walking for 6 weeks ( 5 sessions per week)
224196321|NCT06942208|DIETARY_SUPPLEMENT|Low-dose iron (ferrous sulfate)|Encapsulated low-dose ferrous sulphate (40mg elemental iron)
224196322|NCT06942208|DIETARY_SUPPLEMENT|Yeast-bound iron (ferrous sulfate)|Encapsulated yeast-bound low-dose ferrous sulphate (40mg elemental iron)
224196323|NCT06942208|DIETARY_SUPPLEMENT|High-dose iron (ferrous sulfate)|Encapsulated high-dose ferrous sulphate (150mg elemental iron)
224196324|NCT06943677|DRUG|TQB3019 capsules|TQB3019 capsule is a targeted protein degrader
224196325|NCT06943053|DEVICE|Isolate waterproof dressing (Opsite)|Application of standard Opsite® waterproof dressing directly over the surgical incision following primary total knee arthroplasty. No additional drape or coverage was applied. The dressing remained in place until removal.
223594086|NCT04800237|DRUG|Placebo|oral capsule
223594087|NCT02997059|DRUG|Fluconazole|200 mg/ day
223594088|NCT02997059|OTHER|Placebo|
223594089|NCT00174369|DRUG|PD-0325901|15 mg BID
223594090|NCT03579277|PROCEDURE|Radial Forearm Free Flap|Subjects in this arm will undergo a radial forearm free flap.
223594091|NCT03579277|PROCEDURE|Ulnar Forearm Free Flap|Subjects in this arm will undergo an ulnar forearm free flap.
223594092|NCT03781440|PROCEDURE|Bilateral ESP catheter with lidocaine|All participants will get the Erector Spinae Plane (ESP) catheters. Prior to transfer to the operating room, participants will receive bilateral ESP catheters at T7 level under ultrasound guidance. This arm is the treatment group and will receive lidocaine via alternating side automated infusion pump bolus dosing, continued until chest tube removal or postoperative day 5 (whichever occurs earliest).
223747133|NCT07179588|BEHAVIORAL|Nutrition Education Program|The participants will attend a monthly nutrition education session for 4 months (total 4 sessions). The sessions will be available in person and over teleconference platforms (i.e., Zoom). Each session will be up to 1-hour, which will include nutrition guidelines to manage diet quality.
223747134|NCT07179588|BEHAVIORAL|Nutrition Counseling|Participant will meet with a registered dietitian for one-on-one diet consults once a month for 4 months. These sessions can be in-person or via Zoom. Each session will be up to 1 hour, and will be done to assess if the nutrition guidelines taught during the education sessions are being implemented.
223747135|NCT07181824|OTHER|Diagnostic tedst|"* Radiologic signs: 2 consecutive thorax x-ray with new onset pneumonia AND~* One of the following criteria~  * Fever \>38,3°C without any other cause~ * Leucocytes \< 4000/mm3 or ≥ 12000 /mm3~* AND at least two of the following~  * Purulent secretions~ * Cough or dyspnoea~ * Desaturation or increase in FiO2 (+20%)"
223747136|NCT07180927|BIOLOGICAL|4SCAR DLL3 T cells|Infusion of 4SCAR DLL3 T cells at 10\^6 cells/kg body weight via intravenous route
223747137|NCT07179822|BEHAVIORAL|Motor Evoked Potential (MEP) Operant Conditioning|Operant conditioning is a method to induce behavioral learning based on the consequence (reward) of the behavior. With operant conditioning of the motor evoked potential (MEP), the neuronal excitability and behavior of the corticospinal pathway that involves production of MEP is targeted and trained (i.e., up-trained with up-conditioning). The individual is rewarded only for changing the target muscle's MEP size without changing background muscle activity. Since MEP size reflects the corticospinal excitability at or just before the time of stimulation, during MEP up-conditioning trials, the individual is urged to increase the corticospinal excitability for the target muscle.
223594093|NCT03781440|PROCEDURE|Bilateral ESP catheter with saline|All participants will get the Erector Spinae Plane (ESP) catheters. This arm is the control group and will have normal saline administered via ESP catheters, continued until chest tube removal or postoperative day 5 (whichever occurs earliest).
223747138|NCT07180108|DRUG|Psilocybin (high dose)|25 mg pill
223747139|NCT07180108|BEHAVIORAL|Playlist 1|Six hour playlist
223747140|NCT07180108|BEHAVIORAL|Playlist 2|A six hour playlist
223747141|NCT07180108|BEHAVIORAL|Playlist 3|A six hour playlist
223747142|NCT07180108|BEHAVIORAL|Playlist 4|A six hour playlist
223594094|NCT00868127|DRUG|Lapaquistat acetate|"Participants from 01-04-TL-475-008 Monotherapy Study:~Lapaquistat acetate 100 mg, tablets, orally, once daily for up to 48 weeks."
223594095|NCT00868127|DRUG|Lapaquistat acetate and additional lipid-lowering therapy|"Participants from 01-04-TL-475-009 Atorvastatin Add-on Study:~Lapaquistat acetate 100 mg, tablets, orally, once daily and current Atorvastatin therapy for up to 4 weeks.~Then, Lapaquistat 100 mg, tablets, orally, once daily and dose adjustment of Atorvastatin OR additional companion lipid-lowering therapy as needed for target LDL-C for up to 42 weeks."
223594096|NCT05346653|DRUG|SGLT2i|dapagliflozin (10 mg daily)
223747143|NCT07180108|BEHAVIORAL|Playlist 5|A six hour playlist
223747144|NCT07181187|DRUG|MH004 Ointment|MH004 1% ointment applied topically to the affected area as a thin film once or twice daily.
223747145|NCT07181187|DRUG|Vehicle Ointment|Matching vehicle ointment applied topically to the affected area as a thin film once or twice daily.
223747146|NCT07180381|OTHER|PSA and MRI-monitoring|Men with PI-RADS 3 or 4 lesions and a PSA density ≤ 0.15 ng/mL² are actively monitored with PSA testing every six months and MRI annually, instead of undergoing immediate prostate biopsy.
223747147|NCT07180602|BEHAVIORAL|Heart Math Biofeedback Breathing Practices|Phase I and II (0-6 months): Biofeedback will be implemented based on the Heart Math Protocol. Breathing practices will include a variety of yoga and qi gong techniques.
223747148|NCT07180602|BEHAVIORAL|Nutrition Counseling combined with Exercise Counseling|Phase II (3-6 months): Dietary education and an age-and gender-specific diet prescription based on the Mediterranean Diet. Nutrition counseling includes nutrition supplementation to correct deficiencies. Study participants will have a blood test to examine vitamins and minerals and identify deficiencies. Exercise counseling includes developmentally appropriate guidelines for cardiopulmonary, strength and flexibility activities based on guidelines from the ACSM and the AAP. Study participants and parents will be provided with a handout with exercise recommendations to follow at home and links to a website for additional suggestions for developmentally-appropriate physical activities and a tracking tool to assist parents with determining if their child is following the guidelines.
223594097|NCT05346653|OTHER|No SGLT2i|No SGLT2i
223594098|NCT06510010|DRUG|Oxaliplatin With S-1 (SOX) Combined H. Pylori Eradication (Amoxicillin + clarithromycin + omeprazole + colloidal bismuth subcitrate)|"Oxaliplatin With S-1 (SOX) regimen:~S-1: 40mg/m2, oral, bid, D1-14, one cycle every 3 weeks; Oxaliplatin: 130 mg/m2, IV, qd, D1, every 3 weeks for one cycle.~H. pylori eradication regimen:~H. pylori eradication was performed using a quadruple regimen for 14 d. Omeprazole 20 mg bid+Colloidal bismuth subcitrate 220mg bid+Amoxicillin 1g bid+Clarithromycin 500mg bid."
223594099|NCT06510010|DRUG|Oxaliplatin With S-1 （SOX）|"Oxaliplatin With S-1 （SOX） regimen:~S-1: 40mg/m2, oral, bid, D1-14, one cycle every 3 weeks; Oxaliplatin: 130 mg/m2, IV, qd, D1, every 3 weeks for one cycle."
223594100|NCT03415438|DIAGNOSTIC_TEST|Visual Analogue Scale|intensity of pain perception patients feel
223747149|NCT07179666|OTHER|Neural moblization group|The intervention will involve neural mobilization of the tibial nerve, beginning with distal sliding through ankle dorsiflexion and foot eversion, followed by dorsiflexion of the toes. The movement will then be reversed into plantarflexion to allow proximal nerve excursion. In addition, a tensioner technique will be applied, in which participants will perform 45° hip flexion combined with ankle dorsiflexion and eversion, followed by knee extension, to place a controlled tensile load along the tibial nerve pathway.
224196326|NCT06943053|DEVICE|Ioban coverage group|Application of Ioban® iodine-impregnated antimicrobial incise drape over the standard waterproof dressing following primary total knee arthroplasty. The Ioban drape extends 2 cm beyond all edges of the dressing and remains in place until removal.
224196327|NCT06943040|OTHER|There will be no intervention on the participants within the scope of this study.|There will be no intervention on the participants within the scope of this study.
224196328|NCT04148235|OTHER|No Intervention|There is no intervention for this study
224196329|NCT06943417|DEVICE|Over the scope clip|over the scope clip group
224310726|NCT03481218|OTHER|The Satisfaction With Life Scale - SWLS|The SWLS is a short 5-item instrument designed to measure global cognitive judgments of satisfaction with one's life.
224196330|NCT06943625|OTHER|tDCS|"Transcranial direct current stimulation protocol involves 20 minutes of anodal stimulation, with the anodal electrode placed over the motor cortex (primary motor area), and cathodal stimulation applied to the contralateral supraorbital area.~The intensity of the current will be set to 1.5 mA, with the current density ranging from approximately 0.03 to 0.06 mA, with the electrode measuring of 5x7cm. To ensure a gradual and comfortable experience for participants, the current will ramp up and down over 30 seconds at the beginning and end of each session. Each stimulation session will last for 20 minutes, with participants undergoing five sessions per week. The entire intervention protocol will be carried out over a period of four weeks"
224196331|NCT06943625|OTHER|Green light|Green light exposure will be administered using light with a wavelength of about 520 nm. The sessions will take place in a dimly lit room to minimize external light interference and enhance the therapeutic effect of the green light. Each exposure session will last for 2 hours, with participants receiving 3 to 5 sessions per week. The light intensity will be set to 100 lux, a level that is both safe and effective for migraine treatment. The entire intervention protocol will span over four weeks to allow for sufficient evaluation of the effects. During each session, participants will be seated comfortably in a chair to ensure they are relaxed and able to tolerate light exposure without discomfort.
223594101|NCT03415438|DIAGNOSTIC_TEST|posterior capsule tightness|tape measurement for posterior capsule tightness with patients lying at side and horizontally adducting their shoulder.
223594102|NCT03415438|DIAGNOSTIC_TEST|shortness tests for lumbar movements|tape measurement for lumbar movements
223594103|NCT03415438|DIAGNOSTIC_TEST|range of motion tests for lumbar movements|range of motion measurements for lumbar flexion, extension and lateral flexion with goniometer.
223594104|NCT03415438|DIAGNOSTIC_TEST|The thoracolumbar fascia length test|patient sitting straight with shoulders at horizontal plane, both the arms are asked to rotated with primarily spinal rotation. the degree of rotation gives idea about the thoracolumbar fascia length
223594105|NCT03415438|DIAGNOSTIC_TEST|Modify Schober test|tape measurement of spinal flexion between designated regions
223594106|NCT05882461|BEHAVIORAL|90Second Caregiver health letter|Participant receives the weekly health letter via email
223594107|NCT03331757|OTHER|Glucose as reference food|Eleven subjects (male: 2, female: 9) consumed 50g glucose diluted in 300ml water, tested three times, in different weeks, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min.
223594108|NCT03331757|OTHER|Fir honey|Eleven subjects (male: 2, female: 9) consumed 50g available carbohydrates of fir honey diluted in 300ml water, tested once, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min.
223594109|NCT03331757|OTHER|Heather honey|Eleven subjects (male: 2, female: 9) consumed 50g available carbohydrates of heather honey diluted in 300ml water, tested once, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min.
223594110|NCT03331757|OTHER|Citrus honey|Eleven subjects (male: 2, female: 9) consumed 50g available carbohydrates of citrus honey diluted in 300ml water, tested once, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min.
223594111|NCT03331757|OTHER|Pine honey|Eleven subjects (male: 2, female: 9) consumed 50g available carbohydrates of pine honey diluted in 300ml water, tested once, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min.
223594112|NCT03331757|OTHER|Thyme honey|Eleven subjects (male: 2, female: 9) consumed 50g available carbohydrates of thyme honey diluted in 300ml water, tested once, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min.
223594113|NCT03331757|OTHER|Chestnut honey|Eleven subjects (male: 2, female: 9) consumed 50g available carbohydrates of chestnut honey diluted in 300ml water, tested once, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min.
223594114|NCT06034561|DRUG|Bortezomib|Patients should receive one or two courses of this regimen, aiming to achieve complete remission as a bridge to proceed with allogeneic HSCT.
224196332|NCT06943625|OTHER|medicine|Advised medicine by the medical doctors will be utilized by the participants of the study
224310727|NCT03481218|OTHER|Big Five Inventory - BFI; John in Srivastava, 1999|The Big Five Inventory (BFI) is a self-report inventory designed to measure the Big Five dimensions.
224310728|NCT06897644|DRUG|Oxaliplatin|85 mg/sqm iv over 2 hours day 1
223594115|NCT04674488|BIOLOGICAL|TILs|a single center, single-arm, open label, interventional study
223594116|NCT00927238|DEVICE|XL TDR|This will be a lateral approach discectomy and reconstruction with the insertion of the XL TDR device.
223594117|NCT00927238|OTHER|Lumbar fusion surgery|Lumbar fusion surgery
223594118|NCT04787172|RADIATION|Multi Slice computed tomography|use of MSCT as a diagnostic tool in evaluation of patients with congenital cardiovascular anomalies
223594119|NCT03322917|BIOLOGICAL|PRP autologous|Autologous platelet rich plasma: 1 drop / 6 times a day during 6 weeks
223594120|NCT00806728|DRUG|MEDI-507|0.12 mg/kg of MEDI-507 given every third day for 4 doses followed by doses of normal saline on Days 16, 23, 30, and 37.
223594121|NCT00806728|DRUG|MEDI-507|0.12 mg/kg of MEDI-507 given every third day for 4 doses followed by doses of MEDI-507 on Days 16, 23, 30, and 37.
223594122|NCT03864913|DRUG|Testosterone injection|SQ or IM testosterone injections for pubertal induction of transgender male adolescents. Increasing doses per protocol at 3 month and 6 month follow up.
223594123|NCT03864913|BEHAVIORAL|PedsQL questionnarie|Validated Pediatric Quality of Life questionnaire completed by subjects at baseline, 3 month and 6 month study visits.
223594124|NCT03864913|OTHER|Masculinizing effects questionnaire|Subjects complete self-reported questionnaire at 3 month and 6 month study visits.
223594125|NCT03864913|OTHER|Medication experience questionnaire|Subjects complete self-reported questionnaire at 3 month and 6 month study visits.
223594126|NCT00246246|DRUG|risperidone|
223594127|NCT00732108|DRUG|topiramate|50mg orally for 2 weeks, then 100mg orally for 6 weeks
223594128|NCT00732108|DRUG|lactulose placebo pill|1 placebo pill orally for 2 weeks, then 2 placebo pills orally for 6 weeks
223594129|NCT01329939|DRUG|Montelukast|Age-dependent dose, nightly, 24 weeks
223594130|NCT01329939|DRUG|Placebo|Age-dependent dose, nightly, 24 weeks
223594131|NCT01329939|DRUG|Montelukast|Age-dependent dose, nightly, 24 weeks
223594132|NCT01329939|DRUG|Placebo|Age-dependent dose, nightly, 24 weeks
223594133|NCT05994079|DEVICE|High intensity focused ultrasound|"Parameters:~Transducer frequency 7-2-mhz 1.5-9.0-mm focal depth. The pulse duration for each individual exposure ranged from 25 to 40 milliseconds.~Energy per ultrasound pulse ranged from 1.0 to 1.5 J"
223594134|NCT05994079|OTHER|topical firming creams|medical topical firming creams
223594135|NCT03722524|DRUG|amlodipine / indapamide / perindopril arginine FDC|CCB / diuretic / ACE inhibitor
223594136|NCT02321761|DRUG|Amantadine hydrochloride|Drug dosages: day 0-14 no drug will be given Days 15-21 100 mg Days 22-28 200 mg Days 29-42 400 mg Days 43-56 200 day 57-70 no drug will be given
223594137|NCT06530771|DIAGNOSTIC_TEST|ultrasound|Conventional US, SWE, and AP of thyroid nodules were conducted successively with a Supersonic Aixplorer system (SuperSonic Imagine, Aix-en-Provence, France) using a 5-14 MHz linear transducer.
223594138|NCT05901883|DRUG|CEL383|Subjects will receive CEL383
223594139|NCT05901883|DRUG|Placebo|Subjects will receive placebo
223594140|NCT04957368|DRUG|Nitrous Oxide 99 %|Nitrous oxide will be administered at an inspiratory concentration of 50% with concurrent intravenous saline (100ml) for one hour.
223594141|NCT04957368|DRUG|Oxygen + Midazolam|Oxygen will be administered at 50% with intravenous midazolam (0.02mg/kg in 100ml) for one hour
223594142|NCT00007891|BIOLOGICAL|filgrastim|
223594143|NCT00007891|PROCEDURE|autologous bone marrow transplantation|
223594144|NCT00007891|PROCEDURE|peripheral blood stem cell transplantation|
223594145|NCT00007891|RADIATION|indium In 111 monoclonal antibody BrE-3|
223594146|NCT00007891|RADIATION|yttrium Y 90 monoclonal antibody BrE-3|
223594147|NCT04918732|DIAGNOSTIC_TEST|FibroScan|The FibroScan device developed by Echosens (France) measures the liver stifness and steatosis based on a pulse of sound waves that goes through the liver.
223594148|NCT02188654|DRUG|Metformin|500mg/day retarded formulation of metformin
223594149|NCT02188654|DRUG|Placebo|500 mg/day of placebo tablets
224196333|NCT06943248|OTHER|Image-Sand Play Therapy|Over the course of seven sessions, the child initially engaged in chaotic sandbox play, showing difficulty in altering or organizing his scenes. By the fourth session, he began experimenting with different symbols, including familiar TV characters. From the fifth session onward, his play gained structure, evolving into strategic battle scenarios involving animals, loggers, and castles. By the seventh session, hero figures emerged, and the therapist noted improved classroom behavior and cooperation, though social challenges with peers remained.
224196334|NCT06943248|OTHER|Table Top Training Program with Weighted Cuff|"Task include: Stacking cones Lift a cone with one hand and stack it on top of a fixed cone. (The difficulty level was controlled by using resistance bands of varying weights or instructing patients to sit or stand while performing the task.) Task Therapy Program Stacking 3 × 3 cm blocks Pick up blocks one at a time by using one hand and stack them. (The difficulty level was controlled by using resistance bands of varying weights.) Tailwind Use both hands to push the handles of an instrument up and down to the sounds of a metronome.~(The difficulty level was controlled by varying the angle.) Pinch exerciser Take a pinch pin and put it on a rod. (The difficulty level was controlled by varying the resistance of the pinch pin (5 grades) and the diameter of the rod (3 grades).) O'Connor Tweezer Dexterity Test Pick up a pin (2.5 cm long) and put it in a 15 mm hole. (The difficulty level was controlled by using different tweezers.)"
223594150|NCT00185224|DRUG|EV/DNG (Qlaira, BAY86-5027, SH T00658K)|7 treatment cycles of 28 days each (no tablet-free intervals); Days 1-2: 3.0 mg EV; Days 3-7: 2.0 mg EV + 2.0 mg DNG; Days 8-24: 2.0 mg EV + 3.0 mg DNG; Days 25-26: 1.0 mg EV; Days 27 - 28: Placebo
223594151|NCT00185224|DRUG|SH D00264A (Triquilar)|7 treatment cycles of 28 days each (no tablet-free intervals);Days 1-6: 0.03 mg EE + 0.05 mg LNG; Days 7-11: 0.04 mg EE + 0.075 mg LNG; Days 12-21: 0.03 mg EE + 0.125 mg LNG;Days 22-28: Placebo
223594152|NCT03513627|PROCEDURE|Post-occlusive reactive hyperemia test (PORH test)|Compression is applied on the buccal side of the attached gingiva, perpendicular to the long axis of the natural or implant born crown 2 mm far from the gingival margin.
223594153|NCT03560167|DEVICE|AccuCinch® Ventricular Restoration System|AccuCinch® Ventricular Restoration System in Patients with Prior Mitral Valve Intervention (PMVI) and Recurrent Mitral Regurgitation
223594154|NCT03215199|OTHER|NAPT|Web-based depression and distress monitoring application
223594155|NCT02942485|DRUG|Metronidazole|P/r suppositories
223594156|NCT02942485|DRUG|Tinidazole|P/o tablets
223594157|NCT00687674|DRUG|dexamethasone|20 mg orally Days 1, 8, 15, 22 of 28 day cycle
223594158|NCT00687674|DRUG|sorafenib tosylate|Phase I - dose escalating: 200mg once daily dose level -2, 200mg once daily dose level -1, 200mg once daily dose level 0, 200mg twice daily dose level 1, 200mg twice daily dose level 2, 400mg AM \& 200mg PM daily dose level 2a, 400mg twice daily dose level 3 orally days 1-28 every 28 days until progression
223594159|NCT00687674|DRUG|Lenalidomide|Phase I - dose escalating: 5mg level -2, 10mg level -1, 15mg level 0, 15mg level 1, 25mg level 2, 25mg level 2a, 25mg level 3 orally days 1-21 every 28 days until progression
223594160|NCT04844268|BIOLOGICAL|Cohort 1 VACCINE RNA MCTI CIMATEC HDT (HDT-301) vaccine|Intramuscular injections of 1 µg of novel Lipid-Inorganic Nanoparticle (LION) formulated replicating RNA-based vaccine (VACCINE RNA MCTI CIMATEC HDT (HDT-301)) at a dose of 1 µg on days 1 and 28 (group 1) or 1 and 56 (group 2), or a schedule of single dose administration (group 3).
223594161|NCT04844268|BIOLOGICAL|Cohort 2 RNA VACCINE MCTI CIMATEC HDT(HDT-301) vaccine|Intramuscular injections of 5 µg of novel Lipid-Inorganic Nanoparticle (LION) formulated replicating RNA-based vaccine (VACCINE RNA MCTI CIMATEC HDT(HDT-301)) at a dose of 5 µg on days 1 and 28 (group 1) or 1 and 56 (group 2), or a schedule of single dose administration (group 3).
223594162|NCT04844268|BIOLOGICAL|Cohort 3 VACCINE RNA MCTI CIMATEC HDT(HDT-301) vaccine|Intramuscular injections of 25 µg of novel Lipid-Inorganic Nanoparticle (LION) formulated replicating RNA-based vaccine (VACCINE RNA MCTI CIMATEC HDT(HDT-301)) at a dose of 25 µg on days 1 and 28 (group 1) or 1 and 56 (group 2), or a schedule of single dose administration (group 3).
223594163|NCT04844268|BIOLOGICAL|Placebo|Intramuscular (IM) injection of saline (0.9% sodium chloride) on days 1 and 28 (group 1) or 1 and 56 (group 2), or a schedule of single dose administration (group 3), in each cohort.
223594164|NCT05654454|DRUG|Bevacizumab|Bevacizumab 15 mg/kg
223594165|NCT05654454|DRUG|Paclitaxel|Paclitaxel 175 mg/m2
224196335|NCT04971720|DRUG|Sacubitril-Valsartan 49 Mg-51 Mg Oral Tablet|The subject will be randomized, in a double-blind manner to sacubitril/valsartan 49/51 mg once in the morning or once in the evening for a period of 28 days.
224196336|NCT04971720|DRUG|Valsartan 80 mg Oral Tablet|The subject will be randomized, in a double-blind manner to valsartan 80 mg once in the morning or once in the evening for a period of 28 days.
223594166|NCT05654454|DRUG|Carboplatin|Carboplatin AUC 6
223594167|NCT04518540|DRUG|lipoic acid group|"The patients will take lipoic acid for 6 course, the first course of treatment is 14 days with 14 days of rest, and the following course is the first for 10 days, with 14 days interval.The patients will use 600mg domestic lipoic acid in 250ml normal saline by intravenous, once a day.~At the same time, the patients will take domestic riluzole tablets 50mg orally, twice a day."
223594168|NCT04518540|DRUG|control group|The patients will take domestic riluzole tablets 50mg orally, twice a day.
223594169|NCT01122693|DEVICE|eZono - high-quality 2D ultrasound images|higher ultrasound frequencies, better image resolution, better post-processing and user-friendliness.
223594170|NCT01122693|DEVICE|standard 2D ultrasound images|current standard in two-dimensional (2D) ultrasound images
223594171|NCT02623582|BIOLOGICAL|Autologous Anti-CD 123 CAR TCR/4-1BB-expressing T-lymphocytes|Given IV
223594172|NCT02623582|DRUG|Cyclophosphamide|Given IV
223594173|NCT01379196|DRUG|Azithromycin|Tab. Azithromycin 500 mg PO three times weekly for 3 months
223594174|NCT02186678|OTHER|PET-CT|
223594175|NCT05096689|OTHER|MRI|Magnetic Resonance Imaging
223594176|NCT05100576|DEVICE|Telemedicine system users|Telemonitoring by medical devices connected to a software system with a router.
223594177|NCT04369950|DRUG|2% lidocaine with 1:200,000 epinephrine and epidural morphine|Epidurals will be dosed with 2% lidocaine with 1:200,000 epinephrine to T4 level in 5ml increments, epidural morphine 3mg will be given after delivery of neonate. T4 level maintained throughout cesarean delivery with additional epidural doses of 2% lidocaine with 1:200,000 epinephrine for both groups. Post-operative orders of scheduled acetaminophen and ibuprofen, and oxycodone as needed will be written.
223594178|NCT04369950|DRUG|3% 2-chloroprocaine and epidural morphine|Epidurals will be dosed with 3% 2-chloroprocaine to T4 level in 5ml increments, epidural morphine 3mg will be given after delivery of neonate. T4 level maintained throughout cesarean delivery with additional epidural doses of 2% lidocaine with 1:200,000 epinephrine for both groups. This is the critical component to bridge the latency period between the offset of 3% 2-chloroprocaine and the peak action of epidural morphine.Post-operative orders of scheduled acetaminophen and ibuprofen, and oxycodone as needed will be written.
223594179|NCT05839249|OTHER|JJ urological stents|recording complications of JJ stents during COVID19 pandemics
223594180|NCT06038734|DIAGNOSTIC_TEST|gastric ultrasound|Utilize POC gastric ultrasound to identify the presence of retained gastric contents.
224196337|NCT06199518|PROCEDURE|transperitoneal laparoscopic ureterolithotomy (T-LUL)/ retrograde flexible ureteroscopy (R-URS) /Antegrade mini-percutaneous flexible ureteroscopy (A-URS)|extraction or fragmentation of large proximal ureteral stones via different minimally invasive procedures
223594181|NCT00989963|DRUG|Beraprost Sodium Modified Release|60µg Tablets, twice a day for 12 weeks
223594182|NCT00139919|DRUG|Bifeprunox|
223594183|NCT02830321|OTHER|helicopacter pylori stool antigen test (CER TEST BIOTEC)|Stool samples were tested by using one step H.pylori stool antigen test (CER TEST BIOTEC)for the detection of H. pylori antigen in pregnant women with hyperemesis gravidarum
223594184|NCT06122038|DIETARY_SUPPLEMENT|Tart Cherry Extract Powder|Tart Cherry Extract Powder (NordicCherry, SpecNova, LLC). Dispensed during visit 1. Participants will consume 1 dose per day for 10 days.
223594185|NCT06122038|DIETARY_SUPPLEMENT|Placebo|Rice power placebo. Dispensed during visit 1. Participants will consume 1 dose per day for 10 days.
223594186|NCT03326206|OTHER|COPE Program|The COPE Program is a programmatic model that is designed to support to providers, Community Health Representatives, and patients/family members. Patients are referred to the COPE Program under program auspices. COPE referral and participation is part of routine care at all service units in Navajo Area Indian Health Services, and enrollment is not influenced by study participation. Patients receive the same health care services in the same manner and intensity, whether or not they are not enrolled in this observational study.
223594187|NCT05485337|OTHER|visual analog scale|Data collection was carried out at all stages of treatment: medical and nursing brigade, military mobile hospital, military medical clinical center, during rehabilitation, within 12 months of the injury.
223594188|NCT05350852|BIOLOGICAL|ThisCART19A|ThisCART19A is a new type CAR-T cells therapy for patients with acute B-cell leukemia
223594189|NCT00269867|DRUG|Placebo|Matching placebo will be adminstered at Week 0, 2, 6 and every 4 weeks up to Week 54.
223594190|NCT00269867|DRUG|Infliximab 3 mg/kg|Infliximab (anti-TNF chimeric monoclonal antibody \[cA2\]) 3 milligram per kilogram (mg/kg) will be administered as infusion at Week 0, 2, 6 and every 8 weeks or every 4 weeks up to Week 52.
223594191|NCT00269867|DRUG|Infliximab 10 mg/kg|Infliximab (anti-TNF chimeric monoclonal antibody \[cA2\]) 3 milligram per kilogram (mg/kg) will be administered as infusion at Week 0, 2, 6 and every 8 weeks or every 4 weeks up to Week 52.
223594192|NCT04385134|OTHER|No intervention|No intervention
223594193|NCT04548791|BIOLOGICAL|Coagulation Factor VIIa variant|Single intravenous dose and ascending doses of subcutaneous injection of MarzAA, followed by a fixed dose of MarzAA for the treatment of bleeding episodes
223594194|NCT01240200|DRUG|Glargine|oral antidiabetic agents plus once daily insulin glargine via an insulin syringe
223594195|NCT01240200|DEVICE|glargine via insulin pen|oral antidiabetic agents plus insulin glargine in a pre-filled pen
223594196|NCT00068302|DRUG|sirolimus|3-6 subjects will be enrolled into each dose level
223594197|NCT03548467|BIOLOGICAL|VB10.NEO|VB10.NEO is a vaccine and is supplied as a sterile, ready to use solution (14 vaccinations will be given).
224196338|NCT05610813|DRUG|VER-01|Standardized oleoresin of Cannabis sativa L. folium cum flore, THC-chemotype (cannabis leaves and - flowers), corresponding to 21 mg (-)-trans-Δ9-Tetra-hydrocannabinol (THC) per gram drug product
224196339|NCT05610813|DRUG|Opioid therapy|The patient-specific selection of the marketed opioid (based on standard of care and provided for this study) is at the discretion of the investigator and made at Visit 1, i.e., before randomization at Visit 2.
224310729|NCT06897644|DRUG|Irinotecan (CPT-11)|150 mg/sqm iv over 60 minutes day 1
224196340|NCT01887366|DRUG|TV-1380 150 mg|Subjects assigned to TV-1380 150 mg will be administered one intra-muscular (IM) injection once weekly over 12 weeks. The injection volume will be the same for all treatment groups. Therefore, to accommodate the volume required for the highest dosing group (3.0 mL), subjects in this group will receive 3.0 mL IM injection of TV-1380 150 mg (1.5 mL TV-1380 and 1.5 mL placebo/diluents).
224196341|NCT01887366|DRUG|TV-1380 300 mg|Subjects assigned to TV-1380 300 mg will be administered one intra-muscular (IM) injection once weekly over 12 weeks. Subjects in this treatment group will receive 3.0 mL TV-1380.
224196342|NCT01887366|DRUG|Placebo|Subjects assigned to placebo will be administered one intra-muscular (IM) injection once weekly over 12 weeks. Subjects in this treatment group will receive 3.0 mL placebo.
224196343|NCT02871466|DRUG|stem cells infusion|
224196344|NCT04471766|OTHER|Certified cloth face mask plus preventive information|Provision of two face masks sewed locally following a certified model tested for FORCE in the laboratory per residents \> 10 years old
224196345|NCT04471766|BEHAVIORAL|Preventive information|Advice on how to prevent COVID-19 according to the government´ policy
224196346|NCT01314859|DRUG|Nifedipine|"* Oral Treatment with Nifedipine capsules (10mg)~  * Initial dose: 20 mg of nifedipine (2 capsules of 10 mg).~ * Maintenance Dose: 20 mg of nifedipine (2 capsules of 10 mg) every 6 hours.~* Maximum Duration of the treatment: 48 hours."
224196347|NCT01314859|DRUG|Atosiban|"* Intravenously Treatment with Atosiban (7.5mg/ml)~  * Initial Dose: IV bolus injection during 1 minute + Intravenous infusion 7.5 mg/ml during 3 hours.~ * Maintenance: Maintenance intravenous infusion 7.5 mg/ml at least 18 hours to a maximum of 45 hours.~* Maximum Duration of the treatment: 48 hours."
224196348|NCT00016406|BIOLOGICAL|filgrastim|
224196349|NCT00016406|DRUG|cyclophosphamide|
224196350|NCT00016406|DRUG|doxorubicin|
224196351|NCT00016406|DRUG|paclitaxel|
224196352|NCT00016406|PROCEDURE|surgery|
224196353|NCT00563706|DRUG|vabicaserin|This study will utilize a randomized, double-blind, placebo-controlled, comparator-referenced, multicenter, parallel-group adaptive design with placebo, risperidone (4 mg/day), and up to 7 treatment arms of vabicaserin (50, 100, 150, 200, 300, 400 and 600 mg/day) over the course of the study
224196354|NCT00563706|DRUG|risperidone|
224196355|NCT00563706|OTHER|placebo|
224196356|NCT01502800|DRUG|ARQ 761|ARQ 761 will be administered intravenously at a starting dose of 195 mg/m2 IV once weekly. Depending on toxicities observed, up to seven treatment cohorts will be enrolled with dose escalation occurring by doubling (first escalation) and 40% increments thereafter. If dosing is tolerated at all levels and pharmacokinetic data suggest continued escalation is warranted, additional dose levels will
224196357|NCT01502800|DRUG|ARQ 761 Weekly Administration|"If you decide to participate in this study ARQ 761 (beta lapachone) will be given to you through your vein once a week via a Portacath or Hickman line (a device that will make it easier to access your central vein that will be placed under your skin in your upper chest)~You will receive the same dose of ARQ761 each week for 8 weeks. The total infusion time will be determined by your physician, it may be either 2 or 3 hours.~The beginning dose level will be 390 mg/m2."
224196358|NCT01502800|DRUG|Bi-Weekly Administration of ARQ 761|"If you decide to participate in this study ARQ 761 (beta lapachone) will be given to you through your vein bi-weekly via a Portacath or Hickman line (a device that will make it easier to access your central vein that will be placed under your skin in your upper chest)~You will receive the same dose of ARQ761 bi-weekly for 8 weeks. The total infusion time will be determined by your physician, it may be either 2 or 3 hours.~The beginning dose level will be 390 mg/m2."
224196359|NCT01502800|DRUG|Two Consecutive Weeks Administration of ARQ 761 with one week of rest|"If you decide to participate in this study ARQ 761 (beta lapachone) will be given to you through your vein once a week via a Portacath or Hickman line (a device that will make it easier to access your central vein that will be placed under your skin in your upper chest)~You will receive the same dose of ARQ761 for 2 consecutive weeks followed by one week of rest for 6 weeks. The total infusion time will be determined by your physician, it may be either 2 or 3 hours.~The beginning dose level will be 390 mg/m2."
224196360|NCT01827085|DEVICE|Conventional Macintosh laryngoscope|
223594198|NCT03548467|DRUG|Bempegaldesleukin|0.006 mg/kg bempegaldesleukin (NKTR-214) will be administered intravenously q4w for up to 11 doses starting from week 11 or at any dosing visit up to week 34 and for up to week 50 (up to 11 doses). The first 2 doses will be in a Q3W interval and following doses in Q4W intervals.
223594199|NCT02195141|RADIATION|conventional fraction|capecitabine 825mg/m2 p.o. twice daily Radiotherapy 50Gy/25f
223594200|NCT02195141|RADIATION|SIB|Concomitant chemoradiotherapy Radiotherapy with boost Radiotherapy (25 x 2 Gy), with a simultaneous integrated boost up to 56 Gy on the primary tumor capecitabine 825mg/m2 p.o. twice daily
223594201|NCT00765570|RADIATION|Spatially Fractioned Radiation Therapy|evaluate response to radiation therapy by a large bulky tumor influenced by adding a single dose of 15 Gy grid radiotherapy.
223594202|NCT00765570|RADIATION|Treatment Group 1|one treatment of Grid therapy followed by 15 treatments with standard radiation
223594203|NCT00765570|RADIATION|Standard radiation|15 Standard radiation treatments
223594204|NCT00765570|RADIATION|Standard radiation|standard radiation treatment
223594205|NCT03018639|BEHAVIORAL|Dialectical Behavior Therapy|DBT is a cognitive-behavioral treatment program that was developed to treat suicidal Patients with BPD (Linehan, 1993).
223594206|NCT01065701|DRUG|Dexmedetomidine|Intranasal dexmedetomidine is given as premedication prior to induction of anesthesia
223594207|NCT00258804|DRUG|Insulin glargine|
224196361|NCT01827085|DEVICE|Stortz videolaryngoscope|
224196362|NCT03280628|PROCEDURE|Absorbable Sutures|The patient's doctor will close the patient's laceration with absorbable sutures.
224196363|NCT03280628|PROCEDURE|Steri-Strips|The patient's doctor will close the patient's laceration with Steri-Strips.
224196364|NCT03280628|PROCEDURE|Dermabond|The patient's doctor will close the patient's laceration with Dermabond.
224196365|NCT01012531|BIOLOGICAL|Subcutaneous injections with highly polymerized allergen extract|cluster schedule
224196366|NCT01012531|BIOLOGICAL|Subcutaneous injection with placebo|cluster schedule
224196367|NCT02337543|DRUG|NEO6860|NEO6860 is an NCE acting as a TRPV1 antagonist
224196368|NCT02337543|DRUG|Placebo|Placebo
224310730|NCT06897644|DRUG|Leucovorin|Leucovorin 400 mg/sqm (racemic) or l-Leucovorin 200 mg/sqm over 2 hours day 1
224196369|NCT04780360|PROCEDURE|Cayanoacrylate tissue adhesives|Cyanoacrylates are a family of strong fast-acting adhesives with industrial, medical, and household uses. They are various esters of cyanoacrylic acid. The acryl groups in the resin rapidly polymerize in the presence of water to form long, strong chains
224196370|NCT04780360|PROCEDURE|Silk suture|Non Absorbalble suture materiel used to fixed the edges of the incision in place until healing
224196371|NCT00003582|DRUG|amifostine trihydrate|
223594208|NCT04992195|DIAGNOSTIC_TEST|Laboratory tests and Montreal Cognitive Assessment|Laboratory tests at baseline and 16 weeks (+/-4 weeks) after 2nd dose of vaccine and serological testing for IgG antibody. Participants who have a scheduled vaccination date shall undergo an MRI brain 16 weeks (+/-4 weeks) after the second dose of COVID-19 vaccination (either SinoVac or BioNTech). A face-to-face assessment 16 weeks (+/-4 weeks) will also be conducted after the 2nd dose of COVID-vaccine for evaluation of any clinical events, followed by a phone visit every 6 months. Cognitive assessment by MoCA will be performed at baseline, 16 weeks (+/-4 weeks) then every 12 months after the 2nd dose of COVID-19 vaccine.
223594209|NCT04992195|DIAGNOSTIC_TEST|Laboratory tests and Montreal Cognitive Assessment|Laboratory tests at baseline and serological testing for IgG antibody to exclude past COVID-19 infection. The timing of the second MRI brain, laboratory tests, clinical and cognitive assessment will be matched with the timing in the vaccination group are available.
223594210|NCT01590693|DRUG|Botulinum toxin A|The children in Group 2 underwent bilateral treatment with a total of 12 units/kg bodyweight Botox® (Allergan, California, USA). Four injection sites in each calf - two in the proximal third of the lateral and medial gastrocnemius bellies and two distally in the gastrocnemius-soleus complex - were administered. All injections were performed with electromyogram amplifier guidance to ensure intramuscular position. Children in both groups were treated with four weeks of below knee walking casts. Children in group 2 received the casts 1-2 weeks after botulinum toxin A treatment.
223594211|NCT05728398|OTHER|Music|Music played within the fluoroscopy suite during an interventional radiology procedure.
223594212|NCT05728398|OTHER|No Music|No music played within the fluoroscopy suite during an interventional radiology procedure.
223594213|NCT01465815|DRUG|erlotinib hydrochloride|Given PO
223594214|NCT01465815|DRUG|linsitinib|Given PO
223594215|NCT01465815|DRUG|placebo|Given PO
223594216|NCT01465815|RADIATION|radiation therapy|Undergo radiation therapy
223594217|NCT01465815|PROCEDURE|therapeutic conventional surgery|Undergo planned surgery
223594218|NCT01465815|OTHER|laboratory biomarker analysis|Correlative studies
223594219|NCT01139177|DEVICE|Stenting of atherosclerotic lesion(s)|Stenting of atherosclerotic lesions post pre-dilatation of lesion(s)
223594220|NCT00646399|DRUG|Placebo|Phosphate Buffered Saline on Days 0, 1, 2, 9, 16 and 23.
223594221|NCT00646399|DRUG|Pagibaximab 50 mg/mL|Pagibaximab 100 mg/kg dosed on Days 0, 1, 2, 9, 16 and 23
223594222|NCT03791775|DRUG|Polidocanol foam (Atossisclerol® 3%)|The procedure will be performed in the Sims position or lithotomy position. A modified Blonde-Blanchard technique will be adopted, with the tangential injection of polidocanol foam into the submucosa of the apex of each hemorrhoidal pile, without exceeding three piles, and using a self-lighting open-ended anoscope and a 20-G needle in order to reduce bleeding
223747150|NCT07179666|OTHER|Conventional therapy group|The intervention will include manual therapy techniques such as myofascial release and soft tissue mobilization to reduce fascial tension and improve local circulation. Stretching exercises will be prescribed to target the plantar fascia, Achilles tendon, and gastrocnemius-soleus complex in order to enhance flexibility and reduce mechanical strain. In addition, ultrasound therapy will be utilized for its thermal and non-thermal effects to promote tissue healing and reduce inflammation.
223594223|NCT00351065|DRUG|SK3530|
223594224|NCT04138680|BEHAVIORAL|Active Biofeedback|"The active biofeedback session will be done within the 7T MRI. It will include a pre-training run, 3 training runs, and a post-training run. Each run will be comprised of MOTIVATE and REST trials. During each MOTIVATE trial, subjects will be instructed to generate a heightened state of motivation. Participants will be encouraged to identify strategies that are personally relevant or useful and to monitor the efficacy of the strategies. Subjects will simultaneously view a progress bar on the screen during MOTIVATE trials that represents their VTA activity and they will be trained to try to increase the level of the bar by motivating themselves. For the active VTA biofeedback group, the progress bar will be updated every second to accurately convey level of VTA signal activation. During REST trials, all subjects will be instructed to count backwards. During the post-training 'test' run, subjects will be instructed to use the strategies they found to be most effective."
223594225|NCT04138680|BEHAVIORAL|Sham Biofeedback|The sham biofeedback session resembles the active condition, however, the thermometer seen during the MOTIVATE trials will represent yoked sham values.
223594226|NCT06977061|DRUG|Fruquintinib Combined with Sintilimab and Stereotactic Body Radiation Therapy|no other intervention
223747151|NCT07181434|DEVICE|The patient will be equipped with VR headsets|The patient will be equipped with VR headsets showing one of the six scenes from the HealthyMind® program in 3D, accompanied by hypnotic speech during the procedure.
223747152|NCT07180459|PROCEDURE|E-TACE|The 70/100μm drug-loaded microspheres were loaded with anthracyclines (30mg-50mg Idarubicin) at 2mL, and then combined with non-isoionic contrast agents to embolize the tumor supplying arteries, and then 250μm or 400μm drug-loaded microspheres were loaded anthracyclines (30mg-50mg Idarubicin) with 2mL/3mLto embolize the tumor supplying arteries at different grades and diameters.
223747153|NCT07180459|DRUG|Donafenib|400mg QD
223747154|NCT07180615|DRUG|Rifaximin (Xifaxan)|Preoperative gut decolonization protocol based on oral Rifaximin 2x550mg 10 am and 10 pm on the day preceding the surgery
224196372|NCT00003582|DRUG|cisplatin|
224196373|NCT00003582|DRUG|fluorouracil|
224196374|NCT00003582|DRUG|paclitaxel|
224196375|NCT00003582|PROCEDURE|quality-of-life assessment|
224196376|NCT00003582|RADIATION|radiation therapy|
224196377|NCT04554563|OTHER|Core stability training|20 sessions of specific core stability exercise with no external loading.
224196378|NCT04524351|DRUG|Posiphen|Solid oral dosage form, capsule
224196379|NCT04524351|DRUG|Placebo|Solid oral dosage form, capsule
224196380|NCT05912673|DEVICE|renal doppler|Toshiba Aplio ultrasound machine and renal resistive index will be measured (peak systolic velocity- end diastolic velocity/ peak systolic velocity
223594227|NCT02554578|OTHER|Multidisciplinary follow-up programme supported by mHealth|"The follow-up programme integrates an online health platform (app and web) to monitor patients remotely, into the multidisciplinary team workflow, in order to improve heart transplant management.~Patients will use the mobile application designed to help them to manage their health issues and facilitate communication with the transplant team.~Data recorded manually by the patient using the mHealth application include pharmacotherapeutic information (medication adherence, barriers to adherence, side effects, interactions, etc.), clinical symptoms and other relevant clinical information (blood pressure, cardiac frequency, exercise, glucose level, diet, mood, etc.).~mHealth will be used by the transplant team as a complementary way of deliver patient care. Analysis of the data collected by the multidisciplinary team may help to prioritise and provide personalized pharmacotherapeutic and medical interventions to patients and their families."
223594228|NCT02176161|DRUG|Metformin Hydrochloride Extended Release 750mg|Metformin Hydrochloride Extended Release 750mg twice per day for 9 months.
223747155|NCT07180615|DRUG|Metronidazole|Preoperative gut decolonization protocols based on oral Neomycine 2x500mg and Metronidazole 2x500mg 10 am and 10pm on the day preceding the surgery
223747156|NCT07180615|DRUG|Neomycin Sulfate|Preoperative gut decolonization protocols based on oral Neomycine 2x500mg and Metronidazole 2x500mg 10 am and 10pm on the day preceding the surgery
223747157|NCT07180069|OTHER|diet education|Individualized dietary education focused on reducing phosphate intake (food choices, portion control, additives).
223747158|NCT07179952|DRUG|Slow Release DHEA|Slow-release dehydroepiandrosterone capsule
223747159|NCT07179952|DRUG|Placebo|placebo capsule
223747160|NCT07181642|BEHAVIORAL|Diaphragmatic Breathing Program|Participants will learn diaphragmatic breathing exercises and practice them daily for 4 weeks before bedtime.
223747161|NCT07181642|BEHAVIORAL|Neutral Music Listening|Participants will listen to neutral music of the same duration before sleep. This activity does not include any therapeutic breathing exercises and is intended as a control
223747162|NCT07180303|OTHER|Remote training courses covering the latest CRC screening guidelines, identification of high-risk individuals and their standard of care, and dietary intervention strategies. Ongoing support services,|"Remote training courses covering the latest CRC screening guidelines, identification of high-risk individuals and their standard of care, and dietary intervention strategies.~Ongoing support services, such as regular knowledge updates and technical consultations."
223747163|NCT07180303|OTHER|Continuation of routine healthcare services without any additional training interventions.|Continuation of routine healthcare services without any additional training interventions.
223747164|NCT07181512|OTHER|Deep Learning Analysis of Non-contrast Chest CT|Analysis of clearly visualized coronary segments on non-contrast chest CT using deep learning models, compared with CCTA reference standard.
223747165|NCT07180394|DRUG|Botox injection into extraocular muscles|Botulinum toxin in various doses by injecting it into the overacting extraocular musces in strabismus patients, especially pediatric, but also adult cases, to use it as an alternative for strabismus surgery. For children, it will be administered under sedation or general anesthesia and in adults, under topical anesthesia. The pre-operative measurements of the type of strabismus, patterns, deviation, and post-operative results will be studied both in the short and long-term.
223747166|NCT05367544|BEHAVIORAL|Health Education|All participants will receive education regardless of randomization status. On the day of enrollment, participants will be invited to attend education modules focused on HTN risk, diet, physical activity, stress management, and goal setting. Participants will also have access to culturally relevant, weekly online sessions, alternating between cooking shows and exercise
223747167|NCT05367544|BEHAVIORAL|Individual-Level Peer Support|Participants will receive bi-weekly peer support calls for 6 months, followed by monthly calls for another 6 months.
223747168|NCT05367544|BEHAVIORAL|Community-Level Peer Support|Church Leadership in churches randomized to intervention will identify 2-3 Peer Health Advocates from the church who will receive training on ways to promote a culture of health, encouraging church members to attend on-line cooking shows and exercise sessions. After training, these individuals will also work with Church Leadership to form a committee that will develop a project (e.g., community food pantry, farmer's market, Zumba instruction, small church gym) aimed at overcoming structural barriers to healthy behaviors. Each church will receive a small stipend for their project. Churches randomized to education alone will receive the community-level intervention after 12 months of participation in the study (delayed intervention)
223747169|NCT04860141|DRUG|Gabapentin 600mg|The patient will take gabapentin 600mg 2 hours prior to the procedure
223747170|NCT04860141|DRUG|Placebo|the patient will take a pill that looks like gabapentin 2 hours prior to the procedure
223747172|NCT06110676|BIOLOGICAL|LZM012|Recombinant anti-human IL-17A/F humanized monoclonal antibody injection
223747173|NCT06110676|BIOLOGICAL|Secukinumab|Cosentyx
223747174|NCT05845788|PROCEDURE|Peripheral nerve block|Ultrasound guided peripheral nerve block
223747175|NCT03759379|DRUG|Patisiran|Patisiran will be administered by IV infusion.
223747176|NCT03759379|DRUG|Vutrisiran|Vutrisiran will be administered by SC injection.
223747177|NCT00579514|GENETIC|PCR/PCR/LDR Strategy|Evaluate the extent to which polymorphisms in BRCA1, BRCA2, PTEN, T β R1, TGF β-1, DNA repair genes (including ATM and CHK2), APC, ER, PR, MCP-1, MPIF, CCR2/5 and CCR3 are correlated with cancer incidence. Candidate genes will also be selected from 1) cytokine signaling and 2) apoptosis regulatory pathways.
223747178|NCT00075166|PROCEDURE|Stereotactic surgery (SRS)|
223747179|NCT00075166|PROCEDURE|Craniotomy|
223747180|NCT02145039|DRUG|Fludarabine|Fludarabine 30 mg/m2 IV over 30-60 minutes on days -6 through -2 before transplant.
223747181|NCT02145039|DRUG|Cyclophosphamide|Cyclophosphamide 14.5 mg/kg IV over 1-2 hours on days -6 and -5 before transplant and Cyclophosphamide 50 mg/kg IV on days 3 and 4 post-transplant.
223747182|NCT02145039|RADIATION|Total Body Irradiation|TBI 200cGy on day -1 before transplant.
223747183|NCT02145039|BIOLOGICAL|Haploidentical stem cell transplant|Non-T-cell depleted bone marrow infusion
224310731|NCT06897644|DRUG|5-FU (5-fluorouracil)|2400 mg/sqm 46-hours infusion
224310732|NCT06897644|DRUG|gemcitabine|1000 mg/sqm over 30 minutes on Days 1,8,15 of a 28-day cycles
223747184|NCT00183716|BEHAVIORAL|Trauma Recovery and Empowerment Model (TREM)|TREM is a 29-session group intervention for women who have experienced psychological trauma (e.g., childhood physical or sexual abuse), focusing on skill development, understanding the effects of trauma, and empowerment.
223747185|NCT00183716|BEHAVIORAL|Usual care|Participants will receive usual care for women who have experienced psychological trauma.
223594229|NCT06739044|DRUG|Ozempic®|The starting dose is 0.25 mg once weekly. After 4 weeks the dose should be increased to 0.5 mg once weekly. After at least 4 weeks with a dose of 0.5 mg once weekly, the dose can be increased to 1 mg once weekly for 24 weeks.
223594230|NCT06739044|DRUG|HDG1901|The starting dose is 0.25 mg once weekly. After 4 weeks the dose should be increased to 0.5 mg once weekly. After at least 4 weeks with a dose of 0.5 mg once weekly, the dose can be increased to 1 mg once weekly for 24 weeks.
223594231|NCT02883101|BEHAVIORAL|Pulmonary Rehabilitation|"The Rehabilitation Programme will include the following :~i. Patient education ii. Exercise training iii. Ventilator and breathing exercises"
223594232|NCT06141291|DIETARY_SUPPLEMENT|High protein diet|Test the ability of high protein diet (1.4 g protein/kg/day) with branched chain amino acid and cysteine supplementation to decrease bed rest induced muscle atrophy, glutathione depletion and insulin resistance in old subjects.
223594233|NCT06141291|DIAGNOSTIC_TEST|OGTT|Assessment of changes in insulin sensitivity (Oral Glucose Tolerance test and muscle insulin signalling: immunofluorescence and western blot of GLUT-4, IRS-1, MPP/TIMP, etc.) following bed rest in old and young subjects.
223594234|NCT01533662|DRUG|phenylephrine infusion|patients from 60 to 75 years receiving 100micrograms of phenylephrine infusion
223594235|NCT01533662|DRUG|patients receiving saline infusion|patients more than 60 years receiving 100micrograms of saline infusion
223594236|NCT00455143|DRUG|Precedex (Dexmedetomidine)|Dexmedetomidine started prior to surgery and continued for 24 hours postoperatively. Patients will receive dexmedetomidine until discharge from the PACU.
223594237|NCT00455143|DRUG|Placebo|Matching placebo given prior to surgery and continued for 24 hours postoperatively
223594238|NCT01553643|DRUG|Chinese Herb Huang-Chi-Wu-Wu-Tang|Huang-Chi-Wu-Wu-Tang at a rate of 3g two times per day
223594239|NCT01553643|DRUG|placebo|at a rate of 3g two times per day
223594240|NCT07088497|BEHAVIORAL|dietary control|Subjects are required to have dinner at a specific time on the night before the test and to remain fasting on the next day until the test.
223594241|NCT03198806|OTHER|Treadmill aerobic exercise in supine position|The volunteers will be submitted to a cardiovascular rehabilitation session with 40 minutes of treadmill aerobic exercise followed by 60 minutes of recovery at the supine position.
223594242|NCT03198806|OTHER|Treadmill aerobic exercise and water intake in supine position|The volunteers will be submitted to a cardiovascular rehabilitation session with 40 minutes of treadmill aerobic exercise and water intake followed by 60 minutes of recovery at the supine position.
223594243|NCT03198806|OTHER|Treadmill aerobic exercise in orthostatic position|The volunteers will be submitted to a cardiovascular rehabilitation session with 40 minutes of treadmill aerobic exercise followed by 10 minutes of recovery at the orthostatic position.
223594244|NCT03198806|OTHER|Treadmill aerobic exercise and water intake in orthostatic position|The volunteers will be submitted to a cardiovascular rehabilitation session with 40 minutes of treadmill aerobic exercise and water intake followed by 10 minutes of recovery at the orthostatic position.
223594245|NCT07087639|DEVICE|Self-expanding Venous Cannula|"The intervention consists of a self-expanding venous drainage cannula made of polyurethane and reinforced with a flexible metallic mesh. It is designed for transfemoral insertion during on-pump cardiac surgery, including minimally invasive procedures. Once positioned, the cannula expands to its functional diameter to facilitate efficient blood drainage into the extracorporeal circulation system. The configuration used in this study is 680/730 mm in length, 24 Fr, 3/8 diameter. The device is sterile, single-use, and is inserted once on the day of surgery (Day 0) and removed at the end of the procedure. The cannula is used continuously during cardiopulmonary bypass for a maximum duration of 6 hours and is not reused."
223594246|NCT00013169|BEHAVIORAL|Strong Patient Focus|
223594247|NCT00470418|DRUG|NIC5-15|a natural product, found in many foods and plants with mild insulin sensitizing effects
223594248|NCT00470418|DRUG|Placebo|placebo comparator
223747186|NCT00268138|DRUG|elmex gel|elmex gel once a week
223747187|NCT02306356|BEHAVIORAL|Internet-delivered Cognitive Behavior Therapy|
223747188|NCT04523363|DRUG|Metformin|Maximum dosage of 500 mg tablets 2 times a day (with each meal)
223747189|NCT06233474|DRUG|Allocetra|Allocetra-OTS is a cell-based therapy consisting of non-HLA-matched allogeneic peripheral blood mononuclear cells, induced to an apoptotic stable state
223747190|NCT06233474|OTHER|Placebo|The control used in this study will be placebo. Placebo solution containing all excipients except for the Allocetra cells.
223747191|NCT05280535|BEHAVIORAL|Cue Reactivity Task|In the cue-reactivity task, participants will be exposed to either a combustible cigarette or e-cigarette cue (within-subjects randomized order across laboratory sessions) and a neutral water bottle cue. Participants will report their craving for cigarettes and e-cigarettes.
223747192|NCT05280535|BEHAVIORAL|Computerized Visual Dot Probe|In the computerized visual dot probe task, participants will view a series of substance (cigarette or e-cigarette by trial block) versus neutral (water bottle) image trials and then respond to a subsequent image presented behind either the neutral or substance image. Order of block presentation within the task is randomized within-subjects across study sessions (i.e., cigarette OR e-cigarette block first).
223747193|NCT05280535|BEHAVIORAL|Choice Task|In the choice task, participants will choose between smoking their usual brand cigarette or their own e-cigarette over ten sequential ad-libbed trials.
223747194|NCT06835803|RADIATION|Dose-escalated radiation therapy|Dose-escalated radiation therapy involves higher doses of radiation therapy each day of treatment over the three week course of radiation therapy
223747195|NCT06835803|RADIATION|Standard hypofractionated radiation|Standard hypofractionated radiation therapy over 3 weeks
223747196|NCT03485378|RADIATION|Stereotactic Ablative Radiotherapy|Stereotactic ablative radiotherapy for early non-small cell lung cancer and interstitial lung disease
224310733|NCT06897644|DRUG|Nab-paclitaxel|125 mg/sqm over 30 minutes on Days 1,8,15 of a 28-day cycles
223747197|NCT04579380|DRUG|tucatinib|300 mg orally twice daily
223747198|NCT04579380|DRUG|trastuzumab|Given into the vein (intravenously; IV). 8mg/kg IV on Cycle 1 Day 1, and 6mg/kg every 21 days starting on Cycle 2 Day 1
224196381|NCT01852786|OTHER|Contraceptives, Oral, Combined|• The women, presenting for hormonal contraception use and with no contraindications for hormonal therapy, one of the two medicines registered in Lithuania will be administered׃ Daylette (20 micrograms of Ethinylestradiol and 3 mg of Drospirenone) or Lindynette (20 micrograms of Ethinylestradiol and 75 micrograms of Gestoden).
223594249|NCT04913740|OTHER|Ointment and dressing for external use|"1. pay attention to the protection of exposed skin, so that it is local dry.~2. Do a good job of facial moisturizing work before work use moisturizing ointment, more durable and non-irritating cream or emulsion, such as vitamin E cream, petroleum jelly, to do a good job of moisturizing work.~3. Use appropriate dressing to avoid direct contact between the mask and the skin, and select the appropriate type of protective device; Reduce friction by applying foam patches, hydrocolloidal dressings, and empleters to the hair area. However, it should be noted that it must be confirmed that airtightness is good and that the protective effect is still the primary purpose of the medical staff.~4. After work, avoid using irritants to clean the face, and massage local skin with skin moisturizer; (5) If severe skin damage occurs, treat it as prescribed by the doctor"
223594250|NCT02581969|DRUG|Recombinant Factor VIII (Kogenate FS, BAY14-2222)|Administered 20-30 IU/kg 3 times a week
223594251|NCT02581969|DRUG|Recombinant Factor VIII (Kogenate FS, BAY14-2222)|Administered only for bleeding episodes
223594252|NCT05113914|DIAGNOSTIC_TEST|Cardio-pulmonary exercise test|An incremental running test was conducted on the treadmill. Initially, the exercise protocol included standing still for 3 min and walking for 3 min at a constant speed of 4 km/h. After this introductory part, the speed was increased to 8 km/h and then every 3 min by 2 km/h until the volitional exhaustion was reached. During all procedure oxygen consumption was measured with the use of a portable breath-by-breath ergospirometer.
223594253|NCT00089947|DRUG|Thymoglobulin [Anti-Thymocyte Globulin (Rabbit)]|
223594254|NCT00001696|DRUG|Genistein|
223594255|NCT03739515|OTHER|HSCP intervention|A team of HSCPs (physiotherapist, occupational therapist, medical social worker) will provide comprehensive functional assessment to older patients
223594256|NCT03739515|OTHER|ED routine care|ED staff including consultants and nurses will provide patients with routine ED medical care.
223594257|NCT02448290|DRUG|docetaxel plus selumetinib|Selumetinib will be administered orally 75mg twice a day continuously. Docetaxel will be administered as an IV infusion over 1 hour at 60 mg/m2 every 3 week of a 21 days schedule.
223594258|NCT02654938|DRUG|Mobilan (M-VM3)|Mobilan (M-VM3), innovative experimental drug based on non-replicate adenoviral delivery system consisting genomic vector coding TLR5-receptor and its ligand 502s.
223594259|NCT02654938|DRUG|Placebo|5% infusion solution of dextrose
223594260|NCT02479139|BIOLOGICAL|Vehicle|Vehicle for ANT-1207 liniment formulation without active ingredient.
223594261|NCT02479139|BIOLOGICAL|ANT-1207|Botulinum toxin Type A topical liniment (ANT-1207).
223594262|NCT02974569|DEVICE|Computer Symptom Capture Tool|"C-SCAT is an investigator developed app that is delivered via an iPad. The original CSCAT included the 30 symptoms from the Memorial Symptom Assessment Scale. The recently updated version includes two additional symptoms feeling bloated and sexual dysfunction that are included in the adult version of the MSAS.21 These symptoms were added based on feedback from the initial AYA sample of 13-29 year olds and in consideration of the developmental perspectives of the AYA population.The CSCAT allows the user to create an image of his or her symptom experience."
223594263|NCT00908102|OTHER|Moderate|A two level active intervention with a control group was executed for patients suffering from non-acute, moderate LBP in occupational health. Patients were selected by using a self-administered postal questionnaire.
223594264|NCT00908102|OTHER|Mild|A one level intervention with long-term effectiveness and cost-effectiveness was executed for patients suffering from non-acute mild level LBP in occupational health. Patients were selected by using a self-administered postal questionnaire.
223594265|NCT00908102|OTHER|Mild vs. NC|A two level intervention with long-term effectiveness and cost-effectiveness was executed for patients suffering from non-acute mild level LBP in occupational health. Intervention arms were compared to NC - no intervention group.
223594266|NCT00908102|OTHER|Moderate vs. NC|A three level intervention with two control groups was executed for patients suffering from non-acute, moderate LBP in occupational health. RCT intervention groups were compared to NC group - i.e. no intervention.
223594267|NCT04217213|PROCEDURE|Intercostal nerve block|In the experimental group, the surgeons used 0.5% ropivacaine combined with mecobalamine (0.5mg) before the operation to perform intercostal nerve block in the operating incision, closed thoracic drainage incision and one intercostal nerve block in each upper and lower costal cavity, and injected 5ml in each intercostal nerve block.In the control group, surgeons used 0.5% ropivacaine alone before the operation to perform intercostal nerve block through the operating incision, closed thoracic drainage incision and one intercostal nerve block in each upper and lower costal cavity. 5ml was injected into each intercostal nerve block.
223594268|NCT04377152|DRUG|68Gallium-PSMA-11|PSMA-11 Ga 68 Injection is a positron emitting radiopharmaceutical containing radioactive 68Ga-labeled Glu-NH-CO-NH-Lys(Ahx)-HBED-CC (PSMA-11), which is used for diagnostic purposes in conjunction with Positron Emission Tomography (PET).
223594269|NCT04377152|PROCEDURE|Positron Emission Tomography (PET)|A PET scan is an imaging test that helps reveal how your tissues and organs are functioning using a radioactive drug (tracer) to show this activity
223594270|NCT00885482|DRUG|Lamiduvine (Epivir)|Epivir 300 mg
223594271|NCT00885482|DRUG|Atazanavir (Reyataz)|Reyataz 300 mg
223594272|NCT00885482|DRUG|Ritonavir (Norvir)|Norvir 100 mg
223594273|NCT04911972|PROCEDURE|Functional muscle transfer|Muscle transfer to restore lower limb function
223747199|NCT04579380|DRUG|fulvestrant|Given into the muscle (intramuscular; IM) once every 4 weeks starting from Cycle 1 Day 1, plus one dose on Cycle 1 Day 15. Only administered to participants with hormone-receptor positive breast cancer.
223747200|NCT05686317|DEVICE|Edwards APTURE transcatheter shunt system|Treatment with APTURE shunt
224196382|NCT01852786|OTHER|Controls|The women, The women presenting for non-hormonal contraception use, will be recommended BCM or NFPM.
224196383|NCT06439186|DRUG|Lidocain|Local anesthesia
223747201|NCT05686317|DIAGNOSTIC_TEST|Sham procedure|CS angiography
223594274|NCT00084656|BIOLOGICAL|ipilimumab|IV over 90 mins on day 1, wks 1,9,17,25,33,41,53 Dose: 3 mg/kg (Part I), 10 mg/kg (Part II)
223594275|NCT00084656|BIOLOGICAL|Tyrosinase/gp100/MART-1 Peptides|(All subjects in Part I and HLA-A\*0201 positive subjects only in Part II): SC, day 1 of wks 1,3,5,7,9,11,17, 21,25,33,41,53 Dose: 1 mg peptide emulsified in 1 mL Montanide ISA 51 VG.)
223594276|NCT02555605|DRUG|Dexmedetomidine|Children up to the age of 16 years requiring MRI under deep sedation with at least 3 characteristics of respiratory morbidities were identified as having increased risk for adverse respiratory events. Dexmedetomidine was administered as a first bolus of 1 mcg•kg-1 over 10 min, followed by a continuous infusion at 1.0 mcg•kg-1•h-1. Sedation level was assessed by Ramsay Sedation Scale and it was initially recorded at 1-min interval. If the child failed to achieve a minimum RSS of 5, this bolus was repeated once again and the continuous infusion was subsequently increased to 2 mcg•kg-1•h-1. In addition, propofol 0.5 mg.kg-1 iv. was allowed to be administered, in patients still exhibiting movement that could interfere with image acquisition.
223594277|NCT02772978|DRUG|Tolcapone|Tolcapone is in the medication class of catechol-O-methyltransferase (COMT) inhibitors
224196384|NCT02198157|OTHER|urinary catheterization|nullipara women with epidural anaesthesia who pose urination difficulty will be randomize to receive intermittent or continuous urinary catheterization.
223594278|NCT02772978|DRUG|Placebo|A placebo is a tablet or capsule that looks like the study medication (in this case, tolcapone) but does not contain any active ingredients
223594279|NCT02357589|PROCEDURE|2D laparoscopic cholecystectomy|
223594280|NCT02357589|PROCEDURE|3D laparoscopic cholecystectomy|
223594281|NCT02678299|DRUG|PREBEN|
223594282|NCT05047432|OTHER|Non-interventional trial|Non-interventional trial
223594283|NCT01532869|DRUG|Placebo|Subcutaneously weekly, Weeks 0-48
223594284|NCT01532869|DRUG|tocilizumab [RoActemra/Actemra]|162 mg subcutaneously weekly, Weeks 0-48
223594285|NCT01532869|DRUG|tocilizumab [RoActemra/Actemra]|162 mg subcutaneously weekly, Week 48-96
223594286|NCT01700712|DIETARY_SUPPLEMENT|Probiotic Lactobacilli reuteri|
223594287|NCT01700712|DIETARY_SUPPLEMENT|Placebo|
223594288|NCT05954767|DRUG|IS-001|IV injection of IS-001 drug substance with near infrared (NIR) imaging
223594289|NCT03860467|OTHER|collection of patient data|Patient data will be collected using the in-house digital patient record systems and the local digital electroencephalogram (EEG)-database
223594290|NCT00209898|PROCEDURE|Fast initiation procedure|
223594291|NCT00072774|DRUG|DVS-233 SR|
223594292|NCT05893472|COMBINATION_PRODUCT|combination of venetoclax and HAA regimen|Using the combination of venetoclax and HAA regimen as induction therapy in young, newly diagnosed adult acute myeloid leukemia patients under the age of 60.
223594293|NCT01331291|DRUG|bosutinib|Taken orally
223594294|NCT01993563|OTHER|Graded Motor Imagery|"GMI program includes three steps: Implicit Motor Imagery (IMI); Explicit Motor Imagery (EMI) and Mirror Box Therapy (MT).~IMI included a training based on Hand Laterality Discrimination Tasks. During these tasks 60 pictures of right and left hands are projected randomly on a 15 screen. Patients are asked to choose whether the images seen are right or left and therefore to click respectively the right or the left button on a mouse.~EMI training consists in imagining a movement without actual performing it. It will be introduced during IMI's last two sessions and gradually enhanced increasing the complexity of motor skills to be imagined. The therapist shows or explains in details the movements the patient have to mentally rehearsed.~MT treatments will start with simply watching the unaffected hand in the mirror and increased toward functional movement. When possible, gentle movement with the affected hand will be encouraged behind the reflecting part of the mirror."
223594295|NCT01993563|OTHER|Standard treatment|Patients will undergo to a standard treatment, that is thought to be the best option for that specific patients. In our hospital, treatment options include: motor training, functional training, occupational therapy, bilateral arm training or motor treatment using virtual reality devices.
224196385|NCT01947010|BIOLOGICAL|Prevenar 13|
223594296|NCT04314076|OTHER|Rhythmic auditory stimulation|RAS, a Neurologic Music Therapy technique developed to utilize rhythm and timing cues to assist in improving the basic, intrinsic rhythmic movements of gait.
223594297|NCT04314076|OTHER|Gait Training|Continuous overground walking on a track for 30 minutes. Gait training will primarily consist of walking exercise under the supervision of an exercise physiologist.
224196386|NCT01947010|BIOLOGICAL|Pneumovax|
224196387|NCT05420610|OTHER|Control group: Patients being admitted when The advancement of transpulmonary thermodilution(TPTD) device was unavailable.|The control group included patients being admitted when TPTD device was unavailable; and relatively stable patients without the need for TPTD. The adequacy of fluid resuscitation in the control group was monitored by traditional monitoring parameters including vital signs and hourly urine output.
223594298|NCT02027753|DRUG|INSULIN GLARGINE|Pharmaceutical form: solution Route of administration: subcutaneous
223594299|NCT02027753|DRUG|Metformin|Pharmaceutical form: tablet Route of administration: oral
223594300|NCT02027753|DRUG|DPP-4 inhibitor|Pharmaceutical form: tablet Route of administration: oral
223594301|NCT02027753|DRUG|Sulphonylurea|Pharmaceutical form: tablet Route of administration: oral
223747202|NCT06075316|OTHER|Symptom monitoring|Alerts will be sent to providers via email and/or the electronic medical record at pre-specified response thresholds. Providers will be instructed to respond to and document the management of alerts per their clinical routine.
223747203|NCT01284725|DRUG|mycophenolate mofetil or azathioprine|
224196388|NCT05420610|OTHER|Study group: TPTD device was implemented for monitoring.|TPTD device was implemented for monitoring; the inclusion criteria included patients suffering from 2nd degree burn greater than 40% TBSA; a combined 2nd to 3rd degree burn greater than 30% TBSA; or patients with inhalation injury despite the burned surface area.
224196389|NCT01842412|BEHAVIORAL|exercise|one bout of exercise training
224196390|NCT03455842|BIOLOGICAL|BCD-089, 162 mg, s/c, qw|Subcutaneous injections of anti-IL6R every week
224196391|NCT03455842|BIOLOGICAL|BCD-089, 162 mg, s/c, q2w|Subcutaneous injections of anti-IL6R every other week
224196392|NCT03455842|DRUG|placebo|Subcutaneous injections of placebo every week, until week 12. Thereafter subcutaneous injections of anti-IL6R every other week
224196393|NCT04004975|DRUG|Anlotinib|Anlotinib is a multitarget receptor tyrosine kinase inhibitor which inhibits vascular endothelial growth factor receptor (VEGFR) 1-3, fibroblast growth factor receptor (FGFR) 1-4, platelet-derived growth factor receptors (PDGFR) α/β, c-Kit, and Met.
224196394|NCT01716442|DRUG|Rituximab|Per dose: Rituximab 375 mg/m2 (max.500mg/day). efficacy monitored by CD19 cell count. If CD19 cells are not depleted, second or third doses are given at 2-3 weeks interval.
224196395|NCT01716442|DRUG|Placebo|
224196396|NCT02472600|DRUG|Colistin|
224196397|NCT02472600|DRUG|Neomycin|
224196398|NCT02472600|DRUG|Fecal microbiota transplantation (FMT)|FMT consist in the administration of fecal material obtained from healthy donors that has been diluted, homogenized, filtered and reconcentrated. In this study the processed fecal material will be frozen at -80°C after processing and will be administered to patients for up to six months after freezing via a nasogastric tube or via capsules.
224196399|NCT02472600|DRUG|Omeprazole|Administered to inhibit gastric acid secretion before FMT administration if FMT administered via nasogastric tube approach (not used for capsule approach).
224196400|NCT03096106|DEVICE||the investigators just observe the pressure time curve on the ventilation
224196401|NCT05663333|OTHER|Dynamic full-field optical coherence tomography analysis of temporal artery biopsy|Dynamic full-field optical coherence tomography analysis of temporal artery biopsy in the dermatology department before conventional histopathological analysis
224196402|NCT00011037|BIOLOGICAL|ALVAC(2)120(B,MN)GNP (vCP1452)|1 x 10\^ 7 TCID50 administered intramuscularly
223594302|NCT03968185|OTHER|Interfascial infiltration|"Injection of L-bupivacaine (50 mg) and dexamethasone (4 mg) in the interfascial space under ultrasound guidance.~Patients were kept under surveillance for at least one hour before discharge.~Patients were discharged home with a 7 day supply of acetaminophen 1000 mg orally every 6 h, ketoprofen 100 mg, orally twice a day, and muscle relaxant as needed. Patients were instructed to take tramadol 50 mg, orally every 6h as needed for low back pain, in case of insufficient relief."
223594303|NCT03968185|OTHER|Standard medical treatment|"Standard medical treatment include acetaminophen, NSAIDs and muscle relaxant as first line pharmacological treatment and escalation to analgesics level II or morphine if required, as needed for low back pain, in agreement with national guidelines Route of administration (orally or iv) was let at the discretion of the attending emergency physician.~Patients were kept under surveillance for one hour before discharge. Patients were discharged home with a 7 day supply of acetaminophen 1000 mg orally every 6h, ketoprofen 100 mg, orally twice a day, and muscle relaxant as needed. Patients were instructed to take tramadol 50 mg, orally every 6h as needed for low back pain, in case of insufficient relief."
223594304|NCT00778895|BIOLOGICAL|GSK Biologicals' influenza vaccine GSK1557482A|one IM injection at Day 0 for primed subjects (defined as subjects who had a prior 2-dose priming influenza immunization) or two IM injections at Day 0 and approximately Day 28 for un-primed subjects (defined as subjects who have not previously received a complete 2-dose priming influenza immunization).
223594305|NCT00778895|BIOLOGICAL|Vaxigrip|one IM injection at Day 0 for primed subjects (defined as subjects who had a prior 2-dose priming influenza immunization) or two IM injections at Day 0 and approximately Day 28 for un-primed subjects (defined as subjects who have not previously received a complete 2-dose priming influenza immunization).
223594306|NCT04170829|BIOLOGICAL|ChAdOx1 MERS|a replication-deficient simian adenoviral vector expressing the spike (S) protein of MERS Coronavirus.
223594307|NCT03762798|DEVICE|The Bridge|The Bridge (Also known as NSS-2) is a percutaneous, auricular field stimulator developed to alleviate pain through stimulation of peripheral cranial neurovascular bundles in the external ear that could potentially gain access to brain areas involved in fear, pain and nociception. After five days, the subject will return to the clinic for device removal and disposal.
223594308|NCT05032885|OTHER|physiotherapy|"Patients in the intervention group will receive early physiotherapy treatment. This intervention will consist of exercises and physiotherapy techniques commonly used and aimed at improving the patient's respiratory and motor conditioning.~At the respiratory level: diaphragmatic and costal targeted ventilation, pursed-lip breathing and bronchial hygiene techniques if required.~At the motor level: passive, active-assisted kinesitherapy and analytical and global potentiation of the upper and lower limbs that will allow the maintenance and improvement of the articular pathway and will prevent muscle weakness; retraining of transfers and balance; gait reeducation."
223594309|NCT04752345|OTHER|Pharmacoinvasive strategy|Pharmacoinvasive treatment \[full-dose fibrinolysis combined with rescue PCI (in case of failed fibrinolysis) or routine early PCI (3 to 24 hours, in case of successful fibrinolysis)
223594310|NCT04752345|OTHER|Reduced-dose facilitated PCI strategy|Reduced-dose facilitated PCI\[reduced-dose fibrinolysis,simultaneously transfer,immediate coronary angiography and andioplasty when arrived at PCI center(\<3 hours)\]
223747204|NCT01284725|OTHER|immunosuppressive treatment discontinuation|
224196403|NCT00011037|BIOLOGICAL|MN rgp120/HIV-1|0.6 mg administered intramuscularly
224196404|NCT00011037|BIOLOGICAL|ALVAC(2)120(B,MN)GNP (vCP1452) placebo|ALVAC placebo administered intramuscularly
224196405|NCT00011037|BIOLOGICAL|MN rgp120/HIV-1 placebo|Alum placebo administered intramuscularly
224196406|NCT02064400|OTHER|Musculoskeletal Ultrasound|7-joint musculoskeletal ultrasound scan
224196407|NCT02064400|OTHER|Semi-structured patient interview|Semi-structured patient interview
223747205|NCT02717624|DRUG|Acalabrutinib in combination with BR|
223747206|NCT02717624|DRUG|Acalabrutinib in combination with VR|
224196408|NCT01636011|OTHER|Osteopathic Manipulative Medicine Treatment|Osteopathic Manipulative Medicine Treatment
224196409|NCT01636011|OTHER|Light Touch sham|Light Touch sham
224196410|NCT02079493|DEVICE|Total Knee Arthroplasty|Knee replacement
223747207|NCT03115983|DEVICE|LimiFlex|LimiFlex implantation at a single level after surgical decompression.
224196411|NCT05454189|DEVICE|Reduced IPD Flush Schedule|IPD flush every 12 weeks
224196412|NCT05454189|DEVICE|Standard IPD Flush Schedule|IPD flush every 4 weeks
224196413|NCT00700115|DRUG|Kaletra + Isentress|Kaletra 400/100 mg + Isentress 400 mg BID
224196414|NCT00700115|DRUG|Pre-study antiretroviral regimen|Standard doses of pre-study antiretroviral regimen
224196415|NCT02503215|DEVICE|Compression Stockings|To evaluate the effects of compression stockings on fluid shift and sleep apnea in hemodialysis patients with obstructive sleep apnea
223594311|NCT01423474|RADIATION|Image-guided radiotherapy|40 Gy / 5 fractions / 11 days
223594312|NCT01423474|RADIATION|Image-guided radiotherapy|40 Gy / 5 fractions / 29 days
224196416|NCT06170528|DEVICE|AURA_ALZ|AURA\_ALZ includes the WiFi CSI-based human sensing algorithms, as well as the voice and web interfaces. The devices of AURA\_ALZ consists of Fitbit watch, iPad, ASUS routers, Jetson nano, webcam, and Amazon Echo.
224196417|NCT04657861|DRUG|APRIL CAR-T cells|Each subject receive APRIL CAR T-cells by intravenous infusion
224196418|NCT03965754|BEHAVIORAL|Social norms|This intervention introduces recipients to descriptive social norms specifying that a majority of their colleagues have signed up for the program, which sets a normative standard against which recipients are expected to compare themselves and to change their behavior accordingly (i.e., when they realize that their behavior is discrepant from that of relevant others). The personal testimonial from a Geisinger medical director serves as a personal exemplar intended to further enhance the effect of the social norms with an implicit indication that the intended behavior is desirable and feasible.
224196419|NCT03965754|BEHAVIORAL|Loss framing|This intervention frames the status quo as a state from which recipients, via inaction, are slated to forfeit a sizable and precise monetary amount to which they should otherwise feel entitled (via loss aversion and the endowment effect). People tend to be risk-seeking in the domain of losses; therefore, this intervention is hypothesized to increase enrollment in the hope of achieving zero loss by meeting program goals, as opposed to a sure loss via inaction.
224196420|NCT03965754|BEHAVIORAL|Email reminder|This intervention is a standard email reminder that mentions the average premium savings, the speed and ease of starting the process, and the deadline for registering and having health measures on file, plus it provides two button links for registering and finding screenings.
224196421|NCT04130477|DEVICE|Tunnel attachments and light Nickel Titanium wire|Tunnel attachments planned virtually and light Nickel Titanium wire
224196422|NCT04130477|DEVICE|Clear Aligner therapy|Clear Aligner therapy
224310734|NCT06841822|OTHER|SCTL superficial plane block|The purpose of this study was to evaluate whether thoracic paravertebral nerve block performed on superficial SCTL (puncture needle did not break SCTL) was more beneficial to maintaining hemodynamic stability during the induction period of thoracoscopic lobectomy compared with SCTL deep plane (puncture needle break SCTL). We performed an ultrasound-guided paravertebral nerve block while keeping the puncture needle did nit to break through the SCTL. In 20 patients who required CT (3D) imaging to observe drug diffusion 30min after nerve block, cold stimulation was used 30min after the procedure to assess the degree of sensory loss, including the anterior chest wall (midclavian line), lateral chest wall (posterior axillary line), and posterior chest wall (paravertebral area).
223594313|NCT03410342|OTHER|LFV|1 apple/banana/small bunch of grapes per day plus 1 portion of carrot/pepper/tomato per day
223594314|NCT03410342|OTHER|HFV|4 portions of fruits (apples, bananas, grapes, pears) plus 4 portions of vegetables (carrots, cucumber, sweet peppers, tomatoes), of commonly consumed types per day excluding citrus fruits, cruciferous and allium vegetables.
223594315|NCT03410342|OTHER|CC|4 portions of citrus fruits (clementines, grapefruits, lemons, oranges) plus 4 portions of cruciferous vegetables (broccoli, brussels sprouts, cauliflower, kale, savoy cabbage) per day.
223594316|NCT03744520|PROCEDURE|Erector spinae plane block|Local anesthetic infiltration is applied between the erector spinae muscle fascia and transverse process.
223594317|NCT04684992|DEVICE|GEBT Telehealth Administration Usability|Establish the usability of a telehealth platform for the administration of GEBT
223594318|NCT02967601|BEHAVIORAL|STAI (State Trait Anxiety Inventory) questionaire|Each patient would fill the STAI questionaire before Cesarean Section (on the same day, in the morning)
223594319|NCT00667667|DEVICE|vertical vibration device (Vibrafit whole body vibration platform)|3 sessions/week 15 min each, leg exercises performed on whole body vibration platforms with vertical device
223594320|NCT00667667|DEVICE|side alternating vibration device (Board 3000 whole body vibration platform)|3 sessions/week 15 min each, leg exercises performed on whole body vibration platforms with side alternating device
223594321|NCT00667667|BEHAVIORAL|stretching and wellness (control group)|2x10 weeks with 1 session/week of low volume, low intensity wellness training over 12 months
223594322|NCT06186115|COMBINATION_PRODUCT|Gold|Intra articular
223594323|NCT04797962|BEHAVIORAL|Case management|dedicated case management to address social support needs
223594324|NCT02540993|DRUG|Finerenone (BAY94-8862)|Oral tablet; starting dose at 10 mg for subjects with an eGFR between 25 to \< 60 mL/min/1.73m² at the Screening Visit; starting dose at 20 mg for subjects with an eGFR ≥ 60 mL/min/1.73m² at the Screening Visit; dose could be up-titrated from Month 1 onwards or down-titrated at any time during the study; once daily in the morning, until the trial was completed provided there were no safety grounds for discontinuing treatment
223594325|NCT02540993|DRUG|Placebo|Matching placebo, oral tablet, once daily in the morning, until the trial was completed provided there were no safety grounds for discontinuing treatment
223594326|NCT02424045|DRUG|BCD chemotherapy (Bendamustine, Carboplatin, Dexamethasone)|All patients are scheduled to receive 2 cycles of three-weekly BCD. After 2 cycles of BCD, if the patients with complete remission (CR) or partial remission (PR) would be eligible for autologous stem cell transplantation (ASCT), stem cell collection after 3rd cycle of BCD and high dose chemotherapy and ASCT will be conducted. While ineligible patients to ASCT with non-progressive disease after 2 cycles of BCD, will be given 4 additional courses of the BCD regimen.
223594327|NCT02257203|BEHAVIORAL|Sugar Sweetened Beverage Education|Parents will receive an educational module on beverage just after the conclusion of their child's well visit in a private room adjacent to the clinic
223594328|NCT02257203|BEHAVIORAL|Reading Education|Parents randomized to control will receive a 25-minute educational module on the importance of reading to children with instruction in interactive reading techniques that are appropriate to the child's age
223594329|NCT04731532|PROCEDURE|classical respiratory physiotherapy with thoracic vibration|Classical respiratory physiotherapy application: Patient is positioned, postural drainage application is operated by tapping and trifled .
223594330|NCT00409344|DRUG|Dexmedetomidine|A continuous infusion of dexmedetomidine will be started at a dose of 0.8mcg/kg/hr. This will continue for no longer than 24 hours. Four hours post extubation the study drug wii be discontinued using a standard tapering protocol: 0.6mcg/kg/hr for 4 hours then 0.4mcg/kg/hr for 4 hours, then 0.2 mcg/kg/hr for 4 hours and then 0.1mcg/kg/hr for 4 hours and then turned off.
224196423|NCT01929551|OTHER|Mango puree and pear juice beverage|Capillary glucose will be taken every 15 minutes for two hours (starting at time 0) to calculate the area under the curve which is the glycemic index, for each of the products.
224196424|NCT01929551|OTHER|Commercial mango juice|Capillary glucose will be taken every 15 minutes for two hours (starting at time 0) to calculate the area under the curve which is the glycemic index, for each of the products.
223594331|NCT00409344|OTHER|Normal Saline|Normal Saline will be given as the placebo and will administered at 0.8mcg/kg/hr
223594332|NCT01640262|OTHER|Multiparametric magnetic resonance imaging (mMRI)|A mMRI is performed before treatment of the patient and is compared to the standard diagnostic tools for evaluating the clinical stage and diagnose of prostate cancer
224196425|NCT01929551|OTHER|Fresh natural mango|Capillary glucose will be taken every 15 minutes for two hours (starting at time 0) to calculate the area under the curve which is the glycemic index, for each of the products.
224196426|NCT01929551|OTHER|Frozen natural mango|Capillary glucose will be taken every 15 minutes for two hours (starting at time 0) to calculate the area under the curve which is the glycemic index, for each of the products.
224196427|NCT01929551|OTHER|Processed natural mango pulp|Capillary glucose will be taken every 15 minutes for two hours (starting at time 0) to calculate the area under the curve which is the glycemic index, for each of the products.
224196428|NCT01929551|OTHER|Mix of natural mango and pear|Capillary glucose will be taken every 15 minutes for two hours (starting at time 0) to calculate the area under the curve which is the glycemic index, for each of the products.
224196429|NCT01929551|OTHER|50 grams glucose load|Capillary glucose will be taken every 15 minutes for two hours (starting at time 0) to calculate the area under the curve which is the glycemic index, for each of the products.
224196430|NCT02983305|DEVICE|Head-Mounted Display|Head-mounted displays (HMD) are a class of technology that are worn on the user's head and project an image either in front of or into the eye.
224196431|NCT05100277|GENETIC|Oncotype DX® Assay|After surgery, tumoral tissue was used to perform Oncotype Dx®. Patients were evaluated and therapy recommendations - adjuvant chemotherapy (CT) plus hormone therapy (HT) or HT alone - were captured before and after revealing the test results. Results from TAILORx10 were used to guide decisions for or against CT for individual patients. Changes in treatment recommendations were obtained.
224196432|NCT05100277|OTHER|Cost|Changes in treatment costs were estimated from Pérola Byington Hospital.
224196433|NCT06132087|PROCEDURE|Biospecimen Collection|Undergo blood and tissue sample collection
224196434|NCT06132087|PROCEDURE|Computed Tomography|Undergo CT
224196435|NCT06132087|PROCEDURE|Distal Pancreatectomy|Undergo distal pancreatectomy
224196436|NCT06132087|PROCEDURE|Laparoscopy|Undergo laparoscopy
224196437|NCT06132087|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
224196438|NCT06132087|PROCEDURE|Pancreaticoduodenectomy|Undergo pancreaticoduodenectomy
224196439|NCT06132087|OTHER|Questionnaire Administration|Ancillary studies
224196440|NCT06132087|PROCEDURE|Surgical Procedure|Undergo surgical resection
224196441|NCT06132087|PROCEDURE|Total Pancreatectomy|Undergo total pancreatectomy
224196442|NCT02665858|OTHER|OCT Imaging|
224196443|NCT02821546|DRUG|Lactated Ringer's solution|Standard fluid hydration with Lactated Ringer's solution is calculated based on Holiday Segar's equation Aggressive hydration with Lactated Ringer's solution is defined as administration of 150 ml/hour of fluid
224196444|NCT01896518|DRUG|Nicotine polacrilex|
223594333|NCT00490048|PROCEDURE|Induced sputum (inhalation of 3.5% saline)|
223594334|NCT05492981|BEHAVIORAL|Enhanced (intervention) education|See arm description
223594335|NCT01207089|DRUG|AZD8329|AZD8329 Oral Solution 20mg/ml
223594336|NCT01207089|DRUG|Placebo|Placebo AZD8329 Oral Solution
223594337|NCT01009086|DRUG|Placebo|SC injections
223594338|NCT01009086|DRUG|Ustekinumab 45 mg|SC injections
223594339|NCT01009086|DRUG|Ustekinumab 90 mg|SC injections
224196445|NCT01896518|DRUG|Tobacco lozenge|
224196446|NCT00822237|BIOLOGICAL|Varicella Virus Vaccine Live (2007 Process) (Oka/Merck)|VARIVAX (2007 process) in two 0.5 mL doses by injection \~6 weeks apart
224196447|NCT00822237|BIOLOGICAL|Comparator: Varicella Virus Vaccine Live (1999 Process) (Oka/Merck)|VARIVAX (1999 process) in two 0.5 mL doses by injection \~6 weeks apart
224196448|NCT00822237|BIOLOGICAL|Measles, Mumps, and Rubella Virus Vaccine Live (MMR)|M-M-R II in two 0.5 mL doses by injection \~6 weeks apart
224196449|NCT03433482|BIOLOGICAL|MenACWY liquid|At visit 1 (day 1), each subject will receive a single dose of the investigational MenACWY liquid vaccine (GSK3536820A) aged for approximately 24 months in Phase 1 of the study (subjects randomized to study arm ACWY\_Liq24) or vaccine aged for 30 months in Phase 2 of the study (subjects randomized to study arm ACWY\_Liq30), administered by intramuscular injection in the deltoid of the non-dominant arm.
224196450|NCT03433482|BIOLOGICAL|MenACWY|At visit 1 (day 1), each subject will receive a single dose of the MenACWY vaccine in the Phase1 of the study (subjects randomized to study arm ACWY\_1) or in phase 2 of the study (subjects randomized to study arm ACWY\_2), administered by intramuscular injection in the deltoid of the non-dominant arm.
224196451|NCT03890380|DEVICE|Magneto Wire|Patients will be treated with Magneto Wire
224196452|NCT03723460|OTHER|Passive Dietary Monitoring|Passive dietary monitoring devices will be used to monitor dietary intake in household in communities in Ghana and Kenya
224196453|NCT01863394|OTHER|Screening by mothers|
224196454|NCT01863394|OTHER|Active comparator: Screening by community health workers|
224196455|NCT05623826|OTHER|Cognitive- behavioral imagery-based training|The EMI developed and tested here is based on theoretical and empirical findings and consists of several items and a repeated training using various individual scenarios from participants' life that will be presented to participants via an app on their smartphones.
224196456|NCT04217239|PROCEDURE|MIE Ivor- Lewis|minimally invasive esophagectomy (MIE) with intrathoracic anastomosis
224196457|NCT04217239|PROCEDURE|MIE McKeown|minimally invasive esophagectomy (MIE) with cervical anastomosis
224196458|NCT01484717|BEHAVIORAL|contingency management for smoking abstinence|Participants earn the chance to win prizes for breath samples that test negative for cigarette smoking.
224196459|NCT01484717|DRUG|transdermal nicotine|Participants receive an 8 week supply of transdermal nicotine \[21 mg patches (4 wks), 14 mg (2 wks), 7 mg (2 wks)\].
224196460|NCT01484717|BEHAVIORAL|Telephone counseling|Participants receive brief twice weekly telephone counseling.
224196461|NCT02491086|DRUG|Nicotine replacement therapy (NRT) sampling|1-week free NRT
224196462|NCT02491086|BEHAVIORAL|Smoking cessation counseling|Smoking cessation counseling
224196463|NCT00013910|DRUG|NNC 90-1170|
224196464|NCT00919607|DRUG|quetiapine fumarate extended-release|200mg,oral,single dose
224196465|NCT00919607|DRUG|quetiapine fumarate extended-release|300mg,oral,single dose
224196466|NCT04115800|DRUG|Liposomal Sirolimus|Subconjunctival injections of liposomal sirolimus in patients with conventional treatment with moderate and severe dry deye disease
224196467|NCT00885937|DRUG|Dexpanthenol (Sinecort, BAY81-2996)|1 squeeze of Sinecort cream sufficient to cover the area of the application chamber, (=50 mikro liter)
224196468|NCT00885937|DRUG|Positive control, Na-laurylsulfat-solution|50 mikro liter of 0.5 % Sodium-laurylsulfate-solution
224196469|NCT00885937|DEVICE|Untreated skin under application chamber|Application of treatment chamber as in arm 1 and arm 2 on untreated skin
224196470|NCT03289182|DRUG|MabThera|Participants will be administered MabThera 1400 mg (NHL) or 1600 mg (CLL) at the discretion of the physician in accordance with local clinical practice and local labeling.
224196471|NCT01646268|DRUG|Rotigotine|"Transdermal Patch~Content:~2 mg /24 h (10 cm\^2), 4 mg /24 h (20 cm\^2), 6 mg /24 h (30 cm\^2), 8 mg /24 h (40 cm\^2)~For early-stage Parkinson's disease, receive Rotigotine patches in escalating weekly dose (starting with daily doses 2 mg/24 h to 8 mg/24 h) for a maximum 4-week Titration Period, then 24 week maintenance period"
224196472|NCT01646268|DRUG|Placebo Patch|"Transdermal Patch~Size:~10 cm\^2, 20 cm\^2, 30 cm\^2, 40 cm\^2~Subjects randomized to placebo will receive matching placebo patches"
224196473|NCT00906776|DEVICE|Emdogain PLUS|Emdogain treatment followed by Straumann Bone Ceramic application during periodontal surgery
224196474|NCT00906776|DEVICE|Autogenous bone|Autogenous bone application during periodontal surgery
224196475|NCT01307189|DRUG|Tiotropium|Tiotropium diskus inhalation powder, 18ug, once daily
224196476|NCT01307189|DRUG|Placebo|Placebo diskus inhalation powder, once daily
224196477|NCT00461591|DRUG|Apaziquone|A single intravesical dose of Apaziquone 4mg in 40ml instilled into the bladder post-TURBT
224196478|NCT00461591|DRUG|Placebo|A single intravesical dose of placebo instilled into the bladder post-TURBT
224196479|NCT00461591|PROCEDURE|TURBT|TransUrethral Resection of the Bladder Tumor
224196480|NCT03361566|BEHAVIORAL|physical activity|3 different levels of physical activity
223594340|NCT03678233|DRUG|AndroGel 16.2 mg/L|Testosterone gel 1.62 % will be applied to upper arms or shoulders once a day at 9:00 am to dry and intact skin for a period of 28 days or until ICU discharge. The daily dose 101.25 mg in men and 20.25 mg in women.
223594341|NCT00351962|PROCEDURE|Fractionated Stereotactic Radiotherapy|
223594342|NCT03802903|DEVICE|Remo-Wax|topical treatment
224196481|NCT03361566|BEHAVIORAL|energy intake|4 different types of energy intake
224196482|NCT03602846|DIETARY_SUPPLEMENT|Medical Nutrition Therapy|Only given medical nutrition therapy.
224196483|NCT03602846|DRUG|Insulin|Prescribed with rapid acting, intermediate acting, mixed or long acting insulin.
224196484|NCT03602846|DRUG|Oral Antidiabetics|Prescribed with all types of oral anti-diabetics.
223594343|NCT06335355|DRUG|Adebrelimab + SHR-8068 + Pemetrexed + Carboplatin|Adebrelimab,1200mg; SHR-8068, 1.0 mg/kg; Pemetrexed, 500mg/m2; Carboplatin, AUC 5 mg/mL/min
223594344|NCT06335355|DRUG|Camrelizumab + Pemetrexed + Carboplatin|Camrelizumab,200mg;Pemetrexed, 500mg/m2; Carboplatin, AUC 5 mg/mL/min
223594345|NCT06335355|DRUG|Adebrelimab + Pemetrexed + Carboplatin|Adebrelimab,1200mg; Pemetrexed, 500mg/m2; Carboplatin, AUC 5 mg/mL/min
223594346|NCT04628949|DEVICE|aScope™ Duodeno endoscope and aBox™ Duodeno|"The aScope™ Duodeno endoscope is a sterile single-use disposable duodenoscope indicated for endoscopic retrograde cholangiopancreatography (ERCP) procedures.The aScope™ Duodeno endoscope is designed to be used with aBox Duodeno, endoscopic accessories and other ancillary equipment for ERCP procedures.~The aBox Duodeno is the console that is necessary for processing the endoscope camera´s video image, regarding the remote switches and output video and recorder data. The aBox Duodeno is designed to be used with the aScope™ Duodeno endoscope."
224196485|NCT00003104|RADIATION|radiation therapy|
224196486|NCT01133912|DRUG|paclitaxel, gemcitabine, lapatinib|Patients receive paclitaxel and gemcitabine intravenously (iv) on day 1 and 8, and oral lapatinib once daily. Lapatinib with fixed dose will be given once a day p.o. from day 1 without resting during each cycle. The starting doses of paclitaxel 80mg/m2 and gemcitabine 1000mg/m2 iv, on day 1 and 8, and lapatinib 1000mg p.o., daily (dose level 1) will be administered every 21 days.
224196487|NCT04998396|BIOLOGICAL|AAV9 BBP-812|Sterile solution for injection for 1-time use via volumetric infusion pump
224196488|NCT01528839|DRUG|L-Thyroxine|L-Thyroxine as addon to ongoing stable antidepressant and /or mood stabilizing therapy: week 1: 100 mcg; week 2: 200 mcg: week 3 to week 6: 300 mcg
224196489|NCT01528839|DRUG|Placebo|
224196490|NCT05957939|DRUG|Alkaline Glucosodiene Molecules|Toxic chemotherapeutic nutrition of cancer cells by alkaline glucosodiene molecules via targeting metabolic of cancerous tumors: a promising treatment
224196491|NCT02530086|PROCEDURE|Nasogastric tube placement|Placement of a Nasogastric tube
224196492|NCT02530086|PROCEDURE|No Nasogastric tube use|No placement of a Nasogastric tube
224196493|NCT01519635|DRUG|Aliskiren|Drug therapy will be started with an initial 2 weeks on Aliskiren 150 mg followed by a titration to 300 mg Aliskiren if the treatment is well tolerated. A first baseline measurements will be performed before initiating therapy and a second after 8 weeks of treatment (24h after last drug intake) to assess the chronic effect.
224196494|NCT01519635|DRUG|Hydrochlorothiazide|Drug therapy will be started with an initial 2 weeks HCTZ 12.5 mg followed by a titration to 25 mg HCTZ if the treatment is well tolerated. A first baseline measurements will be performed before initiating therapy and a second after 8 weeks of treatment (24h after last drug intake) to assess the chronic effect.
224196495|NCT02325414|DRUG|Zoledronic acid|Intravenous infusion of zoledronic acid 5 mg.
224196496|NCT02325414|DRUG|Placebo|Placebo (saline) infusion to match zoledronic acid
224196497|NCT01800812|BIOLOGICAL|Injections of OM-174|
224196498|NCT05765318|PROCEDURE|QLB|QLB is ultrasound-guided injection of 30 ml bupivacaine 0.25% into quadratus lumborum plane posterior to the end of internal oblique muscle.
224196499|NCT05887102|BEHAVIORAL|PACHA Program|Pharmacists in this group will complete the 85-minutes web-based training, schedule and realize at least 2 telephone consultations with participating women in their pharmacy (in the first month and 4 months after randomization) using standardized consultation guides based on the principles of motivational interviewing and, if necessary, the evidence-based web sheets about strategies to cope with side effects and other AET-related concerns. Women in this group will have access to a web site that includes video capsules to inform women about AET, evidence-based web sheets describing strategies to cope with side effects and other AET-related concerns, testimonies of women who had breast cancer and an AET and a list of resources available for women.
224196500|NCT04939337|DRUG|TH-SC01|Allogeneic Umbilical Cord-derived Mesenchymal Stem cells perilesional injection. Human TH-SC01 cell injection (human umbilical cord mesenchymal stem cells for injection, 5 million cells / ml, 6.0-10.0ml / bottle)
224196501|NCT03105076|OTHER|Decision aids|Shared decision making with decision aids
224196502|NCT00347776|DRUG|azithromycin|oral antibiotic
224196503|NCT00347776|DRUG|topical tetracycline|
224196504|NCT00594568|DRUG|LY450139|Administered orally once daily
224196505|NCT00594568|DRUG|Placebo|Administered orally once daily
224196506|NCT04328168|PROCEDURE|ROM exercises, stretching, positioning, gait training|
224196507|NCT04328168|PROCEDURE|by two physiotherapist under the supervision of a doctor|
223594347|NCT01120925|BIOLOGICAL|MNC|2-3 X 109 cells in 20ML suspension IPV in 4 min
223594348|NCT01120925|BIOLOGICAL|CD133|5-15 X 106 cells in 20ML suspension IPV
223594349|NCT01120925|BIOLOGICAL|Control|Injection of 20 ml Normal saline via IPV
223594350|NCT03135210|OTHER|Open-Chain Leg Exercise|Individuals in the open-chain group will progress through standard mobility progression.
223594351|NCT03135210|DEVICE|Closed-Chain Leg Exercise|Individuals in the closed-chain group will progress through standard mobility exercises with the addition of closed-chain leg exercises using the MOVEO platform.
223594352|NCT05764915|DRUG|RGT-264 phosphate tablets|RGT-264 phosphate tablets will be administered orally once daily (QD).
223594353|NCT00372541|DRUG|ceftriaxone|
223594354|NCT00438594|BEHAVIORAL|home visitation|Home visits from mid-pregnancy until child age 2. Group 2 is visits by a paraprofessional; group 3 is visits by nurses.
223594355|NCT06536556|OTHER|First Assessment|pre-treatment assessment
223594356|NCT06536556|OTHER|Second Assessment|4 days post-treatment assessment
224196508|NCT03448380|DEVICE|FreeStyle Libre Flash Glucose Monitoring System|Subjects will utilize capillary SMBG for managing diabetes for 6 months (control phase) followed by diabetes management using FreeStyle Libre for 6 months (intervention phase).
224196509|NCT05602480|BIOLOGICAL|13-Valent Pneumococcal Polysaccharide Conjugate Vaccine|0.5mL, Intramuscular
224196510|NCT05602480|BIOLOGICAL|13-Valent Pneumococcal Polysaccharide Conjugate Vaccine|0.5mL, Intramuscular
223594357|NCT01192828|DRUG|taurine|Take Taurine for 4 1/2 days, two doses per day
223594358|NCT02687087|DEVICE|Visco-ease|19.6 mg/mL of LMS-611
223594359|NCT02687087|DEVICE|Placebo|Physiological Saline
223594360|NCT00180011|DRUG|Omalizumab|injectable medication
223594361|NCT02103972|DIETARY_SUPPLEMENT|GM080|
223594362|NCT02103972|DIETARY_SUPPLEMENT|Maltodextrin|
223594363|NCT00855972|DRUG|Low Dose Naltrexone|
223594364|NCT01087216|DEVICE|Group Laser = Arm A|Opposite side lesions that will receive only the treatment by topical steroids and UVB phototherapy
223594365|NCT01087216|DRUG|Bras B : The group control|patient to accept habitual treatment of corticoid Opposite side lesions that will receive only the treatment by topical steroids
223594366|NCT00590577|DRUG|Paliperidone palmitate 25 mg eq.|Paliperidone palmitate 150 mg eq. i.m. Day 1 and 25 mg eq. i.m. Days 8, 36, 64
223594367|NCT00590577|DRUG|Paliperidone palmitate 150 mg eq.|Paliperidone palmitate 150 mg eq. i.m. Days 1, 8, 36, 64
223594368|NCT00590577|DRUG|Placebo|Placebo i.m. Days 1, 8, 36, 64
223594369|NCT00590577|DRUG|Paliperidone palmitate 100 mg eq.|Paliperidone palmitate 150 mg eq. i.m. Day 1 and 100 mg eq. i.m. Days 8, 36, 64
223594370|NCT00005116|BEHAVIORAL|psychotherapy|
223594371|NCT03921333|DIETARY_SUPPLEMENT|Low dose response efficacy of plant extracts|300mg
223594372|NCT03921333|DIETARY_SUPPLEMENT|Middle dose response efficacy of plant extracts|500mg
223594373|NCT03921333|DIETARY_SUPPLEMENT|High Dose response efficacy of plant extracts|700mg
223594374|NCT03921333|DIETARY_SUPPLEMENT|Placebo|Cellulose microcrystalline
223594375|NCT03327558|DRUG|Apriso 0.375G ER CAP|ER capsule
223594376|NCT03327558|DRUG|APRISO 375 mg extended-release capsules|375 mg extended-release capsules
223594377|NCT00028574|DRUG|gabapentin|
223594378|NCT00028574|OTHER|placebo|
224196511|NCT05443776|OTHER|Biomaterial implantation|Implant a approved biomaterial by European Regulatory Agencies
224196512|NCT05500729|OTHER|Hamstrings maximal voluntary isometric contraction.|Hamstrings maximal voluntary isometric contraction (MVIC) will be measured with an isometric dynamometer (3 reps x 5 sec work x 10 sec rest). The best rep will be used. Whenever the third one was the best, additional measurements will be taken until a decrease in torque will be obtained to determine the maximum.
224196513|NCT05500729|OTHER|Quadriceps maximal voluntary isometric contraction|Quadriceps maximal voluntary isometric contraction (MVIC) will be measured with an isometric dynamometer (3 reps x 5 sec work x 10 sec rest). The best rep will be used. Whenever the third one was the best, additional measurements will be taken until a decrease in torque will be obtained to determine the maximum.
224196514|NCT00002329|DRUG|Celgosivir hydrochloride|
224196515|NCT01102166|OTHER|Acapella with nebulization|"1. st Phase In this phase the jet nebulizer was connected to the branch end of the Acapella according to manufacturer's recommendations.~   The volunteer did the radio-aerosol inhalation to obtain images of the lung fields scintigraphy static during the period of 300 seconds using an array of at 256x256x16 incidence later, as that encompasses most incidence of lung volume.~2. nd Phase The experimental procedure of this phase was similar to the 1st stage, but what differed was it made an adjustment by placing a pipe T between the mouthpiece and the device Acapella so that the aerosol would be inhaled not pass through the device.~Stage 3 This stage was considered phase control since the aerosol inhalation was performed through the mouthpiece connected directly to the nebulizer as is routinely used in clinical practice as illustrated. The procedure of this phase followed the same protocol of previous phases."
223594379|NCT02722707|DEVICE|magnetic anal sphincter augmentation for fecal incontinence|Surgical placement of HUD called FENIX for female patients that have failed conservative therapy and less invasive therapies or who are not candidates for such therapies
223594380|NCT03141541|BEHAVIORAL|Group based pain management intervention|The intervention is delivered as six separate sessions of each two hours duration over a four month period. The sessions are managed by a multidisciplinary team from the Spine Center, led by a psychologist. Before the first session, each patient in the intervention group participates in an individual consultation with the psychologist or nurse, with the aim of matching expectations for the group intervention, and hereby ensure the patients compliance throughout the intervention.
223594381|NCT03902119|DEVICE|INYBI tool|Patients will lie down in supine position so that the INYBI tool will contact the suboccipital muscles at the posterior arch of the atlas. The therapist will adapt the height of the tool for each individual. All patients will use the softest head of the device. A 50Hz vibration speed will be set sup during 5 minutes.
223594382|NCT03902119|OTHER|Manual suboccipital inhibition|Patients will lie down in supine position.The therapist will be seated at the head of the treatment table. The therapist will keep the metacarpophalangeal joints in a flexed position, while therapists fingertips of both hands will contact with the suboccipital muscles at the posterior arch of the atlas.
223594383|NCT02134678|BEHAVIORAL|self-system therapy|
223594384|NCT02134678|BEHAVIORAL|cognitive therapy|
223594385|NCT01636128|DRUG|difluoromethylornithine|500 mg oral for 14 days, combined with sulindac for 15 days
223594386|NCT01636128|DRUG|Sulindac|150 mg oral for 15 days, combined with DFMO for 14 days
223594387|NCT04349033|BEHAVIORAL|Emotional Disclosure and Brain Education|Patients are interviewed about a number of aspects of their lives (stress, other illnesses, personality, adverse childhood experiences), and these are explored as part of education of the brain's role in their pain.
223594388|NCT04349033|BEHAVIORAL|Emotional Disclosure Only|Patients are interviewed about a number of aspects of their lives, but without brain education
223594389|NCT04349033|BEHAVIORAL|Pain Information Control|Patients are interviewed about their pain history and other basic, non-disclosure information about their health.
223594390|NCT02837042|DRUG|Pembrolizumab|Pembrolizumab will be administered intravenously every 3 weeks.
223594391|NCT05835583|BEHAVIORAL|The theory based integrated program|The theory-based integrated program is administered by a nurse trained in motivational interviewing.In the 12-hour intervention, this program uses motivational interviewing skills to increase the patient's attitude towards medication, enhance the support of significant others around them, and increase the patient's control over their own behavior.
223594392|NCT00418574|BIOLOGICAL|Abagovomab|2 mg/ml SC (subcutaneously)
223594393|NCT00418574|BIOLOGICAL|Placebo|2 mg/ml SC (subcutaneously)
223594394|NCT01506284|PROCEDURE|Forced oscillatory technique (FOT) and laser interferometry (LIR).|"FOT: The stimulating signal is generated by an A/D-D/A board and amplified by a power amplifier that drives a loudspeaker the output of which is connected to inspiratory line of the ventilator. Pressure and flow are measured at the inlet of the endotracheal tube by a piezoresistive pressure transducer and a mesh-type heated pneumotachograph coupled with a differential pressure transducer.~LIR: The scanner unit is made by three laser interferometers, the beams of which are deflected on the chest wall surface by a mirror moved by a stepper motor triggered on the respiratory pattern of patient."
223594395|NCT05899296|DEVICE|dental syringe ( NumBee)|assess the capability of NumBee to reduce anxiety and pain during injection
223594396|NCT05899296|DEVICE|Traditional dental syringe|compare the level of anxiety of the traditional dental syringe and the Number dental syringe
223594397|NCT00306709|BEHAVIORAL|culturally adapted behavior change|Behavior change strategies which have been modified to include spirituality, AA cultural materials and examples woven into the lesson plans, and sustained peer support.
223594398|NCT02136056|BEHAVIORAL|Self-management program (SMP)|A self-management course
223594399|NCT04058886|BEHAVIORAL|Telephone-delivered Mindfulness|The telephone-delivered mindfulness training intervention that will incorporate the following elements: 1) training for primary caregivers (CG) and their caregiving partner (CP) in a telephone-based mindfulness training intervention; 2) groups of up to eight participants (four CG-CP pairs) plus an instructor, on a shared telephone line; and 3) training in a 8-week, modified MBSR program, which places additional emphasis on training in the following: a) mindful experiencing, including mindfulness of feelings and body sensations; b) mindful communication, including non-verbal mindfulness, mindful listening, and mindful speaking; and c) mindful compassion for self and others. Additionally, homework assignments will involve listening to exercises on a dial-in telephone line; and assignments for CG-CP dyads (e.g. mindful listening and communication practices) as well as CG mindfulness practices in the presence of care recipients (e.g. mindful eating, and mindful listening).
223594400|NCT03184285|PROCEDURE|baseline alert 1|measurement in supine position
223594401|NCT03184285|PROCEDURE|Anti-Trendelenburg-position (ATB)|measurement under ATB
223594402|NCT03184285|PROCEDURE|ATB in narcosis|measurement under ATB in narcosis
223594403|NCT03184285|PROCEDURE|baseline in narcosis 1|measurement in supine position in narcosis
223594404|NCT03184285|PROCEDURE|passive leg raising|measurement under passive leg raising
223594405|NCT03184285|PROCEDURE|volume bolus substitution|measurement in supine position after volume bolus (15 ml/kgKG Sterofundin balanced solution intravenous)
223594406|NCT03184285|PROCEDURE|baseline in narcosis 2|measurement in supine position
223594407|NCT03184285|PROCEDURE|start capnoperitoneum|measurement in supine position
223594408|NCT03184285|PROCEDURE|ATB plus capnoperitoneum|measurement under ATB plus capnoperitoneum
223594409|NCT03184285|PROCEDURE|ATB plus capnoperitoneum plus volume bolus substitution|measurement in ATB plus capnoperitoneum after volume bolus (15 ml/kgKG Sterofundin balanced solution intravenous)
223594410|NCT03184285|PROCEDURE|ATB loss of capnoperitoneum|measurement under ATB
223594411|NCT03184285|PROCEDURE|baseline|measurement in supine position
223594412|NCT03184285|PROCEDURE|baseline alert 2|measurement in supine position
223505536|NCT03834298|OTHER|Four Food Elimination Diet|Food allergens are thought to initiate eosinophilic inflammation and dietary elimination of trigger allergens is an effective treatment for EoE. Previous work demonstrates that in both children and adult EoE patients, the food antigens including cow's milk, wheat, egg, soy, peanut/tree nut and fish/shell fish, are the most common food triggers causing esophageal inflammation. Participants will be assigned to single arm treatment / intervention with a diet restricted of the four most common food allergens, milk, soy, wheat and egg, or a four food elimination diet (FFED). With the goal to optimize diet treatment, in Aim 2, eligible participants will undergo sequential food reintroductions based on protocol.
223505537|NCT03764553|DRUG|Liposomal Irinotecan|Iv liposomal irinotecan
223505538|NCT03764553|DRUG|Carboplatin|IV Carboplatin
223505539|NCT03764553|DRUG|Capecitabine|PO Capecitabine
223505540|NCT03764553|DRUG|Oxaliplatin|IV Oxaliplatin
223505541|NCT03764553|DRUG|5-fluorouracil|IV 5-fluorouracil
223505542|NCT03764553|DRUG|Leucovorin|IV Leucovorin
223505543|NCT06025695|COMBINATION_PRODUCT|GSK's liquid oral live attenuated HRV|2 doses of GSK's liquid oral live attenuated HRV study intervention administered orally at Day 1 and Month 1, according to the immunization schedule for HRV study intervention licensed outside of China.
223505544|NCT06025695|COMBINATION_PRODUCT|PCV-free liquid formulation of GSK's oral live attenuated HRV|2 doses of PCV-free liquid formulation of GSK's oral live attenuated HRV study intervention administered orally at Day 1 and Month 1, according to the immunization schedule for HRV study intervention licensed outside of China.
223505545|NCT06518993|DEVICE|Total hip arthroplasty with a Trinity cup and a Meije Duo cementless stem|Subjects clinically suitable for a primary THR surgery with Trinity cup and Meije Duo cementless femoral stem.
223505546|NCT03834883|DRUG|Progesterone|Subjects will receive oral progesterone 400 mg (two x 200 mg capsules) once daily every evening for 7 days
223505547|NCT03834883|DRUG|Ibutilide|Ibutilide 0.003 mg/kg administered to all subjects to moderately lengthen the QT interval
224075084|NCT07071350|OTHER|Pain Interference/TBI-QoL Pain Interference Short-Form|"Evaluated using the TBI-QoL Pain Interference Short-Form, a 10-item questionnaire that measures the extent to which pain interferes with daily activities and overall quality of life. Each BPI-I item is scored from 0=Does not interfere to 10=Completely interferes, and the scale score is the mean of the 7 items. Scores range from 0 to 10 with higher scores indicating greater pain interference."
223505549|NCT06524531|PROCEDURE|Pulsed RF Neuromodulation|RF neuromodulation will be applied to the L2 and L3 segments bilaterally. Each segment will receive treatment for 6 minutes, either sequentially or simultaneously on both sides.
223505550|NCT06524531|BIOLOGICAL|Leukocyte-Rich PRP Injection|Leukocyte-rich PRP will be prepared from the patient's blood and injected into the multifidus muscle at the L2 and L3 levels.
223505551|NCT06524531|PROCEDURE|Physiotherapy Alone|Standard physiotherapy regimen tailored to each participant's needs. This may include exercises to improve flexibility, strength, and endurance of the back muscles, as well as education on posture and body mechanics.
223505552|NCT05147571|DEVICE|Responsive stimulation|The RNS System provides closed loop responsive brain stimulation. The Neurostimulator monitors the electrical activity of the brain to detect abnormal activity that could lead to a seizure. If abnormal activity is detected, the neurostimulator delivers electrical stimulation to the brain through the leads to help prevent the seizure before it occurs.
223505553|NCT05147571|DEVICE|Sham stimulation|For those in the Sham Stimulation group, the RNS System will be set to detect abnormal activity but will not have responsive stimulation enabled. Both Sham and Active groups will undergo therapy testing at each appointment in order to maintain the blind.
223505554|NCT07030270|PROCEDURE|Surfactant Administration through Laryngeal or Supraglottic Airway|"Surfactant Administration through Supraglottic Airway Devices~* Air-Q3 size 0 for neonates: \< 2 kilograms~* i-gel supraglottic airway size 1 for neonates: ≥ 2 kilograms"
223505555|NCT07030270|PROCEDURE|Surfactant Administration through Thin Catheter|Thin Catheter
223505556|NCT05898633|DRUG|Recombinant fragment of human surfactant protein D (rfhSP-D)|Administration of rfhSP-D
223505557|NCT07032480|BEHAVIORAL|Survey-Based Assessment|Participants completed standardized questionnaires including the Beck Depression Inventory (BDI), Pittsburgh Sleep Quality Index (PSQI), and Neck Disability Index (NDI) to evaluate psychological and functional outcomes associated with sleep quality. No experimental intervention was administered.
223505558|NCT07039565|OTHER|Stretching and strengthening exercises|Strengthening exercises were progressively performed for three sets, with 10 to 15 repetitions. The stretching part of the exercises was done with the purpose of increasing the flexibility of the pectoralis and the cervical neck extensors muscles (pectoralis stretch, chin tuck). Exercises have been approved to be effective on the lengthening of the pectoralis minor, activation of the lower trapezius/middle trapezius, serratus anterior, and improvement of the posture
223505559|NCT07039565|OTHER|Diaphragm release technique|the patient will positioned in the supine position. The therapist stand at the head of the patient. The therapist make manual contact bilaterally under the costal cartilages of the lower ribs (7th to 10th ) with hypothenar regions of the hands and last three fingers. During the patient's inspiration, the therapist is gently pulling the points of hands contacts toward the head and slightly laterally, while elevating the ribs simultaneously
224075085|NCT07071350|BEHAVIORAL|Patient Health Questionnaire-9 (PHQ-9)|Assesses the severity of depressive symptoms over the past two weeks. Scores less than 5 almost always signified the absence of a depressive disorder; scores of 5 to 9 predominantly represented patients with either no depression or subthreshold (i.e., other) depression; scores of 10 to 14 represented a spectrum of patients; and scores of 15 or greater usually indicated major depression.
224075086|NCT07071350|BEHAVIORAL|PTSD Checklist for DSM-5 (PCL-5)|The PCL-5 (PTSD Checklist for DSM-5) is a screening tool that assesses the presence and severity of PTSD symptoms according to DSM-5 criteria. It's not a diagnostic tool itself but helps clinicians determine if further evaluation is needed. Scores range from 0 to 80, with higher scores indicating more severe symptoms.
223505560|NCT07046065|DEVICE|Non-cycloplegic Objective refraction|Objective refraction will be measured using an auto-kerato-refractometer/aberrometer without cyclopegia
223505561|NCT07046065|DEVICE|Non-cycloplegic conventional subjective refraction|Performed with Vision-R™
223505562|NCT07046065|DEVICE|Non-cycloplegic subjective refraction (Kids refraction software vA with Vision-R™)|Performed with Vision-R™
223505563|NCT07046065|DEVICE|Non-cycloplegic subjective refraction (Kids refraction software vA with Vision-S™)|Performed with Vision-S™
223505564|NCT07046065|DEVICE|Non-cycloplegic subjective refraction (Kids refraction software vB with Vision-R™)|Performed with Vision-R™
223505565|NCT07046065|DEVICE|Non-cycloplegic subjective refraction (Kids refraction software vB with Vision-S™)|Performed with Vision-S™
223505566|NCT07046065|DEVICE|Cycloplegic subjective refraction (Kids refraction software vA with Vision-R™)|Performed with Vision-R™
223505567|NCT07046065|DEVICE|Cycloplegic subjective refraction (Kids refraction software vA with Vision-S™)|Performed with Vision-S™
223505568|NCT07046065|DEVICE|Cycloplegic Objective refraction|Objective refraction will be measured using an auto-kerato-refractometer/aberrometer with cyclopegia
223505569|NCT07046065|DEVICE|Non-cycloplegic Retinoscopy|Performed with a retinoscope without cycloplegia
223505570|NCT07046065|DEVICE|Cycloplegic retinoscopy|Performed with a retinoscope with cycloplegia
223505571|NCT07046299|PROCEDURE|Endovascular Therapy Plus Best Medical Treatment|Participants assigned to the endovascular therapy arm will receive EVT in addition to best medical treatment. EVT must be initiated within 24 hours of symptom onset and completed within 3 hours of groin puncture. After evaluating vascular anatomy, neurointerventionalists will determine the most appropriate strategy based on the presence of proximal stenosis, occlusion morphology, and vessel tortuosity. Permitted interventions include mechanical thrombectomy, stent thrombectomy, aspiration thrombectomy, intra-arterial thrombolysis, balloon angioplasty, and stent implantation. The choice of treatment approach is left to the discretion of the treating physician, and combinations of techniques are allowed.
223505572|NCT07046299|DRUG|Best Medical Treatment Alone|Participants in this arm will receive best medical treatment and maximal supportive care according to current stroke guidelines, without the use of mechanical thrombectomy or any intra-arterial intervention.
223505573|NCT07046754|OTHER|type of consultation|urgence care, permance care
223505574|NCT07044739|BEHAVIORAL|Patient Education on the Use of Anti-Embolic Stockings|"The researcher will provide verbal information to the patients with the educational material titled Use of Anti-Embolic Stockings, the stages of wearing anti-embolic stockings will be shown to the patients, and the educational material will be left next to the patients in the intervention group. The educational content covers the purpose of using anti-embolic stockings, how to use them, and the points to be considered during use."
223505575|NCT07045662|BEHAVIORAL|Multidisciplinary Assessment|"The participants in the multidisciplinary assessment were followed by multidisciplinary teams from the study target-units, by individual and collective interviews, which mirror the care protocol. The frequency of individual visits was at least every six months by a nurse, a physician, and a nutritionist.~Regarding the collective activities, the educational groups met for approximately 1 hour and 30 minutes on monthly basis over a period of six months. Considering that there were two FHU in the IG, each team held one activity per month.~For the development of the collective activities, methods recognized for intensifying integration and participation, such as using simple language and confirming the participants' understanding of the information covered in the group were recommended."
223505576|NCT07040943|BIOLOGICAL|IL-22BP|During the injection of IL-22BP, there were three dose groups, namely 50 μg, 100 μg, and 150 μg of mRNA, with three participants in each dose group, aiming to evaluate the safety and tolerability of the IL-22BP. The treatment will be administered by intratumoral injection. Enrolled subjects will receive inoculations of IL22BP injection according to their respective dose groups, which include 5 doses for basic immunization and subsequent personalized treatment. During the basic immunization, the first 4 doses will be given at an interval of 1 week each, and the 5th dose will be inoculated 1 month after the 4th dose.
223505577|NCT07046390|DRUG|nerve block with bupivacaine 0.25%|0.25% bupivacaine
223505578|NCT07046390|DRUG|No intervention|No intervention
223505579|NCT07045844|DIETARY_SUPPLEMENT|Pasteurized Donor Milk for Insufficient Breastfeeding|"Participants receive pasteurized donor human milk (pHDM) as supplemental feeding when the clinician determines maternal milk supply is insufficient.~Randomization 1 will occur when the clinician determines that supplemental feeding is required due to insufficient breast milk supply."
223505580|NCT07045844|DIETARY_SUPPLEMENT|Preterm Formula for Insufficient Breastfeeding|"Participants receive preterm formula (PTF) as supplemental feeding when the clinician determines maternal milk supply is insufficient.~Randomization 1 will occur when the clinician determines that supplemental feeding is required due to insufficient breast milk supply."
223594413|NCT03184285|PROCEDURE|torso position rising 30° at the beginning|measurement in the recovery unit
223594414|NCT03184285|PROCEDURE|torso position rising 30° at the end|measurement in the recovery unit
223594415|NCT02332291|DRUG|Escitalopram|Escitalopram 10-20mg daily
223594416|NCT02332291|DRUG|Bupropion XL|Bupropion XL 150-450mg daily
223594417|NCT03328351|OTHER|manual therapy|"1. Manual therapy: One of the following techniques was used for the treatment group based on the patients' response (i.e centralization and reduction of symptoms).~   1. Cervical postero-anterior vertebral mobilization glides:~      a central posteranterior (PA) or unilateral PA oscillatory pressure of grade III on the patient's most symptomatic level for 2 minute and 3 sets .~  2. Cervical lateral vertebral glides :at grade III for 1 minute and 3 sets.~2. Strengthening Exercises:~for deep neck flexor muscles for 10 seconds and repeating it for 10 times."
223594418|NCT03328351|OTHER|Superficial soft tissue massage|"1\. Superficial soft tissue massage: The researcher applied a superficial effleurage massage without moving the deeper tissue for 2 minutes for 3 sets~Strengthening Exercises:~for deep neck flexor muscles for 10 seconds and repeating it for 10 times"
223594419|NCT05036967|DRUG|HF medication|Treatment initiation patterns of patients with Heart Failure (HF) in an outpatient setting from Colombia.
224196516|NCT02046720|DRUG|Propofol induced sedation|"Propofol was administered using a commercially available target-controlled infusion with an incorporated pharmacokinetic model developed by Schnider (Base Primea , Fresenius-Kabi, Brezins, FRANCE)12. The initial effect-site target concentration of propofol (0.5 μg/ml) was incremented by 0.5 μg/ml every 5 minutes to ensure equilibration between plasma concentration and effect site, until loss of eyelash reflex. From the beginning of infusion until LOER patients received no other agent besides propofol for the duration of the trial.~The BIS index was compared between a young population (18 to 64 years old) and an elderly population (65 and more)"
224196517|NCT06561620|DRUG|Befotertinib|Befotertinib is a novel, selective oral third-generation epidermal growth factor receptor tyrosine-kinase inhibitor.
224196518|NCT06501131|OTHER|full-spectrum light exposure|Subjects will stay in a room with full spectrum light for 5 minutes. After 5 minutes wash-out period, altenate to the other arm.
224196519|NCT06501131|OTHER|specific spectrum absence light exposure|Subjects will stay in a room with ordinary LED light for 5 minutes. After 5 minutes wash-out period, altenate to the other arm.
224196520|NCT04220073|BIOLOGICAL|JS005 (recombinant humanized monoclonal antibody against IL-17A)|JS005
224196521|NCT04220073|DRUG|placebo|placebo
224196522|NCT02364882|DRUG|Sildenafil|
224196523|NCT02198820|DRUG|General Anesthesia|General anesthesia with proposal, rocuronium and sufentanil
224196524|NCT02198820|DRUG|Loco Regional Anesthesia|Loco Regional Anesthesia with marcaine
223505581|NCT07045844|DIETARY_SUPPLEMENT|Routine fortification|Randomization 2 will be conducted when the total daily intake of human milk (including own mother's milk \[OMM\] and/or donor pasteurized human milk \[pHDM\] ) reaches between 60-120 mL/kg
223505582|NCT07045844|DIETARY_SUPPLEMENT|Rescue fortification|Randomization 2 will be conducted: Add fortifiers when the body weight is below the 10% growth curve.
223505583|NCT07045753|DEVICE|Transcatheter edge to edge repair|mitral valve transcatheter edge-to-edge repair
223505584|NCT07046377|PROCEDURE|ACB - IPACK|will receive spinal anesthesia and ultrasound-guided Adductor canal nerve block, as well as infiltration of the space between the popliteal artery and the capsule of the posterior knee (IPACK) block.
223505585|NCT07046377|PROCEDURE|GNB - IPACK|will recieve spinal anesthesia and US guided Genicular nerves block and IPACK block.
223505586|NCT07046000|DIAGNOSTIC_TEST|MRI|MRI to assess graft maturation
223505587|NCT07046169|OTHER|Ultrasound-Guided Volume Assessment and Decongestion Strategy (UVADS)|Unique Combination: Simultaneously tracks IVC collapsibility index (\>50%) + pulmonary B-line counts (≤5) to guide therapy, unlike studies using either metric alone.Thresholds Tested: Compares ESC consensus thresholds (IVC \<2.1cm) vs. exploratory Asian-optimized thresholds (IVC \<1.8cm) in Subgroup B.
223505588|NCT07046169|OTHER|clinical assessment|Discharge based on symptoms/signs alone: Clinical congestion score ≤2 + NYHA class ≤II
223505589|NCT07046026|BEHAVIORAL|Standard work pace|On two consecutive days, participants will work at a standard pace of one box per minute during the box carrying protocol
223505590|NCT07046026|BEHAVIORAL|Additional rest breaks|On two consecutive days, participants will work at the standard work pace during the box carrying protocol and have superimposed 5 minutes of rest every 30 minutes.
223505591|NCT07045207|OTHER|LLM-MDT|Leveraging large language models (LLMs) to Generate Multidisciplinary Team (MDT) Treatment Recommendations
223505592|NCT07057310|DRUG|semaglutide or tirzepatide|Semaglutide and tirzepatide will be dosed as per prescription labels
223505593|NCT07057310|BEHAVIORAL|Lifestyle modification intervention|All participants will be recommended the following: 1) low-calorie diet based on their predicted by Harris Benedict resting energy expenditure minus 500 kcal per day; 2) physical activity: a goal of 10,000 steps or more per day; 3) exercise: a goal of 150 minutes or more of moderate-intensity aerobic activity (cardiovascular exercise) per week; 4) limited consumption of liquid calories (i.e. sodas, juices, alcohol, etc.).
223505594|NCT07056465|BEHAVIORAL|Intermittent Carbohydrate Restriction (ICR) Protocol|A novel intermittent carbohydrate restriction (ICR) protocol involving two consecutive low-carbohydrate days (approximately 10% total energy from carbohydrate) followed by five non-restricted days per week, sustained over a 4-week period. Participants receive individualised dietary guidance and support materials to promote adherence in free-living conditions
223505595|NCT07055698|DIAGNOSTIC_TEST|The Navicular Height Drop (NHD) test|Evaluating the test's responsiveness and minimal clinically important difference (MCID) can help determine its clinical relevance in monitoring treatment outcomes.
223505596|NCT07056452|PROCEDURE|hydrodissection technique|injecting a solution of physiological saline containing 0.5% lidocaine along the cutting line
223505597|NCT06878092|BEHAVIORAL|Problem Management Plus (PM+)|Problem Management Plus is a brief, potentially scalable psychological intervention developed by the World Health Organization and is delivered by non-specialised helpers. In brief, the intervention is based on cognitive behavioural therapy (CBT) techniques and typically consists of five weekly, ninety-minute sessions. Participants are taught the following techniques during the sessions: stress management, problem-solving, behavioural activation, and accessing social support. The effectiveness of both the individual and group formats of the PM+ intervention have been shown in a number of large definitive RCTs. For the purposes of this study, an adapted version of PM+ will be used to match the exposure between the two active intervention arms. There will be six, weekly seventy-five-minute sessions
224196525|NCT01902992|DRUG|Depiquick Birch (DPG103)|
224196526|NCT01902992|DRUG|Placebo|
224196527|NCT00299546|DRUG|Placebo|SC injections
224196528|NCT00299546|BIOLOGICAL|Golimumab 50 mg|SC injections
224196529|NCT00299546|BIOLOGICAL|Golimumab 100 mg|SC injections
224196530|NCT02384980|DEVICE|FES (Gait MyoElectric Stimulator)|Functional Electrical Stimulation (FES) will be tested in a group of peripheral arterial disease patients using the Gait MyoElectric Stimulator. The FES device will be applied to the calf and shin muscles on both of the patients legs.
224196531|NCT03099265|DRUG|neoadjuvant mFOLFIRINOX|Patients will receive 8 cycles of mFOLFIRINOX every 2 weeks. mFOLFIRINOX will be dosed as follows: Oxaliplatin 85 mg/m2, followed by folinic acid 400 mg/m2 infused over 120 minutes and irinotecan 135 mg/m2 infused over 90 minutes, followed by 5-fluorouracil 300 mg/m2 IV bolus, followed by 2,400 mg/m2 continuous infusion for 46 hours. Levoleucovorin may be substituted for folinic acid at a dose of 200 mg/m2 infused over 120 minutes.
223747208|NCT03115983|DEVICE|Fusion Instrumentation|Titanium alloy top-loading, polyaxial pedicle screws and cylindrical, titanium alloy rod instrumentation using autograft and/or allograft bone (i.e., cancellous and/or corticocancellous bone only), and/or a synthetic bone graft extender that is on-label for these indications (i.e., decorticated posterolateral gutter only). The TLIF requires a single PEEK or Titanium TLIF cage cleared by FDA for this indication filled with autograft and/or allograft bone (i.e., cancellous and/or corticocancellous bone only).
223747209|NCT03115983|PROCEDURE|Decompression|Surgical decompression at one or two contiguous levels from L1 to S1.
224196532|NCT03099265|DRUG|Stereotactic body radiotherapy (SBRT)|Stereotactic body radiotherapy (SBRT) will be delivered to the primary tumor and any adjacent involved nodes to 33 Gy in 5 fractions over the course of 2 weeks, and within 4 weeks of chemotherapy.
224196533|NCT05214339|DRUG|Hepatic Arterial Infusion(mFOLFOX7) combined with Bevacizumab and Sintilimab|The patient will receive Hepatic Arterial Infusion(mFOLFOX7) on the first day, and intravenous infusion of Bevacizumab on the 4th day, and intravenous infusion of Sintilimab on the 25th day. The intervention is repeated every 3 weeks.
223594420|NCT04118595|BEHAVIORAL|Educational Video|Educational Video: Development of the original video was funded by the John A. Hartford Foundation and used a systematic approach that included a review of literature and current pain management guidelines and input from emergency physicians, geriatricians, and experts in pharmacology, physical therapy, and risk communication. The video offers information about the pharmacologic management of acute musculoskeletal pain (MSP) and recovery-promoting behaviors. Each video section is followed by a multiple-choice question to promote interaction and reinforce learning. The actress for the 13-minute video is a 56-year-old mixed-race woman who presents herself as a healthcare provider. The video script was developed for a grade level 5.5 and will be shown to the patient within 24 hours of the acute care visit. A link to the video is emailed or texted to the patient.
223594421|NCT04118595|BEHAVIORAL|Telecare|Telecare will be provided via a protocol-guided phone call from a nurse care manager 48-72 hours after discharge from the ED or orthopedic urgent care. The call is designed to support patient decision-making regarding analgesics and behaviors following the content presented in the video. Topics covered in the call will include discussion of goals and priorities the patient has for their pain management, current prescriptions and analgesic use (and adjustments if needed), non-pharmacologic methods of pain management, warnings about potential side effects, current healthcare utilization, and open-ended questions to address additional patient care needs. Conversations will be guided by a shared decision making framework in which the nurse suggests pain management options, discusses their pros and cons, and actively elicits feedback from the patient. The telecare call is designed to last 15 minutes.
223594422|NCT04118595|BEHAVIORAL|Correspondence with Primary Care Provider|Following the telecare conversation, a note will be sent directly to the patient's primary care provider using a secure email or an electronic message that includes: 1) The date, time, location and reason for the index visit; (2) Results of diagnostics studies; (3) Discharge prescriptions/ recommendations; (4) A summary of and link to the video, explaining the emphasis on patient knowledge and SDM; (5) A summary of the telecare conversation; and (6) Encouragement for follow-up. PCPs will be asked to confirm receipt of this message.
223594423|NCT00218972|BEHAVIORAL|Aerobic interval training|
223594424|NCT00218972|BEHAVIORAL|moderate intensity training|
223594425|NCT00218972|BEHAVIORAL|Recommendation of regular exercise|
223747210|NCT03115983|PROCEDURE|Fusion|Transforaminal lumbar interbody fusion (TLIF) with concomitant posterolateral fusion (PLF) at a single level after surgical decompression.
223747211|NCT04938765|DRUG|Magnesium sulfate|Effect of 40mg/kg Magnesium sulfate bolus dosed to ideal body weight on intraoperative neuromonitoring
223747212|NCT04938765|DRUG|Normal Saline|20 ml of normal saline bolus will be administered to the control group over 10 mins.
223594426|NCT02220712|DRUG|OPC-14597 IMD|Administration by injection into the deltoid muscle for a total of 5 doses of 400 mg in 4-week intervals
223594427|NCT00760838|DRUG|Azithromycin 250 mg|Azithromycin 250 mg three times a week during treatment period (6 months); run-in period of 2 weeks; wash-out period of 4 weeks
223594428|NCT00760838|DRUG|Placebo|Placebo three times a week during treatment period (6 months); run-in period of 2 weeks; wash-out period of 4 weeks
223594429|NCT06350305|OTHER|questionnaire survey|subjects fill out questionnaires
223594430|NCT03534622|DRUG|Delafloxacin|In this study, thirty subjects who meet the entry criteria will be assigned to 1 of 5 groups (A, B,C, D, or E) to receive 300 mg delafloxacin IV every 12 hours for a total of 7 doses over 4 days
223747213|NCT06394531|DIETARY_SUPPLEMENT|Jaboticaba Peel Extract|Jaboticaba peel extract. Patients will ingest 4 capsules/day of jaboticaba (Plinia Cauliflora) peel extract, providing 3.3g of jabuticaba peel extract daily, containing 600mg of phenolic compounds, for one month.
223747214|NCT06394531|OTHER|Placebo|Placebo. Patients will ingest 4 capsules/day of placebo (corn starch), providing 3.3g of placebo, for one month.
223747215|NCT05722873|BEHAVIORAL|Fasting arm|Study participants will fast one day per week for 12 weeks
223747216|NCT05722873|BEHAVIORAL|Weight maintenance|Study participants will be counseled to maintain body weight
223747217|NCT05722873|BEHAVIORAL|Counseling|Study participants will be counseled on optimal diet and activity recommendations for maintaining/achieving a normal BMI
223747218|NCT06500052|DRUG|BL-M17D1|Administration by intravenous infusion for a cycle of 3 weeks.
224196534|NCT01605539|DRUG|Cannabidiol 400|Subjects in Arm CBD 400 will receive 400mg of Cannabidiol in each of the three test sessions
224196535|NCT01605539|DRUG|Cannabidiol 800|Subjects in Arm CBD 800 will receive 800mg of Cannabidiol in each of the three test sessions
224196536|NCT01605539|DRUG|Control|Subjects will receive a harmless, inactive pill to compare and validate the results of the other arms of the study
224196537|NCT04358822|PROCEDURE|Delayed cord clamping|The umbilical cord will be clamped after specific time intervals
223747219|NCT06401330|PROCEDURE|Bone Scan|Undergo bone scan for patients with metastatic sites outside the chest/abdomen/pelvis documented during therapy
223747220|NCT06401330|DRUG|Carboplatin|Given IV
223747221|NCT06401330|PROCEDURE|Computed Tomography|Undergo CT
224196538|NCT04649931|DEVICE|Ion Mobility Spectrometry (IMS)|Two breathing gas samples will be taken from each study participant using ion mobility spectrometry with an ultrasound-based spirometer. The total sampling time is 1 minute (at least 5-7 breath takes) following an analysis time of 5-12 minutes.
223594431|NCT05908201|BEHAVIORAL|early time restricted eating|The intervention group will eat in a prescribed daily feeding window (9am-5pm) and follow their normal exercise and resistance training routines. We will allow up till +/-1 hour for the eating window start and end times while aiming for an 8 hour eating window.
224196539|NCT05137431|OTHER|HFNO and NIV|"Patients meeting the inclusion criteria will be treated alternately with 2 hours of HFNO and 1 hour of NIV (HFNO-NIV for the same patient in turn). In 24 hours, there will be 16 hours of HFNO, 8 hours of NIV.~Parameters to record~* Respiratory parameters (respiratory rate)~* SpO2~* Ventilator settings~* Patient's tolerance (VAS; between 0-100)~* Arterial blood gas (HFNO and NIV at 1 hour)~* Clinical parameters (D dimer, CRP, ROX index)~Intubation criteria~* Loss of consciousness~* Agitation~* Persistent hypotension~* Need for fluid resuscitation~* Need for vasopressor~* Respiration rate ≥40/min~* SpO2 \<92~* pH\<7.30"
224196540|NCT01079169|DIETARY_SUPPLEMENT|Cranberry capsules|Cranberry capsules, 550mg, or placebo capsules, two capsules three times daily during in-patient rehabilitation
223594432|NCT03624127|DRUG|BMS-986165|Specified dose on specified days
223594433|NCT03624127|OTHER|Placebo|Specified dose on specified days
223594434|NCT03624127|DRUG|Apremilast|Specified dose on specified days
223594435|NCT00153192|DRUG|Marinol (dronabinol)|
223594436|NCT03954262|BEHAVIORAL|observation of propofol ANS response|received an induction bolus or TCI infusion of propofol
223594437|NCT05338879|OTHER|Non-Interventional|No study treatment will be administered on this study.
223594438|NCT02607228|DRUG|Alobresib|Tablet administered orally once daily.
223594439|NCT02607228|DRUG|Enzalutamide|Capsules administered orally once daily.
223594440|NCT03687606|DRUG|Human Chorionic Gonadotropin|White freeze-dried cake or powder with specifications of 1000U, 2000U, 5000U.
223594441|NCT03687606|DRUG|human menopausal gonadotropin|White freeze-dried cake or powder with specification of 75IU.
223594442|NCT05061498|DIAGNOSTIC_TEST|Additional Pacing maneuvers|In order to determine the optimal setting for pacemapping in all participants additional pacing maneuvers (output and cycle length) are performed
223594443|NCT03006224|OTHER|One Lung Ventilation|
223594444|NCT05583760|PROCEDURE|Experimental: Osteopathic manipulation TUG for scaphoid bone|The sequence of execution of the scaphoid TUG technique shall be applied as follows. Patient in the supine position. The inner hand of the intervener makes contact with the pisiform through the hypothenar eminence and ulnar border of the hand over the scaphoid tubercle, the outer hand reinforces the contact. The thumbs are directed to the sole of the patient's foot. The parameters are sought by bringing the sole of the foot into eversion, thus bringing the scaphoid into internal rotation (the direction of correction). In order to reduce the slack, the operator drops his body weight backwards while increasing the internal rotation parameter of the scaphoid. The manipulation is performed by associating a rapid traction movement with an increase of the correction parameter towards the internal rotation of the scaphoid.
223594445|NCT05583760|PROCEDURE|Sham group: Sham osteopathic manipulation TUG for scaphoid bone|The intervention will be performed in the same way as the intervention group, without actually performing the TUG manipulation on the scaphoid bone, only placing it in tension.
223747222|NCT06401330|DRUG|Cyclophosphamide|Given IV
223747223|NCT06401330|BIOLOGICAL|Dactinomycin|Given IV
223747224|NCT06401330|DRUG|Doxorubicin|Given IV
224196541|NCT06380101|OTHER|NEAAR Medical Food|Standardized non-essential amino acid restricted medical food.
224196542|NCT01079572|OTHER|in-person|Follow-up appointments will be completed in-person as per usual
223594446|NCT00002122|DRUG|Azithromycin|
223594447|NCT00002122|DRUG|Rifabutin|
223594448|NCT00002122|DRUG|Fluconazole|
223594449|NCT05068219|PROCEDURE|Usual physical therapy|"Standard rehabilitation for diaphragmatic paresis~* EFA (Expiratory Flow Acceleration) at the upper thoracic level.~* PEP (Positive Expiratory Pressure).~* Expectoration if necessary (coughing up and spitting out)"
223594450|NCT05068219|PROCEDURE|Contract-Relax technique|"The diaphragmatic CR is done in a semi-sitting position.~The CR is composed of 4 steps :~* First maximum inspiration expiration with position of the hands of the physiotherapist on the last ribs and without resistance (Goal: taking rhythm).~* Second maximum inspiration expiration : Free inspiration, expiration with pressure on the last ribs to bring the diaphragm into internal stroke.~* Maximum inspiration against resistance, then maximum expiration with increased pressure.~* Maximum inspiration with dynamic release of resistance (Goal: hyperextension of the diaphragm) followed by maximum expiration with resistance to allow an increase in expiratory flow."
224196543|NCT01079572|OTHER|web-based|Patients who are at least 2 years following knee or hip replacement will complete a questionnaire online and routine x-rays at a PACS enabled imaging center. The patient's surgeon will receive an email from the database summarizing the patient's responses to key questions and will review the x-rays. The surgeon will determine whether the patient needs to be seen in-person.
223594451|NCT04397419|DIETARY_SUPPLEMENT|Red Bull Energy Drink|"The intervention group receives 250 ml Red Bull Energy Drink 2-3 hours after surgery and 500 ml on postoperative day 1.~Regimen:~* 2-3 hours after surgery: 250 ml~* Postoperative day 1: morning and noon (1-1-0-0) 250 ml"
223594452|NCT04397419|OTHER|Still water|"The control group receives 250 ml still water 2-3 hours after surgery and 500 ml on postoperative day 1.~Regimen:~* 2-3 hours after surgery: 250 ml~* Postoperative day 1: morning and noon (1-1-0-0) 250 ml"
223594453|NCT04480216|DEVICE|MAGUS|"An upper endoscopy will be performed with the use of fluoroscopy. The MAGUS will be placed under fluoroscopy. The good positioning and the absence of any complications will be confirmed by gastroscopy.~An injection of contrast agent will be done to be sure of the correct positioning and that no complications was happened.~The patient will be kept overnight, with liquid food for 2 and mashed food up to 7 days post procedure"
223594454|NCT06003088|DRUG|HSK7653(5mg)|Participants will receive a single oral dose of HSK7653(5mg) Formulation A Or a single oral dose of HSK7653(5mg) Formulation B on Day 1 Period 1. Depending on what Formulation was received on Day 1 Period 1, participants will receive either a single oral dose of HSK7653(5mg) Formulation A Or a single oral dose of HSK7653(5mg) Formulation B on Day 1 of Period 2. Each period lasts for 15 days.
223747225|NCT06401330|DRUG|Etoposide|Given IV
223747226|NCT06401330|DRUG|Irinotecan|Given IV
223747227|NCT06401330|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223747228|NCT06401330|PROCEDURE|Nephrectomy|Undergo nephrectomy
223747229|NCT06401330|OTHER|Patient Observation|Undergo observation after nephrectomy
223594455|NCT06003088|DRUG|HSK7653(25mg)|Participants will receive a single oral dose of HSK7653(25mg) Formulation A Or a single oral dose of HSK7653(25mg) Formulation B on Day 1 Period 1. Depending on what Formulation was received on Day 1 Period 1, participants will receive either a single oral dose of HSK7653(25mg) Formulation A Or a single oral dose of HSK7653(25mg) Formulation B on Day 1 of Period 2. Each period lasts for 15 days.
223594456|NCT05564806|DRUG|YH004|All subject will receive YH004 intravenously as single agent every three weeks (Q3W), until intolerable toxicity, disease progression, withdrawal of consent, or Investigator decision, whichever comes first.
223594457|NCT03665688|DEVICE|Outpatient Dilapan-S|After Dilapan-S placement, subjects will be given the option to either return home or to stay in a hotel if transportation is an issue. Subjects will also be instructed to return to L\&D unit 12 hours after insertion, or earlier if any excessive bleeding, rupture of membranes, pain or other concerns (contractions, decreased fetal movement) develop before the 12 hours. After the designated 12 hours' time or earlier, if indicated, subjects are to return and to be admitted to L\&D unit for standard protocol of labor induction.
223594458|NCT03665688|DEVICE|Inpatient Dilapan-S|"After Dilapan-S placement, subjects will be admitted to L\&D unit and standard clinical protocol will be initiated for cervical ripening and labor induction. During the period of 12 hours of cervical ripening subject is to remain nothing per os (NPO), nothing per vagina and undergo continuous fetal heart rate monitoring. No other interventions are to occur during this period of 12 hours, unless clinically indicated."
223594459|NCT04628988|DRUG|CC-90011|Capsule
223747230|NCT06401330|PROCEDURE|Positron Emission Tomography|Undergo PET for patients with metastatic sites outside the chest/abdomen/pelvis documented during therapy
223747231|NCT06401330|PROCEDURE|Ultrasound Imaging|Undergo ultrasound
223747232|NCT06401330|DRUG|Vincristine|Given IV
223747233|NCT06401330|PROCEDURE|X-Ray Imaging|Undergo X-ray
223747234|NCT06153797|BEHAVIORAL|PATH-C|PATH-C, a phone-delivered positive psychology intervention for caregivers of patients undergoing HSCT, consists of the following nine sessions: 1) Enhancing gratitude and increasing awareness for physical activity; 2) Expressing gratitude and goal setting for physical activity; 3) Integrating gratitude and goals for physical activity; 4) Personal strengths and environmental scan to enhance physical activity; 5) Enhancing strengths via reflection on past successes; 6) Integrating strengths to enhance well-being and physical activity; 7) Engaging in enjoyable and meaningful activities; 8) Promoting optimism and integrating long-term activity habits; 9) Integrating meaning for sustainable physical activity goals. Each session takes about 30 minutes, and a trained interventionist will guide participants to complete the sessions.
223747235|NCT05950633|OTHER|Standard of Care|Participants will receive standard of care postoperative instructions
223747236|NCT05950633|OTHER|Active Recovery|Participants will receive instructions to increase their fitness to walking at least 30 minutes a day for 5 days a week following surgery and abdominal and pelvic floor exercises will focus on abdominal wall strengthening and abdominal pressure management, urinary urgency and retention, bowel and constipation management
223747237|NCT05872620|DRUG|Orforglipron|Administered orally
223747238|NCT05872620|DRUG|Placebo|Administered orally
223747239|NCT05802004|DEVICE|Acoustic Stimulation (STIM)|During the in-lab overnight, a headband device will be used to administer acoustic stimulation. Tones will be played during slow-wave sleep to enhance underlying slow-wave activity (0.5 - 4 Hz delta spectral power).
224196544|NCT03514446|DRUG|Antibiotic therapy duration for 7 days|Antibiotic therapy for seven days
223747240|NCT05802004|DEVICE|No Acoustic Stimulation (SHAM)|During the in-lab overnight, the participant will wear a headband device, but the device will not administer acoustic stimulation. The device will be on and will still monitor sleep, but will not play tones.
223747241|NCT05802004|DEVICE|Daily acoustic stimulation (STIM2)|During the \~2 weeks at home, a headband device will be used to administer acoustic stimulation. Tones will be played during slow-wave sleep to enhance underlying slow-wave activity (0.5 - 4 Hz delta spectral power).
223747242|NCT05802004|DEVICE|No daily acoustic stimulation (SHAM2)|During the \~2 weeks at home, the participant will wear a headband device, but the device will not administer acoustic stimulation. The device will be on and will still monitor sleep, but will not play tones.
223747243|NCT04728893|DRUG|Nemtabrutinib|Nemtabrutinib tablets administered orally QD.
223747244|NCT02967692|BIOLOGICAL|Spartalizumab|Spartalizumab powder for solution is used in Part 1 and Part 2, and as concentrate for solution for infusion for Part 3. Spartalizumab is administered via intravenous infusion over 30 minutes once every 4 weeks
223747245|NCT02967692|OTHER|Placebo|Placebo is administered via intravenous infusion over 30 minutes once every 4 weeks
223747246|NCT02967692|DRUG|Dabrafenib|Dabrafenib 150 mg capsules BID is administered orally for Days 1-28 of a 28-day cycle, in fasting conditions.
223594460|NCT04628988|DRUG|Abiraterone|Tablet
223594461|NCT04628988|DRUG|Prednisone|Tablet
223594462|NCT03576716|DRUG|D6-25-hydroxyvitamin D3|Intravenous administration of a deuterium-labeled 25(OH)D3 to evaluate the metabolic clearance of 25(OH)D3
223747247|NCT02967692|DRUG|Trametinib|Trametinib 2 mg tablets QD is administered orally for Days 1-28 of a 28-day cycle, in fasting conditions
223747248|NCT06312735|DEVICE|VR (Reducept)|Reducept is a novel VR intervention that consists of a combination of pain neuroscience education (PNE) and pain management techniques. It includes different psychological therapy modalities (e.g. acceptance and commitment therapy (ACT), cognitive behavioral therapy (CBT) and hypnotherapy) into a single application.
223747249|NCT05223413|DEVICE|RIPC|The procedure will be performed by using an electric auto-control device (modified blood pressure monitor for remote ischemic conditioning, Seagull Healthcare Aps, Denmark) for Remote Ischemic Conditioning in the arm. During the inflation period, the blood pressure cuff is inflated to 200 mmHg to stop blood flow in the arm.
224196545|NCT05424939|PROCEDURE|Colectomy|Colon resection
224196546|NCT05424939|PROCEDURE|Stoma procedures|Any type of colostomy or ileostomy with or without bowel resection
224196547|NCT05424939|PROCEDURE|By-pass/laparotomy/laparoscopy/biopsy|Any palliative surgery without bowel resection
224196548|NCT05552898|DIETARY_SUPPLEMENT|Sleep Study Product Usage|Participants will use their Radicle Sleep study product as directed for a period of 4 weeks.
224196549|NCT00292006|DEVICE|Computerized tomography|
224196550|NCT02344212|BEHAVIORAL|ESENCIAL Para Vivir: a weight loss program for Latinas|Overweight or obese Latina immigrant women were recruited to participate an 8-week weight loss program to reduce or delay their risk of developing diabetes. Data was collected at baseline, program completion, and six months.
224196551|NCT01051076|DRUG|VWF/FVIII concentrates|200 IU/Kg by one or two bolus injections daily. After successful confirmation the dose will be tailed off progressively until discontinuation. Patients will be treated with a VWF/FVIII concentrates according to physician/patients preference.
224196552|NCT00518531|DRUG|alendronate|Subjects will take 70 mg QW of oral alendronate for 1 year. If a subject is randomized to Treatment Sequence A they will receive alendronate for 1 year in Treatment Period 2. If a subject is randomized to Treatment Sequence B they will receive alendronate for 1 year in Treatment Period 1.
224196553|NCT00518531|DRUG|denosumab|Subjects will receive 60 mg of denosumab Q6M SC for 1 year. If a subject is randomized to Treatment Sequence A they will receive denosumab for 1 year in Treatment Period 2. If a subject is randomized to Treatment Sequence B they will receive denosumab for 1 year in Treatment Period 1.
224196554|NCT00032825|DRUG|Ketaconazole|
224196555|NCT00032825|DRUG|Docetaxel|
224196556|NCT04017065|DEVICE|DePuy Synthes MAXFRAMETM system|Patients treated with the MAXFRAMETM system will be followed up from before the surgery until the removal of the device. All treatments are based on individual clinician's judgement and the patient characteristics. The registry does not dictate any specific treatment.
224196557|NCT06652139|DRUG|selinexor combined with BEAM regimen|Selinexor: 60mg po D-10, D-7 and D-4 Carmustine: 300mg/m2 ivgtt D-8 Etoposide: 100mg/m2/d ivgtt q12h D-7-D-4 Cytarabine: 200mg/m2/d ivgtt q12h D-7-D-4 Melphalan: 140mg/m2 ivgtt D-3-D2
224196558|NCT06652139|DRUG|BEAM regimen|Carmustine: 300mg/m2 ivgtt D-8 Etoposide: 100mg/m2/d ivgtt q12h D-7-D-4 Cytarabine: 200mg/m2/d ivgtt q12h D-7-D-4 Melphalan: 140mg/m2 ivgtt D-3-D2
223505598|NCT06878092|BEHAVIORAL|Problem Management Plus with Emotional Processing Module (PM+EP)|To more directly address symptoms of traumatic stress, an adapted version of PM+ containing Emotional Processing module will be trialed in this study. The PM+ strategies discussed above are identical across both interventions apart from the additional module. The Emotional Processing module aims to provide a safe environment for participants to engage in the emotional processing of both positive and negative memories. During the additional session, participants will be asked to imagine significant memories as pieces of a jigsaw puzzle; participants will be asked to illicit three memories, two positive/pleasurable and one negative/frightening. Participants will be assisted in processing these memories through discussing the puzzle pieces, the thoughts and emotions that come with the memory, and future perspectives. Participants will be asked to rate the intensity of emotions before and after they talk about their memories each time they are brought up.
223505599|NCT06878092|OTHER|Care as usual|The comparison group will receive care as usual (CAU) only. CAU for forcibly displaced youth (under 18) in Sweden corresponds to primary health care, education, social protection services, and specialized psychological treatment programs. However, adults are only able to access care that cannot be deferred. Once the individual has received their residence permit, they are able to access all healthcare. Upon first arriving in Sweden, refugees are referred to a municipality by the Swedish Board of Migration (Migrationsverket) until they have their residence permit. The municipality is responsible for education and social services while the regions are responsible for health care. In the regions, primary care is responsible for the first line of treatment but can also refer to the child and adolescent mental health services (CAMHS) if needed. Unaccompanied children might either be placed in families or in residential facilities and benefit from the same systems as accompanied children.
223505600|NCT05136430|BEHAVIORAL|Self-Regulation strategies + large changes (SR)|The first 8 weeks (weeks 1-8) of the 16-week program will include weekly group sessions focused on teaching self-regulation and efforts to produce a 10 lb weight loss to buffer against anticipated post-cessation weight gain. Participants will be taught the core self-regulation skills for controlling their weight. In order to produce an initial weight loss buffer, they will be instructed to self-monitor their intake, given a daily calorie goal, and taught strategies for reducing caloric intake. Structured physical activity, such as brisk walking will also be prescribed and self-monitored. During smoking cessation treatment (weeks 9-16), participants will be asked to continue to use self-regulation skills for monitoring their weight and to use a color zone system (red, yellow, green) to determine what course of action to follow based on whether changes in weight have occurred.
224196559|NCT03487146|DEVICE|hemoperfusion(HP)|These patients were computer-matched into two groups, involving 100 patients with absolute HD vs. 100 cases with HD+HP.HP was performed 1-2 times/per 2 weeks, and each session lasted for two hours.Self-reported sleep disturbance was evaluated before and after observational time (two-year period), which lasted at least 7 hours based on the recommendations presented by National Institute of Health (NIH). Sleep efficiency (%) was calculated as the ratio of sleep duration to total time in bed, and was multiplied by 100.
224196560|NCT02826239|DEVICE|multiple breath washout test (MBW)|measured in upright and supine position
224196561|NCT04406363|OTHER|non interventional|non interventional
224196562|NCT00087763|DRUG|Macugen ™ (pegaptanib sodium injection)|
224196563|NCT03479619|DEVICE|Lancing device A|Glucoject Dual Plus lancing device
224196564|NCT03479619|DEVICE|Lancing device B|Droplet lancing device
224196565|NCT03479619|DEVICE|Lancing device C|Commercially available lancing device
224196566|NCT03479619|DEVICE|28 G lancet|Droplet 28 G
224196567|NCT03479619|DEVICE|30 G lancet|Droplet personal lancet 30 G
224196568|NCT03479619|DEVICE|33 G lancet|Droplet personal lancet 33 G
224196569|NCT03479619|OTHER|Lancing depth setting (1)|The lowest depth setting (1)
224196570|NCT03479619|OTHER|Lancing depth setting (5)|The highest depth setting (5)
224196571|NCT02351206|RADIATION|x-ray, MRI|
224196572|NCT01395342|OTHER|Exercise using stationary bicycle|"Before exercise, blood pressure and heart rate are measured in the sitting position.~Exercise is realized using stationary bicycle (horizontal bench mode) once at week, during 20 minutes under physiotherapist supervision.~The heart rate was maintained at 20% above resting heart rate and up to 140 bpm.~After exercise is performed a leg stretching and a low back stretching. The blood pressure and heart rate are measured in the sitting position."
223505601|NCT05136430|BEHAVIORAL|Healthy Lifestyle Education (LE)|The first 8 weeks (weeks 1-8) of the 16-week program will include weekly group sessions focused on living a healthy lifestyle. Information provided will include education on why weight gain happens while quitting smoking, principles of healthy eating (e.g., simple versus complex carbohydrates), physical activity guidelines, and other topics related to living a healthy lifestyle. Participants can choose to use the healthy lifestyle information and education provided however they would like. Participants will not be asked to use self-regulation strategies during either part of the 16-week program.
223594463|NCT00961194|DRUG|Ketamine|"Initial dosage: 250 mg/5 ml~Three doses of ketamine will be tested:~* 0.35 mg/kg~* 0.7 mg/kg~* 1.4 mg/kg Each patient will receive the indicated dose of oral ketamine or placebo once and if there are not adverse events, he will be able to continue the treatment three times a day, during 7 days (between visit 2 and 3).~The oral ketamine will be administered in form of syrup."
223747250|NCT05223413|DEVICE|Simulated RIPC (Sham)|The procedure will be performed by using an electric auto-control device (modified blood pressure monitor for remote ischemic conditioning, Seagull Healthcare Aps, Denmark) for Remote Ischemic Conditioning in the arm. During the inflation period, the blood pressure cuff is inflated to a low pressure not stopping blood flow in the arm.
224196573|NCT05831475|BEHAVIORAL|Intergenerational Virtual Paired Exercise|Participants will be paired with someone older/ younger and will engage in exercise videos with the ability to simultaneously video chat with their partner while exercising. Participants will log on with their partner twice a week for 8 weeks.
224196574|NCT05831475|BEHAVIORAL|Peer Virtual Paired Exercise|Participants will be paired with someone of the same age group and will engage in exercise videos with the ability to simultaneously video chat with their partner while exercising. Participants will log on with their partner twice a week for 8 weeks.
224196575|NCT01326611|DRUG|Clarithromycin|
224196576|NCT01326611|DRUG|Dextrose|
224196577|NCT04402944|DRUG|Pulmozyme|Pulmozyme 2.5 mg BID
224196578|NCT04402944|DRUG|Placebo|Saline 2.5 mL BID
224196579|NCT06195358|DEVICE|Mobile Health (Smartphone) Application|The intervention arm will receive the smartphone application, which has been designed to engage primary caregivers directly in the active monitoring of their infants' development, and to provide tailored feedback and support for the provision of nurturing care. Study staff will make an initial home visit (less than an hour) to install the application on the caregiver phone and demonstrate use and collect baseline data. Subsequently, in the intervention arm, staff will make monthly visits (approximately 15 minutes duration) to assess functionality of the smartphone and answer questions/reinforce use.
224196580|NCT06195358|OTHER|Printed Caregiving Materials|The control arm will receive printed caregiving materials. In the control arm, staff will make monthly visits (approximately 15 minutes duration) to ask if there are questions about the printed caregiving materials.
224196581|NCT02850159|DEVICE|rTMS and tDCS|Patients underwent five consecutive daily sessions of dual-mode NIBS with high-frequency repetitive transcranial magnetic stimulation (rTMS) over the primary motor cortex of the lower leg and anodal transcranial direct current stimulation (tDCS) over the left dorsolateral prefrontal cortex simultaneously
224196582|NCT02850159|DEVICE|rTMS|Patients underwent five consecutive daily sessions of dual-mode NIBS with high-frequency repetitive transcranial magnetic stimulation (rTMS) over the primary motor cortex of the lower leg and sham anodal transcranial direct current stimulation (tDCS) over the left dorsolateral prefrontal cortex simultaneously
224196583|NCT00096317|DRUG|ixabepilone|
224196584|NCT00096317|DRUG|ketoconazole|
224196585|NCT00551473|DRUG|Lavoltidine|
224196586|NCT00602927|DRUG|Varenicline|Day 1 - Day 3 0.5mg once daily Day 4 - Day 7 0.5mg twice daily Day 8 - Day 13 1.0mg twice daily
224196587|NCT00602927|DRUG|Placebo|Participants will take placebo pills for 13 days using the same regimen as the varenicline study period.
224196588|NCT00250666|PROCEDURE|PCT measurement|Peripheral blood samples were collected in the morning, using vacuum tubes (BD Vacutainer SST II Plus plastic tubes; Becton Dickinson Diagnostic Systems, Allschwil, Switzerland). Circulating plasma PCT levels were measured with a time-resolved amplified cryptate emission technology assay (Kryptor PCT; Brahms AG, Hennigsdorf, Germany), with an assay sensitivity of 0.06 mg/L, approximately fourfold above mean normal levels. Measurements were performed 7 days a week.
224196589|NCT01009073|DRUG|ABT-263|"ABT-263 is taken orally.~Note - The dose and schedule is variable based on Arm and subject to change based on the toxicities observed."
224196590|NCT01009073|DRUG|erlotinib|150 mg of erlotinib is taken orally once daily.
224196591|NCT01009073|DRUG|irinotecan (3-week schedule)|"180 mg/m2 over 90 minutes, irinotecan will be given by intravenous infusion on Day 1 of each 21 day cycle.~Note - The dose and schedule is subject to change based on the toxicities observed."
224196592|NCT01009073|DRUG|irinotecan (weekly schedule)|"75 mg/m2 over 45 minutes, irinotecan will be given by intravenous infusion on Days 1 and 8 of each 21 day cycle.~Note - The dose and schedule is subject to change based on the toxicities observed."
224196593|NCT02769182|DEVICE|Monitoring and training using the system|subjects and caregivers will be trained on using the system and receive a 'user manual' delineating all procedures and possible applications of the system, as well as operations for daily charging of the sensors and smart phone. They will then be fitted with the sensors. The clinician will set all necessary applications, including setting the cognitive games application and the 'network of users'. Users and care givers will be informed of the personalized recommendations system that will provide the user with daily feedback on activity and weekly recommendations and goals for duration of the study. A helpline will be provided in case technological problems occur or for routine support.
224196594|NCT02769182|BEHAVIORAL|Standard of care|Subjects in this group will not receive the system but will encouraged to continue with their daily living routine and provided with recommendations for stretching and strengthening exercises. The control group subjects will be assessed at the same three time points as those in the experimental group. Subjects in both groups will also receive written information about the importance of activity, cognitive enhancing tasks, avoidance of falls and home hazards. In Israel, this information combined with an exercise prescription is considered the 'standard of care' for community-dwelling older adults.
224196595|NCT05916963|DRUG|Furosemide 40 mg|Injection of 40 mg of Furosemide during 10 minutes after the end of the flexible ureteroscopy for destruction of kidney stones with laser.
223594464|NCT02136628|PROCEDURE|Method RTL|"The method consists of two lines of suture, each, over the fascial wound edge. It starts with a suture strand (in this study was used PDS number 0) in one end of the fascial wound where the suture is run longitudinally and parallel to the aponeurotic edge. The needle should go in and out at intervals of 1 cm away and always kept at 0.5 cm from the edge of the fascia. Upon reaching the opposite angle of the wound suture strand another repeating the same process on the fascial edge otherwise used. The ends of the two suture strands are tied in fascial angles.~Thus the fascial wound is sutured with two lines of strengthening its edges. Then proceed to close the wound with continuous súrgete always ensuring that the suture lines remain anchored on suture reinforcement."
223594465|NCT03549715|DRUG|Durvalumab|1500 mg IV D1 every 28 days (2 doses for each patient)
223594466|NCT03549715|DRUG|Tremelimumab|75 mg IV D1 every 28 days ((2 doses for each patient)
224196596|NCT03491800|BEHAVIORAL|Question/Topic Prompt List|A written document containing suggested questions that the family member and/or patient may want to ask the health care provider during the visit. A section is included for the patient to check which behaviors they would like for their family member to engage in during the visit and space is provided for the family member to check which behaviors they are willing to perform during the visit.
224196597|NCT02942537|DEVICE|Microwave treatment|Percutaneous or vaginal application of microwave antenna with microwave treatment of fibroma
224196598|NCT02942537|PROCEDURE|uterine artery embolization|Percutaneous applicaiton of a catheter into the femoral artery and embolization of uterine artery or branches thereof
224196599|NCT01481961|PROCEDURE|repetitive Transcranial Magnetic Stimulation (rTMS)|After locating the left DLPFC, treatment with active rTMS will be directed by 20-minute session during which pulse trains of 5 seconds of 10 Hz spaced 25 seconds (2 trains of pulses per minute or 40 pulse trains per session). Treatment will occur 2 sessions per day during 5 days per week. Subjects will be monitored during rTMS for any side effects or adverse events.
224196600|NCT02414165|BIOLOGICAL|Toca 511|Toca 511 consists of a purified retroviral replicating vector encoding a modified yeast cytosine deaminase (CD) gene. The CD gene converts the antifungal 5-flurocytosine (5FC) to the anticancer drug 5-FU in cells that have been infected by the Toca 511 vector.
224196601|NCT02414165|DRUG|Toca FC|Toca FC is an extended-release formulation of flucytosine and is supplied as 500 mg tablets
224196602|NCT02414165|DRUG|Lomustine|
224196603|NCT02414165|DRUG|Temozolomide|
224196604|NCT02414165|BIOLOGICAL|Bevacizumab|
224196605|NCT06098131|OTHER|Neurodynamic|Neurodynamic Slider and Tensioner Technique
224196606|NCT06563492|DEVICE|insole|evaluation of individuals using different insoles
224196607|NCT06566807|DRUG|Orelabrutinib, obinutuzumab|orelabrutinib，150mg，D1-D28 obinutuzumab，1000mg，D1、D8、D15/cycle1 D1/cycle2-6 . The patients will be treated with 6 cycles of O2 regimen. Patients with CR/PR after 6 cycles of O2 treatment will be treated with 1 year of single-agent orelabrutinib regimen.
224196608|NCT01888978|DRUG|Gem-OX|
224196609|NCT01888978|DRUG|Gem-5FU|
224196610|NCT01888978|DRUG|Gem-Tax|
224196611|NCT01888978|DRUG|Modified FOLFOX-6|
224196612|NCT01888978|DRUG|Ox-Tax|
224196613|NCT01888978|DRUG|FOLFIRI|
224196614|NCT01888978|DRUG|Tax-Iri|
224196615|NCT05341583|DRUG|Ensartinib|Ensartinib 225 mg once daily until disease recurrence or up to 2 years, whichever occurs earlier.
224196616|NCT05341583|DRUG|Placebo|Placebo 225 mg once daily until disease recurrence or up to 2 years, whichever occurs earlier.
224196617|NCT04311411|DRUG|Tirzepatide|Administered SC.
224196618|NCT04311411|DRUG|Placebo|Administered SC.
224196619|NCT04311411|DRUG|Liraglutide|Administered SC.
224196620|NCT00003769|DRUG|perillyl alcohol|
224196621|NCT00003769|PROCEDURE|surgical procedure|
224196622|NCT03533829|DEVICE|Buzzy®|Buzzy® Drug Free Pain Relief which is a medical device designed to reduce vaccination pain when applied to the arm prior to and during a vaccination.
224196623|NCT03533829|BEHAVIORAL|Music|Music will be selected and listened to as a distraction before and during vaccination.
224196624|NCT03867825|DEVICE|Non-invasive hemodynamic monitoring|Impedance cardiography
224196625|NCT06701448|DIAGNOSTIC_TEST|robotic bronchosopy|robotic bronchoscopy
224196626|NCT06701448|DIAGNOSTIC_TEST|Electromagnetic Navigation Bronchoscopy|Electromagnetic Navigation Bronchoscopy
224196627|NCT06701448|DIAGNOSTIC_TEST|Fluoroscopy bronchoscopy|Fluoroscopy bronchoscopy
224196628|NCT05674864|DRUG|Bifidobacterium Infants plus Enterococcus Feacium plus Lactobacillus Acidophilus|Bifidobacterium Infants, Enterococcus Feacium, and Lactobacillus Acidophilus combination will be given as one capsule three times daily for 14 days
224196629|NCT03722849|DRUG|Adenosine Triphosphate|Participants will inhale escalating concentrations of Adenosine Triphosphate (ATP) to induce cough and the urge-to-cough
224196630|NCT03722849|DRUG|Capsaicin|Participants will inhale escalating concentrations of capsaicin to induce cough and the urge-to-cough
224196631|NCT03722849|OTHER|Functional Brain Imaging|Participants will have scans of their brain activity using 3 Tesla (3T) brainstem restricted functional brain imaging (fMRI)
224196632|NCT03962218|PROCEDURE|aquatic physiotherapy|specific aquatic physiotherapy 3 times a week, for 6 weeks, including feet balance exercises (Rating of Perceived Effort (RPE)), slow walking in all directions, walking with obstacles, Ai Chi, exercises of muscular strength. Each session duration is of 40 minutes.
224196633|NCT00055159|PROCEDURE|Pulse-sprayed injection of recombinant tissue plasminogen activator (rtPA)|
224196634|NCT01955031|OTHER|telemonitoring|A telemonitoring program with educational tools is given to people with type 2 diabetes at their home. It is composed of three softwares to improve eating habits available on touchpad, a self-monitoring blood glucose device, a balance to measure weight and fat mass, and a pedometer to evaluate physical activity. Data are securely sent and stored into a web service which delivers a synthesis to patients and health professionals.
224310735|NCT06841822|OTHER|SCTL deep plane block group|Ultrasound-guided thoracic paravertebral nerve block was routinely performed. SCTL was broken by a puncture needle during the ultrasound-guided thoracic paravertebral block. In 20 patients who required CT (3D) imaging to observe drug diffusion 30min after nerve block, cold stimulation was used 30min after the procedure to assess the degree of sensory loss, including the anterior chest wall (midclavian line), lateral chest wall (posterior axillary line), and posterior chest wall (paravertebral area).
224310736|NCT00596037|DRUG|Growth hormone - LB03002|
224196635|NCT01955031|OTHER|Usual care|Patients are recruited during therapeutic educational sessions or appointments by general practitioners or diabetologists who take part into the Regional Health Network in Diabetes DIAMIP. If patients accept to participate to the study and sign up the protocol consent, they are given questionnaires about nutrition, physical activity and quality of life. A dietician analyses with each patient the results of a food inquiry. Patients are randomised into two groups: one arm is trained to the telemonitoring program before receiving it at home, and the other arm follows usual care. During 12 months, the telemonitoring group uses the device. The investigators (GP or diabetologists) can use the specific secured website to follow the measured parameters and to make appropriate decisions about health care of their patient. No consultation are scheduled in advance.
224196636|NCT04583072|DIAGNOSTIC_TEST|The Stockholm3 test|Venipuncture: Prior to the biopsy the blood will be collected in 2 EDTA (lavender top) x 4 ml tubes will be removed after obtaining consent from the subjects.
224196637|NCT04527406|PROCEDURE|posterior hemivertebra resection|The subjects in early surgical group are arranged to be admitted to for surgical treatment very soon. The operation choice is posterior hemivertebrae resection + posterior pedicle screw placement + scoliosis correction. During operation pedicle screws are placed in the adjacent vertebrae of the head and tail of the Hemivertebra. Wedge resection of the hemivertebrae is performed afterward. Finally, two rods are placed between the pedicle screws. Intraoperative fluoroscopy confirms that the internal fixation position is good.
224196638|NCT04527406|PROCEDURE|conservative treatment+ delayed posterior hemivertebra resection|In traditional surgical group, subjects received conservative treatment firstly with custom-made braces to delay the progression of scoliosis. It is planned to use the classic posterior hemivertebrae resection + posterior pedicle screw placement + scoliosis correction to complete the correction around the age of 5. The operation choice is identical with early surgical group. During operation pedicle screws are placed in the adjacent vertebrae of the head and tail of the Hemivertebra. Wedge resection of the hemivertebrae is performed afterward. Finally, two rods are placed between the pedicle screws. Intraoperative fluoroscopy confirms that the internal fixation position is good.
224196639|NCT05785299|DIAGNOSTIC_TEST|Cow's milk|clinical introduction of cow's milk
224196640|NCT05785299|DIAGNOSTIC_TEST|Placebo|clinical introduction of placebo
224196641|NCT05785299|DIAGNOSTIC_TEST|Home introduction|home introduction of cow's milk
224196642|NCT04861168|PROCEDURE|driving pressure guided ventilation|driving pressure guided ventilation
224196643|NCT04861168|PROCEDURE|Conventional protective lung strategy|Conventional protective lung strategy
224196644|NCT04888377|DRUG|Aspirin|Participant's mothers were administered 81mg of Aspirin throughout their pregnancy with the participant.
223594467|NCT03549715|DRUG|MVAC Protocol|"1. Methotrexate 30 mg/m2 IV D1~2. Vinblastine 3 mg/m2 IV D1~3. Adriamycin (doxorubicin) 30 mg/m2 IV D1~4. Cisplatin 70 mg/m2 IV D1"
223594468|NCT05169411|DIAGNOSTIC_TEST|Blood pressure|The first anti-hypertensive prescribed will be categorized as ACEi, ARB, thiazide diuretic, loop diuretic, beta-blocker, calcium channel blocker, other, and none; secondary analyses will combine ACEi and ARB into a single RAAS blocker category. We will conduct additional secondary analyses for specific medications with sufficient sample sizes.
223594469|NCT05169411|DIAGNOSTIC_TEST|Urine protein|Evaluating urine protein for children with CKD and hypertension is another guideline recommendation, but the frequency, type of assessment (qualitative or quantitative urine protein), and utility for patients without hypertension are unclear. We will determine whether urine protein is evaluated at each encounter and create a dichotomous indicator.
223594470|NCT03054324|DIAGNOSTIC_TEST|Fractional Flow Reserve|Coronary fraction flow reserve (FFR), the ratio of the mean coronary pressure distal to a coronary stenosis to the mean aortic pressure during maximal coronary blood flow (hyperemia), defines the hemodynamic significance of coronary artery narrowing.
223594471|NCT03851055|DRUG|Zinc|One arm will receive Zinc Second arm will receive placebo
223594472|NCT00548899|DRUG|Nexavar (Sorafenib)|Tablet, Sorafenib follows a patient specific escalation scheme starting with 200 mg daily up to a maximum dose of 800 mg daily during EC chemotherapy on day 2-19. The achieved dose will be continued during paclitaxel chemotherapy during week 1-11 all day
224196645|NCT04888377|DRUG|Placebo|Participant's mothers were administered placebo throughout their pregnancy with the participant.
224196646|NCT04764825|DRUG|Methadone|"The dosage administered differ in regards to age and tolerance to opioids:~0.2 mg/kg: all patients \<65 years of age and all patients tolerant to opioids (defined as treatment with opioids (at least the last 7days) exceeding 60 oral morphine milligram equivalents daily.~0.15 mg/kg: Opioid naive patients \> 65 years of age."
224310737|NCT06812611|DEVICE|High Energy Laser Group|"The multimodal high energy laser therapy treatment with thermal control (THEAL) will be delivered with an Ixyon XP device (Mectronic, Bergamo, Italy) which allows the delivery of 4 wavelengths (650 nm, 810 nm, 980 nm and 1064 nm), with continuous and pulsed mode, average power up to 30 W, administering 10 sessions every other day.~The patients will simultaneously carry out the rehabilitation treatment exercises, as was expected in the control group."
223594473|NCT05913024|BIOLOGICAL|Enterovirus Type 71 Vaccine|Participants received two doses of the vaccine, 28 days apart
223594474|NCT00559988|DRUG|Home Monitoring Guided OAC|"Active monitoring for atrial episodes through the automatic HM notifications (email, fax, short message service) is required. If the total duration over 48 consecutive hours reaches the predefined anticoagulation condition, and AF/AFL diagnosis is confirmed using the IEGM online, the site instructs the patient by telephone to start OAC. Clinicians continue to monitor patients using HM, and if freedom from AF/AFL reaches the predefined interval, stop of OAC therapy is requested over the telephone. Following stop of anticoagulation, any recurrence of AF/AFL requires restart of OAC therapy.~OAC drugs used: Dabigatran etexilate, Rivaroxaban, Warfarin, other approved VKA"
223594475|NCT00559988|DRUG|Physician-Directed OAC|"Patients will receive physician-directed anticoagulation therapy based on conventional criteria.~OAC drugs used: Dabigatran etexilate, Rivaroxaban, Warfarin, other approved VKA"
223594476|NCT00653081|PROCEDURE|Physical therapy method called Supervised Exercises|Performed at ullevaal Hospital, 45 min each time, 2-3 times pr week in max 12 weeks
223594477|NCT00653081|PROCEDURE|Radial Extracorporeal Shockwave Therapy|Radial Shock Wave therapy performed at ulleval Hospital, once a week, 4-6 times, 3-5 points each time.
224310738|NCT06812611|OTHER|Exercise|Daily exercise
224196647|NCT04764825|DRUG|Morphine|"The dosage administered differ in regards to age and tolerance to opioids:~0.2 mg/kg: all patients \<65 years of age and all patients tolerant to opioids (defined as treatment with opioids (at least the last 7days) exceeding 60 oral morphine milligram equivalents daily.~0.15 mg/kg: Opioid naive patients \> 65 years of age."
224196648|NCT06827626|BEHAVIORAL|Cognitive behavioral therapy for insomnia|Cognitive-Behavioural Therapy for Insomnia (CBT-I) includes behavioral methods, cognitive methods, and sleep hygiene counselling.
224196649|NCT06827626|BEHAVIORAL|Sleep hygiene counselling|Sleep hygiene counselling includes common instructions to improve sleep.
224196652|NCT05077774|DEVICE|Harmony TPV System|Harmony Transcatheter Pulmonary Valve (sizes 22 mm and 25 mm) and Harmony Delivery Catheter System (DCS)
224196653|NCT05279807|DRUG|Zofenopril|Film-Coated tablets administered orally once daily according instructions provided by Principal Investigator.
224196654|NCT05279807|DRUG|Amlodipine|Tablets of 5mg and 10mg administered orally once daily according instructions provided by Principal Investigator.
224196655|NCT03642249|BEHAVIORAL|OSCEs|Scenario-based education intervention, including objective structured clinical examinations (OSCEs)
224196656|NCT03642249|BEHAVIORAL|Lecture|Face-to-face Education using Delirium Care Flip Chart
224196657|NCT03642249|BEHAVIORAL|E-learning|delirium care video
224310739|NCT00802594|DRUG|DB289|A single 100 mg DB289 capsule will be taken by mouth twice a day, morning and evening. Drug is to be taken with a glass of water within 15 minutes of the completion of meal.
224196658|NCT03777839|DIAGNOSTIC_TEST|FDG PET/CT|FDG PET CT imaging with rest perfusion imaging
223594478|NCT01455194|DRUG|Ciclesonide|During the treatment period subjects will inhale two puffs of either 40, 80 or 160 μg ciclesonide in the morning and the evening (corresponding to a total daily dose of 160, 320 or 640 μg)
223594479|NCT02249182|DRUG|LDV/SOF|LDV/SOF FDC administered orally once daily
223594480|NCT02249182|DRUG|RBV|Ribavirin (RBV) oral solution or capsules will be administered orally in a divided daily dose based on weight
223594481|NCT01835834|PROCEDURE|zirconia bridge restoration|
223594482|NCT04942782|OTHER|lumbopelvic stabilization exercises|the patients will receive lumbopelvic stabilization in the form of three parts: 1 Segmental control over primary stabilizers (mainly TrA, deep multifidus, pelvic floor and diaphragm) 2-Exercises in closed chain, with low velocity and low load 3-Exercises in open chain, with high velocity and load
223594483|NCT04942782|OTHER|pilates exercise|the patient will receive pilates exercise in the form of Breast stroke prep, Side leg lift series, One leg circle, Hundreds, Shoulder bridge, and Spine stretch forward
224196659|NCT06533410|DIAGNOSTIC_TEST|The FM Diagnosis and Assessment Scale will be filled out, and there will be no other interventions beyond that|The FM Diagnosis and Assessment Scale will be filled out, and there will be no other interventions beyond that
224196660|NCT06304688|OTHER|Yoga and Mediterranean Diet intervention|"It will last 12 weeks with a frequency of 2 sessions per week and each lasting 50 minutes.~* Warm-up phase (10 minutes): Conscious and gentle breathing. Gentle movements of the neck, shoulders, arms and legs to increase blood circulation and flexibility.~* Training phase (30 minutes): Series of gentle postures adapted to the needs of older adults. Includes standing, sitting and lying postures for relaxation and stretching. It will begin with basic postures and breathing techniques and will gradually advance as participants gain confidence.~* Return to calm (10 minutes): Deep relaxation in a lying position to integrate the benefits of the practice and promote total relaxation of the body and mind.~The Mediterranean diet consisted of: i) carbohydrates constitute 50% of the daily intake; ii) fats represented 35%; and iii) proteins represented 15%."
224196661|NCT06415032|PROCEDURE|Mastectomy with Quilting sutures without drain placement|The nipple-areola complex is removed, and dissection of skin flaps is performed using electrocautery. The breast tissue, including the prepectoral fascia is removed from the pectoral muscle. After the mastectomy, the skin flaps are sutured onto the pectoral muscle using polyfilament absorbable sutures (e.g. Stratafix PDS® 1 CT needle) placed at 4- to 5-cm intervals in two or three rows depending on the extent of the skin flaps. Care is taken to prevent dimpling of the skin. The axillary region is also approximated. Care is taken to prevent damage to nerves and blood vessels. No suction drains are placed. For skin closure, the edges are sutured using absorbable monofilament sutures (e.g. Biosyn l® 3-0, Monocryl® 3-0) depending on the surgeon's preference.
224196662|NCT06415032|PROCEDURE|Mastectomy with Conventional sutures with drain placement|The nipple-areola complex is removed, and dissection of skin flaps is performed using electrocautery. The breast tissue, including the prepectoral fascia is removed from the pectoral muscle. After mastectomy no flap fixation is performed. The skin is closed in a conventional manner using an absorbable skin suture. One or two suction drains are placed before skin closure. The drains are placed in the mastectomy gutter lateral to the pectoral muscle and/or in the prepectoral area. For skin closure, the edges are sutured using absorbable monofilament sutures (e.g. Biosyn l® 3-0, Monocryl® 3-0) depending on the surgeon's preference. Drain output is recorded daily. Drain removal policy varies among participating centres. In some centres drain removal is based on volume of drained fluids while in other centres it depends on the postoperative time
224196663|NCT03009175|DEVICE|Implantable Cardiac Defibrillator, Cardiac Resynchronization Therapy Defibrillator/Pacemaker|
224196664|NCT05727267|BIOLOGICAL|HEPLISAV B; TherVacB|Administration of the described combinations via the intramuscular route
224196665|NCT05727267|BIOLOGICAL|TherVacB|Administration of the described combinations via the intramuscular route
223594484|NCT04942782|OTHER|conventional therapy|Patients will received strengthening exercises for the abdominal, back, and hip muscles. The patients performed an average of three series of ten repetitions of each exercise. Increases in the number of exercises performed in each session (or load progression) occurred according to individual tolerance
223594485|NCT01032031|DIETARY_SUPPLEMENT|Green tea + vitamin C high dose|One green tea capsule (1250mg catechin) and one vitamin C tablet (100mg) daily for 3 months
223594486|NCT01032031|DIETARY_SUPPLEMENT|Placebo capsule|One capsule daily for 3 months
223594487|NCT02567045|PROCEDURE|annual FIT and colonoscopy in case of a positive test|FIT and colonoscopy in case of a positive test. Annual interval (2 rounds), without diet restriction, 1 stool sample. Positive cut-off 10 mcg Hemoglobin/g feces.
224196666|NCT06176222|DRUG|PRECEDEX INJ★ 2ML|patient received PRECEDEX INJ★ 2ML 0.1\~0.4 mcg/kg/hr intravenous infusion 12 hours after the surgery immediately
224196667|NCT06176222|DRUG|Normal saline|patient received Normal Saline 0.1 ml/kg/hr intravenous infusion 12 hours after the surgery immediately
224196668|NCT05791942|BEHAVIORAL|Reminder of preventive care measures|"The investigators will send randomized participants an SMS reminder encouraging them to click the provided link and close their outstanding, overdue preventive care measures.~The provided link will take them to their MyChart login page; after logging in, they would see their personalized My Action Plan Letter detailing their personalized, overdue preventive care measures."
224196669|NCT05791942|BEHAVIORAL|Persuasion via anecdote|The message will contain an anecdote of a patient whose cancer was caught early through similar, recommended preventive screenings.
224196670|NCT05791942|BEHAVIORAL|Behavioral: Action prompt|The message will prompt people to take care of the health gap right away before it slips their mind.
224196671|NCT05993299|DRUG|Letetresgene autoleucel|Letetresgene autoleucel will be administered.
224196672|NCT05993299|DRUG|Cyclophosphamide|Cyclophosphamide will be used as a lymphodepleting chemotherapy.
224196673|NCT05993299|DRUG|Fludarabine|Fludarabine will be used as a lymphodepleting chemotherapy.
224196674|NCT05644756|BEHAVIORAL|IMPACT Methods to Identify and Prioritize Determinants (Challenge I), Challenge and Match strategies to Prioritized Determinants (Challenge II)|IMPACT Center developed two methods for identifying determinants that involved providers, staff, and youth at community mental health centers in site visit 1: Rapid Ethnographic Assessment, Design Probes. Then, practice partners engage in a facilitated group activity to rate the criticality, chronicity, and ubiquity of the list of determinants in Site Visit 2. Finally, practice partners engage in a third site visit where they create Causal Pathway Diagrams that allow them to match strategies to prioritize determinants and create Implementation Plans.
224196675|NCT05028894|OTHER|No intervention|No intervention
224196676|NCT04634877|BIOLOGICAL|Pembrolizumab|IV infusion
224196677|NCT04634877|DRUG|Carboplatin|IV infusion
223505602|NCT05136430|OTHER|Smoking Cessation Treatment|The second 8 weeks (weeks 9-16) of the 16-week program will include weekly group counseling sessions focused on smoking cessation. The smoking cessation treatment provided will be the same in both arms of the study. In preparation of quitting, nicotine replacement therapy lozenges will be provided for 3 weeks prior to quitting (weeks 6-8). A group quit day will occur on week 9. During the smoking cessation portion of treatment (weeks 9-16), participants will be provided with combination nicotine replacement therapy (patches + lozenges) and daily supportive text messages.
223505603|NCT05147831|OTHER|Remote Ischemic Preconditioning|Place blood pressure cuff around upper, non-dominant arm (e.g. upper left arm in a right-handed patient). Inflate blood pressure cuff to a pressure set at 50 mmHg higher than baseline systolic BP to induce ischemia of arm for 5 minutes. Completely deflate blood pressure cuff to allow for 5 minutes of reperfusion. Subjects would undergo 4 cycles of ischemia and reperfusion,
224196678|NCT04634877|DRUG|Paclitaxel|IV infusion
224196679|NCT04634877|DRUG|Placebo for pembrolizumab|IV infusion
224196680|NCT04634877|DRUG|Docetaxel|IV infusion docetaxel 75 mg/m\^2 Q3W or 25 mg/m2 QW may be given in place of paclitaxel following sponsor consultation if a participant experiences severe hypersensitivity to paclitaxel or an adverse event requiring discontinuation of paclitaxel.
224196681|NCT04634877|DRUG|Cisplatin|Cisplatin 75 mg/m\^2 IV infusion Q3W may be given in place of carboplatin following sponsor consultation if a participant experiences severe hypersensitivity to carboplatin or an adverse event requiring discontinuation of carboplatin.
224196682|NCT04634877|RADIATION|External Beam Radiotherapy (EBRT)|≥4500 cGY given according to local practice, at the discretion of the investigator
223505604|NCT04876950|COMBINATION_PRODUCT|Virtual care with remote automated monitoring|Use of Cloud Diagnostics connected health kit for at home monitoring with virtual clinical from nursing and perioperative physician team.
223505605|NCT05379985|DRUG|RMC-6236|Oral Tablets
224196683|NCT04634877|DRUG|Cisplatin (as radiosensitizer)|If a participant receives external beam radiotherapy (EBRT), then cisplatin 50 mg/m\^2 IV infusion may be administered as a radiosensitizer at the discretion of the investigator, on days 1 and 29
224196684|NCT04634877|RADIATION|Brachytherapy|Given according to local practice, at the discretion of the investigator
224310740|NCT04578444|DRUG|Zanidatamab|Administered intravenously
223505606|NCT05516966|DRUG|HRS9531|Administrated SC
223505607|NCT05516966|DRUG|Placebo|Administrated SC
223505608|NCT05516966|DRUG|Dulaglutide Injection|Administrated SC
223505609|NCT06035328|OTHER|Wheat (Four times per week)|Case wheat allergy that on four times/week dose during one year maintenance phase of wheat OIT
223594488|NCT02567045|PROCEDURE|colonoscopy with sedation|One-time Colonoscopy with sedation.
223594489|NCT01497782|OTHER|Instructor feedback|Intervention group who receives up to three sessions of instructor feedback during completion of a predefined proficiency level on a laparoscopic virtual reality simulator.
223594490|NCT03679026|OTHER|Summarize of participants' characteristics using means and standard deviations or frequencies and percentages|Participants' baseline characteristics will be summarized using means and standard deviations or frequencies and percentages, as appropriate.
224196685|NCT05614128|OTHER|IVIg|Patients will be treated with IVIg as recommended by expert guidelines for treatment of CIDP under care of their primary neurologist. This will not be provided by the study.
224196686|NCT05219643|DEVICE|NAVA|Nava level is set to maintain the target tidal volume: 6-10ml / kg (pbw). The trigger sensitivity is 0.5uv. The expiratory trigger sensitivity: the built-in software of the ventilator is set to 70% of the peak value of diaphragm electrical activity.
224196687|NCT05219643|DEVICE|PSV|According to the doctor's experience, maintain the target tidal volume: 6-10ml / kg (pbw); trigger sensitivity: 1.5-2l/min, expiratory trigger sensitivity: 30% inspiratory peak flow rate.
224196688|NCT02050945|BEHAVIORAL|Resistance training|
224196689|NCT02050945|BEHAVIORAL|Endurance training|
224196690|NCT06631235|OTHER|orthopedic appliance|appliances are used to correct skeletal class II due to mandibular deficiency
224196691|NCT06631235|OTHER|aesthetic orthopedic appliance|aesthetic appliances are used to correct skeletal class II due to mandibular deficiency
224196692|NCT03217422|BIOLOGICAL|VAY736|VAY736
223505610|NCT03808467|BEHAVIORAL|Cognitive Remediation Therapy|Nine individual transdiagnostic CRT sessions will be delivered once per week, each session lasting approximately 45 minutes. Building on previously published CRT manuals for anorexia nervosa and obesity, a transdiagnostic CRT manual developed for this project will be used during the course of CRT treatment. The manual comprises an introduction to CRT for eating disorders, and a detailed nine-session structure incorporating cognitive and behavioral tasks in the following domains; (1) planning-impulsivity, (2) flexibility-rigidity and (3) central coherence-attention to details. A certain set of guiding questions will accompany each task with the aim of stimulating metacognition (i.e. thinking about thinking).
224196693|NCT03217422|OTHER|Placebo|Placebo control with conversion to active VAY736
224196694|NCT06551467|BEHAVIORAL|Online Ayurveda Program for Detox and Lifestyle|The program includes personalized herbal remedies, detoxification procedures, dietary guidelines, yoga exercises, and daily routine practices.
224196695|NCT03985982|DRUG|Botulinum Toxin A|Injection, 20 Units divided in five 0.1 mL i.m injections into the glabellar area
224196696|NCT03985982|DRUG|Placebo|injection, sodium chloride 0.9 % divided in five 0.1 mL i.m injections into the glabellar area
224196697|NCT03985982|DRUG|Botulinum Toxin A|Injection, 20 Units divided in five 0.1 mL i.m injections into the glabellar area in up to 3 treatment cycles
224196698|NCT03093480|BIOLOGICAL|rFVIIIFc|rFVIIIFc 200 IU/kg/day in ITI Period, 50 or 100 IU/kg (adjusted according to Investigator judgement) in tapering Period, and prophylactic regimen in Follow-Up period as powder for injection administered intravenously.
224196699|NCT06025565|DIAGNOSTIC_TEST|Pain Experience Measures|Patient reported outcomes measures, quantitative sensory testing, and physical examination measures.
224196700|NCT06537505|DRUG|Adebrelimab|Q3W,IV
224196701|NCT06537505|DRUG|Apatinib|QoD
224196702|NCT06537505|PROCEDURE|microwave ablation|microwave ablation
224196703|NCT03007615|OTHER|Intimate Lubricant Gel|
224196704|NCT03699995|OTHER|Confocal Microscopy|Undergo confocal microscopy
224196705|NCT03699995|OTHER|Dermoscopy|Undergo digital dermoscopy
224196706|NCT03699995|PROCEDURE|Imaging Procedure|Undergo MoleMapper/Sklip app/native smartphone camera app imaging with smartphone
224196707|NCT03699995|DRUG|Lidocaine|Given SC
224196708|NCT03699995|PROCEDURE|Punch Biopsy|Undergo punch biopsy
224196709|NCT03699995|PROCEDURE|Shave Biopsy|Undergo shave biopsy
224196710|NCT05165277|DRUG|Phosphate Buffer Solution|Phosphate-buffered saline (abbreviated PBS) is a buffer solution commonly used in biological research. It is a water-based salt solution containing disodium hydrogen phosphate, sodium dihydrogen phosphate. The buffer helps to maintain a constant pH. The osmolarity and ion concentrations of the solutions match those of the human body (isotonic).
223594491|NCT04708002|OTHER|early integrated palliative approach model|From the construction of a common vision of palliative care between actors inside and outside the nursing home to the sustainability of palliative care in nursing home.
223594492|NCT05367128|OTHER|Dual task training|All participants will receive cognitive dual task training for 30 min/session, 2-3 sessions/week for 4-6 weeks (a total of 12 sessions). The cognitive dual task training includes 15 min of cognitive task combining with standing task and 15 min of cognitive task combining with walking task. The differences among group are the instructions of task prioritization given by the therapist
224196711|NCT05713916|OTHER|Intervention: Population Health Coordinator|After being notified of the finding of LVH in their patient, the population health coordinator will offer to schedule a dedicated visit for the provider and their patient to discuss this finding through a structured correspondence. Additionally, the population health coordinator will offer to coordinate 24-hour ambulatory blood pressure monitoring before or after the patient visit as part of the evaluation of LVH. Finally, for patients without established cardiovascular care and whose etiology of LVH remains undetermined, the population health coordinator will offer to coordinate a visit with a cardiologist to discuss the finding of LVH.
224196712|NCT06402435|DRUG|Lvonescimab (AK112)|"8Gy×3 SBRT (continuous irradiation) to irradiate the primary lesion (for patients with axillary lymph node metastasis) or 6Gy×3 SBRT (continuous irradiation) to irradiate the primary lesion and axillary lymph node metastasis (for patients without axillary lymph node metastasis) will be administered at first.~Then the first cycle of chemotherapy + AK112 will be given within 24 hours after the end of SBRT.~The total eight cycles of preoperative chemotherapy combined with immunotherapy will be administered.~Surgical resection will be performed within 4-6 weeks after the completion of the eighth cycle.~The chemotherapy regimen consists of: Four cycles of doxorubicin 50 mg/m² (Q3W) + cyclophosphamide 600 mg/m² (Q3W), followed by Four cycles of albumin-bound paclitaxel 125 mg/m², Day 1 and Day 8 (every 28 days).~The immunotherapy drug used is Ivonescimab (AK112) (20mg/kg) , administered every 3 weeks concurrently with chemotherapy for 8 cycles."
224196713|NCT01727804|OTHER|Laser in caries prevention|
224196714|NCT06594588|BEHAVIORAL|Aerobic exercise|Moderate-intensity aerobic exercise for 30-50 minutes three times a week was added to usual medical therapy
224196715|NCT04199312|DEVICE|Magnetic Muscle Stimulation (MMS) device|The MMS device will be used to perform the treatments.
224310741|NCT06649240|DRUG|Statins and/or Ezetimibe|Statin ± Ezetimibe to achieve target LDL-cholesterol level
224310742|NCT06649240|DRUG|PCSK9 inhibitor|The use of PCSK9 inhibitors is permitted to achieve target LDL-cholesterol levels in participants who did not reach the target with statins ± ezetimibe.
223505611|NCT03808467|OTHER|Treatment as usual|According to Norwegian guidelines established by the Norwegian Directorate of Health, the patients are likely to receive treatment focusing directly on the ED symptomatology, i.e normalization of weight in the case of underweight, reduction of binging and purging and normalization of other ED related thoughts and behaviors. Since both in-patients, patients in day treatment and out-patients will be included in the study, the number of hours with therapeutic interventions will vary. Records of the participants' received number of therapeutic hours will be logged weekly during the intervention for participants in both arms of the study.
223594493|NCT02492282|DEVICE|Closed-Loop propofol and remifentanil system by Bispectral Index|
223594494|NCT02492282|DEVICE|Open-Loop propofol and remifentanil by Target Controlled Infusion|
223594495|NCT02492282|DRUG|propofol|
223594496|NCT03050320|OTHER|Exercise|A biomechanical exercise program shown to decrease joint loading will be administered 3 times a week for 12 weeks. Outcomes included mobility performance; pain; strength; cardiovascular fitness; and resilience.
223594497|NCT03050320|OTHER|No Exercise|A no exercise (control) group will be asked to maintain their existing activity level for 12 weeks. Outcomes included mobility performance; pain; strength; cardiovascular fitness; and resilience.
224196716|NCT06575062|PROCEDURE|Direct Pulp Capping with ProRoot MTA|In this intervention, following the removal of carious dentin, the pulp tissue is directly exposed. ProRoot MTA is carefully applied over the exposed pulp to create a protective barrier. The material is mixed according to the manufacturer's instructions and placed directly onto the pulp exposure site. A light pressure is applied to ensure a good adaptation of the material. MTA was covered with resin-modified glass ionomer cement. Restoration was completed using composite resin.
224196717|NCT06575062|PROCEDURE|Pulpotomy with ProRoot MTA|In this procedure, after the removal of the coronal pulp tissue, ProRoot MTA is applied over the exposed root canal orifices. The MTA is mixed according to the manufacturer's instructions and placed in the pulp chamber to cover the root canal entrances. The material is carefully adapted to create a seal that prevents bacterial contamination and promotes tissue healing. MTA was covered with resin-modified glass ionomer cement. Restoration was completed using composite resin.
223594498|NCT02119390|BEHAVIORAL|Staff-delivered intervention sessions|In addition to standard clinical care, participants in the Pill Trial+ arm will receive staff-delivered intervention sessions individualized for each participant at HAART initiation, 1-month, and 3-month follow-up. Two booster sessions will also be provided at two weeks following intervention session 1 (in clinic) and intervention session 2 (by phone) to assess any difficulties using the created adherence plans.
223594499|NCT02119390|OTHER|Demographic Questionnaire|Participants will complete a questionnaire developed for the purposes of the current study assessing basic background information.
223594500|NCT02119390|OTHER|Questionnaires|Self-reported adherence, health-related quality of life and other questionnaire measures will be administered using a password protected laptop the same day as participants' regularly scheduled outpatient clinic appointments.
223594501|NCT01020253|DRUG|alendronate, alfacalcidol|Alendronate: 5mg per day, Tablet, Duration is 48 weeks. Alfacalcidol: 1μg per day, Tablet, Duration is 48 weeks.
223594502|NCT05873491|OTHER|Music therapy|The music therapy sessions will offer sensory workshops of immersive musical listening, digital and acoustic music creation and shared improvised music.
223594503|NCT04904848|OTHER|Survey evaluation|examine the convergent validity and reliability of a Turkish version
223747251|NCT05828108|DRUG|Bitopertin|Dose Escalation: Monthly (every 4 weeks) up to a maximum dose of 60 mg bitopertin (5 mg, 10mg, 20mg, 40mg, 60mg). At each monthly (4 week) interval, a complete blood count (CBC) with differential and a reticulocyte analysis (including reticulocyte hemoglobin) will be collected prior to taking the higher dose. If the absolute reticulocyte count (ARC) is 60,000 /microL or higher, the subject will hold at the current dose level (or return to that level if escalation has already occurred) for an additional 4 weeks. If, after 8 weeks at that dose, response criteria are met this will be considered the minimum effective dose (MED) and shall be the treatment dose throughout the remainder of the study unless modifications are indicated.
223594504|NCT04356040|DEVICE|TactiFlex SE|Radiofrequency ablation with the TactiFlex SE ablation catheter. The procedure should be performed according to the TactiFlex SE investigational Instructions for Use document using the recommended ablation parameters as noted in the document.
223594505|NCT04356040|DEVICE|TactiFlex SE - High Standard Power|Radiofrequency ablation with the TactiFlex SE ablation catheter. Subjects in the High Standard Power Substudy are to undergo the same study procedures as subjects in the main study, except that ablation power settings of 40-50 Watts are to be used in the left atrium, unless there is a medical reason to use a lower power.
223594506|NCT00255775|DIETARY_SUPPLEMENT|broccoli sprout extract|
223747252|NCT06783881|DRUG|Kylo-12|Administered SC.
223747253|NCT06783881|DRUG|Placebo|Administered SC.
224196718|NCT04099368|BEHAVIORAL|Musical pitch training|Crossover design with one group receiving musical training as rehabilitation, second group receiving visual training first as a control rehabilitation.
224196719|NCT03066011|DRUG|Isavuconazonium sulfate|Oral and Intravenous
223505612|NCT01253356|DEVICE|IABP|Insertion of intra-aortic balloon \< or = 3 hours before noncardiac surgery and maintained \> or = 12-24 hours after surgery
223505613|NCT03785847|DIAGNOSTIC_TEST|Ventica|Impedance pneumography measurement
223505614|NCT00480311|OTHER|WHODAS II (World Health Organization Disability Assessment Schedule II)|To determine the measurement characteristics of WHODAS II (World Health Organization Disability Assessment Schedule).
223594507|NCT00255775|PROCEDURE|complementary or alternative medicine procedure|
223594508|NCT04029103|OTHER|knowledge, behaviour, self efficacy|Knowledge, behavior and self-efficacy of both groups were measured before and after the study.
223594509|NCT03234491|DEVICE|DiAS|Diabetes Assistant (DiAS) hybrid closed loop system.
223594510|NCT03234491|DRUG|Afrezza low dose|Afrezza inhaled insulin low dose.
223594511|NCT03234491|DRUG|Afrezza high dose|Afrezza inhaled insulin high dose.
223594512|NCT00001967|DRUG|HAART|
223594513|NCT00967096|DRUG|Rifaximin|Rifaximin for Bone marrow transplant patients
223594514|NCT03042130|OTHER|Standard of care|standard of care
223594515|NCT03042130|DRUG|Iron Carboxymaltose|Two IV doses
223594516|NCT00877396|BIOLOGICAL|Influenza vaccination|Influenza vaccination- 0.5 mL. Children under 9 who have never received a influenza vaccine will receive a 2nd dose (0.5 mL) 4 weeks later.
223747254|NCT04293562|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic HSCT
223747255|NCT04293562|DRUG|Asparaginase Erwinia chrysanthemi|Given IM or IV
223747256|NCT04293562|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223747257|NCT04293562|PROCEDURE|Bone Marrow Aspiration|Undergo BM aspiration
224196720|NCT03066011|DRUG|Voriconazole|Oral and Intravenous
224196721|NCT03066011|DRUG|Posaconazole|Oral and intravenous
224310743|NCT06908876|BIOLOGICAL|IBI302|4 mg IBI302 will be administered by intravitreal injection into the study eye once every 4 weeks for 3 consecutive months, followed by Pro re nata (PRN) regimen.
224310744|NCT06908876|BIOLOGICAL|IBI302|8 mg IBI302 will be administered by intravitreal injection into the study eye once every 4 weeks for 3 consecutive months, followed by PRN regimen.
224310745|NCT06908876|DRUG|Faricimab|6 mg faricimab will be administered by intravitreal injection into the study eye once every 4 weeks for 4 consecutive months, followed by PRN regimen.
223747258|NCT04293562|PROCEDURE|Bone Marrow Biopsy|BM biopsy
224196722|NCT04516356|OTHER|Korean hand acupressure|According to the working principle of Korean hand acupressure; There are active points and areas in the hands and feet that fit the whole body. The active points on the hands and feet are properly matched to reflect the anatomy of the whole organism. Areas in the body and systems suitable for them are in constant contact. In the patient, the signal wave moves from the damaged point or area and reaches the appropriate point immediately. Thus, changes such as severe pain, skin discoloration, hardening, thickening and thinning in some parts of the skin occur at that point. With the stimulation of the effective point, a treatment wave occurs that heals the sick organ.
224196723|NCT00478933|DEVICE|Defibrillator, Dual Chamber ; Implantable|Patient must wear a dual chamber ICD to remain in study. Can be enrolled 10 days prior to implant. Is excluded if device type changes.
224196724|NCT00478933|PROCEDURE|Blood sampling|Blood sampling
224310746|NCT06830044|DRUG|Milsaperidone|Oral milsaperidone
224310747|NCT06830044|DRUG|Placebo|Oral placebo
223505615|NCT05675020|BEHAVIORAL|Zoom Intervention|"This educational program will be delivered via a 45-minute presentation via Zoom.~* The educational presentation will be recorded and emailed to participants within 1 week of intervention to re-watch/review.~* The educational program will promote a healthy lifestyle knowledge and behaviors through education evidenced by the CDC, WHO, and the American Academy of Pediatrics. Educational sessions will include the importance of healthy lifestyle modifications in the adolescent population with a mental health condition(s), lifestyle recommendations versus reality, nutrition, physical activity, screen time, and sleep recommendations and guidelines.~* We will compare the effects of an educational program on healthy lifestyle knowledge and behaviors pre-and post-program (after one month) via a REDCap survey for the adolescent and their parent/legal guardian."
223505616|NCT06496100|DRUG|Triticum Aestivum|The intervention period will be 120 days, looking for effects on appetite regulation and the hormonal axis Leptin, Ghrelin and Adiponectin.
223505617|NCT06496100|DRUG|Placebo (calcined magnesia)|The intervention period will be 120 days, looking for effects on appetite regulation and the hormonal axis Leptin, Ghrelin and Adiponectin.
223505618|NCT04165486|DRUG|ION464|ION464 will be administered by IT injection.
223505619|NCT04165486|DRUG|Placebo|ION464-matching placebo will be administered by IT injection.
223505620|NCT06957366|OTHER|PAUSE Perioperative DOAC Management|PAUSE management is simple and easy to apply as patients having a high-bleed-risk surgery/neuraxial procedure interrupt DOACs for 2 days before and 2 days after surgery without heparin bridging or DOAC level testing.
223505621|NCT06957366|OTHER|ASRA Perioperative DOAC Management|ASRA management is more complex, requiring 72-120 hours DOAC interruption and, in selected patients, pre-operative heparin bridging and DOAC level testing.
223505622|NCT05265637|DEVICE|Visian|Visian implantable collamer lens (ICL)
223505623|NCT06964048|DEVICE|Cold Atmospheric Plasma treatment|Participants in the intervention group will be treated with cold plasma therapy with Plasana One®, as an add-on to the standard of care.
223505624|NCT06964542|PROCEDURE|Multicomponent exercise intervention|Patient will be under the complete supervision of physical therapist in a clinical setup.A total of 18 sessions of supervised multicomponent exercise training, thrice a week on alternate days for 6 consecutive weeks, session will be of 45 mins. Multicomponent exercise training including strength and progressive resistance training exercises, actvities will inc. Seated Marching,heel raises,toe raises, sit - to-stand. And balance training activities will involve tandem stands,single leg stance,weight shifting and resistance activities including weight lifting according to feasibility.
223505625|NCT06964542|PROCEDURE|Non Supervised|In non supervised group , patient will receive all the intervention with the help of exercise diary and guidance provided by the physical therapist. Patient will perform 18 sessions, thrice a week on alternative days, for 6 consecutive days for 45 mins. In diary patient is provided the tick mark table in which patient will mark the attendance on days ptn will perform the exercise. Diary is a complete guidance for home based exercise program which include QR based videos of performance of all exercises and complete guidelines are provided in urdu for the better understanding along with pictorial information. In this program activities that patient will perform includes; stairs climbing, sit to stand, leg raises, side stepping, leg raises with weight on ankles starting from 1kg to 3kg. Walk starting from 20 minutes to 40 minutes till 6 weeks. Resistance and other activities will be included.
223505626|NCT06963333|BEHAVIORAL|Breathing guided exercise|Breathing guided exercise are divided into six sections: relaxing standing, two fields breathing, regulating lung and kidney, turning side finger, running kidney hall and nourishing qi and collecting gong. Exercise time: 5 days a week, 1 to 2 times a day, a total of 24 weeks.
223594517|NCT00877396|BIOLOGICAL|Hepatitis A Vaccine|Hepatitis vaccination- 0.5 mL. Children under 9 who have never received a influenza vaccine will receive a 2nd dose ( saline- 0.5 mL) 4 weeks later.
223594518|NCT02349750|PROCEDURE|endometrial scratch injury|ESI using No.8 neonatal feeding tube
223594519|NCT02929082|RADIATION|IRM with a 5-minute- additional sequence to measure FRM|IRM with a 5-minute- additional sequence to measure FRM for patients in group 1,2 and 3
223594520|NCT01700010|DRUG|Lapatinib and Paclitaxel|"Lapatinib comes in tablet form and is taken by mouth at a dose of 1,000 mg every day. Paclitaxel will be given through the vein (IV) at a dose of 80 mg/m2 on days 1, 8, and 15 at each 28 day cycle. If cancer does not progress and study treatment can be tolerated after 6 cycles of paclitaxel and lapatinib, paclitaxel will be stopped and lapatinib will continue until disease progression, side effects cannot be tolerated, participant is removed from or withdraws from study, or for other reasons.~Subjects with locally advanced disease who respond to treatment and are felt to be appropriate for local therapy may proceed to receive local therapy as deemed appropriate by the managing physician after a minimum of 6 cycles or upon achieving complete remission followed by an additional 2 cycles. Subjects who proceed to receive local therapy will be removed from protocol therapy. Subjects who elect not to receive or are not candidates for local therapy may continue treatment on protocol."
223594521|NCT03778463|OTHER|Synovectomy|Removal of the synovium during total knee arthroplasty
223594522|NCT03052023|PROCEDURE|dual approach laparoscopic inguinal hernioplasty|after pneumoperitoneum is done preperitoneal pneumo-dissection is done and then peritoneal incision done . dissection preperitoneally and sac dissection will be easy approached
223594523|NCT03052023|PROCEDURE|TAPP|pneumoperitoneum is done and then through abdominal approach peritoneal dissection in done and sac reduction and then mesh fixation
223594524|NCT03052023|PROCEDURE|(lichtenstein) repair|inguinal incision is done and inguinal canal approach anteriorly and then sac dissection and excision then mesh fixation to posterior wall and closure the incision in layers
223594525|NCT01868386|RADIATION|Hypofractionated therapy|Shorter courses of increasing doses of radiation therapy will be assessed in each subsequent arm
223594526|NCT01821482|BIOLOGICAL|Dendritic and Cytokine-induced Killer Cells|
223594527|NCT00788710|DRUG|etoricoxib (MK0663) 120 mg|120 mg of etoricoxib (MK0663) for a total of 5 days
223594528|NCT00788710|DRUG|Comparator: Placebo|Placebo tablets once daily on Days 1-5. Total treatment is 5 days.
223594529|NCT00788710|DRUG|etoricoxib (MK0663) 90 mg|90 mg of etoricoxib (MK0663) for a total of 5 days
223594530|NCT04394650|BIOLOGICAL|CC-98633|"Subjects will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) to produce CC-98633.~During CC-98633 production, subjects may receive bridging chemotherapy for disease control. Upon successful generation of CC-98633 product, subjects will receive treatment with CC-98633 therapy.~Study treatment will include lymphodepleting chemotherapy followed by one dose of CC-98633 administered by intravenous (IV) injection."
223594531|NCT03100773|OTHER|Oral health educational strategy|Oral health educational strategy consisted of four consecutive sessions (once a week) about etiological factors of caries (using visual aids), oral hygiene instructions (using models), supervised toothbrushing and explanation of atraumatic restorative treatment (indications and stages).
223594532|NCT03100773|PROCEDURE|Atraumatic Restorative Treatment|Atraumatic Restorative Treatment was performed using hand instruments for opening and cleaning the cavities and a high-viscosity glass-ionomer for restoration.
223594533|NCT04879173|DEVICE|RS85 Ultrasound device|RS85 Ultrasound device manufactured by Samsung Medison
223594534|NCT01978626|BEHAVIORAL|App modules|
223594535|NCT01978626|BEHAVIORAL|Traditional CBT-I|
223594536|NCT04995861|PROCEDURE|Adductor canal block and IPACK block|Peripheral nerve blocks
223594537|NCT05974813|DIETARY_SUPPLEMENT|L-Citrulline|6 g (3 g every 12 h) of L-citrulline for six days
223594538|NCT05974813|DIETARY_SUPPLEMENT|Placebo|6 g (3 g every 12 h) of maltodextrin for six days
223594539|NCT02689167|DRUG|Sunitinib|
223747259|NCT04293562|PROCEDURE|Computed Tomography|Undergo CT
223747260|NCT04293562|DRUG|Cytarabine|Given IV or IT
223747261|NCT04293562|DRUG|Daunorubicin Hydrochloride|Given IV
223747262|NCT04293562|DRUG|Dexrazoxane Hydrochloride|Given IV
223747263|NCT04293562|DRUG|Etoposide|Given IV
224196725|NCT04440137|BEHAVIORAL|Bottle-feeding cessation program|Specific brochure and proper oral hygiene education emphasizing on the benefit of stopping bottle-feeding given to subject
224196726|NCT00384072|DRUG|bazedoxifene BZA-20|
224196727|NCT02444676|OTHER|Stratification and outcomes|No necessary
223594540|NCT03517462|DRUG|Ivermectin 3Mg Tab|ivermectin tablet
223594541|NCT04672915|DIAGNOSTIC_TEST|test of HBV DNA|Real time PCR or nested PCR to check
223594542|NCT01990859|BIOLOGICAL|Ipilimumab|
223594543|NCT02924012|OTHER|video game active|The session lasted 40 minutes. The participants held an active video game session. At the end they were monitored for 60 minutes at rest.
223594544|NCT02924012|OTHER|sedentary video game|The session lasted 40 minutes. The participants held an sedentary video game session, using the traditional joystick. At the end they were monitored for 60 minutes at rest.
223594545|NCT02924012|OTHER|walking|The session lasted 40 minutes. The participants held a walk using the treadmill. At the end they were monitored for 60 minutes at rest.
223747264|NCT04293562|OTHER|Fludeoxyglucose F-18|Undergo FDG-PET
223747265|NCT04293562|DRUG|Gemtuzumab Ozogamicin|Given IV
223747266|NCT04293562|DRUG|Gilteritinib Fumarate|Given PO/NG/G-tube
223747267|NCT04293562|DRUG|Liposome-encapsulated Daunorubicin-Cytarabine|Given IV
223747268|NCT04293562|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223594546|NCT00102427|BEHAVIORAL|Telephone-based collaborative care management|
223594547|NCT01717326|DRUG|Grazoprevir|100 mg tablet orally QD
223594548|NCT01717326|DRUG|Elbasvir|Part A: 20 or 50 mg capsule orally QD Parts B, C, and D: 50 mg capsule orally QD
223594549|NCT01717326|DRUG|Placebo to Elbasvir|Placebo to Elbasvir 20 or 50 mg capsule, orally, once daily for 12 weeks to maintain blind (Part A only)
223594550|NCT01717326|DRUG|Ribavirin|Oral capsules BID at a total daily dose from 800 to 1400 mg based on participant weight
223594551|NCT00771056|DRUG|Hydroxychloroquine|400mg by mouth daily x 1 year
223594552|NCT00459654|DRUG|Radium-223 dichloride (BAY88-8223)|Four Radium-223 injections were given at 4-weekly intervals starting after the first fraction of EBR.
223594553|NCT00459654|DRUG|Saline|Four Saline injections were given at 4-weekly intervals starting after the first fraction of EBR.
223594554|NCT02262754|DRUG|PF-06372865|Dose level 1 daily dosing BID for 1 week followed by dose level 2 daily BID for 3 weeks
223594555|NCT02262754|DRUG|Placebo|Placebo for PF-06372865 and placebo for naproxen daily
223594556|NCT02262754|DRUG|Naproxen|500 mg BID for 4 weeks
223594557|NCT03409250|DRUG|Ranibizumab, Lucentis|Intravitreal injection with Lucentis (Ranibizumab)
223747269|NCT04293562|DRUG|Methotrexate|Given IT
223747270|NCT04293562|DRUG|Mitoxantrone Hydrochloride|Given IV
223747271|NCT04293562|PROCEDURE|Positron Emission Tomography|Undergo FDG-PET
223747272|NCT04293562|OTHER|Questionnaire Administration|Ancillary studies
223747273|NCT04293562|DRUG|Therapeutic Hydrocortisone|Given IT
223747274|NCT05373043|DIETARY_SUPPLEMENT|Mitoquinone|Mito-Q is a supplement that targets mitochondrial function. Linking a triphenyl-phosphonium cation to coenzyme-Q, to produce Mito-Q, results in a lipophilic compound, which, due to the large mitochondrial membrane potential, selectively accumulates within mitochondria. This targeted antioxidant approach results in 50- to 100-fold more Mito-Q accumulation compared to non-targeted antioxidant delivery.
224196728|NCT03772574|DEVICE|Facemask preoxygenation|Standard facemask preoxygenation
224196729|NCT03772574|DEVICE|THRIVE preoxygenation|Preoxygenation using transnasal humidified rapid insufflation ventilatory exchange (THRIVE).
224196730|NCT01700894|BEHAVIORAL|Walking Program + Motivational Interviewing Calls|
224196731|NCT01700894|BEHAVIORAL|Walking Program + Automated Calls|
224196732|NCT01700894|BEHAVIORAL|Walking Program|
224196733|NCT03514160|BEHAVIORAL|Group exercise|Group exercise based on the American College of Sports Medicine guidelines.
224196734|NCT05796401|BEHAVIORAL|Cognitive training|"Cognitive reinforcement using digital applications (PSYCARE application) during 12 weeks~+/- virtual reality based cognitive remediation application : 24 sessions over 12 weeks (only for patients who have a higher cognitive deficits (TMTB score \>110s))"
224310748|NCT05940623|DEVICE|Standard care and home IOP telemonitoring with smart phone-based intervention|We expect that (1) GAT measurements over 30 months of follow-up for patients randomized to Management Paradigm I to be smaller compared with those randomized to Management Paradigm II; and that (2) the rates of RNFL/GCIPL thinning would be slower for those randomized to Management Paradigm I compared with those randomized to Management Paradigm II
224310749|NCT00278252|DRUG|etoposide|
224310750|NCT00278252|PROCEDURE|conventional surgery|
224310751|NCT06912152|BIOLOGICAL|MT027 CAR-T cells|"Prior to MT027 cell infusion, lymphodepleting chemotherapy with fludarabine and cyclophosphamide was administered.~Dose Group 1: 1×10⁷ cells per administration; Dose Group 1: 3×10⁷ cells per administration; Dose Group 1: 6×10⁷ cells per administration; Based on the data obtained, adjustments to the specific number of cells in the established dosage groups and/or the addition of dosage groups may be made after discussion between the collaborators and researchers. A dose reduction titration may also be conducted based on the completed dosage groups."
223505627|NCT06963333|BEHAVIORAL|Flat walking training|Flat walking training can be performed either outdoors or on flat indoor surfaces at a steady pace of 80 to 120 steps per minute for at least 30 minutes each session, raising the heart rate to the target range and maintaining it for over 10 minutes. This should be done 3 to 5 times a week, with 1 to 2 sessions each day, for a total of 24 weeks. The intensity of the exercise is moderate. The target heart rate based on heart rate reserve is calculated as (maximum heart rate during exercise - resting heart rate) × (40-60)% + resting heart rate.
223505628|NCT06160440|DRUG|SC1011|Each subject in the SAD groups participated in 1 treatment period only and reside at the clinical research unit (CRU) from Day -1 (the day before dosing) to Day 7 (144 hours post dose).
223747275|NCT05373043|DIETARY_SUPPLEMENT|Placebo|A placebo will be used in combination with exercise rehabilitation allowing for a double blinded placebo controlled design.
223594558|NCT05407350|DIAGNOSTIC_TEST|Ultrasound, Colonoscopy, MRE|After the initiation of an established treatment of known efficacy for CD (biologic agents including infliximab, adalimumab, ustekinumab or vedolizumab either with or without corticosteroids), repeat IC and MRE will occur at Week 30 (± 6 weeks) (6-9 months); the IUS, IC, and MRE examinations will occur within a 4-week window and with no intervening change in medical therapy. All imaging data will be captured electronically (IUS and MRE with Digital Imaging and Communications in Medicine \[DICOM\] images, and IC with video recordings) for central, blinded reading. Two biopsies will be collected from each segment of the bowel (rectum, sigmoid, descending, transverse, ascending and terminal ileum) during IC, fixed in formalin collection containers, and shipped for histopathology processing and evaluation.
223594559|NCT02693379|DEVICE|D-VIA|"D-VIA images were captured during the cervical examination with a smartphone. Biopsies and cytological samples were taken on all patients and analyzed for gold standard results. Images were shown to off site experts. D-VIA and VIA diagnoses were then compared.~Women who were diagnosed on-site as pathological underwent appropriate treatment at the same consultation. Women who were diagnosed as pathological later by histopathological analyses were asked to return to the clinic for treatment."
223747276|NCT05489705|DRUG|Mavacamten|As per product label
223505629|NCT05299632|DIAGNOSTIC_TEST|99mTc-MIBI planar imaging and SPECT/CT.|Participants will undergo a Tc-MIBI scan and management will be as per the finding of the Tc MIBI scan which is the standard of care.
223747277|NCT05489705|DRUG|Non-mavacamten symptomatic oHCM therapy|Including Beta-blocker (BB), non-dihydropyridine (non-DHP) calcium channel blocker (CCB) and/or disopyramide as per product label
223747278|NCT01536379|DRUG|Belimumab|Belimumab (10 mg/kg) will be given as an intravenous solution over a 1 hour time period administered every 4 weeks for 24 weeks (with an additional dose at Week 2)
223747279|NCT01536379|DRUG|Placebo|Placebo will be given as an intravenous solution over a 1 hour time period administered every 4 weeks for 24 weeks (with an additional dose at Week 2)
224196735|NCT05796401|DRUG|Personalized neuroprotective strategies : Vitamin B12, folinic acid, Omega 3, NAC|"Personalised neuroprotective medication adapted to the individual's biological profile :~* Vitamin B12 : 500 micrograms per day~* Folinic acid : 50 mg per day~* Omega 3 : 1380 mg EicosaPentaenoic Acid (EPA) + 1140 mg DocosaHexaenoic Acid (DHA) per day~* N-acetyl-cysteine (NAC) : 2400 mg per day~duration of supplementation(s) : 12 weeks"
224196736|NCT05796401|OTHER|Treatment as usual (TAU)|Treatment as usual (TAU), including a standardised psycho-education program with a group cognitive behavioural therapy (e.g. I\_Care - You Care) and, in FEP only, second generation antipsychotic from a restricted list (following the recommendations www.orygen.org.au)
224196737|NCT01432743|PROCEDURE|NavX Fusion|Using NavX Fusion to guide catheter ablation
223505630|NCT05299632|DIAGNOSTIC_TEST|F- 18PSMA PET/CT imaging study|F-18 PSMA is an FDA-approved imaging agent used for PET/CT for evaluating metastatic prostate cancer. The findings of the images of F-18 PSMA will be shared with the referring /treating surgeon. However, the findings will not influence the management.
223747280|NCT01538693|DRUG|escitalopram oxalate|10 mg 4.5 hours prior to testing
223747281|NCT01538693|DRUG|Cyproheptadine|8mg 4.5 hours prior to testing
224196738|NCT01432743|PROCEDURE|Cartomerge|Guidance of catheter ablation using Cartomerge guidance
224196739|NCT00617175|DEVICE|Implantable Defibrillator|Number of 30 out of 40 intervals to detect (NID)Fast Ventricular Tachycardia
224196740|NCT00617175|DEVICE|Implantable Defibrillator|number of 18 out of 24 intervals to detect (NID)Fast Ventricular Tachycardia
224196741|NCT02203305|DEVICE|Cochlear Implant|cochlear implantation used a treatment for single-sided deafness and/or asymmetric hearing loss
224196742|NCT02203305|OTHER|Control Group|Subjects in the control group will have had listening experience with a bone-conduction device, which is an approved treatment for SSD.
224196743|NCT03378531|DRUG|AEB1102|modified human arginase I
223747282|NCT01538693|DRUG|sugar pill|4.5 hour prior to testing
223747283|NCT01538693|OTHER|Graded intensity exercise|modified bruce protocol for peak oxygen consumption testing
223747284|NCT05948930|BEHAVIORAL|Progressive aerobic exercise|Progressive aerobic exercise
223747285|NCT05948930|BEHAVIORAL|Adaptive cognitive training|Adaptive cognitive training
223747286|NCT05948930|BEHAVIORAL|Combined|Combine adaptive cognitive and progressive aerobic exercise training
223747287|NCT04916600|DEVICE|NET|NET is an investigational device that received CE-Mark in April 2009 as a Class IIa active medical device
223747288|NCT04159597|DRUG|Upadacitinib|Upadacitinib will be administered as oral solution.
223747289|NCT04304339|OTHER|Hypercapnic respiratory failure|Patients with hypercapnic respiratory failure will be followed without any additional intervention
224196744|NCT00002634|BIOLOGICAL|filgrastim|
224196745|NCT00002634|BIOLOGICAL|monoclonal antibody 3F8|
224196746|NCT00002634|DRUG|cisplatin|
224196747|NCT00002634|DRUG|cyclophosphamide|
224196748|NCT00002634|DRUG|doxorubicin hydrochloride|
224196749|NCT00002634|DRUG|etoposide|
224196750|NCT00002634|DRUG|mesna|
223747290|NCT03759561|PROCEDURE|intubation with videolaryngoscope vs fiberoptic bronchoscope|Tracheal intubation was performed using either videolaryngoscope or fiberoptic bronchoscope under cervical collar application according to the group allocations
224196751|NCT00002634|DRUG|perfosfamide|
224196752|NCT00002634|DRUG|vincristine sulfate|
224196753|NCT00002634|PROCEDURE|autologous bone marrow transplantation|
224196754|NCT00002634|PROCEDURE|in vitro-treated bone marrow transplantation|
224196755|NCT00002634|RADIATION|low-LET cobalt-60 gamma ray therapy|
224196756|NCT00002634|RADIATION|low-LET photon therapy|
224196757|NCT00002634|RADIATION|radioisotope therapy|
224196758|NCT06540352|DRUG|4-Nitro-N-[(1RS)-1-(4-fluorophenyl)-2-(1-ethylpiperidin-4-yl)ethyl]benzamide hydrochloride|The drug Refralon® (n-1-\[(4-fluorophenyl)-2-(1-ethyl-4-piperidyl)-ethyl\]-4-nitrobenzamide hydrochloride) in the dosage form of a concentrate for the preparation of a solution for intravenous administration is registered for medical use in RF June 24, 2014, re-registration was successfully completed on November 20, 2019, registration certificate LP 002510, until December 31, 2025.
223505631|NCT05792722|PROCEDURE|Prostate capsule-sparing radical cystectomy|Patients randomized to this arm will receive the prostate capsule-sparing surgery performed in the form of standard simple prostatectomy. Patients will also have a cystectomy with one of the following urinary diversions: ileal conduit, Indiana Pouch, or orthotopic neobladder.
223747291|NCT01527552|DRUG|biphasic insulin aspart 50|A single dose of each formulation administered subcutaneously (s.c., under the skin) on 2 dosing visits separated by a wash-out period of 6-12 days
223747292|NCT06117774|DRUG|Tarlatamab|Intravenous (IV) infusion
223747293|NCT06117774|DRUG|Placebo|IV infusion
223747294|NCT05581056|DRUG|CFTR modulators|Introduction of CFTR modulators by pneumologists for pneumologic issues
223747295|NCT04320264|PROCEDURE|Weight loss surgery|Severely obese women (BMI \>40) undergo sleeve gastrectomy
223747296|NCT06063603|PROCEDURE|Acupuncture Therapy|Undergo acupuncture therapy
223747297|NCT06063603|BEHAVIORAL|Cancer Pain Management|Receive pain clinic referral
223747298|NCT06063603|BEHAVIORAL|Cognitive Behavior Therapy|Undergo CBT
223747299|NCT06063603|PROCEDURE|Discussion|Participate in focus group
223747300|NCT06063603|OTHER|Educational Intervention|Receive self-guided pain management education materials
223747301|NCT06063603|OTHER|Exercise|Participate in exercise
223747302|NCT06063603|OTHER|Interview|Complete interview
223747303|NCT06063603|PROCEDURE|Massage Therapy|Receive massage
223747304|NCT06063603|BEHAVIORAL|Mindfulness Relaxation|Practice mindfulness
223747305|NCT06063603|PROCEDURE|Pain Therapy|Receive pain treatment/medicine
223747306|NCT06063603|OTHER|Palliative Therapy|Receive palliative care referral
223747307|NCT06063603|BEHAVIORAL|Patient Navigation|Undergo visits with PCM and CHW for pain management
223747308|NCT06063603|OTHER|Referral|Receive pain management referrals
223747309|NCT06063603|PROCEDURE|Spiritual Therapy|Receive spiritual support
223747310|NCT06063603|PROCEDURE|Spiritual Care Referral|Receive spiritual care referral
223747311|NCT06063603|OTHER|Survey Administration|Ancillary studies
224196759|NCT06540352|DRUG|Mannitol|Placebo in tablets
224196760|NCT02050646|OTHER|Low Salt Diet|On Day 0, patients will be randomized to one of the two crossover liberal/low or low/liberal salt diet groups. Each subject will complete two controlled dietary phases: 10-days of low salt diet, a washout period of 3-days, and 10-days of liberal salt diet.
224196761|NCT02050646|OTHER|Liberal salt diet|On Day 0, patients will be randomized to one of the two crossover liberal/low or low/liberal salt diet groups. Each subject will complete two controlled dietary phases: 10-days of low salt diet, a washout period of 3-days, and 10-days of liberal salt diet.
224196762|NCT01403636|DRUG|SAR245409|Pharmaceutical form:capsule Route of administration: oral
224196763|NCT00261352|DRUG|Tesaglitazar|
224196764|NCT00261352|DRUG|Metformin|
224196765|NCT00261352|DRUG|Fenofibrate|
224196766|NCT01821131|OTHER|muffin|
224196767|NCT03586427|DRUG|AGN-241751|AGN-241751 administered orally as a single tablet
224196768|NCT03586427|DRUG|Placebo|Placebo administered orally as a single tablet
224196769|NCT05016570|BEHAVIORAL|Picture narrative information format|Lung screening information formatted as picture narratives
224196770|NCT05016570|BEHAVIORAL|Text with pictures information format|Lung screening information formatted as text and non-narrative pictures
224196771|NCT05016570|BEHAVIORAL|Text-only information format|Lung screening information formatted as text with no pictures
224196772|NCT00544570|BIOLOGICAL|filgrastim|
224196773|NCT00544570|DRUG|carmustine|
224196774|NCT00544570|DRUG|cyclophosphamide|
224196775|NCT00544570|DRUG|etoposide|
224196776|NCT00544570|DRUG|melphalan|
224196777|NCT00544570|PROCEDURE|autologous hematopoietic stem cell transplantation|
224196778|NCT00544570|PROCEDURE|peripheral blood stem cell transplantation|
224196779|NCT00544570|RADIATION|radiation therapy|
224196780|NCT00544570|RADIATION|total-body irradiation|
223594560|NCT05623358|OTHER|Pharmacist-led HFrEF medication optimization|In addition to usual care, participants randomized to the intervention arm will receive co-management of medications by a clinical pharmacist with advanced training and expanded scope of practice, with the aim of achieving optimal medical therapy (OMT) for HFrEF as outlined by the 2021 Canadian Cardiovascular Society (CCS) HF guidelines. This will consist of, where possible, the combination of an angiotensin receptor-neprilysin inhibitor (ARNI), evidence-based beta-blocker, mineralocorticoid receptor antagonist (MRA), and sodium-glucose cotransporter 2 inhibitor (SGLT2i) at target doses, along with personalized therapies as outlined in the 2021 CCS HF guidelines, unless the patient is unable to tolerate these agents/doses.
223594561|NCT05623358|OTHER|Usual care|Both the intervention group and comparator group will receive usual care by the multidisciplinary HF clinic, including standard-of-care clinical pharmacy services. The standard pathway in the HF clinic consists of an initial consultation with the multidisciplinary team (cardiologist, physician trainees, registered nurse and clinical pharmacist), follow-up visits approximately every 3 months with the nurse and cardiologist until discharge, along with telehealth nurse calls for medication titrations.
223594562|NCT01935414|DEVICE|geko™ post-surgery for 48hrs then 4hrs/day until discharge.|
223594563|NCT01935414|DEVICE|TEDS post-surgery for 48hrs then 4hrs/day until discharge.|
223594564|NCT01338584|BEHAVIORAL|Pelvic floor muscle training 3 weeks before radical prostatectomy|Participants in the intervention group need to attend the nurse-led clinic 6 times for practising pelvic floor muscle preoperatively instead of starting the exercise one day before surgery (usual management).
223594565|NCT01338584|BEHAVIORAL|Intensive preoperative pelvic floor muscle training|Patient started to learn pelvic floor muscle 3 weeks before surgery
223594566|NCT04463667|OTHER|exercise|Collect all basic information including intrahepatic fat and fibrosis severity, and assign them to the exercise intervention group (n = 80) and the observation group (n = 20) after conditional screening.
223594567|NCT06141759|OTHER|Exercise|Cheneau brace and Schroth Best Practice exercise
223594568|NCT05409937|OTHER|Water-saturated Improved Hot Weather Combat Uniform|Water-saturated Improved Hot Weather Combat Uniform
223594569|NCT05409937|OTHER|Water-saturated Army Combat Uniform|Water-saturated Army Combat Uniform
223594570|NCT05409937|OTHER|Water-saturated Army Combat Uniform + Silk Weights|Water-saturated Army Combat Uniform + Silk Weights
223594571|NCT02746185|DRUG|rivaroxaban|rivaroxaban, 15 mg BD (Bis in die) for 3 weeks followed by 20mg OD (Omni die) for 9 weeks
223594572|NCT02746185|DRUG|Low-molecular-weight heparin|dalteparin, 200 IU/kg OD for 4 weeks followed by 150 IU/kg OD for 8 weeks
223594573|NCT00006400|DRUG|Hydroxyurea|Participants will receive hydroxyurea.
223594574|NCT00006400|DRUG|Placebo|Participants will receive placebo.
223594575|NCT02933502|DRUG|DSXS topical product|treatment daily for 28 days
223594576|NCT00446082|DRUG|Pasireotide|
224196781|NCT00401310|DRUG|Comparator: Placebo|Placebo IV infusions 1hr/daily over 7 days.
224196782|NCT00401310|DRUG|Comparator: MK0724|MK0724 8 mg/kg/hr 1 hr/daily over 7 days.
224196783|NCT04778319|OTHER|occlusion of tubes|to occlude the fallopian tubes
224310752|NCT06208189|BEHAVIORAL|High-effort session|Participants will perform 3 sets per exercise (total of 21 sets) with as many repetitions they can each set. We anticipate participants will perform \~10 repetitions per set in this session, with a total tempo of \~2.5 seconds per rep, averaging \~25 seconds per set. Resting period between exercises and sets will be 120 seconds. This will lead to a total session time of \~50 min. Their glycemic control will be evaluated during the following \~48 hours.
224310753|NCT06208189|BEHAVIORAL|Low-effort session|Participants will perform 6 sets per exercise (total of 42 sets) but perform half of the anticipated number of repetitions of the HIGH session (i.e., 5 reps). Repetition tempo at \~2.5 seconds will result in \~12.5 seconds per set. Resting period between exercises and sets will be 60 seconds. This prescription will also lead to a total session time of \~50 min. Thus, both the HIGH and LOW session will have similar total volume-load and session density, but differ in perceived effort after each set. Their glycemic control will be evaluated during the following \~48 hours.
223594577|NCT04607876|OTHER|Technological Facilitator|See Enhanced Intervention Arm for full description.
223594578|NCT04607876|OTHER|Standard of Care|Risk factor assessment in first degree relative subjects and implementation of an education program for the randomized participants and their primary care provider.
223594579|NCT04855019|PROCEDURE|shoulder periarticular injection, suprascapular and axillary nerve block|"In the PI group, a mixture of 30 ml bupivacaine 0.5% and 30 ml saline solution will be injected by the orthopedist after the wound is closed.~In the CSAB group, a total of 20 ml 0.5% bupivacaine, 10 ml to the suprascapular notch, 10 ml to the axillary nerve, will be administered preoperatively by the anesthesiologist under ultrasound guidance."
223594580|NCT01784718|DRUG|Buphenyl|
223594581|NCT00087854|DRUG|Amonafide L-malate (drug)|
223594582|NCT01201226|OTHER|Removal of half an ovary|Removal of half an ovary
223594583|NCT04365452|DEVICE|Invia Motion|Invia Motion NPWT system at cesarean delivery
223594584|NCT01577342|DRUG|Moxifloxacin 0.5%|1 drop 4 times daily times 3 days post ranibizumab intravitreal injection
223594585|NCT05391256|DEVICE|Automated flying Drone carrying an Automated external defibrillator (AED)|"Totally n=6 drones are equipped with automated external defibrillators (AEDs). These drones are deployed by the dispatch centre to cases of suspected out-of-hospital cardiac (OHCA) as a complement to standard care (ambulance/EMS) over up to 12 months Monday to Sunday 08:00-22:00. The bystander onsite receives instructions from the dispatcher to retrieve the AED outside the house when it has been delivered by the drone. The bystander attaches the AED to the patients chest to facilitate early defibrillation.~An interventional package directed to the dispatchers is distributed and consists of an e-learning program, an AED -trainer placed at the dispatch center. Within the dispatcher decision tool - there is information how to inform the caller to retrieve the AED. The HEMS-coordinator reminds the dispatcher during the call on operational information. Monthly information to staff of project progress is provided."
224196784|NCT04778319|OTHER|non occlusion of tubes|not to occlude the tubes
224196785|NCT00994045|BIOLOGICAL|Fibrinogen concentrate|Fibrinogen concentrate will be administered initially at 2 grammes per hour by continuous infusion. This rate will be adjusted in response to the clinical picture and results of point of care coagulation tests. The infusion will be used intra-operatively.
224196786|NCT00994045|BIOLOGICAL|Fresh Frozen Plasma|
223594586|NCT05049109|BEHAVIORAL|Integrated Telehealth After Stroke Care|"• 3 week and 8 week follow up visits with pharmacy through telehealth~Patients will provide home blood pressure monitoring kits at discharge for the first three months. The telemonitor that can send blood pressure readings, wirelessly or through telephone, to a secure server where study staff can look at the readings. Any blood pressure readings that are not within normal range will trigger an alert to be sent to study staff who will then follow up with the patient. A trained staff member will show the patient how to use the blood pressure monitor. Patients will be asked to take blood pressure at least 3 days per week and transmit the readings to study staff.~Patients will also be asked to wear an activity monitor starting at 4 weeks."
223594587|NCT05049109|BEHAVIORAL|Usual post-stroke follow-up care|"* 1-2 weeks follow up visit with primary care.~* 4-6 week and 12 week follow up visit with stroke practitioner~* At the end of the study, patients will be asked questions regarding their experience with the telehealth visits, health, medication taking and quality of life"
223594588|NCT04372459|BEHAVIORAL|Online integrated and stepped psychosocial care|"This program features four levels of care, increasing in intensity of psychosocial care as patients move from one level to the next one.~Step 1: Screening and monitoring of several psychosocial variables through the central mobile application of the program (App ICOnnecta't).~Step 2: Online guided and self-help psychoeducation Campus in which patients can consult videos and online resources, co-constructed between health professionals and patients, containing reliable and rigorous information related to the oncological process.~Step 3: Online community of psychosocial support. Participants can choose from 12 cancer-related discussion forums and share with the community any health-related question that worries them fostering, thus, debate and stimulating peer-support.~Step 4: Intensive online group psychotherapy (App ICOnnecta't Videoconsultation), based on the Group Positive Psychotherapy program for cancer survivors (Ochoa, Sumalla, Maté, Castejón, Rodríguez et al., 2010)."
223594589|NCT04372459|BEHAVIORAL|Usual psychosocial care|This active control group will receive the standard psychosocial treatment for cancer survivors in the participating centers, led by a clinical psychologist and consisting of 8 individual, 45/60-minute sessions, each of which every 1-2 months, focused on providing emotional support and psychoeducation during the first year of primary cancer treatment.
223594590|NCT04536207|OTHER|Cryotherapy (apparatus)|Cryotherapy is a pain treatment that uses a method of localized freezing temperatures to deaden an irritated nerve. Cryotherapy is also used as a method of treating localized areas of some cancers (called cryosurgery), such as prostate cancer and to treat abnormal skin cells by dermatologists
223594591|NCT00081211|BIOLOGICAL|PV701|Given intratumorally
223594592|NCT03697681|DRUG|Tranexamic acid|Intravenous infusion of Tranexamic acid(mixed with normal saline) at the dose of 10mg/kg(body weight) for 20 min after induction of anesthesia and then administration another 1mg/kg/hr(body weight) of Tranexamic acid(mixed with normal saline) until the end of the operation.
223594593|NCT03697681|DRUG|0.9% NaCl (normal saline)|The same amount of normal saline solution without the addition of tranexamic acid is administered in the same manner as the experimental group(Tranexamic acid intervention group).
223594594|NCT02372981|DEVICE|mucopexy +/- Doppler-guided haemorrhoidal artery ligation|Mucopexy with or without DG-HAL is performed using a specific device consisting of a proctoscope equipped with a Doppler probe and a light source. The proctoscope model in our study has a sliding part comprising the operating window and Doppler probe for better proximal and distal movement without repositioning the proctoscope during mucopexy.
223594595|NCT04785599|BEHAVIORAL|Exercices|An exercise program. Seven days after lymph node removal, participants began this program at the physiotherapy department. They attended two weekly sessions of 60 minutes each. The sessions at the centre continued for 12 weeks. The program consisted of aerobic exercise, in combination with resistance and stretching exercises.
223594596|NCT04785599|BEHAVIORAL|Informative talk|An informative talk: Patients attended a one-hour long talk about lymphedema. The topics covered were a description of the condition, the risks, and preventive measures to include in their daily life. The recommended measures were those from the general consensus of the International Lymphedema Society, the Spanish Rehabilitation Society and The National Breast and Ovarian Cancer Center
223594597|NCT04785599|DEVICE|Compression garment|"Wearing a flat knit compression garment (CG), class 1. Participants were recommended to wear this CG for an average of 8 hours during the daytime for the first 3 months after surgery, and to remove it at night.~From the fourth month onwards, use of the garment was reduced to 2 hours a day, coinciding with exercises and physical activity."
223594598|NCT06416254|OTHER|Fibre-enriched diet|The fibre-enriched diet contains fibre-enriched foods in which a portion of digestible carbohydrates are replaced with isolated dietary fibres. The fibre-enriched study foods are consumed as part of a full meal plan provided to participants.
223594599|NCT06416254|OTHER|Control diet|The control diet contains non-fibre-enriched study foods. The control study foods are consumed as part of a full meal plan provided to participants.
223594600|NCT00453804|DRUG|injectable naltrexone|
223594601|NCT00453804|DRUG|oral naltrexone|
223594602|NCT03479710|BIOLOGICAL|FMT infusion|Fecal microbiota transplantation via OGD
223594603|NCT03208088|DEVICE|etafilcon A Investigational Toric Multifocal Contact Lens|Test Lens 1
223594604|NCT03208088|DEVICE|etafilcon A Investigational Toric Multifocal Contact Lens|Test Lens 2
223594605|NCT03208088|DEVICE|etafilcon A Investigational Toric Multifocal Contact Lens|Tes Lens 3
223594606|NCT03208088|DEVICE|etafilcon A Investigational Toric Multifocal Contact Lens|Test Lens 4
223594607|NCT03208088|DEVICE|etafilcon A Investigational Toric Multifocal Contact Lens|Control Lens
224196787|NCT05568654|DIAGNOSTIC_TEST|Rapid Diagnostic Testing|Eligible patients in hospitals randomized to this arm will undergo testing for viral pathogens (from November-April) and pneumococcal UAT and procalcitonin testing. A CDSS-based alert will be generated in real time. If the patient is not being admitted to the intensive care unit, the form will append orders for viral pathogen, UAT and procalcitonin testing.
224310754|NCT06208189|BEHAVIORAL|Control|The control session all procedures will be identical to the HIGH session, with the exception of performing the resistance exercises. However, to simulate all other procedures participants will follow all instructions, be positioned on the equipment for the same amount of time as the HIGH session, but will not perform any repetition. Interval between fake sets and exercises will be 120 seconds. Their glycemic control will be evaluated during the following \~48 hours.
224310755|NCT06914102|DRUG|Semaglutide|New use of semaglutide dispensing claim is used as the exposure.
223594608|NCT05018104|OTHER|This is not an interventional study|This study utilizes data from the St. Paul's Hospital Peripheral Nerve Block Database.
223594609|NCT06099834|OTHER|Patients selection|Patient selection were selected according to selected criteria.
223594610|NCT06099834|OTHER|Implnat placement|dental implants were applied as recommended by the manufacturer.
223594611|NCT06099834|OTHER|Recall visits|Following the operations, the stability of the dental implants was measured at the 1st (T1), 4th (T4), and 12th (T12) weeks using Periotest (Periotest M, Modautal/Germany) and Osstell (Osstell AB-W\&H, Sweden) devices.
223594612|NCT04725487|OTHER|Standard integration program with social and health promoting intervention|"* Basic language course, internships, courses in Labour market knowledge and Danish culture~* Physical activity workshops~* Community gardening (garden workshops)~* Entrepreneurship course~* MindSpring course~* Family excursions~* Danish language workshops"
223594613|NCT04725487|OTHER|Standard integration program|Standard integration program (basic language course, internships, courses in Labour market knowledge and Danish culture)
223594614|NCT02403232|PROCEDURE|ASCs injection|"In the infiltration step, adrenalin in a saline solution is infiltrated using a 19-cm specially designed disposable blunt cannula.~The aspiration step is performed by a luer-lock syringe connected to a disposable 19-cm blunt cannula.~The harvested lipoaspirate can be progressively put into the device using multiple 10-cc syringes.~Subsequently, in lithotomy position, a seton will be removed and a fistula tract will be thoroughly curetted and irrigated. After a mucosal flap preparing round the internal opening, cells will be injected in the perianal adipose tissue."
223594615|NCT02403232|DEVICE|ASCs injection|In general anesthesia subcutaneous abdominal adipose tissue will be collected by LIPOGEMS system to prepare ASCS.
223594616|NCT02403232|DEVICE|Closure of fistula tract.|A SALVECOLL-E paste will be injected into the fistula tract.
223594617|NCT02956798|RADIATION|Stereotactic ablative body radiation (SABR)|SAbR treatment regimens including ≥25Gy x1 fraction, ≥12Gy x 3 fractions, or ≥8Gy x 5 fractions.
223594618|NCT02053961|DEVICE|Deep Transcranial Magnetic Stimulation|1Hz dTMS real treatment
223594619|NCT02053961|DEVICE|Deep Transcranial Magnetic Stimulation|1Hz dTMS SHAM treatment
223594620|NCT01892891|DRUG|VBY-036|Cathepsin S inhibitor
223594621|NCT05934864|GENETIC|84-gene penal|84-gene penal was targeted sequenced in 1000 PTCL patients to investigate their mutation profile and molecular subtypes.
223594622|NCT06124794|BIOLOGICAL|PROTOXIN|Clostridium botulinum toxin type A
223594623|NCT02217917|DRUG|Rivipansel|Rivipansel administered as a single dose subcutaneously with rHuPH20 in cross-over fashion. Each subject may receive up to 4 study treatments (placebo and up to 3 doses of rivipansel). The planned dose levels are 350 mg, 1210 mg, and 4200 mg (these are subject to change based on emerging data).
223594624|NCT02217917|DRUG|Placebo|Matched Placebo administered as single dose subcutaneously with rHuPH20.
223594625|NCT02217917|DRUG|Rivipansel|Rivipansel administered q12h for 7 days (a total of 13 doses) subcutaneously with rHuPH20. Planned doses are 1400 mg loading and 700 mg maintenance for 12 doses (these are subject to change based on emerging data).
223594626|NCT02217917|DRUG|Rivipansel|Rivipansel administered q12h for 7 days (a total of 13 doses) subcutaneously with rHuPH20. Planned doses are 2800 mg loading and 1400 mg maintenance for 12 doses (these are subject to change based on emerging data).
223594627|NCT02217917|DRUG|Placebo|Matched Placebo administered q12h for 7 days (a total of 13 doses) subcutaneously with rHuPH20.
223594628|NCT02577016|DRUG|Sitagliptin|50 mg tablet administered orally
223594629|NCT02577016|DRUG|Placebo|Placebo to sitagliptin administered orally
224310756|NCT06914102|DRUG|Placebo|New use of sitagliptin dispensing claim is used as the reference (active-comparator proxy for placebo).
224310757|NCT06917326|DEVICE|Monitoring|Lung monitoring with the Neola device
223594630|NCT02577016|DRUG|Ipragliflozin|50 mg tablet administered orally as background medication
223594631|NCT04411745|OTHER|No intervention, observational study|
223594632|NCT03485170|DIAGNOSTIC_TEST|18F-FDG PET/CT|glucose analogue fluorine-18-fluorodeoxyglucose positron emission tomography with computed tomography scan
223594633|NCT00345722|PROCEDURE|strawberry dietary intervention|
223594634|NCT00852501|OTHER|To perform RT-PCR on the tissue obtained during surgery|The performance of surgery is the standard of care in the management of non-functioning pituitary macroadenomas. The tissue obtained during surgery is routinely sent for histopathological examination. A piece of the tissue will undergo receptor characterisation via RT-PCR.
223594635|NCT04770844|OTHER|Acquisitions|"Three acquisitions of 1 hours during hospitalization will be realized:~* a few days after hospitalization,~* in the middle of the hospitalization,~* a few days before hospital discharge. The child will be lying on his back in a heated cradle and filmed with a specific camera. The signal will be obtained by 2k ZED 2 stereo camera in order to obtain a three-dimensional location of the child"
223594636|NCT02126839|DRUG|Albuterol MDPI|90 mcg/actuation of the multidose dry powder inhaler (MDPI).
223594637|NCT02126839|DRUG|Placebo|Matching Placebo delivered via a multidose dry powder inhaler (MDPI).
223594638|NCT02126839|DRUG|ProAir HFA inhaler|Rescue medication, ProAir hydrofluoroalkane (HFA) inhaler, was dispensed at the run-in visit for the relief of asthma symptoms to be administered as needed.
223594639|NCT02604914|DRUG|ND0612|Subcutaneous solution
223594640|NCT02604914|DRUG|LCIG|Intrajejunal Gel
223594641|NCT00812565|DRUG|Placebo|Commercially available 0.9% isotonic sodium chloride solution.
223594642|NCT00812565|BIOLOGICAL|octagam 10%|octagam 10% was supplied as ready-to-use solutions of human immunoglobulin.
223594643|NCT01369732|DRUG|recombinant human erythropoietin|We administrate the erythropoietin single bolus (500 IU/kg intravenously) 30 min before the commencement of ischemia.
223594644|NCT01369732|DRUG|saline|We administrate the saline single bolus (5ml intravenously) 30 min before the commencement of ischemia.
223594645|NCT04424693|DRUG|Tdap Vaccine Administration|Tdap vaccinations are routinely given during pregnancy between weeks 27 and 36 per guidelines of American College Obstetrics and Gynecology (ACOG) -- but this study uniquely is trying to establish that the earlier Tdap vaccinations reduce preeclampsia by more than 50%
223747312|NCT05732389|DRUG|Nivolumab|Nivolumab is a highly selective fully humanized, IgG4 monoclonal antibody inhibitor of programmed death-1 (PD-1) (17). PD-1 is an inhibitory receptor expressed on the surface of T-cells, B cells, macrophages, and NK cells. Endogenous binding of PD-1 with one of its two ligands PD-L1 and PD-L2 results in production of an inhibitory signal which results in reduction of T-cell proliferation, cytokine production, and cytotoxic activity. This results in significant dampening of the immune response. Nivolumab acts to selectively block the receptor activation of PD-L1 and PD-L2, resulting in a release of PD-1 mediated inhibition of the immune response.
223747313|NCT05732389|DRUG|Ipilimumab|Ipilimumab is a fully humanized monoclonal anti-CTLA-4 antibody that acts as an antineoplastic ICI by selectively binding to cytotoxic T-lymphocyte-associated antigen 4, a molecule located on the surface of cytotoxic T-cells, suppressing the immune response (17). Ipilimumab blocks CTLA-4, leading to a continuously active immune response in malignant cells.
223747314|NCT01272609|DRUG|Timolol + LCP|Three sessions of LCP in 595nm (diameter of spot 7mm; duration of shooting 1,5ms; Fluence 8 J / cm ² if LCP of Candela © or 7 J / cm ² if LCP of Cynosure ©) spaced out of 1 month. Twice-daily applications on the zone treated by the LCP of timolol frost and will be begun that very evening by the first session and will be pursued 15j after the 3rd session of LCP. The maximum surface of treatment will be 100 cms ².
223747315|NCT01272609|DEVICE|LCP|Three sessions of LCP in 595nm (diameter of spot 7mm; duration of shooting 1,5ms; Fluence 8 J / cm ²if LCP of Candela © or 7 J / cm ²if LCP of Cynosure © spaced out of 1 month.
224196788|NCT05568654|OTHER|Pharmacist-led de-escalation|A CDSS algorithm will identify CAP patients who meet study criteria and have negative culture results for greater than 48 hours and generate a list for the antimicrobial stewardship pharmacist, who will be a member of the study team. The alerts will be audited by the pharmacist daily at a centralized location. The pharmacist will attempt to determine whether each patient is clinically stable. The validated measures of clinical stability in patients with CAP are a) resolved vital sign abnormalities (temperature, heart rate, oxygen saturation, blood pressure and respiratory rate) b) normal mental status and c) ability to eat. If the patient appears stable, the pharmacist will communicate their recommendations for de-escalation to the clinical providers via a phone call or page. The de-escalation recommendations made by the pharmacist will be based on a protocol developed by the research team.
224196789|NCT04740762|BEHAVIORAL|Intervention group|The women in the intervention groups were administered a three-session intervention program in addition to the routine care they received.The program encompassed providing the women with an educational booklet, childbirth stories and childbirth videos that were created to reduce their fears of childbirth.The interviews were held a total of three times, in gestational weeks 28-30, 31-33 and 34-36. The duration of the intervention at each visit was 60-80 minutes. Depending on the woman's own preference, she was invited to visit the delivery room at the second or last session and meet the midwives there. The women who did not wish to go to the delivery room were alternatively provided with photographs of the delivery room so they could take a look. Again as part of the education program, the women were given the links to the selected childbirth videos and given the opportunity to watch them.
223594646|NCT01506661|DRUG|Zostavax (varicella zoster virus) vaccine|Standard vaccination protocol for Zostavax will be utilized. 0.65 ml (19,400 plaque forming units) Zostavax will be administered subcutaneously once at the baseline visit
223594647|NCT02653937|DRUG|Tsumura's shigyakusan|"Shigyakusan appears in the early 3rd Century. Four herbal crude medicines included are the following:~Root of Bupleurum falcatum L Unripe fruit of Citrus aurantium Linne var. daidai Makino, Citrus aurantium Linne, or Citrus natsu-daidai Hayata (Rutaceae) Root of Paeonia lactiflora Pall Root and stolon of Glycyrrhiza uralensis Fisher or Glycyrrhiza glabra Linne"
223594648|NCT03824093|BEHAVIORAL|AFIX Only|The intervention will include an in-person AFIX assessment of the practice's adolescent vaccination rates.
223594649|NCT03824093|BEHAVIORAL|AFIX+ Provider Communication Training|The intervention will include an in-person AFIX assessment of the practice's adolescent vaccination rates along with communication training for providers and poster and brochure displays.
223594650|NCT00793130|DIETARY_SUPPLEMENT|Coltect|Two tablets twice daily (BID) during the 2 months of the study. Each tablet contains 500mg Curcumin, 250mg Green tea and 100mcg Selenomethionine.
223594651|NCT03471741|RADIATION|IMRT with concomitant boost|
223747316|NCT05966896|DEVICE|implanted epidural stimulator|implantable multi-programmable neurostimulation system to deliver electrical stimulation to neural targets in the spinal cord
223747317|NCT05059860|DEVICE|Tandem Control IQ Hybrid Closed Loop Insulin Delivery System|The Tandem Control IQ hybrid closed loop insulin delivery system is made up of an externally worn Tandem insulin pump which communicates wirelessly to the Dexcom G6 CGM worn as a patch on the skin. The CGM measures glucose levels transmitting them into the computer within the pump. The computer then calculates how much insulin is required then dose delivery completes the cycle. The Control-IQ™ advanced technology adjusts insulin delivery to avoid glycaemic excursions, while still allowing the user to manually bolus at mealtimes.
223747318|NCT00939809|BIOLOGICAL|Urokinase-Derived Peptide A6|Given SC
223747319|NCT00939809|OTHER|Laboratory Biomarker Analysis|Correlative studies
223594652|NCT03471741|RADIATION|3D-RT with sequential boost|
223594653|NCT02596945|DRUG|Methoxy polyethylene glycol epoetin beta|Methoxy polyethylene glycol epoetin beta is prescribed as per physician's discretion in accordance with the Summary of Product Characteristics (SmPC).
223594654|NCT00873184|BEHAVIORAL|Massage Therapy|The setting for massage intervention will take place at The Duke Center for Living (DCL). . The massage therapists at the DCL work closely with physicians to design appropriate interventions for patients who are receiving treatment at DUMC, including cancer patients. All DCL therapists have completed more than 600 hours of training, are nationally certified and hold a North Carolina license to practice massage. These types include Swedish, deep muscle, myofascial release, trigger point, acupressure, Bowen Technique, sports massage and chair massage.
223594655|NCT00422383|DRUG|rituximab [MabThera/Rituxan]|500mg iv in days 1 and 15, and 500mg iv on days 168 and 182
223594656|NCT00422383|DRUG|rituximab [MabThera/Rituxan]|500mg iv on days 1 and 15, and 1000mg iv on days 168 and 182
223594657|NCT00422383|DRUG|rituximab [MabThera/Rituxan]|1000mg iv on days 1 and 15 and 1000mg iv (or placebo in UK)on days 168 and 182
223594658|NCT04165629|DRUG|Aspirin 300mg and Clopidogrel 300mg|Aspirin 300mg and Clopidogrel 300mg on the day of the PTA
223594659|NCT01853605|DEVICE|Anatomically shaped silicone gel-filled breast implants|Surgical implant
224196790|NCT05920057|BEHAVIORAL|constructive emotional management interventions|The Constructive emotional management interventions sessions were conducted in the activity rooms of the elderly clubs where the researchers met the participants. Participants completed a baseline evaluation of the outcome measures of the researched variables after being found to be eligible for the current study and indicating their willingness to participate willingly. After explaining the study's objectives to participants, the researchers themselves delivered the Constructive Emotional Management Interventions program, which had been vetted by experts in the field.
224196791|NCT05586204|BEHAVIORAL|Eligibility reminder|Patients will receive a reminder of their eligibility for the bivalent COVID-19 booster
224196792|NCT05586204|BEHAVIORAL|Link to a narrow set of vaccine venues|The reminder will encourage people to claim their dose today by booking an appointment. It will contain a link to schedule a booster appointment at UCLA Health and a link to CVS pharmacy
223505632|NCT05792722|PROCEDURE|Nerve sparing radical cystectomy|Patients randomized to this arm will receive the nerve-sparing surgery will be performed in the form of the standard nerve-sparing radical prostatectomy. Patients will also have a cystectomy with one of the following urinary diversions: ileal conduit, Indiana Pouch, or orthotopic neobladder.
223505633|NCT04989517|DRUG|AT193|Topical
223505634|NCT03574714|OTHER|Extracellular pH|Extracellular pH gradient
223505635|NCT04632342|DRUG|HL301 tablet 300mg|"* Experimental group 1 : 2 tablets at once, twice a day~* Experimental group 2 : 2 tablets at once, three times a day"
223505636|NCT04632342|DRUG|Placebo of HL301 tablet|2 tablets at once, three times a day
223505637|NCT01629563|DRUG|PGL4001 5 mg|PGL4001 5 mg daily administration
223505638|NCT01629563|DRUG|PGL4001 10 mg|PGL4001 10mg daily administration
223505639|NCT03165500|DRUG|Diazepam|"Patients' vital signs (blood pressure, heart rate and oxygen saturation) were measured and recorded after 30 minutes of oral sedation with diazepam 5mg, during the extraction procedure and 15 minutes after the extraction.~After the surgical procedure of extraction, the patients remained in recovery in the same room, being the criteria of discharge realized, from the normality of the vital signs and the response to the verbal commands, with the patient responsive and lucid."
223505640|NCT03165500|DRUG|Midazolam|"Patients' vital signs (blood pressure, heart rate, and oxygen saturation) were measured and recorded after 30 minutes of oral sedation with midazolam 7.5mg during the extraction procedure and 15 minutes after the extraction.~After the surgical procedure of extraction, the patients remained in recovery in the same room, being the criteria of discharge realized, from the normality of the vital signs and the response to the verbal commands, with the patient responsive and lucid."
223505641|NCT03165500|DRUG|Nitrous Oxide + Oxygen Gas|"Patients' vital signs (blood pressure, heart rate, and oxygen saturation) were measured and recorded after 30 minutes of sedation Inhalation with the mixture of 40% of nitrou oxide and 60% of oxygen, during the exodontia procedure and 15 minutes later.~After the surgical procedure of extraction, the patients remained in recovery in the same room, being the discharge criteria performed, from the normality of the vital signs and the response to the verbal commands, with the patient responsive and lucid, and after the accomplishment of the test developed by Trieger et al.,(1971)."
223505642|NCT03165500|PROCEDURE|Third molar extraction|Anxious patients in need of third molar extraction
223505643|NCT06391086|DEVICE|NaviFUS® Neuronavigation-guided focused ultrasound system|The treatment protocol consists of once daily treatment for consecutive five tFUS sessions.
223505644|NCT00454142|DRUG|pazopanib hydrochloride|Given PO
223505645|NCT00454142|OTHER|pharmacological study|Correlative studies
223505646|NCT00454142|PROCEDURE|computed tomography|Correlative studies
223505647|NCT04986813|DRUG|Tranexamic acid injection|1 g of TXA in 100 ml of normal saline
223505648|NCT04986813|OTHER|Normal Saline|100 ml
223505649|NCT05890586|DRUG|Fluvoxamine|"Fluvoxamine is a round golden 50 mg tablet that is scored on both sides - one side has APO and the other side has F50 with a partial bisect. All packaging will be labeled to indicate that the product is for investigational use, administered at a dose of 50 mg, twice daily for 10 days."
223505650|NCT05890586|OTHER|Placebo|Each study arm will contain a placebo comparator. Placebo will look similar to study drug and will be administered via the same route of administration and dose. However, placebo will be an inactive substance, containing no study drug.
223505651|NCT00353015|DRUG|Cisplatin|Cisplatin 25 mg/m2 IV days 1, 8 of a 21-day cycle
223505652|NCT00353015|DRUG|Irinotecan|Irinotecan 65 mg/m2 IV days 1, 8 of a 21-day cycle
223505653|NCT03216291|BEHAVIORAL|biofeedback therapy|Biofeedback therapy is a labor-intensive, multi-disciplinary, team approach for the management of patients with anorectal problems. Complete training sessions once a week for 6 weeks in the office.
223505654|NCT03216291|DEVICE|Home Biofeedback therapy|Biofeedback therapy is a labor-intensive, multi-disciplinary, team approach for the management of patients with anorectal problems, but instead of an office therapy, the subject will use a biofeedback device to gain strength in their anorectal muscles. This device will be taught how to use in the first session and then the subject will take it home to complete at least 1 session a day for 6 weeks.
223505655|NCT03513146|PROCEDURE|Oropharyngeal Administration of Mother's Milk (OPAMM)|0.2 ml of own mother's milk will be given by dropper to the oro-pharyngeal pouch, tongue and cheeks and the remaining amount will be given by the regular gavage feeding on intervals and amount regulated by the feeding protocol
223505656|NCT02545127|DRUG|Merotocin|Merotocin nasal spray 400 μg/dose, 2 sprays with 1 spray in each nostril administered 6 to 8 times/day (Day 1 to Day 14).
223505657|NCT02545127|DRUG|Placebo|Placebo nasal spray, 2 sprays with 1 spray in each nostril administered 6 to 8 times/day (Day 1 to Day 14).
223505658|NCT01553500|DIETARY_SUPPLEMENT|glucomannan|glucomannan is administered at dosage of 5g/day in form of biscuits (6 biscuits/day)
223505659|NCT01553500|BEHAVIORAL|lifestyle intervention|hypocaloric diet (25-30 Kcal/kg/day) or isocaloric (40-45 Kcal/kg/day) and physical activity
223505660|NCT05150886|DIAGNOSTIC_TEST|rox index|After HFNC during reassessment, the ROX Index can help suggest which patients will fail HFNC and need to progress to intubation for further ventilatory support.
223505661|NCT02227264|DRUG|Cinacalcet|Cinacalcet, Mimpara® 30mgx1-2 for 4 weeks
223505662|NCT02227264|PROCEDURE|parathyroid adenomectomy|surgical removal of pathologic parathyroid tissue
223747320|NCT06482489|DEVICE|Siemens Magnetom Free.Max 0.55T (Siemens Healthineers, Erlangen, Germany).|Performing low-field MRI to evaluate image quality with patients carrying metallic implants and assess the detection of suspicious prostate lesions.
223505663|NCT06021444|DEVICE|DKM420|A total of 3 doses will be applied at a dose of 2 mL over 3 weeks.
223505664|NCT06021444|DEVICE|Conjuran|A total of 3 doses will be applied at a dose of 2 mL over 3 weeks.
223505665|NCT00882388|DRUG|aspirin|aspirin 100 mg qd for 7 days
223505666|NCT00882388|DRUG|celecoxib|celecoxib 200 mg bid \* 7 days
223505667|NCT00882388|DRUG|aspirin + celecoxib|aspirin 100 mg qd + celecoxib 200 mg bid for 7 days
223505668|NCT00882388|DRUG|aspirin + clopidogrel|asprin 100 mg qd + clopidogrel 75 mg qd for 7 days
223505669|NCT00882388|DRUG|aspirin + clopidogrel + celecoxib|aspirin 100 mg qd + clopidogrel 75 mg qd + celecoxib 200 mg bid
223505670|NCT05881330|DEVICE|ArtiAid Intra-articular Injection|Inject ArtiAid® in the affected joint at weekly interval for 5 weeks.
223505671|NCT02802865|DRUG|Clomiphene|
223505672|NCT02802865|DRUG|Letrozole|
223505673|NCT05071833|DIETARY_SUPPLEMENT|Peppermint oil.|Peppermint oil.
223505674|NCT05071833|OTHER|Placebo|Placebo
223505675|NCT04236466|DEVICE|hyrax appliance|Hyrax will be constructed with bands on maxillary first molars and wire extending on palatal surfaces of teeth till the upper canines.
223505676|NCT04236466|DEVICE|haas appliance|Haas will be constructed with bands on maxillary first molars and wire extending on palatal surfaces of teeth till the upper canines. Acrylic part will be added on palate
223505677|NCT01783015|DRUG|Etanercept|Etanercept 50 mg once-weekly
223505678|NCT01783015|DRUG|Etanercept|Etanercept 50 mg once-weekly
223505679|NCT01783015|DRUG|Placebo|Etanercept placebo once-weekly
223505680|NCT01783015|DRUG|Placebo|Etanercept placebo once-weekly
223505681|NCT03699800|OTHER|Graphomotor intervention program|The graphomotor intervention program aims to promote the development and reinforcement, different skills involved in the learning process of handwriting and has a preventive character. It follows a bodily, playful, multisensory, exploratory (sensory integration) and neuromotor task training approach and focuses on the following intervention domains: segmental awareness, passive relaxation, trunk-limb dissociation, interdigital coordination, attention, planning, spatial organization/orientation and perception.
223505682|NCT00509600|DRUG|Etanercept|0.8 mg/kg Subcutaneously Once A Week for 90 Days
223505683|NCT06500728|DIAGNOSTIC_TEST|Fluorescein and Indocyanine green Angiography|The ophthalmologist frequently recommends fluorescein (FAG) and indocyanine green angiography (ICGA) at baseline (T0) to evaluate retinal and choroidal vascularisation. They can be repeated also after 48-72 hours (T1), 7 ± 2 days (T2), 4 ± 1 weeks (T3), 12 ± 2 weeks (T4) or 26 ± 2 weeks (T5).
223505684|NCT06500728|DIAGNOSTIC_TEST|High-resolution Optical Coherence Tomography|The ophthalmologist often suggests performing HR-OCT initially (T0) to assess the width of the macula and optic nerve with potential signs of ischemic lesions in these areas. This assessment can also be repeated after 48-72 hours (T1), 7 ± 2 days (T2), 4 ± 1 weeks (T3), 12 ± 2 weeks (T4), or 26 ± 2 weeks (T5).
223505685|NCT06500728|DIAGNOSTIC_TEST|Angio-Optical Coherence Tomography|The ophthalmologist often suggests OCT-A at the beginning (T0) to assess the retinal and choroidal vascularization. These tests can also be done after 48-72 hours (T1), 7 ± 2 days (T2), 4 ± 1 weeks (T3), 12 ± 2 weeks (T4), or 26 ± 2 weeks (T5).
223505686|NCT03828669|BEHAVIORAL|Recovery Toolkits|"Recovery Toolkits are presented to patients in a branded bag and include a brochure, a self-help behavioral pain medicine book, a downloadable app, earbuds, and access to digital behavioral medicine (the My Surgical Success program including online educational videos)"
223505687|NCT00677287|BIOLOGICAL|RNF43, TOMM34, VEGFR1 and VEGFR2|Patients will be vaccinated twice a week for 8 weeks. On each vaccination day, RNF43 peptide (1mg), TOMM34 peptide (1mg), VEGFR1 peptide (1mg) and VEGFR2 peptide (1mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection in combination with Tegafur/Uracil/Folinate chemotherapy.
223505688|NCT02184247|DRUG|anhydrous theophylline, 350 mg|
223505689|NCT02184247|DRUG|anhydrous theophylline, 300 mg|
223505690|NCT05875077|DRUG|Dexmedetomidine|compare the effects of dexmedetomidine infusion to propofol infusion during spinal anesthesia, on the incidence of postoperative nausea and vomiting in patients undergoing ureteroscopic procedures under spinal anesthesia.
223505691|NCT05875077|DRUG|Propofol|compare the effects of dexmedetomidine infusion to propofol infusion during spinal anesthesia, on the incidence of postoperative nausea and vomiting in patients undergoing ureteroscopic procedures under spinal anesthesia.
223505692|NCT04057794|DEVICE|Lab Assay for seven genetic variants for Parkinson's Disease|Counseling provided to participant by site clinician/physician/genetic counselor.
223505693|NCT04057794|DEVICE|Lab Assay for seven genetic variants for Parkinson's Disease|Counseling provided to participant by centralized genetic counseling group at Indiana University.
223505694|NCT01692587|OTHER|Protein restrictive diet|To begin a reduced protein diet
223505695|NCT02894138|DRUG|alteplase|
223505696|NCT02894138|DRUG|Placebo|
223505697|NCT03848351|BEHAVIORAL|Oral Hygiene Instruction (OHI)|OHI will be given focusing on electric toothbrushing as first instance and subsequently focusing on interdental cleaning. OHI will be delivered by trained dental hygienist/periodontist. In the first phase the clinician will explain and show the technique to the patient. The patient will be then invited to perform the technique. Each phase will be assisted and monitored by the clinician. Overall, this sequence may be repeated as many times as the clinician would deem appropriate.
223505698|NCT03848351|PROCEDURE|Professional supragingival scaling and polishing|Patients will receive a session of professional supragingival scaling and polishing, that consists of removal of dental plaque and dental calculus from the surface of a tooth, with great care in performing exclusively coronal maneuver. No instrumentation or exploring of the gingival crevice/ sulcus will be performed. Instrumentation will be performed by a trained dental hygienist/periodontist.
223594660|NCT01424033|DRUG|N-Acetylcysteine|600mg by mouth, three times daily for 12 months
223747321|NCT05643716|BEHAVIORAL|Aerobic Exercise|The aerobic exercise intervention is described in the Aerobic Exercise Arm description.
223747322|NCT04447417|DRUG|Dupilumab SAR231893|Pharmaceutical form:solution for injection Route of administration: subcutaneous
224196793|NCT05586204|BEHAVIORAL|Link to a broad set of vaccine venues|The reminder will encourage people to claim their dose today by booking an appointment. It will contain a link to schedule a booster appointment at UCLA Health and a link to vaccine.gov (where people can find a wide set of local pharmacies that carry the bivalent booster).
223505699|NCT05010967|OTHER|High intensity interval training|"HIIT 3 times a week for 8 weeks. For week 1 to 4 , Warm up 5 minutes jogging in place, 6 series of 30 seconds Burpees, 30 seconds recovery, 30 seconds skipping, 30 seconds recovery, 30 seconds lunge, 30 seconds recovery, 30 seconds 1-legged squats, 30 seconds recovery, 30 second leg levers, 30 seconds recovery. the series will have 3 minutes rest in between. Cool down of 10 minutes with gentle stretches.~For week 5 to 8 , Warm up 5 minutes jogging in place, 6 series of 45 seconds Burpees, 45 seconds recovery, 45 seconds skipping, 30 seconds recovery, 45 seconds lunge, 30 seconds recovery, 45 seconds 1-legged squats, 30 seconds recovery, 45 second leg levers, 30 seconds recovery. the series will have 3 minutes rest in between. Cool down of 10 minutes with gentle stretches."
223505700|NCT05010967|OTHER|Yoga Training|Yoga 3 times a week for 8 weeks. 30-50 minutes session, 5 minutes breathing, 15-35 minutes yoga poses (Cat-cow, child's pose, downward dog, plank, Cobra), followed by 10 minutes supine meditation.
223505701|NCT05640635|PROCEDURE|Ventilator weaning first|Ventilator weaning initiated and completed before start of ECMO weaning.
223505702|NCT05640635|PROCEDURE|ECMO weaning first|ECMO weaning initiated and completed before start of ventilator weaning.
223505703|NCT00950092|DEVICE|Numeris-AF Tethered Coagulation System with VisiTrax|Surgical radiofrequency (RF) epicardial ablation using the nContact Numeris-AF Tethered Coagulation System
223505704|NCT05702619|DRUG|Optional non-IMP pimonidazole|patients will be asked to ingest an oral formulation of pimonidazole hydrochloride (HCl) (Oral HypoxyprobeTM-1). Pimonidazole HCl is a marker for hypoxia in tumour tissue when ingested as an encapsulated solid. Following oral administration, pimonidazole distributes throughout the body where it covalently binds to normal and tumour tissues that have regions of low oxygen concentrations (pO2 of ≤ 10 mmHg at 37oC). The tissue binding can be visualised by immunohistochemistry / light microscopy. The capsules are to be taken within 8-16 hours (optimal timepoint 12 hours) before the planned first biopsy within Arm 1 and before radical prostatectomy for patients in Arm 2. If the patient refuses the pimonidazole, forgets to take it, or if it is not available, the patient can still participate in the study and their samples will be stained for hypoxia post-biopsy.
223505705|NCT05702619|DIAGNOSTIC_TEST|CT-guided Bone Biopsy|A CT-guided biopsy of a bone metastasis that is deemed to be easy to biopsy and in an area without major risk for pathological fracture or bleeding will be taken during the biopsy visit. Patients will receive routine local anaesthetic of the region to be biopsied followed by thorough disinfection of the biopsy site with antiseptic wipes. Patients will be asked to fast on the day of the procedure and to have an intravenous cannula inserted to allow the use of medication causing minimal sedation (for example midazolam and/or fentanyl) during the procedure if required to alleviate discomfort or pain.
223505706|NCT05702619|DIAGNOSTIC_TEST|TRUS-guided Targeted Transperineal Prostate Biopsy|Transperineal Prostate Biopsy will be performed following standard clinical practice of local department. This will include pre-operative oral analgesia and prophylactic antibiotic treatment according to local hospital policy for transperineal prostate biopsies.
223505707|NCT05702619|PROCEDURE|Radical Prostatectomy|Radical Prostatectomy will be performed according to standard of care robotic approach and as relayed to the patient by the attending urologic surgeon. The side effects of the surgery are the ones reported in the literature and the latest participant information leaflet provided prior patient consent (e.g. risk of erection disfunction, incontinence, etc.).
223505708|NCT05702619|DIAGNOSTIC_TEST|Whole-body MRI|Whole-body MR imaging (wbMRI) will be performed once, before or after the biopsy study visit, depending on available examination slots in the Department of Radiology. WbMRI images will allow comparison of the numbers of bone metastases detected by routine bone scan and wbMRI for sensitivity assessment of both techniques for oligometastatic disease.
223505709|NCT05702619|DIAGNOSTIC_TEST|Prostate MRI scans|Patients within Arm 2 will be offered the option to undergo additional MR imaging of the pelvis in addition to any standard of care imaging acquired. In patients who agree to undergo additional scans, MRI scans will be performed on 2 occasions prior to the radical prostatectomy. MRI scans will be acquired on either the MR sim diagnostic scanner, on the MR Linac scanner or on both.
223505710|NCT05702619|OTHER|Baseline bloods - for germline testing|"Arm 1 -~* 1-2 x 3.5mL blood samples collected into EDTA tubes for germ line DNA extraction and processing to PBMC for banking and future profiling of immune cell populations~* 1 x 10mL serum tubes for future, biobank related research projects, ie lipidomics, metabolics and microRNA analysis~ARM 2 -~A blood sample (maximum 20ml) will be taken for standard of care blood tests prior to prostatectomy including Full Blood Count, Renal Function and PSA. At the same time these standard of care bloods are taken, additional bloods - a maximum of 30ml - will be taken for research purposes as required for the following downstream analysis:~* Germ line DNA extraction and optional processing to PBMC for banking and future profiling of immune cell populations~* Biobank related research projects, ie lipidomics, metabolics and microRNA analysis"
223747323|NCT04804189|BEHAVIORAL|Guardians 4 Health|Clubs will implement Guardians 4 Health's intervention into their community by incorporating Guardians 4 Health materials into standard Club educational activities.
224196794|NCT05586204|BEHAVIORAL|Doctors' recommendation and value of vaccine|The reminder will contain information about the value of the bivalent booster and doctors' recommendation to get it
224196795|NCT02995239|DRUG|CJ-12420 formulation 2|CJ-12420 formulation 2
224196796|NCT02995239|DRUG|CJ-12420 formulation 1|CJ-12420 formulation 1
224196797|NCT03193996|DEVICE|4DCT|4DCT will be used to assess the location of the torn scapholunate interosseus ligament.
224196798|NCT00494234|DRUG|Olaparib|Participants will receive capsules of olaparib orally as stated in arm description.
224196799|NCT05361005|DRUG|BDB-001 injection|Intravenous injection
224196800|NCT05361005|DRUG|Placebo|Intravenous injection
224196801|NCT00423137|DRUG|BIBW 2948 BS|Capsule
224196802|NCT00423137|DRUG|Placebo|Capsule
224196803|NCT03592680|DIETARY_SUPPLEMENT|Vitamin C|1 gram Vitamin C will be administrated orally, twice a day from 5 days before until 10 days after surgery.
224196804|NCT03592680|OTHER|Placebo|1 gram Placebo will be administrated orally, twice a day, from 5 days before until 10 days after surgery
224196805|NCT04943627|DRUG|Balstilimab (BAL)|Anti-PD-1 Monoclonal antibody
224196806|NCT04943627|DRUG|Topotecan|Chemotherapy
223747324|NCT04835025|DRUG|PD-1/PD-L1 inhibitor|In non-small cell lung cancer, patients with brain metastases received radiotherapy for brain lesions and immunotherapy (including sequential and concurrent model). Those patients would enter the trial group; After patients experiencing PD in this group, follow-up treatment until tumor progression again or death
223747325|NCT05887765|DRUG|Sodium Chloride 0.9% Inj|administration of 5ml 0,9% sodium chloride - 30 minutes before the popliteal nerve block
223747326|NCT05887765|DRUG|0,1mg/kg Dexamethasone|administration of 0,1mg/kg Dexamethasone - 30 minutes before the popliteal nerve block
223747327|NCT05887765|DRUG|0,2mg/kg Dexamethasone|administration of 0,2mg/kg Dexamethasone - 30 minutes before the popliteal nerve block
223747328|NCT06787521|OTHER|evidence-based labor guide|Participants will be provided with written education about potential complications and interventions. Information will be provided at the time of admission for labor induction.
224196807|NCT04943627|DRUG|Vinorelbine|Chemotherapy
224196808|NCT04943627|DRUG|Gemcitabine|Chemotherapy
224196809|NCT04943627|DRUG|Irinotecan|Chemotherapy
224196810|NCT04943627|DRUG|Pemetrexed|Chemotherapy
224196811|NCT03478982|DRUG|Staccato Alprazolam|single dose for inhalation
224196812|NCT03478982|DRUG|Placebos|single dose for inhalation
224196813|NCT03653780|DEVICE|Ekso GT|Walking in the Ekso GT with maximum bilateral assistance for 20 minutes
223594661|NCT06124456|OTHER|Usual Care Control Group|Subjects in the usual care control group will receive health education as the attention control. The program will consist of eight 150-minute bi-weekly sessions covering major health issues relating to general health and NAFLD, to be obtained from publicly accessible resources from the Hong Kong Department of Health. Health education information on non-communicable diseases (e.g., cancers, diabetes, coronary heart diseases, obesity, and mental illness), infectious diseases (e.g., COVID-19), and a healthy lifestyle (e.g., balanced diet, physical activity, good sleep, tobacco use, alcohol cessation, and stress management) will also be distributed to the subjects in the exercise groups through recorded presentation videos and leaflets/pamphlets during the first 16 weeks.
223594662|NCT06124456|OTHER|Moderate-intensity Exercise Intervention|The walking time in each session will be 50 minutes for the moderate-intensity group. The overall weekly exercise volume for the two groups will be the same based on total energy expenditure, as per the WHO's physical activity recommendation (150 minutes of moderate-intensity physical activity weekly is equivalent to 75 minutes of vigorous-intensity physical activity weekly). Five minutes of walking at a normal pace will be included for warm-up and cool-down.
224196814|NCT03733665|OTHER|Patients admitted to hospital|Data is captured in HES for all patient interactions with the NHS (each episode) in England. All patients admitted for heart failure have data captured in the National Heart Failure Audit.
224196815|NCT00820365|DRUG|SC12267 (4SC-101)|Peroral administration of SC12267 (4SC-101) in patients with Inflammatory Bowel Disease over 12 weeks.
224196816|NCT00009750|BIOLOGICAL|filgrastim|
224196817|NCT00009750|BIOLOGICAL|monoclonal antibody m170|
223747329|NCT01010308|DRUG|Nadolol|Nadolol will be administered orally at home starting at 0.5 mg/kg/day divided into 2 doses. Weekly, if BP and heart rate are acceptable, the dose will be increased by 0.5 mg/kg/day up to 2 mg/kg/day.
223747330|NCT06258876|OTHER|PrEP in general practice|Prescription and follow-up of PrEP in general practice
224196818|NCT00009750|DRUG|cyclosporine|
224196819|NCT00009750|DRUG|paclitaxel|
224196820|NCT00009750|PROCEDURE|peripheral blood stem cell transplantation|
224196821|NCT00009750|RADIATION|indium In 111 monoclonal antibody m170|
224196822|NCT00009750|RADIATION|yttrium Y 90 monoclonal antibody m170|
224196823|NCT04448548|OTHER|blood sample taking|For study purposes, blood sample was taken during the first medical examination from patients with suspected infection.
224196824|NCT04585828|DEVICE|Phototherapy with double sided fiber optic pads with blue light at irradiance 30 uW/cm2/nm using Bili Cocoon|The baby will be treated with Bilicocoon for 24 hours. Decrease of total serum biliurubin will be evalueated hereafter.
224196825|NCT04585828|DEVICE|Phototherapy from above using NeoBlue at irradiance of 30 uW/cm2/nm|The baby will be treated with phototherapy from above for 24 hours. Decrease of total serum bilirubin will be evaluated hereafter.
224196826|NCT00593385|DEVICE|iCAST covered stent|Iliac stent implantation
224196827|NCT04907201|PROCEDURE|Cryoneurotomy|Cryoneurotomy or application of a low temperature probe with guidance of ultrasound which is offered to the patients with lower limbs refractory spasticity as a part of their medical cares.
224196828|NCT05005468|DRUG|Camrelizumab|Camrelizumab is given on the first day of each cycle, intravenous drip.
224196829|NCT05005468|DRUG|Famitinib|Famitinib is administered orally, once a day.
224196830|NCT05188768|PROCEDURE|Concentrated Growth Factor Membrane|Concentrated growth factor is produced by the centrifugation of venous blood and platelets are concentrated in a gel layer containing fibrin matrix
224196831|NCT05188768|PROCEDURE|Platelet Rich Fibrin|Platelet Rich Fibrinis produced by the centrifugation of venous blood and platelets are concentrated in a gel layer containing fibrin matrix
224196832|NCT03698825|DRUG|TEW-7197|TEW-7197 50mg tablets + Paclitaxel 80 mg/m2 D1, 8, 15 q 4 weeks TEW-7197 dose will be determined through this dose escalation study
224196833|NCT04227730|DIAGNOSTIC_TEST|culture and PCR for group B streptococcus|all participants were evaluated by vaginorectal specimens for the detection of GBS, The swabs are placed in Amies transport medium and sent to the microbiology laboratory for testing by conventional PCR assay.
224196834|NCT00960648|DEVICE|Xience/Promus|Active prospective registration of patients receiving everolimus-eluting stent
224196835|NCT00960648|DEVICE|Cypher|Retrospective historical controls that received sirolimus-eluting stent
224196836|NCT00348348|DRUG|Besifloxacin|Besifloxacin hydrochloride ophthalmic suspension, 0.6% as base, administered TID for 5 days
224196837|NCT00348348|DRUG|Moxifloxacin solution|Moxifloxacin hydrochloride ophthalmic solution 0.5% administered TID for 5 days.
224196838|NCT04651257|DEVICE|Contrast mammography (CEM)|Contrast mammography in pathological nipple discharge
224196839|NCT02737410|BEHAVIORAL|Gut-directed Hypnotherapy|The GHT protocol used was the Manchester protocol of GHT and consisted of 10 weekly sessions (45 min), with six patients per group over a treatment period of 12 weeks. GHT was performed at the University Hospital by two experienced physicians trained in Manchester (UK).
224196840|NCT01103908|DEVICE|HCE101 Cardiopulmonary Support Monitor|Measurement of cardiac output using ultrasound dilution technology. The ultrasound dilution technology is in the HCE101 Cardiopulmonary Support Monitor.
224196841|NCT02433015|OTHER|Electronic Cigarette|eGo-type electronic cigarette with a supply of 18mg/ml nicotine solution
224196842|NCT02433015|OTHER|Tobacco Cigarette|Smoke own brand of cigarette as previously
223594663|NCT06124456|OTHER|Vigorous-intensity Exercise Intervention|The walking time in each session will be 25 minutes for the vigorous-intensity group. The overall weekly exercise volume for the two groups will be the same based on total energy expenditure, as per the WHO's physical activity recommendation (150 minutes of moderate-intensity physical activity weekly is equivalent to 75 minutes of vigorous-intensity physical activity weekly). Five minutes of walking at a normal pace will be included for warm-up and cool-down.
223594664|NCT03613467|PROCEDURE|VATS lobectomy|Patients who received lobectomy by video-assisted thoracoscopic surgery
223594665|NCT03613467|PROCEDURE|Thoracotomy lobectomy|Patients who received lobectomy by thoracotomy
223594666|NCT05629468|DRUG|Azithromycin|antibiotic
223594667|NCT05629468|DRUG|Probiotic Formula|probiotics
223594668|NCT05629468|DRUG|Benzoyl Peroxide 4 % Topical Cream|topical cream
223594669|NCT00310622|DEVICE|HyperQ Signal recording|
223594670|NCT00888485|BEHAVIORAL|Behavioral interventional program|Cognitive behavioral therapy intervention adapted to coronary disease patients performed in 20 group sessions during one year.
223594671|NCT00516165|DRUG|RAD001|Oral pills taken daily in a 42-day cycle (6 weeks). Cycles will be repeated every 42 days
223594672|NCT03484390|BEHAVIORAL|Mindfulness-based stress reduction|
223594673|NCT03484390|BEHAVIORAL|Wellness Group|
223594674|NCT04072263|BIOLOGICAL|Tumor Infiltrating Lymphocytes (TIL)|Adoptive cell therapy using Tumor-Infiltrating Lymphocytes (TIL) i.v.
223594675|NCT04072263|DRUG|Interferon Alfa 2A|Interferon alpha (IFNα) s.c., may work as a low toxic preconditioning regimens that creates the space required for the infused TIL but that it also supports the TIL by sustaining their persistence and indirectly their function, by upregulation of HLA class I on tumor cells and decreasing the numbers of regulatory T cells.
223594676|NCT04072263|DRUG|Carboplatin|chemotherapy i.v.
223594677|NCT04072263|DRUG|Paclitaxel|Chemotherapy i.v.
223594678|NCT01341028|PROCEDURE|Roux-en-Y gastric bypass (LRYGBP)|Twelve patients underwent laparoscopic Roux-en-Y gastric bypass
223594679|NCT01341028|PROCEDURE|LRYGBP+gastric fundus resection|Twelve patients underwent laparoscopic Roux-en-Y gastric bypass and gastric fundus resection
223594680|NCT04112394|OTHER|local anesthetic injection|A linear ultrasound transducer will be place in a longitudinal parasagittal orientation about 3 cm lateral to spinous process. Local anesthetic mixture will be injected bilaterally into the fascial plane on the deep aspect of erector spinae muscle. Standard perioperative and postoperative analgesia protocol will be given and postoperative pain levels will be determined by Numerical rating scale (NRS).
223594681|NCT04112394|OTHER|Standard perioperative and postoperative analgesia protocol.|Standard perioperative and postoperative analgesia protocol will be given consisting of paracetamol 1 gr IV and tenoxicam 20 mg IV initiated after induction of anesthesia. At the end of the operation patients will receive contramal 1 mg/kg IV before extubation. Postoperative pain levels will be determined by Numeric Rating Scale (NRS) system, 20 minutes intervals in the first hour and at 2th, 6th, 12th and 24 th hour. For the first hour in the postoperative care unit, tramadol 50 mg IV will be given for rescue analgesia with minimum 20 minutes between doses, in patients showing a NRS ≥ 4. Paracetamol 1 g / 12 hour will be given during ward follow-up. In the ward in patients showing a NRS ≥ 4 tramadol 50 mg IV will be given for analgesia.
224196843|NCT02279472|PROCEDURE|Laserex Tango Nd:YAG, Ellex-SuperQ Medical, Australia|All the patients will be achieved with pilocarpine 1% for pupil constriction, laser peripheral iridotomy(LPI) is performed using the ophthalmic neodymium: yttrium aluminium garnet laser (Laserex Tango Nd:YAG, Ellex-SuperQ Medical, Australia) and an VOLK iridotomy contact lens. After LPI, patients will be given topical prednisolone acetate 0.1% for 7 days.
223594682|NCT00376896|DRUG|GW876008 200mcg|GW876008
223594683|NCT00376896|DRUG|GW876008 20mcg|GW876008 20mcg
223594684|NCT00376896|OTHER|Placebo|placebo
223594685|NCT02752373|DEVICE|Brain Sentinel Seizure Detection and Information System|The Brain Sentinel® GTC Seizure Detection and Information System is an ambulatory system designed to continuously monitor and perform real-time analysis of surface electromyography (sEMG) data to detect GTC seizures and to provide an alarm to alert caregivers within 30 seconds of bilateral, appendicular, tonic extension that a seizure is occurring. The System is for recording and storing sEMG data, which is subsequently reviewed by a trained healthcare professional in the outpatient clinical setting. The Brain Sentinel® GTC Seizure Detection and Information System is intended for real time monitoring of pediatric and adult patients who have an arm circumference ranging from at least 16 cm to no greater than 51 cm at the biceps. It may be used in the home or healthcare facilities for real-time monitoring during the day, night, or for continuous monitoring, including during the titration of, or the withdrawal from anti-epileptic drugs.
223594686|NCT03977493|DRUG|Xeomin|One injection of 2.5 to 40 U in each muscle. Injection repeated after 6 weeks if considered necessary
223594687|NCT03977493|DRUG|Placebo - Concentrate|One injection in each muscle.
223747331|NCT06307275|OTHER|Fasting|Fasting for 16 hours from participant last meal of the previous evening's meal to the first meal of the next day. Then for 8 hours, participant is able to eat. During the fasting, participants are allowed to consume water and black coffee/tea. Participants will also keep their normal weekly exercise routine.
223747332|NCT06307275|OTHER|non fasting|Participants will not be fasting during these four weeks. They will eat their normal food intake and keep their normal physical activity levels.
224196844|NCT01258010|DRUG|Tranexamic Acid|Bolus dose of 30 mg/kg of tranexamic acid followed by a continuous intravenous infusion of 16 mg/kg/h of tranexamic acid administered up to 6 hours after surgery.
224196845|NCT01258010|DRUG|Placebo|Bolus dose of normal saline (NaCl 0.9%) of equivalent volume followed by a continuous intravenous infusion of NaCl 0.9% administered up to 6 hours after surgery.
224196846|NCT00000658|DRUG|Bleomycin sulfate|
224196847|NCT00000658|DRUG|Vincristine sulfate|
224196848|NCT00000658|DRUG|Doxorubicin hydrochloride|
224196849|NCT00000658|DRUG|Cyclophosphamide|
224196850|NCT00000658|DRUG|Allopurinol|
223594688|NCT05759897|DRUG|HRS-7535|HRS-7535
223594689|NCT05759897|DRUG|Placebo|Placebo
223594690|NCT02035527|DRUG|sorafenib tosylate|Given daily PO in the a.m.
224196851|NCT00000658|DRUG|Methotrexate|
224196852|NCT00000658|DRUG|Cytarabine|
224196853|NCT00000658|DRUG|Leucovorin calcium|
224196854|NCT00000658|DRUG|Sargramostim|
224196855|NCT00000658|DRUG|Dexamethasone|
224196856|NCT01700686|OTHER|Meal test and dexa scan|Body composition is determined by whole body deca scan and bone mineral density is determined dy dexa scans of the lumbar spine and the proximal femur.
224196857|NCT02031601|DRUG|Erlotinib|150mg po once a day on days 2-15 of each 3 week cycle for 4 cycles; then continue to receive erlotinib150mg po once a day daily until progression
224196858|NCT02031601|DRUG|Gefitinib|250mg po once a day on days 2-15 of each 3 week cycle for 4 cycles; then continue to receive gefitinib 250mg po once a day daily until progression
224196859|NCT02031601|DRUG|Icotinib|125mg po three time a day on days 2-15 of each 3 week cycle for 4 cycles; then continue to receive icotinib 125mg po three time a day daily until progression
224196860|NCT02031601|DRUG|Docetaxel|75 mg/m2 ivgtt on days 1 of each 3 week cycle for 4 cycles
224196861|NCT02031601|DRUG|Pemetrexed|500 mg/m2 ivgtt on days 1 of each 3 week cycle for 4 cycles
224196862|NCT02031601|DRUG|Platinum (cisplatin or carboplatin)|cisplatin -- 75mg/m2 ivgtt on day 1 of each 3 week cycle for 4 cycles or carboplatin -- 5 x AUC ivgtt on day 1 of each 3 week cycle for 4 cycles
224196863|NCT02031601|DRUG|Erlotinib|150mg po once a day daily until disease progression
224196864|NCT02031601|DRUG|Gefitinib|250mg po once a day daily until disease progression
224196865|NCT02031601|DRUG|Icotinib|125mg po three times a day daily until disease progression
224196866|NCT03116958|DEVICE|CPAP + Standard care|CPAP device + Standard management at Sleep Unit. According to Spanish Respiratory Society guidelines during 6 months
224196867|NCT03116958|DEVICE|CPAP + Telemedicine|CPAP+ telemedicine approach. Patients followed up at Sleep Unit according to Spanish Respiratory Society guidelines during 6 months.
224196868|NCT02719613|DRUG|Elotuzumab|Patients will continue to receive treatment with the investigational study drug by intravenous (IV) solution administration at the last dose and schedule received in the previous study.
224196869|NCT02719613|DRUG|Dexamethasone|Patients will continue to receive treatment with non-investigational study drug by oral tablet administration at the last dose and schedule received in the previous study.
224196870|NCT02719613|DRUG|Dexamethasone|Patients will continue to receive treatment with non-investigational study drug by intravenous (IV) solution administration at the last dose and schedule received in the previous study.
224196871|NCT02719613|DRUG|Lenalidomide|Patients will continue to receive treatment with non-investigational study drug by oral capsule administration at the last dose and schedule received in the previous study.
224196872|NCT02719613|DRUG|Bortezomib|Patients will continue to receive treatment with non-investigational study drug by intravenous (IV) or subcutaneous injection solution administration at the last dose and schedule received in the previous study.
224196873|NCT02719613|DRUG|Pomalidomide|Patients will continue to receive treatment with non-investigational study drug by oral capsule administration at the last dose and schedule received in the previous study.
224196874|NCT02719613|DRUG|Nivolumab|Patients will continue to receive treatment with the investigational study drug by intravenous (IV) solution administration at the last dose and schedule received in the previous study.
224196875|NCT00924313|DRUG|(C-11 Acetate)|11C-acetate positron emission tomography (PET)/computed tomography (CT)for 30 minutes, intravenous bolus injection
224196876|NCT04299958|OTHER|Patient diary|In the first visit they will be examined by a neurologist with experience in headache disorders and NH diagnosis will be reviewed. Patients will be invited to participate into the study and they will provide and sign informed consent form. They will be instructed and trained to complete the prospective headache diary during 14 days. A follow up visit will be done within 15 to 30 days to review the data and analyze possible sources of bias.
224196877|NCT00000147|DRUG|Methylprednisolone|
224196878|NCT00000147|DRUG|Prednisone|
224196879|NCT05428306|DRUG|A1: Ibuprofen/Acetaminophen Fixed dose combination (Laboratorios Silanes S.A. de C.V.)|Formula : 200 mg/ 500 mg Pharmaceutical Form: Tablet Dosage: 400 mg / 1000 mg (2 tablets) Administration way: oral
224196880|NCT05428306|DRUG|A2: Ibuprofen (Motrin®, Pfizer S.A. de C.V.)|A2: Pharmaceutical Form: tablet Dosage: 400 mg (1 tablet) Administration way: oral
224196881|NCT05428306|DRUG|A3: Acetaminophen (Tylenol caplets®, from Janssen-Cilag, S.A. de C.V.)|A3:Pharmaceutical Form: tablet Formula: Acetaminophen 500 mg Dosage: 1000 mg (2 tablets) Administration way: oral
224196882|NCT05978375|PROCEDURE|Posterior intra-articular distraction and fusion|Using reduction using posterior intra-articular distraction and fusion technique.
224196883|NCT05978375|PROCEDURE|Anterior transoral release and posterior cantilever reduction and fusion|Using anterior transoral release and posterior cantilever reduction and fusion technique.
224196884|NCT05978375|PROCEDURE|TARP|Using TARP technique.
224196885|NCT04757402|OTHER|Counselling with NSQIP Surgical risk calculator|Use of NSQIP surgical risk calculator to check for patient satisfaction regarding pre operative counseling.
224196886|NCT05121818|PROCEDURE|PCI|Primary percutaneous coronary intervention
224196887|NCT05852106|OTHER|"Surgical Simulation with 3D Heart Model and Parental Education with Congenital Heart Disease Parent Education Booklet and tailored 3D Heart Modeling"|The first step in the modeling process is masking. For this study, the average minimum value for masking ventricles and large vessels was set between 80 and 200 HU (Brüning et al., 2022). Threshold values of min 216 HU - max 1502 HU are used. At these HU values, the blood in the heart and great vessels is masked and the outline of the heart is revealed. Lowering the minimum HU value is necessary to make the heart walls more visible. However, this results in masking unwanted soft tissues other than the heart, such as muscle and fat. The masked unnecessary surrounding tissues are removed first with the cropping mask and then manually by marking along the contours of the heart and great vessels. Thus, a model containing only the heart and the desired large vessels will be created and cleaned from the surrounding tissues. With this mask, 3D reconstruction will be performed, and the model will be ready for printing.
224196888|NCT04427618|DRUG|Tranexamic acid|Intravenous 1g TXA (500mg/5ml, given intermittent over approximately 10 minutes) given within approximately 10 minutes before skin incision
223594691|NCT02035527|DRUG|cisplatin|Given IV over 1 hour following Docetaxel administration
223594692|NCT02035527|DRUG|docetaxel|Given IV 1 hour prior to cisplatin administration
223594693|NCT02035527|OTHER|Correlative Studies|Correlative studies will be performed at the following time points. A total of three biopsies (blood and tumor samples) will be obtained in consenting patients.Pre-treatment biopsy to establish diagnosis and baseline data, Research biopsy obtained at the end of a two week period of sorafenib monotherapy just prior to administration of cycle1 with cisplatin and docetaxel, Research biopsy obtained at the end of two chemotherapy cycles.
223594694|NCT05066165|GENETIC|Arm 1: NTLA-5001|"Autologous WT1-directed TCR T cells engineered ex vivo using CRISPR/Cas9 as intravenous infusion after pre-conditioning chemotherapy.~Cyclophosphamide and Fludarabine will be administered on Day -5, -4, and -3 as intravenous infusion."
223594695|NCT05066165|GENETIC|Arm 2: NTLA-5001|"Autologous WT1-directed TCR T cells engineered ex vivo using CRISPR/Cas9 as intravenous infusion after pre-conditioning chemotherapy.~Cyclophosphamide and Fludarabine will be administered on Day -5, -4, and -3 as intravenous infusion."
223594696|NCT06017726|OTHER|treatment of insulin resistance with appropriate modality according to each patient|insulin resistance will be treated with either diet alone or combined diet and appropriate pharmacological treatment with the net result of normalization of HOMA IR index
223594697|NCT05760859|OTHER|Initial cue|"Symptom volunteered by the patient"
223594698|NCT02305212|BEHAVIORAL|Cogmed|
223594699|NCT02185066|DRUG|Atorvastatin 20mg and Metformin XR 500mg (Reference)|"Group 1 receives Atorvastatin 20mg and Metformin XR 500mg first, then CJ-30056 second, with at 7-day wash-out period in between.~Group 2 receives CJ-30056 first, then Atorvastatin 20mg and Metformin XR 500mg second, with 7-day wash-out period in between."
223594700|NCT02185066|DRUG|CJ-30056 20/500mg (Test)|"Group 1 receives Atorvastatin 20mg and Metformin XR 500mg first, then CJ-30056 second, with at 7-day wash-out period in between.~Group 2 receives CJ-30056 first, then Atorvastatin 20mg and Metformin XR 500mg second, with 7-day wash-out period in between."
223594701|NCT03738618|DRUG|Follitropin delta|"FE 999049 was administered as single daily subcutaneous injections in the abdomen at a starting dose of 15 μg daily that was fixed for the first four stimulation days. Based on ovarian response, the dose could be adjusted by 3 μg, with dose increases implemented not more frequently than once every 2 days and dose decreases implemented per investigator's judgement. The minimum daily dose was 6 μg, and the maximum daily dose was 24 μg.~Participants could be treated for a maximum of 20 days. Coasting, use of dopamine agonist or any other drug to prevent early ovarian hyperstimulation syndrome (OHSS) with the exception of gonadotropin-releasing hormone (GnRH) agonist for triggering of final follicular maturation, was not allowed"
223594702|NCT03738618|DRUG|Placebo|"Placebo was administered as single daily subcutaneous injection dialed to the same value (dose) as FE 999049.~Participants could be treated for a maximum of 20 days. Coasting, use of dopamine agonist or any other drug to prevent early OHSS with the exception of GnRH agonist for triggering of final follicular maturation, was not allowed."
223594703|NCT06410456|OTHER|Schroth exercises|Traditional exercise
223594704|NCT06410456|OTHER|Traditional exercises|Adolescents with idiopathic scoliosis performed conventional exercises four days a week for six months.
224196889|NCT04427618|DRUG|Normal saline|Intravenous 10ml normal saline (placebo) given within approximately 10 minutes before skin incision
224196890|NCT00253071|BEHAVIORAL|Prophylactic combined medical and psychological treatment|"Medical treatment is naturalistic and evidence based according to international recommendations.~Psychological treatment is either group psychoeducation or group cognitive behavioural therapy."
223594705|NCT06435923|DRUG|[14C]-darigabat|Oral capsule
223594706|NCT05117190|PROCEDURE|Facial Allotransplantation|
223594707|NCT01769196|DRUG|Simtuzumab|125 mg/mL single-dose vials administered subcutaneously once a week
223594708|NCT01769196|DRUG|Simtuzumab placebo|Simtuzumab placebo single-dose vials administered subcutaneously once a week
224196891|NCT03962751|BEHAVIORAL|Simultaneous Post Feedback Intervention Delivery|Simultaneous PFI delivery after baseline survey
224196892|NCT03962751|BEHAVIORAL|Sequential Post Feedback Intervention Delivery|Sequential PFI delivery over 3 weeks after baseline survey
224196893|NCT03962751|BEHAVIORAL|Text Message Boosters|Text message boosters on PFI content during week of high risk drinking event
224196894|NCT06316401|PROCEDURE|ESD of large LSTs under SA|endoscopic submucosal dissection of large colorectal lesions under spinal anesthesia
224196895|NCT01472666|DIETARY_SUPPLEMENT|High content of MC-SFA|12 weeks dietary intervention
224196896|NCT01472666|DIETARY_SUPPLEMENT|Whey|12 weeks dietary intervention
224196897|NCT01472666|DIETARY_SUPPLEMENT|Low content of MC-SFA|12 weeks dietary intervention
224196898|NCT01472666|DIETARY_SUPPLEMENT|Casein|12 weeks dietary intervention
224196899|NCT04554355|BEHAVIORAL|School-based PA intervention|Provide moderate to vigorous fun-game based exercises for adolescents with ID in schools to help them reduce obesity and improve fitness levels.
224196900|NCT03327935|DIETARY_SUPPLEMENT|Nutrition|150 Faroese surgical patients randomized to one of the following three arms 1) oral nutritional supplements and advice, 2) oral nutritional supplements and training exercise and 3) Standard hospital procedure. Primary outcome is loss of lean body mass
224196901|NCT03401502|DRUG|Ranolazine|Oral, b.i.d
224196902|NCT03401502|DRUG|Placebos|Oral, b.i.d
224196903|NCT00778206|DRUG|Kuvan|-Recommended post-partum Assessments include: collection of baby's plasma at Birth, 1 Month and 6 months, and collection of mother's plasma and expressed breast milk sample at 1 Month.
224196904|NCT02432027|DRUG|C-82 Topical Gel, Placebo|placebo
224196905|NCT02432027|DRUG|C-82 Topical Gel, 1%|active
224196906|NCT02432027|DRUG|Daivonex cream|comparator
224196907|NCT02432027|DRUG|Diprosis gel|comparator
224196908|NCT01298362|DRUG|Aromatase Inhibitors|
224196909|NCT01298362|DRUG|Chemotherapy|
224310758|NCT04511962|OTHER|Tele-Pulmonary rehabilitation|The tele-rehabilitation programme will be delivered via an NHSX / NHS Digital approved commercial video conferencing application. It will comprise an initial assessment followed by 12 bespoke classes delivered by video link over a 6 week period. Participants will be advised to undertake exercises on 5 days each week.
223594709|NCT00627367|DRUG|Hydromorphone|Hydromorphone 1mg IV, followed by an optional dose of 1mg IV hydromorphone 15 minutes
223594710|NCT00627367|DRUG|Nonprotocolized|An IV opioid the type and dose of which will be determined by the treating clinician
223594711|NCT00680459|DRUG|70% ethanol|70% ethanol lock solution instilled into central venous line of patient with documented infection, in addition to usual care with antimicrobials and supportive therapy. Volume of solution instilled varies from 0.8-1.9ml depending on volume of the lumen and hub of the particular size line being treated. 70% ethanol solution dwells for 4 hours, then is withdrawn and discarded. This procedure repeated daily for 5 consecutive days.
223594712|NCT00680459|DRUG|heparin flush solution|heparin flush (10 units/ml) lock solution instilled into central venous line of patient with documented infection, in addition to usual care with antimicrobials and supportive therapy. Volume of solution instilled varies from 0.8-1.9ml depending on volume of the lumen and hub of the particular size line being treated. Heparin lock solution dwells for 4 hours, then is withdrawn and discarded. This procedure repeated daily for 5 consecutive days.
223594713|NCT04373005|DIAGNOSTIC_TEST|Nasopharyngeal (NP) swab|A dry swab will be inserted through one nostril straight towards the back of the nasal passage and rotated gently before the swab is removed.
223594714|NCT00258817|BIOLOGICAL|Influenza Virus Vaccine (Fluzone®)|0.25 mL, Intramuscular (Day 0 and Day 28)
223594715|NCT00258817|BIOLOGICAL|Influenza Virus Vaccine (Fluzone®)|0.25 mL, Intramuscular (Day 0)
223594716|NCT00668837|DRUG|Paliperidone|
223594717|NCT03833219|BEHAVIORAL|Weekly feedback|Send push notification reporting user's handheld phone use while driving compared to distribution for driver cohort (age, geographic area) each week.
223594718|NCT03833219|BEHAVIORAL|End of intervention period incentive|Notify participant about potential incentive at the end of the intervention period, but do not provide weekly feedback about performance.
223594719|NCT03833219|BEHAVIORAL|Loss-framed weekly incentive|Send push notification reporting user's handheld phone use while driving compared to distribution for driver cohort (age, geographic area) each week. Pay participant weekly according to where they fall on the distribution each week.
223594720|NCT01450098|DRUG|LY2484595 Reference Formulation (RF)|Administered orally
223747333|NCT03598608|BIOLOGICAL|pembrolizumab|Administered as an IV infusion every 3 weeks (Q3W)
223747334|NCT03598608|BIOLOGICAL|Favezelimab|Administered as an IV infusion Q3W
224196910|NCT02973789|DEVICE|NovoTTF-200T|"Patients receive continuous TTFields treatment using the NovoTTF-200T device. TTFields treatment will consist of wearing four electrically insulated electrode arrays on the chest. The treatment enables the patient to maintain regular daily routine.~Other Name: TTFields~Drug: Immune checkpoint inhibitors or docetaxel Patients receive standard of care with Immune checkpoint inhibitors or docetaxel"
224196911|NCT02973789|DRUG|Immune checkpoint inhibitors or docetaxel|Patients receive standard of care with Immune checkpoint inhibitors or docetaxel
224196912|NCT02980666|DRUG|Teduglutide|0.05 mg/kg/day SC injection once daily for 24 weeks.
224196913|NCT02110966|DRUG|Mepivacaine|Drug: Tramadol 1.8 ml of Mepivacaine 2% epinephrine 1:100000.
224196914|NCT02110966|DRUG|Mepivacaine plus Tramadol|0.5 ml of Tramadol mixed with 1.3 ml of Mepivacaine.
223594721|NCT01450098|DRUG|LY2484595 spray-dried solid dispersion-propyl gallate (SDSD-PG)|Administered orally
223594722|NCT01905878|DRUG|DLBS1033|
223747335|NCT05761379|DEVICE|Photobiomodualtion Therapy|low lever light therapy with laser semi-conductor at wavelength of 650nm
224196915|NCT03331302|DRUG|Hyperpolarized Xenon-129 MRI (Experimental)|MRI ventilation scan of the lung with inhaled contrast agent (hyperpolarized Xenon-129)
223594723|NCT03956212|DRUG|Doxycycline 7 days|Patient will be treated with doxycycline orally, 100 mg, bid, 7 days
223594724|NCT03956212|DRUG|Doxycycline 14 days|Patient will be treated with doxycycline orally, 100 mg, bid, 14 days
223594725|NCT06206460|OTHER|Online Assessment|"Online Assessment which consists of:~* Sociodemographic data (life changes, medical and gynaecological history)~* German PMS symptom diary retrospectively for last menstrual cycle~* Quality of Life Inventory (SF-12)~* Expectancy of relief"
223594726|NCT01066728|OTHER|CO2 inhalation|Inhalation of CO2 (3% at the source, approximately 1% inhaled) with room air by nasal prongs at 0.5 l/min for 3 days
223594727|NCT01066728|DRUG|Theophylline|
223594728|NCT00655629|DRUG|Vardenafil ODT (STAXYN, BAY38-9456)|Subjects will receive 12 weeks of PRN (on demand) treatment with Vardenafil 10 mg orodispersible tablet (ODT)
223594729|NCT00655629|DRUG|Placebo|Subjects will receive 12 weeks of PRN (on demand) treatment with matching placebo tablet
223747336|NCT05761379|DEVICE|Single vision spectacles for correction myopia|Provide the distance best corrected vision acuity of refractive error of myopia for all the groups
224196916|NCT03331302|DRUG|Radioactive Xenon-133 scintigraphy (Active Comparator)|Radioactive ventilation scintigraphy of the lung with inhaled radioactive contrast agent (Xenon-133)
224196917|NCT01881178|DIETARY_SUPPLEMENT|NOPALEA|
224196918|NCT00488098|DRUG|GSK372475|
224196919|NCT05375045|DEVICE|dental implantation|an implant is surgically inserted into the maxilla or mandible, and then an abutment is connected to this implant to support the dental prosthesis.
224196920|NCT05144919|BEHAVIORAL|Promotion of a biodiverse diet|"Component 1 - Participatory Identification of Intervention Approach (PIIA) Component 2. Local stakeholder consultation Component 3. Sensitisation of community Diversity club will receive capacity building from a Village health worker based on the prioritised species selected in component 2.~The following topics will be covered for each species selected for promotion:~1. Where to locally source inputs and expected price~2. How/when to prepare plots using organic inputs~3. Planting and best-practice management practices~4. Seed saving and storage~5. Possible intercropping combinations OR ecosystem services provided Component 4. Active Cooking demonstrations and Nutrition Education and counselling: Diversified cooking practices"
224196921|NCT04804319|OTHER|9-days habitual diet|9-days study with habitual diet including one standardized breakfast on a single day
224196922|NCT02454621|BEHAVIORAL|Volitional help sheet|Participants are asked to form implementation intentions using a volitional help sheet (Armitage, 2008).
224196923|NCT05732324|PROCEDURE|IVUS guided PCI optimization|PCI to long lesion will be optimized according to the IVUS.
224196924|NCT05732324|PROCEDURE|FFR guided PCI optimization|PCI to long lesion will be optimized according to the FFR.
223747337|NCT00066066|PROCEDURE|Scaling and root planing|Scaling and root planning (SRP) is the mechanical debridement of the tooth and root surfaces and is standard of care in periodontal therapy.
223747338|NCT00066066|DRUG|Metronidazole|Metronidazole (MET) is an antibiotic that is particularly effective against Gram negative bacterial species. The dose for this study is: 250 mg tid x 14d.
223747339|NCT00066066|DRUG|Amoxicillin|Amoxicillin (AMOX) is a broad spectrum antibiotic and was prescribed at 500 mg tid for 14d.
224196925|NCT05732324|DIAGNOSTIC_TEST|FFR measurement|Fractional flow reserve protocol will be applied for both FFR-guided and IVUS-guided PCI groups. FFR will be measured according to the standard practice using intravenous adenosine. FFR will be recorded before PCI at the distal third of the coronary artery and after PCI at the same location. In FFR optimization group more than one post PCI FFR measurements could be acquired if the operators performed additional optimization. In IVUS optimization group only one post PCI FFR measurement will be recorded after which the procedure will be considered to be finished, and no further interventions will be undertaken. The same FFR measurements will be performed at 9-12 months follow-up.
224196926|NCT00072982|DRUG|fish oil|The object of this intervention is to determine whether treatment of rheumatoid arthritis with a combination of fish oil and borage seed oil is superior to treatment with either oil alone. Each arm of the study will take 13 capsules daily (divided doses) for 18 months.
224196927|NCT00072982|DRUG|borage seed oil|Borage oil 13 capsules divided doses daily for 18 months
224196928|NCT00072982|DRUG|combination fish oil and borage seed oil|Fish oil and borage seed oil capsules - 13 capsules to be be taken daily (divided doses) for a period of 18 months
224196929|NCT00838760|DRUG|TMC558445; TMC310911; Darunavir; Placebo|
224196930|NCT03851562|DRUG|Alprostadil 20 micrograms|Intravenous infusion of PGE1 (Days 0, +1 and +2)
224196931|NCT03851562|DRUG|Placebo|Intravenous infusion of physiological saline solution
224196932|NCT00000518|PROCEDURE|electrophysiology|
224196933|NCT00000518|PROCEDURE|electrocardiography, ambulatory|
224310759|NCT00704730|DRUG|XL184|Gelatin capsules supplied in 25-mg and 100-mg strengths administered orally daily
224310760|NCT00704730|DRUG|Placebo|Gelatin capsules color and size-matched to XL184 capsules administered orally daily
223505711|NCT05702619|OTHER|Baseline bloods for CTCs and ct DNA taken at same time as baseline bloods in Arm 1|2 x 10mL Streck cell-free DNA blood collection tubes® for circulating tumour cell (CTC) collection and circulating tumour DNA (ctDNA) extraction.
223505712|NCT05702619|OTHER|Post-pimonidazole bloods for CTCs and ctDNA|ARM 1 - 2 x 10mL Streck cell-free DNA blood collection tubes® for circulating tumour cell (CTC) collection and circulating tumour DNA (ctDNA) extraction.
223505713|NCT01045265|OTHER|Seminal plasma pharmacokinetics|Measure semen sample concentrations, obtain semen to plasma ratios across the dosing interval, the area under the concentration time curve of raltegravir in semen, the variability in penetration of raltegravir into the seminal compartment over the dosing period.
223505714|NCT02605694|DRUG|Duvelisib|25 mg will be administered orally twice daily (BID) during 21-day cycles (Cycles 1-6) followed by 28-day cycles (Cycle 7 and beyond) until disease progression or unacceptable toxicity
223505715|NCT02605694|DRUG|Rituximab|375 mg/m2 will be administered as an intravenous (IV) infusion on Day 1 of Cycles 1-6 (21-day cycles).
223505716|NCT02605694|DRUG|R-CHOP|"IV infusion on Day 1 of Cycles 1-6 (21-day cycles)~* Cyclophosphamide (750 mg/m2)~* Doxorubicin hydrochloride (50 mg/m2)~* Vincristine sulfate (1.4 mg/m2) (2 mg maximum)~* Rituximab (375 mg/m2)"
223505717|NCT02605694|DRUG|Prednisone|100 mg orally on Days 1-5 of Cycles 1-6 (21-day cycles)
223505718|NCT01426659|BEHAVIORAL|parental stimulation according to protocol|"verbal stimulation every day image of the Protocol Dire et Faire"
224310761|NCT01767961|PROCEDURE|diagnostic imaging|Undergo MBS
224310762|NCT01767961|OTHER|questionnaire administration|Correlative studies
224310763|NCT01767961|PROCEDURE|quality-of-life assessment|Correlative studies
224310764|NCT04007289|DRUG|Apixaban|Administration of Apixaban ; 2 clinical examinations; blood tests, 3 liver and spleen stiffness measurements, 2 contrast enhanced echocardiographies, 1 hepatic ultrasonography, Biological samples collections to identify predictors of thrombosis and liver related events
223505719|NCT02774720|BEHAVIORAL|Centre-based exercise|Participants will come to a centre (University of Waterloo or Toronto Rehabilitation Institute) for a one-hour, small group exercise class each week. The classes will include progressive aerobic and resistance exercise. They will be prescribed additional exercise to be performed independently (either at home or in the community).
223505720|NCT02774720|BEHAVIORAL|Home-based exercise|Participants will be prescribed aerobic and resistance exercise to be performed independently (either at home or in the community). They will receive monthly phone calls to discuss achievements and barriers and to tje adjust exercise prescription.
223505721|NCT02930941|DRUG|Tranexamic Acid|TXA (100 mg/1mL) in to the affected nostril(s) via intranasal atomization device. May repeat 2 doses in each affected nostril(s).
223505722|NCT02930941|DRUG|0.9% Sodium Chloride|0.9% Sodium Chloride (1mL) in to the affected nostril(s) via intranasal atomization device. May repeat 2 doses in each affected nostril(s).
223505723|NCT04319536|OTHER|no intervention|self-sampling
223505724|NCT05100147|PROCEDURE|Uterine closure during Cesarean section|The uterotomy is sutured after the delivery of the fetus and the placenta with an appropriate delayed absorbable suture (number 1 polyglactin 910)
223747340|NCT00066066|DRUG|Doxycycline|The ATRIDOX (doxycycline hyclate) ® product is a subgingival controlled-release product composed of a two syringe mixing system. Syringe A contains 450 mg of the ATRIGEL® Delivery System, which is a bioabsorbable, flowable polymeric formulation composed of 36.7% poly(DLlactide) (PLA) dissolved in 63.3% N-methyl-2-pyrrolidone (NMP). Syringe B contains 50 mg of doxycycline hyclate which is equivalent to 42.5 mg doxycycline. The constituted product is a pale yellow to yellow viscous liquid with a concentration of 10% of doxycycline hyclate. Upon contact with the crevicular fluid, the liquid product solidifies and then allows for controlled release of drug for a period of 7 days. Doxycycline is a broad-spectrum antibiotic synthetically derived from oxytetracycline.
224196934|NCT00000518|DRUG|imipramine|
224196935|NCT00000518|DRUG|mexiletine|
224196936|NCT00000518|DRUG|procainamide|
224196937|NCT00000518|DRUG|quinidine|
224196938|NCT00000518|DRUG|sotalol|
223747341|NCT02268409|DRUG|luspatercept|subcutaneous injection
223747342|NCT02805335|DEVICE|KTFIX PLUS|
224196939|NCT01467518|DRUG|Dolutegravir|Dolutegravir is an experimental drug in the integrase inhibitor class for the treatment of HIV. Dose of 50mg every 12 hours for 5 days.
224196940|NCT01467518|DRUG|Methadone|Methadone is a synthetic opioid used in the treatment of opioid dependence. Subjects will be on individualize stabe dose for 8 days.
224196941|NCT02224495|BEHAVIORAL|Structured exercise training|
224196942|NCT04824612|DEVICE|Photobiomodulation with blue led|Preoperative: every two weeks for 30 days. Postoperative: Immediately after surgery, weekly for 4 weeks, every two weeks for another 4 weeks, and one session in 3rd month. blue LED (470 nm, 0,4W, 24J per point on 10 linear points, total 240J).
224196943|NCT04824612|DRUG|Triamcinolone Hexacetonide|intralesional injection of 20 mg/ml. two injections in the preoperative period with a two-week interval between injections and a monthly injection for three months in the postoperative period. The injections will be intralesional and will not surpass the dermis. The drug will be diluted with the same quantity of 2% lidocaine. The scar will be divided into equal parts of 1 cm² and the drug will be distributed equally, respecting the total dose per session of 20 mg for the face and 40 mg for other topographies.
224196944|NCT04824612|DEVICE|Sham LED|A blue LED without power and biologic effect.
224196945|NCT00804804|OTHER|Sleep deprivation and multiple rest|To determine the evolution of the executive functions during a 40-hour extended wakefulness period or during a 40-hour multiple nap protocol in constant experimental conditions of confinement
223505725|NCT00289978|DRUG|Fingolimod 1.25 mg|Patients self-administered fingolimod 1.25 mg capsules orally once daily.
223505726|NCT00289978|DRUG|Fingolimod 0.5 mg|Patients self-administered fingolimod 0.5 mg capsules orally once daily.
223505727|NCT00289978|DRUG|Placebo|Patients self-administered a fingolimod placebo capsule orally once daily.
223505728|NCT02979054|DEVICE|T4020|
223505729|NCT02979054|DEVICE|Placebo|
223505730|NCT05587647|OTHER|Transition to Adulthood Education Program|"YEGEP was developed by the authors based on the information in the literature, based on the needs of mothers of children who have reached adulthood or are going through. Three training modules are planned in line with current requirements. Education will also be supported by audio-visual and written materials. It is planned that the trainings, which will last for 3 weeks in total, for 1 hour a week for each group, in the form of 3 sessions of 1 hour with these contents, will be held at a disabled center. Titles of training modules:~1. Developmental Period Characteristics of Young Adults with Intellectual Disabilities (Transition to Adulthood, Future Planning / Social Life (employment, peers, etc.)~2. Protecting and Sustaining the Health of Young Adult with Intellectual Disabilities~3. Coping with Stress"
223594730|NCT05810350|DRUG|Aumonertinib 165mg orally once daily and intrathecal chemotherapy with pemetrexed|Patients receive Aumonertinib 165mg orally once daily and intrathecal chemotherapy with pemetrexed (30 mg was administered on days 1 and 8) once every 3 weeks.
223594731|NCT02161991|DRUG|Aprepitant|aprepitant should be give when patients receive platinum based chemotherapy, 125mg for day1, 80mg for day2 and day3.
223594732|NCT02161991|DRUG|placebo|placebo should be give when patients receive platinum based chemotherapy, 125mg for day1, 80mg for day2 and day3.
223594733|NCT06238804|PROCEDURE|KL, Iliofemoral, Ilioinguinal, Iliac fossa and combined approaches|A3.1, A3.2, A3.3
223594734|NCT03255551|DRUG|Amosartan|amosartan is a combination of amlodipine, which is a calcium channel blocker (CCB), and rozatan, an angiotensin II receptor antagonist (ARB), and is an antihypertensive agent
223747343|NCT03653793|OTHER|Natural Health Product: LivRelief Varicose Veins Cream|This product is intended to improve circulation and blood flow to minimize the appearance of varicose veins.
223505731|NCT02569775|BIOLOGICAL|Autologous Bone Marrow Mononuclear Cells|Transplantation of Autologous Bone Marrow Mononuclear Cells
223505732|NCT04249635|DIETARY_SUPPLEMENT|DHA|Women received supplementation of Based on Schizochytrium oil, 100% DHA (DSM) from 14 weeks of pregnancy until delivery.
223594735|NCT00705367|DRUG|Placebo|Infusion, Intravenous, single dose, Day 1
223594736|NCT00705367|DRUG|Abatacept|Infusion, Intravenous, 30mg/kg, single dose, Day 1
223594737|NCT00705367|DRUG|Abatacept|Infusion, intravenous, 10 mg/kg, administered on Days 15 and 29 followed by doses every 4 weeks until the end of the study
223594738|NCT00257361|DRUG|D-Cycloserine|
223747344|NCT06145542|BEHAVIORAL|AR group: aerobic training before resistance training|"Exercise are performed 3 times/wk for 8 wks.~Aerobic training sessions are performed using cycle ergometers. Riding speed is 55-60 rotations/min, at an intensity between 50%-75% of heart rate reserve (HRR). Real-time heart rate monitors are worn by each participant during the session. Aerobic training session lasts for 30 minutes, with an additional 5-minute warm-up and 5-min relaxation training before and after the session, respectively.~Participants perform resistance exercise on a set of strength training equipment. Load of resistance exercise is between 60-80% of repetition maximum (RM) in each set of exercise. Six different groups of resistance exercise (involving contractions and relaxations of biceps, triceps, pectoralis major, latissimus dorsi, quadriceps, and hamstrings) are conducted, with 6 sets of 10 repeated tasks in each group. Participants are instructed to finish each set of exercise task within 60 seconds. Between each two sets, there are 60 s of rest time."
223747345|NCT06145542|BEHAVIORAL|RA group: resistance exercise before aerobic exercise|"Exercise are performed 3 times/wk for 8 wks.~Following a 5-min warm-up exercise, the participants perform resistance training on a set of equipment. Load of resistance exercise is set between 60-80% of repetition maximum in each set of exercise. Six different groups of resistance exercise (involving contractions and relaxations of biceps, triceps, pectoralis major, latissimus dorsi, quadriceps, and hamstrings) are conducted, with 6 sets of 10 repeated tasks in each group. Participants are instructed to finish each set of exercise task within 60 s. Between each two sets, there are 60 seconds of rest time.~Aerobic training sessions are performed using cycle ergometers. Riding speed is 55-60 rotations/min, at an intensity between 50%-75% of heart rate reserve. Real-time heart rate monitors are worn during the entire session. Each aerobic training session lasts for 30 minutes, with an 5-minute relaxation training after the session."
223747346|NCT02619890|OTHER|Brain Glioma Registry|
223747347|NCT02953990|BEHAVIORAL|MOMS Program|
224196946|NCT00804804|OTHER|Sleep deprivation and multiple rest|To determine the evolution of the executive functions during a 40-hour extended wakefulness period or during a 40-hour multiple nap protocol in constant experimental conditions of confinement
224196947|NCT00804804|OTHER|Sleep deprivation and multiple rest|To determine the evolution of the executive functions during a 40-hour extended wakefulness period or during a 40-hour multiple nap protocol in constant experimental conditions of confinement
224196948|NCT00804804|OTHER|Sleep deprivation and multiple rest|To determine the evolution of the executive functions during a 40-hour extended wakefulness period or during a 40-hour multiple nap protocol in constant experimental conditions of confinement
224196949|NCT00563602|OTHER|Hemodynamic guided therapy|"To switch two or more different treatments for the prevention of variceal rebleeding according to the hemodynamic response. All patients in the experimental group will begin by:~1\) LEV + Nadolol. HVPG measurement: if response, no changes, if not, switch to 2) LEV + Nadolol + MNI. HVPG measurement: if response, no changes, if not, switch to: 3) LEV + Nadolol + Prazosin. (drugs carefully titrated until achieve maximum tolerated dose)"
224196950|NCT05562596|DIAGNOSTIC_TEST|Measurement of oxysterol profile, including 20 molecules, in liquor before and after surgery|Samples are quantitated by deuterium-labeled mass-spectrometry amalysis.
224196951|NCT03660657|DRUG|Ozone|Ozone Group: Standard treatment + Ozone therapy (O3/O2) by rectal insufflation. O3/O2 concentration progressively increased from 10 to 30 µg/ml; 40 sessions in 16 weeks.
224196952|NCT03660657|DRUG|Oxygen|Control Group: Standard treatment + Oxygen (O2) by rectal insufflation. O3/O2 concentration = 0 µg/ml (only O2); 40 sessions in 16 weeks.
224196953|NCT01003470|OTHER|acupuncture|Xing Nao Kai Qiao Acupuncture
224196954|NCT01003470|BEHAVIORAL|rehabilitation|Kinesitherapy
224196955|NCT01003470|OTHER|acupuncture and rehabilitation|Xing Nao Kai Qiao Acupuncture plus Kinesitherapy
224196956|NCT01012609|OTHER|cetuximab in conjunction with external beam radiation therapy, followed by cetuximab and irinotecan|External beam radiation therapy (5940 cGy in 180 cGy fractions) with weekly cetuximab (250 mg/m2/dose).4-8 weeks rest, 10 cycles of irinotecan (16 mg/m2/day x 5 consecutive days x 2 weeks) with weekly cetuximab (250 mg/m2/dose) at about 21 day intervals. Research biological evaluations will be performed in consenting patients as an optional portion of the study. Cetuximab is to be given every 7 days (+/- 2 days). Cetuximab does not need to be given on Day 1 of each week.
224196957|NCT05146609|BEHAVIORAL|Screening HCV. HR-HOSPITAL|Screening HCV in high risk population by themselves or at referral hospital.
223505733|NCT00645138|PROCEDURE|Paravertebral Block|"Sedation will be provided with midazolam and fentanyl. The transverse processes of T1-T6 will be located using ultrasound guidance. The area will be prepped with betadine. At each level, a 21 Gauge, 4-inch Stimuplex needle will be inserted in order to make contact with the transverse process. Once the transverse process has been located, the needle will be walked off the process and inserted 1 cm deep to its inferior border. After negative aspiration, 3 mL of 1.5% mepivacaine with epinephrine 1:200,000 and bicarbonate and 3 mL of 0.5% bupivacaine with epinephrine 1:200,000 will be injected. Sedation will be provided with 50-100 mcg/kg/min of propofol during the surgical procedure. Approximately 20 minutes before the end of the procedure, 4 mg of zofran will be administered."
223505734|NCT00645138|PROCEDURE|General Anesthesia|Patients in the general anesthesia group will receive midazolam preoperatively for anxiolysis. Anesthesia will be induced with propofol and fentanyl. An LMA will be inserted and anesthesia maintained with sevoflurane in air and oxygen. 4 mg of zofran will be administered approximately 20 minutes before the end of the surgical procedure. The LMA will be removed and the patient will be transported to the PACU at the conclusion of the surgery.
223505735|NCT04450901|DRUG|YBL-006|Route of Administration: IV infusion; 0.5 mg/kg Q2W
223505736|NCT04450901|DRUG|YBL-006|Route of Administration: IV infusion; 2 mg/kg Q2W
223505737|NCT04450901|DRUG|YBL-006|Route of Administration: IV infusion; 5 mg/kg Q2W
223505738|NCT04450901|DRUG|YBL-006|Route of Administration: IV infusion; 10 mg/kg Q2W
223505739|NCT04450901|DRUG|YBL-006|Route of administration : IV infusion, 200 mg Q2W
223505740|NCT04450901|DRUG|YBL-006|Route of administration : IV infusion, 300 mg Q3W
223505741|NCT04450901|DRUG|YBL-006|Route of administration : IV infusion, 300 mg Q2W
223505742|NCT04450901|DRUG|YBL-006|Route of administration : IV infusion, 200mg Q2W
224196958|NCT05146609|BEHAVIORAL|Screening HCV. HR-DDP|Screening HCV in high risk population by themselves or at drug dependence center.
224196959|NCT05146609|BEHAVIORAL|Screening HCV. GP-HOSPITAL|Screening HCV in general population by themselves or at referral hospital.
224196960|NCT05146609|BEHAVIORAL|Screening HCV. GP-PCC|Screening HCV in general population by themselves or at primary care center.
224196961|NCT02704988|PROCEDURE|Carnoy Solution|The subjects in this group will undergo intervention by having surgery (colorectal cancer resection) and lymph node clearing technique with Carnoy solution
224196962|NCT02704988|PROCEDURE|GEWF Solution|The subjects in this group will undergo intervention by having surgery (colorectal cancer resection) and lymph node clearing technique with GEWF solution
224196963|NCT03082079|PROCEDURE|ESD|Patient in ESD group undergo ESD for GIST, and regular follow-up are carried out for these patients on 72 ±3h,7±2d,14±2d,3 month,6 month,1 year,2 year,3 year,4 year,5 year after the treatment. The investigators record the success rate of operation,en bloc resection,operation time,complication rate,hospitalization days,hospitalization expenses,pathology results and tumor recurrence rate
224196964|NCT01920269|PROCEDURE|Trans-urethral resection|Patients underwent urinary cytology of the bladder and upper urinary tract; random cold-cup biopsies of the bladder and prostatic urethra, and complete transurethral resection of all bladder tumour visible on endoscopy, ensuring muscle is included in resected samples.
224196965|NCT01920269|DRUG|intravesical passive diffusion mitomycin|A dose of 40 mg mitomycin dissolved in 50 ml sterile water is infused intravesically through a Foley catheter, retained in the bladder for 60 min with catheter clamping, and then drained. Patients who have a complete response to the initial 6 weekly treatments underwent a further 10 monthly instillations, with the same dose and methods of infusion as initial assigned treatment.
224310765|NCT04007289|DRUG|Placebo|Administration of placebo ; 2 clinical examinations; blood tests, 3 liver and spleen stiffness measurements, 2 contrast enhanced echocardiographies, 1 hepatic ultrasonography,
224310766|NCT06912711|DRUG|Toripalimab|Triplizumab (240mg, Q3W, 2 cycles, induction)and (240mg, Q3W, 15 cycles, adjuvant)
224310767|NCT06912711|DRUG|Nimotuzumab|Triplizumab (200mg, Q3W, 2 cycles, induction) and (200mg, Q3W, 15 cycles, adjuvant)
224196966|NCT01920269|DEVICE|intravesical electromotive mitomycin|A dose of 40 mg mitomycin dissolved in 100 ml water is instilled and retained in the bladder for 30 minutes with 20 mA pulsed electric current, and then drained. Patients who have a complete response to the initial 6 weekly treatments underwent a further 10 monthly instillations with the same dose and methods of infusion as initial assigned treatment. Intravesical electromotive drug administration is given by a battery-powered generator delivering a controlled electric current that passes between the active intravesical electrode (integrated into a specific transurethral catheter) and dispersive ground electrodes (on skin of the lower abdomen). Operators set active electrode polarity and current intensity on the generator.
224196967|NCT02071472|OTHER|DP medication reconciliation|
224196968|NCT05041868|OTHER|Treatment|After a physical therapy evaluation, the patient underwent a booklet-guided physical exercise program that lasted three months (3 times per week with a duration of 60 minutes per session). Activities included overall stretching and strengthening (flexion, extension, adduction and abduction movements) and muscular endurance exercises (exercises involving open and closed kinetic chains), along with aerobic conditioning using a functional circuit. The patient was evaluated at 2 different timepoints (baseline and after treatment). The physiotherapist contacted the patient by phone weekly to follow the progression of the treatment.
224196969|NCT05460312|DIAGNOSTIC_TEST|prostate biopsy|trans rectal ultrasound guided biopsies of prostate . Biopsy smaples will be referred to staining and western blot analysis.
224196970|NCT04443426|DIETARY_SUPPLEMENT|Oral 3-hydroxybutyrate salts|Comercially available 3-hydroxybutyrate salts with 36 grams of 3-OHB salts three times daily.
224196971|NCT04443426|DIETARY_SUPPLEMENT|Carbohydrate Placebo|Comercially available carbohydrate sports drink. The placebo dose is isocaloric to the 3-hydroxy butyrate dose.
224196972|NCT04443426|DIETARY_SUPPLEMENT|Ketone Monoester|Commercially available ketone monoester in a dosage isocaloric to 3-OHB salts.
224310768|NCT06912711|PROCEDURE|surgery|The complete resection of the nasopharyngeal tumor and its adequate safety boundary must be performed under general anesthesia and under the guidance of nasal endoscopy through bilateral nasal passages. The anterior incisal margin should reach 1-2cm in front of the posterior column of the nasal septum, and the upper incisal margin should reach about 0.5-1cm in front of the upper margin of the posterior nostril. The lateral incisal margin and the lower incisal margin should be individually designed according to the size and location of the tumor. A safe incisal margin of 0.5-1.0cm was obtained, and then the tumor tissue and normal tissue of the incisal margin were ablated layer by layer from the upper incisal margin to the lower incisal margin until no obvious tumor remained under the naked eye.
224310769|NCT06913153|BEHAVIORAL|Diet|
223505743|NCT03098407|DRUG|Buprenorphine|This is a pilot study to establish the feasibility and acceptability of a randomized comparative effectiveness clinical trial comparing office-based buprenorphine vs. federally licensed methadone treatment programs for OD pregnant women.
224196973|NCT04619758|OTHER|Emollient (sunflower oil)|In group A, mothers will be advised to massage their babies with sunflower oil at a dose of 10 mL/kg/day twice a day in equally divided amounts. They will be called for follow up after six months of application of sunflower oil.
223505744|NCT03098407|DRUG|Methadone|This is a pilot study to establish the feasibility and acceptability of a randomized comparative effectiveness clinical trial comparing office-based buprenorphine vs. federally licensed methadone treatment programs for OD pregnant women.
223505745|NCT04324697|PROCEDURE|Horizontal alveolar bone augmentation|Horizontal augmentation in anterior maxilla using allograft shell and autogenous chips with no need for a second surgical site
223505746|NCT06326918|DIAGNOSTIC_TEST|Duodenal mucosal brushing|Duodenal mucosal brushing will be performed at duodenal bulb.
223505747|NCT06326918|DIAGNOSTIC_TEST|Duodenal mucosal biopsy|Duodenal mucosal biopsy will be performed at duodenal bulb.
223505748|NCT05281640|BEHAVIORAL|Affect Dysregulation intervention|See relevant study arm for description
223505749|NCT05281640|BEHAVIORAL|Negative Self Concept intervention|See relevant study arm for description
223505750|NCT05281640|BEHAVIORAL|Disturbed Relationships intervention|See relevant study arm for description
223505751|NCT00267319|DRUG|Glatiramer acetate|
223505752|NCT03008577|OTHER|Change in ambient operating room temperature|
223505753|NCT00720083|DRUG|cisplatin|Given IV
223505754|NCT00720083|DRUG|vandetanib|Given orally
223505755|NCT00720083|RADIATION|radiation therapy|Patients undergo radiotherapy 5 times a week for up to 6.5 weeks.
223505756|NCT01341938|DRUG|Commit® nicotine lozenges (4 mg) & self-help materials|"Participants provided with instructions on standard use of lozenge for nicotine replacement therapy (NRT) \& instructed to use the lozenge any time they have a craving or urge to use ST or tobacco. Dosing: weeks 1-6 one lozenge every 1-2 hours/16 per day, weeks 7-9 one lozenge every 2-4 hours/8 per day, weeks 10-12 one lozenge every 4-8 hours/4 per day + The Enough Snuff video and printed guide providing strategies for tobacco cessation."
223505757|NCT01341938|BEHAVIORAL|Commit® nicotine lozenges (4 mg) & phone counseling & self-help materials|"Three phone counseling sessions to assist in cessation from use of all tobacco + lozenge nicotine replacement therapy (NRT) + The Enough Snuff video and printed guide providing strategies for tobacco cessation."
223594739|NCT02809378|DRUG|Palonosetron|newly developed 5-HT3 antagonists with long half life (48 hrs) intravenous administration prior to anesthesia induction
223594740|NCT02809378|DRUG|sevoflurane|Inhalational anesthetics Halogenated.
223594741|NCT02809378|DRUG|remifentanil|ultra-short acting opioid anesthetics
223594742|NCT02809378|DRUG|pentothal sodium|intra-venous anesthetics for anesthesia induction
223594743|NCT02809378|DRUG|propofol|intra-venous anesthetics for anesthesia induction and maintenance
223594744|NCT01085877|DRUG|estradiol, 25 mcg|Single dose of vaginal tablet containing 25 mcg estradiol (Production site A) followed by another single dose of vaginal tablet containing 25 mcg estradiol (Production site B)
223594745|NCT01085877|DRUG|estradiol, 25 mcg|Single dose of vaginal tablet containing 25 mcg estradiol (Production site B) followed by another single dose of vaginal tablet containing 25 mcg estradiol (Production site A)
223594746|NCT01832155|BEHAVIORAL|Hatha yoga|Hatha yoga poses that were specifically designed by a group of yoga experts for older adults with knee osteoarthritis. Program included physical poses and sequence that focus on strengthening the lower extremities, and relaxation techniques.
224196974|NCT03246685|BIOLOGICAL|Imprime PGG|Imprime PGG is a soluble, β-1,3/1,6 glucan isolated from the cell wall of a proprietary Saccharomyces cerevisiae yeast strain. Imprime PGG acts as a Pathogen-Associated Molecular Pattern (PAMP). Imprime will be administered at a dose of 4 mg/kg IV over a 2-hour infusion time on Days 1, 8 and 15 of each 3-week treatment cycle.
224196975|NCT03246685|DRUG|Pembrolizumab|Pembrolizumab is a humanized monoclonal antibody against the programmed death receptor-1 protein. Pembrolizumab will be given at a fixed dose of 200 mg IV over 30 minutes on Day 1 of each 3-week treatment cycle after the Imprime infusion.
224196976|NCT04231799|PROCEDURE|Bathing|Traditionally, it is the process of washing the newborn in the first hours of life to remove blood, meconium, varnish and other infectious substances.
224196977|NCT04381117|DRUG|Previously Treated with EN3835|No treatment to be administered - Observational only
224196978|NCT02743182|DRUG|Pegylated interferon alfa-2a|
224196979|NCT02800317|PROCEDURE|RISAS|RISAS procedure contains Radioactive Iodine Seed localisation in the Axilla in axillary node positive breast cancer combined with a Sentinel node procedure.
224196980|NCT00582634|DRUG|docetaxel and cisplatin|Docetaxel (75mg/m2) followed by cisplatin (75mg/m2) on day 1 of a 21 day cycle. Both drugs will be administered intravenously over 1 hour each for4 cycles.
224196981|NCT05289921|BIOLOGICAL|HU-014 Inj|HU-014 Inj was given an injection to 5 Upper limb muscle
224196982|NCT00753402|BIOLOGICAL|Endotoxin, Lipopolysaccharide, LPS|Clinical Center Reference Endotoxin, lot 2, sterile saline, 2 ng/kg, bolus IV administration (\~5 minutes)
223505758|NCT01341938|BEHAVIORAL|Phone counseling & self-help materials|"Three phone counseling sessions to assist in cessation from use of all tobacco + The Enough Snuff video and printed guide providing strategies for tobacco cessation."
223505759|NCT03818932|DRUG|Celecoxib|Post-Operative Non Opioid Pain Protocol
223505760|NCT03818932|DRUG|Hydrocodone-Acetaminophen|Traditionally used narcotic pain protocol
223505761|NCT03818932|DRUG|Ketorolac|Post-Operative Non Opioid Pain Protocol
223505762|NCT03818932|DRUG|Gabapentin|Post-Operative Non Opioid Pain Protocol
223505763|NCT03818932|DRUG|Acetaminophen|Post-Operative Non Opioid Pain Protocol
223505764|NCT03818932|DRUG|Diazepam|Post-Operative Non Opioid Pain Protocol
223505765|NCT04017910|DEVICE|EchoMark/EchoSure|Each subject will have an EchoMark implanted at the time of arteriovenous fistula creation, and undergo EchoSure and duplex imaging follow-up.
223505766|NCT01967277|DEVICE|Handi-Dome Laser|One, 30 minute treatment, every other day for 16 weeks.
223505767|NCT01967277|DEVICE|Incandescent red light source.|One, 30 minute treatment, every other day for 16 weeks.
223505768|NCT01676350|PROCEDURE|IO access using EZ-IO®|IO line placed using an FDA-approved device called an EZ-IO®.
223505769|NCT03539198|RADIATION|Proton Stereotactic Body Radiation Therapy (SBRT) (5 fractions; 3500-4500 cGy)|Patients will be receiving proton SBRT
223505770|NCT03539198|RADIATION|Proton Stereotactic Body Radiation Therapy (SBRT) (3-5 fractions; various dose and fractionation regimens depending on treatment site).|Patients will receive proton SBRT.
223505771|NCT03539198|DRUG|Nivolumab 3 mg/kg IV q2 weeks|Patients will receive Nivolumab x2 cycles before SBRT q2 weeks, and continued q2 weeks after SBRT until progression or at the discretion of the treating physician.
223505772|NCT03539198|RADIATION|Proton or Photon SBRT (3-5 fractions; various dose and fractionation regimens depending on treatment site).|Patients with further oligoprogression (5 or fewer sites) will be eligible to receive additional SBRT to all sites of oligoprogression.
223505773|NCT01975649|DRUG|Tribulus Terrestris|patients will use 750 mg/day during 120 days
223505774|NCT01975649|OTHER|Placebo|patients will use placebo pills with the same shape of the drug
223505775|NCT06260839|PROCEDURE|magnetic resonance neurography|preoperative magnetic resonance neurography and assisted design of surgical approach
223505776|NCT06260839|PROCEDURE|no magnetic resonance neurography|Preoperative magnetic resonance neurography was not performed, and general minimally invasive surgery was performed
224196983|NCT00753402|BIOLOGICAL|Endotoxin, Epinephrine|Clinical Center Reference Endotoxin, lot 2, sterile saline, 2 ng/kg, bolus IV administration (\~5 minutes/Epinephrine 30mcg/kg/min
224196984|NCT00030056|DRUG|GM-CSF (granulocyte-macrophage colony-stimulating factor, sargramostim)|
224310770|NCT05065567|DRUG|Droperidol|Patients with suspected cannabis hyperemesis syndrome and enrolled in the study will be randomized based on the week to 2.5mg droperidol IV
223505777|NCT00585585|DRUG|betahistine dihydrochloride|oral, 50-300 mg, daily
223505778|NCT06323720|OTHER|Quantitative Sensory Testing|Assessment of the heat and cold pain thresholds, temporal summation, conditioned pain modulation, pressure pain thresholds, electrical pain thresholds, and withdrawal reflex.
223505779|NCT00103506|DRUG|Bortezomib (VELCADE)|1.3 mg/m\^2 by rapid (bolus) i.v. administration given on Days 1, 4, 8, and 11 of each 21-day cycle for up to 8 cycles.
223505780|NCT00103506|DRUG|Bortezomib (VELCADE)|1.3 mg/m\^2 by rapid (bolus) i.v. administration given on Days 1, 4, 8, and 11 of each 21-day cycle for up to 8 cycles..
223505781|NCT00103506|DRUG|Doxorubicin hydrochloride (DOXIL/CAELYX)|mg/m\^2 by i.v. infusion will be given on Day 4 of every 21-day cycle after the administration of bortezomib (VELCADE) for up to 8 cycles.
223505782|NCT05214950|DEVICE|ORI monitoring|Oxygen reserve index monitoring during the surgery
223505783|NCT05740384|DEVICE|Sonotubometry Assessment|"The exact order of the measurements will be randomised:~* Recording type 1: No sound applied, 10 seconds recording of baseline noise, followed by recording when the participant is asked to swallow 3 times.~* Recording type 2: White noise applied, 10 seconds recording of baseline noise, followed by recording when the participant is asked to swallow 3 times.~* Ask for subjective feedback (did you hear a change in the sound in your ear on swallowing?) after each recording~* This is repeated using the contralateral ear and nostril. After successful recording, the microphone will be removed.~For comparison, tubomanometry measurements will be performed on each ear. Tubomanometry is an alternative method to assess the middle ear and Eustachian tube. Afterwards, the participant's involvement in the study will be complete. The entire involvement will take about 50 minutes."
223505784|NCT05916924|OTHER|Collection of clinical data including manual muscle test (MMT), range of motion (ROM), Fugl-Meyer assessment (FMA), berg balance scale (BBS) and kinetic data via video shooting|Collection of clinical data including manual muscle test (MMT), range of motion (ROM), Fugl-Meyer assessment (FMA), berg balance scale (BBS) and kinetic data via video shooting
224196985|NCT00615927|DRUG|Imatinib Mesylate & Hydroxyurea|"Imatinib administered orally on daily. Imatinib is local irritant \& must be taken in sitting position; mini of 2hrs should be allowed between last drug intake \& going to bed. Imatinib doses 400mg/600mg administered once daily, whereas daily doses of 800mg/\> administered as equally divided dose taken twice day. Dose for imatinib: Pts not receiving p450-inducing antiepileptic drugs: 400 mg/day. Pts receiving p450-inducing antiepileptic drugs: 500 mg twice day. It is recommended that pts take their prescribed imatinib mesylate at same time that they take their prescribed hydroxyurea, however, 30-60min interval between agents is acceptable if required for practical/other compliance issues.~Hydroxyurea administered orally twice day. Dosing will begin on day 1 of cycle 1 \& continue daily. Drug is approximately 80 percent bioavailable. Dose will be 500mg twice day for all pts."
224196986|NCT04128059|DRUG|BVRS-GamVac-Combi|"BVRS-GamVac-Combi, a combined vector vaccine for the prevention of Middle East respiratory syndrome, lyophilisate for the preparation of a solution for intramuscular administration"
224196987|NCT04128059|OTHER|placebo|placebo
223505785|NCT02288871|RADIATION|Cardiac CT-scan|"ECG gated CT angiography of the heart will be performed on a 128-slice dual-source and two Stellar detectors CT system with retrospective ECG-gating (Siemens/SOMATOM Definition Flash - Siemens, Germany, 100kV, 395.75 mAs).~In details, multi-phase images will be acquired to reconstruct between 10 and 100% of the cardiac cycle (10% increments) with a slice thickness of 1 mm. Examination will include left ventricular outflow tract, aortic root, coronary sinus, ascending aorta together with the prosthetic valves."
223505786|NCT00585169|DRUG|Memantine Hydrochloride|10 mg/day for two weeks, dose increase to 20 mg at week 3, 30 mg at week 4 unless clinical improvement is achieved with a lower dose. Total treatment is 10 weeks.
223505787|NCT00710970|DRUG|Tamoxifen|Tamoxifen is administered at 20 mg/day as a single daily oral dose. Tamoxifen is continued until progressive disease or intolerable grade 3 or 4 side effects occur due to tamoxifen.
223505788|NCT05656976|OTHER|Provision of self sampling device by the GP|In a group of 45 GP practices, over a course of 9 months, all long-term unscreened women with a GMD will be addressed by their GP when they consult for any reason. The GP will discuss the pros and cons of screening for cervical cancer, the various options for screening for cervical cancer including the possibility of using a SSD. For this, the GP can use on accessible brochure and video materials. After the woman agrees, she is given a self-taking kit that she can use when and where it suits her and send it to the lab with the prepaid envelope. The woman is informed of the result of the Human Papilloma Virus test result by her GP according to the usual way in the practice (e.g. via letter, by phone or during the next consultation).
223505789|NCT05656976|OTHER|Provision of self sampling device by letter|In the second arm, a second group of 45 GP practices in Flanders will be recruited. With the intervention of the Centre for Cancer Prevention (Flanders), 25 at randomly selected long-term unscreened women with a Global Medical Form (in dutch: 'Globaal Medisch Dossier, GMD) in one of these practices will receive an envelope containing a letter of invitation from their GP for cervical cancer screening, a brochure with the advantages and disadvantages of cervical cancer screening and more specifically the use of a self-taking kit, and a self-taking kit. If the woman wishes, she can use the kit when and where it suits her and send it to the lab with the pre-paid envelope. As in arm A, the woman will be informed of the Human Papilloma Virus test result by her GP according to the usual way in the practice (e.g., by letter, by phone or during the next consultation). All women will receive a study-related reminder letter after 4 months.
223505790|NCT01495273|PROCEDURE|Transtracheal injection|Experimental group will undergo transtracheal injection using needle connected to a nerve stimulator device.
223505791|NCT01495273|PROCEDURE|Transtracheal injection|Control group will undergo transtracheal injection with a standard needle/syringe assembly.
223505792|NCT01894646|RADIATION|Positron Emission Tomography (PET) Imaging|
223505793|NCT01028560|BIOLOGICAL|Allergen extracts (subcutaneous injections)|Allergy immunotherapy consists of regular subcutaneous injections of an individualized mixture of allergen extracts according to the allergy sensitization profile of each child. Increasing doses of allergen extract are given in 1-2 injections until a predetermined maintenance dose is reached. This maintenance dose varies by extract and accords to the general practice guidelines of immunotherapy. To increase safety, the cumulative monthly maintenance doses are divided into biweekly visits during the maintenance phase (year 2-3)
223594747|NCT01832155|BEHAVIORAL|Hatha Yoga|The same intervention was provided to the wait-list control group at the end of 8 weeks when the intervention completed their intervention classes.
223594748|NCT01055314|BIOLOGICAL|Cixutumumab|Given IV
223505794|NCT01028560|OTHER|Standard of care|standard of care asthma and allergy treatment
223505795|NCT03055221|DRUG|Intravenous Treprostinil|Intravenous treprostinil supplied in 20-mL vials and diluted to the appropriate concentration for administration.
223505796|NCT00961012|PROCEDURE|The Big Squeeze|Trunk release as per MSIP protocol. Standing at the foot of the bed, facing the subject, Experimenter A grasps both ends of the flat sheet to pull the trunk forward and away from the mattress surface. As the trunk release procedure is performed, Experimenter A checks to verify that the laser beam shines through to the opposite wall to confirm that the shoulders have cleared the mattress.
223505797|NCT04264962|DRUG|Yang Yin Fu Zheng Jie Du therapy|Yang Yin Fu Zheng Jie Du is a Chinese herbal compound.
223505798|NCT04264962|OTHER|Routine medical care|Routine medical care
223594749|NCT01055314|DRUG|Cyclophosphamide|Given IV
223594750|NCT01055314|BIOLOGICAL|Dactinomycin|Given IV
223594751|NCT01055314|DRUG|Doxorubicin Hydrochloride|Given IV
223594752|NCT01055314|DRUG|Etoposide|Given IV
223594753|NCT01055314|DRUG|Ifosfamide|Given IV
223594754|NCT01055314|DRUG|Irinotecan Hydrochloride|Given IV
223594755|NCT01055314|OTHER|Laboratory Biomarker Analysis|Correlative studies
223594756|NCT01055314|DRUG|Temozolomide|Given PO
223594757|NCT01055314|DRUG|Vincristine Sulfate Liposome|Given IV
223594758|NCT04701567|DIAGNOSTIC_TEST|Magnetic resonance imaging|Advanced multiparametric MRI techniques to diagnose hepatic and pancreatic disease
223594759|NCT00572013|DRUG|Rituxan|375mg/m2 IV on days -20 to -8. Infusion to begin at rate of 50mg/hour for 1st hour.If no toxicity rate may be increased. A second infusion 375mg/m2 given 30days post transplant and again at 60 days post transplant
223594760|NCT00572013|DRUG|BEAM|BCNU(carmustine)on day -6 300mg/M2 IV, etoposide 100mg/M2 BID on days -5 through -2, cytarabine 100mg/m2 BID on days -5 through -2, melphalan 140mg/m2 IV on day -1
224196988|NCT06182410|DRUG|Defibrotide|Given intravenously (IV)
224310771|NCT05065567|DRUG|Haloperidol|Patients with suspected cannabis hyperemesis syndrome and enrolled in the study will be randomized based on the week to 5mg haloperidol IM
223505799|NCT04401631|DEVICE|Blood Collection|"Between-Run Reproducibility K3-EDTA venous whole blood 3 mL 1 venous draw~Operator-to-operator imprecision (abioSCOPE) K3-EDTA capillary whole blood 0.05 mL/draw; 0.15 mL total 3 finger sticks (3 different fingers)~Sample type comparison (abioSCOPE) K3-EDTA capillary whole blood, venous serum, venous K3-EDTA plasma 0.35 mL (finger stick), 9 mL of whole blood to get a minimum of 3 mL of serum and 9 mL of whole blood K3-EDTA to get a minimum of 3 mL of plasma 1 finger stick; 1 venous draw into serum tube (9 mL) and 1 venous draw into K3-EDTA plasma tube (9 mL), in total 18 mL~Method comparison (abioSCOPE and ImmunoCAP/Phadia) K3-EDTA capillary whole blood, venous K3-EDTA plasma 0.05 mL (finger stick), 9 mL of whole blood to get a minimum of 3 ml of plasma 1 finger stick; 1 venous draw into K3-EDTA plasma tube (9 mL tube)"
223594761|NCT00572013|PROCEDURE|Autologous stem cell transplant|following chemotherapy, on day 0 of treatment, the previously stored hematopoietic stem cells will be reinfused via the central venous line
223594762|NCT00098683|DRUG|amifostine trihydrate|
223594763|NCT06112691|DEVICE|taking fundus photos using non-mydriatic fundus camera - FundusScope Rodenstock|using artificial intelligence to identify diabetic retinopathy in the early stages using fundus photography.
223594764|NCT01279616|DRUG|Fludarabine monophosphate|180 mg/m2 over 6 days.
223594765|NCT01279616|DRUG|Rituximab|375 mg/m2 on day -13 and day -3
223594766|NCT01279616|DRUG|Busulfan|AUC 1000-1200 microM.mt
223594767|NCT01279616|DRUG|ATG|2.5 mg/kg for 3 days
223594768|NCT01279616|DRUG|Cyclophosphamide|50 mg/kg on day +3
223594769|NCT01279616|DRUG|Mycophenolate mofetil|15 mg/kg q 8 hours
223594770|NCT01279616|DRUG|Tacrolimus|0.03 mg/kg /d
223594771|NCT04811495|OTHER|Physiotherapy treatment|A treatment plan is carried out which aims to improve pain, muscle balance and range of motion of the temporomandibular joint.
223594772|NCT02462720|DRUG|Varithena®|Varithena® treatment in accordance with full prescribing information and instructions for use
223594773|NCT02462720|DEVICE|Radiofrequency ablation|Radiofrequency ablation conducted per physicians' standard of care.
223594774|NCT04467281|DRUG|89Zr-DFO-daratumumab|Patients will undergo 89Zr-DFO-daratumumab PET/CT once before standard of care therapy and once again afterward, for a total of two research scans.
223594775|NCT04467281|DIAGNOSTIC_TEST|PET/CT|Patients will undergo 89Zr-DFO-daratumumab PET/CT once before standard of care therapy and once again afterward, for a total of two research scans.
223594776|NCT02914665|DRUG|elamipretide|20 mg elamipretide administered intravenously once daily for 7 consecutive days
223594777|NCT02914665|DRUG|Placebo|Placebo administered intravenously once daily for 7 consecutive days
224196989|NCT00744029|BEHAVIORAL|educational material|Educational letter indicating stroke symptoms and emphasizing the importance of calling the emergency medical services (EMS) as well as a bookmark and sticker with the EMS telephone number.
224196990|NCT06566027|OTHER|Skeletal, dental, soft tissue index changes in Activator group|After being interviewed and provided by a doctor with two kinds of appliances (Activator and EF class II standard) for treating class II malocclusion, the patients choose their appliance. The patients were separated into two groups (30 in each). Group 1 was treated with an Activator appliance (Activator group), whereas Group 2 was treated with an EF class II standard appliance (EF line group)
224310772|NCT05065567|DRUG|Ondansetron 8mg|Patients with suspected cannabis hyperemesis syndrome and enrolled in the study will be randomized based on the week to ondansetron
224310773|NCT06546774|DIETARY_SUPPLEMENT|Melatonin|In the study group, patients will receive melatonin supplementation for at least two months prior to IVF cycles
224310774|NCT05345613|DRUG|Tranexamic acid|Submucosal injection of standard solution including TXA during EMR procedure
224310775|NCT05345613|DRUG|Standard|Injection of standard solution
224310776|NCT06937294|DRUG|Metformin|Participants are administered metformin with an initial dose of 500 mg/day, which was incrementally increased by 500 mg/day each week until the maximum tolerated dose. The maximum dose of metformin is set at 2000 mg/day.
223505800|NCT01243424|DRUG|linagliptin|linagliptin tablets 5mg QD
223505801|NCT01243424|DRUG|glimepiride|glimepiride over-encapsulated tablet 1-4 mg QD
223505802|NCT01243424|DRUG|linagliptin placebo|linagliptin placebo
223505803|NCT01243424|DRUG|glimepiride placebo|glimepiride placebo
223505804|NCT03614585|BEHAVIORAL|12 weeks of High-intensity Interval Training|Cardiovascular exercise
223594778|NCT00972530|BEHAVIORAL|immobilisation in a triangular sling|"Intervention group: Immobilisation 48 hours in a triangular sling (mitella)~Control group: normal activity without restrictions"
223594779|NCT06582134|BEHAVIORAL|Sham BMBI|Participants are requested to listen to the recordings 3 times a week, for 3 months (in a standardized sequence e.g., 1-2-3 and repeat) on Mondays-Wednesdays-Fridays. They are instructed to listen right before they sleep and encouraged to use them whenever they feel stressed or in pain.
223594780|NCT06582134|BEHAVIORAL|BMBI|Participants are requested to listen to the recordings 3 times a week, for 3 months (in a standardized sequence e.g. A-B-C and repeat) on Mondays-Wednesdays-Fridays. They are instructed to listen right before they sleep and encouraged to use them whenever they feel stressed or in pain.
223594781|NCT02384733|RADIATION|Loco-regional RT|
223594782|NCT05163652|BIOLOGICAL|SARS-CoV-2 Vaccine, Inactivated (Vero Cell)|the third dose immunization schedule of SARS-CoV-2 inactivated vaccine
223594783|NCT00183625|BEHAVIORAL|Individual Placement and Support (Supported Employment)|
223594784|NCT00183625|BEHAVIORAL|Social Skills Training|
223594785|NCT00183625|DRUG|Olanzapine|
223594786|NCT00183625|DRUG|Risperidone|
223594787|NCT00156416|BEHAVIORAL|Mindfulness Meditation|8 weeks of meditation training
223594788|NCT04022252|DEVICE|Cheese dental laser|810 nm GaAlAs diode laser device
223594789|NCT04022252|DEVICE|OrthoPulse|850 nm LED (light emitting diode)
223594790|NCT04022252|OTHER|Placebo|810 nm GaAlAs diode laser device
223594791|NCT02681471|OTHER|5% Mannitol|Traditional monopolar TURP was performed by using and irrigation fluid containing 5% mannitol ( Resectisol Eczacibasi-Baxter).
224196991|NCT03963960|DEVICE|Hemodialysis with low dialysate flow|Hemodialysis with low dialysate flow
223594792|NCT02681471|OTHER|0,9% Sodium chloride|Bipolar TURP was carried out by using a 24 Fr TURis (OLYMPUS) resectoscope and irrigation fluid containing 0,9 % sodium chloride.
223594793|NCT02681471|DEVICE|monopolar resectoscope|
224196992|NCT03963960|DEVICE|Conventional triweekly high-flow hemodialysis|Conventional triweekly high-flow hemodialysis
224196993|NCT03669627|BIOLOGICAL|aTIV Primer|MF59-adjuvanted trivalent influenza virus primer: 2 doses (0.25mL) one month apart
223594794|NCT02681471|DEVICE|bipolar resectoscope TURis|
223594795|NCT02769910|DRUG|Capsaicin 24 Hours|Dermal patches for transdermal application of Capsaicin, applied for 24 hours
223594796|NCT02769910|DRUG|Capsaicin 1 Hour|Dermal patches for transdermal application of Capsaicin, applied for 1 hour
223594797|NCT02769910|OTHER|Qutenza Demo Patch|Dermal patches mimicking active Qutenza patches. Used as control in comparison of Capsaicin efficacy. Applied for 24 hours.
223594798|NCT05215834|DRUG|Remifentanil|"1. Remimazolm and Remifentanil (RR group): anesthesia was induced with remimazolam 6 mg/kg/h by continuous intravenous (IV) infusion and with the effect-site concentration of remifentanil 4 ng/ml and until the loss of consciousness (LoC), followed by remimazolam 1-2 mg/kg/h and remifentanil 3 ng/ml until the end of surgery.~2. Propofol and Remifentanil (PR group), anesthesia was induced with the effect-site concentration of propofol of 6.0 μg/ml and remifentanil 4 ng/ml, and until the loss of consciousness (LoC), followed by the effect-site concentration of propofol of 2-4 μg/ml and remifentanil 3 ng/ml until the end of surgery."
223594799|NCT01969955|DRUG|nanoparticle albumin-bound paclitaxel|Nanoparticle albumin-bound paclitaxel is given at 130 mg/m2 intravenously on day 1 and 8, every 21 days.
223594800|NCT01633658|DIETARY_SUPPLEMENT|cholecalciferol|a single dose of 2500 micrograms of cholecalciferol
223594801|NCT01633658|DIETARY_SUPPLEMENT|25(OH)D|a single dose of 625 micrograms of 25(OH)D
223594802|NCT00626171|PROCEDURE|Allergen Challenge|Allergen challenge
223594803|NCT00414518|DRUG|Tenofovir disoproxil fumarate/Emtricitabine|300 mg Tenofovir disoproxil fumarate/ 200 mg emtricitabine tablet taken orally once daily
223594804|NCT00414518|DRUG|Lopinavir/Ritonavir|Three 400 mg lopinavir/ 100 mg ritonavir soft gel capsules taken orally twice daily
223594805|NCT05249569|DRUG|Axitinib|Axitinib to be administered orally BID
223594806|NCT05249569|DRUG|Avelumab|Avelumab to be administered as a 1-hour IV infusion on Day 1 and Day 15 of each 28-day cycle.
223594807|NCT05249569|DRUG|Bavituximab|Bavituximab to be administered weekly on Days 1, 8, 15 and 22 of the 28-day cycle.
223594808|NCT00189605|DEVICE|Perc-DLR/Perc-DLG|Device technique will be used per IFU
223594809|NCT00189605|DRUG|Fluoroscopy guided transforaminal epidural steroid injection (TFESI)|Injection of steroid solution into the lumbar level
224196994|NCT03669627|BIOLOGICAL|QIV Primer|Unadjuvanted quadrivalent influenza vaccine primer: 2 doses (0.5mL) one month apart
223594810|NCT00337090|DRUG|YM178|
223594811|NCT02450162|PROCEDURE|lateral rectus recession (bilateral)|Two types of recession (conventional or hang-back method) are typical surgeries for correcting intermittent exotropia. It depends on surgeon's decision at the time of surgery.
223594812|NCT05340036|PROCEDURE|Bimaxillary orthognathic surgery using conventional plates|"le fort I osteotomy will carried out in the classic way guided by the classic landmarks (maxillary roots apices) as described by Wassmund.~Complete separation of the maxillary segment using chisels and mallets in regular fashion.~Reposition maxilla using the interocclusal wafer while mandible is gently positioned to centric relation position.~Mandible is maintained in place until fixation of the maxilla with plates and screws takes place.~Complete separation of the mandibular segment using chisels and mallets in regular fashion.~Repositioning of mandible using the final interocclusal wafer while condylar segment is gently positioned to centric relation position.~Fixation of mandibular segments with plates and/or screws in regular fashion.~Incision was closed with 4-0 resorbable sutures in a continuous running fashion."
223594813|NCT05340036|PROCEDURE|Bimaxillary orthognathic surgery using patient specific plates|"The cutting guide of the maxilla will be placed onto the exposed bony surface and manipulated to the best fit.~Then, the guide will be fixed using four 2.0-mm screws to avoid any mobilization during drilling of the reference holes. Sixteen reference holes will be established using the cutting guide; eight on each side.~Then, a reciprocating saw will be used to perform the planned Le Fort I osteotomy. After adequate maxillary mobilization and removal of bony interferences, the maxilla will be repositioned using the patient-specific osteosynthesis material guided by the previously established reference holes and fixed using 2.0-mm screws.~Then, the mandibular cutting guide will be fixed in the same manner and bilateral sagittal split osteotomy will be carried out.~After adequate mobilization, the mandible will be repositioned by the patient-specific osteosynthesis material using the reference holes made by cutting guide and fixed using 2.0-mm screws."
223594814|NCT03907150|DIAGNOSTIC_TEST|Strain ultrasound|Post-interpretation of recorded ultrasound loops
223594815|NCT00252603|DRUG|Galantamine|
223594816|NCT06584526|OTHER|Physical Therapy|30 minutes of physical therapy with education, manual therapy and therapeutic exercise at both temporomandibular and cervical regions (same programme than the experimental groups).
223594817|NCT06584526|OTHER|Physical Therapy and Aerobic Exercise|30 minutes of physical therapy with education, manual therapy and therapeutic exercise at both temporomandibular and cervical regions, combined with a 30 minutes aerobic exercise programme on a cycle ergometer.
224196995|NCT03669627|BIOLOGICAL|aTIV Booster|MF59-adjuvanted influenza virus vaccine booster: 1 dose (0.25mL), year 2
224196996|NCT03669627|BIOLOGICAL|QIV Booster|Unadjuvanted quadrivalent influenza vaccine booster: 1 dose (0.5mL), year 2
224196997|NCT03984994|OTHER|Aerobic exercise training|3 months of center-based, supervised treadmill exercise
224196998|NCT03984994|OTHER|Strength training|3 months of center-based, supervise strength training
224196999|NCT03775694|DEVICE|dMRI Scan|Data will be collected from cases where dMRI scans were obtained as part of the subject's previous treatment.
224197000|NCT02611076|BEHAVIORAL|Stop Smoking for Good Intervention in Spanish (SS-SP)|Assessments will occur at six-month intervals, through 24 months.
224197001|NCT02611076|BEHAVIORAL|Usual care (UC)|Assessments will occur at six-month intervals, through 24 months.
224197002|NCT00924820|DRUG|Bevacizumab|10 mg/kg by vein over about 1 hour, every 2 weeks.
224197003|NCT04983589|DRUG|Pilocarpine HCl|Pilocarpine HCl ophthalmic solution 1.25% ocular drops.
224197004|NCT04983589|DRUG|Vehicle|Oxymetazoline HCl and pilocarpine HCl placebo ocular drops.
223594818|NCT06584526|OTHER|Physical Therapy and Strength Exercise|30 minutes of physical therapy with education, manual therapy and therapeutic exercise at both temporomandibular and cervical regions, combined with a 30 minutes strength exercise programme.
223594819|NCT02082704|BEHAVIORAL|SE Game on DSME|Investigators created an online educational game by incorporating game mechanics into an evidence-based form of online education, termed 'spaced education' (SE). Based upon two psychology research findings (the spacing and testing effects), SE has been shown in randomized trials to improves knowledge acquisition, boosts learning retention for up to two years, and durably improves clinical behavior.
223594820|NCT02082704|BEHAVIORAL|SE Game on American History|Investigators created an online educational game by incorporating game mechanics into an evidence-based form of online education, termed 'spaced education' (SE). Based upon two psychology research findings (the spacing and testing effects), SE has been shown in randomized trials to improves knowledge acquisition, boosts learning retention for up to two years, and durably improves clinical behavior.
223594821|NCT05412368|OTHER|Focus Groups|Focus Groups
223594822|NCT03817112|DRUG|Dexmedetomidine Hydrochloride 0.1 MG/ML|Dexmedetomidine Hydrochloride 0.1 MG/ML infusion at 0.2-0.7 mcg/kg/min
223594823|NCT03817112|DRUG|Propofol 10 MG/ML|Propofol 10 MG/ML infusion at 0.3 -4 mg/kg/h
223594824|NCT02140749|DIETARY_SUPPLEMENT|sc-FOS 2g/day|Chewing tablets containing Short-chain fructooligosaccharides 2g/day
223594825|NCT02140749|DIETARY_SUPPLEMENT|sc-FOS 4g/day|Chewing tablets containing short-chain Fructooligosaccharides 4g/day
223594826|NCT02140749|DIETARY_SUPPLEMENT|sc-FOS 8g/day|Chewing tablets containing short-chain Fructooligosaccharides 8g/day
223594827|NCT02140749|DIETARY_SUPPLEMENT|Placebo|Chewing tablets without short-chain Fructooligosaccharides
223594828|NCT01764828|DRUG|Refametinib (BAY86-9766)|
223594829|NCT01764828|DRUG|Gemcitabine|
223594830|NCT05787925|DRUG|Topical corticosteroid and Vitamin E|"26 patients who will administrate topical corticosteroid: triamcinolone acetonide 1% oral gel Kenacort-A Orabase \* three times daily for 8 weeks applied after meals and at night with avoidance of foods and drinks for 30 minutes after the application. In addition to one capsule of 400 mg oral systemic vitamin E supplement\* will be prescribed once daily at the morning"
223594831|NCT05787925|DRUG|Topical corticosteroid|"26 patients will administrate topical corticosteroid: triamcinolone acetonide 1% oral gel Kenacort-A Orabase three times daily for 8 week that will be applied after meals and at night with avoidance of foods and drinks for 30 minutes after the application"
223594832|NCT04566432|OTHER|Observation|observe the association of ctDNA with efficacy of treatment
223594833|NCT03933228|PROCEDURE|Interscalene-Cervical Plexus Block|Ultrasound-Guided Combined Interscalene-Cervical Plexus Block
223594834|NCT03933228|PROCEDURE|Supraclavicular-Cervical Plexus Block|Ultrasound-Guided Combined Supraclavicular-Cervical Plexus Block
223594835|NCT02545764|OTHER|Strength and neuromuscular exercise programme|12 weeks strength and neuromuscular exercise programme for the lower extremity
223594836|NCT06583278|DEVICE|transcranial magnetic stimulation|The stimulations were performed by MagStim Rapid2.
224197005|NCT02999516|OTHER|Motor imaginary|Participants imagine doing a motor task watching a video recording
224197006|NCT02999516|OTHER|Non Motor imaginary|Participants watch a television documentary
224197007|NCT02999516|OTHER|tDCS|transcranial direct current stimulation (tDCS) stimulation during 20 minutes in the motor cortex (bilaterally) at 1mA of intensity.
223594837|NCT01119092|OTHER|"Sham (laying of hands) intervention"|The clinician will place his/her hands in a position to perform the AP joint mobilizations but will not actually perform them. The sham treatment will be performed 3 times and each will last a period of 60 seconds with a one minute rest in between.
223594838|NCT01119092|OTHER|Grade IV AP joint mobilizations|3 60-second treatments of Grade IV AP joint mobilizations of the talus during each treatment session, with a one minute rest in between each treatment.
223594839|NCT01447732|DRUG|CEP-37250/KHK2804|"Part 1 is based on the CEP-37250/KHK2804 tolerability and safety data from three subjects enrolled in a cohort, enrollment at the next dose level or additional subjects into the ongoing cohort will occur based upon the number subjects with DLT at a given dose level. Dose depends on subject's body weight. Part 1 includes intervention of CEP-37250/KHK2804.~Part 2 will receive CEP-37250/KHK2804 at a dose to be determined following completion of Part 1."
223594840|NCT05716347|BIOLOGICAL|the recombinant SARS-CoV-2 S-Trimer vaccine/inactivated SARS-CoV-2 vaccine|one booster dose intramuscularly in the deltoid muscle of the upper arm.
223594841|NCT02105038|OTHER|Spinner knob|
223594842|NCT02105038|OTHER|No Knob|
223594843|NCT02678923|DRUG|MDCO-216|
223594844|NCT02678923|DRUG|Placebo|
223594845|NCT02376023|OTHER|mHealth|Text and voice messages sent to study participants reminding them to schedule a PAP smear.
223594846|NCT05700032|DIAGNOSTIC_TEST|high MI impulses|patients will receive intermittent high MI impulses(\>1.0) in addition to low MI imaging. LVOT VTI will be measured at different times per protocol.
223594847|NCT05700032|DIAGNOSTIC_TEST|low MI impulses|patients will receive low MI imaging only. LVOT VTI will be measured at different times per protocol.
223594848|NCT07087379|DRUG|Intensive statin treatment|"Intensive statin group:~Atorvastatin 80mg, orally administered 12 hours before surgery Atorvastatin 80mg, orally administered 2 hours before surgery"
223594849|NCT07087379|DRUG|Placebo Control|Placebo, tablets, oral administration 12 hours before surgery Placebo, tablet, oral administration 2 hours before surgery
223594850|NCT07089732|DIETARY_SUPPLEMENT|GLP-1 formula liquid drink|One glass jar (50 g) of the GLP-1 formula liquid drink was administered once daily, 30 minutes prior to the first meal of the day.
223594851|NCT07089732|DIETARY_SUPPLEMENT|Placebo|One glass jar (50 g) of the placebo liquid drink was administered once daily, 30 minutes prior to the first meal of the day.
224197008|NCT02999516|OTHER|tDCS sham|tDCS stimulation during 30 seconds in the motor cortex (bilaterally) at 1mA of intensity and then 19 minutes and 30 seconds without any stimulation.
224197009|NCT02999516|OTHER|Neurofeedback|EEG monitoring of the cerebral cortex in real time with positive feedback in the computer screen when participants motor cortex is activated. The positive feedback consist in an object that moves to the top of the screen when activation occurs in the motor cortex. This task last during 20 minutes.
223594852|NCT04766554|DEVICE|Cerebral oximetry monitor (The INVOS® Cerebral/Somatic Oximeter) and protocol-based interventions|In the intervention group, an alarm threshold below 15% of the baseline rSO2 value will be established. Based on the predetermined algorithm the rSO2 will be maintained at or above 85% of the baseline measurements. If the rSO2 reaches levels below 15% of the baseline values or below 50% in absolute value for over 30 seconds, protocol-based interventions will be performed to restore rSO2 to baseline levels.
223594853|NCT01439178|DRUG|Intravitreal Avastin injection|Bevacizumab (1.25 mg in 0.05 ml) (Avastin; Genentech Inc., San Francisco, CA, USA) will be injected through the pars plana at 3.5 mm from the limbus, using 30 gauge needle.
223594854|NCT03038854|OTHER|Test GUM|Growing up milks (GUMs) are milk-based drinks with vitamins and minerals for toddlers and pre-school children.
223594855|NCT03038854|OTHER|Standard GUM|Growing up milks (GUMs) are milk-based drinks with vitamins and minerals for toddlers and pre-school children.
224197010|NCT02999516|OTHER|Neurofeedback sham|EEG monitoring of the cerebral cortex in real time with randomized feedback in the computer screen despite motor cortex activation. The positive feedback consist in an object that moves to the top of the screen in a randomized time. This task last during 20 minutes.
223594856|NCT03038854|OTHER|Cows' milk|Homogenized store-bought full fat cow's milk.
223594857|NCT06522399|PROCEDURE|TAMIS mucosectomy|internal Delorme's procedure using TAMIS
223594858|NCT03764267|DRUG|Remifentanil|"Five minutes before infiltration of the local anesthestic by the surgeon, patients received an initial maintenance infusion of remifentanil 0.1 µg/kg/min and ketofol mixture 0.3 ml/kg (propofol 25 µg /kg/min and ketamine 10 µg/kg/min). ketofol mixture was prepared in a ratio of 1:2.5 (100 mg ketamine 2 mL (100 mg), propofol 1% 25 mL (250 mg), and glucose 5% 23 ml, total volume of 50 ml, each ml contain 2 mg ketamine + 5 mg propofol).~Throughout the surgery, titration of the infusion rate of the remifentanil and ketofol were indicated by vital signs and expression of pain"
223594859|NCT03764267|DRUG|general anesthetic|general anesthetic was induced with a bolus dose of remifentanil (1 ug/kg over 30 second) and propofol (2 mg/kg) followed by insertion of a laryngeal mask airway (LMA). After the induction of anaesthesia and securing the airway, patient' lungs were ventilated with volume controlled ventilation, 50% oxygen/air mixtures in a circle system. .Anesthesia was maintained with remifentanil (0.5 ug/ kg/ min) and propofol (5 mg/kg/h). Remifentanil and propofol titrated to keep heart rate and the blood pressure within 20% of the baseline values and maintain BIS between 40 and 60, respectively. Patient movements were treated with additional i.v. bolus doses of remifentanil 0.5 ug/kg
223594860|NCT02004977|BEHAVIORAL|Improve access to the school breakfast program|Access to the school breakfast program is defined as implementation of a grab-n-go cart outside of the school cafeteria, policy change allowing students to eat in the hallway and marketing of the program. in rural high schools.
223594861|NCT05558462|DRUG|XC8|A single dose of R or T drug in each of 2 periods of the study in fasted conditions
223594862|NCT00098306|DRUG|Maraviroc (UK-427,857)|Maraviroc was given either once or twice per day with the dose adjusted according to the optimized background therapy
223594863|NCT00098306|DRUG|Optimized Background Therapy|Maraviroc was given either once or twice per day with the dose adjusted according to the optimized background therapy
223594864|NCT00098306|DRUG|Optimized Background Therapy|Patients will be randomly (2:2:1) assigned to one of three groups: Optimized Background Therapy \[OBT (3-6 drugs based on treatment history and resistance testing)\] + maraviroc (UK-427,857) 150 mg taken once daily, OBT + maraviroc (UK-427,857) 150 mg taken twice daily, or OBT alone.
223594865|NCT00098306|DRUG|Placebo|Patients will be randomly (2:2:1) assigned to one of three groups: Optimized Background Therapy \[OBT (3-6 drugs based on treatment history and resistance testing)\] + maraviroc (UK-427,857) 150 mg taken once daily, OBT + maraviroc (UK-427,857) 150 mg taken twice daily, or OBT alone.
223594866|NCT00098306|DRUG|Optimized Background Therapy|Patients will be randomly (2:2:1) assigned to one of three groups: Optimized Background Therapy \[OBT (3-6 drugs based on treatment history and resistance testing)\] + maraviroc (UK-427,857) 150 mg taken once daily, OBT + maraviroc (UK-427,857) 150 mg taken twice daily, or OBT alone. The study will enroll over approximately a 9 month period with 48 weeks of treatment.
223594867|NCT05920408|DRUG|EXS21546|EXS21546 Granule in Capsule
223594868|NCT02971150|BEHAVIORAL|Brief Behavioral Treatment for Insomnia|
223594869|NCT02974049|DRUG|Albendazole|"Subjects in Arms 1, 2, and 4 will receive 400mg of Albendazole~Subjects in Arm 3 will receive 800mg of Albendazole"
223594870|NCT02974049|DRUG|Ivermectin|Subjects in Arms 1 and 4 will receive 200mg/kg body weight
223594871|NCT02974049|DRUG|Diethylcarbamazine|Participants in Arm 4 will receive 6mg/kg of Diethylcarbamazine per body weight
223594872|NCT01423916|DRUG|OPC-34712 (4mg)|Arms assigned to this intervention receive 4mg.
223594873|NCT01423916|DRUG|Moxifloxacin|Arms assigned to this intervention will receive 400mg.
223594874|NCT01423916|DRUG|OPC-34712 (12mg)|Arms assigned to this intervention receive 12mg.
223594875|NCT01423916|DRUG|Placebo|OPC-34712 placebo
223594876|NCT03468582|COMBINATION_PRODUCT|123I radiolabeled 3BNC117|123I radiolabeled 3BNC117
223594877|NCT00641082|DRUG|Clevudine|30mg for 48 weeks
224197011|NCT05991622|DRUG|Combined LAI Treatment: Cabenuva and Sublocade|A preliminary test of the combined LAI treatment will be conducted with a total of 40 individuals diagnosed with HIV and OUD that meet all other study inclusion criteria. Treatment will take place primarily at TMH IC (n=30), however, about one-quarter of participants will undergo the pilot test at the RIDOC (n=10). Participants will complete a baseline interview, receive the combined LAI treatment (described below), and complete follow-up assessments at 1-, 3-, and 6-months following initiation of injectable medication. Of the 40 participants, 25 will be purposefully selected to engage in qualitative interviews to assess the strengths and limitations of the clinical protocol and combined treatment as well as describe their reasons for LAI uptake or discontinuation. We will also elicit feedback from clinic staff and other key stakeholders regarding the delivery of the clinical protocol and other implementation factors
223594878|NCT00641082|DRUG|Adefovir dipivoxil|10mg for 48 weeks
224197012|NCT00790972|DRUG|Sinofresh|two sprays in each nostril three times daily for one week
224197013|NCT00790972|DRUG|Placebo|two sprays in each nostril three times daily for one week
223594879|NCT01274520|DEVICE|The Medtronic Portable Bypass System (PBS®)|Will be used for machine perfusion of liver grafts.
223594880|NCT06253169|DIAGNOSTIC_TEST|HPV DNA self-test|HPV DNA swab from the cervix performed by the patient herself.
223747348|NCT04171817|DRUG|Chlorhexidine|The goal of this work is to assess the effect of chlorhexidine (CHX)-based interventions--specifically use of pre-session chlorhexidine shampoo for the dog and use of chlorhexidine wipes on the dog's fur--on patient exposure to hospital-associated pathogens during the sessions with the dogs
223747349|NCT02505230|BEHAVIORAL|Eating|Participants will have 20 minutes to eat as much or as little of a meal (consisting of pasta alone or pasta with zucchini and squash presented in 3 different ways)
223747350|NCT05643235|DEVICE|Medtronic LINQ-2 Insertable Cardiac Monitor (ILR)|Patients initiating BTK inhibitors will be offered the option of monitoring using the Medtronic Insertable Cardiac Monitor (ILR). The device will be implanted by a certified and credentialed electrophysiologist to enable monitoring to begin at least 24 hours prior to the first administration of the BTK inhibitor. Monitoring data will be collected prospectively until the patient withdraws consent, the device is removed, or up to 60 months
223594881|NCT03429257|OTHER|Exposures of interest: Maternal EED and Aflatoxin Exposure|Maternal EED, measured via lactulose: mannitol (L:M) ratios and serum concentrations of antibodies to the bacterial components flagellin and lipopolysaccharide (LPS); Maternal aflatoxin exposure, measured via serum concentration of AFB1-lysine adduct
223594882|NCT00367276|DRUG|Yasmin (30 µg EE, 3 mg Drospirenone, BAY86-5131)|Yasmin, SH T 470 FA; 30 µg ethinylestradiol and 3 mg drospirenone, oral administration over 6 treatment cycles, one tablet per day for 21 days followed by a 7 day pill-free interval.
224197014|NCT02478216|PROCEDURE|Remote ischemic preconditioning|The tourniquet was applied at the opposite site from operation thigh in the both groups. The thigh was covered with blanket to conceal the tourniquet inflation and deflation. A total of 3 cycles of tourniquet inflation for 5 minutes with 2 × systemic systolic arterial blood pressure of arrival at operation room and deflation were performed.
223505805|NCT03614585|BEHAVIORAL|12 weeks of Moderate-Intensity Continuous Training|Cardiovascular exercise
223505806|NCT02246036|DEVICE|APD probe|The probe will be placed in the patient with an endoscopic procedure by a gastroenterologist (standard procedure for post-pyloric tubes placement).
223594883|NCT03848767|DEVICE|AID System|AID System
223594884|NCT03848767|DRUG|Insulin Lispro|Individualized doses of insulin lispro administered via the AID system to maintain glycemic control except during meal challenges.
223594885|NCT01896583|DRUG|ASP7147|300 mg, tablet, twice per day for 4 weeks oral
223594886|NCT01896583|DRUG|Placebo|
223594887|NCT01966445|BIOLOGICAL|GSK2849330|Solution containing 100 mg/millilter (mL) GSK2849330 for intravenous infusion
223594888|NCT04684953|PROCEDURE|Throid autotransplantation|Operative
223747351|NCT00156533|DRUG|Zolpidem|10 mg of Zolpidem
223747352|NCT00156533|DRUG|Sugar Pill|
223747353|NCT06629662|PROCEDURE|Sleeve gastrectomy|Sleeve gastrectomy with laparoscopic or robotic approach
224197015|NCT02654561|DRUG|Heparin Sodium|A bottle solution of Heparin Sodium(2ml:12500IU) is added to 50ml saline and administered i.v. continuously for 24 hours, which last 7 days or until the death or discharge. The same amount of 0.9% saline as the heparin group will be administered in the placebo group.
223505807|NCT02598999|DRUG|ALX-009|Solution for inhalation administered through nebulization
223505808|NCT02598999|DRUG|OSCN-|Solution for inhalation administered through nebulization
223505809|NCT02598999|DRUG|bLF|Solution for inhalation administered through nebulization
223505810|NCT02598999|DRUG|Placebo|Solution for inhalation administered through nebulization, Sodium Chloride 0.9%
223505811|NCT00008268|BIOLOGICAL|filgrastim|
223505812|NCT00008268|DRUG|melphalan|
223505813|NCT04803435|OTHER|Telemedicine Consultation|Brief telemedicine consultation, blindedto subsequent face-to-face evaluation.
223505814|NCT04803435|OTHER|Face-to-face Consultation|Direct face-to-face evaluation (without telemedicine consultation before).
223505815|NCT02074137|DRUG|CABAZITAXEL XRP6258|Pharmaceutical form:Solution Route of administration: Intravenous
223594889|NCT04684953|DRUG|Hormone|thyroid hormone replacement therapy
223594890|NCT01656070|DRUG|oral cholecalciferol 1000000 UI (vitamin D3)|
223747354|NCT02143440|BEHAVIORAL|The initial assessment of daily insulin dose.|
223747355|NCT02029833|OTHER|Regular Canola Oil|
223747356|NCT02029833|OTHER|High Oleic Canola Oil|
223747357|NCT02029833|OTHER|Western Type Diet - Common Dietary Oils|
223747358|NCT04372667|BEHAVIORAL|Community score card approach|"The CSC intervention is a participatory community approach. Health care workers (HCWs), PMTCT clients identified the issues that most impacted PMTCT service quality and uptake, and came together to implement actions for improvement. The core implementation strategy is using dialogue in a participatory forum that engages both service users and service providers. The CSC consists of five core phases, repeated on a regular basis (called rounds), for the life of the project. The five core phases include:~1. Phase I: Planning and preparation~2. Phase II: Conducting the Score Card with the community~3. Phase III: Conducting the Score Card with service providers~4. Phase IV: Interface meeting and action planning~5. Phase V: Action plan implementation and follow-up"
223747359|NCT01948817|DRUG|Deferasirox|Deferasirox 20mg/kg taken BID
224197016|NCT02654561|DRUG|Saline|For all the severe sepsis or septic shock patients, normal saline will be administered for fluid resuscitation according to the Guideline of Survival Sepsis Campaign.
223505816|NCT02074137|DRUG|Prednisone|Pharmaceutical form:Tablet Route of administration: Oral
223505817|NCT02074137|DRUG|Prednisolone|Pharmaceutical form:Tablet Route of administration: Oral
223505818|NCT01034527|OTHER|Neuromuscular Training|Combination of exercises and phases to initiate lateral trunk perturbations that force the athlete to decelerate and control the trunk in order to successfully perform the techniques.
223594891|NCT01656070|DRUG|Placebo|
223594892|NCT02435706|PROCEDURE|Flapless immediate implant placement|Experimental group: No elevation of flap prior to immediate implant placement
223594893|NCT02435706|PROCEDURE|Flap assisted immediate implant placement|Control group: Flap will be elevated prior to immediate implant placement
223594894|NCT02435706|DEVICE|Implant and temporary crown|Both groups receive this intervention
223594895|NCT01374178|DRUG|LY2963016|Administered subcutaneously
223594896|NCT01374178|DRUG|Lantus|Administered subcutaneously
223505819|NCT05862441|DRUG|AV2-SA2|AV2 is a combination of FDA GRAS-label approved organic compounds (natural essential oils: carvone, eugenol, geraniol, and nerolidol) that is postulated to be able to prevent viral entry and proliferation by deactivating the infectious virions before they enter the cell. Salicylic acid (SA) formulations are the most commonly used preparations in the treatment of warts. SA is an organic acid that destroys epidermal cells and softens hyperkeratotic epidermis. Implementation of AV2-SA combination therapy would ensure permanent lesion clearance by on the one hand inactivation of HPV by AV2, and on the other hand elimination of the lesion by SA treatment.
224197017|NCT03654495|OTHER|Exergame training|"Training on Medical Device (MD): Dividat Senso, DIV-SENSO-H, Dividat GmbH, Software development: ISO 62304:2016; designed to train aspects of executive functions (EFs; divided attention, working memory, inhibition, and shifting) and physical functions through Virtual Reality video game training.~FITT training principles are implemented; Frequency: three times per week, Intensity: individually adapted VG (allowing training progression), Type: combination of cognitive and motor training, and Time: 20 min training sessions. Training lasts 6 weeks (18 training sessions). Participants train 20 min, three times per week. Training includes one session of each VG (4 min) in a pre-defined order and short breaks (\~1 min) for game change."
224197018|NCT03654495|OTHER|Usual Care Training|Routine (standard) therapy given based on conventional current-best-evidence Rehabilitation. Preoperative Phase: Diminish inflammation, swelling, and pain; Restore normal range of motion (especially knee extension); Restore voluntary muscle activation Immediate Postoperative Phase (Day 1-7): Restore full passive knee extension; Diminish joint swelling and pain; Restore independent ambulation Early Rehabilitation Phase (Week 2-4): Maintain full passive knee extension; Gradually increase knee flexion; Muscle training Controlled Ambulation Phase (Week 4-10): Restore full knee ROM; Improve lower extremity strength; Enhance proprioception, balance, and neuromuscular control Advanced Activity Phase (Week 10-16): Normalize lower extremity strength; Enhance muscular power and endurance; Improve neuromuscular control; Perform selected sport-specific drills.
224197019|NCT03297710|OTHER|Quality-of-Life Assessment|Ancillary studies
224197020|NCT03297710|RADIATION|Radiation Therapy|Undergo radiation therapy
224197021|NCT03297710|DRUG|Trifluridine/Tipiracil Hydrochloride Combination Agent TAS-102|Given PO
224197022|NCT01761123|BIOLOGICAL|VXA-A1.1|
224197023|NCT00151658|DEVICE|Coronary Drug Eluting Stents for PCI|
224197024|NCT05185791|OTHER|Pre-ERAS® phase (current clinical practice)|Descriptive recordings of pre-intra-post-operative clinical endpoints and demographic parameters.
224197025|NCT05185791|OTHER|Post-ERAS® implementation phase|Descriptive recordings of pre-intra-post-operative clinical endpoints and demographic parameters.
223505820|NCT05862441|DRUG|SA|Salicylic acid (SA) formulations are the most commonly used preparations in the treatment of warts. SA is an organic acid that destroys epidermal cells and softens hyperkeratotic epidermis.
223505821|NCT04819620|DRUG|PN-232|Active Drug
223505822|NCT04819620|DRUG|Placebo|Matching Placebo
223505823|NCT03973593|BEHAVIORAL|Enhancing contraceptive counseling on method continuation and switching|Health care workers and Community Health Volunteers will be trained on a contraceptive counseling package that enhances information on method continuation and switching. This will be done in the ten intervention facilities prior to enrollment of clients into the cohort study.
223505824|NCT02669537|DEVICE|GoPro Camera|The gopro camera will be used to record the procedure which will be reviewed by the resident prior to performing a second procedure of the same type.
223505825|NCT02011464|DRUG|Exparel|Exparel is infiltrated into posterior compartment for pain control
223505826|NCT02011464|OTHER|Saline|Saline is infiltrated into posterior compartment for control
223505827|NCT00732693|DRUG|Ethinylestradiol / Norethisterone|"Oral ethinylestradiol 30mcg and norethisterone 1.5mg daily for weeks 1-3, followed by 7 pill free days"
223505828|NCT00732693|DRUG|Estradiol / Progesterone|Transdermal estradiol 100mcg daily for week 1, then 150mcg daily for weeks 2-4; and vaginal progesterone pessaries 200mg twice daily for weeks 3-4
224197026|NCT02331459|OTHER|Multicomponent training intervention|"Intervention characteristics: 24weeks, 5days/week, 60min/session Day 1, 3 and 5 15 min (a) 40 min (b) 5 min (d) Day 2 and 4 15 min (a) 40 min (c) 5 min (d)~Legend:~min. =minutes a = Proprioception exercises, postural sway and dynamic balance, coordination and flexibility of the lumbo-pelvic area b = Aerobic training 65% maximal Heart rate c = Strength training arms and legs d = Stretching"
224197027|NCT02331459|OTHER|Nutritional intervention|"Enrolled patients will receive nutritional information on optimal daily energy intake, ensuring at least a daily protein intake of 1 g. of by kg of weight.~Calcium plus vitamin D (total amount 1200 mg calcium plus 800 IU of vitamin D) Vitamin D will be provided if calcidiol (Cldl) blood levels are lower than 30 ng/ml.~Cldl 20-29 ng/dl it will provide calciferol 20.000 IU every 15 days (3 months) Cldl 10-19 ng/dl it will provide calciferol 20.000 IU every 10 days (3 months) Cldl 1-9 ng/dl it will provide calciferol 20.000 IU every 7 days (3 months)"
224197028|NCT02057224|PROCEDURE|Renal denervation using Medtronic Symplicity System (mono-electrode)|Secondary hypertension is excluded by an extensive preoperative clinical investigation and the renal artery anatomy is visualized by computer tomography (with contrast). By cannulating the femoral artery both renal arteries are treated by a radiofrequency-catheter, 4-6 ablations in each artery.
224197029|NCT02720796|OTHER|PDX drug sensitivity testing|Patient derived xenograft (PDX) models will be developed for each patient and drug activity assessed in their personalized PDX model. PDX drug sensitivity information will be provided to the treating physician.
224197030|NCT04104152|OTHER|CSD1902-11|A 2.4% nicotine ENDS product
224197031|NCT04104152|OTHER|CSD1902-12|A 2.4% nicotine ENDS product
224197032|NCT04104152|OTHER|CSD1902-13|A 2.4% nicotine ENDS product
224197033|NCT04104152|OTHER|CSD1902-14|A 2.4% nicotine ENDS product
224197034|NCT04104152|OTHER|CSD1902-21|A 5.0% nicotine ENDS product
224197035|NCT04104152|OTHER|CSD1902-22|A 5.0% nicotine ENDS product
224197036|NCT04104152|OTHER|CSD1902-23|A 5.0% nicotine ENDS product
224197037|NCT04104152|OTHER|CSD1902-24|A 5.0% nicotine ENDS product
223594897|NCT05821725|DEVICE|Hyaluronic acid|Hyaluronic acid and hemostatic sponge
223594898|NCT05821725|DEVICE|Control|Hemostatic sponge
223594899|NCT00524017|BIOLOGICAL|cetuximab|given IV
223594900|NCT05788497|DRUG|Hemorrane plus|Hemorrane 10 mg/g rectal ointment + 30 mg/g benzocaine
223594901|NCT05788497|DRUG|Hemorrane|Hemorrane 10 mg/g rectal ointment
224197038|NCT02092207|DRUG|KL7016 900mg|oral administration, 150mg 3tab, bid
224197039|NCT02092207|DRUG|KL7016 600mg|oral administration, 150mg 3tab, bid
224197040|NCT02092207|DRUG|Placebo|oral administration, 150mg 3tab, bid
223505829|NCT02532946|BEHAVIORAL|Bedsider.org counseling|Contraceptive counseling was done while women kept the computer/tablet throughout their visit to facilitate discussion of website information with their providers.
223505830|NCT02645708|PROCEDURE|Retrograde Intrarenal Surgery|Patients undergo Retrograde Intrarenal Surgery
223505831|NCT02645708|PROCEDURE|EPVL after RIRS|Patients in Group 2 undergo EPVL after RIRS
223505832|NCT05001503|DEVICE|Stability UO|STABILITY UO is a standalone software, based on a Bayesian model, which quantifies the risk of an individual patient developing severe oliguria (0.3mg/kg/hr for 6 hours). The model identifies at risk patients by predicting future urine output, using only previously recorded urine output values for that individual, allowing clinicians to see the predicted risk of a patient developing severe oliguria in real time.
223505833|NCT05803954|OTHER|Sustained natural apophyseal glides (SNAGS)|SNAGS will be applied with the patient sitting comfortably on a stool. The therapist stand behind the patient and the medial border of one thumb's distal phalanx is placed on the articular pillar on the chosen side of the suspected site of lesion. The thumb nail slope at approximately 45 degree (in the direction of the eyeball). SNAGS mulligan will be given by active movement followed by passive overpressure based on the movement restricted by frequency of treatment will be three sets of ten repetitions. SNAG the anteroposterior mobilization of the second cervical vertebrae is sustained for 10 to 30 s depending on response. A maximum of 6 repetitions will be given if there is a reduction in headache intensity at the time of the first application. A total of 20 oscillations (1 oscillation/1 second) will be given to each joint with a total duration of 15 minutes
223505834|NCT05803954|OTHER|Neural mobilization|Neural mobilization will be applied with grade three neural mobilization and traditional therapy: Subjects will be placed in supine position and remained relaxed with the feet uncrossed. The patient will be slightly angled obliquely for easier access to the scapula. The therapist will be depressed the scapula with concomitant upper extremity joint positioning as per median nerve bias i.e., ULTT2 (shoulder abduction, elbow extension with forearm supination, wrist and fingers extended and ulnar deviated and thumb abduction). The wrist will be used as a tension factor and at the point where tension was felt by the therapist and perceived by the subject. Grade 3 oscillations were given rhythmically and slowly to each joint from proximal to distal. A total of 20 oscillations (1 oscillation/1 second) were given to each joint with a total duration of 15 minutes.
223505835|NCT05803954|OTHER|Traditional physical therapy|traditional therapy will be applied in the form of stretching for bilateral upper and middle trapezius muscles and bilateral neck rotators and isometric strengthening exercises for neck rotators, extensors, side bending muscles. Exercise was repeated for ten repetitions per session. In addition to hot pack was placed over the neck and upper part of shoulders musculature. This was being applied for ten min, over middle trapezius trigger Point itself.
223505836|NCT03926598|BEHAVIORAL|Patient and/or Family Member Intervention|On the Patient Login Screen, log in using your last name and session ID provided by the research team on the Surveys Screen, click on a pending survey when the survey opens, respond to the survey submit the survey log out of the Guide-Goals Application.
223505837|NCT03926598|BEHAVIORAL|Certified Diabetes Educator Intervention|On the Provider Login Screen, log in using the username and password provided by the research team on the Patients Screen, choose patient Will Owens on the Visit Status Screen, add comments needs to be followed up regarding ketosis education in the comments for provider text box on the Visit Status Screen, add a goal for the patient log out of Goals-to-Guide application.
223505838|NCT03926598|BEHAVIORAL|Physician Intervention|On the Provider Login Screen, log in using the username and password provided by the research team on the Patient Screen, add a new patient on the Edit Patient Screen, add the Diabetes Family Responsibility Questionnaire on the Edit Patient Screen, create a survey access code to share with the patient.
223505839|NCT03926598|BEHAVIORAL|Front Desk Staff Intervention|On the Provider Login Screen, log in using the username and password provided by the research team on the Patients Screen, choose patient Will Owens on the Visit Status Screen, add comments needs to be followed up regarding ketosis education in the comments for provider text box on the Visit Status Screen, add a goal for the patient log out of Goals-to-Guide application.
223505840|NCT03926598|BEHAVIORAL|Nurse Intervention|On the Provider Login Screen, log in using the username and password provided by the research team on the Patients Screen, choose patient Will Owens on the Visit Status screen, change HbA1C value to 10% on the Visit Status screen, change Nephropathy evaluation to Abnormal log out of Guide to Goals application.
223505841|NCT06225752|DRUG|Probucol|Inclusion Days 1-30: Probucol 1000mg/day (500mg per dose, twice daily, a minimum of 4 hours should elapse between each pair of doses.) Inclusion Days 31 and beyond: Probucol 500mg/day (250mg per dose, twice daily, a minimum of 4 hours should elapse between each pair of doses.)
223505842|NCT06225752|DRUG|Placebo probucol|Inclusion Days 1-30: Placebo Probucol 1000mg/day (500mg per dose, twice daily, a minimum of 4 hours should elapse between each pair of doses.) Inclusion Days 31 and beyond: Placebo Probucol 500mg/day (250mg per dose, twice daily, a minimum of 4 hours should elapse between each pair of doses.)
223505843|NCT03418974|DRUG|Pitavastatin|Capsule/Tablet, oral, follow the doctor's advice Participants will receive pitavastatin treatment for 3 or 12 weeks.
223505844|NCT03418974|DRUG|Atorvastatin|Capsule/Tablet, oral, follow the doctor's advice Participants will receive atorvastatin treatment for 3 or 12 weeks.
223505845|NCT03418974|DRUG|Rosuvastatin|Capsule/Tablet, oral, follow the doctor's advice Participants will receive rosuvastatin treatment for 3 or 12 weeks.
223505846|NCT00108537|DRUG|bupropion and transdermal patch|
223505847|NCT00108537|DRUG|transdermal patch and nicotine inhaler|
224197041|NCT03821805|OTHER|Foot reflexology massage|Foot reflexology technique of Father Josef was used as massage intervention
224197042|NCT06540430|BEHAVIORAL|The Use of a Mobile Application for Stoma Self-Care|The intervention group will use a mobile application where patients input their stoma condition, allowing healthcare professionals to monitor and manage their care. The app provides patients with information on diet, physical activity, stoma care, emotional support, and daily living needs.
224197043|NCT04631432|DIAGNOSTIC_TEST|Pre-screening|Document upload of Autism diagnosis certificate. Participants can request to show their certificate via a Zoom meeting with the researcher instead of uploading it.
223594902|NCT05788497|DRUG|Placebo|Rectal ointment
224310777|NCT06937294|DRUG|Placebo|Participants are administered a placebo, starting with one tablet per day, followed by an incremental increase of one tablet per week. In the absence of adverse reactions, the dosage is escalated up to a maximum of four tablets per day.
224310778|NCT03173638|PROCEDURE|intravitreal injection of MSV|A unique intravitreal injection of MSV in acute fase of NAION
224310779|NCT00600808|DRUG|BPLG-003|
223505848|NCT00710554|DRUG|Sativex|containing THC (27 mg/ml):CBD (25 mg/ml), in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring. Maximum permitted dose was eight actuations in any three hour period and 24 actuations (THC 65 mg: CBD 60 mg) in 24 hours
223505849|NCT00710554|DRUG|Placebo|containing peppermint oil, 0.05% (v/v), quinoline yellow, 0.005% (w/v), sunset yellow, 0.0025% (w/v), in ethanol:propylene glycol (50:50) excipient.
223505850|NCT01972971|OTHER|patient education|one by one patient education
223505851|NCT00805220|OTHER|Nordic Walking|Walking training with and without poles will be twice a week. The sessions last 20 minutes each and consist of walking, stretching and mobility exercises. This will last 8 weeks in a total of 16 sessions. A therapist will closely monitor your exercises and modify them according to your needs and comfort
223505852|NCT02296801|DRUG|Letrozole|
223505853|NCT02296801|DRUG|palbociclib|
223505854|NCT00335192|DRUG|Patients in treatment with 3TC + TDF + LPV/rtv, stop tenofovir during 4 weeks|3TC (300 mg/24 h, 1 tablet/24 h) + Lopinavir/ritonavir (400 mg/12 h, 3 tablets/12 h)
223505855|NCT00335192|DRUG|Patients in treatment with ABV + TDF + LPV/rtv, stop tenofovir during 4 weeks|ABV (300 mg/12 h, 1 tablet/12 h)+ Lopinavir/ritonavir (400 mg/12 h, 3 tablets/12 h)
223505856|NCT00335192|DRUG|Patients in treatment with 3TC + ABV + TDF+ LPV/rtv, stop TDF during 4 weeks|3TC (300 mg/24 h, 1 tablet/24 h)+ ABV (300 mg/12 h, 1 tablet/12 h)+ Lopinavir/ritonavir (400 mg/12 h, 3 tablets/12 h).
223505857|NCT04294849|OTHER|Magnetic Resonance Imaging|A. Phosphorous 31 MR Spectroscopy to evaluate skeletal muscle metabolism via measurement of depletion and recovery of phosphocreatine (PCr) B. Non-invasive arterial spin labeling MRI to evaluate lymphatic flow velocities and venous flow
223505858|NCT04294849|OTHER|Bicycle Ergometry|To measure peak VO2 as a representation of global aerobic fitness
223505859|NCT04294849|OTHER|Lab Panel|A. Inflammatory lab panel (IL-6, IL-8, TNF alpha, P-selectin, high sensitivity CRP, IL-6 receptor, TNF R1/R2) drawn at diagnosis B. Thrombin Generation Assay to measure hypercoagulability and Thromboelastography prior to initiating anticoagulation
223505860|NCT04294849|BEHAVIORAL|Questionnaires|A. Dalhousie Dyspnea Scale B. Godin Leisure Time Exercise Questionnaire C. Pediatric Venous Quality of Life Questionnaire
223505861|NCT02003027|DRUG|BT injection|
223505862|NCT00578058|OTHER|Counseling and Sound Therapy|Tinnitus counseling and sound therapy
223505863|NCT01301001|DRUG|Placebo oral capsule|Placebo 2 capsules am and 3 capsules pm
223505864|NCT01301001|DRUG|Gabapentin|Gabapentin 1200 mg am and 1800 mg pm
223505865|NCT05595395|DRUG|Enteral Dose Form|"In this intervention arm, fluid substitution is primarily done via enteral administration. The used substance for enteral fluid administered is going to be tap water. Intravenous fluid of choice is going to be Elomel isoton."
223505866|NCT05595395|DRUG|Intravenous Infusion|"In this intervention arm, fluid substitution is primarily done via intravenous administration. The used substance for intravenous fluid administered is going to be Elomel isoton."
223505867|NCT03854448|DEVICE|holter monitoring|"Transthoracic Echocardiography (TTE) Left atrial ( LA) volume will be measured using standard apical two- and four-chamber views on the frame just prior to mitral valve opening and as specified by current American Society of Echocardiography guidelines (10) LA volume is indexed to body surface area. Mitral inflow velocity is obtained in the apical four-chamber view by placing a pulsed-Doppler sample volume between the tips of the mitral leaflets. Mitral annular velocity is assessed during the early phase of diastole(e=) using pulsed-wave Doppler sampling of septal mitral annular motion from the four chamber view.~24 to 48 hours Holter monitoring after 1 month after PCI"
223505868|NCT00552162|PROCEDURE|NOTES Transvaginal Cholecystectomy|The gallbladder will be dissected free and will be removed through an incision in the vagina.
223505869|NCT00552162|PROCEDURE|NOTES Transvaginal Appendectomy|The appendix will be dissected free and will be removed through an incision in the vagina.
223505870|NCT04224051|DRUG|Metformin|Metformin target dose 2 g daily
223505871|NCT04224051|OTHER|Standard care|Abdominal aortic aneurysm surveillance
223505872|NCT05663788|OTHER|E-learning module|"The intervention is a structured e-learning module on a web-based platform (www.trainingopticaldiagnosis.com) that consists of:~* 10 modules, including theoretical knowledge and multiple exercises.~* 2 seminars with a tutor (after Module 5 and Module 10)~* feedback from the tutor on three cases recorded by the participant.~* 20-images test before and after the content described above (10 Modules, 2 seminars with tutors and feedback on three cases)~All the Gastroenterologists participating in the study will predict deep submucosal invasion in their routine colonoscopies and will register clinical outcomes during 12 months. The randomisation and intervention will be conducted 6 months after starting to predict deep submucosal invasion and registering clinical outcomes."
223505873|NCT06040450|OTHER|Questionnaire survey|On outdoor sports practice activity, barriers to practice, impacts on well-being.
223505874|NCT03043820|DRUG|Raloxifene|Oral selective estrogen receptor modulator (SERM).
223505875|NCT03043820|DRUG|Placebo|Tablets identical in form and color to intervention.
223505876|NCT03012152|PROCEDURE|Standard conservative breast surgery|
223505877|NCT03012152|PROCEDURE|Oncoplastic breast surgery|
223505878|NCT05562635|COMBINATION_PRODUCT|5% polymer gel with CBD application|Bilateral application of 5% polymer gel with CBD intraorally, on the masseter muscle
223594903|NCT03277365|OTHER|Receive genetic risk information|Risk scores are provided by ResearchKit app.
223594904|NCT04856904|DRUG|Trifarotene Cream|Participants will apply a thin a layer of trifarotene (CD5789) 50 mcg/g cream to the face once daily, in the evening for 24 weeks
223594905|NCT04856904|DRUG|Trifarotene Vehicle Cream|Participants will apply a thin a layer of trifarotene vehicle cream to the face once daily, in the evening for 24 weeks
224310780|NCT06285994|PROCEDURE|High frequency jet ventilation|Use of high frequency jet ventilation during bronchoscopy
224310781|NCT01777360|DEVICE|ALAIR, radiofrequency catheter for bronchial THERMOPLASTY|radiofrequency catheter for bronchial THERMOPLASTY
224310782|NCT02969174|OTHER|zimin Lu,Guo Sa|chengzhong Liu
223505879|NCT05562635|COMBINATION_PRODUCT|10% polymer gel with CBD application|Bilateral application of 10% polymer gel with CBD intraorally, on the masseter muscle
223505880|NCT05562635|COMBINATION_PRODUCT|Placebo intervention|Application of placebo without CBD
223505881|NCT04468009|BIOLOGICAL|Convalescent plasma|Convalescent plasma from patients recovering from Covid-19 and which had anti-SARS-Cov-2 antibodies
223505882|NCT00657501|DRUG|testosterone gel|once daily transdermal gel, 300 mcg
223505883|NCT00657501|DRUG|placebo gel|once daily transdermal placebo gel
223505884|NCT05540600|DRUG|Digoxin 0.25 mg|Patients will have the dose of one tablet of 0.25mg per day
223594906|NCT06358092|DIAGNOSTIC_TEST|Hepatic venous pressure gradient|HVPG is a measurement used to assess portal hypertension, a condition characterized by increased blood pressure in the portal vein, which carries blood from the digestive organs to the liver. HVPG measurement involves inserting a catheter into the hepatic vein via jugular vein puncture to directly measure the pressure within the liver. By comparing the pressure in the hepatic vein with that in the portal vein, HVPG provides valuable information about the severity of portal hypertension and helps in predicting clinical outcomes in patients with liver cirrhosis and related conditions. HVPG measurements are crucial in guiding treatment decisions, assessing treatment response, and predicting the risk of complications such as variceal bleeding and liver failure.
223594907|NCT06358092|DIAGNOSTIC_TEST|Two-Dimensional Shear Wave Elastography|2D-SWE is a non-invasive imaging technique used to assess tissue stiffness, particularly in the liver. This technology utilizes ultrasound to generate shear waves within the tissue being examined. By measuring the speed of these shear waves as they propagate through the tissue, 2D-SWE can provide quantitative information about tissue elasticity or stiffness. In the context of liver disease, including cirrhosis and fibrosis, 2D-SWE is valuable for evaluating the degree of liver stiffness, which correlates with the severity of liver fibrosis. This information aids in diagnosis, staging, and monitoring of liver diseases, allowing for early detection of complications and assessment of treatment response. Compared to traditional biopsy-based methods, 2D-SWE offers the advantage of being non-invasive, rapid, and repeatable, making it a preferred modality for assessing liver stiffness in clinical practice.
223594908|NCT02756494|BIOLOGICAL|Ischemic Stroke|Ischemic Stroke in Chinese Young Adults
223594909|NCT02924740|BEHAVIORAL|Pelvic Floor Muscle Training|Pelvic floor muscle training consist of fast (2 second) and slow contractions (5-s contraction, 10-s hold, 5-s relaxation, totally 20-s). One set of exercises includes ten fast and ten slow voluntary PFM contractions (VPFMCs). During week 1 and 2, participants will be instructed to perform two sets of exercises per day (20 fast and 20 slow contractions per day), which was progressively increased by two sets: four sets per day at week 3 and 4 (40 fast and 40 slow contractions per day); six sets per day at week 5 and 6 (60 fast and 60 slow contractions per day); eight sets per day at week 7 and 8 (80 fast and 80 slow contractions per day); ten sets per day from week 9 to week 12 (100 fast and 100 slow contractions per day).
223594910|NCT02924740|BEHAVIORAL|Vaginal Tampon Training|Vaginal tampon training will be applied for 5 days a week for 12 weeks. Exercises with tampons will be performed two days a week by physiotherapist (first author) and three days a week by patients. One set of tampon exercises consist 15 contractions. During vaginal tampon training, from week 1 to week 12, patients were instructed to perform two sets of exercises for five days a week (two days by physiotherapist, three days by themselves).
223594911|NCT01812512|BEHAVIORAL|Teaching for Interactive Patient Self-Management (TIPS) for Heart Failure (HF|The curriculum plan adapts components from the Rochester Participatory Decision-Making Scale (RPAD) and recent advances in communication skills training for chronic disease to develop a valid and reliable intervention specific to Home Telehealth (HT) shared decision making, effective telehealth communication, and patient self-management for heart failure (HF), using established best-practices and Veteran input. Veteran volunteers will participate in video recorded simulations to promote nurse care coordinator (NCC) active participation and problem-solving during the course. Scenarios are taken from transcribed actual HT interactions from the first exploratory RRP study of HT. The course is set up as one live session, one online module, and a final live session for more difficult conversations.
223594912|NCT01137253|DRUG|Trimethaphan|Trimethaphan 4 mg/min IV, for the duration of the study (approximately 2 hours)
223594913|NCT01137253|DRUG|Placebo|Response to intrabrachial vasodilators during IV saline infusion
223594914|NCT04029298|BEHAVIORAL|Lifestyle Interventions|Educational based intervention to enhance lifestyle modifications such as diet, exercise, patient activation, and medication adherence
223594915|NCT02929212|OTHER|Solid Meal|Subjects will receive solid meals during meal study
223594916|NCT02929212|OTHER|Liquid Meal|Subjects will receive liquid meals, during meal study
223594917|NCT02929212|DRUG|Acetaminophen|All subjects given acetaminophen to measure gastric emptying
223594918|NCT02929212|OTHER|Single, 600 kcal meal|Subjects will receive a single, 600 kcal meal during meal study
223594919|NCT02929212|OTHER|Multiple, 200 kcal meals|Subjects will receive three, 200 kcal meals, during meal study
223594920|NCT04190277|DEVICE|Open-loop condition|Patient's standard insulin pump setting combined with continuous glucose monitoring sensor
223594921|NCT04190277|DEVICE|Closed-loop condition|Closed-loop algorithm system paired with continuous glucose monitoring sensor
223594922|NCT04619498|DEVICE|PediAppRREST|PediAppRREST is a new audiovisual interactive app for tablets developed to support the management of pediatric cardiac arrest. It sequentially displays directions on recommended management interventions. It was specifically designed to guide the team leader to perform resuscitation interventions in the sequence/timing and modality reported by the American Heart Association Pediatric Advanced Life Support (AHA-PALS) guidelines.
223594923|NCT04619498|OTHER|AHA-PALS pocket reference card|It is a 10 cm x 16.5 cm, full-color, 2-sided, 6-panel card that shows the American Heart Association Pediatric Advanced Life Support (AHA-PALS) treatment algorithms. By providing a quick reference tool, it serves as a cognitive aid for healthcare providers who either direct or participate in the management of pediatric respiratory and/or cardiovascular emergencies, including cardiac arrest.
223594924|NCT03094715|DEVICE|Thrombectomy|Mechanical thrombectomy with state of the art thrombectomy devices (i.e. stent-retrievers, aspiration catheters). Devices will be used per instructions for use (IFU).
224310783|NCT04051619|DRUG|intranasal oxytocin, 40 IU, twice a day for 7 days|Adjunct therapy
223747360|NCT06241339|OTHER|Mat Pilates|"Mat Pilates training will last 12 weeks, with three weekly trial sessions being held at 48-72h intervals. Each session will last approximately 60 minutes, including: 5 minutes of warm-up (light calisthenic exercises for the shoulder and pelvic girdles); 50 minutes of Mat Pilates exercises; 5 min back to calm.~Upon arriving at the training site, volunteers will rest for 10 minutes in a sitting position, after which BP measurements will be taken and HR at rest. Throughout consecutive training sessions, participants will perform Pilates method exercises with a progressively greater degree of difficulty and complexity, following the official recommendations for prescription of resistance exercise for individuals with BP elevated and post-stroke. The exercises will be performed in single sets of 10 repetitions. Groups will be advised to maintain daily activities without physical exercise during the 12-week period."
223747361|NCT01940809|DRUG|Dabrafenib|Given PO
224197044|NCT04631432|BEHAVIORAL|Task session|"The Iowa Gambling task- four decks of cards on the computer screen. Each card yields a reward, but might also yield a loss. In each trial, the participant selects a card. Consequently, the card is exposed, displaying the gain and the loss for that trial. Through contingent feedback, participants are expected to learn that some deck are better than others.The task will include 120 trials.~Block of trials without feedback- four decks of cards on the computer screen. Each card yields a reward, but might also yield a loss. In each trial, the participant selects a card. Consequently, the card is exposed, but the gain and the loss for that trial are not displayed. The task will include 30 trials.~Social Responsiveness Scale, 2nd Edition (SRS-2; adult-self report):(Constantino \& Gruber, 2012) The brief autism quotient scale:(AQ10; Baron-Cohen et al., 2001) Brief intelligence test (Similarities-MAB + Raven Set 1)"
224310784|NCT01442324|PROCEDURE|Irreversible electroporation (IRE)|Needle-like electrodes are inserted through the liver and in the lesion without exceeding its deepest margin, at which point the IRE NanoKnife™ System (AngioDynamics) is started.
224310785|NCT06277089|OTHER|Casts|According to level of scoliosis cast done and recast in a serial manner
223747362|NCT01940809|BIOLOGICAL|Ipilimumab|Given IV
223747363|NCT01940809|OTHER|Laboratory Biomarker Analysis|Correlative studies
223747364|NCT01940809|BIOLOGICAL|Nivolumab|Given IV
223747365|NCT01940809|DRUG|Trametinib|Given PO
223505885|NCT05540600|DRUG|Bisoprolol|Patients will have the dose of bisoprolol 2.5 mg or 5 mg twice a day based on the arterial pressure at randomization
223505886|NCT03053830|DRUG|Ketamine|0.5mg/kg ketamine in normal saline. Infusion will be delivered during a 40 minute interval
223505887|NCT04784780|DRUG|Elobixibat 10mg|Patients with chronic constipation are administered Elobixibat 10mg for 12 weeks
223505888|NCT04784780|DRUG|Placebo|Patients with chronic constipation are administered placebo for 12 weeks
223505889|NCT04354688|DEVICE|T3 Certain Tapered Implant|Patients will be randomized to receive either the T3 Certain Tapered with DCD (Test) or the T3 Certain Tapered without DCD (control/active comparator). Both types of implants will be rehabilitated in the same manner (early loading)
223505890|NCT06251830|DIAGNOSTIC_TEST|MRI exam with Magnetic Resonance Fingerprinting|"Acquisition of MRI data with technique Magnetic Resonance Fingerprinting"
223505891|NCT03243188|OTHER|Qualitative interview|Qualitative data will be obtained through semi-structured interviews with adults with cancer and palliative care needs. Patients will be invited to bring their carer to the interview. EG will conduct and transcribe up to 30 audio-recorded semi-structured interviews, which will be carried out at the patient's preferred location (either at home, over the phone, or in a pre-booked room at St Joseph's Hospice). EG will ask questions relating to sociodemographic data (recording this on the Personal Information Sheet) prior to starting the interview.
223505892|NCT05485350|DRUG|Anlotinib Hydrochloride|12 mg/d, d1-14, q3w
223505893|NCT05485350|DRUG|penpulimab|200mg, ivgtt, d1, q3w
223505894|NCT05485350|RADIATION|SBRT|55-180Gy
223505895|NCT04366583|DEVICE|argon plasma coagulation|Olympus electrosurgical unit/argon plasma coagulation unit (PSD-60/Endoplasma, Olympus Corp., Tokyo, Japan)
223505896|NCT04366583|DEVICE|hemoclipping|clipping device (Olympus HX 110/610, Olympus Corp., Tokyo, Japan)
223505897|NCT01641666|DRUG|Boceprevir|Boceprevir will be dosed orally at a dose of 800 mg three times daily (TID) for a total daily dose of 2400 mg.
223505898|NCT01641666|DRUG|Peginterferon Alfa-2b 1.5 mcg/kg/week|Peginterferon alpha-2b will be administered subcutaneously at a dose of 1.5 mcg/kg each week.
223505899|NCT01641666|DRUG|Ribavirin|Ribavirin will be administered orally at a dose of 800 mg/day to 1400 mg/day in two divided daily doses (BID).
223505900|NCT02491450|DRUG|Heterosofir|1 tablet contains 400 mg sofosbuvir
223505901|NCT02491450|DRUG|Sovaldi|1 tablet contains 400 mg sofosbuvir
223505902|NCT02957227|DEVICE|No intervention is part of this study but patients use an EEG device during observational data collection.|
223505903|NCT03128164|DRUG|HMPL-689|Two strengths of HMPL-689 capsules (2.5 mg and 10 mg) will be used for clinical studies. The drug products are capsules.
223505904|NCT03682393|DRUG|Hydrocortisone|100mg 1x3 hydrocortison intravenously for three days after mitral valve surgery or until atrial fibrillation onset
223505905|NCT03682393|DRUG|Placebos|100mg 1x3 intravenous fysiologic saline for three days after mitral valve surgery or until atrial fibrillation onset
223505906|NCT01441414|BIOLOGICAL|PF-04856884|15 mg/kg/week intravenously \[IV\] until toxicity or disease progression
223505907|NCT01441414|DRUG|Axitinib (AG-013736)|5 mg PO BID
223505908|NCT01441414|DRUG|Axitinib (AG-013736)|5 mg PO BID
223505909|NCT04258098|DRUG|Oral antibiotics ( Streptomycin ,metronidazole )|Either polyethylene glycol or magnesium sulphate was adopted as laxative one day before surgery. Clyster was conducted on surgery morning. Streptomycin 1g plus metronidazole 0.2g was prescribed 3 times a day for 3 days before surgery in the OA+MBP group patients.
223505910|NCT03915054|DRUG|AREG-TRIGGER|"Oocytes in AREG-TRIGGER medium will be mature in AREG + FSH + HSA + Insulin + Estradiol medium.~Per case (6mL) 5940 µL Basal Medium~* 60 µL IVM MIX Do not need to filtrate media."
223505911|NCT03915054|DRUG|CONTROL-TRIGGER|"Oocytes in CONTROL-TRIGGER medium will be mature in FSH + hCG + GH + HSA medium.~Per case (5 mL) 4.3 ml IVM Medicult Medium (Vial 2) 0.5 ml HSA (from stock 10% solution) 50µl FSH (from stock 7.5 IU/ml) 5µl hCG (from stock 100 IU/ml) 75 µl GH (from stock 0.66mg/ml)"
223505912|NCT01433978|DRUG|Eltrombopag|
223505913|NCT01433978|DRUG|Avatrombopag|
223594925|NCT03094715|OTHER|Best medical care|Best medical treatment will be performed as detailed in established Standard Operating Procedures, following regional guidelines (American Heart Association (AHA), European Stroke Organisation (ESO), Deutsche Schlaganfall-Gesellschaft (DSG), local country, etc.). If applicable, the reason for iv tissue plasminogen activator (tPA) ineligibility has to be documented on the eCRF.
223747366|NCT04592029|DRUG|TACE combined with sintilimab and bevacizumab|Sintilimab and bevacizumab are administered at 3-7 days after the first TACE. The study includes dose escalation and dose expansion stage. 6-9 subjects will be enrolled in dose escalation stage for the safety and efficacy evaluation. Then, Sintilimab 200mg/kg IV. q3w+ select specific dose of bevacizumab (7.5mg/kg or 15 mg/kg IV. q3w), expand to 36-39 patients for the further safety and efficacy study. The study treatment of sintilimab and bevacizumab lasts up to 24 months. TACE can be repeated when indicated clinically.
223747367|NCT05339620|PROCEDURE|implant driver facilitated micro-osteoperforations|"3 micro-osteoperforations(in a vertical pattern) are done on the randomly allocated experimental side , distal to canine under local anesthesia. the other side of the mouth is used as a control.~alginate impression is taken before the intervention ."
223747368|NCT04843709|DRUG|MRG004A|Administrated intravenously
223747369|NCT01914185|OTHER|Comprehensive School Health (CSH)|APPLE Schools uses a CSH approach to health promotion which addresses health through four inter-related pillars 1) positive social and physical environments 2) teaching and learning 3) healthy school policy 4) partnerships and services. A key component of the APPLE Schools intervention was the placement of a full-time School Health Facilitator in each school. Their role was to facilitate the development and implementation of the project, to ensure that it met the schools' unique needs for health promotion, and that it aligned with the core principles of CSH.
223747370|NCT04699682|OTHER|Control|During follow-up visits, as part of this research, additional stool samples are taken every month (M1 to M12).
223747371|NCT04699682|OTHER|BHR Case|"During follow-up visits, compared to the usual management of patients with BHRe (monthly sampling for 6 consecutive months), additional samples are taken as described below:~\- stool samples taken at different times:~* every 7 days during the first month (M1)~* every 14 days for the following months until the end of the patient's participation (M2 to M12)."
223747372|NCT02608268|DRUG|MBG453|Anti human TIM-3 monoclonal antibody. MBG453 administered via intravenous (i.v.) infusion either every 2 weeks (Q2W) or every 4 weeks (Q4W).
223747373|NCT02608268|DRUG|PDR001|Anti-human PD-1 monoclonal antibody. PDR001 administered via intravenous (i.v.) infusion either every 2 weeks (Q2W) or every 4 weeks (Q4W).
223747374|NCT02608268|DRUG|Decitabine|commercially available chemotherapy
223747375|NCT04602637|OTHER|Training load|Monitoring training load during covid
223747376|NCT01196546|DRUG|vildagliptin/metformin|
223747377|NCT05627882|DIAGNOSTIC_TEST|Forward viewing endoscope|Additional examination with standard forward viewing endoscope
223747378|NCT02539381|PROCEDURE|Formal Perimetry (Goldman or Octopus visual Field)|
223747379|NCT02539381|PROCEDURE|Albert's visual inattention test|
224197045|NCT04259905|BEHAVIORAL|Active video game teleconference support group|12 sessions of teleconferenced support group meetings, including active video game play + self-paced walking monitored by Fitbit wearable device
224197046|NCT04259905|BEHAVIORAL|Standard support group + pedometer|3 monthly sessions of in-person standard support group meetings + self-paced walking monitored by pedometer
224197047|NCT01279265|DIETARY_SUPPLEMENT|Nutramigen with Enflora|Hypoallergenic formula with probiotic - Lactobacillus GG
224197048|NCT01279265|DIETARY_SUPPLEMENT|Nutramigen A+|Hypoallergenic formula without lactobacillus
224197049|NCT00477620|BEHAVIORAL|Wearing of reading glasses during prolonged near work|
224197050|NCT00641810|BEHAVIORAL|Caffeine reduction|Reduction in daily caffeine consumption from usual amounts to none.
224197051|NCT02098707|OTHER|Stabilometric Platform|Stabilometric platform is a device used for assessment and training of balance basing on ground reaction force evaluation in static conditions.
224197052|NCT02775409|PROCEDURE|Subcutaneous placement|The tissue expander will be placed above the muscle.
224197053|NCT02775409|PROCEDURE|Submuscular placement|The tissue expander will be placed below the muscle
224197054|NCT00726440|DEVICE|Navigator®|Patients will be encouraged to use the Navigator® all the time and to modify their treatment according to the device measurments. Patients will also follow and educational process in order to adapt insulin doses according to each sensor data
223594926|NCT06136065|DIAGNOSTIC_TEST|68 Gallium -Fibroblast Activating Protein Inhibitor -46 Positron emission tomography / Computerized tomography|68 Gallium -Fibroblast Activating Protein Inhibitor -46 Positron emission tomography / Computerized tomography scan
223594927|NCT00439036|BEHAVIORAL|Behavior Therapy|The Act-ODT intervention will consist of 24 50-minute sessions delivered weekly in the context of a methadone dose reduction program. Sessions will begin during the methadone run-up/stabilization period approximately 4 weeks prior to the onset of dose reduction and will continue through the 20 week detoxification.
223594928|NCT00439036|BEHAVIORAL|Drug Counseling|
223594929|NCT02578173|DEVICE|AVERT PLUS|
223747380|NCT02539381|PROCEDURE|Star cancellation visual inattention test|
223747381|NCT02539381|PROCEDURE|Visual field assessment to confrontation|
223747382|NCT02539381|PROCEDURE|Visual inattention assessment to bilateral stimuli|
223747383|NCT02539381|DEVICE|Digital tumbling E visual accuity assessment|
223747384|NCT02539381|DEVICE|Digital visual field assessment|
223747385|NCT02539381|DEVICE|Digital line crossing assessment|
223747386|NCT02539381|DEVICE|Digital shape cancellation assessment|
223747387|NCT03163745|PROCEDURE|paracentesis|paracentesis will be done for all patient for ascitic fluid study and ascitic fluid culture
223747388|NCT06055855|PROCEDURE|Traditional Two-Needle Arthrocentesis|Participants in this group will undergo arthrocentesis using the traditional two-needle technique. The procedure involves the placement of one or two needles into the temporomandibular joint (TMJ) to irrigate the joint space. Needle placement is guided by anatomical landmarks.
223747389|NCT06055855|PROCEDURE|Surgery-Guided Arthrocentesis|Participants in this group will receive arthrocentesis facilitated by a surgical guide. The guide is generated through pre-operative planning and is designed to aid in the accurate placement of the needle into the TMJ.
224197055|NCT00726440|DEVICE|Navigator®|Patients will follow the same educational process as group1 concerning insulin doses adaptation.The duration of the use of the devicewill be determined at the consultation every each 3 months.
224197056|NCT00726440|DEVICE|Placebo|Patients will have their usual follow up with self-monitoring blood glucose
224197057|NCT04136522|PROCEDURE|conventional pancreaticoduodenectomy|In this subgroup, the surgeon will perform pancreaticoduodenectomy without isolation of superior mesenteric artery and dissection of nerve plexus and lymph node around superior mesenteric artery.
224197058|NCT04136522|PROCEDURE|total mesopancreas excision including superior mesenteric artery first approach|In this subgroup, the surgeon will identify and isolate superior mesenteric artery before pancreatic transection, they dissect soft tissues including nerve plexus and node around superior mesenteric artery.
224197059|NCT04141085|OTHER|Endometrial biopsy|All groups will undergo a mock frozen embryo transfer cycle with an endometrial biopsy being performed as opposed to an embryo transfer
224197060|NCT05075551|DEVICE|Acupuncture|Hwato brand disposable acupuncture needles (size 0.30 × 75mm; size 0.30 × 40mm) will be used.SP6 is on the tibial aspect of the leg, posterior to the medial border of the tibia, 3 cun superior to the prominence of the medial malleolus; BL23 is in the sacral region, in the second posterior sacral foramen; BL54 is in the fourth posterior sacral foramen, 3 cun beside the median sacral crest; BL35 is in the buttock region, 0.5 cun lateral to the extremity of the coccyx.
224310786|NCT03831204|DEVICE|biopac|"Acoustic cardiography was performed for all participants using the BIOPAC system with Student Lab software version 3.7.2. An electrocardiogram was obtained by two electrodes placed at the right upper limb and the lower left limb. Simultaneously heart sounds were recorded with a specific sensor placed at the mitral focus."
223505914|NCT01433978|DRUG|Standard of care|"Permitted ITP concomitant background therapies are as follows:~* Corticosteroids and/or azathioprine taken at a stable dose for 4 weeks before randomization;~* Mycophenolate mofetil (MMF) or danazol taken at a stable dose for at least 12 weeks before randomization;~* Cyclosporine A (CsA) (due to the fact that it is a P-glycoprotein-mediated transport \[P-gp\] inhibitor) is to be avoided unless deemed medically necessary; CsA taken at a stable dose for at least 12 weeks before randomization.~At the discretion of the investigator, participants will be allowed to use aspirin, other salicylates, or approved adenosine diphosphate (ADP) receptor antagonists, (eg, clopidogrel, prasugrel) during the study once their platelet count had risen.~Participants treated with proton pump inhibitors (PPIs) and H2 antagonist therapy will receive a stable dose for at least 6 weeks prior to randomization. Treatment with these therapies must have been completed at least 2 weeks prior to randomization."
223505915|NCT04228315|DRUG|Primaquine|radical cure dosing
223505916|NCT05639439|DEVICE|"Ventilation using the Fastrach intubating laryngeal mask airway and glottic view using fibrescope - Group A"|"Insertion of the intubating laryngeal airway device Fastrach, evaluation of the ventilation sufficiency and perfection of installation/ anatomical application to the larynx (evaluation with fiberoptic bronchoscope)"
223505917|NCT05639439|DEVICE|"Ventilation using the Proseal laryngeal mask airway and glottic view using fibrescope- Group B"|"Insertion of the laryngeal airway device Proseal, evaluation of the ventilation sufficiency and perfection of installation/ anatomical application to the larynx (evaluation with fiberoptic bronchoscope)"
223505918|NCT05639439|DEVICE|"Ventilation using the I-gel supraglottic airway device and glottic view using fibrescope- Group C"|"Insertion of the supraglottic airway device I-gel, evaluation of the ventilation sufficiency and perfection of installation/ anatomical application to the larynx (evaluation with fiberoptic bronchoscope)"
223505919|NCT05639439|DEVICE|"Ventilation using the Protector laryngeal airway device and glottic view using fibrescope- Group D"|"Insertion of the laryngeal airway device Protector, evaluation of the ventilation sufficiency and perfection of installation/ anatomical application to the larynx (evaluation with fiberoptic bronchoscope)"
223505920|NCT01820104|DRUG|lansoprazole, 30 mg per day for 6 days|
223505921|NCT01773889|DRUG|Denileukin Diftitox/SC Pegylated IFNα-2a|
223505922|NCT02441257|PROCEDURE|control ventilation|patients are randomly divided to receive control or spontaneous ventilation randomly.
223505923|NCT02441257|PROCEDURE|spontaneous ventilation|patients are randomly divided to receive control or spontaneous ventilation randomly.
223505924|NCT05092503|DRUG|JINZHEN Granules for Oral Solution|JINZHEN granules will be dissolved in drinking water and administered orally.
223505925|NCT05092503|DRUG|Placebo|Placebo granules will be dissolved in drinking water and administered orally.
223505926|NCT03203707|BEHAVIORAL|Interpersonal and Social Rhythm Therapy|The Brief IPSRT intervention for at-risk youth includes : 1) Psychoeducation about risk for BP ; 2) Social rhythm therapy (SRT) aiming to establish and maintain stable routines to protect against onset of mood symptoms in vulnerable individuals ; and 3) Interpersonal Psychotherapy (IPT) centering on the adolescent's feelings about having a parent with BP, and linking stressful family events to mood. The intervention is delivered in 8 in-person sessions over 6 months of treatment. Parents are involved in the psychoeducation sessions, and further involvement is determined as clinically appropriate based on age and developmental status.
223505927|NCT03834259|PROCEDURE|sitting position|keeping the patient in a sitting position after spinal anaesthesia
223505928|NCT03834259|PROCEDURE|supine position|keeping the patient in supine position after spinal anaesthesia
223505929|NCT02722603|DRUG|gabapentin|75 mg/ml gabapentin syrup
223505930|NCT02722603|DRUG|tramadol|100 mg/ml tramadol oral drops
223505931|NCT02722603|OTHER|placebo tramadol|placebo tramadol oral drops
223505932|NCT02722603|OTHER|placebo gabapentin|placebo gabapentin syrup
223505933|NCT00272558|DRUG|Carboplatin and Vinorelbine|
223505934|NCT02058407|DRUG|GSK2793660 solution|Clear, colourless solution at a unit dose strength of 0.1 mg/mL, in a glass bottle
223505935|NCT02058407|DRUG|GSK2793660 capsule|Size zero swedish orange capsule at a unit dose of 3 mg, 10 mg, 20 mg and 50 mg
223505936|NCT02058407|DRUG|Placebo solution|Matching placebo to GSK2793660 solution
223505937|NCT02058407|DRUG|Placebo capsule|Matching placebo to GSK2793660 capsule
223505938|NCT02618733|DRUG|Ticagrelor|90mg, twice a day
223505939|NCT02618733|DRUG|Clopidogrel|75mg, once a day
223505940|NCT03882372|DEVICE|Nasal high flow|See arm description.
223505941|NCT00295412|DRUG|quetiapine (drug)|
223747390|NCT00729729|DRUG|PCA|Placebo tablet, once
224197061|NCT05075551|DEVICE|Sham acupuncture|Hwato brand disposable acupuncture needles (size 0.30 × 75mm; size 0.30 × 40mm) will be used.These volunteers will receive relatively shallow needling at bilateral sham SP6, BL54, BL23 and BL35. This treatment gets involved in the same duration and frequency of sessions, but the treatment was delivered superficially at non-acupuncture points 10 mm to the lateral of corresponding acupuncture and not above a meridian line (10mm to SP6, BL54, BL23 and BL35).The same equipment of fMRI scanner will be used.
223594930|NCT01111279|BIOLOGICAL|gpASIT+TM|1 subcutaneous injection every 7 days, during 29 days.
223594931|NCT01111279|BIOLOGICAL|gpAST+TM/adjuvant|1 subcutaneous injection every 7 days, during 29 days
223594932|NCT01111279|BIOLOGICAL|Placebo solution|1 subcutaneous injection every 7 days, during 29 days
223594933|NCT02488746|DEVICE|GERDX(TM)|Endoscopic full thickness resection of subepithelial gastric tumors using the GERDX suturing device.
223594934|NCT02830620|OTHER|Dosage of chimiokines|
223594935|NCT03044184|DRUG|Tranexamic Acid|Transamine is an antifibrinolytic medication given systemically via the intravenous route
223594936|NCT00077649|DRUG|ribavirin [Copegus]|600mg po bid for 48 weeks
223594937|NCT00077649|DRUG|ribavirin [Copegus]|800mg po bid for 48 weeks
223594938|NCT00077649|DRUG|peginterferon alfa-2a (PEG-IFN alfa-2a) [Pegasys]|180 micrograms sc weekly for 48 weeks
223594939|NCT00077649|DRUG|peginterferon alfa-2a (PEG-IFN alfa-2a) [Pegasys]|270 micrograms sc weekly for 48 weeks
223594940|NCT01278082|DRUG|Budesonide|Alternating daily dosing with 2 x 3 mg budesonide capsules OD and 1 x 3 mg budesonide capsule OD every second day
223594941|NCT01278082|DRUG|Placebo|Alternating daily dosing with 2 placebo capsules OD and 1 placebo capsule OD every second day.
223594942|NCT01641822|DRUG|AZLI|Aztreonam for Inhalation Solution (AZLI) 75 mg 3 times daily combined with diluent administered using an eFlow nebulizer
223594943|NCT01641822|DRUG|Placebo to match AZLI|Placebo to match AZLI 3 times daily combined with diluent administered using an eFlow nebulizer
223594944|NCT01641822|DRUG|Tobramycin inhalation solution|Tobramycin inhalation solution (TIS) 300 mg 2 times daily using a PARI® LC Plus nebulizer and DeVilbiss Pulmo-Aide® air compressor
224197062|NCT05075551|OTHER|fMRI scan|Both two group will get fMRI scan week 0 (before treatment), week 12 (after treatment) and week 36 (following up). The resting-state fMRI data will be obtained by using a 3.0T GE MR 750 MRI scanner with an eight-channel phase array head coil at the Huashan Hospital, Shanghai. The high resolution T1-weighted magnetic resonance images will be collected by a three-dimensional fast spoiled gradient-echo dual-echo sequence \[repetition time (TR) = 8100 ms; echo time (TE) = 3.1 ms; FA = 8 deg; matrix=256 × 256; field of view (FOV)=25.6× 25.6 cm2; slice thickness=1 mm; no gap and 156 slices\]. The whole resting state fMRI data will be acquired by using a gradient-recalled echo-planar imaging pulse sequence (TR/TE = 2,000/30 ms; FA = 90°; acquisition matrix = 64×64; FOV = 22×22 cm2; slice thickness= 4 mm; 43 slices and total 240 time points; no gap).
224197063|NCT03476395|OTHER|shoulder range of motion in IR/ER, strength of the IR/ER muscles and Scapular Dyskinesis Test. Core endurance test.|Passive shoulder range of motion using a digital application Clinometer. Isometric strength of the shoulder IR/ER using a HHD measured. Scapular Dyskinesis Test uses a visual scoring system. Core Endurance is teste by measuring the time (s).
224197064|NCT00747110|DRUG|budesonide|3x 3mg budesonide capsules once daily
223594945|NCT02821364|OTHER|Advanced Life Support|IV FLUIDS, INTUBATION
223594946|NCT03813381|BEHAVIORAL|Calorie and protein restriction diet|"Patient in intervention arm will be given individualized dietary advice on the basis of WCRF/AICR recommendations. The aim of healthy dietary advice will be the reduction of patient's total daily calorie intake up to 600 kcal below their energy requirements and 0.8g of protein/Kg body weight mostly form plant-origin food.~Patients, periodically, will meet the dietitian for a 45-minute nutritional counselling session and a trained nurse for a 15-minute health coaching session.~Each patient in the IA will be involved in at least three 4-hour cooking classes.~Patients in the IA, after a medical/cardiac evaluation to assure their physical ability for exercise, will attend Nordic walking sessions of moderate intensity two times per month during the 24 months of intervention."
223594947|NCT04448353|DIAGNOSTIC_TEST|vascuCAP|adverse event and phenotype classification model
223594948|NCT00215865|DRUG|PEGIntron plus ribavirin|
223594949|NCT01174212|PROCEDURE|Prophylactic Antibiotics|Preoperative Antibiotics
223594950|NCT01174212|PROCEDURE|Control Antibiotics|Antibiotics will be held until intraoperative cultures have been obtained.
224197065|NCT00747110|DRUG|mesalazine|3x 1000mg mesalazine onc daily
224197066|NCT04801017|DRUG|OT-101|TGF β2 specific synthetic 18 mer phosphorothioate antisense oligodeoxynucleotide
224197067|NCT04801017|DRUG|Artemisinin|Herbal Supplement/ Purified extract from Artemisia
224197068|NCT04801017|DRUG|Placebo|0.9% sodium chloride injection
223594951|NCT04149678|DRUG|Ozanimod|Ozanimod
223594952|NCT04149678|DRUG|Cyclosporine|Cyclosporine
223594953|NCT02421601|DRUG|Condoliase|1.25 U, intradiscal injection, one time
223594954|NCT00804934|DRUG|Lucentis|0.5mg Lucentis every four months
223594955|NCT00810784|BEHAVIORAL|Education|(1) a risk-assessment tool completed at the time of a hospital admission, (2) structured educational sessions on VTE prevention, and (3) audit-feedback where institutional data was reviewed during the educational sessions. These sessions were given once to the clinical pharmacists and on three separate occasions to the medicine house officers.
223594956|NCT02145598|DRUG|Lenalidomide|after 6 cycles VMP Patients will receive Lenalidomide given as two capsules 5 mg capsules p.o. daily until progressive disease (PD)
223594957|NCT02145598|DRUG|Placebo|after 6 cycles VMP Patients will receive Placebo given as two capsules 5 mg capsules p.o. daily until progressive disease (PD)
223594958|NCT03275948|OTHER|whole grain|whole grain rye
223594959|NCT03275948|OTHER|reference|white wheat bread
223594960|NCT06135610|DIAGNOSTIC_TEST|Postive SAR-CoV-2 PCR nasopharyngeal swab|Diagnosed Covid-19 confirmed by a positive of SAR-CoV-2 PCR nasopharyngeal swab.
223594961|NCT00480870|DRUG|donepezil|donepezil 5 mg 1 p / day for 1 month and 2p / day for 5 months on.
223594962|NCT00480870|DRUG|Placebo|Placebo 1p / day for 1 month and 2 / day for 5 months on
223747391|NCT00729729|DRUG|PCA|PO, 700mg, once
224197069|NCT00762073|DRUG|budesonide|oral suspension
223747392|NCT00729729|DRUG|PCA|PO, 1000mg, once
223505942|NCT03612895|BEHAVIORAL|Internal Care Coordination|This individual will primarily initiate, guide, and optimize adherence to the care that others deliver, rather than providing direct care his or herself. S/he will call the smoker to conduct a brief assessment of tobacco use and readiness to quit, offer brief counseling and motivational intervention, describe the available pharmacologic and behavioral options, help the smoker to choose among them, and link the smoker to chosen resources. The resources offered will include both internal (health care system based) and external (community based) tobacco cessation resources.
223505943|NCT03612895|BEHAVIORAL|External Community Referral|Massachusetts (MA) Helpline services include an assessment of smoking history and readiness to quit, advice to quit, self-help materials and telephone counseling. For smokers who set a quit date in the next 30 days, the Helpline offers up to 5 proactive telephone counseling calls with options for text messaging and web-based resources. It also provides eligible smokers 4 weeks of free nicotine patch or gum mailed to their home.
223505944|NCT03612895|BEHAVIORAL|Usual Care|Participants will be given the number to the MA Smokers Helpline and advised to contact their primary care provider for additional assistance in quitting smoking.
223505945|NCT00315029|BEHAVIORAL|evidence based decision aid|evidence based decision aid
223505946|NCT00315029|BEHAVIORAL|Possible reimbursement 4th IVF/ICSI cycle when necessary|Potential reimbursement 4th IVF/ICSI cycle when necessary
223505947|NCT02731768|BEHAVIORAL|Standard|Participants will receive an evidence-based behavioral weight control program focused on physical activity and reducing caloric intake. They will be provided with a Fitbit Zip and digital body weight scale for self-monitoring of physical activity and body weight, respectively.They will track caloric intake via the MyFitnessPal smartphone application. They will have access to a study website and attend weekly, in-person group counseling sessions.
223505948|NCT02731768|BEHAVIORAL|Social support-enhanced|Participants will receive the same intervention components as the Standard group.Participants will also be provided with two extra Fitbit Zips and digital body weight scales to share with up to two persons in their social circle who will be invited to serve as their support partners.
223505949|NCT02731768|DEVICE|Fitbit Zip|
223505950|NCT02731768|DEVICE|Digital body weight scale|
223505951|NCT01638299|DEVICE|Hypo-Hyper Minimizer (HHM) System|Adjustment of Insulin dosing during meal time
223505952|NCT00252473|DEVICE|MedTec S-frame Immobilization Masks|
223505953|NCT02565186|DRUG|Lasmiditan|oral tablet
223505954|NCT00976391|BIOLOGICAL|albiglutide + insulin glargine|albiglutide in combination with insulin glargine
223505955|NCT00976391|DRUG|insulin glargine + preprandial lispro insulin|insulin glargine in combination with preprandial lispro insulin
223505956|NCT03115658|BEHAVIORAL|Physical Activity|12 week print based intervention
223505957|NCT05768464|DRUG|Toripalimab|240mg intravenously every 3 weeks
223505958|NCT05768464|DRUG|Axitinib|5mg orraly twice daily
223505959|NCT05156125|DRUG|VTX002|Dose A tablet administered orally once daily
223505960|NCT05156125|DRUG|VTX002|Dose B Tablet administered orally once daily
223505961|NCT05156125|DRUG|Placebo|Placebo Tablet for VTX002 administered orally once daily
223505962|NCT06053476|PROCEDURE|Thoracic epidural analgesia|After correct placement of the epidural catheter, a local anaesthetic (ropivacaine, levobupivacaine or bupivacaine) will be started and, according to in house protocols, an opioid will be added to the epidural solution. A provisional stop of the administration of the epidural infusion is planned after 48 hours (on the second postoperative day).
223505963|NCT06053476|PROCEDURE|Single-shot paravertebral block|At the beginning of surgery, before pleurectomy, a single shot PVB will be placed at 10 levels (T2-T11) by the surgeon with Ropivacaine 7.5mg/mL and 2-3mL per site under direct thoracoscopic vision. The injection site will be chosen at the paravertebral space, just lateral adjacent to the sympathetic trunk.
223505964|NCT06053476|PROCEDURE|Late chest tube removal|"Postoperatively, the chest tube is connected to a Thopaz+ system (Medela inc.) and installed to -2 or -5 cm H2O.~The chest tube will be left in place during a fixed period of 3 postoperative days. The chest tube will be removed at the earliest at POD 3 in case the following criteria are met:~1. The patient is lucid and capable of sitting up straight in bed on his/her own~2. No air leakage indicated by the Thopaz+ system during at least 4 hours, or \<15 mL/min air leakage during at least 6 hours~3. Postoperative X ray (performed at least 4 hours after surgery or ultimately performed the morning of POD1) demonstrating complete lung expansion at the level of the hilum.~4. Absence of bloody drainage by the Thopaz+ system"
223505965|NCT06053476|PROCEDURE|Early chest tube removal|"Postoperatively, the chest tube is connected to a Thopaz+ system (Medela inc.) and installed to -2 or -5 cm H2O.~The chest tube will be removed at the earliest at 4 hours postoperatively in case the following criteria are met:~1. The patient is lucid and capable of sitting up straight in bed on his/her own~2. No air leakage indicated by the Thopaz+ system during at least 4 hours, or \<15 mL/min air leakage during at least 6 hours~3. Postoperative X ray (performed at least 4 hours after surgery or ultimately performed the morning of POD1) demonstrating complete lung expansion at the level of the hilum.~4. Absence of pure blood drainage by the Thopaz+ system"
223505966|NCT00768638|DRUG|Atorvastatin|Atorvastatin 10mg 1co id (10mg active) Placebo 40mg 1co id (40mg inactive)
223505967|NCT00768638|DRUG|Atorvastatin|Atorvastatin 40mg 1co id (40mg active) Placebo 10mg 1co id (10mg inactive)
223505968|NCT00556959|DRUG|high dose clonidine HCl sustained release|high dose clonidine HCl sustained release tablets for 8 weeks
223505969|NCT00556959|DRUG|low dose clonidine HCl sustained release|low dose clonidine HCl sustained release tablets for 8 weeks
223505970|NCT00556959|DRUG|placebo|placebo tablets for 8 weeks
223505971|NCT02996786|DIETARY_SUPPLEMENT|Danggui Buxue Tang|Danggui Buxue Tang purchased from Kaiser Pharmaceutical
223505972|NCT02996786|OTHER|Placebo|Consisting of corn starch and carboxymethyl cellulose
223505973|NCT02852434|DRUG|Lidocaine Gel (2%)|
223505974|NCT02852434|DRUG|Lidocaine Paracervical Block (1%)|
223594963|NCT02266212|PROCEDURE|5 ml arterial blood|A sample of 5 ml arterial blood will be withdraw to test the arterial blood oxygen saturation, CO2 content, carbon monoxide (CO) content and carboxyhemoglobin (COHg).
224310787|NCT03831204|DIAGNOSTIC_TEST|prognostic scores|Effect and GWTGHF were calculated for every patient
224310788|NCT03510598|DEVICE|The ZELTIQ CoolSculpting System|The CoolSculpting machine will be used to perform the treatments.
223594964|NCT06050785|DRUG|Vancomycin|ACL graft will be soaked in vancomycin versus gentamycin
223594965|NCT03631420|BIOLOGICAL|Human Umbilical Cord Derived-Mesenchymal Stem Cells|Cohort 1 : 3 million cells/kg ; Cohort 2 : 10 million cells/kg ; Cohort 3 : 30 million cells/kg
224310789|NCT03510598|DRUG|Kybella 20 MG in 2 ML Injection|Injectable drug called KYBELLA® (deoxycholic acid)
223505975|NCT03166956|DIETARY_SUPPLEMENT|Glutamine and vitamin C enteral supplement|Subjects in the GA group received enteral supplement of 10 g L-glutamine and 90 mg vitamin C per serving provided by Nutritec-Enjoy Nutrition Inc. (Taipei, Taiwan). Subjects in the C group received isocaloric maltodextrin as placebo.
223505976|NCT00471042|DRUG|Buprenorphine|Dose is determined according to the participants' individual need.
223505977|NCT04303637|BEHAVIORAL|Phone use|Objective and subjective reports of smartphone use (e.g., number of hours, number of pick-ups, how phones are used)
223505978|NCT03203512|DIETARY_SUPPLEMENT|Fish oil capsules|Each serving contains 360mg eicosapentaenoic acid (EPA), 270mg docosahexaenoic acid (DHA) and total supplement is 1.8 g per day n-3 PUFA for 12 weeks
223505979|NCT03203512|DIETARY_SUPPLEMENT|High-oleic safflower oil capsules|High-oleic safflower oil capsules for 12 weeks
223505980|NCT00858052|DEVICE|Saline-filled breast implant [IDEAL IMPLANT (R)]|Breast augmentation
223505981|NCT06193967|BEHAVIORAL|Caregiver Praise|Caregivers will provide praise for child's engagement in dietary self-monitoring behaviors as a form of positive reinforcement
223505982|NCT06193967|BEHAVIORAL|Gamification|DSM logs will include gamification (points, levels, virtual pets) as positive reinforcement for child's engagement in dietary self-monitoring behaviors
223505983|NCT02783989|OTHER|white wine|A dietary beverage: a market white wine, 13º alcohol
223505984|NCT02783989|DIETARY_SUPPLEMENT|tyrosol|tyrosol in capsules
223505985|NCT02018887|DRUG|LY2969822|Capsules administered orally
223505986|NCT02018887|DRUG|Placebo|Capsules administered orally
223505987|NCT02917499|DEVICE|TMS|Transcranial magnetic stimulation
223505988|NCT06634615|OTHER|VR patient education video|The educational video is created by converting the information provided by the service nurses into a video when the patient is admitted to the ward for surgery. The video will show a 2-3 minute animation of a nurse giving information. In a patient room, the service nurse will come to the newly admitted patient and explain the concept of cholecystectomy, the reasons for removing the gallbladder, how laparoscopic cholecystectomy is performed, the advantages of laparoscopic surgery compared to open surgery, the preparation process before and on the day of surgery, the conditions to be monitored after surgery, the importance of nutrition and fluid intake, defecation, the importance of early mobilization and discharge.
223505989|NCT06634615|OTHER|VR family interview|Patients will have a 5-minute video call with their families in a 360° designed home environment using virtual reality glasses in the operating room waiting area.
223505990|NCT06636591|COMBINATION_PRODUCT|Device: Multimodal Tumor Thermal Therapy System Drug: Camrelizumab Drug: Nab paclitaxel Drug: Carboplatin|Drugs was given a few days after multimodal thermal therapy
223505991|NCT06636591|COMBINATION_PRODUCT|Device: Multimodal Tumor Thermal Therapy System Drug: Camrelizumab Drug: Nab paclitaxel Drug: Carboplatin Drug: Goserelin|Drugs was given a few days after multimodal thermal therapy
223505992|NCT01286649|OTHER|Human autologous hair follicle cells|Human autologous hair follicle cells suspended in cell medium
223505993|NCT01286649|OTHER|Cell medium|Cell medium
223505994|NCT02931110|DRUG|CBL0137|CBL0137 administered IV weekly on Days 1 and 8 of repeated 21 day treatment cycles. Number of Cycles: 2 or until progression or unacceptable toxicity develops
223505995|NCT04346238|OTHER|Reuse of existing data from patients' medical records|Reuse of existing data from patients' medical records
223505996|NCT00231933|BEHAVIORAL|Person-centered planning (PCP)|PCP aids participants in discovering a vision of a desirable future and developing a plan for achieving that goal. Techniques include providing direction in the planning process, involving significant others, generating focus on assets and capacities, identifying and providing access to integrated community settings, and promoting acceptance of set backs as part of the path to success.
223505997|NCT00231933|BEHAVIORAL|Community integration (CI)|CI includes recovery group sessions and community integration activities.
223594966|NCT01272765|OTHER|Placebo|Placebo
223505998|NCT00231933|BEHAVIORAL|Illness management recovery (IMR)|IMR focuses on nine topic areas: recovery strategies; facts about psychosis; a stress-vulnerability model; building social support; reducing relapses; effective use of medications; coping with stress; coping with problems or symptoms; and meeting health care needs.
223505999|NCT04162275|DRUG|Finamine tablets|taken Finamine tablets orally
223506000|NCT04162275|DRUG|Placebo tablets|taken Placebo tablets orally
223506001|NCT00250861|DRUG|Rituximab|
223506002|NCT00250861|DRUG|Aldesleukin|
223506003|NCT05551221|DRUG|Silodosin Capsules|Silodosin is a α1A-adrenergic receptor antagonist which can relax the smooth muscle of bladder and prostate, relieves the dynamic obstruction of bladder outlet, and improves the lower urinary tract symptoms caused by BPH. The instruction of Silodosin Capsule (Qianweitai®) is 4mg/capsule，1 capsule/time, bid, after breakfast and dinner.
223506004|NCT05551221|DRUG|Ningmitai capsule|Ningmitai Capsule (Ningmitai®) is Traditional Chinese Medicine which has already used in treatment of urinary system disease (eg. CPPS, BPH) in China for more than twenty years. The instruction of Ningmitai Capsule is 0.38g/capsule, 4 capsule/time, tid.
223594967|NCT01272765|DIETARY_SUPPLEMENT|IHBG-10|500 mg IHBG-10
223594968|NCT01665352|DRUG|TTP054|Administered orally once daily for 12 weeks.
223594969|NCT01665352|DRUG|Placebo|Administered orally once daily for 12 weeks.
223594970|NCT01504347|BIOLOGICAL|Multivalent recombinant OspA Lyme Borreliosis Vaccine|Primary vaccination (6 study arms of 50 subjects each): 3 intramuscular injections containing either dose A, B or C in an adjuvanted or non-adjuvanted formulation (6 different formulations) given in monthly intervals (recruited in 3 sequential cohorts)
223594971|NCT01504347|BIOLOGICAL|Multivalent recombinant OspA Lyme Borreliosis Vaccine|Booster vaccination 9-12 months after first vaccination in Section 1 subjects
223747393|NCT03873987|DRUG|Current Formulation of Oritavancin|Current formulation of oritavancin (3 hour infusion of 1200 mg in 1000 ml of D5W)
223747394|NCT03873987|DRUG|Kimyrsa|New formulation of oritavancin (1 hour infusion of 1200 mg in 250 ml of saline)
224197070|NCT00762073|DRUG|placebo|oral suspension matching budesonide
224197071|NCT00331929|DEVICE|Minato A 500 AS spirometer|Spirometry at rest
223506005|NCT05551221|DRUG|Tamsulosin|Tamsulosin is α1A-adrenergic receptor which has used in treatment of BPH for few years. The instruction of Tamsulosin Capsule is 1 tablet at a time, 1 time a day.
223506006|NCT01145222|DRUG|A. CNS 7056|Initial low dose plus supplemental doses as necessary.
223506007|NCT01145222|DRUG|B. CNS 7056|Initial intermediate dose plus supplemental doses as necessary.
223506008|NCT01145222|DRUG|C. CNS 7056|Initial high dose plus supplemental doses as necessary.
223506009|NCT01145222|DRUG|D. Midazolam|Initial standardized dose plus supplemental doses as necessary.
223506010|NCT00327132|DRUG|Omeprazole, Amoxicillin, Clarithromycin|
223506011|NCT00454402|DRUG|Alfuzosin|
223506012|NCT00927186|DRUG|Teriparatide|"20 microgram (mcg) subcutaneous (SC) injection per day for 12 months. Placebo intravenous (IV) infusions were given to maintain blind.~After completing 12 months of treatment, all participants are eligible to participate in an additional 12-month extension."
223506013|NCT00927186|DRUG|Zoledronic Acid|"5 milligram (mg) intravenous (IV) infusion administered once during 1 year study. Placebo subcutaneous (SC) injections were given to maintain blind.~After completing 12 months of treatment, all participants are eligible to participate in an additional 12-month extension."
223506014|NCT01507389|DRUG|liraglutide|Single dose of 0.75 mg injected subcutaneously (under the skin)
223506015|NCT01571609|OTHER|first phase insulin secretion (FPIR), Hyperinsulinemic euglycemic clamp (HEC), glucose tracer, and palmitate tracer|"FPIR: intravenous infusion of 20 % glucose 0.3 mg/kg in 2 minutes followed by blood sampling at times 0, 2, 4, 6, 8, and 10. Duration 10 minutes.~HEC: intravenous infusion of actrapid 1mU/kg/minute, simultaneous infusion of 20 % glucose at variable rate to reach plasma blood glucose level of 5 mmol/L. Duration 120 minutes~Glucose tracer: bolus of 3H3glucose (12µCi) followed by infusion of 3H3glucose (0,12 µCi/min). Duration 120 minutes.~Palmitate tracer:\[9,10-3H\]-palmitate 0,3 µCi/min. Duration 60 minutes."
223506016|NCT01339182|DRUG|Pegylated-Somatropin|Daily s.c, randomized with Saizen, 0.1IU/kg or 0.15IU/kg for the first week, followed by one week wash-out, and then s.c, single dose of pegylated-Somatropin, 10mcg/kg.
223506017|NCT01339182|DRUG|YPEG-Somatropin|Daily s.c, randomized with Saizen, 0.1IU/kg or 0.15IU/kg for the first week, followed by one week wash-out, and then s.c, single dose of pegylated-somatropin, 30mcg/kg.
223506018|NCT01339182|DRUG|YPEG-Somatropin|Daily s.c, randomized with Saizen, 0.1IU/kg or 0.15IU/kg for the first week, followed by one week wash-out, and then s.c, single dose of pegylated-somatropin, 60mcg/kg.
223506019|NCT01339182|DRUG|YPEG-Somatropin|Daily s.c, randomized with Saizen, 0.1IU/kg or 0.15IU/kg for the first week, followed by one week wash-out, and then s.c, single dose of pegylated-somatropin, 120mcg/kg.
223506020|NCT01339182|DRUG|YPEG-Somatropin|Daily s.c, randomized with Saizen, 0.1IU/kg or 0.15IU/kg for the first week, followed by one week wash-out, and then s.c, single dose of pegylated-somatropin, 200mcg/kg.
223506021|NCT01698008|OTHER|Diabetes Doctor Mobile app|Diabetes Doctor is a mobile application software. The mobile phone application allows a subject to register blood glucose values obtained from their fingerstick glucose meter readings, the type and amount of insulin they are administering, any notes they would like to document, and the date and time of each entry. All data will be entered by the subject manually. The data will be submitted through encryption coded private servers and can be retrievable by a physician on a password protected website for privacy. A physician will evaluate this information to recommend a change of the subject's insulin regimen. The recommended insulin regimen will be delivered to the patient using the same website and received by the subject on the same mobile application software.
223506022|NCT05416281|OTHER|Robotic Vacuum|Participants will be provided with a Roomba iRobot vacuum and will be asked to use the vacuum in their home for 8 weeks. Exposure to environmental exposures will be evaluated before and after the intervention using silicone wristbands.
223506023|NCT02053584|DEVICE|Dario™ Blood Glucose Meter|Each subject will undergo a finger prick and also provide a venous blood sample
223506024|NCT02053584|DEVICE|YSI2003|Blood samples will be tested using YSI (gold standard) for comparison to evaluate accuracy.
223506025|NCT01427946|DRUG|IPI-504|
223506026|NCT01427946|DRUG|Everolimus|
223506027|NCT01011283|DRUG|decitabine|decitabine 20 mg/m\^2 /day intravenous (IV) infusion for 5 days every 28 days
223506028|NCT01011283|DRUG|azacitidine|azacitidine 75 mg/m\^2 /day subcutaneous (SC) injection for 7 days every 28 days
223506029|NCT00950924|DEVICE|Simultaneous Vision Bifocal Soft Contact Lenses|Simultaneous Vision Bifocal Soft Contact Lenses will be prescribed such that the distance vision as measured by manifest subjective refraction will be properly corrected by the near vision add power and undercorrected by the distance power.
223506030|NCT00950924|DEVICE|Single Vision Soft Contact Lenses|Single vision soft contact lenses will be prescribed to properly correct the distance vision as measured by manifest subjective refraction.
223506031|NCT00132483|BEHAVIORAL|Instruction in physical training program|Instruction in physical training program.
223594972|NCT01504347|BIOLOGICAL|Multivalent recombinant OspA Lyme Borreliosis Vaccine|3 intramuscular injections at monthly intervals (using 2 formulations selected from Section 1) in seronegative and seropositive subjects (N=350) and a booster vaccination at 6 months or at 9-12 months (Cohorts 4: seronegatives; Cohort 5: seropositives)
223506032|NCT00949663|DRUG|Placebo|Intravenous infusion of 1% human albumin in normal saline
223506033|NCT00949663|DRUG|Glucose-dependent Insulinotropic Polypeptide (GIP)|Intravenous infusion of GIP (4 pmoles x kg-1 x min-1) in 1% human albumin in normal saline
223506034|NCT00949663|DRUG|Xenin-25|Intravenous infusion of xenin-25 (4 pmoles x kg-1 x min-1) in 1% human albumin in normal saline
223594973|NCT00774020|DRUG|Zoledronic acid|5mg, i.v. single dose
223747395|NCT05646511|RADIATION|SCRT|5x5 Gy: 25 Gy
224197072|NCT03055273|BEHAVIORAL|SOCIABLE|SOCIABLE services involve a nurse, and occupational therapist and a handyman to support function among older adults with end stage renal disease. There is particular emphasis on supporting the social function and the physical and everyday living function.
224197073|NCT01891136|DRUG|Peanut protein|Subjects will receive increasing amounts of peanut protein over the modified rush phase and the build-up phase of the protocol. Once the subject reaches the maintenance phase of the study, they will remain on that dose until they reach the oral food challenges at the end of the study.
224197074|NCT03683264|OTHER|Ultrasound diagnosis of avulsion of the levator ani muscle|In the multi-view ultrasound images, complete avulsion was defined as an abnormal insertion of LAM in the lower pubic branch identified in all three central slices, i.e. in the plane of minimal hiatal dimensions (PMD) and the 2.5 and 5.0mm slices cranial to this one. Levator hiatus measurements, transverse diameters, anteroposterior diameters and area were also determined in the same plane (PMD).
224197075|NCT04514224|OTHER|Gabby implementation|Iimplement an evidence-based preconception care intervention, Gabby, into community-based health settings
224197076|NCT04514224|OTHER|Evaluate the Gabby implementation|Assess implementation outcomes using the Proctor Implementation Outcomes Framework
223506035|NCT00949663|DRUG|Glucose-dependent Insulinotropic Polypeptide plus Xenin-25|Intravenous infusion of GIP plus xenin-25 (4 pmoles each x kg-1 x min-1) in 1% human albumin in normal saline
223506036|NCT00520442|DRUG|ibuprofen|
223506037|NCT00520442|DRUG|acetamin w codeine|
223506038|NCT02852733|OTHER|end-of-life emergencies' management|
223506039|NCT02822287|DRUG|Acetylcystine|Clear oral solution containing 2% acetylcysteine (g/mL) in a 100 mL amber glass bottle.
223506040|NCT03233685|BEHAVIORAL|Visual Training|The visual training will be performed 3 times a week for 40 minutes, at the end of warm up and before the technique training. The subjects will be performed a progression of exercise to improve their visual ability, their velocity of interpretation and transformation. The training will be performed with specific panels approved for visual training (S.V.T.A., Torino, Italy).
223506041|NCT03233685|BEHAVIORAL|Normal Training|Normal training routine
223506042|NCT02933476|DEVICE|Vibrotactile Stimulation|The tactile stimulator is being tested for an off-label use as treatment for Parkinson's disease. There are nodes embedded into the fingertips of gloves that gently vibrate in an alternating pattern. The sensation is similar to the feeling of a phone vibrating. This is a non-significant risk device.
223506043|NCT01556100|DRUG|18F-DTBZ AV-133|A total 40 PD subjects will be included in this study. PD subjects between 20 and 80 years of age may be eligible for this study. Candidates are screened with a medical history and physical examination, and blood test.
223506044|NCT00416754|OTHER|counseling intervention|subjects will receive genetic counseling
223506045|NCT01272895|DEVICE|Coronary Intervention (GENOUS stent)|GENOUS stent (Coronary Intervention)
223506046|NCT01159353|DRUG|Insulin glulisine|Insulin glulisine 100 U/ml, solution for injection in vial Dose: 0.2 U/Kg Administration: single subcutaneous injection with syringe in the periumbilical abdomen within 2 minutes before the standard meal
223506047|NCT01159353|DRUG|Insulin aspart|Insulin aspart: 100 U/mL, solution for injection in vial Dose: 0.2 U/Kg Administration: single subcutaneous injection with syringe in the periumbilical abdomen within 2 minutes before the standard meal
223506048|NCT02246985|DIETARY_SUPPLEMENT|Control|The bread and mayonnaise in this meal does not have vegetable powders incorporated into them. Hence this meal does not contain carotenoids.
223506049|NCT02246985|DIETARY_SUPPLEMENT|Vegetable bread only|A vegetable powder (carrot and tomato) containing bread portion will be served alone. The amount of vegetable powder in the bread portion will be standardised to contain a known amount of carotenoids.
223506050|NCT02246985|DIETARY_SUPPLEMENT|Plain bread with vegetable mayonnaise|Plain bread will be served with a vegetable powder (carrot and tomato) containing mayonnaise. The amount of vegetable powder in the mayonnaise will be standardised to contain a known amount of carotenoids.
223506051|NCT02246985|DIETARY_SUPPLEMENT|Vegetable bread with plain mayonnaise|A vegetable powder (Carrot and tomato) containing bread portion will be served with plain mayonnaise. The amount of vegetable powder in the bread portion will be standardised to contain a known amount of carotenoids
223506052|NCT05891327|DIETARY_SUPPLEMENT|Maca|2.25 g Lepidium meyenii (Maca) extract twice per day for 12 weeks
223506053|NCT05891327|DIETARY_SUPPLEMENT|Placebo|Placebo
223506054|NCT01035307|GENETIC|gene expression analysis|
223506055|NCT01035307|GENETIC|microarray analysis|
223506056|NCT01035307|GENETIC|proteomic profiling|
223506057|NCT01035307|OTHER|laboratory biomarker analysis|
223506058|NCT04376632|DIETARY_SUPPLEMENT|Pecan ADD|Raw pecan halves without dietary substitution instructions
223506059|NCT04376632|DIETARY_SUPPLEMENT|Pecan SUB|Raw pecan halves with instructions to substitute pecans with isocaloric foods in the habitual diet
223594974|NCT00642863|DIETARY_SUPPLEMENT|Ferrous Sulfate (liquid) + vitamins A and D|a single daily dose of 1-2 mg/kg of elemental iron (5 mg from 6 wk to 9 mo and 15 mg from 9 to 18 mo.) and 1500 IU vitamin A and 500 IU vitamin D from 6 wk to 18 mo.
223594975|NCT00642863|DIETARY_SUPPLEMENT|vitamins A and D|a single daily dose (liquid) of 1500 IU vitamin A and 500 IU vitamin D from 6 wk to 18 mo.
223594976|NCT00642863|DIETARY_SUPPLEMENT|Ferrous sulfate (liquid)|Infants who become iron deficient/anemic at 9 or 18 mo will take a single daily dose of 3 mg/kg of elemental iron for 3 months.
223594977|NCT01608503|PROCEDURE|lung deflation|lung was deflated during respiration cycle
223594978|NCT01608503|PROCEDURE|lung inflation|lung was inflated during respiratory cycle
223594979|NCT05200689|DEVICE|Kinesiotaping (KT)|"Kinesio taping will only be applied for a period of 5 days. Initial Kinesio taping will first occur one day after surgery.~It will be placed directly on the chest wall on a trigger point. Physiotherapists will be instructed to maintain a standard Tape length (To body size ratio) and tension among all patients of all KT groups. The edges of the tape must be rounded, to prevent premature peeling. The adhesive side of the tape must not be touched after removing its backing, to prevent any decrease in tape adherence. It will be applied using both I and Star applications. Star and I KT application is done directly above the main pain trigger point. This point is found via chest palpitations. The Tape will be replaced every 48 hours by the physiotherapist until the end of therapy. The tape must be placed after stretching the skin."
223594980|NCT00122655|DRUG|non-nucleoside reverse transcriptase inhibitors|
223594981|NCT00122655|DRUG|nucleoside reverse transcriptase inhibitors|
223594982|NCT00122655|DRUG|protease inhibitors|
223594983|NCT03336385|DIETARY_SUPPLEMENT|Naxus|Non-digestible polysaccharides arabinoxylan (Naxus)
223594984|NCT03336385|DIETARY_SUPPLEMENT|Oatwell|Non-digestible polysaccharides oat beta-glucan (Oatwell)
223594985|NCT03336385|DIETARY_SUPPLEMENT|Placebo|Maltodextrin as placebo
223594986|NCT02462993|DRUG|Aloe Vera|Local drug delivery of aloe vera gel
223594987|NCT02445066|DIETARY_SUPPLEMENT|Vitamin D3|
223506060|NCT05507229|BIOLOGICAL|Hillchol vaccine|HillChol®(BBV131) (Whole cell inactivated Stable Hikojima expressing both Inaba and Ogawa LPS) inactivated bacteria of a stable recombinant Vibrio cholerae O1 El Tor Hikojima serotype strain expressing approximately 50% each of Ogawa and Inaba O1 LPS antigens.
223506061|NCT05507229|BIOLOGICAL|Shanchol Vaccine|Shanchol™ (Killed Bivalent (O1 and O139) Whole Cell Oral Cholera Vaccine)
223506062|NCT02959892|DRUG|Amphetamine|Amphetamine tablets.
223506063|NCT02959892|DRUG|TAK -041|TAK-041 oral suspension.
223506064|NCT02959892|DRUG|[11C] (+)-4-propyl-(+)-4-propyl-9-hydroxynaphthoxazine (PHNO)|\[11C\]PHNO injection.
223506065|NCT03494192|OTHER|Scapula Retraction Exercise Group|"physiotherapy program consists of manual therapy, supervised stretching and scapulothoracic muscles strengthening exercises and home exercise programme including stretching and strengthening exercises will be applied two times a week total 24 sessions.~After 24 sessions completed, patients will proceed to reduced exercise program until the 6-month follow-up."
223506066|NCT03494192|OTHER|Scapula Retraction +Glenohumeral Rotational Exercise Group|"physiotherapy program consists of manual therapy, supervised stretching and scapulothoracic and also rotator cuff muscles strengthening exercises and home exercise programme including stretching and strengthening exercises will be applied two times a week total 24 sessions.~After 24 sessions completed, patients will proceed to reduced exercise program until the 6-month follow-up"
223506067|NCT00006135|DRUG|acyclovir|
223506068|NCT06009354|OTHER|Rehabilitation|The control group will receive post-operative usual practices. The study group will receive multi-component education in addition to the usual practices.
223506069|NCT06025058|DEVICE|Easy Dew MD Regen Cream|The subject applies the provided medical device twice a day (morning and evening) to areas with symptoms of dry skin so that it can be absorbed well.
223506070|NCT00580294|DRUG|Oxymorphone|IV PO
223506071|NCT03099863|DRUG|Cystoscopic Fluid containing Neosporin G. U. Irrigant|Normal saline cystoscopic fluid containing Neosporin G. U. Irrigant 1mL/1000mL
223506072|NCT03099863|PROCEDURE|Cystoscopy|Diagnostic cystoscopy performed during pelvic floor surgery
223506073|NCT03099863|DRUG|Cystoscopic Fluid/Placebo|Normal saline cystoscopic fluid
223506074|NCT05424809|BEHAVIORAL|Shared decision-making model|"The model is based on a person-centred care process, where an exchange of information is carried out between the health professional and the patient to make the best decision that is consistent with the person's values and preferences.~A six-stage process constitutes the model: 1) Identificacion of the decision point, 2) design of a specific patient decision aid, 3) identification of possible barriers and ways to overcome them, 4) training for professionals, 5) 3-steps implementation of shared decision-making in clinical practice, 6) evaluation"
223506075|NCT02399800|PROCEDURE|Celiac Block with triamcinolone and bupivicaine|Endosonography of the pancreas performed following by analgesic injection
223506076|NCT02399800|PROCEDURE|No Celiac Block|EUS but no celiac block performed
223506077|NCT02399800|DRUG|Intra Plexus Triamcinolone and Bupivicaine Injection|Injection of Triamcinolone and Bupivicaine into celiac plexus for pain relief
223506078|NCT03148925|BIOLOGICAL|SELA-070|Sub-cutaneous injection, multiple dose
223506079|NCT03148925|BIOLOGICAL|Saline|Sub-cutaneous injection, multiple dose
223506080|NCT03407911|OTHER|Harvested|Metagenomic exam of Gingival crevicular fluid harvested by adsorbent paper point around periodontal teeth and implant affected by peri-implantitis
223506081|NCT01706380|BEHAVIORAL|Interactive voice response with personal feedback|Personal feedback is given at the end of each automated telephone follow-up call, and reports back to the patient whether his och her symptom status is better, worse or equal, compared to the previous telephone call.
223506082|NCT01706380|BEHAVIORAL|Interactive voice response without personal feedback|Control condition. Identical follow-up but without personal feedback.
223506083|NCT02145520|DRUG|Magnesium Sulfate|The use of magnesium sulfate intravenous in patient with bronchiolitis in pediatric emergency; follow Broncholitis severity score and length of stay
223506084|NCT02145520|OTHER|placebo|use of placebo with standard therapy
223747396|NCT05646511|DRUG|CAPOX|Six cycles of CAPOX capecitabine 1000 mg/m2 orally twice daily on days 1-14, oxaliplatin 130 mg/m2 intravenously on day 1, every 3 weeks
223506085|NCT05832814|BEHAVIORAL|Integrated training|For rhythm-guided walking exercise, the home exercise intensity, that is, the walking speed can be prescribed based on the incremental shuttle walking(ISWT) result. A rhythm matching with the walking speed can be calculated. Then patients will be provided a group of melodies identified by the calculated rhythm, which are also popular with the elder. During exercise, the patients are required to walking on a fixed speed identical with the rhythm. For singing training, patients follow the audios and videos to take training at home, which are recorded by singing teachers and physiotherapists prior to the trial. Each session includes technical instructions in order to achieve better respiratory control during singing.
223506086|NCT05832814|BEHAVIORAL|Rhythm-guided exercise training|For rhythm-guided walking exercise, the home exercise intensity, that is, the walking speed can be prescribed based on the incremental shuttle walking test(ISWT) result. A rhythm matching with the walking speed can be calculated. Then patients will be provided a group of melodies identified by the calculated rhythm, which are also popular with the elder. During exercise, the patients are required to walking on a fixed speed identical with the rhythm.
223506087|NCT06134895|DRUG|Tramadol with Ketamine|Tramadol with Ketamine is being provided randomly using prospective, double-blind
223506088|NCT06134895|DRUG|Tramadol|Tramadol alone is being provided randomly using prospective, double-blind
223506089|NCT01271166|DRUG|Imatinib, Fluorouracil, Oxaliplatin, Leucovorin and Bevacizumab|
223506090|NCT00799864|DRUG|Rilpivirine|Patients will receive rilpivirine (RPV) tablet 25 milligram dose or an adjusted dose orally once daily in Cohort 1 (adolescents aged \>=12 to \<18 years) up to 240 weeks. Patients will receive RPV weight-adjusted dose orally once daily in Cohort 2 (children aged \>=6 to \<12 years) or 25 mg once daily for up to 48 weeks.
223506091|NCT00799864|DRUG|Zidovudine|Type=exact, form= appropriate pediatric formulation, unit=mg, route=oral. The patients may receive this selected NRTI together with another NRTI once daily for up to 48 weeks (Cohort 2) and 240 weeks (Cohort 1).
223506092|NCT00799864|DRUG|Abacavir|Type=exact, form=appropriate pediatric formulation, unit=mg, route=oral. The patients may receive this selected NRTI together with another NRTI once daily for up to 48 weeks (Cohort 2) and 240 weeks (Cohort 1).
223594988|NCT05028270|PROCEDURE|Balloon technology;Microcatheter technology|Describe each group's intervention in sufficient detail, including how and when to give the intervention Suspend or modify the criteria for interventions that have been assigned to the subject (such as changing the dose of the drug due to hazards or subject requirements or improvement/deterioration of the condition, etc.) Strategies to improve the compliance of intervention programs, and other measures to monitor compliance (such as the return of drug tablets, laboratory inspections, etc.) Related care and interventions allowed or prohibited during the trial
223594989|NCT00166491|DRUG|Insulin|
223594990|NCT00938691|PROCEDURE|Intradermal Suture|
223594991|NCT00938691|PROCEDURE|Intradermal Suture|
223594992|NCT00599638|DRUG|pregabalin|75mg bid titrating to 150mg bid on day 4
223594993|NCT00599638|DRUG|pregabalin/PF-00489791|Pregabalin 75mg bid titrating to 150mg bid on day 4; PF-00489791: 4mg od titrating to 10mg od on day 4
223594994|NCT00599638|DRUG|Placebo|Placebo
223594995|NCT01463202|DRUG|Depot medroxyprogesterone acetate|Postpartum administration of DMPA (prior to hospital discharge)
223594996|NCT01463202|DRUG|Depot medroxyprogesterone acetate|Delayed administration of DMPA (4-6 weeks postpartum)
223594997|NCT02553408|DEVICE|FreeStyle Precision Neo-Meter|Participants will receive a free glucose meter (Neo) and test strips from their care providers with education and instructions on how to use the meter to monitor their glucose level. Three months after the start of using the meter, participants will be interviewed on their experiences, likes and dislikes about the meter.
223594998|NCT02895945|BIOLOGICAL|Antihemophilic Factor (Recombinant), Porcine Sequence (BAX 802)|In case of major surgery, FVIII target level is ≥80% for major surgeries/ procedures and ≥50% for minor surgeries/ procedures.
223594999|NCT03730415|PROCEDURE|Viscoelastic (VE) Guided Transfusion|A viscoelastic analyzer (ROTEM) will be used to guide the transfusion algorithm during the burn wound excision of subjects enrolled into this arm
224197077|NCT05488067|DRUG|atorvastatin|Oral atorvastatin treatment for ALGS children with xanthoma
224197078|NCT03408327|DEVICE|Wearable technology|Fitness wristband \& APP
224197079|NCT03408327|BEHAVIORAL|LINE group|Promote social interaction
224197080|NCT03408327|BEHAVIORAL|Group activities|Which was developed by applying social cognitive theory
224197081|NCT03408327|DEVICE|Health promotion manual|Which was about general physical activity promotion content
224197082|NCT04622540|PROCEDURE|External biliary drainage|Application of external biliary drainage through duct-to-duct anastomosis
223595000|NCT03225924|DRUG|Entospletinib|200mg or 400mg twice a day for 7 days every 21 cycles - total of 8 cycles
223595001|NCT03225924|DRUG|Rituximab|cycles of 21 days - 375mg/m²
223595002|NCT03225924|DRUG|Cyclophosphamide|cycles of 21 days - 750 mg/m²
223595003|NCT03225924|DRUG|Doxorubicin|cycles of 21 days - 50mg/m²
223595004|NCT03225924|DRUG|Vincristine|cycles of 21 days - 1.4mg/m²
223595005|NCT03225924|DRUG|Prednisone|cycles of 21 days - 40mg/m²
223595006|NCT04768803|BIOLOGICAL|acylated and unacylated ghrelin dosages|realization of plasma samples to evaluate of levels of ghrelin and collection of plasma and cells
223595007|NCT00953940|DRUG|Isotonic saline|Isotonic saline administrated i.v at 1.5 ml/Kg/h , 8 to 12 h before surgery
223595008|NCT03286283|DEVICE|J-Plasma|Dermal resurfacing procedure with J-Plasma.
223595009|NCT04005079|DRUG|Pilocarpine|2% pilocarpine in the postoperative period in addition to standard postoperative drops (Prednisolone acetate and Ofloxacin)
223595010|NCT04005079|DRUG|Ofloxacin|Standard of care
223595011|NCT04005079|DRUG|Prednisolone|Standard of Care
224197083|NCT03699956|COMBINATION_PRODUCT|RRx-001 + eLOOP Device|RRx-001 is a small molecule anticancer drug which is mixed with patient's own blood using the eLOOP device
223595012|NCT04882787|DEVICE|BTE hearing aid|Amplification
223595013|NCT03117413|OTHER|Positron emission tomography scan|"* Binaural hearing assessments: speech recognition in noise and sound source localization~* Voice perception assessment: voice/non-voice discrimination task, free categorization task~* Positron emission tomography examinations under ecological auditory stimuli (voice/non-voice discrimination task)"
223595014|NCT06010407|OTHER|Survey|"* Working Alliance Inventory~* Attitude Towards Psychiatry-30 Scale"
223595015|NCT03693547|DRUG|utidelone injection|utidelone monotherapy in patients with advanced NSCLC by utidelone
223595016|NCT06287307|OTHER|Placebo|The placebo will be used in the allocated group in addition to our lifestyle program for the duration of 68 weeks in total.
223595017|NCT06287307|DRUG|Semaglutide 2.4 MG/0.75 ML Subcutaneous Solution [WEGOVY]|The semaglutide will be used in the allocated group in addition to our lifestyle program for the duration of 68 weeks in total.
223595018|NCT06506890|OTHER|Use of C-Polar coated HVAC Filter versus conventional HVAC Filter|comparing the difference in reduction of bioaerosols between HVAC filters.
224197084|NCT03699956|DRUG|Cisplatin/carboplatin plus etoposide|Standard of care platinum doublet chemotherapy
224197085|NCT05198414|OTHER|Focus group|Qualitative research methodology with healthcare workers
224197086|NCT05180994|DRUG|Topical infliximab|Infliximab eye drops (10mg/ml) administered four (4) times per day for three (3) months.
224197087|NCT05180994|OTHER|No topical infliximab|No treatment with infliximab.
224197088|NCT04706494|DIETARY_SUPPLEMENT|AlphaWave® LTheanine|200 mg of AlphaWave® LTheanine
224197089|NCT04706494|DIETARY_SUPPLEMENT|Placebo|microcrystalline cellulose
224197090|NCT01293682|DRUG|Calcitriol|In pill form, 45 micrograms once a week for 12 weeks
224197091|NCT05888818|OTHER|Cold application|A cold application (with a cold gel pack) will be applied to the upper part of the neck for 5 minutes.
224197092|NCT00589966|BEHAVIORAL|Coping Skills Training|Coping Skills Training teaches skills for managing physical, emotional, and social challenges of symptoms commonly experienced by men who have undergone treatment for early stage prostate cancer. Coping skills include activity pacing, managing negative mood, communication enhancement, and applied relaxation.
224197093|NCT00589966|BEHAVIORAL|Prostate Cancer Education|Prostate Cancer Education provides information on the following topics: common treatment side-effects, medical options for symptom management, nutrition to support recovery, and guidelines for communicating with your healthcare team.
224197094|NCT05797948|DRUG|Obinutuzumab|Obinutuzumab Injection 1000mg ivgtt C1-C4 d1；
224197095|NCT05797948|DRUG|Zanubrutinib|Zanubrutinib 160mg (2 capsules) oral bid；
223595019|NCT04130698|BEHAVIORAL|Distress Tolerance|The group-level intervention is comprised of one 2-hour weekly group sessions with overweight smokers to learn skills and strategies consistent with distress tolerance intervention to quit smoking and lose weight.
223747397|NCT05646511|DRUG|CAPOXIRI|Six cycles of CAPOXIRI capecitabine 800 mg/m2 orally twice daily on days 1-14, oxaliplatin 130 mg/m2 intravenously on day 1 and irinotecan 150 mg/m2 intravenously on day 1, every 3 weeks
223747398|NCT05739851|DRUG|DA-1229_01 2.5/500mg (Before)|single dose administration (one tablet once a day)
223747399|NCT05739851|DRUG|DA-1229_01 2.5/500mg (After)|single dose administration (one tablet once a day)
223747400|NCT05563753|DRUG|ABT|any antibiotic therapy in the first week of life
223747401|NCT06020560|DRUG|Dalteparin Prefilled Syringe|Patients will via a software module (Through a patient journal system) be allocated to either dalteparin or tinzaparin. Clusters are timeframes of 1 hour.
223747402|NCT06020560|DRUG|Tinzaparin profiled syringe|Patients will via a software module (Through a patient journal system) be allocated to either dalteparin or tinzaparin. Clusters are timeframes of 1 hour.
224197096|NCT05797948|DRUG|Lenalidomide|Lenalidomide 25mg (1 capsule) oral C1-C4 d1-d10.
224197097|NCT05797948|DRUG|CD19/CD22 CAR-T|Targets of CAR-T cells are tandem CD19/CD22. 1 \* 10 \^ 7/kg dual-target CAR-T cells were reinfused with 10%, 30% and 60% of the total dose on d1, d2, d3 respectively.
224197098|NCT05797948|DRUG|Azacitidine For Injection|Azacitidine For Injection 100mg i.h. d1-d5;
224197099|NCT05797948|DRUG|Fludarabine|Fludarabine 300mg/m2 ivgtt d3-d5;
224197100|NCT05797948|DRUG|Cyclophosphamide|Cyclophosphamide 300mg/m2 ivgtt d3-d5.
224197101|NCT06420726|BEHAVIORAL|Resistance Exercise|Supervised resistance exercise
224197102|NCT01854125|BIOLOGICAL|autologous bone marrow mesenchymal stem cells transplantation|Autologous MSCs were infused to patients using interventional method via hepatic artery . The catheter was inserted to proper hepatic artery. After the catheter placed at proper hepatic artery was confirmed by angiography, autologous bone marrow MSCs were infused slowly for 20-30 minutes.
224197103|NCT01854125|BIOLOGICAL|autologous bone marrow msenchymal stem cells transplantation|
224197104|NCT06279468|PROCEDURE|intervertebral disc release|After standard posterior instrumentation and fusion in scoliosis cases, Ponte osteotomies are performed on vertebrae with a Nash-Moe classification of 1 degree or higher. The intervertebral discs on the convex side of the scoliosis, situated between the vertebrae that have undergone Ponte osteotomy, will be approached and incised parallel to the intervertebral space. The intervertebral disc and endplate cartilage were incised and separated using reamers. Subsequently, the intervertebral space was expanded and irrigated, and the fragments of the intervertebral disc were extracted using nucleus pulposus forceps. Impacting bone graft into the intervertebral space, thus sustaining the optimal height of intervertebral space.
224310790|NCT06197269|OTHER|Short duration antibiotics|antibiotic therapy will be stopped at the time of randomization i.e. 72 hrs after starting treatment
224310791|NCT06197269|OTHER|Standard duration antibiotics|Antibiotics will be continued for 5-7 days more, 72 hrs after starting treatment.
223595020|NCT04130698|DRUG|transdermal nicotine patch|Participants will use the patch for 8 weeks as outlined by the recommended usage for steps 1-3 going from 21mg for 4 weeks, 14mg for 1 week, and 7mg for 1 week.
223595021|NCT04130698|BEHAVIORAL|Active Health Control|The group-level intervention is comprised of one 2-hour weekly group sessions with overweight smokers to learn skills and strategies consistent with psychoeducation intervention to quit smoking and lose weight.
223595022|NCT05943782|PROCEDURE|onlay manufactured by milling|indirect restorations for treating mutilated molars manufactured by CAD/CAM subtractive technique
223747403|NCT03573986|BIOLOGICAL|[18F]fluoromisonidazole|positron emitting radiopharmaceutical that has been studied in vivo in humans for measurement of regional hypoxia in a number of tumor types with positron emission tomography (PET/CT)
223747404|NCT03573986|DRUG|Bevacizumab|Bevacizumab (Avastin, Genentech/Roche) is a humanized monoclonal antibody that binds to VEGF preventing its interaction with VEGFRs resulting in suppression of VEGF signaling.
223747405|NCT03573986|RADIATION|positron emission tomography (PET/CT).|PET-CT Scan 1.) before start of Bevacizumab up to approximately 4 weeks and 2.) within 12-22 days of start of Bevacizumab
223747406|NCT00930150|BEHAVIORAL|Targeted cognitive training|Adaptive computer exercises that systematically increase in task difficulty as each participant's performance ability improves
223747407|NCT00930150|BEHAVIORAL|Computer control|Commercially available computer games selected based on quality, ability to hold interest, and lack of disturbing content
223747408|NCT00930150|BEHAVIORAL|Bridging groups|Weekly group meetings that help participants apply their cognitive skills to everyday functioning, promote group identity, and promote socialization
223747409|NCT00930150|BEHAVIORAL|Health and wellness groups|Weekly group meetings that teach participants health and wellness skills
223747410|NCT00001487|DRUG|Dehydroepiandrosterone|
223747411|NCT01119989|DIETARY_SUPPLEMENT|Fructose+maltodextrin placebo|
223747412|NCT01119989|DIETARY_SUPPLEMENT|amino-acid + fructose|
223747413|NCT05277246|OTHER|Irrigant concentration|The success of endodontic treatment is directly related to infection control. In successful endodontic treatment, it is necessary to perform an ideal irrigation both in order to gain a better understanding of the complex anatomical structure of the root canals and to increase the efficiency of the instruments and methods used during the canal preparation. Sodium hypochlorite (NaOCl) solution is the standard irrigation agent for cleaning and disinfection of root canal. In this study, the effect of NaOCI on level of IL-8 different concentration will be evaluated.
223747414|NCT05277246|DRUG|NaOCI|NaOCI
223747415|NCT03302585|DRUG|Vitamin D3|50,000 IU/d of oral vitamin D3 x 5 days followed by 10,000 IU/d of oral vitamin D3 x 85 days
223747416|NCT03302585|DRUG|Placebo/Standard of Care Vitamin D3|50,000 IU/d of oral vitamin D3 x 5 days followed by 40,000 IU/d of oral vitamin D3 x 85 days
223747417|NCT03340337|DEVICE|Neo-Russian|"Subjects will receive Neo-Russian electrical stimulation with three reps (5 sec work x 120 sec rest), and the Maximal Electrical Induced Contraction (MEIC) will be measured. They will be asked how uncomfortable the stimulation was, using Visual Analogue Scale (VAS).~One week later, subjects will receive a fatigue protocol that consists in 21 reps (5 sec work x 5 sec rest), and the Maximal Electrical Induced Contraction (MEIC) will be measured for each contraction."
224197105|NCT06279468|PROCEDURE|Ponte osteotomy|After standard posterior instrumentation and fusion in scoliosis cases, Ponte osteotomies are performed on vertebrae with a Nash-Moe classification of 1 degree or higher. Subsequent corrective procedures can be performed immediately following Ponte osteotomy completion. The deformity was corrected using the bilateral rod rotation and segmental derotation technique after inserting rods. Under fluoroscopic guidance, compression, distraction, and in situ bending maneuvers were implemented as needed. Allograft bone material was utilized for the purpose of bone fusion
224197106|NCT01824095|DIETARY_SUPPLEMENT|Dietary supplement|
224197107|NCT02001038|OTHER|Survey|
224197108|NCT00491322|DIETARY_SUPPLEMENT|Ergocalciferol|Ergocalciferol 50000 international units once a week for 12 weeks
224197109|NCT00491322|DIETARY_SUPPLEMENT|Ergocalciferol placebo|Ergocalciferol placebo once a week for 12 weeks
224197110|NCT00660855|DRUG|parecoxib/valdecoxib|parecoxib 40 mg intravenously after recovery from anesthesia; if pain persisted, the patient could receive an optional second drug dose on Study Day 1 (only) if more than 4 hours after the first dose. When the patient was able to tolerate oral medication, one valdecoxib 40 mg tablet was administered by mouth once daily in the morning until a maximum period of 7 days.
224197111|NCT06652724|BEHAVIORAL|Dynamic interpersonal therapy (DIT)|"Dynamic interpersonal therapy (DIT) is a dynamically oriented brief psychotherapeutic intervention based on attachment and mentalization theory that views symptoms of depression and anxiety as responses to interpersonal difficulties.~This intervention helps patients to understand the connection between their symptoms and their relationships by identifying a core, non-conscious, repetitive pattern of relating. Previous studies have shown positive results: significant reductions have been observed for the variables somatic symptom severity, depression, anxiety, and general psychiatric symptoms.~It consists of 16 sessions (one per week) for a total of 4 months."
224197112|NCT06652724|BEHAVIORAL|technique of expressive writing (TSE)|"The expressive writing technique created by Pennebaker has shown beneficial health effects in different contexts since, through writing, it is possible to mentally reorganize a difficult event, allowing the mind to find meaning to what has happened or is happening. This technique can be a resource that can promote activation from the ability to recognize, express, and process the unspoken emotional, psychological, and relational, helping to achieve emotional and physiological feedback. Although the application of expressive writing in patients with fibromyalgia is an under-explored area of investigation in the international literature, several studies have shown its effectiveness in some chronic syndromes.~It consists of 8 meetings (one every fortnight) for a total of 4 months."
224310792|NCT06344585|OTHER|Drop out patients who had their first access in 2021 were additionally asked to answer to a phone -call questionnaire to assess their motivation of discontinuation|"A prospective comprehensive analysis of the data contained within patient charts, encompassing personal histories and demographic details, was extracted from the internal database of the Humanitas Fertility Center. This analysis aimed at elucidating the individual reasons for treatment discontinuation after the initial clinical visit throughout the year 2021. Additionally a tailored questionnaire was administered to patients via telephone by a member of Humanitas Fertility Center staff in July 2023.~The questionnaire was submitted to the patients via a phone call. The questionnaire comprised nine questions with response limited to 'Yes' and 'No' options for all queries."
224310793|NCT00009815|DRUG|etoposide|
224310794|NCT00009815|DRUG|leucovorin calcium|
224310795|NCT00009815|DRUG|tegafur-uracil|
224310796|NCT01129687|PROCEDURE|Microsurgery|Patient would under to total, near-total, or subtotal resection of tumor
224310797|NCT01129687|PROCEDURE|Stereotactic radiation therapy|Patient who has sign of growth of tumor remnant would undergo this treatment
224310798|NCT03035929|DRUG|Dexamethasone|A single dose of dexamethasone IV 4 mg will be administered.
224310799|NCT02886624|DRUG|Grazoprevir/Elbasvir|Once-daily, oral grazoprevir/elbasvir combination therapy at fixed-dose (100mg/50mg) for 8 weeks
224310800|NCT04949360|BEHAVIORAL|Online Cognitive-Behavioral Therapy for Insomnia and complementary therapies|The CBTi-O and CBTi-O+ interventions are based on real life user experience. The users will have access to different versions of the platform. The intervention will last eitght weeks.
223595023|NCT05943782|PROCEDURE|Onlay manufactured by 3D printing|indirect restorations for treating mutilated molars manufactured by CAD/CAM additive technique
223595024|NCT05380167|DIETARY_SUPPLEMENT|BRJ Nitrate|Participants in this group drank daily for 12 weeks a 70 mL bottle of Beet It Sport drink with nitrate.
224310801|NCT04949360|BEHAVIORAL|Regular Cognitive Behavioural Therapy for Insomnia|This is the gold standard behavioral treatment for insomnia and will be performed by independent board-certified sleep psychologists. The treatments will last eight weeks and the appointments will be made by video-calls.
224310802|NCT04949360|BEHAVIORAL|Sleep hygiene - minimal intervention|It is composed by educational material about normal sleep pattern and sleep hygiene. It will be delivered by SleepUp app.
224310803|NCT05496244|DEVICE|Laparoscopy|Laparoscopic surgery
224310804|NCT05496244|DEVICE|Robotic-assisted surgery|Robotic-assisted surgery
224310805|NCT06490185|OTHER|Clinical data collection|Clinical significance of peri-appendiceal abscess and phlegmon in acute complicated appendicitis patients undergoing emergency appendectomy
224310806|NCT04952818|DIAGNOSTIC_TEST|RANK/RANKL(RANK: Receptor Activator of Nuclear factor Kappa-Β /RANKL:Receptor Activator of Nuclear factor Kappa-Β Ligand)|Immunohistochemical staining was performed using the following antibodies: anti-RANK antibody from Bioss Company (No.bs-2695R) and anti-RANKL antibody from Abcam (No.ab222215).
223595025|NCT05380167|DIETARY_SUPPLEMENT|BRJ Placebo|Participants in this group drank daily for 12 weeks a 70 mL bottle of Beet It Sport drink without nitrate
223595026|NCT01026220|BIOLOGICAL|bleomycin sulfate|Given IV or SC
223595027|NCT01026220|DRUG|doxorubicin hydrochloride|Given IV
223595028|NCT01026220|DRUG|liposomal vincristine sulfate|Given IV
223595029|NCT01026220|DRUG|vinorelbine tartrate|Given IV
223595030|NCT01026220|DRUG|cyclophosphamide|Given IV
223595031|NCT01026220|DRUG|etoposide phosphate|Given IV
223595032|NCT01026220|DRUG|prednisone|Given IV
223595033|NCT01026220|BIOLOGICAL|filgrastim|Given IV or SC
223595034|NCT01026220|DRUG|ifosfamide|Given IV
223595035|NCT05547789|DRUG|non steroidal anti inflammatory drugs|effect of non steroidal anti inflammatory drugs on macular changes
224197113|NCT06652724|OTHER|Treatment as Usual (TAU)|The usual treatment involves two contacts by a rheumatologist/neurologist (depending on the clinical condition of the patient) during a four-month period, lasting about 10-15 minutes each, in which patients will be followed up medically. This treatment represents the active control group, planned to monitor specific aspects of the psychotherapeutic intervention, which aims to equate a good standard of primary care.
224197114|NCT03591666|DRUG|Anlotinib|Anlotinib p.o. qd
223506093|NCT00799864|DRUG|Tenofovir disoproxil fumarate|Type=exact, form=appropriate pediatric formulation, unit=mg, route=oral. The patients may receive this selected NRTI together with another NRTI once daily for 240 weeks (Cohort 1).
223506094|NCT00799864|DRUG|Lamivudine|Type=exact, form=appropriate pediatric formulation, unit=mg, route=oral. The patients may receive this selected NRTI together with another NRTI once daily for up to 48 weeks (Cohort 2) and 240 weeks (Cohort 1).
223506095|NCT00799864|DRUG|Emtricitabine|Type=exact, form=appropriate pediatric formulation, unit=mg, route=oral. The patients may receive this selected NRTI together with another NRTI once daily for up to 48 weeks (Cohort 2) and 240 weeks (Cohort 1).
223506096|NCT02659228|DEVICE|EEG recording|EEG recording with anesthetic (DIPRIVAN)
223506097|NCT02659228|DRUG|Anesthetics, Intravenous|The participant will receive an intravenous infusion of propofol (DIPRIVAN Injectable Emulsion USP 1%, AstraZeneca).
223506098|NCT06384703|DIAGNOSTIC_TEST|Taking blood for kit study|Taking blood for kit study (Elisa kit)
223506099|NCT05100966|OTHER|FitJoints Multi-modal Intervention|"Exercise: The study physiotherapist will prescribe an exercise program tailored to the participant's individual ability and preference with functional movements to mimic activities of daily living.~Nutritional consultation and protein supplement: The site research assistant will coach participants to improve their nutrition, determine their daily protein target, and provide educational tools on how to achieve their target. Protein supplements will be provided to participants.~Vitamin D: Participants will be provided with vitamin D3 (1000 IU) tablets to reduce the risk of falls and to preserve muscle strength and functional ability. They will be instructed to take one tablet daily for the duration of the intervention period.~Medication optimization: The study pharmacist will conduct a medication review and provide, if required, recommendations for medication optimization."
223506100|NCT04607447|BEHAVIORAL|low intracranial pressure strategy treatment|"1. Supine position for 16h-18h daily, with head toward the affected side in most of the time, and 15-20 cm elevation of lower limbs.~2. Abdominal belt compression"
223506101|NCT04607447|DRUG|Atorvastatin plus Dexamethasone|Atorvastatin plus Dexamethasone
223506102|NCT04617223|PROCEDURE|Endoscopic sinus evacuation|Evacuation of the sinus by using endoscope
223506103|NCT03364686|BIOLOGICAL|Biotin-Labeled Red Blood Cells|We will collect 500 mL of blood. The blood will be processed and split into two bags and labeled with a naturally occurring vitamin, biotin. The blood will then be re-infused back into the same participant at 2 time points (5-7 days and 35-42 days after storage).
223506104|NCT00954655|GENETIC|mutation analysis|
223506105|NCT00954655|GENETIC|polymorphism analysis|
223506106|NCT00954655|OTHER|laboratory biomarker analysis|
223506107|NCT00791882|BEHAVIORAL|Social Skills Training|A program developed during 20 weeks according to adapted BELLACK 's manual (1997),including sessions in group one hour per week.
223506108|NCT03255590|BEHAVIORAL|Configuration task|Training the impaired hand on a configuration task
223506109|NCT01104272|DEVICE|LipoSonix (Ultrasound treatment of Subcutaneous Adipose Tissue)|Study of Adipose Tissue Treatment Using Focused Ultrasound
223506110|NCT04983498|DRUG|Ondansetron 4 MG|PONV prophylaxis for participants with an apfel score of 2 or greater (ondansetron 4 mg IV), an additional dose of ondansetron 4mg IV will be available in recovery if the patient has nausea/vomiting despite prophylaxis.
223506111|NCT04983498|DRUG|Lactated Ringers, Intravenous|Goal directed IV fluids to be administered starting preop per the NMH Colorectal ERAS protocol (LR @ 5mL/kg/hr).
223506112|NCT04983498|OTHER|Early Mobilization|Patient transferred up to the chair (within 5-30 minutes of admission to the recovery room) based on nursing parameters and patient safety.
223506113|NCT04983498|OTHER|Early PO Intake|Patient will be offered PO intake within 15-30 minutes of admission to the recovery room post-procedure based on nursing parameters and patient safety.
223506114|NCT01098357|DRUG|Biochaperone PDGF-BB Low dose|BioChaperone PDGF-BB low dose is applied as a spray every two days at the dose of 12.5 µg/cm2 for up to 20 weeks
223506115|NCT01098357|DRUG|Biochaperone PDGF-BB High dose|BioChaperone PDGF-BB high dose is applied as a spray every two days at the dose of 25 µg/cm2 for up to 20 weeks
223506116|NCT01098357|DRUG|Regranex|Regranex gel is applied once daily at the dose of 6.25 µg/cm2 for up to 20 weeks
223506117|NCT01098357|DRUG|Biochaperone PDGF-BB Very Low Dose|BioChaperone PDGF-BB Very Low Dose sprayed on the wound every two days (e.g., Mondays, Wednesdays and Fridays) for 20 weeks or until complete wound healing, at the dose of 4 µg/cm²/application
223506118|NCT04295265|DEVICE|smartphone message|Receive daily whatsapp/ SMS message to remind the drug intake
223506119|NCT04656080|BEHAVIORAL|CPET exercise testing|"* The cardiopulmonary exercise testing (CPET) is done.~* EKG testing will be done as part of the CPET test. Allosure testing will be done at baseline and then at 1 hr, 4 hrs, 1 day, 7 days after CPET."
223506120|NCT01032278|OTHER|Laboratory Biomarker Analysis|Blood drawn for biomarker analysis at baseline, before each chemotherapy visit, 6 months after starting chemotherapy, and 12 months after completion of chemotherapy.
223506121|NCT01032278|BEHAVIORAL|Questionnaires|Symptom questionnaire completion at baseline, beginning of every third cycle of chemotherapy, 6 months after starting chemotherapy, and 12 months after completion of chemotherapy.
223506122|NCT00917982|OTHER|vision therapy|
223506123|NCT00158470|DRUG|efavirenz|
223506124|NCT00158470|DRUG|didanosine|
223506125|NCT00158470|DRUG|lamivudine|
223506126|NCT01260753|DRUG|UR-63325|UR-63325
224197115|NCT04092608|PROCEDURE|GDFT|The titration of fluid will be based on stroke volume variation. The goal is to maintain this variable \< 13% during surgery with multiple mini fluid challenge of 100 ml of balanced crystalloid.
224197116|NCT04092608|PROCEDURE|LOW CVP (restrictive group)|Goal = CVP \< 7mmHg and only 2 ml/kg/h max during surgery.
224197117|NCT00455923|DRUG|Seretide|Seretide
224197118|NCT00455923|DRUG|Flixotide|Flixotide
224197119|NCT00733642|BIOLOGICAL|PF-04360365 1 mg/kg|PF-04360365 1 mg/kg infused as a single dose
224197120|NCT00733642|BIOLOGICAL|PF-04360365 3 mg/kg|PF-04360365 3 mg/kg infused as a single dose
224197121|NCT00733642|BIOLOGICAL|PF-04360365 5 mg/kg|PF-04360365 5 mg/kg infused as a single dose
224197122|NCT00733642|BIOLOGICAL|PF-04360365 10 mg/kg|PF-04360365 10 mg/kg infused as a single dose
224197123|NCT04912804|OTHER|Questionnaires|SF-12, GHQ-12 and HAQ
224197124|NCT06538935|DRUG|adbelimumab|adbelimumab：1200mg iv d1 q3w
224197125|NCT06538935|PROCEDURE|SBRT|SBRT: SBRT: 8-30Gy/1-6F（dose is determined according to the tumor diameter）; tumor thrombus dose 30Gy /5-6F;
224197126|NCT06538935|DRUG|apatinib|apatinib：250mg po, qd
224197127|NCT01449149|RADIATION|Proton Therapy|
224197128|NCT05680987|PROCEDURE|RFN-Advanced Retrograde Femoral Nailing System|RFN-Advanced Retrograde Femoral Nailing System for patients with a distal femur or femoral shaft fracture requiring surgery
224197129|NCT00483119|DRUG|intravenous immunoglobulin|Gamunex 10% 500/mg/kg/day x four days per cycle total of four cycles
224197130|NCT00483119|DRUG|cyclophosphamide|cyclophosphamide dose of 2mg/kg/day divided into three-times daily oral administration
224197131|NCT05803941|DRUG|AAA617|Long-term follow-up (LTFU) safety study of adult participants with prostate cancer that have received at least one dose of AAA617 from parent interventional Novartis sponsored clinical trials.
224197132|NCT05564962|DIAGNOSTIC_TEST|Quality and Independence of Gait Classification Scale for Duchenne Muscular Dystrophy (QIGS-DMD)|MFM is a valid and reliable measure to evaluate the severity of the motor deficit of both ambulatory and non-ambulatory children with neuromuscular diseases. MFM consists of 32 items in 3 dimensions and is scored as a percentage of the maximum possible score which higher scores indicate better functional status. VLERS is a 10-item ordinal scale that identifies the functional status of the lower limbs. According to VLERS, level 1 indicates that the patient can walk independently and climb stairs without assistance while level 10 indicates is the patient is bedridden.
224197133|NCT00694226|BEHAVIORAL|brief motivational intervention|Brief intervention, consisting in an intervention with the adolescent and a session with parents or mentors. The session with the adolescent lasted 60 minutes. Materials related to the interview were developed according to previous reports on the subject. After building a good rapport the interviewer involved the patient in an initial discussion about the results of the evaluation. This led to a review of the drugs used by the subject and an elicitation of positives and negatives of drug use. The relationship between drug use and current and long-term goals was explored. Discrepancies and problems in the future related to substance use were examined, and information and counseling was offered. The basic components of the motivational interview approach were contemplated, and several skills were used by the interviewers. The individual session with parents or mentors consisted in the presentation of educational materials and a brief counseling intervention on parenting skills.
224197134|NCT00694226|BEHAVIORAL|treatment as usual|Treatment as usual (TTU): After completion of the intervention, individuals and their families went on to receive standard care at the Child and Adolescent Psychiatry and Psychology Department according to the primary diagnosis.Individuals assigned to this group and their parents or tutors received standard care and no further intervention other than completion of the assessment protocol.
224197135|NCT06091826|DRUG|NFL-101|Subcutaneous injections
224197136|NCT06091826|DRUG|Placebo|Subcutaneous injections
224197137|NCT05033795|DIETARY_SUPPLEMENT|Water A|2 L of water A per day
223506127|NCT01260753|DRUG|Fluticasone propionate nasal spray|Fluticasone propionate nasal spray
223506128|NCT01260753|DRUG|Placebo|Placebo to UR 63325 and fluticasone propionate nasal spray
223506129|NCT00094666|DRUG|MK0928, gaboxadol / Duration of Treatment - 6 weeks|
224197138|NCT05033795|DIETARY_SUPPLEMENT|Water B|2 L of water B per day
223506130|NCT00094666|DRUG|Comparator: placebo / Duration of Treatment - 6 weeks|
223506131|NCT05486702|OTHER|Time Restricted Eating|Time restricted eating (TRE) can be divided into early TRE (eTRE) and late TRE (lTRE), depending on the time of day of the eating window.
223506132|NCT03058016|OTHER|Personalized recommendations for diet|Personalized recommendations for effective diet, lifestyle and activities based on the patient's parameters measurements and reactions
223506133|NCT02358395|DRUG|BBI608|Administered continuously twice daily with doses separated by 9-15 hours.
223506134|NCT02358395|DRUG|Sorafenib|Sorafenib 400 mg twice daily (800 mg total daily dose).
223506135|NCT03428555|BEHAVIORAL|Integrated Care Pathway|The intervention is a integrated care pathway based on the NICE Clinical Practice Guidelines and measurement-based care in the form of a flow chart. Each decision point on the pathway is guided by results of self-report measures for depression (the Mood and Feelings Questionnaire), functional impairment (Columbia Impairment Scales) and family functioning (the McMaster Family Assessment Device). The results of these scales and protocol recommendations are fed back to the patients, families and clinicians in order to make further treatment decisions
224197139|NCT00994266|DIETARY_SUPPLEMENT|Diamel|Two Diamel tablets (Orally administered) three times a day (just before each meal: breakfast, lunch and dinner), for 24 weeks, in combination with the standard treatment consisting in two daily doses of insulin and proper diet.
224197140|NCT00994266|DIETARY_SUPPLEMENT|Placebo|Two Placebo tablets (Orally administered) three times a day (just before each meal: breakfast, lunch and dinner), for 24 weeks, in combination with the standard treatment consisting in two daily doses of insulin and proper diet.
224197141|NCT01405989|DRUG|darexaban|oral
224197142|NCT01405989|DRUG|ketoconazole|oral
223506136|NCT03428555|BEHAVIORAL|Treatment As Usual|Treatment As Usual represents what clinicians would typically do when presented with an adolescent with depression. There is no algorithm provided to guide clinical decision-making and no systematic measurement-based care.
223506137|NCT00324194|DRUG|MGCD0103|MGCD0103 oral dose given 2 times per week.
223506138|NCT06339762|BEHAVIORAL|Self-Compassion Training|Self-Compassion Training
223506139|NCT05854264|DIETARY_SUPPLEMENT|standard enteral nutrition|standard enteral nutrition. The calories (25 kcal/kg/die) and protein (1.2 g/kg/die) target will be progressively reached in the first week of ICU stay.
224197143|NCT03917966|DRUG|SHR-1210+docetaxel+nedaplatin|neoadjuvant chemotherapy:SHR-1210, 200mg,q2w, a total of 3 times; docetaxel 75mg/m2 ivgtt d1, nedaplatin 75mg/m2 ivgtt d1, q3w, for 2 cycles.The patient was evaluated after 2 cycles of neoadjuvant chemotherapy. The surgery was performed 3-4 weeks after the completion of neoadjuvant chemotherapy.
224197144|NCT03917966|DRUG|SHR-1210+Apatinib|SHR-1210, 200 mg, q2w; Apatinib, 250mg, qd; 4 weeks is a cycle, a total of 2 cycles
224197145|NCT02279888|DEVICE|CardioMEMS HF System|Pulmonary artery pressure sensor
224197146|NCT02161809|BEHAVIORAL|Healthy Eating and Physical Activity|The Healthy Eating and Physical Activity (HEPA) intervention aims to increase the quality of foods and beverages and physical activity opportunities in summer day camps. Through staff-level training, physical activity opportunities are modified to provide children with a substantial amount of meaningful physical activity. Through working with foods service providers, changes to the types of foods and beverages served will be made.
224197147|NCT03096457|DRUG|Paromomycin Sulfate|topical application 2 times a day during 20 days
224197148|NCT03096457|DRUG|Pentamidine Isethionate|3 Intralesional injections at days 1,3 and 5
224197149|NCT03096457|OTHER|Placebo|topical application 2 times a day during 20 days
224197150|NCT02042807|DRUG|Placebo|
224197151|NCT02042807|DRUG|MCS®|
224197152|NCT02147015|DRUG|Glucocorticoids|
224197153|NCT02147015|DRUG|Antibiotics|
224197154|NCT02147015|DRUG|Inhaled corticosteroid (ICS)|
224197155|NCT02147015|DRUG|Long-Acting Muscarinic Antagonists(LAMA)|
224197156|NCT02147015|DRUG|Short-acting beta2-agonist (SABA)|
224197157|NCT02147015|OTHER|Physical treatments|
224197158|NCT02147015|DRUG|long-acting beta2-agonist (LABA)|
224197159|NCT01510340|BEHAVIORAL|VIH-TAVIE|The tailored virtual intervention is composed of four interactive computer sessions hosted by a virtual nurse who engages the PLHIV in a medication-intake self-management skills-learning process.
224197160|NCT03091478|DRUG|Pembrolizumab|200mg every 3 weeks
224197161|NCT04519294|DEVICE|SURE|The SURE stone evacuation procedure is a technique intended to more easily and completely remove a kidney stone during a kidney stone treatment. The urologist first uses a laser to break the kidney stone into small pieces. Then with the SURE procedure, the pieces are gently vacuumed out of the kidney instead of retrieving the pieces one-by-one with a basket or leaving them to pass naturally in the urine. Basketing is allowed and might be used with the SURE procedure, if needed to remove some small stones.
224197162|NCT04519294|DEVICE|Standard Ureteroscopy (Basketing)|This is a treatment in which the urologist uses a laser to break a kidney stone into small pieces and then uses a tool called a basket to retrieve the pieces one at a time.
224197163|NCT00040209|DRUG|JP 1730|
224197164|NCT00040209|DRUG|IV Levodopa|
224197165|NCT00040209|DRUG|IV Apomorphine|
224197166|NCT03148873|DEVICE|RespiraSense patient respiratory monitor system|Subjects will have their respiratory rate monitored for two hours using three different methods for capturing it
223506140|NCT05854264|DIETARY_SUPPLEMENT|specialized nutrition|specialized enteral nutrition. The calories (25 kcal/kg/die) and protein (1.2 g/kg/die) target will be progressively reached in the first week of ICU stay.
224197167|NCT04298203|DRUG|Phentermine-Topiramate|The study medication to be tested for this study is a combination of phentermine and topiramate.
224197168|NCT04298203|DIETARY_SUPPLEMENT|Meal Replacement Therapy|The first six weeks of the study, subjects will receive meal replacement therapy in an effort to reduce their BMI by at least 5%.
224197169|NCT04298203|OTHER|Placebo|A pill that looks like Phentermine-Topiramate but has no active medication.
224310807|NCT01235481|DEVICE|Exercise DVD|Exercise DVD added to usual care during maintenance phase of pulmonary rehabilitation
223506141|NCT02809781|BIOLOGICAL|Intravenous infusion of MSCs|Intravenous infusion of MSCs:Human bone marrow-derived MSCs 1.0E+6 MSC/kg, IV drop
223506142|NCT02809781|DRUG|Etanercept|50mg,hypodermic injection,once per week, for 12 weeks
223506143|NCT05161156|COMBINATION_PRODUCT|Test Product (tiotropium bromide inhalation powder)|A single dose of test product
223506144|NCT05161156|COMBINATION_PRODUCT|18 mcg of Spiriva (Reference Product)|A single dose of reference product (Spiriva)
223506145|NCT05161156|COMBINATION_PRODUCT|Placebo|A single dose of placebo
223506146|NCT03712618|BIOLOGICAL|Platelet Transfusion - LONG Platelet Transfusion|Platelets transfused over 4-HOURS
223506147|NCT03712618|BIOLOGICAL|Platelet Transfusion - SHORT Platelet Transfusion|Platelets transfused over 60-minutes
224197170|NCT03987555|OTHER|Blood draws|Blood draws for serum and peripheral blood mononuclear cell isolation collected throughout treatment course
224197171|NCT03987555|OTHER|QLQ-CIPN20 Survey|20-item self-reported survey for participant reported symptoms related to chemotherapy-induced peripheral neuropathy
224197172|NCT03987555|OTHER|PR-CTCAE Survey|124-item survey addressing chemotherapy-induced peripheral neuropathy concerning severity of the numbness and tingling and the degree these symptoms interfere with daily activities.
224197173|NCT03173625|DRUG|AC-076 for s.c. administration|Lyophilized AC-076A to be reconstituted with 1 mL of water for injection
224197174|NCT03173625|DRUG|Placebo|Sterile 0.9% w/v sodium chloride solution
224197175|NCT01699321|BEHAVIORAL|Your Move (physical activity)|Materials that are provided will aim to increase a participant's minutes of physical activity.
224197176|NCT01699321|OTHER|Your Money (financial empowerment)|Materials that are provided to participants will direct them to resources for financial health.
224197177|NCT05939388|DEVICE|Auricular Acupressure Pads|Pads containing seeds that are placed on specific sites of the ear that are thought to help with pain.
224197178|NCT05598255|DRUG|Dexamethasone|During standard anaesthetic management: IV administration of dexamethasone (0,5mg/kg, with a maximum dose of 5mg).
224197179|NCT05598255|PROCEDURE|Caudale Blockade with levobupivacaine|Administration of levobupivacaine 0,25%0,5ml/kg through the hiatus sacralis lege artis, before incision.
224197180|NCT05598255|PROCEDURE|Dorsal penile nerve block with levobupivacaine|Administration of levobupivacaine 0,5% 0,1ml/kg on each side of the midline as described in Hadzic's textbook of regional anaesthesia, before incision.
224197181|NCT01462409|DEVICE|RESMed S9 with humidifier H5i and heated tube Climate Line|At stable ambient room temperature and different CPAP pressure levels, 8 and 12 cmH2O, with and without additional leakage, humidity and temperature is measured inside of a patients nasal mask. Controlled heated humidification with heated tubing (Climate Line).
224310808|NCT01235481|BEHAVIORAL|Usual Care|Usual care during maintenance phase post pulmonary rehabilitation
224197182|NCT01462409|DEVICE|CPAP without humidification|At stable ambient room temperature and different CPAP pressure levels, 8 and 12 cmH2O, with and without additional leakage, humidity and temperature is measured inside of a patients nasal mask. Without any humidification.
224197183|NCT01462409|DEVICE|CPAP with heated humidification|At stable ambient room temperature and different CPAP pressure levels, 8 and 12 cmH2O, with and without additional leakage, humidity and temperature is measured inside of a patients nasal mask. With controlled heated humidification and standard tubing.
224197184|NCT02717156|PROCEDURE|Computed Tomography|Correlative studies
224197185|NCT02717156|OTHER|Laboratory Biomarker Analysis|Correlative studies
224197186|NCT02717156|BIOLOGICAL|Pembrolizumab|Given IV
224197187|NCT02717156|PROCEDURE|Positron Emission Tomography|Correlative studies
224197188|NCT02717156|BIOLOGICAL|Recombinant EphB4-HSA Fusion Protein|Given IV
224197189|NCT06648434|DRUG|Zunsemetinib|Patients should take zunsemetinib approximately 12 hours apart (if twice daily dosing) or 24 hours apart (if once daily dosing) at the same time(s) every day, with 8 oz of water.
224197190|NCT06648434|DRUG|mFOLFIRINOX|Includes oxaliplatin, irinotecan, leucovorin, and 5-FU.
224197191|NCT06488300|DRUG|Ribavirin|"Oral ribavirin 400 to 1000mg three times a day for 5 days. Each tablet contains 200mg, The total daily dosage in adults is weight dependent as outlined below;~* 40-59.9kg = 1200mg/day~* 60-79.9kg = 1800mg/day~* 80-99.9kg = 2400mg/day~* ≥100kg = 3000mg/day"
224197192|NCT06488300|DRUG|Molnupiravir|Oral molnupiravir 800mg BD for 5 days
224197193|NCT06488300|DRUG|Favipiravir|Oral favipiravir 1800mg BD on Day 0, and 800mg BD for a further 4 days
224197194|NCT05922761|DRUG|Belumosudil|Kinase inhibitor, tablet taken orally
224197195|NCT05922761|DRUG|Fluticasone|Via inhalation by metered-dose inhaler.
224197196|NCT05922761|DRUG|Azithromycin|Semi-synthetic macrolide antibiotic, taken orally
224197197|NCT05922761|DRUG|Prednisone|Corticosteroid, taken orally
224197198|NCT05922761|DRUG|Montelukast|Leukotriene Receptor Antagonist, taken orally
224197199|NCT01068041|DRUG|PH3|Each PH3 tablet, 530 mg/tablet, contains 250 mg of active ingredient. The placebo tablet contains no active ingredient.
224197200|NCT00602667|DRUG|Induction Chemotherapy|All patients will receive 4 identical cycles of induction chemotherapy including highdose (5 g/m2 or 2.5g/m2 for patients less than or equal to 31 days of age at enrollment) intravenous methotrexate and standard dose vincristine, cisplatin, and cyclophosphamide.
224197201|NCT00602667|DRUG|Low-Risk Therapy|Induction will be followed by further conventional chemotherapy with carboplatin, cyclophosphamide, and etoposide. After consolidation, patients will receive 6 cycles of oral maintenance chemotherapy with cyclophosphamide, topotecan, and depending on the diagnosis, either erlotinib or etoposide (VP-16).
224197202|NCT00602667|DRUG|High-Risk Therapy|High risk patients will also receive vinblastine with each course of induction chemotherapy. Induction will be followed by either chemotherapy with targeted intravenous topotecan and cyclophosphamide or optional craniospinal irradiation (CSI). CSI will be offered only to patients who reach 3 years of age by the end of induction only. After consolidation, all patients will receive 6 cycles of oral maintenance chemotherapy with cyclophosphamide, topotecan, and depending on the diagnosis, either erlotinib or etoposide (VP-16).
224310809|NCT05954221|PROCEDURE|Red cell lysis buffer (RCLB) application|The tissue is lysed with 50% concentration of RCLB for 15 min on a shaking device. If the lysis is judged to be insufficient, it can be repeated one more time. Finally, the treated tissue will be fixed with 10% formalin.
224310810|NCT05954221|PROCEDURE|Conventional processing|The tissue is fixed with 10% formalin.
224197203|NCT00602667|DRUG|Intermediate-Risk Therapy|"Induction will be followed by consolidation focal radiotherapy (RT) to the tumor bed. Patients less than 12 months old upon completion of induction will receive low risk chemotherapy to delay RT until the age of 12 months. After consolidation, patients will receive 6 cycles of oral maintenance chemotherapy with cyclophosphamide, topotecan, and depending on the diagnosis, either erlotinib or etoposide (VP-16).~Note: The option to receive focal proton beam irradiation was suspended 10/29/2015. Focal photon beam irradiation continues as part of the treatment plan."
224197204|NCT03500029|RADIATION|Transcranial magnetic stimulation (TMS)|TMS treatment group is treated with TMS for 20-40 minutes a time, 5 times a week. The stimulation parameters were 20 Hz and 80% MT. Each stimulation continues for 2 seconds, and the interval time of stimulation is 58 seconds.
224197205|NCT03500029|DRUG|antidepressants|Medication group is treated with anti-depression for 6 weeks. The drugs and their doses belong to the first-line treatment for depression in the current guideline .
224197206|NCT02401724|OTHER|Transcranial direct current stimulation|
224197207|NCT02401724|OTHER|Action Training|
224197208|NCT01569321|DEVICE|MRI|
224197209|NCT01569321|DEVICE|PET-CT scan|
224197210|NCT01569321|DEVICE|PEM scan with ClearPemSonic|
224197211|NCT06293963|BEHAVIORAL|Guideline Daily Amounts label|Labels that list the amount and percent of daily value of added sugar, sodium, or saturated fat, modeled after Guideline Daily Amounts labels.
224197212|NCT06293963|BEHAVIORAL|Interpretive text-only label|Interpretive text-only labels that state when a product contains high amounts of added sugar, sodium, or saturated fat.
224197213|NCT06293963|BEHAVIORAL|Interpretive magnifying glass icon label|Interpretive labels that state when a product contains high amounts of added sugar, sodium, or saturated fat, containing a magnifying glass icon.
224197214|NCT06293963|BEHAVIORAL|Separated interpretive magnifying glass icon label|Interpretive labels that state when a product contains high amounts of added sugar, sodium, or saturated fat, containing a magnifying glass icon. Each nutrient will be on a separate label.
224197215|NCT06341127|DRUG|Fluoxetine|Oral fluoxetine daily, 2.5 to 5 mg.
224197216|NCT05221762|DIAGNOSTIC_TEST|Cardiovascular magnetic resonance (CMR)|Cardiovascular magnetic resonance (CMR) at 3 Tesla
224197217|NCT04088617|DIETARY_SUPPLEMENT|Ketone monoester|Acute ingestion of (R)-3-hydroxybutyl (R)-3-hydroxybutyrate prior a 2-hour high carbohydrate mixed meal tolerance test.
224197218|NCT04088617|DIETARY_SUPPLEMENT|Placebo|Acute ingestion of a taste-matched placebo prior a 2-hour high carbohydrate mixed meal tolerance test.
224310811|NCT00422578|DRUG|tadalafil|
224310812|NCT02784444|DRUG|MSDC-0602K|MSDC-0602K capsules
224310813|NCT02784444|DRUG|Placebo|Placebo capsules
224310814|NCT05328336|DRUG|Tislelizumab Nab paclitaxel|"Drug: Tislelizumab Tislelizumab 200mg will be administered on Day 1 every 3 weeks for 3 cycles~Other Names:~• BGB-A317 Drug: Nab paclitaxel Nab paclitaxel 200mg will"
224310815|NCT05235945|BEHAVIORAL|Online exercise intervention|Described in arm descriptions
224310816|NCT04144478|OTHER|Web based education|Web based education
224310817|NCT01406483|OTHER|Platelet reactivity assessment|Platelet reactivity, as measured by the Chrono-log Lumi-Aggregometer, VerifyNow P2Y12 assay, and Vasodilator Stimulated Phosphoprotein (VASP) flow cytometry assay.
224310818|NCT03151291|DIETARY_SUPPLEMENT|β-hydroxy-β-methylbutyrate (HMB)|daily intake of 3 g HMB
224310819|NCT03151291|DIETARY_SUPPLEMENT|L-carnitine (LC)|daily intake of 4 g LC
224310820|NCT03151291|DIETARY_SUPPLEMENT|Eicosapentaenoic acid (EPA)|daily intake of 2.2 g EPA
224310821|NCT03151291|OTHER|Whole-Body Electromyostimulation (WB-EMS)|WB-EMS training is performed 2x/week for 12 weeks; Stimulation protocol: Frequency of 85 Hz, pulse duration of 0.35 ms, stimulation period of 6 sec, resting period of 4 sec; supervised by certified training instructors/physiotherapists participants perform simple exercises during the stimulation period following a video tutorial
224310822|NCT05788614|DEVICE|Reverse shoulder arthroplasty|Reverse shoulder arthroplasty
224310823|NCT06209541|BEHAVIORAL|Internet-based cognitive behavioral therapy (ICBT)|All participants get treatment and are thus included in experimental groups, no matter the randomization result. It consists of eight treatment weeks with weekly support. The treatment format will differ between the four groups, depending on type of treatment content and type of support.
224310824|NCT06632470|DRUG|Secretome injection|Patient will receive 3 ml of secretome intramuscular injection every two weeks for four months
224310825|NCT06632470|DRUG|Vitamin B12 Injection|Patient will receive 1 ampule of vitamin b 12 intramuscular injection as a placebo drug every two weeks for four months
224310826|NCT03848637|DRUG|CKD-375|Test drug
224310827|NCT03848637|DRUG|D387|Reference drug
224310828|NCT03173430|DRUG|Blinatumomab|Blinatumomab (Blincyto), an anti-CD19/anti-CD3 bi-specific T cell engager
224310829|NCT00010426|DRUG|cysteamine hydrochloride|
224310830|NCT01664130|RADIATION|stereotactic body radiation therapy|Undergo SBRT
223595036|NCT05930236|DIAGNOSTIC_TEST|Lumbar medial branch block|The lumbar medial branch block on three lumbar levels (L3-L4, L4-L5 and L5-S1) will be performed by ultrasound-guidance in a longitudinal plane and the correct placement of the needle will be verified by radiography to show if the two modalities are equivalent.
223595037|NCT05930236|DRUG|Lidocain|Linisol infiltration with depomedrol and omnipaque
223595038|NCT05930236|DRUG|Methylprednisolone|infiltration with linisol and omnipaque
223747418|NCT03340337|DEVICE|Aussie|"Subjects will receive Aussie electrical stimulation with three reps (5 sec work x 120 sec rest), and the Maximal Electrical Induced Contraction (MEIC) will be measured. They will be asked how uncomfortable the stimulation was, using Visual Analogue Scale (VAS).~One week later, subjects will receive a fatigue protocol that consists in 21 reps (5 sec work x 5 sec rest), and the Maximal Electrical Induced Contraction (MEIC) will be measured for each contraction."
223747419|NCT03340337|DEVICE|RBS|"Subjects will receive RBS electrical stimulation with three reps (5 sec work x 120 sec rest), and the Maximal Electrical Induced Contraction (MEIC) will be measured. They will be asked how uncomfortable the stimulation was, using Visual Analogue Scale (VAS).~One week later, subjects will receive a fatigue protocol that consists in 21 reps (5 sec work x 5 sec rest), and the Maximal Electrical Induced Contraction (MEIC) will be measured for each contraction."
223747420|NCT01160068|DRUG|Metformin|Metformin Tablets 1000 mg
223747421|NCT01160068|DRUG|Glucophage|Glucophage 1000 mg tablets of Bristol-Myers Squibb
223747422|NCT01591291|DRUG|Ondansetron + Brief Behavioral Enhancement Treatment|Ondansetron 4ug/kg twice daily
223747423|NCT01591291|DRUG|Placebo + Brief Behavioral Enhancement Treatment|Placebo twice daily
223747424|NCT00942396|DEVICE|Full Field Digital Mammogram (Planmed Sophie Nuance)|Full Field Digital Mammogram
223747425|NCT00003120|DRUG|paclitaxel|135 mg/m2 IV every 28 days
224310831|NCT01664130|PROCEDURE|quality-of-life assessment|Ancillary studies
223595039|NCT05930236|DRUG|Omnipaque|infiltration with linisol and methylprednisolone
223595040|NCT03843801|DEVICE|Endomina|The intervention will be performed under general anesthesia with tracheal intubation. Endomina will be introduced into the stomach over guide wires and then fixed to the endoscope. The procedure will include the placement of transmural anterior-posterior sutures in the stomach in order to achieve a gastric remodelling. Patient will be kept overnight after the procedure.
223595041|NCT00120601|DRUG|Naltrexone|
223595042|NCT00120601|DRUG|Acamprosate|
223747426|NCT03146988|DRUG|RGB-02 or Neulasta® (pegfilgrastim)|Pre-filled syringe containing 6 mg RGB-02 or Neulasta® in 0.6 mL, administered as subcutaneous injection into the abdominal area
223747427|NCT02520011|DRUG|Alvocidib|
223747428|NCT02520011|DRUG|Cytarabine|
223747429|NCT02520011|DRUG|Mitoxantrone|
223747430|NCT01504321|DRUG|Moxonidine|0.2 mg/day moxonidine for 2 weeks 0.4 mg/day moxonidine for 3 months
224310832|NCT01664130|OTHER|laboratory biomarker analysis|Correlative studies
224310833|NCT03590912|DRUG|Mometasone 50 Mcg/Inh Nasal Spray|One spray in each nostril once daily for one month
224310834|NCT03590912|DRUG|Antibiotics + Antihistamine (levocetirizine) + Nasal decongestants (Oxymetazoline 0.025%)|Children in this group will be treated with antiboitics (syp cefpodoxime) at 10 mg/kg/day in two divided dose for a week, plus antihistamine and nasal decongestants. Oral levocetirizine (Syrup levocet 2.5 mg/5ml) 1.25 mg once daily for age up to six years, 2.5 mg once daily for elder children for a month, plus oxymetazoline (Nasivion) 0.025%, 4 drops twice daily for two weeks
224310835|NCT03590912|DRUG|Steroid Drug (prednisolone)|This group will be treated with steroid drugs. Oral prednisolone, 1 mg/kg body weight daily in two divided dose for 1 week followed by half mg/kg/day in two divided dose for next one week.
224310836|NCT04749238|DEVICE|NucleoCapture device|Device: 100 ml NucleoCapture selective DNA adsorber. Treatment with NucleoCapture in one arm
224310837|NCT03133338|DEVICE|pelvic binder|The requirement of angioembolization can be predicted by the presence of intravenous contrast extravasation (ICE) on computed tomography (CT)
223595043|NCT03550404|BEHAVIORAL|Seasons of Care App|A web-based mobile application (app) called the Seasons of Care Elder Navigation Guide will assist elders, their families/caregivers, healthcare providers, outreach workers, and other community members in navigating healthcare and insurance systems. The app has the added advantage of being easy to update to respond to future changes in health care and insurance, and sustainable because it is not dependent on intensive training, developing, and retaining of individuals in professional navigation positions.
223595044|NCT05435417|RADIATION|CBCT radiation|CBCT scanning
223595045|NCT03776461|DEVICE|Venus Viva|The Venus Viva™ is a non-invasive medical aesthetic device, intended for use in dermatologic and general surgical procedures, requiring ablation and resurfacing of the skin, using the Viva applicator.
223595046|NCT00667290|BEHAVIORAL|Treadmill exercise|Graded treadmill walking 3 times per week for 3 months
223595047|NCT06174909|DRUG|Calcium Hydroxide|After completion of canal and shaping ,canal was dried and CH was placed as an intracanal medicament. A total of 100 mg of CH powder was dispensed and mixed with one drop of pro-pylene glycol on a clean and dry glass slab to prepare a thick paste-like consistency. This paste was carried into the canal and access opening was restored temporarily with temporary cement
223595048|NCT06174909|DRUG|Triple Antibiotic paste|After completion of cleaning and shaping ,canal was dried and tripe antibiotic was placed as intracanal medicament.It was prepared by removing the coating and crushing of antibiotic ciprofloxacin500mg,metronidazole 400mg,, and clindamycin tablets separately using a mortar and pestle. It was prepared by removing the coating and crushing of antibiotic ciprofloxacin500mg,metronidazole 400mg,, and clindamycin tablets separately using a mortar and pestle. This paste was placed gently compacted into the canal and access opening was restored with temporary cement
223595049|NCT01897090|OTHER|Elimination Diet|
223595050|NCT01897090|OTHER|Dietary Guidelines for Americans|
223595051|NCT00073281|PROCEDURE|Islet transplantation|
223595052|NCT02190890|PROCEDURE|Dry needling|
223595053|NCT02190890|PROCEDURE|Control|
223595054|NCT01415492|BEHAVIORAL|HD2|The intervention was delivered via either print materials or access to a HD2 Web Site. ADDITIONAL NOTE: A sub-set of these participants was randomly selected to receive the Electronic Reminders through the intervention. Those who were selected could choose to receive the Electronic Reminders either as text messages or as automated phone reminders.
223595055|NCT01415492|BEHAVIORAL|HD2+|The intervention was delivered via either print materials or access to a HD2 Web Site. In addition participants received two coaching calls from Health Coaches. ADDITIONAL NOTE: as noted above, a sub-set of these participants was randomly selected to receive the Electronic Reminders through the intervention. Those who were selected could choose to receive the Electronic Reminders either as text messages or as automated phone reminders.
223595056|NCT06237556|OTHER|Placebo|Patients in the control group will receive placebo.
223595057|NCT06237556|DRUG|Melatonin 5 MG|Three days before the operation patients will receive 5 mg of melatonin (Melatonin, Nature Made, Canada, and USA) one hour before assigned sleep time until the time of discharge from hospital.
223595058|NCT04782947|DEVICE|Exoskeletal assisted walking|Exoskeletal assisted walking includes the use of robotic suit to train participant to walk with different level of assistance.
223595059|NCT04782947|DEVICE|Epidural Stimulation|lumbo-sacral epidural simulation at the beginning of the study.
223595060|NCT04782947|PROCEDURE|Resistance Training|Using two forms of resistance training to increase muscle size. The first form includes seated leg extension exercise for 12 weeks followed by a second form that includes sit-to-stand exercise using participant's body weight.
223595061|NCT04782947|DEVICE|delayed-ES|lumbo-sacral epidural simulation starting 6 months after the beginning of the study.
223595062|NCT04782947|PROCEDURE|no-Resistance training|The participants will perform 24 weeks of passive movement or passive stretching from seated position.
223595063|NCT04365933|DRUG|EYP001a|Oral tablets
223595064|NCT04365933|DRUG|Entecavir|Oral tablets
223595065|NCT04365933|DRUG|Pegylated interferon alpha2a|Subcutaneous
223595066|NCT04226040|BEHAVIORAL|DOW and illness perception|Acutely ill patients are exposed to a survey regarding their degree of worry and illness perception
223595067|NCT05024136|DEVICE|Limon essential oil aromatherapy|Subjects receive three times 30 mins aromatherapy of Limon essential oil per time for the month. Anthropometric measurements such as blood pressure (systolic blood pressure \[SBP\] and diastolic blood pressure \[DBP\]), autonomic nerve parameters including a. SDNN (standard deviation of all normal to normal intervals index); b. HRV（heart rate variability）; c. LF（0.04-0.15 Hz）and HF（0.15-0.4 Hz）were measured every week. PSQI（Pittsburgh sleep quality index）and HADS (Hospital Anxiety and Depression Scale) were measured initial and ten ends.
223595068|NCT05024136|DEVICE|Vetiver essential oil aromatherapy|Subjects receive three times 30 mins aromatherapy of vetiver essential oil per time for the month. Anthropometric measurements such as blood pressure (systolic blood pressure \[SBP\] and diastolic blood pressure \[DBP\]), autonomic nerve parameters including a. SDNN (standard deviation of all normal to normal intervals index); b. HRV（heart rate variability）; c. LF（0.04-0.15 Hz）and HF（0.15-0.4 Hz）were measured every week. PSQI（Pittsburgh sleep quality index）and HADS (Hospital Anxiety and Depression Scale) were measured initial and ten ends.
223595069|NCT01389323|DRUG|Daclatasvir|Tablet, Oral, 60 mg, once daily, 24 weeks
223595070|NCT01389323|DRUG|Peg-Interferon Alfa-2a|Syringe, Subcutaneous Injection, 180 μg, Once weekly, 24 or 48 weeks depending on response
223595071|NCT01389323|DRUG|Ribavirin|Tablet, Oral, 1000 or 1200 mg based on weight, Twice daily, 24 or 48 weeks depending on response
223595072|NCT03886155|PROCEDURE|Biopsy|During clinically-scheduled trigger finger release surgery, soft tissue will be removed from the trigger finger tenosynovium (which may include synovial sheath and subcutaneous fat tissue) and send to pathology to be analyzed with amyloid-specific staining.
223595073|NCT00303888|DRUG|docetaxel|Given IV
223595074|NCT00303888|DRUG|idronoxil|Given orally
223595075|NCT00303888|OTHER|placebo|Given orally
223595076|NCT05096312|DIETARY_SUPPLEMENT|Zinc gluconate|oral zinc gluconate 200mg
223595077|NCT05096312|DRUG|Adapalene 0.003 MG/MG / Benzoyl Peroxide 0.025 MG/MG Topical Gel [Epiduo]|Adapalene 0.3% + Benzoyl peroxide 2.5% gel applied once daily in the evening
223595078|NCT05096312|OTHER|Placebo|contains cornstarch
223747431|NCT01504321|DRUG|Placebo|Encapsulated lactose powder
223747432|NCT05442164|BEHAVIORAL|DANAKIR support network|"The DANAKIR intervention will consist of:~* Structured written discharge information~* Invitation to the DANAKIR monthly information meeting DANAKIR meetings The monthly meetings are a core component of the support network. One time each month, a meeting will be held at Herlev Hospital with the participation of an emergency surgeon, an emergency surgery dedicated nurse, a dietician, and a physiotherapist. Each professional (surgeon, nurse, dietician, physiotherapist) will host an informative 15 minute session regarding the postoperative course after major emergency surgery. Following the presentations time for questions in plenum and private with the different experts will be held. Furthermore, there will be an opportunity for networking at the DANAKIR meeting. Each meeting is planned to last 2 hours. At the end of each meeting the patients will be asked to evaluate the meeting and content."
223747433|NCT03229265|DRUG|Patiromer|Patiromer (8.4 grams) will be taken daily at 3 hours after oral tacrolimus and MMF dosing by subjects commencing 3 days (± 1 day) prior to visit 1.
223747434|NCT00002052|DRUG|Ceftriaxone sodium|
223595079|NCT05501951|OTHER|tDCS stimulation|The transcranial direct current stimulation (tDCS) method has emerged in the recent years as a non-invasive, safe, cheap, convenient and effective means to modulate brain functions and behaviours
223747435|NCT00002052|DRUG|Ampicillin sodium|
223747436|NCT00002052|DRUG|Amoxicillin trihydrate|
223747437|NCT02850458|DEVICE|implant-retained overdentures|patients treated with an implant-retained overdenture in the mandible
223595080|NCT05501951|OTHER|Sham stimulation|For the sham group, the electrode positioning will be randomly allocated to be identical to either the DLPFC or the OFC group, and active stimulation will be delivered for the first 30 seconds only
223595081|NCT01760590|PROCEDURE|Manual Manipulation|A grade 5 thrust to the thoracic spine
223595082|NCT01760590|PROCEDURE|Mobilization|A grade 1-4 mobilization directed at thoracic spine
223595083|NCT02526251|OTHER|observational|No intervention
223595084|NCT00445276|DRUG|Diacerein|
223595085|NCT02647346|DEVICE|Daily use of podimetrics smart-foot mat|
223595086|NCT00000713|DRUG|Ampligen|
223595087|NCT04506801|DIETARY_SUPPLEMENT|Probalans senior|Participants were told to consume 9 drops of study probiotics/placebo once a day for next 12-week intervention.
223595088|NCT04506801|OTHER|Placebo|Participants were told to consume 9 drops of study placebo one a day for the next 12-week intervention
223595089|NCT05768984|OTHER|Empowerment program|It is planned to conduct the empowerment program online (zoom session). For this, to protect each individual's privacy, a quiet, bright and ventilated, spacious physical environment and technological elements such as computers, headphones, microphones and internet connection are needed. The empowerment program was planned as a total of 10 sessions, one session per week. In the program, goals and objectives have been established for each session. These aims and objectives will be shared with the participants before each session. The application time of each session is planned as an average of 90 minutes.
223595090|NCT02578329|BEHAVIORAL|Intensively advised Mediterranean diet|Mediterranean Diet: fatty fish 3 times/week; legumes 2-3 times/week; vegetables twice/day; fresh fruits twice/day; 30 to 45g olive oil/day; 1-2 glasses red wine/day; less than 150g red meat/week
223595091|NCT02578329|BEHAVIORAL|usual low-fat dietary advice|usual low-fat dietary advice for cardiovascular disease
223595092|NCT04772781|DRUG|S (+) - Ibuprofen|S (+) - Ibuprofen + placebo of Ibuflex®
223595093|NCT04772781|DRUG|Ibuflex®|Ibuflex® + placebo of S (+) - Ibuprofen
223595094|NCT00003552|DRUG|allogeneic lymphocytes|
223595095|NCT00003552|DRUG|anti-thymocyte globulin|
223595096|NCT00003552|DRUG|cyclophosphamide|
223595097|NCT00003552|DRUG|fludarabine|
223595098|NCT00892138|BEHAVIORAL|Mindfulness training|7 week course modeled on MBSR according to Kabat-Zinn
223595099|NCT04515108|OTHER|Clinical assessment|Perinatal outcomes and diagnostic value of hematologic parameters were compared between pregnancies with and without COVID-19.
223595100|NCT01867138|DRUG|Cefazolin|
223595101|NCT01867138|DRUG|Vancomycin|
223595102|NCT01867138|DRUG|Amikacin|
223595103|NCT03822000|OTHER|Survival|Elderly patients with fall-induced femoral fracture who were survived.
223595104|NCT03822000|OTHER|Death|Elderly patients with fall-induced femoral fracture who were dead.
223595105|NCT00907166|DRUG|CPI-613|IV infusion of CPI-613 given on Days 1,4, 8, 11, 15, 18, of 28 day cycle in cancer patients.
223595106|NCT00907166|DRUG|CPI-613|IV infusion of CPI-613 given on Days 1, 4, 8, 11, 15, 18, of 28 day cycle in patients with pancreatic carcinoma.
223595107|NCT00907166|DRUG|Gemcitabine|IV infusion of 1000 mg/m\^2 of Gemcitabine given on Days 1, 8, and 15 of a 28 day cycle in patients with pancreatic carcinoma.
223595108|NCT00907166|DRUG|Gemcitabine|IV infusion of 1000 mg/m\^2 of Gemcitabine given on Days 1, 8, and 15 of a 28 day cycle in cancer patients.
223747438|NCT05215743|DRUG|Antioxidant therapy|Active therapy
223747439|NCT05215743|DRUG|NaCl 0.9%|Placebo
223747440|NCT03320252|DEVICE|Endurant Chimney Graft Technique|Medtronic Endurant II and Endurant IIs Stent Graft Systems and balloon-expandable covered stent graft systems approved for use in the renal arteries. These devices will be utilized in a chimney graft configuration.
223747441|NCT00099125|DRUG|irinotecan hydrochloride|
223747442|NCT00099125|DRUG|temozolomide|
223747443|NCT00099125|PROCEDURE|adjuvant therapy|
223747444|NCT00099125|RADIATION|radiation therapy|
223747445|NCT03335982|PROCEDURE|transendoscopic enteral tubing in mid-gut|A TET tube was inserted into mid-gut through the nasal orifice and fixed on the pylorus wall by one tiny titanium endoscopic clip under anesthesia.
223747446|NCT03656419|PROCEDURE|photodynamic therapy|aPDT with methylene blue and red led irradiation.
223747447|NCT03656419|PROCEDURE|Tongue scraper|Tongue scraper 10 times from de back to the top.
223747448|NCT03232385|DEVICE|MR-US Fusion Arm|Use of Clear Guide SCENERGY for MR-US fusion guidance
223747449|NCT03232385|PROCEDURE|Renal Biopsy or Ablation|Standard of Care
223747450|NCT02088983|DIETARY_SUPPLEMENT|CDP-Choline|Capsule
223747451|NCT02088983|DIETARY_SUPPLEMENT|Cellulose|Capsule
223747452|NCT01878201|DRUG|Fimasartan|Fimasartan 30 mg
223747453|NCT01878201|DRUG|Valsartan|Valsartan 80 mg
224197219|NCT06650670|DIETARY_SUPPLEMENT|Dietary Supplement: Placebo|Each participant will consume 2 capsules per day in one of the main meals without any restriction in the diet or in their life habits
223595109|NCT00907166|DRUG|Gemcitabine|IV infusion of 1000 mg/m\^2 of Gemcitabine given on Days 1, 8, and 15 of a 28 day cycle in patients with pancreatic carcinoma.
223595110|NCT00844558|OTHER|Gait Training|Gait training with a physical therapist 2/week for the first 3 months followed by 1/week for the following 3 months
223595111|NCT00844558|OTHER|Control|There is no intervention associated with this arm of the study
223595112|NCT01123824|DRUG|CLOPIDOGREL|"Pharmaceutical form: tablets~Route of administration: oral"
223595113|NCT01123824|DRUG|placebo|"Pharmaceutical form: matching tablets~Route of administration: oral"
223595114|NCT03070821|OTHER|rtfMRI neurofeedback training|Information about the state of brain activation was given to subjects. That information was visualised as a thermometer bar. Subjects tried to modulate that activation while performing a mental imagery task.
223595115|NCT03070821|DEVICE|3T MRI|A 3T Siemens MRI scanner was used to implement rtfMRI neurofeedback training.
223595116|NCT00288262|DRUG|melatonin 0.5 mg|
223747454|NCT01063764|DRUG|Levetiracetam|"First Period: Dry syrup 50 %, 20 mg/kg/day or 1000 mg/day, 40 mg/kg/day or 2000 mg/day, 60 mg/kg/day or 3000 mg/day, twice daily administration Per Os (PO) for 14 weeks.~Second Period: Dry syrup 50 % or tablets (250 mg and 500 mg strengths), 20 to 60 mg/kg/day or 1000 to 3000 mg/day, twice daily administration Per Os (PO) until indication granted."
223747455|NCT00697515|DRUG|LDX|oral, 30, 50, or 70 mg once-daily for 4 weeks during dose optimization, and then for 1 week during each crossover during the adult workplace environment setting
223747456|NCT00697515|DRUG|Placebo|Placebo administered once-daily for one week during the adult workplace environment setting
223595117|NCT06168266|DEVICE|Eccentric bike|Received eccentric cycling exercise
224197220|NCT06650670|DIETARY_SUPPLEMENT|Dietary Supplement: EPP|Each participant will consume 2 capsules per day in one of the main meals without any restriction in the diet or in their life habits
224197221|NCT02874235|BEHAVIORAL|Receptive music therapy|16 sessions of a length of one hour comprising of receptive music psychotherapy with 5 - 15 minutes of music listening included
224197222|NCT02874235|BEHAVIORAL|Psychological treatment|16 sessions of a length of one hour comprising of verbal based psychotherapy based on principles from Narrative Exposure Therapy or Cognitive Behavioral Therapies
224197223|NCT00000509|BEHAVIORAL|diet, sodium-restricted|
223595118|NCT06168266|OTHER|conventional group|Received conventional treatment
223595119|NCT05080374|OTHER|Spinal Manipulation + exercise program|high-speed, low-amplitude spinal manipulation plus a trunk exercise program
223595120|NCT05080374|OTHER|Spinal manipulation + Kinesiotaping|high-speed, low-amplitude spinal manipulation plus elastic bandage (Kinesiotaping) application to the trunk area
223595121|NCT05080374|OTHER|spinal manipulation + respiratory exercise|high-speed, low-amplitude spinal manipulation plus a breathing exercise program for the diaphragmatic muscles
223595122|NCT05900973|DRUG|Darolutamide Oral Tablet [Nubeqa]|Oral use of Darolutamide as an Inducer of Increased Expression of Prostate-specific membrane antigen (PSMA) in patients with Localized prostate cancer
223595123|NCT05975060|BIOLOGICAL|XBB.1.5 Vaccine (Booster)|Omicron sub variant XBB.1.5 SARS-CoV-2 rS /Matrix-M Adjuvant the monovalent \[5 μg/50 μg\] NVX-CoV2601) XBB.1.5 Vaccine (Booster)
223595124|NCT05975060|BIOLOGICAL|XBB.1.5 Vaccine (single dose)|Omicron sub variant XBB.1.5 SARS-CoV-2 rS /Matrix-M Adjuvant the monovalent \[5 μg/50 μg\] NVX-CoV2601) XBB.1.5 Vaccine ( single dose)
223595125|NCT03401060|DRUG|Denosumab|Each subcutaneous injection will occur every 6 months during 3 years for a total of 7 injections
223595126|NCT03401060|DRUG|Placebo|Each subcutaneous injection will occur every 6 months during 3 years for a total of 7 injections
223595127|NCT02555384|OTHER|crowded drawing task|Marking inverted signs on a sheet where symbols are presented close to one another
223595128|NCT02555384|OTHER|uncrowded drawing task|Marking inverted signs on a sheet where there is a larger distance between symbols
223595129|NCT05593627|DRUG|Lithium Carbonate 250 MG Oral Tablet|Patients undergoing heart valve surgery withcardiopulmonary bypass will take 250mg lithium carbonate
223595130|NCT05593627|DRUG|Calcium Carbonate 500 MG Oral Tablet|Patients undergoing heart valve surgery withcardiopulmonary bypass will take 500mg calcium carbonate
223595131|NCT01802307|RADIATION|Brachytherapy|
223595132|NCT02229526|DIETARY_SUPPLEMENT|Low dose fish oil|Four 1g gelatine capsules with fish oil (Pikasol: 32 % eicosapentaenoic acid (20:5n-3), 23 % docosahexaenoic acid (22:6n-3) and 2 mg tocopherol/ml)) corresponding to 2.7 g n-3 fatty acids per day.
223595133|NCT02229526|DIETARY_SUPPLEMENT|Low dose olive oil|Four 1 g capsules with olive oil (72 % oleic acid (18:1n-9) and 12 % linoleic acid (18:2n-6)) per day.
223747457|NCT01185795|DIETARY_SUPPLEMENT|Cardioviva™ yogurt|L. reuteri cardioviva in yogurt, twice per day (BID), 6 weeks
223747458|NCT01185795|DIETARY_SUPPLEMENT|Placebo yogurt|yogurt, twice per day (BID), 6 weeks
223747459|NCT05377021|BEHAVIORAL|Lifestyle change|"In the project, 33 women in the first group will receive diet intervention for 12 weeks, and 33 women in the second group will receive diet and exercise combination intervention."
223747460|NCT02174458|PROCEDURE|Body Contouring Surgery|Patients after bariatric surgery (BS) and patients with no history of BS but after natural weight loss and some degree of skin laxity who underwent Body contouring will be included after written informed consent is obtained.
223747461|NCT04029714|PROCEDURE|Active Surveillance|Active monitoring of prostate cancer and curative treatment if there are signs of tumor progression.
223747462|NCT01088009|DRUG|lamivudine|patients in this arm will receive oral lamivudine 100mg,daily for 24 weeks; if patients with HBV DNA higher than 1000 copies/ml at week 24, add on adefovir to week 104; otherwise, keep lamivudine monotherapy to week 104
223747463|NCT01088009|DRUG|lamivudine|Patients will receive oral lamivudine 100mg,daily for 104 weeks, if HBV DNA breakthrough, add on oral adefovir 10mg daily
223747464|NCT01088009|DRUG|lamivudine, adefovir|patients in this arm will receive oral lamivudine 100mg daily and adefovir 10mg for 104 weeks
224197224|NCT00000509|BEHAVIORAL|diet, potassium-supplementation|
224197225|NCT03884556|DRUG|TTX-030|Variable dose and schedule
224197226|NCT03884556|DRUG|Pembrolizumab|Dose and schedule per standard of care
224197227|NCT03884556|DRUG|Gemcitabine|Dose and schedule per standard of care
223747465|NCT03468907|DRUG|Telbivudine 600mg|Pregnant mothers who opted for antiviral therapy would start on oral LDT 600 mg daily between gestational weeks 24 and 28.
223747466|NCT03468907|DRUG|Tenofovir disoproxil fumarate 300mg|Pregnant mothers who opted for antiviral therapy would start on oral TDF 300 mg daily between gestational weeks 24 and 28.
224197228|NCT03884556|DRUG|nab paclitaxel|Dose and schedule per standard of care
224197229|NCT03957161|OTHER|Continuation of ACEi and/or ARBs|Patients will continue or start taking ACEi and/or ARBs
224197230|NCT02549612|DEVICE|Moniri Otovent|Please see arm description.
223595134|NCT02229526|DIETARY_SUPPLEMENT|High dose fish oil|Nine 1g gelatine capsules with fish oil (Pikasol: 32 % eicosapentaenoic acid (20:5n-3), 23 % docosahexaenoic acid (22:6n-3) and 2 mg tocopherol/ml)) corresponding to 6.1 g n-3 fatty acids per day.
223595135|NCT02229526|DIETARY_SUPPLEMENT|High dose olive oil|Nine 1g gelatine capsules with olive oil (72 % oleic acid (18:1n-9) and 12 % linoleic acid (18:2n-6)) per day.
223595136|NCT00099866|DRUG|vildagliptin|
223595137|NCT00099866|DRUG|Metformin Comparator|
223595138|NCT04715698|OTHER|ICG-guided drug selection|anti-hypertensive drug selection based on patient's hemodynamic profiling and physician's experience
223595139|NCT04715698|OTHER|empirical drug selection|anti-hypertensive drug selection based on physician's experience only
223595140|NCT01590654|DRUG|Single Ascending Dose (SAD) Cohorts GS-9620|This study will enroll cohorts of 6 eligible, unique subjects per cohort, randomized to either active drug or placebo (5:1) within each cohort. Subjects in Single Ascending Dose (SAD) Cohorts will receive a single dose of GS-9620.
223595141|NCT01590654|DRUG|Multiple Ascending Dose (MAD) Cohorts GS-9620|This study will enroll cohorts of 6 eligible, unique subjects per cohort, randomized to either active drug or placebo (5:1) within each cohort. Subjects in Multiple Ascending Dose (MAD) Cohorts will receive GS-9620 once weekly for two weeks (QW x 2 doses).
223595142|NCT02156336|DRUG|Ranolazine|Oral administration, BID; for a maximum of 51 days.
223595143|NCT02156336|DRUG|Placebo|Oral administration, BID; for a maximum of 51 days.
223595144|NCT02048488|DRUG|TSR-011|Number of cycles until progression or unacceptable toxicity develops.
223595145|NCT05009667|DEVICE|Angiography-derived Index of Microcirculatory Resistance|"caIMR will be measured by pressure sensors which are produced by Suzhou Rainmed Medical Technology Co., Ltd.~caIMR is calculated based on angiography images and Hyperemic Pa estimated from resting Pa according to prespecified equation."
223595146|NCT05009667|DEVICE|Pressure wire-based Index of Microcirculatory Resistance|"IMR will be measured by thermodilution method with pressure wire and arterial physiological detector which are produced by St. Jude Medical.~IMR = Pd ∙Tmn"
223595147|NCT06527534|DRUG|Filgotinib|Patients will receive pills of Filgotinib 200 mg qd for 12 weeks
223595148|NCT06527534|DRUG|Adalimumab|Patients will receive subcutaneous injections of Adalimumab 40 mg q2wk for 12 weeks
223595149|NCT03824600|DIAGNOSTIC_TEST|Fractional Flow Reserve Motorized Pullback|A pullback device (Volcano R 100, San Diego CA, USA), adapted to grip the coronary pressure wire (PressureWire X, St Jude Medical, Minneapolis, USA), set at a speed of 1 mm/sec to pullback the pressure-wire until the tip of the guiding catheter during continued pressure recording.
223595150|NCT02470884|DEVICE|Boston Scientific Fully Absorbable Scaffold|Attempt to implant the Boston Scientific Fully Absorbable Scaffold.
223595151|NCT04530500|GENETIC|COVID-19 Androgen Sensitivity Test (CoVAST)|The CoVAST Test is an in-vitro non diagnostic test. The test reports the genetic health risk of male patients in developing severe symptoms following COVID 19 infection. The genetic information provided by this test will help physicians evaluate the association of AR gene polymorphism with disease severity and mortality following COVID-19 infection. The CoVAST Test is indicated for reporting of the following variant associated with the following gene.
223595152|NCT04857411|BEHAVIORAL|Peers LEAD plus HLWD|Combined Peers LEAD and Healthy Living with Diabetes is a culturally-appropriate program to increase medication adherence
223747467|NCT05506202|OTHER|Individual basic body awareness therapy|"Basic Body Awareness Therapy (BBAT) is a physiotherapeutic intervention directed toward patients' functional movement quality. The development of BBAT was based on the hypothesis of persons' lacking contact with and lacking awareness on their own body, with their inner life, external environment and in the relation to other persons. Thus, it leads to dysfunctional movement, pain and other body functions. BBAT focus on multi-perspective within a person including physical, physiological, psycho-social-cultural and existential perspectives. It directs patients to be aware, guides patients to have mental contact with their body, monitors internal sensations and external environment, and thus, to enhance the self-regulated behavior and positive emotional state."
223747468|NCT05506202|OTHER|Respiratory physiotherapy interventions|Comprehensive physical and psycho-social assessment and treatments are included. Both basic and advanced respiratory physiotherapy interventions, including respiratory muscles training, breathing techniques, bronchial hygiene maintenance, assisting in non-invasive ventilation therapy and oxygen therapy titration, are provided according to assessment findings.
223747469|NCT03455465|OTHER|Community Health Worker Assessment|Participants will be approached by a community health worker who will ask them to complete an assessment of needs and offer to enroll them in post-discharge services to help address the needs identified.
224197231|NCT04749901|OTHER|Psycho-emotional and semiological measures|Surveys, interviews and measures
224197232|NCT00012766|BEHAVIORAL|Integrated team care|
224197233|NCT07006610|DEVICE|Kinesio Tex® Gold Taping|Elastic kinesio tape applied postoperatively to the facial region and left in place for 5 days.
224197234|NCT07006610|DEVICE|Hilotherm® Facial Cooling System|A polyurethane facial mask delivering continuous +17°C water cooling for 48 hours post-surgery.
224197235|NCT06365424|DRUG|Fenofibrate|Fenofibrate (200 mg/day)
223595153|NCT01508260|PROCEDURE|Aquapheresis|Participant connected to aquapheresis pump through an intravenous (IV) catheter placed in forearm. Average treatment is about 24 hours but can extend up to 7 days.
223595154|NCT01508260|DRUG|Furosemide|20-40 mg by vein every 8 hours as indicated for optimal diuresis to achieve negative fluid balance or 0.5 to 5 mg per hour by continuous infusion.
224197236|NCT06365424|DRUG|UDCA|Ursodeoxycholic acid (13-15 mg/kg/day)
224197237|NCT01352923|OTHER|blood test|preparation of blood platelets
224197238|NCT04984499|DEVICE|Dental implant|"The procedure used to accomplish its intended use is as follows :~The recipient implant site is prepared using a drilling sequence, then the implant is placed at the crestal level with a cover screw to allow the tissues healing. After this healing phase, the final prosthesis will be loaded on the implant."
224197239|NCT05647733|PROCEDURE|Low splanchnic blood volume restrictive fluid management strategy|Hemodynamic goal-directed restrictive fluid management strategy.
224197240|NCT05647733|PROCEDURE|Optimized cardiac output liberal fluid management strategy|Permissive intraoperative hemodynamic goal-directed fluid management strategy that optimizes cardiac output throughout surgery
224197241|NCT05647733|PROCEDURE|Phlebotomy|Retrieval of blood in a blood donation bag performed prior to dissection and transfused back after graft reperfusion
224197242|NCT01243645|BEHAVIORAL|biofeedback training|
224197243|NCT00361790|DRUG|Escitalopram on days -7 to day 14; Aripiprazole dosed starting Day 1 to day 14: 3 days at 10 mg, 4 days at 15 mg and 7 days at 20 mg|Tablets, Oral, Escitalopram: 10 mg; Aripiprazole: 10, 15, 20 mg, once daily, 14 days.
224197244|NCT00202254|BEHAVIORAL|Physiotherapy|
224197245|NCT00202254|BEHAVIORAL|Occupational therapy|
224197246|NCT00202254|BEHAVIORAL|Speech pathology|
224197247|NCT05390294|PROCEDURE|Surgical intervention with or without postoperative adjuvant therapy|Surgical intervention with or without postoperative adjuvant therapy
224197248|NCT03315780|DRUG|Dulaglutide|Administered SC
224197249|NCT03315780|DRUG|Placebo|Administered SC
223506148|NCT04213638|OTHER|Single Microneedle Radiofrequency therapy|Subjects are treated with three consecutive sessions of Single Microneedle Radiofrequency therapy at 2-week intervals, with a follow-up visit 12 weeks after the final third treatment. Each treatment session took approximately 30-60 minutes.
223506149|NCT04213638|OTHER|Photodynamic therapy|Subjects are treated with three consecutive sessions of Photodynamic therapy at 2-week intervals, with a follow-up visit 12 weeks after the final third treatment.
223506150|NCT00047268|DRUG|cytarabine|
223506151|NCT00047268|DRUG|mercaptopurine|
223506152|NCT00047268|OTHER|laboratory biomarker analysis|
223506153|NCT00047268|PROCEDURE|allogeneic bone marrow transplantation|
223506154|NCT00047268|PROCEDURE|biopsy|
223506155|NCT00047268|PROCEDURE|peripheral blood stem cell transplantation|
223506156|NCT00001082|DRUG|Levocarnitine|500 mg tablet taken orally daily
223506157|NCT00001082|DRUG|Adefovir dipivoxil|120 mg tablet taken orally daily
223506158|NCT00001082|DRUG|Adefovir dipivoxil placebo|Oral placebo tablet taken daily
223506159|NCT00626860|BIOLOGICAL|DC/tumor fusion vaccine|SC vaccinations administered to each patient at 3-week intervals for 2-3 doses
223506160|NCT04725981|PROCEDURE|Total laparoscopic hysterectomy|Control group: colpotomy closure technique: 3 Z-sutures PDS 0 Intervention group: colpotomy closure technique: 3 Z sutures with PDS 0 and 1 continuous suture with V-Loc 2-0
223506161|NCT06122961|OTHER|No treatment given|No treatment given
223506162|NCT06192745|BEHAVIORAL|no screen control with dim light and calming activities|Non-screen-based quiet activities for 1 hour before bed in room lighting 40-50 lux
223506163|NCT06192745|BEHAVIORAL|unfiltered Bright tablet screen|Bright light screen media exposure will be delivered on an iPad Pro provided by the research team which will be set to the brightest light intensity setting for 1 hour before bed in room lighting 40-50 lux
223506164|NCT06192745|BEHAVIORAL|Filtered dim tablet screen|Filtered dim light screen media exposure will be delivered for 1 hour before bed in room lighting 40-50 lux on an iPad Pro provided by the research team. A blue light filter will be used to alter the spectral distribution of the emitted light and the screen brightness will be dimmed to the lowest possible setting
223506165|NCT06192745|BEHAVIORAL|Exciting content|We will create a 1-hour recording of movie clips containing exciting content from age-appropriate movies for 8- to 11-year-old children as rated by Common Sense Media.
223506166|NCT06192745|BEHAVIORAL|Calming Content|We will create a 1-hour recording of movie clips containing calming content from age-appropriate movies for 8- to 11-year-old children as rated by Common Sense Media.
223506167|NCT06213805|PROCEDURE|Minimally invasive microsclerostomy|"MIMS is a filtering glaucoma surgery, which consists of creating a sclero-corneal drainage channel, to allow the flow of aqueous humor and therefore the reduction of intraocular pressure.~This surgery is extremely quick, lasting 3 to 5 minutes, according to recent MIMS studies, in contrast to the duration of a trabeculectomy, the classic glaucoma surgery, which varies between 20 and 60 minutes."
223506168|NCT00004163|DRUG|Trastuzumab|
223506169|NCT06209086|DEVICE|skeletal anchored twin block|"This appliance was constructed as the modified Twin Block used for the first group in addition to the following modifications:~* Addition of mini-implants interdentally between the mandibular second premolar and mandibular first molar.~* Wire hooks: wire hook element in the lower part of the appliance was incorporated in the region of incisal capping with free end projecting at the canine region on both sides.~* Intra-oral elastics were attached from the mini-implant to the wire hook bilaterally."
223506170|NCT01210443|DRUG|Sitaxentan|sitaxentan sodium 100 mg
223506171|NCT02737787|BIOLOGICAL|WT1 Vaccine|
223506172|NCT02737787|DRUG|Nivolumab|Nivolumab will be administered intravenously as a 30-minute infusion per institutional guidelines on weeks 0, 2, 4, 6, 8, 10 and 12.
223506173|NCT02737787|BIOLOGICAL|NY-ESO-1 Vaccine|Patients will be vaccinated with the NY-ESO-1 OLP4 vaccine. Patients will receive a 1.0 mL emulsion of NY-ESO-1 OLPs with Poly-ICLC and Montanide.
223506174|NCT05208632|OTHER|INTERSCALEN BLOCK APPLICATION WITH USG|40 patients, including ASA1-2, 20 patients over the age of 18, who were planned for upper extremity surgery, in the interscalen group, and 20 in the supraclavicular group, were included in the study. Demographic data of the patients were recorded by measuring PI and PVI values at baseline before the block and at the 1st, 5th, 10th, 15th, and 20th minutes after the block, both simultaneously.
223506175|NCT04174820|OTHER|Functional Magnetic Resonance Imaging (fMRI)|list of the tests: Box and Blocks test, Nine Hole Peg test, walkway GAITRite, EXALang tests, NEPSY II subtests, BRIEF, FEE, WISC 5 tests
223506176|NCT01936974|DRUG|Gemcitabine|Patient to receive gemzar
223506177|NCT01936974|DRUG|Bevacizumab|Patient to receive avastin
223506178|NCT01936974|DRUG|Carboplatin|Patient to receive carboplatin
223747470|NCT01810666|BIOLOGICAL|Recombinant Factor VIII (Kogenate FS, BAY14-2222)|Participants received Recombinant Factor VIII (Rec. factor VIII) on-demand treatment for 12 weeks followed by a 12 weeks prophylaxis treatment phase. The dose and mode of prophylaxis treatment was 25 IU/Kg, 3 times/per week. The dose in on-demand treatment was decided by physician according to the package insert or the current standard of care.
224197250|NCT03876795|BIOLOGICAL|Bone Marrow Concentrate|Bone Marrow Concentrate injection
224197251|NCT01361308|DRUG|Brisdelle (paroxetine mesylate)|Subjects will be randomized to receive either Brisdelle (paroxetine mesylate) Capsules 7.5 mg or placebo in a 1:1 ratio, administered once daily at bedtime beginning on Day 1 and continuing up to Day 84
224197252|NCT01361308|DRUG|Placebo capsules|Subjects will be randomized to receive either Brisdelle (paroxetine mesylate) Capsules 7.5 mg or placebo in a 1:1 ratio, administered once daily at bedtime beginning on Day 1 and continuing up to Day 84
224197253|NCT01081431|DRUG|Lenalidomide|10 mg d1-d21 of a 28-day cycle
223747471|NCT02528162|BEHAVIORAL|education|Evaluation of education for GDM
223747472|NCT04398758|DRUG|SanaCutan Basiscreme|In this study, the SanaCutan Basiscreme will be used as a cream for twice daily application on the whole body (eyes and mucous membranes have to be omitted) for a duration of 6 months (main phase) or 12 months (main + follow-up phase) or less (if the child develops atopic dermatitis).
223747473|NCT04357210|PROCEDURE|fistula tract excision and anal sphincter reconstruction|The primary fistulous tract was excised together with any secondary tracts or residual cavities. Then on of the reconstructive steps was performed
223747474|NCT02292290|DRUG|Liraglutide|4 week lead-in 0.6mg Liraglutide OD up to 1.2mg OD after 2 weeks if poor response
223747475|NCT02292290|DRUG|Liraglutide|4 week lead-in 0.6mg Liraglutide OD up to 1.2mg after two weeks if poor response.
223747476|NCT02292290|DRUG|Sulfonylurea or Pioglitazone|Addition to Metformin
223747477|NCT02292290|DRUG|Maintain dual therapy (Sulf/Pio) as comparator to Liraglutide|As per clinical guidelines for prescription
224197254|NCT06371027|PROCEDURE|Minimally Invasive Surgery Technique (MIST) + Novel Silk Fibroin (SF) nanofiber membrane|Minimally Invasive Surgery Technique (MIST) + Novel Silk Fibroin (SF) nanofiber membrane placement in the area that contains an intraosseous defects with Probing depth (PD) ≥5 mm
224197255|NCT06371027|PROCEDURE|Minimally Invasive Surgery Technique (MIST) + collagen membrane|Minimally Invasive Surgery Technique (MIST) + collagen membrane placement in the area that contains an intraosseous defects with Probing depth (PD) ≥5 mm
223506179|NCT01936974|DRUG|Cisplatin|Patient to receive cisplatin
223506180|NCT01936974|DRUG|Oxaliplatin|Patient to receive Oxaliplatin
223506181|NCT04323566|DRUG|Rituximab|"Rituximab 500 mg, dissolved in 250 ml NaCl in an infusion bag, covered with non-see-through plastic~* administered iv over a course of max 180 minutes~* at 0 and 4 months (treatment-first arme) OR at 8 and 12 months (placebo-first arm)"
223506182|NCT00986583|DRUG|Succinylcholine|Succinylcholine will be administered pre-induction over a period of 5 seconds
223506183|NCT03730701|BEHAVIORAL|Prevention program for stroke|The prevention program include individual and group intervention sessions supported by a digital platform. The program will be personally tailored in relation to what the person needs and what to change and the individuals rediness for change. The digital platform will support the person during and in between sessions by prompting goals and goal-fulfilment, logging activities, step counts and provide a forum for sharing and reflection.
223506184|NCT05783765|BEHAVIORAL|Heightened Drive to Eat|Participants' eating rate and eating in the absence of hunger will be assessed during a videotaped experimental meal. The relative reinforcing value of food will be assessed using a computerized behavioral choice task.
223506185|NCT06330519|DRUG|Dexamethasone sodium phosphate injection|Patients receive 0.8ml of dexamethazone by periodontal ligament injection 30 minutes before the inferior alveolar nerve block
223506186|NCT06330519|OTHER|1,1,1,2 tetrafluoroethane|EndoIce (1,1,1,2 tetrafluoroethane) applied on the buccal, lingual (3 s/surface), and occlusal surfaces (4 s) for a total of 10 s then standard IANB was administered
223506187|NCT06330519|OTHER|intraoral soft tissue cryotherapy|Small ice packs (wrapped in sterile gauze) placed intraorally in the mouth on the vestibular surface of the treated tooth for 5 minutes then standard IANB was administered
223506188|NCT04584554|BEHAVIORAL|BETTER Transitional Care Intervention|Patient and family will receive pre- and post-discharge support and education from interventionist.
223506189|NCT06057428|PROCEDURE|Decompressive surgery|Decompressive surgery for lumbar spinal stenosis
223506190|NCT03958604|PROCEDURE|Neurostimulation|Spinal cord stimulation with burst modality for discogenic low back pain
223506191|NCT02253238|BEHAVIORAL|Quality of Life Survey|Quality of life survey completed at baseline, 7 days after radiation therapy (RT) and at 6 - 8 weeks after RT.
223506192|NCT02253238|BEHAVIORAL|Health Management Surveys|Confidence in health management survey; completed at baseline and 6 - 8 weeks after RT.
223506193|NCT02253238|OTHER|Monitoring Devices|Home use of CYCORE devices (blood pressure monitor, weight scale, electronic tablet, palm-sized plug-in computer)
223506194|NCT02253238|BEHAVIORAL|Symptoms Surveys|"Behavioral: Symptoms survey 1; completed at weeks 1, 3, 5, and 7 days after RT, and at 6 - 8 weeks after RT.~Behaviorial: Symptoms survey 2; completed at baseline, weeks 1, 3, 5, and 7 days after RT, and at 6 - 8 weeks after RT."
223506195|NCT02253238|BEHAVIORAL|Device Usability Survey|Device usability survey; completed at weeks 1, 3, 5, and 7 days after RT.
223506196|NCT02506439|DIETARY_SUPPLEMENT|10 mcg Vitamin D3|Once daily, 10mcg (400IU) dose of vitamin D3 taken from baseline visit (approx 15 weeks gestation) until endpoint (delivery)
223506197|NCT02506439|DIETARY_SUPPLEMENT|20 mcg Vitamin D3|Once daily, 20mcg (800IU) dose of vitamin D3 taken from baseline visit (approx 15 weeks gestation) until endpoint (delivery)
223506198|NCT02506439|DIETARY_SUPPLEMENT|Placebo|Once daily, placebo capsule containing 0mcg (0IU) of vitamin D3 taken from baseline visit (approx 15 weeks gestation) until endpoint (delivery)
223506199|NCT02807181|DRUG|Cisplatin-gemcitabine|Systemic chemotherapy
223506200|NCT02807181|DEVICE|Radiation: SIRT + chemotherapy (cisplatin-gemcitabine)|SIR-Spheres microspheres followed by systemic chemotherapy
223747478|NCT01727141|DRUG|QVA149|QVA149 was supplied in a capsule form in blister packs for use in the Novartis Concept1 SDDPI
223747479|NCT01727141|DRUG|QAB149|QAB149 was supplied in capsule form in blister packs for use in the Novartis Concept1 SDDPI.
224197256|NCT06371027|PROCEDURE|Minimally Invasive Surgery Technique (MIST)|Minimally Invasive Surgery Technique in the area that contains an intraosseous defects with Probing depth (PD) ≥5 mm
224197257|NCT04085562|DRUG|Bisoprolol Fumarate 5-10 mg|Bisoprolol as antihypertensive drug in patients on hemodialysis
224197258|NCT04085562|DRUG|Amlodipine 5-10 mg|Amlodipine as antihypertensive drug in patients on hemodialysis
223506201|NCT06144502|BEHAVIORAL|5Ways@School|"The 5Ways@School intervention is a teaching material consisting of five elements; Take notice, Be active, Keep Learning, Connect, and Give. The intervention will be given in an ordinary classroom setting by the class' main teacher in two school hours of 45 minutes each week for six consecutive weeks, i.e., a total of 12 school hours. The teaching sessions will consist of presentations of the five elements, videos, reflection exercises, focused group discussions, creative group work, and giving the pupils small challenges to practice what they have learned between the weekly sessions."
223506202|NCT01087619|PROCEDURE|Parathyroid surgery|Parathyroid Surgery (regardless of surgical strategy; i.e., focused operation, unilateral- or bilateral neck exploration)
223506203|NCT05610839|BEHAVIORAL|Acceptance-Enhanced Behavior Therapy|8-module intervention delivering acceptance-enhanced behavior therapy through a fully automated website. This intervention was adapted from the Acceptance-enhanced behavior therapy workbook (Woods \& Twohig, 2008).
223506204|NCT00290628|DRUG|anti-thymocyte globulin|
223506205|NCT00290628|DRUG|busulfan|
223506206|NCT00290628|DRUG|cyclophosphamide|
223506207|NCT00290628|DRUG|cyclosporine|
223506208|NCT00290628|DRUG|filgrastim|
223506209|NCT00290628|DRUG|melphalan|
223506210|NCT00290628|DRUG|methylprednisolone|
223506211|NCT00290628|DRUG|mycophenolate mofetil|
223506212|NCT00290628|PROCEDURE|radiation therapy|
223506213|NCT00290628|PROCEDURE|umbilical cord blood transplantation|
223506214|NCT02113046|PROCEDURE|pancreatico-jejunal anastomosis|
223506215|NCT02113046|PROCEDURE|traditional anastomosis|
223506216|NCT00063999|DRUG|Carboplatin|Given IV
223506217|NCT00063999|DRUG|Cisplatin|Given IV
223506218|NCT00063999|DRUG|Doxorubicin Hydrochloride|Given IV
224197259|NCT01001195|DRUG|AGN-210669 ophthalmic solution, 0.1%|One drop of AGN-210669 ophthalmic solution, 0.1% in both eyes each evening from Day 1 through the evening prior to Day 29. Selected sites: One additional drop in both eyes on Day 29.
224197260|NCT01001195|DRUG|AGN-210669 ophthalmic solution, 0.075%|One drop of AGN-210669 ophthalmic solution, 0.075% in both eyes each evening from Day 1 through the evening prior to Day 29. Selected sites: One additional drop in both eyes on Day 29.
224197261|NCT01001195|DRUG|AGN-210669 ophthalmic solution, 0.05%|One drop of AGN-210669 ophthalmic solution, 0.05% in both eyes each evening from Day 1 through the evening prior to Day 29. Selected sites: One additional drop in both eyes on Day 29.
224197262|NCT01001195|DRUG|bimatoprost ophthalmic solution 0.03%|One drop of bimatoprost ophthalmic solution 0.03% in both eyes each evening from Day 1 through the evening prior to Day 29. Selected sites: One additional drop in both eyes on Day 29.
223506219|NCT00063999|BIOLOGICAL|Filgrastim|Given SC
223506220|NCT00063999|OTHER|Laboratory Biomarker Analysis|Correlative studies
223506221|NCT00063999|DRUG|Paclitaxel|Given IV
223506222|NCT00063999|BIOLOGICAL|Pegfilgrastim|Given SC
223506223|NCT00063999|OTHER|Quality-of-Life Assessment|Ancillary studies
223506224|NCT01466231|DRUG|Everolimus|Tablets p.o. 10 mg daily until progression, unacceptable toxicity, complete response or inability of the subject to comply with study requirements.
223506225|NCT02634697|BEHAVIORAL|Relaxation Response Resiliency Program|8-week group intervention teaching relaxation and psychological resiliency enhancing skills. Topics include the relaxation response, meditation, and yoga
223506226|NCT02192086|OTHER|goal directed fluid therapy|"The treatment group will initially be given a 1L bolus after induction over 20 minutes (first liter may be Lactated Ringers solution or Plasmalyte, subsequent fluid will be Plasmalyte) followed by maintenance infusion at a rate of 5mL/kg/hr until the graft kidney is removed from ice. After removing the organ from ice, the kidney recipient will be administered supplemental crystalloid until PVI is 10 or lower. Plasmalyte will be warmed in accordance to the departmental hypothermia protocol. A PVI of 12 or lower will be maintained until emergence of anesthesia, at which time the PVI monitor will be removed and all patients will be managed by existing standards (pain control, fluid replacement, hemodynamic goals, etc).~a.At the time the treatment group begins receiving goal directed fluid therapy the anesthesia team is to wean any vasopressors aggressively with the goal of terminating infusion as quickly as is safe."
223506227|NCT02192086|OTHER|Control Group|"Control patients will be given a constant infusion of crystalloid (first liter may be Lactated Ringers solution or Plasmalyte, subsequent fluid will be Plasmalyte) at a rate determined by the following: 70mL/kg for the duration of the surgery, 1L bolus after induction (over 20-30 minutes) followed by the remainder as a constant infusion determined by (70mL/kg \* wt - 1000mL) / 160 minutes (using the local average of approximately 180 minutes of operative time).~a.A Masimo PVI monitor will be placed on the patient on an extremity not affected by an AV fistula and recorded for evaluation, but no fluid administration decisions will be made based on it (providers will not have access to its values)."
223506228|NCT01647880|DRUG|Verum arm receiving Gilenya®|
223506229|NCT01647880|DRUG|Active Comparator receiving Extavia®|
223506230|NCT00976300|DRUG|Cyclosporine A|Cyclosporine arm (CyA group) consisted of oral cyclosporine A (CyA) 4-5mg/kg/day (given in two divided doses) for 9 months followed by gradually decreasing dose of cyclosporine (3.75-1.25 mg/kg/day) within the next 9 months. The dosage of concomitant glucocorticoids was driven and tapered according to a single treatment protocol.
224197263|NCT04380493|DIAGNOSTIC_TEST|hepatic transient elastography using S probe and M probe|
224197264|NCT03839693|BIOLOGICAL|botulinum toxin, Type A|topical liniment
224197265|NCT03839693|BIOLOGICAL|Vehicle|Vehicle Formulation
224197266|NCT00473928|DRUG|POT-4|Single intravitreal injection.
224197267|NCT02060526|DRUG|Recombinant human heparan N-sulfatase [rhHNS]|Recombinant human heparan N-sulfatase \[rhHNS\]
224197268|NCT01900925|PROCEDURE|Prescriptive Hip Exercises and Manual Therapy techniques|1\) Clam Abduction exercises in sidelying, 2) Hip extension in quadruped, 3) a unilateral bridge,and; 1) anterior to posterior mobilization of the hip with distraction, 2) long axis distraction of the hip and 3) posterior-anterior mobilization of the hip in prone
224197269|NCT01900925|PROCEDURE|Pragmatic low back pain treatment|"1. advise to stay active,~2. discourage bed rest,~3. appropriate medication use,~4. reassurance.~5. Short term use of manipulation/medication,~6. supervised exercise,~7. cognitive behavioral therapy,~8. multidisciplinary treatment,~9. termination of use of modalities."
224197270|NCT03165630|BEHAVIORAL|Transportation incentives|Free transportation only for the first 3 months post-discharge.
224197271|NCT03165630|BEHAVIORAL|Transportation and rehabilitation services incentives|Free transportation and rehabilitation services 3 months post-discharge.
224197272|NCT01262274|DRUG|Anastrozole|ANA is given 1mg daily for 24 weeks.
224197273|NCT01262274|DRUG|Anastrozole plus tegafur-uracil|ANA is given 1mg daily for 24 weeks. UFT is given by 270mg/m2 twice a day for 24 weeks.
224197274|NCT02342574|DRUG|F901318|Administration of active compound
224197275|NCT02342574|DRUG|Placebo|Administration of placebo
224197276|NCT00216073|DRUG|Capecitabine|Capecitabine 825 mg/m2 po bid, days 1-14
224197277|NCT00216073|DRUG|Oxaliplatin|Oxaliplatin 100 mg/m2 IV, day 1
224197278|NCT00216073|DRUG|Trastuzumab|Trastuzumab 6mg/kg IV, day 1. 8 mg/kg loading dose given in cycle 1 for patients without previous trastuzumab therapy only.
224197279|NCT03818867|PROCEDURE|Insertion of cervical cerclage|insertion of a stitch around the neck of the womb in order to provide extra support.
224197280|NCT03296904|DEVICE|CLs++|Familiarization/training with the customized combination of the CLs++ ortho-prosthesis modules
224197281|NCT06514586|DRUG|Oxytocin|Oxytocin gel 600 IU . 1mg/g
224197282|NCT06514586|OTHER|Hydroxypropyl methylcellulose|Placebo
224197283|NCT04485624|OTHER|No intervention|Observational study
224197284|NCT06123624|DRUG|Desflurane Inhalation Solution|Keeping the anesthesia using desflurane inhalation solution as 1 minimal alveolar concentration
224197285|NCT06123624|DRUG|Sevoflurane Inhalation Solution|Keeping the anesthesia using sevoflurane inhalation solution as 1 minimal alveolar concentration
224197286|NCT06613412|DIAGNOSTIC_TEST|Remote Robotic Bronchoscopy system|Utilization of a remote robotic bronchoscopy system for the biopsy of patients with pulmonary peripheral lesions
224197287|NCT00006014|DRUG|semaxanib|
224197288|NCT04243655|DEVICE|HA 330-II|One unit for 2-4 hours treatment, for 3 consecutive days
224197289|NCT04243655|DRUG|Standard medical treatment (SMT)|SMT as per patients requirement- Management of cerebral edema/intracranial hypertension: prophylactic antibiotics, administration of mannitol or 3% saline for severe elevation of Intra Cranial Pressure, volume replacement and pressor support (noradrenaline, doubutamine, dopamine) as needed, NAC and correction of metabolic parameters.
224197290|NCT03109613|DEVICE|Positive end-expiratory pressure (PEEP)|level changes as per arm description
224197291|NCT03572049|DRUG|SUBA itraconazole|SUBA itraconazole study drug will consist of two 65 mg capsules to be taken three times a day with food for days 1-3 of study. For days 4-180 of study, two 65mg capsules will be taken twice daily with food.
224197292|NCT03572049|DRUG|Conventional itraconazole|Conventional itraconazole comparator drug will consist of two 100 mg capsules to be taken three times a day with food for days 1-3 of study. For days 4-180 of study, two 100 mg capsules will be taken twice daily with food.
224197293|NCT01578603|DIETARY_SUPPLEMENT|xylitol|6 g/day, for a month, by chewing 2g three times daily after meals.
224197294|NCT01578603|DIETARY_SUPPLEMENT|casein phosphopeptide amorphous calcium phosphate complex|two pieces of the commercial presentation three times daily after meals
223506231|NCT00976300|DRUG|Cyclophosphamide|Cyclophosphamide (CPH) therapeutic arm (CPH group) consisted of 8 boluses of intravenous cyclophosphamide (10mg/kg) given within 9 months in subsequently prolonged intervals (2x3weeks, 4x4 weeks, 2x6 weeks) followed by 4-5 oral cyclophosphamide boluses (10mg/d in 6-8 week intervals). The dosage of concomitant glucocorticoids was driven and tapered according to a single treatment protocol.
223506232|NCT04593329|DRUG|TIRADENTES ASSOCIATION|Tiradentes association tablet
223506233|NCT04593329|DRUG|DIPYRONE|Dipyrone 500 mg
223506234|NCT04593329|DRUG|TRAMADOL|Tramadol 50 mg
223506235|NCT04593329|OTHER|TIRADENTES ASSOCIATION PLACEBO|Tiradentes association placebo tablet
223506236|NCT04593329|OTHER|DIPYRONE PLACEBO|Dipyrone placebo tablet
223506237|NCT04593329|OTHER|TRAMADOL PLACEBO|Tramadol placebo capsule
223506238|NCT01866735|OTHER|Standardized Rehabilitation Therapy|
223506239|NCT01171573|PROCEDURE|Venepuncture|Venepuncture - Taking blood
223506240|NCT01458145|BEHAVIORAL|Minding the Baby Home Visiting Program|Weekly home visits for one year followed by bi-weekly home visits until child is 24 months of age provided to young at risk families by a team of nurse practitioner and social worker home visitors
224197295|NCT00976859|BEHAVIORAL|Imagery Modification|Research via internet concerning the frequency of skin exchange and disputation of the collected information; in the guided imagery modification the therapist instructs the patient to imagine the feeling of being contaminated and the process of peeling off their former contaminated skin and the maturing of hundreds of new clean skin cells
224197296|NCT00976859|BEHAVIORAL|Waitlist control group|Patients in the wait list control group are treated after a waiting period of five weeks
224197297|NCT02384837|DEVICE|EXCEL biodegradable polymer-coated sirolimus-eluting stent|
224197298|NCT05388032|BEHAVIORAL|Sodium Reduction Intervention|The sodium reduction intervention is a dietician-led behavioral intervention consisting of two phases, first a 3-month intensive intervention phase, followed by a 9-month maintenance phase. The overall goal of the intervention is to reduce sodium intake to \<2,300 mg per day based on the most recent guideline from the National Academies of Medicine. Both phases will include individual and group behavioral modification counseling designed to facilitate a reduction in dietary sodium intake.
224197299|NCT04698707|OTHER|Vascularized lymph node flap transfer|Patients who have received VLNT as their primary treatment but with minimal improvement
224197300|NCT04698707|OTHER|Patients without prior lymphedema surgery|Patients without prior lymphedema surgery
224197301|NCT03173807|BEHAVIORAL|diet and exercise guidance and modifications|Review of diet, food diary, and guidance from the dietician; review of activity journal, assessment of body composition, tests for gait, balance and muscle strength, and new assignment from the exercise trainer
224197302|NCT02105207|OTHER|Lung Ultrasound|Lung ultrasound evaluation is performed after clinical assessment and before chest radiography
224197303|NCT02105207|OTHER|Chest Radiography|Chest Radiography is performed after clinical evaluation without using ultrasound assessment
224197304|NCT03895827|BEHAVIORAL|Recovery Initiation and Management after Overdose (RIMO)|RIMO uses motivational interviewing and linkage assistance techniques to get people who have had a recent opioid overdose reversal to go to medication-assisted treatment (MAT), stay in MAT, and, if they drop out, go back to MAT treatment.
223506241|NCT03306121|DRUG|TPF+CCRT|"Patients receive paclitaxel liposome (135mg/m2 on day 1) , cisplatin (25mg/m2 on day 1-3) and 5-fluorouracil (750mg/m2 civ 120h) every three weeks for three cycles of induction chemotherapy before radiotherapy.~Patients receive IMRT and cisplatin (100mg/m2) every three weeks for three cycles during radiotherapy (D1,D22,D43 of RT)"
223506242|NCT03306121|DRUG|CCRT+ PF|"Patients receive cisplatin (80mg/m2 on day 1) and 5-fluorouracil (1000mg/m2 civ 96h) every four weeks for three cycles 4 weeks after radiotherapy.~Patients receive IMRT and cisplatin (100mg/m2) every three weeks for three cycles during radiotherapy (D1,D22,D43 of RT)"
223506243|NCT00031005|PROCEDURE|modified stem cell transplant|
223506244|NCT00816270|PROCEDURE|Bilateral Upper eyelid blepharoplasty|Bilateral upper lid blepharoplasty was performed on each patient by the same experimented surgeon using a standard technique. One side (right or left upper eyelid) was randomly chosen for experimental closure with liquid bandage and the opposite eyelid served as the control being used a 6/0 nylon continuous sutures.
223506245|NCT02096536|DRUG|Vancomycin|vancomycin administration based on decision of treating physician
223506246|NCT00968942|DRUG|Botulinum Toxin Type A|RT001 (Botulinum Toxin Type A Topical Gel) Dose A applied topically at Baseline (Day 0) and at Week 4 on the lateral canthal areas
223506247|NCT00968942|DRUG|Placebo|Placebo (Dose B) applied topically at Baseline (Day 0) and at Week 4 on the lateral canthal areas
223506248|NCT03556176|BEHAVIORAL|Exercise|Three exercises sessions - 30 min (light: 45 - 50%, moderate: 65 -70% and vigorous: 85 - 90% Heart Rate Maximal).
223506249|NCT03556176|BEHAVIORAL|Quiet rest|Quiet rest during 30 min
223506250|NCT03767894|DEVICE|EMG Band|The MyHand orthosis provides tension to the digits to open the fingers on demand. This group will wear an EMG band to control and activate the MyHand orthosis.
223595155|NCT02134730|BEHAVIORAL|FRIENDS for life|Friends for life (FFL). The FFL is a prevention program created by professor Paula Barrett, Brisbane, Australia. It is based on cognitive behavioral treatment strategies, for example the link between thoughts and feelings, negative and positive thoughts, breathing and relaxing exercises, support from others, breaking challenging situation in smaller steps, and problem-solving techniques. The children's workbook comprises practice-sheets for use during class, and homework assignments. The group leader manual comprises detailed instructions to all exercises.
223595156|NCT01343732|DEVICE|Deep TMS|deep transcranial magnetic stimulation
223595157|NCT02283203|DRUG|APOTEL max|The study drug is provided in a form of bag with 100ml final volume and it is directly connected to the infusion device that leads to a catheter already cannulated in one antecubital vein.
223595158|NCT02283203|DRUG|Placebo|Placebo is provided in a form of bag with 100ml final volume and it is directly connected to the infusion device that leads to a catheter already cannulated in one antecubital vein. Placebo contains water for injection and inactive vehicles.
223595159|NCT02044861|DRUG|PFK-158|IV dose escalation
223595160|NCT01046214|DRUG|Bupropion HCl|Budeprion XL™ 300 mg Extended Release Tablet dosed once daily for 8 days, in the morning, after an overnight fast of at least 10 hours, with the reference-placebo tablet
223595161|NCT01046214|DRUG|Bupropion HCl|Wellbutrin XL® 300 mg Extended Release Tablet dosed once daily for 8 days, in the morning, after an overnight fast of at least 10 hours, with the test-placebo tablet
223595162|NCT06543342|BEHAVIORAL|Bystander Brief Motivational Intervention|Group-based interactive intervention, conducted in two sessions, including multiple tasks and exercises to identify different levels of risk behavior, different types of strategies, and practicing responding to different scenarios. Personal goals for helping friends stay safe, and identifying whether intervention as a bystander was successful are included.
223595163|NCT06041633|DIAGNOSTIC_TEST|Clinical|Questionnaire
223595164|NCT01807377|DRUG|PF-05175157|200 mg tablet administered twice per day for 14 days
223595165|NCT01807377|DRUG|Midazolam|2mg administered as single doses on Days 0 and 11
223595166|NCT01807377|OTHER|Placebo|Placebo administered twice per day for 14 days
223595167|NCT01807377|DRUG|Midazolam|2mg administered as single doses on Days 0 and 11
223595168|NCT00700505|DEVICE|FlowPants(R) Garment|"The garment is shaped like a pair of boxer briefs. Garment heating is battery-powered.~The garment is activated and begins to heat up 5-15 minutes prior to voiding."
223595169|NCT03245983|BEHAVIORAL|Questionnaire and interview|Cancer patients will answer questionnaires and will be interviewed by a pshychologist to assess their spirituality and quality of life toward their disease
223595170|NCT05304897|PROCEDURE|PRP treatment|PRP treatment for bronchopleural fistula
223595171|NCT03033264|DRUG|Dinoprostone|10 mg of a Dinoprostone vaginal insert.
223595172|NCT03033264|DEVICE|Double lumen cervical ripening balloon.|Double lumen cervical ripening balloon.
223595173|NCT04462965|COMBINATION_PRODUCT|Toripalimab|Injection,Specification 240mg/6ml, 3 mg/kg for the dose, iV, every 2 weeks a dose cycle, up to 1 year; Temozolomide: 100mg or 20mg, Every 4 weeks a dose cycle, up to 6 cycles Cisplatin: Injection, 20mg,Every 4 weeks a dose cycle, up to 6 cycles
223595174|NCT04462965|COMBINATION_PRODUCT|Temozolomide|Placebo：Injection,Specification 240mg/6ml, 3 mg/kg for the dose, iV, every 2 weeks a dose cycle, up to 1 year; Temozolomide: 100mg or 20mg, Every 4 weeks a dose cycle, up to 6 cycles Cisplatin: Injection, 20mg,Every 4 weeks a dose cycle, up to 6 cycles
223595175|NCT03514433|OTHER|TRIP Patient Navigation Intervention|The TRIP intervention will replace the current standard of care at the 5 participating hospitals once it is rolled out on-site. Any TRIP eligible patients receiving patient navigation services over the course of the study will receive the enhanced services.
223595176|NCT04629846|DRUG|Trastuzumab|Trastuzumab IV infusion in 3-week cycles. Neoadjuvant treatment: 8 milligrams per kilogram (mg/kg) loading dose for Cycle 1, followed by 6 mg/kg for Cycles 2-4.
223595177|NCT04629846|DRUG|QL1209|QL1209 IV infusion in 3-week cycles. Prior to surgery (neoadjuvant treatment): 840 milligrams (mg) loading dose for Cycle 1, followed by 420 mg for Cycles 2-4.
224197305|NCT03895827|OTHER|Passive Referral to Treatment Control|Currently neither first responders or emergency department staff regularly refer people to any kind of substance use after an opioid overdose reversal. In the passive referral condition they will at least get a brochure with information on recently expanded and publicly-funded medication-assisted treatment in their community.
224197306|NCT04365127|DRUG|Progesterone 100 MG|Subcutaneous administration twice daily
224197307|NCT02856282|DRUG|Pirinase Hayfever Relief for Adults 0.05% Nasal Spray|Aqueous suspension of 0.05% micronised fluticasone propionate.Each actuation contains 50 micrograms of fluticasone propionate
224197308|NCT01849029|BEHAVIORAL|Cognitive Processing Therapy-Cognitive|Cognitive Processing Therapy-Cognitive (CPT-C) uses education about trauma reactions, emotional processing, and cognitive strategies to reduce trauma-related cognitive distortions. CPT is a manualised 12 session cognitive behavioral treatment for PTSD which offers an alternative to purely exposure based interventions. CPT has a smaller exposure component than imaginal exposure therapy and is therefore potentially more acceptable to clients or practitioners seeking alternatives to purely exposure focused treatments. CPT-C omits the written trauma account, and includes more practice of cognitive techniques during the sessions. The treatment was developed for twice weekly sessions over 6 weeks. It also directly targets associated problems such as depression, guilt and anger.
224197309|NCT00057330|BIOLOGICAL|HSV vaccine or SB208141, GSK Biologicals' glycoprotein D (gD)-Alum/3-deacylated form of Monophosphoryl Lipid A (MPL) candidate genital herpes vaccine|the vaccine was administered intramuscularly in the non-dominant deltoid
223506251|NCT03767894|DEVICE|Shoulder harness|The MyHand orthosis provides tension to the digits to open the fingers on demand. This group will wear a shoulder strap to control and activate the MyHand orthosis, either with shoulder elevation or shoulder depression.
223506252|NCT01895647|DEVICE|EMS|Electric muscle stimulation with programmed warm-up, stimulation and cool-down in 32 minutes
223506253|NCT04243837|DRUG|LYT-100 BCRL|BCRL patients will receive LYT-100 BID for 6 months
223506254|NCT04243837|DRUG|Placebo BCRL|BCRL patients will receive Placebo BID for 6 months
223506255|NCT05481281|DRUG|Dexmedetomidine|I/V bolus of dexmedetomidine 0.1 mg/kg as a 20 ml solution, followed by 0.04mg/kg/hr infusion
223506256|NCT05481281|DRUG|Ketamine|0.2 mg/kg iv of ketamine diluted to 20 ml followed by 0.1 mg/kg/hr infusion
223506257|NCT02555098|DEVICE|Sapphire contact lenses|Each subject randomized to wear either the test or control contact lenses as a matched pair and cross over to the second matched pair
223506258|NCT02555098|DEVICE|senofilcon A contact lenses|Each subject randomized to wear either the test or control contact lenses as a matched pair and cross over to the second matched pair
223506259|NCT02845492|OTHER|Qigong|Qigong is a mind-body exercise based around gentle exercise and the cultivation of a meditative focus on bodily sensations
223506260|NCT02845492|OTHER|Complete Health Improvement Program (CHIP)|The CHIP program is a validated weekly wellness and exercise program designed to promote health and wellbeing.
223506261|NCT02558751|BIOLOGICAL|23-valent pneumococcal polysaccharide vaccine|One standard adult dose of the 23-valent pneumococcal polysaccharide vaccine
223506262|NCT02558751|BIOLOGICAL|13-valent pneumococcal conjugate vaccine|One dose of the 13-valent pneumococcal conjugate vaccine, PCV13, followed 8 weeks later by one dose of the 23-valent pneumococcal polysaccharide vaccine, PPV23.
223506263|NCT05236127|OTHER|Soccer Heading|A standardized and reliable soccer heading protocol will be used for the experiment. A triaxial accelerometer embedded in a head-band pocket and positioned directly below the external occipital protuberance (inion) to monitor linear and rotational head accelerations. A JUGS soccer machine will be used to simulate a soccer throw-in with a standardized ball speed of 25mph. The ball speed is similar to when soccer players make a long throw-in from the sideline to mid-field. Soccer players frequently perform this maneuver during practice and games. Subjects will stand approximately 40ft away from the machine to perform the heading. Participants perform 20 standing headers with 1 header per 30 seconds. The subjects will be instructed to direct the ball back toward the JUGS soccer machine in the air.
223506264|NCT05236127|OTHER|Intermittent Fasting|The purpose of this study is to examine the effect of intermittent fasting on the acute neural responses to subconcussive head impacts. The study is designed to identify the effects of 20 controlled soccer headings in college-aged soccer players in one of four groups (fasted, pre-fasted, post-fasted, or control) through the use of neural-injury blood biomarkers, magnetic resonance spectroscopy, functional, and diffusion MRI, and ocular-motor function across 4 acute time points. Participants will be randomly designed to one of the four groups which consist of an 8 day fast, 5 day fast, 3 day fast, or the non-fasted control group.
223506265|NCT03849989|PROCEDURE|Skin biopsy|"Skin biopsy:~Tissue samples will be taken by punch biopsy according to the daily routine of the Department of Dermatology of the Maastricht UMC+.~Steps:~* Skin desinfection with chlorhexidine digluconate 1% solution~* Local anaesthesia with lidocaine hydrochloride 1%~* Biopsy specimens are taken with sterile punch device (disposable biopsy punch delivered by kai medical)~* Biopsy specimens are retrieved with sterile pincer and cut with sterile blade~* Wound is stitched with a single transcutaneous stich using absorbable suture (vicryl 4.0).~* Wound will be treated with R/ fusidic acid ointment 3 to 5 times per day for two weeks~* In the first week after laser therapy the wound will be covered by R/ Urgotull non-adhesive gauze, R/ Cutisoft cotton non-sterile gauze and R/ Klinipress exsupad absorbing bandage."
223506266|NCT04215575|DEVICE|glaucoma implant procedure (Baerveldt)|A 350 mm2 Baerveldt glaucoma implant was placed in the superotemporal quadrant in 25 patients randomized to BGI group. A limbus-based conjunctival flap was dissected, and the implant was sutured to sclera 10 mm posterior to the limbus. A scleral graft was used to cover the limbal portion of the tube, and the conjunctiva was closed.
223595178|NCT04629846|DRUG|Pertuzumab|Pertuzumab IV infusion in 3-week cycles. Prior to surgery (neoadjuvant treatment): 840 milligrams (mg) loading dose for Cycle 1, followed by 420 mg for Cycles 2-4.
223595179|NCT04629846|DRUG|Docetaxel|Docetaxel IV infusion in 3-week cycles. Neoadjuvant treatment: 75 mg/m2 for Cycles 1-4
223595180|NCT04629846|PROCEDURE|surgery|All participants who are eligible for surgery will undergo surgery and have their pathologic response evaluated.
223747480|NCT01727141|DRUG|NVA237|NVA237 was supplied in capsule form in blister packs for use in the Novartis Concept1 SDDPI.
223747481|NCT01727141|DRUG|Placebo|Placebo was supplied in capsule form in blister packs for use in the Novartis Concept1 SDDPI.
223747482|NCT00448071|DRUG|MTR107|
224197310|NCT00057330|BIOLOGICAL|Havrix™, GlaxoSmithKline (GSK) Biologicals' licensed Hepatitis A vaccine|the vaccine was administered intramuscularly in the non-dominant deltoid
224197311|NCT02074982|DRUG|AIN457 300 mg|
224197312|NCT02074982|DRUG|ustekinumab 45/90 mg|
224197313|NCT02074982|DRUG|placebo secukinumab|Placebo
224197314|NCT03892902|DRUG|ACT-541468|Film-coated tablet for oral use at a dose strength of 50 mg.
224197315|NCT03892902|DRUG|Zopiclone 7.5 mg|Over-encapsulated to maintain blinding.
224197316|NCT03892902|OTHER|Placebo|Matching to maintain blinding.
224197317|NCT03305159|DRUG|Povidone-Iodine|Patients will receive povidone iodine for the surgical preparation of the vagina.
224197318|NCT03305159|DRUG|4% Chlorhexidine Gluconate|Patients will receive 4% chlorhexidine gluconate for the surgical preparation of the vagina.
224197319|NCT00594581|DRUG|Juvista (avotermin) plus placebo, standard-care (within-subject controls)|Intradermal Juvista (avotermin) at 50ng or 200ng per 100μl per linear cm of wound margin
224197320|NCT02763410|OTHER|PRBC transfusion|
224197321|NCT00802295|DRUG|Gonadotrophins|Administration of standard ovarian stimulation protocol
224197322|NCT00802295|DRUG|Low dosis Gonadotrophin|
224197323|NCT00188058|DEVICE|Setting of positive end-expiratory pressure|
223506267|NCT04215575|DEVICE|glaucoma implant procedure (Ahmed)|A 184 mm2 Ahmed glaucoma implant was placed in the superotemporal quadrant in 56 patients randomized to AGV group. A fornix-based conjunctival flap was dissected, and the implant was sutured to sclera 10 mm posterior to the limbus. The Ahmed tube left patent and viscoelastic substance injected into anterior chamber. A scleral graft was used to cover the limbal portion of the tube, and the conjunctiva was closed.
223506268|NCT02280499|DEVICE|standard PROMOS prosthesis|
223506269|NCT02882516|OTHER|Visible light exposure|Subjects will be exposed to visible colored light for 15 minutes. The visible light will be generated by red-green-blue light emitting diodes light cans.
223506270|NCT04799665|DIAGNOSTIC_TEST|Breast CT|This is a cross-sectional clinical study to determine the feasibility of breast CT for breast density assessment and association of CT-derived density measures with metabolic syndrome in overweight/obese Mexican-origin women in Southern Arizona. There is no intervention.
223506271|NCT01903044|PROCEDURE|BM-MNC injection|BM-MNC cells will be injected in aliquots of 1 ml at multiple regions of the leg muscles
223506272|NCT00120848|BIOLOGICAL|HPV 16/18 VLP AS04|
223506273|NCT05916066|DIETARY_SUPPLEMENT|Nicotinamide|Tabletts of 500mg Nicotinamide (B3-vitamin)
223595181|NCT03037983|DEVICE|Repetitive transcranial magnetic stimulation|rTMS is a non-invasive procedure, in which the administration of a transient magnetic field induces electrical currents in specific, targeted brain regions. The intervention will be administered in 20 sessions lasting 50 minutes each over the course of 2-6 weeks. Up to two sessions may be scheduled per day with a one-hour interval in-between.
223595182|NCT03037983|DEVICE|Sham|Subjects will still attend treatment sessions as outlined in the rTMS intervention. However, the device will not deliver any stimulation to the subject.
223595183|NCT04114110|OTHER|RTLS data|data extraction from RTLS
223595184|NCT03899051|PROCEDURE|interdental papilla reconstructive surgery with PRF|Papilla reconstruction would be done with platelet rich fibrin
223595185|NCT03899051|PROCEDURE|interdental papilla reconstructive surgery with subepithelial connective tissue graft|Papilla reconstruction would be done with subepithelial connective tissue graft
223595186|NCT01862549|BEHAVIORAL|Dialectical Behavior Therapy for children|
223595187|NCT01862549|BEHAVIORAL|Treatment as Usual|
223595188|NCT01776866|PROCEDURE|Coronary Angiography|Coronary angiography include standard coronary angiography (SA) and dual-axis rotational coronary angiography (DARCA). Patient first undergo SA of either left or right coronary system followed by DARCA.
223595189|NCT01894022|DRUG|Ambrisentan 5 mg|Round, white, film-coated, immediate-release tablets, containing 5 mg ambrisentan. Subjects will be dosed orally once daily. Subjects may receive 5mg, or 10 mg of ambrisentan OD.
223595190|NCT05030480|DIAGNOSTIC_TEST|renal functions|urea, creatinine, GFR
223595191|NCT02807688|BEHAVIORAL|Health Promotion Intervention|"The intervention package consists of the following elements:~i. educational sessions on the importance of diet and fitness; ii. motivational interviews to maintain participants in the program, to discuss participants' physical conditions, habits and opinions as to diet and fitness; iii. monitoring the participation in the program and health behaviour, specifically for diet and fitness, and adherence to the intervention on diet and fitness; iv. regular physical exercise under the guide and supervision of an expert trainer."
223595192|NCT03134690|PROCEDURE|delayed start|In this protocol, ovarian stimulation will be started from ninth day of menstrual cycle .
223595193|NCT03134690|PROCEDURE|Conventional|In this protocol, ovarian stimulation will be started from the 2th or 3th day of the menstrual cycle.
223595194|NCT04994678|OTHER|Virtual Reality Training|The Virtual reality based training group will receive a game based virtual reality training via XBOX 360or wii fit balance games. Player will be required to rapidly leaning away, squat to avoid overhead obstacles and try small jump to avoid lower obstacles, single leg stance, in addition person will required to do half squatting, side to side jumps and vertical jumps. Treatment will be provided 3 times a week or 6 weeks with each session lasting for 30-50 minutes. Progressively challenge will be increased.
223595195|NCT04994678|OTHER|Moderate Aerobic Exercise Training|Moderate intensity continuous Aerobic exercises (Recombinant/Stationary cycling for 10-15 min with progression followed by treadmill walking for 10-15 min with progression, as well as stepping and Jogging). The session will be preceded by 5-7 minute warm-up \&amp; 7-10 min cool-down.
223595196|NCT00123045|BEHAVIORAL|health education|
224197324|NCT05558735|OTHER|urine collection|urine collection as part of the care and usual follow-up in the context of suspected prostate cancer
224197325|NCT05558735|OTHER|canine detection|urine sample will be placed in a detection cone to be sniffed by 6 trained dogs
224197326|NCT01387958|DRUG|LCQ908|
224197327|NCT01387958|DRUG|Placebo|
224310838|NCT03357835|OTHER|Trauma Decision System|At the time of application, color codes indicating the urgency of the patients will be given according to the demographic data of the patients, the type of trauma and the vital signs were directed by the software program. As a result of the software program's direction, patients will be coded as green-yellow-orange-red area and patient care will be made in accordance with these codes.
224310839|NCT02336724|DRUG|Famitinib|
224197328|NCT02938819|OTHER|Goal-oriented upper-limb intervention|The Goal-oriented upper-limb intervention evaluated patients' expectations and the environmental factors influencing the performance of the specific task were identified for each of the three tasks. Patients were asked to perform the activity at home. After this, the observable target behavior corresponding to the target activity was determined. Then, an occupational and a physical therapist worked together with the patient to identify the assistance required to perform this activity such as human assistance, technical aids, assistive devices or verbal guidance.
224197329|NCT02938819|OTHER|Standard upper limb intervention|The standard upper limb intervention involved active upper limb range of motion, manual dexterity involving grasp and manipulation of small pieces such as marbles and stretching upper limb exercises.
224197330|NCT00302068|BEHAVIORAL|Supervised Aerobic Exercise|Supervised aerobic exercise, three times per week, for 16 weeks.
224197331|NCT00302068|DRUG|Sertraline|Sertraline (Zoloft), daily, for 16 weeks.
224197332|NCT00302068|DRUG|Placebo Pill.|Placebo pill, daily, for 16 weeks.
224197333|NCT03969160|BEHAVIORAL|Imaginal exposure|Imaginal exposure to mental imagery of phobic and neutral stimuli
224197334|NCT00051766|BEHAVIORAL|Computer-based Intervention|
224197335|NCT05769465|DRUG|disease modifying treatments|Patients will be enrolled if exposed to nusinersen, risdiplam, onasemnogene abeparvovec
224197336|NCT01445366|DEVICE|High volume post dilution hemodiafiltration|The midweek dialysis sessions of the patients is changed once to a 4 hours high volume post dilution hemodiafiltration (HDF) session, and once to an 8 hours high flux hemodialysis (HD) session.
224197337|NCT01445366|DEVICE|high flux hemodialysis|The midweek dialysis sessions of the patients is changed once to a 4 hours high volume post dilution hemodiafiltration (HDF) session, and once to an 8 hours high flux hemodialysis (HD) session.
224310840|NCT03844217|DRUG|Macimorelin 0.5mg/kg body weight|oral Macimorelin stimulation test with the dose of 0.5mg/kg body weight Macimorelin
223506274|NCT06240559|DEVICE|External imaging panel|The IP will be placed on the side of the treatment table and will acquire data during the whole treatment, which will be compared against information derived from the treatment plan. The IP based method can detect errors and information about motion and treatment uncertainties that are not currently available.
223506275|NCT04561531|OTHER|3%NaCl|Intervention is infusion of 3%NaCl which is defined in arms of experiment.
223506276|NCT03830970|DIETARY_SUPPLEMENT|Canned beans of multiple varieties|Daily rotation of different varieties of canned beans including black, navy, pinto, red kidney and white kidney
223506277|NCT03830970|DIETARY_SUPPLEMENT|White Rice|Minute Rice Long Grain White Rice
223506278|NCT02826551|DRUG|Marcaine|Pain control medication to theoretically reduce the amount of posterior knee pain that is common after ACL surgery by placing the injection into the posterior capsule of the knee during surgery. This is very easy and safe to accomplish as the surgeon will have direct visualization of the posterior capsule during the surgery.
223506279|NCT02826551|OTHER|Ice|
223506280|NCT02826551|DRUG|Percocet|
223506281|NCT02826551|DEVICE|Knee Brace and Crutches|
223506282|NCT04199039|OTHER|Effect on Endotracheal Tube Fixation Methods on Hemodynamic Parameters During Endotracheal Suction|"When the study started, the first 43 patients were assigned to the control group and the following 43 patients were assigned to the study group in the CVS ICU. ET fixation in the control group was performed with plasters, which are routinely used in the ICU where the study was conducted. ET fixation of the patients in the study group was performed with an ET holder (AnchorFast Oral Endotracheal Tube Fastener, Hollister, Liberlyville, USA) when they arrived at the CVS ICU.~The patients' SBP, DBP, HR and SpO2 values, which were displayed on the bedside monitor (Nihon Kohden, Tokyo), were recorded on the Hemodynamic Parameters Form just before, during, and at the end of endotracheal suction, and in the following 5th and 15th minutes."
223506283|NCT05610267|DEVICE|Retrospective chart review|The retrospective chart review will include the full consecutive series of patients between 22 years and 80 years old who underwent abdominal wall reconstruction for achart hernia with Integra Gentrix® Surgical Matrix during the time period between November 1, 2017, and present (90 days prior to the start of data collection).
223506284|NCT00977561|DRUG|figitumumab|Figitumumab (20 mg/kg)
223506285|NCT00977561|DRUG|Cisplatin (Or Carboplatin)|Cisplatin (75 mg/m2 IV on Day 1) or Carboplatin AUC 5
223506286|NCT00977561|DRUG|Etoposide|Etoposide (100 mg/m2 IV on Days 1, 2 and 3)
223506287|NCT00977561|DRUG|Cisplatin (Or Carboplatin)|Cisplatin (75 mg/m2 IV on Day 1) or Carboplatin AUC 5
223506288|NCT00977561|DRUG|Etoposide|Etoposide (100 mg/m2 IV on Days 1, 2 and 3)
223506289|NCT01482286|DRUG|Metformin|Subjects randomized to the metformin treatment group will receive 1000 mg extended release metformin hydrochloride tablets (Bristol Myers Squibb) twice per day with food approximately 8 hours apart.
223506290|NCT01482286|BEHAVIORAL|Dietary Restriction|Subjects randomized to the dietary restriction group will reduce their energy intake by 25% of their weight maintenance energy intake determined at baseline. Total energy expenditure as measured by a 14-day doubly labeled water (DLW) study will be used to determine the baseline energy intake of each subject. There will be no gradual ramping of dietary restriction. The 25% energy reduction goal will apply from the first day of the intervention for a period of 24 weeks. Subjects will be asked to not modify their normal level of physical activity.
223506291|NCT01482286|BEHAVIORAL|Exercise Training|"For the aerobic training component, subjects are required to meet a weekly energy expenditure target of 10 kcal per kg of body weight per week (KKW).~The resistance training program will be performed 2 days a week. The resistance program includes 9 exercises. The 9 primary exercises are seated chest press, seated row, shoulder press, lat pull down, double leg press, leg extension, leg curl, back extension and abdominal crunch."
223506292|NCT05648916|OTHER|Celecoxib|Retrospectively comparing patients with and without heterotopic ossification who have been exposed to celecoxib and underwent cementless total hip joint replacement surgery.
223506293|NCT04453254|OTHER|Whole Food Meal|Isocaloric/ macronutrient whole food meal
223506294|NCT04453254|OTHER|Supplement Food Meal|Isocaloric/ macronutrient supplement food meal
223506295|NCT04942509|BEHAVIORAL|Coloring as a brief mindfulness-based intervention|Participants watched an instructional video on mindful coloring at the beginning of the intervention and colored mindfully for at least 5 days or 100 minutes in total during a 10-day period. The intervention included a coloring booklet that contained mandala patterns for coloring.
223747483|NCT03054857|DRUG|Dexmedetomidine|After skin incision, the dexmedetomidine group received a loading dose of 0.5 mcg/kg of Dexmedetomidine in 20 minutes followed by a continuous IV infusion at 0.4 mcg/kg/hr until the end of operation.
223747484|NCT03054857|DRUG|Placebo|The control group received a loading dose and continuous IV infusion of normal saline at the same volume and rate as in the dexmedetomidine group
223747485|NCT01957748|BEHAVIORAL|SoC + ALERT Intervention|Enhanced retention efforts and education modules will be implemented by the ALERT Specialist to ensure retention to care.
223747486|NCT03740425|PROCEDURE|Blood Transfusion|Blood Transfusion in patients who underwent transcatheter aortic valve implantation (TAVI)
223747487|NCT03812692|DEVICE|MATRx plus|The MATRx plus device is a feedback-controlled mandibular positioner that uses data collected during sleep to control movement of the mandible in real-time using a mandibular positioner. The test provides a prediction of the individual's response to oral appliance therapy; i.e., if the individual can treat his or her obstructive sleep apnea using a mandibular advancing oral appliance. For individuals predicted to respond to the therapy, the test also provides a mandibular position at which the appliance will be effective.
223747488|NCT02477501|DRUG|Norepinephrine|continuous infusion
223747489|NCT02477501|DRUG|Ephedrine|continuous infusion
223747490|NCT03488316|PROCEDURE|Carie removal|Carie removal with a low speed handpiece
223747491|NCT03488316|PROCEDURE|Absolute isolation|Absolute isolation with rubber dam
223747492|NCT03488316|DRUG|Manipulation of the temporary filling material based on Calcium Hydroxide|Manipulation of the temporary material based on Calcium Hydroxide according to the manufacturer's recommendations.
223747493|NCT03488316|DRUG|Manipulation of the temporary filling material based on Mineral trioxide aggregate|Manipulation of the temporary material based on Mineral trioxide aggregate according to the manufacturer's recommendations.
223747494|NCT03488316|PROCEDURE|Material insertion on the root canal|Material insertion on the root canal according to the manufacturer's recommendations
223747495|NCT03488316|PROCEDURE|Material re-insertion on the root canal accordging to the infection needs.|Material re-insertion on the root canal according to the manufacturer's recommendations
223747496|NCT03488316|PROCEDURE|Definiteve canal root obturation|Definiteve canal root obturation with gutta-percha and definitive cement.
223747497|NCT03488316|PROCEDURE|Definitve restoration|Definitve restoration confecction.
224197338|NCT01035021|DRUG|use of rocuronium when the LMA is inserted|Anesthesia is induced with a propofol and remifentanil in both groups, however rocuronium 0.06 mg/kg is injected only in group R. Insertion of LMA is performed by the standard technique according to the manufacturer's instruction. In group N, rocuronium is administered for the operation.
224197339|NCT01829321|DRUG|GLPG0974|1 capsule in the morning and 1 capsule in the evening with food during 28 days
224197340|NCT01829321|DRUG|Placebo|1 capsule in the morning and 1 capsule in the evening with food during 28 days
224197341|NCT01826006|DEVICE|Excimer laser|
224197342|NCT01826006|DEVICE|Manual Thrombus Aspiration|
224197343|NCT04555798|DRUG|Meropenem Injection|patients of both groups given meropenam 1 gram every 8 hours till we collect the sputum culture
224197344|NCT04555798|DEVICE|A-V ECMO|Only patients of group B connected to A-V ECMO for two weeks
223506296|NCT03134638|DRUG|SY-1365 (Part 1)|"Two dosing schedules will be evaluated in dose escalation and a dose(s)/schedule(s) will be determined for Part 2:~* Twice weekly: SY-1365 will be administered by intravenous infusion over 1 or 2 hours twice a week for 3 weeks of each 4 week (28 day) cycle.~* Weekly: SY-1365 will be administered by intravenous infusion over 1 or 2 hours once a week for 3 weeks of each 4 week (28 day) cycle."
223506297|NCT03134638|DRUG|Carboplatin|Carboplatin will be administered on Day 1 of each 3 week (21-day) cycle (Part 2 only)
223506298|NCT03134638|DRUG|Fulvestrant|Fulvestrant will be administered as an intramuscular (IM) dose of 500 mg every 2 weeks for the first 3 doses on Day 1 and Day 15 of the first 28-day cycle (Cycle 1), and on Day 1 of the second 28 day cycle (Cycle 2), and monthly thereafter starting on Day 1 of Cycle 3 (Part 2 only)
223506299|NCT03134638|DRUG|SY-1365 (Cohort 2)|In combination with carboplatin, SY-1365 will be administered by intravenous infusion over 1 or 2 hours for 2 weeks of each 3 week (21-day) cycle (Part 2 only)
223747498|NCT03462316|BIOLOGICAL|NY-ESO-1（TCR Affinity Enhancing Specific T cell Therapy）|NY-ESO-1（TCR Affinity Enhancing Specific T cell Therapy）
223747499|NCT00469482|OTHER|Sedation,RASS Targeted plus BIS Monitoring|Providing patient sedation utilizing standard of care methods (RASS) plus BIS monitoring
223747500|NCT00469482|OTHER|Sedation, RASS Targeted|Patient sedation utilizing standard of care methods (RASS targeted)
223747501|NCT02998801|OTHER|IPAD|Patients undergoing surgery will watch the video using an PAD
223747502|NCT02998801|OTHER|VR Goggles|Patients undergoing surgery will watch the video using goggles
223747503|NCT03291210|OTHER|normal inspired oxygen fraction|receives inspired oxygen fraction of 0.3
224197345|NCT01335620|DRUG|Raltegravir|400 mg twice daily
224197346|NCT01335620|DRUG|Tenofovir|245 mg once daily
223747504|NCT03291210|OTHER|high inspired oxygen fraction|receives inspired oxygen fraction of 0.8
223747505|NCT02603432|BIOLOGICAL|Avelumab|1 hour intravenous infusion every 2 weeks (Q2W) in 4 week cycles
223747506|NCT02603432|OTHER|Best Supportive Care|BSC will be administered as deemed appropriate by the treating physician, and could include treatment with antibiotics, nutritional support, correction of metabolic disorders, optimal symptom control and pain management (including palliative radiotherapy), etc. BSC does not include any active anti-tumor therapy, however local radiotherapy of isolated lesions with palliative intent is acceptable.
223747507|NCT02603432|BIOLOGICAL|Following the planned interim analysis for this study: Avelumab|1 hour intravenous infusion every 2 weeks (Q2W) in 4 week cycles
224197347|NCT01335620|DRUG|Emtricitabine|200mg once daily
224197348|NCT02951182|DRUG|TEZ|
224197349|NCT02951182|DRUG|IVA|
224197350|NCT02951182|DRUG|VX-440|
224197351|NCT02951182|DRUG|Matched Placebo|
224310841|NCT03844217|DRUG|Macimorelin 0.75mg/kg body weight|oral Macimorelin stimulation test with the dose of 0.75mg/kg body weight Macimorelin
224310842|NCT00554606|DRUG|Canakinumab|Canakinumab
224310843|NCT05782959|BIOLOGICAL|BCD-245|BCD-245 is administered as prolonged intravenous infusions during each cycle
223747508|NCT01321788|DRUG|TINZAPARIN|Eligible women following cesarean section will randomly receive once-daily injections of study drug (4,500 IU tinzaparin sodium within 12 to 24 hours postpartum and continued for two (2) weeks postpartum.
223747509|NCT01321788|DRUG|PLACEBO|Eligible women following cesarean section will receive a once-daily injections of placebo within 12 to 24 hours postpartum and continued for two (2) weeks postpartum.
223747510|NCT00017433|DRUG|arsenic trioxide|
223747511|NCT03756298|DRUG|Atezolizumab|Atezolizumab is 1,200 mg iv. administered every 3 weeks for 8 cycles with capecitabine (2,000mg/m2/day, day 1-14, every 3 weeks for 8 cycles)
223747512|NCT03756298|DRUG|Capecitabine|capecitabine monotherapy (2,500mg/m2/day, day 1-14, every 3 weeks for 8 cycles)
223747513|NCT04014075|DRUG|Trastuzumab deruxtecan|Antibody component covalently conjugated to a drug component, prepared by dilution based on body weight for intravenous (IV) infusion
223747514|NCT03462212|DRUG|Carboplatin|chemotherapy medication
223747515|NCT03462212|DRUG|Paclitaxel|chemotherapy medication
223595197|NCT04965532|DRUG|sevoflurane anesthesia|Sevoflurane enhances the effects of rocuronium and significantly prolongs the duration of action of rocuronium and the time to recovery.
223595198|NCT04965532|DRUG|Propofol Injection|Propofol is most commonly used for intravenous anesthesia. In contrast to sevoflurane, propofol has no effects on rocuronium.
223747516|NCT03462212|DRUG|Bevacizumab|Angiogenesis inhibitor
223747517|NCT03462212|DRUG|Rucaparib|PARP inhibitor
223747518|NCT02450227|DIETARY_SUPPLEMENT|Spinach - Whole leaf (10 mg lutein)|Identical spinach meals processed in two different ways by Frigodan, served alone or together with habitual diet
223747519|NCT02450227|DIETARY_SUPPLEMENT|Spinach - Minced (10 mg/lutein)|Identical spinach meals processed in two different ways by Frigodan, served alone or together with habitual diet
223747520|NCT02666183|BEHAVIORAL|Video-C|use videoconferencing to provide personalized information aimed at enhancing self -efficacy and providing emotional support for distant caregivers of patients with advanced cancers
223747521|NCT02666183|BEHAVIORAL|Nurse Coaching|structured conversations with registered nurses aimed at providing emotional support
223747522|NCT02666183|BEHAVIORAL|Web-Only|Access to a website with caregiving resources, resources for distant care givers, and cancer information
223747523|NCT06304142|BEHAVIORAL|Rehabilitation therapy|"Rehabilitation therapy includes Diet management: Avoiding consumption of irritant foods and beverages, such as spicy foods, caffeine, alcohol, and acidic foods. Controlling portion sizes and meal timing, and adopting smaller, more frequent meals.~Lifestyle adjustments: Avoiding lying down or bending immediately after meals, maintaining a sitting or upright position for at least 2 hours. Adjusting sleeping positions by elevating the head of the bed to reduce nighttime acid reflux. Avoiding excessive exertion and managing stress levels.~Rehabilitation training: Strengthening the control of esophageal and gastric muscles through rehabilitation exercises to improve the function of the gastroesophageal sphincter and prevent gastric fluid reflux."
223747524|NCT06304142|PROCEDURE|Injection|The percutaneous approach via the paratracheal route was used for Stellate ganglion block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
223747525|NCT06304142|DRUG|Lidocaine hydrochloride|Based on the invention above, the patients in the observation group were provided with Stellate ganglion block, using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g).
223747526|NCT01957462|DEVICE|Coloplast Test V|Coloplast Test product V is a newly developed 1-piece ostomy appliance
223747527|NCT01957462|DEVICE|Coloplast Test X|Coloplast Test X is a newly developed 1-piece ostomy appliance
223747528|NCT05954052|DRUG|Glutathione|Giving supplement orally
223747529|NCT02541071|BEHAVIORAL|Stress Film|
223747530|NCT02541071|DRUG|Yohimbine|
223747531|NCT02541071|DRUG|Clonidine|
223747532|NCT02541071|DRUG|placebo|
223595199|NCT02782026|DEVICE|Exhaled Breath Olfactory Signature (Artificial Nose)|
223747533|NCT04906785|DRUG|CKD-385|Test Drug
223747534|NCT04906785|DRUG|D744|Reference Drug
223595200|NCT03578328|PROCEDURE|targeted temperature management|Temperature control to targeted temperature (32-36C) after return of spontaneous circulation after cardiac arrest and resuscitation
223595201|NCT02728297|PROCEDURE|Staged ETS|Thoracoscopic approach of sympathetic ganglia T3-T12 on one side, retraction of the diaphragm and lung laterally to expose the ganglia then ablation of each ganglion using electrocauterization.
223595202|NCT03001778|OTHER|Usability Testing|"Usability testing of ready made workouts in a group format."
223595203|NCT04741763|DIETARY_SUPPLEMENT|EyePromise Visual Edge|A dietary eye supplement containing 8 mg zeaxanthin and 4 mg lutein and additional proprietary nutrients
223595204|NCT01623739|PROCEDURE|Placement of a dental implant|Type 1 implant placement Type 2 implant placement
223595205|NCT03579641|DEVICE|HeartLogic Sensors|HeartLogic Sensors
223595206|NCT02013245|BIOLOGICAL|MTBVAC live vaccine|Live-attenuated Mycobacterium tuberculosis vaccine
223747535|NCT03528746|OTHER|Isotonic Exercise|Participants will complete dynamic leg extension in a leg extension machine with a range of motion from approximately 90 degrees flexion to full extension. Each repetition will be completed with a 3s concentric contraction, 0s isometric and 4s eccentric contraction.This will be repeated for 8 repetitions and for 5 sets with 2 minutes rest between each set, as per Rio and colleagues. The load used during the isotonic exercise will be equivalent to participants 8 repetition maximum, which will be determined by an experienced tester in a standardised manner according to NSCA guidelines.
223747536|NCT03528746|OTHER|Isometric exercise|Participants will complete isometric quadriceps exercise, where they must hold a load statically for 45s with their knee in 60° flexion. This will be repeated for 5 sets with 2 minutes rest between each set. A load of 70% of the maximal voluntary isometric contraction (MVIC) will be used. MVIC will be assessed in an isokinetic dynamometer as per Rio and colleagues. Participants will be seated in a stable position in the dynamometer with the knee at 60° of knee flexion. First they will be familiarised with the procedure. Standardised instructions will be issued for participants to perform a maximal effort knee extension against the dynamometer for 3seconds. After a short break, the test will be repeated three times and the MVIC will be peak torque recorded during these three efforts.
224197352|NCT06091176|DEVICE|Amicomed®|This app helps users track their blood pressure readings over time with analysis and history features. It generates graphs and charts to display trends and patterns, and users can set reminders to take blood pressure readings. Additionally, the app offers personalized recommendations for lifestyle, including personalized diet plans, and physical exercise programs based on the user's information. Using cognitive-behavioral techniques and motivational levers, the app helps users overcome barriers to lifestyle changes and provides personalized feedback and coaching. It also includes a database of evidence-based strategies for behavior change, and users can receive notifications, reminders, and rewards to stay motivated.
224197353|NCT06091176|DEVICE|Digital Placebo|Subjects will be provided with a white label mobile app, which allows to (1) add blood pressure measurements, (2) access the history of recorded measurements. No notification system will be implemented.
224197354|NCT06091176|OTHER|Usual Care|Usual Care (UC): Subjects assigned to control group will receive care as usual care, including self-monitoring indications.
224197355|NCT02303275|BEHAVIORAL|Lifestyle Change|"Intervention: Lifestyles Change Program (LCP)~The LCP is a 12-week multi-disciplinary program that incorporates a holistic approach to chronic disease management, which will be tailored to our study population, patients with chronic heart failure. The core of the LCP includes:~Clinician, Dietician, Exercise physiologist, Counselor, Nurse Case Manager Medical oversight by board-certified Cardiologist, Exercise prescription, Stress management classes (yoga, meditation, guided imagery), Group support, lifestyle change lectures, body composition analyses, grocery store tour, cooking classes, Music Wellness, and resiliency classes."
224197356|NCT02303275|BEHAVIORAL|Lifestyle Change|The lifestyle change program consists of classes conducted three times a week for 12 weeks at the Scripps Center for Integrative Medicine. Each day participants will spend about four to five hours in a variety of classes such as monitored exercise, group support, mindful-yoga and meditation, vegetarian cooking classes, music-centered wellness, mind-body lectures, and resiliency training.
224197357|NCT02824042|DRUG|Anetumab ravtansine (BAY94-9343)|Anetumab ravtansine given IV On Day 1 of each 21-day treatment cycle Part 1: Cycle 1 Day 1: 6.5 mg/kg of body weight (BW) Cycle 2 Day 1: 0.6 mg/kg BW Part 2: Cycle 1 Day 1: 6.5 mg/kg BW Cycle 2 Day 1: 6.5 mg/kg BW (planned dose) Continuous treatment: Cycles ≥3 Day 1: 6.5 mg/kg BW once every 3 weeks (Q3W)
224197358|NCT02824042|DRUG|Itraconazole|Itraconazole 100 mg oral capsules given by mouth Cycle 1 (Day 18): 200 mg twice daily (BID) (Days 19 - 21): 200 mg once daily (QD) Cycle 2 (Days 1-8): 200 mg QD 12 days in total (Part 1 or Part 2)
223506300|NCT03134638|DRUG|SY-1365 (Cohort 5)|In combination with fulvestrant, SY-1365 will be administered by intravenous infusion over 1 or 2 hours once a week for 3 weeks of each 4 week (28-day) cycle (Part 2 only)
223506301|NCT03134638|DRUG|SY-1365 (Part 2 Single Agent)|SY-1365 will be administered by intravenous infusion over 1 or 2 hours twice a week for 3 weeks of each 4 week (28 day) cycle
223506302|NCT03366415|DRUG|gemcitabine and cisplatin (Induction and adjuvant chemotherapy)|Patients receive gemcitabine (1000 mg/m² d1,8) and cisplatin (25mg/m² d1-3) every 3 weeks for 2 cycles before IMRT and after IMRT.
223506303|NCT03366415|RADIATION|IMRT|Intensity modulated-radiotherapy (IMRT) is given as 2.2 Gy per fraction with five daily fractions per week for 6-7 weeks to a total dose of 66 or 70.4 Gy to the primary tumor
223506304|NCT03366415|DRUG|gemcitabine and cisplatin (Induction chemotherapy)|Patients receive gemcitabine (1000 mg/m² d1,8) and cisplatin (25mg/m² d1-3) every 3 weeks for 2 cycles before concurrent chemoradiotherapy.
223506305|NCT03366415|RADIATION|IMRT and concurrent cisplatin|Intensity modulated-radiotherapy (IMRT) is given as 2.2 Gy per fraction with five daily fractions per week for 6-7 weeks to a total dose of 66 or 70.4Gy to the primary tumor, concurrently with cisplatin 30mg/m² every week.
223506306|NCT00083707|DRUG|Thalidomide|
223506307|NCT01526746|DRUG|Tasimelteon|20mg capsule, once
223506308|NCT01526746|DRUG|Tasimelteon|20mg, once
223506309|NCT03826004|DRUG|Clemastine|Clemastine fumarate 2mg/2ml intramuscular injection is administrated into the gluteus maximus muscle
223506310|NCT03826004|DRUG|Saline Solution|Saline solution 2ml intramuscular injection is administrated into the gluteus maximus muscle
223506311|NCT04696770|BEHAVIORAL|Mindfulness|Mindfulness techniques will be taught to the participants
223506312|NCT00202995|DRUG|Glatiramer Acetate|20 mg s.c. daily
223506313|NCT00202995|DRUG|Betaseron|250 mg every other day
223506314|NCT00202995|DRUG|Rebif|44 ug 3 times a week
223595207|NCT02013245|BIOLOGICAL|Commercially available BCG live vaccine|Live-attenuated Mycobacterium bovis vaccine
223595208|NCT03342092|OTHER|Questionnaire|Questionnaires distributed to the families 15 days before child's medical consultation + anthropometric measures and data collected from the personal interview with school nurse
223595209|NCT04510103|DRUG|Moisturizer A, F#9155-005|OTC Monograph Drug. Used twice daily on left or right lower leg per randomization schedule.
223595210|NCT04510103|OTHER|Moisturizer B, F#E1387-004|Cosmetic Moisturizer. Used twice daily on left or right lower leg per randomization schedule.
223595211|NCT04510103|PROCEDURE|Regression|2 week regression period after 6 weeks of moisturizer use.
223595212|NCT04510103|PROCEDURE|Non-Regression|Physical insult (tape stripping) on the lower leg after 6 weeks of moisturizer use.
223595213|NCT00065845|PROCEDURE|Burch urethropexy at time of sacrocolpopexy|The Burch colposuspension procedure entails the retropubic placement of at least two stitches in the vaginal tissue lateral to each side of the urethra, and suspension of these stitches from Cooper's ligament (the iliopectineal line at the superior aspect of the posterior pubic bone).
223595214|NCT03782922|OTHER|Exercise Training Program|10min of coordination and strength training (2-3x per week) during 2-6 weeks
223595215|NCT05185414|DIAGNOSTIC_TEST|Venipuncture and skin biopsy for RNA extraction|"* Blood sampling (standard venipuncture)~* Skin biopsy (fibroblasts)"
223595216|NCT04294147|DRUG|Galcanezumab|Administered SC
223595217|NCT04294147|DRUG|Erenumab|Administered SC
223595218|NCT00002812|DRUG|asparaginase|Given IV
223595219|NCT00002812|DRUG|cyclophosphamide|Given IV
223506315|NCT00000975|DRUG|Itraconazole|
223506316|NCT04367935|DRUG|Pentoxifylline|Pentoxifylline tablets 400mg three times daily for 2 months
223595220|NCT00002812|DRUG|cytarabine|Given IV
223595221|NCT00002812|DRUG|daunorubicin hydrochloride|Given IV
223595222|NCT00002812|DRUG|dexamethasone|Given IV
223595223|NCT00002812|DRUG|doxorubicin hydrochloride|Given IV
223595224|NCT00002812|DRUG|idarubicin|Given IV
223595225|NCT00002812|DRUG|mercaptopurine|Given IV
223595226|NCT00002812|DRUG|methotrexate|Given PO
223595227|NCT00002812|DRUG|pegaspargase|Given IV
223595228|NCT00002812|DRUG|prednisone|Given PO
223595229|NCT00002812|DRUG|thioguanine|Given IV
223595230|NCT00002812|DRUG|vincristine sulfate|Given IV
223595231|NCT00002812|RADIATION|radiation therapy|
223595232|NCT05392803|DEVICE|Active then Sham Treatment|"Application of 30 days of nonthermal, pulsed shortwave (radiofrequency) therapy; then sham treatment after a 7-day washout period"
223595233|NCT05392803|DEVICE|Sham then Active Treatment|"Application of 30 days of sham treatment; then 30 days of nonthermal, pulsed shortwave (radiofrequency) therapy after a 7-day washout period"
223595234|NCT03884647|DEVICE|DELPhI system|DELPhI software is acquiring and analyzing the TMS evoked response recorded with the EEG.
223595235|NCT00180583|DEVICE|Guidant GALILEO Intravascular Radiotherapy System|Treatment of single or multivessel long diffuse coronary stenosis with the Guidant GALILEO Intravascular Radiotherapy System
223595236|NCT05930691|DIAGNOSTIC_TEST|Optic nerve sheath diameter measurement|Prediction of intracranial pressure by using Ultrasonography on optic nerve sheath diameter.
223595237|NCT05618418|OTHER|No intervention|No intervention
223595238|NCT05295355|DRUG|Tiotropium Bromide Combined With Odaterol|2 puffs once daily at the same time of the day for 52 week
223595239|NCT02566733|DRUG|Remiva|Target controlled infusion of remifentanil (generic drug, Remiva™)
223595240|NCT02566733|DRUG|Ultiva|Target controlled infusion of remifentanil (brand-named drug, Ultiva™)
223595241|NCT00254891|DRUG|PF-3512676 + Paclitaxel + Carboplatin|"* PF-3512676: 0.2 mg/kg subcutaneously Days 8 and 15 of each 21 day cycle x 6 cycles then weekly as maintenance until disease progression or unacceptable toxicity.~* Paclitaxel: 200 mg/m2 intravenously Day 1 of each 21 day cycle x 6 cycles.~* Carboplatin: AUC 6 intravenously Day 1 of each 21 days cycle x 6 cycles."
223595242|NCT00254891|DRUG|Paclitaxel + Carboplatin|"* Paclitaxel: 200 mg/m2 intravenously Day 1 of each 21 day cycle x 6 cycles.~* Carboplatin: AUC 6 intravenously Day 1 of each 21 days cycle x 6 cycles."
223595243|NCT00604045|BEHAVIORAL|Attention Bias Modification (ABM)|The ABM comprised a probe detection paradigm described above, modified to facilitate the allocation of attention away from threatening material. In this task, the probe always replaced the neutral word. Stimuli comprised a different set of 12 threat-neutral word pairs different than those used in the attention bias assessment. Participants completed 288 training trials: 2 (probe type) x 2 (probe location) x 2 (threat location) x 12 (threat-neutral word pairs) x 3 (repetition). Thus, although there were no explicit instructions to direct attention away from threat words, on all trials, the position of the neutral word indicated the position of the probe.
223595244|NCT00604045|BEHAVIORAL|Attention Control Condition (ACC)|The ACC condition was identical to the ABM procedure with the exception that the probe appeared with equal frequency in the position of the threat and neutral words, such that attention was neither trained towards nor away from threat.
223595245|NCT04492163|DEVICE|TTFields|"TTFields treatment will consist of wearing four electrically insulated electrode arrays on the head. The treatment enables the patient to maintain regular daily routine.~Other Names:~• TTFields"
223747537|NCT04090593|OTHER|Patient Education 101: Mobile Health Education Tool|Intervention is interactive, mobile (tablet-or-smart-phone delivered), educational module that patients engage with during hospital admission.
223747538|NCT04377282|OTHER|Food-1|Cooked buckwheat
223747539|NCT04377282|OTHER|Food-2|Cooked couscous
223747540|NCT04377282|OTHER|Food-3|Water
223595246|NCT01984996|DEVICE|Freedom ProFlor Inguinal Hernia Implant|
223595247|NCT00779207|BEHAVIORAL|weight loss and exercise|10% weight loss through diet and exercise plus multicomponent exercise training three times a week
223595248|NCT00779207|BEHAVIORAL|weight loss|10 percent weight loss through diet and behavioral modification
223595249|NCT02781168|DEVICE|use of earmuffs|The earmuffs are brand Natus® Pediatrics, Neonatal Noise Attenuators called MiniMuffs®, San Carlos, California, USA, which allow the reduction of sound pressure levels 7 to 12 decibels. Are devices that have oval and anatomical shape that allow proper positioning of the ears of newborns. They are made with a soft foam and has hydrogel adhesive on the outer edges for attachment to the skin.
223595250|NCT03363880|OTHER|trauma treatment team|Establishing the trauma management system included a trauma treatment team. The severe trauma treatment team will be composed by the physicians from departments of emergency, orthopedic trauma, urology, cardiothoracic surgery, neurosurgery, general surgery, anesthesiology, and ICU.
223595251|NCT03363880|OTHER|Basic experimental settings|Establishing the trauma management system without a trauma treatment team.
223595252|NCT01887353|DRUG|Ranolazine|Patients will take ranolazine 1000 mg tablets twice daily
223747541|NCT02584504|DRUG|Alirocumab|Solution for injection, one subcutaneous injection in the abdomen, thigh, or outer area of upper arm with a disposable auto-injector.
223747542|NCT02584504|DRUG|Placebo|Solution for injection, one subcutaneous injection in the abdomen, thigh, or outer area of upper arm with a disposable auto-injector.
223747543|NCT02584504|DRUG|Atorvastatin|Atorvastatin 5 mg tablet orally.
223747544|NCT02584504|DRUG|Non-statin Lipid-Modifying Therapy|Ezetimibe, Bezafibrate or Fenofibrate at stable dose as background therapy.
223747545|NCT02584504|OTHER|Diet Alone|Stable cholesterol-lowering diet as background therapy.
223595253|NCT01887353|DRUG|Placebo|Placebo pill manufactured to mimic ranolazine 1000 mg tablets. Patients will be instructed to take two pills a day.
223595254|NCT00699335|DRUG|Fentanyl|Fentanyl transdermal patch. This was an observational study - therefore, the physician decided about dosage according to individual needs
223595255|NCT05512780|DRUG|Dalpiciclib|"An exploratory study of a single-arm, open design~All subjects enrolled will receive the following treatment:~Dalpiciclib combined with Letrozole, 28 days as one cycle."
223595256|NCT04581551|PROCEDURE|SWE assessor 1|"SWE for 6 shoulder muscles will be performed.~* m. supraspinatus~* m. infraspinatus~* m. rhomboideus major~* m. deltoideus~* m. pectoralis major~* m. pectoralis minor"
223747546|NCT04659746|DEVICE|MejoraCare|mHealth solution to support remote monitoring of symptoms and patient empowerment through education.
223747547|NCT03810066|DRUG|Osimertinib|All patients will be treated with osimertinib 80 mg/d for one cycle (28 days).
224197359|NCT03864406|DRUG|Cobicistat|Each tablet of Tybost contains 150 mg of cobicistat.
224197360|NCT03864406|DRUG|Darunavir/Cobicistat|Each tablet of Prezcobix contains 800 mg of darunavir and 150 mg of cobicistat.
224197361|NCT03864406|DRUG|Rivaroxaban|Each tablet of Xarelto contains 10 mg of rivaroxaban.
224197362|NCT03204006|DRUG|Dexmedetomidine|Dexmedetomidine preinduction
224197363|NCT03204006|DRUG|sterile saline|normal saline preinduction
224197364|NCT05512585|OTHER|awake prone positioning with advanced respiratory support (high-flow nasal cannula or continuous positive airway pressure)|in this group, healthy subjects will stay in prone position for 20 mins with respiratory support of high-flow nasal cannula or CPAP
224197365|NCT03004612|COMBINATION_PRODUCT|Linagliptin + metformin|Linagliptin-Metformin 2.5/850mg twice daily plus a lifestyle modification program based on nutritional assesment, physical activity prescription and general counseling
224197366|NCT03004612|DRUG|Metformin|Metformin 850mg twice daily plus a lifestyle modification program based on nutritional assesment, physical activity prescription and general counseling
224197367|NCT03664570|DEVICE|VIPUN Balloon Catheter|The VIPUN Balloon Catheter is a nasogastric balloon catheter consisting of a standard nasogastric double lumen Sump catheter and a balloon attached to this catheter. Once the catheter is advanced into the stomach, the balloon can be inflated. The inflated balloon dimensions and intraballoon pressure are such that intragastric motility can optimally be assessed without inducing epigastric symptoms.
224197368|NCT04828980|DEVICE|Oculus Quest: TRIPP|This is a VR experience that focuses on meditation and mindfulness
224197369|NCT04828980|DEVICE|Oculus Quest: Angry Birds|This is an active gaming VR experience that utilizes controllers to aim and launch objects at targets.
224197370|NCT03115320|DRUG|Human chorionic gonadotropin|Human chorionic gonadotropin (Pregnyl, 5000IU) is used in the medication group to confirme the ovulation.
224197371|NCT03115320|OTHER|Home ovulation test|The ovulation in the natural menstrual cycle is confirmed by the home ovulation tests from the urine.
224197372|NCT06537336|DEVICE|QoL|QoL measurements were conducted using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaires-Core30 (EORTC-QLQ-C30).
224197373|NCT06537336|DEVICE|lung function|lung function tests using spirometry
224197374|NCT01828164|DEVICE|Ultrasound|The Aevo System™ is an ultrasound emitting dental device.
224197375|NCT01828164|DEVICE|Sham comparator|Ultrasound not activated in the comparator side of the device.20 minutes per day of ultrasound treatment on the active side of the device. The device consists of a mouth guard type device with transducers embedded in the mouth guard. In the split mouth design, the treatment arm consist of the side of the mouth with the transducers activated while the comparator arm has the transducers deactivated.
224197376|NCT04100902|DRUG|ODACTRA 12 SQ-HDM Sublingual Tablet|Subjects are randomized to either HDM-AIT or Placebo for 24 weeks of therapy
224197377|NCT04100902|DRUG|Placebo sublingual tablet|Subjects are randomized to either HDM-AIT or Placebo for 24 weeks of therapy
224197378|NCT02269800|DRUG|Benzalkonium chloride solution|Tid, 7 days
224197379|NCT02269800|DRUG|Normal saline|Tid, 7 days
224197380|NCT00183170|DRUG|Alcohol|Participants report for their first dosing night where they receive several alcohol/beer drinks sufficient to raise their BrAC to 0.10 g%. Participants are breath-tested after completing their required dose. Participants return in a week for the 2nd session and receive placebo drinks. Participants are breath-tested after completing their placebo drinks.
224197381|NCT00183170|OTHER|Placebo|Participants report for their first night where they receive several placebo drinks. Participants are breath-tested after completing their placebo drinks. Participants return in a week for the 2nd session and receive alcohol drinks sufficient to raise their BrAC to 0.10 g%. Participants are breath-tested after completing their required dose.
224197382|NCT02784028|OTHER|SGM-101|Administration of SGM-101 prior surgery
224197383|NCT00830011|BEHAVIORAL|cognitive behavioral therapy|Ten sessions of manualized CBT delivered by a PhD level psychologist
224197384|NCT00830011|OTHER|standard medical care|any care recommended by physician for treatment of diabetic neuropathy including medication.
224197385|NCT00761969|OTHER|Implementation of the European Guidelines on cardiovascular Disease Prevention in Clinical Practice|Life-style modification advice and prescribing standard cardioprotective medication (antiplatelet agents, statins, antihypertensive agents) according to the European Guidelines on Cardiovascular Disease Prevention in Clinical practice.
224197386|NCT05804123|DRUG|0.9% NaCl physiological saline Nasal-spraying|0.9% NaCl physiological saline is prepared by extracting 5 mL from 0.9% NaCl intravenous infusion 500 mL PP bottle (B.Braun, Germany, product declaration No. VD-32732-19), and then pouring it into the same opaque plastic spraying 10 mL-bottle that is used for LiveSpo Navax.
223506317|NCT03492268|BIOLOGICAL|BCMA-CART|After a conditioning therapy, each patient will receive a treatment of BCMA-CART originated from their own peripheral blood mononuclear cells
223506318|NCT02645162|BEHAVIORAL|Community-based Preschool|"* Preschool sessions in community-based preschool~* Run by trained community youth leaders from the same village."
223506319|NCT03950388|BEHAVIORAL|Intervention|Wards randomly assigned to receive the intervention will have a Band 8a Psychologist based on the ward for 0.5FTE for 7 months. During this time, all patients will be involved with the proposed stepped model of care intervention at one of three levels. The level the patient receives will be decided by the multidisciplinary ward team. At Step one, all patients will have a psychological formulation developed by the psychologist in conjunction with the patient or members of the ward team. At Step 2, all qualified nurses will be trained and supervised to deliver guided self-help material of psychological interventions targeting key problem areas for patients. At Step 3, patients will be offered up to 16, one-to-one therapy sessions with the psychologist.
223747548|NCT03102918|DRUG|Cannabidiol|Participants will receive either up to 800 mg Epidiolex over a 6-week treatment period.
223747549|NCT03102918|DRUG|Placebo|Participants will receive placebo over a 6-week treatment period.
223747550|NCT01716013|DEVICE|BondEase|topical skin adhesive
224197387|NCT05804123|COMBINATION_PRODUCT|LiveSpo Navax®|In Vietnam, LiveSpo Navax® is manufactured as a Class-A medical device product (Product declaration No.210001337/PCBA-HN) under manufacturing standards approved by Hanoi Health Department, Ministry of Health, Vietnam (Certificate No YT117-19) and ISO 13485:2016
223506320|NCT04677036|OTHER|No intervention is given|No intervention given
223506321|NCT03598764|PROCEDURE|Classic head extraction during Cesarean section|by putting the fingers of the right inside the lower uterine segment to deliver the head
223506322|NCT03598764|PROCEDURE|External pop out technique|The palmar aspect of the fingers will be resting on the uterovesical peritoneal reflection not directly on the fetal head.
223506323|NCT04903509|DRUG|BI 1820237|BI 1820237
223506324|NCT04903509|DRUG|Placebo|Placebo
223506325|NCT04903509|DRUG|Saxenda®|Saxenda®
223506326|NCT04903509|DRUG|Paracetamol-ratiopharm®|Paracetamol-ratiopharm®
223506327|NCT02103946|PROCEDURE|Serratus Anterior Muscle Plane block (SAM block)|The US probe is placed in the mid-axillary line at level of the 6th intercostal space. From caudal to cranial, an in-plane approach, the block needle is inserted until the tip is placed between SAM and intercostal muscles and the LA injection will be visualized in real-time. The injection usually consists of 0.4ml/kg of bupivacaine 0.25% plus adrenaline (5ug/ml). Intraoperatively, all subjects will receive a general anesthetic using inhaled anesthetic and oxygen. Intravenous fentanyl will be administered for cardiovascular stability to noxious stimuli.For postoperative analgesia, all subjects will receive oral acetaminophen. Patients will receive a ketorolac IV injection then morphine as a rescue analgesic for breakthrough pain.
223506328|NCT02103946|PROCEDURE|Paravertebral Block|After skin preparation and sterile draping applied. Target paravertebral space will be located using US guidance. The paravertebral space between the third and fourth thoracic vertebrae will be identified in a parasagittal view approximately 3 cm lateral to midline on the side of surgery. A local anesthetic skin wheal will be raised caudal to the ultrasound transducer. A 17-gauge, Tuohy-tip needle will be inserted through the skin wheal in-plane beneath the ultrasound transducer and directed to the paravertebral space. Normal saline (5 mL) will be injected via the needle to help identify the paravertebral space and observe the pleura being displaced anteriorly. 0.4 ml\\kg of 0.25% Bupivacaine with epinephrine, 5 μg/mL, will be slowly injected with gentle aspiration every 3 mL.
223506329|NCT05483634|DRUG|Vaginal estrogen supplement|Daily vaginal estrogen supplement, then twice per week. Continue for three months.
223506330|NCT05483634|PROCEDURE|Platelet-rich plasma injection|Monthly platelet-rich plasma injection for three months
223506331|NCT05484557|DRUG|Apixaban|treatment for 6 to 12 weeks
223506332|NCT05484557|DRUG|Enoxaparin Sodium|treatment for 6 to 12 weeks
223506333|NCT03116867|OTHER|sonosalpingography|transvaginal ultrasound with saline infusion
223506334|NCT02507999|DEVICE|Flotrac|Flotrac guided intervention
223506335|NCT06473428|BEHAVIORAL|respiratory muscle training|Inspiratory muscle training with two sessions per day, five repetitions per session, six days a week for eight weeks.
223506336|NCT06473428|BEHAVIORAL|Expiratory Muscle Training|Expiratory muscle training with two sessions per day, five repetitions per session, six days a week for eight weeks.
223506337|NCT06473428|BEHAVIORAL|Placebo-Controlled Expiratory Muscle Training|Placebo-controlled expiratory muscle training with two sessions per day, five repetitions per session, six days a week for eight weeks.
223506338|NCT01208909|PROCEDURE|diagnostic 5-ALA and MRI for tumor resection|diagnostic 5-ALA and MRI for tumor resection
223506339|NCT00481104|DRUG|Tesofensine|
223506340|NCT06331481|OTHER|Fullicular fluid for cytology and biocemical analysis|"The fullicular fluid in the oocyte retrieval process is consider to medical waste. This fluid contains a verity of proteins, mitochondria and verity of cells.~The investigators using this fluid to learn about the evironment of the oocyte and its quality."
223506341|NCT05357378|DEVICE|Hip Innovation Technology Reverse Hip Replacement System|Implantation of the Investigational Device is performed using standard surgical procedures for THA, as described in the Instructions for Use (IFU). The control hip systems will be implanted in accordance with their respective IFU, which are also in line with standard surgical approaches for THA.
223595257|NCT04581551|PROCEDURE|SWE assessor 2|"SWE for 6 shoulder muscles will be performed.~* m. supraspinatus~* m. infraspinatus~* m. rhomboideus major~* m. deltoideus~* m. pectoralis major~* m. pectoralis minor"
223595258|NCT04581551|PROCEDURE|Stretch intervention|Transversal stretch of pectoralis major muscle on the hemiplegic side.
223595259|NCT04581551|PROCEDURE|No stretch intervention|Passive mobilisation of the hemiplegic hand.
223595260|NCT00083135|BIOLOGICAL|filgrastim|
223595261|NCT00083135|PROCEDURE|autologous bone marrow transplantation|
223595262|NCT00083135|PROCEDURE|peripheral blood stem cell transplantation|
223595263|NCT00083135|RADIATION|iobenguane I 131|
223595264|NCT00049660|DRUG|capecitabine|
223595265|NCT00049660|DRUG|vinorelbine tartrate|
223595266|NCT01069705|DRUG|Tobramycin inhalation powder|Tobramycin dry powder for inhalation in capsules administered by the T-326 inhaler.
223595267|NCT00441805|DEVICE|Radio Frequency|
223595268|NCT00292539|DEVICE|Any pacemaker with right ventricular pacing option|
223595269|NCT03989401|OTHER|Multimedia video health education|The experimental group conducted multimedia video education while admission.
223595270|NCT06190080|OTHER|Digestive endoscopy|Digestive endoscopies are performed in the operative room under general anaesthetic 3 months after the introduction or change of treatment. Biopsies of the upper, middle and lower thirds of the esophagus will be taken and analyzed for pathology.
223595271|NCT02772185|DEVICE|active tDCS|Duration: 30 minutes; Intensity: 2 mA; Placement:left and right parietal cortex, left and right DLPFC, left inferior frontal gyrus and left superior temporal gyrus
223595272|NCT02772185|DEVICE|sham tDCS|The procedure is the same as for active tDCS, but the in the placebo tDCS the stimulation is non-active / sham.
223595273|NCT02772185|BEHAVIORAL|real CT|Cognitive tasks designed to relate to the region of the brain being stimulated (left and right parietal cortex, left and right DLPFC, left inferior frontal gyrus and left superior temporal gyrus).
223595274|NCT02772185|BEHAVIORAL|placebo CT|Videos (short films) will be presented during the neurostimulation
223595275|NCT02258113|DEVICE|Ocusweep|A novel reaction-time based visual field device.
223595276|NCT02258113|DEVICE|Ocusweep OcuRT|Vision based choice reaction time test method
223595277|NCT00451516|DRUG|Herbal medicine (St. John's wort and Kava)|
223747551|NCT01716013|PROCEDURE|CWCD|traditional closure methods of sutures, staples or adhesive strips
224310844|NCT00956800|OTHER|Accu-Chek 360 software|Study group which will receive 3 routine office visits in the same time, and have two visits conducted by computer interaction, using the Accu-Chek 360 software.
224197388|NCT05804123|DRUG|Augmentin 500Mg Tablet|Augmentin (GlaxoSmithKline Pte, product declaration No. VN-20169-16) is an oral antibiotic available in the form of 625 mg tablets, which are prescribed as routine treatment for children and adults, respectively.
224197389|NCT05804123|DRUG|Acetylcysteine|Acetylcysteine 200 mg (STADA Vietnam, product declaration No. VD-22667-15) is an oral expectorant, which is prescribed as routine treatment for children and adults, respectively.
224197390|NCT05804123|DRUG|Xylometazoline Nasal|Otrivin (Xylometazoline 0.05%) (Novartis VietNam, product declaration No. VN-15558-12) is a nasal-spraying decongestant, which is prescribed as routine treatment for children and adults, respectively.
224197391|NCT05804123|DRUG|Cefotaxime|Imetoxim 1g (Cefotaxime 1g) (Imexpharm Pharmaceutical, product declaration No. VD-26846-17) is an injection or infusion-administrative antibiotic, which is prescribed as routine treatment for children.
224197392|NCT05804123|DRUG|Ciprofloxacin|Ciprofloxacin 0.3% (Vidipha Central Pharmaceutical, product declaration No. VD-15205-11) is an antibiotic ear drop, which is prescribed as routine treatment for children.
224197393|NCT06604806|PROCEDURE|PENG Block|With the patient in the supine position, the ultrasound probe is placed transversely over the anterior superior iliac spine (ASIS). After identifying the ASIS, the transducer is aligned with the pubic ramus and rotated approximately 45 degrees to become parallel to the inguinal crease. The transducer is moved medially until the anterior inferior iliac spine (AIIS), iliopubic eminence (IPE), and psoas tendon are clearly visualized as anatomical landmarks. After confirming the correct location with saline injection, 50 mg of 0.25% bupivacaine will be administered.
224310845|NCT00956800|OTHER|Normal care|Control group will receive 5 routine office visits in one year
223506342|NCT05357378|DEVICE|Already-marketed semi-constrained uncemented hip systems using a metal-on-XLPE or ceramic-on-XLPE bearing combination.|"Control Arm subjects will receive one of the already-marketed semi-constrained uncemented hip systems using a metal-on-XLPE or ceramic-on-XLPE bearing combination.~* DePuy Synthes CORAIL® or DePuy Synthes ACTIS™ Total Hip System in combination with DePuy Synthes PINNACLE™Complete Acetabular Hip System.~* Zimmer Biomet Taperloc®, Zimmer Z1™ Cementless Femoral Hip Stem System or Zimmer Biomet AVENIR® Complete Hip System in combination with Zimmer Biomet G7® Acetabular System.~* Stryker Accolade® II femoral stem in combination with Stryker Trident® II acetabular cup.~* Smith \& Nephew ANTHOLOGY® Total Hip System in combination with Smith \& Nephew R3® Acetabular System"
223506343|NCT06392191|PROCEDURE|Rhombic intercostal nerve block(Received liposomal bupivacaine 93 mg and bupivacaine 25 mg diluted to 20 ml)|The patient was placed in lateral recumbency and placed medial to the medial border of the scapula in the oblique sagittal plane using a line array ultrasound probe to identify ultrasound landmarks, trapezius, obliques, intercostals, pleura, and lungs, The block needle was then entered in-plane at the T5 level, with the margins retracting on insertion, and the nerve block perforating needle was imaged and then inserted into the fascial gap between the trapezius and the external intercostal muscles. Receive liposomal bupivacaine 93 mg and bupivacaine 25 mg diluted to 20ml.
223506344|NCT06392191|PROCEDURE|Rhombic intercostal nerve block(Receive standard bupivacaine 105 mg diluted to 20 ml with dexamethasone 5 mg.)|The patient was placed in lateral recumbency and placed medial to the medial border of the scapula in the oblique sagittal plane using a line array ultrasound probe to identify ultrasound landmarks, trapezius, obliques, intercostals, pleura, and lungs, The block needle was then entered in-plane at the T5 level, with the margins retracting on insertion, and the nerve block perforating needle was imaged and then inserted into the fascial gap between the trapezius and the external intercostal muscles. A mixture of standard bupivacaine 105 mg diluted to 20 ml with dexamethasone 5 mg was received.
224197394|NCT06604806|PROCEDURE|Quadro-Iliac plane block|With the patient in the prone position, a low-frequency convex transducer (2-6 MHz) and a 22G x 100 mm peripheral nerve block needle (Stimuplex® Ultra 360®, B-Braun) will be used. The transducer will be placed transversely at the L3 level to identify the spinal processes, followed by lateral movement to visualize the transverse process within the erector spinae muscle. The transducer will then be rotated parasagittally and moved caudally to locate where the Quadratus Lumborum muscle (QLM) attaches to the iliac crest. After confirming the location with saline, 50 mg of 0.25% bupivacaine will be administered under the fascia of the QLM.
224310846|NCT04990700|PROCEDURE|Partial rib resection|1 cm partial rib resection during thoracotomy opening
224310847|NCT03323437|DRUG|Risperidone|Participants will meet with a study doctor physician once per week (about 3 times total) to monitor progress and side-effects of risperidone, which includes taking 4 assessments each time. After 4 weeks of taking Risperidone, participant will be assessed and scanned with the MRI/MRS scanner again.
224310848|NCT05379907|OTHER|SIGNATERA™ ctDNA testing|Information collection about how SIGNATERA™ ctDNA testing changes how doctors make treatment recommendations to patients with early-stage pancreatic cancer.
224310849|NCT00372151|DIETARY_SUPPLEMENT|L-Theanine|400 mg/day, caps.
224310850|NCT00372151|OTHER|Placebo|caps.
224310851|NCT03214029|DIAGNOSTIC_TEST|Cardiac troponin testing|Fresh EDTA plasma samples will be measured with both the hs-cTnI (Abbott) and hs-cTnT (Roche) assays.
223595278|NCT06474403|PROCEDURE|standard Sugarbecker's operation|Eligible candidates who have developed parastomal hernias following stoma creation and consented to the study will undergo laparoscopic TEP repair. The procedure involves an initial unilateral transrectal incision followed by the creation of an preperitoneal or retro-rectus space where a mesh is positioned to reinforce the abdominal wall and the stoma. Also it will has was formed oblique hernia canal. The operative and postoperative outcomes of these patients will be studied in comparison with control group treated with the traditional Sugabecker's operation.
223595279|NCT06474403|PROCEDURE|modified Sugarbecker's operation|Eligible candidates who have developed parastomal hernias following stoma creation and consented to the study will undergo laparoscopic TEP repair. The procedure involves an initial unilateral transrectal incision followed by the creation of an preperitoneal or retro-rectus space where a mesh is positioned to reinforce the abdominal wall and the stoma. Also it will has was formed oblique hernia canal. The operative and postoperative outcomes of these patients will be studied in comparison with control group treated with the traditional Sugabecker's operation.
223747552|NCT02506335|DRUG|Cholate testing|The patient receives simultaneously an oral dose of d4-cholate and an IV dose of 13C-cholate, which are stable isotopes; there is no radioactivity or radiation exposure.
224197395|NCT01785199|PROCEDURE|Head elevation by an automatic adjustable bed|The automatic device is initiated when the patient suffers from apnea ≥ 10 seconds, which is detected by an ultra-wideband (UWB) sensor placed under the bed. The head will be slightly elevated at an angle of 10 degrees lasting 10 seconds and then be put down softly.
224197396|NCT04540172|BEHAVIORAL|Music Therapy|"Mahur tune, one of the nonverbal instruments of the Traditional Turkish Music Authorities, was selected for the study with the opinion of a music therapy specialist."
224197397|NCT04540172|BEHAVIORAL|Progressive Muscle Relaxation Exercise|"In this study, the steps of applying progressive muscle relaxation exercise were created with the guidance of the Relaxation Exercises  materials of the Turkish Psychological Association."
223595280|NCT05385250|OTHER|Bone sparring radiotherapy|Observation of late side effects from the pelvic bones after bone-sparring radiotherapy for anal cancer
223595281|NCT01879969|PROCEDURE|classic procedure of planning|analysis of pictures, 2D radiographs and aesthetics; model surgery and acrylic splint
223595282|NCT01879969|PROCEDURE|computer assisted orthognathic planning and surgery of asymmetric patients|
223595283|NCT02760316|DRUG|AZD9567 10 mg|Oral suspension Multiple doses 5 days of treatment Once daily
223595284|NCT02760316|DRUG|AZD9567 20 mg|Oral suspension Multiple doses 5 days of treatment Once daily
223747553|NCT01138280|DEVICE|CWP 103H (Gambro, Sweden): a heat disinfection device|Heat disinfection can increase temperature to 95c in the RO water treatment system and then in the piping system link to dialysis machines in each hemodialysis center per night
223747554|NCT01785576|BEHAVIORAL|Couple-Based CBT Intervention|Patients and partners will receive 4 sessions of a couple-based cognitive behavioral intervention focusing on communication and spousal support.
223747555|NCT04777539|OTHER|At-home natalizumab treated MS patient|"MS patient who are treated with natalizumab in at-home hospitalization (HAD) setting / according at-home hospitalization program"
223747556|NCT05433779|DEVICE|Neosense Umbilical Catheter|The Neosense umbilical catheter is used instead of the routinely used umbilical catheter
223747557|NCT00898703|OTHER|flow cytometry|
223747558|NCT00898703|OTHER|immunoenzyme technique|
224197398|NCT05952570|DIETARY_SUPPLEMENT|oral protein nutritional supplement (Fresubin protein powder)|50 patients will receive oral protein nutritional supplement (Fresubin protein powder 25mg/5scoops per hemodialysis session) 1 hour before the start of the session (predialytic) for 3 months
224197399|NCT05952570|OTHER|routine nutrition regimen|50 patients will receive a routine nutrition regimen for 3 months. (control group)
223595285|NCT02760316|DRUG|AZD9567 40 mg|Oral suspension Multiple doses 5 days of treatment Once daily
223595286|NCT02760316|DRUG|AZD9567 80 mg|Oral suspension Multiple doses 5 days of treatment Once daily
223595287|NCT02760316|DRUG|Prednisolone 20 mg|Oral Multiple doses 5 days of treatment Once daily
223595288|NCT02760316|DRUG|AZD9567 125 mg|Oral Multiple doses 5 days of treatment Once daily
223595289|NCT02760316|DRUG|AZD9567 155 mg|Oral Multiple doses 5 days of treatment Once daily
223595290|NCT02760316|DRUG|Prednisolone 5 mg|Oral Multiple doses 5 days of treatment Once daily
223595291|NCT02760316|DRUG|Prednisolone 40 mg|Oral Multiple doses 5 days of treatment Once daily
224197400|NCT02778269|DEVICE|12-lead ECG T-shirt|The 12-lead ECG T-shirt system consists of three parts: the recording device, amplifier boards and the T-shirt.The T-shirt has 10 textile ECG electrode patches. The patches should be in contact with the patient's skin to record the electrical activity of the heart. The electrodes are made of electrically conductive textile. They are sewn into the inside of the T-shirt and are padded with foam. The cables to the device can be attached to snap fasteners on the outer side of the T-shirt on the ECG electrode patches.
224197401|NCT02778269|DEVICE|Dexcom G4-System|Continuous Glucose Monitoring
223595292|NCT01512992|PROCEDURE|Home telehealth|"Patients receive tailored intervention according to their clinical complexity.~All patients in the intervention group receive:~* Personalised care plan~* Education on self-management~* Access to a personalized online health folder~* Access to Call center~* Access to primary care and hospital specialists; follow-up visits for evaluation of clinical recovery and care plan adjustments (if needed).~Patients with LOW complexity additionally receive:~* Daily videoconferences for the 1st week after discharge~* Remote monitoring for respiratory parameters. Sensors are selected on an individual basis by the medical specialists.~Patients with HIGH complexity additionally receive:~* Videoconferences for at least 1 month after discharge, scheduled on an individual basis.~* Remote monitoring for respiratory parameters.~* One monthly phone call from the call centre to promote and assess patient self-management."
223595293|NCT05607862|OTHER|Home Physiotherapy Group|The intervention group will receive 2 sessions per week for 8 weeks supervised and assisted by a physiotherapist at the patient's home. Muscle strengthening exercises of the lower and upper limbs, stretching, coordination and balance exercises, gait re-education with the relevant technical aids, a pattern of exercises to be performed daily by the patient and health education guidelines will be carried out.
223595294|NCT05607862|OTHER|Control Group|The control group will be given health education guidelines and will continue with their usual medical-pharmacological treatment. All patients included in this study will receive physiotherapy treatment, and those in the control group will be treated once the intervention and the post-intervention assessment have been completed.
223747559|NCT00898703|OTHER|laboratory biomarker analysis|
223747560|NCT06579586|BEHAVIORAL|Survey study|The Parent's State and Trait Anxiety Inventory (STAI), Anxiety Sensitivity Index-3 (AS-3), and Pain Catastrophising Scale for Parents (PPS-PPS) were completed one day before the operation to measure anxiety level.
223747561|NCT01268384|DRUG|Gemcitabine plus Capecitabine|Gemcitabine 1,250 mg/m2 mixed with 0.9% saline 500 ml i.v. for 10 mg/m2/min on D1 and D8 Capecitabine 950 mg/m2 b.i.d. po from D1 to D14 every 21 days
223747562|NCT01469286|DEVICE|TEA|Electroacupuncture at ST36
223747563|NCT01469286|DEVICE|Sham-TEA|Electroacupuncture at sham-points
223747564|NCT04332328|DIETARY_SUPPLEMENT|Diet|Group of diet types
223747565|NCT01458899|DRUG|TC-5214|Oral tablets, single 4mg dose
223747566|NCT04765358|OTHER|Virtual Clinic|CGM, Clinical Care Support and Behavioral Health Support
223747567|NCT02731729|DRUG|ipilimumab|
223747568|NCT02731729|DRUG|nivolumab|
224197402|NCT03940898|DEVICE|repetitive transcranial magnetic stimulation|"There are two types of stimulation equipment, one is the transcranial magnetic stimulator model Magpro X100 produced by Danish Medtronic, and the other is the CCY-I TMS stimulator produced by Wuhan Eride, model B9076. The stimulating magnetic head uses an 8 shaped coil, and the stimulation site is the cerebellar vermis (ie, 1 cm below the occipital bulge), and the stimulation intensity is 100% of the motor threshold.The base frequency of the iTBS mode is 5 Hz, and one short burst stimulus occurs every 200 milliseconds. In each short array, three single pulses with a frequency of 50 Hz are buried, and each 10 short burst stimulation intervals are 8 seconds, for a total of 200 short burst stimulations. The total number of stimulation pulses is 600 per day.It takes 3 minutes and 20 seconds to complete one intervention. All participants were intervened once a day for 5 times a week for 2 weeks for a total of 10 times."
223747569|NCT04625608|DRUG|Paracetamol|Standard care of 3 ml/kg water, plus 15 mg/kg oral paracetamol suspension, a minimum of 1 hour prior to the induction of general anaesthesia.
223747570|NCT04625608|OTHER|Standard care|Standard care of 3.6 ml/kg water, a minimum of 1 hour prior to the induction of general anaesthesia.
223747571|NCT05658744|BEHAVIORAL|Video group|Insulin administration video was sent to the mobile phones of the patients assigned to the video group
223747572|NCT03073096|PROCEDURE|LVA at time of nodal dissection|Patients will receive a lymphatic-venous anastomosis at time of their required nodal dissection
223747573|NCT05850650|OTHER|Application of a collagen sponge after surgical extraction of impacted 3rd molar|Application of a collagen sponge after surgical extraction of impacted 3rd molar
223747574|NCT05850650|OTHER|No collagen sponge application after surgical extraction of impacted 3rd molar|No collagen sponge application after surgical extraction of impacted 3rd molar
223747575|NCT03839589|BEHAVIORAL|Mindfulness Based Stress Reduction Adapated (MBSR-A)|Mindfulness-based stress reduction (MBSR) is a group-based intervention developed in 1979 by Dr. Jon Kabat-Zinn to provide mindfulness training in order to decrease stress and improve overall well-being. MBSR has been shown to be effective for a series of patient outcomes including depression, anxiety disorders, sleep disorders, and chronic pain management. MBSR is a structured intervention delivered through an 8-week course of up to 30 participants who meet for 2.5 hours per week.
223747576|NCT02627612|BEHAVIORAL|Pro Vetus|Volunteer mentors (a mix of Veterans and non-Veterans) in the civilian community work with transitioning Veterans for approximately four months within five transition domains (1. Employment/Education, 2. Housing, 3. Family and Legal, 4. Social/Community/ Physical Fitness and 5. Medical Care).
223747577|NCT02627612|BEHAVIORAL|Team Red, White, and Blue (TM RWB)|TM RWB is a 501(c)(3) non-profit, Veteran support organization found in 2010. Its mission is to enrich the lives of America's Veterans by connecting them to their community through physical and social activity. Central to TM RWB's mission is that inspiring Veterans to become physically active will create opportunities to establish authentic connections to other Veterans, active duty military, and civilians as well as improve the chances for continued successful integration. Enrollment in TM RWB takes place by simply signing up online and providing a name, email address, and zip code (teamrwb.org). TM RWB is not designed as a mental health intervention.
224197403|NCT01465594|PROCEDURE|transurethral catheter after EERPE/ RALP|transurethral catheter after EERPE/ RALP
224197404|NCT01465594|PROCEDURE|suprapubic catheter after EERPE /RALP|suprapubic catheter after EERPE /RALP
224197405|NCT01743495|BEHAVIORAL|10 home-based functional services sessions over 4 months.|The program consists of up to 10 home-based functional services sessions over 4 months.
224197406|NCT02351050|DEVICE|Sonolysis|continual transcranial Doppler monitoring of middle cerebral artery
224197407|NCT02351050|OTHER|Sham procedure|sham transcranial Doppler monitoring of middle cerebral artery
224197408|NCT00399204|DRUG|Pioglitazone vs Metformin|
223506345|NCT00675363|PROCEDURE|Protocolized Sedation|Nurse-directed protocol for administering sedation and/or analgesia.
223506346|NCT00675363|PROCEDURE|Protocolized sedation, with daily interruption|Nurse-directed protocols for administering sedation and/or analgesia, with daily interruption of sedation/analgesia
223506347|NCT04689009|DEVICE|EmoLED|The treatment with EmoLED, in addition to the SOC, will be performed during each visit for 60 seconds on each 5 cm diameter sub-area of the selected lesion.
223506348|NCT04689009|PROCEDURE|current Standards Of Care|"The lesions will be cleansed with saline solution and, if necessary, surgical debridement will be performed with the most suitable method. At this point, if patient is included in EmoLED Group, the EmoLED treatment starts. After EmoLED application (EmoLED Group) or after cleansing (SOC Group), a polyurethane foam dressing will be applied on the lesion. In case of clinical signs of infection, a silver dressing will be applied.~Then an elasto-compressive double layer dressing of the limb with cohesive fixation bielastic latex-free bandage will be carried out."
223506349|NCT02187055|DRUG|Tofacitinib with methotrexate|Tofacitinib 5 mg twice daily, oral for 12 months Methotrexate (previous stable dose 15-25 mg) every week, oral for 12 months Placebo for adalimumab every other week, subcutaneous for 12 months
223506350|NCT02187055|DRUG|Tofacitinib without methotrexate|Tofacitinib 5 mg twice daily, oral for 12 months Placebo for methotrexate (previous stable dose) every week, oral for 12 months Placebo for adalimumab every other week, subcutaneous for 12 months
223506351|NCT02187055|BIOLOGICAL|Adalimumab with methotrexate|Placebo for tofacitinib twice daily, oral for 12 months Methotrexate (previous stable dose 15-25 mg) every week, oral for 12 months Adalimumab 40 mg every other week, subcutaneous for 12 months
223506352|NCT01718067|DEVICE|VAKÜM system|15 minutes, twice a day.
223506353|NCT01718067|OTHER|conventional manual ELTGOL technique|20 minutes twice a day
223506354|NCT02269605|OTHER|Placebo|Group 1: Placebo (sodium chloride 0.8 %) at single dose
223506355|NCT02269605|DRUG|Bryostatin 1 (10ug/m2)|Group 2: Bryostatin 1 (10ug/m2) at single dose
223506356|NCT02269605|DRUG|Bryostatin 1 (20ug/m2)|Group 3: Bryostatin 1 (20ug/m2) at single dose
223506357|NCT02673385|OTHER|Brazelton scale|
223506358|NCT03044288|OTHER|New adhesive strip|This is a strip made of a newly developed adhesive. This adhesive might in the future be part of an ostomy product.
223506359|NCT03044288|OTHER|Standard adhesive strip|this is a standard adhesive strip (hydrocolloid). This adhesive is currently used in marketed ostomy devices.
223506360|NCT03808454|DRUG|PRP|The investigators draw 10cc of blood and concentrate the blood to get the platelet rich plasma
223506361|NCT03808454|OTHER|Rehabilitation|strengthening ex, posture training,...
223747578|NCT03548012|BEHAVIORAL|The Carer Support Needs Assessment Tool (CSNAT) intervention|The CSNAT intervention is a caregiver-led approach where the caregiver first identifies his/her needs of support in the CSNAT, which consists of 14 support domains. Then the practitioner facilitates the intervention where the caregiver prioritizes which domains to discuss. In the conversation, the caregiver's domain priorities and subsequently identified support needs are discussed with the practitioner to agree on actions/solutions and a shared action plan. The intervention will be offered each caregiver twice: the first time between 0 and 13 days after enrollment, and the second time between 15 and 27 days after enrollment.
223506362|NCT03808454|COMBINATION_PRODUCT|PRP+Rehabilitation|combine PRP and Rehabilitation
223506363|NCT04891653|DRUG|BR790|Subjects will receive oral administration of BR790.
223506364|NCT03384485|DIAGNOSTIC_TEST|antiphospholipid syndrome|blood test for enzyme test,plasma and Lys-3-3 plasma
223506365|NCT06126575|DRUG|Elacestrant dihydrochloride|A single oral dose of 200 mg elacestrant (2 x 100 mg tablets).
223506366|NCT05249465|BEHAVIORAL|Core behavioral weight loss intervention|"All participants will receive a 6-month core behavioral obesity treatment consisting of goal setting, behavioral lessons, action plans, and tailored feedback - all of which will be delivered remotely."
223506367|NCT05249465|BEHAVIORAL|Self-monitoring diet|Participants randomized to receive this component will be instructed to self-monitor their dietary intake daily via the Fitbit mobile app. Participants will receive a daily calorie goal.
223506368|NCT05249465|BEHAVIORAL|Self-monitoring weight|Participants randomized to receive this component will be instructed to self-monitor their body weight daily via a wireless e-scale (e.g., the Fitbit Aria Scale).
223506369|NCT05249465|BEHAVIORAL|Self-monitoring steps|Participants randomized to receive this component will be instructed to self-monitor their step count daily via a wrist-worn Fitbit activity monitor. A daily step goal will be given that will adapt based on progress.
223506370|NCT00090428|BEHAVIORAL|Gluten- and casein-free diet|Participants will follow a gluten-free and casein-free diet for 18 weeks. All children received individual EIBI interventions to decrease the confound of different types of therapies.
223506371|NCT00090428|BEHAVIORAL|Placebo controlled diet|Participants will follow a gluten-free and casein-free diet for 18 weeks. They will receive double blind placebo controlled challenge snacks that contain gluten, casein, gluten+casein or placebo with measurement of response. They remain on the gluten free and casein free diet for the entire study period.
223506372|NCT04939935|DRUG|Metformin XR|Extended release metformin.
223506373|NCT04939935|OTHER|Control|Placebo is inactive tablets that is identical to the intervention Metformin tablets.
223506374|NCT06342752|DIAGNOSTIC_TEST|Breath test|Early detection of volatile organic compounds (VOCs) in breath from preterm infants, collected at several timepoints within the first 4 weeks of life to predict BPD before diagnosis is made at 36 weeks PMA.
223506375|NCT06342752|OTHER|Throat swabs|A throat swab will be taken on several timepoints within the first 4 weeks of life to detect airway mucin expression. A second throat swab will be taken as proxy for the airway microbiome.
223506376|NCT06342752|OTHER|Placental samples|After birth, placental biopsies will be collected for headspace VOCs analysis. A placental swab and a biopsy will be taken for microbiome analysis.
223506377|NCT06342752|OTHER|Vaginal swab|A vaginal swab will be taken before birth for microbiome analysis.
223506378|NCT06342752|OTHER|Endotracheal aspirates|Collection of aspirates, as part of routine care, to detect mucin expression and the lung microbiome.
223506379|NCT02563431|DEVICE|SYSTAM - SP-ED|"* Positioning in bed, wheelchair and standing with classics materials (pillow, holds, sling) on day J0 until J7 or Exit.~* Daily passive mobilisation of the upper member by a therapist.~* Be careful of shoulder's coaptation in care and functional activities (toilet, dressing, transfers)"
223506380|NCT02563431|DEVICE|Ultrasling ER 15°Donjoy - 4P-ED|"* Positioning in bed, wheelchair and standing with specific materials (holds, sling in external rotation and abduction) on day J0 until J7 or Exit.~* A training of the patient and members of family on pathology, risk, use of material~* Daily passive mobilization of the upper member by a therapist.~* Be careful of shoulder's coaptation in care and functional activities (toilet, dressing, transfers) and active patient training for use the other side for support hemiplegic shoulder to prevent diastasis."
223506381|NCT02455011|BIOLOGICAL|REMD-477|
223506382|NCT02123875|OTHER|Physiotherapy|
223506383|NCT02123875|OTHER|Control arm|Routine hospital based physiotherapy
223506384|NCT05737745|BEHAVIORAL|Self-monitoring|Tracking physical activity and fruit/vegetable intake.
223506385|NCT05737745|BEHAVIORAL|Group-dynamics|Survivors act as team captains, facilitating interactions between themselves and their support team members and providing goal directed feedback.
223506386|NCT05737745|BEHAVIORAL|Weekly virtual sessions- Standard|Weekly 30 minute virtual sessions include support group/team building sessions and 15 minutes of physical activity.
223506387|NCT05737745|BEHAVIORAL|Newsletters- Standard|Weekly newsletters support attainment of physical activity and nutrition goals.
223506388|NCT05737745|BEHAVIORAL|Newsletters- Yoga|Weekly newsletters support attainment of physical activity and nutrition goals, while including mindfulness principles.
223506389|NCT05737745|BEHAVIORAL|Weekly virtual sessions- Yoga|Weekly 30 minute virtual sessions include support group/team building sessions and 15 minutes of yoga.
223506390|NCT03626675|PROCEDURE|phaco- trabeculectomy|combined phaco-trabeculectomy surgery
223506391|NCT00859846|PROCEDURE|Arterial line placement|"The following measures will be collected and compared.~1. Time (in seconds) required for successful placement of the arterial line. This is the time elapsed between either palpation or placement of ultrasound probe on the patient's wrist and the successful demonstration of arterial waveform on the anesthesia monitor.~2. number of attempts, defined as forward advancements of needle, required to cannulate the artery.~3. number of separate skin punctures.~4. number of arteries into which entry is attempted."
223506392|NCT02473744|OTHER|subcutaneous drainage|After topic analgesia, three subcutaneous channels are created and an absorbent pad collects the lymphatic fluid.
223506393|NCT01454999|BEHAVIORAL|CTI|Web-based computerized, tailored intervention (CTI) for smoking cessation, based on the transtheoretical model of change.
223506394|NCT00001931|DRUG|N-0923|
224197409|NCT01612988|DRUG|BOMP|"Day-8 OMB prephase:~Ofatumumab 300 mg IV day -8 Methylprednisolone 100 mg TD IV day -8~BOMP cycle 1 and 2 :~Ofatumumab 1000 mg IV day 1 and day 15 Bendamustine 70mg IV day 2 and ady 3 Methylprednisolone 1000 mg/m² IV day 1, 2 and 3 Methylprednisolone 100 mg TD IV day 15~BOMP cycle 3 to 6 :~Ofatumumab 1000 mg IV day 1 Bendamustine 70mg IV day 2 and day 3 Methylprednisolone 1000 mg/m² IV day 1, 2 and 3"
224197410|NCT01353586|DEVICE|nMARQ™ System|The nMARQ™ System is indicated for catheter-based electrophysiological mapping for the treatment of drug refractory recurrent symptomatic paroxysmal atrial fibrillatioon.
224197411|NCT04510558|DEVICE|Stoma closure with non-resorbable mesh (ULTRAPRO Advanced Mesh, Ethicon, Johnson & Johnson) in the sublay position|"* Antibioprophylaxis using cefuroxime and metronidazole~* Standard disinfection and sterile draping~* Circular incision around the stoma using the scalpel blade~* Dissection around the stoma until entering the abdominal cavity~* Closure of the stoma using a linear stapler~* A midline laparotomy may be performed or not~* Realization of an extra-corporeal or intra-corporeal side-to-side handsewn anastomosis~* Closure of the posterior aponeurosis using separate Maxon 2-0 stitches~* Application of an ULTRAPRO Advanced Mesh, Ethicon, Johnson \& Johnson, with +2cm on the edges, secured by 4 stiches of Maxon 2-0~* Closure of the anterior aponeurosis using separate Maxon 2-0 stitches~* No subcutaneous stitches~* Partial purse string skin closure using Monocryl 3-0~* Standard wound dressing"
224310852|NCT04249869|DRUG|VGH-AD1|VGH-AD1 includes Yi-gan-san 3.0g, Huan-shao-dan 1.0g, Danshen(Radix et Rhizoma Salviae Miltiorrhizae) 0.75g, Tian-ma(Rhizoma Gastrodiae) 0.75g, Gou-teng(Ramulus Uncariae Cum Uneis) 0.375g, and Ba-ji-tian(Radix Morindae Officinalis) 0.375g, two times per day, each serving a small packet of 7.5 grams of concentrated granules.
224310853|NCT03086759|PROCEDURE|platelet rich plasm|intra-articular infiltration with platelet rich plasm
224310854|NCT03086759|DRUG|Triamcinolone Hexacetonide|intra-articular infiltration withTriamcinolone Hexacetonide
223506395|NCT04308135|DIAGNOSTIC_TEST|Neuro-radiological tools:|"MRI brain: to measure white matter~c) Ultrasonographic examination of extracranial vessels: The intimal medial thickness of the common carotid artery (CCA-IMT) will be measured in B-mode. The carotid arteries will be evaluated for the presence of atherosclerotic lesions (plaques) either soft or hard .The residual lumen and degree of stenosis will be measured. The peak systolic velocity will be detected."
223506396|NCT04308135|DIAGNOSTIC_TEST|cognitive tests|"All patients will be evaluated for global cognitive assessment by: Montreal Cognitive Assessment (MoCA) (Arabic version) Visuospatial skills will be assessed by Clock Drawing Tests from MoCA test and copy the intersecting pentagons from Addenbrooke's test (Arabic version) Language will be examined by semantic fluency from Addenbrooke's test (Arabic version) and similarities from Wechsler Adult Intelligence Scale (WAIS) Attention will be evaluated by digit span from Wechsler test),and by the number of seconds needed to sequence numbers using a pencil (Trail making test A) from MoCA test . For the evaluation of memory, participants will complete Wechsler memory subset~, and the investigators also will use their three-item recall from the Mini-Mental State Examination( MMSE). Executive functions will be measured by Wisconsin card sorting test and also verbal fluency test from Addenbrooke's test. Frontal Assessment Battery (FAB) scale"
223506397|NCT04308135|DIAGNOSTIC_TEST|lab investigations|Each patient will undergo full lab investigations:\[lipid profile ,complete blood count, uric acid ,Hemoglobin A1c (HbA1c), liver functions, renal functions, and electrolytes\]
223506398|NCT04308135|DIAGNOSTIC_TEST|Beck depression inventory (BDI)(Arabic version)|Clinical Tool for depression
223506399|NCT04308135|DIAGNOSTIC_TEST|Clinical Tools for Urinary symptoms:|the International Consultation on Incontinence Questionnaire-Short Form (ICIQ-SF) Scale (Arabic version)
223506400|NCT04308135|DIAGNOSTIC_TEST|Freezing of gait questionnaire|"Clinical Tools for Gait (in on and off state ), Gait will be assessed by:~* .Freezing of gait questionnaire~* Berg balance scale.~* 10 meter walk test .~* Timed up and go test."
223506401|NCT04308135|DIAGNOSTIC_TEST|non-motor symptoms scales (NMSS).|Clinical Tool for assessment of non-motor symptoms of PD
223506402|NCT04308135|DIAGNOSTIC_TEST|Movement Disorders Society- Unified Parkinson's Disease Rating Scale (MDS-UPDRS):|"Clinical Tools for assessment of the neurological severity and stage of disease Clinical Tool for assessment of the neurological severity and stage of disease during OFF and ON states, Hoehn and Yahr scale. The presence of lower limb parkinsonism will be determined by a two-point difference between upper limb and lower limb scores of bradykinesia, rigidity or postural instability from part III of the MDS-UPDRS. Patients will be examined in the early morning, in 'OFF' state, with MDS-UPDRS, Hoehn and Yahr and freezing of gait questionnaire(FOG-Q) scales. Immediately afterwards, they will take their regular first dose of levodopa. After 1 hour, patients will be examined again with the same tests and scales.~Response to levodopa will be determined as patients who reached a percentage reduction exceeding 25% in part III of the MDS-UPDRS"
223506403|NCT04308135|DIAGNOSTIC_TEST|ELIZA for alpha-synuclein|measuring serum of alpha-synuclein, tau and their autoantibodoies
223506404|NCT04308135|OTHER|transcranial color-coded duplex(TCCD)|TCCD using phase array 2.4 Hz probe for evaluation of cerebral vasomotor reactivity (CVR) by measuring the Breath holding index(BHI),flow velocities and pulsatility index of middle cerebral artery and posterior cerebral artery on both sides.
223506405|NCT04308135|OTHER|extracranial carotid duplex|to assess atherosclerosis, stenosis of carotids
223506406|NCT04308135|OTHER|The Arabic version of Parkinson's Disease Questionnaire( PDQ-39)|Clinical tool for quality of life of PD patients
223506407|NCT04113993|DRUG|Bazedoxifene Acetate|Oral Bazedoxifene dosed at 40 mg daily for 12 weeks
223506408|NCT04113993|DRUG|Placebo|Identically packaged placebo capsule daily
223506409|NCT03100292|OTHER|Sleeve gastrectomy or Roux-en-Y gastric bypass|
223506410|NCT02520466|DIETARY_SUPPLEMENT|flavanol-rich drink vs flavanol-free drink|Patients will be randomized to either a flavanol-rich drink or a flavanol-free drink of similar volume, taste and calory and sugar content
223506411|NCT01972984|DRUG|Anastrozole|Participants will be instructed to take one tablet of anastrozole orally per day with fluids. This tablet will be taken at the same time every day. Participants will be given a drug diary to record drug administration and aid in drug compliance. Should the participant miss a dose they will be asked to record it in their diary and resume the normal dose schedule the next day.
223506412|NCT01044199|BIOLOGICAL|PCEC rabies vaccine given intradermally|PCEC rabies vaccine will be given intradermally compared with intramuscular administration (standard), in 2 different schedules: Pre-Exposure schedule for participants never vaccinated against rabies before; and Booster schedule for participants vaccinated against rabies in the past.
224197412|NCT04510558|PROCEDURE|Stoma closure without mesh|"* Antibioprophylaxis using cefuroxime and metronidazole~* Standard disinfection and sterile draping~* Circular incision around the stoma using the scalpel blade~* Dissection around the stoma until entering the abdominal cavity~* Closure of the stoma using a linear stapler~* A midline laparotomy may be performed or not~* Realization of an extra-corporeal or intra-corporeal side-to-side handsewn anastomosis~* Closure of the posterior aponeurosis using separate Maxon 2-0 stitches~* Closure of the anterior aponeurosis using separate Maxon 2-0 stitches~* No subcutaneous stitches~* Partial purse string skin closure using Monocryl 3-0~* Standard wound dressing"
223747579|NCT03762655|DEVICE|Neuro-Spinal Scaffold|"The investigational product (Neuro-Spinal ScaffoldTM or Scaffold) is a porous bioresorbable polymer scaffold comprised of a synthetic biomaterial, poly(lactic-co-glycolic acid)-b-poly(L-lysine) (PLGA-PLL). The Scaffold is cylindrical in shape (3 mm diameter) and is available is three lengths (6 mm, 8 mm, 10 mm) for optimal fit in the intraspinal lesion cavity.~Based upon pre-clinical testing, the Scaffold is expected to be resorbed from the site of implant within 4 to 8 weeks."
223747580|NCT03595410|OTHER|Recurrence laryngeal cancer|Recurrence laryngeal cancer has a wide range of invasion, rapid progression and poor prognosis.
223747581|NCT05947851|DRUG|Nemtabrutinib|5 and 20 mg tablets
223747582|NCT05947851|DRUG|Venetoclax|10, 50, and 100 mg tablets
223747583|NCT05947851|BIOLOGICAL|Rituximab|100 mg/10 mL, 500 mg/50 mL (10 mg/mL) IV Infusion
224197413|NCT00585468|DRUG|Myfortic|Myfortic 720 mg orally twice daily
224197414|NCT01285180|DRUG|Daxas|500 microgram, oral, once daily as add-on therapy to existing therapy
223506413|NCT01044199|BIOLOGICAL|PCEC rabies vaccine administered intramuscularly|PCEC rabies vaccine will be given intradermally compared with intramuscular administration (standard), in 2 different schedules: Pre-Exposure schedule for participants never vaccinated against rabies before; and Booster schedule for participants vaccinated against rabies in the past.
223506414|NCT02928432|DRUG|Steroids switch|Change of prednisone 5mg/12h to dexamethasone 0.5mg/24h
223506415|NCT05788380|OTHER|EXERCİSE|EXERCISE FOR HEALTH AND PAIN IMPROVEMENT
223506416|NCT03122665|DRUG|Nefopam Low dose|Continuous intravenous infusion at 0.5 mg/ml for three hours.
223506417|NCT03122665|DRUG|Nefopam High dose|Continuous intravenous infusion at 1.0 mg/ml for three hours.
223506418|NCT02757014|DRUG|Coppertone (BAY987517)|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation Number - R84-087)
223506419|NCT04682613|BEHAVIORAL|"Experimental: Prevention Program young In Favor of Myself, active teachers"|"Prevention program: young In Favor of Myself, with teacher participation"
223506420|NCT04682613|BEHAVIORAL|"Experimental: Prevention Program young In Favor of Myself, no teacher involvement"|"Prevention program: young In Favor of Myself, without teacher participation"
223506421|NCT04864769|DIETARY_SUPPLEMENT|Krill protein hydrolysate|Ingestion of 35 g Krill protein hydrolysate
223506422|NCT04864769|DIETARY_SUPPLEMENT|Soy protein isolate|Ingestion of 35 g Soy protein isolate
223506423|NCT04864769|DIETARY_SUPPLEMENT|Whey protein isolate|Ingestion of 35 g Whey protein isolate
223506424|NCT04864769|DIETARY_SUPPLEMENT|Water|Ingestion of water (control)
223506425|NCT00165698|DRUG|menatetranone|15 mg three times a day orally for 12 months
223506426|NCT00165698|DRUG|alfacalcidol|0.25 μg twice a day orally for 12 months
223506427|NCT02850562|BEHAVIORAL|Walking|The Walking Arm will walk 5 times per week for at least 10 minutes/day at the start of the study and build to 30 minutes/day by the 3-month time point.
223506428|NCT02850562|BEHAVIORAL|Walking + Exercise|The Walking + Exercise Arm will walk 2 times per week for at least 10 minutes/day at the start of the study and build to 30 minutes/day by the 3-month time point and in addition, complete exercises to improve strength and balance on 3 days each week.
223506429|NCT00723242|DRUG|Viraferon-peg and Rebetol|
223506430|NCT02547935|DRUG|Dapagliflozin 10 mg|Tablets administered orally once daily for 24 weeks.
223506431|NCT02547935|DRUG|Saxagliptin 2.5 mg|Tablets administered orally once daily for 24 weeks.
223506432|NCT02547935|DRUG|Matching Placebo for Dapagliflozin 10 mg and Saxagliptin 2.5mg|Tablets administered orally once daily for 24 weeks.
223506433|NCT01647685|DRUG|Nanocort|Two weekly IV infusions of 150 mg Nanocort (PEG-liposomal prednisolone sodium phosphate).
223506434|NCT01647685|DRUG|Methylprednisolone|Two weekly infusion iv methylprednisolone sodium succinate 125 mg infusion.
223506435|NCT01647685|DRUG|Placebo|Saline solution (same solution brand as used to dilute/prepare Nanocort injection)
223506436|NCT02487836|DEVICE|Type WallFlex or Evolution biliary, stent system|Laying of a stent biliary
223506437|NCT03599466|DRUG|BF-Lisinopril Tablets 20mg|BF-Lisinopril Tablets 20mg is a generic product manufactured by Bright Future Pharmaceuticals Factory O/B Bright Future Pharmaceutical Laboratories Limited
223506438|NCT03599466|DRUG|Zestril Tab 20mg|Zestril Tab 20mg will be used as a reference drug in this study
223506439|NCT03168997|DRUG|Memantine Hydrochloride|Memantine Hydrochloride treatment according to clinical routine treatment
223506440|NCT03068520|DIAGNOSTIC_TEST|PET MR|PET MR with 18 Fluorodopa (\[18F\]-DOPA) will be performed on patient at set intervals
223506441|NCT05508594|DRUG|CT001|Intranasal
223506442|NCT05508594|DRUG|Placebo|Intranasal
223506443|NCT05508594|DRUG|Sufentanil|Intranasal
223506444|NCT05508594|DRUG|Ketamine|Intranasal
223506445|NCT03461861|DRUG|AGB101 220 mg|AGB101 oral dose of 220 mg/day capsule, given as once-daily dosing.
223506446|NCT03461861|OTHER|Placebo|Placebo, oral capsule given once-daily.
223506447|NCT02416271|DRUG|Teriparatide|Administered SC
223506448|NCT02416271|DRUG|Alendronate|Administered orally
223506449|NCT02416271|DIETARY_SUPPLEMENT|Calcium|Administered orally
223747584|NCT01217970|DRUG|Ibudilast 20mg|Ibudilast 20mg BID
223747585|NCT01217970|DRUG|Ibudilast 50mg|Ibudilast 50mg BID
223747586|NCT01217970|DRUG|Placebo oral tablet|
223747587|NCT03144492|BIOLOGICAL|Blood volume collected specifically for this study|The subject will be sitting in a chair, and a needle will be inserted into a vein in their arm. Study Team will draw about 45ml or 3 tablespoons of whole blood for research.
224197415|NCT04379232|BIOLOGICAL|Screening test for covid ( RT PCR and CT Chest)|Each patient was screened before surgery with RT PCR and CT Chest. Post operatively, if symptoms, patients are tested with RT PCR and CT Chest
223595295|NCT05848362|OTHER|Blood Glucose Measurement Values Taken by Different Methods|"In total, blood samples will be collected from 3 different sites (central venous catheter, capillary, arterial catheterization) in the same patient. In total, with 5 different techniques from 3 different regions from the same patient;~ARTERIAL BLOOD SAMPLE i) Washing with 5 cc 1% Heparin fluid ii) Washing with 10 cc 1% Heparin fluid CAPILAR BLOOD SAMPLE iii) Right / Left Fingertip iv) Thumb base CENTRAL VENOUS CATHETERIZATION BLOOD SAMPLE will be collected."
223595296|NCT01601262|DEVICE|Low Intensity Extracorporeal Shock waves (Cardiospec 1000)|We will apply the cardiospec 1000 unit for LI-ESWL in the penile and inguinal areas, 300 shocks per area, total of 1500 shocks. Full description of treatment series can be seen in the detailed protocol.
223595297|NCT02340416|DEVICE|Transcranial Doppler Ultrasound, DWL Doppler BoxX|
223595298|NCT01978223|PROCEDURE|Stool sample collection|Stool samples will be collected from all children enrolled in the study, within 48 hours of admission to the hospital/ ED. Stool samples will be tested to determine the presence or absence of rotavirus (RV). Additionally, for RV-positive cases, the stool samples will be tested to determine the RV genotypes.
223595299|NCT02209896|DEVICE|The Reprieve system|BlueWind Medical neurostimulator for the treatment of neuropathic pain
223595300|NCT02622893|DRUG|Transperitoneal laparoscopic nephrectomy|After the surgery: 10 ml 0.25% bupivacaine through epidural catheters before extubation and continuous infusion of 0,1% bupivacaine and 1 µg/ml fentanyl 5 ml/h with patient-controlled boluses of an additional 4 ml, with a lockout time of 20 min and 4-h limit of 30 ml by a patient controlled epidural analgesia (PCEA) device
224197416|NCT02272569|DEVICE|STARflo Glaucoma Implant|Implantation of the STARflo Glaucoma Implant following surgical technique described in European labelling. Procedure does not require the use of anti-fibrotic medications.
224197417|NCT02615652|OTHER|no intervention|no intervention, observational study
224197418|NCT01017965|DEVICE|Actimeter + blood pressure monitoring|Patients will receive an actimeter that they will wear for 3 days and an ambulatory blood pressure monitoring device that they will keep for 24 hours.
224197419|NCT00978120|BIOLOGICAL|H1N1 vaccine high dose|30 mcg of unadjuvanted Novartis H1N1 vaccine delivered as two, 15 micrograms (mcg), intramuscular injections. Each 30 mcg dose is administered 21 days apart.
224197420|NCT00978120|BIOLOGICAL|H1N1 vaccine low dose|15 mcg of unadjuvanted Novartis H1N1 vaccine delivered in two intramuscular injections 21 days apart
224197421|NCT05031559|BEHAVIORAL|Episodic Future Thinking|Participants are invited to imagine themselves in a positive situation after COVID-19 public health restrictions and guidelines are lifted. They are then reminded that their actions are able to change how soon this future can be achieved.
224197422|NCT05031559|BEHAVIORAL|Compassion Training|Participants are invited to imagine themselves in someone else's situation, who is in a bad situation due to COVID-19 (e.g., ER nurse, family of someone in ICU). They are then reminded that their decisions have an impact on the occurrence of these situations.
224197423|NCT05031559|BEHAVIORAL|Sham|Participants are invited to reflect on some COVID-19 related news, and reminded that their actions have bearing on the COVID-19 situation.
224197424|NCT01977703|OTHER|Ultra Conservative ICD Programming|
224197425|NCT01977703|OTHER|Traditional ICD Programming|
224197426|NCT03215602|OTHER|NEMEX and education + strength training|Optimizing sensorimotor control and achieving functional stability. Increasing knee extensor muscle strength. Teaching everyday disease management.
224197427|NCT03215602|OTHER|NEMEX and education|Optimizing sensorimotor control and achieving functional stability. Teaching everyday disease management.
224197428|NCT06565884|DEVICE|Home radiofrequency skin treatment instrument|Subjects in the experimental group were treated with the test instrument combined with medical ultrasonic coupler for 5 days a week according to the prescribed use method (duration of use: 10 minutes for the whole face, continuous use twice a day, a total of 20 minutes) for 12 weeks. To evaluate the reduction of wrinkles before and after treatment and the changes of laboratory instruments.
224197429|NCT06565884|OTHER|Ultrasonic coupler for medical purposes|In control group, medical ultrasonic coupler was evenly applied on face and orbit for 5 days a week (duration: 20 minutes) for 12 consecutive days Week. To evaluate the reduction of wrinkles and the change of laboratory instruments before and after use.
223595301|NCT02622893|DRUG|Retroperitoneal laparoscopic nephrectomy|After the surgery: 10 ml 0.25% bupivacaine through epidural catheters before extubation and continuous infusion of 0,1% bupivacaine and 1 µg/ml fentanyl 5 ml/h with patient-controlled boluses of an additional 4 ml, with a lockout time of 20 min and 4-h limit of 30 ml by a patient controlled epidural analgesia (PCEA) device
224310855|NCT03086759|PROCEDURE|Isotonic Saline Solution|intra-articular infiltration with Isotonic Saline Solution
223595302|NCT02776254|OTHER|START|Point of care testing for rapid ART initiation
223595303|NCT02776254|OTHER|CAG|Community Adherence Group
223595304|NCT02776254|OTHER|UAG|Urban Adherence Group
223595305|NCT02776254|OTHER|FAST-TRACK|Prescription refill only
223595306|NCT02999633|DRUG|Isatuximab SAR650984|Pharmaceutical form:solution Route of administration: intravenous
223595307|NCT02999633|DRUG|dexamethasone|Pharmaceutical form:pills Route of administration: oral
223595308|NCT02999633|DRUG|dexamethasone|Pharmaceutical form:solution Route of administration: intravenous
223595309|NCT02999633|DRUG|acetaminophen|Pharmaceutical form:pills Route of administration: oral
223747588|NCT05071092|BEHAVIORAL|Dietary counselling|Participants assigned to the intervention group will receive coaching from a dietitian to improve adherence to the Dutch dietary guidelines. Several behavioral change techniques will be used.
223747589|NCT00485446|PROCEDURE|blood analysis|
223747590|NCT03167762|DEVICE|Fluorescence and thermal imaging|Two cameras used to take images of the skin. One, to measure the fluorescence from the photosensitiser, and the second to measure the surface temperature of the skin
223747591|NCT05629338|COMBINATION_PRODUCT|Autologous Spray Dried Plasma|Evaluation of the Safety of Ascending Doses of Autologous Spray Dried Plasma in Healthy Volunteers
224310856|NCT00537420|DRUG|Nasal Placebo|Nasal placebo, three times a day, 30 minutes before a meal for 24 weeks.
224310857|NCT00537420|DRUG|Placebo Capsule|Placebo capsules will be taken once daily with or without food.
224310858|NCT00537420|DRUG|PYY3-36|Nasal PYY3-36, three times a day, 30 minutes before a meal for 24 weeks.
224310859|NCT00537420|DRUG|PYY3-36|Nasal PYY3-36 three times a day, 30 minutes before a meal for 24 weeks.
224310860|NCT00537420|DRUG|PYY3-36|Nasal PYY3-36 three times a day, 30 minutes before a meal for 24 weeks.
223747592|NCT05953584|DRUG|Etavopivat|Participants will receive a dose of 400 mg (two 200 mg oral tablets) etavopivat once daily.
223747593|NCT05953584|DRUG|Hydroxyurea|Participants will receive a stable dose of HU.
224310861|NCT00537420|DRUG|Sibutramine|Sibutramine will be taken once daily with or without food
223506450|NCT02416271|DIETARY_SUPPLEMENT|Vitamin D|Administered orally
223506451|NCT02416271|DRUG|Placebo-Oral|Administered orally
223506452|NCT02416271|DRUG|Placebo-SC|Administered SC
223506453|NCT01411371|PROCEDURE|Catheter ablation of persistent atrial fibrillation|Catheter ablation of AF as described previously by our group (e.g. Hunter et al, Heart 2010).
223506454|NCT01411371|DRUG|Medical treatment alone|Medical treatment of persistent AF as 'normal care'. Patients are randomised to medical treatment alone for atrial fibrillation. Treatment will be as per current guidelines for persistent atrial fibrillation, with rate control as first line (using beta-blockers, calcium channel blockers and digoxin as indicated) and rhythm control as second line (using sotalol, dronedarone, or amiodarone as indicated). (Both groups will receive standard heart failure medication including angiotensin converting enzyme inhibitors, beta blockers, aldosterone antagonists, and diuretics as indicated).
223506455|NCT07057024|OTHER|Clinical and eye movements|"Eye tracking in virtual reality environment:~Clinical and psychometric assessment :~* Auto-assessment scales : State-Trait Anxiety Inventory (STAI-TRAIT/ STAI-STATE), Fagerström Test For Nicotine Dependance (FTND), Annett handedness questionnaire, Alcohol Use Disorders Identification Test (AUDIT), Substance Use Risk Profile Scale (SURPS)~* Hetero-assessment scales : Mini International Neuropsychiatric Interview (MINI DSM version 5), Young Mania Rating Scale (YMRS), Hamilton Depression Scale (HDRS), Positive And Negative Scale for Schizophrenia (PANSS)"
223506456|NCT06898463|DRUG|Melatonin (N-acetyl-5-methoxytryptamine)|0.1 mg/kg oral melatonin was administered twice
223506457|NCT06898463|DRUG|Ketamine|0.3 mg/kg intravenous ketamine was administered during anesthesia induction.
223506458|NCT06143397|DEVICE|TTNS (Transcutaneous tibial nerve stimulation)|Electrodes will be placed in two areas simultaneously (posterior tibial nerve and parasacral locations). Only the electrodes going to the tibial region will be activated, the parasacral electrodes will not be active. A Biolito (MTR+Vertriebs GmbH, Berlin) stimulator will be used to perform posterior tibial nerve stimulation. Stimulation will be delivered via two 50 mm x 50 mm adhesive electrode pads under the left medial malleolus and 5 cm proximal to the distal electrode. Appropriate electrode site will be confirmed by the presence of big toe plantar flexion during stimulation (stimulus intensity will be adjusted according to the patient's tolerance for 200 μs duration at 10 Hz frequency). Stimulation will be applied 2 days a week, each application for 30 minutes, for 6 weeks.
223506459|NCT06143397|DEVICE|PNS (Parasacral nerve stimulation)|Electrodes will be placed in two areas simultaneously (posterior tibial nerve and parasacral locations). Only the electrodes going to the parasacral region will be activated, the tibial electrodes will not be active. For parasacral region stimulation, electrodes will be positioned symmetrically in the parasacral region under the posterior superior iliac spines to stimulate the S2 and S3 nerve roots. A duration of 200 μs at a frequency of 10 Hz will be set with the Biolito (MTR+Vertriebs GmbH, Berlin) stimulator. The intensity level will be adjusted according to the tolerance of the patient. Stimulation will be applied 2 days a week, each application for 30 minutes, for 6 weeks.
223506460|NCT06143397|DEVICE|Sham stimulation|Electrodes will be placed in three areas simultaneously. These regions are the tibial and parasacral locations and the scapular region, with a distance of approximately 4 cm between the electrodes. Of these three regions, only the channel to the scapular region will be activated, the remaining two regions will be closed. Regarding the sham group, the parameters used in the scapular region will be applied with a frequency of 100 Hz, a pulse duration of 100 μs, and 30 minutes. This configuration is known as conventional transcutaneous electrical nerve stimulation and is commonly used for non-invasive and non-pharmacological treatment of pain.Stimulation will be applied 2 days a week, each application for 30 minutes, for 6 weeks.
223506461|NCT06143397|BEHAVIORAL|Behavioral treatment|It includes techniques and skills to prevent incontinence and restrain the urge to urinate. It also includes lifestyle interventions such as losing weight, relieving constipation, quitting smoking, reducing caffeine, managing uric acid, wearing non-restrictive, easily removable clothing, reducing emotional stress, and correcting faulty frequent urination by introducing avoidance and distraction techniques. Additionally, advice on proper voiding position and an exercise protocol will be given. The exercise protocol will include three sets of 8-10 near-maximal contractions in lying, sitting and standing positions. Each contraction will be based on the endurance of the pelvic floor muscles and the participant will aim to hold the muscles for 10 seconds. They will be told to do it twice a day, morning and evening. Participants will perform the behavioral training protocol at home.
223506462|NCT02929004|DEVICE|Vibrasens|Transcutaneous vibrations are used. This device allows vibrations from 25 to 150 Hz with an amplitude of 1 mm. In our study the frequency used is 50 Hz.
223506463|NCT03137004|DRUG|Docetaxel|Docetaxel 50mg/m2 in 60 min on day 1 and repeated every 14 days.
223506464|NCT03137004|DRUG|S-1|S-1 was administered orally at 40 mg/m2 twice daily on days 1-7 of each cycle. Patients with a body surface area of less than 1.25 m2 received 80 mg S-1 daily, those with a body surface area of 1.25 m2 or more but less than 1.5 m2 received 100 mg S-1 daily, and those with a body surface area of 1.5 m2 or more received 120 mg S-1 daily.
223506465|NCT00176137|PROCEDURE|preoperative radiochemotherapy|
223506466|NCT07056933|OTHER|Minoxidil solution iontophoresis|The half of the scalp of the participants will be treated with 5% minoxidil solution through Iontophoresis that will be applied at small low voltage (typically 10 V or less) continuous constant current (typically 0.5 mA/cm2 or less) to push a charged drug into skin or other tissue, twice daily at home.
223506467|NCT07056933|OTHER|saline solution iontophoresis|The other half of the scalp of the participants will be treated with placebo saline solution ( control) with the current application.
223506468|NCT04526561|PROCEDURE|Latissimus dorsi flap|Breast reconstruction
223506469|NCT04526561|PROCEDURE|Thoracodorsal artery perforator flap to breast|Breast reconstruction
223506470|NCT04526561|PROCEDURE|Deep inferior epigastric perforator flap|Breast reconstruction
223506471|NCT06068400|BIOLOGICAL|BCMA/GPRC5D double CAR-T|BCMA/GPRC5D double CAR-T is a new type CAR-T cells therapy for patients with Multiple Myeloma.
223747594|NCT05268289|DRUG|Iptacopan (part 1)|Taken for 52 Weeks
224197430|NCT01731821|PROCEDURE|pancreaticojejunostomy|"Nonstented stump closed pancreaticojejunostomy:~Close the pancreatic stump with interrupted inverting sutures around the papillary-like pancreatic duct.~A small full-thickness enterotomy was penetrated on the jejunal wall for connecting to the papillary-like pancreatic duct by placing 4-6 sutures from the periductal parenchyma to the whole-layer jejunum hole. After that, interrupted sutures between the front wall of pancreatic stump and the seromuscular jejunum were performed by 4-0 absorbable sutures to complete the anastomosis.~Duct-to-mucosa pancreaticojejunostomy:Two layer anatomosis with Duct-to-Mucosa pancreaticojejunostomy is performed by suturing the pancreatic parenchyma to the jejunal seromuscular layer and no stenting tube was used."
224197431|NCT01923207|DRUG|DX-2930|
223506472|NCT02927483|DIETARY_SUPPLEMENT|Endolex Forte®|Endolex Forte® oral capsules administered from Baseline Visit until Day 180, two capsules per day.
223506473|NCT02927483|DIETARY_SUPPLEMENT|A combination of diosmin and hesperidin|A combination of diosmin and hesperidin is a combination of micronized diosmin (450 mg) and micronized hesperidin (50 mg) film-coated tablets administered from Baseline Visit until Day 180, two tablets per day.
223506474|NCT02487199|DRUG|ombitasvir/paritaprevir/ritonavir and dasabuvir|Tablet; ombitasvir coformulated with paritaprevir and ritonavir, dasabuvir tablet
223506475|NCT02487199|DRUG|ombitasvir/paritaprevir/ritonavir|Tablet; ombitasvir coformulated with paritaprevir and ritonavir
223506476|NCT04692688|DRUG|APX3330|APX3330, a small-molecule oral tablet, is a Ref-1 inhibitor that can potentially reduce proinflammatory and hypoxic signaling that contributes to several eye diseases.
223506477|NCT04692688|DRUG|Placebo|Placebo tablets are identical to APX3330 tablets except for the absence of the active pharmaceutical ingredient.
223506478|NCT04753177|DRUG|Ribocyclib, fulvestrant, triptorelin|Neoadjuvant treatment will last 24 weeks in both groups. A follow-up examination will be carried out every 8 weeks. In the group of combined hormone therapy, repeate cor-biopsy of the tumor is planned to assess the Ki-67
224197432|NCT01923207|DRUG|Placebo|placebo, subcutaneous administration
224197433|NCT03529045|DEVICE|Vagus Nerve Stimulation (VNS) Therapy|The VNS Therapy System is a commercially available device that will be used by licensed medical practitioners trained in the use of VNS Therapy, per the practitioners' medical judgement.
224197434|NCT04216953|DRUG|Cobimetinib|"Adults: 20mg film coated tablet~Paediatrics:~i) powder for oral suspension containing 250mg of cobimetinib~ii) for pediatric patients ≥12 years-old and with a BW ≥60kg : 20mg film coated tablet same as adults"
224197435|NCT04216953|DRUG|Atezolizumab|20-mL glass vial containing 1200 mg of atezolizumab.
223506479|NCT04753177|DRUG|Doxorubicin, cyclophosphamide, paclitaxel|Neoadjuvant treatment will last 24 weeks in both groups. A follow-up examination will be carried out every 8 weeks. In the group of combined hormone therapy, repeate cor-biopsy of the tumor is planned to assess the Ki-67
223506480|NCT03539705|OTHER|There is no intervention|There is no intervention
223506481|NCT06549114|DRUG|Leniolisib|The doses selected will range from 10 to 70 mg twice daily (BID) (resulting in total daily doses ranging from 20 to 140 mg per day).
223506482|NCT05860400|BEHAVIORAL|Healthy life style|Healthy diet, regular exercise, and quitting smoking
223506483|NCT05860400|DRUG|Secondary prevention for atherosclerotic coronary artery disease|Antiplatelet therapy, as well as medications for control of heart rate, blood pressure, low-density lipoprotein cholesterol, and blood glucose
223506484|NCT05860400|DRUG|Immunosuppressive therapy|Glucocorticoids and/or immunosuppressive agents
223506485|NCT05860400|PROCEDURE|Coronary revascularization|Percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG).
223506486|NCT05860400|DRUG|Supportive therapies|Medical interventions for prevention and treatment of the side effects of the above treatment, such as abnormal liver function, hypocalcemia, hypokalemia, peptic ulcer, infection, et al.
223506487|NCT00816673|DRUG|placebo Circadin|Placebo tabs of Prolonged release melatonin
223506488|NCT00816673|DRUG|Circadin|prolonged release melatonin 2 mg taken daily 2 hours before bed-time for 3 weeks
223506489|NCT04837846|OTHER|Differing Tube Voltage Administration|Subjects will undergo CCTA utilizing a scan and contrast media injection protocol that will be tailored to individual body habitus.
223506490|NCT05882903|DRUG|Betamethasone Dipropionate Nasal Cream 0.0644%|Betamethasone Dipropionate Nasal Cream 0.0644% is applied topically to the inflamed tissue of the sinus using a pre-filled syringe and applicator under the guidance of an endoscope. Up to 5g on each side of the sinus (10g in total).
223506491|NCT05882903|DEVICE|Pre-filled syringe and applicator device|Cream is pre-filled to a syringe and applicator device to facilitate the topical application direct to the sinus under endoscopic guidance.
223506492|NCT03965299|DEVICE|VERUM TTNS|"* Daily 30-minute TTNS intervention is performed 5 days a week during a treatment period of 6-9 weeks, until 3-month post assessments~* During a preparation phase of several minutes, sensory and motor thresholds are assessed and stimulation intensities are adjusted for the following 30-minute treatment phase"
223506493|NCT03965299|DEVICE|SHAM TTNS|"* Daily 30-minute SHAM intervention is performed 5 days a week during a treatment period of 6-9 weeks, until 3-month post assessments~* During a preparation phase of several minutes, sensory and motor thresholds are assessed and stimulation intensities are adjusted for the following 30-minute treatment phase"
223506494|NCT03278340|BEHAVIORAL|Sun Safe Workplaces - Technology|After randomization, program staff will contact managers at the recruited employer and schedule the initial web-enabled visit in the first 6 months. Follow-up meetings will be scheduled as needed to discuss policy adoption, and managers will schedule employee education using the SSW-T online training. Staff will follow-up with managers through Month 34 (Wave 1) or Month 46 (Wave 2). Electronic materials will be published on KB's state-of-the-art web server for employers to access and use.
223506495|NCT03278340|BEHAVIORAL|Sun Safe Workplaces -In Person|After randomization, program staff will contact managers the recruited employer and schedule the initial in-person visit in the first 6 months. Follow-up meetings will be scheduled as needed to discuss policy adoption; managers will schedule employee education with SSW-IP project staff. Printed materials will be sent to SSW-IP employers 3 times during the intervention. Staff will follow-up with managers through Month 34 (Wave 1) or Month 46 (Wave 2).
223506496|NCT05966194|DRUG|RRx-001|RRx-001 for injection (4 mg or 8 mg)
223506497|NCT05966194|RADIATION|Intensity Modulated Radiation Therapy (IMRT)|Intensity Modulated Radiation Therapy of up to 72 Gy
223595310|NCT02999633|DRUG|ranitidine|Pharmaceutical form:solution Route of administration: intravenous
223595311|NCT02999633|DRUG|diphenhydramine|Pharmaceutical form:solution Route of administration: intravenous
223595312|NCT06504186|DRUG|Blinatumomab|"* Ph-negative B-ALL: bephedolumab (≥ 45 kg: 9 mcg/d D1-2, 28 mcg/d D3-14 or 28 mcg/d D1-14; \< 45 kg: 5 mg/m2/d D1-2, 15 mg/m2/d D3-14) in 28-day cycles for 3 cycles.~* Ph-positive B-ALL: treatment with bephytoin + TKIs, bephytoin (≥ 45 kg: 9 mcg/d D1-2, 28 mcg/d D3-14 or 28 mcg/d D1-14; \< 45 kg: 5 mg/m2/d D1-2, 15 mg/m2/d D3-14) in 28-day cycles for 3 cycles."
223747595|NCT05268289|DRUG|Iptacopan (part 2)|Taken for 52 Weeks
223595313|NCT03262441|DRUG|Mycophenolate Mofetil 500Mg Tab|500 mg once daily for one week. If tolerating the drug, then initiate twice daily for 22 months
223595314|NCT01545050|BIOLOGICAL|Placebo matching with BMS-945429|Injection, Intravenous (IV), 0 mg, Day One Only, One Day
223595315|NCT01545050|BIOLOGICAL|Placebo matching with BMS-945429|Injection, Subcutaneous (SC), 0 mg, Every 4 weeks, 8 weeks
223595316|NCT01545050|BIOLOGICAL|Placebo matching with BMS-945429|Injection, Subcutaneous (SC), 0 mg, Week 4 Only, One Day
223595317|NCT01545050|BIOLOGICAL|Placebo matching with BMS-945429|Injection, Subcutaneous (SC), 0 mg, Every 4 weeks, Up to 48 weeks
223595318|NCT01545050|BIOLOGICAL|BMS-945429|Injection, Intravenous (IV), 600 mg, Day One Only, One Day
223595319|NCT01545050|BIOLOGICAL|BMS-945429|Injection, Subcutaneous (SC), 200 mg, Week 8 only, One Day
223595320|NCT01545050|BIOLOGICAL|BMS-945429|Injection, Intravenous (IV), 300 mg, Day One Only, One Day
223595321|NCT01545050|BIOLOGICAL|BMS-945429|Injection, Subcutaneous (SC), 100 mg, Week 8 Only, One Day
223595322|NCT01545050|BIOLOGICAL|BMS-945429|Injection, Subcutaneous (SC), 400 mg, Day One and Week 4, 4 weeks
223595323|NCT01545050|BIOLOGICAL|BMS-945429|Injection, Intravenous (IV), 150 mg, Day One Only, One Day
223747596|NCT05268289|DRUG|Placebo + standard of care|Taken for 52 Weeks
223747597|NCT05268289|DRUG|Iptacopan + placebo|Taken for 52 Weeks
223747598|NCT01686841|DEVICE|The Zeltiq System|Non-invasive cooling is applied to the treatment area with a defined cooling rate and duration.
223747599|NCT04377256|PROCEDURE|Ridge preservation: Tooth extration and immediat bone grafting in the socket|Following the tooth extraction, the socket is filled with a mixture of xenogenic bone and hyaluronic acid and sealed with an epithelio-connective arrested from the maxillary palate
223747600|NCT04970901|DRUG|Loncastuximab Tesirine|Intravenous (IV) infusion
223747601|NCT04970901|DRUG|Polatuzumab Vedotin|IV infusion
223595324|NCT01545050|BIOLOGICAL|BMS-945429|Injection, Subcutaneous (SC), 100 mg, Every 4 weeks, Up to 48 weeks
223747602|NCT04970901|DRUG|Glofitamab|IV infusion
223747603|NCT04970901|DRUG|Mosunetuzumab|Subcutaneous (SC) injection
223747604|NCT04970901|DRUG|Obinutuzumab|IV infusion
223595325|NCT01545050|BIOLOGICAL|BMS-945429|Injection, Subcutaneous (SC), 200 mg, Every 4 weeks, Up to 48 weeks
223595326|NCT01545050|BIOLOGICAL|BMS-945429|Injection, Subcutaneous (SC), 200 mg, Every 4 weeks, Up to 96 weeks, depending on when subject enters this period
223595327|NCT04552106|DIETARY_SUPPLEMENT|3 caps x3/day|3 capsules 3 times daily for 28 days
223595328|NCT04552106|DIETARY_SUPPLEMENT|3 caps x2/day|3 capsules 2 times daily for 28 days
223595329|NCT04552106|DIETARY_SUPPLEMENT|2 caps x3/day|2 capsules 3 times daily for 28 days
223595330|NCT04552106|DIETARY_SUPPLEMENT|2 caps x2/day|2 capsules 2 times daily for 28 days
223595331|NCT04552106|DIETARY_SUPPLEMENT|3 caps x1/day|3 capsules 1 times daily for 28 days
223595332|NCT02258087|RADIATION|LDR Brachytherapy|In spinal anaesthesia patients' prostate are treated with low-dose-rate or brachytherapy using transrectal ultrasound guidance. Radiation sources (iodine-125 isotopes) are implanted into the prostate through transperineal needle insertion. Real time dose planning is applied. The prescribed dose to the whole prostate is 145 Gy.
223595333|NCT02258087|RADIATION|HDR Brachytherapy|In spinal anaesthesia patients' prostate are treated with one fraction of HDR brachytherapy. The prescribed dose to the whole prostate is 1x19 Gy. Ir-192 radioactive stepping source is used for the treatment with after-loading technique. Transperineal approach, rectal ultrasound guidance, inverse treatment planning, real time intraoperative needle position update and dose optimization is applied.
223595334|NCT03399955|DRUG|Paromomycin|Paromomycin (20 mg/kg/d) IM for 14 days
223595335|NCT03399955|DRUG|Ambisome|AmBisome® (20 mg/kg total dose) IV over 7 days
223595336|NCT03399955|DRUG|Miltefosine|Miltefosine oral (allometric dosing) for 42 days (arm 1) or 28 days (arm 2)
223595337|NCT02051634|DRUG|Fermented Papaya Preparation (FPP)|A total of 9 grams of FPP per day (divided into three 3 gram doses) will be consumed for 8 weeks. Participants will consume three 3g sachets containing FPP per day - once 30-40 min before breakfast, once 30-40 min before lunch, and once 30-40 min before dinner. Participants will open the sachet, slowly empty contents into their mouth, and let it dissolve before swallowing.
223747605|NCT06475131|DRUG|BL-B16D1|Administration by intravenous infusion for a cycle of 3 weeks.
223747606|NCT06574321|BEHAVIORAL|Teen Talk High School Refresher (TTHSR)|"TTHSR is designed to equip 11th and 12th grade students with the knowledge and skills necessary to make informed sexual health decisions as they move from high school into adulthood, in order to prevent behavioral risk factors that contribute to unintended pregnancy and sexually transmitted infections.~Most students this age will have received prior SHE. TTHSR is a 5-hour booster intervention, delivered in five 1-hour sessions during late high school, intended to enhance the effectiveness of previous SHE."
223747607|NCT06034821|DRUG|Subanesthetic dose intravenous ketamine (KET)|This trial will use standard dose of ketamine (0.5mg/kg infusion over 40 min period) in accordance with research studies that have used ketamine as an antidepressant. Treatments will be given two times a week for a maximum of 8 treatments during the acute arm of the study. The investigators will be able to modify dose and number of treatments as indicated clinically per pragmatic clinical trials procedures. Patients will be clinically assessed prior to each treatment to evaluate response and appropriateness of continuation of treatment. Per FDA guidelines a maximum 60mg/dose will be given regardless of body weight.
224197436|NCT02801734|OTHER|EQUIP|Patients in the EQUIP intervention group will receive four face-to-face sessions. The focus of these sessions is to equip patients with the skills and strategies needed to cope with common symptoms experienced by lung cancer patients.
223747608|NCT06034821|DEVICE|Electroconvulsive therapy (ECT)|ECT will be given in a standard manner 3 times a week for 4 weeks. The Initial ECT treatment will be Right Unilateral (RUL) ultra-brief pulse at 6x seizure threshold determined during titration at first visit. If there is not satisfactory improvement with RUL the investigator may change to Bilateral (BL) utilizing brief pulse using 0.5 modified half-age method to determine stimulus intensity. The seizure threshold may increase during the course of treatment and the dose of the electric stimulus may need to be increased incrementally. It is suggested to change to bilateral after three to five RUL treatments if response to treatment is not satisfactory. Treatments will be given three times a week for up to 4 weeks.
223747609|NCT06289101|BEHAVIORAL|text4FATHER|Receipt of twice-weekly texts that include resource links and instructions to support behavior change (e.g., videos, infographics) and start mid-pregnancy and continuing through 2 months of age.
223747610|NCT03446040|BIOLOGICAL|BMS-986258|Specified dose on specified days
223747611|NCT03446040|BIOLOGICAL|Nivolumab|Specified dose on specified days
223747612|NCT03446040|DRUG|rHuPH20|Specified dose on specified days
223747613|NCT05124860|DIAGNOSTIC_TEST|Indirect calorimetry|Measurement of metabolic rate (kcal/day) by respiratory gas analysis.
223747614|NCT03548792|RADIATION|RSA radiostereometric analysis|Tantalum beads will be inserted in polyethylene Component and in bone to assess micromotion of Components in radiographs
223747615|NCT03548792|BEHAVIORAL|Clinical comparison|ActivePAL, walking speed
223747616|NCT06572085|DRUG|Butylphthalide and Sodium Chloride Injection|All enrolled patients will undergo standard treatment as per international guidelines, concurrently receiving either NBP or placebo therapy. Patients in the experimental group will receive intravenous infusion of 100ml NBP injection twice daily, while patients in the control group will receive intravenous infusion of 100ml saline solution twice daily. Each patient will receive continuous medication for 14 days.
223747617|NCT06572085|DRUG|Saline Solution|All enrolled patients will undergo standard treatment as per international guidelines, concurrently receiving either NBP or placebo therapy. Patients in the experimental group will receive intravenous infusion of 100ml NBP injection twice daily, while patients in the control group will receive intravenous infusion of 100ml saline solution twice daily. Each patient will receive continuous medication for 14 days.
223747618|NCT03205059|BEHAVIORAL|LST MS curriculum+ Bullying/Cyberbulling serious game|The prevention materials for middle school bullying and cyberbullying will (1) utilize both interactive classroom sessions and serious/educational games (digital games used to educate in an entertaining format); (2) positively change social norms surrounding bullying and cyberbulling; (3) challenge positive expectancies about bullying and cyberbullying; (4) enhance protective factors by building social, self-regulation, and relationship skills throughout the interactive learning and behavioral rehearsal; and (5) include booster sessions.
223747619|NCT03205059|BEHAVIORAL|LST MS curriculum|The evidence-based LifeSkills Training program has been successfully used as a universal, school-based substance abuse and violence prevention program for middle school youth. The goals of the LST program are to teach youth the personal self-management skills, social skills, and other life skills needed to successfully resist drug and alcohol use, navigate developmental tasks, increase resilience, and facilitate healthy psychosocial development.
223747620|NCT05961735|OTHER|PECS II Block|The Pecs II block is applied to the patients after induction of anesthesia .
223747621|NCT05961735|OTHER|Combined Serratus Anterior Plane Block|Combined Serratus Anterior Plane Block is applied to the patients after induction of anesthesia .
223747622|NCT01820481|DRUG|WIN-901X dose level 1|100mg Bid, PO, 12weeks
223747623|NCT01820481|DRUG|WIN-901X dose level 2|200mg Bid, PO, 12weeks
224197437|NCT03242707|BIOLOGICAL|Autologous adipose tissue injection|"20ml to 40ml of subcutaneous adipose tissue will be aspirated from the abdomen. Adipose tissue will be processed using the Lipogems device, a closed-loop processing device used in medical procedures involving the harvesting, concentrating and transferring of autologous adipose tissue.~The resulting fat product will be delivered locally via ultrasound-guided, intra-articular injection."
224197438|NCT03242707|DRUG|Hyaluronic Acid|Synvisc-One® is a high molecular weight sodium hyaluronate.
224197439|NCT05819411|BEHAVIORAL|Project iSTRIVE|This intervention includes 6 face-to-face therapy sessions with a trained clinician to develop skills to counter internalized stigma and shame as barriers to HIV self-care. Both the intervention group and the active control group will also receive a mobile app-based iDOT intervention.
224197440|NCT05819411|BEHAVIORAL|incentivized Directly Observed Therapy (iDOT)|Both the intervention group and the active control group will receive a mobile app-based iDOT intervention.
224197441|NCT04426552|DRUG|dexmedetomidine|will have a bolus of dexmedetomidine one μg/kg (Precedex; Hospira, Inc, Lake Forest, IL) administered for 10 minutes, followed by a continuous infusion at 0.7 μg • kg-1 • h-1 during FOI
223747624|NCT01820481|DRUG|WIN-901X dose level 3|300mg Bid, PO, 12weeks
223747625|NCT01820481|DRUG|Placebo|Bid, PO, 12weeks
223747626|NCT02066467|DEVICE|Left Ventricular lead implant: ACUITY X4® Lead Family|Implantation of (cardiac re-synchronization therapy with defibrillator) CRT-D devices for heartfailure treatment
223747627|NCT04341909|PROCEDURE|ERCP|endoscopic retrograde cholangiopancreatography
223747628|NCT04919356|GENETIC|G2019S LRRK2|No cost genetic testing for G2019S LRRK2
223506498|NCT05966194|DRUG|Cisplatin for injection 100 mg/m2|Cisplatin for injection 100 mg/m2
223506499|NCT05206604|DRUG|PF-07295324|Ointment
223506500|NCT05206604|DRUG|PF-07259955|Cream
223506501|NCT05956392|BEHAVIORAL|Screen-use reduction + Sleep extension|60 minutes of a participants' daily screen-use time on school days will be repurposed for more sleep time.
223506502|NCT05040542|OTHER|maternal exposure during pregnancy|maternal exposure during pregnancy (e.g., environmental exposures and maternal inflammatory states)
223506503|NCT04512183|OTHER|High-Fidelity Simulation|Teaching strategy based on high-fidelity simulation, which simulates the reality of health care to promote meaningful learning.
223506504|NCT04512183|OTHER|Low-Fidelity Simulation|Teaching strategy based on low-fidelity simulation, which simulates the reality of health care using less technological and less interactive mannequins.
223506505|NCT03735498|OTHER|Psychological Intervention|Promote effective coping and reduce caregiving burden
223747629|NCT06175273|DIETARY_SUPPLEMENT|Oral Nutrition Supplement|8oz (240mL) per dose at least once a day, but up to six times per day depending on estimated nutrient needs. The formula will equate to 1.0kcal/mL
223747630|NCT06175273|DIETARY_SUPPLEMENT|Tube Feed|EN will have a feeding tube placed and started on tube feeds via a designated pump for overnight feeds, meeting at least 50% of estimated energy needs
223506506|NCT05760677|DRUG|pioglitazone group: lifestyle intervention+ metformin+ orlistat (obese patients)+ pioglitazone|the pioglitazone group： classic treatment: lifestyle intervention+ metformin+ orlistat (obese patients)+ pioglitazone
223506507|NCT05760677|DRUG|the Chiglitazar group: lifestyle intervention+ metformin+ orlistat (obese patients)+ Chiglitazar|the Chiglitazar group: lifestyle intervention+ metformin+ orlistat (obese patients)+ Chiglitazar (32mg QD)
223506508|NCT00713180|PROCEDURE|Pterygium excision followed by grafting|Pterygium will be excised followed by either free conjunctival or limbal conjunctival graft obtained from the upper part of the globe. The graft will be kept in place by sutures
223595338|NCT02051634|DRUG|Sugar Pill|A total of 9 grams of placebo (sugar) per day (divided into three 3 gram doses) will be consumed for 8 weeks. Participants will consume three 3g sachets containing placebo per day - once with breakfast, once with lunch, and once with dinner. Participants will open the sachet, empty contents into their mouth, and let it dissolve before swallowing.
223595339|NCT04666194|PROCEDURE|Cold forceps|
223595340|NCT04666194|PROCEDURE|Cold snare|
223595341|NCT04666194|PROCEDURE|Hot snare|
223595342|NCT01501994|OTHER|GRUVE accelerometer (MUVE, inc.)|Physicians in the experimental group will be given an accelerometer for 2 weeks (without feedback) prior to starting the study and will continue to have their activity monitored for the duration of the study. The accelerometer monitors movement and accurately estimates physical activity energy expenditure. They will receive feedback about their activity for the remainder of the trial. Physicians in the control group will wear the accelerometer but not receive feedback for the first 14 weeks of the trial. They will receive feedback for the last 12 weeks of the trial as they crossover to the experimental group.
223595343|NCT01501994|OTHER|walking workstation|The physicians in the experimental group will be provided with a walking workstation. The walking workstation has a computer keyboard, computer monitor and telephone attached to an exercise treadmill (assembled by the investigators). This allows the user to walk at 1 mile per hour while dictating, typing, responding to e-mail, etc. The treadmill can be placed in an examining room if the physician wishes to use it while dictating notes or it can be placed in a separate office. For the last 12 weeks of the study the experimental group will not use the walking workstation while the control grop will use the workstation (crossover).
223595344|NCT01501994|PROCEDURE|exercise counseling|After the first two weeks of baseline data collection, the experimental group will receive exercise counseling for the next 12 weeks. They will be advised to make use of the accelerometer and the walking workstation as well as how to increase their activity in other ways. This group will not receive exercise counseling for the last 12 weeks of the study while the control group will cross over and receive exercise counseling for the last 12 weeks of the study (the control group will not receive exercise counseling for the first 14 weeks of the study).
223595345|NCT03235089|DEVICE|Test Lens|Daily disposable contact lens
223595346|NCT03235089|DEVICE|Control Lens|Focus Dailies All Day Comfort contact lens (nelfilcon A)
223595347|NCT04108806|PROCEDURE|Endovascular therapy|Ballon dialtation of the diseased artery
223595348|NCT01595555|BEHAVIORAL|Stress Free Now|8 week mindfulness online program with the following content: 8 Weekly lesson of the week (audio), 8 Weekly mindfulness practice (audio), Daily articles on concepts and information about stress, relaxation and mindfulness, Daily motivational quotes and tips, Biweekly email reminder to participate in the program.
223595349|NCT01363115|DIETARY_SUPPLEMENT|Orange Juice fortified with Calcium and Vitamin D|Three 240 mL glasses of orange juice fortified with 350 mg Ca and 100 IU of D per serving
223595350|NCT01363115|DIETARY_SUPPLEMENT|Orange juice without Ca or VitD|Three 240 mL glasses of orange juice without Ca or VitD
223595351|NCT01363115|BEHAVIORAL|Nutritional Counseling|Individual and group nutritional counseling by a registered dietitian
223595352|NCT01032499|DRUG|oxytetracycline, taro elixir|comparison of treatment efficacy between oxytetracycline and taro elixir
223595353|NCT01032499|DRUG|Taro Elixir|Taken orally one tablespoon (15 mL) of Taro Elixir 3 times daily for breakfast, lunch and dinner.
223595354|NCT03337009|BEHAVIORAL|Naloxone Navigator (NN)|Patients prescribed chronic opioid therapy will be identified and recruited to enroll in the study. Patients randomized to receive the web-based animated video (Naloxone Navigator) will be sent a link to the video after enrollment. The web-based, animated video provides education on what is an opioid overdose, how to prevent it, how to recognize an overdose, and how to respond with naloxone. This video also encourages patients to pick up naloxone from a pharmacy under a standing order.
223595355|NCT05997706|PROCEDURE|Testicular biopsy|Testicular biopsy is a clinical procedure for extraction of testicular tissue
223595356|NCT03969017|DRUG|pegylated interferon (Peg IFN)α-2b|Participants in NAs+Peg IFN Group will be treated by Peg IFNα-2b （180ug per week, the dose will be changed to 135ug or 90ug per week during the treatment if patients could not tolerate the side effects of Peg IFNα-2b). Peg IFNα-2b treatment will be performed until HBsAg \<0.05IU/ml, with a maximum duration of 48 weeks.
223595357|NCT03969017|DRUG|Nucleoside （acid）analogue (NAs)|Both of NAs Group and NAs+Peg IFN Group will be treated with NAs as before enrollment.
223595358|NCT00953563|DEVICE|Unite Biomatrix|collagen based, decellularized equine pericardial dressing for skin surface wounds
223595359|NCT02747368|DEVICE|Ocusweep system|Comparison of Ocusweep system to conventional visual acuity, contrast sensitivity and visual field testing.
223595360|NCT04654455|OTHER|Describe the evolution of dry eye between 1 month and 3 months post-LASIK|Dry eye will be assessed through the OSDI (Ocular Surface Disease Index) questionnaire. The questionnaire will be dispensed during consultations by an orthoptist or an intern/junior doctor, at 1 month and at 3 months post-LASIK.
223595361|NCT00751855|BEHAVIORAL|Prolonged Exposure therapy|10 weekly sessions
223595362|NCT00751855|DRUG|Hydrocortisone|30mg 45 minutes prior to each PE session including imaginal exposure (8 total)
223595363|NCT00751855|DRUG|placebo|placebo
223595364|NCT00915291|OTHER|Web-based educational modules|Interactive case-based modules that includes video vignettes of clinical interactions between hypothetical patients interacting with physicians
224197442|NCT04426552|DRUG|sevoflurane|preoxygenated using face mask with 100% oxygen for 3 min to increase oxygen reserve and then inhalational induction will be started with sevoflurane in 100% oxygen using Ayre's piece circuit/MapelsonD circuit according to age and weight of the patient while performing fiberoptic intubation
224197443|NCT03176953|DRUG|topiramate|active medication
224197444|NCT03176953|BEHAVIORAL|prolonged exposure|psychotherapy
224197445|NCT03176953|DRUG|placebo|non-active medication
224197446|NCT01151501|DEVICE|noninvasive positive pressure ventilation|Patients in whom the spontaneous breathing trial fail and in whom exclusion criteria are not present during this period were randomly allocated. Patients who are randomized to NPPV goup will be extubated and non-invasive ventilation (BiPAP Vision, Respironics Inc., Murrysville，Pennsylvania) will be delivered immediately after extubation using spontaneous/timed (S/T) mode. Expiratory positive airways pressure (PEEP) was initially set at 4 cmH2O and gradually increased to 6-8 cmH2O or more；and fraction of inspired oxygen (FiO2) was set to achieve pulse oximeter oxygen saturation (SpO2) \>92% in cooperation with PEEP. On condition that tidal volume is no less than 6ml/kg，continuous positive airway pressure (CPAP) is permitted to apply，in which the adjusting procedures of CPAP and FiO2 is similar with PEEP and FiO2 in S/T mode. NPPV is terminated When patients can spontaneously breath oxygen provided by a Venturi device at FiO2≤0.35 for more than 24 hours with SpO2\>92%.
224197447|NCT03668379|BEHAVIORAL|Augment w/mHealth|"Non-responders to the first stage treatment of BAT alone may be re-randomized to this augmented intervention to receive text-message support in addition to the BAT intervention."
223747631|NCT06175273|DRUG|Cyproheptadine|0.25mg/kg/d divided BID. May titrate by 4mg increments to a max of 12mg/day.
224197448|NCT03668379|BEHAVIORAL|Maintenance|"Responders to the 1st-stage treatment of either 1. BAT or 2. BAT \& mHealth will continue in maintenance mode. These participants will not receive any additional interventions during the 2nd-stage treatment."
224197449|NCT03668379|BEHAVIORAL|Switch to CBT & mHealth|"Non-responders to the 1st-stage treatment of either 1. BAT or 2. BAT \& mHealth may be re-randomized to switch interventions in the form of an intensified dose of Cognitive Behavioral Therapy (CBT). CBT is eight sessions long and covers five modules that can be re-arranged to fit patient needs. Sessions will be scheduled once a week to facilitate more contact with participants. An identical text-messaged tool will be used."
224197450|NCT03668379|BEHAVIORAL|Augment w/BAT & mHealth|"Non-responders to the BAT \& mHealth intervention may be re-randomized to receive an additional dose of BAT \& mHealth in the form of an additional session of BAT."
224197451|NCT00286936|DRUG|Zolpidem|
224197452|NCT01068418|DIETARY_SUPPLEMENT|Vitamin D (cholecalciferol)|cholecalciferol 15,000 IU daily for 30 days
223506509|NCT02609906|DEVICE|PhilosTM with augmentation (Depuy-Synthes)|"All fractures will initially be immobilised by a Gilchrist-bandage. This is the same procedure as for patients who do not attend this or any other trial and will be performed by the doctor on-duty in the emergency room. Patients will be admitted to the trauma ward after that. On the same day or at the latest on day after this patients will be informed about the current investigation, screened, included and randomized by one of the study doctors to our trial after written consent will be obtained as described above.~Operative treatment is exclusively performed by the below mentioned study doctors. This group will be treated by the angle stable plate fixation system PhilosTM with augmentation (Depuy-Synthes)."
223506510|NCT02609906|DEVICE|MultiLoc®-Nail (Depuy-Synthes)|"All fractures will initially be immobilised by a Gilchrist-bandage. This is the same procedure as for patients who do not attend this or any other trial and will be performed by the doctor on-duty in the emergency room. Patients will be admitted to the trauma ward after that. On the same day or at the latest on day after this patients will be informed about the current investigation, screened, included and randomized by one of the study doctors to our trial after written consent will be obtained as described above.~Operative treatment is exclusively performed by the below mentioned study doctors. This group will be treated by the multiplanar proximal humeral nail MultiLoc® (Depuy-Synthes)."
223506511|NCT06214962|BEHAVIORAL|(multiple training modalities, MTM)|"1. Invite experts to discuss the course content of each unit of MTM, and then invite teachers to take pictures , and combine them into one course for the benefit of the elderly in the institution.~2. Select 3 units to try out in the dementia base, and make corrections based on the feedback of the elders and the base staff.~3. Continue to complete other units based on the experience of the first 3 units.~(2) In the Rizhao part, experts are mainly used to develop various course modules suitable for the elderly with dementia in Rizhao, and each module unit is tested on the elderly with dementia and then revised The planning task is mainly to establish a solution strategy. The method is to set up an activity course module planning or design group to develop various course modules suitable for Rizhao demented elders."
223506512|NCT05235256|PROCEDURE|bilateral sphenopalatine ganglion block|peripheral n block
223506513|NCT05235256|PROCEDURE|bilateral greater occipital nerve block|bilateral greater occipital nerve block
223506514|NCT05235256|DRUG|lidocaine plus dexamethasone|lidocaine plus dexamethasone
223506515|NCT00709345|BEHAVIORAL|Cognitive behavioral sessions|Participants will receive 26 weekly 1-hour small-group sessions and 26 weekly 30-minute individual sessions with a study facilitator. After completing treatment, participants will also receive 6 monthly 1-hour booster sessions. All sessions will focus on promoting healthy behaviors, dieting, and exercise.
223506516|NCT00709345|BEHAVIORAL|Time-matched attention control sessions|Participants will receive 26 weekly 1-hour small-group sessions and 26 weekly 30-minute individual sessions with a study facilitator. After completing treatment, participants will also receive 6 monthly 1-hour booster sessions. All sessions will focus on improving communications, developing healthy techniques for coping with stress, and resolving conflicts.
223747632|NCT06175273|DRUG|Olanzapine|2.5mg once a day (at night). May titrate by 2.5mg increments to max of 10mg/day
223747633|NCT06175273|OTHER|Standard of Care|Diet education on high protein, high calorie food consumption
223747634|NCT01482793|PROCEDURE|Vertebroplasty|AVAmax radiopaque bone cement is injected into the vertebral body using a 13 G or 11 G vertebroplasty needle.
223747635|NCT02195076|OTHER|non-invasive detection of cancer odor|The odor VOCs of the specimens will be subjected to our system for detection by the biosensors. If the sample is cancerous the biosensors will report it (YES signal). If the sample s not cancerous, the biosensors will not report it (NO signal).
223595365|NCT03546088|DEVICE|fiberoptic naso-tracheal intubation|The trachea will be intubated under direct fiberoptic view after a fiberoptic upper airway examination. The flexible nasolaryngoscope will be armed with an intubating tube and passed inside tracheal lumen trough one of the nostrils.
223595366|NCT03546088|DRUG|Topical anaesthesia|Topical anaesthesia with lidocaine will be provided through nebulisation and instillation. The intubating tube will be lubricated with a gel containing lidocaine.
223747636|NCT02602587|BIOLOGICAL|Blood sample|additional samples of blood in acts planned in the prognostic or follow-up protocols.
223747637|NCT02602587|BIOLOGICAL|Bone marrow sample|additional bone marrow sample in acts planned in the prognostic or follow-up protocols.
223747638|NCT02617823|PROCEDURE|lateral position|patients placed on their left side after epidural catheter insertion
223747639|NCT00456521|DRUG|Naltrexone SR 32 mg/ bupropion SR 360 mg/ day|
223747640|NCT00456521|DRUG|Placebo|
223747641|NCT00456521|BEHAVIORAL|Intensive group lifestyle modification counseling|
223506517|NCT06222294|DRUG|Remimazolam Tosilate|Loading dose: 0.08mg/kg Maintenance dose: IV remimazolam tosilate, dose range 0-2.0mg/kg/h, increment or decrement of 0.1-0.2mg/kg/h
223506518|NCT06222294|DRUG|Propofol Medium and Long Chain Fat Emulsion Injection|Loading dose: 0.3-0.5mg/kg Maintenance dose: IV Propofol Medium and Long Chain Fat Emulsion Injection, dose range 0.3-4.0mg/kg/h, increment or decrement of 0.3-0.6mg/kg/h
223506519|NCT04250402|PROCEDURE|Resection|Radical resection.
223506520|NCT04408209|PROCEDURE|Convalescent Plasma|"Convalescent Plasma - early treatment of patients with severe COVID-19. Clinical and laboratory data of patients will be collected before initiation of the procedure, 30 minutes after the first dose, 30 minutes after the second dose and 30 minutes after the third plasma dose and then on days 1-7, 14, 21, 28, 35 from the start of treatment. In case of adverse reactions during transfusion such as acute shortness of breath, haemodynamic instability or high pre-existing and non-disease-related fever, the transfusion will be interrupted and detailed recording of the event as well as updating the Adverse Events Management Committee will be performed.~In addition to the standard assessments, the titer of neutralizing anti-SARS-CoV-2 antibodies will be measured in a sample drawn prior to plasmapheresis.~All donors will be tested for:~1. the titer of IgG anti-SARS-CoV-2 antibodies (Pasteur Institute)~2. the titer of neutralizing anti-SARS-CoV-2 antibodies (Pasteur Institute)"
223506521|NCT03556384|DRUG|Temozolomide|"Temozolomide 85 mg/m2 will be administered orally for 21 days followed by 7 days without treatment in 28 day cycles.~Treatment will continue for 6 months (with option to continue if benefiting treatment) or until disease progression or unacceptable toxicity (whichever occurs first). All patients will have regular evaluations for assessment of safety parameters"
223506522|NCT02014103|DRUG|Prograf|Administration of each formulation will be determined by sequence.
223506523|NCT02014103|DRUG|Tacrolimus, Sandoz|Administration of each formulation will be determined by sequence.
223506524|NCT02014103|DRUG|Tacrolimus, Reddy Laboratory|Administration of each formulation will be determined by sequence.
223506525|NCT02014103|DRUG|Tacrolimus, Mylan|Administration of each formulation will be determined by sequence.
223506526|NCT02014103|DRUG|Tacrolimus, Accord|Administration of each formulation will be determined by sequence.
223506527|NCT02014103|DRUG|Tacrolimus, Pancea Biotech Limited|Administration of each formulation will be determined by sequence.
223506528|NCT04605146|BEHAVIORAL|Tele-monitoring|"The tele-monitoring will consist in filling in a specific questionnaire once a week in the first 6 months, every 2 weeks until 12 months, and on-demand (in case of upcoming toxicity, at any time). These questionnaires will be reviewed by a coordinating nurse. According to the result of the questionnaire, the coordinating nurse will adapt patients' management, either by giving them a phone call, or inviting them to directly contact their medical department, or even plan an emergency hospitalization if necessary. The coordinating nurse will closely work with the investigator to adapt patients' management.~Quality of life questionnaire (FACT-G) will also be filled in at inclusion, M3 and M12."
223506529|NCT05240976|DRUG|NMDAE plus AIFA|Use of an NMDA enhancer plus a drug with anti-inflammatory property for the treatment of ultra-resistant schizophrenia.
223506530|NCT05240976|DRUG|NMDAE plus Placebo Cap|Use of an NMDA enhancer plus placebo as a comparator
223506531|NCT03186157|PROCEDURE|Decompressive craniectomy|Decompressive craniectomy is a surgical procedure used to treat patients with acute intractable intracranial hypertension. It includes removing a large portion of lateral skull wall in order to alleviate the effects of increased intracranial pressure and allow the brain to expand.
223506532|NCT03186157|PROCEDURE|Cranioplasty|Cranioplasty is a routine neurosurgical procedure to repair the continuity of the bone tissue of the skull with autologous bone or synthetic bone flap from heterologous material.
223506533|NCT06023368|DRUG|Num Vapocoolant Spray|Spray applied around port prior to access
223506534|NCT06023368|DRUG|EMLA Cream|cream applied around the port prior to access
223506535|NCT06260618|DEVICE|Gelfoam|GELFOAM Sterile Compressed Sponge is a medical device intended for application to bleeding surfaces as a hemostatic. It is a water-insoluble, off-white, nonelastic, porous, pliable product prepared from purified porcine skin, Gelatin USP Granules and Water for Injection, USP. It may be cut without fraying and is able to absorb and hold within its interstices, many times its weight of blood and other fluids.
223595367|NCT03546088|DRUG|Light sedation|The patient will be sedated with a combination of midazolam, fentanyl administered intravenously in small boluses until the desired level of sedation is achieved as expressed of The Observer's Assessment of Alertness/Sedation Scale (OAA/S) of 4 or 5.
223595368|NCT04735146|OTHER|Adapted physical activity|"Participants in the experimental group will undergo the adapted physical activity program that will be co-designed during phase I of the study.~The 6-week program is aimed at improving the quality of life; increase the physical activity levels according to recommended guidelines; improving body awareness through an educational component; maintain and ameliorate the previous functions (for women previously active) and build the exercise background for sedentary women; increase physical fitness and functional capacity."
223595369|NCT03238924|DRUG|Oxytocin|40 IU oxytocin nasal spray, self-administered
223747642|NCT04070391|DIETARY_SUPPLEMENT|vitamin B6|oral administration
223747643|NCT04070391|OTHER|control|oral administration
223747644|NCT02451228|OTHER|Serial blood collection|Serial blood collection from IV for pharmacokinetic and pharmacodynamic analysis. No drug, device, or biologic intervention. Opportunistic.
223747645|NCT01316276|DRUG|Liposomal amikacin for inhalation|"* Liposomal amikacin for inhalation is provided as a sterile aqueous liposomal dispersion for inhalation via nebulization.~* 590 mg of liposomal amikacin for inhalation is administered once daily using the PARI Investigational eFlow® Nebulizer.~* Administration time is approximately 13 minutes.~* Liposomal amikacin for inhalation will be administered in two consecutive extension periods, each consisting of 6 cycles for a total of 12 cycles. Each cycle consists of 28 days on-treatment followed by 28 days off-treatment."
223595370|NCT03238924|DRUG|Placebos|Saline nasal spray, self-administered
223595371|NCT02980627|BEHAVIORAL|Therapy with Mobile App Enhancement|"Treatment includes 12 weekly therapy sessions with daily RR app use between sessions. Intervention is CBT-based and specifically draws from ACT. ACT is a contextual behavior therapy that emphasizes the function of behavior (e.g., affect regulation) and helps individuals accept (or tolerate) emotional discomfort for a broader purpose (i.e., personal values). Broadly, treatment will focus on improving diabetes management by increasing patients' capacity to effectively cope with psychological barriers to self-care using acceptance and mindfulness strategies."
223595372|NCT04775264|PROCEDURE|Pulsed Electric Field Ablation|Catheter ablation of Ganglionated Plexi (GP) structures on the epicardial surface of the heart during cardiothoracic surgery
223595373|NCT06292676|OTHER|skills retained for home birth delivery in emergency|skills on mannequin for home birth scenario in emergency
223595374|NCT06001619|DRUG|Prostate hyperplasia medication|The dosages prostatic hyperplasia medication: dutasteride 0,5 MG x1 or finasteride 5 MG x1 or combination of dutasteride and tamsulosin 0,5/0,4 MG x1.
223595375|NCT06001619|DRUG|LhRH-antagonist|The starting dose in prostatic cancer patient cohort of LHRH antagonist degarelix is 120 MGx2 and the maintenance dose is 80 MGx1.
223595376|NCT01277484|DRUG|Decitabine|"1\. Dose finding study (cycle 1-cycle4)~* Indicated dose for 5 consecutive days every 28 days~* Cohort 1: 5mg/m2 of decitabine~* Cohort 2 and 3:Dose escalation up to 15mg/m2 using a mechanism-based pharmacokinetic / pharmacodynamic model"
223595377|NCT00004275|DRUG|growth hormone|
223595378|NCT00004275|DRUG|oxandrolone|
223595379|NCT06405477|DIETARY_SUPPLEMENT|L-arginine|Capsules of 3 grams of L-arginine per Dose
223595380|NCT06405477|DIETARY_SUPPLEMENT|Placebo|Capsules of 3 grams of maize Starch per Dose
223595381|NCT00324376|DRUG|Sevelamer hydrochloride|
223595382|NCT06197763|DRUG|Colesevelam|625 mg tablets - 3 tables twice per day of Colesevelam or placebo for 6 weeks (crossover), interspersed by 8 week of washout time.
223595383|NCT06197763|OTHER|Control Arm|No Treatment: baseline assessment only
223595384|NCT04358224|BIOLOGICAL|Dupilumab Prefilled Syringe|open-label
223595385|NCT02422849|OTHER|hospital specialist|
223595386|NCT02422849|OTHER|General Practitioner|
223595387|NCT05809362|DEVICE|WHOOP 4.0 Strap|Subjects will receive both the WHOOP 4.0 Strap and the BioTel ePatch and will continuously wear each for one week. Data will be collected and analyzed by the study team upon return of the both devices from the subject.
223595388|NCT05809362|DEVICE|BioTel ePatch|Subjects will receive both the WHOOP 4.0 Strap and the BioTel ePatch and will continuously wear each for one week. Data will be collected and analyzed by the study team upon return of the both devices from the subject.
223595389|NCT04147806|RADIATION|IGRT 45 Gy in 5 fractions of 9 Gy|Administration of 9 Gy in five consecutive days, to a total dose of 45 Gy radiation
223595390|NCT04147806|RADIATION|IGRT 24 Gy single dose|Administration of a single dose of 24 Gy in one session
223595391|NCT04147806|DRUG|Dexamethasone|4 mg by mouth on treatment days only
223747646|NCT04820972|DRUG|Antiplatelet Agents|using antiplatelet agents in 3 days after surgery
223747647|NCT06414967|OTHER|Music Intervention|Music therapy carried out with Music Care
223747648|NCT00605475|DRUG|Canakinumab|Canakinumab given as single dose IV injection of 0.03 mg/kg, or single dose IV infusion at doses of 0.1 mg/kg 0.3 mg/kg, 1.5 mg/kg or 10 mg/kg.
223595392|NCT04147806|DRUG|Tamsulosin|0.4 mg by mouth daily starting the day of simulation and until 2 weeks post-treatment.
223595393|NCT01705106|DRUG|capecitabine|Given PO
223595394|NCT01705106|DRUG|celecoxib|Given PO
223595395|NCT01705106|OTHER|pharmacological study|Correlative studies
223595396|NCT01705106|OTHER|laboratory biomarker analysis|Correlative studies
223595397|NCT01705106|OTHER|pharmacogenomic studies|Correlative studies
223595398|NCT04667104|DRUG|JNJ-73763989|JNJ-73763989 injection will be administered subcutaneously once every 4 weeks.
223595399|NCT04667104|DRUG|Tenofovir disoproxil|Tenofovir disoproxil film-coated tablet will be administered orally once daily.
223595400|NCT04667104|DRUG|Tenofovir alafenamide (TAF)|TAF film-coated tablet will be administered orally once daily.
223595401|NCT04667104|DRUG|Entecavir (ETV) monohydrate|ETV monohydrate film-coated tablet will be administered orally once daily.
223595402|NCT04667104|DRUG|PegIFN-alpha2a|PegIFN-alpha2a injection will be administered subcutaneously once weekly.
223595403|NCT02401984|OTHER|Screening|Participants will fill out a short screening questionnaire where different aspects of mental health and behavioral problems will be assessed.
223595404|NCT05284916|BEHAVIORAL|liver diseases admissions|The different patterns of liver disease related admissions after the era of DAAS
223595405|NCT02943421|PROCEDURE|Transverse B-Lynch suture|
223595406|NCT02188849|OTHER|Resistance exercise training|All participants will be subjected to resistance training of upper and lower limbs, using elastic bands and tubing and free weights. Training will be calibrated at 60% of one repetition maximum for each muscle group with three sets of 15 repetitions with one minute rest between each set. All exercises will be additionally calibrated to be of moderate intensity according to the Borg scale. The exercise load will be adapted according to the progression of each participant.
223595407|NCT02188849|DRUG|Creatine|Creatine powder 5 g day
223595408|NCT01271374|DRUG|amlodipine and olmesartan|Weeks 1-2: Azor® 5/20 Weeks 3-14: Azor® 10/40 Weeks 15-18: Azor® 10/40+HCTZ 25 Weeks 19-20: Azor® 10/40+HCTZ 25 + spironolactone 25 once daily
223595409|NCT01271374|DRUG|losartan and HCTZ|Weeks 1-2: Hyzaar® 50/12.5 Weeks 3-14: Hyzaar® 100/25 Weeks 15-18: Azor® 10/40+HCTZ 25 Weeks 19-20: Azor® 10/40+HCTZ 25 + spironolactone 25 once daily
223747649|NCT00605475|DRUG|Placebo|Placebo to Canakinumab given as single dose IV injection of 0.03 mg/kg, or single dose IV infusion at doses of 0.1 mg/kg 0.3 mg/kg, 1.5 mg/kg or 10 mg/kg.
224310862|NCT06634121|DEVICE|Transcatheter mitral valve edge-to-edge repair (M-TEER)|M-TEER is performed via a transfemoral venous approach. After puncture of the interatrial septum the mitral valve is repaired using either the PASCAL or MitraClip device.
224310863|NCT00096603|DRUG|Raptiva (efalizumab)|
224197453|NCT03155269|DIETARY_SUPPLEMENT|Fortified Beverage Powder|The tumbler will be filled with water up to the 200 mL mark. The entire contents of one sachet (Fortified beverage powder) will be gradually emptied in the tumbler with intermittent stirring to avoid formation of lumps. The reconstituted product will be consumed by the participants immediately orally.
224197454|NCT03155269|DIETARY_SUPPLEMENT|Non fortified beverage Powder|The tumbler will be filled with water up to the 200 mL mark. The entire contents of one sachet (Non fortified beverage powder) will be gradually emptied in the tumbler with intermittent stirring to avoid formation of lumps. The reconstituted product will be consumed by the participants immediately orally.
224197455|NCT05666648|OTHER|Sitz Bath|Individual patients were randomized to either receive 'sitz baths' or 'no sitz baths' treatment for 4 weeks. Patients were asked to have 'sitz bath' once in morning and again at bedtime, after each week pain scores and healing of fissure were assessed. Main outcome measures were validated
224197456|NCT05888649|BEHAVIORAL|Community Clusters|Assessment of the determinants for community preparedness to EVD outbreaks and acceptance of EVD vaccines.
224197457|NCT03125564|PROCEDURE|Fecal Microbiota Transplantation|Fecal microbiota transplantation
224197458|NCT03125564|PROCEDURE|Sham|Infusion of sham
224197459|NCT03125564|PROCEDURE|Fecal and Mucosal Microbiota Assessment|To assess the fecal and mucosal microbiota before and after Fecal Microbiota Transplantation
224197460|NCT01450670|DIETARY_SUPPLEMENT|Kibow Biotics|Month 1, one capsule three times daily (90 Colony forming units); Month 2, two capsules three times daily (180 CFU's); Month 3, three capsules three times daily (270 CFU's). Continued on tolerated maintenance dosage for an additional 6 months. Once tolerated dosage is identified the patient will be continued on that maintenance dosage for an additional 6 months. All medical, physical, clinical, QOL and other parameters will be monitored as well.
224197461|NCT04733807|BIOLOGICAL|BNT162b2 mRNA Covid-19 Vaccine|Hospital employers vaccinated with BNT162b2 mRNA against Sars-Cov2 are studied for serum antibody response.
224197462|NCT04453475|BEHAVIORAL|Training session adressing information and health literacy|The training sessions are provided online and as alternative to face-to-face treatments which cannot be provided as before due to the safety regulations relating to Covid-19
224197463|NCT00557700|DRUG|Administration of inhaled tiotropium bromide|Administration of inhaled tiotropium bromide
224197464|NCT00557700|DRUG|Administration of placebo|Administration of placebo
224197465|NCT05244109|OTHER|Blood sample|Blood samples (2 times; 21mL per visit)
224197466|NCT05244109|DRUG|anti-TNF antibody administration|Anti-TNF antibody administration, according to current recommendations and randomization results
224197467|NCT05244109|DRUG|anti-IL-17 antibody administration|Anti-IL-17 antibody administration, according to current recommendations and randomization results
224197468|NCT00021476|BEHAVIORAL|Behavioral treatments|
224197469|NCT00021476|BEHAVIORAL|Physical therapy|
224197470|NCT03544567|DRUG|Oraxol|oral paclitaxel will be supplied in capsules and oral HM30181A-US in tablets
224197471|NCT03813160|DRUG|Lenabasum 20 mg|oral capsule
224197472|NCT03813160|DRUG|Lenabasum 5 mg|oral capsule
224310864|NCT00309049|DRUG|Ixabepilone|Capsules / IV formulation, Oral/IV, 15 mg IV and 30 mg Oral (3 capsules) in cycle 1 with a sequence of IV oral and oral dosage and 40 mg IV dose every 3 weeks on cycle 2 onwards, 3 times in cycle 1 (21 days) and every 3 weeks from cycle 2 onwards, 48-96 weeks depending on response.
224310865|NCT00309049|DRUG|Ixabepilone|Capsules / IV formulation, Oral/IV, 15 mg IV and 30 mg Oral (3 capsules) in cycle 1 with a sequence of oral IV and oral dosage and 40 mg IV dose every 3 weeks on cycle 2 onwards, 3 times in cycle 1 (21 days) and every 3 weeks from cycle 2 onwards, 48-96 weeks depending on response.
223506536|NCT06260618|DEVICE|Chitodex|"The Chitogel Endoscopic Sinus Surgery Kit contains components and equipment for the preparation of a nasal gel to be applied to the sinus cavities via a supplied and specifically designed malleable cannula.~The Gel preparation will take approximately 30 minutes, so preparation must start sufficiently in advance of when the Gel is expected to be used in surgery.~Once the Gel has been prepared it should be applied to the sinus cavities on both sides within six hours using the malleable cannula supplied with the Kit.~The Gel must be prepared on a sterile surface following these instructions. There are two main components to the Gel.~1. Dextran Aldehyde (B), which is a dry powder, and is reconstituted into a liquid form through mixing the powder with a liquid Sodium Phosphate Buffer (A). Both of these components are supplied sterile.~2. The second component Chitosan Succinamide (C), is a liquid and is also supplied sterile."
223506537|NCT06019819|OTHER|strengthening exercise|Perform general physical training activities conducted in schools including upper limb forward elevation, lateral elevation, touching toes in standing and cervical range of motion, strengthening exercise will be performed for 3days a week for 4 weeks.
223506538|NCT06019819|OTHER|Postural correction exercises|Chin Tuck, Strengthening shoulder retractors, Stretching sternocleidomastoiD, Pectorals stretch For strengthening exercises 3 sets of 10 repetitions were performed with 6 seconds rest period between each set and a hold of 6 seconds. Stretching exercises will be performed in 3 sets of 10 repetitions ,30 seconds hold and 30 seconds rest period between each exercise. The exercises were performed 3days a week for 4 weeks.
223595410|NCT00017407|BIOLOGICAL|ISIS 3521|
223595411|NCT00017407|DRUG|carboplatin|
223595412|NCT00017407|DRUG|paclitaxel|
223595413|NCT03219684|DIAGNOSTIC_TEST|serum protein ,kidney function ,liver function.,serum cholesterol|monthly review of serum protein kidney function ,liver function and serum cholesterol in all patients
223595414|NCT00162812|DRUG|Epirubicin|100 mg/m² every three weeks (4 cycles) or every two weeks (6 cycles)
223595415|NCT00006433|DRUG|Doxil|
223595416|NCT00006433|PROCEDURE|heat treatment|
223595417|NCT03595488|DRUG|Dupilumab|dupilumab 300 mg subcutaneous injection every 2 weeks
223595418|NCT00235287|DRUG|Candesartan and enalapril|24 weeks of treatment with Candesartan in incremental doses (4,8,16 mg), where Enalapril is added in incremental doses (5,10 and 20 mg)the last 8 weeks.
224197473|NCT03813160|DRUG|Placebo|oral capsule
224197474|NCT06540872|DRUG|[68Ga]Ga-FAPI-46|Participants receive the weakly radioactive drug \[68Ga\]Ga-FAPI-46 through their vein and lie in an imaging device (PET/MRI) for 30 minutes. After a break of 30 minutes, they will lie in the imaging device for another 15 minutes.
224197475|NCT02264886|RADIATION|MRI-guided stereotactive body radiation therapy|
224197476|NCT04034875|OTHER|Questionnaire|questionnaire
224197477|NCT05270772|BIOLOGICAL|CAR-T-19 Cells|T cells were isolated from the PBMC of patients, transduced with lentivirus, expanded in vitro, and infused into patients. The escalated doses include 0.5×10\^6/kg,1.5×10\^6/kg, 5.0×10\^6/kg CAR+ cells.
224310866|NCT00309049|DRUG|Ixabepilone|Capsules / IV formulation, Oral/IV, 15 mg IV and 30 mg Oral (3 capsules) in cycle 1 with a sequence of oral oral and IV dosage and 40 mg IV dose every 3 weeks on cycle 2 onwards, 3 times in cycle 1 (21 days) and every 3 weeks from cycle 2 onwards, 48-96 weeks depending on response.
224310867|NCT04987385|DIETARY_SUPPLEMENT|Protein supplementation|Patients will receive a box with 7 sealable of 90-gram protein containers that will be dissolved in maximal 1L liquid (i.e., water or milk) that should be integrated in the usual daily hydration volume documented at baseline and taken daily for the following 7 days, while keeping their usual meal composition and usual fluid intake. A wash-out period of minimum 7 days between Protein supplementation and Oral urea will be performed.
224310868|NCT04987385|DIETARY_SUPPLEMENT|Oral urea|Patients will receive a box with 7 30-grams urea sealable containers. The total daily oral urea dosage of 30 grams that will be dissolved in maximal 1L of a liquid of choice (water, milk, juice, …) that should be integrated in the usual daily hydration volume documented at baseline and taken daily for the following 7 days, while keeping their usual meal composition and usual fluid intake.
223506539|NCT06964126|OTHER|Horticulture activities|In the study, the elderly individuals in the experimental group will have a total of 8 sessions of gardening activities once a week (on Thursday) for 2 months. Before the gardening activities, the garden and environment will be prepared by the researcher, the elderly individuals will be informed about the day's activities and, if necessary, videos about the activities will be watched and photographs related to the sessions will be shown.
223506540|NCT06964022|OTHER|Sham-BFR|Six-week prehabilitation program (2/week): Unilateral Leg Press and Leg extension exercise with 30% of the individual 1RM by using a sham-BFR intervention with 20mmHg exercise pressure.
223506541|NCT06964022|OTHER|BFR|Six-week prehabilitation program (2/week): Unilateral Leg Press and Leg extension exercise with 30% of the individual 1RM by using a BFR intervention with an exercise pressure corresponding to 60% of the individual LOP.
223506542|NCT06964386|OTHER|The traditional physical therapy rehabilitation exercises|"It included 30 minutes of exercises as:~* Incorporated stretching (adductors, calf, and hamstring muscles)~* Range of motion for hip, knee, and ankle joints.~* Core stability exercises.~* climbing stairs and weight-bearing activities for strengthening, such as sit-to-stand and attaining standing position by half kneeling"
223506543|NCT06964386|OTHER|balance training on traditional balance board|Balance training included: - Side stepping - Stepping backward - Changing the center of gravity in one-foot balance.
223506544|NCT06964386|OTHER|program on special form of balance board|"Standing holding on the sticks of balance board (first by two sticks, then graduated by one stick).~2- Changing the grasp of hand on sticks (reciprocal catching the sticks by right and left hand).~3- Stride standing on balance board. 4- Make exercises advanced by remove sticks and throwing the ball. 5- All previous exercises do with eye closed and eye opened"
223506545|NCT02169401|DEVICE|Implantation with the commercially available Axium Neurostimulator|
223506546|NCT02149160|DRUG|FRM-0334|
223506547|NCT02149160|DRUG|Placebo|
223506548|NCT03508297|DIAGNOSTIC_TEST|In-vivo imaging|Skin cancer is imaged using RCM and a diagnosis is recorded before patient is returned to standard of care (biopsy).
223506549|NCT05980455|DEVICE|Enterra® Therapy System|The Enterra® Therapy System for gastric electrical stimulation (GES) is indicated for the treatment of chronic intractable (drug refractory) nausea and vomiting secondary to gastroparesis of diabetic or idiopathic etiology in patients aged 18 to 70 years.
223595419|NCT00235287|DRUG|candesartan and enalapril|24 weeks of treatment with Enalapril in incremental doses (5, 10, 20 mg), where Candesartan is added in incremental doses (4,8,16 mg) in the last 8 weeks.
223747650|NCT00605475|DRUG|Metformin|Participants continued on their stable daily dose of metformin throughout the study
224197478|NCT02592070|BEHAVIORAL|Walking|Participants will walk on the treadmill for 30 minutes at a moderate intensity.
224197479|NCT06111794|OTHER|REACH TBI|Resources for Enhancing All Caregivers' Health - Traumatic Brain Injury (REACH TBI) is a six-session, telephone intervention for Caregivers of Veterans and Services Members with TBI. The intervention focuses on problem solving training, stress management, and psychoeducation. Trained Program Coaches will deliver the REACH TBI intervention by meeting one-on-one via telephone with participants.
224197480|NCT05181176|DIETARY_SUPPLEMENT|Coffee|3 weight-loss interventions comprised of a similar dietary recommendation with either coffee (coffee group), tea (tea group) or placebo (herbal tea).
224197481|NCT05181176|DIETARY_SUPPLEMENT|Green tea|3 weight-loss interventions comprised of a similar dietary recommendation with either coffee (coffee group), tea (tea group) or placebo (herbal tea).
224197482|NCT05181176|DIETARY_SUPPLEMENT|Herbal tea (placebo)|3 weight-loss interventions comprised of a similar dietary recommendation with either coffee (coffee group), tea (tea group) or placebo (herbal tea).
224197483|NCT01975129|DRUG|Vagitocin|
224197484|NCT06193044|DRUG|Amlodipine/Valsartan|Amlodipine 10 mg \&valsartan 160 mg
224197485|NCT06193044|DRUG|Amlodipine 10 mg &valsartan 160 mg (Exforge)|Amlodipine 10 mg \&valsartan 160 mg
224197486|NCT00104962|DRUG|lenalidomide|Given orally
224197487|NCT02944344|BEHAVIORAL|Four Conversations|The online Four Conversations program consists of tutorial videos, printable documents, and live sessions with a counselor to educate subjects on shared decision making and care planning for those with advanced disease.
224197488|NCT05054621|BIOLOGICAL|Heterologous prime-boost schedule with AZD1222 and MVC-COV1901|Participants will be divided into two subgroups according to the intervals, 28-42 days and 56-70 days, between the prime and booster doses.
224197489|NCT05054621|BIOLOGICAL|Homologous prime-boost schedule with two doses of AZD1222|Participants will be divided into two subgroups according to the intervals, 28-42 days and 56-70 days, between the prime and booster doses.
224197490|NCT00943826|DRUG|Bevacizumab|10 mg/kg intravenously q2w in the Concurrent and Maintenance Phases. 15 mg/kg intravenously q3w in the Monotherapy Phase.
224197491|NCT00943826|DRUG|Temozolomide|75 mg/m\^2 once daily for 6 weeks, followed by 150-200 mg/m\^2 once daily on days 1-5 of six 4 week cycles.
224197492|NCT00943826|RADIATION|Radiation therapy|30 fractions of 2 Gy delivered on days 1-5 per week for 6 weeks.
224197493|NCT00943826|DRUG|Placebo|Intravenously q2w in the Concurrent and Maintenance Phases and q3w in the Monotherapy Phase.
224197494|NCT06567665|DIETARY_SUPPLEMENT|Leucine|Leucine is a dietary supplement that can be easily purchased over the counter at health food stores. It is an essential amino acid and is involved in stimulate muscle protein synthesis.
224197495|NCT00326625|DRUG|40 mg glatiramer acetate|parenteral drug
224197496|NCT00326625|DRUG|Placebo|
224197497|NCT00517868|DRUG|URG101|Bladder instillation of URG101 or Placebo in random order on treatment 1 and treatment 2 followed by an open-label URG101 on treatment 3 within the same week.
224197498|NCT00517868|DRUG|Placebo|Liquid formulation without active URG101 drug components
224197499|NCT01894542|DIETARY_SUPPLEMENT|Cod protein from presscake|6g protein per day for 8wk
224197500|NCT01894542|DIETARY_SUPPLEMENT|Cod protein from presscake + stickwater|6 g protein per day for 8 wk
224197501|NCT01894542|DIETARY_SUPPLEMENT|Control|
224197502|NCT05230160|OTHER|Intermittent Fasting|"Intermittent Fasting (IF) is a dietary intervention that involves periodic intervals of no or very limited energy intake. Fasting and feeding intervals vary and the practice of IF commonly consists of either a daily fast for 16 hours, a 24-hour fast on alternate days, or a fast two days per week on non-consecutive days.~For the study, the IF group will be asked to fast for 16 consecutive hours, 6 days per week. This means they will have an 8-hour eating window (e.g., eat from 10 a.m. to 6 p.m.) each day. They will be asked to eat the same types of food and the same amounts as usual, but only during the 8-hour eating window."
224197503|NCT04766970|BEHAVIORAL|ADOS-2 Module 4|Assessment in person using standardized Autism Diagnostic Observation Schedule, 2nd Edition (ADOS-2) Module 4.
224197504|NCT04766970|BEHAVIORAL|Adapted Telehealth ADOS-2 Module 4|Assessment via telehealth/teleconference platform using an adapted ADOS-2, Module 4 assessment protocol.
224310869|NCT01226771|DRUG|"Ribavirin loading dose given"|PEG-IFN α-2a 180 μg/week plus loading (≥26 mg/kg/day for 2 weeks followed by ≥13 mg/kg/day) and concentration targeted (≥ 2.5 mg/L, i.e ≥ 10.25 μmol/L, as measured after 4 weeks of therapy) dosing of ribavirin and response guided treatment duration (RVR 24 weeks, non-RVR 48 weeks, pEVR consider 72 weeks), follow-up period 24 weeks
223595420|NCT00235287|DRUG|candesartan and enalapril|8 weeks of treatment with Candesartan in incremental doses (4,8,16 mg), followed by 8 weeks of treatment with Enalapril in incremental doses (/5,10,20 mg). The treatment in the last 8 out of the 24 weeks is a combination of Candesartan in incremental doses (4,8,16 mg) and Enalapril 20 mg.
223595421|NCT00235287|DRUG|candesartan and enalapril|8 weeks of treatment with Enalapril in incremental doses (5,10,20 mg), followed by 8 weeks of treatment with Candesartan (4,8,16 mg). The treatment in the last 8 out of the 24 weeks is a combination of Candesartan 16 mg and Enalapril in incremental doses (5,10,20 mg)
223595422|NCT01630889|DRUG|Roxadustat|Oral capsule
223595423|NCT04814056|DRUG|Afatinib Dimaleate|Afatinib is the second-generation TKI drug, which can irreversibly bind to receptors of erbB family. Afatinib will be administered orally at a dose of 40 mg per time, Q.D. If a patient cannot tolerate a dose of 40mg due to adverse reactions, when the adverse reactions restore to level 1 (CTCAE 5.0) or below, the dosage could be adjusted to 30mg per day, Q.D.
223595424|NCT03217214|DIAGNOSTIC_TEST|Thermography|Passive thermography for Phase I subjects and Active Thermography for Phase II subjects
223595425|NCT01587235|DRUG|Ezetimibe/simvastatin|Algorithm based treatment using 10/10mg, 10/20mg and 10/40mg ezetimibe/simvastatin combination tablets orally once daily.
223595426|NCT01587235|DRUG|Other Statin|Participants are prescribed a statin (any other than Vytorin) as per routine standard of care
223747651|NCT06329479|BEHAVIORAL|Cognitive behavioural therapy for Insomnia (CBT-I)|A psychoeducational and evidence-based skills and strategies course for insomnia delivered online over four lessons through ThisWayUp. This will be completed during an 8-week feasibility trial.
223747652|NCT06329479|DEVICE|Bright Light Therapy|Daily bright light therapy for 30 minutes on waking delivered using the Lumie-L light box during an 8-week feasibility trial.
224197505|NCT02122744|DEVICE|Super Rapid Magstim Stimulator|"The repetitive transcranial magnetic stimulation (rTMS) is able to modify cortical excitability and reactivity. 1Hz rTMS inhibits the cortex, 10Hz excites it. In particular, a new paradigm of rTMS, the rTMS quadri pulse has a more lasting and effective activity.~The side effects are rare and transient: migraine,contractions of the muscles of the neck due to muscle stimulation by the electromagnetic field of the coil."
224197506|NCT02122744|DEVICE|Super Rapid Magstim Stimulator (sham)|coil perpendicular to the scalp
224197507|NCT01708694|DIETARY_SUPPLEMENT|Amylose|One group of participants will consume a yogurt containing 45 g of amylose (the slowly digesting starch) for 3 months.
224310870|NCT01226771|DRUG|"Priming dose of ribavirin given"|Standard-of-care dosing of ribavirin (≥13 mg/kg/day) without PEG-IFN for 4 weeks followed by 24-48 additional weeks of PEG-IFN α-2a 180 μg/week plus standard-of-care dosing of ribavirin (≥13 mg/kg/day) and concentration targeted (≥ 2.5 mg/L, i.e ≥ 10.25 μmol/L, as measured after 28 days after the initiation of ribavirin) dosing of ribavirin and response guided treatment duration (RVR 28 weeks, non-RVR 52 weeks, pEVR consider 76 weeks), follow-up period 24 weeks
223595427|NCT01854424|OTHER|Bronchoalveolar lavage (BAL) before day 2 , between days 5-7 and days 10-14 of evolution.|All the samples will be obtained during current care in the first week of evolution, and the last set of samples (BAL and blood sample between day 10-14) only in patients still under ventilation at this time point.
223747653|NCT06329479|BEHAVIORAL|Individualised activity plan|An individualised activity plan is created at baseline and adjusted weekly aiming to increased daytime physical activity and reduce sedentary behaviours. The activity plan takes into consideration personal interests, perceived barriers to activity and develops an activity plan using Specific Measureable Achievable Realistic and Timely (SMART) goals. This will take place during an 8-week feasibility trial.
223595428|NCT00848224|BEHAVIORAL|systems-based and pharmacist-mediated program|Patients in the SI were seen by a study pharmacists prior to discharge to establish a relationship with the patient, explain the pharmacist's role in the study, provide education about all discharge medications and a medication card listing all medications and their manner of use, and set the framework for the follow-up telephone calls. Patients received pharmacist-delivered adherence counseling telephone contacts that took place at two weeks following discharge, and at months 1, 3, 6, and 9 oriented towards assisting patients to remain adherent to prescribed lipid-lowering and other medications, and also towards ensuring that all patients were either documented to be at the LDL-C goal, or were assisted to reach the goal by facilitating the scheduling of repeat lipid measurement as needed and providing information, guidelines and prompts to the patient's physician or nurse practitioner.
223595429|NCT04599595|DEVICE|Peristeen (Coloplast)|"Patients with severe intestinal dysfunction impairment (PAC QoL score ≥ 32) will be offered the adoption of the TAI (Transanal Irrigation) with Peristeen Device as a way to manage their own evacuation, replacing any other measure used until that moment (suppositoires, clisms exceptionally cc) with the exception of the possible intake of macrogols and/or prebiotics and/or probiotics which instead patients can continue. This treatment will be proposed to all patients with severe impairment of intestinal function.~The TAI training with Peristeen will be carried out at the surgical clinic of the Surgical Department of the Ferrara University Hospital, Italy, by the health personnel involved in the study, usually in a single session, but more sessions may be necessary, with the continuation of the TAI for 4 weeks or with patient's exclusion from the study if the guarantees of appropriate use of the device will not be reached."
223595430|NCT03905902|BIOLOGICAL|DCVAC/OvCa|activated autologous dendritic cells
223595431|NCT03905902|BIOLOGICAL|DCVAC/OvCa placebo|placebo for activated autologous cells
223595432|NCT00605345|DRUG|Darbepoetin alfa|As prescribed
223595433|NCT00605345|DRUG|methoxy polyethylene glycol-epoetin beta [Mircera]|120, 200 or 360 micrograms sc 4-weekly (starting dose)
223595434|NCT05073198|OTHER|Education brochure|In the content of the brochure about testicular cancer and CCTM prepared in line with the literature; It includes information such as the definition of testicular cancer, testicular cancer risk factors and symptoms, the importance of early diagnosis in testicular cancer, how CCTM is performed, and what to do in case of differences after the examination. Expert opinion was obtained from three faculty members (a professor from the Department of Urology, a professor in Public Health Nursing and a physician faculty member) regarding the content validity of the educational brochure created before the research.
223595435|NCT04621487|DRUG|Amoxicillin|14 days 1 gr bid
223595436|NCT04621487|DRUG|Metronidazole|14 days 500 mg bid
223595437|NCT04621487|DRUG|Clarithromycin|14 days 500 mg bid
223595438|NCT04621487|DRUG|Pantoprazole 40mg|40 mg bid 14 days
223595439|NCT04621487|DRUG|according to antibiogram|according to antibiogram
223595440|NCT05669651|OTHER|Fecal Microbiota Transplantation|Fecal microbiota transplantation (FMT) refers to the transplantation of functional flora from healthy people's feces into patients' intestines to rebuild new intestinal flora and achieve the treatment of intestinal and parenteral diseases. In this study, 100 patients with recurrent hepatic encephalopathy were randomly divided into 1:1 groups to receive FMT with different amounts of bacteria, observe the therapeutic effect and adverse reactions of hepatic encephalopathy, and evaluate the effectiveness and safety of the two groups of patients. At the same time, the blood and stool samples of patients with recurrent hepatic encephalopathy before and after FMT were collected clinically, the composition of bile acid and other metabolites in stool and serum samples was analyzed, and the effective core flora was identified to clarify the mechanism of intestinal bacteria transplantation for the treatment of recurrent hepatic encephalopathy.
223595441|NCT00000470|PROCEDURE|cardiac surgical procedures|
223595442|NCT00000470|PROCEDURE|cardiopulmonary bypass|
223595443|NCT05660447|DRUG|Netarsudil 0.02% Ophthalmic Solution [RHOPRESSA]|One drop of rho-kinase (ROCK) inhibitor in the vitrectomized eye, once daily in the evening starting on postoperative day 1 after RRD repair surgery, till post-operative day 56
223595444|NCT05660447|DRUG|Glycerin 0.2%/Hypromellose 0.2%/Peg 1%/Soln,Oph,Ud|Patients enrolled in the control group will receive a placebo (one drop of artificial tears) once daily in the evening starting on postoperative day 1 after RRD repair surgery, till post-operative day 56
223595445|NCT01031862|OTHER|3H-Cholesterol|A single dose of 25-50 μCi 3H free cholesterol -albumin complexes (containing approximately 0.1 - 0.3 mg of cholesterol) will be administered intravenously as a slow bolus injection within 1-2 minutes.
223595446|NCT04427449|BIOLOGICAL|CD44v6-specific CAR gene-engineered T cells|4SCAR-CD44v6 Infusion of 4SCAR-CD44v6 T cells at 10\^6 cells/kg body weight
223595447|NCT02488993|OTHER|Prospective Phase Rifaximin-α 550mg|Prospective data collection of all patients receiving rifaximin-α 550 mg from the point of study entry.
223595448|NCT02488993|OTHER|Prospective Phase No Rifaximin-α 550mg|Prospective data collection of all patients not receiving rifaximin-α 550 mg from the point of study entry.
223595449|NCT02488993|OTHER|Retrospective Phase|Review of medical records and electronic hospital admissions data for patients with HE who have not received rifaximin-α 550 mg during the previous 12 months.
223595450|NCT00012168|DRUG|isosulfan blue|
223595451|NCT00012168|GENETIC|polymerase chain reaction|
223595452|NCT00012168|OTHER|immunohistochemistry staining method|
223595453|NCT00012168|PROCEDURE|lymphangiography|
224310871|NCT01226771|DRUG|"Group C (Standard-of-Care)"|PEG-IFN α-2a 180 μg/week plus standard-of-care dosing of ribavirin (≥13 mg/kg/day without any measurement of ribavirin concentration) and response guided treatment duration (RVR 24 weeks, non-RVR 48 weeks, pEVR consider 72 weeks), follow-up period 24 weeks
223595454|NCT00012168|PROCEDURE|radionuclide imaging|
223595455|NCT00012168|PROCEDURE|sentinel lymph node biopsy|
223595456|NCT00012168|RADIATION|technetium Tc 99m sulfur colloid|
223595457|NCT03395002|DRUG|Tiotropium/Salmeterol/Fluticasone 9/50/500 mcg Inhalation Powder|Tiotropium/Salmeterol/Fluticasone 9/50/500 mcg Inhalation Powder (1 puff) twice daily via Discair® for two days.
223595458|NCT03395002|DRUG|Tiotropium 18 mcg Inhalation Powder|Tiotropium 18 mcg Inhalation Powder (1 puff) once daily via Handihaler® for two days.
223595459|NCT03395002|DRUG|Salmeterol/Fluticasone 50/500 mcg Inhalation Powder|Salmeterol/Fluticasone 50/500 mcg Inhalation Powder (1 puff) twice daily (approximately every 12 hr) via Diskus® for two days
224197508|NCT01708694|DIETARY_SUPPLEMENT|Amylopectin|"The second group will consume a yogurt containing 45 g of a different starch called amylopectin (the placebo) for 3 months."
223595460|NCT00865319|RADIATION|Radiolabeled (99Tc) EC-DG (ethylenedicysteine-deoxyglucose)|one injection of Technetium ethylenedicysteine-deoxyglucose to yield a target activity of 20mCi (range 20-30 mCi) to be given by slow IV push (over 3-5 minutes) 1mg of EC-DG to be injected
223595461|NCT00865319|RADIATION|18 F fluorodeoxyglucose|single injection of 18F FDG (range 10-20mCi)
223595462|NCT04619355|DEVICE|NIRS-IVUS|Near-infrared spectroscopy-intravascular ultrasound can be implemented in parallel with intravascular ultrasound and provides important information for predicting prognosis by measuring the lipid component of atherosclerotic plaques.
223595463|NCT02501525|DEVICE|RIRS with ureteral access sheath|Ureteral access sheath will be used during RIRS.
223595464|NCT02501525|DEVICE|RIRS without ureteral access sheath|Ureteral access sheath will not be used during RIRS.
223595465|NCT02572622|OTHER|non -surgical spinal decompression therapy|it is a kind of traction therapy, it has an special traction design which can provide intermittent traction as to herniation levels.
223595466|NCT02572622|OTHER|deep friction massage,|deep friction massage is a kind of massage targeting deep muscles for decreasing pain and increasing function
223595467|NCT02572622|OTHER|electrotherapy|electrotherapy is consist of hot pack, ultrasound and TENS. electrotherapy agents were help decreasing pain, increasing metabolism of tissues.
223595468|NCT02572622|OTHER|exercise|special lumbar stabilization exercises were applied in advanced protocol.
223595469|NCT04723680|OTHER|Qualitative interview|Qualitative semi structured interview
223595470|NCT06066008|DRUG|ZM-01-L|rAAV-hRS1 intravitreal injection of low dose
223595471|NCT06066008|DRUG|ZM-01-H|rAAV-hRS1 intravitreal injection of high dose
223595472|NCT01221493|PROCEDURE|Cryo biopsy|Cryoprobe, Erbe Company
223595473|NCT05698953|OTHER|Reiki|Reiki is applied to the Reiki group for 20-30 minutes for three consecutive days.
223595474|NCT05698953|OTHER|Placebo|Placebo group is applied to the sham Reiki group for 20-30 minutes for three consecutive days by an independent nurse during the same application period.
224197509|NCT02277548|DRUG|Lyrica 300 mg|Lyrica 300 mg per day
223595475|NCT05021575|OTHER|Data collection on outpatient care|"Outpatient data from 1 January to 30 November of the analysed year were obtained from National Health Insurance Fund under the Ministry of Health.~Outpatient data related to cardiovascular diseases (CVD) were collected as described:~1. data on visits were collected using ICD-10 codes I00-I99 and other CVD related codes (e.g., certain Z, Q codes, J81.0, R57.0)~2. data were collected from CVD prevention program~3. data on interventional cardiology were collected from day care facility regardless of the diagnosis.~Date of the visit, patient age, sex and municipality, service level (primary, secondary or tertiary), type of service and main diagnosis were recorded."
223595476|NCT05021575|OTHER|Data collection on hospitalisation|"Hospitalisation data from 1 January to 30 November of the analysed year were obtained from National Health Insurance Fund under the Ministry of Health.~Data on hospitalisation were collected if any of the diagnoses (principal or secondary) were in I00-I99 range. Hospitalisation data covered hospitalisation date, patient age, sex, municipality and outcome. Data on cardiovascular procedures performed during hospitalisations included date of the procedure and ACHI (Australian Classification of Health Interventions) code."
223595477|NCT05021575|OTHER|Data collection on cardiovascular mortality|Data on cardiovascular mortality were obtained from death certificates provided by Causes of Death Registry from Institute of Hygiene and covered the period from 1 January to 31 December of the analysed year. Death certificates were included in the study when cause of death was adjudicated to be in I00-I99 range. Date and place of death (hospital, home, other or unspecified), patient age and sex were recorded.
223595478|NCT05021575|OTHER|Data collection of patients presenting to the tertiary care centre with acute coronary syndrome|Demographic, clinical and percutaneous coronary intervention (PCI) related data were collected from 1st March to 30th June of the analysed year. The timing of the chest pain onset, call for medical help, first medical contact (FMC), arrival to PCI centre, and PCI procedure were analysed.
223595479|NCT01674205|BIOLOGICAL|A/swine/Missouri/4296424/2006 (H2N3) x A/Ann Arbor/6/60 ca (H2N3 MO 2006/AA ca)|
223595480|NCT01674205|BIOLOGICAL|A/chicken/Hong Kong/G9/97 (H9N2) x A/Ann Arbor/6/60 ca (H9N2 G9/AA ca)|
223595481|NCT01674205|BIOLOGICAL|2012-2013 trivalent seasonal live attenuated influenza vaccine (FluMist®)|
223595482|NCT01674205|BIOLOGICAL|Vaccine placebo (Leibovitz-15 [L-15])|
223595483|NCT01674205|BIOLOGICAL|Vaccine placebo (FluMist®)|
223595484|NCT00566254|DRUG|Zonisamide|8mg/kg per day for approximately 24 weeks.
223595485|NCT00566254|DRUG|Placebo|
223595486|NCT00238238|BIOLOGICAL|rituximab|Given IV
223595487|NCT00238238|DRUG|lenalidomide|Given orally
223595488|NCT03662516|DRUG|PF-04965842|Orally bioavailable small molecule that selectively inhibits JAK 1 by blocking the adenosine triphosphate (ATP) binding site.
223595489|NCT03662516|DRUG|Ethinyl estradiol (EE) and levonorgestrel (LN)|Single dose of Oral tablet containing 30 ug EE and 150 ug of LN
223747654|NCT06329479|OTHER|Clincial review|Two clinical reviews will take place during an 8-week feasibility trial and consider uncontrolled symptoms, medication and blood test abnormalities which may impact on rest and physical activity levels
223747655|NCT00183300|BEHAVIORAL|Prolonged Exposure Therapy|
224197510|NCT02277548|DRUG|Placebo|
224197511|NCT01843439|DIETARY_SUPPLEMENT|Magnesium|
224197512|NCT01843439|BEHAVIORAL|Education for asthma action plan|
224197513|NCT01843439|BEHAVIORAL|hot-lines for acute exacerbation of asthma|
224197514|NCT01843439|BEHAVIORAL|Inhaler technique training|
224197515|NCT01901939|OTHER|exercise|daily tailored low level pedaling exercise at bedside
224197516|NCT04943510|OTHER|Physical exercices|"surface EMG: surface electrodes will be positioned on the muscles to evaluate the level of muscle activation~non invasive muscular neurostimulations : application of a percutaneous electrical stimulation of the motor nerve of the considered muscle and a direct electrical stimulation of the muscle"
224310872|NCT00952211|DEVICE|CPAP|CPAP at therapeutic pressure during nighttime
224310873|NCT00952211|DEVICE|CPAP at sub-therapeutic pressure|CPAP delivered at sub-therapeutic pressure at nighttime
223747656|NCT05875233|OTHER|Elix Daily Harmony|"Elix Daily Harmony is a clinical-strength, organic blend of hormone-balancing Traditional Chinese Medicine (TCM) herbs and adaptogens. Contains Angelica Sinensis, licorice, ginger, Bupleurum, Cyperus Rotundus, White Peony, Mint, Poria, Atractylodes, White Ginseng, Reishi, Rehmannia Root, and Astragalus.~Participants should add 3 droppers full (half a teaspoon or 2.5 ml) of Elix Daily Harmony to their tea or other warm or room temperature beverage each morning, 1-2 hours after their first meal. The product should not be taken with iced drinks or with food."
224197517|NCT01243307|DRUG|CT327 (or placebo) followed by placebo (or CT327)|"During treatment/testing period 1, subjects will apply 0.25 g CT327 (or placebo) to 4 test fields of skin (2 on their arms and 2 on their legs) twice daily, 12 hours apart for a total of 7 applications.~During treatment/testing period 2, subjects will apply 0.25 g placebo (or CT327) to 4 different test fields of skin (2 on their arms and 2 on their legs) twice daily, 12 hours apart for a total of 7 applications."
224197518|NCT03130556|DRUG|Glasdegib|Subjects receive 100 mg single dose of ICH glasdegib under fasted condition with washout and then 100 mg single dose of Phase 2 tablet under fasted condition with washout in a randomized fashion. Finally subjects either receive a 100 mg single dose ICH tablet after a high fat, high calorie meal or receive a 100 mg single dose of ICH tablet after repeated daily dosing with rabeprazole.
223595490|NCT03731078|OTHER|CBT Informed physical therapy Intervention|The 12 physical therapy sessions delivered in Massachusetts General Hospital outpatient physical therapy sites sessions include:1) evaluation and education; 2) strategy identification and goal setting; 3) functional strengthening part one; 4) functional strengthening part two; 5) pre-gait activities with distraction; 6) gait training with distraction and use of strategies; 7) minimizing tremor with use of strategies; 8) higher level balance training; 9) functional reintegration part one; 10) functional reintegration part two; 11) identification of strategies to limit recurrence; 12) education for relapse prevention.Patients will also be given and asked to complete the self-guided CBT workbookL Overcoming Functional Neurological Symptoms: A Five Area Approach. They will be asked to complete the first two chapters over the first 4 weeks and the remaining 8 chapters over the following 8 weeks.
223595491|NCT03458689|PROCEDURE|Left hemicolectomy, laparoscopic technique|Left hemicolectomy, Laparoscopic technique
223595492|NCT01345669|DRUG|Placebo|Once daily
223595493|NCT01345669|DRUG|Afatinib|Once daily
223595494|NCT04933461|DEVICE|Safety lancet|There are sterile, single-use safety lancets designed for the sampling of capillary blood from the fingertip of patients.
223595495|NCT01793883|DRUG|40 mg Laninamivir Octanoate|
223595496|NCT01793883|DRUG|80 mg Laninamivir Octanoate|
223595497|NCT01793883|DRUG|Placebo|
223595498|NCT01392209|OTHER|Bevacizumab & Stereotactic Radiotherapy|Treatment: (until treatment failure): bevacizumab 10 mg/kg IV once every two weeks on days 1 (+/- 3 days) and 15 (+/- 3 days) of every cycle (Cycle defined as 28 days). On day 28 (or up to 2 days before) of cycles 1 and 2 (and for every other cycle thereafter) patients will undergo a physical and radiological re-evaluation (MRI). Patients will begin stereotactic radiotherapy beginning anywhere from day 7 to day 10 of cycle 2 with escalating fraction sizes (interpatient - there is no intrapatient escalation). Assessment of response will be performed following cycles 1 and 2 then following every two cycles.
223595499|NCT05448391|DRUG|RIST4721|RIST4721 tablets, 100 mg are blue, oval, biconvex film-coated tablets
223595500|NCT00004113|DRUG|temozolomide|
223595501|NCT02478255|DRUG|Hyperpolarized 129-Xenon gas|Hyperpolarized xenon will be administered in multiple doses in volumes up to 25% of subject total lung capacity (TLC) followed by a breath hold of up to 15 seconds. Subsequent 129Xe doses will only be administered once the subject is ready to proceed.
223595502|NCT02478255|DEVICE|MRI|Conventional 1H MRI will be used to provide anatomical reference scans, as well as pulmonary perfusion.
224197519|NCT03130556|OTHER|High Fat, High Calorie Meal|A subset of subjects in the study will receive a high fat, high calorie meal prior to being administered a single 100 mg tablet ICH tablet of glasdegib.
223595503|NCT05330091|DIETARY_SUPPLEMENT|Once Daily Women's Probiotic|Active product
223595504|NCT05330091|OTHER|Placebo|Placebo product
223595505|NCT01226576|DEVICE|MRgFUS Treatment|Local treatment of prostate cancer using Magnetic Resonance Imaging guided endorectally applied focused ultrasound energy
223595506|NCT01412385|BIOLOGICAL|Immune Globulin Subcutaneous (Human), 20%|Subcutaneous infusion (regulated via a pump), Epoch 2 only (all subjects)
223595507|NCT01412385|BIOLOGICAL|Immune Globulin Intravenous (Human), 10%|Intravenous infusion (regulated via a pump)
223595508|NCT01412385|BIOLOGICAL|Human Normal Immunoglobulin (Subcutaneous - Intramuscular Immunoglobulin)|Subcutaneous infusion (regulated via a pump)
223595509|NCT02012712|BEHAVIORAL|Personal Health Record (PHR)|"Iowa PHR is a Web-based application that features a tabbed interface design. Users can enter, view, and print their current and past medicines, allergies, health conditions, and health event tracking over time. An embedded tutorial video provides assistance with the system. The PHR was developed and refined using participatory design and focus group sessions as well as evaluation in a usability laboratory. The resulting design emphasizes the reduction of physical and cognitive demands on users, focusing on simplicity, readability, and quick navigation.~Iowa PHR displayed a message when a user entered a medication with an associated Assessing Care of Vulnerable Elders project (ACOVE-3) safety concern. This included 16 safety issues for 12 drugs or drug classes with safety concerns. We also adapted four general medication use patient safety indicators from the ACOVE project and displayed them to all users on a rotating basis upon login."
223747657|NCT05875233|OTHER|Elix Cycle Balance|A tailored blend of medicinal herbs to holistically support menstrual symptoms by treating underlying imbalances. Participants should take 3 droppers full (half a teaspoon or 2.5 ml) of Elix Cycle Balance daily before bed with tea or other warm or room temperature beverage. The product should not be taken with iced drinks or with food.
223747658|NCT00020696|DRUG|cisplatin|
223747659|NCT00020696|DRUG|tirapazamine|
224197520|NCT03130556|DRUG|Rabeprazole|A subset of subjects will receive repeated daily dosing of 40 mg rabeprazole for 7 days with 100 mg single dose of ICH glasdegib being administered on Day 7.
224197521|NCT00405496|DRUG|Difluprednate Ophthalmic Emulsion|
224310874|NCT00552851|DRUG|pegvisomant|booster dosage 80 mg once sc., than 10 mg once per day, uptitration in steps of 5 mg up to an IGF-1 level in the normal range (every 4 weeks), max. 30 mg once per day. Duration of treatment: one year
223747660|NCT03849404|BIOLOGICAL|Adalimumab|Patients in AVT02 arm will receive an initial loading dose of AVT02 80 mg (2 × 40 mg) administered subcutaneously (SC), followed by 40 mg given SC once every other week (EOW) starting 1 week after the loading dose, and will continue to receive AVT02 until Week 48 Patients in EU-Humira arm will receive an initial loading dose of Humira 80 mg (2 × 40 mg) administered SC, followed by 40 mg given SC EOW starting 1 week after the loading dose and will continue to receive Humira until Week 48
223747661|NCT06434662|DRUG|mitoxantrone hydrochloride liposome|Mitoxantrone hydrochloride liposome (24 mg/m\^2) on day 1, every 4 weeks
223747662|NCT06434662|DRUG|Cytarabine|Cytarabine (1.0 g/m\^2, q12h ) on day 1,3,5, every 4 weeks
223747663|NCT06434662|DRUG|Venetoclax|Venetoclax 100 mg on day 2，200 mg on day 3，400 mg on day 4-10, every 4 weeks
224197522|NCT06568523|DIAGNOSTIC_TEST|MAGENTIQ-COLO.|This is a diagnostic performance study; no randomization will be conducted. All subjects will undergo the same study procedures. The endoscopist performing the examinations cannot be blinded for the output of the investigational device in this study. Due to the nature of the intervention, it is not guaranteed that the patient is not awake during the procedure, therefore blinding for the patient is also not feasible.
224310875|NCT03568097|DRUG|Avelumab|10 mg/kg will be given as intravenous infusion (IV) every two weeks (q 2 weeks) until disease progression.
223595510|NCT03736876|BEHAVIORAL|About Us|Each program session includes an initial soap opera-like story to build interest and illustrate key concepts, 2-3 group-based activities with reflection, individual app-based work on tablets to allow for personalization of the content, and a group-based debrief to reflect on the day and reinforce key messages. The group-based content is delivered by trained facilitators from the participating school-based health centers. The app-based content is housed on a secure website and accessed through tablets with unique log-ins for each participant. Activities are completed individually during the session (e.g., completing a poll; watching and responding to a brief video). Several lessons include homework activities that encourage communication between students and a caring adult.
223595511|NCT00223249|DRUG|Quetiapine|
223595512|NCT02380040|DEVICE|PPG|A PPG device will be applied to subjects in the right hand, left hand and one of the legs. Data will be recorded into a computer software
223595513|NCT03100175|BEHAVIORAL|physiotherapy|strength training for upper and lower limbs fitness and balance work out
223595514|NCT03223259|BEHAVIORAL|Injury Prevention Workshops|Each workshop will last 90 minutes and consist of approximately 20-30 minutes of lecture, 30 minutes of movement, no more than 20 minutes for a pre-test (workshop 1) or post-test (workshop 2), and remaining time for Q\&A.
223595515|NCT04720300|OTHER|MaaS app|The MaaS App will be downloaded to students' smartphones and will provide real-time, multimodal trip planning to students on demand when they open the app.
223595516|NCT04720300|OTHER|No app|students receive no app or housing information
223595517|NCT01507480|DRUG|Bevacizumab|There are five increasing doses of bevacizumab nasal spray (25mg/mL): 10 mg, 25 mg, 50 mg, 75, mg and 100 mg. Each test dose is a single dose divided into five fractions and administered into each nostril every 30 minutes for 2 hours:
223595518|NCT04518488|OTHER|Exercises|Personalized and individualized exercises for lower limb soft-tissue sarcoma of each participant in this group.
223595519|NCT04518488|OTHER|Informational Support Group (Control group)|The focus for participants in the Informational Support Group will be on needs for information and psychosocial support during the pre-operative period.
223595520|NCT00731471|BIOLOGICAL|MVA85A|Modified vaccinia virus Ankara expressing antigen 85A from Mycobacterium tuberculosis. Both arms will receive two vaccinations six months apart.
223595521|NCT03412383|DRUG|Pyrotinib|Pyrotinib 400mg/day
223595522|NCT00525096|DRUG|placebo|2 tablets twice a day per os
223595523|NCT00525096|DRUG|Celecoxib|2\*200 mg tablets twice a day per os
223595524|NCT00525096|DRUG|Exemestane|Exemestane 25 mg per day per os
223747664|NCT03741556|OTHER|questionaire|a questionaire is sent to each participans
223747665|NCT01094496|BIOLOGICAL|CDX-1307 Vaccine Regimen|CDX-1307 vaccine co-administered with immune adjuvants (GM-CSF, Poly-ICLC and Resiquimod)
223747666|NCT01094496|DRUG|Chemotherapy|
223747667|NCT00002259|DRUG|Mitoxantrone hydrochloride|
223747668|NCT06409559|DEVICE|Pelvic reconstruction plate without interfragmentary screws|The posterior wall fracture will be operatively stabilized with a pelvic reconstruction plate and interfragmentary screws placed through the plate.
223747669|NCT06409559|DEVICE|Pelvic reconstruction plate with interfragmentary screws|The posterior wall fracture will be operatively fixed with a buttress plate applied under compression without interfragmentary lag or position screws.
223595525|NCT04597073|PROCEDURE|Initial Periodontal Therapy|Oral hygiene education, including the use of toothbrushes and dental floss and/or interproximal brushes, was given to them. After one week Chronic Periodontitis group received nonsurgical periodontal therapy consisting of scaling and root planing (quadrant by quadrant) using manual scalers and curettes under local anesthesia. No antibiotics or any medications were prescribed during the treatment. Periodontal treatment was performed by the same investigator
223747670|NCT04283006|DRUG|CD20/CD22 dual Targeted CAR T-cells|Each subject receive CD20/CD22 dual Targeted CAR T-cells by intravenous infusion
223747671|NCT04634864|DEVICE|Anodal tDCS|40 minutes of 2mA intensity direct current stimulation was delivered over both the right and left motor cortex simultaneously
223747672|NCT04634864|DEVICE|sham tDCS|The stimulator was switched off after 2 minutes of stimulation.
223747673|NCT02795728|OTHER|Application of the GIC based sealant|Application of the GIC based sealant was carried out according to the manufacturer's instructions.
223747674|NCT02795728|OTHER|Resin based sealant|Application of the resin based sealant on the occlusal surfaces was carried out as per the manufacturer s recommendations.
223747675|NCT03131336|DRUG|PeproStat|solution for local application
223747676|NCT03131336|DRUG|Saline|solution for local application
223747677|NCT05505032|DRUG|Oxygen|Determination of FiO2 threshold value as an indicator of hyperoxemia in anesthesia stages.
223595526|NCT03281083|DRUG|Levothyroxine Sodium|
223595527|NCT04113525|DEVICE|MyoRegulator™ System|Paired transcutaneous spinal and peripheral nerve stimulation
223595528|NCT05503056|OTHER|art therapy|six sessions of art therapy with licensed therapists
223595529|NCT05503056|OTHER|nothing|no intervention to this group
223595530|NCT03212456|DRUG|opioid-free group|We'll study if the opioid-free anesthesia can reduce the biochemical recurrence of prostate cancer.
223595531|NCT03212456|DRUG|Opioid Group|This group will receive fentanyl in the induction of anesthesia.
223595532|NCT03212456|PROCEDURE|transversus abdominal plane block with ropivacaine|The opioid-free group will receive transversus abdominal plane block with ropivacaine 0,375% 20 ml each side
223595533|NCT03212456|PROCEDURE|transversus abdominal plane block with placebo|the non-opioid free group will receive transversus abdominal plane block with physiological solution 0,9% 20 ml each side
223595534|NCT00432770|DRUG|ARC1779|
223595535|NCT00051922|BIOLOGICAL|PolyEnv1|Recombinant vaccinia virus vaccine
223595536|NCT01129661|BIOLOGICAL|CSL112 (reconstituted HDL)|Single escalating intravenous doses of CSL112
223595537|NCT01129661|BIOLOGICAL|normal saline (0.9%)|Single intravenous dose of normal saline (0.9%)
223595538|NCT02160691|DEVICE|Anxiety Meter|This is a new device developed to measure changes in heart rate and translate these into a visual display of arousal level in children with autism spectrum disorder.
223595539|NCT01706783|DRUG|somapacitan|Subcutaneous (s.c., under the skin) administration once weekly (Days 1, 8, 15 and 22) of 4 different doses of NNC0195-0092 (somapacitan) in an escalating order
224197523|NCT06039956|PROCEDURE|Sentinel lymph Node Biopsy|The SLNB will be performed with 5 ml of undiluted methylene blue injected in equal aliquots, peri-tumoral, followed by a 5-minute massage prior to skin incision. Sentinel nodes will be defined as those that have uptake / visible blue staining or suspicious palpable nodes at the discretion of the operating surgeon. Sentinel nodes will be placed in formalin and sent separately. This will be followed by an immediate completion ALND, which will be similarly placed in formalin and sent separately from the SLNB specimen. Specimen radiographs will be performed on all specimens to confirm location of clip within SLNB vs. ALND specimens.
224197524|NCT05505851|OTHER|Control|Hip Flexor Stretch 30 seconds hold 3 repetitions on each side Thoracolumbar extensors stretch 30 second holds 3 repetitions Abdominal Curl ups with hands at side 10 repetitions 2 sets Progression: • Abdominal curl up with arms crossed • Abdominal curl ups with hands behind head Pelvic bridging 10 seconds hold 10 repetitions 2 sets
224197525|NCT05505851|OTHER|Sequential Core Stability Corrective Exercise Approach|"1. Corrective Exercises~2. Diaphragm Training Program As per standardized pulmonary rehabilitation guidelines,. Participant will be advised to breathe in gently with an improved tidal volume for ten repetitions, then after a short interval of break 15 repetitions will be done again. 30 Repetitions in set of 15, 15 with the interval rest. 2 sets.~3. Pelvic floor Muscle training Participants will be asked to do pelvic floor training with high intensity (close to maximum) contractions with holding each muscle contraction for 6-8 seconds with relaxation of 6 seconds. Total 8 to 12 contractions.~4. Core Stability exercises~   1. Beginning~  2. Progressing~  3. Advanced"
224197526|NCT00758225|DRUG|Idebenone|Patients ≤ 45 kg: 450 mg/day (1 tablet 3 times a day) Patients \> 45 kg: 900 mg/day (2 tablets 3 times a day)
224197527|NCT02234427|DRUG|Aspirin|2-week aspirin therapy (81mg/day)
224197528|NCT01412307|DRUG|Lenalidomide|10, 15, 20 or 25 mg orally per cohort day 1-28 in a 28 days cycle
224197529|NCT01412307|DRUG|Bendamustine|intravenous on days 1, 8 and 15 of each 28-days cycle at fixed dose of 60 mg/m2, as a 30-60 min i.v. infusion
224197530|NCT01412307|OTHER|Bio-specimen Retention|Samples with DNA and without DNA
224310876|NCT02857751|BEHAVIORAL|Surf therapy|The NMCSD surf therapy program is approximately 6 weeks in duration. Each surf therapy session lasts 2-3 hours and occurs in a group setting that can accommodate up to 20 service members per session. Each service member is paired with a surf instructor who works with him or her each week for the 6-week session. Goals are individually-tailored to the service member (based on participant's level of comfort in the water, experience with surfing, etc.) and can incorporate both physical and psychological objectives.
223595540|NCT01706783|DRUG|Norditropin NordiFlex®|Subcutaneous (s.c., under the skin) administration daily for 28 days. The daily dosing will be the same as the pre-trial daily dose of human growth hormone (hGH) taken by the adult with growth hormone deficiency
223595541|NCT01730586|DRUG|Abraxane|220 mg/m2 administered by vein on Day 1. A cycle of therapy is defined as 21 days.
223595542|NCT02211430|BEHAVIORAL|Cognitive-Behavioral Counseling (CBC)|Participants of CBC were educated about the effects of smoking on their personal health and their pregnancy during session 1 (45 minutes counseling), and were encouraged to explore their risk perceptions and emotions, for themselves and their unborn child. During session 2, the 15-minute counseling segment highlighted the cognitive and emotion barriers undermining the participant's motivation to quit and the self-regulatory techniques for resisting personal smoking triggers. Session 3 (45 minutes counseling) involved reviewing smoking status and smoking history over the course of the pregnancy, as well as the effects of smoking on both their health and the health of their infant. Booster session was held by phone for 15 min.
223595543|NCT02211430|BEHAVIORAL|Best Practice (BC) Control|"For ethical considerations, and consistent with practice guidelines for treating tobacco addiction (Fiore et al., 2000) which mandates that every pregnant smoker be offered smoking cessation treatment, the control group has been designed to be comparable to the current best practice guidelines for smoking cessation treatments. This condition, devised from a review of the current literature, will include one brief (5-15 minutes) prenatal individual session (session 1) consisting of smoking cessation education and advice, on-site brochure pick up (session 2), and a second brief postpartum individual session (session 3) followed by receipt of a newsletter (session 4)."
223595544|NCT00941122|DEVICE|Eluted Swab|Comparison of Eluted Swab with AMIES swab for detection of MRSA/VRE
223595545|NCT00061633|DRUG|Telavancin|Telavancin 7.5 mg/kg/day IV (intravenously) for up to 14 days
223595546|NCT00061633|DRUG|Vancomycin or antistaphylococcal penicillin|Vancomycin 1 Gram IV (intravenously) every 12 hrs or nafcillin 2 Grams, oxacillin 2 Grams, or (in South Africa) cloxacillin 0.5 - 1 Gram, IV (intravenously) every 6 hrs for up to 14 days.
223595547|NCT02542787|DRUG|VSN16R|Small molecule
223595548|NCT02542787|OTHER|Placebo|dummy tablet
223595549|NCT04255641|OTHER|time lapse analysis|grading of the embryos before freezing using time lapse/
223595550|NCT00842543|DIETARY_SUPPLEMENT|Fruit and Vegetable Juice Concentrate (FVJC)|Take FVJC or placebo twice a day for 6 months while receiving dietary and physical activity counseling from a Registered Dietician.
223595551|NCT00842543|DIETARY_SUPPLEMENT|Placebo|Take FVJC or placebo twice a day for 6 months while receiving dietary and physical activity counseling from a Registered Dietician.
223595552|NCT04904874|DEVICE|intense pulsed light|treatment with 3 sessions of intense pulsed light, the second one after 2 weeks, the third one after 6 weeks
223595553|NCT01838915|DIETARY_SUPPLEMENT|Prebiotics+Glutamine|"Prebiotics are nondigestible food ingredients, generally oligosaccharides, that modify intestinal microbiota balance by stimulating the growth of beneficial bacteria.~Glutamine is a non-essential amino acid that can be metabolized by epithelial cells, enhancing barrier function."
223595554|NCT01838915|DIETARY_SUPPLEMENT|Placebo|Maltodextrin, 20 g.
223595555|NCT01486342|RADIATION|PET-CT scan|"PET-CT imaging with \[18F\]FDG will be performed within 24 hours of admission to the ICU. All patients imaged will be those remaining on mechanical ventilation at the time of PET imaging.~A low-dose CT scan (50 effective mAs) will be obtained with placement of the participant such that the lungs are centered within the field of view. After completing the transmission scan, 10 mCi of \[18F\]FDG will be injected intravenously at the start of a 60-minute dynamic scan acquisition and the intravenous (IV) catheter flushed with 10 ml saline. Imaging will be obtained with the following framing schedule: 24 5-sec, 6 3-minute and 8 5-minute frames."
223595556|NCT03738891|DEVICE|Zeltiq CoolSculpting System alone|The CoolSculpting System will be used to perform the treatments in Cohort 3.
223595557|NCT03738891|DEVICE|Electromagnetic Muscle Stimulation alone|The EMS device(s) alone are used in Cohort 1.
223595558|NCT03738891|DEVICE|EMS followed by CoolSculping|Cohort 2 group will be treated with EMS followed by CoolSculpting
223595559|NCT03738891|DEVICE|CoolSculpting followed by EMS|Cohort 4 will be treated first with CoolSculpting, followed by EMS.
223595560|NCT00003411|DRUG|motexafin gadolinium|
223595561|NCT00003411|RADIATION|radiation therapy|
223595562|NCT00003202|DRUG|cisplatin|
223595563|NCT00003202|DRUG|gemcitabine hydrochloride|
223595564|NCT00003202|RADIATION|radiation therapy|
223595565|NCT01483183|DRUG|OPC-108459|"Part 1: single dose OPC-108459, 10-minute constant rate IV infusion to achieve specified Cmax target~Part 2: single dose OPC-108459, 10-minute constant rate IV infusion to achieve Cmax target concentration from Part 1; if failure to convert to sinus rhythm, second dose OPC-108459 administered, 10-minute constant rate IV infusion to achieve target concentration from Part 1"
223595566|NCT01483183|DRUG|Placebo|Placebo dose, 10-minute constant rate IV infusion
223595567|NCT00239928|DRUG|pegaptanib sodium|1 drop per dosed eye per protocol.
223595568|NCT03971565|BIOLOGICAL|Blood sample 5 milliliter|The blood of the patients will be collected during their hospitalization of the hematology department participating in the research
223595569|NCT03491514|OTHER|Test Granola|51 g Test Granola
223595570|NCT03491514|OTHER|Control Granola|54.1 Control Granola
223595571|NCT05893719|DEVICE|iNedit, iNdeep, iNtercept|Patients to undergo mechanical thrombectomy with iNedit, iNdeep and iNtercept
223595572|NCT05418088|BIOLOGICAL|Anti-CD19/CD20/CD22 CAR T-Cells|Given IV
223595573|NCT05418088|DRUG|Cyclophosphamide|Given IV
223595574|NCT05418088|DRUG|Fludarabine Phosphate|Given IV
223595575|NCT05418088|PROCEDURE|Echocardiography|Undergo echocardiography
223595576|NCT05418088|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA scan
223595577|NCT05418088|PROCEDURE|Biopsy|Undergo tissue biopsy
223595578|NCT05418088|PROCEDURE|Pheresis|Undergo apheresis
223595579|NCT05418088|PROCEDURE|Bone Marrow Aspiration and Biopsy|Undergo bone marrow aspiration and biopsy
223595580|NCT05418088|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223595581|NCT02098265|DEVICE|Functional Electric Stimulation (FES)|FES uses low energy electrical pulses to artificially generate body movements in individuals with muscle paralysis. FES can be used to generate muscle contraction in otherwise paralyzed limbs to restore function.
223595582|NCT02098265|BEHAVIORAL|Behavioral Assessments|These assessments will include measures of upper extremity motor assessments, standard stroke scales, and measures of activities of daily living.
223595583|NCT02098265|OTHER|Magnetic Resonance Imaging|A functional magnetic resonance image will be collected.
223747678|NCT05505032|DEVICE|Masimo Root Radical 7|We use it to measure the oxygen reserve index (ORi).
223595584|NCT02098265|OTHER|EEG|EEG electrodes will be attached to the participant's scalp using a standard, commercially available electrode cap. Proper electrode placement is made according to the international 10-20 system, ensuring complete electrode coverage over sensorimotor cortex.
223595585|NCT02098265|OTHER|RecoveriX|RecoveriX is a brain driven rehabilitation system for stroke patients that pairs mental activities with motor functions.
223595586|NCT02098265|OTHER|Delay|10 week delay before intervention
223595587|NCT02098265|DEVICE|BCI-FES|
223595588|NCT04375059|OTHER|using interactive attention training system|using the interactive attention training system to children with Attention Deficit Hyperactivity Disorder
223595589|NCT02794233|OTHER|Impedance measurements|Refer to study description
223595590|NCT04942405|BIOLOGICAL|TURCOVAC|Two doses at 28-day interval, each inoculation dose is 0.5 mL. Two doses of dosage (vaccine contains 600 subunit of SARS-CoV-2 virus antigen) experimental vaccine at the schedule of day 0,28
223595591|NCT04942405|BIOLOGICAL|CoronaVac|Two doses at 28-day interval, each inoculation dose is 0.5 mL. Two doses of dosage (vaccine contains 600 subunit of SARS-CoV-2 virus antigen) vaccine at the schedule of day 0, 28
223595592|NCT00208533|DRUG|Aripiprazole|Aripiprazole 5 mg to 30mg, individually titrated
223595593|NCT06584266|DIAGNOSTIC_TEST|Transoesophageal echocardiography|Imaging data obtained with transoesophageals echocardiography will be retained as well as data from transthoracic echocardiography and from other imaging modalities, if available
223595594|NCT06584266|PROCEDURE|Catheter ablation|Cathether ablation of atrial fibrillation substrate using one of available methods.
223595595|NCT06583967|OTHER|Physical Training|Group 1 - Elliptical Trainer Group 2 - Treadmill
223747679|NCT02596854|DEVICE|Neurological MRI|Neurological MRI image collection
223595596|NCT00661817|BEHAVIORAL|Lifestyle Modification Program|"Participants will receive a behavior change prescription and skills training, offered via the Internet or through a combination of tailored print materials and an interactive voice response system, together with support strategies to enhance the intensity of the interpersonal and social-environmental support."
223595597|NCT00661817|BEHAVIORAL|Usual Care and Reading Materials|"Participants in this group will receive usual medical care provided by their own primary care providers. They will also receive the NHLBI's Aim for a Healthy Weight brochure at the baseline study visit and again at the beginning of Year 2."
223595598|NCT01847976|DRUG|Doxycycline|Participants will be asked to take 100 mg of Doxycycline by mouth twice a day for 12 weeks.
223595599|NCT03082092|DRUG|Methylprednisolone Sodium Succinate|single intravenous dose of 125mg methylprednisolone diluted in 2.1ml of diluent given on induction of total knee replacement
223595600|NCT03082092|DRUG|Placebos|0.9% intravenous saline (2.1ml) intravenously on induction of total knee replacement
223747680|NCT00107211|BIOLOGICAL|therapeutic autologous dendritic cells|
223595601|NCT00896025|DRUG|N-acetylcysteine|"Patients will be included in the trial from the onset of any hepatic coma grade and will receive NAC for the following 72 hrs.~NAC Solutions: The N-acetylcysteine will be added to 5% dextrose in defined concentrations according to the sequence of four specific doses required for the study.~i.Solution A: 150 mg/kg bodyweight in 250 ml 5% dextrose over one hour~ii.Solution B: 50 mg/kg in 500 ml 5% dextrose over four hours~iii.Solution C: 125 mg/kg in 1000 ml 5% dextrose over 19 hours~iv.Solution D: 150 mg/kg in 1000 ml 5% dextrose per 24 hours~v.Solution E: 150 mg/kg in 1000 ml 5% dextrose per 24 hours"
224197531|NCT06016231|DEVICE|Light Adjustable Lens|The Light Adjustable Lens (LAL) is a posterior chamber, UV absorbing, three-piece, foldable, photoreactive silicone intraocular lens with a squared posterior optic edge intended to be implanted in the capsular bag following phacoemulsification. Selective exposure of the implanted RxSight LAL using the Light Delivery Device (LDD) to deliver a spatially profiled UV light produces modifications in the lens curvature resulting in a spherical or spherocylindrical power change post-operatively. A subsequent lock-in exposure is delivered to the implanted LAL to stabilize the lens power.
224197532|NCT06519422|DRUG|Tranexamic Acid 500 MG|Tablets
224197533|NCT06519422|OTHER|Matched placebo|Matched placebo tablets (inactive ingredients only, including microcrystalline cellulose, magnesium stearate BP and lactose)
224197534|NCT05263024|DEVICE|atrial appendage clip|During cardiac surgery, atrial fibrillation patients were treated with atrial appendage clipping
223747681|NCT00107211|PROCEDURE|conventional surgery|
224197535|NCT02080624|DRUG|Drug: Topical Rapamycin|"After signing this consent form, you will be asked to undergo some screening tests or procedures to find out if you can be in the research study.~A medical history, which involves questions about your health history, any medications you are taking or plan to take, any allergies and the treatments you received for your CM.~A physical exam, during which you will be asked about any problems that you might be having. Additionally, your clinician will check your vital signs (blood pressure, heart rate, weight and height). The doctor will also evaluate your performance status, which indicates how much your illness affects your activity level.~Blood tests, which will be done to make sure your hemogram, triglyceride and cholesterol levels are normal.~A pregnancy test for females will be done to check that you are not pregnant. If theses tests show that you are eligible to participate in the research study, you will begin the study treatment."
224197536|NCT06568627|DRUG|EscharEx (EX-03)|a sterile lyophilized powder containing a concentrate of proteolytic enzymes enriched in bromelain (anacaulase-bcdb). The powder and sterile water are mixed to form a gel prior to application on the wound area.
224197537|NCT06568627|DRUG|Placebo (Gel vehicle)|A sterile powder containing excipients only (no proteolytic enzymes). The powder and sterile water are mixed to form a gel prior to application on the wound area
224197538|NCT02364414|DEVICE|3Shape TRIOS (R)|Direct intra-oral scan of teeth and dentition
223595602|NCT05602701|OTHER|Preoperative assessment|Preoperative assessment of physical fitness
223595603|NCT03887234|PROCEDURE|Coracoclavicular ligament reconstruction|Arthroscopically conducted ligament reconstruction for the treatment of an AC dislocation
223595604|NCT00196144|DEVICE|Individualized Programming of PVAB|Performance of a test to detect far-field R-wave sensing
223595605|NCT00196144|DEVICE|Nominal PVAB|nominal pacemaker settings
223595606|NCT00642161|DRUG|budesonide|
223595607|NCT03100058|DRUG|LIK066|LIK066 will be supplied in different doses as tablets to be taken orally.
223595608|NCT03100058|DRUG|Placebo|Placebo
223595609|NCT04357808|DRUG|Sarilumab|Single dose treatment with sarilumab 2 x 200 mg subcutaneously
223595610|NCT04357808|OTHER|Standar of care|Usual clinical care
223595611|NCT02792153|DRUG|Estradiol|AN participants will be prescribed 28 days of transdermal estradiol 0.1 mg/d (Days 1-28) plus 10 days (days 21-31) oral medroxyprogesterone 2.5 mg/d.
223595612|NCT03276546|BEHAVIORAL|shared decision-making tool (SHARE-D)|questionnaire
223747682|NCT00107211|PROCEDURE|neoadjuvant therapy|
223747683|NCT03330431|BEHAVIORAL|Progressive Muscle Relaxation (PMR)|"All groups undergo a PMR session, but they differ regarding the treatment before the PMR session. Two groups watch a video before undergoing PMR, the control group reads a text before undergoing PMR.~Progressive muscle relaxation (PMR) is a technique for learning to monitor and control the state of muscular tension. It was developed by American physician Edmund Jacobson in the early 1920s.~The technique involves learning to monitor tension in each specific muscle group in the body by deliberately inducing tension in each group. This tension is then released, with attention paid to the contrast between tension and relaxation."
223747684|NCT03225911|DEVICE|Lateral wedge insole (insole)|The lateral wedge insole is an orthotic device that is placed inside the shoe. It has different thicknesses, with the lateral side being thicker than the medial side. This difference in thickness leads to the lateral side being higher than the medial side, with a different angulation.
223747685|NCT03225911|DEVICE|simple knee sleeve (sleeve)|The simple knee sleeve is support which is worn around the knee with no hinge or provide external valgus moment.
224197539|NCT01265875|DRUG|Human Secretin|Dose Escalation
224197540|NCT05275673|DRUG|sapanisertib|capsules for oral administration
224310877|NCT01025453|DRUG|Temsirolimus and Sorafenib|Treatment will be with sorafenib 200 mg orally twice a day and temsirolimus 25 mg intravenous weekly. A cycle will be equivalent to 4 weeks of treatment.
223595613|NCT00136045|DRUG|Rotigotine|
223595614|NCT05302271|BIOLOGICAL|AAVrh.10hFXN, serotype rh.10 adeno-associated virus (AAV) gene transfer vector expressing the cDNA coding for human FXN|AAVrh.10hFXN will be administered intravenously.
223595615|NCT05302271|DRUG|Prednisone|All participants will remain immunosuppression therapy with prednisone for a total of 14 weeks.
223595616|NCT00651638|DRUG|Treatment with ARQ 197|Treatment with ARQ 197
223595617|NCT05244083|OTHER|Mirror Therapy|Therapy consisting of perfoming bimanual activities with a mirror placed on the patient's sagital plane, so it creates the brain illusion that the impaired limb moves the same way and quality that the unimpaired does.
223747686|NCT03225911|DEVICE|simple knee sleeve + lateral wedge insole|The lateral wedge insole is an orthotic device that is placed inside the shoe. It has different thicknesses, with the lateral side being thicker than the medial side. This difference in thickness leads to the lateral side being higher than the medial side, with a different angulation. The simple knee sleeve is support which is worn around the knee with no hinge or provide external valgus moment.
223747687|NCT03100708|PROCEDURE|PIPAC|"* Cisplatin 7.5 mg/m2 body surface in 150 ml NaCl 0,9% + Doxorubicin 1.5 mg/m2 body surface in 50 ml NaCl 0,9% in patients with ovarian, gastric, pancreatic cancer and in primary peritoneal tumors.~* Oxaliplatin 92 mg/m2 body surface in 150 ml dextrose solution in patients with colorectal cancer.~The chemotherapeutics will be admitted to the abdomen by a nebulizer at a pressure of 200 psi and 12 mmHG with 0.5 mL/sec. Afterwards the chemotherapeutics can react for 30min before the abdominal gas will be drained to the clinics filtering system."
223747688|NCT00632333|BIOLOGICAL|URLC10, TTK, KOC1, VEGFR1, VEGFR2, cisplatin, fluorouracil|Escalating dose of multiple peptides (URLC10, TTK, KOC1 VEGFR1, and VEGFR2) emulsified with Montanide ISA51 will be administered by subcutaneous injection on days 15, 22, 28 and 35 of treatment cycle. Doses of each peptide are planning 0.5mg, 1mg and 3mg/body. Chemotherapy plus radiation therapy will be done as follows: fluorouracil (400mg/m2) on day1-5 and 8-12, cisplatin (40mg/m2) on days 1 and 8, radiation (2Gy) on days 1-5, 8-12 and 15-19. Two cycles of combination of chemoradiation therapy and epitope peptide vaccine therapy will be done.
224310878|NCT03893097|DRUG|Praziquantel|40 mg/kg at baseline
223595618|NCT05244083|OTHER|Program without Mirror Therapy|Bimanual exercises performed with both upper limbs.
223595619|NCT00731146|OTHER|Ultrasound Minimum Effective Anesthetic Volume|Each sequential participant in this group will be assigned a dose based on the success or failure of the previous participant's block. The starting dose will be 10mL of 0.5% ropivacaine. Each success will decrease the dose by 2.5mL and each failure will subsequently increase the dose by 2.5mL.
223595620|NCT00731146|OTHER|Nerve Stimulator Minimum Effective Anesthetic Volume|Each sequential participant in this group will be assigned a dose based on the success or failure of the previous participant's block. The starting dose will be 10mL of 0.5% ropivacaine. Each success will decrease the dose by 2.5mL and each failure will subsequently increase the dose by 2.5mL.
223595621|NCT06256744|OTHER|exercise|Resistance exercise
223595622|NCT03993522|OTHER|Symptom limited cardiopulmonary exercise test & Sub-maximal cardiopulmonary exercise test|Exercise tests on cycle ergometer for the purpose of collecting expired breath gasses
223595623|NCT03522220|BEHAVIORAL|3D navigation video game intervention|Participants intensively train with a video game (Super Mario DS)
223595624|NCT03522220|BEHAVIORAL|video game intervention without 3D navigation|Participants train with a video game (Super Mario Bros)
223595625|NCT03522220|BEHAVIORAL|No 3D navigation|Participants read on a kindle device (control group)
223595626|NCT05385055|OTHER|THS use|N/A: No intervention was assigned.
223595627|NCT05385055|OTHER|Cigarette smoking|N/A: No intervention was assigned.
223595628|NCT05385055|OTHER|Smoking abstinence|N/A: No intervention was assigned.
223595629|NCT00000358|DRUG|Lofexidine|
223595630|NCT00774800|DRUG|Humalog|
223747689|NCT05102786|OTHER|40007388|A non-combusted cigarette used with heated tobacco device 20020064
223747690|NCT05102786|OTHER|40007385|A non-combusted cigarette used with heated tobacco device 20020064
223747691|NCT05102786|OTHER|40007387|A non-combusted cigarette used with heated tobacco device 20020064
223747692|NCT05102786|OTHER|40007386|A non-combusted cigarette used with heated tobacco device 20020064
223747693|NCT00076011|DRUG|Vascular Endothelial Growth Factor Receptor [VEGFR] and Platelet-Derived Growth Factor Receptor [PDGFR] inhibitor|
223747694|NCT02952014|DIETARY_SUPPLEMENT|C4 Extreme|Pre-Workout Dietary Supplement
223747695|NCT02952014|DIETARY_SUPPLEMENT|C4 Extreme (without Advantra Z|Pre-Workout Dietary Supplement
223747696|NCT02952014|DIETARY_SUPPLEMENT|Placebo|Pre-Workout Dietary Supplement
224310879|NCT03893097|DRUG|Artesunate + Mefloquine|4mg/kg artesunate and 8 mg/kg mefloquine at baseline (3 consecutive days) and repeated at Week 6 and Week 12
223595631|NCT00774800|DRUG|Humulin-R|
223595632|NCT00774800|DRUG|Recombinant human hyaluronidase PH20 (rHuPH20)|
223595633|NCT00774800|OTHER|Liquid meal|
223595634|NCT03914755|DRUG|Tucatinib|Administered via oral tablet
223595635|NCT04548804|DIAGNOSTIC_TEST|ECG-Imaging|A body surface potential mapping and a cardiac + low dose CT-scan
223595636|NCT02780544|BEHAVIORAL|skin-to-skin contact|skin-to-skin contact with parent during eye examination.
223595637|NCT02780544|DEVICE|incubator|staying in incubator during eye examination.
223595638|NCT02780544|DRUG|Sucrose|oral sucrose before eye examination
223595639|NCT01331109|DRUG|Milnacipran|maximum tolerated dose (50, 75, or 100 mg/day tablets); for 52 weeks.
223595640|NCT02992392|DRUG|Liposic|one eye of the participant recieved Lipoic
223595641|NCT02992392|DRUG|Tears Naturale Forte|the other eye of the participant recieved Tears Naturale Forte
223595642|NCT01389492|OTHER|frozen meat cutlets meal|250 g of meat cutlets
223595643|NCT01389492|OTHER|meat meals|250 g of meat meal for 4 days
223595644|NCT04583332|OTHER|Rhymes|"Participants will be provided with a choice of 3 Nursery rhymes (Wheels on the bus, Old McDonald and Twinkle Twinkle Little Star) Objects pertaining to the 3 rhymes will be placed on a board Children will be given prompts as per their need and will be marked on the type of prompt given.~These children will transit to pictures and Makaton symbols, if they are able to make choices using objects."
224310880|NCT01056042|DRUG|intramuscular depot medroxyprogesterone acetate|150 mg, Intramuscular, every 3 months
223595645|NCT04583332|OTHER|Individual Items in Rhymes|"Participants will be provided with a choice of 3 pictures within the initial choice making of the 2 Nursery rhymes (Wheels on the bus and Old McDonald ) Wheels on the Bus will include - mama/wipers/horn McDonalds - cow/dog/cat Objects pertaining to the 3 rhymes will be placed on a board Children will be given prompts as per their need and will be marked on the type of prompt given.~These children will transit to pictures and Makaton symbols, if they are able to make choices using objects."
223595646|NCT04583332|OTHER|Objects|Participants will be provided with 2,3 and 4 sensory objects. Participants will opt for an object by making a choice between these objects, if this is achieved then the child will be moved to picture level and symbol.
224197541|NCT05476809|BEHAVIORAL|smart-cloth assisted home nursing|The upgraded smart-cloth assisted home nursing integrate smart-cloth monitoring system, home nursing, and family caregiver feedback app. The persons living with dementia will be asked to wear a smart cloth 24 hours a day and will be monitored on abnormal activity level, going out alone, abnormal number of getting-up at night, fall risks. In addition, monitoring for medication, abnormal life pattern, quality of hired help will also be included. The warning signals, along with weekly summary and related information will be sent to the family caregiver interactive App after the assessment of the home care nurses to provide guidance for family care.
224197542|NCT03659617|DEVICE|xenograft (BioOss Collagen)|Alveolar ridge preservation using xenograft (BioOss Collagen) and implant placement at 3 different time intervals (3, 6 and 9 months)
224197543|NCT03280472|BEHAVIORAL|Cognitive Bias Modification|"CBM training. For those in the CBM condition, participants will complete a task. In this task, they will read ambiguous, two- to four-sentence social-related scenarios on the computer. The final word in the scenario will have a missing letter. Participants will type the missing letter. Participants will also be asked to answer a Yes/No comprehension question about the scenario. The missing letter will resolve the ambiguity of the scenario in a positive way, intended to train participants to have more positively-biased interpretations of ambiguous social information"
224197544|NCT03280472|BEHAVIORAL|Symptom tracking|Participants will track their symptoms
224197545|NCT04941014|BEHAVIORAL|Light Physical Activity|The guidelines from Rapid Assessment of Physical Activity (RAPA) participants were asked to perform Leisure Walk for 35 minutes
224197546|NCT04941014|BEHAVIORAL|Moderate Physical Activity|The guidelines from Rapid Assessment of Physical Activity (RAPA) participants were asked to perform Brisk Walk for 30 minutes
224197547|NCT04941014|BEHAVIORAL|Vigourous Physical Activity|The guidelines from Rapid Assessment of Physical Activity (RAPA) participants were asked to perform jogging for 15 minutes
224197548|NCT06425718|PROCEDURE|Postoperative Pain Management Technique|Patients who will undergo cesarean section under spinal anesthesia will be included. Comparing postoperative pain and opioid consumption in groups
224197549|NCT01958593|DRUG|Placebo|Placebo with therapy administered in two blinded experimental sessions. Participants in this group in Stage 1 may take part in Stage 2.
224197550|NCT01958593|DRUG|Midomafetamine HCl|Participants will receive MDMA-assisted therapy during two blinded experimental sessions. After unblinding, may receive a third session of open-label MDMA-assisted therapy.
224197551|NCT01958593|BEHAVIORAL|Psychotherapy|Psychotherapy before and after experimental sessions.
224197552|NCT04614402|DEVICE|Edwards PASCAL Transcatheter Valve Repair System|The Edwards PASCAL Valve Repair System is indicated for the percutaneous reconstruction of an insufficient tricuspid valve.
224197553|NCT04614402|DEVICE|Edwards PASCAL Precision Transcatheter Valve Repair System|The Edwards PASCAL Precision Valve Repair System is indicated for the percutaneous reconstruction of an insufficient tricuspid valve.
224197554|NCT06169839|BEHAVIORAL|Providing BLS and AED trainings given by the Ministry of Health with Low Realism Simulation.|the theoretical part of the Certificate of Participation TYD and OED training, the curriculum of which is created by the Ministry of Health, will be explained (by the researcher) (1hours). Skill training with Low Realism Simulation (1 hour) Basic CPR Manikin (classical training given by the Ministry of Health),
224197555|NCT06169839|BEHAVIORAL|Providing BLS and AED trainings given by the Ministry of Health with High Reality Simulation|the theoretical part of the Certificate of Participation TYD and OED training, the curriculum of which is created by the Ministry of Health, will be explained (by the researcher) (1 hours). Skill training with High Reality Simulation (1 hour) SimMan® 3G (Laerdal medical)
224197556|NCT06169839|BEHAVIORAL|Providing BLS and AED trainings given by the Ministry of Health with Virtual Reality|the theoretical part of the Certificate of Participation TYD and OED training, the curriculum of which is created by the Ministry of Health, will be explained (by the researcher) (1 hours). Skill training with Virtual Reality Application Supported Simulation (1 hour) Application training will be given with 3D MedSim.
223595647|NCT03694704|DEVICE|FineHearing strategy|Cochlear implant with FineHearing strategy
224197557|NCT06165679|DRUG|Prilocaine|The patients will receive a single injection of spinal anesthesia using prilocaine plus fentanyl
224197558|NCT06165679|DRUG|Bupivacaine|The patients will receive a single injection of spinal anesthesia using Bupivacaine plus fentanyl
224197559|NCT02195271|DEVICE|Transcranial Direct Current Stimulation (tDCS)|
224197560|NCT02195271|DRUG|Melatonin|
224197561|NCT06046586|BEHAVIORAL|Support and information|Emotional and technical support. Information about the long-term effects of cancer.
224197562|NCT06046586|BEHAVIORAL|Behavioral activation|Behavioral activation with existential themes and emphasis on values and relationships.
224197563|NCT06046586|BEHAVIORAL|Systematic exposure with mindfulness training|Systematic exposure with mindfulness training with a focus on anxiety about health and/or death, body image, and cancer-related trauma.
224197564|NCT06046586|BEHAVIORAL|Promotion of health behaviors|An overview of self-management techniques in terms of physical exercise, dietary advice, and strategies for improved sleep.
224197565|NCT03660059|DRUG|Peficitinib|Oral
224197566|NCT03660059|DRUG|Plaebo|Oral
223595648|NCT02779790|OTHER|Liquid Meal Replacements|An intervention that contains a mixture of protein, carbohydrate, and fat, along with added vitamins and minerals in liquid ready-to-drink or powder formulas that require mixing.
223595649|NCT01435135|BIOLOGICAL|ALVAC-HIV|1 mL per injection containing 10\^6 CCID50/dose administered
223595650|NCT01435135|BIOLOGICAL|AIDSVAX B/E|1 mL per injection (300 ug dose/antigen for a total of 600ug/dose administered)
223595651|NCT01435135|BIOLOGICAL|ALVAC-HIV Placebo|1 ml per injection
223595652|NCT01435135|BIOLOGICAL|AIDSVAX B/E Placebo|1 ml per injection
223595653|NCT06363539|DRUG|Clobetasol Propionate .05 Mg in 100 mL TOPICAL LOTION|steroid used for umblical granuloma
223595654|NCT06363539|DRUG|Silver Nitrate|silver nitrate used for treatment
223595655|NCT01558453|DRUG|Oxaliplatin|"Oxaliplatin will be administered in a 130 mg/m² dose, 2 hour IV infusion, once every 3 weeks. Each cycle will last 3 weeks, or 21 days. Drug will be administered till progression disease or untolerable adverse event.~NOTE: patients with ≤ 12 months old will receive a 4,3 mg/kg dese (based on a 30 kg/m² conversion; i.e: in a 130 mg/m² dose, divided by 30)."
223595656|NCT01882699|DEVICE|Cereve Sleep System|cerebral hypothermia
223595657|NCT06583564|PROCEDURE|ICG lymphangiography procedure|All patients underwent standard complete mesocolic excision (CME) or total mesorectal excision (TME) with curable purpose using ICG lymphangiography procedure
223595658|NCT00479856|DRUG|Lapatinib|Small molecule tyrosine kinase inhibitor
223595659|NCT00479856|DRUG|Capecitabine|Chemotherapy
223595660|NCT00479856|DRUG|Docetaxel|Chemotherapy
223595661|NCT00479856|DRUG|nab-Paclitaxel|Chemotherapy
223595662|NCT04521985|PROCEDURE|thoracolumbar kyphosis surgery|patients receiving surgery or not
223595663|NCT03917914|DRUG|Bisoprolol|As in arm description
223595664|NCT03917914|DRUG|Placebo Oral Tablet|As in arm description
223595665|NCT04845178|DRUG|ABP-450|ABP-450 (prabotulinumtoxinA) contains a 900 kDa botulinum toxin type-A complex produced by the bacterium Clostridium botulinum.
223595666|NCT04845178|DRUG|Placebo|0.9% sodium chloride, sterile, unpreserved, USP/PhEur
223595667|NCT05888753|PROCEDURE|Adrenalectomy|Scheduled adrenal surgery
223595668|NCT00139555|DRUG|amlodipine/benazepril|
223595669|NCT06443983|OTHER|AI-supported case|In the artificial intelligence-supported case lesson, students will listen to audio and visual content prepared by artificial intelligence.
223595670|NCT04047979|BIOLOGICAL|Shingrix®|A zoster vaccine recombinant, adjuvanted, recently approved by the FDA for prevention of herpes zoster (shingles) in adults aged 50 years and older. It is given in two doses (0.5 mL each): at 0 and 2 to 6 months.
223595671|NCT02293603|BIOLOGICAL|Allogeneic Cardiosphere-Derived Cells (CDCs)|Intracoronary delivery of CAP-1002 or placebo
223595672|NCT02440243|DRUG|Purethal|prerseasonal course of SCIT - three years
223595673|NCT02440243|DRUG|Purethal -placebo|preseasonal course of SCIT - three years
223595674|NCT05037019|PROCEDURE|Radiation therapy|Women diagnosed with early stage breast cancer are given a single dose of stereotactic body radiation therapy (SBRT) prior to any other treatment in the context of delayed lumpectomy due to the COVID-19 pandemic.
223595675|NCT05326867|DEVICE|Infiltration of 2% Lidocaine with Needle|Infiltration of 2% Lidocaine with Needle
223595676|NCT05326867|DEVICE|Infiltration of 2% Lidocaine without Needle|Free needle infiltration of lidocaine can be an alternative to reduce epidural needle insertion pain. The study of Gozdemir et al. found that 10% lidocaine infiltration without needle was less painful than 2% lidocaine infiltration with a 27G needle with no significant difference in analgesia effect during epidural needle insertion. This study aimed to compare infiltration of lidocaine with and without needle for epidural needle insertion
223595677|NCT04091243|DRUG|Romosozumab|Experimental drug for the treatment of glucocorticoid induced osteoporosis
223595678|NCT00661622|DRUG|GM-CSF|2,000 mcg injected into the liver every 4 weeks alternating between right or left lobe when tumors present throughout liver.
223595679|NCT00661622|PROCEDURE|Embolization|A catheter will be introduced to one of the hepatic arteries by way of the femoral artery (groin) to allow injection of GM-CSF in combination with ethiodized oil and gelatin sponge providing a temporary blockage of the blood supply from the hepatic (liver) artery
223595680|NCT03012711|OTHER|Neuromuscular exercise training|
223595681|NCT06975007|DEVICE|Paro Robotic Companion Seal|Paro is an interactive robotic companion designed to simulate the behaviour of a baby harp seal. It responds to touch, light, sound, posture and temperature, providing tactile and social interaction for stress relief.
223595682|NCT06975007|DEVICE|Weighted Sensory Toy|A soft, weighted animal-shaped toy (dog) designed to provide deep pressure stimulation. Participants hold or interact with the toy for 15 minutes following a stress induction task to promote relaxation and stress reduction.
223595683|NCT04360876|DRUG|Dexamethasone injection|Dexamethasone intravenous 20mg daily for 5 days followed by 10mg daily for 5 days
223595684|NCT04360876|DRUG|Placebos|Placebo delivered intravenously on the same dosing schedule as dexamethasone
223595685|NCT04481217|OTHER|Self-questionnaires battery|"* Childhood trauma questionnaire (Bernstein, Ahluvalia, Pogge, \& Handelsman, 1997; Bernstein et al., 2003)~* The Young schema questionnaire short form (SQ-SF ; Cottraux \& Black, 2006; Young, 1998).~* Dissociative experiences scale (Laroi et al., 2013).~* Launay-Slade hallucination scale (Bentall \& Slade, 1985; Launay \& Slade, 1981)~* Cardiff Anomalous Perceptions Scale (Bell et al., 2006)"
223595686|NCT04481217|OTHER|Socio-demographic screening|age; gender; education; highest diploma; job; marital status; living place
223595687|NCT02205528|DRUG|Liraglutide|Liraglutide will be self-administered daily via SC injection according to manufacturer specifications.
223595688|NCT02205528|DRUG|Metformin|Metformin hydrochloride immediate- or extended-release oral tablets will be supplied by the participant or investigational site as standard-of-care treatment beginning at least 8 weeks prior to randomization and throughout the 12-week treatment period. Metformin will also be continued during the 4-week follow-up. Dose selection will be based upon manufacturer specifications.
223595689|NCT02205528|DRUG|Placebo|Matching placebo to NNC0090-2746 will be self-administered daily via SC injection.
223595690|NCT02205528|DRUG|NNC0090-2746|NNC0090-2746 solution will be self-administered in daily doses of 1.8 mg via SC injection.
223595691|NCT04016259|DEVICE|Cranial Electrical Stimulation (CES)|CES will be applied for 60 minutes per session daily for 2 weeks (Monday to Friday) via the Alpha-Stim M Electromedical Products International, Inc., Mineral Wells, TX).
223595692|NCT04016259|DEVICE|Sham-CES|For sham CES, the electrodes will be identical look and be placed in the same positions as for active stimulation, but the stimulator will not deliver electrical current.
223595693|NCT03694431|OTHER|Tech-supported HBPC|Palliative care provided consistent with recommendations from the National Consensus Project for Quality Palliative Care
223595694|NCT03694431|OTHER|Standard HBPC|Palliative care provided consistent with recommendations from the National Consensus Project for Quality Palliative Care
223595695|NCT06468020|OTHER|The Gather.town gaming intervention|The online game-based learning intervention (oGBL): The investigator will develop the oGBL intervention based on Rational Emotive Behavior Therapy (REBT), which consists of 8 sessions and plays a game through the Gather.Town platform.
223595696|NCT03068754|DRUG|Acthar|Repository corticotropin for subcutaneous injection
223595697|NCT03068754|DRUG|Placebo|Matching placebo for subcutaneous injection
223595698|NCT01391936|PROCEDURE|Tension Band Wiring|AO technique of TBW for fixation of fracture.
223747697|NCT00581776|DRUG|Bortezomib|Administered by IV at 1.3 mg/m2 days 1 and 4 of each 21 day cycle.
223747698|NCT00581776|DRUG|Rituximab|Administered by IV 375 mg/m2 IV day 1 of each cycle during induction chemotherapy, then weekly for four weeks during consolidation therapy; and then once every 12 weeks for up to 5 years (or until disease progression).
223747699|NCT00581776|DRUG|Cyclophosphamide|Administered by IV at 300 mg/m2, 6 doses spaced 12 hours apart on days 1-3 of each cycle, to start after completion of rituximab infusion
223595699|NCT01391936|PROCEDURE|Plate fixation|Patients in this arm will receive plate and screw fixation of their olecranon fracture.
223595700|NCT02466009|DRUG|Regorafenib|Regorafenib 120 mg (3 tablets) each day for 21 days of a 28 day cycle with the possibility of an increase in the dose to 160 mg (4 tablets).
223747700|NCT00581776|DRUG|Doxorubicin|Given as a continuous infusion, 50 mg/m2 over 48 hours days 1-2 of each cycle, to start after completion of rituximab infusion.
223747701|NCT00581776|DRUG|Vincristine|1 mg administered by IV on day 3 of each cycle.
223747702|NCT00581776|DRUG|Dexamethasone|40 mg orally on days 1-4 of each cycle.
223747703|NCT03804112|DIAGNOSTIC_TEST|Ultrasound exam with Doppler|Ultrasound exam of the neck to search a perivascular inflammation at the level of the carotid bifurcation.
224197567|NCT03660059|DRUG|Disease-modifying antirheumatic drugs (DMARDs)|"As necessary concomitant medications, DMARDs listed below will be administered orally unless specified.~For subjects who are inadequate responders to methotrexate (MTX): MTX. For subjects who are intolerant of MTX: either of DMARDs listed; hydroxychloroquine, salazosulfapyridine, gold (injection or oral), D-penicillamine, lobenzarit, actarit, bucillamine and iguratimod."
224197568|NCT06829719|BIOLOGICAL|TTV DNAemia|Every 3 months, one sample added at the same time (7mL) of a routine laboratory analysis for TTV DNAemia
223595701|NCT02898298|BEHAVIORAL|Positive Emotion Regulation Training|Participants will receive a 3-session psycho-educative training on emotion regulation.
223595702|NCT04046978|OTHER|ConM SOSIP 50 ug and ConS UFO 50 ug|Intramuscular injection of synthetic viral immunogens ConM SOSIP and ConS UFO
223595703|NCT04046978|OTHER|Mos3.1 100 ug|Intramuscular injection of synthetic viral immunogen Mos3.1
223595704|NCT04046978|OTHER|Mos3.2 100 ug|Intramuscular injection of synthetic viral immunogen Mos3.2
223595705|NCT04046978|OTHER|Mos3.3 100 ug|Intramuscular injection of synthetic viral immunogen Mos3.3
223595706|NCT04046978|OTHER|Mos3.1 33 ug, Mos3.2 33 ug and Mos3.3 33 ug|Intramuscular injection of synthetic viral immunogens Mos3.1, Mos3.2 and Mos3.3
223595707|NCT03383380|DRUG|Rapamycin|Gain-of-function (GOF) PIK3CD mutations lead to PI3Kδ hyperactivity, with the downstream mediators Akt and mTOR hyperphosphorylated. The mammalian/mechanistic target of rapamycin inhibitor rapamycin may be effective to control the progress of this disease.
223595708|NCT04945109|OTHER|Mankai beverage|Recommended background healthy diet with Mankai supplementation after main meal (300 ml)
223595709|NCT04945109|OTHER|Water (control)|Recommended background healthy diet with water supplementation after main meal (300 ml)
223595710|NCT01177566|DRUG|pimecrolimus|pimecrolimus 1% cream twice daily
223595711|NCT01177566|DEVICE|topical medical device|Eletone cream three times daily
223595712|NCT06071156|DRUG|Anakinra|Anakinra, an IL-1 antagonist, is particularly interesting because it limits the self-sustained pathway of recurrent pericarditis and may reduce the recurrences
223595713|NCT03672526|DEVICE|measure of injection pressure by compuflo|injection pressure mesured by Compuflo
223595714|NCT01436266|DRUG|Misoprostol|400 mcg buccally 2 hours prior to procedure
223747704|NCT03804112|BIOLOGICAL|Blood samples|blood count , CRP and viral serologies (herpes virus, chlamydia, mycoplasma),
223747705|NCT06019156|BEHAVIORAL|Exercise video distribution of Metaverse|Participants received a 10-minute exercise video each week with a load of about 4 to 8 metabolic equivalents of task (METs) in the metaverse space, for eight videos delivered to encourage exercise.
223747706|NCT06019156|BEHAVIORAL|Exercise video distribution of YouTube|Participants view exercise videos with the same content as the metaverse group.
223747707|NCT05853250|OTHER|Reiki/manual therapy|Reiki is delivered by gentle hand placement either on or slightly above the body by certified Reiki practitioners. In this study, Reiki will be delivered first, for 15 minutes and will involve light placement of hands on patients' head, chest, shoulders, hands, knees, and feet (\~ 3 minutes to each body part). Manual therapy techniques include light effleurage to head and feet (for 5 minutes; \~ 2.5 minutes to each body part) by the Reiki practitioner who delivered the Reiki therapy.
223747708|NCT05340881|BEHAVIORAL|Bright Light Exposure|Research coordinator will follow-up with participant on Days 2 \& 5, and weekly thereafter to assess for the presence of potential side effects. If side effects are present with bright light initiation and they do not resolve by Day 5, the intervention will be discontinued.
223747709|NCT05340881|BEHAVIORAL|Dim Light Exposure|A placebo pair of glasses that is identical in form to the bright light glasses with the exception of light intensity will be used in a manner identical to the bright light glasses.
223747710|NCT05340881|OTHER|Cognitive Assessment|Cognitive examinations will be completed in-person and remotely via an online platform; caregivers and participants will also be asked to complete questionnaires assessing fatigue, sleep, and mood. These outcomes will be completed at baseline (prior to intervention/placebo), Week 4, Week 6 (end of intervention/placebo), and Week 8 (2-weeks post intervention/placebo).
223747711|NCT04701281|COMBINATION_PRODUCT|Intra-arterial LIOX + Capecitabine|5 - 7 LIOX (liver isolation oxaliplatin) intra-arterial infusions over 8 weeks + capecitabine
224197569|NCT06829719|OTHER|EQ-5D-5L questionnaire|Completed every 6 months and each time a complication of interest occurs
224197570|NCT06829719|BIOLOGICAL|Biological tests|Biological tests as routine care procedure (creatinine, CNI pre-dose trough level) will be performed every 6 months
223595715|NCT01436266|OTHER|Folic acid|2mg buccally 2 hours prior to procedure
224197571|NCT04830358|BIOLOGICAL|EuPCV15|15-valent Pneumococcal conjugate vaccine
223506550|NCT04289298|BEHAVIORAL|Engage-A|Therapist will encourage participants to engage in physical and social activities that are pleasurable or rewarding. Engage is a stepped care psychotherapy based on what is known about how older adults respond to depression interventions. Stepped care is a model of treatment that starts with the minimum effective therapeutic techniques first, and then based on how well people respond to treatment, additional therapeutic techniques are added until people are recovered from their depression.
223595716|NCT01302197|OTHER|No intervention|longitudinal follow-up after stroke
223595717|NCT02036008|OTHER|Liver MRI with Gdfos|"Participants will receive Gdfos at a dose of 10 mL of 0.25mmol/mL. This will be administered automatically using an MRI-compatible power injector, as a bolus through an intravenous line placed in an antecubital vein at a rate of 1.5 mL/s followed by 25 mL of 0.9% saline flush.~Participants will be imaged using a 3.0 T MRI scanner with an 8 channel body phased array coil utilized covering the entire liver. Images of the liver will be obtained including: axial precontrast phase, axial arterial phase, axial portovenous phase, axial 5 minute delayed phase, axial 10 minute delayed phase, axial 20 minute delayed phase.~This study will be performed within 4 weeks of the MRI study with EcGd."
223595718|NCT02036008|OTHER|Liver MRI with EcGd|"Participants will receive a liver MRI with EcGd as per clinical institutional protocol.~Participants will receive EcGd at a dose of 0.1 mL/kg body mass up to 10 mL. This will be administered automatically using an MRI-compatible power injector, as a bolus through an intravenous line placed in an antecubital vein at a rate of 1.5 mL/s followed by 25 mL of 0.9% saline flush.~Participants will be imaged using a 3.0 T MRI scanner with an 8 channel body phased array coil utilized covering the entire liver. Images of the liver will be obtained including: axial precontrast phase, axial arterial phase, axial portovenous phase, axial 5 minute delayed phase, axial 10 minute delayed phase, axial 20 minute delayed phase. Additional noncontrast images will be obtained as per institutional protocol, including diffusion weighted imaging, in/out of phase imaging, and T2 weighted imaging."
223595719|NCT05522595|DEVICE|S360|"In the first part of the intervention, after the CISS questionnaire completion by the patient, participant's eyes movements measurement will be performed using the reference procedure (standard of care).~A first diagnosis is established according to the interpretation of the results by a first evaluator.~In the second part of the intervention, the participant's eyes movements will be measured using the medical device S360.~A second diagnosis is established according to the interpretation of the software's displayed data by a second evaluator."
223595720|NCT05378061|DRUG|Pituitary adenylate cyclase activating polypeptide-38|Study participants will be allocated to receive continuous intravenous infusion of 10 pmol/kg/min PACAP-38.
223595721|NCT05378061|DRUG|Placebo|Study participants will be allocated to receive continuous intravenous infusion of 20 mL placebo (isotonic saline).
223747712|NCT06187467|OTHER|Clinical and technological-aided assessments and questionnaires|Assessments and questionnaires to quantify cortical and motor activities using portable EEG and lower limb sensors during dynamic balance and gait activities.
223747713|NCT05992168|DEVICE|Stent-Retriever|all the participants in this group will be performed with Stent-Retriever
223747714|NCT04028206|DIETARY_SUPPLEMENT|Hydroxymethylbutyrate|Hydroxymethylbutyrate supplementation at 3.0 g/day with dietary advice.
223747715|NCT04028206|DEVICE|Low-magnitude High Frequency Vibration (LMHFV)|Low-magnitude High Frequency Vibration is a non-invasive biophysical intervention which provides mechanical stimulation with no reported adverse effects. Our previous studies on bone showed that LMHFV can help boost the patients' bone mineral density (BMD) and muscle health.
223506551|NCT04289298|OTHER|Training and utilizing Engage-A therapy|Therapist will be trained in Engage-A therapy and given supervision while utilizing this therapy.
223506552|NCT00620035|DRUG|Radiopaque Etonogestrel Implant|One implant inserted for a 3-year treatment period
224075087|NCT07071350|OTHER|HRV Biofeedback (HRV-B)|participants will receive weekly biofeedback training over a six-week period. Each session includes approximately 30-40 minutes of biofeedback training where participants are affixed with HRV monitoring equipment. They will be guided to synchronize their heart rate variability (HRV) through slow diaphragmatic breathing and focusing on positive emotions. This process involves viewing real-time HRV patterns on a computer monitor, with coaching to help participants achieve resonant frequency breathing.
224075088|NCT07071350|OTHER|Psychoeducational (Edu) Comparator Intervention|Six weekly meetings 30-40 minutes, viewing standardized educational content on concussion recovery. No information on breathing will be provided to participants in the Edu group.
224075089|NCT01707849|DRUG|EVL arm|Patients will be randomized at day 28th post-transplant. This group will receive Tacrolimus+Everolimus.
224075090|NCT01707849|DRUG|MMF arm|Patients will be randomized at day 28th post-transplant. This group will continue of current immunosuppressive regimen (Tacrolimus+MMF) / no everolimus introduction.
224075091|NCT05100641|BIOLOGICAL|AV-GBM-1|Therapeutic autologous dendritic cell vaccine
224075092|NCT05100641|BIOLOGICAL|Autologous monocytes|Autologous monocyte control
224075093|NCT06609005|DRUG|INV-9956|INV-9956 is co-administered with dexamethasone and fludrocortisone acetate
224075094|NCT03226704|PROCEDURE|Leukapheresis|Leukapheresis
224075095|NCT07082686|DRUG|ICP-248|Eligible patients will receive ICP-248 orally as per the protocol
224075096|NCT06909825|DRUG|FPI-2265|PSMA ligand radiolabeled with Ac225
224075097|NCT06909825|DRUG|Olaparib|Poly (ADP-ribose) polymerase (PARP) inhibitor
224075098|NCT06911229|DEVICE|Deep Brain Stimulation (DBS)|Patients will receive DBS in the clinically-optimized setting.
224075099|NCT05807139|OTHER|Placebo|Placebo
224075100|NCT05807139|DRUG|Spironolactone|"Spironolactone and its matched placebo will be encapsulated into hard gelatin capsules, in same color, size and taste, to allow blinding.~Participants will receive 2x50 mg/day, 2x100 mg, and 2x200 mg/day in three sessions (Stages); these Visits always occur in ascending order of dosage. In the remaining session, participants receive the placebo.~Spironolactone is approved by the FDA, commercially available, and used in clinical practice for the treatment of hypertension, NYHA Class III-IV heart failure, edema in cirrhotic patients, and primary hyperaldosteronism. Comprehensive information about spironolactone, including its pharmacological properties, are provided in the Prescribing Information."
224075101|NCT06922318|DRUG|ZEN-3694|One ZEN-3694 pill (48 mg) will be taken each day of each BATZEN cycle.
223747716|NCT04028206|BEHAVIORAL|Elastic-band Exercise|"Subjects enrolled in the elastic-band exercise group will be instructed with 1 session of group training (at baseline) and 1 follow-up home visit (at 4 weeks) including instructions on 5-10 min warm-up and cool-down routines, 30 min chair-based resistance exercises using Thera-Bands as previously reported with training to both upper and lower body muscle groups including both hand and knee extensor muscles. The subjects will be instructed to perform the instructed exercises 3 times per week, one hour after HMB intake, for 12 weeks. The elastic band strengths will be progressively increased from 1.3 kg to 2.1 kg (yellow to green) of tensional force as instructed by a qualified coach in our project team based on each subject's multiple repetition maximum, where multiple repetition maximum is defined by reaching fatigue by 8 repetitions of stretching."
223747717|NCT06580847|BEHAVIORAL|Group Singing|12 week choir program consisting of 1.5 hours of in-person instruction per week.
223747718|NCT06580847|BEHAVIORAL|Audiobook Club|12 week audiobook club program consisting of 1.5 hours of in-person discussion per week.
223747719|NCT01319812|DEVICE|Astron Stents|Implantation of self-expanding, bare-metal, nitinol stents for treatment of peripheral artery disease affecting the iliac artery.
223747720|NCT01319812|DEVICE|Pulsar Stents|Implantation of self-expanding, bare-metal, nitinol stents for treatment of peripheral artery disease affecting superficial femoral or proximal popliteal arteries.
224197572|NCT04830358|BIOLOGICAL|Prevenar13|13-valent Pneumococcal conjugate vaccine
224197573|NCT04274101|OTHER|Clinical Manifestations|Clinical manifestations in patients treated with Nifurtimox and Benznidazole
224197574|NCT04274101|DIAGNOSTIC_TEST|Serologic response|Serologic response in patients treated with Nifurtimox and Benznidazole
224197575|NCT04274101|DIAGNOSTIC_TEST|Direct method|Direct method tests in patients treated with Nifurtimox and Benznidazole
224197576|NCT04274101|BEHAVIORAL|Adverse events|Adverse events in patients treated with Nifurtimox and Benznidazole
224310881|NCT01056042|DRUG|ethinyl estradiol 30 micrograms, gestodene 75 micrograms|one tablet orally, everyday
223506553|NCT04889651|DRUG|BR9004|BR9004: Abiraterone acetate 200mg, Boryung Pharmaceutical Co., Ltd.
223506554|NCT04889651|DRUG|BR9004-1|BR9004-1: Zytiga Tab. 500mg (Abiraterone acetate 500mg), Janssen Korea
223506555|NCT05067244|DRUG|MDMA|MDMA assisted psychotherapy
223506556|NCT05299970|OTHER|Fermented porridge|A millet porridge (fermented or not, depending on group allocation) serving will be provided to participants daily, for consumption. consumption will be directly observed.
223506557|NCT01292265|BIOLOGICAL|Certolizumab Pegol|Certolizumab Pegol (CZP) subcutaneous (sc) injections of 400 mg at Weeks 0, 2 and 4, followed by 200 mg at Weeks 6, 8 and 10.
223506558|NCT05792930|BEHAVIORAL|cognitive-behavioral therapy and biofeedback therapy|Complete eight sessions of cognitive-behavioral therapy and biofeedback therapy within three months.
223506559|NCT04558138|OTHER|Discharge timing|Patients will be discharged home on the day of surgery as opposed to POD #1
223506560|NCT03588429|DRUG|Sevoflurane|Anesthesia was maintained with sevoflurane in patients undergoing standardized nociceptive stimulus (long-lasting tetanic stimulus of the ulnar nerve; 30 s, 50 mA, 50 Hz, square-wave).
223506561|NCT03588429|DRUG|Isoflurane|Anesthesia was maintained with isoflurane in patients undergoing standardized nociceptive stimulus (long-lasting tetanic stimulus of the ulnar nerve; 30 s, 50 mA, 50 Hz, square-wave).
223506562|NCT04970589|OTHER|Mango|400g of mango/day
223506563|NCT04970589|DIETARY_SUPPLEMENT|Probiotics|1 probiotics capsule/day
223506564|NCT04970589|OTHER|Placebo|1 Placebo capsule/day
223506565|NCT04481438|OTHER|Acupunch Exercises|The acupunch exercise program was developed based on Jing-Luo theory of tranditional Chinese Medicine. The experiment group will receive Acupunch exercise for 40 minute sessions, 3 times a week, for 24 weeks
223506566|NCT04377919|DIETARY_SUPPLEMENT|Cranberry|The patients will receive 2 capsules per day containing 500mg of cranberry extract for 8 weeks
223506567|NCT04377919|DIETARY_SUPPLEMENT|Placebo|The patients will receive 2 capsules per day containing 500mg of maize starch for 8 weeks
223506568|NCT06076226|OTHER|No intervention, observation study|No intervention, observation study
223506569|NCT00283985|DRUG|Kidrolase|6000 u/ m2 IM at J2, J4 and J6 and J8. 3 to 6 cycles.
223506570|NCT00283985|DRUG|Methotrexate|3 gr/m2 at J1
223506571|NCT00283985|DRUG|Dexamethasone|40 mg/ per os at J1, J2 and J4.
223506572|NCT00283985|DRUG|Erwinase|"In case of allergy to Kidrolase~20000 u/m2 en IM at J2, J4, J6 et J8. 3 to 6 cycles"
223506573|NCT04229381|PROCEDURE|Physical Therapy|Undergo physical therapy
223506574|NCT04229381|OTHER|Quality-of-Life Assessment|Ancillary studies
223506575|NCT04229381|OTHER|Questionnaire Administration|Ancillary studies
223506576|NCT04229381|PROCEDURE|Relaxation Therapy|Undergo progressive muscle relaxation
223506577|NCT03811119|DEVICE|MANTA vascular closure device|Collagen based vascular closure device
223506578|NCT03811119|DEVICE|Suture based vascular closure device|Suture based vascular closure device (ProGlide)
223506579|NCT05085756|BEHAVIORAL|Puma|One psychoeducation module followed by two transdiagnostic modules tailored to primary depression or anxiety symptoms, followed by three participant-choice modules, and ending with two transdiagnostic modules.
223506580|NCT01691911|PROCEDURE|Remote preconditioning|Immediately after induction of anaesthesia, a standard, CE-approved tourniquet cuff will be placed around one arm of the patient. It will then be inflated to a pressure of 200mmHg for 5 minutes. For patients with a systolic blood pressure \>185mmHg, the cuff will be inflated to at least 15mmHg above the patient's systolic blood pressure. The cuff will then be deflated and the arm allowed reperfuse for 5 minutes. This will be repeated so that each patient receives a total of 4 ischaemia-reperfusion cycles. In all other respects, the procedure and peri-operative care will follow the routine practices of the surgeons and anaesthetists involved.
223506581|NCT05861453|DRUG|Epeleuton|Participants will receive 2000mg Epeleuton (DS102) capsules twice daily.
223506582|NCT06636331|OTHER|Continuous Suprainguinal Fascia Iliaca Compartment Block|Using PCRA and Local Anesthetic Ropivacaine 0.2% continuous 2ml/hr and demand dose 5ml as needed.
223506583|NCT06636331|OTHER|Continuous Epidural|Using PCEA and Local Anesthetic Ropivacaine 0.2% continuous 2ml/hr and demand dose 5ml as needed.
223595722|NCT05243589|OTHER|Proprioceptive training|"Proprioceptive training included exercises on different floor textures composed of 10 stations of exercises with the objective of stimulating the sole of the foot where participants had to coordinate gait by stepping with alternate feet on markers placed on the ground and the progression was manipulated through modifications of speed and direction.~Sequence of materials was 10 cm-thick foam, wood box with beans, two-cm thick mat with a density lower than the foam, wood box with cotton, two-cm thick mat volunteers sat on a bench and trained feet flexors by grasping with the toes a towel put on the floor, Two proprioception balls was used with an eight cm diameter with external projections resting on the floor a box with grains and sandpaper. After that joint Positional Sense Exercises were performed."
223595723|NCT05243589|OTHER|routine physical therapy|Routine physical therapy included range of motion exercises for bilateral ankle joints (5 min.), functional balance training (15 min.) involving sit to stand (5 times); standing weight shift (5 times each); functional reach- sideway and anterior for touching targets set by the therapist (5 times each); bipedal heel rise for 20 seconds (5 times); unipedal standing for 15 seconds (5 times each) and unipedal standing with knee bending for 15 second (5 times each). Other exercises was practiced as wobble board training (6 min).
223595724|NCT03221361|DEVICE|thermoplastic complete denture|a device used ti substitute teeth for edentlous patient made of thermoplastic resin
223595725|NCT03221361|DEVICE|conventional acrylic resin complete denture|A device used to substitute the teeth for edentlous patient made of acrylic resin
223595726|NCT05257902|DRUG|choline alphoscerate|400mg bid/day
223595727|NCT05257902|DRUG|Placebo|Placebo 1T bid/day
223595728|NCT00638976|DRUG|eptifibatide|Enrolled patients will be randomized in the catheterization laboratory, after the decision to perform PCI by means of planned implantation of DES \>33 mm in length in the same coronary vessel, to IV placebo or IV eptifibatide (double bolus \[180 microg/kg\] followed by infusion \[2 microg/kg per minute\] for 18 to 24 hours after the procedure
223595729|NCT00638976|DRUG|placebo|Enrolled patients will be randomized in the catheterization laboratory, after the decision to perform PCI by means of planned implantation of DES \>33 mm in length in the same coronary vessel, to IV placebo or IV eptifibatide (double bolus \[180 microg/kg\] followed by infusion \[2 microg/kg per minute\] for 18 to 24 hours after the procedure
223595730|NCT02427503|PROCEDURE|Asthma with NP and require surgery|To evaluate the effect on asthma of functional endoscopic sinus surgery of bilateral sinonasal polyposis in patients diagnosed with persistent asthma and grade II or III sinonasal polyposis.
223595731|NCT03034902|DEVICE|Combined EEG and fNIRS|The EEG+NIRS recordings will be obtained via an extended EEG cap that is applied to the subject's head. Changes in neuronal activity and hemodynamics will be measured. The EEG component is the microEEG by BioSignal Group, UA. The fNIRS component is the NIRScout 24x32, NIRx Medizintechnik GmbH, Germany
223595732|NCT00880646|DIETARY_SUPPLEMENT|Oolong tea containing L-arabinose and indigestible dextrin|
223595733|NCT00880646|DIETARY_SUPPLEMENT|Oolong tea (Placebo)|
223595734|NCT00000382|BEHAVIORAL|Infant-Parent Psychotherapy|
224197577|NCT02261558|OTHER|Clinical Improvisation Instrumental Music Therapy|Select an instrument of choice (and instruments for caregiver/s if applicable) Play/improvise and expand playing 10 minutes, inclusive of clinical improvisation (melody, harmony, timbre, and rhythmic idioms) where musical communication will be fostered and therapeutic goals will be addressed by the therapist in the music. Closure through verbal reflection and sharing (5 minutes)
224197578|NCT02261558|OTHER|Clinical Vocal Improvisation|\* 5 minutes of warm up. Select a few favorite songs of choice. Play/improvise and expand playing 10 minutes, inclusive of clinical improvisation (melody, harmony, timbre, and rhythmic idioms) where musical communication will be fostered and therapeutic goals will be addressed by the therapist in the music. Identify themes and issues addressed and/or paralleled in the song and/or within the self Closure through verbal reflection and sharing (5 minutes)
224310882|NCT03594058|DRUG|Solabegron modified release tablets, low dose|Solabegron modified release tablets low dose or high dose or matching placebo once daily for 12 weeks.
224310883|NCT03594058|DRUG|Solabegron modified release tablets, high dose|Solabegron modified release tablets low dose or high dose or matching placebo once daily for 12 weeks.
224310884|NCT03594058|DRUG|Matching Placebo|Solabegron modified release tablets low dose or high dose or matching placebo once daily for 12 weeks.
223595735|NCT00000382|BEHAVIORAL|Child Protective Services|
223595736|NCT00000382|BEHAVIORAL|Psychoeducational Home Visitation|
223595737|NCT00000382|BEHAVIORAL|Parent Education|
223595738|NCT04015674|OTHER|Exercise group|Aerobic exercise on a stationary bicycle
223595739|NCT04015674|OTHER|Control group|In a rest
223595740|NCT01554800|DRUG|ACP-501|A single dose infusion
223595741|NCT01122849|DEVICE|Prototype Nasal Dilator|Prototype nasal dilator AB2R11
223747721|NCT05156879|DRUG|Aspirin|75mg, one time/day
224310885|NCT03881423|DRUG|Rocuronium Bromide|DEEP block to PTC 1-3
224310886|NCT02935621|BEHAVIORAL|Mindfulness-Oriented Recovery Enhancement (MORE)|Mindfulness-Oriented Recovery Enhancement (MORE) is a group behavioral intervention that unites mindfulness training, cognitive reappraisal, and positive psychological principles into an integrative intervention strategy targeting mechanisms of pain and opioid misuse.
223595742|NCT01122849|DEVICE|Marketed Nasal Strip|Breathe Right Nasal Strip- Clear small/medium
223595743|NCT01122849|DEVICE|Placebo Nasal Strip|Placebo strip
223595744|NCT00952900|BEHAVIORAL|Biobehavioral|6 sessions of Biobehavioral treatment modalities that include relaxation/biofeedback, stress management, and coping skills techniques.
223595745|NCT00952900|BEHAVIORAL|Active Coping/Attention Intervention|6 sessions of didactic educational techniques to expose patients to the causes of TMD, as well as introducing them to traditional treatment modalities for intervening with acute TMD problems.
223747722|NCT05156879|DRUG|Drospirenone ethinyl estradiol|1 table/day, 21 consecutive days, 28 days as a cycle of use
224310887|NCT02935621|BEHAVIORAL|Support Group|A conventional support group will allow participants to express emotions, share experiences, and receive social support under the guidance of a skilled therapist.
224310888|NCT00872794|DEVICE|DePuy ASR™ Hip System|A metal-on-metal bearing surface replacement system for use in resurfacing hip arthroplasty.
224310889|NCT04100720|DEVICE|Cardiovalve Transfemoral Tricuspid Valve|The Cardiovalve Transfemoral Tricuspid Valve System is intended for use in patients with severe, symptomatic Tricuspid regurgitation
223747723|NCT03615326|BIOLOGICAL|Pembrolizumab|200 mg on Day 1 of each 3-week cycle as an IV infusion.
223747724|NCT03615326|BIOLOGICAL|Placebo|Solution for IV infusion on Day 1 of each 3-week cycle.
223595746|NCT00665964|DEVICE|X-3 polyethylene|highly cross-linked polyethylene for knee arthroplasty
223747725|NCT03615326|DRUG|Cisplatin|80 mg/m\^2 on Day 1 of each 3-week cycle as an IV infusion, administered as part of FP chemotherapy regimen.
224197579|NCT03250663|BEHAVIORAL|Online Treatment response|Electronic treatment response survey to track use of study medication, EUCRISA (crisaborole) ointment 2%.
223595747|NCT00665964|DEVICE|N2Vac polethylene|conventional polyethylene
223595748|NCT02828332|OTHER|Vineland II (VABS -II)|semi-structured interview with a psychologist; Measure 4 areas: Communication, skills of daily living, socialization and skills Motrices
223595749|NCT02828332|OTHER|Quality of life|Evaluation of the quality of life and comorbidities
223595750|NCT03256253|DRUG|Pregabalin|pregabalin up to 600 mg/day
223595751|NCT04071678|BEHAVIORAL|Careful examination during endoscopic procedures to identify lesions|When the AI model alarms, check carefully to confirm the lesion
223595752|NCT04496453|OTHER|Childhood vaccination decision support tool|Participants receive childhood vaccination decision support tool
223595753|NCT03712488|DEVICE|flowcytometry|four colour flowcytometry
223595754|NCT02447809|DRUG|Clopidogrel|(ASA 100mg daily and Clopidogre 75mg daily)\* 12 month.
223595755|NCT02447809|DRUG|acetylsalicylic acid (ASA)|
223595756|NCT05505409|DRUG|Pirfenidone|Drug:pirfenidone CTD-ILD patients treated with pirfenidone up to the maximum tolerable dose Drug: glucocorticoid and immunosuppressant CTD-ILD patients treated with glucocorticoid and immunosuppressant according to the condition of the disease
223595757|NCT05505409|DRUG|glucocorticoid and immunosuppressant|Drug: glucocorticoid and immunosuppressant CTD-ILD patients treated with glucocorticoid and immunosuppressant according to the condition of the disease
223595758|NCT02526225|DRUG|Ginkgo diterpene lactone meglumine injection|5 ml/times, 1 time/day.Before use, the drug slowly added to the 0.9% sodium chloride injection diluted in 250 ml, slow intravenous drip.
223595759|NCT02526225|DRUG|Ginkgo diterpene lactone meglumine injection simulation|5 ml/times, 1 time/day.Before use, the drug slowly added to the 0.9% sodium chloride injection diluted in 250 ml, slow intravenous drip.
223595760|NCT03760679|DEVICE|Laryngeal mask Supreme evaluation|Device: Laryngeal mask Supreme evaluation
223595761|NCT03760679|DEVICE|i-gel evaluation|Device: i-gel evaluation
223595762|NCT03054779|OTHER|Canola Oil|Regular canola oil will be iso-calorically incorporated into fruit smoothies made with milk and consumed twice daily.
223595763|NCT03054779|OTHER|High oleic acid canola oil|High oleic acid canola oil will be iso-calorically incorporated into fruit smoothies made with milk and consumed twice daily.
223595764|NCT03054779|OTHER|Western diet oil combination|"A typical Western diet fat intake as a control treatment, comprised of 11% MUFA, 11% PUFA (9% omega-6 fatty acids and 2% omega-3 fatty acids), and 13% SFA, will be iso-calorically incorporated into fruit smoothies made with milk and consumed twice daily"
223595765|NCT01678625|DEVICE|Train-of-four ratio calculation (T4-EMG)|TOF ratios will be compared between the EMG and AMG groups
223747726|NCT03615326|DRUG|5-FU|800 mg/m\^2/day continuous on Days 1-5 of each 3-week cycle (120 hours or per local standard), administered as part of FP chemotherapy regimen.
223747727|NCT03615326|DRUG|Oxaliplatin|130 mg/m\^2 on Day 1 of each 3-week cycle over 2 hours as an IV infusion, administered as part of CAPOX chemotherapy regimen and as part of SOX chemotherapy regimen.
223747728|NCT03615326|DRUG|Capecitabine|1000 mg/m\^2 as oral capsules BID on Days 1-14 of each 3-week cycle, administered as part of CAPOX chemotherapy regimen.
223747729|NCT03615326|DRUG|S-1|Combination product of tegafur, CDHP, and Oxo. Oral capsules BID on Days 1-14 of each 3-week cycle based on body surface area (BSA): \<1.25 m\^2 BSA =40 mg, 1.25 to \<1.5 m\^2 BSA=50 mg, ≥1.5 m\^2 BSA=60 mg. Administered as part of SOX chemotherapy regimen.
223747730|NCT03615326|BIOLOGICAL|Trastuzumab|8 mg/kg loading dose and then 6 mg/kg maintenance dose administered IV on day 1 of each 3-week cycle.
223747731|NCT02435472|BEHAVIORAL|Exercise|This open-label, two-arm randomized controlled trial (RCT) will investigate the effects of 16 weeks of structured aerobic training, relative to usual care (print material with physical activity guidance) in 76 men with histologically confirmed low-risk prostate adenocarcinoma on active surveillance. The only investigational therapeutic agent being tested in this trial is a behavioral intervention in the form of aerobic training.
223747732|NCT02435472|OTHER|Cardiopulmonary Exercise Test (CPET)|Exercise capacity test to assess peak oxygen consumption (VO2peak)
223747733|NCT04796376|PROCEDURE|combined partial fistulectomy or fistulotomy and cutting seton procedure|Partial excision of fistulous tract or just fistulotomy plus cutting seton procedure which is a rubber band or threads put through fistulous tract
224197580|NCT03250663|DRUG|EUCRISA|Participants are given EUCRISA (crisaborole) ointment 2%.
224197581|NCT02331680|DRUG|OPC-41061|
224197582|NCT02331680|DRUG|OPC-41061|
224197583|NCT02331680|DRUG|Placebo|
224197584|NCT01080157|DEVICE|SCOUT DS measurement|Non-invasive 3-5 volar forearm scan
224197585|NCT01252914|DEVICE|iStent Supra Stent|Implantation of one iStent Supra Stent through a small temporal clear corneal incision
224197586|NCT02363504|OTHER|7 Tesla MRI with memory task and non-invasive neurostimulation|This is not an intervention, we investigate the neural mechanisms
224197587|NCT03054272|BEHAVIORAL|Video|A 13-minute video based on a suggested CICO algorithm from the Difficult Airway Society that was produced at the University of Montreal Simulation Centre using high-fidelity settings.
224197588|NCT05780359|DEVICE|Drug eluting stent|Sirolimus drug-eluting self-expanding stent available from 20mm to 250mm in length, 3.5mm to 7.5mm in diameter of superficial femoral and proximal popliteal arteries (SFA/PPA) cases for inhibiting in-stent restenosis and improve long-term outcome.
224197589|NCT05780359|DEVICE|drug coating balloon|A proprietary lipophilic coating technology that uses magnesium sterate as excipient, facilitates paclitaxel transfer to the vessel wall, enhances drug delivery, and brings minimal downstream effect. Available from 20mm to 300 mm in length, 3mm to 12 mm in diameter, fits every SFA cases, reduces radiation exposure time.
223595766|NCT03083223|OTHER|position|Subjects were placed consecutively in random order in five different positions. SaO2 and vital signs were measured at each position after 10, 25, and 40 minutes.
224197590|NCT02345902|DRUG|Haloperidol|haloperidol 1.25 mg P.O q.d
223595767|NCT02522130|DRUG|Lidocaine|intracervical injection
223595768|NCT02522130|DRUG|oral misoprostol|oral treatment
223595769|NCT02522130|DRUG|naproxen|oral treatment
223595770|NCT02522130|OTHER|placebo|oral treatment
223595771|NCT02524873|DEVICE|Geneticure Collection Kit for Pharmaocogenetics of Hypertension|Buccal (cheek) swab kit for DNA collection for analysis of genes for hypertension
223595772|NCT05387057|BEHAVIORAL|Exergame training according to the 'Brain-IT' exergame-based training concept|For an overview, our 'Brain-IT' exergame-based training concept consists of an individually adapted multi-domain exergame-based simultaneous cognitive-motor training with incorporated cognitive tasks that will be adopted with a deficit-oriented focus on the neurocognitive domains of (1) learning and memory, (2) executive function, (3) complex attention, and (4) visuospatial skills. According to the training concept, each participant is instructed to train 5x/week for 24 min per session resulting in a weekly exercise volume of 120 min. All training sessions are planned to take place at participant's homes using the exergame training system 'Senso Flex' (Dividat AG, Schindellegi, Switzerland). For a detailed description of the complete 'Brain-IT' exergame-based training concept with sufficient details to allow full replication, consider our methodological paper (doi: 10.3389/fnagi.2021.734012).
223595773|NCT05387057|BEHAVIORAL|Usual Care|The control group will proceed with usual care as provided by the (memory) clinics where the patients are recruited.
223595774|NCT05407857|BEHAVIORAL|multi-modal non-pharmacological intervention|multi-modal non-pharmacological intervention including the management with nutrition, exercise and cognitive programs
223595775|NCT03997825|DEVICE|Basivertebral Nerve (BVN) Ablation|Single follow-up visit of previously treated participants from the SMART trial.
223595776|NCT01528722|DRUG|Bupivacaine|0.25% 20ml administered intraperitoneal
223595777|NCT01528722|OTHER|Normal saline|sodium chloride 0.9% solution
223595778|NCT02600091|BEHAVIORAL|Mindfulness-Based Cognitive Therapy|The MBCT intervention is manualised and delivered to groups. The aim of the MBCT intervention is to increase mindfulness skills and to facilitate their use in relation to emotional wellbeing and diabetes self-management. Participants will attend on 8 occasions, once per week, for 2 hours. These meetings will have a standard structure. First, participants will describe their efforts to practice mindfulness at home over the previous week, followed by discussion of an educational topic relevant to the aims of the course. Finally, the group will do a mindfulness practice together, and the home practice for the following week will be set. In-between meetings, participants are asked to practice mindfulness by listening to an audio file or CD for about 30 minutes per day.
223595779|NCT00003066|DRUG|docetaxel|
223595780|NCT00003066|DRUG|estramustine phosphate sodium|
224197591|NCT02345902|OTHER|Placebo|placebo 1.25 mg P.O q.d
224197592|NCT02345902|OTHER|non-pharmacologic measures|A. Reorientation (i.e., calendar, clocks, familiar objects) B. Glasses and hearing devices for the particular patients needing such aids C. Avoidance of physical restraints D. Limitation of excessive personnel shifts or hospital room E. A tranquil and comfortable environment, especially at night, to avoid interruptions (i.e., dim light, low levels of noise) F. Adequate schedules for medication administration and to take vital signs or medical procedures G. Sleep hygiene (light in the room and movement during the day) H. Avoidance of dehydration I. Avoidance of medications use which are associated with delirium (e.g., psychoactive medications)
224310890|NCT00674349|PROCEDURE|surgery|staging surgery
224310891|NCT04117919|DRUG|paper mulberry leaf|Topical steroids+paper mulberry leaf The botanical origin of paper mulberry leaf is Broussonetia papyrifera (L.) Vent.
224310892|NCT04117919|DRUG|Triamcinolone (Encort-A) 0.1%15g/Tube|only Topical steroids
224310893|NCT01890447|OTHER|Web-based survey questionnaire|Data collection will be done via web-based questionnaires generated by Sawtooth Software. Subjects will be asked for their ideal alternative (acceptance to immunisation) by selecting the factors that suit them the most. The subjects are then presented several sets of alternatives built around their ideal choice.
223595781|NCT01089205|DRUG|Metformin|
223595782|NCT00501865|DRUG|GW273225|GW273225 will be available as white tablets containing 25 mg GW273225.The study drug will be taken with 240 milliliters of water at room temperature.
223595783|NCT00383162|DRUG|Combination Product (sumatriptan succinate / naproxen sodium)|Bilayer tablet containing 85mg sumatriptan (as 119mg sumatriptan succinate; fast disintegrating/rapid release formulation) active ingredient in one layer, and 500mg naproxen sodium active ingredient in the second layer.
223595784|NCT00383162|DRUG|Placebo|Matching placebo tablet.
223595785|NCT06457698|PROCEDURE|Double-puncture TMJ arthrocentesis under local anaesthesia|The first puncture involved carefully palpating the lateral rim of the glenoid fossa. A 5-cc syringe was prepared with a mixture of 3 cc of Ringer lactate and 1.8 cc of lidocaine with epinephrine. A 21-G needle connected to the syringe was gently inserted into the TMJ skin area. Once the needle tip made contact with the posterior slope of the eminence of the upper joint compartment, it was oriented vertically to access the upper compartment, allowing the surgeon to perform a validation step. For the second puncture, the joint was maintained at maximum distention with continuous inflow through the first portal, while the surgeon felt insufflation/distention in the anterior joint area. The second portal was established using a 21-G needle with successful fluid outflow. After completing an effective circuit, joint washing was carried out using intra-articular hydraulic pressure with at least 150 ml of Ringer lactate solution.
223595786|NCT00767819|DRUG|Everolimus|2.5 and 5 mg tablets taken orally and starting dose was 10 mg daily for all patients
223595787|NCT00333918|DRUG|bromfenac ophthalmic solution|
223595788|NCT00333918|DRUG|placebo comparator|
223595789|NCT01819350|OTHER|G1, G2 and G3|Nutritional, respiratory and endocrine group applicated 12 subjects
223595790|NCT01819350|OTHER|G4 and G5|Application of trhree pediadic medidines of antibiotic group on dental biofilm 12 subjects
223595791|NCT02588209|BEHAVIORAL|Strategic Memory Advanced Reasoning Training|SMART teaches strategies to improve the ability to process information.
223595792|NCT02588209|BEHAVIORAL|Brain Health Workshop|Brain Health Workshop provides information about brain health in a seminar format. Topics include: sleep, nutrition, and exercise.
223595793|NCT02696239|DEVICE|V-lock suture|
223595794|NCT02696239|DEVICE|Vicryl Suture|
223595795|NCT02696239|DEVICE|Lapra-Ty II|
223595796|NCT01323140|DRUG|testosterone matrix transdermal system|
224197593|NCT01973699|OTHER|visualization in shoulder arthroscopy|Evaluating the effect of performing shoulder arthroscopy with and without epinephrine on visualization
223595797|NCT05727514|OTHER|music composition|4-session music composition program for participants lead by a composer-mentor, includes optional viewing of online string quartet performances of final musical scores
223595798|NCT01554995|DRUG|LCB01-0371|LCB01-0371 50mg (Cohort 1) 100mg (Cohort 2) 200mg (Cohort 3) 400mg (Cohort 4) 600mg (Cohort 5)
223595799|NCT01554995|DRUG|Linezolid|Linezolid 600 mg (Cohort 9) none
223595800|NCT06276166|OTHER|No intervention|No intervention
223595801|NCT01452503|DEVICE|Path Women's Condom|comparison between 3 types of female condoms
223595802|NCT01452503|DEVICE|FC2 female condom|comparison between 3 types of female condoms
223595803|NCT01452503|DEVICE|Reddy 6 female condom (V-Amour)|comparison between 3 types of female condoms
223595804|NCT05091515|OTHER|Personal protective equipment from biological hazard|Includes: isolation clothing, mask, eyewear, overshoes
223595805|NCT04602247|DIETARY_SUPPLEMENT|SIC|Sodium Iron Chlorophyllin, whose bioavailability is to be studied
223595806|NCT04602247|DIETARY_SUPPLEMENT|SIC + AA combined|Sodium Iron Chlorophyllin and ascorbic acid. The ascorbic acid should not have an effect on Sodium Iron Chlorophyllin
223595807|NCT04602247|DIETARY_SUPPLEMENT|FeSO4|Ferrous sulfate serves as a positive control, whose iron bioavailability is known
223595808|NCT04602247|DIETARY_SUPPLEMENT|FeSO4 + AA combined|Ferrous sulfate serves as a positive control and the addition of ascorbic acid, further enhances its bioavailability
223595809|NCT04602247|OTHER|EP + FeSO4 combined|Chlorophyllin with an empty porphyrin ring, given along with FeSO4 to study if there is an incorporation of Fe into the porphyrin ring as it passes the gastric system
224197594|NCT04926337|DEVICE|Tight Fitting Facemask|Preoxygenation with tight facemask, 10 L/min, 100% oxygen.
224197595|NCT04926337|DEVICE|High Flow Nasal Oxygen (HFNO)|Preoxygenation with high flow nasal oxygen, 40-70 L/min, 100% oxygen.
224197596|NCT00145106|DRUG|Tazarotene 0.1% gel + placebo capsule, Oral minocycline (100 mg capsule) + vehicle gel, Tazarotene 0.1% gel + oral minocycline (100 mg capsule)|
224197597|NCT02231502|OTHER|Vegetable-based convenience food|
224197598|NCT02231502|OTHER|Vegetable meal|
224197599|NCT03479957|BEHAVIORAL|REMOTE-CR|The patients randomized to remotely monitored exercise can either work out with self-selected activities e.g. Nordic-walking, cycling, skiing or participate in supervised exercise session via video link. Remotely monitored exercise training sessions will be offered monday-friday 13.00-16.00.
224197600|NCT03479957|OTHER|Control|The patients randomized to be controls will receive individualized information and instructions regarding current exercise recommendations but will not be monitored or coached during their exercise sessions (usual care)
223595810|NCT04602247|OTHER|EP + FeSO4 + AA combined|Chlorophyllin with an empty porphyrin ring, given along with FeSO4 to study if there is an incorporation of Fe into the porphyrin ring as it passes the gastric system. Ascorbic acid is given along with the intervention to see if there is any difference in the fractional iron absorption when compared to EP+ FeSO4
223595811|NCT00642447|DRUG|helium:oxygen mixture|
223595812|NCT02804035|COMBINATION_PRODUCT|sc2Wear Furosemide|Drug-device combination product of buffered furosemide injection, (Furosemide Injection Solution), 8 mg/mL, and patch pump (sc2Wear Furosemide Pump)
223747734|NCT02258126|OTHER|Multidisciplinary intervention program|"Exercise group:~The intervention program includes an education program promoting healthy dietary habits and physical activity (nutritionist), supportive therapy and behavioral advice for the family to improve nutrition and physical activity (psychologist) (2 times/month, for children and parents) and supervised exercise (3 times/week, 90 mins) program for 6 months."
223747735|NCT00547742|PROCEDURE|PET/CT Scan|
223747736|NCT00547742|PROCEDURE|phlebotomy|
223747737|NCT04464122|DRUG|Somatostatin analog; chemotherapy|According to current ENETS guidelines, patients will be treated by somatostatin analogs or chemotherapy, recommended respectively as first line therapy in neuroendocrine tumours or neuroendocrine neoplasms.
223747738|NCT03811431|PROCEDURE|Contrast enhanced ultrasound guided liver biopsy|Conventional liver biopsy
223747739|NCT05434260|DEVICE|Surgiphor Irrigation Solution|use of Surgiphor wound irrigation solution during surgery
223747740|NCT05434260|DEVICE|Sterile saline|Use of sterile saline as a irrigation solution during surgery
223595813|NCT01939639|DRUG|Placebo|intranasal application, sodium chloride solution, 3 puffs per nostril
223595814|NCT01939639|DRUG|Oxytocin|24 IU Oxytocin, intranasal application 45 min prior to the experiment
223595815|NCT06432504|OTHER|Caffeine content|Participants will drink the same volume of coffee with different amounts of caffeine.
223595816|NCT03492801|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
223595817|NCT03492801|OTHER|Laboratory Biomarker Analysis|Correlative studies
224197601|NCT05140473|BEHAVIORAL|perceived workload|Perceived workload takes into account the acts and care performed but also the pressure felt of having been efficient in its task, the efforts made and the level of frustration felt.
224197602|NCT02736331|DIETARY_SUPPLEMENT|Treatment 1|Treatment 1 Beverage
224197603|NCT02736331|DIETARY_SUPPLEMENT|Treatment 2|Treatment 2 Beverage
224197604|NCT00210366|DRUG|Idarubicin|
224197605|NCT04002466|OTHER|Risk factors for anemia|Diet, iron, vitamin B12, folate, inflammation, soil transmitted helminth infection, malaria, other morbidities and other health/nutrition/sociodemographic factors
224197606|NCT03957291|DRUG|Chlorhexidine|chlorhexidine administration prior to ophthalmic surgery (compared to Povidine iodine )
224197607|NCT03957291|DRUG|Povidone-Iodine|Povidine iodine administration prior to ophthalmic surgery (compared to chlorhexidine)
224197608|NCT02553291|BEHAVIORAL|SystemCHANGE|
224197609|NCT02553291|BEHAVIORAL|Control|
224197610|NCT01048710|OTHER|No intervention|
224197611|NCT06178276|DIAGNOSTIC_TEST|behavior|behavioral measurements will be performed during the oral comprehension testing
224197612|NCT06178276|DIAGNOSTIC_TEST|physiology|physiologic (autonomic) measurements will be performed during the oral comprehension testing
224197613|NCT06178276|DIAGNOSTIC_TEST|imaging|central (brain) measurements will be performed during the oral comprehension testing
224197614|NCT03158857|DRUG|Sofosbuvir 400 mg|These drugs are being offered as part of routine care
223595818|NCT03485196|OTHER|Microsatellite instability|The microsatellite instability status are definite to three type:MSI-H, MSI-L,and MSS. The gastric cancer patients who received D2 resection were included in 3 groups：MSI-H group， MSI-L group，and MSS group. All patient must be accept fluorouracil(5-FU) based adjuvant chemotherapy. We will analyze the relationship between MSI status and efficacy of 5-FU based adjuvant chemotherapy by observing the survival period of patients with different MSI status.
223595819|NCT00002218|DRUG|CI-1012|
223595820|NCT02726022|DRUG|Peginterferon alfa-2a|As per treating physician discretion and according to summary of product characteristics.
223595821|NCT02726022|DRUG|Ribavirin|As per treating physician discretion and according to summary of product characteristics.
223595822|NCT03360058|BEHAVIORAL|Small Talk Big Difference Immediate access training|Immediate access to 1 hour online training and supporting print materials for implementation in primary care practice
223595823|NCT03360058|BEHAVIORAL|Small Talk Big Difference delayed access training|Delayed access (by 4 months) to 1 hour online training and supporting print materials for implementation in primary care practice
223595824|NCT01142427|OTHER|Cytology Specimen Collection Procedure|Correlative studies
223595825|NCT01142427|OTHER|Laboratory Biomarker Analysis|Correlative studies
223595826|NCT01781780|BEHAVIORAL|General Nutrition Recommendations|
223595827|NCT01781780|BEHAVIORAL|Breakfast Recommendation|
223595828|NCT01781780|BEHAVIORAL|No Breakfast Recommendation|
223595829|NCT01886703|BEHAVIORAL|Pedometer Walking Program|All subjects will be prescribed a low-intensity walking program based on their current activity level and an daily assigned step count goal (with the current physical activity recommendations of 30 minutes of moderate-to-vigorous activity per day or 150 minutes per week as the ideal goal). Participants will be provided with face-to-face counseling and written material describing their specific individualized walking program. Participants will also be instructed to maintain their normal activities as much as possible during the intervention period. Participants will be given a pedometer and instructed to wear it at least 5 days per week for the duration of the study.
224197615|NCT04071925|PROCEDURE|Urethroplasty|Open reconstructive surgery to restore urethral patency in case of urethral stricture disease.
224197616|NCT02700893|DRUG|atropine+ propofol|Atropine bolus: 20 µg/kg Propofol injected over 60 seconds: 1 mg/kg for infants \< 1000g - Renewable once 2.5 mg/kg for infants \> 1000G - Possible additional dose of 1 mg/kg
223595830|NCT05772013|DRUG|Azithromycin Pill|"Participants will take azithromycin according to their standard of care prescription.~If the participant is on the seasonal azithromycin treatment arm, they will only take azithromycin during the winter months (October-March) followed by matched placebo (April-September)."
223595831|NCT05772013|DRUG|Placebo|The placebo tablets will be matched in appearance, taste and smell to the azithromycin tablets.
223595832|NCT00915551|DRUG|PEP005 (Ingenol Mebutate) gel, 0.015%|once daily for 3 consecutive days
223595833|NCT00915551|DRUG|Vehicle Gel|once daily for 3 consecutive days
223595834|NCT00187525|DRUG|Memantine|
223595835|NCT00762541|DEVICE|MEL 80 Treatment of High Myopia|The reduction or elimination of myopia \> -7.00 D to -12.00 D, and astigmatism less than or equal to -6.00 D at the spectacle plane (myopia with or without astigmatism), with a maximum MRSE ≤ -12.00 D.
224197617|NCT02700893|DRUG|atropine + atracurium + sufentanil|Atropine bolus: 20 µg/kg Atracurium: 0.3 mg/kg- Possible additional dose of 0.1 mg/kg Sufentanil: 0.1 µg/kg for infants \< 1000g 0.2 µg/kg for infants \> 1000g
224197618|NCT00975793|OTHER|Early Goal Directed Therapy (EGDT)|Randomised allocation of early goal-directed therapy (EGDT). EGDT involves treatment with intravenous fluids, and medications to support the blood pressure and heart following a protocol. A special catheter is inserted to monitor central blood oxygen levels and the standard treatments are given according to the blood oxygen level reading. EGDT is given for 6 hours, then the patient receives standard care.
224197619|NCT02335411|BIOLOGICAL|pembrolizumab|IV infusion
224197620|NCT02335411|DRUG|cisplatin|IV infusion
224197621|NCT02335411|DRUG|5-FU|IV infusion
224197622|NCT02335411|DRUG|capecitabine|oral tablets
224197623|NCT02101957|DRUG|RP103|
224197624|NCT02101957|DRUG|Placebo|
224197625|NCT01891669|DRUG|PF-06263507|Part 1 - PF-06263507 will be administered intravenously in 21-day cycles in cohorts of 2 or more patients starting at a dose of 0.05 mg/kg. Increases in dose will continue until MTD is determined.
224197626|NCT01891669|DRUG|PF-06263507|Part 2 - Patients with select tumor types will be treated at the MTD or Recommended Phase 2 dose selected in Part 1.
223595836|NCT00235716|DRUG|dl-alpha-tocopherol|"Alpha-tocopherol will be given as an oral dose of 1000 IU twice a day (morning and evening). The form of vitamin E that will be used in this study will be hard gel capsules of dl-alpha-tocopheryl acetate (synthetic) vitamin E."
223595837|NCT00235716|DRUG|Memantine|A moderate-affinity NMDA antagonist. Memantine will be titrated over four weeks to a maintenance dose of 10 mg twice a day. During week 1 patients will take one 5-mg memantine tablet in the morning. During week 2 patients will take one 5-mg memantine tablet in the morning and one in the evening. During week 3 patients will take two 5-mg memantine tablets in the morning and one 5-mg tablet in the evening. Beginning with week 4, participants will take four 5-mg tablets daily, two in the morning and two in the evening.
223595838|NCT00235716|DRUG|dl-alpha-tocopherol|"Alpha-tocopherol will be given as an oral dose of 1000 IU twice a day (morning and evening). The form of vitamin E that will be used in this study will be hard gel capsules of dl-alpha-tocopheryl acetate (synthetic) vitamin E."
223595839|NCT00235716|DRUG|Memantine|A moderate-affinity NMDA antagonist. Memantine will be titrated over four weeks to a maintenance dose of 10 mg twice a day. During week 1 patients will take one 5-mg memantine tablet in the morning. During week 2 patients will take one 5-mg memantine tablet in the morning and one in the evening. During week 3 patients will take two 5-mg memantine tablets in the morning and one 5-mg tablet in the evening. Beginning with week 4, participants will take four 5-mg tablets daily, two in the morning and two in the evening.
223595840|NCT00235716|DRUG|Placebo|Matching placebos for dl-alpha-tocopherol and memantine.
223595841|NCT03746041|DRUG|abaloparatide|In cycle 1, patients will be treated with single-agent, subcutaneous (SQ) abaloparatide at a dose of 80 mcg/day for 28 days.
223747741|NCT04696939|DRUG|Atezolizumab|Atezolizumab intravenous infusion was administered at a dose of 1200mg on Day 1 of each 21-day cycle.
224197627|NCT06116799|DEVICE|Orthotic|Arch support orthotic
223595842|NCT03746041|DRUG|bevacizumab|In cycles 2-4 (each cycle is 28 days), patients will be treated with SQ abaloparatide at a dose of 80 mcg/day and intravenous (IV) bevacizumab 5 mg/kg on days 1 and 15.
223595843|NCT02523573|PROCEDURE|Adult ARF ICU patients needing BAL with HFNC|bronchoalveolar lavage is performed in spontaneously breathing patients under high flow nasal cannula oxygen
223595844|NCT04390841|DEVICE|Cardiac Stimulator|The subjects will receive the intracardiac electrophysiological examination, during which the subjects will be subject to diagnostic electrical stimulation by the Qubic Stim Cardiac Stimulator. The subjects will also receive the clinical follow-up visit after cardiac electrical stimulation until they are discharged from the hospital.
223595845|NCT03036189|BEHAVIORAL|baa nnilah|7 meetings in the community led by a trained community facilitator
223595846|NCT00745433|DRUG|repaglinide|Start dose and frequency at the discretion of the physician following clinical practice
223595847|NCT00745433|DRUG|metformin|Start dose and frequency at the discretion of the physician following clinical practice
223595848|NCT00006196|DRUG|Vitamin D|
223595849|NCT01860950|DEVICE|anodal tDCS|a single 20-minute session of transcranial direct current stimulation (tDCS) with the anode electrode placed over the left DLPFC and the cathode electrode attached to the right shoulder
223595850|NCT01860950|DEVICE|cathodal tDCS|a single 20-minute session of transcranial direct current stimulation (tDCS) with the anode attached to the right shoulder and the cathode electrode placed over the left DLPFC.
223595851|NCT01860950|DEVICE|sham tDCS|Participants were provided pain education during 20 minutes of sham tDCS. For sham, the device was turned on for 30 seconds to temporarily mimic tingling and skin sensations of real tDCS and then ramped-down to 0mA for the duration of the 20-minute session
224197628|NCT01171274|BEHAVIORAL|Hatha Yoga|"* 9 weeks of Hatha Yoga, designed for treating chronic neck pain, as a group intervention.~* One class of 90 minutes per week, 10 minutes training at home each day."
224197629|NCT01171274|BEHAVIORAL|Information regarding exercises and behaviour|"* 9 weeks of exercises practiced at home.~* Patients receive detailed information regarding appropriate exercises and behaviour for chronic neck pain patients."
224197630|NCT04802421|PROCEDURE|alveolar recruitment manoeuver|alveolar recruitment manoeuver are recommended during general anesthesia to prevent pulmonary atelectasis
224197631|NCT05735119|DEVICE|Tapestry Biointegrative Implant|Collagen-based implant composed of type I bovine collagen and poly(D,L-lactide). It is designed to function as a non-constricting, protective layer between the tendon and surrounding tissues. Preclinical studies of the Tapestry implant showed dense collagenous fibrous connective tissue ingrowth into and around the implant.
224197632|NCT04434612|DEVICE|OXSIGHT smart glasses|OXSIGHT smart glasses are head-mounted electronic LVAs designed for LV patients with visual field loss.
224197633|NCT05416268|DIAGNOSTIC_TEST|Electroretinography|Two different electroretinogram devices (Diopsys NOVA and LKC RETeval Devices) will be evaluated with two different electrode arrays (Diopsys Lid Electrodes and LKC RETeval Self-Adhering Electrode Arrays).
224197634|NCT03478813|BEHAVIORAL|Voiding school|Children are educated on the kidneys, bladder and bowel function, the importance of regular voiding and drinking habits, and avoidance of constipation. Balloons, books, videos, animations, the pictures of a satisfied and irritated bladder and a poo-cars formula track are used to exemplify the function of urinary and defecation systems. During toilet visits children are given advise about an adequate and relaxed toilet posture with the help of little bench under the feet if needed. Each child also make their own timetable for peeing, pooing, and water drinking times, which they then should learn to follow in day-care, pre-school and at home. At the end of each session child, parent and public health nurse/urotherapist discuss any individual advice and the homework for the next time.
224197635|NCT01233349|DEVICE|Litramine|2 tablets 3 times daily (oral consumption, 30 minutes after meal)
224197636|NCT01233349|DEVICE|Placebo|2 tablets 3 times daily (oral consumption, 30 minutes after meal)
224197637|NCT04535518|DRUG|IVIG|IVIG at a single dose of 2 g/kg
224197638|NCT04535518|DRUG|Aspirin|Aspirin 30 mg/kg in oral per day (given in 3 divided doses), then 3 to 5 mg/kg per day when fever subsides for 72 hours and C-reactive protein (CRP) is normal. Aspirin will be continued for at least 6 weeks after onset of illness.
224197639|NCT04535518|DRUG|Infliximab|Intravenous infliximab at single dose of 5 mg/kg, given more than 2 hours.
224197640|NCT02014909|BIOLOGICAL|KTN3379|Single agent KTN3379 or in combination administered until unacceptable toxicity or progressive disease
223595852|NCT00467233|PROCEDURE|Laser Treatment|Laser treatment to half of the face at each study visit
223595853|NCT00467233|PROCEDURE|Acid Peel|Acid peel to half of the face at each study visit
223595854|NCT05316506|OTHER|Anticipated Discomfort Language|This language involves pain descriptors provided from physician to patient during procedure.
223595855|NCT05316506|OTHER|Objective Descriptive Language|This language involves neutral/objective descriptors provided from physician to patients during procedure.
223595856|NCT01204216|BIOLOGICAL|re-infusion of biotin labeled cells|"Subjects will participate in experiments involving re-infusion of biotin-labeled cells in which a small volume (\< 10 ml) of autologous, biotinylated erythrocytes will be re-infused to determine cell lifespan and in vivo HbA1c formation rate.~These experiments require a series of small, precisely timed post-infusion blood samples over a period of 4 months, with each subject undergoing the procedure twice separated by an interval of at least 8 month"
223595857|NCT01204216|BIOLOGICAL|Re-infusion of biotin labeled cells|"Subjects will participate in experiments involving re-infusion of biotin-labeled cells in which a small volume (\< 10 ml) of autologous, biotinylated erythrocytes will be re-infused to determine cell lifespan and in vivo HbA1c formation rate.~These experiments require a series of small, precisely timed post-infusion blood samples over a period of 4 months, with each subject undergoing the procedure twice separated by an interval of at least 8 months.~small volume (\< 10 ml) of autologous, biotinylated erythrocytes will be re-infused to determine cell lifespan and in vivo HbA1c formation rate."
223595858|NCT01204216|BEHAVIORAL|Diabetes education/diabetes medication adjustment|Between the initial 3-4 month trial period and the second infusion of biotin labeled cells approximately 8 months later,subjects will receive diabetes education from a CDE. In addition,if needed, diabetes medications may be adjusted by the study endocrinologist to improve subject's glycemic control.
224197641|NCT03075826|DRUG|SGI-110|subcutaneously at a dose of 60 mg/m2
223747742|NCT04696939|DRUG|Carboplatin|Carboplatin intravenous infusion was administered at a dose of 75mg/m\^2 on Day 1 of each 21-day cycle.
223747743|NCT04696939|DRUG|Etoposide|Etoposide intravenous infusion was administered at a dose of 100 mg/m\^2 on Day 1 of every 3-day cycle.
223747744|NCT05471518|OTHER|No intervention|No intervention
223747745|NCT04665037|DRUG|Posaconazole IV 6 mg/kg|POS 6 mg/kg body weight by IV infusion
223747746|NCT04665037|DRUG|Posaconazole PFS 6 mg/kg|POS nominal 6 mg/kg body weight based on weight bands taken orally
223747747|NCT06320730|OTHER|Observational study, records of blood glucose level after reperfusion|Analyzes blood glucose level after reperfusion by dividing it into two groups: those with blood glucose levels between 110 and 180 and those with blood glucose levels below 110 or above 180.
223747748|NCT00829374|DRUG|Dimebon|5 mg orally three times daily
224197642|NCT03337373|DRUG|cisatracurium|A single dose of 0.2 mg/kg intravenous bolus cisatracurium will be administered and blood samples will be taken before and at least 7 occasions post dose (at 1, 5, 10, 12, 15, 20, 30, and/or 60 minutes after a single bolus).
224197643|NCT00650806|DRUG|Canagliflozin (JNJ-28431754)|One 50 mg, 100 mg, or 300 mg over-encapsulated tablet orally (by mouth) once daily for 12 weeks.
224197644|NCT00650806|DRUG|Placebo|One matching placebo capsule orally once daily for 12 weeks.
224197645|NCT02430168|PROCEDURE|Percutaneous nephrolithotomy|
223747749|NCT00829374|DRUG|Dimebon|20 mg orally three times daily
224197646|NCT02430168|PROCEDURE|Retrograde intrarenal surgery|
224197647|NCT03542500|BEHAVIORAL|Youth Readiness Intervention (YRI)|The Youth Readiness Intervention integrates six CBT-based, empirically-supported practice elements shown to have transdiagnostic efficacy across disorders ranging from major depressive disorder to PTSD and conduct disorders. The YRI's six evidence-based components are delivered in three phases common in trauma-informed interventions: stabilization, integration, and connection.
224197648|NCT03542500|BEHAVIORAL|Entrepreneurship Training|The youth capacity development component of GIZ's Entrepreneurship Training includes the following core components: financial literacy, entrepreneurship, and vocational training delivered through six modules (agro-processing, solar photovoltaic installation and maintenance, governance and conflict resolution, psychosocial competencies, entrepreneurship, employability). Youth will be trained at training sites and have access to a youth center in the area. These centers will have agricultural equipment and machinery available for youth to use.
224310894|NCT04918485|OTHER|preoperative psychological intervention|including closing the relationship between nurse and patient , knowledge education,
224310895|NCT04505956|DEVICE|Holmium laser lithotripsy with Moses Technology|Holmium laser energy will be delivered for the ureteroscopic fragmenting of kidney stones. Energy will be generated by the commercial available, FDA approved Lumenis PulseTM P120H laser system and Moses laser fiber. Renal stones will be fragmented using a dusting technique. Moses laser settings will be turned on.
224310896|NCT04505956|DEVICE|Holmium laser lithotripsy without Moses Technology|Holmium laser energy will be delivered for the ureteroscopic fragmenting of kidney stones. Energy will be generated by the commercial available, FDA approved Lumenis PulseTM P120H laser system and Moses laser fiber. Renal stones will be fragmented using a dusting technique. Moses laser settings will be turned off.
223747750|NCT00829374|DRUG|Placebo comparator|Placebo orally three times daily
223747751|NCT05601986|OTHER|Physiotherapy and Rehabilitation Program|"The program will be held for 8 weeks, 2 days a week, with 40-minute sessions. Relaxation phase: Progressive relaxation. Stretching phase: Stretching exercises for the muscles of the gastrocnemius, hamstrings, hip flexors, hip adductors Strengthening phase: Isometric strengthening exercises for the tibialis anterior, quadriceps, hip extensors, and hip abductors muscles.~Balance training phase: Two legs, one leg, balance with eyes open and eyes closed.~Weight-bearing phase: Weight transfer to the front, back, and sides using the balance board."
223747752|NCT05601986|OTHER|Additional Motor Imagery Training to Physiotherapy and Rehabilitation Program|The program will be held for 8 weeks, 2 days a week, with 40-minute sessions. Relaxation phase, Stretching phase, Strengthening phase,Balance training phase and Weight-bearing phase. Additional to the Physiotherapy and Rehabilitation Program, the Additional Motor Imagery Training program will be carried out for 8 weeks, 2 days a week, in addition to the 40-minute physiotherapy and rehabilitation program, accompanied by 25-30 minutes of supervision. It will be conducted by the researcher on two non-consecutive days of the week, by making appropriate appointments for the participants. During the program, participants will be asked to be in a quiet room. Sessions will consist of 4 consecutive phases: video watching, relaxation, motor imagery, and return to the environment.
223747753|NCT04896320|DRUG|Tucatinib|Tucatinib is a highly selective, oral, reversibly Her2 small molecule tyrosine kinase inhibitor (TKI).
223747754|NCT06098807|BEHAVIORAL|Family Centered Treatment for Problematic Gaming and Excessive Screen Use|Based on earlier implementation research with parents and children the treatment is likely to consist of a low number of sessions ;one session per week during a period of four weeks with high quality content. The sessions will be performed at CAP location in Lund. The treatment will be performed by a clinician at CAP who could be a doctor, psychologist or health counselor - all with cognitive behavioral therapy competence. The sessions will be in group settings, separately for children and parents. In that sense, children will be included in a group with other children and parents will be included in a group with other parents. Each group will have 1-2 therapists leading the program. The theme of the week will be the same for both parent and child group, although the delivery will potentially differ. We expect that a session will last approximately 90 min with a 15-minute coffee break included.
223747755|NCT02631954|DRUG|Vorico Injection 200mg(Voriconazole)|Vorico Injection 200mg(Voriconazole) to administered intravenously once
223747756|NCT02631954|DRUG|Vfend®(Voriconazole) IV 200mg|Vfend®(Voriconazole) IV 200mg to administered intravenously once
223747757|NCT05771207|DIETARY_SUPPLEMENT|soy protein|The intervention is made up of soy protein supplements (30g/d) and dietary pattern modification.
223747758|NCT05771207|DIETARY_SUPPLEMENT|whey protein|The intervention is made up of whey protein supplements (30g/d) and dietary pattern modification.
223747759|NCT05771207|DIETARY_SUPPLEMENT|placebo|The intervention is made up of maltodextrin (30g/d) and dietary pattern modification.
223747760|NCT06365853|DRUG|Mirvetuximab Soravtansine|Mirvetuximab soravtansine is an antibody drug conjugate designed to target folate receptor α (FRα). It consists of the humanized anti-FRα monoclonal antibody (mAb) M9346A attached via a cleavable disulfide linker to the cytotoxic maytansinoid, DM4.
224310897|NCT04632511|DEVICE|MetaSAMP|Rectal Sampler
224310898|NCT05022589|OTHER|Computerized Plasticity-Based Adaptive Cognitive Training|Computerized plasticity-based adaptive cognitive training requiring a total maximum of 50 treatment sessions, 5 sessions per week, \~30 minutes per session.
224310899|NCT01181960|DRUG|Risperidone long acting injectable - New Starts|Patients who switch to Risperidone long acting injectable or receive an initial injection of Risperidone long acting injectable within the 30 days prior to enrollment will be eligible for inclusion in the Risperidone long acting injectable New Starts cohort.
224310900|NCT01181960|DRUG|Risperidone long acting injectable - Continuous Users|Patients who have been on Risperidone long acting injectable for at least 6 months before baseline, with no gaps between injections of more than 30 days will be eligible for inclusion in the Risperidone long acting injectable Continuous Users cohort.
224310901|NCT01181960|DRUG|Paliperidone Palmitate -New and Continuous Users|Patients newly initiating Paliperidone Palmitate or on Paliperidone Palmitate at the time of enrollment
224310902|NCT01181960|DRUG|Other Antipsychotics - New Starts|Participants in the other antipsychotic cohort may be newly started on any oral or injectable antipsychotic other than Risperidone long acting injectable and Paliperidone Palmitate
224310903|NCT02730026|DRUG|Ketoprofen|Clinical efficacy of the Ketoprofen 100 mg was study after lower third molar surgery.
224310904|NCT02730026|DRUG|Ketoprofen and Omeprazole|Clinical efficacy of the Ketoprofen 200 mg and Omeprazole 20 mg will be study after lower third molar surgery.
223595859|NCT02992509|DEVICE|EMED detruset(TM) intravesical electrical stimulation|"There will be a total of 8 therapy sessions, each lasting 15 minutes. The sessions will be done in a serial fashion, 2 per week for 4 consecutive weeks. The electrical parameters utilized will be those previously determined to be appropriate for OAB and UUI. As the beneficial effect of electrical stimulation is dependent on a maximal level of stimulation, the stimulation voltage will be increased during the first minute of treatment until the maximum tolerated by the patient is established and then backed-off by 1-2 Volts. The therapy will continue for 15 minutes in total for each session. The VAS will be marked by the patient before each treatment session throughout the therapy period, and other questionnaires will be administered."
223595860|NCT05301309|BEHAVIORAL|breastfeeding consultation|Integrative early breastfeeding support and intervention programs: breastfeeding for prematurity brochure, group education class, weekly interview, one-by-one breastfeeding consultation and online peer group support.
223595861|NCT04967339|DEVICE|Foot deformity correcting insoles|Foot deformity correcting insoles (e.g. insoles with medial arch support for plano-valgus deformity)
223595862|NCT04967339|DEVICE|Lateral wedge insoles|Lateral wedge insoles
223595863|NCT00001009|DRUG|Dextran sulfate|
223595864|NCT02348307|DRUG|FYU-981, (Oral single dosing)|Subjects randomized to the FYU-981 arm receive active drug, FYU-981.
223595865|NCT02348307|DRUG|Placebo, (Oral single dosing)|Subjects randomized to the placebo arm receive placebo.
223595866|NCT04741672|BEHAVIORAL|Providing guidance after discharge routine procedure and calling one week after discharge.|Guidance will be given to mothers after routine discharge. After one week, she will be called by phone and her questions about infant care will be answered.
223595867|NCT04741672|BEHAVIORAL|Discharge routine procedure.|Discharge routine procedure.
223595868|NCT01124955|OTHER|Acupuncture|The intervention group (IG) are submitted to five acupuncture sessions using Yamamoto New Scalp Acupuncture(YNSA)
223595869|NCT01124955|OTHER|Non-penetrating acupuncture|The placebo group (PG) are submitted to five non-penetrating acupuncture sessions using YNSA.
223595870|NCT02891382|BEHAVIORAL|Diabetes education|Participants interact with a diabetes educator (DE), every two weeks.
223747761|NCT06365853|DRUG|Lubricating Eye Drops|Lubricating artificial tears should be administered at least 15 minutes after corticosteroid or brimonidine eye drop administration.
223747762|NCT06365853|DRUG|Prednisolone acetate ophthalmic suspension 1% eye drops|Self-administration of prednisolone acetate ophthalmic suspension 1% eye drops as prescribed by the treating physician.
224075102|NCT06922318|DRUG|Testosterone cypionate|On day 1 of each BATZEN cycle testosterone cypionate (400 mg) injection to the buttocks will be administered.
223595871|NCT02891382|BEHAVIORAL|Goal setting|Goals for weight loss and change in levels of HbA1c
223595872|NCT02891382|BEHAVIORAL|Companion Support|Patient has a companion/team support partner to support achieving goals.
223595873|NCT02891382|BEHAVIORAL|Individual Reward|The cash reward is given to the patient with diabetes.
224075103|NCT06922318|DRUG|Enzalutamide|Enzalutamide 160 mg (four 40 mg capsules) taken daily by mouth on each ZENZA cycle.
224075104|NCT06922318|DRUG|Luteinizing hormone-releasing hormone (LHRH) analogue|Patients will continue on ADT with LHRH agonist (i.e. Zoladex, Trelstar, Eligard or Lupron) or LHRH antagonist (Degarelix or Relugolix) if not surgically castrated throughout the duration of the study to inhibit endogenous testosterone production.
224075105|NCT06917664|DRUG|sacubitril/valsartan|Sacubitril/valsartan therapy after isolated CABG
224075106|NCT07124403|DIAGNOSTIC_TEST|blood sampling|DPD Activity wil be assessed from blood samples
224075107|NCT07124403|DIAGNOSTIC_TEST|Blood sampling|Measurement of uracilemia and assessment of renal function
224075108|NCT07141745|PROCEDURE|Pulsed field ablation of reccurent atrial arrythmia|Substrate modification strategy based ablation of reccurent atrial arrythmia following pulmonary viens isolation employing pulsed field ablation with 3D guidance and high density mapping
224075109|NCT07141745|PROCEDURE|Radiofrequency ablation of reccurent atrial arrythmia (standard of care)|Standard radiofrequncy ablation of reccurent atrial arrythmia following pulmonary vien isolation employing substrate modification strategy
224075110|NCT03843385|DRUG|encapsulated faecal microbiota filtrate|Multidonor stool mixed with sterile normal saline, homogenized, filtered, centrifuged, air pressure filtered, encapsulated in hypromellose capsules and frozen.
224075111|NCT03843385|DRUG|encapsulated faecal microbiota|Multidonor stool mixed with sterile normal saline, homogenized, filtered, encapsulated in hypromellose capsules and frozen.
224075112|NCT03843385|DRUG|Placebo|Sterile saline encapsulated in hypromellose capsules and frozen.
223595874|NCT02891382|BEHAVIORAL|Shared Reward|Patients with diabetes and their companion support will each receive 50% of the cash reward.
223595875|NCT00586976|DRUG|Ropivacaine|0.3% ropivacaine infusion at 4 ml/hr for 64 hours.
223595876|NCT00586976|DRUG|Normal saline|Normal saline infusion at 4 ml/hour for 64 hours.
223595877|NCT02023047|DRUG|Nifedipine 12 mg coated suppositories|
223595878|NCT05553184|DRUG|Formoterol Fumarate 12 micrograms Inhalation Powder|At time 60 minutes, a total of 48 micrograms will be inhaled within 3 minutes: 4 inhalations of 12 micrograms of fumarate formoterol (Oxeze® Turbuhaler®).
223595879|NCT05553184|DRUG|Nicotinic Acid 50 MG Oral Tablet|a total dose of 1050 MG will be ingested. From time 0 to 180 minutes, doses of 150 MG will be repeated every 30 minutes.
223595880|NCT05553184|OTHER|Acute Cold Exposure|Participants will be fitted with a liquid-conditioned tube suit. The liquid-conditioned tube suit will be perfused with 18°C water using a temperature- and flow-controlled circulation bath from time 0 to 180 min.
223595881|NCT05553184|DIAGNOSTIC_TEST|Positron Emission Tomography (PET)|PET imaging using C11-palmitate (time 90), C11-acetate (time 120) and F18-Fluorodeoxyglucose (FDG) (time 150)
223595882|NCT05553184|DIAGNOSTIC_TEST|Indirect calorimetry|will be repeated every hour, for 20 minutes, using Vmax29n.
223595883|NCT05553184|DIAGNOSTIC_TEST|dual-energy x-ray absorptiometry (DEXA scan)|Whole body scan
223595884|NCT05553184|PROCEDURE|Biopsy|After local anesthesia with 2% xylocaine without epinephrine, 100-200 mg of subcutaneous adipose tissue will be sampled by needle (14G) biopsy
223595885|NCT05553184|PROCEDURE|iv lines|for stable tracer perfusion and blood sampling
223595886|NCT05553184|PROCEDURE|Electromyogram (EMG)|Surface electrodes will be used to measure skeletal muscle activity and shivering intensity
223595887|NCT00266682|DEVICE|Pacing Lead|
223595888|NCT03286816|DRUG|SodiumChloride|
223595889|NCT03286816|DRUG|Sodium Lactate|
223595890|NCT00723359|DRUG|BT062|biologic
223595891|NCT06469528|DRUG|Colchicine 0.5 MG|Low dose daily colchicine
223595892|NCT03042884|BEHAVIORAL|Questionnaires|"Inpatient Group: Participants complete a questionnaire about any symptoms they may have had in the past 24 hours. The questionnaire should take about 5 minutes to complete.~Within 24 hours of being discharged, same questionnaire about symptoms and a questionnaire about experience with the wearable exercise tracker. These questionnaires should take about 10 minutes total to complete.~Outpatient Group: Participants complete 2 questionnaires about any symptoms they may have had in the past 24 hours and their current level of physical function. These should take about 10 minutes total to complete.~At the end of the 14-day period, participant called by the study staff to remind them to complete the same 2 questionnaires about symptoms and level of physical function. Participants complete another questionnaire about their experience with the wearable exercise tracker. These questionnaires should take about 15 minutes total to complete."
223595893|NCT03042884|DEVICE|Wearable Exercise Tracker Watch|"Inpatient Group: Participants receive a wearable exercise tracker watch upon admission to acute inpatient rehabilitation unit. Participant to wear the exercise tracker watch on their wrist for 24 hours a day. Device to be returned within 24 hours before being discharged.~Outpatient Group: Participants receive a wearable exercise tracker watch to wear on their wrist for 24 hours a day for 14 days. Device to be returned at next visit."
223595894|NCT05126849|OTHER|Allogenic transplantation|"1. Conditioning regimen Fludarabine (30mg/m2/day i.v: day -6 to day -2), pre-transplant cyclophosphamide (14.5 mg/kg/day i.v: day -6 and day -5), and Total Body Irradiation (2 Gray on day-1)~2. Stem cell source Bone Marrow~3. GVHD Prophylaxis Rabbit ATG dosed at 0.5 mg/kg on day -9 and 2 mg/kg on days -8 and -7, Cyclophosphamide 50 mg/Kg/day at D+3 and D+4, Tacrolimus (residual 8-12 microg/L) and mycophenolate (MMF) from D+5. In absence of GvHD, MMF will be stopped at D35 and tacrolimus at day 365.~4. Prevention of EBV reactivation Rituximab 150mg/m2 intravenously at Day+5 post HSCT, Each infusion of Rituximab will be preceded by administration of anti-pyretic and an antihistaminic, e.g. paracetamol and diphenhydramine."
223595895|NCT03505528|DRUG|Nanoparticle albumin-bound paclitaxel|Abraxane is administered intravenous at a constant dose of 100mg/m2
223595896|NCT03505528|DRUG|Phenelzine Sulfate|Nardil is administered orally from a starting dose of 15mg/d to a maximum of 90mg/d
223595897|NCT00147303|DRUG|MCI-9042|
223595898|NCT03274518|DEVICE|Expanded Hemodialysis|"Intervention: Conversion from conventional HD to expanded hemodialysis por 1 month.~High cutoff with high retention onset dialyzers allow clearance of middle molecules, without reducing significantly serum concentration of albumin. It allows higher convective clearance in comparison to conventional hemodialysis, but it is unknown if such clearance is similar to online hemodiafiltration. Therefore, the aim of the present intervention is to compare this dialyzer with online hemodiafiltration"
223595899|NCT03274518|DEVICE|Online Hemodiafiltration|"Intervention: Conversion from conventional HD to online Hemodiafiltration por 1 month.~Online hemodiafiltration has been associated with lower incidence of intradialytic hypotension in comparison to conventional hemodialysis."
223595900|NCT04346849|PROCEDURE|Pulpotomy|Cutting the coronal portion of the pulp and application of a calcium silicate based material followed by restoration
223595901|NCT02516228|DEVICE|GTEN 100|"Stimulation will be focused on the seizure generating cortex. All patients enrolled in the study will have a pre-treatment baseline evaluation period. During this time, the patient (and/or family) will maintain the seizure diary that simply tracks the number of seizure the patient experiences each day.~During this baseline period, two two-hour EEG recordings (to be completed on 2 separate days) will be acquired. This baseline EEG data will be used to establish baseline inter-ictal spike rate as well as classification of the inter-ictal spikes used to localize seizure onset zone. Using the localization information, patients will be treated with the device for five concurrent days."
223747763|NCT06365853|DRUG|Brimonidine tartrate ophthalmic solution eye drops|Self-administration of brimonidine tartrate ophthalmic solution eye drops as prescribed by the treating physician.
223747764|NCT03425331|DRUG|Ipilimumab|Ipilimumab is a type of immunotherapy. Immunotherapy works by stimulating the body's own immune system to attack cancer cells
223595902|NCT00692419|BEHAVIORAL|Symptom management nurse intervention|A symptom management nurse will facilitate the management of pain, sexual dysfunction and depression in patients enrolled in one arm of the study
223747765|NCT03425331|DRUG|Nivolumab|Nivolumab is a type of immunotherapy. Immunotherapy works by stimulating the body's own immune system to attack cancer cells
223747766|NCT00979888|OTHER|educational intervention|
223595903|NCT00692419|BEHAVIORAL|Feedback intervention|Pain, sexual dysfunction and depression will be assessed monthly and feedback will be given to renal providers on the presence and severity of these symptoms. Treatment will be left at the discretion of the renal provider
223595904|NCT05150210|DEVICE|Robotic-Assisted Surgery|da Vinci SP Surgical System, instruments, and accessories in pulmonary lobectomy and thymectomy for benign and malignant disease.
223595905|NCT03916484|BEHAVIORAL|AllyQuest HIV Medication Adherence app-delivered intervention|"AQ provides daily ART reminders and calendar; weekly tailored message; monthly appointment and refill reminders; social support via daily chat wall; daily challenge featuring skills-building and articles; education center; narrative collections; in app account rewards daily use by adding or subtracting small financial reward dependent on daily app use; personalized profile and avatar. Participants have 24-hour access to all features of the AQ app."
223595906|NCT03916484|BEHAVIORAL|AllyQuest HIV Medication Adherence app-delivered intervention + NSC|In AQ+, participants receive all of AQ and have the added ability to text in the app with an adherence counselor, using Next Step Counseling (NSC). NSC is an interactive, client-centered motivational intervention to improve ART adherence. Key components of NSC include: review experiences with adherence, exploration of adherence facilitators and barriers, identification of adherence needs, identification of strategies to meet needs, and development of an adherence action plan. AQ+ includes unprompted check-in messages from the NSC counselor and scheduled in-app NSC sessions approximately every other week.
223595907|NCT03937960|OTHER|Carbohydrate restricted group|Prescribed low carbohydrate diet with set recipes
223595908|NCT03937960|OTHER|Standard low fat diet|Diet with less than 20% total calorie intake from dietary fats
223747767|NCT00979888|OTHER|informational intervention|
223747768|NCT00979888|OTHER|psychosocial support for caregiver|
224197649|NCT00568464|DRUG|VCR, CTX, ADM; IFO, VP-16|VCD: VCR 2 mg d1, CTX 1200 mg/m2 d1, Mesna 240 mg/m2 tid d1, ADM 75mg/m2 d1, G-CSF 300 ug/d d5-11; IE: IFO 1800mg/m2 d1-5,Mesna 360 mg/m2 tid d1-5,VP-16 100 mg/m2 d1-5,G-CSF 300 ug/d d6-12; q3w. Surgery or radiation will be done to the patients with local diseases after four cycles of VCD/IE.
224197650|NCT06650605|DRUG|123I-ATT001|123I-ATT001
223747769|NCT00979888|OTHER|questionnaire administration|
223747770|NCT00979888|PROCEDURE|dyspnea management|
223747771|NCT00979888|PROCEDURE|management of therapy complications|
223747772|NCT04483908|DIAGNOSTIC_TEST|blood draw|2x 10ml of blood, one vial to obtain the antibodies and one vial in ethylenediaminetetraacetic acid (EDTA) (or citrate-treated) to obtain peripheral blood mononuclear cells (PBMCs)
224197651|NCT06149351|DIAGNOSTIC_TEST|Bio-fluid analysis for the implementation of a diagnostic test for sport related concussion|Saliva of participants will be sampled for analysis of biomarkers of interest (nucleic acids and proteins). The nucleic acids biomarkers will be quantified by reverse transcription followed by amplification (RT-PCR) and Next Generation Sequencing (NGS) techniques while enzymatic assay methods (ELISA) methods will be used to quantify protein biomarkers.
224310905|NCT03729726|BEHAVIORAL|Future Foundation 2.0 PREIS Program|The Future Foundation 2.0 PREIS intervention model uses a placed-based collective impact framework to provide a comprehensive intervention model, including: academic support and college and career readiness services, evidence-based social emotional learning instruction to strengthen protective factors and promote healthy transitions to adulthood, and trauma-informed, medically accurate, and age appropriate sexual health education. Moreover, the 2.0 PREIS program model features a unique student advocacy component designed to ensure that youth and their families receive the wraparound supports necessary for their students to remain on track for school success.
224310906|NCT01804348|DEVICE|AL-SENSE 1-Step|a single AL-SENSE 1-Step to use up to 12 hours or until they notice any wetness.
224310907|NCT01305044|BEHAVIORAL|Tai Chi Chih|Tai Chi Chih (TCC), a westernized and manualized form of the ancient TC Chuan, consists of a series of 20 simple, repetitive, non-strenuous movements that involve no physical contact and emphasize a soft, flowing continuity of motion. This form of meditation through movement consists of a standardized protocol that emphasizes slow, fluid, continuous forms that integrate mental concentration, awareness, balance, shifting of body weight, gentle movement, imagery, muscle relaxation and breathing control. TCC was developed for use with elderly persons.
224310908|NCT01305044|BEHAVIORAL|Health Education Classes|The Health Education classes serve as an attention control group, are led by gerontology specialists, physicians, and other health professionals, and focus on topics that are relevant to elderly cancer survivors.
224310909|NCT06247397|DEVICE|Added high-flow oxygen therapy|Added high-flow oxygen therapy using the device Lumis HFT during nighttime and at the patient's discretion daytime, with the usual care (low-flow oxygen therapy) the rest of the time.
224310910|NCT06247397|OTHER|Standard care|Standard care with low-flow oxygen therapy in accordance with clinical routine.
224310911|NCT01392625|BIOLOGICAL|Autologous hMSCs|"Cells will be administered via the Biosense Webster MyoStar NOGA Injection Catheter System will be tested in 18 patients via transendocardial injection:~Group 1 (18 patients) Eighteen (18) patients will be treated with Auto-hMSCs: 20 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 1 x 108 (100 million) Auto-hMSCs."
223747773|NCT04483908|DIAGNOSTIC_TEST|fingertip tests for POC assays|performing POC test by taking two blood drops from the fingertip
223747774|NCT04483908|DIAGNOSTIC_TEST|saliva collection|saliva collection: the patient delivers saliva into an adsorbent filter, which is placed in the Salivette tube, centrifuged at 1,600x g for 15 min at 4°C to remove cells and debris. Native supernatant is used for testing.
223747775|NCT04483908|DIAGNOSTIC_TEST|collection of swabs|collection of nasopharyngeal and oropharyngeal swabs for PCR testing on the control group (eg negative subpopulation)
223747776|NCT01516944|DRUG|Tegafur, Gimeracil and Oteracil Potassium Capsules；Oxaliplatin|Tegafur，Gimeracil and Oteracil Potassium Capsules 80 mg/m2 D1-D14 q3wk and Oxaliplatin 130 mg/m2 D1 q3wk for six cycles postoperation
223747777|NCT01516944|DRUG|Tegafur, Gimeracil and Oteracil Potassium Capsules；Oxaliplatin|Tegafur，Gimeracil and Oteracil Potassium Capsules 80mg/㎡ ,D1-D14 q3wk and Oxaliplatin,130 mg/㎡ D1 q3wk for two cycles preoperation, Tegafur，Gimeracil and Oteracil Potassium Capsules ,80 mg/㎡ D1-D14 q3wk and Oxaliplatin,130 mg/㎡ D1 q3wk for six cycles postoperation
223747778|NCT01516944|DRUG|Oxaliplatin; Capecitabine|Capecitabine,2000 mg/㎡ D1-D14 q3wk and Oxaliplatin,130 mg/㎡ D1 q3wk for two cycle pre-operation, Capecitabine,2000 mg/㎡ D1-D14 q3wk and Oxaliplatin,130 mg/m2 D1 q3wk for six cycles postoperation
223595909|NCT02675530|DRUG|ketamine|"For healthy volunteer arm of study, NMDA antagonist ketamine will be administered. 0.23 mg/kg over 1 minute, followed by 0.58 mg/kg/hour for 30 minutes, followed by 0.29 mg/kg/hour for 50 minutes.~No drug administration for patients with schizophrenia"
224197652|NCT04041063|DEVICE|Upper limb robotic training|"Subjects will remain seated in their own wheelchair in front of the InMotion Hand™ Robot (Interactive Motion Technologies, Massachusetts, MA, Figure 6) facing a video screen.~The arm of the participants will be abducted, forearm supported, and hand grasping a cone shaped handle. Velcro straps will lightly hold the forearm and fingers secure. The InMotion Hand™ robot attaches to the InMotion Arm™ robots to provide 'assisted-as-needed'™ gross grasp and release motion and support for functional reach. In each session, patients perform a total of 1024 movement repetitions (Cortes et al., 2013). Patients will receive a total of 18 sessions (3x/week, 6 weeks) comprising one hour of interactive hand robotic training. The interactive robotic features involve visuomotor task, moving the robotic manipulandum according to targets on a computer screen mounted at eye level."
224197653|NCT04041063|PROCEDURE|Nerve transfer surgery|C5 injury; Teres minor branch of axillary nerve transferred to long head of triceps branch of radial nerve (RN); Brachialis branch of musculocutaneous nerve to anterior interosseous nerve (AIN); Supinator branch of RN to posterior interosseous nerve (PIN). C6 injury; Teres minor branch of axillary nerve to long head of triceps branch of RN; Extensor carpi radialis brevis (ECRB) branch of RN to AIN; Supinator branch of RN to PIN. C7 injury with preserved triceps, loss of grasp/release; Pronator teres branch of median nerve to AIN; Terminal branch of ECRB branch of RN to flexor pollicis longus branch of AIN; Supinator branch of RN transferred to PIN. C7 injury with preserved triceps/finger extension, loss of grasp; Pronator teres branch of median nerve to AIN; Terminal branch of ECRB branch of RN to flexor pollicis longus branch of AIN.
224197654|NCT04456998|DRUG|GB002 (seralutinib)|Capsule containing GB002 (seralutinib)
224197655|NCT04456998|DRUG|Placebo|Matching capsule containing placebo
224310912|NCT01392625|BIOLOGICAL|Allogeneic hMSCs|"Cells will be administered via the Biosense Webster MyoStar NOGA Injection Catheter System will be tested in 18 patients via transendocardial injection:~Group 2 (18 patients) Eighteen (18) patients will be treated with Allo-hMSCs: 20 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 1 x 108 (100 million) Auto-hMSCs."
224310913|NCT00833001|DEVICE|GYNECARE PROLIFT+M* Pelvic Floor Repair System|Pre-shaped mesh implants made of GYNECARE GYNEMESH M composite mesh, comprised of absorbable polyglecaprone 25 monofilament fiber and nonabsorbable polypropylene monofilament fiber
223595910|NCT04450329|DRUG|SB15 (Proposed aflibercept biosimilar)|Subjects randomized into SB15 group will receive SB15 2 mg (0.05 mL) via intravitreal injection every 4 weeks for the first 3 months, followed by 2 mg (0.05 mL) once every 8 weeks until Week 48. Starting at Week 32, subjects transited from Eylea to SB15 will receive SB15 2 mg (0.05 mL) via intravitreal injection every 8 weeks.
223595911|NCT04450329|DRUG|Eylea (Aflibercept)|Subjects randomized into Eylea group will receive Eylea 2 mg (0.05 mL) via intravitreal injection every 4 weeks for the first 3 months, followed by 2 mg (0.05 mL) once every 8 weeks until Week 48.
223595912|NCT05229029|DRUG|TCM Formula|TCM herbs：White peony 10g, angelica 10g, Astragalus 20g, Atractylodes macrocephala 10g, tangerine peel 6g, Poria cocos 10g, raw land 10g, cinnamon 3g, Polygala tenuifolia 6g, Schisandra chinensis 6g, raw licorice 6g.
223595913|NCT05229029|DRUG|Placebo|Mainly made of dextrin and caramel, containing 1/30 concentration of experimental group drugs
223595914|NCT03515642|BEHAVIORAL|HIIT group|Physical Training
223595915|NCT06430723|PROCEDURE|Total hip arthroplasty|Total hip arthroplasty using short stem via an minimally invasive anterolateral approach
223595916|NCT00395421|DRUG|NM283 plus Peg-IFNα-2a|200 mg QD 180 µg QW
223595917|NCT05709639|OTHER|Individualized counselling in nutrition|Individualized counselling in nutrition - collaborate on a nutrition plan
223595918|NCT01675193|BEHAVIORAL|Disinvestment protocol|Omission of population-based child vision screening visits at 6-9 and 14-24 months: Children in the intervention group will not be eye screened at age 6-24 months
223595919|NCT05368168|DEVICE|Posterior tibial nerve stimulation (PTNS)|"Posterior tibial nerve neurostimulation in postoperative patients treated for rectal neoplasms for 6 weeks at a rate of 2 sessions per week (12 sessions).~The sessions will be carried out by the nursing staff of the anorectal functional testing cabinet. The sessions will begin 3 weeks after hospital discharge for patients without lateral ileostomy and after ileostomy closure for patients with lateral ileostomy."
223595920|NCT02736981|BEHAVIORAL|Behavioral Weight Loss (BWL)|The intervention represents an adapted version of gold-standard evidence based adult behavioral weight loss that has been tailored specifically to meet the needs of 18-25 year olds. The program includes personalized dietary and physical activity prescriptions, training in behavioral strategies, weekly lesson content, and reporting of key behaviors and personalized feedback and coaching.
223595921|NCT02736981|BEHAVIORAL|BWL + Autonomous Motivation|The intervention represents an adapted version of gold-standard evidence based adult behavioral weight loss that has been tailored specifically to meet the needs of 18-25 year olds. The program includes personalized dietary and physical activity prescriptions, training in behavioral strategies, weekly lesson content, and reporting of key behaviors and personalized feedback and coaching. Participants in this arm will receive coaching that places an increased emphasis on their values and personal choices, and also have the option to attend several experiential group sessions that will help those interested to apply the material and skills they are being taught (e.g., cooking demonstration, circuit training class).
223595922|NCT02736981|BEHAVIORAL|BWL + Extrinsic Motivation|The intervention represents an adapted version of gold-standard evidence based adult behavioral weight loss that has been tailored specifically to meet the needs of 18-25 year olds. The program includes personalized dietary and physical activity prescriptions, training in behavioral strategies, weekly lesson content, and reporting of key behaviors and personalized feedback and coaching. Participants in this arm will have the opportunity to receive small monetary incentives in weeks 2-24 for tracking weight and calorie intake, and will be eligible for a raffle based on weight loss.
223595923|NCT00727155|BEHAVIORAL|Adjusting to Chronic Conditions Using Education Support and Skills|This psychosocial intervention uses a combination of cognitive-behavioral therapy and disease self-management techniques.
223595924|NCT00644111|DRUG|Bupivicaine, Hydromorphone|0.1% Bupivicaine with 0.015mg hydromorphone per mL at 6 mL per hour in Arm 2
224197656|NCT04456998|DEVICE|Generic Dry Powder Inhaler|Generic dry powder inhaler for GB002 (seralutinib) or placebo delivery
224197657|NCT01363531|OTHER|Antibiotic prescription strategies|The patients enrolled will be randomized between four treatment strategies or arms. Patients randomized to delayed treatment arms or direct treatment, doctors can choose the antibiotic that they consider appropriate depending on such local resistance or practice.
224197658|NCT03511391|DRUG|Nivolumab or Pembrolizumab or Atezolizumab|per national standard of care
224310914|NCT02279134|RADIATION|Adjuvant Chemoradiation|Patients receive Paclitaxel 135-150mg/m2 (D1 and D29) and Cisplatin or Nedaplatin 50-75mg/m2 (D1 and D29) every 4 weeks, concurrent with radiotherapy. Prophylactic polyethylene glycol recombinant human G-CSF is administered 48 hours after chemotherapy. Treatment repeats every 28 days for 2 courses in the absence of disease progression or unacceptable toxicity.
223595925|NCT00644111|DRUG|Saline Placebo|Saline placebo continuous epidural infusion of 6 mL per hour in Arm 1
223595926|NCT03555682|DIETARY_SUPPLEMENT|2-HOBA|2-HOBA is a compound found in buckwheat and is given as 2-HOBA acetate
223595927|NCT03555682|DIETARY_SUPPLEMENT|Placebo|Placebo Comparator
223595928|NCT06293313|PROCEDURE|Mindfulness training|Before starting the study, an appointment will be made to meet with the students participating in the mindfulness group with randomization on the specified day and time. The students and the researcher will meet in a quiet, calm room of the school. Students will be informed about the practice of mindfulness and their written and verbal consents will be obtained before participating in the study. Then, a pre-test will be applied to the students who agree to participate in the study.
223595929|NCT06293313|OTHER|Will not be given any application|Before starting the research, the students in the control group determined by the randomization method will be informed about the research. Written and verbal consent will be obtained from the students that the students agree to participate in the research. Afterwards, students will meet in a quiet and calm room of the school on the specified day and time. Before starting the research, students will be given a pre-test. A mid-term test will be performed 8 weeks after the pre-test.
223595930|NCT04869306|DEVICE|Hyaluronic acid gel|After lower third molar removal, the test group 1 will additionally receive hyaluronic acid gel prior to wound closure.
223595931|NCT04869306|DEVICE|Hyaluronic acid gel + carrier|After lower third molar removal, the test group 2 will additionally receive hyaluronic acid gel with a collagen carrier prior to wound closure.
223595932|NCT05492864|PROCEDURE|extrusion of the anterior teeth|sectional leveling and alignment of the teeth, then using of the extrusion arch as an overlay wire to treat the open bite
223595933|NCT02561221|BEHAVIORAL|Lifestyle Counseling|"Trained health coaches delivered the active intervention - a comprehensive, high-intensity program, as recommended first-line therapy by the 2013 American Heart Association/American College of Cardiology/The Obesity Society Guidelines."
223595934|NCT03673020|BIOLOGICAL|ASV® AGEN2017 + QS-21 Stimulon® adjuvant|Neoantigen Vaccine
223595935|NCT02592460|OTHER|poor-polyamines diet|Patients in this will receive a poor-polyamines diet during a week before and a week after foot surgery
223595936|NCT02592460|OTHER|high polyamines diet|Patients in this will receive a high-polyamines diet during a week before and a week after foot surgery
223595937|NCT00504894|DRUG|Placebo|A low dose given intravenously one time for just under an hour while the subject is shown visually stimulating images in an MRI machine.
223595938|NCT00504894|DRUG|Propofol|A low dose of propofol 0.90 μgml-1, given intravenously while the subject is shown visually stimulating images in an MRI machine.
223595939|NCT00504894|DRUG|Thiopental|A low dose of thiopental 3.0 μgml-1, given intravenously while the subject is shown visually stimulating images in an MRI machine.
223595940|NCT04851756|DEVICE|CRet|In prone position, subjects will get a 7 min preparation massage with CRet on resistive mode (80-100W), on the lumbar area, followed by a 5 min preparation massage with CRet on resistive mode (100-120 W) on the hamstrings. Then a 5 min Functional Massage (F.M) with passive anckle dorsiflexion and CRet on resistive mode (110-120 W) will be performed on the gastrocnemius medialis and lateralis, followed by a 4 min F.M with CRet on capacitive mode (180-250VA) on the mentioned area. In supine position, a 5 min F.M with passive knee flexion and CRet on resistive mode (110-140W) will be performed on the rectus femoris, followed by a 4 min F.M with passive knee flexion and CRet on capacitive mode (180-250VA) on the mentioned area. A physiotherapist will monitor the temperature of the patient's treated area every 2 minutes.
223747779|NCT06004700|OTHER|Mobile Application|The current app contains a disease activity questionnaire, a mood scale, a sleep scale, a pain scale, and a functional status scale. The app triggers a brief set of questions each day and allows patients to answer them within 24 hours.
223747780|NCT06002347|BEHAVIORAL|STAC Parent Module for Middle School|"The STAC Parent Module is a 30-minute pre-recorded online presentation that includes normative feedback, didactic information, a review of the student STAC strategies and corresponding strategies parents can use to support students who act as defenders, and information about perceptions vs. facts about bullying."
223747781|NCT02864251|BIOLOGICAL|Nivolumab|Specified dose on specified days
223747782|NCT02864251|BIOLOGICAL|Ipilimumab|Specified dose on specified days
224197659|NCT03511391|RADIATION|SBRT|Stereotactic body radiotherapy is administered to maximally 3 lesions in 3 fractions of 8Gy prior to the second/third cycle of checkpoint inhibitors.
223747783|NCT02864251|DRUG|Pemetrexed|Specified dose on specified days
223747784|NCT02864251|DRUG|Cisplatin|Specified dose on specified days
223747785|NCT02864251|DRUG|Carboplatin|Specified dose on specified days
223747786|NCT00299260|BIOLOGICAL|CMV gB vaccine|20 micrograms
224197660|NCT01465048|BIOLOGICAL|Plasmodium falciparum sporozoites 2sites|Aseptic, purified, cryopreserved Plasmodium falciparum sporozoites, 2,500 sporozoites, 50ulx2, 2 intradermal injection sites
224197661|NCT01465048|BIOLOGICAL|Plasmodium falciparum sporozoites 1 site|Aseptic, purified, cryopreserved Plasmodium falciparum sporozoites, 2,500 sporozoites, 50ulx2, 2 intramuscular injection sites
223747787|NCT00299260|DRUG|Placebo|normal saline
223747788|NCT01701115|PROCEDURE|Low Dose (20 ml) Local Anesthetic Volume for Interscalene Block|"Anesthetic volume:~Investigational group: A 1:1 Mepivacaine 1.5%: Bupivacaine 0.5% mixture for a total of 20 mL"
223747789|NCT01701115|PROCEDURE|Control Dose (40 mL) Local Anesthetic Volume for Interscalene Block|"Anesthetic volume:~Control group: A 1:1 Mepivacaine 1.5%: Bupivacaine 0.5% mixture for a total of 40 mL"
223747790|NCT01701115|DRUG|Low Dose (20 mL) Local Anesthetic (Mepivacaine:Bupivacaine)|
224197662|NCT01465048|BIOLOGICAL|Plasmodium falciparum sporozoites 1site|Aseptic, purified, cryopreserved Plasmodium falciparum sporozoites, 25,000 sporozoites, 50ulx2, 2 intramuscular injection sites
224197663|NCT03906565|DRUG|utidelone injection|utidelone monotherapy in patients with advanced or metastatic CRC by iv transfusing utidelone injection
224197664|NCT06505902|OTHER|Exercise|Exercise by bicycle and performing diffusing capacity measurements at the same time with arterial blood gasses.
224197665|NCT02530801|DRUG|Bevacizumab|Subconjunctival injection of Bevacizumab combined with 5 fluorouracil in the recurrent pterygium
224197666|NCT02530801|DRUG|5 fluorouracil|Subconjunctival injection of Bevacizumab combined with 5 fluorouracil in the recurrent pterygium
224197667|NCT06649175|OTHER|Exercise|"Close kinetic chain (CKC) exercises :~1. Supine wall push exercise: Start position: supine with the both leg against wall, other limb straight. Exercise action: push against wall for thirty seconds.~2. Wall push against Swiss ball exercise: Start position: Supine with a Swiss ball between patient's legs and the wall. Exercise action: push against the wall for thirty seconds.~3. Supine half bridging exercise: Start position: Lying on back, knees bent Exercise action: keeping spine neutral and hinging up from the hips, move into a bridge."
224197668|NCT06649175|OTHER|Exercise|"Control Group (A): will receive the traditional physical therapy (PT) , the traditional physical therapy program will include the following:~* Stretching exercise for shortening muscle of lower limbs (LL) mainly (hip flexors, adductors, knee flexors and ankle planter flexors).~* Balance training from standing while giving perturbations.~* Balance board training.~* Step ups: repeated stepping anteriorly and laterally onto a step with both legs alternatively, progressing to higher step and decreasing upper extremity support.~* Forward and backward walking (with or without handheld mobility devices).~* Side walking (with or without handheld mobility devices).~* Walking in astride line (with or without handheld mobility devices)."
224197669|NCT04757896|PROCEDURE|Lateral costoclavicular approach|USG guided lateral costoclavicular approach for brachial plexus block
224197670|NCT04757896|PROCEDURE|Medial costoclavicular approach|USG guided medial costoclavicular approach for brachial plexus block
223595941|NCT04851756|DEVICE|Sham CRet|"In prone position, subjects will get a 7 min preparation massage with CRet on resistive mode (0 W), on the lumbar area, followed by a 5 min preparation massage with CRet on resistive mode (0 W) on the hamstrings. Then a 5 min Functional Massage (F.M) with passive anckle dorsiflexion and CRet on resistive mode (0 W) will be performed on the gastrocnemius medialis and lateralis, followed by a 4 min FM with CRet on capacitive mode (0 VA) on the mentioned area. In supine position, a 5 min F.M with passive knee flexion and CRet on resistive mode (0W) will be performed on the rectus femoris, followed by a 4 min F.M with passive knee flexion and CRet on capacitive mode (0VA) on the mentioned area.~A physiotherapist will monitor the temperature of the patient's treated area every 2 minutes."
223595942|NCT05413148|BIOLOGICAL|Subtenon injection of Wharton jelly derived mesenchymal stem cells|Single subtenon's injection for single eye
223595943|NCT05413148|BIOLOGICAL|Subtenon injection of Wharton jelly derived mesenchymal stem cell exosomes|Single subtenon's injection for single eye
223747791|NCT01701115|DRUG|Control Dose (40 mL) Local Anesthetic (Mepivacaine:Bupivacaine)|
223747792|NCT03943875|BIOLOGICAL|9-valent HPV vaccine, 2 dose efficacy|Evaluate the efficacy of 2 doses of the HPV vaccine across a 12 month period following the 1st dose among 15-26 year old males and females.
223747793|NCT03943875|BIOLOGICAL|9-valent HPV vaccine, 3 doses standard timing|Will be comparison group for 2 dose efficacy group.
223747794|NCT03067181|OTHER|Best Practice|Undergo observation
224197671|NCT06043830|DRUG|Acetazolamide|Acetazolamide 250 mg 2 capsules by mouth nightly
224197672|NCT06043830|OTHER|Placebo|Sugar capsule manufactured to match encapsulated Acetazolamide 2 capsules by mouth nightly
224197673|NCT06015061|DIAGNOSTIC_TEST|Contrast-enhanced ultrasound(CEUS)|CEUS is a quantitative kinetic imaging modality that can assess intravascular blood flow in PPGL tumors.
224197674|NCT05967533|DRUG|Fermented Wheat Germ Extract|Given orally (PO)
224197675|NCT04593277|OTHER|Internet Mobile Technology|Use INSPIRE mobile application
224197676|NCT04593277|OTHER|Internet-Based Intervention|Access to a study-specific control website
224197677|NCT04593277|OTHER|Questionnaire Administration|Ancillary studies
224197678|NCT04593277|PROCEDURE|Supportive Care|Receive telehealth stepped care
224197679|NCT04593277|OTHER|Informational Intervention|Receive printed SCP materials
224197680|NCT03994965|DRUG|Pimavanserin 34 milligrams (MG) [Nuplazid]|Daily treatment with 34 mg per os for 6 weeks. Followed by a wash-out period up to 14 days, do to the theoretical risk of corrected QT interval (QTc) prolongation. Conventional anti-psychotic treatment will be initiated only upon normal ECG.
224197681|NCT04373330|BEHAVIORAL|Intensive Lifestyle Intervention|There will be 14 sessions delivered over the course of 6 months; materials consist of CHW lesson plans, participant workbooks, and the DVD series. These materials will be adapted for use in HELP-VM and will include information on migraine and its management as well as mental health resources available to Veterans for common illnesses like depression and post-traumatic stress disorder and modifying physical activity recommendations for Veterans with limited mobility.
223595944|NCT05413148|OTHER|Placebo|Single Subtenon injection of saline for a single eye
223595945|NCT05090852|DEVICE|Hi-VNI|Hi-VNI used instead of or along with endotracheal intubation or jet ventilation to provide oxygen to patients during upper airway surgery
223595946|NCT05670418|DEVICE|Quantitative Electroencephalography|Each qEEG examination of one person lasted about 20 minutes and included two stages: the first-recording of brain waves with eyes closed (5 min), the other with eyes open (5 min)
223595947|NCT02661074|OTHER|Questionnaire|"A questionnaire will be completed in order to collect data on:~* Potential allergic manifestations after fish contact: asthma, allergic rhinitis, conjunctivitis, chronic or acute urticaria, dermatitis/eczema, or severe allergic manifestations (angioedema, bronchospasm, anaphylaxis),~* Occupational and/or domestic exposure to fish."
223595948|NCT01196416|DRUG|Cisplatin|Given IV
224197682|NCT06490874|DEVICE|CGM device - Metformin group|Individuals randomized to metformin will be provided with a CGM device (Dexcom, Inc, San Diego, CA) to be worn for up to 10 days (minimum \>5 days) at two pregnancy (randomization to metformin or insulin, late third trimester \> 340/7 weeks) and three postpartum timepoints (immediately after delivery, \~6 weeks, and \~2 years).
223595949|NCT01196416|DRUG|Gamma-Secretase Inhibitor RO4929097|Given PO
223595950|NCT01196416|OTHER|Laboratory Biomarker Analysis|Correlative studies
223595951|NCT01196416|OTHER|Pharmacological Study|Correlative studies
223595952|NCT01196416|DRUG|Temozolomide|Given PO
223595953|NCT01196416|DRUG|Vinblastine Sulfate|Given IV
223595954|NCT05116696|PROCEDURE|For chronic limb-threatening ischemia (CLTI) patients revascularisation surgery; for colorectal liver metastasis (CRLM) patients metastatic liver surgery|"For chronic limb-threatening ischemia (CLTI) patients that represents one of the revascularisation methods (endovascular, open surgery, hybrid).~For the colorectal liver metastasis (CRLM) patients that represents liver resection with adjuvant chemo- or radiotherapy"
223595955|NCT04501796|DRUG|Double-Blind NT-I7|Administered by intramuscular (IM) injection
223595956|NCT04501796|DRUG|Double-Blind Placebo|Placebo
223595957|NCT02841241|DRUG|Esmolol|Esmolol infusion
223595958|NCT01029041|OTHER|Strengthening Exercises|Exercises that aim the improvement of muscular strength of arms and legs
223595959|NCT01029041|OTHER|Stretching exercises|Exercises that aim the improvement of muscular flexibility of arms, legs and spine
223595960|NCT00148941|BIOLOGICAL|SB213503 lot 1|SB213503 lot 1 vaccine was administered as a single dose by intramuscular injection in the deltoid at Day 0.
223595961|NCT00148941|BIOLOGICAL|SB213503 lot 2|SB213503 lot 2 vaccine was administered as a single dose by intramuscular injection in the deltoid at Day 0.
223595962|NCT00148941|BIOLOGICAL|SB213503 lot 3|SB213503 lot 3 vaccine was administered as a single dose by intramuscular injection in the deltoid at Day 0.
223595963|NCT00148941|BIOLOGICAL|Infanrix|Infanrix vaccine was administered as a single dose by intramuscular injection in the deltoid at Day 0.
223747795|NCT03067181|PROCEDURE|Biopsy Procedure|Undergo a tumor biopsy
224197683|NCT06490874|DEVICE|CGM device - Insulin group|Individuals randomized to insulin will be provided with a CGM device (Dexcom, Inc, San Diego, CA) to be worn for up to 10 days (minimum \>5 days) at two pregnancy (randomization to metformin or insulin, late third trimester \> 340/7 weeks) and three postpartum timepoints (immediately after delivery, \~6 weeks, and \~2 years).
224197684|NCT04882085|DRUG|Zavicefta, Ceftazidime-Avibactam|CAZ-AVI 2.5 g (2 g ceftazidime + 0.5 g avibactam) administered IV as a 2 hour infusion every 8 hours. Dose adjustments are available for participants with CrCL ≤50 mL/min.
223595964|NCT00148941|BIOLOGICAL|IPOL|IPOL vaccine was administered as a single dose by subcutaneous injection in the deltoid at Day 0.
223595965|NCT00148941|BIOLOGICAL|M-M-R II|M-M-R II vaccine was administered as a single dose by subcutaneous injection in the deltoid at Day 0.
223595966|NCT00011622|DEVICE|Continuous ambulatory subcutaneous glucose monitor|
223595967|NCT02736565|BIOLOGICAL|pbi-shRNA™ EWS/FLI1 Type 1 Lipoplex|"Lipoplex is given intravenously as a single administration twice a week for 4 weeks for a total of 8 infusions per cycle followed by 2 weeks of rest. Treatment may continue as long as there is clinical benefit, no evidence of disease progression, and no other withdrawal criteria are met.~First dose started on Cycle 1 Week 1 Day 1 followed by observation and safety assessment for 13 days. If no toxicity was observed, then another single administration of study agent was given at Cycle 1 Week 3 Day 1 followed by observation and safety for 6 days. If no toxicity was observed, then study agent was given twice a week on Days 1 and 4 over 3 weeks, for a total of 8 infusions per cycle, followed by a 2-week washout before starting each subsequent cycle. Cycle 1 = 8 weeks. Each subsequent cycles = 6 weeks."
223595968|NCT04241302|DIAGNOSTIC_TEST|Pure Tone Audiogram|A Pure Tone Audiogram is done in a sound proof room in both cases of Free Field Voice Test and Free Field Click Tests to identify the Pure Tone Average (Hearing Threshold Average of 500Hz,1000Hz and 2000Hz).
223595969|NCT05500430|DEVICE|Air abrasion sandblasting aluminum oxide particles (Al2O3) AquaCare single (Velopex, Medivance Instruments Ltd., London, UK)|Air abrasion sandblasting aluminum oxide particles (Al2O3) Aqua Care single (London, UK) will be done for the defective area then repairing with bioactive injectable composite, Beautiful Flow Plus X F00 (Shofu, Japan).
223595970|NCT02668913|OTHER|Diagnostic analysis|Molecular profiling
223595971|NCT02673684|DEVICE|Experimental NSS|5-Day Active electro auricular device that delivers electrical impulses that stimulate the neurovascular bundles in the ear.
223595972|NCT02673684|DEVICE|Sham NSS|(5 minute active) Electro Auricular Device that delivers electrical impulses to neurovascular bundles in the ear.
223595973|NCT01252979|DIETARY_SUPPLEMENT|Medium-Chain Triglycerides|Subjects will take supplemental MCT oil 3 times a day for 6 months
223595974|NCT02262962|OTHER|Redesigned Well-Child Care|The Well-Child Visits will be enhanced using a newly-designed model of care. Parents will have access to Parent Coach during child's routine well visits, Well Baby Help Line, Well-Visit Planner, and HealthyTxt Messaging service.
223747796|NCT03067181|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223747797|NCT03067181|BIOLOGICAL|Bleomycin Sulfate|Given IV
223747798|NCT03067181|DRUG|Carboplatin|Given IV
223747799|NCT03067181|DRUG|Cisplatin|Given IV
223747800|NCT03067181|PROCEDURE|Computed Tomography|Undergo a CT scan
223747801|NCT03067181|DRUG|Etoposide|Given IV
223747802|NCT03067181|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223747803|NCT03067181|OTHER|Pharmacogenomic Study|Correlative studies
223747804|NCT03067181|PROCEDURE|Pulmonary Function Test|Undergo a pulmonary function test
223747805|NCT03067181|OTHER|Quality-of-Life Assessment|Ancillary studies
223747806|NCT03067181|OTHER|Questionnaire Administration|Ancillary studies
223747807|NCT04165798|DIAGNOSTIC_TEST|Tumor Imaging|Participants will undergo tumor imaging using either a magnetic resonance imaging (MRI) scan or a computed tomography (CT) scan.
223747808|NCT04165798|PROCEDURE|Tumor Tissue Collection|Participants without archival tumor tissue samples will undergo tumor tissue collection for newly obtained tumor tissue.
224197685|NCT04882085|DRUG|Best Available Treatment|main treatment expected to be used as either monotherapy or in combination are colistin, tigecycline, fosfomycin, amikacin, and meropenem
224197686|NCT05662111|DRUG|Etidronate|The dosage of etidronate is 20 mg/kg for twee weeks and ten weeks off. Etidronate is given in capsules of 200 mg. Etidronate capsules are administered orally. During the study, participants will receive etidronate in four periods of two weeks during the twelve months of follow-up.
224197687|NCT05662111|DRUG|Placebo|Placebo is given in capsules and are administered orally. During the study, participants will receive placebo in four periods of two weeks during the twelve months of follow-up.
224197688|NCT05631847|PROCEDURE|Endovascular treatment|It is the emergency surgical removal of emboli which are blocking blood circulation. The strategies that were used for endovascular treatment included stent retrievers, thromboaspiration, balloon angioplasty, stent deployment, intraarterial thrombolysis (with alteplase), or combinations of these approaches that were left to the discretion of the treating team.
223506584|NCT02218151|OTHER|Patient-Centered Medical Home (PCMH)|Subjects will receive their conditioning chemotherapy +/- radiation and stem cells in the hospital or day hospital, after which they will receive care during the neutropenic/recovery period at home. Advanced Practice Providers (APP) will travel to subjects' homes in the morning, where they will perform the same daily assessment as standard care. They will draw labs and bring them back to the hospital for processing. When results are available, a second home visit is made to deliver necessary interventions. Subjects will have internet access through cellular-networked iPads and have daily videoconferences with their physicians. Daily follow up at home will continue until discharge as per above criteria.
223506585|NCT02218151|OTHER|Standard Care|Subjects will receive their conditioning chemotherapy +/- radiation and stem cells in the hospital or day hospital, after which they will receive care during the neutropenic/recovery period inpatient or outpatient. Advanced practice providers (APPs) will perform histories and physical exams. Nurses will collect labs and inpatient rounds occur twice daily, or for outpatients receiving care through our outpatient clinics, a healthcare provider typically sees them daily for the first month following transplant or discharge from the day hospital.
223506586|NCT05649553|BEHAVIORAL|digital game and video animation based diabetes education|While creating the digital game and video animation, an agreement was made with a software company and this company was responsible for the software and repair of the game. Digital games and video animations cover the basic educational topics of Type 1 diabetes. Expert opinions were received from experts in the field of Child Health and Disease Nursing to ensure the suitability of the content of the educational material. The name of the game site and how to use it were explained to the children in the intervention group by the researcher. In addition, children in the intervention group were given usernames and passwords to log in to the site. Game Sections; What is Diabetes? Medical Nutrition Treatment in Diabetes, Insulin Treatment and Application, Exercise and Physical Activity in Diabetes, Complications of Type 1 Diabetes Mellitus, Diabetes Management at School.
223506587|NCT05940636|OTHER|Activity-based rehabilitation+electrical stimulation|Balance training will occur three times per week for four weeks, totaling 12 two-hour sessions. In both groups, you will be asked to stand on a force plate while playing visual feedback training (VFT) games as part of the standing balance training. A force plate is similar to a bathroom scale that you can stand on which measures your body sway during movement. Visual feedback training (VFT) is a type of activity that includes weight-shifting movements in the upright stance. VFT will be done in both groups. There will be different games as shown in figure 1 and the order of the games will be randomly chosen in each session. During each game, there will be targets that will be presented on the screen and you will have to navigate toward them . You will be able to rest between games as needed.
223506588|NCT02726269|DRUG|CLA (Clarithro+Lanso+Amoxi)|Tablets of oral administration administered to subjects randomized to this group twice daily for 10 days.
223506589|NCT02726269|DRUG|PLA (Panto+Levoflox+Azithro)|Tablets of oral administration to subjects randomized to this group once daily for 10 days.
223506590|NCT00004201|DRUG|carboplatin|
223506591|NCT00004201|DRUG|cisplatin|
223506592|NCT00004201|DRUG|gemcitabine hydrochloride|
223506593|NCT04132466|DEVICE|Defibrillation using the ASSURE wearable cardioverter defibrillator therapy delivered via a waveform delivery test system|defibrillation using a 170 joule biphasic truncated exponential waveform designed for the ASSURE wearable cardioverter defibrillator
223506594|NCT02362932|OTHER|Sanitation|Shared sanitation
223506595|NCT06341283|DRUG|Abemaciclib and Letrozole/Anastrozole|Take the treatment with Abemaciclib and Letrozole/Anastrozole at the same time.
223506596|NCT06341283|DRUG|Letrozole or Anastrozole|Take the treatment with Letrozole or Anastrozole.
223506597|NCT06341283|DRUG|Abemaciclib and Fulvestrant|Take the treatment with Abemaciclib and Fulvestrant at the same time.
223506598|NCT06341283|DRUG|Fulvestrant|Take the treatment with Fulvestrant only.
223506599|NCT03769974|BEHAVIORAL|Motor imagery|Two series of 30 seconds training of motor imagery in each manual engine gesture
223506600|NCT03769974|BEHAVIORAL|Action observation|Two series of 30 seconds training of action observation training in video format in each manual engine gesture
223506601|NCT03769974|BEHAVIORAL|Placebo intervention|Two series of 30 seconds of observation and imagination of a landscape during for each manual motor sequence
223506602|NCT04594083|DEVICE|Palm Stimulator|The Palm Stimulator, developed by the present researchers for the first time, is 1.6 cm in diameter, 4 cm in length, and has a cylindrical, non-slippery structure for an easy grip to ensure maximum contact with the palm The Palm Stimulator consists of blunt protrusions that will provide a tactile stimulus on the palm. The blunt protrusions do not penetrate into the skin. The simulator design is based on the gate-control theory, which allows for a reduction in the perceived amount of pain experienced during injection by closing the pain gate in the spinal cord in creating a stimulus on the skin.
223506603|NCT04594083|DEVICE|ShotBlocker|ShotBlocker was placed in the ventrogluteal area properly 20 seconds before injection. It was fixed at the injection site until the injection process was completed.
223506604|NCT05259176|DEVICE|transcranial Direct Current Stimulation (tDCS)|Direct current transcranial stimulation will be applied for 20 minutes over the left posterior parietal cortex with an intensity set to 2 mA.
223506605|NCT05259176|DEVICE|Sham stimulation (sham-tDCS)|The same positioning of electrodes as the stimulation condition will be used, but the current will be applied for 30 seconds and then progressively reduced.
223506606|NCT05259176|DEVICE|Behavioural|Treatment for upper limbs ideomotor apraxia (Smania et al., 2000)
223595975|NCT06024018|DEVICE|high intensity electromagnetic technology device, diet restriction, and walking|thirty obese males (30 males) will undergo dietary caloric restriction and will be instructed to walk 10,000 continuous steps every day using the pedometer application for 3 months. Also they will undergo high intensity electromagnetic technique (40 minutes for every session) on abdomen of males which will be 3 sessions per week for 3 months
223595976|NCT06024018|BEHAVIORAL|diet restriction and walking|thirty obese males (30 males) will undergo dietary caloric restriction and will be instructed to walk 10,000 continuous steps every day using the pedometer application for 3 months.
223595977|NCT01596036|BEHAVIORAL|Early appointment (within 10 days)|Patients will receive an appointment to cardiac rehabilitation within 10 days from anticipated hospital discharge.
223595978|NCT01596036|OTHER|Routine referral (at 5 weeks)|Standard Referral to Cardiac Rehabilitation
223595979|NCT01092663|DRUG|Colesevelam HCl|Subjects will be given 3.75 g/day. Subjects will be given 3 tablets (625mg each) with breakfast and 3 tablets (625mg) with dinner for 12 weeks.
223595980|NCT01092663|DRUG|Sitagliptin|Subjects will be given 100mg/day. Subjects will be given 1 tablet (100mg) with breakfast for 12 weeks.
223595981|NCT00085449|BIOLOGICAL|alemtuzumab|
223595982|NCT00085449|DRUG|cyclosporine|
223595983|NCT00085449|DRUG|fludarabine phosphate|
223595984|NCT00085449|DRUG|melphalan|
223595985|NCT00085449|DRUG|mycophenolate mofetil|
223595986|NCT00085449|PROCEDURE|peripheral blood stem cell transplantation|
224197689|NCT05631847|DRUG|Intravenous thrombolysis (Alteplase)|Alteplase is used in the intravenous thrombolysis. It catalyzes the conversion of plasminogen to plasmin, the major enzyme responsible for clot breakdown.
224197690|NCT00965562|DRUG|Fluoxetine|Fluoxetine 20 mg per day for 4 menstrual cycles. For the fifth menstrual cycle, all women will receive calcium. Women on Fluoxetine will continue taking it in addition to 1200mg of calcium.
223595987|NCT00085449|RADIATION|radiation therapy|
223595988|NCT03006692|OTHER|With arterial blood gas, parameters not being normal can be corrected|If arterial blood gas is analysed answers provide the possibility to make more accurate diagnosis and treat specific abnormal parameters (e.g. electrolytes, oxygenation and so forth).
223595989|NCT04571996|DRUG|ODM-104|Capsule
223595990|NCT04571996|DRUG|Paracetamol|Rapidly dissolving tablet
223595991|NCT03932630|OTHER|Low carbohydrate diet|The study intervention will be an eucaloric low carbohydrate diet (15-20 % of carbohydrates) for 2 weeks.
223595992|NCT03932630|OTHER|balanced diet|The control intervention will be a energy-matched balanced diet (50 % of carbohydrates) for 2 weeks.
223595993|NCT05591716|PROCEDURE|Bilateral same-session flexible ureterorenoscopy|The patient was in the lithotomic position. A semi-rigid ureteroscope was passed into the bladder, then a roadrunner was placed. A flexible urethroscope is guided along the roadrunner to the kidney. In the kidney, the concrement is fragmented with laser energy. The fragments were extracted using a basket. Then a revision of the kidney is performed using a flexible urethroscope. A ureteral stent was placed in the pelvis.The ureteroscope was extracted together with the case with the ureteral revision: there was no damage to the ureter.Next, this procedure is performed from the other side. Urine was excreted from the bladder using a Nelaton catheter.
223595994|NCT05591716|PROCEDURE|Unilateral same-session flexible ureterorenoscopy|The patient was in the lithotomic position. A semi-rigid ureteroscope was passed into the bladder, then a roadrunner was placed. A flexible urethroscope is guided along the roadrunner to the kidney. In the kidney, the concrement is fragmented with laser energy. The fragments were extracted using a basket. Then a revision of the kidney is performed using a flexible urethroscope. A ureteral stent was placed in the pelvis. The ureteroscope was extracted together with the body with revision of the ureter: there was no damage to the ureter. Urine was excreted from the bladder using a Nelaton catheter.
223595995|NCT05697796|PROCEDURE|Two different surgical methods|SSLF：sacrospinal ligament fixation EHUS：Extraperitoneal high sacral ligament suspension
223747809|NCT04165798|PROCEDURE|Blood Sample Collection|"Participants will have blood samples drawn for analysis of:~* genetics~* ribonucleic acid (RNA)~* serum biomarker~* plasma biomarker~* circulating tumor DNA (ctDNA)"
224197691|NCT00965562|DRUG|Calcium|1200 mg of calcium to be taken for 5 menstrual cycles.
223595996|NCT05167591|DIAGNOSTIC_TEST|Drug concentration measurement|Measurement of paracetamol concentration in capillary, venous plasma and saliva samples after standard premedication with paracetamol
223595997|NCT04720092|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Granules for oral suspension, 10 mg, oral, single dose
223595998|NCT04720092|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Tablet, 10 mg, oral, single dose
223595999|NCT05961137|OTHER|Incorporation of Rapid Fluid Infusion Device in Prehospital Suspected Sepsis Protocol|Modified protocol specifying intravenous crystalloid infusion Rapid Fluid Infusion Device. The protocol states that for patients meeting the sepsis alert criterion, EMS will provide basic medical care, oxygen, a 12-lead electrocardiogram, attempt placement of an IV catheter and initiate administration of 30mL/kg of fluids.
223596000|NCT05961137|OTHER|Conventional Prehospital Suspected Sepsis Protocol|Conventional protocol employing intravenous crystalloid infusion via gravity or pressurized-bag. The protocol states that for patients meeting the sepsis alert criterion, EMS will provide basic medical care, oxygen, a 12-lead electrocardiogram, attempt placement of an IV catheter and initiate administration of 30mL/kg of fluids.
223596001|NCT04095091|DEVICE|4D Planar US Transducer|This 4D planar US transducer is being developed and validated to provide a novel image-guidance technique to directly track tumor motion during radiation therapy that is coupled to a pre-treatment calibration training image set consisting of a simultaneous 4D ultrasound and 4D magnetic resonance imaging (MRI) acquisition.
223596002|NCT05650853|OTHER|Transrectal ultrasound|Examinations for observation of the pre, per and post-ejaculatory phases
223596003|NCT05650853|OTHER|Urethroscopy|Examinations for observation of the pre, per and post-ejaculatory phases
223596004|NCT00697710|DRUG|50 mg S-777469|S-777469, 50 mg BID
223596005|NCT00697710|DRUG|200 mg S-777469|S-777469, 200 mg BID
223596006|NCT00697710|DRUG|800 mg S-777469|S-777469, 800 mg BID
224197692|NCT00965562|DRUG|Placebo|For 5 cycles, women will receive placebo. At the end of the fourth cycle, all women will receive 1200 mg of calcium in addition to the placebo medication.
224197693|NCT02255045|DRUG|Meloxicam|1 Meloxicam Vaginal Ring (MVR) for 4-6 days
224197694|NCT02255045|DRUG|Diclofenac Potassium|1 tablet 50 mg diclofenac every 12 hours for 4-6 days
224197695|NCT02255045|DRUG|Placebo Oral|1 placebo tablet every 12 hours for 4-6 days
224197696|NCT02255045|DRUG|Placebo Vaginal|1 placebo vaginal ring for 4-6 days
224197697|NCT02546180|OTHER|Viewing YouTube videos|The on-line patient education program will highlight postoperative care.
224197698|NCT02546180|OTHER|Standard preoperative education|Standard preoperative education will be provided by the surgeon, physician extender and paramedical staff in the clinic.
224310915|NCT02279134|RADIATION|Adjuvant Radiation|Patients undergo radiotherapy once daily 5 days a week for an average of 5.5 weeks within 12 weeks after surgery in the absence of disease progression or unacceptable toxicity.
224310916|NCT02279134|DRUG|Paclitaxel|135-150mg/m2 (D1 and D29)
224310917|NCT02279134|DRUG|Cisplatin or Nedaplatin|50-75mg/m2 (D1 and D29)
224310918|NCT04061525|PROCEDURE|Percutaneous coronary intervention with FFR measurement and intracoronary ECG registration|Measurement of fractional flow reserve (FFR), registration of intracoronary ECG and radioscopic registration of wire tip movement in the main and in the side branch in the beginning, at the end and during every step of coronary bifurcation percutaneous intervention.
224310919|NCT00292058|DEVICE|Videoconference equipment (telepsychiatry)|
224310920|NCT04774016|OTHER|Test formula A without added pre- and pro-biotic|An identical formula as test formulas fortified with 2.20 mg iron as FeSO4-58 and 0.05 mg native iron per serving (235 ml), but without added pre- or probiotic.
224310921|NCT04774016|OTHER|Test formula B with synbiotic|Test formula fortified with 2.20 mg iron as FeSO4-57 and 0.05 mg native iron per serving (235 ml) and added synbiotic.
224310922|NCT04774016|OTHER|Test formula C with HMOs|Test formula fortified with 2.20 mg iron as FeSO4-54 and 0.05 mg native iron per serving (235 ml) and added HMOs.
223506607|NCT01447771|BEHAVIORAL|Decision control preference scale|At time 1, participants in the intervention group will be asked to complete the Decision Control Preference Scale.The range of decision control is measured by the Decision Control Preference (DCP) Scale. The scale is used to measure the preferred or actual role in decision making using five response statements: two represent an active or patient-controlled role, one a shared or collaborative role, and two represent a passive or provider-controlled role. The preferred level of decision making control will be known by the participant in the intervention group and the information given to the oncologist prior to the consultation regarding adjuvant therapy
223506608|NCT00664040|OTHER|Aspirin|The aspirin intervention (81 mg per day) will last a total of 14 days. Pills will be provided in a pre-loaded pillbox. The field team will visit the subject at his/her home at least once to insure adherence to the aspirin intervention and to monitor for adverse side effects. On day 14 of the aspirin intervention, the subject will visit the clinic for a fasting blood draw for platelet aggregation and inflammatory marker studies. A pill count will be performed to assess adherence. The subject can miss up to four aspirin doses over the two-week period; however, an aspirin must be taken each day for the three days prior to clinic visit 2. The aspirin intervention can be extended for up to three days (17 days total) to meet the latter criteria. If more than four doses were missed, then the physician should be contacted and the patient should be withdrawn from the aspirin intervention. Platelet aggregation will be measured 1 hour after the last dose of aspirin.
223506609|NCT00664040|OTHER|Cold Pressor Test|This intervention consists of the participant placing his or her hand and wrist into ice water for 2½ minutes. The blood pressure is taken before and after the arm is removed from the water. An ultrasound machine is used to take pictures of the brachial artery in the left arm before and after the arm is removed from the water.
223506610|NCT00664040|OTHER|High Fat Meal|The participants are given a high fat milk shake consisting of 83% fat. Blood samples are drawn from a catheter placed in the participant's arm prior to the test. The samples are drawn before the milk shake and at 1, 2, 3, 4, and 6 hours after the milk shake is consumed. Before and at 2, 4 and 6 hours following the meal the ultrasound is used to obtain images of the brachial artery.
223506611|NCT00664040|OTHER|Dietary Salt|The salt intervention will consist of 6 days of an isocaloric high salt diet (270 mmol/d) followed by a washout period of at least 8 days and then a low salt diet (40 mmol/d). All food will be prepared by a registered dietician and dietary technicians in a specially equipped kitchen. The specific foods will consist of approximately 50% carbohydrates, 35% fat, and 15% protein. Dietary potassium will remain constant at 120 mmol/d. A food diary will be kept for each diet and subjects will be instructed to eat only the food provided. A field nurse will visit the home on days 3 and 5 of each diet to insure that neither diet is acutely affecting the health status of the subject. A first AM void spot urine will be obtained to measure sodium, potassium and creatinine on the 4th, 5th, and 6th days of each diet to insure compliance. Blood pressure will be measured using an ambulatory blood pressure monitor for 24 hours on the last day of each diet.
223506612|NCT01245751|BIOLOGICAL|Zoster Vaccine, Live|Single approximately 0.65-mL subcutaneous injection of Zoster Vaccine, Live on Day 1 of the study
223506613|NCT05448027|DEVICE|Low intensity laser therapy|It will be applied for Group (A), by a pulsed diode low intensity laser device (Endolaser 422 Cp 400, Enraf - nonius apparatus) (Enraf, Rootterdam, Netherlands). with a wave length of 905 nm, mean power output of 400 mWatt, frequency of 10000 Hz and dose of 300 J/cm² . Laser probe will be applied perpendicularly and directly with an irradiation time of 30 sec for each point
223506614|NCT05448027|DEVICE|High intensity laser therapy|It will be applied for Group (B), by pulsed high intensity laser therapy with pulsed Nd:YAG laser produced by HIRO 3.0 devices (ASA, Arcugnano, Vicenza , Italy). The high intensity laser therapy apparatus used postulates (Nd:YAG), with pulsed emission of wave length ( 1064nm ), very high power peaks (3kW), high intensity obtained (up to 15,000 W/cm2), high level of fluency/energy density (510-1,780 mJ/cm), very short pulse duration (120-150 μs), low frequency (10-40 Hz), duty cycle of about 0.1 % and total energy of 880 J
224197699|NCT05397847|BEHAVIORAL|Education|"Rational Drug Use in Elderly Individuals~1. Training: Through home visits, an average of 30 minutes of training will be given to elderly individuals (drugs, rational drug use, the importance of rational drug use, and what the elderly should do for rational drug use). Question-answer method and visual materials will be used in the training.~2. Training: An average of 20 minutes of training will be given, including a brief repetition of the topics covered in the first training, via a home visit. Visual materials will be used in the training."
224197700|NCT05397847|OTHER|Rational Drug Use Guide|At the end of the first training, a rational drug use guide will be given to elderly individuals, including the topics explained.
224197701|NCT05397847|OTHER|Medicine Box|Elderly individuals will be given a medicine box large enough to be carried in the pocket when appropriate, so that the elderly people do not forget their medicines and use them regularly, with a 7-day medicine compartment that organizes their medicines and a daily (morning, noon, evening and night) medicine box.
224197702|NCT05397847|BEHAVIORAL|Counseling|After the training, counseling services will be given to elderly individuals regarding rational drug use. Within the scope of the counseling service, it will be ensured that the drugs used by the elderly person are regulated and their questions about rational drug use will be answered.
224197703|NCT03142919|BIOLOGICAL|Lipopolysaccharide|Lipopolysaccharide (LPS) derived from E. Coli group O 113:H10:K negative
224197704|NCT03142919|BIOLOGICAL|Placebo|Saline solution
224197705|NCT03147209|BEHAVIORAL|Health Coaching|This intervention will consist of health coaching, goal setting and self directed activities to improve strength and balance.
224197706|NCT03792633|BIOLOGICAL|huCART19|IV injection
224310923|NCT01667835|BEHAVIORAL|Yoga Intervention|12 week 90 minute hatha yoga session offered three (3x) per week. Hatha yoga is a form of structured physical exercises known as asanas, combined with breathing exercises called pranayama, and relaxation techniques. The yoga intervention consists of 9 different yoga poses (asanas) and 3 different breathing exercises (pranayama) that can be easily replicated and readily performed by individuals who are middle-aged and older, overweight, unfit, or who suffer from a chronic illness.
224310924|NCT04177446|DIETARY_SUPPLEMENT|a production consist of various oligopeptides and the whey protein|patients will be given extra protein intake except the basic energy intake
224310925|NCT04177446|DIETARY_SUPPLEMENT|basic energy intake|supplement as basic energy intake
223506615|NCT00985192|DRUG|everolimus|
224197707|NCT05382637|DRUG|Somatropin|Daily growth hormone at a starting dose of 50 mcg/kg/day and escalating
224197708|NCT04973007|DRUG|Gadoxetate disodium|Gadoxetate disodium is now mainly used for the purpose of HBP liver MR imaging to save MR scanner time and total examination time.
224197709|NCT04973007|DRUG|Gadobenate dimeglumine|The most commonly used MR contrast agent in abdominal imaging is gadobenate dimeglumine, which has mainly the characteristics of an extracellular agent used for most indications of MR examinations.
224197710|NCT05054725|DRUG|RMC-4630|RMC-4630 administered orally as a capsule
224197711|NCT05054725|DRUG|Sotorasib|Sotorasib administered orally as a tablet
224310926|NCT04177446|DIETARY_SUPPLEMENT|maltodextrin|used as placebo in the control group
224310927|NCT03782909|BEHAVIORAL|Behaviour change intervention|"The behaviour change intervention consists of;~1. Feedback via an app based food diary~2. Coaching with problem solving and implementation plans~The intensive phase consists of 2 home visits and 4 phone calls and the use of the app The maintenance phase consists of use of the app if the PWCF wishes to continue using it"
223506616|NCT00985192|OTHER|laboratory biomarker analysis|
223506617|NCT00274794|BIOLOGICAL|filgrastim|10mcg/kg/d subcutaneously, beginning 48 hours after completion of Etoposide
223506618|NCT00274794|BIOLOGICAL|rituximab|375 mg/m2, IV, Once per week for 3 weeks.
223506619|NCT02707744|OTHER|no intervention|
223506620|NCT02429739|BEHAVIORAL|Working memory Training|"The child will use the computer program at home under parental supervision for 25 sessions, each lasting 30 - 45 minutes and the family has 6 weeks to complete the training. Each session consist 8 different tasks presented by an animated robot. The tasks all require the child to hold information in working memory and to manipulate the information.~Other name: Cogmed RoboMemo"
223506621|NCT03387046|DIETARY_SUPPLEMENT|D-aspartate|D-aspartate 2660 milligram (mg) once daily in the form of oral solution for 24 weeks.
223506622|NCT03387046|DRUG|Placebo|Placebo matched to D-aspartate once daily in the form of oral solution for 24 weeks.
223506623|NCT03387046|BIOLOGICAL|IFN beta-1a|IFN beta-1a was administered subcutaneously at a dose of 44 microgram (mcg) three times a week for 24 weeks.
223506624|NCT03387046|DRUG|Methylprednisolone|Methylprednisolone 1000 mg was administered intravenously once daily for 5 consecutive days.
223506625|NCT00252889|DRUG|Topotecan and pegylated doxorubicin|Doxil 40 mg/m2 day 1 and topotecan was to be escalated in cohorts of patients
223506626|NCT02405637|DRUG|simulated amniotic fluid 20cc/kg/day enterally|simulated amniotic fluid 20cc/kg/day enterally for a maximum of 7 days.
223506627|NCT02405637|DRUG|distilled water|distilled water 20 ml/kg/day for maximum of 7 days.
223506628|NCT06277830|DEVICE|Wearable sensor|Participants will wear a pendant sensor for 7 days and then participate in an on-site examination with using a tablet designed to evaluate weakness in MG.
223506629|NCT01346241|BEHAVIORAL|Intensive Panic Control Treatment (IPCT)|A manualized treatment that consists of psychoeducation about panic disorder
223506630|NCT05172310|DRUG|68Ga-FAPI-46|"* \[68Ga\] Ga-FAPI-46 Solution for Injection is manufactured at the Karolinska University Hospital Radiopharmacy facilities, for imaging studies with Positron Emission Tomography (PET).~* It is a radiolabelled Fibroblast Activation Protein Inhibitor (FAPI) used for PET of a number of different cancer entities.~* Depending on the labelling yield 50 - 370 megabecquerel (MBq) of \[68Ga\] Ga-FAPI-46 Solution for Injection will be administered intravenously 60 minutes prior to whole-body PET image acquisition."
223506631|NCT05172310|DEVICE|PET/CT|"* Combined PET and computed tomography (CT) imaging with 68Ga-FAPI-46 will be performed using the same protocol on a Biograph 6 PET/CT scanner (Siemens, Erlangen, Germany) and General Electrics (GE) Discovery 710, Milwaukee, Wisconsin, USA at the Department of Nuclear Medicine, Karolinska Huddinge within 2 weeks before surgery.~* PET/CT imaging will be performed in dynamic mode at one bed position centered over the primary tumor for 45 minutes.~* At 60 minutes post injection, a whole-body PET will be acquired."
223506632|NCT03561740|DRUG|capecitabine|additional metronomic chemotherapy of capecitabine
223506633|NCT02614027|OTHER|Evaluation of metabolic syndrome|Evaluation and analytical determinations of the different components of the syndrome
223506634|NCT02614027|OTHER|Evaluation of changes in fat by DXA while on current therapy|Comparison of changes in fat (visceral and subcutaneous) by dual X-ray absorptiometry since therapy initiation
223596007|NCT00697710|DRUG|Placebo|Matching Placebo
223596008|NCT04328272|DRUG|Hydroxychloroquine 200 Mg Oral Tablet|Hydroxychloroquine administered orally with water
223596009|NCT04328272|DRUG|Azithromycin 500Mg Oral Tablet|Azithromycin administered orally with water
223596010|NCT04328272|DIETARY_SUPPLEMENT|Glucose tablets|administered orally with water
223596011|NCT03892135|OTHER|Interviews with parents of children with juvenile idiopathic arthritis|Interviews with parents of children with juvenile idiopathic arthritis
223596012|NCT03892135|OTHER|Interviews with children with juvenile idiopathic arthritis|Interviews with children with juvenile idiopathic arthritis
223596013|NCT03892135|OTHER|Interviews with Physicians|Interviews with Physicians
223596014|NCT02014779|BEHAVIORAL|eChange|A web-based relapse intervention program consisting of 14 modules. The patient will have access to therapist support through a secure messaging system
223596015|NCT02014779|BEHAVIORAL|Face-to-face therapy|Face-to-face psychotherapy, consisting of 20 sessions. The content will be different for different therapists, but all have an evidence based approach to therapy
223596016|NCT03688620|OTHER|Passive enhanced safety surveillance|Prospective data collection starting at Visit 1 (Day 1) and ending at Visit 2 (Day 8 or when the ADR card was returned by mail) for all subjects who have previously been vaccinated against influenza in preceding seasons or aged ≥9 years at the time of vaccination, or ending at Visit 4 (Day 36 or when the last ADR card was returned by mail) for children aged \<9 years who have not previously been vaccinated against influenza in preceding seasons). Subjects had up to 14 days post vaccination to return their ADR card (at the next study visit or by mail).
223596017|NCT05485324|OTHER|visual analog scale|Data collection was carried out at all stages of treatment: medical and nursing brigade, military mobile hospital, military medical clinical center, during rehabilitation, within 12 months of the injury.
223596018|NCT02670967|DIETARY_SUPPLEMENT|Soluble Fibre|
223596019|NCT01699074|DIETARY_SUPPLEMENT|1 gram of White Korean Ginseng|1 gram of White Korean Ginseng
223596020|NCT01699074|DIETARY_SUPPLEMENT|3 grams of White Korean Ginseng|3 grams of White Korean Ginseng
223596021|NCT01699074|DIETARY_SUPPLEMENT|6 grams of White Korean Ginseng|6 grams of White Korean Ginseng
223596022|NCT01699074|DIETARY_SUPPLEMENT|3 grams of Wheat Bran Control|3 grams of Wheat Bran Control
223596023|NCT01699074|DIETARY_SUPPLEMENT|500mg of Korean Red Ginseng|500mg of Korean Red Ginseng
223596024|NCT01399710|PROCEDURE|CT colonography|Participants were placed on a CT table and a small flexible rectal catheter was positioned. N-butyl-scopolamine was administered intravenously if this was common practice in the participating center. Immediately before scanning, pneumocolon was obtained through insufflation of room air or carbon dioxide, either manually by means of a balloon pump or with an automatic device, until maximum tolerance was reached. CT colonography was performed with the participant in supine and prone positions with the following scanning protocol: 120 kilovolt peak (kVp), 50 or fewer effective mA per second, and a section thickness not greater than 1.25 mm.
223596025|NCT01399710|PROCEDURE|colonoscopy|Colonoscopy was performed at least 3 hours after CT colonography. The endoscope was advanced to the cecum and the entire length of the bowel was examined during endoscope withdrawal. The endoscopist was initially blinded to the result of CT colonography; at the end of each bowel segment evaluation, CT colonography results for that segment were disclosed (segmental unblinding). If a lesion measuring 6 mm or larger was detected at CT colonography but not at colonoscopy, the segment was reexamined to resolve the discrepancy
223596026|NCT01399710|DEVICE|CT Colonography with computer assisted diagnosis (CAD),CADCOLON -im3D SpA., Torino Italy|Each CT colonography study was read in two phases. In the first phase the radiologist interpreted the examination without activating the CAD algorithm. This phase of reporting was defined as unassisted reading. Then the radiologist activated the CAD algorithm which pinpointed a series of colorectal lesion-like structures (i.e. lesion candidates) on both the prone and supine acquisition. All lesion candidates were examined. The second phase of reporting was defined as CAD-assisted reading.
223596027|NCT02769169|DRUG|Lucentis® (Raibizumab) double-dose|Give patients 1 injection per month at the beginning 3 months. Give patients additional injection as needed. One injection contains 1mg of Lucentis® (Raibizumab). Intervention 'double-dose: Ranibizumab 1mg, 3 injection plus prn' has not been included in any Arm/Group Descriptions.
223596028|NCT02769169|DRUG|Lucentis® (Raibizumab) regular-dose|Give patients 1 injection per month at the beginning 3 months. Give patients additional injection as needed. One injection contains 0.5mg of Lucentis® (Raibizumab). regular-dose: Ranibizumab 0.5mg, 3 injection plus prn
223596029|NCT01008904|DRUG|magnesium oxide|Given PO
223596030|NCT01008904|OTHER|questionnaire administration|Ancillary studies
223596031|NCT01008904|PROCEDURE|quality-of-life assessment|Ancillary studies
223596032|NCT03190616|DRUG|apatinib|apatinib 500mg/qd, 28d/cycle
223596033|NCT00128986|PROCEDURE|Tomotherapy|3T MRS scans (3T magnetic resonance spectroscopy)
223596034|NCT00772681|DRUG|docetaxel and cisplatin|3 cycles of docetaxel 75mg/m2 and 100mg/m2 cisplatin combination every 3 weeks
223596035|NCT02097654|OTHER|SENATOR software generated pharmacotherapy advice report.|
223596036|NCT02846701|DRUG|duloxetine|The concentration of duloxetine is measured by liquid chromatography coupled to tandem mass spectrometry on blood sample
223596037|NCT01873625|BIOLOGICAL|mesenchymal cell transplantation|Mesenchymal stem cell transplantation in patients with rheumatoid arthritis for resurfacing of articular cartilage of knee due to osteoarthritis.
223596038|NCT01873625|BIOLOGICAL|placebo|
223596039|NCT01183065|DRUG|Pralatrexate With Vitamin B12 and Folic Acid|Patients will be treated with 30 mg/m2 of pralatrexate intravenously once weekly for 3 weeks in a 4 week cycle with vitamin supplementation. Patients will take 1.0-1.25 mg oral folic acid on a daily basis. Folic acid should be initiated during the 10-day period preceding the first dose of pralatrexate and dosing will be continued during the full course of therapy and for 30 days after the last dose of pralatrexate. Patients will also receive a vitamin B12 (1 mg) intramuscular injection no more than 10 weeks prior to the first dose of pralatrexate and every 8-10 weeks thereafter. Subsequent vitamin B12 injections may be given the same day as treatment with pralatrexate.
223596040|NCT02456857|BIOLOGICAL|Bevacizumab|Given IV
223596041|NCT02456857|DRUG|Everolimus|Given PO
223596042|NCT02456857|OTHER|Laboratory Biomarker Analysis|Correlative studies
223596043|NCT02456857|DRUG|Pegylated Liposomal Doxorubicin Hydrochloride|Given IV
223596044|NCT00781859|DRUG|125 µg Ocriplasmin|125µg ocriplasmin intravitreal injection
223596045|NCT00781859|DRUG|Placebo|Placebo intravitreal injection
223596046|NCT01029847|DRUG|Adalimumab|Sc. inj. adalimumab 40 mg every other week for 42 to 48 weeks. At week 24, clinical non-responders (not fulfilling primary outcome measure) were allowed treatment with other drugs, following local treatment guidelines.
224310928|NCT01794897|DRUG|Experimental: Valacyclovir treatment|Patients will have a placebo run-in for two weeks after which they will be evaluated for the variables of interest and then randomized to either VAV or placebo group in a 1:1 proportion. The VAV group will receive 1.5 g Valacyclovir by mouth, twice daily for 16 weeks, after which they will be followed up without VAV for 4 weeks to monitor delayed adverse effects.
224310929|NCT01794897|DRUG|Placebo comparator|Patients will have a placebo run-in for two weeks after which they will be evaluated for the variables of interest and then randomized to either VAV or placebo group in a 1:1 proportion. Subjects in the placebo arm will receive placebo for 16 weeks, after which they will be followed up without placebo for 4 weeks to monitor delayed adverse effects.
224310930|NCT02351271|DEVICE|Femto LDV Z8|Femtosecond laser-assisted cataract pre-treatment: Capsulotomy and lens fragmentation, followed by ultrasound phacoemulsification
223506635|NCT03794544|DRUG|Durvalumab|Durvalumab 1500 mg IV will be administered Q4W (on Week 1 Day 1) until disease progression, unacceptable toxicity, or other reason of treatment discontinuation over a 28-day treatment period.
224310931|NCT02351271|DEVICE|Manual capsulorhexis&lens fragmentation|Control treatment where the capsulorhexis is performed manually and the lens fragmentation is performed by the stop and chop technique with the phaco emulsification device
223506636|NCT03794544|COMBINATION_PRODUCT|Oleclumab|Oleclumab 3000 mg IV will be administered Q2W (on Week 1 Day 1 and Week 3 Day 1) until disease progression, unacceptable toxicity, or other reason of treatment discontinuation over a 28-day treatment period.
223506637|NCT03794544|COMBINATION_PRODUCT|Monalizumab|Monalizumab 750 mg IV will be administered Q2W (on Week 1 Day 1 and Week 3 Day 1) until disease progression, unacceptable toxicity, or other reason of treatment discontinuation over a 28-day treatment period.
223506638|NCT03794544|COMBINATION_PRODUCT|Danvatirsen|Danvatirsen 200 mg IV will be administered on Days 1, 3, and 5 of Week 0 (7-day danvatirsen lead-in period) and later every week (on Week 1 Day 1, Week 2 Day 1, Week 3 Day 1, and Week 4 Day 1) until disease progression, unacceptable toxicity, or other reason of treatment discontinuation over a 28-day treatment period.
223506639|NCT04078516|DIAGNOSTIC_TEST|Perception Threshold Tracking (PTT)|low-current electrical stimulation of both large- and small nerve fibers.
223506640|NCT04078516|DIAGNOSTIC_TEST|Axon-flair mediated respons|Laser-doppler examination of small blood vessels in the peripheral skin.
223506641|NCT04078516|DIAGNOSTIC_TEST|Heart rate variability|4 measurements of heart rate.
223506642|NCT04078516|DIAGNOSTIC_TEST|Quantitative Sensory Testing (QST)|Seven tests measuring 13 parameters including heat- and cold-detection and pain thresholds, mechanical pain treshold, mechanical detection threshold, pressure pain treshold and vibration threshold.
223506643|NCT04078516|DIAGNOSTIC_TEST|Peripheral blood pressure and transcutaneous oxygen tension|Ankle/brachial index, toe/brachial index, TcpO2.
223506644|NCT04078516|DIAGNOSTIC_TEST|Magnetic Resonance Imaging (MRI)|MRI-scans of peripheral nerves and the central nervous system. Blood oxygen level dependent (BOLD) MRI.
223506645|NCT04078516|DIAGNOSTIC_TEST|Questionnaires|Questionnaires for detecting painful neuropathy
223506646|NCT04078516|DIAGNOSTIC_TEST|Corneal Confocal Microscopy /CCM)|Confocal microscopy of the cornea measuring NBD, NFD, NFL
223506647|NCT02320825|RADIATION|single-fraction SRS|
223506648|NCT02320825|RADIATION|high-dose hypofractionated SRS|
223506649|NCT02320825|BEHAVIORAL|Quality of Life Measures|
223506650|NCT05232305|DIETARY_SUPPLEMENT|Pomegranate Peel|Standard bread and test breads (with added pomegranate peel) to be used in the study will be produced by Asst. Prof. Özlem ÖZPAK AKKUŞ in the Nutrition Principles Laboratory of Toros University. For standard bread, 900 ml of water, 42 fresh yeast, 12 g of salt and 12 g of sunflower oil will be added to 1000 g of sifted whole wheat flour and the prepared bread mixture will be divided into 40 equal parts. To make bread with pomegranate peel added, 1000 g of sifted whole wheat flour, 20 g of pomegranate peel powder, 914 ml of water, 42 g of fresh yeast, 12 g of salt and 12 g of sunflower oil will be added and the prepared bread mixture is divided into 40 equal parts with 500 mg of pomegranate peel powder in each piece).
223506651|NCT04336800|DEVICE|LiverMultiscan|The LiverMultiscan is a quick 15 min, contrast free scan that non-invasively provides three metrics of liver health namely liver fat, iron and fibro-inflammation
223506652|NCT06253429|DRUG|Thioctic Acid 333 MG Oral Capsule|Antioxidant compound which serve as a cofactor for mitochondrial respiratory enzymes
223506653|NCT06253429|DRUG|Captopril 25Mg Tab|Oral angiotensin-converting enzyme inhibitors
223506654|NCT03106402|DRUG|topical bromfenac sodium hydrate|
223506655|NCT00676052|DRUG|GSK233705 12.5mcg|Once daily via dry powder inhaler
223506656|NCT00676052|DRUG|GSK233705 25mcg|once daily via dry powder inhaler
223506657|NCT00676052|DRUG|GSK233705 50mcg|Once daily via dry powder inhaler
223506658|NCT00676052|DRUG|GSK233705 100mcg|Once daily via dry powder inhaler
223506659|NCT00676052|DRUG|GSK233705 200mcg|Once daily via dry powder inhaler
223506660|NCT00676052|DRUG|Placebo|Once daily via dry powder imhaler
223506661|NCT06450340|BEHAVIORAL|Moderate-intensity aerobic exercise refers to rhythmic and long-lasting exercise with increased heart rate, slight sweating and slight wheezing.|Sessions lasted 60 minutes each and took place three times a week for 12 weeks for each of the study groups.
223506662|NCT05135780|OTHER|Osteopathic manual treatment|Between 5 and 8 sessions of osteopathy will be carried out, and the time interval between sessions may vary depending on the need and individual evolution of each child, assessed by the team of osteopaths.
223596047|NCT01029847|DRUG|Placebo|"sc. inj. placebo every other week, week 0, 2, and 4. Sc. inj. adalimumab 40 mg every other week from week 6.~At week 24, clinical non-responders (not fulfilling primary outcome measure) were allowed treatment with other drugs, following local treatment guidelines."
223596048|NCT01211821|DRUG|metoprolol|Tablets, Oral, 200 mg, once, 1 day
223596049|NCT01211821|DRUG|BMS-914392|Tablets, Oral, 60 mg, once daily, 7 days
223596050|NCT05546229|PROCEDURE|Microneedle based interstitial fluid collection|Interstitial fluid will be collected from the skin using microneedles and suction.
223596051|NCT01983774|DRUG|Esomeprazole|
223596052|NCT01983774|DRUG|Placebo|Sugar pill
224310932|NCT01594255|DRUG|sotrastaurin|
224310933|NCT01594255|DRUG|sotrastaurin|
224310934|NCT01594255|DRUG|placebo to sotrastaurin|
224310935|NCT01594255|DRUG|Avelox|
224197712|NCT06131723|BEHAVIORAL|Behaviorally informed tickler email|The email notification from patients' PCP office will inform patients that a new review of their records shows they are due for an important medical exam. This intervention harnesses behavioral principles related to importance (medical exam described as important), personalization (records described as belonging to participants), urgency (participants are asked to sign in and make the recommended appointment as soon as possible), timeliness (participants are told that there has been a new review of their records), source effects and accountability (participants are told that a message from their PCP's office is waiting for their response). To make it easier for patients to find and review the MAP letter, the email also contains a link that directs patients to the MAP letter on their patient portal.
224197713|NCT05128955|DEVICE|Splenic artery embolization with vascular embolic coils or plugs|Splenic artery embolization with vascular embolic coils or plugs
224197714|NCT03179462|DIETARY_SUPPLEMENT|Pork intake|Each participant will consume 2 ounces of cooked lean pork.
224197715|NCT03179462|DIETARY_SUPPLEMENT|Mixed nuts intake|Each participant will consume 1 ounce of mixed nuts.
224197716|NCT03179462|DIETARY_SUPPLEMENT|Tofu intake|Each participant will consume 2 ounces of tofu.
224197717|NCT00816166|DEVICE|Pharos Vitesse Neurovascular Stent System (Stent implantation) + Medical therapy (Aspirin and Clopidogrel)|Implantation of one or more balloon-expandable Pharos Vitesse stents to treat neurovascular ischemic lesions + Medical therapy \[Treatment with aspirin (81-325 mg daily for the duration of the study) and Clopidogrel (75 mg daily for first 3 months)\]
224197718|NCT00816166|DRUG|Aspirin and Clopidogrel (Medical therapy)|Medical therapy alone \[Treatment with aspirin (81-325 mg daily for the duration of the study) and Clopidogrel (75 mg daily for first 3 months)\]
224197719|NCT01074853|DRUG|propranolol|10mg twice daily escalated to 80mg once daily
224197720|NCT01074853|DRUG|placebo|Matched placebo
224197721|NCT05493683|DRUG|Disitamab vedotin|2.0mg/kg，q2w
223506663|NCT05135780|OTHER|Social education|"* Intervention in children:~  * During the school year there will be activities of two days per week with a duration of 2.5 hours per session in the afternoon.~ * The activities will focus on school reinforcement, facilitating snacks and having a recreational space.~ * Groups will be made by age ranges (from 4 to 6 and from 7 to 12) of maximum 10 children, due to the current COVID situation. The number could vary in the event of a change in measures at the institutional level.~* Family intervention:~  * Quarterly tutoring spaces between the coordinators and the team of social educators to evaluate needs, specify objectives and assess evolution.~ * Monthly group spaces for mothers managed by the team of educators where they will exchange experiences and create an informal support network.~ * Monthly spaces shared between parents and children accompanied by the educational team, where family ties will be worked through play."
223506664|NCT02361684|BEHAVIORAL|Blended CBT treatment|Internet based blended CBT depression treatment combines individual face-to-face cognitive behavioural therapy (CBT) with CBT delivered through an Internet based treatment platform with mobile phone components (either integrated in the treatment platform or as a separate system). The core components of the CBT treatment are: (1) psycho-education, (2) cognitive restructuring, (3) behavioural activation, (4) positive psychology, and (5) relapse prevention. These will be delivered over 10 sessions. For this study, the ratio between the number of face-to-face sessions and the number of online module will be 1/3 face-to-face and 2/3 online.
223506665|NCT02361684|OTHER|Treatment as usual|Treatment as usual (TAU) is defined as the routine care that subjects receive when they are diagnosed with depression in the primary care system. In practice, this means that treatment as usual may vary between patients. We will not interfere with treatment as usual but we will monitor carefully which health care services are utilized by usual care patients using patient records and through self-report
223506666|NCT00661219|DRUG|Levitra (Vardenafil, BAY38-9456)|BAY 38-9456 (vardenafil) will be supplied as 5 mg tablets, 10 mg tablets, and 20 mg tablets.
223506667|NCT00661219|DRUG|Placebo|Identical placebo will be matched for each vardenafil dosage form and will be indistinguishable from active treatment.
223506668|NCT00929097|OTHER|Implementation aids|"* Patients and clinicians have access to a website with information on familial colorectal cancer risk; a risk assessment tool and decision aids~* Clinicians receive the guidelines and a risk communication tool, as well as education"
223506669|NCT00929097|OTHER|Control|Dissemination of guidelines
223506670|NCT01512537|RADIATION|Narrowband UVB|UVB 3 times a week
223506671|NCT01512537|DIETARY_SUPPLEMENT|Vitamin D and calcium|1 daily tablet of 1600 IU vitamin D3 and 1000 mg calcium
224197722|NCT05493683|DRUG|Tislelizumab|400mg，q6w
224197723|NCT05499481|DRUG|Antibiotic|"The investigators will perform two concomitant RCTs, depending on the presence of infected osteosynthesis material at enrolment:~\- SALATIO 1. Infected implant not removed (or new material inserted): Randomization 6 vs. 12 weeks (+/- 5 days) of total antibiotic therapy counted since the first debridement for infection. Early switch to oral targeted therapy.~\- SALATIO 2. Infected implant without residual material (definitive removal or within the interval of a two-stage exchange): Randomization 3 vs. 6 weeks (+/- 5 days) of total antibiotic therapy counted since the first debridement for infection. Early switch to oral targeted therapy."
224197724|NCT03047408|PROCEDURE|Video polysomnography|the main objective of our study is to longitudinally evaluate clinical and vPSG features of RBD, including measure of RSWA, in patients with PD-RBD, after three years from the diagnosis of RBD, in order to ascertain whether RBD features remain stable over time. The possible remission of RBD with the progression of PD would question indeed its reliability as prognostic bio-marker.
224197725|NCT02798302|OTHER|Flush rate oxygen using a standard flowmeter (Precision Medical, 8MFA). See description for details. This is specific.|A standard oxygen flowmeter will be fully opened and oxygen will be administered for three minutes.
224197726|NCT02563366|OTHER|BM-MSCs|BM-MSCs are from third-party healthy volunteer donors.
224197727|NCT02563366|OTHER|Saline|Saline is the placebo of MSCs in this study.
224197728|NCT04842318|DRUG|BR for 6 cycles +R for 8 cycles|The patients will be given Bendamustine (90mg/m2 d1,2, every 28 days for total 6 courses) combined with Rituximab (375mg/m2 d0, every 28 days for total 6 courses) followed by Rituximab (375mg/m2 d1, every 3 months for total 8 courses)
224310936|NCT04267029|DIAGNOSTIC_TEST|TADPOL battery (deep clinicolaboratory profile)|"profile dimensions:~* hemolytic~* allergic~* cardiorenal~* inflammatory~* leukoagglutinating~* exploratory bioarchive"
224310937|NCT05831371|DIAGNOSTIC_TEST|TEP FDG|FDG TEP peformed in clinical routine
224310938|NCT01711892|BEHAVIORAL|Soccer training|
223596053|NCT05747534|DRUG|Larazotide Acetate|AT1001 (Larazotide) is a locally acting, non-systemic, octapeptide inhibitor of the zonulin receptor that has shown efficacy in a large variety of animal models of inflammation. The effectiveness of AT1001 in controlling paracellular permeability as a tight junction regulator has been widely demonstrated in animal models both in vitro and in vivo. In MIS-C, prolonged presence of SARS-CoV-2 in the GI tract leads to release of zonulin, a biomarker of intestinal permeability, with subsequent trafficking of SARS-CoV-2 antigens into the bloodstream, leading to hyperinflammation (Yonker, et. al. 2021). Five children treated with AT1001 (through an Emergency Investigational New Drug request authorized by the FDA) displayed a decrease in plasma SARS-CoV-2 Spike antigen levels, inflammatory markers, and symptom improvement superior to that achieved with the current standard of treatment for MIS-C (ie. immunoglobulin, systemic steroids) (Yonker, et. al. 2021) (Yonker, et. al. 2022)
223596054|NCT05747534|DRUG|Placebo|Matching placebo will be administered orally four times a day (QID) to participants in the placebo arm.
224197729|NCT04842318|DRUG|RCHOP for 6 cycles +R for 8 cycles|The patients will be given RCHOP (Rituximab 375mg/m2 ivgtt, D0, Cyclophosphamide 750mg/m2, ivgtt D1, doxorubicin 50mg/m2,ivgtt D1, Vincristine 1.4mg/m2（max 2mg）, ivgtt D1 Prednisone 60mg/m2 （max 100mg）,PO,D1-D5 every 21 days for total 6 courses) followed by Rituximab (375mg/m2 d1, every 3 months for total 8 courses)
224197730|NCT04842318|DRUG|R2 for 6 cycles + R2 maintenance|The patients will be given Lenalidomide (25mg/d, po, D1-10, every 21 days for total 6 courses) combined with Rituximab (375mg/m2 d0, every 21 days for total 6 courses) followed by Lenalidomide (25mg/d, po, D1-10, every 28 days for total 6 courses) combined with Rituximab (375mg/m2 d1, every 3 months for total 8 courses)
223596055|NCT03402828|DRUG|Any topical drug treatment|Any treatment strategy used to prevent relapse of psoriasis symptoms
223596056|NCT00668538|DRUG|Brentan (miconazole)|Vaginal suppository 1200 mg at day 6
223596057|NCT06502834|DIETARY_SUPPLEMENT|D piger|Probiotic d piger
223596058|NCT06502834|DIETARY_SUPPLEMENT|Placebo|Placebo
223596059|NCT01008449|DEVICE|Surgical staples|Surgical staples will be used once for wound closure.
223596060|NCT01008449|DEVICE|Absorbable Surgical Suture|Absorbable surgical suture will be used for subcuticular closure at the time of wound closure for cesarean delivery.
223596061|NCT05532605|OTHER|cardiac rehabilitation phase I protocols|cardiac rehab phase I protocols: ankel pumps, limbs ROMs, bed mobility. Do 5-10 minutes daily of breath awareness practice on your own.
223596062|NCT05532605|OTHER|Cardiac rehab phase I protocols + Mindfullness base therapy|cardiac rehab phase I protocols: ankel pumps, limbs ROMs, bed mobility. Do 5-10 minutes daily of breath awareness practice on your own. Plus Mindfullness base therapy
223596063|NCT01220180|DRUG|pregabalin (Lyrica)|Pregabalin treatment can be started with a dose of 150 mg per day. Based on individual subject response and tolerability, the dosage may be increased to 300 mg per day after 1 week. The maximum dosage of 600 mg per day may be achieved after an additional week.
223596064|NCT01220180|DRUG|pregabalin (Lyrica)|"Peripheral neuropathic pain: Pregabalin treatment can be started at a dose of 150 mg per day. Based on individual subject response and tolerability, the dosage may be increased to 300 mg per day after an interval of 3 to 7 days, and if needed, to a maximum dose of 600 mg per day after an additional 7-day interval.~Central neuropathic pain: Pregabalin treatment can be started at a dose of 150 mg per day. Based on individual subject response and tolerability, the dosage may be increased to 300 mg per day after an interval of 1 week, and if needed, to a maximum dose of 600 mg per day after an additional 1 week interval. In case that tolerability could not be shown in the targeted daily dose, dose reduction may be considered."
223596065|NCT01220180|DRUG|pregabalin (Lyrica)|The recommended dose of pregabalin for fibromyalgia is 300 to 450 mg/day. Dosing should begin at 75 mg two times a day (150 mg/day) and may be increased to 150 mg two times a day (300 mg/day) within 1 week based on efficacy and tolerability. Subjects who do not experience sufficient benefit with 300 mg/day may be further increased to 225 mg two times a day (450 mg/day). Treatment with doses above 450 mg/day is not recommended.
223596066|NCT05113992|OTHER|aromatherapy massage|In the intervention group, 4% massage oil (3 ml jojoba fixed oil, 2% Frankincense and 2% Myrrh essential oil mixture) was applied on the skin on the forearm
223596067|NCT05113992|OTHER|classic massage|In the placebo massage group, jojoba fixed oil was applied to the skin on the forearm.
223596068|NCT01098526|DRUG|GSK1349572|GSK1349572 is an experimental drug under development for the treatment of HIV. It is in the class of integrase inhibitors.
223596069|NCT01098526|DRUG|Efavirenz|Efavirenz is a drug that has been approved by the FDA for the treatment of HIV. It is in the class of non-nucleoside reverse trancriptase inhibitors.
223596070|NCT00761202|DRUG|A sterile solution containing sodium carboxymethylcellulose and glycerin, preserved with PURITE®|Eyedrops as required, but at least 3 times per day
223596071|NCT00761202|DRUG|Sodium hyaluronate|Eyedrops as required, but at least 3 times per day
223596072|NCT00524615|DRUG|spironolactone|25 mg of spironolactone once daily or placebo for 2 months
223596073|NCT02386826|DRUG|INC280|"Dose Escalation: INC280 by mouth (PO) twice daily for 28 days according to the following schedule until the maximum tolerated dose (MTD) is determined:~Dose Level 1 (starting dose): 200 mg (divided dose of 100 mg twice per day) Dose Level 2: 400 mg (divided dose of 200 mg twice per day) Dose Level 3: 800 mg (divided dose of 400 mg twice per day)~Dose Expansion: INC280 PO twice daily at the MTD determined in the dose escalation phase"
223596074|NCT02386826|BIOLOGICAL|bevacizumab|bevacizumab: 10 mg/kg IV every 2 weeks. Patients with unresectable GBM will be given 15 mg/kg IV every 4 weeks.
224075113|NCT07143994|OTHER|eccentric exercise|This study's interventions are distinguished by the specific application of eccentric and concentric exercise programs tailored for elite athletes with grade II hamstring strains.
224197731|NCT04209673|OTHER|Multimodal Pain management including TENS unit|Patient receiving multimodal pain management strategies which includes the use of TENS.
224075114|NCT07143994|OTHER|concentric exercise|This study's interventions are distinguished by the specific application of eccentric and concentric exercise programs tailored for elite athletes with grade II hamstring strains.
224075115|NCT07142824|PROCEDURE|burn dressing using Tilapia-Fish Skin|we use tilapia fish skin as a healing dressing in burn patients
224075116|NCT07142824|PROCEDURE|burn dressing using regular dressing|we use regular dressing in burn patients
224075117|NCT07143448|BIOLOGICAL|HS235|Subcutaneous Injection
224075118|NCT07143448|OTHER|Placebo|Subcutaneous Injection
223506672|NCT00221325|DRUG|Intraventricular Rituximab Plus MTX|"Intraventricular injection of rituximab into an Ommaya reservoir on day 1 of each week. Intraventricular rituximab plus methotrexate (MTX) on day 4 of each week.~First three patients at dose A : 25 mg rituximab on day 1, and MTX (12 mg) plus rituximab (10 mg) on day 4 each week.~If there are no dose limiting toxicities at Dose A in all of the first 3 patients or in 5 of the first 6 patients, the next 3 patients will receive dose level B: 25 mg rituximab on day 1, and combination MTX (12 mg) plus rituximab (25 mg) on day 4 of each week.~Oral leucovorin rescue 24 hours after each MTX administration. Maximum injections will be 16 over 9-weeks. Subjects who experience a partial response at week 10 will be given the option for extended dosing."
224075119|NCT07143045|DRUG|zorifertinib|Cohort A and B will receive zorifertinib as first line treatment
224197732|NCT04209673|OTHER|Multimodal Pain management not including TENS unit|Patient receiving multimodal pain management strategies which does not includes the use of TENS.
224197733|NCT04775550|DRUG|Daratumumab|Subcutaneous, dosage per protocol, dose days vary per cycle. Cycle =28 days
223506673|NCT00120250|DRUG|Eszopiclone|The total study duration is 8 weeks, with subjects receiving 3mg eszopiclone or placebo nightly for 3 weeks, followed by a 1 week washout period, followed by 3 weeks of the alternate condition, followed by another 1 week washout.
223506674|NCT02968290|PROCEDURE|Cataract Surgery|Implant of intraocular lens hydrophobic or Implant of intraocular lens hydrophilic (Device)
223506675|NCT02968290|DEVICE|Alcon AcrySof SA60AT|Implant of intraocular lens hydrophobic
223506676|NCT02968290|DEVICE|Bausch Lomb AkreosA|Implant of intraocular lens hydrophilic
223506677|NCT03710733|RADIATION|Sequential boost|Boost (10 Gy/4 fx/1 week) is given after whole breast irradiation
223506678|NCT03710733|RADIATION|Concomitant boost|Boost (8 Gy/15 fx/3 weeks) is given with whole breast irradiation
223506679|NCT04555369|GENETIC|ct-DNA|The enrolled mCRC patients will perform ct-DNA testing to evaluate drug efficacy of chemotherapy, at the time of baseline and after the first cycle of chemotherapy.
223506680|NCT06428474|OTHER|Health education|Oral health education program designed for orphans children
223506681|NCT05333744|DRUG|Prednisone|Prednisone po, 20mg per day for 2 weeks, if response (Plt 30-100×100\^g/L),gradually taper to the maintenance dose（5-10mg per day）until 6 weeks after delivery; if not response, gradually taper to withdrawal.
223506682|NCT05333744|DRUG|Recombinant Human TPO|rhTPO im, 300U/kg per day for 2 weeks, if response (Plt 30-100×100\^g/L), taper to 300U/kg for twice per week until 6 weeks after delivery; if not response, drug withdrawal.
223506683|NCT04443777|OTHER|Resistance Training|Both groups will perform the resistance training protocol that will consist of a warm-up on the bench press and leg press, both with workload at 50% of 1-RM. After a 2-minute rest, the resistance training session will be started. It will consist of 4 sets of bench press and leg press exercises at 65% of 1-RM with maximum repetitions until concentric failure, with the execution speed of 2x2. The bench press exercises will be followed by the leg press exercises with no interval between them. A 2-minute interval will allowed after each series of exercises.
223506684|NCT03794323|DRUG|BI 764122|Tablet
223506685|NCT03794323|DRUG|Placebo|Tablet
223506686|NCT01404260|DRUG|Gefitinib|Gefitinib 250mg/d every cycle d15-25,and Gefitinib 250mg/d from d15 of last cycle until disease progression
223506687|NCT01404260|DRUG|Gemcitabine +Carboplatin|Gemcitabine 1250mg/m2+Carboplatin AUC=5, every 4 weeks, maximum 4 cycles
223506688|NCT02623270|DEVICE|Noninvasive Ventilator, V60 (Philips)|The noninvasive ventilator will be set to deliver 10 breaths per minute with a pressure setting of 8 cm H2O during exhalation and 20 cm H2O during inspiration. The inspired oxygen fraction given by the ventilator will be set at the maximum level (100% oxygen).
223506689|NCT02623270|DEVICE|Manual Bag|Oxygen will flow through the standard breathing circuit with the fresh gas flow rate set at 10 L/min and the patient will be ventilated. The anesthesia provider will manually bag mask ventilate the patient until the anesthesiologist feels comfortable that the patient can be ventilated appropriately.
223506690|NCT03300336|BEHAVIORAL|STRIDE|Implementation of STRIDE inpatient hospital mobility program
223506691|NCT03987880|PROCEDURE|4.0 mm treatment|PiXL treatment with UV irradiation in a central 4.0-mm ring-shaped zone of the cornea.
223506692|NCT03987880|PROCEDURE|3.5 mm treatment|PiXL treatment with UV irradiation in a central 3.5-mm ring-shaped zone of the cornea.
223506693|NCT04541342|PROCEDURE|initial arthroscopy with medial opening-wedge high tibial osteotomy fixed by a plate system then second look arthroscopy with plate removal|It is a joint preserving procedure especially preferred in young patients for whom arthroplasty is not desirable. The procedure promotes regeneration by causing lateral shift of the weight-bearing axis, thus decreasing load on the medial compartment and widening the medial joint space.Many of the patients complains of irritation through the plate and wish metal removal after healing of the osteotomy.All patients will undergo initial arthroscopy before high tibial osteotomy (HTO). During arthroscopy, debridement of the degenerate tissues and meniscal tears if present will be performed. Then opening-wedge high tibial osteotomy (OWHTO) will be performed and fixed by a plate system. Second-look arthroscopy will be conducted at the time of plate removal after healing of the osteotomy. This will be after about 6 months up to one year.
223506694|NCT03612700|OTHER|CPFA-rich foods|Daily consumption of Grana Padano cheese (50 g) and whole milk (250 mL) for 3 weeks.
223506695|NCT06516731|DIETARY_SUPPLEMENT|pH Balanced Cleanser|Participants will use the pH Balanced Cleanser daily during showers. The cleanser should be applied to the vulva with clean hands, gently worked into a lather, and rinsed clean. Participants will complete baseline and weekly questionnaires and vaginal pH tests over an 8-week period to evaluate the effects on vulvar and vaginal health, including odor and pH levels, and assess the tolerability of the product.
223506696|NCT01964560|DRUG|Lacosamide|"Pharmaceutical form: oral solution~Concentration: 1 mg/kg - 6 mg/kg BID (2 mg/kg/day - 12 mg/ kg/day)~Route of administration: oral use"
223506697|NCT01964560|DRUG|Lacosamide|"Pharmaceutical form: tablet~Concentration: 50 mg - 300 mg BID (100 mg/day - 600 mg/day)~Route of administration: oral use"
224075120|NCT07144228|DEVICE|HeLP TM|lab test for prostate cancer
224075121|NCT07143708|OTHER|Glaucoma Surgery with Amniotic Membrane|Arm 2: Glaucoma Surgery with Amniotic Membrane Participants undergo glaucoma surgery with either a PreserFlo MicroShunt or a XEN Stent, as determined by the treating surgeon. In this group, the implanted stent is covered with an amniotic membrane patch to reduce postoperative scarring and improve long-term outcomes. Follow-up visits are scheduled as per standard of care for glaucoma surgery (up to 12 months).
224197734|NCT04775550|DRUG|Bortezomib|Subcutaneous, dosage per protocol, dose days vary per cycle. Cycle =28 days
223596075|NCT02549131|PROCEDURE|Randomizing to Suture or Staple closure of Cesarean section|Randomizing to either surgical subcuticular suture or surgical staples in women of BMI greater than 40 undergoing Cesarean section delivery.
223596076|NCT04313478|BEHAVIORAL|Low Birth Weight and Normal Weight infants|This cross-sectional study included LBW and NW infants at between 3 and 9 months of age. The levels of trunk control were investigated by using the Segmental Assessment Trunk Control (SATCo). The Alberta Infant Motor Scale (AIMS) were used for assessment of gross motor performance and identify typical and atypical motor development of infants.
223596077|NCT04499287|OTHER|15-minute walk at preferred walking speed.|
223596078|NCT04499287|DIETARY_SUPPLEMENT|Fiber|9 grams soluble fiber
223596079|NCT04499287|OTHER|control|control
223596080|NCT02713659|BEHAVIORAL|Early Literacy Promotion|Parents will receive a book with developmentally appropriate advice about reading at each well child visit from one week through 5 months of age, as well as weekly text reminders related to reading. From 6 months of age, both groups will receive standard literacy promotion and will attend study visits every six months until age 2.
223596081|NCT02713659|BEHAVIORAL|Standard Literacy Promotion|Parents will receive weekly text messages about child safety, and no books before the age of 6 months from their provider. From 6 months of age, both groups will receive standard literacy promotion and will attend study visits every six months until age 2.
223596082|NCT06478303|OTHER|Motor imagery|Participants were asked to imagine arm or foot movements.
223596083|NCT06478303|OTHER|Action reading|Participants were asked to read sentences involving arm or foot movements
223596084|NCT06478303|OTHER|Motor localizer|Participants were asked to perform arm or foot movements
223596085|NCT02439034|DRUG|Paracetamol|Paracetamol 1 g IV then 1 g 3 times a day IV or oral (PO)
223596086|NCT02439034|DRUG|Ketoprofen|Ketoprofen\* 100 mg (IV then PO) : Ketoprofen 100 mg IV 2 times a day or Ketoprofen LP 100 mg PO 2 times a day.
223596087|NCT00406679|DRUG|Paracetamol (acetaminophen) solution experimental|1 gm IV
223596088|NCT00406679|DRUG|paracetamol (acetaminophen) solution commercial|1 gm IV
223596089|NCT00406679|DRUG|placebo|equivalent volume IV 0.9% sodium chloride (equivalent volume)
223596090|NCT01640899|DEVICE|Shoe Insoles|Shoe insoles is an orthotic devices which are used to prevent, relieve, or reduce pain in lower extremities. The insoles give a mechanical support for the body by put it in a good alignment.
223596091|NCT00855049|DRUG|Acetaminophen|Intranasal acetaminophen administration
223596092|NCT00855049|DRUG|Acetaminophen|Oral acetaminophen administration
223596093|NCT03601702|DEVICE|Mechanical thrombectomy with EmboTrap ® II Device|Endovascular treatment with mechanical thrombectomy using EmboTrap ® II Device (Neuravi)
223596094|NCT00232856|DEVICE|drug-eluting stent|PCI
223596095|NCT00195156|DRUG|ATRA-IV|
223596096|NCT00195156|DRUG|Depakote|
223596097|NCT02211066|DRUG|Clopidogrel|
223596098|NCT02211066|DRUG|Ticagrelor|
223596099|NCT04434014|DIETARY_SUPPLEMENT|proper diet|diet containing all essential vitamins
223596100|NCT01242852|PROCEDURE|Office hysteroscopy (in combination with a 'Saline Infusion Sonography'(SIS))|Routine fertility work-up, added up with diagnostic tests. In 5 research centers the extra tests consist of SIS \& hysteroscopy (HY). In the other research hospitals it consists of only a HY. The HY examination will be scheduled on Day 3-12 of a cycle. It will be performed in an outpatient setting with a vaginoscopic approach. A 5-mm diameter continuous flow hysteroscope and a 30º direction of view will be used. The uterus will be inspected methodically a endometrial biopsy obtained and the findings recorded into a standardized form. Intrauterine pathology is defined as septum, endometrial polyp, submucous myoma, adhesions \& endometritis. These will be treated, using scissors, Versapoint, grasping forceps, polyp snare or antibiotics. In 5 of the research hospitals, 1 week prior to the HY, also a SIS will be performed. Via a catheter saline solution will be infused into the uterine cavity as distention media. The findings at the following sonography will be standardized recorded.
223596101|NCT01067469|DRUG|Standard Dose Bevacizumab|10 mg/kg by vein (IV) over 90 minutes on Days 1, 15, and 29 of 6 week cycle.
223596102|NCT01067469|DRUG|Low Dose Bevacizumab|5 mg/kg IV over 90 minutes on Day 1 and 22 (every 3 weeks) of 6 week cycle.
223596103|NCT01067469|DRUG|Lomustine|Starting dose of 75 mg/m2 administered orally at sleep time on Day 3 of every 6 week cycle.
223596104|NCT01078844|DRUG|memantine|memantine 5-20 mg daily
223596105|NCT01078844|DRUG|Placebo|Look-alike placebo
224197735|NCT04775550|DRUG|Lenalidomide|Oral, dosage per protocol, days 1-21 per cycle
224197736|NCT04775550|DRUG|Dexamethasone|Oral, dosage per protocol, dose days vary per cycle. Cycle =28 days
224197737|NCT05653388|OTHER|Plasma Collection|Patients will provide tissue and blood samples. No medical intervention will be completed for study purposes
224197738|NCT04099446|OTHER|Non-interventional|There is no intervention for this study
224197739|NCT02202811|BEHAVIORAL|Forced Desynchrony|all sleep opportunities and other activities will be scheduled by the experimenter so that by the end of the study these activities are spread evenly across all phases of the internal body clock.
224197740|NCT00900471|OTHER|biologic sample preservation procedure|
224197741|NCT00900471|OTHER|medical chart review|
223596106|NCT06035848|PROCEDURE|Association of the components of metabolic derangement and paracentesis.|"In the intervention group were determined:~1. Components of metabolic derangement~2. Paracentesis. Determination of surgery: 3 positive points of the components of the metabolic derangement and a positive paracentesis.~The components of the metabolic derangement are the 7 parameters described by Tepas: positive blood culture, metabolic acidosis, neutropenia, bandemia, thrombocytopenia, hyponatremia and hypotension, being considered positive when 3 or more parameters are present.~Paracentesis was considered positive according to Kosloske's criteria: obtaining more than 0.5ml of serohematic fluid, Gram-positive fluid and obtaining fecal material.~Both groups had the same pre, trans and postoperative care."
223596107|NCT06035848|PROCEDURE|Bell's criteria: pneumoperitoneum|In the control group, the surgery was determined according to Bell's criteria, in the presence of radiographic pneumoperitoneum as an absolute indication for surgery.
224310939|NCT04105140|DRUG|Oxytocin|intranasal administration of oxytocin (24 IU)
224310940|NCT04105140|DRUG|Placebo|intranasal administration of placebo (24 IU)
223596108|NCT03931798|DIAGNOSTIC_TEST|Visual Scanning Test|The Visual Scanning Test (VST) involved a visual search for a target between similar visual distractors, projected in the far space, so as to simulate the search within a visual field. It is overall composed by four trials, each trial contained 20 cases and made up by 20 stimuli. On about the 80% of cases, the test provided the presence of target in the left, center or in right hemispace. In the remaining 20% of cases, the test provided the presence of a catch trial (absence of the target), to assess the presence of frontal disturbances or malingering. The test is constructed according to an increasing attentional load for the target on the left-hemispace. Participants, sitting in front a blank wall, were required to actively and free explore the projected visual field to search for the visual target, naming its identification (saying YES or NO). During the task, the examiner annotated the reaction times and the errors.
223596109|NCT00857519|DRUG|Melphalan, Carboplatin|Intra-arterial chemotherapy.
223596110|NCT04943432|BEHAVIORAL|Behavioral Activation|8 sessions of harm reduction-focused Behavioral Activation for Substance Use
224197742|NCT06652789|BEHAVIORAL|Sleep hygiene|"The intervention will be conducted over 6 weeks, and consist of engaging patients (and caregivers) in two 60-minute face to face sessions 3 weeks apart, and twice weekly telephonic follow ups lasting for 20 minutes each during the 6-week period.~The 2 Direct face to face sessions in local language will focus on health education about sleep. (After taking consent)~1. st session (60 mins) Information will be given about lifestyles that can affect sleep positively or negatively- adequate sleep time required for health, healthy and unhealthy sleep habits~2. nd session Participants will be asked to indicate how many of the sleep hygiene techniques they were able to successfully implement since the previous session Successes and barriers will be discussed. provide solutions for standard difficulties faced Twice a week telephone calls. The participants will be followed up through telephonic conversation twice weekly with a gap of three to four days in between each call."
224197743|NCT06653777|DRUG|Pemigatinib|Pemigatinib will be administered orally once daily for 2 weeks followed by a 1-week off (intermittent schedule 2/1).
223506698|NCT01438944|DRUG|Nicabate 21mg transdermal NRT|Nicabate 21mg Transdermal NRT Patch applied daily for 14 days Testing at Baseline, Day 4, Day 14 and 14 days post.
224197744|NCT04542252|DRUG|SyB V-1901|SyB V-1901 10 mg via IV infusion for 2 hours
224197745|NCT04542252|DRUG|Cyclosporine|200 mg Capsule
224197746|NCT04343508|OTHER|Fortified rice|100 g of rice was fortified with 150 µg vitamin A (Vitamin A palmitate), 0.5 mg vitamin B1 (thiamin mononitrate), 7 mg vitamin B3 (niacin amide), 0.6 mg vitamin B6 (pyrodoxine hydrochloride), 1 µg vitamin B12 (cyanocobalamin), 130 µg folic acid, 4 mg iron (ferric pyrosphosphate), and 6 mg zinc (zinc oxide).
224197747|NCT04232761|DRUG|Radium-223 dichloride (Xofigo, BAY88-8223)|Drug administration as determined by treating physician
224197748|NCT04352075|DRUG|Autologous biologic drug of innovative therapy /cell therapy drug|Articular knee injection of microfat associated with a dose of 3 billions of platelets or associated with a dose of 1 billion of platelets or with saline solution
224197749|NCT02649127|BEHAVIORAL|imaginal therapy|imaginal exercise of Prolonged Exposure therapy
224197750|NCT02649127|BEHAVIORAL|exercise|aerobic training at a frequency of a minimum of 3 sessions per week, at vigorous intensity \[i. e., \>60% of oxygen uptake reserve (VO2R)\], and a time of 20-25 minutes each bout of training
224197751|NCT02649127|BEHAVIORAL|self-care|meeting with a nurse to review and discuss publically available written materials that outline approaches for dealing with posttraumatic stress symptoms
224197752|NCT00794222|DEVICE|Mobile Tracking Young People's Experiences (mobiletype)|A mobile phone self-monitoring program, based on momentary sampling techniques, that prompts young people to complete it four times a day. The program asks several questions about daily activities, mood, stress, eating and exercise.
224197753|NCT05809440|OTHER|20-minute mindful breathing session|A 20-minute mindful breathing session guided by a trained medical doctor. The session consisted of four 5-minute breathing exercises done consecutively. Participants were instructed to close their eyes and bring their attention to their breathing, and re-direct their attention back to their breathing once they were distracted.
224197754|NCT00673712|DEVICE|Continuous Sternal Block|Elastomeric Pump for Continuous Infusion of Local Anesthetic
224197755|NCT00673712|DRUG|Opioid based analgesia|"Opioid Analgesic agents delivered by:~PCA on demand mode IV injections PRN IM injections PRN Oral PRN"
224197756|NCT05951205|BIOLOGICAL|Exa-cel|Administered by intravenous (IV) infusion following myeloablative conditioning with busulfan.
224197757|NCT03432130|OTHER|Structural training program|15-week experimental structural training protocol
223596111|NCT01081743|OTHER|Intervention of the social worker|Systematic home visits and regular follow-ups by phone from a social worker
223596112|NCT05236244|OTHER|İntervention group|Diaphragmatic Breathing Exercises
223596113|NCT06086834|OTHER|McKenzie Retraction Exercises|McKenzie Retraction exercises 5 days a week and 10-15 times for active exercises and 5-6 repetitions of clinician assisted exercise for a period of 4 weeks and a rest interval of 2 minutes between exercises.
223596114|NCT06086834|OTHER|Bruegger's Exercise|Bruegger's Exercise will be started from 10 seconds hold to 30 seconds with 2 seconds increment in every session. Rest time will be 30 seconds, 4 sets 12 times repetition, for duration of 30 mins per session, 5 days a week for a period of 4 weeks.
223596115|NCT02687698|OTHER|Ketogenic diet|The proposed ketogenic diet will concern a low glucidic diet with 60-70% of lipidic intake and 20-30% of proteins.
224197758|NCT02086734|OTHER|Perfusion-CT|"1. Baseline Perfusion CT-Scan (before AAT)~2. Follow-Up I Perfusion-CT Scan 7 days after start with AAT~3. Follow-Up II Perfusion-CT Scan 8 weeks after start with AAT"
224197759|NCT04169789|DIETARY_SUPPLEMENT|Lactobacillus reuteri ATCC PTA 6475 (L. reuteri 6475)|L.reuteri high or low dose with cholecalciferol compared to cholecalciferol only.
223506699|NCT01894360|DRUG|Belimumab 200 mg/mL|Clear to opalescent, colorless to pale yellow sterile solution sterile solution for SC injection in a single-use liquid formulation of Belimumab 200 mg/mL will be supplied in 1mL long glass prefilled syringe or autoinjector device.
223506700|NCT00378560|BIOLOGICAL|Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine|V501; Gardasil, 0.5 ml injection in 3 dosing regimen
223506701|NCT00378560|BIOLOGICAL|Comparator: Placebo|Placebo 0.5 ml injection in 3 dosing regimen
223596116|NCT02272218|PROCEDURE|bariatric lap band surgery|The intervention in this study is laparoscopic gastric banding (LAGB) surgery as a treatment option for obese patients with pain from knee osteoarthritis (KOA) refractory to medical treatment
223596117|NCT02889445|DRUG|4-Demethyl-4-cholesteryloxycarbonylpenclomedine|IV administration as described
223596118|NCT01299116|DRUG|DMPA|Injectable contraceptive, containing 150 mg depot medroxyprogesterone acetate (DMPA) and marketed in the US as Depo-Provera® or containing 104 mg DMPA and marketed as Depo-SubQ Provera 104®.
223596119|NCT01299116|DRUG|oral contraceptives|Oral contraceptives (any variety of formulations are permitted)
223747810|NCT02053467|OTHER|Champlain BASE eConsult Service|After undergoing registration, which includes orientation and brief training on the use of the service, physicians randomized to intervention arm will be able to submit patient-specific clinical questions to specialists through a secure, web-based application. Specialists are asked to respond within 7 days and, for each eConsult, are able to: (1) provide a recommendation, (2) request more information, or (3) recommend a face-to-face referral. The communication between PCPs and specialists is iterative and the discussion can occur back and forth until, ultimately, the PCP closes the case.
223747811|NCT01948973|DEVICE|Subsensory|The stimulation is here set to 90% of the sensory threshold
223747812|NCT01948973|DEVICE|OFF|The stimulation is here turned OFF
223747813|NCT01948973|DRUG|Suprasensory|The stimulation is here set suprasensory
223747814|NCT02143609|DRUG|oxygen|Nocturnal nasal oxygen during stay at 2048 m
223747815|NCT02143609|DRUG|sham oxygen (room air)|Sham oxygen (room air) via nasal cannula, 3 L/min, at 2048 m
223747816|NCT00725556|OTHER|Speech Therapy|Speech Therapy
223747817|NCT04850014|OTHER|Anthropomorphism|Height, weight, body surface area, body mass index, exact age (date of birth or age in days, months and years), falling which year of birth gender
224075122|NCT07143708|OTHER|Glaucoma Surgery without Amniotic Membrane|Arm 1: Glaucoma Surgery without Amniotic Membrane Participants undergo glaucoma surgery with either a PreserFlo MicroShunt or a XEN Stent, as determined by the treating surgeon. No modifications are made to the procedure. Follow-up visits are scheduled as per standard of care for glaucoma surgery (up to 12 months).
224075123|NCT07143409|OTHER|epidemiology and medical treatment strategies|Analysis of the epidemiology and medical and surgical treatment strategies for fungal IPEV in France between January 2013 and January 2023
224075124|NCT07146438|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|rTMS will be delivered with the MagPro X100 system equipped with a Cool-DB80 coil and a Localite neuronavigation system. Neuronavigation will be performed for anatomical landmarking and co-registration of the brain to Talairach stereotaxic space, with the co-registered coil vertex coordinate (x0, y+60, z+60) as performed in previously published work on dmPFC-rTMS and which represents \~25% of the nasion-inion distance. Posterior coil handle orientation will be used with stimulation parameters of 20Hz repetition rate, 2 second stimulation duration, 20 second inter-train interval, and 50 trains, for a total of 2000 pulses per day. Stimulation will be delivered at 100% of extensor hallucis longus muscle resting motor threshold (MT), as determined by the PI. rTMS will be delivered 5 days per week (Monday through Friday) for 6 weeks for a total of 30 treatment sessions, in keeping with established protocols. Trained research staff will perform daily rTMS treatments and monitor participants.
224075125|NCT07146438|BEHAVIORAL|Supportive Therapy (ST)|"Supportive therapy (ST) is a nondirective talk therapy focused on enhancing coping skills, strengthening existing resources, and improving daily functioning. Core techniques will include active listening, encouragement, validation, reframing, clarification (summarizing and paraphrasing), and naming problems. Participants will receive two ST sessions per week during the 6-week rTMS course. General goals include using the therapeutic relationship to foster adaptation, improve self-esteem, and support overall well-being. Each session will last 53-60 minutes and take place concurrently with rTMS, with the participant remaining in the TMS treatment room throughout."
224075126|NCT07146438|BEHAVIORAL|Exposure and Response Prevention (ERP) Therapy|ERP is a form of cognitive-behavioral therapy designed to reduce obsessive-compulsive symptoms by weakening the association between feared stimuli and maladaptive responses. It promotes the formation and recall of non-threatening associations to counter fear-based learning. The participant and therapist will collaboratively create a hierarchy of OCD triggers, rated using the Subjective Units of Distress Scale (SUDS). ERP will begin with exposures rated 4-7 on the SUDS, while participants refrain from engaging in compulsions. Each trigger will be repeated until the SUDS rating decreases by at least 50% before progressing to the next item. Between-session ERP homework will be assigned, and participants will be provided self-monitoring homework rating forms to complete for subsequent review with the therapist. Each ERP session will last 53-60 minutes and will be conducted concurrently with rTMS, with the participant remaining in the TMS treatment room throughout.
224075127|NCT07144462|DRUG|Fludarabine|Specified dose on specified days
224075128|NCT07144462|DRUG|Cyclophosphamide (C)|Specified dose on specified days
224075129|NCT07144462|GENETIC|NEUK203-215 Injection|Specified dose on specified days
224075130|NCT06947473|DRUG|umbilical cord blood CD19-BCMA CAR-T cells infusion|Approximately 3-5 days prior to umbilical cord blood CD19-BCMA CAR-T cell infusion, subjects are treated with FC regimen (fludarabine and cyclophosphamide) for lymphodepletion. CAR-T cell infusion are performed 48 h after completion of chemotherapy.
224075131|NCT07143786|DRUG|iNSC-EV01|Intravenous induced neural stem cell-derived exosome
224075132|NCT07143786|DRUG|Placebo|iNSC-EV01 mimics
224075133|NCT07142954|OTHER|P-tau217 Test|A plasma test measuring phosphorylated tau at Position 217 (P-tau217).
224075134|NCT03406897|DRUG|Cholecalciferol|Oral Administration
224075135|NCT03406897|DRUG|Omega 3 fatty acid|Oral Administration
224075136|NCT05279456|BIOLOGICAL|Advax-CpG55.2 adjuvanted recombinant spike protein|recombinant SARS-CoV-2 spike protein formulated with Advax-CpG55.2 adjuvant
224075137|NCT06351540|DRUG|Cannabis|cannabis with 0, 5, or 30 mg THC will be inhaled via vaporization
224075138|NCT06257966|DRUG|Exendin-4 Fc fusion protein injection(1.2mg）|1.2mg, subcutaneous injection in the abdomen, biweekly, 54 weeks of treatment.
224075139|NCT06257966|DRUG|Exendin-4 Fc fusion protein injection（2.4mg）|The first dose of 1.2 mg was administered subcutaneously in the abdomen, and after two weeks, the dose was adjusted to 2.4 mg, followed by a continuation of treatment for 52 weeks.
224075140|NCT06257966|DRUG|Dulaglutide|1.5 mg dulaglutide injection subcutaneously once a week for 54 weeks.
224197760|NCT06210828|BEHAVIORAL|Telerehabilitation|Two weekly exercise sessions over a 12-week period at home via LINE Video call with physical therapist. Focusing on lower extremity strengthening and balance exercises. In addition to the guided sessions, participants are encouraged to perform self-directed exercises one day per week.
224197761|NCT06210828|BEHAVIORAL|Control|Receive fall prevention exercise brochure
224197762|NCT02008396|DRUG|Placebo|Subjects will receive capsules of lactose of identical appearance to MDMA capsules during each of two experimental sessions. Capsules will be administered along with therapy.
224197763|NCT02008396|DRUG|Midomafetamine HCl|Participants in Group 1 receive 75 or 100 mg during the two experimental sessions and participants in Group 2 receive 100 or 125 mg during two experimental sessions.
224197764|NCT02008396|BEHAVIORAL|Therapy|Therapy conducted throughout experimental sessions. Therapists will use a largely nondirective approach. There will be periods of structured and unstructured interactions. The structured interactions will be selected based on elements of therapeutic interventions that are currently in use in this population for the treatment of social anxiety.
224197765|NCT06311851|DRUG|Bevacizumab|Infusion of Bevacizumab-loaded hepaspher through transarterial chemoembolization.
224197766|NCT04162756|BIOLOGICAL|Brexucabtagene Autoleucel (KTE-X19)|A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells/kg administered intravenously.
224197767|NCT04162756|DRUG|Fludarabine|Administered per package insert
224197768|NCT04162756|DRUG|Cyclophosphamide|Administered per package insert
224197769|NCT05534958|DEVICE|Accexible|Speech Analysis
224197770|NCT03220880|DRUG|Intranasal dexmedetomidine|Intranasal dexemedetomidine (100 mcg/mL), 0.5 to 4 mcg/kg
224197771|NCT04307017|OTHER|StimaWell®EMS|The StimaWell®EMS device is a 12-channel medium-frequency device with modulated low frequency using a high-tech stimulation suit for the trunk and strap electrodes for the arms and legs allowing whole-body stimulation. The device has 70 preprogramed training programs based on goals (e.g., strengthening, endurance training, aerobic training).
224197772|NCT01092130|DRUG|Vitamin D|2000 IU vitamin D daily, for 6 weeks
224197773|NCT00390676|DRUG|ADH -1 and carboplatin|
223596120|NCT01299116|DRUG|Implanon®|Subdermal contraceptive implant, marketed in the US as Implanon® or Nexplanon® (containing 68 mg of etonogestrel)
223596121|NCT01299116|DRUG|ParaGard®|Intrauterine device marketed in the US as ParaGard® (a T-shaped plastic device containing 380mm2 of copper surface)
223596122|NCT01299116|DRUG|Mirena®|Intrauterine system, marketed in the US as Mirena® (containing 52 mg of levonorgestrel)
223596123|NCT00236756|DRUG|topiramate|
223596124|NCT01620944|DRUG|Atazanavir|Capsule, oral, 300 mg, Once daily (QD), 96 weeks
223596125|NCT01620944|DRUG|Ritonavir|Tablets, oral, 100 mg, QD, 96 Weeks
223596126|NCT01620944|DRUG|Lamivudine|Tablet, oral, 300 mg, QD, 96 Weeks
223747818|NCT04850014|OTHER|Relevant clinical datas|"Medical history Concomitant medication Paracetamol intake : dosage, delay, context, route of intake Alcohol intake Smoking status (including active and passive exposition or no exposition) Curative treatment / Antidote / purifying treatment received and time of introduction Clinical signs, Acetaminophen concentration in plasma with associated accurate time of sampling (date, hour and time following acetaminophen intake Liver and kindney function assessment by measure measuring plasma concentration of: AST, ALT, Factor V, Prothrombin, APTT, INR, albuminemia, bilirubin, phosphorus, pH, creatitine. And GFR estimation.~Imaging."
224197774|NCT00390676|DRUG|ADH -1 and docetaxel|
224197775|NCT00390676|DRUG|ADH -1 and capecitabine|
224197776|NCT04486586|DEVICE|Active tDCS plus Speech-Language Therapy|Stimulation will be delivered by a battery-driven constant current stimulator. The electrical current will be administered to a pre-specified region of the brain (inferior frontal gyrus). The stimulation will be delivered at an intensity of 2 mA (estimated current density 0.04 mA/cm\^2; estimated total charge 0.048 C/cm\^2) in a ramp-like fashion for a maximum of 20 minutes. Speech-language therapy will target apraxia of speech (AOS).
224197777|NCT04486586|DEVICE|Sham plus Speech-Language Therapy|Speech-language therapy will be administered during sham stimulation. Current will be administered in a ramp-line fashion but after the ramping the intensity will drop to 0 mA. Speech-language therapy will target apraxia of speech (AOS).
224197778|NCT04423107|DRUG|Acetaminophen, Ibuprofen|Acetaminophen (Tylenol) 15 mg/kg q6h and Ibuprofen (10 mg/kg) q6h
224197779|NCT04423107|DRUG|Acetaminophen, Ibuprofen, Oxycodone|Acetaminophen (Tylenol) 15 mg/kg q6h, Ibuprofen q6h, and Oxycodone 0.1 mg/kg q6h
223596127|NCT01620944|DRUG|Tenofovir/Emtricitabine|Tablets, oral, 300/200 mg, QD, 48 Weeks
223596128|NCT01338857|DRUG|Sorafenib (Nexavar)|"Sorafenib (in tablet form) will be administered orally BID (approximately every 12 hours). Grapefruit juice is not allowed while taking sorafenib. A cycle of therapy is considered to be 28 days and there is no interruption between cycles. Patients may receive up to a total of 12 cycles provided that no off-protocol or off-study criteria are met.~Children/adolescents (\< 18 years of age, non-NF1): 200 mg/m2/dose PO twice daily (rounded to the nearest 50 mg increment as per Section 4.1) to a maximum of 400 mg PO twice daily~Adults (greater than or equal to 18 years of age, non-NF1): 400 mg PO twice daily~NF1 patients (regardless of age): 80 mg/m2/dose PO twice daily (rounded to the nearest 50 mg increment as per Section 4.1) to a maximum of 150 mg PO twice daily"
223596129|NCT04088591|DRUG|Ascorbic Acid 500Mg/Ml Inj|Ascorbic acid 200mg/kg/day administered upon suspicion or confirmation of sepsis every 6 hours for a total duration of 96 hours
223596130|NCT04088591|DRUG|Dextrose in Water|50 ml of 5% dextrose in water every 6 hours for a total duration of 96 hours
223596131|NCT02708420|DEVICE|Glidescope|This standard GlideScope (GS) technique involves a midline laryngoscopy followed by insertion of a styletted endotracheal tube, once an adequate view of the vocal cords is achieved.
223596132|NCT02708420|DEVICE|Macintosh Laryngoscope|This technique involves a laryngoscopy followed by insertion of a styletted endotracheal tube, once an adequate view of the vocal cords is achieved.
223596133|NCT01123707|DRUG|Aripiprazole|Aripiprazole oral capsules
223596134|NCT01123707|DRUG|Escitalopram|Escitalopram oral capsules
223596135|NCT02237261|DRUG|Bendamustine, Bortezomib, Prednisone|"Cycle 1 (d1-42) - Induction:~Bortezomib: 1.3 mg/m2 s.c.: d1, 4, 8, 11, 22, 25, 29, 32 Bendamustine: 90 mg/m2 iv, d1, 2 Prednison: : 60 mg/m2 po,, d1-4~Cycle 2-9 (d1-28) - Consolidation:~Bortezomib: 1.3 mg/m2 s.c.: d1, 8, 15, 22 Bendamustine: 90 mg/m2 iv: d1, 2 Prednison: 60 mg/m2 po: d1-4"
223596136|NCT02458183|BIOLOGICAL|DTaP-IPV combination vaccine|0.5-mL IM
223596137|NCT02458183|BIOLOGICAL|DTaP vaccine and IPV vaccine|0.5-mL IM
224197780|NCT04760639|DIAGNOSTIC_TEST|Breath test|Participants provide a breath sample
224197781|NCT04241081|BEHAVIORAL|Interrupting Prolonged Sitting with Periodic Interval Exercise: Effect on Postprandial Lipemia|This is a behavioral intervention designed to determine the effect of breaking up prolonged bouts of sitting every 2 hours and every 6 hours with 5 sets of 4 second bouts of maximum effort bicycle ergometer accelerations compared to sitting alone on the blood triglyceride response and whole body fat oxidation after a high fat meal.
223747819|NCT02955979|OTHER|CT scan with iodinated contrast agents|"Before the CT scan, the investigators with iodinated contrast agents, the following data will be collected in the medical record: creatinine prior to injection, comorbidities and child characteristics, associated treatments and risk factors of acute renal failure, as well as the injection pattern.~After the CT scan the investigators will collect the characteristics of the injection type, osmolarity and volume of contrast used and the appearance of a possible allergic reaction.~Then 24 and 48 hours and day 7 will collect serum creatinine, urine output and vital replacement therapies may be necessary."
223747820|NCT03576001|DRUG|Testosterone Undecanoate|administered through injections by study staff
223747821|NCT03576001|BEHAVIORAL|hybrid exercise|hybrid exercise: functional electrical stimulation of lower extremity with leg cycling (FES-LC) and arm ergometry, supervised for two weeks and then home-based
224075141|NCT06257966|DRUG|Metformin|Metformin hydrochloride tablets, oral administration, 54 weeks of treatment
223596138|NCT04739878|PROCEDURE|Airway Ultrasound|Comparison between Airway ultrasound and CT cervical
223596139|NCT02474251|OTHER|Continuous positive airway pressure device|GROUP B ONLY will be evaluated on two randomized counterbalanced nights, on one they will undergo a full night of therapeutic CPAP; on the other the investigators will withdraw CPAP during SWS only. A morning LP will be performed approximately 10 hours after sleep onset in both visits
223596140|NCT04519853|BEHAVIORAL|Low Glycemic Load Diet|Food delivery service will provide a low glycemic load diet for 8 weeks
223596141|NCT01876693|PROCEDURE|prophylactic percutaneous gastrostomy|prophylactic percutaneous gastrostomy with nutrition counselling
223596142|NCT04378114|DEVICE|Guardian™ Sensor (3) connected to a Guardian™ Connect Transmitter. C sensor algorithm applied retrospectively to raw sensor data.|Characterize the impact of acetaminophen ingestion on the accuracy of Guardian™ Sensor (3) when C sensor algorithm is used.
224075142|NCT02392429|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
224075143|NCT02392429|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow biopsy and aspiration
224075144|NCT02392429|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy and aspiration
223596143|NCT04378114|DEVICE|Guardian™ Sensor (3) connected to a Guardian™ Connect Transmitter. Zeus sensor algorithm applied retrospectively to raw sensor data.|Characterize the impact of acetaminophen ingestion on the accuracy of Guardian™ Sensor (3) when Zeus sensor algorithm is used.
223596144|NCT04378114|DRUG|Acetominophen|One time administration of acetaminophen.
223596145|NCT01299402|DIETARY_SUPPLEMENT|Soulera Herbal Blend|This a powder blend of various reputed adaptogenic herbs. The dosage will be one 8.6 gram powder sachet daily.
223596146|NCT01299402|DIETARY_SUPPLEMENT|Placebo|The placebo will be a similar tasting and looking powder blend as the Soulera Herbal Blend. The dosage will be 8.6 grams per sachet daily.
223596147|NCT05683002|DIETARY_SUPPLEMENT|Aronia supplementation|As described in experimental arm
223596148|NCT05683002|DIETARY_SUPPLEMENT|Cellulose supplementation|As described in placebo comparator arm
223596149|NCT01727414|DRUG|OROS-Methylphenidate and placebo for inattentive type pts|Every participant receives low dose MPH, medium dose MPH, high dose MPH, and placebo for one week each in a triple-blinded fashion.
223596150|NCT01727414|DRUG|OROS-Methylphenidate and placebo for combined type pts|Every participant receives low dose MPH, medium dose MPH, high dose MPH, and placebo for one week each in a triple-blinded fashion.
223596151|NCT03807284|BEHAVIORAL|A group psychosocial course|A 2 hour, weekly group psychosocial therapy RCAS course that aims to improve confidence and help adjustment after a stroke.
223596152|NCT03720002|DIETARY_SUPPLEMENT|HF2|placebo
223596153|NCT05862090|DRUG|RLD2301|Take it once a day per period.
223596154|NCT05862090|DRUG|RLD2007|Take it once a day per period.
223596155|NCT04793334|PROCEDURE|sleeve gastectomy|routine sleeve gastrectomy
223596156|NCT02389439|DRUG|Pyronaridine-artesunate|
223596157|NCT01801852|BIOLOGICAL|NKT cells|
224075145|NCT02392429|DRUG|Chemotherapy|Given anthracycline IV
224075146|NCT02392429|PROCEDURE|Computed Tomography|Undergo FLT PET/CT
224075147|NCT02392429|DRUG|Cytarabine|Given IV
224075148|NCT02392429|OTHER|Fluorothymidine F-18|Undergo FLT PET/CT
224075149|NCT02392429|OTHER|Laboratory Biomarker Analysis|Correlative studies
224075150|NCT02392429|PROCEDURE|Positron Emission Tomography|Undergo FLT PET/CT
224075151|NCT06484322|BEHAVIORAL|Strategies Empowering Activities in Everyday life (SEE 2.0)|SEEs internet-based intervention process begins with supporting the client to explore the need of and readiness for changes in everyday life. Thereafter, the client is supported to self-analyse their engagement in activities in everyday life along with use of management strategies in everyday life. Next, the client takes on web- modules including short educational movies with subsequent analyses and reflections. The modules aim to support the development of self-management by improving the knowledge of how strategies and changes in daily activities can prevent disabilities and contribute to improved health. After that, the focus is on establishing an activity plan with goals and activity-based management strategies to promote an active everyday life. The clients' implementation of the plan is supported through follow-up meetings. During the whole intervention process, the client is regularly supported by an occupational therapist through feedback and online guiding dialogues.
224075152|NCT06129474|OTHER|Proton Pump Inhibitor deprescribing tool|The intervention is targeted to the Swiss Primary care practice. It involves educational material and resources to guide the safe deprescribing of inappropriate PPIs, for both general practitioners and patients.
224075153|NCT06569108|DRUG|KN057|KN057 will be administered subcutaneously once a week.
224197782|NCT06995703|BEHAVIORAL|Pre-Visit Patient Text Message|Patients will be sent a text message reminder 1 day prior to their scheduled primary care visit. This message will remind them of their upcoming appointment, highlight that they may be overdue for their mammogram, and encourage them to speak with their provider or schedule now by using the provided online scheduling link or phone number. Patients who do not have a cell phone number listed in the EHR will receive automated voice recording (AVR).
224197783|NCT06995703|BEHAVIORAL|Post-Visit Patient Text Messages|Patients will be sent text message reminders 4 days and 14 days after their completed primary care visit if they have not yet scheduled or completed their screening mammogram. The message delivered at 4 days post-visit will remind the patient to schedule and that appointments are available for them. The message delivered at 14-days post-visit will again encourage the patient to schedule their mammogram, if one has not already been scheduled or completed. Both messages will include a scheduling phone number and link to self-schedule online. Patients who do not have a cell phone number listed in the EHR will receive automated voice recording (AVR).
224197784|NCT06995703|BEHAVIORAL|Smart Data Element (SDE)|The clinician-facing Smart Data Element (SDE) in the EHR will be visible to the provider and care team during the visit encounter. The SDE will display as a section in pre-charting, check-in, and rooming and will notify the clinician and care team that a pre-visit communication was sent to the patient regarding scheduling an overdue mammogram and including results from prior work that show that patients are more likely to complete their screening if they receive an order and recommendation from their provider.
224197785|NCT06993662|COMBINATION_PRODUCT|Group A. The combination of pharmacotherapy and individual cognitive behavioral psychotherapy by anxiety disorders and depression.|The combination of pharmacotherapy (anxiolytics (tavor, clonotril, lexotanil), antidepressants (SSRI, SNRI) and individual cognitive behavioral psychotherapy by anxiety disorders and depression.
224197786|NCT06993662|COMBINATION_PRODUCT|Group B. The combination of pharmacotherapy and individual cognitive behavioral psychotherapy by PTSD|The combination of pharmacotherapy (anxiolytics (tavor, clonotril, lexotanil), antidepressants (SSRI, SNRI) and individual cognitive behavioral psychotherapy by PTSD
224197787|NCT06993662|COMBINATION_PRODUCT|Group C. The combination of pharmacotherapy and individual cognitive behavioral psychotherapy by obsessive-compulsive disorder.|The combination of pharmacotherapy and individual cognitive behavioral psychotherapy by obsessive-compulsive disorder.
224197788|NCT06993662|COMBINATION_PRODUCT|Group D.The combination of pharmacotherapy and individual cognitive behavioral psychotherapy by bipolar disorder|The combination of pharmacotherapy (anxiolytics (tavor, clonotril, lexotanil) antidepressants (SSRI, SNRI), mood stabilizers (lithium, depakine), antipsychotics (clozapine and atypical antipsychotics)) and individual cognitive behavioral psychotherapy by bipolar disorder.
223506702|NCT06272682|PROCEDURE|Systemic bethametasone injection|betamethasone intramuscular injection in the treatment of carpal tunnel syndrome
223506703|NCT06272682|PROCEDURE|Local bethametasone injection|Local betamethasone injection under ultrasound in the carpal tunnel, in the treatment of carpal tunnel syndrome
223506704|NCT01518036|DRUG|somatropin|2.9 IU/m\^2/day. Administered as once daily subcutaneous injection until final height is reached
223506705|NCT01518036|DRUG|somatropin|4.3 IU/m\^2/day. Administered as once daily subcutaneous injection until final height is reached
223506706|NCT02683798|DIETARY_SUPPLEMENT|Continuous energy restriction|1 x formula food (202-209kcal) meal replacement per day
223506707|NCT02683798|DIETARY_SUPPLEMENT|Intermittent energy restriction|4 x formula food (202-209kcal) total diet replacement per day, on 2 days per week
223506708|NCT02926846|DRUG|Intravenous vancomycin & gentamicin with adjunctive lavage|"Intravenous vancomycin and gentamicin are administered, together with adjunctive lavage performed by automated peritoneal dialysis machine over 48 to 72 hours.~(choice of antibiotic is adjusted in accordance with the microbiology report when available)"
223506709|NCT02926846|DRUG|Intraperitoneal vancomycin & gentamicin|"Intraperitoneal vancomycin and gentamicin are administered, with the usual continuous ambulatory peritoneal dialysis schedule maintained.~(choice of antibiotic is adjusted in accordance with the microbiology report when available)"
223506710|NCT04370847|PROCEDURE|Spinal Anesthesia|Performed at the L3-L4 or L4-L5 interspace using a 25-gauge spinal needle
223506711|NCT04370847|DRUG|Intrathecal Bupivacaine|Bupivacaine 12.5 mg (2.5 mL 0.5%) will be administered in the subarachnoid space
223506712|NCT04370847|DRUG|Intrathecal Fentanyl|Fentanyl 15 μg will be administered in the subarachnoid space
223506713|NCT04370847|PROCEDURE|Cesarean Delivery|Lower segment cesarean section using the Pfannenstiel incision
223506714|NCT04370847|RADIATION|lung ultrasound scans|lung ultrasound scans will be performed while the patient is in the supine position with left lateral tilt by 30 degrees using a 2-5 MHz curved array transducer. The echo comet score (ECS) which corresponds to the amount of EVLW will be obtained by the 28-rib interspaces technique. An increased amount of (EVLW) is diagnosed by multiple B-lines or 'comet tails' which are defined as discrete laser-like vertical hyperechoic reverberation artifacts that arise from the pleural line and extend to the bottom of the screen without fading and move synchronously with lung sliding. The sum of the B-lines found on each of the 28 chest-wall areas yields the ECS.
223506715|NCT04370847|OTHER|Ultrasound Assessment of the Inferior Vena Cava|The IVC largest and smallest diameters will be measured proximal to the opening of the M-mode using s2-4 MHz transducer placed longitudinally in the subcostal region.
223506716|NCT04370847|OTHER|Optic nerve sheath diameter|Optic nerve sheath diameter measurement will be conducted in two axes of transverse and oblique sagittal using a 12-4MHz linear array transducer. Depth of the optic nerve will be localized and marked at 3 mm behind the retinal and optic nerve junction transverse diameter of optic nerve sheath will be calculated. The reported ONSD corresponds to the mean of the four values obtained for each patient transverse and sagittal plane for both eyes.
223506717|NCT04370847|DRUG|ringer acetate|1000 ml ringer acetate will be administered over 2 hours.
223506718|NCT04370847|DRUG|Intravenous Ephedrine|Intravenous ephedrine 3, 5, and 10 mg will be administered when Systolic blood pressure decreases below 120, 110, and 90 mmHg, respectively.
224197789|NCT06993662|COMBINATION_PRODUCT|Group E. The combination of pharmacotherapy and individual cognitive behavioral psychotherapy by schizophrenia and psychotic disorders|The combination of pharmacotherapy (anxiolytics(tavor, clonotril, lexotanil), antidepressants (SSRI, SNRI), antipsychotics (clozapine and atypical antipsychotics)) and individual cognitive behavioral psychotherapy by schizophrenia and psychotic disorders.
223596158|NCT04119011|BIOLOGICAL|Probiotic|(Lactobacillus acidophilus, lactobacillus casei, lactobacillus lactis) and Bifidobacterium (Bifidobacterium bifidum, bifidobacterium longum, bifidobacterium infantis) lactose, sugar, milk powder, oligosaccharides, ascorbic acid, citric acid, maltodextrin, and orange flavor
224197790|NCT06993662|COMBINATION_PRODUCT|Group F.The combination of pharmacotherapy and individual cognitive behavioral psychotherapy by personality disorders|The combination of pharmacotherapy (anxiolytics (tavor, clonotril, lexotanil), antidepressants (SSRI, SNRI), antipsychotics (clozapine and atypical antipsychotics) and individual cognitive behavioral psychotherapy by personality disorders.
224197791|NCT00179101|PROCEDURE|Deep Brain Stimulation|
223596159|NCT04119011|OTHER|Placebo|lactose, sugar, milk powder, oligosaccharides, ascorbic acid, citric acid, maltodextrin, and orange flavor
223596160|NCT01973556|OTHER|Pharmacist-Physician Collaborative Medication Therapy Management|
223596161|NCT06027450|OTHER|NHIg prescription|Analysis of NHIg prescription
223596162|NCT03018977|OTHER|The sedative weaning protocol group|After physician decide to wean sedative or analgesic drugs. We divided to 2 groups including high risk group and low risk group. The sedative weaning protocol were used in these patients which rely on the high risk or low risk group.
223596163|NCT03018977|OTHER|The usual group|After physician decide to wean sedative or analgesic drugs. The sedative/analgesic drugs were weaned depend on physician
223596164|NCT05236504|DIETARY_SUPPLEMENT|Melatonin and magnesium-containing pod|A 50-100mL hot water drink, obtained from a coffee pod machine, containing 1.9mg of melatonin and 200mg of magnesium in a powdered form, will be ingested 30 minutes before bedtime. Total duration of this intervention: 4 weeks, after which 1 week of washout will occur, before switching to the other intervention.
223596165|NCT05236504|OTHER|Placebo comparator|A 50-100mL hot water drink of identical taste, obtained from an identical pod with the same ingredients except melatonin and magnesium, will be ingested 30 minutes before bedtime. Total duration of this intervention: 4 weeks, after which 1 week of washout will occur, before switching to the other intervention.
223596166|NCT01975597|PROCEDURE|Bone marrow aspirates and biopsy|
223596167|NCT04305561|PROCEDURE|Contrast-enhanced ultrasound|"Ultrasound contrast agent: Stabilized sulfur hexafluoride microbubbles (SonoVue®, Bracco).~An 18 G needle will be placed in an antecubital vein and directly attached to a three-way stopcock with an extension tube.~The SonoVue® will be prepared and shaken shortly before injection in accordance with the instructions provided in the product information leaflet.~The patient will be injected with 1.2 ml SonoVue® at a pace of 1-2 ml/s using the 180 degree straight-flow channel of the three-way stopcock, directly followed by a 10 ml bolus of sodium chloride 9 mg/mL (0.9%) injected into the 90 degree channel of the three-way stopcock at a pace of approximately 2 ml/s.~A full examination will typically require one to two injections of 1.2 ml of SonoVue® (one injection per suspected parathyroid adenoma)."
223596168|NCT02670668|OTHER|Mutation analysis|
223596169|NCT02172404|DEVICE|Placebo capsule administered via the HandiHaler®|
223596170|NCT02172404|DEVICE|Ipratropium metered dose inhaler (MDI)|
223596171|NCT06524622|DEVICE|Point-of-care ultrasound (POCUS)|Point-of-care ultrasound (POCUS) measurements will be performed for all participants
223596172|NCT03582995|PROCEDURE|Flap Surgery for root coverage with Alloderm and xenograft|A coronally positioned FLAP technique with AlloDerm® GBR and osseous xenograft will be used for root coverage
223596173|NCT03582995|PROCEDURE|Tunnel Surgery for root coverage with Alloderm and xenograft|A coronally positioned TUNNEL technique with AlloDerm® GBR and osseous xenograft will be used for root coverage.
223596174|NCT01796821|DRUG|Vehicle gel|"Clinical diagnosed lesion site(s): Topical application once daily with occlusive dressing.~Clinical normal skin on treated area: Topical application thrice daily without occlusive dressing.~Total application \<1,500 mg gel per day."
223596175|NCT01796821|DRUG|SR-T100 gel with 1.0 % SM|"Clinical diagnosed lesion site(s): Topical application once daily with occlusive dressing.~Clinical normal skin on treated area: Topical application thrice daily without occlusive dressing.~Total application \<1,500 mg gel per day."
223596176|NCT01796821|DRUG|SR-T100 gel with 2.3% SM|"Clinical diagnosed lesion site(s): Topical application once daily with occlusive dressing.~Clinical normal skin on treated area: Topical application thrice daily without occlusive dressing.~Total application \<1,500 mg gel per day."
223596177|NCT00002921|DRUG|suramin|
223596178|NCT00002921|DRUG|therapeutic hydrocortisone|
223596179|NCT06393023|DEVICE|Continuous Positive Airway Pressure|Although this study is designed as an observational cohort study, where patients were not assigned to intervention or non-intervention groups, there is still an intervention project indicator present in the observational cohort. The intervention in this study involves the use of Continuous Positive Airway Pressure (CPAP) treatment. CPAP is a commonly used therapy for obstructive sleep apnea (OSA) and other sleep-related breathing disorders. The principle of CPAP treatment lies in maintaining a constant airway pressure during sleep to prevent the collapse of the upper airway and ensure unobstructed breathing. The patient wears a mask connected to a CPAP machine, which generates a steady stream of air to provide the necessary pressure.
224197792|NCT02880709|DIETARY_SUPPLEMENT|Special diet|Tate and energy content adjusted with spices to obtain maximal intake
224197793|NCT02461407|DRUG|Anlotinib|Anlotinib p.o. qd
224197794|NCT02461407|DRUG|Placebo|Placebo p.o. qd
224197795|NCT05368428|OTHER|Transcutaneous Electrical Nerve Stimulation|Undergo TENS
223596180|NCT03757377|DEVICE|BackBeat Moderato System|Eligible patients randomized after optimization phase to PHC ON for 12 months. Patients continue standard or modified anti-hypertension medical regime at discretion of the investigator
223596181|NCT03757377|DEVICE|BackBeat Moderato Sytsem|Eligible patients randomized after optimization phase to PHC OFF for 12 months. Patients continue standard or modified anti-hypertension medical regime at discretion of the investigator.
223596182|NCT02568592|DIETARY_SUPPLEMENT|High Fat|High Fat - Carbohydrate (20%), Fat (65%), Protein (15%)
223596183|NCT02568592|DIETARY_SUPPLEMENT|Normal|Normal - Carbohydrate (50%), Fat (35%) and Protein (15%)
224197796|NCT01843660|DRUG|Tramadol HCl-Paracetamol|Participants will receive 1 to 2 tablets of tramadol HCl-paracetamol orally once daily (each tablet containing tramadol 37.5 milligram \[mg\] and paracetamol 325mg) for up to a total duration of 6 hours. Additional dose may be given based upon the clinical requirement.
224197797|NCT06864533|DRUG|Docetaxel|Chemotherapy will start 4-8 weeks after the completion of radiotherapy. The chemotherapy regimen will consist of docetaxel 75 mg/m² administered intravenously on Day 1, repeated every 21 days for a total of 4-6 cycles. In cases of significant neuroendocrine differentiation and if well-tolerated, a combination of docetaxel and carboplatin (docetaxel 75 mg/m² and carboplatin AUC 4-6) will be used. Pre-treatment with dexamethasone will be administered to reduce potential side effects.
224197798|NCT04759352|OTHER|Post-test genetic counseling delivered by telephone|Participants enrolled in the experimental arm will receive genetic counseling for test result communication by telephone.
224197799|NCT00209560|DRUG|fospropofol disodium|
224197800|NCT00759369|OTHER|Water prescription|Water prescription in 12 to 16 equally divided doses
224197801|NCT02361801|DRUG|Liberal dobutamine protocol|All patients will receive dobutamine at the cardiopulmonary bypass weaning.
224197802|NCT02361801|DRUG|Restrictive dobutamine protocol|Patients will receive dobutamine during the first 8 hours after cardiopulmonary bypass weaning only if they have a cardiac index of ≤ 2.5L/min/m2 and at least one sign of tissue hypoperfusion: ScvO2 ≤ 70% and / or urine output \< 2 mL/Kg/h despite adequate fluid replacement.
224197803|NCT04325191|DIETARY_SUPPLEMENT|Melatonin|Daily consumption of a high sodium diet and melatonin for 10 days
224197804|NCT04325191|OTHER|Placebo|aily consumption of a high sodium diet and placebo for 10 days
223747822|NCT05726552|OTHER|Laughter therapy|"Laughter therapy will be applied for 50 minutes, 12 sessions, 3 days a week. The therapy, which starts with the stimulation of the acupuncture points in the palm and acquaintance with hand clapping for an average of 10 minutes, continues with deep breathing and breathing exercises that include diaphragmatic breathing. The childish games section, which is played to reveal and trigger simulated laughter, is the section where laughter starts as if and turns into reality.~The last part is the part where the group makes eye contact for no reason and for no reason, and laughs for at least 3 minutes unconditionally. In the last part, wish meditation and relaxation sessions are performed."
223747823|NCT04194346|PROCEDURE|Lung ultrasound|Healthy volunteers will have lung ultrasonography at 15 predetermined sites for a common volume continuum between 5 and 15 cc/kg. For each volume, 3 respiratory cycles will be recorded.
224197805|NCT00795886|DRUG|RAPAMYCIN|Rapamycin (RAPA, RapamuneR) (sirolimus) is an immunosuppressive agent that was approved by the FDA in 1999. It is a macrocyclic lactone that is structurally similar to Tacrolimus (FK506) and binds to the same intracellular protein as FK506, FKBP1,2,3, but it has an entirely different mechanism of action and a different principal target protein. The target of the RAPA: FKBP complex is the mammalian target of rapamycin (mTOR). Unlike the calcineurin inhibitors cyclosporine (CSA) and - FK506, RAPA exerts its effects by inhibiting growth factor-driven transduction signals in the T-cell response to alloantigen, thus preventing proliferation among T and B lymphocytes3,4.
223506719|NCT04370847|DRUG|Intravenous Syntocinon|Immediately after delivery, syntocinon 10 IU will be added to the running crystalloid solution.
223506720|NCT05285163|BEHAVIORAL|palliative care educatiom|The patients in the intervention group were presented palliative care training in addition to their usual care
223506721|NCT05812157|DIETARY_SUPPLEMENT|Daily dietary supplementation with Fibruline|Supplementation with 12 grams per day of Fibruline reconstituted with 60mL of water, once a day
223506722|NCT05812157|DRUG|Anti-IL-17 therapy|Patients in both groups will be on anti-IL-17 therapy
223506723|NCT05586087|OTHER|Experimental group|The High-Speed Resistance Training program has 16 weeks, with three sessions per week with 50-60min, each session being comprised of five-six exercises, two-three sets, and six-ten reps/exercise. The intensity is gradually increased after each session in accordance with the movement velocity (\>1.3 to 0.75 m/s) representing approximately 20% to 60% of one repetition maximum. Participants execute the exercises rapidly and explosively making all repetitions for each shortening phase (concentric phase) performed as quickly as possible with the lengthening phase of the muscle (eccentric phase) being controlled for 2-3 s. The velocity of the concentric phase in each exercise is monitored through a BEAST™ sensor (Beast Technologies, Brescia, Italy).
223506724|NCT02170012|DRUG|PF-06743649|20 mg tablet once daily dosing for 14 days
223506725|NCT02170012|DRUG|Placebo|Placebo tablet once daily dosing for 14 days
223506726|NCT02170012|DRUG|PF-06743649|To be decided dose, tablet once daily dosing for 14 days
223506727|NCT02170012|DRUG|Placebo|Placebo tablet once daily dosing for 14 days
223506728|NCT02170012|DRUG|PF-06743649|To be decided dose, tablet once daily dosing for 14 days
223506729|NCT02170012|DRUG|Placebo|Placebo tablet once daily dosing for 14 days
223506730|NCT02170012|DRUG|PF-06743649|To be decided dose, tablet once daily dosing for 14 days
223506731|NCT02170012|DRUG|Placebo|Placebo tablet once daily dosing for 14 days
223506732|NCT02170012|DRUG|PF-06743649|To be decided dose, tablet once daily dosing for 14 days
223506733|NCT02170012|DRUG|Placebo|Placebo tablet once daily dosing for 14 days
223506734|NCT04719923|BEHAVIORAL|Children with autism spectrum disorders|Subjects affected by autism spectrum disorders
223506735|NCT05708222|DEVICE|MEB-001|The study is for the development of a software medical device. The study participant will complete study specific questionnaires and undergo a routine sleep study. The medical device will not provide any treatment or interventions.
223506736|NCT06194994|BEHAVIORAL|Parent Management Training|Behavioral parent training program aimed at increasing compliance and positive behaviours while decreasing disruptive behaviours
223506737|NCT06194994|BEHAVIORAL|Tuning Your Temper|Cognitive behavioural treatment for children focusing on arousal reduction, problem solving and cognitive restructuring.
223506738|NCT03631121|DRUG|Basalin to Lantus|continuous glucose monitoring system will used twice when patients are using Basalin and Lantus respectively to assess glycemic variation.
224197806|NCT00860756|OTHER|Relaxation CD|A music CD specifically created for this study to promote effective sleep while deployed. It includes sleep instructions tailored to the military deployment environment. The CD includes a voice directed meditation component that helps focus the listener on relaxation in preparation for sleep. The second track is specifically designed music to promote slow breathing and induce sleep.
224197807|NCT03372265|DRUG|Ropivacaine 0.2%|Perineural infusion using a peripheral nerve block catheter and a portable infusion pump.
224197808|NCT03336918|DRUG|Lithium|"Open-label lithium treatment for Bipolar Disorder Subjects~Healthy Controls only repeat testing - no intervention"
224197809|NCT06995742|DEVICE|Device Array Use|Study participants assigned to the intervention study arm will wear a wireless Bluetooth capable vital sign detection array, with one device externally worn on each of their chest, one finger, and one arm, with healthcare providers using an additional oral temperature probe.
224197810|NCT06995742|DEVICE|Routine Vital Sign Measurement|Study participants randomized to the control arm will have their vital signs obtained by routine means, without use of the wireless vital sign device array.
224197811|NCT00805857|DRUG|Tipranavir|
224197812|NCT00526929|DRUG|darbepoetin alfa|10 mcg NESP administered SC every other week 15 mcg NESP administered SC every other week 20 mcg NESP administered SC every other week 30 mcg NESP administered SC every other week 40 mcg NESP administered SC every other week 50 mcg NESP administered SC every other week 60 mcg NESP administered SC every other week 80 mcg NESP administered SC every other week 100 mcg NESP administered SC every other week
224197813|NCT01477541|OTHER|PM/ON integration|Professional midwives or obstetric nurses are integrated into clinic staff and delivering services.
224197814|NCT05230342|DIETARY_SUPPLEMENT|A package containing a mix of functional foods|Participants will be provided with a nutritional strategy based on functional foods to use over the 2 week trial. These will be nopal, chía seeds, inulin, soy protein and genistein.
223596184|NCT02568592|DIETARY_SUPPLEMENT|Normal + Extra Fat|Normal + Extra Fat - Carbohydrate (50%), Fat (65%), Protein (15%). Carbohydrate and protein intake identical in absolute amounts to NORMAL, with an additional 30% extra energy coming from fat.
223596185|NCT03465267|DEVICE|Armeo power|"Intervention with Armeo power rehabilitation robot for upper extremity (made by Hocoma), which provide assistive force.~The intervention was done 4 weeks, 5 times/week, 30 minutes/day."
223596186|NCT03465267|DEVICE|Armeo spring|"Intervention with Armeo spring rehabilitation robot for upper extremity (made by Hocoma), which is operated only by participants, without any assistive force from robot.~The intervention was done 4 weeks, 5 times/week, 30 minutes/day."
223596187|NCT06525233|OTHER|Physiotherapy and rehabilitation|The aerobic exercise is very crucial part of cardiac rehabilitation. This study compares the effects of interval and continuous training which are the two types of aerobic training on persons' life quality and exercise capacity diagnosed coronary artery disease patients.
224197815|NCT05230342|OTHER|Placebo ingredient group|The control group will receive a comparable set of food items that contain an equivalent number of calories per portion but without the added functional ingredients
224197816|NCT06674629|DEVICE|High flow oxygen therapy|Application of high flow oxygen therapy through asymmetric cannula at 40 and 60 L/m
224197817|NCT00024271|BIOLOGICAL|recombinant interferon gamma|
224197818|NCT00024271|DRUG|cisplatin|
224197819|NCT00024271|DRUG|doxorubicin hydrochloride|
224197820|NCT00024271|DRUG|gemcitabine hydrochloride|
224197821|NCT00024271|DRUG|mitomycin C|
224197822|NCT00024271|PROCEDURE|conventional surgery|
223596188|NCT04564677|DEVICE|Ifabond (Péters surgical)|Ifabond (Péters surgical) is a CE-marked synthetic surgical glue for internal and external use. The glue is non-toxic, biocompatible and biodegradable. It is commercially available and can be used for mesh fixation, as tissue adhesive, for sealing of sutured tissue and for hemostasis.
223596189|NCT01959243|DRUG|Brimonidine Tartrate|Ophthalmic solution to be applied as directed.
223747824|NCT03605797|OTHER|follow up of cases fixed by posterior tension band plate|Follow up of the reduction and functional outcome evaluation using the Majeed functional outcome score
224197823|NCT00024271|PROCEDURE|hyperthermia treatment|
224197824|NCT00024271|RADIATION|radiation therapy|
224197825|NCT03826771|BEHAVIORAL|Power training|high-intensity lower extremity resistance training
223596190|NCT01959243|DRUG|Vehicle|Ophthalmic solution to be applied as directed.
224197826|NCT03826771|BEHAVIORAL|Stretching|upper and lower body range of motion exercises
224197827|NCT06999109|BEHAVIORAL|TEAM-LEADS|TEAM-LEADS will be an online, self-administered intervention for stress reduction and cardiovascular health behavior promotion in adolescents and young adults with juvenile-onset systemic lupus erythematosus and dermatomyositis
224197828|NCT07000409|OTHER|Medical management regimen|Patients will receive the standard medical regimen alone.
224197829|NCT07000409|OTHER|Erector spinae plane (ESP) block|Patients will receive erector spinae plane (ESP) block with betamethasone with standard medical regimen.
224197830|NCT06999707|RADIATION|Photon radiotherapy|"* 39.6-72.6 Gy in 22 fractions for tumors ≤1 cm from hepatic hilum, bowel, and heart.~* 30-66 Gy in 10 fractions for tumors \>1 cm from hepatic hilum, bowel, and heart.~* 27.5-50 Gy in 5 fractions using stereotactic body radiation therapy (SBRT) techniques"
224197831|NCT06999707|DRUG|Tremelimumab|Tremelimumab 300 mg will be administered as an IV infusion for one dose
223596191|NCT01959243|DRUG|Sodium Fluorescein|For use as needed during the study for evaluating corneal damage.
223596192|NCT01959243|DRUG|Fluorescein Sodium and Benoximate Hydrocholoride Ophthalmic Solution USP|For use as needed during the study for intraocular pressure and dilated ophthalmoscopy.
223596193|NCT01227005|BIOLOGICAL|Transfusion of blood products|The intervention will be either a) administration of 1 unit of whole blood plus pooled products or b) administration of component therapy (red blood cells, plasma, platelets).
224197832|NCT06999707|DRUG|Durvalumab|Treatment Duration Guidelines: \* Complete Response (CR): Patients who achieve a CR within one year of treatment will continue durvalumab for a total duration of two years. \* Partial Response (PR): Patients who achieve a PR should continue durvalumab until achieving CR, disease progression (PD), or for a total duration of two years. \* Stable Disease (SD): Patients with SD will receive duvalumab for a total of 6 doses.
223596194|NCT05502510|BEHAVIORAL|MyHealthyPregnancy|MyHealthyPregnancy is a mobile application prescribed to expectant mothers in conjunction with normal prenatal care. The application uses behavioral decision science principles to identify risks of preterm birth and alert the mother and care team of these risks.
223596195|NCT00243984|DRUG|topiramate|
223596196|NCT06192680|DRUG|Liposomal irinotecan|70 mg/m² IV
223596197|NCT06192680|DRUG|Capecitabine|1000 mg/m² PO BID
223596198|NCT06192680|DRUG|Bevacizumab|5mg/kg IV
223596199|NCT05417191|BEHAVIORAL|Conventional fish|Participants initially randomized to this intervention arm will be provided with conventional sea bream fillets and will be asked to consume them twice weekly for 8 weeks. Conventional sea bream fillets will be produced by a fish farming company using standard procedures. Participants will also be instructed to keep the reception of prescribed medications and dietary supplements stable and not to change their lifestyle habits (e.g. other dietary habits besides fish consumption, physical activity habits or sleep habits) during the intervention. After a 6-week wash-out period (no fish consumption), participants will cross over to the other intervention arm.
223596200|NCT05417191|BEHAVIORAL|Enriched fish|Participants initially randomized to this intervention arm will be provided with conventional sea bream fillets and will be asked to consume them twice weekly for 8 weeks. Conventional sea bream fillets will be produced by a fish farming company using a diet enriched with olive pomace. Participants will also be instructed to keep the reception of prescribed medications and dietary supplements stable and not to change their lifestyle habits (e.g. other dietary habits besides fish consumption, physical activity habits or sleep habits) during the intervention. After a 6-week wash-out period (no fish consumption), participants will cross over to the other intervention arm.
223596201|NCT04956653|OTHER|Without additional intervention|Only patients' information was collected
223596202|NCT00048100|PROCEDURE|Apheresis|Apheresis for T-Cell collection
223596203|NCT00048100|BIOLOGICAL|Stem Cell Transplant|Stem cell or marrow infusions of allogeneic donor lymphocytes activated by acute leukemia derived dendritic cells (DC/ADL).
223596204|NCT00629798|DRUG|Busulfan, Melphalan, Fludarabine, Anti-Thymocyte Globulin, Palifermin, Stem cell transplant|Patients will receive Palifermin 60 mcg/kg/day IV on three consecutive days with the last dose administered no less than 24 and no more than 48 hr prior to start of cytoreduction. The preparative regimen to be used for transplants will consist: of busulfan administered in 12 doses over three days of 0.8 mg/kg IV for patients \> or = to 4 years of age or 1.0 mg/kg IV for patients \< 4 years of age; melphalan 70 mg/m2 IV x 2 days; and, fludarabine 25 mg/m2 IV x 5 days
223596205|NCT03080363|DRUG|Bupivacaine|10 ml %0.5 bupivacaine
223596206|NCT03080363|DRUG|Lidocaine|10 ml %2 lidocaine
223596207|NCT02554981|DRUG|Cyclosporine 0.05% Ophthalmic Emulsion|Cyclosporine 0.05% Ophthalmic Emulsion (RESTASIS®) 1 drop instilled in each eye twice a day.
223596208|NCT01108380|PROCEDURE|Plasma pheresis, Right portal vein embolization|"Plasma pheresis : With insertin of 2 intravenous line, plasmapheresis will be done with COBE BCT Inc. It will be performed under supervision of clinical laboratorians and doctors.~Right portal vein : Under ultrasonography guided, left portal vein be punctured. Right portal vein will be embolized by coil or gelfoam."
223596209|NCT01114438|DEVICE|EndoBarrier Gastrointestinal Liner|EndoBarrier Gastrointestinal Liner is intended to remain in vitro for 12 months.
223596210|NCT06529861|DIAGNOSTIC_TEST|[15O]H2O-PET Imaging|This imaging technique will be used to measure myocardial blood flow (MBF) and myocardial blood flow reserve (MBFR) in patients. The PET-CT scan involves the use of the radioactive tracer \[15O\]H2O to visualize blood flow in the heart, providing crucial data on coronary microvascular function.
223596211|NCT06528912|OTHER|Radiotherapy|Follow-up
223596212|NCT00753363|OTHER|Weight Loss|6 months of weight loss
223596213|NCT00753363|OTHER|Aerobic Exercise Training|6 months of aerobic exercise training
223596214|NCT00428844|DRUG|daptomycin|6 mg/kg
223596215|NCT00428844|DRUG|daptomycin|8 mg/kg
223596216|NCT00428844|DRUG|vancomycin|1 gram
223596217|NCT00428844|DRUG|teicoplanin|6 mg/kg; used only at UK sites
223596218|NCT00428844|DRUG|nafcillin|1-2 gram
223596219|NCT00428844|DRUG|oxacillin|1-2 gram
224197833|NCT07002489|DIETARY_SUPPLEMENT|Nuotelande Shuhuajun Study Product|Participants in this arm need to take in the assigned product - Nuotelande Shuhuajun Study Product, 1 capsule per day, for 14 consecutive days. Don't take in similar products in the following 7 days (regression phase).
224197834|NCT02500147|DRUG|Metformin|Metformin ER 500 mg once a day for one week and 1000 mg once a day for the remainder of the six months
223596220|NCT00428844|DRUG|flucloxacillin|1-2 mg
223596221|NCT05801614|OTHER|Low carb diet|Low calori diet
224197835|NCT02500147|DRUG|Placebo|One placebo pill per day for one week and then two placebo pills per day for the remainder of the six months
223596222|NCT02684188|BEHAVIORAL|Enhanced rural discharge and transition|While in the treating hospital, patients from small towns and rural communities are engaged in package of procedures designed to improve the transitions home, including a functional needs assessment that produces a plan that matches available rural community service providers to a patient's transitions needs and the provision of enhanced recovery supports to the patient.
223596223|NCT00005859|DRUG|tipifarnib|
223596224|NCT03450265|DEVICE|Hemopatch|Applied according to the current instruction for use (IFU). According to the IFU, a maximum of 7 Hemopatch 45 x 90 mm patches can be used in adults.
223596225|NCT03450265|DEVICE|Tachosil|Applied according to the current instruction for use (IFU).
223596226|NCT00488826|BIOLOGICAL|7-valent pneumococcal conjugate vaccine|
223596227|NCT00488826|BIOLOGICAL|Diptheria and tetanus toxoids and accelular pertussis vaccine (DTaP)|
223596228|NCT03032549|DIETARY_SUPPLEMENT|RTD|Ready to Drink Supplement
223596229|NCT03032549|DIETARY_SUPPLEMENT|Placebo|Placebo
223596230|NCT05700227|RADIATION|Daily Adaptive External Beam Radiation Therapy|Daily adaptive external beam radiation therapy delivered on Varian Ethos treatment system.
223596231|NCT02292706|DRUG|Sofosbuvir|Exposure of interest for participants who received sofosbuvir in a previous Gilead study for chronic HCV infection.
223596232|NCT02292706|DRUG|Ribavirin|
223596233|NCT02292706|DRUG|LDV/SOF|Exposure of interest for participants who received LDV/SOF in a previous Gilead study for chronic HCV infection.
224197836|NCT07000656|DEVICE|Micturition Desire-Relaxation Training Device|The device was developed by Shanghai Children's Medical Center in collaboration with Shanghai University of Engineering Science. It plays relaxation videos through a VR device and monitors the subjects' brain waves in real time using electroencephalography to evaluate their relaxation levels. The relaxation material is adjusted accordingly, and urination is recorded after training. Urine is collected and analyzed with a flow meter, generating a diagnostic report.
224197837|NCT07000656|DEVICE|Sham device|Participants diagnosed with nocturnal enuresis, daytime urinary incontinence, and urinary frequency will be screened at Shanghai Children's Medical Center, and eligible patients will be recruited. Participants will be randomly assigned to the sham training group, in which they will wear the device without powering it on for 10 minutes each session, 5-10 times a day, for 4 weeks.
223596234|NCT02292706|DRUG|SOF/VEL|Exposure of interest for participants who received SOF/VEL in a previous Gilead study for chronic HCV infection.
223596235|NCT02292706|DRUG|SOF/VEL/VOX|Exposure of interest for participants who received SOF/VEL/VOX in a previous Gilead study for chronic HCV infection.
223596236|NCT02292706|DRUG|Other SOF-Based Regimen|"The other SOF-based regimens may have included the following:~* BMS-790052 (Daclatasvir) + GS-7977 (SOF) with or without RBV~* LDV/SOF + GS-9669, GS-7977 (SOF) + with or without RBV + TMC-435 (Simeprevir)~* LDV/SOF + Vedroprevir (VDV), LDV/SOF + GS-9669 (250 mg and 500 mg)~* LDV/SOF + VDV + RBV~* Simeprevir + SOF~* TMC-435 (Simeprevir) + VEL/SOF"
223596237|NCT02292706|OTHER|Ineligible parent treatment|Participants were enrolled from ineligible parent treatment group.
223596238|NCT01378468|OTHER|"oral triglyceride tolerance test (not a therapeutic intervention as such but a new diagnostic test)"|see Ebinger et al., IJS, 2010
223596239|NCT01229722|DEVICE|Beeper|Beepers are handheld portable devices which can be attached to a belt. At regular intervals corresponding to the participant's preferred reminder time, they buzz for a few minutes or until the participant presses a button to stop the buzzing.
223596240|NCT01229722|DEVICE|ARemind|ARemind will personalize reminder messages based on adherence levels and facilitate patient phone calls with social workers/adherence counselors when appropriate. It will also consist of a text-messaging or interactive voice response (IVR) or phone-based pill count remote adherence assessment module.
223596241|NCT02725866|DRUG|Paritaprevir/ritonavir/ombitasvir|Co-formulated tablet
223596242|NCT02725866|DRUG|Dasabuvir|Tablet
223596243|NCT02725866|DRUG|Ribavirin|Tablet
223596244|NCT01549977|DRUG|Febuxostat|Febuxostat tablets
223596245|NCT01549977|DRUG|Placebo|Febuxostat placebo-matching tablets
223596246|NCT05556577|DRUG|investigational medicine product (IMP)|Investigational medicine product (IMP) received at SURMOUNT-CN trial
223596247|NCT05556577|OTHER|placebo|Placebo received at SURMOUNT-CN trial
223596248|NCT02161419|DRUG|Roniciclib (BAY1000394)|Patients will receive roniciclib treatment as a 3 days on / 4 days schedule off with two 2.5 mg tablets twice daily for a total dose of 10.0 mg/day during 6 cycles (21 days each) of chemotherapy with Carboplatin/etoposide or Cisplatin/etoposide and continue thereafter as monotherapy until tumor progression, unacceptable toxicity, death, consent withdrawal, or withdrawal from the study.
223596249|NCT02161419|DRUG|Placebo|Patients will receive placebo treatment as a 3 days on / 4 days schedule off with two tablets twice daily during 6 cycles (21 days each) of chemotherapy with Carboplatin/etoposide or Cisplatin/etoposide and continue thereafter as monotherapy until tumor progression, unacceptable toxicity, death, consent withdrawal, or withdrawal from the study
223596250|NCT02413047|DRUG|Azathioprine|Medication will be given in pill form to patients to take daily as long as the patient has not been intolerant to it in the past.
223596251|NCT02413047|DRUG|6 mercaptopurine|Medication will be given in pill form to patients to take daily as long as the patient has not been intolerant to it in the past as an alternative to imuran
223596252|NCT02413047|DRUG|Methotrexate|Medication will be given in subcutaneous injection form once a week if the patient cannot take imuran or 6 mercaptopurine.
224197838|NCT05460832|DRUG|MBS2320 5 mg|Oral capsule
223596253|NCT03595527|DIAGNOSTIC_TEST|HIV and HCV screening|HIV test: ARCHITECT HIV Ag/Ab Combo, Abbott HCV test: ARCHITECT Anti-HCV, Abbott
223596254|NCT04443166|COMBINATION_PRODUCT|A platelet-rich plasma (PRP)+ hyaluronic acid (HA) program|a combination of intra-articular knee injection with platelet-rich plasma (PRP) and hyaluronic acid (HA)
223596255|NCT05825976|DIETARY_SUPPLEMENT|Omega-3 Fatty ACids|Intervention consists of two different doses of omega-3: high concentration (Intervention group 1) and low concentration (Intervention group 2).
223596256|NCT05825976|OTHER|Control|Supplementation with extra virgin olive oil as a for of positive placebo control.
223596257|NCT00379054|BEHAVIORAL|telephone based skills training intervention|
223596258|NCT00671606|PROCEDURE|Intraoperative Lymphatic Mapping|Intraoperative hysteroscopic injection of patent blue dye and radiocolloid for detection of sentinel lymph nodes.
223596259|NCT02303860|DRUG|ORM-12741 MR A|Modified release formulation of ORM-12741
223596260|NCT02303860|DRUG|ORM-12741 MR B|Modified release formulation of ORM-12741
223596261|NCT02303860|DRUG|ORM-12741 IR|Immediately release formulation of ORM-12741
223596262|NCT03424603|DRUG|STRO-001|intravenous antibody drug conjugate
224197839|NCT05460832|DRUG|MBS2320 20 mg|Oral capsule
224197840|NCT05460832|DRUG|MBS2320 40 mg|Oral capsule
224197841|NCT05460832|DRUG|Placebo|Oral capsule
223596263|NCT05856019|OTHER|J Stroke Myofascial Release|Group A will receive J stroke myofascial release on planter fascia (with hot pack for 10-15 minutes on calf) 3 sessions per week for 4 weeks.
223596264|NCT05856019|OTHER|Ischemic Release on Gastrocnemius through Dry Cupping|Group B will ischemic release on gastrocnemius (with hot pack for 10-15 minutes on calf) 3 sessions per week for 4 weeks.
223596265|NCT03043651|DRUG|Oral treprostinil|Sustained-release oral tablets for TID administration
223747825|NCT05404373|OTHER|Normobaric Hyperoxia (NBO)|NBO was inhaled as early as possible before revascularization, and inhaled for 1h/2h/4h according to different groups
223747826|NCT05404373|OTHER|Low flow oxygen|immediately given oxygen inhalation at a ventilation rate of 1L/ min using a oxygen storage mask and keep giving oxygen for 4 hours.
223747827|NCT03836482|DEVICE|Selective Cytopheretic Device|Treatment will be delivered for 4 hours a day for up to 6 consecutive days.
224197842|NCT05397002|PROCEDURE|patient specific inverted L mandibular osteotomy modified with inferior alveolar nerve relocation|preoperative CBCT was requested for virtual planning and fabrication of cutting and drilling guides. Cutting lines were outlined to be consisted of four cuts; lateral ostectomy to uncover and lateralize the inferior alveolar nerve (IAN), posterior cut run horizontally from the anterior border of the ramus to a point just above the mandibular foramen, two anterior vertical cuts run from the anterior end of the lateral ostectomy to the inferior mandibular border. The guide was removed and the osteotomy lines were completed then the mandibular setback was oriented and fixed using pre-bent plates osteosynthesis. Plane transfer was checked using CBCT and Inferior alveolar nerve function was assessed.
224197843|NCT06672159|DEVICE|Two defibrillators|DSED procedure consists of pads placed in anterior-lateral position, and in anterior-posterior position. Defibrillations will be given in rapid sequence, less than a second apart. All other aspects of resuscitation in accordance to existing guidelines.
224197844|NCT06672159|DEVICE|One defibrillator|Standard OHCA treatment according to existing guidelines.
224197845|NCT07005635|OTHER|Listening Music|Music group students listen Beethoven Moonlight Sonata during scrubing hands
224197846|NCT07005635|OTHER|Alarm|Alarm group students listen alarm sound at the end of the (2 min) during scrubing hands
224197847|NCT07005440|OTHER|Functional Training|Each training session includes a preparation phase (warm-up, neuromuscular activation, dynamic stretching, and core activation), followed by two main modules: motor skill development (walking, jumping, crawling, throwing, pushing, catching) and physical fitness (balance, agility, endurance). Sessions conclude with motor skill consolidation and static stretching. Training spans 12 weeks: once weekly during weeks 1-8, and twice weekly during weeks 9-12
224197848|NCT07005440|OTHER|Dynamic Play Exercise|This includes warm-up (for 3-5 mins), rhythmic exercise (5-10 mins), games (7-10 mins) and free play exercises (10-15 mins). This group will receive the lesson once a week during week 1-8 and twice a week during 9-12 weeks
223596266|NCT04383054|BEHAVIORAL|'More minutes' conversation (Moving medicine)|For the interventions in this study we have chosen to use the Moving Medicine conversation tools because they are an evidence-based PA intervention tool. The Moving Medicine 'more minutes' conversation tool initially involves the investigator exploring the participant's understanding of PA. Improving patients' knowledge of the benefits of PA may empower them to increase their PAL because knowledge of the benefits of PA may motivate patients to increase their PAL. The division of the Moving Medicine conversation tools into chronic health conditions is important because it will allow the investigator to explore topics relating to PA which are specific to the participant's own medical co-morbidities. For example, in a patient with known ischaemic heart disease the investigator could discuss how PA helps to prevent the risk of further heart attacks and the development of heart failure (Moving Medicine).
223596267|NCT04383054|BEHAVIORAL|'one minute' conversation (Moving medicine)|For the interventions in this study we have chosen to use the Moving Medicine conversation tools because they are an evidence-based PA intervention tool. The Moving Medicine 'more minutes' conversation tool initially involves the investigator exploring the participant's understanding of PA. Improving patients' knowledge of the benefits of PA may empower them to increase their PAL because knowledge of the benefits of PA may motivate patients to increase their PAL. The division of the Moving Medicine conversation tools into chronic health conditions is important because it will allow the investigator to explore topics relating to PA which are specific to the participant's own medical co-morbidities. For example, in a patient with known ischaemic heart disease the investigator could discuss how PA helps to prevent the risk of further heart attacks and the development of heart failure (Moving Medicine).
223596268|NCT05281055|PROCEDURE|Endovascular thrombectomy|Timely thrombectomy for acute ischemic stroke patients with large vessel occlusion by either stent retriever, thrombosuction, others, or combination methods.
223596269|NCT04196673|DEVICE|Alcon SN60WF|Implantation of an intraocular lens Alcon SN60WF
223596270|NCT04196673|DEVICE|Hoya Vivinex|Implantation of an intraocular lens Hoya Vivinex
223596271|NCT03605316|PROCEDURE|Deep brain stimulation (DBS)|Neurosurgical treatment by stereotactic implantation of electrodes in the brain that affects the functioning of subcortical neuronal circuits
223596272|NCT00486382|BIOLOGICAL|Leish-111f + MPL-SE Adjuvant|
223596273|NCT02841462|DEVICE|Intra-bursal thermal ablation|A single 3-minute intra-bursal perfusion of a physiological saline solution at increasing temperatures using the Ablaflex device.
224310941|NCT03722667|BEHAVIORAL|Technology-based Component|This intervention is comprised of three technology components: a) six weekly web-based modules focused on improving knowledge and skills to manage hypertension; (b) personalized medication adherence support (SMS reminder messages, adherence feedback, health and lifestyle tips) through Medisafe app; and (c) self-monitoring blood pressure to support self-managing hypertension.
224310942|NCT03722667|BEHAVIORAL|TechSupport|"The TechSupport intervention is the combination of both an behavioral and emotional intervention.~Technology-based Components: This intervention is comprised of three technology components: a) six weekly web-based modules focused on improving knowledge and skills to manage hypertension; (b) personalized medication adherence support (SMS reminder messages, adherence feedback, health and lifestyle tips) through Medisafe app; and (c) self-monitoring blood pressure to support self-managing hypertension.~Positive Psychological Training (PPT): This intervention will include a structured online training and skill building for PPT accessible by smartphone on techniques to promote optimism, resilience, well-being, and self-confidence."
224310943|NCT00198250|DRUG|venlafaxine|Venlafaxine taper dose from 37.5mg for one week to 75 mg for 3 weeks
223596274|NCT00435851|DRUG|Thyrogen, thyroid hormone withdrawal, iode 131|
223596275|NCT01000324|PROCEDURE|Blood sampling|Blood sampling at Year 16, 17, 18, 19 and 20 and at the time of challenge dose administration and 14 days and one month after challenge dose administration (if challenge dose needed).
223596276|NCT01000324|BIOLOGICAL|Engerix-B|Engerix-B will be administered to subjects who are not seroprotected against hepatitis B
223596277|NCT01000324|BIOLOGICAL|Havrix|Havrix will be administered to subjects who are seronegative for anti-HAV antibodies
223596278|NCT04450095|DRUG|Ambrisentan 10 MG|be given once a day for 5 days, starting 48 hours before surgery
223596279|NCT02316886|DEVICE|Coronary intervention|bioabsorbable vascular scaffolds (BVS) (early period) or everolimus-eluting stents (middle and late period) + Optimal Medical Treatment
223596280|NCT02316886|DRUG|Optimal Medical treatment|
223596281|NCT05626127|OTHER|No interventions|As this is a observational study, there are no interventions.
224197849|NCT07007507|BEHAVIORAL|Aerobic Exercise|Aerobic exercise is performed by repeating sequences of light to moderate intensity activities for extended periods of time.(12) The American Heart Association recommends that for stroke survivors, exercise intensity should be 40%-70% of VO2 reserve or heart rate (HR) reserve; 55%-80% HR max; RPE 11-14 Borg rating of perceived exertion (RPE) scale 6-20 scale, 3-5 days/week, 30-60 min/session (or multiple 10 min sessions)
224197850|NCT07007156|OTHER|NECPAL positive|This group has a positive result for NECPAL scale
224197851|NCT07005830|BEHAVIORAL|Twin Hearts Meditation|Twin Hearts Meditation (THM) is a 21-minute guided meditation practice developed by Master Choa Kok Sui as part of Pranic Healing \& Arhatic Yoga (Sui, 2005).
224197852|NCT06545019|BEHAVIORAL|Informative Video on Perioperative Anxiety and Maternal Satisfaction|An informative video designed to address potential sources of perioperative anxiety and dissatisfaction during elective lower segment caesarean section under spinal anaesthesia. The video provides details about the procedure, expected sensations, and management of discomfort to enhance patient understanding and reduce anxiety. It is administered to the intervention group of patients scheduled for elective caesarean section, allowing them to view it on their personal devices before the surgery.
224197853|NCT07005622|OTHER|O2 Trainer|The O2 Trainer uses varying caps to limit airflow during inspiration.
223596282|NCT02508324|BIOLOGICAL|haplo-identical cells (donor)|Treatment: Haplo-identical healthy related donor. i.e. Parent, child, sibling, possibly third degree or further removed relative (cousin, aunt, nephew etc). They will be collected using standard methods and approximately 3 x10\^6 CD34 cells/kg will be infused within 72 hours after completion of the treatment.
223596283|NCT02508324|BIOLOGICAL|umbilical cord blood unit (CBU)|Treatment: The CBU unit must supply a minimum of 0.5 x107/kg and a maximum of 2.5x107/kg nucleated cell dose pre-cryopreservation. The unit must match at a minimum of 4 of 6 at HLA-A, -B antigens, -DRB1 alleles with the recipient. Mismatches (0-2) can be at any loci -. Although molecular level typing will be available for the patient and the CBU unit, a match is defined at intermediate resolution for HLA-A and -B and at high resolution for -DRB1. The CBU donor will also have undergone HLA typing of the mother, thus allowing determination of the CBU-IPA and NIMA. CBU grafts used in this study will be investigational units that meet all criteria for clinical use. Better matching units will be preferred over less matching units as long as the CBU dose exceeds 0.5 x107 nucleated blood cells/kg
223596284|NCT06319859|DRUG|Morphine|The patients will receive 0.1 mg morphine with 15 mg heavy bupivacaine intrathecally
223596285|NCT06319859|DRUG|Placebo|The patients will receive 15 mg heavy bupivacaine with 0.1 ml saline intrathecally
223596286|NCT06128122|PROCEDURE|Intrarticular and subcutaneous dextrose injection with timed measurement of dextrose levels|"Step one: 30 mL of 12.5%/0.1% lidocaine will be injected into the knee using an inferomedial approach. Using ultrasound guidance, a 20-gauge 2-inch I.V. catheter will be placed in the suprapatellar pouch, by which samples of synovial fluid from the pouch will be withdrawn and analyzed for glucose level.~Step two: 3 mL of D5W will be injected into a marked spot on the back of the upper arm. A sensor/transmitter (Dexcom G7 Dexcom) is placed at the site of injection. The sensor/transmitter will begin providing dextrose levels at 5 minute intervals beginning one-half hour after placement of the sensor/transmitter, transmitted to a paired smart phone."
223596287|NCT03597061|BEHAVIORAL|Healthy Start to Feeding|The intervention provides parent education and skills training on a responsive feeding approach to introduction of healthy foods in infancy. Session content is manualized and administered by interventionists with expertise in child development and behavioral strategies for managing child eating behaviors under the supervision of a licensed clinical child psychologist and pediatric occupational therapist. Sessions are conducted individually with participants and primary caregivers and include educational content, handouts and instructions, modeling of skills by the interventionist, caregiver practicing of skills in session, establishment of behavioral goals, and problem solving barriers to implementation of treatment content. Content will include topics such as allowing infants' own hunger and satiety cues to guide the feeding experience, introducing healthy foods, parental attunement to infant satiety cues, and promoting infants' own self-feeding.
223596288|NCT04166617|OTHER|Conventional therapy|conventional physcial therapy rehabilitation for the upper limb
223596289|NCT04166617|OTHER|Leap motion plus conventional therapya|leap motion plus conventional physcial therapy rehabilitation for the upper limb
223596290|NCT04919096|DRUG|SCB-420|Subjects randomised to SCB-420 arm will receive a total of 3 doses of SCB-420 as an intravitreal injection of 2 mg into the study eye every 4 weeks on Day 1, Week 4, and Week 8.
223596291|NCT04919096|DRUG|Aflibercept|Subjects randomised to Aflibercept arm will receive a total of 3 doses of Aflibercept as an intravitreal injection of 2 mg into the study eye every 4 weeks on Day 1, Week 4, and Week 8.
223596292|NCT00411632|DRUG|Bexarotene|400 mg/m\^2 by mouth daily x 28 Days
223596293|NCT00411632|DRUG|Erlotinib|150 mg by mouth daily x 28 Days
223596294|NCT00761527|DRUG|Desloratadine Syrup|"Desloratadine (Aerius) Syrup;~Dose selection was based upon the age of the participant, and the timing of dose for each participant was once daily (QD) as described in the Product Insert for 14 days:~* Children 6 through 11 years of age, 5 mL (milliliters) of Aerius Syrup (2.5 mg \[milligrams\] of desloratadine)~* Children 1 through 5 years of age, 2.5 mL of Aerius Syrup (1.25 mg of desloratadine)~* Children 6 months to 11 months of age, 2 mL of Aerius Syrup (1 mg of desloratadine)"
223596295|NCT03265782|DRUG|ibuprofen|drug was adminstred with a loading dose 10 mg/kg/day followed by 5 mg/kg/day in 2 doses with 24 hrs apart for 3 days
223596296|NCT03265782|DRUG|paracetamol|drug was administred for 3 consequetive days in a dosev 15 mg/kg/dose every 6 hrs and follow up echo was done after 3 days
224197854|NCT07005622|OTHER|Deep breathing|Comparator/placebo for the control group
224197855|NCT07006194|DIETARY_SUPPLEMENT|Nicotinamide Tablet|One nicotinamide tablet per day during the month preceding surgery
224197856|NCT07005336|DRUG|Uliledlimab|30 mg/kg, administered on Days 1 and 8 of Cycle 1 (C1D1 and C1D8), then once every 3 weeks (Q3W) starting from C2D1,at most 35 cycles
224197857|NCT07005336|DRUG|Sintilimab|Intravenous infusion at a recommended dose of 200 mg once every 3 weeks，at most 35 cycles
224197858|NCT07005336|DRUG|Pemetrexed|Intravenously at a recommended dose of 500 mg/m2 body surface area (BSA) ,once every 3 weeks until the disease progresses.
224197859|NCT07005336|DRUG|Gemcitabine|1000 mg/m2, administered on Days 1 and 8 ,once every 3 weeks (Q3W) for 4 cycles
224310944|NCT05908630|OTHER|Hypothermia|"Accidental hypothermia is defined as: an involuntary drop in core body temperature \<35C"
224197860|NCT07005336|DRUG|Cisplatin Or Carboplatin|"Cisplatin: 5 mg/m2 administered intravenously every 3-4 weeks for 4 cycles~Carboplatin:75 mg/m2, administered intravenously every 3-4 weeks for 4 cycles"
223596297|NCT00934674|DRUG|SKI-606 (Bosutinib)|"Arm 1 - Commercial Tablet manufactured by Excella~Arm 2 - Clinical Tablet manufactured by Wyeth Montreal"
224197861|NCT07006285|OTHER|Measure of T2 biomarkers|"T2 Biomarkers are estimated via induced sputum:~Sputum is induced through increasing concentrations from 0.9 or 3% to 4% and 5% of hypertonic solution.~Assessment of nonspecific bronchial hyperresponsiveness is realized by metacholine challenge"
224197862|NCT06303713|DRUG|Carboplatin|Platinum coordination compound, premixed aqueous solution of 10mg/ML, via intravenous (into the vein) infusion per protocol.
224197863|NCT06303713|DRUG|177Lu-PSMA-617|Radioligand therapy, single-dose vial, via intravenous (into the vein) infusion per protocol.
223596298|NCT01477112|DIETARY_SUPPLEMENT|Betacarotene|6 mg betacarotene in caplets for 45 days (daily)and reevaluate parameters 30 days after finishing supplementation
223596299|NCT01477112|DIETARY_SUPPLEMENT|Controls. No treatment|Evaluate at time 0, 45 days and 75 days, but without receiving betacarotene supplements
223596300|NCT02904018|OTHER|teleconsultation|Patients performing oral care required as a result of their diagnosis by teleconsultation in vulnerable populations (elderly, disabled adults).
223596301|NCT02599233|OTHER|Telephone conctact at 3 months|Patients will be contacted at 3 months post-surgery for pain questionnaires.
223596302|NCT02599233|OTHER|In hospital pain evaluation|Patients will evaluate their pain levels via a verbal numerical scale on days 1(or-1), 2, 3, 4, 5, 6 \& 7.
223596303|NCT02599233|OTHER|In hospital questionnaires|Patients are required to fill out the HADS and PCS questionnaires between on day -1 or +1.
223596304|NCT02050087|DEVICE|Simple sling.|
223596305|NCT02050087|DEVICE|Neutral brace|
223596306|NCT05845853|OTHER|scapular PNF technique|"PNF Technique is based on movement patterns to facilitate and correct sensory-motor function,then correct the impaired impulses emerging from proprioceptive receptors in the muscle. Therefore, it decreases pain and improve the strength of muscles.~PNF position renders a greater amount of sensory input coming from the periphery than that in the neutral position ."
223596307|NCT01431963|DRUG|Lamictal|No comparison.
223596308|NCT00554372|GENETIC|JX-594: Recombinant vaccinia virus (TK-deletion plus GM-CSF)|Patients will be randomized 1:1 to one of two total doses (1e8 or 1e9 pfu)and injected intratumorally in 1-5 intrahepatic tumors on Days 1, 15, and 29.
223596309|NCT02725541|DRUG|Trastuzumab emtansine|HER2-targeted antibody drug conjugate of trastuzumab and DM1
223596310|NCT03599323|DRUG|Clotrimazole 1% (Empecid L Cream, BAYB5097)|Consumers who self-select and are then deemed appropriate users of the product by the pharmacist for treatment of Vulvar itching with rash due to recurrent vaginal candida (only in patients previously diagnosed and treated by a doctor).
223596311|NCT05583019|DEVICE|GENEActiv Accelerometry Device|a watch like wearable sensor
223596312|NCT05583019|DEVICE|Centrepoint Insights Watch (CPIW) Accelerometry Device|a watch like wearable sensor
223596313|NCT05583019|DEVICE|Apple Watch Accelerometry Device|a watch like wearable sensor
223596314|NCT05583019|DEVICE|Polysomnography|Sleep monitor
223596315|NCT05583019|DEVICE|Videography|Thermal Camera
223596316|NCT03123991|BEHAVIORAL|UP-A adapted as a preventive intervention|The Spanish Version of the Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders in Adolescents (UP-A) adapted as a school-based anxiety and depression preventive intervention. The UP-A (Ehrenreich-May et al., 2016) is a transdiagnostic anxiety and depressive disorders treatment protocol that implement a set of core principles to address common factors underlying youth anxiety and depressive symptoms in an individual setting. Core modules of the UP-A include: (1) Building and Keeping Motivation; (2) Getting to Know Your Emotions and Behaviors; (3) Behavioral Activation; (4) Sensational Awareness; (5) Being Flexible In Your Thinking; (6) Awareness of Emotional Experiences; (7) Situational Emotion Exposures and (8) Keeping it Going - Maintaining Your Gains.
223596317|NCT03123991|BEHAVIORAL|Same than experimental group (EG), after EG finishes|The Spanish Version of the Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders in Adolescents (UP-A) adapted as a school-based anxiety and depression preventive intervention. The UP-A (Ehrenreich-May et al., 2016) is a transdiagnostic anxiety and depressive disorders treatment protocol that implement a set of core principles to address common factors underlying youth anxiety and depressive symptoms in an individual setting. Core modules of the UP-A include: (1) Building and Keeping Motivation; (2) Getting to Know Your Emotions and Behaviors; (3) Behavioral Activation; (4) Sensational Awareness; (5) Being Flexible In Your Thinking; (6) Awareness of Emotional Experiences; (7) Situational Emotion Exposures and (8) Keeping it Going - Maintaining Your Gains.
223596318|NCT02567994|DRUG|Teneligliptin|Subjects will visit the center on Week 4, 12 and 24 during the entire 24-week treatment period. Total study duration will be approximately 28weeks and the subjects will be to practice exercise/diet control together.
223596319|NCT02412332|PROCEDURE|Bone marrow harvesting|Approximately 200 mL of bone marrow will be surgically collect from the iliac crest (pelvis) of the patient under spinal anesthesia.
223596320|NCT02412332|PROCEDURE|Liposuction|Approximately 50 mL of adipose tissue (fat) will be surgically collected from the abdominal region of the patient under spinal anesthesia.
223596321|NCT05211817|BEHAVIORAL|Complex lifestyle intervention|Volunteers will undergo a 3-month comprehensive lifestyle modification, consisting of a combined aerobic-strength training intervention, nutritional and psychological counseling. Regular examinations (body weight, waist circumference, body composition by bioimpedance) will be performed every week. Probands in the intervention and control groups will have the opportunity to participate in a long-term program of physical activity at BMC SAS after the end of the study.
223747828|NCT02730572|DRUG|Concerta|This is an observational study. Participants who have been on Concerta for at least 60 days will be observed.
223747829|NCT02730572|DRUG|Concerta AG formulation|This is an observational study. Participants who have been on Concerta for at least 60 days and switch to authorized generic will be observed.
224197864|NCT03153319|DRUG|Adalimumab Injection [Humira]|Investigational Drug
224197865|NCT03153319|DRUG|Saline Solution for Injection|Placebo Comparator
224197866|NCT07005089|PROCEDURE|Laparotomy or laparoscopic ovarian cystectomy|to evaluate diagnostic accuracy of ultrasound and tumors markers in diagnosis of complex ovarian cysts in adolescent with histopathological correlation.
223596322|NCT05211817|DIETARY_SUPPLEMENT|Carnosine|3 months carnosine supplementation (2 g per day) will be given in parallel with a complex lifestyle modification. Carnosine is a dipeptide of beta-alanyl l-histidine, which is found in skeletal muscle and in certain areas of the brain. It is a well-tolerated and approved food supplement in Slovakia. Scientists have extensive experience with the administration of carnosine (deCourten, Ukropcová et al, Obesity 2015 https://doi.org/10.1002/oby.21434; Schon, Ukropcova et al, 2019 DOI: 10.3390 / nu11061196 and others). Carnosine has the potential to positively affect glucose metabolism, and improve the adaptive response to exercise training interventions.
223596323|NCT02133807|PROCEDURE|Specific Lp(a) apheresis|"Specific Lp(a) apheresis procedures were carried out weekly with Lp(a) Lipopak columns (POCARD Ltd., Moscow, Russia) according to the standard protocol"
223596324|NCT02921087|DEVICE|Test Daily Disposable Soft Contact Lenses|Worn daily for 7 +/- 2 days
223596325|NCT02921087|DEVICE|Control Daily Disposable Soft Contact Lenses|Worn daily for 7 +/- 2 days
223596326|NCT00900367|OTHER|high performance liquid chromatography|
223596327|NCT00900367|OTHER|laboratory biomarker analysis|
223596328|NCT00900367|PROCEDURE|spectroscopy|
223596329|NCT05138887|DRUG|Tetrahydrobiopterin|The experimental group1 was administered BH4 orally with a dose of 2 mg/kg.d, once per day, and the experimental group 2 was administered BH4 orally witha dose of 5 mg/kg.d, two times a day (If the drug dose is within the range of 151-250mg, the drug dose is 200mg) or three times a day (If the drug dose is within the range of 251-350mg, the drug dose is 300mg). The oral administration of pills was started on the same day of the first radiation treatment, and ended three months after the treatment ended.
223596330|NCT00687531|DRUG|Mometasone Furoate|Mometasone Furoate 400 mcg once daily, in the evening through 12 weeks.
223596331|NCT00000643|DRUG|Pyrimethamine|
223596332|NCT00000643|DRUG|Leucovorin calcium|
223596333|NCT04651608|BEHAVIORAL|manuel acupressure|Acupressure was applied once by the researcher 30 minutes before applying the chemotherapeutic agent with medium or high emetogenicity to the randomized child. 3 fingers were placed on the child's wrist with their fingers and the region (point P6) between the flexor carpi radians and palmaris longus 1 cm below. Acupressure was applied to the wrist of the child by press for 2 minutes. The same procedure was applied to the other wrist. Then, data were recorded in accordance with the data collection procedure.
223596334|NCT04651608|BEHAVIORAL|sea-band acupressure|30 minutes before applying the chemotherapeutic agent with medium or high emetogenicity to the randomized child, sea-band acupress was applied by the researcher. The P6 point on the wrist was identified and marked with the child's own fingers. A sea band was attached to both wrists of the child by the researcher. The attached sea-band was allowed to remain for 15 minutes and was removed by the researcher at the end of the period. Separate sea-band was attached to each child. Acupress wrist bands, which are produced in separate sizes for adults and children, were used during the application, taking into account the physical development of the child, pediatric for the age range of 5-12, and adult size sea-band for the age of 12. Acupress application with sea-band was done once. Then, data were recorded in accordance with the data collection procedure
223596335|NCT04651608|BEHAVIORAL|placebo manuel acupressure|Placebo manual acupress was applied in the next protocol for the child who was administered manual acupressure.
223596336|NCT04651608|BEHAVIORAL|placebo sea-band|Placebo sea-band was applied in the next protocol for the child who was administered sea-band acupressure.
223596337|NCT00619307|DRUG|Rebif New Formulation + prophylactic Ibuprofen|Subjects, currently on Rebif® 44 mcg three times a week, using Rebiject II as an injection device and having received Rebif® full dose 44 mcg three times a week for at least 6 months, receives systematically 400 mg ibuprofen as prophylactic treatment against flu-like symptoms on days when Rebif New Formulation 44 mcg three times a week is injected
223596338|NCT00619307|DRUG|Rebif New Formulation + ibuprofen PRN|Subjects, currently on Rebif® 44 mcg three times a week, using Rebiject II as an injection device and having received Rebif® full dose 44 mcg three times a week for at least 6 months, should not administer Ibuprofen before the first Rebif New Formulation injection. If flu-like symptoms occur after the 44 mcg Rebif New Formulation injection then the subject can administer 400 mg ibuprofen. This should only be administered after the Rebif New Formulation injection and not before the Rebif New Formulation injection.
223596339|NCT02544659|DRUG|pamidronate disodium|the patients will be administered pamidronate disodium 1 mg/kg, IV, QD, for 3 days, and every 3 month (up to month 6)
223596340|NCT03210961|DRUG|PF-06826647 tablet|PF-06826647 tablet for oral administration
223596341|NCT03210961|DRUG|PF-06826647 oral suspension|PF-06826647 suspension for oral administration (oral suspension to be administered to the 3mg starting dose cohort only)
223596342|NCT03210961|OTHER|Placebo oral solution/suspension|placebo oral solution for the single ascending dose, first cohort only
223596343|NCT03210961|OTHER|Placebo tablet|Matching placebo tablet
223596344|NCT05187819|DIAGNOSTIC_TEST|predictive value of a blood test|Evaluation of the clinical value of a new blood based test for diagnosis of Alzheimer's disease in a general practice population.
223596345|NCT03088527|DRUG|RAD140|RAD140 will be supplied as formulated drug-in-capsules for oral administration.
223596346|NCT05999266|DIAGNOSTIC_TEST|Ultrasonographic Measurements|In patients with or without knee pain, the cartilage thickness measurement of the knee joint will be measured from 3 points by ultrasound. At the same time, Quadriceps and Hamstring muscle thickness measurements of the patients will be made from the midpoints where the muscle thickness is the highest.
223596347|NCT03208634|DEVICE|Robotic intervention|One-month robotic intervention. Twelve sessions, three sessions a week, 40 minutes each. Twenty minutes of fully assisted reaching + 20 minutes of assisted Hand-to-Mouth
223596348|NCT00561288|DRUG|acetaminophen|2 x 1000 mg doses per day
223596349|NCT00561288|OTHER|cornstarch|2 x 1000 mg cornstarch per day
224197867|NCT00270738|PROCEDURE|Indirect training of the PFMs via transversus abdominis|Individual visit: twice a month for 4 months. Exercise regimen: diaphragmatic breathing, tonic activation, muscle strengthening, functional expiratory patterns, and impact activities.
223596350|NCT00940758|DRUG|PEP02|Dose escalation: 50-100 mg/m2 biweekly
223596351|NCT02106871|DRUG|Sildenafil|50mg of Sildenafil daily for 4 weeks
223596352|NCT00602420|DRUG|naproxen|Oral naproxen twice daily for 5-8 days.
223596353|NCT00602420|OTHER|placebo|Oral placebo twice daily for 5-8 days.
223596354|NCT01926990|DEVICE|perfusion computed tomography|Undergo perfusion CT
223596355|NCT04803149|DEVICE|Cooled Radiofrequency|Delivery of energy to ablate sensory nerves via cooled radiofrequency probe
223596356|NCT04803149|DEVICE|Conventional Radiofrequency|Delivery of energy to ablate sensory nerves via standard or conventional radiofrequency probe
223596357|NCT00657982|DRUG|RAD001|10mg BID
223596358|NCT02842164|OTHER|Tension group|
223596359|NCT02842164|OTHER|No tension group|
223596360|NCT02842164|OTHER|Foley catheter Balloon|
223596361|NCT06206993|BEHAVIORAL|Resistance training including the Kieser A5 pelvic floor trainer|In the RECON Study participants of both arms will receive machine-based resistance training. Experimental group will additionally train with Kieser A5 pelvic floor trainer.
223596362|NCT06206993|BEHAVIORAL|Resistance training without pelvic floor biofeedback Kieser A5 pelvic floor trainer|In the RECON Study participants of both arms will receive machine-based resistance training. Active Comparator trains without the pelvic floor biofeedback device A5 and undergo conventional pelvic floor muscle training with a physiotherapist once a week before the resistance training unit starts.
224197868|NCT00270738|PROCEDURE|pelvic floor muscle training|Individual visit: twice a month for 4 months. Exercise: intensive pelvic floor muscle training
224197869|NCT00270738|PROCEDURE|home exercise|PFM exercise at home: at least six high-intensity (near-maximum) contractions 3 times per day at home, with an aim at holding each muscle contraction for 10 seconds, with at least a 10-second rest between contractions.
224197870|NCT06687382|BIOLOGICAL|MBK-01|Initial dose of 4 capsules of MBK-01 (heterologous lyophilized intestinal microbiota coming from healthy donors) orally the first day, followed by a single daily capsule during 16 days. Participants will receive a total dose of 20 capsules of MBK-01.
224197871|NCT06687382|BIOLOGICAL|MBK-01|Initial dose of 4 capsules of MBK-01 (heterologous lyophilized intestinal microbiota coming from healthy donors) orally the first day, followed by a single daily capsule for 16 days and a maintenance dose 3 months after the ending of the initial dose. The maintenance dose is administered the same as the initial dose: 4 capsules of MBK-01 orally the first day, followed by a single daily capsule for 16 days. Participants will receive a total dose of 40 capsules of MBK-01.
224197872|NCT07019688|OTHER|Standard Information|Participants will receive only the standard written information routinely provided prior to dental procedures. This version does not include any additional content related to frequently asked questions.
224197873|NCT07019688|OTHER|Clinician Information|Participants will receive written information prepared by clinicians, which includes responses to the most frequently asked questions collected from patients undergoing same procedures.
223596363|NCT01178268|DEVICE|XIENCE V EECSS|Patients who will receive this stent.
223596364|NCT01178268|DEVICE|CYPHER SELECT PLUS SECSS|Patients who will receive this stent.
223596365|NCT00592124|DRUG|Tenofovir disoproxil fumarate|300 mg tablet daily
223596366|NCT00592124|DRUG|Tenofovir gel|1 gm/100 ml of 1% gel vaginally daily
223596367|NCT00703924|DRUG|WR 279,396|A topical cream containing 15% paromomycin and 0.5% gentamicin. Approximately 0.0005 mL per mm2 of skin lesion
223596368|NCT00703924|DRUG|Placebo|Topical cream vehicle. Approximately 0.0005 mL per mm2 of skin lesion
224197874|NCT07019688|OTHER|AI Info|Participants will receive written information generated by ChatGPT, based on the identified frequently asked questions and formulated specifically for this study.
224197875|NCT06697028|OTHER|Usability and Comparison|PACER will be used to assess cardiorespiratory fitness in individuals with rheumatic diseases. The results will be compared with those of healthy individuals, and the relationship between body composition and VO2 max will be examined.
224197876|NCT07022535|DIAGNOSTIC_TEST|KELIM|"(i) Patients with KELIM \>=1 will receive radiological assessment and undergo interval debulking surgery if the disease is operable.~(ii) Patients with KELIM \<1 will have alternative management, such as addition of bevacizumab or changing to dose-dense chemotherapy, and defer the interval debulking surgery"
224197877|NCT07022535|DRUG|Carboplatin plus Paclitaxel|Chemotherapy as neaodjuvant chemotherapy
224197878|NCT07022535|PROCEDURE|Interval debulking surgery|Interval debulking surgery
223596369|NCT05856981|DRUG|ADU-1805|anti-SIRPα monoclonal antibody
223596370|NCT05856981|DRUG|Pembrolizumab|Keytruda
223596371|NCT00002868|BIOLOGICAL|filgrastim|
223596372|NCT00002868|BIOLOGICAL|recombinant interferon alfa|
223596373|NCT00002868|DRUG|busulfan|
223596374|NCT00002868|DRUG|cytarabine|
223596375|NCT00002868|DRUG|etoposide|
223596376|NCT00002868|DRUG|hydroxyurea|
223596377|NCT00002868|DRUG|idarubicin|
223596378|NCT00002868|PROCEDURE|peripheral blood stem cell transplantation|
223596379|NCT01131910|BIOLOGICAL|TBE-vaccine|Solution of 0.5 ml for intramuscular use. Given in 2 doses separated by 1 month to healthy individuals less than 60 years old. (3 doses 0+1+3 months to those are 60 and above in Sweden)
223596380|NCT01131910|BIOLOGICAL|TBE-vaccine|Solution for injection 0.5 ml im. 2 or 3 doses first years, 1 dose next year
223596381|NCT01131910|BIOLOGICAL|Vaccination against TBE|0.5 ml im at 0 and 1 month ( less than 60 years old) or 0 and 1 and 3 months (at least 60 years old)
223596382|NCT00323648|DRUG|Whether or not giving postoperatively antibiotics to patients with an uncomplicated acute cholecystitis|Whether or not giving postoperatively antibiotics to patients with an uncomplicated acute cholecystitis.
223596383|NCT01606969|DRUG|scalp infiltration solution|Dex group: Dexmedetomidine 2mcg/ml-containing 1% lidocaine scalp injection by neurosurgeon(dosage: according to incision length)
223596384|NCT01606969|DRUG|scalp infiltration solution|1:100000 epinephrine-containing 1% lidocaine scalp injection by neurosurgeon(dosage: according to incision length)
223596385|NCT05314465|OTHER|Median nerve mobilization|Median nerve mobilization was given 20 oscillations per minute for 3 times \& repeated 3 times with a pause of 1 minute between each sets for 5times/week for 4weeks.
223596386|NCT00253123|DRUG|risperidone|
223596387|NCT03712683|DRUG|Thyroxine|Thyroxine was prescribed with the diagnosis of SCH and continued when pregnancy was confirmed
223596388|NCT06344429|DEVICE|Stellest Lenses|"All subjects are recruited and randomized to 3 treatment groups at the baseline visit.~A Group：Stellest Lenses spectacle (ST)"
223596389|NCT06344429|COMBINATION_PRODUCT|Stellest Lenses+0.05% atropine|"All subjects are recruited and randomized to 3 treatment groups at the baseline visit.~B Group：Combined Treatment"
223596390|NCT06344429|DRUG|Single vision Lenses+0.05% atropine|"All subjects are recruited and randomized to 3 treatment groups at the baseline visit.~C Group：0.05% Atropine with single vision"
223596391|NCT03077919|DRUG|Ropivacaine|0.5% ropivacaine
223596392|NCT03077919|DRUG|Sham treatment|preservative-free normal saline
223596393|NCT05737251|BEHAVIORAL|PoET|PoET consists of two online-sessions, each 3.5 hours within groups of 30 people. The following lessons regarding positive psychology constructs were conducted (including short information on each construct and specific exercises): happiness, hope, humour, optimism, gratitude, self-efficacy, flow, meaningfulness, forgiveness, spirituality and resilience.
223596394|NCT04533321|DRUG|Afatinib|Afatinib is approved therapy for SCC of the lung after progression with standard of care chemotherapy.
223596395|NCT00934219|DRUG|Omega-3-Acid Ethyl Esters|LOVAZA, 1 g caps; High Dose Arm for 4 months, while on a standard therapy for hypertriglyceridemia (fibrates, +/-metformin). Standard Dose Arm for 3 months, while on a standard, unchanged therapy for hypertriglyceridemia (fibrates +/- metformin).
223596396|NCT03592368|DEVICE|IBT|Interpretation bias training
223596397|NCT01040442|OTHER|vibration stimuli|A single physical therapist performed the intervention using a Novafon SK2‡ vibratory stimulation device at a frequency of 100 Hz and sway amplitude of 2 mm. The participants of the experimental group received vibratory stimulation, applied slowly by sliding the head of the device over the entire plantar region for ten minutes for each foot at every session. During the intervention, the participants remained in the supine position on an examination table.
223596398|NCT01822418|DRUG|agomelatine|Augmentation of antipsychotic therapy with 25 to 50 mg agomelatine as a single oral dosage per day
223596399|NCT03875742|DEVICE|Ultraplex 360(Braun)|"This group will use as first needle the ultraplex 360 (Braun)"
223596400|NCT03875742|DEVICE|STIMUPLEX D SH, 30°(Braun)|"This group will use as first needle the  STIMUPLEX D SH, 30° (Braun)"
223596401|NCT06078436|DEVICE|Pulmonary artery catheter|Pulmonary artery catheter monitoring or not
223596402|NCT02944786|BEHAVIORAL|HOPE-model|There are four sessions of person-centered health dialogues. The sessions also include pain/stress management and education about stress and pain (the HOPE model that is an adolescent-centered school health prevention program when adolescents have chronic pain).
223596403|NCT02039284|DEVICE|SES|SES group received the SES training in addition to traditional rehabilitation. Each SES session involved electrical stimulation followed by UE training in addition to home program.The novel SES programs were conducted three times per week, for 12 weeks. Each SES session involved electrical stimulation followed by UE training in addition to home program. The SES was applied to the forearm and whole hand with mesh glove for 20-30 minutes and arm with wrap for 20-30 minutes. The pulse width was set to 300 us for all stimulation levels. The frequency was set to 40-50 Hz.
224197879|NCT07005219|PROCEDURE|Root canal shaping with One Curve Mini #25/0.4 and passive ultrasonic irrigation|Participants in this group underwent root canal shaping using a One Curve Mini #25/0.4 rotary file. After mechanical preparation, passive ultrasonic irrigation (PUI) was performed using a VDW Ultra device with an IRRI S 21/25 ultrasonic tip. Irrigation was activated with 3% sodium hypochlorite (NaOCl) in three 20-second cycles, using 1 ml per cycle. The ultrasonic tip was placed 2 mm short of the working length without contacting canal walls.
223596404|NCT02039284|DEVICE|VCT|The UE VCT programs were conducted three times per week, for 12 weeks. Each UE VCT session involved upper limb cycling training followed by UE training in addition to home program. The cycling program consisted of a warm-up exercise, twenty repetitions of hand push-up movements in the sitting position, UE cycling, and a cool-down exercise. The warm-up and cool-down exercises involved stretching and relaxing the head, neck, and the upper and lower body.
223596405|NCT02039284|DEVICE|VRCIT|VRCIT group received the VRCIT training in addition to traditional rehabilitation, conducted three times per week, for 12 weeks. Each VRCIT session involved practice of functional tasks with the more affected UE followed by virtual-reality based eye-hand coordination tasks with the more affected UE for, in addition to home program, and restraint of the less affected UE for 3.5 to 4 hours per day. The functional training of the more affected UE focused on massive practice of functional activities using the more affected arm, with the principles of shaping and repetitive task practice applied during training.
223596406|NCT02039284|DEVICE|traditional rehabilitation program|The absence of muscle contractions was controlled by the investigator the sham stimulation was carried out identically, but the stimulation amplitude was set to 0 milliampere(mA). Subjects were not informed about the stimulation level and were instructed to distract attention from the stimulation.
223596407|NCT05362760|DRUG|Abemaciclib + Aromatase Inhibitor|Abemaciclib 150 mg orally every 12 hours plus Aromatase Inhibitor ( Anastrozole 1 mg, Letrozole 2.5 mg or exemestane 25 mg orally every 24 hours on Days 1 to 28 of a 28-day cycle)
223596408|NCT05362760|DRUG|Abemaciclib + Fulvestrant|Abemaciclib 150 mg orally every 12 hours plus Fulvestrant (500 mg intramuscularly on Days 1 and 15 of Cycle 1, then on Day 1 of Cycle 2 and beyond on Day 1 of a 28-day cycle)
223596409|NCT03499314|DEVICE|Active RS-tDCS +At-Home Manual Dexterity Training|Bilateral M1-SO electrode placement; Active= anodal 2.0 mA dose × 20 minutes
223596410|NCT03499314|DEVICE|Sham RS-tDCS +At-Home Manual Dexterity Training|"Designed to ensure blinding, includes initial and ending ramp-up/down stimulation for 60 seconds"
223596411|NCT03499314|OTHER|Manual dexterity training|Manual dexterity training will be based on the at-home study in MS by Kamm and colleagues, where the training was completed by participants in their homes and demonstrated to be superior to strength training.
223596412|NCT02625844|OTHER|No intervention|No intervention administered in this study.
223747830|NCT02730572|DRUG|Concerta EG formulation|This is an observational study. Participants who have been on Concerta for at least 60 days and switch to equivalent generic will be observed.
223747831|NCT04583891|BEHAVIORAL|IntelliCare|IntelliCare is a self-guided, fully automated suite of 6 apps designed for brief, frequent check-ins to promote skill acquisition. IntelliCare has been shown in both general deployment and human-supported trials to be efficacious in reducing symptoms of depression and anxiety.
224197880|NCT07005219|PROCEDURE|Root canal shaping with One Curve Mini #35/0.4 and passive ultrasonic irrigation|Participants in this group underwent root canal shaping using a One Curve Mini #35/0.4 rotary file. The same passive ultrasonic irrigation protocol was applied as in Arm 1, using 3% NaOCl in three 20-second cycles with 1 ml per cycle. The ultrasonic tip was positioned 2 mm short of the working length without contacting the canal walls.
223617822|NCT00793195|DRUG|SMOFlipid 20%|Dosing will be formulated according to a Nomogram for Parenteral Nutrition (PN) composition, which takes into account the percentage of the subject's caloric intake consumed parenterally. PN solution will be infused continuously over 12-24 hours by infusion pump, and the duration each day will depend on the enteral tolerance of the child. PN shall not be discontinued, unless the patient is taking 95% of calories enterally with good growth as evidence by appropriate weight gain. Subjects will receive the trial lipid for a total duration of 12 weeks or if they develop a serum conjugated bilirubin (sustained for 7 days) of 100 umol/l (6mg/dl) or full enteral tolerance prior to this end-point. Once the trial lipid is discontinued, in the event that PN is continued, subjects will return to the standard lipid preparation. A final follow-up data-point will be collected 4 weeks after the trial lipid is stopped.
223747832|NCT04583891|BEHAVIORAL|Psychoeducation|The Patient Education app will contain content relevant for general distress management. This includes information about thoughts/worries, prevalence of mood symptoms, CBT strategies for coping with negative affect, and other information typical of education-based mental health apps. The structure of this app will closely mirror patient education websites and apps which mimic the form and structure of apps that target cancer survivors and that primarily provide educational information about cancer and related symptoms.
223747833|NCT04583891|BEHAVIORAL|Coaching|The randomization of added coaching vs. no added coaching after 1 week will only be carried out in the IntelliCare group. Coaching is a human supported approach to optimizing the use and benefit of the IntelliCare apps.
223747834|NCT05705531|PROCEDURE|Biospecimen Collection|Undergo blood specimen collection
223747835|NCT05705531|OTHER|Electronic Health Record Review|Undergo medical record abstraction
223747836|NCT05705531|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
224197881|NCT07023484|DIAGNOSTIC_TEST|KELIM|(i) Patients with KELIM =\>1 will receive radiological assessment and undergo internal debulking surgery if the disease is operable. (ii) Patients with KELIM \<1 will have alternative management, such as addition of bevacizumab or changing to dose-dense chemotherapy, and defer the interval debulking surgery
224197882|NCT07023484|DRUG|Carboplatin plus Paclitaxel|Neoadjuvant chemotherapy
224197883|NCT07023484|PROCEDURE|Interval debulking surgery|Interval debulking surgery
224197884|NCT07028463|BEHAVIORAL|ALERT-ED|Patient receives link to the Livi Chatbot in After Visit Summary
224197885|NCT01633762|DRUG|meropenem, gentamicin, vancomycin (together)|"4 days antibiotic treatment, per oral, once daily: vancomycin 500 mg (Vancomycin Hospira), powder for concentrate; gentamycin 40 mg (Hexamycin®), solution; meropenem 500 mg (Meropenem Hospira), powder for concentrate; The three drugs are dissolved and combined to a cocktail (with approximately 100 ml of apple juice)"
224197886|NCT05011240|BEHAVIORAL|Paediatric Autism Communication Therapy (PACT)|PACT is a parent-mediated therapy that aims to improve children's social-communication development. During PACT, a therapist uses video-feedback of parent-child play interactions to coach the parent in how to improve their sensitivity and responsiveness to their child's social-communication and interaction behaviours and to implement evidence-based strategies that facilitate social-communication development.
224197887|NCT05011240|BEHAVIORAL|Psychoeducation|Control participants will receive monthly psychoeducation sessions led by a developmental specialist
224197888|NCT03285581|DEVICE|truSculpt RF|Subjects will receive RF treatments
224197889|NCT06702228|DIAGNOSTIC_TEST|Six minute walk test (6MWT)|Assessment of exercise capacity by the carrying out of a 6MWT at 0, 6 and 12 months.
224197890|NCT06702228|DIAGNOSTIC_TEST|Computer-tomography of the thorax (CT Thorax)|Radiological assessment via CT Thorax, preferably high-resolution CT thorax at baseline on entering the study and at one year. CT images will be collected on study end. CT images in all subjects will be evaluated by three readers blinded to any other interpretation and conforming to ATS-guidelines. Coded data from CT scans will be shared with our collaborator Professor Simon Walsh at Imperial College, London who will use computational methods to identify novel radiologic phenotypes linked to disease behaviour of our patient's fibrotic lung disease.
224197891|NCT06702228|OTHER|Quality of life questionnaires.|Qality of life questionnaires including; modified Medical Research Council (mMRC) dyspnea scale, The King's Brief Interstitial Lung Disease Questionnaire (KBILD), The Leister Cough Questionnaire and the EQ-5D-3L questionnaire are measured at 0, 6 and 12 months
224197892|NCT06702228|DIAGNOSTIC_TEST|Genetic Testing|10ml of serum will be collected for DNA extraction and analysed for causative and at risk genetic mutations
224197893|NCT06702228|DIAGNOSTIC_TEST|Spirometry|We will carry out spirometry at baseline, 6 and 2 months including forced vital capacity and diffusing capacity of the lungs for carbon monoxide.
224197894|NCT06702228|DIAGNOSTIC_TEST|Serology|Serology which may indicate an underlying diagnosis of ILD will be carried out on study entry. This will include a full blood count, renal profile, liver profile, C-reactive protein, creatine kinase, erythrocyte sedimentation rate, antinuclear antibodies, anticyclic citrullinated peptide antibodies, rheumatoid factor, an extended myositis antibody panel, sjögren's antibodies, scleroderma antibodies and a hypersensivity pneumonitis panel if clinically indicated.
224197895|NCT06702228|OTHER|Other Quality of Life Questionnaires|Patient Global Assessment and Clinician Global Assessment scores completed at 0, 6 and 12 months
224197896|NCT06702228|OTHER|PatientMPower Home Monitoring App|Continuous at home monitoring of patients using home-based digital spirometry and pulse-oximetry with real-time feedback readings to patient and clinician. Smartphone app for patients, spirometer and pulse oximeter are connected to the app via Bluetooth. Patients are asked to take 2 readings per week.
224197897|NCT04853069|DRUG|Transdermal estradiol gel|Patients will receive standard care +/- (randomsed 1:1) transdermal 17ß-estradiol gel (3 mg; applied to forearm, upper arm and shoulder) for ten days.
224197898|NCT03493204|OTHER|Meal delivery|The food will be pre-packaged for storage and patient will prepare these meals at home
223747837|NCT05705531|OTHER|Survey Administration|Complete surveys
224197899|NCT03493204|OTHER|Standard pamphlet with Dietary Advice|Explains how to maintain a low-sodium diet
224310945|NCT01786889|BIOLOGICAL|blood and urine|Blood collection and urine collection after consent of the patient
223747838|NCT00973479|DRUG|Golimumab|Participants will receive 2 mg/kg of golimumab intravenously over 30 ± 10 minutes. Group 1: at Weeks 0, 4, and every 8 weeks thereafter (up to Week 100). Group II: Weeks 24, 28, and every 8 weeks thereafter (up to Week 100); Early escape: at Week 16, 20 and every 8 weeks thereafter (up to Week 100).
224197900|NCT03534089|OTHER|Standard infant fomula|Infants with iron deficiency anemia randomly divided into this group were given the same dose of ferralia with other groups,and were fed with infant formula without lactoferrin supplementation.
224197901|NCT03534089|OTHER|Low level LF infant formula|Infants with iron deficiency anemia randomly divided into this group were given the same dose of ferralia with other groups,and were fed with infant formula supplemented with low level of lactoferrin (38mg/100g).
224197902|NCT03534089|OTHER|High level LF infant formula|Infants with iron deficiency anemia randomly divided into this group were given the same dose of ferralia with other groups,and were fed with infant formula middle supplemented with high level of lactoferrin (76mg/100g).
223596413|NCT05349786|OTHER|Physical activity program|A physical activity program lasting at least 30 minutes each session was applied to HF patients in the intervention group, three days a week for three months. A pedometer was used to visualize the walking performed in the physical activity program and to record reliably. After the data obtained in the pre-test, the pedometers, which were calibrated and checked by the researchers, were delivered to the patients. At the end of each day of walking with pedometer monitoring, they were asked to record data such as the number of steps, walking hour, walking time, distance and complaints encountered during walking on the walking monitoring chart given to the patient by the researchers. Weekly phone calls and monthly home visits were made to the patients in order to determine the continuation of the medical treatment and walking program used by the patients, to increase their motivation and to detect or intervene in any situation related to the walking program.
223596414|NCT06271889|DEVICE|Non-stress test|It will be performed with the HUNTLEIGH brand BD4000XS-2 model NST device located at the maternity clinic to listen to the fetal heart sound, approximately min 3 max 5 min will be listened to. According to the studies conducted in the literature, the half-life of adrenaline in plasma is 3 minutes when an invasive/noninvasive intervention is performed on an adult individual. Therefore, the fetal heart rate will be listened to for 3 minutes (Dalal \& Grujic; 2021; https://www.medicines.org.uk/emc/product/6284/smpc#gref https://www.ncbi.nlm.nih.gov/books/NBK482160 / )
223617823|NCT00952302|DRUG|Iron sucrose|Single intravenous infusion of iron 200 mg
223617824|NCT00952302|DRUG|Normal saline|Single intravenous infusion of normal 0.9% saline 100 mls (as placebo)
223617825|NCT00952302|PROCEDURE|Venesection|Isolvolaemic venesection of total 2 litres of blood - 500 mls each day for 4 days, replaced with normal saline.
223617826|NCT00952302|DRUG|Iron sucrose|Two intravenous infusions, each of 200 mg of iron, separated by one day.
223617827|NCT00952302|DRUG|Normal saline|Two intravenous infusions of normal 0.9% saline 100 mls (as placebo), separated by one day.
223617828|NCT03300401|DRUG|Perflutren Lipid Microspheres|Receive intravenous injection just prior to ultrasound
223617829|NCT03300401|DRUG|Sulfur Hexafluoride Lipid Microspheres|Receive intravenous injection just prior to ultrasound
223617830|NCT03300401|DEVICE|Dynamic Contrast-Enhanced Ultrasound Imaging|Undergo Contrast-Enhanced Ultrasound Imaging
223617831|NCT03300401|DEVICE|Positron Emission Tomography|Undergo PET/CT
223617832|NCT03300401|DEVICE|Computed Tomography|Undergo CT scan
223617833|NCT03300401|BIOLOGICAL|Yttrium-90 (90Y)|Given IV
223617834|NCT03624673|PROCEDURE|endoscopic robot-assisted simple enucleation|Simple enucleation consists of excising the tumor by blunt dissection following the natural cleavage plane between the peritumoral capsule and the renal parenchyma without removing a visible rim of healthy renal tissue.
223617835|NCT03624673|PROCEDURE|standard robot-assisted partial nephrectomy|Standard partial nephrectomy is defined as the excision of the tumor and of an additional margin of healthy peritumor renal parenchyma.
223617836|NCT04214223|OTHER|Pre-Anesthesic Consultation|Classical Pre-Anesthesic Consultation with an anesthesist of the maternity hospital of Nancy (France)
223617837|NCT04214223|OTHER|Pre-Anesthesic Numerical Evaluation|Home-based Pre-Anesthesic Numerical Evaluation with the aid of a questionnaire, achieved with a computer, digital tablet or smartphone, on a secured platform.
223617838|NCT06143358|DRUG|Qingkepingchuan Granules|Qingkepingchuan Granules,Take it three times a day with water after meals.
223617839|NCT06143358|OTHER|conventional treatment|Oxygen intake, selection of appropriate antibiotics based on lab results, and other treatments
223617840|NCT01755364|BIOLOGICAL|AdimFlu-V|
223617841|NCT00182169|DRUG|Human recombinant growth hormone|
223617842|NCT02343146|BEHAVIORAL|Type One Training (TOT)|The intervention is comprised of a number of modes of delivery including in person, use of parent peer consultant, telephone intervention, and text messaging. The intervention is based on Social Cognitive Theory and previous work of the investigators.The focus of the intervention is on working with parents to improve child eating and physical activity behaviors as a means of improving glycemic control in very young children with type 1 diabetes.
223617843|NCT02126722|PROCEDURE|Gastroscopy|Gastroscopy with multiple biopsies will be performed in all patients enrolled
223617844|NCT02126722|DEVICE|EndoFaster test|During the gastroscopy the EndoFaster test will be carried out in all patients enrolled.
223617845|NCT02126722|OTHER|Clo test|During the gastroscopy the Clo test will be carried out in all patients enrolled.
223617846|NCT02126722|OTHER|Faecal Helicobacter pylori antigen|On the day of the endoscopic procedure all the enrolled patients will bring a stool sample for the detection of Helicobacter pylori antigen.
223617847|NCT04243694|BEHAVIORAL|Mindfulness training|Participants of the intervention group will receive 6-weeks of mindfulness training.
223617848|NCT04662567|DRUG|acetaminophen|compare the postoperative pain 1 hour and \~24h post surgery
223617849|NCT01668459|DRUG|Cabazitaxel|25 mg/m2, IV (in the vein) on day 1 of each 21 day cycle. Number of Cycles: maximum 6
223617850|NCT01668459|OTHER|Best Supportive Care|Best Supportive Care including single agent chemotherapy as determined by the patient's study physician
223617851|NCT00170508|BIOLOGICAL|Fluzone®|
223617852|NCT01702974|DRUG|vitamin D (cholecalciferol) and PBA (sodium phenylbutyrate)|Dose of interventions: 5,000 IU of vitamin D (cholecalciferol tablets) once daily and 500 mg PBA (sodium phenylbutyrate tablets) twice daily for 16 weeks.
223617853|NCT01702974|DRUG|Placebo tablets|Placebo tablets for vitamin D once daily and placebo tablets for PBA (phenylbutyrate) twice daily for 16 weeks.
223617854|NCT04300985|DRUG|Dexmedetomidine|Patients will start receiving dexmedetomidine 15 minutes before general anesthetic induction.
223596415|NCT03291717|BEHAVIORAL|Bridging Community Gaps Photovoice (BCGP)|Participants assigned to this group will be part of the 6-month long BCGP intervention, which involves a 12- week class that meets weekly, followed by three booster sessions - one per month in the three months following the class, and up to 24 sessions of individual support as needed throughout the 6 months provided on a weekly basis either in person or by phone. The BCGP classes follow a manualized curriculum with sessions that combine didactic information, Photovoice exercises, and group discussions to empower participants in pursuing community participation goals, all refined with input from individuals with a lived experience.
223596416|NCT01618695|DRUG|Perampanel|"Core study: 4 milligram (mg) group- Week 0 Once daily 2 milligram per day (mg/day), Week 1 to Week 18 Once daily 4 mg/day; 8 mg group- Week 0 Once daily 2 mg/day, Week 1 Once daily 4 mg/day, Week 2 Once daily 6 mg/day, Week 3 to Week 18 Once daily 8 mg/day; 12 mg group- Week 0 Once daily 2 mg/day, Week 1 Once daily 4 mg/day, Week 2 Once daily 6 mg/day, Week 3 Once daily 8 mg/day, Week 4 Once daily 10 mg/day, Week 5 to Week 18 Once daily 12 mg/day.~Extension study: 4 mg group- Week 19 to Week 22 Once daily 4 mg/day, Week 23 Once daily 6 mg/day, Week 24 Once daily 8 mg/day, Week 25 Once daily 10 mg/day, Week 26 to Week 75 or more Once daily 12 mg/day; 8 mg group- Week 19 to Week 22 Once daily 8 mg/day, Week 23 Once daily 10 mg/day, Week 24 to Week 75 or more Once daily 12 mg/day; 12 mg group- Week 19 to Week 75 or more Once daily 12 mg/day."
223596417|NCT01618695|DRUG|Placebo|"Core study: Week 0 to Week 18 Once daily placebo.~Extension study:~Week 19 to Week 22 Once daily placebo, Week 23 Once daily perampanel 2 mg/day, Week 24 Once daily perampanel 4 mg/day, Week 25 Once daily perampanel 6 mg/day, Week 26 Once daily perampanel 8 mg/day, Week 27 Once daily perampanel 10 mg/day, Week 28 to Week 75 or more Once daily perampanel 12 mg/day."
223596418|NCT00068757|BIOLOGICAL|trastuzumab|
223596419|NCT00068757|DRUG|lonafarnib|
223596420|NCT00068757|DRUG|paclitaxel|
223596421|NCT00068757|OTHER|pharmacological study|
223596422|NCT04692519|BEHAVIORAL|Duet Language Intervention Modules|The Duet 2.0 intervention modules promote the following guiding principles that help build effective communication. Below are the 5 principles covered in the six Duet modules: 1) General Awareness: Awareness and knowledge of child development 2) Creating Opportunities: Opportunities for communication during everyday activities 3) Conversational Duets: Rhythmic and reciprocal early language interactions 4) Scaffolding: Providing just enough help to support child independence 5) Harmonizing: Using the strategies together. These modules, which include behavioral strategies, real-life and animated examples of high-quality early language interactions, and interactive scenarios. The modules were informed and narrated by community members and carefully designed to address specific needs of high-risk communities. The modules have also been translated into Spanish, making sure to encompass specific cultural and dialect needs. Translation accuracy was verified by a qualified Spanish translator.
223596423|NCT03046576|DIAGNOSTIC_TEST|plasma DPP4 activity|DPP4a was determined by enzymatic assays.
223596424|NCT04492501|PROCEDURE|Therapeutic Plasma exchange|1-1.5 plasma volume exchange, 2/3rd plasma should be replacing with FFP to avoid coagulopathy, adequate dieresis to prevent volume overload, 1-5 sessions in total, 1 session daily
223596425|NCT04492501|BIOLOGICAL|Convalescent Plasma|"Convalescent plasma as part of replacement therapy (200-400ml) if reported within 14 days of illness. An IgG titer of \> 1.320 will be considered suitable for use. It will be Collected from person previously infected with Covid-19 and meet following criteria;~1. After 28 day of illness till 3 months~2. Symptom free 2 weeks prior to donation~3. Negative two consecutive PCRs any time between initial positivity and before donation~4. Anti SARS-CoV2 IgG positive, IgM negative~5. Fulfills healthy donor criteria as per WHO/AABB guidelines~6. Volume of plasma to be collected: 900-1200 ml through Apheresis OR plasma separated from phlebotomy donation"
223596426|NCT04492501|DRUG|Tocilizumab|A predefined number of patients having evidence of cytokine release storm with normal procalcitonin level for three consecutive days, a normal blood culture and IL-6 level \> 3 times ULN will be given 1-2 doses of Tocilizumab (80mg IV) . Following contraindications to Tocilizumab will be considered (Allergy to any monoclonal Ab, ANC \< 1000, Platelets \< 50, ALT or AST \> 5 times ULN, Pregnancy and breast feeding, Post TB lung). Some patients will receive it alone in addition to standard treatment whereas in few patients where indicated it will be given in combination with MSC or Remdesivir or both
223596427|NCT04492501|DRUG|Remdesivir|It will be given to selected patients who have evidence of hypoxemia and presented with in 14 days of illness. For adults requiring invasive mechanical ventilation the dosage of remdesivir is a single loading dose of 200 mg sta on Day 1 followed by once daily maintenance doses of 100 mg IV for 9 days (days 2 through 10). For adults not requiring invasive mechanical ventilation 5 standard doses will be used. However, patients with known hypersensitivity to Remdesivir, multi organ failure, ALT \> 5 times ULN and GFR \< 30ml/minute will not be given Remdesivir. In some patients, where indicated other novel treatments including MSC therapy, Tocilizumab and therapeutic plasma exchange will be given.
223596428|NCT04492501|BIOLOGICAL|Mesenchymal stem cell therapy|Single Dose of 2 x 106 cells/kg will be administered either alone or in combination with other novel therapies. At Armed Forces Bone Marrow Transplant Centre (AFBMTC), MSCs will be isolated from bone marrow harvested cells. About 50ml bone marrow will be collected from iliac crest using aseptic technique in syringes primed with anticoagulant. The collected sample will be diluted with Phosphate Buffer Saline (PBS) and MSCs will be separated using density gradient centrifugation. After resuspension the cells will be seeded at a fixed concentration of 100,000 cells/cm2 in specially designed flasks and incubated at 37Oc in 5% CO2. Medium will be changed after every third day till harvesting of MSCs from the flasks. Once confluent (approximately day 20) the cells will be harvested with sterile techniques using Trypsin- EDTA solution.
223747839|NCT00973479|OTHER|Placebo|Participants will receive placebo intravenous infusion over 30 ± 10 minutes as: Group I: at Week 16 and 24; Group II: at Weeks 0, 4, 12, 16, and 20; and for early escape: at Week 24.
223747840|NCT00973479|DRUG|methotrexate (MTX)|Participants will be maintained on their stable dose of commercial MTX (between 15 to 25 mg/week) throughout the study.
224197903|NCT04427306|DRUG|T-Vec|(talimogene laherparepvec) will be given prior to surgery. Standard care the patients receive the drug after sugery
224197904|NCT05936190|DRUG|Lidocaine IV|Intravenous infusion rate of lidocaine is 2 mg/kg/min
224197905|NCT05936190|DRUG|Lidocaine|Intravenous infusion rate of lidocaine is 1 mg/kg/min
224197906|NCT00208858|DRUG|Topiramate|
224310946|NCT01786889|BEHAVIORAL|Questionnaire|The patient complete the questionnaire alone at home
224310947|NCT01786889|BEHAVIORAL|Telephone interview|The patient will be contacted by the CRA for a telephone interview of around one hour
223596429|NCT02342899|DEVICE|Outpatient NIV Set Up using AVAPS AE (Manufactured by Philips-Respironics)|Intervention set ups will follow a standard protocol for the automated device (A40 AVAPS-AE machine;Manufactured by Philips-Respironics, Murraysville, Pittsburgh, US) and patients will be discharged with the machine and a full face mask or nasal interface. Patients will then undergo a 1-2 night home oximetry study to ensure adequate control of overnight oxygenation. Patients will be reviewed clinically as an outpatient at 6 weeks and adherence to non-invasive ventilation will be evaluated and an arterial blood gas measurement will be undertaken. A full clinical review and optimisation of NIV and interface will be performed at this visit. Patients will be reviewed at 3 months as an inpatient where overnight transcutaneous carbon dioxide level and SpO2 studies will be performed. All other patient-centred, physician-centred and healthcare utilisation measurements will be assessed at baseline, 6 weeks and 3 months.
223596430|NCT02342899|DEVICE|Inpatient NIV Set Up using spontaneous/timed (S/T) mode pressure support ventilation (Manufactured by Philips-Respironics)|The patient will follow a specialist nurse-led protocolised set up of spontaneous/timed (S/T) mode pressure support ventilation (A40 AVAPS-AE machine; Manufactured by Philips-Respironics, Murraysville, Pittsburgh, US) using limited respiratory polygraphy, including overnight TcCO2 (Trascutaneous Carbon Dioxide) and SpO2 (Oxygen Saturation) studies. Following the inpatient set-up, patients will be reviewed as an outpatient at 6 weeks and adherence with non-invasive ventilation will be evaluated and arterial blood gas measurements will be performed. Patients will then be reviewed at 3 months as an inpatient where overnight respiratory polygraphy, TcCO2 and SpO2 studies will be repeated. All other patient-centred, physician-centred measurements and healthcare utilisation measurements will be assessed at baseline, 6 weeks and 3 months.
223596431|NCT00881348|DRUG|LACTIC ACID(ND)|Dermacyd infantile (Lactic Acid)
223596432|NCT01684319|DIETARY_SUPPLEMENT|Formula milk free of cow's milk protein|
223596433|NCT01684319|DIETARY_SUPPLEMENT|Placebo|Infant formula milk
223596434|NCT04346446|DRUG|Convalescent Plasma Transfusion|Convalescent Plasma Transfusion
224197907|NCT00786058|DRUG|OFF in experimental arm|OFF was given according to a six week cycle. FA (500 mg/m2 , 0.5h, i.v.) and 5-FU (2,600 mg/m2, 24-hour, i.v.) were administered on days 1, 8, 15, and 22. Oxaliplatin (85 mg/m2 , 2-4 h, i.v.) was administered directly before FA/ 5-FU on days 8 and 22.
223596435|NCT04346446|OTHER|Supportive Care|Supportive Care
223596436|NCT04346446|DRUG|Random Donor Plasma|Random Donor Plasma will be transfuse from 200 to 600 mL according to the patient requirement
223596437|NCT01481337|PROCEDURE|Colonic polypectomy or endoscopic mucosal resection (EMR)|Resection of colonic polyps using polypectomy tehnique (with electrocoagulation) or mucosal resection (EMR or mucosectomy) with injection of physiological serum thus resection with electrocoagulation.
223596438|NCT02376179|DEVICE|Cuffed ETT|
223596439|NCT05921565|BEHAVIORAL|Interventional Behavioral Arm|All participants will receive a weight loss intervention that includes 8 coaching sessions guided by a workbook they will at their baseline visit. During these sessions, they will meet with a health coach individually for up to 10-15 minutes via telephone or video conference to learn and discuss weight loss strategies. Health coaches will provide feedback and instruction (by phone or email) based on progress and challenges encountered during the intervention. Participants will receive a weight management app custom-built for the research study. The app will display participants' dietary intake, physical activity, and weight data and goals on the smartphone, and participants will use the app to log dietary intake, physical activity, and weight daily.
223596440|NCT02466984|DRUG|metoclopramide intravenous|Administration route
224197908|NCT01127529|BIOLOGICAL|Protein C Concentrate (Human)|Commercially available Ceprotin will be prescribed, obtained and administered by the investigator according to local standard of care.
224197909|NCT02939508|OTHER|Colon originated: Neostigmin, Colonoscopy decompression, Surgery|
224197910|NCT02939508|OTHER|Non-colon originated: Neostigmin, Colonoscopy decompression|
224197911|NCT04752111|DRUG|Esmolol|administration of a loading dose esmolol infusion 0.5 mg/kg in 30 ml isotonic saline in the IV line, followed by an IV infusion of esmolol 0.05 mg/kg/min till the completion of surgery
224197912|NCT06021028|PROCEDURE|complex proximal carious cavities in posterior teeth.|Selective enamel etching with 37% phosphoric acid for 30 second will be done then the bonding agent will be applied following the manufacturer's instructions.
224197913|NCT01034345|DRUG|Sirolimus|Switch from calcineurin inhibitor maintenance immunosuppression to sirolimus treatment at the doses needed to reach trough blood levels 8-15 ng/mL.
223747841|NCT06037421|OTHER|Human breast milk sampling|Human breast milk sampling
223747842|NCT06037421|OTHER|Saddle sampling|Saddle sampling
223747843|NCT06037421|OTHER|Skin sampling|Skin sampling
223747844|NCT06037421|OTHER|Saliva sampling|Saliva sampling
223747845|NCT06037421|OTHER|blood sampling|blood sampling
224197914|NCT01034345|DRUG|Calcineurin inhibitor|Patients will maintain the same immunosuppressive regimen based on calcineurin inhibitors. No modifications in the treatment will be conducted.
224197915|NCT03458351|DEVICE|Remote ischemic preconditioning|Four cycles of 5 min of ischemia, which is induced by a blood pressure cuff in the upper arm inflated to 200 mmHg, followed by 5 min of reperfusion, during which the cuff is deflated.
224197916|NCT03458351|DEVICE|Sham control|The same blood pressure cuff is placed around the upper arm, but the cuff is inflated to 10 mm Hg and ischemic preconditioning is not induced.
224197917|NCT04926129|OTHER|Other: Assessments|Administered as specified in the treatment arm.
224197918|NCT06428331|DRUG|SKB518 for injection|SKB518 for injection is administered every 3 weeks (q3w) until radiographic disease progression (PD), intolerable toxicity, death, or discontinuation of treatment, whichever occurs first.
224197919|NCT01200251|DRUG|Bimatoprost eyelash gel|Bimatoprost 0.03% solution was compounded into a gel - patients used on eyelash margin once daily placing gel with a fingertip or Q-tip for 6 months
224197920|NCT06177145|OTHER|HASCV-R program|"Healthy nutrition, Active life, Ways to cope with Stress, Cancer and cancer screening, Vaccination - Reproductive health Training programme"
224197921|NCT07034352|BEHAVIORAL|Health Impact 360|Participants will be assigned to a team and teams will meet 1-2 times per week for sessions at a local community organization. Sessions will be up to 2 hours long and will include two parts: (1) 30-60 minutes of activities related to physical, mental, social, financial, and community health, and (2) 60-75 minutes of group physical activity (walking), including stretches to warm up and cool down.
224197922|NCT07034352|OTHER|Usual care - Wait list control|Participants will be on this for approximately 16 weeks and be asked to complete data collection information at baseline and 16 weeks.
224197923|NCT02827747|OTHER|Antioxidants (Vitamins A,C,E) plus GSH|Study medication would contain 500 milligrams of vitamin C, 400 International Units of vitamin E, and 15 milligrams of beta-carotene (the equivalent to 25,000 International Units of vitamin A).The study medication would also contain 1000mg of Glutathione (GSH).
224197924|NCT02827747|OTHER|Placebo|Placebo pill
224197925|NCT02827747|DIETARY_SUPPLEMENT|Centrum|Centrum
223596441|NCT03917095|DEVICE|The Colonic Transendoscopic enteral Tubing.|The medications were infused into the colon through the Colonic Transendoscopic enteral Tubing(TET).
223596442|NCT03917095|DRUG|Glutamine|The medications were infused into the colon
223596443|NCT03917095|DRUG|Mesalazine|The medications were infused into the colon
223596444|NCT05062135|DRUG|Progesterone 400 Mg Vaginal Suppository on PCOS|The same drug will be used in control group
223596445|NCT06335316|PROCEDURE|Injection|The percutaneous approach via the paratracheal route was used for Stellate ganglion block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
223596446|NCT06335316|DRUG|Lidocaine Hydrochloride|the patients were provided with Stellate ganglion block, using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g)
223596447|NCT06335316|BEHAVIORAL|Comprehensive therapy|All the participants are provided with the comprehensive rehabilitation (routine rehabilitation and swallowing function training). The routine rehabilitation included intervention for risk factors (blood pressure, blood lipids, blood glucose, smoking and alcohol restriction, exercise, etc.).
223596448|NCT06335316|BEHAVIORAL|placebo|The percutaneous approach via the paratracheal route was used for Stellate ganglion block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck. Only normal saline was used
223596449|NCT04077853|DRUG|17 Hydroxyprogesterone Capronate|Intramuscular injection 250 mg
223596450|NCT02243735|DRUG|Ferrous fumarate|Patients randomized to standard care with ferrous fumarate will receive three tablets of 200 mg daily from randomisation until day before surgery
223596451|NCT02243735|DRUG|ferric(III)carboxymaltose|Patients randomized to intravenous iron (ferric(III)carboxymaltose) will be dosed according to Summary of Product Characteristics (SPC) depending on body weight and Hb value and administered in one or two infusions with one week in between. A maximum dose of 1000mg or 15mg/kg per week will be administered
223596452|NCT01248741|RADIATION|HDR prostate brachytherapy|"HDR prostate brachytherapy to be delivered in 2 fractions of 10 Gray as a boost combined with external beam radiotherapy"
223596453|NCT00255541|DRUG|Tesaglitazar|
223596454|NCT00255541|DRUG|Glibenclamide|
223596455|NCT03716219|OTHER|Exercise Training|Physical activity in children and adults with asthma.
223747846|NCT06966258|BEHAVIORAL|Inspire HER Intervention|The Black Impact intervention is an academic-community-government partnership adapted from the Diabetes Prevention Program and American Heart Association Check, Change, Control programs based on stakeholder feedback and to afford incorporation of additional evidence-based strategies for influencing target outcomes. The intervention is a 24-week community-based lifestyle intervention to improve cardiovascular health among Black men. Each participant will be assigned to a group with \>5 participants based on participant proximity to a central community meeting location. Each team will be guided weekly by a health coach who delivers content and coaching around the lifestyle intervention modeled on the diabetes prevention program and check, change, control blood pressure program, a community health worker who helps to address social needs and connects participants to primary care services, and a trainer who leads physical activity. Teams meet for 90 minutes per week.
223747847|NCT00362115|DRUG|Azilsartan Medoxomil|Azilsartan medoxomil 5 mg and comparator matching placebo tablets, orally, once daily for up to 8 weeks.
224197926|NCT02827747|COMBINATION_PRODUCT|Dietary Sources|From dietary sources of vitamins.
224197927|NCT05583838|DRUG|rhTPO|initial therapy: rhTPO s.c, 300 or 600U/kg daily based on baseline platelet count; maintenance therapy: rhTPO s.c, 300 \~ 600U/kg every other day depends on platelet count.
224197928|NCT05583838|DRUG|Eltrombopag|initial therapy: Eltrombopag oral, 25 or 50mg daily based on baseline platelet count; maintenance therapy: Eltrombopag oral, 25 \~ 75mg daily or every other day depends on platelet count.
224197929|NCT06429800|DRUG|ATA3219|ATA3219 is an allogeneic chimeric antigen receptor (CAR) T-cell therapy containing a second generation CD19 CAR construct in Epstein Barr virus (EBV) T cells, administered intravenously on Day 1.
224197930|NCT06717958|DRUG|Ivosidenib 250 MG (milligram)|oral
224197931|NCT07040696|DEVICE|Venous excess ultrasound score (VEXUS)|Doppler examination of inferior vena cave, portal vein, hepatic vein, and intrarenal vein will be conducted by an experienced operator
224197932|NCT06716710|BEHAVIORAL|Art therapy group|In addition to the medical treatments that the pregnant women in the study group will receive in the clinic for 4 weeks, a mandala coloring session will be held 3 days a week, 2 times a week under the supervision of the researcher. In order to ensure standardization in the pregnant women included in the study group, each pregnant woman will be given the same mandala work box (36 colored coloring pencils, file, eraser, pencil sharpener and the same mandala prints for all pregnant women). The selection of mandala patterns will be determined by the researchers. In the second week of the training, the researcher will evaluate the STAI TX1 and STAI TX 2, Pregnancy Stress Scale, and FOBS fear of birth scale. At the end of the four-week activity, the researcher will evaluate again.
224310948|NCT03653910|DEVICE|Airtraq|Airtraq is a kind of videolaryngoscope for intubation
223596456|NCT02454478|DRUG|Lenvatinib|
223747848|NCT00362115|DRUG|Azilsartan Medoxomil|Azilsartan medoxomil 10 mg and comparator matching placebo tablets, orally, once daily for up to 8 weeks.
224310949|NCT03653910|DEVICE|Macintosh|Macintosh is a traditional laryngoscope for intubation
223596457|NCT02454478|DRUG|Everolimus|
223596458|NCT00866073|DRUG|Decitabine 15 mg/m2 i.v.|Decitabine at 15 mg/m2 i.v. x 3 hours, three times daily on three consecutive days
224197933|NCT06716710|OTHER|Control group|In addition to the medical treatments that the pregnant women in the control group will receive in the clinic for 4 weeks, no other application will be made. After two weeks, the researcher will evaluate them using the STAI TX1 and STAI TX 2, Pregnancy Stress Scale, and FOBS fear of childbirth scale. At the end of the fourth week, the researcher will evaluate them again.
224197934|NCT07040969|DRUG|Spray of spirulina derivatives|An oral spray formulated with purified spirulina-derived exosomes.
224197935|NCT07040969|DRUG|Spray of placebo|The placebo oral spray will be formulated with inactive ingredients matched in appearance and flavor profile to the active spirulina-derived product.
224197936|NCT07040969|RADIATION|Radiotherapy|One of the inclusion criteria for the study was that patients with squamous carcinoma of the head and neck (including nasopharyngeal carcinoma) needed to receive either radiotherapy alone or simultaneous radiotherapy and chemotherapy.
224197937|NCT06713746|DIAGNOSTIC_TEST|growth differentiation factor 15|rowth differentiation factor-15 (GDF-15) is a novel cytokine secreted by a variety of cells like macrophages, adipocytes, normally expressed in high amounts by placenta
223596459|NCT04683367|PROCEDURE|laparoscopic surgery|laparoscopic repair of hernia
223596460|NCT04243993|OTHER|Calcium silicate cement|Calcium silicate cement for using in endodontic treatments i.e. pulpotomy, orthograde MTA apical barrier, root perforation repair, and endodontic microsurgery.
223596461|NCT04102527|OTHER|Questionnaires|"Patients have to complete the study questionnaires every 2 months :~* Digestive Functional Score of Neurological Patients~* Bowel Function Index~* Severity score for constipation~* Bristol Scale~* Constipation assessment scale~* Estimate scale of risk of constipation"
224197938|NCT06724146|DEVICE|Sofwave and Pure Impact|"The Sofwave System, comprised of an applicator and a console, generates high intensity, non-focused ultrasonic energy which can be delivered percutaneously to tissues.~Pure Impact is an EMS module. This module is wirelessly connected to and controlled by the SofWave console. It functions independently from the existing ultrasound module. Pure Impact generates electrical impulses, which are delivered through electrodes on the skin in direct proximity to the muscles to be stimulated."
224197939|NCT06724211|OTHER|Treatment bundle of care|The treatment bundle of care will consist of: the use of plasmalyte for fluid management, maintaining mean arterial pressure \> 75 mmHg, identify and treat blood glucose \> 9 mmol/L, and a restrictive criteria for red blood cell transfusions (i.e. hemoglobin (Hb) \< 70 g/L).
223596462|NCT04701190|DRUG|Noradrenalin 10 microgram bolus|The noradrenaline bolus dosage of 10 microgram will be administered to the patient at the same time of obtaining cerebrospinal fluid running freely.
223596463|NCT04701190|DRUG|Noradrenaline 5 microgram bolus|The noradrenaline bolus dosage of 5 microgram will be administered to the patient at the same time of obtaining cerebrospinal fluid running freely.
223596464|NCT04701190|DRUG|Noradrenaline 0.1 microgram/kg/minute infusion|"Infusion dosage: 0.1 microgram/kg/minute After the end of the injection of heavy marcaine 0.5% to the subarachnoid space, the infusion of noradrenaline with a 0.1 microgram/kg/minute dosage will be started.~Noradrenaline will be continued until 5 minutes after delivery of fetus."
223596465|NCT04701190|DRUG|Noradrenaline 0.05 microgram/kg/minute infusion|"Infusion dosage: 0.05 microgram/kg/minute After the end of the injection of heavy marcaine 0.5% to the subarachnoid space, the infusion of noradrenaline with a 0.05 microgram/kg/minute dosage will be started.~Noradrenaline will be continued until 5 minutes after delivery of fetus."
223747849|NCT00362115|DRUG|Azilsartan Medoxomil|Azilsartan medoxomil 20 mg and comparator matching placebo tablets, orally, once daily for up to 8 weeks.
223747850|NCT00362115|DRUG|Azilsartan Medoxomil|Azilsartan medoxomil 40 mg and comparator matching placebo tablets, orally, once daily for up to 8 weeks.
223747851|NCT00362115|DRUG|Azilsartan Medoxomil|Azilsartan medoxomil 80 mg and comparator matching placebo tablets, orally, once daily for up to 8 weeks.
223747852|NCT00362115|DRUG|Olmesartan|Olmesartan 20 mg and comparator matching placebo tablets, orally, once daily for up to 8 weeks.
223747853|NCT00362115|DRUG|Placebo|Matching placebo tablets, orally, once daily for up to 8 weeks.
223596466|NCT04701190|DRUG|Infusion dosage: 0.075 microgram/kg/minute infusion|"nfusion dosage: 0.075 microgram/kg/minute After the end of the injection of heavy marcaine 0.5% to the subarachnoid space, the infusion of noradrenaline with a 0.075 microgram/kg/minute dosage will be started.~Noradrenaline will be continued until 5 minutes after delivery of fetus."
223596467|NCT04701190|PROCEDURE|Spinal anesthesia|Spinal anesthesia using 0.5% 10 milligram heavy bupivacaine plus 12.5 microgram fentanyl
223596468|NCT01874080|DRUG|Saxagliptin/Metformin|
223747854|NCT01001611|DRUG|CKD-501 0.5mg|0.5 mg/tablet, orally, 1 tablet once daily for 24 weeks or 52 weeks (If extension study)
223747855|NCT01001611|DRUG|Placebo|Indistinguishable tablet from CKD-501, Orally, 1 tablet once daily for 24 weeks
223596469|NCT05760768|BEHAVIORAL|Individualized exercise guidance|Participants accept individualized exercise guidance. They are also managed continuously through WeChat group chat during prenatal clinical interval.
223596470|NCT00771966|PROCEDURE|Standard therapy|Standard therapy
223596471|NCT00771966|PROCEDURE|Maximization of cardiac stroke volume with fluid infusion|Maximization of cardiac stroke volume with fluid infusion
223596472|NCT04096287|BIOLOGICAL|PNT001|PNT001 diluted in 5% dextrose
223596473|NCT04096287|DRUG|Placebo|5% dextrose
223747856|NCT06473259|DRUG|Docetaxel|6 courses of docetaxel 75 mg/sqm iv
224197940|NCT06724211|OTHER|Control Group|Routine clinical care for kidney transplant patients
224197941|NCT06723756|DRUG|Treatment A: BGF MDI HFO|Participants will receive 2 inhalations of BGF MDI HFO (Budesonide/glycopyrronium/fomoterol fumarate pressurized inhalation suspension 160/14.4/4.8 μg per actuation) as a single dose via oral inhalation administered during 1 Treatment period.
224197942|NCT06723756|DRUG|Treatment B: BGF MDI HFA|Participants will receive 2 inhalations of BGF MDI HFA (Budesonide/glycopyrronium/fomoterol fumarate pressurized inhalation suspension 160/14.4/4.8 μg per actuation) as a single dose via oral inhalation administered during 2 Treatment periods.
224197943|NCT06722456|DIAGNOSTIC_TEST|Analysis of protein signatures in stool samples|Stool protein signatures are to be established in parallel to standard clinical evaluation of the intestinal inflammatory activity.
224310950|NCT04063423|PROCEDURE|blood sample|Blood sample at start and at the end of the dialysis session; membrane scoring after dialysis; total cell volume measurement of dialyzer after dialysis; micro-CT of dialyzer after dialysis.
224310951|NCT03868150|DRUG|Amiodarone Injection|Patients stratified into the amiodarone study group were administered amiodarone until day of discharge. Amiodarone administration began intraoperatively with the administration of a 150 mg IV amiodarone loading bolus prior to separation from coronary pulmonary bypass, followed by 1 mg/min IV amiodarone for six hours (360 mg), then 0.5 mg/min IV amiodarone for 18 hours (540 mg), then transitioned to 400 mg oral amiodarone twice a day until discharge. In total, patients in the amiodarone treatment group received 1,050mg of IV amiodarone plus 800mg/day of oral amiodarone thereafter until discharge.
224310952|NCT03868150|DEVICE|Intraoperative Rapid Atrial Pacing|Intraoperative rapid atrial pacing for 30 seconds after cannulation and prior to initiation of cardiopulmonary bypass by having the surgeon attach insulated forceps to the superior right atrial free wall and connected to a temporary pacemaker to burst pace at a rate of 800 bpm for 30 seconds (pulse width 1.0 ms, output: 20 mA) Patients are monitored for successful atrial fibrillation induction defined as 30 seconds of sustained atrial fibrillation on ECG.
224310953|NCT01903135|PROCEDURE|Blood test analysis in the clinical labs|for specific measurement of plasmatic bicarbonate
224197944|NCT06724107|RADIATION|UVC|It is proposed to evaluate and compare the ISQ at 1 week, 2 weeks, 3 weeks and 4 weeks in patients undergoing implant placement surgery by comparing photofunctionalised (study group) and non-photofunctionalised (control group) implants in both native bone and grafted bone. To assess whether immediate loading can be carried out before 4 weeks and how long the waiting time for implant loading can be reduced, by performing predictability curves.
224310954|NCT01903135|PROCEDURE|Pneumologist consult to establish the diagnosis of OHS|"complete respiratory check-up: Arterial blood gases analysis, spirometry, anthropometry, polygraphy or polysomnography.~Medical history, previous treatments."
224310955|NCT01563835|DRUG|bupivacaine, fentanyl|10mL of 0.125% of bupivacaine plus 50 mcg fentanyl, injected through an epidural catheter.
224197945|NCT06724042|DRUG|ISM5939|ISM5939 tablets will be administered orally once daily (QD).
224197946|NCT06724042|DRUG|Cisplatin|Cisplatin will be administered intravenously in combination with ISM5939 on day 1 during each cycle.
224197947|NCT06724042|DRUG|Docetaxel|Docetaxel will be administered intravenously in combination with ISM5939 on day 1 during each cycle.
224310956|NCT01563835|DRUG|fentanyl|fentanyl IV PCA with boluses 25-50 mcg, 3-6 minute lockout.
224310957|NCT03960203|DIAGNOSTIC_TEST|InSight|Clinical decision support (CDS) system for severe sepsis detection and prediction
224310958|NCT04132700|DEVICE|Q-NRG Metobolic Cart Device|ICU pateints will be measured using the Q-NRG device for up to 30 mins. These measurements will take place every other day while the patients are in the ICU. Then they will occur a minimum of 3 times a week until discharge.
224310959|NCT02287818|DRUG|Placebo|Placebo twice daily from Day 1 to Week 12
224310960|NCT02287818|DRUG|AC-201|AC-201 CR tablet 100 mg twice daily from Day 1 to Week 12
224310961|NCT02287818|DRUG|Febuxostat|Febuxostat 40 mg once daily from Week 4 to Week 16; titration to 80 mg once daily at Week 8 as needed to achieve serum uric acid concentration \<6 mg/dL
224310962|NCT04708574|BEHAVIORAL|Lifestyle intervention|
224310963|NCT04708574|OTHER|Placebo - Control|
223747857|NCT06473259|DRUG|Apalutamide Oral Tablet|240 mg /daily orally
224197948|NCT06724042|DRUG|Pembrolizumab|Pembrolizumab will be administered intravenously in combination with ISM5939 on day 1 during each cycle.
224197949|NCT06185335|GENETIC|ANB-010, dose 1|Adeno-associated viral vector carrying the FVIII gene single infusion at dose 1.
224197950|NCT06185335|GENETIC|ANB-010, dose 2|Adeno-associated viral vector carrying the FVIII gene single infusion at dose 2.
224197951|NCT06185335|GENETIC|ANB-010, dose 3|Adeno-associated viral vector carrying the FVIII gene single infusion at dose 3.
224197952|NCT07044115|DRUG|Recombinant Humanized Monoclonal Antibody MIL62 Injection|"Phase 1b:~Intravenous infusion. Dose group 1 (500mg), dose group 2 (1000mg); administered on Day 1 of Weeks 1, 3, 25, 27, 53, 55, and 77. Dose group 3 (500mg), administered on Days 1, 2, 3, 4, 25, 26, 27, 28, 53, 54, 55, 56, 77, and 78 of each respective week.~Phase 2:~Use the dose and frequency determined in Phase 1b."
224197953|NCT07044115|DRUG|placebo|"Phase 1b:~Intravenous infusion. Dose group 1 (500mg), dose group 2 (1000mg); administered on Day 1 of Weeks 1, 3, 25, 27, 53, 55, and 77. Dose group 3 (500mg), administered on Days 1, 2, 3, 4, 25, 26, 27, 28, 53, 54, 55, 56, 77, and 78 of each respective week.~Phase 2:~Use the dose and frequency determined in Phase 1b."
224310964|NCT04444674|BIOLOGICAL|ChAdOx1 nCoV-19|Dose of 5-7.5x10\^10vp of ChAdOx1 nCoV-19
223747858|NCT06473259|DRUG|Enzalutamide Oral Tablet|600 mg /daily orally
224197954|NCT07043608|DRUG|Zanzalintinib|Given orally (PO)
224310965|NCT04444674|BIOLOGICAL|Normal saline 0.9%|Normal saline 0.9% as placebo
223747859|NCT06473259|DRUG|Abiraterone acetate tablets|1000 mg /daily orally
223747860|NCT06473259|DRUG|Darolutamide Oral Tablet|600 mg/daily orally
223747861|NCT06473259|RADIATION|radiotherapy|radical radiotherapy on primary tumor
223747862|NCT06473259|DRUG|Triptorelin|3,75 mg im/4 w
223747863|NCT01741181|DRUG|Vitamin D supplementation|Vitamin D3 marketed by oneNine57
223747864|NCT01741181|DRUG|Placebo Pill|Placebo pill supplied by oneNine 57 imported to Singapore with approval and import licence from HSA.
224310966|NCT03257865|DRUG|Brexpiprazole|Brexpiprazole was administered orally with flexible dosing from 2 to 4 mg/day; titrated to a maximum of 4 mg/day for 3 weeks.
224310967|NCT03257865|DRUG|Placebo|Administered orally daily for 3 weeks.
224310968|NCT04730648|DRUG|PCSK9 inhibitor|For newly diagnosed ACS patients with diabetes, multivessel occlusion, or recurrent ACS attack, who are willing to accept PCSK9 inhibitor injection.
224310969|NCT01616030|OTHER|Knee-extension strength training of the fractured limb|Daily knee-extension strength training with 3 x 10 repetitions using an intensity of 10 Repetition Maximum (RM) for the hip fractured limb started as soon as possible after surgery.
224310970|NCT03574948|DRUG|5-HTP|8 weeks active substance 5-HTP (2 x 100mg per day)
224310971|NCT03574948|DRUG|Placebo oral capsule|8 weeks placebo (2 x 1 caps per day)
224310972|NCT01121848|DRUG|Leucovorin|"Pharmaceutical form:vials of 50 mg/5 mL or 500 mg/50mL Route of administration: IV~Dose regimen:"
224197955|NCT07043608|DRUG|Investigator Choice of Bone Strengthening Agents (BSA)|One BSA will be chosen, at the discretion of the investigator and given intravenously (IV)
224197956|NCT07043608|RADIATION|Non-Investigational Radiation Therapy (RT)|Non-investigational RT is permitted for symptomatic bone metastases.
224197957|NCT07043608|PROCEDURE|Bone Scan|Undergo Bone Scan
224197958|NCT07043608|PROCEDURE|Computerized tomography (CT) Scan|Undergo Imaging
224197959|NCT07043920|OTHER|Behavioral Assessment (No therapeutic intervention will be administered)|"Participants will complete two validated questionnaires:~The Fagerström Test for Nicotine Dependence (FTND) - to assess levels of nicotine dependence.~The International Physical Activity Questionnaire - Short Form (IPAQ-SF) - to quantify weekly physical activity levels (walking, moderate, vigorous)."
224197960|NCT06719661|DRUG|Dapagliflozin 10mg|Uncontrolled type 2 diabetic patients receive dapagliflozin 10 mg tablet once daily. They are asked to take it for 3 months, then return for their final assessment after 3 months
224197961|NCT06719661|OTHER|Clinical Pharmacist-led Intervention|Patients with uncontrolled type 2 diabetes will undergo dosage intensification of their dual or triple oral hypoglycemic medicines up to maximum daily doses. Further, they will be advised on specific dietary modification, education on the importance of adherence, strategies to improve adherence, including giving pill boxes, and regular follow-up every month via telephone-based communication.
224197962|NCT06719661|OTHER|Standard therapy group|Patients are receiving their standard dual or triple oral hypoglycemic therapy only.
224197963|NCT06722196|DRUG|topical amiodarone|amiodarone soaked patch placed on the left atrial roof at the end of surgery
224197964|NCT06722196|OTHER|saline solution patch|saline solution soaked patch placed on left atrial roof at the end of surgery
224197965|NCT06724783|DEVICE|Collagen membrane|Implant placement with simultaneous GBR covered with a collagen membrane
224197966|NCT06724497|PROCEDURE|face scanning pre and post orthognathic surgery|patient will be scanned pre operative using both scanners and then undergo orthognathic surgery then will be rescanned again 6 montsh later
223506739|NCT04574557|DIAGNOSTIC_TEST|micro RNA|"miRNA was isolated from serum using a miRNeasy Mini Kit (Qiagen, Cat; 217004)cDNA was isolated from obtained miRNA samples using a miScript Reverse Transcription Kit (Qiagen, Cat; 218060) Quantitative Real-Time PCR (qPCR) will be done using (miScript SYBR Green PCR Kit Qiagen Cat. No: 218073)The qPCR assays were performed in duplicate The relative expressions of Three miRNAs were selected for RT-PCR validation Two were selected from over-expressed miRNAs (miR-34a, miR-146b), one from under-expressed miRNAs (miR-122) were analyzed using the standard 2-ΔΔCT method. These miRNAs were selected due to their pathophysiological relation with NASH.~Predicted gene targets of all differentially expressed miRNAs will be identified. Genes with functions that are potentially relevant to the pathogenesis of NASH and gene targets that are commonly studied e.g. lipogenesis (e.g. FAS), inflammation (c-JUN kinase) will be included in the study"
223506740|NCT00602784|BIOLOGICAL|IC41|
223506741|NCT03266484|DIETARY_SUPPLEMENT|Probiotic Mixture|The probiotic supplement contains 8 different strains of bacteria and participants will be dosed in two dosages per a total of 40 billion bacteria daily.
223506742|NCT03266484|DIETARY_SUPPLEMENT|Placebo|A placebo which is identical to the probiotic mixture. Participants will be dosed in two dosages daily.
223506743|NCT05045599|BEHAVIORAL|Capacity Building of Health care workers and providers to deliver integrated Family Planning and Maternal, Newborn and Child Health|Community engagement to improve awareness, and use of family planning products and services
223506744|NCT03904186|BEHAVIORAL|QUIT|QUIT is a transdiagnostic Cognitive Behavioral Therapy-based smoking cessation protocol designed to address distress intolerance, anxiety sensitivity, and anhedonia in people living with HIV who smoke. QUIT is delivered in 9 60-minute individual weekly sessions over a 10-week period. Sessions are active, with treatment components practiced within and outside of the session. Participants will also receive the transdermal nicotine patch for 8 weeks, starting when they attempt to quit smoking during week 7 of the study.
223506745|NCT03904186|BEHAVIORAL|Time-Matched Control (TM)|Participants will receive a standard smoking cessation treatment, based on the clinical practice guidelines from the U.S. Department of Health and Human Services, Treating Tobacco Use and Dependence. Treatment will be delivered in nine, 60-minute sessions over a ten-week period. The treatment is based on a treatment protocol developed and used previously by Dr. Zvolensky. Because clinical guidelines recommend that all smokers attempting to quit smoking receive pharmacotherapy, participants will also receive the transdermal nicotine patch for 8 weeks.
223506746|NCT05391074|DIETARY_SUPPLEMENT|postbiotics (IGENH35.3A)|postbiotics to induce microbiota epigenetic factors
223506747|NCT05391074|DIETARY_SUPPLEMENT|vitamins (AREDS formulation and recommended daily dose)|vitamins (AREDS to prevent AMD progression
223506748|NCT04091308|OTHER|Usual Care|Usual care involves physiotherapeutic rehabilitation in an unknown format, and will, therefore, be monitored closely and described accordingly.
223506749|NCT04091308|OTHER|Usual Care with Protein Supplementation|The intake of protein supplementation (ARLA PROTINO) will be consumed by participants in the form of protein-enriched yogurts for easy consumption two times daily, with each bottle containing 14 g of protein.
223506750|NCT04091308|OTHER|Individualized Physical Exercise Training with Protein Supplementation|Besides getting prescribed individualized physical exercise training programs, this group will consume protein supplementation (ARLA PROTINO) in form of protein enriched yogurts for easy consumption, two times daily, with each bottle containing 14 g of protein.
224197967|NCT06723249|DIETARY_SUPPLEMENT|stingless bee honey|Participants under intervention group will receive 20g of stingless bee honey in a packet form but participants under control group will not receive any stingless bee honey
224197968|NCT06710626|DEVICE|Assistive Robotic Arm|The intervention involves using the N1 Implant, a wireless brain-computer interface (BCI), to enable participants to control the Assistive Robotic Arm through neural signals.
224197969|NCT07048665|DIAGNOSTIC_TEST|CT Imagesa in HCCT|Cross-sectional imaging with computed tomography (CT) scanning and magnetic resonance imaging (MRI) is most commonly used to detect hepatocellular carcinoma (HCC). CT scanning is frequently the first examination; however, MRI has superior contrast resolution and may better detect lesions less than 1 cm in diameter
224310973|NCT01121848|DRUG|OXALIPLATIN|"Pharmaceutical form: Lyophilized powder for injection (50 mg/vial or 100 mg/vial) or aqueous solution (50 mg/10 mL and 100 mg/20 mL) Route of administration: IV~Dose regimen:"
224310974|NCT01121848|DRUG|5-Fluorouracil|"Pharmaceutical form: vials of 5 g/100mL Route of administration: IV~Dose regimen:"
224197970|NCT03241134|OTHER|Dry needling|Dry needling (DN) is a myofascial treatment technique, in which a thin, solid filiform needle is inserted directly into the MTrP. During dry needling, local twitch responses (LTR) can be elicited. These are involuntary contractions of muscle fibers, leading to muscle relaxation, an increase in blood flow,recovery of the muscle metabolism and thus a reduction of pain and stiffness.
224197971|NCT03241134|OTHER|Sham needling|During sham needling, a solid, filiform needle is inserted in the skin surface at the trigger point location, without penetrating the fascia and muscle tissue.
223617855|NCT04300985|DRUG|Sham treatment|Patients will start receiving saline solution infusion 15 minutes before general anesthetic induction.
224197972|NCT07046832|DEVICE|Augmented Reality Guided Biopsy|Augmented Reality system in adjunct to standard of care guidance for needle guidance during a percutaneous biopsy
224197973|NCT07046832|DEVICE|Ultrasound Guided Biopsy|Ultrasound guided biopsy as a part of standard of care.
224197974|NCT06724835|DRUG|XKDCT293|Autologous targeted Nectin4 chimeric antigen receptor T cell injection
224197975|NCT06724835|OTHER|CAR-T cell|Nectin-4-CAR-T
224197976|NCT06884917|OTHER|Sleep Hygiene Training|Written consent will be obtained from the women, and a Personal Information Form will be applied. The General Comfort Scale (GCS) will be applied to the women. The Pittsburgh Sleep Quality Index (PSQI) will be applied to the women. Each level will include the physical, socio-cultural, psycho-spiritual, and environmental dimensions where the requirements to ensure comfort arise.
224310975|NCT05405348|BEHAVIORAL|Intervention|The patients did not eat anything during hemodialysis.
224310976|NCT00400816|DRUG|temozolomide|Schedule of Temozolomide administration: Temozolomide, 150 mg/m2/d x days 1-7 and 15-21, given every 28 days \[i.e., 7 days on/7 days off\]
223506751|NCT04389671|DRUG|Lucinactant|Lucinactant administered as a liquid at a dose of 80 mg total phospholipids (TPL)/kg lean body weight delivered
223506752|NCT02604667|OTHER|Blood tests|"Study participants will undergo a single, peripheral blood draw. Blood specimens will be used to perform hematological biomarker testing and leukocyte RNA gene expression analysis.~Hematological biomarker testing will be performed to better elucidate the mechanisms of ischemic stroke in cancer patients and will include markers of coagulation, platelet function, and endothelial integrity. This analysis will occur at MSKCC.~Leukocyte RNA gene expression analysis will be performed to evaluate whether patients with cancer and stroke more often have cardioembolic mechanisms than patients with stroke and no cancer. This analysis will occur at the University of California, Davis where investigators have previously shown that differential RNA expression patterns can predict stroke subtypes."
223617856|NCT04300985|DRUG|Magnesium Sulfate|Patient will start receiving magnesium infusion (20 mg/kg/h) 15 minutes before general anesthetic induction.
223617857|NCT03446755|DEVICE|intra uterine Cook balloon|Insertion of a hearth shaped intrauterine balloon immediately after hysteroscopic adhesiolysis and left in place for 7 days under antibiotic prophylaxis.
223617858|NCT00917930|BEHAVIORAL|physical training|intensive cardiac rehabilitation program
223617859|NCT03752138|DRUG|Group 1: TK216|Starting Dose: 288 mg/m2 given by vein on Days 1-7 of a 21 day cycle.
223617860|NCT03752138|DRUG|Group 2: TK216|Starting Dose: 144 mg/m2 given by vein on Days 1-7 and 15-21 of a 23 day cycle.
223617861|NCT03752138|DRUG|Part 2: Decitabine 10mg/m2|10mg/m2 by vein on Days 1-10 of a 28 day cycle.
223617862|NCT03752138|DRUG|Part 2: Decitabine 20 mg/m2|20 mg/m2 by vein on Days 1-10 of a 28 dayi cycle.
223617863|NCT03752138|DRUG|Expansion Phase TK216|Expansion cohort will receive the RP2D of TK216
223617864|NCT03752138|DRUG|Expansion Phase Decitabine|Expansion cohort will receive the RP2D of Decitabine
223617865|NCT03752138|DRUG|Part 2: TK216|Recommended dose from Part 1.
223617866|NCT05979948|DRUG|Zanubrutinib|Zanubrutinib, 160 mg oral capsules twice daily for 12 months
223617867|NCT05979948|DRUG|Bendamustine|Bendamustine, 70-90 mg/m2 on days 1 and 2 of each cycle for 6 cycles.
223617868|NCT05979948|DRUG|Rituximab|Rituximab, 375 mg/m2 intravenously on day 0 of each cycle for 6 cycles
223617869|NCT01269112|DEVICE|citrate regional anticoagulation|"Patients randomly allocated to 2 treatment groups:~Treatment A: - Regional citrate-based anticoagulation with the Prismocitrate® 10/2 solution (GAMBRO) Treatment B: - Standard unfractionated heparin anticoagulation"
223617870|NCT01269112|DEVICE|citrate regional anticoagulation|"Patients randomly allocated to 2 treatment groups:~Treatment A: - Regional citrate-based anticoagulation with the Prismocitrate® 10/2 solution (GAMBRO) Treatment B: - Standard unfractionated heparin anticoagulation"
223617871|NCT01062750|BIOLOGICAL|adipose tissue derived stromal cells dosage|single administration of autologous adipose tissue derived stroma cells via intrahepatic arterial catheterization
223617872|NCT00702858|DRUG|Blue Citrus|Five 700 mg Capsules three times a day to equal 15 capsules per day for 3 months
223617873|NCT00702858|DRUG|Placebo|Five Placebo capsules three times a day to equal 15 capsules per day for 3 months
223617874|NCT04118465|PROCEDURE|external cephalic version|external cephalic version
223617875|NCT02123134|DRUG|ATX-101|Formulated as an injectable solution containing deoxycholic acid at a concentration of 10 mg/mL.
223617876|NCT02123134|DRUG|Placebo|Phosphate buffered saline placebo for injection
223617877|NCT03729648|BEHAVIORAL|Expressive Arts Therapy|The intervention brings together the strengths of different art modalities, such as visual art, music, movement, dance, drama and writing to assist reflect and response in individuals to their personal issues. Such variety of art forms multiplies the avenues by which a person in therapy may seek meaning, clarity, insight and healing.
223617878|NCT02458716|PROCEDURE|Robotic Assisted Radical Prostatectomy|Undergo RARP
223617879|NCT02458716|PROCEDURE|Conventional open retropubic radical prostectomy|Undergo conventional open RRP
223617880|NCT02458716|OTHER|Laboratory Biomarker Analysis|Correlative studies
223617881|NCT02458716|OTHER|Quality-of-Life Assessment|Ancillary studies
223617882|NCT02458716|DRUG|ADT (androgen deprivation therapy) (i.e. leuprolide) plus an androgen receptor inhibitor (i.e. bicalutamide)|LHRH agonist or antagonist (i.e. leuprolide) plus an androgen receptor inhibitor (i.e. bicalutamide)
223747865|NCT06335381|OTHER|Northwell Pregnancy & Peds Chats|The Northwell Pregnancy \& Peds Chats is a personalized care digital chatbot delivered via the Conversa platform. At Northwell, patients are enrolled automatically to receive the chats when they initiate prenatal care. Chats are accessible on a smartphone, tablet, and computer. During the prenatal and postpartum periods, participants receive a weekly chat via text message or email with a link to the platform. Each chat begins with asking if there are any updates the patient wants to share regarding their pregnancy. The chats provide timely, brief educational tools and resources. They are also designed to capture clinical, behavioral health, and social health concerns that triggers yellow flags (e.g., lack of transportation to obstetrics appointment) or red flags (e.g., elevated blood pressure) that go to a 24/7 nurse-led call center who follows up to connect the participant to clinical, behavioral health, or social services as needed.
224310977|NCT04223557|DEVICE|focused power ultrasound treatment|Patients will be placed in the lateral decubitus position and receive treatment with sequential bilateral PRF ablation. Before the treatment, a professional sonographer will be responsible for the length, thickness, and width of PRF sac measurement and localisation, and utilise the ultrasonic diagnostic transducer to delineate the targeted region. The treatment will launch layer-by-layer. After confirming accurate localization of the treatment, layer-by-layer PRF ablation will be performed on the patients. The device generates and delivers a pattern of conic-shaped ultrasound energy to the PRF sac noninvasively. The treatment of FPU-mediated PRF ablation will be implemented once.
224310978|NCT04223557|DEVICE|Sham treatment|Participants will receive the same procedure as those in the FPU treatment including PRF ultrasonic measurement and localization and focused ultrasound treatment parameters setting, except that no energy will be delivered to the PRF.
223596474|NCT04332874|PROCEDURE|Isolated Limb Infusion|ILI will be performed within 18 days of initiation of pembrolizumab. ILI (infusion of melphalan and dactinomycin into the affected limb via arterial catheter) will be performed in the interventional radiology suite under anesthesia. In pediatric patients, the pediatric pharmacist w ill be consulted prior to the procedure, and an appropriate prophylactic anti-emetic therapy and dose will be selected for the individual patient.
223596475|NCT04332874|DRUG|Pembrolizumab|Pembrolizumab at a dose of 200 mg will be administered intravenously on Day 1 and every 3 weeks(+/= 3 days) thereafter. In adolescent patients, the dosing of pembrolizumab w ill be 2 mg/kg up to a maximum of 200 mg.
223596476|NCT04332874|DRUG|infusion of melphalan and dactinomycin|infusion of melphalan and dactinomycin
223596477|NCT01096693|DRUG|Urocortin 2, Urocortin 3|"After a 20 minute infusion of intra arterial saline, healthy volunteers will receive ascending doses of intra arterial Urocortin 2 (3.4, 34 and 340 pmol/min to achieve estimated end-organ concentrations of 0.06, 0.6 and 6 µg/L, respectively), Urocortin 3 (3.4, 34 and 340 pmol/min to achieve estimated end-organ concentrations of 0.06, 0.6 and 6 µg/L, respectively) and Substance P (a control endothelium-dependent vasodilator that evokes endogenous t-PA release \[2, 4 and 8 pmol/min\]). This will be co-infused with either Astressin 2B (in one of the two doses determined from Protocol 1) or saline placebo.~Bilateral venous blood sampling will be performed at baseline, immediately before the start and after each dose of Urocortin 2 and 3, to later estimate net release of tPA and PAI-1 and for plasma measurements of Urocortins 2 and 3."
223596478|NCT01096693|DRUG|Saline placebo|"After 20 minutes of intra arterial saline infusion, incremental doses of Urocortin 2, 3 and Substance P will be administered (in doses similar to Active comparator arm), co infused with saline placebo.~Bilateral venous blood samples will be taken at baseline, immediately before the start of Ucn2/Ucn3 infusion and at the end of each dose of Ucn2/Ucn3 for subsequent calculation of net release of t-PA and PAI-1."
223596479|NCT04141540|GENETIC|Molecular analyses|Comparaison of the molecular profil between two monozygotic twins carrying a deletion 22q11.2
223596480|NCT02602119|DRUG|OTL38|Infusion of OTL38 prior to surgery
223596481|NCT02411435|DRUG|CAB|CAB 30 mg as 1 tablet will be administered orally with 240 mL of water in the fasted state.
223596482|NCT02411435|DRUG|RIF|RIF 600 mg as 2 capsules of 300 mg will be administered orally with 240 mL of water in the fasted state.
223596483|NCT03648957|BEHAVIORAL|Lifestyle counselling|First behavioral counselling session will be conducted before discharge and follow-up session will be offered with 3-4 weeks intervals either by telephone or in the outpatient clinic.
223596484|NCT03648957|BEHAVIORAL|Usual care|Usual stroke care discharge session; including written and verbal encouragement to a healthy lifestyle.
223596485|NCT03648957|DEVICE|Activity tracker|Participants are encouraged to wear a activity tracker to monitor their physical activity
223596486|NCT05344586|OTHER|Hamstring stretching program with neural load|Participants will perform a hamstring stretch with neural load on their dominant leg. They will stretch five days a week, carrying out two repetitions of one minute each, taking a thirty second break in between. The stretch will be performed in a standing position with their dominant leg on a surface at a mid-thigh height approximately, where their knee is not fully stretched and remains unlocked and their back is in a neutral position. Participants will be encouraged to keep a maximum stretching sensation without feeling any pain. To perform the stretch, different tension parameters will be added in the following order (the next parameter shall not be introduced until the previous one has been exhausted): ankle dorsiflexion, cervical and craniocervical flexion, and hip flexion.
223596487|NCT05344586|OTHER|Hamstring stretching program without neural load|Participants will perform a hamstring stretch without neural load on their dominant leg. They will stretch five days a week, carrying out two repetitions of one minute each, taking a thirty second break in between. The stretch will be performed in a standing position with their dominant leg on a surface at a mid-thigh height approximately, where their knee is not fully stretched and remains unlocked and their back is in a neutral position. Participants will be encouraged to keep a maximum stretching sensation without feeling any pain. To perform the stretch, tension will be added by flexing their hip, keeping their ankle relaxed and their spine neutral.
223596488|NCT00325117|DRUG|Vildagliptin|
223596489|NCT03813264|OTHER|Routine outcome measures (ROM)|The proposed study consists of two complementary processes: the first is the routine collection of clinical data using ROM; The second process is MATRIX-based intervention that is expected to improve the course of treatment.
224310979|NCT04675814|OTHER|Adapted Physical Activity (APA)|Adapted Physical Activity (APA)
224310980|NCT02677714|RADIATION|99mTc-rhAnnexin V-128|Kit for the preparation of 99mTc-rhAnnexin V-128
224197977|NCT07047261|PROCEDURE|Adjunctive use of Xanthan-Chlorexidine based gel|"The chlorhexidine and xanthan-based gel contains 0.5% chlorhexidine digluconate, 1% chlorhexidine dihydrochloride, and 0.5% xanthan gel. Xanthan is a polymer that creates a three-dimensional, pseudo-plastic network with water, forming a stable gel that allows a slow and prolonged release of chlorhexidine, allowing effectiveness for about 30 days. Chlorhexidine digluconate is released immediately upon application, whereas Chlorhexidine dihydrochloride is gradually delivered the following days, providing bacteriostatic and bactericidal effects for up to two weeks, helping the prevention of recolonization of treated site.~The clinician cleaned and dried the implant site using compressed air and applied the XanCHX gel on the implant sites assigned to the test group, positioning the blunt needle at the bottom of the pocket and gently extruding the product while moving it out of the site. Finally, the patient was instructed not to drink or rinse for the following hour."
224197978|NCT07044934|OTHER|No Intervention: Observational Cohort|This observational cohort includes female patients undergoing non-cardiac surgery. No intervention was administered as part of the study protocol. Preoperative serum uric acid levels were measured, and patients were followed for the development of postoperative acute kidney injury. Data were analyzed retrospectively to assess the association between uric acid levels and acute kidney injury, with subgroup analyses based on menopausal status (premenopausal vs. postmenopausal women).
224197979|NCT06887062|DRUG|Bosentan|6 weeks of treatment with Bosentan, a dual endothelin receptor antagonist, administered to the large vessel vasculitis patient group
224197980|NCT00938275|DRUG|0.5g SRT2104|"SRT2104 will be supplied in two forms: as 0.5g powder which will be prepared by the pharmacist/designee into a liquid suspension and as two hard gelatin capsules, each containing 0.25g SRT2104. The dosing vehicle for the liquid suspension is 1% (by weight) hypromellose acetate succinate in water, which is used as a suspension aid and a dispersant for the SRT2104.~Each formulation of test material will be administered orally, in a single dose to the subjects in the fasted state and following consumption of a standard meal. Neither the investigator nor the subjects enrolled will be blinded to treatment assignment."
224197981|NCT00526227|DEVICE|Secura ICD|Secura Implantable Cardioverter Defibrillator (ICD) will be implanted
224197982|NCT07048548|BEHAVIORAL|Thyroid Function Monitoring|This study will include healthcare professionals from the radiology and nuclear medicine departments at INMOL Cancer Hospital with at least one year of radiation exposure. A total of 44 participants will be selected through purposive sampling. Data will be collected using a structured questionnaire and blood tests for thyroid hormones (TSH, T3, T4) to assess thyroid function. Blood analysis will be conducted using CLIA or ELISA methods. The aim is to detect any association between low-dose radiation exposure and thyroid dysfunction.
223506753|NCT02604667|OTHER|Transcranial Doppler Microemboli Detection Study|Study participants will undergo a single Transcranial Doppler Microemboli Detection Study at NYPH/WCMC or MSKCC within two weeks of enrollment. Both middle cerebral arteries will be insonated for 30 minutes by a trained technician or stroke neurologist certified in neurosonology using a fixed headset to assess for the rate and laterality of microemboli.
223506754|NCT00693459|DEVICE|Circular Anal Dilator for Transanal Hemorrhoidectomy|The Circular Anal Dilator for Transanal Hemorrhoidectomy (product #CAD01) allows the standard of care Ferguson hemorrhoidectomy to be performed and does not alter the steps of the operation. The presumed advantages are the ability of the dilator to guide an accurate dissection and also to decrease the overall time it takes to perform hemorrhoidectomy.
223506755|NCT00510562|PROCEDURE|Cranial osteopathic manipulation|This treatment is performed by exaggerating the motion asymmetry with a minimum of pressure (a few ounces) and holding the position until the motion becomes symmetrical.
223506756|NCT00510562|PROCEDURE|Sham/Placebo|A laying on of hands with no treatment being performed.
223506757|NCT00665886|DEVICE|Open Intravenous System - Vasocan®|Vasocan® Safety catheter 18 G x 45 mm (Ref. 4248139S), 20 G x 33 mm (Ref. 4248112S) y 22 G x 25 mm (Ref. 4248090S)with wings and a passive safety mechanism. To the control catheters a three-way tap ('stopcock') with extension tubing 10 cm long (Connecta® Extra 3) from BD (ref 394995)will be added.
223506758|NCT00665886|DEVICE|Closed Intravenous System - Nexiva®|BD Nexiva® Catheter (18G x 45 mm, 20 G x 32 mm, 22 G x 25 mm) (Ref. 383609,Ref. 383606,Ref. 383602) BD QSyte®, Ref. 385100 Catheter material is Vialon®. The entire system is Latex and PVC free.
223506759|NCT05659420|BEHAVIORAL|Cardiac rehabilitation comprised aerobic exercise on a treadmill accompanied by an electrocardiogram monitoring device and a blood pressure monitor|aerobic exercise on a treadmill (T7M, Motus, Paju, South Korea) accompanied by an electrocardiogram monitoring device (Q-Tel Rehabilitation Management System, Mortara Inc., Milwaukee, WI, USA) and a blood pressure monitor
223506760|NCT03122366|DIAGNOSTIC_TEST|Detection of single nucleotide polymorphisms (SNP)|Asp299Gly SNP in the third exon of the TLR4 gene will be detected in blood
223506761|NCT00673114|BIOLOGICAL|haplo/cord transplant|T-cell depleted haplo-matched cells from related donor and unrelated umbilical cord blood
223506762|NCT04447066|OTHER|No intervention|No intervention - VHIT will be used but without intervention
223506763|NCT04378088|OTHER|Validation of CEBuS|Validation of a new score for bubbles in the colon.
223506764|NCT02610257|DEVICE|Mechanical stimulus (vibration) applied on the forearm|"Local vibration will be applied using a custom-made vibratory system (named Vibrators) consisted of small vibratory devices (constructed using DC micro motors (Faulhaber® - Switzerland) bearing an eccentric load, enclosure on a PVC involucre). Vibrators measure 4.5cm x 2cm x 2cm and weight 27-31g each. Vibrators were custom-made especially for this study and therefore do not have a trade name.~Vibrators will be positioned either on the extensor carpi radialis brevis (ECRB) muscle belly or on the olecranon region. Devices will be kept in place using regular elbow elastic supports."
223506765|NCT04865978|DRUG|Apixaban|Patients randomized to apixaban will be started on a dose of 5 mg BID.
223506766|NCT04865978|DRUG|Warfarin|Patients randomized to warfarin will be started on a dose per institutional protocol and titrated to an INR goal of 2.0 - 2.5.
223506767|NCT04865978|DEVICE|LVAD implant|Subjects will undergo HeartMate 3 LVAD implant prior to randomization
223506768|NCT01009242|BIOLOGICAL|CDP6038|"Single dose:~1 mg/kg CDP6038 IV"
223506769|NCT01009242|BIOLOGICAL|CDP6038|"Single dose:~0.1mg/kg CDP6038 IV"
223506770|NCT01009242|BIOLOGICAL|CDP6038|"Single dose:~1.0mg/kg CDP6038 SC"
223596490|NCT06832280|OTHER|Educational Website Developed by Study Team|This website was developed by the study team in previous research studies.
223596491|NCT06832280|OTHER|Basic Educational Website|This website is a basic education website about hypospadias.
223596492|NCT05658588|DEVICE|Cytosorb|Cytosorb cartridge It is composed of polystyrene divinylbenzene and polyvinylpyrrolidone copolymers and targets molecules in the 5-50 kDa range, which includes the molecular mass of several cytokines
224197983|NCT07047222|BEHAVIORAL|Behavioral change communication (BCC) module|The behavior change communication (BCC) module was designed to enhance awareness and promote effective management of menstrual disorders through structured lifestyle and behavioral guidance. It consisted of three 1-hour sessions: (1) education on menstrual disorders and related risk factors; (2) healthy dietary practices; and (3) physical activity (including yoga) and other lifestyle improvements. Sessions were held from May 20 to June 30, 2023, at three public universities in Bangladesh and were delivered by trained female educators. All session dates were approved by university authorities. Activities included interactive presentations, yoga demonstrations, pamphlet distribution, quizzes, and gift giveaways. To reinforce and support behavior change, follow-up visits were conducted every two months from July 15, 2023, to January 15, 2024.
224197984|NCT06736548|BEHAVIORAL|The Sleep Treatment Education Program Together (STEP-Together)|STEP-Together is delivered in a single videoconference group session delivered live by a presenter. During the session, the participants are able to see and hear the presenter, view the presentation slides, and ask questions. The presentation includes educational information on the problem of insomnia after cancer and specific suggestions for improving sleep. Suggestions are presented in four sections addressing lifestyle issues, sleep environment, sleep timing, and managing expectations and challenges. During the course of the session, participants are asked to use these suggestions to develop an individual sleep action plan they will use to improve their sleep.
223506771|NCT01009242|OTHER|Placebo IV|"Single dose:~Placebo IV"
223506772|NCT01009242|OTHER|Placebo SC|"Single dose:~Placebo SC"
223506773|NCT01009242|DRUG|CDP 6038 SC|Optimized CDP6038 SC doses based on outcome of Cohort 1 with placebo
223506774|NCT01009242|DRUG|Methotrexate|Individual stable doses of methotrexate.
223506775|NCT05638139|BIOLOGICAL|SygeLIX-F + SygeLIX-G|SygeLIX-F (plug) is inserted through the internal orifice while cryptoglandular space is filled by SygeLIX-G (gel).
223506776|NCT03835117|DRUG|Wide-spectrum nutritional supplement|Comprehensive powder with 33 dietary supplements and 1 dietary supplement via gel capsule.
223506777|NCT03835117|OTHER|Placebo|Inactive placebo comparator
223506778|NCT06444542|BEHAVIORAL|Guardant Shield|Blood-based colorectal cancer screening
223506779|NCT05949216|BEHAVIORAL|Musical engagement sessions|Musical engagement sessions will be 2 hours long and involve improvisation and sight-reading of sheet music. Participants will supply their own instrument of choice to play. There will be four sessions total.
223506780|NCT04900935|BEHAVIORAL|POISE|POISE (Patient-centered, Optimal Integration of Survivorship and palliative carE) is a brief, population-specific intervention that consists of four sessions with palliative care specialists who have been additionally trained to evaluate and address the specific psychosocial issues and health-promoting behaviors of patients with long, uncertain cancer trajectories.
223506781|NCT01584388|DRUG|Rituximab|Rituximab 1000 mg IV times two doses, separated by approximately 15 days.
223506782|NCT01433588|DEVICE|The Calmer|This platform, called the Calmer, interacts with the infant to help reduce stress to help promote better outcomes. Infants can be placed on it for care to mimic Kangaroo Care, maternal skin to skin.
223506783|NCT01433588|OTHER|Standard of Care|Infant would receive the standard of care for bloodwork, provided a soother and facilitated tucking.
223506784|NCT02544815|DRUG|Digoxin|Digoxin 0.25 mg pills
223506785|NCT02544815|DRUG|Placebo|Placebo pills
223506786|NCT01414829|PROCEDURE|Gastroscopy|The reason for gastroscopy will be not related to the study
223506787|NCT04935294|DRUG|Danicopan|Oral tablet.
223506788|NCT04268966|DRUG|Brincidofovir|
223506789|NCT02668315|BIOLOGICAL|Transplantation of cord blood expanded with UM171|Myeloablative or submyeloablative conditioning regimen followed by an expanded cord blood transplant
223506790|NCT03039985|DEVICE|Zirconia crowns (Prettau®)|Monolithic zirconia molar crowns are, after randomization, placed in patients with or without bruxism
223506791|NCT03039985|DEVICE|lithium disilicate crowns (IPSe.max®)|lithium disilicate molar crowns are, after randomization, placed in patients with or without bruxism
223506792|NCT04824287|OTHER|pelvic floor muscle exercise|pelvic floor muscle exercises training from the researcher using the Roy Adaptation Model in addition to routine discharge training Face-to-face training was given to the individuals in the experimental group on the day before the operation, on the second and third postoperative days, and on the day of discharge. The training continued with phone calls at the first, second and third weeks and the first, second, third, and sixth months after the surgery Patients practiced exercises 6 month after surgery
223506793|NCT01293955|DRUG|JOINS 200mg|1 tablet at each time, 3 times a day
223506794|NCT01293955|DRUG|Placebo|placebo of Joins 200mg
223506795|NCT05068830|DRUG|ExPlas|"ExPlas (plasma from fit donors) is a Investigational Medicinal Product. ExPlas is plasma drawn by plasmapheresis once a month for 4 months, from a total of 30 donors (aged 18-40, BMI ≤27 kg/m2 and VO2max \>50 mL/kg/min) at the Blood Bank at St. Olavs Hospital. All unites will be virus inactivated by the Intercept method (Cerus corporation, US) in accordance with the procedures at Blood Bank at St. Olavs Hospital.~The transfusion volume will be 200 mL at every time point.~The main study consists of 6 rounds of examinations in addition to 12 plasma transfusions during the time span of one year (weekly transfusions in 3 four-week periods) and one round of examinations 2 years after baseline. A follow-up visit is also planned 5 years after baseline."
223506796|NCT05068830|DRUG|Octaplasma|"Octaplasma is defined as a Investigational Medicinal Product. Octaplasma is human pooled plasma produced by Octapharma (Lachen, Switzerland). The transfusion volume will be 200 mL at every time point .~The main study consists of 6 rounds of examinations in addition to 12 plasma transfusions during the time span of one year (weekly transfusions in 3 four-week periods) and one round of examinations 2 years after baseline. A follow-up visit is also planned 5 years after baseline."
224197985|NCT06736548|BEHAVIORAL|Coaching Session|Coaching sessions are brief (\<1hour) sessions intended to support participants in implementing their personal sleep self-management plan. In the session, participants are asked to review their progress with their plan, report on areas of sucess and difficulty with adoption, and to problem solve with the study team as needed to support their sucessful implementation their plan.
223596493|NCT02615340|DRUG|Melatonin|Study drug will be given at 21:00 - 23:59 daily, starting on the day of enrolment until ICU discharge, death, or up to 14 days, as most critically ill patients are at greatest risk of delirium in the first two weeks of admission. The study medication will be given by mouth (PO or per os) or if needed, via the feeding tube followed by a flush with 20mL water. Doses can be given up to midnight if administration needs to be delayed for procedures or investigations.
223596494|NCT02615340|DRUG|Placebo|Study drug will be given at 21:00 - 23:59 daily, starting on the day of enrolment until ICU discharge, death, or up to 14 days, as most critically ill patients are at greatest risk of delirium in the first two weeks of admission. The study medication will be given by mouth (PO or per os) or if needed, via the feeding tube followed by a flush with 20mL water. Doses can be given up to midnight if administration needs to be delayed for procedures or investigations.
223596495|NCT03251937|DEVICE|Spectra WaveWriter SCS System|Multiple modalities of stimulation therapy
223596496|NCT05494437|COMBINATION_PRODUCT|PP-01 High Dose|Cannabinoid-1 (CB1) partial agonist / GABAergic modulator
223596497|NCT05494437|COMBINATION_PRODUCT|PP-01 Low Dose|CB1 partial agonist / GABAergic modulator
223596498|NCT05494437|DRUG|Placebo|Placebo comparator
223596499|NCT05494437|DRUG|Nabilone|CB1 receptor
223596500|NCT05494437|DRUG|Gabapentin|GABAergic modulator
223596501|NCT04788394|OTHER|data review|"In this retrospective study investigators will include all children and adolescents (≤ 18 years old) with pre-existing CKD and laboratory confirmed SARS-CoV-2 infection who were treated at Hamad General Hospital, in Doha, Qatar during this pandemic using the electronic medical records since 1st March 2020 till January 20th, 2022. Indications for testing patients for SARS CoV-2 infection included:~* Clinical features suggestive of COVID-19 (fever, cough, dyspnea, rhinorrhea, sore throat, diarrhea, myalgia, anosmia, or ageusia).~* Close contact (within 6-ft of an infected person for 15 min or longer) within an individual diagnosed with SARS-CoV-2 infection \[40\].~* Admission for management of the underlying disease. le against the age-specific upper limit of reference interval (ULRI) values according to Hamad Hospital guidelines. Acute kidney injury will be defined as a serum creatinine 1.5 times greater than the ULRI.~to determine:"
223596502|NCT04788394|OTHER|data comparing|"In this retrospective study investigators will include all children and adolescents (≤ 18 years old) with pre-existing CKD and laboratory-confirmed SARS-CoV-2 infection who were treated at Hamad General Hospital, in Doha, Qatar during this pandemic using the electronic medical records since 1st March 2020 till January 20th, 2022. Indications for testing patients for SARS CoV-2 infection included:~* Clinical features suggestive of COVID-19 (fever, cough, dyspnea, rhinorrhea, sore throat, diarrhea, myalgia, anosmia, or ageusia).~* Close contact (within 6-ft of an infected person for 15 min or longer) within an individual diagnosed with SARS-CoV-2 infection \[40\].~* Admission for management of the underlying disease. le against the age-specific upper limit of reference interval (ULRI) values according to Hamad Hospital guidelines. Acute kidney injury will be defined as a serum creatinine 1.5 times greater than the ULRI.~to determine:"
223596503|NCT03478800|PROCEDURE|Acupuncture|Each treatment would take approximately 15-20 minutes and would take place immediately after practice for a total of five treatments. The needles are standard (0.2mm diameter #36 gauge 1 inch stainless steel) and during each treatment, 3-6 needles would be placed in the lower extremity in any of the following muscle groups: quadriceps, hamstrings, anterior tibialis, gastrocnemius-soleus complex, medial head of the gastrocnemius, peroneal muscles, or iliotibial band. The athletes would complete brief pre- and post-treatment surveys.
223596505|NCT00889525|DRUG|Cabergoline|Dose 1 mg/week in divided doses, increased by 1 mg/week every month, to the maximum of 5 mg/week. If response is seen than the dose at which response is seen is continued until the end of the study.
223747866|NCT06335381|BEHAVIORAL|Prenatal Telehealth Visits|The MOMs CMC/RN (interventionists) will deliver up to 12 bi-weekly self-management support telehealth visits during the prenatal period. The first telehealth visit will be 30-45 minutes in duration and follow-up visits will be 15-20 minutes. These telehealth visits will involve clinical and behavioral health check-ins; navigation to clinical, behavioral health, and social services as needed; screening for social needs during the initial telehealth visit; follow-up on referrals to resources to address social needs; and self-management support. MOMs CMCs/RNs will assess progress with engagement in self-management behaviors including asking about minutes and type of physical activity, self-monitoring (blood pressure, blood sugar, weight), and taking medications. The MOMs CMC/RN will provide brief maternal health education and support the participant in establishing behavior change goals and facilitating problem solving to address barriers to achieving goals each session.
223747867|NCT06335381|OTHER|Postpartum Telehealth Visits|The MOMs CMC/RN will conduct a telehealth visit (with navigation as needed) by phone 24 and 72 hours after labor and delivery. After the 72-hour call, telehealth visits with navigation will occur bi-weekly until 6 weeks postpartum. These telehealth visits will be 15-20 minutes in duration. Telehealth visits will include a brief clinical and behavioral health check-in, screening for social needs, navigation to clinical, behavioral health, and social services as needed, and follow-up on referrals to community resources and social services. During each visit, participants will be asked if they have experienced any signs or symptoms of concern (e.g., pain, discomfort, headaches, bleeding), screened for depression and anxiety, and be reminded about upcoming medical appointments. The CMC or RN will navigate the participant to the appropriate provider (e.g., OB, cardiologist, behavioral health) or services (e.g., emergency, social, community-based resources) as needed in a timely manner.
224197986|NCT06722742|DRUG|Ketamine only|Inj: Ketamine given to group K following spinal anesthesia
224197987|NCT06722742|DRUG|Tramadol|Inj Tramadol given to group T following spinal anesthesia
224197988|NCT07047469|PROCEDURE|Group (1): spinal anesthesia with median approach|patients undergoing orthopedic surgery will receive spinal anesthesia with median approach under ultrasound guided techniques
224197989|NCT07047469|PROCEDURE|Group (2): spinal anesthesia with paramedian approach|patients undergoing orthopedic surgery will receive spinal anesthesia with paramedian approach under ultrasound guided techniques
224197990|NCT07047846|OTHER|Dynamic soft tissue mobilization|Begin with gentle heat application or light massage to warm up the tissue for 5 minutes. Assess the range of motion and identify specific areas of tightness and pain. - Use hands or specialized tools to apply sustained pressure to the fascia and underlying muscles, concentrating on the scapular, pectoral, deltoidal, and rotator cuff muscles. Apply specific DSTM techniques to the identified muscles, gradually increasing the intensity as tolerated by the patient. Follow up with gentle stretching and strengthening exercises to maintain the gained ROM and improve muscle function.For subscapular are release Gentle circular movements over the subscapularis region to decrease the tension and increase the freedom of this muscle.For Supraspinatus and Infraspinatus Work Specific exercise over these muscles to help relieve pain and improve the shoulder joint.
223506797|NCT05068830|DRUG|Saline|"Saline is provided by the hospital pharmacies in Central Norway. The infusion volume will be 200 mL at every time point.~The main study consists of 6 rounds of examinations in addition to 12 saline infusions during the time span of one year (weekly transfusions in 3 four-week periods) and one round of examinations 2 years after baseline. A follow-up visit is also planned 5 years after baseline."
223506798|NCT05908656|PROCEDURE|Investigational procedure|Subjects that consent will have a single blood draw either via a finger stick or via venous blood draw (blood will be placed on a 5 spot blood card) used to determine whether they have Gaucher Disease or ASMD
223506799|NCT01115621|OTHER|Glutenfree diet during the first year of life|Glutenfree diet during the first year of life
223506800|NCT04308694|DRUG|Pharmacy-based methadone administration and dispensing|Eligible participants receiving between 6- and 13-days of methadone take-home doses will have methadone administration and dispensing transferred from the opioid treatment program to the partnered community pharmacy. Each participant will be assessed monthly for 3 months (at 1, 2, and 3 months following intake/baseline) to explore the feasibility of transferring their methadone administration and dispensing to the select community pharmacy.
223506801|NCT04267315|PROCEDURE|Trigger point injection|1mL injections of 1% lidocaine in the muscles identified active trigger points at the day of intervention (pectoralis major, serratus anterior, levator scapulae, latissimus dorsi, infraspinatus).
223506802|NCT04267315|PROCEDURE|Subcutaneous saline injection|0.2mL subcutaneous saline injections superficial to the muscles identified with active trigger points at the day of intervention (pectoralis major, serratus anterior, levator scapulae, latissimus dorsi, infraspinatus).
223506803|NCT04267315|OTHER|Comprehensive Rehabilitation program|Patients in both groups will undergo standard of care rehabilitation delivered by a Physiatrist, which may include Physical Therapy, Occupational Therapy, Exercise Physiologist, Rehabilitation Nurse, Psychologist, as per Physiatrist's prescription. Both the comprehensive rehabilitation program and pain medications will continue to be managed by participant's Physiatrist, who will be blinded to patient's allocation. The researchers will be responsible for TPI and for data collection.
223506804|NCT04234230|OTHER|Prevalence Survey|Questionnaire survey on self-management
223506805|NCT02908321|BEHAVIORAL|CBT|The group based manualised CBT intervention consists of The Cool Kids Anxiety Program: Autism Spectrum Disorder Adaptation (Cool Kids ASD).
223506806|NCT03780725|DRUG|BI 754111|Solution for infusion
223506807|NCT03780725|DRUG|[89Zr]Zr-BI 754111|Solution for infusion
223506808|NCT03780725|DRUG|BI 754091|Solution for infusion
223506809|NCT05967910|OTHER|chronic psychological stress|Chronic psychological stress includes symptoms of anxiety and depression.
223506810|NCT00347945|PROCEDURE|Pencil Push-ups|
223506811|NCT00347945|PROCEDURE|Office-based Vision Therapy|
223506812|NCT00347945|PROCEDURE|Placebo Office-based Vision Therapy|
223506813|NCT03559309|DIAGNOSTIC_TEST|Magnet Resonance Tomography, Carotid Arteries Sonography, Flow-mediated Dilation, Fat-tolerance Test, Laboratory Testing|Patients treated with Alirocumab in the clinical routine will have additional diagnostic tests as stated above. The clinical trial will be conducted as an open label, single arm study. The diagnostic tests will be done at baseline (BL) and after 10 weeks of treatment (W10) with Alirocumab.
223506814|NCT03242733|OTHER|Ultrasound assessment of gastric contents|Ultrasound assessment of gastric contents is performed in fasted elderly patients for hip fracture surgery.
223506815|NCT02502071|DRUG|sodium bicarbonate|All participants will receive 2 doses of 1950mg sodium bicarbonate
223506816|NCT06427174|DRUG|Fascia iliaca block|For the group who will receive the fascia iliaca block …. After induction of the general anesthesia and before skin incision, fascia iliaca block will be performed in the patient while he is in the supine position
223506817|NCT06427174|DRUG|Caudal block|second group will receive the caudal block, we use bupivacaine 0.5 mg / kg.
223506818|NCT02957123|DRUG|Intranasal auto-M2-BFs|Delivery is performed with the aerosol inhaler device (nebulizer), 2.0 mL once a day up to 30 days.
223506819|NCT03969758|DRUG|Ciprofloxacin|will receive tablet Ciprofloxacin (500 mg BDS) and tablet Metronidazole (800 mg TDS) for 2 weeks orally. Percutaneous aspiration or drainage of the liver abscess will be done when there is enough liquid content/pus amenable for aspiration or drainage. Percutaneous drainage or aspiration will be done in liver abscess with size of ≥ 5 cm and \<5 cm respectively.
223506820|NCT03969758|DRUG|Cefixime|will receive tablet Cefixime (200 mg BDS) and tablet Metronidazole (800 mg TDS) for 2 weeks orally. Percutaneous aspiration or drainage of the liver abscess will be done when there is enough liquid content/pus amenable for aspiration or drainage. Percutaneous drainage or aspiration will be done in liver abscess with size of ≥ 5 cm and \<5 cm respectively.
223506821|NCT00984633|DRUG|Rocuronium bromide (Org 9426)|0.6 mg/kg injection intubation dose
223506822|NCT00984633|DRUG|Rocuronium bromide (Org 9426)|0.9 mg/kg injection intubation dose
223506823|NCT00984633|DRUG|Sevoflurane|0.5-2.0% intravenous maintenance anesthesia
223506824|NCT00984633|DRUG|Propofol|4-10 mg/kg/hr maintenance anesthesia
223506825|NCT00375310|DRUG|Gemcitabine, Sorafenib|"Gemcitabine is given IV~Sorafenib is given orally of varying doses:~1. Sorafenib 200 mg po qd ( during combination therapy)~2. Sorafenib 400 mg po qd ( during combination therapy)~3. Sorafenib 400 mg po bid ( during combination therapy)"
223506826|NCT00375310|PROCEDURE|Radiotherapy|1.8 Gy CTV daily for 5 weeks
223596506|NCT01771159|DEVICE|TBC|"The anchor is capped and surgically implanted in the extra-peritoneal space of the suprapubic region of pubic hair of the lower abdomen using sutures sandwich and secure the anchor between the rectus abdominis muscle and the detrusor \[bladder\] muscle. Skin is closed over the implant and the bladder is drained with a Foley urethral catheter. The Phase I implant is left in place for 3+ months to allow fibroblasts and collagen from the adjacent muscles to grow into the porous PTFE and effect robust, water--tight bonding of anchor to both rectus and bladder muscles.~After a local anesthesia is injected, the remaining components of the TBC are connected forming a water-tight union of the anchor to the urinary bladder."
223747868|NCT06335381|OTHER|Home Blood Pressure Monitor|Participants will receive an Omron 10 home blood pressure monitor to use throughout the study period. Along with the cuff, participants will receive written (postcard) and video instructions (https://youtu.be/p9UEDv6nvwU) on how to accurately measure their blood pressure. Participants with diagnosed chronic hypertension or preeclampsia during the prenatal period will be encouraged to measure their blood pressure twice a day; participants without these conditions will be encouraged to measure their blood pressure twice a week. During the postpartum period, participants will be encouraged to follow their provider recommendations in terms of how often they should measure their blood pressure. Participants will be allowed to keep the blood pressure monitor after the study has completed.
224197991|NCT07047846|OTHER|Bowen Technique and 3 moves|As the client sits, take a position across from the shoulder that needs attention. Hold the side you are working on by its forearm. Arrange the forearm so that it is horizontal at about chest level, keeping the elbow at a 90˚ angle and the shoulder apart from the trunk. Move 1: This is an anterior move that involves placing the fingers of the other hand over the midpoint of the triceps and posterior deltoid tendon, which is situated deeper. The ideal way to execute the exercise is to adduct the shoulder joint to its maximum ROM while placing the thumb of the same hand on the humeral head.Move 2: After the shoulder has fully adducted to the other side, strike the humeral head percussionally in the neck's direction. Move 3: Put the arm back in the beginning position and work the anterior deltoid at its midpoint with a supero-lateral move. Then take a pause for 2 minutes and repeat the moves. Complete 3 sets of all these moves in 35 minutes including 2 minutes pause after these 3 moves.
223596507|NCT03989362|DRUG|Vopratelimab|Specified dose on specified days
223596508|NCT03989362|DRUG|Ipilimumab|Specified dose on specified days
223747869|NCT06335381|OTHER|Fitbit|Participants will receive a Fitbit to use during the study period. Participants will be asked to wear the Fitbit on their wrist throughout the day to track all activity (e.g., walking, other physical activity, sedentary activity, and sleep). All data including minutes of activity and step counts will be stored on a secure web-based platform that aggregates data from the Fitbit device. Participants will be encouraged to sync their Fitbit device every 5 days with their phone to ensure data is up to date. Participants will be allowed to keep the Fitbit after the study has completed.
223747870|NCT04629248|DRUG|Obinutuzumab|Open Label: An intravenous (IV) infusion of 1000 milligram (mg) of obinutuzumab will be administered at Week 0, Week 2, Week 24, and Week 26. Participants who relapse during the open-label treatment period may be eligible for further treatment.
224197992|NCT07046962|OTHER|Intervention Type Device: Manual pump expressing breast milk|"Since this study aimed to examine the macronutrient content of milks expressed from the same mother with three different methods, one day apart, the data collection process was carried out in stages. The methods determined by randomization were hand expressing breast milk, hand pumping and electric pumping.~Hand expressing: Milk was expressed by hand until the milk flow stopped at the mother's breast. While the baby was sucking from one breast, the other breast was milked, and a 10 cc sample was taken from the collected milk and placed in sterile fallopian tubes."
224197993|NCT07046962|OTHER|Intervention Type Device: Hand pumping breast milk|"Since this study aimed to examine the macronutrient content of milk expressed from the same mother with three different methods, one day apart, the data collection process was carried out in stages. The methods determined by randomization were hand expressing breast milk, manual pump expressing and electric pump expressing.~Manual pump expressing: Milk was expressed with a manual pump until the milk flow stopped in the mother's breast. While the baby was sucking from one breast, the other breast was milked, and a 10 cc sample was taken from the collected milk and placed in sterile fallopian tubes."
224197994|NCT07046962|OTHER|Intervention Type Device: Electric pumping breast milk|"Since this study aimed to examine the macronutrient content of milk expressed from the same mother with three different methods, one day apart, the data collection process was carried out in stages. The methods determined by randomization were hand expressing breast milk, manual pump expressing and electric pump expressing.~Electric pump expressing: Milk was expressed with an electric pump until the milk flow stopped in the mother's breast. While the baby was sucking from one breast, the other breast was milked, and a 10 cc sample was taken from the collected milk and placed in sterile fallopian tubes."
224197995|NCT07046884|BEHAVIORAL|Integrated Oncological Decision-making Model|In the IODM-based practice, the following three information components should be incorporated when forming a personalized treatment plan: 1. State-of-the-art oncological treatment options with advantages and disadvantages; 2. General health status based on physical, psychosocial, and emotional functioning; 3. Goals and preferences of the patient, both in treatment and daily life. Together with the professionals, optimal tools and strategies to integrate these components within the care path will be discussed.
223506827|NCT04394559|BEHAVIORAL|Discharge Order Sets|Discharge order sets will be implemented in the electronic health record and will provide surgeons a guideline for a recommended dose and duration of opioids for each commonly performed orthopedic surgery.
223506828|NCT04394559|BEHAVIORAL|Pharmacist-Led Discharge Counseling and Communication|Two visits by a trained inpatient pharmacist, including an intake visit to determine previous barriers to safe medication use, and a discharge counseling session with patients and caregivers regarding safe and effective opioid use after discharge; pharmacist communication with providers regarding the post-discharge pain management plan.
223506829|NCT04394559|BEHAVIORAL|Post-discharge Pain Management Follow-up|An outpatient pharmacist pain management follow-up visit (with additional contact as needed) embedded within routine post-operative care for managing pain and opioid use.
223506830|NCT04394559|BEHAVIORAL|Patient Engagement Pain Management App|A mobile patient-reported outcomes application for assessing pain, function, and possible development of opioid use disorder.
223596509|NCT05813704|DEVICE|Coronary Crossing System of Shanghai MicroPort Rhythm|The mechanical vibration generated by the Coronary Crossing System through the piezoelectric effect is amplified and transmitted to the distal end of the guidewire to achieve high-frequency vibration at the tip of the guidewire, and then achieve efficient and safe penetration of the fibrous cap of the CTO.
223596510|NCT01193114|BEHAVIORAL|Ecologically Based Treatment (EBT)|Substance abuse treatment (the Community Reinforcement Approach), case management and housing.
223747871|NCT04629248|DRUG|Tacrolimus|Open Label: Participants will receive tacrolimus at a starting oral dose (PO) of 0.05 mg/kilogram (kg) (participant dry weight) per day divided into two equal doses given at 12-hour intervals, titrated to serum trough level 5-7 Nanograms per millilitre (ng/mL). Optimized tacrolimus dose will be maintained for a maximum 52 weeks dependent on response and then tapered over 8 weeks. Participants who relapse during the open-label treatment period will have their dose of tacrolimus tapered over 8 weeks and may be eligible for further treatment.
223747872|NCT04629248|DRUG|Methylprednisolone|Premedication: Methylprednisolone 80 mg IV will be administered between 30 and 60 minutes prior to the obinutuzumab infusion in all study periods.
223747873|NCT04629248|DRUG|Acetaminophen|Premedication: Acetaminophen (650-1000 mg, or equivalent dose of a similar agent) PO or IV will be administered between 30 and 60 minutes prior to the obinutuzumab infusion in all study periods.
223747874|NCT04629248|DRUG|Diphenhydramine|Premedication: Diphenhydramine (50 mg, or equivalent dose of a similar agent) PO or IV will be administered between 30 and 60 minutes prior to the obinutuzumab infusion in all study periods.
223596511|NCT01193114|BEHAVIORAL|Treatment as Usual (TAU)|Treatment/intervention as normally provided by community service agencies that service substance abusing homeless families.
223596512|NCT03536234|DRUG|Triptorelin acetate depot|3.75 mg triptorelin depot (monthly injections). 3 doses in total
223596513|NCT05240365|DEVICE|SDF modified Hall technique|"* Preparation for Hall technique and selection of the crown.~* Clinical application of SDF.~* Cementation of the selected crown."
223747875|NCT04804397|DIETARY_SUPPLEMENT|Sucrose|Sucrose sweetened soft drinks
223747876|NCT04078685|PROCEDURE|Standard catheter ablation|Radiofrequency catheter ablation using a standard ablation catheters: not equipped with contact-force sensing
223747877|NCT04078685|PROCEDURE|Contact Force-sensing-based catheter ablation|Radiofrequency catheter ablation using a Contact-Force-sensing ablation catheter
223747878|NCT00001086|DRUG|Indinavir sulfate|
223747879|NCT00001086|DRUG|Abacavir sulfate|
223747880|NCT00001086|DRUG|Efavirenz|
223747881|NCT06851559|DRUG|Vonoprazan|Vonoprazan will be administered orally as a tablet
223596514|NCT05240365|DEVICE|Conventional pulpotomy and stainless steel crown|"* Teeth will be anesthetized .~* Rubber dam will be used and high suction in pulpotomy procedure.~* Cavity outline will be performed by sterile #330 high speed bur using water spray.~* Caries will be removed by large spoon excavator.~* pulpal exposure will be occurred then the roof of pulp chamber will be removed by low speed round bur. Hemostasis will be obtained by applying pressure with moist cotton pellet with saline.~* Teeth will be treated by using sterile cotton pellet with formcresol for three to five min then, remove it.~* Pulp stumps of will be dressed with reinforced zinc oxide eugenol, IRM®\*~* Tooth Preparation will be done followed by placement of stainless-steel crown"
223596515|NCT02434419|DEVICE|PENS|The participants underwent one 30-min session every week for 12 consecutive weeks. PENS was delivered by a needle electrode inserted in the medioclavicular line, 2 cm below the clavicle at a 90° angle towards the skin at a depth of approximately 1 cm. PENS was undertaken at frequency of 20 Hz at the highest amplify (0-20 mA) without causing pain. PENS was delivered simultaneously in both pectoral muscles.
223596516|NCT02434419|OTHER|Specific training|Patients underwent specific training exercises to improve pectoral fitness.
223596517|NCT03953469|DIETARY_SUPPLEMENT|Passiflora incarnata|One-time administration of 1/8 tsp solid extract Passiflora incarnata providing 900mg of Passiflora incarnata
223596518|NCT01873040|BEHAVIORAL|Social Media plus information pages|Participants will receive access to the study vaccine website information pages and social media feature including blogs, discussion forums, expert chats, and ask an expert.
223596519|NCT01873040|BEHAVIORAL|Vaccine Information Pages|Participants will receive access to the study vaccine website information pages.
223596520|NCT00467129|GENETIC|microarray analysis|
223596521|NCT00467129|GENETIC|mutation analysis|
223747882|NCT06851559|DRUG|Placebo|Placebo will be administered orally as tablet
223747883|NCT03965962|BIOLOGICAL|VRVg-2|"Pharmaceutical form: Powder and solvent for suspension for injection;~Route of administration: IM"
223747884|NCT03965962|BIOLOGICAL|Purified Inactivated Rabies Vaccine|"Pharmaceutical form: Powder and solvent for suspension for injection;~Route of administration: IM"
223747885|NCT03965962|BIOLOGICAL|Human Diploid Cell Vaccine (HDCV)|"Pharmaceutical form: Powder and solvent for suspension for injection;~Route of administration: IM"
223747886|NCT03965962|BIOLOGICAL|Rabies immune globulin (human)|"Pharmaceutical form: Solution for injection;~Route of administration: IM"
223747887|NCT06368817|RADIATION|3-Dimensional Conformal Radiation Therapy|Undergo 3D-CRT
224197996|NCT07047898|DRUG|The group receiving dexmedetomidine infusion|Dexmedetomidine will be administered intravenously at an infusion dose of 0.2-0.7 µg/kg/hour during the maintenance phase of anesthesia.
224197997|NCT07047898|DRUG|The group not receiving dexmedetomidine infusion|Infusion will not be given.
223596522|NCT00467129|GENETIC|polymerase chain reaction|
223596523|NCT00467129|GENETIC|polymorphism analysis|
223596524|NCT00467129|OTHER|laboratory biomarker analysis|
223596525|NCT00467129|OTHER|questionnaire administration|
223747888|NCT06368817|PROCEDURE|Biospecimen Collection|Undergo blood and CSF sample collection
223747889|NCT06368817|DRUG|Carboplatin|Given IV
223747890|NCT06368817|DRUG|Etoposide|Given IV
223747891|NCT06368817|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
223747892|NCT06368817|PROCEDURE|Lumbar Puncture|Undergo LP
223747893|NCT06368817|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223747894|NCT06368817|OTHER|Questionnaire Administration|Ancillary studies
223747895|NCT06368817|PROCEDURE|Surgical Procedure|Undergo second-look surgery
223747896|NCT06363851|DRUG|Kylo-11|Administered SC.
223747897|NCT06363851|DRUG|Placebo|Administered SC.
223596526|NCT03045718|BEHAVIORAL|Horticultural Therapy|The Horticultural Therapy intervention will be delivered by trained facilitators at the Therapeutic Garden at Hort Park, and consists of 1 hour sessions weekly for 9 months. The Horticultural Therapy program is designed to stimulate the senses through interaction with the tasks and the environment, promote social interaction and also to promote a sense of self-worth through completion of projects. It encompasses a range of activities including general gardening and also project-based craft activities.
223596527|NCT02431078|PROCEDURE|Routine comprehensive treatment|Radical gastrectomy for gastric cancer and postoperative adjuvant chemotherapy
223596528|NCT03454607|DEVICE|FREE robot|FREE robot to hold endoscope
223596529|NCT01939327|DRUG|Lenalidomide/Rituximab|
223596530|NCT05643950|DEVICE|Foley catheter|"Silicone Foley catheters are transurethral balloon catheters used for the treatment of bladder emptying disorders, as well as for drainage of urine from the urinary tract, continuous fluid irrigation, and/or medication administration. Its use is suitable for a prolonged period of no more than 29 days and is used in Urology, Internal Medicine, Surgery, Obstetrics and Gynaecology Services.~For this study, conventional Foley-type catheters whose use is approved in Spain for routine use will be used. Silicone Foley catheters, usually available in 2- and 3-way, are made of silicone and consist of a body, drainage funnel, inflation funnel, irrigation funnel (if present, only on 3-way catheters) and balloon valve. The product is sterile and single use."
223596531|NCT05643950|DEVICE|T-Control catheter|The T-control® catheter is a flexible, sterile silicone tube with an inflatable balloon at the distal tip, a polytetrafluroethylene membrane integrated into its body, and a sliding fluid control valve. The valve, built into the catheter, provides additional functions to the catheter, such as turning urine flow on and off after insertion (functions currently provided by accessories such as caps or valves) and controlling urination during the insertion process (function that is not provided by any other device). In this way, accidental loss of urine can be avoided from the first moment of use until its withdrawal. Additionally, it has a safety cap that reduces the possibility of accidental movements of the valve before use or during transport and fixing. The design has been developed in such a way that, once inserted, it facilitates autonomous use even for the elderly or patients with limited manual dexterity. The device is sterile and single use, like any conventional Foley catheter.
223596532|NCT01930838|PROCEDURE|Gastric bypass operation|
223596533|NCT04587310|DIAGNOSTIC_TEST|Laparoscopic Sleeve Gastrectomy|bariatric surgery
223596534|NCT04522167|DRUG|FYB203 (Proposed aflibercept biosimilar)|Patients will receive 1 IVT injection of FYB203 every 4 weeks for the first 3 consecutive doses, followed by 1 IVT injection every 8 weeks through study completion.
223596535|NCT04522167|DRUG|Eylea® (Aflibercept)|Patients will receive 1 IVT injection of Eylea® every 4 weeks for the first 3 consecutive doses, followed by 1 IVT injection every 8 weeks through study completion.
223596536|NCT03698552|BIOLOGICAL|ADCT-602|Starting dose of ADCT-602: 30 μg/kg given by vein.
223596537|NCT04044339|DRUG|TD-5202|Study Drug to be administered orally
223596538|NCT04044339|DRUG|Placebo|Placebo to be administered orally
223747898|NCT06971289|OTHER|blood test|blood test as part of routine care
224197998|NCT07048145|DEVICE|Vaginal Kegel Exercise Ball|A 90-gram medical-grade silicone device with internal jiggle balls used intravaginally for 30 minutes daily in the first 3 weeks and 1 hour daily in the final 3 weeks.
224197999|NCT07048145|BEHAVIORAL|Pelvic Floor Muscle Training|Participants will perform daily Kegel exercises for 6 weeks, starting with 5 sets per day and increasing to 10 sets per day in the final 3 weeks. Each set consists of 10 fast and 10 slow contractions.
223596539|NCT01400568|DRUG|LPS challenge with nebulized LPS|20,000 EU of Clinical Center Reference Endotoxine (CCRE) will be applied by an AKITA® Jet Nebulizer under the constant supervision of the site staff.
223596540|NCT01400568|DRUG|fluticasone propionate (FP)|The dosage of FP will be 2 mg. This dosage will be inhaled by 4 puffs of Flutide® forte 500 Diskus® 500 µg / dose according to the package insert.
223596541|NCT02801565|DRUG|Conventional controlled ovarian stimulation proctol|Conventional controlled ovarian stimulation proctol without rhGH.
223596542|NCT04800848|DEVICE|Mask|Physical Fitness is evaluated with the use of a face mask
223596543|NCT06474637|DEVICE|AEON Endoscopic Powered Stapler Handle and Reload|The AEON™ Endoscopic Stapler places two triple-staggered rows of titanium staples while simultaneously transecting between the two triple-staggered rows of staples. The size of the staples and staple line length are based on the selection of the Stapler Reload (2.0mm, 2.5mm, 3.25mm, 4.0mm, 5.0mm and 5.5mm).
223596544|NCT01107314|OTHER|Phlebotomy|Blood draws (total 48 cc blood)
223596545|NCT04346836|BEHAVIORAL|Low-intensity, general-fitness exercises|"24 session of low-intensity, general-fitness exercises (12 weeks, twice a week)~A single session of exercise lasted 40 minutes and consisted of 42 low-intensity, general-fitness exercises. Perception of effort was monitored using the Borg 6-20 rating the perceived exertion (RPE).~Thirty-three exercises were done sitting down, seven standing, and two in the hand-and-knees position. The exercises were classified as either aerobic, musculo-articular, or stabilising. The aerobic portion served as a general warm-up for the subsequent exercises, and the musculo-articular section focused on strengthening muscles and enhancing the mobility of joints in the upper limbs, the lower limbs and the torso. Stabilising exercises were designed to improve the stability of the body and to augment spatio-visual coordination."
223596546|NCT04346836|BEHAVIORAL|Psychoeducation|A psychoeducation provided by psychotherapist. Twenty minutes of psychoeducation, which contained mini lectures about mental well-being, psychohygiene and healthy dietary habits.
223596547|NCT01506999|BIOLOGICAL|MULTIGENE SCREENING FOR SINGLE SNPS|DNA will be genotyped employing a multicolour assay system for SNPs based on TaqMan MGB (Minor Groove Binder) probes.
223596548|NCT01258023|BIOLOGICAL|Fluad 1x|"15 µg antigen/strain:~* A/California/07/2009 (H1N1) - like strain~* A/Perth/16/2009 (H3N2) - like strain~* B/Brisbane/60/2008- like strain MF59 adjuvant 9.75µg ai 0.5ml"
223596549|NCT03529981|OTHER|Tuned Vibroacoustic Stimulation (TVS)|TVS is an exteroceptive cue that may reduce subjective and physiological indicators of stress and increase behavioral performance
223596550|NCT03529981|OTHER|no active intervention|No intervention will be administered
224198000|NCT06329921|OTHER|PTT protocol|Patients will be monitored using the nurse-managed PTT protocol.
224198001|NCT06329921|OTHER|anti-Xa protocol|Patients will be monitored using the pharmacy-managed anti-Xa protocol.
224198002|NCT06212544|BEHAVIORAL|Immediate Intervention|Enhanced microeconomic intervention
223596551|NCT03734003|DEVICE|liquid nitrogen|As an active comparator, for patients with cutaneous warts, liquid nitrogen crytherapy is applied
223596552|NCT03734003|DEVICE|controllable infrared bioeffect system|As an experimental arm, for patients with cutaneous warts
223596553|NCT04082715|DRUG|carbidopa/levodopa and celecoxib|Every patient of this arm will get one bottle of carbidopa/levodopa and one bottle of celecoxib. At treatment initiation, Carbidopa/Levodopa will be taken once daily for 3 days, then twice daily for 3 days, and then thrice daily over one week and then continue on that dose for the duration of the treatment period (12 weeks total). At the last treatment visit (end of the treatment period), patients will begin tapering off the medication as follows. S/he will start with carbidopa/levodopa twice daily for 3 days and then once daily for 3 days before discontinuing it completely.Celecoxib will remain constant once daily for patients of this arm throughout the treatment period, but it will not be given during the tapering down at the end of the treatment period(12 weeks total).
223747899|NCT01798472|PROCEDURE|cemented hemiarthroplasty|Patients aged 80 years and older operated with an cemented hemiarthroplasty. Fixation of the wedge-shaped, polished ChromCobalt steel femoral stem to host bone by use of PolyMetylMetAcrylat bone cement. The acetabulum is not replaced. The prosthesis articulates with the patients acetabulum with an unipolar, femoral head made of ChromCobalt steel.
223747900|NCT01798472|PROCEDURE|reverse hybrid total hip arthroplasty|Patients aged 65 to 79 years operated with an uncemented femoral component combined with cemented acetabular cup. The femoral stem is fixed to the host bone by press-fit technique. We use a tapered, proximally hydroxyapatite coated, titanium stem. The acetabular cup is fixed to the host bone with bone cement. We use an all-polyethylene design. Bone cement consists of PolyMetylMetAcrylat.
223747901|NCT01798472|PROCEDURE|cemented total hip arthroplasty|Patients aged 65 to 79 years operated with a cemented femoral stem combined with a cemented acetabular cup. Femoral and acetabular component are fixed to the host bone by use of bone cement. The femoral stem is a polished, wedge-shaped design made of ChromCobalt steel. The acetabular cup is fixed to the host bone with bone cement.The acetabular cup an all-polyethylene design. Bone cement consists of PolyMetAcrylat.
223747902|NCT01798472|PROCEDURE|uncemented hemiarthroplasty|"Patients aged 80 years and older are randomized to uncemented hemiarthroplasty. Fixation of the tapered, proximally hydroxyapatite coated, titanium stem to the host bone by press-fit-technique. The acetabulum is not replaced. The prosthesis articulates with the patients acetabulum with an unipolar, femoral head made of ChromCobalt steel."
223747903|NCT04919577|DIAGNOSTIC_TEST|X-ray|We defined RSS as (1) the presence of symptoms such as nausea, vomiting, or abdominal fullness, (2) refasting after liquid or semi-liquid diets, (3) imaging methods (X-ray, CT, upper gastroenterography) confirmed without mechanical obstruction. All three conditions must be met at the same time and should occur within 30 days after operation.
224198003|NCT06212544|BEHAVIORAL|Delayed Intervention|Usual care and then access to enhanced microeconomic intervention
224198004|NCT05131828|DRUG|Metformin and clemastine in combination|"Metformin hydrochloride 500 mg prolonged release (SR) tablet for oral administration.~Clemastine hydrogen fumarate 1.34 mg tablet for oral administration."
223747904|NCT00500851|DEVICE|Electromagnetic imaging for jejunal tube placement (CORTRAK)|Jejunal feeding tubes are placed using electromagnetic imaging (CORTRAK)
223747905|NCT00500851|DEVICE|Endoscopy|Endoscopic placement of jejunal feeding tubes
223747906|NCT05525845|OTHER|Functional Magnetic Resonance Imaging (pCASL-MRI)|MRI's will be performed at multiple points on each visit day.
224198005|NCT05131828|DRUG|Placebo|Placebo tablets to match both metformin and clemastine tablets.
223747907|NCT05525845|OTHER|Intragastric Balloon|Intragastric Balloon will be placed during Visit 2 study day and inflated to maximum tolerated volume. Patient will then be scanned in the MRI.
223747908|NCT05525845|OTHER|Elemental Meal|Patient will ingest the tasteless elemental meal until their maximum level of fullness. Once full, the patient will be scanned in the MRI.
223747909|NCT05525845|OTHER|Hedonic Meal|Patient will ingest meal of their choice from a local food delivery service and eat until they reach their maximum level of fullness. Once full, the patient will be scanned in the MRI
223747910|NCT04278079|PROCEDURE|Pars Plana Vitrectomy with Internal Limiting Membrane peel|Pars plana vitrectomy with staining and peeling of internal limiting membrane
223747911|NCT01547000|DRUG|placebo|Administered up to 8 weeks.
223747912|NCT01547000|DRUG|extended-release guanfacine (Intuniv)|1 mg tablets; flexible dosing up to 4 mg/day for up to 16 weeks.
224198006|NCT02892916|DRUG|Ketamine|A bolus of low intravenous dose (sub-anaesthetic) 0.5 mg/kg ketamine following induction of anaesthesia.
224198007|NCT02892916|DRUG|Placebo|A bolus of an intravenous normal saline solution following induction of anaesthesia.
223747913|NCT00867451|BEHAVIORAL|Sleep Intervention|A structured sleep protocol is taught to parents, use of a white noise generator
223747914|NCT00867451|DRUG|Melatonin|Body Weight \<40mg will be given 3mg at bedtime for two weeks Body Weight \>40mg will be given 6 mg at bedtime for two weeks
223747915|NCT01834014|DRUG|Bevacizumab|5 mg/kg intravenously administered over 90 minutes (can be reduced to 30 minutes at the minimum) on day 1 of a 2-week cycle. Liver resection if resectable after 8 cycles or continue until progression of disease.
224198008|NCT04299646|RADIATION|Steretactic radiotherapy|Steretactic radiotherapy
224198009|NCT06657326|DEVICE|BioFreedom™ Ultra cobalt-chromium Biolimus A9™-coated stent|Stent implantation
224198010|NCT06657326|DEVICE|BioFreedom™ stainless steel Biolimus A9™-coated stent|Stent implantation
224198011|NCT05163548|DEVICE|PerQseal Plus Device|Percutaneous closure of femoral artery access site created by 14 to 22 F sheaths (up to 26 F arteriotomy) in patients undergoing Percutaneous Transcatheter procedures.
223747916|NCT01834014|DRUG|Cetuximab|250 mg/m2 intravenously administered over 60 minutes (400 mg/m2 over 120 minutes as the initial dose) on day 1 and day 8 of a 2-week cycle. Liver resection if resectable after 8 cycles or continue until progression of disease.
223747917|NCT01834014|DRUG|L-OHP|85 mg/m2 intravenously administered over 120 minutes on day 1 of a 2-week cycle. Liver resection if resectable after 8 cycles or continue until progression of disease.
223747918|NCT01834014|DRUG|l-LV|200 mg/m2 intravenously administered over 120 minutes on day 1 of a 2-week cycle. Liver resection if resectable after 8 cycles or continue until progression of disease.
224198012|NCT02787148|BEHAVIORAL|Cognitive behavioral therapy|
223596554|NCT04082715|DRUG|placebo1 and celecoxib|Every patient of this arm will get one bottle of placebo1 and one bottle of celecoxib. At treatment initiation, placebo1 will be taken once daily for 3 days, then twice daily for 3 days, and then thrice daily over one week and then continue on that dose for the duration of the treatment period (12 weeks total). At the last treatment visit (end of the treatment period), patients will begin tapering off the medication as follows. S/he will start with placebo1 twice daily for 3 days and then once daily for 3 days before discontinuing it completely. Celecoxib will remain constant once daily for patients of this arm throughout the treatment period, but it will not be given during the tapering down at the end of the treatment period(12 weeks total).
223596555|NCT04082715|DRUG|placebo1 and placebo2|Every patient of this arm will get one bottle of placebo1 and one bottle of placebo2. At treatment initiation, placebo1 will be taken once daily for 3 days, then twice daily for 3 days, and then thrice daily over one week and then continue on that dose for the duration of the treatment period (12 weeks total). At the last treatment visit (end of the treatment period), patients will begin tapering off the medication as follows. S/he will start with placebo1 twice daily for 3 days and then once daily for 3 days before discontinuing it completely. placebo2 will remain constant once daily for patients of this arm throughout the treatment period, but it will not be given during the tapering down at the end of the treatment period(12 weeks total).
223596556|NCT02352753|DRUG|Denosumab|Subcutaneous (SC) injection.
223596557|NCT05672706|PROCEDURE|CFR and IMR group|Participants will undergo repeat intracoronary adenosine administration during CFR and IMR measurement
223596558|NCT02490592|OTHER|Fluoride Foam|Fluoride foam - Flúor Care (NaF 1.23%) (G1)
223596559|NCT02490592|OTHER|Fluoride gel|Fluoride gel - Flugel FFA (NaF 1.23%) (G2)
223596560|NCT00539305|DRUG|testosterone gel|50-100mg applied topically daily for six months
223596561|NCT00539305|DRUG|placebo gel|applied topically daily for six months
223596562|NCT00921843|DRUG|Methadone 0.1mg/kg|Subjects will receive methadone as their intraoperative opioid.
223596563|NCT00921843|DRUG|Methadone 0.2mg/kg|Subjects will receive methadone as their intraoperative opioid.
223747919|NCT01834014|DRUG|5-FU|400 mg/m2 intravenous bolus on day 1 of a 2-week cycle. Liver resection if resectable after 8 cycles or continue until progression of disease.
223747920|NCT01834014|DRUG|5-FU|2400 mg/m2 continuous infusion over 46 hours on day 1 and 2 of a 2-week cycle. Liver resection if resectable after 8 cycles or continue until progression of disease.
223747921|NCT06010940|DIETARY_SUPPLEMENT|Dietary supplement|nasogastric tube and oral care
223747922|NCT06010940|OTHER|Physical therapy|Designed physical therapy program consisting of neuromuscular electrical stimulation in addition to exercises for oropharyngeal muscles.
223747923|NCT00469560|DRUG|Deferasirox|
223747924|NCT01408030|DRUG|Sterile saline|0.9%, 0.1 ml spray in each nostril bid
223596564|NCT00921843|DRUG|Methadone 0.3mg/kg|Subjects will receive methadone as their intraoperative opioid.
223596565|NCT00921843|DRUG|Control|Subjects will not receive methadone as their intraoperative opioid.
223596566|NCT05909384|OTHER|Survey|Multiple rounds of surveys collecting information on sepsis diagnosis and management in resource-limited settings.
223596567|NCT02930304|OTHER|first physiotherapy|physiotherapy program consists of cold pack, Transcutaneous electrical nerve stimulation (TENS), and home exercise programme including stretching and eccentric strength exercises will be applied five times a week total 15 sessions
223747925|NCT01408030|DRUG|Bevacizumab|1% solution in saline, 0.1 ml spray in each nostril bid
223747926|NCT01408030|DRUG|Estriol|0.1% suspension in methylcellulose, 0.1 ml spray in each nostril bid
223747927|NCT01408030|DRUG|Tranexamic Acid|10% solution in saline, 0.1 ml spray in each nostril bid
223747928|NCT04142554|DRUG|Parsaclisib|Parsaclisib tablets (1.0, 2.5 or 5 mg) are administered orally daily for up to 14 days
223596568|NCT02930304|OTHER|second physiotherapy|physiotherapy program consists of cold pack, Transcutaneous electrical nerve stimulation (TENS), and home exercise programme including stretching and eccentric strength exercises will be applied five times a week total 15 sessions. Kinesio taping will be applied two times per week total six times in addition to conventional physiotherapy
223596569|NCT02930304|OTHER|third physiotherapy|physiotherapy program consists of cold pack, Transcutaneous electrical nerve stimulation (TENS), and home exercise programme including stretching and eccentric strength exercises will be applied five times a week total 15 sessions. Extracorporeal shockwave therapy (ESWT) will be applied one times per week total three session.
223596570|NCT03979885|BEHAVIORAL|Smoking cessation counseling (Quitline)|Quitline offers community-based counseling session with a cessation counselor.
223596571|NCT03979885|BEHAVIORAL|Smoking cessation pharmacotherapy (e.g, nicotine replacement therapy)|Participants will be encouraged to speak to their doctors about using highly effective pharmacotherapies for smoking cessation.
223596572|NCT03979885|BEHAVIORAL|Financial incentives for smoking cessation|Participants will receive financial incentives for bioconfirmed smoking cessation.
223596573|NCT03979885|BEHAVIORAL|Financial incentives for use of evidence-based smoking cessation therapies|Participants will receive financial incentives for the use of evidence-based smoking cessation therapies including Quitline counseling, community-based smoking cessation programs and pharmacotherapies
223596574|NCT05281198|DIETARY_SUPPLEMENT|tart cherry juice|2, 8oz bottles of Montmorency tart cherry juice daily; 8oz taken in AM, 8oz taken in PM
223596575|NCT05281198|DIETARY_SUPPLEMENT|Placebo|2, 8oz bottles of placebo juice daily; 8oz taken in AM, 8oz taken in PM
223596576|NCT02870101|DIAGNOSTIC_TEST|Nucleic acid amplification test 1 for NG and CT|A combination test using real-time PCR to detect DNA from NG and CT.
223747929|NCT05701410|DIAGNOSTIC_TEST|DPD scintigraphy|Bone tracer scintigraphy, diagnostic for transthyretin amyloidosis.
223747930|NCT02130661|DRUG|Rilapladib 25 mg|White, round, biconvex, film coated tablet of 25 mg. Taken orally along with food.
223747931|NCT02130661|DRUG|Rilapladib 250 mg|White, round, biconvex, film coated tablet of 250 mg. Taken orally along with food.
223747932|NCT02130661|DRUG|Itraconazole|100 mg capsule with a blue opaque cap and pink transparent body. Taken orally along with food.
223747933|NCT03755687|OTHER|Art Therapy Intervention|Standardized mixed media art directives.
223747934|NCT01424423|DRUG|Placebo|Placebo
223747935|NCT01424423|DRUG|GSK1223249|I.V. Infusion
223596577|NCT02870101|DIAGNOSTIC_TEST|Nucleic acid amplification test 2 for NG and CT|A combination test using target amplification to detect RNA from NG and CT.
223596578|NCT02870101|DIAGNOSTIC_TEST|Nucleic acid amplification test 3 for NG and CT|A combination test using real-time PCR to detect DNA from NG and CT.
223596579|NCT02481531|OTHER|Previously marketed infant formula|
223596580|NCT02481531|OTHER|Previously marketed formula using a similar protein|
223596581|NCT04899505|OTHER|Evaluation on appearance of unpleasant body odors|Percentage of patients reporting discomfort with unpleasant body odor that occurred during their treatment. This percentage will be calculated from the response to item Q1 of the patient questionnaire during the fourth course of chemotherapy in the AJA oncology department.
223596582|NCT02403401|DRUG|Levonorgestrel (BAY98-7196)|Levonorgestrel 40 µg/d intravaginal ring (treatment for 365 days, 28 days wearing period for each ring)
223596583|NCT05660317|OTHER|Tip control score|Scoring of endoscopist's tip control performing snare tip soft coagulation to the margins of a endoscopic mucosal resection (EMR) defect
223596584|NCT06075407|DEVICE|Assessment of fluid responsiveness by electrical cardiometry|"Electrical cardiometry (EC) measurements: by the ICON\_ hemodynamic monitor (ICON Cardiotropic, Inc., La Jolla, CA 92307; Osyka Medical GmbH, Berlin, and Germany, model C3).~Transthoracic echocardiography (TTE) measurements will be performed equipped with echo probe. SV of the left ventricle will be calculated using LVOT diameter (D) just below the aortic valve from parasternal long-axis view and VTI measured in LVOT from apical 5 chamber view (by pulsed wave Doppler)."
223596585|NCT03168178|DRUG|Standard Antibiotic Treatment|"Participants randomized to this intervention will receive standard antibiotic treatment.~The placenta will be submitted for pathologic exam after delivery and investigators will collect maternal and neonatal outcomes"
223596586|NCT03168178|OTHER|No Antibiotic Treatment|Participant randomized to this arm of the study will not receive antibiotics. The placenta will be submitted for pathologic exam after delivery and investigators will collect maternal and neonatal outcomes
223596587|NCT01431053|DRUG|aspirin|Aspirin 50mg po daily
223596588|NCT01431053|DRUG|Exemestane|Exemestane 25mg po daily
223596589|NCT01957813|BEHAVIORAL|Lifestyle Counseling|"Peer educators will be trained using existing materials to deliver accurate messaging on FP/dual method use, during individual encounters and in group sessions.~Screening for unmet FP need in DICs Providing job aids to FP counselors Expanding FP methods with intra-uterine contraceptive devices (IUCD) and implants Time change in DIC hours of operation"
224198013|NCT03728101|DRUG|Simvastatin, Dabigatran Etexilate|The subjects receive dabigatran etexilate with and without simvastatin administration
224198014|NCT06053203|OTHER|Exposure of interest - Moderate or High-risk Preeclampsia|No intervention
223596590|NCT01957813|OTHER|Standard Health Services|Peer education and health services
223596591|NCT03806686|BIOLOGICAL|Placebo|Sterile normal saline
223596592|NCT03806686|BIOLOGICAL|ID93+GLA-SE|ID93 is a recombinant protein antigen comprising 4 antigens from Mycobacterium tuberculosis (Mtb). The adjuvant GLA-SE is a TLR4 agonist in a stable oil-in-water emulsion.
223747936|NCT03239587|BEHAVIORAL|Musical Intervention|Participants wait for 30 minutes in waiting area with a Steinway Spirio grand piano that plays 30 minutes of simulated piano music.
224310981|NCT04380766|PROCEDURE|Evaluation of changes in the diagnostic-therapeutic pathway for patients affected by pancreatic cancer|Comparison between the pre-COVID and COVID groups of general, clinical, endoscopic and surgical outcomes
224310982|NCT00335114|DRUG|cyclosporine ophthalmic emulsion|
223596593|NCT05137028|OTHER|Otago Exercise|"Otago exercise protocol~Strengthening exercise:~Resistance exercise for knee flexors, knee extensors, hip abductor, ankle dorsiflexors, ankle planterflexors~Balance exercise:~knee bending, backward walking, walking and turning around, sideway walking, tendem stance, tendem walking, one leg stand, heel walking, toe walking, heel to toe walking, sit to stand, stair walking"
223596594|NCT00534547|PROCEDURE|Duodenal Exclusion|duodenal-jejunal bypass
223596595|NCT06166199|BEHAVIORAL|HIIT combined with resistance training|"Patients with SLE will undergo supervised HIIT on an ergometercycle, 4 x 4 minutes interval, (85-90% of maximal heart rate in 4 minutes and lower intensity for another 4 minutes etc). The HIIT is combined with resistance exercises for upper and lower extremity. In total the training takes around 50 minutes per occasion and will be performed 2 times/week, for 3 months. In addition, the patients will exercise, according to the program, by themselves once a week.~Between months 3 and 6 the patients exercise by themselves, 3 times/week, with video-call/telephone support from a physiotherapist once a week."
223596596|NCT06418490|DEVICE|Three-dimensional visualization technology|Three-dimensional reconstruction technology is a software that can collect CT and MRI data, perform image segmentation and three-dimensional reconstruction of the liver, gallbladder, dilated bile ducts, pancreas, venous, and arterial systems step by step. The software is called Abdominal Medical Image 3D Visualization Software (MI-3DVS, software copyright registration number: 2008SR18798).The AR-ANS (Software Copyright No.: 2018SR840555) is an intraoperative navigation system that integrates three-dimensional visualization technology.This modification provides visual guidance for surgeons when ligating or protecting critical vascular tissues during surgery.
223596597|NCT00392730|DIETARY_SUPPLEMENT|Remove Mn from PN if evidence of increased brain Mn on MRI|Withhold Mn-containing trace element cocktail and add zinc, copper and chromium individually to PN
223596598|NCT02166619|DEVICE|tDCS + physical therapy|"Bihemispheric tDCS involves application of very low-amplitude direct currents (2 mA or less) via surface scalp electrodes. It produces a sub-sensory level of electrical stimulation wich remains imperceptible by most people during application. In a small percentage of patients, it may cause minimal discomfort with a mild tingling sensation, which usually disappears after a few seconds. Depending on the polarity, tDCS can increase or decrease corticomotor excitability. Anodal tDCS is able to facilitate neurons depolarization - increasing cortical excitability - while, on the other hand, cathodal tDCS hyperpolarizes the resting membrane potential, reducing the neuronal firing and the cortical excitability.~Other: Physical Therapy"
223596599|NCT00413036|DRUG|lenalidomide|once daily oral capsule
223596600|NCT04435275|OTHER|Virtual Assistant first, then Human Coach|Instructions to aid healthcare worker adherence to proper PPE and intubation and extubation procedure is given by a VA (e-coach) in place of a safety officer (a human coach).
224310983|NCT03429010|PROCEDURE|"New guideline anesthesia strategy team"|"New guideline anesthesia strategy team"
224198015|NCT03560960|DRUG|Pramlintide challenge test|Enrolled subjects will have a pre-trial blood draw (3 ml) and will be placed with an IV needle for future blood draws. Pramlintide will be subcutaneously injected in the abdominal area. For each arm the participants will be randomized so that half will be given a dose of 0.8 mcg/kg and the other half of the arm a dose of 1.6 mcg/kg. Blood will be drawn before and at 5, 30, 60, and 180 min after injection. Vital signs and blood glucose will also be checked at these time points. Thirty minutes after the injection, subjects will be offered a standard meal. Subjects will have a final check of vital signs and blood glucose approximately 15 min before discharge.
224198016|NCT01721369|DIAGNOSTIC_TEST|Transient Loss of Consciousness (T-LOC)|
223506831|NCT02968875|DEVICE|Endurance Training|40 people will submitted to endurance training: 20 will perform a continuous training and 20 will perform an interval training. The variables that will be analyzed are maximum aerobic power, endurance, heart rate, prehension strength, Mini-Mental State Examination (MMSE), REY's test, biological examination and level of BDNF plasma, before and after the intervention and one month after the end of the intervention and one month after the end of the intervention.
223506832|NCT02968875|OTHER|therapeutic education meetings|Group of 20 people will be the control group and will not perform ET. However, they will have 9 therapeutic education meetings.
223596601|NCT04435275|OTHER|Human Coach first, then Virtual Assistant|instructions to aid healthcare worker adherence to proper PPE and intubation and extubation procedure is given by a safety officer (a human coach).
223596602|NCT05454657|DEVICE|Heart rate variability biofeedback + treatment as usual|"Heart rate variability biofeedback is a biobehavioral intervention involving rhythmic breathing at resonance frequency (RF) that stimulates the baroreflex and increases heart rate variability.~Treatment as usual may include any outpatient substance use disorder treatment or mutual-help group participation."
223596603|NCT05454657|BEHAVIORAL|Treatment as usual only|Treatment as usual may include any outpatient substance use disorder treatment or mutual-help group participation.
223596604|NCT05532202|BEHAVIORAL|NICU Mom and Baby Net|See arm descriptions.
223596605|NCT05532202|OTHER|NICU Developmental Awareness System|See arm description.
223596606|NCT06530368|OTHER|Calisthenic home exercise programs|Participants in the second group were informed about calisthenic home exercise programs face to face and were asked to perform these exercises as home exercises for eight weeks.
223596607|NCT01369641|PROCEDURE|Insertion of Pressure Equalization (PE) Tubes|If the subject consents to participate in the study, a separate consent for insertion of pressure equalization (PE) tubes will be obtained. The PE tubes will then be inserted into the posterior inferior quadrant of the tympanic membrane in the office under topical anesthesia.
223596608|NCT01369641|DRUG|Sodium Thiosulfate (STS)|Drops of STS will be added to the experimental ear only prior to initial cisplatin infusion.
223596609|NCT01369641|OTHER|Saline (Placebo)|Drops of balanced saline solution will be added to the placebo comparator ear prior to initial cisplatin infusion.
223596610|NCT01369641|DRUG|Cisplatin|Cisplatin chemotherapy infusion in the dose range of 80-120mg/m2
223596611|NCT04151433|PROCEDURE|Comparison between 2 different laparoscopic techniques in conservative surgical treatment of endometriomas (both arms are existing and accepted surgical strategies).|cf. different arms
223596612|NCT06007820|PROCEDURE|Large Volume Thoracocentesis|Large Volume Thoracocentesis
223596613|NCT06007820|PROCEDURE|Pigtail Catheter|Pigtail Catheter
223596614|NCT05301010|DRUG|Faceptor|NNG-TMAB (trastuzumab) 150 mg, 440 mg, lyophilized power for injection, manufacturered by Nanogen Pharmaceutical Biotechnology JSC.
223596615|NCT05301010|DRUG|Herceptin|Herceptin (trastuzumab) 150mg, 440mg, powder for concentrate for solution, manufactured by Roche.
223596616|NCT05301010|DRUG|Docetaxel|The drug Docetaxel in this study has the brand name Taxotere manufactured by Sanofi company.
223747937|NCT03239587|PROCEDURE|Blood Draws|"No Musical Intervention - Control Group: Blood drawn before, and about 30 minutes after participant stands in the waiting room without music.~Musical Intervention Group: Blood drawn before, and about 30 minutes after in waiting room with a Steinway Spirio grand piano that plays 30 minutes of simulated piano music."
223747938|NCT03239587|BEHAVIORAL|Questionnaires|Participants complete 2 questionnaires about anxiety and stress levels. It should take about 20-30 minutes to complete.
223596617|NCT01749878|DRUG|REGN1500|
223596618|NCT01749878|DRUG|placebo|
223596619|NCT00398840|DRUG|ARQ 171|
223596620|NCT06583265|DRUG|Observational|To observe if endometrial compaction ≥ 5% in down regulated FET cycles increases clinical pregnancy rate.
223596621|NCT01317901|DRUG|TRU-016|100 mg TRU-016 lyophilized solution for infusion at 10 or 20 mg/kg (or 6 mg/kg, if necessary) on Days 1 and 15 of each 28 day cycle
223596622|NCT01317901|DRUG|Bendamustine|Bendamustine by IV administration on Days 1 and 2 of each 28 day cycle.
223596623|NCT01317901|DRUG|Rituximab|Rituximab by IV administration at 375 mg/m\^2 on Day 2 of each 28 day cycle.
223596624|NCT05574088|PROCEDURE|Apical patency with file|After an informed consent , One group will receive apical patency intervention with k file number 10 while the other will be control group
223596625|NCT00913939|PROCEDURE|MRI Guided Needles to deliver HDR Brachytherapy|Patients in this arm will receive two fractions (treatments) of brachytherapy over 14 days (+/- 7 days).
223596626|NCT00913939|PROCEDURE|MRI Guided Needles to deliver HDR Brachytherapy|Patients in this arm will receive 2 fractions (treatments) of brachytherapy before the start of RT, and 4-5 weeks towards the end of EBRT.
223596627|NCT00544791|DRUG|melatonin|5 mg, oral, daily dose for 6 months
223596628|NCT00544791|DRUG|placebo like melatonin tablets|
223747939|NCT00104455|DRUG|activated recombinant human factor VII|
223747940|NCT00729183|DRUG|Odanacatib|Odanacatib 50 mg tablets, taken orally once weekly for 24 months.
223596629|NCT00098579|DRUG|alvocidib|Given IV
223596630|NCT00098579|DRUG|doxorubicin hydrochloride|Given IV
223596631|NCT03494582|PROCEDURE|Sacral Hysteropexy|Abdominal approach for uterine suspension
223747941|NCT00729183|DRUG|Placebo|Matching placebo tablets to odanacatib taken orally once weekly for 24 months.
223747942|NCT00729183|DRUG|Vitamin D3|Vitamin D3 tablets (5600 IU) taken orally once weekly for 24 months.
223747943|NCT00729183|DRUG|Calcium supplement|Calcium supplement 500 mg tablet taken orally once daily (up to \~1200 mg total) for 24 months.
224310984|NCT05998512|OTHER|Observational register|This is a non-interventional observational registry on patients
224198017|NCT06939322|OTHER|Use of the Log-AFTER software|The LOG-AFTER software is used for long-term follow-up care after cancer to empower patients
224198018|NCT06937242|DEVICE|Ottobock C-Leg 4 Microprocessor Knee|Subjects in the intervention group who can walk more than 0.83m/s in the 2-minute walk test (2MWT) will receive the Ottobock C-Leg 4, a stance-and-swing microprocessor knee.
224198019|NCT06937242|DEVICE|Ottobock Kenevo|Subjects in the intervention group who can walk up to 0.83m/s (3km/hr) in the 2-minute walk test (2MWT) will receive the Kenevo, a stance-only microprocessor knee.
224198020|NCT06943235|DRUG|Probiotics|Subjects received probiotics before radiotherapy
224198021|NCT06943235|RADIATION|concurrent Hyperfractionated Radiotherapy|Increase radiation dose on the basis of conventional radiotherapy
223596632|NCT03494582|PROCEDURE|sacrospinous Hysteropexy|Transvaginal approach for uterine suspension
223596633|NCT01561742|DRUG|Minocycline|Minocycline will be given orally at 200 mg a day for 4 months
223596634|NCT01561742|DRUG|Placebo|EquivalentPlacebo will be given
223596635|NCT01059994|DRUG|Placebo sildenafil|Oral, daily, 1 week.
223596636|NCT01059994|DRUG|Sildenafil|oral, 25mg, daily for 1 week
223596637|NCT06976645|PROCEDURE|Levator muscle resection|Levator muscle resection
224198022|NCT06942728|DEVICE|nLIFE EyeFitness|A software called nLIFE EyeFitness, certified as a Class I Medical device, allows to carry out individualized rehabilitation exercises at home, using own PC or tablet, with monitoring by the Center's operators.
224198023|NCT06943261|OTHER|task oriented training|The 8-week intervention program targets fine motor and functional play skills in children through progressive weekly activities. Week 1 focuses on eye-hand coordination (e.g., stacking blocks, bead stringing), followed by grasp and release control in Week 2 (e.g., object transfer tasks). Week 3 enhances reaching and precision (e.g., targeting and catching), while Week 4 develops bilateral coordination (e.g., buttoning, tearing paper). Week 5 works on visual-motor planning (e.g., drawing, tracing), and Week 6 encourages daily functional play (e.g., pouring, pretend cooking). Week 7 combines skills (e.g., dressing a doll, coin placement), and Week 8 consolidates learning through review and practice of previous tasks.
224310985|NCT03792295|DRUG|acetominophen, ibuprofen, oxycodone|Multimodal pain treatment group
224310986|NCT03792295|DRUG|Oxycodone|Classic opiod pain treatment group
224310987|NCT04790708|RADIATION|Lutetium-177 (177Lu)-DOTATOC|5 cycles of 3,7 e 5,55 gigabequerel (GBq) of 177Lu-DOTATOC every 8-10 weeks. Cumulative activity: 18,5 e 27,75 GBq
223596638|NCT00773773|OTHER|serum specimens obtained will be utilized for proteomic profiling comprising MALDI-TOF MS, and serum biomarker assays.|Patients referred for prostate biopsy as part of their routine care are to be recruited. Patients will undergo standard medical evaluation/care by undergoing a prostate biopsy because of an elevated PSA blood test and/or an abnormal digital rectal prostate examination. The protocol involves obtaining the research blood sample at the time of routine pre-biopsy blood draw. As such, an extra five (40 mL) tubes of blood will be drawn. The serum specimens obtained will be utilized for proteomic profiling comprising MALDI-TOF MS, and serum biomarker assays.
223596639|NCT05393973|OTHER|Core stability exercises along with conventional physical therapy|"Core stability exercises included neck isometric exercises(flexion, extension, lateral flexion, rotation), chin tuck, chin tuck into towel, cervical extension + 10 minutes hot pack+ 10 minutes stretching (cervical flexors, extensors, rotators), session will be of 30-40 minutes, three times a week, for 4 weeks duration.~Chin Tuck: In standing subject pulls back the chin( as if trying to make a double chin) while keeping the eyes level. This will be done for 15 repetitions.~Cervical extension: In a standing position, the subject grasps the base of the neck, with both hands while extending the neck as far as possible. This will be done for 15 repetitions"
223596640|NCT05393973|OTHER|Swiss ball exercises along with the conventional physical therapy protocol|Swiss ball exercise will be executed in the following order, assume supine posture on the treatment bed by fully extending their legs and putting them back on the bed in the most comfortable posture with hands on the abdomen. Second, while in the supine posture, support the head with one hand and insert a small Swiss ball near the back of the head with the other hand. Third, after having contacted the ball to the area below the back of the head, slowly turn the head and neck in the shape of the number '8'. Fourth, after having set 3 repetitions of rotating the head and neck for 10 seconds and then taking 10 seconds of general resting as 1 set of exercise, a total of 3 sets of exercise were executed with 1 minute of general resting taken between each set of exercise. Then perform neck flexion, extension, side bending, and rotation, hold each movement for 10 seconds + Hot pack (10 minutes) + 10 minutes of cervical stretching. Perform the exercise three times a week for 4 weeks duration.
223596641|NCT04311931|OTHER|Active Dance Program|All Creative Dance sessions comprised five phases: 1) opening ritual (5 min), in which participants will be welcomed and will be informed about the objectives and structure of the session; 2) warm-up (15 min), in which body muscle groups will be activated through the introduction of basics elements of movement; 3) main phase (30 min), will be proposed individual, pair and group activities, in order to achieve the objectives described above. This phase will end with a choreography composition; 4) cool-down (5 min) with stretching and physiological parameters normalization; and 5) ending ritual (5 min), in which the participants will be invented to share their sessions' experience and they will fill a sheet with attendance, exercise intensity perception (Borg Scale) and satisfaction's (Caregiver Treatment Satisfaction questionnaire).
223596642|NCT02760810|DEVICE|Marketed Contact Lens|Narafilcon A
223596643|NCT02564328|GENETIC|Intravenous stem cell transplantation|Intravenous injection of autologous bone marrow mesenchymal stem cell transplantation
223747944|NCT06161805|DRUG|Esketamine hydrochloride|Esketamine dosing regimen is set at 0.1 mg/kg/h as starting dosage. Dosage will be gradually increased based on heart rate, oxygen saturation, blood pressure and side effects (e.g. nausea and dissociative effects) during a period of 8 hours to a maximum of 0.5 mg/kg/h (in steps of 0.1-0.3-0.5 mg/kg/hour). This dosage regimen is similar to that used earlier by Sigtermans et al. \[1\].
223747945|NCT06161805|DRUG|Placebo|8 hour infusion with saline (NaCl 0.9%)
223747946|NCT04706143|BIOLOGICAL|COVID-19 Vaccines|different available vaccines: live inactivated, mRNA and viral vector vaccines
223747947|NCT03807011|DRUG|fentanyl group|fentanyl 2 μg/kg
223747948|NCT03807011|DRUG|remifentanil group|remifentanil 0.2 μg/kg/min
223747949|NCT03637803|DRUG|MRx0518|MRx0518 is a live biotherapeutic product consisting of a lyophilised formulation of a proprietary strain of bacterium. The study dosing regimen is one capsule two times per day for the duration of the treatment period.
224198024|NCT06943261|OTHER|conventional therapy|The control group will receive standard physical therapy consisting of general exercises aimed at improving overall strength, flexibility, and gross motor skills, without specifically targeting visual-motor integration or fine motor skills. Sessions will also include non-specific recreational activities such as free play or unstructured tasks. The intervention will be conducted three times per week, with each session lasting 45-60 minutes, over a total duration of 8 weeks.
223596644|NCT04133714|DEVICE|multi-channel tDCS|multi-channel transcranial direct current stimulation, tDCS
223596645|NCT04133714|DEVICE|single-channel tDCS|single-channel transcranial direct current stimulation
223596646|NCT04556318|DEVICE|Ion Mobility Spectrometry (IMS)|Two breathing gas samples will be taken from each study participant using ion mobility spectrometry with an ultrasound-based spirometer. The total sampling time is 1 minute (at least 5-7 breath takes) following an analysis time of 5-12 minutes.
223596647|NCT03250572|DIAGNOSTIC_TEST|serum ferritin|serum samples and ferritin ELISA test
223596648|NCT03369613|DEVICE|transcranial electrical stimulation|The device is a Neoprene headcap that holds an array of padded electrodes close to the scalp to stimulate the underlying brain.
223596649|NCT05840588|DRUG|Antibiotic Treatment|Antibiotic Amoxicillin or Amoxicillin/Clavulanic acid
223596650|NCT05840588|DIETARY_SUPPLEMENT|Probiotic Bifidobacterium breve PRL2020 treatment|Probiotic Bifidobacterium breve PRL2020
223596651|NCT04494308|OTHER|biomarker identification|flow cytometric analysis of eosinophils membrane molecules
223596652|NCT00820222|DRUG|capecitabine|oral medication; daily dose divided into morning and evening dose and taken for 14 days of 21 day cycle
223596653|NCT00820222|DRUG|lapatinib|oral medication; daily dose taken once a day
223596654|NCT00820222|DRUG|trastuzumab|infusion therapy; loading dose of 8mg/kg, followed by 6mg/kg given every 3 weeks
223596655|NCT01742689|DRUG|Desmopressin intranasal spray|10 microgram per puff, 40 microgram is Descript
223596656|NCT01742689|DRUG|Placebo intranasal spray|Saline spray identical to desmopressin, administered as 4 sprays
223596657|NCT01742689|DRUG|Indomethacin suppository|Indomethacin suppository 100 milligram single dose
223747950|NCT03637803|DRUG|Pembrolizumab 25 MG/1 ML Intravenous Solution [KEYTRUDA]|Pembrolizumab is a potent humanised immunoglobulin G4 (IgG4) monoclonal antibody (mAb) with high specificity of binding to the programmed cell death 1 (PD1) receptor , thus inhibiting its interaction with programmed cell death ligand 1 (PD-L1) and programmed cell death ligand 2 (PD-L2). The study dosing regimen is 200mg (two 4ml vials of 25mg/ml solution) for IV infusion once every three weeks.
224198025|NCT06942169|BEHAVIORAL|Mindfulness-Based Self-Compassion Training|Mindfulness-Based Self-Compassion Training is a very comprehensive approach that addresses the awareness and acceptance of individuals towards their bodies, as well as encouraging them to live a conscious life. Studies found that self-compassion increases well-being during menopause (Brown, 2015; Arab et al., 2020). Psychiatric nursing is a special field that works to evaluate, diagnose, and enhance mental health in every area where people are present.
223596658|NCT05188495|DRUG|trastuzumab(Henlius®) combined with Pertuzumab(Perjeta®) and Chemotherapy|trastuzumab(Henlius®) combined with Pertuzumab(Perjeta®) and Chemotherapy； TPC:treatment of physician's choice,include taxanes，Gemcitabine, capecitabine, vinorelbine
223596659|NCT00932165|DRUG|Exemestane|"Aromasin® Tablets 25mg, depending on the Investigator prescription. Frequency and duration are according to Package Insert as follows.  The usual adult dose is 25 mg of exemestane administered orally once daily after a meal."
223596660|NCT06005519|OTHER|low AGE diet education|Participants were divided into ten-person groups. Each group was individually invited for a face-to-face meeting where they were provided with a 50-minute low-AGE diet education prepared in accordance with the recommendations of the American Diabetes Association and the Turkish Society of Endocrinology and Metabolism. During the first 20 minutes of the education, a PowerPoint presentation highlighted the importance of choosing plant-based, low-AGE foods and emphasized cooking methods such as boiling, steaming, and preparing meals with added liquids. Participants were advised against frying, roasting, and grilling. Additionally, information was provided on marinade techniques and the use of spices or ingredients such as lemon or vinegar to lower pH in meals. Following the education, participants were given a dietary diary to record their food intake and were asked to self-assess their diet adherence on a scale of 1 to 10 on a weekly basis.
223596661|NCT03795090|COMBINATION_PRODUCT|Regular Patient privacy curtain|Laundered curtains, used in the hospital, coming from the hospital inventory.
223596662|NCT03795090|COMBINATION_PRODUCT|Antimicrobial Coated curtains|Antimicrobial coating consist of active polymers that are approved by USFDA and USEPA.
223596663|NCT00002140|DRUG|Ethambutol hydrochloride|
223596664|NCT00002140|DRUG|Clarithromycin|
223596665|NCT00002140|DRUG|Azithromycin|
223596666|NCT00242593|DRUG|Rosiglitazone|4 mg twice daily oral rosiglitazone or placebo pill for 18 months
223596667|NCT05105867|BIOLOGICAL|Anti-CD19 Universal CAR-T Cells injection|Anti-CD19 Universal CAR-T Cells injection will be administered by vein after lymphodepletion.
224310988|NCT04790708|RADIATION|Yttrium-90 (90Y)-DOTATOC|5 cycles of 1,85 e 2,775 GBq of 90Y-DOTATOC every 8-10 weeks. Cumulative activity: 9,25 e 13,875 GBq
223596668|NCT04038762|PROCEDURE|cuff deflation-inflation -deflation method|Nasotracheal intubation placed with video-laryngoscopy assistance, via the tracheal tube cuff inflation-deflation method with or without the aid of Magill forceps
223596669|NCT00588094|DRUG|Rituximab, Ifosfamide, Carboplatin, VP-16, Mesna, G-CSF, Stem Cell Transplant|"ANC must be ≥1000/µl and platelet count must be ≥50,000/µl. Rituximab will be administered at a dose of 375 mg/m2 IV on days 1 and 3 of the each cycle. Premedication will be given.ICE will be administered as follows: Day 3: Etoposide 200 mg/m2 IV q12 hrs x 3. Day 4: Ifosfamide 10 g/m2 and MESNA 10 g/m2 mixed and infused together as a continuous infusion over 48 hours. Day 5: Carboplatin IV dosed by the Calvert formula using an AUC of 5.~Carboplatin dose (mg) = 5 x (Clcr + 25) For the first ten patients enrolled, G CSF will be administered beginning on day seven of each cycle and G CSF will continue until stem cell collection is completed. The dose will be 960 ug or 10 ug/kg if weight is greater than 100 kg.~For the remaining patients, G-CSF will be administered for 10 days beginning on day 7 for cycle 1. The dose will be 300-480 ug/d. For cycle 2 the dose will be 960 ug or 10ug/kg if weight is \> 100kg. Leukapheresis will continue."
223596670|NCT06010134|OTHER|Physical Therapy Program|Physical Therapy Program plus Whole Body Vibration
223596671|NCT01336023|DRUG|insulin degludec/liraglutide|Insulin degludec/liraglutide treatment will be initiated and titrated (individually adjusted) twice weekly according to the mean self measured plasma glucose (SMPG) (fasting). Insulin degludec/liraglutide is injected subcutaneously (under the skin) once daily.
223596672|NCT01336023|DRUG|insulin degludec|Insulin degludec treatment will be initiated with 10 U and titrated (individually adjusted) twice weekly according to the mean SMPG (fasting). Insulin degludec is injected subcutaneously (under the skin) once daily.
223596673|NCT01336023|DRUG|liraglutide|Liraglutide will be started with 0.6 mg and subsequent 0.6 mg weekly dose escalation to 1.8 mg. Liraglutide dose of 1.8 mg/day will be continued for the remaining part of the trial. Liraglutide is injected subcutaneously (under the skin) once daily.
223596674|NCT03134131|DRUG|ONC201|ONC201 is an oral, small molecule selective antagonist of DRD2 that induces tumor cell death.
223596675|NCT03951116|DRUG|FCN-437|FCN-437c is a selective and potent CDK4/6 dual inhibitor, with broad antitumor activity in preclinical pharmacology models, favorable physical and pharmacokinetic (PK) properties, and acceptable toxicity profile in nonclinical studies.
223596676|NCT04805710|DRUG|clopidogrel combined with rivaroxaban arm|Patients who have been selected will be randomized to the clopidogrel combined with rivaroxaban arm. clopidogrel 75 mg once daily and rivaroxaban 10 mg once daily
223596677|NCT03137329|BEHAVIORAL|Exercise program|Physical therapy for aerobic and resistance training exercises
223596678|NCT03137329|DIETARY_SUPPLEMENT|Nutrition|Nutrition supplementation via HMR for lifestyle arm only
223596679|NCT03137329|PROCEDURE|WLS|Weight loss surgery as planned
223596680|NCT04597840|PROCEDURE|Incisional hernia repair with reinforcement of biosynthetic mesh|The biosynthetic mesh (Phasix or Bio-A meshes) will be placed as a sublay in the retromuscular position to reinforce midline fascial closure. All the surgical procedure (including placement and fixation of the mesh) will be performed according to a standardized protocol.
223596681|NCT04597840|PROCEDURE|Incisional hernia repair with simple suture or synthetic mesh reinforcement.|Based on the discretion of the surgeon, the incisional hernia repair will be done by simple suture or by synthetic mesh reinforcement. All the surgical procedure (including placement and fixation of the mesh if applicable) will be performed according to a standardized protocol.
223596682|NCT03837132|BEHAVIORAL|Palliative care assessment|Patients with advanced pancreatic cancer will have regular palliative care assessment with palliative care team
223596683|NCT05437432|PROCEDURE|VITA AMBRIA|25 onlay restroations will be fabricated from Vita-ambria glass ceramic press system.
223596684|NCT05437432|PROCEDURE|IPS e.max press|25 onlay restroations will be fabricated from IPS e.max glass ceramic press system.
223596685|NCT00504374|BEHAVIORAL|Questionnaire|Symptoms questionnaire lasting about 5 to 10 minutes.
223596686|NCT03369002|DRUG|seladelpar|Oral single dose 10 mg
223596687|NCT00783458|DRUG|Mometasone Furoate Nasal Spray|One dose (2 sprays in each nostril) of Mometasone Furoate Nasal Spray
223596688|NCT00783458|DRUG|fluticasone nasal spray|One dose (2 sprays in each nostril) of fluticasone nasal spray
223596689|NCT04510896|OTHER|InheRET|Primary Appropriate Referral Rates 6-months pre-intervention vs post-intervention Compare appropriate genetic counseling referral rates (as defined by NCCN guidelines) per patient (across all sites) in the pre-intervention vs post- intervention period. Only referrals to Michigan Medicine genetics clinics will be included in the statistical analysis. Having access to MM health records, we will be able to assess the appropriateness of the referrals.
223596690|NCT04510896|OTHER|Patient Acceptance|Acceptance by Patients Over the course of the study Acceptance measures will include completion rates and levels of ease of use of InheRET by the patient. Impact measures will include uptake of advised risk management interventions. We will qualitatively describe why patients do not follow up with their referral. We will explore patterns of acceptance and impact levels by demographic and clinical data using correlation, t- tests, ANOVA, or their non-parametric equivalents.
223596691|NCT04510896|OTHER|Physician Acceptance Survey|Secondary Acceptance by Physicians Over the course of the study Acceptance by physicians will measure the physician effort required to deploy and use InheRET in their respective clinics, and overall satisfaction. Impact measures will include appropriate referral rates and rates of genetic testing. We will qualitatively describe why patients are not referred for genetic counseling if indicated. We will explore patterns in acceptance and impact levels by demographic and clinical data using correlations, t-tests, ANOVA, or their non-parametric equivalents.
223596692|NCT04373746|DEVICE|NICCI|Non-invasive beat-to-beat blood pressure monitor capable of producing a waveform similar to an invasive arterial line.
223596693|NCT06547073|OTHER|Virtual reality exercise training|Beat saber
223596694|NCT06547073|OTHER|Traditional exercise training|Bench slides, supine active assisted flexion, pendulum exercise, seated active assisted external rotation
223596695|NCT06213181|OTHER|Mindfulness intervention|It consists of 8 weekly sessions with a duration of 2 hours each. A variety of mindfulness practices including mindful movement will be introduced in all sessions. Participants will approach meditation as something natural and everyday, with the possibility of directing attention in all the moments and activities of daily life. Body scanning practices and conscious breathing will also be included. We will work in the group, with reflections and readings, as well as carrying out meditation and mindfulness practices, during the week, so that they can be carried out in the daily life of each participant. The intervention based on mindfulness will focus on the areas of well-being and personal skills such as attention, communication, emotional regulation and decision making.
223596696|NCT04194125|DRUG|177Lu-DOTATOC|Four administrations of 5,55GBq up to 7,4 GBq 177Lu-DOTATOC will be administered at 8-week intervals.
223596697|NCT00304863|DRUG|Lactobacillus GG|This arm will receive the additional probiotic of lactobacillus GG
223596698|NCT03813992|DRUG|MED2005|Topical Product
223596699|NCT03869879|OTHER|Feedback-assisted physical therapy|The system uses unobtrusive, wearable, inertial sensors with real-time algorithms to provide real-time feedback on: step time asymmetry, foot clearance, arm swing, trunk lateral range, and foot strike angle during gait.
223596700|NCT03869879|OTHER|Traditional physical therapy|Therapists will treat these patients with traditional therapeutic modalities and practices.
223747951|NCT03766854|DRUG|insulin icodec|Participants will receive subcutaneous (s.c.) injections of insulin 287 once weekly for 8 weeks
223747952|NCT03766854|DRUG|Insulin glargine U100|Participants will receive s.c. injections of insulin glargine once weekly for 2 weeks
224198026|NCT06221787|PROCEDURE|1565 nm non-ablative fractional laser combined with normal saline|After 1565 nm non-ablative fractional laser treatment, patients with melasma were smeared with normal saline and to compared with those smeared with exosomes after laser treatment.
224198027|NCT06221787|PROCEDURE|microneedles combined with hUCMSC-Exos|the hUCMSC-Exos were applied while rolling a microneedle roller and to compared with those used 1565 nm non-ablative fractional laser or PBASM combined with hUCMSC-Exos.
224198028|NCT06221787|PROCEDURE|1565 nm non-ablative fractional laser combined with hUCMSC-Exos|After 1565 nm non-ablative fractional laser treatment, patients with melasma were smeared with hUCMSC-Exos and to compared with those smeared with normal saline after laser treatment.What's more,compared with those used microneedles or PBASM combined with hUCMSC-Exos.
224198029|NCT06221787|PROCEDURE|PBASM combined with hUCMSC-Exos|a plasma named Peninsula Blue Aurora Shumin Master (PBASM) rolling each area for 8-10 min before applying the hUCMSC-Exos in the entire face. And to compared with those used 1565 nm non-ablative fractional laser or microneedles combined with hUCMSC-Exos.
224198030|NCT06943352|OTHER|Sensory Bins|The sensory bin is a basket filled with different objects of different shapes, sizes, and textures.
224198031|NCT06943352|OTHER|Drawing and Painting|Colored pencils and watercolors will be used.
224198032|NCT04074109|COMBINATION_PRODUCT|Teleyoga|the yoga protocol will be delivered via a tablet computer to groups of participants
224198033|NCT04074109|BEHAVIORAL|In-person yoga|the yoga protocol will be delivered by a yoga instructor in the room to group of participants
224198034|NCT03923907|BEHAVIORAL|EIM intervention group|As in arm description
224198035|NCT05205824|OTHER|algorithm validation|stroke subjects are measured to validate algorithms previously developed after including healthy subjects
224198036|NCT03359278|PROCEDURE|open reduction and internal fixation|The volar approach was used for open reduction and internal fixation of distal radius fractures
224198037|NCT06186466|OTHER|Observational Survey and Analysis|This study does not involve a clinical or medical intervention. Instead, it employs an observational survey method to gather data from family members of patients who visited the Health Sciences University Van Training and Research Hospital's emergency department between December 1, 2023, and June 1, 2024. The study aims to use logistic regression analysis to identify factors influencing the intent of violence against healthcare professionals. The survey includes structured questionnaires and scales developed based on theoretical frameworks and previous research. The gathered data will be statistically analyzed using the G\*Power software to assess the significance and impact of various factors on the propensity for violence.
224310989|NCT04790708|RADIATION|177Lu-DOTATOC + 90Y-DOTATOC|"3 cycles of 3,7 e 5,55 GBq of 177Lu-DOTATOC alternated with 2 cycles of 1,85 e 2,775 GBq of 90Y-DOTATOC every 8-10 weeks.~Cumulative activity: 18,5 e 27,75 GBq of 177Lu-DOTATOC and 9,25 e 13,875 GBq of 90Y-DOTATOC"
223596701|NCT01408342|DRUG|Alemtuzumab and Rituximab|"* Alemtuzumab 10 mg (5 mg/m2 in patients under 30 kg weight) subcutaneous days 1,2 and 3~* Rituximab 100 mg (50 mg/m2 in patients under 30 kg weight)intravenous days 4,11,18,25~* Cyclosporine 3 mg/kg starting day 21"
223596702|NCT04842981|DRUG|Tocilizumab|Tocilizumab and Sarilumab are considered equal. Patients are assigned the treatment based on national and local guidelines. Intervention will be administered according to the approved posology.
223596703|NCT04842981|DRUG|Sarilumab|Tocilizumab and Sarilumab are considered equal. Patients are assigned the treatment based on national and local guidelines. Intervention will be administered according to the approved posology.
223596704|NCT00656435|DRUG|Bevacizumab|Patients will receive intravitreal injection of 1.25 mg of bevacizumab (0.05 ml) 7 to 9 days before vitrectomy
224198038|NCT03585595|OTHER|Blood pressure lowering strategy|The proposed trial will test a treatment strategy of different systolic BP goals and not specific medications. It remains unclear whether a particular class of antihypertensive drug offers an advantage over others in secondary stroke prevention. Therefore, the BP treatment protocol is flexible in terms of the choice and doses of antihypertensive medications. However, we will emphasize the use of drugs best demonstrated to be effective in lowering CVD in outcome trials and recommended in current clinical guidelines.
224198039|NCT03068429|DRUG|Sertraline Hydrochloride|first week: sertraline hydrochloride 50mg/day, second week: sertraline hydrochloride 100mg/day, third week: sertraline hydrochloride 150mg/day, fourth week: sertraline hydrochloride 200mg/day OBS.: Other SSRIs (fluoxetine, paroxetine, escitalopram) with equivalent dosage schedules can be used if patients report prior intolerance to sertraline
224198040|NCT00246675|DRUG|Frusemide|
224198041|NCT05011162|DEVICE|Digital ACT|Study participants will receive 12 weeks of Digital Acceptance and Commitment Therapy (ACT).
224198042|NCT00814762|BIOLOGICAL|HIV Vaccine 732462|Two doses reconstituted adjuvanted vaccine, injected intramuscularly, at an interval of approximately one month.
223506833|NCT03095976|PROCEDURE|Amnion-Chorion allograft membrane on the root surface of periodontally diseased site.|Application of Amnion-Chorion allograft membrane (ACM) on the root surface of periodontally diseased teeth in conjunction with corticocancellous allograft bone substitute covered by ACM in a combination GTR treatment of periodontal intrabony and furcation defects
223506834|NCT02539407|OTHER|Pharmacokinetics|
223506835|NCT04916665|DRUG|Teduglutide|bridging intestinal failure with teduglutide until reconstruction
224310990|NCT04790708|RADIATION|Re-treatment 177Lu-DOTATOC|3 cycles of 3,7 e 5,55 GBq of 177Lu-DOTATOC every 8-10weeks. Cumulative activity: 11,1 e 16,65 GBq of 177Lu-DOTATOC
224310991|NCT04790708|RADIATION|Re-treatment 90Y-DOTATOC|3 cycles of 1,85 e 2,775 GBq of 90Y-DOTATOC every 8-10 weeks Cumulative activity: 5,55 e 8,325 GBq of 90Y-DOTATOC
224310992|NCT04628793|DRUG|PF-07258669|PF-07258669 will be prepared as an oral solution and/or suspension given in escalating single doses to be determined
223506836|NCT03488485|DRUG|Direct Acting Antivirals|DAAs given in patients with viremic chronic hepatitis C
223506837|NCT01309100|DEVICE|Investigational Lens|Bausch \& Lomb investigational silicone hydrogel lens on a daily wear basis for 1 week.
223506838|NCT01309100|DEVICE|Acuvue Oasys Lens|Johnson \& Johnson Acuvue Oasys contact lens on a daily wear basis for 1 week.
223506839|NCT01309100|DEVICE|Air Optix Aqua Lens|Ciba Vision Air Optix Aqua contact lens on a daily wear basis for 1 week.
223506840|NCT02825537|DEVICE|Compression stocking|A class III (20 to 36 mm Hg) elastic compression stocking according to the french classification
224310993|NCT04628793|DRUG|Placebo|Matching placebo will be prepared as an oral solution and/or suspension given in each cohort
223596705|NCT01377870|BIOLOGICAL|intravenous injection of mesenchymal stem cells|15 patients with relapsing remitting multiple sclerosis underwent intravenous injection of mesenchymal stem cell
223596706|NCT01377870|BIOLOGICAL|injection of cell free media|Patients who are in control group underwent media injection but after 6 months they will be transplanted by stem cell.
223596707|NCT00666965|DRUG|SPM 962|transdermal application, 1 time per day, 0-6.75 mg/body, titration, 6weeks
223596708|NCT02788058|DRUG|EGFR-TKI|Gefitinib 250mg po qd or Erlotinib 150mg po qd or Icotinib 125mg po tid
223596709|NCT02788058|RADIATION|Thoracic Hypofractionated Radiotherapy|40-45 Gy/5-15f
223596710|NCT02547584|PROCEDURE|Catheter ablation|Pulmonary vein antrum isolation (PVAI) plus entire posterior wall plus coronary sinus plus left part of the septum. This intervention will be received by all as standard of care
223747953|NCT03388229|BEHAVIORAL|not an intervention|it was observation not intervention
223747954|NCT05046886|BEHAVIORAL|Standardized|Participants are instructed to follow a Mediterranean-style diet. Dietary counseling is paired with SCT-based behavioral counseling, which focuses on the role played by self-referent thought in the maintenance of behavior change. Self-efficacy (e.g., the participant's confidence in their ability to engage in healthier behavior) is derived from four major sources of information: mastery experiences, social modeling, verbal persuasion, and physiological states. Participants self-monitor their diet using a mobile app and receive real-time feedback from the app on macronutrient distribution.
223747955|NCT05046886|BEHAVIORAL|Usual Care Control (UCC)|Participants are instructed to follow a Mediterranean-style diet,
224198043|NCT00814762|BIOLOGICAL|Placebo vaccine|Two doses of placebo, injected intramuscularly, at an interval of approximately one month
224198044|NCT04089657|DRUG|Apatinib Mesylate|Apatinib 500mg qd, oral, taken half an hour after a meal
224198045|NCT04089657|DRUG|Sintilimab|Sintilimab 200mg intravenously on day 1
224198046|NCT06330506|OTHER|Pressure ulcer prevention pack|The pressure ulcer prevention package to be prepared by the researchers will be applied
224198047|NCT03194295|BEHAVIORAL|Community Support Intervention Group|This 12-week community support intervention is designed to activate and harness the powerful influences of drug-free family and friends to enhance recovery support and participation in community activities. Addiction Treatment Services (ATS) participants and their CSPs will be directed to participate in recovery-oriented community activities together 2 times per week and work together toward developing regular drug-free social support for the ATS participant. The group provides an opportunity for both the participant and CSP to discuss their experiences participating in the scheduled activities. For those electing not to engage in community activities, problem-solving strategies will be used to remove obstacles to participation, with other group members providing support and encouragement.
224198048|NCT03194295|BEHAVIORAL|Substance Use Disorder Educational Group|This 12-week educational group is designed as an attention-control group. Group topics include: 1) definition of substance dependence, 2) the disease model, 3) medical aspects, 4) mood, 5) personality, 6) self-esteem, 7) relapse prevention, 8) HIV/AIDS, 9) anger, 10) negative thinking, 11) nutrition, and 12) assertiveness. Participants will be assigned 2 homework assignments each week based on the topic.
223596711|NCT03752658|DRUG|Tenofovir Alafenamide|The dose of tenofovir alafenamide (TAF) will be 25mg tablet taken orally once daily with food for 36 months, patients will be treated with TAF alone or in combination with anti-HBV agents
223596712|NCT02935413|DEVICE|tDCS|Device: verum tDCS real transcranial direct current stimulation,10 sessions, 2mA for 20 minutes Behavioral: VRT Vision restoration training, 10 sessions, 20 minutes
223596713|NCT02935413|BEHAVIORAL|Standard rehabilitation|Standard rehabilitation procedures involving PC-based training of saccades and visual exploration
223596714|NCT01653236|DRUG|Boceprevir|
223596715|NCT01653236|DRUG|Peginterferon alfa-2b|
223596716|NCT01653236|DRUG|ribavirin|
223596717|NCT01340599|DIETARY_SUPPLEMENT|defined green tea catechin extract|Given PO
224198049|NCT04244162|DIAGNOSTIC_TEST|Brain Imaging|Magnetic resonance imaging (MRI) using diffusion tensor imaging (DTI)-based mean diffusivity (MD) measures.
224198050|NCT04244162|DIAGNOSTIC_TEST|Cognitive testing|Wide Range Assessment of Memory and Learning (WRAML2), Montreal Cognitive Assessment (MoCA), and Confusion Assessment Method for the ICU -severity (CAM-ICU S) tests.
224198051|NCT04244162|DIAGNOSTIC_TEST|Blood Biomarkers|Inflammatory markers
224198052|NCT06649760|BEHAVIORAL|Gain and loss framed mobile text messages|To assess the effect of message framing on enhancing oral health practices in a group of refugees
223596718|NCT01340599|OTHER|placebo|Given PO
223596719|NCT01340599|OTHER|immunohistochemistry staining method|Correlative studies
224310994|NCT04500093|PROCEDURE|Capsulotomy with Repair|Capsulotomy with Repair
223596720|NCT01340599|OTHER|immunoenzyme technique|Correlative studies
224310995|NCT04500093|PROCEDURE|Capsuloectomy|Capsuloectomy
223596721|NCT01340599|OTHER|questionnaire administration|Ancillary studies
223596722|NCT01340599|PROCEDURE|therapeutic conventional surgery|Undergo radical prostatectomy
223596723|NCT01340599|OTHER|high performance liquid chromatography|Correlative studies
223596724|NCT01340599|OTHER|mass spectrometry|Correlative studies
223596725|NCT02207959|DRUG|Proflavine Hemisulphate salt|The stomach will be sprayed with 1-10 ml of 0.01% proflavine using a standard endoscopic spray-catheter.
223596726|NCT02207959|PROCEDURE|White-light examination|standard white light examination
223596727|NCT02207959|PROCEDURE|Imaging with High Resolution Microendoscope|HRME will be inserted through the biopsy channel of the endoscope, gently placed against the mucosa, and images of suspicious areas will be obtained.
223596728|NCT02861482|DEVICE|Bakri Balloon|Gradually increase the liquid volume inside Bakri Balloon to 250-500ml until bleeding is decreased or stopped
223596729|NCT02861482|DRUG|Oxytocin|using oxytocin(usage:20IU oxytocin in 500ml lactated Ringer's, ivgtt to a maximum of 60IU) for the first step when dealing with PPH before laying Bakri Balloon
223596730|NCT02861482|DRUG|Hemabate|using Hemabate (usage:250-500ug im) for the first step when dealing with PPH before laying Bakri Balloon
223596731|NCT02861482|DRUG|Duratocin|using Duratocin (usage:100ug iv) for the first step when dealing with PPH before laying Bakri Balloon
223596732|NCT02861482|PROCEDURE|Uterine Massage|continuous uterine massage for the first step when dealing with PPH before laying Bakri Balloon
223596733|NCT02861482|PROCEDURE|B-lynch Suture|One of conservative surgical procedures if Bakri Balloon didn't work
223596734|NCT02861482|PROCEDURE|Uterine Artery Embolization using sponges|One of conservative surgical procedures if Bakri Balloon didn't work
223596735|NCT02861482|PROCEDURE|Cervical cerclage|One of conservative surgical procedures if Bakri Balloon didn't work
223596736|NCT02861482|PROCEDURE|Hysterectomy|Hysterectomy with all the above measures not working
223596737|NCT02861482|DRUG|Blood Product|transfusion of blood product if necessary no matter which surgical procedure has been taken
223596738|NCT02533895|BIOLOGICAL|AV0113 DC-CIT|Mature loaded DCs will be injected intra-nodally into tumour free lymph nodes or subcutaneously close to tumour free lymph nodes at weekly intervals for at least 6 weeks.
223596739|NCT02533895|OTHER|Data evaluation|"For obtaining a clearer picture of AV0113's utility in the treatment of bone and soft tissue sarcoma, a LT follow-up investigation of the 14 Sarcoma patients, which will be treated using the AV0113 DC-CIT technology, is planned, in order to gather first evidence for a potential LT effect of DC-CIT with AV0113.~Furthermore, a comparison of the 14 sarcoma patients treated with AV0113 DC-CIT with a cohort of matched historic control patients that were treated using standard of care will be conducted. It is planned to analyse 42 control sarcoma patients that will be matched for disease, recurrences, relapses etc"
223596740|NCT05551884|PROCEDURE|Metabolites and HVPG|"HVPG measurement are performed by well-trained interventional radiologists in accordance with standard operating procedures.~All enrolled patients were analyzed for potential differential metabolites using metabolomics."
223596741|NCT04569357|DRUG|Prospekta|Oral administration.
223596742|NCT04569357|DRUG|Placebo|Oral administration.
223596743|NCT03698656|BEHAVIORAL|Spiritual Interview|Three patient interviews (45 to 60 minutes) will be conducted by the study nurse at the beginning of the study and approximately 2 and 4 month later, according to the program of the medical care. Each interview will be conducted according the active listening method of Carl Rogers.
223596744|NCT03845959|DRUG|TD0019 oral capsule|TD0019 are green, hard capsule with size 0, containing yellow herbal powder with special smell of herbal.
223596745|NCT03845959|DRUG|Placebo oral capsule|Placebo
223596746|NCT03854383|DRUG|Isosorbide mononitrate|Administration of isosorbide mononitrate vaginaly together with misoprostol in induction of labor in postdate women
223596747|NCT03854383|DRUG|Misoprostol|Used intravaginally to ripe the cevix in induction of labor
223596748|NCT05333380|DEVICE|ECG/PPG monitoring|"The enrolled patients will wear an ECG patch and watch at the same time to collect ECG and PPG data respectively. The data collection time is from the day of hospitalization to before the ablation operation, and from 2 hours after the removal of ECG monitoring equipment to before leaving the hospital. The monitoring duration of each patient shall not be less than 18 hours."
223596749|NCT01865383|BEHAVIORAL|Microfinance and Health Leadership|Microfinance and Health Leadership: Participants will be eligible to receive small loans and business training as part of the microfinance component. Nominated leaders in camps will receive health leadership training on prevention of HIV risk behaviors and gender based violence perpetration, and then pass on knowledge to camp members.
223596750|NCT01267526|DEVICE|Easypod™|Saizen (Somatotropin) administered by easypod™ as defined in SAIZEN® Canadian Product Monograph
223596751|NCT02939768|OTHER|High-intensity interval training (HIIT)|The HIIT sessions will be performed on cycle ergometers and will be consisted of 10 x 60-s cycling intervals interspersed with 60 s recovery. Individual workloads will be selected to elicit \~90% maximal heart rate attained in the cardiorespiratory fitness test (HRmax). A passive or active recovery will be given among high-intensity stimulus. Each training session will include 3-min warm-up and 2-min cool-down phase performed \~50% (HRmax), totalling 25 min. This intervention will last 10 weeks.
223596752|NCT02939768|OTHER|Strength training (ST)|ST protocol will consist of three sets performed at maximum weight that participants could move eight times with good technique in the following exercises: supine bench press (pectoralis major), leg press (quadriceps, biceps femoris, gluteus maximus), lat pulldown (latissimus dorsi), leg extension (quadriceps), shoulder press (deltoids), leg curl (biceps femoris) and abdominal crunch (abdominal muscles). It will be given 1-min rest between series, totalizing approximately 35 min of ST. This intervention will last 10 weeks.
223596753|NCT02939768|OTHER|ST combined with HIIT (ST+HIIT)|Participants in the ST+HIIT group will execute ST and HIIT (in this order) above described in the same training session, lasting approximately 60 min. This intervention will last 10 weeks.
223596754|NCT02697188|DRUG|Testosterone undecanoate|Single-day dose as QD or BID for 3 of 5 crossover periods
223596755|NCT02697188|DRUG|Testosterone enanthate|Single-day dose for 2 of 5 crossover periods
223596756|NCT05406102|DRUG|Remimazolam|Patients received an initial dose of 0.1mg/kg of remimazolam (add to 0.05 mg/kg top-ups doses to a total of up to five times within 15minutes).
223596757|NCT05406102|DRUG|Propofol group|Patients received an initial dose of 1.5mg/kg of propofol(add to 0.5 mg/kg top-ups doses to a total of up to five times within 15minutes).
223596758|NCT01623388|PROCEDURE|Oral glucose tolerance test for Phase I|Oral glucose tolerance test for Diabetic patients in phase I
223596759|NCT02447978|BIOLOGICAL|Infanrix|Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed Indicated as a 5-dose series in infants and children 6 weeks to 7 years of age.
223596760|NCT02447978|BIOLOGICAL|Pediarix|Diphtheria and Tetanus Toxoids and Acellular Pertussis Ad-sorbed, Hepatitis B (Recombinant) and Inactivated Poliovirus Vaccine Indicated as a 3-dose series in infants born of hepatitis B surface antigen (HBsAg)-negative mothers. PEDIARIX may be given as early as 6 weeks of age through 6 years of age (prior to the 7th birthday).
223596761|NCT02447978|BIOLOGICAL|Kinrix|Diphtheria and Tetanus Toxoids and Acellular Pertussis Ad-sorbed and Inactivated Poliovirus Vaccine
224198053|NCT00822601|DEVICE|rTMS|Arm 1 (experimental) : rTMS, 4 weeks of stimulation with RMT frequency 1Hz, intensity 100% of RMT for 20 minutes (1500 pulses), 5 minutes of trains with 2 minutes of intra-train intervals to both SMA. Treatment will be given 5 times a week for 4 weeks.
224198054|NCT00822601|DEVICE|Sham Comparator|sham rTMS (using a placebo coil), 4 weeks of stimulation, will mimic the active treatment mentioned above.
224310996|NCT03486691|OTHER|Routine measurement of left lobe|Routine preoperative measurement of left lobe
224310997|NCT03486691|OTHER|control group|no routine preoperative measurement of left lobe
223747956|NCT05046886|BEHAVIORAL|Personalized Guidance to Minimize Postprandial Glycemic Response (PPGR)|Participants are instructed to follow a Mediterranean-style diet. Dietary counseling is paired with SCT-based behavioral counseling, which focuses on the role played by self-referent thought in the maintenance of behavior change. Self-efficacy (e.g., the participant's confidence in their ability to engage in healthier behavior) is derived from four major sources of information: mastery experiences, social modeling, verbal persuasion, and physiological states. Participants self-monitor their diet using a mobile app and receive real-time feedback from the app on their predicted PPGR to meals and snacks at the time they enter them into their smart phone. PPGR predictions will be generated from a gut microbiome-based machine learning algorithm.
224198055|NCT05547516|DRUG|Standard infusion chemotherapy|standard infusion chemotherapy (including gemcitabine, mitomycin, epirubicin, etc.), dissolved in 50mL normal saline or glucose, intravesical infusion chemotherapy, retained for 60min. Perfusion can be performed within 24 hours after surgery, and then once a week for a total of 8 times, and then once a month until 12 months after surgery
224198056|NCT05547516|PROCEDURE|BL - 5 ala PDT|BL - 5 ala PDT - plan: 5ALA 1.5g (Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd), dissolved in 50mL normal saline, was infused into the bladder for 2 hours before surgery and before each cystoscopy. Blue laser irradiation was performed under a flexible cystoscope at 30mW/cm2 for 21min. PDT was performed during the operation and at 3, 6, and 9 months after the operation.
224198057|NCT01577082|DRUG|CHF1535 200/6 µg|CHF 1535 (BDP/FF) 800/24 µg daily during 12 weeks
224198058|NCT01577082|DRUG|BDP 100 µg|Beclomethasone Dipropionate 800µg daily during 12 weeks
223747957|NCT06585449|DRUG|ALN-HTT02|ALN-HTT02 will be administered intrathecally
224198059|NCT01656850|OTHER|Almond diet first, then NCEP Diet|whole almonds will be incorporated into a control diet which is a NCEP step 2 diet. Whole almonds will replace 20% daily calorie intake. Subjects were assigned to receive almond diet for 12 weeks after a 2-weeks run-in period. After washout 2 weeks, change diet to NCEP Diet for 12 weeks
223506841|NCT02825537|OTHER|No use of compression stocking|No use of compression stocking
223506842|NCT02540434|DEVICE|ROTEM|ROTEM delta will be used to identify intraoperative coagulation abnormalities. A blood sample and reagents are placed into a small cup. A pin suspended from a wire is immersed into the sample. The pin rotates back and forth at a fixed angle. The movement of the pin is optically monitored and converted into a real time measurement that is represented graphically. Prior to clot formation, pin rotation is unhindered and is graphically represented as a straight line. As the subject's blood sample starts to clot, strands of clot form between the pin and the cup wall, restricting the movement of the pin depending on the strength of the clot. Graphically, this is represented as a symmetrical widening of the curve.
223506843|NCT02540434|OTHER|Cryoprecipitate|Subjects with hypofibrinogenemia who are randomized to the Cryoprecipitate arm will be transfused with Cryoprecipitate
223506844|NCT02540434|DRUG|RiaSTAP|Subjects with hypofibrinogenemia who are randomized to the RiaSTAP arm will be transfused with concentrated fibrinogen
223506845|NCT01261377|DEVICE|Bi-level positive airway pressure (BPAP)|The level of BPAP will be titrated to treat OSA as well as hypoxemia and hypercapnia. The duration of therapy will be six months.
223506846|NCT01261377|DRUG|Oxygen|Oxygen will be titrated to keep resting oxygen saturation (as measured by pulse oximeter) more than 88 percent. The duration of therapy will be six months.
223506847|NCT01261377|DEVICE|CPAP|The level of CPAP will be titrated to treat OSA. The duration of therapy will be six months.
223506848|NCT00674232|DRUG|600 mcg misoprostol|single dose of misoprostol taken orally
223506849|NCT00674232|PROCEDURE|Surgical treatment|Either dilation and curettage or manual vacuum aspiration, as per local protocol
223506850|NCT00792389|OTHER|Warm humidified C02|Insufflation of warmed humidified gas during laparoscopic cholecystectomy
223506851|NCT00792389|OTHER|Cool dry C02|Insufflation of cool dry gas during laparoscopic cholecystectomy
223506852|NCT00084279|DRUG|Consensus Interferon-Alpha, Interferon Gamma-1b, Ribavirin|interferon gamma-1b: 0.25 and 0.5 mL, SQ, 3x per week interferon alfacon: 0.3 mL and 0.5 mL, SQ, once a day Ribavirin: 2 capsules in a.m., 3 capsules in p.m.; daily
223506853|NCT04386837|OTHER|Turkish Aphasia Rapid Test|Same
223506854|NCT00565760|DRUG|Q8003|Capsules
223506855|NCT00565760|DRUG|Placebo|Capsules
223506856|NCT00003501|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Refractory or Recurrent High-Grade Stage II - IV Non-Hodgkin's Lymphoma will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
223506857|NCT00852982|BEHAVIORAL|Exercise|Nordic walking, with walking poles, five hours per week during four months
223506858|NCT02787798|DRUG|valsartan/sacubitril 100 mg|Treatment with 100 mg tablets during 2 to 4 weeks
223506859|NCT02787798|DRUG|valsartan/sacubitril 200 mg|Treatment with 200 mg tablets during 2 to 4 weeks
223506860|NCT02787798|PROCEDURE|Microneurography|Microneurography recording of sympathetic nervous system activity in muscle destiny
223506861|NCT02285309|PROCEDURE|Cardiac Surgery and enoximone|Does diastolic function change with cardiac surgery +/- enoximone
223506862|NCT01968785|RADIATION|Radiation Dose 25 Gy|Renal Denervation is performed using the Beta-Cath 3.5F to a deliver radiation dose 25 Gy to the renal artery.
223506863|NCT01968785|RADIATION|Radiation Dose 50 Gy|Renal Denervation is performed using the Beta-Cath 3.5F to a deliver radiation dose 50 Gy to the renal artery.
223506864|NCT04479384|OTHER|Manual therapy - osteopathic techniques|"* HVLAT if any somatic dysfunction in T1-T5~* Stretch intrathoracic fascia x 3~* Recoil sternum x 3~* Cranial base release, 4 phases"
223506865|NCT00051350|OTHER|CARB|
223506866|NCT00117000|DRUG|testosterone undecanoate|
223506867|NCT04313439|OTHER|Online cognitive therapy (I-CT)|"The treatment is an online cognitive therapy consisting of a structured self-help program over ten weeks, divided into eight modules, administered in an encrypted web platform. The program is based on the treatment manual The treatment of Obsessions by Stanley Rachman. In this treatment, the participant is recommended to perform daily exercises in order to identify and modify interpretations made about the importance of their obsessive thoughts. A designated therapist have email contact with the participant within the encrypted platform."
223596762|NCT01453907|DRUG|"ETI-204, Anthim"|intravenously, single dose
224198060|NCT01656850|OTHER|NCEP diet first, then Almond diet|NCEP diet first, then Almond diet. Subjects were assigned to receive NCEP diet for 12 weeks after a 2-weeks run-in period. After washout 2 weeks, change diet to almond diet for 12 weeks
223596763|NCT01453907|DRUG|placebo|intravenously, single dose
224198061|NCT02157181|DRUG|2CdA +/- Rituximab|Cladribine 0.14 mg/kg daily subcutaneous bolus injection Rituximab 375 mg/m² infusion
224198062|NCT01767649|OTHER|Caesarean|Collection of tissues and blood
224198063|NCT01767649|OTHER|Vaginal delivery|Collection of tissues and blood
224198064|NCT04114591|PROCEDURE|anterior resection|The distance from anal verge, preoperative radiotherapy and presence of stoma were analysed
224198065|NCT00795210|DRUG|Growth hormone|Recombinant Human Growth Hormone (Teva pharmaceuticals), with one arm receiving 6mcg/kg SC once daily for two weeks and the other arm receiving 2mg SC once daily for two weeks
224198066|NCT00795210|DRUG|Growth Hormone Releasing Hormone|Tesamorelin (GHRH) 2mg SC QD x 2 weeks
224198067|NCT03653637|BEHAVIORAL|Project Life Force|A novel, 10-session group intervention to enhance currently mandated VA suicide safety planning by involving Veterans who are at high-risk for suicidal. The PLF intervention augments the SSP in a group treatment with skills training, and psychoeducation, to maximize use and effectiveness of the plan. Overall, PLF aims to enhance suicide coping skills, safety planning and connection to others. The primary purpose is to enhance the safety plan with skills training in emotion regulation, building of support and distress tolerance, and enable even acutely-suicidal Veterans to be able to implement the steps of the safety plan.
224198068|NCT03653637|BEHAVIORAL|Treatment as Usual|The comparison condition will be an assessment-only treatment-as-usual (TAU). Participants in the TAU condition will receive safety planning and specified clinical support, as mandated by their high-risk status.
224198069|NCT03361332|OTHER|Behavioral and fMRI|Subjects and patients will perform temporal-judgment-tasks (considered an indirect measure of the sense of agency) in an event-related fMRI setting. In the first task, they will hear a sound either caused by a voluntary key press or by the passive displacement of the same finger by the experimenter. Following each trial, subjects will estimate the delay between the finger movement and the subsequent sound, which will be presented at variable latencies after the key press. There will be also control-trials characterized by the active or passive movement with a subsequent sound presented with a delay that excludes causality inferences.
224198070|NCT06346080|OTHER|Survey|Discrete choice survey
224198071|NCT04642131|DIETARY_SUPPLEMENT|Caffeine supplementation|Participants will wear standard insoles and ingest caffeine in liquid form (3mg/kg) with carbohydrates.
224198072|NCT04642131|DEVICE|Personalized insoles|Participants will wear personalized insoles and ingest a drink of carbohydrates without caffeine
224310998|NCT01655576|PROCEDURE|Placental drainage|After delivery of the newborn, umbilical cord at mothers end, will be left unclamped until delivery of the placenta.
223596764|NCT06289309|DEVICE|Neuromonitoring of the recurrent laryngeal nerves|The NIM Vital system (Medtronic, Jacksonville, US) operates with surface electrodes integrated with an endotracheal NIM TriVantage tube 7.0-8.0 in diameter, which is inserted by an anesthetist between the vocal folds under direct vision during intubation. The standardized technique of IONM RLNs wll be used, including initial vagal response evaluation at the beginning and final vagal response evaluation at the end of surgery (IONM = L1+V1+R1+R2+V2+L2) according to the recommendations formulated by the International Intraoperative Neural Monitoring Study Group. The nerves will be stimulated using a monopolar electrode and the interrupted stimulation technique at 1mA, 100ms impulse duration and 4Hz frequency. In case of the bifurcated RLN nerves, the assessment includes post-stimulation response of each nerve branch. Adduction of the vocal folds is detected by the endotracheal tube electromyography and abduction by finger palpation of muscle contraction in the posterior cricoarytenoid.
223596765|NCT00417430|DRUG|ICI 182,780 (Faslodex)|
223596766|NCT05556694|DIAGNOSTIC_TEST|calculation of cumulative fluid balance|\- We will calculate cumulative fluid balance as daily fluid balance within four days of the event of interest. Cumulative fluid balance will be computed as the sum of daily fluid balances over the previous 24 hours, calculated by total fluid input minus total fluid output on a specific day of ICU admission over the first four calendar days of mechanical ventilation. Insensible fluid loss, such as perspiration or evaporative water loss related to respiration will not be routinely assessed and will not be included in the calculation of cumulative fluid balance. The cumulative fluid balance from day 0 to day 1 will be labelled as day 1, and the following days as day 2 and day 3. Cumulative fluid balance at day 3 refers to the cumulative fluid balance during the first four calendar days.
223747958|NCT06585449|DRUG|Placebo|Placebo will be administered intrathecally
223747959|NCT02867709|DRUG|Ubrogepant|Ubrogepant tablet(s) orally for the treatment of a qualifying migraine attack.
224198073|NCT04642131|OTHER|Control condition|Participants will wear standard insoles and ingest a drink of carbohydrates without caffeine
224198074|NCT00296192|DRUG|Rotigotine nasal spray|Rotigotine- HCl 2.5mg/mL nasal spray, dosage per puff of 275µg per 110µg administered in up to 4 deliveries
224198075|NCT00296192|OTHER|Placebo|placebo nasal spray 1, 2 3, and 4 puffs
224198076|NCT02070367|OTHER|Somatosensory rehabilitation|
224198077|NCT02070367|OTHER|Usual treatment: physiotherapy|
224310999|NCT02041065|DEVICE|Waterjet induced dissection|Waterjet induced dissection of the liver during resection.Waterjet dissection device mechanically separates hepatic tissue from bile ducts and vessels, the latter two to be separately ligated.
224311000|NCT02041065|DEVICE|CUSA induced dissection|Ultrasound based destruction of the liver
224311001|NCT03039426|DRUG|Bupivacaine|0.5% bupivacaine 20ml divided in two; 10 ml intraperitoneal infiltration and 10 ml subcutaneous infiltration
224311002|NCT03039426|DRUG|Diclofenac|diclofenac 75 mg intramuscular, 2 hours postoperation
224311003|NCT02315430|DRUG|Cabozantinib S-malate|Given PO
224311004|NCT02315430|OTHER|Laboratory Biomarker Analysis|Optional correlative studies
224311005|NCT03741426|DRUG|Olaparib|Olaparib 300mg twice daily, oral medication administered for at least 2 weeks and up until the morning of nephrectomy. Arms 2, 3 and 5
224311006|NCT03741426|DRUG|Cediranib|Cediranib 20mg once daily, oral medication administered for at least 2 weeks until 36 hours prior to nephrectomy. Arms 1 and 3
224311007|NCT03741426|DRUG|Durvalumab|Durvalumab 1500mg intravenous infusion administered once, no greater than 4 weeks prior to nephrectomy
223596767|NCT01853878|BIOLOGICAL|Recombinant PRAME protein combined with the AS15 Adjuvant System GSK2302032A|Intramuscular administration
223596768|NCT01853878|BIOLOGICAL|Placebo|Intramuscular administration
223596769|NCT03134339|DRUG|Nicotine saline 0.00mcg/kg/s|saline 0.00mcg/kg/s
223596770|NCT03134339|DRUG|Nicotine 0.24 mcg/kg/s|nicotine 0.24 mcg/kg/s
223596771|NCT03134339|DRUG|Nicotine 0.048 mcg/kg/s|nicotine 0.048 mcg/kg/s
224198078|NCT06701916|BEHAVIORAL|Intervention group.|The intervention will be carried out by a multidisciplinary team composed of nurses, doctors, social workers, and psychologists from each hospital. Through this intervention, a narrative from the patients will be obtained regarding their goals, desires, capabilities, and resources related to their health situation. A health plan will be jointly created, reflecting both short- and long-term objectives, identifying the resources available to the person and within their immediate environment, and outlining how they want and expect to receive support from healthcare professionals.
224198079|NCT06701916|BEHAVIORAL|Usual care|Usual care for the outpatient management of Chronic Heart Failure.
224198080|NCT04898946|BIOLOGICAL|CoronaVac Vaccine|CoronaVac Vaccine
224198081|NCT04898946|BIOLOGICAL|BNT162b2 Vaccine|Covid-19 BNT162b2 Vaccine
224198082|NCT02306018|DEVICE|EV1000™/volumeView™|
224198083|NCT04360213|DEVICE|Advanced multimodal wireless vital signs monitor|Investigators have developed a lightweight, stretchable 'skin-like' membranes, called skin sensors. These small, paper-thin monitors were created by matching the mechanical properties of skin, and can be applied to the skin's surface without skin disturbance. Each patch is encapsulated using medical grade materials and applied using single use medical grade skin adhesive integrated with eco-fused fabric (moisture wicking layer between adhesives). The adhesive may be changed between uses, and the device itself can be cleaned with Super Sani-Cloth®, commonly used in the hospital setting.
224198084|NCT00698009|DRUG|Fludarabine|25 mg/m\^2 By Vein Daily Over 30 minutes Starting 6 days before the NK cell infusion (considered Day -6) and once a day through Day -2.
223596772|NCT03134339|DRUG|Nicotine 0.024 mcg/kg/s|nicotine 0.024 mcg/kg/s
223596773|NCT04314011|BIOLOGICAL|Human umbilical cord mesenchymal stem cells（HUC-MSCs）|Human umbilical cord mesenchymal stem cells（HUC-MSCs）
223596774|NCT04314011|BIOLOGICAL|Placebo|Placebo
224311008|NCT02076490|OTHER|Physical/Occupational therapy|At least 10 individual sessions over the clinical intervention period of 4 weeks followed by a 6 weeks self-management phase.
223596775|NCT05151757|OTHER|A standard image training set|The standard image training set will consist of about 50 normal optic nerve images of people without glaucoma and about 50 images of people with glaucoma. Training is done in 3 modules.
223596776|NCT01361178|DRUG|SQ IVIG|Group 1 will receive SQ IgG at the lower end of the dosing range at 100 mg/kg/week and group 2 will receive SQ IgG at the higher end of the dosing range at 200 mg/kg/week
223596777|NCT00391625|DRUG|GA-GCB|15-60 U/kg every other week via intravenous infusion
223596778|NCT00876434|DRUG|Sirolimus|
223596779|NCT01399866|DRUG|D-cycloserine|2 single weekly doses, 50 mg capsule
223596780|NCT01399866|DRUG|Placebo|
223596781|NCT02082730|DEVICE|ASARM|The ASARM system combines objective and subjective measurements of sleep, rest and activity patterns by using a combination of low-cost devices and technologies. The patient wears a wrist-mounted Actigraphy device to measure their energy expenditure, and carries an electronic diary (a Smartphone app) for recording their activities and their subjective measures of mood and energy level. These synchronise daily with a remote server, accessible by the clinician through a web interface, to allow monitoring, data analysis and feedback to the patient.
223596782|NCT04193774|DIAGNOSTIC_TEST|Conjunctival swab|Swab of the conjunctival fornices of both eyes
223596783|NCT04193774|DRUG|Oxybuprocaine Hydrochloride 0.4% Eye Drops|One drop of topical anesthesia in one eye
223596784|NCT04193774|DRUG|artificial tears|One drop of artificial tears in the other eye
224198085|NCT00698009|DRUG|Cyclophosphamide|60 mg/kg By Vein Daily Over 2 Hours On Days -5 and -4
224198086|NCT00698009|BIOLOGICAL|Natural Killer Cell Infusion|Natural Killer Cell Infusion on Day 0.
224198087|NCT00698009|DRUG|Mesna|12 mg/kg By Vein, Over about 15 minutes, Five Times Per Day on Days -5 and -4.
224198088|NCT00698009|DRUG|Interleukin-2|"Received under skin three times weekly for 9 total doses following NK Cell Infusion:~For patients weighing 45 kg or more, dose administered is 10 Million units three times weekly for 9 total doses. For patients less than 45 kg, dose administered is 5 Million units/m2 (max dose 10 Million units) three times weekly for 9 total doses."
224311009|NCT04712981|BEHAVIORAL|HOPE|Peer leaders/role models will be trained in HOPE intervention fundamentals and assigned to online community groups with participants.
224311010|NCT05105412|DRUG|Lenalidomide and Gemcitabine (Dose level 11)|lenalidomide 25 mg/day D1-D14 and gemcitabine 1000 mg/m2 D1, D8
224311011|NCT05105412|DRUG|Lenalidomide and Gemcitabine (Dose level 21)|lenalidomide 15 mg/day D1-D14 and gemcitabine 1000 mg/m2 D1, D8
223596785|NCT03916081|DRUG|Roflumilast Cream 0.05%|Roflumilast 0.05% cream for topical application
223596786|NCT03916081|DRUG|Roflumilast Cream 0.15%|Roflumilast 0.15% cream for topical application
223596787|NCT03916081|DRUG|Vehicle Cream|Inactive vehicle cream matched to roflumilast cream for topical application.
223596788|NCT05018663|OTHER|Artificial Intelligence software ROSE|Rapid on-site evaluation (ROSE) of Endoscopic Ultrasound (EUS) guided FNA/FNB (Fine Needle Aspirate/Fine Needle Biopsy) of pancreatic solid lesions (PSLs) has been shown in improve diagnostic yield. The availability and performance of ROSE at EUS performing centers is variable. With strides in Artificial Intelligence (AI) capabilities over the years, the University of Texas at Health Sciences Center at Houston in collaboration with Haystac is developing an artificial intelligence based proprietary system to analyze slides from EUS FNA/FNB samples at bedside.
223596789|NCT05753163|COMBINATION_PRODUCT|HAIC-FOLFOX combined with Sintilimab and Regorafenib|HAIC (FOLFOX: oxaliplatin 85mg/m2, 5- fluorouracil 2500mg/m2, calcium folinate 400mg/m2) was given every 4-6 weeks for 2-4 cycles depending on pts' health status, in combination with Sintilimab (200mg, iv, d1) and regorafenib (80mg, po, d1-21) every 3 weeks for up to 6 months .
223596790|NCT01708135|BEHAVIORAL|Use of smartphone app|
223596791|NCT02820025|DRUG|doxapram|
223596792|NCT02820025|OTHER|saline|
223596793|NCT01247194|DRUG|PPI-461|capsule, oral, once daily for 3 days
223596794|NCT01247194|DRUG|Placebo|capsules, oral, once daily for 3 days
223596795|NCT04233619|DIAGNOSTIC_TEST|optical coherence tomography|non-invasive test performed by an Ophthalmologist that allows three-dimensional imaging of the retinal vasculature
223596796|NCT01496820|DIETARY_SUPPLEMENT|GO2KA1|GO2KA1(chitosan oligosaccharide)1500mg/day for 12weeks
223596797|NCT01496820|DIETARY_SUPPLEMENT|Placebo|placebo 1500mg/day for 12weeks
223596798|NCT03244826|OTHER|Shared Care|Shared Care involves four specific strategies to allow patients to have a portion of their care locally after HCT, where clinic and laboratory visits are equally shared between the local oncologist and primary HCT team
223596799|NCT03244826|OTHER|Standard Care|The usual care provided by the transplant center at DFCI.
223596800|NCT03051919|OTHER|observation|
223596801|NCT03080636|OTHER|Aerobic exercise|30 minutes of treadmill exercise at 60-70% of heart rate reserve
223596802|NCT03080636|OTHER|Resistance exercise|30 minutes of circuit resistance session at 40% of 1 maximun repetition test
224311012|NCT05105412|DRUG|Lenalidomide and Gemcitabine (Dose level 31)|lenalidomide 10 mg/day D1-D14 and gemcitabine 1000 mg/m2 D1, D8
223596803|NCT03080636|OTHER|Control session|30 minutes seated resting
223596804|NCT00051896|DRUG|GBR 12909|
223596805|NCT05571020|OTHER|mat pilates|Both groups adapted for their rides by not participating in a different exercise and meal. In the study, they were not found in any store in the control groups. In the Mat-Pates Group, information about the 5 key elements of the study and pilates team, perspective (-neck-shoulder-waist-abdominal placement), lumbopel stabilization, scapular stabilization, review and information was covered. Then, in the study groups, it was purchased from groups of 5-6 people at most for one hour a day. In order to participate in all these application activities, he continues his life without participating in any evaluation.
223596806|NCT06143982|BEHAVIORAL|Brief Intensive Trauma Treatment|BITT is an outpatient, intensive, one-week individual trauma therapy program. BITT is based on well-established protocols, consisting of two 90-minutes trauma therapy sessions a day (trauma exposure in the morning and EMDR in the afternoon), two psychomotor therapy sessions a day (1x60 minutes, 1x45 minutes), one 90-minutes psycho-education and social support skill training for parents a day, and a 90-minutes family therapy session at the end of the week (sharing the trauma narrative).
223596807|NCT04764318|BEHAVIORAL|Remote patient monitoring for hypertension|The intervention involves making available remote physiologic monitoring services for hypertension patients allowable under Medicare for blood pressure (and weight if desired) when ordered by a patient's clinician.
223596808|NCT04764318|BEHAVIORAL|Remote patient monitoring with care management|The intervention involves making available remote physiologic monitoring services for hypertension patients allowable under Medicare for blood pressure (and weight if desired) when ordered by a patient's clinician and providing care management services to support the enrollment and active use of this service.
223596809|NCT02971553|DEVICE|Upright Resuscitator with PEEP|
223596810|NCT02971553|DEVICE|Upright Resuscitator|
223596811|NCT05938036|DRUG|ALT-100 mAb|Experimental: Part A : ALT-100 mAB (Dose Escalation) 90 eligible participants will be randomized at a 2:1 ratio to receive a single dose of ALT-100 mAb.
223596812|NCT05938036|DRUG|ALT-100 (Placebo)|Normal saline solution via IV solution
223596813|NCT00166530|DRUG|ezetimibe (+) simvastatin|Vytorin® combination tablet of ezetimibe 10 mg plus simvastatin 20 mg once daily for 12 weeks. Tablets
223747960|NCT02867709|DRUG|Placebo-matching Ubrogepant|Placebo-matching ubrogepant tablet(s) orally for the treatment of a qualifying migraine attack.
223747961|NCT06374797|DRUG|Auxora|1.25 mL/kg (2.0 mg/kg of zegocractin) intravenously (IV) over 4 hours at 0 hours, and then 1.0 mL/kg (1.6 mg/kg of zegocractin) IV over 4 hours at 24, 48, 72 and 96 hours for a total of 5 doses.
223747962|NCT06374797|DRUG|Placebo|1.25 mL/kg IV over 4 hours at 0 hours and then 1.0 mL/kg IV over 4 hours at 24, 48, 72, and 96 hours for a total of 5 doses.
223747963|NCT05287451|OTHER|RIsk-Reducing Salpingectomy (RRS)|complete questionnaires, standard-of-care laparoscopy to check the abdominal area before the assigned procedure
223747964|NCT05287451|OTHER|Risk-Reducing Oophorectomy-RRO|complete questionnaires, standard-of-care laparoscopy to check the abdominal area before the assigned procedure
223747965|NCT05287451|OTHER|Risk-Reducing Salpingo-Oophorectomy-RRSO|complete questionnaires, standard-of-care laparoscopy to check the abdominal area before the assigned procedure
224311013|NCT05105412|DRUG|Lenalidomide and Gemcitabine (Dose level 41)|lenalidomide 10 mg/day D1-D14 and gemcitabine 800 mg/m2 D1, D8
224311014|NCT00400595|DRUG|Mupirocin ointment|topical ointment (already in widespread clinical use)
224311015|NCT00400595|DRUG|Polysporin Triple|
223596814|NCT00166530|DRUG|simvastatin|Zocor®; simvastatin 40 mg once daily for 12 weeks. Tablets
223596815|NCT00166530|DRUG|atorvastatin|20 mg atorvastatin once daily for 12 weeks. Tablets
223596816|NCT06166108|DRUG|transversus abdominis plane (TAP) block in Abdominal hysterectomy|Comparative evaluation of magnesium sulphate versus dexamethasone as an adjuvant to bupivacaine in ultrasound guided transversus abdominis plane block for Abdominal hysterectomy as postoperative analgesia.
223596817|NCT00025246|DRUG|imatinib mesylate|Given orally
223596818|NCT00025246|OTHER|laboratory biomarker analysis|Correlative studies
223596819|NCT02744417|BEHAVIORAL|Smoking cessation counseling|Multidisciplinary smoking cessation counseling, performed by a team comprising physicians, nurses, a psychologist and dentists. It consisted of four 1-h counselling lectures delivered by physicians, psychologist-assisted cognitive behavioural therapy, and counseling provided by dentists during the active phase of the treatment and maintenance session, using motivational interviewing techniques
223596820|NCT02744417|PROCEDURE|Non-surgical periodontal therapy|Full-mouth supra and subgingival scaling and root planing (with curettes and ultrasonic scaler); oral hygiene instruction and motivation and removal of intra-oral plaque retentive factors
223596821|NCT02744417|DRUG|Nicotine replacement therapy|Nicotine replacement therapy: chewing gum (Nicorette chewing gum 2-4mg) and patches (Nicorette patches 15-25mg)
223596822|NCT02744417|DRUG|bupropion hydrochloride|bupropion hydrochloride 150mg
223596823|NCT02744417|DRUG|Varenicline|Varenicline 0,5mg
223596824|NCT00995657|DRUG|Fluticasone Propionate|Inhaled Fluticasone Propionate 50mcg bid
223596825|NCT00995657|DRUG|Fluticasone Propionate|Inhaled Fluticasone Propionate 250mcg bid
223596826|NCT04369157|PROCEDURE|Elective surgery|Patients will be scheduled to undergo elective orthopaedic (knee/hip replacement) or colorectal surgery.
224198089|NCT04946669|DRUG|Abatacept|Abatacept is a CTLA-4 fusion protein that inhibits T cell activation by competitively binding to CD80/CD86 and blocking the second signal. To date, Abatacept has been approved by the FDA for the treatment of three types of rheumatoid immune diseases (refractory rheumatoid arthritis, juvenile idiopathic arthritis, and active psoriatic arthritis). The international consensus of experts recommends abacepil as a second-line regimen for the treatment of refractory dermatomyositis based on the evidence of case reports. However, to date, there is no relevant report or clinical study registration information of Abatacept in the treatment of dermatomyositis.
224198090|NCT05984329|OTHER|Retrospective analysis of patients' choice|Retrospective analysis of patients' choice of tonic or Burst DR(TM) waves for their analgesic effect.
223596827|NCT03959917|PROCEDURE|transurethral resection of the prostate|Surgical removal of benign prostatic tissue
223596828|NCT02387008|DEVICE|GUIDOR® membrane with FDBA|horizontal bone augmentation with synthetic GUIDOR® membrane + FDBA
223596829|NCT02387008|DEVICE|GUIDOR® membrane|horizontal bone augmentation with synthetic GUIDOR® membrane
223596830|NCT02387008|DEVICE|Bio-Gide® membrane with FDBA|xenograft BioGide® membrane + FDBA
224198091|NCT06652191|PROCEDURE|Direct catheterization with non-dilation|Under the guidance of real-time ultrasound, the right internal jugular vein was punctured and a guide wire was inserted, place the catheter into the vessel directly along the guide wire without using an dilator to expand the skin
224198092|NCT06652191|PROCEDURE|Catheterization after expanding the skin with a dilator|Under the guidance of real-time ultrasound, the right internal jugular vein was punctured and a guide wire was inserted, after the skin is expanded with a dilator, the catheter is inserted into the vessel along the guide wire
224198093|NCT01644461|OTHER|Autologous Human Platelet Lysate|All subjects will receive a single injection of Autologous Human Platelet Lysate in the nasolabial region
224198094|NCT04849858|DRUG|Bupivacaine|Participants in this group will receive a TAP block using the drug Bupivacaine.
224198095|NCT04849858|DRUG|Liposomal bupivacaine|Participants in this group will receive a TAP block using the drug Liposomal Bupivacaine.
224311016|NCT05742763|COMBINATION_PRODUCT|Ibuprofen and PRP|The primary research purpose is to determine if the use of ibuprofen \[arm #1\] vs acetaminophen \[arm #2\] vs a placebo control group \[arm #3\] with the intervention of a series of three injections of LP-PRP into the knee joint, leads to significantly greater reductions in average knee pain severity, and increases in physical function and quality of life, in patients with symptomatic moderate KOA, and grade 2 or 3 radiographic changes defined by the Kellgren-Lawrence (K-L) classification system.
224198096|NCT04849858|DRUG|Liposomal bupivacaine|Participants in this group will receive a TAP block using the drug Liposomal Bupivacaine followed by a re-dosing during their hospitalization
224198097|NCT00308100|DRUG|Hydroxyethylstarch 130/0.4|HES 130/0.4, administered intra- and perioperatively, max. daily dose: 33ml/kg BW; if needed, additionally albumin is administered (ratio crystalloid to colloid= 1:1)
224198098|NCT00308100|DRUG|5% Albumin|5% albumin, administered intra- and perioperatively
224198099|NCT04130009|PROCEDURE|Tourniquet use|Use of Tourniquet in The TKA
223506868|NCT06344286|DIETARY_SUPPLEMENT|Minimal enteral nutrition|The babies were randomized into two groups based on whether they received MEN during TH. While the babies fed with MEN during TH constituted the study group, the control group was composed of the babies who were given the same amount of distilled water according to the same protocol. Two groups were compared in terms of demographic characteristics, clinical outcomes, NIRS and Doppler measurements.
223506869|NCT06344286|DIETARY_SUPPLEMENT|Distilled water|The babies were randomized into two groups based on whether they received MEN during TH. While the babies fed with MEN during TH constituted the study group, the control group was composed of the babies who were given the same amount of distilled water according to the same protocol. Two groups were compared in terms of demographic characteristics, clinical outcomes, NIRS and Doppler measurements.
223506870|NCT06197295|DRUG|Solifenacin with vaginal estrogen cream|Solifenacin 5mg with vaginal conjugated equine estrogen (CEE) 0.625 mg
223506871|NCT06197295|DRUG|Combination pharmacotherapy|Solifenacin 5mg and Mirabegron 25mg
223506872|NCT02333968|BEHAVIORAL|Self-management support|The 12-week intervention consists of an iPad application for patients that is connected to a web application for nurses. Every morning and evening patients register pain and related symptoms by use of a pain diary. Patients are also requested to register medication intake. Graphical feedback is provided based on registered pain scores and medication intakes. Patients receive education on causes and treatment of pain, symptoms that require action, and methods to better control pain. Patients communicate with nurses via text message functionality within the application. Specialized nurses remotely monitor and analyze the patients' situation once every workday. Nurses have the opportunity to collaborate with the treating physician, pain specialist or multidisciplinary team.
223506873|NCT03757676|BEHAVIORAL|No Play|Participants in this group were asked not to download or play Pokémon Go during the study period and were asked to simply continue with their normal daily activities. Participants were asked to wear the Fitbit device and use the GPS app on their mobile phones during the 6-week study period. Starting the fifth week, participants were prompted to complete five (5) brief daily surveys on their phones via the EMA app.
223506874|NCT03757676|BEHAVIORAL|At Will Play|Participants in this group were asked to download Pokémon Go and play for at least 30 minutes initially, then play as much or as little as desired during the 4 week intervention period, with no specific instruction or goals for play. Participants were asked to wear the Fitbit device and use the GPS app on their mobile phones during the 6-week study period. Starting the fifth week, participants were prompted to complete five (5) brief daily surveys on their phones via the EMA app.
223506875|NCT03757676|BEHAVIORAL|Goal Oriented Play|Participants in this group were asked to download and play Pokémon Go and achieve a minimum player level of 20 within the game during the study period. They were given materials that described game features and functions to show them how to play the game. There were no restrictions on which features to pursue within the game to achieve this goal nor on how long or how frequent their play sessions should be. Upon reaching their goal (Level 20), participants were encouraged to continue to play as much or as little as they desired. Participants were asked to wear the Fitbit device and use the GPS app on their mobile phones during the 6-week study period. Starting the fifth week, participants were prompted to complete five (5) brief daily surveys on their phones via the EMA app.
224198100|NCT02650609|DRUG|Methylprednisolone|
223596831|NCT04294836|DRUG|Curcumin|BCM-95® (CURCUGREEN®) is a 100 percent pure extract of turmeric with enhanced bio-availability and bio-efficacy. Its powerful health-promoting benefits are derived from the colorful and aromatic qualities of the Indian spice
223596832|NCT04294836|DRUG|Placebo oral tablet|PLACEBO Capsules 500mg
223596833|NCT00094848|DRUG|TRAIL-R1 mAb (TRM-1; HGS-ETR1)|
223596834|NCT04770948|DEVICE|19 gauge needle|EBUS-TBNA performed using 19G needle
223596835|NCT04770948|DEVICE|22 gauge needle|EBUS-TBNA performed using 22G needle
223596836|NCT01423266|PROCEDURE|12-week supervised weight loss intervention|Patients in the 2 study arms will participate in an intensive 12-week supervised weight loss intervention and will be seen by the same dietician at regular intervals: baseline, 2 weeks, 4 weeks, 8 weeks, and 12 weeks. Participants will receive personalized nutrition counseling and support during each of these visits. Participants will be randomized to either the HP or SP diet and assigned to receive one of two standard structured energy-restricted meal plans (1200, 1500 Kcal/day) based on the computed calorie deficit
223596837|NCT05414552|DRUG|ECP|Treatment with ECP for irAEs with 2 cycles performed on two consecutive days, for the first 4 weeks repeated every week, and from week 5 to 12 repeated every two weeks
223596838|NCT00416455|RADIATION|fludeoxyglucose F 18|Undergo FDG PET/CT
223596839|NCT00416455|PROCEDURE|positron emission tomography|Undergo FDG PET/CT
223596840|NCT00416455|PROCEDURE|computed tomography|Undergo FDG PET/CT
223596841|NCT00416455|DRUG|ferumoxtran-10|Undergo femoxtran-10 MRI
223596842|NCT00416455|PROCEDURE|magnetic resonance imaging|Undergo femoxtran-10 MRI
223596843|NCT00416455|PROCEDURE|diagnostic lymphadenectomy|Undergo extraperitoneal, laparoscopic, or trans-peritoneal lymphadenectomy
223596844|NCT00416455|PROCEDURE|lymph node biopsy|Undergo pelvic and abdominal lymph node biopsy
223596845|NCT01515046|DRUG|Gemcitabine with escalating ascorbic acid|"Gemcitabine 1000 mg/m2 weekly for 3 weeks with one week off (this is 1 cycle)~Ascorbate dose is targeted to achieve plasma level of 350 mg/dL. Infusions are given twice weekly, each week of a cycle (4 weeks to a cycle)"
223596846|NCT01660503|DIETARY_SUPPLEMENT|0 grams SCF|Given in snack foods (muffins and flavored beverage)
223596847|NCT01660503|DIETARY_SUPPLEMENT|10 grams SCF|Given in snack foods (muffins and flavored beverage)
223596848|NCT01660503|DIETARY_SUPPLEMENT|20 grams SCF|Given in snack foods (muffins and flavored beverage)
223596849|NCT04939792|DRUG|Vitamin D|Capsules ingested orally
223596850|NCT04939792|DRUG|Placebo|Capsule ingested orally
223596851|NCT04939792|DRUG|Vitamin D + L-cysteine|Capsule ingested orally
223596852|NCT04939792|DRUG|L-cysteine|Capsule ingested orally
223596853|NCT00348309|DRUG|Rosiglitazone Extended Release 2mg|Rosiglitazone Extended Release 2mg OD
223596854|NCT00348309|DRUG|Rosiglitazone Extended Release 8mg|Rosiglitazone Extended Release 8mg OD
223747966|NCT06591377|DRUG|Ticagrelor 90 MG|The ticagrelor arm will receive (a 180mg loading dose of cilostazol during the first 24 hours of stroke onset, followed by 90mg once daily from the 2nd day to the 90th day) and an open-label loading 300 mg aspirin, followed by a maintenance dose of 75 mg aspirin
223747967|NCT06591377|DRUG|Cilostazol 100 MG|The cilostazol arm will receive (a 200 mg loading dose of clopidogrel during the first 24 hours of stroke onset, followed by 100 mg twice daily from the 2nd day to the 90th day) and open-label loading 300 mg aspirin, followed by a maintenance dose of 75 mg aspirin.
224198101|NCT02650609|DRUG|Placebo|
224198102|NCT02305329|DRUG|BIA 9-1067|
224198103|NCT03464786|DEVICE|Lando® absorbable collagen membrane|Subjects who are fit for the study will be randomized to either intervention arms.
223596855|NCT00348309|OTHER|Placebo|Placebo
223596856|NCT00348309|OTHER|Donepezil|Donepezil (At least 6 months of ongoing donepezil therapy for Alzheimer's disease, with stable dosing for at least the last 2 months (and with no intent to change for the duration of the study).
223596857|NCT00622388|DRUG|Ofatumumab|8 weekly intra-venous (i.v.) infusions, 1 x 300mg and 7 x 1000mg
223747968|NCT06591377|DRUG|Aspirin 75mg|The ticagrelor arm will receive (a 180mg loading dose of cilostazol during the first 24 hours of stroke onset, followed by 90mg once daily from the 2nd day to the 90th day) and an open-label loading 300 mg aspirin, followed by a maintenance dose of 75 mg aspirin
224198104|NCT03464786|DEVICE|Geistlich Bio-Gide resorbable bilayer membrane|Subjects who are fit for the study will be randomized to either intervention arms.
224198105|NCT02365818|BIOLOGICAL|CG0070|
224198106|NCT05211037|DIAGNOSTIC_TEST|Kidney function assessment|kidney clearance measured by scintigraphy
224198107|NCT06138041|DRUG|intravenous lidocaine infusion|Lidocaine bolus of 2mg/kg after induction , and then continuous infusion with 2 mg/kg/h until the participate transfer out of postoperative anesthesia care unit.
223596858|NCT03507738|BIOLOGICAL|MT-5625 low dose|Intramuscular injection
223596859|NCT03507738|BIOLOGICAL|MT-5625 middle dose|Intramuscular injection
223596860|NCT03507738|BIOLOGICAL|MT-5625 high dose|Intramuscular injection
223596861|NCT03507738|BIOLOGICAL|Rotarix|Oral administration
223596862|NCT03507738|BIOLOGICAL|Placebo|Intramuscular injection
223596863|NCT03194113|BEHAVIORAL|Trauma-focused treatment|Weekly sessions
223596864|NCT03194113|BEHAVIORAL|Emotion regulation training|Managing and tolerating negative emotions, e.g. anger, sadness. Weekly sessions; preparatory to Prolonged exposure treatment
223596865|NCT03194113|BEHAVIORAL|Intensive Trauma-focused treatment|Intensive version (3 sessions per week) of Trauma-focused treatment
223596866|NCT00828750|DRUG|Eltrombopag oral tablets|Eltrombopag oral tablets once daily
223596867|NCT04189029|OTHER|Extensive phenotyping|Prospective assessment of physical evaluation, biomarkers and omics, cardiac and vascular imaging and telemonitoring of cardiovascular parameters for 14 days.
223596868|NCT01710098|DRUG|Degarelix|subcutaneous injection
223596869|NCT04548518|BIOLOGICAL|GPO Tri Fluvac vaccine|Each dose of Tri Fluvac contains a total of 45 micrograms (μg) hemagglutinin (HA) per 0.5 ml dose (15 μg HA per strain per dose), to be administered by intramuscular (IM) injection. Tri Fluvac is manufactured and formulated into a multiple-dose vial vaccine (2 doses) using thimerosal at relatively low concentration as preservative (≤ 5.75 μg mercury/ dose). Each 0.5 ml dose of vaccine may contain residual amounts of ovalbumin (≤ 1.0μg), formaldehyde (≤ 100μg), tween 80 (≤ 0.9μg), triton x-100 (≤0.05μg) and gentamicin (≤0.075μg).
223596870|NCT04548518|BIOLOGICAL|Licensed influenza vaccine|The comparator licensed influenza vaccine is a seasonal trivalent inactivated split virion influenza vaccine recommended for Southern Hemisphere in 2020
224198108|NCT06138041|DRUG|Saline|Same volume of normal saline in bolus and continuous infusion as lidocaine group.
224198109|NCT02495974|DRUG|enzalutamide|oral
224198110|NCT04633434|BEHAVIORAL|The Talk Parenting Skill for Alexa|In a 4-week period, families use at home a prototype Bedtime Routine module of the Talk Parenting program, a smart speaker app designed to provide parents with in-situ experiential support for building positive family routines. The prototype Bedtime Routine module of Talk Parenting guides families in creating a healthy bedtime routine to foster healthy sleep habits, provide experiential practice in self-regulation skills, and promote a positive parent-child relationship.
224198111|NCT03354143|OTHER|Standard Care|Calcium channel blocker (CCB, amlodipine), angiotensin II receptor blocker (ARB, losartan), and other antihypertensive drugs will be used to reduce 24-hour SBP ≤ 130 mmHg.
224198112|NCT03354143|OTHER|Intensive Treatment|Calcium channel blocker (CCB, amlodipine), angiotensin II receptor blocker (ARB, losartan), and other antihypertensive drugs will be used to reduce 24-hour SBP ≤ 120 mmHg.
224198113|NCT04328311|OTHER|Watermelon Juice|500 mL watermelon juice (What a Melon), containing \~1 g of L-citrulline.
224198114|NCT04328311|OTHER|Water|500 mL low nitrate water
224198115|NCT03891732|DIAGNOSTIC_TEST|MRI prostate|plain biparametric MRI prostate
224198116|NCT00160771|BEHAVIORAL|Joint Motion Analysis|Joint motion will be recorded for analysis.
224198117|NCT06566391|DRUG|Ipilimumab|Nivolumab and Ipilimumab (sequential) for a total of four doses followed by Nivolumab
224198118|NCT02220621|DEVICE|Crosslinked hyaluronic acid gel|After hysteroscopic adhesiolysis, MateRegen Gel IU is applied into the uterine cavity together with a Foley balloon catheter.
224198119|NCT02220621|DEVICE|Foleys balloon catheter|After adhesivolysis, the Foleys balloon catheter is inserted into the uterine cavityand expanded with normal saline.
224198120|NCT06031948|DEVICE|active iTBS|Each participant will receive 1800 pulse active iTBS (100% RMT) in each session, 3 sessions per day, 5 days per week for 8 weeks.
224311017|NCT05742763|COMBINATION_PRODUCT|Acetaminophen and PRP|The primary research purpose is to determine if the use of ibuprofen \[arm #1\] vs acetaminophen \[arm #2\] vs a placebo control group \[arm #3\] with the intervention of a series of three injections of LP-PRP into the knee joint, leads to significantly greater reductions in average knee pain severity, and increases in physical function and quality of life, in patients with symptomatic moderate KOA, and grade 2 or 3 radiographic changes defined by the Kellgren-Lawrence (K-L) classification system.
224311018|NCT05742763|COMBINATION_PRODUCT|Placebo and PRP|The primary research purpose is to determine if the use of ibuprofen \[arm #1\] vs acetaminophen \[arm #2\] vs a placebo control group \[arm #3\] with the intervention of a series of three injections of LP-PRP into the knee joint, leads to significantly greater reductions in average knee pain severity, and increases in physical function and quality of life, in patients with symptomatic moderate KOA, and grade 2 or 3 radiographic changes defined by the Kellgren-Lawrence (K-L) classification system.
224311019|NCT02558348|DRUG|AL3818|Administered orally
223596871|NCT04087135|OTHER|direct laryngoscopy|Participants will intubate the hemoptysis cadaver model in simulation with direct laryngoscopy MacIntosh blade.
223596872|NCT04087135|OTHER|videolaryngoscopy McGrath|Participants will intubate the hemoptysis cadaver model in simulation with videolaryngoscopy using McGrath and the short curved blade (XBlade)
223747969|NCT06591377|DRUG|Aspirin 75mg|The cilostazol arm will receive (a 200 mg loading dose of clopidogrel during the first 24 hours of stroke onset, followed by 100 mg twice daily from the 2nd day to the 90th day) and open-label loading 300 mg aspirin, followed by a maintenance dose of 75 mg aspirin.
223747970|NCT05166109|DRUG|Vamorolone|Vamorolone 4.0% wt/wt oral suspension will be administered for the duration of the study.
223747971|NCT05166109|DRUG|Placebo|Placebo to Vamorolone 4.0% wt/wt oral suspension will be administered for the duration of the study.
224198121|NCT06031948|DEVICE|active iTBS|Each participant will receive 1800 pulse active iTBS (100% RMT) in each session, 3 sessions per day, 5 days per week for 8 weeks.
224198122|NCT06031948|DEVICE|sham iTBS|Each participant will receive 1800 pulse sham iTBS (100% RMT) in each session, 3 sessions per day, 5 days per week for 8 weeks.
224198123|NCT06031948|DEVICE|sham iTBS|Each participant will receive 1800 pulse sham iTBS (100% RMT) in each session, 3 sessions per day, 5 days per week for 8 weeks.
224198124|NCT03296059|OTHER|conventional treatment with RBC transfusion|Besides conventional treatment, neonates is given RBC transfusion.
224198125|NCT03296059|OTHER|conventional treatment|neonates is treated with conventional treatment.
224198126|NCT06190860|OTHER|Autologous Leukocyte and platelet-rich fibrin|Participants will be treated with L-PRF plugs and membranes from autologous venous blood. Participants will have drawn blood after venipuncture (median cubital vein) into sterile, glass-coated plastic 9 mL tubes without anticoagulant. These tubes will be centrifuged at 2700 rpm for 12 min (Relative Centrifugal Forces-clot = 408 g). After tooth extraction, participants in the experimental group will be treated with L-PRF plugs and membranes.
224198127|NCT06190860|OTHER|Intraoral Scan|Intraoral scan will be taken in the treated zone after tooth extraction and after four months.
224198128|NCT06190860|RADIATION|Computed Tomography|Cone Beam Computed Tomography in the treated zone will be taken after tooth extraction and after four months.
224198129|NCT06190860|OTHER|Biopsy|Before dental implant placement, a biopsy (2 mm in diameter) will be taken. The biopsy will be analyzed by Micro-computed tomography and decalcified and included in paraffin for histological sections.
224198130|NCT03560765|DEVICE|MED|Training in the use of mainstream electronic devices with accessibility options
224198131|NCT03560765|OTHER|Buddy|A buddy who will meet with the participant regularly for social interaction, and assistance with use of any MED purchased
224198132|NCT01510704|DRUG|APD421|IV
224198133|NCT01510704|DRUG|Placebo|IV
224198134|NCT00709449|DRUG|moxaverine|intravenous infusion of 150 mg in 250 ml NaCl, applied over 30 minutes.
224198135|NCT00709449|DRUG|moxaverine|intravenous infusion of 150 mg in 250 ml NaCl, applied over 30 minutes.
224198136|NCT00709449|DRUG|moxaverine|intravenous infusion of 150 mg in 250 ml NaCl, applied over 30 minutes.
224198137|NCT02264340|BEHAVIORAL|Relaxation technique Autogenic Training|Autogenic Training
223596873|NCT04087135|OTHER|videolaryngoscopy McGrath with suction|Participants will intubate the hemoptysis cadaver model in simulation with videolaryngoscopy using McGrath and the short curved blade (XBlade) and a suction they will advanced directly before the optic of the camera.
224198138|NCT02264340|BEHAVIORAL|Combined treatment Autogenic Training + Cervical exercises and postural correction|Autogenic Training + Cervical exercises and postural correction
224198139|NCT00659945|DRUG|Aprepitant plus Ondansetron|Aprepitant plus Ondansetron
224198140|NCT00659945|DRUG|Ondansetron plus placebo|Ondansetron plus placebo
224198141|NCT02208518|PROCEDURE|endoscopy ultrasound elastography|During a endoscopy ultrasound (EUS) procedure, in patients with normal pancreas at EUS, elastography was performed using a software already included in Hitachi-Avius machine, pressing the button and obtaining colors and pressure curve given by the software
223596874|NCT05293236|DRUG|ApTOLL|ApTOLL is an aptamer (DNA single strain) designed to block TLR4 (toll-like receptor 4)
223596875|NCT05293236|OTHER|Saline|Saline for intravenous infusion
223596876|NCT00321633|DRUG|carboplatin|
223596877|NCT00321633|DRUG|docetaxel|
223596878|NCT06259539|BEHAVIORAL|YouTube nutrition education|For those in the intervention group, the YouTube training modules had step-by-step recipe demonstrations, strategies on how to get your child to eat more new foods, social stories, First-Then visual chart, and other nutrition education materials. All the videos were less than 5 minutes long, and parents were assigned 2 videos per week for 8 consecutive weeks. Parents answered 2 open-ended questions each week related to the educational materials they reviewed.
223596879|NCT03852095|OTHER|minor trauma|following the management of the patient's fracture in the emergency department, the patients / parents are recalled 2 months (J60) after the visit to the emergency room, and are interviewed by following the pre-established interrogation form, which checks the good agreement of the patient. treatment performed with the given sheet and recommendations, and assesses the satisfaction.
223596880|NCT04611451|OTHER|classic lumbar home exercise|classic lumbar home exercise
223596881|NCT04611451|DEVICE|Whole body vibration|Whole body vibration (WBV), which is a new treatment method and applied through the device, is defined as mechanical repetitive motion or oscillatory motion occurring around a balance point
223596882|NCT04611451|OTHER|Whole body vibration exercise|Whole body vibration exercise
223596883|NCT02634502|PROCEDURE|radiofrequency ablation|
223747972|NCT05502718|OTHER|Stretching and Strengthening Exercises|The patients in the study group will be given exercise videos. These exercise videos will be selected in accordance with the patient's cervical dystonia type (Torticollis, laterocollis, retrocollis, anterocollis). During the exercises, stretching exercises will be applied to the muscle groups that cause dystonia, and isometric strengthening exercises will be applied to the contralateral muscle groups. Videos including breathing exercises and rhythmic coordination exercises will also be given to all patients in the study and control groups. Patients will be asked to do these exercises for 10 repetitions, three times a day, five days a week. Patients will be asked to mark after each exercise on the exercise chart prepared to determine continuity and compliance with exercise. Patients will be called and followed up on a weekly basis with the exercise chart given to the patients and by telephone.
224198142|NCT02208518|DEVICE|EUS-elastography|
224198143|NCT00660101|BIOLOGICAL|OVax: Autologous, DNP-Modified Ovarian Cancer Vaccine|OVax: Autologous, DNP-Modified Ovarian Cancer Vaccine cells in suspension dosage - depends on arm route - intradermal frequency - weekly x7, booster at 6 months
224198144|NCT03179488|DEVICE|Spinal TENS|Spinal TENS stimulation over back through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft, Netherlands)
224198145|NCT03179488|DEVICE|Sham stimulation|Sham stimulation over back through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft, Netherlands)
224198146|NCT02190162|DRUG|Tantum Verde® mouthwash|
224198147|NCT02190162|OTHER|Placebo mouthwash|Mouthwash with placebo solution
224198148|NCT04707612|OTHER|No intervention.|No intervention.
224198149|NCT01509638|DRUG|Group 1 Standard of Care|Patients in this group will receive IV morphine sulfate or Sponsor-approved equivalent via PCA pump, as needed.
224311020|NCT05319210|PROCEDURE|Venous catheter application|To examine the effect of virtual reality glasses and buzzy application on pain management during venous catheter insertion in children.
224311021|NCT03242200|OTHER|Mobile Health App|Mobile Health is a multi-featured app designed to enable participants to self-record and track their health and wellness. Participations will set up a profile and complete questionnaires. The app also records the amount of time and features of programs accessed.
223596884|NCT02634502|DRUG|S-1|
223596885|NCT03704714|DRUG|Cyclophosphamide|Given IV
223596886|NCT03704714|DRUG|Doxorubicin Hydrochloride|Given IV
223596887|NCT03704714|BIOLOGICAL|Nivolumab|Given IV
223596888|NCT03704714|DRUG|Prednisone|Given PO
223596889|NCT03704714|OTHER|Quality-of-Life Assessment|Ancillary studies
223596890|NCT03704714|BIOLOGICAL|Rituximab|Given IV
223596891|NCT03704714|DRUG|Vincristine Sulfate|Given IV
223596892|NCT04079114|DEVICE|Patients who received the Stafit Acetabular System|Patients, suffering from severe hip pain and disability, requiring primary total hip arthroplasty with high risk of dislocation, who meet the inclusion/exclusion criteria.
223596893|NCT01364389|DRUG|AIN457|3 mg/kg
223596894|NCT01364389|DRUG|ACZ885|3 mg/kg
223596895|NCT01364389|DRUG|Prednisone|20 mg
223596896|NCT01364389|DRUG|Placebo|Matching placebo to AIN457, ACZ885 and prednisone
223596897|NCT00851461|DRUG|Goserelin|Goserelin 10.8 mg SC every 3 months
223596898|NCT00851461|PROCEDURE|Electrophysiologic study|Nerve conduction study Electromyogram
223596899|NCT00851461|PROCEDURE|tissue biopsy|skin and muscle biopsy before and after treatment every year
223596900|NCT03875352|PROCEDURE|CHG technique|The CHG technique includes treatment using dressing with chlorhexidine.
223596901|NCT03875352|PROCEDURE|HMG technique|The HMG technique includes treatment using hydrophilic methacrylate gel and transparent foil.
223596902|NCT01068158|DRUG|0.5% Ivermectin Cream|Up to 4 ounces of 0.5% Ivermectin Cream applied to hair and scalp on day 1.
223596903|NCT01068158|DRUG|Placebo control|up to 4 ounces of topical vehicle control to head and scalp on day 1.
223596904|NCT00562146|PROCEDURE|placement of spiral nasojejunal tube|spiral nasojejunal tube will be placed after enrollment of the patients
224198150|NCT01509638|DRUG|Group 2 EXPAREL|Patients in this group will receive 266 mg EXPAREL diluted with preservative-free 0.9% normal saline to a total volume of 30cc and administered via wound infiltration prior to wound closure. When not contraindicated, 30 mg IV ketorolac will be given at the end of surgery. If not indicated, IV non-steroidal anti-inflammatory drug (NSAID) may be substituted per the site's standard of care.
223596905|NCT05755659|DRUG|Fosaprepitant Dimeglumine for Injection|The specification of Fosaprepitant Dimeglumine for injection is 150 mg, and the usage and dosage is: when preventing nausea and vomiting caused by HEC, this product is used in combination with dexamethasone and 5-HT3 antagonist. The dosage of Fosaprepitant Dimeglumine for injection is 150 mg, and the infusion time is 20-30 minutes. The intravenous infusion is completed 30 minutes before the beginning of chemotherapy on the first day.
223596906|NCT04246632|DEVICE|CapsoCam Colon Capsule Endoscopy|CapsoCam® Colon is intended to provide visualization of the colon and the detection of colon polyps in adults.
223596907|NCT00698334|DRUG|INH, Rifampicin, Ethambutol and Pyrazinamide|Directly Observed Treatment Short-course; Thrice weekly (INH 600 mg, Rifampicin 450 mg \[600 mg if more than 59 kg\], Ethambutol 1200 mg, Pyrazinamide 1500 mg)
223596908|NCT00698334|DRUG|INH, Rifampicin, Ethambutol and Pyrazinamide|Directly Observed Treatment Short-course; Thrice weekly (INH 600 mg, Rifampicin 450 mg \[600 mg if more than 59 kg\], Ethambutol 1200 mg, Pyrazinamide 1500 mg)
223596909|NCT03625999|BEHAVIORAL|video game training exercise|"The game, called The Silent Service and developed by our collaborators, is an online game with an underwater theme, and is comprised of 5 distinct mini-games, each of which demands auditory attention. The mission is to navigate an underwater scene, listening and responding to 'sonar' (e.g., an oddball in a stream of sounds). For example, participants may have to respond to an oddball sound stream to protect their submarine from a looming sea monster, while successfully ignoring a distractor sound stream (responses to the distractor sound stream allow the sea monster to damage the submarine). The five games share the same underlying framework of detecting oddballs while ignoring distractors but have unique artwork and 'backstories' to keep players interested. There is a hierarchical reward structure for 'leveling up' across the game that helps players to stay engaged and interested while playing."
223596910|NCT04309058|DRUG|Vitamin D drops|Vitamin D-deficient UC patients are divided into two groups, one group is given orally with Vitamin D drops 400IU / d, while the other group do not interfere.
223596911|NCT04969692|PROCEDURE|warming to increase local skin (puncture site) temperature|According to the group of participants, investigator applies the warmer to the hands and wrists of the participants, makes a local temperature of 40℃ gradually, and maintains it for about 10 minutes in warming group (which is divided in to warming-palpation (WP) and warming-US (WU) group).
223596912|NCT00244491|BEHAVIORAL|Care Transitions Intervention|
223596913|NCT02620488|BEHAVIORAL|Guided Imagery|Brief guided imagery session with a trained clinician focused on relaxation and pleasant imagery.
223596914|NCT02861859|DRUG|Olanzapine|Olanzapine 5 mg (2 x 2.5 mg) PO OD (once a day) on days 1-4.
223596915|NCT02861859|DRUG|Olanzapine Placebo|Olanzapine Placebo 5 mg (2 x 2.5 mg) PO OD (once a day) on days 1-4.
223596916|NCT00991406|DEVICE|FES|Surface stimulation to contract the muscles in the lower extremity
223596917|NCT01955538|OTHER|Control|Psychiatric treatment as usual for 6 months according to best clinical practice.
223596918|NCT01955538|OTHER|Basic Body Awareness Therapy|20 weeks, 1 hour/week.
223596919|NCT01955538|OTHER|Mixed physical activity|20 weeks, 1 hour/week.
223596920|NCT03295019|DEVICE|Test Oral Spray|HA formulation of FDA listed ingredients
223596921|NCT03295019|DEVICE|Placebo Oral Spray|Placebo formulation without the active ingredients
223596922|NCT03450733|DEVICE|Wright Medical Technology Metal-on-Metal Total Hip System|Subjects in Group 1 previously implanted prior to the study start date will be identified from Investigator records. Collected data will be evaluated in aggregate and cross-sectioned by year of implantation. Subjects will be cross-sectioned by the time that has elapsed between implantation and the initial visit (e.g. 5 years, 6 years) using contiguous visit windows (number of years + 6 months). Subject data will be grouped in order to create cross-sectional epochs of ≤ 8 years and \> 8 years.
223596923|NCT06267664|DRUG|Patients with migraine treated with triptans, Lasmiditan or Gepants|Patients will complete the study information in their smartphones, tablets or computers, using a QR code or a link that will redirect hem to the study questionnaires. RedCap will be used in the study.
223596924|NCT01300572|PROCEDURE|Allogeneic Bone Marrow Transplantation|Undergo allogeneic bone marrow transplant
223596925|NCT01300572|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic PBSC or bone marrow transplant
223596926|NCT01300572|DRUG|Cyclosporine|Given PO or IV
223596927|NCT01300572|DRUG|Fludarabine Phosphate|Given IV
223747973|NCT05502718|OTHER|Breathing and Rhythmic Coordination Exercises|The patients in the study group will be given exercise videos prepared in the Department of Physical Medicine and Rehabilitation of Ankara University Faculty of Medicine. . Videos including breathing exercises and rhythmic coordination exercises will also be given to all patients in the study and control groups. Patients will be asked to do these exercises for 10 repetitions, three times a day, five days a week.
223747974|NCT04234568|PROCEDURE|Biospecimen Collection|Correlative studies
223747975|NCT04234568|PROCEDURE|Computed Tomography|Undergo CT
223596928|NCT01300572|BIOLOGICAL|Indium In 111 Anti-CD45 Monoclonal Antibody BC8|Given IV (dosimetric dose)
223596929|NCT01300572|OTHER|Laboratory Biomarker Analysis|Correlative studies
223596930|NCT01300572|DRUG|Mycophenolate Mofetil|Given PO or IV
223596931|NCT01300572|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo allogeneic PBSC transplant
223596932|NCT01300572|OTHER|Pharmacological Study|Correlative studies
223596933|NCT01300572|RADIATION|Total-Body Irradiation|Undergo TBI
223596934|NCT01300572|RADIATION|Yttrium Y 90 Anti-CD45 Monoclonal Antibody BC8|Given via central line (therapeutic dose)
224198151|NCT04361669|OTHER|Medication safety review|Implementation of a medication safety review using a clinical decision support system
224198152|NCT00552422|DRUG|domperidone|10mg orally four times per day
224198153|NCT03484858|OTHER|High glycaemic index meal and exercise|
224311022|NCT03781037|BEHAVIORAL|GIVE Module|The GIVE Module is a brief cognitive behavioral intervention targeting youths' beliefs that they are a burden or drain on others. It consists of two sessions embedded within a larger CBT protocol for anxiety or depression.
224311023|NCT04182282|BEHAVIORAL|CARES Dementia-Friendly Hospitals Online Training and Certification Program|The CARES Dementia-Friendly Hospitals Online Training program is a 4-course, 16-module, video-based training program for hospital staff members. The CARES Dementia-Friendly Hospitals Online Certification Program is a 100-point certification exam evaluating knowledge from the online training protocol.
224311024|NCT03288701|DEVICE|Seca medical Body Composition Analyser 515|Comparison of reduction of whole body water and body weight in patients with decompensated heart failure under forced diuretic treatment
224311025|NCT06452667|PROCEDURE|platelet-rich fibin|Each case will receive 3 sessions of microneedling therapies with one month interval. Each case will receive platelet-rich fibin therapy on one side of the face. The other side of the face was treated with platelet-rich palsma.
223596935|NCT03845738|DEVICE|OsseoSpeed EV implant|The investigational product (OsseoSpeed EV implant) is already included in a restoration in the subject at enrollment, thus this study does not involve the installation of any investigational products.
223596936|NCT03021772|DRUG|Neostigmine|Patients will receive intravenous 3mg/kg lidocaine 2 % (diluted with normal saline to 40 ml) + 0.5 mg neostigmine for Bier block.
223596937|NCT03021772|DRUG|Dexamethasone|Patients will receive intravenous 3mg/kg lidocaine 2 % (diluted with normal saline to 40 ml) + 8 mg dexamethasone for Bier block.
223596938|NCT01086943|DEVICE|LT2420|
224198154|NCT03484858|OTHER|High glycaemic index meal and rest|
224198155|NCT03484858|OTHER|Low glycaemic index meal and exercise|
224198156|NCT03484858|OTHER|Low glycaemic index meal and rest|
224198157|NCT00627094|DEVICE|Biatain|A standard polyurethane foam dressing Biatain non-adhesive (Coloplast A/S) with an elastic semi-permeable backing film, size 15x15 cm. The product is CE marked.
224198158|NCT00627094|DEVICE|Biatain Ibu|Biatain Ibu non-adhesive (Coloplast A/S), a polyurethane foam dressing with an elastic semi-permeable backing film with an added pain relieving medicinal substance ibuprofen (Albermarle Inc.), size 15x15 cm. The product is CE marked.
224198159|NCT01744275|DIETARY_SUPPLEMENT|Omega 3 fatty acids|
224198160|NCT01744275|DIETARY_SUPPLEMENT|corn oil|Placebo
224311026|NCT06452667|PROCEDURE|platelet-rich palsma|Each case will receive 3 sessions of microneedling therapies with one month interval. Each case will receive platelet-rich palsma therapy on one side of the face. The other side of the face was treated with platelet-rich fibin.
224311027|NCT06332989|OTHER|stroke-APP|Ambulane paramedics will use an online application to fill in several observations on scen
224198161|NCT02237768|DRUG|DIRITHROMYCIN 500 MG ENTERIC COATED TABLET|
224198162|NCT02237768|DRUG|DYNABAC 250 MG ENTERIC COATED TABLET|
224198163|NCT01040624|RADIATION|< 15% risk of + LN|Total of 54 Cobalt gray equivalent (CGE) over 30 treatments to prostate + seminal vesicles (SV), then proton boost total of 23.4-27 CGE over 13-15 treatments to prostate +/- SV. Low dose docetaxel every week during radiation therapy (RT) followed by androgen deprivation therapy for 6 months.
224198164|NCT01040624|RADIATION|> 15% risk of + LN|Total of 45 Gy over 25 treatments to prostate + SV + LN, then proton boost total of 32.4-36 CGE over 18-20 treatments to prostate + SV. Low dose docetaxel every week during RT followed by androgen deprivation therapy for 6 months.
224311028|NCT03741712|DRUG|SHR3680|Tablet. Specifications of 80mg
224311029|NCT03741712|DRUG|SHR2554|Tablet. Specifications of 50mg and 200mg
224311030|NCT03337958|DEVICE|Ventilatory re-education|The first day of intervention consisted primarily in ventilatory re-education. During the realization of the technique he was videotaped with a Tablet so that later the patient could be seen and on the video to be able to give him the guidelines for the correction. On the second and third day of the intervention, ventilation re-education was performed and the inhalation technique was subsequently trained.
224311031|NCT05267730|BEHAVIORAL|Conectar Jugando Game Program|Modern Board and Card Games as Cognitive Training in Rural Elementary Classrooms
224311032|NCT04322565|DRUG|Colchicine|Cochicine 1mg/day
224311033|NCT04015908|DRUG|Celecoxib|Celecoxib 100mg
224311034|NCT04015908|DRUG|Acetaminophen|Acetaminophen 325mg
224311035|NCT04015908|DRUG|Pregabalin|Pregabalin 50 mg
224311036|NCT04015908|DRUG|Oxycodone|oxycodone 5-10 mg
224311037|NCT04015908|DRUG|Percocet|Percocet (oxycodone 5mg/acetaminophen 325 mg)
223506876|NCT03264950|DIAGNOSTIC_TEST|Elastography|"an ultrasound exam after selecting the best acoustic window, a region of interest (ROI) is placed in an area of the liver perpendicular to the liver capsule, taking care not to include large vasculature or biliary structures.~Similarly an acoustic window will be selected for the pancreas as well"
223506877|NCT00640432|DRUG|Diclofenac|75 mg oral capsule twice daily for 7 days
223506878|NCT00640432|DRUG|Celecoxib|400 mg oral capsule followed by 200 mg oral capsule with the evening meal (\>=4 hours from first dose) on Day 1 then 200 mg oral capsule twice daily for 6 days
223506879|NCT06449248|OTHER|Checking of appropriateness of OLP diagnosis|The above mentioned interventions will be carried out through the accurate analysis of patients' clinical records
223506880|NCT03066557|PROCEDURE|TACE and Apatinib|TACE and Apatinib 250mg po qd
223506881|NCT03066557|PROCEDURE|TACE|TACE
223506882|NCT05275244|DEVICE|KD Intra-Articular® gel|Depending on the joint, 3 injections will be administrated to the patient: KD Intra-Articular® gel 2.2% - 44 mg in 2 ml - (Pronolis® HD one 2.2%) in the case of shoulder and hip, or KD Intra-Articular® gel 1.6% - 16 mg in 1 ml - (Pronolis® HD mini 1.6%) in the case of the ankle and base of the thumb. The administration of the infiltrations will be with an interval of one week.
223506883|NCT03656575|BIOLOGICAL|synovial fluid biomarker concentrations|Synovial fluid samples will be obtained pre-injection, Post Injection 3 Weeks, Post Injection 6 Weeks, Post Injection 9 Weeks, Post Injection 3 Months, Post Injection 6 Months, Post Injection phone call at 1 Year
223506884|NCT02588755|PROCEDURE|TACE+Tegafur|Tegafur: 40mg bid for 3 continuous months in 4 months. TACE: 4 or 8 weeks after resection.
223506885|NCT02588755|PROCEDURE|TACE|TACE alone
223506886|NCT05807750|OTHER|Post-discharge income supplement|$300 income supplement
223506887|NCT05807750|OTHER|Enhanced care planning|Enhanced care planning provided by a nurse care manager
224198165|NCT01232075|DRUG|Extended letrozole regimen|"Letrozole (Femara; Novartis pharma AG, Basle, Switzerland) 2.5mg /day is administered from cycle day 1 to 9 .~Human chorionic gonadotropin (Pregnyl; N.V. Organon, Oss, Holland) ( 10.000 IU/I.M ) is administered to trigger ovulation when at least one follicle measures more than 18mm in mean diameter .Intrauterine insemination is performed 36 - 40 hours after HCG injection .~Starting from cycle day 9 , ultrasound scans are repeated daily to monitor follicle growth . Serum estradiol and endometrial thickness are measured on the day of HCG administration.~Serum B-subunit HCG is measured 2 weeks after IUI to diagnose pregnancy ."
223596939|NCT02556060|DRUG|Lamotrigine|Starting from 25 mg/day in the first week, then titrated up to 200 mg/day for 12 weeks
223596940|NCT02556060|DRUG|Placebo|Same dosing schedule as study drug
223596941|NCT03485521|PROCEDURE|The tracheobronchial aspiration|"Reading of the procedures of the tracheobronchial aspiration (legislative framework, rules of hygiene, procedures, undesirable effects) The Practical Group participates in a practical work lasting two hours and the Stimulation Group is in simulation with a procedural practice of tracheobronchial suction as part of a simulation sequence. This group benefits from the methodology of the simulation with a part of briefing, a part simulated session and to finish the debriefing.~The experiment finished with a real activity on patients with tracheotomy with in this environment the reproduction of the procedure"
223596942|NCT02160145|DRUG|Tolvaptan (OPC-41061)|Tolvaptan tablets (15 or 30 mg) will be self-administered orally as split-dose regimens, once upon awakening and another approximately 8 to 9 hours later.
224198166|NCT01232075|DRUG|Clomiphene citrate regimen|"Clomiphene citrate(Clomid; Aventis pharma S.AE, Global Napi pharmaceuticals, Cairo, Egypt) 100 mg/day is administered from cycle day 3 to 7.~Human chorionic gonadotropin (Pregnyl; N.V. Organon, Oss, Holland) ( 10.000 IU/I.M ) is administered to trigger ovulation when at least one follicle measures more than 18mm in mean diameter .Intrauterine insemination is performed 36 - 40 hours after HCG injection .~Starting from cycle day 9 , ultrasound scans are repeated daily to monitor follicle growth . Serum estradiol and endometrial thickness are measured on the day of HCG administration.~Serum B-subunit HCG is measured 2 weeks after IUI to diagnose pregnancy ."
224198167|NCT01959217|BEHAVIORAL|PM Component Text Reminders|The number of PM components (strategic encoding, monitoring, and cue salience) that will comprise the tailored text reminders will be determined by Phase 1.
224198168|NCT02151552|DRUG|Endotoxin (E. coli O:113, Reference Endotoxin)|The endotoxin will be reconstituted with sterile water to a final concentration of 2,000 endotoxin units/ml. The dose of 4 ng/kg will be prepared to a final volume of 2 ml and will be administered using a 5F balloon-tipped monitoring catheter inserted via a fiberoptic bronchoscope into the lateral segment of the right middle lobe of the lung on the morning of Day 2.
223596943|NCT02160145|DRUG|Placebo|Matching placebo tablets will be self-administered orally as split-dose regimens, once upon awakening and another approximately 8 to 9 hours later
223596944|NCT04959305|DRUG|HCP1803-3|Take it once daily for 8 weeks orally.
223596945|NCT04959305|DRUG|RLD2003|Take it once daily for 8 weeks orally.
223596946|NCT04959305|DRUG|RLD2004|Take it once daily for 8 weeks orally.
223596947|NCT04959305|DRUG|RLD2005|Take it once daily for 8 weeks orally.
223596948|NCT04959305|DRUG|HPP2003-3|Placebo drug. Take it once daily for 8 weeks orally.
223596949|NCT04959305|DRUG|HPP2005|Placebo drug. Take it once daily for 8 weeks orally.
223596950|NCT03887858|DRUG|Harnal-D Tab.|Harnal-D Tab. 1T single oral administration under fasting
223596951|NCT03887858|DRUG|Chong Kun Dang Tamsulosin HCl Tab.|Chong Kun Dang Tamsulosin HCl Tab. 1T single oral administration under fasting condition
223596952|NCT02239315|OTHER|Tumor RNA Disruption Assay™ (RDA)|Tumor RNA Disruption Assay™ (RDA) to generate RDA score from fine needle aspiration biopsy samples of breast cancer obtained 7-14 days after the first, second and third cycles of neoadjuvant chemotherapy; and, if there is a change of chemotherapy regimen, after the first cycle of the new chemotherapy.
223596953|NCT00164515|BEHAVIORAL|Personalized exercise programme (PEP)|Physician referred overweight and obese clients to 24 month personalized exercise programme at the U. of Illinois, Chicago
223596954|NCT04558372|OTHER|exhaled breath sampling|The participants breath through non-rebreathing mask until the reservoir bag is full. The reservoir bag is connected to Hepa-filter at one side, and another side of Hepa-filter is connected to the electronic-nose (Genosvid) device.
223596955|NCT04558372|OTHER|exhaled breath sampling|The participants breath through non-rebreathing mask until the reservoir bag is full. The reservoir bag is connected to Hepa-filter at one side, and another side of Hepa-filter is connected to the electronic-nose (Genosvid) device.
223596956|NCT04558372|OTHER|exhaled breath sampling|The participants breath normally using a mask for 2 times then they are asked to inhale and exhale in a forced expiratory volume through an e-nose tube connected to the Hepa-filter at the inlet.
223596957|NCT00375518|DRUG|Atorvastatin|Atorvastatin 40 mg once a day beginning 7 days before the operation. Surgical procedures will be as planned and unaffected by this study. Starting from the day after surgery, patients will be given their study drug for an additional 7 days.
223596958|NCT00375518|DRUG|Placebo|Placebo given beginning 7 days before the operation. Starting from the day after surgery, patients will be given their study drug for an additional 7 days.
223596959|NCT00854841|DRUG|Dasatinib and Imatinib|"Dasatinib Dasatinib will be administered orally at a dose of 100 mg QD. During the first month, subjects will be instructed to take dasatinib in the morning.~Imatinib Imatinib will be administered orally at a dose of 600 mg once daily (QD). Each 600 mg dose should be administered with a meal and taken with a large glass of water. If a scheduled dose is missed for more than 12 hours or dosing is interrupted for toxicity or for any other reason, these doses should be omitted."
223596960|NCT02197650|DRUG|suspension of erythrocytes encapsulating L-asparaginase|Erythrocytes encapsulating L-asparaginase
223747976|NCT04234568|DRUG|Lutetium Lu 177 Dotatate|Given IV
223747977|NCT04234568|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223747978|NCT04234568|DRUG|Triapine|Given PO
223747979|NCT06117813|DEVICE|Nu.T|Participants receive visual perceptual training using the Nu.T software.
223747980|NCT06117813|OTHER|No-Treatment Control|No-treatment was administered during control period.
223747981|NCT05497284|DRUG|LTP001|LTP001 administered once daily in the morning
223747982|NCT05497284|DRUG|Placebo|Placebo to LTP001 administered once daily in the morning
223747983|NCT05497284|DRUG|Standard of Care (SoC)|nintedanib, pirfenidone, or neither
223596961|NCT03273309|OTHER|Vibratory Perineal Stimulus|Vibratory perineal stimulus will be applied in patients randomized to this group through an intravaginal probe which emits vibratory pulses, with the device fixed in the following parameters:on time = 8 seconds, off time = 16 seconds, total time = 20 minutes. The intervention time will be 6 weeks, with sessions held once a week.
223596962|NCT03273309|OTHER|Transvaginal Electrical Stimulation|The transvaginal electrical stimulation will be applied in patients randomized to this group through an intravaginal probe which emits electrical pulses, with the device fixed in the following parameters: frequency = 50 Hz, pulse width = 300ms,on time = 8 seconds, off time = 16 seconds, total time = 20 minutes. The intervention time will be 6 weeks, with sessions held once a week.
223747984|NCT05775614|DEVICE|UroTainer®|Clinical effect of preventive treatment - catheter flushing with UroTainer®
223747985|NCT05775614|DEVICE|Saline|Clinical effect of preventive treatment - catheter flushing with saline solution
223747986|NCT06285370|DRUG|Mogamulizumab|Mogamulizumab will be administered at the dose of 1.0 mg/kg as an intravenous (iv) infusion over at least 1 hour on Days 1, 8, 15, and 22 of Cycle 1 and on Days 1 and 15 of subsequent cycles. Each treatment cycle is set as 28 days. Subjects will continue the treatment of mogamulizumab until any of the criteria for study withdrawal is met.
223747987|NCT06501118|OTHER|Education|"1. Standardized materials to discuss the rationale and procedural aspects of the intervention, including details on the specific oxygen target-related modifications to the mechanical ventilation order-set prior to starting the intervention phase.~2. Virtual respiratory therapist (vRT) - directed real-time feedback on adherence to the SpO2 target range as a part of the mechanical ventilation order-set embedded in UCHealth EHR (EPIC)."
224198169|NCT02151552|DRUG|[18F](+/-)NOS|7 mCi of \[18F\](+/-)NOS will be injected intravenously at the start of a 60-minute dynamic PET scan acquisition
224198170|NCT00658203|DEVICE|New Living CHF|PEA CRT optimization
224198171|NCT00658203|DEVICE|New Living CHF|Standard optimized CRT.
224198172|NCT05602025|BIOLOGICAL|Depemokimab|Depemokimab will be administered via a SSD or autoinjector.
224198173|NCT05478356|DRUG|low-dose atropine eye drops|low-dose atropine eye drops
224198174|NCT05478356|DEVICE|orthokeratology|orthokeratology, ortho-K lenses
224198175|NCT03740035|DEVICE|eHealth for Sedentary Behavior|Prostate cancer patients will be testing the usability and acceptability of the eHealth web app for sedentary behavior
224198176|NCT02921607|OTHER|Observational group|Participants will be asked to complete a questionnaire prior to discharge and 3 months later to follow up
224198177|NCT01649999|DRUG|peficitinib|oral
224198178|NCT01649999|DRUG|Placebo|oral
224198179|NCT04067856|DRUG|Bevacizumab Injection|Intravitreal injection
224198180|NCT02637518|OTHER|Assessment of frailty tools in elderly people|Assessment of the tools as screening/diagnosis instruments in older adults attended in Primary Care. To build the integration of tools in algorithms to be used in each setting of care and along the settings to permit an integrated care in different conditions (isolated assessment or sequential assessment)
224198181|NCT04138173|BEHAVIORAL|Tele coaching intervention|"A.Education about the importance of PA. During a one-to-one interview with the coach motivation, self-efficacy, barriers, favorite activities and strategies to become more active are discussed.~B. Step counter providing direct feedback.~C.A smartphone with a project-tailored application. The application provides automated coaching by displaying an activity goal (number of steps) and feedback on a daily basis. The feedback comes with a graphical presentation. Patients' targets are automatically revised weekly.~D.Telephone contacts triggered in the case of non-compliance with wearing the step counter, failure to transmit data or failure to progress. Coaches are alerted by a note at the coaches' backend to take contact with the patient if needed."
224198182|NCT02376582|BIOLOGICAL|DNA|DNA co-administered with protein at month 0, 1 and 6
224198183|NCT02376582|BIOLOGICAL|AIDSVAX B/E|Protein co-administered with DNA at month 0,1 and 6
224198184|NCT03504527|DRUG|triple combinations|inhaled budesonide(160ug,bid),formotero(4.5ug,bid) and tiotropium bromide(18μg,qd)
224198185|NCT03504527|DRUG|double combinations|inhaled formotero(4.5ug,bid) and tiotropium bromide(18μg,qd)
224311038|NCT02257697|DRUG|Mizoribine (MZR)|
224311039|NCT02257697|DRUG|Cyclophosphamide (CTX)|
223506888|NCT02642276|OTHER|Exercise training|Patients to be randomized to the 'maximal walking group' or 'submaximal group' will undergo exercise training sessions 3 times per week for a period of 12 weeks.
223506889|NCT05449262|OTHER|functional resistance training GROUP A|"Session of 45-60 min. Warm up prior to training Warm up 6-7 min of mild cardiovascular exercise followed by 3-4 min stretching~Cool down post training A cool-down of 1 min of mild cardiovascular exercise followed by 4 min of stretching"
223506890|NCT05449262|OTHER|functional resistance training GROUP B|"Session of 45-60 min Warm up prior to training Warm up 6-7 min of mild cardiovascular exercise followed by 3-4 min stretching~Cool down post training A cool-down of 1 min of mild cardiovascular exercise followed by 4 min of stretching"
223506891|NCT04145271|DEVICE|Resuscitative Endovascular Balloon Occlusion of the Aorta (REBOA)|Resuscitative Endovascular Balloon Occlusion of the Aorta (REBOA) is a minimally invasive damage control procedure for life-threatening abdominal and/or pelvic haemorrhage. It involves temporary occlusion of the aorta with an endovascular balloon, providing proximal control to the site of vascular injury whilst supporting cerebral and myocardial perfusion
223506892|NCT01049672|DRUG|Alfentanil|Titrated to a maximum dose of 50mg in 24 hours subcutaneously
223506893|NCT01049672|DRUG|Diamorphine|Titrated to a maximum dose of 500mg in 24 hours given subcutaneously
223506894|NCT04875273|DEVICE|Magnetic Tape® aplicación|Magnetic tape® is applied without creating any tension on the paravertebral skin of the lumbar spine
223506895|NCT04875273|DEVICE|Kinesiology Tape application|Kinesiology tape is applied without creating any tension on the paravertebral skin of the lumbar spine
223506896|NCT01127477|DRUG|1: Hydroxyethyl starch 130/0.4, 6 %|1: Up to 50 ml 6 % hydroxyethyl starch 130/0.4/kg body weight administered intravenously from start of surgery (skin incision) until two hours after end of surgery.
223506897|NCT02955550|DRUG|rhIL-2|Human recombinant Interleukin-2
223506898|NCT02955550|BIOLOGICAL|PNK-007|PNK-007 is a culture-expanded cell population derived from human cord blood hematopoietic stem/progenitor cells.
223506899|NCT02818062|BIOLOGICAL|Cytokines dosage in Aqueous humor|Specify details not covered in associated Arm Description.
223596963|NCT02359513|DRUG|Antidepressants|bulimic patients are treated during 3 months
223596964|NCT02359513|DRUG|Positron Emission Tomography (PET)|PET scan using \[18F\]MPPF is performed before and after (3 months)antidepressant treatment
224198186|NCT04148469|PROCEDURE|Dry needling|Dry needlin is a manual therapy technique used for miofascuial pain syndrom treatment. The patient will be supine, in a confortable position. The therapist localizes the trapezius trigger point number 2 and then performes the needling until 2 REL are obtenined. The patient will remain supine during 15 minutes.
223596965|NCT02006849|DRUG|Acthar|FDA approved drug being used in this study for sub-nephrotic proteinuria. Given Investigational New Drug (IND) exemption by FDA.
223596966|NCT05850338|DEVICE|cold pad pillow|cold pad pillow application when women have vasomotor symptoms for 8 weeks
223596967|NCT05850338|BEHAVIORAL|autogenic training|Autogenic relaxation for three times a day for eight weeks
223596968|NCT00003336|BIOLOGICAL|anti-thymocyte globulin|The regimen varies according to the underlying cause of the anemia.Patients receive high-dose chemotherapy and/or radiotherapy as a conditioning regimen beginning 6-9 days before the umbilical cord blood transplant (UCBT).
223596969|NCT00003336|DRUG|busulfan|The regimen varies according to the underlying cause of the anemia.Patients receive high-dose chemotherapy and/or radiotherapy as a conditioning regimen beginning 6-9 days before the umbilical cord blood transplant (UCBT).
223596970|NCT00003336|DRUG|cyclophosphamide|The regimen varies according to the underlying cause of the anemia.Patients receive high-dose chemotherapy and/or radiotherapy as a conditioning regimen beginning 6-9 days before the umbilical cord blood transplant (UCBT).
223596971|NCT00003336|DRUG|melphalan|The regimen varies according to the underlying cause of the anemia.Patients receive high-dose chemotherapy and/or radiotherapy as a conditioning regimen beginning 6-9 days before the umbilical cord blood transplant (UCBT).
223596972|NCT00003336|DRUG|methylprednisolone|The regimen varies according to the underlying cause of the anemia.Patients receive high-dose chemotherapy and/or radiotherapy as a conditioning regimen beginning 6-9 days before the umbilical cord blood transplant (UCBT).
223596973|NCT00003336|PROCEDURE|bone marrow ablation with stem cell support|
223596974|NCT00003336|PROCEDURE|umbilical cord blood transplantation|One day after the conditioning regimen is completed, patients receive the UCBT.
223596975|NCT00003336|RADIATION|radiation therapy|The regimen varies according to the underlying cause of the anemia.Patients receive high-dose chemotherapy and/or radiotherapy as a conditioning regimen beginning 6-9 days before the umbilical cord blood transplant (UCBT).
223596976|NCT02421289|DRUG|Efavirenz|There will be adjusted dose of efavirenz in CYP2B6 guide group
223596977|NCT02421289|DRUG|Efavirenz|If the patients was diagnosed as hypersensitivity to EFV, they will receive boosted-PI instead.
223596978|NCT02421289|OTHER|CYP450 2B6|All patients will be monitored drug level which should be in therapeutic level.
223596979|NCT03249987|OTHER|bladder diary|electronic diary to be completed for 3 days before crossover onto paper diary for 3 days
223596980|NCT00634062|DRUG|Lamotrigine|Subject in active active drug group will receive lamotrigine tablets 12.5 per day for the first week of the study. Dose of lamotrigine can be increased to 25mg per day during the second week of the study and may be increased each week thereafter for the next 9 weeks by 25mg per day. Subjects in active treatment group will receive lamotrigine for total of 12 weeks
223596981|NCT00634062|DRUG|Placebo|Subjects will receive 12.5mg of inert placebo per day during the first week of the study. Inert placebo can be increased to 25mg per day during the second week of the study and by 25mg per day each week for the next 9 weeks. Subjects can receive a total of 12 weeks of placebo.
224198187|NCT04148469|PROCEDURE|Transcutaneous Nerve Stimulation.|Transcutaneous Nerve Stimulation (TENS) is a current used for pain treatment. The needle will be used as the negative pole and a adhesive patch 2 centimeters lateral will be the positive pole. The frecuency selected will have 2 Hz with pulses of 120 microseconds. The currente will be applied for 15 minutes.
224198188|NCT04148469|PROCEDURE|Placebo needling|No active technique is performed with the placebo needling. Patient will be supine and a placebo needle willb be performed. The patient will remain supine for 15 minutes.
223596982|NCT03335280|DRUG|68Ga-citrate PET/MR|Study participants will undergo the 68Ga-citrate PET/MR imaging after all screening and baseline assessments have been completed. Patient shall begin imaging between 120 and 360 minutes after the injection of the radiopharmaceutical. Coverage for the scan will extend from the patient's vertex to the neck. The entire imaging study will take roughly 90 minutes.
223596983|NCT04338737|OTHER|timming of feeding|post-operative oral feeding receiving water and clear fluid after surgery, followed by soft food and regular diet
223596984|NCT02238860|DRUG|Entacavir|Entacavir-0.5 mg ,OD,for
223596985|NCT02238860|DRUG|Tenofovir|Tenofovir ,300 mg,OD,for 48 weeks
223596986|NCT02098278|DRUG|CAT-2003|
223596987|NCT02098278|DRUG|Placebo|
223596988|NCT01108523|DEVICE|HP828-101|
223596989|NCT06037408|DRUG|20mM sodium pyruvate nasal spray|The product is a 20 mM (0.2%, 2.2 mg/mL) sodium pyruvate nasal spray in 0.9% sodium chloride with benzalkonium chloride preservative, pH 7.2 (N115). Subjects will self-administer 3 squirts per nostril of the nasal spray, 3 times daily; upon wakening, noon/midday, and before bedtime.
223596990|NCT06037408|OTHER|Saline Placebo control nasal spray|The placebo is 0.9% sodium chloride with benzalkonium chloride preservative, pH 7.2. Subjects will self-administer 3 squirts per nostril of the nasal spray, 3 times daily; upon wakening, noon/midday, and before bedtime.
223596991|NCT04978818|DRUG|Vaxelis|Eligible infants will be block randomized to one of two study arms.
223596992|NCT04978818|DRUG|PedvaxHIB|Eligible infants will be block randomized to one of two study arms.
223596993|NCT04517643|OTHER|Therasphere Therapy|TheraSphere is a radiotherapy treatment for primary and secondary liver neoplasia. This is an imaging study that will examine 3-5 patients who have been treated for metastatic colorectal cancer in the liver using TheraSphere®. Participation in the study involves an additional post-treatment SPECT/CT or PET/CT scan at (0-6) hours.
223747988|NCT04726852|DEVICE|Concurrent comparison|Concurrent comparisons at defined procedure events
223747989|NCT06804239|BEHAVIORAL|User guide with prompts|A user guide and prompts to assist use of an Online Pain-Management Resource
223747990|NCT03878446|DRUG|Somapacitan|Somapacitan injected under the skin once a week.
224198189|NCT01696266|OTHER|No treatment given|Patients will be asked to complete a two-part patient self-assessment questionnaire (SAQ) comprising a retrospective cross-sectional evaluation (Part 1), and a prospective observational evaluation (Part 2).
223596994|NCT04186338|DEVICE|Omnidirectional accelerometer monitor (3x3 cm and 16 g, Actical®, Philips Respironics)|All participants were instructed to wear monitors for five consecutive days except during water-based activities. Data for each participant was collected to ensure included three valid weekdays. Daily activity energy expenditure (kcal/kg/min), and sedentary, light, moderate and vigorous levels (min) were examined using a software program.
223596995|NCT04277039|OTHER|osteopathic treatment + cognitive training|This intervention is a combination of manipulative osteopathic treatment and cognitive training to be administered each week for a 12-week study period
223596996|NCT04277039|OTHER|osteopathic treatment|manual treatment using osteopathic procedure. 8 sessions for a 12 week study period
223596997|NCT04277039|OTHER|usual care|administration of non-steroid inflammatory drug according to international guidelines
223596998|NCT05252663|PROCEDURE|Quake device training|In Quake breathing, patients were advised to take a deep breath and hold it for 3-5 seconds. The patient had the mouthpiece firmly sealed to the lips and were asked to inhale and exhale completely
223596999|NCT05252663|PROCEDURE|Traditional chest physiotherapy|postural drainage - percussion
223597000|NCT00911339|DRUG|Atorvastatin|Atorvastatin 10 mg associated with stent genous
223597001|NCT00911339|DRUG|Atorvastatin|Atorvastatin 80 mg associated with stent genous
223597002|NCT03800511|DIAGNOSTIC_TEST|sliding test|ultrasound detected sliding test before doing repeated caesarean section
223597003|NCT04557046|DIAGNOSTIC_TEST|Nasal Swab|Collection of one more nasal swabs
223597004|NCT04557046|DIAGNOSTIC_TEST|Nasopharyngeal swab|Collection of one more nasopharyngeal swabs
223597005|NCT04557046|DIAGNOSTIC_TEST|Throat swab|Collection of one more throat swabs
223597006|NCT04557046|DIAGNOSTIC_TEST|Fingerstick|Collection of capillary blood from one or more fingersticks
223597007|NCT04557046|DIAGNOSTIC_TEST|Saliva specimen|Collection of free drool
223597008|NCT03248089|DIAGNOSTIC_TEST|Guardant360|Cell-free circulating tumor DNA (cfDNA) targeted next-generation sequencing (NGS) panel.
223597009|NCT00004689|DRUG|amithiozone|
223597010|NCT00004689|DRUG|clarithromycin|
223597011|NCT00004689|DRUG|ethambutol|
223597012|NCT00004689|DRUG|rifampin|
223597013|NCT00004689|DRUG|streptomycin|
223597014|NCT05043389|OTHER|myofunctional therapy program|Exercise oral cavity muscle
223597015|NCT01085292|DRUG|NOX-E36|Multiple dose 0.25 mg/kg or placebo i.v. to healthy volunteers; dosing frequency q2d
223597016|NCT01085292|DRUG|NOX-E36|Multiple dose of 0.0625 mg/kg, 0.125 mg/kg, 0.25 mg/kg or placebo i.v. to patients with type 2 diabetes mellitus (ratio 3:1); dosing frequency q2d
223597017|NCT05574842|BEHAVIORAL|Double duty interventions using nutrition behavior change communication approach|The packages of the double-duty interventions were modified and adapted from the 2017 WHO policy brief report and Hawkes et al., 2020. These interventions are optimized strong education and nutrition behavior change communication focused on promotion of healthy diets (adequate adolescent nutrition, dietary diversity), physical activity (doing moderate intensity physical exercise, avoiding sitting for log time), prevent undue harm from energy-dense foods (avoiding Junk processed foods, avoiding fizzy sweetened drinks, street fast foods, chips, salt, sugar, fats etc.), and regulations on marketing foods from the customer side (e.g., buying of packed foods frequently).
223597018|NCT05118334|DRUG|Sintilimab|(IBI310 1mg/kg IV, Q3W+ Sintilimab 200 mg IV, Q3W)until progressive disease,intolerable toxicity, start of a new antitumor treatment, withdrawal of informed consent, loss to follow-up, death or other situations requiring termination of treatment specified in the protocol, whichever occurs first.
223597019|NCT05118334|DRUG|IBI310|(IBI310 1mg/kg IV, Q3W+ Sintilimab 200 mg IV, Q3W) until progressive disease,intolerable toxicity, start of a new antitumor treatment, withdrawal of informed consent, loss to follow-up, death or other situations requiring termination of treatment specified in the protocol, whichever occurs first.
223597020|NCT03897595|DEVICE|MPact Cup|Quadra®-H, Quadra®-C, AMIStem®-H or AMIStem®-C femoral stem and Mpact® Acetabular hip system with CoCr Femoral Head or Ceramic MectaCer BIOLOX® Femoral Head
223597021|NCT01735370|DRUG|Etodolac Tablets USP 500mg|500 mg tablet once a day
223597022|NCT01735370|DRUG|Etodolac Tablets USP 500 mg|500 mg tablet once a day
223597023|NCT00829959|BEHAVIORAL|Questionnaire|1 - 2 questionnaires, lasting 10-15 minutes.
223597024|NCT02215005|DRUG|Telmisartan|
223597025|NCT02215005|DRUG|Ramipril|
223597026|NCT01750905|DRUG|CD-NP|CD-NP 5 ug/kg subcutaneous injection (SQ)
223597027|NCT01750905|DRUG|Placebo|Vehicle (D5W) SQ
223597028|NCT00532506|DRUG|SK-0403|
223597029|NCT04478448|DRUG|Flupirava|1 tablet contains 200 mg Favipiravir
223597030|NCT04478448|DRUG|Avigan|1 tablet contains 200 mg Favipiravir
223597031|NCT02072369|OTHER|VAEDA Glove|Voice And EMG-Driven Actuated glove used during training
223597032|NCT02072369|OTHER|Occupational Therapy|novel upper extremity occupational therapy focused on the hand
223597033|NCT05399290|DRUG|Doxycycline Hyclate|100 mg vs 20 mg doxycycline hyclate BID for 12 weeks
223597034|NCT00258323|DRUG|cisplatin|20mg/m2d/IV continuous infusion x days
223597035|NCT00258323|DRUG|fluorouracil|1000mg/m2/d IV continuous infusion x 4 days
223597036|NCT00258323|DRUG|Iressa|250mg po qd days 1-28 then x 2 years
223597037|NCT00258323|PROCEDURE|conventional surgery|conventional surgery
223597038|NCT00258323|RADIATION|radiation therapy|150 cGy bid
223597039|NCT00064051|DRUG|gemcitabine hydrochloride|
223597040|NCT00064051|DRUG|triapine|
223597041|NCT02123368|DRUG|Hyaluronic acid|Single intraarticular injection of Hyaluronic acid (Hyal One)
223597042|NCT02123368|BIOLOGICAL|10 million Bone marrow mesenchimal stem cells|10 million of Bone marrow mesenchimal stem cells
223597043|NCT02123368|BIOLOGICAL|100 million Bone marrow mesenchimal stem cells|100 million of Bone marrow mesenchimal stem cells
223597044|NCT03222024|OTHER|routine medical care|This is an observational study for clinical course and outcomes of severe ischaemic stroke; therefore, interventions are prescribed by responsible doctors based on patients' clinical conditions, which is not interfered by current study
224198190|NCT05571618|DRUG|ADC|Patients with prior exposure to ADC (either in the adjuvant setting or metastatic disease are allowed).
224198191|NCT03718221|OTHER|Usual Care FIT Screening Strategy|Patients in usual care neighborhoods will receive FIT kits randomly throughout the year.
224198192|NCT03718221|OTHER|GeoMail FIT Screening Strategy|Patients in treated neighborhoods will receive kits at the same time.
224198193|NCT02766959|OTHER|Observational study|
224198194|NCT04843891|DRUG|[64]Cu Macrin|Up to 15 mCi of \[68Ga\]CBP8 will be administered to each subject.
223597045|NCT02483117|OTHER|Adaptation of the CIA|Adaptation of the CIA into Spanish was performed using the backward-forward translation process, which ensures conceptual. Forward translation into Spanish was carried out by two independent native Spanish speaking translators who were fluent in English. Two other independent translators, totally blind to the original version, whose native language was English and who were fluent in Spanish, back-translated the consensus version into English. After reaching consensus on a final translated version, it was sent to the CIA's original author (Dr. Bohn) who gave her approval. We undertook a cognitive debriefing process with a group of 5 ED patients to identify any problems with language. The pre-final version was administered to two small groups, one made up of patients (a sample of 5 respondents) and the other of clinical experts (2 psychiatrists and 2 psychologists who were experts on ED).
223597046|NCT01549925|OTHER|Standard Surgical resection|standard surgical resection using clamps and surgical ligatures
223597047|NCT01549925|DEVICE|LIGASURE|resection using the FDA-approved LIGASURE device during omentectomy and resection of the recto-sigmoid portion of the colon
223597048|NCT02020317|BEHAVIORAL|decision support in potassium-inc. drug-drug-interactions|display of computer-based reminders for serum potassium monitoring and hyperkalemia alerts
223597049|NCT03706183|DIAGNOSTIC_TEST|Ischemia-modified albumin|The biomarker was investigated in many studies and it was associated with the ischemia and tissue injury.
224198195|NCT00004646|DRUG|prednisone|
223597050|NCT03706183|DIAGNOSTIC_TEST|Hearing thresholds|The hearing levels will be determined for each group.
223597051|NCT05037058|OTHER|Quality improvement activities|Quality improvement activities
223597052|NCT04356235|PROCEDURE|A: expander-silicone implant exchange and contralateral symmetrization with mastopexy and if needed with volume reduction|expander-silicone implant exchange and contralateral symmetrization with mastopexy and if needed with volume reduction
223597053|NCT04356235|PROCEDURE|B: expander-silicone implant exchange with contralateral symmetrization with mastopexy and Ultrapro sling|expander-silicone implant exchange with contralateral symmetrization with mastopexy and Ultrapro sling
223597054|NCT04356235|PROCEDURE|C: expander-silicone implant exchange and contralateral symmetrization with mastopexy and silicone implant augmentation|expander-silicone implant exchange and contralateral symmetrization with mastopexy and silicone implant augmentation
223597055|NCT04356235|PROCEDURE|D: expander-silicone implant exchange and contralateral symmetrization with mastopexy and Utrapro sling and silicone implant augmentation|expander-silicone implant exchange and contralateral symmetrization with mastopexy and Utrapro sling and silicone implant augmentation
223597056|NCT04356235|PROCEDURE|E: unilateral simple mastectomy|unilateral simple mastectomy
223597057|NCT04356235|PROCEDURE|F: after bilateral SSM, ASM, NSM, expander-implant exchange|after bilateral SSM, ASM, NSM, expander-implant exchange
223597058|NCT06470646|PROCEDURE|Endovascular therapy|Endovascular therapy is a minimally invasive interventional approach that utilizes the vascular system as a pathway to access and treat various pathological conditions within the body.By employing specialized catheters and devices,endovascular techniques enable precise delivery of therapeutic agents or interventional procedures directly to the targetsite,without the need for conventional open surgery.
224198196|NCT00595946|DRUG|Lubiprostone|24 mcg capsules twice daily (BID)
224198197|NCT00595946|DRUG|Placebo|0 mcg capsules twice daily (BID)
224198198|NCT02374008|DRUG|Ropivacaine|
224198199|NCT06096909|DRUG|Tafolecimab|The PCSK9 mAb in this study is defined as Tafolecimab 150mg q2w subcutaneously. For the two groups of lipid-lowering regimens, the lipid-lowering drug regimens other than PCSK9 mAb were maintained throughout the study as much as possible in accordance with the guidelines related to blood lipids, provided that no serious safety problems occurred.
224198200|NCT06096909|DRUG|Cholesterol Absorption Inhibitor|Cholesterol absorption inhibitors (like Ezetimibe and Hybutimibe) are based on physician decisions, but need to be routinely dosed. Examples of Medications that Meet Study Requirements: Ezetimibe 10mg Po qd.
224198201|NCT06096909|DRUG|Statin|Statin are based on physician decisions, but need to be routinely dosed. Examples of Medications that Meet Study Requirements: Atorvastatin 20mg Po qn, Rosuvastatin 10mg Po qn or Pitavastatin 4mg Po qn.
223597059|NCT03326622|OTHER|standard care|A standard care program based on American Academy of Neurology guidelines (Range Of Motion (ROM) exercises, gait and balance training )at home or another rehabilitation units without intensity control.
224198202|NCT03056456|DRUG|LY900014|Administered subcutaneously (SC)
223747991|NCT03878446|DRUG|Norditropin®|Norditropin® injected under the skin once a day.
224198203|NCT03056456|DRUG|Insulin Lispro (Humalog)|Administered SC
224198204|NCT05950828|BEHAVIORAL|SkillTalk|A subscription-based microskills video training library designed to enhance the skills of high school sex educators to implement the frequently used core components of sexual and reproductive health (SRH) curricula.
224198205|NCT00142961|DRUG|Atomoxetine|atomoxetine
224198206|NCT00142961|OTHER|placebo|
224198207|NCT05549271|PROCEDURE|Laparoscopic Mini-gastric bypass|The laparoscopic Omega Loop Bypass performed 5 years ago consisted of a long gastric tube, stapled approximately 1.5 cm from the left of the lesser curvature of the antrum to the angle of His, a narrow gastric tube calibrated to be approximately 1.5 cm wide, an Omega loop of 200 cm, a unique gastro-jejunal anatomosis of 200cm from the ligament of Treitz, using a linear stapler
224198208|NCT05549271|PROCEDURE|Laparoscopic Roux-en-Y Gastric ByPass (RYGBP)|The laparoscopic Roux-en-Y Gastric Bypass performed 5 years ago consisted of : a small gastric pouch (about 30cc), an antecolic alimentary limb, a gastro-jejunal anastomosis using a linear stapler, a 150cm long alimentary limb, a 50cm biliary limb, a latero-lateral jejuno-jejunal anastomosis, closure of the mesenteric defects.
224311040|NCT02538965|DRUG|Lenalidomide|Lenalidomide will be administered orally once daily for the first 21 days of every 28-day cycle. The starting dose will be 2 mg/kg/day with a maximum dose of 70 mg/day. Number of cycles: 12, or until evidence of progressive disease. Participants will also be discontinued if unresolved toxicities as described in the protocol occur, or if dose reductions are required and subject does not tolerate minimum dose level of 1mg/kg/day.
223747992|NCT05687591|DEVICE|Amplatzer Amulet Left Atrial Appendage Occlusion Device|The Amplatzer Amulet LAAO is a transcatheter, self-expanding device intended for use in preventing thrombus embolization from the left atrial appendage. The device is constucted from a nitinol mesh and consists of a lobe and a disc connected by a central waist. Polyester patches are sewn into both the lobe and disc to facilitate occlusion. The lobe has stabilizing wires to improve device placement and retention. The device has threaded screw attachments at each end for connection to the delivery and loading cables. The device has radiopaque markers at each end and at the stabilizing wires that permit visibility during fluoroscopy.
224198209|NCT04369885|DEVICE|Go Home tablet with linked GoSpiro and 3230 Pulse Oximeter|All participants will receive the intervention consisting of a home telemedicine tablet platform (GoHome) that will collect multiple spirometry tests each week (including both forced and slow spirometry measurements), pulse oximetry, and QoL Questionnaire responses. The platform will remind patients to take their medications remind patients to perform measurements, send patients helpful information, and execute a UNC clinic established COPD Action Plan.The backend of the platform is a remote server (Monitored Therapeutics CarePortal) that collects the data, send out alerts to the Principal Investigator and can track and trend the data for them.
224311041|NCT05437315|BIOLOGICAL|bi-4SCAR GD2/PSMA T cells|Infusion of bi-4SCAR GD2/PSMA T cells at 10\^6 cells/kg body weight via IV
224311042|NCT00354692|DRUG|Sodium Ferric Gluconate and Iron sucrose|
224311043|NCT00308880|DRUG|Transamin|
223597060|NCT03326622|OTHER|moderate exercise|A moderate exercise protocol two times per week in a treadmill in the lower range of the training zone determined by Cardiopulmonary Exercise Testing, monitored by continuous pulse oximetry evaluation.
223597061|NCT01914653|DEVICE|Silk surgical mesh|A CE Marked, 510(k) cleared, knitted, multi-filament, bioengineered, silk mesh indicated for use as a transitory scaffold for soft tissue support and repair
223597062|NCT03036618|DIETARY_SUPPLEMENT|Quinoa|Test wheat bread roll (approximately 160g weight) delivering 20 g quinoa consumed per day.
223597063|NCT03036618|DIETARY_SUPPLEMENT|Wheat|Test wheat bread roll (approximately 160g weight) without quinoa.
223597064|NCT03489928|DRUG|Oral Misoprostol|Prostaglandin E1 - 100ug tablet, divided in half by pharmacy staff to be administered by mouth.
223597065|NCT03489928|DRUG|Vaginal Misoprostol|Prostaglandin E1 - 100ug oral tablet, divided in quarters by pharmacy staff, vaginal placement of one or two quarters as needed every 6 hours
223597066|NCT03489928|DRUG|Dinoprostone|Prostaglandin E2 - 1-2mg gel manufactured for vaginal use; placed vaginally every 6 hours as needed.
223597067|NCT05713435|DEVICE|intravaginal laser|application of intravaginal laser
223597068|NCT03718858|PROCEDURE|Interscalene Block|15 mL ropivacaine 0.5% will be injected in 5 mL aliquots in order to achieve spread adjacent to C5 and C6 nerve roots.
223597069|NCT03718858|PROCEDURE|Superior Trunk Nerve Block|15 mL ropivacaine 0.5% will be injected in 5 mL aliquots in order to achieve spread adjacent to Superior Trunk Nerve.
223597070|NCT03951558|OTHER|Diet for calciuria prevention|Dietary recommendations for water, salt, calcium and proteins according to age and DIR
223597071|NCT03951558|DRUG|Hydrochlorothiazide|Hydroclorothiazide recommendations for hypercalciuria
223597072|NCT03903887|BIOLOGICAL|anti-PD1 antibody-activated TILs|Participants would receive one dose of anti-PD1 antibody-activated TILs at the final cycle of docetaxel and cisplatin (DP) regimen chemotherapy.
223597073|NCT02400541|BEHAVIORAL|Cognitive remediation therapy|"Our scheme comprises 10 biweekly sessions ( 5 in group and 5 single) . Each session last about 45 minutes.~Individual sessions will be held with the patient and a therapist trained in the CRT; group sessions will be led by two therapists trained in CRT and regroup the maximum 5 patients."
223597074|NCT02400541|OTHER|relaxation therapy|Our scheme comprises 10 biweekly sessions. Each session last about 45 minutes.
223597075|NCT03387358|DEVICE|Nasal bridle securement device for small bore feeding tubes|A Nasal bridle securement device is an alternative method to securing small bore feeding tubes which are most commonly secured with adhesive tape to the nose. A nasal bridle securement device instead secures the feeding tube to a cloth ribbon that is inserted in one nostril, over then nasal bridle and out the other nostril.
224311044|NCT05213039|OTHER|assessments|All of the children with cerebral palsy will be assessed by two different physiotherapist observers. The timed 360° turn test, Expanded and revised Gross Motor Function Classification System (GMFCS-E\&R) for functional motor levels of the subjects, lower extremity muscle tone will be measured with the Modified Ashworth Scale (MASH) at the beginning of the one-time study and recorded. Pediatric Berg Balance Scale, Timed Up and Go Test, Pediatric Functional Reaching test and Modified Four Square Stepping Test, 3m walking back test (3MGYT) will be performed.Evaluations will be made by two separate physiotherapists with at least 5 years of experience in this field. The time it took for individuals to complete activities during the tests with a stopwatch will be recorded.
224311045|NCT00203710|DEVICE|Concentric Retriever Device|
224311046|NCT03200912|DRUG|Ingenol Mebutate (Picato®)|Brand product
223597076|NCT02476292|OTHER|online questionnaire|The online questionnaire includes questions about vasculitis, employment and work status before diagnosis and over the course of the disease, work capacity and the financial impact of vasculitis.
223597077|NCT02541734|DRUG|Gelofusine|Infusion of gelofusine
223597078|NCT02541734|RADIATION|111In-exendin 4 SPECT/CT|111In-exendin 4 SPECT/CT
223597079|NCT02541734|DRUG|Placebo|
223597080|NCT03913494|DEVICE|Transoral Neurostimulation Device (Snoozeal)|Use of the Transoral Neurostimulation Device for 20 minutes, morning and night, every day for at least 4 weeks.
223597081|NCT03639506|PROCEDURE|autologous mitochondria transplantation|inject autologous mitochondria from bone marrow mesenchymal stem cells into oocyte
223597082|NCT03639506|COMBINATION_PRODUCT|autologous mitochondria from bone marrow mesenchymal stem cells into oocyte as well as intracytoplasmic sperm injection (ICSI)|autologous mitochondria transplantation
223597083|NCT03639506|DRUG|intracytoplasmic sperm injection (ICSI)|intracytoplasmic sperm injection (ICSI)
224198210|NCT04637815|BEHAVIORAL|Motivational Network Intervention|Every 2 weeks, residents attend meetings with their case manager. These meetings are customized to the needs of the resident at the time of the meeting. Participants randomized into the Motivational Network Intervention arm are offered an additional discussion about their social networks. Case managers ask participants to answer a series of standardized questions about people they know. After these questions are answered, case managers show participants a series of images representing these answers. While showing these images, case mangers engage the participant in discussions about what they notice using Motivational Interviewing techniques. The goal is to discuss what the participant wants to change and state strategies about achieving these changes.
223597084|NCT02430987|DIAGNOSTIC_TEST|Female sexual function index questionnaire|"Sexual function was assessed by completion of the Female Sexual Function Index (FSFI), a questionnaire validated for Brazilian Portuguese with 19 items measuring female sexual function. Cut-off points of \>23 and \> 26.5 were adopted to define a diagnosis of Female Sexual Function based on the Diagnostic and Statistical Manual of Mental Disorders, 4th edition, Text Revision (DSM -IV- TR) by the American Psychiatric Association, duration criteria \> 24 weeks.~A score of 5 or less on the combination of items comprising the desire domain of the FSFI questionnaire was used to define the diagnosis of Hypoactive Sexual Desire Disorder (HSDD) in postmenopausal women We consider that a score of 6 or more the woman does not present with HSDD."
223597085|NCT02430987|DIAGNOSTIC_TEST|Evaluation of presence of metabolic syndrome|The MetS diagnosis was determined by following the guidelines defined by the Adult Treatment Panel (ATP III) (8): (1) Abdominal circumference (AC) ?88cm; (2) HDL-cholesterol \< 50mg/dL; (3) triglycerides \> 150mg/dL; (4) arterial blood pressure (SAH) \> 130/85mmHg; and (5) fasting glucose \> 110mg/dL. The women considered as carrying MetS were those with at least three of the components described.
223597086|NCT02430987|DIAGNOSTIC_TEST|Evaluation of the body mass index|women were stratified into 3 groups by body mass index (BMI): Group 1: BMI of 18.5 to 24.9kg/m2 (Normal BMI Group), Group 2: BMI of 25 to 29.9kg/m2 (Overweight Group); Group 3: BMI of 30kg/m2 to 34.5kg/m2 or higher) (Obese Group
223597087|NCT01597024|OTHER|Breakfast Study|Participants (male and female, lean and obese, children, teenagers, adults, and elderly) will take part in 4 morning sessions, consuming a test breakfast milk based beverage and appetite. Biomarkers in blood will be measured and behavioural questionnaires completed. We will also collect a single saliva sample from each participant to examine genetic traits related to appetite, food choice, body weight, and energy expenditure. There will be two milk based beverages, one protein enriched (30% protein from calories) and one normal protein (15% protein). Participants will be offered a morning snack buffet to assess ad libitum energy intake. Phase 1 will also include a subgroup of malnourished male and female elderly participants. However, this group will only complete two morning sessions during which they will consume a low protein and a high protein milk based beverage. Appetite will be recorded and libitum energy intake will be measured. In addition, 24hr energy intake will be recorded.
223597088|NCT01597024|OTHER|fMRI Study|We will fMRI scan normal weight and overweight subjects of both gender from the four different age groups only: 8-10, 13-17, 24-45 and 65-75 years. Participants will be measured twice, on separate days, either after an overnight fast or after a test meal, fed to satiation (because hunger will modulate the response to food presentation). The participants will conduct a computerised task that will be performed in the scanner to assess hedonic responses to food cues. Physiological biomarkers will be measured during both trials for the assessment of appetite hormone circulation. Saliva samples will be taken for DNA analysis. DNA extraction techniques will be used to examine genetic traits linked to appetite, food choice, body weight, and energy expenditure.
223597089|NCT01566487|DRUG|Quetiapine fumarate|Quetiapine fumarate tablets 300mg
223597090|NCT04680819|DIETARY_SUPPLEMENT|Anatolian Propolis|Health workers who agree to participate in the study will be accepted as the study group, and healthcare professionals who do not agree to participate in the study will be considered as the control group. The study group will be asked to take 20 drops of Propolis drop form twice a day in the morning / evening, and the control group will not receive any treatment and both groups will be followed. In this process, patients diagnosed with COVID-19 will be determined. PCR test positivity taken from the throat for the diagnosis of COVID-19 will be accepted. The research will cover a period of 1 month. At the end of 1 month, patients diagnosed with COVID-19 in the study and control groups will be compared. Thus, the protective properties of Anatolian propolis will be determined.
223597091|NCT06312319|DEVICE|Respiratory training|Respiratory training using the EMST 150 device to increase inspiratory and expiratory muscle strength.
223597092|NCT06312319|OTHER|Orofacial exercises|The exercises will include activities to improve orofacial structures such as mobility, strength and coordination.
223597093|NCT01612208|DEVICE|Periarticular Locking Plate (NCB, Zimmer)|The proximal plate segment will be applied to the diaphysis using four 5.0 mm MotionLoc screws. The plate will not be compressed onto the femoral diaphysis to preserve periosteal perfusion and to enable controlled motion between the plate and the diaphysis. If desirable, temporary spacers of the NCB set may be used in the proximal plate segment to facilitate 1-2 mm plate elevation over the diaphysis. Only MotionLoc screws will be used for fixation of the NCB plate proximal to the fracture site.
223597094|NCT01612208|DEVICE|MotionLoc Screw|The NCB Polyaxial Locking Plate System is indicated for temporary internal fixation and stabilization of fractures and osteotomies of long bones. These MotionLoc screws have a reduced 3.4 mm diameter mid-shaft section to bypass the near cortex. By avoiding rigid constraint in the near cortex, the MotionLoc screw design increases the working length of the screw, allowing for elastic flexion of the screw shaft within a controlled motion envelope in the near cortex.
223597095|NCT03143764|BEHAVIORAL|Commuting with electrically assisted bicycles|25 participants were provided with electrically assisted bicycles fitted with GPS bike computers to record usage
223597096|NCT02484482|DRUG|CKD-519 200mg / Fasting, Standard Meal, High Fat Meal|
224198211|NCT04637815|OTHER|Usual Care|Residents attend regular case management meetings with their case managers as a condition of their residency in the housing program. These sessions are customized do the needs of the resident at the time of the meeting. Participants randomized into the usual care arm will be offered these sessions every 2 weeks.
224198212|NCT06031922|DEVICE|Microprocessor controlled knee|Microprocessor controlled knee
224311047|NCT03200912|DRUG|Generic Ingenol Mebutate|Generic formulated to have the same therapeutic effect of the brand
224311048|NCT03200912|DRUG|Vehicle Foam|It does not contain active ingredient. A placebo to test the sensitivity of the active treatments.
223597097|NCT00613093|DRUG|Temodar and O6-Benzylguanine (BG)|"Objectives of study are to define role of BG in restoring Temodar sensitivity in patients with Temodar-resistant malignant glioma and to further define the toxicity of combination therapy using Temodar + BG. 2 separate strata accrued independently of each other: Stratum 1-patients with glioblastoma multiforme (GBM). Stratum 2-patients with anaplastic glioma (AG).~BG at 120mg/m2 administered intravenously over 1 hour followed immediately by 48-hour infusion at 30mg/m2/24 hours. Temodar 472mg/m2 administered orally, in fasting state, within 60 minutes of end of the 1-hour administration of BG infusion. Treatment cycles may be repeated every 28 days following dose of Temodar from previous cycle."
223597098|NCT03848949|DEVICE|Evenup|Orthotic which increases effective leg length.
223597099|NCT04088526|COMBINATION_PRODUCT|intervention group|Through effective intervention combined with drugs and dietary guidance within 3 to 6 months, all the observation markers including blood pressure and laboratory results will reach the target target value.
223597100|NCT05670613|OTHER|CDSS Canceling|The use of Clinical Decision Support System in Parenteral Nutrition
223597101|NCT03309930|BEHAVIORAL|Comprehension Acquired Brain Injury|For study 1 participants will be exposed to 3 conditions as stated in previous descriptions and will last 1 to 2 sessions. Study 2 will begin with 1 session with the researcher lasting about 30 minutes. Then participants will be asked to complete practice at home for about 15 minutes each day for 2 weeks using a computer/iPad. Study 2 Post Testing and Maintenance Sessions 1 and 2: approximately 60 minutes per session.
223597102|NCT03470753|OTHER|Number of Exercises|Subjects will receive either 2 or 4 exercises to evaluate the short-term recall and performance.
223597103|NCT03470753|OTHER|Type of Instruction|The type of instruction in phase 1 will be compared: Instruction by providing a handout only vs being instructed by a provider and practiced by the patient with provider feedback.
223597104|NCT03470753|OTHER|Delivery Type|In phase 2 subjects will be provided 4 exercises using only a handout vs delivered to them electronically with the addition of a video.
223597105|NCT03470753|OTHER|Mobile Reminder|A text-message based mobile reminder tool will be utilized to engage with subjects via texting on a daily basis to provide reminders and encouragement to perform their home exercises.
223597106|NCT00533624|DRUG|Mycophenolate Sodium Delayed Release Tablets|Myfortic® 1,440 mg/day
223597107|NCT00533624|DRUG|Mycophenolate Mofetil|Cellcept® 2,000 mg/day
223597108|NCT03565835|DRUG|Abiraterone Acetate|Abiraterone Acetate with Prednisone and with Discontinuation of GnRH Analogue
223597109|NCT03565835|DRUG|Prednisone|Abiraterone Acetate with Prednisone and with Discontinuation of GnRH Analogue
223597110|NCT06446791|PROCEDURE|Mehri Turki Surgical Technique of the Webbed Neck|The incision was made at the junction of the hairless skin and the hairy skin from the mastoid up to the acromion. A subcutaneous undermining allows direct visual control to excise the fibrotic band. Then the hairy skin with a triangular shape was excised. The closure of the defect was done after undermining an anterior cervical flap which was translated in a posterosuperior direction. Z plasty was performed in front of the acromion to prevent scar contracture. Surgical scars are concealed in the hairline which was well placed. The same procedure is done at the same surgical field on the other side to achieve perfect symmetry.
223597111|NCT06198335|OTHER|Modified Perichondral Approach Thoracoabdominal Nerve block|M-TAPA block will be performed to Group M-TAPA at the end of the surgery, using US (Vivid Q) while the patient is in the supine position After providing aseptic conditions, the high frequency linear US probe (11-12 MHz, Vivid Q) will be covered with a sterile sheath, and an 80 mm block needle (Braun 360°) will be used. The US probe will be placed in the sagittal plane where the midclavicular line intersects with the costal cartilage corresponding to the costochondral angle. Using the In Plane technique, the probe is gently pushed to visualize the lower part of the costochondral angle at the central level, advancing the block needle in the caudal-cranio direction, 5 ml of saline will be injected into the layer between the transverse abdominal muscle and the lower plane of the costal cartilage, and the block location will be confirmed. After the block location is confirmed, a total of 20 ml + 20 ml of 0.25% bupivacaine (total 40 ml for both sides) will be injected bilaterally
223597112|NCT06198335|OTHER|Transversus Abdominal Plane block|TAP block will be performed to Group TAP at the end of the surgery, using US (Vivid Q) while the patient is in the supine position. After providing aseptic conditions, the high frequency linear US probe (11-12 MHz, Vivid Q) will be covered with a sterile sheath, and an 80 mm block needle (Braun 360°) will be used. USG will be placed transversely on the mid-axillary line between the iliac crest and subcostal planes. Using the In Plane technique, the block needle will be advanced into the fascial plane between the internal oblique and transversus abdominis muscles and the location will be confirmed by administering 5 ml of saline. The block needle will be advanced into the fascial plane between the internal oblique and transversus abdominis muscles and the location will be confirmed by administering 5 ml of saline.and than 20 ml of 0.25% bupivacaine (total 40 ml for both sides) will be injected bilaterally
223597113|NCT03834935|DRUG|Elidel (pimecrolimus 1%)|topical application of product on all lesions, twice daily. Sunscreen will not be indicated, and hygienic habits will not be changed
223597114|NCT03834935|DRUG|Cold Cream|Topical application on all lesions, twice daily. Sunscreen will not be indicated, and hygienic habits will not be changed
223597115|NCT03665272|PROCEDURE|deepithelialized gingival graft fixation|one group's deepithelialized gingival graft fixed by sutures and other one's by tissue adhesive.
223597116|NCT03750643|DRUG|LY3454738|Administered IV
223597117|NCT03750643|DRUG|LY3454738|Administered SC
223597118|NCT03750643|DRUG|Placebo|Administered IV
223597119|NCT06153472|DEVICE|VR-based intervention|The Virtual Reality-based sensory stimulation intervention will last for up to fourteen days, with all interventions administered by a research team. The primary outcomes will include delirium incidence, duration, and severity. The secondary outcomes will encompass patients' psychological well-being (post-traumatic stress disorder, sleep quality, and ICU memory), patients' clinical outcomes, and other outcomes (quality of life, independence, and cognitive function).
224311049|NCT01960049|PROCEDURE|ropivacaine + iv PCA|
224311050|NCT01960049|PROCEDURE|saline and IV PCA|
224311051|NCT02341391|BIOLOGICAL|TissueGene-C(Low dose)|3.0 x 10\^6 cells
224311052|NCT02341391|BIOLOGICAL|TissueGene-C(Medium dose)|1.0 x 10\^7 cells
224311053|NCT02341391|BIOLOGICAL|TissueGene-C(High dose)|3.0 x 10\^7 cells
223597120|NCT05331794|BEHAVIORAL|Training on BIOFIT-Park|"Participant will perform one strength training session on the new line of outdoor fitness equipment BIOFIT-Park. 6 machines will be used. The training will consist of 3 sets of 15-20 repetitions, working at 60-65% RM. The execution speed will be 1x1, the rest between machines will be 20 seconds and macropauses of 90 seconds between series."
223597121|NCT05331794|BEHAVIORAL|Training on gym park equipament|Participant will perform one strength training session on a gym park equipment. 6 machines will be used. The training will consist of 3 sets of 15-20 repetitions, working at 60-65% RM. The execution speed will be 1x1, the rest between machines will be 20 seconds and macropauses of 90 seconds between series.
223597122|NCT02744651|DEVICE|EUS-FNA|"Please note the text in section Arm description"
224198213|NCT01305460|DRUG|Azacitidine|"Treatment will consist of azacitidine 75mg/m2/d for 5 days every 14 days for 4 cycles.~* Patients achieving CR or PR will be then treated with 4 cycles of azacitidine 75mg/m2/d for 5 days every 21 days followed by cycles of azacitidine 75mg/m2/d for 7 days administered every 28 days (cycles 9 and beyond), to be continued until progression/relapse or toxicity arises.~* Patients not obtaining CR or PR after the initial 4 cycles of azacitidine-14 will continue to receive azacitidine 75mg/m2/d for 5 days every 14 days for 4 additional cycles (cycles 5 to 8). If they achieve CR, PR or HI after 8 cycles, they will then be treated with azacitidine 75mg/m2/d for 5 days every 21 days (cycles 9 to 12) and subsequently cycles of azacitidine 75mg/m2/d for 7 days administered every 28 days (cycles 13 and beyond) until progression/relapse or toxicity arises.~* Patients not obtaining CR, PR or HI after 8 cycles of azacitidine-14 will go off-study."
223597123|NCT02744651|DEVICE|EUS-Endodrill biopsy|"Please note the text in section Arm description"
223597124|NCT01686282|DIETARY_SUPPLEMENT|Freeze-dried Blueberry Powder|8 weeks of freeze-dried taken in two doses of 22g each per day.
223597125|NCT01686282|DIETARY_SUPPLEMENT|Placebo|8 weeks of freeze-dried taken in two doses of 22g each per day.
223597126|NCT04522479|OTHER|Change the injection time of long acting GnRH-a|The whole dose of long acting GnRH-a drug was changed to be injected on day 21st-23rd day of menstruation
223597127|NCT03214042|DEVICE|K-rod dynamic stabilization system|Sixty-seven patients with lumbar degenerative diseases were treated with K-rod dynamic stabilization system. All patients were followed for 2 years. K-rod dynamic stabilization system was purchased from Biotech, USA, consisting of titanium alloy pedicle screw, titanium alloy line and polyether ether ketone (PEEK) shell between pedicle screw heads.
223597128|NCT05407779|BIOLOGICAL|BCD-180, dose 1|anti-TRBV9 monoclonal antibody single infusion at dose 1
223597129|NCT05407779|BIOLOGICAL|BCD-180, dose 2|anti-TRBV9 monoclonal antibody, single infusion at dose 2
223597130|NCT05407779|BIOLOGICAL|BCD-180, dose 3|anti-TRBV9 monoclonal antibody, single infusion at dose 3
223597131|NCT05407779|BIOLOGICAL|BCD-180, dose 4|anti-TRBV9 monoclonal antibody, single infusion at dose 4
223597132|NCT05407779|BIOLOGICAL|BCD-180, dose 5|anti-TRBV9 monoclonal antibody, single infusion at dose 5
223597133|NCT05407779|BIOLOGICAL|BCD-180, dose 6|anti-TRBV9 monoclonal antibody, single infusion at dose 6
223597134|NCT05407779|BIOLOGICAL|BCD-180, dose 7|anti-TRBV9 monoclonal antibody, single infusion at dose 7
223597135|NCT03253328|DRUG|Active Arm N-acetyl cysteine (NAC)|N-acetyl cysteine (NAC) 1200mg twice a day for 6 days post-amputation
223597136|NCT03253328|DRUG|Placebo Arm|Placebo 1/2 normal saline infusion twice a day for 6 days post-amputation
223597137|NCT02607111|DRUG|Dalteparin|
223597138|NCT02353728|DRUG|Nilotinib|
223597139|NCT02872272|DRUG|Treatment with Amikacin|Aminoglycosides. Blood sampling for pharmacokinetic evaluation
223597140|NCT03167528|BEHAVIORAL|Relaxation|Relaxation
223597141|NCT03167528|BEHAVIORAL|Hypnosis|Hypnosis
223597142|NCT03167528|BEHAVIORAL|Holistic gymnastics|holistic gymnastics
223597143|NCT03167528|DEVICE|Transcutaneous electrical nerve stimulation (TENS)|TENS
223597144|NCT03167528|BEHAVIORAL|Sophrology|Sophrology
223597145|NCT02301624|BIOLOGICAL|Eculizumab|Intravenous administration of eculizumab.
223597146|NCT02301624|DRUG|Placebo|Intravenous administration of matching placebo. Participants received placebo only during the Blind Induction Phase.
223597147|NCT03147989|DRUG|MultiHance|gadolinium contrast agent
223597148|NCT06330337|DRUG|Temozolomide（TMZ） injection or oral administration|Oral administration of TMZ150-200mg/m2/ day, continuous use for 5 days, discontinued for 23 days, for a treatment cycle, a total of 6 cycles.
223597149|NCT06330337|DRUG|Albumin-Bound Paclitaxel(ABX) intravenous drip|ABX was administered intravenously at a dose of 110mg/m2 on days 1 and 8 of a 28-day treatment cycle
223597150|NCT06330337|DEVICE|Specific mode electroacupuncture stimulation(SMES) intervention|"Patients take supine position. After skin disinfection with 75% ethanol routine disinfection, the stainless needle (size 0.25mm×40mm, Hua Tuo brand, Suzhou Medical Supplies Company Ltd in Jiangsu, China) will be inserted in GV20（Baihui) and the stainless needle(size 0.25mm×25mm, described above) will be inserted in GV26 (Shuigou), acupoints will be stimulated manually until patients feel soreness, distension or heaviness (the reaction of De Qi). Then, the needles are stimulated by using an acupuncture point nerve stimulator (HANS-200, Nanjing Jinsheng, Ltd., China) with a frequency of 2/100 Hz and an intensity of 3 mA for 40 min (a homemade relay cycled power to the electrode for 6 sec on and 6 sec off).The 28-day treatment cycle was followed by simultaneous intervention with ABX on days 1 and 8."
223597151|NCT00895310|DRUG|Ketoconazole|Ketoconazole is taken three times a day by mouth.
224198214|NCT06636682|BIOLOGICAL|FK-PC101|Up to 7 doses of FK-PC101 will be administered intradermally between Day 1 and Day 180. The immune adjuvant Bacillus Calmette Guérin (BCG) will be given concurrently with Dose 1 (day 1) and Dose 2 (day 8).
223597152|NCT00895310|DRUG|Hydrocortisone|Hydrocortisone is taken by mouth 20 mg every morning and 10 mg every evening.
223597153|NCT02772627|DRUG|Nebicapone|Nebicapone 100 mg tablets; oral route.
223597154|NCT02772627|DRUG|Placebo|Placebo tablets; oral route.
223597155|NCT06136611|DEVICE|TTFields|TTFields will be delivered through 4 transducer arrays with 9 insulated electrodes each placed on the shaved scalp and connected to a portable device set to generate 200-kHz electric fields within the brain.
223597156|NCT00006026|DRUG|rubitecan|
223597157|NCT00654459|DIETARY_SUPPLEMENT|Mixture of Berberine, Policosanol, Red Yeast, Placebo|A tablet one a day for 6 weeks
224198215|NCT06636682|BIOLOGICAL|Standard of Care (SOC)|Subject receives Investigator-defined standard of care, excluding adjuvant therapy. If prostate cancer recurs before 12 months after radical prostatectomy, subjects are eligible to receive up to 7 doses of intradermal FK-PC101 vaccine (first 2 given concurrently with BCG).
223597158|NCT00659230|DRUG|Nepicastat|100-800mg
223597159|NCT00659230|DRUG|Placebo|100-800mg placebo
223597160|NCT00901121|DEVICE|Straumann BoneCeramic|Straumann BoneCeramic (500-1000 microns, 0.5g)
223597161|NCT00901121|DEVICE|Bio-Oss|Bio-Oss spongiosa granules, size of particle 0.25-1 mm
223597162|NCT03226470|BIOLOGICAL|T512|T512 suppository contain 500 µg of T512 and suppocire.
223597163|NCT00420121|PROCEDURE|laboratory analysis|blood withdrawal for laboratory analysis
223597164|NCT00557453|DRUG|Antibiotic treatment|Cefuroxime 750mg X3/d, Ampicillin 2G X4/d, Flagyl 500mg X3/d, Augmentin 1G X3/d, Gentamycin 240mg X1/d, Clindamycin 600mg X3/d, Ciprofloxacin 400mg X2/d All drugs will be administered IV until clinical improvement.
223597165|NCT00557453|DRUG|No antibiotics|Allowed medications for both groups will include PPI / H2 blockers, home medication, SC insulin for diabetes, and SC clexane if indicated.
223597166|NCT05132777|DRUG|JMT101|JMT101, 6 mg/kg, IV infusion once every two weeks (one treatment cycle is 4 weeks).
223597167|NCT05132777|DRUG|Osimertinib Mesylate Tablets|Osimertinib, 160 mg, Oral administration once daily (one treatment cycle is 4 weeks).
223597168|NCT00547521|DRUG|abatacept|solution, subcutaneous injection, 125 mg/kg, weekly, 106 days in short term; long term is open
223597169|NCT00547521|DRUG|Methotrexate (MTX)|Participants who were currently receiving methotrexate at a stable dose ≥ 10 mg for at least 4 weeks
223597170|NCT06448039|DRUG|Fibroblast Growth Factor 2|Randomized double-blinded placebo-controlled treatment of 20 patients with chronic (\>6 month), dry tympanic membrane perforations will be repaired with a gelatin sponge soaked with FGF2 or saline in a 3:1 ratio, then covered with a fibrin glue. Up to four applications will be administered at 3 week intervals or until complete healing is observed.
223597171|NCT06448039|DRUG|Saline control|Randomized double-blinded placebo-controlled treatment of patients with chronic (\>6 month), dry tympanic membrane perforations will be repaired with a gelatin sponge soaked with saline, then covered with a fibrin glue. Up to four applications will be administered at 3 week intervals or until complete healing is observed.
223597172|NCT03109184|BEHAVIORAL|Project STRONG|The web-based program consists of a number of games, activities, and didactic information that teens move through with their parent. Didactic information introduces teens and parents to specific emotion management, communication, and problem solving strategies as well as sexual health and healthy relationship information. Games and activities allow parents and teens to practice and apply strategies to developmentally appropriate situations.
223597173|NCT05192460|BIOLOGICAL|neoantigen tumor vaccine with or without PD-1/L1|In dose escalation phase, subjects will receive neoantigen tumor vaccine only. In dose expansion phase, subjects will receive neoantigen tumor vaccine combination with PD-1/L1.
223597174|NCT05897606|COMBINATION_PRODUCT|Multiviamins and minerals|The intervention group received one capsule of multivitamin and minerals supplements every day, one hour after breakfast, for 12 weeks.
223597175|NCT05897606|COMBINATION_PRODUCT|Placebo|Placebo
223597176|NCT04974801|DEVICE|Provox Life|Use of Provox Life range of HMEs for different situations and their attachments (adhesives and laryngectomy tubes)
223597177|NCT04974801|DEVICE|Usual Care|Continued Usual Care routines.
223597178|NCT03857100|OTHER|Audit and feedback - letter and report|letter describing project and report of participants' outlier status and how participants compare to peers
223597179|NCT04781686|DRUG|Camrelizumab|Camrelizumab (200mg) will be given i.v. on day 1 of each 3-week cycle
224198216|NCT05518565|OTHER|No intervention|No intervention
224198217|NCT01103076|DEVICE|Polyamide HD membrane|Single use polyamide membrane
224198218|NCT04688489|DIETARY_SUPPLEMENT|Carbloading and maltodextrin|The intervention is a dietary intervention that consists of a supplement of maltodextrin and added dietary carbohydrates. The supplement (20 g for women and 30 g for men) will be given to patients before and after a scheduled training, while the carbohydrates are given with meals. The extra carbohydrates given at meal time consists of extra potatoes, rice, bread, fruit, juice or other carbohydrate-rich food items.
224198219|NCT03005262|DRUG|MLN8237|
224198220|NCT06565897|DRUG|Test regimen|toothpaste \& manual toothbrush
224198221|NCT06565897|DRUG|Control regimen|toothpaste \& manual toothbrush
223597180|NCT04781686|DRUG|Apatinib Mesylate|Apatinib (250mg) will be administered orally once a day .
223597181|NCT04781686|DRUG|S1|S1 (BSA\<1.25 40mg, BSA \>=1.25-\<1.5 50mg, BSA \>=1.5 60mg) will be administered orally twice daily on days 1-7 of each 3-week cycle
223597182|NCT04781686|DRUG|Docetaxel injection|Docetaxel (75mg/m2 IV.drop) will be administered on day 1 of each 3-week cycle, for six cycles.
223597183|NCT04017091|DIAGNOSTIC_TEST|Virtual Reality Cognitive Training|Bimodal VR-Stroop (ClinicaVR: Apartment Stroop) Patient find themselves seated with a virtual apartment, where they see a living room, in front of a flat-screen TV set, a kitchen and a window. This intervention consisted of two Stroop conditions across all 8 sessions. In Condition 1 (Inhibition), Patients indicated when the color named (audio stimulus) matched the color shown (visual stimulus). Participants were to withhold their response in mismatched trials. In Condition 2 (Interference), Participants clicked the mouse when the color heard was the same as the ink color; not the word printed.
223597184|NCT02729441|DRUG|ramipril|Comparison of two renin angiotensin aldosterone inhibitors
223597185|NCT02729441|DRUG|perindopril|Comparison of two renin angiotensin aldosterone inhibitors
223597186|NCT05388617|DEVICE|Brera|The applicators will be placed in contact with the skin. The entire defined treatment area will then be treated by delivering energy to the skin. Temperature may be continuously monitored and recorded during treatment. Parameters may be adjusted throughout the treatment to increase subject comfort.
223597187|NCT01031979|DRUG|Yohimbine|alpha-2 adrenergic receptor antagonist
224198222|NCT05087173|DEVICE|Chatbot|An interactive chatbot for patient decision aid A chatbot of patient decision aid embedded into a mobile application which is able to bidirectionally interact with patients and provide standard general information, quantitative risk information on the possible outcomes of COVID-19 vaccination.
224198223|NCT00138801|DRUG|Ceftriaxone|
224198224|NCT00138801|DRUG|Doxycycline|
224198225|NCT01338701|PROCEDURE|Traditional Chinese Acupuncture (TCA)|An acupuncturist will examine and evaluate subjects before inserting thin, sterile stainless steel needles at specific points on their body. Patients will receive 10 treatments over a 6 week period.
224198226|NCT01338701|PROCEDURE|Auricular (Ear) Acupuncture|An acupuncturist will insert sterile stainless steel needles and an ASP ear needle into various points in subject's outer ear. The ASP is a shorter needle that will stay in the participant's ear for a few days. Patients will receive 10 treatments over a 6 week period.
223597188|NCT01031979|DRUG|Placebo|Placebo
224198227|NCT01338701|OTHER|Usual Care|Subjects do not receive acupuncture during the 6 week study time period. Instead, they continue to receive medical care for headaches and other symptoms. They can elect to receive up to 10 ear acupuncture treatments between the 6- and 12-week assessments.
224198228|NCT01470352|DRUG|Doluxetine|30 mg/d
223597189|NCT01018485|DRUG|Botulinum Toxin Type A|Intramuscular injection in affected limb up to 100 Units. Two doses (one placebo, one active) 3 months apart.
224198229|NCT01470352|DRUG|Placebo|suger pill 30mg/d
224198230|NCT06047964|DEVICE|DCB|Intracranial paclitaxel drug-eluting balloon catheters (SeQuent® Please CIS)
223597190|NCT02809339|OTHER|Questionnaires|
223597191|NCT03808012|OTHER|Braking performance in a brake simulator|Braking performance is tested in a real middle size car cabin to simulate ergonomic conditions of driving a car. This testing cabin has been equipped with customised equipment to allow measurement of reaction time, foot transfer time, brake response time and brake force.
223597192|NCT00301418|DRUG|Erlotinib|Tarceva®: Will be given at a starting dose of 150mg QD dose for the first cycle which is 28 days. This will be followed by 14 days of 100mg PO on a bid schedule and 150mg PO on a bid schedule for the final 14 days of the second cycle. Assuming no dose limiting toxicity, 150 mg PO tid will be continued for up to 10 more cycles. This is an outpatient regimen, in which the drug is admininistered orally. Tumor response will be assessed after every 2nd treatment cycle. Patients may receive a maximum of 12 cycles of treatment under this research protocol.
224198231|NCT06047964|DEVICE|POBA|Intracranial PTA balloon catheter
224198232|NCT01232764|OTHER|Exposure to multi-disciplinary wound care team|"Phase 1: In Person Support (3 mths)~Advance Practice Nurses (APNs) affiliated with Enhanced Multi-Disciplinary visit LTC facilities on a weekly basis. The APN may communicate with other members of an EMDT via telephone or online.EMDTs will collectively teach and mentor LTC facility wound care teams throughout the study.~Phase 2: Remote Support (2-11 mths) In the second phase, EMDTs will support LTC facility staff remotely via telephone and online communication, visiting the facilities on an as needed basis only.~All PU treatment will be based on RNAO evidence-based guidelines (updated in 2007)contextualized to the LTC setting."
224198233|NCT03323021|OTHER|Dehydrated human amnion/chorion membrane|dehydrated human amnion/chorion membrane
223597193|NCT03831100|BEHAVIORAL|BRIGHT|The BRIGHT intervention consists of 5 weekly, 60-minute, tablet-based, one-one telehealth sessions with a licensed therapist. BRIGHT Therapist: A licensed clinical psychologist with extensive experience managing pyscho-oncologic concerns in patients with HNC will deliver BRIGHT.
224311054|NCT02264860|DIETARY_SUPPLEMENT|Zinc and SAMe|The subjects will have the supplements dispensed at visit 2. They will be contacted weekly for the next three weeks to ensure that they are tolerating the supplements without significant side-effects. If these side-effects are significant then the dose of zinc will be decreased for all subjects to 15 mg of elemental zinc/day; if symptoms persist the SAMe dose will then be decreased by 25% (to 1200 mg/day) and then by 50% (to 800 mg/day) if necessary until the supplements are tolerated. 12 mg of zinc and 800 mg of SAMe is the lowest dose possible.
223597194|NCT03831100|BEHAVIORAL|Active Control|AC consists of 5 weekly sessions of videos about HNC survivorship that are delivered using a telemedicine platform. Each AC session (Table 5) is a compilation of shorter videos featuring HNC survivors, caregivers, and oncologists discussing non-body image aspects of HNC survivorship.
224198234|NCT03323021|OTHER|Standard of Care|Standard of Care
223597195|NCT04005599|DRUG|Remifentanil group|Venous general anesthesia with propofol and remifentanil.
224198235|NCT04172727|DRUG|Bupivacaine Hcl 0.25% Inj|ultrasound-guided bilateral TFP block with 20 mL of 0.25% bupivacaine
224198236|NCT04172727|DRUG|saline 0.9%|ultrasound-guided bilateral TFP block with 20 mL of saline 0.9%
223597196|NCT04005599|DRUG|Magnesium sulfate group|Venous general anesthesia with propofol and magnesium sulfate
223597197|NCT03430934|COMBINATION_PRODUCT|NAVI mapping with Indocyanine green|Moh's tumor imaging with Indocyanine green
223597198|NCT00772265|BIOLOGICAL|Wosulin N|Total Dose per subject will be 0.4IU/Kg given Subcutaneously.
223597199|NCT00772265|BIOLOGICAL|Novolin N|Total dose per subject will be 0.4 IU/Kg given Subcutaneously.
223597200|NCT04459377|DRUG|S-Ketamine|"Patients are randomized to three groups. Randomization in blocks of six patients stratified by sex. A list of serial numbers and randomized group affiliation is produced which is open to the pharmacy's manufacturing staff and closed to the staff of the trial. The pharmacy prepares filled syringes with investigation drug in accordance with randomized group affiliation.~All groups are sedated with midazolam intravenously to a defined end point. A syringe pump with volume accuracy ± 2% injects the test drug (P, K1 or K2). One infusion set is coupled between the syringe and a three-way connection, which in turn is connected to a peripheral venous catheter (PVK). This PVK is also used for blood sampling. Blood is sampled at two occasions. Directly preoperatively and two hours after surgery. The third molar is surgically removed."
224198237|NCT06568718|DRUG|bovhyaluronidase azoximer|Longidaze 3000 IU intramuscularly once every 5 days with a course of 5 injections; Longidaze 3000 IU rectal suppositories once every 3 days with a course of 10 applications; Longidaze 3000 IU rectal suppositories once every 7 days with a course of 10 applications.
224198238|NCT06568718|DRUG|tamsulosin|Tamsulosin 0.4mg per os every day
224198239|NCT03144219|DIAGNOSTIC_TEST|Transcranial Doppler (TCD) ultrasound monitoring|TCD monitoring comatose patients in ICU looking for signs of impaired cerebral compliance
224198240|NCT03144219|DIAGNOSTIC_TEST|Non invasive intracranial compliance monitoring|A sensor of cardiac beat by beat cranial dilation will be used for monitoring intracranial compliance, in non-invasive fashion.
224198241|NCT02273349|DEVICE|Lung Volume Reduction Coil (PneumrX Inc.)|Endoscopic Lung Volume Reduction
223747993|NCT06979193|BEHAVIORAL|SAATHI intervention (Augmented PM+ counseling)|Study participants in this arm will attend six weekly peer-led sessions, each approximately 90-minutes in length, designed to empower them to make decisions about their lives and build resilience. PM+ is a psychological intervention developed by the World Health Organization, based on principles of cognitive behavioural therapy. It includes components such as understanding adversity and psychoeducation on mental health, managing stress, problem-solving, behavioural activation, and strengthening social support. The PM+ model in this study is augmented with additional elements, including self-empowerment strategies, motivational interviewing, psychoeducation on intimate partner and community violence, mindful meditation and safety planning. Participants will also be introduced to best practices and lessons learned that support danger assessments and avoidance of risk of future violence. The intervention aims to improve participants' overall circumstances and mental well-being.
223747994|NCT06979193|BEHAVIORAL|SAATHI intervention with Peer-Led Group Meetings|"These 11-monthly peer-led group sessions are designed to enhance social support, build resilience, and reinforce the application of augmented PM+ strategies in daily life. They provide a safe space for reflection and mutual encouragement among study participants. The group sessions focus on managing stress, strengthening self-regulation, building self-esteem, fostering social connectedness, and promoting positive identity development.~Group sessions involve identifying and discussing the barriers and facilitators related to practicing slow breathing techniques, problem-solving strategies, maintaining physical activity, navigating intimate partner and community violence, understanding social support networks, and planning for safety in various situations faced by sexual and gender minorities."
223747995|NCT06590740|DRUG|Budesonide-Formoterol treatment|Budesonide 160 μg/formoterol 4.5 μg, 1 inhalation, BID
223747996|NCT03017651|DIETARY_SUPPLEMENT|OM3-supplement 1|1g of OM3-supplement 1 will be given to subjects to look at DHA/EPA blood absorption
223747997|NCT03017651|DIETARY_SUPPLEMENT|OM3-supplement 2|1g of OM3-supplement 2 will be given to subjects to look at DHA/EPA blood absorption
223747998|NCT05382286|DRUG|Sacituzumab Govitecan-hziy|Administered intravenously
223747999|NCT05382286|DRUG|Pembrolizumab|Administered intravenously
223748000|NCT05382286|DRUG|Paclitaxel|Administered intravenously
223748001|NCT05382286|DRUG|nab-Paclitaxel|Administered intravenously
223748002|NCT05382286|DRUG|Gemcitabine|Administered intravenously
223597201|NCT04459377|DRUG|Sodium Chloride 0.9% Inj|"Patients are randomized to three groups. Randomization in blocks of six patients stratified by sex. A list of serial numbers and randomized group affiliation is produced which is open to the pharmacy's manufacturing staff and closed to the staff of the trial. The pharmacy prepares filled syringes with investigation drug in accordance with randomized group affiliation.~All groups are sedated with midazolam intravenously to a defined end point. A syringe pump with volume accuracy ± 2% injects the test drug (P, K1 or K2). One infusion set is coupled between the syringe and a three-way connection, which in turn is connected to a peripheral venous catheter (PVK). This PVK is also used for blood sampling. Blood is sampled at two occasions. Directly preoperatively and two hours after surgery. The third molar is surgically removed."
223597202|NCT04010877|BIOLOGICAL|CLL-1, CD33 and/or CD123-specific CAR gene-engineered T cells|Infusion of CLL-1, CD33 and/or CD123-specific CAR-T cells
223597203|NCT02175979|DIETARY_SUPPLEMENT|enriched enteral nutrition|enriched enteral tube feeding perioperative
223597204|NCT02175979|DIETARY_SUPPLEMENT|standard|standard of care
223597205|NCT01107665|DRUG|Pazopanib and Paclitaxel|Paclitaxel will be administered intravenously at a starting dose of 80mg/m2 weekly for 3 weeks followed by a 1-week rest. Pazopanib will be administered orally, in a continuous regimen, with a starting dose of 800mg daily.
223597206|NCT05632302|DEVICE|nICP|The nICP probe contains infrared light sources that illuminate the deep brain tissue of the frontal lobe. Photodetectors in the probe detect the backscattered light, which is modulated by pulsation of the cerebral arteries.
223597207|NCT04131062|BEHAVIORAL|Electronic Consent (iPad)|Participants who receive the intervention will be consented using an electronic app presented via iPad and developed according to the Sage eConsent framework.
223597208|NCT04280796|BEHAVIORAL|psychophysical tasks|"All participants perform two psychophysical tasks to assess sensory-discriminative and emotional-motivational pain responses independently from each other.~In addition, in Substudy 1 an operant learning paradigm will be implement to dissociate these responses, increasing the sensory-discriminative pain responses compared to emotional-motivational pain responses by contingent monetary reinforcement or vice versa.~In Substudy 2, responses of chronic pain patients will be compared to those of healthy participants to characterize possible alterations and operant learning will be operationalized to decrease emotional-motivational pain responses, which are assumed to be already increased in the patients."
223597209|NCT04280796|BEHAVIORAL|cognitive task|In Substudy 3 participants will perform a psychophysical task to assess metacognition in pain perception as an indicator of the cognitive-evaluative pain component.
223597210|NCT02035917|DEVICE|Locking plate|
223597211|NCT02035917|DEVICE|Non-Locking plate|
223597212|NCT03565016|OTHER|no interventional study|no interventional study
223597213|NCT00771888|DRUG|lanreotide|lanreotide
223597214|NCT02211612|DIETARY_SUPPLEMENT|PUFA-group|
223748003|NCT05382286|DRUG|Carboplatin|Administered intravenously
223748004|NCT06858475|DEVICE|CONTROL-IQ (Tandem™)|interaction with the CONTROL-IQ (Tandem™) hybrid closed-loop (HCL) system in individuals with type 1 diabetes
223748005|NCT06673264|DEVICE|Soft Neural Probe|sub-acute insertion of the soft neural probe with neural signal recording
223748006|NCT06673004|PROCEDURE|Ovarian tissue allo-transplantation|Participants will receive donor ovarian tissue with immunosuppression
223748007|NCT07000708|BEHAVIORAL|TRE: Time-restricted eating|The daily eating pattern is reduced to 8 h/day. The first meal will be before 10:00 AM.
223748008|NCT06923774|DEVICE|Ion endoluminal system|Lung nodule biopsy and/or localization procedure using the Ion endoluminal system per sites' standard of care
223597215|NCT02211612|DIETARY_SUPPLEMENT|SFA-group|
223748009|NCT06620302|BIOLOGICAL|Bcl-XL Proteolysis Targeting Chimera DT2216|Given IV
224198242|NCT05665816|DEVICE|Stent PULSAR® -18 T3,|"Post-authorization, prospective and multicenter registry to evaluate the clinical results of the PULSAR® -18 T3 stent, in the treatment of de novo or restenotic lesions of the superficial femoral and/or popliteal artery, primarily as salvage, in a population of patients residing in Spain and in real life conditions."
224198243|NCT03537625|DIETARY_SUPPLEMENT|Green tea|We made a dietary supplement from Cammellia sinesis O. Kunze, and made tablets containing extract.
223597216|NCT03282513|DRUG|AG-120 (Ivosidenib)|Single 500 mg dose of AG-120 (Ivosidenib).
223597217|NCT03609411|PROCEDURE|Splenectomy|Splenectomy was performed after hepatectomy, in an extra-hilar manner with manual ligation of splenic vessels.
223597218|NCT02008227|DRUG|Atezolizumab|1200 mg IV infusion on Day 1 of each 21-day cycle
223597219|NCT02008227|DRUG|Docetaxel|75 mg/m\^2 IV infusion on Day 1 of each 21-day cycle
223597220|NCT06330480|OTHER|Intervention group|Subjects will be invited for a home-based screening (phase 1) that includes home-based testing; urine collection for detection of elevated albuminuria, and a heart rhythm measurement for detection of atrial fibrillation. Both home-based tests will be performed with CE-marked medical devices used according to their intended use. A subset of the population will also receive a short questionnaire. Depending on the results of the home-based tests, subjects might be invited for further screening in a diagnostic screening facility (phase 2), that includes collection of physical data, blood, and urine for the assessment of parameters that are indicative of cardiovascular disease, chronic kidney disease, diabetes type 2 or their risk factors. Participants will also receive a questionnaire. Based on the results of the diagnostic screening, participants may be referred to their GP for appropriate treatment according to the prevailing guidelines (phase 3)
223597221|NCT03161106|DIETARY_SUPPLEMENT|Nutrition|Nutrional group-30 kcal/kg with 1.5 grm protein with protein supplements
223597222|NCT03161106|DRUG|Lactulose|Lactulose plus diet consumed by patient
223597223|NCT03161106|DIETARY_SUPPLEMENT|Diet|Protein Powder 15 to 20 gm/meal/day
223597224|NCT04299035|PROCEDURE|Erector spinae plane block|Erector spinae plane block
223597225|NCT03811314|DEVICE|Strength training|Using dumbbells, butterfly machine and vertical leg press machine for strength training, 12 repetition maximum weight for 12 repetition, three times a day, five days a week, for a total of four weeks
223597226|NCT03811314|DEVICE|Aerobic training|Using stationary bicycle to perform cardiopulmonary endurance training in 50-70 heart rate reserve for 20 minutes, five days per week, for a total of four weeks
224198244|NCT01554917|DRUG|Iguratimod|taken orally, 2 tablets/day (bid)
224198245|NCT05702827|DRUG|Bupivacaine-Meloxicam|All patients will receive standard of care but the study arm will also receive Bupivacaine-Meloxicam in addition.
224198246|NCT02187406|PROCEDURE|Modified ankle athletic taping|
224198247|NCT02187406|PROCEDURE|Traditional ankle athletic taping|
224198248|NCT02586909|DRUG|RVT-101 35 mg tablets|once daily, oral tablets
224198249|NCT00103155|PROCEDURE|conventional surgery|
223506900|NCT03786055|BEHAVIORAL|Somatic Yoga and Meditation (SYM)|A Hanna somatics and somatic yoga and meditation (SYM) protocol was designed to address sensory-motor amnesia and reduce trauma which creates reflex patterns that lead to chronic muscular contractions. The movements use voluntary muscular contraction and slow controlled eccentric contraction, with the constant focus on sensation to increase the resting length of muscles. Movements are performed slowly and gently with the least possible effort and are never forced. The protocol is endorsed by the US Army Surgeon General as treatment for chronic pain. The meditations are trauma informed and evidence based supporting pain modulation, healing and well-being.
223597227|NCT03811314|DEVICE|Isokinetic trinaing|Using Biodex isokinetic dynanometer and set it in isokinetic mode in 60 degree per second
223597228|NCT03811314|DEVICE|Isotonic training|Using Biodex isokinetic dynanometer and set it in isotonic mode at 60% of the maximal peak torque
223597229|NCT05687162|BEHAVIORAL|Overcoming Loneliness three-week intervention|A self-guided online loneliness intervention with three 10-20 minute sessions. The intervention content draws heavily from Internet Cognitive Behavioral Therapy for Loneliness and follows the form of single-session mental health interventions.
223597230|NCT05687162|BEHAVIORAL|Overcoming Loneliness single-session intervention|The Overcoming Loneliness Three-Week Intervention condensed into a single-session intervention lasting 20-30 minutes.
223597231|NCT05687162|BEHAVIORAL|"Single-session Sharing Feelings program"|"A self-guided online supportive therapy intervention with a single 20-30 minute session intended to encourage users to share feelings with close others. Slightly modified from the Sharing Feelings intervention"
223748010|NCT06620302|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223748011|NCT06620302|DRUG|Irinotecan|Given IV
223748012|NCT05214768|DRUG|CC-93538|Specified dose on specified days
223748013|NCT05214768|DRUG|Placebo|Specified dose on specified days
224198250|NCT00103155|PROCEDURE|radiofrequency ablation|
224198251|NCT03943199|DIAGNOSTIC_TEST|Visual Analogue Scale for pain|Will be assessed at 0´, 30´, 60´, 90 minutes and 18 hours after the application of the analgesic.
224311055|NCT02572414|BEHAVIORAL|Health Promotion Intervention|Men Together Making a Difference Health Promotion Intervention, which included three, 3-hour weekly sessions, implemented in small groups by trained facilitators using scripted manuals, was designed to increase self-efficacy, outcome expectancy, and skills for behaviors tied to cardiovascular disease, diabetes, hypertension, and cancer. It encouraged men to adhere to guidelines for physical activity, 5-a-Day diet, and colon cancer screening. It encouraged at least 30 min of moderate-intensity aerobic activity on 5 days or at least 20 min of vigorous-intensity aerobic activity on 4 days and muscle-strengthening activity on at least 2 days each week. Participants identified their personal barriers to engaging in the recommended behaviors and strategies for surmounting those barriers.
223506901|NCT05663593|DRUG|HSK31858, tablet|Starting dose in single ascending dose: 5 mg
223748014|NCT07007962|DRUG|rilzabrutinib|Pharmaceutical form:Tablet-Route of administration:Oral
223748015|NCT07003594|OTHER|Jigsaw IV technique|The Intervention Group receives training in cardiothoracic examination using the Jigsaw IV technique.
223748016|NCT05041322|DRUG|Buspirone|Subjects take 30 mg buspirone HCl (15 mg twice a day) for 14 Days.
223748017|NCT05041322|DRUG|Placebo|Subjects take placebo pills (twice a day) for 14 Days.
223748018|NCT06626269|DIAGNOSTIC_TEST|Blood sample|"In cohort A: 3 or 4 blood samples (for plasma and PBMC collection) : at baseline (before immunotherapy initiation); at 3 months ; at 12 months; on case of severe or unexpected toxicity.~In cohort B: 3 blood sampes (for plasma and PBMC collection): at baseline (before treatment initiation); at 3 months ; at 12 months~In cohort C: 2 blood samples (for plasma and PBMC collection) : at baseline (at the time of surgery); at 3 months (after surgery)"
223748019|NCT06626269|OTHER|Tumor tissue|Cohort A and B: 1 tumor block in paraffin at diagnosis + 1 tumor block in paraffin at progression (optional) Cohort C: Fresh tumoral tissue fragments for TIL and CAF + 1 tumor block in paraffin at time of surgery.
223748020|NCT06381141|DRUG|CLN-619|Anti-MICA/MICB monoclonal antibody
223748021|NCT05926947|DIETARY_SUPPLEMENT|Verum A|Formulation of polyphenols from olive leaf extract, blackcurrant extract, pomegranate extract, grapefruit extract
223748022|NCT05926947|DIETARY_SUPPLEMENT|Verum B|Formulation of polyphenols from olive leaf extract, blackcurrant extract, white kidney bean extract, chromium picolinate and Zinc bisglycinate
223748023|NCT05926947|DIETARY_SUPPLEMENT|Placebo|Micro crystalline cellulose
223748024|NCT06682208|PROCEDURE|ES catheter|ES catheter for postoperative pain control
223748025|NCT06682208|PROCEDURE|Intercostal nerve cryoablation (INC)|INC used for postoperative pain control
223748026|NCT07016620|PROCEDURE|Transperineal Laser Ablation (TPLA)|Outpatient treatment with Transperineal Laser Ablation (TPLA) as a salvage therapy after previous Minimally Invasive Surgical Therapies (MIST)
223748027|NCT07010406|DRUG|Povetacicept|Injection for Subcutaneous Administration.
223748028|NCT07007312|DRUG|Ziftomenib|Oral administration
223748029|NCT07007312|DRUG|Placebo|Oral administration
223748030|NCT07007312|DRUG|Venetoclax|Oral administration
223748031|NCT07007312|DRUG|Azacitidine (AZA)|Intravenous or subcutaneous administration
223748032|NCT07007312|DRUG|Daunorubicin|Intravenous administration
223748033|NCT07007312|DRUG|Cytarabine (Ara-C)|Intravenous administration
223748034|NCT04686435|OTHER|Non-surgical treatment such as physiotherapy, exercise, corticosteroid injection, medication, acupuncture|Treatment consisting of different non-surgical interventions as recommended by the orthopedic specialist and decided upon in shared decision making with the patient
223748035|NCT04686435|PROCEDURE|Surgery|Surgery can consist of rotator cuff repair, Bankart repair, subacromial decompression, biceps tenodesis or tenotomy, acromioclavicular joint resection.
223748036|NCT01502423|BIOLOGICAL|Adalimumab|Subcutaneously 40 mg every other week (eow) or every week (ew) (as dosing requires)
223748037|NCT07012187|OTHER|They will watch a video on subcutaneous injection application using virtual reality technology (virtual reality glasses).|Students will watch a video on subcutaneous injection application using virtual reality technology (virtual reality glasses).
223748038|NCT00567892|DEVICE|rTMS|"Stimulation Settings:~Frequency -- 1Hz on 330 sec (5 min 30 sec.) per train for the first 5 trains with the last train 350 sec. (5 min. 50 sec.) in duration Off -- 90 sec (1 min. 30 sec.) Intensity -- 110% of motor threshold Duration -- 42½ minutes (total 2000 pulses in 6 trains)"
223506902|NCT05663593|DRUG|Placebo, tablet|Matching placebo
223748039|NCT07022600|DEVICE|Diaphragmatic ultrasound|diaphragmatic excursion will be conducted at baseline and at 2 and 24 hours postoperatively
223748040|NCT07024615|DRUG|ASP2138|Subcutaneously
223748041|NCT07024615|DRUG|Oxaliplatin|Injection
223748042|NCT07024615|DRUG|Leucovorin|Injection
223748043|NCT07024615|DRUG|5-FU|Injection
223748044|NCT07024615|DRUG|Irinotecan|Injection
223748045|NCT07024615|DRUG|Gemcitabine|Intravenously
223506903|NCT05254210|DEVICE|RF Device (Potenza™)|Test spots may be performed prior to the first treatment. Following test spots, for the treatment, the tip will be placed in contact with the skin. Parameters may be adjusted throughout the treatment and will determined by the Clinician.
223506904|NCT01636544|PROCEDURE|contralateral healthy tissue biopsy|At the time of surgery, a part of the specimen, plus a biopsy of the healthy (control) contralateral mucosa (i.e. right border of the tongue for a SCC of the left border, left cheek for a dysplasia of the right cheek and so on) will be harvested for research and immediately frozen at -80°C first in dry ice, then in a -80°C freezer.
223506905|NCT01457430|DRUG|Icatibant|30 mg subcutaneous dose of Icatibant
223506906|NCT01765881|DRUG|Misoprostol|administration of Misoprostol 25 micrograms capsule by intravaginal route every 4 hours, up to 4 capsules
223506907|NCT01765881|DRUG|Dinoprostone|administration of one sustained released pessary of 10 milligrams by intravaginal route
223506908|NCT04947904|OTHER|Reduction of the patient's fluid intake during the first 7 days|The volume of fluids infused to the patient will be reduced by the doctor in charge of the patient for the first 7 days of the patient's stay in the intensive care unit according to a protocol with instructions to reduce fluid intake as far as possible in terms of maintenance fluids, dilution of medication and artificial nutrition. This protocol will be begun immediately following the patient's inclusion on Day 1 and pursued for 7 days after inclusion (i.e. from Day 1 - to Day 7). The fluid restriction strategy does not involve the administration of any medication (i.e. diuretics). A clinical pharmacist will help the intensive care teams apply the fluid restriction protocol with a daily check. If the restrictive strategy leads to hypovolemia and / or a electrolyte anomaly (sodium, potassium, chloride, etc.), the physician in charge will be authorised to treat these anomalies in conformance with the protocol recommendations.
223506909|NCT00360854|DRUG|erlotinib hydrochloride|
223506910|NCT00360854|GENETIC|mutation analysis|
223506911|NCT00360854|GENETIC|polymorphism analysis|
223506912|NCT00360854|OTHER|laboratory biomarker analysis|
223506913|NCT00360854|OTHER|pharmacological study|
223506914|NCT00360854|RADIATION|radiation therapy|
223506915|NCT00625729|BIOLOGICAL|aldesleukin|Day 0-14, 10 million international units, 3 times per week for 6 doses
223506916|NCT00625729|BIOLOGICAL|allogeneic natural killer cells|Day 0 infusion of cells (1.5-8 x 10\^7 cells/kg).
223506917|NCT00625729|BIOLOGICAL|rituximab|Administered Day -8, day -1, day +6 and day +13, intravenously (IV) 357 mg/m\^2
223506918|NCT00625729|DRUG|cyclophosphamide|60 mg/kg intravenous (IV) on Day -5.
223748046|NCT07024615|DRUG|Nab-paclitaxel|Intravenously
224311056|NCT02572414|BEHAVIORAL|Health Awareness Control Intervention|Health Awareness Control Intervention consisted of one 1-hour small-group session led by a trained facilitator. Participants viewed and discussed video clips on physical activity, fruit and vegetable consumption, and colon cancer screening.
224311057|NCT02309138|DIAGNOSTIC_TEST|Gestational diabetes screening with fasting 3 hour 100 gm|Participants receive fasting 3 hour 100 gm oral glucose tolerance test
223597232|NCT05687162|BEHAVIORAL|The Blu Surfer program: a popular online content-based intervention for psychological distress|The Blu Surfer Program is a 25-minute SSI the research team developed centered on popular online content relevant to mental health. In the SSI, the user is first asked to select the kinds of support they would like to view. Next, the user is asked to explore a library of annotated popular online content (filtered by their desired kinds of content) and to select the content they find personally valuable. Finally, the SSI provides the user an annotated list of the content they selected. Users can keep this list to draw from, build on, or share later on as they wish.
223597233|NCT05687162|BEHAVIORAL|The Action Brings Change (ABC) Program (TEAM Lab version)|The ABC project is a 20-30-minute SSI for teens based on behavioral activation. It was found to be efficacious for reducing depression, anxiety, hopelessness, and self-hate and increasing perceived control and agency in youth (link to SSI: https://osf.io/ch2tg/, license: http://creativecommons.org/licenses/by-nc-sa/4.0/). The researchers modified the phrasing in the intervention to make it more relevant to both teens and adults, as the original was designed for only teens.
223597234|NCT05687162|BEHAVIORAL|Online help-seeking as usual|"This intervention, created by the present research team, aims to emulate how one might find support on their own using the internet. In this condition, participants are asked to browse the internet for 25 minutes to find popular online content relevant to their personal struggles and create an annotated list of links to the content they find useful. The intervention is similar to a self-study condition, which found self-study and a video intervention equally increased mental health knowledge. The survey platform provides text entry boxes to help each participant create their guide and then provides a text version of their guide for them to keep."
223597235|NCT05687162|BEHAVIORAL|The Lonely Blu Surfer program: a popular online content-based intervention for loneliness|The Lonely Blu Surfer Program is a 25-minute SSI the research team developed centered on popular online content relevant to loneliness. In the SSI, the user is first asked to select the kinds of support they would like to view. Next, the user is asked to explore a library of annotated popular online content (filtered by their desired kinds of content) and to select the content they find personally valuable. Finally, the SSI provides the user an annotated list of the content they selected. Users can keep this list to draw from, build on, or share later on as they wish.
223597236|NCT05687162|BEHAVIORAL|Overcoming loneliness SSI 8-minute version|A shortened version of an online self-guided intervention based on principles of CBT for loneliness. The research team created this intervention by cutting lengthy didactic material and exercises from the 23-minute version, while maintaining its core concepts.
223597237|NCT03261453|DEVICE|Active Elipse Device|Intervention Device
223597238|NCT03261453|DEVICE|Elipse Sham Device|Control Device
223597239|NCT01806909|BIOLOGICAL|Ad4-H5-Vtn|
223597240|NCT03727932|DEVICE|VioOne HIV Profile Supplemental Assay|The VioOne™ HIV Profile™ Supplemental Assay is an enzyme-linked immunosorbent assay (ELISA) for confirmation and differentiation of individual antibodies directed to various gene products of Human Immunodeficiency Virus Type 1 (HIV-1 Group M \& Group O) and Type 2 (HIV-2) in human serum or plasma. The HIV Profile™ is intended as an aid in the diagnosis of infection with HIV-1 and/or HIV-2.
223597241|NCT00534963|PROCEDURE|cervical vs. uterine placement of balloon catheter|
223748047|NCT07024615|DRUG|Capecitabine|Oral
223748048|NCT04383743|DRUG|Cisplatin|Given IV
224311058|NCT02309138|DIAGNOSTIC_TEST|Gestational diabetes screening with fasting 2 hour 75g|Participants receive fasting 2 hour 75 gm oral glucose tolerance test
224311059|NCT03645239|PROCEDURE|Mechanical Temporal Summation assessment|A 180 gram von Frey filament is applied on the subject's forearm. Patient will then be asked to rate the pinprick pain score on a verbal rating scale, 0-100. Following this, 10 consecutive touches at random locations are applied with a 1 second interstimulus interval and within a 1 cm diameter circle. The patient will then be asked to rate the 10th pain score (0-100). The Mechanical Temporal Summation Score is obtained by the difference between the 11th pain score and the 1st pain score. If the score is greater than zero, the patient is implied to have presence of Mechanical Temporal Summation.
224311060|NCT03645239|OTHER|Preoperative pain assessment|"Patients will be asked to rate, using a 0-10mm visual analog scale (VAS), their surgical anxiety level (On a scale of 0-100, with 0 being not anxious at all to 100 being extremely anxious, how anxious are you about your upcoming surgery?), their anticipated pain (On a scale of 0-10, with 0 being no pain at all and 10 being pain as bad as you can imagine, how much pain do you anticipate experiencing after your upcoming surgery?), and using a categorical scale, their anticipated pain medication need (On a scale of 0 to 5, with 0 being none at all, 1 being much less than average, 2 being less than average, 3 being average, 4 being more than average, and 5 being much more than average, how much pain medication do you anticipate needing after your upcoming surgery?)."
224311061|NCT03645239|OTHER|Questionnaires|Questionnaires including Hospital Anxiety and Depression Scale (HADS), EQ-5D-3L, Edinburgh Postnatal Depression Scale (EPDS), Pain Catastrophizing Scale (PCS), Central Sensitisation Inventory (CSI), pain survey and breastfeeding questionnaire will be administered to the patient.
223748049|NCT04383743|DRUG|Doxorubicin|Given IV
223748050|NCT04383743|DRUG|Methotrexate|Given IV
223748051|NCT04383743|BIOLOGICAL|Pegfilgrastim|Given SC
223748052|NCT04383743|BIOLOGICAL|Pembrolizumab|Given IV
223748053|NCT04383743|PROCEDURE|Radical Cystectomy|Undergo standard of care radical cystectomy
223748054|NCT04383743|DRUG|Vinblastine Sulfate|Given IV
224311062|NCT03645239|OTHER|Headspace|The mindfulness exercise mobile application, Headspace, will be downloaded into the patients' mobile devices. Patients will be asked to experience a mindfulness exercise for 10-30 minutes before delivery. HADS and pain score will be asked after the intervention.
224311063|NCT02399319|PROCEDURE|Internal Fixator|Internal fixator refers to pins usually inserted into the iliac bones and then connected together by clamps and bars that are inserted under the skin, internally.
224311064|NCT02399319|PROCEDURE|Symphyseal Plate|A plate that spans across the symphysis to maintain reduction and stability.
223597242|NCT00962325|BEHAVIORAL|Intervention to increase physical activity|This will be a 6-week preoperative intervention to increase structured walking activity. This will be accomplished through weekly individual face-to-face sessions involving tailored instruction in use of standard behavior change strategies such as self-monitoring, goal-setting, stimulus control, etc.
223597243|NCT00978146|DRUG|Hydroxyurea|Patients will take oral hydroxyurea with a starting dose of 20 mg/kg daily. Patients will remain on hydroxyurea as long as there is a response or stability in tumor size and associated toxicities are manageable. Maximum treatment duration will be one year.
223597244|NCT02453503|DRUG|Licorice|licorice mucoadhesive films evey 6 hours for two weeks
223597245|NCT02453503|DRUG|Triamcinolone Acetonide|Triamcinolone acetonide mucoadhesive films 1 mg every 6 hours for two weeks.
224198252|NCT04639570|OTHER|KneuroKnits|The KneuroKnits program will be based upon current knitting education practices and leading practices in facilitation of social participation for individuals with neurodevelopmental disorders, physical disabilities, and acquired brain injuries. The program will consist of 4 weekly sessions in which participants will learn knitting fundamentals and have opportunities to socialize over a shared occupation. The 4 weekly sessions of the KneuroKnits curriculum will include related knitting and social skills themes of the week. Each session will begin with a structured lesson on the knitting topic of the day, and will then continue into knitting practice and social interaction. Participants will be encouraged to practice their new skills (knitting and social) between sessions, and will be allowed to keep all materials that they use or create.
224198253|NCT00877799|DRUG|CR845|CR845 (0.024 mg/kg) administered the day after surgery (Day 1)
224198254|NCT00877799|DRUG|CR845|CR845 (0.008 mg/kg) administered the day after surgery (Day 1)
224198255|NCT00877799|DRUG|CR845|CR845 (0.040 mg/kg) administered immediately after surgery (Day 0)
224198256|NCT00877799|DRUG|Placebo|Matched placebo administered the day after surgery (Day 1)
224198257|NCT00877799|DRUG|Placebo|Matched placebo administered immediately after surgery (Day 0)
224198258|NCT01187615|DRUG|Regorafenib (BAY73-4506) - sequential / Cisplatin / Pemetrexed|In Part A of this trial, regorafenib will be administered in a sequential dosing with a seven day wash out period before the next infusion of pemetrexed and cisplatin. Regorafenib will be administered at a dose of 160 mg qd from Day 2 to Day 14 followed by a 7 days break. Pharmacokinetics of regorafenib will be assessed on Day 14 of Cycle 1 and Day 1 of Cycle 2.
224198259|NCT01187615|DRUG|Regorafenib (BAY73-4506) - continuous / Cisplatin / Pemetrexed|In Part B of this trial, regorafenib will be administered continuously from Day 1 to Day 21. Only in Cycle 1, regorafenib dosing will start on Day 2 in order to assess the pharmacokinetics of pemetrexed and cisplatin without concomitant regorafenib dosing. Pharmacokinetics of regorafenib will be assessed on Day 21 of Cycle 1 and on Day 1 of Cycle 2.
224198260|NCT04054011|DRUG|Deoxycholic Acid|Deoxycholic acid (Kybella) 10 mg/ mL subcutaneous
224198261|NCT03136978|DIAGNOSTIC_TEST|Evaluation of M1 and M2 macrophages by flow cytometry.|To assess surface expression of macrophage markers, tissue samples will be stained for flow cytometry with fluorochrome-conjugated monoclonal antibodies against CD14, CD68, CCR7 and CD80 to identify M1, whereas fluorochrome-conjugated monoclonal antibodies against CD14, CD68, CD163 and CD206 to identify M2.
224198262|NCT04237779|BIOLOGICAL|PRP injection into at least one testis|Autologous blood obtained from peripheral vein will be used to prepare PRP following standard protocols. PRP injection will be performed under local anesthesia. Sperm analysis, testicular volumes (using orchiometer), serum FSH and testosterone measurements will be re-evaluated at 8 weeks post-procedure. On the third month after the procedure, presence of spermatozoa will be reassessed in micro testicular sperm extraction (TESE) material.
224198263|NCT05254015|BEHAVIORAL|Cognitive Rehabilitation and Exposure/Sorting Therapy (CREST)|Cognitive Rehabilitation and Exposure/Sorting Therapy (CREST) includes cognitive rehabilitation of executive functioning and exposure therapy for discarding/not acquiring.
224198264|NCT05254015|BEHAVIORAL|Case Management|Case management includes linking to resources, monitoring health, and safety hazards.
224198265|NCT03724292|DRUG|Placebo|Dose-matched placebo administered as oral capsule(s) once daily
224198266|NCT03724292|DRUG|VTP-43742|VTP-43742 administered as oral capsule(s) once daily
224198267|NCT01035112|PROCEDURE|MRI|
224198268|NCT00210925|DRUG|topiramate|
224198269|NCT03889405|DEVICE|INVU™|The subject will undergo continuous recording of the uterine contractions and the fetal heart rate (FHR) for 30 to 60 min using INVU™.
223597246|NCT02347306|OTHER|Telephone interview|
223597247|NCT01332253|DRUG|Intravenous ibuprofen|Participants will receive a single 10mg/kg dose of intravenous ibuprofen diluted in normal saline at the induction of anesthesia.
223597248|NCT01332253|OTHER|Normal Saline|Participants will receive a comparable weight based volume of normal saline as a placebo comparator at the induction of anesthesia.
223597249|NCT03420274|BEHAVIORAL|NEST|This is a point-of-care shared decision-making instrument.
223597250|NCT03420274|BEHAVIORAL|Usual care|This group will utilize usual care with respect to healthcare provider practice for education and counseling.
223597251|NCT01277874|DEVICE|Nasal CPAP|NCPAP is delivered via nasal prongs placed into infant's nares. It may be delivered via ventilator or by bubble.
223748055|NCT06692036|OTHER|Adaptive Blood Purification (ABP)|Patients in the intervention group, based on standard treatment, received two 6-hour adaptive blood purification (ABP) treatments within 24 hours after enrollment, that is, patients did not indicate renal replacement therapy (RRT), only coupled plasma filtration-adsorption (PFAD) therapy is used to adsorb inflammatory factors; for patients with acute kidney injury (AKI) and meeting RRT indications, PFAD-RRT treatment is used.
223748056|NCT05926011|DEVICE|RGn600|RGn600 with a 10 Hz-pulsed wave mode light emission
224198270|NCT03889405|DEVICE|IUPC|The study participants will undergo continuous recording of the uterine contractions by IUPC.
224198271|NCT03889405|DEVICE|TOCO|Some of the study participants will undergo continuous recording of the uterine contractions and the fetal heart rate (FHR) by TOCO as well.
223597252|NCT01277874|DEVICE|Oscillatory NCPAP|Bird Industries pneumatic diaphragm is attached to NCPAP patient circuit to provide oscillations.
223597253|NCT03127176|OTHER|Genome sequencing of fecal samples|Fecal samples will be collected and then frozen in the morning pre-prandial after having fasted overnight. DNA will be separated and stored at -80°C in our center (Biobanc) until assayed. Sequencing will be performed with the most appropriate platform.
224198272|NCT06652126|OTHER|Microbiological examinations.|"* BMR testing by rectal swab (combined with nasal swab in some centers) on admission to the ICU and weekly as part of routine care.~* Microbiological samples (blood cultures, respiratory and urinary samples, etc.) as part of routine care at the request of the clinicians in charge of the patient."
224198273|NCT02981667|OTHER|Exercise intensity|Participants were randomized to 1 or 2 exercise intensities, moderate or high (interval training).
224311065|NCT06633159|DEVICE|MitraClip|surgical intervention to correct mitral regurgitation by percutaneous transcatheter implantation of the MitraClip G4 clip on the mitral valve leaflets
224311066|NCT00819637|DRUG|arformoterol (RR formoterol)|"Group 1 will receive nebulized arformoterol 15 ug every 20 minutes for 3 doses.~Group 2 will receive nebulized arformoterol 15 ug first dose and then placebo every 20 minutes for 2 doses."
224311067|NCT00819637|DRUG|placebo|Group 2 will receive nebulized arformoterol 15 ug first dose and then placebo every 20 minutes for 2 doses.
224311068|NCT00819637|DRUG|levalbuterol|Group 3 will receive nebulized levalbuterol 1.25 mg every 20 minutes for 3 doses.
224311069|NCT03150407|DEVICE|VR101 Device (Efficacy)|Self-insertion of VR101 Device for 7 days, followed by replacement with a fresh VR101Device, until 4 each Devices have been used for 7 days each, with total consecutive device use equal to 28 days
224311070|NCT03150407|OTHER|Sham Control Ring|Self-insertion of Sham Ring for 7 days, followed by replacement with a fresh Sham Ring, until 4 each Sham Rings have been used for 7 days each, with total consecutive Sham use equal to 28 days
223506919|NCT00625729|DRUG|fludarabine phosphate|Day -6 through day -2, 25 mg/m\^2 intravenous (IV)
223506920|NCT03705611|DIAGNOSTIC_TEST|HIV self-testing only|Partners will be asked to self-test for HIV following receipt of the test kit from their sexual contact at home or in the community. They will also get information about the partner's clinic -- an HIV testing service room dedicated to providing HIV testing, confirmatory HIV testing, and referral to HIV treatment and prevention services including couples counselling.
223506921|NCT03705611|BEHAVIORAL|HIV self-testing secondary accuracy|A monetary incentive provided conditional on clinic attendance and fulfillment of secondary accuracy procedures such as undergoing on spot finger prick rapid HIV testing
223506922|NCT01578720|DRUG|EYLEA (Aflibercept) intravitreal injection|Intravitreal Injection once every 8 weeks with 3 initial monthly doses
223506923|NCT01047397|DRUG|1278863A|25mg, 50mg, 100mg
223506924|NCT01047397|DRUG|Placebo|matching placebo
223506925|NCT04844346|DIETARY_SUPPLEMENT|Plant stanol mini drinks|Oat milk based mini drinks (100 mL) containing 2g plant stanols each (delivered as plant stanol esters).
223506926|NCT04844346|DIETARY_SUPPLEMENT|Placebo mini drinks|Oat milk based mini drinks (100 mL) without added plant stanols (delivered as plant stanol esters).
223506927|NCT04844346|BIOLOGICAL|COVID-19 vaccine|First dose of one of the COVID-19 vaccines. Participants have to wait until they are invited to receive the vaccine by the government; this study does not interfere with national planning of the vaccines.
223506928|NCT04055389|DRUG|Antithrombin III|"Patients with reversal of flow or sluggish flow in the main portal vein (\<15 cm/s by Doppler ultrasound exam) will be enrolled and randomized to either weekly infusions of AT-III (half-life \~4 days) at a weight-based dosage according to the following formula:~\[Desired level of AT (100%) - Subject level of AT (%)\] \* subject weight (kg) 1.4~or placebo for 24 weeks of therapy."
223506929|NCT04055389|OTHER|Placebo|No study drug
223506930|NCT06059079|OTHER|No Intervention|No Intervention
223506931|NCT04560309|DRUG|L-alanyl-L-glutamine dipeptide|Intravenous infusion of 0.5 mg/kgbw L-alanyl-L-glutamine dipeptide diluted in normal saline to volume of 500 mL, started after induction of anesthesia for 24 hours.
223506932|NCT04560309|DRUG|Placebo|Intravenous infusion of 500 mL normal saline, started after induction of anesthesia for 24 hours.
223506933|NCT04146909|DIAGNOSTIC_TEST|Hyperinsulinemic-euglycemic clamp|After an overnight fast and an equilibration period lasting 2 hours, the 2-step euglycemic-hyperinsulinemic clamp study will be performed. A primed-continuous infusion of regular insulin will be given at 8 mU/(m2 × min) during the first 2 hours, and increased to 40 mU/(m2 × min) for the subsequent 2 hours. Plasma glucose levels will be measured every 5 min, and a variable glucose infusion will be initiated to maintain levels at ∼90 mg/dl. Plasma samples will be drawn at baseline and throughout the infusion period for measurement of isotope enrichment, insulin, NEFA, glycerol turnover, and additional hormones which may be altered with lactation. Approximately 160 mL of blood will be drawn at this visit.
223506934|NCT05085405|BEHAVIORAL|Clinician notification|"An anticoagulation clinic nurse sends a templated letter to the patient's clinician and identifies the patient as high risk for upper GI bleeding, summarizes options for medication optimization (e.g., discontinuation of antiplatelet therapy or initiation of a proton pump inhibitor for gastroprotection), provides a link to guidance on evidence-based use of antiplatelet therapy, and asks that the clinician manage any medication changes.~In this arm, patients receive no additional interventions beyond that provided during treatment as usual."
223506935|NCT05085405|BEHAVIORAL|Clinician Notification with Nurse Facilitation|"An anticoagulation clinic nurse sends an individualized letter to the patient's clinician which identifies the patient as high risk for upper GI bleeding and summarizes options for medication optimization (e.g., discontinuation of antiplatelet therapy or initiation of a proton pump inhibitor for gastroprotection), but in addition includes a summary of the patient's history of atherosclerotic cardiovascular disease and a concise guidance summary on appropriate use of antiplatelet therapy for relevant indications. The anticoagulation nurse will assist with order entry for any new medications and also provide education on medication changes to the patient upon request by the clinician.~In this arm, patients receive no additional interventions beyond that provided during treatment as usual."
223597254|NCT01487265|DRUG|BKM120 and Erlotinib|BKM120 and Erlotinib will be given once daily. Erlotinib 100 mg PO will be administered. During Cycle 1-Week 1 all patients will receive 80 mg PO daily BKM120. After the first week of Cycle 1, the dose of BKM120 will escalate to 100 mg PO daily and treatment will continue as long as there are no unexpected or prohibitive toxicities, or disease progression.
223597255|NCT05987696|DRUG|CD33/CLL1 dual CAR-NK cell|NK cell therapy
223597256|NCT05987696|DRUG|Cyclophosphamid|Lympho-conditioning Agent
223597257|NCT05987696|DRUG|Fludarabine|Lympho-conditioning Agent
223597258|NCT05987696|DRUG|Cytarabine|Lympho-conditioning Agent
223597259|NCT05987696|DRUG|CD33 CAR-NK cell|NK cell therapy
223597260|NCT05987696|DRUG|super NK cell|NK cell therapy
224198274|NCT01388101|DEVICE|Electrosensing antibody probing system (e- Ab sensor)|Electrosensing antibody probing system (e- Ab sensor), which was developed for the rapid and sensitive detection of hapten, proteins, or viral antigen in medical samples, will be used for analyzing the interaction kinetics between specific anti- LECT2 and its antigen (LECT2 with liver cancer) present in the specimens of patients with liver cancer. The system incorporates the use of engineered semiconductive antibodies or virus in vertical and lateral chip (eAbchip) or lateral flow through (eAbsignal) formats. In electrosensing antibody probing, semiconductive antibodies are bound as a suitable electrosensing probe, which specifically and selectively binds targeted molecules (i.e. specific LECT2) in the test specimens.
223597261|NCT04995211|DEVICE|Assessment of resting energy expenditure|We will assess the resting metabolic rate and respiratory exchange ratio of twenty healthy adults, with every metabolic cart on two days in the morning. The assessment will last 30 minutes on each metabolic cart, with 15-minute breaks between measurements. The order of the metabolic carts will be randomly selected and replicated the second day.
224198275|NCT06002425|OTHER|Clinician-Directed Treatment Plan|In this approach, clinicians do not employ any technological assistance and rely solely on their professional expertise and experience to formulate treatment plans for participants.
224198276|NCT06002425|OTHER|ChatGPT-Assisted Treatment Plan|In this approach, clinicians utilize the ChatGPT technological tool, formulating treatment plans for participants based on its suggestions and their own professional expertise.
224198277|NCT03823859|DIAGNOSTIC_TEST|Indirect calorimetry|Resting energy expenditure
224198278|NCT03823859|DIAGNOSTIC_TEST|Dual energy X-ray Absorptiometry (DXA)|Body composition
224198279|NCT03823859|DIAGNOSTIC_TEST|Blood sampling|fT4, fT3, TSH, HDL, LDL, triglycerides, cholesterol, HbA1c, Glucose Thyroid panel
224198280|NCT02264509|PROCEDURE|Ankle-Brachial index|The only procedure to be performed is the measurement of ABI for the diagnosis of arterial insufficiency.
224198281|NCT04356196|DRUG|Verapamil|Verapamil is a phenylalkylamine calcium channel blocker used in the treatment of high blood pressure, heart arrhythmias, and angina
224198282|NCT04356196|DRUG|Bisoprolol|Bisoprolol is a cardioselective β1-adrenergic blocking agent used to treat high blood pressure.
224198283|NCT04356196|DRUG|Placebo oral tablet|Placebo oral tablet
224198284|NCT04020614|OTHER|Survey|A survey with 13 questions will be applied to the patients
223597262|NCT04311125|PROCEDURE|Mini posterior approach Total Hip Replacement|Total hip replacement in patients suffering from hip osteoarthritis using the mini posterior approach
223597263|NCT04311125|PROCEDURE|Anterior approach total hip replacement without a traction table|Mini Anterior approach total hip replacement in patients suffering from hip osteoarthritis without the aid of a traction table
223597264|NCT04311125|PROCEDURE|Anterior approach total hip replacement with a traction table|Mini Anterior approach total hip replacement in patients suffering from hip osteoarthritis with the aid of a traction table
224198285|NCT00669110|DRUG|Desvenlafaxine Succinate Sustained-Release Tablets (DVS SR)|"* tablet~* subjects randomly assigned to 10-200 mg/day by age group~* 6 month treatment period(\~182 days)"
224198286|NCT06566235|BEHAVIORAL|Culturally adapted DBT-A-ST group|"The culturally adapted DBT-A-ST consists of 15 weekly group sessions, each lasting 120 minutes, including a 10-minute break. It maintains the core elements of standard DBT-A, including its philosophical foundation and treatment strategies.~Therapists focus on teaching DBT skills through various methods such as modeling, structured behavioral rehearsals, and feedback. Each session begins with a 40-minute group mindfulness exercise and homework review, followed by 60 minutes dedicated to skill-specific didactics and experiential activities, concluding with a 10-minute homework assignment. Two group leaders facilitate the sessions, and participants track their skill usage daily with diary cards, which are reviewed weekly."
224198287|NCT06566235|BEHAVIORAL|Activities-based support group (ASG)|ASG, based on principles of client-centered supportive therapy, is widely used by occupational therapists in mental health settings. ASG therapists aim to foster a sense of belongingness, maintain unconditional positive regard, provide empathy, psychoeducational and a treatment structure. Two group leaders held the sessions, teaching DBT skills and using cognitive behavioral strategies are prohibited. Each session starts with a review of their experiences over the last week (30 min), a support-building activity (30 min), and ends with an open group discussion about topics participants choose each week (50 min). For homework, participants will be asked to think about issues discussed and to track daily social support on diary cards.
224198288|NCT01766141|OTHER|Spinal manipulation|Spinal manipulation will consist of a single high velocity low amplitude thrust to a hypomobile vertebral segment determined by the treating clinician to contribute to the problem.
224198289|NCT04839835|OTHER|waiting room enriched with music, paintings and artificial plants|waiting room enriched with music, paintings and artificial plants
224198290|NCT04846075|BEHAVIORAL|Ramadan fasting, praying, and welfare for poor|Abstaining from food, drink, smoking, and sexual activity duirng daytime; ritualistic praying at specific time of a day for five or more times; volunteering for communities or donation
224198291|NCT03037918|DIETARY_SUPPLEMENT|Yakult light|A fermented milk drink containing the probiotic Lactobacillus casei Shirota
224198292|NCT01870921|DRUG|Ticagrelor|90mg/tablet, 1 tablet bid
224198293|NCT01590537|DRUG|Levonorgestrel (Mirena, BAY86-5028)|intrauterine system containing 52 mg levonorgestrel, with daily release of 20 mcg levonorgestrel
223597265|NCT02184858|DRUG|lisinopril, ACE-inhibitor|Lisinopril 0.1mg/kg/d, titration with + 0.1mg/kg/d. Max; daily dose: 0.4mg/kg. CAVE: dose reduction in case of renal impairment
223597266|NCT01992835|OTHER|Grass pollen allergen extract|Each subject will be challenged with a grass pollen allergen extract and with placebo.
223597267|NCT01992835|OTHER|placebo|
223597268|NCT02583295|BEHAVIORAL|Music sound|The recorded preferred songs or music (commercially available) listened by CD player connected to the patient ears before induction of anesthesia and continued during intra operative period
224198294|NCT01590537|DEVICE|Copper IUD|Copper device, inserted intrauterine
224198295|NCT03659032|PROCEDURE|Pediatric Manual Therapy|
223748057|NCT05926011|DEVICE|RGn600 Sham|RGn600 inactivated
223748058|NCT06271967|DEVICE|TactiFlex™ Ablation Catheter Sensor Enabled™|Pulsed field ablation (PFA)/radiofrequency (RF) ablation with the TactiFlex™ Ablation Catheter Sensor Enabled™
224198296|NCT03659032|PROCEDURE|Educational Physical Therapy|
223597269|NCT02583295|BEHAVIORAL|Maternal sound|The recorded maternal voice (while they are singing the most popular songs their children like or telling a story to help their children to sleep) listened by CD player connected to the patient ears before induction of anesthesia and continued during intra operative period
223597270|NCT05523050|PROCEDURE|active surgical intervention|two kinds: one is colostomy, and the other one is colonic exclusion
223748059|NCT07030465|DEVICE|The press needle, antihistamine, and moisturizer therapy|Device: Press Needle (PN) PN is applied unilaterally on acupoints LI11, SP10, ST36, and SP6 alternately. It consists of an adhesive patch with a small sterile needle retained for 3-4 days before replacement. This procedure is repeated over a 4-week period. Needle sizes is 0.22 × 1.5 mm), and all procedures follow standard aseptic protocols. PN provides prolonged stimulation with cumulative effects in a minimally invasive manner. Participants continue their routine hemodialysis and conventional treatments for CKD-associated pruritus (CKDaP).
223748060|NCT07030465|DEVICE|The sham press needle, antihistamine and moisturizer therapy|Sham PN uses adhesive patches without needles, applied to the same acupoints (LI11, SP10, ST36, and SP6) with the same retention schedule (3-4 days over 4 weeks) as the intervention group. All procedures, including placement and instructions, are performed identically to maintain blinding. There is no skin penetration or real acupoint stimulation. Participants continue their routine hemodialysis and conventional treatments for CKDaP.
223748061|NCT05737927|DRUG|Glucose 8 g coated beads (47% w/w)|After an overnight fasting of about 10 hours, the subjects were administered 8 g glucose of the coated Glucose beads formulation starting at 8:00 (time 0; administration time was staggered beginning at 8:00 for the first group of subjects) in sitting position.
224198297|NCT04688502|OTHER|High intensity interval training|High intensity interval training: 6 sets x 8 bench press, 10 pull-ups, and maximal number of box jumps (each set lasting 60 sec, with 4 minutes rest between sets)
223597271|NCT04878965|DEVICE|Smartwatch|Smartwatch apparatus to measure strong emotions (e.g., anxiety)
223597272|NCT00965575|DRUG|Melatonin|Sustained release formula (Brand: Jigsaw); dosage will be 9mg for all subjects. Taken 30 minutes prior to bedtime for four weeks.
224198298|NCT04688502|OTHER|Continuous exercise training|5 pull-ups, 10 push-ups, and 15 body-weight squats, repeated for 30 minutes
224198299|NCT04127994|OTHER|Comparing 3 versus 6 meals in type 2 diabetes patients|We will compare a 3 meals regimen versus a 6 meal regimen in patients with type 2 diabetes and overweight or obesity, to analyze which of the regimens have better outcomes in glycemic variability
224198300|NCT05209139|DIETARY_SUPPLEMENT|Beetroot juice|One serving 70 mL of beetroot juice (6.4 mmol of NO3-; Beet-It-Pro Elite Shot, James White Drinks Ltd., Ipswich, UK) 3 h before initiating the testing session.
224198301|NCT05209139|DIETARY_SUPPLEMENT|Beetroot juice placebo|One serving 70 mL of beetroot juice placebo (0.04 mmol of NO3-; Beet-It-Pro Elite Shot, James White Drinks Ltd., Ipswich, UK) 3 h before initiating the testing session.
224198302|NCT05527288|DRUG|Drug: [18F]florbetaben|All eligible patients will receive a single administration of the imaging agent \[18F\]florbetaben at a radioactive dose of 300 MBq.
224198303|NCT04762771|DRUG|Colchicine|"Colchicine dosing = 0.6 mg bid x 30 days Decrease dose to 0.3-0.6 mg daily or every other day in setting of gastrointestinal intolerance (nausea, diarrhea, emesis, abdominal discomfort) Decrease dose to 0.6 mg daily in the setting of weak or moderate CYP3A4 inhibitor Decrease dose to 0.3 mg daily in the setting of strong CYP3A4, P-glycoprotein inhibitors, or protease inhibitors Decrease dose to 0.3 mg daily in the setting of chronic kidney disease (CKD) stage ≥ 4 (CrCl ≤ 30 ml/min) or liver failure (aspartate aminotransferase /alanine aminotransferase \> 3x normal).~Decrease dose to 0.6 mg every 14 days in patients with end stage renal disease (ESRD) or requiring dialysis Route of Administration: oral"
224198304|NCT06416527|DEVICE|Photobiomodulation (Experimental)|The photobiomodulation with a diode emitting light (LED) cluster device will be positioned on the cervical region of each patient (for 10 minutes each).
224311071|NCT03150407|DEVICE|VR101 Device (Safety)|Following the 4-week use of shams and a 3-week washout period participants randomized to the Safety Study will use a new VR101 device every 7 days for 13 consecutive weeks.
224311072|NCT02186288|OTHER|High-flow nasal cannula oxygen|
224311073|NCT05810688|OTHER|eating rehabilitation training|The experimental group will receive eating rehabilitation training, including oral care, saliva gland massage, oral exercise, feeding strategy, and swallowing skill education.
224311074|NCT05950178|DIAGNOSTIC_TEST|Apnea test under high-flow oxygenation|Apnea test under high-flow oxygenation in patients with a confirmed clinical brain death by a standard apnea test (under standard oxygen therapy)
224311075|NCT02975778|DEVICE|Pain Monitor™|Pain measured by Pain Monitor™
224311076|NCT01165528|PROCEDURE|type of mechanical ventilation|patients are randomized to receive one of the two types of mechanical ventilation for ARDS
224311077|NCT05373628|DIAGNOSTIC_TEST|Gradient and pulse imaging|A novel diffusion-based magnetic resonance imaging method
223748062|NCT05737927|DRUG|Glucose 12 g coated beads (47% w/w)|After an overnight fasting of about 10 hours, the subjects were administered 12 g glucose of the coated Glucose beads formulation starting at 8:00 (time 0; administration time was staggered beginning at 8:00 for the first group of subjects) in sitting position.
223748063|NCT05737927|DRUG|Glucose 16 g coated beads (47% w/w)|After an overnight fasting of about 10 hours, the subjects were administered 16 g glucose of the coated Glucose beads formulation starting at 8:00 (time 0; administration time was staggered beginning at 8:00 for the first group of subjects) in sitting position.
223748064|NCT05737927|DRUG|Glucose 12 g uncoated beads|After an overnight fasting of about 10 hours, the subjects were administered the uncoated Glucose beads formulation containing 12 g glucose starting at 8:00 (time 0; administration time was staggered beginning at 8:00 for the first group of subjects) in sitting position.
224311078|NCT00423371|DEVICE|sodium hyaluronate|EUFLEXXA™ is supplied in a single-dose syringe containing 20 mg/2 ml of 1% sodium hyaluronate. Each subject will receive three single dose injections into the target first CMC joint on study weeks 0, 2 and 4.
224311079|NCT00423371|DEVICE|placebo|Placebo is supplied in a disposable prefilled glass syringe. Each single-dose syringe will contain 2 mL of phosphate buffered saline. Each subject will receive three single dose injections into the target first CMC joint on study weeks 0, 2 and 4.
223597273|NCT00965575|DRUG|Placebos|Placebo. Taken 30 minutes prior to bedtime for four weeks.
223597274|NCT02529163|OTHER|Late-life Schizophrenia ICP|"The ICP medication algorithms first trial begins with:~* Risperidone titrated to a max dose~Failure to Risperidone will lead to a second trial with either:~* Quetiapine OR Aripiprazole~If subject refuses or if this trial does not work, then offer:~* Ziprasidone or Loxapine~Failure of 2 anti-psychotic trials results in:~* Clozapine trial~If subject refuses a Clozapine trial then:~* Olanzapine offered~titrations occur over 33-36 day period (inpatient) or 12 week period (out patient) with each 0.5 mg titration after the target dose requiring a CGI-E~If compliance is an issue then a depot preparation:~* Paliperidone~* Risperidone~* Flupentixol~* Aripiprazole~Physicians will be prompted for non-pharmacological interventions"
223597275|NCT02529163|OTHER|Treatment as Usual|"The TAU group will be offered non-pharmacological interventions such as (but not limited to):~* metabolic monitoring~* skin hygiene~* pain management~* nutritional counseling~* family counselling~* Financial/housing support~* Group CBT (Cognitive Behavioral Therapy)~Physicians treating this group will use their own discretion as they will not be prompted like the ICP group.~Pharmacological interventions contain anti-psychotic medication selected at the discretion of the treating physician provided it fall under the current standard of care such as:~* Risperidone~* Aripiprazole~* Quetiapine~* Olanzapine~* Paliperidone~* Clozapine~* Ziprasidone~Max dosing and the time to reach the target dose is done at the discretion of the treating physician."
223748065|NCT05737927|DRUG|Glucose 12 g coated beads (60% w/w)|After an overnight fasting of about 10 hours, the subjects were administered the coated Glucose beads formulation (60 % w/w glucose/bead; 12 g glucose) starting at 8:00 (time 0; administration time was staggered beginning at 8:00 for the first group of subjects) in sitting position.
223748066|NCT05737927|DRUG|Glucose 12 g coated beads (47% w/w)|After an overnight fasting of at least 10 hours, the subjects were administered the new developed Glucose beads formulation containing 12 g glucose starting at 8:00 (time 0; administration time was staggered beginning at 8:00 for the first group of subjects) in sitting position. Treatment duration: Day 1 - Day 4
223748067|NCT06879340|DRUG|DuoCAR20.19.22-D95|Patient derived autologous T cells, lentiviral transduced to generate, using the Miltenyi CliniMACS Prodigy® closed transduction system, a Duo-CAR-T cells targeting cell surface antigens CD19/20/22.
223748068|NCT06879340|DRUG|Fludarabine (Conditional therapy)|Lymphodepletion chemotherapy
224198305|NCT06416527|PROCEDURE|Pompage Technique (manual therapy)|To perform cervical Pompage the patient lies comfortably on their back or sits upright. The therapist locates the target area on the cervical spine. Using gentle pressure, the therapist applies traction to the cervical spine, stretching the muscles and fascia. The traction is held for 20 seconds. The therapist then releases the traction, allowing the cervical spine to return to its neutral position. This process will be repeated 3 times, with adjustments made based on the patient's response and comfort level.
223597276|NCT02388334|OTHER|to develop a standardized questionnaire|"to develop, from the caregivers' point of view, a standardized questionnaire evaluating 1) their quality of life (QOL) as related to the disease of the assisted and 2) their expectations concerning the global quality of professional management (care, coordination, information...).~The development of this standardized tool will also :~* identify the specific support needs of the caregivers~* study the links between the quality of care as perceived by the professionals, patients and caregivers~* identify the characteristics of the caregivers (status) and patients (disease type, disease-modifying drug (DMD) initiation, disease duration) associated with questionnaire results."
223597277|NCT02451020|OTHER|Altitude exposure|Participants will stay for 3 weeks at an altitude of 3200 m
223597278|NCT01959841|DRUG|ASP2151|200 mg once daily or 400 mg once daily
223597279|NCT01959841|DRUG|valaciclovir|1000 mg three times daily
223597280|NCT03234413|DRUG|Botulinum toxin type A|Botulinum toxin type A
223597281|NCT04579159|DEVICE|Preventicus heartbeat app in combination with wearables|CE certified devices
223597282|NCT04270084|BEHAVIORAL|Alive-Family|All participants receive lifestyle modification through use of m-health app
223597283|NCT00780416|DRUG|MP-424|750 mg every 8 hours for 12 weeks
224311080|NCT03369197|DEVICE|Nasal Mask|Nasal anesthesia mask which covers the nose and attaches to the anesthesia circuit, allowing for variable positive pressure by setting the pop-off valve
224311081|NCT03369197|DEVICE|Control: Nasal Cannula|Nasal cannula as per usual care
224311082|NCT03421730|COMBINATION_PRODUCT|VR647 Inhalation Suspension (budesonide) 1 mg/2 mL delivered by the VR647 Inhalation System|The VR647 Inhalation System consists of the VR647 Inhalation System 1 control unit, a VR647 nebulizer handset, a mouthpiece and VR647 Smart Cards designed specifically for this trial.
223597284|NCT00780416|DRUG|Ribavirin|600 - 1000 mg/day based on body weight for 24 weeks
223597285|NCT00780416|DRUG|Peginterferon Alfa-2b|1.5 mcg/kg/week for 24 weeks
223597286|NCT00780416|DRUG|Ribavirin|600 - 1000 mg/day based on body weight for 48 weeks
223597287|NCT00780416|DRUG|Peginterferon Alfa-2b|1.5 mcg/kg/week for 48 weeks
223597288|NCT03849222|PROCEDURE|Apexification|
223748069|NCT06879340|DRUG|Cyclophosphamide (Conditional therapy)|Lymphodepletion chemotherapy
223748070|NCT05781698|DRUG|Mesalamine|mesalamine is the cornerstone used for the treatment of mild to moderate ulcerative colitis
223748071|NCT05781698|DRUG|Fenofibrate|Fibrates, which are specific pharmacological agonists of PPARα, have been widely used in the treatment for hypercholesterolemia and hypertriglyceridemia
223748072|NCT06710340|DIETARY_SUPPLEMENT|Nuts in the first meeting|30g of walnuts
223748073|NCT06710340|OTHER|Nuts in the second meeting|30g of walnuts
223748074|NCT07036003|DRUG|Somatropin (recombinant human growth hormone)|Study participants will deliver Somatropin via self-administered subcutaneous injection into the abdomen or gluteal region once per day for six weeks at a dose of 0.5mg/day per body surface area (0.5mg/m2/day).
223748075|NCT07036003|DRUG|bacteriostatic saline placebo|Study participants will deliver bacteriostatic saline via self-administered subcutaneous injection into the abdomen or gluteal region once per day for six weeks in an identical delivery device to the experimental arm.
224198306|NCT06416527|DEVICE|Photobiomodulation (Placebo)|The photobiomodulation with a diode emitting light (LED) cluster device will be positioned on the cervical region of each patient (for 10 minutes each) with the device turned off (inactive), simulating the time with a recorded beep sound.
224311083|NCT03421730|COMBINATION_PRODUCT|1 mg/2 mL Pulmicort Respules delivered by a conventional jet nebulizer|Commercial Pulmicort Respules (budesonide inhalation suspension 1 mg/2 mL) delivered by a conventional jet nebulizer operated to sputtering.
223597289|NCT03849222|DRUG|MTA|
223748076|NCT07036445|PROCEDURE|Epidural Steroid Injection|Intervention consists of interlaminar CT guided epidural steroid injection
224198307|NCT02969473|DRUG|Docetaxel|"Radiotherapy: All patients underwent conventional radiotherapy, 1.8-2.0 Gy per fraction and 5 fractions per week. The prescribed dose was 60-64 Gy to PTV1 and 50 Gy to PTV2. Patients received either three-dimensional conformal radiotherapy (3D-CRT) or intensity-modulated radiation therapy (IMRT). 3D-CRT treatment plans were calculated by Pinnacle planning system and IMRT treatment plans were calculated by Monacle planning system. All patients were treated with a 6-MV or 8-MV linear accelerator.~Chemotherapy: All patients received two cycles of chemotherapy concurrently with radiotherapy. Patients assigned to the DP group received two cycles of DP regimen (docetaxel 60 mg/m2 delivered on day 1 and cisplatin 80 mg/m2 delivered on day 1) at a 3-week interval. In cases of grade 4 hematologic toxicity or severe non-hematologic toxicities, dose adjustment was performed in the subsequent chemotherapy cycle."
224198308|NCT02969473|DRUG|Fluorouracil|"Radiotherapy: All patients underwent conventional radiotherapy, 1.8-2.0 Gy per fraction and 5 fractions per week. The prescribed dose was 60-64 Gy to PTV1 and 50 Gy to PTV2. Patients received either three-dimensional conformal radiotherapy (3D-CRT) or intensity-modulated radiation therapy (IMRT). 3D-CRT treatment plans were calculated by Pinnacle planning system and IMRT treatment plans were calculated by Monacle planning system. All patients were treated with a 6-MV or 8-MV linear accelerator.~Chemotherapy: All patients received two cycles of chemotherapy concurrently with radiotherapy. Patients assigned to the PF group received two cycles of PF regimen (cisplatin 80 mg/m2 delivered on day 1 and 5-FU 1000 mg/m2 continuous infusion over 24 hours daily on days 1-4) at a 3-week interval. In cases of grade 4 hematologic toxicity or severe non-hematologic toxicities, dose adjustment was performed in the subsequent chemotherapy cycle."
223597290|NCT03849222|DRUG|Ca(OH)2|
223597291|NCT03849222|DRUG|Apical matrix|collagen membrane (Biocollagen; Bioteck:Turin, Italy)
223597292|NCT04340544|DRUG|Hydroxychloroquine|Hydroxychloroquine Sulfate is an anti-malarial and anti-rheumatic drug and seems to be a potential candidate for the treatment of COVID-19 since it is able to block virus infection by increasing the endosomal pH, required for virus/cell fusion, it affects the activation of p38 mitogen-activated protein kinase (MAPK), involved in the replication of HCoV-229E and can interfere with the terminal glycosylation of ACE2, thus inhibiting SARS-CoV-2 infection.
224198309|NCT04706520|DIETARY_SUPPLEMENT|Study Beverage Consumption|All participants will follow the same intervention as the study staff is blinded in addition to the participant. Randomized participants will be asked to consume 2 bottles per day of a study beverage for 12 weeks. Compliance checks will occur remotely by having participants send photos of their bottles each day and weekly phone/video calls with intervention staff. Participants will be asked to keep their diet and activity level consistent throughout the 12 weeks.
224198310|NCT06568666|OTHER|Lumbar spinal manipulation|Lumbar spinal manipulation was performed in the lateral recumbent position and HVLA thrust was applied to the segment where dysfunction was detected. The spinal process was determined as the contact point and the direction of HVLA thrust was from posterior to anterior.
223597293|NCT04340544|DRUG|Placebo|Placebo capsules
223597294|NCT04768543|DEVICE|Upper airway stimulation (Inspire Medical Systems, Inc.)|phasic hypoglossal nerve stimulation device
223597295|NCT02005588|DRUG|amino acid chelated iron|the drug will be given to pregnant women 14-18 weeks' gestation who prove to have iron deficiency anemia. the dose will be given according to hemoglobin level. for hemoglobin 7-9 g/dl, 2 capsules will be given daily. for hemoglobin 9.1-11 g/dl, 1 capsule will be given daily. complete blood picture and serum ferritin will be measured at 22-23, 29-30 and 36-37 weeks' gestation.
223597296|NCT02005588|DRUG|iron salt (ferrous fumarate)|this drug will be given to pregnant women 14-18 weeks' gestation with iron deficiency anemia. the dose will be given according to hemoglobin level. for hemoglobin 7-9 g/dl, 2 capsules will be given daily, and for hemoglobin 9.1-11 g/dl, 1 capsule will be given daily. complete blood picture and serum ferritin will be measured at 22-23, 29-30 and 36-37 weeks' gestation.
223597297|NCT02255084|BEHAVIORAL|Group 1 remove self sample kit at gp consulting room or perform pap smear|"Selected general practitioners are briefly informed about the study and they receive a package of kits for vaginal self-sampling.~Selected women receive a mail inviting them either to remove a kit for vaginal self-sampling at their general practitioner's consulting room or to perform a pap smear. When women choose the vaginal self-sampling, a HPV test is performed on the sample in a virology laboratory."
223597298|NCT02255084|BEHAVIORAL|Group 2 perform self sample at home or pap smear|"Selected general practitioners are briefly informed about the study. Selected women receive a mail inviting them either to perform a vaginal self sampling at their home (with the kit provided) or to perform a pap smear.~When women choose the vaginal self-sampling, a HPV test is performed on the sample in a virology laboratory."
223597299|NCT04653194|DRUG|Biktarvy|Combination single tablet anti-retroviral therapy: bictegravir 50mg/emtricitabine 200mg/tenofovir alafenamide 25mg
223597300|NCT04653194|DRUG|Symtuza|Combination single tablet anti-retroviral therapy: darunavir 800mg/cobicistat 150mg/emtricitabine 200mg/tenofovir alafenamide 10mg
223597301|NCT00666224|DRUG|Glatiramer Acetate (DB)|Double blind period (DB): glatiramer acetate (GA) by subcutaneous injection, 20mg, once daily, for up to 36 months or until conversion to clinically definite multiple sclerosis (CDMS).
223748077|NCT07036445|PROCEDURE|Epidural platelet-rich plasma injection|Intervention consists of interlaminar CT guided epidural platelet-rich plasma injection after recovery of plasma by blood sampling and centrifugation
223748078|NCT07038733|PROCEDURE|Peripheral Blood Sample for Immune Analysis|A peripheral blood sample will be collected at the time of surgery.
223748079|NCT07038733|PROCEDURE|Tumor Sample for Analysis|Extra tumor which is left over following clinical diagnoses will be collected.
223748080|NCT07038733|PROCEDURE|Adjacent non-malignant kidney for analysis|Extra normal tissue which is left over following clinical diagnoses will be collected.
223748081|NCT07038733|PROCEDURE|Draining lymph node(s) for analysis|Draining lymph nodes which have been identified by the surgeon visually, potentially using a tracer (injection of up to 5mg of ICG into the peritumor kidney) will be collected.
223597302|NCT00666224|DRUG|Placebo|Double blind period (DB): subcutaneous injection of placebo, once daily, for up to 36 months or until conversion to CDMS
223597303|NCT00666224|DRUG|Glatiramer Acetate (OL)|Open label period (OL): glatiramer acetate (GA), 20 mg, subcutaneous injection, once daily, given for up to an additional 24 months.
223597304|NCT05498519|DRUG|SY-4798|FGFR4 selective inhibitor
223597305|NCT03466853|DIAGNOSTIC_TEST|Clinical assessment of nutritional status (CANS) score|Systematized inspection and estimation of loss of SC tissues and muscles of nine superficial physical parameters including hair and buccal fat in the cheeks, chin and neck, arms, back, inter or subscapular skin, buttocks, legs, chest, and abdominal wall skin. These signs will be rated from 1 (worst, severe FM) to 4 (best, well nourished), and the highest and lowest total scores are 36 and 9, 3respectively. A total score of \<25 is considered as fetal malnutrition.
223597306|NCT03466853|DIAGNOSTIC_TEST|Anthropometric indices|weight, length and head circumference
223748082|NCT07038733|PROCEDURE|Regional non-draining lymph node(s) for analysis|Regional lymph nodes which have been deemed as non-draining by the surgeon will be collected.
223748083|NCT07037901|DRUG|IMG-007|Participants will receive IMG-007 subcutaneously.
223748084|NCT07037901|DRUG|Placebo|Participants will receive a placebo subcutaneously.
224198311|NCT06568666|OTHER|Sacroiliac joint manipulation|The participant lies on his/her side on the healthy side; the lower knee is in extension while the upper knee is flexed and placed in the popliteal fossa of the lower knee. The participant's hands are left free on the ribs at the lower level. The practitioner crosses the movement barrier with the stabilizing hand, allowing the tissues to relax. The practitioner performs HVLA thrust of the iliac bone into posterior or anterior rotation (in the opposite direction of dysfunction) with the stabilizing hand
224198312|NCT05620706|BIOLOGICAL|GPC3 CAR-T cells|patients treated with GPC3 CAR-T cells
224198313|NCT00693056|DRUG|Placebo|Placebo (w/o API)
224198314|NCT00693056|DRUG|RX-10100 5mg|5 mg/dose of RX-10100
224198315|NCT00693056|DRUG|RX-10100 10mg|10 mg/dose of RX-10100
224198316|NCT00693056|DRUG|RX-10100 15mg|15 mg/dose of RX-10100
224198317|NCT05148286|DRUG|Treatment|For the treatment group, 200cc of 20% human albumin with 15 cc per kg of crystalloid will be administered over 1\~2h for initial fluid resuscitation. The treating physicians can choose the type of fluid, such as balanced fluid or isotonic saline.
224198318|NCT05148286|DRUG|Placebo|For the control group, 30 cc per kg of crystalloid will be administered according to the usual practice. The treating physicians can choose the type of fluid, such as balanced fluid or isotonic saline.
224198319|NCT05581199|DRUG|Batoclimab 680 milligrams (mg) subcutaneous (SC) weekly|Batoclimab is a fully human anti-neonatal fragment crystallizable receptor (FcRn) monoclonal antibody
224198320|NCT05581199|DRUG|Batoclimab 340 mg SC weekly|Batoclimab is a fully human anti-neonatal fragment crystallizable receptor (FcRn) monoclonal antibody
224198321|NCT05581199|DRUG|Placebo|Matching placebo SC
224198322|NCT06544954|DIETARY_SUPPLEMENT|Freeze-dried grape powder|48 grams powder
223597307|NCT03466853|DIAGNOSTIC_TEST|Proportionality indices|MAC/HC ratio (Calculation for each infant and value will be plotted on and compared with a standard curve). Ponderal index . A PI \<2.2 is considered as malnutrition). Body mass index (BMI= weight (kg) / length2 (m). A BMI \<11.2 kg/m2 is considered as malnutrition)
223597308|NCT02678507|OTHER|Prescription Opioid Misuse and Abuse Questionnaire (POMAQ)|
223597309|NCT02032498|DRUG|Indocyanine Green|Superficial injection of ICG in combination with deep injection of 99mTc-HSA to evaluate the complementarity of the two techniques
223597310|NCT00654979|DEVICE|SafeFlo IVC Filter|SafeFlo IVC Filter
223597311|NCT02091765|BEHAVIORAL|Internet-based cognitive behavioral therapy.|
223597312|NCT01128192|DRUG|pasireotide|Pasireotide 600 μg (batch number Y050DE) or 900 μg bid (batch number Y1270908) for subcutaneous injection. Placebo (batch number Y069HC) for subcutaneous injection.
223597313|NCT01126944|DEVICE|heart mate II|left ventricular assist device
223597314|NCT03521141|DRUG|Nicotine patch|FDA-approved smoking cessation pharmacotherapy
223597315|NCT03521141|DRUG|Varenicline|FDA-approved smoking cessation pharmacotherapy
223748085|NCT06704347|BIOLOGICAL|XT-150|XT-150 is a small piece of plasmid DNA (genetic material) that produces a variant of the anti-inflammatory cytokine, Interleukin 10 (IL-10).
223748086|NCT06721091|DRUG|VNA-318|"Part 1 will consist of administration of VNA-318 at the doses of 5 mg to 180 mg in 5 successive cohorts.~Part 2 will consist of administration of VNA-318 in 3 successive cohorts. The doses will be selected based on safety and tolerability assessments, aw well as the observed PK and PD data from the SAD part.~For each SAD and MAD cohort, a sentinel group of 2 subjects will initially be randomized to receive VNA-318 or placebo (1:1 ratio)~Once PK suggests that the therapeutic dose has been reached in the SAD part, the SAD and MAD parts of the study could be run in parallel"
223748087|NCT06721091|DRUG|Placebo|"Part 1 (SAD) will consist of administration of matching placebo at the doses of 5 mg to 180 mg in 5 successive cohorts.~Part 2 will consist of administration of matching placebo in 3 successive cohorts. The doses will be selected based on safety and tolerability assessments, aw well as the observed PK and PD data from the SAD part.~For each SAD and MAD cohort, a sentinel group of 2 subjects will initially be randomized to receive VNA-318 or placebo (1:1 ratio)"
224198323|NCT06544954|OTHER|Placebo powder|48 grams powder
224198324|NCT06224413|OTHER|No Intervention|This is non-interventional study.
224198325|NCT04409509|BIOLOGICAL|Garadacimab, Factor XIIa Antagonist Monoclonal Antibody|Garadacimab, Factor XIIa Antagonist Monoclonal Antibody administered intravenously
224198326|NCT04409509|DRUG|Placebo|CSL312 diluent administered intravenously
224198327|NCT05160675|OTHER||No intervention
224198328|NCT02608827|DEVICE|Resperate®-InterCure Ltda|The device-guided breathing - Resperate®-InterCure Ltda, uses sound to guide and therefore reduce the respiration rate in individuals.
224198329|NCT02608827|OTHER|Music group (GC)|The patients in this arm will hear slow music - Music group (GC).
224198330|NCT06185140|OTHER|cardiac rehabilitation program|Cardiac rehabilitation program
224198331|NCT06185140|OTHER|TELEA platform|TELEA platform
224198332|NCT05159739|GENETIC|Blood Draw or Saliva/Cheek Cell Sample:|Collected samples will immediately undergo genetic analysis to determine the presence or absence of potential candidate genes responsible for the increased incidence of PJI.
223597316|NCT03521141|GENETIC|Nicotine metabolism|Information on nicotine metabolism will be used to inform selection of medication.
223597317|NCT03521141|GENETIC|Genetically-informed lung cancer risk score|This intervention uses information from a person's genes and smoking and family medical histories to estimate lung cancer risk compared to current smokers.
223597318|NCT03521141|BEHAVIORAL|"NCI Clearing the Air"|A booklet-led intervention designed by the NCI to support cessation at any stage of a quitter's journey, whether they are still thinking about quitting, have made the decision to quit, or have already taken steps to quit and just need help maintaining their new lifestyle.
223597319|NCT00239889|DRUG|Salmon calcitonin|
223597320|NCT05443256|DEVICE|Transcranial Magnetic Stimulation|Figure 8 coil stimulation
223597321|NCT03574883|DEVICE|tACS|tACS is a non-invasive stimulation technique that works by delivering a weak sinusoidally oscillating electrical current to the surface of the skull to entrain oscillations in the brain.
223597322|NCT03574883|DEVICE|tDCS|tDCS is a form of neuromodulation method where very low levels of constant current are delivered to specifically targeted areas of the brain
223597323|NCT03335774|DRUG|Hydrocortisone Acetate Suppository, 25 mg (Nivagen)|One (1) Hydrocortisone Acetate Suppository, 25 mg is inserted into the anal canal twice daily (morning and evening) for 2 weeks (14 days).
223748088|NCT06885073|DEVICE|CPMX2|CPMX2 - Non-invasive pressure estimation
223748089|NCT07048340|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|CBT-I intervention will include four 45-60 minute sessions with a clinician. The sessions will include CBT-I components such as sleep psychoeducation, bedtime routines and sleep hygiene, graduated exposure, cognitive restructuring, and SRT in one of the intervention groups. The protocol is based on previous studies of CBT-I for school-aged children.
223748090|NCT07048340|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia without SRT|This intervention will include four 45-60 minute sessions with a clinician. The sessions will include CBT-I components such as sleep psychoeducation, bedtime routines and sleep hygiene, graduated exposure, and cognitive restructuring. Sleep Restriction Therapy will not be included in the intervention. The protocol is based on previous studies that delivered CBT-I to school-aged children.
223748091|NCT06599580|BEHAVIORAL|Training caregivers to screen children for malnutrition relapse|Caregivers enrolled in the trial who are assigned to the two experimental arms, will be provided mid-upper arm circumference tapes and trained on how to screen their child for malnutrition relapse and asked to bring their child back to the clinic if relapse is detected.
223748092|NCT06599580|OTHER|Reduced follow-up schedule|Caregivers in one of the caregiver mid-upper arm circumference screening arms, will be asked to adhere to a reduced follow-up clinic visit schedule for when they bring their child to the clinic for planned visits. The standard of care includes monthly visits for the first 3 months post recovery, but those randomized to the reduced follow-up schedule arm, will not bring their child to the clinic for planned visits 1 month and 2 months after baseline.
223748093|NCT04292288|DIAGNOSTIC_TEST|Biochemical observational|no intervention - observational
223748094|NCT06887231|OTHER|VR+TENS|Patients will perform task-oriented movements in an immersive scenario while receiving congruent electrical stimulation. During each session, multiple games will be played, with the type and difficulty calibrated based on the patient's level of impairment.
223748095|NCT06887231|OTHER|Conventional rehabilitation|Patients will perform dose-matched conventional rehabilitation (aligned with the intervention group), which will include physiotherapy, occupational therapy, and physical therapy.
223748096|NCT01275495|BEHAVIORAL|Telephone Assessment and Skill-Building Kit (TASK II)|
223748097|NCT01275495|BEHAVIORAL|Information, Support, and Referral (ISR)|
223748098|NCT03442738|PROCEDURE|Endocuff group|Endocuff Vision cap on Standard colonoscope
223748099|NCT06742190|BIOLOGICAL|Empasiprubart|Intravenous infusion of empasiprubart
223748100|NCT06742190|BIOLOGICAL|IVIG (Intravenous Immunoglobulin)|Intravenous infusion of IVIg
223748101|NCT06742190|OTHER|Empasiprubart-placebo|A placebo resembling the empasiprubart treatment
223748102|NCT06742190|OTHER|IVIg-placebo|A placebo resembling the IVIg treatment
223597324|NCT03335774|DRUG|Placebo (Vehicle) Suppository (Nivagen)|One (1) Placebo (Vehicle) Suppository is inserted into the anal canal twice daily (morning and evening) for 2 weeks (14 days).
223597325|NCT04561258|BIOLOGICAL|AGT103-T|An autologous, genetically modified PBMC product enriched with HIV-specific and resistant CD4 T cells
223597326|NCT06140173|PROCEDURE|Low osmolar contrast|100 mL of 350 mg omnipaque will be administered via nasogastric tube
223748103|NCT06894225|DRUG|ACT001|Patients recruited and have signed informed consent will be initiated on ACT001 400mg twice a day. Treatment course will repeat every 28 days in the absence of disease progression or unacceptable toxicity
223748104|NCT06888505|DRUG|Dapagliflozin (Forxiga)|Participants in the dapagliflozin arm received dapagliflozin 10 mg tablets, administered orally once daily for 4 months, in addition to their standard anthracycline-based chemotherapy regimen. This treatment was given continuously throughout the chemotherapy period to evaluate its cardioprotective effects against anthracycline-induced cardiac toxicity.
223748105|NCT06888505|OTHER|Placebo|Participants in the control arm received a placebo tablet identical in appearance, dosage form, frequency, and duration to dapagliflozin, but containing no active ingredients. The placebo was administered orally once daily for 4 months alongside the participant's standard anthracycline-based chemotherapy regimen and served as the control to evaluate the cardioprotective efficacy of dapagliflozin.
223748106|NCT07049276|PROCEDURE|Index lymph node resection|The largest lymph node affected with melanoma
223597327|NCT06140173|PROCEDURE|Sterile water|100 mL of sterile water will be administered via nasogastric tube
223597328|NCT01078363|DRUG|ramipril|Use of a ACE ( angiotension converting enzyme) inhibitors post heart Transplant for Blood pressure control.
223597329|NCT01078363|DRUG|Placebo|Use of a placebo post heart Transplant for Blood pressure control.
223597330|NCT05423964|DIAGNOSTIC_TEST|AI use in Endoscopy Room|The use of AI versus no AI in comparing the detection of adenomas during Endoscopy procedures.
223597331|NCT05423964|OTHER|Non-AI use Standard of Care endoscopy room|Non-AI use in comparing the detection of adenomas during Endoscopy procedures.
223597332|NCT02312297|DRUG|Minocycline hydrochloride|extended release tablets 135 mg
223748107|NCT07049276|PROCEDURE|Therapeutic lymph node dissection|Removal of all nodes in the melanoma affected lymph node basin
223748108|NCT04369846|DRUG|GM-XANTHO onitment|Onitment application
223748109|NCT04369846|DRUG|Placebo onitment|Onitment application
223748110|NCT07059455|OTHER|Erector Spinae (ESP) Block with Bupivacaine (Marcaine®)|Under general anesthesia, patients in the ESP group will be positioned in the left or right lateral decubitus position, depending on the side of the surgical procedure. After the T10 spinous process is identified by manual examination, sterile conditions will be established. The transverse process and erector spinae muscles will be visualized using an ultrasound probe. Using an in-plane technique, 20 ml of 0.25% bupivacaine will be injected between the transverse process and erector spinae muscles using a 22-gauge blocking needle.
224198333|NCT05346458|DEVICE|Intra coronary rapid-exchange iKOs microcatheter intervention|Patients planned for an invasive coronary physiology (pressure-wire) study and who meet the inclusion criteria and none of the exclusion criteria can be enrolled. Participants will undergo preparation for their clinical procedure (angiogram with pressure wire study) in the normal manner. Arterial cannulation will be performed via the radial or femoral artery) under local anaesthesia. The sheath will be inserted and a pre-procedure blood sample taken for Troponin T level. A coronary angiogram will be performed as per standard clinical practice prior to cannulating the coronary artery to be studied. The pressure studies will be performed sequentially, first with a pressure wire before using the iKOs™ microcatheter. Following withdrawal of the iKOs™ microcatheter. A pressure wire assessment is repeated after the microcatheter is withdrawn. The case will then proceed as clinically indicated. Post-procedure the participant will be managed according to standard clinical practice.
224198334|NCT04087005|OTHER|hominis placental pharmacopuncture|Hominis placental pharmacopuncture is human placental extract, which has been used in traditional Korean medicine to treat chronic diseases, including frailty, cough, anorexia, and fatigue, by enhancing the body's resistance.
224198335|NCT04329156|OTHER|Digitally Flip Technique|A prefabricated shell will be made then after implant placement, the shell will be attached to a plastic abutment using flowable composite to make a customized healing abutment.
224198336|NCT04329156|OTHER|Stock Healing Abutment|After implant placement, a stock healing abutment will be placed onto the implant and screwed on. It will be selected to be 1-2 mm above the gingival margin and slightly smaller in diameter than the intended final restoration.
224198337|NCT03165851|OTHER|Risk-stratified therapy|Dose-dense intensive chemotherapy and high dose of Ara-C in the consolidation therapy.
224311084|NCT03847298|OTHER|Physical activity and physical fitness assessment|Physical fitness was assessed using Munich Physical Fitness Test (MFT). The SenseWear Armband metabolic holter device was used to record the physical activity level for consecutive 7 days. The functional exercise capacity of the individuals was assessed by the six-minute walking test (6MWT) and cardiorespiratory capacity was assessed by maximal exercise test on the treadmill.
224311085|NCT00118534|BEHAVIORAL|Integrated Care for Smoking Cessation in PTSD patients|Smoking cessation therapy is integrated with PTSD therapy.
224311086|NCT00118534|BEHAVIORAL|Standard of Care|Patients interested in quitting smoking are referred to a separate smoking cessation clinic, per standard of care.
223597333|NCT04685265|DRUG|anle138b|capsule containing excipient and anle138b
223597334|NCT04685265|DRUG|Placebo|matching placebo capsule containing excipient
223597335|NCT00557635|PROCEDURE|Chirurgical procedure|Chirurgical procedure to treat pseudo-arthrosis, with of osseous matrix implantation and autologous bone marrow injection.
223597336|NCT05173909|DEVICE|BIS closed-loop target controlled infusion|BIS was monitored by connecting the BIS monitor (BISXP, Aspects Medical Systems, USA). The corresponding value was set on the BIS detector and connected to the targy-controlled infusion pump to automatically adjust the plasma drug concentration of propofol
223597337|NCT00044772|DRUG|Venlafaxine ER|
224198338|NCT00566397|DRUG|PF-04494700|15 mg for 6 days followed by daily dosing of 5mg
224198339|NCT00566397|DRUG|PF-04494700|60 mg for 6 days followed by daily dosing of 20mg. Dosing in this arm has been discontinued.
224311087|NCT00311324|BEHAVIORAL|Special Intervention|
223597338|NCT00852865|DRUG|Lactobacillus farciminis|1 capsule per day. Each capsule containing 4\*109 CFU
223597339|NCT00852865|DRUG|Placebo|1 capsule per day
223597340|NCT01271725|DRUG|Vinorelbine 25 mg/m2 weekly|Patients to additionally receive vinorelbine at a dose of 25 mg/m2 weekly on disease progression on afatinib monotherapy
224311088|NCT00311324|BEHAVIORAL|Delayed Intervention|
224311089|NCT00961402|BEHAVIORAL|Wellness Control|6-month wellness control
224311090|NCT00961402|BEHAVIORAL|Exercise Intervention|6 month exercise intervention
224311091|NCT03364543|OTHER|Access to the Medical-Legal Partnership Group|The Medical-Legal Partnership Group are lawyers in clinics who address health-harming legal needs.
224311092|NCT03364543|OTHER|Access to social worker and a community worker|Access to social worker and a community worker, but no systematic process for addressing health-harming legal needs.
224311093|NCT02901548|DRUG|Durvalumab|Durvalumab will be given every 4 weeks at 1500 mg/kg IV for total of 12 months/13 doses.
223597341|NCT01271725|DRUG|Afatinib 40mg once daily (OD)|Patient to receive afatinib monotherapy at a dose of 40 mg/d until progression of their disease
223597342|NCT01271725|DRUG|Paclitaxel 80 mg/m2 weekly|Patients to additionally receive paclitaxel at a dose of 80 mg/m2 weekly on disease progression on afatinib monotherapy
223597343|NCT01702025|DRUG|Placebo|Yellow corn meal in gel capsules
223597344|NCT01702025|DRUG|Aminophylline|National Drug Code (NDC) 0143-1020-01
223748111|NCT07059455|OTHER|Quadratus Lumborum (QL) Block|Following standard anesthesia monitoring, patients will be placed in the lateral decubitus position. After the field is sterilized, a 2-5 MHz convex ultrasound probe (Samsung, HM70 EVO) will be placed between the iliac crest and costal arch at the level of the posterior axillary line. The transverse process of the L4 vertebra, erector spinae, QL, and PM muscles will be visualized. After inducing local anesthesia with 2% lidocaine (2 ml), a blocking needle (22G\*100 mm, Braun) will be advanced from posterolateral to anteromedial, inserting it between the QL and PM muscles, and 20 ml of 0.25% bupivacaine will be injected.
223597345|NCT01702025|DRUG|Methazolamide|NDC 0781-1072-01
223597346|NCT01702025|DRUG|Aminophylline+Methazolamide|NDC 0143-1020-01 and NDC 0781-1072-01
224198340|NCT00566397|DRUG|Placebo|Placebo
224198341|NCT06182748|OTHER|Training on eccentric ergocycle|Subjects will train on eccentric ergocycles. In eccentric cycling, pedals push against the user's feet in the opposite direction, user has to slow down pedals and quadriceps muscles lengthen during contraction.
223597347|NCT03354273|DRUG|PET MPI|Flurpiridaz (18F) Injection. All participants received 2 IV boluses of Flurpiridaz (18F) Injection in a large peripheral vein: 1 at rest and 1 during stress. The dosages of Flurpiridaz (18F) Injection administered at rest and during stress conditions did not exceed a total of 14 mCi (520 MBq) for an individual participant.
223597348|NCT03354273|DRUG|SPECT MPI|SPECT imaging was used 99mTc-based myocardial tracers. SPECT agents utilised for the purposes of this clinical study was administered as per American Society of Nuclear Cardiology or European Association of Cardiovascular Imaging standards, where applicable. All participants undergone SPECT MPI.
223597349|NCT03354273|DRUG|Pharmacological stress agents|Pharmacologic stress agents were restricted to the following 3 agents, as permitted by local marketing authorisations and availability: adenosine, dipyridamole, and regadenoson. Administration was through an IV line.
223597350|NCT02551263|DRUG|Eribulin|Eribulin 1.4 mg/m2 will be administered intravenously over 2 to 5 minutes on day 1 and 8 of every 21-day cycle, in a real-world setting.
223597351|NCT03590353|DEVICE|Dual Chamber Pacemaker|1\. Conducting venipuncture. Subclavian vein is our first choice. Then we set up two venous channels and implant two guiding wires into postcava. 2.Putting 2 sheathing canals into heart along with guiding wires. 3.Locating the sheathing canals, and putting electrodes into canals. 3.Adjusting the electrodes and revolving them anticlockwise to lead them to right atrium and right ventricle respectively under the X-ray. 4.Immobilizing electrodes. 5. Some ways to determine whether the electrode is fixed or not: the head of the electrodes could beat rhythmically with atrium or ventricle or by testing damage current. 6.Removing the canals and suturing.
223597352|NCT03590353|DEVICE|His Bundle Pacemaker|1.Conducting venipuncture. Subclavian vein is our first choice. Then we set up two venous channels and implant two guiding wires into postcava. One of the guide wire is 120cm in length, 0.035 or 0.038 in diameter, which is required to lead the C315 sheathing canal. 2.Putting C315 sheathing canal into heart along with guiding wires. 3.Locating the C315 sheathing canal, and adjusting the head of C315 towards ideal pacing location. 3.Implanting the spiral electrodes and fixing them. Leading the spiral electrode to the side of his bundle along the C315 canal under the X-ray. The other electrode is leaded to right atrium like dual chamber pacemaker under the X-ray. 4.Revolving the 3830 electrode suitably to Immobilizing it in cardiac muscle. If the electrode can get his electric potential and produce his bundle pacing successfully, we revolve the 3830 electrode and immobilize it.
223597353|NCT04709445|DIAGNOSTIC_TEST|ICG-NIRF Imaging plus ingress and egress analysis|intraoperative NIRF Imaging using the fluorescence agent ICG (indocyanine-green) before and after anastomosis formation, postoperative analysis of ingress and egress for specific regions of interest
223597354|NCT05693350|DIAGNOSTIC_TEST|DUS|Duplex ultrasound
223597355|NCT01721226|DEVICE|Intervention Arm (computer-based CARE+ Corrections tool)|Study participants in the intervention arm will complete the computer-based CARE+ Corrections tool at baseline. The CARE tool provides tailored feedback based on the participants' responses to a series of questions included in the counseling session. Participants in this arm of the study recruited inside the DC DOC will receive typical discharge planning services as conducted by the correctional facility. Participants will be followed for six months after release/study enrollment. At the post-release baseline visit, participants in the intervention arm will receive a cell phone/SMS text messaging intervention consisting of using cell phone-delivered SMS text messages with the intent of improving linkage to community HIV care and adherence to ART (if prescribed.)
223597356|NCT01721226|OTHER|Educational video on opiate overdose prevention|Participants in the Control Arm will view an educational video on opiate overdose prevention in jail prior to release. Control arm participants will be followed after release/study enrollment, just like participants in the Intervention Arm, and Plasma Viral Loads will be collected from them at baseline and follow-up.
223748112|NCT06788028|BEHAVIORAL|Usual Care|All participants receive the usual care via standard mental health services offered by the NMHC to the public free of charge. Participants will have access to these public services regardless of whether or not they choose to participate in this study. If they refuse to participate in the research study, they will still have access to usual care.
223748113|NCT06788028|BEHAVIORAL|Family Strengthening|Families will engage in 12 weekly (1-1.5 hours) of family strengthening sessions, led by trained facilitators from the Research and Education Center. Groups will be composed of approximately 5 caregiver-child dyads. Sessions are designed to improve family functioning, strengthen child-parent relationships, enhance parenting strategies, and prevent emotional and behavioral problems among at-risk children.
223748114|NCT06788028|BEHAVIORAL|Mental Health Screening, Referral and Connection to Services|Children will receive 12 sessions of individual mental health services. Clinicians are trained in the Attachment, Regulation, and Competency (ARC) framework. Services include a clinical assessment performed by a psychiatrist, development of an individual care plan, and corresponding mental health services, informed by ARC.
224198342|NCT06182748|OTHER|Training on concentric ergocycle|Subjects will train on regular concentric ergocycles. In concentric cycling, quadriceps contract to push pedals.
224198343|NCT04510870|DRUG|Ferric Carboxymaltose Injection|Infusion prior the start of IVF/ICSI cycle. Dosing according to the summary of product characteristics (SmPC) chart. Placebo infusion before frozen embryo transfer if needed.
224198344|NCT04510870|DRUG|NaCl infusion|Placebo infusion prior the start of IVF/ICSI cycle. Ferric Carboxymaltose infusion before frozen embryo transfer if needed. Dosing according to the summary of product characteristics (SmPC) chart.
224198345|NCT00005009|BIOLOGICAL|Varivax®|Each participant will receive 2 doses of Varivax 6 to 8 weeks apart.
224198346|NCT06453707|DIAGNOSTIC_TEST|SpinChip hs-cTnI|SpinChip Platform, consisting of the SpinChip hs-cTnI test (self-contained cartridge) and SpinChip Analyzer (instrument)
224198347|NCT00673868|BIOLOGICAL|CMV Specific Cytotoxic T Lymphocytes|CMV Specific Cytotoxic T Lymphocytes will be infused between days 30 and 40 post-transplant at a dose ranging from 2- 5 x e5 cells/kg.
223597357|NCT01484535|PROCEDURE|Ankle Aspiration|Ankle aspiration will be performed through either a standard anterolateral or anteromedial approach, depending on the conditions of the soft tissue. The anterolateral approach will be the preferred method due to the higher reproducibility of intra-articular needle placement. The anteromedial approach will be reserved for patients whose soft tissues over the anterolateral portal are compromised. Sterile preparation of the limb will be achieved with the use of chlorhexidine or Betadine. An 18 gauge needle will be introduced into the ankle joint and a syringe will be used to aspirate the ankle until no more hemarthrosis is able to be removed. The amount of hemarthrosis aspirated will be recorded. Following the procedure, care will continue as per standard of care.
223597358|NCT01484535|PROCEDURE|Ankle aspiration Standard Anterolateral|Placebo ankle aspiration will be performed through a standard anterolateral. Sterile preparation of the limb will be achieved with the use of chlorhexidine or Betadine. An 18-gauge needle will be introduced into the skin. The needle will be held in the skin for 5-10 seconds in an effort to simulate the pain and time-lag experienced with aspiration. The needle will not pass the fascia or ankle joint capsule. Following the procedure, care will continue as per standard of care.
223597359|NCT02292563|PROCEDURE|Colonoscopist only|Only Colonosopist Observe during Colonoscopy (single observer)
223597360|NCT02292563|PROCEDURE|Experienced Endoscopy Nurse Participation|Experienced Endoscopy Nurse Participation Observation during Colonoscopy (Both endoscopist and endoscopic nurse observe)
223597361|NCT04200118|OTHER|Observational|non intervention
223597362|NCT03053947|DRUG|Intranasal Ketamine|Administration of intranasal ketamine at a dose from 3 to 9 mg/kg for safe and effective procedural sedation for laceration repair in the ED for children aged 1 to 12 year-old.
223597363|NCT05399563|OTHER||
223597364|NCT02975050|OTHER|Location|
223597365|NCT04949594|DEVICE|TENS|application on muscles where pain is situated (cervical)
223597366|NCT04522349|DEVICE|Greifer then Axon-Hook|Each participant is fitted with a Greifer and assessed after two weeks home-trial. Then he is fitted with Axon-Hook and assessed after two weeks home trial.
223597367|NCT04522349|DEVICE|Axon-Hook then Greifer|Each participant is fitted with a Axon-Hook and assessed after two weeks home-trial. Then he is fitted with Greifer and assessed after two weeks home trial.
223597368|NCT06072417|OTHER|Assessment without intervention at High altitude|Assessments at High altitude corresponding to Baseline measures
223597369|NCT06072417|OTHER|Relocation to sea level for 2 days|Participants will be relocated to sea level and intervention and have assessements there.
223597370|NCT01913002|DRUG|LX4211 800 mg|
223597371|NCT01913002|DRUG|LX4211 2000 mg|
223597372|NCT01913002|DRUG|moxifloxacin 400 mg|
223597373|NCT01913002|DRUG|LX4211 Placebo|
223597374|NCT05875298|OTHER|physical therapy protocol|the patients will receive physical therapy protocol in the form of therapeutic ultrasound (pulsed mode n An intensity of 1.7 W/cm² for maxillary, respectively in A frequency of 1.7 MHz in Duration of treatment of ten minutes for each maxillary sinus and five minutes for each side), Hot pack that will be applied eight minutes at each maxillary area and manual drainage technique for maxillary sinus.
223748115|NCT06788028|OTHER|Economic Empowerment|Child Development Accounts (CDAs) will be opened to facilitate family savings. The project will provide $50 as seed money to open a savings account in the child's name. Savings of up to $20 per month will be matched with study funds at a rate of 2:1 and placed in the CDA account. Caregivers and children will also engage in 12 weekly (1-1.5 hours) of financial education sessions, led by facilitators from the Research and Education Center.
224198348|NCT04235725|OTHER|Harmonized Depression Outcome Measures|This is an observational study where retrospective data on previous disease status and patient characteristics will be collected and combined with longitudinal data from these data sources on outcomes during the study timeframe.
224311094|NCT02901548|PROCEDURE|Cystoscopy with Biopsy|Cystoscopy with biopsy and transurethral resection of the bladder tumor (TURBT) (if indicated) will be performed at baseline, month 3, 6, 9, 12, 18, and 24. The month 6 and 24 cystoscopy will be done in the operating room with mapping biopsy. Rest of the cystoscopic exam with biopsy will be performed in the out-patient office setting and if clinically indicated will be repeated in the operating room. Participants will be off study if any of the biopsies document muscle invasive (T2 or above) urothelial carcinoma. Participants will also be off study if their month 6, 9, 12, 18 biopsies show persistent (month 6) or recurrent CIS or invasive (T1 or above) urothelial carcinoma. Otherwise, participants will remain on study until after the month 24 mapping biopsy.
224311095|NCT02942030|OTHER|Computerized assesment battery|All participants will do a computerized assessment battery to identify specific attentional profile
224311096|NCT02882308|DRUG|Olaparib|50/25 mg BD split x 5 days
223597375|NCT05875298|OTHER|physical therapy protocol and medical drugs|the patients will receive physical therapy protocol and medical drugs in the form of therapeutic ultrasound (pulsed mode n An intensity of 1.7 W/cm² for maxillary, respectively in A frequency of 1.7 MHz in Duration of treatment of ten minutes for each maxillary sinus and five minutes for each side), Hot pack that will be applied eight minutes at each maxillary area and manual drainage technique for maxillary sinus. The drugs will be concentrated sea water 3% and Local corticosteroids nasal spray.
223597376|NCT05875298|OTHER|medical drugs|The drugs will be concentrated sea water 3% and Local corticosteroids nasal spray.
223597377|NCT03828331|OTHER|Prosthetic/Bicycle Configuration|The investigators will measure the biomechanics (motion, forces, and muscle activity) and metabolic rates while subjects ride using an initial bike fit and three taller pylon lengths (PL) for the affected leg (AL) in increments of 6.8 mm using a pedal attachment position (PAP) beneath the prosthetic forefoot. Then, using the optimal (most efficient) PL, the investigators will measure the biomechanics and metabolic rates while subjects ride using three shorter crank arm lengths (CALs) for the AL in decrements of 6.8 mm using a PAP beneath the prosthetic forefoot. On Day 2, the investigators will repeat the protocol of Day 1, but have riders use a PAP beneath the pylon for their AL.
223597378|NCT04022863|DIAGNOSTIC_TEST|TEP|Tumor Educated Platelets
223597379|NCT04022863|DIAGNOSTIC_TEST|ctDNA|circulating tumor DNA
224311097|NCT02882308|DRUG|Cisplatin|60 mg/m\^2 d1-d5
223597380|NCT00746863|DRUG|0.125% Marcaine|Patients randomized to the intervention arm will receive 60 cc of 0.125% Marcaine injected into the retropubic space along the tract that the suprapubic mid-urethral trocar will follow (one on each side) for a total of 120 cc of 0.125% Marcaine, prior to the placement of the mid-urethral sling via the suprapubic approach.
223597381|NCT03229109|DEVICE|Spectrophon dehydration body monitor|Participants (both males and females) were assigned to physical activity (running), biosensor was attached to subject's wrist
223597382|NCT04207749|DEVICE|LID015385 contact lenses|Investigational soft contact lenses
223597383|NCT04207749|DEVICE|Comfilcon A contact lenses|Commercially available soft contact lenses
223597384|NCT04207749|DEVICE|CLEAR CARE|Hydrogen peroxide-based cleaning and disinfecting solution
223597385|NCT00913419|DRUG|Cyclobenzaprine HCl Tablets 10 mg, Cord Laboratories|
223597386|NCT00913419|DRUG|Cyclobenzaprine HCl Tablets 10 mg, Merck Sharp & Dohme|
223597387|NCT05511571|DEVICE|Transcutaneous electrical neural stimulation (TENS)|The TENS group: TENS application was implemented by the researchers in the patient room. The conventional TENS application took 30 minutes per session. The application continued until frequency reached 100 Hz, the pulse width reached 100 μs, and the current impedance reached a point where the women felt needling or tingling according to their tolerance. Before the application, the women were asked to lie in a supine position, and the area/skin where TENS would be applied was cleaned and dried. Two electrodes of TENS were placed 2 cm above the cesarean incision, and the other two electrodes 2 cm below the incision. The women were allowed to rest during the application, and they were accompanied by the researcher. A total of five TENS sessions, including two at four-hour intervals on the first day and three at eight-hour intervals on the second day, were held.
223597388|NCT05511571|OTHER|Progressive relaxation exercises (PRE)|The PRE group: The PRE application was implemented in the patient room. A quiet and calm environment was prepared in the room for the intervention. The PRE application was implemented by the women under the researchers' instructions. Each session lasted 30 minutes. A total of five sessions, including two at four-hour intervals on the first day and three at eight-hour intervals on the second day, were held. The PRE application includes exercises based on stretching and then the relaxation of different muscle groups, accompanied by deep breathing. The exercises were carried out in the following way: First doing a deep breathing exercise and then stretching all the muscles from feet to face accompanied by breathing in, keeping the breath, and finally relaxing the muscles by breathing out at the same time.
223597389|NCT05511571|OTHER|Transcutaneous electrical neural stimulation (TENS) and Progressive relaxation exercises (PRE)|The TENS+PRE group: The PRE and TENS applications were carried out together in this group. The administration of the interventions was the same as in groups where only TENS and only PRE applications were carried out. In this group, first, a 30-minute PRE application was implemented, which was followed by a 30-minute-TENS application.
223597390|NCT02585921|BEHAVIORAL|Video Interventions|Participants will watch 2 5-minute videos and then discuss them as a group.
223597391|NCT02585921|BEHAVIORAL|Donation Discussion Education|Participants will learn techniques for introducing and discussing organ donation with parents and guardians.
223597392|NCT05126836|DRUG|Cilostazol 100Mg Tab|Cilostazol Twice a Day
223597393|NCT05126836|DRUG|Placebo|Placebo
223597394|NCT01651325|DRUG|Isavuconazole|oral
224311098|NCT02882308|DRUG|Olaparib|300 mg BD x 21-28 days.
224311099|NCT02882308|DRUG|Durvalumab|1500 mg d1
223597395|NCT01651325|DRUG|dextromethorphan|oral
223597396|NCT06455501|PROCEDURE|Ventral mesh rectopexy|Ventral mesh rectopexy is performed with a superficial peritoneal incision from the right side of the sacral promontory, extended over the right outer border of the mesorectum, towards the deepest part of pouch of Douglas, sparing the right hypogastric nerve. In women, the vagina is retracted anteriorly and a dissection of the rectovaginal septum is performed down to the pelvic floor. A strip of mesh is attached to the ventral part of distal rectum and then fixed upon the sacral promontory.
223597397|NCT00370916|BEHAVIORAL|Physician-initiated medication reconciliation|Physician house staff performed and documented medication reconciliation after hospital admission with the assistance of a CPRS template
223597398|NCT00370916|BEHAVIORAL|Pharmacist-initiated medication reconciliation|Pharmacist performed and documented medication reconciliation
223597399|NCT00406172|DRUG|Bevacizumab|
223597400|NCT05669053|BEHAVIORAL|Super U Story intervention|Participants in this condition will be asked to play a Roblox adventure video game called 'Super U Story'. They will play the game once and have between 6 - 30 minutes to complete the game.
223597401|NCT05669053|BEHAVIORAL|Alternative Roblox game|Participants in this condition will be asked to play an alternative Roblox adventure video game called Rainbow Friends Story (colour story). They will play the game once and have between 6 - 30 minutes to complete the game.
223597402|NCT05669053|BEHAVIORAL|Online word search|Participants in this condition will have 20 minutes to complete a series of word searches online.
223597403|NCT05591391|OTHER|Mallya cap|After Mallya cap is correctly attached to the insulin pen, it will automatically record treatment information (dose, time and date of injection) and send in real time to the Health2Sync's platform by Bluetooth transmission. Suggestions regarding dose titration and glycemic control will be communicated on the Health2Sync's platform.
223597404|NCT05591391|OTHER|Standard care|Suggestions regarding dose titration and glycemic control will be communicated by weekly telephone calls.
223597405|NCT00668668|DRUG|Lactic acid (Dermacid)|
223597406|NCT03260296|OTHER|self-administered structured questionnaire|"Data will be collected by self-administered structured questionnaire. The aim of the study and the way of filling the questionnaire will be explained to the students, and then he/she fills the questionnaire by him/her self.~The questionnaire will assess smartphones addiction and some of its associated factors and its health consequences"
223597407|NCT02641301|DRUG|Sustained release morphine sulfate, 30 mg|A single oral administration of a capsule of sustained release morphine sulfate, 30 mg, on one day.
223597408|NCT06476353|OTHER|Analysis of Force and Pressure Requirements across Syringe Sizes for Pain Management Procedures|The investigators are analyzing the compression force required to plunge different syringe sizes to determine the operator's burden.
223597409|NCT05377138|OTHER|Online PEP/PrEP delivery|Delivery of PEP or PrEP after online consultation and HIVST image upload.
223597410|NCT02075788|OTHER|Commercial white bread|
223597411|NCT02075788|OTHER|Corn based products (porridge etc.)|
223597412|NCT02075788|OTHER|Millet based products (porridge etc.)|
223597413|NCT05813691|DIAGNOSTIC_TEST|Meridan Bioscience Point of Care test against HCV antibodies|Point of care evaluation of antibodies against HCV obtaining a drop of capillary blood via puncture of the fingertip. If antibodies were detected, HCV RNA assay will be performed.
223597414|NCT01835223|DRUG|Tivozanib (1mg)|Given PO
223597415|NCT01835223|DRUG|Tivozanib (1.5mg)|Given PO
223597416|NCT05767112|OTHER|Supplement administation|HMB was administred in 3 different forms: 1) HMB-FA in clear capsules; 2) HMB-Ca in gelatine capsules; 3) HMB-Ca dissolved in water. All treatments provided 1g of HMB. Blood samples were taken before and on multiple time points following ingestion.
223597417|NCT03226496|BEHAVIORAL|motivational interviewing|
223597418|NCT00244101|DRUG|PS Group|Intubation, prophylactic surfactant administration shortly after delivery, and subsequent stabilization on ventilator support.
223597419|NCT00244101|DEVICE|NCPAP Group|Early stabilization on nasal continuous positive airway pressure (NCPAP) with selected intubation and surfactant administration for clinical indications.
223597420|NCT00244101|DRUG|ISX Group|Intubation, prophylactic surfactant administration shortly after delivery, and rapid extubation to nasal CPAP.
223597421|NCT03761238|DEVICE|Molecular Adsorbent Recirculating System|MARS therapy will start within 24-48 h after randomization and be given on 3 consecutive days in sessions of 8-12 h. The patients are observed for 2 days following the last session, with focus on bilirubin INR and signs of encephalopathy, and can thereafter receive 3 additional sessions in case of no or partial response to treatment.
223748123|NCT06828120|DRUG|Taneasy 600mg granules|Treatment of respiratory affections characterized by thick and viscous hypersecretion due to acute bronchitis,chronic bronchitis and its exacerbation, plumonary emphysema,mucoviscidosis and bronchiectasis.
223748124|NCT06828120|DRUG|Fluimucil 600mg granules|Treatment of respiratory affections characterized by thick and viscous hypersecretion due to acute bronchitis,chronic bronchitis and its exacerbation, plumonary emphysema,mucoviscidosis and bronchiectasis.
224198349|NCT06208670|BEHAVIORAL|Progressive muscle relaxation exercises|PMI is among the non-pharmacological methods nurses can offer caregivers (Yılmaz et al., 2019). Health professionals, especially nurses, should evaluate all women of reproductive age in terms of PMS, plan educational interventions that will increase their awareness of the issue and enable them to develop appropriate coping strategies, support the planned educational interventions through written or visual materials, provide effective and quality counseling services, and aim to improve women's decreased quality of life (Abay \& Kaplan 2019; Aksoy Derya et al. 2019; Akmalı et al. 2020). Women can be advised to do relaxation exercises such as walking, running, swimming, and yoga regularly (at least 30 minutes a day) as they reduce stress by increasing endorphin levels and improve heart rate, lung capacity, and general health (Penedo \& Dahn, 2005; ACOG, 2015; Khajehei 2015).
224311100|NCT02113618|BEHAVIORAL|Cogmed training|Cogmed® working memory training session consists 90 trials and lasts for approximately 30 minutes per day, 5 days a week and during a total training period of 5 weeks (i.e. total training time approximately 12,5 hours). In order to complete the study each subject must complete 20 - 25 training sessions within maximum 6 weeks. The program adjusts the difficulty of the different tasks trial-by-trial, which allows for each subject to train at a level adjusted to his or her current Working memory capacity
223597422|NCT03761238|OTHER|Standard medical treatment (SMT)|Patient management and standard medical treatment (SMT) as specified in the study protocol.
223597423|NCT01504841|DRUG|Etravirine (ETR)|ETR was administered as 25-mg scored tablets and/or 100-mg tablets swallowed whole or dispersed in an appropriate liquid vehicle following a meal. Children took the specified dose orally twice daily within 30 minutes following a meal. Dose was decided according to dosing tables in protocol.
223748125|NCT07074756|DRUG|Chemotherapy|Receive standard of care chemotherapy
223748126|NCT07074756|PROCEDURE|Computed Tomography|Undergo CT
223748127|NCT07074756|OTHER|Internet-Based Intervention|Receive access to the remote chemotherapy management and patient monitoring platform
223597424|NCT05979519|BEHAVIORAL|Fresh Funds for Mom's|"Participants will enroll in Instacart Fresh Funds program. Once enrolled participants will select foods that are eligible in the Fresh Funds to be delivered to their home each week for 12 weeks.~Those in standard care will maintain usual care with their healthcare provider. The standard care arm after the initial 12-weeks and post intervention survey will then select foods that are eligible in the Fresh Funds to be delivered to their home each week for 12 weeks."
223748128|NCT07074756|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223748129|NCT07074756|PROCEDURE|Neurologic Examination|Ancillary studies
223748130|NCT07074756|OTHER|Questionnaire Administration|Ancillary studies
223748131|NCT07074756|BEHAVIORAL|Surveillance|Undergo surveillance
223748132|NCT06470542|DRUG|2 x 20 ml of Ropivacaine 0.2% Injectable Solution|2 x 20ml 0.2% Ropivacaine - ultrasound-guided iPACK + ACB
223748133|NCT06470542|DRUG|2 x 20ml of Ropivacaine 0.2% Injectable Solution|2 x 20ml 0.2% ropivacaine - ultrasound-guided ESPB at the L1 and S1 level
223748134|NCT04586023|DRUG|Fenebrutinib|Participants will receive fenebrutinib.
223748135|NCT04586023|DRUG|Teriflunomide|Participants will receive teriflunomide.
223748136|NCT04586023|DRUG|Placebo|Participants will receive teriflunomide-matching placebo or fenebrutinib-matching placebo.
224198350|NCT06208670|BEHAVIORAL|Violent tendency Scale|Violent tendency Scale
224198351|NCT02103985|DRUG|JNJ-39823277|Participants will receive 100 mg of JNJ-39823277 tablet orally (by mouth) as a single dose.
223597425|NCT05979519|BEHAVIORAL|Standard Medical care|Those in standard care will maintain usual care with their healthcare provider. The standard care arm after the initial 12-weeks and post intervention survey will then select foods that are eligible in the Fresh Funds to be delivered to their home each week for 12 weeks or be provided the medically tailored meals for 12 weeks.
223597426|NCT05979519|BEHAVIORAL|Medically Tailored Frozen Meals|Participants will enroll in the MTM program. Once enrolled participants will receive 10 frozen meals delivered by Door Dash to their home each week for 12 weeks.
223597427|NCT04417231|DEVICE|CRP apheresis|"Selective CRP apheresis by use of the PentraSorb-CRP"
223597428|NCT01468350|DRUG|dalfampridine-ER 10mg|
223597429|NCT01468350|OTHER|Placebo|
223597430|NCT03149055|DRUG|Isavuconazole|Intravenous or oral: Isavuconazonium sulfate 372 mg Q 8hour for 6 doses as loading dose, followed by 372 mg Q day as maintenance dose.
223597431|NCT01554449|PROCEDURE|serious game reeducation|It's a daily session (45 minutes) of reeducation by serious game (kinect) compared to a daily session (45 minutes) of conventional reeducation
223597432|NCT01554449|PROCEDURE|functional MRI|the functional MRI (siemens) will be done on 25 stroke patients and 12 healthy volunteers at baseline and at 6 weeks.
223597433|NCT06432335|OTHER|E-Socket Monitoring|Limb-socket motion data is collected during participant take-home use. Bimonthly telephone interviews are conducted to assess participant residual limb health status. Analysis is conducted to determine if limb motions and activity changes precede limb health changes.
223597434|NCT02629822|DRUG|Doravirine/lamivudine/tenofovir disoproxil fumarate|FDC tablet containing MK-1439 (doravirine) 100 mg / lamivudine 300 mg / tenofovir disoproxil fumarate 300 mg taken by mouth.
223597435|NCT04440813|BEHAVIORAL|Education and Training by Clinicians|Training in the use of PPE and education about the risks of blood exposure.
223597436|NCT04440813|BEHAVIORAL|Training and Education from Traditional Healers and Clinicians|Training in the use of PPE and education about the risks of blood exposure.
223597437|NCT05882149|DIETARY_SUPPLEMENT|Single strain probiotic|"Sugar-free chewing gum with single strain probiotic and zinc.~The dosage will be 2 chewing a day, served at the same time and chewed for 6 minutes outside meals (for example 2h after breakfast or lunch)."
223597438|NCT05882149|DIETARY_SUPPLEMENT|Placebo|"Sugar-free chewing gum.~The dosage will be 2 chewing a day, served at the same time and chewed for 6 minutes outside meals (for example 2h after breakfast or lunch)."
223597439|NCT03679624|DRUG|Ibrutinib|Ibrutinib, 420mg orally, once daily
223597440|NCT03679624|DRUG|Daratumumab|Daratumumab, 16 mg/kg intravenously, weekly for 8 weeks, bi weekly for 16 weeks, then monthly for up to 19 months.
223597441|NCT05030350|DRUG|PH94B|Nasal spray
223597442|NCT01610336|DRUG|INC280|During Phase Ib, INC280 was taken at escalating doses. During Phase II part, INC280 was taken at recommended Phase II dose.
223597443|NCT01610336|DRUG|Gefitinib|Gefitinib 250 mg taken once daily
223597444|NCT05805046|DEVICE|Negative Pressure Wound Therapy System|The study device combines a sterile dressing comprising gelling fibre technology to absorb wound exudate with negative pressure applied to the wound via a vacuum pump.
223597445|NCT00741013|DRUG|placebo pill and placebo IV|"Placebo pill every four hours, starting 16 hours before intrabronchial LPS and ending 24 hours after intrabronchial LPS~Placebo IV starting 2 hours before intrabronchial LPS and ending 24 hours after intrabronchial LPS"
223597446|NCT00741013|DRUG|Lovastatin pill and placebo IV|"lovastatin pill every four hours, total of 80 milligrams a day, starting 16 hours before intrabronchial LPS and ending 24 hours after intrabronchial LPS~Placebo IV starting 2 hours before intrabronchial LPS and ending 24 hours after intrabronchial LPS"
223597447|NCT00741013|DRUG|placebo pill and recombinant human activated protein C IV|"placebo pill every four hours, total of 80 milligrams a day, starting 16 hours before intrabronchial LPS and ending 24 hours after intrabronchial LPS~recombinant human activated protein C IV 24 micrograms per kg per hour starting 2 hours before intrabronchial LPS and ending 24 hours after intrabronchial LPS"
223597448|NCT00741013|BIOLOGICAL|Endotoxin|Endotoxin 4 ng/kg instilled bronchoscopically in all volunteers 12 hours after starting lovastatin treatment and 2 hours after starting recombinant human activated protein C treatment.
223597449|NCT02139865|BEHAVIORAL|30% 1RM|Participant exercises using a protocol tailored at 30% of their 1RM
223597450|NCT02139865|BEHAVIORAL|80% 1RM|Participant exercises using a protocol tailored at 80% of their 1RM
223597451|NCT00572208|DRUG|Gabapentin group|"Gabapentin group:~Preoperative (2 h before surgery): Tablet Gabapentin 1200 mg (blinded)~1. st Postoperative day: Tablet Gabapentin 300 mg twice a day (blinded)~2. nd Postoperative day: Tablet Gabapentin 300 mg twice a day (blinded)~3. rd Postoperative day: Tablet Gabapentin 300 mg twice a day (blinded)~4. th Postoperative day: Tablet Gabapentin 300 mg twice a day (blinded)~5. th Postoperative day: Tablet Gabapentin 300 mg twice a day (blinded)"
223597452|NCT05637788|DIAGNOSTIC_TEST|CT Scan Radiomics Features Extraction|Extraction of CT radiomics data through AI
223597453|NCT02133781|BIOLOGICAL|Fluzone® 2009-2010 Formula|This vaccine is given intramuscularly
223597454|NCT02133781|BIOLOGICAL|FluMist® 2009-2010 Formula|This vaccine is given intranasally
223597455|NCT04556279|PROCEDURE|adrenalectomy|Surgical removal of an adrenal gland containing an aldosterone secreting adenoma.
223597456|NCT04556279|DRUG|Aldosterone Antagonist|Medical treatment of primary hyperaldosteronism.
223597457|NCT01928901|DRUG|administration of Sinupret|
223597458|NCT01928901|DRUG|administration of Bronchipret|
223597459|NCT01928901|DRUG|administration of Sinupret Placebo|
223597460|NCT01928901|DRUG|administration of Bronchipret Placebo|
223597461|NCT02173171|OTHER|Information collection|Q3M Information collection
223597462|NCT00006195|DRUG|risperidone|
223597463|NCT00006195|DRUG|olanzapine|
224198352|NCT05075109|DEVICE|High Frequency TENS|30 minutes of high frequency TENS (100 Hz, 200 us) over the muscle belly of triceps and wrist extensors, for 5 days per week over 8 weeks combined with task related training.
223597464|NCT05099796|PROCEDURE|Transforaminal epidural steroid injection|
223597465|NCT05099796|PROCEDURE|Caudal epidural steroid injection|
223597466|NCT03594136|DEVICE|Raumedic Neurovent-P-tel|Insertion of a Neurovent-P-tel in adults to study normal intracranial pressure
223597467|NCT01618825|DRUG|Lamotrigine Tablets 25 mg|2 x 25 mg tablet once a day
223597468|NCT01618825|DRUG|Lamotrigine|2 x 25 mg tablet once a day
224198353|NCT05075109|DEVICE|Low Frequency TENS|30 minutes of low frequency TENS (20 Hz, 0.2 us) over the muscle belly of triceps and wrist extensors, for 5 days per week over 8 weeks. And combined with 30 minutes of TRT.
224198354|NCT05075109|OTHER|Task Related Training|"Each session of TRT would include:~1\. postural control, 2. shoulder mobilization, 3. weight bearing exercises 4. Functional activities that will comprise of simple tasks to more advanced movement patterns as follows:~* Reaching activities~  1. Forward supported reach with cane on tabletop~ 2. Reaching against gravity~ 3. Reaching overhead with active wrist/hand movements~ 4. Dynamic reaching to target e.g. catch a ball~* Grasping, holding and release~  1. Grasp, hold and release objects with gravity minimized~ 2. Pick up and move/release small objects on table~ 3. Pick up and move/release large objects without proximal support~ 4. Incorporate pinch grips in hold and release including stacking, lifting and overhead activity~* Upper limb ADL~  1. Brushing hair, putting on scarf~ 2. Opening bottles, turning off water tap~ 3. Writing, drawing~ 4. Folding of towels, hanging towels and setting table~ 5. Self-feeding"
224198355|NCT06187207|DIAGNOSTIC_TEST|Hand acceleration time (HAT) measurement|Hand Duplex Ultrasound to measure the Hand Acceleration Time (HAT)
224198356|NCT01785251|DEVICE|Neuromuscular Electrical Stimulation|Applied using a custom built, medically approved stimulator called the Duo-STIM. NMES to be applied to the calf muscles to elicit a muscular contraction to eject blood through the venous system.
224198357|NCT03495167|DRUG|SyB C-1101|SyB C-1101 (rigosertib sodium) will be administered to two cohorts of patients; each receives either twice daily (560 mg before breakfast and 560 mg before dinner) or twice daily (840 mg before breakfast and 280 mg before dinner. SyB C-1101 will be administered orally twice daily for 21 consecutive days, followed by a 7-day observation period. The treatment period of 28 days (21 days of administration + 7 days of observation) constitutes 1 cycle.
224198358|NCT05219513|DRUG|RO7443904|RO7443904 will be administered by subcutaneous (SC) or IV infusion on Cycle (C) 1 Day (D) 10, C2D3, and C2D8. From C3 onward, RO7443904 will be given every 3 weeks (Q3W), for up to 12 cycles (C = 21 days).
224198359|NCT05219513|DRUG|Glofitamab|Glofitamab will be administered through IV infusion starting with step-up dosing (2.5 mg/10 mg/30 mg) on C1D1, C1D8, and C2D1. Starting in Cycle 3, glofitamab will be given in 30 mg doses every three weeks (Q3W) with RO7443904, for up to 12 cycles (Cycle = 21 days).
224198360|NCT05219513|DRUG|Obinutuzumab|Obinutuzumab will be administered once through IV infusion, at a 1 g dose in Cycle 1, on either Day -7, -4, or -3 (C1D-7, C1D-4, C1D-3).
223506936|NCT05085405|BEHAVIORAL|Clinician Notification / Patient Activation|"An anticoagulation clinic nurse sends a templated letter to the patient's clinician and identifies the patient as high risk for upper GI bleeding, summarizes options for medication optimization (e.g., discontinuation of antiplatelet therapy or initiation of a proton pump inhibitor for gastroprotection), provides a link to guidance on evidence-based use of antiplatelet therapy, and asks that the clinician manage any medication changes.~Patient Activation:~An anticoagulation clinic nurse sends the patient an 8-page written guide, either through the patient portal or by mail. The guide provides education on upper GI bleeding risk and encourages patients to talk with their clinician about medication changes to reduce their bleeding risk."
223506937|NCT05085405|BEHAVIORAL|Clinician Notification with Nurse Facilitation / Patient Activation|"An anticoagulation clinic nurse sends an individualized letter to the patient's clinician which identifies the patient as high risk for upper GI bleeding and summarizes options for medication optimization (e.g., discontinuation of antiplatelet therapy or initiation of a proton pump inhibitor for gastroprotection), but in addition includes a summary of the patient's history of atherosclerotic cardiovascular disease and a concise guidance summary on appropriate use of antiplatelet therapy for relevant indications. The anticoagulation nurse will assist with order entry for any new medications and also provide education on medication changes to the patient upon request by the clinician.~Patient Activation:~An anticoagulation clinic nurse sends the patient an 8-page written guide, either through the patient portal or by mail. The guide provides education on upper GI bleeding risk and encourages patients to talk with their clinician about medication changes to reduce their bleeding risk."
223506938|NCT05645185|DIAGNOSTIC_TEST|Diagnosis test|Tests can be used: immunofluorescence, immunodot, western blot, tests CBA on sera or CSF.
223506939|NCT01737619|PROCEDURE|Computed Tomography|Undergo PET/CT
223506940|NCT01737619|DRUG|Indocyanine Green Solution|Given via superficial and deep cervical injection
223506941|NCT01737619|OTHER|Laboratory Biomarker Analysis|Correlative studies
223506942|NCT01737619|PROCEDURE|Lymph Node Mapping|Undergo lymph node mapping
223506943|NCT01737619|PROCEDURE|Lymphadenectomy|Undergo full lymphadenectomy
223506944|NCT01737619|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
223506945|NCT00529581|DRUG|C105|
223506946|NCT01983904|DEVICE|deep brain stimulation with short & long pulse width|surgical implantation for bilateral electrodes and stimulation using short and long pulse width
223506947|NCT03167398|BIOLOGICAL|Fecal Microbiota Transplantation|Patients able to swallow will be given capsulized FMT using 15 capsules a day for two consecutive days. Patients will be treated concomitantly with omeprazole 20mg once in the evening before FMT and daily for the next 2 days.
223506948|NCT00400205|DRUG|Docetaxel|Docetaxel 75 mg/m2, intravenous infusion over 1 hour, mixed with normal saline per institutional standard, day 1 and then every 3 weeks.
223506949|NCT00400205|DRUG|Cisplatin|Cisplatin 100 mg/m2, intravenous infusion over 30 minutes to 3 hours, day 1 and then every 3 weeks.
223506950|NCT00400205|DRUG|5-fluorouracil|5-fluorouracil 1000 mg/m2/day, 24 hour continuous infusion over 4 days, every 3 weeks.
223506951|NCT02455323|OTHER|Suboccipital inhibitory|According to this technique, the suboccipital musculature is palpated until contact is made with the posterior arch of the atlas, and progressive and deep gliding pressure is applied, pushing the atlas anteriorly. The occiput rests on the hands while the atlas is supported by the fingertips. Finger pressure must be maintained for 10 minutes to produce the therapeutic effect of inhibiting the suboccipital soft tissues. The aim is to suppress spasm of the muscles and in general of the suboccipital soft tissues which are responsible for any dysfunctional mobility of the occiput, atlas, or even the axis.
223597469|NCT03783299|DIAGNOSTIC_TEST|Standard RDT and HS-RDT|All household members (residents and temporary visitors) aged 18 months and older will be invited to participate in an RDT and blood collection component. After consenting, the MTAT team will capture axillary temperature, and test each individual using both a standard RDT (SD Bioline Pf/Pv RDT) and HS-RDT (SD Bioline Malaria Ag P.f High Sensitive Cat# 05FK140)
224311101|NCT02113618|BEHAVIORAL|Standard Training|Standard training session in an online training and also consists 90 trials and lasts for approximately 30 minutes per day, 5 days a week and during a total training period of 5 weeks. In order to complete the study each subject must complete 20 - 25 training sessions within maximum 6 weeks. The program does not increase in difficultly level
223748137|NCT07123753|OTHER|EXERCİSE|The aim of this study is to examine the effects of classical foot exercises and foot core exercises on pain, balance, gait and lower extremity performance in adolescents with pes planus. This study is planned to be a randomized controlled trial. Participants will be randomly divided into 2 groups. Classic foot exercises will be applied to individuals in the classical foot exercises group for 12-15 minutes, and foot core exercises will be applied to individuals in the core exercises group for 12-15 minutes twice a week for a total of 8 weeks. Pes planus status of individuals included in the study will be evaluated with the navicular drop test. Pain will be evaluated with the foot function test, balance with the star balance test, gait analysis with the footprint method and lower extremity muscle performance with the functional muscle strength assessment for individuals in both groups before and after the application. The evaluations will be applied face to face by the same physiotherapi
223748138|NCT06902454|DEVICE|densah drill technique|ten patients with maxillary sinus pneumatization will be undergo sinus floor elevation using densah drill technique with implant placement
224198361|NCT05219513|DRUG|Tocilizumab|Tocilizumab will be administered as necessary to treat cytokine release syndrome (CRS).
224198362|NCT03689595|OTHER|Sample of Blood|Collection of blood sample from participants
224198363|NCT01912547|PROCEDURE|Blood draw for TEG analysis|Blood drawn for TEG analysis
223597470|NCT03783299|DIAGNOSTIC_TEST|Standard RDT and HS-RDT|All individuals will be invited to participate in an RDT and blood collection component. Informed consent will be obtained from all participants. After consenting, the PNs will capture axillary temperature, and test each individual using both a standard RDT (SD Bioline Pf/Pv RDT) and HS-RDT (SD Bioline Alere Malaria Ag Pf High Sensitive Cat #05FK140). Dried blood spots (DBS) will also be collected on all HRPs if deemed feasible.
223597471|NCT03783299|DRUG|Artemether-lumefantrine|If found positive by standard RDT or HS-RDT, treatment will be administered, and women of reproductive age will be assessed as outlined in the protocol. All individuals who have provided informed consent, test positive by either HS-RDT or standard RDT, are ≥18 months old, are not pregnant or breastfeeding, and who do not have symptoms associated with severe malaria or another severe illness, will be offered an age-appropriate course of AL (age-specific blister packages) and SLD-PQ according to national treatment guidelines.
223748139|NCT06436183|DRUG|Camoteskimab|Drug Product
223748140|NCT06436183|DRUG|Placebo|Inactive substance
223748141|NCT06792734|DRUG|BTM-3566|Oral Solution
224198364|NCT02288650|OTHER|early refeeding|
224311102|NCT03897985|DEVICE|Narcotrend TM|Measurement of anesthesia depth
224311103|NCT01955083|DEVICE|Pillar implant|Subjects receive pillar implant of the soft palate under local anesthesia as an outpatient procedure on sitting position. Using the delivery tool of the pillar implant system, the mucosa of the soft palate close to the hard palate-soft palate junction (approximate 0.5 cm) was punctured in the midline. The needle was inserted to the uvular muscle and moved parallel to the curve of the soft palate towards the tip of the uvula. After reaching the insertion point, the implant was delivered steadily after which the needle was withdrawn. This process was repeated for the second and third implants in the bilateral para-midline with a 0.2 cm horizontal distance from the first implant.
223748142|NCT06903845|PROCEDURE|video call|Conduct video training every two weeks emphasizing medication adherence.
223748143|NCT06903845|DEVICE|Medication reminder app|Medication reminder app will remind patients to take your medication.
223748144|NCT07094334|OTHER|Action Observation|This study, in contrast to prior research, will examine both the acute effects of action observation therapy and its impacts at the peripheral level.
223748145|NCT07094334|OTHER|Action Observation combined with Motor Imagery|This study, in contrast to prior research, will examine both the acute effects of action observation therapy combined with motor imagery and its impacts at the peripheral level.
223748146|NCT07094334|OTHER|Sham (No Treatment)|Participants in this intervention group will watch landscape and nature-themed videos for the duration corresponding to the intervention period applied in the other groups.
223748147|NCT07090330|DRUG|ORKA-001 Induction Dose|ORKA-001 Induction Dose, administered by subcutaneous (SC) injection
223748148|NCT07090330|OTHER|Placebo|Placebo administered by subcutaneous (SC) injection
223748149|NCT07090330|DRUG|ORKA-001 Maintenance Dose|ORKA-001 Maintenance Dose, administered by subcutaneous (SC) injection
224198365|NCT02288650|OTHER|refeeding only in the recovery room (usual practice).|
224198366|NCT06085586|OTHER|Early Weight Bearing|Full weight bearing (100%) initiated at 4 weeks postoperatively
224198367|NCT06085586|OTHER|Normal Weight Bearing|Full weight bearing (100%) initiated at 6 weeks postoperatively
224198368|NCT06477354|DIETARY_SUPPLEMENT|ACEMg|Softgel capsules
224198369|NCT04199741|DRUG|89Zr-DFO-SC16.56|Injection of 2 mCi of 89Zr-DFO-SC16.56 for Phase I participants. Dose for Phase II will be determined by results from Phase I.
224198370|NCT04199741|DRUG|SC16.56, Phase I, Cohort 2|7.5mg
224198371|NCT04199741|DRUG|SC16.56, Phase I, Cohort 3|22.5mg
224198372|NCT04199741|DRUG|SC16.56, Phase II|Dose for Phase II will be determined by results from Phase I.
224198373|NCT05922033|DRUG|Patient-led Insulin (intervention group)|Individuals randomized to this arm will initiate night-time insulin of 10 units. The type of basal insulin will be left to the discretion of the provider with levemir or glargine preferred over NPH. On day 0 of initiation of insulin, the patient will initiate night-time (or prior to sleep if alternate sleep schedule) insulin of 10 units (glargine, detemir, or NPH). Patient will check their fasting blood glucose in the morning and record their values. If the value is below 70 they will decrease their insulin dosage that night by 2 units; if the value is above 95 they will increase their insulin dosage that night by 2 units; and if the value is between 70 and 95, they will maintain the same insulin dosage that night. The patients will continue this algorithm for the remainder of the pregnancy. If the patient does not have a fasting blood glucose, the patient will maintain the dose of basal insulin at the prior dose.
224198374|NCT05922033|DRUG|Provider-led Insulin (standard care)|Individuals randomized to this arm will receive standard care and titration of insulin will be determined by the individual providers.
224311104|NCT01955083|DEVICE|Radiofrequency|Subjects receive radiofrequency under local anesthesia as an outpatient procedure on sitting position. radiofrequency energy was delivered via a generator (Somnus® Model S2, Gyrus-ACMI Corporation, Maple Grove, MN, USA) with the power set to 10 watts and the maximal target temperature to 85°C. The needle electrode was inserted through the mucosa into the muscle layer at the entry points (approximately 1 cm below the hard palate-soft palate junction). The electrode was kept in place until 600 J had been delivered at the midline and 300 J at both para-midline sites (approximately 1 cm horizontal distance).
223597472|NCT03783299|DRUG|Primaquine Phosphate|If found positive by standard RDT or HS-RDT, treatment will be administered, and women of reproductive age will be assessed as outlined in the protocol. All individuals who have provided informed consent, test positive by either HS-RDT or standard RDT, are ≥18 months old, are not pregnant or breastfeeding, and who do not have symptoms associated with severe malaria or another severe illness, will be offered an age-appropriate course of AL (age-specific blister packages) and SLD-PQ according to national treatment guidelines.
223597473|NCT00852787|DRUG|Digoxin immune fab|Intravenously one time
223597474|NCT00852787|DRUG|Placebo|Intravenously one time
223597475|NCT06025981|OTHER|Preliminary Phase|In the preliminary phase, the characterization of the functionality of the SWalker robotic system, as well as the functionality of the Virtual Reality system, will be carried out. All descriptive usability questionnaires completed by the participants and electro-biomechanical parameters will be collected using the robot's measurement systems to analyze the functionality.
223597476|NCT06025981|OTHER|Phase I - Early gait rehabilitation|In the first phase, the participants will carry out the rehabilitation program for hip fracture in acute phase that will last 6 weeks. Participants will be randomized between control and experimental groups. In which the therapeutic intervention is based on the usual rehabilitation guidelines that integrate exercises aimed at improving strength, gait, functional mobility and balance. In the case of the experimental group, a robotic walker will be used to practice walking.
223597477|NCT06025981|OTHER|Phase II - Maintenance gait function ( with VR)|In the second phase, participants will carry out a 6-week program to consolidate walking function. Participants will be randomized between control and experimental groups. In which the therapeutic intervention is based on the use of the robotic system for gait exercise. In the case of the experimental group, the use of virtual reality will also be integrated.
223597478|NCT01559675|DRUG|Hydrocortisone High Dose|Patients receive Hydrocortisone 100 mg at surgical incision followed by 100mg IV every 8 hours for the first 24 hours, followed by 75 mg IV every 8 hours for 24 hours, followed by 50 mg IV every 8 hours for 24 hours, followed by 50 mg IV every 12 hours, followed by Prednisone 20 mg orally when oral diet is resumed
223748150|NCT06631846|OTHER|Music therapy|"Participants in the music therapy group (MTG) will be comfortably lying on the bed in a reclined position of 30-45 degrees. Using a headphone, participants will be instructed to select a volume that is comfortable to their ears and listen to the music titled as The Best Relaxing Piano and Flute Music Ever which will be played for 30-minutes every day for 1-week. Patients will be encouraged to focus on the music and let it fill their senses."
223597479|NCT01559675|DRUG|Hydrocortisone Low Dose|1/3 IV equivalent dose (IVED) (hydrocortisone equivalent of the patient's preoperative steroid dose) at surgical incision, followed by 1/3 IVED for 24 hours, Patients subsequently treated with 1/4 IVED every 8 hours starting Postoperative day (POD 1), followed by 1/6 IVED every 8 hours on POD 2 and every 12 hours starting POD 3. On POD 4 or when the patient was tolerating a regular diet, oral prednisone equal to the most recent IV hydrocortisone dose resumed
223597480|NCT00636285|DRUG|Placebo|Placebo
223597481|NCT00636285|DRUG|BSYX-A110|BSYX-A110, Dosed intravenously, 3 mg/kg
223597482|NCT00636285|DRUG|BSYX-A110|BSYX-A110, Dosed intravenously, 10 mg/kg
223597483|NCT03322410|BIOLOGICAL|modified Peritoneal Equilibration test|"Peritoneal permeability status determined by modified Peritoneal Equilibration test with complete drainage at 60 minutes as described for Twardowsky~*  High : D/P creatinine\>0,8; D/D0 glucose\<0,25~*  High average : 0,65\< D/P creatinine \<0,8; 0,25\< D/D0 glucose \<0,38~*  Low average : 0,5\< D/P creatinine \<0,65; 0,39\< D/D0 glucose \< 0,48~*  Low  : D/P creatinine\<0,5 ; D/D0 glucose\>0,49."
223597484|NCT02189291|PROCEDURE|Immediate catheter removal|The indwelling catheter will be removed prior to exiting the operating room.
223597485|NCT02189291|PROCEDURE|Post op day 1 catheter removal|For patients assigned to catheter removal on post operative day one, which is the standard of care at this point.
223597486|NCT01771237|BEHAVIORAL|MyPeeps Manualized Group Intervention|Topics include: HIV/STI transmission, interpersonal communication, stigma management, condom use, substance use and risky sex, HIV-related harm reduction
223597487|NCT01771237|BEHAVIORAL|Standard Sexual Health Education|Topics include: HIV/STI transmission facts, myths regarding HIV transmission, information on effectiveness of condom use
223597488|NCT04750304|BEHAVIORAL|Application ARTHe|Patient will use ARTHe Application for 3 months
223597489|NCT00291018|DEVICE|Total Disc Replacement|Total Disc Replacement using ProDisc-C
223748151|NCT06631846|OTHER|Mindfulness meditation|Mindfulness meditation group (MGT)will be listening to audio of Guided Mindfulness Meditation Series 1 by Jon Kabat-Zinn. Similar to MTG, participants in MMG will be lying on the bed in a reclined position of 30-45 degrees. A headphone to listen to the audio of guided MM will be provided to all the participants. Participants will begin with relaxation technique by focusing on deep breathing to help calm their body and mind. This will be followed by focusing on the present moment, letting go of any thoughts or distractions that come up. Participants can focus on their breath, bodily sensations, or a specific object in their environment. Finally, the session will end by expressing a gratitude for their body and mind and setting an intention to carry the feelings of relaxation and mindfulness with them throughout the day. Similar to MTG, MMG will engage in 30-minutes of MM every day for 1-week.
223748152|NCT06631846|OTHER|Music therapy and mindfulness meditation|Music therapy and mindfulness meditation group will be receiving both music therapy and mindfulness meditation in the same body position as MTG and MMG. Firstly, participants will listen to MT for 30-minutes followed by MM for another 30-minutes. In between the 2 interventions, a 15-minute of break will be provided to all participants. Intervention will be carried out every day for 1-week.
223597490|NCT00291018|DEVICE|ACDF|Anterior Cervical Discectomy and Fusion
223597491|NCT01496469|DRUG|Febuxostat|Febuxostat 80 mg, tablets, orally, once daily for up to 6 weeks
224198375|NCT06222879|DRUG|HRS-8080; SHR-A1811|Participants will receive HRS-8080 and SHR-A1811
224198376|NCT06222879|DRUG|HRS-8080; SHR-A2009|Participants will receive HRS-8080 and SHR-A2009
224198377|NCT06222879|DRUG|SHR-A2009; SHR-1316|Participants will receive SHR-A2009 and SHR-1316
224198378|NCT06577714|DIAGNOSTIC_TEST|Electromechanical wave imaging (EWI)|EWI is a high-frame rate ultrasound technique that images the electromechanical wave corresponding to the propagation of the onset of myocardial contraction in response to electrical activation, namely electromechanical coupling.
224198379|NCT03707145|BEHAVIORAL|Consultation|The consultation will provide advice (including a short written report) about promoting healthy lifestyles, tailored to the individual
223597492|NCT01496469|DRUG|Placebo|Febuxostat placebo-matching tablets, orally, once daily for up to 6 weeks.
223597493|NCT05219682|OTHER|electroencephalographic measurement|recording brain activity in mirror therapy, haptic and tactile stimulation and in mirror therapy using virtual reality
223597494|NCT02356718|BEHAVIORAL|Cognitive training activities|Training activities consist of computer tasks designed to improve memory and cognition. The intervention consists of 45-minute training sessions delivered regularly during inpatient treatment.
223597495|NCT02356718|BEHAVIORAL|Inpatient psychosocial therapy|Group psychosocial therapy delivered in an inpatient setting.
223597496|NCT05502354|DEVICE|removal of transanal drainage tube|removal of transanal drainage tube after laparoscopic anterior resection for rectal carcinoma according to postoperative CRP trajectory
223748153|NCT06631846|OTHER|Cardiac rehabilitation|Control Group will not receive any other therapy except the conventional post-operative cardiac rehabilitation. Other 3 intervention groups will also be participating in the usual cardiac rehabilitation program. Cardiac rehabilitation will be conducted during phase I, where rehabilitation will focus on early mobilization and ambulation of participants with a target heart rate of resting heart rate + 30 beats, with the non-strenuous exercises in the bed or at the bedside, focusing on a range of motion and limiting hospital deconditioning.
223748154|NCT06908616|DIAGNOSTIC_TEST|Cord blood|Cord blood samples will be collected during routine G6PD testing. An additional 3 mL will be obtained non-invasively from the umbilical cord to determine the expression of Duffy antigens using serologic gel testing.
224198380|NCT03707145|BEHAVIORAL|Online Support|The participant will have access to an online platform 'FACET', to monitor themselves periodically, obtain feedback about their functional ability, receive recommended diet, exercise and physical activity interventions and record the adherence to any intervention.
224198381|NCT03707145|BEHAVIORAL|Empowered|The participant will be actively encouraged to contribute to their own consultation and take co-ownership and responsibility for the action plan.
224198382|NCT05963022|DRUG|Tirzepatide|Administered SC
224198383|NCT05963022|DRUG|Placebo|Administered SC
224198384|NCT01355653|DEVICE|thermal therapy|heat therapy device, topical, two applications, at 0-3 hours and 4-6 hours on treatment day
224198385|NCT01355653|DEVICE|ThermaCare heatwrap|heatwrap, topical, one time application, 8 hour duration
224198386|NCT05014672|DRUG|Setanaxib|Oral tablets, 400mg per tablet
224198387|NCT05014672|DRUG|Placebo|Oral tablets
224198388|NCT06431308|BEHAVIORAL|nutritional intervention|A nutrition guidance before initiation of AOM treatment include recommendations for food choices and eating habits to minimize the occurrence and severity of GI symptoms during the up-titration phase, will be given by registered dietitian (RD) from the study team. Next, each week, participants will provide weekly reports of GI symptoms occurrence and severity, by responding to queries sent via WhatsApp/SMS and for occurring symptoms, an automatically structured nutrition and behavioral treatment recommendations will be sent . If participants expressed an interest in personalized dietary guidance on this matter, the study team RD will contact him/her by telephone, within a range of 48 hours, to provide individualized recommendations. Three days after each report of GI symptom(s), participants will receive an additional message and will be asked to report the occurrence and severity of the GI symptom, and their compliance with the specific dietary instructions received.
224198389|NCT05006313|DEVICE|Intraoperative fluorescence angiography|Intraoperative fluorescence angiography will be used to assess tissue perfusion following initial debridement of wound.
224198390|NCT04455620|BIOLOGICAL|BNT151|intravenous (IV)
224311105|NCT00693043|DRUG|lidocaine hydrochloride|Study group will have up to 2 mg/kg of Lidocaine administered to the skin and additional Lidocaine(3mg/kg)infused through an atomizer using a specialized tip attached to the sterile leur lock syringe into the pleural cavity. The Intrapleural lidocaine dose will be given in a fixed dose of 3 mg/kg. Serum levels will be obtained at 30, 60, and 120 minutes after initial intradermal administration
223597497|NCT02843503|DEVICE|Arterialized-venous reference (YSI)|All patients will be fitted with the a CGM system, Dexcom G5 Mobile, patients receive an iv-catheter to sample venous blood. The samples will be arterialized using a heated-hand-box (arterialized-venous reference (YSI). Blood will be drawn for the determination of glucose concentrations using arterialized-venous sampling techniques per YSI.
223597498|NCT02843503|DEVICE|Venous reference measurement (YSI)|All patients will be fitted with the a CGM system, Dexcom G5 Mobile, patients receive an iv-catheter to sample venous blood. Blood will be drawn for the determination of glucose concentrations using venous sampling techniques measured per YSI.
223597499|NCT02843503|DEVICE|Capillary reference (SMBG)|All patients will be fitted with the a CGM system, Dexcom G5 Mobile, patients receive vingerstick measurements to sample capillary blood measured per Self Monitoring of Blood Glucose (SMBG) device.
223597500|NCT04553900|DIAGNOSTIC_TEST|Transesophageal Echocardiography|Placement of a transesophageal probe and performance of a diagnostic Transesophageal echocardiography examination.
223597501|NCT00193180|DRUG|Imatinib|Imatinib
223597502|NCT00193180|DRUG|Docetaxel|Docetaxel
223597503|NCT01357551|BEHAVIORAL|Maintenance intervention|Theoretically-informed maintenance intervention that involves in-person group visits that transition to individualized telephone calls, and the frequency of contact gradually decreases over time.
223597504|NCT00668603|DRUG|17-b-estradiol|2mg oral daily for 6 months
223597505|NCT00668603|DRUG|17-b-estradiol + medroxyprogeterone acetate|2mg E2 + 5mg MPA daily for 6 months
223597506|NCT00668603|DRUG|17-b-estradiol hemihydrate|1 mg skin gel daily for 6 months
223597507|NCT00668603|DRUG|placebo pill + gel|placebo daily for 6 months
223597508|NCT01565681|DRUG|ASP1240|infusion
223597509|NCT01565681|DRUG|Placebo|infusion
223597510|NCT06141447|DRUG|Oxytocin + normal saline|40 units IV oxytocin once in a 1000 mL bag of normal saline
223597511|NCT06141447|DRUG|Normal saline|1000 mL bag of normal saline alone
223597512|NCT02644785|DRUG|protamine|Protamine infusion exposures
223597513|NCT05362058|DRUG|Insulin Efsitora Alfa|Administered SC
223597514|NCT05362058|DRUG|Insulin Degludec|Administered SC
223597515|NCT03090204|PROCEDURE|ultrasound measurements|ultrasound measurements of myocardial deformation of free wall right ventricle at 4 time points during a session of intermittent hemodialysis : before the intermittent hemodialysis connection, just after starting hemodialysis, after 1 hour of hemodialysis and 5 minutes before restitution
223597516|NCT04954768|OTHER||This is a observational study, and there is no interventions.
223597517|NCT01235234|DRUG|CF101|orally q12h
223597518|NCT00534859|DEVICE|High Risk PCI|High Risk Percutaneous Coronary Intervention
223597519|NCT03406013|BEHAVIORAL|Written Information|Receive written information on diet and exercise relevant to older men with prostate cancer
223597520|NCT03406013|BEHAVIORAL|Prescription|Participants receive tailored exercise prescription and tailored diet recommendations
223597521|NCT03406013|BEHAVIORAL|Technology|Participants receive motivational text messages and can electronically log and track their exercise and diet habits
223748155|NCT06913257|DEVICE|ESWT Combined with Standard Rehabilitation|Participants in the experimental arm will receive a combination intervention comprising ESWT delivered by certified technicians using a validated device for post-burn scars, along with standard rehabilitation therapy. ESWT sessions will be standardized (e.g., 3,000 pulses per session, weekly for 8 weeks) and will be integrated with a comprehensive rehabilitation program encompassing physical therapy, scar management exercises, and patient education. The specific parameters (e.g., energy level, frequency) will be reported based on established guidelines.
224198391|NCT06647446|OTHER|Exercise supported by the digital physiotherapy and telerehabilitation software TRAK|8 week home therapeutic exercise program that includes flexibility and strength exercises scheduled through the software of digital physiotherapy and telerehabilitation TRAK. The program will be carried out with a frequency of 3 weekly sessions, preferably on alternate days. The program will be carried out with the support of the TRAK software (https://www.trakphysio.com/es/), which allows the exercises to be carried out in front of a camera that, with the help of an artificial intelligence system, offers feedback to the participant and allows you to keep a record of the sessions. As an addition to the home sessions, two face-to-face sessions will be held in the first and fifth weeks, respectively. The exercise program includes three levels of difficulty (easy, intermediate and difficult), with patients advancing to subsequent levels once each level is successfully overcome.
223597522|NCT03406013|BEHAVIORAL|Coaching|Participants receive access to an exercise and diet coach to provide advice by phone and/or email
223597523|NCT02489383|OTHER|Continuous Exercise Training|The continuous training (CT) will be held in two weekly sessions lasting total of 40 minutes and 5 minutes for heating and 5 to slowdown, and the duration will be 24 sessions (3 months). The exercise sessions will be will be performed on a stationary bicycle, with the initial intensity of 70% of VO2max. If the subject sustain continuously training intensity for 2 consecutive sessions without symptoms breathing, exercise intensity will be increased by 5% of heart rate. The patient may stop the activity if he has any symptoms or respiratory distress, returning it as soon present improvement. Throughout the training, will be monitored heart rate and the level of perception subjective effort (modified Borg scale).
223597524|NCT02489383|OTHER|Interval Exercise Training|The interval training (IT) will be held in two weekly sessions. The IT is individualized and will be performed on a stationary bicycle. Training sessions will be performed with total duration of 40 minutes consisting of 5 minutes extender, 30 minutes from the main part (IT), finishing with five minutes back to calm. In the main part (of 5 to 30 minutes), the patient will perform the exercise with high intensity in the first two weeks, the exercise will be conducted with an intensity 80% of maximum capacity obtained in cycle ergometer test and will cycle for 30 seconds followed by a 30 second recovery period. In the 3rd and 4th weeks, the intensity will be increased to 100% of the maximum obtained. After this period, the intensity will be increased by 5% charge.
223597525|NCT02489383|BEHAVIORAL|Education Program|The education program will discuss issues related to asthma and physical activity. Presentations and group discussions will be carried out, including information about asthma pathophysiology, medication and peak flow meter skills, self-monitoring techniques, environmental control, benefits and current recommendations of physical activity.
223597526|NCT03863431|OTHER|High-fat diet|"Participants will consume a high fat diet for 14 days with approximately 65% of energy from fat. The diet will also provide an energy excess, at 130% of energy requirements.~Participants will be provided with all of their meals and snacks throughout the study."
223597527|NCT03863431|OTHER|High-carbohydrate diet|"Participants will consume a high fat diet for 14 days with approximately 70% of energy from carbohydrate. The diet will also provide an energy excess, at 130% of energy requirements.~Participants will be provided with all of their meals and snacks throughout the study."
223597528|NCT05156957|OTHER|physiotherapeutic intervention|The intervention consists of a brief physiotherapeutic assessment by a short physical performance battery, a brief information on the expected course of the condition and instructions on self-management regarding back friendly behaviour (eg. respecting the pain, staying active and back friendly movement strategies). Additionally, three exercises for daily self-guided therapy are included to the intervention: Turning in bed and coming to a sitting position, sit to stand and squats standing in front of a wall.
223597529|NCT02172378|DRUG|Tiotropium inhalation capsules|
223597530|NCT02172378|DRUG|Placebo inhalation capsules|
223597531|NCT03499834|BIOLOGICAL|Immune Killer Cells (IKC)|Autologous cells of the immune system. Intravenous Injection (I.V.) frequency: One injection per week, twenty-four injections on-treatment
223597532|NCT04574401|DRUG|IS-002|Intravenous injection of IS-002 Investigational Drug
223597533|NCT01402713|BIOLOGICAL|GC1107|GC1107-T5.0: low dose, GC1107-T7.5: high dose
223597534|NCT01402713|BIOLOGICAL|TD_PUR INJ / SK Td vaccine|step 1(phase 2)-TD\_PUR INJ step 2(phase 3)-SK Td vaccine
223597535|NCT04991675|BEHAVIORAL|pelvic floor muscle exercises|During the first visit, the anatomy of the pelvic floor and the purpose of the program were explained. Exercises were taught in the supine position, as described by Kegel (1948), it was confirmed that the women learned to use the correct muscles with vaginal palpation. During the exercise, the participants were informed not to pull the abdomen inwards, not to tighten their legs and hip muscles, and not move their pelvis.
223597536|NCT04991675|BEHAVIORAL|diaphragmatic breathing exercises|During the first visit, the anatomy of the diaphragm and abdominal wall and the purpose of the program were explained. Diaphragmatic breathing exercise was taught in supine position. The movement of the symphysis pubis was examined to confirm that the pelvic floors' movement was also involved breathing. Abdominal palpation was used to elicit unawareness of the diaphragmatic breathing and to assess whether contractions were performed correctly.
224198392|NCT06647446|OTHER|Standard home-based exercise|8 week home therapeutic exercise program that includes flexibility and strength exercises scheduled through a dossier and an exercise diary. The program will be carried out with a frequency of 3 weekly sessions, preferably on alternate days. The program will be carried out with the support of an information dossier of the exercises to be performed and a monitoring diary in which everything related to the sessions carried out will be noted.. As an addition to the home sessions, two face-to-face sessions will be held in the first and fifth weeks, respectively. The exercise program includes three levels of difficulty (easy, intermediate and difficult), with patients advancing to subsequent levels once each level is successfully overcome.
224198393|NCT06646965|PROCEDURE|individual dietetic counseling|only the pregnant patient receives dietetic counseling
224198394|NCT06646965|PROCEDURE|family-based dietetic conseling|the pregnant patient and her companion receive dietetic counseling
224198395|NCT00400985|DEVICE|Implantable device: monitoring of intrathoracic impedance using the OptiVol diagnostic tool.|SENSE-HF is non randomized trial. Study divided in 3 phases among which the first phase is blinded towards device diagnostic data.
224198396|NCT04409327|DRUG|RTB101|Oral RTB101 10 mg hard gelatin capsule once daily for 4 weeks
224198397|NCT04409327|DRUG|Placebo|Oral matching placebo once daily for 4 weeks
224198398|NCT05527782|DRUG|modified TPF|modified TPF: modified docetaxel-cisplatin-fluorouracil followed by concurrent chemoradiotherapy
224198399|NCT05527782|OTHER|Quality of life assessment (QoL)|Quality of life assessment with questionnaires: EORTC QLQ-C30 and QLQ H\&N-35
224198400|NCT05522816|DRUG|KX01 0.01% (0.1 mg/g)|Stage 1: 6 patients (KX01 0.01% \[0.1 mg/g\])
224198401|NCT05522816|DRUG|Placebo|Contains same excipients with KX01 but do not contain Tirbanibulin
224198402|NCT05522816|DRUG|KX01 0.1% (1.0 mg/g)|Stage 2: 6 patients (KX01 0.1% \[1.0 mg/g\])
224198403|NCT05522816|DRUG|KX01 1% (10 mg/g) for 5 days|Stage 3: 6 patients (KX01 1% \[10 mg/g\]) for 5 days
224198404|NCT05522816|DRUG|KX01 1% (10 mg/g) for consecutive 5 days and 2 days rest for 1 cycle, and repeat up to 4 cycles|Stage 4: 6 patients (KX01 1% \[10 mg/g\])for consecutive 5 days and 2 days rest for 1 cycle, and repeat up to 4 cycles
224198405|NCT03093688|BIOLOGICAL|Infusion of iNKT cells and CD8+T cells|The eligible patients receive twice infusions of iNKT cells(1E8\~1E10) and CD8+T cells(1E7\~1E9) in one course of treatment.
224198406|NCT06256484|DRUG|ATA3219|ATA3219 is allogeneic anti-CD19 chimeric antigen receptor T-cell, administered intravenously on Day 1.
224198407|NCT02901184|DRUG|Spironolactone|Treatment with Spironolactone tablets on top of standard care
224198408|NCT02901184|OTHER|Standard care|Standard care does not involve Spironolactone
224198409|NCT01883141|PROCEDURE|Electrophysiological Study|Subjects will receive pacing from one right ventricular lead and one left ventricular catheter/lead with multiple LV pacing spots
224198410|NCT03388528|DIETARY_SUPPLEMENT|Low Residue Diet Intervention|All patients will be provided with a LRD plan (\< 10g fibre per day) for 12 weeks between visits 2 and 3. They will also be supplemented with multivitamin and mineral tablet or liquid (Forceval) to meet nutrient requirements (prescribed as standard care). The dietitian will provide written and oral information about the LRD and weekly telephone calls to assess patient's progress on the diet.
223597537|NCT01356459|DEVICE|Mepilex Border Dressing|Soft silicone self adherent dressing
223597538|NCT03205683|OTHER|Intraneural facilitation (INF)|INF is a novel non-invasive therapy based on the principle of restoring vascular function at the capillary level in peripheral nerve.
223748156|NCT06913257|BEHAVIORAL|Standard Rehabilitation Therapy Alone|Participants in the control arm will receive the institution's standard rehabilitation therapy for managing post-burn scars, including physical therapy, occupational therapy, and scar-massage techniques. Treatment frequency and duration will mirror the experimental arm's rehabilitation component to ensure consistency. No ESWT will be provided.
223748157|NCT06916598|OTHER|Delphi study|This Delphi study involves multiple iterative rounds until a stable consensus or dissensus is reached on all the statements.
224198411|NCT06142955|DEVICE|MAGSTIM Rapid2 TMS system|The device will administer TMS pulses in bursts at fixed intervals for a total of 600 pulses over 190 seconds after first assessing the participants motor threshold (MT). During the sham stimulation condition, the TMS coil will be tilted 90° tangential to the scalp during the administration so that the orientation is not biologically active and will not elicit a muscle contraction. This sham condition will look and sound just like real TMS.
224198412|NCT02565537|PROCEDURE|LASIK|WFG vs. WFO LASIK
223597539|NCT03205683|OTHER|Sham INF|Will be performed by a different therapist than actual INF. The patient will be asked to do the following combination of passive range of motion (PROM) and active ROM activities to promote blood flow in the affected arm.
223597540|NCT01602289|BIOLOGICAL|LY2875358|Administered IV
223597541|NCT01602289|DRUG|Erlotinib|Administered orally
223597542|NCT01602289|DRUG|Gefitinib|Administered orally
223597543|NCT00064961|BEHAVIORAL|Individualized dietary-control and exercise program|
223597544|NCT00064961|BEHAVIORAL|Weight-management and smoking cessation maintenance|
223597545|NCT00064961|BEHAVIORAL|Smoking Cessation program|
223597546|NCT02076282|OTHER|1 MRI scan|"For healthy volunteers: 1 MRI scan without contrast~For patients: 1 MRI scan with contrast"
223597547|NCT01053494|PROCEDURE|massage therapy|Undergo massage therapy
223597548|NCT01053494|OTHER|questionnaire administration|Ancillary studies
223597549|NCT01053494|PROCEDURE|quality-of-life assessment|Ancillary studies
223597550|NCT01053494|OTHER|intervention by caregiver|Undergo massage by caregiver
223597551|NCT01053494|PROCEDURE|standard follow-up care|Undergo standard follow-up care
223597552|NCT03397342|DEVICE|CPAP machine|Use of CPAP machine during MRI
223597553|NCT04417335|BIOLOGICAL|BCG vaccine|Bacille Calmette-Guérin is a live attenuated strain of Mycobacterium bovis developed in 1921 to prevent tuberculosis and other mycobacterial related infections.
223597554|NCT04417335|BIOLOGICAL|Placebo|0.9% NaCl
223597555|NCT03369912|BIOLOGICAL|CSJ148|Active
223597556|NCT03369912|OTHER|Placebo|No Drug
223597557|NCT01035281|DRUG|Nabilone, flexible dosing|nabilone at 0.5 - 4 mg/day
223597558|NCT04102072|DIAGNOSTIC_TEST|Trendelenburg Maneuver|In the Trendelenburg position, the body is laid supine with the feet higher than the head by 15-30 degrees. The venous return increases in the trendelenburg position which in turn increases the stroke volume.
223597559|NCT04102072|DIAGNOSTIC_TEST|dobutamine stress test|Dobutamine was infused intravenously at the initial dose of 2.5 ug/kg/min. Echocardiography was performed after 5-10 minutes of continuous infusion, and hemodynamic data were recorded.
223597560|NCT02540070|PROCEDURE|Periarticular|
223597561|NCT02540070|PROCEDURE|Motor free|
223597562|NCT02540070|PROCEDURE|Motor free with dex|
223597563|NCT02540070|DRUG|Ropivacaine|
223597564|NCT02540070|DRUG|epinephrine|
223597565|NCT02540070|DRUG|morphine|
223597566|NCT02540070|DRUG|Ketorolac|
223597567|NCT02540070|DRUG|Dexmedetomidine|
223597568|NCT02540070|DRUG|saline|
223597569|NCT06269939|BEHAVIORAL|STEM|Memory technique training
223597570|NCT06028009|PROCEDURE|Injection of platelet-rich plasma|Injection of autologous platelet-rich plasma into anterior vaginal wall
223597571|NCT06028009|PROCEDURE|Injection of saline|Injection of sterile normal saline into anterior vaginal wall
223597572|NCT04878913|DRUG|C21|C21 was administered in the VP-C21-006 trial
223597573|NCT04878913|DRUG|Placebo|Placebo was administered in the VP-C21-006 trial
223597574|NCT04734145|DIAGNOSTIC_TEST|Breathprinting test|Consented, enrolled participants will undergo a breathprinting test (e-nose) during the presurgical visit and at the same facility as their presurgical or prebiopsy visit, before any attempt is made to obtain cytohistological diagnosis of the pulmonary nodule.
223597575|NCT05476172|DRUG|Dienogest Pill|The effect of dienogest on endometriosis pain symptoms.
223597576|NCT05476172|DRUG|Norethindrone Acetate|The effect of Norethindrone Acetateon endometriosis pain symptoms.
223597577|NCT03265340|DEVICE|dTMS|
223597578|NCT01458418|DRUG|Montelukast|Those in Montelukast 10mg/day group will receive two 5mg tablets of Montelukast.
223597579|NCT01458418|OTHER|placebo|Those in the placebo group will receive 2 placebo tablets per day. Those in the Montelukast 5mg/day will receive 1 placebo tablet per day.
223597580|NCT01458418|DRUG|5 mg Montelukast|Subject will receive one 5mg tablet of Montelukast and one placebo tablet per day.
223597581|NCT02389036|DRUG|SDD Oral Paste|A six-hourly topical application of 0.5g paste, containing colistin 10mg, tobramycin 10mg and nystatin 125,000 IU, to the buccal mucosa and oropharynx
223597582|NCT02389036|DRUG|SDD Gastric Suspension|2\. A six-hourly administration of 10 mL of a suspension containing 100 mg colistin, 80 mg tobramycin and 2 x 10 \^6 IU nystatin, to the gastrointestinal tract via a gastric/post-pyloric tube
223597583|NCT02389036|DRUG|Intravenous Antibiotic|A four-day course of an intravenous antibiotic in patients not already receiving a therapeutic antibiotic
223597584|NCT00286494|DRUG|Alogliptin and pioglitazone|Alogliptin 12.5 mg, tablets, orally, once daily and pioglitazone 30 mg or 45 mg, tablets, orally, once daily for up to 26 weeks
223597585|NCT00286494|DRUG|Alogliptin and pioglitazone|Alogliptin 25 mg, tablets, orally, once daily and pioglitazone 30 mg or 45 mg, tablets, orally, once daily for up to 26 weeks
223597586|NCT00286494|DRUG|Pioglitazone|Alogliptin placebo-matching tablets, orally, once daily and pioglitazone 30 mg or 45 mg, tablets, orally, once daily for up to 26 weeks
223597587|NCT04776317|BIOLOGICAL|ChAdV68-S|Chimpanzee Adenovirus serotype 68 - Spike (ChAdV68-S) is a replication-defective, E1, E3 E4Orf2-4 deleted adenoviral vector based on chimpanzee adenovirus 68 (C68, 68/SAdV-25, originally designated as Pan 9), which belongs to the sub-group E adenovirus family. A single 0.5 mL intramuscular injection will be administered in the deltoid muscle. When possible, the prime vaccine and boost vaccine should be administered in different arms.
223597588|NCT04776317|BIOLOGICAL|ChAdV68-S-TCE|Chimpanzee Adenovirus 68 - Spike plus additional SARS-CoV-2 T cell epitopes (ChAdV68-S-TCE) is a replication-defective, E1, E3 E4Orf2-4 deleted adenoviral vector based on chimpanzee adenovirus 68 (C68, 68/SAdV-25, originally designated as Pan 9), which belongs to the sub-group E adenovirus family. A single 0.5- or 1.0-mL (depending on dose level) intramuscular injection will be administered in the deltoid muscle. When possible, the prime vaccine and boost vaccine should be administered in different arms.
223597589|NCT04776317|BIOLOGICAL|SAM-LNP-S|Self-Amplifying mRNA - Lipid Nanoparticles - Spike (SAM-LNP-S) is a SAM vector based on Venezuelan Equine Encephalitis Virus (VEEV). A single 0.25 mL or 0.5 mL (depending on dose level) intramuscular injection will be administered in the deltoid muscle. When possible, the prime vaccine and boost vaccine should be administered in different arms.
223597590|NCT04776317|BIOLOGICAL|SAM-LNP-S-TCE|Self-Amplifying mRNA - Lipid Nanoparticles -Spike plus additional SARS-CoV-2 T cell epitopes (SAM-S-TCE) is a SAM vector based on Venezuelan Equine Encephalitis Virus (VEEV). A single 0.25 or 0.5 mL (depending on dose level) intramuscular injection will be administered in the deltoid muscle. When possible, the prime vaccine and boost vaccine should be administered in different arms.
223597591|NCT04776317|OTHER|Sodium Chloride, 0.9%|The diluent used for this study will be 0.9% Sodium Chloride Injection, USP, and is a sterile, nonpyrogenic, isotonic solution of sodium chloride and water for injection. Each milliliter (mL) contains sodium chloride 9 mg. It contains no bacteriostat, antimicrobial agent or added buffer and is supplied only in single-dose containers to dilute or dissolve drugs for injection. 0.308 mOsmol/mL (calc.). 0.9% Sodium Chloride Injection, USP contains no preservatives.
223597592|NCT05257824|DRUG|Aspirin 100mg|"1. short-term dual antiplatelet: dual antiplatelet agents for 6 months~2. long-term dual antiplatelet: dual antiplatelet agents for 12 months"
223597593|NCT05257824|DRUG|Clopidogrel 75mg|"1. short-term dual antiplatelet: dual antiplatelet agents for 6 months~2. long-term dual antiplatelet: dual antiplatelet agents for 12 months"
223597594|NCT04207060|DRUG|Indomethacin|One capsule of 50 mg of indomethacin will be taken orally twice a day for a total of 28 days.
223597595|NCT04207060|DRUG|Placebo|One capsule of lactose not containing active study drug will be taken orally twice a day for a total of 28 days.
223597596|NCT04207060|PROCEDURE|Endoscopy for Pancreatic Function Testing|All subjects in the study (regardless of which treatment arm they are randomized to) will undergo an upper endoscopy during which they will receive an endoscopic pancreatic function test. An upper endoscopy will be performed during the baseline visit and at the follow-up visit at day 28 of the treatment (2 endoscopies total per each subject). Specifically, during the upper endoscopy, secretin will be administered intravenously at a weight-based dose of 0.2 mcg/kg over 1 minute. Fluid will be aspirated from the duodenum through the endoscope from 0-10 minutes and 10-20 minutes following secretin administration. The collected fluid will then be sent to the laboratory for analysis.
223597597|NCT06025032|GENETIC|HG205|The study will enroll up to 2 cohorts, evaluating a starting dose plus a higher or lower dose
223597598|NCT02524158|BEHAVIORAL|Yoga Therapy for CLBP|Classes begin with a few minutes of simple seated breathing exercises. Depending on their mobility, participants can sit either on the floor or on a chair. This is followed by gentle warm-up stretches. Participants are then led through a series of standing postures, seated postures and floor postures. The difficulty of the poses will gradually increase over the duration of the 12 weeks, and appropriate modifications are offered to participants whenever needed. Deep and rhythmic breathing will be emphasized throughout. Each class will end with a supine resting pose.
223597599|NCT03238625|DRUG|Lidocaine and sodium bicarbonate|Lidocaine and sodium bicarbonate ratio 3:1
223597600|NCT03238625|DRUG|Lidocaine and sodium bicarbonate|Lidocaine and sodium bicarbonate ratio 9:1
223597601|NCT03238625|DRUG|Lidocaine|Lidocaine injection
223597602|NCT03238625|DRUG|Sodium cloride 0.9%|Placebo
223597603|NCT05122091|DRUG|Fruquintinib + SOX|Fruquintinib：5mg qd for 2 weeks on and 1 week off, q3w； SOX: Tegafur gimeracil oteracil potassium capsule: 40-60mg bid（dosage according to body surface area），d1-14，q3w； Oxaliplatin：130mg/m2，intravenous (IV) ，d1，q3w.
223597604|NCT03671304|DEVICE|Fitbit Versa|"Participants will receive a Fitbit Versa and instructions on its use. Participants will be asked to wear the device for eight weeks, removing it only for charging and when engaging in activities in which the device could be submerged in water (bathing, swimming, etc.).~At enrollment, participants will indicate a preferred time to receive affective framing messages and EMA prompts (morning), and intention planning prompts (evenings). Participants will receive affective framing messages and intention planning prompts on a randomized schedule, such that participants will receive each message type on 50% of days."
223597605|NCT05962892|OTHER|No Intervention|No Intervention
223597606|NCT02718716|DRUG|UCB7665|"* Intervention Type: Biological/Vaccine~* Pharmaceutical Form: Powder for solution for infusion~* Concentration: 100 mg/ml - Route of Administration:~Subcutaneous infusion"
223597607|NCT04316637|DRUG|Arimoclomol|Participants receive prescribed arimoclomol by oral administration
223597608|NCT00033553|DRUG|carboplatin|Arm A: AUC=6 IV over 30 min for 2 cycles then AUC=2 IV over 30 min q wk for 7 wks Arm B: AUC=5 IV over 30 min for 2 cycles
223748158|NCT06916598|OTHER|Structured Interview|"Structured interviews will be conducted by members of the steering committee and an independent qualitative research expert. A pilot-tested case vignette along with a Likert scale-based questionnaire, will be employed to gather insights regarding the impact and severity of PPCs. The impact of the individual components of PPCs will be evaluated on a 7-point Global Rate of Change (GRC) scale (from very much worse to very much better) to calculate the minimal clinical important difference. Patient care representatives will be engaged in anonymous voting on the questionnaire. PPCs' rankings and key themes synthesised from the interviews will be shared with the panel in the second Delphi round, facilitating the integration of patient perspectives into the consensus process."
223748159|NCT06920381|DRUG|Gebauer's Ethyl Chloride Topical Spray|Prior to injection of lidocaine, the investigator will apply ethyl chloride spray, Gebauer's Ethyl Chloride Topical Spray, continuously for 4 to 10 seconds until the skin turns white. This application will be done from a distance of 8 to 18 cm (3 to 7 inches) to the right side of the tumor lesion.
223748160|NCT06907290|DRUG|Brelovitug 300 mg|Route of administration- Subcutaneous Injection
223748161|NCT06907290|DRUG|Brelovitug 900 mg|Route of administration- Subcutaneous Injection
223748162|NCT06907290|DRUG|Delayed Treatment with Brelovitug 300mg|Route of administration- Subcutaneous Injection
223748163|NCT06912893|DEVICE|radial shock wave therapy|treatment of the nervus medianus on the level of the carpal tunnel with radial shock wave therapy with 1500 impulses, 5 Hz and 1,5 bar
223597609|NCT00033553|DRUG|gemcitabine hydrochloride|1000 mg/sq m IV over 30 min days 1 \& 8 repeat q 21 days for 2 cycles; then 35 mg/sq m IV over 30 min 2X wk for 7 wks
223597610|NCT00033553|DRUG|paclitaxel|225 mg/sq m IV over 3 hrs q 21 days for 2 cycles, then 45 mg/sq m IV over 1 hr q wk for 7 wks
223748164|NCT06912893|DEVICE|focused shock wave therapy|treatment of the nervus medianus on the level of the carpal tunnel with focused shock wave therapy with 1500 impulses, 5 Hz and 0,05 mJ/mm²
223748165|NCT07118891|BIOLOGICAL|ABCL635|Participants will receive SC administrations of ABCL635
223748166|NCT07118891|BIOLOGICAL|Placebo|Participants will receive SC administration of placebo (5% dextrose solution)
223597611|NCT00033553|RADIATION|radiation therapy|3-D XRT 7400 cGy total after induction (during cycles 3-9)
223597612|NCT05160376|OTHER|Self-help CBT with email reminder and text message|"An online transdiagnostic self-help intervention that is delivered through an online mental health platform.~Email reminder and text message will be sent to remind participant to complete the module"
223597613|NCT05160376|OTHER|Feedback calls on participants' progress|Feedback calls (approximately 15 minutes) on participants' progress from a clinical psychology trainee or an undergraduate trained psychology student under the supervision of a clinical psychology professor
223597614|NCT01683825|DRUG|F-18 florbetapir PET|Cardiac PET images will be obtained following injection of F-18 labeled Florbetapir (Trade Name: Amyvid)
223597615|NCT01428739|DEVICE|MRS|Procedure
223597616|NCT05343377|DIAGNOSTIC_TEST|circulate free methylated EBV DNA|Accuracy of circulating free methylated EBV DNA in predicting 2-year PFS
223597617|NCT04869358|DRUG|Ofatumumab|Ofatumumab 20 mg s.c. on days 1, 7, 14, week 4 and every 4 weeks thereafter
223597618|NCT06965894|DEVICE|Johnston Pressure Splint|Application of a Johnston pressure splint to the lower extremity.
223597619|NCT06965894|OTHER|Rehabilitation Program|Rehabilitation program including neurodevelopmental therapy and proprioceptive neuromuscular facilitation (PNF) techniques.
223597620|NCT04164732|DRUG|LCZ696|LCZ696 orally twice daily
223597621|NCT04164732|DRUG|Placebo|placebo
223597622|NCT06584305|PROCEDURE|AI-Powered Body Dysmorphic Disorder Screening Procedure|The AI-Powered Body Dysmorphic Disorder Screening Procedure involves using an AI tool to evaluate patients for Body Dysmorphic Disorder (BDD) before undergoing elective cosmetic surgery. The screening integrates the Body Dysmorphic Disorder Questionnaire (BDDQ) with additional psychological assessments. The AI system processes the collected data to produce a risk score, guiding surgeons in making informed decisions about the need for psychological evaluation or intervention, and determining the suitability of patients for surgery.
223597623|NCT01597713|DRUG|NNC 0148-0000-0362|Subjects will be randomised to receive a single dose of NNC 0148-0000-0362 orally within each dose group
223597624|NCT01597713|DRUG|insulin glargine|As an active comparator, one standard dose will be given subcutaneously (s.c., under the skin) within each dose group
223597625|NCT01597713|DRUG|placebo|Subjects will receive a single dose of oral placebo within each dose group
223597626|NCT01597713|DRUG|NNC 0148-0000-0362|Single low dose administered orally in randomised order on three dosing visits separated by a wash-out period
223597627|NCT01597713|DRUG|NNC 0148-0000-0362|Single high dose administered i.v. in randomised order on three dosing visits separated by a wash-out period
223597628|NCT01597713|DRUG|NNC 0148-0000-0362|Single high dose administered orally in randomised order on three dosing visits separated by a wash-out period
223597629|NCT04700826|DRUG|Direct Oral Anticoagulants|choice of DOAC (apixaban, dabigatran, edoxaban or rivaroxaban) according to local practice
223597630|NCT06348797|DRUG|α-PD-L1/4-1BB DLL3 CAR-T (BHP01)|Preconditioning with fludarabine, cyclophosphamide, based chemotherapy regimen at sub-clinical doses; Bridge radiotherapy with 15 Gray (Gy)/5 fractions; α-PD-L1/4-1BB DLL3 CAR-T (BHP01): the first dose was 5x10\^5/kg.
223597631|NCT06974435|BEHAVIORAL|Interval training and electromagnetic therapy|Combined application of moderate intensity interval training and low frequency pulsed electromagnetic field therapy, in addition to pharmacotherapy.
223597632|NCT06974435|BEHAVIORAL|Interval exercise training|Application of moderate intensity interval training, in addition to pharmacotherapy.
223597633|NCT06974435|BEHAVIORAL|Electromagnetic therapy|Application of low-frequency pulsed electromagnetic field therapy, in addition to pharmacotherapy.
223597634|NCT06974435|OTHER|Control group (No intervention group)|Only Pharmacotherapy.
223597635|NCT04302545|PROCEDURE|Cystoinflation|Bladder retrofill with 300cc saline to distend the bladder to recognize bladder outline
223597636|NCT04865237|BIOLOGICAL|SARS-CoV-2 Virus 1x10^1 TCID50|SARS-CoV-2, intranasally, (1x10\^1 TCID50)
223597637|NCT04865237|DRUG|Remdesivir|VEKLURY™
224314243|NCT04511260|DEVICE|NuEra Tight VRF Handpiece|"The VRF is a Model that belongs to the NuEra Tight RF Family, specific for the treatment of small areas.~The NuEra is FDA cleared (K151296) for a wide range of indications including but not limited to, selected medical conditions such as temporary relief of pain, muscle spasms, and increase in local circulation. The NuEra Tight VRF with the small area handpiece is CE marked in Europe and currently under review by the FDA. The system and its accessories, are intended to be use for a wide range of indications including, but not limited to:~· Provide heating for the purpose of elevating tissue temperature for selected medical conditions such as temporary relief of pain, muscle spasms, and increase in local circulation of soft tissue."
223597638|NCT04865237|BIOLOGICAL|SARS-CoV-2 Virus 1x10^2 TCID50|SARS-CoV-2, intranasally, (1x10\^2 TCID50)
223597639|NCT04865237|BIOLOGICAL|SARS-CoV-2 Virus 1x10^3 TCID50|SARS-CoV-2, intranasally, (1x10\^3 TCID50)
223597640|NCT06975657|BEHAVIORAL|Wellbeing skills for reentry|A 6-week, in-person meditation training program for formerly incarcerated adults, with practices and concepts grounded in the four pillars of the Healthy Minds Program (awareness, connection, insight, and purpose)
224314244|NCT00117910|DRUG|pegfilgrastim|
223597641|NCT06974630|OTHER|Cervical erector spinae plane block|Patients will receive bilateral ultrasound-guided cervical erector spinae plane block using 15 ml of bupivacaine 0.25% on each side.
223597642|NCT06974630|OTHER|Cervical plexus block|Patients will receive bilateral ultrasound-guided superficial cervical block using 15 mL of 0.25% plain bupivacaine on each side of the neck.
223597643|NCT06974617|DRUG|Sphenopalatine block|Patients will receive 2 ml of 2% lidocaine using a nasal applicator in each nostril.
223597644|NCT06974617|DRUG|Botulinum Toxin Type A|Patients will receive Botulinum Toxin Type A 100 units administered in a fixed dose and site paradigm.
223597645|NCT06975449|BEHAVIORAL|Multicomponent Physical Exercise Program (Vivifrail)|Vivifrail physical training, 5 times/week, 50-60 minutes/session for 12 weeks
223748167|NCT07119112|DEVICE|Surgical drain stripping device|We have developed a device to fully compress the surgical drain tubing without compromising the integrity of the tubing to clear the drain fluid/debris more effectively than the current standard of care.
223748168|NCT07119112|OTHER|Standard of Care (Investigator Choice)|Current standard of care for surgical drain tube stripping involves running fingertips down the length of the tubing compressing the drain tubing to clear fluid/debris.
223597646|NCT06976632|BEHAVIORAL|Helfer Skin Tap Tecnique|"In the first phase of the study, pregnant women who agree to participate and meet the sampling criteria will be informed about the study, and their written and verbal consents will be obtained. Then, the Individual Identification Form will be completed.~In the second phase, the vital signs of the pregnant women will be measured by the nurse involved in the study. Following this, tetanus vaccination will be administered to the pregnant women in the intervention group using the Helfer Skin Tap technique in accordance with the Helfer Skin Tap IM Injection Procedure Guideline.~In the third phase of the study, pain will be assessed using the Numerical Pain Scale immediately after the procedure and 15 minutes later by the nurse, and the vital signs of the pregnant women will be measured again. To evaluate the long-term effects of pain, participants will be contacted via a link, and pain assessments will be conducted at the 24th and 48th hours following the vaccination."
223597647|NCT06976632|BEHAVIORAL|Local Cold Application|"In the first phase of the study, pregnant women who agree to participate and meet the sampling criteria will be informed about the study, and their written and verbal consents will be obtained. Then, the Individual Identification Form will be completed.~In the second phase, the vital signs of the pregnant women will be measured by the nurse involved in the study. Subsequently, tetanus vaccination will be administered to the pregnant women in the intervention group using a cold compress gel, based on the Cold Compress Gel IM Injection Procedure Guideline developed in line with the relevant literature.~In the third phase of the study, pain will be assessed using the Numerical Pain Scale immediately after the procedure and 15 minutes later by nurse, and the vital signs of the pregnant women will be measured again. Pain assessment will be repeated at the 24th and 48th hours following the vaccination."
223597648|NCT06976827|OTHER|Dietary and physical activity monitoring during the 3-months post-hospitalization period|Three consultations with a private dietician, one consultation with the general practitioner, three months of APA monitoring
223597649|NCT06975020|DRUG|Participants will prepare their cannabis product ad libitum and inhale the prepared product as usual for a maximum of 15 minutes.|Participants will prepare and inhale their cannabis product ad libitum for a maximum of 15 minutes. Prior to inhaling cannabis (the baseline), and for three hours thereafter, biological samples (e.g., blood) will be collected. Participants will be asked to complete a series of questionnaires addressing their (subjective) neurocognitive function and well-being, as well as their self-rated driving ability and subjective cannabis effects.
223597650|NCT06976580|PROCEDURE|conventional local anesthetic injection|A conventional infiltration anesthesia will be conducted on the lumbar area of the patient, targeting the epidermis and subcutaneous tissue. A 25G syringe will be used, with the needle angle set between 30° and 45°. 1cc of 1% lidocaine will be injected. The target size of the wheal is 5-10 mm.
223597651|NCT06976580|PROCEDURE|skin stetching technique for local anesthetic injection|Skin stretching techinique will be applied to the local anesthetic injection site by stretching the skin around the needle entry point.
223597652|NCT01093872|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|"Upon recruitment, all patients will undergo a 1 week treatment consisting of 5 rTMS sessions~Repetitive TMS consists of 1000 stimulations/ day at 1 Hz and 110% of the motor threshold, for five consecutive days over the left AC."
223597653|NCT01423734|OTHER|magnetic resonance imaging (MRI)|"Each patient will undergo clinical and research MRI examinations. Before any MRI examination, the patient will answer a standard radiology MR department questionnaire form, with specific questions addressing contra-indications to MRI. The questionnaire form will be reviewed by radiology personnel as per standard practice.~During the research MRI, the patient will be monitored visually and communication will be maintained between the patient and the MR technologists via a speaker system. At the termination of the study, the patient will be evaluated by the MR department radiology personnel as done routinely. Two breath hold DWI sequences will be performed for each patient. Since this is a reproducibility study, identical scan parameters will be used for the clinical and research MRI. The multiple b value DWI will be performed using the enhanced DW sequence that have been recently made available on our 3.0 Tesla MR 750 scanners at the Breast and Imaging Center."
223597654|NCT02690714|BIOLOGICAL|Plasminogen (Human) intravenous|Prometic Plasminogen (Human) intravenous infusion given as single dose of 6.6 mg/kg in Segment 1 and repeat doses in Segments 2 and 3.
223597655|NCT03867942|DRUG|Monolayer group|Monolayered combination of gemigliptin and rosuvastatin
223597656|NCT03867942|DRUG|Bilayer group|Bilayered combination of gemigliptin and rosuvastatin
223597657|NCT01714999|PROCEDURE|Bursectomy|Bursectomy of the OB and PB are performed in the operation theatre under sterile conditions. In case of a laceration of the OB a leash, in case of PB a redon drainage (Charr. 10) is inserted. After application of a sterile bandage a cast is applied in both cases. Patient will receive AB for 5 days, the affected limb will be immobilized until removal of the stiches after 12-14 days.
223597658|NCT01714999|PROCEDURE|Bursal reconstruction|The bursal laceration is treated within in ER setting. The wound is cleaned and thoroughly washed, if needed the wound margins are excised. The wound is then closed using simple suture and a plaster applied and removed 5 days later. Antibiotics are be administered for 5 days
223597659|NCT01754571|BEHAVIORAL|Cognitive behavior therapy|Behavior therapy, including Relaxation, cognitive rebuilding.
223597660|NCT00859157|PROCEDURE|therapeutic conventional surgery|Patients undergo tumescent or standard mastectomy
223597661|NCT01195480|GENETIC|donor-derived EBV-specific cytotoxic T-cells (EBV-CTL) transduced with the retroviral vector SFGalpha-CD19-CD3zeta|All patients will be treated at the same total dose level of 2 x 10\^8/m2
223748169|NCT06919094|BEHAVIORAL|Life Story Club|Virtual group reminiscence therapy will be provided by the Life Story Club©. Participants will meet virtually via Zoom© with their group (6-10 people) weekly for one hour over a 12-week period to exchange life stories and share in conversation. Groups will be conducted in entirely in English or Spanish, based on participant preference. Each week, the LSC© facilitator will guide the group with question prompts to encourage participants to share personal information, build friendships \& rapport, and create a sense of community. LSC© facilitators are trained in group interview techniques, technology management, and know how to respond appropriately to sensitive information that may emerge during group exchanges.
224314245|NCT01326650|DRUG|Vitamin D|daily oral vitamin D supplement of 100 micrograms for three years
224314246|NCT01326650|DRUG|placebo|daily oral placebo supplement for three years
223597662|NCT01195480|BIOLOGICAL|Irradiated donor-derived Lymphoblastoid Cell Line|"The initial cohort of 5 patients (regardless of arm of study) will be treated as described. If transduced CTL infusion is safe in this initial cohort and real-time DNA PCR studies demonstrate that transduced CTL are undetectable in \> 50% of patients by 2 months post-infusion, the remaining 25 patients (in either arm of the study) will be treated as above but with an additional vaccination of CD19-zeta-transduced EBV-LCL infusion.~Vaccination will consist of 3 doses of 5 x 10\^6 irradiated (70Gy) donor-derived EBV-lymphoblastoid cell line used to generate CTL and will be administered subcutaneously into the thigh (volume 0.3 ml) at day -2, week 4 and 8 post-transduced CTL infusion."
223597663|NCT02202538|DEVICE|Indego|Indego
223597664|NCT04379778|OTHER|Aerobic exercise|Progressive moderate to high intensity aerobic exercise.
223597665|NCT00618878|PROCEDURE|Electroacupuncture|twice a week for 26 treatments in total
223597666|NCT00618878|PROCEDURE|Laser Therapy|twice a week for a total of 26 treatments
223597667|NCT01457846|DRUG|AZD4547|Tablets taken, oral, twice daily, commencing with a 2 week on AZD4547, 1 week off AZD4547 schedule.
223597668|NCT01457846|DRUG|paclitaxel|Infusion administered once a week, 3 weeks on and 1 week off
223597669|NCT02899702|DRUG|PRIVIGEN (CSL Behring)|"Single administration of intravenous immunoglobulin solution Privigen® (CSL Behring AG, Bern, Switzerland) at a dose of 2g / kg. IGIV 2g/kg within 12 hours following PICU admission (or outbreak of first shock signs).~The treatment of toxic shock will be standardized. It consists of antibiotics: Amoxicillin-clavulanate and clindamycin (or Rifampicin, Rifadine® if allergic). Antibiotics are not considered as experimental treatments for this study. All treatments essential for the treatment of acute condition will be allowed and are not considered as experimental treatments for this study."
223597670|NCT02899702|DRUG|Albumin|"4%(LFB) ALBUMIN Single administration of human Albumin 4% diluted albumin (VIALEBEX® LFB), within 12 hours following PICU admission (or outbreak of first shock signs). Isovolume - so dose of 0.8 g/kg (4gG, 100 ML, Sodium chloride 0.61 G / 100ML Water for injections QSP 100 ML Sodium caprylate 0.3 G / 100ML) We chose as placebo albumin diluted to 4% because this solution has the advantage of having a comparable osmolality.~The treatment of toxic shock will be standardized. It consists of antibiotics: Amoxicillin-clavulanate and clindamycin (or Rifampicin, Rifadine® if allergic). Antibiotics are not considered as experimental treatments for this study. All treatments essential for the treatment of acute condition will be allowed and are not considered as experimental treatments for this study."
223597671|NCT01810497|PROCEDURE|Use of ear bandage|Elastic bandage to be used on the postoperative period of otoplasty, starting immediately after the procedure. To be used 24hours/day for the specified period.
224198413|NCT06339632|OTHER|Transcutaneous electrical phrenic nerve stimulation (TEPNS)|"The characteristics of the electrical current: biphasic waves, set at a stimulation frequency of 10 Hz, pulse width of 200 μs, rise time of 1.0 second, on time of 1.0 second, fall time of 1.0 second, and off time of 2 seconds, resulting in 12 stimuli per minute. The application of TEPNS will initially be performed by defining the trajectory of the phrenic nerve in the cervical region. The negative pole (active point), a stick with a spherical tip for micro-current of 2 mm will be positioned with slight pressure in the region of the phrenic nerve pathway between the two heads of the sternocleidomastoid muscle. Additionally, at the positive pole (passive point), a self-adhesive electrode sized (2.0 x 2.0 cm) will be positioned on the skin in the shoulder region. The intensity, measured in milliamperes (mA), will be adjusted to the maximum tolerated by the patient. The total stimulation time will be 10 minutes, applied continuously in a single session."
224311106|NCT06571513|BEHAVIORAL|Written Exposure Therapy|During session one of the written exposure therapy intervention, the therapist will provide psychoeducation about PTSD and the rationale for the proposed intervention. Psychoeducation and treatment rationale are scripted to ensure consistency. The therapist will provide the participant with instructions for writing about the same trauma memory (their recent sexual assault) during each session. They will be asked to look back at the event and write for 30 minutes about the details of the event including what they saw, heard, felt, smelled, etc. without regard for spelling or grammar. The participant will self-report Subjective Units of Distress Scale (SUDS) levels to the therapist at the beginning and end of each session. After 30 minutes, the therapist will ask the participant to stop writing, review the experience of writing and discuss as needed, and conclude the session.
223597672|NCT03902834|OTHER|Fitbit|Use the wearable technology (Fitbit) and proven behavioural change techniques to precondition patients prior to lung cancer surgery
223597673|NCT01180010|PROCEDURE|Low Dose CT|"A chest CT uses special radiographic equipment using x-rays to capture images of the chest, and with the aid of a computer, processes the images to create cross-sectional pictures or slices of the areas of interest. The images can then be printed out or examined on a monitor. The CT scanner is a large unit with a hole running directly through its center, giving the appearance of a doughnut. During the scanning, patients will lie flat on their back on a table, and they are periodically asked to hold their breath. The table will first move through the scanner to determine the correct starting position. The rest of the scans are made as the table moves more slowly through the cavity in the scanner."
223597674|NCT02161757|BIOLOGICAL|Tralokinumab|Subcutaneous injection
223597675|NCT02161757|OTHER|Placebo|Subcutaneous injection
223597676|NCT02443818|DRUG|Sirolimus|Low dose sirolimus will be given in daily dosing to achieve trough levels of 2-6 ng/ ml.
223597677|NCT01224080|DEVICE|Adiana placement|All patients will undergo the Adiana Tubal Occlusion procedure. This procedure will be done in an office based setting and last approximately 1 hour.
223597678|NCT04271033|DEVICE|Carotid Artery Stenting|"Carotid artery stenting according to local clinical experience and ESC/ESVS guidelines using exclusively CGuard™, MicroNet covered stent under proximal or distal intraprocedural cerebral protection according to tailored CAS algorithm."
223597679|NCT03029091|DRUG|Losartan Potassium|Losartan potassium
223597680|NCT05071014|DRUG|Pembrolizumab|Pembrolizumab: 200mg/dose delivered by IV infusion
223597681|NCT05071014|PROCEDURE|Image-guided cryoablation|Cryoablation will be used to treat a designated lesion with preference given to a lesion that is symptomatic or at risk of causing symptoms. Per institutional standards, complete ablation of the lesion will be attempted.
224198414|NCT06339632|OTHER|Transcutaneous electrical diaphragm stimulation (TEDS)|The characteristics of the electrical current are: biphasic waves, set at a stimulation frequency of 30 Hz, pulse width of 400 μs, rise time of 1.0 second, on time of 1.0 second, fall time of 1.0 second, and off time of 2 seconds, resulting in 12 stimuli per minute. Two self-adhesive electrodes sized (5.0 x 5.0 cm) will be used, positioned in the bilateral parasternal region next to the xiphoid process and the other electrode in the intercostal space between the 6th and 7th ribs bilaterally, at the mid-axillary line. The intensity, measured in milliamperes (mA), will be adjusted to the maximum intensity tolerated by the patient until diaphragmatic contraction is observed with the naked eye, without contraction of other muscles in the abdominal region. The total stimulation time will be 10 minutes, applied continuously in a single session.
224198415|NCT06852612|DIETARY_SUPPLEMENT|Fructose|40g fructose (free and bound, max amount of fructose from added free sugar/saccharose 25g)
224198416|NCT06852612|DIETARY_SUPPLEMENT|Fructose and galactose|10g galactose (mostly from lactose) plus 40g of fructose (free and bound, max amount of fructose from added free sugar/saccharose 25g)
223597682|NCT00503321|DRUG|Tegafur/gimeracil/oteracil potassium (S-1), Krestin (PSK)|S-1 80mg/m2 4weeks on 2 weeks off, PSK 3g/day
223597683|NCT00503321|DRUG|Tegafur/gimeracil/oteracil potassium (S-1)|S-1 80mg/m2, 4weeks on followed by 2 weks off
223748170|NCT06914362|PROCEDURE|global postural reeducation|"Global postural reeducation included the following GPR postures according to the Souchard approach \[7\]: lying on back with the legs extended and arms folded, lying on back with the legs flexed and arms folded, lying on back with the legs extended and arms open, lying on back with the legs flexed and arms open, sitting with legs extended and standing with the back against the wall.~Each posture was performed by the patient under the physiotherapist supervision and was held for 15 to 20 minutes.~Besides, each patient was asked to repeat the exercises daily at home."
223748171|NCT06914362|PROCEDURE|conventional rehabilitation|"Conventional reeducation included manual therapy approaches such as spinal mobilization which aims to restore joint mobility and alleviate muscular tension.~It included also exercise therapy focusing on strengthening core muscles, improving lumbar flexibility, and enhancing posture to stabilize the spine and reduce strain on surrounding structures.~Modalities like heat therapy, cold therapy, and transcutaneous electrical nerve stimulation (TENS) were also used to manage pain and promote muscle relaxation. Additionally, education on ergonomic principles was part of the program to adopt healthy habits and prevent recurrence of pain."
223748172|NCT06913686|BEHAVIORAL|Music intervention|"experimental controlled study will be conducted at the La Marsa tennis club in Tunis, Tunisia, utilizing a rigorous methodology to collect data from competitive young tennis players aged 12-18. This study employs a three-phase design: first, participants' musical preferences are profiled to create personalized music sequences; second, their mental performance is evaluated through pre- and post-intervention questionnaires measuring perception of success, emotional state, emotion regulation, and flow, with a 45-minute training session followed by a music-accompanied exercise; and third, physical performance is assessed using a battery of tests for muscular strength, endurance, agility, and flexibility, conducted both with and without music to determine its impact.~Data collection will be done using a questionnaire that has been developed based on the literature."
223748173|NCT05017506|OTHER|A survey will be made.|A survey will be made.
224198417|NCT05770362|OTHER|lifestyle questionnaire|The changes in lifestyle by lifestyle questionnaire during and after home isolation
224198418|NCT04486859|DRUG|LMWH/Rivaroxaban|combined prevention
224198419|NCT04486859|DEVICE|IPC|mechanical prevention
224198420|NCT04624282|DIAGNOSTIC_TEST|different diseases|Patients will be divided into three groups, including chronic superficial gastritis ,chronic atrophic gastritis and gastric carcinoma.
224198421|NCT00194038|DRUG|Aripiprazole|Patients were continued on treatment with their existing mood stabilizing medication, and upon enrollment were initiated on aripiprazole augmentation treatment. The initial starting dose of aripiprazole was 5 mg/day, with gradual upward titration as tolerated. Initiation of new additional antipsychotic medications was not permitted during the course of the study, and antipsychotic medications prescribed at study start were tapered and discontinued by week 4 of the study if possible.
224198422|NCT00306124|DRUG|Levodopa|
224198423|NCT03310281|DEVICE|HOLD: Videogame|Videogame-like digital therapy
224198424|NCT04635956|DRUG|Drug therapy|6 courses of platinum/etoposide/bevacizumab/camrelizumab and a total period of 12 months bevacizumab/camrelizumab
224198425|NCT05754359|BEHAVIORAL|I'm an Active Hero (IAAH) Intervention Program|"The I'm an Active Hero (IAAH) programme is a 10-week intervention aimed at increasing physical activity and decreasing sedentary behaviour in preschool-aged (aged 3-5 years) children. It is anticipated to begin in February 2023 to May 2023. Assessments will be conducted at baseline and immediately following the intervention. The IAAH-intervention will be implemented by the preschool teachers, who will have two teacher training sessions with the main researcher (myself). The IAAH-intervention involves environmental modifications (a classroom) to create areas with sufficient space for active play; classroom sessions these will be implemented for 10 weeks (a minimum of one hour per week); and parent involvement, such as the provision of parental-child interaction homework activities and written information (tip cards, posters, and newsletters). for parents on how to encourage their children to be active."
224198426|NCT03039829|DIETARY_SUPPLEMENT|Creatine nitrate, low dose|Creatine nitrate at 3.0 grams (2.0 grams creatine, 1.0 gram nitrate, 3.0 grams dextrose)
224198427|NCT03039829|DIETARY_SUPPLEMENT|Creatine nitrate, high dose|Creatine nitrate at 6.0 grams (4.0 grams creatine, 2.0 grams nitrate)
223597684|NCT00465647|DRUG|Hydromorphone|Oral hydromorphone solution dosed every 6 hours up to 9 doses. Dose is determined based on the expected weight range for each age group.
223597685|NCT00881647|OTHER|Cognitive Behavioral Treatment for Insomnia (CBT-I)|CBT-I includes strategies and instructions targeted toward improving the quality of sleep and resolving problems falling and staying asleep
223597686|NCT03225703|BEHAVIORAL|Hopping|A unilateral, hopping based exercise programme lasting six months.
223597687|NCT00794885|DRUG|Enalapril/folic acid|Enalapril/folic acid, (10mg enalapril/0.8mg folic acid)/tablet, taken orally and once daily for a maximum of 5 years. Combination with other anti-hypertension drugs are allowed.
223748174|NCT01239368|PROCEDURE|Adoptive Immunotherapy|Th1 (type 1 T helper cells)/Tc1 (T cytotoxic cells, type 1) Rapa cell infusion will be evaluated after administration of a 7-day or 14-day course of immune depleting chemotherapy (pentostatin plus cyclophosphamide regimen).
223748175|NCT01239368|BIOLOGICAL|Rapamycin-Generated Autologous Th1/Tc1 Cells (modified primary human T cells)|Six Th1/Tc1 Rapa cell doses will be tested in cohorts of 1-6 subjects each: ranging from 10e(5) to 15 x 10e(6) cells/kg of body weight.
223748176|NCT01239368|BIOLOGICAL|Th1/Tc1 Rapa Cell Therapy|Th1/Tc1Rapa: 5 x 10e(6) cells/kg
223748177|NCT04790682|BIOLOGICAL|assessment of the predictive value of ctDNA level of the prominent mutant allele variation between baseline and week 6, on response to treatment according to RECIST 1.1 criteria.|"* At pre-screening NGS analysis on tumor tissue (slides). Only patients with at least 1 mutation at NGS on the tumor tissue will ultimately be enrolled in the main study, to have the possibility to follow the mutation using ctDNA.~* Main study will be initiated after results of the NGS and before initiation of pembrolizumab. Blood specimens will be taken with EDTA tubes or streck tubes at the time of puncture for pembrolizumab infusion at baseline before starting treatment, at 3 weeks, 6 weeks and then every 6 weeks (30 ml at Baseline then 20 ml of blood). Blood immunomonitoring will be done before starting the treatment, at 6 weeks and at 18 Week. An additional measurement will be performed if treatment is stopped before the end of the study (18 ml of blood).~* Optional blood samples will be realized to analyse the degree of activity of the plasmatic lymphocytes before starting the treatment and at 6 weeks and (18 ml of blood)."
223748178|NCT04850222|DRUG|Fluoxetine|Subjects will be randomized to take Fluoxetine (10mg by mouth per day). The randomized drug will be prescribed by the orthopedic team on the day randomization so that the patient may be monitored for side effects during the remainder of their hospitalization. The patient will be prescribed the randomized medication on the day of discharge and a 90 day supply will be provided by the inpatient research pharmacy.
223748179|NCT04850222|DRUG|Calcium|Subjects will be randomized to take Calcium supplementation (1000mg by mouth per day). The randomized drug will be prescribed by the orthopedic team on the day randomization so that the patient may be monitored for side effects during the remainder of their hospitalization. The patient will be prescribed the randomized medication on the day of discharge and a 90 day supply will be provided by the inpatient research pharmacy.
223748180|NCT04269759|OTHER|Survey|pregnant women will answer to a survey regarding their oral health knowledge, attitudes and practices for themselves and their unborn child
223597688|NCT00794885|DRUG|Enalapril maleate|Enalapril, 10mg/tablet, taken orally once daily for a maximum of 5 consecutive years. Combination with other anti-hypertension drugs are allowed.
223597689|NCT02272166|DRUG|propofol|
223748181|NCT04269759|OTHER|dental care|pregnant women will have a dental care
223748182|NCT04993781|BEHAVIORAL|eSTEPS CDS|Primary care clinics at Brigham and Women's Hospital will be randomized to receive the eSTEPS CDS or usual care. The University of Texas Medical Branch (UTMB) will be the replication site, with all participating primary care practices receiving the eSTEPS CDS.
223748183|NCT04960046|PROCEDURE|Placement of an infraclavicular perineural catheter using a costoclavicular approach|"The high-frequency linear probe will be used to image the axillary artery in the long axis and nearby nerve structures of interest, namely the posterior, lateral and medial bundles. The plane chosen will be located inferior to the clavicle, also in its distal third. The needle will be inserted with a latero-medial orientation in the plane. The initial injection will be a single injection laterally to the axillary artery, where the three nerve bundles are still joined together.~The catheter will then be positioned and its location verified by injecting an additional 5 mL of bupivacaine into the catheter under direct ultrasound visualization. Catheter fixation will be standardized to minimize the risk of accidental displacement and the point of entry of the catheter to the skin will be covered with an opaque dressing."
224198428|NCT03039829|DIETARY_SUPPLEMENT|Placebo|Placebo at 6.0 grams (6.0 grams dextrose)
223597690|NCT02272166|DRUG|Sevoflurane|
223597691|NCT00230503|DRUG|pradefovir mesylate|
223597692|NCT00230503|DRUG|adefovir dipivoxyl|
223597693|NCT03872856|DEVICE|BP-ICAN|"One of two home blood pressure monitor devices will be used.~1. Omron 7 Series Wrist cuff~2. Omron 10 Series Upper Arm cuff"
223597694|NCT00516867|RADIATION|UV radiation|UV radiation with 99.5% UVA and 0.5%UVB
223597695|NCT00516867|RADIATION|UV radiation|UVB 1.4 % and UVA 98.6
223597696|NCT02205242|DRUG|Azithromycin|From day 1 up to and including day 3: 500 mg azithromycin or placebo PO once a day From day 4 up to and including day 90: 250 mg azithromycin or placebo PO once every 2 days
223597697|NCT02205242|DEVICE|Dynaport®|Registering physical activity during 7 days post discharge from hospital (0 months), 3 months and 9 months
223597698|NCT02205242|DRUG|Placebo|
223597699|NCT05862311|DIAGNOSTIC_TEST|ELISA|ELISA(enzyme-linked immunosorbent assay)
223597700|NCT00487292|BEHAVIORAL|naps and pulses of bright light|
223597701|NCT06485388|DRUG|Propofol|Venous blood samples will be taken from the patients included in the study and incubated with propofol (dose: 100, 250, 500 and 1000µM) after appropriate procedures in the laboratory environment. . After incubation, all resuspensions will be subjected to flow cytometric analysis to evaluate erythrocyte NO synthase activity and erythrocyte-mediated NO release.
223597702|NCT06485388|DRUG|Thiopental|Venous blood samples will be taken from the patients included in the study and incubated with thiopental (dose: 100, 250, 500 and 1000µM) after appropriate procedures in the laboratory environment. . After incubation, all resuspensions will be subjected to flow cytometric analysis to evaluate erythrocyte NO synthase activity and erythrocyte-mediated NO release.
223597703|NCT01240135|DEVICE|FID 114675A multi-purpose disinfecting solution (MPDS)|Daily regimen, 14 days: Thoroughly wet and rub each side of study contact lens for 10 seconds, rinse each side of the lens for 10 seconds, and soak contact lens for at least 6 hours.
223597704|NCT01240135|DEVICE|renu fresh Multi-Purpose Solution (MPS)|Daily regimen, 14 days: Wet study contact lens with 3 drops and rub each side of the lens for 20 seconds, rinse each side of the lens for 5 seconds, and soak contact lens for at least 4 hours.
223597705|NCT01240135|DEVICE|Galyfilcon A contact lenses (Acuvue Advance)|A fresh pair of contact lenses matching subject's pre-study lenses, including parameters, dispensed at the beginning of each period for daily wear, minimum 8 hours per day, 14 days.
223597706|NCT00002148|DRUG|OPC 14117|
224198429|NCT02862002|OTHER|"therapeutic education of type caratif"|"study the effects of a therapeutic education program type caratif, based on a communication pedagogy, with the patient receiving opioid therapy in medical oncology"
223597707|NCT02168608|OTHER|Remote ischemia precondition|Three cycles of 5-min ischemia/5-min reperfusion induced by a blood pressure cuff placed on the right upper arm served as RIPC stimulus.
223597708|NCT02168608|OTHER|None remote ischemia precondition|Placed an uninflated cuff on the right upper arm for 30 min.
223597709|NCT06006403|BIOLOGICAL|CD123 targeted CAR-NK cells|Administration method: intravenous infusion； Subjects will receive conditioning therapy by Fludarabine and Cyclophosphamide before cell infusion.
224198430|NCT02862002|OTHER|Standard care|patients receiving standard care of cancer pain.
224198431|NCT04636437|DRUG|Doravirine 100 Mg|Participants received a 100 mg tablet by mouth daily with or without food.
223597710|NCT03682913|BEHAVIORAL|P-CIT protocol|Personalized inhibitory control training for one week.
223597711|NCT03682913|BEHAVIORAL|Placebo|without personalized inhibitory control training for one week.
223597712|NCT01371305|DRUG|BG00011|BG00011 will be administered at varying doses via subcutaneous (SC) injection
223597713|NCT01371305|DRUG|Placebo|Sterile normal saline (0.9% Sodium Chloride for Injection) via Subcutaneous (SC) injections.
223597714|NCT03796351|DRUG|MT10107|"Subjects will be administered a single equivalent dose of MT10107 and Botox® by intramuscular injection to the EDB muscles of contralateral feet. Five cohorts of eligible subjects will be studied; Group A (2 U dose), Group B (5 U dose), Group C (10 U dose), Group D (20 U dose) and Group E (30 U dose).~The foot in which each drug is to be administered (i.e. left or right) will be assigned in a randomized manner."
223597715|NCT03796351|DRUG|Botox|"Subjects will be administered a single equivalent dose of MT10107 and Botox® by intramuscular injection to the EDB muscles of contralateral feet. Five cohorts of eligible subjects will be studied; Group A (2 U dose), Group B (5 U dose), Group C (10 U dose), Group D (20 U dose) and Group E (30 U dose).~The foot in which each drug is to be administered (i.e. left or right) will be assigned in a randomized manner."
223597716|NCT03825016|DRUG|Lidocaine Hydrochloride|Lidocaine infusion on hystroscopic media during office hystroscopy
223597717|NCT03825016|DRUG|Diclofenac Sodium|Oral Diclofenac Sodium
223597718|NCT01915979|BIOLOGICAL|Plasma rich in growth factors (PRGF)|
223597719|NCT01915979|DRUG|Celestone cronodose (Bethametasone)|
223597720|NCT05583084|OTHER|Investigation|
223597721|NCT02677857|BEHAVIORAL|Common intervention components for Lifestyle|Participants in these conditions will receive standard care and one of the Lifestyle conditions. There are several components that will be identical for both Lifestyle conditions. These components include treatment structure, dietary goals, and cognitive behavioral strategies.
223597722|NCT00311259|DRUG|Melatonin (drug)|
223597723|NCT00311259|DRUG|Laktose|
223597724|NCT03368235|DRUG|AZD9567|oral OD SGRM administered as suspension
223597725|NCT03368235|DRUG|Prednisolone|oral capsules of 20 mg prednisolone administered OD for two weeks
223597726|NCT01112748|DRUG|Topical lidocaine patch|Topical lidocaine patch 5%; up to 3 patches to cover the area of maximum pain for 12 h a day.
224198432|NCT04636437|DRUG|Integrase strand transfer inhibitors|INSTIs were acquired through the standard of care locally.
224198433|NCT04636437|DRUG|Tenofovir alafenamide/emtricitabine|NRTIs (TAF/FTC) were acquired through the standard of care locally.
224198434|NCT04636437|DRUG|tenofovir disproxil fumarate/emtricitabine|NRTIs (TDF/FTC) were acquired through the standard of care locally.
224198435|NCT00116246|PROCEDURE|McRobert's manoeuvre|
224198436|NCT00066417|DRUG|cyclophosphamide|
224198437|NCT00066417|DRUG|cyclosporine|
224198438|NCT00066417|DRUG|fludarabine phosphate|
224198439|NCT00066417|DRUG|methylprednisolone|
223597727|NCT01799551|BEHAVIORAL|Ca CBT|Clients in intervention group will receive a CBT intervention using a manual. Intervention was developed for use in primary and secondary care using a series of qualitative studies (Naeem et al a, 2010, Naeem et al c, 2009, Naeem et al, 2009, Naeem et al, in press) during the last 5 years in Pakistan and has proven to be effective in a pilot study (Naeem et al, 2011). Intervention will consist of 6 sessions and will focus on psycho-education, symptoms management, changing negative thinking, problem solving, improving relationships and communication skills. One person from the family will be involved as a facilitator.
223597728|NCT06347263|OTHER|Entire papilla preservation technique|Minimally invasive periodontal surgery
224198440|NCT00066417|DRUG|therapeutic allogeneic lymphocytes|
223597729|NCT05315089|OTHER|Virtual reality games +conventional exercises|Virtual reality games +conventional exercises
223597730|NCT05315089|OTHER|Conventional exercises|Conventional exercises
223597731|NCT02828020|DRUG|Ubrogepant|50 mg ubrogepant tablet(s) orally for the treatment of a qualifying migraine attack.
223597732|NCT02828020|DRUG|Placebo-matching Ubrogepant|Placebo-matching ubrogepant tablet(s) orally for the treatment of a qualifying migraine attack.
223597733|NCT03691363|BEHAVIORAL|M-STEP|Youth will be assessed using actigraphy at baseline, and will then be asked to exercise for 1) a duration of 10 minutes \> MVPA at baseline with 2) HR\>120 while being monitored by a Fitbit. Youth will be asked to exercise daily, and intensity and duration will be increased every few days for a goal of 60 minutes per day at a HR\>140 (low end of MVPA). The intervention will be 6 weeks in duration.
223597734|NCT00391924|DRUG|Dehydroepiandrosterone|
223597735|NCT00216489|DRUG|rabeprazole sodium|
223597736|NCT00085891|DRUG|Quetiapine Fumarate|
223597737|NCT00682955|DRUG|Zinc Sulphate|20 mg per day, Zinc Sulphate tablet has been given to subjects.
224198441|NCT00066417|DRUG|thiotepa|
224198442|NCT00066417|PROCEDURE|allogeneic bone marrow transplantation|
224198443|NCT00066417|PROCEDURE|biological therapy|
224198444|NCT00066417|PROCEDURE|bone marrow ablation with stem cell support|
224198445|NCT00066417|PROCEDURE|bone marrow transplantation|
224198446|NCT00066417|PROCEDURE|chemotherapy|
224198447|NCT00066417|PROCEDURE|leukocyte therapy|
224198448|NCT00066417|PROCEDURE|non-specific immune-modulator therapy|
224198449|NCT00066417|PROCEDURE|peripheral blood lymphocyte therapy|
223597738|NCT00682955|DRUG|Zinc Sulphate|20 mg per day of Zinc Sulphate in suspension form has been given to subjects.
223597739|NCT06039618|OTHER|Referral to Centre of Higher Organizational Level|Referral to Centre of Higher Organizational Level. This means referral from a primary neonatal care center to a secondary one, or from the secondary to the tertiary center.
223597740|NCT03991429|DIAGNOSTIC_TEST|Simultaneous functional MRI and urodynamic studies|"Double lumen 7 Fr MRI-compatible catheters will be placed in the bladder and rectum. A Phillips Ingenia 3.0T full body MRI scanner with standard 12 channel head coil will be used. Instructions to communicate using right hand signals representing full urge and voiding or attempt of voiding will be given. Signs will be shown to the patient when filling of the bladder is begun and when filling is stopped. Also, in order to keep our noise-to-signal ratio low, all stimulators including any extra visual stimuli and the UDS machine will be removed from the MRI scanner room. The filling and voiding cycle will be repeated up to 4 times in each patient. Bladder will be aspirated after each voiding. This algorithm will be performed before, and, 3 and 6 months following BOO procedure."
223597741|NCT03991429|BEHAVIORAL|Questionnaires|Each patient will provide a detailed history and undergo a complete physical examination. Each patient will have the following assessments: IPSS and Incontinence Severity Index (ISI), Patient Global impression of severity (PGI-S) and improvement (PGI-I), International Index of Erectile Function (IIEF-5), MRI Safety Screening Questionnaire.
223597742|NCT03991429|OTHER|Post Void Residual (PVR), Uroflow and Bladder Diary|Follow-up assessments: Uroflow and PVR assessment, bladder diary, and all questionnaires will be repeated in all patients at one, three, and six months.
224198450|NCT00066417|PROCEDURE|peripheral blood stem cell transplantation|
223597743|NCT03991429|DIAGNOSTIC_TEST|Urinalysis|Urine sample
223597744|NCT01517386|PROCEDURE|thoracic surgery|unilateral thoracic surgery under paravertebral block and general anesthesia
223597745|NCT00336557|PROCEDURE|NAbs testing|blood drawn for a Binding Antibody (BAb) and Neutralizing Antibody (NAb) test.
223597746|NCT02645630|OTHER|Right Cervical Manipulation|We will use a high-velocity, mid-range, left rotational force to the right articular pillar of C3, on the right articular pillar of C4 with the patient in supine, with left rotation and right side-bending.
223597747|NCT02645630|OTHER|Left Cervical Manipulation|We will use a high-velocity, mid-range, left rotational force to the left articular pillar of C3, on the left articular pillar of C4 with the patient in supine, with right rotation and left side-bending.
223597748|NCT02645630|OTHER|Sham Cervical Manipulation|The sham procedure will simulate C3/C4 manipulation in both sides without any therapeutic thrust
223597749|NCT03366467|OTHER|SADE|The SADE: the sensory stimuli addressed are visual and auditory, as follows: (i) Visual sensation. All ceiling fluorescent lighting are removed. The adapted lighting consisted of slow-moving, repetitive visual color effects created by a projector, in the child's visual field. (ii) Auditory stimuli include rhythmic music, which was heard via loudspeakers.
223597750|NCT03366467|OTHER|RDE|The RDE utilized fluorescent lighting on the ceiling, without special visual effects and without music stimulation.
223597751|NCT06395532|OTHER|Observetional|After admission to the ICU, patients will be continuously monitored with ICU standard monitoring in addition to IPI using (Capnostream™ Medtronic). IPI will be recorded after transfer to the ICU, as well as at 2, 6, 12, 18 and 24 hours.
223597752|NCT00483795|DRUG|sodium citrate, sodium chloride, sodium borate, propylene glycol. citrate, tetronic 1304, AMP 95|
223597753|NCT05230849|DEVICE|dry needling|is a physiotherapy treatment for neurological patients and studies the efficacy of dry needling by studying several pre-treatment and post-treatment variables after the experimental treatment.
224198451|NCT00066417|PROCEDURE|radiation therapy|
223597754|NCT05230849|OTHER|convencional treatment|is a physiotherapy treatment for neurological patients
223597755|NCT04238169|DRUG|Bevacizumab|7.5mg/kg once every three weeks
224198452|NCT00065169|DRUG|Celecoxib|
224198453|NCT05897411|BEHAVIORAL|Unmasking previous conditioning procedure|An explanation of the method for aversive conditioning of the comfort meal (masked administration of the meal with a high fat supplement) will be provided.
224198454|NCT05897411|BEHAVIORAL|No unmasking of previous conditioning|An explanation of the method for aversive conditioning of the comfort meal (masked administration of the meal with a high fat supplement) will not be provided.
224198455|NCT03696420|OTHER|Coordinates of active plots and VIM landmarks calculation|Stimulation efficacy will be assessed by comparing, according to usual care, the clinical evaluation (FTM scale) with and without stimulation, and the four contacts of each electrode will be tested clinically, with an accelerometer and an electromyography to determine which one is the most active on tremor. Coordinates of the anatomical landmarks will be calculated on the pre-operative MRI and those of the active plots on the fusion between post-operative CT-scan and pre-operative MRI.
224198456|NCT01994369|DRUG|EC17|
224198457|NCT03486015|DRUG|Sterile water|2 ml of sterile water
223597756|NCT04238169|DRUG|Toripalimab|240 mg once every three weeks
223597757|NCT04238169|RADIATION|SBRT|30-50Gy/5F（2-4 lesions）
223597758|NCT02239952|DRUG|Sunitinib|50 mg once daily, oral use for 14 days
223597759|NCT02239952|DRUG|vandetanib|300 mg, once daily, oral use for 14 days
223597760|NCT02239952|DRUG|Erlotinib|150 mg, once daily, oral use for 14 days
223597761|NCT01249547|DRUG|axitinib|starting dose of 5 mg twice daily for 4 consecutive weeks without interruption.
223597762|NCT04233450|OTHER|BodyBabe questionnaire|assessment of young mothers' perceptions using self-questionnaires
223597763|NCT05006950|DEVICE|Stryker1688 Fluorescence imaging system|The purpose of this study is to use SPY fluorescence imaging systems and indocyanine green (ICG) as a tool to determine the percentage of successful critical anatomy recognition and to describe complications associated with intra-operative decision making in patients undergoing laparoscopic cholecystectomy.
223597764|NCT05374629|BEHAVIORAL|Use different methods of teaching|Both groups will receive a smoking cessation education guideline and post-test three months after the intervention.
224198458|NCT03486015|DRUG|30% glucose|2 ml of 30% glucose
223597765|NCT03012204|DEVICE|real LFrTMS at unaffected M1|"Compare the effect of LFrTMS at unaffected M1 to that of all sham stimulation on motor rehabilitation after cerebrovascular disease .~rTMS: Repetitive Transcranial Magnetic Stimulation. Combination Elements: ①6 hertz(Hz) rTMS at unaffected M1 before LFrTMS at unaffected M1 ;②6 Hz rTMS at affected M1;③1 Hz rTMS at unaffected M1.~The four groups are the combinations of real or sham ①/②/③."
223748184|NCT04960046|PROCEDURE|Placement of an infraclavicular perineural catheter by paracoracoid approach|"The high-frequency linear probe will be used to image the axillary artery in the short axis and nearby nerve structures of interest, namely the posterior, lateral and medial bundles. The plane chosen will be located inferior to the clavicle, in its distal third. The needle will be inserted with a cranio-caudal orientation in the plane. The initial injection will be a single injection posterior to the axillary artery, the expected distribution being a U distribution around the artery.~The catheter will then be positioned and its location verified by injecting an additional 5 mL of bupivacaine into the catheter under direct ultrasound visualization. Catheter fixation will be standardized to minimize the risk of accidental displacement and the point of entry of the catheter to the skin will be covered with an opaque dressing."
223748185|NCT06315699|DRUG|Clemastine Fumarate Tablets|The dose was administered 2mg once daily in a double-blind random crossover method
223748186|NCT06315699|DIETARY_SUPPLEMENT|fructose|The dose was administered 2mg once daily in a double-blind random crossover method
223597766|NCT03012204|DEVICE|real primed LFrTMS at unaffected M1|"Compare the effect of primed LFrTMS at unaffected M1 to that of LFrTMS at unaffected M1 on motor rehabilitation after cerebrovascular disease .~rTMS: Repetitive Transcranial Magnetic Stimulation. Combination Elements: ①6 hertz(Hz) rTMS at unaffected M1 before LFrTMS at unaffected M1 ;②6 Hz rTMS at affected M1;③1 Hz rTMS at unaffected M1.~The four groups are the combinations of real or sham ①/②/③."
223597767|NCT03012204|DEVICE|combined rTMS at both M1|"Compare the effect of combined rTMS at both M1 to that of primed LFrTMS at unaffected M1 on motor rehabilitation after cerebrovascular disease .~rTMS: Repetitive Transcranial Magnetic Stimulation. Combination Elements: ①6 hertz(Hz) rTMS at unaffected M1 before LFrTMS at unaffected M1 ;②6 Hz rTMS at affected M1;③1 Hz rTMS at unaffected M1.~The four groups are the combinations of real or sham ①/②/③."
223597768|NCT03012204|DEVICE|all sham stimulation|used as controls to eliminate the placebo effect of all kinds of combinated rTMS
223597769|NCT03422666|DRUG|Teduglutide|Teduglutide
223597770|NCT03422666|DRUG|Placebo|Placebo
223597771|NCT04983420|OTHER|non-alcoholic Pilsner|intake of 1 L non-alcoholic Pilsner per day for 2 weeks
223597772|NCT04983420|OTHER|non-alcoholic wheat beer|intake of 1 L non-alcoholic wheat beer per day for 2 weeks
223597773|NCT04983420|OTHER|apple spritzer|intake of 1 L apple spritzer per day for 2 weeks
223597774|NCT04983420|OTHER|lemonade|intake of 1 L lemonade per day for 2 weeks
223597775|NCT05322369|OTHER|periodontal charting only|Periodontal charting only
223597776|NCT02481778|OTHER|Blood sampling|
223597777|NCT01504685|PROCEDURE|Banded Laparoscopic Roux-en-Y gastric bypass|"A 6.5-cm polypropylene Marlex mesh was placed immediately cephalad to the gastrojejunostomy. The gastrojejunostomy was hand-sewn in 2 layers using 3-0 Polyglactin for the internal and 3-0 silk for the external layer.~The length of alimentary and biliopancreatic limbs was approximately 150 cm and 50 cm, respectively."
223748187|NCT05352828|DRUG|Nivolumab|Dose: 480 mg or 6 mg/kg Q4W
223748188|NCT05352828|DRUG|Autologous CD30.CAR-T|Dose: 2 x 10e8 cells/m2
223748189|NCT05352828|DRUG|Fludarabine|Dose: 30 mg/m2/day x 3 days
223748190|NCT05352828|DRUG|Bendamustine|Dose: 70 mg/m2/day x 3 days
223597778|NCT01504685|PROCEDURE|Unbanded Laparoscopic Roux- en-Y gastric bypass|"A hand-sewn gastrojejunostomy in 2 layers using 3-0 Polyglactin for the internal and 3-0 silk for the external layer.~To ensure a diameter of 1-1.5 cm,a 32F bougie was used to calibrate the gastro jejunum anastomosis. The length of alimentary and biliopancreatic limbs was approximately 150 cm and 50 cm, respectively."
223597779|NCT05041972|DRUG|ARX788|ARX788 will be administered by intravenous (IV) infusion every 3 weeks (Q3W).
223597780|NCT01339897|DRUG|5 mg/N6022|Intravenous formulation, given at doses of 5 mg once each day over 7 days.
223597781|NCT01339897|DRUG|Placebo|Same administration procedures as active
223597782|NCT01339897|DRUG|10mg/N6022|Intravenous formulation given at doses of 10 mg once each day over 7 days.
223597783|NCT01339897|DRUG|20mg/N6022|Intravenous formulation given at doses of 20 mg once each day over 7 days.
223597784|NCT01138501|DRUG|turoctocog alfa|Subjects will be treated 3 times per week or every second day with intravenous injections of turoctocog alfa. The dose range for preventive treatment is 25-60 IU/kg body weight depending on treatment regimen.
223597785|NCT01138501|DRUG|turoctocog alfa|Subjects will undergo half-life evaluation of their current factor VIII product and pharmacokinetic session with turoctocog alfa before entering preventive treatment (subjects with available evaluation of terminal half-life within the last year are to be excluded from receiving factor VIII). Intravenous injections. The dose range for preventive treatment is 25-60 IU/kg body weight depending on treatment regimen.
223597786|NCT03063268|BEHAVIORAL|Trust-Enhanced Messaging on E-Consent|Messaging with trust-enhanced modification to the language that the research team has identified as beneficial additional knowledge to provide to participants. This messaging was reviewed by participants from Phase I and edited as suggested.
223597787|NCT03063268|BEHAVIORAL|Interactive features on E-Consent|Interactive hyperlinks to open up to further information for key words that participants from Phase I and prototype design and testing have identified as gaps in subject knowledge and provision of information to subjects.
223748191|NCT03752307|DRUG|Isoxsuprine Hydrochloride|Compounded Isoxsuprine hydrochloride capsules
223748192|NCT03752307|DRUG|Placebo|Identical microcrystalline cellulose placebo manufactured to mimic Isoxsuprine Hydrochloride 10 MG capsules
223748193|NCT03752307|DRUG|Corticosteroid|This can be any accepted regimen, including daily iv methylprednisolone 1000 mg/day or 600mg oral prednisone two times a day at approximately 8AM and noon
223748194|NCT02143115|PROCEDURE|Optical colonoscopy|Examination of the colon with a colonoscope
223748195|NCT02143115|RADIATION|CT-Colonography|A computerized X-ray that may find out if there are polyps or cancers and also pictures the contents of the abdomen and pelvis
223748196|NCT00417794|DRUG|Strattera|escalating dosage: 0.5 mg/kg, 1.0 mg/kg, and 1.4 mg/kg titrated up or down according to adverse effects to therapy
223748197|NCT00417794|DRUG|Placebo|0.25 mg/kg, 0.5 mg/kg, 1.0 mg/kg, or 1.4 mg/kg once each morning with breakfast.
224311107|NCT06571513|BEHAVIORAL|Unemotional Writing|During the unemotional writing sessions, the therapist will read instructions for writing about non-emotional topics. The participant will be instructed to describe what they did the day before the session from the time they woke up until the time they went to bed, as objectively as possible, without regard for spelling or grammar. The therapist will then leave the participant with a written version of the instructions for 30 minutes while the participant writes. The participant will self report Subjective Units of Distress Scale (SUDS) levels to the therapist at the beginning and end of each session. After 30 minutes, the therapist will ask the participant to stop writing, review the experience of writing and discuss as needed, and conclude the session.
223597788|NCT03063268|BEHAVIORAL|Standard E-Consent|Standard consent currently used by the University of Florida (UF) IRB with no trust-enhanced messaging or interactive hyperlinks that provide further information for subjects.
223597789|NCT01656668|DRUG|BC1036|
223597790|NCT03809819|PROCEDURE|laparoscopic Vecchietti vaginoplasty|Patients who underwent laparoscopic Vecchietti vaginoplasty
223597791|NCT03809819|DIAGNOSTIC_TEST|FSFI questionnaire|Completion of FSFI questionnaire
223597792|NCT03809819|DIAGNOSTIC_TEST|UDI-6 questionnaire|Completion of UDI-6 questionnaire
223597793|NCT03809819|DIAGNOSTIC_TEST|IIQ-7 questionnaire|Completion of IIQ-7 questionnaire
223597794|NCT03696589|BEHAVIORAL|Physical Activity Coaching|Based in the self-determination theory, participants will be coached on beneficial exercises, how to utilize supports and overcome barriers to PA engagement. Emphasis of exercise coaching will be on increasing aerobic exercise engagement and will include us of Fitbit devices to facilitate uptake and monitor aerobic exercise. Intervention will be delivered by a physical or occupational therapist, who will work with the participant to develop a plan, set goals and targets, and track changes. Additional resources that will support exercise engagement will be provided. Participants will have the choice to receive their face-to-face session either in person or remotely via secure video-based service.
223597795|NCT04534881|DRUG|Progesterone 200 MG|Subjects will be randomized to receive generic micronized progesterone 200 mg or placebo tablets, to be taken at bedtime daily.
223597796|NCT04534881|DRUG|Placebo|Subjects will be randomized to receive generic micronized progesterone 200 mg or placebo tablets, to be taken at bedtime daily.
223597797|NCT05412628|DIAGNOSTIC_TEST|Oral swab test|In this study, we will perform tissue biopsy at esophageal tumor site in esophageal cancer patients and perform random biopsy at middle esophagus in patients without esophageal cancer. Besides, we will take oral swab in all participants.
223597798|NCT04564872|DRUG|HSK7653 10 mg Q2W|HSK7653 5 mg (2 tablets) and placebo 25 mg (1 tablet) Q2W, placebo of linagliptin 5 mg QD, oral, week 1 to week 24; HSK7653 25 mg Q2W, oral, week 25 to week 52.
223597799|NCT04564872|DRUG|HSK7653 25 mg Q2W|HSK7653 25 mg (1 tablet) and placebo 5 mg (2 tablets) Q2W, placebo of linagliptin 5 mg QD, oral, week 1 to week 24; HSK7653 25 mg (1 tablet) Q2W, oral, week 25 to week 52.
223597800|NCT04564872|DRUG|Linagliptin 5 mg QD|Linagliptin 5 mg QD, placebo of HSK7653 25 mg (1 tablet) and 5 mg (2 tablets) Q2W, oral, week 1 to week 24; HSK7653 25 mg Q2W, oral, week 25 to week 52.
223597801|NCT00847197|DRUG|MK1903|Three 50 mg capsules MK1903 by mouth every 8 hours for 4 weeks. All participants will receive placebo for a 2 week run-in period.
223597802|NCT00847197|DRUG|Comparator: Placebo|Three 50 mg capsules placebo to MK1903 every 8 hours for 4 weeks. All participants will receive placebo for a 2 week run-in period.
223597803|NCT01506011|DRUG|Amlodipine Besylate/Benazepril HCl|Amlodipine Besylate/Benazepril HCl 10 mg/40 mg capsules
223748198|NCT03657888|BEHAVIORAL|Family Club Denmark (FCD)|Participation in Family Club Denmark
223748199|NCT03657888|OTHER|Wait-list control|Participants on the waiting list
223748200|NCT04348513|DRUG|T3 solution for injection|For example, for a patient of 77Kg of weight, a dose of 6ml (60 μg) will be administered as a bolus intravenously over 2-3 min within 60 min of respiratory support initiation. Then, the patient for the next 24 hours will receive 21ml of the product (total of 210 μg of T3) that will be diluted in NaCl 0.9% and administered with a pump at a steady flow rate of 10.4 ml/h for a total duration of 48 hours. From day 3 till successful weaning or end of follow-up, the patient will receive 50% of this dose, 10.5 ml of the product (total of 105 μg of T3) that will be diluted in NaCl 0.9% and administered with a pump at a steady flow rate of 5.2 ml/h.
223748201|NCT04348513|DRUG|Placebo|Same as with T3 solution for injection.
223597804|NCT00013013|PROCEDURE|Systems Support|
223597805|NCT01791101|DRUG|Eltrombopag|
223597806|NCT02551029|OTHER|Capsaicin|
223597807|NCT02551029|OTHER|Placebo|
223597808|NCT00875290|DEVICE|Real-time glucose sensor|Children assigned to this intervention will use a real-time sensor continuously
223597809|NCT01124591|BEHAVIORAL|Brief motivational intervention|two session delivered two weeks apart
223597810|NCT03395951|DRUG|Diuretics|Observation of hemodynamics during diuretics treatment within clinical indication.
223597811|NCT03776591|PROCEDURE|Open surgery|
223597812|NCT03776591|PROCEDURE|Right colectomy|
223597813|NCT03776591|PROCEDURE|Laparoscopic surgery|
223597814|NCT03776591|PROCEDURE|Central lymphadenectomy and vascular ligation|
223597815|NCT01906528|DRUG|Mivacurium|Effect of Mivacurium in males vs females
223597816|NCT04617015|DRUG|Ipratropium Bromide|All subjects receive inhaled ipratropium once with measurement of spirometry before and after. Bronchodilator response of subjects with depression is compare to that of subjects without depression.
223597817|NCT05443711|OTHER|No intervention, observational study|No intervention, observational study
223597818|NCT05688020|DRUG|Tranexamic acid|Tranexamic acid will be injected as part of the injectate during endoscopic resection.
223597819|NCT05688020|DRUG|Epinephrine injection|Epinephrine will be injected as part of the standard injectate used during endoscopic resection.
223597820|NCT02105675|BIOLOGICAL|Dendritic Cells DCVAC/PCa|DCVAC/PCa is the experimental therapy added on to Docetaxel
223597821|NCT02105675|DRUG|Docetaxel|Docetaxel is Standard of Care First Line Chemotherapy
223597822|NCT04569981|OTHER|Climbing|The patients in the Climbing Group (CG) followed a 12-weeks long climbing trainings course in small groups of 3-4 participants with a certified climbing instructor.
223597823|NCT04569981|OTHER|Unsupervised activity group|The patients in the unsupervised activity group (UAG) received education European physiotherapy guidelines for physical activity recommended by the WHO of recommended activity and followed their self-selected activities over 12 weeks.
223597824|NCT05325840|OTHER|music terapy|The aim of this study was to examine the effects of the music concert applied during the nonstress test procedure on the health of the fetus, the anxiety level of the pregnant woman and blood pressure.
223597825|NCT06226584|DIETARY_SUPPLEMENT|multiple-strain probiotics|Juice HA capsule which contains more than one strain of probiotics
223597826|NCT03992443|DRUG|CUSA-081|Participants received 1 or 2 doses of CUSA-081, 0.70 mg/2 mL, directly into the catheter lumen
223597827|NCT00444340|DRUG|Enbrel (Etanercept)|
223597828|NCT04306653|DRUG|ACTH|patients with acute gout will receive 100 IU ACTH IM
223597829|NCT04306653|DRUG|Betamethasone|patients with acute gout will receive 6 mg of betamethasone
223597830|NCT03985371|DRUG|EDTA Eye Drops|One drop in the Band Keratopathy affected eye only, two times per day for six months.
223597831|NCT03659071|OTHER|questionnaire VSP-A|VSP-A (écu et Santé Perçue de l'Adolescent et de l'enfant): Lived and perceived health of the adolescent and child developed from the exclusive point of view of the child, for which reference values in French population are available. The self-questionnaire used is a questionnaire developed and validated in French for children and adolescents, according to the standards in force, apprehending 9 dimensions (vitality, psychological well-being, relations with friends, leisure, family relations, good physical, relationships with teachers, school work, self-esteem)
223597832|NCT03462381|DIETARY_SUPPLEMENT|Protein|Three endurance training sessions weekly with protein supplementation post-exercise and before sleep.
223597833|NCT04477655|PROCEDURE|Awake prone positioning|Patients will be asked to remain in prone position or lateral decubitus throughout the day as long as possible.
223597834|NCT04477655|PROCEDURE|Standard oxygen therapy|Oxygen therapy through high flow nasal cannula (HFNC). Inspired fraction of oxygen will be titrated to maintain a capillary saturation of ≥92%
223597835|NCT04518683|DEVICE|Perineal rehabilitation with mobile applications for women with SUI|"Physiotherapy: Sessions with the physiotherapist will consist of information on anatomy, perineal awareness and behavioural therapy. The therapist will educate the patient on pelvic floor contraction/relaxation. the sessions will remain personalized and standardized like a classic treatment, and will also aim to work on motivation. 9 sessions during 3 months.~Home Program: The home program will be done with a mobile application equipped with a vaginal probe. The exercises should be done 3x/week for 10 minutes. The correct use of the prob will have been checked during the sessions with the physiotherapist. This training will work on the strength, relaxation and endurance of the pelvic floor.The program includes 3 levels of difficulty. Once the user has successfully completed one level, she can move on to the next."
223597836|NCT04518683|DEVICE|Classic perineal rehabilitation for women with SUI|"Physiotherapy: Sessions with the physiotherapist will consist of information on anatomy, perineal awareness and behavioural therapy. The therapist will educate the patient on pelvic floor contraction/relaxation. The sessions will remain personalized and standardized like a classic treatment, and will also aim to work on motivation. 9 sessions during 3 months.~Home program: The home program will be done without a mobile application. The exercises will have been explained during the sessions with the physiotherapist by oral instructions. The exercises will be done 3x/week for 10 minutes. The correct realization of the exercises will have been verified during the sessions with the physiotherapist."
223597837|NCT06384755|BEHAVIORAL|Honest Open Proud program|The HOP program involves peer facilitated sessions, in which different stigma and disclosure related topics are introduced to the group, relevant tasks are completed individually, followed by group or two-and-two discussions related to the following topics: week 1 = pros and cons with disclosure, week 2 = different ways of disclosing, week 3 = formulating individual decisions of disclosure, week 6 = evaluating disclosure or non-disclosure in practice.
223597838|NCT04374955|DIETARY_SUPPLEMENT|Activia Probiotics Shot|The product contains Actiregularis - at least 2x106 cfu / g.
223597839|NCT04374955|OTHER|Routine care|Routine care of the hospital will be provided.
223597840|NCT01743040|DIAGNOSTIC_TEST|CADence|"Patients with chest pain and two or more coronary risk factors and who were already indicated for nuclear stress test were enrolled in the study. The CADence was performed prior to nuclear stress test. Patients underwent standard angiogram based upon normal clinical judgement. In all other patients a CT angiogram followed.~CADence is a handheld equipped with acoustic sensor technology, a patient booklet, remote algorithm and final report."
223597841|NCT02458443|OTHER|Isometric resistance training|Isometric handgrip exercise using a hand dynamometer
223597842|NCT01894243|DRUG|Olaparib tablet dosing|Part A - single 300mg oral dose olaparib (administered as 2x150mg tablets) Part B - 300mg oral dose olaparib (administered as 2x150mg tablets) bd
223597843|NCT03686475|OTHER|Biodentine|pulpotomy for primary molars , clinical and radiographic evaluation at 1,3,6 and 12month
223597844|NCT03686475|OTHER|MTA pulpotomy|MTA pulpotomy
223597845|NCT00284310|PROCEDURE|Anamnesis and clinical examination|Anamnesis and clinical examination to follow.
223748202|NCT06162754|OTHER|A questionnaire and TREALD scales were applied to parents.|The survey, which included questions about sociodemographic characteristics and space maintainer awareness, was administered to parents face to face. Then, parents' oral health literacy levels were measured with TREALD-30 and TREALD-30A scales.
223748203|NCT00143702|DRUG|d4T|See Detailed Description.
223748204|NCT00143702|DRUG|Abacavir|See Detailed Description.
223748205|NCT00143702|DRUG|Riboflavin and Thiamine (Supplementation)|See Detailed Description.
223748206|NCT02822521|OTHER|Mobile Application|A mobile health application that asks daily questions about participants' pain, function, and disease activity.
223748207|NCT02822521|OTHER|Population Management System|Study staff will act as care managers behind a web-based dashboard to monitor participants' responses to the daily questions on the mobile application and connect them with their HCPs.
223597846|NCT05800912|OTHER|Narrative photography|"Students were shown real-life written stories, audio, and videos using a private online platform. The training activity included four modules: i) heart transplantation waiting list; ii) life expectancy, fear of death, and organ rejection; iii) post-transplant physical and functional limitations; and iv) lack of knowledge of physical exercise patients can perform.~The students were encouraged to think about how they would feel if they had undergone heart transplantation. Afterward, they had to communicate these feelings using up to three photographs and reflective explanatory text.~Two weeks later, the students met a heart transplantation expert patient followed by an educator-guided debate. Students' images were shared and discussed. Moreover, students were encouraged to explain their feelings and their acquired skills (two hours)."
223597847|NCT05800912|OTHER|Traditional learning|"A participatory lecture was carried out, in which cardiac rehabilitation in heart transplantation patients was explained. Then, there was an educator-guided debate about protocols and actions (one hour).~Second, the students autonomously prepared clinical cases on physical limitations, physical exercise, risk factors, and life after transplantation (two hours).~Two weeks later, the clinical session was held among students (2 hours). They adopted the roles of physical therapists or transplant patients to work on: i) post-transplant physical and functional limitations; ii) lack of knowledge of the physical exercise the patient can perform; iii) control of cardiovascular risk factors; iv) life post-transplant."
223597848|NCT00223704|DRUG|HOE 140|HOE 140 (a bradykinin B2 receptor antagonist) was started in the operating room after induction of anesthesia and before heparinization, continued throughout the bypass period, and discontinued at the end of surgery. HOE 140 was given as an intravenous bolus of 22 µg/kg over one-half hour followed by an infusion of 18 µg/kg/hr.
223597849|NCT00223704|DRUG|Aminocaproic Acid|Aminocaproic acid (an antifibrinolytic drug) was started in the operating room after induction of anesthesia and before heparinization, continued throughout the bypass period, and discontinued at the end of surgery. Aminocaproic acid was given as an intravenous bolus of 100 mg/kg over one-half hour followed by an infusion of 30 mg/kg/hr.
223597850|NCT00223704|DRUG|Placebo|Normal saline (placebo) was started in the operating room after induction of anesthesia and before heparinization, continued throughout the bypass period, and discontinued at the end of surgery.
223597851|NCT05077293|OTHER|Best Practice Alert (BPA)|A BPA will fire in the EHR reminding care providers of the best practice when prescribing medical therapies for heart failure patients.
223597852|NCT05077293|OTHER|In-Basket Message|An In-Basket message will be sent biweekly to care providers with a reminder of the best practice when prescribing medical therapies for heart failure
223597853|NCT03392623|DRUG|Retinoic acid|topical administration in melasma lesions
223597854|NCT03392623|DEVICE|colorimetry measurement|Measurement of erythema and luminosity through a colorimeter
223597855|NCT03392623|DRUG|sunscreen|topical administration in melasma lesions
223597856|NCT03392623|DRUG|Niacinamide|topical administration in melasma lesions
223597857|NCT03530501|OTHER|Diet|Very low calorie ketogenic diet followed by low calorie diet
223597858|NCT03530501|DIETARY_SUPPLEMENT|Synbiotic1|B. lactis, Lactobacillus rhamnosus, B. longum ES1 and prebiotics fiber
223597859|NCT03530501|DIETARY_SUPPLEMENT|Synbiotic2|B. animalis subsp. lactis and prebiotics fiber
224311108|NCT04574440|DEVICE|multichannel fNIRS monitoring|Patients who will be enrolled in this study will be monitored during cardiac surgery using multichannel fNIRS monitoring. This consists of wearing the NIRS cap that will be positioned on the patient's head according to international operational guidelines and will be secured to the temporal region of the patient's forehead. The NIRS cap is entirely non-invasive and does not pose any additional risk to the patient. Monitoring will be commenced prior to the induction of anesthesia. Subsequent surgical and medical care will not be affected.
223597860|NCT04228432|OTHER|Dedicated and coordinated monitoring|"* Coordinated monitoring performed by a dedicated nurse: consultation before hormonotherapy initiation~* Monitoring at home over a period of 6 months using an e-monitoring tool: assessment of adverse events and completion of GIRERD questionnaire at week 3 and week 6."
223597861|NCT00119171|DRUG|Ispinesib|
223597862|NCT00119171|DRUG|Capecitabine|
223597863|NCT06351722|DIAGNOSTIC_TEST|Before non-surgical periodontal treatment|"Clinical Measurements and Laboratory Measurement Saliva and serum samples will be collected from all patients initially. Clinical parameters will also be recorded initially. Plaque index (PI) and gingival index (GI) will be recorded at four sites per tooth. Full-mouth probing depth (PD) and clinical attachment level (CAL) will be detailed per tooth at six sites, and the percentage of bleeding areas will be recorded as present or absent within 20 seconds after probing using a binary scoring system. A calibrated periodontologist (ZTE) will record all clinical parameters using manual probing.~Following sampling, both serum and saliva samples will be stored at -80°C until analysis. Concentrations of NLRP3, ASC, caspase-1, IL-18, IL-1beta, TNF-alfa, IL-10, TGF-beta, and SIRT-1 will be analyzed by specific enzyme-linked immunosorbent assay (ELISA) kits in both serum and saliva samples. LncRNA SNHG5 and MEG3 will be examined using Real-time PCR."
223597864|NCT06351722|PROCEDURE|non-surgical periodontal treatment|Treatment will be performed using ultrasonic devices followed by root planing with gracey curettes. SRP will be completed in two visits, each consisting of quadrants every 2 days. Oral hygiene instructions will include demonstrating proper brushing techniques and the use of interdental cleaning aids as needed. Saliva and serum samples will be collected again at the 3-month follow-up visit, all clinical parameter records will be repeated by the same clinician (ZTE), and oral hygiene instructions will be reconfirmed as needed. After the collection of 3-month records and samples, all patients with persistent pockets will be subjected to a standard periodontitis treatment protocol.
223597865|NCT06351722|DIAGNOSTIC_TEST|3rd month after non-surgical periodontal treatment|"All clinical and laboratory evaluations described under the heading Before non-surgical periodontal treatment will be repeated in the 3rd month after NSPT."
223597866|NCT06418451|PROCEDURE|sacrospinous ligament fixation (SLFF)|SSLF is a surgical procedure used to treat vaginal apex prolapse by fixing the vaginal apex to the right sacrospinous ligament. The procedure involves marking and incising the posterior vaginal wall, dissecting the vaginal rectal space, and placing sutures on the outer one-third of the ligament. These sutures connect the vaginal apex to the attachment point of the right uterosacral ligament. Anterior/posterior vaginal wall repair procedures can be performed if needed, without using implant materials. SSLF provides enhanced support for the vaginal apex.
223597867|NCT06418451|PROCEDURE|modified ischial spinous fascia fixation (modified ISFF)|The modified ISFF procedure involves making a midline incision along the posterior fornix of the vagina, exposing the ischial spine fascia. Two sutures are placed around the ischial spine and passed through the mucosa of the anterior and posterior vaginal walls, lifting the vaginal apex and anterior wall towards the spine. The procedure also allows for additional anterior/posterior vaginal wall repair if necessary, without using implant materials.
223597868|NCT05282420|PROCEDURE|intravitreal injection of Ranibizumab|intravitreal injection of Anti-VEGF Ranibizumab (Lucentis®; manufactured in the United States by Genentech/Roche)
223597869|NCT05282420|PROCEDURE|intravitreal injection of Aflipercept|intravitreal injection of Anti-VEGF Aflibercept (Eylea®; manufactured in the United States)
223597870|NCT05282420|DRUG|Ranibizumab|Ranibizumab
223597871|NCT05282420|DRUG|Aflibercept|Aflipercept
223597872|NCT05677009|DEVICE|BUFEO system|In the BUFEO Condition, the subject will receive oxygen through the BUFEO system.
223597873|NCT05677009|OTHER|Standard of Care|Standard Condition is the baseline apparatus utilized by the subject at the time of enrollment in the study. In the hospital setting, the supplemental oxygen delivery may come from compressed oxygen cylinders or liquid oxygen and is often delivered through a port in the facility wall at the bedside.
223597874|NCT00001088|BIOLOGICAL|APL 400-047|
223597875|NCT00001088|DRUG|Bupivacaine hydrochloride|
223597876|NCT04088110|DRUG|Pyrotinib|Pyrotinib were administered 400 mg orally daily. Oral administration within 30 minutes after breakfast, and continuous administration for 21 days for 1 cycle.
223597877|NCT04088110|DRUG|Trastuzumab|Trastuzumab were administered every 3 weeks intravenously (8 mg/kg loading doses followed by 6 mg/kg maintenance doses).
223597878|NCT04088110|DRUG|Aromatase Inhibitors|The investigator chose an aromatase inhibitor (either anastrozole, letrozole or exemestane 1 mg/2.5 mg/25 mg), once daily, oral.
223597879|NCT00830180|BIOLOGICAL|Anti-NGF AB|Solution for injection, 10 mg, one injection/8 weeks
223597880|NCT01832532|DRUG|liraglutide|daily use of drug. Titrated up from 0.6mg/day to 1.8mg/day or highest tolerated dose
223597881|NCT04368793|BEHAVIORAL|Remote pulmonary rehabilitation|The pulmonary rehabilitation intervention includes respiratory exercise, barehanded aerobic training, exercise prescription of elastic band impedance training, respiratory muscle strength training, etc.
223597882|NCT02950844|OTHER|Novel mapping algorithm|"Mapping and ablation of atrial fibrillation drivers identified by the STAR mapping algorithm.~In a sub-study a novel mapping system (CARTOFINDER, Biosense Webster, Inc, CA) was used in mapping drivers in AF."
223597883|NCT04016844|DEVICE|transcranial direct current stimulation or SHAM|"A tDCS device (Soterix) will deliver a small direct current through two sponge surface electrodes (5cm × 5cm, soaked with 15 mM NaCL). The positive electrode will be placed over the motor cortex representation of the more affected leg, and a second electrode will be placed on the forehead above the contralateral orbit.~In the sham condition, the participants will receive the initial 30 seconds of stimulation, after which the current will be set to 0. The same tDCS device (Soterix) will be used."
224311109|NCT02763826|DEVICE|transcranial direct current stimulation|brain stimulation using progressively increasing amounts of direct currents and in a variety of electrode montages
223597884|NCT06356389|DRUG|JX11502MA|Oral capsule
223597885|NCT06356389|DRUG|Placebo|Oral capsule
223597886|NCT02868047|PROCEDURE|Endoscopic Ultrasound|Patients will undergo elective upper endoscopic ultrasound to evaluate the pancreas in patients both with and without chronic pancreatitis
223597887|NCT06506825|DIAGNOSTIC_TEST|Gastric Cancer AI-driven Data Integration Genomic Analysis Biomarker|Enter the clinical and related test, examination and treatment information of all gastric cancer patients, and find risk factors that affect the prognosis
223597888|NCT02628561|DEVICE|Transcranial direct current stimulation|
223597889|NCT02628561|BEHAVIORAL|Constraint-Induced Movement Therapy|
223597890|NCT05278832|DRUG|QLS31905|QLS31905 injection
223597891|NCT00996255|DRUG|PHA-793887|Escalating doses of PHA-793887 administered weekly by IV infusion for 3 consecutive weeks in 4-week cycles.
223597892|NCT05797597|DRUG|Aspirin 300 Mg Oral Tablet|8-week treatment of aspirin, then after 2-weeks washout the next treatment arm is placebo for 8 weeks
223597893|NCT05797597|DRUG|Placebo|8-week treatment of placebo, then after 2-weeks washout the next treatment arm is aspirin for 8 weeks
223597894|NCT02687581|DEVICE|IO-therapy Glasses|12-hour of 50% intermittent occlusion therapy on the fellow eye.
223597895|NCT02687581|DEVICE|patch|6-hour of eye patch on the fellow eye
223597896|NCT04797546|PROCEDURE|Adductor Canal Block|Continous peripheral nerve block
223597897|NCT04797546|DEVICE|Morphine Patient Controlled Analgesia|Morphine Patient Controlled Analgesia Delivery System
223597898|NCT01431391|BIOLOGICAL|sipuleucel-T|Sipuleucel-T is an autologous cellular product consisting of antigen presenting cells (APCs) activated with PA2024, a recombinant fusion protein composed of prostatic acid phosphatase (PAP), linked to granulocyte-macrophage colony-stimulating factor (GM-CSF).
223597899|NCT01431391|DRUG|leuprolide acetate|45.0 mg depot injection, 2 doses 6 months apart
223597900|NCT04849715|DRUG|parsaclisib|parsaclisib will be administered orally once daily.
223597901|NCT04849715|DRUG|rituximab|rituximab is administered IV on Day 1 of each 28-day cycle for 6 cycles.
223597902|NCT04849715|DRUG|bendamustine|bendamustine is administered IV on Day 1 and 2 of each 28-day cycle for 6 cycles.
223597903|NCT04849715|DRUG|Placebo|placebo will be administered orally once daily
223597904|NCT04929080|BIOLOGICAL|JS004 , Recombinant humanized IgG4k monoclonal antibody specific to BTLA for injection Intravenous infusion|200mg:JS004 , Recombinant humanized IgG4k monoclonal antibody specific to BTLA for injection Intravenous infusion
223597905|NCT04929080|BIOLOGICAL|JS004 , Recombinant humanized IgG4k monoclonal antibody specific to BTLA for injection Intravenous infusion|600mg:JS004 , Recombinant humanized IgG4k monoclonal antibody specific to BTLA for injection Intravenous infusion
223597906|NCT04929080|BIOLOGICAL|JS001 and JS004|Part B: 100mg JS004 + 240mg JS001 or 200mg JS004+ 240mg JS001
223597907|NCT02274545|BIOLOGICAL|H7N9 Anhui 2013/AA ca|10\^7.0 fluorescent focus units (FFU); 0.5 mL of vaccine will be delivered as a nasal spray by an Accuspray device (0.25 mL per nostril)
223597908|NCT02274545|BIOLOGICAL|Inactivated subvirion H7N9 vaccine|30 mcg
223597909|NCT06526910|BEHAVIORAL|Swallowing exercises|Standard-of-care swallowing exercises include tongue exercise. The experimental part added in Phase 3 includes some participants completed standard-of-care exercises again and others completing standard-of-care exercises and motor imagery practice of those exercises.
223597910|NCT04919837|OTHER|Low vision aids|the assisting devices fitting for low-vision patients
223597911|NCT01960153|DRUG|Tadalafil|Tadalafil tablets, 20 mg to 40 mg per day x 48 weeks
223597912|NCT01960153|DRUG|Placebo|Placebo of tadalafil. Subjects will take one tablet once per day and will be titrated to two tablets once per day after one week. Subjects are on study drug for the duration of the trial.
223597913|NCT03512392|OTHER|Conservative fluid and deresuscitation strategy|Conservative administration of intravenous fluid and active deresuscitation using diuretics or renal replacement therapy for eligible patients
223597914|NCT03512392|OTHER|Usual care strategy|Usual care at the discretion of the clinical team
223597915|NCT03993041|BEHAVIORAL|Cognitive-behavioral therapy (CBT)|Study therapists will deliver cognitive-behavioral therapy (CBT) based on an emotion-focused, transdiagnostic protocol. CBT targets problematic thoughts, feelings, and behaviors through goal-oriented, systematic procedures. The intervention used in this study is designed to target emotional processing with an emphasis on present-focused awareness, cognitive flexibility, emotional avoidance, awareness and tolerance of physical sensations, and situation-based emotion exposure. The intervention is designed to help individuals better understand emotional experiences in order to respond to intense emotions in a more adaptive way.
224198459|NCT06575244|OTHER|Community-based sailing|A nurse-led community-based sailing programme is validated by an expert panel including professionals from various fields, such as a registered nurse, academia, and qualified sailing instructors, delivered in a group of 6 participants, incorporating experiential learning, with the aid of materials including dinghies with Universal design, safety boats, buoys, buoyancy aids, supplementing with a waterproof sailing booklet. The intervention is developed and facilitated by a registered nurse (principal investigator).
224198460|NCT06575244|OTHER|Crafting activities|Participants in the attention control group will participate in crafting activities. Activities match the time and attention dedicated by the intervention group. Activities are designed to have no impact on resilience.
224198461|NCT03010163|OTHER|Health Fair|Testing includes weight, height, waist and blood pressure testing. In the event that the participants are unable to meet in person for health measurements, the staff will accept self-reported measurements over the phone.
224198462|NCT03010163|OTHER|Pedometer|The Fitbit One/Alta/Inspire wireless tracking pedometers measures steps taken, calories burned, distance traveled and sleep pattern. The Fitbit Alta/Inspire also sends reminders to move, which are notifications that remind the wearer to walk at least 250 steps each hour. If the wearer has not walked 250 steps within the hour, the device will vibrate and send an on-screen reminder 10 minutes before the hour. The reminders to move will be turned off during baseline and will be turned on at randomization for all participants.
224198463|NCT03010163|OTHER|Text Messaging|Daily healthy living advice and encouraging messages about walking through text messages
224198464|NCT03010163|OTHER|Social Network Support|Family or friends will provide encouragement and remind participants to maintain in a healthy lifestyle and increase daily walking activities
224198465|NCT06277921|PROCEDURE|Elective Surgery for gastric cancer|Resection of the esophagus and the gastroesophageal junction via open, laparoscopic or robotic approach
224198466|NCT06525623|OTHER|Recommendation: No Further Resuscitation|Treatment teams are encouraged not to administer any additional fluids
224198467|NCT06525623|OTHER|Recommendation: Resuscitation with Crystalloid|Treatment teams are encouraged to administer crystalloid. Amount of resuscitative fluid will be determined by treatment team's clinical assessments and usual standards of care
224198468|NCT06525623|OTHER|Recommendation: Resuscitation with Colloid|Treatment teams are encouraged to administer colloid. Amount of resuscitative fluid will be determined by treatment team's clinical assessments and usual standards of care
224198469|NCT06525623|OTHER|Recommendation: Standard of Care IV Albumin|Treatment teams are encouraged to administer 1 g/kg/d IV albumin (maximum 100 g/day) over 2 days
224198470|NCT02303327|RADIATION|EBRT + HDR brachytherapy boost|Standard radiotherapy (EBRT, 23 fractions) with the addition of High Dose-Rate (HDR) brachytherapy boost within 3 weeks of beginning or finishing the EBRT.
224198471|NCT02303327|RADIATION|Hypofractionated Dose Escalation Radiotherapy|Radiation therapy (higher radiation dose per treatment) will be given once a day, five days a week, over approximately 5 weeks.
224198472|NCT02303327|DRUG|Androgen deprivation therapy|28 months of androgen deprivation therapy (injections every 4 months for a total of 28 months)
224311110|NCT05523791|DIETARY_SUPPLEMENT|Fortiral|Twice a day, patients took 10 g of powder containing 92.5% whey protein with 2.7% cysteine; emulsifier: soy lecithin, lactose free to be reconstituted with 150-200 ml of water.
223597916|NCT00187447|DRUG|indomethacin (two different dosing regimens)|
223597917|NCT02913378|PROCEDURE|Osteosynthesis with locking plate|Open reduction and osteosynthesis with locking plate
223597918|NCT02913378|PROCEDURE|Sling|Conservative treatment with sling and rehabilitation
223597919|NCT06379269|DEVICE|App healthcare|Self-developed app: includes home stretching and strengthening exercises, muscle release technique instruction.
223597920|NCT06379269|OTHER|Control|general education and home rehab program
224198473|NCT04678440|DRUG|[18F]F-AraG Imaging|Total body PET imaging using \[18F\]F-AraG
224198474|NCT05487625|BEHAVIORAL|High-ventilated cigarette alone|High-ventilated cigarettes are the only available cigarettes in the Experimental Tobacco Marketplace which increases in price across trials. Other nicotine/tobacco products are available in the Experimental Tobacco Marketplace at market price. Note that all participants will complete all the specified conditions.
224198475|NCT05487625|BEHAVIORAL|Low-ventilated cigarette alone|Low-ventilated cigarettes are the only available cigarettes in the Experimental Tobacco Marketplace which increases in price across trials. Other nicotine/tobacco products are available in the Experimental Tobacco Marketplace at market price. Note that all participants will complete all the specified conditions.
224311111|NCT05523791|DIETARY_SUPPLEMENT|Mg++|Twice a day, patients took 2.250g of magnesium pidolate (=184 mg of Magnesium++ ione) powder twice a day to be reconstituted with 150-200 ml of water
223597921|NCT01887847|DRUG|Nicotine (Pharmaceutical Productions Inc.)|An investigational 2 mg sublingual nicotine tablet (Pharmaceutical Productions Inc.) will be administered in a randomized crossover design in 6 male and female otherwise healthy smokers.
223597922|NCT01887847|DRUG|Nicotine (Pharmaceutical Productions Inc.)|A Commit® 2 mg nicotine lozenge (GlaxoSmith Kline)will be administered in a randomized crossover design in 6 male and female otherwise healthy smokers.
223597923|NCT01990612|PROCEDURE|Elective Induction of Labor|Women randomized to induction of labor will undergo induction via oxytocin at 39 weeks 0 days to 39 weeks 4 days. Those with an unfavorable cervix (modified Bishop score \< 5) will first undergo cervical ripening (method left to the discretion of the patient's physician) in conjunction with or followed by oxytocin stimulation unless a contraindication arises.
223597924|NCT00079716|DRUG|SGN-40 (anti-huCD40 mAb)|0.5-8 mg/kg IV (in the vein) on Day 1; 0-8 mg/kg on Day 4; 0.5-16 mg/kg on Days 8 and 15; 0-16 mg/kg on Day 29.
223597925|NCT05258916|PROCEDURE|Nurse consultation|nurse consultation carried out within two weeks after maternity discharged
223597926|NCT02974842|DEVICE|MAKO 7|Hysteroscopic cell sampling
223597927|NCT03968848|DRUG|acalabrutinib|A 50-mg single oral dose of acalabrutinib will be administered.
223597928|NCT00360724|DRUG|Duloxetine (Cymbalta)|duloxetine medication up to dose of 120 mg/day
223597929|NCT00123604|DRUG|Carvedilol|25 mg twice daily for five months.
223597930|NCT00123604|DRUG|Metoprolol|200 mg twice daily for five months.
223597931|NCT02300181|DIETARY_SUPPLEMENT|Placebo|
223597932|NCT02300181|DIETARY_SUPPLEMENT|Bacillus subtilis var natto DC-15|
223597933|NCT03633812|OTHER|Observational study, Beta blocker medication history|Observational study, Beta blocker medication history
223597934|NCT04794881|OTHER|24 hours|Performing a lumbar puncture at 24 hours after a traumatic lumbar puncture
223597935|NCT04794881|OTHER|48 hours|Performing a lumbar puncture at 48 hours after a traumatic lumbar puncture
223597936|NCT02355210|DIETARY_SUPPLEMENT|Bifidobacteria adolescentis BD1|packet containing 10\^9 cells of Bifidobacteria adolescentis BD1
223597937|NCT02355210|DIETARY_SUPPLEMENT|Bifidobacteria animalis subsp. lactis BB-12|packet containing 10\^9 cells of Bifidobacteria animalis subsp. lactis BB-12
223597938|NCT02355210|DIETARY_SUPPLEMENT|Bifidobacteria adolescentis BD1 and galactooligosaccharide|packet containing 10\^9 cells Bifidobacteria adolescentis BD1 and 5 g galactooligosaccharide
224198476|NCT05487625|BEHAVIORAL|High- and low-ventilated cigarette with high-ventilated cigarettes increasing in price|High- and low ventilated cigarettes are available in the Experimental Tobacco Marketplace with high-ventilated cigarettes increasing in price across trials. Other nicotine/tobacco products are available in the Experimental Tobacco Marketplace at market price. Note that all participants will complete all the specified conditions.
224311112|NCT01272492|OTHER|Computer Use|Participants use the computer with the 5 modules on infant/toddler feeding/nutrition
224311113|NCT05980689|DRUG|AK104|During neo-CRT: 2 cycles of AK104, 10mg/kg d1 q3w. After neo-CRT: 3 cycles of AK104, 10mg/kg d1 q3w.
224311114|NCT05980689|DRUG|Capecitabine|During neo-CRT: 825mg/m2 bid Monday-Friday per week
223597939|NCT02355210|DIETARY_SUPPLEMENT|Bifidobacteria animalis subsp. lactis BB-12 and galactooligosaccharide|packet containing 10\^9 cells B animalis subsp. lactis BB-12 and 5 g galactooligosaccharide
223597940|NCT02355210|DIETARY_SUPPLEMENT|galactooligosaccharide|5 g galactooligosaccharide
223597941|NCT02355210|DIETARY_SUPPLEMENT|Placebo|lactose powder, 5 grams
223597942|NCT02847104|OTHER|dynamic insulin protocol|Adaptation of insulin infusion rate according to hourly capillary blood glucose and dynamic insulin protocol
223597943|NCT02847104|OTHER|static insulin protocol|Adaptation of insulin infusion rate according to hourly capillary blood glucose and static insulin protocol
223597944|NCT00151502|DRUG|Atorvastatin|
223597945|NCT01105598|DRUG|ETC-1002 or placebo|ETC-1002 (ascending dose), daily for 14 days
223597946|NCT01105598|DRUG|ETC-1002 or placebo|ETC-1002 (optimized dose), daily for 28 days
223597947|NCT01105598|DRUG|ETC-1002 or placebo|ETC-1002 (20 mg), daily for 14 days
223597948|NCT01344070|DRUG|one of the 15 drugs listed below|single, oral, immediate-release, non-combinational innovator formulation
223597949|NCT01344070|DRUG|one of the 15 drugs listed below|single, oral, immediate-release, non-combinational generic formulation a
223597950|NCT01344070|DRUG|one of the 15 drugs listed below|single, oral, immediate-release, non-combinational generic formulation b
223597951|NCT01344070|DRUG|one of the 15 drugs listed below|single, oral, immediate-release, non-combinational generic formulation c
223597952|NCT01835002|DEVICE|Transcorneal electrostimulation|Weekly stimulation for 30 minutes with current of TES delivered of 150% of the individual phosphene threshold.
223597953|NCT02673502|DIETARY_SUPPLEMENT|simple carbohydrate drink|Patients will ingest 400 ml of the simple carbohydrate drink consisting of commercial orange juice without pulp which contains 50 grams fructose/galactose 2 hours before surgery.
223597954|NCT02673502|DIETARY_SUPPLEMENT|complex carbohydrate drink|Patients will ingest 400 ml of the complex carbohydrate drink containing 50 grams of maltodextrin powder in water ( orange food color and artificial orange flavor have been added to the drink) 2 hours before surgery
223597955|NCT01347996|DRUG|histamine dihydrochloride and IL-2|Ceplene 0.5 mg subcutaneously twice daily and IL-2 1 µg/kg \[16,400 IU/kg\] body weight twice daily for 10, 21 day cycles
223597956|NCT04697732|OTHER|General anesthesia|Following emergence from general anesthesia, patients will be evaluated at 4 different timepoints; (a) One hour after emergence, (b) Twenty four hour after emergence (c) One week after emergence (d) One month after emergence. The first interview will be made face-to-face in the recovery unit, and other interviews will be made by phone.
223597957|NCT04225793|DRUG|Eziklen®|"The Eziclen solution should be taken in the one-time use regimen in morning before procedure.~Consumption of the full volume of the Eziklen® solution of the preparation and the additional amount of water or a clear liquid should be completed at least 2 hours and no later than 4 hours before the procedure."
224198477|NCT05487625|BEHAVIORAL|Low- and high-ventilated cigarette with high-ventilated cigarettes increasing in price|Low- and high-ventilated cigarettes are available in the Experimental Tobacco Marketplace with low-ventilated cigarettes increasing in price across trials. Other nicotine/tobacco products are available in the Experimental Tobacco Marketplace at market price. Note that all participants will complete all the specified conditions.
223748208|NCT05894850|OTHER|AI based automatic surveillance (AS) system (ENDOANGEL-AS) reminds the patients through by telephone .|An automatic surveillance (AS) system to accurately identify post-polypectomy patients, assign surveillance intervals for different risks of patients and proactively follow up with patients at certain times. AI based automatic surveillance (AS) system (ENDOANGEL-AS) reminds patients by telephone.
223597958|NCT04225793|DRUG|MoviPrep|"The Moviprep® solution should be taken in the one-time use regimen in morning before procedure.~Consumption of the full volume of the Moviprep® solution should be completed at least 2 hours and no later than 4 hours before the procedure."
223597959|NCT00004245|DRUG|sodium salicylate|
223597960|NCT04797806|DRUG|Anlotinib|Anlotinib 12 mg once a day from day 1 to 14 of a 21-day cycle.
224198478|NCT05487625|BEHAVIORAL|Usual, high- and low-ventilated cigarette with usual cigarettes increasing in price.|Usual cigarette, low- and high-ventilated cigarettes are available in the Experimental Tobacco Marketplace with usual cigarettes increasing in price across trials. Other nicotine/tobacco products are available in the Experimental Tobacco Marketplace at market price. Note that all participants will complete all the specified conditions.
224198479|NCT04928677|DRUG|Codrituzumab|For Phase A (Dose Escalation), the starting dose (dose level 1) will be 10 mg/kg with 1 planned dose escalation to 20 mg/kg (dose level 2) if dose level 1 is determined to be safe and tolerable. Once a RP2D/MTD is identified in Phase A, then Phase B (hepatoblastoma expansion cohort) will open and allow for enrollment of up to 10 additional patients.For both phases, patients will receive codrituzumab IV once per week for a period of 21 days per cycle. Patients will be eligible for up to 25 cycles.
224198480|NCT01323829|OTHER|EMG Guidance of Injection|The use of the EMG guidance is the experimental part of the study. We will perform EMG Needle testing in order to pin-point the best location for the patients Botox injections.
224198481|NCT05315687|DEVICE|Y-90 SIR-Spheres|Y-90 SIR-Spheres
224198482|NCT05315687|PROCEDURE|Yttrium-90 Microsphere Radioembolization|Undergo Y90 radioembolization
224198483|NCT05315687|OTHER|Systemic Therapy|Systemic Therapy
224198484|NCT05495724|DRUG|Disitamab Vedotin Tislelizumab|Disitamab Vedotin 120mg will be administered on Day 1 of each cycle for 4 treatment cycles;Tislelizumab 200mg will be administered on Day 2 of each cycle for 4 treatment cycles.
224198485|NCT05495724|DRUG|Disitamab Vedotin|Disitamab Vedotin
224198486|NCT03762187|BEHAVIORAL|Self-affirmation|Individuals select important values and then write about why that value is important to them.
223597961|NCT04797806|DRUG|Icotinib|Icotinib：125 mg/tablet，three times a day，fasting or serving with food. It should be continued until disease progression or intolerable toxicity or patients withdraw of consent.
224198487|NCT03762187|BEHAVIORAL|Positive living counseling|Each of the clinics from which participants were recruited conducts positive living counseling as part of their treatment programs. This counseling is conducted by counselors who are trained and monitored by the Lesotho Network of AIDS Support Organizations (LENASO) and consistent with the positive prevention framework (see Bunnell et al., 2005 for description). Each counseling session focused on addressing positive living goals such as the importance of taking one's medications on time and every day, using protection with every partner, and the importance of maintaining a healthy lifestyle.
224198488|NCT01695681|OTHER|Gluten-free diet|Dietary advice by clinical dietitian
224311115|NCT05980689|RADIATION|Neoadjuvant Radiotherapy|IMRT DT: 50Gy/25Fx
224311116|NCT02871492|DRUG|Pritelivir 5% w/w ointment|
223597962|NCT03669237|PROCEDURE|different reconstruction methods|Different reconstruction methods should be performed after sphincter preservation surgery in two groups.The methods include end-to-end anastomosis or end-to-side anastomosis
223597963|NCT05597553|OTHER|Premixed MTA|The premixed Bio-ceramic putty during setting become hard and expand slightly providing a superior long-term seal
223597964|NCT05597553|OTHER|Powder/liquid MTA|Mineral trioxide aggregate (MTA) is a silicate material that is said to aid in faster bridge formation with fewer tunnel defects, less pulpal inflammation, and the maintenance of pulpal integrity. It is widely used in pediatric dentistry due to its excellent sealing properties.
223597965|NCT00002517|DRUG|cytarabine|
223597966|NCT00002517|DRUG|daunorubicin hydrochloride|
223597967|NCT00002517|DRUG|dexamethasone|
223748209|NCT05894850|OTHER|AI based automatic surveillance (AS) system (ENDOANGEL-AS) reminds the patients through message.|An automatic surveillance (AS) system to accurately identify post-polypectomy patients, assign surveillance intervals for different risks of patients and proactively follow up with patients at certain times. AI based automatic surveillance (AS) system (ENDOANGEL-AS) reminds patients through message.
224198489|NCT00457795|DRUG|brimonidine 0.1% (Alphagan® P)|Brimonidine 0.1%, 1 drop three-times daily for 4 weeks
223597968|NCT00002517|DRUG|etoposide|
223597969|NCT00002517|DRUG|idarubicin|
223597970|NCT00002517|DRUG|mitoxantrone hydrochloride|
223597971|NCT00002517|DRUG|thioguanine|
223597972|NCT00002517|PROCEDURE|allogeneic bone marrow transplantation|
223597973|NCT00002517|RADIATION|radiation therapy|
223597974|NCT05084092|RADIATION|Intraoperative Radiotherapy (IORT)|If biopsy is positive, local treatment with IORT will be performed. After IORT (15,40 Gray at 2 mm dept), the applicator will be removed and surgery will be continued in a standard fashion.
224198490|NCT05805579|DIAGNOSTIC_TEST|Diaphragmatic echography|Diaphragmatic echography
224198491|NCT01959984|OTHER|100g Standard Noodles|Subjects are required to take 100g standard noodles,and then blood samples are collected at 0min,30min,60min,120min,180min.
224198492|NCT01959984|OTHER|75g Oral Glucose|Subjects are required to take 75g glucose solution,and then blood samples are collected at 0min,30min,60min,120min,180min.
224198493|NCT00495950|BEHAVIORAL|Questionnaire|Questionnaires relating to symptoms experienced during and following standard cancer treatment.
224311117|NCT02871492|DRUG|Pritelivir ointment matching placebo|
224311118|NCT02871492|DRUG|Zovirax® cream|
224311119|NCT02256436|BIOLOGICAL|pembrolizumab|IV infusion
224311120|NCT02256436|DRUG|paclitaxel|IV infusion
224311121|NCT02256436|DRUG|vinflunine|IV infusion
224311122|NCT02256436|DRUG|docetaxel|IV infusion
223597975|NCT05084092|PROCEDURE|Brain surgery|Surgery should be performed according to the local standard of care, preferentially as image-(neuronavigation) guided surgery. To establish the diagnosis of a metastasis and to exclude primary CNS tumors, lymphomas, SCLCs or germinomas it will be performed a peroperative biopsy
223597976|NCT06031363|DRUG|Indomethacin Suppository|Patients in the regular dose group are given indomethacin suppository 100 mg anal plug immediately after operation, patients in the low dose group are given indomethacin suppository 50 mg anal plug immediately after operation, and patients in the high dose group are given indomethacin suppository 150 mg anal plug immediately after operation.
223597977|NCT00171847|DRUG|Letrozole|
223597978|NCT00171847|DRUG|Trastuzumab plus Letrozole|
223597979|NCT00171847|DRUG|Letrozole|
223597980|NCT02240264|DIETARY_SUPPLEMENT|Krill oil capsules|1 year supplementation with Krill oil provided by Aker BioMarine Antarctic AS equalling almost the daily recommended amount of 450 mg of EPA/DHA intake per day.
223597981|NCT02240264|DIETARY_SUPPLEMENT|Placebo|Capsules containing a fatty acid mixture that reflects the fatty acid composition of the average European diet.
223597982|NCT00033891|DRUG|Infliximab|
223597983|NCT04217044|DIAGNOSTIC_TEST|Histopathology images based prediction of molecular pathology|Histopathology images based prediction of 1p/19q co-deletion, MGMT methylation, IDH and TERTp mutations or molecular subgroups by leveraging AI
223597984|NCT06280508|DRUG|Adebrelimab, Apatinib, Gemcitabine, cisplatin|Chemotherapy combined with Adebrelimab and Apatinib neoadjuvant therapy for 3 cycles before surgery, and Adebrelimab combined with Apatinib adjuvant therapy for 6 months after surgery
223748210|NCT05894850|OTHER|Manually remind the patients|Medical staff remind patients manually .
224198494|NCT05587075|PROCEDURE|Filiform needle|A needle treatment: guide patients take lying or sitting, keep relaxed, select Jingjiaji Point, Fengchi Point, Jianjing Point, Tianzhu Point, Houxi point, Hegu Point, Waiguan Point, preoperative, marker points, conventional disinfection, application specification of 0.35mmx50mm disposable sterile acupuncture needle, in the marker quick needle subcutaneous, slow needle to feel acid swelling feeling, keep needle 30min, once a day, last 5d for 1 course, a total of 4 courses of treatment.
224198495|NCT05587075|PROCEDURE|Long round needle|Long round needle treatment: mark tendon lesions, take 3-5 tendon lesion points for needle point, after injection of 0.5% lidocaine 1mL, local anesthesia, to hold long round needle, slowly hierarchical detection to tendon lesion points, patients feel acid, hemp, swelling feeling is appropriate, to close method line knot treatment: straight to tendon lesions point surface, scraping, to remove the surface adhesion. Do not cross the superficial surface of the clavicle, sternocleidomastoid muscle deep surface, gentle action. After the needle was released, the pinhole was covered with a disposable dressing, bandaged for 2d, once a week, once for 1 course, and for a total of 4 courses of treatment.
224198496|NCT00524901|DRUG|Epoetin alpha|A single dose of epoetin alpha during CABG for three vessel disease, 60.000 IU intravenously.
224198497|NCT00524901|DRUG|NaCl 0.9%|A single dose of NaCl 0.9% during CABG for three vessel disease, 1 ml intravenously.
224198498|NCT00352664|DRUG|Donepezil|5 mg once a day by mouth for 7 day cycle. After evaluation on Day 8, all participants will be offered donepezil every day for 7 days.
224198499|NCT00352664|DRUG|Placebo|Placebo tablet once a day by mouth for one 7 day cycle. After evaluation on day 8, all participants offered donepezil every day for 7 days.
224198500|NCT03682211|DRUG|Fentanyl Citrate|50 μg/ml fentanyl citrate (Sublimaze, Janssen Cilag, Ltd, Marketing Authorisation No. PA 0748/044/001) administered intranasally using the MAD Nasal Intranasal Mucosal Atomiser Device
224198501|NCT03682211|DRUG|Morphine sulphate|10 mg/ml Morphine sulphate BP (Antigen Pharmaceuticals, Marketing Authorisation No.PA 73/20/1) administered intravenously.
224198502|NCT02743598|DRUG|Liraglutide|
224198503|NCT02030509|OTHER|Quick diagnosis program|
223597985|NCT05072730|DEVICE|Super High Pressure Balloon (OPN NC)|"Strategy of super high-pressure balloon angioplasty after unsuccessful lesion preparation with conventional NC balloon angioplasty.~Optical coherence tomography (OCT) imaging will be performed after lesion preparation with OPN balloon. Optional additional pre-dilatation with OPN/standard NC balloon is permitted at the operator´s discretion. Following lesion preparation, stenting will be performed in the same setting using a latest-generation everolimus-eluting stent (XIENCE; Abbott Vascular, Chicago, IL, USA). Optional post-dilatation with OPN balloon or standard NC balloon is permitted at the operator´s discretion."
224198504|NCT04029142|DIAGNOSTIC_TEST|Review of routine lab data|Review of routine lab data from pregnant women (first trimester)
224198505|NCT06167083|DIAGNOSTIC_TEST|Machine Learning to Estimate Mortality|Using deep learning we try to develop an algorithm and anticipate mortality
224198506|NCT04913285|DRUG|KIN-2787|KIN-2787 will be administered orally twice daily in 28-day cycles
223597986|NCT05072730|DEVICE|Intravascular lithotripsy (IVL)|"Strategy of IVL after unsuccessful lesion preparation with conventional NC balloon angioplasty.~Optical coherence tomography (OCT) imaging will be performed after lesion preparation with IVL balloon. Optional additional pre-dilatation with standard NC balloon is permitted at the operator´s discretion. Following lesion preparation, stenting will be performed in the same setting using a latest-generation everolimus-eluting stent (XIENCE; Abbott Vascular, Chicago, IL, USA). Optional post-dilatation with standard NC balloon is permitted at the operator´s discretion."
223597987|NCT02467582|DRUG|Aspirin|Aspirin 100 mg daily
223597988|NCT02467582|DRUG|Placebo|Placebo
223597989|NCT02008344|DRUG|favipiravir|"Administered twice daily over 5 consecutive days for a total of 10 doses.~* Day 1: 1800 mg twice daily (loading doses)~* Days 2 through 5: 800 mg twice daily"
223748211|NCT05515939|DEVICE|InPen Insulin Pen|The InPen is a reusable smart insulin pen for people living with diabetes. The device uses Bluetooth technology to send dose information to a mobile application. The InPen can be used to deliver insulin, help calculate insulin doses, and estimate carbohydrates for meals
224198507|NCT04913285|DRUG|KIN-2787 and binimetinib|Continuous and Ramp-Up cohorts: KIN-2787 (exarafenib) and binimetinib will be administered orally twice daily in 28-day cycles Intermittent Cohort: KIN-2787 will be administered orally twice daily and binimetinib will be administered twice daily for 5 days on, 2 days off for 28-day cycles
224311123|NCT06173141|OTHER|low- to moderate-continuous intensity cycling exercises:|"aerobic exercise during dialysis using Pedal machine at low- to moderate continuous intensity rating from 11 to 13 on the Borg scale for 15-30 minutes.~warming up and cool down (approximately 10 minutes) in form of free active exercise of the lower extremities"
223748212|NCT04678245|BEHAVIORAL|Above the Influence-Vaping (ATI-V)|Peer-nominated 8th grade and 9th grade Peer Leaders (PL) will be trained in a half day ATI-V training. Adult Advisors (AA) will attend a half day ATI-V AA training and the PL training. The training day builds leadership skills in the PLs, develops skills for rising above pressure to vape including identification of personal reasons to rise, identification of healthy support people, teaching accurate use statistics, and sharing stories of prior success in rising above negative pressures. The ATI-V team of PLs and AAs then will run four interactive messaging campaigns to reach the rest of the student body. These four campaigns are (1) Introduction to ATI-V and My Reasons to Rise (2) Gain and Loss (3) Who's Got My Back (4) The Facts. Each campaign features a portion in which PLs model healthy norms and behaviors, and a second portion in which all the rest of the students engage in an interactive component to build and demonstrate the target skill.
223748213|NCT06030921|OTHER|Osteopathic Structural Exam, State - Trait Anxiety Questionnaire|During a single patient encounter they will fill out the State-Trait Anxiety Questionnaire , and undergo a Osteopathic Structural Exam
223748214|NCT05689788|DEVICE|High-intensity laser therapy|punctual technique on the 6 bilateral points of the cervical region and shoulder girdle, to be followed by a sweep technique on both trapezius muscles (upper portions). The parameters proposed by Dundar et al. will be used: an average power of 3 W, 60 J per point (360 J), and 500 J for manual scanning (1000 J). For the application of laser therapy, the 12 W BTL-6000 equipment that emits at 1064 nm wavelengths will be used.
223748215|NCT05689788|PROCEDURE|Stretching exercise|Three sets of bilateral passive static stretching will be performed for the upper trapezius, levator scapulae, and scalene muscles. Each series will last 30 seconds, followed by a 30-second rest interval. The exercises will be carried out with the participant in a seated position in a chair with a backrest.
224198508|NCT04620590|DRUG|Dapagliflozin 10 MG [Farxiga]|Dapagliflozin is a stable, reversible, highly selective, and orally active inhibitor of human renal sodium glucose co-transporter 2 (SGLT2), the major transporter responsible for glucose reabsorption in the kidney. Patients will receive one tablet dapagliflozin 10 mg per day for a total period of 14±1 days. This dose is the recommended dose for monotherapy and for add-on combination therapy with other glucose-lowering medicinal products including insulin to improve glycaemic control in T2DM.
223597990|NCT02008344|DRUG|placebo|"Administered twice daily over 5 consecutive days for a total of 10 doses.~* Day 1: 1800 mg twice daily (loading doses)~* Days 2 through 5: 800 mg twice daily"
223748216|NCT05689788|DEVICE|Sham High-intensity laser therapy|Intervention in which the therapist performs a HILT simulation application, performing all of the steps and movements for an administration without actually receiving the treatment.
224198509|NCT06013371|DRUG|PF-07038124|topical PDE4 inhibitor
224198510|NCT06013371|DRUG|Placebo Ointment|matching placebo
224198511|NCT05919043|OTHER|Upper limb-based movement priming (UL-priming)|Repetitive upper limb movements administered to the beat of a metronome.
224198512|NCT05919043|OTHER|Lower limb-based movement priming (LL-priming)|Repetitive lower limb movements administered to the beat of a metronome.
224198513|NCT05919043|OTHER|Sham priming|Auditory stimulation.
224198514|NCT06205251|DEVICE|POWERbreathe Plus IMT|"Inspiratory muscle training will be performed using the POWERbreathe Plus IMT (POWERbreathe International Ltd., Warwickshire, UK), a commercially available inspiratory pressure threshold device. In this type of training, airflow is occluded until the generated inspiratory pressure reaches the predetermined threshold, which can be set at increments of 8 cm H2O.~During the first week of training, the target intensity will be set at 50% of baseline maximal inspiratory pressure (MIP.) During the second week, the target intensity will be set at 60% of baseline MIP. Beginning at the third week and for the remainder of the training program, the target intensity will be set at 75% of the participant's baseline MIP. The target volume will be 5 sets of 6 breaths per day (total of 30 breaths per day), separated by 1-minute rest breaks between sets. The frequency of training will be 5 days per week, for a duration of 6 weeks."
224198515|NCT02970877|BIOLOGICAL|Fecal filtrate from 150 g stool from healthy lean donors|150 g stool from healthy lean donors will be diluted in 0.9% normal saline to a total volume of 450 mL. Preparation from frozen stool.
224198516|NCT02970877|BIOLOGICAL|Fecal filtrate from 150 g of the recipient's own stool|150 g stool from the recipient will be diluted in 0.9% normal saline to a total volume of 450 mL. Preparation from frozen stool.
224198517|NCT03885401|BEHAVIORAL|Enhanced care planning|The intervention includes (1) screening for unhealthy behaviors, mental health needs, and social needs, (2) creation of a care plan, (3) quarterly updates to the plan, (4) a clinical navigator and community health worker to support accomplishing the care plan, (5) registry of community resources and programs, and (6) messaging and video-visit system for team members.
224198518|NCT05456607|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|Cognitive Behavioral Therapy for Insomnia consists of the standard features of this well-established insomnia treatment that will be delivered in this study via a mobile optimized web app. Participants also have access to an intervention coach/guide as needed.
224198519|NCT05456607|BEHAVIORAL|Cognitive Behavioral Therapy for Depression|Cognitive Behavioral Therapy for Depression consists of the standard features of this well-established depression treatment that will be delivered in this study via a mobile optimized web app. Participants also have access to an intervention coach/guide as needed.
224311124|NCT06173141|OTHER|moderate- to high-interval intensity cycling exercises|"aerobic exercise during dialysis using Pedal machine at moderate-to-high interval intensity rating from 12 to 15 on the Borg scale for 15-30 minutes.~warming up and cool down (approximately 10 minutes) in form of free active exercise of the lower extremities"
223597991|NCT00674674|DRUG|Topotecan|"Induction (4 weeks): Patients will receive IT topotecan for 5 consecutive days during weeks 1 and 3.~The Induction period is the first 4 weeks of therapy."
223597992|NCT00674674|DRUG|Topotecan|Consolidation (6 weeks): Patients will receive IT topotecan for 5 consecutive days during weeks 1 and 4. The Consolidation period is 6 weeks in duration. Consolidation begins immediately after completion of the 4th week of Induction.
223597993|NCT00674674|DRUG|Topotecan|Maintenance (4 weeks for 11 courses): Patients will receive IT topotecan for 5 consecutive days during week 1. Each course of Maintenance is 4 weeks in duration. Maintenance begins immediately after completion of the 6th week of Consolidation.
223597994|NCT00735722|DEVICE|HIFU AF Ablation|Concomitant left atrial ablation using High Intensity Focused Ultrasound (HIFU)
223597995|NCT03068702|DEVICE|Optical Coherence Tomography Angiography|
223597996|NCT05958797|DRUG|Chloroquine|Chloroquine will be administered according to body weight at a total dose of 25 mg base/kg over 3 days (10 mg base/kg on Day 0; 10 mg base/kg on Day 1 and 5 mg base/kg on Day 2). Correct drug dosage will be determined using the dosing chart (in accordance
223597997|NCT05958797|DRUG|Primaquine|For Pf patients, primaquine at 0.75 mg base/kg body weight single dose will be given on Day 3 for Pf patients; For Pv patients primaquine will be withheld for 28 days and will be given after Day 28 follow-up, at 0.25 mg base/kg per day for 14 days.
223597998|NCT02469350|OTHER|Serious game|Rehabilitation with serious game
223597999|NCT01748838|DRUG|CTX-4430|Ascending single oral doses of CTX-4430 will be administered to subjects in 6 cohorts on day 1. Following a 14-day washout, subjects in two of the six cohorts will cross-over, fed a high fat diet and administered different single oral doses of CTX-4430
223598000|NCT01748838|OTHER|Mannitol|excipient blended with CTX-4430 in capsules
223598001|NCT01748838|DRUG|Placebo|Single oral doses of placebo will be administered to subjects in 6 cohorts on day 1. Following a 14-day washout, subjects in two of the six cohorts will cross over, fed a high fat diet and administered single oral doses of placebo
223598002|NCT01748838|DRUG|CTX-4430|Ascending repeat doses of CTX-4430 will be administered orally, once-daily, to subjects in 4 cohorts on days 1-14.
223598003|NCT01748838|DRUG|Placebo|Repeat doses of placebo will be administered orally, once-daily, to subjects in 4 cohorts on days 1-14.
223748217|NCT06797440|OTHER|Dual tasks of digital technology|The intervention activities of this study were cognitive and physical activity training using Nintendo Switch twice a week, 60 minutes each time (5 minutes of warm-up and cool-down exercises, 10 minutes of stretching exercises, and 40 minutes of exercise combined with cognitive training) for a total of 8 weeks. train. Both groups filled in basic data (demographics and disease characteristics) and underwent cognitive function measurements and physical activity function measurements at pretest (T0), 4th week (T1), and 8th week (T2).
223748218|NCT06309017|OTHER|Nutrition specialist|Nutrition specialist to help improve nutritional status by diet, oral nutrition supplements or parenteral nutrition.
224198520|NCT05456607|BEHAVIORAL|Mood Monitoring|The mood monitoring intervention is based on mood tracking principles in broader mood management interventions, but without any psychoeducational content or cognitive-behavioral exercises. Instead, participants will get access to a mobile optimized web app that allows users to enter their mood, tag related events, and view trends over time to raise awareness of how activities influence certain mood states.
224198521|NCT05477147|DEVICE|Catheter Ablation|Cardiac catheter ablation for recurrent AF after previous ablation (catheter or surgical).
224198522|NCT04581473|DRUG|CT041 autologous CAR T-cell injection|Up to 3 times CT041 autologous CAR T-cell injection infusion
224198523|NCT04581473|DRUG|Physician's Choice（Paclitaxel or Irinotecan or Apatinib or Anti-PD-1 antibody）|Physician's choice of any BSC listed above
224198524|NCT06228534|PROCEDURE|Root coverage with tunneling technique|THIS IS THE INTERVENTION GROUP THE RECIPIENT AREA OF THE CONNECTIVE GRAFT IS PREPARED.
224198525|NCT06374732|BEHAVIORAL|High-intensity interval training|The experimental group will perform 6-to-10-minute of high-intensity interval training at the beginning of their physical education lessons or physical activity lessons.
223598004|NCT01748838|OTHER|Mannitol|excipient blended with CTX-4430
223598005|NCT03683342|PROCEDURE|Ankle Block|Ankle block will be performed prior to surgery under ultrasound guidance
223598006|NCT03683342|PROCEDURE|Sciatic nerve block|Sciatic nerve block will be performed prior to surgery under ultrasound guidance
223598007|NCT00866255|DEVICE|endotracheal tube pressure measurement probe|The endotracheal tube pressure measurement probe is inserted into the endotracheal tube prior to intubation for measurement of tracheal pressure at the tip of the endotracheal tube.
224198526|NCT06374732|BEHAVIORAL|Control group|The control group will maintain their normal behaviour, including regular physical education lessons and physical activity lessons.
224198527|NCT04961437|OTHER|Diaphragmatic ultrasound and electrical impedance tomography|"A diaphragmatic ultrasound in a half sitting position. The diaphragmatic excursion and the thickening fraction of the right hemi-diaphragm will be measured.~\- Acquisition of 10 minutes of regional pulmonary ventilation by electrical impedance tomography."
224198528|NCT05980260|OTHER|Symptom-based Dosing Approach|During this approach to care, all enrolled infants with NOWS at the study site will be treated with the symptom-based dosing approach if they meet the withdrawal threshold for pharmacologic treatment. Participants may receive up to 3 doses of the study site's preferred opioid during a 24-hour period to treat signs of withdrawal once the threshold for pharmacologic intervention is met. If a 4th dose is required within a 24-hour period, the study site will transition to the scheduled opioid taper algorithm used at the study site to complete the infant's pharmacologic treatment.
224198529|NCT05980260|OTHER|Scheduled Opioid Taper Approach|During this approach to care, all enrolled infants with NOWS at the study site will be treated with the study site's usual scheduled opioid taper approach, as detailed in each site's treatment algorithm, if they meet the withdrawal threshold for pharmacologic treatment.
224198530|NCT03539952|DRUG|Penicillamine (D1-W12)|Penicillamine during baseline period (D1-W12)
224198531|NCT03539952|DRUG|TETA 4HCL (W12-60)|TETA 4HCL during post randomisation and 1st extension period (W12-W60)
224198532|NCT03539952|DRUG|Penicillamine (W12-W60)|Penicillamine during rondomisation and 1st extension period period (W12-W60)
224198533|NCT03539952|DRUG|TETA 4HCL (60-<W108)|TETA 4HCL during 2nd extension period (W60-\<W108)
224311125|NCT06173141|OTHER|hemodialysis sessions only|hemodialysis sessions only
224311126|NCT01564264|PROCEDURE|Sentinel Lymph Node Biopsy|Sentinel node biopsy after injections of 0.4 mci of Technetium 99 in the cervix and 4 mL of Patent Blue into the myometrium followed by standard retroperitoneal lymph node dissection
224311127|NCT03583086|DRUG|Vorolanib|Given by mouth
224311128|NCT03583086|BIOLOGICAL|Nivolumab|Given by IV
223598008|NCT04160858|OTHER|Exercise|Spinal Cord Injury Exercise Guidelines: Participants will begin at the Starting Level which is 20 mins of moderate to vigorous aerobic activity 2x/week \& 3 sets of 10 repeats of strength training 2x/week. They will progress to Advanced Level which is 30 mins of moderate to vigorous aerobic activity 3x/week and 3 sets of 10 repetitions of strength training 2x/week. The intervention duration is 6 months.
223598009|NCT04160858|OTHER|Control|Wait-list control
223598010|NCT02291419|DRUG|ticagrelor|ticagrelor 90 mg bid
223598011|NCT02291419|DRUG|aspirin|aspirin 81 mg daily
223598012|NCT06136013|BEHAVIORAL|HIIT|1 minute of exercise at 90% of their PPO, followed by a 1-minute rest at 40-60% of their peak power output using a cycle ergometer.
223598013|NCT04066478|DRUG|Dehydroepiandrosterone|75mg Dehydroepiandrosterone daily
224198534|NCT06652321|PROCEDURE|Endothelial Side Up Femtosecond Laser Assisted DSAEK|"The Femto LDV Z8 laser system will be set to create a 100 μm thick graft with a 7.5 mm diameter.~The graft will be inverted, placed endothelial side up in the anterior chamber, and coated with Viscoat. A fixation ring will center the graft by holding the scleral rim with forceps.~After cutting, the cornea should remain endothelium-up, stained with Trypan Blue, and dissected using a blunt spatula. The graft will be placed on a Busin glide and coated with Viscoat.~A 3-4 mm corneal incision will be made, and Descemet's membrane will be marked and stripped. The graft will be inserted using the Busin glide, spreading automatically. A small air bubble will fill the anterior chamber to compress the graft for 10 minutes."
224198535|NCT02698319|BEHAVIORAL|Copenhagen Triage Algorithm|The Copenhagen Triage Algorithm is a new triage method for faster triage in the ED
223598014|NCT04066478|DRUG|Placebo|Placebo
223598015|NCT01115673|DRUG|Acetaminophen|Acetaminophen Caplet - single dose
223748219|NCT06309017|DIETARY_SUPPLEMENT|Ensure Surgery Immunonutrition shakes|All study subjects, including subjects without malnutrition, will be given the Ensure Surgery Immunonutrition Shakes for prior to surgery as per standard of care. All subjects will also receive additional shakes starting as an inpatient when diet is advanced.
224198536|NCT03495752|OTHER|Bruce Fatigue Protocol|Participant will perform the Bruce protocol as a fatigue stimulus to examine the impact of fatigue on the FSDT
224198537|NCT02702375|OTHER|Fructose-containing Sugars|
224198538|NCT01261299|DRUG|Carbon-14-labeled carboplatin|Patients are eligible for this study if they have non-small cell lung cancer or bladder cancer and will receive cisplatin or carboplatin-based chemotherapy for the treatment of cancer. They will receive one microdose of C-14-carboplatin approximately 4 hours before scheduled biopsy/surgery. One blood draw and a few milligrams of leftover tumor tissue will be taken for analysis of carboplatin-DNA adduct levels. The dose of carboplatin will be about 1/100th the therapeutic dose.
224198539|NCT03026894|RADIATION|Panoramic Radiograph|Measurement of bone resorption
224198540|NCT03026894|DEVICE|T-Scan III occlusal system|Recording percentage of force in maximum intercuspation
224198541|NCT02463058|OTHER|exercise under hot and humid conditions protocol|"acclimatization day protocol: 2 hour effort performed in a climatic chamber, which include walk on a treadmill at 5 Km/h on a 2% incline under heat conditions (40 deg. centigrade \& 40% RH) Core (rectal) and skin temperature and heart rate will be monitored continuously~experiment days (3 days): 2 hour effort (2 cycles of: 50 min walk and 10 min rest-sitting) performed in a climatic chamber, which include walk on a treadmill at 5 Km/h on a 2% incline under heat conditions (30 deg. centigrade \& 60% RH) Core (rectal) and skin temperature and heart rate will be monitored continuously."
224198542|NCT06975189|DEVICE|Lung ultrasound group|Infants in the intervention arm will receive lung ultrasound as their first line imaging. Clinicians will be permitted to order a chest x-ray if they require further information or if the lung ultrasound findings are inconclusive or not consistent with the clinical findings.
224198543|NCT06975189|DIAGNOSTIC_TEST|Standard Care|Infants in the standard group will receive chest X-ray as their first line imaging tool. Lung ultrasound will not be permitted in this group.
223598016|NCT01115673|DRUG|Placebo Control|0 mg Caplet - single dose
223598017|NCT03949608|OTHER|E-learning|"The intervention consists of the presentation and installation of an internet tool to educate the patient about his heart condition and about his medications in addition to usual care. The tool is an interactive web-hosting video called Mon Coeur, mon BASIC adaptable to smartphones and tablets. The total length of the video is around 15 minutes. The e-learning is interactive because of the possibility to click in the video to have more details about a particular point. The tool includes a part about the heart and particularly about the ACS (physiopathology, diagnosis, coronarography, angioplasty). A second part includes an education about the medications prescribed. The patient will select the medication being prescribed and receive information about it."
223598018|NCT01564147|OTHER|immediate therapeutic education|Access to the course of immediate therapeutic education
223598019|NCT01564147|OTHER|therapeutic education delayed|Group receiving therapeutic education 6 months later (control group)
223598020|NCT05001204|DRUG|68Ga-NOTA-RM26|68Ga-NOTA-RM26 were injected into the patients before the PET/CT scans
223598021|NCT00488735|BEHAVIORAL|Cognitive-behavioral rehabilitation|
223598022|NCT00488735|BEHAVIORAL|Traditional primary care|
223598023|NCT05257291|DRUG|Melatonin|Supplementation with 1 mg/day of melatonin for 1 year
224198544|NCT06978114|DRUG|BL-B01D1|Administration by intravenous infusion for a cycle of 3 weeks.
224198545|NCT06978114|DRUG|Pembrolizumab|Administration by intravenous infusion for a cycle of 3 weeks.
224198546|NCT06591455|DRUG|Fenofibrate|Fenofibrate 200mg/day
224198547|NCT06591455|DRUG|UDCA (Ursodeoxycholic acid)|UDCA 13-15mg/kg/day
224198548|NCT06588972|DIETARY_SUPPLEMENT|Medium Chain Triglyceride solution|Placebo
224198549|NCT06588972|OTHER|Cannabis Sativa|Group 2: Cannabis sativa extract with CBD (45mg/day).
224198550|NCT05649072|BEHAVIORAL|Genetic Testing and Counseling|Participants will be asked to collect a saliva sample for hereditary cancer and genetic testing
224198551|NCT05649072|BEHAVIORAL|Screening Form|Participant will be answering demographic details
224198552|NCT06610760|DRUG|Ursodeoxycholic Acid|Subjects will be instructed to take one capsule (250mg) of ursodeoxycholic acid three times daily, and visit the hospital every 4 weeks for evaluation of the subjective symptoms and to receive a new supply of medication.
224198553|NCT06610760|DRUG|Placebo|Subjects will be instructed to take one capsule (250mg) of placebo three times daily, and visit the hospital every 4 weeks for evaluation of the subjective symptoms and to receive a new supply of medication.
224198554|NCT06604884|DEVICE|Treatment of Intracranial Aneurysms|Embolization of aneurysms using the Pipeline™ Vantage Embolization Device with Shield Technology™
224198555|NCT03075215|DEVICE|Device Programming of the Boston Scientific Cardiac Resynchronization Therapy Defibrillator (CRT-D)|The optimization during the standard of care visits in the first 12 months following implantation
224198556|NCT00774722|DRUG|Metronidazole|10% ointment, three times daily for 14 days
223598024|NCT00003712|DRUG|temsirolimus|"•Part I: Patients receive CCI-779 IV over 30 minutes on days 1-5, followed by a 9 day rest period. Treatment courses repeat every 2 weeks in the absence of disease progression or unacceptable toxicity.~The maximum tolerated dose for part I is defined as the dose level at which 33% of patients experience dose limiting toxicity.~•Part II: Patients receive the same treatment schedule as part I. Three patients with CNS tumors are entered at the dose of CCI-779 determined to be the MTD in Part I. At least 3 patients are entered at each dose level in part II."
223598025|NCT03443804|DRUG|Test(DW1401)|DW1401+Placebo of Stillen tab.
223598026|NCT03443804|DRUG|Reference(Stillen tab.)|Stillen tab.+Placebo of DW1401
223598027|NCT02227667|DRUG|MEDI4736|Patients will be seen the day of administration of MEDI4736. A medical history, with particular reference to toxicities, including medication review, and physical examination will be conducted at each treatment visit.
223598028|NCT03295760|DRUG|Q10 Coenzyme|
224198557|NCT06610266|DRUG|Weifuchun|Subjects will be instructed to take four tablets (1400mg) of Weifuchun three times daily, and visit the hospital every 4 weeks for evaluation of the subjective symptoms and to receive a new supply of medication.
224198558|NCT06610266|DRUG|Folic Acid|Subjects will be instructed to take one tablet (5mg) of folic acid three times daily, and visit the hospital every 4 weeks for evaluation of the subjective symptoms and to receive a new supply of medication.
224198559|NCT01160029|DRUG|Nateglinide|Nateglinide Tablets 120 mg
224198560|NCT01233284|DRUG|tiotropium bromide 2.5µg once daily|Efficacy and safety comparison of 3 doses of inhaled tiotropium (1.25µg, 2.5µg and 5µg) versus placebo
224198561|NCT01233284|DRUG|Tiotropium matching Placebo once daily|Efficacy and safety comparison of 3 doses of inhaled tiotropium (1.25µg, 2.5µg and 5µg) versus placebo
224198562|NCT01233284|DRUG|tiotropium bromide high dose once daily|Efficacy and safety comparison of 3 doses of inhaled tiotropium (1.25µg, 2.5µg and 5µg) versus placebo
224198563|NCT01233284|DRUG|tiotropium bromide 1.25µg once daily|IMP
224198564|NCT02628184|OTHER|Maternity Services Development Programme|The Maternity Services Development Programme was implemented to improve care for local families (service users) involved with maternity services. The aim was to improve care during the early stages of a family's development and to establish foundations for long-term well-being. One aspect of the programme worked to improve the delivery of care by facilitating collaboration and joint-planning between service providers. The programme uses local city Children's Centres to co-locate services (different agencies or professionals who are working within the same locality). The aim of co-location was to promote stronger collaboration between maternity services and other service provider agencies to develop stronger partnerships, and to help identify those who are (or who may become) vulnerable.
224198565|NCT00912756|DRUG|cilostazol|200 mg/day BID
224198566|NCT04259541|DIAGNOSTIC_TEST|Psychodiagnostic|Intensity and frequency of specific symptoms, signs of problems in mental health
223598029|NCT01593592|DIETARY_SUPPLEMENT|Lactobacillus reuteri|Will receive triple therapy (omeprazole 20 mg b.i.d., amoxicillin 1000 mg b.i.d, clarithromycin 500mg b.i.d) and L. reuteri (is a mixture of L. reuteri DSM 17938 and L. reuteri ATCC PTA 6475, will be delivered a dose of 1x108 CFU each strain, means giving daily chewable tablet containing 2x108 CFU/day) for 2 weeks followed by L. reuteri for another 2 weeks.
223598030|NCT01593592|DIETARY_SUPPLEMENT|Placebo|Will receive triple therapy (omeprazole 20 mg b.i.d., amoxicillin 1000 mg b.i.d, clarithromycin 500mg b.i.d) and a placebo (1.5 mg per dose as chewable tablets) for 2 weeks followed by placebo for another 2 weeks.
223598031|NCT01593592|DRUG|Omeprazole|All patients will receive omeprazole 20 mg b.i.d for 2 week
223598032|NCT01593592|DRUG|Amoxicillin|amoxicillin 1000 mg b.i.d for 2 weeks
223598033|NCT01593592|DRUG|Clarithromycin|clarithromycin 500mg b.i.d for 2 weeks
223748220|NCT06958731|DEVICE|TuoRen Ultrasonic System|The Single-operator Laser-assisted T-shaped probe consisted of TuoRen Ultrasonic System (TUR200, Shenzhen Tuoren Bio-Medical Electronics Co., LTD) with a T-shaped probe (L38T7C), a 3D-printed probe-carrying enclosure with a linear laser transmitter ( ZLM120AL650-22130BXS, Shenzhen Zhonglai Technology Co., Ltd.) and ultrasonic probe manipulator.
223748221|NCT06958731|DEVICE|Huasheng Color Ultrasonic Diagnostic System|Ultrasonic (Huasheng Color Ultrasonic Diagnostic System, Navi s, Shenzhen Huasheng Medical Technology Co., LTD.) and a 4.0MHz phased probe were used for the short-axis out-of-plane internal jugular vein catheterization
224198567|NCT06379854|OTHER|chest physiotherapy|Postural Drainage Frequency: 3 sessions/week Intensity: 5 to 10 minutes Time: For 4 weeks Type: chest physiotherapy Percussion F: 3 sessions/week I: 3 to 5 minutes T: For 4 weeks T: chest physiotherapy Vibration F: 3 sessions/week I: 3 to 5 minutes T: For 4 weeks T: chest physiotherapy Shaking F: 3 sessions/week I: 3 to 5 minutes T: For 4 weeks T: chest physiotherapy Huffing and coughing F: 3 sessions/week I: 3 to 5 minutes T: For 4 weeks T: chest physiotherapy
224198568|NCT06379854|OTHER|trunk rotation exercises,deep diaphragmatic also chest physiotherapy|"Postural Drainage Frequency: 3 sessions/week Intensity: 5 to 10 minutes Time: For 4 weeks Type: chest physiotherapy~Percussion F: 3 sessions/week I: 3 to 5 minutes T: For 4 weeks T: chest physiotherapy~Vibration F: 3 sessions/week I: 3 to 5 minutes T: For 4 weeks T: chest physiotherapy~Shaking F: 3 sessions/week I: 3 to 5 minutes T: For 4 weeks T: chest physiotherapy~Huffing and coughing F: 3 sessions/week I: 3 to 5 minutes T: For 4 weeks T: chest physiotherapy~Deep Diaphragmatic Breathing Exercise F: 3 sessions/week I: 3 to 5 minutes T: For 4 weeks T: chest physiotherapy TLFROM F: 3 sessions/week I: 5 to 10 minutes T: For 4 weeks T: Mobilization Exercises TFROM F: 3 sessions/week I: 5 to 10 minutes T: For 4 weeks T: Mobilization Exercises"
224198569|NCT02045017|DRUG|Pomalidomide and Dexamethasone|
224311129|NCT01696279|DRUG|Lanthanum Carbonate|Lanthanum Carbonate 1500 mg to 3000 mg powder will be administered orally.
224198570|NCT00928863|OTHER|implementation aids|testing a taylor made strategy for implementation NVOG guideline and MOET instruction in 3 hospitals
224198571|NCT03953651|OTHER|Follow-up|Onset of Major Adverse Cardiovascular Event of death from all causes will be collected at 3 and 6 months after inclusion.
224311130|NCT01696279|DRUG|Calcium Carbonate|Calcium carbonate will be administered orally at a total daily dose based on standard clinical practice. The total daily dose may be adjusted as appropriate, until the target serum phosphorus level is achieved or until a maximum daily dose of 6500 mg is reached.
223748222|NCT06958744|OTHER|Functional Inspiratory Muscle Training (FIMT) group|Training will be given with the Powerbreath inspiratory muscle training device. Unlike traditional inspiratory muscle training, the exercises given in FIMT aim to integrate the functional capacity of respiratory muscles into daily life activities and include dynamic exercises in different positions with variable resistances. In this respect, it is defined as functional. Preparatory training will be given 4 weeks before starting FIMT: participants will be taught basic respiratory muscle training, respiratory control and exercises, and will be taught to perform the exercises while maintaining the spine in a neutral position. Patients will then be taken to FIMT for 3 days/6 weeks with a physiotherapist. On the other 3 days of the week, only inspiratory muscle training will be performed. The intensity of inspiratory muscle training will be increased from mild to moderate (Mild: Effort level between 20-40% of MIP or between Borg 2-3, Moderate: 50-60% of MIP or Borg 4-6).
223748223|NCT06958744|OTHER|Control group|Thoracic expansion exercise will be performed for 10 weeks. The participant will be asked to practice 4 times a day as a home program.
223748224|NCT03913754|OTHER|Psycho-social consequences of lupus erythematosus|It will be necessary to take into account the psychosocial experience of the disease \[47\] and to allow a narrative exploration of this experience and its psycho-social consequences both for the patients and their spouses (ie the experiential dimension of the disease in connection with the life trajectory, the life of a couple, elaborate representations concerning the disease). The purpose of this approach is not only to question the meaning of the disease (beliefs, representations), the psycho-social management of the disease, its inclusion in the socio-cultural condition of the patients, but also to allow an analysis of the inscription. of the disease in the relationship and its implications (relational, affective, sexual) and its impact on the possibilities of social participation.
223598034|NCT03319823|DRUG|Thiazide Treatment Group|"Thiazide Treatment Group: Non-diabetics with sleep systolic blood pressure of 125-139 mm Hg and awake systolic blood pressure \<160 mm Hg Participants will be treated with Indapamide 0.625mg once a day After 4 weeks of treatment, the investigators will monitor chemistries/electrolytes with a fingerstick point of care device and repeat ambulatory blood pressure monitoring the investigators will repeat ambulatory blood pressure monitoring at 4, 8, and 12 weeks after treatment initiation.~If sleep systolic blood pressure is \< 120 mm Hg, the investigators will continue treatment"
223598035|NCT03319823|DRUG|Intensified Thiazide Treatment Group|At 4 weeks of therapy, individuals initially assigned to the Thiazide treatment group whose ambulatory blood pressure recheck showed a sleep systolic blood pressure \>120 mm Hg, the investigators will intensify their blood pressure medications by adding on Telmisartan 40 mg and Amlodipine 5 mg. In two week intervals, labs and ambulatory blood pressure will be measured. If the systolic blood pressure \>120, then the doses of Telmisartan and Amlodipine will be up-titrated until the sleep systolic blood pressure is \<120.
223748225|NCT06958458|BEHAVIORAL|Mother Integrated Care|In order to empower mothers whose premature infants have been hospitalized in the neonatal intensive care unit (NICU) for at least three days, a four-step neonatal care training program will be provided. Through the empowerment of the mother, the empowerment of the family will also be supported. The family will no longer be considered as visitors but will be involved in the infant's care in the NICU as parents. Data collection forms will be completed before the training begins, one day prior to discharge, and one week after discharge.
223748226|NCT00292864|DRUG|SNS-032 Injection|
223748227|NCT04700358|OTHER|Blood sampling|"Screening: Blood sampling of 15 ml whole blood~B cell isolation: Blood sampling of max. 400 ml whole blood or 6% of the total blood volume (♀ 65 ∓ 10 ml/kg; ♂ 77 ∓ 10 ml/kg)"
224198572|NCT04570033|DIAGNOSTIC_TEST|We assessed sensitivity of 18F-FCH PET/CT in preoperative localisation of hyperfunctioning parathyroid tissue in patients with primary hyperparathyroidism|We prospectively enrolled 65 consecutive patients with PHPT who underwent neck ultrasound (US) and parathyroid scintigraphy (99mTc/99mTc-MIBI dual phase). Twenty-two patients had unsuccessful parathyroid surgery prior to the study. PET/CT scans were performed 65.0 ± 13.3 min after injection of 218.5 ± 31.9 MBq of 18F-fluorocholine (FCH). Three experienced nuclear medicine physicians assessed the detection rate of hyperfunctioning parathyroid tissue. Response to parathyroidectomy and clinical follow-up served as a reference test. Per-patient sensitivity and positive predictive value (PPV) were calculated for patients who underwent surgery.
224198573|NCT02756182|DEVICE|TDOC air-charged catheter|Urodynamic study utilizing a single catheter technique to measure WP \& AC measurements
223748228|NCT02732483|DRUG|Endo-Clot(TM)|The patients agreed in this study, bleeding control will going to be done with Endo-Clot(TM)
223748229|NCT00715325|DEVICE|Protectiscop CS|Patients who are indicated for screening colonoscopy will be recruited into the trial. The ProtectiScope CS sleeve is assembled on the colonoscope.standard colonoscopy is performed. Subjects will be followed for 1-month post procedure.
223748230|NCT00734279|DRUG|Leuprolide Acetate - Early Puberty Leuprolide Visit|Dose of 10 mcg/kg Sub cutaneous once at 0800 on day 2 of the Early Puberty Luprolide Visit
224198574|NCT06991673|BEHAVIORAL|Behavioral Treatment|"Positive Activity Interventions within Ane-Roadmap App~Positive Piggy Bank - Capture happy moments by mentally savoring them, recording details, and depositing them into a piggy bank. Open it when you need a boost.~Gratitude Diary - Write two unique things daily for which you're grateful. Smile as you record them to enhance gratitude.~Savoring - Each day, spend 2-3 minutes fully enjoying two positive experiences. Log them for reflection.~Pleasant Activity Scheduling - Plan and engage in enjoyable activities at least twice weekly. Treat them as important appointments.~Random Acts of Kindness - Perform five intentional kind acts in a day, four for others and one for yourself.~Signature Strengths - Use a personal strength in a new way daily and reflect on its impact.~Love Letter - Express deep appreciation to a loved one in a heartfelt letter and share it with them.~Engaging with Beauty - Keep a log of beautiful moments in nature, art, or human kindness."
224311131|NCT03258203|OTHER|Preventing Overweight Using Novel Dietary Strategies|The study tests the effectiveness for weight loss and weight maintenance of four diets differing in macronutrient composition: moderate in fat (40% energy) with two different protein levels (15% and 25%), and low in fat (20% energy), also with 15% and 25% protein levels.
224311132|NCT01881984|DRUG|Ravicti|Open-label design comparing Ravicti at doses of 2, 4, and 6 grams/m2/day
224311133|NCT04941079|OTHER|no intervention|no intervention
223598036|NCT03319823|DRUG|Combination Medication Treatment Group|"Combination Medication Treatment Group: Diabetics or sleep systolic blood pressure of ≥ 140 mm Hg, or awake systolic blood pressure of ≥ 160 mm Hg~* Participants will be treated with starting doses of a long acting blood pressure regimen of Telmisartan 40 mg and Amlodipine 5 mg daily~* After 2 weeks, the investigators will monitor chemistries/electrolytes with a fingerstick point of care device and repeat ambulatory blood pressure monitoring~  * If sleep systolic blood pressure is \< 120 mm Hg, the investigators will continue treatment and repeat ambulatory blood pressure again in another 2 weeks to assess reproducibility~ * If sleep systolic blood pressure is \> 120 mm Hg, the investigators will increase Telmisartan dose to 80 mg and the Amlodipine dose to 10 mg. Ambulatory blood pressure monitoring will be checked again after 2 weeks of therapy to verify efficacy."
223598037|NCT00389493|DRUG|Risperidone|Dosage of 0.5 mg to 4.0 mg per day as tolerated
223598038|NCT00389493|BEHAVIORAL|Exposure/ritual prevention therapy (EX/RP)|EX/RP is a form of cognitive behavioral therapy. Participants assigned to EX/RP will attend therapy sessions twice per week. In EX/RP, participants will be exposed to feared objects or ideas, and will be encouraged not to carry out a compulsive response.
223598039|NCT00389493|DRUG|Placebo|Placebo capsules will be identical in appearance to those of risperidone.
223598040|NCT00924768|BIOLOGICAL|20K EU CCRE|Inhalation of CCRE
223598041|NCT02449161|DRUG|MPA|
223598042|NCT02449161|DRUG|placebo|
223598043|NCT00791089|DRUG|LOVAZA Omega 3-acid ethyl esters|Treatment with omega-3 fatty acids (4g/day) for 4 weeks before and 3 months after radiofrequency catheter ablation for AF.
223598044|NCT00791089|DRUG|LOVAZA|(EPA+DHA 4 gram/day) for 4 weeks before and 3 months after the ablation procedure.
223598045|NCT00791089|OTHER|placebo|Control group will receive placebo before \& after ablation.
223598046|NCT04596748|DIETARY_SUPPLEMENT|Probiotic|Bacillus Subtilis, Bacillus Clausii, Bacillus Coagulans, Bacillus Indicus HU36, MCC 102
223598047|NCT04596748|DIETARY_SUPPLEMENT|Placebo|Placebo caps
223598048|NCT03047031|DRUG|Nintedanib|Nintedanib
223598049|NCT03047031|DRUG|Pirfenidone|Pirfenidone
223598050|NCT04832191|DEVICE|CE-SM|contrast enhanced spectral mammography \&contrast enhanced magnetic resonance imaging
223598051|NCT00089531|DRUG|VRC-HIVDNA016-00-VP|
223748231|NCT00734279|DRUG|Ganirelix - Early Puberty Ganirelix Visit|Dose of 2.5 mcg/kg Sub-cutaneous once at 17:30 on day 1 of the Early Puberty Ganirelix Visit and once at 08:00 on day 2 of the Early Puberty Ganirelix Visit
223748232|NCT00734279|DRUG|Ganirelix - Delayed Puberty Ganirelix Visit|Ganirelix is administered at a dose of 2.5 mcg/kg sub cutaneous at 17:30 on day 1 and once at 08:00 on day 2 of the Ganirelix Delayed Puberty Visit
223598052|NCT02474420|DRUG|Amlodipine|amlodipine titrated up to 10 mg daily or maximum tolerated dose, whichever comes first
223598053|NCT02474420|DRUG|Deferasirox|Deferasirox administered per standard of care by the treating physician
223598054|NCT00646360|DIETARY_SUPPLEMENT|DHA|400 mg/d of docosahexanoic acid (DHA) during pregnancy
223598055|NCT00646360|DIETARY_SUPPLEMENT|Placebo|2 tablets daily during pregnancy
223598056|NCT05099835|DRUG|Botox|injected 10 mL of 0.1% bupivacaine with 100 Botox units (BOTOX®, Allergan Inc., Irvine, CA, USA)
223598057|NCT05099835|DRUG|triamcinolonacetonide|triamcinolonacetonide stellate ganglion injection
223598058|NCT04116125|PROCEDURE|Radiotherapy|Adjuvant radiotherapy on axillary region
223598059|NCT03084601|DRUG|Calcium Hydroxide, Iodoform, paste|mixture of calcium hydroxide and iodoform
223598060|NCT03084601|DRUG|3-mixtatin|3-mixtatin mixture of ciprofloxacin, metronidazole, cefixime, and simvastatin
223598061|NCT03850028|OTHER|89Zr-atezolizumab PET scans|"The anti-PDL1 antibody atezolizumab, labeled with Zirconium-89 (89Zr) will be used as a molecular imaging tracer for PET scanning.~These 89Zr-atezolizumab PET scans will be performed before and after induction therapy (R-CHOP) and at suspected relapse during or after consolidation treatment with atezolizumab (treatment trial HOVON 151)."
223598062|NCT05579808|PROCEDURE|Epidural Analgesia|Using an aseptic technique while the patient is in sitting position, an epidural catheter was placed at the L2-L3 or L3-L4 interspace. Analgesia was established with the epidural administration of a low dose of local anaesthetic, plus a lipid-soluble opioid (ropivacaine 0.1% and sufentanyl 0.5%, 20 mL). Analgesia was maintained with a top-up regimen, using intermittent manual epidural boluses of increasing concentrations of ropivacaine, with up to 0.15% at full dilation, according to specific needs of individual participants.
223598063|NCT04379492|DRUG|Hydroxychloroquine|Participants will receive hydroxycholoroquine (200-mg tablets) 2 tablets orally q12h for 2 doses on day 1 (load), followed by 1 tablet orally q12h for days 2-5.
223598064|NCT04379492|OTHER|Placebo|Participants will receive masked placebo given as 2 tablets orally q12h for 2 doses on day 1, followed by 1 tablet orally q12h for days 2-5.
223598065|NCT06087575|DEVICE|Supira System|The Supira System is a minimally invasive, miniaturized percutaneous ventricular assist device (pVAD) system that is intended to provide temporary (≤4 hours) hemodynamic support to patients undergoing a HRPCI procedure. The Catheter is inserted percutaneously via the femoral artery, across the aortic valve, and into the left ventricle under fluoroscopic guidance, with a portion remaining in the ascending aorta. The left ventricle is unloaded by pumping blood from the ventricle into the ascending aorta and systemic circulation.
223598066|NCT04591158|DEVICE|Butterfly iQ|The Butterfly iQ is an ultrasound system that enable diagnostic ultrasound imaging and measurement of anatomical structures and fluids of adult and pediatric patients. It is a non-invasive device and does not impose any health hazards.
223748233|NCT00734279|DRUG|Leuprolide Acetate- Delayed Puberty Leuprolide Visit|Leuprolide acetate is given at a dose of10 mcg/kg at 0800 on day 2 of the Delayed Puberty Leuprolide Visit
223748234|NCT05447156|BEHAVIORAL|Tailored QuitGuide app|This is an app not available to the public. It was developed/tailored based on an app available to the public and can be downloaded.
223748235|NCT05447156|BEHAVIORAL|Standard QuitGuide app|This is an app available to the public.
223748236|NCT00002733|BIOLOGICAL|aldesleukin|
223748237|NCT00002733|BIOLOGICAL|recombinant interferon alfa|
223748238|NCT00002733|BIOLOGICAL|therapeutic tumor infiltrating lymphocytes|
223748239|NCT00002733|DRUG|cimetidine|
223748240|NCT02002364|PROCEDURE|tracheal intubation|
223748241|NCT01254227|DRUG|Deferasirox and Deferoxamine|
223598067|NCT05860231|DEVICE|Foley catheter|"Silicone Foley catheters are transurethral balloon catheters used for the treatment of bladder emptying disorders, as well as for drainage of urine from the urinary tract, continuous fluid irrigation, and/or medication administration. Its use is suitable for a prolonged period of no more than 29 days and is used in Urology, Internal Medicine, Surgery, Obstetrics and Gynaecology Services.~For this study, conventional Foley-type catheters whose use is approved in Spain for routine use will be used. Silicone Foley catheters, usually available in 2- and 3-way, are made of silicone and consist of a body, drainage funnel, inflation funnel, irrigation funnel (if present, only on 3-way catheters) and balloon valve. The product is sterile and single use."
223598068|NCT05860231|DEVICE|T-Control catheter|The T-control® catheter is a flexible, sterile silicone tube with an inflatable balloon at the distal tip, a polytetrafluroethylene membrane integrated into its body, and a sliding fluid control valve. The valve, built into the catheter, provides additional functions to the catheter, such as turning urine flow on and off after insertion (functions currently provided by accessories such as caps or valves) and controlling urination during the insertion process (function that is not provided by any other device). In this way, accidental loss of urine can be avoided from the first moment of use until its withdrawal. Additionally, it has a safety cap that reduces the possibility of accidental movements of the valve before use or during transport and fixing. The design has been developed in such a way that, once inserted, it facilitates autonomous use even for the elderly or patients with limited manual dexterity. The device is sterile and single use, like any conventional Foley catheter.
223598069|NCT04936815|DIAGNOSTIC_TEST|Transthoracic echocardiography|Transthoracic echocardiography for the detection of congenital or acquired structural heart disease.
223598070|NCT00482625|DRUG|erlotinib hydrochloride|Given PO
223598071|NCT00482625|PROCEDURE|conventional surgery|Undergo pancreatectomy
223598072|NCT00482625|OTHER|immunohistochemistry staining method|Correlative studies
223598073|NCT00482625|GENETIC|protein expression analysis|Correlative studies
223598074|NCT00482625|PROCEDURE|biopsy|Correlative studies
223598075|NCT00482625|OTHER|pharmacological study|Correlative studies
223598076|NCT00482625|OTHER|laboratory biomarker analysis|Correlative studies
223598077|NCT04971356|DRUG|Aspirin 100mg for 1-month (immediately after PCI)|Aspirin for 1-month immediately after PCI to be a part of medication treatment in the Experimental arm
223598078|NCT04971356|DRUG|Ticagrelor 90mg for 6-month (immediately after PCI)|Ticagrelor for 6-month immediately after PCI to be a part of medication treatment in the Experimental arm
223598079|NCT04971356|DRUG|Aspirin 100mg for 6-month (6-month post PCI)|Aspirin for 6-month at 6 months post-PCI (after the discontinuation of the 6-month Ticagrelor treatment) to be a part of medication treatment in the Experimental arm
223598080|NCT04971356|DRUG|Aspirin 100mg for 12-month (immediately after PCI)|Aspirin for 12-month immediately after PCI to be a part of medication treatment in the Reference arm
223598081|NCT04971356|DRUG|Ticagrelor 90mg for 12-month (immediately after PCI)|Ticagrelor for 12-month immediately after PCI to be a part of medication treatment in the Reference arm
223598082|NCT02673463|DRUG|Spironolactone|25 mg once daily
223748242|NCT00891644|OTHER|Case Management|"Clinical personnel at each AMTU site may work with other personnel from organizations authorized to have access to personal health information to identify clients identified as HIV positive within the past 6 - 18 months.~Initial contact will be made by persons at source organizations who are authorized to have access to personal health information. Persons so authorized will explain the nature of the research study and request permission from the client for subsequent contact by research personnel from the AMTU site. If permission for contact is received, research personnel at each site will attempt calls as specified by the potential participant or at random times (before 12:00 pm; between 12:00 - 4:00 pm; and between 4:00 - 10:00 pm) for no more than 10 attempts."
224198575|NCT04959019|BEHAVIORAL|Supervised combined endurance and resistance training (CERT)|Subjects will undergo up to 18 supervised sessions of a structured exercise program of combined endurance and resistance training (CERT). Supervised CERT will occur for 3 days/week, approx. 1 hr per session. Endurance training will start at 15 minutes and progress to 30 minutes of cycling on a stationary recumbent bicycle at 65-85% of heart rate reserve by week 3. Resistance training volume and intensity (baseline determined from strength tests) will progress over the first four sessions to 3 sets of 8-12 repetitions to volitional fatigue for 8 movements, with alternating upper-body and lower-body movements during the session. Progression will be incorporated throughout the trial for both endurance and resistance training to maintain relative intensity.
224198576|NCT04959019|BEHAVIORAL|Delayed supervised combined endurance and resistance training (CERT)|After a 6-week delay period (no-exercise control), subjects will undergo up to 18 supervised sessions of a structured exercise program of combined endurance and resistance training (CERT). Supervised CERT will occur for 3 days/week, approx. 1 hr per session. Endurance training will start at 15 minutes and progress to 30 minutes of cycling on a stationary recumbent bicycle at 65-85% of heart rate reserve by week 3. Resistance training volume and intensity (baseline determined from strength tests) will progress over the first four sessions to 3 sets of 8-12 repetitions to volitional fatigue for 8 movements, with alternating upper-body and lower-body movements during the session. Progression will be incorporated throughout the trial for both endurance and resistance training to maintain relative intensity.
224198577|NCT01058707|DRUG|MLN0128|MLN0128 capsules
223598083|NCT02673463|DRUG|Placebo|Visually identical to spironolactone, once daily
223598084|NCT00282659|DRUG|magnesium L-lactate|
223598085|NCT05263414|DEVICE|tVNS|tVNS allows the non-invasive activation of the Vagus Nerve by delivering electrical pulses to the sensory afferent fibers of the auricular, thick-myelinated, branch of the vagus nerve in the outer ear. TVNS seems to engage the same neural pathways of invasive VNS methods and may provide a novel, bottom-up NIBS method to promote GABA release. tVNS will be performed by using a CE marked tVNS device. It consists in a programmable stimulation unit connected to two titan ear electrodes that are mounted on a gel frame, allowing to generate and transfer electric impulses from the stimulation unit to the surface of the skin, where the electrodes are applied.
223598086|NCT04206371|DIAGNOSTIC_TEST|Defibrillator threshold testing|Under general or local anesthesia. Induction of Ventricular Fibrillation or R-wave synchronized shock
223598087|NCT01994265|DRUG|Warfarin|Warfarin once daily, at fast, targeting INR between 2 and 3
223598088|NCT01994265|DRUG|Dabigatran|
223598089|NCT01054482|DRUG|Pre-operative chemotherapy|Docetaxel 75 mg/m2 + Carboplatin AUC(area under the curve)=6 on D1, q3 weeks, Pre-Op \& Post-Op (total 4 cycles)
223598090|NCT01054482|OTHER|Pre-operative concurrent chemoradiation therapy|"Chemotherapy: Docetaxel 20 mg/m2 + carboplatin area under the curve = 2 on D1 and 8, q3weeks, Pre-Op \& Post-Op: 2 cycles (total 4 cycles).~Concurrent thoracic radiotherapy: Preoperative Thoracic radiation: 180cGy/fx, total: 4500cGy, 25fx"
223598091|NCT03832335|DIAGNOSTIC_TEST|Measurement of aniseikonia tolerance|Adding sizeglasses of different percent before right and left eye and measure the impact on stereopsis
223598092|NCT01598909|DRUG|Arnica|Application of Arnica ointment periorbitally
223598093|NCT01598909|DRUG|Placebo ointment|Application of Arnica ointment, twice a day, for the period of one week.
223748243|NCT00891644|OTHER|Snowball sampling|"Snowball sampling assumes that social networks of HIV sero-positive persons in treatment may overlap with those of HIV sero-positive persons not in treatment.~When a site is assigned to identify HIV positive adolescents not in care by snowball sampling, all HIV positive persons in care at the site will be invited to refer other adolescents known to them as HIV positive, but not in care, for possible participation in the study.~Printed information containing a brief description of the research in English and in Spanish and contact information of site study personnel will be provided to in-care adolescents at the site for distribution to those known HIV positive adolescents who are not in care."
224198578|NCT01914107|PROCEDURE|real-time monitoring and instruction of cancer pain|as description in arm
224198579|NCT01914107|PROCEDURE|standard cancer pain care|as description in arm
224198580|NCT03922191|OTHER|Data extraction from medical files|Data extraction from medical files
224198581|NCT06124859|OTHER|Functional capacity tests|"Maximal effort test on cycloergometer (1st visit)~Maximal effort test, 6-minute stepper test, 6-minute walk test, 5-times sit to stand test. A minimum rest period of 15 minutes must be observed between these tests (2nd Visit)"
224198582|NCT06425822|DIAGNOSTIC_TEST|Left atrial electroanatomical mapping|Left atrial electroanatomical mapping (substrate and functional mapping)
224198583|NCT01821391|DRUG|NDL-PDT|Metvix natural daylight photodynamic therapy
224198584|NCT01821391|DRUG|c-PDT|Metvix conventional photodynamic therapy
223598094|NCT04804163|DEVICE|telesurgery by domestic robot|telesurgery of the upper urinary disease by domestic robot
223598095|NCT02915042|DRUG|Dexmedetomidine|Analgesic Efficacy
223598096|NCT02915042|DRUG|Placebo|Saline placebo
223598097|NCT03178604|OTHER|Classic massage|It involves applying the classic massage techniques: effleurage (gliding or sliding movement over the skin with a smooth continuous motion following the direction of the muscle fibers of the superficial muscles in a distal to proximal direction); petrissage (lifting, wringing, or squeezing of soft tissues in a kneading motion, or pressing or rolling of the tissues under or between the hands); tapotement (various parts of the hand striking the tissues at a fairly rapid rate). The general objective is to improve extensibility of muscle, tendon, fascia, joint capsule, and ligamentous structures.
223598098|NCT03178604|OTHER|Sham massage|This group received a placebo intervention at the same time as the other group, maintaining only soft touch with the participant without exerting any mechanical pressure.
223598099|NCT03719742|OTHER|Sponsor Test Products|Baby Bee Foaming Cleanser(at least once daily but not more than twice daily), BB Baby Ultra Gentle Lotion (Once immediately after cleansing and again approximately 10-12 hours after cleansing)
223598100|NCT03652935|BEHAVIORAL|Mindfulness Based Stress Reduction|
224198585|NCT01821391|DRUG|placebo c-PDT|Metvix placebo conventional photodynamic therapy
224198586|NCT01773434|DRUG|MORAb-004|"MORAb-004 5 mg/mL is administered as an intravenous infusion (IV) in an escalating dose design and will not be escalated or de-escalated in individual participants.~Part 1 (Dose escalation): 4 weekly administrations of 2, 4, 8, and 12 mg/kg in four different cohorts on Days 1, 8, 15, and 22 of a 4-week cycle (28 days).~Part 2 (Cohort expansion): 4 and 8 mg/kg on Days 1, 8, 15, and 22 of a 4-week cycle (28 days) and 12 mg/kg biweekly administration on Days 1 and 15 of a 4-week cycle in different cohorts. The dosages in Part 2 can be amended considering the results of Part 1."
224198587|NCT05534646|DRUG|Apalutamide|Standard of care Apalutamide 240 mg administered orally and daily on Days 1-28 of every 28 day cycle
224198588|NCT05534646|DRUG|Carotuximab|"Carotuximab administered intravenously at the following doses:~Cycle 1 Day 1: 3 mg/kg Cycle 1 Day 4: 7 mg/kg Cycle 1 Day 8: 10 mg/kg Cycle 1 Day 15: 10 mg/kg Cycle 1 Day 22: 10 mg/kg Cycle 2 Day 1: 15 mg/kg Cycle 2 Day 15: 15 mg/kg Cycle 3+ Day 1: 15 mg/kg After completion of cycle 2, dosing of carotuximab will continue at a q4 week schedule using the 15 mg/kg dose."
223598101|NCT03652935|OTHER|Health Education Series|This is an active comparator condition that consists of 8 weekly classes related to health.
223598102|NCT02472301|DIETARY_SUPPLEMENT|cowpeas complementary food|cowpeas supplementary food that will be approximately 15% of the calculated total daily intake. Children will receive the food for 12 months.
223598103|NCT02472301|DIETARY_SUPPLEMENT|corn-soy flour|Corn-soy flour supplementary food that will be approximately 15% of the calculated total daily intake. Children will receive the food for 12 months.
223598104|NCT02472301|DIETARY_SUPPLEMENT|common bean complementary food|common bean supplementary food that will be approximately 15% of the calculated total daily intake. Children will receive the food for 12 months.
223598105|NCT03325374|OTHER|Questionnaires and examination|Patients with in the BLB patients study will have interview and questionnaire carried out.
223598106|NCT02037516|DEVICE|Accelomyography|quantitative measurement of the train-of-four with the TOF Watch to determine timing of administration of neostigmine and extubation To assure patient flow the time to reversal administration will be limited to approximately 30 minutes after achieving 4 twitches in qualitative monitoring
223598107|NCT02037516|DRUG|Neostigmine|Neostigmine is used to reverse the effects of neuromuscular blocking agents
224198589|NCT05328999|DIETARY_SUPPLEMENT|Probiotics (Omnibiotic (R))|As intervention in the randomized placebo controlled double blind trial, 30 males will receive either probiotics or placebo once daily for 3 months. Sperm count and microbiome analysis before and after intervention will be performed.
223598108|NCT02037516|DEVICE|Qualitative Monitor|Qualitative (tactile or visual) assessment of residual neuromuscular paralysis
224198590|NCT03832907|DEVICE|Dexcom G6 CGM - Continues Glucose Monitoring sensor system|A blinded factory-calibrated continues glucose monitoring sensor system Dexcom G6 will be placed shortly after admission. Two CGM devices will be inserted in all patients - one in the abdomen and one in the arm to also assess differences in blood glucose readings between upper extremity and abdominal insertion sites. Information on CGM readings will be collected daily during the hospital stay and after hospital discharge for 10 days using the Dexcom Studio software to download the Dexcom receiver data.
224198591|NCT03832907|DIAGNOSTIC_TEST|POC BG - Point-of-Care Blood Glucose monitoring|Standard of care - bedside point-of-care (POC) capillary blood glucose (BG) monitoring will be done before meals and bedtime daily during the hospital stay and after hospital discharge for 10 days.
224198592|NCT00271037|PROCEDURE|Colpocleisis prolapse repair surgery|
224198593|NCT00271037|PROCEDURE|sling or other to treat or prevent stress incontinence|
223598109|NCT04803695|DIAGNOSTIC_TEST|Microbial biofilm diagnose|Usage of new microbiological methods for biofilm detection
223598110|NCT05148806|DIAGNOSTIC_TEST|self-administered lateral flow assays|The lateral flow device to be used is the Fortress COVID-19 Total Antibody Device for the detection of IgM and IgG SARS-CoV-2 against the spike protein. The device has been evaluated for use in detecting anti-S in transplant patients and found to have a sensitivity of 92% and specificity of 95%.
223598111|NCT02816801|OTHER|Butler-Program 2.0|Internet based intervention for elderly, in which they learn how to use e-mail, video conferencing and a blog, in addition to virtual relaxation exercises.
223598112|NCT01576497|PROCEDURE|EUS-FNA|EUS-FNA with suction/10, 15, 20 to-and-fro motion vs. EUS-FNA without suction/10, 15, 20 to-and-fro motion Visual assessment as stoping rule: 20 to-and-fro motion at different site will be performed when EUS-FNA sampling with 10, 15, 20 to-and-fro motion is unsatisfactory.
223598113|NCT01576497|DEVICE|EUS-FNA with suction|For this prospective single-blinded randomized trial, two 10cc syringes was prepared. Two syringe was provided as same performance. However, one syringe is falsely made as suction syringe (fake one). During EUS-FNA, two syringe is randomly assigned and loaded by a nurse. Thus, operator was blinded which syringe is with suction or without suction.
223598114|NCT01576497|DEVICE|EUS-FNA without suction|For this prospective single-blinded randomized trial, two 10cc syringes was prepared. Two syringe was provided as same performance. However, one syringe is falsely made as suction syringe (fake one). During EUS-FNA, two syringe is randomly assigned and loaded by a nurse. Thus, operator was blinded which syringe is with suction or without suction.
223598115|NCT04628429|DRUG|Erenumab|anti-CGRP-receptor monoclonal anti-body
223598116|NCT04628429|DRUG|Galcanezumab|anti-CGRP-ligand monoclonal anti-body
223598117|NCT04628429|DRUG|Fremanezumab|anti-CGRP-ligand monoclonal anti-body
223598118|NCT03121365|BEHAVIORAL|Digital/E-Book Arm|Promotion of early reader digital e-book reading
223598119|NCT03121365|BEHAVIORAL|Standard/Board Book Arm|Promotion of early reader board book reading
223598120|NCT00704704|DRUG|5-aza-cytidine and Thalidomide|5-AZA-Cytidine 75mg/m2 5 days a month. 12 months. Thalidomide 50mg orally daily for 6 months.
223598121|NCT04286815|DEVICE|Lentiviral Vector Gene Therapy|Lentiviral vector to transfer IL2RG complementary DNA to patients'bone marrow stem cells
224198594|NCT04794049|DRUG|Lactulose|In experiment cohort, patients do not use standard bowel preparation regimen, they totally drink 300ml lactulose.
224198595|NCT04794049|DRUG|Polyethylene Glycol (PEG)|In control cohort, patients use the standard split-dose bowel preparation regimen,
224198596|NCT00718627|BIOLOGICAL|Human Heterologous Liver Cells|Multiple applications of liver cell suspension for infusion
224198597|NCT01977482|DRUG|GSK1278863|Film coated tablets containing 1 mg, 2 mg, 5 mg, or 25 mg of GSK1278863
224198598|NCT01977482|DRUG|Placebo|Matching placebo tablet for GSK1278863
224198599|NCT01977482|DRUG|rhEPO|rhEPO will be procured from local market
224198600|NCT00221416|DRUG|Aripiprazole|5-20 mg/day
223598122|NCT03653988|PROCEDURE|PEC I/II blocks by anesthesiologist - pre-operative|PEC I/II blocks by anesthesiologist - pre-operative; PEC I/II block to anesthetize the pectoral, intercostobrachial, third to sixth intercostal and long thoracic nerves. The PEC I/II blocks are pectoralis field blocks where local anesthetic medication is injected under ultrasound guidance between the tissue planes of pectoralis major and minor muscles (PECS I) and in the plane of the serratus anterior muscle at the level of the third rib (PEC II). Group I will have the PEC block administered by the anesthesiologist prior to surgical incision.
223598123|NCT03653988|PROCEDURE|PEC I/II blocks by surgeon - intra-operative|PEC I/II blocks by surgeon - intra-operative; PEC I/II block to anesthetize the pectoral, intercostobrachial, third to sixth intercostal and long thoracic nerves. The PEC I/II blocks are pectoralis field blocks where local anesthetic medication is injected under ultrasound guidance between the tissue planes of pectoralis major and minor muscles (PECS I) and in the plane of the serratus anterior muscle at the level of the third rib (PEC II).
223598124|NCT02511886|DRUG|Arbaclofen Placarbil|Arbaclofen Placarbil
223598125|NCT02511886|DRUG|Placebo|Placebo matched tablets
223598126|NCT02262702|DRUG|Paracetamol 665 mg|Paracetamol 665 mg tablet
224198601|NCT06099509|OTHER|Self-administered oral glucose tolerance test|Participants will be asked to self-administer the postpartum 75-gram oral glucose tolerance test. They will be provided the glucose solution and instructions. A 4 week virtual visit will be arranged where the test results will be reported to the provider and appropriate follow up arranged based on the results of their screen.
223598127|NCT02262702|DRUG|Paracetamol 500 mg|Paracetamol 500 mg tablet
223598128|NCT00656864|DRUG|Pioglitazone|Starting dose at 15 mg for two weeks, then titrated up to 45 mg in the subsequent 2 weeks.
223598129|NCT00656864|DRUG|Placebo|placebo
224198602|NCT06615986|DIETARY_SUPPLEMENT|Cardiosyn|Two sachets by mouth daily. Each dose (sachet) is 8.1 grams. For 2 doses it will be 16.2 grams per person per day.
224198603|NCT06995352|DRUG|Popliteal nerve block including liposomal bupivacaine|10 mL of unencapsulated bupivacaine 0.375% and 10 mL of liposomal bupivacaine 1.33% (Exparel, Pacira BioSciences, Tampa, Florida) admixed within a 20 mL syringe.
224198604|NCT06995352|DRUG|Adductor canal nerve block including liposomal bupivacaine|10 mL of unencapsulated bupivacaine 0.375% and 10 mL of liposomal bupivacaine 1.33% (Exparel, Pacira BioSciences, Tampa, Florida) admixed within a 20 mL syringe.
223598130|NCT06256341|OTHER|Cell cultivation, Antigen testing|"day 10, peripheral blood mononuclear cells were re-stimulated with the virus antigen U54 for 6 hours and, thereafter, stained for surface markers (CD3, CD4, CD8, CD56) and intracytoplasmatic activation markers (IL-2, IFN-γ, TNF-α) for flow cytometric detection of virus-specific T-cells. T-cells with intracytoplasmic expression of activation markers after stimulation with the virus antigen are HHV-6-specific T-cells. This indicated HHV-6 specific cellular immunity.~No more interventions in human except blood sampling, only basic research."
223598131|NCT02683434|DEVICE|Kinesio Taping application|Therapeutic taping application applied to skin affecting muscle, fascia, circulation, ligaments, tendons and joints.
223598132|NCT05908903|COMBINATION_PRODUCT|Drinks with active ingredients such as poria and GABA|Take drinks half an hour before bedtime, 10ml/bag/day, daily. Subjects are uniformly using skin care products provided by the sponsor during the test.
223598133|NCT00491582|DRUG|Growth hormone replacement therapy in growth hormone deficient patients only.|Genotropin once/daily sc., titration scheme according to the consensus guidelines of the GH and IGF-research society Duration: 6 months
223598134|NCT01959139|DRUG|PEGPH20|3 ug/kg on Day 1, IV over 15 minutes
223598135|NCT01959139|DRUG|Oxaliplatin|85 mg/m\^2, on Day 2, IV over 2 hours
224198605|NCT06995352|DRUG|Continuous popliteal nerve block with normal saline|A perineurial infusion of normal saline (basal rate 5 mL/h; patient-controlled bolus of 4 mL; 30 minute lockout) with the reservoir (500 mL) and pump provided by the Investigational Drug Service and continued until postoperative day 3 or until the reservoir is exhausted.
224198606|NCT06995352|DRUG|Popliteal nerve block with exclusively unencapsulated bupivacaine|20 mL of unencapsulated bupivacaine 0.375% with epinephrine (1:400,000) within a 20 mL syringe.
224198607|NCT06995352|DRUG|Adductor canal nerve block with exclusively unencapsulated bupivacaine|20 mL of unencapsulated bupivacaine 0.375% with epinephrine (1:400,000) within a 20 mL syringe.
224198608|NCT06995352|DRUG|Continuous popliteal nerve block with unencapsulated bupivacaine|A perineurial infusion of unencapsulated bupivacaine 0.125% (basal rate 5 mL/h; patient-controlled bolus of 4 mL; 30 minute lockout) with the reservoir (500 mL) and pump provided by the Investigational Drug Service and continued until postoperative day 3 or until the reservoir is exhausted.
224198609|NCT06673966|OTHER|Regular follow-up assessments without intervention.|Participants will receive a 3-month follow-up with clinical information, biological samples, and imaging data collected at baseline, 1st and 3rd months. The baseline assessment will include demographic information, medical history and previous medication use. At baseline and follow-up, patients' physical examination data (height, weight, waist and hip circumference, etc.), clinical symptom assessment scales (PANSS, SANS, SAPS, CDSS, CPSS, CGI, GAF, PSP, and SAS) and MCCB cognitive assessment data, blood and cerebrospinal fluid samples, MRI, and EEG data will be collected. Collection and store of blood and cerebrospinal fluid samples for routine laboratory tests and multi-omics including immunohistology, inflammation-related molecules, single-cell sequencing, extracellular vesicles, and other assays.
224198610|NCT06673966|OTHER|Cross-sectional assessment|Volunteers' physical examination data (height, weight, waist circumference, hip circumference, etc.), scale assessments (SCID, SCL-90, and CPSS) and MCCB cognitive assessment data, blood samples, MRI, and EEG data will be collected. Blood was collected and stored for exploring differences between patients and healthy individuals.
224198611|NCT05470777|COMBINATION_PRODUCT|"CD22/CD19 CAR T and auto-HSCT sandwich strategy"|The patients received sequential infusion of CD22 and CD19 CAR-T cells (co-stimulatory molecule was 4-1BB and infusion dose was 5\*10\^6/kg respectively) after standard induction and consolidation chemotherapy. Autologous stem cells mobilization and collection were performed 6-8 weeks after CAR-T infusion. Modified BuCy as conditioning regimen for Auto-HSCT was used 4 weeks after successful stem cell collection. CD22 and CD19 CAR-T cells were re-infused 2 days after Auto-HSCT. Patients were followed up and minimal residual diseases (MRD) was monitored by flow cytometry and second-generation gene sequencing of IgH rearrangement.
224198612|NCT06999174|DIAGNOSTIC_TEST|Multiparametric MRI|Diagnostic multiparametric liver MRI, performed at three time points: before (≤14 days), 24 hours after, and 4-6 weeks after TACE or 3 months after SIRT.
223598136|NCT01959139|DRUG|Leucovorin|400 mg/m\^2, on Day 2, IV over 2 hours
223598137|NCT01959139|DRUG|Irinotecan|180 mg/m\^2, on Day 2, IV over 1.5 hours
223598138|NCT01959139|DRUG|5-fluorouracil|2,400 mg/m\^2, Days 2-4, IV over 46 hours
223598139|NCT04756804|DRUG|70% v/v Isopropyl Alcohol Surgical Solution|Patient preoperative skin preparation
223598140|NCT04756804|DRUG|2%w/v Chlorhexidine Gluconate / 70% v/v Isopropyl Alcohol|Patient preoperative skin preparation
223598141|NCT00004932|DRUG|imatinib mesylate|
224198613|NCT06865144|DRUG|Netarsudil ophthalmic solution 0.02%|Apply one drop in each eye every evening
224198614|NCT06865144|DRUG|Artificial tears|Apply one drop in each eye every evening
224198615|NCT06669585|DRUG|Cannabis (smoked flower)|Self-Directed Use (ad-libitum)
224198616|NCT07000604|OTHER|Mouth Care Training|Patients will be educated on how to care for their mouths after using inhaled medication.
224198617|NCT05554471|DEVICE|MYNX CONTROL™ Venous Vascular Closure Device 6F-12F|Mynx Control Venous VCD 6F-12F is indicated for use to seal femoral venous access sites while reducing times to hemostasis and ambulation.
223598142|NCT02317848|OTHER|polygraphy and ECG|polygraphy and ECG during hospitalisation for acute heart failure to see Persistence of the severity of SAS after 2 months
223598143|NCT02199925|DRUG|Gammaplex 5%|
223598144|NCT01819896|DRUG|Pacemaker and defibrillator|
223598145|NCT03282929|DEVICE|Part 1|A single dose of 500 μg epinephrine (0.5 mL Suprarenin®) will be administered i.m. and s.c. by using a needle and a syringe in randomized order
223598146|NCT03282929|DEVICE|Part 2 Group 1|300 μg epinephrine auto-injector (Emerade, Bausch and Lomb, 23 mm needle length)
223598147|NCT03282929|DRUG|Part 2 group 2|500 μg epinephrine auto-injector (Emerade, Bausch and Lomb, 23 mm needle length)
223598148|NCT03282929|DEVICE|Part 2 group 3|300 μg epinephrine auto-injector (Fastjekt, MEDA Pharma, 16 mm needle length)
223598149|NCT03282929|DEVICE|Part 2 Group 4|300 μg epinephrine auto-injector (Jext, Alk-Abelló, 15 mm needle length)
223748244|NCT00891644|OTHER|Referral Lists|AMTU staff will develop lists of potential participants at their sites who have had an initial HIV-related health care visit but not received additional visits within the 12 mos prior the list (or before protocol screening) or have completed initial and follow up visits but dropped out of care for 12 or more mos. Back-up lists will be made of potential participants who have gone 9-12 mos and 6-9 mos without a visit. Clinical staff at each AMTU may work with staff from other organizations authorized to access personal health information to find potential participants. 1st contact will be made by persons at source organizations who are authorized to access personal health information. Authorized staff will explain the study and ask permission for contact by research staff at the AMTU site. If so, research staff will attempt calls as specified by the potential participant or at random (before 12 pm; between 12-4 pm; and between 4-10 pm) for no more than 10 attempts.
224198618|NCT05267652|OTHER|Preoxygenation with Non-Invasive Positive Pressure Ventilation|The delivery of oxygen and ventilation by non-invasive mechanical ventilation via a tight-fitting mask from the initiation of preoxygenation until the initiation of laryngoscopy. Trial protocol will not dictate the brand or type of mechanical ventilator that will be used to deliver non-invasive ventilation.
224198619|NCT05267652|OTHER|Facemask Oxygen|The delivery of supplemental oxygen via a non-rebreather mask or bag-mask device without manual ventilation from the initiation of preoxygenation until induction. Trial protocol will not dictate the brand or type of facemask. The decision between use of a non-rebreather mask and use of a bag-mask device will be made by treating clinicians. The decision of whether to provide manual ventilation with a bag-mask device between induction and laryngoscopy will be made by treating clinicians.
224198620|NCT03313297|DRUG|AZD4017|AZD4017 is a novel orally bioavailable small molecule inhibitor of 11β-HSD1 enzyme activity. It is potent and highly selective in vitro and in vivo. The half maximal inhibitory concentration (IC50) for inhibition of 11β-HSD1 activity (cortisone to cortisol conversion) is 2nM. AZD4017 is selective (\> 2000x) for 11β-HSD1 over human recombinant 11β-HSD2 and the closely-homologous enzymes 17β-hydroxysteroid dehydrogenase 1 and 17β-hydroxysteroid dehydrogenase 3 in vitro.
224198621|NCT03313297|DRUG|Placebo|Matching placebo
224198622|NCT07005869|PROCEDURE|brachial plexus tumors excision|excision of brachial plexus tumors
224198623|NCT07006051|OTHER|Exposed group|All subjects are tested pre-season for their sport. They are then prospectively followed for orthopaedic and/or concussive injury. If injuries occur, then repeat testing is performed.
223598150|NCT05529836|DEVICE|electroacupunture|The participants in EA group will receive acupuncture with PSD at bilateral Hegu (LI4), bilateral Quchi (LU5), bilateral Xuehai (SP10) and bilateral San Yinjiao (SP6). After skin disinfection, followed at an angle of 90°, acupuncture needles were inserted approximately 50 to 60 mm into the skin. When achieving qi, connect the four pairs of electrodes, two each on bilateral Quchi (LI4) and Hegu (LI11), two each on bilateral Xuehai (SP10) and San Yinjiao (SP6), and they are all ipsilateral to one another. The duration of the electroacupuncture stimulation is 30 minutes, and the current intensity ranges from 1 to 5 mA with a continuous wave of 20 Hz. For two weeks straight, the participants will have three therapy sessions each week (preferably every other day), for a total of six sessions.
223598151|NCT05529836|DEVICE|sham electroacupuncture|Participants in the SEA group will receive sham electroacupuncture with PSD, but not energizing the electropuncture device. Procedures, electrode placements, and other treatment settings are the same as in the EA group but with no electricity output only.
223598152|NCT05529836|DEVICE|sham acupuncture|Participants in the SAC group will receive sham acupuncture with PSD and PSN on sham acupoints (the non-meridian and non-acupuncture points). Procedures, electrode placements, and other treatment settings are the same as in the EA group but with no skin penetration, electricity output, or needle manipulation for achieving qi.
223598153|NCT01946737|RADIATION|HD-CTCA with Adaptive statistical iterative reconstruction (ASIR)|
223598154|NCT01946737|RADIATION|Active Comparator: Invasive coronary angiography (ICA)|
223598155|NCT00730080|DRUG|Sapropterin (Kuvan)|20mg/kg/day taken once daily or as otherwise prescribed by physician as standard care.
223598156|NCT01009606|OTHER|Usual strategy|Usual strategy
223748245|NCT01511523|DIETARY_SUPPLEMENT|RGMA001|3 capsules administered BID once a day.
223598157|NCT01009606|OTHER|Modified strategy|Proposition to a relative to witness the cardiopulmonary resuscitation of a family member and debriefing ot the situation
223598158|NCT00630344|DRUG|RAD001|
223598159|NCT00630344|DRUG|Bicalutamide|
223598160|NCT03996031|DEVICE|Plan to Thrive smartphone application|All participants in this single-arm pilot study will receive access to Plan to Thrive. This mobile care management program is comprised of modules including educational interventions, health behavior trackers containing built-in reminders, symptom monitoring, and navigator services (see attached content). Access to intervention modules and individualized navigator services according to patients' needs as captured by 1) their patient-reported outcome (PRO) assessments via Plan to Thrive's symptom monitoring feature, and 2) patient requests.
223598161|NCT04368715|DEVICE|Laser-assisted frenectomy with 2780 nm Er:Cr;YSGG and 940 nm diode laser|
223598162|NCT05345275|OTHER|The facial expressions analyzed|The facial expressions associated with pain were analyzed by the researchers in the OpenFace program. The patient's pain scores were estimated in the Python program by combining the numerical outputs of facial expression analyses with machine learning algorithms.
223598163|NCT05529069|DRUG|Pirtobrutinib|Given by PO
223748246|NCT01511523|DIETARY_SUPPLEMENT|Sugar Pill|Placebo
224198624|NCT07006805|BIOLOGICAL|CABA-201|Single intravenous infusion of CABA-201 following preconditioning with fludarabine and cyclophosphamide
223748247|NCT01263301|DEVICE|carotid duplex|Carotid duplex in the differential diagnosis of subclavian steal syndrome due to Arteriovenous Hemodialysis access in the Ipsilateral arm
224198625|NCT07007325|DRUG|[68Ga]Ga-PentixaFor|\[68Ga\]Ga-PentixaFor PET-CT
224198626|NCT07007026|OTHER|Immersive Virtual Reality|The intervention program was implemented over a period of eight weeks, with three ses-sions per week, each lasting 35 minutes.
224198627|NCT07007026|OTHER|Traditional Home-based Exercises|The participants were instructed to adhere to the exercise program thrice weekly for a period of eight weeks.
223598164|NCT05529069|DRUG|Venetoclax|Given by PO
223598165|NCT05968807|BEHAVIORAL|iParent2Parent Program|iParent2Parent is an online peer support mentorship program that is based on the iPeer2Peer online peer support mentorship program, which has been established in multiple chronic disease populations as a self-management intervention, including in chronic pain and juvenile idiopathic arthritis populations. The iParent2Parent program connect parents one-to-one with other parents of pediatric solid organ transplant (SOT) recipients who are trained to offer vital peer support and mentorship.
223598166|NCT04219592|DIAGNOSTIC_TEST|IgG4 measurement (non-interventional, just obtaining data from medical records)|IgG4 measurement in mg/dL
223598167|NCT05484245|DEVICE|Sonography|Surgeon detects brain mass lesion and assesses extent of it's resection with sonography
223598168|NCT05283421|DIAGNOSTIC_TEST|Estrogen|Women will receive active estrogen treatment or placebo prior to the colposcopic examination
223598169|NCT05283421|DIAGNOSTIC_TEST|Placebo|Women will receive active estrogen treatment or placebo prior to the colposcopic examination
223598170|NCT05081206|DRUG|Propofol infusion via manually controlled pump.|Patients will receive propofol bolus 2.5-3 mg/kg, for anesthesia induction and anesthesia maintenance was continued according to the Mc Farlan scheme, meaning continuous propofol infusion is used, with gradual reduction of the infusion speed in timely manner, depending on the duration of surgery: 15mg/kg/h...13mg/kg/h...11mg/kg/h...9mg/kg/h...6mg/kg/h.
223598171|NCT05081206|DRUG|Propofol infusion via target controlled pump.|Pedfusor model was used for delivering target controlled plasma concentration, with target concentration for anesthesia induction of 4 mcg/kg body weight and then 3 mcg/kg.
223598172|NCT02117180|OTHER|FODMAP's diet|The safety and efficacy of a low FODMAP diet will be evaluated in a convenience sample of children with functional gastrointestinal disorders, over a 6 week intervention period.
223598173|NCT05639530|BIOLOGICAL|IBI333|Intravitreal injection of IBI333
223598174|NCT06583525|OTHER|Intensive Transition Support|A multidisciplinary transition team (nurse practitioner and social worker) will coordinate the transition process for each patient across multiple settings, focused on the youth's highest priority needs while also supporting the caregivers. Participants will receive case management and care navigation using an intensive transition support model provided through the partnership of a transition team. The transition team will collaborate with the participants existing care team to help coordinate care, provide consultation, and support adult and primary care accepting these youth for 1 year following the transfer. This Intervention is modelled on best practices by Health Quality Ontario's Quality Standards for Transition from Youth to Adult Health Care Services to support youth at high risk of having poor transitional outcomes as they move from pediatric to adult care.
223598175|NCT06583356|BEHAVIORAL|Motivational interviewing|Participants will receive motivational interviewing intervention previously, delivered face-to-face at participants' home, 1 session, followed by 2 brief follow-up sessions. Each session is expected to last approximately 30 to 45 minutes.
223748248|NCT03265249|DEVICE|BRIDGE device|an externally placed, FDA-cleared device that delivers percutaneous electrical stimulation with alternating frequencies to branches of cranial nerves (V, VII, IX, and X) through the external ear via a field effect
223748249|NCT05862532|DIETARY_SUPPLEMENT|TeTrimTeas welsh Herbal tea with rhubarb root|TeTrimTeas welsh Herbal tea with green tea and rhubarb root
223748250|NCT05862532|DIETARY_SUPPLEMENT|TeTrimTeas welsh Herbal tea with senna|TeTrimTeas welsh Herbal tea with green tea and senna
223748251|NCT05862532|DIETARY_SUPPLEMENT|TeTrimTeas welsh Herbal tea with green tea|TeTrimTeas welsh Herbal tea with green tea
224198628|NCT07006935|BEHAVIORAL|Clubhouse Model of Psychosocial Rehabilitation for Serious Mental Illness|The Clubhouse Model (CM) is a strengths-focused, evidence-based, and comprehensive approach to psychosocial rehabilitation for serious mental illness. The CM uses an intentional community of support to create a safe and holistic setting to practice real-world functioning. The core of the CM is the 'work-ordered day', a concept where members, as opposed to patients, are integral to and needed for the successful daily operation of the Clubhouse. Members choose a 'work unit' each day of attendance. Most clubhouses have four work units, such as (1) Administration (e.g., database management); (2) Hospitality (e.g., Clubhouse cafe); (3) Membership (e.g., employment programs); and (4) Communications (e.g., newsletter). Other unique aspects include its voluntary and humanistic nature, prioritization of member choice, unrestricted and flexible membership, and the elimination of provider-patient hierarchy. The CM has a sophisticated accreditation process based on 37 international standards.
223748252|NCT01614990|DRUG|Macimorelin|Subjects will receive macimorelin (1 mg/kg) and matching placebo (Powerade®) daily for 7 days.
223748253|NCT01614990|DRUG|Placebo|placebo (Powerade®) daily for 7 days.
223748254|NCT00834210|DRUG|Dapsone|Dapsone topical gel 5%, 1 pea-size amount BID x 12 weeks and Tazarotene Cream 0.1%, 1 pea-size amount QD x 12 weeks
223748255|NCT00834210|DRUG|Tazarotene|Tazarotene Cream 0.1%, 1 pea-size amount QD x 12 weeks
223748256|NCT00001053|BIOLOGICAL|HIV p17/p24:Ty-VLP|
223748257|NCT00001053|BIOLOGICAL|Aluminum hydroxide|
223748258|NCT02890979|OTHER|Cytology Specimen Collection Procedure|Undergo cytology specimen collection procedure using a swallowable sponge cell sampling device
223748259|NCT02890979|OTHER|Laboratory Biomarker Analysis|Correlative studies
223748260|NCT02890979|OTHER|Quality-of-Life Assessment|Ancillary studies
223748261|NCT02890979|DEVICE|Swallowable Sponge Cell Sampling Device|Undergo cytology specimen collection procedure using a swallowable sponge cell sampling device
223748262|NCT02307851|BIOLOGICAL|Quadrivalent VLP Vaccine|
223748263|NCT02307851|BIOLOGICAL|Comparator TIV|
223748264|NCT06250023|OTHER|Early shift til oral antibiotic treatment for osteomyelitis|To investigate whether early transition to oral AB treatment after one week of IV treatment is non-inferior to the current national guideline of continued IV AB treatment for two to four weeks followed by oral AB treatment for PVO.
223748265|NCT03684512|BEHAVIORAL|Group Exercise Sessions|Remote exercise sessions delivered over group video conference
224311134|NCT03555383|DIAGNOSTIC_TEST|Coagulation factor levels|The minimal functional hemostasis reserve capacity are defined by triggers as hematocrit: 27%, platelets: 30 G/l, Fibrinogen (FI): 1g/l, FII-FV-FVII-FX: 30%, Antithrombin III: 40%, FXIII: 60% levels. The estimate blood volume methodology is used for to determine the amount of allowable blood loss in volume (ml) that does not require replacement based on current and trigger levels. The individualized pyramid of intervention defined as hemostasis reserve capacity are followed at every studied patient. All measurements and calculations are performed before liver transplantation (T1), at arrival on Intensive Care Unit (T2) and 12-24-48 hours after liver transplantation (T3-4-5).
224198629|NCT07006935|BEHAVIORAL|Usual Community-Based Mental Health Care|Usual care includes services typically available in the community at mental health agencies, including case management, including Assertive Community Treatment, counseling, peer support services, psychoeducational support groups, family support groups, supported education/employment, permanent supportive housing, and medication management.
224198630|NCT07005570|OTHER|Short-course radiotherapy followed by sequential chemotherapy combined with PD-1 monoclonal antibody and bevacizumab|Short-course radiotherapy → PD-1 monoclonal antibody and bevacizumab combined with CAPOX regimen chemotherapy (4 cycles) → PD-1 monoclonal antibody combined with CAPOX regimen chemotherapy (2 cycles) → undergo surgery or watch-and-wait strategy within 2-4 weeks after the last dose of capecitabine.
224198631|NCT07005570|OTHER|Short-course radiotherapy followed by sequential chemotherapy|Short-course radiotherapy → CAPOX regimen chemotherapy (6 cycles) → undergo surgery or watch-and-wait strategy within 2-4 weeks after the last dose of capecitabine.
224198632|NCT04624828|PROCEDURE|Radiotherapy|"RT treatment Schedule as for clinical practice: Stereotactic body radiation treatment (SBRT) will be delivered with image guidance (image-guided radiation therapy or IGRT) and in the form of volumetric modulated arc therapy (VMAT).~RT treatment Schedule: SBRT will be delivered in 1 to 6 fractions on bone or lymph node metastases. The dose and fractionation schedule will depend on the size and location of the lesion and the surrounding normal tissue constraints."
224198633|NCT04624828|DRUG|androgen deprivation therapy (ADT)|"ADT as for clinical practice:~* for oligorecurrent patients, ADT will be started at time of polimetastatic progression after SBRT;~* for oligoprogressive patients, ADT will be continued during SBRT and untill polimetastatic progression"
224198634|NCT04624828|BIOLOGICAL|immune evaluation|We will use the flow cytometer FACSymphony, to analyse multiple immune populations from a limited sample of blood. We will monitor the dynamics of most innate (monocytic and granulocytic cells, Natural killer cells) and adaptive (T cells, B cells) immune subsets in the peripheral blood of PC patients before and after RT. We will deeply characterize CD4+ and CD8+ T cell subpopulations circulating in the patients enrolled in the study. In this attempt our panel will include markers of T cell differentiation and activation, including CD25, CD39, PD-1, CTL4, KLRG1, TIM3. We will analyse neutrophils subpopulations and investigate the functional profile of granulocytes in enrolled patients. Markers such as CD66b, CD24, CD16, MHC-II, LOX1, CD36 and CD62L will be included in our analysis. In conclusion our experimental strategy will result in a comprehensive profiling of the immune landscape in PC patients at single cell level.
224198635|NCT07008391|DIAGNOSTIC_TEST|high sensitivity Troponin I|Study participants in the intervention group will have the high-sensitivity Troponin I blood test analyzed during emergency medical service (EMS) care using the point-of-care Siemens Atellica® VTLi system. The test result will be documented in the EMS electronic medical record (FRAPP), transmitted along with the ECG, and communicated verbally to the receiving hospital during handover.
224198636|NCT05017831|BEHAVIORAL|Family Based Treatment|Family Based Treatment (FBT) is an evidence based treatment in which parents are responsible for adolescent re-nourishment. They play an active role in treatment and their self-efficacy to make decisions regarding their child's treatment is empowered.
224198637|NCT05017831|BEHAVIORAL|Cognitive Remediation Therapy|Cognitive Remediation Therapy (CRT) is an adjunctive treatment focused on increasing set-shifting ability and developing meta-cognition. CRT is a behavioral treatment that presents tasks to participants in a standardized order within each session. Each task has a number of levels. Participants stay at the same task-based level until mastered. They then move up a level on that task. participants can be at different levels on different tasks within each session. After completion of tasks, participants are asked to reflect on their thought processes in solving the tasks. Standard prompts are used to guide the discussion.
224198638|NCT07006857|OTHER|Exercise|Exercise without music
224198639|NCT07006857|OTHER|Low Frequency|396 Hertz (Hz), 417 Hz, 528 Hz, 639 Hz
224198640|NCT07006857|OTHER|High Frequency Music|741 Hz, 852 Hz, 963 Hz
224198641|NCT04880850|DRUG|Insulin icodec|Participants will receive subcutaneous (s.c.) injections of insulin icodec once weekly for 26 weeks
224198642|NCT04880850|DRUG|Insulin glargine|Participants will receive subcutaneous (s.c.) injections of insulin glargine once daily for 26 weeks
224198643|NCT04880850|DRUG|Insulin aspart|Participants will receive subcutaneous (s.c.) injections of insulin aspart 2-4 times daily for 26 weeks
224198644|NCT01608321|DEVICE|rTMS|Repetitive Transcranial Magnetic Stimulation
224198645|NCT01608321|DEVICE|Sham device|Placebo Device that simulates active rTMS treatment
224198646|NCT03417102|DRUG|fitusiran|solution for injection; by subcutaneous (SC) injection
224198647|NCT03417102|DRUG|Bypassing agents|solution for injection; by intravenous (IV) injection
224198648|NCT00034476|DRUG|sPLA2 Inhibitor|
224198649|NCT02062385|BIOLOGICAL|V260|V260 (RotaTeq™; live, oral, pentavalent rotavirus vaccine)
224198650|NCT02062385|BIOLOGICAL|Placebo to V260|Placebo control
224198651|NCT02062385|BIOLOGICAL|OPV|Oral poliovirus vaccine administered according to the standard of care
224198652|NCT02062385|BIOLOGICAL|DTaP|Diphtheria, Tetanus, Acellular Pertussis vaccine administered according to the standard of care
224198653|NCT02978300|DEVICE|NIV/HFNC|Pressure support level to achieve an expired tidal volume between 6 and 8 ml/kg of predicted body weight Positive end expiratory pressure from 5 to 10 cm H2O, aiming a PEEP level ≥ 8 cm H2O FiO2 set to achieve SpO2 ≥ 92%
223598176|NCT05695885|BEHAVIORAL|STEPS|behavioral counseling
223598177|NCT05695885|BEHAVIORAL|Services as usual (SAU)|behavioral counseling normally provided
223598178|NCT04090463|RADIATION|Intraoperative radiotherapy|"IORT will be delivered as follows:~1. Radical resection --\> delivery of 10-15 Gy to the tumor bed~2. Non radical resection --\> delivery of 15-20 Gy to the tumor in situ"
223598179|NCT02561442|DRUG|ceftriaxone|
223598180|NCT06216210|DRUG|opioid-FREE anesthesia.|"They received opioid-free anesthesia. These patients were provided a multimodal combination infusion. The administration of this infusion commenced at a dosage of 0.2 micrograms per kilogram per hour of dexmedetomidine. The Modified Mulimix cocktail, consisting of dexmedetomidine at a concentration of 10 ug/ml, Ketamine at a concentration of 2.5 mg/ml, and Lignocaine at a concentration of 20 mg/ml, was administered to a patient weighing 100 kg and if the weight is 110 Kg the rate will be increased by 10 percent, etc.,"
223598181|NCT06216210|DRUG|opioid-CONTAINING anesthesia.|The process of inducing anesthesia included the injection of fentanyl at a dosage of 2 micrograms per kilogram during the induction phase. Additionally, morphine was administered at a dose of 0.03 milligrams per kilogram at the time of port insertion.
224198654|NCT02978300|DEVICE|HFNC|Gas flow of 60 l/min and FiO2 set to achieve SpO2 ≥ 92%
224198655|NCT04272320|DRUG|Bupivacaine Hydrochloride|Ultrasound-guided Transversalis Fascia Plane Block with 0.5 ml/kg %0.25 bupivacaine
224198656|NCT04592822|DRUG|WD-1602|dabigatran etexilate mesylate granules for oral suspension
224198657|NCT04592822|DRUG|Pradaxa®|dabigatran etexilate capsules
224198658|NCT01666301|DRUG|comparison between darbepoetin alfa and C.E.R.A. and different administration intervals|
224198659|NCT04089423|DEVICE|Fujifilm SILVAMP TB LAM|Fujifilm SILVAMP TB LAM detects the presence of lipoarabinomannan (LAM) in urine with a visually read lateral flow test that uses silver amplification.
223598182|NCT03258775|OTHER|water intake|After an overnight fast participants' RMR will be measured by indirect calorimetry for 30 minutes after which either a low (250ml) or high (500ml) dose of water will be consumed followed by an additional 90 minutes of indirect calorimetry. The test day will be repeated after 7-10 days with the second dose of water. The order in which the dose of water will be consumed will be randomized
223598183|NCT00904488|DRUG|Addition of oral Metolazone|Addition of oral metolazone 5 mg daily to continued current dose of intravenous bolus furosemide
223598184|NCT00904488|DRUG|Furosemide dose escalation|Furosemide dose escalation via either IV bolus (2-2.5 x current dose) or continuous infusion (2-2.5 x current dose administered over previous 24 hours)
223598185|NCT03415945|DEVICE|Cardiac resynchronization therapy (CRT)|All study participants have a clinical indication for CRT and will receive CRT implantation as part of their routine medical care. Additionally, participants will receive temporary left and right ventricular septal pacing electrodes and a temporary PressureWire to investigate the acute hemodynamic effect of left ventricular septal pacing, using patients as their own controls.
223598186|NCT05073926|OTHER|No intervention is part of the study protocol|No intervention is part of the study protocol. The choice of treatment for latent tuberculosis is is made by the treating physician.
223598187|NCT01599013|DRUG|Vinflunine, Gemcitabine|"* Vinflunine 280 or 250 mg/m2, IV administration over 20 minutes (starting dose based on baseline creatinine clearance value), Day 1 every 3 weeks up to progression or unacceptable toxicity or patient's refusal~* Gemcitabine 750 or 1000 mg/m2, IV administration over 30 minutes (starting dose based on baseline creatinine clearance value), Day 1 and 8 every 3 weeks up to progression or unacceptable toxicity or patient's refusal"
223598188|NCT01599013|DRUG|Vinflunine, Carboplatin|"* Vinflunine 280 or 250 mg/m2, IV administration over 20 minutes (starting dose based on baseline creatinine clearance value), Day 1 every 3 weeks up to progression or unacceptable toxicity or patient's refusal~* Carboplatin AUC 4.5, IV administration over 60 minutes, Day 1 every 3 weeks up to progression or unacceptable toxicity or patient's refusal"
223598189|NCT00818051|RADIATION|intensity-modulated radiation therapy|Given as 48, 53, or 56 Gy
223598190|NCT00380731|BEHAVIORAL|Individual Cognitive Behavioral Therapy|CBT includes 16 weekly 60-minute individual CBT sessions for social anxiety disorder.
223598191|NCT02181283|BEHAVIORAL|W+W|"Web-delivered brief intervention: Participants receive a 30-40 minute Web-based intervention which includes a tailored review of participants' goals/values, feedback regarding their present alcohol/prescribed opioid/sedative use patterns and consequences, developing a discrepancy between their alcohol or prescribed drug use, ability to meet goals and values through a decisional balance exercise, and formulation of a tailored change plan.~Web booster sessions: Web boosters will be completed at 1, 2 and 3 months post-BI. Content is tailored to the individual based on answers to baseline questions and responses during Web-based BI. Web-based Booster will: 1) briefly ascertain current AOS use, 2) changes in AOS since completing Web BI, 3) progress toward goals, and 4) plans and encouragement for next steps."
223748266|NCT03684512|BEHAVIORAL|Individual Support Sessions|Individual education/support/feedback sessions delivered over video chat
223748267|NCT03684512|BEHAVIORAL|Facebook Group|Facebook group for parents to provide additional support and education
224198660|NCT04762810|DRUG|Cyclophosphamide and glucocorticoids|Prednisone/prednisolone: started at 0.6-0. 8mg/kg.d for 2 to 4 weeks, tapered at 5mg per 1-2 weeks before 15mg per day, and tapered at 2.5-5mg per 2 weeks to equal to or less than 5mg per day in 6 months. Cyclophosphamide 50mg per day for 6 months and decrease to 50mg Qod for 6 months.
224198661|NCT04762810|DRUG|Glucocorticoids|Steroids have fast onset of action and multiple anti-inflammatory effects. Prednisone/prednisolone: started at 0.6-0. 8mg/kg.d for 2 to 4 weeks, tapered at 5mg per 1-2 weeks before 15mg per day, and tapered at 2.5-5mg per 2 weeks to equal to or less than 5mg per day in 6 months.
224198662|NCT07036484|BEHAVIORAL|Online program|We tested the feasibility of the introductory modules of an online couple-based program (STORK), designed to be grounded in empirically established risk and protective factors associated with couples' perinatal sexual well-being. STORK is a web-based program including psychoeducation and behavioral tasks to be completed by couples
224198663|NCT07035249|DRUG|Low Dose DCSZ11|Patients will receive DCSZ11 at 600 mg every three weeks (Q3W).
224198664|NCT07035249|DRUG|Medium Dose DCSZ11|Patients will receive DCSZ11 at 800 mg Q3W.
224198665|NCT07035249|DRUG|High Dose DCSZ11|Patients will receive DCSZ11 at 1200 mg Q3W.
224198666|NCT07035249|DRUG|Standard Treatment|The available standard treatment for head and neck cancer patients.
224198667|NCT07037043|DRUG|hydrocortisone plus fludrocortisone|"* Hydrocortisone 200 mg/day for 5 days or until ICU discharge, starting at the initiation of cardiopulmonary bypass (CPB), administered intravenously via syringe pump in a double-blind manner~* Fludrocortisone 50 µg/day in the morning for 5 days or until ICU discharge, administered orally or via nasogastric tube (if the patient is sedated), diluted in a glass of water, in a double-blind manner"
223598192|NCT02181283|BEHAVIORAL|W+P|"Web-delivered brief intervention: Participants receive a 30-40 minute Web-based intervention which includes a tailored review of participants' goals/values, feedback regarding their present alcohol/prescribed opioid/sedative use patterns and consequences, developing a discrepancy between their alcohol or prescribed drug use, ability to meet goals and values through a decisional balance exercise, and formulation of a tailored change plan.~Peer booster sessions: The peer supporter will work with participants at 1, 2, and 3 months post-Web-based BI. Peer supports will address Service Members' own goals and will provide emotional and informational support."
223598193|NCT00005773|DRUG|Inhaled Nitric Oxide|Study gas was initiated at a concentration of 5 ppm, and the dose was increased to 20 ppm when the infant had \<=20 mm Hg increase in PaO2 (less than full response).
224198668|NCT07037043|DRUG|placebo of hydrocortisone plus fludrocortisone|"* Placebo for hydrocortisone (0.9% NaCl) administered following the same protocol as fludrocortisone in the intervention group~* Placebo for fludrocortisone (capsule containing microcrystalline cellulose diluted in a glass of water) administered following the same protocol as fludrocortisone in the intervention group"
223598194|NCT00005773|DRUG|Standard iNO therapy|Begin a sham initiation of iNO in term and near-term infants in respiratory failure with an oxygenation index (OI) between 15-25; initiated actual iNO therapy based on standard threshold (OI \>=25).
223598195|NCT00930553|BIOLOGICAL|alemtuzumab|Alemtuzumab 12 mg/day IV infusion on 5 consecutive days if the participants had no prior alemtuzumab exposure (ie, first treatment course). All subsequent treatment courses were for 3 days only.
223598196|NCT01964963|DRUG|Alogliptin|Alogliptin tablets
223598197|NCT05668286|DRUG|A combination of 1 mL of triamcinolone acetonide (40 mg/mL) and 1 mL of prilocaine hydrochloride (2%)|patients in group 1 received an anterior extra-articular steroid injection under USG guidance, patients in group 2 received posterior intra-articular steroid injection under USG guidance. A combination of 1 mL of triamcinolone acetonide (40 mg/mL) and 1 mL of prilocaine hydrochloride (2%) were injected to all patients.
223598198|NCT03629522|DRUG|Ondansetron 8Mg/4mL Injection|investigators administrated intravenously Ondansetron 8 mg 5 minutes before spinal anesthesia.
223598199|NCT02183766|DIETARY_SUPPLEMENT|Galactooligosaccharide prebiotic|6 mL once a day
223598200|NCT02183766|DRUG|Maltodextrin|6 mL once a day
223598201|NCT01691157|OTHER|Evidence based exercise protocol|An evidence based graduated exercise rehabilitation protocol will be provided and supervised by a physiotherapist. patients will receive 6 sessions of supervised physiotherapy
223598202|NCT01691157|OTHER|Usual physiotherapy without exercise|Will receive modified usual physiotherapy care that can consist of any physiotherapeutic modalities normally provided except exercise. this may consist of postural advice, taping, electrotherapy, acupuncture, manual joint mobilizations of the shoulder, cervical or thoracic spine.
223598203|NCT03470207|PROCEDURE|Post-pulmonary embolism follow up protocol|Structured post-pulmonary embolism follow up protocol (outlined in Aim 1)
223598204|NCT03648515|DIAGNOSTIC_TEST|Plaster models|The impressions taken of the dental arches will be poured with hard gypsum in order to make use of the models for taking measurements. These measurements will be considered the gold standard.
223598205|NCT03648515|DIAGNOSTIC_TEST|Digital Images of the dental arches|The dental arches will be captured using a dedicated camera in order to be used for measuring the outcomes.
223598206|NCT03648515|DIAGNOSTIC_TEST|Digital images of models|The poured dental models will be captured using a dedicated camera in order to be used for measuring the outcomes.
223598207|NCT04879966|DRUG|Infliximab|Infliximab was used as induction therapy in UC patients, the maintenance treatment was decided by the researcher
223598208|NCT04879966|DRUG|Corticosteroid|Corticosteroids was used as induction therapy in UC patients, the maintenance treatment was decided by the researcher
223598209|NCT01415141|DRUG|Peginterferon alfa-2a|180ug subcutaneously, weekly
223598210|NCT01415141|DRUG|Ribavirin|"Administered orally twice a day as follows:~weight \< 75kg - 1000mg weight ≥ 75kg - 1200mg"
223598211|NCT01415141|DRUG|telaprevir|750mg every 8 hours, orally
223598212|NCT00051909|DRUG|LY451395|
223748268|NCT01012622|DRUG|Osmotic Release Oral System (OROS) Methylphenidate Hydrochloride|OROS methylphenidate hydrochloride (HCL) will be given orally once daily at an initial dose of 18 milligram (mg) for participants below 30 Kilogram (kg) and 27 mg for those over 30 kg of body weight. The dose will be increased by 9 mg or 18 mg every week for up to Week 8, followed by a maximum maintenance dose of 54 mg orally once daily up to Week 12 during which the dose can be decreased by 9 mg depending on tolerability.
223748269|NCT04428892|BEHAVIORAL|Pedagogyc Strategy|Simulation can be used as a pedagogic tool that provides students with significant learning regarding decision-making in interacting with people, in this case patients with LBP. It is a potential strategy for developing diverse skills focused on the safety of the patient and the therapist.
224198669|NCT07038551|DRUG|Naldemedine|over-encapsulated capsule of either 0.2 mg of naldemedine
224198670|NCT07038551|DRUG|Placebo|over-encapsulated capsule of placebo
224198671|NCT06708416|DRUG|ONO-1110|ONO-1110 tablets once a day
224198672|NCT06708416|DRUG|Placebo|Placebo tablets once daily
224198673|NCT06709976|DEVICE|Vaginal microbiome swab|All swabs were collected using FLOQSwabs™ (Copan Italia SpA, Brescia, Italy). The patients were instructed to spread the labia with one hand, insert the swab 3-5 cm beyond the vaginal orifice with the other hand, and rotate the swab along the vaginal wall for 10-15 seconds.
223598213|NCT05696756|BEHAVIORAL|Personalized Web-based training for EMMA app|Participants will complete six sessions of training to support uptake and habit formation of EMMA app use with a personalized web-based training platform.
223598214|NCT05696756|BEHAVIORAL|Motivational Interviewing: Clinician Support|Participants will receive weekly brief check-ins with clinicians to motivate and support the problem-solving and habit formation aspects of the web-based training.
223598215|NCT06117865|BEHAVIORAL|Module 1|Module 1: Introduction to IBS by a gastroenterologist.
223598216|NCT06117865|BEHAVIORAL|Module 2|Module 2:Introduction to pain physiology and how the nervous system works by a physiotherapist including practical exercises.
223598217|NCT06117865|BEHAVIORAL|Module 3|Module 3: Evidence-based guidelines for diet and lifestyle advice (NICE Guidelines) by a clinical dietitian.
223598218|NCT06117865|BEHAVIORAL|Module 4|Module 4: Intervention: behavioral therapy (exposure therapy and cognitive behavioral therapy).
223598219|NCT06117865|BEHAVIORAL|Module 5|Module 5: Intervention: The low FODMAP diet.
224198674|NCT06709976|DEVICE|Menstrual Blood Collection via Menstrual Cup|Self-collect menstrual blood during 24 hours in 2 blocks of 12 hours
224198675|NCT03577418|BEHAVIORAL|Templated, clinician-facilitated intervention to align everyday living preferences assessment|"In step 1, persons living with dementia or cognitive impairment (PLWD/CI) will complete the PELI (hereafter, assessment PELI-CI for Cognitive Impairment) to articulate their preferences. In step 2, care partners will consider the preferences of PLWD/CI; care partners will complete concurrent but separate proxy PELI assessments from the perspective of the PLWD/CI (i.e., as if acting as surrogate decision-makers; hereafter assessment PELI-CP for Care Partner). In the Intervention (step 3), the study clinician will ask the PLWD/CI to identify up to 3 social engagement preferences that matter most to them. Second, in discussion with the PLWD/CI and care partner, the study clinician will review areas where there is a difference in ratings between the PELI-CI and PELI-CP. The study clinician will then ask the PLWD/CI to identify up to 3 items of disagreement that are most important for the care partner to know about. A 1-page Preferences Priorities document will then be created."
224198676|NCT06722703|PROCEDURE|shock wave lithotripsy|Extracorporeal shock wave lithotripsy will be performed using a third-generation electromagnetic lithotripter The focal depth is 110 mm; the focal area is 7 mm (radial) and 45-50 mm (axial), and the focal pressure is 6-30 MPa). The procedure is performed in a supine or prone position without anesthesia. Stone localization and simultaneous real-time monitoring during the process will be performed by ultrasound). The shock frequency is 60-90 (shock waves/min). The total number of shock waves applied for one session is between 1500 and 2500 waves, or the session is stopped at a significant stone fragmentation is detected. The voltage applied per session ranged from 10 to 16 kV with stepwise power ramping strategy. All procedures in the SWL group are outpatient procedures.
224198677|NCT06722703|PROCEDURE|Flexible ureteroscope lithotripsy|All F-URS cases will be performed by a single surgeon (HMI). A guidewire is placed in the upper urinary tract through a rigid cystoscope under fluoroscopic guidance. An 8-10 F dual lumen catheter is used to dilate the intramural ureter and to fix a second guidewire with hydrophilic coat. The 7.5 F flexible ureteroscope is passed into the upper urinary tract in a monorail fashion over the second wire. A holmium-YAG laser is used at an energy setting of 0.8-1 J and a rate of 10-15 Hz. A 200 µm laser fibre is used for delivering laser energy to the stones. A 2.2 F tipless nitinol basket is used to displace the stones from the lower pole to an upper pole calyx before disintegration. Adequate fragmentation is considered when fragments are smaller than the diameter of the guide wire. Stone fragments will be left for spontaneous passage. At the end of the procedure, the whole collecting system will be inspected for residual stones and a double pigtail ureteric stent will be left for 2 weeks t
224198678|NCT06724952|DRUG|MTX S.C or IM and Silymarin 140 mg tab|IM or S.C Methotrexate plus Silymarin tablets 140 mg once daily for 3 months.
224198679|NCT06724952|DRUG|MTX S.C or IM|IM or SC Methotrexate plus placebo tablet once daily for 3 months.
224198680|NCT06723002|DRUG|Atherolive 500mg/day|"Patients will receive a study drug (olive leaf extracts) which will be prescribed at dose of 250 mg (one capsule ) twice daily ( total500mg daily) for one month.~patients will be assigned to one of three arm using a computer-generated randomization list ( 1:1:1 allocation )."
224311135|NCT01241110|DRUG|Ofloxacin group A, Azitromycin group B|Group A (treated by Ofloxacin 400 mg. + Metronidazole 500mg) and Group B (a single dose of oral Azitromicine 1gr + Metronidazole 500mg) for 10 days, were compared in terms of side effects and efficacy.
224311136|NCT01241110|DRUG|azitromycin|azitromicin vs ofluxacin
224311137|NCT04515381|OTHER|Therapeutic Touch|Therapeutic Touch
224311138|NCT04515381|OTHER|Control group|Making measurements at the beginning of the research and 4 weeks
224311139|NCT04515381|OTHER|Sham Therapeutic Touch|Sham Therapeutic Touch
224311140|NCT01912378|DRUG|Oxytocin|
223598220|NCT01109355|OTHER|lung mechanics ventilatory|To perform the evaluation of lung mechanics ventilatory mode was changed to control volume with the following parameters: tidal volume (Vt) = 8ml/kg weight, peak flow (PF) = 6 x minute volume, fraction of inspired O2 (FiO2) = 40%, respiratory rate (RR) = 16 bpm, sensitivity = 1 cmH2O. The following variables were monitored: PIC, Blood Pressure (BP), heart rate (HR), peak pressure in the airways (pp.) and plateau pressure of the respiratory system (Ppl.), these values were monitored with PEEP = 5 cmH2O. PEEP employed ranged from 0 to 14 cmH2O. To eliminate a possible physiological accommodation by the progressive increase of PEEP, the range of values was determined by drawing a sealed envelope for each patient, ranging from 2 to 2 cmH2O.
223598221|NCT01109355|OTHER|Hemodynamic and intracranial pressure|At each value of PEEP the patient was ventilated for a period of five minutes to carry out monitoring of ICP, BP, HR, PPC and peripheral oxygen saturation (SpO2). The ICP monitoring catheter was kept closed for drainage and open for monitoring, since the arrival of the surgical block, was only open for drainage if there was an increase in ICP above 20 mmHg.
223598222|NCT00005608|DRUG|leucovorin calcium|
223598223|NCT00005608|DRUG|tegafur-uracil|
223598224|NCT06018623|OTHER|It is an observational study and no non-routine procedures will be performed on patients. Routine anesthesia procedure will be applied to the patients|"It is an observational study and no non-routine procedures will be performed on patients.~Routine anesthesia procedure will be applied to the patients"
223598225|NCT00241345|DRUG|Valganciclovir|
223598226|NCT00241345|DRUG|Ganciclovir|
223598227|NCT00497406|PROCEDURE|Salivary gland transfer|Retrograde flow method
224311141|NCT01912378|DRUG|Placebo nasal spray|
223598228|NCT00497406|PROCEDURE|Helical Tomotherapy treatment|total of 30 fractions
223598229|NCT05405335|OTHER|Prone Positioning Maneuver|intermittent prone positioning for eight hours per day for seven days. each cycle should not be less than 30 minutes or more than 3 hours.
223598230|NCT02636530|BEHAVIORAL|Ground Reaction Forces|6 month exercise program that loads the body via gravitational forces.
223598231|NCT02636530|BEHAVIORAL|Joint Reaction Forces|6 month exercise program that loads the body via loading the joints.
223748270|NCT02994732|DRUG|[14C]-BVD-523|\[14C\]-BVD-523 administered as a 600-mg (approximately 200 µCi) oral dose to 6 healthy male subjects following a 2-hour fast from food (not including water) that follows breakfast.
223748271|NCT00706641|DRUG|Dasatinib|Dasatinib 100 mg administered orally once daily for 4 weeks duration (+/- 1 week)
223598232|NCT04085497|OTHER|Treatment|KT application: KT application includes 2 stages. The banding in the first step is directed to the patellar tendon in order to absorb the load of the knee. The second step is directed directly on the medial plica to benefit from its analgesic effect. For the first step, an I-band is measured from the top of the patella to the tuberositas tibia. I-band is 6 cm wide and 5 mm thick. This I-band is cut into Y-band. First, the part of the band above the patella is pasted with 10% tension. Then the patient's knee is flexed to maximum flexion and the tails of the band are pasted around the patella with 0% tension. The tails of the band are combined together on the tuberositas and completed. For the second step, 4 I-bands 8 cm long and 1.5 cm wide are prepared. The middle of the I-bands is attached to the medial plica with a 0% tension, giving a star shape.
223598233|NCT01184924|BEHAVIORAL|Evaluation of the Arthritis Foundation Tai Chi Program|The primary goal of this study is to assess the effectiveness and feasibility of the arthritis foundation (AF) Tai Chi Program for People with Arthritis. Arthritis, the most prevalent chronic condition in the US and a leading cause of disability, is characterized by chronic pain and progressive impairment of joints and soft tissues. Promoting physical activity is a key public health strategy to addressing arthritis management, but more scientific data regarding effectiveness and feasibility are need to support the promotion of the AF Tai Chi Program as an exercise intervention for people with arthritis. Participants will be randomly assigned to the intervention or delayed control arm of the study.
223598234|NCT01224717|DRUG|PTH134|
223598235|NCT01224717|DRUG|Placebo|
223748272|NCT00706641|PROCEDURE|Radical Cystectomy|Radical cystectomy should be performed no sooner than 8 hours but preferably within 24 hours of the last administered Dasatinib dose. All attempts should be made for the patient to have their surgery after 8 hours but within 24 hours of their last dose of dasatinib. If surgery delay is imperative, dasatinib therapy should continue until at least 24 hours before planned surgery.
223748273|NCT05963087|DRUG|Cetuximab Dabrafenib Tislelizumab|Dabrafenib 150mg，BID, Cetuximab 250mg/m2, Tislelizumab 200mg Treatment every three weeks
223748274|NCT01441674|BEHAVIORAL|Animal Assisted Therapy|There will be a therapy dog and dog trainer present working with the patient for the AAT arm.
223748275|NCT05301088|OTHER|Chocolate Scent|"Chocolate Scent:Children in this group will be given chocolate scent sniffing as a non-pharmacological distraction method.~Stress Ball:Stress ball squeezing will be used as a non-pharmacological distraction method for children in this group."
223748276|NCT02535741|DEVICE|Triathlon CR Total Knee System|Primary total knee replacement
223748277|NCT04369794|BIOLOGICAL|BCG|0.1 ml of lyophilized, live and attenuated intradermal BCG vaccine, containing between 2 and 8 x 1.000.000 C.F.U in a single dose
223748278|NCT04369794|BIOLOGICAL|Placebo|0.9% saline in the same volume as the BCG vaccine in a single dose
223748279|NCT03559712|OTHER|Collaborative care, Telemental health|Children who are referred to the collaborative tele-mental health care arm, Arm (1), will be given a follow-up appointment with the physician at the same primary care center who have successfully completed the pre-trial didactic program designed by Drs. Albanna and Hamoda. The trained child health physician will conduct assessments, treat and manage the patient. All while having weekly clinical supervision with the specialist.
223748280|NCT01442415|BEHAVIORAL|Lifestyle modification|Weekly lifestyle modification sessions including dietary counseling and physical activity
223748281|NCT01990274|PROCEDURE|GeneXpert MTB/RIF assay|Automated nucleic-acid amplification test (fully integrated) test for TB
224198681|NCT06723002|DRUG|Atherolive 1000/day|"Patients will receive a study drug (olive leaf extracts) which will be prescribed at dose of 500 mg (two capsule ) twice daily ( total 1000mg daily) for one month.~patients will be assigned to one of three arm using a computer-generated randomization list ( 1:1:1 allocation )."
224198682|NCT06723002|DRUG|Placbo_Atherolive|"Patients will receive placebo which will be prescribed one capsule twice daily for one months.~patients will be assigned to one of three arm using a computer-generated randomization list ( 1:1:1 allocation )."
224198683|NCT06723847|PROCEDURE|Robotic pancreaticoduodenectomy|All procedures are performed used a standard technique of our center for robotic pancreaticoduodenectomy
224198684|NCT06723990|DRUG|Neoadjuvant standard treatment for HER2+|NEOADJUVANT SETTING
224198685|NCT06723990|DRUG|Adjuvant standard treatment for HER2+|ADJUVANT SETTING
224311142|NCT04371900|BEHAVIORAL|Mother receives voucher valued at 100% of cost of name-brand IUD (March 4, 2019-March 31, 2023)|M-CARES randomized vouchers for contraception valued up to 100% of inserting a name-brand IUD (e.g., Skyla, Paraguard, Mirena) for women with out of pocket costs at Planned Parenthood. This intervention occurred from March 4, 2019, forward.
223598236|NCT01224717|DRUG|Forsteo|
223748282|NCT01990274|PROCEDURE|Smear microscopy|Smear microscopy involve sputum smear with either ziehl-neelsen or auramine-O staining of slides and light or fluorescence microscopy reading
223748283|NCT00749320|OTHER|Arterial Spin Labeling Magnetic Resonance Imaging|ASL MRI performed at different time intervals on participants receiving sunitinib or pazopanib for treating RCC
223748284|NCT04566419|DEVICE|HFNC - Airvo 2|high flow nasal cannulae delivering 60 l/min
223748285|NCT04566419|OTHER|Oxygen|oxygen delivered by Venturi mask
223748286|NCT00798369|DRUG|Canakinumab|Randomized patients received one s.c. injection of canakinumab and placebo matching triamcinolone acetonide (0.9% sodium chloride) intramuscularly (i.m.) once, on Day 1. The i.m. injection was recommended to be administered deeply into the gluteal muscle.
223748287|NCT00798369|DRUG|Canakinumab|Randomized patients received one s.c. injection of canakinumab and placebo matching triamcinolone acetonide (0.9% sodium chloride) intramuscularly (i.m.) once, on Day 1.
223748288|NCT00798369|DRUG|Canakinumab|Randomized patients received one s.c. injection of canakinumab and placebo matching triamcinolone acetonide (0.9% sodium chloride) intramuscularly (i.m.) once, on Day 1.
223748289|NCT00798369|DRUG|Canakinumab|Randomized patients received one s.c. injection of canakinumab and placebo matching triamcinolone acetonide (0.9% sodium chloride) intramuscularly (i.m.) once, on Day 1.
223748290|NCT00798369|DRUG|Canakinumab|Randomized patients received one s.c. injection of canakinumab and placebo matching triamcinolone acetonide (0.9% sodium chloride) intramuscularly (i.m.) once, on Day 1.
224198686|NCT06724263|DRUG|B1962|B1962 has higher VEGF anti angiogenic activity than its competitors. Phase I clinical trials have shown that B1962 has excellent safety and promising therapeutic effects. Large scale clinical studies may achieve better therapeutic effects than similar competitors targeting the same target
224198687|NCT04954027|BEHAVIORAL|Questionnaires|"5 visits are planned during the study :~* the inclusion visit : during this visit the patient's non-opposition is obtained and then the patient answer to self-administered questionnaires online~* 4 telephone interviews for follow-up by investigator"
224198688|NCT07046780|DRUG|Observation arm|To observe the efficacy and safety of Iparomilimab and Tuvonralimab in the treatment of patients with solid tumors in the real world
223598237|NCT04755036|OTHER|Survey and case vignette|We sent a survey and case vignette cases to every responsible in each center
224198689|NCT07048080|BEHAVIORAL|(P)rehabilitation Progresive Resistance Exercise Training|The (p)rehabilitation intervention program will be based on supervised whole-body RET performed 3 times/week before (2-week) and up to 12 weeks after surgery, with one day in-between sessions. Training will consist of a 10-min warm-up, followed by one warm-up and 4 sets on leg press, leg-extension and leg abductor machines. Upper body exercises (chest press, lat pulldown and horizontal row will be performed with 2 sets of each exercise. During the 2-week training before surgery, the workload will be increased from 70% (week 1) to 80% (week 2) of 1RM (10 repetitions in each set). After surgery, the workload will be increasing from 50% of 1RM to 80% from the last 6 weeks. All the participants included in the per-protocol analysis must complete at least 80% of the training sessions. We will take into consideration the mobility precautions so as not to dislocate the prosthesis (avoid hip flexion of 90 degrees and more; do not perform adduction exercises and hip rotations).
224198690|NCT07048080|BIOLOGICAL|Prehabilitation Group Deuterated Water|In a sub-study, the first 10 participants of the (P)rehabilitation group will be included to study the effects of 2 weeks prehabilitation on tissue protein synthesis rates. A two-week deuterium oxide (2H2O or 'heavy water') loading protocol will be conducted during the two week before THR surgery to assess diurnal rates of musculoskeletal protein synthesis. This 2H2O method enables the assessment of muscle, cartilage and bone tissue protein synthesis rates when tissue samples are collected after the 2 weeks of prehabilitation.
223598238|NCT04578184|DIAGNOSTIC_TEST|Corneal epithelial thickness measurements|Corneal epithelial thickness measurements using two optical coherence tomography devices in healthy and keratoconus corneas.
223598239|NCT06361017|PROCEDURE|endovascular thrombectomy|All individuals were anesthetized, with local or general anesthesia dependent on the cooperation level of the patient. During the procedure, it was mandatory to administer intravenous heparin to maintain the activated clotting time between 250 and 300 s, except for subjects who received intravenous alteplase. The procedures were performed through the femoral artery. The selection of stent retriever type and size, along with any required devices, such as guide wires and catheters, as well as the intervention strategy, was at the interventionists' discretion.
223598240|NCT05844241|OTHER|Music and Theta Auditory Beat Stimulation|Listening to music and ABS for 30 minutes.
223598241|NCT05844241|OTHER|Audiobooks|Listening to audiobooks for 30 minutes
223598242|NCT03222297|DEVICE|early skull repair|Patients with craniocerebral injury were randomized into test group (n = 40) with early skull repair using titanium mesh within 1-3 months after decompression.
223598243|NCT03222297|DEVICE|late-stage skull repair|Patients with craniocerebral injury were randomized into control group (n = 46) with late-stage skull repair using titanium mesh within 6-12 months after decompression.
223598244|NCT04345679|BIOLOGICAL|anti-SARS-CoV-2 convalescent plasma|Infusion of one unit of anti-SARS-CoV-2 convalescent plasma \~200 mL over 4 hours
223598245|NCT03874572|BIOLOGICAL|Allogeneic adipose derived stem/stromal cells|Culture expanded allogeneic adipose derived stem/stromal cells
223598246|NCT04425382|DRUG|Darunavir/Cobicistat|Darunavir/Cobicistat (800mg/150mg) 1 tablet PO once daily
223598247|NCT04425382|DRUG|Lopinavir/Ritonavir|Lopinavir/Ritonavir (200mg/50mg) 2 tablets PO twice daily
223598248|NCT04417153|BEHAVIORAL|Mindfulness Based Intervention|The mindfulness-based intervention consists of either four (MF) or eight (MBSR) 2-hour sessions covering various mindfulness techniques (e.g. mindfulness of breath, body and movement, senses and informal practice, and empathy and compassion). Participants will be provided handouts for the information covered during these talks and discussions.These can be done either face to face or online.
223598249|NCT00328367|DRUG|aripiprazole|aripiprazole augmentation of clozapine
223598250|NCT00328367|DRUG|placebo|placebo
223598251|NCT02967510|DRUG|Estriol|
223598252|NCT02967510|DRUG|Placebo|
223748291|NCT00798369|DRUG|Triamcinolone acetonide|Randomized patients received triamcinolone acetonide 40 mg i.m. once and placebo matching canakinumab s.c. once, on Day 1.
223748292|NCT03646110|PROCEDURE|Minimally invasive esophagectomy|Minimally invasive esophagectomy is a surgical procedure for esophageal resection
223598253|NCT01104727|PROCEDURE|4-Ports Cholecystectomy (4PC)|a 12mmHg pneumoperitoeum is created either by a 10mm umbelical Hasson's port or by a Verress needle followed by a 10 mm umbelical port insertion; further one 10mm and two 5mm ports are placed according to the preferred technique. A straight or angulated laparoscope may be used. Laparoscopic graspers, monopolar hook, bipolar forceps, scissors and 10mm clips-applier are used. A plastic bag system might be used for gall bladder extraction if necessary. In both 10 and 12mm accesses, fascia is sutured with resorbable sutures. Skin is secured by either metallic agraffes or interrupted sutures.
223598254|NCT01104727|PROCEDURE|Single-Port Cholecystectomy (SPC)|"a 2.5cm long skin incision around the umbilicus is performed. The subcutaneous tissue is dissected, the muscular fascia exposed and incised along the middle line (linea alba) respecting the muscular tissue. Peritoneum is identified and incised. The Single-Port device is inserted and anchored.~In order to retract the gallbladder a transcutaneous suture is placed in the right hypocondrium with a straight needle and a monofilament thread which are passed through the fundus and knotted outside the skin. The following steps reproduce the traditional laparoscopic cholecystectomy. Each centre will be left free to use dedicated instruments and which or traditional laparoscopic ones."
223598255|NCT00437424|DRUG|Brivanib|Tablet, Oral, Brivanib 400 mg, based on Day 1 PK, QD, until progression
223598256|NCT03237715|OTHER|Assessment of unbound bilirubin levels|Collection of residual blood for measurement of unbound bilirubin
223598257|NCT01177189|DIETARY_SUPPLEMENT|Vitamins C, E, and alpha lipoic acid|Oral antioxidant cocktail or placebo to be consumed daily
223598258|NCT04152915|DRUG|Semaglutide|Increasing doses of semaglutide administered s.c. (subcutaneouly, under the skin) once weekly for 7 weeks
223598259|NCT00456287|DEVICE|CPAP (Continuous Positive Airway Pressure)|
224198691|NCT07048080|BIOLOGICAL|Usual Care Group Deuterated Water|In a sub-study, the first 10 participants of the Usual Care group will be included to study the effects of 2 weeks prehabilitation on tissue protein synthesis rates. A two-week deuterium oxide (2H2O or 'heavy water') loading protocol will be conducted during the two week before THR surgery to assess diurnal rates of musculoskeletal protein synthesis. This 2H2O method enables the assessment of muscle, cartilage and bone tissue protein synthesis rates when tissue samples are collected after the 2 weeks of usual care.
223598260|NCT04239742|DIAGNOSTIC_TEST|F18-fluciclovine PET/CT|370 MBq ±10% 18F-Fluciclovin + low-dose CT scan, from skull base to pelvis.
223598261|NCT04239742|DIAGNOSTIC_TEST|F18-PSMA-1007 PET/CT|4 MBq/kg ±10% F18-PSMA + low-dose CT scan, from skull base to pelvis
223598262|NCT02675608|BIOLOGICAL|Influenza Virus Vaccine|On the first visit, subjects are vaccinated with the 2015-2016 seasonal flu vaccine.
223598263|NCT02668887|BEHAVIORAL|Quality of Life, status of employment|
223598264|NCT06214546|OTHER|Regular walking|Participants perform 6 overground walking trials (12.5 m) without support system. Participants perform all measurements (regular walking, Myosuit, ZeroG) on one single measurement day.
223598265|NCT06214546|DEVICE|Myosuit|Participants perform 6 overground walking trials (12.5 m) while wearing the Myosuit. ZeroG and Myosuit intervention will be performed in random order.
223598266|NCT06214546|DEVICE|ZeroG|Participants perform 6 overground walking trials (12.5 m) while walking in the ZeroG. ZeroG and Myosuit intervention will be performed in random order.
223598267|NCT06459479|OTHER|Conversational Artificial Intelligence Simulations|Use of Conversational Artificial Intelligence Simulations generate medical scenario.
224198692|NCT07048080|OTHER|Usual Care|Participants assigned to the usual care group will receive the usual therapy, medical monitoring, and educational lectures after surgery. No intervention is planned before total hip replacement surgery. The patient is hospitalized for surgery. At hospital discharge, the usual care group will start with standard rehabilitation (sessions: 1st month, 2-3x/week, 2nd month 1-2x/week and 3rd month 1x/month) based on mobility and strength exercises without using progressive RET with machines until 3 months after surgery.
224198693|NCT07048782|OTHER|Observational assessment of clinical outcomes|This is a non-interventional observational study. No treatment or behavioral intervention is administered.
224198694|NCT06722339|DEVICE|low intensity transcranial focused ultrasound stimulation (TUS)|"Low-intensity transcranial focused ultrasound (TUS) provides an energy source with millimeter resolution that can be focused anywhere in the brain safely and effectively for non-invasive and transient neuromodulation. TUS is an important advance and of great significance for brain-mapping efforts, diagnostics, and therapies in neuroscience and particularly promising for addiction therapy as it provides unprecedented non-surgical access to the brain regardless of depth.~Low intensities of focused ultrasound (TUS) are used so that tissue damage does not occur, but neural activity can be modulated by mechanical effects."
224198695|NCT06722859|PROCEDURE|Open surgical decompression in degenerative lumbar canal stenosis|Open surgical decompression in degenerative lumbar canal stenosis
224198696|NCT06722859|PROCEDURE|Microsurgical decompression|Microsurgical decompression of degenerative lumbar canal stenosis
224198697|NCT06732882|DRUG|AZD4604|Participants will receive AZD4604 via Genuair/Turbuhaler device.
224198698|NCT06732882|OTHER|Placebo|Participants will receive placebo via Genuair/Turbuhaler device.
224198699|NCT06732882|DEVICE|Genuair|Participants will either receive AZD4604 or placebo via Genuair device.
223598268|NCT05906121|DRUG|lidocaine-ketamine infusions|Lidocaine and ketamine are infused over a period of 30 minutes. The dosage of lidocaine is 4mg/kg is maintained throughout the infusions, and the dosage of ketamine is increased within the first three infusions from 0.15mg/kg at the first, to 0.25mg/kg at the second and 0.5mg/kg at the third infusion. In case patients already experiencing sufficient analgesic effect and/or improvement in quality of life after the 1st or 2nd infusion or if side effects do not allow a further dose increase, no further step up of ketamine dosage is made. As a part of this study, at the end of the first, second and third infusion, side effects will be screened using customized questionnaires (SF - MPQ, BDI-II)
223598269|NCT01711450|PROCEDURE|Paravertebral block|Injection of local anaesthesia into paravertebral space to provide analgesia
223598270|NCT01711450|PROCEDURE|Control sham procedure|Injection of Normal saline into the paravertebral space
223598271|NCT01336413|DRUG|Pregnenolone|Pregnenolone 50 mg BID x 14 DAYS, followed by Pregnenolone 150 mg BID x 14 DAYS, followed by Pregnenolone 250 mg BID x thereafter for the remainder of the 8-week trial
223598272|NCT01336413|DRUG|Placebo|Same as active comparator, except placebo dispensed.
223598273|NCT04954924|OTHER|standardized physiotherapy program and Kinesio tape|
223598274|NCT04256681|OTHER|SNAP questionnaire|The SNAP questionnaire will be administered 2 times in 2 consecutive days to evaluate its reliability. The questionnaire will be self-filled by the patient. Then the SPRS scale and, where possible, the 6MWT will be administered.
223598275|NCT00856544|DRUG|CP-690,550|Film coated tablet, 5 mg PO BID, 1 year
223598276|NCT00856544|DRUG|CP-690,550|Film coated tablet, 10 mg PO BID, 1 year
223598277|NCT00856544|DRUG|Placebo|Film coated tablet, 1 tablet PO BID, 3-6 months
223598278|NCT00856544|DRUG|Placebo|Film coated tablet, 1 tablet PO BID, 3-6 months
223598279|NCT02870634|DRUG|Cu(II)ATSM|copper-containing synthetic small molecule
223598280|NCT00787189|DEVICE|The Hearing Laser|Two 6-minute low level laser light applications to the head/neck/ears region, each one week apart.
223598281|NCT00787189|DEVICE|Placebo Laser|inactive low level laser light therapy with no therapeutic output
223598282|NCT03190434|DEVICE|AL-SENSE|The AL-SENSE reacts differently when in contact with amniotic fluid than it does with urine. The indicator changes color to blue-green and fades back to yellow in case of urine and changes to stable blue-green in case of amniotic fluid.
223598283|NCT01458262|OTHER|systemic and cerebral oxymetry|oxymetry measurement using near infrared spectroscopy
223598284|NCT00252408|DRUG|Hormone replacement therapy|
223598285|NCT00811681|DRUG|pioglitazone|administered orally once a day after the first visit and for a total of 2 years. Initially, Pioglitazone will be started at 15mg /day. Dosage will then increase by 15mg /d/ week up to the maximal dose of 45mg /day
224198700|NCT06732882|DEVICE|Turbuhaler|Participants will receive either AZD4604 or placebo via Turbuhaler device.
223598286|NCT00811681|DRUG|Placebo|a placebo administered orally once a day after the first visit and for a total of 2 years.
223598287|NCT00123175|DEVICE|Intrauterine Device|Mirena and Provera
223598288|NCT00356967|DRUG|dianicline|
223598289|NCT04486014|PROCEDURE|Erector spinae plane block|Erector Spinae Group (Group E) will receive bilateral ultrasound-guided erector spinae plane block using 30 ml hyperbaric bupivacaine 0.25% will be injected between erector spinae muscle and transverse process of T4
223598290|NCT04486014|PROCEDURE|Serratus anterior plane block|Serratus anterior Group (Group S) will undergo bilateral ultrasound-guided serratus anterior plane block with 30 ml hyperbaric bupivacaine 0.25% will be injected above or below serratus anterior muscle at the level of 4th and 5th rib on the midaxillary line
223598291|NCT04202237|OTHER|Speckle Doppler imaging|Speckle Doppler Laser imaging
223598292|NCT04202237|OTHER|Blood sample|Blood sampling
223598293|NCT04909866|COMBINATION_PRODUCT|TACE+Lenvatininb+Camrelizumab|Patients included in the trial were treated with TACE, lenvatinib combined with Camrelizumab.
223598294|NCT01766180|DRUG|Fruitflow-II|150 mg/day for 3 months, orally
223598295|NCT01766180|DRUG|resVida|150 mg/day for 3 months, orally
223598296|NCT06371846|OTHER|Selected signals from Pacing System Analyzers|Comparative observational, prospective, multicenter study between the signals obtained by PSA vs MPS of consecutive patients who underwent a LBBAP strategy as first intention.
223598297|NCT04220944|DRUG|Sintilimab|Sintilimab (200mg) was administered intravenously over 30-60 min every 3 weeks.
223598298|NCT04220944|PROCEDURE|Microwave Ablation|The ablation area should covered at least two thirds the size of the nodules.
223598299|NCT04220944|PROCEDURE|TACE|Patient was treated with epirubicin lipiodol emulsion(Epirubicin 40mg, Lipiodol 10ml).Embolic materials such as gelfoam or microsphere was aslo administered until complete stasis in segmental or subsegmental arterial branches.
223598300|NCT05285540|DRUG|DT-216|DT-216 will be administered by intravenous (IV) injection
223598301|NCT05285540|DRUG|DT-216 matching Placebo|Placebo will be administered by intravenous (IV) injection
223598302|NCT02181764|DRUG|KRN23|Single SC administration on day 1: 0.3, 0.6 and 1.0 mg/kg
223598303|NCT00336297|PROCEDURE|Woman Abuse Screening Tool|
224198701|NCT00710840|PROCEDURE|Minimally Invasive Total Knee Arthroplasty [TKA Min]|TKA Min is a procedure in which diseased and painful joint surfaces of the knee are replaced by metal and plastic components shaped to allow continued motion of the knee. TKA Min, as opposed to TKA Traditional, employs smaller skin incisions and smaller instrumentation and avoids turning the knee cap out and dislocating the knee. This procedure also avoids disrupting the knee extensor mechanism and the suprapatellar pouch and minimizes extreme knee flexion during surgery.
223598304|NCT00336297|PROCEDURE|Partner Violence Screen|
223598305|NCT00336297|PROCEDURE|Computerized screening|
223598306|NCT00336297|PROCEDURE|Face to face screening|
223598307|NCT00336297|PROCEDURE|Written screening on forms|
223598308|NCT04331470|DRUG|Levamisole Pill + Budesonide+Formoterol inhaler|Levamisole 50 mg tablet has to be taken 1-2 tablets every 8 hours Budesonide+Formoterol has to be inhaled 1-2 puff every 12 hours
223598309|NCT04331470|DRUG|Lopinavir/Ritonavir + hydoxychloroquine|Hydroxy Chloroquine 200mg single dise Lopinavir/Ritonavir 2 tablets every 12 hours
223598310|NCT05881954|PROCEDURE|Groin infection|Femoral artery reconstruction with tubulized pericardium patch
223598311|NCT00387634|BIOLOGICAL|TBE vaccine for adults|Serology blood draw.
223598312|NCT02330692|OTHER|No intervention|
223598313|NCT00066404|BIOLOGICAL|recombinant adenovirus-hIFN-beta|
223598314|NCT00108316|DRUG|Fluoxetine (Liquid Prozac)|
223598315|NCT03619772|OTHER|Bilateral|Participants will control game using EMG from both upper limbs.
223598316|NCT03619772|OTHER|Unilateral|Participants will control game using EMG from the more impaired upper limb.
223598317|NCT02289794|BIOLOGICAL|E.coli bioconjugate vaccine|Single dose, intramuscular injection (0.5 mL)
223598318|NCT02289794|BIOLOGICAL|Placebo|Single dose, intramuscular injection (0.5 mL)
223598319|NCT05179148|BEHAVIORAL|Motivational Interviewing|MI is a client-centered counselling style for strengthening a person's own motivation and commitment to change. MI helps evoke the person's own motivation for changes through reflective listening, engaging, evoking, and planning
223598320|NCT02982421|BEHAVIORAL|Group art therapy|Participants will engage in an art therapy group tailored at emotion expression related to the experience of breast cancer survivorship.
224198702|NCT00710840|PROCEDURE|Total Knee Arthroplasty (TKA) Traditional|TKA is a procedure in which diseased and painful joint surfaces of the knee are replaced by metal and plastic components shaped to allow continued motion of the knee.
224198703|NCT07047495|OTHER|prostate patient|patients with prostate cancer treated with RT at IEO
223598321|NCT02982421|BEHAVIORAL|Control|Participants will receive Psychoeducational material in the form of a lecture and will engage in the coloring of mandalas.
223598322|NCT05375721|PROCEDURE|ST36 acupoint injection|"ST36 is located on the lateral surface of leg, 3 cun distal to the lower border of the patella, 1 finger-breadth lateral to the anterior crest of the tibia, between the tibialis anterior muscle and the tendon of the extensor digitorum longus. (The breadth of patient's middle finger was the proportional unit of measure the cun, defined as the distance between the two medial ends of the creases of the interphalangeal joints when the patient's middle finger is flexed)."
223598323|NCT05216341|DRUG|OLP-1002|"Stage 1: A total of 5 participants will be enrolled in each arm in Stage 1.~Each participant will receive one single dose of OLP-1002 by subcutaneous injection.~Stage 2: Up to 90 participants will be randomised on Day 1 to one of 3 treatment arms, in the ratio of 1:1:1 to receive one single dose of OLP-1002 (1 µg or 2 µg) or placebo.~Each participant will receive one single dose of OLP-1002 or placebo by subcutaneous injection."
223598324|NCT05816434|BEHAVIORAL|Sleep extension|\>1 hour additional time in bed per night for 1 week.
223598325|NCT04996485|DRUG|Secukinumab Injection|Pathogenetic therapy with biologic drugs
223598326|NCT04996485|DRUG|Ustekinumab Injection|Pathogenetic therapy with biologic drugs
223598327|NCT04996485|DRUG|Dupilumab Injection|Pathogenetic therapy with biologic drugs
223598328|NCT04996485|OTHER|Symptomatic therapy|Active external agents, Emollients, systemic retinoids if needed
223598329|NCT05168020|BEHAVIORAL|Safety Behavior Fading for Social Anxiety|Participants are asked to reduce or eliminate safety behaviors via text message reminders and checklists to monitor progress
223598330|NCT05168020|BEHAVIORAL|Unhealthy Behavior Fading|Participants are asked to reduce or eliminate unhealthy behaviors via text message reminders and checklists to monitor progress
223598331|NCT00001894|PROCEDURE|pacemaker implantation|
223598332|NCT00001894|PROCEDURE|percutaneous transluminal septal ablation (PTSA)|
223598333|NCT04085757|DRUG|long interval dinoprostone|A small envelope including two labeled plastic bags (A \& B) (each bag containing either 1 dinoprostone tablet(3mg) or 1 identically appearing placebo tablet) will be packaged in sequentially numbered sealed envelopes. In long interval dinoprostone group, bag (A) contains dinoprostone tablet and bag (B) contains placebo tablet. After signing the informed consent, the sequentially numbered sealed envelopes will be opened (according to the sequence of attendance of the patient) by the study nurse. Tablets in bag (A) will be inserted 12 hours before office hysteroscopy and tablets in bag (B) will be inserted 3 hours before office hysteroscopy.
223598334|NCT04085757|DRUG|short interval dinoprostone|A small envelope including two labeled plastic bags (A\& B) (each bag containing either 1 dinoprostone tablet(3 mg) or 1 identically appearing placebo tablet) will be packaged in sequentially numbered sealed envelopes. In short interval dinoprostone group, bag (A) contains placebo tablet and bag (B) contains dinoprostone tablet. After signing the informed consent, the sequentially numbered sealed envelopes will be opened (according to the sequence of attendance of the patient) by the study nurse. Tablets in bag (A) will be inserted 12 hours before office hysteroscopy and tablets in bag (B) will be inserted 3 hours before office hysteroscopy.
223598335|NCT03935243|BEHAVIORAL|equine assisted therapy|The equine assisted group therapy is carried out by a riding therapist (nurse psychiatry HF, certified riding therapist SG-TR). There is a detailed plan for the PT.
223598336|NCT03935243|BEHAVIORAL|activating control phase|The control phase includes a generally activating employment offer, such as board games, light physical activations, roundtables and artistic design.
223598337|NCT00296140|BEHAVIORAL|self management of PSD symptoms|
223598338|NCT00296140|PROCEDURE|screening and treatment of PSD|
223598339|NCT03612765|BEHAVIORAL|Push-Pull-Hold Program|Developed based on concepts of motivational interviewing, temporal framing, empowerment. It is tailored to Singaporean patients and includes contextual self-care information and tips.
223598340|NCT03124082|DRUG|Remifentanil|continuous infusion intraop
223598341|NCT03124082|DRUG|Ketamine|bolus 0,5 mg/kg + infusion 0,25 mg/kg/h
223598342|NCT03124082|DRUG|Lidocaine|lidocaine bolus 1 mg/kg + infusion 1 mg/kg/h
223598343|NCT03124082|DRUG|Clonidine|clonidine 4 mcg/kg
223598344|NCT01651871|DRUG|S-555739 Dose 1|
223598345|NCT01651871|DRUG|S-555739 Dose 2|
223598346|NCT01651871|DRUG|Cetirizine HCl Dose 1|
223598347|NCT01651871|DRUG|S-555739 placebo|
223598348|NCT01651871|DRUG|Cetirizine HCl placebo|
223598349|NCT04165603|PROCEDURE|Preoperative Infusion of Indocyanine Green|preoperatively infuse indocyanine green through peripheral vein
223598350|NCT01856582|BIOLOGICAL|CD34+|CD34+ cells are selected using the CliniMACS System; without preparative regimen
223598351|NCT02338050|BIOLOGICAL|Moxetumomab Pasudotox|
223598352|NCT03144375|OTHER|Medical optimization and education|Medical treatment and education about the sinusitis disease process prior to surgery as compared to baseline surgical and treatment counseling
223598353|NCT03144375|PROCEDURE|Standard of Care sinus surgery|
223598354|NCT02596789|DEVICE|"TMS Magpro®, Magventure Inc device"|
223748293|NCT02407769|DIETARY_SUPPLEMENT|Late evening supplementation with branched chain amino acids|The patients will drink a Enterex Hepatic bag (500 Kcal, 18.6g of proteins of which 8.63g are branched chain amino acids, 71.7g of carbohydrates and 15.4g of lipids) during late evening (after 19:00 hours) in comparison with the late evening snack group which will eat a snack based in food with the next nutrimental facts (480 Kcal, 19g of proteins based in casein and vegetables sources, 17g of lipids and 63g of carbohydrates) during the same schedule that intervention group.
223748294|NCT04475588|DRUG|Itolizumab IV infusion|"First dose of 1.6 mg/kg dose iv infusion, , investigator discretion to continue with 1.6 mg/kg dose every 2 weeks or 0.8 mg/kg weekly regimen up to 4 weeks.~BSC: similar to Arm B"
223748295|NCT04475588|DRUG|Best supportive care (BSC)|Best supportive care (BSC) included drugs like antivirals, antibiotics, Hydroxychloroquine, oxygen therapy, LMWH, Steroids, Vitamins and Zinc
223598355|NCT05318872|DEVICE|ENDOSWIR|Patients were enrolled for surgery of their cancer and give their consents to the participation to that study. Characteristics of anonymized patient (sex, age, medical history, and tumoral characteristics) will be collected. During surgery, the excisional specimen will be sent in a fresh state for pathological examination (gold standard). The pathologist will determine 10 zones on a cross-section of the specimen which will be analyzed by SWIR, and compared between the two techniques.
223598356|NCT04871958|DEVICE|Continuous glucose monitoring (CGM, Dexcom G6)|"The Dexcom G6 sensor will be placed on the back of the upper arm at admission and changed after 10 days. In the participants randomized to Real-time CGM, glucose values will be transmitted through Bluetooth to a mobile phone at the bedside. From this phone data are transmitted to a tablet in the nursing station.~In the blinded CGM group, sensor readings will be blinded to patient and healthcare providers.~The MDI groups will be managed with basal/bolus insulin regimen, as clinically indicated.~V-Go will be placed on the abdomen each morning. Insulin-naïve patients randomized to the V-Go system will start at the lowest basal rate (20 UI/24h).~On daily basis, expert diabetologists will retrospectively review CGM data and provide indications for insulin therapy adjustments."
223598357|NCT02805855|DRUG|Autologous Adipose-Derived Mesenchymal Stromal Cells|Human, autologous, culture expanded, adipose derived, mesenchymal stromal cells (AMSCs) produced on site in the Mayo Clinic Human Cellular Therapy Laboratory using current good manufacturing practices (cGMPs).
223598358|NCT03359252|PROCEDURE|non-stent assisted coiling|non-stent assisted coiling of unruptured intracranial aneurysm
223598359|NCT03359252|PROCEDURE|stent assisted coiling|stent assisted coiling of unruptured intracranial aneurysm
223598360|NCT00596830|DRUG|CP-751,871 (Figitumumab)|CP 751,871 is a potent and selective fully human monoclonal antibody against the insulin like growth factor 1 receptor (IGF-1R). Patients in Arm A will receive CP-751, 871 intravenously every 21 days for up to six cycles.
223598361|NCT00596830|DRUG|Carboplatin|Carboplatin is a standard chemotherapeutic agent used in patients with lung cancer. Patients in Arm A will receive carboplatin intravenously every 21 days for up to six cycles.
223598362|NCT00596830|DRUG|Paclitaxel|Paclitaxel is a standard chemotherapeutic agent used in patients with lung cancer. Patients in Arm A will receive paclitaxel intravenously every 21 days for up to six cycles.
223598363|NCT00596830|DRUG|Carboplatin|Carboplatin is a standard chemotherapeutic agent used in patients with lung cancer. Patient in Arm B will receive carboplatin intravenously every 21 days for up to six cycles.
223598364|NCT00596830|DRUG|Paclitaxel|Paclitaxel is a standard chemotherapeutic agent used in patients with lung cancer. Patient in Arm B will receive paclitaxel intravenously every 21 days for up to six cycles.
223748296|NCT04173026|OTHER|Provider-level intervention|Provider minder is a provider-based scheduling and reminder system for stroke screening in SCD
223748297|NCT04173026|OTHER|Patient-level intervention|50% of centers are randomized to a single stroke screen coordinator as the point of contact for sickle stroke screen
223748298|NCT01483105|BEHAVIORAL|DVD Self-Hypnosis Training Program|The DVD training program contains instructional materials developed by an experienced psychiatrist and psychologist at the Department of Psychiatry at Stanford University School of Medicine. Parents will be instructed to review these materials, watch the DVD, and practice the self-hypnosis exercises every day for a week with their child prior to the upcoming procedure. Parents are encouraged to practice self-hypnosis during their child's VCUG procedure.
223748299|NCT04991545|DEVICE|Application of Infrared (Active IRD/ IRRIS) device|"The first operator experienced with video-laryngoscopy intubation will do Before inducing anesthesia, the second operator will open the randomization envelope and adhere IRRIS/IRD device to the anterior skin of the neck above the sternal notch according to the group of patients After confirming lack of discomfort during application of the IRRIS/IRD device,~After complete relaxation, Laryngoscopy will be performed by the first operator using video laryngoscope (Glidescope Verathon Medical, BC, Canada or C-Mac Storz, Germany) to insert the tracheal tube. The endotracheal tube will be armed with a malleable stylet and to be molded to a curved 'hockey stick or the same curve of the laryngoscopic blade's shape. We will divide the patient according to device into two groups:~1. Group A: control group~2. Group B: Intervention group using Infrared"
223748300|NCT04311879|DEVICE|Soft tissue Diode laser application|post-operative soft tissue diode laser application
223748301|NCT04311879|OTHER|Placebo|mock diode laser application
223748302|NCT01112527|DRUG|PF-00299804|Taken orally once a day
223748303|NCT02804984|GENETIC|ICUS|
223748304|NCT01475630|PROCEDURE|physical therapy|mobilisation of the jaw, exercises, boostering information on avoiding parafunctions
223748305|NCT01475630|PROCEDURE|control|relaxation
223748306|NCT05686213|BEHAVIORAL|combined aerobic exercise + resistance exercise intervention (AE + RE)|The AE + RE intervention group will be offered a supervised exercise program which includes both aerobic and resistance exercise. Exercise sessions will take place twice a week with a duration of 60 minutes. The training load will be tailored to a patient's individual fitness level throughout the intervention. Patient will be asked to be physically active on an additional day in the week on their own (for at least 30 minutes at moderate intensity) according to the ACSM guidelines for patients with cancer.
223748307|NCT05686213|BEHAVIORAL|Aerobic exercise prior to daily radiotherapy sessions (ExPR)|Patients in the ExPR in-hospital exercise intervention group will be offered an aerobic exercise program at moderate intensity. The exercise sessions will take place 5 days a week (only weekdays), and will have a duration of 30 minutes including a warming-up (5 min) and cooling-down (5 min). Total exercise volume will be aimed at 150 min per week. The sessions will take place within an hour before the daily radiotherapy session.
224198704|NCT07047495|OTHER|breast patients|patients with breast cancer treated with RT at IEO
224198705|NCT07048470|DIETARY_SUPPLEMENT|Synbiotic|The patients received synbiotics (containing Lactobacillus helveticus R0052 60%, Bifidobacterium infantis R0033 20%, Bifidobacterium bifidum R0071 20% and frukto-oligosaccharide 80 mg) supplementation
223748308|NCT06112028|DRUG|Tongxinluo capsule|On the basis of conventional treatment, the study participants in the experimental group were given Tongxinluo capsule for 12 months.
223748309|NCT06112028|OTHER|Primary therapy|Routine oral aspirin enteric-coated tablets, clopidogrel bisulfate tablets and rosuvastatin calcium tablets (or atorvastatin calcium tablets)
223748310|NCT04762680|BIOLOGICAL|SARS-CoV-2 recombinant protein vaccine Phase 2 Formulation 1|Pharmaceutical form: Emulsion for injection Route of administration: Intramuscular injection
224198706|NCT07048470|DIETARY_SUPPLEMENT|Placebo|Patients received placebo capsules
224198707|NCT07048054|DRUG|TrophiPatch: allogeneic adipose-derived stromal cell patch|Topical application of an allogeneic adipose-derived stromal cell patch
224311143|NCT04371900|BEHAVIORAL|Mother receives voucher valued at 50% of cost of name-brand IUD (August 26, 2018-March 3, 2019)|M-CARES randomized vouchers for contraception valued up to 50% of inserting a name-brand IUD (e.g., Skyla, Paraguard, Mirena) for women with out of pocket costs at Planned Parenthood. This intervention occurred after November 4, 2019.
223598365|NCT06224179|PROCEDURE|ultrasound guided subcostal TAP block|"patients will be randomly divided into two groups using a computer generated random number chart.~Group A received ultrasound guided subcostal TAP block,"
223598366|NCT06224179|PROCEDURE|ultrasound guided combined posterior and subcostal TAP block|"patients will be randomly divided into two groups using a computer generated random number chart.~Group B received ultrasound guided combined posterior and subcostal TAP block,"
223598367|NCT00887926|BIOLOGICAL|IMC-EB10|Cohort 1 will receive IMC-EB10 intravenously for 3 weekly infusions, followed by a 1-week observation period. The starting dose in Cohort 1 will be 5 mg/kg. After all participants in Cohort 1 complete the first cycle of therapy, dose escalation for subsequent cohorts will proceed as follows: Cohort 2 - 10 mg/kg, Cohort 3 - 20 mg/kg, Cohort 4 - 30 mg/kg. Participants who experience a dose-limiting toxicity (DLT) will not receive further IMC-EB10 treatment, but will continue to be followed on the protocol. Participants may continue to receive IMC-EB10 therapy, in the absence of treatment failure, treatment intolerance, or other withdrawal criteria for additional 28-day cycles at the same dose that they initially received. Dosing for Cycle 2 and beyond will be administered on Days 1, 8, 15, and 22 of a 28-day treatment cycle
223598368|NCT00964821|BIOLOGICAL|trivalent influenza vaccine|Patients or normal volunteers who will be vaccinated against the flu.
224198708|NCT07048730|OTHER|Questionnaire|"A standardized questionnaire was specifically developed for the study to explore:~* Women's socio-demographic data~* Data about their hematological disease (type of leukemia, conditioning protocol, relapses, graft-versus-host disease etc.)~* Information received by patients prior to transplantation concerning gynecological complications~* Symptoms, screening, diagnosis and treatment of the main gynecological complications~* Patients fertility (spontaneous or after assisted reproductive treatments)"
224198709|NCT06719947|DEVICE|Active HD-tDCS|10 sessions of anodal HD-tDCS stimulation (neurostimulator coupled with a 4x1 HD-tDCS multichannel adapter) with a defined electrical current intensity over the cortical representation zone of the left diaphragmatic motor cortex
223598369|NCT00964821|OTHER|Immunoenzyme technique|This test will determine the level of antibodies in participants who have been vaccinated against the flu and those who have not been vaccinated against the flu.
223598370|NCT00964821|OTHER|Laboratory biomarker analysis|This test will count the number of T cells (the cells that kill the flu virus) in participants who have been vaccinated against the flu and those who have not been vaccinated against the flu.
223598371|NCT02461940|BEHAVIORAL|Adolescent Behavioral Intervention|Session 1 focuses on STI/HIV education and self-reflection. Session 2 aims to increase the awareness of STI/HIV preventive strategies by instilling condom use and negotiation skills. Motivational Interviewing is used during the behavioural counselling. Session 3 reviews the goal on safer sex set by the participant and examines the successful strategies on safer sex and identifies triggers for relapse. Success stories are shared to renew their motivation. Session 4 reinforces the progress of the participant by recapitulating the knowledge and motivation explored in previous sessions. The online sessions, by phone/SMS/Whatsapp are conducted 2 months after the second and third sessions to find out if they face any difficulties and to reinforce prevention information covered previously.
223598372|NCT00880191|DRUG|dexamethasone|Given orally
223598373|NCT00880191|DRUG|gabapentin|Given orally
223598374|NCT00880191|OTHER|placebo|Given orally
223598375|NCT00236236|DEVICE|Cardiac Resynchronization Therapy|
223598376|NCT04903054|BIOLOGICAL|Lulizumab|Lulizumab is a pegylated, humanized monovalent domain antibody construct that is specific for human cluster of differentiation CD28.
223598377|NCT04903054|DRUG|Tacrolimus|Standard of Care: Renal transplant rejection prophylaxis.
223598378|NCT04903054|BIOLOGICAL|Thymoglobulin®|Standard of Care: Renal transplant rejection prophylaxis.
223598379|NCT04903054|DRUG|Methylprednisolone|Standard of Care: Renal transplant rejection prophylaxis.
223598380|NCT04903054|DRUG|Mycophenolate Mofetil|Standard of Care: Renal transplant rejection prophylaxis.
223598381|NCT04903054|DRUG|Prednisone|Standard of Care: Renal transplant rejection prophylaxis.
223598382|NCT05499468|OTHER|Popular-Opinion Leader-led encouragement during training meetings and informal conversation|Investigators adapted evidence-based principles from the Popular Opinion Leader framework to increase utilizations of existing one-on-one emotional support resources for physicians-in-training at Stanford (an effective HIV prevention intervention developed by the CDC for changing social norms and reducing behavioral risk factors led by influential members of a community, trained to promote behavior change). All intervention activities designed to encourage utilization were delivered as part of health promotion during pre-existing clinical training meetings and no data was collected during these workshops. Identified POLs were recruited and trained to encourage their colleagues to use existing support resources and engage in two 30-60 minute workshops scheduled to occur during training meetings.
223598383|NCT04617730|DEVICE|Mepitel® film|This study is a comparative study between the standard procedure, which is to prescribe a hydro-active colloidal gel called Flamigel® to be applied to the irradiated area, and the use of Mepitel® Film.
223598384|NCT04617730|OTHER|Flamigel®|The control arm will be treated according to the standard of care.
224198710|NCT06719947|DEVICE|Simulated HD-tDCS|10 sessions of sham anodal HD-tDCS stimulation (neurostimulator coupled with a 4x1 HD-tDCS multichannel adapter) over the cortical representation zone of the left diaphragmatic motor cortex. The device will provide a 30-second ramp and then maintain a minimal, non-effective continuous current
223748311|NCT04762680|BIOLOGICAL|SARS-CoV-2 recombinant protein vaccine Phase 2 Formulation 2|Pharmaceutical form: Emulsion for injection Route of administration: Intramuscular injection
223748312|NCT04762680|BIOLOGICAL|SARS-CoV-2 recombinant protein vaccine Phase 2 Formulation 3|Pharmaceutical form: Emulsion for injection Route of administration: Intramuscular injection
224198711|NCT06896565|DRUG|nano hydroxy apatite varnish|Intervention (1)
224311144|NCT06446258|OTHER|Manual therapy (myofascial release, soft tissue mobilization)|Soft tissue mobilization will be performed by a team of experienced manual therapists.
224311145|NCT01441947|DRUG|Cabozantinib|Given orally daily with a starting dose of 40 mg
223598385|NCT04619732|DIAGNOSTIC_TEST|Monitoring biochemical concentrations during cold machine perfusion|Three microdialysis probes will be introduced into the kidney tissues, the vein and ureter in order to measure creatinine, glucose and lactate while the organ is undergoing cold perfusion prior to transplantation.
223598386|NCT02097030|DEVICE|filcon II 3|Participants wear a first pair of lenses for three days and then crossover and wear a second pair of lenses for three days.
223598387|NCT02097030|DEVICE|etafilcon A|Participants wear a first pair of lenses for three days and then crossover and wear a second pair of lenses for three days.
223598388|NCT02097030|DEVICE|nelfilcon A|Participants wear a first pair of lenses for three days and then crossover and wear a second pair of lenses for three days.
223598389|NCT05538676|DIAGNOSTIC_TEST|BPA-PET imaging|PET imaging
223598390|NCT01645410|DRUG|Atorvastatin Calcium Tablets, 40 mg|Atorvastatin Calcium Tablets, 40 mg of Dr. Reddy's Laboratories Limited
223598391|NCT00034827|DRUG|CI-1040|
223598392|NCT01919801|DRUG|Icatibant|Single dose of 30 mg icatibant administered within 12 hours of the onset of an acute attack of ACE-I-induced angioedema
223598393|NCT01919801|DRUG|Placebo|
223598394|NCT05539313|DEVICE|High-density mapping|Patients will undergo magnetic resonance imaging of both atria, and interventional high-density mapping of both atria.
223598395|NCT01843062|DRUG|Selumetinib|3 capsules of 25 mg strength orally twice a day for approximately 5 weeks treatment period
223598396|NCT01843062|DRUG|Placebo|3 capsules ( to match Selumetinib capsules) orally twice a day for approximately 5 weeks treatment period
224198712|NCT06896565|DRUG|Potassium Nitrate Gel|Intervention (2)
223598397|NCT01843062|DRUG|Radioactive Iodine Therapy|A single oral radioactive iodine dose of 100 mCI(3.7 GBq) 131I (+/-10% at the time of administration)to be administered 30 days after randomization. Additionaly, Thyrogen (Recombinant human TSH) will be used to stimulate iodine uptake according to the manufacturer's recommendation(0.9 mg intramuscular injection once a day for the 2 days prior to the dose of radioactive iodine)
223598398|NCT01090440|DRUG|GSK1144814|This study is an open label, randomised, three-way cross-over study to evaluate the pharmacokinetics, effect of food, safety and tolerability of a new tablet formulation of GSK1144814 in healthy male and female (non-child bearing potential) subjects. Sixteen subjects will be enrolled to provide a minimum number of 12 evaluable subjects. The doses to be administered will be 100 mg and 200mg in the fasted state, and 100mg following a high fat breakfast.
224198713|NCT06896565|DRUG|Varnishes, Fluoride|Control
224198714|NCT06748690|PROCEDURE|mucosal cutting biopsy|"Under intravenous anesthesia, the patient inserted a gastroscopy (Olympus GIF-260J) through the mouth and used a disposable high-frequency cutting knife to cut open the surface mucosa of the tumor. Biopsy forceps were used to extract tissue that could be fully evaluated for pathological examination. Use a disposable hemostatic clip to suture the mucosal incision, and after thorough observation of the hemostasis, withdraw from the endoscope.~("
224198715|NCT06748690|PROCEDURE|endoscopic ultrasound-guided-fine needle aspiration|2\) EUS-FNA group: Standard (Endoscopic Ultrasonography-Guided Fine-Needle Aspiration) EUS-FNA technology was used, and electronic linear array ultrasound endoscopy (GF-UCT-260, Olympus, Japan) was used to scan and locate the lesion. Puncture needle (Boston Scientific, USA) was used for aspiration biopsy. The thickness of the puncture needle depends on the size, hardness, and location of the tumor.
224198716|NCT06896968|BEHAVIORAL|Earthquake Preparedness and Awareness Training|Earthquake Preparedness and Awareness Training + standard education
224198717|NCT03222856|DRUG|Pembrolizumab|MK3475 (pembrolizumab) will be supplied directly as a solution for infusion in a single-use vial. Each vial contains 100 mg of MK3475 (pembrolizumab) in 4 ml of solution.
223598399|NCT05289479|PROCEDURE|Pre-heating of resin composite before application|the effect of preheating of resin composite before application in class II cavities
223598400|NCT05289479|PROCEDURE|no pre-heating of resin composite before application|The control group
223598401|NCT04569227|DRUG|EC-18|2000 mg PO daily
223598402|NCT04569227|DRUG|Placebo|PO daily
223598403|NCT01677858|DRUG|Carfilzomib|Carfilzomib was administered as a 30-minute IV infusion on days 1, 8, and 15 of each 28-day treatment cycle.
223598404|NCT01677858|DRUG|Dexamethasone|Dexamethasone was administered at a dose of 40 mg IV or orally (PO) on days 1, 8, 15, and 22 for the first 8 cycles; starting with cycle 9 dexamethasone was administered on days 1, 8, and 15.
223598405|NCT00481923|DRUG|rimonabant (SR141716)|
223598406|NCT04343456|PROCEDURE|Salvage surgery with massive debulking|For patients with regorafenib treatment and facing local progression, we remove the tumor with progression and achieve cytoreduction.
223598407|NCT03761901|DRUG|1L treatment|chemotherapy, EGFR TKI, immunotherapy, other
223598408|NCT03761901|DRUG|2L Treatment|Chemotherapy, EGFR TKI, immunotherapy, other
223598409|NCT03761901|DRUG|3L treatment|chemotherapy, EGFR TKI, immunotherapy, other
223598410|NCT00773747|DRUG|Vorinostat|Four 100 mg capsules vorinostat taken orally, once daily, on Days 1 through 14 of each 21-day treatment cycle.
223598411|NCT00773747|DRUG|bortezomib|1.3 mg/m2 of bortezomib by IV push, on Days 1, 4, 8, and 11 of each 21-day treatment cycle.
223598412|NCT00773747|DRUG|placebo to vorinostat|Four placebo capsules taken orally, once daily, on Days 1 through 14 of each 21-day treatment cycle.
223598413|NCT03547895|DRUG|Sofosbuvir 400mg (Sovaldi) + Daclatasvir 60 mg (Daklinza) + Ribavirin 200 mg (Rebetol)|sofosbuvir 400mg+ribavirin 400mg+daclatasvir 60 mg were adminstered for 3 months
223598414|NCT03547895|DRUG|vitamin K (Phytomenadione) 10 mg+ furosemide and spironolactone (Lasilactone) 50 mg + milk thistle (Silymarin) 140 mg + Albumin infusion|symptomatic therapy for liver support, control of ascites and bleeding tendency.
223598415|NCT04260347|DRUG|Alteplase|Intravenous injection
223598416|NCT02893696|OTHER|Various sitting time|Various sitting time
223598417|NCT01472068|DEVICE|Inko RS Device|30 minute pre-programmed treatment for 5 days out of 7. Treatment to be carried out while standing.
223598418|NCT02669212|BEHAVIORAL|Cardiopulmonary Exercise Test (CPET)|All participants will undergo an exercise stress test
223598419|NCT00828763|DRUG|[14c}-GSK1349572|HIV-Integrase inhibitor labelled with a carbon 14 marker
224198718|NCT03222856|DRUG|Eribulin|Eribulin will be supplied as a clear and colourless aqueous solution for injection provided in glass vials containing 2 ml. Each 2 ml vial contains eribulin mesylate equivalent to 0.88 mg eribulin.
224198719|NCT05925322|BEHAVIORAL|"Engage & Connect Psychotherapy"|9-weeks of weekly psychotherapy sessions focused on social reward exposure
224198720|NCT05925322|BEHAVIORAL|Symptom Review and Psychoeducation (SRP)|9-weeks of weekly psychotherapy sessions focused on symptom review and psychoeducation about depression and aging
224198721|NCT06898255|DRUG|GFS202A injection|Participants will receive GFS202A intravenously every 3 weeks (Q3W) in a 21-day cycle. The treatment duration was 12 weeks.
223598420|NCT02113033|DEVICE|Equilia® Vagal Nerve Stimulation|Vagal Nerve Stimulation synchronized with cardiac activity
223598421|NCT01661894|DEVICE|BrainPalTM|Brain-computer Interface (BCI) is a direct communication pathway between a human brain and an external device. It is a technology that enables people to interact with computers through their thoughts. Electroencephalography (EEG) is the best studied non-invasive interface facilitating such communication. The BCI system will take EEG recordings from the prefrontal cortex to determine the participants' state of attention with high specificity. The training program developed using this patented technology may be useful for individuals who experience difficulty with memory and sustaining their attention.
223598422|NCT00275067|DRUG|arsenic trioxide|Arsenic trioxide administered intravenously at a dose of 0.20mg/kg Daily x 5 week then twice per week
223598423|NCT00275067|DRUG|temozolomide|Temozolomide administered orally once per day 1 hour prior to radiation therapy at a dose of 75 mg/m2 x 42 days; at a dose of 200mg/m2 for 5 days every cycle (1 cycle = 28 days) after radiation therapy
223598424|NCT00275067|RADIATION|radiation therapy|All patients will receive 5940-6120 cGy of radiation therapy as 28-33 treatments/fractions (180-200 cGy/treatment) depending on whether they receive standard 3-D conformal radiation therapy or intensity modulated radiation therapy.
224198722|NCT03934372|DRUG|Ponatinib|Ponatinib administered as a tablet or age-appropriate formulation for pediatric participants according to age-based cohort assignment.
224198723|NCT02346747|BIOLOGICAL|Vigil|The bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Vaccine, Vigil is made up of irradiated autologous tumor cells which have been electroporated ex vivo with the Vigil plasmid designed to suppress expression of both the TGFβ1 and TGFβ2 proteins while simultaneously expressing rhGMCSF protein.
224198724|NCT02346747|OTHER|Placebo|"To maintain placebo effect and eliminate bias due to volumetric differences, the number of Vigil doses manufactured from harvested tissue (except if below 4) will be used to guide manufacture of the same number of doses of placebo for each subject. Placebo will consist of freeze media \[10% DMSO (dimethyl sulfoxide; Cryoserv USP; Mylan Institutional USP), 1% Human Serum Albumin (ABO Pharmaceuticals) in Plasma-Lyte A, pH 7.4 (Baxter)\]. Depending upon randomization assignment, placebo or Vigil will be delivered in identical vials and drawn up in 'covered' syringes for intradermal injection."
224198725|NCT04587687|DRUG|Bendamustine Hydrochloride|Given IV
223598425|NCT05034601|PROCEDURE|ESPB group|A 21-gauge 100-mm needle will be inserted into the fascial layer beneath the iliocostalis, longissimus, and spinalis muscles. A bolus of 0.25% ropivacaine 0.5 ml/kg will be injected into the fascial layer. Contralateral ESPB will be performed similarly.
223598426|NCT05034601|PROCEDURE|TPVB group|A 21-gauge 100-mm insulated needle will be inserted into the paravertebral space via an in-plane parasagittal approach. After perforating the costotransverse ligament, 0.25% ropivacaine 0.5 ml/kg will be injected. Anterior movement of the pleura indicated the appropriate spread of the local anesthetics in the paravertebral space. The process will be repeated on the contralateral side.
223598427|NCT04099784|OTHER|Developmental score according to The Ages & Stages Questionnaires®, Third Edition - ASQ®-3|Ages \& Stages Questionnaires®, Third Edition (ASQ®-3) is a developmental screening tool designed for use by early educators and health care professionals. It relies on parents as experts, is easy-to-use, family-friendly and creates the snapshot needed to catch delays and celebrate milestones.
223598428|NCT04099784|OTHER|Physical development and General Health|Physical development and General health examination
223598429|NCT04099784|OTHER|Developmental Red flags|Developmental Red flags Questionnaires
223598430|NCT02470325|DRUG|Avidekel oil|Avidekel cannabis oil 6:1 CBD:THC
223598431|NCT02470325|DRUG|Enriched Avidekel oil|Enriched Avidekel cannabis oil 20:1 CBD:THC
223598432|NCT03549104|BEHAVIORAL|Fear Reduction Intervention|FREE
223598433|NCT03549104|BEHAVIORAL|Attention Control|DSMES
223598434|NCT05536687|DEVICE|FeetMe|"Healthy volunteers will wear the insoles at 2 visits in hospitals (D0 and D8) and 2 visits at home (D1 and D7). The visits at the hospital will be composed of 3 tests of 6 min. in various conditions in a hospital environment :~* In degraded conditions, i.e. a 10m corridor, evaluated simultaneously by the FeetMe® system and an evaluator~* In degraded condition, a 10m corridor, evaluated simultaneously by the FeetMe® system and an odometer and evaluator~* Under the conditions recommended for the 6-minute test (ref), i.e. a 30m corridor, evaluated simultaneously by the FeetMe® system and the evaluator A rest time of 15 min minimum will be respected between each test. The visits at home will be composed of a 6-minute test at home or outdoors (quiet place, flat, hard surface, few or no passages, ideally no obstacles, covered if weather conditions are not suitable) with a 10-meter track that you can define simply with equipment provided by the promoter."
223598435|NCT05389176|DRUG|Esmolol|a continuous esmolol infusion titrated to maintain heart rate between 70/min and 100/min
223598436|NCT03078855|DIETARY_SUPPLEMENT|Vitamin D|vitamin D3 2,000 IU daily
223598437|NCT03078855|BIOLOGICAL|Rituximab|Administered weekly x 4
223598438|NCT03078855|OTHER|Placebo|methylcellulose
223598439|NCT06196346|BEHAVIORAL|Psychotherapy|see group description
223598440|NCT01770171|DRUG|Bevacizumab|Carboplatin AUC 5+ Paclitaxel 175 mg/mq+Bevacizumab 15 mg/kg q 21 for 6 -8 cycles + Bevacizumab 15 mg/kg
223598441|NCT01770171|DRUG|Carboplatin AUC 5+Paclitaxel 175 mg/mq q 21 for 6-8 cycles|Carboplatin AUC 5+Paclitaxel 175 mg/mq q 21 for 6-8 cycles
223598442|NCT00391027|DRUG|Insulin Glargine (Lantus®)|Patient will be randomized to Lantus® while remaining on pre-study oral hypoglycemic agents.
223598443|NCT00391027|DRUG|Inhaled Human Insulin (Exubera®)|Patient will be randomized inhaled insulin while remaining on pre-study oral hypoglycemic agents.
223598444|NCT02816489|DEVICE|Clarity SL MBT brackets; 3M Unitek, Monrovia, CA, USA|(passive self-ligating ceramic orthodontic brackets with stainless steel archwire slot liner)
223598445|NCT02816489|DEVICE|Gemini MBT brackets; 3M Unitek, Monrovia, CA, USA|(conventional stainless steel orthodontic brackets ligated with elastomeric ligature)
223598446|NCT01916434|OTHER|High PUFA Salmon Fillets|High EPA/DHA levels in feed and in salmon fillets (\~15% of total feed fatty acids, equal to wild salmon), 2 salmon fillets per week for 18 weeks, on top of habitual fish consumption.
223598447|NCT01916434|OTHER|Sustainable PUFA salmon|'Sustainable' levels of EPA/DHA in feed and in salmon fillets (\~6-8% of total feed fatty acids), 2 salmon fillets per week for 18 weeks, on top of habitual fish consumption.
223598448|NCT01916434|OTHER|No salmon|The placebo group will continue to consume their habitual diet.
223598449|NCT03570541|DRUG|Ropivacaine|30 mL ropivacaine 0,375% administered on each side as bilateral TQL blocks
223598450|NCT03570541|DRUG|Acetaminophen|Every six hours postoperative, all patients are administered 1 g of acetaminophen.
223598451|NCT03570541|DEVICE|Patient controlled analgesia|PCA-pump with IV-Morphine. 5 mg administered per bolus. Lock-out time and max. dosage standardized.
223598452|NCT03570541|DRUG|Morphine|intravenously administered morphine via PCA-pump
223598453|NCT03570541|DRUG|Saline|30 ml saline 0,375% administered on each side as bilateral TQL blocks
224198726|NCT04587687|DRUG|Brentuximab Vedotin|Given IV
224198727|NCT06828380|RADIATION|Particle beam radiation therapy|The prescribed dose and fractionation for proton therapy to the PTV will be determined by the physician, taking into account the dose-volume constraints of normal tissues such as the liver and bowel.
224311146|NCT01441947|DRUG|Fulvestrant|Given intramuscularly 500 mg on Days 1 and 15 of the first 28 day cycle, then on Day 1 only each cycle after
224198728|NCT06900881|COMBINATION_PRODUCT|Kefir Mouth Wash|A kefir-based mouthwash was developed with active bacterial and yeast cultures, including Lactococcus lactis, Lactococcus cremoris, Lactococcus diacetylactis, Lactobacillus acidophilus, Saccharomyces cerevisiae, and Kluyveromyces lactis, along with maltodextrin and 3% fat milk. The recipe also calls for milk from Pegah, Iran. The milk is initially heated to boiling point and then allowed to cool to room temperature (25°C). After cooling, the kefir powder will be dissolved in the cooled milk and mixed well. For every 1 liter of milk, 3g of kefir starter yogurt (Yogourmet, France) will be added. The inoculated milk will then be transferred into a clean, airtight container, and the lid will be sealed. The container will be left at room temperature for approximately 24 hours until the kefir curd forms. After 24 hours, the kefir will be refrigerated for about 8 hours to halt the fermentation process.
223598454|NCT03570541|DIAGNOSTIC_TEST|Blood samples|On the day of surgery, postop day 1+2 and day 10-14, all patients will have blood samples taken for immunological analysis
223598455|NCT03570541|BEHAVIORAL|Quality of recovery-15 questionaire|On the day of surgery, postop day 1+2 and day 10-14, all patients are asked to fill out a short questionaire.
223598456|NCT03570541|DIAGNOSTIC_TEST|Orthostatic hypotension|Before surgery, and 3, 6 and 24 hours postop. All patients are tested for orthostatic hypotension.
223598457|NCT02186665|DRUG|calcitriol ointment|
223598458|NCT02186665|DRUG|placebo comparator|
223598459|NCT03618316|DRUG|Imeglimin|2 singles oral doses of imeglimin 1,500 mg (one at day 1 and one at day 8)
223598460|NCT03618316|DRUG|Cimetidine|400 mg of cimetidine bid from Day 5 to Day 10
223598461|NCT00663754|BEHAVIORAL|Dissonance-based eating disorder prevention program|Participants will engage in verbal, written, and behavioral exercises in which they will critique the thin ideal. These exercises will be conducted in sessions and in homework activities. The exercises will aim to increase body image satisfaction by helping participants to think critically about the thin ideal and to discuss some of the problems associated with the pursuit of this ideal.
223598462|NCT00663754|BEHAVIORAL|Educational brochure|Participants will receive a mailed educational brochure about a healthy body image only.
223598463|NCT06016868|PROCEDURE|Tumor tissue|Each newly diagnosed patient with LACC who meets the inclusion criteria will undergo cervical cancer biopsy either during the outpatient clinical examination or during examination during anesthetic. Part of the biopsy will be sent for histopathological analysis, while the remaining tissue will be embedded in OCT compound and immediately frozen at -80°C prior to transfer to biobank for subsequent analysis.
223598464|NCT06016868|PROCEDURE|Blood sample|Every patient will undergo a peripheral venous blood sample which will be processed to analyze the presence of the proteins codified by three RNA species (ANXA2-NDRG1-STAT1). This blood sample will be performed before starting the treatment with exclusive CTRT.
223598465|NCT06393179|OTHER|pressure-volume curve with a low-flow insufflation of 5 L/min|The patient undergoes a pressure-volume curve with a low-flow insufflation of 5 L/min while in a state of analgesia, sedation, and absence of spontaneous breathing.
223598466|NCT00281346|PROCEDURE|Doppler echocardiography|Echocardiography
223598467|NCT01111344|DIETARY_SUPPLEMENT|Glizigen + Viusid|"Glizigen (spray, 60 mL bottle with applicator): Dosage commensurate with surface (up to a maximum of 10 cm2) to be treated. From 3 to 5 ambulatory applications (One nebulization corresponds to 2 short pulses).~* 1 to 3.9 cm2 \_\_\_\_\_\_\_\_\_\_\_\_\_\_3 daily applications~* 4 to 6.9 cm2 \_\_\_\_\_\_\_\_\_\_\_\_\_\_4 daily applications~* 7 to 10 cm2 \_\_\_\_\_\_\_\_\_\_\_\_\_\_5 daily applications Treatment will last from 5 days to 8 weeks according to clinical improvement.~Viusid (Syrop, 500 mL flask): 12.5 ml every 8 hours for 12 weeks. Viusid syrop should be dissolved in water, fruit juice or milk before ingestion."
223598468|NCT01111344|DIETARY_SUPPLEMENT|Placebo|"Placebo Glizipen (spray, 60 mL bottle with applicator): Dosage commensurate with surface (up to a maximum of 10 cm2) to be treated. From 3 to 5 ambulatory applications (One nebulization corresponds to 2 short pulses).~* 1 to 3.9 cm2 \_\_\_\_\_\_\_\_\_\_\_\_\_\_3 daily applications~* 4 to 6.9 cm2 \_\_\_\_\_\_\_\_\_\_\_\_\_\_4 daily applications~* 7 to 10 cm2 \_\_\_\_\_\_\_\_\_\_\_\_\_\_5 daily applications Treatment will last from 5 days to 8 weeks according to clinical improvement.~Placebo Viusid (Syrop, 500 mL flask): 12.5 ml every 8 hours for 12 weeks. Viusid syrop should be dissolved in water, fruit juice or milk before ingestion."
223598469|NCT04348032|DRUG|PLD 40mg/m2 ivgtt q4w +Apatinib 250mg po qd|Patients receive PLD and apatinib at the same time. The dose of intravenous chemotherapy drug is calculated according to the body surface area, and the dose of oral drug apatinib is 250mg qd. Dose suspension and dose reduction are allowed only when patients have serious adverse reactions. The intravenous chemotherapy drug PLD dose is only allowed to be down-regulated twice (one time is to reduce the standard dose by 25%), and the oral drug apatinib dose is only allowed to be reduced once (250mg gravity QD changed to 250mg gravity Qod). Otherwise the patients will drop out of the study.
223598470|NCT04348032|DRUG|PLD 40mg/m2 ivgtt q4w|The dose of intravenous chemotherapy drug is calculated according to the body surface area. When patients have serious adverse reactions, dose suspension and dose reduction are allowed. The PLD dose is only allowed to be down-regulated twice (one time is to reduce the standard dose by 25%).
223598471|NCT00230841|DEVICE|nebulized humidity|
223598472|NCT02056093|DEVICE|PSV mode|Application of PSV in all patients
223598473|NCT02056093|DEVICE|PAV mode|Application of PAV mode in all patients
223598474|NCT02056093|DEVICE|NAVA|
223598475|NCT03843983|DEVICE|Lipiflow® application|"Lipiflow® will be applicated in both lids of each eye during 12 minutes once. Firstly, a drop of anesthetic will be instilled in each eye. Then, while the participant stays with his eyes closed, a one-used applicator will be placed covering the subject's lid. The instrument applies heat and pressure in the lid during 12 minutes. Time frame: between 2 and 7 days after visit 1.~Then, there will be 3 follow-up visits in 3, 6 and 12 months after treatment."
223598476|NCT06251583|DEVICE|duramesh suture|Duramesh-suture will be used for trocar closure in the experimental group
223598477|NCT00349869|BEHAVIORAL|yoga|8-week yoga program.
223598478|NCT02443168|DRUG|AG-221|Part 1: oral solution containing 100 mg \[14C\]-AG-221
223598479|NCT02443168|RADIATION|14C AG-221|5 mL of 100 micrograms \[14C\] AG-221 given intravenously 4 hours after swallowing the formulated tablet.
223598480|NCT05527821|DRUG|Surufatinib|Surufatinib 250mg will be taken orally once daily continuously on a 21-day cycle
223598481|NCT05527821|DRUG|Sintilimab|Sintilimab 200mg will be intravenously administered on Day 1 of each cycle
223598482|NCT05527821|RADIATION|Short course radiotherapy|5Gy\*5F short course radiotherapy will be delivered
223598483|NCT06115590|DIETARY_SUPPLEMENT|Nutritional supplement|Nutritional intervention hypothesized to have an acute anxiolytic effect
223748313|NCT04762680|BIOLOGICAL|SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (D614)-AS03, Dosage A|Pharmaceutical form: Emulsion for injection Route of administration: Intramuscular injection
223598484|NCT06116006|OTHER|Upper limb pointing movements in 3 experimental conditions|Recording of cerebral hemodynamic with fNIRS during upper limb pointing movements with a robotic device in three conditions: movements with robot assistance, movements without robot assistance and movements with robot resistance. Each subject are recorded during 6 trials for each condition (18 trials). The order is counterbalanced among the subjects.
223598485|NCT01578577|BEHAVIORAL|EHMI|The EHMI intervention consists of multiple components, all leveraged by the Epic EHR platform (Verona, WI). The EHMI intervention 1) activates patients to review their medication list and identify any adherence-related concerns, 2) automates a process for providing plain language, patient-centered print medication information for new and refilled prescriptions, and 3) provides additional print tools to help patients more effectively engage their providers, consolidate their regimen, and generally promote safe use and adherence.
223598486|NCT01578577|BEHAVIORAL|Nurse Educator + EHMI|This intervention is a combination of the use of a nurse educator and the EHMI tools described in the EHMI intervention arm. A nurse educator perform the following: 1) perform medication and medical record review 2)assess adherence and medication problems 3) provide counseling to promote safe and effective medication use 4) follow-up with patients after their visit to confirm they have filled all prescriptions, and can accurately teach back their medicine regimen, 5) communicate with prescribing physician when problems are identified.
223598487|NCT01763606|DRUG|Enoxaparin|Patients will be receive 6 months of subcutaneous enoxaparin (1 mg/kg BID with a maximum starting dose of 100 mg BID. Patients who weigh more than 100 kg will start at a dose of 100 mg BID; their subsequent dosing will be guided by hematology and may change.
223598488|NCT01763606|DRUG|Aspirin|Patients will receive 6 months of oral aspirin (81 mg per day unless a higher dose is preferred by study physicians although the maximum acceptable dose will be 325 mg per day).
223598489|NCT00160836|DEVICE|"Tissue sampling (G.I.U.M. catheter)"|
223598490|NCT06970873|OTHER|Evaluation of Knowledge, Attitude, and Practice of Pediatric Dentists|Evaluation of Knowledge, Attitude, and Practice of pediatric dentists toward Obstructive Sleep Apnea among Children
223598491|NCT06976346|DRUG|HRG2010 Capsule, Sinemet®, Madopar®|In each period under fasting conditions, subjects received oral administration of either HRG2010 Capsule dose 1, HRG2010 Capsule dose 2, Sinemet®, or Madopar®.
223598492|NCT06977009|PROCEDURE|Occlusal Reduction|"patients will be allocated to either undergo occlusal reduction (Intervention group) where all occlusal contacts on the functional and non-functional cusps as well as on the marginal ridges will be reduced using a diamond bur, or not undergo occlusal reduction (Control group) where all occlusal contacts will remain intact.~The presence or absence of contact will be confirmed using articulating paper where occlusal surfaces will be dried and articulating paper will be held between the teeth with the mandible guided to the centric position. Intact occlusion will be assessed by examining the marks on the teeth.~A high-speed handpiece with copious coolant will be used to remove occlusal contacts (Intervention group) or just moved above the surface of the tooth without contacting the occlusal surface (Control group) to facilitate patient blinding."
223598493|NCT02482467|OTHER|Hormonal analysis, pelvic US|
223598494|NCT03330639|OTHER|Capsaicin|Capsaicin is a homeopathic medication and there for this drug is not subject to the requirements of the FDA.
223598495|NCT03330639|OTHER|Placebo|This group will receive the saline placebo solution.
224198729|NCT06900881|DRUG|Chlorhexidine 0,12%Biofresh Mouthwash|Chlorhexidine mouthwash is used as a standard treatment (Scitra Co for Biofresh LIC, P.O. Box 87218, Dubai, U.A.E.). It contains 0.12% Chlorhexidine Digluconate, purified water, sodium saccharin, cremophor, flavor, and glycerin.
223598496|NCT06493903|BEHAVIORAL|Positive Minds, Strong Joints|In this10-week physical and mental health intervention, participants will receive recommended exercise intervention and evidence-based mental health intervention for pain, depression and anxiety.
223598497|NCT05427240|OTHER|Pre-Test Intervention|Secure and accessible by private code only, the web-based intervention will provide users with a the results of their clinical genetic testing results and a detailed summary of what those results mean. Additionally, an individualized summary will also be included.
223598498|NCT05427240|OTHER|Standard of Care|Standard of Care with a Genetic Counselor by Remote Services
223598499|NCT05427240|OTHER|Post-Test Intervention|Secure and accessible by private code only, the web-based intervention will provide users with a the results of their clinical genetic testing results and a detailed summary of what those results mean. Additionally, an individualized summary will also be included.
223598500|NCT03938506|OTHER|cuff pressure of the endotracheal tube|The endotracheal intubation will be performed after the anesthetic induction. The cuff will be inflated using the air by the palpation method. The cuff pressure of the endotracheal tube will be measured using the manometer.
223617883|NCT05574023|DEVICE|Use of Predictive Alarm for hypoglycaemia or hyperglycaemia|"Patients use CGM sensor with Predictive Alarm set at 70 mg/dl in 20 minutes for hypoglycemia and at 250 mg/dl in 20 minutes for hyperglycemia.~1. in case of alarm from the hypoglycemia predictive algorithm, the indicated treatment was 0.1g of sugar/kg of body weight;~2. in case of alarm from the hyperglycemia predictive algorithm, the indication was to give an extra shot of rapid-acting insulin. The dose will be calculated on the basis of personal insulin sensitivity factor (ISF), considering as target a blood glucose of 120 mg/dl and 250 mg/dl as the projected blood glucose level that will be reached in 20 minutes. This could be done only if there is no active insulin on-board, after at least 3 hours from the last rapid-acting insulin injection."
223748314|NCT04762680|BIOLOGICAL|SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03|Pharmaceutical form: Emulsion for injection Route of administration: Intramuscular injection
223748315|NCT04762680|BIOLOGICAL|SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (D614)-AS03, Dosage B|Pharmaceutical form: Emulsion for injection Route of administration: Intramuscular injection
224198730|NCT06861452|DRUG|RR001|RR001, a cell-based gene therapy administered following administration of chemotherapy (Nab-PTX 125 mg/mq and GEM 1000 mg/mq)
223598501|NCT04153916|DEVICE|Neurotrigger eye blinking stimulator|"Phase 1 - The first stage is composed of a one-time participation for about three hours and involves:~1. Verifying compliance of the patients with the research inclusion and exclusion criteria~2. Completion of the study clinical report form (CRF) for this stage~3. Placement of the single use mini-electrodes that will be adhered to the facial skin near the non-blinking eye and coupled to the Neurotrigger stimulator to elicit eyelid closure.~Participants may be enrolled to the second phase up to one year from the first phase visit In the second stage the duration of the participation is about three weeks (six days a week) and includes daily use of the device for up to 10 hours a day. During nights the patient will continue is standard pattern of either eye closure or leaving the eye open, as the patient used to do prior to the study.~This stage will involve a patient with a partner that is designated to support the patient closely during the placement and adjustment of the system"
224198731|NCT06805877|OTHER|Predictive Analytics and Clinical Decision Support|The intervention will include automated EHR notifications to clinicians at 16 OCHIN community health centers about patients who are likely to benefit from PrEP. These patients will be identified by an HIV prediction model that was developed and validated during the pilot phase of this study using historical OCHIN EHR data. For patients above a preselected threshold of predicted HIV risk, clinicians will be notified at the point of care that the patient may benefit from PrEP and will be provided with EHR-based tools to support discussions and prescribing. The intervention will also include coaching on PrEP and the decision support tool, as well as project team support during the trial period.
224198732|NCT06821204|OTHER|Health education group|Participants will be given one session (40 minutes) of training on the definition and importance of hygiene, the rules and importance of hand washing, the importance of cleaning make-up materials, which method, material and how often they should be cleaned, and the health risks that may occur if they are not cleaned.
224198733|NCT06821204|OTHER|control group|No intervention will be applied to participants in this group.
224198734|NCT06928831|OTHER|Experimental|Course materials were shared with the students in the flipped group one week before the theoretical lesson. Google Classroom platform was used so that students could easily access these materials and repeat them at any time and frequency they wanted. A link and QR code were shared with the students to log in to the system. The frequency of downloading and watching the course materials was monitored by the researcher. Next week, the theoretical course was taught in line with the flipped learning model.
224198735|NCT06928831|OTHER|Experimental|The link to the mobile application developed for mobile learning was shared with the students in this group. Students were given 2 weeks to use the application, and students had the opportunity to read and watch the content in the application at any time and frequency they wanted.
224198736|NCT03384836|OTHER|Laboratory Biomarker Analysis|Correlative studies
224198737|NCT03384836|BIOLOGICAL|Pembrolizumab|Given IV
224198738|NCT03384836|DRUG|Propranolol Hydrochloride|Given PO
224198739|NCT06904300|DRUG|AK112 + paclitaxel|AK112 (20 mg/kg IV, D1/D15) + paclitaxel (80 mg/m² IV, D1/D8/D15), Q4W
224198740|NCT06904300|DRUG|Paclitaxel ± ramucirumab|Paclitaxel (80 mg/m² IV, D1/D8/D15) ± ramucirumab (8 mg/kg IV, D1/D15), Q4W
224198741|NCT04213703|OTHER|No intervention|There is no intervention for this study
224198742|NCT05412290|DRUG|Mosunetuzumab|"Mosunetuzumab is administered intravenously in a step-up dosing strategy. The doses will be 1 mg on C1D1, 2 mg on C1D8, 60 mg on C1D15, 60 mg on C2D1, and 30 mg for all doses following."
223598502|NCT04211129|OTHER|acupuncture|Patients receiving acupuncture and mild moxibustion, whom were treated 3 times per week for 12 weeks and followed up for 36 weeks. CV12 and Bilateral ST37, SP6, SP4, LR3, KI3, LI4 and LI11 were selected for acupuncture and bilateral ST25 and ST36 were selected for moxibustion. Hwato acupuncture device was used to blind the subjects, and had the deqi sensation. The surface temperature of acupoints was maintained at 43℃± 1℃ for moxibustion.
223598503|NCT04211129|OTHER|Sham acupuncture|Patients receiving sham acupuncture and sham mild moxibustion, whom were treated 3 times per week for 12 weeks and followed up for 36 weeks. CV12 and Bilateral ST37, SP6, SP4, LR3, KI3, LI4 and LI11 were selected for acupuncture and bilateral ST25 and ST36 were selected for moxibustion. Same Hwato acupuncture device was used to blind the subjects, but do not puncturing into the skin and do not have the deqi sensation. The surface temperature of acupoints was maintained at 37℃± 1℃ for moxibustion.
223598504|NCT06975826|PROCEDURE|Laparscopic percutaneous internal ring suturing (PIRS) technique in Management of inguinal hernia|Laparscopic percutaneous internal ring suturing (PIRS) technique
223598505|NCT06975826|PROCEDURE|Laparscopic inguinal herniotomy in pediatrics|Laparoscopic intraperitoneal purse string suture sac closure technique in pediatrics.
223598506|NCT06974994|DIETARY_SUPPLEMENT|Synbiotic Supplement|Bifidobacterium bifidum and human milk oligosaccharides (HMOs)
223598507|NCT06974994|OTHER|Placebo|Maltodextrin
223598508|NCT06975384|OTHER|Exposure: sleep disturbance status|"The assessment of sleep disturbance was conducted using Pittsburgh Sleep Quality Index (PSQI) and Insomnia Severity Index (ISI). Patients with a PSQI score \> 5 or an ISI score \> 7 were categorized as sleep disturbance patients.~The assessment of chronotype was conducted using reduced Morningness-Eveningness Questionnaire (rMEQ). Patients with an rMEQ score 18-25 were categorized as the morning type, those with an rMEQ score 12-17 as the intermediate type, and those with an rMEQ score 4-11 as the evening type."
223598509|NCT06975475|DRUG|SHR-A1811,tratuzumab,pyrotinib,Nab-Paclitaxel|SHR-A1811:4.8mg/kg tratuzumab:Initial 8mg/kg followed by 6mg/kg pyrotinib:320mg Nab-Paclitaxel:100-150mg/m2
223598510|NCT00326248|DRUG|GW679769 (casopitant)|
224198743|NCT06902285|DRUG|Magnesium Threonate|Participants will receive a daily 145 mg pill by mouth 30 minutes before going to sleep
224198744|NCT06902285|OTHER|Control|Participants will receive two sugar pills daily by mouth 30 minutes before going to sleep
224198745|NCT06905691|OTHER|Conventional Training|Patients will execute the concentric and eccentric phases unilaterally, maintaining consistent load levels, with each phase lasting 2 seconds.
224198746|NCT06905691|OTHER|Eccentric Training|The concentric phase will be performed bilaterally in approximately 1 second, followed by the unilateral eccentric phase lasting approximately 3 seconds.
224198747|NCT04960280|DEVICE|©VoqX stethoscope|Computerized auscultation detects both infrasound and audible sounds and is capable of amplifying auscultated sounds by a factor of thirty.
224198748|NCT06374576|BEHAVIORAL|Lecture on eHealth literacy|There will be a lecture on eHealth literacy. The lecture will be delivered by one well-trained lecturer. , the lecture will be held for old adults in small groups, including a structured curriculum consisting of 4 parts: 5 minutes for the introduction, 40 minutes for the lecture and demonstration, and 40 minutes for hands-on session, 5 minutes for wrapping up. The contents covered in the 40-minute lecture were as follows: 1) smartphone internet basics; 2) introduction of the website prepared for this study; 3) evaluation of the credibility of online health information.
223598511|NCT06531317|DEVICE|transcranial Direct Current Stimulation|The treatment follows an approved neuromodulation protocol at our center (approved on Nov. 4 2021, valid until Nov. 4 2024). tDCS will be administered with a battery-powered DC stimulator (Sooma tDCS, Helsinki, Finland), using saline-saturated circular electrodes with a diameter of 6 cm². The anode will be positioned over C3 to stimulate the primary motor cortex (M1), and the cathode over the contralateral supraorbital area (FP2). For asymmetric pain, stimulation targets the M1 contralateral to the more painful side, and for symmetric pain, the dominant hemisphere (C3) is stimulated. The maximum current is 2 mA (current density: 0.06 mA/cm²). Each session lasts 30 minutes, conducted daily for two weeks (Monday to Friday), totaling 10 sessions. All stimulation parameters adhere to general safety guidelines for transcranial electrical stimulation (Bikson et al., 2016).
223598512|NCT06531317|DIAGNOSTIC_TEST|Electroencephalography|64-channel active-electrode EEG with impedances kept \~5KOhm
224198749|NCT06374576|BEHAVIORAL|Digital intervention on eHealth literacy|1-week digital intervention, which are multiple messages about the lecture topic will be provided
224198750|NCT06374576|BEHAVIORAL|Lecture on general health|A lecture session that focus on the general health but not eHealth literacy will be provided
223598513|NCT03317782|DEVICE|NoL index|The NoL/PMD-200 (Medasense Biometrics Ltd, Ramat Yishai, Israel) is a multi-parameter index (0-100) that incorporates heart rate, heart rate variability (0.15-0.4 Hz band power), plethysmograph wave amplitude, skin conductance level, number of skin conductance fluctuations (NSCF), and their time derivatives9 using a non-linear regression technique. A higher index indicates higher nociception, and an index \<20 indicates adequate analgesia.
223598514|NCT04020497|BEHAVIORAL|Ensemble programme|Ensemble is a individualized programme to address informal caregiver's specific unmet needs, emotions and social resources, in order to offer a targeted support in five sessions.
223598515|NCT04020497|OTHER|SAU|"Informal caregivers have often to manage the situation in usual different ways. Support as usual (SAU) alone consists of an informal support by patient's clinical team. Specific psychoeducational programs depending on patient's illnes (like Profamille for schizophrenia) or peer-support depending to the voluntary work of families' associations. Some general professional services focused on informal caregivers or relatives in order to inform and orient them if they are avaible in the study area. No attempts have been made to standardize this treatement as SAU depend to informal caregiver's need and knowledge of the health system, also her/his capacity or possibility to be in contact with patient's clinical team."
223598516|NCT01846741|DEVICE|M106 VNS Therapy System|
223598517|NCT00696839|BEHAVIORAL|Cognitive-behavioral therapy|3 sessions of CBT: introduction of CBT, training in relaxation and guided imagery, and troubleshooting/closure. 50 minute sessions with an HIV-experienced treating psychologist in Beck-type CBT. Participants will be given an audiorecording of the 2nd session to be used in private home practice, as desired.
223598518|NCT00088894|DRUG|gemcitabine hydrochloride|Given IV
223598519|NCT00088894|BIOLOGICAL|bevacizumab|Given IV
223598520|NCT00088894|OTHER|placebo|Given IV
223598521|NCT00088894|OTHER|laboratory biomarker analysis|Correlative studies
223598522|NCT00088894|OTHER|pharmacogenomic studies|Correlative studies
223598523|NCT00088894|OTHER|pharmacological study|Correlative studies
223598524|NCT00500825|PROCEDURE|Measurement of Resting Energy Expenditure|Non-invasive measurement of Resting Energy Expenditure
223598525|NCT05564585|OTHER|Kinesio Taping|Kinesio tape was applied over the calf muscle of either leg.
223598526|NCT05564585|OTHER|Sham Taping|The sham tape was applied over the calf muscle of either leg.
224198751|NCT06374576|BEHAVIORAL|Digital intervention on general health|1-week digital intervention, which are multiple messages about the lecture topic will be provided
224198752|NCT04932603|OTHER|Standard of care, with intervention of the multidisciplinary team|Patients with AF, aged of 75 years or more, with evaluation of their antithrombotic treatment by the multidisciplinary team. The review of patient's file by the multidisciplinary team is based on physician decision. These patients are hospitalized in one of the 6 geriatrics units participating in the study and / or are hospitalized in another ward but their clinical file is reviewed by the multidisciplinary team.
224198753|NCT06440005|DRUG|AGX101|Antibody Drug Conjugate
224198754|NCT06076889|BEHAVIORAL|Power over Pain Portal|Youth from different ages, sexes, gender, sexual orientations, races, dwelling and school/employment status will receive access to the portal for 2 months. The portal consists of self-assessment tools (bi-weekly check-ins to provide users with feedback on their mood, anxiety, pain, and sleep and guide decision making on choice of interventions), evidence-based virtual educational (pain neuroscience) and cognitive behavioural therapy (CBT) pain interventions that are delivered in a stepped care manner based on participant needs/preference.
223598527|NCT02376803|DRUG|Warfarin|Morning vs Evening administration
223598528|NCT01822392|BEHAVIORAL|Online Parent Management Training (Interactive)|
223598529|NCT01822392|BEHAVIORAL|Online Parent Management Training (Recorded)|
223748316|NCT04762680|BIOLOGICAL|SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03 Alternative Exploratory Formulation 1|Pharmaceutical form: Emulsion for injection Route of administration: Intramuscular injection
223748317|NCT04762680|BIOLOGICAL|SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03 Alternative Exploratory Formulation 2|Pharmaceutical form: Emulsion for injection Route of administration: Intramuscular injection
223748318|NCT04762680|BIOLOGICAL|SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03 Alternative Exploratory Formulation 3|Pharmaceutical form: Emulsion for injection Route of administration: Intramuscular injection
223748319|NCT04762680|BIOLOGICAL|SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03 Alternative Exploratory Formulation 4|Pharmaceutical form: Emulsion for injection Route of administration: Intramuscular injection
223598530|NCT04917913|DIETARY_SUPPLEMENT|Digestive enzyme blend|Subjects will take 3 capsules (one per meal) of digestive enzymes (50mg) daily for 30 days.
223598531|NCT04917913|DIETARY_SUPPLEMENT|Placebo|Subjects will take 3 capsules (one per meal) of a placebo (50mg) daily for 30 days.
223598532|NCT01618149|RADIATION|dual energy x-ray absorptiometry|before the surgery of total knee arthroplasty and after the surgery 6 months and 12 months
223598533|NCT01839149|DRUG|TI-001|TI-001 is intranasal oxytocin
224198755|NCT06247930|DIETARY_SUPPLEMENT|Vitamin D3|2000 IU per day for 6 weeks (two capsules of 800 IU plus one capsule of 400 IU), followed by 800 IU (one capsule of 800 IU) per day for 6 weeks.
223598534|NCT01839149|DRUG|Placebo|
223598535|NCT01628965|DRUG|SPM 962|SPM 962 transdermal patch once a daily up to 36.0 mg/day
223598536|NCT05262283|OTHER|No intervention|No intervention was made.
223598537|NCT02823379|BEHAVIORAL|Physical Activity|A Smartphone delivered physical activity program
223598538|NCT02823379|BEHAVIORAL|Wellness|A Smartphone delivered wellness intervention focused on topics other than physical activity (e.g., skin care, oral health, and breast exams).
223598539|NCT00075738|DRUG|cisplatin|
223598540|NCT00075738|DRUG|fluorouracil|
223598541|NCT00075738|DRUG|irinotecan hydrochloride|
223598542|NCT00075738|DRUG|leucovorin calcium|
223598543|NCT05944627|BIOLOGICAL|FURESTEM-OA Kit Inj.|FURESTEM-OA Kit Inj. is a combination medical product in which FURESTEM-OA Inj. (solution 1) is the primary mode of action and CAM Inj. (solution 2) acts as an auxiliary. The product is administered after mixing solution 1 and solution 2.
223598544|NCT05944627|BIOLOGICAL|Placebo|placebo administration in Phase 2a clinical trial
223598545|NCT04330027|BIOLOGICAL|Growth factors|A new patented product named lyophilized Growth Factors that is an advanced and refined form of conventional platelet-rich plasma
224198756|NCT06247930|DIETARY_SUPPLEMENT|Vitamin D3 placebo|Three capsules for 6 weeks, followed by one capsule for 6 weeks.
224198757|NCT06247930|BEHAVIORAL|Mental health education|The mental health education consists of providing a brochure and videos containing information about mental health problems.
224198758|NCT06894446|DIETARY_SUPPLEMENT|Numeta G13%E|Dose selected and dosing schedule are as deemed appropriate by the ordering attending physician in conjunction with the Investigator.
224198759|NCT06894446|DIETARY_SUPPLEMENT|Compounded Parenteral Nutrition (cPN) solution|Will be administered as institutional SOC procedure for the hospital.
223598546|NCT04330027|OTHER|Saline|0.9% Sodium Chloride
223598547|NCT05122429|BEHAVIORAL|e-Health Treatment|Self-guided e-health treatment with two of the arms providing delayed (44min) text or video support from a therapist.
223598548|NCT01402739|OTHER|Point of Care Coagulation Monitoring Guided Transfusion Algorithm|(thromboelastometry, aggregometry, blood gas analysis)
223598549|NCT01402739|OTHER|standard coagulation monitoring guided transfusion algorithm|aPTT, ACT, platelet count, hemoglobin, fibrinogen
223598550|NCT03057782|DEVICE|Waveguard (TM) EEG cap|The device is an EEG cap - a non-invasive EEG positioning system used to quickly place a large number of surface electrodes in a quick and consistent manner on the head. The device will measure electrophysiological signals from the scalp at the time points in the study listed in the protocol.
223598551|NCT03057782|DEVICE|Micro Movement Sensor|This device is not FDA approved. This device is in clinical use for all age groups and used for research purposes by neurologists, physiologists and anesthesiologists. In this study, the device is used to monitor breathing and movement in children; the device is not used for validation purposes.
223598552|NCT03057782|DEVICE|Pico Movement Sensor|This device is not FDA approved. This device is in clinical use for all age groups and used for research purposes by neurologists, physiologists and anesthesiologists. In this study, the device is used to monitor respiration rate and gross body movement in children. The device will not be used for validation purposes.
223598553|NCT03057782|DEVICE|QS Piezostimulator|This device is not FDA approved. This device is used for research purposes by neurologists and physiologists. It is a mechanical tactile stimulator for use in functional imaging experiments like MEG, fMRI or EEG. The stimulation is realized by using several different pin matrices. In this study, the device is used to stimulate the children's extremities in order to elicit somatosensory evoked responses.
223598554|NCT03057782|DEVICE|tactileTM sensory evaluator|This device is not FDA approved. This device is used for clinical and research purposes by neurologists and physiologists. It is used to stimulate the children's extremities in order to elicit somatosensory evoked responses.
223598555|NCT00365274|DRUG|Cyclophosphamide|Given IV 750 mg/m\^2 day 1
223748320|NCT04762680|BIOLOGICAL|SARS-CoV-2 adjuvanted recombinant protein vaccine, bivalent (D614+B.1.351)-AS03|Pharmaceutical form: Emulsion for injection Route of administration: Intramuscular injection
223598556|NCT00365274|DRUG|Doxorubicin hydrochloride|Given 50 mg/m\^2 IV day 1
223598557|NCT00365274|DRUG|vincristine sulfate|Given 1.4 mg/m\^2 IV
223598558|NCT00365274|DRUG|prednisone|100 mg orally daily days 1 - 5
223598559|NCT00365274|DRUG|SGN-30|12 mg/kg weekly IV over 2 hours once weekly for 3 weeks.
223598560|NCT01884272|DRUG|lesinurad 400 mg|
223598561|NCT01884272|DRUG|naproxen 250 mg|
223598562|NCT01884272|DRUG|indomethacin 25 mg|
223598563|NCT00196508|DEVICE|High Viscosity DERMABOND|
223598564|NCT00360568|DRUG|Levodopa-carbidopa intestinal gel|Infusion should be kept within a range of 0.5-10 mL/hour (10-200 mg levodopa/hour) and is usually 2-6 mL/hour (40-120 mg levodopa/hour).
223598565|NCT00360568|DEVICE|CADD-Legacy® 1400 ambulatory infusion pump|
223598566|NCT00360568|DEVICE|PEG tube|percutaneous endoscopic gastrostomy tube
223598567|NCT00360568|DEVICE|J-tube|jejunal tube
223598568|NCT01399320|PROCEDURE|cyanoacrylate|excision of the sinus under local anesthesia the packing of the wound by cyanoacrylate dressing
223598569|NCT01642108|DRUG|Sitagliptin|50 mg once per day
223748321|NCT05102110|DIAGNOSTIC_TEST|Oricol Test|Assessment of rectal mucus for material from aero-digestive cancers.
223748322|NCT02082210|DRUG|Emibetuzumab|Administered Intravenously (IV)
223748323|NCT02082210|DRUG|Ramucirumab|Administered Intravenously (IV)
224198760|NCT06909539|DEVICE|Home Pelvic Floor Trainer|"The intervention utilizes a perineometer device with biofeedback features.~This device employs external electrodes to measure pelvic floor muscle strength. It then provides real-time feedback through a smartphone application during exercise sessions. The application uses gamification to engage users and track progress. Patients can choose between two games: a bird game or a space-themed game. In the bird game, patients activate their pelvic floor muscles to make the bird fly upward. In the space game, pelvic floor contractions fire a laser or activate a shield. A visual bar displays the strength of pelvic floor contractions. Games are designed to be played for 5 minutes daily, 7 days a week, with increasing difficulty as the user progresses through levels."
224198761|NCT06830174|DEVICE|Starstim system|Transcranial direct current stimulation (tDCS)
224198762|NCT06027619|DRUG|Topical aminolevulinate (10% ALA gel)|10% ALA gel to the entire face, without occlusion, followed by a prespecified incubation period
224198763|NCT06027619|DEVICE|Red light illumination|Illumination of red light of narrow spectrum of 635 nm with a light dose of approximately 37 J/cm2
224198764|NCT06910605|DRUG|"drug holidays (D)"|Participants omit three consecutive daily doses of ADHD-medication (stimulant).
224198765|NCT06876597|DEVICE|Motor-cognitive interactive robot|Motor-cognitive interactive robot-assisted training integrates motor and cognitive rehabilitation using an upper limb rehabilitation robot. If patients cannot actively lift the robotic arm, an eye-tracking mode detects movement intention and guides the arm along predefined trajectories, adjusting motor and cognitive loads dynamically. As motor function improves, training shifts to an active mode with increased resistance. Patients complete cognitive tasks before moving the robotic arm, while the system monitors movement parameters and provides real-time feedback. Training consists of 60-minute sessions, five days per week for four weeks. Motor load progresses by increasing robotic arm speed or resistance, while cognitive load advances based on task accuracy, ensuring personalized and adaptive rehabilitation.
224198766|NCT06876597|DEVICE|Motor-focused robot|Motor-focused robot-assisted training primarily emphasizes motor rehabilitation through the use of an upper limb rehabilitation robot. When patients are unable to actively lift the robotic arm, an eye-tracking mode is employed to guide movements, with adjustments made solely to the motor load. As motor function improves, the training transitions to an active mode, progressively increasing resistance while maintaining a constant, minimal level of cognitive difficulty. Patients are required to complete cognitive tasks before initiating movement of the robotic arm, while the system monitors key movement parameters and provides real-time feedback. Training consists of 60-minute sessions, five days per week for four weeks. Motor load is progressively increased by adjusting the speed or resistance of the robotic arm, while cognitive load remains consistently at the lowest level throughout the training.
224198767|NCT06876597|BEHAVIORAL|Conventional rehabilitation training|Conventional rehabilitation training adheres to internationally established guidelines and employs task-oriented approaches tailored to activities of daily living (ADLs). The therapeutic regimen incorporates fundamental motor skill exercises, including but not limited to grasp-and-release maneuvers, targeted reaching, fine motor skill development (e.g., button manipulation, zipper operation), and bilateral coordination tasks (e.g., garment folding, towel wringing). The intervention protocol emphasizes progressive task difficulty and functional task integration, with each session lasting 60 minutes. The treatment schedule consists of daily sessions, five times per week, over a four-week duration.
223598570|NCT02068287|DRUG|Esmolol|After, at least six hours of hemodynamic optimization, patients with an hyper dynamic shock received a conventional management with a continuous infusion of Esmolol titrated to gain a 20% reduction in heart rate. This infusion is maintained for six hours.
223598571|NCT05606055|DRUG|BIC/FTC/TAF: Bictegravir/emtricitabina/tenofovir alafenamida fumarato|This is a study to assess the impact of immediate ART (FAST ART or SDT) against conventional treatment (CT) on the time to reach an undetectable HIV-1 viral load.
223598572|NCT04006392|DEVICE|Erchonia FX-635|The Erchonia FX-635 has three independent 17 milliWatts (mW) 635 nanometer (nm) red laser diodes mounted in scanner devices.
223598573|NCT04006392|DEVICE|Placebo Laser|Non-therapeutic output.
223598574|NCT05508893|RADIATION|CT Angiography|A CTA will be performed on asymptomatic individuals
223598575|NCT05508893|DIAGNOSTIC_TEST|Exercise stress test|A routine exercise stress test will be performed on a bicycle
223598576|NCT00951652|BEHAVIORAL|CBT|
223598577|NCT00951652|OTHER|Interpersonal and emotional processing therapy|
223598578|NCT00951652|BEHAVIORAL|supportive listening|
223748324|NCT02397330|DRUG|bupivacaine|
223748325|NCT02397330|DEVICE|ultrasound|ultrasound guided nerve blocks
223598579|NCT00002961|DRUG|cyclophosphamide|Arms A and B Day 2 and 3: Cyclophosphamide 60 mg/kg intravenously; Administer 20 mg/ml concentration over 2 hours.
223598580|NCT00002961|DRUG|cyclosporine|"graft vs. host disease (GVHD)prophylaxis: starting on day-1, cyclosporin 1.5 mg/kg IV every 12 hours or by continuous infusion.~When the patient tolerates adequate oral intake, cyclosporin therapy may be changed from IV to oral administration. Cyclosporin therapy should be continued at full dose until day +50. if the patient has less than Grade 2 GVHD, cyclosporin may be tapered by 5-10% weekly until completely off cyclosporin therapy."
223598581|NCT00002961|DRUG|etoposide|Day 4 (arms A/B): 40 mg/kg over four hours intravenously
223598582|NCT00002961|DRUG|methotrexate|"methotrexate 15 mg/m2 IV on day +1 (do not give until 24 hours after marrow infusion), and 10mg/mg2 IV on days +3 and +6.~Methotrexate may be held after two doses for bilirubin .2 mg/dL. If serum creatinine is \>2x baseline, methotrexate will be omitted. If the presence of ascites or pleural effusion, methotrexate will be omitted."
223748326|NCT02397330|DRUG|morphine|
223748327|NCT04190134|BEHAVIORAL|Socially Assistive Robot for Low Vision Rehabilitation|A socially assistive robot will be customized to engage in dialog and conversations to motivate and encourage optimal use of new magnification devices for reading at home by individuals with vision loss.
223748328|NCT06311890|DRUG|N-chlorin e6 triglumine|a photodynamic therapy with chlorin-e6
223748329|NCT06311890|PROCEDURE|acne removal surgery|acne removal surgery will be given before red light exposure
223598583|NCT00002961|PROCEDURE|allogeneic bone marrow transplantation|Bone marrow infusion given on day 0
223598584|NCT00002961|RADIATION|Total Body Irradiation|Day 0: Marrow Transfusion; Day 1: rest; Day 2 and 3: Cyclophosphamide 60 mg/kg; Day 4: Etopophos 40 mg/kg over four hours; Day 5,6 and 7: Total Body Irradiation (TBI) \[200 cGy twice a day (BID)\].
223598585|NCT00002961|DRUG|Busulfan|"Conditioning Regimen Arm B:~Day 0: Marrow infusion; Day 1: Rest; Day 2 and 3: Cyclophosphamide 60 mg/kg; Day 4: Etopophos 40 mg/kg over four hours; Day 5,6,7 and 8: Busulfan 0.8 mg/kg intravenous (IV) every 6 hours x 4 doses.~Patients \</= 20kg to receive busulfan 1.0 mg/kg/dose IV\*\*Busulfan oral preparation may be substituted: 1mg/kg/dose by mouth (po) for patients \>20kg and 1.25 mg/kg/dose by mouth (po) for patients \</= 20 kg."
223598586|NCT00002961|DRUG|Mesna|Dosing per institutional preference for hemorrhagic cystitis. Mesna 300 mg/m2 as a 15 minute infusion prior to each dose of cyclophosphamide, then at 3,6,9,12, 18 and 21 hours after initiation of each cyclophosphamide infusion. Alternative method of Mesna administration is 10 mg/kg prior to cyclophosphamide and 100 mg/kg/24 hours by continuous infusion.
223598587|NCT00002961|RADIATION|Radiation|"Central Nervous System (CNS) therapy:~a) CNS Leukemia prior to study entry: No TBI i) No prior CNS irradiation: 2340 centigray (cGy) in 13 fractions of 180 cGy to the cranial field and 600 cGy in 200 cGy fractions to the spinal field prior to conditioning. II) \>/= 1800 cGy prior CNS irradiation: 1800 cGy to cranial field and 600 cGy spinal prior to conditioning. If prior radiation therapy (RT) doses \>3000 cGy have been administered or CNS Leukemia prior to study entry: TBI, consult with Principal Investigator (PI). Recommend: 1) no prior CNS irradiation: 600 cGy in 3 fractions to the cranial field prior to conditioning or overlapping with TBI.~Testicular Boost Irradiation: a) overt testicular leukemia at relapse: No TBI 2400 cGy in 12 fractions prior to conditioning; b) overt testicular leukemia at relapse: TBI 1200 cGy in 6 fractions over 8-10 days prior to conditioning. c) No overt testicular leukemia: 200 cGy first and last fractions of TBI-"
223598588|NCT02878837|DRUG|Dexmedetomidine|
223598589|NCT02878837|DRUG|Midazolam|
223598590|NCT05474222|OTHER|Horizon Eagle Fatherhood Program - classroom instruction|The intervention group (the Horizon Eagle Fatherhood Programming) receives 40 hours of classroom instruction
223598591|NCT02920515|DRUG|Triptorlin or Leuprorelin|Gonadotrophin releasing hormone agonists (GnRHa)
223598592|NCT02920515|DRUG|Zhibo dihuang pills|Traditional Chinese Medicine
223598593|NCT02920515|DRUG|Dabu ying pills|Traditional Chinese Medicine
223598594|NCT05347303|OTHER|Finding-oriented orthopedic manual therapy treatment combined with foam roller|Blind randomized controlled clinical trial, where a total of 87 people, men and women, of legal age, university athletes of collective disciplines will be evaluated. The experimental group will receive foam roller therapy and manual therapy guided by findings (n = 44) for 8 weeks.
223598595|NCT05347303|OTHER|Foam roller treatment|Subjects will perform slides on the instrument using their body weight on the following muscles: quadriceps, hamstrings, gastrocnemius, and tensor fascia lata, for 60 seconds with 3 repetitions for each. Each repetition will have a rest period of 30 seconds, this will be done on both lower limbs.
223598596|NCT01683578|OTHER|Variable Ventilation|
223598597|NCT01158391|DEVICE|NTrainer® Intervention|
223598598|NCT01158391|DEVICE|Control Intervention|
223598599|NCT04514211|DRUG|Propofol|General anesthesia using propofol infusion
223598600|NCT04514211|DRUG|Sevoflurane|General anesthesia using sevoflurane
223598601|NCT03302637|OTHER|16S rRNA gene sequencing assay|extraction of genomic DNA from oral samples using the Mobio DNA Isolation Kit. 16S rRNA amplicons covering variable regions V3 to V4 will be generated using primers (347F-5'GGAGGCAGCAGTRRGGAAT'-3' and 803R 5'-CTACCRGGGTATCTAATCC-3')66 incorporating adapters and a sample barcode sequence at PI's lab. Amplicons will be sequenced with the Roche 454 FLX Titanium sequencing system at the NYU genome technology center, following the manufacturer's specifications.
223598602|NCT02343198|DEVICE|Custom-built research muscle stimulator|Muscle stimulator
223598603|NCT04379076|DRUG|Interleukin-7|Intramuscular (IM) administration of CYT107 at 3 μg/kg followed, after 48hrs of observation, by 10 μg/kg twice a week for 2 weeks or
223598604|NCT04379076|DRUG|Placebos|Intramuscular (IM) placebo (normal saline) at the same frequency
223598605|NCT01734759|DRUG|Taste Test|"Before the taste test each participant will fill out an informed consent form and an enrollment survey. Each participant will receive 0.5 mL of each study medication in the taste test. During the taste test each medication in a class will be labeled with a color name so as to prevent any bias from preconceived taste perception. They will record their perception of the medications taste on a visual analog scale (VAS). An anaphlyaxis kit will be on hand in case of emergencies. Between samples participants will cleanse their palate with a saltine cracker and 30 mL of water. 5 different classes of medications will be tested.~Medications to be sampled and the corresponding dose of the test dose are:~* Cephalosporins: cefdinir 12.5 mg, cefixime 10 mg~* Penicillins: penicillin VK 12.5 mg, amoxicillin 12.5 mg~* Analgesic/antipyretics: acetaminophen 16 mg, ibuprofen 10 mg~* Steroids: prednisolone 1.5 mg, prednisone 0.5 mg~* H2 receptor blockers: famotidine 4 mg, ranitidine 7.5 mg"
224198768|NCT06929988|OTHER|Creanz Lotion|"Mode of Usage: Apply sufficient quantity of Creanz Nourishing Body lotion to face and body for smooth and moisturised skin.~Frequency: Twice a Day Route of Administration: Topical"
224198769|NCT06933225|OTHER|WOW fusion Microneedling Device, 1.00 mm|One treatment session on the whole face, on D0 and second treatment on D30.
224198770|NCT06935877|DRUG|Hyaluronic acid injection|traditional rehabilitation programs
224198771|NCT06935877|DRUG|Triamcinolone Acetonide injection|traditional rehabilitation programs
223598606|NCT02794545|PROCEDURE|cART course|The investigators would start regular cART course immediately for early infection patients to achieve functional cure.
223598607|NCT01694836|BIOLOGICAL|s.c. injection|3 years of therapy followed by 2 years (seasons) of treatment-free observational period
224198772|NCT06941935|OTHER|Etiological Classification and Digital Intervention|Eligible participants will first undergo a 1-week home blood pressure diary and 24-hour ambulatory blood pressure assessment. After a confirmed diagnosis of hypertension, etiological subtyping will be performed. Based on the blood pressure evaluation results and etiological classification, the most appropriate antihypertensive medication will be selected. Simultaneously, a personalized lifestyle prescription will be provided according to the patient's individual circumstances. Following medication initiation, participants will continue to monitor their blood pressure through home diaries. Monthly evaluations will be conducted, and if blood pressure fails to reach the target value, medication adjustments will be made based on the blood pressure diary until target levels are achieved. This regimen will be maintained long-term.
224198773|NCT06942416|DRUG|Paclitaxel and Cisplatin/ Carboplatin|Paclitaxel and Cisplatin Paclitaxel: 135 mg/m², intravenous infusion, Day 1, every 3 weeks (Q3W). Cisplatin: 75 mg/m², intravenous infusion, Days 1-3, every 3 weeks (Q3W). Carboplatin 0.3-0.4g/m², intravenous infusion, Day 1, Q3W .Duration: 4-6 cycles.
224198774|NCT06942416|DRUG|Iparomlimab and Tuvonralimab|Iparomlimab and Tuvonralimab 5mg/kg, intravenous infusion, Day 1, Q3W. Duration: Continuous administration until disease progression, death, intolerable toxicity, subject's voluntary withdrawal, investigator's decision for withdrawal, or a maximum of 24 months.
223598608|NCT03934853|DEVICE|Dynamic Dental Navigation|Aid in dental implant placement in humans
223598609|NCT06328309|BEHAVIORAL|Rehabilitation treatment|This group is given rehabilitation treatment. The main intervention measures included: 1) non-invasive ventilator treatment, generally at least once every night and typically not exceeding continuous daily usage.; 2) attention to feeding and sleeping positions, with a recommended sleeping position of lateral recumbent and the head of the bed raised by 20-30°; 3) swallowing function training, such as tongue muscle stretching training, assisted anterior jaw protrusion training, lemon ice stimulation to the soft palate, pharyngeal wall, etc., generally 5 days per week, twice per day, 5-20 minutes each time; 4) pulmonary ultrashort wave therapy, generally at least 2-3 times a week, and not more than once a day; 5) physical therapy, such as intensive training for gross motor functions including lifting the head, turning over, sitting, crawling, standing, etc., generally 3-5 days per week, 1-2 times per day, 5-20 min each time.
223598610|NCT06328309|BEHAVIORAL|Myofascial Release Therapy|Myofascial release, also known as fascial release or fascial manipulation, is a physical therapy used to treat muscle and fascial tissue tension or pain. It involves applying appropriate pressure and stretching to release tight fascia and soft tissues, improving blood circulation, alleviating pain, and promoting rehabilitation. Myofascial release therapy is commonly used to treat muscle spasms, chronic pain, skeletal and joint issues, among others.
223598611|NCT04458415|OTHER|Traxi Panniculus Retractor (TPR)|Surgeon uses the Traxi Panniculus Retractor (TPR) surgical retraction device to retract the panniculus during C-Section.
223598612|NCT04458415|OTHER|Silk Tape|Surgeon uses silk tape to retract the panniculus during C-Section.
223598613|NCT06236490|DIAGNOSTIC_TEST|Blood Oxygen Level Test|The study participants rested for 15 minutes before measuring the BOLT score. During this time they were carefully instructed on how to perform the measurement. It was underlined that we do not measure how long one can hold their breath, but the time it takes for the body to react to lack of air and feel the desire to breathe. After a few normal breaths through the nose, after the exhalation, the participants held their breath until they felt the first definite desire to breathe or felt the first involuntary contractions of the respiratory muscles. The first was assessed by the participants, the latter was also visually assessed by the researchers. The nose was closed with the fingers to prevent any gas exchange. The researchers measured the time with a Finis 3x300M stopwatch (FINIS USA, Livermore, CA, USA). Time in seconds, to one decimal place, was noted as a BOLT score. The visualisation of BOLT is presented in Figure 2.
223598614|NCT06236490|DIAGNOSTIC_TEST|Wingate Anaerobic Test|WAnT was conducted with Monark 874E Cycle Ergometer (Monark Exercise AB, Sweden). Before WAnT, the participants performed a 5-minute warm-up with resistance ranging from 0.8 to 1.2 W/kg. Next, the participants performed a maximal 6-second sprint, with the resistance adjusted to 7.5% of the individual body mass. After a rest interval of 2 to 5 minutes, the participants underwent a 30-second WAnT with resistance set at 7.5% of the individual body mass. They were instructed to attain the highest peak power output as quickly as possible and maintain the highest power output throughout the entire duration of the test. The participants received motivating and enthusiastic verbal support. The following indices were measured and included in the further analysis: peak power (Ppeak), total work (TW), WSSR. All the indices were calculated with the dedicated software (MCE 6.0, JBA Z. Staniak, Poland) linked to the cycle ergometer.
223598615|NCT06236490|DIAGNOSTIC_TEST|Cardiopulmonary Exercise Test|CPET was performed with the Cortex Metamax B3 (Cortex Biophysik GmbH, Leipzig, Germany), breath-by-breath method, and Cyclus II Ergometer (RBM, Leipzig, Germany). Participants underwent an incremental ramp test, commencing at 55-70W and incrementally increasing the load by 0.17-0.28 W·sec-1, individually adjusted for body mass. The participants were instructed to continue the effort until total exhaustion. All the participants fulfilled the maximum effort criteria (Wiecha et al. 2023): 1) respiratory exchange ratio ≥ 1.10, (2) present VO2 plateau (growth \< 100 mL·min-1 in VO2 despite increased cycling power), (3) respiratory frequency ≥ 45 breaths·min-1, (4) declared subjective exertion intensity during CPET ≥ 18 according to the Borg Scale (Borg 1998), (5) blood lactate concentration ≥8 mmol·L-1, (6) peak heart rate ≥ 15 beats·min-1 below predicted maximal heart rate (HRmax) (Lach et al. 2021).
223598616|NCT00879528|OTHER|Patients with negative PET after salvage therapy|"All patients included in the study will treat with a salvage scheme according to each center.~After the end of salvage therapy, consolidation depends on the outcome of PET:~PET negative: These patients will follow a standard treatment that includes high-dose chemotherapy with reinfusion of autologous peripheral stem cells."
224198775|NCT06942416|RADIATION|Radiotherapy|Site Selection: Original site, lymph nodes, lung metastasis, bone metastasis, adrenal metastasis, brain metastasis, and other relatively isolated, well-vascularized lesions. Select at least one suitable lesion for radiotherapy based on the impact of the recurrent or metastatic lesion on the body, prioritizing lesions that cause symptoms, are life-threatening, or are expected to cause symptoms.All tumor lesions will be irradiated, which can be done in phases. Dosage and Fractionation: Conventional or hypofractionated radiotherapy, with a biologically effective dose (BED) of ≥ 72 Gy. Dose adjustments can be made for brain metastases. Timing: After completing relevant baseline examinations, radiotherapy can be implemented generally after 4-6 cycles of systemic therapy, or after the first cycle for small, solitary metastatic lesions. echnique: IMRT, TOMO, SBRT, 3D-BT, interstitial implantation therapy, or proton therapy.
224198776|NCT06942338|DEVICE|Corsano CardioWatch 287-2|Temperature readings from wearable Cardiowatch BT sensor, wearable Radius-T BT sensor, tympanic temperature and rectal temperature will be collected. Each participant will remain in the study as long as the rectal temperature is measured with a maximum of 24 hours. Other than the wearable Cardiowatch, the Radius-T sensors, and the rectal thermometer no additional interventions will take place due to the study. Temperature monitoring of patients will be performed according to hospitals routine care and will not be affected by the study. Patients may receive additional treatment to ensure best care.
224198777|NCT06941883|DRUG|Botulinum toxin injection under anatomical landmark|Patients received botulinum toxin injections under the anatomical landmark.
224311147|NCT05775211|BIOLOGICAL|Intrauterine administration of PBMC immunomodulated with IFNt|Standard density gradient centrifugation will be performed to obtain autologous PBMC from patients' peripheral blood (9 ml). Isolated cells will be suspended in RPMI 1640 supplemented with 10% HSA (human serum albumin) and incubated in the presence of 500 IU/ml IFNt for 24 h at 37˚C. The cultured cell suspension will be introduced into the uterine cavity via a catheter.
223598617|NCT00879528|OTHER|Patients with positive PET after salvage therapy|"All patients included in the study will treat with a salvage scheme according to each center.~After the end of salvage therapy, consolidation depends on the outcome of PET~PET positive, the consolidation therapy consists of 2 phases:~* phase1:common to all consists in a series of high-dose chemotherapy with Melphalan 200 mg/sqm, followed by reinfusion of autologous peripheral stem cells~* phase2:depends on the availability of a compatible donor. If there is a donor, the patient will continue with an allogeneic transplant preceded by a reduced intensity conditioning.~If there is not a donor, the patient will continue with a second round of high-dose chemotherapy with BEAM with reinfusion of autologous peripheral stem cells."
223598618|NCT00486668|DRUG|doxorubicin|60 mg/m2 IV every 21 days for cycles 1-4
223598619|NCT00486668|DRUG|cyclophosphamide|600 mg/m2 IV every 21 days for cycles 1-4
223598620|NCT00486668|DRUG|paclitaxel|80 mg/m2 IV on days 1, 8, and 15 every 28 days for cycles 5-8
223598621|NCT00486668|DRUG|trastuzumab|First dose: 4 mg/kg IV, subsequent doses: 2 mg/kg IV weekly beginning on day 1 of the first paclitaxel cycle until 1-7 days before surgery
223598622|NCT00486668|DRUG|lapatinib|Group 2: 1250 mg PO daily beginning on day 1 of the first paclitaxel cycle until 1 day before surgery. Group 3: 750 mg PO daily beginning on day 1 of the first paclitaxel cycle until 1 day before surgery.
223598623|NCT03455816|DEVICE|Social Diabetes App|"Social diabetes is an app for diabetes, free with CE mark, that by means of the incorporation of a glucometer (glucomen Areo) allows through NFC technology the automatic introduction of data in the application"
223598624|NCT03455816|DEVICE|Usual clinical monitoring group (Control group)|Active Comparator: Usual clinical monitoring group (control group) This group does not use the App. This group have an intermediate visit at 3 months with de doctor to see blood glucose self-monitoring and propose adjustments
223598625|NCT03012867|OTHER|Diben, Fresenius Kabi|Patients receive Diben continously for 7 days
223598626|NCT03012867|OTHER|Fresubin original fibre, Fresenius Kabi|Patients receive Fresubin original fibre continously for 7 days
223598627|NCT05279950|DEVICE|Full-mouth ultrasonic debridement with piezoelectric device (EMS, mini piezon)|the use of ultrasonic oscillating tips allows supragingival and subgingival biofilm and dental calculus removal
224198778|NCT06941883|DRUG|Ultrasound-guided botulinum toxin injection|Patients received ultrasound-guided botulinum toxin injection
224198779|NCT06942533|DEVICE|EMST with SpiroGym app|"Participants will performe an expiratory muscle training using an Expiratory Muscle Trainer (EMST150; Aspire Products, LLC, United States). Participants will be instructed to perform five sets of five forceful expirations coupled with SpiroGym app.~The SpiroGym app video feedback: During a correct performance of the expiratory manoeuvre with the expiratory handheld device, the exhalation valve opens, and the air flow increases the sound level detected by the microphone. Simultaneously, the application gives visual feedback on the mobile phone screen in real time using a curve depicting the current sound level, and the task of the patient is to keep the curve in the training zone depicted by two lines corresponding to the low and high level, respectively."
224198780|NCT06942533|DEVICE|EMST without SpiroGym app|Participants will performe an expiratory muscle training using an Expiratory Muscle Trainer (EMST150; Aspire Products, LLC, United States) without video feedback . Participants will be instructed to perform five sets of five forceful expirations.
224198781|NCT06943313|DIAGNOSTIC_TEST|68Ga-pAKTi PET/CT probe|A total of 20 patients with breast cancer will be enrolled. Screening will be conducted within 14 days prior to administration of 68Ga-pAKTi (from Day -14 to Day -1). Subjects who meet all inclusion criteria and none of the exclusion criteria will receive an intravenous injection of 68Ga-pAKTi on Day 0, followed by PET/CT imaging.
224311148|NCT06851442|DRUG|TQB3912 tablets in combination with fulvestrant injection± TQB3616 capsules|Protein kinase B(AKT) inhibitors+Cyclin-dependent kinase 4/6(CDK4/6) Inhibitor+Estrogen receptor antagonists.
224311149|NCT06417086|OTHER|Acupuncture|The main acupoints are DU 24, EX-HN 3, DU 20, EX-HN 1, GB 12, HT 7, KI 6, GB39, and then selecting other acupoints according to TCM syndrome. There will be 12 weeks of 3-session treatment for each participant in total.
224311150|NCT06417086|OTHER|Sham Acupuncture|The Streitberger placebo needle will be used to simulate an acupuncture procedure without penetrating the skin. The main acupoints are DU 24, EX-HN 3, DU 20, EX-HN 1, GB 12, HT 7, KI 6, GB39, and then selecting other acupoints according to TCM syndrome. There will be 12 weeks of 3-session treatment for each participant in total.
224311151|NCT06417086|DRUG|Donepezil|Donepezil 5 mg will be given once daily before bed-time for 12 weeks.
224311152|NCT03679676|DRUG|Omalizumab|Omalizumab is injected every 2 to 4 weeks
223598628|NCT05279950|DEVICE|Full-mouth ultrasonic debridement with magnetostrictive device (Cavitron Select, Dentsply)|the use of ultrasonic oscillating tips allows supragingival and subgingival biofilm and dental calculus removal
224198782|NCT06941636|DRUG|5U/0,1 ml Botulinum toxin A|Botox® 100 U (AbbVie) will be dissolved in 2 milliliters of room-temperature sterile isotonic saline, resulting in a solution concentration of 5 U/0.1 mL. Each patient will receive a total dose of 50 U, administered bilaterally into the masseter and temporalis muscles.
224198783|NCT06941636|DRUG|10U/0,1 ml Botulinum toxin A|Botox® 100 U (AbbVie) will be dissolved in 1 milliliters of room-temperature sterile isotonic saline, resulting in a solution concentration of 10 U/0.1 mL. Each patient will receive a total dose of 100 U, administered bilaterally into the masseter and temporalis muscles.
224198784|NCT06941948|OTHER|PSQI|PSQI
223598629|NCT01985568|BEHAVIORAL|Sequential BT|Both study arms (Standard BT and Sequential BT) will receive an identical 6 month group-based weight loss program, followed by an identical 6 month group-based weight maintenance program, followed by an identical 6 months of weight maintenance phone support. Both groups will also receive an identical 6 month exercise intervention. Groups will differ only in the timing of exercise initiation. Sequential BT will be asked not to begin exercise during months 0-6. They will receive a progressive exercise program and exercise behavior support during months 7-12.
224311153|NCT03679676|DRUG|Dupilumab|"Dupilumab is injected every 2 weeks~combination, or placebo."
224311154|NCT03679676|OTHER|Placebo|Placebo is injected every 2 to 4 weeks
224198785|NCT06943586|GENETIC|CYP2C19 Genotype Guided DAPT (dual antiplatelet therapy)|CYP2C19 is a gene that encodes an enzyme responsible for metabolizing several medications, including the antiplatelet drugs.
224198786|NCT06941649|PROCEDURE|Expansive open-door laminoplasty via intermuscular space approach|The cervical laminoplasty via intermuscular space approach will apply bilateral blunt dissection to create the operative space between capital semispinalis muscle and cervical semispinalis muscle
224198787|NCT06941649|PROCEDURE|cervical single-door laminoplasty via the conventional approach|The cervical laminoplasty via the conventional approach will apply median dissection of the cervical spinous ligament and seperate muscles to expose the whole lamina of cervical vertebrae.
223598630|NCT01985568|BEHAVIORAL|Standard BT|Both study arms (Standard BT and Sequential BT) will receive an identical 6 month group-based weight loss program, followed by an identical 6 month group-based weight maintenance program, followed by an identical 6 months of weight maintenance phone support. Both groups will also receive an identical 6 month exercise intervention. Groups will differ only in the timing of exercise initiation. Standard BT will begin exercise immediately upon starting the 6 month dietary weight loss intervention. They will receive a progressive exercise program and exercise behavior support during months 0-6.
223598631|NCT01940081|OTHER|Transthoracic echocardiography|
223598632|NCT01940081|OTHER|Exercise test|
223598633|NCT01940081|OTHER|24-hour Holter electrocardiogram|
223598634|NCT01940081|OTHER|Contrast-enhanced magnetic resonance imaging|
223598635|NCT01940081|OTHER|123-iodine metaiodobenzylguanidine imaging|
223748330|NCT01168635|BEHAVIORAL|Spirometry 360 program - Virtually-delivered spirometry quality improvement program|"The Spirometry 360 program includes:~1. Spirometry Fundamentals™: A basic guide to lung function testing, a computer-based training program that teaches primary care providers how to coach patients to produce high-quality spirometry tests and accurately interpret spirometric data;~2. Spirometry Learning Lab: Case-based teaching of spirometry in practice guides test administrators and interpreters through clinical examples in an interactive virtual classroom setting. These sessions are led by expert clinical faculty and are archived for future reference and review;~3. Spirometry Feedback: Tailored analysis of providers' spirometry testing sessions offers monthly individualized feedback reports by clinical experts on spirometry tests performed in the clinic."
223748331|NCT04475133|OTHER|Ultrasound guided percutaneous neuromodulation|It is a technique that consists in the electrical stimulation of peripheral nerve trunks, inserting an acupuncture needle in its path and using it as an electrode to apply electrical current
223748332|NCT03493828|PROCEDURE|TAP block using Bupivacaine 0.5%|Following completion of the Cesarean delivery, the abdomen was aseptically prepped with ChloraPrep®. A Sonosite ultrasound machine (S-nerve) with a 14-8 MHz linear probe was used to visualize the lateral abdominal wall muscles and transversus abdominis plane. A 2 or 4 inch stimuplex (Braun) needle was advanced under ultrasound guidance to the transversus abdominis plane. After negative aspiration, 15 ml of Bupivacaine 0.5% was incrementally injected on each side. The spread of solution within the transversus abdominis plane was visualized with the ultrasound.
223748333|NCT03493828|PROCEDURE|TAP block using Bupivacaine 0.25%|Following completion of the Cesarean delivery, the abdomen was aseptically prepped with ChloraPrep®. A Sonosite ultrasound machine (S-nerve) with a 14-8 MHz linear probe was used to visualize the lateral abdominal wall muscles and transversus abdominis plane. A 2 or 4 inch stimuplex (Braun) needle was advanced under ultrasound guidance to the transversus abdominis plane. After negative aspiration, 15 ml of Bupivacaine 0.25% was incrementally injected on each side. The spread of solution within the transversus abdominis plane was visualized with the ultrasound.
224198788|NCT06942468|DRUG|Topical nano preparation of Phenytoin|Topical nano preparation of Phenytoin will be used to treat atrophic post-acne scars. It will be in form of spanlastics.
224198789|NCT06942468|DEVICE|Fractional CO2 laser|Fractional CO2 laser will be used alone for treatment of atrophic post acne scars.
224198790|NCT06941870|DRUG|Efanesoctocog alfa|Pharmaceutical form:Lyophilized powder in a sterile vial that requires reconstitution with sterile water for injection (diluent)-Route of administration:Intravenous
224198791|NCT06955936|DEVICE|Efferon CT|"Efferon CT (JSC Efferon, Moscow, RF) is a device for extracorporeal blood purification by direct hemoadsorption. Detoxification is carried out by sorption of cytokines and other products of endogenous intoxication with a molecular size of up to 55 kDa.~The therapy will be performed once no later than 4 hours after the diagnosis of cardiogenic shock.~The duration of hemoadsorption is from 4 to 12 hours. The rate of hemoadsorption is from 80 to 150 ml/min. Anticoagulation is systemic (heparin or sodium citrate)."
224198792|NCT00519948|DRUG|new MPS, opti-free express no rub MPS|
224198793|NCT06065436|DRUG|Collagenase Clostridium Histolyticum|Total of 8 Intralesional injection (0.90 mg), administered as four separate injection series. Within each series, subjects will receive two injections, administered approximately 1-7 days apart.
224198794|NCT06065436|DEVICE|Storz Duolith LiSWT|Single low intensity shockwave therapy consistent of 1,500 shocks at a rate of 120 shocks/minute and using a power setting of 0.09 mJ/mm2. These treatments will occur four separate times, before each of the four separate CCH injection series.
224198795|NCT05442190|DRUG|Hypericin|SGX302 is synthetic hypericin formulated as a 0.25% hypericin ointment or gel.
224198796|NCT05442190|DRUG|Placebo|Placebo ointment is identical to SGX302 ointment (color matched) but it does not contain hypericin.
224198797|NCT04633824|OTHER|Retrospective Electronic Medical Record Review|Patients will be assessed retrospectively for evidence of successful or failed epidural extension in the setting of need for cesarean section
224198798|NCT04224506|OTHER|No intervention|There is no intervention for this study.
224198799|NCT05643651|DRUG|Rivaroxaban Oral Tablet [Xarelto]|Administered in an age- and bodyweight-adjusted, 15 mg-equivalent dose regimen proposed by model- and clinical evidence-informed precision dosing
224198800|NCT05643651|DRUG|Aspirin or Clopidogrel|Aspirin \[3 \~5mg/(kg·d) once daily\] or Clopidogrel \[1.0 mg/kg; once daily\]
223598636|NCT01940081|OTHER|Blood samples|
223598637|NCT01940081|GENETIC|Genetic analysis|
223598638|NCT01940081|PROCEDURE|Invasive electrophysiological study|
223598639|NCT01940081|PROCEDURE|Endomyocardial biopsy|
223598640|NCT01940081|PROCEDURE|Intraoperative biopsy|
224198801|NCT05643651|DRUG|Warfarin|Warfarin 0.05\~0.12 mg/(kg·d) once daily. INR should maintain within 1.5 to 2.5
223598641|NCT01940081|PROCEDURE|Intraoperative mapping and/or ablation|
223598642|NCT03824587|DRUG|Tenapanor|Active Drug
223598643|NCT03824587|DRUG|Placebo|Inactive Drug
223598644|NCT03824587|DRUG|Phosphate Binder Agents|standard of care phosphate binder use at study entry was maintained throughout the entire study
223598645|NCT02338700|BIOLOGICAL|MV|MV is an intravenous intralipid suspension with 5 various vaccines, including DPT (diphtheria, pertussis, and tetanus ), typhoid, Staphylococcus aureus, paratyphoid A and B. Accessories include microbial A, lecithin, Twain-80, span 20 and soy-bean oil for
223598646|NCT02338700|OTHER|standard treatment|Patient will receive a comprehensive histological and imaging check up to evaluate the histological type, stage of the disease and performance status. Then the patient will receive standard treatment, in brief, surgical resection for early stage patients and systemic treatment including chemotherapy for advanced stage patients, according to NCCN guide line.
223598647|NCT03331523|DRUG|Calcipotriene/Betamethasone Dipropionate|Topical suspension 0.005%/0.064% (Glenmark Pharmaceuticals Ltd)
223598648|NCT03331523|DRUG|Taclonex®|Calcipotriene/ betamethasone dipropionate topical suspension, 0.005%/0.064% (LEO Pharma Inc.)
223598649|NCT03331523|DRUG|Placebo|Placebo of Calcipotriene/ betamethasone dipropionate topical suspension, 0.005%/0.064% (Glenmark Pharmaceuticals Ltd.)
223598650|NCT02407782|DRUG|Ivermectin|oral ivermectin, 200μg/kg given at baseline and at day 10.
223598651|NCT02407782|DRUG|Permethrin|topical permethrin 5% cream applied at baseline and at day 10.
224198802|NCT05727865|BEHAVIORAL|Online CBT following cardiac surgery|It will include psychoeducation, behavioral activation to address post-operative fatigue and depression, interoceptive exposure to reduce fear of cardiac-related symptoms and in-vivo exposure to reduce avoided situations, and activities to enhance physical activity and wellbeing. Labeling (i.e., describing post-operative and/or cardiac-related symptoms, thoughts, and feelings) will be used continuously during treatment to enhance the effect of exposure and pain management
224198803|NCT03108664|DRUG|SYL1001 ophthalmic solution|1 drop in the affected eye
224198804|NCT03108664|DRUG|Vehicle opthalmic solution|1 drop in the affected eye
224198805|NCT01970423|DEVICE|CRT|The new device is the first CRT-P that relies on a physiological parameter, respiration, to allow the pacemaker to follow the patient's breath and help create an appropriate pacing rate.
224198806|NCT01970423|DEVICE|conventional right ventricular stimulation|
224198807|NCT05772728|DRUG|Cidapenem combined with azacitidine and mitoxantrone liposome (CAM) regimen|CAM regimen (every 21 days as a treatment cycle). Cetapenem 20 mg orally twice weekly Azacitidine 75 mg/m2 subcutaneously d1-7 Mitoxantrone liposomes 20 mg/m2 intravenous d6
224198808|NCT02568501|BEHAVIORAL|Daily feedback|Daily feedback on glucose levels from wireless glucometers
224198809|NCT02568501|BEHAVIORAL|Financial incentive|Participant receive a $2 daily financial incentive framed as a loss with money allocated upfront and taken away each day of non-adherence to goal
224198810|NCT03379038|OTHER|Progressive Physical Therapy|Stretching of the tight muscle, positioning, abdominal co activation; rolling etc to decrease muscle tone and functional independence.
224198811|NCT03379038|OTHER|Maintenance Physical Therapy|Same Physical therapy protocol but aim was to maintain current level of spasticity and functioning
224198812|NCT05890235|DRUG|Ningmitai Capsule|Ningmitai Capsule (Ningmitai®) is Traditional Chinese Medicine which has already used in treatment of urinary system disease (eg. CPPS, BPH) in China for more than twenty years. The instruction of Ningmitai Capsule is 0.38g/capsule, 4 capsule/time, tid.
224198813|NCT05890235|DRUG|Tamsulosin Hydrochloride|Tamsulosin is α1A-adrenergic receptor which has used in treatment of BPH for few years. The instruction of Tamsulosin Capsule is 1 tablet at a time, 1 time a day.
224198814|NCT00706901|BEHAVIORAL|Arm 1 GMI|Participants randomized to GMI received four structured, back-to-back, 75-minute sessions in one week consistent with the central principles and spirit of MI (Miller \& Rollnick 2013) and based on a manualized protocol (Martino \& Santa Ana 2013; Santa Ana \& Martino, 2009). Designed for dually diagnosed patients, a focus of the intervention is to examine the relationship between the substance use and the co-existing psychiatric disorder(s) and the importance of proactively treating both conditions.
223598652|NCT00986362|DRUG|Ocriplasmin|175µg ocriplasmin intravitreal injection
223598653|NCT00986362|DRUG|Placebo|Placebo intravitreal injection
223598654|NCT00439062|DRUG|Roxithromycin|
223598655|NCT00260416|PROCEDURE|Primary angioplasty with stent and abciximab|
223598656|NCT02715986|DEVICE|3T MRI|Four visits will be conducted during the prospective follow during which will be carried out a 3T MRI examination, assessment of assessment of depressive symptomatology and anterograde memory: within 7 days prior to the first session of ECT, within 48 hours after the first ECT session, within 48 hours after the first effective ECT session and within 10 days of the last session of ECT.
223598657|NCT01791478|DRUG|PI3K inhibitor BYL719|Given PO
223598658|NCT01791478|DRUG|letrozole|Given PO
223598659|NCT01791478|OTHER|laboratory biomarker analysis|Correlative studies
223598660|NCT01791478|OTHER|pharmacological studies|Correlative studies
223598661|NCT06320314|OTHER|tested product (2039125 03)|application twice a day of the tested product (in the morning and evening) and a sunscreen (in the morning and at midday) to the face for 3 months
223598662|NCT04938011|DRUG|progesterone|the transfer of day 6 blastocyst on the 6th day of progesterone supplementation
223598663|NCT04938011|DRUG|progesterone|the transfer of day 6 blastocyst on the 7th day of progesterone supplementation
223598664|NCT02006979|OTHER|exercise|An acute bout of exercise performed 24 hours prior to every anthracycline infusion.
223598665|NCT03170193|DRUG|AMG 529|Ascending single doses of AMG 529 by subcutaneous (SC) or intravenous (IV) injection
223598666|NCT03170193|DRUG|Placebo|Single doses of matching placebo by SC or IV injection
223598667|NCT01700153|OTHER|Robotic-assisted therapy|This robotic device is designed to intensively rehabilitate the upper limb. Indeed, this robot allows the patient to perform a lot of active, passive, or assisted exercises. The level of assistance is determined and provided by the robot in function of the patient capacity.
223598668|NCT01700153|OTHER|Classical therapy|conventional therapy will be performed by therapists specialized in neuro-pediatric rehabilitation
223598669|NCT01368081|DRUG|Metformin|Metformin tablets 500-2250 mg a day (twice or three times per day)
223598670|NCT01368081|DRUG|BI 10773|BI 10773 low dose tablet once daily
223598671|NCT01368081|DRUG|Placebo (low dose)|Placebo tablets once daily
223598672|NCT01368081|DRUG|BI 10773|BI 10773 high dose tablet once daily
223598673|NCT01368081|DRUG|Placebo (high dose)|Placebo tablets once daily
223598674|NCT01301859|BEHAVIORAL|TIP|Treatment visits as usual with MD
223598675|NCT04492761|BEHAVIORAL|qualitative study|The qualitative approach will be based on content analysis of - Isemi-structured nterviews of families
223598676|NCT03855683|BEHAVIORAL|Unified Protocol for The Treatment of Emotional Disorders|Unified Protocol (UP) is is an 8-week intervention designed to specifically benefit individuals who report co-occurring symptoms of anxiety, stress, and mood by providing them with psychoeducation regarding (mal)adaptive emotion regulation, as well as with skills for effectively responding to stress. UP is based on a cognitive-behavioral framework and uses cognitive and behavioral therapy techniques. Each session of UP group therapy is 90 minutes in duration. Sessions themselves generally include a review of homework and previously discussed concepts, introduction of new material, and in-session discussions/activities.
223598677|NCT02992535|DEVICE|Intense Pulse Light Energy delivery (IPL)|
223748334|NCT03493828|PROCEDURE|TAP block using Normal Saline|Following completion of the Cesarean delivery, the abdomen was aseptically prepped with ChloraPrep®. A Sonosite ultrasound machine (S-nerve) with a 14-8 MHz linear probe was used to visualize the lateral abdominal wall muscles and transversus abdominis plane. A 2 or 4 inch stimuplex (Braun) needle was advanced under ultrasound guidance to the transversus abdominis plane. After negative aspiration, 15 ml of normal saline was incrementally injected on each side. The spread of solution within the transversus abdominis plane was visualized with the ultrasound.
223748335|NCT05041296|DIAGNOSTIC_TEST|Cardiac magnetic resonance scan|Multiparametric cardiac magnetic resonance including traditional and quantitative functional and structural parameters
224198815|NCT00706901|BEHAVIORAL|Arm 2 IHMD|Participants randomized to IHMD received a 27 day VA Care Coordination Home Telehealth (CCHT) program targeting acute recovery from alcohol and other drug disorders. IHMD consisted of daily assessment combined with dialogues consisting of motivational interviewing, cognitive behavioral therapy, and 12-step (mutual self-help) facilitation.
224198816|NCT00706901|BEHAVIORAL|Arm 3 TCC|TCC consisted of a 4-session psychoeducational group (75 minutes per session). Material was delivered using a power point presentation on topics
224198817|NCT06519539|BEHAVIORAL|PORTIONS-4 behaviour change strategies|The intervention includes 4 components, including: a portion control tool set previously developed and tested in our laboratory; a supporting guide (physical book) with dietary, activity and behavioural recommendations; a mobile application aligned with the guide; and biweekly telephone calls from the psychologist and/or dietitian.
224198818|NCT03028077|DIETARY_SUPPLEMENT|GS-3K8|GS-3K8 (ultrafiltered red ginseng extract) 1 g/day
224198819|NCT03028077|DIETARY_SUPPLEMENT|GINst15|GINst15 (hydrolyzed ginseng extract) 1 g/day
224198820|NCT03028077|DIETARY_SUPPLEMENT|Placebo|Placebo 1 g/day
223598678|NCT06128746|DEVICE|Repetitive Transcranial Magnetic Stimulation|1 Hz rTMS treatment for 20 mins, follow by 30 mins intensive limb training
223598679|NCT06128746|DEVICE|Sham Repetitive Transcranial Magnetic Stimulation|Sham Hz rTMS treatment for 20 mins, follow by 30 mins intensive limb training
223598680|NCT01609881|DRUG|Acuvail|Dosing of drug 3 days prior to surgery
223748336|NCT02164227|OTHER|Respiratory pattern|
223748337|NCT06226727|DRUG|BR1019|One tablet administered alone
223748338|NCT06226727|DRUG|BR1019-1|One tablet administered alone
223748339|NCT06226727|DRUG|BR1019-2|One tablet administered alone
223748340|NCT00052728|DRUG|tamoxifen citrate|
223748341|NCT00052728|DRUG|tipifarnib|
223748342|NCT00231101|DRUG|Quetiapine|
223748343|NCT06115928|DEVICE|Virtual reality|Participants will perform cardiac rehabilitation with hardware-type technology consisting of a PICO 4® head mounted display (HMD) headset and the software TREADMILL XR®.
224198821|NCT03077854|RADIATION|Functional Lung Avoidance Thoracic Radiotherapy|"* Chemoradiation for non-small cell lung cancer: 60 Gy in 30 once-daily fractions (Dose reduction to 54 Gy in 30 once-daily fractions is allowed)~* Radiation alone for non-small cell lung cancer: 60 Gy in 25 once-daily fractions (Dose reduction to 55 Gy in 25 once-daily fractions is allowed)~* Chemoradiation for small-cell lung cancer: 45 Gy in 30 twice-daily fractions"
223598681|NCT01609881|OTHER|Placebo|Artificial tears qid for 3 days preoperatively
223598682|NCT01616251|OTHER|Acute effect of animal and vegetable protein rich meals with comparable dietary fibers content on appetite sensation and energy intake|4-arm crossover study with the objective to examine if vegetable protein (beans and peas) can suppress subjective appetite (VAS and ad libitum EI) compared to isocaloric meals enriched with either red meat or egg with similar distribution of macronutrients and content of dietary fibers.
223598683|NCT04456374|OTHER|Performance testing|Soccer-specific performance will be evaluated by measuring flexibility, jumping ability, maximum speed, repeated spring ability, agility and endurance.
223598684|NCT05895240|DRUG|Ulinastatin|Nine MiU Ulinastatin in three divided doses 8 hourly for 3-5 days
223598685|NCT01211340|BEHAVIORAL|ACTIVE|Assessing Caregivers for Team Intervention via Video Encounters: this intervention uses video technology to bridge geographic distance to empower hospice caregivers to participate in plan of care meetings for their patient
223598686|NCT00004274|DRUG|Estrogen|
223598687|NCT05612425|BEHAVIORAL|Safety Behavior Fading for Appearance Concerns|Participants are asked to reduce or eliminate safety behaviors via text message reminders and checklists to monitor progress.
223598688|NCT05612425|BEHAVIORAL|Unhealthy Behavior Fading|Participants are asked to reduce or eliminate unhealthy behaviors via text message reminders and checklists to monitor progress.
223598689|NCT03755661|BEHAVIORAL|MI&TXT4MSM|brief in-person intervention followed by text messaging
223598690|NCT05614648|DRUG|Clonidine Micropellets|0.975 mg clonidine hydrochloride as 3 micropellets administered in one injection
223598691|NCT05614648|DEVICE|Tuohy epidural needle|18-gauge Tuohy epidural needle using a custom-built injector
223598692|NCT05047848|DRUG|Chidamide|chidamide 30mg orally，Biw
223598693|NCT05047848|DRUG|Fulvestrant|Fulvestrant 500mg i.m. injections every 28 days (Cycle n Day 1) with 1 additional dose on Day 15 of Cycle 1
223598694|NCT03144986|DEVICE|Deep Insula-coil rTMS|Before administering TMS participants will undergo cue stimuli provocation, consisting of 32 professional color images of high calorie, sweet and savory food. This will follow with TMS. All subjects will receive prefrontal deep TMS (18 Hz, 2 sec on, 20 sec off, over approximately 30 min) 5 times per week, for 6 weeks, for a total of 30 sessions as a part of an active treatment phase. Maintenance treatment phase will include two sessions of rTMS (18 Hz, 2 sec on, 20 sec off, over approximately half an hour) weekly for the period of 6 weeks.
223598695|NCT02469519|DRUG|Betamethasone - ACTIVE|antenatal corticosteroid (ACS) is to be given by injection 24 hours apart for two doses.
224198822|NCT03077854|RADIATION|Standard Thoracic Radiotherapy|"* Chemoradiation for non-small cell lung cancer: 60 Gy in 30 once-daily fractions (Dose reduction to 54 Gy in 30 once-daily fractions is allowed)~* Radiation alone for non-small cell lung cancer: 60 Gy in 25 once-daily fractions (Dose reduction to 55 Gy in 25 once-daily fractions is allowed)~* Chemoradiation for small-cell lung cancer: 45 Gy in 30 twice-daily fractions"
223598696|NCT02469519|OTHER|Normal Saline - PLACEBO|normal saline of the same quantity as with the experimental drug is to be given by injection 24 hours apart for two doses
223598697|NCT05659472|BEHAVIORAL|Combination mindfulness spiritual-based cognitive therapy plus hypnosis|The intervention was divided into eight components in eight sessions, namely (1) psychoeducation and intention, (2) awareness of breathing mindfulness, (3) body scan, (4) comfort training through daily activity/comfort exercises, (5) self-compassion / having a great soul with acceptance, gratitude, and sincerity, (6) planning happiness through independent healthy behavior targets, (7) independent healthy behavior (8) independent healthy behavior evaluation. Each therapeutic component of each session is further divided into three sub-components, namely psychoeducation, training, and hypnosis.
223598698|NCT05659472|BEHAVIORAL|Mindfulness-based cognitive therapy|The program curriculum consists of the automatic pilot; living in our heads; gathering the scattered mind; recognizing aversion; allowing and letting be; thoughts as thoughts; kindness in action; maintaining and extending new learning.
223598699|NCT02193308|DRUG|Telmisartan/Amlodipine FDC|
223598700|NCT02193308|DRUG|Telmisartan|
223598701|NCT02193308|DRUG|Amlodipine|
223598702|NCT00351325|DRUG|BMS-663513|mg/kg, IV, 0.3, 1, 3, 10 mg/kg, q 3 wks, up to 24 weeks
223598703|NCT02277119|DEVICE|Maestro|OCT machines used for diagnostic purposes
223598704|NCT02277119|DEVICE|iVue|OCT machines used for diagnostic purposes
223598705|NCT00999297|OTHER|Dihydrocapsiate|Capsules will contain dihydrocapsiate 3 mg/d or 9 mg/d or placebo
223598706|NCT00999297|OTHER|Dihydrocapsiate|Capsules will contain dihydrocapsiate 3 mg/d or 9 mg/d or placebo
223748344|NCT00992082|DRUG|ropivacaine, ketorolac and epinephrine|Spinal injection: bupivacaine 17.5 mg (3,5 mL) + 0.25 mL 0.9% saline. Local Infiltration Analgesia: 400 mg ropivacaine, 30 mg ketorolac and 0.5 mg epinephrine (total volume 166 ml) are infiltrated by the surgeon into the soft tissues peri-articularly during the operation. On the first and on the second postoperative morning, 200 mg ropivacaine, 30 mg ketorolac and 0.1 mg epinephrine, total volume 22 ml, are injected intraarticularly via the catheter.
223748345|NCT00992082|DRUG|morphine|Spinal injection: bupivacaine 17.5 mg (3.5 mL) + 0.1 mg (0.25 mL) morphine. No intraarticular injections are given.
223748346|NCT02109146|DRUG|Prophylactic Transcatheter Arterial Chemoembolization|Participants enrolled in the adjuvant TACE group received one to two cycles of TACE with an interval of 4\~6 weeks, and the first TACE was given within 1 week after randomization.
224198823|NCT01362231|DRUG|GS-6624|Patients will be treated with GS-6624 (125 or 200 mg) administered IV over 1 hour on specific days during the treatment period.
224198824|NCT05198739|OTHER|Video Interaction Project (VIP) program|Video Interaction Project (VIP) is a strengths-based, family-centered intervention designed to enhance parenting practices/relationships and child development by promoting positive parenting practices such as pretend play, shared reading, and daily routines. In VIP's core component, a VIP coach video-records the parent / child for 3-5 minutes playing/reading with a provided toy and/or book, then reviews the video with the parent to facilitate self-reflection on the interaction and identifies and reinforces strengths. In the US, VIP is delivered in the context of pediatric primary care visits, with a COVID-19 remote adaptation (see Section 6 for details). Research staff will delivery VIP through video calls with subjects in Brazil.
224198825|NCT02246244|DRUG|Escitalopram|
224198826|NCT02246244|OTHER|Placebo|
224198827|NCT03542864|DIETARY_SUPPLEMENT|Nasogastroduodenal Protocol|Complete nutrition (carbohydrates, lipids, proteins, vitamins, oligoelements)
224198828|NCT03542864|OTHER|Control|Progress registration of body composition values
224198829|NCT03542864|OTHER|Data analysis|Statistical analysis of all data
224198830|NCT05131152|DRUG|Cyclosporine|0.05% cyclosporine Eye Drops; Sodium Hyaluronate Eye Drops, 0.02% Fluoromethalone Eye Drops.
224198831|NCT05131152|DEVICE|oculus keratograph, in vivo laser confocal microscopy, Functional slit lamp biomicroscopy|oculus keratograph, in vivo laser confocal microscopy, Functional slit lamp biomicroscopy
223598707|NCT00999297|OTHER|Dihydrocapsiate|Capsules will contain dihydrocapsiate 3 mg/d or 9 mg/d or placebo
223598708|NCT05137977|PROCEDURE|Intensive Care|Invasive ventilation more than 24hs.
223598709|NCT01494597|DRUG|isavuconazole|oral
223748347|NCT02109146|OTHER|Observation|Participants enrolled in the observation group were subjected to active surveillance without any adjuvant treatment.
224311155|NCT04636164|DIAGNOSTIC_TEST|Model Dermatology (deep neural networks; Build 2020)|Physicians in the DNN group take pictures of the skin lesion and use the algorithm by uploading pictures.
224311156|NCT03243058|BIOLOGICAL|ILT-101 (Aldesleukin; IL-2)|Administration of Low-Dose Interleukin-2 (ILT-101) for two years
224311157|NCT03243058|OTHER|Treatment-Placebo Arm|Administration of Low-Dose Interleukin-2 (ILT-101) for one year, and then placebo for the second year.
223598710|NCT01494597|DRUG|cyclosporine|oral
223598711|NCT05694299|DEVICE|Nasal bridle|Bridle Pro® Nasal Tube Retaining System (Applied Medical Technology Inc., Brecksville, OH, USA)
223598712|NCT05694299|OTHER|Nasal patch|Regular adhesive tape for medical use.
223598713|NCT01631097|DRUG|Tivozanib hydrochloride|Single oral capsule 1.5 mg tivozanib hydrochloride
223598714|NCT00028236|DRUG|Gene-Transduced Autologous CD34+ Stem Cells|
223598715|NCT00116116|DRUG|efavirenz, stavudine extended release, lamivudine|
223598716|NCT06145958|DRUG|Luteinising Hormone-Releasing Factor Analogue|Androgen Deprivation Therapy
223598717|NCT02381340|DEVICE|ACE stapling procedure|Endoscopic trans-oral gastroplication
223598718|NCT00683839|BEHAVIORAL|Brief tobacco counseling|Public health dental professionals provide brief counseling during routine visits based on the Clinical Practice Guidelines 5 As (Ask, Advise, Assess, Assist, Arrange), including offering free Nicotine Replacement Therapy and referral to a Tobacco Quit Line. Pharmacologic: nicotine patch or lozenge maximum 12 week course.
223598719|NCT00562991|DEVICE|measurement of exhaled NO is used to guide treatment|exhaled NO
223748348|NCT06236711|DEVICE|tDCS|tDCS is a form of noninvasive transcranial stimulation of the brain by delivering low-intensity electrical current to the scalp through two electrodes. The Soterix Medical 1×1 Low Intensity Transcranial DC Stimulator Model 1300A (Soterix Medical, Inc., New York, NY, USA) device will be used in the study. The tDCS device is comprised of a small battery-operated control box that delivers the current through electrodes placed on the scalp, held in place by elastic bands or head straps and worn over the forehead like a headband.
223748349|NCT06513962|OTHER|Best Practice|Receive standard chemotherapy
224198832|NCT06650020|OTHER|synchronous online learning|Each participant in this cohort selected a suitable and peaceful learning environment, characterized by ample lighting and strong network connectivity. Equipped with laptops, participants logged into the Tencet conference software ten minutes prior to the session, entered their authentic names, completed the sign-in process five minutes before the course started, and kept their cameras activated throughout the session. During the instructional phase, both the teacher and control group were physically present. While the teacher instructed the control group, screen sharing through Tencet conference software allowed trainees in the experimental group to have clear visual access to instructional materials while audibly receiving instruction through microphones.
224198833|NCT06650020|OTHER|the traditional offline model of centralized training|The control group adhered to the traditional offline model of centralized training, which involved a training facility spanning 100 square meters and accommodating seating for 150 participants. The front section of the training room was equipped with various amenities, such as a projection screen, podium, computer, and microphone, all available for use by the instructors. Throughout the training period, the lecturer provided in-person instruction on-site, allowing trainees to engage in real-time interaction by raising their queries.
224198834|NCT00823680|DRUG|Placebo|po bid for 4 weeks
224198835|NCT00823680|DRUG|RO5027838|200mg po qd for 4 weeks
224198836|NCT00823680|DRUG|RO5027838|50mg po bid for 4 weeks
224198837|NCT00823680|DRUG|RO5093151|400mg po bid for 4 weeks
223748350|NCT06513962|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
224198838|NCT00823680|DRUG|RO5093151|10mg po bid for 4 weeks
224198839|NCT05378568|OTHER|the selection scheme of peripheral venous access devices|"Based on the Facilitator Toolkit of the promoting action on research implementation in health services integrated framework(i-PARIHS), the implementation plan of peripheral intravenous infusion device selection in hospitalized children was formulated and applied, so as to change the practice behavior of nurses in the intervention group. The specific process mainly includes: tailoring evidence; baseline review; situational analysis; promotion and implementation strategy like lectures, group discussions, operation demonstrations, and scenario simulations."
224198840|NCT05378568|OTHER|the existing nursing routine|To choose infusion device according to nurse's working experience. First, nurse placed a peripheral intravenous catheter. The patients and family decide whether to place the central intravenous infusion device according to the recommendation of the medical staff.
224198841|NCT03014427|OTHER|Biological Database|Biological Database
224198842|NCT04478994|BIOLOGICAL|TEPEZZA|TEPEZZA is a fully human anti-IGF-1R mAb. TEPEZZA will be provided in single-dose 20 mL glass vials as a freeze-dried powder. Each vial of TEPEZZA must be reconstituted with 10 mL of water for injection. Reconstituted TEPEZZA solution must be further diluted in 0.9% (w/v) sodium chloride (NaCl) solution prior to administration. TEPEZZA will be administered in 100 mL or 250 mL infusion bags (100 mL infusion bags for doses up to 1800 mg and 250 mL infusion bags for doses \> 1800 mg).
224198843|NCT04478994|OTHER|Placebo|Placebo will consist of normal saline (0.9% NaCl) solution and will be administered in 100 mL or 250 mL infusion bags, as would be appropriate, per weight-based dosing volumes (100 mL infusion bags for doses up to 1800 mg and 250 mL infusion bags for doses \> 1800 mg).
224311158|NCT03243058|OTHER|Placebo Arm|Participants in this group will receive a placebo injection for two years.
224311159|NCT00235404|OTHER|Multicomponent treatment|Specialized care in preparing recharge to home
224311160|NCT00235404|OTHER|usual care|Usual recharge directly from hospital to home
223748351|NCT06513962|OTHER|Electronic Health Record Review|Ancillary studies
223748352|NCT06513962|OTHER|Survey Administration|Ancillary studies
223748353|NCT06513962|DRUG|Triptorelin Pamoate|Given IM
223748354|NCT04345614|DRUG|Auxora (Part 1)|Auxora will be given at 2.0 mg/kg (1.25 mL/kg) on Day 1 and then 1.6 mg/kg (1.0 mL/kg) on Days 2 and 3. All doses of Auxora will be administered intravenously (IV) over 4 hours.
223748355|NCT04345614|DRUG|Standard of Care (Part 1)|Patients received standard of care
224311161|NCT05646043|BEHAVIORAL|Physical training|Physical training consists of endurance walking and strength training. The basis for determining the number of steps per day is the baseline value of each patient. This will increase by 10-15% every week until the surgery date. The assumption of a total load increase is 120-180% compared to the baseline.
224311162|NCT05646043|BEHAVIORAL|Muscle strength training|Muscle strength training will take place using exercises to strengthen the upper and lower limbs and to strengthen the trunk. There will be a set of 5 exercises in two difficulty variants. The study subjects will perform this set 7 days a week, and will repeat the assembly a total of two times. The total time of strength training is 10 min.
223598720|NCT01108198|DRUG|Mometasone furoate cream|Study cream was applicated once per day for 4-8 weeks.
223598721|NCT01108198|DRUG|moisturizing cream|study cream was applicated once per day for 4 to 8 weeks
223598722|NCT02242383|DRUG|Telmisartan|
223598723|NCT02242383|DRUG|Telmisartan in combination with hydrochlorothiazide|
223598724|NCT03588936|DRUG|Nivolumab (.25 mg/kg)|Participants will receive Nivolumab at one of two dose levels every 2 weeks for 4 treatments.
223598725|NCT03588936|DRUG|Tocilizumab|Participants will receive 2 doses of tocilizumab
223598726|NCT03588936|DRUG|Nivolumab (.5 mg/kg)|Participants will receive Nivolumab at one of two dose levels every 2 weeks for 4 treatments.
223598727|NCT05894811|DIAGNOSTIC_TEST|oral glucose tolerance test|Nine blood samples were collected from subjects within 4 hours of oral glucose administration, 0 min before oral glucose administration, and 10, 20, 30, 60, 90, 120, 180, 240 min afterwards, and 4 mL of venous blood was collected at each time point for glucose, C-peptide and insulin concentrations.
223598728|NCT05894811|DIAGNOSTIC_TEST|MRI|Using MRI to quantify of fat content in the liver and pancreas of the subjects
223598729|NCT02331017|BEHAVIORAL|Speech perception tests and self-rating questionnaire|Speech perception test results and self-rating questionnaire scores will be analyzed by means of non-parametric statistical tests. The statistical tests will be chosen in accordance with the number and type of variables in each test. Correlation between audiological variables (aided and unaided hearing thresholds in the non implanted ear, aided speech perception abilities in the HA-alone condition) and the bilateral-bimodal benefit will be examined. Moreover, possible relationship between self-rating questionnaire scores and speech perception test results will be assessed.
223598730|NCT00219778|DRUG|mifepristone|
223598731|NCT04071418|RADIATION|3D-printing Template-assisted CT-guided I-125 Seeds Implantation|(1) positioning and preoperative plan design;(2) 3D printing template design and production;(3) reset and seeds implantation;(4) intraoperative optimization;Postoperative dose verification.Dosimetric parameters include: dose D90 and D100 reaching a certain percentage target volume; Target volume V100, V150 and V200 reaching a certain percentage of prescribed dose;And the dose of organs at risk: Dmean, D2cc, d0.5cc, d0.1cc. Regular follow-up was conducted after treatment.
223598732|NCT04699461|DRUG|Loncastuximab Tesirine|IV infusion
223598733|NCT04699461|DRUG|Idelalisib|Oral tablet
223598734|NCT01183455|DRUG|Aralast NP|Participants will receive IV infusions of Aralast NP (90mg/kg) once a week for 12 weeks.
223598735|NCT01183455|DRUG|Placebo|Participants will receive IV infusions of placebo once a week for 12 weeks.
223598736|NCT03068767|DIETARY_SUPPLEMENT|Vitamin D|
223598737|NCT00001644|DRUG|Indinavir|
223748356|NCT04345614|DRUG|Auxora (Part 2)|Auxora will be given at 2.0 mg/kg (1.25 mL/kg) on Day 1 and then 1.6 mg/kg (1.0 mL/kg) on Days 2 and 3. All doses of Auxora will be administered intravenously (IV) over 4 hours.
223748357|NCT04345614|DRUG|Placebo (Part 2)|Placebo will be given at 2.0 mg/kg (1.25 mL/kg) on Day 1 and then 1.6 mg/kg (1.0 mL/kg) on Days 2 and 3. All doses of Placebo will be administered intravenously (IV) over 4 hours.
223748358|NCT04922918|BIOLOGICAL|Ligilactobacillus salivarius MP101|Administration of the strain through a fermented milk
223748359|NCT05469100|DRUG|Selpercatinib|Administered orally
223748360|NCT04538703|BEHAVIORAL|acne vulgaris|Social media use of acne vulgaris patients, a questionnaire will be asked the patients and try to learn how they use social media for getting information about their disease.
223506952|NCT02455323|OTHER|Spinal manipulative|This technique is performed along an imaginary vertical line passing through the odontoid process of the axis. No flexion or extension and very little lateroflexion are used. Application is bilateral. First, cephalic decompression is performed lightly, followed by small circumductions. Selective tension is applied to take up tissue slack and create a firm joint barrier. Manipulation is then performed with rotation towards the manipulated side in a helicoidal cranial movement. This technique is designed to correct a generalized dysfunction with the aim of restoring occiput, atlas, and axis joint mobility
223506953|NCT02455323|OTHER|Combined treatment|Consisted in applying the above two techniques using exactly the same sequence: first the SI technique, and then the SM technique.
223506954|NCT02455323|OTHER|Control group.|The subjects received no treatment, but attended the same number of sessions, maintaining the resting position for longer than the experimental groups, and underwent the same evaluations (test for arterial compromise, and the three assessments).
223506955|NCT02173366|BEHAVIORAL|Change Club Intervention|
223506956|NCT00137280|BEHAVIORAL|Collaborative Chronic Illness Care Model|A care model that integrates greater availability of clinical information, reorganizes the practice system and provider roles, fosters care coordination, and focuses on evidence-based protocols--specifically supported employment and wellness services for individuals with schizophrenia.
223506957|NCT05856747|DRUG|TBP-PI-HBr|TBP-PI-HBr tablets.
223506958|NCT03623100|BEHAVIORAL|Speech Production Treatment.|Speech production treatment will be delivered in two phases: Imitation and Spontaneous Production. Treatment will be provided two times weekly in 1-hour sessions, for up to 19 sessions. Every child's intervention program will target a single phoneme that was excluded from his or her phonemic inventory. Each treatment phoneme will be targeted through the production of five words that will be initially introduced to the child using a storybook reading format. Imitation treatment will continue until a child maintains 75% accurate production of the treated phoneme over two consecutive sessions (i.e. performance-based criterion) or until seven consecutive sessions are completed (i.e. time-based criterion). Spontaneous Production will continue until the child maintains either a performance-based criterion of 90% accurate production of the treated phoneme over 3 consecutive sessions, or a time-based criterion of 12 consecutive sessions.
223598738|NCT00001644|DRUG|Zidovudine|
223598739|NCT00001644|DRUG|Lamivudine|
223598740|NCT00001644|DRUG|Nevirapine|
223598741|NCT00001644|PROCEDURE|Blood testing|
223598742|NCT00001644|PROCEDURE|Lymph node biospy|
223598743|NCT00001644|PROCEDURE|Leukapheresis|
223598744|NCT05261009|DRUG|Peri-capsular Nerve Group (PENG)|PENG block for postoperative pain management
223598745|NCT05261009|OTHER|Lumbar Plexus Block (LPB)|LPB for postoperative pain management
223598746|NCT05400304|DIAGNOSTIC_TEST|radiomics|The high-throughput extraction of large amounts of quantitative image features from medical images
223598747|NCT00003775|DRUG|leflunomide|
223748361|NCT04588649|DRUG|THK-5351|\[18F\]THK-5351 PET Imaging
223748362|NCT04588649|DRUG|AV-45|\[18F\]AV-45 PET Imaging
223748363|NCT04109638|DEVICE|Endonovo SofPulse|The active device emits PEMF signal whereas the placebo device does not emit a PEMF signal. The active device is on for 15 minutes at a time, every two hours, for 10 days.
223748364|NCT05230082|OTHER|Acupuncture|Acupuncture treatments will be separated by a minimum of two days and a maximum of 14 days. Treatment sessions will be identical for both groups. Standard, sterile stainless-steel, disposable needles will be inserted at acupuncture points with a total of 18 needles for each treatment session. The depth of the needle will be approximately 10-20 millimeters. Needles will be left in place for 30 minutes.
223598748|NCT04794127|DRUG|Trabectedin|Patients will be treated with Trabectedin administered at a dose of 1.5 mg/m2-1.3 mg/m2 (according to investigator's choice, with a top-dose of 2.6 total mg per cycle) as a 24-hour continuous infusion via a central venous access every 3 weeks and pioglitazone given continuously at the daily dose of 45 mg by oral route.
224311163|NCT05656872|PROCEDURE|Transverse Abdominis Plane Block|Group T, will be performed in a supine position after skin sterilization, a linear high-frequency transducer Siemens acuson x300 3-5 MHZ will be placed in the transverse plane to the lateral abdominal wall in the mid-axillary line, between the lower costal margin and iliac crest. The abdominal wall muscles (external oblique, internal oblique, and transversus abdominis) will be visualized. A blunt tip,20-gauge, short bevel needle(Pajunk Sonoplex, Germany) will be inserted in-plane and advanced anterior to posterior under continuous visualization until the tip reaches between the internal oblique and the transversus abdominis muscle. After negative aspiration, 20 mL of bupivacaine 0.25%, lidocaine 1% will be injected. Separation of the internal oblique and transversus abdominis with a distinct pocket of local anesthetic in-between will be observed. The procedure will be repeated following the same steps on the other side.
223598749|NCT04794127|DRUG|Pioglitazone Oral Product|Patients will be treated with Trabectedin administered at a dose of 1.5 mg/m2-1.3 mg/m2 (according to investigator's choice, with a top-dose of 2.6 total mg per cycle) as a 24-hour continuous infusion via a central venous access every 3 weeks and pioglitazone given continuously at the daily dose of 45 mg by oral route.
223598750|NCT04167137|DRUG|SYNB1891|SYNB1891 was administered as an IT injection over a dose range of 1 x 10\^6 to 3 x 10\^8 live cells in Arm 1 and 1 x 10\^7 to 3 x 10\^7 in Arm 2.
223598751|NCT04167137|DRUG|Atezolizumab|Atezolizumab was administered in accordance with its recommended dose and schedule (1200 mg IV Q3W).
223598752|NCT02762331|DRUG|Ascorbic Acid|Comparing safety and efficacy of IV Vitamin C in CABG patients
223598753|NCT02762331|DRUG|Placebo|Placebo intervention
223598754|NCT01942070|DEVICE|Bioresorbable vascular scaffold|
223598755|NCT01942070|DEVICE|Durable polymer everolimus-eluting metallic stent|
223598756|NCT02728466|DIETARY_SUPPLEMENT|Flavanol and procyanidin supplement|Sustained intake (2x daily over 1 month) of a cocoa-based supplement containing flavanols (monomers) and procyanidins (dimers to decamers)
223598757|NCT02728466|DIETARY_SUPPLEMENT|Procyanidin-containing supplement|Sustained intake (2x daily over 1 month) of a cocoa-based supplement containing procyanidins (dimers to decamers)
223598758|NCT02728466|DIETARY_SUPPLEMENT|control supplement deprived of flavanols and procyanidins|Placebo comparator: flavanol and procyanidin deprived supplement Sustained intake (2x daily over 1 month) of a macro-and micronutrient matched supplement
223598759|NCT01748825|DRUG|MK-1775 (AZD1775)|MK-1775 (AZD1775) is an inhibitor of Wee1-kinase.In preclinical models, MK-1775 selectively enhanced chemotherapy-induced death of cells deficient in tumor protein p53 (p53) signaling.
223598760|NCT01849419|DRUG|Within-subjects (MDMA)|This was a within-subjects, double-blind, double-dummy, placebo-controlled experiment during which each participant received a single dose of MDMA (0.75, 1.5 mg/kg) on two session, oxytocin (20 IU) as an active control on one session (see second Intervention), and placebo one session (see third intervention).
223598761|NCT01849419|DRUG|Within-subjects (oxytocin)|This was a within-subjects, double-blind, double-dummy, placebo-controlled experiment during which each participant received oxytocin (20 IU) on one session, MDMA on two sessions (see first Intervention), and placebo on one session (see third Intervention).
223598762|NCT01849419|DRUG|Within-subjects (placebo)|This was a within-subjects, double-blind, double-dummy, placebo-controlled experiment during which each participant received placebo on one session, MDMA on two sessions (see first Intervention), and oxytocin (20 IU) on one session (see second Intervention).
223598763|NCT05940818|BEHAVIORAL|the intensive oral care|the intensive oral care
223598764|NCT03477058|OTHER|WO 3308 cosmetic product for topical use|Application on the entire body at least once a day over two weeks
223598765|NCT02819687|DRUG|RDX5791|
223598766|NCT02819687|DRUG|Placebo|
223598767|NCT01116973|OTHER|PICC|Peripheral inserted catheter placement to take the reading
223598768|NCT03665311|BIOLOGICAL|25% Albumin fluid|25% Albumin fluid (100 mL)
223598769|NCT03665311|OTHER|Normal Saline|0.9% Normal Saline (100 mL)
223748365|NCT04461015|DRUG|0.4mU Insulin followed by withdrawal period followed by 0.8mU study|Clamp study with insulin infused at 0.4 mU/Kg/min, followed by a 2 week withdrawal period followed by a clamp study with insulin infused at 0.8 mU/Kg/min
223748366|NCT04461015|DRUG|0.8mU Insulin followed by withdrawal period followed by 0.4mU study|Clamp study with insulin infused at 0.8 mU/Kg/min, followed by a 2 week withdrawal period followed by a clamp study with insulin infused at 0.4 mU/Kg/min
223598770|NCT03882645|OTHER|CHH-diet|"This study took the DASH Diet as the basic model and developed the Chinese Heart Healthy Diet ( CHH-diet) according to the principles in the 2016 Dietary Guidelines for Chinese Residents. The nutrients targets in CHH-diet are set as following: fat % of total kcal: 25-27% (saturated: 6%; monounsaturated: 12%; polyunsaturated: 8%); carbohydrate % of total kcal: 55-60%; protein % of total kcal: 17-19%; dietary fiber: 30 g/day; sodium: 3000 mg/day; potassium: 3700 mg/day; magnesium: 500 mg/day; calcium: 1200 mg/day. The total energy will be set according to how much participants are eating in run-in period."
223598771|NCT03882645|OTHER|local usual diet|The nutrients targets and total energy in usual diet are set according to how much participants are eating in run-in period.
223598772|NCT04487652|OTHER|Gingival recession coverage|The Modified Coronally Advanced Tunnel technique in conjunction with a palatal subepithelial connective tissue graft will be performed.
223598773|NCT04487652|DRUG|with CoQ10 spray application|After surgical recession coverage a CoQ10 spray will be applied during the early phase of wound healing.
223598774|NCT04487652|DRUG|with placebo spray application|After surgical recession coverage a placebo spray will be applied during the early phase of wound healing.
223598775|NCT04841772|DIETARY_SUPPLEMENT|Recover Vegan Protein Supplement|Post exercise protein supplement (26g pea protein)
223598776|NCT04841772|DIETARY_SUPPLEMENT|Placebo|Post exercise placebo supplement (32g maltodextrin)
223598777|NCT05595772|DRUG|Drug: Growth Factors (CGF)|Application of biological membrane of Concentrated growth factor (CGF) over bone grafting and implant
223598778|NCT05595772|DRUG|Drug: Growth Factors (PRGF)|Application of biological membrane of Plasma rich in growth factors combined with Xenogeneic bone grafting material around immediate implant
224198844|NCT05543226|DRUG|PHGG-rich enteral nutrtiion|PHGG-rich enteral nutrition
224198845|NCT02524366|DEVICE|Artificial Urinary Sphincter|
224198846|NCT05246631|DRUG|Dexamethasone injection|Group A consisted of patients given 5 mg intravenous dexamethasone after induction.
223748367|NCT01633892|PROCEDURE|Fat Grafting|
224198847|NCT05246631|DRUG|Haloperidol Injection|Group B consisted of patients given 1 mg intravenous haloperidol one hour before the surgery ended
224198848|NCT03906929|DEVICE|buried intramedullary K-wire|Using of buried kirschner wire in pediatric forearm fixation
224198849|NCT03906929|DEVICE|exposed intramedullary K-wire|Using of exposed kirschner wire in pediatric forearm fixation
224198850|NCT04928625|DRUG|SHR-A1904|SHR-A1904
224198851|NCT03429465|OTHER|EVO Cognitive Remediation Game|EVO (formerly called Neuroracer) is a neuroscience-inspired plasticity trainings in the form of a video driving game that uses adaptive algorithms and dual-tasking paradigms to target the CCN. Work from our group (Project:EVO) recently showed that 4 weeks of EVO training is associated with increased neural recruitment in brain regions associated with CNN, superior improvement in cognitive control performance (i.e., working memory, sustained attention) when compared to an evidence-based psychotherapy (Problem-Solving Therapy), and improved depression outcomes similar to Problem-Solving Therapy among older adults (Areán, Hallgren, Jordan, Gazzaley, Atkins, Heagerty, \& Anguera, 2016; Journal of Medical Internet Research).
224198852|NCT05805072|DRUG|Selinexor|Selinexor 60 mg/day, orally on d1,4,8,11
224198853|NCT05805072|DRUG|Homoharringtonine|Homoharringtonine 1 mg/day intravenously on days 3 to 9
223506959|NCT03623100|BEHAVIORAL|Speech Production + Speech Perception Treatment.|This speech treatment condition will be administered in the same way as the Speech Production treatment. The difference in conditions will be that speech treatment in this condition will last for 50 minutes rather than 60 minutes. The remaining 10 minutes of each session will involve the speech perception training. These speech perception tasks will involve previously recorded word-level productions focusing on the same phoneme that is addressed in speech production treatment in word-initial position. A variety of words produced correctly and incorrectly by adults and children will be presented in pairs and the children will have to determine if the words contain the same word-initial phoneme or two different phonemes.
223506960|NCT01783236|DRUG|IV Acetaminophen|1000mg IV Ofirmev given every six hours for a total of four doses.
223506961|NCT01783236|DRUG|Saline Placebo|Normal saline placebo given every six hours for a total of four doses if randomized to the placebo arm.
224198854|NCT05805072|DRUG|Cytarabine|cytarabine 10 mg/m2 q12h, intravenously on days 3 to 9
223506962|NCT05001165|OTHER|Proactive Panel Management Clinics for HFrEF|Novel clinic based on review of panel HFrEF data and impromptu telephone or video patient contacts/visits.
223506963|NCT04000724|BEHAVIORAL|Text Messaging (Text+Step)|Participants receive three culturally competent, theory-based pre-written messages per day sent on a predetermined schedule. Participants who still exhibit sexual risk and do not uptake and/or adhere to PrEP at the 3-month assessment may also receive eCoaching for up to 12 weeks.
223506964|NCT04000724|BEHAVIORAL|WebApp (App+Step)|Participants receive access to a culturally competent password-protected web-based application with transgender-specific resources, support, and health information. Participants who still exhibit sexual risk and do not uptake and/or adhere to PrEP at the 3-month assessment may also receive eCoaching for up to 12 weeks.
223506965|NCT04000724|BEHAVIORAL|Information/No Step|Participants in the Information/No Step intervention will receive access to a static website with information about trans health, HIV/STI information and local resources tailored for transgender persons.
223506966|NCT00002246|DRUG|Stavudine|
223506967|NCT00455455|DRUG|Optifree RepleniSH Multipurpose Disinfecting Solution|lens care system
223506968|NCT00455455|DRUG|ReNu Multiplus Multipurpose Solution|lens care system
223506969|NCT06116032|DIAGNOSTIC_TEST|Methylation Cytometry|Assessment of the ability of Methylation Cytometry in pre-treatment peripheral blood and in repeated measures over the duration of treatment to predict treatment response or occurrence of adverse events.
223506970|NCT02523638|DRUG|Pegylated-Proline-Interferon alpha-2b in a Pre-filled Pen|Subjects will continue to receive the dosage which delivers the optimal disease response (hematocrit \[Hct\]\<45%, platelets \[PLTs\]\<400 x 109/L and leukocytes \[WBCs\]\<10 x 109/L), as determined in the PROUD-PV study, preferably at the level of target blood values.
223506971|NCT03312166|DEVICE|Compression device|"interventions on patient are :~* surgical excision of ear lobe keloid~* application of compression device on sutured skin"
223506972|NCT06016660|OTHER|Physiotherapy|Resistance exercise, Neuromuscular electrical stimulation, and Transcutaneous electrical stimulation
223506973|NCT03228576|COMBINATION_PRODUCT|Extended release Tacrolimus-Everolimus association|Envarsus® will be used as Tacrolimus Certican® will be used as Everolimus
223506974|NCT04915300|DRUG|Apabetalone|Apabetalone 100mg p.o. (tablets) BID for 24 weeks treatment period.
223506975|NCT04915300|DRUG|Placebo|Placebo p.o. (tablets) BID for 24 weeks treatment period.
223506976|NCT00239291|DRUG|Gefitinib, radiotherapy|
223506977|NCT02039570|OTHER|Transvaginal scan|transvaginal scan conducted using duplex ultrasonography
223506978|NCT03006575|RADIATION|split-course radiotherapy|split-course chest radiation at 40-51 Gy/10-17f and 15-24 Gy/5-8f
223506979|NCT03006575|DRUG|concurrent chemotherapy|weekly docetaxel(25mg/㎡) and nedaplatin(25mg/㎡) concurrent with chest radiation
223506980|NCT03808909|OTHER|Continuous Labor Support|Participants in the intervention condition will be assigned a doula who is a lay person trained to provide emotional and practical support to individuals throughout labor and delivery.
223506981|NCT00299754|DRUG|Misoprostol|
223506982|NCT03570138|DEVICE|FREESTYLE LIBRE device, a Flash Continuous Glucose Monitoring System|Specific therapeutic education for diabetes self management
223506983|NCT03570138|DEVICE|Usual self monitoring Blood Glucose device|Standard therapeutic education for diabetes self management
223506984|NCT01827943|DRUG|Temsirolimus|Temsirolimus
223506985|NCT00736736|OTHER|Additional Hip Muscle Strengthening to Leg Press Exercise|
223506986|NCT00736736|OTHER|Leg Press Exercise|
224198855|NCT05805072|DRUG|Aclacinomycin|aclacinomycin 10 mg/day intravenously on days 3 to 6
224198856|NCT05805072|DRUG|Granulocyte Colony-Stimulating Factor|granulocyte colony-stimulating factor 50-600 mcg/m2/day intravenously from days 2 to start, this dosage will be adjusted according to the hemogram,
224198857|NCT05805072|DRUG|Decitabine|Decitabine 20 mg/m2/day intravenously on days 1 to 5.
224198858|NCT05805072|DRUG|Azacitidine|Azacitidine 20 mg/m2/day subcutaneously on days 1 to 7
224198859|NCT04066101|GENETIC|high caries risk|DNAs were obtained from epithelial cells in buccal mucosa and were extracted with Genomic DNA Isolation Kit Genotyping for a variant was carried out on a Roche Applied Science LightCycler® 480 (Roche Diagnostics GmbH, Mannheim, Germany) with real-time polymerase reaction of Taqman
224198860|NCT04066101|OTHER|caries activity|"Dental caries lesions of all patient scored as initial, moderate or advanced caries~Initial lesion; clinically detectable lesion Moderate; visible signs of enamel breakdown Advanced; enamel was fully cavitaed"
224198861|NCT04216134|DRUG|Gallium Ga 68-labeled PSMA-11|Given IV
224198862|NCT04216134|PROCEDURE|Positron Emission Tomography|Undergo 68GA-PSMA-11 PET
224198863|NCT06176417|PROCEDURE|horizontal ridge augmentation by decompression technique.|Instead of a cover screw, a 2-mm healing abutment was used after implant insertion
224198864|NCT06176417|PROCEDURE|horizontal ridge augmentation by ridge splitting technique using piezosurgery.|horizontal ridge augmentation was done using piezosurgery tips and bone expanders
224311164|NCT05656872|PROCEDURE|Ilioinguinal-iliohypogastric block|Group I, will receive an Ultrasound-guided IIIH block that will be performed in a supine position after skin sterilization, a linear high-frequency transducer Siemens acuson x300 3-5 MHZ will be placed on the line between the anterior superior iliac spine and the umbilicus, where 3 layers of muscles (extra-abdominal oblique, intra-abdominal oblique, and transverse abdominis) will be visible on the inner side of the anterior superior iliac spine.A blunt tip,20-gauge, short bevel needle(Pajunk Sonoplex, Germany) will be inserted in-plane and advanced anterior to posterior under continuous visualization until the tip reaches between the internal oblique and the transversus abdominis muscle next to the iliohypogastric/ilioinguinal nerve. After negative aspiration, 20 mL of bupivacaine 0.25%, lidocaine 1% will be injected. The procedure will be repeated following the same steps on the other side.
224311165|NCT00873457|DRUG|perifosine|Perifosine 50 mg will be taken orally twice a day for a maximum of six 28-day cycles
224311166|NCT01625832|PROCEDURE|intermittent coronary sinus occlusion|Patients undergo two 2-minute coronary balloon occlusions. Patients are randomized to CSO first or CSO second.
223748368|NCT03899584|DRUG|4-Aminopyridine|Each patient will take 10 mg per kilogram of weight (example: a person weighing 60 kg, will take two capsules three times a day after meals, for a total of 6 capsules / day). Each capsule will contain 10 milligrams of 4-Aminopyridine that will allow to be administered sequentially at progressively higher doses / day. The dose of 4-aminopyridine will increase 10 mg / 2 to 4 weeks.
223748369|NCT03899584|DRUG|Placebo oral capsule|The placebo arm will include a placebo of microcrystalline cellulose.
223748370|NCT04234282|PROCEDURE|Manual Physical Therapy|Orthopedic manual physical therapy targeting the knee joint and soft tissues with complementary exercises targeted at their impairment.
223748371|NCT05257811|DEVICE|NextSense EEG-enabled earbuds|Each NextSense EEGBud device includes custom-fit earbuds with biometric sensors to detect EEG, motion (via tri-axial accelerometers), and heart rate. A ring laser scanner is used to capture the unique geometry of each participant's ear and external auditory canal. Digital models of the individual ear scans are generated and used to create custom fit, 3D-printed earbuds. This design process allows for consistent contact with the inner surface of the ear canal, providing high quality signal capture of brain activity, cardiac activity, and eye movements.
223748372|NCT00146146|DRUG|testosterone undecanoate alone|1000 mg/12 weeks
223748373|NCT00146146|DRUG|testosterone undecanoate plus letrozole|TU 1000 mg/12 weeks Letrozole 2.5 mg/day
223748374|NCT00146146|DRUG|testosterone undecanoate plus dutasteride|TU 1000 mg/12weeks Dutasteride 0.5 mg/day
224198865|NCT01002417|DRUG|MCS-2 15 mg/day|One MCS-2 15 mg soft-gel capsule plus one matching placebo capsule, oral daily for 12 weeks.
224198866|NCT01002417|DRUG|MCS-2 30 mg/day|Two MCS-2 soft-gel capsules, oral daily for 12 weeks.
224198867|NCT01002417|DRUG|Placebo|Two matching placebo soft-gel capsules, oral daily for 12 weeks.
224198868|NCT03829527|BEHAVIORAL|Psychotherapy|Psychological intervention combining a standardized treatment manual with a smartphone application
224198869|NCT04197882|BIOLOGICAL|OrienX010 Combination with Toripalimab injection|OrienX010 Produced by Oriengene Biotechnology Co.,Ltd. Strength: 1.0 mL/vial. Toripalimab infusion Produced by Junshi Biosciences Co., Ltd. Strength: 240 mg/6 mL/vial; Sterile water injection dosage form; Expiry date: 24 months; Date of manufacture: Based on the date of manufacture indicated in the product package.
224198870|NCT04100369|DIAGNOSTIC_TEST|laboratory|Arm
224198871|NCT06103162|DEVICE|flexible feeding plate|One mm thick clear thermoplastic sheet was adapted over the cast using a vacuum-forming machine.
224198872|NCT06390280|PROCEDURE|intraoperative Fraction of Inspired Oxygen|Group I intraoperative Fraction of Inspired Oxygen 30%, Group II intraoperative Fraction of Inspired Oxygen 80% applied group.
224198873|NCT01807780|BIOLOGICAL|biological monitoring|
223506987|NCT01029873|DRUG|Cisplatin|Intravenous infusions; 2 treatment courses; 2 treatment cycles for each course; 70mg/m2 on day 1 of cycle 1 for each course
223506988|NCT01029873|BIOLOGICAL|ALT-801|"Intravenous infusions; cycle 1: day 3 and 5; cycle 2: day 1, 3 and 5; nine day rest period between cycles; seven day recovery period between courses~Stage 1: dose escalation (0.04 mg/kg, 0.06 mg/kg, 0.08 mg/kg)~Stage 2: dose expansion (dose at MTD)"
223506989|NCT03335566|DRUG|Sonazoid™|Single Dose of Sonazoid™ 0.12 µL MB/kg as I.V. injection.
223506990|NCT03335566|DRUG|SonoVue®|Single Dose of SonoVue® 2.4 mL as I.V. injection.
223506991|NCT01084135|DRUG|Rivastigmine|At the baseline visit (week 0), the subject will begin rivastigmine treatment at a dose of 0.75 mg bid. This dose will be continued for two weeks and then increased to 1.5 mg bid for an additional eight weeks. At the week 10 safety visit, the dose will be increased to 4.5 mg/day (3.0 mg and 1.5 mg) for an additional 10 weeks. Subjects receiving placebo will maintain the same schedule. If a subject is unable to tolerate a particular dose, the dose will be lowered to the previously tolerated dose, down to a minimum of 0.75 mg bid. If the subject is unable to tolerate the 0.75 mg bid dose he/she will be dismissed from the study.
223506992|NCT01084135|OTHER|Liquid Placebo|Subjects receiving placebo will maintain matched titration volume increase as treatment arm. The placebo will be matched to liquid rivastigmine in consistency and taste.
224198874|NCT04334122|OTHER|Instrument-assisted soft tisue mobilization|"All patients in the experimental group were given a traditional physiotherapy program applied in lumbar disc herniation for 4 weeks (20 sessions) and 5 days a week.~In addition to the traditional physiotherapy program, the patients in the experimental group were subjected to tool-assisted soft tissue mobilization 3 times a week (12 sessions with 1 day interval).~All evaluations were repeated to all patients in the experimental and control groups after four weeks."
223598779|NCT05595772|PROCEDURE|Surgery: Dental Implant surgery|Immediate implant following extraction
223598780|NCT05595772|PROCEDURE|Tooth extraction|A Traumatic tooth extraction
223598781|NCT05595772|PROCEDURE|Xenogenic bone grafting|Application of bovine bone grafting over area of dehiscence around immediate implant
224198875|NCT04334122|OTHER|Traditional physiotherapy|All patients in the control group were given a traditional physiotherapy program applied in lumbar disc herniation for 4 weeks (20 sessions) and 5 days a week.
223598782|NCT02103413|DEVICE|EUS-BD|When the ERCP was unsuccessful, we tried one-step EUS-BDS using a linear-array echoendoscope (GF-UCT 240-AL 10 or AL 5, Olympus Medical Systems, Tokyo, Japan) at the same ERCP unit on the same session. EUS-BDS was performed by EUS-guided choledocoduodeostomy (EUS-CD) or EUS-guided hepaticogastrostomy (EUS-HG) at the discretion of involved endosonographers. Based on our modified protocol from two our proposed protocols, EUS-BD with transmural stenting was only considered.
223598783|NCT02103413|DEVICE|PTBD|PTBD was performed in selected patients with an 8.5F catheter inserted under fluoroscopic or ultrasound guidance by experienced interventional radiologists or endoscopists.
223598784|NCT03125772|DEVICE|TAXUS Element™ Paclitaxel-Eluting Stent System|Texus Element is the next generation Boston Scientific paclitexel-eluting coronary sten and received DCGI approval on April 13th, 2010.
223598785|NCT03125772|DEVICE|Xience PRIME Everolimus-Eluting Stent System|The Everolimus-eluting stent manufactured and distributed by Abbott Vascular Santa Clara, CA, as Xience Prime.
223598786|NCT00044902|DRUG|epratuzumab|
223598787|NCT04790071|OTHER|Conventional physical therapy|Conventional physical therapy: The patients received physical therapy to the shoulder, transcutaneous electrical nerve stimulation, and stretching and strengthening exercises (5 days per week for three weeks in a total of 15 sessions).
223598788|NCT04790071|OTHER|Conventional physical therapy plus dry needling|Conventional physical therapy plus dry needling: The patients received physical therapy to the shoulder, including transcutaneous electrical nerve stimulation, stretching, and strengthening exercise (5 days per week for three weeks in a total of 15 sessions). And also, a total of 3 dry needling sessions were applied at 7-day intervals.
223598789|NCT05420649|PROCEDURE|Non-intubated Laryngomicrosurgery|Non-intubated LMS was performed with assistance of Optiflow (HFNO).
224198876|NCT03183739|DRUG|ASP8062|ASP8062 will be administered orally.
224198877|NCT03183739|DRUG|Placebo|Placebo will be administered orally.
224198878|NCT01939834|DEVICE|Overnight CLC|Overnight Closed-Loop Control (CLC) is run on the DiAs which is a medical platform that uses a smart-phone to connect to a continuous glucose sensor to insulin pump. The cell phone runs the CLC and is connected to work with the insulin pump and continuous glucose monitor to help keep the blood sugar in a desired range.
224198879|NCT01939834|DEVICE|Sensor-Augmented Pump Therapy (SAP)|The subject will be on their home insulin pump (UVA) or study pump (Italy) and using a CGM per their usual care.
224198880|NCT04895046|DRUG|Niraparib|300 mg taken orally (all cycles)
224198881|NCT04895046|DRUG|Dostarlimab|500 mg (cycles 1-4) intravenously
224198882|NCT04895046|DRUG|Dostarlimab|1000 mg (cycle 5+) intravenously
224311167|NCT03299946|DRUG|Cabozantinib|Cabozantinib (40mg) will be taken by mouth daily for 8 weeks.
224311168|NCT03299946|DRUG|Nivolumab|Nivolumab 240mg intravenously every 2 weeks (days 14, 28, 42, and 56 for a total of four doses), in combination with Cabozantinib 40mg by mouth daily for 8 weeks.
223506993|NCT00663351|DEVICE|Reflection Ceramic-Ceramic Total Hip Replacement|Intervention: all patients in study required (intervention) a total hip replacement, and were randomized to receive either the (Study Device)Reflection Ceramic Acetabular System or the(Control Device) Reflection FSO V (5 hole)acetabular system. Both arms received either a Synergy porous coated or Spectron EF stem.
223598790|NCT05535829|OTHER|Laboratory analysis of samples|Laboratory analysis of samples
223506994|NCT00663351|DEVICE|Reflection FSO V Total Hip Replacement|Intervention: all patients in study required (intervention) a total hip replacement, and were randomized to receive either the (Study Device)Reflection Ceramic Acetabular System or the(Control Device) Reflection FSO V (5 hole)acetabular system. Both arms received either a Synergy porous coated or Spectron EF stem.
223506995|NCT04992741|OTHER|education and motivational interview|The control group will remain subject to the routine process without any intervention.
223506996|NCT04740879|BEHAVIORAL|Be Mindful|The online 4-week Be Mindful intervention was designed to follow the same outline as typical in-person 8-week MBCT courses. Week 1 and Week 2 introduce the topic of mindfulness and encourage its daily use, whereas Week 3 and Week 4 teach the individual to decenter from thoughts and utilize mindfulness when coping with stressors. Each week focuses on a separate mindfulness topic, which is initially presented to the individual in a short (under 5 minute) video containing didactic information and an overview of the experiential activities that will be introduced in subsequent videos. The intervention is provided entirely through audio, video, and text provided on the Be Mindful website (BeMindfulOnline.com).
223506997|NCT01356485|DRUG|MP4CO|43 mg/mL pegylated carboxyhemoglobin \[≥ 90% CO hemoglobin saturation\] in physiological acetate electrolyte solution
223506998|NCT01356485|DRUG|Sodium chloride solution|Normal saline (0.9% sodium chloride solution)
223506999|NCT00567112|DRUG|10 mg MK-0941 DFC (fasted)|single dose of 10 mg MK-0941 dry filled capsules (DFC) administered in a fasted state
223507000|NCT00567112|DRUG|10 mg MK-0941 OCT (after meal)|single dose of 10 mg MK-0941 oral compressed tablet (OCT) administered after consumption of a high-fat meal
223507001|NCT00567112|DRUG|10 mg MK-0941 OCT (before meal)|single dose of 10 mg MK-0941 oral compressed tablet (OCT) administered before consumption of a standard breakfast
223507002|NCT00567112|DRUG|10 mg MK-0941 OCT (fasted)|single dose of 10 mg MK-0941 oral compressed tablet (OCT) administered in a fasted state
223507003|NCT06500689|DRUG|Allisartan Isoproxil/Sustained-Release Indapamide|"Double-blind period (Week 1\~Week 12): Allisartan Isoproxil/Sustained-Release Indapamide.~Open-label period (Week 13\~Week 52): Allisartan Isoproxil/Sustained-Release Indapamide."
223507004|NCT06500689|DRUG|Allisartan Isoproxil|"Double-blind period (Week 1\~Week 12): Allisartan Isoproxil.~Open-label period (Week 13\~Week 52): Allisartan Isoproxil/Sustained-Release Indapamide."
223507005|NCT05141747|DRUG|MRG002|Administrated intravenously
224198883|NCT01118949|DRUG|Lacosamide|Lacosamide is supplied as 50 mg, 100 mg, 150 mg, and 200 mg tablets. Subjects will begin a Dose-Titration Phase of Lacosamide at 100 mg/day (50 mg bid, approx. 12 hours apart, once in the morning and once in the evening) for 1 week. Three (3) weekly increases will follow until the subject reaches a dosage of 200 mg/day, 300 mg/day, or 400 mg/day, as deemed clinically appropriate. The final titration will be followed by a 6-week Maintenance Phase. Subjects who complete the Maintenance Phase have the opportunity to enroll in an open-label extension study; those who do not enroll will begin a 3-week End-of-Study Phase when Lacosamide will be tapered off gradually at a recommended rate of 200 mg/day/week.
224198884|NCT01438827|DRUG|Avanz Phleum pratense|Suspension for Injection, Every 6 weeks for one year
223507006|NCT00236964|DRUG|Iron Sucrose + Erythropoietin|The total dose of iron sucrose was 1,000 mg. Participants also received erythropoietin 2,000 units subcutaneously on Days 1, 8, 15, 22, 29, and 36.
223507007|NCT00236964|DRUG|Oral Iron + Erythropoietin|Oral iron 325 mg three time daily for 29 days. Participants also received erythropoietin 2,000 units subcutaneously on Days 1, 8, 15, 22, 29, and 36.
223507008|NCT04063137|DIETARY_SUPPLEMENT|Anthocyanin fortified bread with beef patty (35% fat)|Bread is fortified at a 4% level using 25% (w/w) anthocyanin black rice extract. It is served with a beef patty (35% fat) to simulate a high-fat diet.
223507009|NCT05999370|BEHAVIORAL|Nutrition|"The nutrition intervention will be based on needs assessed by indirect calorimetry, patient-generated subjective global assessment, and 24hr recall conducted at baseline, enabling individualized caloric and protein targets.~Deficits in nutrient intake will be addressed with one-on-one dietary counselling and supplementation at baseline in a quantity that matches the estimated deficit in intake. Adherence will be monitored using 24-hr recalls and weight status by the dietitian weekly."
223507010|NCT05999370|BEHAVIORAL|Exercise|The exercise intervention will include both a resistance and an aerobic component to be performed a total of 5 times a day, 5 times per week, 5 minutes each session, totaling 125 minutes per week. The ability to perform exercises as prescribed will be monitored with a weekly in-person or virtual supervised session.
224198885|NCT01438827|DRUG|Placebo|Suspension for Injection, Every 6 weeks for one year
224198886|NCT06652282|OTHER|Pilates exercises|Before starting the training program, patients will learn key Pilates elements, including diaphragmatic breathing, neutral position, rib cage placement, shoulder placement, and head and neck placement. The exercise program includes Pilates-based mat exercises and Pilates-based theraband exercises, with patients placed in supine, prone, and kneeling positions to perform exercises for the affected shoulder. The patient will be placed in various positions for optimal results.
224198887|NCT06652282|OTHER|proprioceptive neuromuscular facilitation|Before starting the training program, patients will learn key Pilates elements, including diaphragmatic breathing, neutral position, rib cage placement, shoulder placement, and head and neck placement. The exercise program includes Pilates-based mat exercises and Pilates-based theraband exercises, with patients placed in supine, prone, and kneeling positions to perform exercises for the affected shoulder. The patient will be placed in various positions for optimal results.
224198888|NCT06652282|OTHER|The conventional program|Each patient was in the supine position and will receive stretching exercise for the flexors and adductors, and strengthening for the extensors, abductors and scapular stabilizers of the affected shoulder
224198889|NCT00243672|DRUG|Atorvastatin|
224198890|NCT00243672|DRUG|Gemfibrozil|
224198891|NCT03255226|DRUG|Tolvaptan|Tolvaptan 1% granules or tolvaptan 15 mg tablet with water once daily.
224198892|NCT06505473|BEHAVIORAL|music-CBT|notched relaxation music combined with personalized CBT
224198893|NCT05557968|OTHER|Conventional Therapy|"conventional therapy will be given for stroke patients and three assessments i.e. pre, post and follow up surveys, a session of 30 minutes, 3 times weekly for a six week period.~Total 18 sessions would be performed on each patient for six weeks"
224198894|NCT05557968|OTHER|Action Observation Therapy (AO)|"The video consists of :~1. Ascending and descending the step box.~2. Ascending and descending the stairs in the treatment room.~3. Holding the handrails to climb and descend the stairs inside and outside the building.~4. Climbing and descending the stairs inside and outside the building without holding the handle.~5. Climbing and descending the sidewalk block"
224198895|NCT04029766|DRUG|HSK3486|
224198896|NCT04303065|DRUG|Dexamethasone Oral|It will be a short and descending course of oral dexamethasone: 4mg/6 hours (2 days); 4 mg/8 hours (2 days); 2 mg/6 hours (2 days); 2 mg/8 hours (2 days); 1 mg/8 hours (2 days); 1 mg/12 hours (2 days).
224198897|NCT04303065|DRUG|Placebo oral tablet|The preparation and conditioning of the placebo capsules will be carried out following the standardized work procedures of the pharmaceutical laboratory and its quality controls, previously authorized by the Agencia Española del Medicamento (AEMPS).
224198898|NCT01231880|DRUG|Four monthly IPT with dihydroartemisinin Piperaquine (DP)|Given every 4 months (once a school term)
224198899|NCT01231880|DRUG|Monthly IPT using DP|Given every month
224198900|NCT01231880|DRUG|Placebo given every month|No active ingredient
224198901|NCT03504839|DEVICE|Subcutaneous ICD with same day discharge|Receiving a SICD and discharged the same day
224198902|NCT00685763|RADIATION|Proton radiation and chemotherapy|"Proton radiation 59.4 CGE in 33 fx at 1.8 CGE per fx over 7 weeks .~Chemotherapy:~Capecitabine (Xeloda ®) 1,000 mg by mouth twice a day, 5 days/week (M-F) Consolidation Chemotherapy: Suggested Regimen - Gemcitabine total of 12 doses"
224311169|NCT04106661|OTHER|Tai Chi|Physical activity requiring slow, controlled whole body movement and weight shifting.
224311170|NCT04514432|OTHER|Music|If patients experienced agitation, they were able to request to listen to music for 30 minutes. They listened to genre playlists generated by the music application Spotify.
223617884|NCT05574023|DEVICE|Use of Alarm on Threshold for hypoglycaemia or hyperglycaemia|"in case of alarm of hypoglycemia, the indicated treatment was 0.3g of sugar/kg of body weight, max 15g.~in case of alarm of hyperglycemia, the indication will be to give an extra shot of rapid-acting insulin. The dose will be calculated on the basis of personal insulin sensitivity factor (ISF), considering as target a blood glucose of 120 mg/dl and 250 mg/dl as blood glucose level to correct. This could be done only if there is no active insulin on-board, after at least 3 hours from the last rapid-acting insulin injection."
223617885|NCT02448277|DEVICE|Macintosh Laryngoscope|the device is to assist nasotracheal intubation
223617886|NCT02448277|DEVICE|Pentax Airway scope|the device is to assist the nasotracheal tube into trachea
224198903|NCT04602208|PROCEDURE|Retrospectively review of medical data in patients treated by focal HIFU for primary localized prostate cancer|This study concern the patients with localized prostate cancer treated by Focal HIFU for low or intermediate risk disease. Three surgeons experienced in HIFU performed the procedures. Patients were treated with the Ablatherm device \[EDAP TMS S.A., Vaulx-en-Velin, France\] until July 2013 and then with the Focal-One device \[EDAP TMS S.A.\]. The data of all the patients treated between November 2009 to December 2016, at Edouard Herriot Hospital (Lyon, France), were prospectively maintain within a central database and retrospectively reviewed. The study primary outcome was retreatment-free survival (RFS) defined as any additional further treatment: local (FT/PGA for in-field or out-of-field recurrences or radical prostatectomy or external beam radiotherapy or whole gland HIFU) or systemic salvage treatment, a positive biopsy revealing PCa with an ISUP grade≥ 2 in nontreated patients, PCa metastasis or PCa specific death. The adverse events and functional outcomes were also evaluated.
224198904|NCT02237066|DEVICE|Chocolate PTA Balloon Angioplasty|OCT imaging of diseased vessel is treated with an Angioplasty Procedure using the Chocolate PTA Balloon Catheter followed by OCT imaging of the treated area immediately after balloon use and 10 minutes later
224198905|NCT02237066|DEVICE|Standard PTA Balloon Angioplasty|OCT imaging of diseased vessel is treated with an Angioplasty Procedure using a standard PTA Balloon Catheter followed by OCT imaging of the treated area immediately after balloon use and 10 minutes later
224198906|NCT00988039|DRUG|Aluvia + 2NRTIs|"Aluvia (lopinavir/ritonavir 400mg/100mg), twice daily~The choice of NRTIs will be at the discretion of the managing clinician and based on the local standard of care and drug availability, taking into account patient's previous drug exposure and side effects on first-line therapy."
224198907|NCT00988039|DRUG|Aluvia + raltegravir|"Aluvia (lopinavir/ritonavir 400mg/100mg) twice daily~raltegravir (400mg) twice daily"
224198908|NCT00988039|DRUG|Aluvia monotherapy|"Aluvia (lopinavir/ritonavir 400mg/100mg) twice daily~raltegravir (400mg) twice daily for the first 12 weeks only"
224198909|NCT01741259|DRUG|Meperidine|
224198910|NCT06119737|OTHER|Exercise|Effects of exercises on TSH levels
224198911|NCT06563661|OTHER|The 21-style specific dance exercises|The 21 dance styles (dance in a group), chosen and modified from seven dance styles, including cha-cha, jive, rumba, salsa, waltz, tango, and macarena, were developed by a group of experienced dance and rehabilitation experts and have been previously practised by a group of older adults in our pilot work, demonstrating good feasibility and positive participants' feedback.
224198912|NCT05167396|DEVICE|Retinaute (BioSerenity)|Wearable device in the form of a virtual reality headset for the recording of electrophysiological measurements such as electroretinogram (ERG) and electrocenphalogram (EEG), ISCEV standards
224198913|NCT05167396|DEVICE|EEG Headset 64 electrodes (BioSemi)|EEG headset with 64 electrodes for the recording of visual cortical electrophysiological signals
224198914|NCT05167396|DEVICE|MonPackOne (Metrovision)|"Standard device for the recording of electroretinography (ERG) measurements, ISCEV standards~WARNING : Device used only in 3 healthy controls to address the secondary objective"
224198915|NCT03994991|DEVICE|active TMS|Transcranial magnetic stimulation
224198916|NCT03994991|DEVICE|sham TMS|Sham transcranial magnetic stimulation
224198917|NCT01853969|OTHER|Typing assessment|
224198918|NCT00027573|BIOLOGICAL|filgrastim|
224198919|NCT00027573|BIOLOGICAL|therapeutic allogeneic lymphocytes|
224198920|NCT00027573|DRUG|cyclophosphamide|
224311171|NCT06287528|BIOLOGICAL|19-28z/IL-18 CAR T cells|19-28z/IL-18 CAR T cells are an investigational new drug (IND) for the treatment of R/R B-ALL
224311172|NCT06682546|DRUG|ET-26HCl 0.6mg/kg group|The initial dose is 0.6 mg/kg, intravenous injection,with an additional 50% starting dose if needed (30second±5second bolus completion). Infusion time was 1minute ± 5second.
223507020|NCT05549453|DEVICE|Nexstim SNBT use|Active device use
223507021|NCT05938192|PROCEDURE|vaccination|Patients will have surgery (followed by vaccination) for managing HPV-related lesions
223507022|NCT05670197|OTHER|No intervention. Participants will take part in a qualitative interview|No intervention. Participants will take part in a one-off, audio-recorded qualitative interview, lasting up to 60 minutes. The interviewer will ask about participants' views on complex digital remote monitoring.
223507023|NCT05853913|BEHAVIORAL|Exercise|Exercise will be walking/jogging at a medium to hard intensity for 1 hour.
223507024|NCT05872945|DIAGNOSTIC_TEST|Electrocardiogram|Study by Artificial Intelligence the biosignal or biodata from profesional football players
223507025|NCT04702750|BEHAVIORAL|Targeted memory reactivation (odors)|I will unobtrusively and repeatedly present learning-related odors during sleep using an olfactometer. This method was shown to improve memory in various tasks. The odors will be presented in blocks with short breaks in-between. Odors will be pleasant as to not wake the participant up. The odors will be presented during non-rapid eye movement sleep (sleep stage 2 and slow wave sleep). The odors presented will be non-congruently associated with instructions in a previous learning task. This manipulation is within-subject - all participants will be exposed to all the odors during sleep, but odors will be associated with different instructions for each participant (counterbalanced).
224311173|NCT06682546|DRUG|ET-26HCl 0.8mg/kg group|The initial dose is 0.8 mg/kg, intravenous injection,with an additional 50% starting dose if needed (30second±5second bolus completion). Infusion time was 1minute ± 5second.
224311174|NCT06682546|DRUG|Etomidate Injectable Product 0.3mg/kg group|The initial dose is 0.3 mg/kg, intravenous injection,with an additional 50% starting dose if needed (30second±5second bolus completion).Infusion time was 1minute ± 5second.
224311175|NCT06972030|BEHAVIORAL|Motivational interviewing|After the pre-test, motivational interviewing-based training consisting of six sessions, once a week, will be applied to the students in the experimental group. A pre-test, post-test (after 6 weeks) and control test will be applied to both groups. At the end of the training, training materials will be shared with the students.
224311176|NCT06970782|DRUG|Vebreltinib|Subjects will receive Vebreltinib Enteric-coated Capsule orally twice per day (BID).
224311177|NCT06970782|DRUG|PLB1004|Subjects will receive PLB1004 80mg orally once per day (QD).
224311178|NCT06970782|DRUG|Pemetrexed plus Carboplatin or Cisplatin|Subjects randomized to the control group received pemetrexed 500 mg/m² + platinum-based chemotherapy (carboplatin AUC 5 or cisplatin 75 mg/m²) via intravenous infusion for 4-6 cycles (determined by the investigator) as initial therapy, followed by pemetrexed maintenance therapy (500 mg/m²) until disease progression, intolerable toxicity, initiation of new antitumor therapy, death, loss to follow-up, or other treatment-terminating conditions (whichever occurred first).
223598791|NCT03960892|BEHAVIORAL|Problem Management Plus (PM+)|This intervention is based on the WHO treatment guidelines for conditions related to stress (WHO, 2013). It is a 5-session intervention that is delivered by trained non-specialists, and is available in individual and group delivery formats for both children and adults. PM+ includes evidence-based techniques such as; problem solving, stress management, behavioral activation, and accessing social support. It has proved to be effective by two randomized controlled trials (RCTs) in Kenya and Pakistan (Bryant, Dawson, Schafer, Sijbrandij, \& van Ommeren, 2016; Rahman, Hamdani, Awan, Bryant, Dawson, Khan, Mukhtar-ul-Haq Azeemi, et al., 2016).
223598792|NCT00317382|DEVICE|Ultrasound|Ultrasound used to visualize spine to determine best location for lumbar puncture.
223598793|NCT04412707|DRUG|Melphalan|Peripheral versus central administration
223598794|NCT04412707|DRUG|Dexamethasone|Oral tablets
223598795|NCT01332747|DRUG|safoof e muhazzil|"drug is composed of 5 herbal(Carum Carvi,Trachyspermum copticum,Foeniculum Vulgare,Origanum Vulgare,Ruta Graveolens) 1 animal origin (Lac)and 1 mineral origin (Borax) ingredients.~to be given in a dosage of 5 gms twice daily"
223598796|NCT01332747|DRUG|compressed tablet of safoof e muhazzil|"drug is composed of 5 herbal(Carum Carvi,Trachyspermum copticum,Foeniculum Vulgare,Origanum Vulgare,Ruta Graveolens) 1 animal origin (Lac)and 1 mineral origin (Borax) ingredients.~compressed into tablets of 1 gm each+ binders qs. dose is 5 tablets twice daily"
223598797|NCT01332747|DRUG|Atorvastatin|atorvastatin 10 mgs once daily
223598798|NCT03586115|DEVICE|Critical flicker frequency assessment|All patients will undergo critical flicker frequency assessment to evaluate the presence of minimal hepatic encephalopaty. In addition, hepatic elastometry will be assessed to evaluate the presence of advanced liver fibrosis.
223598799|NCT06486415|DIAGNOSTIC_TEST|serum BHCG testing|Taking 5ml blood samples every 2 hours for 5 times for measurement of BHCG. Blood samples will be taken from the median cubital and cephalic veins which is located inner side of the elbow.
223598800|NCT02275442|OTHER|EPICES scale|
223598801|NCT02335593|DIETARY_SUPPLEMENT|Zinc Sulphate|Zinc Sulphate Hard Gel capsules 110mg
223598802|NCT02335593|OTHER|Corn Starch filled Hard Gel Capsules|Corn Starch filled Hard Gel Capsules
223598803|NCT02335593|DRUG|Epoetin alfa 2000-4000 IU solution for injection|Epoetin alfa 2000-4000 IU solution for injection
223598804|NCT02335593|DRUG|Iron Hydroxide Saccharate Complex Solution for injection|Iron Hydroxide Saccharate Complex Solution for injection
223598805|NCT03831035|OTHER|Genetic analyse by whole exome sequencing|Exome sequencing requires analytic, bio informatic and interpretation steps.
223598806|NCT03956524|BIOLOGICAL|EuTCV|Single 0.5 mL dose of TCV of EuBiologics co., Ltd.
224198921|NCT00027573|DRUG|fludarabine phosphate|
224198922|NCT00027573|DRUG|methotrexate|
224198923|NCT00027573|DRUG|tacrolimus|
224198924|NCT00027573|PROCEDURE|peripheral blood stem cell transplantation|
224198925|NCT06537531|OTHER|Compare VCI scale|Compare VCI scale
224198926|NCT05246982|DRUG|HLX07+HLX10+oxaliplatin+capecitabine|HLX07 1500mg+HLX10 300mg+oxaliplatin 130mg/m2+capecitabine 1000mg/m2 q3w
224198927|NCT05246982|DRUG|HLX07|HLX07 1500mg q3w
224198928|NCT06023758|DRUG|KN026|KN026：30 mg/kg Q3W
224198929|NCT06023758|DRUG|KN046|KN046：5 mg/kg Q3W
224198930|NCT06023758|DRUG|XELOX|Oxaliplatin 130mg/m2 d1，Capecitabine 1000mg/m2 d1-14，Q3W
224198931|NCT06653335|BEHAVIORAL|Education Support Programme via Text Message|All students to be included in the study will be pre-tested via Google Form's. After the pre-test, the students in the experimental group will be sent images created by the researchers via text message for 4 weeks (22 days) and consisting of the information given in the Basic Principles and Practices in Midwifery Course. Each visual will contain one piece of information. The researchers will send 6 visuals to the students in the experimental group via text message every day for 4 weeks, except Saturdays and Sundays. The post-test will be applied immediately after the end of the implementation process. The messages will be short and contain a single piece of information.
224198932|NCT03673137|DEVICE|Irreversible electroporation|During the IRE process, we employed a CT scanner and an ultrasound system to guide percutaneous insertion of the electrode probes (one main electrode and one to three standard electrodes were used per treatment). The electrode number, electrode-insertion mode and intraoperative parameters were decided upon during pretreatment planning. The IRE parameters were visually simulated in the pulse generator and set up as follows: energy was applied at 1500 V/cm for 90 ms/pulse for a total of 7-9 pulses. After an initial testing pulse train was discharged to establish the best voltage value, the remaining 80 pulses were completed in 1-2 minutes. After ablation, we confirmed completion of IRE by measuring real-time resistance or current changes, in addition to intraoperative ultrasound and CT.
224198933|NCT03673137|DRUG|Gemcitabine|Gemcitabine hydrochloride (Qilu pharmaceutical \[Hainan\] Co., Ltd. Haikou, China\] was administered by intravenous infusion at a dose of 1000 mg/m2.
224198934|NCT00056537|DRUG|ABR-217620|Starting dose: 0.5 mcg/kg; subsequent doses: individual, based on pre-treatment level of anti-SEA/E-120, body weight, and toxicities observed in prior patients on study; IV; one bolus injection each day for 5 consecutive days; up to 3 cycles
224198935|NCT00637598|RADIATION|Mammography and tomosynthesis imaging|All subjects receive the same radiation dose associated with mammography and tomosynthesis imaging (which is comparable to mammography).
223598807|NCT03956524|BIOLOGICAL|Typbar-TCV™|Single 0.5 mL dose of TCV of Bharat Biotech
223598808|NCT03956524|BIOLOGICAL|Typhim Vi®|Single 0.5 mL dose of Vi capsular polysaccharide vaccine of Sanofi Pasteur
223598809|NCT03064919|BEHAVIORAL|Curriculum Testing|An evidence-based curriculum for teaching preschool children to eat in response to internal hunger and fullness signals was developed by refining an existing curriculum. State-of-the art theories in early childhood science education, innovative virtual technology to provide more realistic simulations of hunger and fullness, and a parent training component to improve long-range sustainability were incorporated. This 9-wk intervention will be tested by forty children (ages 4-5). Key outcomes will be children's adjustment in intake in response to a first course (energy compensation) and children's intake of tasty snacks when not hungry (eating in the absence of hunger). Additionally, the investigators will measure other variables likely to impact the success of the curriculum, for example: child gender/age, parent feeding practices, parent education, infant feeding practices, child/parent weight status, and others.
223598810|NCT02959359|DRUG|Ledipasvir 90mg/Sofosbuvir 400 mg|A 12 week Harvoni (Ledipasvir 90mg/Sofosbuvir 400 mg ) plus ribavirin will be provided after confirmation of curative treatment.
223598811|NCT02959359|DRUG|Ribavirin|A 12 week Harvoni (Ledipasvir 90mg/Sofosbuvir 400 mg ) plus ribavirin will be provided after confirmation of curative treatment.
223598812|NCT01370265|DRUG|Regadenoson|Regadenoson (0.4 mg/5 ml IV) was administered intravenously over 10 seconds, followed immediately by saline flush.
223598813|NCT01370265|DRUG|Adenosine|Adenosine (140 μg/kg/min) was administered intravenously over 6 minutes.
223598814|NCT01370265|DRUG|N-13 ammonia|Ammonia N-13 Injection is a radioactive diagnostic agent for Positron Emission Tomography (PET) indicated for diagnostic PET imaging of the myocardium under rest or pharmacologic stress conditions to evaluate myocardial perfusion in patients with suspected or existing coronary artery disease. The N-13 ammonia used in the study was synthesized by the Mayo Cyclotron Facility as per routine institutional clinical protocol.
223598815|NCT03063463|PROCEDURE|pneumatic dilation|Pneumatic dilation of the lower esophageal sphincter (LES) consists of inserting a guide wire under visual control into the stomach and to pass the balloon over the guide wire. The balloon is inflated, disrupting the muscle fibers of the sphincter.
224198936|NCT02396238|DEVICE|Celution Device|ADRCs prepared using the investigational Celution Device
224198937|NCT02396238|OTHER|Placebo|Placebo
224198938|NCT02341573|DRUG|experienced chinese herbal formulas|At the acute stage of asthma :Shegan mixture ; At the remission stage:Huangqi Bushen mixture; 10-30 mL , 2 times a day, for 3 months.
224198939|NCT02341573|DRUG|leukotriene receptor antagonist and bronchial relaxant|At the acute stage of asthma : etinoline,twice a day for 7 days; At the remission stage: Singulair, once daily for 3 months.
224198940|NCT03245359|DEVICE|Short-term ON-Q|single port, select-a-flow pump connected to saphenous nerve block catheter until medication in initial balls are depleted (usually 2-4 days)
224311179|NCT06213233|DRUG|Placebo|Participant will take placebo days 1-28 during study treatment. Given the pragmatic design, participants will be instructed to take the study drug whenever participants wish, with suggested starting dosing of 0.2 milliliter (mL) in the morning and 0.2mL in the evening (up to 1.2mL per day).
224311180|NCT06213233|DRUG|Cannabidiol|Participant will take Epidiolex days 1-28 during study treatment. Given the pragmatic design, participants will be instructed to take the study drug whenever participants wish, with suggested starting dosing of 0.2 milliliter (mL) in the morning and 0.2mL in the evening (up to 1.2mL per day).
224311181|NCT06338956|DRUG|LDL reduction therapy|LDL reduction therapy
224311182|NCT05830838|PROCEDURE|Computed Tomography|Undergo PET/CT
223598816|NCT03063463|PROCEDURE|surgical myotomy|This procedure destroys the muscles at the gastroesophageal junction, allowing the valve (LES) between the esophagus and stomach to remain open.
223598817|NCT04608604|OTHER|Physiotherapy|Patients will be randomized in either physiotherapy 1 or physiotherapy 2. Physiotherapy programs are individually tailored based on a structured standardized series. In order to not unblind potential participants, detailed description of both interventions will be provided after recruitment has been finished.
223598818|NCT02454777|BEHAVIORAL|Exercise Intervention|Undergo HIT
223598819|NCT02454777|OTHER|Laboratory Biomarker Analysis|Correlative studies
223598820|NCT02454777|OTHER|Quality-of-Life Assessment|Ancillary studies
223598821|NCT02454777|OTHER|Questionnaire Administration|Ancillary studies
224311183|NCT05830838|RADIATION|Image-Guided Adaptive Radiation Therapy|Undergo daily adaptive online replanning for SBRT
223598822|NCT03043391|BIOLOGICAL|Polio/Rhinovirus Recombinant (PVSRIPO)|PVSRIPO will be delivered intratumorally by convection-enhanced delivery (CED) using an intracerebral catheter placed within the enhancing portion of the tumor. A stereotactic biopsy will be performed prior to virus administration. Immediately following the stereotactically-guided tumor biopsy, a catheter will be implanted in the operating room at a site the same or different from that used for the biopsy using sterile techniques under general anesthesia. The entire volume of PVSRIPO to be delivered will be pre-loaded into a syringe by the investigational pharmacist and connected to the catheter under sterile conditions in the Pediatric Intensive Care Unit (PICU) just prior to beginning of infusion.
223748375|NCT05557539|BIOLOGICAL|blood samples, urine samples and nasopharyngeal swabs|The following samples will be collected: First time point : 6 blood sample tubes (5mL EDTA, 5mL heparinized and 7.5mL heparinized, 5mL citrate, 5mL serum, 5mL Tempus Blood RNA Tube); 1 urine sample (10mL in a sterile collector) and 1 naso-pharyngeal swab (1mL UT medium). Second time point : 5 blood sample tubes (5mL EDTA,5mL heparinized and 7.5mL heparinized, 5mL serum, 5mL Tempus Blood RNA Tube); 1 urine sample (10mL in a sterile collector) and 1 naso-pharyngeal swab (1mL UT medium).
224198941|NCT03245359|DEVICE|Short-term ON-Q|single port, fixed flow pump connected to posterior knee catheter until medication in initial balls are depleted (usually 2-4 days)
224198942|NCT03245359|DRUG|Short-term ON-Q|Bupivacaine 0.125%
224198943|NCT03245359|DEVICE|Long-term ON-Q|single port, select-a-flow pump connected to saphenous nerve block catheter until day 7 post-operative
224198944|NCT03245359|DEVICE|Long-term ON-Q|single port, fixed flow pump connected to posterior knee catheter until day 7 post-operative
224198945|NCT03245359|DRUG|Long-term ON-Q|Bupivacaine 0.125%
224311184|NCT05830838|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
224311185|NCT05830838|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
223598823|NCT01732770|BIOLOGICAL|Denosumab|Denosumab 60 mg administered by subcutaneous injection once every 6 months.
223598824|NCT01732770|DRUG|Zoledronic Acid|Zoledronic acid 5 mg administered by intravenous infusion once a year
223598825|NCT01732770|DRUG|Placebo to Denosumab|Administered by subcutaneous injection once every 6 months
223598826|NCT01732770|DRUG|Placebo to Zoledronic Acid|Administered by intravenous infusion once a year
223598827|NCT02815592|DRUG|BMS-986012|
223598828|NCT02815592|DRUG|Cisplatin|
223598829|NCT02815592|DRUG|Etoposide|
223598830|NCT02815592|DRUG|Platinum|
223598831|NCT02815592|DRUG|Carboplatin|
223598832|NCT02474602|DEVICE|Active or Placebo Phototherapy (MR4)|Participants performed a strength training. Forty-eight subjects practiced a training protocol with 80% of the load, measured through 1-repetition maximum test. The strength training lasted 12 weeks and the evaluations were done monthly. Phototherapy, active or placebo, were applied in 6 different points of quadriceps muscle depending the group randomized, before and after each training session.
223598833|NCT01768364|DRUG|Trimetoprim-Sulfa (Bactrim)|
223598834|NCT01768364|OTHER|No antibiotics|
223598835|NCT05253885|DEVICE|Smartphone use|"* Smartphone addiction scale (short version) higher than 33~* Smartphone users of 4-5 inches screen size smartphones, weighing 140-160 grams and dimensions less than 159\*79\*9 mm."
223598836|NCT03851159|DIETARY_SUPPLEMENT|Nyaditum resae®|Heat-killed Mycobacterium manresensis
223598837|NCT03851159|OTHER|Mannitol|Placebo
223598838|NCT05095259|DRUG|insulin human|Hyperinsulinemic glucose clamp studies require that insulin is administered at a steady continuous rate to achieve stable levels of hyperinsulinemia. To reach this, insulin needs to be infused intravenously using a standard intravenous pump system. The insulin dose will be adjusted according to the body surface area, aiming for insulin levels of \~170 mIU/l, which is within the physiological range. Thus, for a subject with a bodyweight of 70 kg, body length of 180 cm and - consequently - a body surface area of 1.936 m2, the required insulin infusion can be calculated as: 1.936 x 60 x 60 ÷ 1000 = 7.0 units per hour
223598839|NCT05095259|DRUG|Epinephrin|Epinephrine are prepared in 100 ml isotone saline solution according to weight and infused in 3 different infusion rates: 10 ng∙kg-1∙min-1, 25 ng∙kg-1∙min-1 and 50 ng∙kg-1∙min-1, for 20 minutes each. After each adrenaline infusion, substrate response will be measured by blood samples of glucose, lactate, free fatty acids, alanine, β-hydroxybutyrate, glycerol and insulin. Furthermore, cardiovascular measurements such as pulse and blood pressure are monitored as well.
223598840|NCT05095259|PROCEDURE|Muscle biopsy|With the study subject resting in the supine position, the skin is disinfected on the lateral side of the thigh around 15 cm above the knee, with chlorhexidine alcohol. Then 3-4 mL of local anaesthetic (lidocaine 20 mg/mL) is injected into the skin, subcutaneous tissue and in the upper part of the muscle with a very thin needle. When the anaesthetic effect has set in after a couple of minutes an insertion is made in the skin and the subcutaneous tissue through which the biopsy cannula is inserted into the muscle. A small piece (around 150 mg) of the muscle is collected, which may be experienced as somewhat unpleasant, but will last for a very short while ( \~1-2 seconds). The needle is removed, a sterile Band-Aid is applied, and the study subject can leave the site after termination of the trial. The biopsy may cause some muscular tenderness for 2-3 days corresponding to minor muscular trauma.
223598841|NCT05095259|PROCEDURE|Adipose tissue biopsy|With the study subject resting in the supine position, the skin is disinfected on one side of the abdomen around 5-10 cm lateral from the umbilicus to the knee, with chlorhexidine alcohol. Then 3-4 mL of local anaesthetic (lidocaine 20 mg/mL) is injected into the skin, subcutaneous tissue and in the upper part of the adipose tissue with a very thin needle. When the anaesthetic effect has set in after a couple of minutes an insertion is made in the skin and the subcutaneous tissue through which the biopsy cannula is inserted into the adipose tissue. A small piece (around 1 gram) of the adipose tissue is collected, which may be experienced as somewhat unpleasant, but will last for a very short while ( \~1-2 seconds). The needle is removed, a sterile Band-Aid is applied, and the study subject can leave the site after termination of the trial. The biopsy may cause some tenderness for 2-3 days corresponding to minor trauma.
223748376|NCT02140099|BEHAVIORAL|Healthy Relationships Plus Program (HRPP)|The Healthy Relationships Plus Program (HRPP) is an out-of-school time program that is facilitated by a teacher or other youth leader. HRPP sessions use interactive teaching strategies to discuss healthy relationships, dating violence, personal values/boundaries, communication skills, emotional health and well-being, and helping friends.
224198946|NCT03847532|GENETIC|Sanger sequencing method|Amplification of the examined fragments of the MutYH gene was conducted using the PCR machine TP4-PCR-01-Tertsik (DNA-Technology, Russia) containing 25 μL of the reaction mixture: 0.1-1.0 μg genomic DNA; 0.25 μM of each original oligoprimer; 200 μM of each nucleosidetriphosphate; 1 U Taq polymerase; PCR buffer (500 mM Tris, 500 mM KCl, pH 8.74); 2.5 μL MgCl2 (25 mM)); deionized water; 20-30 μL of mineral oil. For MutYH gene analysis (Transcript ENST00000257430) Primer3 software (http:// frodo.wi.mit.edu/primer3/input.htm) was selected and 16 primer pairs. The variants of the primary structure in the obtained fragments were revealed using SSCP. DNA fragments containing electrophoretically identified variants were sequenced.
224198947|NCT00798707|DRUG|Desvenlafaxine Succinate Sustained-Release (DVS SR)|25 mg tablet, once daily dosing for 8 weeks
224311186|NCT05830838|OTHER|Questionnaire Administration|Ancillary studies
224311187|NCT05830838|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
223598842|NCT05095259|DRUG|Glucagon|Glucagon is prepared in doses of 10 µg, 25 µg, and 50 µg and intravenously injected with intervals of 2 hours. After each glucagon injection, blood samples will be drawn to measure plasma glucose, glucagon, lactate, free fatty acids, alanine, amino-acids, β-hydroxybutyrate, glycerol and insulin. Furthermore, cardiovascular measurements such as pulse and blood pressure are monitored as well.
223598843|NCT05095259|DEVICE|IPRO 2 Medtronic Minimed|All potential subjects will receive a blinded continuous glucose sensor at Visit 1. At the following visits, the continuous glucose monitor (CGM) will be reviewed for hypoglycaemia episodes and replaced at the same time. At Visit 2 a final screening of the inclusion criteria will take place, which involves the CGM data of the first week. A blinded CGM will be installed a week before every visit.
223748377|NCT02140099|BEHAVIORAL|Control Condition (Classroom Activities)|
223748378|NCT02004028|DRUG|VS-6063|
223748379|NCT03697668|DRUG|Imatinib|triple combination for the treatment of malaria
223598844|NCT05095259|PROCEDURE|7 Tesla (7T) Magnetic Resonance Imaging|Subjects will undergo a hyperinsulinemic euglycaemic glucose clamp, as mentioned above, in the MRI scanning room. After 30 minutes of stable normoglycaemia, subjects are taken into the MRI scanner (Philips Achieva 7.0 T) where brain, liver, thigh and calf muscle are scanned. After every anatomically different area, the subjects must be taken out of the scanner, while scanning coils are replaced. All subjects are advised to lie still and press the alarm button if necessary.
223598845|NCT05095259|PROCEDURE|Indirect Calorimetry using Jaeger Oxycon Champion|Resting metabolic rate will be estimated, after reaching stable plasma glucose level, via a hyperinsulinemic euglycaemic clamp, as mentioned above. This will be done by indirect calorimetry, using a ventilated hood system (Jaeger Oxycon Champion, software version 4.3, Jaeger, Mijnhardt). Subjects are instructed to lie down and rest for a period of 30 minutes. Subjects are also instructed not to move, talk or sleep unless necessary during the period of measurement. The recorded measurement after 5 minutes to 30 minutes will be used for analysis.
223598846|NCT05095259|PROCEDURE|Core temperature and thermography using Thermovision SC645|Thermography (Thermovision SC645, FLIR Systems, Wilsonville, OR, USA) is used to determine cutaneous vascular perfusion. Data is analogue-digital converted and sampled at 100 Hz (Powerlab, ADInstruments, Colorado Springs, CO, USA).
223598847|NCT05095259|DEVICE|Freestyle Libre 2|All potential subjects will receive a continuous glucose sensor at Visit 1. At the following visits, the CGM will be reviewed for hypoglycaemia episodes and replaced at the same time. At Visit 2 a final screening of the inclusion criteria will take place, which involves the CGM data of the first week. A CGM will be installed a week before every visit.
223598848|NCT00125957|DRUG|Wellbutrin|
223598849|NCT00125957|DRUG|Placebo|
223598850|NCT03565380|OTHER|12-week community-based multi-model Tai Chi rehabilitation program|Participants will receive 12 x 90 minute sessions of supervised exercises over 12 weeks. In addition to usual care, supervised exercise will be held at the Center of Sports Training and Rehabilitation inside the University and each class will be restricted to no more than 8 participants to ensure sufficient personalized attention. Each training session involves warm-up together with stretching of lower extremity muscles, strengthening exercises of the major lower extremity muscle groups by Theraband, balancing exercise, Tai Chi training, and rest/ cool-down. All lower-extremity exercises will be performed bilaterally.
223598851|NCT03565380|OTHER|Usual post-operative care|No intervention will be provided
223598852|NCT03565380|OTHER|Untreated asymptomatic controls|No intervention will be provided
223598853|NCT02016079|DIETARY_SUPPLEMENT|omega-3|200 ml fruit drink containing omega-3
223598854|NCT06243640|DRUG|Buagafuran capsules, 15mg/ capsule|Subjects took Buagafuran capsules; twice per day, respectively, after breakfast and dinner for 8 weeks;
223598855|NCT06243640|DRUG|Buagafuran capsules mimic, 0mg/ capsule|Subjects took Buagafuran capsules mimic. twice per day, respectively, after breakfast and dinner for 8 weeks;
223598856|NCT00871338|BIOLOGICAL|GSK2197870A|3 doses given at 2, 3 and 4 months of age
223598857|NCT00871338|BIOLOGICAL|Prevenar™|3 co-administered doses, intramuscular into right thigh
223598858|NCT00871338|BIOLOGICAL|Menitorix™|1 booster dose at 12 months of age
223598859|NCT00871338|BIOLOGICAL|Pediacel™|3 doses given at 2, 3 and 4 months of age
223598860|NCT00871338|BIOLOGICAL|Menjugate™|2 doses given at 3 and 4 months of age
223598861|NCT00305435|DRUG|Romiplostim (AMG-531)|Romiplostim (AMG-531)
223598862|NCT02391363|BEHAVIORAL|Cognitive behavior treatment|Anxiety management skills with the option to included religious/spiritual beliefs and practices
223598863|NCT02391363|BEHAVIORAL|Information and referral|Resource counseling and follow-up for mental health and basic needs
223598864|NCT04329910|OTHER|no intervention|no intervention - observational only
223598865|NCT02934724|PROCEDURE|Self sample from vagina|Self sample using The Rover's Evalyn Brush
223598866|NCT02934724|PROCEDURE|Self sample from the oral cavity|Self sample using COPAN FloqSwab
223598867|NCT02934724|OTHER|Questionnaire|Questionnaire about vaccination status and sexual behaviour
223598868|NCT02744885|DIETARY_SUPPLEMENT|Crave Crush|Crave Crush is a dietary supplement that affects sweet taste receptors on the tongue.
224198948|NCT00798707|DRUG|Desvenlafaxine Succinate Sustained-Release (DVS SR)|50 mg tablet, once daily dosing for 8 weeks
224198949|NCT00798707|DRUG|placebo|Matching placebo tablets (25 or 50 mg). Daily dosing for 10 +/- 4 days during a placebo lead-in period, and then 8 weeks during the double-blind period.
224198950|NCT06649877|BIOLOGICAL|MK-6194|single injected dose
223598869|NCT02744885|DIETARY_SUPPLEMENT|Placebo Comparator: Placebo|The placebo tablet is comparable in taste and is comprised primarily of sorbitol.
223598870|NCT05605106|DIAGNOSTIC_TEST|speckle tracking echocardiography|"Speckle tracking is a recent development in image processing that uses proprietary software to automatically determine the movements of these points, which appear sonographically as speckles, within the myocardium over time. Tracking the movements of these speckles throughout the cardiac cycle yields positive values when the two points are moving away from one another, as in diastole, and negative values when they are moving towards one another, as in systole"
223598871|NCT05605106|PROCEDURE|Percutaneous coronary intervention|Percutaneous coronary intervention refers to a family of minimally invasive procedures used to open clogged coronary arteries (those that deliver blood to the heart). By restoring blood flow, the treatment can improve symptoms of blocked arteries, such as chest pain or shortness of breath.
223598872|NCT00126360|DRUG|Timing of Anastrozole in respect to radiotherapy|
223598873|NCT04886908|OTHER|Data extraction from medical files|Data extraction from medical files
223598874|NCT05013359|OTHER|No treatment given|No treatment given
223598875|NCT03315312|DRUG|Fluoride Varnishes|Fluoride varnish is randomly applied on randomly selected first permanent molar. This study uses a natural clinical setting, where clinicians use methods and procedures that are routinely applied in public dental clinics.
223617887|NCT02448277|DEVICE|Glidescope|the device is to assist the nasotracheal tube into trachea
223617888|NCT00024336|DRUG|tamoxifen citrate|
223617889|NCT00024336|RADIATION|radiation therapy|
223617890|NCT01475435|PROCEDURE|non- surgical periodontal treatment|scaling and root planning
223617891|NCT01475435|PROCEDURE|Prophylaxis|Periodontally healthy patients will receive oral hygiene instructions and prophylaxis.
223617892|NCT00914186|DRUG|TS022|Lotion
223598876|NCT03315312|DRUG|Fissure Sealants|Resin-based fissure sealant is applied on contra-lateral first permanent molar and each child serves as its own control. This study uses a natural clinical setting, where clinicians use methods and procedures that are routinely applied in public dental clinics.
223598877|NCT06099431|PROCEDURE|Mandibular marginal resection and reconstruction|Intraoral buccal and lingual incisions 2-3 mm away from the free gingival margins were carried out around the teeth to be included in the resection. The osteotomy lines were marked using a long shank surgical tapered fissure bur. The osteotomies completed and the resected segment was removed.
223598878|NCT06099431|DEVICE|mandibular osteosynthesis a 2.3mm reconstruction bone plate|a 2.3 mm reconstruction bone plate was then fit in place and fixed to both the proximal and distal segments
223598879|NCT00003505|DRUG|antineoplaston A10|
223598880|NCT00003505|DRUG|antineoplaston AS2-1|
223598881|NCT00003505|PROCEDURE|alternative product therapy|
223598882|NCT00003505|PROCEDURE|biological therapy|
223598883|NCT00003505|PROCEDURE|biologically based therapies|
223598884|NCT00003505|PROCEDURE|cancer prevention intervention|
223598885|NCT00003505|PROCEDURE|complementary and alternative therapy|
223598886|NCT00003505|PROCEDURE|differentiation therapy|
223598887|NCT02089074|BEHAVIORAL|Drug use counselling|
224198951|NCT03473145|BEHAVIORAL|Health Coaching|Health Coaching sessions will be aimed at goal setting, implementing strategies, overcoming barriers, \& relapse prevention.
224198952|NCT03473145|DEVICE|activPAL inclinometer|Participants in the intervention study arms (B \& C) will wear the ActivPAL device for the first 4 weeks of the program and then again in weeks 8 and 9. The device will monitor their sitting and standing time and will allow Health Coaches to provide feedback and will assist the participant in developing an action plan.
224198953|NCT03473145|OTHER|Tools to Prompt Standing or Prompt Sit-to-Stand Transitions.|Participants in the intervention study arms (B \& C) will receive tools to prompt standing or sit-to-stand transitions such as wearable wrist devices, standing desks or tables (Group B only), mechanical and/or electronic timers, or access to mobile apps or computer programs.
223598888|NCT02470598|OTHER|Treatment with Adapted Automated Peritoneal Dialysis (aAPD)|This is a purely non-interventional, observational study, where treatment decisions are completely guided by the discretion of the attending nephrologists
223598889|NCT01156766|DEVICE|- locking anterior plate|"The number of osteoporotic fractures, among which the fractures of the lower extremity of the radius (16 % of fractures seen in emergencies) is going to increase. Several surgical techniques are described in particular locking plates and intrafocal pinning techniques.~The aim of the study is to compare (X-ray assessments and functional outcome) these two types of treatment by using a prospective, randomised multicentric analysis."
223598890|NCT00001870|DRUG|Acetylcholine|
223598891|NCT04597385|OTHER|Long-term Follow-Up|No intervention
223598892|NCT02311114|OTHER|In Depth interview|In Depth interview will be conducted for 30-60 min using semi-structured questionnaire to assess participants experience with telehomecare program.
223598893|NCT02311114|OTHER|Observational fieldwork|Observational fieldwork will conducted to observe everyday routine activities related to telehomecare. May last up to 1h per observation.
223598894|NCT02311114|OTHER|Survey|Surveys with participants will be conducted using validated survey tools.
223598895|NCT02688686|BIOLOGICAL|genetically modified dendritic cells + cytokine-induced killer|This Phase I/II Study to evaluate clinical efficacy, safety of genetically modified dendritic cells in combination with cytokine-induced killer cell treament in NSCLC with bone metastases.
223598896|NCT00997282|DRUG|OPC-262 2.5 mg|orally administered once daily for 24 weeks
223598897|NCT00997282|DRUG|OPC-262 5 mg|orally administered once daily for 24 weeks
223598898|NCT00997282|DRUG|Placebo|orally administered once daily for 24 weeks
223598899|NCT01559272|DRUG|Paliperidone IR (Period 1)|Type= exact number, unit= mg, number=1, form= injection, route= intramuscular use. Single injection with 1 mg paliperidone IR in the gluteal or deltoid muscle.
223617893|NCT00914186|DRUG|Vehicle|Lotion
223617894|NCT00505557|PROCEDURE|Transaxillary dual plane technique|
223617895|NCT03536156|OTHER|Four intra-oral optical impression taken successively|"Four intra-oral optical impression images will be taken successively on a patient:~Optical impressions are designed to record adjacent implant site teeth and peri-implant soft tissue PEI using an Optical Camera. The optical camera works like a camera and does not come into contact with the patient's mucous membranes or teeth. The images obtained are saved in STL format on an anonymized file.~The 4 aligned surfaces thus obtained will be cut using a 3D image processing software. A fixed cylinder will extract the PEI from the 4 surfaces. The volume of these 4 PEIs at T0 min, T30 sec, T2 min and T5 min will be calculated using a software"
223617896|NCT02568514|DEVICE|Secure text messaging|A smartphone and web application that allows physicians and other health care professionals to communicate to each other by secure text message
223617897|NCT02271698|DRUG|Dexamethasone|Intravenous dexamethasone at incision and 24h after incision will be compared in 3 doses and placebo administered in a fourth group
223617898|NCT02271698|OTHER|Placebo|Placebo injection of saline at surgical incision and a repeat placebo saline injection 24h after incision.
223617899|NCT03010527|DRUG|Bimekizumab|Subjects will receive bimekizumab injections every four weeks (Q4W)
223617900|NCT03010527|OTHER|Placebo|Subjects will receive Placebo injections every four weeks (Q4W)
223617901|NCT01038141|PROCEDURE|Surgery for advanced haemorrhoidal disease|Milligan Morgan vs Recto Anal Repair
223617902|NCT05182788|DIETARY_SUPPLEMENT|Placebo pressed candy|consume 2 tablets per day for 8 weeks
223617903|NCT05182788|DIETARY_SUPPLEMENT|CHOLESWISE pressed candy|consume 2 tablets per day for 8 weeks
223617904|NCT03921749|DEVICE|Shockwave|"Both shockwave interventions will be administered without local anaesthesia. Three sessions will be administered at one-week intervals. During each session, 2000 pulses (1000 shots at the patellofemoral and tibiofemoral borders of the target knee and 1000 shots on the subchondral bone of the medial tibia condyle of the affected knee) will be delivered at 5 Hz. Energy flux density was 0.20 mJ/mm2 for patients in the focused group while radial shock waves were transmitted with 0.17 mJ/mm2 corresponding to a 3-bar energy level setting."
223617905|NCT06528366|DIETARY_SUPPLEMENT|Chlorella pyrenoidosa|Functional food, organically pressed into tablets (Registration with Anvisa/MS/Brazil: 6.7273.000)
223748380|NCT03697668|DRUG|Dihydroartemisinin-piperaquine|standard malaria treatment
223748381|NCT03826862|RADIATION|CT three-dimensional reconstruction|All patients will receive CT three dimensional reconstruction before surgery
223598900|NCT01559272|DRUG|Paliperidone palmitate F015 (Panel A: treatment group 1)|Type= exact number, unit= mg, number=300, form= injection, route= intramuscular use. Single injection with 300 mg eq. 3-month formulation paliperidone palmitate F015 manufactured by milling technique A, in the gluteal muscle.
223598901|NCT01559272|DRUG|Paliperidone palmitate F015 (Panel A: treatment group 2)|Type= exact number, unit= mg, number=300, form= injection, route= intramuscular use. Single injection with 300 mg eq. 3-month formulation paliperidone palmitate F015 manufactured by milling technique B, in the gluteal muscle.
223748382|NCT05943912|OTHER|Single Vision Spectacle Lens|36 months of therapy
223748383|NCT05943912|OTHER|Defocus Incorporated Multiple Segments (DIMS) Spectacle Lens|36 months of therapy
223748384|NCT06424912|PROCEDURE|Vivifi's Surgical Procedure|"Subjects undergo Vivifi's surgical procedure for treatment of BPH. The study procedure will be performed in the operating room, under general anesthesia.~Subject will undergo a bilateral anastomosis of the internal spermatic vein to the inferior epigastric vein and ligation of the deferential vein via bilateral inguinal/subinguinal incision.~The investigators can use of a coupler with appropriate ring size (to be measured intra-operatively based on vessel size) to perform the vascular anastomosis and standard sutures for ligation. The coupler is an FDA approved commercial device. Alternatively, the anastomosis can also be performed using sutures. Incision closure will proceed per institution standard of care."
223748385|NCT04323280|DRUG|Dexamethasone therapy|Dexamethasone 20MG once daily for 4 days with additional colchicine therapy for 3 months
223748386|NCT04323280|DRUG|NSAID therapy|NSAIDS (Ibuprofen or Aspirin) or Glucocorticoid (Prednisone) therapy for 3 weeks with addional colchicine therapy for 3 months
223748387|NCT04306315|BIOLOGICAL|Brodalumab|Brodalumab is an anti-IL-17 receptor antibody, which blocks the inflammatory effects of IL-17 in the skin.
223748388|NCT05563077|OTHER|Moderate-intensity interval training (MIIT)|MIIT group: participants will perform 3 sessions per week for 4 months. Each session will involve a ∼3 min warm-up (joint mobility exercises and walking at ∼2.2 METs), a ∼40-50 min main period (∼6-7 reps of 4 min at ∼4.2 METs, with 3 min of active recovery at ∼2.2 METs between each interval), and a ∼3-min cool-down (joint mobility exercises and walking at ∼2.2 METs). We will select the same aerobic dose of training (i.e., kcal/kg of body weight per week) to match total energy expenditure in both exercise groups.
223748389|NCT05563077|OTHER|Moderate-intensity continuous training (MICT)|MICT group: participants will perform 3 sessions per week for 4 months. Each session will involve a ∼3 min warm-up (joint mobility exercises and walking at ∼2.2 METs), a ∼40-50 min main period at ∼3.2 METs, and a ∼3-min cool-down (joint mobility exercises and walking at ∼2.2 METs).
223748390|NCT02885142|PROCEDURE|Local excision for early rectal cancer|
223748391|NCT03905122|DEVICE|bioreactans tool|It is a completely non-invasive method by bioreactance method and it can be done to measure the intra-body fluid status with the help of the probes.
223748392|NCT06832098|COMBINATION_PRODUCT|Nicotine patches plus nicotine mouth spray|Transdermal HABITROL® patches (21mg/24 hrs) plus NICORETTE® QUICKMIST mouth spray (1mg nicotine/spray dose)
223748393|NCT06832098|OTHER|Nicotine Tapering Plan|Tapering plan based on their current e-juice nicotine concentration and frequency of vaping upon entry to the trial. Participants will use their own vapes and nicotine e-liquid.
223748394|NCT06107413|DRUG|ABBV-400|Intravenous (IV) Infusion
223748395|NCT06107413|DRUG|Bevacizumab|IV Infusion
223748396|NCT06107413|DRUG|Folinic Acid|IV Infusion
223748397|NCT06107413|DRUG|Fluorouracil|IV Infusion
223748398|NCT06107413|DRUG|Irinotecan|IV Infusion
223748399|NCT06834360|DRUG|Itepekimab (SAR440340)|Pharmaceutical form: Solution for injection in prefilled syringe. Route of administration: Subcutaneous
223748400|NCT06834360|DRUG|Placebo|Pharmaceutical form: Solution for injection in prefilled syringe. Route of administration: Subcutaneous
223748401|NCT06834360|DRUG|Mometasone furoate nasal spray (MFNS)|Pharmaceutical form: Solution for administration via spray pump. Route of administration: Intranasal spray
223748403|NCT02808130|OTHER|hyperlipidemia, periodontitis, gingivitis|GCF samples were collected using periopaper strips. Prior to sample collection, each site was gently air-dried, all supragingival plaque was removed, and the area was carefully isolated to prevent samples from being contaminated by saliva
223748404|NCT05235165|PROCEDURE|Biospecimen Collection|Undergo collection of tissue and blood
223598902|NCT01559272|DRUG|Paliperidone palmitate F015 (Panel B: treatment group 1)|Type= exact number, unit= mg, number= 75, form= injection, route= intramuscular use. Single injection with 75 mg eq. 3-month formulation paliperidone palmitate F015 in the gluteal muscle.
223598903|NCT01559272|DRUG|Paliperidone palmitate F015 (Panel B: treatment group 2)|Type= exact number, unit= mg, number=150, form= injection, route= intramuscular use. Single injection with 150 mg eq. 3-month formulation paliperidone palmitate F015 in the gluteal muscle.
223598904|NCT01559272|DRUG|Paliperidone palmitate F015 (Panel B: treatment group 3)|Type= exact number, unit= mg, number=450, form= injection, route= intramuscular use. Single injection with 450 mg eq. 3-month formulation paliperidone palmitate F015 in the gluteal muscle.
223748405|NCT05235165|PROCEDURE|Computed Tomography|Undergo CT
223748406|NCT05235165|OTHER|Questionnaire Administration|Ancillary studies
223748407|NCT05235165|PROCEDURE|Thoracoscopy|Undergo video-assisted thoracoscopic surgery or VATS
223748408|NCT05235165|PROCEDURE|Thoracotomy|Undergo open thoracic surgery
223748409|NCT06306573|DEVICE|CardioMEMS HF System|The CardioMEMS HF System provides pulmonary artery (PA) hemodynamic data to monitor and manage HF subjects. The CardioMEMS HF System measures PA pressure which clinicians use to initiate or modify HF treatment.
223748410|NCT00470574|BIOLOGICAL|QS21|
223748411|NCT00470574|BIOLOGICAL|sialyl Lewisª-keyhole limpet hemocyanin conjugate vaccine|
223748412|NCT00470574|OTHER|immunoenzyme technique|
223598905|NCT01559272|DRUG|Paliperidone palmitate F015 (Panel B: treatment group 4)|Type= exact number, unit= mg, number=300, form= injection, route= intramuscular use. Single injection with 300 mg eq. 3-month formulation paliperidone palmitate F015 in the deltoid muscle.
223598906|NCT01559272|DRUG|Paliperidone palmitate F015 (Panel B: treatment group 5)|Type= exact number, unit= mg, number=450, form= injection, route= intramuscular use. Single injection with 450 mg eq. 3-month formulation paliperidone palmitate F015 in the deltoid muscle.
223598907|NCT01559272|DRUG|Paliperidone palmitate F016|Type= exact number, unit= mg, number=150, form= injection, route= intramuscular use. Single injection with 150 mg eq. 3-month formulation paliperidone palmitate F016 in the gluteal muscle.
223598908|NCT01559272|DRUG|Paliperidone palmitate F015 (Panel D: treatment group 1)|Type= exact number, unit= mg, number=525, form= injection, route= intramuscular use. Single injection with 525 mg eq. 3-month formulation paliperidone palmitate F015 in the gluteal muscle.
223598909|NCT01559272|DRUG|Paliperidone palmitate F015 (Panel D: treatment group 2)|Type= exact number, unit= mg, number=525, form= injection, route= intramuscular use. Single injection with 525 mg eq. 3-month formulation paliperidone palmitate F015 in the deltoid muscle.
223598910|NCT01559272|DRUG|Paliperidone palmitate F015 (Panel D: treatment group 3)|Type= exact number, unit= mg, number=350, form= injection, route= intramuscular use. Single injection with 350 mg eq. 3-month formulation paliperidone palmitate F015 in the gluteal muscle.
223598911|NCT01559272|DRUG|Paliperidone palmitate F015 (Panel D: treatment group 4)|Type= exact number, unit= mg, number=175, form= injection, route= intramuscular use. Single injection with 175 mg eq. 3-month formulation paliperidone palmitate F015 in the deltoid muscle.
223598912|NCT04794270|DEVICE|ACUVUE OASYS® 1-Day for Astigmatism - TAM 24|TEST
223598913|NCT04794270|DEVICE|ACUVUE OASYS® 1-Day for Astigmatism|CONTROL
223598914|NCT00844012|DRUG|Continuous OC (clormadinone acetate plus ethinil-estradiol - Belara®, Grunenthal, Milan, Italy)|Low-dose monophasic OC containing 2.0 mg clormadinone acetate plus 0.03 mg ethinil-estradiol (Belara®, Grunenthal, Milan, Italy) will be administered with a continuous regimen.
223598915|NCT00844012|DRUG|Cyclic OC (clormadinone acetate plus ethinil-estradiol)|Low-dose monophasic OC containing 2.0 mg clormadinone acetate plus 0.03 mg ethinil-estradiol (Belara®, Grunenthal, Milan, Italy) will be administered with a cyclic regimen.
223598916|NCT04311489|DRUG|Ularitide|Continuous intravenous infusion for 48 hours at a dose of 30 ng/kg/min. Depending on effect and/or side effects dose can be adjusted to 15 ng/kg/min or 45 ng/kg/min.
223598917|NCT04311489|DRUG|Placebo|Continuous intravenous infusion for 48 hours at a bodyweight-adjusted infusion rate.
223598918|NCT02485132|OTHER|Observational|Investigators propose to perform a one-week baseline testing (pre-initiation of the SU), at initiation (first week after the first dose of the SU) and after a 3 months follow-up of treatment with a SU, including CGMS reading, medical history measures, quality of life and diabetes treatment satisfaction.
223598919|NCT00441246|DRUG|Mucinex D (600 mg guaifenesin and 60 mg pseudoephedrine HCl extended-release bi-layer tablets)|
223598920|NCT00704938|BIOLOGICAL|aldesleukin|Intravenous (IV) aldesleukin 720,000 IU/kg every 8 hours for a maximum of 15 doses.
223598921|NCT00704938|BIOLOGICAL|anti-p53 T-cell receptor-transduced peripheral blood lymphocytes|Intravenous (IV) anti-p53 TCR transduced PBL will be administered at a a dose of 1 x 10\^8 cells to 5 x 10\^10 cells.
223598922|NCT00704938|BIOLOGICAL|autologous dendritic cell-adenovirus p53 vaccine|Ad-p53 DC vaccine, up to 2 x 10\^8 ad-p53 DCs per dose will be administered subcutaneously, divided into 4 injections, one into each of the 4 extremities. Ad-p53 DCs will be administered subcutaneously on day 7 (± 2 days), day 14 (between day 14 and day 18), and day 28 (between day 25 and day 42) post T cell infusion.
223598923|NCT00704938|BIOLOGICAL|filgrastim|subcutaneously at a dose of 5 mcg/kg/day (not to exceed 300 mcg/day).
223598924|NCT00704938|DRUG|cyclophosphamide|60mg/kg/day (Days-7,-6)
223598925|NCT00704938|DRUG|fludarabine phosphate|25mg/m\^2 (Days -5, -4, -3, -2, and -1)
223598926|NCT02103491|DIETARY_SUPPLEMENT|Salt administration|Participants were provided with 3 plastic bags each one containing 4 white capsules (e.g., a total of 12 capsules). In the salt group, the capsules were filled with a commercially available product that contains buffered electrolyte salts (Saltstick caps, Saltstick, California US). The total amount of electrolytes provided in the salt group was: 2580 mg of sodium (113 mmol), 3979 mg of chloride (112 mmol), 756 mg of potassium (19.3 mmol) and 132 mg of magnesium (5.4 mmol). In the control group, participants received the same number of capsules with the exact same appearance but filled with an isocaloric placebo (cellulose). All the participants were instructed to ingest the contents of the first bag in the transition between the swimming and cycling sections, the second bag around the middle of the cycling leg and the third bag during the transition between the cycling and running sections.
223598927|NCT02103491|DIETARY_SUPPLEMENT|Placebo administration|
223598928|NCT03410563|BEHAVIORAL|Auditory inputs|Three different auditory inputs
223598929|NCT00265317|DRUG|erlotinib|erlotinib 150 mg daily by tablets in a continuous regimen, until progression or unacceptable toxicity
223598930|NCT00265317|DRUG|sunitinib|Sunitinib 37.5 mg daily by oral capsule in a continuous regimen plus erlotinib 150 mg daily by tablets in a continuous regimen, until progression or unacceptable toxicity
223598931|NCT00265317|DRUG|erlotinib|erlotinib 150 mg daily by tablets in a continuous regimen, until progression or unacceptable toxicity
223598932|NCT00265317|DRUG|placebo|Placebo daily by oral capsule in a continuous regimen plus erlotinib 150 mg daily by tablets in a continuous regimen, until progression or unacceptable toxicity
223598933|NCT01262859|DRUG|bevacizumab|Bevacizumab, 15 mg/kg IV over 30 minutes (if this infusion rate was well tolerated), every 3 weeks until completion of radiation The initial dose will be delivered over 90+/-15 minutes. If the first infusion is tolerated without infusion associated adverse events (fever and/or chills), the second infusion may be delivered over 60+/-10 minutes. If the 60 minute infusion is well tolerated, all subsequent infusions may be delivered over 30+/-10 minutes.
223598934|NCT05727735|DEVICE|Medtronic Signia Stapler|The Signia Stapler is a powered stapler that can be used for tissue dissection and vessel sealing during surgery.
223598935|NCT05727735|DRUG|Da Vinci Vessel Sealer Extend Energy Device with SureForm Stapling|The Vessel Sealer Extend Energy Device is integrated with the da Vinci system and uses bipolar energy technology to facilitate tissue dissection and vessel sealing.
223598936|NCT00051376|DRUG|L-Arginine|
223748413|NCT00470574|OTHER|immunologic technique|
223598937|NCT04091880|BIOLOGICAL|EV71 vaccine and influenza vaccine|simultaneously administrated with EV71 vaccine and influenza vaccine
223598938|NCT04091880|BIOLOGICAL|EV71 vaccine|administrated with EV71 vaccine only
223598939|NCT04091880|BIOLOGICAL|influenza vaccine|administrated with influenza vaccine only
223598940|NCT02510001|DRUG|PF-02341066|PF-02341066 (Crizotinib) 250mg OD or 200mg BD or 250mg BD Days 1-28 continuously
223598941|NCT02510001|DRUG|PD-0325901|PD-0325901 2mg - 8mg BD with Run in Day -7 to Day-1 on Cycle 1 Day1, then Day 1-21 every 28 day cycle.
223748414|NCT00470574|OTHER|laboratory biomarker analysis|
223748415|NCT06519188|OTHER|Nebulization application with 5 ml isotonic sodium chloride|Nebulization application with 5 ml isotonic sodium chloride in the morning and evening for two months.
223748416|NCT04609566|DRUG|brentuximab vedotin|1.8 mg/kg given into the vein (IV; intravenously) every 3 weeks
223598942|NCT02510001|DRUG|Binimetinib|Binimetinib 30mg or 45 mg BD either continuously or Days 1-21 every 28 days
223748417|NCT04609566|DRUG|pembrolizumab|200 mg given intravenously every 3 weeks
223748418|NCT00636909|DRUG|Cyclophosphamide|preparative cytoreduction
223748419|NCT00636909|DRUG|fludarabine|preparative cytoreduction
223748420|NCT00636909|DRUG|cyclosporine|immunosuppressive therapy
223748421|NCT00636909|DRUG|methotrexate|immunosuppressive therapy
223748422|NCT00636909|BIOLOGICAL|G-CSF|foster engraftment
223748423|NCT03506373|DRUG|Ibrutinib|Given PO
223748424|NCT03506373|DRUG|Ixazomib Citrate|Given PO
223748425|NCT03506373|OTHER|Laboratory Biomarker Analysis|Correlative studies
223748426|NCT03506373|OTHER|Pharmacodynamic Study|Correlative studies
223748427|NCT03506373|OTHER|Pharmacokinetic Study|Correlative studies
223748428|NCT06848803|BEHAVIORAL|AI- driven simulation platform|This investigation will draw upon existing literature exploring the intersection of AI in education, reflective practice, emotional intelligence, and professional integration. By synthesizing these perspectives, we aim to provide a comprehensive overview of the transformative potential of AI-driven SLPs in shaping future professionals. Furthermore, this analysis will consider the ethical implications of using AI in education, including issues related to data privacy, algorithmic bias, and the potential displacement of human interaction.
223748429|NCT05779475|OTHER|No treatment given|Participants will not receive any investigational treatment in this study.
223748430|NCT04349618|OTHER|PROTECTIVE VENTILATION|Protective ventilation with tidal volume 6 mL/kg of predicted body weight further adjusted to keep plateau pressure below 30 cm H2O and pH above 7.20, and PEEP set using the PEEP FiO2 table of the ARMA trial
223748431|NCT04349618|OTHER|ULTRAPROTECTIVE VENTILATION|Ultraprotective ventilation with tidal volume reduction down to 4 mL/kg further adjusted to keep plateau pressure below 30 cm H2O and pH above 7.20, and PEEP set using the PEEP FiO2 table of the ARMA trial
223748432|NCT05616104|DEVICE|FLEX Vessel Prep System|"The FLEX Vessel Prep System to create circumferential, continuous micro-incisions along the length of the stenosis by performing a retrograde pullback through the lesion.~Following FLEX, standard balloon angioplasty is performed with an uncoated PTA balloon sized to meet the reference vessel diameter, according to its corresponding Instructions for Use. Once advanced into the lesion, the balloon should be inflated according to the site's standard of care."
223748433|NCT05920421|PROCEDURE|diaghragm affection by ultrasound before and after the blocks|the participant will assess diaphragm sparing in each block and evaluate effectiveness of infraclavicular subomohyoid blocks and subomohyoid subscapularis blocks according to intraoperative and postoperative analgesia and diaphragm affection and comparing them with interscalen and with each others
224198954|NCT02094573|DRUG|Brigatinib|Brigatinib tablets
224198955|NCT03312764|BEHAVIORAL|Online diabetes prevention program|Digital delivery of Intensive behavioral counseling for diabetes prevention and healthy lifestyle management. Recipients have access to online curriculum, a live health coach, group-based communication forums, and connected technology to track weight and physical activity.
224198956|NCT03312764|BEHAVIORAL|Standard Care|One-on-one or small group sessions with a dietitian or a trained health professional to advise on physical activity, healthful nutrition and risk reduction for diabetes.
224198957|NCT02102217|PROCEDURE|PRECious|Standardized measurement of serum CRP levels on postoperative day 3,4 and 5.
223598943|NCT06831513|DEVICE|Serkel 3D CRO|Serkel 3D CRO is intervention for those with deformational plagiocephaly and already qualified for a cranial remolding orthosis
223598944|NCT00830492|DRUG|clomiphene citrate|100 mg from cycle day 3 through 7
223598945|NCT00830492|PROCEDURE|Ultrasound|cycle day 8
223598946|NCT00830492|DRUG|GnRH antagonist|Daily, started with dominant follicle greater than 14 mm (Ganirelix , Organon, Netherlands).
223598947|NCT00830492|DRUG|gonadotopin (HMG)|75 IU human menopausal gonadotropin (Menogon, ferring, pharmacenticals , Germany)
223598948|NCT00830492|DRUG|buserelin|Buserelin (suprefact, Aventis, Frankfurt, Germany) 500µg subcutaneously (S.C.) everyday for menstrual cycle 21, until the baseline evaluation, which takes place in the first few days of menstruation. If baseline levels of estradiol (\<50 pg/ml ) had been achieved, then the dose of buserelin would be reduced to 250µg.
223598949|NCT00830492|DRUG|rFSH|150-225 IU recombinant FSH (r\_FSH) (Gonal F, Serono, Aubnne, Switzerland) S.C.
223598950|NCT04042324|DRUG|Triferic|Triferic (ferric pyrophosphate citrate, FPC), an iron-replacement product, is an iron complex in which iron(III) is bound to pyrophosphate and citrate.
223598951|NCT04042324|DRUG|Heparin|Unfractionated heparin (UFH): a common anticoagulant used during hemodialysis treatments.
224198958|NCT05905874|OTHER|Machine learning-based prediction model|The machine learning-based prediction model will be used to forecast whether the presence of DVT and/or PTE or not in AECOPD patients after standardized treatment.
224198959|NCT02985567|OTHER|Intraocular pressure evaluation|Intraocular pressure checked with Icare rebound tonometer at 25 minutes after induction, followed by every 10 minutes until sedation was complete.
224198960|NCT06704139|DRUG|Morphine - .25 mg|Fifty patients will receive intrathecal morphine
224198961|NCT06704139|DRUG|fentanyl + morphine|Fifty patients will receive intrathecal morphine and fentanyl
224198962|NCT06704139|DRUG|Ondansetron + Dexamethasone|All patients will receive a compination of intravenous 4mg ondansteron and 8mg dexamethasone 15 minutes before spinal anathesia
224198963|NCT02256202|OTHER|Interview|Monitoring interviews to show medical and economic advantages of given therapy
223598952|NCT03765892|OTHER|Questionnaire (Adult)|"Patients and case control will have to respond to the study questionnaire on the online entry platform to compare the distribution of socio-professional categories.~Answering the questionnaires will take 45 minutes."
223598953|NCT03765892|OTHER|Questionnaire (Children)|"Patients and case control will have to respond to the study questionnaire on the online entry platform to compare the proportion of subjects having repeated grades.~Answering the questionnaires will take 45 minutes."
223598954|NCT03325959|DEVICE|Hyperbaric oxygen therapy (HBOT) treatment|60 HBOT sessions at 2 ATA 100% oxygen
223598955|NCT03325959|DRUG|Cymbalta / Lyrica treatment|one of the two medications currently licensed for the treatment of FMS in Israel, i.e. Cymbalta and Lyrica.
223598956|NCT03325959|DEVICE|Crossover Hyperbaric oxygen therapy|60 HBOT sessions at 2 ATA 100% oxygen after crossover
224198964|NCT01510587|BEHAVIORAL|4-Health Educational curriculum|During the intervention, parents meet about every 3 weeks (90 min/session) in small groups with facilitators. During meetings classroom activities aim to integrate 3 areas: 1) parents' knowledge about healthy diets, physical activity and improved body image; 2) parents' understanding, skills and potential roles as positive change-agents (i.e., parenting and behavior management); and 3) parents' learning and practicing cognitive-behavioral exercises that encourage specific skills within the family/home setting. Between monthly meetings, participants explore a suggested online websites or facilitator-assigned questions and provide feedback. The majority of outside time/assignments for parents is spent doing take-home activities with their preteen child and family.
224198965|NCT01510587|BEHAVIORAL|Healthy Living Information|During the Healthy Living Information intervention, participants receive packets delivered to their homes by mail at intervals similar to the meeting intervals for the educational curriculum intervention. (10 total packets.) Approximately every three weeks between late September 2011 and April 2012, corresponding approximately to the meeting times for the 4-Health Educational Program, participants in the Healthy Living Information control group receive mailed packets of information.
224198966|NCT00646607|DRUG|FOLFOX (Oxaliplatin, 5Fluorouracil, Lederfolin)|To assess whether a 3-month FOLFOX-4 treatment is at least equivalent to a 6-month FOLFOX-4 treatment
224198967|NCT00646607|DRUG|FOLFOX (Oxaliplatin, 5Fluorouracil, Lederfolin)|standard treatment
224198968|NCT01876628|DRUG|Flucloxacillin|Intravenous or oral Flucloxacillin. Minimum dose 500mg four times each day. Target duration 5 days less pre-recruitment beta-lactam duration.
224198969|NCT01876628|DRUG|Clindamycin|Clindamycin dose 300mg four times each day for 2 days, within 48 hours of commencing flucloxacillin. Clindamycin is over-encapsulated and externally identical to placebo.
224198970|NCT01876628|DRUG|Placebo oral capsule|Placebo is externally identical to the over-encapsulated clindamycin and is taken four times each day for 2 days
224198971|NCT04445194|BIOLOGICAL|Recombinant new coronavirus vaccine (CHO cell) low-dose group|Intramuscular injection of deltoid muscle of upper armof 25μg/0.5ml/person doseRecombinant new coronavirus vaccine (CHO cells).
224198972|NCT04445194|BIOLOGICAL|Recombinant new coronavirus vaccine (CHO cells) high-dose group|Intramuscular injection of deltoid muscle of upper armof 50μg/0.5ml/person doseRecombinant new coronavirus vaccine (CHO cells).
223617906|NCT06528366|DEVICE|High Definition Transcranial Direct Current Stimulation|Neuromodulation Technics, non invasive, target and safety
223617907|NCT02834481|DEVICE|ANI/NIPE|ANI/NIPE monitors is a continuous noninvasive measurement of the parasympathetic tone, as a component of the autonomous nervous system. It uses the tiny variations of heart rate induced by each respiratory cycle (natural or induced) to quantify parasympathetic tone (respiratory sinus arrhythmia).
223617908|NCT00764699|DRUG|rhIGF (Increlex)|rhIGF will be administered as a subcutaneous injection per the following schema: First 2 weeks: 40 mcg/kg BID; Weeks 3 and 4: 80 mcg/kg BID; Subsequent weeks: 120 mcg/kg BID.
223617909|NCT04744675|DRUG|Triamcinolone Acetonide 40mg/mL|Triamcinolone acetonide is a synthetic glucocorticoid corticosteroid with marked anti-inflammatory action, in a sterile aqueous suspension suitable for intramuscular, intra-articular, and intrabursal injection.
224198973|NCT04445194|BIOLOGICAL|Recombinant new coronavirus vaccine (CHO cells) placebo group|Intramuscular injection of deltoid muscle of upper armof 0.5ml/person doseRecombinant new coronavirus vaccine (CHO cells).
223617910|NCT04744675|DRUG|Saline Injection|Saline is a buffer solution commonly used in biological research. It is a water-based salt solution containing disodium hydrogen phosphate, sodium chloride and, in some formulations, potassium chloride and potassium dihydrogen phosphate. The buffer helps to maintain a constant pH. The osmolarity and ion concentrations of the solutions match those of the human body.
223617911|NCT04744675|DRUG|Bupivacaine|Bupivacaine is an anesthetic that is commonly used as a local numbing agent, including intramuscular, intra-articular and intrabursal injections.
223617912|NCT06415318|DRUG|Paclitaxel + Ifosfamide + Cisplatin & Toripalimab|Paclitaxel + Ifosfamide + Cisplatin \& Toripalimab
223617913|NCT02050113|DEVICE|Custom Made Fenestrated or Branched Stent Graft|The surgeon will place a custom made graft, t-Branch device or modify commercially available stent grafts to match the anatomy of the patient being treated. Small fenestrations (holes) will be made in the stent graft so that additional stents can be inserted through the fenestration and into the blood vessels that lead to the kidneys, intestines or liver. These stents allow blood to flow freely to these organs. If the aneurysm is in the aortic arch stents may be placed in the carotid and subclavian arteries. This surgery is done through small incisions in the groin and sometimes in the upper arm.
223617914|NCT02818868|DRUG|apixisaban|
223617915|NCT01755234|DRUG|Sevoflurane|Sevfoflurane inhaled administered by laryngeal mask airway or endotracheal tube
223617916|NCT01755234|DRUG|Propofol|Propofol administered via intravenous catheter at an initial rate of 1.0 -2.0 mg/kg then the Propofol infusion rate will be titrated to keep a bispectral index between 40-60
223617917|NCT01865422|OTHER|parent-proxy QoL chronic cough specific questionnaire (PC-QOL)|
223617918|NCT01320189|DIETARY_SUPPLEMENT|Differences in protein content of meals|Differences in protein content (energy percent) of meals
223617919|NCT00151385|PROCEDURE|single blood draw|
223617920|NCT01572181|DRUG|Fludarabine IV- Busulfan IV (Busilvex®) - Anti-thymocyte globulines (Thymoglobuline®)|"* IV fludarabine (30 mg/m²/day for 5 days)~* IV Busulfan (Busilvex 3.2 mg/kg/day for 4 days) (the Busulfan dose is to be adapted to the weight of the child according to the drug label)~* Anti-thymocyte globulines (Thymogolubuline, 2.5 mg/kg/day for 2 days)."
223598957|NCT02950480|DRUG|zafirlukast|Patients will begin treatment with zafirlukast on post-operative day one following placement of tissue expander(s) once determined safe from a surgical recovery standpoint. They will be continued on the standard dosing (20mg PO twice per day) of zafirlukast through expander fill (6-12 weeks, up to 18 weeks for women receiving radiation). Treatment will be stopped 48 hours prior to expander-implant exchange, which is equivalent to five half-lives of the drug. Patients will be seen every 1 to 2 weeks for expander fill, and will be assessed clinically based on the Baker classification system of capsular contracture every two weeks.
223598958|NCT02950480|OTHER|Standard of Care (no intervention)|Standard of Care (no intervention)
223598959|NCT05904067|BIOLOGICAL|COVID Convalescent Plasma|200 ml of COVID Convalescent Plasma at +14 days, +28 days, +2 months, and +3 months following hematopoietic stem cells transplantation.
224198974|NCT05052827|DIETARY_SUPPLEMENT|Milk Protein Concentrate|"Protein provided at 0.35 g/kg fat free-mass. Macronutrient and Amino Acid Content provided below.~Per 100 g protein powder:~Calories (Cal): 363 Carbs (g): 5.60 Protein (g): 82.60 Fat (g): 1.12 Total BCAA (g): 15.67 Total EAA (g): 34.66 Total AA (g): 83.27"
224198975|NCT05052827|DIETARY_SUPPLEMENT|Rice Protein Isolate|"Protein provided at 0.35 g/kg fat free-mass. Macronutrient and Amino Acid Content provided below.~Per 100 g protein powder:~Calories (Cal): 394 Carbs (g): 6.50 Protein (g): 86.70 Fat (g): 2.39 Total BCAA (g): 14.98 Total EAA (g): 30.62 Total AA (g): 86.11"
224198976|NCT05052827|DIETARY_SUPPLEMENT|Soy Protein Isolate|"Protein provided at 0.35 g/kg fat free-mass. Macronutrient and Amino Acid Content provided below.~Per 100 g protein powder:~Calories (Cal): 377 Carbs (g): 2.12 Protein (g): 88.8 Fat (g): 0.60 Total BCAA (g): 13.88 Total EAA (g): 31.74 Total AA (g): 89.39"
224198977|NCT00929201|DRUG|Sitagliptin phosphate/metformin hydrochloride FDC|Single dose sitagliptin/metformin 50/500 mg FDC tablet after consumption of a high-fat meal in one of two treatment periods.
224198978|NCT00929201|DRUG|Sitagliptin phosphate|Single dose sitagliptin 50 mg tablet after consumption of a high-fat meal in one of two treatment periods.
224198979|NCT00929201|DRUG|Metformin hydrochloride|Single dose metformin 500 mg tablet after consumption of a high-fat meal in one of two treatment periods.
224198980|NCT02049580|DRUG|Thiotepa|Thiotepa (10 mg/kg /day) will be administered every 12 h, at day -6
224198981|NCT02049580|DRUG|Fludarabine|"Fludarabine (30mg/m2/day x 4 days) will be dosed according to renal function. For decreased creatinine clearance (CCr) (≤ 61 mL/min) Fludarabine dosage should be reduced as follows:~CCr 46-60 mL/min, fludarabine = 24 mg/ m2/day"
224198982|NCT02049580|DRUG|Cyclophosphamide|"Pre-transplantation Cyclophosphamide(Cy) 30 mg/kg/day will be administered as a 1-2 hour intravenous infusion with a high volume fluid flush on Days -5.~Cy will be dosed according to the recipient's ideal body weight (IBW), unless the patient weighs more than 125% of IBW, in which case the drug will be dosed according to the Adjusted IBW (AIBW)~Cyclophosphamide \[50 mg/kg/day IBW\] will be given on Day 3 post-transplant (between 60 and 72 hours after marrow infusion) and on Day 4 post-transplant (approximately 24 hours after Day 3 cyclophosphamide). Cyclophosphamide will be given as an IV infusion over 1-2 hours (depending on volume)."
224198983|NCT03489239|DRUG|Tenofovir Alafenamide|subjects switching from Entecavir to single arm TAF 25mg
224198984|NCT06116994|OTHER|The buccal infiltration anesthesia with a camouflaged dental syringe (Angelus ™)|In the test group, subjects will receive buccal infiltration anesthesia with the a camouflaged dental syringe. The used camouflaged dental syringe (Angelus ™) will consist of an alligator-shaped syringe sleeve that covers the dental syringe and makes it more friendly without affecting its function. The alligator-shaped syringe sleeve has three main components, which are the mouth, trunk, and rear feet. The mouth of the alligator sleeve covers the local anesthesia needle, the trunk covers the syringe barrel of the traditional dental syringe, and the rear feet hold the finger grip.
224198985|NCT06116994|OTHER|The buccal infiltration anesthesia with a conventional dental syringe|In the control group, subjects will receive buccal infiltration anesthesia with the conventional dental syringe.
224198986|NCT03187873|BEHAVIORAL|Chama cha MamaToto|Chamas are a community-led model of peer support for women in pregnancy and infancy. Chamas are highly gendered institutions that women have relied on for survival to pool resources. Using this existing cultural script, chamas have been tailored to the needs of pregnant women. Central to the approach is the integration of health, social and financial literacy education with a savings/loans program. Chamas are designed to improve MNCH by generating positive peer support for women to advocate for themselves and account for the care they receive.
224198987|NCT06567457|BIOLOGICAL|SCB-2023B vaccine, a monovalent Omicron XBB.1.5 recombinant SARS-CoV-2 trimeric S-protein subunit vaccine for COVID-19|intramuscular injection
224198988|NCT06567457|BIOLOGICAL|SCB-2019 vaccine, a monovalent wu-hu1 SARS-CoV-2 trimeric S-protein subunit vaccine for COVID-19|intramuscular injection
224198989|NCT00159367|DEVICE|Repetitive magnetic stimulation to the quadriceps|
224198990|NCT02354352|DRUG|Eplerenone|26 Subjects will take Eplerenone, one 50mg capsule by mouth once daily for 12 months.
224198991|NCT02354352|DRUG|Spironolactone|26 Subjects will take Spironolactone, one 50mg capsule by mouth once daily for 12 months.
223598960|NCT02737124|DRUG|Acetaminophen|Acetaminophen will be given 24 hours before scheduled surgery.
223598961|NCT02737124|OTHER|Placebo|Placebo will be given to subjects 24 hours before scheduled surgery.
223598962|NCT03333629|BEHAVIORAL|Enhanced early detection|standardized screening
223617921|NCT01418144|PROCEDURE|Transversus abdominis plane (TAP) block|Bilateral UL-guided TAP block with 20 ml of ropivacaine 0,5%
223617922|NCT01418144|PROCEDURE|Placebo TAP block|Bilateral placement of 20 ml of saline 0,9% in the transversus abdominis plane
223617923|NCT05432492|DRUG|AK112|IV infusion, specified dose on specified days
223617924|NCT03987477|BEHAVIORAL|Interpretation bias modification program|Brief online program aimed at the modification of negative interpretation biases.
223617925|NCT03987477|BEHAVIORAL|Waiting list|Waiting list procedure for the control group.
223617926|NCT04811703|DRUG|Combined PIPAC / IV chemotherapy treatment|Addition of cisplatin-doxorubicin PIPAC sessions to carboplatin-paclitaxel systemic Chemotherapy
223617927|NCT04034823|BIOLOGICAL|KN035|KN035 5 mg/kg s.c. Q3W
223617928|NCT04034823|BIOLOGICAL|Trastuzumab|8 mg/kg IV loading followed by 6 mg/kg Q3W IV
224198992|NCT05657964|DEVICE|Gokhale sensor|Participants enrolled in the Gokhale Arm will be provided the Gokhale PostureTracker, a wearable posture monitoring sensor developed for interactive posture coaching, and a loaner smartphone with pre-installed App. Participants will be provided instruction to apply the sensor on their lumbar area and receive real-time visual feedback on their posture kinematic during the class. Participants can also perform normal daily activities while wearing the device. Data collected by the sensor will be sent to a HIPAA compliance server and shared with Stanford researchers.
223598963|NCT02249611|DEVICE|Mobile physical activity promotion tool|"1. Mobile activity sensor~2. Smartphone with APP~3. Interactional webpage of internet~4. Evidence based health information~5. Individualized reminding messages according to the data from activity recording system~6. Personal counseling from professional personnel"
223598964|NCT02249611|OTHER|Standard care|Counseling on lifestyles with health education material
223598965|NCT04637425|DRUG|Ismigen|Sublingual tablets containing 7 mg of bacterial lysate from the following bacteria: Staphylococcus aureus, Haemophilus influenzae serotype B, Klebsiella pneumoniae, Klebsiella ozaenae, Neiserria catarrhalis, Streptococcus viridans, Streptococcus pyogenes, Streptococcus pneumoniae (6 strains: TY1/EQ11, TY2/EQ22, TY3/EQ14, TY5/EQ15, TY8/EQ23, TY47/EQ24) - sublingual use 1 tablet per day over 10 days for 3 successive months.
223598966|NCT04637425|DRUG|Placebo|Matched tablets without any active substance.
223598967|NCT04561908|DEVICE|Transseptal puncture with Brockenbrough-needle|Conventional transseptal puncture with Brockenbrough-needle
223598968|NCT04561908|DEVICE|Microguidewire-assisted transseptal puncture|Microguidewire-assisted transseptal puncture (0.014-inch microguidewire)
223598969|NCT04428957|OTHER|Telemonitoring|Daily telemonitoring of heart rate (HR), blood pressure (BP), pulse oximetry (SpO2), spirometry (FVC), activity (accelerometry) and severity of cough and dyspnea
223598970|NCT01183949|DRUG|AT7519M|"Part A: Nine patients will receive AT7519M as an intravenous infusion on days 1, 4, 8 and 11 of a three week cycle. The starting dose of AT7519M will be 21mg/m\^2/dose and will be increased to 27mg/m\^2/dose during subsequent cycles in the absence of AT7519M-related toxicities.~Part B: Amendment clarified there will be no further exploration of AT7519M as a monotherapy.~Part C: Amendment modified dose escalation to a conventional 3 + 3 design with a maximum total of 14 patients will be treated at the maximum tolerated dose."
224198993|NCT04219800|BEHAVIORAL|Patient-centered counselling and written material|Patient-centered counselling and written material regarding occupational sedentary behaviour, with telephone follow-ups after 1 and 5 weeks.
223507026|NCT04702750|BEHAVIORAL|Targeted memory reactivation (sounds)|I will unobtrusively and repeatedly present learning-related sounds during sleep using speakers. This method was shown to improve memory in various tasks. The sounds will be presented several seconds apart and the volume will be so adjusted as not to disturb the participant's sleep. The sounds will be presented during non-rapid eye movement sleep (sleep stage 2 and slow wave sleep). The sounds presented will be congruently related to the images in the previous learning task. This manipulation is within-subject - all participants will be exposed to sounds, but different specific sounds will be presented for each individual participant.
223598971|NCT01183949|DRUG|Bortezomib|Part C will treat between 3-26 patients with a combination of bortezomib and AT7519M in a dose escalation design. The starting doses for the dose escalation are bortezomib 1 mg/m2 and AT7519M 14 mg/m2.
224198994|NCT04219800|BEHAVIORAL|mHealth|"1. Activity tracker armband (Garmin Vivofit); warns of prolonged sitting and counts daily steps.~2. SMS text messages; reminds of activity breaks.~3. Mobile video instruction for standing pause gymnastics."
223598972|NCT06370013|DRUG|Tinengotinib|Subjects on this rollover study may continue to receive tinengotinib at the dose that they were previously receiving on the TransThera parent study. Dose may be decreased by one dose level from the previously-received dose upon study entry, based on physician discretion.
223598973|NCT04327726|DRUG|Dexmedetomidine Nebulization|ultrasonic nebulization of 1 µg/kg dexmedetomidine for PDPH treatment
223507027|NCT06460051|PROCEDURE|Maxillary nerve block|Ultrasound-guided, suprazygomatic approach, infrazygomatic window
223598974|NCT04327726|OTHER|0.9% Saline Nebulization|nebulization of 4mL 0.9% saline
223598975|NCT02744196|BIOLOGICAL|Acellbia|Acellbia is rituximab biosimilar, monoclonal antibody which binds CD20.
224198995|NCT02885259|DRUG|rHuPH20|human immunoglobulin and one vial of recombinant human hyaluronidase
224198996|NCT00002628|BIOLOGICAL|filgrastim|
223598976|NCT02744196|DRUG|Placebo|Placebo solution will look identical to the Acellbia solution.
223598977|NCT02744196|DRUG|Methotrexate|
224198997|NCT00002628|DRUG|carboplatin|
224198998|NCT00002628|DRUG|cyclophosphamide|
224198999|NCT00002628|DRUG|mesna|
223598978|NCT03567746|PROCEDURE|Underwater EMR|Polypectomy is performed under full water emersion avoiding the use of submucosal injection.
223617929|NCT04034823|DRUG|Docetaxel|100 mg/m2 Q3W IV
224199000|NCT00002628|DRUG|paclitaxel|
223617930|NCT04100382|DEVICE|Laser and SLA|Patients will be randomized into two groups, control group for SLA implants, and study group will receive the Laser treated implants. Implants will be placed classically in the posterior maxillary region and their stability will be measured by ISQ device at the placement. Measurements will be taken again at 2, 4, 6, 8 , 10 and 12 weeks.
223617931|NCT02493036|DRUG|SYN-010|
223617932|NCT05674058|OTHER|No intervention|According to clinical practice.
223617933|NCT00218504|DRUG|Tetrahydrocannabinol|Participants will be randomly assigned to receive an oral dose of 10 mg of THC, 20 mg of THC, or placebo.
223617934|NCT03103126|BEHAVIORAL|Combined resistance exercise and walking|Combined resistance exercise and walking
223617935|NCT00878956|DRUG|Sodium Bicarbonate|In all patients body weight adjusted dose of study medication will be achieved by infusion of sodium bicarbonate at a dose of 0.5 mmol/kg body weight (=bolus) diluted in 250 mL over 1 hour immediately after the induction of anesthesia, prior to the first surgical incision followed by continuous intravenous infusion of 0.2 mmol/kg/hr (=maintenance) diluted in 1000 mL 23 hours (total dose of 5 mmol/kg over 24 hours).
223617936|NCT00878956|DRUG|Sodium Chloride|In all patients body weight adjusted dose of study medication will be achieved by infusion of sodium chloride at a dose of 0.5 mmol/kg body weight (=bolus) diluted in 250 mL over 1 hour immediately after the induction of anesthesia, prior to the first surgical incision followed by continuous intravenous infusion of 0.2 mmol/kg/hr (=maintenance) diluted in 1000 mL 23 hours (total dose of 5 mmol/kg over 24 hours).
223598979|NCT03567746|PROCEDURE|Conventional EMR|It will be performed in a 2-step procedure. First the formation of a submucosal injection underneath the polyp to create a submucosal safety cushion. Then EMR is performed with a polipectomy snare.
223598980|NCT05121948|DRUG|HC-7366|HC-7366 drug product is an immediate release capsule formulation of HC-7366 potassium salt monohydrate (HC-7366-K) in a hard gelatin capsule for oral administration. Each capsule contains HC-7366-K monohydrate (the active ingredient), lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, colloidal silicon dioxide, and magnesium stearate. Capsules are supplied in 3 strengths: 10, 25, and 100 mg HC-7366 free acid equivalent.
223598981|NCT04649463|DIAGNOSTIC_TEST|Open ABPM results|ABPM results were used in the decision making for adjustments in antihypertensive medication at follow up visit.
223598982|NCT01121432|PROCEDURE|endobronchial ultrasound-guided transbronchial needle aspiration|One time for aspiration/biopsy. The duration about 1-2 hour.
223598983|NCT03912779|BEHAVIORAL|C2Hear RLOs|Freely available online RLOs
223598984|NCT03912779|BEHAVIORAL|Printed hearing aid booklet|Departmental printed hearing aid booklet (standard care)
223598985|NCT05200676|DEVICE|ePatch|ePatch registers the heart rate continuously when attached to the chest of the participant.
223598986|NCT05200676|DEVICE|SmartPill|SmartPill is swallowed and passes through the digestive system while sending information to a recording device. The pill is passed in the stool and not reused.
223598987|NCT05300789|OTHER|Follow-up|There is no intervention. Patients are just going to be registered and oncologic follow-up data are going to be recorded.
223598988|NCT06393972|DRUG|Tofacitinib 5 MG BID|Tofacitinib 5 MG BID
223598989|NCT01247168|DRUG|AZD2461|oral capsules, continuous dosing and intermittent dosing
223598990|NCT05750576|DEVICE|Chlorhexidine-impregnated dressings|Sterile adhesive transparent dressings impregnated with Chlorhexidine Gluconate gel applied to ECMO cannulae for up to 7 consecutive days for each dressing, in the absence of exudation or bleeding at the point of insertion and until explantation of the ECMO, sometimes requiring dressing changes.
223598991|NCT05750576|DEVICE|Non impregnated dressings|Single transparent adhesive dressings not impregnated with Chlorhexidine Gluconate applied to ECMO cannulae for up to 7 consecutive days for each dressing, in the absence of exudation or bleeding at the point of insertion and until explantation of the ECMO, sometimes requiring dressing changes.
223598992|NCT05615207|OTHER|Motor Imagery as compared to physical practice for balance tasks|We will investigate if using motor imagery (mentally imagining and practicing a task) as a means of balance training is as effective as physical practice
223598993|NCT05097443|DRUG|Orelabrutinib+R-CHOP; Orelabrutinib+R-DA-EPOCH; Orelabrutinib+R-HD MTX;Orelabrutinib+R+other chemotherapies|"Orelabrutinib+R-CHOP： Orelabrutinib 150mg qd; R-CHOP：Rituximab 375mg/m2 d0, Cyclophosphamide 750mg /m2 d1, Doxorubicin 50mg /m2 or Doxorubicin liposome 30-40 mg /m2 d1, Vincristine 1.4mg /m2 or Vindesine 3mg /m2 d1, Prednisone 100mg d1-5.~Orelabrutinib+R-DA-EPOCH： Orelabrutinib 150mg qd； R-DA-EPOCH：Rituximab 375mg/m2 d0, Etoposide 50mg/ m2, Epirubicin 15mg/ m2, Vincristine 0.4mg/ m2, d1-4, Cyclophosphamide 750mg/ m2 d5, Prednisone 60mg/ m2 d1-5.~Orelabrutinib+R-HD-MTX: Orelabrutinib 150mg qd; R-HD-MTX: Rituximab 375mg/m2 d0, Methotrexate 3.5g/ｍ2 d1.~Orelabrutinib+ R+other regimens: Orelabrutinib 150mg qd； R+other regimens: Rituximab 375mg/m2 d0. The dose of other drugs depends on the regimen.~All regimens follow every 21 days is one cycle, which can be extended to 28 days per cycle according to patients' specific tolerance.~Dose adjustments of Orelabrutinib are allowed. The initial dose is 150 mg, QD, while the first adjustment is 100 mg, QD and the second adjustment is 50 mg, QD."
223598994|NCT02268825|DRUG|MK-3475|"MK-3475 in combination with mFOLFOX6 in a 14 day cycle~Phase 1 and safety expansion Phased Regimen mFOLFOX6 Administered Day 1 of each cycle Leucovorin 400 mg/m2 IV 5-FU 400 mg/m2 IV bolus followed by 2400 mg/m2 IV over 46 hrs Oxaliplatin (Eloxatin) 85 mg/m2 IV~MK-3475 IV to be administered before mFOLFOX6 starting with Cycle 3 (after 28 days of chemotherapy alone); day 1 of each cycle (q 2 weeks)~Phase 1: 2 dose levels of MK-3475 Level -1: 50mg IV q 2 weeks Level 1: 75mg IV q 2 weeks Level 2: 200mg IV q 2 weeks~Safety Expansion: MK-3475 at highest tolerated dose"
224199001|NCT00002628|PROCEDURE|peripheral blood stem cell transplantation|
223598995|NCT05414630|DRUG|Envafolimab|Envafolimab: 300 mg，D1，Q3W, until PD or intolerable toxicity. The duration of treatment with Envafolimab should not exceed 2 years.
223748434|NCT06392984|DIAGNOSTIC_TEST|Pectus deformity study form|Pectus deformity study form consisting of clinical and radiological measurements of participants aged 6-18 years who applied to the outpatient clinic with chest deformity will be filled in detail.
224199002|NCT02437526|OTHER|Analytic treatment interruption|
223748435|NCT06392984|DIAGNOSTIC_TEST|Pulmonary function test|Pulmonary function tests (PFTs) are noninvasive tests that show how well the lungs are working. The tests measure lung volume, capacity, rates of flow, and gas exchange. This information can help your healthcare provider diagnose and decide the treatment of certain lung disorders. Investigators will use handheld spirometry device for measurement. Three measurements will be made. In these three measurements; FEV1(Forced Expiratory Volume In One Second) (Liter-L), FEV1 (%predicted), FVC (Forced Vital Capacity) (Liter-L), FVC (%predicted), FEV1/FVC (%) and FEV1/FVC (%predicted) will be evaluated. The arithmetic average of the results of these three measurements will be taken.
224199003|NCT04973644|DEVICE|Remote monitoring devices+Internet management platform|Remote monitoring devices collects blood glucose, total cholesterol, serum ketones and serum uric acid,then upload data to the platform.
224199004|NCT05629741|DRUG|CMTX-101|Administered as specified in the treatment arm
224199005|NCT05629741|DRUG|Placebo|Administered as specified in the treatment arm
224199006|NCT06574386|DIAGNOSTIC_TEST|Neurodevelopmental assessment|Neurodevelopmental assessment
224199007|NCT04242264|OTHER|Placebo|0.9% Sterile Normal Saline, USP
224199008|NCT04242264|BIOLOGICAL|Shigella sonnei strain 53G|1.5 x 10\^3 Colony Forming Units (cfu) Shigella sonnei 53G, a virulent strain of wildtype Shigella sonnei
224199009|NCT04242264|BIOLOGICAL|WRSs2|10\^6 Colony Forming Units (cfu) dose of an oral live-attenuated Shigella sonnei vaccine candidate derived from a virulent S. sonnei strain Moseley (WRSs2)-a live, attenuated vaccine that has been manufactured under cGMP conditions at the WRAIR PBF
224199010|NCT00542646|PROCEDURE|Endovascular Intervention|Peritoneal Lined Stent Endovascular Intervention
224311188|NCT06968533|DIAGNOSTIC_TEST|AI-ECG guided diagnosis|Participants undergo screening using the AI-ECG system. Participants identified as medium- to high-risk for LV dysfunction (LVEF \<50%) are recommended for echocardiography to confirm the diagnosis and guide subsequent management.
224199011|NCT05129527|DEVICE|InspirerMundi app|"Patients in the experimental group, in addition to usual care, will be invited to use the InspirerMundi app for 4 months to support adherence to preventive inhaled medication and their asthma self-management. The purpose of the InspirerMundi app is to transform the adherence process into a positive experience through immediate and pleasant rewards. The InspirerMundi app integrates 3 main components: monitoring (symptoms, control, adherence), gaming and social/peer support.~Participants will be able to include their action plan in the app. Within the action plan, the application can lead to changes in the medication effectively taken, which means that the therapeutic level can be adjusted according to the action plan.~Participants in the experimental arm will be able to share with their physician, through the app, their medication adherence and asthma control data in the 3 months visit, and whenever patients wish during the study period."
223598996|NCT04482582|RADIATION|Cryoneurolysis|Patients will be offered a minimally invasive solution known as cryoneurolysis. By directly applying a cold cryoneurolysis probe to the nerves the axon is destroyed, resulting in Wallerian degeneration of the distal nerve without distorting epineurial or perineurial tissue. Application of cryoneurolysis will help reduce the amount of narcotics the patient would need to take and instead provide them longer term pain control with minimal risk.
223598997|NCT04482582|OTHER|Standard of Care|Patients will be provided regular standard of care at the Stanford Hospital with long-term follow-up provided at the Stanford Center for Reconstruction after Chest Wall Injury.
223598998|NCT00607867|OTHER|LoBAG30 diet|A LoBAG30 diet consists of 30% of total energy intake as carbohydrate, 30% protein, and 40% fat.
223598999|NCT00607867|OTHER|Control Diet|A control diet consists of 55% of total energy intake as carbohydrate, 15% protein, 30% fat
223599000|NCT00043732|DRUG|SCIO-469|
223599001|NCT04350996|OTHER|Wearable alcohol sensor|BACtrack Skyn, is a novel transdermal blood alcohol sensor developed by BACtrack, a company established for police-grade breathalyzers, and winner of the Wearable Alcohol Biosensor Challenge sponsored National Institute on Alcohol Abuse and Alcoholism.
223599002|NCT01961622|DEVICE|Florence D2A or similar closed loop glucose control system|Subject's glucose level will be controlled by the Florence D2A or similar automated closed loop glucose control system. The system comprises of FreeStyle Navigator 2 ® Continuous Glucose Monitoring (CGM) System (Abbott Diabetes Care, Alameda, CA, USA), Dana R Diabecare subcutaneous insulin infusion pump (Sooil Corp. Seoul, South Korea)or similar insulin pump, and MPC-based glucose control algorithm running on a smartphone
223599003|NCT01961622|DEVICE|CSII with real-time CGM|Subject glucose level controlled by usual insulin pump therapy in conjunction with real time continuous glucose monitoring (CGM)
223599004|NCT00711971|DRUG|EPA-rich fish oil supplement|1060 mg EPA plus 274 mg DHA
223599005|NCT00711971|DRUG|DHA-rich fish oil supplement|900 mg DHA plus 180 mg EPA
223599006|NCT00711971|DRUG|placebo|control arm
223599007|NCT02644343|DEVICE|Custom Sound|Custom Sound is the programming software used to program Nucleus cochlear implants.
223599008|NCT01909089|DRUG|Spinal administration of chloroprocaine.|"In order to determine the minimum effective dose that is to be given spinally, an up-down sequential allocation will be used.~Efficacy of the analgesia will be evaluated by a 100mm visual analogue pain score (VAPS). There are two possible outcomes here:~* effective: the VAPS is 10mm or lower after the 15 minutes of monitoring. An effective result will decrease the test dose of chloroprocaine with 2mg for the next patient in this study.~* Ineffective: the VAPS is more than 10mm after 15 minutes of monitoring. An ineffective result will increase the test dose of chloroprocaine with 2mg for the next patient in this study. Patients who indicate an ineffective result will receive a rescue treatment by the administration of 12ml levobupivacaine epidurally."
223599009|NCT01199809|DRUG|Placebo|multiple doses
223599010|NCT01199809|DRUG|RO5310074|multiple ascending doses
223617937|NCT04380389|DIAGNOSTIC_TEST|hypoxia|Brief stable arterial oxygen desaturation in healthy volunteers and sampling arterial blood when a stable level of hypoxia has been attained.
223617938|NCT05459467|OTHER|Exercise|12 weeks high intensity exercise programme
223617939|NCT01507922|DRUG|Fenoverine|Fenoverine 100mg three times a day for 8 weeks
223617940|NCT01507922|DRUG|Timebutine|Timebutine maleate 150mg three times a day for 8 weeks
223617941|NCT03846050|BEHAVIORAL|BAC feedback/warning|Participants will receive a warning when their BAC reaches a set limit. The cutpoint for this warning is not disclosed but is well below the legal limit for driving. Warning will notify them that their results indicate it is not safe for them to drive.
223617942|NCT03846050|BEHAVIORAL|No BAC feedback/warning|Participants will receive no information on their current intoxication and will be asked to report less information on their driving decisions.
223617943|NCT02884024|OTHER|no intervention|there is no intervention in this study
223617944|NCT00639470|OTHER|easy to read fact sheets|easy to read fact sheets with illustrations and without illustrations
223617945|NCT03001557|DRUG|Lemborexant 2.5 mg|Lemborexant 2.5 mg tablets
223617946|NCT03001557|DRUG|Lemborexant 5 mg|Lemborexant 5 mg tablets
223617947|NCT03001557|DRUG|Lemborexant 10 mg|Lemborexant 10 mg tablets
223617948|NCT03001557|DRUG|Lemborexant 15 mg|Lemborexant 5 mg and 10 mg tablets
223617949|NCT03001557|DRUG|Lemborexant-matched placebo|Lemborexant-matched placebo tablets
223617950|NCT01794000|DRUG|Prasugrel|Administered orally
223617951|NCT01794000|DRUG|Placebo|Administered orally
223617952|NCT00754585|DEVICE|Logic Back Grahl Duo Back Model DB11-01|The device is placed against the back rest of a chair. The tension of the straps are adjusted for each participant to obtain the ENP.
223617953|NCT04718207|DEVICE|Brain positron emission tomopgraphy (PET) - scan|Patients who performed brain PET/CT scans in the nuclear medicine department from December 2017 to December 2020.
223617954|NCT03360435|DIETARY_SUPPLEMENT|Patch MD MultiVitamin Plus patch|The transdermal patch contains vitamins A, D, E, K2, C, thiamine, riboflavin, niacin, pantothenic acid, pyridoxine, biotin, folic acid, cyanocobalamin, calcium, iron, phosphorous, iodine, magnesium, zinc, selenium, copper, manganese, chromium, molybdenum, potassium, chloride, and boron.
223617955|NCT02915666|DRUG|Digoxin Combination|Digoxin 0.25 mg PO daily will be given for 8-week cycles
223617956|NCT02915666|DRUG|Dabrafenib|dabrafenib 150mg PO twice daily for 8-week cycles
223617957|NCT02915666|DRUG|Trametinib|trametinib 2 mg PO daily for 8-week cycles
223599011|NCT03079596|PROCEDURE|ERAS perioperative cares|Patient's preoperative counseling \& education before surgery No Bowel preparation Oral Carbohydrate Solution (OCS) loading until 2hours before surgery Fluid restriction \& Management by pulse contour analysis or transesophageal doppler Early mobilization Early oral feeding (postoperative 1 day - sips of water, 2 days - semifluid diet (SFD), 3 days - soft blended diet (SBD)) Epidural patient controlled analgesics (no opioids analgesics) Postoperative Nausea Active Control Thromboembolism prophylaxis by low molecular weighted heparin (LMWH) Perioperative High content Oxygen therapy No drain insertion No Levin tube Patients will be discharged at POD#4 if there's no problem.
223599012|NCT03079596|PROCEDURE|Conventional perioperative cares|No Patient's preoperative counseling \& education before surgery Bowel preparation No Oral Carbohydrate Solution (OCS) loading until 2hours before surgery Conventional Fluid Management by clinical signs (Urine output, heart rate etc.) Conventional Mobilization Conventional oral feeding (POD#2 SOW, #3 SFD, #4 SBD) IV PCA Postoperative Nausea Control if needed No Thromboembolism prophylaxis No or Low Content Oxygen therapy Routine drain insertion Levin tube insertion if needed
223599013|NCT05769205|DEVICE|MRI|MRI with contrast
223599014|NCT05076890|DIETARY_SUPPLEMENT|15 mg/g Full Spectrum Hemp Extract|HPMC capsules containing full spectrum standardized hemp extract in liquid form.
223599015|NCT05076890|DIETARY_SUPPLEMENT|50 mg/g Full Spectrum Hemp Extract|HPMC capsules containing full spectrum standardized hemp extract in liquid form.
223599016|NCT01198639|DEVICE|manual administration of iv anesthetics (propofol and remifentanil) using the Toolbox platform|the anesthesiologists are instructed to maintain the BIS values between 40 and 60 throughout anesthesia using target controlled infusion method
223599017|NCT01198639|DEVICE|closed-loop administration of iv anesthetics (propofol and remifentanil) using the Toolbox platform|an algorithm is used to maintain automatically the BIS values between 40 and 60
223599018|NCT01584739|DRUG|AZD8683|Multiple dose, oral inhalation (Healthy volunteers) Multiple dose, oral inhalation (COPD patients)
223599019|NCT01584739|DRUG|Placebo|Multiple dose, oral inhalation (Healthy volunteers) Multiple dose, oral inhalation (COPD patients
223599020|NCT00738751|DRUG|Panobinostat (LBH589)|Panobinostat was taken twice weekly, for 2 out of 3 weeks of each cycle. Each cycle was defined as a 21-day period. Four dose levels of panobinostat in combination with erlotinib were planned: 1) dose level 1 (DL1) = panobinostat 20 mg by mouth (PO) twice weekly for 2 out of 3 weeks + erlotinib 100 mg PO daily; 2) dose level 2 (DL2) = panobinostat 30 mg and erlotinib 100 mg; 3) dose level 3 (DL3) = panobinostat 30 mg and erlotinib 150 mg; and 4) dose level 4 (DL4) = panobinostat 40 mg and erlotinib 150 mg. Doses were not escalated over the course of treatment of an individual participant.
223599021|NCT00738751|DRUG|erlotinib|Erlotinib was taken daily without interruption. Each cycle was defined as a 21-day period. Panobinostat was taken twice weekly, for 2 out of 3 weeks of each cycle. Four dose levels of panobinostat in combination with erlotinib were planned: 1) dose level 1 (DL1) = panobinostat 20 mg by mouth (PO) twice weekly for 2 out of 3 weeks + erlotinib 100 mg PO daily; 2) dose level 2 (DL2) = panobinostat 30 mg and erlotinib 100 mg; 3) dose level 3 (DL3) = panobinostat 30 mg and erlotinib 150 mg; and 4) dose level 4 (DL4) = panobinostat 40 mg and erlotinib 150 mg. Doses were not escalated over the course of treatment of an individual participant.
223748436|NCT06392984|DIAGNOSTIC_TEST|Ultrasonographic Diaphragm Thickness Measurement|Diaphragm thickness (millimeter-mm) will be measured in the supine position with a 6-14 Mhz lineer, conventional ultrasound probe (Mindray DC-8, Shenzen Mindray Bio-Medical Electronics CO. LTD.,P.R. China) at the end of inspiration and expiration from the intercostal space on the anterior axillary line. The measurements will be evaluated by making three measurements from the right 8-9. intercostal space where the diaphragm is best visualized. End-expiratory (Forced residual capacity-FRC) (millimeter-mm), end-inspiratory (Total Lung Capacity-TLC) (millimeter-mm)) and thickening rate (%) (thickness TLC / thickness FRC) will be evaluated three times and the arithmetic average of these three measurements will be taken.
223748437|NCT00885755|DRUG|Standard taxane therapy|As prescribed
223748438|NCT00885755|DRUG|capecitabine [Xeloda]|1000mg/m2 po bid on days 1-14 of each 3-week cycle (only in patients who have progressed)
223748439|NCT00885755|DRUG|trastuzumab [Herceptin]|8mg/kg iv loading dose on day 1 of first 3-week cycle, and 6mg/kg iv on day 1 of each subsequent cycle
223748440|NCT04572230|DEVICE|Endovascular treatment of intracranial aneurysms using a flow-diverting stent|The flow diverter brings about a reduction of blood flow to the aneurysm, which progresses over time into forming a stable thrombus within the aneurysm, as well as eventual aneurysm scarring and retraction. The flow diverter also acts as a scaffold for tissue growth across the neck of the aneurysm, which blocks the aneurysm from the artery blood flow.
223748441|NCT04315337|BEHAVIORAL|Virtual Kitchen Training|VR Training will include repeated practice of a single, everyday task in a non-immersive VR context (e.g., VR Breakfast) using a laptop with a touch-screen interface for four days over the course of one week.
223748442|NCT00913471|OTHER|blood samples|"Chronic patients - a one time blood sample (12 mL) and questionnaire; 10 subjects will donate a 3-5mm skin tissue sample.~Longitudinal Patients - 5 blood samples (12 mL each, totaling 60 mL at the following time points: within 48 hours, one week, one month, 6 months and 18 months post injury to coincide with standard visits) and questionnaire. 10 subjects will donate a 3-5mm skin sample.~Healthy, pain free volunteers - a one time blood sample (12 mL), vital signs per standard CRU protocol and questionnaire confirming they are healthy."
223748443|NCT04478006|GENETIC|RNA-seq|Gene expression and fusion transcripts analysis
224199012|NCT05129527|OTHER|Usual care|Usual care will consist of pharmacological treatment and medical monitoring through routine medical visits.
224199013|NCT05948917|BEHAVIORAL|Mind-Body Skills Groups|The mind-body skills groups consist of supportive small group sessions with about 8-10 participants per group. Participants of these groups learn and practice mind-body techniques including: meditation, self-expression through drawings, autogenics and biofeedback, guided imagery, body awareness, and genograms.
224199014|NCT05097066|PROCEDURE|Neurosurgical procedure|Any neurosurgical procedure in the National Neurosurgical Audit Programme (NNAP) Coding Framework of neurosurgical procedures.
224199015|NCT02384200|DRUG|nitrofurantoin monohydrate/macrocrystalline capsules|1 week course of preoperative nitrofurantoin monohydrate/macrocrystalline capsules 100 milligrams twice daily
224199016|NCT02384200|DRUG|ampicillin|IV (2 g)
224199017|NCT02384200|DRUG|gentamicin|IV (5 mg/kg)
224199018|NCT02384200|DRUG|vancomycin|IV (1 g)
224199019|NCT02384200|DRUG|ceftriaxone|IV (2 g)
223748444|NCT04478006|GENETIC|whole exon sequencing|Genetic alternation analysis
223599022|NCT05587192|DIAGNOSTIC_TEST|18F-PSMA-1007 PET/CT based on diagnostic model|All enrolled patients will receive 18F-PSMA-1007 PET/CT based USTC diagnostic model before gaining the final pathological diagnosis to be used as experimental arm.
223599023|NCT04843761|BIOLOGICAL|Remdesivir|Administered by IV infusion, daily for 10 days. Initial loading dose is 200 mg with all subsequent doses 100 mg.
223748445|NCT04478006|OTHER|Cytogenetics test|Remission and relapse are monitored by cytogenetic analyses.
223748446|NCT05612412|OTHER|Morning Exercise|Standardized treadmill exercise session starting at approximately 0700
223748447|NCT05612412|OTHER|Evening Exercise|Standardized treadmill exercise session starting at approximately 1800
223748448|NCT05030298|RADIATION|Radiation Therapy|Undergo radiation therapy
223748449|NCT05030298|RADIATION|Radiosurgery|Undergo radiosurgery
223748450|NCT05030298|PROCEDURE|Stereotactic Biopsy|Undergo MRI-guided stereotactic biopsy
223748451|NCT05030298|DRUG|Temozolomide|Drug
223748452|NCT05030298|PROCEDURE|Tumor Treating Fields Therapy|Undergo TTF
223599024|NCT04843761|DRUG|Remdesivir Placebo|Commercially available 0.9% sodium chloride solution. Administered by IV infusion daily for 10 days.
223748453|NCT05030298|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
224199020|NCT06219499|DRUG|ONC-841|ONC-841 is a humanized monoclonal antibody.
224199021|NCT06219499|OTHER|Placebo|Placebo
224199022|NCT00544778|BIOLOGICAL|filgrastim|
224199023|NCT00544778|DRUG|dexrazoxane hydrochloride|
223599025|NCT04843761|BIOLOGICAL|Aviptadil|Administered by IV infusion over 12 hours per day for 3 days. Participants are no longer being randomized to this intervention.
223599026|NCT04843761|DRUG|Aviptadil Placebo|Commercially available 0.9% sodium chloride solution. Administered by IV infusion over 12 hours per day for 3 days.
223748454|NCT05030298|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223748455|NCT05030298|PROCEDURE|Biopsy|Undergo biopsy
223748456|NCT05030298|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
223748457|NCT05784506|OTHER|Macronutrients|Four successive food tolerance tests (glucose, protein, butter and olive oil) at one-week intervals.
223748458|NCT05784506|OTHER|Mixed meal tolerance test (MMTT)|Mixed meal tolerance test (MMTT)
223748459|NCT04591574|BIOLOGICAL|Red Blood Cells (Transfusion)|Participants will receive RBC transfusions in accordance with trial protocol (intervention group) or usual care, which is in accordance with the NICE guidelines
223748460|NCT04746664|BEHAVIORAL|Nutritional counselling|Individual-based nutrition counselling guided with the health belief model (HBM) and the theory of planned behavior (TPB) will be implemented.
223748461|NCT04859751|DRUG|VB4-845 Injection|Intravesical administration of VB4-845 Injection.
223748462|NCT00703612|PROCEDURE|Autologous Adipose-derived Stem cells|Intravenous administration of autologous activated stromal vascular fraction derived from 100-120 ml lipoaspirate following mini-liposuction of abdominal adipose tissue.
224199024|NCT00544778|DRUG|doxorubicin hydrochloride|
223599027|NCT04843761|DRUG|Corticosteroid|In line with NIH treatment guidelines, corticosteroids such as dexamethasone, prednisone, methylprednisolone or hydrocortisone may be administered as SOC.
223599028|NCT03005548|DEVICE|Transcranial direct current stimulation|"Transcranial direct current stimulation. All eligible patients will be treated with patient-controlled IV morphine analgesia by PCA (PCA pump (CADD-Legacy PCA Pump, Deltec, Inc.) IV morphine bolus 1 mg, lockout time 10 mins.).~Device: wireless tDCS (StarStim, NeuroElectrics) non-invasive brain stimulation with a pair of electrodes with saline-soaked pads for delivery of direct current at intensity 2 mA for 20 mins."
223748463|NCT06417385|DEVICE|taVNS soterix device|Soterix is a custom modified, FDA-cleared electrical stimulator that meets the criteria of the FDA for investigational use. Neoleads will be placed in order to deliver electrical stimulation using microcurrent (\<2.5mA) with breastfeeding, on with sucking and swallowing and off with rest for 5 feeds per week for 2 weeks.
223748464|NCT04585087|OTHER|Dietary Intakes|6 levels of threonine intake will be provided by the protein liquid drink
223748465|NCT05869604|BEHAVIORAL|HEALTHY AYA|8-session health lifestyle behavior intervention combining behavioral symptom management strategies with strategies to improve diet and increase physical activity.
223748466|NCT05869604|OTHER|Education Control|Participants will receive paper materials on topics of relevance to adolescent and young adult cancer survivors.
223748467|NCT05087147|DEVICE|0.7 mm stainless steel orthodontic wire|0.7 mm stainless steel orthodontic wire
223748468|NCT05087147|DEVICE|Banded space maintainer|band and loop space maintainer
223748469|NCT02301273|OTHER|Usual Physiotherapy|o Patients will receive the usual physiotherapy treatment in ICU in Iceland from day 5 after intubation, which adheres to international standards of practice, including the potential for no treatment. Usual physiotherapy once daily for 20 minutes.
223748470|NCT02301273|OTHER|Enhanced Physiotherapy|o Patients will receive the intervention physiotherapy treatment consisting of exercises and a progressive upright positioning and mobilization (20 minutes) twice daily from day 3 (\>48 hours) after intubation including the potential for no treatment, if they are stable, even though they are not completely alert, Total treatment time of 40 minutes.
224199025|NCT00544778|DRUG|ifosfamide|
224199026|NCT00544778|DRUG|irinotecan hydrochloride|
224199027|NCT00544778|GENETIC|protein expression analysis|
224199028|NCT00544778|OTHER|immunoenzyme technique|
224199029|NCT00544778|PROCEDURE|adjuvant therapy|
224199030|NCT00544778|PROCEDURE|conventional surgery|
224199031|NCT00544778|PROCEDURE|neoadjuvant therapy|
224199032|NCT00544778|RADIATION|radiation therapy|
224199033|NCT06101251|BEHAVIORAL|Driving Tips|Each week participants will receive a safe driving tip for one of the four behaviors via text message.
224199034|NCT06101251|BEHAVIORAL|Standard Feedback|Each week participants will receive a text message showing their overall driving score (out of 100) and subscores for distraction, hard braking, fast acceleration, and speeding (all running averages). The scoreboard will indicate whether their scores have gone up, down, or stayed the same. The message will include a link to a dashboard.
223599029|NCT03005548|DRUG|Morphine|"In Sham comparator group All eligible patients will be treated with patient-controlled IV morphine analgesia (PCA) (PCA pump (CADD-Legacy PCA Pump (Deltec, Inc.) morphine IV bolus 1 mg, lockout time 10 mins).~Device: wireless tDCS (StarStim, NeuroElectrics) non-invasive brain stimulation with a pair of electrodes with saline-soaked pads for delivery of direct current at intensity 2 mA for 30s at the beginning."
223599030|NCT02768519|DRUG|OTS167IV|diluted to final concentration with cherry syrup
223599031|NCT02768519|OTHER|Cherry syrup|
223599032|NCT03683017|DEVICE|OrthoPulse 2.0|Patients are given OrthoPulse 2.0, an extended OrthoPulse device with no zone control (ability for doctor to control treatment regions). Patients complete 10 minute treatments (5 minutes each arch) every day.
223748471|NCT06538818|DEVICE|Ultra Phonophoresis|"Therapeutic pulsed ultrasound using Phyaction UbMF ultrasound device in presence of a hyaluronic acid-containing gel will be applied gel pad over the wrist and along the course of median nerve at the carpal tunnel.~The following parameters will be used: intensity of 1.0 W/em2 at a 1MHz frequency for 5 minutes and pulsed (25%) ultrasound waves to transfer the hyaluronic acid-containing gel. This therapy will be applied for 5 min/session, 5 d/wk, for 3 weeks.~The following parameters will be used:~* intensity of 1.0 W/cm2~* 1MHz frequency~* pulsed (25%)~* 5 min/session, 5 d/wk, for 3 weeks."
224199035|NCT06101251|BEHAVIORAL|Assigned Focus Area Feedback|Each week feedback will focus the participant's attention on the driving behavior with the greatest opportunity for improvement based on their baseline driving behavior. Participants will be assigned a goal for the week of a score 5 points (3 points in the case of Driver Focus) better than their baseline for that area. If they meet the goal, they will be given a new goal 5 points higher; if they fall short, they will be asked to try for the same goal again. If they improve sufficiently-or if their improvement stalls out-they will be assigned a new behavior to focus on.
224199036|NCT06101251|BEHAVIORAL|Study Dashboard (Standard)|By clicking the link in the feedback text, they will be able to view a weekly dashboard that provides detailed information about their baseline, best, last, and average scores for each of the four behaviors, plus descriptions of the four behaviors.
224199037|NCT06101251|BEHAVIORAL|Study Dashboard (focused)|Same as standard study dashboard, except participants will see at the top of the dashboard how well they are doing relative to their weekly goals.
224199038|NCT06101251|BEHAVIORAL|UBI-like Behavioral Incentive|At the end of the 12-week intervention period, their overall driving score will be translated into a $0-$100 reward amount. For example, a participant with an overall driving score of 84 at the end of the intervention period would receive $84 in compensation.
224199039|NCT06101251|BEHAVIORAL|Sef-Chosen Focus Area Feedback|Participants will be asked to select which driving behavior they want to focus on improving, and to set a goal for the week that is above their baseline score. If they meet the goal, they will be asked to set a new, higher goal; if they fall short, they will be asked to try for the same goal again. If they improve sufficiently-or if their improvement stalls out-they will be asked if they want to focus on a new behavior.
224199040|NCT05694923|DRUG|Empagliflozin 10 MG|non fatty liver non alcoholic patients Will receive empaglifizon sodium glucose cotransporter in minimum dose 10 mg
224199041|NCT05007938|DRUG|Icotinib|Icotinib is a EGFR ihibitior.
224199042|NCT05007938|DRUG|Befotertinib|An orally available, irreversible, third-generation，mutant-selective epidermal growth factor receptor（EGFR）inhibitor. Befotertinib combine with icotinib means that both drugs will be given together until disease progression or meet the discontinuation criteria.
224199043|NCT05697445|OTHER|Mobilization Techniques|Combination of Cranial and Cervical Mobilization for Cervicogenic headache Patients treatment
224199044|NCT05697445|OTHER|Conventional Treatment|Cervicogenic headache exercises
224199045|NCT01750034|PROCEDURE|Closed method|Subjects will have their wounds managed by covering with gauze and changing this gauze 3 to 7 times per week.
224199046|NCT01750034|PROCEDURE|Open method|Subjects will have their burns managed by keeping the wounds exposed to the air.
224199047|NCT03126175|DEVICE|Below elbow immobilization|20cm wide gypsum in the forearm cut to fit the thumb.
224199048|NCT03126175|DEVICE|Above elbow immobilization|20cm wide gypsum in the forearm cut to fit the thumb associated a elbow splint made with a 15cm width on the ulnar aspect of the forearm that begins at the middle of the forearm and extends into the armpit.
224199049|NCT00471237|DRUG|Ronacaleret|100mg, 200mg, 300mg, 400mg
223599033|NCT03683017|DEVICE|OrthoPulse 2.1|Patients are given OrthoPulse 2.1, an extended OrthoPulse device with zone control (ability for doctor to control treatment regions). Patients complete 10 minute treatments (5 minutes each arch) every day.
224199050|NCT00471237|DRUG|Teriparatide|PTH (1-34)
224199051|NCT00471237|DRUG|Alendronate|Bisphosphonate
224199052|NCT00373282|DRUG|Triamcinolone acetonide|
224199053|NCT06032260|OTHER|Enriched panettone|Volunteers consumed 100 grams of panettone enriched with fiber (JAX Plus® (Heallo srl, Milano, Italy), a soluble fiber with Arabinoxylans from wheat and barley
224199054|NCT06032260|OTHER|Panettone standard|Volunteers consumed 100 grams of panettone standard
224199055|NCT02314130|DIETARY_SUPPLEMENT|Dietary therapy|A enteral diet formulation was developed to meet dietary requirements of adult patients. The formulation was standarized in household measures so that caregivers would prepare it and delivered it at the patients' home. Anthropometric measurements and blood samples were taken at baseline and at the end of the intervention which lasted four months.
224199056|NCT02320734|DRUG|Rocuronium|Rocuronium given continuously to reach deep neuromuscular block
224199057|NCT03005717|DRUG|LIPO-202|
224199058|NCT03005717|DRUG|Placebo for LIPO-202|Lyophile manufactured to mimic LIPO-202 lyophile.
224199059|NCT04719208|OTHER|Water (E) Mouth rinse with the solution provided|Subject will be asked to perform a simple mouth rinse for 2 minutes with one of the 5 mouth washes to be tested.
224199060|NCT04719208|OTHER|Chlorhexidine gluconate (A) Mouth rinse with the solution provided|Subject will be asked to perform a simple mouth rinse for 2 minutes with one of the 5 mouth washes to be tested.
224199061|NCT04719208|OTHER|Hydrogen peroxide (B) Mouth rinse with the solution provided|Subject will be asked to perform a simple mouth rinse for 2 minutes with one of the 5 mouth washes to be tested.
224199062|NCT04719208|OTHER|Betadine (C) Mouth rinse with the solution provided|Subject will be asked to perform a simple mouth rinse for 2 minutes with one of the 5 mouth washes to be tested.
223599034|NCT03683017|DEVICE|Invisalign 3.5 Day Wear|Patients are are fitted with sets of clear orthodontic Aligners by a qualified Principal Investigator (PI) using a ClinCheck plan by Align Technology. Aligners are worn for approximately 22 hours a day, and switched every 3.5 days.
223599035|NCT03683017|DEVICE|Fixed Orthodontic Appliances (Braces)|Patients are fitted with a set of brackets and wires, as per standard orthodontic treatment by a qualified Principal Investigator (PI).
223599036|NCT04880655|DEVICE|WSD|Post debridement and within 24 hours of injury, wound care and WSD applied daily
223599037|NCT04880655|DEVICE|Dressed with bacitracin and petrolatum gauze|Post debridement and within 24 hours of injury, wound care and dressing applied daily
223599038|NCT00458458|DRUG|Norethindrone Acetate (NA)|52 weeks of treatment with Norethindrone Acetate
223599039|NCT00458458|DRUG|GnRH Agonist (Lupron Depot)|24 weeks of treatment with Lupron Depot then 28 weeks of treatment with Norethindrone Acetate
223599040|NCT02238158|DRUG|Atrovent® inhalets|
223599041|NCT06231368|BIOLOGICAL|CNCT19 CAR-T cell therapy|CNCT19 was a second-generation CAR T-cell with scFv derived from clone HI19α and 4-1BB/CD3-ζ costimulatory domain.
223599042|NCT03606187|DEVICE|Stimgenics SCS Programming Approach|Stimgenics SCS Programming approach Using Intellis(TM) SCS system
223599043|NCT03606187|DEVICE|Standard SCS Programming Approach|Standard SCS Programming approach using Intellis(TM) SCS system
223599044|NCT04328220|DIAGNOSTIC_TEST|chest ultrasound|"A point-of-care lung ultrasound exam will be performed within 24h of admission to PICU and serial follow up according to each case.~chest x-ray will be performed for comparison with ultrasound findings."
223599045|NCT00811616|DEVICE|Supralimus-Core™|Sirolimus Eluting Cobalt Chromium based coronary stent system
223599046|NCT00811616|DEVICE|Supralimus™ Core™ Sirolimus eluting stent|Supralimus™ Core™ Sirolimus eluting stent intended to treat coronary artery disease.
223599047|NCT03704688|DRUG|Trametinib 0.5 mg|0.5mg PO q daily
223599048|NCT03704688|DRUG|Trametinib 1 MG|1.0 mg PO q daily
223599049|NCT03704688|DRUG|Trametinib 1.5 MG|1.5mg PO q daily
223599050|NCT03704688|DRUG|Trametinib 2 mg|2 mg PO q daily
223599051|NCT03704688|DRUG|Ponatinib 15 MG|15mg PO q daily
223599052|NCT03704688|DRUG|Ponatinib 30 MG|30mg PO q daily
223599053|NCT02551822|DEVICE|sacral neuromodulator|The Implanted Pulse Generator will be set via randomization to continuous vs cycling stimulation.
223599054|NCT00394550|PROCEDURE|supraglottoplasty with laser|"Polysomnogram, fiberoptic flexible laryngoscopy, adenotonsillectomy, direct laryngoscopy, bronchoscopy, laser supraglottoplasty, general anesthesia, a proton-pump inhibitor ibuprofen, acetaminophen with codeine without alcohol, or other narcotic containing medication, antibiotic, possible use of other analgesics per anesthesia None of these procedures are new or experimental. Our investigation pertains to a broader use of the laser supraglottoplasty to include children with obstructive sleep apnea and laryngomalacia, as opposed to the more traditional use of laser supraglottoplasty for only severe laryngomalacia in young children"
223599055|NCT00394550|PROCEDURE|supraglottoplasty with laser|laser excision of laryngomalacia (floppy tissue) on one side of the supraglottis
224199063|NCT04719208|OTHER|Alcohol mouthwash (Listerine) (D) Mouth rinse with the solution provided|Subject will be asked to perform a simple mouth rinse for 2 minutes with one of the 5 mouth washes to be tested.
224199064|NCT01605370|DRUG|Nebivolol|Nebivolol 2.5 mg once daily
224199065|NCT01605370|DRUG|Metoprolol succinate|Metoprolol succinate 50 mg once daily
224199066|NCT00112086|DRUG|Neoadjuvant chemotherapy (Paclitaxel and Carboplatin)|
224199067|NCT06499272|PROCEDURE|Conventional occupational therapy sessions + NeuronUP|Occupational therapy sessions are based on cognitive stimulation, manipulative skill training and psychomotor skills. In addition, 2 sessions per week are conducted with two Nintendo Switch games.
224199068|NCT06499272|PROCEDURE|Conventional occupational therapy sessions|Occupational therapy sessions are based on cognitive stimulation, manipulative dexterity training and psychomotor skills.
224199069|NCT00578448|DRUG|Belatacept|IV infusion
223599056|NCT01985750|DRUG|d-cycloserine|250mg d-cycloserine or identical placebo given immediately to the first 4 sessions of a 6-week course pulmonary rehabilitation.
223599057|NCT01985750|DRUG|placebo|"Other Names:~comparison of d-cycloserine or placebo on enhancing the beneficial effects of pulmonary rehabilitation on breathlessness perception~250mg d-cycloserine or identical placebo given immediately to the first 4 sessions of a 6-week course pulmonary rehabilitation"
223599058|NCT03962075|PROCEDURE|laparoscopic paravaginal repair|Using a 10mm laparoscope, with video camera, was introduced through the umbilical trocar. Another 5 mm in suprapubic area and two 10 mm trocars in right and left lateral abdominal sides were introduced. The larger trocar was needed to accommodate the passage of needles into the abdomen. Spacing of trocars sufficiently from each other was needed to facilitate laparoscopic suturing. Transperitoneal approach to retropubic space was used. Two to four polypropylene sutures were applied on each side. Sutures were tied with intracorporeal technique
224199070|NCT05975762|PROCEDURE|surgical rib fixation|open reduction and internal rib fixation
224311189|NCT00468650|DRUG|sildenafil citrate|Tablets, 50mg and 100mg , Medication will be taken orally with a glass of water approximately one hour (30 min to 4 hours) before sexual activity. Subjects are to take one dose in any calendar day.Eligible patients fulfilling all inclusion/exclusion criteria will be assigned at Visit 2/Week 0 (Baseline) to receive sildenafil 50 mg as needed (PRN) during the first two weeks, and,thereafter, at Visit 3/Week 2, all enrolled subjects will be up titrated to sildenafil 100 mg PRN for the following four weeks.
223599059|NCT03647644|DIAGNOSTIC_TEST|Coagulation Laboratory Testing|Standard coagulation testing (Platelet count, Fibrinogen, PT/INR, aPTT), and Thromboelastogram as is routine and per institutional protocol in this population.
223599060|NCT04847934|BEHAVIORAL|distraction methods|distraction methods
223599061|NCT05482230|PROCEDURE|Intubation and bronchial blocker placement performed in lateral position|In the lateral position group, patients were positioned laterally (as required for surgery) before anesthesia induction. After anesthesia induction, both endotracheal intubation and bronchial blocker placement were performed while the patient remained in the lateral position.
223599062|NCT03450954|PROCEDURE|Amniotic membrane transplant|Amniotic membrane graft was transplanted onto the bullous cornea by the inlay technique
224199071|NCT03728166|BEHAVIORAL|Electronic alert|"On-screen electronic alert that notifies the provider about the increased risk for VTE after discharge and indication for thromboprophylaxis will be issued 48 hours after admission. This first on-screen electronic alert will provide the clinician with the opportunity to consider extended-duration, post-discharge thromboprophylaxis and start any required processes for prior authorization or medication coverage. The provider then will be given on-screen options to either order thromboprophylaxis (betrixaban or low-molecular weight heparin for 35 days) from a Extended-Duration VTE Prevention order template, follow a link to evidence-based practice guidelines, or defer prescribing extended-duration, post-discharge thromboprophylaxis."
223599063|NCT06088719|PROCEDURE|axillary surgery|one group undergoes axillary surgery
223599064|NCT02265250|OTHER|MRI|Noncontrast T1- and T2-weighted 3.0 T MRI of the bilateral carotid, coronary, and superficial femoral arteries
223599065|NCT02265250|OTHER|PET/MRI|Simultaneous 18F-NaF PET/MRI of the bilateral carotid, coronary, and superficial femoral arteries
223599066|NCT02265250|OTHER|Laboratory blood test|Cardiovascular biomarkers
223599067|NCT05467228|DEVICE|vibro-tactile stimulation (VTS)|To apply vibro-tactile stimulation, participants will use a wearable device. It contains two vibratory motors (Precision MicrodrivesTM, Model 307 - 100) that are low-voltage (\~1V), non-invasive and will be located approximately above the lateral portions of the thyroid cartilage. For this protocol, they vibrate at frequencies between 40 - 100 Hz (i.e., 100 times per second
223599068|NCT05870878|OTHER|Standard care|Individual lifestyle consultation
223599069|NCT05870878|OTHER|Lifestyle program|Lifestyle program focusing on lifestyle advice, coping with stress and adherence to a healthy(er) lifestyle. This program consists of 3 group sessions and an online platform.
223599070|NCT04264364|PROCEDURE|Laparoscopic sleeve gastrectomy|Bariatric surgical intervention
223599071|NCT04264364|PROCEDURE|Endoscopic sleeve gastroplasty|Endoscopic bariatric procedure
223599072|NCT04803227|DRUG|Emricasan|Emricasan 25 mg BID (days 1-14). Oral (capsule) administration.
223599073|NCT04803227|OTHER|Placebo|Placebo BID \*days 1-14). Oral (capsule) administration.
223599074|NCT01440816|BIOLOGICAL|Tavokinogene Telseplasmid (tavo)|Patients received intratumoral injection(s) of tavo.
223599075|NCT01440816|DEVICE|OncoSec Medical System (OMS)|Electroporation via OMS was performed immediately following intratumoral injection of tavo. A sterile applicator containing 6 stainless steel electrodes arranged in a circle were placed around the tumor. The applicator was connected to the OMS power supply and six pulses were administered to each tumor lesion at the approximate point of tavo injection.
223748472|NCT06138730|BEHAVIORAL|Appa Complete|Weekly mentorship meetings \& guided CBT videos. Participants assigned to Appa Complete will have unlimited access to the Appa website and materials described in Appa Lite, along with weekly mentorship meetings with a trained and supervised near-peer mentor with whom they have been matched. Matching is based on preference for mentor gender, racial/ethnic minority status, and LGBTQ status and is designed to increase the sense of identification with the mentor and peer-mentor alliance. Virtual meetings begin with a review and discussion of the video and other materials for the week. Mentors ask about how clients are incorporating their CBT learnings into their life, share ways they have used the focal skills in their own lives, illustrate skills use in popular culture, and provide problem solving strategies. Each week has a specific prompt to ensure that clients are applying the concepts and skills they are learning and can talk about any questions or reflections with their mentors.
223748473|NCT06138730|BEHAVIORAL|Appa Lite|Unguided EBP videos and materials. Participants assigned to the Appa Lite condition will have unlimited access to the Appa website, including short form CBT-based videos and materials such as an emotions wheel pdf and thoughts, feelings, and behavior worksheets. The website is structured so that the materials are presented in a developmentally appropriate manner consistent with evidence-based principles in a 12-week format, beginning with general psychoeducation to define mental health, proceeding to introducing CBT and basic CBT skills such as identifying thoughts, feelings, and behaviors, layering on applying specific CBT skills, and ending with reflective journal exercises. Client progress through the materials will be completely unguided.
224199072|NCT00981695|BIOLOGICAL|MVA.HIVA|1 dose of 5 x 10\^7 pfu of MVA.HIVA administered intramuscularly
224199073|NCT01976104|DRUG|avatrombopag (lower baseline platelet count)|60 mg avatrombopag (3 x 20 mg tablets)
223599076|NCT03776201|OTHER|Balance Training|We expect that a balance training intervention that utilizes an external focus of attention will lead to the adoption of balance strategies that are protective against falls. The mechanism for this behavioral change will be identified using a Dynamical Systems Theory framework (i.e., entropy) to quantify postural sway characteristics before, during and after the training. We will determine whether the balance intervention utilizing an external focus of attention will lead to positive benefits through the three specific aims.
223599077|NCT02858947|PROCEDURE|Aelite Flo|Microhybrid flowable composite
223599078|NCT02858947|PROCEDURE|x-tra base|Bulk-fill flowable composite
223599079|NCT00847886|DRUG|LX3305|Daily oral intake of LX3305 for 14 days.
223599080|NCT00847886|DRUG|LX3305 Placebo|Matching placebo dosing with daily oral intake for 14 days.
223599081|NCT00847886|DRUG|Methotrexate|Once weekly stable-dose methotrexate.
223599082|NCT00313105|DRUG|Smokeless tobacco (Oliver Twist pellets)|individual visits with counseling
223599083|NCT00313105|BEHAVIORAL|smoking cessation counseling|individual visits
223748474|NCT03405779|PROCEDURE|Lung ultrasonography|Mechanically ventilated patients suffering from pulmonary diseases will undergo a lung ultrasonography during their stay in the intensive care unit (ICU)
223748475|NCT03916627|DRUG|cemiplimab|Administered intravenous (IV)
223748476|NCT03916627|DRUG|Platinum Doublet|Administered intravenous (IV)
223599084|NCT04430504|BEHAVIORAL|multidisciplinary telerehabilitation|weekly video meetings to instruct and monitor self-exercises at home
223599085|NCT01687101|DRUG|STOPAIN topical gel|STOPAIN topical gel is topical menthol 6% gel applied as 2 to 4 pumps of gel applied behind the ears and to the occipital region of the neck in one or two applications within 2 hours of the onset of the migraine.
223748477|NCT03916627|DRUG|fianlimab|Administered IV
223748478|NCT06554795|DRUG|DB-1419|Administered Injection of Vein (I.V.)
224199074|NCT01976104|DRUG|placebo (lower baseline platelet count)|60 mg placebo (3 x 20 mg matching placebo tablets)
224199075|NCT01976104|DRUG|avatrombopag (higher baseline platelet count)|40 mg avatrombopag (2 x 20 mg tablets)
223599086|NCT05322434|OTHER|The Effect Of Online Breastfeeding Counseling Given At The Post-Birth Period On Breastfeeding Behavior|The aim of the study is to investigate breastfeeding behavior and initiation of solid food by giving breastfeeding counseling to women within the framework of the Health Belief Model for 6 months from birth.
223599087|NCT05743361|DIAGNOSTIC_TEST|Blood sampling|Detection of ANA, AMA, anti-dsDNA, anti-ENA, anti-MPO, anti-PR3, aPL, RF, ACPA, anti- TPO, anti-TG
223599088|NCT06524193|BEHAVIORAL|Telepractice group voice therapy|"* Voice therapy delivered in group basis via telepractice.~* The voice therapy program will include both indirect and direct voice therapy, in accordance with the current best practice recommendations. Indirect voice therapy will include information counselling on voice production and disorder and vocal hygiene. Direct voice therapy will adopt the resonant voice therapy approach and also head and neck relaxation exercises, which has shown to be effective for muscle tension dysphonia."
223599089|NCT06524193|BEHAVIORAL|Face-to-face group voice therapy|"* Voice therapy that will be delivered in group basis in-person with patients.~* The voice therapy program will include both indirect and direct voice therapy, in accordance with the current best practice recommendations. Indirect voice therapy will include information counselling on voice production and disorder and vocal hygiene. Direct voice therapy will adopt the resonant voice therapy approach and also head and neck relaxation exercises, which has shown to be effective for muscle tension dysphonia."
223599090|NCT00627250|DRUG|Amantadine|Amantadine 100 mg every morning and 12 noon
223599091|NCT02953574|PROCEDURE|daily sleep enhancement nursing protocol|
223599092|NCT01426022|OTHER|Nutrition|Moderate alcohol consumption with dinner (3 glasses of sparkling white wine, containing ca. 30 g alcohol)
223599093|NCT01426022|BEHAVIORAL|mood manipulation|Mood will be manipulated by changing the ambiance in either a pleasant or unpleasant way.
223599094|NCT05144711|PROCEDURE|Selective caries excavation|Selective caries excavation leaving stained but leathery dentine towards the pulp
223599095|NCT05144711|PROCEDURE|Non selective caries excavation|Complete excavation of caries regardless of the risk of pulp exposure
223599096|NCT03958357|DEVICE|Advanced Gynecological Applicator configuration|The Advanced Gynecological Applicator Venezia configuration is a gynaecological applicator for intracavitary and interstitial brachytherapy. The applicator consists of tubes, caps and templates to place needles, which can be combined to reach a wide range of target areas. The tubes and possibly used needles, guide the radioactive source of the afterloader to the target volume. Dose optimization and dose fractionation is performed with the goal of adapting the dose to the target volume without exceeding the dose volume constraints for the surrounding normal tissues according to the standard cervical cancer treatment of the centre.
223599097|NCT01672424|OTHER|Ice Chips|11 ounces of ice chips given to the laboring parturient
223599098|NCT01672424|OTHER|Protein Drink|Patients will receive 11 ounces of a protein shake which contains 30 grams of protein
223599099|NCT04131179|BEHAVIORAL|Youth Culturally Adapted Manual Assisted Psychological Therapy (Y-CMAP)|"Y-CMAP is a manual assisted brief psychological intervention based on the principles of Cognitive Behaviour Therapy (CBT), including 8-10 sessions delivered over three months.~This intervention includes evaluation of the self-harm attempt, psycho education, crisis skills, problem solving and simple cognitive techniques to manage emotions, negative thinking,relapse prevention strategies and training on anger management and assertiveness."
223599100|NCT02546492|DRUG|Acthar gel|Administration of the study drug in addition to the current maintenance immunosuppressive agents
223599101|NCT03920254|DRUG|TD-1473 Dose A|See Arm description
224311190|NCT06509477|DEVICE|Hyaluronic acid Lunaphil Ultra (by Espad Pharmed Co.)|Two treatments will be allowed over a 2-week period (initial treatment plus one touch-up) to achieve optimal correction of the NLFs based on investigator's opinion
224311191|NCT06509477|DEVICE|Hyaluronic acid Juvederm Ultra 4® (by Allergan Co.)|Two treatments will be allowed over a 2-week period (initial treatment plus one touch-up) to achieve optimal correction of the NLFs based on investigator's opinion
223599102|NCT03920254|DRUG|TD-1473 Dose B|See Arm description
223748479|NCT02788461|RADIATION|Chemoradiotherapy|Patients will receive radiotherapy of 60Gy in 30 fractions (5x per week) with concurrent cisplatin and etoposide chemotherapy.
224311192|NCT02639052|DRUG|Botox|10 units of Botox will be intradermally injected into one 4x4cm area on the volar forearm on 1st study visit.
223599103|NCT03920254|DRUG|TD-1473 Dose C|See Arm description
223599104|NCT03979859|DRUG|WCK 4873|
223599105|NCT03979859|DRUG|Placebo Oral Tablet|
223599106|NCT00823667|OTHER|educational intervention|Palliative care intervention at weeks 3,4,5 and 6 post study enrollment
223599107|NCT00823667|OTHER|medical chart review|Occurs at 1 year post study enrollment
223599108|NCT00823667|OTHER|questionnaire administration|Occurs at baseline, 6 weeks, 12 weeks, 24 weeks, 36 weeks and 52 weeks post study enrollment
223599109|NCT00823667|PROCEDURE|end-of-life treatment/management|Occurs at baseline, 6 weeks, 12 weeks, 24 weeks, 36 weeks and 52 weeks post study enrollment
223599110|NCT00823667|PROCEDURE|psychosocial assessment and care|Occurs at baseline, 6 weeks, 12 weeks, 24 weeks, 36 weeks and 52 weeks post study enrollment
223599111|NCT00823667|PROCEDURE|quality-of-life assessment|Occurs at baseline, 6 weeks, 12 weeks, 24 weeks, 36 weeks and 52 weeks post study enrollment
223599112|NCT03968835|OTHER|Bacitracin|For the first 30 people, bacitracin will be applied and covered with xeroform and gauze.
223599113|NCT03968835|OTHER|Skin Graft|For the next 30 patients, the amputated composite skin and soft tissue unit will be thinned out to become a full thickness skin graft.
223599114|NCT05492097|BEHAVIORAL|Exercise Therapy|Traditional exercise therapy and NMES
223599115|NCT05492097|BEHAVIORAL|Exercise Therapy and Robotic Walking Training|Traditional exercise therapy and Robotic Walking Training
223599116|NCT04090333|OTHER|Standard withdrawal therapy|All painkillers are abruptly stopped for a 2 months period.
223599117|NCT04896281|DIETARY_SUPPLEMENT|Phenylalanine-free milk|Once a plasma PHE level of ≥ 95 μM is noted, phenylalanine-free diet (Phenex-2®, Abbott Nutrition, Ohio, USA; or Phenyl-Free 2®, Mead Johnson Nutrition, Minnesota, USA) is started as the only nutrition source for enteral feeding, as per the recommendation of dieticians, in the following 4 days. The phenylalanine-free diet is free of PHE but is enriched with protein, potassium, tyrosine, and antioxidant micronutrients. After the completion of the study, diet will be back to normal diet for all patients.
223599118|NCT00402467|DRUG|Rivaroxaban (BAY59-7939)|2.5mg bid
223599119|NCT00402467|DRUG|Rivaroxaban, (BAY59-7939)|5mg bid
223748480|NCT02788461|RADIATION|Chemoradiotherapy with Integrated Boost Dose|Patients will receive an RT integrated boost to tumor subvolumes (max boost dose of 85Gy) in 30 fractions (5x per week) with concurrent cisplatin and etoposide chemotherapy.
223748481|NCT04131634|RADIATION|Stereotactic Ablative Radiation|A stereotactic relocalization system that relies upon stereoscopic radiographs, implanted fiducials, or near real-time CT based verification will be used.Investigators will have the discretion to choose from biologically equivalent dose levels using 1, 3 or 5 fractions. All active lesions need to be addressed by local therapy
223748482|NCT02127242|PROCEDURE|ureteroscopic air-pressure ballistic lithotripsy|In case of large, hard or impacted stones ureteroscopic air-pressure ballistic lithotripter is used for fragmentation. The probe of the lithotripter target towards the stone and then fragmented.
223748483|NCT05191706|DRUG|Dexamethasone|single anterior chamber injection
223748484|NCT05191706|DRUG|Prednisolone Acetate Ophthalmic|topical administration four times a day for 28 days, followed by treatment taper
224199076|NCT01976104|DRUG|placebo (higher baseline platelet count)|40 mg placebo (2 x 20 mg matching placebo tablets)
223599120|NCT00402467|DRUG|Rivaroxaban, (BAY59-7939)|10 mg bid
223599121|NCT00402467|DRUG|Rivaroxaban, (BAY59-7939)|20mg bid
223599122|NCT00402467|DRUG|Enoxaparine|30mg bid
223599123|NCT00402467|DRUG|Enoxaparine|30mg bid
223599124|NCT01427426|DIETARY_SUPPLEMENT|All Greens|All Greens is a mixture of organic alfalfa powder, barley, wheat grass juice powder, lycopene, cranberry juice extract, rosehips, grapeseed phytosomes, soya extract, Acidophilus, bromelain, apple pectin, and other ingredients. All Greens is approved by Health Canada and available to the public for purchase.
223599125|NCT01427426|OTHER|Control Formulation|The Control Formulation is a rice-flour based product that has been designed to mimic the All Greens in appearance and taste.
223599126|NCT03355066|DRUG|SM08502|SM08502 tablets to be administered orally.
223599127|NCT03250182|DRUG|PT010|PT010; Budesonide, Glycopyrrolate, and Formoterol Fumarate Inhalation Aerosol. Administered as 2 inhalations per use as instructed per the protocol.
223599128|NCT05274269|DRUG|ELX/TEZ/IVA|Fixed-dose combination (FDC) tablets for oral administration.
223599129|NCT05274269|DRUG|IVA|Tablet for oral administration.
223599130|NCT05274269|OTHER|Placebo (matched to ELX/TEZ/IVA)|Placebo matched to ELX/TEZ/IVA for oral administration.
223599131|NCT05274269|OTHER|Placebo (matched to IVA)|Placebo matched to IVA for oral administration.
223599132|NCT04375111|PROCEDURE|Serratus anterior plane block|•Serratus anterior plane block will be carried out with the patient lying in the lateral position. After skin disinfection, the ultrasound probe will be applied parallel to and between the 5th and 6th ribs in the mid axillary region, for identification of the superficial latissimus dorsi muscles and deep anterior serratus muscles. Then, 25 ml of isobaric bupivacaine 0.25% will be injected above the serratus anterior muscle.
223599133|NCT04375111|PROCEDURE|Transversus thoracic plane block|•Transversus thoracic plane block will be carried out with the patient lying in the supine position. After skin disinfection, the ultrasound probe will be applied parallel to and between the 4th and 5th ribs connecting at the sternum. Then, 15 ml of isobaric bupivacaine 0.25% will be injected between the transversus thoracic muscle and the internal intercosatal muscle.
223599134|NCT02718209|DEVICE|Mid-Infrared Spectroscopy with ATR|
223599135|NCT02255227|BIOLOGICAL|Prevenar 13|one dose for arm 1 and 2 doses for arm 2
223599136|NCT02255227|BIOLOGICAL|Pneumo 23|one dose
223599137|NCT04067258|DIAGNOSTIC_TEST|EDI-OCT|"EDI-OCT (enhanced depth imaging spectral domain optical coherence tomography) wiil be performed in all study participants.~Three sets of measurements in the macular (horizontal and vertical) and peripapillary area will be averaged."
223599138|NCT04612257|OTHER|Insulin-alone closed-loop|40-hour intervention period using the insulin-alone closed-loop system.
224199077|NCT01317199|DRUG|Muscadine Plus Grape Skin Extract|Phase I: Dose escalation starts at 500mg pills given by mouth once daily for 28 days per cycle
224199078|NCT01317199|DRUG|Low-dose MPX|Randomly-assigned participants receive one capsule of drug (500mg MPX) and seven capsules of placebo composed of pulverized rice, once daily for up to 12 cycles (28 days per cycle).
224199079|NCT01317199|DRUG|High-dose MPX|Randomly-assigned participants receive 8 capsules of drug (4000mg MPX) once daily for up to 12 cycles (28 days per cycle).
223599139|NCT05243082|DEVICE|Radio frequency ablation|Radio frequency ablation of pancreatic neuroendocrine tumors
223599140|NCT05211206|OTHER|IV fluids|Amount of intravenous fluids delivered
223599141|NCT02115763|DRUG|Caffeine|
223599142|NCT02115763|DRUG|Placebo|
223599143|NCT00398034|DRUG|Testosterone Gel|
223599144|NCT05917418|DIETARY_SUPPLEMENT|nutritional support|nutritional support
223599145|NCT01621711|BEHAVIORAL|Linkage patient activation intervention|"Usual Care plus Linkage encompassed Usual Care with the exception that the six 45-min Linkage patient activation education groups replaced the six 45-min Usual Care medical education groups, plus a linkage phone call (and/or a facilitated email) with the patient, clinician, and Primary Care physician.~The patient activation intervention components -- 1) six 45-min Linkage sessions on activation regarding overall health behaviors and 2) a linkage phone call (and/or a facilitated email) with the patient, clinician, and PC physician -- were delivered by a clinical psychologist."
223599146|NCT04240574|DEVICE|Debritom|hydrosurgery device that utilizes micro water jet technology that has been designed to debride acute and chronic wounds precisely and in a tissue-preserving manner.
223748485|NCT04592913|DRUG|Durvalumab|Human monoclonal antibody
223748486|NCT04592913|DRUG|FLOT chemotherapy|A combination treatment made up of flurouroacil + leucovorin + oxaliplatin + docetaxel
223748487|NCT03451149|DEVICE|Radiofrequency wire (Powerwire)|Using a radiofrequency wire in lieu of a needle for penetrating the liver during transjugular intrahepatic portosystemic shunt creation.
223748488|NCT04466540|DRUG|Hydroxychloroquine|Hydroxychloroquine pharmaceutical form will be tablets of 400 mg.
223748489|NCT04466540|DRUG|Placebo|Hydroxychloroquine placebo
223748490|NCT06208293|BEHAVIORAL|KPZ Program (KPZ)|The KPZ package includes a culturally adapted approach to a co-designed safety plan. The assigned Peers will provide safety planning and Brief Contact Follow-Up. Contact follow up sessions will occur at the household level.
223599147|NCT03067389|DIAGNOSTIC_TEST|Diagnostic test|Genetic diagnostic test
223599148|NCT02055378|DRUG|Atropine|topical 0.125% atropine eye drops
223599149|NCT02055378|DEVICE|auricular acupoint stimulation|Five auricular acupoints (Shenmen, Xin, Yan, Mu 1 and Mu 2) Tapping stimulation was administered by using a 1-mm alloy ball (Magrain®; Sakamura, Kyoto, Japan) three times a day, each time for five minutes.
223599150|NCT06552936|OTHER|Diode Laser 980 nm.|A Diode laser is commonly used in simple surgical procedures on soft tissue, such as skin or mucosa. Its tip can work when non-activated, causing inductive effects, and when activated, it causes the ablation of soft tissue.
223599151|NCT02106494|DRUG|APF530|
223599152|NCT02106494|DRUG|Ondansetron|
223599153|NCT02106494|DRUG|Ondansetron placebo|
223599154|NCT02106494|DRUG|APF530 placebo|
223599155|NCT02106494|DRUG|Fosaprepitant|
223599156|NCT02106494|DRUG|Dexamethasone|
223599157|NCT05159115|OTHER|Low-FODMAP diet|4 weeks of a diet low in fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAPs)
223748491|NCT06208293|BEHAVIORAL|Enhanced Usual Care (EUC)|Participants receive usual care enhanced by Lady Health Workers (LHWs) trained in WHO Mental Health Gap Action Programme (mhGAP) that will link at-risk women with the primary care facility based medical officer. The LHWs will follow the mhGAP protocol for imminent or low risk of suicide including ensuring the participant is safe, removing or reducing means, assigning a family member to ensure safety (if appropriate), providing psychoeducation, and referring and accompanying the individual to their primary care health center where a mhGAP trained doctor is staffed to resume care or make a referral to specialized care. Additionally, all women and healthcare workers are provided a 24 hour hotline number (hosted by a Pakistani based mental health organization called Taskeen) and are briefed on exactly what will happen if participant calls.
223748492|NCT05774860|OTHER|No intervention|No intervention
223748493|NCT02046408|OTHER|Computer Tablet|
223748494|NCT04394663|DRUG|High-dose oral omeprazole|Local made oral omeprazole 40 mg twice daily will be prescribed for 72 hours after randomization.
223748495|NCT04394663|DRUG|Standard IV PPI|Pantoprazole 8mg/hour IV continuous drip will be prescribed for 72 hours after randomization
223748496|NCT00232258|DRUG|Nolpitantium besylate|
223748497|NCT03170128|PROCEDURE|Outpatient physical therapy in addition to standard follow-up visits|Patients in Group 1 will be given a prescription for outpatient physical therapy.
223748498|NCT03170128|BEHAVIORAL|Home exercises in addition to standard follow-up visits|Patients in Group 2 will be carefully instructed on home exercises for range of motion and strengthening of their affected elbow. All therapy regimens will be prescribed at initial presentation, as is the current practice. All other care will be identical for patients in both groups. This
223748499|NCT06381531|DIAGNOSTIC_TEST|Imaging with CT and MRI|Quantitative and anthropometric analysis of brain and skull strutcure of imaging (CT/ MRI) undertaken as part of diagnosis or treatment for patients with brain tumor
224199080|NCT01317199|DRUG|Placebo oral capsule|Randomly-assigned participants receive 8 capsules once daily of placebo composed of pulverized rice for up to 12 cycles (28 days per cycle).
224199081|NCT01353209|DRUG|Letrozole|2.5 mg daily for twelve months
224199082|NCT01353209|DRUG|Placebo|placebo given daily for twelve months
224199083|NCT04775693|DEVICE|RE (Robotic Exoskeleton)|Participants will continue to receive their prescribed standard of care physical therapy/gait training. They will also utilize the robotic exoskeleton twice a week during their inpatient stay and 3 times a week for 5 weeks as an outpatient (for outpatient, only if in the RE group). The Robotic Exoskeleton is a device that will be strapped to the chest and legs and worn over the shoulders like a backpack that will assist in walking. It uses sensors and participant motion to move. A licensed physical therapist will be assisting participants as they use the device.
224199084|NCT04775693|OTHER|SOC (standard of care)|Traditional physical therapist driven gait training.
223599158|NCT05159115|OTHER|Starch- and Sucrose Reduced Diet (SSRD)|4 weeks of a diet low in starch and sucrose
223599159|NCT04289961|DIAGNOSTIC_TEST|Portal vein sampling|During Endoscopic UltraSound guided-Fine Needle Aspitation (EUS-FNA) a curvilinear echoendoscope is advanced to the distal stomach or duodenal bulb to provide a window of access to a branch of the PV. After verifying venous flow by Doppler signal, a 19-gauge EUS-FNA needle is advanced transhepatically into the portal vein branch. With the needle in the portal vein, the stylet is removed and negative-pressure suction is applied to aspirate blood. A transhepatic approach for portal vein branch access is an absolute requirement of this technique in order to minimize the risk of bleeding. The puncture site is monitored under EUS for complications.
223599160|NCT06507696|OTHER|Ice Application|Drinking water was placed in a syringe and filled in the refrigerator
223599161|NCT06507696|OTHER|Wetted Gauze Application|Sterile gauze soaked with drinking water
224199085|NCT01445015|BEHAVIORAL|Stress management program|10 session intervention utilizing a cognitive behavorial program with a goal of stress reduction
224199086|NCT01445015|OTHER|Peer viewed movies|PG rated movies to be viewed over 10 sessions in peer setting
224199087|NCT06542445|DRUG|Oral CBD oil enriched with terpenes|"Stage I dosing, increasing titration:~days 1-2: 2.5 mg/kg BW/day; days 3-4: 5 mg/kg BW/day; day 5-7: 7.5 mg/kg BW/day; days 8-35: 10 mg/kg BW/day.~Stage II dosing, increasing titration:~days 36-37: 2.5 mg/kg BW/day; days 38-39: 5 mg/kg BW/day; day 40-42: 7.5 mg/kg BW/day; days 43-70:10 mg/kg BW/day."
224199088|NCT06542445|DRUG|Oral Placebo|Oral placebo oil that is similar in appearance and taste to the CBD oil. Titration and dosing identical to those described for the CBD oil.
224199089|NCT06043219|OTHER|Action Observation|"Action observation is defined as watching human movement either via a pre-recorded video or a live demonstration (Eaves et al, 2022). In the current study action observation will be via a pre-recorded video.~Eaves, D.L., Hodges, N.J., Buckingham, G., Buccino, G. and Vogt, S., 2022. Enhancing motor imagery practice using synchronous action observation. Psychological Research, pp.1-17."
223599162|NCT01255995|DEVICE|Capsular Tension Ring|Capsular Tension Ring
223599163|NCT06960668|BEHAVIORAL|Nature for Body Image|The intervention will include a range of activities in nature (e.g., in a public park), such as meditation, body scans, and grounding exercises.
223599164|NCT06960668|BEHAVIORAL|Simple nature exposure|The intervention will simply involve spending time in nature (e.g., in a public park), without specific guidelines.
223599165|NCT06960668|BEHAVIORAL|Structured Built Environment Exposure|The intervention will mirror the activities of the structured nature exposure intervention (e.g., meditation, body scans, and grounding exercises), but without any exposure to nature.
223599166|NCT01858740|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo CD45RA+ T cell-depleted allogeneic peripheral blood stem cell transplant
223599167|NCT01858740|DRUG|Fludarabine Phosphate|Given IV
223599168|NCT01858740|OTHER|Laboratory Biomarker Analysis|Correlative studies
223599169|NCT01858740|DRUG|Methotrexate|Given IV
223599170|NCT01858740|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo CD45RA+ T cell-depleted allogeneic peripheral blood stem cell transplant
223599171|NCT01858740|BIOLOGICAL|T Cell-Depleted Hematopoietic Stem Cell Transplantation|Undergo CD45RA+ T cell-depleted allogeneic peripheral blood stem cell transplant
223599172|NCT01858740|DRUG|Tacrolimus|Given IV or PO
223599173|NCT01858740|DRUG|Thiotepa|Given IV
223599174|NCT01858740|RADIATION|Total-Body Irradiation|Undergo TBI
223599175|NCT03719911|BEHAVIORAL|Live diabetes coaching program|Live diabetes coaching program
223748500|NCT06639412|BEHAVIORAL|Networking the indigenous parent-teacher association and agriculture development agents with the PHC unit to enhance NCD prevention & control services.|The intervention will be networking the indigenous parent-teacher association and agriculture development agents with the PHC unit to enhance NCD prevention \& control services. In this major activity, the project team will establish the network by incorporating agricultural development agents and parents- teacher associations to the health post as foundational actors for educating the community on NCD prevention and control measures. We will implement tier system training to effectively create awareness on NCD and to enhance the NCD care-seeking behavior of the community.
223748501|NCT06639412|OTHER|Usual care|The community in the control group will get noncommunicable disease prevention and control measures given through the health care system.
223748502|NCT00367081|DRUG|TMX-SMX (Bactrim(R))|
224199090|NCT06043219|OTHER|Motor Imagery|"Motor imagery practice is defined as the structured engagement in motor imagery over time for the purpose of acquiring and enhancing motor skills (Eaves et al, 2022).~Eaves, D.L., Hodges, N.J., Buckingham, G., Buccino, G. and Vogt, S., 2022. Enhancing motor imagery practice using synchronous action observation. Psychological Research, pp.1-17."
224199091|NCT06043219|OTHER|Traditional Teaching|Traditional anatomical teaching via a powerpoint slide deck
223599176|NCT01080846|DRUG|Misoprostol|600 mcg of sublingual misoprostol
223599177|NCT02994875|DIETARY_SUPPLEMENT|N-acetylcysteine|NAC is an FDA-approved dietary supplement with antioxidant properties that is available over-the-counter. NAC has no contraindications.
223599178|NCT02994875|OTHER|Placebo|Sugar pill
223599179|NCT00410007|BEHAVIORAL|High Sodium Diet|250-350 mmol
223599180|NCT00410007|BEHAVIORAL|Low Sodium Diet|25-35 mmol
223599181|NCT00410007|BEHAVIORAL|Hypertonic saline infusion|7 ml/ kg of 3% saline were given over 30 minutes.
223599182|NCT00413790|DRUG|Darifenacin|Darifenacin tablets 15 mg once daily
223599183|NCT00413790|DRUG|Tolterodine|Tolterodine extended release (ER) 4 mg once daily
223599184|NCT00413790|DRUG|Placebo|Placebo tablet once daily
223599185|NCT06959758|DIETARY_SUPPLEMENT|Probiotic Arm|It is administered daily to children with functional constipation, alongside standard laxative treatment (PEG 3350) for the first 12 weeks, and then continued alone for the remainder of the 52-week study period. The study evaluates whether BioKid LR® helps maintain normal bowel movements after stopping PEG.
223599186|NCT06959758|DRUG|Placebo|A placebo maltodextrin powder is administered daily to children with functional constipation, alongside standard laxative treatment (PEG 3350) for the first 12 weeks, and then continued alone for the remainder of the 52-week study period.
223748503|NCT00367081|DRUG|Pyrimethamine plus Sulfadiazine plus leucoverin|
223748504|NCT01839552|DRUG|Fentanyl Citrate Nasal Spray (FCNS)|
223748505|NCT02175420|BIOLOGICAL|BCG|
223748506|NCT02175420|BIOLOGICAL|TFV|
223748507|NCT05617365|COMBINATION_PRODUCT|Osteopathic Manipulative Therapy and Exercise Therapy|"At the physician's discretion, each subject will receive a minimum of 4 treatments up to a maximum of 8 treatments over the 12-week duration of the study (Haas et. al., 2018). The patients may be treated in the seated, prone and/or supine positions. Duration of treatment will depend on the degree of documented dysfunction but will be limited to one half hour. The techniques utilized by the physician may vary for many reasons including the degree of restriction, acuity, or patient cooperation.~The THE protocol will involve subjects performing cyclic voluntary retraction and protrusion of their head."
223748508|NCT01062282|DRUG|Iloprost (Ventavis BAYQ6256)|Patients with pulmonary arterial hypertension, classified as New York Heart Association functional class III or IV where the treating physician has chosen Ventavis as a suitable treatment prior to inclusion into this non-interventional study. Patients should not have received prior treatment with Ventavis
223748509|NCT02989350|DIETARY_SUPPLEMENT|Lactobacillus reuteri DSM 17938|Lactobacillus reuteri DSM 17938 vs Placebo
223748510|NCT02989350|DIETARY_SUPPLEMENT|Placebo|Lactobacillus reuteri DSM 17938 vs Placebo
224199092|NCT00313482|DRUG|Sargramostim|250 mcg/m2 SC days 2-15 of each cycle
224199093|NCT00313482|DRUG|Docetaxel|75 mg/m2 IV over 1 hour on Day 1 of each cycle
224199094|NCT00313482|DRUG|Prednisone|5 mg orally BID on Day 1 continuously
223599187|NCT01068769|DRUG|regorafenib|Taken orally, once a day in the morning for 3 weeks followed by a one week rest period
223599188|NCT01625546|DEVICE|Whole Body Hyperthermia system|The Whole Body Hyperthermia system uses water-filtered infrared-A (wIRA) heat radiation. The rise in the body's core temperature is correspondingly rapid and well-tolerated. There are two phases of the thermal challenge, 1) Irradiation phase during which the patient lies recumbent with his/her head positioned outside the tent. The wIRA irradiators are arranged above the exposed upper part of the body; and 2) Heat retention phase during which the patient lies in the chamber with the walls of the tent positioned to retain heat.
223599189|NCT06960720|OTHER|Resistance Exercises|Twice-weekly resistance exercises completed in 45 minutes using resistance bands and a physical therapy workout plan.
223599190|NCT01877213|BEHAVIORAL|Coaching with coordinate care|The coordinator nurse will manage ambulatory care with the patient's GP and participate to patient's education.
223599191|NCT01020552|OTHER|Provision of PAC job aids and provider training on the use of the job aids|Facility-level intervention applied to all study facilities
223599192|NCT03371784|DRUG|Hydrocortisone|I.V. administration
224199095|NCT04027907|OTHER|Flowcytometry|detect platelet activity in T2DM by surface expression of platelet receptors determined by flowcytometry using different monoclonal antibodies (CD62 and CD63).
224199096|NCT01278381|PROCEDURE|Pancreaticoduodenectomy|Resection of pancreatic lesion
224199097|NCT04124302|DRUG|Insulin Glulisine|A kind of bolus insulin will be insulin glulisine if participant used insulin glulisine before entering the trial.
224199098|NCT04124302|DRUG|Insulin Aspart|A kind of bolus insulin will be insulin aspart if participant used insulin aspart before entering the trial.
224199099|NCT04124302|DRUG|Insulin Lispro|A kind of bolus insulin will be insulin lispro if participant used insulin lispro before entering the trial.
224199100|NCT02293876|DEVICE|LACRIBELL®|Hypromellose and dextran based eyedrop, used in the treatment of dry eye.
224199101|NCT02293876|DEVICE|LIPOSIC®|Carbomer and Sorbitol based gel, used in the treatment of dry eye.
224199102|NCT02293876|DEVICE|Glad wrap|A clear plastic wrap occluding eye and orbital area, turning the space into a moisture chamber.
224199103|NCT02079974|DRUG|Pravastatin|20 mg pravastatin sodium daily for 3 months
224199104|NCT03112720|DEVICE|Epidural Blood Patch|A device: 17 gauge Tuohy needle will be placed to the epidural space using the loss of resistance technique. Once positioned a sterile stylet will be replaced within the needle to maintain the sterility of the epidural space. A tourniquet may be used to identify a peripheral venous site, which will be sterilely prepped with betadine x3 and then chloraprep. Venipuncture will be performed with a device: 20gauge or larger needle. 20mL of blood will be aspirated in a sterile system into an appropriately sized syringe. After sterile transfer, this autologous blood will be slowly injected into the epidural space.
224199105|NCT03112720|DRUG|Sphenopalatine Ganglion Block|The drug: 5% lidocaine ointment, a local anesthetic, will be applied to the end of a device: long channeled cotton tipped applicator inserted into both nares and placed over the mucosa in the area of posterior aspect of the middle ethmoid, toward the presumed anatomic location of the sphenopalatine ganglion, evidenced by a slight resistance at the appropriate depth. 5mL of drug: 1% lidocaine solution will then be injected into the hollow shaft of the device: applicator and allowed to topically anesthetize the ganglion by gravity flow for 30 minutes.
223507028|NCT03774654|GENETIC|CD19.CAR-aNKT cells|"Patients will be given the T-cell product by intravenous injection (into the vein through an IV line) at the assigned dose..~Dose Level 1: 1 x 10\^7/m2. Dose Level 2: 3 x 10\^7/m2. Dose Level 3: 1 x 10\^8/m2. Dose Level 4: 3 x 10\^8/m2."
223507029|NCT01140373|BIOLOGICAL|engineered autologous T cells|Three cohorts of patients each will receive escalating doses of transduced autologous chimeric T lymphocytes at 1 x 10\^7 CAR+ T cells/kg, 3 x 10\^7 CAR+ T cells/kg, and 1 x 108 CAR+ T cells/kg, respectively. One patient will be initially added to the three already enrolled in cohort 1 using a new variant vector expressing the P28z CAR, and up to three patients may be added to each cohort, for a total of up to six each, in the case of Grade 3 toxicity and/or sub-optimal imaging. A 4th cohort of three patients may be added if an anti-PSMA effect is observed either immunologically or radiographically or if there is preferential targeting of the cells at a particular dose level. The dose level of the 4th cohort would be from a previously tested dose level. All patients will receive one dose of cyclophosphamide (Cy) at 300mg/m2 iv one day prior to infusion of T cells.
223507030|NCT01140373|DRUG|cyclophosphamide|Three cohorts of patients each will receive escalating doses of transduced autologous chimeric T lymphocytes at 1 x 10\^7 CAR+ T cells/kg, 3 x 10\^7 CAR+ T cells/kg, and 1 x 10\^8 CAR+ T cells/kg, respectively. One patient will be initially added to the three already enrolled in cohort 1 using a new variant vector expressing the P28z CAR, and up to three patients may be added to each cohort, for a total of up to six each, in the case of Grade 3 toxicity and/or sub-optimal imaging. A 4th cohort of three patients may be added if an anti-PSMA effect is observed either immunologically or radiographically or if there is preferential targeting of the cells at a particular dose level. The dose level of the 4th cohort would be from a previously tested dose level. All patients will receive one dose of cyclophosphamide (Cy) at 300mg/m2 iv one day prior to infusion of T cells.
223507031|NCT05310643|DRUG|Nivolumab|"Induction therapy with nivolumab 240 mg; 4 infusions, every 3 weeks.~Maintenance therapy with nivolumab 480 mg; 21 infusions, every 4 weeks."
223507032|NCT05310643|DRUG|Ipilimumab|Induction therapy with ipilimumab 1 mg/kg; 4 infusions, every 3 weeks.
223507033|NCT05011383|DRUG|High dose testosterone|High dose testosterone is administered subcutaneously once monthly until progression or toxicity
223599193|NCT03371784|DRUG|Placebo|I.V. administration
223599194|NCT05240625|DEVICE|"aetherAI Computer-aided Polyp Detection (CADe) Systems for Colonoscopy"|"The investigational medical device is intended to automatically detect potential polyps via colonoscopy in real-time during colonoscopy examinations.~The subject device contains an artificial intelligence/machine learning (AI/ML) advanced algorithm to aid the endoscopists in detection of colonic mucosal lesions and the detected polyps will be highlighted to the endoscopists during the real-time colonoscopy procedures."
223599195|NCT05240625|PROCEDURE|Standard colonoscopy|Standard colonoscopy procedure.
223599196|NCT02764658|DEVICE|Pulmonary recovery on the AECOPD|The combination effect of negative pressure ventilation, limb muscle exercise training program and fibit monitor on acute exacerbation of AECOPD. To investigate the daily physical activity in routine care patients with after AECOPD and stable stage.
223599197|NCT02764658|OTHER|Routine care on the AECOPD|To investigate whether daily physical activity、hypoxia and hyperinflation were associated with airway inflammation and PRG4 in Routine care patients wtih AECOPD and stable stage.
223599198|NCT02764658|OTHER|Routine care on the stable COPD|To investigate whether daily physical activity、hypoxia and hyperinflation were associated with airway inflammation and PRG4 in Non-Pulmanary recovery patients wtih stable COPD.
223599199|NCT00709618|DRUG|Lapatinib, Vinorelbine|Vinorelbine intravenously once weekly for 3 weeks, followed by a rest week in a 4-week cycle) plus lapatinib daily
223599200|NCT04370353|DIETARY_SUPPLEMENT|Cocoa flavanols|Flavonoid-rich cocoa powder, containing 100mg total flavanols per 316mg.
223599201|NCT04370353|DIETARY_SUPPLEMENT|Placebo supplement|Microcrystalline filler, containing 0mg total flavanols.
223599202|NCT02116452|DIETARY_SUPPLEMENT|Supplemented Formula|50:50 mixture of GOS/PDX formula will be administered
223599203|NCT01578655|DRUG|cabazitaxel|Cabazitaxel (25mg/m² IV) is administered on day 1 of each 21-day cycle until disease progression, unacceptable toxicity, or completion of 10 cycles
223599204|NCT01578655|DRUG|prednisone|Prednisone (10 mg PO) is administered daily until disease progression, unacceptable toxicity, or completion of 10 cycles
223599205|NCT01578655|DRUG|custirsen sodium|Custirsen is administered as 3 loading doses (640 mg IV each) within 9 days, followed by weekly custirsen (640 mg IV) during each 21-day cycle until disease progression, unacceptable toxicity, or completion of 10 cycles
224199106|NCT05784168|OTHER|Manual therapy|"6 weeks, 12 sessions in total, 2 times a week of manual therapy: spinal manipulation, specific mobilisations and stretches. Manual therapy treatments are carried out by a physiotherapist with more than 10 years of experience.~In addition, 6 weeks, 5 times a week, a programme of therapeutic exercises at home: muscle strengthening and stretching, balance and coordination training, spinal stabilisation exercises."
223599206|NCT05314907|DEVICE|Explanation on how to use self-sampling device and training in the screening visit.|"During the screening visit, woman is offered to participate in the study. If she accepts, informed consent is signed, a sociodemographic questionnaire is collected, and a cervical sample is collected for HPV detection by the health professional in the consultation.~Then, the professional informs the woman of how to carry out the self-collection using Evalyn Brush and after the woman collects an HPV sample by self-sampling in the same medical center as a trainning.~Finally, a new cervibrush (Evalyn brush) is given to the woman for home self-sampling, together with written and picture-based instructions on how to obtain the sample and an acceptability questionnaire. After one month from the screening visit, woman is requested to return the self-collected sample together with the questionnaire in person to the recruitment centre."
223599207|NCT05314907|OTHER|Only explanation on how to use self-sampling device.|"During the screening visit, woman is offered to participate in the study. If she accepts, informed consent is signed, a sociodemographic questionnaire is collected, and a cervical sample is taken for HPV detection by the health professional in the consultation.~Then, the professional informs the woman of how to carry out the self-collection using Evalyn.~Finally, a Evalyn brush is given to the woman for home self-sampling, together with written and picture-based instructions on how to obtain the sample and an acceptability questionnaire. After one month from the screening visit, woman is requested to return the self-collected sample together with the questionnaire in person to the recruitment centre."
223599208|NCT01362829|OTHER|Determined by intended physician|We perform a prospective observational study. All the treatment for the patients are determined by intended physicians.
223599209|NCT00709072|BEHAVIORAL|SMS (Short Message Service) reminders|SMS reminders sent every 2 weeks
223599210|NCT05842252|PROCEDURE|greater trochanter transfer, subtrochanteric valgus osteotomy|greater trochanter transfer, subtrochanteric valgus osteotomy fixation by wagner TB and locked plate
223599211|NCT04570631|DRUG|Eftozanermin alfa|Intravenous (IV) infusion
223599212|NCT04570631|DRUG|Bortezomib|Intravenous (IV) or Subcutaneous (SC) injection
223599213|NCT04570631|DRUG|Dexamethasone|Oral Tablet
224199107|NCT05784168|OTHER|Exercise therapy|"6 weeks, 12 sessions in total, 2 times a week therapeutic exercise programme under the supervision of a physiotherapist. The exercise programme consisted of muscle strengthening and stretching, balance and coordination training, spinal stabilisation exercises.~In addition, 6 weeks, 5 times a week, a programme of therapeutic exercises at home: muscle strengthening and stretching, balance and coordination training, spinal stabilisation exercises."
224199108|NCT05206669|BEHAVIORAL|Health Messages|Brief messages providing information about the effectiveness of HPV vaccines. Messages included embedded links where participants could find more information.
224311193|NCT02639052|DRUG|Saline|10 units of the Saline vehicle will be intradermally injected into one 4x4cm area on the contralateral volar forearm on the 1st study visit.
223599214|NCT04042909|BEHAVIORAL|Counter Attitudinal Advocacy|same as Counter Attitudinal Advocacy arm
223599215|NCT04042909|BEHAVIORAL|Personalized Normative Feedback|same as Personalized Normative Feedback arm
223599216|NCT04441580|DEVICE|CADe colonoscopy using GI Genius device|We wanted to compare the diagnostic yield obtained by using CADe colonoscopy to the yield obtained by the standard colonoscopy (SC) in a FIT-positive screening population.
223599217|NCT04600934|DEVICE|Shockwave|Shockwave Medical, Inc. Peripheral Lithoplasty® System
223599218|NCT04600934|DEVICE|Plain old balloon angioplasty|POBA
223599219|NCT03019718|OTHER|GSA-Online plus|A 12-week online writing intervention based on the Core Conflictual Relationship Theme Method (CCRT) with feedback provided by online therapists.
223599220|NCT06464536|OTHER|Compression|conventional surgical gloves that are commonly used in hospitals will be used for compression therapy of both hands
224311194|NCT04926948|OTHER|Immunotherapy|Immunotherapy
224311195|NCT04926948|OTHER|Quality-of-Life Assessment|Ancillary studies
223599221|NCT03575611|PROCEDURE|Biopsy|Undergo tumor biopsy
223599222|NCT03575611|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223599223|NCT03575611|PROCEDURE|Computed Tomography|Undergo CT and/or PET/CT
223599224|NCT03575611|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223599225|NCT03575611|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
223599226|NCT03575611|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
223599227|NCT05345717|DRUG|Belatacept Injection|Patient will initiate belatacept therapy and will received 2 cycles of proteasome inhibitor therapy
223599228|NCT06002945|OTHER|Blood sample|Each blood draw will involve removing approximately 75 mL (5 tablespoons) of blood
223599229|NCT01009008|DEVICE|Patient Activated Controlled Expansion Device|Patient activated controlled expansion for post-mastectomy breast reconstruction
223599230|NCT03492541|OTHER|Propylene glycol-based eye drops|Nano-emulsion ocular lubricant
223599231|NCT00500994|DEVICE|MRI|The imaging study will use a block design to (i) optimize amygdala activation to emotionally valenced images, (ii) to optimize analysis of PPI and (iii) to optimize the go/no-task design. G. T2-sensitive functional images will be obtained on a MRI system with a 1.5 Tesla superconducting magnet and a standard head coil. An echo planar image sequence (TR=2500msec, TE=33 msec, 90 flip angle) with 30 contiguous 2mm thick coronal oblique slices with 1 mm interslice gap centered over the amygdala, tilted 30 to the anterior, to improve susceptibility artifact. Three-dimensional anatomical images will be taken for the co-registration of the functional images.
223748511|NCT03959085|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223748512|NCT03959085|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
223748513|NCT03959085|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
223748514|NCT03959085|PROCEDURE|Bone Scan|Undergo bone scan
223748515|NCT03959085|DRUG|Calaspargase Pegol|Given IV
224199109|NCT06303024|OTHER|personalized combined physical and cognitive intervention|The exercise intervention will be aerobic and performed on a stationary bicycle and will comply with the basic principle of progressive overload. An incremental exercise test until exhaustion on a bicycle ergometer will be applied to determine directly measured VO2-max in order to customize and personalize the training on each patient. The progressive aerobic exercise (PAE) will last 12 weeks with two sessions per week. Continuous training will be alternated with interval training during the program. The intervention included two weekly training sessions. One session will involve continuous exercise initially commencing at 10 min and progressing towards 30 min/session. Ultimately, a computer based cognitive rehabilitation program will be carried out twice a week for 12 weeks, using the Rehacom software. Participants will begin at level 1 on each RehaCom module and advance through the program as dictated by their performance. Each session will be programmed to last 60 minutes.
224199110|NCT00283621|DRUG|Aranesp (darbepoetin alfa)|
224199111|NCT00283621|DRUG|Neulasta (pegfilgrastim)|
224199112|NCT00283621|DRUG|Adriamycin|
224199113|NCT00283621|DRUG|Ifosfamide|
224311196|NCT04926948|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
223507034|NCT04579198|BEHAVIORAL|Caregivers' Aid to Accelerate Recovery after pediatric Emergencies (CAARE)|The intervention, CAARE (Caregivers' Aid to Accelerate Recovery after pediatric Emergencies), consists of four components: First, all caregivers of PTI patients (ages 0-11) will be given brief education in the hospital related to children's and caregivers' emotional recovery. Second, all families will receive an in-hospital risk-reduction session. These sessions will address avoidance and trauma triggers; scheduling of pleasurable activities; and coping strategies. Third, all caregivers will receive the CAARE app-based components before discharge. The app will engage caregivers for 30 days via an automated SMS system. MHealth components of care will reinforce risk-reduction strategies. Fourth, 30 days post-discharge, a brief behavioral health screen will be completed by caregiver and child to assess need for more intensive screening by a mental health provider. Caregivers/children reporting elevated symptom levels will receive a comprehensive screening and referral process.
223507035|NCT04445571|PROCEDURE|Thin catheter technique or standard ET-tube for surfactant administration|Surfactant administration by intubation with regular ET-tube followed by immediate extubation to CPAP (INSURE) or by thin catheter during spontaneous breathing and continued CPAP.
223599232|NCT05471089|DEVICE|Diathermy by emission of Radiofrequency|Applied only to experimental group
223599233|NCT05471089|OTHER|Therapeutic exercise|Applied to both arms/groups
223599234|NCT00734968|DRUG|Nitrofurantoin|Nitrofurantoin 100mg PO BID for 3 days post operatively following the placement of a sub-urethral sling for the treatment of stress urinary incontinence
223599235|NCT00734968|OTHER|Placebo|6 tablets to be taken 1 tablet PO BID. These tablets are identical to nitrofurantoin 100mg tablets.
223599236|NCT00005084|PROCEDURE|conventional surgery|
223599237|NCT00005084|PROCEDURE|magnetic resonance spectroscopic imaging|
223599238|NCT00005084|RADIATION|radiation therapy|
223599239|NCT00894361|PROCEDURE|TKA surgery with the rotating platform mobile-bearing knee design|Depuy Sigma RP rotating platform design
223599240|NCT00894361|PROCEDURE|TKA surgery with the all-polyethylene tibia knee design|Depuy Sigma fixed-bearing design with all-polyethylene tibia
223599241|NCT05612256|DIAGNOSTIC_TEST|Electrical impedance tomography (EIT)|EIT is the measurement of impedance changes of the lung against the flow of alternating electrical currents applied to the thorax. The signal of the electrodes is transmitted to a monitor, which enables real-time assessment of lung aeration and changes in lung volume. EIT is able to reconstruct impedance changes with a high temporal resolution and allows calculation of tidal volumes, relative stretch of lung tissue and areas of poor ventilation. Areas with impedance changes of \< 10 % of the maximum impedance changes are called 'Silent Spaces'.
223599242|NCT05612256|DIAGNOSTIC_TEST|Forced oscillation technique (FOT)|FOT enables non-invasive assessment of lung mechanics using sound waves to inform about the respiratory impedance of the respiratory system (Zrs). Reactance of the respiratory system (Xrs) as part of Zrs is a surrogate measure of compliance of the respiratory system. Xrs was previously used to identify optimal PEEP level, i.e., the PEEP at highest compliance equivalent, in newborn infants using a setup requiring research-specific hardware and software. The FOT module integrated in the commercially available neonatal ventilator is routinely used. FOT measurements are performed twice at each PEEP level to assess the reproducibility of the measurements.
223599243|NCT05612256|DIAGNOSTIC_TEST|Saturation oxygenation pressure index (SOPI)|SOPI is assessed non-invasively and calculated from standard monitoring parameters such as PEEP, fraction of inspired oxygen pressure (FiO2) and peripheral oxyhaemoglobin saturation (SpO2) (PEEP x FiO2 x 100) / SpO2). SOPI is used to provide information on ventilation to perfusion ratio dependent on PEEP level.
223599244|NCT04386954|PROCEDURE|observational study|observation study
223599245|NCT06583746|OTHER|Group1|30 children with DCP were included. The lower extremity evaluations of these cases were made according to ICF. Modified Ashworth Scale (MAS) was used for body structure and functions, Gillette Functional Assessment Questionnaire (FAQ) was used for activity and Pediatric Functional Independence Measure (WeeFIM) was used for participation.
223599246|NCT06549426|DRUG|anti-seizure medication + sedative agent(s)|"Stepwise approach:~1. a single dose of a parenteral benzodiazepine (lorazepam, midazolam, or diazepam) and a first parenteral anti-seizure medication (levetiracetam, valproate, or lacosamide)~2. a second parenteral anti-seizure medication plus a first continuous parenteral sedative agent (midazolam or propofol)~3. a second continuous parenteral sedative agent (midazolam, propofol, or ketamine)"
223599247|NCT03642496|BIOLOGICAL|Low dose ET019002- T Cells|ET019002- T Cells are autologous T cells transduced expressing a novel anti-CD19 (ET019002) chimeric antigen receptor,and are administered by intravenous infusion with the dose of 0.75×10\*6/kg.
223599248|NCT03642496|BIOLOGICAL|Middle dose ET019002- T Cells|ET019002- T Cells are autologous T cells transduced expressing a novel anti-CD19 (ET019002) chimeric antigen receptor,and are administered by intravenous infusion with the dose of 1.5×10\*6/kg.
223748516|NCT03959085|PROCEDURE|Computed Tomography|Undergo CT
223748517|NCT03959085|DRUG|Cyclophosphamide|Given IV
223748518|NCT03959085|DRUG|Cytarabine|Given IV, IT, or SC
223748519|NCT03959085|DRUG|Daunorubicin Hydrochloride|Given IV
223748520|NCT03959085|DRUG|Dexamethasone|Given PO or IV
223748521|NCT03959085|DRUG|Doxorubicin Hydrochloride|Given IV
223507036|NCT01266083|BIOLOGICAL|Galinpepimut-S|Galinpepimut-S admixed with the adjuvant Montanide following specified schedule
223507037|NCT01266083|BIOLOGICAL|GM-CSF|subcutaneous injection
223507038|NCT01266083|OTHER|Montanide|adjuvant
223507039|NCT06544148|DEVICE|Electrical impedance tomography|In addition to routine critical care with a pulmonary artery catheter already in place (PAC), an electrical impedance tomography (EIT) belt will be placed in patients enrolled in this study. Data will be analyzed offline and clinical trajectory and/or decisions will not be impacted by this additional monitoring. EIT is a non-invasive, safe, and radiation-free medical imaging modality.
223507040|NCT06779604|PROCEDURE|Infraclavicular Block with Dexmedetomidine and Dexamethasone|"Infraclavicular block with Dexmedetomidine and Dexamethasone was performed at least 30 min before the start of the operation. The patient was positioned in a supine position arms at the sides or in 90 degree abduction, head turned to the other side. Infraclavicular block was performed with the lateral sagittal technique, while the USG probe was placed under the clavicle and medial to the coracoid process, providing a brachial plexus image in the form of a hyperechoic outer ring and hypoechoic circles, like a classic honeycomb image. A local anesthetic mixture was injected with a 100 mm block needle with negative aspiration and its spread in tissue planes was observed.~If the VAS score was 3 or above, tramadol 1 mg kg-1 was administered as an analgesic drug."
223507041|NCT06539351|OTHER|Skin biopsy|4mm skin punch biopsy
223507042|NCT06964308|PROCEDURE|thoracoscopic pleural biopsy.|This intervention aims to evaluate the diagnostic efficacy, safety, and clinical outcomes of thoracoscopic pleural biopsy in the management of pleural diseases.
223507043|NCT06963385|DIAGNOSTIC_TEST|Radiomics|To correlate radiomic features obtained from ultrasound images with the molecular/genomic profiling to identify new hallmarks for stratification of endometrial cancer patients into different classes of risk
223507044|NCT06963866|BIOLOGICAL|autologous stem cell transplantation|Patients in this arm will receive autologous hematopoietic stem cell transplantation (ASCT). Prior to ASCT, the patients underwent 3-4 cycles of induction chemotherapy.
223507045|NCT06963866|BIOLOGICAL|CAR-T|The T cells are genetically modified to express a chimeric antigen receptor targeting BCMA and are infused 3 days after ASCT at a target dose of ≥2.0×10\^6 cells/kg.
223507046|NCT06963541|OTHER|No intervention; Observational study|No interventions are associated with either group. This is an observational study without experimental procedures.
223507047|NCT05397873|DEVICE|Biofeedback training|The training of oculomotor functions is done on the biofeedback module of a microperimeter MAIA.
223507048|NCT00545948|DRUG|Vinorelbine followed by Cisplatin|Vinorelbine 25 mg/m2 IV over 6-10 minutes on days 1 and 8, followed by Cisplatin 75 mg/m2 IV over 60 minutes on day 1 (every 21 days x 4 cycles).
223507049|NCT00545948|DRUG|Pemetrexed followed by Cisplatin|Pemetrexed 500 mg/m2 IV infusion over approximately 10 minutes on day 1, followed by Cisplatin 75 mg/m2 IV over 60 min on day 1 (every 21 days x 4 cycles)
223507050|NCT01810107|PROCEDURE|Children Examined with the OCT Probe|The child undergoing therapy will have the Optical Coherence Tomography (OCT) probe to examine the vocal fold.
223507051|NCT03467945|DRUG|Metformin/Gliclazide Fixed Combination|Participants received single oral dose of Metformin and Gliclazide fixed combination tablet in treatment period 1, 2, 3 or 4.
223507052|NCT03467945|DRUG|Metformin|Participants received single oral dose of Metformin tablet in treatment period 1, 2, 3 or 4.
223507053|NCT03467945|DRUG|Gliclazide|Participants received single oral dose of Gliclazide tablet in treatment period 1, 2, 3 or 4.
223507054|NCT00153478|BEHAVIORAL|Brief Motivational Counseling|
223507055|NCT05996731|PROCEDURE|Skin biopsy|A punch biopsy is a 15-minute low-risk procedure performed through a sterile circular blade (usually 3-4 mm) under local anesthesia. Briefly, the instrument is rotated down through the forearm epidermis and dermis perpendicular to its physiological lines of relaxation and into the subcutaneous fat, by producing a cylindrical core. Punch biopsy site can be closed with a single suture and generally produce only a minimal scar.
223507056|NCT05137340|OTHER|Nasal continuous positive airway pressure|Preterm infants with spontaneous breathing are stabilized on non-invasive respiratory support (PEEP of 6 cmH2O and FiO2≤0.40) in the delivery room and during admission to NICU, and then randomly selected to start NCPAP within 30 minutes of birth. Under NCPAP, the calf pulmonary surfactant will be administered via MISA method within 120 minutes after birth if infants are clinically diagnosed with RDS.
223507057|NCT05137340|OTHER|Non-invasive positive pressure ventilation|Preterm infants with spontaneous breathing are stabilized on non-invasive respiratory support (PEEP of 6 cmH2O and FiO2≤0.40) in the delivery room and during admission to NICU, and then randomly selected to start NIPPV within 30 minutes of birth. Under NIPPV, the calf pulmonary surfactant will be administered via MISA method within 120 minutes after birth if infants are clinically diagnosed with RDS.
223507058|NCT01509807|DRUG|IV morphine sulfate or Sponsor-approved equivalent|Patients enrolled in this group will receive IV morphine sulfate or Sponsor-approved equivalent via a patient-controlled analgesia (PCA) pump, as needed.
223507059|NCT01509807|DRUG|EXPAREL|Patients enrolled in this group will receive 266 mg EXPAREL diluted with preservative-free 0.9% normal saline to a total volume of 30 cc and administered via wound infiltration prior to wound closure. When not contraindicated, 30 mg IV ketorolac will be given at the end of surgery. If not indicated, IV non-steroidal anti-inflammatory drug (NSAID) may be substituted per the site's standard of care.
223507060|NCT06171399|BEHAVIORAL|"All Natural descriptor"|Participants in the nine intervention conditions will be shown four cannabis edibles packages that have been altered to contain one of the product descriptors of interest. All participants will see the same four products, and each condition will see the products with the same descriptor.
223507061|NCT06171399|BEHAVIORAL|"Gluten-free descriptor"|Participants in the nine intervention conditions will be shown four cannabis edibles packages that have been altered to contain one of the product descriptors of interest. All participants will see the same four products, and each condition will see the products with the same descriptor.
223599249|NCT03642496|BIOLOGICAL|High dose ET019002- T Cells|ET019002- T Cells are autologous T cells transduced expressing a novel anti-CD19 (ET019002) chimeric antigen receptor,and are administered by intravenous infusion with the dose of 3.0×10\*6/kg.
223599250|NCT06121089|PROCEDURE|ileocecal resection with extended D3 lymphadenectomy.|Laparoscopy ileocecal resectionith extended D3 lymphadenectomy including 201, 202, 203 and 213 groups of lymph nodes. Manual double-row ileo-ascendo-anastomosis.
223599251|NCT06121089|PROCEDURE|Right hemicolectomy with D3 lymphadenectomy.|Laparoscopy right hemicolectomy with D3 lymphadenectomy including 201, 202, 203, 213, 211, 212, 221, 222-rt groups of lymph nodes. Manual double-row ileo-transverse-anastomosis.
223599252|NCT06309589|DRUG|Vitamin D|experimental group received UDCA combined with vitamin D3 (1200 IU per day) treatment
223599253|NCT00133861|DRUG|Botulinum toxin|
223599254|NCT00626444|DRUG|Intravenous vitamin C|Up to 100 gms of intravenous vitamin C, three times per week for 10 weeks.
223599255|NCT06485323|DEVICE|MRI pelvimetry|MRI of the pelvis
223599256|NCT01871441|RADIATION|Total-body irradiation|Undergo TBI
223599257|NCT01871441|BIOLOGICAL|Donor lymphocytes infusion (DLI)|Undergo DLI
223599258|NCT01871441|DRUG|Cyclophosphamide|Given IV
223599259|NCT01871441|PROCEDURE|Allogeneic hematopoietic stem cell transplantation (HSCT)|Undergo haploidentical allogeneic HSCT
223599260|NCT01871441|DRUG|Tacrolimus|Given IV
223599261|NCT01871441|DRUG|Mycophenolate mofetil|Given IV
223599262|NCT01024842|BIOLOGICAL|MVA.HIVconsv low dose|Three intramuscular injections of MVA.HIVconsv alone at a dose of 1x10\^8 pfu at week 0, 4 and 12.
223599263|NCT01024842|OTHER|Placebo low dose|Three intramuscular injections of placebo alone (200ul) at week 0, 4 and 12.
223599264|NCT01024842|BIOLOGICAL|MVA.HIVconsv high dose|Three intramuscular injections of MVA.HIVconsv alone at a dose of 4x10\^8 pfu at week 0, 4 and 12.
223599265|NCT01024842|OTHER|Placebo high dose|Three intramuscular injections of placebo alone (800ul) at week 0, 4 and 12.
223599266|NCT05541679|DEVICE|Right ventricular septal pacing followed by left bundle branch area pacing|All patients will undergo implantation of right ventricular septal lead, left bundle branch area lead, and atrial lead in the absence of permanent atrial fibrillation with a CRT-pacing generator. Patients will be randomized to pacing protocols based on group assignment and crossover during the study.
223599267|NCT05541679|DEVICE|Left bundle branch area pacing followed by right ventricular septal pacing|All patients will undergo implantation of right ventricular septal lead, left bundle branch area lead, and atrial lead in the absence of permanent atrial fibrillation with a CRT-pacing generator. Patients will be randomized to pacing protocols based on group assignment and crossover during the study.
223599268|NCT05775731|DIAGNOSTIC_TEST|Tests for markers of inflammation and activated hemostasis|Volunteers who do not have exclusion criteria, are invited to complete the three questionnaires and to choose a date for blood drawing based on whether they are shift workers or not. Blood is immediately processed for platelet markers, and stored for inflammation and coagulation markers
223599269|NCT00933465|DRUG|Imodium (Loperamide Hydrochloride) syrup|"syrup (orally), max dose per day; 16x 5ml spoonfuls (80ml) Titrated from low dose to clinically relevant dose as described by the patient and their symptoms.~Taken at times suitable for the patient, either at regular intervals as defined by patient needs, or as single dose when needed the most."
223599270|NCT00933465|DRUG|Imodium (Loperamide hydrochloride) tablets|"tablets (orally) max dose per day; in chronic diarrhea, 8 capsules (16 mg) titrated from low dose to clinically relevant dose as described by patient and their symptoms.~Taken at times suitable for the patient, either at regular intervals as defined by patient needs, or as single dose when needed the most"
223599271|NCT02707328|DRUG|Gemcitabine|
223599272|NCT02707328|DRUG|nab-paclitaxel|
224199114|NCT02801149|PROCEDURE|Wrist Magnetic Resonance Imaging (MRI)|Patients that enter this group are randomised to receive non-standard care with a 3-sequence MRI scan of the scaphoid following the initial conventional radiography.
223599273|NCT02707328|RADIATION|CyberKnife|
223599274|NCT03831217|PROCEDURE|mid urethral sling surgery|patients with clinically and/or urodynamically proven stress urinary incontinence underwent mid urethral sling surgery under general anesthesia.
223599275|NCT03111953|PROCEDURE|Roux-en-Y Gastric Bypass Surgery|"In Roux-en-Y Gastric Bypass Surgery a small gastric pouch is created and connected to a segment of jejunum. Bowel continuity is restored by reconnecting the Roux limb and the biliopancreatic limb approximately \~75-150 cm distal to the gastrojejunostomy. Therefore, ingested food bypasses most of the stomach, the entire duodenum, and a short segment of the jejunum."
223599276|NCT03111953|PROCEDURE|Biliopancreatic Diversion Surgery|In Biliopancreatic Diversion Surgery a horizontal gastrectomy is conducted leaving a portion of the stomach, which is connected to the small intestine, \~250 cm from the ileocecal valve and the biliopancreatic limb is connected to the ileum, \~50 cm from the ileocecal valve. Digestive secretions from the biliopancreatic limb mix in the common channel, where ingested food is also delivered by the alimentary limb.
223599277|NCT00243711|DRUG|Carboxymethylcellulose sodium and Glycerin|
223599278|NCT03969927|DEVICE|Low-Fidelity PDS|"The principal investigator recently developed a low cost ($10,000) low fidelity portable driving simulator (PDS) in the University of Kansas Laboratory for Advanced Rehabilitation Research in Simulation (LARRS) that measures 25.5 Wide, 32.5 High, and 25 Deep and requires only approximately 4 square feet of space.~This intervention uses the PDS to retrain study participants and improve their driving related skills."
223599279|NCT03969927|DEVICE|High Fidelity Fixed-Base Simulator|This intervention uses the large high-fidelity fixed-base driving simulator to retrain study participants and improve their driving related skills.
223599280|NCT00418327|DRUG|Tarceva (Erlotinib Hydrochloride)|tablets of 25 mg, 100 mg and 150 mg 75 to 150 mg/m² Once daily
223599281|NCT02794519|DRUG|Sirukumab|This intervention will be provided in a 1.0 mL pre-filled syringe (PFS) fitted with spring-powered, disposable autoinjector device for single SC use that is permanently assembled on the syringe. The sirukumab PFS is aseptically filled to deliver a dose of 50 mg/1.0 mL of sirukumab.
223599282|NCT02794519|DRUG|Placebo|This intervention will be provided in a 1.0 mL pre-filled syringe (PFS) fitted with spring-powered, disposable autoinjector device for single SC use that is permanently assembled on the syringe. The sirukumab PFS is aseptically filled to deliver a dose of 50 mg/1.0 mL of sirukumab.
224311197|NCT01340326|DRUG|high dose of valsartan|comparison of different dosages of drug
223748522|NCT03959085|BIOLOGICAL|Inotuzumab Ozogamicin|Given IV
223748523|NCT03959085|DRUG|Leucovorin Calcium|Given PO or IV
223748524|NCT03959085|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223748525|NCT03959085|DRUG|Mercaptopurine|Given PO
223748526|NCT03959085|DRUG|Methotrexate|Given IT or IV
223748527|NCT03959085|DRUG|Pegaspargase|Given IV or IM
223748528|NCT03959085|PROCEDURE|Positron Emission Tomography|Undergo PET
223748529|NCT03959085|DRUG|Prednisolone|Given PO or IV
223748530|NCT03959085|OTHER|Questionnaire Administration|Ancillary studies
223748531|NCT03959085|RADIATION|Radiation Therapy|Undergo testicular radiation therapy
224199115|NCT05151887|OTHER|Muscle protein synthesis|The meals contain a total of 0.45 g protein/kg body mass (36 g protein for an 80 kg person). To account for differences in body mass, the investigators will scale the meal content to ensure 0.45 g/kg body mass for different body mass ranges (i.e., 65-75 kg, 75-85 kg, etc.). As such, carbohydrate, fat, and total energy content of the meals will also be scaled to body mass. The test meals are composed out of regular whole food items which will be purchased from local shops. The muscle protein synthetic response following meal ingestion will be assessed by the use of stable isotope tracer methodology
223599283|NCT02794519|DRUG|Rescue medication|Rescue medication (salbutamol/albuterol) shall be supplied to subjects at Screening for use when needed during the study.
223599284|NCT03041896|DEVICE|coflex® Interlaminar Technology|Interlaminer Technology
224199116|NCT01489306|DRUG|MDT-637|Inhaled doses of MDT-637 over a 10 day period
223599285|NCT05512416|DRUG|dalpiciclib plus letrozole|Six 4-week cycles of dalpiciclib orally, 150mg, day 1-21, and letrozole orally, 2.5 mg, day 1-28
224199117|NCT01489306|DRUG|MDT-637|Inhaled doses of MDT-637 over a 10 day period
224199118|NCT03356470|OTHER|F-FDG PET/CT|F-FLT PET uses a thymidine analogue that accumulates in proliferating tissue. Proliferating tissue could include malignant lesions or immune cells. In this study, FLT PET/CT will be utilized as a molecular imaging tool to detect immune activation after administration of immune checkpoint blockade with pembrolizumab or nivolumab.
223748532|NCT03959085|RADIATION|Radiation Therapy|Undergo cranial radiation therapy
223748533|NCT03959085|DRUG|Thioguanine|Given PO
223748534|NCT03959085|DRUG|Vincristine Sulfate|Given IV
223748535|NCT03169647|BEHAVIORAL|Listening-based intervention|Participants will listen to pre-specified material on a CD
223748536|NCT00048607|DRUG|aprepitant|
224199119|NCT04279873|DIAGNOSTIC_TEST|Microbiological diagnostics on pulmonary secretion|Culture, 16s, 18s, next generation sequencing
224199120|NCT05186376|PROCEDURE|bimaxillair osteotomy with maxillar segmentation|Patients who underwent bimaxillair osteotomy with maxillar segmentation
224199121|NCT06082427|DEVICE|Virtual reality hypnosis|VRH was delivered through a 3D virtual reality headpiece equipped with a head-tracking system based on hypnosis induction and suggestions (relaxation, comfort, and safety). The complete intervention lasted 17 minutes.
223599286|NCT00002201|DRUG|Ritonavir|
223599287|NCT00002201|DRUG|Nelfinavir mesylate|
223599288|NCT04362423|DEVICE|fNIRS|Near infrared spectroscopy (NIRS) is a non-invasive, portable, relatively inexpensive optical technology similar to pulse oximetry except that it measures total hemoglobin, oxy-hemoglobin, and deoxyhemoglobin in brain tissue (capillaries) rather than arteries.
223599289|NCT02638168|DRUG|Immediate Release Methylphenidate|The medication assessment procedure will be a double-blind, within-subject evaluation of placebo and matching evening dose of IR MPH rounded to the nearest 2.5mg increment with a max IR MPH dose of 0.3mg/kg. Expected evening dose range will be from 2.5mg to 20mg with most participants receiving between 5 to 15mg per evening dose. Dose will be determined based on current dose of their morning extended release stimulant
223748537|NCT00048607|DRUG|Comparator: paroxetine HCL|
223748538|NCT00048607|DRUG|Comparator: Placebo (Unspecified)|
223748539|NCT05308446|BIOLOGICAL|Cetuximab|Given IV
223748540|NCT05308446|DRUG|Encorafenib|Given PO
223748541|NCT05308446|BIOLOGICAL|Nivolumab|Given IV
223748542|NCT04994717|DRUG|Blinatumomab|Continuous intravenous (cIV) infusion
223748543|NCT04994717|DRUG|Low-intensity chemotherapy regimen|Intravenous (IV), oral (PO), subcutaneous (SC), or intrathecal (IT) administration.
223748544|NCT04994717|DRUG|SOC chemotherapy regimen|Intravenous (IV), oral (PO), subcutaneous (SC), or intrathecal (IT) administration.
223748545|NCT05442554|DRUG|Brentuximab vedotin|Brentuximab vedotin IV infusion.
223748546|NCT04061811|DIAGNOSTIC_TEST|Diagnostic biomarker study|Comparing circulating concentrations of NT-proBNP, GDF15, and neprilysin (NEP) along with NEP activity in patients with and without HF, as diagnosed by clinical parameters and post-dialysis echocardiography.
223748547|NCT01191580|BEHAVIORAL|Interpersonal Psychotherapy|Interpersonal Psychotherapy will consist of twelve 50-minute sessions delivered within a period of 16 weeks. IPT is divided into three phases.
223748548|NCT01191580|BEHAVIORAL|Problem-Solving Therapy|Problem-Solving Therapy will also consist of 12 50-minute sessions. The goals of the PST are: 1) to assist patients to identify and link life situations related to the depression; 2) to increase the effectiveness of the patient's problem-solving attempts at coping with current problems based on an intervention carried out in a concrete, structured and, unambiguous manner.
223748549|NCT01191580|BEHAVIORAL|Brief Supportive Psychotherapy|"The treatment approach will follow the standard supportive therapy approaches used in depression and medical illness, as noted below.~Brief Supportive Psychotherapy has a biopsychosocial perspective, recognizing contributions of genetic predisposition and neuroendocrine factors (Novalis et al., 1993, p. 257-277). Its goals are to maximize patient function during crisis, to support the patient's judgment with the therapist's reasoning skills, and to engender hope for recovery. Primary techniques and practices include reality testing; being relatively accepting of existing defenses but attempting to restructure them when appropriate; and, using self-esteem enhancing measures."
223748550|NCT06451523|OTHER|Alliance180 Program|The Alliance180 Program promotes feelings of neuropsychological safety and trust in the context of a 3-day program, which includes the transformative equine experience.
223748551|NCT06166277|PROCEDURE|Ablation procedure|Cardioneuroablation procedure or permanent pacemaker placement
224311198|NCT01340326|DRUG|usual dose of valsartan|comparison of different dosages of drug
223599290|NCT02638168|DRUG|Placebo|inert placebo ingredient
223599291|NCT01633164|BEHAVIORAL|SCI Reinvention Protocol Participants|The intervention involves participation in a six week psychologically-based educational intervention. During the course, 8 specific skills are reviewed in order to specifically address reframing a person's method of looking at events, build confidence by focusing on personal strengths, develop methods of recognizing and appreciating the good in one's life and express gratitude for positive attributes. These skills are presented in a specific sequence so that participants can gain mastery of introductory concepts before undertaking those that are both more difficult and complex.
223599292|NCT01633164|OTHER|Waitlist Group|Wait list arm will begin study intervention after 4 1/2 months.
223599293|NCT06240949|DEVICE|Positional Release Technique|Positional Release Technique will be applied on iliopsoas muscle. Treatment time will be 30 minutes per session, 4 times/week for 4 weeks in the hospital setting.
223599294|NCT06240949|DEVICE|Manual Pressure Technique|Manual Pressure Technique will be applied on iliopsoas muscle. Treatment time will be 30 minutes per session, 4 times/week for 4 weeks in the hospital setting.
223599295|NCT00513942|OTHER|Fetal Movement Counting|Women in the intervention group will receive an information pamphlet. The main items will be basic information and interpretation of fetal activity and instructions when to contact health professionals if experiencing DFM.
223599296|NCT03765450|DRUG|Infliximab|Patients will receive infliximab at the discretion of their physician as part of standard of care.
223599297|NCT04124705|DRUG|Armour® Thyroid|Administered orally once a day. the daily dose could range from 1/4 - 2 grains.
223599298|NCT04124705|DRUG|Levothyroxine|Administered orally once a day; the daily dose could range from 25- 200 µg.
223599299|NCT03343834|BIOLOGICAL|biological collection|"At D0:~* blood samples~* saliva sample~At D8: blood sample~the results will be compared to the analysis of EBV transcripts that are specific for the latent or replicative phase of the virus by reverse transcription-quantitative PCR (RT-qPCR), and to the detection of free virus in the saliva, which is associated with viral reactivation"
223599300|NCT03010280|DIETARY_SUPPLEMENT|Immunonutrition|Balanced high-protein formula enriched with Omega-3 fatty acids. 200 ml of formula every 8 hours during 10 days preoperatively
223599301|NCT03010280|DIETARY_SUPPLEMENT|Balanced high-protein formula|Balanced high-protein formula, without Omega-3 fatty acids. 200 ml of formula every 8 hours during 10 days preoperatively
223599302|NCT04123145|DIAGNOSTIC_TEST|Iron status testing|Iron status testing
223599303|NCT03821467|DEVICE|Dual beam Doppler Fourier-domain OCT (DOCT)|Retinal blood flow will be assessed using DOCT.
223599304|NCT03821467|DEVICE|Dynamic Vessel Analyzer (DVA)|Retinal vessel diameters and oxygen saturation will be measured with the DVA device.
223599305|NCT03821467|DEVICE|Optical coherence tomography (OCT)|Retinal morphology will be imaged using OCT.
223599306|NCT06975904|PROCEDURE|m-CIMT with VR exer-games by Kinect Xbox 360|Virtual reality workout session will be for about 30 minutes Warm-up exercise will be for 5 minutes including relaxed breathing For week 1-3: Soccer and Space Bubble Pop games will be used For week 4-6: 20,000 Leaks and Rally Ball games will be used 5 minutes will be given for cool down.
223599307|NCT06975904|PROCEDURE|m-CIMT with Task-Specific Functional Training|Begin with low-intensity exercises and progress to moderate to high intensity; session will be for about 30 minutes Warm-up for 5 minutes;one minute of rest for every five minutes of exercise For week 1-3: Assisted standing and weight shifting, Heel raises, Toe taps, Supported stepping, Unassisted standing and balance tasks will be used For week 4-6: Progressive stepping exercises, Heel-to-toe standing,
223748552|NCT04548596|DIAGNOSTIC_TEST|Transcranial Doppler|"In this study, the investigators will primarily use the monitor mode of the Transcranial Doppler (TCD, non-invasive FDA approved device) to record cerebral blood flow velocity (CBFV) signals from the Middle Cerebral Artery and Internal Carotid Artery. TCD data and intracranial pressure (ICP) data will be collected in the following four scenarios. Each recording is up to 60 minutes in length:~External ventricular drain (EVD) closed to drainage for a 24 hour period as part of the EVD weaning protocol per standard of care (SOC): The Initial reading will be done within 4 hours of EVD closing. The second reading will be done within 4 hours of anticipated removal of EVD.~EVD closed most of the time and opened to drainage when the ICP becomes elevated per SOC~EVD with Intra-Parenchymal fiber optical ICP sensor per SOC~Intra-Parenchymal fiber optical ICP sensor per SOC"
223748553|NCT05947682|OTHER|Adipose tissue harvesting|Adipose tissue harvesting (40-60g) during the abdominal liposuction or lipoaspiration under general anaesthesia which is performed according to usual care
223599308|NCT06976684|PROCEDURE|Extended Reality (XR)-Assisted CT-Guided Localization|This study plans to collect approximately 20 localization cases from multiple centers within our hospital. Initially, two sets of preoperative simulated CT scans (at end-inhalation and end-exhalation) will be performed in the CT suite to construct a usable model of the surgical posture and the lesion. Subsequently, in the hybrid operating room, a digital twin model will be applied to the patient using a metaverse platform. Guided by virtual localization lines, percutaneous injection of Patent Blue dye will be carried out at end-exhalation for accurate marking of the lesion. Immediately after the injection, intraoperative CT within the hybrid operating room will be used to verify the localization. If the accuracy is suboptimal (with a deviation greater than 2 cm), standard CT-guided Patent Blue dye localization will be performed as a supplementary measure to complete the localization and proceed with surgery.
223599309|NCT06975579|DEVICE|Ultrasound image processing|The COSIE study examines the coherence of ultrasound to improve the estimation of the backscatter coefficient.
223748554|NCT05064033|OTHER|Pragmatic Set of intervention and posterior capsular stretch|Group 1 will receive a pragmatic set of interventions, including Serratus Anterior Stretch,Rotator Cuff Facilitation,Acromilcalavicular joint Mobilization,Stretch of Pectoralis Major and Minor,Thoracic Manipulation and posterior capsular stretch.
223748555|NCT05064033|OTHER|Pragmatic Set of intervention and Sleeper Stretch|Group 2 will receive a pragmatic set of interventions, including Serratus Anterior Stretch, Rotator Cuff Facilitation, Acromilcalavicular joint Mobilization, Stretch of Pectoralis Major and Minor, Thoracic Manipulation and sleeper stretch.
223748556|NCT06799416|BIOLOGICAL|ARGX-109|administrations of ARGX-109
223748557|NCT06799416|OTHER|Placebo|administrations of placebo comparator
224311199|NCT04975893|BIOLOGICAL|mRNA-1647|No investigational product will be administered during the Primary Extension Phase or to the participants in the Observational Group.
223507062|NCT06171399|BEHAVIORAL|"Vegan descriptor"|Participants in the nine intervention conditions will be shown four cannabis edibles packages that have been altered to contain one of the product descriptors of interest. All participants will see the same four products, and each condition will see the products with the same descriptor.
223507063|NCT06171399|BEHAVIORAL|"100% Organic descriptor"|Participants in the nine intervention conditions will be shown four cannabis edibles packages that have been altered to contain one of the product descriptors of interest. All participants will see the same four products, and each condition will see the products with the same descriptor.
223599310|NCT05985967|DEVICE|PBMT-sMF|PBMT-sMF applied in the lower limbs with different doses per muscle group.
223599311|NCT05985967|DEVICE|Shock wave|Shock wave therapy applied in the lower limbs for 30 minutes.
223599312|NCT05985967|DEVICE|Pneumatic compression|Pneumatic compression applied in the lower limbs for 30 minutes.
223599313|NCT05985967|OTHER|Passive recovery|Volunteers laid in supine position resting for 30 minutes.
223599314|NCT06576206|OTHER|Bin therapy and finger gnosia|Schedule bin therapy sessions 2-3 times per week at first, increasing the frequency as participants get used to it. Data will be collected twice i.e., at the start of the study and after completion of 6 weeks of treatment by using outcome measure tools
223599315|NCT06576206|OTHER|conventional therapy|schedule conventional therapy with 20-50 minutes of each session with each set comprises of 10-12 repetitions of each exercise
223599316|NCT02450292|PROCEDURE|Bioabsorbable screw fixation|
223599317|NCT05107570|OTHER|Cold exposure|Cold air exposure (\~ 9°C, maximum 1 hour duration)
223599318|NCT01636986|DEVICE|Delefilcon A contact lenses|Silicone hydrogel contact lenses for daily wear, daily disposable use
223599319|NCT01636986|DEVICE|Etafilcon A contact lenses|Hydrogel contact lenses for daily wear, daily disposable use
223599320|NCT05777135|DRUG|Ringer Lactate prior to surgery and Propofol|Ringer Lactate prior to surgery and Propofol dose requirement for induction of anaesthesia will be noted
223599321|NCT04867733|OTHER|Micropatch (microneedle patch)|Each micropatch contains an array of 50 microneedles.
223599322|NCT06168617|DIAGNOSTIC_TEST|Performance tasks in daily life|Evaluation of performance tests executed by patients in real-life situations.
223599323|NCT01537822|PROCEDURE|Hysteroscopic morcellator|Morcellation will be performed with the HM (TRUCLEAR, Smith \& Nephew, Andover, USA). The rotary blade is used for polypectomy and removal of residual placental tissue; the reciprocating blade is used for myomectomy. The blade has a window-opening at the end with cutting edges through which tissue is aspirated by means of a vacuum source. The removed tissue is discharged through the device, collected in a pouch and made available for pathology analysis.
223599324|NCT01537822|PROCEDURE|Resectoscope|Resectoscopy will be performed with a rigid 8.5 mm bipolar resectoscope (Karl Storz GmbH, Tuttlingen, Germany), equipped with a 0 or 30 degree optic. Normal saline is used for distension and irrigation of the uterine cavity. Fluid balance is closely monitored using a Hystero pump (Richard Wolf GmbH, Knittlingen, Germany) or Hysteromat pump (Karl Storz GmbH, Tuttlingen, Germany).
223599325|NCT05876845|OTHER|Combined pre-, pro-, and post-biotic supplement|Participants will take 2 capsules daily with water, with their first meal of the day.
223599326|NCT03700437|OTHER|Fasting-Mimicking Diet|Chemo-immunotherapy + FMD (fast-mimicking diet)
223599327|NCT00002822|DRUG|carboplatin|
223599328|NCT00002822|DRUG|cisplatin|
223507064|NCT06171399|BEHAVIORAL|"Handcrafted descriptor"|Participants in the nine intervention conditions will be shown four cannabis edibles packages that have been altered to contain one of the product descriptors of interest. All participants will see the same four products, and each condition will see the products with the same descriptor.
223507065|NCT06171399|BEHAVIORAL|"Made with live resin descriptor"|Participants in the nine intervention conditions will be shown four cannabis edibles packages that have been altered to contain one of the product descriptors of interest. All participants will see the same four products, and each condition will see the products with the same descriptor.
223599329|NCT00002822|DRUG|cyclophosphamide|
223599330|NCT00002822|DRUG|doxorubicin hydrochloride|
223599331|NCT00002822|DRUG|etoposide|
223599332|NCT00002822|DRUG|ifosfamide|
223599333|NCT00002822|DRUG|mesna|
223599334|NCT00002822|DRUG|vincristine sulfate|
223599335|NCT00002822|RADIATION|radiation therapy|
223599336|NCT03187808|OTHER|Single thoracic manipulation|The subjects, who were randomly allocated to single thoracic manipulation group, will receive the single thoracic manipulation interventions directly to both sides of zygapophyseal joints of T6-T7. Each subject will be asked to lie on prone position on an experimental table. After that, the researcher will mark on both sides of zygapophyseal joints of T6-T7. Then, the subject will be instructed to take a deep inhalation and exhalation. During the exhalation, the therapist will perform the single thoracic manipulation (screw thrust technique) at zygapophyseal joints of T6-T7. If the audio pop is not heard during the first attempt, the therapist will ask the subject to reposition and repeat the technique. The procedure will be performed for maximum of 2 attempts and within 2 minutes.
223599337|NCT03187808|OTHER|Special massage technique (RT technique)|The special massage technique or RT technique is a treatment that was developed by Puntumetakul and colleagues in 2013 (copyright registration number 314783). The subjects in this group will be asked to lie on side lying position with 90 degrees of hip flexion and 90 degrees of knee flexion. The researcher will perform the RT technique by press their thumb on the treatment lines beside the posterior vertebral line from level of inferior angle of scapula to the lowest rib for 5 seconds per point and 3 sets per treatment line (Figure 8). Total time of this procedure is approximately 2 minutes.
223599338|NCT05675228|OTHER|data collection|Knowledge about genital herpes
223599339|NCT02643342|DEVICE|Orthokeratology|
223599340|NCT03706300|DRUG|Guaifenesin and Pseudoephedrine Hydrochloride Extended Release Tablets 1200/120 mg|
223599341|NCT00644436|DEVICE|Tetrix|single topical application
223599342|NCT00644436|DEVICE|Tetrix|Single topical application
223599343|NCT02093338|DIETARY_SUPPLEMENT|Lactobacillus fermentum CECT5716|
223599344|NCT02093338|OTHER|Placebo Comparator: maltodextrin|Placebo
223599345|NCT02291588|DRUG|AMG 811|A single dose of AMG 811 or placebo will be adminstered.
223599346|NCT02291588|DRUG|Placebo|contains no active drug
223599347|NCT02210416|PROCEDURE|inguinal hernia surgery|
223599348|NCT02880917|DEVICE|tDCS-Sham|Sham tDCS will involve an identical electrode montage, with stimulation ceasing after a 30-second ramp-up period to provide equivalent scalp sensation.
224199122|NCT01476527|PROCEDURE|Deep Brain Stimulation|Deep Brain Stimulation (DBS) is a neurosurgical procedure involving the implantation of deep brain electrodes, connected via a subcutaneous extension wire, to an implantable pulse generator (IPG, or 'battery') that is implanted below the collarbone
224199123|NCT05514327|RADIATION|ultra-fraction radiotherapy|the R/R DLBCL patients would receive ultra-fraction radiotherapy as bridging therapy before the CD19 CART cell infusion
223599349|NCT02880917|DEVICE|tDCS-Active|tDCS was delivered using the anode electrode positioned over the left dorsolateral prefrontal cortex (DLPFE) and the cathode electrode at supra orbital right region. The electrodes were placed into a 25-35 cm2 square sponge immersed in saline solution for better current conductivity. Current density used was 2 mA and electrodes attached to the scalp were sustained by rubber band.
223599350|NCT02880917|OTHER|Cognitive training|. The cognitive training consisted of an online application of a Dual N-Back task .The Training will last for 8 days.
223599351|NCT02251210|DRUG|BIIL 284 BS low dose|
223599352|NCT02251210|DRUG|BIIL 284 BS medium dose|
223599353|NCT02251210|DRUG|BIIL 284 BS high dose|
224199124|NCT05785273|DEVICE|Pupillometer|1st pupil evaluation between induction of general anesthesia and onset of surgery. After incision, at least 3 pupil evaluations are performed. Measurements are spaced 15 minutes apart and also taken at least 10 minutes after any variation in drugs dosage
224199125|NCT02048527|OTHER|Global|Single medium for the culture of embryos from Day1 to Day 5
224199126|NCT02048527|OTHER|Origio|Sequential media medium for the culture of embryos from Day1 to Day 3 (ISM1) and from Day 3 to Day 5 (BlastAssist)
224199127|NCT00563927|PROCEDURE|Conventional RT|
224199128|NCT00563927|DRUG|Cisplatin|
224199129|NCT00563927|DRUG|5-fluorouracil|
223507066|NCT06171399|BEHAVIORAL|"Fast-acting descriptor"|Participants in the nine intervention conditions will be shown four cannabis edibles packages that have been altered to contain one of the product descriptors of interest. All participants will see the same four products, and each condition will see the products with the same descriptor.
223507067|NCT06171399|BEHAVIORAL|"Relax descriptor"|Participants in the nine intervention conditions will be shown four cannabis edibles packages that have been altered to contain one of the product descriptors of interest. All participants will see the same four products, and each condition will see the products with the same descriptor.
223507068|NCT06171399|BEHAVIORAL|"Energy Boost descriptor"|Participants in the nine intervention conditions will be shown four cannabis edibles packages that have been altered to contain one of the product descriptors of interest. All participants will see the same four products, and each condition will see the products with the same descriptor.
223507069|NCT06171399|BEHAVIORAL|No descriptor (control)|Participants in the nine intervention conditions will be shown four cannabis edibles packages that have been altered to contain one of the product descriptors of interest. All participants will see the same four products, and each condition will see the products with the same descriptor.
223599354|NCT02251210|DRUG|Placebo|
223599355|NCT06194071|OTHER|Completion of questionnaires and on-site visits during an 18 months follow-up after TBI|"We will evaluate the same outcomes and use the same questionnaires at 6, 12 and 18 months post-TBI.~For patients we will evaluate:~* Functional Outcome (GOS-Extended)~* Health-related Quality of Life (QOLIBRI)~* Neurocognitive tests (MoCA)~* Independence (Barthel Index)~* Daily issues (BICOQ)~* Anxiety and depression symptoms (HADS)~* Medico-economic evaluation (EQ5D-5L)~For Relatives we will evaluate:~* Symptoms of anxiety and depression (HADS)~* The appreciation of the patient's daily issues from their point of view (dedicated Bicoq for relatives)~* Burden of care (ZARIT)~Throughout the follow-up we will nest a qualitative research programs which will focus on several aspects:~* feasibility of such follow-up (6 months is the primary endpoint) defined as the drop-out rate, complete or incomplete completion of scales and their reasons~* factors that may lead to drop-out or the contrary that solidifies the follow-up"
223599356|NCT02141139|DRUG|NSAIDS (ketorolac and ibuprofen)|
223599357|NCT05170178|BEHAVIORAL|inclusion and familiarization|"* presentation of the study purpose and the protocol to the volunteer~* clinical examination to check inclusion and exclusion criteria~* Familiarization with the crying of one assigned baby, by listening to several bath cries from this baby"
223617958|NCT04122326|BEHAVIORAL|Workstation Modification|Participants are asked to work in a sequence of workstation setups for ten minutes each. The sequence include 1. sitting with workstation adjusted by the participant, 2. sitting with workstation adjusted to promote proper posture, 3. sitting with workstation adjusted to promote unnatural posture, 4. standing with workstation adjusted by the participant, 5. standing with workstation adjusted to promote proper posture, and 6. standing with workstation adjusted to promote unnatural posture. After the sequence of setups, the participant allowed to adjust the workstation in either sitting/standing to work in 60 minutes in their own desired position.
223617959|NCT03898726|BIOLOGICAL|laparoscopical l cuff closure|closure of vaginal cuff following hysterectomy
223617960|NCT00134303|DRUG|Metformin|Metformin is used.
223617961|NCT00425646|BIOLOGICAL|bevacizumab|
223617962|NCT00425646|DRUG|imatinib mesylate|
223617963|NCT00677404|BIOLOGICAL|BM-MNC injection|Bone marrow aspiration A total volume of 400 ml bone marrow will be aspirated from the iliac crest under epidural anaesthesia
223617964|NCT04353128|DRUG|Melatonin 2mg|2 mg of prolonged release melatonin tablets per os (P.O.) before bedtime for 12 weeks
223617965|NCT04353128|DRUG|Placebo oral tablet|Identically looking placebo tablets P.O. before bedtime for 12 weeks
223617966|NCT03650088|BEHAVIORAL|Behavioral weight loss with digital tools|Participants will monitor their diet in a study smart phone app using a 'traffic light' approach where foods are categorized as red (high fat and/or calorie), yellow (moderate fat/calorie, high nutrient), or green (low fat/calorie, high nutrient) and adhere to a red food limit recommendation, weigh daily on a digital scale whose data syncs to the study app, gradually increase physical activity and track it using a wearable device for which data is also synced to the app, and monitor blood glucose using Continuous Glucose Monitoring. Participants will meet weekly with a trained interventionist for behavioral lessons (adapted from Diabetes Prevention Program curriculum) and counseling.
223617967|NCT05114408|OTHER|4 week trimodal prehabilitation course|"trimodal prehabilitation in mixed: stationary and at-home structure"
223617968|NCT05753488|DIAGNOSTIC_TEST|graft function|renal transplantation
223599358|NCT05170178|BEHAVIORAL|fMRI acquisition and closure|"* Second phase of familiarization, listening again to bath cries of their assigned baby. These cries will be different from those listened during the first familiarization phase.~* MRI acquisition: after acquisition of the anatomical images (5 min), the subjects will listen to 64 cries divided into 4 functional MRI sessions of 10 minutes each. The cries will be those of their baby or of unknown babies, evoked in a painful (vaccination) or a non-painful (bath) situation, presented in a pseudo-random order. Participants will be asked to assess whether they recognize their baby (yes/no) and whether they recognize a pain cry (yes/no).~* debriefing~* Protocol ending"
223599359|NCT03197922|BEHAVIORAL|MIE Treatment|"Appointments consist of a series of sitting routines (i.e., sits). Each sit consists of 10 min on the toilet, followed by 1 min of standing, then repeating the 10 min on the toilet 1 min off, for up to 32 cumulative minutes of sitting. The first sit occurs prior to the administration of any medication providing an opportunity for an independent continent bowel movement."
223599360|NCT03197922|DRUG|Glycerin Suppository|If no continent bowel movement occurs with the first sit, trained staff administer a dose of a liquid glycerin suppository, immediately followed by another sit to ensure any resulting bowel movement is continent. Glycerin suppositories are replaced by bisacodyl if 2 days pass without a continent bowel movement using the liquid glycerin suppository. Behavioral intervention consists of potent positive reinforcers when a continent bowel movement occurs. As independent continent bowel movements begin to occur, the need for the medical regimen diminishes, and is gradually faded out entirely.
223599361|NCT03197922|COMBINATION_PRODUCT|Treatment as Usual (TAU)|Participants randomized to the Treatment as Usual (TAU) group will continue to receive outpatient medical treatment of encopresis according to best practice guidelines by the pediatric gastroenterologist. In addition, participants in the TAU group will receive a 2-hour individual appointment in clinic with a doctoral level clinician with extensive experience in behavioral treatments for encopresis. During the appointment, the clinician will review strategies to increase continence by providing parent education on the following topics: how to collect and evaluate data on their child's bowel movements, how to establish and use a sit schedule, identifying behaviors that are precursors to bowel movements and how to use them to increase the probability of a bowel movement being continent, consequences for incontinence, and reinforcement for continence.
223599362|NCT02263261|OTHER|Flex HD Pliable Perforated HADM|Human Acellular Dermal Matrix
223599363|NCT00979225|OTHER|Medication Management report|Patients receive medication management reports delivered to their clinic-based caregivers for pharmacotherapy clinical decision support at point-of-care.
223599364|NCT00979225|OTHER|Care manager email notices|Community-based care managers receive email notices if the patient has not seen his/her primary care provider in the past 6 months, has low adherence to medications, and has no scheduled appointment.
223599365|NCT03459638|OTHER|Screening for DM, ASCVD, MetS and OSAS|Finger stick analysis, questionnaires and clinical measurements
223599366|NCT01575925|DRUG|4 mg Oral POM + 40 mg Oral DEX|
223599367|NCT01575925|DRUG|2 mg Oral POM + 40 mg Oral DEX|
223599368|NCT00610389|BIOLOGICAL|immunotherapy with dendritic cells|We will administer four daily doses (repeated every 24 hours)o dendritic cells in two cycles one month apart. We will administer systemic treatment with PEG-IFN alfa and GM-CSF to potentiate activity.
223599369|NCT03489512|DRUG|A (Chloraprep)|Chloraprep will be used for the insertion and maintenance of the intravascular device while it is in use (Chlorhexidine 2% + alcohol 70%)
223599370|NCT03489512|DRUG|B (Clorhexidine 2%)|Aqueous clorhexidine (2%) will be used for the insertion and maintenance of the intravascular device while it is in use
223599371|NCT01987583|PROCEDURE|Wet cupping|Wet cupping is the process of using a vacuum at different points on the body in order to gather the blood in that area. Then apply few superficial incisions (small, light scratches using a razor) on those areas, followed by repeating the vacuum on the same areas in order to remove 'harmful' blood which lies just beneath the surface of the skin.
223599372|NCT01987583|OTHER|Conventional treatment|According to Saudi Hypertension management guidelines, hypertension patients may require life style modification alone , especially for newly diagnosed cases, or my require life style modification and drug treatment. This will be decided by the treating team in the hospital.
223599373|NCT05807685|BEHAVIORAL|laughter therapy|Description: Laughter therapy session will be applied online for 25-30 minutes once a week for 2 months by the researchers who has the Laughter therapy certificate to the application group. In the laughter therapy session, the practices of introducing the practitioner and introducing the therapy, breathing exercises for a healthy life, keeping the rhythm accompanied by music, turning the laughter that started as if it were childlike games into reality will be carried out.
223599374|NCT00285168|BEHAVIORAL|Bone Density Decision Aide|Absolute 10-year Fracture Risk Report
223599375|NCT01844778|DRUG|Tobramycin Inhalation Powder|Tobramycin Inhalation Powder was administered via TOBI® Podhaler (T-326 inhaler).
223599376|NCT01844778|DRUG|Tobramycin inhalation solution|Tobramycin inhalation solution was administered via nebuliser
223599377|NCT01844778|DRUG|Colistimethate|Colistimethate was administered via nebuliser.
224199130|NCT04257773|BEHAVIORAL|REACH Forgiveness Workbook Intervention|Participants will be asked to complete the REACH Forgiveness Workbook
224199131|NCT03384576|OTHER|Music intervention|Classical music to be played in the Emergency waiting room
224199132|NCT03384576|OTHER|No music|No music played in emergency waiting room
224199133|NCT03815227|OTHER|Outpatient birth|Maternity out the same date or the next day of the birth and home-based follow up with a liberal midwife
224311200|NCT04975893|OTHER|mRNA-1647|Lyophilized product that is reconstituted with saline then diluted with a special diluent to reach the desired concentration
223507070|NCT06099275|DIAGNOSTIC_TEST|Transthoracic Echocardiography|Cardiac output measured by transthoracic echocardiography (TTE)
223507071|NCT04877054|BEHAVIORAL|Adherence Treatment Program|4 telehealth sessions including a combination of psycho/medical education plus a motivational interviewing component.
223507072|NCT04877054|BEHAVIORAL|Education only|The control group will receive an education-only session. Education will include medication purpose and adherence strategy recommendations delivered in a single telehealth session.
223507073|NCT06043570|DEVICE|Remote Monitoring arm|Patients will be follow-up using remote monitoring. In the RM follow-up arm, the patients are not mandated to visit the clinic unless there is unscheduled call due to adverse event notification.
223748558|NCT02529618|DEVICE|integrated Display Enhanced Testing for Cognitive Impairment and mild traumatic brain injury (iDETECT)|iDETECT offers an open platform for an evaluation of cognitive, balance, and oculomotor performance after mild traumatic brain injury (mTBI). It is a rugged, portable, neurocognitive assessment tool designed specifically for use in field and triage settings for the rapid evaluation of functional neurologic impairment after potential concussive injury.
223748559|NCT02529618|DEVICE|Riddell High Impact Technology (HIT) System|The Riddell HIT system incorporates six acceleration sensors into standard football helmets worn during practice and game play. A computerized sideline system captures information on linear and rotational acceleration, as well as magnitude, duration, and location of impact for each player
223748560|NCT02529618|DEVICE|i1 Biometrics Vector Mouth Guard|The i1 Biometrics Vector Mouth Guard is an impact intelligence system that contains a collection of impact sensing mouth guards, housing accelerometer and gyroscope technology that allows real-time collection and storage of biomechanical impact data. Sensors in the mouth guard communicate directly with a sideline assessment base station and allows for immediate assessment and evaluation of hit exposure.
224199134|NCT05356546|OTHER|Study-required procedures include: tissue collection from device capsule, questionnaire collection, and photo collection|Enrolled participants will have already received the TYRX™ Absorbable Antibacterial Envelope and will be clinically indicated to have a replacement with any market-released, commercially available (in the geographies they are used) CIED and lead(s) with or without the use TYRX™ Absorbable Antibacterial Envelope, as prescribed by and used on-label by their physician.
224199135|NCT00236730|DRUG|topiramate|
223599378|NCT02681315|DEVICE|HHHFNC 6 liter minute|Infants allocated to HHHFNC at 6 L/min. will be extubated to a HHHFNC flow of 6 L/min. Eligible infants will be enrolled while receiving mechanical ventilation. The timing of extubation will be determined by the clinical team and all infants will start caffeine prior to extubation.
223599379|NCT02681315|DEVICE|HHHFNC 3 liters/min|Infants allocated to HHHFNC at 3 L/min. will be extubated to a HHHFNC flow of 3 L/min. Eligible infants will be enrolled while receiving mechanical ventilation. The timing of extubation will be determined by the clinical team and all infants will start caffeine prior to extubation.
223599380|NCT05740865|PROCEDURE|open posterior instrumented thoracolumbar surgery|Both group previously received open posterior instrumented thoracolumbar surgery in 4 centers
223599381|NCT01623869|OTHER|Laboratory Biomarker Analysis|Correlative studies
223599382|NCT01623869|BIOLOGICAL|Trebananib|Given IV
223599383|NCT05453045|DRUG|Albendazole|tablet administration after a meal contaning approximate 15 g of fat
223599384|NCT05974319|OTHER|Dry heat application|Dry heat application: The region where the invasive intervention will be performed will be determined by the nurse in charge of the shift. The researcher will heat the thermoregulated electric pad and set it to 42°C. After making sure that there are no contraindications in the application of the electric pad device, a dry heat of 42°C will be applied to the determined area with the electric pad for 5 minutes.
223599385|NCT05974319|OTHER|Dry cold application|Dry cold applicaiton: The region where the invasive intervention will be performed will be determined by the nurse in charge of the shift. After the researcher is sure that there are no contraindications in the application of the gel pad, dry cold will be applied to the determined area with the gel pad for 3 minutes.
223599386|NCT05040074|DEVICE|SQ-Kyrin Transcatheter Edge-to-Edge Valve Repair System|Transesophageal echocardiography-guided, implantable mitral valve clip repair system
223599387|NCT01812265|DRUG|PF-06305591|single Dose
223599388|NCT01812265|DRUG|PF-06305591|single Dose
223599389|NCT01812265|DRUG|Placebo|Single Dose
223599390|NCT04260945|BIOLOGICAL|CD19/CD20 Dual-CAR-T cells|CD19/CD20 Dual-CAR-T cells are prepared via lentiviral infection. 5 days prior to infusion of CAR-T cells, subjects receive fludarabine at dose 30mg/m2/day and cyclophosphamide treatment at dose 250mg/m2 for 3 days and take a rest for 2 days before infusion.CD19/CD20 Dual-CAR-T cells will be intravenously infused with a escalated dose of 0.6-3×106 cells/kg.
223748561|NCT03375411|DEVICE|Stent INC1|Coronary intervention with conventional angioplasty technique but with a novel bare metal stent.
223748562|NCT03011814|BIOLOGICAL|Durvalumab|Given IV
223748563|NCT03011814|OTHER|Laboratory Biomarker Analysis|Correlative studies
223748564|NCT03011814|DRUG|Lenalidomide|Given PO
223748565|NCT01097018|DRUG|Capecitabine|1000 mg/m2 BID/ Days 1-14
224199136|NCT05483569|OTHER|Complex Decongestive Physiotherapy|Complete or complex decongestive physiotherapy (CDP) is a treatment for lymphedema, a condition in which excess fluid (lymph) collects in a part of the body. Damage to the lymph nodes or vessels, or a blockage leading to chronic swelling, usually causes lymphedema.
224199137|NCT05483569|OTHER|Multidimensional Diaphragmatic Breathing Exercises|Diaphragmatic breathing is an exercising technique to help strengthen your diaphragm and fill your lungs with air more efficiently.
224199138|NCT05483569|OTHER|Facial Release Technique|Fascial release is a manual therapy method that is applied holistically to the muscles and surrounding fascia through mechanical stimulation. It is a comprehensive approach to the evaluation and treatment of the muscular and fascia system in the body.
223748566|NCT01097018|DRUG|Perifosine|50 mg daily x 21 days
223748567|NCT01097018|DRUG|Placebo|1 pill daily x 21 days
223599391|NCT01153698|DRUG|dabigatran|anticoagulation
223748568|NCT01817725|BIOLOGICAL|HBV vaccine (Engerix B)|Engerix-B (20μg/ml, GlaxoSmithKline Biologicals) is administered intramuscularly at 0, 2, 4, 6, 8, 10, 12 months. The dosage will be 20μg in those \<= 20 years old and 40μg in those \> 20 years old.
223748569|NCT02606188|DEVICE|Modified High-flow nasal cannula|Modified High-flow nasal cannula
223748570|NCT02606188|DEVICE|nasal cannula|Conventional oxygen therap
223748571|NCT05858788|DRUG|SAR441566|Tablet
224199139|NCT04938869|OTHER|Educational Intervention|Receive basic diabetes mellitus education
223599392|NCT02793791|PROCEDURE|minimally invasive ablation therapies|Including RFA (radiofrequency ablation);MWA (microwave ablation); PEI (percutaneous ethanol injection),etc.
223599393|NCT02152319|DEVICE|KHV reporting|Clinicians will view the KHV motor symptom severity reports and use KHV to videoconference with subjects to titrate medications.
223599394|NCT02152319|PROCEDURE|Standard care|Subjects will receive the same disease management as if they were not participating in this study.
223599395|NCT05942547|DRUG|Diosmin|diosmin 600mg twice daily
223599396|NCT05942547|DRUG|Placebo|twice daily
223599397|NCT02602418|OTHER|Adaptive WM CogMed Training|"12 different computerized visual and spatial Working Memory tasks will be presented at each sessoin. Each session will involve 8 of the 12 tasks, and each subject is required to complete 25 training sessions, 30-40 minutes per day, 4-5 days per week over a 5-8 week period (minimum 20 sessions). The tasks will become more difficult in an adaptive manner, which is hypothesized as optimal for learning and training effects."
223748572|NCT01813669|BEHAVIORAL|Integrative Coping Group|"The proposed 12-week intervention will integrate yoga-based skills with cognitive-behavioral principles. The development of this program was based on existing and empirically-validated cognitive-behavioral interventions for youth (i.e., Coping Cat and Cat Project; Kendall et al.) and therapeutic yoga interventions (e.g., Galantino et al., 2008 for review). The intervention will be broken down into four three-week modules, which address the following:~Module 1: Introduction to group and awareness of body Module 2: Awareness of emotion and developing an understanding of the mind-body connection Module 3: Focus on cognitive process Module 4: Experiential practice and therapeutic discussions"
223599398|NCT02602418|OTHER|Nonadaptive WM CogMed Training|"The same 12 computerized visual and spatial working memory tasks will be presented, but at a fixed (non-adaptive) and low difficulty level. 5 sessions per week x 5 weeks fora total of 25 sessions (minimum 20 sessions)."
223599399|NCT03640221|DRUG|Ertugliflozin|The sodium-glucose cotransporter 2 (SGLT2) inhibitors are an exciting new class of antidiabetic drugs that cause a modest reduction in high blood pressure and large reductions in the risk of cardiovascular disease (CVD) outcomes and renal outcomes in patients with advanced type 2 diabetes and very high CVD risk. However, the mechanistic underpinning of these CVD benefits is not well understood. this arm will allow us to test our hypothesis.
223599400|NCT03640221|DRUG|Hydrochlorothiazide 12.5mg|comparator arm allow us to mimic the mild anti hypertensive effect seen with the SGLT-2 inhibitors in order to enable us to differentiate whether the cardiovascular protection seen with the SGLT-2 inhibitors is secondary to its antihypertensive effects vs the potential decrease in sympathetics.
223599401|NCT03640221|DEVICE|Microneurography|"Multiunit recordings of postganglionic sympathetic nerve activity will be obtained with unipolar tungsten microelectrodes inserted selectively into skeletal muscle nerve fascicles of the peroneal nerve. The nerve signals are amplified, filtered (bandwidth 700-2000 Hz), rectified and integrated to obtain a mean voltage display of sympathetic nerve activity. Sympathetic bursts are counted by inspection of the neurograms. A deflection on the mean voltage display is counted as a burst if it has a minimal signal to noise ratio of 2:1. The interobserver and intraobserver variations in identifying bursts are \<10% and \< 5%, respectively."
223599402|NCT03640221|OTHER|SKNA recordings|SKNA recordings will be captured by placing ECG electrodes on the chest wall. Recordings will be obtained simultaneously with microneurographic recording. The two techniques will undergo identical filtering and processing of the neurophysiologic inputs which are then displayed simultaneously using identical output functions.
223599403|NCT03640221|OTHER|Static Handgrip|Subjects will perform static handgrip at 33% MVC for 2 minutes, using a Stoelting recording handgrip dynamometer. Force output will be recorded continuously and displayed on the computer screen in real time to provide the subject with visual feedback. MVC will be determined for each subject at the beginning of each experiment. Subjects will be instructed to avoid straining maneuvers, changes in breathing, and contraction of non-exercising muscles during the experimental protocols. Ratings of perceived exertion (RPE) will be obtained at the end of each exercise by using a 6- to 20-unit Borg scale. Static handgrip at 33% MVC is accompanied by reflex increases in muscle sympathetic nerve activity caused by activation of the acid-sensing unmyelinated muscle afferents.
223599404|NCT03640221|OTHER|Post-handgrip forearm vascular occlusion|This will be performed by inflating a pneumatic cuff on the upper exercising arm to suprasystolic pressure (220 mmHg) beginning 10 seconds before the subject stops gripping and ending 2 minutes into the post-exercise period. The vascular occlusion maintains intramuscular acidosis and thus the stimulation of acid-sensing unmyelinated skeletal muscle afferents and their reflex increase in muscle sympathetic nerve activity and BP, while the muscular relaxation eliminates central command and the attendant increase in heart rate (which returns to the baseline level). As soon as the cuff is release and the forearm circulation is restored, muscle sympathetic nerve activity quickly returns to the baseline level and BP soon follows.
223599405|NCT03640221|OTHER|Testing of the Arterial Baroreflex Function|We will compare effects of Ertugliflozin vs. low-dose HCTZ on sinoaortic baroreflex function in hypertensive diabetic subjects during both spontaneous fluctuations in arterial pressure and during decreases and increases in arterial pressure induced by the Valsalva maneuver. The aim of this protocol is to determine if the sympathetic nerve, as well as the heart rate, component of the sinoaortic baroreflex can be augmented by the SGLT2 inhibitor. After obtaining stable baseline recordings, arterial pressure, heart rate, and muscle sympathetic nerve activity will recorded during spontaneous fluctuations in BP over 5 minutes and during both decreases in BP during phase III of the Valsavla maneuver and during the phase IV overshoot in BP upon its release. Frequent accurate measurement of arterial pressure will be obtained with a highly-rated oscillometric arm monitor that records 6 BP readings per minute (Welch Allyn Vital Signs Monitor).
223599406|NCT04899453|DRUG|Methotrexate|400ug intravitreal injection every week for 4 doses in the induction phase, every 2 weeks for 2 doses as consolidation, then every month for 10 doses
223599407|NCT04899453|DRUG|Rituximab|Rituximab 375mg/m2 intravenous infusion d1, every 21 days for 1 cycle. 6 cycles will be prescribed as protocol
223599408|NCT04899453|DRUG|Zanubrutinib|160mg Bid, oral. 21-day cycle for 6 cycles in the induction phase and for 2 years in the maintenance phase
223599409|NCT02106403|OTHER|Prototype disinfectant spray formulation|0.13% w/w BAC and 1% MGA. After wounding, the product will be held approximately 10 cm above the wounding area, and sprayed twice towards the wound
223599410|NCT02106403|OTHER|Reference product|0.13% w/w BAC. After wounding, the product will be held approximately 10 cm above the wounding area, and sprayed twice towards the wound
224199140|NCT04938869|OTHER|Medical Device Usage and Evaluation|Use CGM device and app
224199141|NCT04938869|OTHER|Survey Administration|Ancillary studies
224199142|NCT05362669|BEHAVIORAL|SMS invitation|Behavioral: SMS to invite to cervical cancer screening using HPV self-sampling.
224199143|NCT05362669|BEHAVIORAL|Phone call invitation|Behavioral: Phone call to invite to cervical cancer screening using HPV self-sampling.
224199144|NCT03585166|PROCEDURE|lpaparoscopic hepatectomy|laparoscopic hepatectomy： laparoscopic hepatectomy for hepatocellular carcinoma.
223599411|NCT02106403|OTHER|Negative control|0.9% w/v sodium chloride solution. After wounding, the product will be held approximately 10 cm above the wounding area, and sprayed twice towards the wound
223599412|NCT01303601|DRUG|olanzapine|"Tablet The initial dose of olanzapine was 5mg daily and raised to 10 mg/day. After week 1, flexible dosing was allowed based on symptom response, up to 20 mg daily, as tolerated.~daily 6 weeks"
223599413|NCT01303601|DRUG|Starch|
223599414|NCT05189028|DRUG|gemcitabine and cisplatin|Neoadjuvant chemotherapy:gemcitabine and cisplatin
223599415|NCT03653728|DEVICE|Near infrared spectroscopy|"All patients would be receiving the same treatment including application of non-invasive monitoring with near-infrared spectroscopy (NIRS) together with the standard of care with interval CT Brain scan for all patients.~Non-invasive monitoring with near-infrared spectroscopy (NIRS) is very safe and is in current daily routine clinical use for intraoperative patients."
223599416|NCT05642299|DEVICE|MBCI-SR|Participants will be asked to wear and EEG+NIRS cap and a soft robotic glove on their stroke-impaired hand. The participant will be instructed to ask to imagine to picture moving the stroke-imparied hand in the mind. The brain signal (EEG and NIRS data) will be recorded as a reference. When the participant pictures this move again, upon detection of such imagined move by MBCI-SR system, the glove will be activated and assists the participants to perform a specific upper limb task based on individual ability. There are six different activities of daily living (ADL)-oriented tasks enacted through a virtual arm and virtual objects, which formed the visual feedback for the participants. These tasks include scanning goods, moving an object upward to a cabinet, using two hands to move a towel, pouring of water into a cup, eating action and fine motor movement of picking up a small block using two fingers. Training intensity is 1.5 hours for 3 times a week for 6 weeks, a total of 18 sessions.
223599417|NCT03828851|OTHER|Domiciliary care - Activities of Daily Living|Home-based ADL training.
223599418|NCT03533244|DRUG|0.1% AG-86893 Eye Drops|One drop, three times daily to the study eye for 28 days
223599419|NCT03533244|DRUG|0.3% AG-86893 Eye Drops|One drop, three times daily to the study eye for 28 days
223599420|NCT03533244|DRUG|Vehicle Eye Drops|One drop, three times daily to the study eye for 28 days
223599421|NCT00473538|BEHAVIORAL|Structured exercise training|
223599422|NCT00473538|BEHAVIORAL|Hypocaloric hyperproteic diet|
223599423|NCT03799276|OTHER|Opticare study|"Each patient will be evaluated by~* An HIV physician~* A nurse~* A social worker~* A psychological therapist~* A cultural mediator/member of patients community if needed for migrants~Following these interviews and visits, a multisciplinary team will define for each patient an individualized OPTICARE program based on the following items: clinical, psychological/psychiatric, social status and follow up visits will be planned with the patient.~Regular (Day 15 and monthly) phone calls will be set up during the first six months of the OPTICARE program, to assess the clinical status and ART adherence.~Patients will have their medical, biological and social status assessed through visits at W4, W12, W24, W36 (medical and social status only) and W 48 with all members of the OPTICARE team."
223599424|NCT00995995|DRUG|Rosiglitazone|Rosiglitazone
223599425|NCT01496846|DRUG|IANB Articaine|IANB anesthesia given with 1.7cc of 4% articaine, 1:100,000 epinephrine.
223599426|NCT01496846|DRUG|SUP Articaine|After unsuccessful IANB with articaine, proceed to give 1.7cc of 4% articaine with 1:100,000 epinephrine in buccal mucosa as a supplemental infiltration injection (SUP).
223599427|NCT01496846|DRUG|SUP Lidocaine|After unsuccessful IANB with articaine, proceed to give 1.7cc of 2% lidocaine with 1:100,000 epinephrine in buccal mucosa as a supplemental infiltration injection (SUP).
223599428|NCT05196685|DIAGNOSTIC_TEST|Carotid Doppler USG|All Doppler ultrasonography measurements will be made in a dimly lit room at room temperature, with the patient in the supine position, the head slightly hyperextended, the patient looking to the left when measuring the right side, and the patient looking to the right when measuring the left side. In all patients, common carotid artery (CCA), internal carotid artery (ICA) and vertebral artery (VA) gray scale and color Doppler ultrasonography wşll be performed using the GE 9L Linear Probe. Color Doppler examination will be performed with a frequency of 4.0/8.0 MHz.
223599429|NCT04590716|OTHER|Data Collection|This is a non-interventional study conducted on the participant's smartphones to record MG related symptoms and conditions.
223599430|NCT04955327|DRUG|A. Paniculata|Extract from A. Paniculata
223599431|NCT04955327|DRUG|A. Chilensis|Extract from A. Chilensis
223599432|NCT04955327|DRUG|A. Paniculata and A. Chilensis|Combination of A. Paniculata and A. Chilensis
223599433|NCT04955327|DRUG|Microcrystalline cellulose|Placebo comparator
223599434|NCT02024724|DRUG|Bupivacaine|4 mL of 0.25% bupivacaine
223599435|NCT02024724|DRUG|Triamcinolone|40 mg of Triamcinolone
223599436|NCT02024724|DRUG|Dexamethasone|4 mg of Dexamethasone
223599437|NCT01772576|DEVICE|Reliance 4-Front lead implantation|The patients selected for participation should be from the investigator's general patient population with an indication for implantation of a single or dual chamber ICD or CRT-D system.
223599438|NCT02019875|DRUG|Rifampin|P450 inducer
223599439|NCT02019875|DRUG|Clarithromycin|CYP3A4 and Pgp inhibitor in both intestine and liiver
223599440|NCT02019875|OTHER|Grapefruit Juice|CYP3A4 inhibitor in intestine
223599441|NCT02019875|OTHER|Placebo|
223599442|NCT00317096|PROCEDURE|FCM|Active comparator: Chemotherapy
223599443|NCT00317096|PROCEDURE|R-FCM|experimental: Chemotherapy with additional rituximab
223599444|NCT00317096|DRUG|rituximab maintenance|2 courses of rituximab maintenance after completion of salvage therapy
223599445|NCT00317096|OTHER|observation only|no Intervention after completion of FCM or R-FCM
223599446|NCT01651663|DRUG|Arbidol (Umifenovir)|Arbidol (Umifenovir)/Placebo will be administered at a dosage of 800 mg/day (2 capsules q.i.d.) for 5 days.
223599447|NCT01651663|OTHER|placebo|Arbidol (Umifenovir)/Placebo will be administered at a dosage of 800 mg/day (2 capsules q.i.d.) for 5 days.
223599448|NCT01651663|DRUG|Arbidol (Umifenovir)|Medically healthy exposed subjects will be administered Arbidol (Umifenovir)/Placebo at a dosage of 200 mg/day (2 capsules q.d.) for 10 days.
223599449|NCT01651663|OTHER|placebo|Medically healthy exposed subjects will be administered Arbidol (Umifenovir)/Placebo at a dosage of 200 mg/day (2 capsules q.d.) for 10 days.
224199145|NCT03585166|PROCEDURE|open hepatectomy|open hepatectomy: open hepatectomy for hepatocellular carcinoma
224199146|NCT00677066|PROCEDURE|Home oxygen therapy|Administer oxygen at home or in hospital
224199147|NCT03843866|OTHER|4-0 Monocryl|sutures and steri-strips
224199148|NCT03843866|OTHER|Adhesive Glue|Adhesive Glue
224199149|NCT02088866|DRUG|Transdermal Lidocaine|The intervention will use 5% commercially available transdermal lidocaine in clinical practice for the treatment of tinnitus. This dose will be tailored to patient preference.
223599450|NCT05374330|OTHER|Electroacupuncture|Acupuncture needles are inserted into the body at standardized acupuncture points. An electrical current is then applied to 4 needles through 2 channels of electrical current. The sham group receives the same protocol with sham needles and sham electrical current.
223599451|NCT04356352|DRUG|Lidocaine|1 mg/kg lidocaine to a max of 100 mg administered approximately 30 seconds prior to the administration of propofol, with pain score obtained before the propofol is administered.
223599452|NCT04356352|DRUG|Esmolol|0.5 mg/kg esmolol to a max of 50mg administered approximately 30 seconds prior to the administration of propofol, with pain score obtained before the propofol is administered.
223599453|NCT04356352|OTHER|Placebo|saline water administered approximately 30 seconds prior to the administration of propofol, with pain score obtained before the propofol is administered.
223599454|NCT03202134|OTHER|opioid free anesthesia|general anesthesia blocking reflexes without using an opioid
223599455|NCT04717817|DEVICE|Inspiratory muscle training (IMT) using an IMT Threshold device (Philips)|Inspiratory muscle training on a daily basis prior to surgery during 2-3 weeks
224199150|NCT01504126|DRUG|Chemotherapy|Undergo standard chemotherapy
224199151|NCT01504126|DRUG|Propranolol Hydrochloride|Given PO
224199152|NCT01504126|OTHER|Quality-of-Life Assessment|Ancillary studies
224199153|NCT01504126|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgical resection
224199154|NCT02920866|BEHAVIORAL|Functional Strength Integration (FSI)|FSI intervention involves strengthening of the hip musculature combined with focused techniques emphasizing early initiation of hip muscle recruitment to stabilize the pelvis, integrating strength and movement pattern training to maximize functional recovery. The FSI program consists of therapeutic exercise in 3 domains: pelvic stability (PST) training, functional training (FT), and strength training (ST). PST includes early surgical-limb weight bearing and core muscle strengthening, progressively increasing in difficulty based on performance benchmarks and therapist monitoring. FT focuses on gait and stair climb exercise, progressing to higher level agility training. ST includes progressive, resistance exercise to improve lower extremity muscle strength. The ST exercises include use of weighted pulleys/weight-training machines. Therapists will determine an 8-rep max for muscle groups and weight will be increased by 10% every 2 weeks to maximize hypertrophy and strength gains.
224311201|NCT03065218|DRUG|99mTc sestamibi|The administration of the diagnostic radioisotope, 99mTc sestambi, to image possible metastases in patients with differentiated thyroid cancer.
223599456|NCT04717817|OTHER|Standard physiotherapy|Standard instructions and physiotherapy prior to surgery during 2-3 weeks
223599457|NCT00615173|DRUG|tacrolimus (FK506)|Started: 0.05-0.1mg/kg/d,divided into two daily dose at 12hr; the blood level:5-10ng/ml in induction phase;and 4-6ng/ml in maintenance phase;
223599458|NCT00615173|DRUG|cyclophosphamide or azathioprine|Induction phase: CTX 0.75g/m2 monthly Maintenance phase: AZA 2mg/kg/d.
223599459|NCT00357825|DRUG|[S,S]-Reboxetine|
223599460|NCT02355444|DIETARY_SUPPLEMENT|blackberry polyphenol enriched beverage|Double-blind intervention study, cross-over design with one 250 mL bottle of high-dose blackberry polyphenol beverage per day or placebo (blackberry beverage with minimal polyphenol) in Phase one followed by cross-over in Phase two.
223599461|NCT02355444|DIETARY_SUPPLEMENT|blackberry beverage with minimal polyphenol concentrations|Double-blind intervention study, cross-over design with one 250 mL bottle of high-dose blackberry polyphenol beverage per day or placebo (blackberry beverage with minimal polyphenol) in Phase one followed by cross-over in Phase two.
223599462|NCT05150522|BIOLOGICAL|BCMA CAR-T cells|BCMA CAR-T cells infusion
223599463|NCT00966550|OTHER|Tomato|Tomato with high carb/fat meal
223599464|NCT00966550|OTHER|Non-tomato|Non-tomato with high carb/fat meal
223599465|NCT00379912|DRUG|Azacitidine|Azacitidine 50 mg/m2 subcutaneously qod for two consecutive weeks every four weeks.
223599466|NCT00379912|DRUG|Erythropoietin|Erythropoietin 60,000IU subcutaneous injection weekly while on protocol therapy
223599467|NCT00379912|DRUG|Azacitidine (Monotherapy)|Azacitidine 50 mg/m2 subcutaneously qod for two consecutive weeks every four weeks.
223599468|NCT03404297|OTHER|Locally sourced compression therapy|The dressing is made up of a zinc oxide impregnated compression wrapping
223599469|NCT03999840|DRUG|cemdisiran|Cemdisiran has been designed to reduce the level of C5 mRNA in the liver, thereby reducing levels of circulating C5 protein, inhibiting terminal complement pathway activity, and preventing formation and deposition of the MAC (C5-b9) on endothelial cells in the kidney.
223599470|NCT03999840|DRUG|Placebos|The control drug for this study will be a placebo (sodium chloride 0.9% w/v for SC administration). Placebo will be prepared and labelled identically to cemdisiran.
223599471|NCT00621140|DRUG|linagliptin|active
223599472|NCT00621140|DRUG|placebo|placebo
223599473|NCT02052401|OTHER|Domiciliary Intervention|Two time domiciliary application of an standardized protocol consisting of: a) evaluation of pharmacological and non pharmacological therapies adherence. b) application of a Checklist of home safety measures. c) development of a patient oriented occupational routine d) education in strategies for elderly global stimulation e) education strategies for identifying red flags and for correct use of health services.
223599474|NCT05226312|OTHER|Local Warm Compress|The warm application will be made by the researcher for 15 minutes three times a day according to the local warm application process steps.
223599475|NCT04887896|DEVICE|GS500|Device: GS500
223599476|NCT04887896|DEVICE|Placebo|Device: Placebo
224311202|NCT02337296|BEHAVIORAL|ADHERE|"ADHERE entails a face-to-face 30 minute session during week 1 while in the clinic/office and three subsequent ADHERE phone calls for 10 minutes each, weekly during weeks 2-4 to promote symptom management and adherence to their oral agent regimen. The face-to-face intervention and phone interactions will consist of Motivational Interviewing and Cognitive Behavioral Therapy interaction strategies. Each patient will be given a Medication Management and Symptoms Management Toolkit, to assist with symptom management at home.~All patients (intervention and control) receive weekly assessments of symptom severity and oral agent adherence (weeks 2-7). At exit (week 8), all patients receive an assessment of depressive symptoms, self-efficacy, beliefs, motivation, symptom severity, and adherence."
224311203|NCT00979914|OTHER|Patient education programme|The intervention consisted of five group sessions, three hours for each session. The focus was on self-efficacy. Eight to ten patients participated in the programme at the same time.
224311204|NCT01455363|PROCEDURE|BCC surgery|This clinical trial will use skin flap model for trunk and facial BCC, with respect the classical excision margin of BCC surgery (3-4mm): after local anesthesia, a little random pattern skin flap will be raised around the BCC, then the cutaneous pedicle will be clamped with surgical clamp for 3 minutes and clamp released.
223599477|NCT03296449|PROCEDURE|CPAP|A recruitment maneuver will be applied to the ventilated lung. Immediately continuous positive airway pressure, at a pressure of 2-3cmH2O will applied to the non-ventilated lung for 20 minutes by the Mallinckrodt Bronchocath Disposable CPAP system (a recognised anesthetic breathing system design for CPAP).
224199155|NCT02920866|BEHAVIORAL|Control Group (CON)|Observed practice patterns from previous investigations and discussion with physical therapists indicate that patients receive rehabilitation services during the 2-3 day hospital stay after THA, but not routinely after hospital discharge. Yet, to control for attention and volume of rehabilitation for the FSI group, patients in the control group will attend outpatient physical therapy for 14 visits (40 minute sessions) over 8 weeks. This control program will mimic the typical postoperative experience for patients in our community, in which patients independently manage their activity. This program will focus on patient education, functional ADL training, and therapeutic exercise. However, the activities in the exercise domain will be limited to low load exercise such as isometric muscle exercise, range of motion (ROM), and flexibility activities. These activities are specifically designed to mirror usual care activity.
224199156|NCT04254926|BEHAVIORAL|Revie ⊕|Revie ⊕ is a positive approach centered on the resources and strengths of the patient, and it consists of an intervention that focuses on the individual's life review. Revie ⊕ allows specialist nurses to discuss life events with cancer patients, to identify the significant elements, and to explore how the diagnosis has changed their values and preferences. The intervention is geared toward working with the patient to discover their potential, to identify their strategies for coping with the events of their life, and to thereby accompany them in achieving a better understanding of themselves and what defines their identity. The intervention also allows their concerns surrounding death to be addressed, in addition to providing clarity in regard to the life projects. In the end, as a conclusion to the intervention, the patient is provided a booklet recounting the salient features of their life review along with photographs, quotes, or images.
224311205|NCT01455363|OTHER|Tourniquet ischemia|In case of limb BCC, limb tourniquet will be used, and occluded during 3 minutes upstream to the BCC location.
224311206|NCT01455363|OTHER|Laser speckle imaging|During all steps of experimentation, laser speckle imaging will be used to measure continuously the peri-tumoral and tumoral perfusion, start from tumor excision, up to10 minutes after tumor pedicle clamp or tourniquet release.
224311207|NCT04672486|BEHAVIORAL|POD Adventures|"Participants in the intervention arm will receive information about local services/national helplines and a brief problem-solving intervention that is delivered through a smartphone app with telephone guidance from a lay counsellor. The intervention is grounded in stress-coping theory, with a technical focus on practical problem solving. The emphasis on problem solving reflects the primacy of psychosocial stressors in adolescent help-seeking. Moreover, problem-solving is among the most commonly used practice elements in evidence-based psychological interventions for children and adolescents globally.~The content of the app comprises two sections: 'Adventures' which teaches problem-solving concepts and methods through contextually-appropriate games; and 'My POD' which scaffolds the student through the application of step-by-step problem-solving procedures to their own prioritized problems."
224311208|NCT04791423|BIOLOGICAL|GRAd-COV2|GRAd-COV2 is a replication-defective gorilla adenoviral vector (GRAd) encoding the SARS-CoV-2 surface glycoprotein (S, Spike) antigen under the control of CMV immediate early promoter. The encoded Spike antigen is stabilized in pre-fusion conformation by introducing 2 proline residues
224311209|NCT04791423|OTHER|Placebo|Saline solution
223507074|NCT06278649|BEHAVIORAL|Relaxation and Guided Imagery|Listening to a 15 minute relaxing pre-recorded script while laying down on an exercise mat
223507075|NCT03722888|DEVICE|smokeSCREEN video game|smokeSCREEN video game is web-based videogame intervention focused on tobacco use prevention in teens. The game has 1.5-2 hours of unique game play and focuses on combustible cigarettes, e-cigarettes, and flavored tobacco products.smokeSCREEN. Guided by the social cognitive theory and the theory of planned behavior, smokeSCREEN addresses a range of challenges that teens often face involving peer pressure and the use of tobacco products. Participants are provided access to the smokeSCREEN game through a private, password-protected website link and instructed to complete the game.
223507076|NCT04159480|DEVICE|Experimental - Cogito Companion|Cogito Companion
223599478|NCT03296449|PROCEDURE|HFJV|A recruitment maneuver will be applied to the ventilated lung. Immediately, high-frequency jet ventilation, with a driving pressure of 0.5 atm and a respiratory rate of 100 cycles per minute will applied to the non-ventilated lung for 20 minutes using the Monsoone III Jet Ventilator (Acutronic, Hirzel, Switzerland). Monsoone III is a recognised ventilator design for HFJV.
223599479|NCT02277808|DRUG|500mg Amikacine (Amukin®) diluted in 4mL NaCl (0,9%)|
223599480|NCT02277808|DEVICE|Respirgard II|
223599481|NCT02277808|DEVICE|Isoneb®|
223599482|NCT02073019|DRUG|BL-8040|
223599483|NCT02073019|DRUG|Placebo|
223599484|NCT02873338|DRUG|Dociparstat sodium|Subjects received 4 mg/kg dociparstat intravenous (IV) bolus followed by doses of 0.125 or 0.25 mg/kg/hr dociparstat given on Days 1 through 7 with standard induction therapy, on Days 1 through 5 or 7 with standard re-induction therapy, and on Days 1, 3, and 5 with standard consolidation therapy.
223599485|NCT02873338|DRUG|Idarubicin|Subjects received 12 mg/m2/day idarubicin by slow (10 to 15 minutes) intravenous (IV) injection daily on Days 1, 2 and 3 of induction therapy, and on Days 1 and 2 of re-induction therapy.
223599486|NCT02873338|DRUG|Cytarabine|Subjects received 100 mg/m2/day cytarabine by continuous intravenous (IV) infusion on Days 1 through 7 of induction therapy and on Days 1 through 5 of re-induction therapy. During consolidation therapy, subjected received 1.0 g/m2 cytarabine IV infusion given over 3 hours every 12 hours on Days 1, 3, and 5.
223599487|NCT03657095|DRUG|Esuberaprost|Sodium tablets
223599488|NCT03657095|DRUG|Placebo|Placebo tablets, which are identical in size and appearance to those containing Esuberaprost.
223599489|NCT00245843|BEHAVIORAL|Mother Infant Transaction Program (MITP)|Psychosocial intervention. 11-session one hour standardized intervention program. The aim of the MITP is to help parents to appreciate their infant's unique characteristics,temperament and developmental potential.
223599490|NCT04292314|DRUG|Omega 3|Omega-3 supplementation (300-400mg EPA \& 200-300mg DHA) per day for 8 consecutive months up to 10 months
223748573|NCT05735223|PROCEDURE|Maximal urethral length preservation technique of robot assisted radical prostatectomy (RALP).|Stretched flaccid penile length (SFPL) was measured by a single male assessor at preoperative visit, and at the time of catheter removal (10 days post-surgery). The subjects were blinded to the measurements to prevent bias. Multiparametric MRI (MP-MRI) of the prostate were reviewed when available for surgical planning. All subjects underwent RALP with MULP using the technique previously published by Hamada et al. Continence defined as requiring no pads was assessed at 3 and 6 months postoperatively.
224199157|NCT00498004|DRUG|Quetiapine, Risperidone|The dose of quetiapine will be titrated over 4 days to 300mg/day (50mg at day 1, 100mg at day 2, 200mg at day 3 and 300mg at day 4) and thereafter flexible dose will be administered depending on the clinical state. The dose of risperidone will be titrated as following 2mg at day 1 and 4mg at day 4 and thereafter flexible dose will be administered depending on the clinical state. The dosage of drugs should be 400-800mg/day of quetiapine and 4-6mg/day of risperidone between 6 and 8 weeks of trial.
224199158|NCT01312948|DEVICE|Prototype mask (known as Pixi)|This is a prototype mask to be used with continuous positive airway pressure (CPAP) or non-invasive ventilation (NIV) therapy. The mask attaches to the face, covering the nose, and is kept in place with headgear. Therapy is delivered through the mask via a tube which attaches to the CPAP or NIV device.
224199159|NCT01301625|DEVICE|MitraClip Implant|Percutaneous mitral valve repair using MitraClip implant.
224199160|NCT03087448|DRUG|Ceritinib|"ALK tyrosine inhibitor, 300 mg - 450 mg PO daily.~Phase I dose escalation:~1. Ceritinib 300mg~2. Ceritinib 450mg~3. Ceritinib 450mg~The Phase II doses will be determined by Phase I dose escalation study"
224199161|NCT03087448|DRUG|Trametinib|"MEK kinase inhibitor, 1.5 mg - 2.0 mg PO daily.~Phase I dose escalation:~1. Trametinib 1.5mg~2. Trametinib 1.5mg~3. Trametinib 2.0mg~The Phase II doses will be determined by Phase I dose escalation study"
224199162|NCT02686437|OTHER|TheraBand Kinesiology Tape|Kinesiology taping technique is designed to target muscles and lymphatic system. Limited research is available for specific conditions, including low back pain, but it is theorized to correct muscle function by inhibiting or facilitating the muscle, improve blood flow, reduce pain, and improve joint alignment.
224199163|NCT02992808|DRUG|recombinant gonadotropins|
223599491|NCT04292314|DRUG|Nigella Sativa Oil|Nigella sativa supplementation (1g black seed oil contain 1% thymoquinone) per day for 8 consecutive months up to 10 months
223599492|NCT04292314|DRUG|Hydroxyurea|hydroxyurea medication (5 to 15mg/kg) per day for 8 consecutive months up to 10 months.
223599493|NCT04292314|DRUG|Honey|Natural honey(2.5 mg/kg dissolved in 250 ml water) per day for 8 consecutive months up to 10 months.
223599494|NCT04292314|DRUG|Deferoxamine|deferoxamine (SubQ infusion: 20 to 40 mg/kg/day over 8 to 12 hours, 6 to 7 nights per week, maximum daily dose: 40 mg/kg/day)for 8 consecutive months up to 10 months.
223748574|NCT00510354|DRUG|Imatinib mesylate|
223748575|NCT02694146|DRUG|Platelet rich plasma|Platelet rich plasma (PRP) is a platelet concentrated obtained from autologous blood centrifugation. This concentration technique provides larger amounts of biologically active molecules, mainly growth factors that are responsible for tissue repair. PRP (platelet rich plasma) contains a higher concentration of platelets from baseline (150,000-350,000 / ul).
224199164|NCT02992808|DRUG|HP-HMG|
224199165|NCT05821023|OTHER|messages|Different messages describing either the benefits of breast cancer screening aimed at supporting continued screening or messages describing the harms of over-screening and making recommendations to stop screening
224199166|NCT01995656|DRUG|Placebo - Capsule|Administered orally
224199167|NCT01995656|DRUG|LY3108743 - Capsule|Administered orally
224199168|NCT01995656|DRUG|Placebo - Solution|Administered orally
224199169|NCT01995656|DRUG|LY3108743 - Solution|Administered orally
224199170|NCT02721043|BIOLOGICAL|Peptides|Each subject will receive ten (10) total doses of PGV001. PGV001 will be administered on study visit: v4, v6, v8, v10, v12, v14, v16, v18, v20 and v22.
223599495|NCT04292314|PROCEDURE|blood transfusion session|Regular blood transfusion session based on patient hematological profile starts from one session every 2 weeks.
223599496|NCT00627055|DRUG|LPV/r|LPV/r dosing = 400mg/100mg orally q12h for 48 weeks
223599497|NCT00627055|DRUG|LPV/r + TDF/FTC or TDF/3TC|TDF/FTC (Truvada) 1 pill orally q 24 hr or TDF 300mg orally q 24 hr/3TC 300mg orally q 24 hr (or 3TC 150mg orally q 12 hr) for 48 weeks
223599498|NCT00393614|DRUG|levetiracetam|20 mg pr. kg a day
223599499|NCT02497690|BEHAVIORAL|Telemedicine|Half of subjects will undergo six months of ART administered via telehealth. Therapy will be provided in the usual manner, except a computer will be used to facilitate the interaction.
223599500|NCT02497690|BEHAVIORAL|In-person ART|Half of subjects will undergo six months of ART administered in person. Therapy will be provided in the usual manner.
223599501|NCT00973245|DRUG|Xarelto (Rivaroxaban, BAY59-7939)|10mg od
223599502|NCT00973245|DRUG|Xarelto (Rivaroxaban, BAY59-7939)|15mg od
223599503|NCT00973245|DRUG|Xarelto (Rivaroxaban, BAY59-7939)|20mg od
223599504|NCT00973245|DRUG|Warfarin|Dose-adjusted warfarin based on target INR values
223599505|NCT04439981|DIETARY_SUPPLEMENT|Ice cream|Curcumin extract was added into ice cream
223599506|NCT03432559|DIAGNOSTIC_TEST|endoscopy|endoscopy of pharynx, upper esophagus, mid esophagus, cardia, gastric fundus, und gastric body
223599507|NCT03534375|OTHER|The study is an observational cross sectional study|An intervention will not be performed
223599508|NCT04831177|PROCEDURE|Laser in situ keratomileusis|Laser in situ keratomileusis LASIK is a procedure used to correct different types of ametropia through a creation of corneal flap whether with femtosecond laser or mechanically with a microkeratome followed by application of excimer laser to correct different refractive errors including Myopia, Hyperopia and Astigmatism.
223507077|NCT04159480|BEHAVIORAL|Active Control|Use of MyCAP
223507078|NCT03520387|PROCEDURE|Lumbar medial branch nerve radiofrequency ablation (LRFA)|Radiofrequency ablation of the dorsal rami of the lumbar spinal nerves, using electrode placement parallel to the medial branches, 18G electrodes or larger, and 2 lesions per nerve.
224199171|NCT02721043|DRUG|Poly-ICLC|Each subject will receive ten additional (10) total doses of the Poly-ICLC. The additional Poly-ICLC dose will be administered on study visit: v5, v7, v9, v11, v13, v15, v17, v19, v21 and v23.
224199172|NCT02721043|DRUG|Lenalidomide|10mg once daily oral dose for maintenance therapy in multiple myeloma patients.
224199173|NCT03237325|DRUG|SGX942|1.5 mg/mL SGX942 administered as a 4 minute IV infusion, twice per week starting within 3 days after initiating radiation therapy and continuing through 2 weeks after radiation therapy ends.
224199174|NCT03237325|DRUG|Placebo|Placebo is 0.9% sodium chloride (normal saline). The treatment preparation, frequency and duration of therapy are identical to that of the active drug.
224199175|NCT01993238|DEVICE|Liposonix System (Model 2)|Treatment of subcutaneous adipose tissue of the abdomen using high intensity focused ultrasound (Liposonix System Model 2).
224199176|NCT01993238|DRUG|Pre-treatment analgesia|Pre-treatment analgesia (combination of ondansetron, ketorolac, and hydromorphone)
224199177|NCT01283659|OTHER|Standard Imaging|
224199178|NCT01283659|OTHER|Advanced Imaging|
223507079|NCT03520387|PROCEDURE|Simulated LRFA with targeted steroid injections|Performed in an identical fashion to the experimental arm (LRFA), except for medial branch lesioning, which will not be done in simulated LRFA, and 2) the simulated LRFA control group will receive an injection of triamcinolone acetonide at each site where a radiofrequency lesion would normally be applied.
223599509|NCT02436954|PROCEDURE|CO2 insufflation at intra-abdominal pressure 8 mmHg|insufflation of CO2 gas into peritoneum for maintaining the pressure of 8 mmHg
223599510|NCT02436954|PROCEDURE|CO2 insufflation at intra-abdominal pressure 12 mmHg|insufflation of CO2 gas into peritoneum for maintaining the pressure of 12 mmHg
223599511|NCT03905850|DRUG|somapacitan|5 mg/1.5 ml and 10 mg/1.5 ml doses administered s.c. (subcutaneously, under the skin)
224199179|NCT02684370|DRUG|risankizumab|Risankizumab administered by subcutaneous (SC) injection
223507080|NCT03520387|BEHAVIORAL|AcTIVE-CBT|AcTIVE-CBT involves a standardized CBT protocol for pain, delivered via a video telehealth interface. AcTIVE-CBT also incorporates use of an activity tracker to provide objective feedback on activity levels, which can inform participants' and providers' impressions of goals and progress.
223507081|NCT03520387|BEHAVIORAL|TBSCE|TBSCE control is a focused program of CBT involving an initial 60-minute telephone education session by a psychologist; the provision of printed educational materials on chronic pain self-management, and a workbook for CBT self-management; and structured, written plans for weekly practice, reading and homework using the workbook.
223507082|NCT03336866|DRUG|Placebo|Normal saline
223507083|NCT03336866|DRUG|IXT-m200|IXT-m200 is an anti-methamphetamine monoclonal antibody
223507084|NCT06081062|BIOLOGICAL|Fabagal® (Agalsidase beta)|1 mg/kg every 2 weeks for 12 months
223507085|NCT06081062|DRUG|Active comparator (Agalsidase beta)|1 mg/kg every 2 weeks for 12 months
223599512|NCT02929459|DIETARY_SUPPLEMENT|Riboflavin Dose 1|
223599513|NCT02929459|DIETARY_SUPPLEMENT|Riboflavin Dose 2|
223599514|NCT02929459|OTHER|Placebo|
223599515|NCT03821610|DRUG|Fludarabine|IV
223599516|NCT03821610|DRUG|Melphalan|IV
223599517|NCT03821610|DRUG|Alemtuzumab|IV
223599518|NCT03821610|DRUG|Cyclophosphamide|IV
223599519|NCT03821610|DRUG|Mesna|IV
223599520|NCT03821610|RADIATION|Total Body Irradiation (8Gy)|TBI (8Gy)
223599521|NCT03813914|DIETARY_SUPPLEMENT|Sineos|glycyrrhizic acid 38 mg + Cinnamomum Zeylanicum 150 mg + corosolic acid 480 mcg 2 pills per day
223599522|NCT06262243|OTHER|electric blankets|"While the patient is in surgery; An electric blanket will be placed under the bed mattress, and the bed will be placed on the electric blanket.~The bed sheet will be laid, and the blanket used in the clinic will be laid on top of the bed sheet.~-The electric blanket will be turned on at hot setting 20 minutes before the patient leaves the surgery. After the mother is placed in a heated bed, the electric blanket will be unplugged when the temperature reaches 36.5."
223599523|NCT02116088|BEHAVIORAL|Teacher Coaching|
223599524|NCT01802190|GENETIC|Deafness patients|SLC17A8 et POU4F3 mutations genes analysis on blood samples of deafness patients.
223599525|NCT03441230|DEVICE|Balloon characteristics|Different size balloon
224199180|NCT02684370|DRUG|placebo for risankizumab|Placebo for risankizumab administered by subcutaneous (SC) injection
224199181|NCT02684370|DRUG|ustekinumab|Ustekinumab administered by subcutaneous (SC) injection
224199182|NCT02684370|DRUG|placebo for ustekinumab|Placebo for ustekinumab administered by subcutaneous (SC) injection
224199183|NCT05003752|RADIATION|External beam radiation therapy, High-dose-rate brachytherapy|Combined hypofractionated external beam radiation therapy (EBRT) plus high dose-rate brachytherapy (HDR-BT) schedule (total dose of EBRT 36 Gy/ in 12 fractions of 3 Gy plus HDR-BT with a total physical dose of 14 Gy in a single fraction)
224311210|NCT03938714|PROCEDURE|Hemorrhoidectomy|Excision of third and fourth degree hemorrhoids
223599526|NCT01947764|BEHAVIORAL|HADITHI Intervention|"The HADITHI Intervention consists of a culturally adapted, multi-component clinic-based intervention designed to support families in pediatric HIV disclosure in Kenya.~In addition to the Usual Care components, the HADITHI Intervention clinics will have the following intervention components:~Culturally modified curricula materials, including videotaped narratives, to guide counseling and group sessions.~Dedicated disclosure counselors to initiate and conduct disclosure, with one-on-one counseling for caregivers and children, as well as family-based sessions.~Post-disclosure peer support groups, facilitated by the disclosure counselors, for children who have gone through disclosure."
223599527|NCT03633266|PROCEDURE|anti-VEGF|vitreoretinal surgery combined with intraoperative anti-VEGF
224199184|NCT05003752|DRUG|Goserelin 10.8 mg|Androgen deprivation will be administered based on NCCN guidelines in patients with unfavorable intermediate/high risk organ-confined prostate cancer
224199185|NCT04221373|DEVICE|Ekso™ powered exoskeleton|Powered exoskeletal-assisted walking (EAW) for early training
224199186|NCT04221373|OTHER|Standard of care|Participants will receive standard of care of acute inpatient rehabilitation.
224199187|NCT04904952|DRUG|N-acetylcysteine tablet 600mg|N-acetylcysteine tablet 600mg/day and doubling weekly to reach a maximum dose of 2400mg/day (at week-3) for remaining 7 weeks along with SSRIs
224199188|NCT04904952|DRUG|Placebo tablet 600mg|Placebo tablet 600mg/day and doubling weekly to reach a maximum dose of 2400mg/day (at week-3) for remaining 7 weeks along with SSRIs
224199189|NCT04179188|PROCEDURE|Bariatric surgery|Classical Bariatric surgery (ring, Sleeve gastrectomy or Bypass)
224199190|NCT00212446|DEVICE|Electrical Intervention (EI)|Electrical intervention (EI) is bipolar, constant-current (1-20 mA), square-wave pulses in 20% duty cycles. Women in preterm labor have an electrode placed vaginally; tocodynamometric contraction timing and fetal heart rate are monitored continuously. Successive 20-minute periods include pre-control period (C1); the EI period, in which a 10-second current burst is delivered at expected contraction times; and a post-EI control period (C2).
224199191|NCT04532827|BEHAVIORAL|Case formulation with web-program|"The first meeting includes an interview to establish understanding on the participant´s symptomatology and current life situation, a case formulation (CF) will be build based on it. The CF is presented in the second session and modifications can be made to ensure acceptability for the participant. Goals for web program (WB) are set based on the CF and understanding of the factors contributing to the participant´s wellbeing.~WB modules are instructed to complete during the week. Modules include psychoeducation, experiential exercises and training aimed at improving wellbeing and psychological flexibility. Web-therapist will offer written feedback. The participants can contact the therapist via the WB and al messages will be replied within one week. Automatic reminders will be sent if a participant has not been active in the WB, the therapists will call participants who have discontinued using the WB."
224199192|NCT03592082|DRUG|Bismuth Subsalicylate|BSS 524 mg ((2) 262 mg tablets) given four times per day for 14 days
224199193|NCT03592082|DRUG|standard antibiotic therapy|antibiotic therapy administered per standard protocol
224199194|NCT04219046|DRUG|Naloxégol oxalate|Oral administration once daily
224311211|NCT00732550|PROCEDURE|Single trocar cholecystectomy|Patients with symptomatic cholelithiasis will be operated using the single trocar surgery approach
224311212|NCT00732550|PROCEDURE|Standard laparoscopic cholecystectomy|Patients with symptomatic cholelithiasis will undergo a standard laparoscopic cholecystectomy
224311213|NCT01781741|COMBINATION_PRODUCT|therapeutic lymphadenectomy (TEMLA) and Stereotactic Body radiation therapy (SBRT)|Undergo TEMLA and SBRT
223507086|NCT03185351|DRUG|Bupivacaine|20 ml of 0.5% bupivacaine using supraclavicular BPB.
223507087|NCT03185351|DRUG|Midazolam|midazolam 0.03 mg/kg dissolved in 5 ml normal saline (0.9%) using supraclavicular BPB
223507088|NCT03185351|DRUG|Midazolam|0.03 mg/kg of midazolam by I.V. route
223507089|NCT06063343|DRUG|KAND145|In Part 1 of the study, single ascending doses of KAND145 will be administered; in Part 2 of the study, multiple ascending doses (BID for 8 days) of KAND145 will be administered.
223599528|NCT03633266|PROCEDURE|PRP|vitreoretinal surgery combined with intraoperative PRP
223599529|NCT01337544|OTHER|HAPLOIDENTICAL IL-15 STIMULATED NK CELLS|ONE MEGADOSE 30 DAYS AFTER TRANSPLANTATION (DOSE WILL DEPEND ON PATIENT BODY WEIGHT)
223599530|NCT02639520|DRUG|Canephron® N|2 tablets 3 times a day for 7 days
223507090|NCT06063343|DRUG|Placebo|Participants randomized to the placebo arms will receive placebo at the same dosing frequency as the experimental arms.
223507091|NCT03402087|DRUG|Methotrexate|Specified dose on specified days
223507092|NCT03402087|DRUG|Leucovorin|Specified dose on specified days
223507093|NCT03402087|DRUG|BMS-986165|Specified dose on specified days
223507094|NCT00373087|DRUG|entacapone|entacapone
223507095|NCT00373087|DRUG|l dopa versus placebo|l dopa versus placebo
223507096|NCT04322695|BEHAVIORAL|Rehabilitation Education Care Program|The RECP contained the following domains: (1) assessment and detection of disability; (2) home exercise; (3) activities to improve mobility; (4) dietary management; (5) patient education; and (6) vocational counseling.
223507097|NCT05301777|DEVICE|Computed tomography|Computed tomography
223507098|NCT02830633|PROCEDURE|LNTME|Patients in this group received laparoscopy-assisted nerve-preserved TME for treatment of rectal cancer
223507099|NCT02830633|PROCEDURE|OTME|Patients in this group received traditional open TME for treatment of rectal cancer
223507100|NCT04723069|DRUG|Control Group|metronidazole tablets + doxycycline hyclate tablets, are consecutively taken for 14 days, while Fuke Qianjin capsule simulation is consecutively taken for 28 days.
223599531|NCT02639520|DRUG|Fosfomycin trometamol|1 sachet of 8 g of granules; one single dose on Day 1
224199195|NCT04219046|DRUG|Placebo oral tablet|Oral administration once daily
224199196|NCT01946295|DRUG|Famotidine|100mg x 2 p.o.
224199197|NCT01946295|DRUG|Placebo|
224199198|NCT05726123|DEVICE|The Exopulse Mollii Suit on a Fibromyalgia patient|The present study consists of a comparative, randomized, controlled and clinical trial conducted to explore and compare the acute and chronic effects a treatment session with the Exopulse Mollii Suit, a treatment session with the Exopulse Mollii Suit combined with VR and a training session have on a Fibromyalgia patient.
224199199|NCT00421746|DRUG|Piboserod|
224199200|NCT02203604|BIOLOGICAL|aldesleukin|Given IV
224199201|NCT02203604|BIOLOGICAL|ipilimumab|Given IV
224199202|NCT02203604|OTHER|laboratory biomarker analysis|Correlative studies
224199203|NCT00773201|DRUG|Sotalol 80 mg|healthy subjects will receive an unique dose of Sotalol and will have an effort test on ergonomic bicycle, an auditive stimulation and a taking of DNA
224199204|NCT06153758|DRUG|Danuglipron|Danuglipron oral tablets
224311214|NCT01781741|OTHER|quality-of-life assessment|Ancillary studies
224311215|NCT02730351|DRUG|Fluticasone furoate/ Vilanterol 100 mcg/25 mcg|FF/VI 100/25 mcg will be administered via ELLIPTA inhaler once daily in the evening
224311216|NCT02730351|DRUG|Fluticasone propionate 250 mcg|FP 250mcg will be administered via DISKUS inhaler, twice daily, once in the morning and once in the evening
223599532|NCT02639520|DRUG|Canephron® N-placebo|2 tablets 3 times a day for 7 days
223748576|NCT02694146|DRUG|Hylan G-F 20|Hylan G-F 20 is a viscous, sterile and non-pyrogenic elasto fluid containing hylan. Hylans are byproducts from hyaluronate (hyaluronic acid sodium salt), consisting of repeating disaccharides of N-acetylglucosamine and sodium glucuronate. Hylan G-F 20 replaces and supplements the synovial fluid. It is effective at any stage of the joint pathology.
223748577|NCT05624437|OTHER|data record|data record
223748578|NCT02567006|BEHAVIORAL|SMS message|SMS messages will be delivered at 6, 4, and 2 days before the next scheduled date of the primary vaccines for the intervention group
223748579|NCT02567006|OTHER|Usual care|Health clinic nurse provides regular appointment in the vaccination card with no active reminders
223748580|NCT01852812|DRUG|Montelukast Oral Granules (OG)|Montelukast 4 mg in one sachet
223748581|NCT01852812|DRUG|Montelukast Chewable Tablets (CT)|Montelukast 5 mg in one tablet
223748582|NCT01684371|OTHER|Two oily solutions (Blue Dotted and Orange Dotted Elmore Oils)|Thirty participants received Blue Dotted Elmore Oil and another thirty received the Orange dotted Elmore Oil, they applied the oils three times daily on the affected knees for four weeks and stopped usage on the fifth week (flush out period) and on the 6 week, the two group switched to Orange and Blue Elmore Oil respectively. All throughout applications, they filled out their diaries to indicate changes in their mobility, moods, feeling of well being and ability to do their daily work at home or at work every week.
223599533|NCT02639520|DRUG|Fosfomycin trometamol-placebo|1 sachet of 8 g of granules; one single dose on Day 1
223599534|NCT00308971|DRUG|Alpha, gamma, beta, and delta (mixed) tocopherols|approximately 666 IU daily (1 pill) for 4 months
223599535|NCT00308971|DRUG|alpha lipoic acid|600 mg daily (2 pills 300 mg each) for 4 months
223599536|NCT00308971|DRUG|placebo|placebo for alpha, gamma, beta, and delta (mixed) tocopherols; 1 pill daily for 4 months
223599537|NCT00308971|DRUG|placebo|placebo for alpha lipoic acid; 2 pills daily for 4 months
223599538|NCT01467921|DRUG|oxaliplatin|oxaliplatin 85 mg/m2 will be given intravenously on day 1 for over 2 h
223599539|NCT01107847|PROCEDURE|low flow pressure volume manoeuvre|In all patients a standard low flow pressure volume manoeuvre is applied by a respirator with a constant gas flow of 4 l/min starting at a zero end-expiratory pressure up to a tidal volume of 2 l or until a maximum airway pressure of 35 cm H2O was reached.
223599540|NCT05608551|BEHAVIORAL|Animal-assisted trauma-focused therapy|Animal-assisted trauma-focused therapy (AA TF-CBT) is a specific form of trauma treatment, in which one or more animals are integrated into the therapy. AA TF-CBT follows a structured, standardized therapy manual.
223599541|NCT05608551|BEHAVIORAL|Standard trauma-focused therapy|Standard trauma-focused therapy (AA TF-CBT) is a standardized trauma therapy following a structured manual.
223599542|NCT02128412|DEVICE|Oversized stent deployed at low pressure (Multi-Link Bare Metal Stent or Xience Prime Evenolimus Eluting Stent)|Stent can include both bare metal stents and drug eluting stents. Depending on availabilities, different stent brands may be used.
223599543|NCT02128412|DEVICE|Stent deployed at high pressure (Multi-Link Bare Metal Stent or Xience Prime Evenolimus Eluting Stent)|Stent can include both bare metal stents and drug eluting stents. Depending on availabilities, different stent brands may be used.
223748583|NCT03610932|DIETARY_SUPPLEMENT|Vitamin C|Taken as 3 500mg capsules.
223599544|NCT02253784|DRUG|Dexamethasone|
223748584|NCT03610932|OTHER|Placebo|Taken as 3 500mg capsules.
223748585|NCT02182362|DRUG|BI 201335 NA|
224311217|NCT02730351|DRUG|Placebo via ELLIPTA inhaler|Placebo will be administered via ELLIPTA inhaler once daily in the evening
223599545|NCT02253784|DRUG|Bupivacaine|
223599546|NCT01870310|PROCEDURE|Catheterised renal denervation|
223599547|NCT02980133|DRUG|Fluticasone Propionate|Fluticasone propionate was administered via MDPI per the dose and schedule specified in the arm.
223599548|NCT02980133|DRUG|Fluticasone Propionate/Salmeterol|Fluticasone propionate/salmeterol was administered via MDPI per the dose and schedule specified in the arm.
223599549|NCT02980133|DRUG|Placebo MDPI|Matching placebo was administered via MDPI per the schedule specified in the arm.
223599550|NCT05141084|OTHER|Education, lifestyle|The weight loss program itself is the intervention, which will involve lifestyle modifications and intervention.
223599551|NCT05387668|DRUG|BGB-23339|Administered orally as a tablet.
223599552|NCT05387668|DRUG|Placebo|Administered orally as a tablet.
223599553|NCT02919514|OTHER|Physical training on hard surface.|Physical training on hard surface.
223748586|NCT02182362|DRUG|Placebo|
223748587|NCT00005926|DRUG|Gemcitabine|
223748588|NCT00005926|DRUG|Herceptin|
223748589|NCT00005926|PROCEDURE|Radiation therapy|
223748590|NCT03463564|DEVICE|Insulin pump|Continuous subcutaneous insulin infusion consisting of the delivery of insulin lispro as basal rate and boluses administered before meals.
223748591|NCT03463564|DRUG|Insulin injections|Four injections of insulin daily consisting in three bolus of a rapid-acting analog lispro or aspart before breakfast, lunch and dinner and one injection of insulin glargine or degludec at bed-time of basal insulin
223748592|NCT01707953|DRUG|Midodrine|Midodrine 5mg as capsule, administered twice (5 and 23 hours after end of surgery).
223748593|NCT01707953|DRUG|Placebo|Placebo capsule to mimic midodrine
223748594|NCT04903327|BIOLOGICAL|COVI-MSC|COVI-MSC are allogeneic culture-expanded adipose-derived mesenchymal stem cells
223748595|NCT04903327|DRUG|Placebo|Excipient solution
223748596|NCT04760912|DRUG|Rocuronium|Rocuronium used for neuromuscular blokade during anesthesia and anesthesia without rocuronium
223748597|NCT04760912|PROCEDURE|General anesthesia for surgery|General anesthesia with standard anesthetic monitoring,
223748598|NCT00097799|DRUG|Tipranavir|500 mg twice daily
223748599|NCT00097799|DRUG|Ritonavir|200 mg twice daily
224199205|NCT01650142|OTHER|No intervention|No intervention
224199206|NCT06566651|OTHER|Emotion Discrimination Task (EDT)|It estimates the subjective bias and sensitivity in discriminating between happy and angry facial expressions of different intensities of emotional expression
224199207|NCT04945226|DRUG|Finasteride 1mg Tablet|Propecia Tablet 1mg
224199208|NCT04945226|DRUG|IVL3001|Finasteride long acting injection
224199209|NCT03186287|OTHER|Eccentric training|Eccentric phase of resistive shoulder exercises will be performed three sets of 15 repetitions once a day for 12 weeks using therabands. Participants will be supervised by the physiotherapist 3 days a week for the first 6 weeks, 2 days a week for the next 3 weeks and 1 day a week for the last 3 weeks.
224199210|NCT03186287|OTHER|Concentric training|Concentric phase of resistive shoulder exercises will be performed three sets of 15 repetitions once a day for 12 weeks using therabands. Participants will be supervised by the physiotherapist 3 days a week for the first 6 weeks, 2 days a week for the next 3 weeks and 1 day a week for the last 3 weeks.
224199211|NCT03186287|OTHER|Standard physiotherapy|The participants will receive standard physiotherapy. The standard physiotherapy exercises will be supervised by the physiotherapist, same as intervention exercises.
224199212|NCT03824015|BEHAVIORAL|Keeping Adults Physically Active (KAPA) intervention|The Keeping Adults Physically Active (KAPA) intervention included six 60-90 minute group motivational interviewing sessions which were supported by a pedometer and a file containing information about locally run physical activity services, a home exercise booklet and written information on different types of lifestyle and transport related physical activity. During sessions the KAPA participants created physical activity plans and reflected on their physical activity diaries and personal physical activity goals. Various sub-sets of behaviour change techniques were delivered to help support the participants in continuing to be active.
224199213|NCT03824015|OTHER|Usual Care|Usual care was delivered for the duration of the KAPA feasibility study. The usual care participants finished the original Falls Management Exercise program and went on to being offered the service provider's usual care package. Upon initiating the KAPA feasibility study it was unknown what the service provider would deliver as usual care. Therefore a study objective was to describe the usual care package delivered by the service providers.
224199214|NCT06344676|OTHER|Cognitive|Tree 10 minutes individual sessions per week involving memory, attention and executive functions tasks.
224199215|NCT06344676|OTHER|Mobility|Two 30 minutes group session per week involving physical activity assisted by a social robot.
224199216|NCT06344676|OTHER|Social|One 60 minutes group session per month assisted by a social robot that facilitates talking about costumes and traditions.
224199217|NCT06344676|OTHER|Relational|Unrestricted individual interaction of the user with the Pepper robot to obtain information of interest for the user (menu, time, date, place and calendar of activities of the residential. center) and 1 individual monthly videoconference with the family of 10 minutes of duration.
224199218|NCT06344676|OTHER|Usual Care|Attentions and treatments received by the persons before the enrollment in the study.
224199219|NCT01114126|DRUG|Neu-P11|comparison of different dosages of drug
224199220|NCT01114126|DRUG|Neu-P11 placebo|comparison of different dosages
224199221|NCT02966366|DEVICE|Cochlear implant|
224199222|NCT02372786|DRUG|2,5% lidocaine / 2,5% prilocaine cream|The treatment area will be divided in two equal parts with white markings. Between these two areas an area of 1 cm will be marked. This area will be left untreated, to avoid possible spill-over effects of the two anaesthetic creams. A thick layer of 2,5% lidocaine / 2,5% prilocaine cream will be applied on one side to the intact skin under plastic occlusion (average of 1,5-2g per 10 cm2) 60 minutes before laser treatment.
224311218|NCT02730351|DRUG|Placebo via DISKUS / ACCUHALER|Placebo will be administered via DISKUS / ACCUHALER, twice daily, once in the morning and once in the evening
224311219|NCT04838548|DRUG|MRG003|Administered intravenously
224311220|NCT00128830|DRUG|Etravirine (ETR)|Participants will receive 800 mg of ETR (2 x 4 tablets of formulation TF035) twice daily and after the formulation switch they will receive 200 mg of ETR (2 x 2 tablets of formulation F060) twice daily until the participants benefitted from etravirine or it became comercially available.
223599554|NCT02919514|OTHER|Physical training on sand surface.|Physical training on sand surface.
223599555|NCT02919514|OTHER|Physical training on soft surface.|Physical training on soft surface.
223599556|NCT01954108|DEVICE|hyaluronic acid sodium salt|
223599557|NCT01954108|DEVICE|ESWT|
223599558|NCT01969032|DRUG|Paclitaxel, Carboplatinum, Doxorubicin, Endoxan, Capecitabine|Paclitaxel 60 mg/m2 IV weekly plus Carboplatinum AUC2 IV weekly for 9 weeks, then Doxorubicin 25 mg/m2 IV weekly plus Endoxan 50 mg per os q.i.d. plus Capecitabine 500 mg t.i.d for 9 weeks
223599559|NCT00384332|DRUG|orally-disintegrating olanzapine|5 to 20 mg (daily) orally disintegrating olanzapine for approx.8 weeks.
223599560|NCT00384332|DRUG|regular olanzapine|5-20 mg. olanzapine daily for approximately 8 weeks.
223599561|NCT02560012|DRUG|Sunitinib|One 50-mg capsule taken orally once daily, on a schedule of 4 weeks on treatment followed by 2 weeks off
223599562|NCT02560012|DRUG|Temsirolimus|25 mg by an IV infusion over 30-60 minutes, once a week
223599563|NCT02560012|DRUG|Sorafenib|400 mg (2 tablets) orally twice daily without food
223599564|NCT02560012|DRUG|Pazopanib|800 mg orally once a day without food, at least 1 hour before or 2 hours after a meal
223599565|NCT02560012|DRUG|Everolimus|10 mg orally once daily with or without food
223599566|NCT02560012|DRUG|Axitinib|5 mg orally twice daily
223599567|NCT01007838|OTHER|Progressive resistance training programme|Progressive resistance training programme using a dialysis specific fitness machine: 80 % of predicted one repetition max, weight lifted will be increased when three sets of ten repetitions can be completed without failure.
223599568|NCT01007838|OTHER|Sham exercise|Lower body stretching exercise using the easiest rehabilitation elastic Theraband
223599569|NCT01007838|OTHER|Progressive resistance training|Progressive resistance training programme using a dialysis specific fitness machine: 80 % of predicted one repetition max, weight lifted will be increased when three sets of ten repetitions can be completed without failure.
223599570|NCT01007838|OTHER|Sham exercise|Lower body stretching exercise using the easiest rehabilitation elastic Theraband
223599571|NCT06392269|DIAGNOSTIC_TEST|Tasso+SST|Clinical evaluation of capillary blood samples collected using the Tasso+SST device for downstream analyte testing.
223599572|NCT05964543|DRUG|Q-1802 Injection,Oxaliplatin Injection,Capecitabine|Q-1802：A dose Q-1802 will be administered intravenously Q2W. XELOX（oxaliplatin，capecitabin）: 21 days as a cycle Oxaliplatin will be administered 130mg/m2 as a 2-hour IV infusion,administer once on the first day, with 21 days as a cycle Capecitabine will be administered 1000mg/m2 orally twice daily (D1-D14),21ds is one cycle.
223748600|NCT03966755|BEHAVIORAL|UFA dietary recommendations|The face-to-face intervention will be performed by a research nutritionist that reviews the dietary recall and provides a list of commonly available foods rich in unsaturated fatty acids (UFA) (monounsaturated fatty acids (MUFA) and polyunsaturated fatty acids (PUFA)), together with individual instructions on how to integrate the recommended foods in the daily dietary pattern based on the dietary recall, and also to emphasize that the recommended food should be consumed as listed, and not as part of processed food (i.e., guacamole for avocado, hazelnut chocolate for nuts, pesto for olive oil, fish sticks for fatty fish). Extra-virgin olive oil or canola oil or nuts will be considered first choice for daily consumption of UFA-rich food, but a list of daily food substitutes will be also provided .
223748601|NCT00019396|DRUG|flt3 ligand|
223748602|NCT00019396|DRUG|gp100 antigen|
223748603|NCT00019396|DRUG|MART-1 antigen|
223748604|NCT00019396|DRUG|Montanide ISA-51|
223748605|NCT00019396|DRUG|tyrosinase peptide|
223748606|NCT05922631|PROCEDURE|Airway pressure release ventilation|ventilator parameters were set according to the study protocol, P high: Tidal volume (VT) was set at 6ml/kg of ideal body weight, and plateau pressure (Pplat) was measured. Initial Phigh was set at Pplat, usually 20-32 cmH2O. The APRV end-expiratory flow rate was set at 75% of the peak expiratory flow rate.
223748607|NCT05922631|PROCEDURE|low tidal volume|The ARDSnet method was used for LTV mechanical ventilation, and the tidal volume was set according to 4-8ml/kg, so that the Pplat was \<30cmH2O
223748608|NCT00821470|PROCEDURE|core decompression|core decompression procedure only
223748609|NCT00821470|PROCEDURE|Bone marrow implantation into the necrotic lesion|
223748610|NCT01572337|PROCEDURE|Non-invasive ventilation|Early non-invasive ventilation will be given to patients at an early stage of acute respiratory failure
223748611|NCT01572337|OTHER|Standard care|
223748612|NCT05462028|DEVICE|Vibration training|The vibration sessions were performed and supervised by a stroke care experienced registered nurses/researchers who had both nurse and physiotherapist license. The wearable leg vibration training with vibration frequency = 30 Hz, vibration amplitude = 1 mm in the WG was applied by the wearable leg vibration device (Myovolt, New Zealand) which fits comfortably around the knee and hamstring or calf and delivers focal vibration treatment. While the lower-extremity weight bearing vibration training with vibration frequency = 20 Hz, vibration amplitude = 3 mm in the LG was applied the Cozy Fit (HY-806, China) vibration device with vertical direction, which participants stand with both feet upright on the vibrator in a seated position.
223748613|NCT05462028|BEHAVIORAL|ergometer exercise|ergometer exercise training
223748614|NCT02067910|DRUG|Abatacept SC|Weekly subcutaneous administration of 125 mg Abatacept
223748615|NCT02250443|DRUG|BYM338 (Bimagrumab)|
223748616|NCT01549964|DRUG|Fasiglifam (TAK-875)|Fasiglifam (TAK-875) tablets
223748617|NCT01549964|DRUG|Sitagliptin|Sitagliptin tablets
223507101|NCT04723069|DRUG|Test Group|metronidazole tablets + doxycycline hyclate tablets simulant are consecutively taken for 14 days, while Fuke Qianjin capsule is consecutively taken for 28 days.
223507102|NCT06581666|OTHER|No special intervention, all participants will be asked to complete same set of questionnaire.|No special intervention, all participants will be asked to complete same set of questionnaire.
223507103|NCT04599335|DEVICE|2% HA|2% HA
223507104|NCT04913675|BIOLOGICAL|sotrovimab|Sotrovimab 500 mg given by intravenous infusion over 15 min
223507105|NCT04913675|BIOLOGICAL|sotrovimab|Sotrovimab 500 mg given by intramuscular injection
223507106|NCT04913675|BIOLOGICAL|sotrovimab|Sotrovimab 250 mg given by intramuscular injection
223507107|NCT04913675|BIOLOGICAL|sotrovimab|Sotrovimab 2000 mg given by intravenous infusion over 60 min
223507108|NCT04913675|BIOLOGICAL|Sotrovimab|Sotrovimab 2000 mg given by intravenous infusion over 30 min
223748618|NCT01549964|DRUG|Placebo|Placebo-matching tablets
223748619|NCT00521196|DEVICE|DC Stimulator (Transcranial Direct Current Stimulator)|Subjects will receive a total of 10 sessions of either active tDCS or sham tDCS over a four-week period (administered every other day during weekdays over the course of one month). During each tDCS session, two electrodes are placed over selected areas of the brain. The anode is placed on the motor cortex contralateral to the side where migraines predominant; the cathode is placed near the supraorbital area, opposite the anode. A small battery powered device drives 2 mA of direct current through the two electrodes. The direct current will flow through the electrodes, penetrate the scalp, and create a flow of electrical current in the brain. The procedure will last 20 minutes. For sham tDCS, an alternate method of stimulation will be used.
223507109|NCT04913675|BIOLOGICAL|Sotrovimab|Sotrovimab 2000 mg given by intravenous infusion over 15 min
223507110|NCT04913675|BIOLOGICAL|Sotrovimab|Sotrovimab up to 3000 mg given by intravenous infusion over 90 min
223507111|NCT01559285|DRUG|0.75% ropivacaine concentration|0.75% ropivacaine 8ml was injected epidurally after induction of general anesthesia
223507112|NCT01559285|DRUG|0.375% ropivacaine concentration|0.375% ropivacaine 8ml was injected epidurally after induction of general anesthesia
223507113|NCT01559285|DRUG|0.2% ropivacaine concentration|0.2% ropivacaine 8ml was injected epidurally after induction of general anesthesia
223507114|NCT00000483|DRUG|estrogen|
223507115|NCT00000483|DRUG|clofibrate|
223507116|NCT00000483|DRUG|dextrothyroxine sodium|
223507117|NCT00000483|DRUG|niacin|
223507118|NCT00114478|DRUG|Epinephrine|
223507119|NCT00114478|DRUG|albuterol (salbutamol)|
223507120|NCT05020522|DIAGNOSTIC_TEST|Luminal Index MRI (LI-MRI)|Multiecho T2 sequence; eventual biopsy of lesion(s) detected with LI-MRI only.
223507121|NCT05020522|DIAGNOSTIC_TEST|LI-MRI targeted prostate biopsy|Biopsy targeted to suspicious lesions detected with LI-MRI only
223507122|NCT05020522|DIAGNOSTIC_TEST|Plasma methylation signature (ctMethSig)|Blood sample.
223507123|NCT05812599|OTHER|Educational Module|The COVID Test Learning Module will present four multi-part character scenarios that someone might experience when considering testing for COVID-19. Participants will answer questions about the character's behavior. Accurate guidelines will be provided in response to each scenario to educate participants about what to do in nuanced COVID testing decision-making situations.
223748620|NCT04181333|DRUG|TRASTUZUMAB BS|"Regimen A or regimen B is used for HER2-overexpressing breast cancer.~RegimenB is used for HER2-overexpressing unresectable advanced or recurrent gastric cancer in combination with other anti tumor agent(s).~Regimen A: The recommended dose for trastuzumab (genetical recombination) \[Trastuzumab Biosimilar 3\] in adult patients is 4 mg/kg (weight) at initial dose and 2 mg/kg after the second dose, in both of them, by IV drip infusion over 90 minutes once daily every week.~Regimen B: The recommended dose for trastuzumab (genetical recombination) \[Trastuzumab Biosimilar 3\] in adult patients is 8 mg/kg (weight) at initial dose and 6 mg/kg after the second dose, in both of them, by IV drip infusion over 90 minutes once daily every 3 weeks.~If the initial dose is well tolerated, the dosing time after the second dose can be shortened up to 30 minutes."
223748621|NCT02290821|DRUG|placebo|
223748622|NCT02290821|DRUG|Placebos|
223748623|NCT05231785|DRUG|ALN-APP|ALN-APP will be administered intrathecally (IT)
223748624|NCT05231785|DRUG|Placebo|Placebo will be administered IT
223748625|NCT04330560|DEVICE|Exercise telemonitoring connects to healthcare platform|The participant is required to wear the fitness tracker every day during waking hours throughout the 12 weeks of intervention (except during sleeping, bathing, and swimming) link to the healthcare practitioner
223748626|NCT04330560|DEVICE|Exercise self-monitoring|The participant is required to wear the fitness tracker every day during waking hours throughout the 12 weeks of intervention (except during sleeping, bathing, and swimming) for exercise self-monitoring.
223748627|NCT04330560|DEVICE|Exercise teleconsultation|Conducted through smartphone video call app.
223748628|NCT04330560|PROCEDURE|Other CR components|Including dietary, psychology, education conducted at the center.
223748629|NCT04330560|PROCEDURE|Standard care|Undergoing standard care by cardiac rehabilitation at the center
223748630|NCT03559322|DEVICE|iNAP® Lite Sleep Therapy System|Class II intraoral devices for snoring and/or obstructive sleep apnea
223748631|NCT02449174|BIOLOGICAL|Frozen Microbiota|Frozen Microbiota will be delivered via enema route.
223748632|NCT02449174|BIOLOGICAL|Lyophilized Microbiota|Lyophilized Microbiota will be delivered orally.
223748633|NCT06115863|OTHER|Early Cognitive Stimulation Interventions|early cognitive stimulation interventions refer to multi-dimensions of stimulative evidenced-based interventions, which are done during the first 24 hours from patient admission to the ICU. They are designed to stimulate cognitive function domains that are impacted by delirium such as attention, registration, recall, and language.
223748634|NCT03710655|DRUG|Apitox - pure honeybee toxin|Intradermal injection of 0.01 microliters
223748635|NCT03710655|DRUG|Placebo|Intradermal injection of 0.01 microliters
223748636|NCT02009631|DRUG|Veliparib (ABT-888)|
223748637|NCT02009631|DRUG|Placebo|
223748638|NCT01914406|OTHER|high intense interval training|Each AIT session consisted a 10 minute warm-up period followed by 16 minutes of interval training consisting of intervals of 4-3-2 and 1 minutes duration at 85-95% of their peak capacity separated by 2-4 min active rest.
223748639|NCT01914406|OTHER|continuous moderate training|Continued exercise 45 min.
223748640|NCT04174287|DRUG|F-18-AV45|The study will enroll 200 patients with prodromal AD and mild AD dementia and 100 normal controls, men and women aged 55-80 years across core clinical criteria of prodromal AD and mild AD dementia based on IWG-2 criteria.
223748641|NCT06050499|DEVICE|Microdialysis catheter + biosensor|"Microdialysis catheter from linton instrumetal 63 MD Catheter"
223748642|NCT01272830|DRUG|Placebo|Two capsules taken twice daily with meals
223748643|NCT01272830|DRUG|Apatone®B|Two capsules taken twice daily with meals
223748644|NCT00751348|BIOLOGICAL|PriorixTM|Subcutaneous administration in left upper arm
223748645|NCT00751348|BIOLOGICAL|VarilrixTM|Subcutaneous administration in right upper arm
223748646|NCT00751348|BIOLOGICAL|Priorix-Tetra®|Subcutaneous injection in left upper arm
223748647|NCT06348303|DRUG|Metaxalone m640 mg oral tablet|Metaxalone partially micronized 640 mg tablet
223748648|NCT06348303|DRUG|Metaxalone 800 mg oral tablet|Metaxalone non-micronized 800 mg oral tablet
223748649|NCT02284646|OTHER|Personalized physical training program|9-week personalized physical training program (ergometric bicycle)
223748650|NCT03880903|DRUG|normal saline and salbutamol|patients will recieve treatment with nebulized salbutamol and normal saline every 4 to 6 in hours
223748651|NCT03880903|DRUG|hypertonic saline and salbutamol|patients will recieve treatment with nebulized salbutamol and hypertonic saline 3% in adose of 4ml every 4 to 6 hours
223748652|NCT03880903|DRUG|Hypertonic saline|patients will recieve treatment with nebulized hypertonic saline 3% in adose of 4ml every 4 to 6 hours
223748653|NCT05210790|DRUG|Placebo|Placebo
223507124|NCT03075943|DIETARY_SUPPLEMENT|InSea2|Daily supplement: 2 capsules of InSea2
223507125|NCT03075943|DIETARY_SUPPLEMENT|Placebo|Daily supplement: 2 capsules of Placebo
223507126|NCT02975700|DRUG|PLX3397|1000 mg/day (400 mg in the morning and 600 mg in the evening)
223748654|NCT05210790|DRUG|Rusfertide|Experimental drug
223748655|NCT01986868|OTHER|Coronary MR Angiography (CMRA)|Stable patients who have undergone a clinically indicated CCTA study for suspected Coronary Artery Disease will undergo a research CMRA with contrast (Multihance or Optimark)total dose of up to 0.2 mmol/kg IV. Possible administration of oral beta-blocker (metoprolol)intravenous doses of 5mg IV metoprolol may be given every 2 minutes up to a maximal dose of 15 mg IV.
223748656|NCT06470464|DRUG|Thalidomide combined with TGA chemotherapy (nab-paclitaxel + gemcitabine+ epirubicin)|The oral dose of thalidomide is 1.5-2.5mg/kg/d daily (maximum 28g). Each cycle lasts for 21 days (every three weeks), and if treatment parameters are met as described in the study, cycle two and subsequent cycles begin on day 22. Treatment will be discontinued if there is drug-related dose-limiting toxicity or disease progression. Tumor response assessment will be repeated using AFP and LDH every one cycle and imaging examination every two cycles. Children who complete the trial may continue this regimen or undergo surgery or radiation therapy if their disease goes into remission.
223507127|NCT03568071|DRUG|MOR 106|The active pharmaceutical drug substance of MOR106 is a human immunoglobulin gamma-1 (IgG1) monoclonal antibody that binds with a high apparent affinity to human IL-17C.
223507128|NCT03568071|DRUG|Placebo|A sodium chloride infusion container with IV solution without addition of MOR106 drug product will be used as placebo in the proposed clinical study.
223507129|NCT04981756|OTHER|observation|This observational study does not have any intervention.
223748657|NCT04258943|DRUG|Bosutinib|"Patients with R/I disease are enrolled at a dose of 400 mg/m2 (DL2B) based on tolerability and PK analysis. Once the RP2D for R/I patients (RP2DR/I) is determined in the Phase 1, subsequent patients with R/I disease will be enrolled at the RP2DR/I for this subpopulation for the Phase 2 component of the study (see section 1.6.3 and section 3 for details).~\- Patients with newly diagnosed disease are being enrolled on Phase 2 component only, at RP2DND dose of 300 mg/m2. (see section 1.6.3 and section 3 for details)"
223748658|NCT02730299|DRUG|NiCord® (omidubicel)|
223748659|NCT02730299|OTHER|Cord Blood Unit|Cord blood unit
223748660|NCT03475381|DRUG|Ivacaftor+lumacaftor|1 year follow-up after initiation of ivacaftor+lumacaftor
223748661|NCT06640478|OTHER|NUTRI-Beta Counseling|Dietary Counseling focused on anti-inflammatory foods
223599573|NCT04348006|DRUG|Bortezomib 3.5 MG|"VCD protocol~* V, Alvocade®: Day 1, 4, 8, 11 (1.3 mg/m2 SC)~* C, Cyclophosphamide: 300 mg/m2 IV over 30 min (day 1, 8, 15)~* D, Dexamethasone oral: 40mg (days 1 to 4)~VRD protocol:~* V, Alvocade®: Day 1, 4, 8, 11 (1.3 mg/m2 SC)~* R, Lenalid® cap 25 mg po (day 1 to 21)~* D, Dexamethasone oral: 40mg (days 1 to 4)"
223599574|NCT03483298|OTHER|ICSI|The cryopreserved pre-TESA ejaculate and TESA specimen will be thawed on the day of oocyte retrieval per protocol for ICSI
223599575|NCT06115356|DIAGNOSTIC_TEST|Vitamin D Plasma Level|Blood test measured in ng/ml
223599576|NCT06115356|DIAGNOSTIC_TEST|Bioelectrical Impedance Analysis (BIA) technique|Measurements of body composition were conducted with Bioelectrical Impedance Analysis (BIA) technique, asking the participants to stand on the device barefoot to complete the analysis. Among all parameters, BMI, phase angle (PhA), total body water (TBW), extracellular (ECW) and intracellular water (ICW), body fat index, and fat and muscular mass were recorded.
223599577|NCT06115356|DIAGNOSTIC_TEST|Ferritin|Ferritin plasma levels were measured in μg/L
223599578|NCT06115356|DIAGNOSTIC_TEST|C reactive protein (CRP)|CRP plasma levels were measured in mg/L
223599579|NCT06115356|DIAGNOSTIC_TEST|Inflammation-based prognostic scores|Glasgow Prognostic Score/modified Glasgow Prognostic Score (GPS/mGPS), Prognostic Nutritional Index (PNI), Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte ratio (PLR), Lymphocyte-to-monocyte ratio (LMR), Systemic immune-inflammation index (SII) were calculated using blood test results
223599580|NCT06115356|OTHER|Liver biopsy|A liver biopsy was used to study nonalcoholic steatohepatitis (NASH) and fibrosis according to the Kleiner-Brunt classification
223599581|NCT04185389|OTHER|HPV and cytology co-testing (via Liquid based collection device)|Liquid-based cytology co-testing is a procedure in which that a cervical sample is taken, and can be co-tested for HPV and standard cytology at the same time. It is collected in the same way that a traditional Pap is collected
223599582|NCT02574689|BEHAVIORAL|HIPP|The physical activity intervention is based on the Social Cognitive Theory and Transtheoretical Model and includes motivation-matched physical activity manuals and individually-tailored computer expert system feedback reports. Tailored reports are based on participants' monthly update survey data and cover: 1) current stage of change; 2) self-efficacy; 3) decisional balance; 4) social support; 5) outcome expectations; 6) enjoyment; 7) progress feedback; 8) normative feedback; 9) self regulation. The computer expert system draws from a bank of 330 messages addressing different levels of psychosocial and environmental factors affecting physical activity.
223599583|NCT02574689|BEHAVIORAL|Wellness contact control|"Cancer prevention information on topics other than physical activity (e.g., Add Fruits and Veggies to Your Diet) from the American Cancer Society website (www.cancer.org) are mailed to control participants at the same time points that the HIPP Intervention participants receive their physical activity intervention materials."
223599584|NCT02725229|PROCEDURE|parasternal block|parasternal block and PCA for sternotomy pain
223599585|NCT02725229|DEVICE|TENS group|TENS and PCA for sternotomy pain
223748662|NCT06640478|DIETARY_SUPPLEMENT|Standard dietary counseling|Standard of Care therapy: Nutrition counseling per the ADA clinical guidelines and USDA MyPlate model
223748663|NCT06640478|DIETARY_SUPPLEMENT|Free weekly produce foods|Free weekly produce
223599586|NCT02725229|DEVICE|control group|PCA for sternotomy pain
223599587|NCT03147534|DEVICE|InstaTemp MD|The InstaTemp MD is a hand held electronic infrared thermometer that is intended to accurately measure human body temperature without contact with the human body.
223599588|NCT03147534|DEVICE|"Welch Allyn, rectal"|"The Welch Allyn rectal thermometer is intended to measure human body temperature."
223599589|NCT03147534|DEVICE|"Welch Allyn, oral"|"The Welch Allyn oral thermometer is intended to measure human body temperature."
223599590|NCT03147534|DEVICE|Covidien, tympanic|The Covidien tympanic thermometer is intended to measure human body temperature.
223599591|NCT06396624|RADIATION|Intervention Group photobiomodulation|Seven spots on child's thorax and two spots on the face will be irradiated with 40s per point of photobiomodulation.
223599592|NCT06396624|OTHER|Control Group|The photobiomodulation device will positioned in seven spots on thorax and two in child's face, but it will not emit any time of radiation, since the device will be turned off.
223599593|NCT00695422|GENETIC|polymerase chain reaction|PCR for HPV DNA detection, performed on specimens collected at baseline, every 6 months while on parent protocol, treatment discontinuation on parent protocol, final visit on parent protocol.
223599594|NCT00695422|OTHER|cytology specimen collection procedure|Detection of HPV-associated neoplasia at baseline, every 6 months while on parent protocol, treatment discontinuation on parent protocol, final visit on parent protocol.
223748668|NCT04991935|DRUG|CC-93538|CC-93538
223748669|NCT06971146|OTHER|Nurse-Led Self-Management Support|"The intervention offers four distinct support options. Patients are free to choose the option that best suits their preferences and needs.~I1: App-Based Monitoring - Patients receive an app that provides relevant health information, including short educational videos, images, and other resources. Every three months, the app sends a pop-up reminder.~I2: Reminder by Letter - Patients receive a friendly reminder every three months via e-Boks or postal mail (for those without e-Boks access) encouraging continued treatment adherence.~I3: SMS Reminder - Patients receive a text message every three months to remind them to continue their treatment.~I4: Phone Call Check-In - A nurse contacts the patient by phone three times per year at scheduled intervals to provide support and ensure they remain on track with their treatment."
223748670|NCT06971146|OTHER|GP-follow up|Patients in the control group will be discharged from the hospital and continue with routine care provided by their general practitioner (GP). The GP will receive a discharge letter outlining the recommended treatment plan. In addition, patients will receive a letter containing key information about their condition, along with a recommendation to consult their GP annually for ongoing disease monitoring.
223748671|NCT06531824|DRUG|BI 690517|BI 690517
223599595|NCT00695422|OTHER|histological technique|Detection of HPV-associated neoplasia at baseline, treatment discontinuation on parent protocol, final visit on parent protocol.
223599596|NCT00695422|PROCEDURE|colposcopic biopsy|Where observed during HRA, collection of tissue for detection of HPV-associated neoplasia at baseline, treatment discontinuation on parent protocol, final visit on parent protocol.
223599597|NCT00889642|DEVICE|Iontophoretic Drug Delivery System with Lidocaine/Epinephrine|Active- 10.5% Lidocaine/0.179% Epinephrine
223599598|NCT00889642|DEVICE|Iontophoretic Drug Delivery System with Epinephrine|Placebo- 0.179% Epinephrine
223599599|NCT04888013|OTHER|Positive Birth Environment|The intent is to surround the woman and her caregivers with specific types of auditory, visual, and tactile stim uli. One key feature of the ambient room is what is missing-the standard hospital bed. As an alternative, a portable double-sized mattress with several large pillows is set up in a corner of the room. The intent is to allow the woman freedom in positioning and to permit close contact with support people, and to limit the routine use of continuous elec tronic fetal heart rate monitoring and other technologies during normal labor. Lighting is dimmed. A wide variety of music selections are also available.
223599600|NCT05329064|BIOLOGICAL|BNT162b2 Pfizer-BioNTech/Comirnaty|"The study will use 10mcg of BNT162b2 (Pfizer-BioNTech/Comirnaty®) for each dose.~Two doses will be given at 2 months apart between doses."
223599601|NCT02207218|DRUG|turoctocog alfa|No treatment given. Patients will be treated with commercially available NovoEight®. Patients will be treated according to local clinical practice at the direction of the physician.
223599602|NCT00996983|DRUG|ziconotide|intrathecal ziconotide starting at 2.4 micrograms/day, with titration daily to achieve adequate pain control up to maximum dose of 21.6 micrograms/day
223599603|NCT02724527|DRUG|Cavosonstat|CFTR modulator that stabilizes CFTR
223599604|NCT02724527|DRUG|Placebo|Matched Placebo capsule
223599605|NCT01805557|DRUG|R-DHAP|"* Rituximab 375 mg/sqm iv day 0 or 1~* Cisplatin 100 mg/sqm iv day 1 in 6-hours infusion~* Cytarabine 2000 mg/sqm in 3-hours infusion iv day 2 and day 3~* Dexamethasone 40 mg day 1-4~* Pegfilgrastim 6 mg sc monodose 24 hours after the end of chemotherapy or G-CSF from day 5 till stem cell harvest during mobilization's course (II o III cycle R-DHAP)~* Rituximab 375 mg/sqm iv 24 hours before apheresis as purging in vivo during second courses of therapy"
223599606|NCT01805557|DRUG|BR-DHAP|"* Rituximab 375 mg/sqm iv day 0 or 1~* Bortezomib SC 1.5 mg/sqm day 1, day 4~* Cisplatin 100 mg/sqm iv day 1 in 6-hours infusion~* Cytarabine 2000 mg/sqm in 3-hours infusion iv day 2 and day 3~* Dexamethasone 40 mg day 1-4~* Pegfilgrastim 6 mg sc monodose 24 hours after the end of chemotherapy or G-CSF from day 5 till stem cell harvest during mobilization's course (II o III cycle R-DHAP)~* Rituximab 375 mg/sqm iv 24 hours before apheresis as purging in vivo during second courses of therapy Chemotherapy R-DHAP and BR-DHAP will be repeated every 28 days."
223599607|NCT00478686|PROCEDURE|Phlebotomy|5 to 7.5 milliliter (mL) Blood Sample
223599608|NCT00837850|DEVICE|Bone cement 1|Bone cement SmartSet® HV
223599609|NCT00837850|DEVICE|Bone cement 2|Bone cement Palacos R
223599610|NCT01392287|DRUG|Memantine|"Dosing Form: Tablet~Dosage: 5mg, 10 mg~Description:~Memantine hydrochloride (Namenda®), a low to moderate affinity uncompetitive (open-channel) NMDA antagonist, is manufactured and supplied by Forest Laboratories, Incorporated. Only the subjects in the depression group will receive the study drug memantine HCl. Per psychiatrist's instructions, subjects may remain on the maximum dosage of memantine HCl allowed by the study protocol for a given week, or reduce the dosage if concerns regarding tolerability arise. The dosage of memantine HCl cannot be increased more rapidly than the dosing schedule listed below.~Memantine HCl Dosing Schedule:~5 mg qAM week 1 5 mg qAM and 5 mg qHS for week 2 10 mg qAM and 5 mg qHS for week 3 10 mg BID for week 4, 5, 6, 7, and 8"
223599611|NCT05964036|DEVICE|active TMS|Participants will receive 10 sessions per day of 1800 pulses per session, lasting for 5 days. Individualized target in the DMPFC will be generated using the pBFS method
223599612|NCT05964036|DEVICE|sham TMS|The parameters in the sham arm are the same as in the active stimulation group. Stimulation was delivered by the same device as the active group fitted with a sham coil
223599613|NCT04927572|DRUG|FMX114|Active Comparator
223599614|NCT04927572|OTHER|Vehicle|Placebo Comparator
223599615|NCT05785936|PROCEDURE|Desensitization|Patients that received apheresis and anti-cluster of differentiation antigen 20 for desensitization priori to kidney transplantation
223599616|NCT00852241|DRUG|Restalyne|one syringe of Restylane® (1.0cc) will be used total for both tear trough areas.
223599617|NCT00852241|DRUG|Perlane|One syringe of Perlane® (1.0cc) will be used total for both tear trough areas.
223748672|NCT06531824|DRUG|Placebo matching BI 690517|Placebo matching BI 690517
223748673|NCT06531824|DRUG|Empagliflozin|Empagliflozin
223748674|NCT06421779|BEHAVIORAL|Virtual reality (VR)|Children watch underwater experience video by wearing the virtual reality glass during the skin prick test.
223748675|NCT05894421|DRUG|TQB2223 injection+ Penpulimab Injection|TQB2223 is an anti lymphocyte activation gene-3 (LAG-3) antibody. Penpulimab Injection is an anti-PD-1 antibody.
224311221|NCT00128830|DRUG|Nucleotide reverse transcriptase inhibitors (NRTIs)|Participants will receive 2 additonal approved antiretrovirals (ARVs) along with ETR. ARVs may be NRTIs and/or allowed protease inhibitors (PIs) and/or enfuvirtide (ENF).
223599618|NCT02339792|OTHER|E-learning|e-learning program of medical education, focused on teaching and implementing Comprehensive Geriatric Assessment (CGA) added to geriatric pharmacological notions (GPNs)
223599619|NCT02524418|PROCEDURE|Cholangiopancreatoscopy|An ERCP with cholangioscopy/pancreatoscopy will be performed using the Spyglass DS. Clinical outcomes will be collected and analyzed.
223599620|NCT03342118|DRUG|Phloroglucin(Flospan®)|The experimental group was taken with Phloroglucin(Flospan®) before endoscopy.
223599621|NCT03342118|DRUG|Normal saline|The control group was treated with normal saline before endoscopy
223748676|NCT01776775|DEVICE|Abdominal binder|"The abdominal binder is worn from immediately after the operation and continuously for 7 days and nights. The belts are standard abdominal binders (ostomy belts) from ETO garments© with standard height of 22 cm. and five different sizes in width (S, M, L, XL, XXL- depending on waist measure). A fitting will be done for all included patients before the operation by waist measurement according to the recommendation from the company (see below). When applied, the patients are advised to apply the belt in a lying position."
223748677|NCT01209364|DEVICE|Durolane is a device, methylprednisolone in a drug|single intraarticular injection
223748678|NCT00002067|DRUG|Megestrol acetate|
223748679|NCT05300906|BEHAVIORAL|personalized 2-week mobile wellbeing intervention|"For the study, 27 versions of a 2-week mobile wellbeing intervention are created. These versions vary on content (Cognitive Behavioral Therapy, meaning, positive psychology), feedback (text, text with avatar, pre-recorded video) and design (non-gamified, competitively gamified, storyline gamified). At baseline, participants preview all variations and indicate their expected engagement. Participants in the personalized condition will receive the optimal combination of content, feedback and design, based on their baseline engagement scores.~Each version of the intervention consists of a module per day. Each module contains psychoeducation and exercises based on content of the version. Moreover, each module contains pre-specified general feedback and supportive messages."
223748680|NCT05300906|BEHAVIORAL|non-personalized 2-week mobile wellbeing intervention|"For the study, 27 versions of a 2-week mobile wellbeing intervention are created. These versions vary on content (Cognitive Behavioral Therapy, meaning, positive psychology), feedback (text, text with avatar, pre-recorded video) and design (non-gamified, competitively gamified, storyline gamified). At baseline, participants preview all variations and indicate their expected engagement. Participants in the non-personalized condition will receive a random version of the intervention.~Each version of the intervention consists of a module per day. Each module contains psychoeducation and exercises based on content of the version. Moreover, each module contains pre-specified general feedback and supportive messages."
223748681|NCT02039674|BIOLOGICAL|Pembrolizumab|IV on Day 1 of each 3-week cycle prior to chemo/immunotherapy
223748682|NCT02039674|DRUG|Paclitaxel|IV on Day 1 of each 3-week cycle for a maximum of 4 administrations
223748683|NCT02039674|DRUG|Carboplatin|IV on Day 1 of each 3-week cycle for a maximum of 4 administrations
223748684|NCT02039674|BIOLOGICAL|Bevacizumab|IV on Day 1 of each 3-week cycle
223748685|NCT02039674|DRUG|Pemetrexed|IV on Day 1 of each 3-week cycle
224199223|NCT02372786|DRUG|7% lidocaine / 7% tetracaine cream|The treatment area will be divided in two equal parts with white markings. Between these two areas an area of 1 cm will be marked. This area will be left untreated, to avoid possible spill-over effects of the two anaesthetic creams. A thin layer of 7% lidocaine / 7% tetracaine cream (1mm) will be applied on the other side to the intact skin (average of 1,3g Pliaglis per 10 cm2) 60 minutes before laser treatment.
224199224|NCT02372786|DEVICE|Neodymium-doped yttrium aluminium garnet (Nd:Yag) laser|Acne keloidalis nuchae: during this study a 1064 nm Nd:yag laser with a spot size of 7-10 mm, and a fluence of 35-60J/cm2, (depending on the effective and safe clinical response), a pulse duration of 20-35 ms and 2 passes will be used.
224199225|NCT02372786|DEVICE|Q-switched nd Yag laser|Tattoo removal: we will use a 3 mm spotsize and a fluence depending on the absorption of the laser light, which is visible as skin whitening.
224311222|NCT00128830|DRUG|Protease inhibitors (PIs)|Participants will receive 2 additonal approved antiretrovirals (ARVs) along with ETR. ARVs may be NRTIs and/or allowed protease inhibitors (PIs) and/or enfuvirtide (ENF).
224311223|NCT00128830|DRUG|Enfuvirtide (ENF)|Participants will receive 2 additonal approved antiretrovirals (ARVs) along with ETR. ARVs may be NRTIs and/or allowed protease inhibitors (PIs) and/or enfuvirtide (ENF).
224311224|NCT05739552|OTHER|Telerehabilitation program|Application of customised respiratory and/or motor rehabilitation exercises to be carried out directly at the patients' home after hospital discharge in order to evaluate its effects.
223599622|NCT06440551|BEHAVIORAL|TeleSalud Healthy Eating- Physical Activity/Sedentary Behavior (HE-PA/SB)|Participants will meet via telehealth for 4 months (twice a week for 3 months and then once per week for 1 month) for a TeleSalud HE-PA/SB Class, after which they will attend one maintenance meeting per month for 4 months. Weekly, Day 1 (Healthy Eating \& PA-SB Class): Participants will receive a 50-min. healthy eating class. Physical Activity- Sedentary Behavior (PA-SB) Class: By discussing barriers and strategies to overcome barriers, this will help to increase self-efficacy. We will engage in Latino-centered moderate impact (increasing to vigorous) aerobics with Latino or salsa movements and music for 45-50 minutes. Aspects of kickboxing aerobics will be integrated. Goal: Exercise a minimum of 150-250 min./ week of moderate intensity. Weekly, Day 2: PA-SB identical PA-SB to Day 1. Maintenance (Months 5-8): Meetings once/ month for 70 min. for HE/PA-SB class, including 25 min. to discuss diet and PA-SB barriers. Goal: Exercise a minimum of 150-250 min./week.
223599623|NCT06440551|BEHAVIORAL|TeleSalud General Health Intervention|Weekly: Participants will meet via telehealth for 4 months (twice a week for 3 months and then once per week for 1 month) for a TeleSalud General Heath Class, after which they will attend one maintenance meeting per month for 4 months. Participants will meet and discuss general health topics (not diet or PA). Examples of the general health topics are: Back Pain, Muscle Strains, Alcohol Use, Stress \& Coping, Oral and Dental Health, Safety Tips, Emergency Preparedness. The content is relevant to Latinos, and information is focused on Latino men. Maintenance (Months 5-8): Participants will meet via telehealth once/ month for 70 min. to discuss general health topics. To enhance motivation to complete the study and assessments, this group will receive a copy of the TeleSalud HE-PA/SB intervention manual and related materials after the maintenance period ends.
223748686|NCT02039674|BIOLOGICAL|Ipilimumab|IV on Day 1 of each 3-week cycle for a maximum of 4 administrations
223748687|NCT02039674|DRUG|Erlotinib|Orally tablet once daily
223748688|NCT02039674|DRUG|Gefitinib|Oral tablet once daily
223748689|NCT03874520|OTHER|Video triage|The operator will offer the parent calling regarding the sick child to assess the child on video, as compared to the current standard; on the telephone.
223748690|NCT02145728|BEHAVIORAL|Individual Cognitive Functional Therapy|Cognitive functional therapy (CFT) is a novel, patient centred behavioural intervention which addresses multiple dimensions in non-specific chronic low back pain (NSCLBP). It combines a functional behavioural approach of normalising provocative postures and movements while discouraging pain behaviours, with cognitive restructuring of the NSCLBP problem.
223748691|NCT02145728|BEHAVIORAL|Group Exercise Classes|Each class involves a combination of education, exercise and relaxation/mindfulness. The education topics include pain and the nervous system, posture and ergonomics, exercise and relaxation and sleep. The exercise component includes 10 stations of a combination of aerobic, strength and flexibility exercises. These will be walking/jogging on the spot, mini-squats, sit to stands, wall push ups, bridging, step-ups and a combination of leg and low back stretches. The relaxation/mindfulness component will take place at the end of each class and will involve breathing and relaxation of the body.
223748692|NCT02258321|DRUG|PPI-668 tablet|
223748693|NCT02258321|DRUG|PPI-668 capsule|
223748694|NCT02598427|DRUG|Pertuzumab|Pertuzumab will be administered intrathecally via a lumber puncture. The dosing cohorts are described above in the arm description.
224199226|NCT00914511|DRUG|avanafil 200mg|single dose tablet of 200mg avanafil
223748695|NCT02598427|DRUG|Trastuzumab|Trastuzumab will be administered intrathecally via a lumber puncture. The dosing cohorts are described above in the arm description.
223748696|NCT02561637|BEHAVIORAL|Case management|
223748697|NCT02561637|BEHAVIORAL|Control group|
224199227|NCT00914511|DRUG|avanafil 200mg|single tablet dose of 200mg avanafil
224199228|NCT03586778|OTHER|dry needling|Dry Needling targeting the posterior musculature of the thoraco-lumbar spine and hips
224199229|NCT03586778|OTHER|manual therapy|Manual Therapy(mobilization/ manipulation) to address joint mobility of the thoraco-lumbar spine and hips
224199230|NCT03586778|OTHER|therapeutic exercise|Exercise designed to improve performance of the paraspinal and abdominal musculature as well as the hip musculature. The exercise portion will also include a stretching program targeting the trunk and hip muscles which have been placed in a shortened position as a result of poor postures.
224199231|NCT00039572|DRUG|boronophenylalanine-fructose complex|
223507130|NCT04501445|BEHAVIORAL|Written Summary of Rounds|The summary was organized as follows for each of the most important ICU problems: 1) Description of the problem, 2) Ways the ICU team is addressing the problem i.e. consultations, diagnostic tests, and treatments. 3) An assessment of whether the problem is improving or worsening.
223507131|NCT06222424|OTHER|outpatient prescription issues|Evaluation of utility will involve describing all Emergency Medicine Pharmacist (EMP)-written prescriptions pursuant to resolution of prescription issues realized after discharge
223507132|NCT05660538|DRUG|Suzetrigine|Tablets for oral administration.
223507133|NCT05660538|DRUG|Pregabalin|Capsules for oral administration.
223507134|NCT05660538|DRUG|Placebo (matched to SUZ)|Placebo matched to SUZ for oral administration.
223507135|NCT05660538|DRUG|Placebo (matched to pregabalin)|Placebo matched to pregabalin for oral administration.
223507136|NCT05415527|OTHER|Presence of sarcopenia evaluated prior to neoadjuvant chemotherapy and during chemotherapy as part of optimised management(dietician and APA).|"Sarcopenia will be evaluated by CT-scan. This method will be combined with a bone mineral density test which is also a way of entering into a more specific approach to sarcopenia screening.~The patients will receive optimised treatment by nutritional monitoring and adapted physical activity (APA) in addition to follow-up for sarcopenia."
223507137|NCT02082288|OTHER|Edessy ICSI Outcome Embryo Score|"EIOS:~Age (ys) \>35 (0) 30-35 (1) \<30 (2) No of retrived oocyte \<5 (0) 5-9 (1) ≥ 10 (2) No of EC embryos \<2 (0) 2-4 (1) \>4 (2) No of good quality embryos \<3 (0) 3-5 (1) \>5 (2) No of embryos transferred -------- (0) ≤2 (1) \>2 (2)"
223507138|NCT04518410|BIOLOGICAL|bamlanivimab 7000mg|Administered by single IV infusion. Participants are no longer being randomized to this intervention.
223507139|NCT04518410|BIOLOGICAL|BRII-196+BRII-198|1000 mg (BRII-196)/1000 mg (BRII-198) combination therapy. Administered by consecutive IV infusions as single dose. Participants are no longer being randomized to this intervention.
223507140|NCT04518410|BIOLOGICAL|AZD7442 (IV)|300 mg AZD7442 (150 mg AZD8895 + 150 mg AZD1061). Administered by IV infusion as single dose. Participants are no longer being randomized to this intervention.
223507141|NCT04518410|BIOLOGICAL|AZD7442 (IM)|Administered intramuscularly as 2 separate injections sequentially (300 mg AZD8895 then 300 mg AZD1061) for one dose. Injections administered in the side of the thigh, one injection in each thigh. Participants are no longer being randomized to this intervention.
223748698|NCT01638806|PROCEDURE|Group I: Primary PCI|Patients are treated with Aspirin, ADP-blocker and heparin and field-triaged or transferred immediately to an invasive center for PPCI
223748699|NCT01358357|DRUG|Lurasidone|Lurasidone 20 mg daily (days 1-3), Lurasidone 40 mg daily (days 4-7), Lurasidone 20-80 mg daily (flexible dose) thereafter
223748700|NCT01358357|DRUG|Placebo|20-80 mg flexible dose
223748701|NCT01826487|DRUG|Ataluren|Ataluren will be administered as per the dose and schedule specified in the arm.
223748702|NCT01826487|DRUG|Placebo|Placebo will be administered as per the schedule specified in the arm.
223748703|NCT01902264|DRUG|EE20/DRSP/L-5-MTHF (Beyaz, BAY98-7071)|One tablet DRSP 3 mg/EE 0.02 mg/ Levomefolate calcium 0.451 mg daily for 24 days, followed by one hormone-free tablet L-5-MTHF 0.451 mg daily for 4 days over 24 weeks
223748704|NCT06316141|OTHER|Aqua Jogging|This group performed aqua jogging for 60 minutes consisting of 10 minutes warming up, 40 minutes aqua jogging or land jogging and 10 minutes cooling down.
223748705|NCT06316141|OTHER|Land based Jogging|This group performs land jogging for 60 minutes consisting of 10 minutes warming up, 40 minutes aqua jogging or land jogging and 10 minutes cooling down.
223599624|NCT00118430|BEHAVIORAL|Stepped Care|Stepped care will consist of 12 weeks of antidepressant therapy, followed by a pain self-management program (PSMP) in those who fail to achieve both a good pain and global clinical response to antidepressant therapy. Treatment will be delivered by a nurse depression-pain clinical specialist (DPCS) who will be trained in providing both components of the stepped care treatment. The DPCS will meet weekly to review cases with a physician-investigator who will also be available to discuss any management issues that arise between the weekly case meetings. All participants will have six clinical contacts with the DPCS during the acute treatment phase and two clinical contacts during the continuation phase to assess medication adherence, adverse effects, and depression response.
223599625|NCT00118430|DRUG|Antidepressants|Participants will be assigned to one of the following antidepressant regimens: venlafaxine (37.5 mg, increased to 75, 150, 225 mg); duloxetine (60 mg, increased to 120 mg); fluoxetine (20 mg, increased to 30 to 40 mg); sertraline (50 mg, increased to 100 to 150 mg); citalopram (20 mg, increased to 30 to 40 mg); paroxetine (20 mg, increased to 30 to 40 mg); or nortriptyline (25 mg, increased to 50 to 75 mg).
223599626|NCT00118430|DRUG|Usual Care|This group will receive care as usual from their providers and completes the same outcome assessments as the stepped care group.
223599627|NCT03521245|OTHER|RNA sequencing|Next Generation Sequencing of RNA from tumor samples, rRNA-depleted.
223599628|NCT03521245|OTHER|Transcriptome analysis|Analysis of RNA-seq data using the Oncobox algorithm.
223599629|NCT03521245|DRUG|Trastuzumab|Standard Trastuzumab treatment regimen recommended for breast cancer
223599630|NCT03521245|DRUG|Chemotherapy|Standard chemotherapy regimen recommended for breast cancer
223599631|NCT01012778|BEHAVIORAL|Climb Up ADHD and Dyslexia Program|Using a peer mediated multimodal intervention program for ADHD and Dyslexia use Yoga, Meditation, Play therapy administered by (trained) high school volunteers
223599632|NCT05293158|DRUG|Hepatect CP 50 I.E./ml infusion solution|"Application of i.v. (intravenously) HBIGs for ≥6-weeks:~Day (D) 0-7: 10.000 IU D14 until end-of-treatment: 10.000 IU once per week HBIGs will be given until LT/liver resection."
223599633|NCT02147288|DEVICE|Renasys*GO Negative Pressure Wound Therapy System|Continuous, mechanical negative pressure wound therapy applied to drain in the immediate post-operative period (vs standard, closed-suction JP drains).
223599634|NCT00891384|DRUG|Lenalidomide|Patients will receive maintenance therapy according to their assigned treatment arm: 25 mg daily for 21 days every 28 days. During the treatment period patients will be seen every 4 weeks until disease progression is documented. All patients who have to discontinue the study drug will be followed until disease progression.
223748706|NCT03642223|OTHER|Stable iron isotopes|Participants have to consume a test meal containing stable iron isotopes in order to determine iron absorption
223748707|NCT00825045|DRUG|risperidone|Following the baseline clinical and cognitive assessments, risperidone will be initiated at 0.5-1.0 mg/day and subsequently increased by 0.25 - 1.0 mg on a weekly basis with the target of clinical stabilization (i.e. 20 or more % reduction in the total BPRS score) until a maximum dose of 4.0 mg/day is reached. To achieve this, a weekly assessment with BPRS will be performed. Physicians-of-record will be closely liaised with investigators. Dosage modification will be performed following this dosing schedule, however, this can be changed by treating physicians to meet clinical necessity. For example, in case psychotic symptoms are not controlled by this dosing schedule, facilitated dose increment will be allowed.
224199232|NCT03217500|PROCEDURE|Corneal epithelial autograft|After removal of the recipient's pterygium tissue, a donor epithelial tissue equal in length to the bared limbus, will be obtained from the peripheral epithelial of the same eye (corneal epithelial autograft) using femtosecond laser technology. The epithelial graft will be sutured to the recipient limbal bed, with the goal of reconstruction of palisades of Vogt. The graft will act as a barrier to regrowth of pterygium. The area of the graft will be left with the Tenon capsule exposed.
224199233|NCT03217500|PROCEDURE|Limbal conjunctival autograft|After removal of the recipient's pterygium tissue, an adjustable diamond knife will be used to create a superficial circumferential incision at the corneal end of the limbal vascular arcade, equal in length to the bared limbus. This will be followed by harvesting the limbal-conjunctival flap. The limbal-conjunctival autograft will be sutured to the recipient bed, with the Tenon capsule exposed. The graft will serve as a barrier to regrowth of pterygium.
224199234|NCT03217500|PROCEDURE|Simple removal|Simple removal of the recipient's pterygium tissue, with the Tenon capsule exposed.
223599635|NCT00891384|DRUG|Lenalidomide|Patients will receive maintenance therapy according to their assigned treatment arm:5 mg daily for 21 days every 28 days. During the treatment period patients will be seen every 4 weeks until disease progression is documented. All patients who have to discontinue the study drug will be followed until disease progression
223599636|NCT00744107|DEVICE|PCI with the Cobra™ Cobalt Super Alloy Coronary Stent System|stent placement, single-arm study
223599637|NCT00669383|DRUG|betamethasone|12 mg IM q 24 hours x 2 doses
223599638|NCT00669383|DRUG|placebo|Placebo IM q 24 hours x 2 doses
223599639|NCT04546542|OTHER|Parallel Assignment|We will evaluate 75 patients with pSS (Consenso Americano-europeu de 2002 / EULAR/ACR Classification Criteria, 2016) of both sexes at baseline and 6-months
223599640|NCT05340790|DRUG|Dose 1 to 5 of Antimicrobial Peptide PL-18 Vaginal Suppositories|Escalating doses of 1 mg (0.1%)、2.5mg (0.25%)、5 mg (0.5%)、10mg (1%)、15 mg (1.5%)；single dose administration；topical vaginal suppository ；multiple-dose administration after single dose administration a 3-day wash out period ; once-daily for 6 consecutive days;
223748708|NCT02910076|DRUG|Hydroxychloroquine|200 MG Plaquenil three times a day
223748709|NCT02475551|DRUG|IdeS|Intravenous infusion
223599641|NCT05340790|DRUG|Placebo dose 1 to 5 of Antimicrobial Peptide PL-18 Vaginal Suppositories|Dose 1、2、3、4 and 5 of Antimicrobial Peptide PL-18 Vaginal Suppositories respective placebos；single dose administration；topical vaginal suppository ；multiple-dose administration after single dose administration a 3-day wash out period ; once-daily for 6 consecutive days;
223748710|NCT04689295|OTHER|exercise programme 1|Schroth three dimensional scoliosis therapy method
223748711|NCT04689295|OTHER|exercise programme 2|Traditional scoliosis exercises
223748712|NCT02101047|DRUG|Phenylephrine|
224199235|NCT03217500|DEVICE|Diamond knife|A diamond knife to create a particular shaped limbal graft for transplantation
224199236|NCT03217500|DEVICE|Femtosecond laser|A commercial femtosecond laser to create a particular shaped graft for transplantation
224199237|NCT01561573|DEVICE|Point of care ultrasound|A bedside ultrasound machine will be used to image the colles fracture during the fracture reduction process.
224199238|NCT00138658|DRUG|custirsen sodium|Custirsen sodium (OGX-011) was to be infused intravenously over 2 hours on Days -7, -5, and 3 of Cycle 1 (pretreatment loading dose). OGX 011 was then to be infused for 2 hours weekly on Days 1, 8, and 15 of a 21-day cycle. Gemcitabine (GEM) was to be infused intravenously for 30 minutes on Days 1 and 8 and either cisplatin (CIS) or carboplatin (CARBO) were to be infused intravenously on Day 1 of this 21-day cycle. Patients were to receive a maximum of 6 cycles (1 cycle = 21 days)
224199239|NCT01932515|BEHAVIORAL|A revised screening instrument for use in Deaf children|
224199240|NCT03564015|OTHER|Smartphone app|Apple or Android app to provide education to guide functional recovery and allow recording of pain, management, and functional outcome using the Activities Scale for Kids performance version (ASKp) at home
224199241|NCT03564015|OTHER|Paper handout|Paper handout to guide functional recovery. Also includes a version of the smartphone app described above that only allows recording of pain, functional outcome, and management at home.
224199242|NCT03296397|BIOLOGICAL|Vaccination with Gardasil|Vaccination with Gardasil in patients apparently cured of external genital warts
224199243|NCT03296397|BIOLOGICAL|Injection of Normal Saline|Injection of Normal Saline in patients apparently cured of external genital warts
224199244|NCT01354015|DEVICE|DRMS|USE OF TEXT MESSAGING SYSTEM
224199245|NCT03843905|OTHER|no intervention|The aim of this translational research project is to study the impact of these new prognostic tools on surgical and oncologic results in a prospective cohort of patients who underwent CRC surgery at the Digestive Surgery Department of the University Hospital of Clermont-Ferrand (France)
224199246|NCT00119080|BIOLOGICAL|meningococcal conjugate vaccine (Menactra)|
224199247|NCT04269746|DIAGNOSTIC_TEST|CCAT1|Long Non coding RNA
223507142|NCT04518410|DRUG|SNG001|1.3 mL solution administered once daily for 14 days using Aerogen Ultra nebulizer (inhalation device). Participants are no longer being randomized to this intervention.
223507143|NCT04518410|DRUG|Camostat|200 mg (2 x 100 mg) film-coated tablets administered orally every 6 hours for 7 days. Participants are no longer being randomized to this intervention.
223507144|NCT04518410|BIOLOGICAL|BMS-986414 + BMS-986413|Administered subcutaneously (SC) as 4 separate injections for one dose (two injections of C135-LS 200mg and two injections of C144-SL 200mg). Participants are no longer being randomized to this intervention.
223507145|NCT04518410|BIOLOGICAL|SAB-185 (3,840 Units/kg)|Administered by IV infusion as single dose. Participants are no longer being randomized to this intervention.
223507146|NCT04518410|BIOLOGICAL|SAB-185 (10,240 Units/kg)|Administered by IV infusion as single dose. Participants are no longer being randomized to this intervention.
223507147|NCT04518410|DRUG|CASIRIVIMAB + IMDEVIMAB|600 mg casirivimab and 600 mg imdevimab, administered together as single IV infusion as one-time dose at study entry. Participants are no longer being randomized to this intervention.
223507148|NCT04518410|DRUG|Placebo for Bamlanivimab 7000mg|Commercially available 0.9% sodium chloride solution. Participants are no longer being randomized to this intervention.
223507149|NCT04518410|DRUG|Placebo for Bamlanivimab 700mg|Commercially available 0.9% sodium chloride solution. Participants are no longer being randomized to this intervention.
223507150|NCT04518410|DRUG|Placebo for BRII-196+BRII-198|Commercially available 0.9% sodium chloride solution. Participants are no longer being randomized to this intervention.
223507151|NCT04518410|DRUG|Placebo for SNG001|Trisodium citrate dihydrate, di-sodium hydrogen-phosphate, sodium dihydrogen-phosphate dihydrate, racemic methionine (DL-methionine) and water. 1.3 mL solution administered once daily for 14 days using Aerogen Ultra nebulizer (inhalation device). Participants are no longer being randomized to this intervention.
223507152|NCT04518410|DRUG|Placebo for Camostat|200 mg (2 x 100 mg) film-coated tablets administered orally every 6 hours for 7 days. Participants are no longer being randomized to this intervention.
223507153|NCT04518410|DRUG|Placebo for SAB-185 (low dose)|Commercially available 0.9% sodium chloride solution. Participants are no longer being randomized to this intervention.
223507154|NCT04518410|DRUG|Placebo for BMS-986414 + BMS-986413|Administered SC as 4 separate injections for one dose. Participants are no longer being randomized to this intervention.
223507155|NCT04518410|DRUG|Placebo for AZD7442 (IV)|Commercially available 0.9% sodium chloride solution. Participants are no longer being randomized to this intervention.
223507156|NCT04518410|DRUG|Placebo for AZD7442 (IM)|Commercially available 0.9% sodium chloride solution. Participants are no longer being randomized to this intervention.
223507157|NCT04518410|DRUG|Placebo for SAB-185 (high dose)|Commercially available 0.9% sodium chloride solution. Participants are no longer being randomized to this intervention.
223507158|NCT04518410|BIOLOGICAL|bamlanivimab 700mg|Administered by single IV infusion. Participants are no longer being randomized to this intervention.
223507159|NCT03462563|DEVICE|INTERCEED™|when the definite decision to create a temporary ostomy is made, patients will be randomized in 1:1 ratio to either the treatment arm (INTERCEED™) or the control arm (standard of care treatment: no adhesion barrier, no placebo). In subjects assigned to the treatment arm, the INTERCEED™ must be applied beneath the target incision site (the midline incision mainly for the removal specimen)
223507160|NCT03462563|DEVICE|Placebo|During the Phase 1 operation, when the definite decision to create a temporary ostomy is made, patients will be randomized in 1:1 ratio to either the treatment arm (INTERCEED™) or the control arm (standard of care treatment: no adhesion barrier, no placebo).
223507161|NCT04028505|DRUG|Terlipressin Injectable Product|"Intravenous terlipressin will be obtained from Clinical Trials Unit, AKUH pharmacy in standard IV infusion form.~Participants who are randomized to the intervention arm will be administered a continuous infusion of Terlipressin at a rate of 0.5mg/hour for the first 24 hours. Participants randomized into the control group will be administered a bolus form of Terlipressin at a rate of 2mg every six hourly for the first 24 hours respectively. In case of weekends/public holidays intravenous terlipressin will be obtained from the main pharmacy of AKUH."
223507162|NCT04835753|DEVICE|shock wave|true radial ESWT.A rESW pneumatic device (SHOCK MED, Italy) was used to provide one session per week (for a total of 12-week)
224199248|NCT06282250|BEHAVIORAL|Bright light therapy + Psycho-education + Imagery focused Cognitive Therapy|"Week 1-3: BLT will be administered for 30 minutes on five consecutive days, starting on Monday of the work week, between 7:30 AM and 10:00. The effect of the light therapy is evaluated by means of the Self-Rated Quick Inventory of Depressive Symptoms (QIDS-SR). Further treatment strategy is determined on the basis of these results:~* If the patient has achieved remission (QIDS-SR \< 6), BLT has been successful and the patient can continue with PE and IMCT.~* If there is insufficient or no response (QIDS-SR of 6 or higher), BLT is extended with five more sessions the following week.~* If necessary, a third week is optional.~Week 2-4: Psycho Education will follow, 1 session.~Week 3/4-9/10: ImCT will follow, 6 sessions."
224199249|NCT06282250|BEHAVIORAL|Blue-light blocking glasses + Psycho-education + Imagery focused Cognitive Therapy|"Week 1-3: blue-light blocking glasses will be administered. Week 2-4: Psycho Education will follow, 1 session.~Week 3/4-9/10: ImCT will follow, 6 sessions."
224199250|NCT06282250|BEHAVIORAL|Psycho-education + Imagery focused Cognitive Therapy|"Week 1: Psycho Education, 1 session.~Week 2-7: ImCT will follow, 6 sessions."
224199251|NCT00297063|DRUG|Rosiglitazone|
224199252|NCT03791567|BIOLOGICAL|Donislecel (allogeneic islets of Langerhans for transplant)|Intervention Description: The drug product consists of allogeneic human islets of Langerhans (islets) in serum-free transplant medium (indicator-free CMRL 1066 medium with HEPES, without sodium bicarbonate and supplemented with human albumin).
224199253|NCT02495636|DRUG|CDX-1401|CDX-1401 1mg will be administered intracutaneously every 2 weeks for 4 doses (priming), followed by every 12 week dosing (booster)
224199254|NCT02495636|DRUG|MPDL3280A|MPDL3280A 1200 mg will be administered intravenously every 3 weeks.
224199255|NCT02531958|OTHER|Eggs|Participants will complete a 2-week washout period followed by intake of 1, 2, and 3 eggs per day for 4 weeks each.
223507163|NCT04835753|OTHER|traditional physical therapy program|lower limbs muscles stretch and strength in addition to balance and gait training
223507164|NCT05153434|DRUG|ARD-101|Twice Daily, Oral Administration
223507165|NCT05704036|DRUG|Transdermal estrogen|Transdermal estradiol 0.1 mg/day, applied once weekly
223507166|NCT05704036|DRUG|Progesterone|Progesterone 200 mg daily for 10 days/month, if participant is not on progesterone-containing contraceptive
223507167|NCT02223130|BEHAVIORAL|Cognitive Behavioral Therapy techniques|Participants attend 9 weekly group sessions. Each of the weekly sessions is led by a mental health professional and a peer facilitator who use Cognitive Behavioral Therapy techniques to work with participants in tracking their cognitions, emotions and behaviors in response to stressful/discrimination experiences.
223507168|NCT01284088|DEVICE|PrePex™ device for adult male circumcision|The PrePex™ device is designed to enable bloodless male circumcision procedure with no anesthesia and no sutures.
223507169|NCT01284088|PROCEDURE|Surgical circumcision|The penis will be surgically circumcised according to one of the WHO recommended circumcision methods as described in the Manual for Male Circumcision under Local Anaesthesia Version 2.5C January 2008
223507170|NCT04860583|OTHER|Renal ultrasound|
223507171|NCT01740427|DRUG|PD-0332991|PD-0332991, 125mg, orally once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment
223507172|NCT01740427|DRUG|Letrozole|Letrozole, 2.5mg, orally once daily (continuously)
223507173|NCT01740427|DRUG|Placebo|Placebo, 125mg, orally once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment
223507174|NCT01740427|DRUG|Letrozole|Letrozole, 2.5mg, orally once daily (continuously)
223507175|NCT05800847|DRUG|Gabapentin|Gabapentin will be administered for 2 days at 100 mg q8h for titration to avoid side effects. The next 12 days, gabapentin will be taken at 300 mg q8h.
223507176|NCT05800847|DRUG|Placebo|Placebo will follow the same dosing pattern as gabapentin to allow for blinding. Placebo will be encapsulated with a gelatin capsule to mimic the look of gabapentin.
223507177|NCT05890677|PROCEDURE|Surgical Intervention|LVA (Lymphovenous Anastomosis) and VLNT (Vascularised Lymph Node Transfer) are two advanced microsurgical techniques that are increasingly implemented in clinical practice in specialized centers and that are already carried out after health insurance application according to local standard of care. They have been studied in their respective mode of action as well as in their effectiveness in treating chronic BCRL (Breast Cancer-Related Lymphedema) in a multitude of mostly observational and single center studies with highly encouraging results. Patients in the interventional arm A will receive surgery with one of the two approaches or a combination of both, in a one or two-stage method, at the discretion of the treating surgeon. Depending on local standards one or both of the above might be combined with liposuction to the affected arm in a one or two-stage approach as well.
223507178|NCT05890677|PROCEDURE|Conservative Complex Physical Decongestion Therapy|Patients randomized to the control arm will receive CDT (Conservative Complex Physical Decongestion Therapy), which currently is considered as the best available standard of care. For this, patients will be referred to one of the dedicated LE (physical/skin) therapy clinics, if not already treated by one, according to their place of residence for continuation of standard conservative therapy. Recommendations to the procedures and treatment frequency of the conservative therapy will be made, but CDT will be done at the discretion of the treating physiotherapist.
223507179|NCT06462586|DRUG|Lumateperone|Lumateperone 42 mg capsules administered orally, once daily
223507180|NCT06462586|DRUG|Placebo|Matching capsules administered orally, once daily
223507181|NCT04796207|DIETARY_SUPPLEMENT|Fish Oil (DPA+EPA 2:1 ratio) Capsules|The Treatment Arm intervention consists of providing participants with 3 grams of DHA and EPA (2:1 weight ratio) in capsular form. In order to meet the required 3 grams of DHA and EPA, participants were given 6 capsules to be taken with meals (preferably breakfast, although capsules were provided at lunch when they couldn't be provided at breakfast). Capsules were given 5 times a week during the regular football season.
223507182|NCT04796207|DIETARY_SUPPLEMENT|High Oleic Safflower Oil Capsules|"The Placebo Arm intervention consists of providing participants with 3 grams of high-oleic safflower oil in a 1:1 allocation ratio in capsular form. In order to maintain the study masking, participants in the Placebo Arm were given 6 capsules (the same as the Treatment Arm) to be taken with meals (preferably breakfast, although capsules were provided at lunch when they couldn't be provided at breakfast). Capsules were given 5 times a week during the regular football season."
223748713|NCT01618409|BEHAVIORAL|PictureRx card|An illustrated format of medication instructions that includes pictures of the medications and icons to illustrate their purpose
223748714|NCT00244946|BIOLOGICAL|therapeutic autologous lymphocytes|Lymphocytes collected by standard apheresis technique either prior to or post stem cell mobilization and collection
223748715|NCT00244946|DRUG|carmustine|
223748716|NCT00244946|DRUG|cytarabine|
223748717|NCT00244946|DRUG|etoposide|
223748718|NCT00244946|DRUG|melphalan|
223748719|NCT00244946|PROCEDURE|peripheral blood stem cell transplantation (PBSCT)|
223748720|NCT05245760|DRUG|Intravenous Tislelizumab|Participants will receive 200mg, every three weeks for up to 51 weeks
223748721|NCT05245760|DRUG|Chemotherapy|Carboplatin (AUC2) and Paclitaxel (50mg/m2), Weekly x 5 weeks
223748722|NCT05245760|RADIATION|Fractionated radiation|Concurrent with chemo, x5 weeks
223748723|NCT05245760|PROCEDURE|Esophagectomy|Surgical resection of cancer after chemoradiation therapy when no disease progression found.
223748724|NCT06390969|OTHER|Survey|Cross-sectional online survey
223748725|NCT05603689|DIETARY_SUPPLEMENT|Isocaloric ketogenic diet|The ICKD definition was based on the works of Sansone (2018) and Trimboli (2020). We defined ICKD as a daily CHOs ingestion \< 30 to 50 g.d-1, without any limitation in fat consumption. Participants self-selected their own diet based on a list of advised and forbidden foods developed to fit the definition of ICKD. There were no instructions to limit calories.
223748726|NCT03098537|DRUG|enteral nutrition + proton pump inhibitor|Critically ill patients receiving any form of enteral nutrition will be included into the study. The patients will be randomized either enteral nutrition only group or enteral nutrition and proton pump inhibitors group. This group will receive enteral nutrition and proton pump inhibitor
223748727|NCT03098537|OTHER|enteral nutrition only|Critically ill patients receiving any form of enteral nutrition will be included into the study. The patients will be randomized either enteral nutrition only group or enteral nutrition and proton pump inhibitors group. This group will receive only enteral nutrition.
224311225|NCT03058653|PROCEDURE|Small fluid boluses of 50 ml|Participants will receive small 50ml boluses of fluid up to 250ml in total. The remainder will be given as infusion pump method at a rate of 1000ml/hour which will complete in 15 minutes. In total, the 500ml will be given over 25 minutes.
223748728|NCT04405648|BEHAVIORAL|CVS GROUP|the students will respond to CVS-F3 questionnaire to report their potential CVS complains and associated screen factors as screen-time, screen-size, screen-resolution and other factors.
223507183|NCT04443608|DRUG|Patiromer Powder for Oral Suspension [Veltassa]|Powder will be mixed with a liquid (water, apple or cranberry juice) and given to patient to drink
223507184|NCT04443608|DRUG|Placebo|Powder will be mixed with a liquid (water, apple or cranberry juice) and given to patient to drink
223507185|NCT04828967|OTHER|Hypnosis|Hypnosis is added to the conventional group
223507186|NCT01738178|DRUG|Caffeine|
223507187|NCT01738178|DRUG|Placebo|
223507188|NCT01221909|DRUG|Tranexamic acid|Single dose TA 500mg or placebo will be given in DCR surgery right after the first surgical incision.
223507189|NCT01221909|DRUG|saline solution|5cc saline solution
223748729|NCT05543122|DRUG|either of Atenolol, Bupropion, Brivaracetam, Escitalopram, Fluconazole, Lacosamide, Lamotrigine, Levetiracetam, Methotrexate or Ezetimibe|This is a cohort study of pharmacokinetics of drugs in milk. Participants in the group are those breastfeeding women on the listed drugs at steady state, who are prescribed these drugs for clinical reasons outside this study framework.
224311226|NCT03058653|DEVICE|LIDCORapid Monitor|Addition of the LIDCORapid Monitor to measure stroke volume
224311227|NCT02686645|BIOLOGICAL|Fecal Microbiota|The fecal microbiota will be by retention enema administered through a rectal tube.
224311228|NCT02686645|DRUG|vancomycin|All subjects will be pre-treated with vancomycin 125 mg po qid X 7 days prior to the fecal microbiota.
223507190|NCT00204789|DRUG|Difluoromethylornithine|
223507191|NCT05644418|DEVICE|Flow Controlled Ventilation (FCV)|FCV is started with the same settings as PCV (PEEP, Ppeak, FiO2) and after 30 minutes FCV is optimized concerning the driving pressure and PEEP using the dynamic compliance. After a total of 60 minutes the flow is adjusted based on the arterial blood gas.
223507192|NCT00115388|PROCEDURE|Screening for chlamydia using self-taken vaginal swabs|Women in the intervention group will be tested for chlamydia and those found to be infected will be referred for treatment and partner notification
223507193|NCT01501097|PROCEDURE|Continuous Renal Replacement Therapy|Patients will be randomized to either arm :early HV-crrt(50ml/kg/h) or Control group
223507194|NCT02838238|DRUG|Capecitabine|
223507195|NCT02838238|DRUG|Placebo|
223507196|NCT01663376|PROCEDURE|Autologous Adipose Tissue derived MSCs Transplantation|Intramuscular injection of Autologous Adipose Derived Mesenchymal Stem Cells. Dose : 1x10e8 \~3x10e8 cells
223507197|NCT03394573|OTHER|OCT guided treatment arm|Intravitreal injection of Aflibercept for DME OCT guided
223507198|NCT03394573|OTHER|VA guided treatment arm|Intravitreal injection of Aflibercept for DME VA guided
223507199|NCT02708173|BIOLOGICAL|One dose of Quadrivalent Influenza Virus Vaccine|
223507200|NCT02708173|BIOLOGICAL|One dose of Quadrivalent Influenza Virus Vaccine|
223507201|NCT05443854|DRUG|Aminoglycosides intervention|"Antibiotic therapy and prophylaxis will be in line with more recent IDSA and ESCMID guidelines \[3, 28, 50\].~Systematic aminoglycoside therapy using Amikacin at a dose of 25 to 30 mg/Kg per dose, at a rate of a maximum of 1 infusion per day will be delivered.~Recommended duration will be of three days or until microbiological documentation."
223507202|NCT05443854|BEHAVIORAL|Lack of protective isolation intervention|"Protective isolation will be avoided until ICU discharge is deemed possible. Specific measures regarding nutrition (including avoidance of food consider at risk of fungal contamination) and water protection will be maintained.~Extended universal hygiene measures will be maintained and use of mask will be advocated during viral epidemic periods.~A high degree of compliance as regard to antifungal prophylaxis guidelines and local standard hygiene procedures will be advocated"
223507203|NCT05443854|OTHER|No systematic aminoglycosides intervention - standard arm|"Antibiotic therapy and prophylaxis will be in line with more recent IDSA and ESCMID guidelines \[3, 28, 50\].~No systematic aminoglycoside therapy will be provided except in presence of predefined specific organ infection (such intra-vascular infection such endocarditis for example) or drug-resistant infection requiring aminoglycosides."
224199256|NCT05434975|PROCEDURE|Interscalene brachial plexus block|"For single shot-ISBP block, 15 ml of 0.5% bupivacaine + 10 ml of 2% prilocaine, a total of 25 ml of local anesthetic, will be administered to all patients.~For the block procedure, an imaginary horizontal line drawn from the thyroid cartilage to the sternocleidomastoid (SCM) muscle will followed and the lateral of the SCM muscle will be cleaned with povidine iodine. At the C6 level to be blocked, the nerve roots will be detected by ultrasound. 25 ml of local anesthetic will be injected around the plexus roots with a 22 G 80 mm echogenic needle. The distribution of the local anesthetic applied to the area, which expands the tissues and separates the nerve roots from other tissues, will be seen on ultrasound."
224199257|NCT04836832|DRUG|Acalabrutinib|Given PO
224311229|NCT02686645|DRUG|Loperamide|The subject will take 4 mg of loperamide after the morning bowel prep (approximately 1 hour prior to the procedure) and 2 mg again after the procedure.
224199258|NCT04836832|DRUG|Duvelisib|Given PO
224199259|NCT04985032|RADIATION|stereotactic body radiation therapy|Treatment technique used to deliver a highly focused and accurate radiation dose to a defined target volume outside the brain; the entire course of therapy delivered in five fractions or less
224311230|NCT02686645|DRUG|metronidazole|If unable to tolerate vancomycin, then it will be substituted with metronidazole 500 mg po tid X 7 days prior to the fecal microbiota.
224311231|NCT04955535|PROCEDURE|Arthroscopic synovectomy|Arthroscopic synovectomy
223507204|NCT05443854|OTHER|Protective isolation intervention - standard arm|"Protective isolation will be provided systematically as currently practiced in participating centers. Modality will be in line with recent SRLF guidelines, we will recommend for the patients to receive an isolation the maximal available isolation with the aim to provide:~1. High-efficiency air filtration \[filtration of 99.7% of particles greater than or equal to 0.3 µm; International Organization for Standardization (ISO) class 5 or better\]~2. Geographical isolation in an individual room~3. Technical isolation, including a face mask and a cap. This approach of isolation will however be pragmatic on the basis of the best available level of isolation in line with recommendation, while not delaying ICU admission and patients' care"
223507205|NCT04203056|DRUG|Aripiprazole Lauroxil|12 month longitudinal aripiprazole lauroxil treatment and assessment follow-through
223507206|NCT04203056|DRUG|ARI-ORAL|oral aripiprazole
223507207|NCT04203056|DRUG|AL-NCD|Aripiprazole Lauroxil 675 MG/2.4 ML Intramuscular Suspension, Extended Release
223507208|NCT06449664|BEHAVIORAL|ADT-train|A new training concept is tested on men with prostate cancer receiving androgen deprivation therapy
223507209|NCT03509584|RADIATION|hypofractionated radiotherapy|Stereotactic hypo-fractionated irradiation (3 x 8 Gys) radiotherapy fraction
223507210|NCT03509584|DRUG|nivolumab|administration of nivolumab
223507211|NCT03509584|DRUG|Ipilimumab|administration of ipilimumab
223507212|NCT05701735|BEHAVIORAL|CECIL Patient Decision Aid|"The CECIL patient decision aid explicitly identifies the disease, the index decision, and the treatment options, describes the positive and negative features and consequences of each option, and guides the patient in examining personal values and preferences, to arrive at a quality and realistic decision.~The decision aid will be developed and validated according to the guidelines and standards published by the International Patient Decision Aids Standards (IPDAS) Collaboration."
223507213|NCT02405962|BEHAVIORAL|ACT|Four sessions of group-based ACT integrated with asthma education. Each session will compose of pediatric asthma education based on guidelines of Global Strategy for Asthma Management and Prevention Revised 2011, plus group-based Acceptance and Commitment Therapy (ACT). The goal of ACT is to enhance the psychological flexibility of the parents, enabling them to (1) become aware of their thoughts and feelings regarding their child's asthma and its management, (2) accept and adapt flexibly to challenging situations, and (3) take actions to achieve valued goals in childhood asthma management.
223507214|NCT02405962|BEHAVIORAL|Control|One session of educational talk about pediatric asthma care, as the usual care. To ensure the equivalency of the assigned sessions between groups, after attending the talk in the first week, the parents in the Control group will receive three telephone calls, starting from the second week on a weekly basis. This arrangement can also minimize the interference of the usual care naturalistically available in the study setting.
223507215|NCT00303797|DRUG|17-N-allylamino-17-demethoxygeldanamycin/bortezomib|
223507216|NCT00303797|DRUG|sorafenib tosylate|
223507217|NCT04267042|DRUG|Budesonide|Budesonide is a corticosteroid that is commonly used intranasally to treat CRS.
223507218|NCT04267042|DEVICE|Mucosal Atomization Device|MAD is a device used as an addition to a syringe to atomize medication to increase area of distribution. It is used to administer budesonide within the nasal passages and sinuses to administer medication for CRS.
223507219|NCT04267042|DEVICE|NeilMed squeeze bottle for Impregnated Nasal Saline Irrigation|INSI is delivered using a NeilMed squeeze bottle. It is used to administer budesonide within the nasal passages and sinuses to administer medication for CRS.
223507220|NCT03679884|DRUG|Daridorexant 10 mg|Daridorexant 10 mg film-coated tablets
223507221|NCT03679884|DRUG|Daridorexant 25 mg|Daridorexant 25 mg film-coated tablets
223507222|NCT03679884|DRUG|Daridorexant 50 mg|Daridorexant 50 mg film-coated tablets
223507223|NCT03679884|DRUG|Placebo|Matching placebo film-coated tablets
223507224|NCT01107457|BIOLOGICAL|Ixekizumab|Administered subcutaneously
223507225|NCT01107457|DRUG|Placebo|Administered subcutaneously
223507226|NCT05013775|DIAGNOSTIC_TEST|Computed tomography|Computed tomography to gauge response after preoperative chemotherapy cycles and excluded the development of interval metastases or irresectable disease
223507227|NCT05013775|DIAGNOSTIC_TEST|Diagnostic laparoscopy with peritoneal lavage|Diagnostic laparoscopy lavage to exclude (small-volume) metastases and determine local resectability
223507228|NCT01793922|PROCEDURE|PD|pneumodilation
223507229|NCT01793922|PROCEDURE|POEM|peroral endoscopic myotomy
224311232|NCT00063219|DRUG|MAC-321|
224311233|NCT03822065|DRUG|LY03005|80 mg oral tablet single dose
224311234|NCT04521582|DRUG|Amlodipine|The facility-based community health worker will receive protocol-driven training to initiate amlodipine for hypertensive patients. These patients will receive lifestyle counseling by Female Community Health Volunteer through home visits (5 times \[including baseline and end of the study\] in the active municipality and 3 times \[including baseline and end of the study\] in the control municipality).
223748730|NCT02136576|DEVICE|Sensodyne|Subjects will be instructed to brush with Sensodyne twice daily (2 minutes each time in the morning and the evening) during the duration of the study.
223748731|NCT02136576|DEVICE|Crest Cavity Protection & MI Paste Plus|Subjects will be instructed to brush twice daily (2 minutes each time in the morning and the evening) using Crest Cavity Protection toothpaste. They will be instructed to apply MI Paste Plus (CPP-ACP with fluoride) twice daily to the study teeth after brushing their teeth. MI Paste Plus will be applied to the study teeth with a finger.
223748732|NCT02136576|DEVICE|Clinpro 5000|Subjects will be instructed to brush with Clinpro 5000 twice daily (2 minutes each time in the morning and the evening) during duration of the study.
223748733|NCT01656590|OTHER|High Protein and Exercise Therapy along-with Nocturnal Enteral Feeding|"1. High Protein and Moderate Carbohydrate Nutrition designed by our nutritionist for every patient based on his/her nutrition requirements, age \& gender~2. 500 cc Formula - Nutren Replete with Fiber overnight \[8 hours\] via gastrostomy tube~3. Conditioning Exercise once daily"
224199260|NCT04679233|OTHER|Prescription aerobic exercise|high intensity interval training, 5 weeks, 2 sessions/week - supervised by a clinician.
224199261|NCT01984970|DEVICE|videolaryngoscope|McGrath Series 5 videolaryngoscope is one kind of portable videolaryngoscopes, which has been usde in both unexpected and anticipated difficult intubation.
224199262|NCT02217397|DEVICE|OA, CPAP, combination therapy|
224199263|NCT00771654|DRUG|Phentermine|Subjects will receive Phentermine 37.5mg everyday for one year
223507230|NCT04585360|OTHER|Questionnaires evaluating anxiety and depression symptoms, tiredness, and quality of life|"Realization of specific questionnaires evaluating:~* psychiatric symptoms (self-assessment according to the SLC-90R questionnaire and hetero-assessment by the internist doctor of the center according to the M.I.N.I. questionnaire)~* fatigue (Multidimensional Fatigue Inventory (MFI-20), French version, in self-assessment)~* quality of life (SF36 self-assessment questionnaire)"
223507231|NCT02204735|BEHAVIORAL|Eat majority of calories in the morning|
223507232|NCT02204735|BEHAVIORAL|Eat the majority of calories in the evening|
223748734|NCT02258230|DEVICE|3D mode of the 3D Laparoscopic Video System|Olympus 3DV-190 3D Visualization Unit. LTF-190-10-3D: ENDOEYE FLEX 3D Videoscope.
223748735|NCT02258230|DEVICE|2D mode of the 3D Laparoscopic Video System|Olympus 3DV-190 3D Visualization Unit. LTF-190-10-3D: ENDOEYE FLEX 3D Videoscope.
223748736|NCT00690092|BIOLOGICAL|Spherule-derived coccidioidin|1.27 ug of sterile, injectable product (spherule-derived coccidioidin). Product was administered once by intradermal injection along with positive and negative control agents and results read after 48 hours.
223748737|NCT04028752|BIOLOGICAL|Blood collected specifically for this study|The subject will be sitting in a chair, and a needle will be inserted into a vein in the arm. Study Team will draw about 45ml or 3 tablespoons of whole blood for research.
223748738|NCT04317911|OTHER|Catheter Ablation|Patients with preserved ejection fraction presenting for catheter ablation via of atrial fibrillation are included in this study and prospectively observed regarding arrhythmia-related, functional and biomarker-associated outcomes.
223748739|NCT00537381|DRUG|Docetaxel|Docetaxel 75 mg/m\^2 as intravenous infusion every 3 weeks.
223748740|NCT00537381|DRUG|Prednisone|Prednisone 5 mg orally twice daily.
223748741|NCT00537381|BIOLOGICAL|Intetumumab|Intetumumab 10 mg/kg as intravenous infusion every week for initial 6 weeks, then every 3 weeks.
223748742|NCT00537381|DRUG|Placebo|Placebo matching to intetumumab, as intravenous infusion every week for initial 6 weeks, then every 3 weeks.
223748743|NCT02590939|DEVICE|CEFALY Active|Active external trigeminal nerve stimulation
223748744|NCT02590939|DEVICE|CEFALY Placebo|Placebo external trigeminal nerve stimulation
223748745|NCT06029634|DIAGNOSTIC_TEST|T-bet B cell|The frequency, function, and phenotype of T-bet B cells was tested
223748746|NCT00864149|DRUG|Carvedilol 12.5 mg Tablets, single dose|A: Experimental Subjects received Shasun Chemicals and Drugs Ltd. formulated products under fed conditions
223748747|NCT00864149|DRUG|Coreg® 12.5 mg Tablets , single dose|B: Active comparator Subjects received GlaxoSmithKline, USA formulated products under fed conditions
223748748|NCT05218473|DIAGNOSTIC_TEST|Prolonged ECG monitoring|Using 14-day continuous electrocardiography patch monitoring to increase the detection rate of paroxysmal atrial fibrillation in acute ischemic stroke patients without known atrial fibrillation.
223748749|NCT05218473|DIAGNOSTIC_TEST|Conventional procedure group|Using serial 12-lead electrocardiograms once daily for five days or conventional 24-h Holter monitoring to detect new atrial fibrillation
223507233|NCT05330377|DRUG|Gilteritinib 40 MG Oral Tablet|Gilteritinib is an oral FLT3 inhibitor, and is active against both FLT3-ITD and FLT3-TKD mutations. Gilteritinib will be given orally according to the assigned phase I dose cohort starting day 6 until day 19. Participants will be given the daily dose with water as at the same time each morning. Gilteritinib should be taken at least 2 hours after or 1 hour before consuming food.
223507234|NCT05330377|DRUG|Cladribine|Cladribine is given intravenously at a dose of 5 mg/m2 I.V. over 2 hours once per day on days 1 to 5.
223507235|NCT05330377|DRUG|Cytarabine|Cytarabine is given intravenously at a dose of 2,000 mg/m2 I.V. over 4 hours once per day on days 1 to 5, given second, 2 hours after cladribine.
223507236|NCT05330377|DRUG|Filgrastim|Filgrastim (GCSF) or biosimilar, will be given at a dose of 300 mcg S.C. once per day on days 0 to 5, started 24 hours prior to chemotherapy. If WBC is \> 20 × 109/L on day 0, the filgrastim dose on day 0 will be omitted.
223507237|NCT05330377|DRUG|Mitoxantrone|Mitoxantrone is given intravenously at a dose of 10 mg/m2 I.V. over 2 hours once per day on days 1 to 3.
223507238|NCT03996213|OTHER|head down position|Head-down position will be achieved by 30 degrees tilting of the whole operating table 1-minute before induction of anesthesia. The position will be maintained for 15 minutes after induction of anesthesia
224199264|NCT00771654|OTHER|Placebo|daily for one year
224199265|NCT06456749|COMBINATION_PRODUCT|Integrated Disease Management|For COPD, they are encouraged to seek further cares and manage COPD on a regular basis. For smokers, they will be given a digital health intervention based on CBT. For participants with symptoms of depression or anxiety, another digital health intervention is provided. For abnormal BMI participants, a knowledge brochure will be provided and a medical worker from the township hospital will tell the harm of abnormal BMI. For hypertension and type 2 diabetes, we will actively include them into the National Essential Public Health program.
223599642|NCT01447953|OTHER|Activity targeted pain rehabilitation|An activity and life-role targeting rehabilitation programme (ALAR) provided by one of the care givers in the multi-professional rehabilitation teams at each of the eight participating primary health care centres, by ten weekly 1-hour treatment sessions.
223599643|NCT01447953|OTHER|Treatment as usual|Usual treatment with type of treatment modalities, number, frequency and duration of visits according to the judgement of the muli-professional teams at each primary health care centre.
223599644|NCT00968877|DRUG|Cholecalciferol|capsule 40 000 IU (p.o.) once per week, in 8 weeks.
223599645|NCT02948738|BEHAVIORAL|Interactive Asthma Education|Active participation to develop asthma action plan and teach back cycles for asthma inhaler teaching/training
223599646|NCT02948738|BEHAVIORAL|Standard Asthma Education|Basic review of asthma action plan and inhaler use
223599647|NCT04560153|OTHER|karate kata|sessions of karate kata every week during 4 months
223599648|NCT01874444|DEVICE|1|repetitive transcranial magnetic stimulation (Figured 8-Coil MCF-B65): 1000 stimuli of 1Hz rTMS over the left DLPFC (110% motor threshold) followed by 2000 stimuli of 1 Hz rTMS over the left temporal cortex (110% motor threshold), each consisting of 4 days of rTMS treatment. Participants will have an MRI scan and MEG recoding at the performed a week before rTMS. And MEG recording after 7day the application of rTMS
223599649|NCT01874444|DEVICE|2|"repetitive transcranial magnetic stimulation (Figured 8-Coil MCF-B65): 3000 stimuli of 1 Hz rTMS over the left temporal cortex (110% motor threshold), each consisting of 4 days of rTMS treatment.~Participants will have an MRI scan and MEG recoding at the performed a week before rTMS. And MEG recording after 7day the application of rTMS."
223599650|NCT01874444|DEVICE|3|"repetitive transcranial magnetic stimulation (Figured 8-Coil MCF-B65): 3000 stimuli of 1 Hz rTMS over the left frontal cortex (110% motor threshold) each consisting of 4 days of rTMS treatment.~Participants will have an MRI scan and MEG recoding at the performed a week before rTMS. And MEG recording after 7day the application of rTMS."
223599651|NCT01874444|DEVICE|4|"Sham rTMS, applied with the same combination of parameters as active rTMS, except for the number of stimulations per session.~Participants will have an MRI scan and MEG recoding at the performed a week before rTMS. And MEG recording after 7day the application of rTMS."
223599652|NCT02990676|BEHAVIORAL|Computerised cognitive training|Computerised cognitive training regime
223599653|NCT02173587|DIETARY_SUPPLEMENT|Mussel oil capsules|Each mussel oil capsule contained 200mg thick shell mussel lipid extract and 200mg corn oil.Each patient in this group received daily four mussel oil capsules (containing 800mg mussel oil and 800mg corn oil) for first two months and two mussel oil capsules per day thereafter
223599654|NCT02173587|DIETARY_SUPPLEMENT|Corn oil capsules|Each corn oil capsule contained 400mg corn oil.Each patient in this group received daily four corn oil capsules (1600mg corn oil) for first two months and two corn oil capsules per day thereafter
223599655|NCT02427776|BIOLOGICAL|Autologous CD4+T cells stimulated and expanded ex vivo by a MOG peptide modified by the introduction of a thioreductase motif into the flanking residues of the T cell epitope|1 administration comprising 5 - 50 millions of cells
223599656|NCT02955342|OTHER|no intervention|no intervention
223599657|NCT02069392|BEHAVIORAL|Cognitive remediation training|
224199266|NCT03759509|BEHAVIORAL|aerobic exercise|the experimental group, in which aerobic exercise training is given three times a week, a total of twenty-four times in eight weeks
223599658|NCT02069392|DRUG|Nicotine polacrilex lozenge|Of interest are the effects of nicotine on cognitive remediation training benefits.
223599659|NCT02997982|DRUG|Valaciclovir 500Mg Tablet|Valaciclovir treatment (oral, 500 mg tablets). First week: 500 mg three times daily, second to fourth week: 1000 mg three times daily.
223599660|NCT06445816|DRUG|chemotherapy|"* Parents whose consent was obtained will be asked to fill out the Mother and Child Information Collection Form and Psychological Resilience Scale, respectively.~* Immediately after receiving chemotherapy, the pain levels of the children will be measured with the Facial Expressions Pain Scale - Faces Pain Scale-Revised (FPS-R).~* The psychological resilience scale will be applied to mothers."
223599661|NCT00305630|DRUG|Periocular injection of triamcinolone acetonide 40mg|
224199267|NCT00939965|DRUG|isotretinoin|
224199268|NCT00939965|GENETIC|DNA analysis|
224199269|NCT00939965|GENETIC|polymerase chain reaction|
224199270|NCT00939965|OTHER|laboratory biomarker analysis|
224199271|NCT00939965|OTHER|pharmacological study|
224199272|NCT02758509|DRUG|Pegylated interferon alfa-2a + Ribavirin|
224199273|NCT02758509|DRUG|Pegylated interferon alfa-2a + Ribavirin + Boceprevir|
223599662|NCT02536222|OTHER|Case investigation of malaria passively detected cases with FT/FDA|Systematic reactive malaria case investigation will be performed in all villages of the six intervention health posts. All malaria cases passively detected in a health post or in the community and confirmed with a positive rapid diagnostic test (RDT) will be considered an index case and will be investigated. A team (field worker and community health worker) will visit the household of the index case and the five closest households (in a 100 meter radius) and will test by RDT all the consenting individuals living in the households. Any households with at least one positive RDT (including the index case) will receive a systematic focal drug administration (FDA) treatment with DHAP through which all members will be treated.
223599663|NCT00269633|DEVICE|Blue Light Box 467 nm|467 nm Blue LED Light
223599664|NCT00269633|DEVICE|Red Light Box 657 nm|657 nm Red LED Light
223599665|NCT00386321|DRUG|Yttrium 90 -labeled ibritumomab tiuxetan (Zevalin)|
223599666|NCT00500396|PROCEDURE|Open-Sky Vitrectomy|Open-Sky vitrectomy with removal of the Tunica vasculosa lentis and retinal reattachment
223599667|NCT04415411|OTHER|Nursing care based on the Theory of Human Caring|Planned nursing care based on 10 caritas processes of Theory of Human Caring.
224199274|NCT02758509|DRUG|Pegylated interferon alfa-2a + Ribavirin +Telaprevir|
224199275|NCT02758509|DRUG|Ledipasvir/Sofosbuvir|
224199276|NCT02758509|DRUG|Ombitasvir/paritaprevir/ritonavir+Dasabuvir|
224199277|NCT02758509|DRUG|Daclatasvir+Sofosbuvir|
224199278|NCT02758509|DRUG|Simeprevir+Sofosbuvir|
224199279|NCT06265376|BEHAVIORAL|Educational Video|A recorded educational video will be presented to the patient prior to meeting with the provider at the presurgical meeting
224199280|NCT01815372|PROCEDURE|Single penetration dual injection (SPEDI) block technique to block the sciatic and the saphenous nerve with one needle penetration of the skin|
224199281|NCT01815372|PROCEDURE|The classical popliteal sciatic nerve block combined with the mid-femoral saphenous nerve block|
224199282|NCT05193435|OTHER|Pelvic floor exercises|Pelvic floor exercises for types I and II muscle fibers will be performed
224199283|NCT05193435|OTHER|Stabilization exercises|Lumbar spinal stabilization exercises will be performed
224199284|NCT03623217|BEHAVIORAL|Qualitative interviews with participants|For the development and validation of a questionnaire.
224199285|NCT06439134|DIAGNOSTIC_TEST|Pulmonary Ultrasound, Respiratory Function Test|Volunteers underwent pulmonary ultrasound and respiratory function test
224199286|NCT02511873|DRUG|Fycompa|Subjects will take Fycompa for 6 weeks with a dose range of 2mg to 8mg daily
224199287|NCT02511873|DRUG|Placebo|Placebo (looks like study drug but has no active ingredients) for 6 weeks with a dose range of 2mg to 8mg daily
224199288|NCT05878496|PROCEDURE|fixation by plate and screws|reduction and fixation of pediatric fracture neck femur by plate and screws
224199289|NCT04944485|OTHER|(FIT SA F03, SHOFU, USA)|Self adhesive giomer containing nanohybrid flowable composite
224199290|NCT04944485|OTHER|(Neo Spectra™ ST, Dentsply, Sirona, USA)|Conventional technique using putty nanohybrid resin composite
224199291|NCT00502749|BEHAVIORAL|Exercise program|Daily group or personal exercise programs designed to promote flexibility, endurance, and strength.
224199292|NCT00502749|BEHAVIORAL|Questionnaires|Questionnaires taking 15 minutes to complete.
224199293|NCT01856296|PROCEDURE|Biopsy|
224199294|NCT03733301|DRUG|Baricitinib|Administered orally.
224199295|NCT03733301|DRUG|Topical corticosteroid|Administered as standard-of-care.
224199296|NCT03733301|DRUG|Placebo|Administered orally.
223507239|NCT03996213|OTHER|leg elevation position|Leg elevation position will be achieved by raising the patient legs for 30 cm using two standard pillows positioned under the heels 1-minute before induction of anesthesia. The position will be maintained for 15 minutes after induction of anesthesia
223507240|NCT04691232|BIOLOGICAL|Regulatory T cells|Autologous, ex vivo expanded, regulatory T cells
223507241|NCT03640377|DRUG|Praziquantel|Praziquantel given as crushed tablets (40 or 80 mg/kg)
223507242|NCT03432962|OTHER|no intervention - recoding of food recall only|recoding of food recall
223507243|NCT04721262|DEVICE|Hyperfine Portable MRI|The Hyperfine device is a newly developed MRI unit that has multiple potential advantages over standard CT or MRI including portability, easier upkeep, open design, and ease of use. Unlike CT, the Hyperfine device does not use moving parts or X-rays to generate images. Unlike routine MRI, the Hyperfine device uses two permanent magnets with open space between and around them, rather than a super-cooled superconducting magnetic tube. In contrast to CT and routine MRI, the device can be wheeled from place to place and moved into position with the patient remaining on a gurney or hospital bed. Relative to routine MRI, the device uses a very low magnetic field strength of 64 mT compared to 1.5 T or 3 T, making it safer for patients or environments with medical devices having metallic components.
223507244|NCT05033457|PROCEDURE|unilateral biportal endoscopy technique or percutaneous endoscopic transforaminal discectomy|Treatment of lumbar intervertebral disc herniation with unilateral biportal endoscopy technique in unilateral biportal endoscopy technique group.Treatment of lumbar intervertebral disc herniation with percutaneous endoscopic transforaminal discectomy in percutaneous endoscopic transforaminal discectomy group.
223507245|NCT04299620|DEVICE|Digital Image Analysis|Analysis of images
223507246|NCT04299620|PROCEDURE|Radical Prostatectomy|Undergo standard of care radical prostatectomy
223507247|NCT04299620|PROCEDURE|Transrectal Ultrasound|Undergo transrectal ultrasound
223507248|NCT02455180|DRUG|Ascorbic Acid|Patients receive vitamin C 4 times in either high (5g) or moderate (1g) dose. Vitamin C will be administered intravenously (ascorbinezuur CF 100 mg/ml, Centrafarm BV, Etten Leur, Netherlands) in 50ml of NaCl 0.9%, infused over 30 minutes.
223507249|NCT06398639|OTHER|Polygenic Risk Score (PRS)|"Participants will be put into PRS cohorts based on their genetic data.~All participants enrolled into the study will receive a PSA screening test and an mpMRI, regardless of their polygenic risk score."
223507250|NCT00105508|DRUG|Sarizotan|Subjects will receive sarizotan 1 milligram orally twice daily for 24 weeks.
223507251|NCT00105508|DRUG|Placebo|Subjects will receive placebo matched to sarizotan orally twice daily for 24 weeks.
223507252|NCT01574560|BEHAVIORAL|Brochure|Information regarding secondhand smoke and creating a healthy home environment.
223507253|NCT01574560|BEHAVIORAL|Counseling|Receives brochure and counseling sessions focusing on changing smoking behaviors and/or other health behaviors.
223507254|NCT00086307|DRUG|Pramipexole|Pramipexole will be titrated so patients receive the following medication three times per day during the weeks noted: .125 milligrams (mg) in week 1, .250 mg in week 2, .5 mg in week 3, and .75 mg in weeks 4 to 6.
223507255|NCT00086307|DRUG|Escitalopram|Escitalopram will be started at 10 mg/day and patients will continue on this throughout the study.
223507256|NCT03294655|BEHAVIORAL|Pilot Resilience Building Intervention|The intervention will include a brief one-on-one visit in which psychoeducational information on building resilience will be given via a PowerPoint presentation, which will include exercises for the participants to engage in over the following four weeks in their daily lives. After the presentation participants will also develop a personalized intervention plan where they will choose at least five areas of the American Psychological Association 10 Strategies for Building Resilience on which to specifically focus. Participants will also receive a pamphlet of abbreviated information from the PowerPoint presentation.
223507257|NCT00362609|DRUG|pantoprazole|
223507258|NCT00311805|BIOLOGICAL|Autologous Stem Cells (CD34+)|Intramuscular Injections
223507259|NCT00508846|BEHAVIORAL|Questionnaire|Two-part telephone questionnaire lasting about 60 minutes total.
223507260|NCT01746160|DRUG|C1 Implant|Patients treated with dental implants.
223507261|NCT00559351|PROCEDURE|transthoracic esophagectomy 2-field extended lymphadenectomy|right thoracotomy, mobilization of the esophagus, mediastinal lymph node dissection, laparotomy, gastric tube formation, abdominal lymph node dissection, anastomosis in the neck
224199297|NCT03415139|DRUG|Oral Glucose Tolerance Test (OGTT)|A standard OGTT will be performed. During OGTT 75gm of glucose will be given followed by phlebotomy.
224199298|NCT03415139|DRUG|2 OGTTs with and without GLP-1 analogue|A standard OGTT will be performed and a second OGTT procedure will be repeated on a different day with GLP-1 analogue.
223599668|NCT00545896|PROCEDURE|Extracorporeal shockwave therapy|Extracorporeal application of shockwaves on the surface of chronic wounds.
223599669|NCT05532280|DRUG|Etoricoxib 90 mg film coated tablet|an immediate-release tablet containing 90 mg of Etoricoxib
223599670|NCT05532280|DRUG|Arcoxia 90 mg film coated tablet|an immediate-release tablet containing 90 mg of Etoricoxib
223599671|NCT04598412|OTHER|No intervention|Cross-sectional
224199299|NCT03415139|DRUG|Hyperglycemic clamp procedure|During the hyperglycemic clamp procedure, D20 will given, followed by phlebotomy.
224199300|NCT04725214|DRUG|Anlotinib|Anlotinib With STUPP Regimen
224199301|NCT00380861|DEVICE|Total knee replacement using the PFC Sigma RPF knee implant.|Total knee replacement
224199302|NCT00380861|DEVICE|Total knee replacement using the PFC Sigma RP knee implant|Total knee replacement
223599672|NCT02927938|PROCEDURE|Allogeneic HCT|Allogeneic HCT
223599673|NCT02927938|DRUG|Consolidation chemotherapy|Cytarabine-based consolidation chemotherapy
223599674|NCT04129892|BEHAVIORAL|"In Favor of My Resilient Self Academic course"|Assessing the effect of an academic course on student's emotional resilience.
223599675|NCT05273541|BIOLOGICAL|Coronavirus vaccination|Patients in this trial need to accept a prime-boost vaccination against SARS-CoV-2 after 6 to 8 months of the first vaccination
223599676|NCT02386501|DRUG|ADXS31-164|
223599677|NCT02476006|DRUG|ALIROCUMAB SAR236553 (REGN727)|Pharmaceutical form:solution Route of administration: subcutaneous
223599678|NCT02476006|DRUG|placebo (for injection training only)|Pharmaceutical form:solution Route of administration: subcutaneous
223599679|NCT02476006|DRUG|ezetimibe|Pharmaceutical form:capsule Route of administration: oral
223599680|NCT02476006|DRUG|atorvastatin|Pharmaceutical form:tablet Route of administration: oral
224199303|NCT00262483|DRUG|VX-950|
224199304|NCT00262483|DRUG|ribavirin|
223599681|NCT02476006|DRUG|rosuvastatin|Pharmaceutical form:tablet Route of administration: oral
223599682|NCT02476006|DRUG|simvastatin|Pharmaceutical form:tablet Route of administration: oral
223599683|NCT00240669|DEVICE|Resorbable device PLLA/PGA|
223599684|NCT00240669|DEVICE|Titanium device|
223599685|NCT03872791|BIOLOGICAL|KN046|KN046 at a dose level of 3 or 5 mg/kg via intravenous infusion on Days 1 and 15 of 28-day cycle
223599686|NCT03872791|DRUG|Nab-paclitaxel|Nab-paclitaxel at dose level of 100 mg/m2 via intravenous infusion on Days 1, 8 and 15 of 28-day cycle
223599687|NCT00997594|PROCEDURE|Radiofrequency ablation|Radiofrequency (RF) ablation was done after RF electrodes were placed in the adrenal tumor in the adrenal RF ablation group. RF ablation was done after RF electrodes were placed in the targeted abdominal tumors other than adrenal gland in the abdominal RF ablation other than adrenal gland group.
223599688|NCT02611817|DRUG|Vedolizumab SC 108 mg|Vedolizumab SC Injection.
223599689|NCT02611817|DRUG|Placebo|Vedolizumab placebo-matching SC injection.
223599690|NCT02611817|DRUG|Vedolizumab IV 300 mg|Vedolizumab IV Injection.
223599691|NCT02919254|DIETARY_SUPPLEMENT|Beet It Sport Shot|Commercially available concentrated beetroot juice supplement intended for athletes.
223599692|NCT02919254|OTHER|Placebo|Fruit juice cordial containing negligible nitrate
223599693|NCT01429701|DRUG|polymyxin B sulphate + prednisolone + benzocaine + clioquinol|applied 3 times / day at lesion
223599694|NCT01429701|DRUG|betamethasone + gentamicin + tolnaftato + cleoquinol|applied 3 times / day at lesion
223599695|NCT04499560|DIETARY_SUPPLEMENT|Supplement Drink|Superfoods based nutritional supplement
223599696|NCT04197180|PROCEDURE|Hybrid Argon Plasma Coagulation|Argon Plasma Coagulation after water injection for local ablation
223599697|NCT00363623|DEVICE|Silicone hydrogel contact lens|
223599698|NCT02836405|DEVICE|Transcranial Magnetic Stimulation|Single pulses of TMS as well as continuous theta burst stimulation (cTBS) will be applied to the motor cortex.
223599699|NCT00931606|BIOLOGICAL|Sotatercept|up to 4 subcutaneous doses of sotatercept given once every 28 days
223599700|NCT00931606|DRUG|Placebo|up to 4 subcutaneous doses of placebo given once every 28 days
223599701|NCT02549547|BEHAVIORAL|Group Medical Visits|"Cohorts will participate in a weekly series of 14 Group Medical Visits (GMVs) co-led by a psychiatrist and an exercise professional. Each two-hour Group Medical Visit will be divided into three sections:~* Group check in/out; enter patients weekly step count into database; review and outline the day's group program - 20 minutes~* Group discussion, regarding selected physical activity topics including psychiatric issues - 50 minutes~* Physical activity component - 50 minutes The 'content' or curriculum of the GMVs will support participant Self-Management/Activation. Research has consistently emphasized the role of positive feedback, social support, reinforcement, goal setting, and motivation for improving person's self-perception to uptake physical activity."
224199305|NCT00262483|DRUG|peginterferon alfa-2a|
224199306|NCT05619484|DEVICE|Smart AFO|Diagnostic ankle-foot orthosis with AFO stiffness and range of motion settings adjusted using a mobile application
224199307|NCT00337727|DRUG|aprepitant|aprepitant 125 mg capsule; aprepitant 80 mg capsule Three day treatment period.
224199308|NCT00337727|DRUG|Comparator: ondansetron|Ondansetron 8 mg capsule Three day treatment period.
224199309|NCT00337727|DRUG|Comparator: dexamethasone|dexamethasone 12 mg tablets; 20 mg tablets Three day treatment period.
224199310|NCT00337727|DRUG|Comparator: fosaprepitant dimeglumine|fosaprepitant dimeglumine 115 mg
224199311|NCT00337727|DRUG|Comparator; Placebo (unspecified)|dexamethasone 12mg Pbo tablets.
224199312|NCT00337727|DRUG|Comparator; Placebo (unspecified)|Aprepitant 80 mg \& 125 mg Pbo capsules.
224199313|NCT00320801|DRUG|Buprenorphine transdermal patch|Buprenorphine transdermal patch 5 mcg/h applied for 7-day wear
224199314|NCT00320801|DRUG|Buprenorphine transdermal patch|Buprenorphine transdermal patch 20 mcg/h applied for 7-day wear
224199315|NCT05659082|DEVICE|Laser Interstitial Thermal Therapy|Ventral capsulotomy for OCD using laser interstitial thermal therapy
224199316|NCT05039931|DRUG|GNC-035|Administration by intravenous infusion.
224199317|NCT00577031|DRUG|bevacizumab [Avastin]|7.5mg iv on day 1 of each 3 week cycle
224199318|NCT00577031|DRUG|Oxaliplatin|130mg/m2 iv on day 1 of each 3 week cycle
224199319|NCT00577031|DRUG|Xeloda|1000mg/m2 po bid on days 1-14 of each 3 week cycle
223599702|NCT00432406|DRUG|Infliximab|Infliximab 5 mg/kg given at day 1, week 2, week 6
223599703|NCT00432406|DRUG|Etanercept|Etanercept 25 mg twice weekly
224199320|NCT05044182|PROCEDURE|Decompression and drainage seton|Incision the internal sphincter over the fistula tract in intersphinteric space to achieve decompression then drainage seton will be put around external sphincter.
224199321|NCT05044182|PROCEDURE|Cutting seton|Cutting seton is introduced from outside openning to internal openning and encircling the internal and external anal sphincter.
224199322|NCT06515639|OTHER|Diet therapy for Classic IF diet group|The 16:8 intermittent fasting model was applied for six weeks. Time restrictions were tailored to fit the participants' lifestyles, with feeding times set between 10:00-12:00 and 18:00-20:00 for all participants. The classic intermittent fasting diet was planned with a macronutrient distribution of 45-60% carbohydrates, 10-15% protein, and 25-30% fat. Additionally, total energy intake was reduced by 500-750 kcal.
224199323|NCT06515639|OTHER|Diet therapy for low carb-High fat IF diet group|The 16:8 intermittent fasting model was applied for six weeks. Time restrictions were tailored to fit the participants' lifestyles, with feeding times set between 10:00-12:00 and 18:00-20:00 for all participants.The low carb-high fat intermittent fasting diet included 10-30% carbohydrates and 50-65% fat.Additionally, total energy intake was reduced by 500-750 kcal.
224199324|NCT06337344|BEHAVIORAL|Baduanjin|The treatment group will individually perform single-session Baduanjin by following a video broadcasted the standardised BDJ protocol, which lasted for 12 minutes including 6 times of BDJ movements. Breathing rhythm is emphasised to be followed by participants.
224199325|NCT06337344|BEHAVIORAL|Exercise|The active control group will individually perform 8-sets of aerobic exercise movement by following a video selected by registered physiotherapist.
224199326|NCT06337344|BEHAVIORAL|Video Viewing|The control group will individually watch a 12-minute video with 6-minute introducing BDJ practice and 6 minute introducing aerobic exercise. This control group is used for controlling the effect of behavioural movement and brain activity generated by passive video viewing.
224199327|NCT06567223|PROCEDURE|Vibration Therapy|will receive the whole body vibration therapy. Patient will be ask to stand on the vibration plate in semi flexed knee position will 3 minute time of rest and therapy. It will be given for four weeks three days per week. Acceleration will be 18.0 meter per second square and frequency will be from 30 to 40 Hz. Intensity of the therapy will increase throughout all the sessions
224199328|NCT06567223|COMBINATION_PRODUCT|Rhythmic auditory stimulation therapy.|will receive rhythmic auditory stimulation therapy. Rhythmic auditory stimulation will be given for 90 minutes along with 30 minutes of conventional physiotherapy. It will consist of 15 minutes of general body warming metronome rhythm which proceed towards RAS music based exercise of 60 minutes. This period also ends up with 15 minutes of relaxation exercise. Relaxing Music was provided through headphones having voice cancellation property for 15 min. The total session will be given three days per week for four weeks. Exercises such as lateral walking military march, anterior walking, one toe and one heel walking along with posterior walking through progression with the speed of the rhythm is done
224199329|NCT05237674|BEHAVIORAL|The TEACHOUT intervention|"The core component of the Intervention is a two-day training course on EOtC given to elementary school teachers followed by the teachers committing to apply EOtC for at least five hours a week, delivered in 1-2 weekly sessions for one school year (in this study, August 2022 to June 2023).~In the training course knowledge and understanding of the practice and theory of EOtC is facilitated in presentations and talks supplemented by illustrative examples in workshops and plenum discussions on local implementation. The 1-2 weekly EOtC sessions during the school year 2022-2023 may be delivered by one or more teachers simultaneously in various school subjects, at various places outside the school buildings."
224199330|NCT05863325|DRUG|HB1801|HB1801 will be administered by intravenous (IV) injections on the first day of each cycle.
223507262|NCT00559351|DRUG|neoadjuvant chemotherapy (cisplatin, 5-fluorouracil)|21-day combination systemic chemotherapy regimen consisted of a continuous infusion of cisplatin (20mg/m2/day) on days 1-5, 17-21 and 5-fluorouracil at 300mg/m2/day on days 1-21 followed by 3-phase transthoracic esophagectomy with 2-field extended lymphadenectomy after 3 week interval
223507263|NCT00559351|RADIATION|neoadjuvant chemoradiotherapy|21-day combination systemic chemotherapy regimen consisted of a continuous infusion of cisplatin (20mg/m2/day) on days 1-5, 17-21 and 5-fluorouracil at 300mg/m2/day on days 1-21 with concurrent external beam fractionated irradiation to a total dose of 30Gy (2Gy fractions on days 1-5, 8-12, 15-19) followed by 3-phase transthoracic esophagectomy with 2-field extended lymphadenectomy after 3 week interval
223599704|NCT00860171|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Autologous stem cells given via central catheter
223599705|NCT00860171|RADIATION|Iodine I 131 Monoclonal Antibody BC8|Given IV
223599706|NCT00860171|OTHER|Laboratory Biomarker Analysis|Correlative studies
223599707|NCT05542758|OTHER|Total Body HIIT Program|One repetition maximums (1RM) and body weight (BW) will be recorded at prior to and at 6 weeks to tailor the program. The circuit will be completed twice during each session and the exercises will include: squats, medicine ball forward chest throws, medicine ball overhead throw, farmers walk, seated shoulder press, seated row sitting on a fitness ball, aerobic riser step-ups, foot ladder drills, and twisting medicine ball passes. The anaerobic component will be completed once during a session and on a stationary bike. The progression of exercise:rest seconds will be 20:40 for Weeks 1-4, 30:30 for Weeks 5-8, and 40:20 for Weeks 9-12. Each session will start with a 5 minute warm up and end with a 5-minute cool down. Participants will be given real time feedback about heart rate (goal range: 85-95% HRmax) and exercise movement velocity. Participants will be encouraged to surpass the velocity of the previous repetition.
223599708|NCT06529913|DIAGNOSTIC_TEST|Collection of environmental, biological, and clinical data|"All enrolled patients/healthy volunteers will undergo:~* measurement of serum and urine concentration of metals (nickel, cobalt, chromium, palladium, molybdenum, aluminium, and copper).~* Patch test to metals.~* Within-breath analysis of oscillometry parameters.~* Measurement of serum zonulin.~* Measurement of serum levels of protein oxidation products."
223599709|NCT02560272|BIOLOGICAL|Minhai-HIB|0.5ml, intramuscular
223599710|NCT02560272|BIOLOGICAL|Act-HIB®|0.5ml, intramuscular
224199331|NCT05863325|DRUG|Taxotere|Taxotere will be administered by intravenous (IV) injections on the first day of each cycle.
224199332|NCT02494804|DRUG|Temozolomide|Capsules supplied in 5-mg, 20-mg, 100-mg, 140-mg, 180-mg, and 250-mg strengths; dosed at 200 mg/m2/day for 5 consecutive days, repeated every 28 days
223599711|NCT02170870|DRUG|Exendin 9-39|Exendin 9-39 will be administered intravenously (1,200 pmol/kg bolus followed by infusion at 300 pmol/kg/min).
223599712|NCT02170870|DRUG|Microlipid|Lipid infusion {66.7 mL Microlipid (0.5 gm/mL diluted in water to 222 ml).
223599713|NCT02170870|DRUG|Placebo|Normal saline infusion will be prepared to match the appearance of Exendin 9-39
223599714|NCT00837070|PROCEDURE|Percutaneous zygapophyseal cyst rupture|Patients will be treated by introducing a 20G spinal needle in the inferior joint recess of the zygapophyseal joint.1 ml of celestone-chronodose,1 ml of Marcain 5 mg/ml and 1-3 ml of contrast media:Omnipaque 240 will be injected until the cyst ruptures.
224199333|NCT02494804|BIOLOGICAL|CIK|The patients received autologous cytokine-induced killer cells transfusion one week after Temozolomide treat
224199334|NCT05025904|BEHAVIORAL|Real-time fMRI neurofeedback (rt-fMRI NFB)|Real-time fMRI neurofeedback targeting control of the left medial prefrontal cortex. Participants continuously received visual feedback on the level of activity within the 2D region of interest corrected to the whole-slice brain volume activity. Up- and downregulation blocks were switched for better control.
223617969|NCT03076762|DRUG|intravesical onabotulinumtoxinA injection|Each vial of onabotulinumtoxinA will be diluted with 10 ml of normal saline, resulting in 10U onabotulinumtoxinA per 1.0 ml. Patients assigned for suburothelial BoNT-A injections received 20 injections in the bladder body whereas those assigned trigonal injections will receive 10 sites injections at the trigonal area (5 injections behind interureteric ridge and 5 inside the trigone).
223617970|NCT03111836|BEHAVIORAL|Control Group|Received general information about blood pressure control. All subjects will be sent 16 e-messages on a weekly schedule.
223507264|NCT02622022|DRUG|Morphine hydrochloride|
223507265|NCT02622022|OTHER|Placebo|
223507266|NCT05033600|DEVICE|S.C.I.O.|The devices read, emit and entrain Electromagnetic waves of the body.
223507267|NCT05618847|DEVICE|Acapella,ACBTS|Every subject will perform supervised ACBTs with and without acapella for four weeks. Three sessions per week will be given with 20 repetitions in two sets
223507268|NCT05618847|OTHER|ACBTs|Every subject will perform supervised ACBTs with and without acapella for four weeks. Three sessions per week will be given with 20 repetitions in two sets
223507269|NCT01663805|DRUG|Everolimus|Everolimus is started immediately after transplantation, the dosage of 1.5 mg twice a day, adjusted to achieve and maintain the blood level of 3-8 ng/mL.
223507270|NCT02278237|BEHAVIORAL|VME Group|Received inhaler education through VME (virtual education module)
223617971|NCT03111836|BEHAVIORAL|Expert-Driven Group|The user-driven e-Counselling group will receive a lifestyle program where the user are able to choose areas of focus. All subjects will be sent 16 e-messages on a weekly schedule.
223617972|NCT03111836|BEHAVIORAL|User-driven group|The user-driven e-Counselling group will receive a lifestyle program where the user are able to choose areas of focus. All subjects will be sent 16 e-messages on a weekly schedule.
223617973|NCT01425034|OTHER|casts for the thumb|The 'Cast' group will be placed in a thumb spica short arm cast with the thumb IP joint free. They will be allowed digit, thumb IP and elbow range of motion.
223617974|NCT01425034|OTHER|Motion group|The 'Motion' group will be placed in a forearm based thumb spica splint with the thumb IP free. They will be allowed digit, thumb IP and elbow range of motion.
223617975|NCT03439501|DRUG|avelumab|"* Study drug: Avelumab (PD-L1 inhibitor; MSB0010718C)~* Dosage: 10 mg per body weight (kg) of a subject every two weeks~* One cycle consists of two injection of avelumab (28 days).~* The treatment cycle will be repeated until progression of disease or unacceptable toxicity and dose adjustments are permitted for patients who are unable to tolerate the side effects of drugs within each cycle."
223617976|NCT01931423|BEHAVIORAL|Placental cord drainage|
223617977|NCT04696081|OTHER|occurence of atrial fibrillation|all adult patients with an active cancer and experiencing atrial fibrillation will be consecutively include. Active cancers will be defined according Agnelli et al. (NEJM 2020; 382:1599-1607).
223617978|NCT01900795|DRUG|V117957|V117957 4.5 mg suspension taken orally after surgery.
223617979|NCT01900795|DRUG|Ibuprofen|Ibuprofen 400 mg tablets taken orally after surgery.
223617980|NCT01900795|DRUG|Placebo|Placebo taken orally after surgery.
223617981|NCT04122365|OTHER|Chest Wall Mobilization Program|Soft tissue therapy and joints mobilization
223617982|NCT04122365|OTHER|Control|Routine limbs exercises and education
223617983|NCT02368665|DRUG|Amlodipine 5mg|\- Daily oral administration for 8 weeks
223617984|NCT02368665|DRUG|Amlodipine 5mg, Candesartan cilexetil 16mg|\- Daily oral administration Amlodipine 5mg for 8 weeks
223617985|NCT02368665|DRUG|Amlodipine 10mg, Candesartan cilexetil 16mg|\- After 8 weeks of administration, Amlodipine 10mg and Candesartan cilexetil 16mg once a day for 8 weeks
223617986|NCT01295359|OTHER|Ground Walking Program|The patients will walk on a corridor, for 40min, once a day. The speed will be controlled through a metronome, that will be programed to a frequency of steps/min determinated as 80% of the mean frequency of steps performed in six minutes walk test of that day. The 40min will be divided in 3min of walk and 2min of rest, totalizing 24min of exercise and 16min of rest. Furthermore, these patients, in sitting position, will receive orientation to do calm and slow inspirations and expirations, associated with pursed lips expiration. They will try to maintain its Respiratory Rate in 6bpm, during four minutes.
223617987|NCT00887302|PROCEDURE|Gastric Band|Places a band over the upper portion of the stomach.
223617988|NCT00887302|PROCEDURE|Gastric Sleeve|Stapling stomach vertically to reduce size of stomach and removal of larger curve portion of the stomach
223617989|NCT00887302|PROCEDURE|Gastrostomy Tube|Tube is inserted into the stomach that delivers nutrition directly into the stomach.
223617990|NCT03022877|DRUG|Levosimendan|In a prospective randomized setting, patients are included with an acute STEMI of the anterior wall. A bolus administration Levosimendan with/without following continuous infusion over 24 hours compared to a control group (placebo) will be examined. The initiation of therapy is carried out for 10 min. prior to reperfusion. The coronary Intervention is performed immediately after inclusion at the latest within 6 hours after the onset of symptoms. The administration of Levosimendan is based on a fixed schema: Bolus: 12 µg/kg over 10 min I. V., starting 10 min before recanalization and an addition of 0.1-0.2 µg/kg/min i. v. for 24 hours in the continuous infusion group.
223617991|NCT04562454|OTHER|Specific diet|use a specific diet in different days with CGM to konw GI of different food in diabetes
224199335|NCT05025904|BEHAVIORAL|Сognitive behavioral therapy (CBT)|A combination of individual and small-group cognitive behavioral therapy by an experienced medical psychologist and a psychiatrist.
224199336|NCT05025904|BEHAVIORAL|EEG neurofeedback (EEG NFB)|EEG neurofeedback targeting frontal alpha asymmetry index. Participants continuously received visual feedback on their frontal alpha asymmetry index. Up-regulation condition only was utilized.
224199337|NCT05923333|DIETARY_SUPPLEMENT|B. infantis Rosell®-33|B. infantis Rosell®-33 + maltodextrin
224199338|NCT05923333|DIETARY_SUPPLEMENT|Placebo|Maltodextrin
224199339|NCT01082601|PROCEDURE|Pulmonary Vein Isolation (PVI)|Subjects with clinical indication for PVI, either paroxysmal or persistent AF failing medical management with rate or rhythm control medications.
224199340|NCT04469322|DIAGNOSTIC_TEST|Mental Health DNA Insight Test (Pathway Genomics)|Pharmacogenetic report based on the patients DNA profile at \~45 SNP markers covering 16 genes
224199341|NCT04469322|DIAGNOSTIC_TEST|Sham Test|"Names of 53 medications listed with use as directed"
224199342|NCT05101057|DEVICE|SpinalogicTM Bone Graft Stimulator|The SpinalogicTM is a portable, battery-powered, microprocessor-controlled, non-invasive bone growth stimulator. The device is currently approved and commercially indicated as an adjunct electrical treatment to primary lumbar spinal fusion surgery for one or two levels.
224199343|NCT02241200|DRUG|DA3880|
224199344|NCT02241200|DRUG|Aranesp|
224199345|NCT00109278|BIOLOGICAL|V205C, measles, mumps, and rubella virus vaccine live|
224199346|NCT00109278|BIOLOGICAL|Comparator: Measles, Mumps, and Rubella Virus Vaccine Live|
224311235|NCT04521582|BEHAVIORAL|Lifestyle counselling|Female Community Health Volunteer will provide lifestyle counseling at the participant's home
223599715|NCT03412812|RADIATION|6 Gy|As focal radiation techniques are utilized more frequently in the treatment of brain metastases, there is increasing need to accurately define the appropriate patient and tumor characteristics for focal therapy. Unfortunately, not all patients are good candidates for single fraction stereotactic radiosurgery (SRS) since large tumors and those in unfavorable locations have been associated with unacceptable rates of treatment-related toxicity. Five fraction stereotactic radiation has proven to be a more effective treatment for these patients that aren't good candidates.
223617992|NCT04684264|OTHER|Heart Failure Prevention Clinic|Heart Failure Prevention Clinic is a pharmacist-directed practice in collaboration with an attending cardiologist that uses evidence-based guidelines to optimize medications and lifestyle interventions for heart failure prevention.
223617993|NCT02308956|BEHAVIORAL|Integrated mental health in primary care|A task-shared model of collaborative mental health care integrated into the primary care setting.
223617994|NCT02308956|BEHAVIORAL|Psychiatric nurse-led specialist care|A centralised, psychiatric nurse-led, hospital out-patient service with outreach from project outreach workers
223617995|NCT06316908|DRUG|Unilateral Neurolytic Celiac Plexus Block with Absolute Alcohol|Participants assigned to the unilateral neurolytic celiac plexus block group underwent a minimally invasive procedure where a solution of absolute alcohol was injected unilaterally into the celiac plexus under image guidance. The procedure was performed by an experienced interventional pain specialist. Prior to the injection, local anesthesia was administered to minimize discomfort. Once positioned correctly, a needle was inserted into the designated area, and a small amount of absolute alcohol was injected to disrupt the neural pathways responsible for transmitting pain signals from the abdominal region. The intervention aims to provide long-term pain relief for participants suffering from chronic abdominal pain.
223617996|NCT06316908|DRUG|Bilateral Neurolytic Celiac Plexus Block with Absolute Alcohol|Participants allocated to the bilateral neurolytic celiac plexus block group underwent a similar minimally invasive procedure as described above, with the exception that the injection of absolute alcohol was administered bilaterally into the celiac plexus. The procedure was performed by an experienced interventional pain specialist under image guidance, with local anesthesia administered prior to the injection to ensure patient comfort. Following correct needle placement, absolute alcohol was injected into both sides of the celiac plexus to disrupt neural pathways responsible for transmitting pain signals from the abdominal region. The intervention aims to provide comparable or potentially enhanced long-term pain relief compared to the unilateral approach, with the additional benefit of targeting both sides of the celiac plexus.
223617997|NCT00546624|DRUG|MK0777|
223617998|NCT04138303|OTHER|Exercise Protocol|The exercise protocol consists of a nine-week progressive intense-conditioning program involving six consecutive days (Monday-Saturday) of one-hour exercises and one-day rest weekly for a total of 54 days of exercise. Exercises are performed in person as a group with other participating subjects and lead by certified instructors. Exercises will involve a variety of activities ranging from running, cycling, whole-body functional movements, power movements, and open-chain weight lifting with barbells and resistance bands.
223617999|NCT04138303|OTHER|Calorie-Restrictive Low Carbohydrate Diet (CR-LC)|Consists of weekly nutrition plans, counseling and monitoring by on-site registered dietitians and nutritionists for nine weeks. CR-LC consists of caloric and macronutrient restrictions. Caloric restrictions involves a 40% deficit from calculated total daily energy expenditure. Macronutrient restriction involves a high protein, low carbohydrate diet (35% protein, 25% carbohydrate and 40% fat).
223618000|NCT04138303|OTHER|Ancestral Diet (AD)|Consists of weekly nutrition plans, counseling and monitoring by on-site registered dietitians and nutritionists for nine weeks. AD consists of consuming only whole foods and avoiding processed foods. Emphasis will be on food quality with no caloric or macronutrient restrictions.
223618001|NCT01176058|DRUG|Anidulafungin/Fluconazole|Anidulafungin:IV,100 mg daily preceded by an initial 200 mg dose on Day 1, 14 - 42 days Fluconazole: IV/Oral, 400mg,QD,14 - 42 days
223618002|NCT02528825|DRUG|Remifentanil titration|Initial concentration being 1.5ng/ml for the first patient The smooth emergence was defined as extubation without cough-a strong and sudden contraction of the abdomen. The predetermined concentration was decreased by 0.5 ng/ml for the next patient if the patient did not cough during emergence and similarly, if the patient coughed anytime during emergence, it was considered failed smooth emergence and predetermined concentration was increased by 0.5 ng/ml.
223618003|NCT05220306|DEVICE|Monitoring of vital signs|The MouthLab is a hand-held device. The user holds the unit in their left hand with the Mouthpiece between the teeth and lips and breathes normally into the device for 30 seconds.
223618004|NCT06079333|DRUG|dabrafenib/trametinib|braf/mek-inhibition
223507271|NCT06294353|DEVICE|WELT-ED (CBT based DTx)|The product delivers Cognitive Behavioral Therapy for Eating Disorders (CBT-ED) through a software interface (iOS and Android), designed to engage patients in a structured and interactive manner. It operates by analyzing patterns in the patient's lifestyle and eating data, identifying problematic behaviors associated with their eating disorder. Based on this analysis, the software sets daily learning objectives aimed at fostering positive cognitive and behavioral habits. By providing tailored guidance and support, the product seeks to assist patients in making sustainable changes, ultimately contributing to the improvement of eating disorder symptoms. This approach combines the principles of CBT-ED with the convenience and accessibility of digital technology, offering a personalized therapeutic experience to support patients in their recovery.
223507272|NCT06294353|BEHAVIORAL|Standard Treatment|In the control group, from screening/baseline (Visit 1) to 8 weeks (Visit 5), counseling and support therapy will be conducted at all visits. Participants can continue taking SSRI medications and other antipsychotic drugs that they were already taking for the treatment of eating disorders during the trial period. However, the intake of any additional antipsychotic drugs, other than those already being taken (including SSRIs), is prohibited during the trial period.
223507273|NCT01416051|DIETARY_SUPPLEMENT|Olibra|Fractionated palm oil and fractionated oat oil in the proportion of 95:5
223507274|NCT01416051|OTHER|Placebo|100% milk fat
223507275|NCT04483947|DRUG|AZD2693|Subcutaneous administration of AZD2693 multiple ascending doses in participants with NASH and who are carriers of the PNPLA3 148M risk allele(s).
223507276|NCT04483947|OTHER|Placebo|Participants randomised to placebo will receive the corresponding dose volume of solution as participants receiving AZD2693 within the same cohort
223507277|NCT05280808|DEVICE|Experimental phone app used for self-fitting of hearing aids|This software allows participants to set up hearing aids as appropriate for their hearing loss
223507278|NCT06100445|BEHAVIORAL|Semi structured interviews|Gaining qualitative data
223507280|NCT00484900|DRUG|Co-Arinate FDC|
223507281|NCT00484900|DRUG|Coartem|
223507282|NCT05577104|PROCEDURE|Negative pressure wound therapy (NPWT)|For patients in the NPWT group, the wound bed preparation was facilitated by vacuum-assisted closure (VAC).
223507283|NCT05577104|PROCEDURE|conventional moist dressings|For patients in the control group, the wound bed preparation was facilitated by conventional dressing change method (with alginates ).
223507284|NCT04692051|DRUG|Nab-paclitaxel + Cisplatin|Nab-paclitaxel 125mg/m2 IV on D1,8 plus Cisplatin 75mg/m2 IV on D1 , every 21 days.
223507285|NCT04692051|DRUG|Gemcitabine + Cisplatin|Gemcitabine1000mg/m2 IV on D1,8 plus Cisplatin 75mg/m2 IV on D1 , every 21 days.
223507286|NCT06132750|OTHER|No intervention|No intervention
223507287|NCT02050295|PROCEDURE|Nerve block washout|Saline will be infused through the perineural catheter to reverse motor block.
223507288|NCT02050295|PROCEDURE|Sham washout|Infusion of saline to maintain catheter patency.
223507289|NCT02050295|DRUG|Saline|
223507290|NCT04419974|DIAGNOSTIC_TEST|Molecular Diagnosis|Double-blind molecular diagnosis for the SCA3/MJD mutation.
223507291|NCT04419974|DIAGNOSTIC_TEST|Clinical Scales - Baseline|SARA, NESSCA, ICARS, INAS, SCAFI, CCFS will be applied on baseline.
223507292|NCT04419974|DIAGNOSTIC_TEST|Blood Draw - Baseline|"Blood collection on baseline for evaluation of~* Candidate genes expression~* Serum proteins~* Lymphocytic proteins"
223507293|NCT04419974|DIAGNOSTIC_TEST|Quality of Life Assessment - Baseline|Participants fill out 2 self-reported quality of life questionnaires.
223507294|NCT04419974|DIAGNOSTIC_TEST|Clinical Scales - Follow-up 12 months|SARA, NESSCA, ICARS, INAS, SCAFI, CCFS will be applied 12 months after baseline for prospective evaluation.
223507295|NCT04419974|DIAGNOSTIC_TEST|Blood Draw - Follow-up 12 months|"Blood collection 12 months after baseline for prospective evaluation of~* Candidate genes expression~* Serum proteins~* Lymphocytic proteins"
223507296|NCT04419974|DIAGNOSTIC_TEST|Quality of Life Assessment - Follow-up 12 months|Participants fill out 2 self-reported quality of life questionnaires for prospective evaluation.
223507297|NCT04419974|DIAGNOSTIC_TEST|Clinical Scales - Follow-up 24 months|SARA, NESSCA, ICARS, INAS, SCAFI, CCFS will be applied 24 months after baseline for prospective evaluation.
223507298|NCT04419974|DIAGNOSTIC_TEST|Blood Draw - Follow-up 24 months|"Blood collection 24 months after baseline for prospective evaluation of~* Candidate genes expression~* Serum proteins~* Lymphocytic proteins"
223507299|NCT04419974|DIAGNOSTIC_TEST|Quality of Life Assessment - Follow-up 24 months|Participants fill out 2 self-reported quality of life questionnaires for prospective evaluation.
223507300|NCT06814093|PROCEDURE|Robotic surgery|Robotic surgery for radical resection of middle and low rectal cancer
223507301|NCT06814093|PROCEDURE|Laparoscopic surgery|Laparoscopic surgery for radical resection of middle and low rectal cancer
223507302|NCT01767389|OTHER|The GLP-1 receptor agonist users|The GLP-1 receptor agonist users are classified based on the receipt of a GLP-1 receptor agonist at the index date. GLP-1 receptor agonists included in this study are exenatide and liraglutide
223507303|NCT01767389|OTHER|DPP-4 inhibitor users|DPP-4 inhibitor users are classified based on the receipt of a DPP-4 inhibitor prescription at the index date. The DPP-4 inhibitors included in this study are sitagliptin, saxagliptin, linagliptin, combination of sitagliptin and metformin (Janumet), and combination of sitagliptin and simvastatin (Juvisync)
223507304|NCT01767389|OTHER|Other ADA users|Classes of ADA's other than GLP-1 receptor agonists and DPP-4 inhibitors will be included in the 'other ADA' exposure group
223618005|NCT02757989|OTHER|transplantation|allogeneic hematopoietic stem cell transplantation in patients with donor
223618006|NCT05418322|BEHAVIORAL|Oral Hygiene Intervention|The oral hygiene instructions given in the two methods will be prepared in Bahasa Malaysia and English versions with the same content to avoid bias. The oral hygiene education will be validated by three dental specialists. A similar large dental teeth model and toothbrush will be used for the purpose of oral hygiene demonstration.
223618007|NCT02579213|OTHER|observational study done only in women candidate for amniocentesis|As a part of routine test in women with obstetrical indication for amniocentesis, we take 30 cc of amniotic fluid. only additional 3 ml of the amniotic fluid are needed for examination by electronic sensors.
223618008|NCT00003815|BIOLOGICAL|bleomycin sulfate|
223618009|NCT00003815|DRUG|carmustine|
223599716|NCT03412812|RADIATION|7 Gy|As focal radiation techniques are utilized more frequently in the treatment of brain metastases, there is increasing need to accurately define the appropriate patient and tumor characteristics for focal therapy. Unfortunately, not all patients are good candidates for single fraction stereotactic radiosurgery (SRS) since large tumors and those in unfavorable locations have been associated with unacceptable rates of treatment-related toxicity. Five fraction stereotactic radiation has proven to be a more effective treatment for these patients that aren't good candidates.
224199347|NCT03490331|OTHER|Transplantation surgery of genetically corrected cultured epidermal autograft (ATMP)|Surgergical procedure for transplantation under anaesthesia of genetically corrected cultured epidermal autograft (Hologene17) on blistering skin areas of JEB patients. By taking some autologous epidermal cells, a new layer of transgenic tissue is grown in the laboratory. This layer of tissue - containing genetically modified stem cells - is then implanted by a surgeon into the damaged area. The implantation can be done in one or more areas and repeated in case of failure of the first surgery.
224199348|NCT06354127|DRUG|DWP450|The test drug or control drug is injected on the day of administration.
224199349|NCT06354127|DRUG|Botox®|The test drug or control drug is injected on the day of administration.
224199350|NCT06192069|OTHER|Sustainable Heat Strain Prevention Program for Agricultural Elderly Workers (SHiP-AEW)|The SHiP-AEW is a 4-week multifaceted intervention program focused on evidence-based heat strain prevention strategies for agricultural workers over 60 years old. Delivered through weekly 1-hour sessions, the program incorporates the following primary components:
224199351|NCT06067191|DRUG|RV299|Oral Suspension
224199352|NCT06067191|DRUG|Placebo|matching placebo
224199353|NCT00323362|DRUG|gemcitabine hydrochloride|1000 mg/m2 given intravenously at a FDR of 10 mg/m2/min on Days 3 and 10, every 21 days.
224199354|NCT00323362|DRUG|imatinib mesylate|400 mg/day orally, given Days 1-5 and 8-12 every 21 days
224199355|NCT05527301|DRUG|Lactobacillus Fermentum|Lactobacillus Fermentum
224199356|NCT05527301|DRUG|Placebo|Placebo
224199357|NCT02018601|PROCEDURE|BRILMA|
224199358|NCT02018601|PROCEDURE|paravertebral block|
224199359|NCT02018601|DRUG|dexketoprofen|
224199360|NCT02018601|DRUG|paracetamol|
224199361|NCT04764669|DRUG|E2027|Oral hypromellose capsules.
223599717|NCT03412812|RADIATION|8 Gy|As focal radiation techniques are utilized more frequently in the treatment of brain metastases, there is increasing need to accurately define the appropriate patient and tumor characteristics for focal therapy. Unfortunately, not all patients are good candidates for single fraction stereotactic radiosurgery (SRS) since large tumors and those in unfavorable locations have been associated with unacceptable rates of treatment-related toxicity. Five fraction stereotactic radiation has proven to be a more effective treatment for these patients that aren't good candidates.
223618010|NCT00003815|DRUG|cyclophosphamide|
224199362|NCT03340246|PROCEDURE|Delayed sclerotherapy|See arm descriptions
224199363|NCT03340246|PROCEDURE|Immediate phlebectomy|See arm description
223618011|NCT00003815|DRUG|cytarabine|
223618012|NCT00003815|DRUG|doxorubicin hydrochloride|
223618013|NCT00003815|DRUG|etoposide|
223618014|NCT00003815|DRUG|melphalan|
223618015|NCT00003815|DRUG|prednisolone|
223618016|NCT00003815|DRUG|vincristine sulfate|
223618017|NCT00003815|PROCEDURE|autologous bone marrow transplantation|
223618018|NCT00003815|RADIATION|radiation therapy|
223618019|NCT00006326|DRUG|Indinavir sulfate|
223618020|NCT00006326|DRUG|Ritonavir|
223618021|NCT00006326|DRUG|Delavirdine mesylate|
223618022|NCT03480152|BIOLOGICAL|National Cancer Institute (NCI)-4650, a messenger ribonucleic acid (mRNA)-based, Personalized Cancer Vaccine|Patients will receive a messenger ribonucleic acid (mRNA)-based vaccine intramuscularly at two-week intervals for four cycles (one course of treatment). Patients may be vaccinated with a second and final course of treatment using the same vaccine dose. The second course may start approximately four weeks (plus or minus 2 weeks) from the last vaccine dose of the first course.
223618023|NCT04166812|DIAGNOSTIC_TEST|oscillometry|assessment of peripheral airway resistance using oscillometry
223618024|NCT04166812|DIAGNOSTIC_TEST|multiple breath washout testing|assessment of ventilation heterogeneity using multiple breath washout testing
223618025|NCT04166812|DIAGNOSTIC_TEST|spirometry|assessment of lung function using spirometry
223618026|NCT04166812|DIAGNOSTIC_TEST|body plethysmography|assessment of lung function using body plethysmography
223618027|NCT04166812|DIAGNOSTIC_TEST|fractional exhaled nitric oxide|assessment of eosinophilic airway inflammation using fractional exhaled nitric oxide
223618028|NCT04166812|DIAGNOSTIC_TEST|transfer factor|assessment of gas transfer using single breath transfer factor for carbon monoxide
223618029|NCT04166812|DIAGNOSTIC_TEST|health status|assessment of health status using validated questionnaires (St. George's Respiratory Questionnaire \[SGRQ\], COPD Assessment Test \[CAT\])
223618030|NCT04166812|DIAGNOSTIC_TEST|computed tomography|assessment of lung structure and function using computed tomography (only in patients with clinical indication, Heidelberg site)
223618031|NCT04166812|DIAGNOSTIC_TEST|induced sputum|various biomarkers (subgroup of approximately 75 patients, Großhansdorf site)
223618032|NCT05877196|BEHAVIORAL|Moderate Intensity Continuous Training (MICT)|Aerobic cycling at a moderate intensity (50-75% of heart rate reserve) for 30-50 minutes, 3 times per week for 3-6 months.
223618033|NCT05877196|BEHAVIORAL|Chair-based Stretch|Stretching while seated for 30-50 minutes, 3 times per week for 6 months.
223618034|NCT05877196|BEHAVIORAL|High-Intensity Interval Training (HIIT)|Aerobic cycling at a vigorous intensity (80-90% of heart rate reserve 4-minute bouts with 4-minute recovery intervals) for 40 minutes, 3 times per week for 3 months.
223618035|NCT05877196|BEHAVIORAL|Combined Aerobic Resistance Exercise (CARE)|6 full-body strength-building exercises followed by 30 minutes of MICT cycling (described above). Total duration is 60 minutes, 3 times per week for 3 months.
223618036|NCT06306170|RADIATION|Image Guided Radiotherapy|Patients treated with IGRT, IMRT, SBRT for Gynecological cancer will be evaluated
223618037|NCT05777603|DRUG|aerosolized aztreonam|antibiotic with gram-negative bacteria coverage
223618038|NCT05777603|DRUG|aerosolized vancomycin|antibiotic with gram-positive bacteria coverage
224199364|NCT03953391|OTHER|Tea|Subjects walk to a nearby area and prepare a cup of 150 ml tea once every hour. The tea is consumed whilst being seated at their desks.
224199365|NCT03953391|OTHER|Water|150 ml water is served to subjects once every hour. The water is consumed whilst being seated at their desks.
224199366|NCT04769830|OTHER|Bowel sound|The characteristic data of bowel sounds, such as 24-hour average intestinal rate, duration of gastrointestinal sounds, amplitude, maximum frequency and average frequency, were collected to observe the differences of intestinal sounds among different AGI grades.
224199367|NCT05875116|BEHAVIORAL|Virtual reality|The activities will be carried out with the Virtual Reality team, for 1 hour, twice a week, for 12 sessions (6 weeks). It will be indicated to repeat the activities at home, on similar equipment and with the same or similar software, at least 1 hour a day, at least 3 days a week.
224199368|NCT05875116|BEHAVIORAL|Modified constraint-induced movement therapy|"Physical and occupational therapy activities will be carried out with the paretic upper limb, while the patient has the healthy upper limb attached to the chest, for 1 hour, twice a week, for 12 sessions (6 weeks). It will be indicated to repeat the activities at home, 1 hour a day, at least 3 days a week. In addition, the participant will perform activities of daily living with the free paretic arm and the fixed healthy arm, for 5 hours a day."
224199369|NCT05875116|BEHAVIORAL|Usual Physical and Occupational Therapy|The physical and occupational therapy activities that are usually practiced in the Medical Unit will be carried out for 1 hour, twice a week, for 12 sessions (6 weeks). It will be indicated to repeat the activities at home, for 1 hour a day, at least 3 days a week.
224199370|NCT03868176|OTHER|short message service|short message service
224199371|NCT00807040|PROCEDURE|Mitral Valve Repair with Annuloplasty|The annuloplasty ring will be chosen by the surgeon. The ring is sized to the anterior leaflet and intertrigonal distance. A semi-rigid or rigid annuloplasty ring will be used, and if tethering is present, a subvalvar procedure will be performed.
224199372|NCT00807040|PROCEDURE|Mitral Valve Replacement|Mitral valve replacement will include complete preservation of the subvalvar apparatus. The technique of preservation, choice of prosthetic valve, and technique of suture placement will be dependent on the surgeon's preference. The prosthetic valve will be tested for paravalvular leaks by using the left ventricular saline infusion test.
224199373|NCT00625846|OTHER|Laboratory Biomarker Analysis|Correlative studies
224199374|NCT00625846|DRUG|Pazopanib Hydrochloride|Given PO
224199375|NCT01816334|DRUG|methylprednisolone|
224199376|NCT01816334|DRUG|Ketoprofen|
224199377|NCT01816334|DRUG|Sodium Chloride|
224311236|NCT02528513|DRUG|midazolam|Midazolam is started with an infusion bolus of 0.03-0.30 mg/kg and continuous infusion of 0.03-0.20 mg/kg/h, with the dosage adjusted to RASS score (-3 to 0).
223599718|NCT03412812|RADIATION|9 Gy|As focal radiation techniques are utilized more frequently in the treatment of brain metastases, there is increasing need to accurately define the appropriate patient and tumor characteristics for focal therapy. Unfortunately, not all patients are good candidates for single fraction stereotactic radiosurgery (SRS) since large tumors and those in unfavorable locations have been associated with unacceptable rates of treatment-related toxicity. Five fraction stereotactic radiation has proven to be a more effective treatment for these patients that aren't good candidates.
223599719|NCT04142177|OTHER|Pain EASE|The internet-based pain self-management program consists of open access to the Pain EASE program (Pain E-health for Activity, Skills, and Education) for the duration of participation in the trial. Pain EASE has 10 pain coping skill modules: pain education, setting personal goals, planning meaningful activities, physical activity (stretching, body mechanics, and a pedometer-based walking program), relaxation, developing healthy thinking patterns, pacing and problem-solving, improving sleep, effective communication, and future planning.
223599720|NCT04142177|PROCEDURE|Tailored exercise|Findings from the initial examination and the Keele STarT Back Screening Tool (Hill, et al., 2011) will be used by the physical therapist to guide and tailor the intervention to individual participants which will involve up to 8 treatment sessions with ongoing home exercise. For most participants, exercise and physical activity will focus on walking in addition to motor control and stabilization exercises for the low back with flexibility exercises when lumbar spine stiffness is present.
224199378|NCT01010724|DRUG|bIAP|
224199379|NCT01010724|DRUG|Placebo|
224199380|NCT04776135|DRUG|MT-1186|Suspension
224199381|NCT00544713|DRUG|Carboxymethylcellulose and Glycerin based artificial tear|As directed by Investigator at the end of each study visit: 1 to 2 drops in each eye, 1 to 2 times a day up to every hour while awake
224199382|NCT00544713|DRUG|Carboxymethylcellulose|As directed by Investigator at the end of each study visit: 1 to 2 drops in each eye, 1 to 2 times a day up to every hour while awake
224199383|NCT02972086|BEHAVIORAL|Behavioral Parent Training (BPT)|A specific intervention modality that has been shown to improve key functional outcomes in youth with ADHD.
224199384|NCT03955016|OTHER|Pulmonary rehabilitation|"Rehabilitation program consisting of 2 weeks inpatient (supervised training 5 times per week), 2 weeks outpatient (supervised sessions 3 times per week) and 11 weeks home-based exercise training (weekly phone call).~During the inpatient phase, patients will receive on top of the supervised training sessions a consultation of the dietitian, PH psychologist, social worker and specialized nurse. During the ambulatory rehabilitation phase patients will have 2 session with the occupational therapist.~Every supervised training session contains:~1. Interval training on a cyclo-ergometer~2. Strength training of the upper and lower extremities~3. Guided walks"
224199385|NCT02511587|BIOLOGICAL|FSME-Immune vaccination|booster vaccination with FSME-Immune
224199386|NCT01282879|DRUG|Itraconazole|200mg bid, oral solution, until a dose of prednisone was tapered to 10mg/day in case of prednisone alone therapy group, or until prednisone was stopped in case of CNIs plus prednisone, CNIs plus prednisone plus mycophenolate mofetil, or mycophenolate mofetil plus prednisone group, etc.
224311237|NCT02528513|DRUG|Fentanyl|Fentanyl is used with bolus dosage of 1-2ug/kg and maintenance dosage of 1-2ug/kg/h, with the dosage adjusted to critical care pain observation tool（CPOT）score(0-1).
224311238|NCT02528513|DRUG|propofol|After the spontaneous breathing trial safety screen is passed, midazolam is switched to propofol, which is administered at the maintenance dosage of 0.50-3.00mg/kg/h, with the dosage adjusted to RASS score (-2 to 0).
223599721|NCT04142177|OTHER|Continued Care and Active Monitoring|CCAM will not be standardized keeping in line with the pragmatic nature of this trial. CCAM may be variable across sites and for individual participants reflecting de facto clinical practice for cLBP. Clinical practice may involve pharmacological and non-pharmacological treatments for cLBP. Current analgesics (including opioids, acetaminophen, NSAIDs, topical analgesics (capsaicin), serotonin-norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants, skeletal muscle relaxants, and alpha-2-delta ligands (gabapentin-like drugs)) and non-pharmacological treatments may be continued by participants. CCAM participants will be encouraged to discuss pain problems with their treating physician, but not begin new treatments if possible. Patients will specifically be discouraged from starting CBT, chiropractic, or yoga. Other than this, there will be no attempt by study personnel to influence pain management.
223618039|NCT05777603|DRUG|pembrolizumab|standard of care therapy/monoclonal antibody for patients with advanced NSCLC
224199387|NCT03844802|OTHER|Local Dry needling and exercise|"Deep dry needling will be applied bilaterally in the locus of active or latent myofascial trigger points of several neck shoulder muscles (scalene muscles, levator scapulae, splenius cervicis, multifidus cervicis and upper trapezius). The presence of active or latent myofascial trigger points will be assessed according to the diagnostic procedures described by Travell and Simons. The dry needling intervention technique will be the fast in-fast out Hong technique, with a minimum of 3 to 6 local twitch responses to be elicited.~Patients will perform a home based therapeutic neck exercises program."
224199388|NCT03844802|OTHER|Distal Dry needling and exercise|"Patients in this group will undergo deep dry needling at a remote spot from the locus of the myofascial trigger point. As a result no local twitch response should be elicited. As in the previous group, dry needling will be carried out in the same assessed muscles (scalene muscles, levator scapulae, splenius cervicis, multifidus cervicis and upper trapezius) with active or latent myofascial trigger points, according to the diagnostic procedures described by Travell and Simons. The intervention technique chosen for these participants will be to insert the needle in a location in the same muscle, but far away (at least 1 to 1.5 cm) from the location of the myofascial trigger point. Likewise, the needle will be inserted without the intention to evoke local twitch responses. Therefore, the entry and exit of the needle will be performed in a slower fashion.~Patients will perform a home based therapeutic neck exercises program."
223618040|NCT02907424|DIETARY_SUPPLEMENT|2 months of treatment|standard 2 months of treatment
223618041|NCT01722539|DRUG|Sulfadoxine-pyrimethamine|Tablets 500 mg sulfadoxine - 25 mg pyrimethamine will be given as single oral dose of ½ tablets per 10 kg of weigh: 1 tablet for weigh less than 20 kg, 1.5 tablets in 20-29 kg, and 2 tablets for children of weigh 30 or more
223618042|NCT01722539|DRUG|Piperaquine|Piperaquine tablet 320 mg manufactured by Sigma Tau will be used at two treatment doses of 16-24 mg/kg at 24 hours intervals as follows: 1 tablets for weigh 15-19 kg, 1.5 tablets for 20-29 kg, and 2 tablets for 30-39 kg, and 2.5 tablets for 40 kg or more.
223618043|NCT01722539|DRUG|Albendazole|One oral 200 mg will be given to children of 1-2 years and one oral dose of 400 mg to children older than 2 years. The treatment will be repeated at 4-months in the follow-up in accordance with the WHO guideline.
223618044|NCT01722539|DRUG|Praziquantel|Praziquantel is a tremacide used for treatment of infections due to schistosomes. Praziquantel will be given as one dose of 40 mg/kg at enrolment and at 12 months follow up.
223618045|NCT03044366|OTHER|general anesthesia management of preterm infants|general anesthesia management of preterm infants
223618046|NCT02354274|RADIATION|Escalated: Inhomogeneous dose plan|
223618047|NCT02354274|RADIATION|Standard: Homogeneous dose plan|
223618048|NCT03018236|DRUG|Alcohol N-acetylcysteine|1200 mg of NAC per day, taken in two doses, for subjects with alcohol use disorder
223618049|NCT03018236|DRUG|Alcohol Placebo|Flour pills looking exactly the same as the active compound, for subjects with alcohol use disorder
223618050|NCT03018236|DRUG|Cocaine N-acetylcysteine|1200 mg of NAC per day, taken in two doses, for subjects with cocaine use disorder
223618051|NCT03018236|DRUG|Cocaine Placebo|Flour pills looking exactly the same as the active compound, for subjects with cocaine use disorder
223618052|NCT03142529|DRUG|colon lotion|The colon lotion used in this clinic trial is a kind of hospital preparation. It is brown liquid,which consists of Rhubarb, Concha ostreae and some other traditional Chinese medicine.The colon lotion is diluted from 30ml to 150ml each time and will be used once a day for 10 days.
223618053|NCT05413746|DEVICE|Reoxcare antioxidant dressing|After wound cleaning activities, wound bed debridement if necessary and elimination of hyperkeratotic edges, wounds are treated with Reoxcare as primary dressing and the approppriate secondary dressing for adequate exudates management
223618054|NCT00687401|BIOLOGICAL|Infliximab|Infliximab 5 mg/kg of body weight administered as an infusion at Weeks 0, 2, 6 (induction phase), and 14 (maintenance phase).
223618055|NCT05806320|OTHER|Intrauterine Sound Listening Group 1|This group consisted of 15 infants with 26-32,6 GW. A total of one hour of noise measurement was made inside and outside the incubator before, during and after the procedure. The babies were listened to the sound obtained in 3 time periods. If the baby is fed enterally, the feeding of the baby was completed at 10.15/13.00/16.15 before the application, the baby was placed in the prone position and the baby was rested for 30 minutes to ensure gastric emptying. Before the procedure, the baby was watched with a monitor device and recorded on video between 10.45-11.00/13.30-13.45/16.45-17.00. During the baby procedure, uterine sound was listened to the baby in the prone position monitored with a monitor device and recorded on video between 11:00-11.30/13.45-14.15/17.00-17.30 hours. After the procedure, the baby was watched with a monitor device and recorded on video between 11.30-11.45/14.15 and 14.30/17.30-17.45.
223618056|NCT05806320|OTHER|Intrauterine Sound Listening Group 2|This group consisted of 15 infants with 33-36,6 GW. A total of one hour of noise measurement was made inside and outside the incubator before, during and after the procedure. The babies were listened to the sound obtained in 3 time periods. If the baby is fed enterally, the feeding of the baby was completed at 10.15/13.00/16.15 before the application, the baby was placed in the prone position and the baby was rested for 30 minutes to ensure gastric emptying. Before the procedure, the baby was watched with a monitor device and recorded on video between 10.45-11.00/13.30-13.45/16.45-17.00. During the baby procedure, uterine sound was listened to the baby in the prone position monitored with a monitor device and recorded on video between 11:00-11.30/13.45-14.15/17.00-17.30 hours. After the procedure, the baby was watched with a monitor device and recorded on video between 11.30-11.45/14.15 and 14.30/17.30-17.45.
223599722|NCT04142177|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|Participants randomized to CBT in Step 2 will receive treatment with a trained therapist using the VA's CBT-chronic pain (CBT-CP) protocol involving one planning session and 9 treatment sessions (10 total) over 3 months. The VA's CBT-CP protocol consists of 11 core CBT-CP modules that can be completed in up to 10 sessions. Weekly, individual sessions of 45-50 minutes are recommended, although it is recognized that bi-weekly or other arrangements are often made to fit practical needs.
223599723|NCT04142177|PROCEDURE|Spinal Manipulation Therapy (SMT)|After examination by a qualified Doctor of Chiropractic (DC), a SMT intervention consisting of up to 10 sessions over 3 months will be designed focusing on spinal manipulation and/or mobilization of the lower thoracic, lumbar and/or sacroiliac joints. Adjunctive use of myofascial and/or stretching techniques are allowed as they are commonly used along with SMT, and can be considered a standard accompaniment to SMT.
223748750|NCT06201533|BEHAVIORAL|combined physical-cognitive exercise|A combined physical-cognitive exercise will be delivered in the form of exergame, where the participants move their body to interact with the game.
223748751|NCT04718142|DEVICE|vNEP|Apply vNEP therapy to the anterior surface of the throat with a variable negative pressure ranging from -20 cmH2O up to -35 cmH2O and vNEP devices of varying shapes and sizes.
223748752|NCT00930566|DRUG|methoxsalen|"UVADEX® is supplied in a 10 mL single-use vial. Each mL of solution contains 20 mcg of UVADEX®.~In the ECP process, UVADEX® will be injected directly into the Recirculation Bag of the extracorporal circuit after completion of the buffy coat collection, just prior to pressing the photoactivation button. The dose of UVADEX used to inoculate these cells will be calculated based on the treatment volume collected during the plasma/buffy coat collection process, usinge the following formula :~Treatment Volume in mL x 0.017 = Dose of UVADEX® (in mLs) required for administration into the recirculation bag.~After the cells are inoculated with UVADEX, the buffy coat/plasma suspension is irradiated with ultraviolet-A light and then reinfused back into the patient."
223748753|NCT00930566|PROCEDURE|Extracoporal Photopheresis (ECP)|"In the ECP process, UVADEX® will be injected directly into the Recirculation Bag of the extracorporeal circuit after completion of the buffy coat collection, just prior to pressing the photoactivation button.~After the cells are inoculated with UVADEX, the buffy coat/plasma suspension is irradiated with ultraviolet-A light and then reinfused back into the patient."
223748754|NCT03879382|BIOLOGICAL|anti-CD19/BCMA CAR-T cells|Retroviral vector-transduced autologous T cells to express anti-CD19 and anti-BCMA CARs
223748755|NCT03879382|DRUG|Fludarabine|30mg/m2/d
223748756|NCT03879382|DRUG|Cyclophosphamide|300mg/m2/d
223748757|NCT02081079|DRUG|LDV/SOF|LDV/SOF (90/400 mg) FDC tablet administered orally once daily
223748758|NCT05363384|DRUG|CT-L01|FDC tablet, single dose, oral administration
223748759|NCT05363384|DRUG|Alogliptin Benzoate 25 mg|Alogliptin Benzoate 25 mg, oral administration
223748760|NCT05363384|DRUG|Metformin HCl XR 1,000 mg|Metformin HCl XR 1,000 mg, oral administration
223748761|NCT05195723|DRUG|WP1122|Oral solution
223748762|NCT05195723|DRUG|Placebo|Oral solution
223748763|NCT02225743|OTHER|Observation Of Temperature|Participants temperature will be recorded perioperatively.
223748764|NCT04099160|OTHER|Evaluation|The Turkish version of the Revised Neurophysiology of Pain Questionnaire will be applied to patients with chronic spinal pain at the beginning of the study and a week later. The Visual Analogue Scale and the Short Form-36 (SF-36) questionnaire will be applied to patients only at the beginning of the stuy.
223748765|NCT02535845|BEHAVIORAL|Project Voice|Project Voice tablet-based intervention plus informational video
223748766|NCT02535845|BEHAVIORAL|HPV Informational Video|Informational video only
223599724|NCT04142177|PROCEDURE|Yoga|The Yoga for Veterans with cLBP program consists of up to 10 weekly, 60-minute instructor-led sessions along with 15-20 minutes of yoga practiced at home each non-session day. The initial session is 75 minutes (15 minutes longer than the other sessions). The yoga program can be considered classical hatha yoga with influences from Iyengar and Viniyoga yoga. These styles emphasize modifications and adaptations including the use of props such as straps and blocks to minimize the risk of injury and make the poses accessible to people with health problems and limitations (Iyengar, 1979). The instructor leads participants through a series of 23 yoga poses (32 total variations) at a slow-moderate pace.
223599725|NCT05487261|DRUG|Sacubitril-valsartan|level 1-24 / 26mg 2 times a day, level 2-49 / 51mg 2 times a day, level 3-97 / 103mg 2 times aday
223599726|NCT05487261|DRUG|Enalapril|level 1-2.5 mg twice a day, level 2-5 mg twice a day, level 3-10 mg twice a day
223599727|NCT05487261|DRUG|placebo|placebo matching for 24 / 26mg, 49 / 51mg, 97 / 103mg 2 of sacubitril/valsartan
223748767|NCT04130230|DRUG|Neostigmine|Neostigmine continuous infusion plus standard therapy for sepsis and septic shock.
223748768|NCT04130230|DRUG|Standard therapy|Standard therapy for sepsis and septic shock
223748769|NCT04941456|OTHER|Open Tracheostomy|Participants will perform the six minute walk test with an open tracheostomy. Participants will complete 1 to 3 session over approximately three-weeks.
223748770|NCT04941456|DEVICE|PMV in place|Participants will perform the six minute walk test with a PMV in place. Participants will complete 1 to 3 sessions over approximately three-weeks.
223748771|NCT04745598|BEHAVIORAL|Control group: Dental Model|\- Patients receive a demonstration of plaque control methods (modified Bass dental brushing technique and the use of the electric toothbrush) using a dental model.
223748772|NCT04745598|BEHAVIORAL|Computer-assisted teaching format group|\- Patients receive a Powerpoint presentation containing:
223748773|NCT04745598|BEHAVIORAL|Plaque-disclosing group|\- Patients place a few drops of a plaque-disclosing solution on the tongue and run the tongue over all the teeth and gums. With the aid of a hand mirror, patients can observe the stained plaque residue on their teeth
223748774|NCT04745598|BEHAVIORAL|Intra-oral camera group|\- An ACTEON Soprocare® intraoral camera is used during the examination and explanation of oral hygiene strategies.
223748775|NCT03057665|DEVICE|Atomic Biomagnetometer|Measure magnetic field of fetal heartbeat
223748776|NCT00075426|DRUG|arsenic trioxide|
224311239|NCT02528513|DRUG|Dexmedetomidine|After the spontaneous breathing trial safety screen is passed, midazolam is switched to dexmedetomidine, which is administered at an infusion bolus of 0.5μg/kg over 10 min (given or not according to patients' condition) and the maintenance dosage of 0.2-0.7ug/kg/h, with the dosage adjusted to RASS score (-2 to 0).
223599728|NCT05487261|DRUG|Placebo|placebo matching for 2.5 mg, 5 mg, 10 mg of enalapril
223599729|NCT01350232|DRUG|Fludarabine|Subjects will receive fludarabine at a dose of 30 mg/m2 daily for 4 days as part of the preparative regimen
223748777|NCT05487482|OTHER|Ageing Safe from the Risk (ASRi) Model of safety culture|For the intervention groups, planning will be done to provide education and training. Families will be given modules on Safety Culture in the Elderly. Materials provided about the safety of the elderly include changes in the elderly, the concept of safety in the elderly, the type of danger to the elderly, how to prevent harm in the elderly, the first handling in case of accidents, and the role of the family in the efforts of elderly safety. The material will be delivered by experts in elderly health and patient safety (professionals from health centers, social services, and academics). In addition to education and training, families will also receive home visits to check and monitoring the condition of the elderly at home related to adverse events and the home environment. Measuring will be done every 4 weeks by using a monitoring book.
223748778|NCT05188209|DRUG|MRG003|Administered intravenously
223748779|NCT02912234|DRUG|Apixaban|Multiple-dose clarithromycin and single-dose Apixaban
223748780|NCT02912234|DRUG|Clarithromycin|Multiple-dose clarithromycin and single-dose Apixaban
223748781|NCT04085198|PROCEDURE|Light physics enhanced 'no-touch' hysteroscopy|The light source used in hysteroscopy provides an illumined environment during the imagination with these techniques. During hysteroscopy, the light reflecting from the adjacent tissue appears bright, however, this reflection is weaker in farther tissue and these structures appear dark. This information will be used in determining the route from the vaginal introitus to the uterine cavity during the hysteroscopy.
223748782|NCT04085198|PROCEDURE|Standard hysteroscopy|Anatomical structures as illumined by the light source of the camera will be used to find the route from the vaginal introitus to the uterine cavity
223748783|NCT05106244|OTHER|Real-Time Guidance of Home Care for Patients with PICC or PORT|the experimental group adopted the family self-nursing mode, mainly by the patients' family members to observe the catheter and do regular nursing, and the specialist nurses provided remote real-time online guidance to monitor the family nursing of central venous catheter. The procedures are as follows: (1) make nursing videos recorded by central venous catheter specialist nurses; (2) evaluate the nursing operation ability of the patients' family members and carry out relevant training and health education, repeat until they are qualified; (3) distribute nursing guidance prescriptions and maintenance manuals for central venous catheters; (4) provide online simulated realistic nursing video materials; (5) provide real-time telephone audio and video connection to complete remote nursing guidance. (6) set up a home nursing volunteer service group, establish a doctor-patient exchange group by using Wechat and other media.
223748784|NCT00699556|DRUG|21mg transdermal nicotine patch (Nicoderm CQ)|21mg transdermal nicotine patch
223748785|NCT00699556|DRUG|1mg nicotine nasal spray|two 0.5mg/sprays, one to each nostril (dose = 1mg) The nicotine nasal spray is formulated by the Investigational Drug Service at Yale-New Haven Hospital. It is similar in concentration to Nicotrol.
223748786|NCT00699556|DRUG|placebo nasal spray|saline combined with capsaicin to mimic the brief nasal irritation from active nicotine spray The placebo nasal spray is formulated by the Investigational Drug Service at Yale-New Haven Hospital.
223599730|NCT01350232|DRUG|Cytarabine|Subjects will receive cytarabine at a dose of 2 g/m2 daily for 4 days, approximately 4 hours after the fludarabine
224199389|NCT03844802|OTHER|Sham dry needling and exercise|"Patients in this group will undergo sham-placebo dry needling. For that purpose, placebo dry needling will be carried out in the same muscles previously described (scalene muscles, levator scapulae, splenius cervicis, multifidus cervicis and upper trapezius) with active or latent myofascial trigger points. The intervention technique will be carried out in the locus of the trigger point but using placebo needles. For this placebo group, a simulation needle procedure using a Dong Bang placebo needle, similar to the Streitberger needle, will be used. The placebo needles evoke mechanical stimulation without piercing the skin; hence, patients experience a pressure sensation similar to that of a real needle.~Patients will perform a home based therapeutic neck exercises program."
224199390|NCT03844802|OTHER|Exercise|Patients will perform a home based therapeutic neck exercises program.
224199391|NCT00062075|DRUG|romidepsin|Given IV
224199392|NCT02435875|OTHER|no intervention|Antihypertensive drug as intervention is used to see if it can improve baroreflex sensitivity to stable perioperative hemodynamic
224199393|NCT00474370|DRUG|Vicriviroc|One tablet of vicriviroc 30 mg once daily.
223599731|NCT01350232|DEVICE|Cellular Infusions|"Subjects will receive the cellular product in 2 steps. The first is a lymphocyte infusion of 2 X 10e8 lymphocytes/kg on the day they receive total body irradiation. The second is a CD34 enriched stem cell product approximately 48 hours after the cyclophosphamide.~The CliniMACS® Plus Instrument will be used for the selection of human CD34+ hematopoietic stem and progenitor cells in human allogeneic hematopoietic stem cell transplantation."
223599732|NCT01350232|RADIATION|Total Body Irradiation|All subjects will receive 200cGy TBI in a single fraction on the AM they receive the lymphocyte infusion
223599733|NCT01350232|DRUG|Cyclophosphamide|All subjects will receive cyclophosphamide at a dose of 60 mg/kg at approximately 72 and 96 hours after the lymphocyte infusion
223748787|NCT06287866|PROCEDURE|Pinch Graft|In the pinch graft technique, the investigators will numb and then shave off a thin piece of skin and place it in the wound bed.
223748788|NCT06588322|OTHER|Blood samples will be taken on several times (36 mL of blood taken at each time):|"* Inclusion visit (T0): prior to initiation of Olaparib treatment~* Follow-up period (T1 to T8): every 3 months for a maximum of 24 months~* End of study (Tx): on definitive cessation of Olaparib treatment for any reason (progression, toxicity or definitive cessation of treatment after 2 years)."
224199394|NCT00474370|DRUG|Placebo|One tablet of placebo once daily.
224199395|NCT05409300|BIOLOGICAL|BBIBP-CorV|Inactivated COVID19 vaccine, adjuvanted with aluminum hydroxide
224199396|NCT04273659|DIETARY_SUPPLEMENT|Pulses and cereals|Dietary intervention. Ingestion of pulses with cereals and gastrointestinal health.
224199397|NCT03253159|BEHAVIORAL|Hypnosis|The conversational hypnosis (10-15 min) is standardized and performed just before intravenous general anesthesia induction in the operative room.
224199398|NCT05046275|OTHER|Data analysis|No intervention, data analysis only
224199399|NCT01759056|DRUG|AVX 470|active comparator
224199400|NCT01759056|DRUG|Placebo|
223599734|NCT01350232|DRUG|Bortezomib|Subjects will receive bortezomib 1.3 mg/kg on Day 1,4,8, and 11 of a 21 day cycle. This will be repeated for 2 cycles.
223599735|NCT01350232|DRUG|Rituximab|Subjects will receive rituximab 375 mg/m2 on day 1 and day 8 of a 21 day cycle, on days they will also be receiving rituximab. This will be repeated for 2 cycles.
223599736|NCT01350232|PROCEDURE|Plasmapheresis|Subjects who continue to have detectable anti-donor antibody will receive plasmapheresis to reduce the antibody further
223599737|NCT00491491|DRUG|ibritumomab tiuxetan|0.4 mCi/kg
223599738|NCT00491491|PROCEDURE|BEAM chemotherapy and autologous stem-cell transplantation|
223599739|NCT03130920|PROCEDURE|Preconditioning|"Local ischemic preconditioning (LIPC) is process during which a short period of ischemia is followed by a period of reperfusion prior to the prolonged ischemia which seems to render organs more tolerant to the IR(ischemic-reperfusion) injury.~Remote ischemic preconditioning (RIPC) involves the protection of an organ from prolonged ischemia by brief periods of ischemia and reperfusion to a remote organ."
223599740|NCT05210387|OTHER|Duration of therapy|"In experimental group patients with severe infection caused by MDR-GNB and who present a clinical response on day 7 (±1) of adequate antimicrobial therapy, the therapy will be suspended.~The active control group will continue therapy until day 14 (±1)."
223599741|NCT03828617|BIOLOGICAL|20vPnC|20vPnC
223599742|NCT03828617|BIOLOGICAL|20vPnC|20vPnC
223599743|NCT03828617|BIOLOGICAL|20vPnC|20vPnC
223599744|NCT03828617|BIOLOGICAL|13vPnC|Pneumococcal conjugate vaccine
223599745|NCT05027867|DRUG|KRT-232|Administered by mouth
223599746|NCT03826186|DEVICE|Traditional (loss-of-resistance technique) thoracic epidural placement|Thoracic epidurals will be administered using the traditional loss-of resistance technique.
223748789|NCT06356857|DIAGNOSTIC_TEST|Myocardial perfusion imaging (MPI) using [O15]H2O-PET-CT|Re-scan for comparison with initial scan
223748790|NCT02280941|OTHER|single photon emission computed tomography|Single photon emission computed tomography (SPECT) imaging will be done.
224199401|NCT04557293|DEVICE|Continuous Positive Airway Pressure (CPAP) treatment|Treatment of Obstructive sleep apnoea syndrome with CPAP
224199402|NCT01067339|DRUG|darapladib|darapladib, tablet, 160 mg, by mouth, one time daily, 6 month duration
224199403|NCT01067339|DRUG|placebo|placebo, by mouth, once daily for six months
224199404|NCT00890409|DEVICE|Cooling cap (YJW608-04B)|A semiconductor water circulation cooling device (YJW608-04B, Henyang Radio Manufactory, Hunan, China) was used to conduct head cooling. The hypothermia group was fitted with a cooling cap around the head for 72 hours. The temperature of the cap could be adjusted between 5 to 20 degree C and was automatically regulated by a servo-controlled temperature probe placed in the nasopharynx to maintain the nasopharyngeal temperature at (34±0.2)degree C. All infants were nursed under a servo-controlled radiant warmer and the rectal temperature was maintained at 34.5 to 35 degree C. Head cooling was started within 6 hours after birth for 72 hours followed by spontaneous re-warming and the average time to reach the target temperature was 2 hours.
224199405|NCT05355194|OTHER|Kinesiotape|"Patients will be instructed to inhale while taping the application. The tape will be applied in a vertical direction from just below the navel to the pubic region, another tape will be applied over the initial tape in the horizontal direction with minimal stretch. Another tape will be applied over the lumbosacral region making a V shape. The arms of V shall lie over the lumbar region while the base shall rest over the caudal region. Taping will be maintained for at least 48 hours.~The interventions shall be applied for two consecutive menstrual cycles."
224199406|NCT05355194|OTHER|Pelvic Tilts|Patients will be asked to lie in a supine position with legs bent and toes facing forward. Afterward, they will be instructed to pull their belly inwards while pushing pelvis towards the ceiling and keep hip muscles tightened. This position will be maintained for 5 seconds with 3 sets of 20 repetitions. Pelvic tilts must be performed throughout the menstrual cycle.
224199407|NCT04131439|DIAGNOSTIC_TEST|Computed Tomography and Magnetic resonance imaging|Preoperative imaging for patients undergoing cochlear implants
224199408|NCT00147472|OTHER|PET scan in addition to conventional CT imaging|PET scans, Pre and post radiation treatment
224199409|NCT03992261|DRUG|Halobetasol Topical Foam|Foam
223599747|NCT03826186|DEVICE|CompuFlo thoracic epidural placement|Pressure sensing technology to consistently and accurately identify the thoracic epidural space.
223599748|NCT04196465|DRUG|IMC-001|IMC-001 is a fully human anti-programmed cell death ligand 1 (PD-L1) recombinant monoclonal antibody that strongly binds to PD-L1 to inhibit its binding to programmed cell death protein 1 (PD-1) or B7-1 (CD80). IMC-001 showed robust dose-dependent efficacy in animal models and no evidence of toxicity in cynomolgus monkeys
223599749|NCT02013297|RADIATION|SBRT treatment|"For Brain metastasis the SBRT treatment consists on 3 fractions of 8 Gy or 5 fractions of 7 Gy or 1 fraction of 18 Gy for a single metastasis which is less than 20 mm.~For primary or secondary pulmonary tumors the SBRT treatment consists on 3 fractions of 15 Gy or 5 fractions of 10 Gy for peripheral lesions and on 5 fractions of 8 Gy for proximal lesions.~For primary or secondary spinal or para-spinal tumors the SBRT treatment consists on 3 fractions of 9 Gy or 5 fractions of 7 Gy.~For previously irradiated tumors (same locations) the SBRT treatment consists on 5 to 8 fractions of 5 Gy.~For relapsed Ependymoma previously irradiated the SBRT treatment will be allocated by surgical stratified randomization and consists on either 3 fractions of 8 Gy or 5 fractions of 5 Gy."
223599750|NCT00648362|DRUG|Glimepiride Tablets 1 mg|1mg, single dose fasting
223599751|NCT00648362|DRUG|Amaryl® Tablets 1 mg|1mg, single dose fasting
223599752|NCT03432169|OTHER|Yoga (stretching plus mindfulness)|Stretching plus mindfulness
223599753|NCT03432169|OTHER|Stretching|Stretching alone
223599754|NCT01362894|DEVICE|nelfilcon A contact lens|Commercially marketed, nelfilcon A, toric, soft contact lens for daily disposable wear.
223599755|NCT01362894|DEVICE|etafilcon A contact lens|Commercially marketed, etafilcon A, toric, soft contact lens for daily disposable wear.
223599756|NCT02289807|DRUG|Cisplatin|concurrently with cisplatin 100 mg/m² every 3 weeks for 3 cycles during IMRT
223599757|NCT02289807|RADIATION|IMRT|Intensity modulated-radiotherapy (IMRT) is given as 2.0-2.30 Gy per fraction with five daily fractions per week for 6-7 weeks to a total dose of 66 Gy or greater to the primary tumor
223618057|NCT02920892|DRUG|AFQ056|12.5 mg - 100 mg oral suspension (liquid)
223618058|NCT02920892|DRUG|Placebo|Placebo oral suspension (liquid)
223748791|NCT06622655|DEVICE|Powered orthosis|Home rehabilitation (2 months, 30 minutes/day, 5 days/week) during which subjects will practice walking with the device at home.
223748792|NCT06485843|DRUG|OA-SYS|OA-SYS is made of several types of cells obtained from fat tissue for the treatment of osteoarthritis.
223599758|NCT02780284|BEHAVIORAL|Physical activity intervention|150 minutes per week of moderate intensity cardiovascular exercise. The exercise sessions will include a minimum of 30 minutes of exercise each day, 3 to 5 times per week for a total of 150 minutes of exercise per week.
223599759|NCT04522596|DRUG|Umeclidinium/vilanterol|Umeclidinium/vilanterol 55/22 μg inhaled once a day
223599760|NCT04522596|OTHER|Placebo|Placebo inhaled once a day
223599761|NCT04355819|BEHAVIORAL|Disclosure timing|When patients are told that a hernia was present on the CT scan
223599762|NCT00897468|OTHER|laboratory biomarker analysis|Tissue samples will either be collected at the time of medically indicated surgical procedures or through research core biopsies. A sample of urine will also be obtained. Blood will be collected via venipuncture and lymphocytes (mononuclear cells) separated and processed as a source of normal DNA and normal cells.
223599763|NCT00897468|OTHER|medical chart review|patient chart review will occur in conjunction with patient data collection for final analyses.
223748793|NCT02208609|OTHER|Day 1: Maize Tortillas with 20% Amaranth|Subjects received Maize tortillas with 20% Amaranth added.
223748794|NCT02208609|OTHER|Day 2 Maize Tortillas without 20% Amaranth|Maize tortillas without Amaranth.
223748795|NCT07039721|OTHER|Evaluation of echogenicity|Patients ongoing a routine 2nd or 3rd trimester ultrasound will have an extra 5 minutes of ultrasound with a specific intestinal setting
223599764|NCT06040164|OTHER|Observational study|No intervention will be performed
223748796|NCT07036705|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia (CBT-I)|Cognitive behavioral therapy for insomnia (CBT-I) is a behavioral (psychotherapeutic) intervention for insomnia disorder. Participants will complete digital CBT-I online using the Sleep Healthy Using the Internet (SHUTi) program.
224199410|NCT03278639|BEHAVIORAL|Rhythmic Auditory Stimulation|Training will be directed to ameliorate gait and balance
224199411|NCT03278639|BEHAVIORAL|Kinesiology|Training will be directed to ameliorate gait and balance
224199412|NCT01365741|OTHER|Upright position|The test person will ingest Efient in an upright position and remain upright for 2 minutes. After 2 minutes, the test person will lie down, and remain supine for 2 hours, the same way as the person did in the control arm
224199413|NCT02208934|DRUG|PBF-999|5, 10, 20 and 40 mg of PBF-999
224199414|NCT02208934|DRUG|Placebo|Placebo for all dosis of PBF-999
223599765|NCT00082407|DRUG|exenatide|subcutaneous injection, twice daily; 5 mcg for 4 weeks followed by 10 mcg for 48 weeks
223599766|NCT00082407|DRUG|biphasic insulin aspart|subcutaneous injection, twice daily; titration to target blood glucose level
223599767|NCT02586948|DEVICE|extracorporeal CO2 removal (Hemolung device)|ECCO2R in severe exacerbation of COPD patients, requiring invasive mechanical ventilation with persistent respiratory acidosis and dynamic hyperinflation
223599768|NCT04629651|DRUG|Captopril|Oral, to be administered per the dose escalation scheme.
223599769|NCT02253953|DRUG|BILR 355 BS, D1|
223599770|NCT02253953|DRUG|BILR 355 BS, D2|
223599771|NCT02253953|DRUG|BILR 355 BS, D3|
223599772|NCT02253953|DRUG|BILR 355 BS, D4|
223599773|NCT02253953|DRUG|BILR 355 BS, D5|
223599774|NCT02253953|DRUG|BILR 355 BS, D6|
223599775|NCT02253953|DRUG|BILR 355 BS, D7|
223748797|NCT07036705|DEVICE|Passive Body Heating (PBH)|Passive body heating (PBH) is a body-based treatment that participants will complete using a sauna blanket, which is similar in form factor to an adult-sized sleeping bag (head is not within the heated area). Participants will complete at least three 15-minute PBH sessions per week. Participants will complete PBH sessions in the sauna blanket placed on the floor or on a couch (i.e., not in their bed) at a setting of Level 6, 1-2 hours before bed.
223748798|NCT06704152|DRUG|SOC + BSB-1001 Dose Escalation Cohort|Patients will receive BSB-1001 a single intravenous (IV) infusion on day 0 following the infusion of the CD34-allo hematopoietic stem cell transplant (HCT).
223748799|NCT06704152|DRUG|SOC+BSB-1001 Expansion Dose|Patients will receive BSB-1001 a single intravenous (IV) infusion on day 0 following the infusion of the CD34-allo hematopoietic cell transplant (HCT).
223748800|NCT07042802|DRUG|LBL-024 for Injection|LBL-024 Intravenous infusion.
223748801|NCT07042802|DRUG|Paclitaxel Injection|Paclitaxel Intravenous infusion.
223748802|NCT06731998|PROCEDURE|Local Anesthesia|For local anesthetic administration at port sites, 30 mL of 0.1% ropivacaine is injected around the umbilical port site following the completion of the primary surgical procedure. Additionally, 5 mL of 0.1% ropivacaine is injected around each additional port site to ensure effective local anesthesia.
224199415|NCT00625313|DEVICE|HMY Model YA-60BB IOL|Following phacoemulsification cataract extraction, insertion of a Hoya HMY posterior chamber intraocular lens will be performed.
224199416|NCT00769132|DRUG|Comparator: niacin + laropiprant|ER niacin 2 g/laropiprant 40 mg tablet once daily for 7 days
223599776|NCT02253953|DRUG|BILR 355 BS, D8|
223599777|NCT02253953|DRUG|BILR 355 BS, D10|
223599778|NCT02253953|DRUG|Placebo|
224199417|NCT00769132|DRUG|Comparator: niacin|ER niacin 2 g tablet once daily for 7 days
224199418|NCT00769132|DRUG|Comparator: laropiprant|laropiprant 40 mg once daily for 7 days
223599779|NCT02253953|OTHER|high-fat breakfast|
223599780|NCT02253953|DRUG|Ritonavir|
223599781|NCT02611843|BEHAVIORAL|Peer-Supported Web CBT|
223599782|NCT02611843|BEHAVIORAL|Self-Managed Web CBT|
224199419|NCT00769132|DRUG|Comparator: placebo|matching placebo tablets for each of the interventions once daily for 7 days
224199420|NCT03365869|DRUG|Sirolimus|Sirolimus or placebo were added to patients every day
224199421|NCT02534467|DRUG|Montelukast|daily dose according to age for 8 weeks out of 16 weeks of assessment
224199422|NCT06039007|DIETARY_SUPPLEMENT|7-day Fasting-Mimicking Diet (7-DAY FMD)|This medically-designed dietary kit supplies food for 7 days, with Day 1 providing 1100 kcal, while days 2 to 5 provide 800 kcal per day.
224199423|NCT01778309|DIETARY_SUPPLEMENT|n-acetylcysteine supplementation|"n-acetylcysteine administration: 20 mg//kg/day, orally, daily for eight days following exercise~placebo administration: 500 mL orally, daily for eight days following exercise"
223599783|NCT04190901|BEHAVIORAL|Simulated Black Male Physician|Participants in this arm of the experiment viewed one of 10 randomly selected possible images of a simulated Black Male physician. This image was paired with a written treatment and diagnosis of gastroenteritis alongside a contradictory diagnosis and treatment plan for appendicitis from an Online Symptom Checker.
223748803|NCT06731998|PROCEDURE|Laparoscopic Transversus Abdominis Plane block|Surgeon will place 18 gauge needle into the fascial plane between the internal oblique and transversus abdominis muscles. Once the needle is accurately positioned surgeon will inject 15 mL of 0.1% ropivacaine slowly. This procedure is performed bilaterally to ensure comprehensive analgesia. The total volume utilized for the LapTAP block is 30 mL of 0.1% ropivacaine.
223748804|NCT04837131|DRUG|Ixazomib|Ixazomib 4 mg capsule taken orally on days 1, 8, and 15 of a 28-day treatment cycle repeated for 6 cycles
223748805|NCT06743503|GENETIC|UB-VV400|UB-VV400 is a third-generation, self-inactivating (SIN), replication-incompetent, lentiviral vector (LVV) investigational drug product
223748806|NCT06743503|DRUG|Rapamycin|In DF Stage 2, Rapamycin will be given in combination with UB-VV400. For subjects receiving rapamycin, rapamycin dosing will be once daily with a planned start date of Day 4 (approximately 72 hours after the administration of UB-VV400) and continuing for up to 60 days, as tolerated.
223748807|NCT06748053|DRUG|GSK5784283|GSK5784283 will be administered.
223748808|NCT06748053|DRUG|Placebo|Placebo will be administered.
223748809|NCT07055269|OTHER|liver metabolic flux|All participants will be given heavy water (2H2O, deuterium-labelled) and \[U-13C6\]-fructose orally, each followed by the collection of one blood plasma sample. Additional biochemical and clinical parameters including liver fat content by MRI, liver fibrosis and cirrhosis by ultrasound imaging and plasma biochemical profiles will be analyzed.
223748810|NCT07055269|OTHER|ureagenesis capacity|urea and urea cycle metabolites and their enrichment after oral administration of a stable isotope tracer 15NH4Cl will be measured to examine the liver's ability to detoxify ammonia.
223748811|NCT06894979|DRUG|ATM Kinase Inhibitor AZD1390|Given PO
223748812|NCT06894979|PROCEDURE|Biospecimen Collection|Undergo blood and cerebrospinal fluid collection
223748813|NCT06894979|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223748814|NCT06894979|RADIATION|Radiation Therapy|Undergo radiation therapy
223748815|NCT06894979|OTHER|Survey Administration|Ancillary studies
224199424|NCT03361527|OTHER|binaural beamformer|Each study participant will use an Advacned Bionics Naida CI Q90 loaner processor during the course of the study, an Advanced Bionics MyPilot remote control and- if applicable- a SmartPhone. the processors will be programmed with SoundWave and BEPSnet.
224199425|NCT02829229|BEHAVIORAL|Community-based obesity treatment (PP)|Participants in the treatment (PP) arm will receive a 5-component intervention: 1)Behavior change goals; 2)Self-monitoring; 3)Tailored skills training; 4)Video testimonials \& 5)Interpersonal counseling. Both treatment and usual care arms will receive the current standard of care offered to postpartum mothers at WIC.
223599784|NCT04190901|BEHAVIORAL|Simulated Black Female Physician|Participants in this arm of the experiment viewed one of 10 randomly selected possible images of a simulated Black Female physician. This image was paired with a written treatment and diagnosis of gastroenteritis alongside a contradictory diagnosis and treatment plan for appendicitis from an Online Symptom Checker.
223748816|NCT05588609|DRUG|Afatinib Oral Tablet|anti epidermal growth factor receptor (EGFR)/HER2 agent
223748817|NCT05588609|DRUG|Enzalutamide Pill|second-generation androgen receptor antagonist
223748818|NCT05588609|DRUG|Abiraterone acetate tablets|androgen synthesis inhibitor
223748819|NCT05588609|BIOLOGICAL|MCLA-128|full length IgG1 bispecific antibody targeting HER2 and HER3
224199426|NCT00696891|BIOLOGICAL|HBV-MPL vaccine|3-dose intramuscular injection
224199427|NCT00696891|BIOLOGICAL|Engerix™-B|3-dose intramuscular injection
223748820|NCT06762730|DRUG|Zoledronic Acid 5 mg/Bag 100 ml Inj|Zolendric acid will be provided to HIV naïve patients with documented osteopnia
223748821|NCT07052903|DRUG|Nucresiran|Nucresiran 300 mg administered SC q6M
223748822|NCT07052903|DRUG|Sterile Normal Saline (0.9% NaCl)|Sterile Normal Saline (0.9% NaCl) administered SC once q6M
223748823|NCT06055231|BEHAVIORAL|Vape device|Consume THC via vape defice
223748824|NCT06055231|BEHAVIORAL|Joint|Consume THC via joint
223748825|NCT06055231|DRUG|Marijuana via vape device|Given via vape device
223748826|NCT06055231|DRUG|Marijuana via joint|Given via joint
223748827|NCT07056166|PROCEDURE|epidural catheter|Epidural catheter placement for labor analgesia
223748828|NCT07056166|PROCEDURE|spine ultrasonography|An ultrasound scan will be performed on the spine to identify anatomical characteristics of potential interest
223748829|NCT07059182|BIOLOGICAL|Inactivated whole-cell Streptococcus pneumoniae vaccine|Single intramuscular injection of 1 mg protein/0.5 mL wSp vaccine
223748830|NCT07059182|DRUG|Placebo|Single intramuscular injection of 0.5 mL placebo
223748831|NCT06753175|DEVICE|underwater galvanic stimulation by 4-cell bath|"Underwater Galvanic Stimulation:~* Equipment: 4-cell bath~* Procedure: Patients will immerse their affected limbs in the 4-cell bath. Electrical stimulation will be applied at a frequency of 15 Hz and intensity of 20 mA for 20 minutes, 3 times per week (Han et al. 2020)."
223748832|NCT06753175|OTHER|Complete Decongestive Therapy (CDT):|"Complete Decongestive Therapy (CDT):~* Manual Lymphatic Drainage (MLD): 60 minutes per session, 3 days per week.~* Compression Therapy: Multilayer bandaging applied after MLD.~* Exercise: Specific exercises performed with compression in place.~* Skin Care: Routine skin and nail care to prevent infections (Curlett et al. 2020)."
223748833|NCT07066371|BEHAVIORAL|Emotional freedom technique|"Emotional Freedom Technique Application Guidelines~1. Determination of Subjective Units of Disturbance (SUD)~2. Preparation or setup~3. Application of appropriate acupuncture points in order~4. 9-Gamut: An application that allows the two hemispheres of the brain to be stimulated simultaneously~5. Application of appropriate acupuncture points in order again~6. Control of the differentiation in the level of discomfort with SUDS again"
224199428|NCT00661960|DRUG|raltegravir|400mg tablet twice daily by mouth for nine months
224199429|NCT00661960|DRUG|efavirenz|600mg capsule once daily by mouth without regard to food
224199430|NCT00557830|DRUG|Sorafenib Escalated Dose|Patients randomized to Group A will receive sorafenib 600 mg bid for Weeks 5 through 8 (Dose Level 2). Patients who tolerate this dose through Week 8 will be further escalated to Dose Level 3 (800 mg po bid) for Weeks 9 through 12.
223599785|NCT04190901|BEHAVIORAL|Simulated White Male Physician|Participants in this arm of the experiment viewed one of 10 randomly selected possible images of a simulated White Male physician. This image was paired with a written treatment and diagnosis of gastroenteritis alongside a contradictory diagnosis and treatment plan for appendicitis from an Online Symptom Checker.
223599786|NCT04190901|BEHAVIORAL|Simulated White Female Physician|Participants in this arm of the experiment viewed one of 10 randomly selected possible images of a simulated White Female physician. This image was paired with a written treatment and diagnosis of gastroenteritis alongside a contradictory diagnosis and treatment plan for appendicitis from an Online Symptom Checker.
223599787|NCT01626092|DRUG|Campath-1H|A daily dose of 0.3 mg/kg IV over 2 hours will be administered on days - 12, -11, -10, -9, and -8.
223599788|NCT01626092|DRUG|Clofarabine|"A daily dose of 40 mg/m2 will be administered IV over 2 hours on days -9,~-8, -7, -6, and -5."
223599789|NCT01626092|DRUG|Melphalan|A single dose of 140 mg/m2 will be given IV on day -4 over 15 minutes.
223748834|NCT06771453|OTHER|Video Educational Tool Regarding Prenatal Genetics|Video education about prenatal genetics will include content regarding aneuploidy screening and diagnostic testing options, how to make a values-based choice, and specifics of risks/benefits/limitations of each type of testing option.
223748835|NCT07066384|OTHER|breathing yoga|"Yoga Breathing Exercises:~1. Sama Vritti or Equal Breathing:~2. Abdominal Breathing Techniques:~3. Nadi Shodhana or Alternating Breathing:~4. Kapalabhati or Skull Shining Breath:~5. Progressive Muscle Relaxation:~6. Guided Visualization:"
223748836|NCT07066384|OTHER|PMRTs-Progressive Muscle Relaxation Techniques|While patients are breathing in and out, tightening and releasing exercises are applied to 11 different muscle groups. It is applied for 15-20 minutes.
223599790|NCT01626092|RADIATION|Total Body Irradiation with Marrow Boosting|"1. Dose to total body 200 cGy in single dose~2. Dose to bone marrow of the following bones 800 cGy in 5 divided daily fractions (160 cGy x 5 doses ). Treated with up to 3 abutting VMAT photon arcs from top of head to maximum inferior border."
223748837|NCT07067788|DIAGNOSTIC_TEST|Breast Imaging|Intervention using an FDA-approved mammogram machine.
223748838|NCT06776926|BEHAVIORAL|Carbetocin|Use of carbetocin
223748839|NCT07070479|DRUG|Ivonescimab|Ivonescimab 10 mg/kg via intravenous infusion, until the occurrence of intolerable toxicity, withdrawal of informed consent, initiation of new antitumor therapy, loss to follow-up, or death, whichever occurs first.
223599791|NCT01626092|BIOLOGICAL|Hematopoietic stem cell transplantation|Patients will be transplanted using either a related or unrelated allograft. The cell source may be marrow, peripheral blood or cord blood based on donor availability.
223599792|NCT01626092|DRUG|Cyclosporine A|Patients will receive CsA therapy beginning on day -3. Dosing of CsA will be 2.5 mg/kg/dose IV; if the recipient body weight is \<40 kg, dosing will be 3 times daily, and if \> 40 kg, twice daily. An attempt will be made to maintain a trough cyclosporine level of 200 mg/L to 400 mg/L.
223599793|NCT01626092|DRUG|Mycophenolate mofetil|Patients will receive mycophenolate mofetil (MMF) therapy beginning on day -3. Dosing of MMF will be 1 gram three times daily (total daily dose 3 grams/day) if the recipient is \>50 kg, or 15 mg/kg/dose three times daily if the recipient is ≤50 kg. The same dosage is used orally or intravenously.
223599794|NCT06788119|BEHAVIORAL|Cognitive behavioral therapy with in vivo exposure|CBT will be used as the chosen approach for ADs. The main components will be psychoeducation and to help patients to challenge and change unhelpful cognitive distortions (e.g., thoughts, beliefs, and attitudes) and behaviors (e.g., avoidance), develop emotion regulation strategies (e.g., cognitive reappraisal), and learn coping strategies that target problem-solving. The practice is developed in several sessions that usually last between 10 and 20 sessions. Specifically, the exposure component will be considered as the first-line treatment. During the exposure component, patients will confront themselves over a long period of time, repetitively, with a feared stimulus until distress has decreased significantly by the exposure.In this condition participants will receive CBT treatment and be exposed to in vivo situations.
223748840|NCT07070479|DRUG|Nimotuzumab|Nimotuzumab 400 mg via intravenous infusion, Q3W, until the occurrence of intolerable toxicity, withdrawal of informed consent, initiation of new antitumor therapy, loss to follow-up, or death, whichever occurs first.
223748841|NCT07070479|DRUG|Irinotecan liposome|Irinotecan liposome 50mg/m2 via intravenous infusion, D1, D15, Q4W for up to 6 cycles or until intolerable toxicity, subject withdrawal of informed consent, diseases progression, initiation of new antitumor therapy, loss of follow-up, or death, whichever occurs first.
223748842|NCT07070479|DRUG|S-1|S-1, D1-D14, BID, p.o., (BSA \< 1.25 m2, 40 mg/dose; 1.25 m2 ⩽ BSA \< 1.5 m2, 50 mg/dose; BSA ⩾ 1.5 m2, 60mg/dose), Q4W for up to 6 cycles or until intolerable toxicity, subject withdrawal of informed consent, diseases progression, initiation of new antitumor therapy, loss of follow-up, or death, whichever occurs first.
223748843|NCT07070479|DRUG|Mitoxantrone Hydrochloride Liposome|Mitoxantrone hydrochloride liposome 20mg/m2 via intravenous infusion, Q3W for up to 8 cycles or until intolerable toxicity, subject withdrawal of informed consent, diseases progression, initiation of new antitumor therapy, loss of follow-up, or death, whichever occurs first
223748844|NCT07070479|DRUG|PD-1 Inhibitors|PD-1 blockade (comprising tislelizumab \<200 mg/cycle\>, carrellimab \<200 mg/cycle\>, or toripalimab \<240 mg/cycle\>) , Q3W for two years, or until intolerable toxicity, subject withdrawal of informed consent, diseases progression, initiation of new antitumor therapy, loss of follow-up, or death, whichever occurs first.
223748845|NCT03283449|DRUG|18F-AV-1451|
223748846|NCT03283449|DEVICE|PET|PET scanner for brain imaging
223748847|NCT06413680|DRUG|REGN10597|Administered as an intravenous (IV) infusion
224199431|NCT00557830|DRUG|Sorafenib Standard Dose|Patients randomized to Group B will receive Dose Level 1 (sorafenib 400 mg po bid) until progression of disease, intolerable toxicity, patient refusal to continue with the study, or investigator decision to remove the patient from the study.
224199432|NCT00001972|DRUG|15 O Water|
224199433|NCT04182412|PROCEDURE|ARD|surgical reconstruction with laparoscopic technique
224199434|NCT01950325|BIOLOGICAL|VRC-HIVMAB060-00-AB|VRC01 Human Monoclonal Antibody
224199435|NCT03469882|DIETARY_SUPPLEMENT|High protein nutrition|Patients in the HPE group will be submitted to nutritional support preferably through the enteral route. Energy expenditure will be determined by indirect calorimetry. They will receive 2.0 to 2.2 grams/kg/day of protein.
223599795|NCT06788119|BEHAVIORAL|Cognitive behavorial therapy with in vivo exposure plus SYMPTOMS-JIT|CBT will be used as the chosen approach for ADs. The main components will be psychoeducation and to help patients to challenge and change unhelpful cognitive distortions (e.g., thoughts, beliefs, and attitudes) and behaviors (e.g., avoidance), develop emotion regulation strategies (e.g., cognitive reappraisal), and learn coping strategies that target problem-solving. The practice is developed in several sessions that usually last between 10 and 20 sessions. Specifically, the exposure component will be considered as the first-line treatment. During the exposure component, patients will confront themselves over a long period of time, repetitively, with a feared stimulus until distress has decreased significantly by the exposure. In this condition participants will receive CBT treatment and be exposed to in vivo situations with the support of SYMPTOMS-JIT.
223748848|NCT06887049|BEHAVIORAL|ARISE Learning Community Diabetes Distress Screening and Intervention|In-depth training for frontline community health center staff on ARISE algorithm to screen for degree of diabetes distress using T2-DDAS Core. If positive, screen for sources of diabetes distress using T2-DDAS Sources. Discuss results with patient and make any relevant referrals.
223748849|NCT06887049|BEHAVIORAL|ARISE Enhanced Care brief training|Brief training on American Diabetes Association guidelines for screening for diabetes distress using the 7A's model
223748850|NCT07084402|DRUG|Contezolid|contezolid 800mg po q12h for 6 months
223748851|NCT07084402|DRUG|Azithromcyin|azithromycin 500mg po tiw (250mg po tiw if weight below 50kg) for 6 months.
223748852|NCT07084402|DRUG|Rifampicin (RIF)|rifampicin 600mg po tiw for 6 months.
223748853|NCT07084402|DRUG|Ethambutol|ethambutol 25mg/kg po tiw for 6 months.
223748854|NCT07088913|DRUG|Capivasertib|Capivasertib will be administered orally twice in Period 2.
224199436|NCT03469882|DEVICE|Cycle ergometry exercise|Patients will be submitted to two daily sessions of exercise (cycle ergometry) 15 minutes duration each, during the 7 days of the week. The intervention will be maintained exclusively duting the patient's stay in the ICU. The cycle ergometer will be the MotoMed Letto II (Reck Technik, Germany).
223748855|NCT07088913|DRUG|Rosuvastatin|Rosuvastatin will be administered orally once in both Period 1 and Period 2.
224199437|NCT03469882|OTHER|Usual care group|Participants randomized to the usual care group will receive usual care protein and exercise.
224199438|NCT05718505|DEVICE|Atmo Motility Gas Capsule System|"The Atmo System measures whole gut and regional gut transit times. Measurements of GI tract transit times are used for evaluating motility disorders.~Gastric emptying time (GET) is indicated for the evaluation of patients with suspected gastroparesis. Delayed GET is implicated in such disorders as idiopathic and diabetic gastroparesis and functional non-ulcer dyspepsia.~Colonic transit time (CTT) is indicated for the evaluation of colonic transit in patients with chronic constipation, to aid in differentiating slow and normal transit constipation. In the case where ileocecal junction transit cannot be determined the system will report combined Small and Large Bowel Transit Time (SLBTT).~Transit times are derived from measures of temperature, relative humidity, hydrogen concentration, and carbon dioxide concentration, in conjunction with indicators of fermentation activity, capsule tumble, and antenna reflectance. Not for use in pediatric patients."
224199439|NCT05718505|DEVICE|SmartPill Monitoring System|"The SmartPill GI Monitoring System (Medtronic) offers a method for measuring gastric emptying time (GET), small bowel transit time (SBTT), colonic transit time (CTT), small bowel large bowel transit time (SLBTT) and whole gut transit time (WGTT) with a single test, which can be used as an aid for the diagnosis of both gastroparesis and slow transit constipation.~The SmartPill System measures pH, temperature and pressure. It is approved for use in the measurement of GI transit times by the FDA."
224199440|NCT00538473|BIOLOGICAL|GSK Biologicals' influenza vaccine GSK576389A|Single dose, intramuscular injection
224311240|NCT02528513|PROCEDURE|Procedure:sedation assessment|The nursing staff continuously monitored the sedation depth and adjusted the dosages of sedative and analgesic drugs to maintain the sedation target level. The sedation depth were assessed and recorded every 4 h (or more frequently when indicated).
223599796|NCT01358058|RADIATION|Proton radiation|Total dose of 54-59.4 Gy(RBE) at 1.8 Gy(RBE) per daily fraction delivered 5 days per week on weekdays for 6-6.5 weeks.
223748856|NCT06743659|DEVICE|Alert-based computerized decision support|"A program will be designed to run within the Electronic Health Record (EHR) that will identify outpatients with definite, probable, or possible diagnosis of FH. The BPA will calculate the Dutch Lipid Clinic Network score using the following EHR data:~1. Maximum LDL-C level in the laboratory results~2. Abnormal genetic testing for FH in the laboratory results~3. Medical history or problem list entry for tendinous xanthomata or arcus cornealis~4. Medical history, visit diagnosis, or problem list entry of premature CAD, cerebrovascular disease, or PAD~5. Family history of premature CAD, cerebrovascular disease, or PAD~In the Alert phase, an on-screen alert will notify the ambulatory care clinician of record that the patient has a definite, probable, or possible diagnosis of FH. ambulatory care clinician will have the opportunity to proceed to an order template through which a referral for specialty care focused on evaluation and management of FH can be made."
223748857|NCT06235697|RADIATION|Radiation|"46Gy / 23 fractions of EBRT to pelvis and prostate + LDR or HDR boost to prostate OR 25Gy / 5 fractions of EBRT to pelvis and prostate (ultrahypofractionation EBRT (SBRT)) + LDR or HDR boost to prostate.~\+ Adjuvant ADT: Unfavourable Intermediate Risk: 6 months or High / Very High Risk: 24 months"
223748858|NCT06235697|RADIATION|Radiation SBRT only|25Gy / 5 fractions to pelvis + 40 Gy / 5 fractions to prostate (SBRT) (ultrahypofractionation EBRT (SBRT))
224199441|NCT00538473|BIOLOGICAL|Fluarix™|Single dose, intramuscular injection
224311241|NCT02528513|PROCEDURE|Procedure:Weaning|the respiratory therapists managed patients with a daily interruption of continuous sedation and the spontaneous breathing trial (SBT) protocols daily.
224311242|NCT02528513|DRUG|midazolam(used for passing the SBT safety screen)|After the spontaneous breathing trial safety screen is passed,in the midazolam group, midazolam will continue to be used for sedation, with the dosage adjusted to RASS score (-2 to 0).
223599797|NCT00891228|DRUG|Testosterone|Two individual packets of T Gel, each with 5 g of gel applied to each arm delivering a total of 100 mg of T on the skin daily.
223748859|NCT06235697|DRUG|ADT|Assigned at enrollment
223748860|NCT07101809|DEVICE|Steerable Ureteroscopic Renal Evacuation (SURE) using the CVAC System|The CVAC Aspiration System is a sterile, single use, steerable ureteral catheter system with integrated vision, irrigation and aspiration for the treatment and removal of urinary stones (kidney stones, fragments, and dust).
223748861|NCT07101809|DEVICE|Standard Ureteroscopy (URS)|Arm Description: This is a treatment in which the urologist uses a laser to break a kidney stone into very small pieces and then places a tool called a stent to allows the remaining pieces to fall out.
223599798|NCT00891228|DRUG|Nestorone®|Nestorone® Gel will be delivered by a pump configured to deliver a metered volume of Nestorone® Gel containing 8 mg of Nestorone®. For 8 mg Nestorone® dose; Nestorone® Gel will be delivered in 4 mL volume (2 mg Nestorone® mL gel) by pressing two times with 2 mL dispenser head.
223599799|NCT00891228|DRUG|Nestorone®|Nestorone® Gel will be delivered by a pump configured to deliver a metered volume of Nestorone® Gel containing 12 mg of Nestorone®. For 12 mg Nestorone® dose; Nestorone® Gel will be delivered in 4 mL volume (3 mg Nestorone®/mL gel) by pressing two times with 2 mL dispenser head.
223748862|NCT06913933|BEHAVIORAL|Static Progressive Splinting for Persistent Wrist Stiffness|"A commercially available static progressive splint with a turnbuckle mechanism allowing fine-tuned adjustments in wrist flexion and extension.~Instructional materials for home use including written guidelines and an adjustment log."
223748863|NCT06913933|BEHAVIORAL|Dynamic Splinting for Persistent Wrist Stiffness|"Materials:~A commercially available dynamic (spring-loaded) splint designed for the wrist. An instructional manual and daily usage log for participants."
223748864|NCT06917313|DRUG|Fezolinetant|45 mg tablets, administered orally once daily with or without food, to be taken throughout the entire study phase, i.e. 12 weeks
223748865|NCT06917313|DRUG|Placebo|45 mg tablets, administered orally once daily with or without food, to be taken throughout the entire study phase, i.e. 12 weeks
223599800|NCT00891228|DRUG|Nestorone®|Nestorone® Gel will be delivered by a pump configured to deliver 4 mL of gel containing 0 mg of Nestorone® by pressing two times with the 2 mL dispenser head.
223599801|NCT04647123|OTHER|No intervention was applied to the groups the samples will be collected in terms of the diagnosis (hopeless, periodontitis, gingivitis, healthy)|No intervention was applied to the groups the samples will be collected in terms of the diagnosis (hopeless, periodontitis, gingivitis, healthy)
223599802|NCT02088489|DEVICE|Atrial flutter irrigated catheter|A duodecapolar isthmic curve catheter will be introduced to demonstrate cavo-tricuspidal bidirectional block. We performed atrial flutter ablation with conventional irrigated Thermocool® (Biosense Webster, Diamond Bar, CA) catheter Continuous lesions from tricuspidal annulus to inferior vena cava will be realized and then complete isthmic block will be confirmed by bidirectional stimulation
223748867|NCT02195440|DRUG|PRI-724|10 - 160 mg/m2, 7 days CIV (in the vein) with 7 days rest per one cycle. Number of Cycles: 6.
223748868|NCT06935110|PROCEDURE|Cryopreserved aortic patch|After identifying the tracheal or bronchial defect with standard surgical techniques, the airway gap is reconstructed with a patch of human cryopreserved (-80 celsius degree) aortic allograft, which was not matched by the ABO and leukocyte antigen systems. The anastomosis is performed with standard technique for airway anastomosis. An silicon stent is inserted to prevent collapse for the aortic graft.
223748869|NCT07142382|BEHAVIORAL|Ordinary sitz bath, manual flushing sitz bath, electric flushing sitz bath|Ordinary sitz bath, manual flushing sitz bath, electric flushing sitz bath
223599803|NCT02088489|DEVICE|Atrial flutter porous tip catheter|A duodecapolar isthmic curve catheter will be introduced to demonstrate cavo-tricuspidal bidirectional block. We performed atrial flutter ablation with Porous tip Thermocool® SF(Biosense Webster, Diamond Bar, CA)irrigated catheter Continuous lesions from tricuspidal annulus to inferior vena cava will be realized and then complete isthmic block will be confirmed by bidirectional stimulation
223599804|NCT02014168|BIOLOGICAL|Viroflu® and MVA-NP+M1|"2013-2014 season Viroflu, manufactured by Crucell. Contains 15 microgrammes of haemagglutinin (HA) from an H1N1 subtype influenza A virus, an H3N2 subtype influenza A virus and an influenza B virus per 0.5 ml dose.~MVA-NP+M1 manufactured by by IDT Biologika GmbH, Germany. Each vial of MVA-NP+M1 contains 700 microlitres volume at a concentration of 1.3 x108 pfu/ml in 10mM Tris buffer. The dose of MVA-NP+M1 to be used in this study will be 1.5 x108 pfu."
223599805|NCT02014168|BIOLOGICAL|Viroflu® and saline placebo|"2013-2014 season Viroflu, manufactured by Crucell. Contains 15 microgrammes of haemagglutinin (HA) from an H1N1 subtype influenza A virus, an H3N2 subtype influenza A virus and an influenza B virus per 0.5 ml dose.~0.9% saline placebo."
223748870|NCT06948318|DRUG|Mezagitamab|Mezagitamab injection administered SC.
223748871|NCT07147829|BEHAVIORAL|digital detox|The digital detox intervention differs from other clinical interventions in several key aspects. Unlike pharmacological treatments or traditional psychotherapy, it focuses on behavioral modification by intentionally reducing or eliminating engagement with digital devices and social media for predetermined periods. The intervention emphasizes mindful technology use, limits screen time, and encourages offline activities to restore emotional balance and improve sleep quality. Additionally, it targets the cumulative effects of constant digital exposure, such as information overload, social comparison, and digital dependency, which are not typically addressed in standard mental health interventions. This unique focus on managing digital behavior positions digital detox as a complementary strategy for promoting psychological well-being in young adults.
223748872|NCT07155525|DRUG|Pancreaticojejunostomy with Modified N-Butyl-2-Cyanoacrylate (Glubran® 2)|"* Standard duct-to-mucosa pancreaticojejunostomy performed~* Application of 0.5-1.0 mL modified N-butyl-2-cyanoacrylate around the anastomotic site~* Adhesive applied circumferentially around the pancreaticojejunal anastomosis~* Allow 2-3 minutes for polymerization before proceeding~* Standard placement of peritoneal drains"
223748873|NCT07155525|PROCEDURE|Standard(duct-to-mucosa) Pancreaticojejunostomy|"* Patients undergo duct-to-mucosa pancreaticojejunostomy without additional adhesive following pancreaticoduodenectomy.~* Standard placement of peritoneal drains~* All other aspects of surgical care identical to experimental arm"
223748874|NCT07158515|BEHAVIORAL|Tailored cardiac rehabilitation|The program will address the core components of CR.21 Each of the program components will have an individualized assessment with plan and goals set at the program intake visit. The 12-week program will alternate between group and individual sessions each week. Individualized plans will be reviewed every two weeks at the participant individual sessions. Group sessions will address physical activity, nutrition, and other program topics. Duration of the program was chosen to resemble a typical 12-week cardiac rehabilitation intervention. However, the program will have a greater emphasis on cultural tailoring, language concordance, lowering burden of real-time in-person attendance, motivational coaching, and addressing psychosocial needs.
224199442|NCT03009591|OTHER|Experimental group|"Longitudinal surface sliding maneuver over the superficial fascia in the anterior region of the arm and the forearm. Applied in 3 strokes.~* Transverse sliding of the flexor muscles of the wrist and fingers.~* Transverse sliding for the biceps brachii muscle.~* Longitudinal surface sliding over the superficial fascia in the posterior arm region.~* Transverse sliding over the brachial triceps tendon.~* Transverse sliding for the pectoralis major muscle.~* Transverse sliding for the posterior axillary region pectoralis major muscle.~* Induction of the posterior axillary fold.~* Induction (crossed hands over the brachial region and forearm).~* Maneuver of transverse planes for the cervicothoracic region.~* Upper limb telescopic maneuver."
224199443|NCT03829020|DRUG|Bortezomib|Given SC
224199444|NCT03829020|DRUG|Metformin Hydrochloride|Given PO
223599806|NCT00118742|DRUG|mycophenolate mofetil [CellCept]|1-1.5 g orally or intravenously twice daily
223599807|NCT00118742|DRUG|Tacrolimus|As prescribed, for 12 months
223599808|NCT00118742|DRUG|Cyclosporine|As prescribed, for 12 months
223599809|NCT00118742|DRUG|Sirolimus|2-4 mg orally once daily for 9-11 months
223599810|NCT03694834|DRUG|Pembrolizumab|"A single dose of Pembrolizumab (200 mg) will be administered IV over 30 min (-5 /+10 min) approximately 3 weeks prior to the scheduled hysterectomy.~Pembrolizumab (200 mg) will be administered IV over 30 min (-5/+10 min) every three weeks in combination with paclitaxel and carboplatin as adjuvant therapy over 6 cycles. Pembrolizumab should be given on D1 of each cycle after the infusion of cytotoxics."
223599811|NCT03694834|PROCEDURE|Hysterectomy|Hysterectomy/Surgical Staging per institutional standard of care.
223599812|NCT02688985|DRUG|Ocrelizumab|Ocrelizumab will be administered as IV infusion.
223599813|NCT02688985|PROCEDURE|Lumbar Puncture|Participants will receive LP as specified in individual arms. Lumbar puncture is optional at week 52, except for RMS Cohort Arm 3 and PPMS Cohort. In addition, the lumbar punctures in the Long Term Extension phase is every other year.
223599814|NCT02688985|DRUG|Methyloprednisolone|Participants will receive 100 mg of IV methylprenisolone (or an equivalent) prior to ocrelizumab infusion.
223599815|NCT02688985|DRUG|Antihistamine|Participants will receive an antihistamine, such as diphenhydramine, prior to ocrelizumab infusion.
223599816|NCT02445326|DRUG|Dexamethasone|
223599817|NCT02445326|OTHER|Placebo Vehicle|
223599818|NCT03434158|DRUG|Olaparib|300 mg twice a day
223599819|NCT02386163|BIOLOGICAL|MSC from synovial membrane and infrapatellar Fat Pad|
223599820|NCT06233006|OTHER|Assessment|upper extremity functions (hand skills, hand and finger grip strength, reaction time, position sense, upper extremity strength and endurance) and health-related quality of life
223599821|NCT00081055|BIOLOGICAL|autologous expanded mesenchymal stem cells OTI-010|
223599822|NCT00081055|DRUG|busulfan|
223599823|NCT00081055|DRUG|cyclophosphamide|
223599824|NCT00081055|DRUG|cyclosporine|
223599825|NCT00081055|DRUG|methotrexate|
223599826|NCT00081055|PROCEDURE|peripheral blood stem cell transplantation|
223599827|NCT00081055|RADIATION|radiation therapy|
223599828|NCT02665572|BEHAVIORAL|bladder recycling|Bladder recycling will be done by the patient after proper education. It will be started by the instillation of the sterile water in the bladder in amount equal to the estimated bladder capacity. Then the amount will be gradually increased till the patient can withstand filling the bladder with 300 cc of sterile water for 2 hours.
223599829|NCT02061514|PROCEDURE|maintenance with desflurane|in patients allocated to the desflurane group, general anesthesia will be maintained with desflurane
223599830|NCT02061514|PROCEDURE|maintenance with propofol|in patients allocated to the propofol group, general anesthesia will be maintained with propofol
224199445|NCT03829020|DRUG|Nelfinavir Mesylate|Given PO
224199446|NCT02006901|PROCEDURE|microdecompression|a minimal invasive surgical technique
224199447|NCT02006901|PROCEDURE|laminectomy|The traditional open surgical technique: decompression with removal of the spinous process, lamina and often the medial facets
224199448|NCT01277172|BIOLOGICAL|Rituximab|375 mg/m2 IV every 2 weeks for 6 cycles
224199449|NCT01277172|BIOLOGICAL|Rituximab|375 mg/m2 IV every 2 weeks for 6 cycles
224199450|NCT01277172|BIOLOGICAL|Rituximab|375 mg/m2 IV every 2 weeks for 6 cycles
223599831|NCT01726582|DRUG|Milestone 1: Targeted chemotherapy prior to surgery|The molecular profile from the biopsy before surgery will point to a particular chemotherapy treatment.
223599832|NCT01726582|RADIATION|Milestone 2: Chemoradiotherapy (cXRT)|A radio-sensitizing chemotherapy agent (either Gemcitabine or Capecitabine) will be given. Using 3D conformal or intensity-modulated radiation therapy (IMRT) techniques, patients will receive a total dose of 50.4 Gy prescribed to the 95% isodose at 1.8 Gy/fraction (28 fractions).
223599833|NCT01726582|DRUG|Milestone 3: Targeted chemotherapy prior to surgery|The molecular profile from the biopsy before surgery will point to a particular chemotherapy treatment.
223599834|NCT01726582|RADIATION|Milestone 3: Chemoradiotherapy (cXRT)|A radio-sensitizing chemotherapy agent (either Gemcitabine or Capecitabine) will be given. Using 3D conformal or IMRT techniques, patients will receive a total dose of 50.4 Gy prescribed to the 95% isodose at 1.8 Gy/fraction (28 fractions).
223599835|NCT01726582|DRUG|Milestone 4: standard FOLFIRINOX chemotherapy prior to surgery|A biopsy of the borderline tumor does not provide a molecular profile that can be used to target treatment. The treatment will be standard FOLFIRINOX chemotherapy regimen.
223599836|NCT01726582|RADIATION|Milestone 4: Chemoradiotherapy (cXRT)|A radio-sensitizing chemotherapy agent (either Gemcitabine or Capecitabine) will be given. Using 3D conformal or IMRT techniques, patients will receive a total dose of 50.4 Gy prescribed to the 95% isodose at 1.8 Gy/fraction (28 fractions).
223599837|NCT01726582|DRUG|Milestone 5: Targeted chemotherapy after surgery|The molecular profile from the surgical specimen will point to a particular chemotherapy treatment.
223599838|NCT01726582|RADIATION|Milestone 5: Chemoradiotherapy (cXRT)|A radio-sensitizing chemotherapy agent (either Gemcitabine or Capecitabine) will be given. Using 3D conformal or IMRT techniques, patients will receive a total dose of 50.4 Gy prescribed to the 95% isodose at 1.8 Gy/fraction (28 fractions).
223599839|NCT01726582|DRUG|Milestone 6: Gemcitabine after surgery|Chemotherapy treatment with Gemcitabine.
223748875|NCT07158515|BEHAVIORAL|Referral to an external cardiac rehabilitation program|Participants will be referred to an external cardiac rehabilitation program outside of the safety net setting. This is the current standard of care.
223599840|NCT01726582|RADIATION|Milestone 6: Chemoradiotherapy (cXRT)|A radio-sensitizing chemotherapy agent (either Gemcitabine or Capecitabine) will be given. Using 3D conformal or IMRT techniques, patients will receive a total dose of 50.4 Gy prescribed to the 95% isodose at 1.8 Gy/fraction (28 fractions).
223599841|NCT01726582|RADIATION|Milestone 7: Chemoradiotherapy (cXRT)|A radio-sensitizing chemotherapy agent (either Gemcitabine or Capecitabine) will be given. Using 3D conformal or IMRT techniques, patients will receive a total dose of 50.4 Gy prescribed to the 95% isodose at 1.8 Gy/fraction (28 fractions).
223599842|NCT01726582|DRUG|Milestone 8: Targeted chemotherapy after surgery|The molecular profile from the surgical specimen will point to a particular chemotherapy treatment.
223599843|NCT01726582|DRUG|Milestone 9: Gemcitabine after surgery|Chemotherapy treatment with Gemcitabine.
223599844|NCT01726582|OTHER|Milestone 10: No additional therapy after surgery|The molecular profile of the tumor that was removed during surgery points to a lack of treatment affect for available therapies. No additional therapy is recommended.
223599845|NCT05181644|DEVICE|EmoLED treatment|Treatment with the EmoLED device consists of irradiating each area of 5 cm in diameter of the lesion for 60 seconds; if the lesion is larger than 5 cm in diameter, the applications will be repeated up to cover the entire area of interest. EmoLED treatment is additional to the standard therapy for the patient.
223599846|NCT05181644|PROCEDURE|current Standard of Care|The acral lesions will be cleansed with physiological solution, disinfected with a special device and, if necessary, a debridement will be carried out with the most appropriate method.
223599847|NCT04086199|PROCEDURE|Lumbar discectomy|Lumbar discectomy either by an anterior extraperitoneal approach or by a posterior midline approach.
223599848|NCT03274544|OTHER|PROLUNG|"Chinese herbal medicine formula PROLUNG with individual herbs of the formula are listed as follows (weight in granule preparation):~* Huang Qi (Radix Astragali Membranaceus): 2 g~* Dan Shen (Radix Salviae Miltiorrhizae): 1 g~* Jiang Huang (Rhizoma Curcumae Longae): 1 g~* Yin Xing (Semen Gingko Bilobae): 1 g~* Mai Men Dong (Tuber Ophiopogonis Japonoci): 1 g~* Bai He (Bulbus Lilii): 1g~* Jin Yin Hua (Flos Lonicerae Japonicae): 1 g~* Zi Su Ye (Folium Perillae Frutescentis): 1 g~* Yin Yang Huo (Herba Epimedii): 1g"
223748876|NCT07158970|DEVICE|Use of the Pulsenmore home ultrasound device for fetal assessment, guided remotely by a physician.|Standard care
223748877|NCT07160491|OTHER|A novel artificial intelligence assisted mobile application|A novel artificial intelligence assisted mobile application will be used in the experimental group to guide entire reperfusion process in patients with STEMI. The functions of the application include patient screening, education and training, route planning for patient transfer, time management, and quality control, etc.The thrombolytic drug used in this study is tenecteplase (manufacturer: CSPC Pharmaceutical Group Limited, China ).
223748878|NCT07168343|DRUG|One icodextrin exchange|One icodextrin fill volume of 550ml/m2 body surface area which is optimal for most paediatric patients is recommended. The minimum dwell time for an icodextrin exchange will be 7 hours, and range between 7-10 hours.
223748879|NCT07168343|DRUG|Two icodextrin exchanges|In two icodextin exchanges, the dwell times can vary but must be a minimum of 7 hours.
223748880|NCT07168109|PROCEDURE|Enhanced monofocal intraocular lens implantation (monovision strategy)|"Participants will undergo phacoemulsification with the implantation of an enhanced monofocal intraocular lens, targeting -0.5 D in the dominant eye and -2.0 D in the non-dominant eye. The first operated eye will be selected based on the worse corrected distance visual acuity; if both eyes are similar, the eye subjectively perceived by the patient as having worse vision will be chosen. The second eye surgery will be performed within 2 weeks after the first eye surgery. Ocular dominance will be determined preoperatively using the finger method . Intraocular lens power will be calculated using multiple formulas \[Emmetropia Verifying Optical (EVO) version 2.0, Kane, LISA\]."
224199451|NCT01277172|BIOLOGICAL|Rituximab|375 mg/m2 IV every 14 days for 6 cycles
223599849|NCT01181817|OTHER|fMRI and MRS|fMRI and MRS
223748881|NCT07168109|PROCEDURE|Enhanced monofocal intraocular lens implantation (bilateral myopia strategy)|"Participants will undergo phacoemulsification with the implantation of an enhanced monofocal intraocular lens, targeting -2.0 D in both eyes. The first operated eye will be selected based on the worse corrected distance visual acuity; if both eyes are similar, the eye subjectively perceived by the patient as having worse vision will be chosen. The second eye surgery will be performed within 2 weeks after the first eye surgery. Ocular dominance will be determined preoperatively using the finger method. Intraocular lens power will be calculated using multiple formulas \[Emmetropia Verifying Optical (EVO) version 2.0, Kane, LISA\]."
224199452|NCT00959075|DIETARY_SUPPLEMENT|Vitamin B1|100 mg Twice a day
224075154|NCT05753085|DEVICE|Conavi Medical Novasight Hybrid System intervention|Patients for a coronary angiogram who meet the inclusion criteria and none of the exclusion criteria are enrolled. Participants are prepared for angiography and PCI procedure in the usual way. Radial or femoral artery cannulation is done under local anaesthetic and the angiogram performed as per standard practice. IVUS-OCT imaging of the culprit vessel using the Novasight Hybrid system is then performed. If image quality of the IVUS-OCT is suboptimal it will be repeated. If the IVUS-OCT catheter cannot cross the lesion, pre-dilatation is performed. The acquired IVUS-OCT images can be used to optimise PCI. Following PCI, angiography is repeated and if the findings are optimal, IVUS-OCT imaging is repeated. If the PCI results are suboptimal further stent optimisation is performed and IVUS-OCT imaging repeated; The procedure is then completed as clinically indicated. The participant will then receive conventional post PCI care
224075155|NCT04101838|DRUG|Fluzone|inactivated seasonal influenza vaccine
224075156|NCT04101838|DRUG|Flucelvax|inactivated seasonal influenza vaccine
224075157|NCT04101838|DRUG|Fluzone High-Dose|inactivated seasonal influenza vaccine
224075158|NCT04101838|DRUG|Fluad|inactivated seasonal influenza vaccine
224199453|NCT00959075|DIETARY_SUPPLEMENT|Placebo|Sugar pill
223599850|NCT02135237|BEHAVIORAL|Prize Contingency Management for Alcohol Abstinence|The systematic reinforcement of desired behaviors and the withholding of reinforcement for undesired behaviors
223599851|NCT02135237|BEHAVIORAL|Standard Care|
223599852|NCT02906397|DRUG|Galunisertib 150mg by mouth twice a day|on days 1-14 of 28 day cycles
223599853|NCT02906397|RADIATION|Stereotactic Body Radiotherapy (SBRT)|18GY delivered in one fraction between C1D15 and C1D28
224311243|NCT02496936|OTHER|SFA|High saturated fatty acid/SFA oil source
224311244|NCT02496936|OTHER|MUFA|High monounsaturated fatty acid/MUFA oil source
223599854|NCT04789369|BEHAVIORAL|Questionnaires|Assessing the behavioral metrics (quality of life, functionality and fear of movement) with appropriate measurement tools
223599855|NCT03058055|BEHAVIORAL|Placebo|The placebo group will have unstructured lifestyle activities (normal lifestyle activities without restraint).
223599856|NCT03058055|BEHAVIORAL|Origami|Origami lessons (one hour/week) with daily take home Origami activities to complete
223599857|NCT03058055|BEHAVIORAL|Reading|Book club that includes weekly one hour meetings and daily reading assignments
223599858|NCT03100591|DRUG|14C-radiolabeled ACT-132577|Single oral dose of 3.7 megabecquerel (MBq) (100 microcurie \[μCi\]) 14C-radiolabeled ACT-132577 administered as 1 capsule of 25 mg
223599859|NCT01363908|DRUG|SPD602|
223599860|NCT05022966|OTHER|No intervention|Individuals did not received any intervention.
223599861|NCT02868411|OTHER|Rectal Swab|
223599862|NCT02746640|PROCEDURE|Cardiopulmonary resuscitation (CPR)|If there is a cardiopulmonary arrest, investigators observe the working processes of cardiopulmonary resuscitation.
223599863|NCT03437577|DRUG|immediate-release tacrolimus|Standard of care for transplant patients
223599864|NCT03437577|DRUG|extended release tacrolimus|Experimental care
223599865|NCT04720521|DIAGNOSTIC_TEST|OE+white light|Firstly use white light to observe from esophagus to duodenum and then switch OE mode to observe from antrum to esophagus
223599866|NCT04246658|OTHER|conventional physical therapy program|traditional physical therapy program
223599867|NCT04246658|OTHER|gait training on platform swing walkway|gait training on platform swing walkway for 30 minute.
223599868|NCT01848119|DRUG|Gabapentin|
223599869|NCT01848119|DRUG|lactose|
223599870|NCT04280627|OTHER|Sample Collection|This study will involve the collection of oral swabs, saliva, urine and faeces samples, blood and skin scrapings from patients before and after kidney and pancreas transplantation at day 0, day 1, week 1 and at 3, 6 and 12 months post-transplant.
223599871|NCT01984502|RADIATION|CyberKnife Accelerated Hemilarynx Stereotactic Radiotherapy|CyberKnife Accelerated Hemilarynx Stereotactic Radiotherapy
223599872|NCT00513149|DRUG|Clopidogrel|Clopidogrel 600 mg loading
223599873|NCT01423292|PROCEDURE|Ultrasound Guided Transversus Abdominis Plane (TAP) Block|Ultrasound Guided Transversus Abdominis Plane (TAP) Block
223599874|NCT01423292|DRUG|bupivacaine|0.25 bupivacaine 30ml (15ml on each side)
223599875|NCT01423292|DRUG|Placebo|placebo
223599876|NCT02210858|OTHER|Laboratory Biomarker Analysis|Correlative studies
223599877|NCT02210858|DRUG|Tipifarnib|Given PO
223599878|NCT03871244|PROCEDURE|Less red blood cell transfusions|The instructions given to caregivers will be to consider prescribing a red blood cell transfusion only if the hemoglobin level is ≤ 70 g per L.
223599879|NCT03871244|PROCEDURE|More red blood cell transfusion (standard transfusion strategy in PICU)|The instructions given to caregivers will be to prescribe a red blood cell transfusion according to their usual standard practice
223599880|NCT04656743|PROCEDURE|intra-articular injection|The injection will be performed under ultrasound guidance by placing the patient's knee in approximately 90° of flexion with the leg hanging off the side of the bed (left). A high-frequency linear transducer ultrasound probe is placed in the superolateral corner of the patella, directed medially toward the patellofemoral joint space. In the extended leg, from anterior to posterior, the right image shows the quadriceps femoris tendon (QF), suprapatellar fat pad (SF), suprapatellar bursa (SB), prefemoral fat pad (PF), and femur (F). When the knee is flexed to 90°, the size of the suprapatellar bursa image is increased. Using an in-plane approach, the needle will be directed into the suprapatellar joint space, and 20 ml of bupivacaine 0.25% will be injected.
223599881|NCT04656743|PROCEDURE|genicular nerve block|The transducer will be first placed parallel to the long bone shaft and moved up or down to identify the epicondyle of the long bone. The genicular arteries will be identified near the periosteal areas, confirmed by color Doppler ultrasound. Accordingly, genicular nerve block target points should be next to each genicular artery. After using color Doppler to confirm the genicular artery, the needle will be inserted in the plane of the ultrasound probe in the long-axis view. a gentle aspiration will be performed and a 2 mL injection volume will be administered.
223599882|NCT00536471|DRUG|Duloxetine hydrochloride|
223599883|NCT00536471|DRUG|Placebo|
223599884|NCT05981027|OTHER|Mulligan bent leg raise technique|In this study, while the participant was lying on his back on a high bed, the physiotherapist sat on the lateral side of the leg to be treated, placing the popliteal fossa of the participant's knee on his shoulder. The hip and knee of the leg to be stretched were placed in 90° flexion. Distraction was applied to the lower end of the femur, and the participant was asked to push the physiotherapist's shoulder with his leg and then relax. At this relaxation point, the physiotherapist pushed the flexed knee as far as possible in the direction of the ipsilateral shoulder in a painless range.
223599885|NCT05981027|OTHER|Static stretching exercise|The participant lay on a stretcher in the supine position with his back straight. The physiotherapist placed the participant's leg on his shoulder with the knee in full extension and supported by the ankle and flexed the hip as much as possible until a tension was felt in the posterior thigh. This position was maintained for 30 seconds.
223599886|NCT03908359|PROCEDURE|traditional cataract surgery|ACCC+ I/A + PCCC + Anti-vit: anterior continuous capsulorhexis + irrigation/aspiration + posterior capsulorhexis + anterior vitrectomy
223599887|NCT03908359|PROCEDURE|minimal invasive lens surgery|We decreased the size of the capsulorhexis opening to 1.0-1.5 mm in diameter. Then we moved the location of the capsulorhexis to the peripheral area of the lens instead of the central area. A 0.9 mm phacoemulsification probe was used to remove the lens contents and/or cortical opacities.
223599888|NCT01359202|BIOLOGICAL|rfVIIa|80ug/kg IV bolus
223599889|NCT01359202|OTHER|Standard saline solution|Saline
223599890|NCT00328614|DRUG|Samarium-153|Samarium-153 will be administered as a single dose after one month of hormonal therapy. The dose level of Samarium-153 may change to determine maximum tolerated dose (MTD).
224075159|NCT02869282|OTHER|Blood samples|Additional blood samples at baseline, 6, 12, 18 and 24 months.
224075160|NCT02869282|OTHER|Urine samples|Additional urine samples at baseline, 6, 12, 18 and 24 months.
224075161|NCT04229160|DEVICE|Noninvasive mapping (Cardioinsight® system)|Noninvasive mapping (Cardioinsight® system) of the left atria before the Atrial fibrilation ablation procedure
223599891|NCT00328614|DRUG|Total Androgen Suppression (TAS) with Bicalutamide|Patients will receive 5 months of total androgen suppression (TAS) consisting of Zoladex and Casodex. Total androgen suppression will begin 3 months prior to initiation of irradiation.
223599892|NCT00328614|DRUG|Total androgen suppression (TAS) with Goserelin Acetate|Patients will receive 5 months of total androgen suppression (TAS) consisting of Zoladex and Casodex. Total androgen suppression will begin 3 months prior to initiation of irradiation.
223599893|NCT00328614|DEVICE|Radiation Therapy|Radiation therapy will begin 3 months following the initiation of hormone administration. Daily tumor doses will be given 5 days per week for 7-8 weeks.
223599894|NCT05550194|DRUG|ValACYclovir 1000 MG|Valacyclcovir is a targeted anti-viral for varicella zoster virus (VZV).
223599895|NCT05550194|BIOLOGICAL|Shingrix|Vaccine indicated for prevention of herpes zoster
223599896|NCT00477646|BEHAVIORAL|Prevention Care Management|Telephone support over 18 months to help women become screened for breast, cervical and colon cancer. Includes barriers assessment, patient education and motivation, provider recommendation letter, appointment reminder, and some scheduling of appointments.
223599897|NCT00066963|DEVICE|Fluoride Varnish|0.1 mL (1 drop) applied on each of 2 arches
223599898|NCT04543292|DEVICE|MATFILL (PTFE)|Filling of the prosthetic chimney with the compressed material
223599899|NCT03377153|DIETARY_SUPPLEMENT|hesperidin and flaxseed|2 capsuls hesperidin and 30 g flaxseed
223599900|NCT03377153|OTHER|control|no supplementation
223599901|NCT06210230|DIETARY_SUPPLEMENT|MLCT supplementation|MLCT 25g/d for 6 months
223599902|NCT06210230|DIETARY_SUPPLEMENT|Olive oil|Matching placebo (olive oil) 25g/d for 6 months
223599903|NCT00988091|DEVICE|1.2% Sodium Hyaluronate|IA-BioHA is supplied in a disposable 7 ml nominal volume glass syringe containing 60 mg/5 ml of 1.2% sodium hyaluronate. Participants are given a single injection in the target knee on Day 1 of the double-blind period and optionally on the first day of the open-label period (approximately week 27).
223599904|NCT00988091|DEVICE|Buffered Saline|IA-SA is supplied in a disposable 7 ml nominal volume glass syringe containing 5 ml of phosphate buffered saline. Participants are given a single injection in the target knee on Day 1 of the double-blind period.
223599905|NCT03023293|OTHER|n-3 PUFAs consumption and irisin|The investigators plan to collect n-3 PUFAs and irisin information at 24-28 weeks' gestation, 42 days postpartum, 1 year postpartum and 2 years postpartum
223748882|NCT07170670|BEHAVIORAL|CBIP - Cognitive-Behavioral Intervention Package|"Before the procedure, the researcher initiated social interaction with the child (cognitive distraction). Next, suggestions regarding the procedure were provided (guidance). A volunteer parent sat beside the child, providing support by holding the child's non-procedural hand. While the nurse performed the port catheter insertion, the researcher applied one of the behavioral distraction techniques chosen by the child during the pre-procedure phase, such as counting, singing, reading a poem, or answering questions (behavioral distraction). Upon completion of the procedure, the researcher provided positive reinforcement by praising the child (Well done! and You were very brave!) and rewarding the child with a star and smiley face sticker on the collar (positive reinforcement)."
224199454|NCT01833897|DRUG|Standard of Care|Quetiapine, olanzapine-fluoxetine, and lurasidone are approved treatments for bipolar depression. Quetiapine dosing will follow the product label(Anon), and will be titrated over the first 4 days to the target dose of 300 mg. Olanzapine-fluoxetine dosing will also follow standard guidelines. Lurasidone will be started at 20 mg, and titrated up to 60 mg daily as clinically indicated. Study physicians will use clinical judgment to choose between standard-of care treatments, and have the option to titrate standard-of-care within approved ranges, and to prescribe adjunctive benztropine and benzodiazepines if clinically indicated.
224199455|NCT01833897|DRUG|Ketamine|Ketamine administration will be carried out according to the methods as described by previous studies. Subjects will receive ketamine hydrochloride (0.5 mg/kg) intravenously during 40 minutes. This dosage was selected based on previous trials of ketamine for the treatment of refractory depression and bipolar depression. Vital signs (blood pressure, heart rate) will be closely monitored throughout the time of infusion. Subjects will be evaluated for 2 consecutive days during this phase; i.e. treatment days (day 1) and rating days (day 2). Non-responders to ketamine will not proceed into the DCS phase. Response will be a 25% improvement on the Hamilton Depression Rating Scale (HDRS).
223599906|NCT00093652|DRUG|gefitinib|
224199456|NCT01833897|DRUG|D-cycloserine|Immediately after the ketamine infusion, subjects will begin an eight-week treatment of DCS adjunctive to standard of care. DCS dosing will begin at 250 mg for three days→500mg (2 capsules)/day for 1 week → 750 mg (3 capsules)/day for 1 week → and 1000 mg (4 capsules)/day for the remainder of the study.
224311245|NCT02496936|OTHER|PUFA-LA|High polyunsaturated fatty acid (linoleic)/PUFA-LA oil source
223599907|NCT00093652|DRUG|oxaliplatin|
223599908|NCT00093652|PROCEDURE|conventional surgery|
223599909|NCT00093652|PROCEDURE|neoadjuvant therapy|
223599910|NCT00093652|RADIATION|radiation therapy|
223599911|NCT05999500|BEHAVIORAL|Temple stay experience|Temple stay experience includes diet and behavior changes, such as vegetarian meals (ex. Balwoo Gongyang), mindful eating, no overeating, meditation, participation in daily monastic tasks.
223599912|NCT00994422|DRUG|Ivermectin cream|Up to 4 ounces of topical 0.5% Ivermectin Cream applied to the hair and scalp on day 1.
223599913|NCT00994422|DRUG|vehicle control|Up to 4 ounces of vehicle control applied to the hair and scalp on day 1
223599914|NCT01520376|BEHAVIORAL|Counselling|Visit by a psychiatrist at day-30 and day-180 after discarge
223599915|NCT05118698|DRUG|Gynostemma|Patients in the high-dose group and low-dose group will take gynostemma powder with a saponin content of 12% and 8% respectively, 3 times a day for 3 months.
223599916|NCT05118698|OTHER|Spinach|For the spinach powder group, each patient will take spinach powder with nearly no saponin content, 3 times a day for 3 months.
223599917|NCT06109207|DRUG|Camrelizumab|Camrelizumab will be given at at a dose of 200 mg intravenously every three weeks on day 1 of a planned 21-day cycle, and two doses before surgery
223748883|NCT07171320|DRUG|Pregabalin|In the pregabalin monotherapy group, pregabalin will be initiated at 150 mg daily, divided into 2 or 3 doses per day, and increased to 300 mg per day after 3 to 7 days, subsequent increases of 150 mg daily may occur every 3 to 7 days, based on individual patient response and tolerability, with a maximum dose of 600 mg daily.
224311246|NCT02496936|OTHER|ALA|High polyunsaturated fatty acid (alpha-linolenic)/ALA oil source
224199457|NCT04027777|DEVICE|Aktiia.product-P0|The optical signals at the wrist are recorded non-invasively by means of the Aktiia.product-P0 investigational device. The BP measurements are further determined from these optical signals and are compared to the reference double auscultation BP readings. A reference-control volume clamp BP reading is recorded simultaneously.
223599918|NCT06109207|DRUG|Dalpiciclib 100mg|Dalpiciclib will be given at a dose of 100 mg every day orally with three weeks on and one week off. Four weeks is a cycle and it will be given for two cycles.
223599919|NCT06109207|DRUG|Dalpiciclib 150mg|Dalpiciclib will be given at a dose of 150 mg every day orally with three weeks on and one week off. Four weeks is a cycle and it will be given for two cycles.
223599920|NCT06207526|BEHAVIORAL|Blended face-to-face and smartphone intervention|The intervention comprises two phases: an initial stage involves baseline assessment, in-depth app training, psychoeducation, and EMA monitoring for functional analysis. The subsequent phase focuses on identifying and implementing individual coping strategies, forming the basis for daily personalized EMI reminders. Over six days, participants receive ten daily surveys to gauge fluctuations in paranoia and delusional ideation. EMA-derived feedback, considering antecedents and coping responses, shapes a personalized EMI. Four sessions with a psychologist involve discussing app feedback, emphasizing functional analysis, coding coping strategies into the app, assessing utility, and adapting as needed. Post-session two, five coping reminders and an eight-item evening survey are sent daily for two blocks of ten days to monitor delusional ideations and coping strategy effectiveness.
223599921|NCT02087111|DRUG|Telaprevir|375 mg film coated tablets
223599922|NCT02087111|DRUG|40 Kd Pegylated interferon alfa 2a|180 µg in pre-filled syringe for sub-cutaneous injection
223599923|NCT02087111|DRUG|Ribavirin|200 mg tablets
223599924|NCT00276809|BIOLOGICAL|alemtuzumab|
223599925|NCT00276809|BIOLOGICAL|filgrastim|
223599926|NCT00276809|DRUG|carmustine|
223599927|NCT00276809|DRUG|cyclophosphamide|
223599928|NCT00276809|DRUG|cytarabine|
223599929|NCT00276809|DRUG|dexamethasone|
223599930|NCT00276809|DRUG|etoposide|
223599931|NCT00276809|DRUG|fludarabine phosphate|
223599932|NCT00276809|DRUG|melphalan|
223599933|NCT00276809|PROCEDURE|autologous bone marrow transplantation|
223599934|NCT00276809|PROCEDURE|peripheral blood stem cell transplantation|
223599935|NCT00276809|RADIATION|radiation therapy|
223599936|NCT05698602|DEVICE|NivolisMonitor|"NivolisMonitor comprises a sensing element and controller to measure respiratory values, such as pressure and flow optionnally temperature, relative humidity and oxygen concentration, of a patient being treated with a respiratory therapy devices NIV, CPAP or HDN.~NivolisMonitor is inserted between the respiratory assistance device and the mask or cannula inline with the standard patient circuit used routinely with the respiratory assistance device.~NivolisMonitor functions are:~* measure the respiratory values from the builtin sensor (Pressure, Flow, Temperature, Humidity, Oxygen fraction),~* store the measurements in the embedded memory~* extract from the measurement basic respiratory markers:~* detect if and when a patient is using the respiratory assist device,~* calculate leakage~* calculate respiratory frequency~* transmit the measured values via the NivolisBox component to NivolisPortal"
224075162|NCT04229160|DEVICE|long-term cardiac monitoring (LINQ system)|long-term cardiac monitoring (LINQ system) is used to evaluate recurrence rate following AF ablation procedure
224199458|NCT06345183|COMBINATION_PRODUCT|Nivolumab + Ipilimumab combination therapy|As per product label
223599937|NCT05698602|DEVICE|NivolisAnton|"NivolisAnton device enables wireless and remote communication from tcPCO2 monitors which measure transcuteanously CO2 and O2 partial pressures in the blood (tcPCO2 \& tcPO2) .~NivolisAnton device connects to the serial port of tcPCO2 monitor, detects if the monitor is actively measuring blood gas values, collects the measurements from the monitor by following manufacturer's communication protocol and stores the collected values in its internal memory. When applicable per the manufacturer recommendations, NivolisAnton collects the values to apply the drift correction as per the manufacturer recommendations.~NivolisAnton transmits the collected data to external receiving devices, such as Medical Devices (NivolisMonitor or another Medical Device that is granted approved data access by Vivardis) via Bluetooth or data servers (NivolisBox as an example) via WIFI. This data is thereafter transmitted by previously mentioned devices to the NivolisPortal server for archiving."
223599938|NCT00765180|DEVICE|TRE vs. NBI|TRE NBI
223599939|NCT04526041|OTHER|Nasofibroscopy|Laryngeal exploration performed using a flexible fibrescope while singing.
223599940|NCT04526041|OTHER|Electroglottography|Electrography of glottal movement using the EG2-PCX2 system (Glottal enterprises) while singing.
223599941|NCT04526041|OTHER|Air flow measurement + acoustic signal recording|Air flow measurement and acoustic signal recording while singing using the EVA2 system (SQLab-LPL, Aix en Provence, France)
224075163|NCT04229160|PROCEDURE|Atrial Fibrillation ablation procedure|Atrial Fibrillation ablation procedure is done with standard practice
223599942|NCT04526041|OTHER|Questionnaire|Questionnaire on subject singing habits, the way it use and perceive the use of his body when singing.
223599943|NCT00300313|DRUG|Escitalopram|10 to 20 mg / day
223599944|NCT00300313|DRUG|Placebo|1-2 capsules
223599945|NCT01162902|DRUG|Diltiazem treated group|Diltiazem 180mg for 9 months
223599946|NCT01162902|DRUG|Bisoprolol treated group|Bisoprolol 5mg for 9 months
223599947|NCT01162902|DRUG|Candesartan treated group|Candesartan 32mg for 9 months
224075164|NCT06139523|DEVICE|Investigational contact OCT system|Theia imaging is developing handheld OCT systems bring state of the art OCT to the infant bedside. The Theia 1 widefield imaging system is a light weight, high speed (300 kHz), wide field of view (110°) OCT system that address the limitations of current commercial OCT systems. The system is cart mounted, enabling portable, bedside imaging. The system uses a 300 kHz swept source laser operating in 1060nm regime. The Theia system follows the same safety standards as all applicable laser safety standards (ANSI z80.36 or ISO 15004) as the currently approved prior OCT devices. This nearly 10-fold increase in acquisition speed dramatically reduces imaging time and enables acquisition of full retinal volumes in infants. The 110° field of view is provided via a re-usable contact lens that can be sterilized between imaging sessions.
224199459|NCT06345183|COMBINATION_PRODUCT|Pembrolizumab + Lenvatinib combination therapy|As per product label
224311247|NCT02496936|OTHER|LCn3|High polyunsaturated fatty acid (omega-3)/LCn3 oil source
223748884|NCT07171320|DRUG|Pregabalin with desvenlafaxine|In the pregabalin with desvenlafaxine group, the dose titration of pregabalin is identical with pregabalin monotherapy group. Desvenlafaxine will be administered at 50 mg daily with breakfast initially. If the initial dose is well-tolerated, the dose could be further escalated by 50 mg per day after 3 days, up to a maximum of 400 mg per day after 7 days. With each dose increase, AEs will be assessed and categorized as mild, moderate, or severe. If participants tolerate the current dose for 2 to 3 days, it will be maintained, with the expectation that tolerance to AEs will develop. If AEs become intolerable, the dose will be decreased back to the previous dose, which was defined as the maximum tolerated dose. In the combination group, dose titration of both pregabalin and desvenlafaxine will be conducted simultaneously. If AEs occur, the next dose regimen should be determined in consultation with a clinical physician.
223748885|NCT07162207|PROCEDURE|Pinhole surgical technique|A pinhole is created in the site of recession, the grafting material (Bi-layer collagen membrane versus connective tissue graft) is trimmed to fit the size of the recession defect, followed by graft insertion in the tunnel.
223748886|NCT07165951|DRUG|TQB2868 Injection|TQB2868 injection: PD-L1 and Transforming Growth Factor-beta (TGF - β) dual antibody
223748887|NCT07165951|DRUG|Anlotinib Hydrochloride Capsules|Anlotinib Hydrochloride Capsules
223748888|NCT07165951|DRUG|Gemcitabine Hydrochloride Injection|Gemcitabine Hydrochloride Injection
223748889|NCT07165951|DRUG|Paclitaxel for Injection|Paclitaxel for Injection
223748890|NCT07165951|DRUG|TQB2868 Placebo|TQB2868 Placebo without drug substance
223748891|NCT07164820|OTHER|Su Jok Application|Description: The newborn's hands will be used for the application. Su Jok therapy will be administered by applying massage and seeds to the corresponding reflection points on the hand prior to the he
224199460|NCT05013827|BEHAVIORAL|Filling in an online survey|Company representatives are questioned about three aspects: 1) goals in treating patients with neuromodulation for pain, 2) factors that respondents expect to change according to neuromodulation for pain and 3) their definition of success of neuromodulation for pain.
224199461|NCT00421811|DRUG|ADH-1|4 gm IV Days 1 and 8
224199462|NCT00421811|DRUG|melphalan|By Isolated Limb Infusion (ILI), Lower Extremity: 7.5 mg/L (Limb Volume), Day 1 or Upper Extremity: 10 mg/L (Limb Volume), Day 1
223599948|NCT04423692|OTHER|labs|A group of questions to women regarding Corona with laboratory finding suggestive of covid 19 and coagulopathy
223748892|NCT07165106|BEHAVIORAL|Aerobic Exercise|"Participants in this group will receive conventional rehabilitation in combination with supervised treadmill-based aerobic exercise three times per week for 6 weeks. Each exercise session will consist of a 5-minute warm-up, a 15-minute main exercise phase, and a 5-minute cool-down. Walking speed will be individualized based on participant tolerance and progressively increased under clinical supervision. Exercise intensity will be monitored using the modified Borg Rating of Perceived Exertion (scale 6-20).~Weeks 1-2: Main exercise at Borg 10-11 (light-moderate).~Weeks 3-4: Main exercise at Borg 11-12 (moderate).~Weeks 5-6: Main exercise at Borg 12-13 (moderate-high).~Cardiorespiratory responses will be monitored during all sessions, and treadmill speed will be gradually adjusted in accordance with improvements in exercise tolerance while maintaining safety."
223599949|NCT00943332|PROCEDURE|femur fracture repair|all participants will have undergone surgical intervention to repair a femur fracture, the investigators will simply be collecting data after the procedure; participants will not be consented until after the procedure
224199463|NCT03933709|DIETARY_SUPPLEMENT|Nutritional Support System (NSS)|Envelope 1 4.9g of Spirulina, 100mg ascorbic acid, 5mg folic acid and 10mg of glutamine. Was to be added to shake 1 during the first 10 days. Envelope 2 1g PUFAs n-3 and was to be added to shake 2 which was given throughout the intervention. Envelope 3 4.9g of Spirulina Maximum, 100mg ascorbic acid, 5mg folic acid, 5.2g vegetable protein, 125mg nicotinic acid, 50mg zinc, 100 mcg selenium and 800 UI cholecalciferol. Was to be added to shake 1 from day 11 until the end of week 6, after which it was suspended for 10 days and substituted for envelope 5 and then to be retaken until the end of the intervention. Envelope 4. 1g arginine and was to be added to shake 3 from day 8 until the end of the intervention. Envelope 5 contained the same ingredients as envelope 3 with an additional 10mg glutamine and was to be added to shake 1 from the start of week 7 for 10 days, after which envelope 3 was restarted. Probiotic at a dosage of 200 mg every 12 hours for 3 days at the beginning and week 6
223599950|NCT06364462|OTHER|lifestyle intervention|Dietary recommendations should consider energy restriction and exclusion of MAFLD-mediating components (processed food, food and beverages high in added fructose). A Mediterranean type diet is advisable. Both aerobic exercise and resistance training effectively reduce liver fat and should be tailored based on patient preferences to ensure long-term adherence.
223599951|NCT03637478|BEHAVIORAL|Enhanced Systems of Care Team|E-SOC team will be increasing connections between clinical care and community partners, such as schools, juvenile justice and child-serving state agencies, to reduce disparities in access to mental health/substance use evaluation and treatment. All aspects of the care continuum will be provided in a culturally and linguistically competent manner, with child and family-driven care planning. Overall goals are: earlier identification of mental health needs including child trauma; increased treatment access and adherence; care delivered in least restrictive settings; care experience reflecting active youth and family engagement; program sustainability and replicability.
223599952|NCT03100604|DRUG|desflurane,|Patients were divided into two groups according to inhalation agent administered for the surgery; Sevofluran, Group S (n=25) and Desfluran, Group D (N=25).
223599953|NCT03100604|DRUG|Sevoflurane|For a drug, use generic name if established. Use the same name as in the associated Arm/Group Description(s).
224199464|NCT03933709|OTHER|deworming|nitazoxanide at a dosage of 7.5 mg / kg every 12 hours for 3 days.
223599954|NCT05564312|DEVICE|Transabdominal ultrasonographic guidance at embryo transfer.|During embryo transfer in each patient, endometrial thickness, uterine cavity dimensions, distance of transfer catheter to the fundus, distance of released air bubble to the fundus, and distance of air bubble to side walls will be systematically measured and recorded under the guidance of transabdominal ultrasonography.
223599955|NCT01806675|DRUG|18F-fludeoxyglucose (18F-FDG)|18F-FDG will be used as the radiotracer for a regular medical care PET/CT or PET/MRI scan
224199465|NCT03933709|OTHER|recommended diet|WHO Diet
224199466|NCT03855930|DIAGNOSTIC_TEST|functional MRI|During the study, standard motor and sensory paradigms will be performed to establish anatomical and functional patterns in the non-painful state. The patient will then be asked to urinate (to an external collecting tube system).
223599956|NCT01806675|DRUG|18F-FPPRGD2|18F-FPPRGD2 will be used as the radiotracer for a PET/CT or PET/MRI scan. Participants will be injected with less than 10 mCi of 18F-FPPRGD2.
223599957|NCT06557239|DRUG|Lysergic Acid Diethylamide (LSD)|one single dose of LSD in the context of psychedelic assisted psychotherapy as a part of a clinical routine in our department
223599958|NCT01938833|DRUG|Romidepsin|
223599959|NCT01938833|DRUG|Abraxane|
223599960|NCT00836186|RADIATION|Radiation therapy|Patients will receive whole breast radiation therapy at a dose of 180-200 centigray (cGy) per fraction for 23-27 fractions to a total dose of 4600 - 4860 cGy. Additional radiation to the lumpectomy bed (Boost) is at the discretion of the treating physician. The total dose to the tumor bed cannot exceed 6600 cGy.
223599961|NCT00147121|DRUG|Rituximab + Standard CHOP|Rituximab + Standard CHOP
223599962|NCT00147121|DRUG|Rituximab + Bi-weekly CHOP|Rituximab + Bi-weekly CHOP
223599963|NCT02203994|DEVICE|"Duolith® SD 1 T-Top (Storz Medical AG, Switzerland)"|2000 pulses per muscle, energy level: 0.030 mJ/mm2, frequency: 4 Hz
223599964|NCT00087659|DRUG|zoledronic acid|
223599965|NCT00587704|PROCEDURE|PVB using nerve stimulation|5ml of 1% ropivacaine injected incrementally
223599966|NCT00587704|PROCEDURE|PVB using anatomic landmarks|5ml of 1% ropivacaine injected incrementally
223599967|NCT01711125|DRUG|Baclofen 30mg/day|30mg/day 10 mg t.i.d
223599968|NCT01711125|DRUG|Baclofen 75mg/day|75mg/day 25 mg t.i.d
223599969|NCT01711125|DRUG|Placebo|Placebo 3 matched tabs/day
223599970|NCT03864302|BEHAVIORAL|Motor Imagery|Motor imagery (MI) is a psychological technique for improvement of motor skills.(24) MI skill training (MIST) has been used and explored in several disciplines including Sports, Music, Education, Psychology and Medicine.(18) The literature has found positive effects on performances in professional athletes but also on rehabilitation of stroke patients.(25,26) MI is a cognitive imagery of a physical performance, e.g. a high jumper imagine a high jump, prior to performance. MI is not as effective as physical practice, but more effective compared to no training.(27) Further, MI combined with physical practice has been found to be more effective in skill performance in sports compared to physical practice alone.(18) MIST has shown promising results on surgical performances in flexible cystoscopy performed by doctors.(28)
223599971|NCT00532298|BIOLOGICAL|GSK Bio's influenza vaccine GSK576389A [NH 2006/07 season]|Single dose, intramuscular injection, GSK Bio's influenza vaccine GSK576389A formulation recommended for the Northern Hemisphere 2006-2007 influenza season.
223599972|NCT00532298|BIOLOGICAL|GSK Bio's influenza vaccine GSK576389A [NH 2007/08 season]|Single dose, intramuscular injection, GSK Bio's influenza vaccine GSK576389A formulation recommended for the Northern Hemisphere 2007-2008 influenza season.
223599973|NCT00532298|BIOLOGICAL|Fluarix [NH 2006/07 season]|Single dose, intramuscular injection, Fluarix vaccine formulation recommended for the Northern Hemisphere 2006-2007 influenza season.
223748893|NCT07165106|BEHAVIORAL|Resistance Exercise|Participants in this arm will receive conventional rehabilitation combined with supervised resistance training using elastic bands, 3 times per week for 6 weeks. Exercises target major upper- and lower-limb and hip muscles. Each exercise is performed for 3 sets of 10 repetitions with 60-90 seconds rest. Initial band tension is set at the highest tolerable level and progressively increased. The program includes shoulder press, biceps curl, triceps extension, seated leg extension, calf raise, and lateral band walk. All sessions are supervised, emphasizing correct posture, controlled full range of motion, and avoidance of compensatory movements. Patients are guided with verbal and visual cues when necessary.
223599974|NCT00532298|BIOLOGICAL|Fluarix [NH 2007/08 season]|Single dose, intramuscular injection, Fluarix vaccine formulation recommended for the Northern Hemisphere 2007-2008 influenza season.
223599975|NCT00209703|DRUG|Oxaliplatin|
223599976|NCT00209703|DRUG|l-Leucovorin|
223599977|NCT00209703|DRUG|5-Fluorouracil|
223599978|NCT01973998|DRUG|Roflumilast|PDE4 inhibitor
223599979|NCT01973998|DRUG|Placebo|Inactive substance.
223599980|NCT06138990|DIAGNOSTIC_TEST|Pharmacoscopy|Pharmacoscopy (PCY) is an image-based ex vivo drug testing platform developed by the Snijder lab at the ETH Zurich. PCY measures in the drug response of patient cells from small biopsies using automated microscopy and single-cell image analysis. PCY prioritizes treatments based on their specific efficacy against AML cells, while minimizing toxicity to healthy (non-malignant) cells in the patient biopsy.
223599981|NCT06138990|DRUG|Clinical standard-of-care (physician's choice)|Clinical standard-of-care therapy for RR AML selected by the physician (physician's choice).
223599982|NCT06650267|BEHAVIORAL|Fathers for Change (F4C)|Defining features of F4C delivered over 18 sessions: 1) focus on the fathers model of fatherhood as a motivator for change, 2) focus on understanding and identifying feelings, teaching skills to identify and change emotional dysregulation that lead to both SU and FV, 3) co-parent communication skills to reduce stress and improve problem solving, 4) restorative parenting (see Table 1 and figure 1)127. F4C focuses on reflective understanding of emotional experiences, how that impacts thoughts and behaviors related to SU, FV, co-parenting/parenting each session. Through greater self-awareness, the father is better able to apply coping, communication and parenting skills introduced to reduce SU and FV.
223599983|NCT06650267|BEHAVIORAL|Individual Drug Counseling (IDC)|IDC is an individual evidence-based SU treatment84 that incorporates two elements: endorsement of the disease model and the spiritual dimensions of recovery. These elements differentiate the approach from F4C. IDC is influenced by 12-step recovery philosophy and participation in 12-step groups like NA are encouraged. The model places focus on the individual in recovery without a focus on fatherhood or co-parenting. IDC will be offered in an 18-session format.
223599984|NCT06511349|DRUG|YOLT-203|The IP is administered intravenously at the predetermined dose.
223599985|NCT04766775|DEVICE|Silver Diamine Fluoride|Silver Diamine Fluoride (Riva Star) which contains silver, fluoride, ammonia and water.
224199467|NCT02168205|DRUG|Pomalidomide|Capsules
224199468|NCT02168205|OTHER|Caffeine|Capsules
224199469|NCT02168205|OTHER|Tobacco|Cigarettes
224199470|NCT04554225|DRUG|Oxygen gas|Oxygen administered to a patient using ambulatory oxygen
224199471|NCT03562923|DRUG|Test Product|Fluticasone Propionate 100 mcg and Salmeterol 50 mcg Inhalation Powder
224199472|NCT03562923|DRUG|Reference Product|ADVAIR DISKUS® 100/50 (Fluticasone Propionate 100 mcg and Salmeterol 50 mcg Inhalation Powder)
224199473|NCT03562923|DRUG|Placebo|Placebo Product
224199474|NCT03962114|DIETARY_SUPPLEMENT|Vitamin B3|capsules with niagen
223599986|NCT06976294|OTHER|Cognitive Behavioral Approach-Based Psychoeducation|The 'Socio-Demographic Characteristics Form', the 'Post-Traumatic Growth Inventory', the 'Psychological Resilience Scale for Adults', and the 'Event-Related Rumination Inventory' will be administered to individuals in both the intervention and control groups. No intervention will be applied to the control group. For the intervention group, psychoeducation groups based on the cognitive behavioral approach will be formed for the primary caregivers. Eight face-to-face sessions, each lasting 60 to 90 minutes, will be conducted
223599987|NCT06974461|PROCEDURE|Blood Flow Restriction (BFR) Walking|Participants in this group will undergo a supervised treadmill walking program with blood flow restriction (BFR) applied using BFR pressure cuffs. The cuffs are applied to the proximal thighs, and the training pressure starts at 50% of the participant's arterial occlusion pressure (AOP), increasing every two weeks up to 200 mmHg. Walking is performed at 60% of the maximum walking speed, 20 minutes per session, 3 sessions per week for 6 weeks.
223599988|NCT06974461|PROCEDURE|Sham Blood Flow Restriction (Sham-BFR) Walking|Participants in this group will follow the same supervised treadmill walking protocol as the BFR group but with minimal cuff pressure (20 mmHg), which does not restrict blood flow. This simulates the sensation of BFR without physiological impact. The purpose is to serve as a placebo comparator. Walking is performed at 60% of maximum walking speed, 20 minutes per session, 3 sessions per week for 6 weeks.
223748894|NCT07165106|BEHAVIORAL|Conventional Rehabilitation|Participants in this group will receive conventional rehabilitation only, 5 days per week, 1 hour per day, for 6 weeks. The program includes upper and lower limb range of motion exercises, stretching, walking practice, balance and coordination training, proprioceptive exercises, posture correction, obstacle crossing, and turning in place. All sessions are delivered under clinical supervision, with emphasis on correct posture, safety, and full range of motion
223599989|NCT05758402|DIAGNOSTIC_TEST|Routine practice group|Routine practice group
223599990|NCT05758402|DIAGNOSTIC_TEST|EARP group|EARP group
223599991|NCT02208375|DRUG|Capivasertib|Given PO
223599992|NCT02208375|OTHER|Laboratory Biomarker Analysis|Correlative studies
223599993|NCT02208375|DRUG|Olaparib|Given PO
223599994|NCT02208375|OTHER|Pharmacological Study|Correlative studies
223599995|NCT02208375|DRUG|Vistusertib|Given PO
223599996|NCT01325688|DRUG|PEP005 (ingenol mebutate) Gel, 0.05%|PEP005 (ingenol mebutate) Gel, 0.05% for up to three consecutive days
223748895|NCT07168642|BEHAVIORAL|Mothering from the Inside Out|Mothering from the Inside Out (MIO) is an evidence-based individual psychotherapy designed to help caregivers in recovery build stronger relationships with their children. In MIO, caregivers are helped to build their ability to reflect on their own mental states and how they arose. Often, we find that the thoughts and feelings that drive caregiving behavior are actually triggered by early experiences of being cared for. MIO thus aims to provide a safe, therapeutic space where caregivers' internal experiences are taken seriously and clinicians are genuinely interested, curious, and collaborative. MIO also involves helping caregivers to reflect on the possible mental states underlying their children's behavior. We find that by providing some information about child development through an attachment lens, this can help parents see through their children's eyes and feel less stressed.
223599997|NCT01325688|DEVICE|Aluminium disk|
223599998|NCT01325688|DEVICE|OpSite(TM) disk|
223599999|NCT04529343|OTHER|Virtual reality mediated upper extremity rehabilitation|"Game-based exercise will be applied for different range of motion of the upper extremity. Gamified exercise program consisting of 4 different scenarios will be applied 3 days a week for 6 weeks to the patients in the virtual reality group. A session takes an average of 45 minutes.~Games to be applied;~1. Finger flexion-extension (10 minutes / session)~2. Wrist flexion, extension, ulnar and radial deviation (10 minutes / session)~3. Forearm pronation and supination (10 minutes / session)~4. Elbow flexion-extension-shoulder internal and external rotation (15 minutes / session) will have scenarios controlled with. All patients participating in the study will receive exercise therapy in the form of upper extremity stretching, range of motion, and fine skill training 2 days a week for 6 weeks. Each session takes an average of 45 minutes."
223600000|NCT04529343|OTHER|Classical exercise therapy for upper extremities|All patients participating in the study will receive exercise therapy in the form of upper extremity stretching, range of motion, and fine skill training 2 days a week for 6 weeks. Each session takes an average of 45 minutes.
223600001|NCT05118373|BEHAVIORAL|BEHAVIOURAL CHANGE CAMPAIGN FOR COVID-19 PREVENTION IN ZAMBIA|The intervention is a mass media campaign using TV, radio, billboard and posters to disseminate the message. The content are well-produced videos and pictures emphasising the need to wash hands, wear a mask, maintain social distance and clean surfaces. The English version of the video can be viewed at this link: https://youtu.be/tcjaLAxy4Ms.
223600002|NCT02328534|BEHAVIORAL|Blastocyst Formation Rate|"Embryos developed at Day3 cultures, are continued for Day5 culture tho reach blastocyst stage. The percentage of blastocyst produced from cleaved embryos to be evaluated ar rate.~The evaluation with doe one time using Density Gradient semen one time and Swimming down semen another time."
223600003|NCT02328534|PROCEDURE|Blastocyst Rate|"Day 5 embryo transfer achieved pregnancy are compared with total embryo transfer cases at Day5.~The evaluation with doe one time using Density Gradient semen one time and Swimming down semen another time.~Pregnancy confirmed with day 12 after Et and repeated with 48 hours after 1st exam."
223748896|NCT07169357|DRUG|Gengigel|The use of Gingigel or 0.2% hyaluronic gel is expected to enhance healing and decrease discomfort in the post-operative period. It exhibits viscoelastic characteristic which serves as osteo-conductive, anti-edematous, antifungal and bacteriostatic effects.
224311248|NCT04361149|DRUG|Capsaicin Topical Cream (0.075%)|Capsaicin cream will be administered as a topical skin cream
224311249|NCT04361149|DEVICE|Delsys Trigno Galileo System|A wireless surface EMG device. The sensors will be placed on the trapezius and the infraspinatus muscle, and a recording will be performed.
223600004|NCT02328534|PROCEDURE|Pregnancy Rate|"All pregnancy achieved from all ET. Pregnancy confirmed with day 12 after Et and repeated with 48 hours after 1st exam.~The evaluation with doe one time using Density Gradient semen one time and Swimming down semen another time."
223600005|NCT03481140|DEVICE|TissuGlu Surgical Adhesive|lysine-derived urethane adhesive
223600006|NCT04830488|BEHAVIORAL|e-learning didactic module|Participants utilize e-learning
223600007|NCT04830488|BEHAVIORAL|Personal reflection activities|Participants complete questionnaires
224199475|NCT06244095|OTHER|Perturbation Therapy|The applicants were instructed to perform various exercises, including rotating their trunks, tossing a ball, and maintaining pelvis neutrality. They were also asked to reach the toy sideways with one hand. The 6-week intervention was conducted four days a week for 60 minutes each day, focusing on trunk rotation, standing, tossing, and catching the ball in various directions. The training sessions lasted for 20 minutes each.
224199476|NCT06244095|OTHER|Trunk Control Therapy|For the duration of each session, the manual pushes and pulls were administered around once per minute and lasted for 20 minutes. A platform that can be moved in four directions.Choosing to step and stroll when there is an outside disturbance. When routine motions such as sit-to-stand transitions, disruptions are applied when standing, walking, or other activities. Training with continuous disruptions simulates scenarios such as uneven terrain. Both rope and cable excursions are above ground and last for 20 minutes. Briefly explain the platform to the participants. Asked the participants to push the torso and waist against the wall during the session. Emerging barriers during training sessions like small obstacles (e.g. pair of bricks) then Lean the participants with the support of the therapist and let them go. Asked them to Step on a mushy or slick surface in session for 20 minutes. Each intervention session took place for 60 minutes per day four days of week for 6 weeks.
224199477|NCT02996942|BIOLOGICAL|Factor VIII replacement|Patients receive their usual treatment
224199478|NCT00127192|DRUG|sitagliptin phosphate|sitagliptin phosphate 25 mg, 50 mg, 100 mg QD, or 200 mg QD 12-weeks.
224199479|NCT00127192|DRUG|Comparator: placebo (unspecified)|placebo QD 12-weeks
223600008|NCT05024903|OTHER|Serious illness medical planning plus the novel e-health platform (PWG 2.0)|"PWG 2.0 consists of the following components:~1. A diagnostic questionnaire, Preparedness for the Future Questionnaire and bench-marked report that helps users assess their strengths, weaknesses and opportunities for improvement.~2. A comprehensive e-workbook that helps users understand the science behind personal behavior change.~3. Links to webpages with additional e-workbooks and curated content aimed to help users progress on the 30 different attitudes, behaviors, and activities that portend for a better future (topics listed in Appendix A).~4. E-messages delivered via emails (via text an option for those that prefer) with tailored content designed to provide multiple nudges to guide the user to progress through our content.~5. Monthly newsletter with current topics and issues related to the 30 topics and behavior change in general.~6. A virtual consultation with Dr. Heyland, creator of PWG and principal investigator."
223600009|NCT05024903|OTHER|Standard of care|Participants are not planning for their future (PWG 2.0) or using the e-health platform
223600010|NCT05788913|BIOLOGICAL|Heparin|subcutaneous Heparin
223600011|NCT05131191|DIAGNOSTIC_TEST|CT-FFR measurement|Patients were scanned with ≥ 64 row CT according to standard operating specifications. The software obtains the coronary CT angiography image file through the data communication interface. Based on the image processing algorithm, the centerline and contour of the target vessel can be extracted, and then the target vessel can be reconstructed to obtain the three-dimensional size information of the vessel; Based on hydrodynamics calculation and analysis, the fractional flow reserve (FFR) of each position of the target vessel is measured.
223600012|NCT05131191|PROCEDURE|invasive FFR|Insert the pressure guide wire into the finger guide tube and push the pressure guide wire until the pressure sensor just comes out of the orifice of guiding catheter; Equalize PD and PA values;Push the pressure guide wire to the distal end of the lesion, and record the measured blood vessel and position;Record the resting Pd / PA of the pressure guide wire;Nitroglycerin and adenosine triphosphate were administered intravenously according to standard catheter laboratory specifications to achieve maximum hyperemia;Record the FFR value of the in-stent lesions.
223600013|NCT03794154|DRUG|Cymbalta capsule|Active Comparator: Cymbalta®- hard gelatinous capsule with delayed release microgranules ( Eli Lilly do Brasil Ltda) equivalent to 60 mg of duloxetine.
223600014|NCT03794154|DRUG|Duloxetine hydrochloride capsule|Experimental Drug: Duloxetine hydrochloride - hard gelatinous capsule with delayed release microgranules (Pfizer S.R.L - Argentina.) equivalent to 60 mg of duloxetine.
223600015|NCT03574402|DRUG|Avitinib Maleate|300mg orally (PO) twice daily (BID) on day 1-28.
223600016|NCT03574402|DRUG|Afatinib|40mg orally once a day, 28 days as one cycle.
223600017|NCT03574402|DRUG|Crizotinib|250mg PO QD on days 1-28. 28 days as one cycle.
223600018|NCT03574402|DRUG|X-396|225mg PO QD on days 1-28. 28 days as one cycle.
223600019|NCT03574402|DRUG|Chidamide|30mg orally twice weekly, 28 days as one cycle.
224075165|NCT06139523|DEVICE|Investigational noncontact OCT system:|"The investigational noncontact handheld OCT systems in this study is developed at Duke University as the result of collaboration between the Departments of Ophthalmology (Cynthia Toth, MD) and Biomedical Engineering (Joseph Izatt, PhD). This investigational device was previously reviewed and approved for use in adults, children, and neonates in nursery by:~* Intraoperative OCT Guidance of Intraocular Surgery study's (Pro00016827) Data Safety and Monitoring Board Plus (DSMB+) (PI: Toth and Izatt)~* The Analyzing Retinal Microanatomy in Retinopathy of Prematurity to Improve Care study (Pro00069721) Data Safety and Monitoring Committee (DSMC) (PI: Toth) The systems were declared non-significant risk by the Duke University Health System (DUHS) Institutional Review Board under Pro00016827. Staff from the DUHS Clinical Engineering Department evaluated the systems and found that they meet the accepted hospital standards for electrical safety."
224199480|NCT02437175|DIETARY_SUPPLEMENT|ENDO 1/ENDO 2|NUTRI ENDO 1 (1 sequence of 10 tablets on the morning) and NUTRI ENDO 2 ( sequence of 10 tablets at the evening), daily, during 120 days.
224199481|NCT02437175|DIETARY_SUPPLEMENT|Placebo|Placebo: 1 sequence of 10 tablets on the morning and 1 sequence of 10 tablets at the evening, daily, during 120 days.
224199482|NCT01715675|DIETARY_SUPPLEMENT|Plant stanol enriched soy-based yoghurt|Plant stanol enriched soy-based yoghurt
224199483|NCT01715675|DIETARY_SUPPLEMENT|Soy-based yoghurt without added plant stanols|Soy-based yoghurt without added plant stanols
223600020|NCT03574402|DRUG|Pyrotinib Maleate|400mg PO QD on days 1-28. 28 days as one cycle.
223600021|NCT03574402|DRUG|AZD3759|200mg PO BID on days 1-28. 28 days as one cycle.
223600022|NCT03574402|DRUG|Pirotinib|60mg PO QD/40mg PO BID on days 1-28. 28 days as one cycle.
223600023|NCT03574402|DRUG|Nimotuzumab|400mg, iv gtt. on day 1,8,15. 21 days as one cycle.
223600024|NCT03574402|DRUG|Pemetrexed|500mg/m\^2, iv gtt. Q3W. 21 days as one cycle.
223600025|NCT03574402|DRUG|Cisplatin|75mg/m\^2, iv gtt. Q3W on day1. 21 days as one cycle.
223600026|NCT03574402|DRUG|Sintilimab|200mg iv gtt. Q3W on day1. 21 days as one cycle.
223600027|NCT03574402|DRUG|Gemcitabine|1g/m\^2 iv gtt. on day1,8. 21 days as one cycle.
223600028|NCT03574402|DRUG|Gemcitabine|1.25g/m\^2 iv gtt. on day1,8. 21 days as one cycle.
223600029|NCT03574402|DRUG|Carboplatin|AUC5 iv gtt. Q3W on day1. 21 days as one cycle.
223600030|NCT00600899|PROCEDURE|elastomeric pump with reservoir of 500 ml, infusion rate of 8 ml/h|Continuous perisciatic infusion of ropivacaine 2mg/ml (Baxter infusor with 500 ml reservoir and infusion rate of 8 ml/h)
223600031|NCT00600899|PROCEDURE|elastomeric pump with reservoir of 275 ml, infusion rate of 5 ml/h|Continuous perisciatic infusion of ropivacaine 2mg/ml (Baxter infusor with 275 ml reservoir and infusion rate of 5ml/h)
223600032|NCT01354366|OTHER|Infant formula|
223600033|NCT04607369|DEVICE|EyeCTester|Smartphone app that allows vision testing
223600034|NCT01868334|BEHAVIORAL|Pillar 1: Convenient Vaccination Services|"Extend Vaccination Season: Begin vaccinating for influenza as soon as vaccine arrives; use every visit as opportunity to vaccinate; extend the season for influenza by vaccinating in January and beyond.~Use Express Vaccination services such as influenza vaccination clinics, Open access vaccine scheduling (for all vaccines), or dedicated vaccination station. When giving influenza vaccination, screen for need for PPSV/Tdap."
223600035|NCT01868334|BEHAVIORAL|Pillar 2: Patient notification|"Patient Education: notifying patients of doctor recommendations for vaccination; providing information on express vaccination services via email, autodialer, on-hold messages, clinic websites, and/or social media"
224199484|NCT01139242|BEHAVIORAL|Body & Soul nutritional intervention|Pastoral and peer counseling, and church activities/menus to promote increased fruit and vegetable consumption among church members.
224199485|NCT01139242|BEHAVIORAL|Experimental: newsletters and peer counseling|Four tailored newsletters and peer counseling calls to promote CRC screening in church members who are out-of-date with screening. Four tailored newsletters and peer counseling calls to others to increase physical activity.
224199486|NCT05790200|DRUG|Cadonilimab|Cadonilimab (200 mg, administered on the first day of each cycle, Q3W, until there is no clinical benefit)+platinum-based chemotherapy, Q3W, 4-6 cycles), every 3 weeks (21 days) is a treatment cycle.
224199487|NCT02217657|DEVICE|Thermocool Smart Touch Catheter|Physician informed to contact force
224199488|NCT01114386|PROCEDURE|Lung function testing, echocardiography, blood sampling|"All patients will undergo to:~* physical examination~* 6' Minute Walk test~* pulmonary function testing (spirometry + volumes and reversibility testing)~* carbon monoxide diffusing capacity (DLCO) with single-breathe technique~* ECG~* echocardiography"
224199489|NCT05519527|DRUG|Part 1 (STI-6129)|Given by vein (IV)
223600036|NCT01868334|BEHAVIORAL|Pillar 3: Enhanced Office Systems|Routine assessment for office systems flow to ensure staff consistently promoting vaccination: utilization of EMR prompts, review of Immunization tabs within EMR, and/or checking vaccination status as part of vital signs when rooming. Empower staff to vaccinate by use of a standing orders program (SOP). Order a sufficient supply of vaccination to cover increased rates
223600037|NCT01868334|BEHAVIORAL|Pillar 4: Motivation|Utilization of an Office Immunization Champion who will track overall progress towards their goal - setting a goal of increased rates of 20 to 25% for influenza vaccine; monitoring and sharing progress with staff regularly; and changing office systems flow as needed to increased vaccination rates.
223600038|NCT05533970|PROCEDURE|ultrasound-guided high fascia iliaca compartment block|H-FICB was guided by ultrasound before general anesthesia. The patient was supine. First, the probe is placed transversely above the groin. Then slide the probe up and down to reveal a clear image of the internal oblique and sartorius muscles. There is a bowtie-like iliac fascia space at the junction of these two muscles. After the scanning, the needle was inserted behind the probe with the tip pointed to the ventral side under the guidance of real-time ultrasound; the tip passed through the skin into the iliac fascia space and advanced to the inguinal ligament. After no blood was extracted, 1 \~ 2 ml of normal saline was firstly injected to determine whether the tip position was correct.
223600039|NCT01356199|DIETARY_SUPPLEMENT|ARTRONAT|Dietary supplement containing Glucosamine, Chondroïtine and manganese. 6 per day for 8 months.
223600040|NCT01356199|DIETARY_SUPPLEMENT|PLACEBO|PLACEBO. 6 per day for 8 months.
223600041|NCT02951429|DRUG|Pirfenidone|Pirfenidone will be given in the range of 1602 to 2403 milligram per day (mg/day), as 3 divided doses.
223600042|NCT02951429|DRUG|Placebo|Placebo matched with sildenafil.
223600043|NCT02951429|DRUG|Sildenafil|Sildenafil will be given as 20 mg, TID.
223600044|NCT05120141|OTHER|Colgate Cavity Protection Toothpaste|Participants will use Colgate Cavity Protection Toothpaste for brushing teeth twice daily.
223600045|NCT05120141|OTHER|American Dental Association (ADA) Ref Toothbrush|Participants will use soft bristled Toothbrush for brushing teeth twice daily.
223600046|NCT05120141|OTHER|Prototype 1 Mouth Rinse|Participants will use 20 mL of Prototype 1 Mouth Rinse for 30 seconds after brushing twice daily.
223600047|NCT05120141|OTHER|Prototype 2 Mouth Rinse|Participants will use 20 mL of Prototype 2 Mouth Rinse for 30 seconds after brushing twice daily.
223600048|NCT05120141|OTHER|Prototype 3 Mouth Rinse|Participants will use 20 mL of Prototype 3 Mouth Rinse for 30 seconds after brushing twice daily.
223600049|NCT05120141|OTHER|Listerine Cool Mint Mouth Rinse|Participants will use 20 mL of Listerine Cool Mint Mouth Rinse for 30 seconds after brushing twice daily.
223600050|NCT05120141|OTHER|Hydroalcohol Mouth Rinse|Participants will use 20 mL of Hydroalcohol Mouth Rinse for 30 seconds after brushing twice daily.
223600051|NCT02692378|DRUG|sodium bicarbonate 500mg capsules|Defined by active substance and brand names not specified in protocol
223600052|NCT05178485|DRUG|Bupivacain|FDA approved drug
223600053|NCT05178485|OTHER|Normal Saline|FDA approved
224199490|NCT05519527|DRUG|Part 2 (STI-6129)|Given by vein (IV)
224199491|NCT06242977|DRUG|Eutectic mixture of local anesthetics (EMLA; Astra Pharmaceutical Products Inc., Westborough, MA)|The intervention is the utilization of EMLA cream, a topical anesthetic to determine if this reduces pain with local anesthesia infiltration, and for overall procedural pain
224199492|NCT06242977|OTHER|Control cream|This intervention will be for the control group, a simple lotion cream.
224199493|NCT02257411|DEVICE|Ear-sized based|the sizes of the PLMA determined with the ear-based formula were compared with the sizes according to the manufacturer's weight-based formula
223600054|NCT05111028|BIOLOGICAL|Autologous Room Temperature stored Platelet transfusion|An autologous transfusion of platelets stored at 22°C for 7 days.
223600055|NCT05111028|BIOLOGICAL|Autologous Cold Stored Platelet transfusion|An autologous transfusion of platelets stored at 4°C for 7, 14, 21, or 28 days.
223748897|NCT07169357|DEVICE|LASER|PBMT has markedly been effective in reducing pain, inflammation, edema and postoperative discomfort. It is said to be a natural and effective alternative approach to minimize medicaments prescription such as analgesics, anti-inflammatory or antibiotic drugs. With that said, negative outcomes such as drug side effects, bacterial resistance and post-operative complications can be prevented, thus increasing the success of medical care and assuring a better quality of life
223748898|NCT07168733|DEVICE|Inspiratory muscle training|The POWERbreathe® device is a pressure-threshold IMT device that provides resistance during inhalation. The user breathes in through a mouthpiece against an adjustable spring-loaded valve, which opens only when the inspiratory pressure exceeds the set threshold, thereby strengthening the inspiratory muscles over time. Following a one-week familiarization period, the IMT protocol was performed twice daily (morning and evening), five days per week, for four weeks. Each session consisted of 30 breathing cycles, resulting in a total of 60 cycles per day. Prior to training, the device resistance was calibrated to 40% of each participant's maximal inspiratory pressure (MIP), as reported by Çelikel et al. (2025) to promote increases in muscle size and thickness. MIP was reassessed weekly and resistance was increased by 10%; progression was paused if participants experienced excessive strain.
223748899|NCT07168733|OTHER|Control|The group that continues with their normal daily routines
223748900|NCT07171775|PROCEDURE|Experimental - Nanohydroxyapatite|Following selective caries removal under local anesthesia and rubber dam isolation, nanohydroxyapatite paste will be applied directly onto the pulpal dentin surface as the pulp protection material. The cavity will then be restored using a standardized adhesive and resin composite protocol.
223748901|NCT07171775|PROCEDURE|Active Comparator - Biodentine|Following selective caries removal under local anesthesia and rubber dam isolation, Biodentine will be mixed according to the manufacturer's instructions and applied onto the pulpal dentin surface as the pulp protection material. The cavity will then be restored using a standardized adhesive and resin composite protocol. This comparator is distinguished by the use of a calcium silicate-based bioactive material with well-established clinical performance, serving as the reference standard against which nanohydroxyapatite is evaluated.
223748902|NCT07171723|BIOLOGICAL|Liver-Expressed Antimicrobial Peptide 2 (LEAP2)|Continuous intravenous infusion of LEAP2 (Liver-Expressed Antimicrobial Peptide 2), an endogenous inverse agonist and competitive antagonist of the ghrelin receptor (GHSR), administered at 40 pmol/kg/min for 6 hours. LEAP2 inhibits ghrelin-mediated signaling involved in hunger regulation, gastric motility, and growth hormone secretion. This intervention enables investigation of the physiological relevance of ghrelin receptor activity during semaglutide-induced appetite suppression
223748903|NCT07171723|OTHER|Placebo (saline)|Continuous intravenous infusion of isotonic saline (0.9% sodium chloride) for 6 hours. This placebo comparator is used to match the volume, rate, and duration of the active intervention (LEAP2) in a randomized, double-blind, crossover design. The placebo enables assessment of the physiological effects of ghrelin receptor blockade by LEAP2 in individuals with obesity treated with semaglutide
223748904|NCT07171762|DEVICE|Ozonytron XP|This intervention involves the use of ozonated water as a final irrigation solution during root canal treatment in teeth diagnosed with asymptomatic apical periodontitis. Following standard chemomechanical preparation, ozonated water is delivered into the root canal system using a 30-gauge side-vented needle. The aim is to assess the biochemical changes in periapical tissues by evaluating oxidative stress markers (TAS, TOS, MDA, 8-OHdG) in the apical fluid samples collected before and after irrigation. The ozonated water is generated via a medical-grade ozone generator, and its application is designed to minimize cytotoxicity while maximizing antimicrobial and oxidative stress modulation properties. The outcomes are compared to a control group receiving saline irrigation under identical procedural conditions.
224199494|NCT03640442|OTHER|Modified ramped position|This position will be achieved using a special pillow. Shoulders will be elevated and neck will be extended to bring the breasts away from the laryngoscopy. The patient will be positioned so that the tip of the last spinous process (C7) will be at the edge of the pillow. The neck will be extended to the most possible range.
223600056|NCT04975100|DRUG|Sarcosine and SSRI|Patients in the test group will get Sarcosine 500 mg capsules once daily as an add-on to ongoing SSRI treatment
223748905|NCT07171762|OTHER|Physiological saline solution (0.9% NaCl)|Physiological saline solution (0.9% NaCl) was used as the final irrigation agent in root canal treatment.Saline Irrigation Group (Control)
223748906|NCT07173998|OTHER|Survey|SF-36, TSQM-9, qualitative questions
223748907|NCT07180420|DRUG|naloxone IM|naloxone IM to the EDC/forearm muscle
223748908|NCT07179640|DRUG|ALE1|Specified dose on specified days
223748909|NCT07179640|DRUG|Placebo|Specified dose on specified days
224199495|NCT03640442|OTHER|Ramped position|This position will be achieved by elevation of the shoulders and the head elevation till achieving alignment of sternal notch and external auditory meatus
223600057|NCT04975100|DRUG|Placebo and SSRI|Patients in the control group will get identical-looking capsules containing placebo in addition to SSRI at an once daily dose
223600058|NCT01620528|DRUG|elagolix|oral tablet
223600059|NCT01620528|OTHER|placebo|oral tablet
223748910|NCT07180550|OTHER|High-intensity interval training, running|Six sets of 2-minute runs will be performed at an intensity of 90-95% of the maximal aerobic speed (MAS) on a treadmill. The recovery between each set will be 2 minutes, during which the subject will walk at an intensity of 50-60% of MAS.
223748911|NCT07180550|OTHER|High-intensity interval training, cycling|Six sets of 2-minute cycling will be performed at an intensity of 90-95% of the maximal heart rate on a stationary bike. The recovery between each set will be 2 minutes, during which the subject will cycle at an intensity of 50-60% of maximal heart rate.
224199496|NCT04171089|BEHAVIORAL|Child- Safety Plan Intervention|The intervention includes recognizing and knowing the individual's warning signs for a suicidal crisis, their personal coping/distraction skills, people to contact, as well as a restriction of the means to hurt oneself.
224199497|NCT02569931|OTHER|Gait analysis|Participants will be asked to walk on an instrumented treadmill. The study group will undergo gait analysis before surgery and 6 months after surgery. The control group will undergo gait analysis at one visit only.
223600060|NCT05733078|DRUG|Vitamin C|The patient in test group will be provided vitamin C effervescent tablets to use 1 gram daily with their usual dose of Levothyroxine for 12 weeks, with thyroid function tests assessed at 6 and 12 weeks. The patients who wish to continue at the end of 12 weeks will be provided another 12 weeks supply of vitamin C effervescent tablets to use 1 gram daily with their usual dose of Levothyroxine for with thyroid function tests and clinical score assessed at the end of week 24.
224199498|NCT02569931|OTHER|Electromyography|Participants in the study group will undergo electromyography before and 6 months after surgery. Participants in the control group will undergo electromyography at one visit only
224199499|NCT02569931|PROCEDURE|Intra-operative tracking and pressure measurements|Participants in the study group will undergo intra-operative tracking and pressure measurements to see if corrective surgery to stabilise the patella improves tracking and pressure measurements
224199500|NCT00717665|DEVICE|Home blood pressure tele-management system.|Scheduled blood pressure monitoring with transmission of information to a central server for processing and disbursement.
224199501|NCT00717665|OTHER|Usual care.|Patient self-monitoring of blood pressure with results taken by patient to the doctor at scheduled visits.
224199502|NCT01345266|PROCEDURE|Inhalation Profiling|All subects recieve Inhaltion Profiling there are no interventions.
224199503|NCT00993941|PROCEDURE|Autologous BMSCs transplantation|10 ml autologous BMSCs(7\~8log10 cells/ml) were infused to patients using interventional method via portal vein as well as conserved therapy for group B.
224199504|NCT00993941|DRUG|Conserved therapy|Oral or intravenous administration
224199505|NCT02285673|BIOLOGICAL|Umbilical Cord Mesenchymal Stem Cell|
224199506|NCT01454037|PROCEDURE|Prostate cryotherapy|cryoablate the prostate
223600061|NCT05733078|DRUG|Oral Rehydration Salt Formulations|The patients in control group will have a oral rehydration effervescent tablet to take with their usual dose of Levothyroxine for 12 weeks, with thyroid function tests assessed at 6 and 12 weeks. The control group will then be provided vitamin C (intervention) effervescent tablets to use 1 gram daily with their usual dose of Levothyroxine for 12 weeks, with thyroid function tests assessed at 6 and 12 weeks to see if there is any difference on biochemical testing or clinical scores.
223600062|NCT06527417|DEVICE|Neuro Trac Myo Plus Pro|Electrical stimulation parameters; stimuli were monophasic, rectangular, stimulus duration 300 µs, frequency 25 Hertz, amplitude was increased up to a maximum of 100 milliampere until contraction was seen.
223600063|NCT06527417|OTHER|Trunk eccentric exercises|The control group performed back eccentric exercises for 4 weeks, 3 times a week, 3 times in each session
223600064|NCT06526559|DEVICE|Barbed suture|Use of two absorbable barbed sutures for each arm in the ureteropelvic anastomosis in minimally invasive dismembered pyeloplasty
223600065|NCT06526559|DEVICE|PGA suture|Use of two absorbable polyglactin sutures for each arm in the ureteropelvic anastomosis in minimally invasive dismembered pyeloplasty
223600066|NCT00225095|DRUG|Mesenchymal Stem Cells|
224199507|NCT01454037|PROCEDURE|Radical prostatectomy|Remove prostate
224199508|NCT01454037|PROCEDURE|Radiation|Radiate prostate
224199509|NCT04447183|DRUG|Recombinant Human Thyroid Stimulating Hormone for Injection(rhTSH)|rhTSH: 0.9 mg IM daily on two consecutive days;radioactive iodine: 30mCi±1.5mCi or 1.11GBq of 131I oral
224199510|NCT04447183|OTHER|radioactive iodine|radioactive iodine: 30mCi±1.5mCi or 1.11GBq of 131I oral
224199511|NCT03873662|DIAGNOSTIC_TEST|Blood sample|Biochemical markers will be recorded as follows: as soon as possible after the arrival of the patient and insertion of a intravenous line, blood will be drawn for the analysis of arterial blood gases, which are a standard test in patients admitted to emergency department. Blood will be analysed in a bed-side analyzer. Serum lactate and base-excess (BE) will be documented from this blood sample. Another blood sample will be drawn parallelly for biochemical tests which will be sent to the laboratory. These tests standard in patients admitted to emergency department. Serum concentration of NSE and S100B protein will be analysed and recorded from this sample. A sample of blood for the evaluation of the early dynamics of the serum concentration of NSE and S100B will be redrawn after 12 and 48/24 hours after admitting the patient.
224199512|NCT03846960|DEVICE|using specially adapted VNscope|surfactant administration via thin catheter using a specially adapted VNscope
224199513|NCT03846960|DRUG|surfactant administration|surfactant administration via thin catheter using a specially adapted VNscope
224199514|NCT00077766|DRUG|Darbepoetin alfa|Darbepoetin alfa was administered IV, every week or every 2 weeks during Weeks 1 through 52.
224199515|NCT00077766|DRUG|methoxy polyethylene glycol-epoetin beta [Mircera]|RO0503821 was administered IV, every 2 weeks during Weeks 1 through 52. The starting dose of RO0503821 (60, 100, or 180 micro gram \[µg\]) was based on the dose of darbepoetin alfa at the time of randomization (\< 40, 40 to 80, or \> 80 µg per week, respectively).
224199516|NCT02415907|DRUG|[ethyl-1-14C]-idalopirdine|120 mg/2.40 MBq Lu AF67708 (\[ethyl-1-14C\]-idalopirdine) in one capsule for oral administration, single dose
223600067|NCT00225095|DRUG|Hyaluronan|
223600068|NCT01238328|DRUG|Conditioning regimen|"For sibling full match:~* Busulfan 16 mg/kg \>5year - 20 mg/kg \<5year po~* Cyclophosphamide 200 mg/kg iv~For other related full match, sibling or other related with one antigen mismatch and umbilical cord blood:~* Busulfan 16 mg/kg \>5year - 20 mg/kg \<5year po~* Cyclophosphamide 200 mg/kg iv~* Antithymocyte globulin (ATG) rabbit (Thymoglobulin) 10 mg/kg or ATG horse (Atgam) 40 mg/kg~For haploidentical:~* Busulfan 16 mg/kg \>5year - 20 mg/kg \<5year po~* Cyclophosphamide 200 mg/kg iv~* Fludarabine 160 mg/m\^2"
223600069|NCT01238328|DRUG|Graft-versus-host disease (GVHD) prophylaxis|"* Cyclosporin A 1.5 mg/kg/day iv from -2, then 3 mg/kg/day iv (from +7 in peripheral blood stem cell transplant (PBSCT) and +11 in Bone marrow transplantation or Umbilical Cord Blood (UCB) transplantation) then 9 mg/kg/day po~* 10 mg/m\^2 iv day +1 then 6 mg/m\^ iv day +3 and +6 (Not for UCBT)"
223600070|NCT01238328|PROCEDURE|Stem Cell Transplantation|"Patients undergoing Hematopoietic Stem Cell Transplantation from one of below source:~1. Sibling full match~2. Other related full match~3. Sibling or other related with 1 mismatch antigen~4. Cord Blood~5. Haploidentical"
223600071|NCT02077400|DRUG|Cephazolin|Cephazolin
223600072|NCT05199961|BEHAVIORAL|Digital Health Coaching|The digital health coaching program consists of weekly calls and delivery of evidence-based content across health and wellness domains (e.g. nutrition, exercise, physical, emotional and financial health) up to 4 times weekly via text, email or mobile application. The program is 6-months in duration and designed for engagement following CAR T cell infusion.
223748912|NCT07180550|OTHER|High-intensity functional training|Three sets of six repetitions will be performed at 80% of the one repetition-maximum (1-RM) for six exercises. The recovery between exercises will be the minimum time required to switch from one exercise to the next, and between sets, it will be two minutes. Participants will be instructed to move the load as quickly as possible during each repetition.
223748913|NCT07180550|OTHER|Moderate-intensity functional training|Three sets of six repetitions will be performed at 60% of the 1-RM for six exercises. The recovery between exercises will be the minimum time required to switch from one exercise to the next, and between sets, it will be two minutes. Participants will be instructed to move the load as quickly as possible during each repetition.
223748914|NCT07180550|OTHER|Moderate intensity traditional strength training|Three sets of six repetitions will be performed at 60% of the 1-RM for six exercises. The recovery after each set will be two minutes of passive rest. Participants will be instructed to move the load as quickly as possible during each repetition.
223748915|NCT07180550|OTHER|High intensity traditional strength training|Three sets of six repetitions will be performed at 80% of the 1-RM for six exercises. The recovery after each set will be two minutes of passive rest. Participants will be instructed to move the load as quickly as possible during each repetition.
223748916|NCT07181525|DRUG|anti-cytokine antibodies|Different kinds of biologics used to treat inflammatory bowel disease (including anti-cytokine antibodies)
223748917|NCT07181525|DRUG|anti-integrin antibodies|Different kinds of biologics used to treat inflammatory bowel disease (including anti-integrin antibodies)
223748918|NCT07179562|OTHER|"motivational interviewing"|"Randomization for motivational interviewing"
223748919|NCT07179718|DEVICE|neuromuscular electrical stimulation|Neuromuscular electrical stimulation (NMES) is a treatment method in which electrical conduction via surface electrodes is used to stimulate muscle contraction.
223748920|NCT07179718|DEVICE|bicycle ergometer|Exercise training will be performed using the bicycle ergometer method, under the supervision of a physiotherapist, for 30 minutes a day for 5 consecutive days, at the earliest stage when the patient is clinically stable.
223748921|NCT07180264|DRUG|Trastuzumab deruxtecan|Trastuzumab deruxtecan is a combination of the targeted cancer drug trastuzumab (also known as Herceptin) and a chemotherapy drug called deruxtecan or DXd.
223748922|NCT07181876|DEVICE|inguinal hernia repair|Robotic-assisted inguinal hernia repair with the DEXTER robotic surgery system
223748923|NCT07181746|PROCEDURE|leg exercises|The patient in study group will offer 72 planned sessions along 16-week period, each session consisted of 5 minutes walking as a warm-up, followed by 30 to 45 minutes of resistance exercises tolerated by the patient, time maintained until the end of the intervention. Each participant will receive about two to three, personal training session regarding the technique of resistance training until they are perfect in performing the exercises. Participants will receive a booklet with instructions on the Pilates training illustrated by colored pictures. The sessions during the staying the patient's in the hospital will be supervised by the researchers
223748924|NCT07180784|BEHAVIORAL|Mindfulness-based stress reduction (MBSR)|An intervention group offered to students that teaches meditation and yoga techniques, stress physiology, and mindfulness practices. Each group includes 5-6 participants and met once a week for 1.5 hours over a period of 8 consecutive weeks.
223748925|NCT07180784|BEHAVIORAL|Cognitive Behaviour Therapy for Insomnia (CBT-I)|Traditional CBT-I was offered in small group sessions of 5 to 6 participants and lasted 1.5 hours each. They were held once a week over a period of 8 consecutive weeks.
223748926|NCT07181538|DRUG|JLP-2302|taking JLP-2302
223748927|NCT07181538|DRUG|JP-1366|taking JP-1366
223600073|NCT01254825|PROCEDURE|Adductor-Canal-Block, Ropivacain|Ultrasound-guided ACB; 30 mL Ropivacain 7,5 mg/mL. Single dose.
223600074|NCT01254825|PROCEDURE|Adductor Canal Block, Placebo (saline)|Ultrasound-guided Adductor Canal Block; 30 mL Saline. Single dose.
223600075|NCT00597415|DRUG|celecoxib|celecoxib 200mg
223748928|NCT07180901|OTHER|Proactive Risk-Based Optimization and Notifications for Treatment and Outcomes (PRONTO)|Post-implementation of PRONTO-HN system: 1. Pre-operative risk stratification of requiring adjuvant therapy using our predictive model, applied at tumor board. Patients stratified as fast-track vs normal-track. 2. High-risk patients receive intensive preoperative and postoperative coordination. Low-risk patients are monitored but escalated rapidly if adverse pathology is detected. This includes: - pre-operative dental consultation for fast-track - pre-operative oncology consultation for fast-track with high-risk features - target pathology results 14 days post-operatively for fast-track 3. Automated reminders and target dates sent to members of the multidisciplinary team.
223748929|NCT07180576|BEHAVIORAL|Nutrition counseling|Weekly standardized nutrition counseling will be provided by a study RDN to promote adherence and address barriers to adherence, acceptability, and adverse events. The RDN will also document any changes to the CRT regimen and hospitalizations.
223748930|NCT07180576|DRUG|Fresubin Supportan|Two bottles per day of Fresubin Supportan, a fish oil-enriched high calorie, high protein oral nutrition supplement.
223748931|NCT07181811|OTHER|Multiple Sclerosis patients who have been on Ocrelizumab will undergo cognitive and fatigue assessments|The cognitive and fatigue assessments administered in this study are not currently part of the standard clinical care for multiple sclerosis patients on Ocrelizumab. By prospectively assigning participants to undergo these additional assessments, this aspect of the study is considered investigational, and findings may contribute to clinical decision-making regarding the incorporation of cognitive and fatigue assessments into routine management of multiple sclerosis conditions.
223600076|NCT00597415|DRUG|placebo|placebo
223600077|NCT04354883|PROCEDURE|External Chest Compressions on Manikin in Underwater Setting|Two different methods of CPR in an analogue model of mircogravity
223600078|NCT05656482|OTHER|Cats fed with PRO PLAN® LIVECLEAT®|Patient with domestic cats fed with an egg product containing anti-Fel d1 IgY (PRO PLAN® LIVECLEAT®)
223600079|NCT05095168|DRUG|CAN106|CAN106 is a selective inhibitor of complement activation, which binds to the complement component C5.
223600080|NCT05095168|DRUG|Placebo|placebo
223748932|NCT07181590|PROCEDURE|Pulsed Field Ablation|Pulsed Field Ablation using the Volt PFA
223748933|NCT07181915|OTHER|Generic email - control|A generic email delivered to a GP practice alongside a digital feedback report. The generic control email will be the same text each time for all practices within that arm and will contain no suggestions for improving practice.
223748934|NCT07181915|OTHER|Personalised email - Intervention|A personalised achievement email delivered to a GP practice alongside a digital feedback report. The personalised email wording will change based on the achievement of the practice and the content in the feedback reports, which is being distributed as part of the pre-existing quality improvement project, rather than this research study. The recommendations in bullet points within the personalised emails suggesting how to improve care will be informed as relevant succinct summaries of the key guidance contained with the feedback reports, which will be based on either national guidelines or respected published literature. This will be written by the lead researcher for this project (who is the author of the QIP feedback reports themselves) and will be reviewed by the same group that reviews the QIP feedback report content before publication.
223748935|NCT07180706|DEVICE|Histotripsy|Histotripsy is a tumor ablation technique developed in recent years that allows for non-invasive treatment of solid tumors using High-Intensity Focused Ultrasound (HIFU). This method works by physically focusing ultrasound energy at a single point within biological tissue, creating a focal zone of high-power, low-frequency ultrasound that induces mechanical fragmentation (histotripsy) and cavitation effects, dissolving the tissue into fragments and destroying tumor cells. Under real-time ultrasound imaging guidance, various scanning treatment protocols are used to move the focal point throughout the treatment zone, effectively ablating the tumor tissue. The destroyed tumor tissue is gradually absorbed by the body. Since this technique does not require needle puncture, electrode insertion, radiation, or thermal effects, it is minimally invasive and holds the potential to overcome the limitations of existing ablation technologies.
223748936|NCT07180771|DRUG|BR101801|Patients will receive 200mg capsules (100mg+100mg)
223600081|NCT03845595|DEVICE|(LF-rTMS) group|"The (LF-rTMS) (low frequency repetitive transcranial magnetic stimulation) group received 1-hertz (HZ) stimulation at 90% of motor threshold to the hot spot of the primary cerebral cortex, using a 70-mm figure- 8 coil and Magstim Rapid2 stimulator (Magstim Company, USA). Contralesional 1 HZ \*rTMS\* applied over the primary motor area hot spot at 90% of Active motor threshold . Each rTMS session consisted of 1,200pulses; lasting 20 minutes The optimal site of stimulation on the skull are known as the hot spot . Hot spots were found by searching for loci that triggered maximum visible contraction in the contralateral first dorsal interosseous \*FDI\* muscle, while the patient is contracting his whole limb as much as possible ."
223600082|NCT03845595|OTHER|Control group|neurodevelopmental technique (NDT) ( including Bobath and Brunnstrom approaches , proprioceptor and exteroceptor stimulation for the weak and inhibition for the hyperactive muscle groups, proprioceptive neuromuscular facilitation (PNF) specific techniques, Approximation and weight bearing, placing technique). Task-oriented training (moving, grasping and releasing bottles ,cups , small toys). Active participation of the whole hemiparetic upper extremity in different motor task training with coordination and Bilateral arm training exercise.
223600083|NCT00558181|DRUG|rituximab, methylprednisolone|Subjects will receive up-to 6 courses of IV infusion of Methylprednisolone and Rituximab every 21 day.
223748937|NCT07179965|OTHER|Observation|IBD patients
223748938|NCT07180953|DRUG|NaCl 0.9%|iPACK block with Adductor Canal Block (2 x 20ml 0.2% ropivacaine + 1ml 0.9% NaCl) + 2ml 0.9% NaCl iv
223748939|NCT07180953|DRUG|Dexamethasone 4mg|iPACK block with Adductor Canal Block (2 x 20ml 0.2% ropivacaine + 1ml 0.9% NaCl) + 4mg Dexamethasone iv
223748940|NCT07180953|DRUG|Dexamethasone 4mg|iPACK block with Adductor Canal Block (2 x 20ml 0.2% ropivacaine + 2mg Dexamethasone) + 2ml 0.9% NaCl iv
223748941|NCT07180173|RADIATION|Salvage Neck Treatment|Salvage neck treatment, including neck dissection with or without re-irradiation and/or systemic therapy, administered to patients with stage N3 nasopharyngeal carcinoma after completion of definitive concurrent chemoradiotherapy (CCRT) or induction chemotherapy followed by radiotherapy/CCRT.
224199517|NCT02415907|DRUG|[benzyl-7-14C]-idalopirdine|120 mg/2.40 MBq Lu AF67709 (\[benzyl-7-14C\]-idalopirdine) in one capsule for oral administration, single dose
224199518|NCT06442111|DRUG|The intravenous ferritin group|Administer intravenous ferritin approximately 3-7 days before surgery (0.9% normal saline 250ml + 1000 mg of ferric carboxymaltose \[Ferinject™, Vifor Pharma, Glattbrugg, Dwitzerland\], inject over 15 minutes)
224199519|NCT06442111|DRUG|The placebo group|Administer intravenous 10ml of normal saline (Isotonic Sodium Chloride Injection Daihan(50mL/bag)) approximately 3-7 days before surgery
224311250|NCT04361149|DEVICE|Excaliber, Natus Medical|Intramuscular EMG machine. The intramuscular electrode will be inserted into the trapezius and a recording will be performed.
223600084|NCT06546852|BEHAVIORAL|education|Patient education will be provide
223600085|NCT02416895|OTHER|In vivo immunity model|A measure of in vivo immune function.
223600086|NCT00742755|BEHAVIORAL|Prospective intervention|Prospective Intervention: Peer navigator who assists with appointment making, transportation, translations, completing forms, etc.
223600087|NCT00808548|OTHER|counseling, emotional support|
223600088|NCT00808548|OTHER|emotional support|emotional support during the interview
223600089|NCT00808548|OTHER|emotional support|emotional supporting during the interview
223748942|NCT07180485|BEHAVIORAL|whole body vibration training|whole body vibration training and health education booklet
223748943|NCT07180485|BEHAVIORAL|control group|health education booklet
223748944|NCT07181356|OTHER|RIPerC|Each 40 minutes treatment time, 10 minutes as a cycle (cuff inflated to 200 mmHg and maintained for 5 minutes, then deflated for 5 minutes to start the next cycle), a total of 4 cycles
223748945|NCT07181356|OTHER|RIPC|Each 40 minutes treatment time, 10 minutes as a cycle (cuff inflated to 200 mmHg and maintained for 5 minutes, then deflated for 5 minutes to start the next cycle), a total of 4 cycles
223748946|NCT07180628|BEHAVIORAL|Speech Production During functional magnetic resonance imaging (MRI)|Participants will complete a speech production task with 2 conditions (stuttered, non-stuttered) while undergoing functional MRI to assess brain activity. Brain activity will be compared within subjects for the 2 conditions. The intervention is the combination of tasks delivered to all participants. The speaking task is the intervention (modifying agent) and the MRI is a measurement tool, not a therapeutic or modifying agent.
223748947|NCT07181213|PROCEDURE|Adrenalectomy|Surgical removal of patients with unilateral primary aldosteronism in patients selected by the presence of a genetic variant and hypertension
224311251|NCT04361149|OTHER|Placebo Cream|Placebo cream will be administered as a topical skin cream
224311252|NCT05783518|DRUG|desflurane|Intraoperative anesthesia maintenance
224311253|NCT05783518|DRUG|propofol|Intraoperative anesthesia maintenance
223600090|NCT04007419|BEHAVIORAL|Health Promoters and Organ Donation|Promotoras de Donación is a highly engaging and interactive online learning experience, that accommodates multiple learning styles by incorporating a variety of pedagogic approaches. The module consists of two components: a didactic educational component and a skills-based communication component. The didactic component provides basic information about organ donation and transplantation and the need for donors in the Hispanic community, and addresses concerns about donation commonly held by older Latina. The skills-based component provides instruction on the key communication skills needed to effectively engage small groups in discussions about organ donation. This component is intended to build communication self-efficacy or confidence opening the discussion about donation, addressing concerns raised by mature and older women participating in the small group sessions, and promoting the act of donor registration using persuasive, but non-coercive language.
223600091|NCT01569048|DRUG|Propofol and dexmedetomidine|Both group : propofol effect site TCI 2-4 mcg/ml, Remifentanil group : remifentanil effect site-TCI 2-4ng/ml Dexmedetomidine group: dexmedetomidine 0.5mcg/kg loading and 0.5mcg/kg/hr infusion
223600092|NCT01569048|DRUG|propofol and remifentanil|Both group : propofol effect site TCI 2-4 mcg/ml, Remifentanil group : remifentanil effect site-TCI 2-4ng/ml Dexmedetomidine group: dexmedetomidine 0.5mcg/kg loading and 0.5mcg/kg/hr infusion
223600093|NCT03664765|OTHER|UA and RMT|daily oropharyngeal and respiratory muscle exercises
223600094|NCT03664765|OTHER|Sham exercise|Daily sham exercises
223600095|NCT01090063|DRUG|Ustekinumab|Dosing will consist of a 45mg subcutaneous injection for patients weighing less than 100 kg and a 90 mg subcutaneous injection for patients whose weight is greater than 100 kg. Dosing will begin on week 0 followed by subsequent dosing on week 4 and week 16.
223600096|NCT01093391|DEVICE|DRUG ELUTING STENT|Site preparation and percutaneous access should be performed as per standard hospital procedures.It is recommended to cross the target lesion with 0.014-inch exchange-length guide wire. The involved lesion should be predilated with appropriately sized balloons using standard techniques. It is strongly encouraged that the Investigators use similar materials and techniques throughout the study to maintain consistency and standardization of care.A stent consists of an endovascular prosthesis with a metallic mesh structure that is implanted at the site of the artery blockage via catheterization procedure. The objective of stenting is to obtain an angiographic appearance of the expanded stent only outside the limits of the target vessel filled with contrast medium.
223600097|NCT01093391|DEVICE|BARE METAL STENT|Site preparation and percutaneous access should be performed as per standard hospital procedures.It is recommended to cross the target lesion with 0.014-inch exchange-length guide wire. The involved lesion should be predilated with appropriately sized balloons using standard techniques. It is strongly encouraged that the Investigators use similar materials and techniques throughout the study to maintain consistency and standardization of care.A stent consists of an endovascular prosthesis with a metallic mesh structure that is implanted at the site of the artery blockage via catheterization procedure. The objective of stenting is to obtain an angiographic appearance of the expanded stent only outside the limits of the target vessel filled with contrast medium.
223600098|NCT03929640|DRUG|Acetaminophen|Acetaminophen 650 mg tablet every 6 hours
223600099|NCT03929640|DRUG|Placebo|Placebo oral tablet every 6 hours
223600100|NCT03929640|DRUG|Ibuprofen|Ibuprofen 600 mg tablet every 6 hours
223748948|NCT07181460|OTHER|Exercises Program|A program of low-intensity, safe, and functional movements was designed for older adults. It included a warm-up, breathing exercises, chair exercises, strength and mobility exercises, balance exercises, stretching, and a cool-down.
223748949|NCT07181174|DEVICE|Ultrasonographic examination and doppler ultrasonography will be performed using a convex transducer.|-Renal Resistive Index Measurement Method: Ultrasonographic examination and doppler ultrasonography will be performed using a convex transducer. First, the kidney is localised in the flanks with conventional B-mode ultrasonography, after which, color doppler images are acquired. The interlobar arteries were visualised, with the wavelength obtained by creating a 90-degree right-angle with the interlobar artery using a power doppler. After the manual determination of the peak systolic and end-diastolic velocities \* RRI will be calculated by the device using the formula: RRI = (peak systolic velocity - end-diastolic velocity) / (peak systolic velocity). RRI will be measured three times for each kidney and averaged
223748950|NCT07179796|BEHAVIORAL|Observation|Personalized physical activity program tailored to each participant, with variations in frequency, duration, and type of activity based on their preferences, goals, fitness level, and physical ability.
223748951|NCT07180446|BEHAVIORAL|Cardiovascular Exercise|Participants will complete a 12-week supervised cardiovascular exercise program at the TCU Recreation Center. Exercise will occur 5 days per week, beginning with 30 minutes per session and progressing to 60 minutes. Intensity will start at 50% of estimated maximal heart rate and gradually increase to 80% by week 8, remaining at that level through week 12. Exercise modalities may include treadmill walking/running, rowing, elliptical, or cycling, based on participant preference and fitness level. Certified trainers will supervise all sessions to ensure safety, proper technique, and adherence to the intensity targets. Participants will wear ActiGraph heart rate monitors to verify exercise intensity throughout the intervention.
223748952|NCT07180446|DIETARY_SUPPLEMENT|Butyrate|Participants will take a dietary supplement containing sodium butyrate during the final 4 weeks (weeks 8-12) of the 12-week intervention. The supplement will be provided in capsule form, with participants instructed to take six capsules per day-two with each meal. This daily dose is equivalent to 3.6 g of butyric acid, which provides 939 mg of sodium, delivered as sodium butyrate. The supplement is intended to support gut health and potentially enhance insulin sensitivity in individuals who do not respond to exercise alone. Participants will receive a 4-week supply during their 8-week study visit, along with instructions for proper use and monitoring of any side effects.
223748953|NCT07181616|BEHAVIORAL|Adapted W2W|HIV education sessions and questionnaires.
223748954|NCT07181616|BEHAVIORAL|Waitlist Control|HIV education sessions and questionnaires given 4 weeks after W2W intervention.
223748955|NCT07180732|PROCEDURE|Injection moulding technique|A dental technique that uses a transparent silicone index or stent to inject a low-viscosity composite into a pre-planned and approved tooth shape.
223600101|NCT01005758|DRUG|cyclophosphamide|
223600102|NCT01005758|DRUG|cytarabine|
223600103|NCT01005758|DRUG|dexamethasone|
223600104|NCT01005758|DRUG|doxorubicin hydrochloride|
223600105|NCT01005758|DRUG|etoposide phosphate|
223600106|NCT01005758|DRUG|hydrocortisone sodium succinate|
223748956|NCT07180732|DIAGNOSTIC_TEST|Digital smile design|A modern approach that uses digital imaging, videos, and software to create a customized, virtual 3D model of a patient's ideal smile before any treatment begins
223748957|NCT07179783|DRUG|Sacituzumab Tirumotecan|Drug reduction will be implemented according to the research plan.
223748958|NCT07179783|DRUG|Tagitanlimab|Treatment with Sacituzumab Tirumotecan (SKB264, 5mg/kg IV d1 Q2W) and Tagitanlimab (KL-A167 , 900mg IV d1 Q2W) until confirmed by the investigator as imaging disease progression, intolerable toxicity, subject's request to terminate treatment, or other treatment termination criteria specified in the protocol (based on the first patient), with a maximum treatment duration of 24 months for Tagitanlimab. Drug reduction will be implemented according to the research plan.
223748959|NCT07179848|DEVICE|Temporal Interference Stimulation - Treatment first|Receive treatment stimulation for 5 consecutive days, followed by a 2-days washout period, then complete the remaining 5 days of sham stimulation
223748960|NCT07179848|DEVICE|Temporal Interference Stimulation - Sham first|Receive sham stimulation for 5 consecutive days, followed by a 2-days washout period, then undergo 5 days of treatment stimulation
223748961|NCT07181577|DEVICE|Special blanket|Special blanket to be used at home every night in 4 weeks (Phase 1 - RCT) and opportunity for additional 8 weeks (Phase 2 - open trial)
223748962|NCT07181577|DEVICE|Different special blanket|Different special blanket to be used at home every night in 4 weeks (Phase 1 - RCT) and opportunity for additional 8 weeks (Phase 2 - open trial)
223748963|NCT07180667|BEHAVIORAL|Intervention 1: Aerobic Running (AR) Warm-Up|15-minute aerobic running protocol. Heart rate maintained at 60-75% of age-predicted maximum (HRₘₐₓ). Includes 7 minutes light jogging followed by slight intensity increase.
223748964|NCT07180667|BEHAVIORAL|Intervention 2: Static Stretching (SS) Warm-Up|5 minutes light jogging followed by static stretches of six lower-limb muscles (gastrocnemius, quadriceps, hamstrings, hip flexors, adductors, gluteals). Each muscle stretched twice for 30 seconds, finishing with 3-4 minutes of light dynamic movements.
223748965|NCT07180667|BEHAVIORAL|Intervention 3: Dynamic Stretching (DS) Warm-Up|5 minutes light jogging followed by dynamic stretches targeting the same six muscle groups over 10-15 meters with brief rest between repetitions.
223748966|NCT07180667|BEHAVIORAL|Intervention 4: Movement Preparation (MP) Warm-Up|Description: Combination of light jogging, multi-joint mobility drills (e.g., lateral shuffles, inchworms), submaximal sprinting (80-90% max velocity), and low-intensity balance drills adapted from FIFA 11+ and HarmoKnee.
223748967|NCT07179991|DRUG|Desmopressin after protamine reversal|"Desmopressin will be given to participants at a dose of 0.3mcg/kg after protamine reversal at the end of cardiopulmonary bypass (CPB).~Platelet function will be assessed by TEG (Thromboelastography) platelet mapping at the following points:~1. T1 TEG6s: after arterial line insertion before skin incision.~2. T2 TEG6s: after protamine (baseline function after CPB)~3. T3 TEG6s: 30 minutes after desmopressin~4. T4 TEG6s: 6 hours after (intensive care unit) ICU admission~5. T5 TEG6s: 24hours after ICU admission"
223748968|NCT07180277|DRUG|Placebo|2 mg/kg diluted in 100 mL of normal saline (maximum dose 160 mg) , IV once daily for 5 days
223748969|NCT07180277|DRUG|Methylprednisolone (MP)|2 mg/kg diluted in 100 mL of normal saline (maximum dose 160 mg) , IV once daily for 5 days
223600107|NCT01005758|DRUG|imatinib mesylate|
223600108|NCT01005758|DRUG|mercaptopurine|
223600109|NCT01005758|DRUG|methotrexate|
223600110|NCT01005758|DRUG|methylprednisolone|
223600111|NCT01005758|DRUG|pegaspargase|
223600112|NCT01005758|DRUG|prednisolone|
223600113|NCT01005758|DRUG|prednisone|
223600114|NCT01005758|DRUG|vincristine sulfate|
223600115|NCT01005758|OTHER|laboratory biomarker analysis|
223600116|NCT01005758|RADIATION|radiation therapy|
223600117|NCT03940391|DRUG|Chlorpheniramine and midazolam|Administration of chlorpheniramine injection as an adjunctive sedative during sedative endoscopy.
223600118|NCT03940391|DRUG|Midazolam|Administration of midazolam as a sedative during sedative endoscopy as routine clinical practice.
223600119|NCT03261791|DRUG|Apatinib|Apatinib mesylate tablets 500 mg po qd.
223600120|NCT04844853|DEVICE|electroencephalography|128-channel electroencephalography
223748970|NCT07180199|PROCEDURE|Bilateral Lateral Rectus Recession (BLR Recession)|This procedure involved recession of both lateral rectus muscles to reduce large-angle exotropia.
223748971|NCT07180199|PROCEDURE|Bilateral Lateral Rectus Recession with Upward Transposition|This procedure involved bilateral lateral rectus recession combined with upward transposition of the insertion to enhance ocular alignment in patients with large-angle exotropia.
223748972|NCT07181252|DIAGNOSTIC_TEST|Working length of root|"EAL Group: Working length was measured using the Root ZX apex locator (J. Morita Corp., Kyoto, Japan), following the manufacturer's instructions. A #15 K-file was connected to the device and advanced until the display indicated APEX, confirming the location beyond the apical foramen.~DR Group: Working length was determined using a #15 K-file inserted 1 mm short of the estimated radiographic apex. A digital periapical radiograph was taken, and the working length was adjusted accordingly. Repeated radiographs were obtained until the file tip was 1 mm short of the radiographic apex."
224075166|NCT00482014|DRUG|pemetrexed|"Phase 1 - 500 milligram/meter squared (mg/m²), administered intravenously, every 21 days for 3 cycles~Phase 2 - 500 mg/m², administered intravenously, every 21 days for 3 cycles~Consolidation Therapy - 500 mg/m² pemetrexed, administered intravenously, every 21 days for 3 cycles beginning 3 weeks after completion of chemoradiation therapy for each phase"
224075167|NCT00482014|DRUG|cisplatin|"Phase 1 - 30 mg/m² and 75 mg/m², administered intravenously, Days 1, 8, 22, 29 and 43~Phase 2 - 75 mg/m², administered intravenously, every 21 days for 3 cycles"
224075168|NCT00482014|DRUG|carboplatin|"Phase 1 - dosed at area under the curve (AUC) 2 milligram/milliliter\*minute (mg/mL\*min), administered intravenously, Days 1, 8, 22, 29 and 43~Phase 2 - dosed at AUC 5 mg/mL\*min, administered intravenously, every 21 days for 3 cycles"
224075169|NCT00482014|RADIATION|radiation therapy|"Phase 1 - 2 Gray, daily, 5 days a week for Days 1-51~Phase 2 - 2 Gray, daily, 5 days a week for Days 1-45"
224075170|NCT03213301|DRUG|Lurbinectedin|3.2 mg/m2 i.v. every 3 weeks
223748973|NCT07180225|OTHER|Conventional therapy+manual therapy|Conventional therapy contains TENS and physiotherapist-supervised exercise program. These exercises are Wand exercises (15 repetitions each), codman exercises (1 minute in each direction), shoulder wheel exercises (5 minutes total), finger ladder exercises (10 repetitions), isometric exercises (10 repetitions each), capsular stretching exercises (10 repetitions each), pectoral muscle stretching and stabilization exercises (10 repetitions), shoulder stabilization exercises (5 minutes total), and strengthening exercises for the shoulder flexor, extensor, abductor, adductor, internal rotator, and external rotator muscles (15 repetitions each). In addition to them, manual therapy were applied to the shoulder region.
223748974|NCT07180225|OTHER|Conventional therapy+manual therapy+breathing exercises|In addition to the treatment program of Group I, breathing exercises were added. Each manual therapy technique was performed with 10 repetitions per participant. Similarly, participants were instructed to perform each breathing exercise with 10 repetitions. They were also asked to continue the breathing exercises at home, performing them three times a day with 10 repetitions per session for a duration of six weeks.
223748975|NCT07179809|OTHER|Demographics/Lifestyle Survey|Participants will complete all sessions and instruments
223748976|NCT07179536|PROCEDURE|Ambulation after ProGlide Closure|Ambulation time after femoral artery access site closure using the ProGlide vascular closure device was assigned to 2 hours, 6 hours, or 12 hours post-procedure.
223748977|NCT07181785|COMBINATION_PRODUCT|Treatments: anthracycline-based combinations followed or not by involved-field radiotherapy|Anthracycline-based combinations followed or not by involved-field radiotherapy
223748978|NCT07179913|DRUG|Esketamine|For the subjects in the experimental group, esketamine 50mg/2ml was diluted with normal saline up to 50ml (with a concentration of esketamine at 1mg/ml), anesthesia induction begins with intravenous infusion of esketamine 0.25mg/kg (0.375ml/kg•h drug preparation solution), with a pumping duration of 40 minutes.After the operation, esketamine 0.25mg/kg and sufentanil 1.5ug/kg were added to the postoperative analgesic pump dilute to 100ml with normal saline, with a background dose of 2ml/h and a single booster dose of 2ml.
224075171|NCT04897490|OTHER|Evaluation of first line treatment with ATO/ATRA outcome|Evaluation of first line treatment with ATO/ATRA outcome (o event free survival and overall survival and toxicity) in adult patients with APL.
224075172|NCT00683319|DRUG|carboplatin|
223600121|NCT04844853|DEVICE|Tactile stimulation|Vibrotactile sequence on the forearm
223600122|NCT04844853|BEHAVIORAL|Attention Network task (computerized)|Computer-based game challenging orienting and executive attention. The subject must chose which side an animal is going, using left and right buttons, depending on the validity of a cue and the congruency of flankers.
224075173|NCT00683319|DRUG|cisplatin|
224075174|NCT00683319|DRUG|cyclophosphamide|
224075175|NCT00683319|DRUG|methotrexate|
224075176|NCT00683319|DRUG|vincristine sulfate|
223600123|NCT04844853|BEHAVIORAL|Head-toes-knees-schoulders|Following motor commands such as touch your head when they are congruent or incongruent.
223600124|NCT04844853|BEHAVIORAL|Laby 5-12|Test of motor planning using labyrinths
223600125|NCT04844853|BEHAVIORAL|M-ABC 2|Test of motor functions using various subtests of gross and fine motor function.
223600126|NCT04844853|BEHAVIORAL|Stroop animals|Stroop test for preK children using animals instead of words
223600127|NCT05621993|DRUG|Azvudine|Azvudine is a small molecular antiviral drug. On August 9, 2022, Azvudine was included in the Diagnostic and therapeutic protocol for COVID-9 in China.
223600128|NCT01922791|DIETARY_SUPPLEMENT|Comparison of probiotics, fish oil and their combination to placebo|Double-blind randomized placebo controlled intervention
223600129|NCT04584957|DEVICE|VAC therapy|Prophylactic ciNPWT therapy (Prevena® KCI) entails placement of the device over a closed incision immediately post-operatively. Prevena® KCI may be left in place with no additional intervention for up to 7 days.
223600130|NCT06131138|OTHER|Aquatic exercises|This include aquatic exercises thrice as week for 6 weeks.
223600131|NCT06131138|OTHER|Core strengthening|This include core strengthening exercises thrice a week for 6 weeks
223600132|NCT04146935|DRUG|Burosumab Injection [Crysvita]|Burosumab/Crysvita SC injection monthly
223600133|NCT03207633|PROCEDURE|Repetitive trans-magnetic stimulation (rTMS) on DLPFC|Repetitive trans-magnetic stimulation (rTMS) on DLPFC
223600134|NCT03207633|PROCEDURE|Repetitive trans-magnetic stimulation (rTMS) on OFC|Repetitive trans-magnetic stimulation (rTMS) on OFC
223600135|NCT03207633|PROCEDURE|Sham repetitive trans-magnetic stimulation (rTMS)|Sham repetitive trans-magnetic stimulation (rTMS)
224075177|NCT00683319|PROCEDURE|adjuvant therapy|
224075178|NCT00683319|PROCEDURE|cognitive assessment|
224075179|NCT00683319|PROCEDURE|magnetic resonance imaging|
224075180|NCT00683319|PROCEDURE|magnetic resonance spectroscopic imaging|
224075181|NCT00683319|PROCEDURE|quality-of-life assessment|
224075182|NCT03858959|DEVICE|topical agent|"HBX protocol consisted in product application into the periodontal pocket (starting from the base) with a delivery syringe, second saline solution irrigation after 60 seconds to flush-out the product and Teflon-curettes debridement to remove the deposits.~CHX protocol consisted in Teflon-curettes debridement to remove the deposits, associated with a first saline solution irrigation, and product application into the periodontal pocket (starting from the base) with a delivery syringe."
223600136|NCT02683863|DRUG|BG00012 (DMF) (Tecfidera®.)|Subjects will take DMF 120 mg BID for the first 4 weeks of treatment followed by DMF 240 mg BID for 24 weeks.
224075183|NCT00843908|DEVICE|Tension Free Vaginal Tape|Tension Free Vaginal Tape inserted in the conventional manner in a theatre environment
224075184|NCT00843908|DEVICE|Miniarc|The Miniarc suburethral sling will be inserted in the conventional manner in a theatre environment under general anaesthesia
224075185|NCT01178138|DRUG|Prazosin|Prazosin or oral placebo given before methamphetamine or iv placebo to determine effects of prazosin on methamphetamine.
224075186|NCT05902169|DEVICE|SonoCloud-9 (SC9)|Implantation of SC9 device and repeat activation at constant acoustic pressure
224075187|NCT05902169|DRUG|Carboplatin|"Dose of carboplatin AUC 5 mg/ml.min-1 calculated using Calvert's formula:~Dose (mg) = target AUC (mg/mL x minute) x \[glomerular filtration rate (GFR) mL/minute + 25\]."
224075188|NCT05902169|DRUG|Lomustine|Dosed and administered per labelling.
224075189|NCT05902169|DRUG|Temozolomide|Dosed and administered per labelling.
223600137|NCT06332105|DIETARY_SUPPLEMENT|Glytactin|Glycomacropeptide based protein substitute for dietary treatment of PKU
223600138|NCT06332105|DIETARY_SUPPLEMENT|L-AA|Amino acid based protein substitute for dietary treatment of PKU
223600139|NCT04038567|BEHAVIORAL|Mobile mindfulness-based training|The intervention core is a mobile app-based mindfulness training program designed to be used over a 1-month period. All 6 factorial groups will use the app, though the delivery of the app and response to psychological distress symptoms over time will differ by group.
223600140|NCT05846555|PROCEDURE|urologic surgery|surgery
223600141|NCT02128880|BEHAVIORAL|CARRII|CARRII is an interactive, personalized and tailored Internet intervention designed to reduce the risk of AEP among drinking women of childbearing age.
223600142|NCT02128880|BEHAVIORAL|CARRII Education|CARRII Education provides information on women's health related to drinking and contraception in a static website format.
223600143|NCT01881568|DRUG|Tranexamic Acid|Topical administration: 3g of Tranexamic Acid in 100mL of normal saline (0.9% sodium chloride)
223600144|NCT01881568|DRUG|Tranexamic Acid|Intravenous administration of two dosis of Tranexamic Acid (15mg/kg of Tranexamic Acid in 100mL of normal saline each)
223600145|NCT00488696|DEVICE|Endovascular Bifurcated Stent-Graft|Treatment of Aneurysm involving the proximal aortic arch with endovascular bifurcated stent-graft.
223748979|NCT07179913|DRUG|Dexmedetomidine|For the control group subjects, dexmedetomidine at a dose of 0.2mg/2ml was diluted with normal saline up to 50ml(dexmedetomidine concentration of 4μg/ml), anesthesia induction begins with intravenous infusion of 0.5μg/kg (0.083ml/kg•h), with a pumping duration of 40 minutes. The postoperative analgesic pump was added after the operation dilute with normal saline at a dose of 0.5μg/kg of dexmedetomidine and 1.5 μg/kg of sufentanil 100ml, with a background dose of 2ml/h and a single booster dose of 2ml.
223748980|NCT07180979|DRUG|0.9% Sodium chloride|"Sham ultrasound-guided pericapsular nerve group (PENG) block, lateral femoral cutaneous nerve (LFCN) block, lumbar erector spinae plane block (L-ESPB), and sacral erector spinae plane block (S-ESPB).~At each anatomical site, under ultrasound guidance, a block needle will be inserted to the correct position, and 1-2 mL of preservative-free normal saline (0.9% NaCl) will be injected to mimic the sensation of an active block. No local anesthetic will be administered. All patients will receive standard spinal anesthesia with 0.5% ropivacaine, 10-15 mg intrathecally for total hip arthroplasty."
223748981|NCT07180979|DRUG|Ropivacaine 0.2% Injectable Solution|"Ultrasound-guided pericapsular nerve group (PENG) block and lateral femoral cutaneous nerve (LFCN) block, with sham lumbar and sacral ESPBs.~PENG block: 20 mL of 0.2% ropivacaine. LFCN block: 5 mL of 0.2% ropivacaine. Sham lumbar ESPB: 1-2 mL preservative-free normal saline at lumbar ESPB site. Sham sacral ESPB: 1-2 mL preservative-free normal saline at sacral ESPB site. All patients will receive standard spinal anesthesia with 0.5% ropivacaine, 10-15 mg intrathecally for total hip arthroplasty."
223600146|NCT00612196|DRUG|TB-402|Solution for infusion, 0.015ug/kg-1.8mg/kg, single dose, iv infusion over 30 minutes
223600147|NCT00612196|DRUG|Placebo|
223600148|NCT05290116|DRUG|HAIC Combined with Tislelizumab and Apatinib|"Hepatic Arterial Infusion Chemotherapy: FOLFOX6 regimen was infused with chemotherapy drugs: oxaliplatin 130 mg/m2 infusion for 2 hours, folinate calcium 400 mg/m2 infusion for 2 hours, 5-fluorouracil 400 mg/m2 arterial infusion for 10 minutes, 5-fluorouracil 1200 mg/m2 infusion for 23 hours. Every 3 weeks, no more than 4 cycles of HAIC treatment.~Tislelizumab and Apatinib treatment: start at 0-3 days after the end of hepatic arterial infusion chemotherapy: Tislelizumab 200 mg, ivdrip, Q3W; Apatinib 250 mg, po, QD."
223600149|NCT05138315|DEVICE|Metamorphopsia quantification|Alleye App and M.chart examinations will be performed pre- and postsurgically.
223748982|NCT07180979|DRUG|Ropivacaine 0.2% Injectable Solution|"Ultrasound-guided lumbar erector spinae plane block (L-ESPB) and sacral erector spinae plane block (S-ESPB), with sham PENG and LFCN blocks.~Lumbar ESPB: 20 mL of 0.2% ropivacaine at L3 transverse process level. Sacral ESPB: 20 mL of 0.2% ropivacaine at sacral intermediate crest. Sham PENG block: 1-2 mL preservative-free normal saline at PENG site. Sham LFCN block: 1-2 mL preservative-free normal saline at LFCN site. All patients will receive standard spinal anesthesia with 0.5% ropivacaine, 10-15 mg intrathecally for total hip arthroplasty."
224311254|NCT00838435|DRUG|sapropterin dihydrochloride|A dose of 20 mg/kg will be administered dissolved in water or apple juice, based on subject's age and ability, and taken orally once daily with food.
223600150|NCT04429724|DIAGNOSTIC_TEST|Diagnostic test Covid-19|Three blood samples will be taken at day 1, month 3 and month 6 A prospective data collection will be set up at the level of symptoms and co-morbidities at each collection at D1, M3 and M6.
223600151|NCT01478724|DIETARY_SUPPLEMENT|Milk proteins fraction|capsules, one per day, 24 months
223600152|NCT02452450|DRUG|Ibuprofen Acid|
223600153|NCT02452450|DRUG|Ibuprofen Lysine|
223600154|NCT02452450|DRUG|Ibuprofen Sodium|
223600155|NCT02452450|DRUG|Ibuprofen Liquid Capsules|
223600156|NCT02452450|DRUG|Paracetamol|
223600157|NCT05758350|BEHAVIORAL|home based IOPI swallow training|Use IOPI for tongue and labial muscle resistance training. Conventional training was the same as controlled group.
223748983|NCT07180355|DRUG|SGT-212|Adeno-associated virus serotype AAVhu68 containing a codon-optimized complementary DNA (cDNA)
224075190|NCT02381561|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
224075191|NCT02381561|OTHER|Laboratory Biomarker Analysis|Correlative studies
224075192|NCT02381561|OTHER|Pharmacological Study|Correlative studies
224075193|NCT02381561|DRUG|Ropidoxuridine|Given PO
224075194|NCT03269214|DRUG|Topical Phenytoin 5%|Patients received topical Phenytoin 5%+ Tetracycline after necrotic bone debridement .
224075195|NCT01241708|DRUG|Bortezomib|Bortezomib 1.6mg/m2 on day -4 and day -1
224311255|NCT01922804|DIETARY_SUPPLEMENT|K2 vitamin|K2 vitamin tablet
224311256|NCT01922804|DIETARY_SUPPLEMENT|Placebo|Placebo tablets
224311257|NCT00093561|DIETARY_SUPPLEMENT|lycopene|
224311258|NCT02747550|PROCEDURE|LM with TESTO|In subjects allocated to the experimental group, the temporary simultaneous two-arterial occlusions (TESTO) procedure was performed to minimize operative blood loss during laparoscopic myomectomy.
224311259|NCT02747550|PROCEDURE|LM without TESTO|In the control group, no intervention for the temporary simultaneous two-arterial occlusions (TESTO) procedure was made during laparoscopic myomectomy
223600158|NCT01817959|DRUG|Reparixin|Continuous i.v. infusion into a central vein for 7 days, starting approximately 12 hrs (6-18 hrs) before each pancreatic islet infusion.The Investigational Product (IP) were to be administered as an add-on treatment for the immunosuppressant regimen.
223600159|NCT01817959|DRUG|Placebo|Continuous infusion at a volume/rate matching active treatment.The placebo was to be administered as well as an add-on treatment for the immunosuppressant regimen.
223600160|NCT04043650|BEHAVIORAL|HeartSteps|HeartSteps is a smartphone based mHealth intervention that contains the following intervention components: (1) contextually-tailored suggestions for activity; (2) motivational messages aimed at keeping individuals motivated to be active; (3) planning of the next week's activity; and (4) adaptive weekly activity goals. Activity suggestions provide individuals with suggestions for how they can be active, and are tailored based on time of day, user's location, day of the week (weekend/weekday), and weather. Motivational messages are delivered to individuals via a push notification. Activity planning asks users to create a plan of how they will be active in the coming week. Participants are prompted to plan once a week. Each week, as part of the weekly planning, HeartSteps suggests an activity goal for the coming week based on their activity levels the previous week. Participants can edit the suggested goal, and the system-suggested goals top out at 150 minutes of activity per week.
223600161|NCT02326233|BIOLOGICAL|Pen of SB5|
223600162|NCT02326233|BIOLOGICAL|PFS of SB5|
223600163|NCT05494034|DEVICE|Reveal LINQTM|"implantable cardiac monitoring device (Reveal LINQTM)"
223600164|NCT03440489|DIAGNOSTIC_TEST|Six-minute walking test|physical performance of the muscle measured by these tests
223600165|NCT03440489|DIAGNOSTIC_TEST|30 seconds chair stand test|physical performance of the muscle measured by these tests
223600166|NCT04854382|BEHAVIORAL|Tailored information|Tailored information about coronavirus for patients with chronic kidney disease by information videos followed by a teach back procedure
223600167|NCT00923845|DRUG|Pentostatin|Pentostatin: 2- 4mg/m\^2(CrCL based dosing) intravenous (IV) on days 1, 8, and 15
223600168|NCT00923845|DRUG|Sirolimus|Sirolimus: 4 mg by mouth (PO) on days -3 to +7 post-transplant (No Sirolimus administered after day 7 post-stem cell transplant (SCT))
223600169|NCT00923845|DRUG|Cyclophosphamide|Cyclosporine: 2 mg/kg every 12 hours PO or IV starting on day -4 of hematopoietic stem cell transplant (HSCT)
223600170|NCT00923845|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplant (HSCT)|Allogeneic Hematopoietic Stem Cell Transplant
223600171|NCT00923845|PROCEDURE|Th2 rapa cells|Th2 rapa cell Transplantation
223600172|NCT00923845|PROCEDURE|Donor Lymphocyte Harvest|Apheresis
223600173|NCT00923845|PROCEDURE|Induction Therapy|Pentostatin and cyclophosphamide (PC) conditioning regimen.
223600174|NCT00923845|PROCEDURE|GVHD prophylaxis|Short course of sirolimus plus maintenance therapy with sirolimus A.
223600175|NCT00923845|PROCEDURE|Donor Hematopoietic Stem Cell Harvest|Following lymphocyte harvest, donors for recipients will undergo stem cell mobilization and harvest.
223600176|NCT06260306|OTHER|Hip activation home exercise program|The hip activation HEP group will receive a combination of hip musculature activation exercises used by previous researchers that show an increase in hip muscle recruitment. Each participant will perform their respective intervention program at home twice weekly for eight weeks.
223600177|NCT06260306|OTHER|Hip activation plus core stabilization home exercise program|The hip activation plus core stabilization HEP group will receive the same hip exercises, plus core stabilization exercises used by previous researchers. Each participant will perform their respective intervention program at home twice weekly for eight weeks.
223600178|NCT02632487|BEHAVIORAL|Exercise|Center-based walking + balance, stretching, and light resistance
223600179|NCT02632487|BEHAVIORAL|Non-Exercise Physical Activity (NEPA)|Behavioral counseling paired with technology intervention to monitor physical activity
223600180|NCT00917488|OTHER|Standardization of allergenic extract (Gly. domesticus)|Allergenic extract for cutaneous prick-test
223600181|NCT04077515|DRUG|Sirolimus(0.8mg/m2)|The initial use of sirolimus is 0.8mg/m2 administered twice daily.After two weeks of taking the drug, blood concentrations are measured and adjusted appropriately to maintain the targeted blood concentration.
223600182|NCT04077515|DRUG|Sirolimus(0.7mg/m2)|The initial use of sirolimus is 0.7mg/m2 administered twice daily.After two weeks of taking the drug, blood concentrations are measured and adjusted appropriately to maintain the targeted blood concentration.
223600183|NCT01810315|DRUG|TFV 1% gel|
223600184|NCT01810315|DRUG|Estradiol vaginal cream|
223600185|NCT00008528|DRUG|Enfuvirtide|
223600186|NCT05026216|DRUG|Qwo|Collagenase clostridium histolyticum-aaes is a combination of bacterial collagenases AUX-I and AUX-II, in an approximate 1:1 mass ratio, which are isolated and purified from the fermentation of Clostridium histolyticum bacteria. Collagenase AUX-I is a single polypeptide chain consisting of approximately 1000 amino acids. Collagenase AUX-II is a single polypeptide chain consisting of approximately 1000 amino acids.
223600187|NCT05930184|PROCEDURE|peri-wound Transversus Abdominis Plane Block|0.25% bupivacaine 20ml was injected using no24 needle into a plane between internal oblique muscle and transversus abdominis muscle around every wound 2 cm. from wound opening. The procedure was confirmed by laparoscopic vision and the injection was done before removal of laparoscopic port.
223600188|NCT05930184|PROCEDURE|Local wound infiltration|0.25% bupivacaine 20ml was injected using no24 needle into subcutaneous tissue after the abdominal sheet was sutured.
223600189|NCT06469606|DEVICE|AI tool|"Both the arms will undergo the use of AI tool developed in the group. The tool will be trained to detect outcomes."
223600190|NCT00961714|DEVICE|OsseoFix Spinal Fracture Reduction System|All enrolled into the study will be receiving the OsseoFix if meet inclusion / exclusion criteria.
223600191|NCT04807049|OTHER|Observational|Observational
223600192|NCT00639626|DRUG|insulin detemir [rDNA origin] injection|Starting dose of 0.1-0.3 units/kg/day in a once daily subcutaneous injection.
224199520|NCT04543747|DEVICE|HeartWare Ventricular Assist Device|The Medtronic HVAD® System is comprised of three major components: the HVAD Pump with inflow and outflow conduits, a Controller and power sources. In addition to these components, the system includes a Monitor, Battery Charger, AC and DC power adapters, and a Carrying Case. The HVAD® System is indicated for hemodynamic support in patients with advanced, refractory left ventricular heart failure; either as a bridge to cardiac transplantation (BTT), myocardial recovery, or as destination therapy (DT) in patients for whom subsequent transplantation is not planned.
223600193|NCT03470402|OTHER|RealRisks|RealRisks is a web-based patient decision aid with modules on risk assessment, family history and breast cancer, genetic testing, and prevention options. Participants enter family history data into RealRisks, and RealRisks calculates 5-year breast cancer risk, lifetime breast cancer risk, and the probability of carrying a BRCA mutation. This information is then interactively presented to the participant. RealRisks facilitates the participant in identifying their intention to undergo BRCA genetic testing and the factors that are important to the participant in making this decision. RealRisks produces a summary of all of this information that the participant can print and take with her to a health care appointment.
223600194|NCT03470402|OTHER|BNAV|BNAV is a web-based decision support tool for healthcare providers with educational modules on genetic testing, chemoprevention, patient-centered care, and screening. BNAV also provides providers with a table outlining their enrolled patients' breast cancer risk, eligibility for genetic testing, and stated preferences.
223600195|NCT03470402|OTHER|iNYP|Enrolled patients will have their eligibility for BRCA genetic testing flagged in iNYP, the hospital's portal for visualizing EHR data (standard practice).
223600196|NCT03470402|OTHER|Standard Educational Material|Enrolled patient participants will be sent standard educational brochures on genes and breast cancer and the CUMC breast cancer prevention clinic
223600197|NCT03470402|OTHER|High-Risk Message|Enrolled patient participants will receive a letter that informs them that they meet eligibility criteria for BRCA genetic testing, outlines prevention options, and recommends discussing genetic counseling referral with their health care provider (standard practice).
223748984|NCT07181304|BEHAVIORAL|PROMOTE|"PROMOTE components includes 1) peer support, 2) remote patient monitoring of blood glucose (RPM), and 3) integration with clinical care.~1. Peer support delivered by community health workers focused on -- assistance in applying diabetes self-management in daily life, emotional and social support, linkage to clinical care, and ongoing, as-needed support. CHWs visits will include: one-on-one in-person visit, then weekly phone calls for 3 months, then monthly calls for 3 months.~2. RPM team will supply the device and supplies to participants. Data is transmitted electronically to the RPM team through broadband connectivity. Protocols have been developed for research projects; participants will be instructed to monitor blood glucose up to four times a day, based on medication regimen. Levels will be monitored 8 a.m. to 5 p.m. M-F.~3. A monthly report of peer support activities and RPM data will be sent to participants' primary care providers."
223748985|NCT07181304|BEHAVIORAL|DSMES|Diabetes Self-Management Education and Support delivered virtually.
223748986|NCT07180940|DRUG|0.9%NaCl|2 x 20ml 0.2% ropivacaine with 2ml of 0.9% NaCl
223748987|NCT07180940|DRUG|Dexamethasone 4mg|2 x 20ml 0.2% ropivacaine with 2mg of dexamethasone
223748988|NCT07180940|DRUG|Dexmedetomidine|2 x 20ml 0.2% ropivacaine with 25ug Dexmedetomidine
223748989|NCT07180498|DRUG|Chlorhexidine Gluconate 0.12% Mouthwash|Participants will be prescribed to gargle with chlorhexidine, which is the routine recommendation after brushing their teeth 3 times a day for 7 days after the impacted tooth extraction.
223748990|NCT07180498|DRUG|Tea Tree Oil mouthwash|Participants will be prescribed to gargle with tea tree oil-containing water after brushing their teeth three times a day for 7 days following the extraction of an impacted tooth.
224199521|NCT01886105|DRUG|Sm-EDTMP|"Subjects receive a tracer infusion of Samarium-153 EDTMP at 1 mCi/kg. 3D dosimetry using SPECT images are obtained post tracer infusion to determine the distribution of dose delivered to the tumor and surrounding normal tissues. Tracer activity will be applied to development of the external beam radiation (EBT) planning. Second treatment infusion of Samarium will then be implemented. Maximum activity administered will be 30 mCi/kg."
224199522|NCT01886105|OTHER|Autologous Stem Cell Infusion|"Administered 14 days after Treatment infusion of Samarium-153 EDTMP."
223600198|NCT03405428|OTHER|Allen test|Before induction, with firm occlusive pressure held on both the radial and ulnar arteries, the patient is asked to clench his or her fist several times until the palmar skin is blanched. The patient is then instructed to unclench the fist, and then ulnar artery pressure is released while maintaining occlusion of the radial artery. Overextension of the hand and wide spreading of the fingers should be avoided because it can lead to falsely abnormal results. The time required for palmar capillary refill is noted. An abnormal Allen test result was defined as a recovery time of more than 10 seconds.
223748993|NCT07181330|DIAGNOSTIC_TEST|SE-SPTM-PCR microRNA assay|SE-SPTM-PCR (Selective Enrichment and Specific Probe Terminal Mediated PCR) is a microRNA-based diagnostic assay designed to detect hcmv-miR-UL22A-5p in human plasma. In this retrospective observational study, the assay is used on archived plasma samples collected from patients who underwent allogeneic hematopoietic stem cell transplantation (HSCT). The purpose is to evaluate the diagnostic performance of this method in identifying CMV reactivation, compared to standard CMV DNA qPCR testing. This test was not assigned or administered as part of patient care but is the primary focus of retrospective laboratory analysis.
223748994|NCT07181096|DIAGNOSTIC_TEST|assessment of frailty|"This study is a prospective cross-sectional study to assess the prevalence of frailty among 80 cases of renal transplanted patients.~Specific tests will include:~1. Assessment of frailty by Clinical Frailty Scale.~2. Assessment of nutritional status using Patient Generated Subjective Global Assessment (PG-SGA).~3. Comorbidity assessment using Charlson comorbidity score.~4. Six minutes walk test.~5. Muscle strength assessment using hand grip strength (HGS) dynamometer."
223748995|NCT07180511|DRUG|10mg QY201 Placebo tablet|10mg QY201 Placebo tablet
223748996|NCT07180511|DRUG|20mg QY201 Placebo tablet|20mg QY201 Placebo tablet
223748997|NCT07180511|DRUG|10mg QY201 tablet|10mg QY201 tablet
223748998|NCT07180511|DRUG|20mg QY201 tablet|20mg QY201 tablet
223748999|NCT07180251|BEHAVIORAL|CARE program|The CARE program is an 8-week intervention using reflection assisted with CGM. The Abbott factory-calibrated Freestyle Libre Flash Glucose Monitoring (Freestyle Libre 2) system will be used to evaluate glycemic variability.
223749000|NCT07180251|OTHER|Usual Care|Usual care means the participants will receive care from their primary care physicians and nurses during clinic visits at the surgical OPD.
223749001|NCT07181759|PROCEDURE|VISOR|Surgery will be performed using the VISOR through a 14Fr UAS
223600199|NCT03405428|OTHER|Radial artery diameter measurement by ultrasonography|Ultrasonography measurements will be performed with a linear probe before and after induction. The non-dominant hand of the patient will be fixed in the anatomical position on the arm chair. The wrist joint of patient will be extended to 30 degrees with a wrist pad. The USG probe will be transversally placed 2 cm proximal to the styloid process and the short axes of the radial artery will be scanned. The diameter of the radial artery will be measured and recorded.
223600200|NCT03405428|OTHER|Ulnar artery doppler ultrasonography|Ultrasonography measurements will be performed with a linear probe before and after induction. The non-dominant hand of the patient will be fixed in the anatomical position on the arm chair. The wrist joint of patient will be extended to 30 degrees with a wrist pad. The USG probe will be transversally placed 2 cm proximal to the styloid process and the short axes of the ulnar arter will be scanned. The blood fow of ulnar artery will be measured and recorded.
223600201|NCT02945514|OTHER|DayTwo machine learning algorithm|Personally tailored nutrition insights based on DayTwo machine learning algorithm when combining facets of your postprandial glycemic response to food consumed during collection week and your individual gut microbiome composition
223600202|NCT04503824|DIAGNOSTIC_TEST|saliva samples|Salivary expression of lncRNA DQ786243 and IL-17 will be evaluated using qRT-PCR.
223600203|NCT02457949|OTHER|Non-synchronized social assistance receipt|Social assistance disbursement outside government cheque issue week
223600204|NCT02457949|OTHER|cheque divided into two equal disbursements|Social assistance disbursement divided into two equal payments
223600205|NCT04787991|DRUG|Nivolumab (Cohort A)|Nivolumab will be administered intravenously at 360 mg every 3 weeks for up to 2 years.
223600206|NCT04787991|DRUG|Ipilimumab (Cohort A, B and C)|For Cohort A and B, ipilimumab will be administered intravenously at 1mg/kg every 6 weeks for up to 2 cycles. For Cohort C, ipilimumab will be administered intravenously at 1mg/kg on C2D1 and C4D1.
223600207|NCT04787991|DRUG|Hydroxychloroquine (HCQ) (Cohort B)|Hydroxychloroquine will be administered orally daily for up to 2 years.
223600208|NCT04787991|DRUG|Nab-paclitaxel (nP) (Cohort A, B and C)|Nab-paclitaxel will be administered intravenously at 125 mg/m2 for 2 weeks on and 1 week off, for at least 24 weeks, unless treatment discontinuation criteria are met.
223600209|NCT04787991|DRUG|Gemcitabine (gem) (Cohort A, B and C)|Gemcitabine will be administered intravenously at 1000 mg/m2 for 2 weeks on and 1 week off, for at least 24 weeks, unless treatment discontinuation criteria are met.
223600210|NCT04787991|DRUG|NG350A (Cohort C)|NG-350A will be administered intravenously on Cycle 1 Days 15 (1e12 viral particles), 17 (3e12 viral particles), and 19 (3e12 viral particles).
223600211|NCT02065817|OTHER|stable isotope of cholesterol|
223600212|NCT03312426|DRUG|BMS-986205|Single dose, 100 mg administered at Day 1 and at Day 15.
223600213|NCT05998382|BEHAVIORAL|Online group-based parent-mediated intervention program|The program is an online group-based parent-mediated intervention program implemented in 2 sessions of 2 hours once a week for 6 weeks. In the first part of the weekly sessions, the topic of that week is explained to the parents. In the second part, videos recorded by the parents are watched and feedback is given to the parents. At the end of the session, written materials about that week's practices and homework are sent to the parents
223749002|NCT07181759|PROCEDURE|fURS|Surgery will be performed using a standard single-use electronic ureterorenoscope through a 14Fr UAS
223749003|NCT07181564|DRUG|Propofol / Remifentanil|Maintenance of general anesthesia with propofol and remifentanil; no ketamine or magnesium administered.
223749004|NCT07181564|DRUG|Ketamine + Magnesium sulfate (drug combination)|Continuous intraoperative infusion per protocol.
224199523|NCT01886105|RADIATION|External Beam Radiotherapy|"The radiotherapy portion of the combined plan will be delivered according to the judgement of the treating radiation oncologist. The total dose to be used will be modified based on surrounding tissue tolerances as evidenced by Samarium infusion and SPECT image planning.~After the treatment infusion, SPECT scans will again be performed to confirm the total dose delivered and subsequently adjust the EBT portion of the treatment plan, as necessary."
224199524|NCT00006401|DRUG|iNO|Inhaled Nitric Oxide for Preventing Chronic Lung Disease in Premature Infants
223600214|NCT06212830|DRUG|Gabapentin|Gabapentin 200 mg twice a day, starting from the night prior to the procedure and continue 48 hours after
223600215|NCT06212830|DRUG|Targin|Targin 5 mg twice a day after the procedure for 48 hours
223600216|NCT06212830|DRUG|NSAID|Nurofen (NSAID) 200 mg twice a day after the procedure for 48 hours
223600217|NCT06212830|DRUG|Paracetamol|Paracetamol 500 mg every 4 hours during waking hours after the procedure for 48 hours
223600218|NCT06134843|COMBINATION_PRODUCT|DERMASEAL|plasma film containing metallic silver microparticles and fibrin
223600219|NCT01304537|DRUG|Alpha-1 Antitrypsin 40mg (AAT, Glassia®)|Each study group will undergo 3 treatment periods:12 weeks, 8 weeks and 4 weeks.
223600220|NCT01304537|DRUG|Alpha-1 Antitrypsin 60mg (AAT, Glassia®)|Each study group will undergo 3 treatment periods:12 weeks, 8 weeks and 4 weeks.
223600221|NCT01304537|DRUG|Alpha-1 Antitrypsin 80mg (AAT, Glassia®)|Each study group will undergo 3 treatment periods:12 weeks, 8 weeks and 4 weeks.
223600222|NCT00709410|BIOLOGICAL|rBS-WC vaccine|1 mg of recombinant cholera toxin B subunit and approximately 1 x 10\^11 of inactivated whole cells of Vibrio cholerae O1 Inaba and Ogawa, classic and El Tor strains (6). The rBS-WC vaccine is supplied as 3 ml single-dose vials each with a sachet of sodium bicarbonate buffer. Buffer solution will be prepared by dissolving the sachets in drinking water (150 ml water for each sachet of sodium bicarbonate). The full dose of vaccine will be mixed with 40, 75, or 150 ml of buffer solution for persons 2 to 4 years, 5 to 11 years, and over 11 years old, respectively. The vaccine is recommended to be given in two doses with an interval of at least seven days and protection is conferred 7 to 10 days after the second dose.
223749005|NCT07181564|DRUG|Sevoflurane and Remifentanil|Continuous intraoperative infusion per protocol.
223749006|NCT07179939|DRUG|Trastuzumab rezetecan|Trastuzumab rezetecan is a lyophilized powder for injection intravenously. Administered according to label.
224199525|NCT00006401|OTHER|Placebo|Inhaled Nitrogen
224199526|NCT05959824|DEVICE|OR-AT0222|Topical viscous gel containing tamarind seed polysaccharide and isolated pea proteins will be used 3 times a day away from the main meals (breakfast lunch and dinner) for 7 days.
223749007|NCT07179939|DRUG|Pyrotinib|320 mg/d, q.d., p.o. A course of treatment need 21 days.
223749008|NCT07179939|DRUG|Dalpiciclib|125 mg/d, q.d., p.o. day 1-21, every 28 days.
223749009|NCT07179939|DRUG|Trastuzumab|Administered according to label.
223749010|NCT07179939|DRUG|ET: Letrozole/ Anastrozole/ Exemestane/ Fulvestrant/ Leuprorelin/ Goserelin.|Administered according to label.
223749011|NCT07180082|DRUG|Pyrotinib|anti-HER2 tyrosine kinase inhibitor
223749012|NCT07180095|DRUG|Intranasal dexmedetomidine|intranasal dexmedetomidine 2mcg/kg
224199527|NCT05959824|OTHER|Placebo|Topical placebo viscous gel will be used 3 times a day away from the main meals (breakfast lunch and dinner) for 7 days.
224199528|NCT02841332|DRUG|F-MISO|"The fluoro-misonidazole is a positron emission tomography tracer (labeled with Fluorine-18)-specific hypoxia. This compound penetrates into cells where it is reduced by a nitroreductase enzyme. It is rapidly regenerated by reoxidation when the cell is properly oxygenated. This metabolite can accumulate in viable hypoxic cells (necrotic cells that can provide initial reduction reaction of F-MISO).~Moreover, the fixing of this tracer appears to be independent of blood flow. The advantage of this technique is to provide a direct image of hypoxic cells by directly targeting under stress hypoxic."
224199529|NCT02841332|OTHER|Cerebral magnetic resonance imagery|"During the pre-therapeutic imagery session :~* Morphological magnetic resonance imagery ( axial T1 sequence axial T1 post contrast , Flair Axial )~* magnetic resonance imagery spectroscopy sequence~* Perfusion magnetic resonance imagery sequence~* Diffusion magnetic resonance imagery sequence"
224199530|NCT02841332|DRUG|Bevacizumab|Administration of bevacizumab during 7 cycles of treatment (J1, J15, J30, J45, J60, J120 and J180)
224199531|NCT02841332|OTHER|Clinical examination|"During the examination, the following parameters will be checked :~* Neurological examination~* Corticotherapy prescribed~* General status of patient (world health organization score)~* Weight and height~* Control of arterial pressure~* Chirurgical and medical history~* Concomitant treatment"
224199532|NCT04801069|DEVICE|Nocturnal Ventilation|AirCurve 10CS PaceWave (Resmed)
223600223|NCT03298763|GENETIC|MSCTRAIL|"3 doses of MSCTRAIL, administered as an intravenous 60 minutes infusion over 3 cycles, in combination with standard chemotherapy (Cisplatin/Pemetrexed).~After 3 cycles patients will have 1-3 further treatment of pemetrexed and cisplatin without MSCTRAIL."
223600224|NCT03298763|DRUG|Placebo|Placebo will be made up of the same material used to cryopreserve the ATIMP (MSCTRAIL) but will not include the active product
223600225|NCT05176834|DEVICE|B-Cure laser pro|The B-Cure laser pro is a portal, non-invasive, photobiomodulation device, that emits light in the near infrared (808nm) over an area of 1X4.5 cm2 with power output of 250mW, and energy dose of 1J/cm2.
223600226|NCT05735535|DRUG|Antiviral Agents|two-drug one-pill once day
223600227|NCT04519697|DRUG|Mesenchymal Stem Cells|Adult allogeneic bone marrow derived mesenchymal stem cells for the treatment of rectovaginal fistulas in the setting of Crohn's disease.
223600228|NCT04519697|OTHER|Placebo|Normal Saline
223600229|NCT00177255|DRUG|Docetaxel|"Docetaxel 30 mg/m2 will be administered as a 30-minute infusion on days 1 and 8. Each cycle will consist of 21 days.~Cycle 2 will begin on day 22."
223600230|NCT00177255|DRUG|Capecitabine|"Capecitabine 825 mg/m2 bid (total daily dose 1650 mg/m2) will be administered orally for 14 days (days 1-14).~Each cycle will consist of 21 days.~Cycle 2 will begin on day 22."
223600231|NCT04771676|DRUG|Oncorine (H101)|A modified human recombinant type 5 adenovirus with genetic modifications.
223600232|NCT06311422|OTHER|resin nanoceramic block|Resin-based CAD/CAM materials
223600233|NCT06311422|OTHER|zirconia-reinforced lithium silicate|zirconia reinforced lithium silicate ceramic
223600234|NCT01128946|DRUG|NaF|Fluoride toothpaste containing sodium fluoride as 1450 parts per million (ppm) F, 675 ppmF, 450 ppmF, 350ppmF.
223600235|NCT01128946|DRUG|SnF|Fluoride toothpaste containing stannous fluoride (1100 ppmF)
223600236|NCT01128946|DRUG|NaMFP|Fluoride toothpaste containing sodium monofluorophosphate (1000 ppmF)
223749013|NCT07180095|DRUG|Intranasal ketamine|intranasal ketamine 2mg/kg
223749014|NCT07180043|BEHAVIORAL|Structured Behavioral Therapy|Structured patient education, lifestyle modification counseling, and headache diary maintenance without pharmacological prophylaxis.
223749015|NCT07180043|DRUG|Propranolol|Oral propranolol, 1-3 mg/kg/day in two divided doses, titrated according to response, for 12 weeks.
223749016|NCT07181863|BEHAVIORAL|Health coaching|Health coaching is the active component of TECC-DM. In weekly 1-hour sessions, the coach builds a therapeutic relationship, supports goal-setting and behaviour change, addresses mental health needs, coordinates resources, and empowers participants to navigate care. Coaching is delivered according to a standardized protocol, in consultation with the virtual care team, and targets improvements in quality of life and goals of care. Coaches do not provide pharmacological treatment or replace usual diabetes care.
223749017|NCT07181863|OTHER|Educational emails|Participants receive usual diabetes care (e.g., primary care, endocrinology, community supports) plus 10 standardized educational emails over 12 weeks, delivered according to a consistent protocol. Unlike TECC-DM, this approach does not involve a therapeutic relationship, health coach, or interdisciplinary care team.
223749018|NCT07179679|DRUG|TQB2934 injection (subcutaneous injection)|TQB2934 is an anti-CD3(Early T Cell Marker)×BCMA (B cell maturation antigen)double-specific antibody，and the isoform is Native Immunoglobulin G1 ( IgG1), which at one end binds to the CD3 receptor on the surface of T cells ,and the other end binds to BCMA(B cell maturation antigen) to recruit T cells around BCMA-positive cells, which can activate T cells .Active T cells release granzyme and perforin to kill BCMA-positive target cells.
223749019|NCT07179835|PROCEDURE|Full pulpotomy in adults ≥18 years with restorable mandibular first or second molars diagnosed with irreversible pulpitis, with or without apical periodontitis.|Comparison of full pulpotomy with MTA in teeth with and without apical periodontitis
223600237|NCT06085014|OTHER|Standard of care|All patients will undergo, as clinically indicated, AF ablation by pulmonary vein isolation achievable by radiofrequency, cryoenergy, or electroporation. All patients will preliminarily undergo electroanatomic mapping of the atrium by CARTO/Navx/Rhythmia system indifferently. Patients will be given follow-up visits at 3-6-12 months, during which any arrhythmic recurrences will be assessed
224199533|NCT05956782|BEHAVIORAL|Breathe Easier|See Intervention Group (IG) description.
224199534|NCT02926352|BEHAVIORAL|Extinction Training|Up to 40 min. of self-directed repeated exposure to a fear-provoking situation.
224199535|NCT02926352|DEVICE|Low-Level Laser Therapy|1064nm light used to modulate a biological function and induce a therapeutic effect.
223600238|NCT06085014|OTHER|Data collection|There's no patient involvement. Data of patients who underwent ablative procedures two years before the start of the study will be retrospectively analyzed
223600239|NCT01371734|DRUG|Desvenlafaxine Succinate Sustained-Release|Subjects randomized to DVS SR treatment arm will receive 25, 35, or 50 mg/day based on subject weight at the Baseline visit.
223600240|NCT01371734|DRUG|Desvenlafaxine Succinate Sustained-Release|Subjects randomized to DVS SR treatment arm will receive 20, 25, or 35 mg/day based on subject weight at the Baseline visit.
223600241|NCT01371734|DRUG|Placebo|Subjects randomized to the Placebo treatment arm will receive placebo tablets
223749020|NCT07179926|DIAGNOSTIC_TEST|morphometric spine radiography|Patients already on treatment with Pasireotide LAR or Pegvisomant will be evaluated using morphometric spine radiography and lumbar and femoral densitometry. Patients will undergo a 1-year follow-up.
224199536|NCT02926352|DEVICE|Sham Low-Level Laser Therapy|Placebo dose version of LLLT.
224199537|NCT00150137|DRUG|Methimazole|
224199538|NCT05287581|BEHAVIORAL|MOVES|The experimental intervention is a 16-week progressive home-based exercise program in which participants are supported through seven coaching calls based on social cognitive theory and motivational interviewing principles. The individual sessions will provide tailored support for increasing physical activity behavior towards the recommended guidelines of at least 150 minutes of moderate aerobic activity and two strength-training sessions per week. There are no drugs involved in the intervention.
224199539|NCT03843775|DRUG|Binimetinib|Dose level 1 binimetinib 45 mg PO BID. Dose level 2 binimetinib 60 mg oral BID
224199540|NCT03843775|DRUG|Encorafenib|encorafenib 450 mg oral QD
224199541|NCT05076812|DIAGNOSTIC_TEST|measure plasma level of interleukin 38 by ELISA kit|draw 5 ml of venous blood into EDTA tubes and centrifuged then plasma is separated for test
224199542|NCT03062852|DEVICE|Medication safety vest|"The nurses preparing and administering medication will wear a medication safety vest. On the back of the vest, the sentance Do not disturb me. I am preparing medications is written to inform others professional, patients and visitors. A informational flyer will be put in the units to inform patients and visitors about the intervention."
224199543|NCT02181075|DRUG|ThermoDox® (LTLD)|ThermoDox® (LTLD) infusion at a dose of 50mg/m2 whilst under general anaesthetic during intervention (Day 1)
224199544|NCT02181075|DEVICE|Focused Ultrasound of Target Liver Tumour|Whilst the ThermoDox® was circulating in the blood stream, the JC200 Therapeutic Ultrasound device was used to induce mild hyperthermia in a single (region of) a target liver tumour.
223600242|NCT04471324|DEVICE|EBUS cryo probe|patients receive a transbronchial cryo biopsy with the EBUS cryo probe from ERBE and an ultra thin bronchoskope
223600243|NCT04807257|COMBINATION_PRODUCT|Auger Molecular Therapy (AMT)|The AMT consists of intratumorally delivered IUdR and local irradiation via AUTRON Therapy System.
223600244|NCT03565237|BIOLOGICAL|RIXUBIS: On-Demand|RIXUBIS used under standard clinical practice in India: On-Demand treatment.
223749021|NCT07180134|BEHAVIORAL|symptom management health informatics plus Resistance band exercise training|"Access to educational videos and an instant messaging platform for real-time communication, delivered over 12 weeks.~plus Structured resistance band exercise, 3 times per week, \~30 minutes per session, for 12 weeks under research team guidance."
224199545|NCT02181075|DIAGNOSTIC_TEST|Pre-LTLD Biopsy of Target Liver Tumour|
224199546|NCT02181075|DIAGNOSTIC_TEST|Post-LTLD Biopsy of Target Liver Tumour|
224199547|NCT02181075|DIAGNOSTIC_TEST|Post-LTLD+FUS (Post-FUS) Biopsy of Target Liver Tumour|
224199548|NCT02181075|DEVICE|Thermometry of Target Tumour|A clinically approved thermistor or thermocouple was placed in the target liver tumour for real-time thermometry.
224199549|NCT02825875|DRUG|18F DCFPyL- Radiopharmaceutica|
224199550|NCT02246205|PROCEDURE|Pancreaticoduodenectomy|Pancreaticoduodenectomy is the classical operative technique to resect cephalic pancreatic cancer. In a first phase of the surgery, the resection may be performed. In the second phase, the digestive tract must be restored. We planify two different reconstruction techniques.
224199551|NCT01443676|DRUG|Bevacizumab|Bevacizumab will be added to radiotherapy
224199552|NCT01443676|RADIATION|Radiation therapy|Radiation therapy
224199553|NCT03705221|BEHAVIORAL|Healthy Parent Carers group programme|Peer-led group-based weekly programme.
224199554|NCT03705221|BEHAVIORAL|Healthy Parent Carers online resources|Online resources related to health and wellbeing
224199555|NCT04150107|DRUG|ORMD-0801 Treatment A|Treatment A: 24 mg (16 mg capsule + 8 mg capsule) Once Daily (QD) at bedtime
223600245|NCT03565237|BIOLOGICAL|RIXUBIS: Prophylaxis|RIXUBIS used under standard clinical practice in India: Prophylaxis treatment.
223600246|NCT02467842|BIOLOGICAL|NBP607-QIV|Quadrivalent Inactivated Cell Culture-derived Influenza Vaccine containing 4 virus strains; A/H1N1, A/H3N2, B/Yamagata, B/Victoria
223600247|NCT02467842|BIOLOGICAL|NBP607-Y|Trivalent Inactivated Cell Culture-derived Influenza Vaccine containing 3 virus strains; A/H1N1, A/H3N2, B/Yamagata
223600248|NCT02467842|BIOLOGICAL|NBP607-V|Trivalent Inactivated Cell Culture-derived Influenza Vaccine containing 3 virus strains; A/H1N1, A/H3N2, B/Victoria
223600249|NCT04506333|DEVICE|A&D UA-651 Blood Pressure Monitor|Test device to be validated.
223600250|NCT04506333|DEVICE|ADC 740-N Manual Sphygmomanometer|Reference device. Meets or exceeds ANSI/AAMI/ISO 81060-1 as required by ISO/ESH/AAMI standards.
223600251|NCT01297582|DRUG|ONO-6950|1mg, 3mg, 10mg, 30mg,100mg,300mg,1000mg at a single dose; 30mg, 100mg and 300mg for food effect study
223749022|NCT07180134|BEHAVIORAL|Usual Care Group|Standard postoperative nursing care and education routinely provided by the clinical team. No additional interventions will be given.
224199556|NCT04150107|DRUG|ORMD-0801 Treatment B|Treatment B: 8 mg (8 mg capsule) three times a day (TID) 45-90 minutes before meals
224199557|NCT04150107|OTHER|Placebo|Fish oil capsule
224199558|NCT01786837|DEVICE|Functional Magnetic Stimulation|20 minute stimulation will be applied 5 days a week for 5 weeks
223600252|NCT01297582|DRUG|ONO-6950|1mg, 3mg, 10mg, 30mg, 100mg, 300mg, 1000mg at a single dose; 30mg, 100mg and 300mg for food effect study
223600253|NCT01140061|DRUG|MK-0873 Patch|MK-0873 skin patches containing 0.05%. 0.5%, or 2% MK-0873
223600254|NCT01140061|DRUG|MK-0873 Cream|MK-0873 cream containing 0.05%, 0.5%, or 2% MK-0873
224199559|NCT01723371|DRUG|Carvedilol|Carvedilol will be administered orally. The initial dose of carvedilol will be 0.05mg/kg/day divided into 2 doses. After two weeks, at subsequent weekly study visits, the dose of carvedilol will be increased incrementally to 0.1mg/kg in Week 2, 0.2mg/kg in Week 3, 0.4mg/kg in Week 4, 0.6mg/kg in Week 5, and 0.8mg/kg in Week 6, when the target dose of 0.8mg/kg/day (if weight is less than 62.5kg) or 50mg/day (if weight is greater than 62.5kg) is achieved. This dosage, assuming no adverse effects, will be maintained between Weeks 6 and 30 of the study. After the maintenance period from Week 6 to 30, patients will be weaned over 5 to 7 days or continued on a non-study drug supply.
224199560|NCT01412294|DRUG|Capecitabine, Cisplatin|"Drug: Capecitabine Capecitabine will be administered at 1,000 mg/m2 orally, twice daily (2,000 mg/m2 total daily dose) on Days 1 through 14 of each 21-day treatment cycle.~Drug: Cisplatin Cisplatin will be administered at 80 mg/m2 by intravenous infusion on Day 1 of each 21-day treatment cycle."
224199561|NCT01013402|DRUG|Human insulin|The test was performed in the morning after an overnight fasting and the patients remained supine during the procedure. Two intravenous lines in both arms were established before the procedure. Venous blood was obtained for serum glucose before regular insulin (0.1 U/kg ) is injected and 30 and 45 minutes thereafter. If adequate hypoglycemia was not achieved at this period, a second dose of regular insulin (0.05U/kg) was injected intravenously. In subjects who had not reached the aimed hypoglycemia levels, the test was performed in another day with a higher initial insulin dosage (0.2U/kg).
224311260|NCT05145686|DIAGNOSTIC_TEST|Matris metalloproteinase -2, -8, -9 expressions|. The aims of this in vivo study was to compare the expression levels of MMP-2, -8 and -9 in primary molars with reversible and irreversible pulpitis and to compare the clinically and radiographically success of MTA and Biodentine materials at the end of 18 months.
224311261|NCT02497651|DIETARY_SUPPLEMENT|Liquid mixed meal|The subjects will ingest a 400 ml chocolate drink, rich on carbohydrates, fat and lipids. In the following 4 hours, blood samples will be drawn from a PVC for the measurement of plasma glucose, gut- and pancreatic hormones, acetaminophen etc. After the 4 hours, the subjects will be offered an ad libitum meal.
223600255|NCT01140061|DRUG|Placebo Patch|Placebo patches matching MK-0873 0.05%, 0.5%, or 2% patches
223600256|NCT01140061|DRUG|Placebo Cream|Placebo cream matching MK-0873 0.05%, 0.5%, or 2%
223600257|NCT01140061|DRUG|Plain patch|Plain patch containing no MK-0873 or placebo
223600258|NCT01401608|DEVICE|RF Ablation|Ablation of arrhythmogenic ventricular tissue
223600259|NCT02816229|DEVICE|Insertion of endobronchial valve|One or more endobronchial one- way valves will be inserted into the appropriate lung regions
223600260|NCT01303926|DRUG|cisplatin pemetrexed|Cisplatin 75 mg / m2 d1 with Pemetrexed 500 mg / m2 d1 every 3 weeks for 6 cycles followed (in responding or stable patients) by Pemetrexed 500 mg / m2 every 3 weeks, until progression or unacceptable toxicity
223600261|NCT01303926|DRUG|carboplatin paclitaxel bevacizumab|Carboplatin AUC 6 d1 plus Paclitaxel 200 mg/m2 d1 and Bevacizumab 15 mg/kg every 3 weeks for 6 cycles followed in stable or responding patients by Bevacizumab 15 mg/kg every 3 weeks, until progression or unacceptable toxicity
223600262|NCT05717023|BEHAVIORAL|Online guided self-help intervention for sexual distress following sexual assault|4 Sessions of guided self-help will be shared with the participants. These will be in the form of handout and video recordings that participant access through Qualtrics. The intervention is based on research on sexual trauma, psychosexual difficulties and materials developed by Bart's NHS Foundation Trust Sexual Wellbeing Service. It has been made in collaboration with clinicians within the service, experts by experience and the chief investigator.Within the document there are scripts for each session which are read out in the video recordings. The handouts depict the visual images for the video and the materials provided to participant.
223600263|NCT06137651|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
223600264|NCT06137651|PROCEDURE|Computed Tomography|Undergo CT scan
223600265|NCT06137651|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223600266|NCT06137651|RADIATION|Radiation Therapy|Undergo radiation therapy
223600267|NCT06137651|PROCEDURE|Resection|Undergo surgery
223600268|NCT06137651|DRUG|Trotabresib|Given PO
223600269|NCT06137651|DRUG|Vinorelbine|Given IV
223600270|NCT00336414|DRUG|cyclophosphamide-prednisone-azathioprine|
223600271|NCT06514833|BEHAVIORAL|lifestyle recommendations to nap regularly|Participants will receive lifestyle recommendations to nap regularly for 15-30 minutes between 12:00 and 15:00
223600272|NCT06514833|OTHER|No recommendations to nap regularly|No lifestyle recommendations to nap regularly
223600273|NCT03057652|DEVICE|ReWalk|"ReWalk is a type of wearable robotic exoskeleton (WRE). Subjects will be randomly assigned the order of participation in the exoskeleton devices.~ReWalk training sessions will be scheduled for one hour to include don/doff of device, sit to stand, standing balance and walking. ReWalk phase will require 2 hours pre and 2 hours post training for outcome measurement assessments, plus a minimum of 5 training sessions, with the possibility of up to 15 training sessions to reach a minimal assistance level. The total time commitment for each subject will range from 14-20 weeks and cover 27-72 hours."
223600274|NCT03057652|DEVICE|EKSO|"EKSO is a type of wearable robotic exoskeleton (WRE). Subjects will be randomly assigned the order of participation in the exoskeleton devices.~EKSO training sessions will be scheduled for one hour to include don/doff of device, sit to stand, standing balance and walking. EKSO phase will require 2 hours pre and 2 hours post training for outcome measurement assessments, plus a minimum of 5 training sessions, with the possibility of up to 15 training sessions to reach a minimal assistance level. The total time commitment for each subject will range from 14-20 weeks and cover 27-72 hours."
223600275|NCT03057652|DEVICE|REX|"REX is a type of wearable robotic exoskeleton (WRE). Subjects will be randomly assigned the order of participation in the exoskeleton devices.~REX training sessions will be scheduled for one hour to include don/doff of device, sit to stand, standing balance and walking. REX phase will require 2 hours pre and 2 hours post training for outcome measurement assessments, plus a minimum of 5 training sessions, with the possibility of up to 15 training sessions to reach a minimal assistance level. The total time commitment for each subject will range from 14-20 weeks and cover 27-72 hours."
223600276|NCT02425514|DEVICE|Cervios ChronOs|The ACDF surgery will be carried out with Cervios ChronOs after randomization procedure.
223600277|NCT02425514|DEVICE|NovoMax™|The ACDF surgery will be carried out with NovoMax™ after randomization procedure.
223600278|NCT05191108|BEHAVIORAL|mindfulness stres reduction programe|Complaints about PMS and sharing information about these complaints, Practice of breathing focused meditation, mplementation of mindful eating exercises,Raising awareness in daily activities,Teaching the body scanning exercise and repeating this practice during the week with the audio recordings given.Ensuring environmental awareness Ensuring that you live by being aware of the moments experienced during the week, 20 minutes of sitting breathing focused sitting meditation Coping with stress Sharing the experiences of the previous week Implementation of mindful vision practices Explaining the relationship between stress and experienced events.Eating exercises Mindful breathing Ensuring environmental awareness Explaining the importance of thinking about the relationship between stress and their reactions and accepting them without judgment, and sharing the experiences at the end of the day of silence.
223600279|NCT02464514|OTHER|High carbohydrate meal|65% carbohydrate, 17% protein, and 18% fat
223600280|NCT02464514|OTHER|High fat meal|58% fat, 17% protein, and 25% carbohydrate
223600281|NCT06507826|BEHAVIORAL|Self-Compassionate Writing for Caregivers of Older Adults|Self-compassionate writing focusing on one or more self-compassion components (mindfulness, self-kindness, common humanity).
223600282|NCT02708355|DRUG|Esomeprazole 20 mg|Esomeprazole 20 mg banded capsules (22.3 mg esomeprazole magnesium trihydrate)
223600283|NCT02708355|DRUG|Placebo|Placebo capsules
223600284|NCT02669121|BIOLOGICAL|NoV Placebo-matching Saline|NoV placebo-matching saline (0.9% sodium chloride).
223600285|NCT02669121|BIOLOGICAL|NoV GI.1/GII.4 Bivalent VLP Vaccine|NoV bivalent VLP vaccine, adjuvanted with 500 µg aluminum as Al(OH)3.
223600286|NCT03216746|BEHAVIORAL|Oral orientation and App for smartphone|66 adolescents aged between 14 and 19 years. Participants enrolled in this group received standardized oral guidance performed by one of the previously trained researchers and included aspects of general and oral health and, in particular, of periodontal diseases. This intervention was carried out in a classroom, in a group with approximately 20 participants, providing an environment of discussions about the subjects covered. The duration was approximately 15 minutes. The participants also received an App for smartphone containing messages of reinforcement in oral health which was sent during a period of 30 days.
223600287|NCT03216746|BEHAVIORAL|Oral orientation|71 adolescents aged between 14 and 19 years. Participants enrolled in this group received standardized oral guidance performed by one of the previously trained researchers and included aspects of general and oral health and, in particular, of periodontal diseases. This intervention was carried out in a classroom, in a group with approximately 20 participants, providing an environment of discussions about the subjects covered. The duration was approximately 15 minutes.
223600288|NCT03216746|BEHAVIORAL|Video orientation and App for smartphone|63 adolescentes aged between 14 and 19 years. Participants enrolled in this group received oral health information through an audiovisual material produced especially to this research to offer a teaching medium capable of arousing the attention of its audience. The elaboration counted with the participation of three actors, two acting as adolescents and the third as a dental surgeon. The video had a total duration of 14 minutes. The participants also received an App for smartphone containing messages of reinforcement in oral health which was sent during a period of 30 days.
223600289|NCT03216746|BEHAVIORAL|Video orientation|63 adolescentes aged between 14 and 19 years. Participants enrolled in this group received oral health information through an audiovisual material produced especially to this research to offer a teaching medium capable of arousing the attention of its audience. The elaboration counted with the participation of three actors, two acting as adolescents and the third as a dental surgeon. The video had a total duration of 14 minutes.
223600290|NCT04384523|DRUG|OsrHSA 20 mg/kg IV|A single dose of OsrHSA 20 mg/kg IV infusion at a rate lower than 2 ml/min
223600291|NCT04384523|DRUG|OsrHSA 40 mg/kg IV|A single dose of OsrHSA 40 mg/kg IV infusion at a rate lower than 2 ml/min
223600292|NCT04384523|DRUG|OsrHSA 80 mg/kg IV|A single dose of OsrHSA 80 mg/kg IV infusion at a rate lower than 2 ml/min
223600293|NCT04384523|DRUG|OsrHSA 140 mg/kg IV|A single dose of OsrHSA 140 mg/kg IV infusion at a rate lower than 2 ml/min
223749023|NCT01698463|OTHER|Identification of patients at risk, tailored exercise prescription, motivational interviewing, review of behavioural outcomes|"The intervention was delivered in two visits and two follow-up phone calls.~* Physician identifies that the patient is at risk of falls or fractures~* Visit one: individualized exercise prescription by a physiotherapist.~* Visit two: motivational interviewing (behavioural counselling) by kinesiologist~* Phone call 1 and 2: Kinesiologist reviews behavioural components (action planning, coping planning, coping self-efficacy, intentions."
224199562|NCT01013402|DRUG|Human Insulin|0.1U/kg IV pulse.
223600294|NCT04384523|DRUG|OsrHSA 200 mg/kg IV|A single dose of OsrHSA 200 mg/kg IV infusion at a rate lower than 2 ml/min
223600295|NCT04384523|OTHER|Placebo|Normal Saline (0.9% Sodium Chloride)
223600296|NCT00565123|DRUG|0.5% levofloxacin eye drops|0.5% levofloxacin eye drops three times daily to each eye for 5 days
223600297|NCT00565123|DRUG|0.5% levofloxacin eye drops|0.5% levofloxacin eye drops 2 hours on days 1 and 2, and then every 4 hours on days 3-5 (up to 4 times per day)
223600298|NCT02782221|DRUG|Growth Hormone|Subjects are receiving one injection of growth hormone (Genotropin) 0,5 mg
223600299|NCT02782221|DRUG|Pegisomant|One the placebo day the subjects are receiving injection with pegvisomant (Somavert 30 mg) to block the action of endogenous growth hormone
223600300|NCT02629003|DRUG|[11C]Cimbi-36|
223600301|NCT02629003|DRUG|[11C]Cimbi-36-5|
223600302|NCT06524323|DRUG|5-fluorouracil Injection|The mixture contains 2mL of triamcinolone acetonide injection and 4mL of 5-fluorouracil injection, which is diluted with saline to 10mL.
223600303|NCT06524323|DRUG|Triamcinolone Acetonide|The mixture contains 2mL of triamcinolone acetonide injection which is diluted with saline to 10mL.
223600304|NCT02113332|DRUG|Liraglutide|
223600305|NCT02113332|DRUG|Placebo|
223600306|NCT01440205|BEHAVIORAL|Easy list of healthy habits|"The recipient will be prompted to check off yes or no to healthy habits that most people will find fairly easy."
223600307|NCT01440205|BEHAVIORAL|Challenging list of healthy habits|"The recipient will be prompted to check off yes or no to healthy habits that most people will find fairly difficult."
223600308|NCT01440205|BEHAVIORAL|Control|No check box element
223600309|NCT06526065|OTHER|no intervention|no intervention
223600310|NCT00461279|BEHAVIORAL|Cognitive Behavior Therapy|Reframing and understanding cognitions of depression
223600311|NCT00461279|BEHAVIORAL|Interpersonal Psychotherapy|Established psychotherapy for depression
223600312|NCT05411939|OTHER|Shared Decision-Making Tool|The Shared Decision-Making Tool (SDMT) is designed to provide a personalized, patient- centered framework for clinical discussions regarding treatment options for knee osteoarthritis. The tool functions through patient input of information such as pain severity and current symptoms, alongside other demographic information such as age, race, and comorbidities, to offer a series of outcomes to better illustrate how the patient's specific disease presentation will progress. Ultimately, using the SDMT may impact patient behavior if patients change their treatment preferences after utilizing the tool. This can empower them to seek additional support over time and maintain communication with their orthopedist to ensure they are on a healthier path.
223600313|NCT05411939|OTHER|Video|Short video that describes knee osteoarthritis and possible treatment options.
223600314|NCT05411939|OTHER|Standard of Care|Standard of care counseling for a patient presenting with knee osteoarthritis.
223600315|NCT03846284|DRUG|Bupivacaine|caudal block with bupivacaine 0.25% 1mg/kg diluted in 10 cm saline.
223600316|NCT03846284|DRUG|Magnesium sulfate 50mg|caudal block with bupivacaine 0.25% 1mg/kg plus Magnesium sulfate 50 mg diluted in 10 cm saline.
223749024|NCT05833165|BEHAVIORAL|Feasibility of a supportive approach|Evaluating reasons for patients to use the approach
223600317|NCT03846284|DRUG|Magnesium sulfate 30 mg|"caudal block with bupivacaine 0.25% 1mg/kg diluted in 10 cm saline.~\+ I.V injection of Magnesium sulfate 30mg/kg diluted in 10 cm saline over 10 mins then, fol I.V infusion one ampule of Magnesium sulfate 500mg diluted in 50 cm saline with rate 10 mg/kg/h."
223600318|NCT00665548|RADIATION|X-ray; magnetic resonance imaging|"Knee x-rays: acquired in both a standard or weight-bearing position and in non-weight-bearing position to measure joint space width and look at signs of osteoarthritis.~3 Tesla MRI: magnetic resonance imaging of the study knee during weight-bearing conditions and traditional non-loaded condition all acquired with the same sequences."
223600319|NCT05526287|OTHER|Dual-Task Training|"Dual-task training sessions include; walking on treadmill for 10-30 minutes and half of this walking period participants will perform cognitive tasks, cognitive tasks will be repeated on tandem stance position and single leg stance position other half of the session consists of motor-motor dual task activities and gait training on firm and soft surfaces.~Home exercise program includes lower extremity, core stability and balance exercises and will be performed three times a week."
223600320|NCT05526287|OTHER|Home Exercise Program|Home exercise program includes lower extremity, core stability and balance exercises and will be performed three times a week.
223749025|NCT04709575|DRUG|REGN5713|Administered subcutaneously
223749026|NCT04709575|DRUG|REGN5714|Administered subcutaneously
223600321|NCT03515564|BEHAVIORAL|Dance/Movement Therapy, Art Therapy, Mindful Yoga|Utilizing deep breathing, exercise modalities, and social support in all settings
223749027|NCT04709575|DRUG|REGN5715|Administered subcutaneously
223749028|NCT04709575|DRUG|Placebo|Placebo that replaces REGN5713-5714-5715
223749029|NCT05904665|DIAGNOSTIC_TEST|ctDNA methylation dynamic monitoring|ctDNA methylation detection is performed within one month before surgery, within one month after surgery, and every three months after surgery, for a period of 2 years.
223749030|NCT04928326|DIAGNOSTIC_TEST|CorWatch|Non-invasive wearable monitor for the assessment of central venous pressure
223749031|NCT06051942|DEVICE|Robotic Waterjet Treatment|The Aquablation therapy is a minimally invasive, image-guided, heat-free robotic therapy delivered by the AQUABEAM Robotic System. During Aquablation therapy, the AQUABEAM Handpiece is inserted transurethrally into the prostatic urethra. The operating physician then utilizes cystoscopy in conjunction with transrectal ultrasound (TRUS) imaging for real time visualization. The AQUABEAM Robotic System utilizes high-velocity sterile saline waterjet to resect and remove the prostate tissue according to the operating physician's treatment plan.
223600322|NCT04202887|DRUG|Low Dose Fentanyl|10ml bolus: bupivacaine 0.1% + 25mcg fentanyl, followed by a solution of bupivacaine 0.083% + fentanyl 1mcg/ml
223749032|NCT01882127|DRUG|All-Trans Retinoid Acid(ATRA)|patients in ATRA\&High dose-DEX group take All-Trans Retinoic Acid(orally,10mg every 8 hours a day for 12 consecutive weeks) in combination with dexamethasone(intravenously , 40mg/d for 4 consecutive days).
223600323|NCT04202887|DRUG|High Dose Fentanyl|10ml bolus: bupivacaine 0.1% + 100mcg fentanyl, followed by a solution of bupivacaine 0.083% + fentanyl 2mcg/ml
223749033|NCT01882127|DRUG|Dexamethasone|Patients in High dose-DEX treatment group take dexamethasone( orally , 40mg daily for 4 days),patients in ATRA\&High dose-DEX group take All-Trans Retinoic Acid(orally,10mg every 8 hours a day for 12 consecutive weeks) in combination with dexamethasone(intravenously , 40mg/d for 4 consecutive days).
223749034|NCT01935765|OTHER|Polysomnography|Diabetes people: Examination diagnosis of the sleep apnea A night at the hospital
223749035|NCT01935765|OTHER|Evaluation of the autonomous nervous system|blood pressure, Heart frequence, deep breath, Orthostatism, Vasalva, Low blood pressure orthostatic
223749036|NCT01935765|OTHER|Clinical examination of the sleep|Functional signs, collection of medical histories and associated pathologies, Pittsburgh Sleep Quality Index PSQI, Functional Outcomes of Sleep Questionnaire FOSQ, Epworth Sleepiness Scale ESS, Hospital Anxiety and Depression scale HAD
223749037|NCT01935765|OTHER|Clinical examination of diabetology|history of diabet, observance, ophthalmological, renal, macroangiopathic and neuronal complications, Toronto scale, Diabetes Quality of Life (DQOL) Questionnaire
223749038|NCT01935765|OTHER|Biological dosages|Hematology, glycemia, lipids, CRP, creatinine, ferritin, glycosylated hemoglobin, transaminase, microalbuminuria, urine test
223749039|NCT01935765|OTHER|Electrocardiogram (ECG)|Electrocardiogram (ECG)
223749040|NCT01935765|OTHER|Carotid echography|Carotid echography
223749041|NCT01935765|OTHER|Blood pressure|Blood pressure
224199563|NCT00346970|DRUG|Extended-Release Niacin|Extended-Release Niacin tablets week 1-4 500 mg/d week 4-8 1000 mg/d week 9-12 1500 mg/d
224199564|NCT00346970|DRUG|Placebo|Placebo tablets
224199565|NCT01529697|BEHAVIORAL|Active Feedback|The inhaler will be fitted with a device that makes an audio recording of the inhaler use. This audio data will be downloaded to a computer program, analyzed for assessment of whether the steps involved in using the inhaler have been performed correctly. This information will be discussed with the patient.
224199566|NCT04507646|OTHER|True auricular acupuncture|The participant in experimental group will receive acupuncture on ear Shenmen point, ear zero point, and Salivary glands.
223600324|NCT04202887|DEVICE|Gastric Ultrasonography|"The Gastric US will be performed using a portable device with an abdominal probe by the same operator (EF) for all women. The Cross Sectional Area (CSA) of the antrum will be measured in the supine position with the head elevated 45 degrees. CSA will be calculated using the formula (AP x CC x pi)/4, where AC is the anterio-posterior diameter and CC the cranio-caudal diameter. Three consecutive measurements will be performed and the average of the three will be used as the final data. The cutoff used to define a full stomach will be a CSA above 381 mm2, which has been validated in previous studies on laboring woman. Gastric US will be performed immediately after verification of effective epidural analgesia (T0) and intrapartum, two hours after the first measurement (T2h), corresponding to a cumulative dose of 37-97mcg fentanyl in Group LF and 124-240mcg fentanyl in Group HF."
223600325|NCT05188131|DRUG|Intravenous Infusion of Diclofenac Sodium|Intravenous Infusion of Diclofenac Sodium is administered at the dose of 75 mg, diluted in 100 ml of isotonic saline, over 15 minutes.
223600326|NCT05188131|DRUG|Intravenous Infusion of Placebo|Intravenous Infusion of Placebo (represented by 100 ml of isotonic saline) is administered over 15 minutes.
223600327|NCT05439538|DIAGNOSTIC_TEST|SERUM NGAL|Study the sensitivity and the specificity of serum NGAL to detect AKI in myeloma
223600328|NCT05681494|PROCEDURE|Root canal treatment|after access cavity preparation, the working length will be determined. chemo-mechanical preparation will be done, and teeth will be obturated. final restoration will be placed.
223600329|NCT05681494|PROCEDURE|Vital pulp therapy|exposed pulp will be capped with 3 mm calcium silicate material
223600330|NCT03191045|DIAGNOSTIC_TEST|MRI and concomitant perfused manometry of bowel motility|We will carry out serial cine MRI of the bowel. At the same time we will record perfused manometry readings of the bowel in healthy adult participants.
223600331|NCT01340573|DRUG|PegIntron Pen|Peginterferon alfa-2b, 1.5 microgram/kg each week, administered subcutaneously.
223600332|NCT01340573|DRUG|Ribavirin|Dose is based on body weight. Each tablet of ribavirin is 200mg, and given by oral administration. Participants with body weight of \<65 kg were administered 800 mg of ribavirin daily, body weight of 65 kg-85 kg received 1000 mg daily, and participants with a body weight of \>85 kg received 1200 mg of ribavirin daily.
223600333|NCT06468670|DRUG|sintilimab，programmed death 1 monoclonal antibody|"short-course radiotherapy~+sintilimab (200mg, iv, D1, Q3W)"
223600334|NCT05836467|PROCEDURE|Valvular interventions|Any kind of intervention on heart valves
223600335|NCT01794676|GENETIC|Blood draw|Blood draw
223600336|NCT04405076|BIOLOGICAL|Biological: mRNA-1273|Sterile liquid for injection
223600337|NCT04405076|BIOLOGICAL|Placebo|0.9% sodium chloride (normal saline) injection
224199567|NCT04507646|OTHER|sham auricular acupuncture|The participant in control group will receive acupuncture on ineffective point at ear.
224199568|NCT03306875|BEHAVIORAL|Cognitive Training|Individuals will take part in a computer-based cognitive training program. The program is aimed at building attention, processing speed, memory, and executive function.
223600338|NCT04405076|BIOLOGICAL|mRNA-1273.351|Sterile liquid for injection
223600339|NCT01153360|DRUG|liothyronine sodium|liothyronine sodium 20ug, every 12hour (before anesthetic induction, total 4 times)
223600340|NCT01153360|DRUG|placebo|vitamin B12
223600341|NCT06315127|DIETARY_SUPPLEMENT|Human donor milk|The intervention will involve providing donor milk as required as a supplement to parent milk and will last for the duration of the infant's initial hospitalization. The intervention will continue throughout the hospitalization at any time that supplementation is recommended by the clinical team, and is expected to last from 0 to 72 hours post-birth. All donor milk will be aliquoted into individualized syringes in the Rogers Hixon Ontario Human Milk Bank which is located in Sinai Health. The decision regarding the timing and duration of the supplementation will be determined by the medical team in the well-baby unit based on the specific needs and circumstances of each mother-infant dyad. As this study follows a pragmatic approach, the clinical team will assess the need for supplementation based on the mother-infant dyad's condition.
223600342|NCT06315127|DIETARY_SUPPLEMENT|Formula|The intervention will involve providing formula as required as a supplement to parent milk and as a standard of care, and will last for the duration of the infant's initial hospitalization. The intervention will continue throughout the hospitalization at any time that supplementation is recommended by the clinical team, and is expected to last from 0 to 72 hours post-birth. The formula will be supplied from the hospital's inventory in accordance with the standard procedure followed by the well-baby unit to supplement infants. The decision regarding the timing and duration of the supplementation will be determined by the medical team in the well-baby unit based on the specific needs and circumstances of each mother-infant dyad.
223600343|NCT04941846|DRUG|nimodipine and euvolemia|administered nimodipine to prevent vasospasm, and euvolemia was maintained via intravenous hydration
223600344|NCT02661867|BEHAVIORAL|delivery|delivery either vaginal or by cesarean section
224199569|NCT00320073|DRUG|erlotinib hydrochloride|75 mg to 150mg
224199570|NCT00320073|DRUG|pemetrexed disodium|Pemetrexed is administered intravenously over 10 minutes, every 21 days
224199571|NCT00320073|DRUG|vinflunine|Vinflunine is administered intravenously over 20 minutes and should be given after pemetrexed, every 21 days
224199572|NCT02889627|DRUG|Fecal microbiota suspension|The prepared microbiota suspension was infused into the participates' mid-gut or lower gut.
224311262|NCT02497651|OTHER|Skin Biopsy|All subjects will undergo a skin biopsy procedure. Two small (3 mm) biopsies will be taken from the hip area under local anaesthesia. Standard wound treatment will follow.
223600345|NCT00492336|DRUG|rasagiline (Pharmacodynamics)|Rasagiline 1 mg/day for 12 weeks
223600346|NCT00492336|DRUG|Placebo|Placebo 1 tablet each day
224199573|NCT04190056|BIOLOGICAL|Pembrolizumab|Given IV
224199574|NCT04190056|DRUG|Tamoxifen|Given PO
224199575|NCT04190056|DRUG|Vorinostat|Given PO
224199576|NCT03107442|BEHAVIORAL|Aerobic exercise|12-weeks aerobic exercise intervention based on the physical activity guidelines from the American College of Sports Medicine (≥150 min/week of moderate to vigorous \[40-85% of the individual's heart rate reserve\] exercise). Participants will perform the exercise on treadmills at the hospital. The volume and intensity of the exercise will progressively increase throughout the 12 weeks.
224311263|NCT04571151|DRUG|LEXETTE 0.05% Topical Foam|Halobetasol Propionate Topical Foam (Lexette Foam) would be applied over the affected area twice daily for 2 weeks.
224199577|NCT06333431|DEVICE|Glass Waterfall group|Except for the preparation the gastroscopy procedure takes approximately 20 minutes, patients will be asked to focus on portative glass waterfall during the procedure.
223600347|NCT00500955|DRUG|Rosiglitazone|
223600348|NCT00392990|DRUG|Regimen A|Cyclophosphamide (800 mg/m2 IV over 1 hour)+ vincristine (1.5 mg/m2 IV PUSH)+ doxorubicin (40 mg/m2 IV)+ high-dose methotrexate (2,700 mg/m2 IV over 23 hours)+ rituximab (500 mg/m2 IV)(R-CODOX-M) regimen
224199578|NCT06333431|DEVICE|white noise group|Except for the preparation of the patient for the procedure, since the gastroscopy procedure takes approximately 20 minutes, 20-minute white noise be listened using phone
223600349|NCT00392990|DRUG|Regimen B|Rituximab (500 mg/m2 IV once)+ Ifosfamide (1500 mg/m2 IV daily over 3 hours)+ Etoposide (60 mg/m2 IV daily over 1 hour), and Cytarabine (2 grams/m2 IV over 3 hours for 4 doses)
223600350|NCT02381275|DRUG|Tenofovir Disoproxil Fumarate|Observe long-term outcomes of patients using Tenofovir based antiretroviral therapy at the Lighthouse Clinics
223600351|NCT00241904|BEHAVIORAL|Lifestyle Changes|Nutrition counseling, smoking cessation counseling, medication compliance counseling, exercise
223600352|NCT00241904|DRUG|Antiplatelet Agents|Aspirin 81 mg q day
223600353|NCT00241904|DRUG|Beta Blocker|Oral medication
223600354|NCT00241904|DRUG|ACE Inhibitors|Oral medications, received 1-2 times per day
223600355|NCT03764683|DRUG|Suvorexant (Belsomra)|Suvorexant (Belsomra) is approved by the U.S. Food and Drug Administration (FDA) to treat insomnia. It has not yet been studied in people with bipolar disorder who have problems sleeping.
223600356|NCT03764683|DRUG|Placebo|Subjects will take placebo capsules (containing no active substance) identical in appearance to those containing Suvorexant
223600357|NCT02564224|PROCEDURE|Pursestring Wound Closure|Procedure: Pursestring Wound Closure
223600358|NCT02564224|PROCEDURE|Conventional Wound Closure|Procedure: Conventional Wound Closure
223600359|NCT02564224|DEVICE|prolene|
223600360|NCT01150565|DRUG|LiRIS low dose and LiRIS high dose|Drug delivery system containing lidocaine; LiRIS (low or high dose) is inserted into bladder via cystoscopy on Day 1 and removed via cystoscopy on Day 14. Designed to release lidocaine over a 14 day period.
223600361|NCT02685904|BIOLOGICAL|ENIA11|
223600362|NCT02685904|BIOLOGICAL|Placebo|
223600363|NCT04200144|DEVICE|Endoscopic sleeve gastroplasty|Endoscopic sleeve gastroplasty with Overstitch (Apollo Endosurgery)
223600364|NCT01509911|DRUG|TL-118|TL-118 investigational product is supplied as an oral liquid for daily administration at a specific dosing regimen. Treatment protocol includes weekly therapy cycles.
223600365|NCT01509911|DRUG|Gemcitabine|Monthly cycles of 3 weekly treatments a month and one week off of treatment
223600366|NCT04420403|OTHER|Manual Therapy|Cyriax's mobilization techniques will be applied as manual therapy. Before the mobilization, soft tissue mobilization techniques will be applied to relieve muscular spasm and preventing the patient' s anxiety. Bringing, manual traction, manual traction with rotation, manual traction with anterior-posterior gliding and lateral gliding mobilization techniques will be applied. Appropriate mobility techniques will be selected according to the complaints and symptoms of the patients. Cervical mobilization applications will take an average of 15-20 minutes.
223600367|NCT04420403|OTHER|Cervical Stabilazation Exercise (CSE)|The CSE program aims to maintain a neutral spine position and activate deep cervical muscles during exercises. It is performed in stages with gradual progression according to the stages of motor learning and sensory-motor integration, namely, static, dynamic, and functional. The program will start with postural training and then the cervical bracing technique with the activation of deep neck flexors for CSE was performed. The patients will be asked to maintain a neutral spine during the exercises and throughout the day as much as possible. The difficulty and variety of exercises will be increased weekly. It will be carried out 2 days a week for 6 weeks (12 sessions) by the supervisor physiotherapist.
223600368|NCT02027948|OTHER|nutritional and functional assessments|"Patients will undergo nutritional \& functional assessments along the continuum of their chemoradiotherapy treatment. The initial assessment will be measurements of height, weight, \& baseline weight loss. Patients will receive chemotherapy \& radiation as per standard practice at MSKCC, which is induction chemotherapy for approximately 3 weeks, followed by concurrent chemoradiotherapy. A commonly used regimen is weekly carboplatin (AUC 2) with paclitaxel (50 mg/m2) \& radiation consisting of 5040 cGy over 28 fractions. Patients in this study will undergo assessments at three time points (at baseline, after induction chemotherapy, \& post-treatment.) At baseline, all patients will complete the functional assessment, dysphagia scale, \& Mini- Nutritional Assessment (MNA). According to the baseline MNA score, patients will be categorized as normal nutrition, at risk for malnutrition, or malnourished \& receive the appropriate intervention."
223600369|NCT02122224|OTHER|High fiber breakfast|Breakfast will contain 10-11g fiber.
223600370|NCT02122224|OTHER|High Protein Breakfast|Breakfast will contain 19-20g of protein.
223600371|NCT02122224|OTHER|High Protein/High Fiber Breakfast|Breakfast will include 19-22g of protein and 10-12g of fiber.
223600372|NCT04282525|OTHER|ECMO for hemodynamic or respiratory indication|ECMO for hemodynamic or respiratory indication
223600373|NCT02572765|OTHER|PET/CT scan|PET/CT scan
223600374|NCT01997671|OTHER|Information Support System|Practitioners in the intervention group may have access, whenever they want and through the computerized medical record program, to personalized information on their assigned patients who have started treatment of cardiovascular primary prevention with lipid-lowering. This information is updated monthly for 12 consecutive months.Information will be presented in two different and complementary ways to each practitioner: asynchronous information (the patient is not present when the practitioner receives the information) and synchronous information (the patient is present when the practitioner receives the information).
223600375|NCT03797300|DEVICE|Spry Loop Band|Loop band measures pulse oximetry and respiration rate
223600376|NCT05100446|DRUG|Amoxicillin - high dose dual therapy|Eradication with Amoxicillin 1000mg + 500 mg + 1000mg + 500mg, for 15 days.
223600377|NCT05100446|DRUG|Pylera|Eradication with Pylera, for 10 days.
223600378|NCT05100446|DRUG|Esomeprazole 40mg|Esomeprazole 40mg, twice a day.
224199579|NCT03334227|DEVICE|High-Flow nasal cannula (HFNC)|The patient will receive HFNC adjusted for SatO2 \> 92% and with, at least, 30 liters of total flow.
223600379|NCT01631396|DRUG|Sugammadex vs. Neostigmine|"* Sugammadex Group (n=20) - anesthesia induced by Rocuronium 0.4mg/kg body, additional Rocuronium 0.1-0.2 mg/kg body as needed during surgery (not more than x2), muscular blockage reversal using Sugammadex 2.0 mg/kg body.~* Neostigmine Group (n=20) - anesthesia induced by Rocuronium 0.4mg/kg body, additional Rocuronium 0.1-0.2 mg/kg body as needed during surgery (not more than x2), muscular blockage reversal using Neostigmine 0.05 mg/kg body and atropine 0.1 mg/kg body."
223600380|NCT03075709|OTHER|Clinical Pathway (CPW)|CPWs bring the available evidence to a range of healthcare professionals by adapting guidelines to a local context and detailing the essential steps in the assessment and care of patients.
223600381|NCT03865784|OTHER|Experimental|The intervention through Core exercises will consist in the application of a protocol of four Core stabilization exercises. This protocol will consist of the following exercises: abdominal plate, bilateral plate, hunting dog and gluteal bridge. The intervention by Kinesiotape will be performed with the subject in a sitting position with both arms relaxed throughout the body, while the physiotherapist will place the bases of the strips without tension, on the sacroiliac joint. Once this is done, proceed to ask the subject to lean forward applying the rest of the strip, except the distal edge, with a tension of between 15 and 25%, finally requesting the subject to rejoin straining the distal base without tension, on the twelfth dorsal spinous process.
223600382|NCT03865784|OTHER|Control|The intervention through Core exercises will consist in the application of a protocol of four Core stabilization exercises. The objective of the application of the technique based on this type of exercise is to improve muscle strength, endurance and neuromuscular control. This protocol will consist of the following exercises: abdominal plate, bilateral plate, hunting dog and gluteal bridge. The intervention by Kinesiotape will be performed with the subject in a sitting position with both arms relaxed throughout the body, while the physiotherapist will place the bases of the strips without tension, on the sacroiliac joint. Once this is done the tape will be placed without tension and sn movement of the subject.
223600383|NCT05002491|OTHER|High protein diet|Normal vs high protein dietary feeding
223600384|NCT05229250|OTHER|Cycling test|RAMP and MULTI-STAGE test
223600385|NCT05229250|OTHER|Occlusion tests|Occlusion test before and after exercise
223600386|NCT05229250|DEVICE|NIRS during cycling|NIRS devices measuring oxygenation during exercise
223600387|NCT05229250|DEVICE|CPET|Cardiopulmonary exercise testing (heart rate, pulmonary gas exchange) during exercise
223600388|NCT05229250|DEVICE|Echo-Doppler examination|Peak systolic velocity and vascular stiffness measurements in the iliac-aortic tract
223600389|NCT05244551|DRUG|ABSK061|In the escalation part, patients will receive a single dose of oral ABSK061 on C1D1 only, and then BID dosing for the rest of the days of cycle 1 and in subsequent cycles (28-day cycles). The starting dose is 5 mg BID. In the expansion part, patients will each receive oral ABSK061 at the RDE in repeated 28-day cycles.
223600390|NCT02514148|BEHAVIORAL|Therapeutic patient education|Therapeutic patient education based on pain physiology from a biobehavioral perspective adding a training in coping strategies.
223600391|NCT02514148|OTHER|Therapeutic exercise|Therapeutic exercise consist on stretch of cervical-scapular muscles ( Trapezius and angular of the scapula), Cranium-cervical flexor stabilization exercise, auto cervical tractions, shoulders rotation, low intensity exercise ( walking), craniocervical extension, cervical flexion and extension.
223600392|NCT02514148|OTHER|No intervention|No intervention consist on measure the whole variables in chronic migraine patients to compare it with experimental interventions
223600393|NCT02514148|OTHER|Manual Therapy|Manual therapy consist on ; oscillatory traction , maintained craniocervical traction, upper cervical flexion mobilization, side glide roll, anterior-posterior upper cervical mobilization with wedge, lateral glide at the C1-C2 and C2-C3 levels, retraction technique, trigeminocervical neural mobilization , and upper cervical traction, followed by posterior-anterior glide at C4.
223600394|NCT05144867|RADIATION|Stereotactic Radiosurgery|All patients to undergo planning CT simulation with 1mm slice thickness. For all lesions, the gross tumor volume (GTV) will be defined as the visible tumor on CT and/or MRI imaging. A Planning Target Volume (PTV) margin of 2-5 mm will be added. Organs at risk visible in the planning CT scan will be contoured. The doses will be prescribed to approximately 100% isodose level and 95% of the PTV should receive 95% of the prescription dose. Metastases with a maximum diameter of up to 2 cm will be treated with doses of 22 to 25 Gy and those larger than 2 cm will be treated with doses of 18 to 20 Gy.
223600395|NCT02391519|PROCEDURE|Collection of myometrial, cord blood, and placental tissue samples|We propose to collect myometrial, cord blood, and placental tissue samples from women at high altitude (Summit County) and low altitude (Denver) in Colorado in order to determine if residence at altitude during pregnancy changes the vasoreactivity of myometrial arteries (MA).
223600396|NCT01224743|DIETARY_SUPPLEMENT|Blend 1|Blend 1 consists of a combination of Juice Plus+® Orchard (Fruit), Garden (Vegetable), and Vineyard (Berry) blends
223600397|NCT01224743|DIETARY_SUPPLEMENT|Blend 2|Blend 2 consists of a combination of Juice Plus+® Orchard (Fruit) and Garden (Vegetable) blends
223600398|NCT01224743|DIETARY_SUPPLEMENT|Placebo|Placebo capsules are provided by the study sponsor and are identical in appearance to active treatments to ensure blinding.
223600399|NCT00898833|OTHER|laboratory biomarker analysis|
223600400|NCT02502825|OTHER|methacholine|methacholine (0.03,0.06,0.125,0.5,1.0,2.0,4.0,8.0,16.0 mg/ml),Canada
223600401|NCT02502825|DEVICE|Wright Nebulizer|nebulized for 2 minutes with an output of 0.13ml/min
223600402|NCT02502825|DEVICE|Devilbiss646 Nebulizer|nebulized for 2 minutes with an output of 0.13ml/min
223600403|NCT02913495|DRUG|Vaginal Progesterone|
223600404|NCT02913495|DRUG|Intramuscular Progesterone (17 alpha hydroxprogesterone caproate)|
223600405|NCT03779581|OTHER|Self Correction exercises|Active self-correction exercises to restore movements in different planes as close to physiologically normal as possible.
223600406|NCT03779581|DEVICE|orthotic devices|the orthotic devices designed to correct the scoliosis curve
223600407|NCT02255201|DIETARY_SUPPLEMENT|Master Performance Blend Dose 1|Caffeine content: 200 mg
223600408|NCT02255201|DIETARY_SUPPLEMENT|Master Performance Blend Dose 2|Caffeine content: 400 mg
223600409|NCT02255201|DIETARY_SUPPLEMENT|Performance Energy Blend|Caffeine content: 175 mg
224311264|NCT04571151|DRUG|Sorilux 0.005 % Topical Foam|Calcipotriol Foam (Sorilux Foam) would be applied over the affected area twice daily for 2 weeks 5 minutes after the Lexette application. SORILUX Foam contains calcipotriene 50 mcg/g.
223600410|NCT02255201|DIETARY_SUPPLEMENT|Energy Blend|Caffeine content: 200 mg
223600411|NCT02255201|DIETARY_SUPPLEMENT|Placebo|Caffeine content: 0 mg
223600412|NCT06371521|DIETARY_SUPPLEMENT|Sportlegs|Sportlegs contains lactate (from calcium lactate pentahydrate and magnesium lactate dihydrate), magnesium (from magnesium lactate dihydrate), calcium (from calcium lactate pentahydrate), and vitamin D (as cholecalciferol).
223600413|NCT06371521|DIETARY_SUPPLEMENT|Placebo|Empty Capsules to serve as a placebo control
223600414|NCT04382222|PROCEDURE|prenatal ultrasound|prenatal cardiac ultrasound
223600415|NCT04429698|DIAGNOSTIC_TEST|Point of care ultrasonography|Point-of-care Ultrasonography is an imaging method performed with ultrasound aid to facilitate rapid diagnosis and interventions during emergency intervention.
223600416|NCT02861638|DEVICE|Experimental group|Video of the exercises
223600417|NCT02861638|DEVICE|Control group|video of nature scenes
223600418|NCT02861638|DEVICE|Conventional physiotherapy|Mobilization, exercises and transfer practice.
223600419|NCT02493231|DRUG|Nefopam|
223749042|NCT03806413|OTHER|Open heart surgery|The study will be done on patients undergoing open heart surgery in Alexandria University hospitals from January 5th 2019 till January 4th 2020. The 6-item Cognitive Impairment Test (6CIT) and SPMSQ questionnaire will be used. SPMSQ will be done preoperative and daily for 3 days postoperative, at day 7. Phone call for SPMSQ will be done 3, 6 9 and 12 months after surgery.
224199580|NCT05510739|BEHAVIORAL|Motor-cognitive home exercise supported by eHealth technology|10-week, individualized and progressive exercise program targeting functional strength, cardiovascular fitness and physical activity levels. Cognitive exercises are incorporated with motor exercises as an adjunct to the intervention.
223600420|NCT02493231|DRUG|Ketamine|
223600421|NCT02493231|DRUG|Saline|
223600422|NCT05708339|OTHER|virtually fabricated ear prosthesis|virtually designed ear prosthesis
223600423|NCT05708339|OTHER|conventionally fabricated ear prosthesis|conventionally fabricated ear prosthesis
223600424|NCT05191875|DRUG|Saccharomyces Boulardii 250 MG|"Saccharomyces Boulardii:~0.25 g \* 6, Produced by The French encyclopedia pharmaceutical Factory"
223600425|NCT05191875|DRUG|Ilaprazole.Doxycycline. Furazolidone. Colloidal Bismuth Tartrate|"Ilaprazole:~5mg\*6, produced by Livzon Pharmaceutical Group Inc~Doxycycline:~0.1 g \* 10, produced by Jiangsu Yongxin Ltd.~Furazolidone:~0.1g\*100 produced by Tianjin Lisheng Pharmaceutical Co., LTD~Colloidal Bismuth Tartrate:~55 mg \* 36,produced by Shanxi Xinbaoyuan Pharmaceutical Co., LTD"
223600426|NCT03731247|DEVICE|OCTAV Patient|In vivo skin imaging performed by placing the tip of the OCTAV device directly in slight contact with the skin of the patient.
223600427|NCT03731247|DEVICE|OCTAV Control group|In vivo skin imaging performed by placing the tip of the OCTAV device directly in slight contact with the skin of the patient.
223600428|NCT00058682|DRUG|Anidulafungin|
223600429|NCT03052816|DRUG|Ice T|Ice/Tylenol/Toradol with dilaudid for breakthrough
223600430|NCT03052816|DRUG|Motrin/Percocet/Dilaudid for breakthrough|Standard regimen
223749043|NCT03181399|DRUG|Triheptanoin|. Triheptanoin will be taken 4 times per day (approximately every 6 hours: prior to breakfast, lunch and dinner and a mid-afternoon snack) by mouth. It is dosed 4 times per day, divided evenly.
223749044|NCT05375968|DIAGNOSTIC_TEST|Measurement of Splanchnic venous capacitance(SVC)done at Baseline and after 90 min of 75 g glucose in Healthy Controls POTS patients|While segmental bioimpedance is monitored, continuous positive airway pressure (CPAP) will be applied sequentially at 0, 4, 8, 12, and 16 cm H2O for about 30 seconds each. This positive airway pressure will increase the intrathoracic pressure, which is transmitted to the venous circulation. Pressure (CPAP pressure, X axis) - volume (splanchnic vascular volume measured by segmental impedance and expressed as % change from baseline, Y axis) relationships are then constructed to assess for splanchnic venous capacitance
224199581|NCT05510739|BEHAVIORAL|Individualized home exercise program|Individualised home exercise program leaflet involving one initial instruction session. Written instructions involving dose and exercise progression. No support during the 10 week period.
224199582|NCT02738866|DRUG|Palbociclib|Palbociclib will be given orally, continued at the same dose as was received previously; the maximum starting dose will be per the approved label, a dose of 125 mg once daily. Palbociclib will be taken days 1-21, then seven days off treatment to complete one 28 day cycle.
224199583|NCT02738866|DRUG|Fulvestrant|Fulvestrant 500 mg should be administered intramuscularly into the buttocks slowly (1-2 minutes per injection) as two 5 mL injections, one in each buttock, on days 1, 15, and 29 (i.e., Cycle 2 Day 1) and once monthly thereafter (i.e., day 1 of each cycle).
224199584|NCT00139243|DRUG|Taxotere|
223600431|NCT01533142|PROCEDURE|Bariatric surgery|"Patients will be treated with one of two bariatric procedure::~sleeve gastrectomy or gastric bypass"
223600432|NCT01533142|PROCEDURE|Bariatric surgery|Surgical methods vary between hospitals: Voss: sleeve gastrectomy, Haugesund: gastric bypass (Roux-en Y),SUS: gastric bypass (Roux-en Y); Førde: biliopancreatic diversion with duodenal switch (BPD / DS) and sleeve gastrectomy
223600433|NCT00820417|DRUG|Cetuximab/Gefitinib combination and/or monotherapy|
223600434|NCT00820716|OTHER|Exercise training|Comparison of two methods of exercise training: alternate load versus constant load realized at moderate or high intensities
223600435|NCT00408434|DRUG|CS-7017|CS-7017 0.05mg and 1.0mg tablets
224199585|NCT00139243|DRUG|Cisplatin|
224199586|NCT00139243|DRUG|5-Fluorouracil|
223600436|NCT06049030|DRUG|HS-10516|Oral HIF-2α inhibitor
223600437|NCT03803436|PROCEDURE|Liver transplant|Liver transplant from cadaveric donors
223600438|NCT03803436|DRUG|Chemotherapy|mFOLFOX
223600439|NCT03803436|DRUG|Chemotherapy|Panitumumab
223600440|NCT03743701|DIAGNOSTIC_TEST|The method of transrectal ultrasound in В-mode|A linear transrectal ultrasonic sensor with a frequency of 9 MHz is inserted into the rectum lumen to a depth of 10 cm from the edge of the anus. In real time, the rectal wall and anatomical structures of the anal canal are evaluated using linear sections. The localization of the internal fistula opening, the course of the fistula relative to the fibers of the external sphincter and the presence or absence of cellular and wall plug is determined.
224199587|NCT00139243|DRUG|Leucovorin|
224199588|NCT03929601|DRUG|Rituximab-pvvr|All participants will receive Rituximab-pvvr dosing from Week 1 to Week 4 of the trial. Rituximab-pvvr will be given by IV infusion over at least 3 hours, at a dose of 375mg/m2 on four visits each one week apart.
223600441|NCT03743701|DIAGNOSTIC_TEST|The method of transrectal ultrasound examination using three-dimensional image reconstruction.|A mechanical circular transrectal ultrasonic sensor with a frequency of 13 MHz is inserted into the rectum lumen to a depth of 10 cm from the edge of the anus. Within 30 seconds with a scan interval of 2 mm with a length of 10 cm, a circular recording of the anatomical structures of the rectum, surrounding tissue and anal canal takes place, obtaining an array of images in the form of a cube. The study was completed. After, at a convenient time for the researcher is working with a three-dimensional array of images. The resulting cube can be rotated 360 degrees in a circle of its axis, work with the sagittal, frontal and axial plane. To obtain a more visual representation of the exact localization of the internal fistula orifice, the course of the fistula relative to the fibers of the outer sphincter and to design volumetric cellular and wall plug.
224199589|NCT03929601|DRUG|Abatacept|Participants in the active drug arm will receive initial Abatacept dosing at Week 16 of trial. Abatacept will be given by a subcutaneous (SC) formulation weekly for 20 months, and dosing be will determined according to weight: Up to 25 kg: 50 mg (0.4 mL); 25 to \<50 kg receive 87.5 mg (0.7 mL), and \> 50 kg receive 125 mg (1.0 mL).
224199590|NCT03929601|DRUG|Sterile Sodium Chloride|Participants in the placebo arm will receive initial placebo injection at Week 16 of trial. Saline Placebo will be given by a subcutaneous (SC) formulation weekly for 20 months, and dosing volume be will determined according to weight to match active comparator: Up to 25 kg: 0.4 mL; 25 to \<50 kg receive 0.7 mL and \> 50 kg receive 1.0 mL.
224199591|NCT02775383|OTHER|Therapeutic|Observational Study
224199592|NCT00295919|DRUG|fenretinide lipid matrix|
224199593|NCT00295919|DRUG|ketoconazole|
224199594|NCT00295919|OTHER|laboratory biomarker analysis|
224199595|NCT00295919|OTHER|pharmacological study|
224199596|NCT05349734|OTHER|upper body blanket|applying upper body blanket with forced-air blower set to 43℃
223600442|NCT00681928|DRUG|anastrozole|As determined by the subject's physician
223600443|NCT00681928|DRUG|letrozole|As determined by the subject's physician
223600444|NCT00681928|OTHER|questionnaire administration|For cancer patients prior to starting medication and 6 months after starting medication. For healthy controls, one time administration.
223600445|NCT00681928|PROCEDURE|cognitive assessment|For cancer patients prior to starting medication and 6 months after starting medication. For healthy controls, one time administration.
223600446|NCT00681928|PROCEDURE|psychosocial assessment and care|For cancer patients prior to starting medication and 6 months after starting medication. For healthy controls, one time administration.
223600447|NCT05817032|BEHAVIORAL|Telerehabilitation|Exercise prescriptions will be given based on the result of baseline assessment. The intensity of the exercise prescription and level of monitoring will be tailored to each participant's ability and condition. Exercise will be prescribed by a Physical Medicine and Rehabilitation specialist in accordance with standard rehabilitation protocols. Exercise will consist of aerobic exercise, resistance exercise and breathing exercise. Participants are asked to commit to do at least 36 sessions of exercise. Participants will be allowed to have a hybrid approach (10-12 in person, 24-26 virtual) or fully virtual.
223600448|NCT05817032|BEHAVIORAL|Standard rehabilitation care|Exercise prescriptions will be given based on the result of baseline assessment. The intensity of the exercise prescription and level of monitoring will be tailored to each participant's ability and condition. Exercise will be prescribed by a Physical Medicine and Rehabilitation specialist in accordance with standard rehabilitation protocols. Exercise will consist of aerobic exercise, resistance exercise and breathing exercise. Participants are asked to commit to do at least 36 sessions of exercise. Participants will be allowed to have 10-12 in person exercise.
223600449|NCT04000581|OTHER|Best Practice|Receive standard of care
223600450|NCT04000581|OTHER|Physical Activity|Walk for minimum 30 minutes per day
224199597|NCT05349734|OTHER|full underbody blanket|applying full underbody blanket with forced-air blower set to 43℃
224199598|NCT00900328|OTHER|laboratory biomarker analysis|Correlative Studies
224199599|NCT02184988|BIOLOGICAL|Botulinum purified neurotoxin, Type A|The subject is to be injected intra-muscularly into a total of five sites: the mid-line of the procures muscle, the inferomedial aspect of each corrugator muscle and the superior middle aspect of each corrugator, at least 1 cm above the bony orbital rim. Each site is injected with 0.1 ml (4U), for a total of 20 U and 0.5 ml.
224199600|NCT07005583|DRUG|QL1706 Plus Olaparib|QL1706: 5 mg/kg administered via intravenous (IV) infusion every 3 weeks (Q3W). Olaparib: 300 mg (two 150 mg tablets) taken orally twice daily (BID). Treatment will continue until protocol-defined discontinuation criteria are met, including disease progression, unacceptable toxicity, withdrawal of consent, or death.
224199601|NCT07011602|BEHAVIORAL|8-week Physical Activity and Nutrition Program|Participants will be enrolled in an 8-week (Monday-Friday) daily physical activity program where treatment group participants will receive daily physical activity via organized games and daily lutein (6mg/d) snacks.
224311265|NCT04571151|OTHER|Vehicle Foam|Vehicle Foam would be applied over the affected area twice daily for 6 weeks.
224311266|NCT04731753|DEVICE|mechanical debridement|The mechanical debridement is performed using the debridement pad Cutimed DebriClean. After the pad is moistened with wound-cleansing solution, the wound is cleaned using circular movements while applying gentle pressure.
224311267|NCT06513156|BEHAVIORAL|Integrated Infectious Diseases and Substance Use Disorder Clinic (IC)|Integrated medication for opioid/stimulant use disorder and infectious disease care provided into single appointment either in person or via telemedicine with a minimum of monthly appointments for 6 months.
224311268|NCT02422589|DRUG|ceritinib|
224311269|NCT02422589|DRUG|warfarin|
224311270|NCT02422589|DRUG|midazolam|
224311271|NCT02361294|OTHER|Blood samples|
224311272|NCT05716386|DIETARY_SUPPLEMENT|Low salt diet|Low salt diet less than 2 gram per day
224311273|NCT01135186|DRUG|sapropterin dihydrochloride|sapropterin dihydrochloride: 10mg/kg/day
224311274|NCT05749250|DEVICE|Acoustic cavitation of ultrasound enhancing agents|Cavitation therapy
223600451|NCT04000581|OTHER|Questionnaire Administration|Ancillary studies
223749045|NCT05375968|DIAGNOSTIC_TEST|Measurement of Splanchnic venous capacitance(SVC)done at Baseline and after 90 min of 75 g glucose in Healthy Controls|While segmental bioimpedance is monitored, continuous positive airway pressure (CPAP) will be applied sequentially at 0, 4, 8, 12, and 16 cm H2O for about 30 seconds each. This positive airway pressure will increase the intrathoracic pressure, which is transmitted to the venous circulation. Pressure (CPAP pressure, X axis) - volume (splanchnic vascular volume measured by segmental impedance and expressed as % change from baseline, Y axis) relationships are then constructed to assess for splanchnic venous capacitance
223749046|NCT05375968|DRUG|Compare change is SVC and SMA flow due to GIP antagonist GIP(3-30)NH2|Participants with POTS will be randomize to either saline versus GIP(3-30)NH2 acute infusion. We will measure changes in their splanchnic venous capacitance and superior mesenteric arterial flow before and after a 75-g oral glucose challenge during supine and 45-degree head-up tilt positions (orthostatic challenge) for up to 3 hr. Notably, we will assess changes in venous capacitance using segmental impedance to measure the effect of graded positive airway pressure (CPAP) on splanchnic blood volume.
223749047|NCT05375968|DRUG|Compare change is SVC and SMA flow due to saline|Participants with POTS will be randomize to either saline versus GIP(3-30)NH2 acute infusion. We will measure changes in their splanchnic venous capacitance and superior mesenteric arterial flow before and after a 75-g oral glucose challenge during supine and 45-degree head-up tilt positions (orthostatic challenge) for up to 3 hr. Notably, we will assess changes in venous capacitance using segmental impedance to measure the effect of graded positive airway pressure (CPAP) on splanchnic blood volume.
223749048|NCT06456593|DRUG|Obefazimod|Obefazimod is administered once-daily in fed condition (ideally at the same time in the morning).
223749049|NCT06456593|OTHER|Placebo|Matching placebo will be administered QD in fed condition (ideally at the same time in the morning).
224199602|NCT06627322|DRUG|Dual-combination therapy|Group 1: Metformin/DPP-4i-based or Metformin/SGLT2i-based dual-combination therapy. Any oral antiglycemic drugs on the market.
224199603|NCT06627322|DRUG|Triple-combination therapy|Group 2: Metformin/SGLT2i/DPP-4i-based triple-cobmination therapy, or Group 3: Metformin/SGLT2i/Thiazolidinedione-based triple-cobmination therapy Any oral antiglycemic drugs on the market.
224199604|NCT06627322|DEVICE|Dexcom G7, Pasta|Real-time continous glucose monitoring system (CGMS) Device (sensor): Dexcom G7 Device (software): Kakaohealthcare Pasta Barozen Fit is also available.
224199605|NCT03188991|DRUG|NanoPac®|NanoPac® (Sterile Nanoparticulate Paclitaxel) for intracystic injection via endoscopic ultrasound-guided injection (EUS-FNI)
224199606|NCT06902610|DEVICE|Poppins Clinical|Poppins Clinical is a software as a medical device that combines a musical and combines a musical and cognitive training program and written language training program.
224199607|NCT06898281|PROCEDURE|intracardiac echocardiography (ICE)-guided catheter ablation|Intracardiac echocardiography (ICE)-guided catheter ablation.
224199608|NCT06898281|PROCEDURE|Pressure-sensing catheter ablation alone|Pressure-sensing catheter ablation alone
224199609|NCT06652802|BEHAVIORAL|Nurse-Conducted Brief Intervention (NCBI). supplemented with mobile based application.|"* An interactive mobile based application will be developed with the following features to assist in monitoring and preventing relapse.~* Purpose of the Mobile based application: The mobile application will be an interactive tool designed to assist in monitoring and preventing relapse of alcohol use disorder. It will provide various features to support users in their journey to sobriety, including personalized recovery plans, goal setting, progress tracking, stress and craving management tools, educational resources, daily reflection prompts, emergency assistance, personalized reminders, progress reports, and psychoeducational videos.~* The Target population: 40 Male patients selected through randomized sampling, aged between 18 and 59 years, who have participated in Nurse-Conducted Brief Intervention (NCBI) for AUD in the Gastroenterology ward with diagnosis of alcohol dependence use disorder based on ICD-10 who have access to smartphone application and have the ability to use it."
224199610|NCT06652802|BEHAVIORAL|Nurse-Conducted Brief Intervention (NCBI)|"* Nurse-Conducted Brief Intervention (NCBI) is a feasible and acceptable model of care for males diagnosed with Alcohol Use Disorders (AUDs) in gastroenterology settings. The study found that the Nurse-Conducted Brief Intervention (NCBI) had a positive impact on promoting abstinence in patients with AUDs, and the preliminary findings demonstrate probable good outcomes. \[21\].~* It consists of a trained Nurse delivering three individual sessions with the patient over a span of two to three days (15 to 20 mins each) during their period of admission in the ward and one session with the family members."
223600452|NCT02724709|PROCEDURE|Three-dimensional transoesophageal echocardiography|Three-dimensional transoesophageal echocardiography, analysed by eSie valve software (Siemens)
223600453|NCT02724709|PROCEDURE|Computed tomography|Computed tomography, analysed by Synovia Workstation (Siemens)
223600454|NCT00963794|OTHER|Electromagnetic measurement|RC screening was carried out using a Tissue Resonance InterferoMeter probe electromagnetic detector, which consists of a nonlinear oscillator placed in a cylindrical probe about 30 cm long, a radiofrequency spectrum analyzer, and dedicated computer software. Detection of RC is based on the decrease of the electromagnetic signal compared to the mean signal obtained in healthy subjects. The test was performed while the patient stood 120 cm from the receiver. The operator was on the opposite side of the examined pelvis. The detector was kept at close contact to the pelvis surface and was moved through six planes, to obtain a scan of the whole pelvis volume. Based on our previous study, we used the electromagnetic detection system at 465 MHz frequency, in a scale from 0 to 255 arbitrary U.
224199611|NCT06853626|DIAGNOSTIC_TEST|QuidelOrthos TriageTrue hs-cTnI whole-blood assay|Already described
224199612|NCT06914401|PROCEDURE|NIV (Non Invasive Ventilation) and HFNO (High Flow Nasal Oxygen)|"Combination of two procedures Preoxygenation prior to intubation with NIV (Non Invasive Ventilation) and HFNO (High Flow Nasal Oxygen).~During intubation, NIV is stopped and apneic oxygenation is maintained with HFNO"
223600455|NCT00588354|DRUG|Clonidine|200 or 400 micrograms clonidine
223600456|NCT00588354|DRUG|Triamcinolone hexacetonide|40 or 80 milligrams triamcinolone
223600457|NCT00588354|DRUG|Lidocaine HCl|1 ml 2% lidocaine (20 mg/mL)
223600458|NCT02259894|DRUG|BIRT 2584 XX|
223600459|NCT02259894|DRUG|Placebo|
223600460|NCT06180707|DRUG|pregabalin gel|10% pregabalin gel (carbopol-based gel to which the drug has been added) for topical application to teeth before bleaching with hydrogen peroxide
224199613|NCT06914401|PROCEDURE|NIV (Non Invasive Ventilation)|Single procedure Preoxygenation prior to intubation with NIV (Non Invasive Ventilation).
224199614|NCT04062097|DRUG|Dabigatran Etexilate Oral Capsule [Pradaxa]|Dabigatran is the most frequently used direct thrombin inhibitor in secondary stroke prevention in patients with atrial fibrillation.
224199615|NCT04062097|DRUG|Idarucizumab 2.5 GM/50 ML Intravenous Solution [PRAXBIND]|Idarucizumab is the current standard therapy in patients with intracranial bleeding under anticoagulation with dabigatran.
224199616|NCT04062097|DRUG|Vitamin K antagonist|This drug group includes the active substances phenprocoumon and warfarin.
224199617|NCT06935747|COMBINATION_PRODUCT|Medical device: beta-tricalcium phosphate|The description of the intervention for BTCP in the study involves the application of this substance to promote bone regeneration following the extraction of impacted mandibular third molars. BTCP is indicated for the treatment of segmental and cavitary bone loss, aesthetic repairs, and bone augmentations (such as inlay or onlay grafts); for filling dental alveolar bone; for dental implant placement; and for the stabilization of osteotomies and prostheses in dentistry.
224199618|NCT06935747|OTHER|Bovine Hydroxyapatite|The intervention description for Bio-Oss in the study involves the application of this standard material to promote bone regeneration following the extraction of impacted mandibular third molars. Bio-Oss is a commonly used xenograft material known for its osteoconductive properties.
224199619|NCT06943131|OTHER|YWTL EXERCISES|YWTL exercises are shoulder and upper back exercises to improve posture, strengthen upper back. Each letter represents different arm position that copies shape of letter.
224199620|NCT06943131|OTHER|Closed kinetic chain exercises|Closed kinetic chain exercises include corner stretch hold, sleeper stretch hold - lawn mover and robbery maneuver, Scapula clock exercises, wall wash. Low row exercise maneuver, Scapular stabilization of Black burn exercises, press up, push up.
223600461|NCT06180707|DRUG|gel with 5% potassium nitrate and 2% sodium fluoride|gel of 5% potassium nitrate and 2% sodium fluoride for topical application to teeth before bleaching with hydrogen peroxide
223600462|NCT06180707|OTHER|Placebo gel|placebo gel (carbopol-based gel 1%) for topical application to teeth before bleaching with hydrogen peroxide
223600463|NCT03073993|PROCEDURE|feeding tube insertion|Feeding tube was inserted in hemodynamically stable babies for purpose of feeding
223600464|NCT00141128|DRUG|SS-RBX|
223600465|NCT02982941|DRUG|Enoblituzumab|enoblituzumab administered IV weekly for up to 96 weeks
223600466|NCT04219644|DEVICE|Breatheasy device|
223600467|NCT00895453|DRUG|itraconazole|6-months maintenance regimen with monthly single-day itraconazole 200mg twice daily (bid)
223600468|NCT00895453|DRUG|lactobacillus gasseri|Lactobacillus vaginal tablets monthly given through 6 days
223749050|NCT04774523|PROCEDURE|Echo-based assessment of the acute hemodynamic effect of the CRT AutoAdapt feature.|"Patients in the AutoAdapt group undergo the echo-based assessment of the acute hemodynamic effect of the CRT AutoAdapt feature.~Three steps must be followed:~1. Standard AV programming: perform echo for AoVTI assessment.~2. Echo-optimized AV programming: perform standard echo-based AV-optimization (Ritter method or iterative method, according to routine at investigational site); measure AoVTI at optimized setting.~3. AutoAdapt optimized programming: The system allows different programming options for the parameter 'Adaptive AV reduction'. The nominal value is 0.7, but it can be modified to different values ranging from 0.5 to 0.9. The AoVTI shall be measured at standard setting of the Adaptive Av reduction parameter, 0.7."
223749051|NCT04774523|PROCEDURE|Echocardiography AV optimization|Patient in the control group undergo the routine echo-based AV-optimization that is usually performed at the investigational site (Ritter method or iterative method). Performance of an additional VV-delay optimization is left to the investigator discretion
223749052|NCT04774523|PROCEDURE|Echocardiography|Echocardiography must be performed at baseline and 12 month Follow Up to collect the LVEF/LVESD(V)/LVEDD(V)
224199621|NCT06936579|DEVICE|proprioceptive stimulation|"Condition without proprioceptive stimulation: Participants will not receive the stimulus, and MEP activity will be recorded under the same motor cortex stimulation conditions.~Condition with proprioceptive stimulation 1: Participants will receive proprioceptive stimulation through the output plunger, applied continuously for 15 seconds, with 20-second rest intervals, over a total duration of 5 minutes. MEP activity will then be recorded via motor cortex stimulation.~Condition with proprioceptive stimulation 2: Participants will receive proprioceptive stimulation continuously during the application of TMS pulses while MEP activity is recorded."
223600469|NCT00895453|DRUG|classic homeopathy (carcinosin M, nux vomica, pulsatilla M, ferrum metallicum, sepia M, etc. as prescribed)|CH treatment was provided by a licensed CH practitioner. Specifically, a personal history was taken and an individualised treatment scheme was prescribed. The most often used homeopathic remedies were carcinosin M, nux vomica, pulsatilla M, ferrum metallicum, and sepia M. Potencies of homeopathic remedies ranged from C 30 to C 1000.
223600470|NCT03918525|OTHER|Sindhi families|It is an observational study and no intervention is involved
223600471|NCT02071069|DRUG|Cetuximab|400mg/m2 d1,250mg/m2 every week or 500mg/m2 every 2 weeks
223600472|NCT02071069|DRUG|irinotecan|180 mg/m2 IV every 2 weeks
223749053|NCT04774523|OTHER|Self Assessment Score|Patient must complete the self assessment score at 6 and 12 month Follow Up, that will be use for the Packer Clinical Composite Score
223600473|NCT02071069|DRUG|fluorouracil|400mg/m2 on day 1 and 2400mg/m2 civ46h every 2 weeks
223600474|NCT03817268|DRUG|Capecitabine monotherapy|Capecitabine is administered within 6 weeks after resection and after adequate recovery. To reduce the side effects and improve patient compliance, the administered dose is half of the recommendation: 625 mg/m2, bis in die (BID) (1250 mg/m2 per day). A 2-week therapy is followed by a 1-week pause, and a cycle includes 3 weeks. A total of 8 cycles is planned for each patient.
223600475|NCT01931163|DRUG|Everolimus|
223600476|NCT02464722|DRUG|Dexmedetomidine|1 mcg/kg iv loading dose of remifentanil over a period of 60 seconds. Later, an infusion was started at the rate of 0.2-0.4mcg/kg/min.
223600477|NCT02464722|DRUG|Remifentanil|1 mcg/kg iv loading dose of remifentanil over a period of 10 minutes. Later, an infusion was started at the rate of 0.4-0.8mcg/kg/min.
223600478|NCT02464722|DRUG|Epinephrine|Before the start of surgery, 1/100000 epinephrine infiltration was administered to the nasal passages by the surgeon.
223600479|NCT02464722|DRUG|Propofol|Anesthesia was induced with propofol 2 mg kg-1
223600480|NCT02464722|DRUG|Rocuronium|Anesthesia was induced with rocuronium 0.6 mg kg-1
223600481|NCT01441323|BEHAVIORAL|Nutrition|Nutrition classes for 1 hour \& 30 minutes once a week for 16 weeks + motivational interviewing (4 individual sessions)
223600482|NCT01441323|BEHAVIORAL|Strength Training & Nutrition|Strength Training twice a week for 1 hour a day for 16 weeks + Nutrition once a week for 1 hour \& 30 minutes for 16 weeks + motivational interviewing (4 individual \& 4 group sessions)
223600483|NCT04794023|DEVICE|Corneal Ablation|Corneal ablation for the treatment of myopia with/without astigmatism following flap creation using femtosecond laser.
223600484|NCT00206713|DRUG|Sargramostim (Leukine)|6 μg/kg sargramostim administered SC once daily for 8 weeks
223600485|NCT00206713|DRUG|Placebo|Placebo administered SC once daily during the randomized retreatment phase.
223600486|NCT00767767|DRUG|Placebos|IV Saline infusion for 2 hours.
223600487|NCT00767767|DRUG|Propofol 0.45mcg/mL|IV Propofol infusion for 2 hours.
223600488|NCT00767767|DRUG|Propofol 0.90mcg/mL|IV Propofol infusion for 2 hours.
223749055|NCT06835283|DEVICE|Brain Stimulation|This intervention is distinct because it combines two non-invasive brain stimulation techniques, intermittent theta burst stimulation (iTBS) and transcranial direct current stimulation (tDCS), in a sequential manner. Unlike studies that evaluate these techniques individually, this study explores their combined and complementary effects, with iTBS priming the brain to enhance the subsequent impact of tDCS. The sequential design leverages different mechanisms of action: iTBS delivers magnetic pulses to targeted brain areas to modulate neural activity, while tDCS applies a low electrical current for sustained modulation. This approach specifically targets neuropsychiatric symptoms (e.g., mood swings, apathy, and agitation) in individuals with Alzheimer's Disease and related dementias (ADRD), a population often underserved by traditional interventions. The study also evaluates the feasibility of at-home tDCS administration, making it unique in combining clinical and caregiver-managed treat
224075196|NCT05159557|DEVICE|In-Home Technology System|Intelligent bots monitor the in-home sensors, learn typical patterns, and provide caregivers with text messages and alerts via cell phone when worrisome behaviors occur. Caregivers are able to: (a) select services (e.g., warnings for falls, wandering, late night activity); (b) access daily reports (summaries of daily activities that can also be shared with health care providers); and (c) obtain support (e.g. Caregiver Support Groups that connect caregivers with knowledgeable experts and other caregivers, Caregiver Events that provide virtual meetings about relevant topics, and Trusted Circle task management to distribute the caregiving work load).
224075197|NCT05159557|DEVICE|Limited In-Home Technology|Intelligent bots monitor the in-home water leak sensor and provide caregivers with text messages and alerts via cell phone when worrisome conditions occur.
224199622|NCT06940804|BIOLOGICAL|CLDN6 CAR-T|Intravenous (IV) infusion
224199623|NCT06940804|BIOLOGICAL|CLDN6 RNA-LPX|IV injection
224199624|NCT06942442|DRUG|Physician's Choice|Patients who are HLA-A\*02:01-negative and ineligible to receive tebentafusp will be prospectively enrolled onto a separate study arm and treated with physicians' choice of treatment. They will also be radiographically assessed at the same schedule as patients treated with tebentafusp, if feasible, and kept on this treatment arm until progression of disease or unacceptable toxicity on the physicians' choice regimen.
224199625|NCT06942442|DRUG|Tebentafusp|Patients who screen positive for HLA-A\*02:01 and meet the eligibility requirements will be treated with weekly tebentafusp
224199626|NCT06943079|DEVICE|Effect of Hold Relax technique with Blood Flow Restriction technique on functional outcome|Participants are randomly allocated to group A through computerised generated method. The both combine intervention is divided into 3 intervals and their results will be calculated on 0 week, 3rd, and 6th week. On every interval, pain through numeric pain rating scale, range of motion through goniometer, and functional disability through lower extremity functional scale will be measured. 2-3/week frequency of intervention will be applied on the participant.
224199627|NCT06943079|OTHER|Effect of Hold Relax technique without Blood Flow Restriction technique on functional outcomes|Participants are randomly allocated to group B through computerised generated method. The intervention is divided into 3 intervals and their results will be calculated on 0 week, 3rd, and 6th week. On every interval, pain through numeric pain rating scale, range of motion through goniometer, and functional disability through lower extremity functional scale will be measured. 2-3/week frequency of intervention will be applied on the participant.
223600489|NCT00767767|DRUG|Thiopental 1.5mcg/mL|IV Thiopental 1.5mcg/mL infusion for 2 hours
223600490|NCT00767767|DRUG|Thiopental 3mcg/mL|IV Thiopental 3mcg/mL infusion for 2 hours
223600491|NCT06383468|DRUG|AK120|300mg Q2W subcutaneous injection thereafter until week 50.
223600492|NCT01940627|DIETARY_SUPPLEMENT|Ubiquinol|Ubiquinol 200mg/day (two capsules of 100 mg (Breakfast and lunch)) for 14 days
223600493|NCT01940627|DIETARY_SUPPLEMENT|Control|placebo capsules (two capsules (Breakfast and lunch)) for 14 days
223600494|NCT01726985|OTHER|Parameter Based Clinical Disposition|"Parameter Based Clinical Disposition'~Physicians will initiate / titrate medications and obtain consults as usual but are highly encourage to keep patients in the hospital until at least 2 of the following 3 criteria are met:~* NT-ProBNP reduction of \> 23% from peak value during admission~* Fluid Reduction of \> 1.3L (orders for I/O q8h required)~* Serum Sodium of \> 135 mmol/L the day of planned discharge"
223600495|NCT05367323|DEVICE|Pressure algometry (Baseline 2.2-Pound Dolorimeter) and Myoton PRO device (MyotonPRO; Myoton AS, Tallinn, Estonia)|Both instruments are used for the assessment of the L4-5 interspinous space pain pressure threshold and the biomechanical-viscoelastic properties of L4-5 supraspinous ligament respectively
223600496|NCT04375514|DRUG|ARO-ENaC|single or multiple doses of ARO-ENaC by inhalation of nebulized solution
223600497|NCT04375514|DRUG|Placebo|calculated volume to match active treatment by inhalation of nebulized solution
223600498|NCT02146625|DRUG|CJ-40002|
223600499|NCT00197925|BIOLOGICAL|Onco-peptide loaded autologous dendritic cells|
223600500|NCT04371692|OTHER|self-administered questionnaire|Every weeks during 2 months, clinical and occupational questionnaire are performed among a cohort of HCW exposed to covid occupational exposure
224199628|NCT06942559|DEVICE|EEG-Triggered Repetitive Transcranial Magnetic Stimulation (rTMS)|"The rTMS intervention will be delivered using the MagPro XP - Orange Edition stimulator and COOL D-B80 coil to the dorsomedial prefrontal cortex 4 cm anterior to the foot hotspot. EEG data will be analyzed in real-time using the bossdevice MEDICAL and TMS pulses will be synchronized to the negative peak of the frontoparietal theta oscillation.~500 consecutive EEG theta-oscillation negative-peak triggered quadruplet bursts with a 5 ms inter-pulse interval will be applied at an average inter-burst interval of 2 s. The therapeutic intervention consists of 30 sessions of 2000 TMS pulses each for a total duration per treatment session of 17 minutes."
223600501|NCT04371692|DIAGNOSTIC_TEST|SARS-Cov2 testing|Every weeks during 2 month, SARS-Cov2 RT-PCR, serological testing are performed among a cohort of HCW exposed to covid occupational exposure
223600502|NCT04465292|DRUG|Tildrakizumab Prefilled Syringe|Patients will receive Tildrakizumab 100 mg subcutaneously at Weeks 0, 4, and 16. The study staff will administer each dose.
223600503|NCT00208351|DEVICE|Ultima LX Collared Stem - Non-Polished/Blasted Finished|A collared non-polished/blasted finished cementless femoral component for use in total hip replacement.
223600504|NCT00208351|DEVICE|Ultima LX Collared Stem - Polished Finished|A collared polished finished cementless femoral component for use in total hip replacement.
223600505|NCT00208351|DEVICE|Ultima LX Collarless Stem - Non-Polished/Blasted Finished|A collarless non-polished/blasted finished cementless femoral component for use in total hip replacement.
223600506|NCT00208351|DEVICE|Ultima LX Collarless Stem - Polished finished|A collarless polished finished cementless femoral component for use in total hip replacement.
223600507|NCT04193592|DRUG|Pirfenidone|Pirfenidone will be titrated over 14 days, as tolerated, to the full dose of 2403 mg per day, as follows: Days 1 - 7: one capsule TID; Days 8 - 14: two capsules TID; Days 15 to week 52: three capsules TID. Dose may be reduced to manage an adverse event.
223600508|NCT03869606|DEVICE|NICOM by Cheetah Medical|Observational measurement, Cardiac Output, Pre- and Post Anesthesia
223600509|NCT03238833|OTHER|luteal ovarian stimulation|In the in vitro fertilization cycle, controlled ovarian stimulation was started since the luteal phase.
223600510|NCT03238833|OTHER|follicular ovarian stimulation|In the in vitro fertilization cycle, controlled ovarian stimulation was started since the follicular phase.
223600511|NCT02215824|DRUG|BIWH 3|
223600512|NCT02215824|DRUG|Placebo|
223600513|NCT01778101|DRUG|Lansoprazole|lansoprazole 1mg/kg twice a day for 14days
223600514|NCT01736618|DEVICE|S-ICD System|
223600515|NCT02634827|DRUG|Decitabine|Given IV
223600516|NCT02634827|OTHER|Laboratory Biomarker Analysis|Correlative studies
223600517|NCT02634827|DRUG|Midostaurin|Given PO
224075198|NCT06846515|DRUG|AR882 50 mg|Solid Oral Capsule
224199629|NCT06942559|DEVICE|Non-EEG Triggered Repetitive Transcranial Magnetic Stimulation (rTMS)|"The rTMS intervention will be delivered using the MagPro XP - Orange Edition stimulator and COOL D-B80 coil to the dorsomedial prefrontal cortex 4 cm anterior to the foot hotspot.~High-frequency rTMS consisting of 50 trains at 20 Hz (2 s on, 18 s off) will be delivered. The therapeutic intervention consists of 30 sessions of 2000 TMS pulses each for a total duration per treatment session of 17 minutes."
223600518|NCT02561559|RADIATION|Lung metastasis from soft-tissue sarcoma|Tretament based on Intensity Modulated Radiation Therapy (IMRT) using Volumetric Modulated Arc Therapy (VMAT)
223600519|NCT04046731|DIAGNOSTIC_TEST|Skin Testing|Percutaneous skin prick followed by Intradermal Injections of NMBAs at increasing concentrations compared with an established positive and negative control.
223600520|NCT03291860|PROCEDURE|Ovum retrievum|assessment of oocytes collected by ovum retrievum to evaluate the discriminatory power of the antimullerian hormone in ICSI cycles
223600521|NCT00252616|BEHAVIORAL|trophic enteral feeds|10cc/hr
223600522|NCT03637517|DRUG|DSM265-TPGS 34% SDD, 400 mg fasted|New formulation allowing smaller volumes of dissolution in a common vehicle (water), administered to subjects in a fasted state.
223600523|NCT03637517|DRUG|DSM265-TPGS 34% SDD, 400 mg fed|New formulation allowing smaller volumes of dissolution in a common vehicle (water), administered to subjects in a fed state.
223600524|NCT03637517|DRUG|DSM265 25% SDD, 400 mg fasted|Reference formulation used in early clinical trials.
223600525|NCT05922241|OTHER|Costophrenic assisted cough|Therapist places the hands on the costophrenic angles of the patient's rib cage. During the patient's inspiration, the therapist applies a series of three repeated quick-stretch contractions down and in to encourage maximal inspiration. At the end of expiration, the therapist applies a quick stretch down and in on the patient's lower chest to facilitate a stronger diaphragmatic and intercostal muscle contraction. While instructing the patient to cough, the therapist applies strong pressure through the hands in toward the central tendon of the patient's diaphragm
223600526|NCT05922241|OTHER|Anterior chest compression|The therapist puts one arm across the patient's pectoral region to stabilize or compress the upper chest while the other arm is placed either parallel on the lower chest or abdomen below the xiphoid process
223600527|NCT03409341|OTHER|Blood and tumor tissue analysis, Clinical response.|DNA sequencing and functional testing of peripheral blood mononuclear cells. DNA and RNA sequencing and immune cell analysis of tumor. Clinical response at 12 months.
223600528|NCT00819117|DEVICE|Cardiac Resynchronization Therapy implant|Device implant with appropriate leads
223600529|NCT03975569|OTHER|Probiotic vaginal gel|Total daily administration of 2.5 ml of probiotic gel, containing three lactobacilli (Lactobacillus rhamnosus GG, Lactobacillus pentosus KCA1 and Lactobacillus plantarum WCFS1). Final dosage per gram of gel: 10\^9-10\^10 colony forming units of lactobacilli.
224075199|NCT06846515|DRUG|AR882 75 mg|Solid Oral Capsule
224075200|NCT06846515|DRUG|Placebo|Matching Solid Oral Capsule Placebo
224075201|NCT04137887|BIOLOGICAL|Quadrivalent Influenza Vaccine (split virion, inactivated) High-Dose (QIV-HD)|Pharmaceutical form: Suspension for injection in pre-filled syringe Route of administration: Intramuscular
224075202|NCT04137887|BIOLOGICAL|Standard-Dose Inactivated Influenza Vaccine Quadrivalent, Northern Hemisphere strains (QIV-SD)|Pharmaceutical form: Suspension for injection in pre-filled syringe Route of administration: Intramuscular
223600530|NCT00400569|DRUG|Sunitinib Malate (SU011248)|For each 6 week cycle, patients will take SU011248 every day in the morning for 4 weeks followed by a 2 week rest period.
224199630|NCT06943274|OTHER|Standardized Walking Course Activities|"A randomized controlled trial investigate the effect of a standard walking obstacle course on balance, gait and endurance in children with ASD. Activity could include navigating obstacles of varying height and width balancing on beam, stepping over hurdles and walking on different surfaces.~* Balance activities~* Gait activities~* Endurance activities Start with easier task and end with difficulties. SWOC activities performs 2 to 3 times a week for 4weeks."
224199631|NCT06943274|OTHER|Common Physical Activities|Either receive no interventions or engages in a different form of physical activities that doesn't focus on balance gait and endurance e.g standard physical education activities like walking, running, climbing, jumping along with applied behavioral therapy, speech therapy and customized physical therapy.
224199632|NCT06941896|DEVICE|Use of the Atalante Exoskeleton|"Assisted verticalization (sit-to-stand transition)~Orthostatic stabilization (unsupported standing posture)~Assisted locomotion (stabilized walking)"
224199633|NCT06942156|DRUG|Everolimus|Up to 1.5g BID(total 3g daily), PO - Check the blood concentration of Everolimus at each visit
224199634|NCT06942156|DRUG|Mycophenolate mofetil Tablet/Capsule|Up to 1.5g BID(total 3g daily), PO
224199635|NCT06942975|OTHER|Patients with turberculosis|The study plans to collect data from patients with microbiological confirmation of tuberculosis, notified to the SS Hospital Infection Surveillance and Control Antimicrobial Stewardship, in the period between 2019 and 2023, taken in charge by the SC Infectious Diseases of the A.O. SS Antonio e Biagio and Cesare Arrigo of Alessandria (Piedmont Region, Italy).
223600531|NCT06152549|BEHAVIORAL|Maltreatment and Abuse Chronology of Exposure Scale as a stress challenge|The first group (N=250) will receive the Maltreatment and Abuse Chronology of Exposure (MACE) scale first, to assess early life adversity, followed by the standardized test questions. A POMS will be administered before each challenge.
223600532|NCT06152549|BEHAVIORAL|Standardized Maths and Verbal Questions such as the ones used in SATs|The second group (N=250) will be presented with the standardized test questions (Math/Verbal) to assess their stress level, measured through POMS, followed by the Maltreatment and Abuse Chronology of Exposure (MACE) scale.
223600533|NCT06152549|BEHAVIORAL|Chronology of Perceived Discrimination Scale (CPDS)|The group will also receive the Chronology of Perceived Discrimination Scale (CPDS) to assess type and timing of perceived discrimination during the first 18 years of life. A POMS will be administered before and after the intervention/challenge.
223600534|NCT06152549|BEHAVIORAL|International Personality Item Pool (IPIP-NEO)|Participants in both groups will be presented with the abbreviated version of the IPIP-NEO a personality questionnaire that provides ratings on the Five Factor Personality Model. The research team sees this task as non-stressful and even potentially soothing and envisions that it will help to restore an individual's mood before taking the next stressful test and again at the completion of the online session.
223600535|NCT03028779|PROCEDURE|Fast-track Total Hip and knee arthroplasty|To be able to do a total knee or hip arthroplasty and return the patient home in less then 24 hours
223600536|NCT02474953|DIETARY_SUPPLEMENT|Proprietary Curcumin Formulation|
223600537|NCT02474953|DIETARY_SUPPLEMENT|Unformulated Comparator Curcumin Product|
223600538|NCT02919527|OTHER|Self-Myofascial-Release|Self-Myofascial-Release performed at the anterior thigh
223600539|NCT02919527|OTHER|Stretching|Static Stretching performed at the anterior thigh
223600540|NCT05002179|DRUG|Echinaforce Chewable tablets|"Preventive treatment: 3X2 EC tablets daily during 2 + 2 months of prevention after run-in of 1 week and intermittent treatment break of 1 week without treatment + 1 month of voluntary follow-up prevention.~Acute treatment: 5 X 2 EC tablets daily for max. 10 days per individual vRTI or until symptom resolution."
223600541|NCT02113358|DRUG|Intravenous colloid bolus with Voluven|
223600542|NCT02714283|DRUG|inhaled corticosteroid therapy|We will evaluate and compare the clinical effectiveness and safety of long-term inhaled corticosteroid and macrolide antimicrobial therapies
223600543|NCT02714283|DRUG|macrolide therapy|We will evaluate and compare the clinical effectiveness and safety of long-term inhaled corticosteroid and macrolide antimicrobial therapies
223600544|NCT05192655|OTHER|Observation|Observation Study
223600545|NCT02790424|DEVICE|Imaging devices|technological adjustment tests
223600546|NCT03408964|OTHER|biological samples collection and analysis|Participants to the study will be assigned to 4 cohorts according to the stage of disease and planned antitumor treatment at time of study entry; they will be followed up and sampled according to a defined time schedule
223600547|NCT01072253|PROCEDURE|eye amputation|
223600548|NCT00264264|PROCEDURE|Closure Device|
224199636|NCT06941805|DIAGNOSTIC_TEST|Physical Fitness|Physical fitness levels of blue- and white-collar university workers were measured and compared.
224199637|NCT06941805|DIAGNOSTIC_TEST|Physical activity|Weekly physical activity levels of blue- and white-collar university workers were measured and compared.
224199638|NCT06938698|OTHER|PROM collection|PROM collection using a digital health web application. PROMs will be based on the HF Standard Set created by the International Consortium of Health Outcomes Measurements (ICHOM), adapted to the patient follow-up protocol already in use by GEstIC. Half the participants will complete the Kansas City Cardiomyopathy Questionnaire (KCCQ-12) and the other half will complete the Minnesota Living with Heart Failure Questionnaire (MLHFQ).
223600549|NCT00264264|PROCEDURE|Direct Compression|
223600550|NCT00006158|DRUG|Testosterone|
223600551|NCT02171741|DRUG|BIBW 2992|continuous daily dosing for 20 or 13 days
223600552|NCT02171741|DRUG|Docetaxel|single infusion on day 1
223600553|NCT05586841|DRUG|Dalpiciclib|Dalpiciclib: 100 mg/d or 125 mg/d, po., qd, administered on an empty stomach (fasting should be ensured at least 1 hour before and 1 hour after administration). The drug will be administered in a 28-day cycle, with continuously administration in the first 3 weeks (D1-21), and discontinuation in the fourth week (D22-28).
224199639|NCT06943391|DEVICE|laser|patients subjected to a tooth extraction and immediately given an intraoral PBM session with an EPIC X Biolase diode laser (BIOLASE, Inc. USA), with a voltage of 100-240 V, 1.5 A, a power of 0.5 W, and an application of an energy of 15J per cm², for 10-30 seconds at 1 mm of the tissue with an sterile surgical tip. It was applied at three points in the area: buccal, pala-tal/lingual, and occlusal to stimulate the tissue.
223600554|NCT05586841|DRUG|Chidamide|Chidamide: 25 mg/BIW or 20 mg/BIW, po., q2w. The interval between doses should not be less than 3 days (e.g. Monday and Thursday, Tuesday and Friday, Wednesday and Saturday, etc.), administered 30 minutes after meals
223600555|NCT05906355|DEVICE|the wearable filtrating artificial Kidney Device|the wearable filtrating artificial kidney device rapidly for rapid relief of fluid overload in patients
223600556|NCT05906355|DEVICE|traditional hemodialysis machine|the hemodialysis machine currently used in clinical practice to reduce fluid overload in patients
223600557|NCT00620113|DRUG|Odanacatib|Odanacatib tablets 10 mg, 25 mg, or 50 mg (depending upon randomization), taken orally once weekly for 52 weeks.
223600558|NCT00620113|DIETARY_SUPPLEMENT|Vitamin D3|Two Vitamin D3 tablets (5600 IU total) taken orally once weekly for 52 weeks.
223600559|NCT00620113|DIETARY_SUPPLEMENT|Calcium carbonate|Calcium carbonate 500 mg tablet taken orally every day for 52 weeks.
223600560|NCT00620113|DRUG|Placebo|Dose-matched placebo tablets to odanacatib, taken orally once weekly for 52 weeks.
223600561|NCT02065505|OTHER|Mat Pilates|
223600562|NCT02065505|OTHER|Water Pilates|
223600563|NCT02929940|OTHER|No intervention|No Intervention, observational
223600564|NCT02973516|DRUG|P03277 at 0.1 mmol/kg|P03277 will be administered at 0.1 mmol/kg BW (corresponding to 0.2 mL/kg BW) by intravenous (IV) bolus injection at 2 mL/s rate without dilution, followed by a 0.9% saline flush.
223600565|NCT02973516|DRUG|P03277 at 0.05 mmol/kg|P03277 will be administered at 0.05 mmol/kg BW (corresponding to 0.1 mL/kg BW) by intravenous (IV) bolus injection at 2 mL/s rate without dilution, followed by a 0.9% saline flush.
223600566|NCT02461745|DRUG|ombitasvir, paritaprevir/r, dasabuvir + ribavirin|VIEKIRA PAK (two 12.5/75/50 mg ombitasvir, paritaprevir, ritonavir tablets, and two 250 mg dasabuvir tablets) + RBV (ribavirin tablets) for 12 weeks
223600567|NCT02461745|DRUG|ombitasvir, paritaprevir/r, dasabuvir|VIEKIRA PAK (two 12.5/75/50 mg ombitasvir, paritaprevir, ritonavir tablets, and two 250 mg dasabuvir tablets)
223600568|NCT02268994|DRUG|ferric citrate|1 g ferric citrate containing approximately 210 mg of ferric iron
223600569|NCT02268994|DRUG|Placebo|Matching placebo
223600570|NCT03968263|DEVICE|Hycon device(Routine protocol)|Hycon device will be activated half a turn every 3 days.
223600571|NCT03968263|DEVICE|Hycon device(Modified protocol)|The activation period of the hycon device will be modified.
223600572|NCT03968263|DEVICE|Hycon device(Routine protocol) and Vibration(Acceledent)|Hycon device will be activated half a turn every 3 days. Vibration will be applied 2 times 10 minutes per day.
223600573|NCT03968263|DEVICE|Hycon device(Modified protocol) and Vibration(Acceledent)|The activation period of the hycon device will be modified. Vibration will be applied 2 times 10 minutes per day.
223600574|NCT00211887|DRUG|Interferon beta 1-a|The single agent arm is divided into two groups, IFN and GA providing for 3 treatment arms: IFN IM and GA SC (50% of the patients), IFN IM and placebo SC (25% of the patients) and GA SC and placebo IM (25% of the patients).
223600575|NCT00211887|DRUG|glatiramer acetate|The single agent arm is divided into two groups, IFN and GA providing for 3 treatment arms: IFN IM and GA SC (50% of the patients), IFN IM and placebo SC (25% of the patients) and GA SC and placebo IM (25% of the patients).
223600576|NCT00211887|OTHER|placebo|an inactive substance
223600577|NCT05526339|DEVICE|High-flow nasal oxygenation combined with nasopharyngeal airway|The patients receive an oxygen flow of 30 L/min for preoxygenation with a high-flow oxygenation device before losing of conscious. At the time of the abolition of the eyelash reflex, the gas flow was increased to 60 L/min with an inspired oxygen fraction 100% and the nasopharyngeal airway was placed.
223600578|NCT05526339|DEVICE|Regular nasal cannula combined with nasopharyngeal airway|The patients receive an oxygen flow of 6 L/min for preoxygenation with a regular nasal cannula until the end of procedure. At the time of abolition of the eyelash reflex, the nasopharyngeal airway was placed.
223600579|NCT00679874|OTHER|Cardio-vascular MRI|Contrast enhanced CMR studies at baseline, in the middle of chemotherapy and as follow-up
223600580|NCT05784519|DRUG|MSCs eye drops|MSCs were used to prepare single-cell suspension, and 0.9% sodium chloride was added to balance PH value to prepare the effective, safe and stable eye drops. Giving the patient with 5×10\^5 /50μl in each eye, twice a day for 2 weeks.
223600581|NCT02078128|DIETARY_SUPPLEMENT|oral beta-glucans|30 mg/kg, oral every day until wound healed completes or unacceptable toxicity develops.
223600582|NCT02078128|DRUG|oral sugar powder|30 mg/kg, oral every day until wound healed completes or unacceptable toxicity develops.
223600583|NCT01979133|DRUG|Icariin|Participants will receive 20% icariin (100 mg/day) in a commercially available over-the-counter Horny Goat Weed supplement. A dose titration from 100 mg/day to 200 mg/day will be allowed at week 3 participants with less than a 30% reduction in HAMD and/or still using cocaine or alcohol or have a positive urine drug screen. An additional dose titration to 300 mg/day will be allowed at week 6 for participants with less than a 50% reduction in HAMD scores and/or still using cocaine or alcohol or have a positive urine drug screen.
223749056|NCT04216719|BEHAVIORAL|OCM-RISE|OCM RISE will comprise four phases (Exploratory, Preparation, Implementation, and Sustainment). During Exploration, staff will conduct readiness surveys, interviews and system mapping exercises to assess county context. In the Preparation Phase, the needs assessment data will inform county-specific action plans. Guided facilitation during this phase includes court development planning, practice/process improvement strategies, and training on data-driven decision-making to help IACTs operationalize the 10 OCM guidelines, assess performance, and fit the guideline to the local context. In the Implementation Phase, counties will roll out the OCM for 18 months with data feedback, support, and facilitation. Each IACT will receive reports on the performance of its OCM and complete two plan-do-study-act cycles. In the Sustainment Phase, implementation and feedback reports will continue for 6-18 months, but without other external facilitation.
224199640|NCT06942663|OTHER|Surveillance|Close monitoring for disease recurrence.
223600584|NCT01106235|BIOLOGICAL|therapeutic autologous lymphocytes|Given IV
223600585|NCT01106235|BIOLOGICAL|aldesleukin|Given SC
223600586|NCT01106235|DRUG|cyclophosphamide|Given IV
223600587|NCT01106235|PROCEDURE|biopsy|Optional correlative studies
223600588|NCT00486824|DRUG|Indomethacin|One 50 mg tablet of Indomethacin plus 2 pills of placebo followed by one 25 mg tablet of oral indomethacin every 6 hrs for 48 hrs.
224199641|NCT06942663|DRUG|Adjuvant Chemotherapy|The adjuvant chemotherapy regimen will be standardized based on current clinical guidelines and may include combinations of agents such as fluoropyrimidines and oxaliplatin with or without docetaxel. Treatment until the progression of the process is detected or the maximum effect of therapy is achieved (the maximum duration of treatment is 3 months).
223600589|NCT00486824|DRUG|Nifedipine|Three 10 mg tablets of Nifedipine followed by one 20 mg tablet every 6 hrs for 48 hrs.
223600590|NCT00285402|DRUG|AST-726 Low dose|
223600591|NCT00285402|DRUG|AST-726 High dose|
223600592|NCT00285402|DRUG|AST-726 Placebo|
223600593|NCT00715767|BEHAVIORAL|Assessment|"Cognitive Assessment:~Knowledge base and critical thinking will be evaluated by a 50-question BLS multiple-choice examination. At the designated 4 cognitive assessments in the study (pre-course, immediately post course, 3 months and 6 months) 50 equivalent questions will be used to cover all core BLS objectives. Technical Skills Assessment:~Primary outcome measures of adequacy of chest compressions and ventilations as well as key actions for each of the 3standardized basic life support skill tests during 3-minute testing scenarios. Video review by 2independent experts will be utilized for objective assessment of time and order dependent skills, and manikin output will be utilized to assess qualitative effectiveness of skills (adequate ventilation, compression, and defibrillation).~Survey Instrument for Barriers to Acute Medicine Education:~A survey tool will be used to identify barriers to acute medicine education implementation and efficacy."
223600594|NCT00980759|RADIATION|EFI|Para-aortic and Pelvic Irradiation with chemotherapy(cisplatin)
223600595|NCT00980759|RADIATION|Pelvic RT|Only Pelvic Irradiation with chemotherapy(cisplatin)
223600596|NCT04241263|DEVICE|Wireless vital sign monitoring - comparative|Participants who currently have vital sign monitoring will, in addition, have the wireless system attached. We will then collect up to 24 hours of vital sign data from both systems, which will allow us to make direct comparisons between them.
223600597|NCT04241263|DEVICE|Wireless vital sign monitoring - usability|Babies will be recruited who do not currently require vital sign monitoring. The wireless system will be attached to these babies by nurses who have been trained in its use. A parent will then be asked to perform Kangaroo Care for as long as they feel comfortable. After the baby is placed back in its cot, and the sensors have been removed, we will conduct (separate) interviews with the nurse and the parent on the neonatal intensive care unit (NICU).
223600598|NCT04316026|DEVICE|shock wave therapy|Shockwave therapy is a non-invasive treatment creating a series of low energy acoustic wave pulsations that are directly applied through the skin via a gel medium
223600599|NCT00913926|DRUG|E2/LNG oral (Wellnara, BAY86-5029)|Patients in daily life treatment receiving Wellnara according to local drug information.
223600600|NCT04866901|BEHAVIORAL|Slow-Paced Breathing (SPB)|see arm description
223600601|NCT04866901|BEHAVIORAL|Mindfulness (M)|see arm description
223600602|NCT04866901|BEHAVIORAL|Yogic Breathing (SPB+M)|see arm description
223600603|NCT04085913|DRUG|Lidocaine Epinephrine|Preincision injection, as is current practice
223600604|NCT04085913|DRUG|Bupivacaine Hydrochloride-EPINEPHrine|Preincision injection
223600605|NCT04085913|DRUG|Lidocaine Epinephrine, Bupivacaine Hydrochloride-EPINEPHrine|Preincison injection of lidocaine and epinephrine and a postincision injection of Exparel
223600606|NCT01467830|PROCEDURE|Open Inguinal Hernia Repair With Mesh,the Use of Absorbable Versus Non Absorbable Fixation Sutures|use of absorbable sutures to fixate mesh inguinal hernia repair.
223600607|NCT01072994|DIETARY_SUPPLEMENT|Fish Oil|Differential proportional doses of DHA versus DHA and EPA
223600608|NCT02922426|DRUG|ALKS 3831|Daily dosing for 21 consecutive days
223600609|NCT02922426|DRUG|Olanzapine|Daily dosing for 21 consecutive days
224199642|NCT06943651|DEVICE|HealthyW8 Digital Twin of healthy lifestyle recommendations|The applied intervention with the developed healthy lifestyle recommender system will be unique and is not used in any other clinical study. However, a large number of intervention studies on young adults' obesity, considering nudging (e.g. 60 in www.clinical.trials.gov), were found. Among the registered clinical trials in the referred database, 3 considered young adults obesity and saliva salivary analysis, but with a different purpose. Moreover, the type of digital solution that will be tested will put together different aspects that are not usually to see together in the same application. These different lifestyle aspects will be used for personalized recommendations.
223600610|NCT02922426|DRUG|Placebo|Daily dosing for 21 consecutive days
223600611|NCT04635514|PROCEDURE|Lateral colporrhaphy|
223600612|NCT00965419|DRUG|Edivoxetine|0.1 mg/kg/day or participant specific known stable dose, rollover participants (LNBJ \[No NCT number\]) and (LNBF \[NCT00922636\]), up to 0.3 mg/kg/day, oral, daily for up to 5 years.
223600613|NCT03322150|DRUG|Atropine|Atropine injection (0.01 mg/kg, max 0.5 mg) 3 minutes before spinal anesthesia
223600614|NCT03322150|DRUG|Glycopyrrolate|Glycopyrrolate (0.00 4mg/kg, max 0.2 mg) 3 minutes before spinal anesthesia
223600615|NCT03018613|OTHER|Fecal Microbiota Transplantation|Fecal Microbiota Transplantation and the traditional treatments for chronic functional constipation in part 1.
223600616|NCT03018613|OTHER|Normal Saline|Normal saline and the traditional treatments for chronic functional constipation in part 2
223600617|NCT00623870|DRUG|RO5045337|Multiple ascending doses
223600618|NCT02509845|DRUG|C16G2|Antimicrobial peptide
223600619|NCT02509845|OTHER|Placebo|Placebo
223600620|NCT05741398|DEVICE|VR system by Demaod|non-invasive light pulse generated by a non-contacting device for the treatment of the symptoms of dry eyes and MDG
223600621|NCT01694056|OTHER|Soy protein diet|4 weeks high protein diet (20 en%) with 25gr of soy protein per day
223600622|NCT01694056|OTHER|Control diet|4 weeks high mixed protein diet (20 en%)
223600623|NCT05924347|DIAGNOSTIC_TEST|MRI|Longitudinal MRI examination of the thoracic and lumbar spine (T2, T2w, sCT)
223600624|NCT05924347|DIAGNOSTIC_TEST|Scolioscan|3D ultrasound of the spine
224199643|NCT06942013|DEVICE|Computer-Guided Autogenous Cortical Shell Technique (Study Group)|"This study utilizes two patient-specific 3D-printed surgical guides to enhance precision in bone harvesting and fixation for horizontal ridge augmentation in the anterior mandible.~Chin Harvesting Guide~This tooth-supported guide is placed on the exposed mandibular symphysis to ensure accurate osteotomy cuts for harvesting a cortical bone shell.~It directs piezo drill cuts (superior, inferior, and vertical) to minimize errors and prevent damage to vital structures.~Bone Block Fixation Guide~After harvesting, this guide helps in precise fixation of the cortical shell onto the recipient site.~It includes pre-planned screw holes to ensure stable positioning of the graft and improve surgical accuracy.~These guides enhance precision, reduce surgical time, and improve graft stability, making the computer-guided technique superior to the traditional free-hand method."
224311275|NCT04755933|BEHAVIORAL|Raising Confident Children Course|An online learning tool consisting of 8 different modular components, designed to reduce the transmission of anxiety from parents to children. The modular components include: a core starter about anxiety, the role of avoidance, using play to develop childrens confidence, using Emotion Coaching with children, managing difficult behaviour, the role of sleep, exercise and diet, reducing overprotection, modelling confident behaviour and managing difficult behaviour.
223600625|NCT05924347|DIAGNOSTIC_TEST|Skeletal maturity assessment|At one timepoint, a Hand radiograph is taken for digital skeletal maturity assessment
223600626|NCT01563263|BIOLOGICAL|IC43|100 mcg
223600627|NCT01563263|DRUG|Placebo|phosphate buffered saline (PBS) solution containing 0,9 % NaCl
223600628|NCT02231619|BEHAVIORAL|Baseline verbal instruction on LSUPT|
223600629|NCT02798978|DRUG|GSK1795091|GSK1795091 will be supplied as solution for injection vial. Each 5 mL vial contains 0.001 milligram/mL (mg/mL; 1000 ng/mL) or 0.0001 mg/mL (100 ng/mL)of GSK1795091 and will be administered as IV bolus over 2-5 minutes (min) followed by a IV bolus of 10 mL normal saline.
223600630|NCT02798978|DRUG|Placebo|Matching placebo will be supplied as a solution for injection vial and will be administered as IV bolus over 2-5 min followed by a IV bolus of 10 mL normal saline
223600631|NCT00826618|DRUG|ranibizumab|This is an open-label, Phase I study of intravitreally administered 0.5mg ranibizumab in subjects with uveitic CME.
223600632|NCT01557088|OTHER|Blood sampling from the Coronary Sinus and Aorta|Blood samples will be obtained from the aorta and the coronary sinus during the clinically scheduled angiogram and endothelial function testing.
223600633|NCT01557088|PROCEDURE|Intravascular Ultrasound of the coronary artery.|Intravascular Ultrasound will be completed for those subjects testing positive for coronary endothelial dysfunction during a clinically scheduled angiogram and endothelial function testing.
223600634|NCT03712787|DRUG|Tilavonemab|solution for IV infusion
223600635|NCT00732875|BIOLOGICAL|Infliximab + methotrexate (MTX)|Open label Infliximab infusions at weeks 0, 2, and 6 and every 8 weeks + methotrexate (MTX)
223600636|NCT03470090|BEHAVIORAL|Neuromuscular Exercises|In the experimental group, the subjects who were taken into the study were taken to the neuromuscular exercise (NME) program after the pre-treatment evaluations. The subjects in this group were given classical physiotherapy and NME performed 6 days a week, 1 set of 10 times physiotherapist control. NME was including warming, neuromuscular exercises (balance, muscle strengthening, proprioception, sensorimotor system training, joint stabilization and postural control exercises) and cooling periods.
223600637|NCT03470090|BEHAVIORAL|Conventional Group|In the control group, the subjects who were taken into the study were taken to the classical physiotherapy (hotpack (HP), ultrasound (US), transcutaneous electrical stimulation (TENS)) and conventional exercises program after the pre-treatment evaluations.
223600638|NCT01822262|PROCEDURE|minimally invasive cholecystolithotomy with gallbladder reservation|
223600639|NCT01822262|PROCEDURE|laparoscopic cholecystectomy|
223600640|NCT00724984|DRUG|PCI-24781|"Phase I Dose Escalation: Up to 5 cohorts will receive PCI-24781 orally at doses starting at 30mg/m2 two times a day approximately 4-6 hours apart (BID), up to 90mg/m2 administered 5 days/week during the first 21 days of each 28 day cycle until the maximum tolerated dose (MTD) is reached. If a dose limiting toxicity (DLT) occurs, then the next cohort will receive PCI-24781 BID for 7 days every other week (2 times in a 28 day cycle).~Phase II Efficacy Evaluation: All patients will receive PCI-24781 orally at the dosage and regimen determined in Phase I."
223600641|NCT00000422|BEHAVIORAL|Cognitive-behavioral psychotherapy and physical exercise|
223600642|NCT00721188|DRUG|Venofer|Single dose of 7mg intravenous (IV) of iron per kg of body weight for a maximum of 200mg iron IV.
223600643|NCT04814121|DRUG|Suxiao Jiuxin Pills|Suxiao Jiuxin Pills consists Rhizoma Ligustici (Chuan xiong) and Borneolum (Bing pian).
223749057|NCT05771480|BIOLOGICAL|Durvalumab|Participants will receive 1500 mg every 3 weeks, or every 4 weeks (in combination with chemotherapy every 3 weeks, or every 2 weeks, respectively) from cycle 1 to cycle 8 of chemotherapy. Upon completion, participants will receive 1500 mg every 4 weeks (as monotherapy)
223600644|NCT04814121|DRUG|The placebo of Suxiao Jiuxin Pills|The placebo of Suxiao Jiuxin Pills is similar to Suxiao Jiuxin Pills in appearance, smell, and taste.
223600645|NCT00385138|DRUG|Cangrelor|cangrelor bolus (30 mcg/kg) \& cangrelor infusion (4 mcg/kg/min) administered from randomization for at least 2 hours, or until the end of the PCI, whichever is longer with the option to extend up to 4 hours maximum (per investigator discretion)
223600646|NCT00385138|DRUG|clopidogrel|clopidogrel capsules (600 mg) at end of PCI
223600647|NCT00385138|DRUG|Placebo bolus & placebo infusion|placebo bolus (30 mcg/kg) \& placebo infusion (4 mcg/kg/min) administered from randomization for at least 2 hours, or until the end of the PCI, whichever is longer with the option to extend up to 4 hours maximum (per investigator discretion)
223600648|NCT00385138|DRUG|Placebo capsules - end of PCI|Placebo capsules given at the end of PCI to mimic 600mg clopidogrel dosing
223600649|NCT00385138|DRUG|Placebo capsules - end of infusion|Placebo capsules given at the end of infusion to mimic 600mg clopidogrel dosing
223600650|NCT00303485|DRUG|Placebo|po monthly for 6 months
223600651|NCT00303485|DRUG|Vitamin D and calcium supplementation|As prescribed
223600652|NCT00303485|DRUG|ibandronate [Bonviva/Boniva]|150mg po monthly for 6 months
223749058|NCT05771480|DRUG|Gemcitabine monotherapy|Gemcitabine monotherapy as background gemcitabine-based chemotherapy every 3 weeks (i.e., 8 cycles of durvalumab)
223749059|NCT05771480|DRUG|Gemcitabine + cisplatin|Gemcitabine plus cisplatin as background gemcitabine-based chemotherapy every 3 weeks (i.e., 8 cycles of durvalumab) for WHO/ECOG PS 2 participants only
223600653|NCT03928717|BEHAVIORAL|Text-Based Adherence Game|A mobile health intervention facilitated by a cloud-hosted web application and designed to promote adherence to HIV care through text message-delivered gamification strategies including peer comparison, point reinforcement, feedback on adherence outcomes, facilitation of social support, and use of an engaging and culturally-relevant story-line.
223600654|NCT03928717|BEHAVIORAL|Standard of Care (SOC)|A 10- to 20-minute in-person intervention led by a trained HIV treatment adherence counselor focused on providing basic knowledge of HIV and HIV treatment, motivating participants to engage in HIV treatment, and problem-solving barriers to adherence.
223600655|NCT00584259|OTHER|Coffee|3 cups of coffee over a 24 hour period
223600656|NCT02759250|DRUG|ARGX-110|
223600657|NCT03161080|DEVICE|Neovis Total Multi® Eye Drops|Eye Drops containing Sodium hyaluronate (0.18%), lipoic acid, hydroxypropyl methylcellulose
223600658|NCT03161080|DEVICE|Vismed Multi® Eye Drops|Eye Drops containing Sodium hyaluronate (0.18%), potassium chloride, disodium phosphate
223600659|NCT03161080|DEVICE|Hydrabak® Eye Drops|Eye Drops containing sodium chloride (0,9%), sodium dihydrogen phosphate dehydrate
223600660|NCT02110667|DEVICE|Transperineal Ultrasound|
223600661|NCT04064762|DEVICE|Paired Vagus Nerve Stimulation|Stimulation of the vagus nerve that is paired with Prolonged Exposure Therapy.
223600662|NCT01304004|OTHER|Satiety|"Intervention Description: Consumption of the 2 drinkable yogurts separated by 4 weeks:~1. Experimental drinkable yogurt enriched in proteins and fibres~2. Placebo drinkable yogurt (isocaloric and isovolumetric)"
223600663|NCT00730808|DIETARY_SUPPLEMENT|PreOP Booster (food for special medical purposes)|3x1 dosage is given prior to surgery: 2x1 the day prior to surgery; 1x1 3-4h prior to initiation of anaesthesia;
223600664|NCT06239103|DEVICE|Pulsed electromagnetic field therapy|Pulsed electromagnetic field therapy for 10 minutes, using a PEMF device, at 1 mT, 15 Hz.
223600665|NCT06239103|DEVICE|Sham treatment|Sham treatment, using the same PEMF device
223600666|NCT04120402|DRUG|EP-104IAR 25 mg|Single 5 mL intra-articular injection
223600667|NCT04120402|DRUG|Vehicle|Single 5 mL intra-articular injection
223600668|NCT00645021|DRUG|CP-945,598|Administration of CP-945,598 in subjects with mild hepatic function
223600669|NCT00645021|DRUG|CP-945,598|Administration of CP-945,598 in subjects with moderate hepatic function
223600670|NCT00645021|DRUG|CP-945,598|Administration of CP-945,598 in subjects with normal hepatic function
223600671|NCT03790059|DRUG|H101|Intraoperative injection of H101 can improve the efficacy of RFA in hepatocellular carcinoma.
223600672|NCT03790059|PROCEDURE|RFA|Treat the samll HCC with the RFA.
223600673|NCT02709811|DRUG|Electrochemotherapy|
223600674|NCT00635167|DRUG|Contrast Enhanced-Transrectal Ultrasound|Drug Once a subject is identified TRUS schedule will be set up revolving around the EBRT treatment schedule. A schedule of 6 contrast enhanced TRUS examinations per subject is planned as follows: week 0 (prior to EBRT, baseline \[Visit 2\]); week 5 (middle of treatment \[Visit 3\]); week 10 (end of treatment \[Visit 4\]); week 18 (2 months after end of EBRT \[Visit 5\]); week 26 (4 months after end of EBRT \[Visit 6\]); and week 36 (6 months after end of EBRT \[Visit 7\]).
223600675|NCT05320172|DRUG|Autologous platelet rich plasma eye drops|Fifty milliliters of patient's own whole blood will be placed in five 10-ml vacutainer tubes containing anticoagulant-citrate-dextrose solution (1.4 ml) and centrifuged at 200g for 11 min. The upper two layers of the centrifuged blood, the plasma and buffy coat layer will be separated in a sterile manner and diluted to 20 % (v/v) with a sterile saline solution. The final preparation is divided into 5-ml bottles wrapped in aluminum foil for protection from ultraviolet light. The patients are instructed to store these bottles at -20 °C until required. The bottles being used will be maintained under refrigerated conditions at 4 °C.
223600676|NCT04099615|PROCEDURE|Somatosensory Evoked Potentials|We stimulate both median nerves at wrist by means of surface adhesive electrodes. We apply square wave electrical pulses of 0.2 ms duration at a frequency of 5.7Hz. SEPs are recorded in a referential fashion from the C3' and C4' positions and from a reference electrode at Fpz or Cz' electrodes(international 10-20 system) with needle electrodes. The target signal is the presence of N20 response ipsilateral to the stroke site and, if present, measure amplitude and latency comparing with the contralateral if present. SEPs are registered during the whole procedure.
223600677|NCT02901418|BIOLOGICAL|200 IU HBIG|additional 200 IU HBIG within 24 hours was used for the experimental group of newborns
223600678|NCT00917618|OTHER|Exercise|Patients randomized to treatment arm attended 2-3 Spinning classes per week for 12 weeks.
223600679|NCT00917618|OTHER|Control|Patients randomized to the control arm were instructed not to change their baseline exercise programs
223600680|NCT01805479|OTHER|aerobic exercise|the active arm will be asked to perform 60% of maximum heart rate
223600681|NCT01805479|OTHER|stretching and flexibility program|stretching and flexibility program for the Placebo Comparator Arm
223600682|NCT04693286|BIOLOGICAL|novel oral polio type 2 vaccine (nOPV2)|• nOPV2 (C1) is a live-attenuated serotype-2 poliovirus that was derived from a modified Sabin type-2 infectious cDNA clone and propagated in Vero cells (S2/cre5/S15domV/rec1/hifi3). Placebo contain sucrose in buffer.
223600683|NCT04693286|OTHER|Placebo|Placebo contains no active ingradients, only sucrose in buffer
223600684|NCT00031759|DRUG|imiquimod|
223749060|NCT05771480|DRUG|Gemcitabine + oxaliplatin|Gemcitabine + oxaliplatin as background gemcitabine-based chemotherapy every 3 weeks (i.e., 8 cycles of durvalumab)
223600685|NCT00031759|PROCEDURE|Ablative or excisional therapy|
223600686|NCT05217394|OTHER|OTHIG|Occupational Therapy Handwriting Intervention Guideline
223600687|NCT02774369|BEHAVIORAL|Physical exercise|Individualized aerobic intervention program
223600688|NCT02774369|BEHAVIORAL|Cognitive-behavioral therapy|Psychological intervention combining behavioral, cognitive, and educational strategies
223600689|NCT00101985|DRUG|talnetant|
223600690|NCT00334243|DRUG|Microflare protocol for IVF|
223600691|NCT00334243|DRUG|Antagonist protocol for IVF|
223600692|NCT00334243|DRUG|Demi-halt protocol for IVF|
223600693|NCT03261219|DEVICE|Intrapulmonary Percussive ventilation|mode of airway clearance using mouthpiece and alternating air currents applied directly to the airway
223600694|NCT03261219|DEVICE|Chest Physiotherapy Vest (Incourage)|mode of airway clearance using external vibratory vest
224199644|NCT06942013|PROCEDURE|Free-Hand Autogenous Cortical Shell Technique (Control group)|In this group, horizontal ridge augmentation of the anterior mandible is performed using a free-hand technique without computer-guided assistance. Autogenous cortical bone is harvested from the mandibular symphysis using a conventional osteotomy performed manually. The harvested cortical shell is adapted and fixated at the recipient site using titanium mini screws, based on the surgeon's clinical judgment and intraoperative assessment. Bone particulate grafting using a 1:1 ratio of autogenous bone and xenograft material is packed into the defect to enhance volume stability. This approach may result in increased variability in graft positioning, longer surgical time, and higher dependence on surgeon experience.
224199645|NCT06943118|PROCEDURE|Chemical Peels|Chemical peel is a dermatological procedure in which chemical solution is applied to the skin to remove the top layer
224199646|NCT04401995|DRUG|Vidutolimod (CMP-001)|A molecule comprised of a 30 nucleotide strand, flanked by 10 guanines on either end. The nucleotide strand is surrounded by a Qβ viral-like protein. The intended mechanism of action of CMP-001 in oncology is the activation of TLR9 in pDC within the tumor or the tumor-draining lymph nodes (tumor-associated pDC).
224311276|NCT06178432|GENETIC|CRG003 injection|The dose of CRG003 will be calculated according to the participant's weight with single intravenous infusion.
224311277|NCT03470168|DEVICE|Hyperbaric Oxygenation Therapy|Received the Hyperbaric Oxygen therapy treatment at 2.4 ATA for 90 minutes each day.
223600695|NCT02219334|DEVICE|NoseFrida|The NoseFrida has four components, the collection container, an interchangeable filter, flexible tubing and a mouth piece. The end of the collection devise is placed on the patient's nostril, a tight seal is made via the vacuum created from suctioning of the mouth piece and secretions are easily aspirated. This device disassembles for quick disinfecting and cleaning.
223600696|NCT02527785|DRUG|Oxaliplatin, Irinotecan, S-1(OIS)|"Treatment will be delivered every 2 weeks~1. oxaliplatin 65 mg/m2 iv on day 1~2. irinotecan 135 mg/m2 iv on day 1~3. S-1 80 mg/m2/day po on day 1-7"
223600697|NCT06109064|BIOLOGICAL|Unrelated Umbilical Cord Blood|The requirements of unrelated umbilical cord blood: recipient-donor HLA match is 0-3/10, same blood type.
223600698|NCT06109064|DRUG|Venetoclax|Patients will be treated with Venetoclax (100 mg on day 1, 200 mg on day 2 and 400 mg on days 3 to 21)
223600699|NCT06109064|DRUG|Decetabine|Patients will be treated with Decetabine (20mg/m\^2/d on days 1 to 5) or Azacitidine (75mg/m\^2/d on days 1 to 7)
223600700|NCT06109064|DRUG|Azacitidine|Patients will be treated with Decetabine (20mg/m\^2/d on days 1 to 5) or Azacitidine (75mg/m\^2/d on days 1 to 7)
223600701|NCT00589771|DRUG|Saccharomyces boulardii|"1. Saccharomyces boulardii one capsule 250mg TDS for 6 weeks~2. Ispaghula husk 1 Tsf daily after dinner for six weeks"
223600702|NCT00589771|DRUG|Placebo|"1. Cap Placebo TDS for six weeks~2. Ispaghula husk 1 Tsf daily after dinner for six weeks"
223600703|NCT04003740|DEVICE|Home-based transcranial direct current stimulation|The stimulation protocol will include one daily stimulation during the first 4 weeks, 2 weekly stimulations for the next 4 weeks, and one weekly stimulation over the last 4 weeks.
223600704|NCT01692977|OTHER|neuropsychological assessment|
223600705|NCT05729932|DRUG|Inhaled vaporized cannabis|Double-blind cannabis and placebo doses, administered through vaporizer
223600706|NCT05729932|DRUG|Intransal opioid|Double-blind opioid and placebo doses, administered intranasal route
223600707|NCT02891395|DRUG|Imatinib Mesylate and Nilotinib|"For patients under Imatinib Mesylate: the total length of follow up period for those patients will be for 52 weeks following IM treatment, with a follow up at weeks IM4, IM8, IM12, IM26, IM38 and IM52.~For patients requiring a salvage phase: after the switch for nilotinib, the total length of follow up period for this phase will be for 52 weeks following nilotinib treatment, with a follow up at weeks nilo4, nilo8, nilo12, nilo26, nilo38 and nilo52."
223600708|NCT04729075|OTHER|ARDS and COVID19 treatments|Interventions that will be analyzed will include: immunomodulation; oxygen supplementation type, duration and level; mechanical ventilation type, duration; diuresis; inotrope/vasopressors; prone positioning
223600709|NCT04293185|GENETIC|bb1111|Drug Product is administered by IV infusion following myeloablative conditioning with busulfan.
223600710|NCT01108913|DRUG|Bimosiamose|
223600711|NCT01108913|DRUG|Placebo|
223600712|NCT03231007|OTHER|Questionnaire|A structured questionnaire will be administered to maternity service users. Another structured questionnaire will be administered to maternity healthcare professionals, and another to Organisational Leads (e.g. Clinical Directors at each site).
223600713|NCT06172179|OTHER|No interventions|All procedures are observation. No intervention in this study.
223600714|NCT02926989|DRUG|Plasmalyte Glucos 50 mg/mL|Solution contains potassium chloride 5 mmol/L and sodium chloride 140 mmol/L.
223600715|NCT02926989|DRUG|0.45% saline in 5% dextrose|Solution contains potassium chloride 20 mmol/L and sodium chloride 80 mmol/L.
223749061|NCT05771480|DRUG|Gemcitabine + carboplatin|Gemcitabine + carboplatin as background gemcitabine-based chemotherapy every 3 weeks (i.e., 8 cycles of durvalumab)
223600716|NCT05043753|OTHER|Point of care ultrasound to measure the fetal abdominal circumference (POC-US-AC)|"Midwives perform a POC-US to measure the fetal abdominal circumference (AC) and evaluate the quantity of amniotic fluid.~In order to identify the appropriate sonographic plane the following markers need to be identified on POC-US~* Fluid filled fetal stomach on the left.~* Umbilical vein~* Umbilical portion of left portal vein within liver, as it meets the pars transversa (horizontal portion of left portal vein) seen as a right sided  L  or  C  shape.~* Fetal spine seen in cross section Amniotic fluid volume will be evaluated determining the deepest vertical pocket (DVP). Measurement is performed by assessing a pocket of maximal depth of amniotic fluid free of umbilical cord and fetal parts. The transducer is held perpendicularly to the patient's abdomen. The absence of a pocket measuring at least 2 cm in depth and 1 cm in width is indicative of oligohydramnios, while detection of a pocket measuring 8 cm or larger is suggestive of polyhydramnios (ACOG bulletin 175, 2016)."
223600717|NCT06251297|OTHER|Foot reflexology|30 minutes reflexology session
223600718|NCT05357521|OTHER|stress test|TSST- psychosocial stress test
223600719|NCT05485038|PROCEDURE|Tumor resection in awake patient|Surgeon performs critical steps of tumor removal in awake patient and controls his/her motor functions by brain mapping and assessing of voluntary movements
223749062|NCT05771480|DRUG|Gemcitabine + cisplatin + S-1|Gemcitabine + cisplatin + S-1 as background gemcitabine-based chemotherapy every 2 weeks (i.e, 4 cycles of durvalumab)
223600720|NCT05485038|PROCEDURE|Tumor resection in asleep patient|Surgeon removes tumor in asleep patient and controls his/her motor functions by brain mapping
223600721|NCT05294445|PROCEDURE|Ablation of atrial fibrillation (AF)|Cryo-AF-ablation of pulmonary vein (pulmonary vein isolation = PVI)
223600722|NCT05182697|DRUG|SCI-210|Oral CBD oil plus pills of CannAmide (palmitoylethanolamide (PEA) 400 mg twice daily
223600723|NCT05182697|DRUG|Oral CBD oil|CBD- active CBD oil with twice daily CannAmide Placebo pills matched in appearance and taste to CannAmide active pill.
223600724|NCT06489951|DRUG|Solifenacin|The outpatient physician prescribed Solinaxine (up to 0.5mg daily) to the participant orally
223600725|NCT06489951|DIETARY_SUPPLEMENT|vitamin D|The outpatient physician prescribed vitamin d drops (2400iu daily) for the participants, which were taken orally by the participants
223600726|NCT06489951|BEHAVIORAL|Standard behavioral therapy|Participants will receive an initial behavioral therapy session at enrollment and a second behavioral therapy session six weeks later. Education including information about dry OAB, lifestyle adjustments, bladder and pelvic floor training, bowel management, and how to use a bladder diary to record urination
223600727|NCT03886714|DIAGNOSTIC_TEST|Screening for Fabry disease|Screening for the α-galactosidase (GAL) enzyme activity (men + women) and plasma Lyso globotriaosylsphingosine (GL3, women) for the diagnosis of Fabry disease.
223600728|NCT03886714|DIAGNOSTIC_TEST|Screen for α-galactosidase mutation|If necessary (positive for GAL), genetic confirmation tests for Fabry disease will be performed (men + women).
223600729|NCT06765590|DRUG|T, 260 mg/m2, paclitaxel for injection (albumin-bound)|T, 260 mg/m2, paclitaxel for injection (albumin-bound)
223600730|NCT06765590|DRUG|R, 260 mg/m2, paclitaxel for injection (albumin bound).|R, 260 mg/m2, paclitaxel for injection (albumin bound).
223600731|NCT05873842|DEVICE|Trans-femoral TAVI|Trans-femoral TAVI (Trans-catheter Aortic Valve Implantation) with calcified ilio-femoral arteries via PTA (Percutaneous transluminal angioplasty ) or IVL (Intra-vascular Lithotripsy)
224199647|NCT04401995|BIOLOGICAL|Nivolumab|a fully human Ig G4 antibody that blocks PD-1. Nivolumab was initially approved by the FDA for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor. Nivolumab has also been FDA approved to treat patients with advanced squamous non-small cell lung cancer (NSCLC) with progression on or after platinum-based chemotherapy, as well as advanced renal cell carcinoma.
224199648|NCT04401995|OTHER|[18F]F-AraG PET/CT|\[18F\]F-AraG is an 18F-labeled analog of arabinofuranosylguanine (AraG), a compound that has shown remarkably selective accumulation in T cells. It has several advantages over conventional \[18F\] and existing small molecule PET agents being investigated for immuno-monitoring. \[18F\]F-AraG has lower accumulation and more efficient efflux from cancer cells than a dCK agent.
224199649|NCT05987163|DEVICE|GP0116|GP0116 is an injectable, sterile, transparent product.
224199650|NCT05987163|DEVICE|Active Comparator: FDA approved dermal filler device (RHA 3)|FDA approved dermal filler device (RHA 3)
224199651|NCT06536595|OTHER|Scales|Participants were asked to complete the HAnDE-T, MHISS, SF-36 and HAQ when they first came. After 1 week, they were asked to complete HAnDE-T for re-test.
224199652|NCT05060913|DRUG|EMLA Cream|Effect of 5% Emla cream on pricking pain measured on VAS scale.
224199653|NCT05060913|DRUG|Benzocaine Gel|Effect of 20% Benzocaine gel on pricking pain measured on VAS scale.
224199654|NCT02388659|DEVICE|3 Tesla scanning|Approximately 38 brain tumor patients with IDH mutated gliomas and 50 patients with non-glioma disease will be scanned.
224199655|NCT03187899|DRUG|Ropivacaine|0.5% of Ropivacaine will be used patients in both groups. Ropivacaine is very common in the investigator's practice of regional anesthesia. The investigator has experienced minimal adverse effects with 0.5% Ropivacaine used in volume suggested in our study.
224199656|NCT03187899|DRUG|Normal saline|5-10cc of Normal Saline will be given to patients receiving a traditional interscalene block and a sham superficial plexus block.
224199657|NCT01140815|DEVICE|Total Knee Replacement|Smith and Nephew Total Knee Replacement
224199658|NCT01140815|DEVICE|Deuce|Smith and Nephew Bicompartmental Knee Replacement
223600732|NCT02397200|DIETARY_SUPPLEMENT|Nutritional supplementation standardized formula|Powder added to water, containing about 25% of recommended Daily Recommended Intake (DRI) for Calories, high protein (25% of calories) and multi vitamin and mineral (25%-100% of DRI for recommended daily allowance (RDA) or adequate intake )
223600733|NCT02397200|DIETARY_SUPPLEMENT|Placebo|Low caloric formula (Powder added to water), without added vitamins and minerals
223600734|NCT02380443|BIOLOGICAL|AlloStim|AlloStim is an activated living CD4+ Th1 memory cell derived from the blood of normal blood donors and intentionally mismatched to the recipient. AlloStim is bioengineered to express high levels of Type 1 inflammatory cytokines (such as interferon-gamma, TNF-alpha, GM-CSF) and immunomodulatory molecules such as CD40L. AlloStim has CD3/CD28-coated microbeads attached to assure activation upon infusion.
223600735|NCT02380443|PROCEDURE|Cryoablation|Percutaneous partial cryoablation of a single metastatic tumor lesion in the liver. The procedure is conducted under CT or ultrasound image-guidance
223600736|NCT02630472|DRUG|Quinine Sulfate|Our plan is to first study quinine against saline to determine efficacy and safety. The vast majority of patients with rhinosinusitis utilize low pressure / high volume (240mls) sinonasal lavage to cleanse the sinonasal cavity. The patients will be exposed to a maximum of 12mls or 12.0 mg of quinine. In standard tonic water, quinine is 8.3mg/100mls and thus an 8oz glass of Canada Dry tonic water has 19.6mg of quinine. Thus, the maximum systemic exposure in our study (assuming ingestion of the total nasal administration) is less than drinking one glass of tonic water / day. To put this in context, the therapeutic range of quinine to treat malaria is 10mg/kg true ileal digestibility (TID) (2100mg for a 70kg individual) nearly 200 X the dose the investigators are proposing.
223749063|NCT05771480|DRUG|Gemcitabine + S-1|Gemcitabine + S-1 as background gemcitabine-based chemotherapy every 3 weeks (i.e., 8 cycles of durvalumab)
223749064|NCT05771480|DRUG|Gemcitabine + cisplatin + albumin-bound paclitaxel|Gemcitabine + cisplatin + albumin-bound paclitaxel as background gemcitabine-based chemotherapy every 3 weeks (i.e., 8 cycles of durvalumab)
223749065|NCT06211374|BEHAVIORAL|Communication Bridge|Evidence-based speech language therapy treatment will be compared and contrasted in the two arms of the study.
224199659|NCT05077033|DRUG|phIL12 GET|intratumoral phIL12 gene electrotransfer
223749066|NCT01050738|PROCEDURE|Position of catheter|Position of catheter for administration of local anestesia.
223749067|NCT05448482|PROCEDURE|Transobturator tape|Mid urethral sling for treatment of female stress urinary incontinence
223749068|NCT03031171|BEHAVIORAL|Screening patient navigation|The program offered assistance with scheduling, paperwork, arranging transportation, answering questions and providing education about screening and colorectal cancer.
223749069|NCT03031171|BEHAVIORAL|Non-Navigated|Randomly matched sample of non-navigated clinic patients
223600737|NCT02630472|DRUG|Placebo|In order to blind the participants to which arm they have been randomized into, the placebo arm will contain saline solution spiked with 0.5 mg/ml sucrose octaacetate. This solution will produce a bitter flavor similar to the one produced by quinine. There is no evidence that sucrose octaacetate produces nitric oxide production in the sinonasal cavity, nor is there evidence that it has any side effects (it is used to wean babies off of pacifiers) so the investigators feel it is an effective and safe option for a placebo.
223600738|NCT06488105|DRUG|Statin (rosuvastatin 10 or 40 mg daily, depending on risk)|moderate- or high-intensity statin (either rosuvastatin 10 mg daily or rosuvastatin 40 mg daily)
223600739|NCT06488105|BEHAVIORAL|Healthy Lifestyle Counseling|Healthy lifestyle counseling based off the American Heart Association's Life Essential 8 framework
223600740|NCT06488105|OTHER|Outpatient Followup|Emergency Medicine Cardiovascular Risk Assessment for Lipid Disorders (EMERALD) intervention patients will receive either cardiology or primary care referral (depending on risk level) and usual care patients will receive a primary care referral
223600741|NCT04878211|DRUG|Ofatumumab|3 loading doses followed by monthly administrations
223600742|NCT04878211|BIOLOGICAL|mRNA COVID-19 vaccine|Pfizer or Moderna mRNA Vaccine
223600743|NCT04878211|DRUG|interferon or glatiramer acetate|iDMT
223600744|NCT01473628|OTHER|Clinical Observation|Undergo observation
223600745|NCT01473628|RADIATION|Radiation Therapy|Undergo radiation therapy
223600746|NCT01473628|BIOLOGICAL|Rituximab|Given IV
223600747|NCT04774926|DRUG|Brolucizumab|120 mg/ml solution for intravitreal injection
223749070|NCT03392116|BIOLOGICAL|NGM120|Subcutaneous Injection
223749071|NCT03392116|OTHER|Placebo|Subcutaneous Injection
223749072|NCT02857010|BIOLOGICAL|Allogenic mesenchymal stem cells|Cell therapy
223749073|NCT02857010|OTHER|Placebo|Serum without stem cells
223749074|NCT03770572|GENETIC|Low dose CLN-301|Subjects with diagnosis of CLN3 Batten disease will receive a single dose of CLN-301 at low dose
223749075|NCT03770572|GENETIC|High dose CLN-301|Subjects with diagnosis of CLN3 Batten disease will receive a single dose of CLN-301 at high dose
223749076|NCT05384093|DEVICE|High Intensity Stretch Device|High Intensity Stretch and Physical Therapy are used either together or alone to treat study arm.
223749077|NCT00643422|DEVICE|Cirrus™ HD-OCT, Carl Zeiss Meditec AG|the retinal thickness and volume is determined on two different days with the Cirrus™ HD-OCT.
223749078|NCT03941535|DRUG|Vitamin K|Administration of intravenous Vitamin K in doses of 10mg/day, 5mg/day or 2mg/day
223749079|NCT01154309|BEHAVIORAL|Group CBT for Depression and AOD Disorders|18 sessions of 2-hour group CBT
224199660|NCT03939728|RADIATION|Chest radiography and lung ultrasound|We'll include all patients which have, during their stay in pediatric intensive care unit, in order to have a pleural or pulmonary diagnosis, a chest radiography and then a lung ultrasound, at less than 2 hours interval.
224199661|NCT03899545|OTHER|Serratus Plane Block|0.5 ml /kg Bupivacaine/lidocaine mixture will be injected onto the serratus muscle
224199662|NCT03899545|OTHER|Serratus Plane Block plus Pectoral I Block|0.5 ml / kg %0.25 Bupivacaine/ %1 lidocaine mixture will be injected onto the serratus muscle and injected between the pectoralis minor/pectoralis major muscles.2/3 of the total drug will be applied for the serratus plane block and 1/3 of the total drug for the pectoral I block. If the total amount of the drug is less than 30 ml, it will be completed with isotonic saline to 30 ml.
224199663|NCT00883831|PROCEDURE|Individualized manual acupuncture|Acupuncture treatment will be provided according to traditional korean medicine (TKM) theory which focuses on patient's individual symptoms and conditions. 10-12 needles will be inserted into acupuncture point on the body except one arm where arteriovenous fistula is located for hemodialysis access. Needle retention time will be 30 minutes with intermittent manual stimulation to elicit de-qi sensation. Biweekly treatment will be conducted at non-dialysis access day or before hemodialysis at dialysis-access day for 6 weeks.
224199664|NCT04370808|OTHER|Exposure|Individuals with SARS-CoV-2 exposure and COVID-19 symptoms.
224199665|NCT03638479|OTHER|Data Capture|This is no intervention. Participants of all groups will receive data Capture with smartphones, smartwatches and tablets.
223600748|NCT05623241|DIAGNOSTIC_TEST|Liquid Biopsy|Venous blood sampling for liquid biopsy in breast cancer patients after segmentation of the lesion on mammography
223600749|NCT02783599|DRUG|Olaratumab|Administered IV
223600750|NCT02783599|DRUG|Doxorubicin|Administered IV
223600751|NCT02783599|RADIATION|External Beam Radiotherapy|
223600752|NCT06210100|DEVICE|Active iTBS|Mag-TD stimulator
223600753|NCT06210100|DEVICE|Sham iTBS|Mag-TD stimulator
223749080|NCT06104566|DRUG|lisaftoclax +BTK inhibitor|lisaftolax + BTK inhibitor
223749081|NCT06104566|DRUG|BTK inhibitor|BTK inhibitor
223749082|NCT00476021|DEVICE|Levonorgestrel-releasing IUD (Mirena)|levonorgestrel-releasing IUD containing 52 mg levonorgestrel, indicated for use for up to 5 years
223749083|NCT04076800|PROCEDURE|Acupuncture|Acupuncture treatment will include use of somatic points (SP6; ST36; KI3; CV4; CV12; TE5; LI4; LI11; YinTang; ST28; BL23; BL22; BL20; BL13) and auricular points (most tender point on palpation with pressure feelers of 400 gr on Stomach, Endocrine, Spleen, Kidney, Hungry, Shen man and Pancreas auricular points).
223749084|NCT02493699|OTHER|physical exercise- based intervention (Karate techniques training)|
223749085|NCT03023033|BEHAVIORAL|mHealth messaging|SMS appointment reminders and health messaging via mobile phones
223749086|NCT03023033|BEHAVIORAL|Transport Payments|A payment scaled to reflect the cost of typical return transport fare for residents of the clinic catchment area
223749087|NCT00593307|OTHER|high GI|high GI and high carb breakfast
223749088|NCT00593307|OTHER|Low GI|low GI, high carb breakfast
223749089|NCT00593307|OTHER|Low GI Low Carb|low GI low carb breakfast
223749090|NCT00593307|OTHER|High GI Low carb|high GI low carb breakfast
223600754|NCT04760405|OTHER|Tai Chi Easy|Patients will receive two 30-minute small group training sessions (Via Zoom) within 7 days of their scheduled transplant. After the training has been completed the participant will be provided with written (via manual) and electronic (DVD, MP3 file download) materials to continue with self-direct practice throughout the duration of the study.
223600755|NCT05643339|DIAGNOSTIC_TEST|microvascular flow imaging|microvascular flow imaging
223600756|NCT03453580|RADIATION|multislice computed tomography portography|imaging modality
223600757|NCT05133765|DEVICE|Insulin pump|Alterations in insulin pump therapy or carbohydrate consumption
223600758|NCT00633529|DRUG|IMO-2055|0.08, 0.16, or 0.32 mg/kg SC (subcutaneous) on days 1,8,and 15 of every 21 day cycle until evidence of progressive disease, unacceptable treatment-related toxicities, withdrawal of patient consent and/or Investigator decision to withdraw study therapy with documented reason, whichever occurs first.
223600759|NCT03536559|DRUG|CNM-Au8|CNM-Au8 is a dark red/purple-colored liquid formulation consisting of a stable suspension of faceted clean surfaced elemental gold nanocrystals in buffered deionized water with a concentration of up to 0.5 mg/mL of gold. The formulation is buffered by sodium bicarbonate present at a concentration of 0.546 mg/mL. There are no other excipients. The drug product is formulated to be taken orally and will be provided in single dose HDPE containers. The study doses vary by the concentration of gold nanocrystals per milliliter in a volume of 60 mL.
223600760|NCT03536559|DRUG|Placebo|Placebo is liquid with identical color and taste
223600761|NCT01770236|DRUG|IV acetaminophen|Patients randomized to the IV acetaminophen group will receive IV acetaminophen (1000 mg every 6 hours for adults and weight-based for any patient under 50 kg)instead of an On-Q pain pump catheter.
223600762|NCT03630757|OTHER|Treatment|In the study group, a total of 15 sessions of a manual therapy program including myofascial release and mobilization techniques were applied for 60-minute session for 3 weeks(5/wk).
223600763|NCT05356780|DEVICE|Aligner|A method of straightening teeth without fixed braces
223600764|NCT06353282|DRUG|MDMA|MDMA will be dosed in pre-filled capsules and administered orally to participants in two fixed doses - an 80mg dose following the fourth session and a 120mg dose following the ninth session of MDMA to each participant. MDMA experimental medication administration session 1 (8 hours); MDMA experimental medication session 2 (8 hours). Participants will be required to remain in the therapy room for the duration of the experimental medication sessions without the youths' parent/guardian present. The parent/guardian will be invited to attend integration sessions and must be available to drop off and pick up the participant.
223600765|NCT06353282|BEHAVIORAL|Psychotherapy|Treatment session order: Four weekly 90-minute experimental medication preparation psychotherapy sessions; four weekly 90-minute psychotherapy integration sessions, starting the day following the preceding experimental medication session; and Five weekly 90-minute psychotherapy integration sessions, starting the day following the preceding experimental medication session.
223600766|NCT00391313|DRUG|Chloroquine|
223600767|NCT03492606|PROCEDURE|Samples|lumbar puncture, blood and CSF samples, SNPs analysis
223600768|NCT01401517|DRUG|sodium nitrite|0, 40 or 80 mg twice each day for 10 weeks followed by a 1 week escalation of 2 times the dose.
223600769|NCT01000259|OTHER|Laboratory Biomarker Analysis|Samples are analyzed in laboratory studies
223600770|NCT05899400|DIAGNOSTIC_TEST|Diascopic iON Image Analysis System|A scanning digital optical train that images sputum slides for automated analysis by a tuberculosis detecting algorithm
223600771|NCT00728091|DRUG|Satavaptan|tablets
223600772|NCT00728091|DRUG|placebo|tablets
223600773|NCT00288678|PROCEDURE|Health Education|
223600774|NCT04094857|DRUG|HBN-1|Intravenous infusion
223600775|NCT01032720|PROCEDURE|Ultrasound|Ultrasound will be used to image knee joint and guide needle for intra-articular corticosteroid injection.
223600776|NCT01032720|PROCEDURE|Sham ultrasound|Knee CS injection will be performed in the same method as the US-guided injection except that the US machine will be turned off. Study patient will be unaware of whether US machine is on or off.
223749091|NCT04274647|DEVICE|NON-STERILE, POWDER FREE NITRILE EXAMINATION GLOVES, LOW DERMATITIS POTENTIAL, TESTED FOR USE WITH CHEMOTHERAPY DRUGS - BLUE|Approximately 2cm x 2cm square positioned to ensure that the inside portion of the test material maintained skin contact.
223600777|NCT05501834|OTHER|Supracondylar Pin Removal Before Imaging|Patients in the treatment group will: 1. Go to cast room for cast removal, 2. Have pins immediately pulled after cast removal, 3. Go to radiology for X-ray, 4. Will be seen in clinic room by provider. The order of these steps differs from our current standard of care, during which patients' pins are removed following cast removal and x-ray imaging.
223600778|NCT01849094|DRUG|Milrinone 6mg|Administration of study medications, PK sampling If Part B - add on 6 hour haemodynamic invasive measurements
223600779|NCT01849094|DRUG|milrinone 10mg ER|Administration of study medications, PK sampling If Part B - add on 6 hour haemodynamic invasive measurements
223600780|NCT01849094|DRUG|milrinone 14mg|Administration of study medications, PK sampling If Part B - add on 6 hour haemodynamic invasive measurements
223600781|NCT04236362|DRUG|TQB2450|TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.
223600782|NCT04236362|DRUG|Anlotinib|A multi-target receptor tyrosine kinase inhibitor
223600783|NCT00104624|DRUG|docetaxel|
223600784|NCT00104624|PROCEDURE|quality-of-life assessment|
223600785|NCT02369393|BEHAVIORAL|Behavioral Activation|Behavioral Activation intervention promotes the involvement in meaningful activities close to personal values.
223600786|NCT02369393|BEHAVIORAL|Physical Activity|Physical Activity intervention promotes the gradual increase of the frequency and intensity of PA levels, with special attention to motivational strategies.
223749092|NCT01257373|DEVICE|Firebird 2 Cobalt-Chromium Alloyed Sirolimus-Eluting Stent|Firebird2 CoCr-alloyed sirolimus-eluting stent system is the 2nd generation of drug-eluting stent(DES). It was registered successfully on Jan. 16, 2009 in China. This stent is based with a CoCr alloyed metal platform. The length is from 13-33mm, the diameter is from 2.5mm-4.0mm.
223749093|NCT02665871|BIOLOGICAL|one dose of Influenza Vaccine|
223749094|NCT02665871|BIOLOGICAL|one dose of Influenza Vaccine|
223749095|NCT02665871|BIOLOGICAL|placebo|
223749096|NCT02665871|BIOLOGICAL|placebo|
223749097|NCT00514267|DRUG|YM 155|IV
223600787|NCT05904574|OTHER|Autologous blood patch|Approximately 3-4 pieces were taken with the 18 G core biopsy needle until sufficient tissue was obtained. In the autologous blood patch technique, approximately 6-7 ml of blood was taken from the patient with a 10 ml syringe before the procedure. By attaching a 3-way tap to the injector from which the blood is drawn, blood is drawn into a second injector to ensure that the clotted blood is dispersed and homogenized. The prepared autologous blood patch was given through the coaxial needle (approximately 1 ml of autologous blood patch was applied for every 1 cm when the coaxial needle was withdrawn) and the tract formed by the biopsy needle in the parenchyma, pleura, and under the skin was closed with the patient's autologous blood.
224199666|NCT01919437|DEVICE|Web-Enabled Cognitive Neuropsychological Evaluation System|
224199667|NCT02740751|DIETARY_SUPPLEMENT|Still-Tee|The mothers of the babies will receive Still-Tee galactogogue tea
224199668|NCT03680209|OTHER|Simulation|pre-training observation training post training observation
224199669|NCT00003876|DRUG|polifeprosan 20 with carmustine implant|
224199670|NCT00003876|PROCEDURE|surgical procedure|
224199671|NCT00003876|RADIATION|iodine I 125|
224199672|NCT00681876|DRUG|Irinotecan|Irinotecan (IV) 150 mg/m2 on day 1 every two weeks until progression
224199673|NCT00681876|DRUG|Avastin|Avastin (IV) 10 mgr/Kgr on day 1 every 2 weeks until progression
224199674|NCT00681876|DRUG|Erbitux|Erbitux (IV)500 mg/m2 on day 1 every two weeks until progression
224199675|NCT04651660|DEVICE|Neuro Cochlear Implant System|"Before the mastoidectomy, the ear canal is cleaned, the insert earphone is connected to the Eclipse (Oticon Medical software) preamplifier and placed into the ear canal. The EEG scalp electrodes (active, ground electrode) are placed on the patient's head. After the posterior tympanotomy, the reference electrode (eCochG probe) is placed on the cochlear promontory.~The CI electrode array will be inserted following one of the two possible techniques while the eCochG will be recording. The surgeon will either manually insert the array using the Oticon Medical stylet and following the surgery guides and recommendations from Oticon Medical or will control the Robotol insertion angle and drive the robotic arm in the same way."
224199676|NCT04020822|DEVICE|Guardian Sensor (3)|Guardian Sensor (3) connected to Guardian Link (3) Transmitter and/or Guardian Connect Transmitter.
224199677|NCT00882804|DRUG|Hemin infusion|Hemin (Panhematin®, Ovation Pharmaceuticals, Deerfield, IL) will be administered through a large-caliber peripheral vein at a dose of 1.25 mL/kg and at a rate of 60 mL/hour. To enhance stability, Panhematin® will be diluted in \~ 132 mL of 25% albumin to obtain a hemin concentration of 2.4 mg/mL.
224199678|NCT00882804|DRUG|placebo infusion|25 % albumin will be administered through a large-caliber peripheral vein at a dose at a rate of 60 mL/hour.
224199679|NCT01084824|DRUG|Liquid nitrogen and cantharidin|Liquid nitrogen applied to wart(s), then cantharidin 1% topical applied afterward.
224311278|NCT03470168|DEVICE|Normobaric Oxygenation therapy|Received the Normobaric Oxygen therapy treatment at 1 ATA for 90 minutes each day.
224199680|NCT01084824|DRUG|Liquid nitrogen and topical placebo|Liquid nitrogen applied to wart(s), then placebo vehicle applied thereafter.
224199681|NCT00619658|OTHER|telephone follow-up|subjects undergoing medical abortion will recieve a telephone call and be asked a series of clinical questions. Expulsion of the pregnancy will be assessed based on the answers to those questions.
224199682|NCT06213961|OTHER|pecha kucha education|Basic life support training to be given to students will be given by the pecha kucha presentation method.
224199683|NCT03165409|BIOLOGICAL|Nivolumab|Melanoma intervention
223600788|NCT05904574|OTHER|Percutaneous transthoracic biopsy|After determining the lung lobe where the lesion was observed, axial CT images of 5 mm cross-section thickness were obtained so that the upper and lower parts of it could be visualized. After ruling the entry site in the skin, antisepsis and local anesthesia were performed. The coaxial system (17 G) was cautiously advanced and CT images were continuously evaluated to confirm entrance into the lesion. Biopsy was taken and after sufficient tissue samples were taken at the last stage of the biopsy procedure, control CT imaging, including the whole lung, was performed to evaluate complications. The presences of pneumothorax were noted.
223749098|NCT00514267|DRUG|Docetaxel|IV
223749099|NCT00514267|DRUG|Prednisone|Oral
224199684|NCT03165409|BIOLOGICAL|Ipilimumab|Melanoma intervention
223749100|NCT00685243|PROCEDURE|Laser treatment|Fraxel and pulsed dye laser
223749101|NCT00324831|DRUG|autologous immunoglobulin idiotype-KLH conjugate vaccine|
223749102|NCT00324831|DRUG|cyclophosphamide|
224199685|NCT01319994|DRUG|Metformin|Metformin 850mg TDS (12 weeks)
223749103|NCT00324831|DRUG|doxorubicin hydrochloride|
223749104|NCT00324831|DRUG|prednisone|
223749105|NCT00324831|DRUG|rituximab|
223749106|NCT00324831|DRUG|sargramostim|
223749107|NCT00324831|DRUG|vincristine|
223749108|NCT00324831|PROCEDURE|Intervention/procedure|
224199686|NCT01319994|DRUG|Placebo|Placebo 850mg TDS (12 weeks)
224199687|NCT02881866|DRUG|Furosemide|
224199688|NCT02881866|DRUG|Saline|
224199689|NCT04773366|DRUG|Prednisone+Cytarabine+vincristine|Group 1 initial treatment (W1\~W6). Prednisone 40mg/m2×4w, taper 2w; Vincristine 1.5mg/m2 iv d1 of w1,2,3,4,5,6; Cytarabine 100mg/m2 iv/IH d1-4 q2w (w1,3,5)
224199690|NCT04773366|DRUG|Prednisone+Cytarabine+vincristine+Mercaptopurine|Group 1 Consolidation continuation treatment (W7\~W22) . Prednisone 40mg/m2 d1-5 q3w (w7,10,13,16,19,22); VCR 1.5/m2 iv d1 q3w (w7,10,13,16,19,22); Cytarabine 100mg/m2 iv/IH d1-4 q3w (w7,10,13,16,19,22); 6-MP 50mg/m2/d,po,qn
224199691|NCT04773366|DRUG|Prednisone+Cytarabine+vincristine+Mercaptopurine|Group 1 Maintenance continuation treatment (W25\~52) . Prednisone 40mg/m2 d1-5 q3w; Vincristine 1.5/m2 iv d1 q3w; Cytarabine 100mg/m2 iv/IH d1-4 q6w ×3 times (w25,31,37); 6-MP 50mg/m2/d,po,qn
224311279|NCT03878667|DIETARY_SUPPLEMENT|Curves Calcium|Curves Essential Bio-Available Calcium (providing 800 mg/d of calcium \[as calcium citrate malate and calcium citrate\], 400 IU/d of Vitamin D, 300 mg/d of magnesium, 4 mg/d of zinc, 2 mg/d of copper, 2 mg/d of manganese, 198 mg/d of potassium, 100 mg/d of trace mineral complex, and 2 mg/d of boron).
224311280|NCT03878667|DIETARY_SUPPLEMENT|Calcium Carbonate|Calcium (providing 950 mg/d as carbonate)
224311281|NCT03878667|DIETARY_SUPPLEMENT|Placebo|Dextrose placebo
224311282|NCT05670574|PROCEDURE|Surgery with extended (D3) mesenterectomy for small bowel tumors|
223600789|NCT01342588|PROCEDURE|Electric pulse train stimulation|Electric pulse train stimulation of regular probes and screw drivers used in track creation and screw placement Using a standard neurophysiological work station, a series of square wave pulses will be delivered through standard probes and screw drivers using an alligator clip during pedicle probing and screw insertion (4 Hz for 50-200 μsec at 10-30 μAmp)
223600790|NCT05176236|OTHER|Pictographic tracheostomy care handouts|The handouts were developed and validated by Clinical and inter-professional experts based on the hospital's text-based tracheostomy home care instructions.
223600791|NCT03061435|PROCEDURE|Screening anal Pap smear - No high-resolution anoscopy|75% of patients with negative cytology on their anal Pap smear will not receive high-resolution anoscopy
223600792|NCT03061435|PROCEDURE|Screening anal Pap smear - High-resolution anoscopy|25% of patients with negative cytology on their anal Pap smear will receive high-resolution anoscopy. All patients with positive (abnormal) cytology on their anal Pap smear will receive high-resolution anoscopy.
223600793|NCT05943249|PROCEDURE|magnetic resonance|
223600794|NCT00870181|BIOLOGICAL|ADV-TK/GCV|gene therapy
223600795|NCT00870181|PROCEDURE|Surgery|
223600796|NCT00870181|DRUG|systemic chemotherapy|
223600797|NCT01548027|PROCEDURE|Local infiltration group|patients would have 0.5 ml/kg of 0.25% bupivacaine if age \< 6 months or 1 ml/kg if age \> 6 months around the wound by surgeon. The needle will be injected in subcutaneous tissue parallel to the wound.
223600798|NCT01548027|PROCEDURE|TAP block|Surgical TAP block (sTAP: Patients would have 0.5 ml/kg of 0.25% bupivacaine if age \< 6 months or 1 ml/kg if age \> 6 months
223600799|NCT01548027|OTHER|No intervention|No intervention
223600800|NCT05173012|DRUG|SAGE-324|SAGE-324 oral tablets.
223600801|NCT05173012|DRUG|SAGE-324 Matched Placebo|SAGE-324 matched placebo oral tablets.
223600802|NCT03945461|OTHER|Chewing gum|xylitol based, peppermint flavored gum
223600803|NCT02936843|DRUG|Salsalate|1 gram, 3 times daily by mouth (total of 3 grams daily)
223600804|NCT02936843|DRUG|PLACEBO|Placebo for Salsalate; 2 Tablets, 3 times daily by mouth (total of 3 grams daily)
223600805|NCT06411431|PROCEDURE|Early Chest Tube Removal|"Subjects within the Early Removal group will have their chest tube removed if the following criteria are met on the morning of POD#1:~* ≤1 cm of apical pleural separation and no other areas of pleural separation~* No air leak~* No bloody output or concern for bleeding~* \< 400cc of drainage"
223600806|NCT06411431|PROCEDURE|Standard Chest Tube Removal|"Subjects within the Standard Removal group will have their chest tube removal on POD#2 if the following criteria are met on the morning of POD#1:~* ≤1 cm of apical pleural separation and no other areas of pleural separation~* No air leak~* No bloody output or concern for bleeding~* \< 400cc of drainage"
223600807|NCT06411431|DEVICE|Apical Chest Tube|A single apical chest tube will be placed and connected to a suction device at least -20 mmHg suction.
223600808|NCT05186740|DEVICE|ProVee Urethral Expander System|ProVee Expander is placed in prostatic urethra to relieve obstruction due to BPH.
223600809|NCT05186740|PROCEDURE|Urethral Access Sheath|The Urethral Access Sheath is introduced into the prostatic urethra to simulate the placement of the ProVee Expander.
223600810|NCT03668613|DRUG|secukinumab low dose|dose depends on the weight group
223600811|NCT03668613|DRUG|secukinumab high dose|dose depends on the weight group
223600812|NCT01393821|DRUG|menadione topical lotion|Given topically
223600813|NCT01393821|OTHER|placebo|Given topically
223600814|NCT01393821|OTHER|questionnaire administration|Ancillary studies
223600815|NCT01393821|PROCEDURE|management of therapy complications|Given menadione topical lotion
223600816|NCT04339621|DEVICE|LiverMultiscan|The LiverMultiscan is a quick 15 minute, contrast free MRI scan that provides three metrics on liver health namely fat, iron and fibro-inflammatory scores
223600817|NCT05004220|PROCEDURE|Plasmapheresis|Procedure whereby plasma is separated and extracted from anticoagulated whole blood and the red cells retransfused to the donor.
223600818|NCT03515096|DRUG|Eltrombopag|Eltrombopag 50 mg; po; from day 1 to platelet is completely effective recovered after HSCT.
223600819|NCT03515096|DRUG|rhTPO|rhTPO 15000 u; subcutaneously injection; from day 1 to platelet is completely effective recovered after HSCT.
223600820|NCT04336033|OTHER|Counseling|Subjects in the both arms will receive individualized dietetic counseling as the standard dietetic care in Malaysia
223600821|NCT04336033|OTHER|Renal Diet App|Individualized dietetic counseling aided with a newly developed renal diet app for educative purpose and aiding tool to enhance the dietary adherence among CKD patients. Training on the use of the app will be provided to the subjects prior to the commencement of the intervention. Subjects will be trained on the use of the home screen, icons, feedback screens, the process of entering dietary and fluid intake data and selecting portion sizes. Subjects are considered as competent users when they could correctly record the foods and drinks with correct portion size eaten in the past 24 hours and successfully save the data.
223600822|NCT04336033|OTHER|Printed Nutrition Pamphlet|"After the counseling session, a standardized renal nutrition pamphlet prepared by dietitians from Universiti Putra Malaysia and Hospital Serdang will be given for patient's educative purpose.~Since the mobile application is intended for patient's education and self-monitoring (food diary) purposes, and thus, to ensure the comparability between intervention and control groups, the patients in control group will be trained to record their diet intakes manually using the recommended approach 3-day diet records. Nutritional feedback or advices on the diet records will be given to the participants during follow up sessions."
223600823|NCT02211248|OTHER|Multidisciplinary assistance|Multidisciplinary group assistance was effected every two months by all professionals (physician, nurse, dietitian, physiotherapist and psychologist) and consisted in orientations and mechanisms to medication and non-pharmacological adherence (lifestyle changes).
223600824|NCT02211248|OTHER|Conventional treatment and follow up|Assistance was effected by physician and nurse and consisted about adapting to the drug
223600825|NCT02338089|DRUG|Oxytocin|Oxytocin, 100 micromolar solution
223600826|NCT05034250|DIAGNOSTIC_TEST|Blood sample|Blood samples were taken from a peripheral vein as part of clinical routine. Subsequently, the iron status is determined.
223749109|NCT00324831|PROCEDURE|antibody therapy|
223749110|NCT00324831|PROCEDURE|biological therapy|
223749111|NCT00324831|PROCEDURE|chemotherapy|
223749112|NCT00324831|PROCEDURE|colony-stimulating factor therapy|
223507305|NCT07045623|OTHER|centralized management and education group|If assigned to the test group (centralized management and education group), two instructors, one nurse and one nutritionist, will receive an hour of diabetes and high blood pressure 1:15, and will receive an hour of lipid disorder disease and impact 1:15 group education. You will receive a total of 2 hours of education, and you will receive 1 hour of lipid abnormality education conducted in 0 months through a visit in the third month. The dyslipidemia education was conducted in the form of 1:15 small group education or 1:87 group education, which was conducted in 0 months. In particular, the 1:87 form of large-scale education will be operated as a dialogue-oriented lecture that asks and answers questions, and will be conducted by doctors. And in 2 months and 4 months, education on diabetes, high blood pressure, and dyslipidemia will be shortened for 3 minutes through non-face-to-face management phone calls, not face-to-face.
223507306|NCT07046598|BEHAVIORAL|Drop Jump Protocol|A standardized drop jump (DJ) protocol involving 100 total jumps from a 60 cm platform. Participants performed five sets of 20 jumps, with a 10-second rest between jumps and a 2-minute rest between sets. The protocol was designed to induce muscle damage through eccentric loading.
223507307|NCT05937282|DRUG|Dexmedetomidine|Patients will receive infusion of dexmedetomidine in the dose of 0.4 μg/kg/hr. One ml dexmedetomidine (100 μg/ml) will be diluted with 24 ml normal saline in 50 ml syringe pump to achieve dilution of 4 μg/ml.
223507308|NCT05937282|DRUG|Propofol|Patients will receive propofol infusion in the dose of 3 mg/kg/hr. 25 ml propofol 1% (10 mg /ml) in 50 ml syringe pump.
223507309|NCT05937282|DRUG|Lidocain|Patients will receive lidocaine infusion in the dose of 2 mg /kg/hr.25 ml lidocaine 1% (10 mg/ml) in 50 ml syringe pump.
223507310|NCT05937282|DRUG|normal saline|Patients will receive infusion of 25 ml normal saline in 50ml syringe pump (control group).
223507311|NCT07057154|DEVICE|Hbg and RDW|Hbg and RDW as prognstic indicator in critical ill patients
223507312|NCT07055815|DIAGNOSTIC_TEST|Progression of Myopia|The widespread use of digital devices among children has raised concerns about the potential impact on their eye health. Excessive screen time can cause prolonged near focus, reduced outdoor time, and increased blue light exposure, all of which may contribute to myopia progression. Understanding the relationship between digital screen time and myopia progression is crucial for developing effective prevention and intervention strategies to mitigate the growing burden of myopia in children.
223507313|NCT07056985|OTHER|Ankle joint mobilization technique|Combined posterior and lateral mobilization techniques
223507314|NCT07056985|OTHER|Placebo|Placebo interventions simulated with superficial hand contact and minimal manipulation
223507315|NCT06765889|BEHAVIORAL|Mindfulness intervention|The mindfulness intervention will consist of three tracks of mindfulness practice adapted from a traditional Mindfulness-Based Stress Reduction (MBSR) protocol. The three mindfulness tracks will incorporate essential elements of mindfulness practice: a) cultivating attentional stability by directing focus to present-moment bodily experiences (Moore et al., 2012), and b) fostering mindful meta-awareness by nonreactively and nonjudgmentally observing and accepting experiences (Dahl et al., 2015).
223507316|NCT06765889|BEHAVIORAL|Control condition|The sham meditation group will aim to be indistinguishable from meditation practice for newcomers (Zeidan et al., 2015). Non-specific elements of meditation, such as a soothing instructor's voice and terminology designed to create the expectation of authentic mindfulness meditation for those unfamiliar with the practice, will be emphasized. However, the instructions will deliberately exclude the training of the two fundamental cognitive/meta-cognitive processes crucial in mindfulness practice. This intentional omission will involve 1) removing any attentional stability by providing participants with no specific point to anchor their attention and 2) offering no guidance on cultivating mindful meta-cognitive qualities of attention. Participants in the mindfulness group will be taught to observe and accept their present-moment experience without judgment or reaction. In contrast, sham instructions will provide no such guidance.
223507317|NCT06838936|OTHER|Binaural Beats|Mobile application for binaural beats listening
223507318|NCT06729957|BEHAVIORAL|Care Navigation|Care navigation is an intervention that seeks to help patients engage in substance use treatment by increasing motivation and reducing barriers to accessing treatment. The care navigator helps the patient engage in the treatment plan established by the mental health care coordinator.
223507319|NCT00232921|DRUG|caudal volume 1|
223507320|NCT00232921|BIOLOGICAL|caudal volume 2|
223507321|NCT00232921|DRUG|caudal volume 3|
223507322|NCT00411658|DEVICE|Investigational Device|
223507323|NCT00411658|DEVICE|Experimental|
223507324|NCT00411658|OTHER|Cryopreserved|
223507325|NCT02421965|BEHAVIORAL|FOCUS (Smartphone Application)|Participants in the FOCUS group will be given a study smartphone device with FOCUS application and trained by the mHealth support specialist on how to use the functions of the smartphone (i.e. using a touchscreen, call, text) and different features of the FOCUS intervention.
223507326|NCT02421965|BEHAVIORAL|WRAP (Wellness Recovery Action Planning)|Participants allocated to the WRAP group will be provided all other materials (i.e. WRAP binder, handouts) in their first session and will meet weekly in groups with trained facilitators.
223507327|NCT06396299|OTHER|No intervention|No intervention
223507328|NCT02616302|DRUG|Dexlansoprazole|Dexlansoprazole 15 mg, 30 mg, and 60 mg capsules
223507329|NCT06097481|BEHAVIORAL|Narrative Intervention for Chronic Illness-Heart Failure|The Narrative Intervention for Chronic Illness-Heart Failure includes narrative-based, strengths-based, solution-focused brief therapy, and Unitary Caring Science to improve depression (primary outcome) and anxiety (secondary outcome) for people living with heart failure.
223507330|NCT06097481|OTHER|Attention Control|Automated emails at similar time points to the intervention will be sent to participants in this arm. Emails will ask participants to reflect on their illness experience and offer general information about heart failure using standardized handouts from the American Heart Association and Up-To-Date.
223507331|NCT05894746|DIETARY_SUPPLEMENT|gluten-free|see info in arm description
223507332|NCT05894746|DIETARY_SUPPLEMENT|probiotic|see info in arm description
223600827|NCT01385241|BEHAVIORAL|Ipod video|This group will be asked to watch the video on their Ipod Touch in its entirety at least once per week during the first four weeks of the study, and as often as desired in weeks 5-12. The participants will be asked to record the times viewed and their feelings/comments in a viewing log, and will be given surveys at 30 and 90 days.
223507333|NCT05894746|DIETARY_SUPPLEMENT|gluten|see info in arm description
224199692|NCT04773366|DRUG|Prednisone+Cytarabine+vincristine|Group 2 Initial treatment (W1\~W6) . Prednisone 40mg/m2×4w, taper 2w; Vincristine 1.5mg/m2 iv d1 of w1,2,3,4,5,6; Cytarabine 100mg/m2 iv/IH d1-4 q2w (w1,3,5)
224199693|NCT04773366|DRUG|Prednisone+vincristine+Mercaptopurine|Group 2 continuation treatment (W7\~W52) . Prednisone 40mg/m2 d1-5 q3w; VCR 1.5/m2 iv d1 q3w; 6-MP 50mg/m2/d,po,qn
224199694|NCT04773366|DRUG|Prednisone+vincristine|Group 3 Initial treatment (W1\~W6) . Prednisone 40mg/m2×4w, taper 2w; Vincristine 1.5mg/m2 iv d1 of w1,2,3,4,5,6
224199695|NCT04773366|DRUG|Prednisone+vincristine|. Group 3 Continuation treatment (W7\~W52)Prednisone 40mg/m2 d1-5 q3w; Vincristine 1.5/m2 iv d1 q3w
224199696|NCT04773366|OTHER|Local therapy|Local therapy/wait and see. Group 4
223507334|NCT05500131|BEHAVIORAL|Observation|"Ankle joint dorsiflexion was evaluated with the Weight-bearing lunge test through the Leg Motion system (LegMotion, your MOtion®, Albacete, Spain). Subjects were instructed to try to bring the knee to touch the metal rod (initially placed at a distance of 10 cm) without lifting the heel off the ground. The distance achieved was recorded in centimeters.~Single-leg squat test was analyzed through the Leg Motion system (LegMotion, your MOtion®, Albacete, Spain). It consists of performing a monopodial squat to test dynamic knee valgus. They were to perform a single-leg squat to 30° knee flexion. The knee was considered to be aligned if the patella was over the second toe."
223507335|NCT05370144|RADIATION|Hypofractionated radiotherapy|Hypofractionated radiation 23 Gy in 5 fractions with a simultaneous integrated boost of 26 Gy in 5 fractions to the gross tumor volume (GTV) given concurrently over 1 week during week 3 of chemotherapy.
223507336|NCT02793778|DRUG|CROWN|A nutritionally based therapy, formulated as a powder, administered twice a day, preferable 1 hour before or more than 2 hours after meals, for up to 24 weeks
223507337|NCT02793778|DRUG|CROWN Placebo|Placebo, formulated as a powder, administered twice a day, preferable 1 hour before or more than 2 hours after meals, for up to 24 weeks
223507338|NCT01665105|DEVICE|acupuncture|electroacupuncture at at Zusanli, electroacupuncture at Yanglingquan, and acupuncture at non-acupoint.
223507339|NCT03439878|DIETARY_SUPPLEMENT|Galactose|Co-ingestion of d-galactose with a high-fat meal
223507340|NCT03439878|DIETARY_SUPPLEMENT|Glucose|Co-ingestion of d-glucose with a high-fat meal
223507341|NCT06197711|BEHAVIORAL|PRISMA|"PRISMA has been developed adapting PM+, a brief, psychological intervention program based on CBT techniques that are empirically supported and formally recommended by the WHO. The adapted manual was developed to tailor the sessions to the structure of the Swiss prison system and the needs of inmates of jails in Switzerland. PRISMA involves the following elements: stress management, problem-solving, meaningful activities and relapse prevention~PRISMA has four core features:~* Evidence-based problem-solving strategies~* Brief and easy to learn~* Delivered by lay-helpers (trainers)~* Transdiagnostic, addressing depression, anxiety, stress, and practical problems as defined by participants; PRISMA has four sessions."
223507342|NCT00293982|BEHAVIORAL|Physician knowledge of parental expectations for the visit|
223507343|NCT03787212|DEVICE|MiBo ThermoFlo|Test Device
223507344|NCT03787212|DEVICE|Bruder Mask|Control Device
223507345|NCT05802537|BEHAVIORAL|Home-based exergame program|The home-based exergame program was conducted using the Nintendo Switch and Ring Fit Adventure program at participants' homes. The program included a 10-minute warm-up, 30 minutes of main exercise, and a 10-minute cool-down, lasting a total of 50 minutes per session. Sessions were held three times per week for eight weeks. The exercises targeted lower extremity strength, balance, and flexibility and included yoga, leg exercises (e.g., squats, knee lifts), and other activities performed in a gamified virtual environment. Participants received guidance on using the console, and family members were involved to support proper execution of the exercises.
223507346|NCT05802537|BEHAVIORAL|Online education on fall prevention and musculoskeletal health management|The online education intervention consisted of weekly sessions conducted for 50 minutes over an eight-week period, focusing on fall prevention and musculoskeletal health management. Participants joined the sessions via a video-conference platform. The content covered education on aging, musculoskeletal disorders, fall prevention strategies, and understanding falls and fractures. These sessions aimed to enhance participants' awareness and knowledge, thereby helping them adopt preventive behaviors.
223507347|NCT05548452|DRUG|Intestinal Microbiota Transplant (IMT) Capsules|Capsules containing freeze-dried intestinal microbiota from healthy human donors
223507348|NCT05548452|DRUG|Placebo Capsules|"Capsules containing an inactive substance (sugar pill)"
223507349|NCT06334341|BEHAVIORAL|Computer-based simulation training for providers|"A Computer-Based Simulation training for providers, based on the Centers for Disease Control and Prevention Guide for Healthcare Professional: Discussing Sexual Health with Your Patients, current PrEP information, and the Social Cognitive Theory. This is a single-session, 30-minute training module contains educational information with animated narration about PrEP, how to take a sexual health history, understanding internal bias, potential patient barriers to PrEP as well as recorded video-simulated encounters, in which providers view different types of patient/provider interactions."
223507350|NCT06334341|BEHAVIORAL|Best Practice Alert|A Best Practice Alert will alert providers to patients who are part of the Centers for Disease Control and Prevention PrEP priority populations.
223507351|NCT06334341|BEHAVIORAL|HIV Risk Assessment|A risk assessment tool that considers the behaviors - i.e., types of sexual activities, protective behaviors (condoms, PrEP, ART), and other factors (HIV status, sexually transmitted infections) of the respondent.
223507352|NCT06334341|BEHAVIORAL|PrEP Informational Video|A short informational video, tailored to the local Detroit context with themes that will focus on introducing PrEP, stigma surrounding taking PrEP, and potential barriers and how to overcome them.
223507353|NCT04193176|DRUG|Gefapixant|Administered twice daily as an oral tablet of 45 mg
223507354|NCT04193176|DRUG|Placebo|Administered twice daily as a placebo oral tablet matching gefapixant
223507355|NCT06053411|DRUG|Diclofenac|25 mg capsule
223507356|NCT06053411|DIETARY_SUPPLEMENT|curcumin|2,000 mg tablet
223749113|NCT00324831|PROCEDURE|cytokine therapy|
224199697|NCT03081962|DRUG|Bundle|Combination of antibiotic intraperitoneal irrigation with gentamicin and clindamycin solution, use of Triclosan-impregnated sutures and mupirocin application over the skin staples.
223749114|NCT00324831|PROCEDURE|monoclonal antibody therapy|
223749115|NCT00324831|PROCEDURE|non-specific immune-modulator therapy|
224199698|NCT03081962|PROCEDURE|Standard care|Standard care measures include decontamination of the skin during surgery with chlorhexidine alcohol solution, administration of systemic antibiotic prophylaxis and application of thermal blanket to avoid hypothermia. In the standard care protocol, the fascial closure will be performed with a polyglactin suture (without Triclosan impregnation).
223507357|NCT04725903|RADIATION|High-Dose Rate Brachytherapy|Receive high-dose rate brachytherapy boost
223507358|NCT04725903|RADIATION|Proton Beam Radiation Therapy|Undergo proton beam therapy
223507359|NCT04725903|OTHER|Quality-of-Life Assessment|Ancillary studies
223507360|NCT04725903|OTHER|Survey Administration|Ancillary studies
223507361|NCT02370394|BEHAVIORAL|ROSE Program|The ROSE Program was specifically tailored, innovative and relevant to diverse, racial and ethnic perinatal women in a number of ways including the images and content used in the intervention and coordinating study appointments with treatment visits. It was tailored to the current IPV risk assessment, pregnancy or postpartum status of each participant, was designed to reach participants across levels of motivation for change. The content of ROSE was theory-driven, consistent with the Motivational Interviewing model of behavior, and consistent with the literature on effective interventions that address IPV.
223507362|NCT03302611|BEHAVIORAL|Physical Activity-based Interventions|Participants will be randomized to one of two physical activity-based interventions, surf or hike therapy.
223507363|NCT01148420|DRUG|Medroxyprogesterone 17-Acetate|Medroxyprogesterone 20mg orally 3 times a day for 3 days
223507364|NCT01148420|DRUG|medroxyprogesterone acetate|Depo Provera 150mg Intramuscular injection
223507365|NCT05249920|DRUG|Edaravone Dexborneol Concentrated Solution for injection|Edaravone and Dexborneol Concentrated Solution for Injection, 15 ml (37.5 mg, containing edaravone 30 mg and dexborneol 7.5 mg) in 3 ampoule bottles, twice a day for 10 to 14 days.
223507366|NCT05249920|DRUG|Edaravone Dexborneol placebo|Edaravone and Dexborneol placebo, 15 ml in 3 ampoule bottles, twice a day for 10 to 14 days.
223507367|NCT02042001|DRUG|Immediate switch to TDF/FTC/RPV|
223507368|NCT02042001|DRUG|Switch to TDF/FTC/RPV after 24 weeks|Patients will continue current EFV-containing regimen up to week 24 and then will be switched to TDF/FTC/RPV
223507369|NCT01996540|OTHER|Interventional arm: Early best palliative care|Patients will receive standard oncologic care and will be assigned to early systematic best palliative care. They will meet a member of the palliative care team within 2 weeks after enrolment. Thereafter, they shall be visited by a palliative care team member every 2 weeks until death.
223507370|NCT01842178|PROCEDURE|scratching|"Endometrial Injury~* Done between 18-24 days prior to embryo transfer cycle.~* Using transfer catheter.~* Introduction of the same to the uterine fundus.~* Systematic scrapping of the four uterine walls, lengthwise.~* Performed by a skilled doctor.~* Subsequent ultrasound control."
223507371|NCT00685282|BEHAVIORAL|Cognitive Behavioral Therapy|The intervention (CBT) will focus on teaching specific skills which are adapted for women undergoing fertility related problems. Through the sessions the participants will learn relaxation techniques such as breathing, progressive relaxation, and guided imagery. Furthermore, suggestions for making healthier choices for coping and for releasing tension will be reviewed and discussed, with an emphasis on making healthy lifestyle changes with balance and perspective rather than in a punishing or depriving way. Each session will consist of: 20 minutes of stress-reduction behavioral relaxation, 40 minutes of cognitive restructuring and 30 minutes personal tailoring of the behavioral homework between each session.
223507372|NCT00856102|BEHAVIORAL|Exercise|Home-base walking program
223507373|NCT00856102|BEHAVIORAL|Control|Usual care
223507374|NCT01846143|BIOLOGICAL|pBCAR3-phosphopeptide|
223507375|NCT01846143|BIOLOGICAL|pIRS2-phosphopeptide|
223507376|NCT01846143|BIOLOGICAL|2-MpP (pBCAR3-phosphopeptide + pIRS2-phosphopeptide)|
223507377|NCT01927289|PROCEDURE|Proximal Brachial Plexus vs Distal Forearm Block|"Proximal Brachial plexus block: 15 mls saline injected in distal forearm nerve block and 15 mls of 1.5% Mepivacaine injected to the brachial plexus via the supraclavicular approach.~Distal forearm block: 15 mls 1.5% Mepivacaine injected in distal forearm nerve block and 15 mls of saline injected to the brachial plexus via the supraclavicular approach"
223507378|NCT03367585|DIETARY_SUPPLEMENT|Physical exercise + Vitamin D3|Strength exercise + Supplementation of vitamin D3 50,000 IU / week
223507379|NCT03367585|OTHER|Physical exercise|Strength exercise
223507380|NCT00188838|BEHAVIORAL|Psychoeduction|
223507381|NCT00188838|BEHAVIORAL|Cognitive-Behavioral Therapy|
223507382|NCT01014156|DRUG|epoprostenol|titration up to 4 ng/kg/min
223507383|NCT03796130|PROCEDURE|Myomectomy|"This study will include women who have intramural myomas ranging from 3-5 cm~The participants will be randomly allocated into two groups.~In group (1): myomectomy will be performed before ART~In group (2):women will have their trial of ART without myomectomy~In group A, ART will be performed 3 months after myomectomy if the uterine cavity is not opened and 6 months after myomectomy upon inadvertent opening of the uterine cavity during surgery"
223507384|NCT00218894|PROCEDURE|Cataract surgery|surgery one one or two eyes by use of two different types of lenses and correcting for refraction
223749116|NCT00324831|PROCEDURE|therapeutic procedure|
223749117|NCT00324831|PROCEDURE|tumor cell derivative vaccine|
223507385|NCT05826158|DIAGNOSTIC_TEST|18FmFBG imaging on the Large Field of View PET/CT (Total body PET/CT)|18F-mFBG imaging on the Large Field of View PET/CT (Total body PET/CT)
223507386|NCT03927430|PROCEDURE|pars plana vitrectomy with membrane peeling|23-gauge pars plana vitrectomy with peeling of the epiretinal and internal limiting membrane as well as air- or gastamponade
223507387|NCT00260390|DRUG|Testoviron|
223749118|NCT00324831|PROCEDURE|vaccine therapy|
224199699|NCT01340794|OTHER|Laboratory Biomarker Analysis|Correlative studies
224199700|NCT01340794|DRUG|Pazopanib Hydrochloride|Given PO
224199701|NCT02577094|DRUG|90Y-DOTA-Epratuzumab IgG/Epratuzumab IgG|2 injections of 90Y-DOTA- hLL2 IgG- hLL2 IgG at day -21 and day -14. (The 2 drugs are mixted in the same infusion)
224199702|NCT02577094|DRUG|Busulfan|Between the last injection of 90Y-DOTA- hLL2 IgG/hLL2 IgG (J-14) and the allogeneic stem cell transplantation
224199703|NCT02577094|BIOLOGICAL|allogeneic stem cell transplantation.|At Day 0
223749119|NCT01230931|DEVICE|Vitagel|Vitagel (by Stryker) is a topical surgical hemostat spray that results in coagulation. The components are as follows: autogenous blood is drawn and centrifuged to produce a sample of platelets and growth factors; this is combined with a bovine thrombin and collagen solution. When the two are applied together, it produces the hemostatic effect.
223749120|NCT01230931|PROCEDURE|Standard of care|Standard of care for hemostasis in acetabular surgery includes electrocautery/ligation of bleeding vessels, fracture reduction and stabilization, cell-saver, lap packing.
224199704|NCT02577094|DRUG|Fludarabine|Between the last injection of 90Y-DOTA- hLL2 IgG/hLL2 IgG (J-14) and the allogeneic stem cell transplantation
224199705|NCT02577094|BIOLOGICAL|Thymoglobulines|Between the last injection of 90Y-DOTA- hLL2 IgG/hLL2 IgG (J-14) and the allogeneic stem cell transplantation
223507388|NCT02398474|DRUG|TFP block ropivacaine|
223507389|NCT02398474|DRUG|ropivacaine infiltration of the iliac crest bone|
223507390|NCT04679025|OTHER|Exposure - postoperative hyperglycemia|Postoperative hyperglycemia (blood or capillary glucose \> 10.0 mmol/L) within 72 hours of a surgical procedure
223507391|NCT02383485|BEHAVIORAL|Exercise|Heart rate monitors worn by each child at each session
223507392|NCT02383485|BEHAVIORAL|After-school program|Supervised recreational program with token economy
223507393|NCT05298501|OTHER|No intervention/exposure|No interventions/exposures will be administered or evaluated
223507394|NCT02255695|OTHER|School-based exercise program|The exercise program was applied, twice a week, for 8 weeks, with sessions of 50 minutes, in groups of 10 students. The exercise program was elaborate to restore muscular balance through flexibility, endurance and muscular strength. To promote flexibility stretching exercises for rotator neck muscles, lateral neck flexors, levator scapulae, upper trapezius, erector spinae, major and minor pectoralis, rhomboids, spinal lateral flexors, column rotators, piriformis, hamstrings, quadriceps, hip adductors and abductors were applied. Strengthening exercises were applied for the development of strength, endurance and control of deep flexor muscles of the cervical spine, stabilizers of the glenohumeral joint and scapula, abdominals, spine extensors and hip extensors.
223507395|NCT05655897|DEVICE|GeminiOne Transcatheter Valve Edge-to-Edge Repair System|The transcatheter valve clamp system consists of a valve clamp, an adjustable bend mid-tube, and a manipulated inner tube. The adjustable bend introducer catheter consists of an adjustable bend outer tube and dilator. The valve clip is composed of nickel-titanium alloy, cobalt-chromium-nickel-molybdenum-iron alloy, and polyethylene terephthalate material and contains a closure clip, gripping tab, central mechanism, braid, and suture. The adjustable bend guiding catheter is used to provide access to the transcatheter valve clamping system and to reach the designated position. The adjustable curved mid-tube and manipulated inner tube are used to enable the delivery, gripping, and release process of the valve clips within the body.
223507396|NCT00601016|DRUG|Imiquimod 5% cream|Imiquimod 5% cream applied topical on hemangioma once a day , 3 to 7 times a week for a maximum of 4 months.
223507397|NCT00520572|DRUG|AZD9056|
223507398|NCT00520572|DRUG|Etanercept|
223507399|NCT00520572|DRUG|Placebo|
223507400|NCT02181621|DEVICE|Iodosorb|Cadexomer iodine gel
223507401|NCT02181621|DEVICE|Solosite gel|Hydrogel
223507402|NCT02697929|DRUG|sugammadex|
223507403|NCT02697929|DRUG|Neostigmine|
223507404|NCT04635163|OTHER|None intervention|None intervention
223507405|NCT02585102|OTHER|Recommended Vegetable Intake|Subjects will consume vegetables in amounts recommended by the Dietary Guidelines for Americans
223507406|NCT02585102|OTHER|Usual Vegetable Intake|Subjects will consume vegetables in their usual amount
223507407|NCT00960856|DRUG|Fenofibric Acid 105 mg Tablet|One 105 mg tablet administered 30 minutes after the initiation of a low-fat breakfast.
223507408|NCT00960856|DRUG|Fenofibric Acid 105 mg Tablet|One 105 mg tablet administered 30 minutes after the initiation of a standard breakfast
223507409|NCT00960856|DRUG|Fenofibric Acid 105 mg Tablet|One 105 mg tablet administered 30 minutes after the initiation of a high-fat/high-calorie breakfast.
223507410|NCT00960856|DRUG|Fenofibric Acid 105 mg Tablet|One 105 mg tablet administered after an overnight fast of at least 10 hours.
223507411|NCT00908388|DEVICE|GORE TAG® Thoracic Endoprosthesis|Endoprosthetic Implant
223507412|NCT02327780|OTHER|FODMAP diet|
223507413|NCT01217138|DEVICE|Epinephrine autoinjector|We used 2 epinephrine autoinjector trainers and wrapped them by a gray sticky paper. Then,modified one of the trainers by changing gray safety cap to red with an atomizer paint and placing a yellow arrow pointing to the black injection tip.We provided three-step written and visual instruction sheet to use epinephrine autoinjector in Turkish same as given on the original trainer and changed that of the second trainer according to the modifications we made. Scoring system originally devised by Sicherer et al was used. Participants successively doing all steps were accepted to demonstrate autoinjector use correctly. Participants who tackled with black tip of autoinjector in order to eject needle after removing safety cap was regarded as unsuccessful since this may cause unintentional injection of epinephrine. All participants were scored and timed separately.
223507414|NCT00795795|PROCEDURE|Preimplantation Genetic Screening|Preimplantation Genetic Screening
223507415|NCT00795795|PROCEDURE|IVF without PGS|IVF without PGS
223507416|NCT04951453|OTHER|None (observational)|None (observational)
223507417|NCT03845673|DIETARY_SUPPLEMENT|Psyllium|Psyllium fiber (Konsyl; Konsyl Pharmaceuticals, Easton, Md)
223507418|NCT03845673|DIETARY_SUPPLEMENT|Bowel recipe|consisted of 1 cup of unprocessed wheat bran, 1 cup of applesauce, and 1/4 cup of prune juice.
223507419|NCT00919490|DRUG|ABT-333|Tablet, see arms for interventional description
223507420|NCT00919490|DRUG|Placebo|Tablet, see arms for interventional description.
223507421|NCT01652105|DIETARY_SUPPLEMENT|Standard diet versus standard VLCD (Prodimed)|
223507422|NCT06299072|OTHER|Survey|Quantitative questionnaire
223507423|NCT05055336|OTHER|Gastric emptying breath test|The gastric emptying breath test is used to diagnose gastroparesis. Participants ingest spirulina in a meal and samples are taken every 45 minutes for 4 hours.
223507424|NCT05055336|OTHER|Stomach ultrasound|Ultrasound of the fundus of the stomach will be done immediately after ingestion of the test meal, at 15 minutes, and at 30 minutes.
224199706|NCT00741026|DRUG|Olanzapine 10 mg po qhs for 3 days|(1) 10 mg tablets administered orally before bed for three consecutive evenings (Total Dose = 30 mg, 3 tablets)
223749121|NCT04638465|PROCEDURE|Transoral robotic surgery|Transoral resection with neck dissection
223749122|NCT04638465|DRUG|Cisplatin - Dose Level 1|6 Cycles of 40 mg/m2
223600828|NCT05624073|DEVICE|Air-QTM Blocker|The Air-QTM Blocker (Cookgas LLC, Mercury Medical, Clearwater, FL, USA) is a SAD that is intended for use as a primary airway seal and an aid for tracheal intubation in situations of anticipated or unanticipated difficult airways. Its design includes a large airway tube inner diameter, a short airway tube length, and a tethered, removable standard 15mm circuit adapter. These features enable direct insertion of larger tracheal tubes up to 7.5 and 8.5mm inner diameters for Air-Q sizes 3.5 and 4.5 respectively (according to body weight; size 3.5: 50-70Kg, size 4.5:70-100Kg). In addition to the soft blocker channel (guide tube) that acts as a conduit for placing medical devices such as NG (Nasogastric) or Blocker tubes. NG tubes are used to decompress and suction the stomach. Standard NG tubes up to 18 Fr. are suitable for all Air-Q Blocker sizes
223749123|NCT04638465|DRUG|Cisplatin - Dose Level 2|7 Cycles of 40 mg/m2
223600829|NCT05624073|DEVICE|LarySealTM Pro|The LarysealTM Pro is the new generation mask for safe and effective airway management, as it could reduce the risk of aspiration by the integrated suction catheter port to allow effective removal of fluids and gastric contents. So that, it could be a promising airway device as its symmetrical cuff and tube contoured to match the oropharyngeal anatomy for quick and easy first time insertion success. It could be applied in both routine and advanced airway management for patients with a higher risk of a difficult airway, unexpected intubation difficulties, beside to airway control during anesthesia. It was presented in the clinical market in: sizes 3, 4 and 5 (according to the body weight; size 3: 30-50Kg, size 4: 50-70 Kg, and size 5:70-100Kg) that can accept larger tracheal tube up to 7.5 and 8mm inner diameter respectively with maximum suction catheter size of 16 Fr. Both devices accommodated standard conventional endotracheal tubes for intubation.
224199707|NCT00741026|DRUG|Placebo|(1) placebo tablets administered orally before bed for three consecutive evenings (Total Dose = 3 tablets)
223600830|NCT00657579|DRUG|DE-104 ophthalmic solution, low concentration|
223600831|NCT00657579|DRUG|DE-104 ophthalmic solution, medium concentration|
224199708|NCT04910191|DIAGNOSTIC_TEST|Electronic stethoscope|Electronic stethoscope
224199709|NCT03612830|PROCEDURE|Laparoscopy endoscopy cooperated surgery|LECS resects the tumor completely by laparoscopy with the help of the precise positioning and guidance of endoscopy
224199710|NCT03612830|PROCEDURE|Dan Vinchi robot endoscopy cooperated surgery|RECS resects the tumor completely by Dan Vinchi Robot with the help of the precise positioning and guidance of endoscopy
224199711|NCT05773924|DEVICE|triLift system|To evaluate the efficacy of the triLift™ treatment
224199712|NCT04028570|RADIATION|Varying Doses of Background and Boost RT|3+3 radiation dose escalation model to see the maximum tolerated dose for background and boost radiation therapy.
224199713|NCT05058027|DEVICE|GUARDIX-SG®|GUARDIX-SG® 6g prefilled syringe
224199714|NCT05058027|DEVICE|Medicurtain®|Medicurtain® 5ml prefilled syringe
223600832|NCT00657579|DRUG|DE-104 ophthalmic solution, high concentration|
223600833|NCT00657579|DRUG|DE-104 vehicle|
223749124|NCT04638465|RADIATION|Dose Level 1|60 Gy/6 weeks - 2 Gy/fraction, 5 fractions/week
223749125|NCT04638465|RADIATION|Dose Level 2|70 Gy/7 weeks - 2 Gy/fraction, 5 fractions/week
223749126|NCT01285648|PROCEDURE|Cpap|This study did not involved drugs. The Oxygenation index, Borg Scale, pain scale and the presence and duration of thoracic drainage was determined in the immediate postoperative (POi) period and in the first and second postoperative (PO1, PO2) days in 40 patients who underwent elective lung resection,in two groups of intervention: chest physiotherapy, and associate this with cpap
223749127|NCT06450548|OTHER|Parametric acquisition|Parametric acquisition for 18F-FDG PET/CT and 68GA-PSMA PET/CT with 24 h at 15 days of interval
224199715|NCT01504074|BEHAVIORAL|if needed (decided individually) either Acular eye drops, Ultracortenol eye drop or intravitreal triamcinolone injection|if prescribed: Ultracortenol/ Acular eye drops 3-4 times a day, if prescribed: singular intravitreal triamcinolone injection
224199716|NCT01568255|DRUG|Ergocalciferol|Ergocalciferol therapy at 50,000IU for 8 weeks
224199717|NCT01568255|DRUG|Placebo|placebo at 50,000IU for 8 weeks
224199718|NCT02284880|DRUG|BIA 2-093|MF - Marketed formulation
224199719|NCT02284880|DRUG|BIA 2-093|TBM - to-be-marketed
224199720|NCT05329012|DEVICE|DUL- Distal Ulna Locking PLate (I.T.S)|The patients are surgical treated with the Distal Ulna locking plate according to standard surgical procedures to treat the unstable distal ulna fractures.
224199721|NCT04686968|PROCEDURE|Greenhouse Technique|First, the high-strength sutures were passed through the teared tendon, and then Crimson duvet procedure was performed on the footprint from the articular margin of the humeral head to the apex of the greater tubercle, followed by a lateral row anchor.
224199722|NCT04686968|PROCEDURE|Microfracture Combined With Suture Bridge Technique|A three-line anchor suture method is used as in the greenhouse technique, except that the position is between the apex of the greater tubercle and the articular surface. After the rotator cuff is sutured, the bone bed beyond the suture point to the outer edge of the greater tubercle is opened with 2.0mm Kirschner wire every 5mm ( Crimson duvet), 1cm in depth, about 6 in total.
224199723|NCT05104268|DEVICE|Bocaliner|Bocaliner is an orally inserted device that is held within the mouth following the administration of mouthwashes, gels, and rinses that are used to treat pain associated with oral mucositis, and to reduce inflammation and to accelerate healing of oral mucositis.
224199724|NCT01035229|DRUG|Everolimus|Everolimus (labeled as RAD001) was formulated as tablets of 2.5 mg strength and blisterpacked in units of 10 tablets.
224199725|NCT01035229|DRUG|Everolimus Placebo|Everolimus Placebo matched to the everolimus 2.5 mg tablet strength was blister-packed in units of 10 tablets. Matching placebo tablets were formulated to be indistinguishable from the everolimus tablets. Everolimus placebo was taken as a daily oral dose of 7.5 mg and was defined as the control drug.
224311283|NCT03840369|DEVICE|Repetitive Transcranial Magnetic Stimulation to Right Dorsolateral Prefrontal Cortex|Transcranial magnetic stimulation (TMS) works by delivering a magnetic pulse to a focal brain region. TMS has a high degree of safety and has been studied as an intervention for many mental health and neurological conditions. Repetitive TMS (rTMS) delivers pulses at a set time interval in order to modulate neural activity in that region.
224311284|NCT03840369|DEVICE|Sham Repetitive Transcranial Magnetic Stimulation|The sham TMS coil will make a similar sound to the real rTMS coil, but will not deliver a magnetic pulse. This is a no-treatment device.
224199726|NCT01035229|OTHER|Best Supportive Care (BSC)|BSC was defined as drug or non-drug therapies, nutritional support, physical therapy or anything that the Investigator believed to be in the patient's best interest, but excluding other antineoplastic treatments. BSC administered to the patient throughout the study was to be reported on the Concomitant Medication/Significant Non-Drug Therapy electronic case report from (eCRF). Permitted BSC treatments during the study included, but were not limited to, the following: Pain medication to allow the patient to be as comfortable as possible, Bisphosphonates for bone metastases, Localized radiotherapy, for the treatment of pre-existing, painful bone metastases, Nutritional support or appetite stimulants (i.e. megestrol) as recommended by the Investigator, Oxygen therapy and blood products or transfusions
224199727|NCT04460092|DEVICE|5-mm 32-gauge Insulin needles in the first three days of Intervention|32-gauge needles with a length of 5mm to inject insulin in first three days
224199728|NCT04460092|DEVICE|8-mm 32-gauge Insulin needles in the first three days of Intervention|32-gauge needles with a length of 8mm to inject insulin in first three days
224199729|NCT04460092|DEVICE|5-mm 32-gauge Insulin needles in the last three days of Intervention|32-gauge needles with a length of 5mm to inject insulin in second three days
224199730|NCT04460092|DEVICE|8-mm 32-gauge Insulin needles in the last three days of Intervention|32-gauge needles with a length of 8mm to inject insulin in second three days
224199731|NCT01913769|RADIATION|Thallium-201 Myocardial Perfusion Study|One-day Tl-201 stress/rest MPI protocol with pharmacological stress, as daily practice will be applied. CZT camera with multipinhole collimator and stationary detectors scan heart simultaneously. A 10% symmetrical energy window at 140 keV was used. Electrocardiogram-gated scans will be applied. Perfusion images were reconstructed in standard axis and polar maps of the left ventricle were obtained. Scans from CZT was analyzed in consensus by two experienced readers blinded to any information on patient identification. The software package Myovation for Alcyone, QGS and QPS were used for quantitative analysis of MPI polar maps. Automated analysis to determine ejection fraction.
224199732|NCT03731117|DRUG|Furosemide|"Furosemide (FUROSEMIDE®) 20 mg / 2ml, ampoule for injection~1 mg / kg slow intravenous injection 1.5 mg / kg if chronic exposure to diuretics in the week prior to inclusion Measurement of urine output after two and six hours. Compensation of diuresis by same volume of crystalloids over a 6-hour period"
224199733|NCT04552158|DIETARY_SUPPLEMENT|Mediterranean diet|The Mediterranean diet (MedDiet) is a nutritional model inspired by the traditional dietary pattern of some of the countries of the Mediterranean basin. Mediterranean dietary pattern (MDP) gather the following characteristics: abundant consumption of olive oil and high consumption of fruits, vegetables, cereals (preferably as whole grain), legumes, nuts and seeds. The MDP also includes moderate consumption of fish and shellfish, white meat, eggs, and fermented dairy products (cheese and yogurt), as well as relatively small amounts of red meat, processed meats, and foods rich in sugars. Frequent but moderate intake of wine, especially red wine with meals is also recommended
224199734|NCT01628159|DEVICE|Lutonix Drug Coated Balloon|balloon angioplasty with a drug coated balloon
224199735|NCT04681859|DEVICE|High Flow Nasal Oxygen (HFNO) treatment|Administration of High Flow Nasal Oxygen (HFNO) to patients who did not respond to standard low-flow oxygen therapy (non-rebreather mask on 15L/min). Adjust flow-rate and FiO2 as per standard HFNO treatment protocol.
224199736|NCT04681859|DEVICE|Continuous Positive Airway Pressure (CPAP) therapy using OxyJet|Administer CPAP to patients who did not respond to standard low-flow oxygen therapy (non-rebreather mask on 15L/min). CPAP initiated with FiO2 at 40% and a 10cm PEEP. Titrate PEEP to 15 cm if required. Deliver additional oxygen via secondary port if a higher FiO2 is required.
224199737|NCT01041807|DRUG|amlodipine/losartan|amlodipine/losartan (COZAAR XQ) prescribed according to the current local label
224199738|NCT03677609|BEHAVIORAL|Mindset & Communication Training|The mindset training is a two-hour, live training, with a one-hour follow-up one month later, that teaches care providers to recognize, shape, and leverage patient mindsets in healthcare.
223507425|NCT02133677|DRUG|temozolomide 100mg|WBRT: 30 Gy in 15 fractions (2 Gy per fraction, 5 fractions per week) CT: TMZ 200 mg p.o. q.d. x 5 days per week x 3 weeks
223507426|NCT01161121|DRUG|adenosine|Measuring FFR and Coronary Flow Reserve after administration of IV adenosine 140 mcg/kg/min for 2 minutes.
223507427|NCT01161121|DRUG|regadenoson|Measuring FFR and Coronary Flow Reserve after administration of IV regadenoson 0.4 mg over 10 seconds.
223507428|NCT06253208|PROCEDURE|postoperative pain|Postoperative analgesia in laparoscopic sleeve gastrectomies: laparoscopic versus ultrasound-guided transversus abdominis plane block
223507429|NCT04865458|DRUG|HEC89736|HEC89736 tablets QD every 28 days for each cycle
223507430|NCT02549300|OTHER|Connective tissue massage|It is a manual reflex therapy in that it is applied with the therapist's hands which are in contact with the patient's skin. The assessment of the patient and the clinical decision-making that directs treatment is based on a theoretical model that assumes a reflex effect on the autonomic nervous system which is induced by manipulating the fascial layers within and beneath the skin.
223507431|NCT05939609|OTHER|Ballistic Stretching Exercise|It will be applied 4 times a week for 6 weeks and before starting on-water training.
223507432|NCT05939609|OTHER|Extender Exercise|It will be applied 4 times a week for 6 weeks and before starting on-water training.
223507433|NCT05939609|OTHER|Kinesiotaping|It will be applied 4 times a week for 6 weeks and before starting on-water training.
223507434|NCT04514276|OTHER|consecutive fetoneonatal healthcare pathway|(1) early perceiving of pregnant women with higher risks for early fetal growth restrictions via color Doppler sonography, fetal biometry, haemogram check (currently additional screenings) (2) structured care of the high risk women who are pregnant (3) concerted neonatal health care (4) adapted paediatric aftercare, certain dates and responsible persons are scheduled.
223507435|NCT02334410|DEVICE|Whole body vibration (WBV)|Side-alternating WBV
223507436|NCT02677285|OTHER|Different type of wound|
223507437|NCT00205634|DRUG|Biaxin ( clarithromycin)|
223507438|NCT05758142|DIETARY_SUPPLEMENT|Potassium Chloride|Oral administration of potassium chloride tablets
223749128|NCT04270981|DRUG|[14C]-acoziborole capsule, 240 mg containing NMT 9.25 kBq (250 nCi) 14C|960 mg (4 × 240 mg capsules)of acoziborole in oral and fasted condition
223749129|NCT03593408|DRUG|Dexmedetomidine|Administered for sedation management per hospital protocol
223749130|NCT03593408|DRUG|Fentanyl|Administered for sedation management per hospital protocol
223749131|NCT03593408|DRUG|Midazolam|Administered for sedation management per hospital protocol
223749132|NCT03593408|DRUG|Morphine|Administered for sedation management per hospital protocol
224199739|NCT05511805|OTHER|Visual Analogue Scale (VAS),|The pain levels of the individuals participating in the study will be evaluated with the Visual Analog Scale. According to VAS, in the severity of pain; '0' means no pain, '10' means worst pain imaginable. During the study, the participants will be asked to rate their pain experienced in daily life and pain during evaluation between 0-10 points. Individuals with pain intensity of 3 and above according to VAS will be included in the study.
223749133|NCT00489853|DRUG|budesonide/formoterol Turbuhaler 320/9µg|Symbicort (budesonide/formoterol) Turbuhaler 320/9 micrograms
223749134|NCT00489853|DRUG|formoterol Turbuhaler 9µg|Formoterol Turbuhaler 9 micrograms, 1 inhalation twice daily
223749135|NCT00489853|OTHER|Placebo|Placebo, 1 inhalation twice daily
223749136|NCT00518908|DRUG|Sevoflurane|3.2 Vol % for postconditioning
223749137|NCT03324763|OTHER|stool sampling|A stool sample will be collected to perform the H. pylori antigen test
223749138|NCT03650907|BEHAVIORAL|Group exercise program|"Patients in experimental group attend group exercise program, instructed by fitness trainer, at long-term care institutions.~Frequency: 3 times per week. Type: resistance/flexibility/balance training, including warm-up and cold-down. Duration: 1 hour per time, for 16 weeks."
224199740|NCT05511805|OTHER|Oswestry Low Back Pain and Disability Questionnaire|The Oswestry scale will be used to determine the level of functional disability due to low back pain. In this questionnaire, 10 questions are asked about pain intensity, social life, weight lifting, walking, personal care, sitting, sleeping, sexual life, standing and travel. Each question has 6 options and the patient is asked to choose the statement that best describes his or her condition.
224199741|NCT05511805|OTHER|Functional Low Back Pain Scale|The Functional Low Back Pain Scale will be used to evaluate how much the low back pain experienced by the people who will be included in the study affects their daily living activities. Evaluated functions; work and school activities, home activities, wearing shoes or socks, leaning forward, lifting an object from the ground, habits, sleeping, walking, sitting, climbing stairs, standing and driving. The questionnaire consists of 12 questions, and each item scores in the range of 0-5 points.
223749139|NCT03650907|BEHAVIORAL|Self exercise program|Patients in control group receive oral education for self exercise program, mainly resistance muscle training. Patients are requested to do self-training for 16 weeks.
223749140|NCT04760210|OTHER|Control Group|Treatment for this group is conventional physical therapy along with the bed rest.
223749141|NCT04760210|OTHER|Decompression Group|Treatment for this is conventional physical therapy along with the spinal decompression.
223749142|NCT04760210|OTHER|ELDOA|Treatment for this is conventional physical therapy along with the ELDOA.
223749143|NCT06502288|DRUG|625 mg of amoxicillin with combined clavulanic acid tablet|The intervention group must take 625 mg of amoxicillin with combined clavulanic acid tablets three times a day after meals for 7 days following extraction.
223749144|NCT05697042|BEHAVIORAL|MY-Skills for Long COVID|8 week online intervention with therapeutic yoga and self-management education
223749145|NCT04490434|DRUG|DWP14012|DWP14012 40mg, bid
223749146|NCT04490434|DRUG|Celecoxib|Celecoxib 200mg, bid
223749147|NCT04490434|DRUG|Naproxen|Naproxen 500mg, bid
223749148|NCT04490434|DRUG|Meloxicam|Meloxicam 15mg, qd
223749149|NCT03780153|OTHER|No intervention|Observation study. No intervention
223749150|NCT00646412|DEVICE|A-Part® Gel|10 - 20 ml of A-Part® Gel will be administered before abdominal wall closure in a standardised fashion
223749151|NCT05751798|DRUG|Part A: OSE-279 100mg|Human IgG4 mAb against PD-1
223749152|NCT05751798|DRUG|Part A: OSE-279 300mg|Human IgG4 mAb against PD-1
223749153|NCT05751798|DRUG|Part A: OSE-279 600mg|Human IgG4 mAb against PD-1
223749154|NCT05751798|DRUG|Part B: OSE-279 600 mg and OSE2101|OSE-279: OSE-279: Human IgG4 mAb against PD-1 OSE2101: Cancer vaccine
223749155|NCT05751798|DRUG|Part C: OSE-279 600 mg and OSE2101 - HLA-A2 positive|OSE-279: Human IgG4 mAb against PD-1 OSE2101: Cancer vaccine
223749156|NCT05751798|DRUG|Part C: OSE-279 600 mg - HLA-A2 positif|OSE-279: Human IgG4 mAb against PD-1
223749157|NCT05751798|DRUG|Part C: OSE-279 600 mg - HLA-A2 negative|OSE-279: Human IgG4 mAb against PD-1
223749158|NCT05704361|DRUG|RO7121932 IV|Participants will receive RO7121932, as an IV infusion, per the schedule specified in the treatment arms.
223749159|NCT05704361|DRUG|RO7121932 SC|Participants will receive RO7121932, as SC injection, per the schedule specified in the treatment arms.
223749160|NCT05321303|OTHER|Serious Game|"Each participant of the Serious game group played 1 scenario of MetaHospital, a screen-based simulation on the management of diabetic ketoacidosis. Immediately after the serious game was played, 5 open-ended questionnaires were sent to the students to evaluate the game usability."
223749161|NCT05321303|OTHER|Standard Patients|Each participant of the standardized patient's group played 1 scenario on the management of diabetic ketoacidosis and then a 30-minute analysis session with the trainer joined.
223749162|NCT03181828|DRUG|Acetohydroxamic Acid Oral Tablet|A single oral dose of 60 mg/kg acetohydroxamic acid rounded to the nearest 250 mg tablet.
223749163|NCT03181828|OTHER|No treatment|No treatment
223749164|NCT06441409|BEHAVIORAL|Lifestyle intervention|"Patients were intervened with lifestyle only and returned to clinic for tests in 6 months.~Lifestyle intervention included the diet and exercise. Diet was an energy-restricted balanced diet. Exercise requires 5 days a week and 30 minutes every day."
223749165|NCT03762603|DEVICE|Robotic exoskeleton device|It is a non invasive and non significant risk medical device which wraps around operated knee to support motion.
224199742|NCT05511805|DEVICE|Prokin TecnoBody isokinetic balance 2 device|For the one-leg balance test, the subject is positioned on one leg at the origin of the platform. The participant is asked to look at any stationary point or object in front of him. Participants are allowed to experiment on the platform of the meter for approximately 2-3 minutes. The stem sensor apparatus is then attached to coincide with the xiphoid projection. After the torso sensor is attached, the patient is placed in the dominant side position on one foot and the static balance test measurement is started. 30 seconds from the patient in this position. asked to stop.
224199743|NCT05511805|DEVICE|EMG|In our study, electromyography (EMG) device will be used to evaluate muscle strength. Electromyography is a method by which electrical activity analysis of muscles can be performed. In the study, the erector spina and multifidus muscles will be measured. Measurements are made with electrodes placed on the skin surface.
224199744|NCT05511805|DEVICE|Algometer|The pressure perception and pain threshold of pain sensitivity are determined and recorded with an algometer. The details of the application will be explained to the participant and it will be emphasized that the feeling of pressure he feels causes pain and that he should give a 'stop' command. The pressure force is increased until the patient receives the 'stop' command in the area to be applied. It is stopped by the command from the patient and the response on the algometer screen is recorded. These measurements are repeated 3 times. The average of these three recorded measurements is determined.
224199745|NCT05511805|DEVICE|Goniometer|Using the universal goniometer's measure of knee joint range of motion, sense of proprioception will be evaluated. For measurement, subjects are asked to lie on a stretcher in the prone position. The pivot point of the goniometer is placed in the center of the lateral knee joint condyle. The fixed arm of the goniometer is fixed in parallel at the level of the thoracantary major, and the movable arm is positioned at the level of the head of the fibula and the lateral malleolus. First of all, starting from the 0° extension position to the knee joint, the angle desired by the physiotherapist is made and the value in the goniometer is recorded. Then, the patient is asked to bring the knee joint, which is still in 0° extension, to the angle brought by the physiotherapist. Then the angle brought by the patient to the knee joint is recorded.
224199746|NCT01863160|DRUG|0.1% ZEP-3 cream|"Topical application of 250mg ZEP-3 cream (0.1%) vs. placebo 4 times daily The IP is applied to in advanced demarcated sites in a dose escalating mode to 3 different treatment area sizes: small area of 2x1 cm (2 cm2), medium area of 2x5 cm (10 cm2), and large area of 4x5 cm (20 cm2).~The IP ZEP-3 cream will be applied on both ventral forearms (one application site per forearm) in a non-occlusive mode, spread and rubbed over the demarcated area.~* Right arm, single treatment area - ZEP-3 (0.1%)~* Left arm, single treatment area - Placebo cream"
224199747|NCT01863160|DRUG|placebo|"Topical application of 250mg ZEP-3 cream (1.0%) vs. placebo 4 times daily The IP is applied to in advanced demarcated sites in a dose escalating mode to 3 different treatment area sizes: small area of 2x1 cm (2 cm2), medium area of 2x5 cm (10 cm2), and large area of 4x5 cm (20 cm2).~The IP ZEP-3 cream will be applied on both ventral forearms (one application site per forearm) in a non-occlusive mode, spread and rubbed over the demarcated area.~Right arm, single treatment area - ZEP-3 (1.0%)~Left arm, single treatment area - Placebo cream"
224199748|NCT01836094|DRUG|Methylene Blue (USP grade, 280mg oral)|
224199749|NCT01836094|DRUG|Placebo|oral, one time
224199750|NCT05286580|BEHAVIORAL|Morbidity and mortality conference toolkit|"* Standardized slide deck~* Code of conduct~* Conference planning checklist~* Case documentation form"
224199751|NCT01205373|DRUG|BI 671800|High dose oral drinking solution
224199752|NCT01607580|DRUG|low-dose glucocorticoid Methylprednisolone|patients receive low-dose glucocorticoid from day 5 post transplant
224199753|NCT02570217|DEVICE|HHHFNC|infants receive non-invasive respiratory support by mean of HHHFNC
224199754|NCT02570217|DEVICE|NCPAP|infants receive non-invasive respiratory support by mean of NCPAP
224199755|NCT02716519|BIOLOGICAL|Santyl|Collagenase ointment applied topically once per day for up to six weeks
224199756|NCT02716519|OTHER|Standard Care|Standard Care not specified by the protocol; Investigators choose the appropriate standard care treatment for each participant
224199757|NCT01829490|BIOLOGICAL|ChAdOx1 85A|Intramuscular injection
224199758|NCT01829490|BIOLOGICAL|MVA85A|Intramuscular injection
224199759|NCT06149988|DRUG|THC/CBD S.E powder|A single dose of THC/CBD S.E powder- 500 mg, given orally.
224199760|NCT06149988|DRUG|THC/CBD oil|Followed by a 30-day washout- A single dose of THC/CBD oil- 8 mg, given orally (equivalent dose to the powder).
224199761|NCT03313388|DIETARY_SUPPLEMENT|Drink|Beverage to be consumed
224199762|NCT00719407|DRUG|erythropoietin|250 U/kg/dose x 6 doses (n=3); 500 U/kg/dose x 6 doses (n=6); 1,000 U/kg/dose x 6 doses (n=7) 2,500 U/kg/dose x 6 doses (n=8)
224199763|NCT01554059|DRUG|Bevacizumab|Bevacizumab 5mg/m2 D1,D15,D29,D43;
224199764|NCT01554059|DRUG|Oxaliplatin|Oxaliplatin 85mg/m2 D1,D57; Oxaliplatin 85mg/m2 biweekly \* 6 doses 3-4 weeks after radical resection
224199765|NCT01554059|DRUG|5-FU|5-FU 2800mg/m2 civ 48 hours D1,D57; 5-FU 2800mg/m2 civ 48 hours biweekly\*6 doses 3-4 weeks after radical resection; 5-FU 200mg/m2/day civ D15-19,D22-26,D29-33,D36-40,D43-47;
223507439|NCT05758142|OTHER|Placebo|Oral administration of inert placebo tablets
223507440|NCT00002809|BIOLOGICAL|anti-thymocyte globulin|
223507441|NCT00002809|BIOLOGICAL|filgrastim|
223507442|NCT00002809|BIOLOGICAL|sargramostim|
224199766|NCT01554059|RADIATION|Radiotherapy|2GY daily \*20次
223507443|NCT00002809|BIOLOGICAL|therapeutic immune globulin|
223507444|NCT00002809|DRUG|cyclophosphamide|
223507445|NCT00002809|DRUG|methotrexate|
223507446|NCT00002809|DRUG|tacrolimus|
223507447|NCT00002809|PROCEDURE|allogeneic bone marrow transplantation|
224199767|NCT01299428|DEVICE|INVOS 5100|INVOS 5100 IS AN EQUIPMENT THAT MEASURED CEREBRAL OXYGENATION WITH NEAR INFRARED SPECTROPHOTOMETRY METHOD.
223507448|NCT00002809|RADIATION|radiation therapy|
223507449|NCT03001739|DRUG|Urapidil Hydrochloride Injection|Urapidil Hydrochloride Injection or other antihypertensive agents to decrease the BP to the target level.
223507450|NCT00337194|BIOLOGICAL|monoclonal antibody SGN-30|Given IV
223507451|NCT00337194|OTHER|placebo|Given IV
223507452|NCT00337194|DRUG|vinorelbine tartrate|Given IV
223600834|NCT01189695|DRUG|Ritonavir-boosted lopinavir|Lopinavir/ritonavir 200/50 mg every 12 hours
224199768|NCT05992285|DEVICE|transcranial magnetic stimulation|the intensity of stimulus was 80% Resting motor threshold(RMT); the frequency of trains was 50 Hz and the number of pulses was three; and the frequency of intertrain intervals was 5 Hz and pulses number was 200. Two groups were repeatedly stimulated in the dentate nucleus of bilateral cerebellum, the interval of each group was 5min, and the number of stimulation pulses at each site was 1200.
224199769|NCT05731973|PROCEDURE|Intercostal nerve cryoablation|Intercostal nerve cryoablation is applied during Nuss procedure.
224199770|NCT05731973|DRUG|Thoracic epidural analgesia (continuous infusion with sufentanyl (1 µg/ml) and bupivacaine (1.25 mg/ml))|Thoracic epidural is placed prior to Nuss procedure
224199771|NCT05731973|DRUG|Intercostal nerve block (single shot bupivacaine (1.25 mg/ml))|Single shot bupivacaine (1.25 mg/ml) intercostal nerve blocks are placed just anterior to the side of the cryoablation.
224199772|NCT05731973|DRUG|Opioids (oxycodone with prolonged discharge 10 mg PO every 12 hours and oxycodone 5 mg every 6 hours, as needed)|Opioids
223507453|NCT00337194|DRUG|pegylated liposomal doxorubicin hydrochloride|Given IV
223507454|NCT00337194|DRUG|gemcitabine hydrochloride|Given IV
223507455|NCT00337194|OTHER|laboratory biomarker analysis|Correlative studies
223507456|NCT00337194|OTHER|pharmacological study|Correlative studies
223600835|NCT01189695|DRUG|optimized background regimens (OBRs)|Optimized background regimens such as NRTIs, etravirine or raltegravir
223600836|NCT04282707|PROCEDURE|Endoscopic closure of ESD defect|Closure of ESD defect would be performed with clip loop purse string technique
224199773|NCT02504060|DRUG|Starch Placebo|
223507457|NCT03188705|DRUG|Clopidogrel|Participants will receive 300 mg of clopidogrel on the first day, then 75 mg per day for the next 6 days. Measures of pharmacodynamics will be assessed pre- and post-drug administration.
223507458|NCT03188705|DRUG|Aspirin|Participants will receive a single dose of 324 mg aspirin on the last day of clopidogrel administration.
223507459|NCT01640561|BEHAVIORAL|MISC|The Mediational Interventions for Sensitizing Caregivers
223507460|NCT01640561|BEHAVIORAL|UCOBAC|This nutrition/healthcare curriculum for children in poverty and affected by HIV was developed by a non-governmental organization (NGO) operating in Uganda called Uganda Community Based Association for Child Welfare (UCOBAC) with support from UNICEF.
223507461|NCT02019537|PROCEDURE|Steroid injection into the subacromial space|"* Group: Steroid~* Total volume of injection drugs: 4ml(1ml of triamcinolone acetonide 40mg/ml + 3ml of 2% lidocaine)~* The number of injections : only once during the study period~* Injection site : subacromial space~* Material : 25-gauze spinal needle~* Subacromial injections were performed using ultrasonographic guidance."
223507462|NCT02019537|PROCEDURE|Allogeneic PRP injection into the subacromial space|"* Group: Allogeneic PRP~* Total volume of injection drugs: 4ml~* The number of injections : only once during the study period~* Injection site : subacromial space~* Material : 25-gauze spinal needle~* Subacromial injections were performed using ultrasonographic guidance."
223507463|NCT05628272|OTHER|Intravenous infusion of cord blood mononuclear cells|On the basis of the application of granulocyte stimulating factor, the research group was given intravenous infusion of umbilical cord blood mononuclear cells, each infusion ≥1×10\^8, once a week
223507464|NCT05628272|DRUG|application of granulocyte stimulating factor|application of granulocyte stimulating factor
223507465|NCT02794805|DEVICE|¹³C-Octanoate Breath Test|Octanoate Breath Test to be performed on subjects with suspected HCC
223507466|NCT04776876|BIOLOGICAL|Retifanlimab|Given IV
223507467|NCT04776876|DRUG|Telotristat Ethyl|Given PO
223507468|NCT04738162|DRUG|5-Aminolevulinic Acid Hydrochloride, Oral|Application of 5-ALA oral solution (20mg/kg bw) 4 hours (range 3.5-4.5 hours) prior to anesthesia followed by fluorescence-guided tumor resection Tumor resection is performed conventionally using a surgical microscope. A change from white light to blue light is possible at anytime to make the fluorescence visible
223507469|NCT00393380|DRUG|Parathyroid Hormone (teriparatide)|Day +1: PTH 40 mcg, Day +2: PTH 60 mcg, Day +3: PTH 80 mcg, Day +4 to Day +29 or until ANC\>2000/microL: PTH 100 mcg
223507470|NCT03428854|DRUG|LNG-IUS|Levnorgestrel containing IUD
223507471|NCT01674855|DRUG|PEG-G-CSF|Prefilled syringe, 6mg/day, single dosing per cycle, for 6 cycle
223507472|NCT01674855|DRUG|G-CSF|Vial, 100ug/m2/day, multiple dosing per cycle(daily administration, up to 10 days), for 6 cycle
223507473|NCT00766103|OTHER|mild hypo- and hyperventilation|induction of mild hypo- and hypercarbia
223507474|NCT01717859|DRUG|Tocilizumab|All subjects will start at 4mg/kg. After 3 months, if DAS28 \> 3.2, dosage will be escalated to 8 mg/kg.
223507475|NCT04590183|DRUG|FK-506 (Drug)|Twice a day
223507476|NCT04590183|DRUG|Prednisolone Acetate 1% Oph Susp|Four times a day
223507477|NCT01623752|DRUG|Etanercept|The patients will be treated in accordance with the requirements of the labelling of Enbrel® in Germany. The dosage and duration of therapy is to be determined by the physician to meet the patients' individual needs for treatment.
223507478|NCT01623752|DRUG|Etanercept|The patients will be treated in accordance with the requirements of the labelling of Enbrel® in Germany. The dosage and duration of therapy is to be determined by the physician to meet the patients' individual needs for treatment.
223507479|NCT03114397|DEVICE|transcranial direct current stimulation - active|transcranial direct current stimulation will be applied over the left dorsolateral at 2 mA for 20minutes.
223507480|NCT03114397|DEVICE|transcranial direct current stimulation - sham|transcranial direct current stimulation will be applied over the left dorsolateral at 2 mA for 20minutes. The sham intervention consists of 30 seconds of stimulation at the beginning and the end of the 20minutes of intervention.
223507481|NCT02911467|DRUG|Pyruvate (13C)|Pyruvate injection followed by an MRI scan.
223507482|NCT02911467|DEVICE|MRI|MRI scan following the Pyruvate injection
223600837|NCT04282707|OTHER|Gastric ESD without closure of ESD defect|Historical control with patients undergoing ESD without closure of ESD defect
223600838|NCT03386487|DRUG|PF 04457845|Study medication will be administered at 4mg by mouth daily for eight weeks.
224199774|NCT02504060|DRUG|N-acetyl-D-glucosamine|
223749166|NCT06470399|OTHER|Standard therapy group|Participants receive DS prescriptions from a physician based on current standard practices, which include biochemical markers, genetic data, and metabolic profiles.
223600839|NCT03386487|DRUG|Placebo Oral Tablet|Placebo comparator will be administered by mouth daily for eight weeks.
223749167|NCT06470399|OTHER|AI-Guided Group|Participants receive DS prescriptions determined by GenAIS, is an AI system that considers genetic data, metabolic profiles, biochemical markers, and patient history.
224199775|NCT05803876|OTHER|Diagnostic test - monitoring|"Continuous measurement of blood velocity in the middle cerebral artery by transcranial pulsed Doppler (TCD) Atys Medical TCD-X®. The probe attachment system on the patient's head looks like a pair of glasses; it is light and comfortable. The orientation of the robotic probe is automatically readjusted to ensure stable recording quality over time. (recorded on Data Warehouse Connect).~For all patients Vm in (cm/s) will be collected during the adjustment of the mean arterial pressure level between 90% and 70% of the baseline value, without ever going below 60 mmHg for the patients at low risk and 80 mmHg for the patients at high cardiovascular risk."
224199776|NCT00096473|DRUG|Donepezil hydrochloride|
224199777|NCT01173380|OTHER|Soy nuts|Oil roasted soy nuts with 101 milligrams of soy isoflavones per day for 4 weeks
224199778|NCT01173380|OTHER|Matched food|Control food (matched for calories and macronutrients) per day for 4 weeks
224199779|NCT01570127|PROCEDURE|Individualized Acupuncture|The treatment was applied twice a week for 20 minutes for 6 weeks(12sessions)
223600840|NCT00260884|BEHAVIORAL|conventional gastrectomy or radical lymph node dissection|
223600841|NCT04852198|PROCEDURE|OAGB|Simplified gastric bypass procedure
223600842|NCT04852198|PROCEDURE|RYGB|Roux-en-Y gastric bypass. Standard procedure in the Netherlands
223600843|NCT00105690|BEHAVIORAL|Telemedicine intervention|
223600844|NCT03991455|DEVICE|Apyx device|The Apyx device enables approximation and fixation of the vaginal apex to the SSL using a deployable anchoring system.
223600845|NCT05299008|DRUG|Bethanechol|Infants whom will be treated with bethanechol for tracheobronchomalacia in level IV center Neonatal Intensive Care Unit.
223600846|NCT04040920|DEVICE|Ozone|One minute of pretreatment with ozone by using the OzoneDTA device
223600847|NCT04040920|OTHER|Pits and fissure sealants|cleansing of the occlusal surfaces with a nylon brush and polishing toothpaste; surface etching with 36% orthophosphoric acid for 30'', surface cleaning and drying for 30 '', application of the sealing material, polymerization for 60'';
223600848|NCT00273065|DRUG|Neosaxitoxin|
223600849|NCT06451991|OTHER|Use of concept map in clinical practice in nursing students|Concept map will be used in clinical practice in nursing students.
223600850|NCT03239444|DEVICE|Intracardiac echocardiography imaging|Wide visualization of the the heart anatomy and additional devices used during atrial fibrillation ablation procedures.
223600851|NCT00729963|DRUG|Sibutramine|The first group received sibutramine 10 mg for the first 4 weeks, at which time consideration of increasing dosage to 15 mg was re-evaluated in the case of insufficient weight loss (\< 1.8 kg) over the first month of treatment.
223600852|NCT00729963|DEVICE|CPAP|
223600853|NCT05502445|OTHER|educational intervention|"In this group, the steps below are added:on the first day, the delivery of the leaflet on the importance of nutrition in the hospital environment will be added in addition to verbal guidance. On the second day, an educational institutional video with duration of two minutes, will be shown with the title Food Intake and Oral Supplement in Nutritional Rehabilitation via tablet or mobile phone.~When the 24-hour recall will be collected, an assessment of food intake will be performed, mainly of foods that are sources of protein and, when they were less than 75%, strategies must be designed to increase the acceptance or indication of oral nutritional supplements."
223600854|NCT02336672|DEVICE|Cryothermal ablation|Procedures are performed with patients sedated by anaesthesiologists. Device setting and application time are set and recorded on a computer, that analyzes the changes of the tissue's properties. The setting of the maximal application time is based on the results of our previously described ex-vivo and in-vivo studies and is adjusted to the tumour's size, thus ensuring a reduction of procedure-related complications. Application of Power Doppler makes the procedure safer. The HybridTherm probe is guided under real-time EUS into the tumour, and the success of its placement is an index of the treatment's feasibility. The system analyzes the effects on the tissue and EUS records the changes of the tissue, the growing edema around the treated area, and the tissue devitalization.
223600855|NCT02463682|DEVICE|CGM and Insulin Pump|Dexcom G4 Platinum CGM with Share AP Receiver Roche Accu-Chek insulin pump
223749168|NCT05477875|DRUG|oral cannabinoid|dronabinol
224199780|NCT01570127|PROCEDURE|Standardized Acupuncture|The treatment was applied twice a week for 20 minutes for 6 weeks(12sessions) 8 Acupuncture points, GV4, GV3, BL24(bilateral), BL25(bilateral) and GB30(bilateral) were used for all the patients assigned to this group. Sterile Stainless Steel(25mm x 40mm) disposable acupuncture needles manufactured by Dong-Bang Acupuncture Co.(Korea) were used.
224199781|NCT01570127|PROCEDURE|Sham Acupuncture|The treatment was applied twice a week for 6 weeks(12sessions). The sham acupuncture was applied on the 8 same acupuncture points as in the standardized acupuncture group, GV4, GV3, BL24(bilateral), BL25(bilateral) and GB30(bilateral). Each session was 20 minutes long.
223749169|NCT05477875|COMBINATION_PRODUCT|oral codeine/acetaminophen|10 tablets of acetaminophen-codeine combination (300-30mg) without refills.
224199782|NCT01570127|OTHER|Waiting|No interventions were applied to the patients in this group.
223749174|NCT06796075|BEHAVIORAL|Mom♥Health|12-week intervention involving 1) weekly phone calls to mothers regarding education and counseling related to heart healthy lifestyle, as well as strategies for stress reduction; 2) referral to clinical care for identified needs (e.g., elevated blood pressure); and 3) referral to available social resources (e.g., food pantry for identified food insecurity).
223749175|NCT01838031|OTHER|thyroid screening|The thyroid function and antibody will be measured immediately. The subclinical hypothyroidism will be treated individually.
223749176|NCT01572233|BEHAVIORAL|Personalized Physical Activity and Psycho-Education (PPAPE) Program|"1. Effects of Personalized Physical Activity and Psycho-Education Program on Patients with HCV infection~2. The third and fourth year, will be examine on the 12, 24, 36, and 48 weeks during the interferon treatment."
223600856|NCT02463682|DEVICE|Closed-Loop Control System|"The devices that will be used in the Closed-Loop Control System include the following components:~DiAs - a smart-phone medical platform; Dexcom Dexcom G4 Platinum connected to DiAs via Bluetooth CGM receiver; Roche Accu-Chek insulin pump connected to DiAs via wireless Bluetooth; Remote Monitoring Server connected to DiAs via 3G or local Wi-Fi network, and Zone-MPC and HMS algorithms running on DiAs (MPC and HMS)"
223600857|NCT00760318|DRUG|Keppra|There will be flexible dose titration increasing by 250 mg per week for 12 weeks to a maximum of 3000 mg divided BID.
223600858|NCT05050461|OTHER|Immunological analyses|Immunological analyses will be performed at inclusion in both arms
223600859|NCT02703324|DRUG|LY900014|Administered subcutaneously (SC)
223600860|NCT02703324|DRUG|Insulin Lispro|Administered SC
223600861|NCT02694900|OTHER|Manually chest compressions|Chest compressions performed manually without any device
223600862|NCT02694900|DEVICE|Cardiopump|Chest compressions performed with Cardiopump
223600863|NCT02694900|DEVICE|LifeLine ARM|Chest compressions performed using mechanical chest compressions system LifeLine ARM
223600864|NCT01204021|BEHAVIORAL|Tai Chi Chih|12 weeks of weekly classes of Tai Chi Chih
223600865|NCT01204021|BEHAVIORAL|Stress Education Control|Weekly meetings, for 2 hours for 12 weeks discussing issues related to stress education.
223600866|NCT01652339|DRUG|Exforge tab. 10/160mg|
223600867|NCT01652339|DRUG|Lodivixx tab. 5/160mg|
223600868|NCT01883544|DRUG|ALXN1007|
223600869|NCT00606619|OTHER|Conventional feeding|Procedure of Conventional feeding group: Patients are supplied water on day 3 after operation, liquid diet on day 4 and 5 and soft diet on 6 day.
223600870|NCT00606619|OTHER|Early oral feeding|Procedure of Early oral feeding group: Patients are supplied water on day 1 after operation, liquid diet on day 2 and soft diet on day 3 day.
223600871|NCT00891241|DRUG|LMI 1195-101|Single dose, bolus IV injection of LMI 1195
223749177|NCT00256945|PROCEDURE|dental restorative material surface preparation|
223600872|NCT06310421|DIAGNOSTIC_TEST|Screening SMA test|Drops of blood from a puncture from the newborn's heel are collected, dried for 24 hours at room temperature and then sent to the laboratory for analysis. The screening test is a first-level molecular genetic test that allows the identification of patients affected by SMA who present the homozygous deletion of exon 7 of the SMN1 gene using the Real Time polymerase chain reaction (PCR) technique. This qualitative method is based on the use of specific fluorescent probes that discriminate the SMN1 gene from its survival motor neuron 2 (SMN2) homologue and also allow the quality assessment of genomic DNA through amplification of an internal control gene. When a positive testing patient is identified, the birth center is promptly notified to call the family and carry out a further blood sample aimed at confirming the possible diagnosis with a second level test.
223600873|NCT03773237|DIETARY_SUPPLEMENT|SMOFLipid|SMOFLipid will be given to HPN patients to assess the benefits or adverse effects compared to Intralipid.
223600874|NCT03773237|DIETARY_SUPPLEMENT|Intralipid|Intralipid will be given to HPN patients to assess the benefits or adverse effects compared to SMOFlipid
223600875|NCT04078555|DRUG|ENERGI-F703 GEL|"The study medication will be applied twice daily until the end of 84 days or up to the visit confirmation of complete ulcer closure, whichever comes first.~The estimated amount of study medication applied to the ulcer area is 0.25 cm (about 0.11 g) in length per cm2 of ulcer size."
223600876|NCT04078555|DRUG|ENERGI-F703 GEL matched vehicle|"The study medication will be applied twice daily until the end of 84 days or up to the visit confirmation of complete ulcer closure, whichever comes first.~The estimated amount of study medication applied to the ulcer area is 0.25 cm (about 0.11 g) in length per cm2 of ulcer size."
223600877|NCT06312592|BEHAVIORAL|Entrepreneurship School with Gender Lens|"The Entrepreneurship School with Gender Lens (ESGL) is an approach that targets gender based violence survivors and women at-risk to help them develop business ideas, access needed support for the prevention of and response to GBV, exploitation and trafficking, and improve participants' overall self-reliance. Participants will go through a general business curriculum, work on business plans and learn gender issues and ways to mitigate GBV risks. Upon training completion, participants are eligible to pitch their business idea to a panel of experts and receive $800 of seed capital. They will also receive follow-up business advisory support for at least six months, focusing on access to markets and finance and building support networks, in order to continue building self-reliance.~The ESGL will also include a mental health and psychosocial support module."
223600878|NCT04334304|PROCEDURE|Total Knee Prosthesis - type Bicruciate retaining|A total knee arthroplasty will be performed with a bicruciate retaining implant (Journey II, XR). The control group will consist out of patients receiving a posterior stabilized implant (Journey II, BCS).
223600879|NCT04334304|PROCEDURE|Robot-assisted Total Knee Arthroplasty|A total knee arthroplasty will be performed with robot-assistance (NAVIO).
223600880|NCT04334304|PROCEDURE|Total Knee Prosthesis - type Posterior Stabilized|A total knee arthroplasty will be performed with a bicruciate retaining implant (Journey II, XR). The control group will consist out of patients receiving a posterior stabilized implant (Journey II, BCS).
223749178|NCT04723381|OTHER|web based education|Expert support and consultancy were received for the design and preparation of the web page.
223749179|NCT01216527|PROCEDURE|Neo-adjuvant Chemoradiotherapy followed by Surgery|"1. Radiotherapy combined with concomitant chemotherapy:~   Radiotherapy Program:External radiation with a total dose of 40.0Gy is given in 20 fractions of 2.0Gy,5 fractions a week.~   neo-chemotherapy program: Vinorelbine 25mg/m2, IV (in the vein) on day 1 and day 8 of each 21 day cycle. Cisplatin 75mg/m2,IV DRIP on day 1 of each 21 day cycle;or Cisplatin 25mg/m2,IV DRIP on day 1 to day 4 of each 21 day cycle.~   Number of cycles:two~2. surgery:Mckeown Modification Surgery and total two-field lymphadenectomy"
223749180|NCT01216527|PROCEDURE|surgery|two field lymphadenectomy
223749181|NCT04479956|PROCEDURE|Varicose vein surgery|sapheno-femoral junction (SFJ) incompetence, GSV reflux from the groin to below the knee
224075203|NCT01273545|DRUG|PRILIGY (dapoxetine hydrochloride)|The study will observe characteristics of the patients to whom PRILIGY 30-mg and 60-mg tablets are prescribed in Germany by general practitioners and (separately) by urologists, and in Italy by urologists
224075204|NCT03787758|DRUG|SAGE-718|SAGE-718
223749182|NCT05853601|DRUG|Single Dose Theophylline|Subjects are given a single loading dose of theophylline, 5mg/kg IV, within 18 hours after birth. A bioequivalent dose of aminophylline, a more soluble, ethylenediamine salt of theophylline, may be substituted for theophylline. The bioequivalent dose of aminophylline is 120% of the theophylline dose.
223749183|NCT05853601|DRUG|Repeat Dose Theophylline|Subjects are given a loading dose of theophylline, 5mg/kg IV, within 18 hours of birth, and then two subsequent doses (1.2mg/kg iv) at 12 hours and 24 hours after loading dose. A bioequivalent dose of aminophylline, a more soluble, ethylenediamine salt of theophylline, may be substituted for theophylline. The bioequivalent dose of aminophylline is 120% of the theophylline dose.
223749184|NCT01541969|DEVICE|CR Neuromodulation|"Ear level device which delivers patterned sound stimulation.~The experimental arm will use the device fitted according to audiologist training given by the manufacturer/funder. An individually specified sound stimulation algorithm is hypothesised to interrupt tinnitus generating activity in the brain. For the first 12 weeks participants will be asked to wear the device every day for 6 hours, and in blocks of time not less than 1 hour. After 12 weeks participants will be unblinded and continue with the same experimental intervention. In weeks 13-36 participants will be asked to wear the device every day for 4 hours, in continuous blocks of at least 1 hour."
223749185|NCT01541969|DEVICE|Tinnitus masking|The active comparator uses the same ear level device and also delivers patterned sound but the stimulus will be determined according to an algorithm predicted not to break up tinnitus generating activity in the brain. It may have a masking effect. For the first 12 weeks participants will be asked to wear the device every day for 6 hours, and in blocks of time not less than 1 hour. After 12 weeks, the participants will be unblinded and the device algorithm will be reprogrammed in the same way as the experimental intervention. In weeks 13-24 participants will be asked to wear the device for 6 hours per day, in continuous blocks of at least 1 hour. In weeks 25-36 they will be asked to continue using the device every day for 4 hours, in continuous blocks of at least 1 hour.
223749186|NCT05900050|DRUG|VS-01 on top of SOC|Patients will receive VS-01 intraperitoneally on four consecutive days on top of SOC
223749187|NCT05900050|OTHER|SOC (Control Group)|Patients will receive SOC for decompensated cirrhosis and ACLF
223749188|NCT04382833|OTHER|HOT APPLICATION|HOT APPLICATION
223749189|NCT04382833|OTHER|MASSAGE|
224075205|NCT06425627|PROCEDURE|spinal anesthesia|An intrathecal anesthetic technique.
224075206|NCT06425627|PROCEDURE|general anesthesia|An intravenous (combined with inhalation) anesthetic technique.
224075207|NCT06569329|DEVICE|GentleWave System Root Canal Therapy|This device has 510k market approval for its intended use within this study.
224075208|NCT06569329|DEVICE|EdgePro Laser Root Canal Therapy|This device has 510k market approval for its intended use within this study.
224075209|NCT06569329|DEVICE|The ProUltra Piezo Ultrasonic with EndoUltra Tips Root Canal Therapy|This device has 510k market approval for its intended use within this study.
224075210|NCT03438045|BEHAVIORAL|Partnered intervention|CHWs will provide dental education and counseling, lead interactive demonstrations of brushing with fluoride toothpaste and flossing, and improve access to dental care through dental coverage enrollment and linkage to local dentists.
224075211|NCT02168686|GENETIC|ADVM-043|Gene transfer vector administration
224075212|NCT00786877|OTHER|Improved biomass cookstove with exterior ventilation|Improved cookstove design installed in house that is higher efficiency and is vented to the exterior.
224075213|NCT00786877|OTHER|Phase 2 intervention arm (LPG stove)|LPG two burner stove with a 12 month supply of LP gas.
224075214|NCT04295070|BIOLOGICAL|CodaVax-RSV|Codon deoptimized, live-attenuated vaccine against RSV delivered intranasally via dropper
224075215|NCT04295070|BIOLOGICAL|Normal saline|Saline (0.9%) administered via dropper
224075216|NCT06173557|PROCEDURE|entailed calculation of the distances between reference points on the ischium, greater trochanter, and the screwdriver. Measurements were collected from radiographic i|technique of intraoperative measurement of the femoral offset and limb length was used, entailed calculation of the distances between reference points on the ischium, greater trochanter, and the screwdriver. Measurements were collected from radiographic imaging data and surgical reports
224075217|NCT05282823|DEVICE|Boston Scientific Cardiac Cryoablation System|is indicated for cryoablation and electrical mapping of the pulmonary veins for pulmonary vein isolation (PVI) in the ablation treatment of AF as per current and future guidelines and system IFU/ Tenpubunsyo.
224075218|NCT06501274|DEVICE|capsule sponge|capsule sponge sampling device of the oesophagus
224075219|NCT05321836|OTHER|Glucosamine Chondroitin|control group
223507483|NCT03994120|OTHER|RTMS|Altering the connectivity of trans-synaptic pathways
223507484|NCT01870570|OTHER|Reference Glucose|
223507485|NCT01870570|OTHER|Food Product A: Corn Flakes|
223507486|NCT01870570|OTHER|Food Product B: Ginger Bread|
224075220|NCT05321836|COMBINATION_PRODUCT|glucosamine chondritin & Physiotherapy|experimental group
224075221|NCT06576427|DEVICE|Vertex Pulmonary Embolectomy System|Use of Vertex Pulmonary Embolectomy System to treat pulmonary embolism.
223507487|NCT01870570|OTHER|Food Product C:Sandwiched Breakfast Biscuit|
223507488|NCT01870570|OTHER|Food Product D: Crackers Nature|
223507489|NCT01870570|OTHER|Food Product E: Breakfast Biscuit|
223507490|NCT01870570|OTHER|Food Product F: White Bread|
223507491|NCT04429594|OTHER|blood sampling|blood sampling at J0, M6, M12, M24, M36, M48, M60
223507492|NCT01111292|DRUG|Inositol|Given PO
223507493|NCT01111292|OTHER|Placebo|Given PO
223507494|NCT03881800|OTHER|titration- blood sample|Ceftazidime titration
223507495|NCT03357705|PROCEDURE|alveolar ridge preservation with synthetic bone|after tooth extraction
223507496|NCT03357705|PROCEDURE|alveolar ridge preservation with bovine collagen|after tooth extraction
223507497|NCT01954173|RADIATION|3D conformal radiation therapy|Undergo conformal radiation therapy
223507498|NCT01487785|DRUG|LDE225+gemcitabine|Patients will receive increasing doses of LDE225 (from 400 mg), depending on the cohort they are assigned to, orally once daily and standard doses of gemcitabine (1000 mg/m2) on days 1, 8 and 15 of every 28-day cycle. Patients will receive the study treatment until they progressed, experience unacceptable toxicity, withdraw from the study, or the investigator decides it is in their best interest to discontinue the study treatment.
224199783|NCT03217474|PROCEDURE|FLDEB|The eye will be anesthetized, and femtosecond laser technology will be used to remove epithelial tissue (diameter: 8mm; depth: 100micron) that includes the loosened diseased corneal epithelial cells. Antibiotic ointments and drops will be instilled postoperatively.
224199784|NCT03217474|DRUG|Ganciclovir (GCV)|Patient will be treated with GCV orally (200mg, 3 times a day, for 14 days).
224199785|NCT03217474|DEVICE|Femtosecond laser|A commercial femtosecond laser to create a particular shaped graft for transplantation.
224199786|NCT02046239|PROCEDURE|Suture Group|
224199787|NCT02046239|BIOLOGICAL|Staple Group (control)|
224199788|NCT02817269|OTHER|Manual palpation|The manual palpation level will kept constant by applying enough digital pressure to cause the finger nail bed to blanch. When the nail will be turn pale, the amount of pressure will be measured at approximately 3 4kg/cm2 and will be maintained for 5-10 seconds to evoke referred pain. A manual palpation referred pain will be present if the pain radiated far enough for the patient to feel more than just a local pain.
224199789|NCT02817269|OTHER|Deep dry needling|Intramuscular needling will be carried out via deep dry needling into myofascial trigger point (MTrP) area without the introduction any substances. The aim is to elicit a local twitch response upon inserting the needle into the MTrP area and perform a neurological stimulation (by rotating the needle 360 degrees) to more easily evoke referred pain, holding for 10 seconds and then extracting the needle gently. The procedure will be followed by one minute of haemostatic compression.
224199790|NCT00978640|OTHER|fast and exercise|fasting 36 h and exercise 1 h 50% VO2max
224199791|NCT00978640|OTHER|exercise|exercise 1 h 50% VO2max
224199792|NCT03540446|DEVICE|First Relief Treatment|To prove the effectiveness of Percutaneous Electrical Neuro-stimulation therapy for the treatment of conditions associated with peripheral neuropathy, in a double-blind environment.
223600881|NCT04428619|DEVICE|Peripheral Electrical Nerve Field Stimulation (PENFS) Device|Patients will complete daily worst abdominal pain and bowel habit questionnaires for 1 week prior to initial PENFS device placement to provide a baseline. At visit 1, patients will complete the Bowel Symptom Questionnaire, IBS Symptom Severity Scale (IBS-SSS), PROMIS Belly Pain Scale, Gas and Bloating, Constipation, and Diarrhea Scales, Hospital Anxiety and Depression Scale, and Visceral Sensitivity Index, heart rate variability will be measured, and they will have the initial PENFS device placed. Patients will complete daily worst abdominal pain (scale 0-10) questionnaires throughout the duration of the study. They will return every 7 days for a total of 4 visits for device replacement and additional questionnaires, including the IBS-SSS. Four devices will be placed in total (start of weeks 1, 2, 3, and 4). Stimulation time is 5 days/week during each of the 4 consecutive weeks. Additional questionnaires will be completed at the end of week 4 and at extended follow-up (8 weeks).
223600882|NCT04428619|DEVICE|Sham Device|Patients will complete daily worst abdominal pain and bowel habit questionnaires for 1 week prior to initial sham device placement to provide a baseline. At visit 1, patients will complete the Bowel Symptom Questionnaire, IBS Symptom Severity Scale (IBS-SSS), PROMIS Belly Pain Scale, Gas and Bloating, Constipation, and Diarrhea Scales, Hospital Anxiety and Depression Scale, and Visceral Sensitivity Index, heart rate variability will be measured, and they will have the initial sham device placed. Patients will complete daily worst abdominal pain (scale 0-10) questionnaires throughout the duration of the study. They will return every 7 days for a total of 4 visits for device replacement and additional questionnaires, including the IBS-SSS. Four devices will be placed in total (start of weeks 1, 2, 3, and 4). Stimulation time is 5 days/week during each of the 4 consecutive weeks. Additional questionnaires will be completed at the end of week 4 and at extended follow-up (8 weeks).
223600883|NCT05620888|BEHAVIORAL|Walk behavior change: Tailored messages (TM)|"Every afternoon at the same time, the mobile application sends a message to the participants of the TM arm. The message is tailored based on the answers provided to the pre-intervention questionnaire. An example message is: you think you are not able to walk regularly when your morale is low: do not give up because physical activity is also good for the mood! The intervention is provided for 30 days."
223600884|NCT05620888|BEHAVIORAL|Walk behavior change: Non tailored messages (NTM)|"Every afternoon at the same time, the mobile application sends a message to the participants of the NTM arm. The message concerns the emotional well-being resulting from the performance of the physical activity and is not tailored. An example message is: walking regularly in the fresh air improves your mood. The intervention is provided for 30 days."
223600885|NCT05473871|BEHAVIORAL|Faith in Action|"Interpersonal level: Group exercise classes offered 6 days/week (walking, cardio dance, strength training), Kickoff event~Individual level: Motivational Interviewing calls every 6 months, Health handouts on 14 topics distributed at PA classes"
223600886|NCT05473871|BEHAVIORAL|Faith in Action+|Standard Faith in Action Intervention plus: 1) Health Behavior Change Workshop for FBO leaders; 2) Targeted Messaging; and 3) Empowerment Training for Promotoras
223600887|NCT05473871|BEHAVIORAL|Faith in Action++|Enhanced Condition plus: 1) Foster community collaborations and 2) Provide maintenance support
223600888|NCT04381663|PROCEDURE|conservative treatment|conservative treatment for patients with cervical spine stenosis without myelopathy
223600889|NCT04381663|PROCEDURE|surgical treatment|surgical decompress the spinal canal in patients with moderate to severe degenerative cervical spine myelopathy
223600890|NCT05248659|DRUG|Sibeprenlimab 400 mg s.c. Q4weeks|Sibeprenlimab 400 mg s.c. q 4 weeks
223749190|NCT04642456|DIAGNOSTIC_TEST|Balance Assessment Scale|The newly developed balance, based on the Balance Evaluation Systems Test (BESTest) and Trunk Control Measurement Scale (TCMS), will be administered by two raters (normative and clinical database + interrater reliability)
224199793|NCT04132102|DRUG|Afatinib|Afatinib is a member of the second generation TKIs, which binds irreversibly to the erbB family of receptors. Afatinib will be administrated orally with the starting dose of 40 mg tablets, once per day. If patients can't tolerate drug related AEs with 40mg, patients can receive 30mg once per day after AEs recovered to Grade 0-1.
224199794|NCT03348319|OTHER|radiation|Scanning cadaver organs
224199795|NCT05371236|OTHER|Questionnaire|Phase I will use a descriptive qualitative approach to understand pediatric cancer patients' opinions related with spiritual issues and experience. The results of the qualitative study will be used to compare with the items of the original scale, and emerging themes will be used to generate new items. Phase Ⅱ will translates the original scale and validates the psychological properties of scale adapted for pediatric cancer patients.
223749191|NCT04642456|DIAGNOSTIC_TEST|Trunk strength measurement with EMG|A trunk strength protocol in sitting position, using a hand-held dynamometer is developed. During the trunk strength measurements muscle activity of certain muscles of the trunk will be measured using surface electromyography (EMG)
223749192|NCT04642456|DIAGNOSTIC_TEST|MRI spine/pelvis|We will be capturing 3D Magnetic Resonance (MR) images of the subject lying supine with extended knees, using a T1 weighted spine-echo (SE) sequence with interslice distance 3 mm in the area of the hip) extended with full spine MRI images (sagittal full spine T1- and T2- weighted images as part of the standard sagittal view of full spine to check for significant stenosis or spinal cord pathology) and additional T1-weighted axial slices at level L4, T12 and T8 with interslice distance 4 mm.The field of view covers the full spine, pelvis and hip smaller trochanter.
223749193|NCT04642456|DIAGNOSTIC_TEST|EOS stereoradiographic full body exam|Every subject included in the study will undergo a stereoradiographic full body EOS exam completed with Gravity Line (GL) location, recorded by a force plate on the floor
223749194|NCT04642456|DIAGNOSTIC_TEST|Balance Assessment Scale 2|Repeating the newly developed balance test (test-retest reliability) within 2 weeks after first measurement
223749195|NCT04642456|DIAGNOSTIC_TEST|Trunk strength measurement with EMG 2|Repeating the trunk strength protocol with EMG within 2 weeks after the first measurement (test-retest reliability)
223749196|NCT05123222|BIOLOGICAL|ZIKV-SJRP/2016-184 Strain|Zika Virus Strain (San Jose Rio Puerto)
223749197|NCT05123222|BIOLOGICAL|Experimental: ZIKV-Nicaragua/2016 Strain|Zika Virus Strain (Nicaragua)
223507499|NCT01260792|OTHER|questionnaire|The teachers or the professors complete questionnaires on the child on their behavior in classes
223749198|NCT05123222|BIOLOGICAL|Placebo|Saline
223749199|NCT05630274|DRUG|Selpercatinib|Administered orally
223749200|NCT05630274|DRUG|Moxifloxacin|Administered orally
223749201|NCT05630274|DRUG|Placebo|Administered orally.
223749202|NCT02255500|DRUG|Bupivacaine FNB|A single administration of bupivacaine HCl 0.5% with epinephrine 1:200,000 in 20 mL volume will be administered within 2 hours prior to the surgical procedure as an ultrasound-guided FNB.
223749203|NCT02255500|DRUG|EXPAREL Infiltration|A single dose of EXPAREL 266 mg expanded to 60 mL with preservative-free sterile normal saline will be infiltrated into the surgical site just prior to wound closure.
223749204|NCT00265343|DRUG|asenapine|5-10 mg sublingually twice daily for 26 weeks
223749205|NCT00265343|DRUG|olanzapine|5-20 mg by mouth once daily for 26 weeks
223749206|NCT04059731|DIETARY_SUPPLEMENT|Nutrition supplement|Administration twice a day of Survimed OPD or Impact/Atempero depending on arm assigned during 5 postoperative days
223749207|NCT02423863|BIOLOGICAL|Hiltonol|"Wk 1 Days 1, 3 and 5: Poly-ICLC (Hiltonol®) 1 mg (0. 5 ml) IntraTumoral (priming treatment course). Weeks 2-25 Poly-ICLC (Hiltonol®) 1 mg (0.5 ml) IM twice a week with a 48-72 hour interval between the two injections, AND either:~No additional immunotherapy OR~ONLY ONE of the Anti-PD1 or anti-PDL-1 regimens will be administered, per manufacturer's dosing and clinical oncologist's discretion as follows: (Not to be Administered on the same day as Poly-ICLC \[Hiltonol®\]) Either Nivolumab, OR Pembrolizumab, OR Atezolizumab, OR Cemiplimab, OR Durvalumab"
223749208|NCT04865354|DEVICE|Verofilcon A contact lenses|Spherical soft contact lenses for daily disposable wear
223749209|NCT04865354|DEVICE|Somofilcon A contact lenses|Spherical soft contact lenses for daily disposable wear
223749210|NCT01840774|DRUG|Low-dose pain medication (Ketalar) and saline placebo|
223749211|NCT01925404|BEHAVIORAL|Free physical activity classes|100 hours of free activity classes will be provided
223749212|NCT01925404|BEHAVIORAL|Frequent User|Participants can become eligible for prizes by visiting the park more frequently
223749213|NCT05047081|BEHAVIORAL|Scoring Your College Goals Workshop|A two-hour virtual college readiness workshop.
223749214|NCT05047081|OTHER|Placebo|Placebo Treatment-As-Usual Group which does not receive the workshop intervention
223749215|NCT06145360|DRUG|Empagliflozin 10 MG|the impact of incorporating Empagliflozin, an oral sodium-glucose co-transporter 2 (SGLT2) inhibitor, into the existing therapeutic regimen of Insulin+Metformin+DPP4 inhibitor (DPP4I) in poorly controlled type 2 diabetes mellitus (T2DM
223749216|NCT06145360|DRUG|Insulin+Metformin+DPP4 inhibitor (DPP4I)|Group B: usual care group but without Empagliflozin with adjustment of therapy as the standard of care
223749217|NCT00588822|BIOLOGICAL|Rituximab|Rituximab will be given as a 375 mg/m\^2 intravenous infusion once weekly for four doses (days 1, 8, 15, and 22).
223749218|NCT01948739|DEVICE|MAHI EXO-II exoskeleton augmented with BMI system|In this longitudinal study, adult subjects with hemiparesis due to acute or chronic stroke will receive robotic-assisted training through an EEG-based BMI control of robotic exoskeleton to study the changes in upper extremity motor function, cortical plasticity (using the EEG and fMRI). The training will be provided 3x/week for 12 sessions over one-month period.
223749219|NCT00544258|DRUG|PEP005|
224075222|NCT06959810|OTHER|Adapted Onco-Esthetics sessions|Patient will received three sessions of Adapted Onco-Esthetics
224075223|NCT02657135|BEHAVIORAL|Cognitive/Neuropsychological Testing|These tests will be used to determine how the participant will continue with future procedures, and depending on results, may involve the participant returning to complete subsequent testing.
224075224|NCT02657135|OTHER|Vestibular/Ocular-Motor Testing|These assessments will involve a series of tests and questionnaires that focus on physical symptoms of TBI and will include dizziness, balance, ocular-motor coordination, and reflexes.
224075225|NCT02657135|OTHER|Cervical (Neck) Evaluation|These assessments will involve a series of tests and questionnaires that focus on physical symptoms of TBI including neck mobility and pain levels.
224075226|NCT02657135|OTHER|Sleep Evaluation|These evaluations will focus on assessing insomnia (duration, frequency, daytime consequences), combat exposure, and the presence and severity of trauma history.
224075227|NCT02657135|OTHER|HDFT MRI|This MRI aims at providing qualitative and quantitative assessments of the nature, location, and extent of white matter injury.
224075228|NCT02657135|OTHER|MR Spectroscopy (MRS)|This is a noninvasive diagnostic test for measuring biochemical changes in the brain.
224075229|NCT02657135|OTHER|MEG (Magnetoencephalography)|This is a non-invasive neurophysiological technique that measures the magnetic fields generated by neuronal activity of the brain.
224075230|NCT02789813|DRUG|Valproic Acid|Once oral administration of 500mg before exposure therapy.
223600891|NCT05319158|OTHER|MIT-PB, movement imitation therapy for preterm.|The instant an infant showed CS or PR movements, the therapists (or a therapist and a parent) intervened by gently guiding the infants' limbs so as to maneuver and smoothen their movements, thereby imitating normal GM sequences as closely as possible, adding variability to the movement
223600892|NCT05501080|OTHER|Super selective adrenal artery embolization|Superselective adrenal arterial embolization is an operation to inject embolic agent into adrenal artery through catheter to embolize part of adrenal gland, so as to reduce the secretion of adrenal hormone and reduce blood pressure.
223600893|NCT05501080|DRUG|Spironolactone|Aldosterone receptor antagonists are recommended by guidelines for the treatment of bilateral primary aldosteronism.
223600894|NCT04678635|OTHER|Chronic transcranial direct current stimulation|Chronic transcranial direct current stimulation
223600895|NCT06800820|DIETARY_SUPPLEMENT|Chondractiv™ Plus (Hydrolyzed chicken cartilage)|One oral dose
223600896|NCT04909164|DRUG|Immunnotherapy group|Eligible patients are those who receive reimbursed immunotherapy or cytotoxic chemotherapy after failure of platinum-based chemotherapy per current health insurance reimbursement criteria.
224075231|NCT02789813|DRUG|Placebo|Once oral administration of 500mg before exposure therapy.
224075232|NCT02789813|BEHAVIORAL|Fear reactivation|Fear reactivation before exposure therapy.
224075233|NCT02789813|BEHAVIORAL|No fear reactivation|No fear reactivation before exposure therapy.
224075234|NCT02074852|OTHER|Foley urethral catheter|
224075235|NCT01266486|DRUG|Metformin|Extended release Metformin 1500mg once daily for 14-21 days
224075236|NCT00317148|DRUG|Placebos|Placebo capsule
224075237|NCT00317148|DRUG|DHEA capsule|One capsule of DHEA
224075238|NCT03193398|DRUG|BTRX-246040 oral capsule(s)|BTRX-246040 administered once daily to patients with MDD for 8 weeks
224075239|NCT03193398|DRUG|Placebo oral capsule(s)|administered once daily to patients with MDD for 8 weeks
224075240|NCT01394445|DRUG|Physostigmine|continuous intravenous infusion per syringe pump (13 vials of 2 mg/5 ml --\> 26 mg/65 ml; 1 ml = 0.4 mg Physostigmine) at rate of 1 mg/h (2.5ml/h) for 24 hours
224075241|NCT01394445|DRUG|Placebo|"continuous intravenous infusion of 65 ml NaCl 0.9% with syringe pump at rate of 2.5 ml/h for 24 hours~PCA: Patient-controlled analgesia with hydromorphone 0.2 mg/ml, on demand: bolus of 0.2 mg, maximum 5 boli per hour; 4-hour-maximum 4 mg"
224075242|NCT03279380|OTHER|SNP|Screening 150 endurance, 150 power athletes, and 200 healthy control individuals for genetic variant associated to sport performance.
224075243|NCT03279380|OTHER|High Intensity Interval Training (HIIT)|The subgroup (n = 40) of the athletes will participate in the acute exercises (HIIT Training). In order to investigate the acute effects of the exercise the concentration of circulating myokines will be measured (before, post-exercise and 2 h post-exercise). All participants will visit the laboratory at least three times, scheduled 96 h apart. Exercise will be carried out on the cycling ergometer with simultaneous monitoring of physiological responses. Participants will be asked to follow the prescribed diet regime and not to perform any physical activities / trainings the day before measurements. Baseline measurements will include the V̇o 2 peak test. Then the participants will be randomly divided into two groups. The specific acute exercises will be accomplish in the next two visits.
224075244|NCT03279380|OTHER|Low Intensity Continuous Training|The subgroup (n = 40) of the athletes will participate in the acute exercises (LIT Continuous Training). In order to investigate the acute effects of the exercise the concentration of circulating myokines will be measured (before, post-exercise and 2 h post-exercise). All participants will visit the laboratory three times, scheduled 96 h apart. Exercise will be carried out on the cycling ergometer with simultaneous monitoring of physiological responses. Participants will be asked to follow the prescribed diet regime and not to perform any physical activities / trainings the day before measurements. Baseline measurements will include the V̇o 2 peak test. Then the participants will be randomly divided into two groups. The specific acute exercises will be accomplish in the next two visits.
224075245|NCT01396005|DRUG|boceprevir|boceprevir 800 mg (4 x 200 mg capsules), orally, every 8 hours, Day 2 through Day 7
224075246|NCT01396005|DRUG|methadone|methadone, 20-150 mg tablets, liquid, or disket, orally, once per day, Day 1 through Day 8
224075247|NCT01396005|DRUG|buprenorphine/naloxone|buprenorphine/naloxone 8/2-24/6 mg, tablets, sublingual, once per day, Day 1 through Day 8
224075248|NCT03027752|PROCEDURE|Operation carotid endarterectomy with plastic of xenopericardial patch|Under local anesthesia Sol.Novocaini 0.25%, wires or endotracheal anesthesia using the standard access the bifurcation of the common carotid artery, internal carotid artery, isolated on identical distance external carotid artery. Common carotid artery cut then performed a longitudinal arteriotomy on the front of the anterior surface of the internal carotid artery. Under the visual control performs a sequence of endarterectomy of the internal carotid artery. Plastic arteriotomy performed patche of ksenoperikardial (Kemperiplas-Neo) treated with epoxy compounds.
224075249|NCT03027752|PROCEDURE|New method of operation сarotid endarterectomy with autoarterial remodeling of bifurcation CCA|Under local anesthesia Sol.Novocaini 0.25%, or endotracheal anesthesia using the standard access the bifurcation of the common carotid artery, internal carotid artery, isolated on identical distance external carotid artery. Carotid glomus separated and moves downward and backward bifurcation of the common carotid artery. External carotid artery is cut off at an angle of 45º from the mouth with a portion of the common carotid artery, then performed a longitudinal arteriotomy on the front of the medial surface of the internal carotid and posterior-lateral surface of the external carotid artery. Under the visual control performs a sequence of endarterectomy of the internal and external carotid arteries. The final recovery of the arteries is performed by crosslinking of their walls with each other in a side by side type between the internal and external carotid arteries 6/0 Polypropylene thread with two needles.
224075250|NCT03156400|OTHER|Exercise Stress Test|Gradual increase in treadmill grade while collecting respiratory gases.
224075251|NCT04593784|DRUG|Ciraparantag|Ciraparantag: 180 mg, intravenous
224075252|NCT04593784|DRUG|Placebo|Placebo: 0.9% sodium chloride, intravenous
224075253|NCT04593784|DEVICE|Point-of-Care Coagulometer (investigational device)|Perosphere Technologies' Point of Care (POC) Coagulometer Device will be used to measure whole blood clotting time.
224075254|NCT00607308|BIOLOGICAL|PF-04360365|Single dose of 0.1 mg/kg IV on Day 1
224075255|NCT00607308|BIOLOGICAL|PF-04360365|Single dose of 0.5 mg/kg IV on Day 1
223600897|NCT01948063|DRUG|Ubiquinol|Depending on the patient's ability to swallow pills, patients in the experimental group will receive 200mg Ubiquinol in either a pill or a liquid. The liquid form of the study med will be mixed with 50 milliliters of Ensure (a dietary supplement) to ensure blinding. This will be given every 12 hours for 7 days or until hospital discharge.
223600898|NCT01948063|DIETARY_SUPPLEMENT|Placebo|Depending on the patient's ability to swallow pills, patients in the control group will receive a placebo pill or a liquid placebo, which is 50 milliliters of Ensure (a dietary supplement). This will be given every 12 hours for 7 days or until hospital discharge.
223600899|NCT05844358|DEVICE|MySpine MC|Spinal stabilization throught the support of patient specific guide, MySpine MC according to cortical bone trajectory technique
223600900|NCT01858766|DRUG|SOF|400 mg tablet administered orally once daily
223600901|NCT01858766|DRUG|VEL|Tablet administered orally once daily
223600902|NCT01858766|DRUG|RBV|200 mg tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
223600903|NCT01110356|DRUG|Ferinject|Ferric carboxymaltose will be provided in 2 vials of 10 mL containing each 500 mg iron, which will be diluted in 250 mL normal saline for injection. Study drug will be administered by drip infusion immediately after preparation over a minimum of 15 minutes. Placebo patients will be administered 250 mL normal saline for injection over a minimum of 15 minutes.
223600904|NCT01110356|OTHER|Saline|Placebo patients will be administered 250 mL normal saline for intravenous drip over a minimum of 15 minutes.
223600905|NCT01077401|DRUG|Ranibizumab|Intravitreal injections of ranibizumab 0.5mg dose for six monthly treatments then additional treatments with ranibizumab 0.5mg dose if the subject meets re-treatment criteria.
223600906|NCT01077401|DRUG|ranibizumab|Intravitreal injections of ranibizumab 2.0 mg dose for six monthly treatments then additional treatments with ranibizumab 2.0 mg dose if the subject meets re-treatment criteria.
223600907|NCT03544255|PROCEDURE|Biopsy|Two extra EUS-FNA guided pancreatic biopsies collected for only research purposes.
223600908|NCT05715307|OTHER|Intensive training for endocrinologists in T2DM management|"One-week intensive experiential training for endocrinologists includes a 1-week hospitalization experience at Ruijin Hospital, involving health examinations, results interpretation, and integrated training courses for T2DM management.~During the patient intervention period, endocrinologists will each manage approximately 10 T2DM patients, conduct regular follow-ups, and participate in regular training sessions, including experience-sharing meetings."
223600909|NCT05715307|OTHER|Regular training for endocrinologists in T2DM management|"Regular training and communication are implemented by Ruijin Hospital under the guidance of T2DM management.~During the patient intervention period, endocrinologists will each manage approximately 10 T2DM patients, conduct regular follow-ups, and receive regular routine training."
223600910|NCT03517228|DEVICE|BAUM device|The robotic manipulator will be placed at the start of each case. The manipulator will be cleaned and sanitized using the same process as other reusable OR devices. Feasibility will be determined by the rate of successful robotic manipulator docking and if the manipulation of the uterus was successful for the duration of the procedure. The V-Care is an FDA approved uterine manipulator which will attach to the investigational BAUM. Placement of a BAUM will be noted on the operative note.
223600911|NCT03387774|DRUG|Cisplatin|"Patients in both arms received concurrent cisplatin chemotherapy:~100 mg/m² cisplatin given intravenously every 3 weeks on days 1, 22 concurrently with radiotherapy."
223600912|NCT03387774|RADIATION|Intensity Modulated Radiation Therapy|"Patients in both arms received Intensity Modulated Radiation Therapy:~All target volumes were outlined slice by slice on the axial contrast-enhanced CT with MR fusion images in the treatment planning system. The target volumes were defined in accordance with the International Commission on Radiation Units and Measurements Reports 50 and 62. The prescribed dose was 68-72 Gy to PTVnx (Planning target volume of the primary tumor), 64-68 Gy to GTVnd (Gross tumor volume of the cervical lymph node), 60- 64Gy to PTVnd and PTV1 (Planning target volume 1), and 54-58 Gy to PTV2 (Planning target volume 2) in 30-32 fractions. The details of dose limits for organs at risk were based on the study 0225 from The Radiation Therapy Oncology Group (RTOG 0225)."
223600913|NCT03387774|DRUG|Ulinastatin|"Patients in the experimental group were received ulinastatin:~Ulinastatin (UTI): ulinastatin was intravenous drip at a dose of one hundred thousand units added to 100 ml of 0.9% normal saline every time, 3 times every radiation day, and until the end of radiotherapy."
223600914|NCT06160011|OTHER|Electrical dry needling + Conventional physiotherapy|Electrical dry needling and conventional physiotherapy treatment (massage, pressure release): 2 sessions
223600915|NCT06160011|OTHER|Dry needling + Conventional physiotherapy|Dry needling and conventional physiotherapy treatment (massage, pressure release): 2 sessions
223600916|NCT06160011|OTHER|Conventional physiotherapy|Conventional physiotherapy treatment (massage, pressure release): 2 sessions
223600917|NCT04204811|OTHER|Prehabilitation|A program of personalized independent home exercises are outline for participants to complete daily. Prehabilitation coaching will continue weekly until admission for surgical tumor debulking or termination of neoadjuvant treatment for any reason.
223600918|NCT00887510|DRUG|Hydrochlorothiazide|"25 mg tablet once daily for 6 weeks~Other Names:~HCTZ"
223600919|NCT00887510|DRUG|Trandolapril|4 mg tablet once daily for 6 weeks
223600920|NCT00180765|PROCEDURE|Up to 100ml blood will be taken by venupuncture.|
223600921|NCT03832751|OTHER|skin biopsy before and after NB-UVB phototherapy|skin biopsy before and after NB-UVB phototherapy to measure tissue human beta-defensin 1
223600922|NCT03782363|BIOLOGICAL|Autologous CIK Dose level 1|Lymphocytapheresis of the autologous ex-vivo CIK cell expanded in the Cell factory at first level of dose 20.000.000 cell/kgs days 1 and 22
223600923|NCT03782363|BIOLOGICAL|Autologous CIK Dose level 2|Lymphocytapheresis of the autologous ex-vivo CIK cell expanded in the Cell factory at first level of dose 25.000.000 cell/kgs days 1 and 22
223600924|NCT03782363|BIOLOGICAL|Autologous CIK Dose level 3|Lymphocytapheresis of the autologous ex-vivo CIK cell expanded in the Cell factory at first level of dose 20.000.000 cell/kgs days 1 and 15
223600925|NCT03782363|BIOLOGICAL|Autologous CIK Dose level 4|Lymphocytapheresis of the autologous ex-vivo CIK cell expanded in the Cell factory at first level of dose 25.000.000 cell/kgs days 1 and 15
223600926|NCT04063163|DRUG|HLX10|HLX10 is an innovative monoclonal antibody targeting PD-1，developed by Shanghai Henlius Biotech, Inc.
223600927|NCT04063163|DRUG|carboplatin and etoposide|chemotherapeutics
223600928|NCT04063163|DRUG|placebo|placebo
223600929|NCT01340053|DRUG|RDX5791|Capsule, QD
223600930|NCT04728607|DEVICE|Compression device.|A compression device is a device that uses circumferential compression to reduce swelling around a stuck ring. The device is used by placing it near, but not overtop, the offending ring, and then is inflated compressing the finger. The device is applied, and the hand elevated, for approximately five minutes. The device is then removed, and with a small amount of lubricant, the ring is removed.
223600931|NCT00955539|DEVICE|AV-optimization followed by AV- and VV-optimization|Patients are AV-optimized the first 4 months,then AV- and VV-optimized the next 4 months.
223600932|NCT00955539|DEVICE|AV- and VV-optimization followed by AV-optimization only.|Patients are AV- and VV-optimized the first 4 months,then AV-optimized the next 4 months.
223600933|NCT05518357|BIOLOGICAL|LILRB4 STAR-T|Subjects with relapsed/refractory acute myeloid leukemia will be enrolled in the study, and Subjects will receive cytoreductive chemotherapy with cyclophosphamide and fludarabine on days -5, -4 and -3 followed by infusion of STAR-T cells. STAR-T cells will be intravenously infused with a escalated dose of 1E6#3E6#1E7 cells/kg。
223600934|NCT03124576|DEVICE|Implantable loop recorder|Continuous rhythm monitoring Medtronic
223600935|NCT06406023|OTHER|Conventional treatment|"Hot pack will be applied for 10 minutes. AROM's of Hip (5 reps x 2 sets each). Piriformis stretch 3 reps x 20 sec hold x 2 sets. SLR (5reps x 10 sec hold x 2 sets). Sciatic nerve stretch (5 reps x 10 sec hold x 2 sets) for 3 days/ week for 2 weeks.~Strengthening exercises will be performed after 2 weeks of previous intervention of Hip abductors (Hip abduction with band in sitting, standing, side-lying hip raise), and hip extensors (Gluteal bridges, Prone hip extension, Prone hams curl). (5 reps x 2 sets each).~SLR (5 reps x 10 sec hold x 2 sets) each exercise will be performed 3 days/ week for 2 weeks.~Total treatment protocol will be followed for 4 weeks. Each session will be of 30 minutes."
223600936|NCT06406023|OTHER|Instrument assisted soft tissue mobilization|Instrument assisted soft tissue mobilization IASTM with Graston tool along with conventional treatment in first 6 sessions. Apply hot pack for 10 mins on low back as passive warm up then AROM's of Hip (5 reps x 2 sets each) will be performed. Apply Graston tool at 30-60 degrees angle along the length of following muscles Piriformis, Gluteus medius and Hamstrings after applying emollient for 40-120 seconds.
223600937|NCT00757055|DRUG|Ivabradine|Ivabradine titrated to heart rate starting at 5 mg bd and increasing to maximum of 7.5 mg bd or reducing to 2.5 mg if heart rate \< 60 bpm.
223600938|NCT00757055|DRUG|Placebo|No active treatment given
223600939|NCT01848327|DIETARY_SUPPLEMENT|Caprylic Triglyceride|Caprylic Triglyceride is a medical food that is used for the dietary management of the metabolic processes associated with mild to moderate Alzheimer's disease.
223600940|NCT01848327|DIETARY_SUPPLEMENT|Placebo|Placebo (40 gram packet orally once a day for 90 days)
223600941|NCT06802835|DRUG|EGFR Antibody|6 cycles for combined therapy. Maintenance for 1 year.
223600942|NCT06802835|DRUG|PD-1 antibody|6 cycles for combined therapy. Maintenance for 1 year.
223600943|NCT06802835|DRUG|Gemcitabine, Cisplatin|6 cycles for combined therapy.
223600944|NCT06802835|RADIATION|IMRT|IMRT for primary lesion
224199796|NCT00826878|DRUG|Tivozanib (AV-951)|"Subjects will receive 1.0 or 1.5 mg tivozanib (AV-951) once daily continuously beginning on Day 1 for 4 weeks. One cycle will be defined as 4 weeks of treatment. Cycles will be repeated every 4 weeks in the absence of disease progression or unacceptable toxicity.~Minimum of 8 weeks (2 consecutive dosing cycles), if tolerated."
223600945|NCT04951583|COMBINATION_PRODUCT|FMT + ICI|"This study will include 3 cohorts of patients: (1) Patients with advanced or unresectable NSCLC, (2) patients with advanced or unresectable melanoma, and (3) patients with unresectable or advanced uveal melanoma. Patients with NSCLC, melanoma, uveal melanoma and will be analyzed in three separate subgroups given their differing clinical outcomes.~Each group will be treated with ICI as per their respective first line options, in combination with investigational FMT capsules."
223600946|NCT05366634|BIOLOGICAL|MDK-703 or Placebo|Injection
223600947|NCT02920749|DRUG|Sevoflurane group A|In this group anaesthesia was maintained with sevoflurane. Initial and maintenance fresh gas flow was 4 and 1 l/min, respectively. Sevoflurane dosing was adjusted for the same MAP range.
223600948|NCT02920749|DRUG|Sevoflurane group B|In this group anaesthesia was maintained with sevoflurane. Initial and maintenance fresh gas flow was 4 and 1 l/min, respectively. Sevoflurane dosing was set to maintain target BIS levels of 40 to 60 and MAP for controlled hypotension within 60-85 mmHg.
223600949|NCT02920749|DRUG|Propofol group C|In this group anaesthesia was maintained with propofol. Propofol was administered according to protocol. Propofol dosing was adjusted for the same MAP range.
224199797|NCT04476654|BEHAVIORAL|YouTube Video Arm|Participants (n=25) will watch a 20 minute YouTube video that will describe the genetic counseling and testing process and risk/benefit information in a culturally relevant format. Participants will complete pre and post assessments. After the session, participants interested in pursuing genetic counseling and testing services will be referred to a patient navigator who will navigate participants to identified no cost or low cost services.
223600950|NCT02920749|DRUG|Propofol group D|In this group anaesthesia was maintained with propofol. Propofol dosing was set to maintain target BIS levels of 40 to 60 and MAP for controlled hypotension within 60-85 mmHg.
223600951|NCT02595905|DRUG|Cisplatin|Given IV
223600952|NCT02595905|OTHER|Laboratory Biomarker Analysis|Correlative studies
223600953|NCT02595905|OTHER|Placebo Administration|Given PO
223600954|NCT02595905|DRUG|Veliparib|Given PO
223600955|NCT03781414|BIOLOGICAL|CFZ533|Comparison with standard of care immunosuppression
223600956|NCT03781414|DRUG|Tacrolimus - MMF - corticosteroids|Standard of care immunosuppresive regimen
223749220|NCT04230837|DEVICE|Inmediate abutment height|The placement of the implant was done following the manufacturing protocol and using a surgical guide according to the radiological guide previously used. At this time, the Permanent® abutment of 1 or 3 mm was chosen randomly and was placed at 35 Ncm.
223749221|NCT02342483|DIETARY_SUPPLEMENT|MSM|
223749222|NCT04254978|DRUG|Bomedemstat|Oral administration
223749223|NCT02799758|DRUG|NK-104-CR|NK-104-CR 8 mg for 52 weeks
223749224|NCT02799758|DRUG|Livalo® IR|Livalo® IR 4 mg daily for 52 weeks
223600957|NCT06361914|BEHAVIORAL|Digital CBT-I|"Sleep restriction includes behavioral instructions to limit the time spent in bed to increase sleep drive and further reduce time awake in bed.~Stimulus control therapy entails behavioral instructions to strengthen the association between bed and sleep and to eliminate conditioning of non-sleep behavior and bed.~Deactivation/relaxation training involves methods to reduce somatic tension and limit intrusive thought processes that interfere with sleep.~Cognitive therapy helps to identify, challenge, and modify dysfunctional beliefs about sleep.~Sleep hygiene education entails specific information relating to lifestyle and environmental factors that may interfere with or promote sound sleep. Sleep hygiene education also includes specific sleep facilitating recommendations, such as avoiding visual access to a clock in the bedroom, regular sleep scheduling, avoiding long daytime naps, and limiting alcohol, caffeine, and nicotine intake."
223600958|NCT06361914|BEHAVIORAL|Digital Sleep hygiene education|Sleep hygiene education entails specific information relating to lifestyle (diet, exercise, substance use) and environmental factors (light, noise, temperature) that may interfere with or promote sound sleep. Sleep hygiene education also includes specific sleep facilitating recommendations, such as avoiding visual access to a clock in the bedroom, regular sleep scheduling, avoiding long daytime naps, and limiting alcohol, caffeine, and nicotine intake.
223600959|NCT02882828|DRUG|switched from Prograf® to Envarsus®|
223600960|NCT04615650|PROCEDURE|Surgical treatment|Surgical treatment of suprasyndesmotic ankle fractures
223600961|NCT04615650|DEVICE|Ankle orthosis|Non-surgical treatment of suprasyndesmotic ankle fractures
223600962|NCT06213454|DRUG|TAP Anesthesia|ultrasound guided TAP block, 133 mg of liposomal bupivacaine and 15 mL of 0.25% bupivacaine deposited into the TAP on each side for a total of two injections
223600963|NCT06213454|DRUG|Surgeon-Initiated Local Anesthetic|266 mg of liposomal bupivacaine and 30 mL of 0.25% bupivacaine diluted in 130 mL of normal saline (160 mL of solution), 40 mL fascial injection and 40 mL skin injection on either side of the wound
223600964|NCT05782322|BEHAVIORAL|Upper-limb training involving RAS|"Three target bowls, labeled as the left, middle, and right target bowl, will be placed on the table at an equal distance from the main bowl. The distance between a target bowl and the main bowl is set at 30 cm. Wooden beads with a diameter of 2 cm will be put in target bowls. The main bowl will be placed in front of the patient.~Patients will be asked to listen to the RAS sound, use the right hand to take one bead at a time from the left target bowl to the main bowl, repeat this movement for the middle and right target bowls, and keep repeating this order. They should keep their movements consistent with the sound of the RAS, with one RAS sound corresponding to one pick-up movement.~Each daily training will consist of three rounds separated by two 5-minute breaks. Each round will consist of four consecutive sessions (for each session: 2-minute training followed by a 30-second break). The training will last for a total of 7 days."
223600965|NCT05782322|BEHAVIORAL|Upper-limb training without the aid of RAS|"Three target bowls, labeled as the left, middle, and right target bowl, will be placed on the table at an equal distance from the main bowl. The distance between a target bowl and the main bowl is set at 30 cm. Wooden beads with a diameter of 2 cm will be put in target bowls. The main bowl will be placed in front of the patient.~Patients will be asked to use the right hand to take one bead at a time from the left target bowl to the main bowl, repeat this movement for the middle and right target bowls, and keep repeating this order. They are asked to execute the task as fast as possible.~Each daily training will consist of three rounds separated by two 5-minute breaks. Each round will consist of four consecutive sessions (for each session: 2-minute training followed by a 30-second break). The training will last for a total of 7 days."
223749225|NCT02799758|DRUG|Placebo (for NK-104-CR)|NK-104-CR 8 mg placebo for 52 weeks
223600966|NCT00156390|DEVICE|echo-guided left ventricular lead placement|placement of the LV lead of the biventricular pacing device under echocardiographic guidance
223600967|NCT00156390|OTHER|LV lead placement as per standard of care (without echo guidance)|
223749226|NCT02799758|DRUG|Placebo (for Livalo® IR)|Livalo® IR 4 mg placebo for 52 weeks
223749227|NCT02993003|DEVICE|Nasopharyngeal probe|nasopharyngeal probe insertion
223749228|NCT04226066|BIOLOGICAL|T601|"Part1: T601 is injected once (Day1). Dose range: 1E+7, 3E+7, 1E+8, 3E+8, 1E+9pfu.Trial cycle: Day1-21.~For part1, 3+3 dose-escalation. After all patients of one dosage finished DLT evaluation, investigator judged that patients can benefit from treatment and no intolerable toxicity occurred, patients could receive maintenance treatment, and treatment plan is same as Cycle 1."
224075256|NCT00607308|BIOLOGICAL|PF-04360365|Single dose of 1 mg/kg IV on Day 1
224075257|NCT00607308|BIOLOGICAL|PF-04360365|Single dose of 5 mg/kg IV on Day 1
224075258|NCT00607308|DRUG|Placebo|Single dose of placebo IV on Day 1
224075259|NCT00607308|BIOLOGICAL|PF-04360365|Single dose of 10 mg/kg IV on Day 1
224075260|NCT02440815|BEHAVIORAL|Problem Solving Therapy|Problem Solving Therapy (PST) is a brief evidence based psychotherapy that is commonly utilized for treatment of LLD. The problem solving therapy includes 12 weekly in person 50 minute sessions.
224075261|NCT03622099|DRUG|Normal Saline Flush, 0.9% Injectable Solution|As a routine work in adult critical care unit at Menoufia University hospital for patients with circulatory failure, A 100 ml bolus of Normal Saline Flush, 0.9% Injectable Solution was given to the patient over 1 minute through a central venous catheter or jugular cannula. For prediction of responders, echocardiographic parameters measured followed by infusion of the remaining 400 ml of Normal Saline Flush, 0.9% Injectable Solution at a constant rate over 10 minutes then echocardiographic parameters measured again to detect the patient response.
224075262|NCT03109171|OTHER|Laryngopharyngeal sensory test|The sensory measurements will include thresholds for psychophysical sensory thresholds at the velopharynx, hypopharynx and aryepiglottic folds
224075263|NCT00424827|DRUG|Gemcitabine/Fluorouracil with External Beam Radiation|This protocol will assess the antitumor activity of gemcitabine (200 mg/m2 per week) and cetuximab (400mg/m2 loading dose followed by 250 mg/m2 weekly) when given with continuous infusion 5-FU (200 mg/m2/day/M-F) and daily concurrent external beam radiation therapy (50.4 Gy) in patients with non-metastatic, locally advanced pancreatic carcinoma.
224075264|NCT00777569|DRUG|Nicotine free cigarettes|Quest Step 2 contains 0.05 mg nicotine
224075265|NCT00777569|DRUG|Extra-low nicotine cigarettes|Quest 2 cigarettes contains 0.3 mg nicotine
224075266|NCT00777569|DRUG|Nicotine Lozenge|4 mg nicotine lozenge
224075267|NCT00274365|PROCEDURE|videoconference|
224075268|NCT00159289|PROCEDURE|Inhalation of LPS|
223600968|NCT06583863|DRUG|Echinacea Extract|175 mg of Echinacea extract was provided as an immunlant therapy twice daily.
223600969|NCT06583863|DRUG|MetroNIDAZOLE 500 MG Oral Tablet [Flagyl]|500 mg of metronidazole was provided as an oral tablets twice daily
223600970|NCT06584461|DRUG|Lidocaine (drug)|IV lidocaine, administered once during the induction of anesthesia.
223600971|NCT06584461|DRUG|Saline (NaCl 0,9 %) (placebo)|IV placebo (normal saline), administered once during the induction of anesthesia.
223749229|NCT04226066|COMBINATION_PRODUCT|T601+5-FC|"Part2: T601 is injected once (Day1). Dose range: MTD-2, MTD-1 and MTD of Part1. 5-FC is taken on Day5-18 for 14 consecutive days. Trial cycle: Day1-28.~Part3: T601 is injected 3 times (Day1, 8, 15). Dose range: MTD-1 and MTD, or MTD-2 and MTD-1 of Part2. 5-FC is taken on Day5-7, Day12-14 and Day19-32. Trial cycle: Day1-46.~Part4: Protocol revised based on results of Part1-Part3. Preliminary plan: 30 patients with gastric cancer, pancreatic cancer and hepatocellular cancer who have failed standard therapeutic options are enrolled (10 patients for each indication). Treatment plan is same as Part3.~For part2 and part3, 3+3 dose-escalation. After all patients of one dosage finished DLT evaluation, investigator judged that patients can benefit from treatment and no intolerable toxicity occurred, patients could receive maintenance treatment, and treatment plan is same as Cycle 1."
223600972|NCT06584370|PROCEDURE|Pericardial insufflation with carbon dioxide through a transatrial microcatheter|Separate the walls of the pericardium by insufflating the pericardial space with carbon dioide.
223600973|NCT03856827|DRUG|IW-6463|IW-6463 Tablet
223749230|NCT05430490|PROCEDURE|MRI|Multimodal neuroimaging on 3T Prisma Fit MRI
223749231|NCT05430490|OTHER|NeuroPsychological Testing|A series of written, verbal, and motor tasks requiring the participant to follow instructions, remember words and numbers, draw objects, and complete timed actions.
223600974|NCT03856827|DRUG|Matching Placebo|Matching Placebo Tablet
223600975|NCT02644577|DRUG|Metformin|
223600976|NCT02644577|OTHER|Starch|
223749232|NCT05430490|PROCEDURE|Blood Draw|Laboratory reports (CMP, CBC, Lipids)
223749233|NCT05430490|OTHER|Questionnaires|Life history, current behaviors, and substance use surveys
223749234|NCT05430490|PROCEDURE|Lumbar Puncture|Optional procedure which involves obtaining cerebral spinal fluid through a needle in the lower back
223749235|NCT02094716|DRUG|Permethrin Foam 4%|Topical application, whole-body treatment
223749236|NCT02094716|DRUG|Permethrin Foam 5%|Topical application, whole-body treatment
223600977|NCT02960464|DEVICE|Transcranial direct current stimulation|
224199798|NCT04907994|OTHER|Cohort|Nothing. Only implementation of a cohort with data collection via the SNDS.
224199799|NCT00002074|DRUG|Fluconazole|
223600978|NCT02960464|DEVICE|Sham Transcranial direct current stimulation|
223600979|NCT02742376|OTHER|Soft surface|A sponge rectangle used in physiotherapy will be placed on the floor,
223600980|NCT02742376|OTHER|Floor|A marked path on the floor where the subject is instructed to walk.
223600981|NCT02742376|OTHER|Kyboot shoes|Special shoes will be worn by the subject.
223600982|NCT00235144|DEVICE|sirolimus-coated Bx Velocity stent|drug-eluting stent
223600983|NCT00235144|DEVICE|uncoated Bx Velocity stent|bare-metal stent
223600984|NCT01439594|DEVICE|MGH OFDI Imaging|Imaging of Esophagus with OFDI system
223600985|NCT06165042|OTHER|glass hybrid restorative system|In the teeth where the indication is identified, selective caries removal will be performed to eliminate the decayed tooth tissue. Subsequently, for each patient in the study apply glass hybrid restorative system (Equia Forte, GC Europe, Leuven, Belgium)
223600986|NCT06165042|OTHER|Fluoride varnish + Glass hybrid restorative system|In the teeth where the indication is identified, selective caries removal will be performed to eliminate the decayed tooth tissue. Subsequently, for each patient in the study apply Fluoride varnish (SDI Riva Star)+ Glass hybrid restorative (Equia Forte, GC Europe, Leuven, Belgium)
223600987|NCT06451081|BEHAVIORAL|Brief cessation advice|"Participants will receive brief cessation advice following the AWARD (ask, warn, advise, refer, do-it-again) model:~A: Ask about the tobacco use status; W: Warn about the hazards of tobacco use; A: Advise the smokers to quit; R: Refer the smokers to cessation services; D: Do-it-again"
223600988|NCT06451081|BEHAVIORAL|Opt-out active referral|Participants will be automatically referred to a smoking cessation service upon joining the trial, unless they choose to opt out. Contacts of participants will be delivered to a service provider of their choice or based on their living district and preferred treatment modality
223600989|NCT06451081|BEHAVIORAL|Behavioral economic mobile messaging|Participants will receive behavioural economics-informed messages via mobile instant messaging for 3 months
223600990|NCT06451081|BEHAVIORAL|Opt-in active referral|Participants will be offered a referral to a smoking cessation service. Contacts of participants who opt-in will be delivered to a service provider of their choice
223600991|NCT04752358|GENETIC|Autologous genetically modified ADP-A2M4CD8 cells|Infusion of autologous genetically modified ADP-A2M4CD8 on Day 1
223600992|NCT00274508|DRUG|tiotropium bromide|
223600993|NCT01049529|DIETARY_SUPPLEMENT|Docosahexaenoic acid|DHA have oil form. Each neonate is receiving 75 mg/kg/day of DHA in 188 uL/kg/day in two doses per day, since two days before surgery and over six days following cardiovascular surgery
223600994|NCT01049529|DIETARY_SUPPLEMENT|Placebo|Placebo have oil form. Each neonate is receiving 188uL/kg/day of sunflower oil as placebo in two doses per day, since two days before surgery and over six days following cardiovascular surgery
223600995|NCT06549660|DEVICE|Active PBMT|Active with a dose of 165 J per site, resulting in a total dose of 495J.
223600996|NCT06549660|DEVICE|Placebo PBMT|Placebo, without therapeutic dose.
223749237|NCT02094716|DRUG|Vehicle Foam|Topical application, whole-body treatment
223749238|NCT02261636|DRUG|mesalazine|
223749239|NCT00485238|PROCEDURE|Argon laser Iridoplasty|
223749240|NCT00485238|DRUG|Intravenous acetazolamide|
223749241|NCT03547713|BEHAVIORAL|Social feedback|Social feedback regarding performance of a public speech is delivered to participants
223749242|NCT03547713|BEHAVIORAL|Self-referential paradigm|Exposure to traits varying in valence (positive vs. negative) and social domain (power vs. affiliation)
223749243|NCT03547713|BEHAVIORAL|Reward vs. punishment task|Reception of monetary gains vs. losses
223749244|NCT03547713|BEHAVIORAL|Emotional reactivity task|Exposure to emotional faces vs. shapes
224199800|NCT00002074|DRUG|Amphotericin B|
223600997|NCT03536832|PROCEDURE|Cesarean Section with Vicryl|Pfnannenstiel incision will be done under general or spinal anaesthesia. The abdomen will be opened and fetus and plasenta will be delivered. Then abdomen will be closed. Skin will be closed with Vicryl.
223600998|NCT03536832|PROCEDURE|Cesarean Section with Prolen|Pfnannenstiel incision will be done under general or spinal anaesthesia. The abdomen will be opened and fetus and plasenta will be delivered. Then abdomen will be closed. Skin will be closed with prolen.
223601000|NCT04132505|DRUG|Binimetinib|Given PO
223601001|NCT04132505|DRUG|Hydroxychloroquine|Given PO
223601002|NCT05536570|DRUG|IncobotulinumtoxinA 100 UNT|Scalene injection
223601003|NCT05679739|OTHER|Individualized blood pressure strategy|An individualized blood pressure strategy targeting cerebral blood flow, serially guided by near-infrared spectroscopy and transcranial Doppler ultrasound. Assessments are performed on admission, and at 12, 24 and 48 hours post-ROSC.
223601004|NCT04491539|BEHAVIORAL|Finding Respect and Ending Stigma around HIV (FRESH)|The Finding Respect and Ending Stigma around HIV (FRESH) intervention is theoretically informed by Social Cognitive Theory (SCT) and Interpersonal Contact theory (ICT) and was specifically designed for delivery in high-stigma settings, such as Dominican Republic. FRESH was originally developed in Africa to address HIV-related stigma, and later was adapted to address intersectional stigmas experienced by sexual and gender minorities (SGM) living with HIV in the United States Deep South. To our knowledge, FRESH will be the first intervention to address intersectional stigmas experienced by men who have sex with men, transgender women, and people living with HIV in clinical settings in the Spanish-speaking Caribbean.
223601005|NCT00719355|BEHAVIORAL|Walking with poles|Patients walked with poles, 20-45 minutes, 3 times/week for 24 weeks.
223601006|NCT00719355|BEHAVIORAL|Walking exercise|Patients walked for 20-45 minutes, 3 times/week for 24 weeks.
223601007|NCT01835158|DRUG|Cabozantinib S-malate|Given PO
223601008|NCT01835158|OTHER|Laboratory Biomarker Analysis|Correlative studies
223749245|NCT04296552|OTHER|Dietary lowFODMAP intervention|Twelve week strict lowFODMAP dietary intervention, involving restricted intake of fermentable carbohydrates (FODMAPs).
223749246|NCT00748475|BEHAVIORAL|Neurofeedback|
223749247|NCT02515942|DRUG|CLG561|
223749248|NCT02515942|DRUG|LFG316|
223749249|NCT02515942|DRUG|Sham injection|Empty syringe (without a needle) placed against the eye
223601009|NCT01835158|DRUG|Sunitinib Malate|Given PO
223601010|NCT05606276|OTHER|Eccentric Exercise|Individuals will do a randomized crossover intervention involving maximal eccentric contractions (2 sets of 6 per leg; experimental condition)
223601011|NCT05606276|OTHER|Cycle ergometer|Individuals will do a randomized crossover intervention involving cycling (active control) exercise
223749250|NCT01302574|DIETARY_SUPPLEMENT|lactisole|Lactisole-liquid meal: Lactisole (450 ppm) will be mixed with a liquid meal. Liquid meal only: The comparator will be the liquid meal alone.
223749251|NCT01734564|BIOLOGICAL|Hiltonol and autologous dendritic cells|Hiltonol and autologous dendritic cells
223601012|NCT04322617|DRUG|Anlotinib plus the same Immune Checkpoint Inhibitors.|Anlotinib, 8mg po qd, D1-D14 every 21days.
223601013|NCT04322617|DRUG|Anlotinib plus the new Immune Checkpoint Inhibitors.|Anlotinib, 8mg po qd, D1-D14 every 21days.
223601014|NCT04322617|DRUG|Anlotinib|Anlotinib, 8mg po qd, D1-D14 every 21days.
223601015|NCT03623568|DRUG|glecaprevir/pibrentasvir tablets|12 weeks of treatment with Mavyret
223601016|NCT06347679|OTHER|Aroma diffuser with single-note sweet orange essential oil|In a space of 3\*4\*2.6 cubic meters, positioned 10 cm away from the patient, add 4-6 drops (each drop being 0.05 ml) of 100% concentration single-note sweet orange essential oil into the aroma diffuser reservoir containing 120 ml of water.
223749252|NCT01734564|RADIATION|Hiltonol, dendritic cells and radiation|Hiltonol, autologous dendritic cells and radiation therapy. Radiation therapy will pursue an abscopal effect.
223749253|NCT00211458|DRUG|Anecortave Acetate Sterile Suspension (15 mg)|
223601017|NCT06347679|OTHER|Aroma diffuser with single-note tea tree essential oil|In a space of 3\*4\*2.6 cubic meters, positioned 10 cm away from the patient, add 4-6 drops (each drop being 0.05 ml) of 100% concentration single-note tea tree essential oil into the aroma diffuser reservoir containing 120 ml of water.
223601018|NCT06347679|OTHER|Aroma diffuser with water|In a space of 3\*4\*2.6 cubic meters, positioned 10 cm away from the patient, add 4-6 drops (each drop being 0.05 ml) of water into the aroma diffuser reservoir containing 120 ml of water.
223601019|NCT03256201|BEHAVIORAL|Nutritional Counseling|Patients in both arms receive a single counseling session with a licensed dietician to determine individual protein goal for body weight and current dietary intake. Goal is then met through protein supplementation (provided) if needed beyond dietary intake.
223601020|NCT03256201|BEHAVIORAL|Standard Exercise|Patients receive a single instruction session with a physical therapist, for training in moderate intensity (using Rate of Perceived Exertion) exercise including cardiovascular endurance, flexibility, and AROM of upper and lower body. If no other preferred mode of endurance training, a home ergometer is provided for use with arms and/or legs.
223749254|NCT01992731|OTHER|Drug: Follitropine Bèta|
223749255|NCT00149916|DRUG|Mycophenolate sodium (enteric coated)|
223749256|NCT00741481|PROCEDURE|FDG-PET imaging|FDG-PET imaging at D0 and D14 of first course of a new chemotherapy for advanced colorectal cancer
223749257|NCT05420246|DRUG|Ainuovirine|The regimen including Ainuovirine will be given to HIV-1 infected/AIDS patients.
223749258|NCT05160688|BEHAVIORAL|Contingency management|Participants will be paid to abstain from cannabis use.
223749259|NCT03375541|OTHER|Risk Aversion Calculator|The calculator asks the participant to rate their level of aversion to having a set list of potential medication side effects (0 = no concern; 1 = mild concern; 2 = moderate concern; 3 = moderate to severe concern; 4 = severe concern)
223749260|NCT02310919|DRUG|Low dose hCG plus FSH co-trigger|Low dose hCG (1,500 IU) plus FSH (450 IU) co-trigger
223749261|NCT02310919|DRUG|Standard dose of hCG|Standard dose of hCG (10,000 or 5,000 IU) trigger
223749262|NCT01340157|DRUG|Fexinidazole|Single oral dose of 1200mg fexinidazole consisting of 2 tablets dosed at 600mg per tablet.
224075269|NCT00159289|PROCEDURE|Placebo|
224075270|NCT01820325|DRUG|Buparlisib|
223601021|NCT03256201|BEHAVIORAL|Enhanced Exercise|Patients receive a single instruction session with a physical therapist, for training in moderate intensity (using Rate of Perceived Exertion) exercise including cardiovascular endurance, flexibility, and resistance exercise for upper and lower body. If no other preferred mode of endurance training, a home ergometer is provided for use with arms and/or legs.
223749263|NCT04411433|DRUG|Favipiravir (3200 mg + 1200 mg)|"Dosage and method of administration: in a regimen of 2x1600 mg (oral) loading dose on day-1 followed by 1200 mg maintenance dose (2x600 mg, 2 times daily) on day-2 to day-5 (5 days in total).~The treatment duration may be extended up to 14 days with the evaluation of principle investigator."
224199801|NCT01732666|DRUG|Nefopam|20 mg of Nefopam mixed in 100 ml of 0.9% saline IV immediately after induction of anesthesia.
224199802|NCT01732666|DRUG|low dose remifentanil|100 ml of 0.9% saline immediately after anesthesia induction and 0.05µg/kg/min of remifentanil during anesthesia.
224199803|NCT01732666|DRUG|high dose remifentanil|100 ml of 0.9% saline immediately after anesthesia induction and 0.3 µg/kg/min of remifentanil during anesthesia.
224199804|NCT03256526|DRUG|Placebo|0 mg
224199805|NCT03256526|DRUG|PF-06835919 Low Dose|75 mg once daily
224199806|NCT03256526|DRUG|PF-06835919 High Dose|300 mg once daily
224199807|NCT04049448|DRUG|ABX464|All subjects will receive ABX464 administered at 50 mg o.d for an overall period of 2 years (104 weeks).
224199808|NCT02875340|DRUG|VAL401|Risperidone formulated into a liquid lipid filled capsule
224199809|NCT03328468|OTHER|Breathing Exercise|Breathing exercise for stroke patients
224199810|NCT06650917|BEHAVIORAL|the experiment group were treated acupoint massage combined with ear point pressing beans|"Salmeterol Xinafoate and Fluticasone Propionate Powder for Inhalation was used 1 puff each time, 2 times/d.~Patients in the experiment group were treated with auricular point pressing on basis if the treatment of the control group. Selecting 10 acupoints including Tanzhong, Tiantu, Dingchuan(both sides), Feishu(both sides), Yuji(both sides), and Lieque(both sides), and massage each acupoint for about 3 minutes. Acupoint massage once a day from Monday to Friday, lasting for 30 minutes each time. Selecting the Fengxi(both sides), Lung(both sides), Bronchial(both sides), and Shenmen(both sides) acupoints on the ear for ear point pressing beans. The operator rubs the above acupoints with their hands for about 5 minutes, and then performs ear point pressing beans on these 4 acupoints. The ear point pressing beans is performed once a day from Monday to Friday."
224199811|NCT06650917|BEHAVIORAL|the control group were treated with acupoint massage|"Salmeterol Xinafoate and Fluticasone Propionate Powder for Inhalation was used 1 puff each time, 2 times/d.~On this basis, patients in the control group were treated with acupoint massage."
224199812|NCT04170569|BEHAVIORAL|Yoga|Yoga Practice and Program: Yoga practice consisted of 10 weeks. Yoga practice involved following stages; 5-minute breathing exercises in standing or sitting position, 40-minute postpartum period specific asanas and last 15- minute deep relaxation in lying position were made by the researcher.
224199813|NCT01160770|DRUG|Clobazam|Clobazam will be provided in 5 mg, 10 mg and 20 mg tablets and will be dispensed in bottles as needed at each visit. Bottles may be dispensed between visits if necessary. Subjects will start at a common dose level of 0.5 mg/kg, not to exceed 40 mg/day, and must maintain the dose level for 48 hours. After the first 48 hours of the treatment period, investigators will be able to increase, decrease or maintain the subject's dose, up to an approximate maximum daily dose of 2.0 mg/kg (maximum dose of 80 mg/day).
224199814|NCT04904978|OTHER|Blanx Black Toothpaste|Use of Blanx Black Toothpaste twice a day per at least 2 minutes.
224199815|NCT04904978|OTHER|Colgate Sensation White|Use of Colgate Sensation White Toothpaste twice a day per at least 2 minutes
224199816|NCT03213769|DRUG|topical coenzyme Q10 gel|Q10 gel will give 2 times /day after breakfast and evening meal for 7 days.
224199817|NCT03213769|DRUG|Carpabol gel|placebo carbapol gel will give 2 times /day after breakfast and evening meal for 7 days.
224199818|NCT06700902|BEHAVIORAL|Taking Action|Participants in the experimental condition will participate in the Taking Action intervention, which will be delivered in a small group format in 5 weekly 2.5 hour videoconferencing sessions. Taking Action will be implemented using materials available on SAMHSA's website (https://www.co.ozaukee.wi.us/DocumentCenter/View/8198/Taking-Action-A-MH-Recovery-Self-Help-Ed-Program?bidId=). The process will include an overview of key recovery and wellness concepts and the development of an individualized wellness toolbox, which is a list of skills and strategies that a person already uses or would like to use to maintain or regain wellness. Then, participants will make plans for monitoring and addressing distressing mental health symptoms. Instructional techniques will include lectures, discussions, personal examples from facilitators and participants own lives to illustrate key concepts related to self-management, individual and group exercises, and voluntary action plans between meetings.
224199819|NCT05156060|DRUG|Gabapentin|Taken by mouth 3 times per day
224199820|NCT05156060|DRUG|Ketamine|Administered intranasally 3 times per day
224199821|NCT05883527|OTHER|Not applicable as not an intervention - PLwD and family/carers|Exploring the safeguarding process through interviews.
224199822|NCT05883527|OTHER|Not applicable as not an intervention - HCP's|Exploring the safeguarding process through interviews and a focus group.
224199823|NCT03457727|DRUG|Danirixin|Danirixin is being developed as a potential anti-inflammatory agent for the treatment of chronic obstructive pulmonary disorder (COPD) and other inflammatory diseases and influenza. Danirixin reference (600 mg) or test formulation (475 or 600 mg or 600 mg with 5 percent HPMC) immediate release tablets will be administered by oral route in a cross-over manner.
224199824|NCT03457727|DRUG|Omeprazole|Omeprazole is used as an antacid. OMP 40 mg delayed-release capsule will be administered by oral route to randomized subjects.
224199825|NCT01889927|OTHER|Exercise Intervention|The exercise intervention will include aerobic, anaerobic, strength, core conditioning and stretching components.
224199826|NCT04640701|OTHER||
224199827|NCT00566969|DRUG|sugar pill|Subjects randomized to placebo, carvedilol 25mg or 50mg
224199828|NCT00566969|DRUG|Carvedilol 25 mg|subjects randomized to placebo, carvedilol 25mg or 50mg
223507500|NCT01260792|OTHER|Questionnaire|The parents complete a questionnaire on the behavior of their child and on their own behavior
223507501|NCT00271570|DRUG|Infliximab (Remicade)|Remicade was 5 mg/kg IV (single dose)
223507502|NCT00271570|BIOLOGICAL|Intravenous immunoglobulin (IVIG)|2nd dose of IVIG (2g/kg)
223507503|NCT06274476|OTHER|implant placement|ridge splitting piezo surgery and implant placement
224199829|NCT00566969|DRUG|Carvedilol 50 mg|subjects randomized to placebo, carvedilol 25mg or 50mg
224199830|NCT04649892|DRUG|Naltrexone|Patients will receive daily doses of Naltrexone, starting at 50mg and increasing 25mg per week until reaching 200mg or the maximum tolerated by the patient
224199831|NCT04649892|DRUG|Placebo|Patients will receive daily doses placebo matching tablets for the 12 weeks of the study. Throughout this period, possible adverse effects will be monitored weekly.
224199832|NCT04649892|BEHAVIORAL|Psychoeducational|Participants will also attend to 4 sessions of psychoeducational intervention in weeks 2, 4, 6, and 8
224199833|NCT04649892|DEVICE|Eye-tracking|"The attentional bias of the participants will be assessed using the Eye-tracking device in 4 moments throughout the study:~* Before taking the first dose of naltrexone or placebo.~* One hour after taking the first dose of naltrexone or placebo.~* One week after continuous and daily use of naltrexone or placebo.~* At the end of the intervention, after 12 weeks of continuous and daily use of naltrexone or placebo."
224199834|NCT01626794|BIOLOGICAL|VARIVAX™ VEP|Two 0.5 mL subcutaneous doses administered on Days 1 and 91
224199835|NCT01626794|BIOLOGICAL|VARIVAX™ 2007 Process|Two 0.5 mL subcutaneous doses administered on Days 1 and 91
224199836|NCT01626794|BIOLOGICAL|M-M-R™ II|Two doses administered on Days 1 and 91 concomitantly with VARIVAX™ VEP or VARIVAX™ 2007 Process
224199837|NCT00018174|DRUG|Fluoxetine|
224199838|NCT00018174|BEHAVIORAL|Behavioral group smoking cessation treatment|
224199839|NCT00018174|DRUG|Placebo|
224199840|NCT06111131|DEVICE|Enteroscopy|A procedure that uses a specially equipped endoscope to examine the small intestine lining. An enteroscopy uses an endoscope, a tube with a light and camera on the end and the endoscope, in the case of this study, is equipped with a single balloon overtube to advance the scope deeper into the small intestine, to reach the middle third of the small bowel.
224199841|NCT03763539|PROCEDURE|SWL|Shock wave lithotripsy
224199842|NCT02591173|DRUG|Angiotensin-(1-7)|This is a biologically active endogenous angiotensin peptide. It may play an important role in the regulation of blood pressure by dilating blood vessels.
224199843|NCT02591173|DRUG|Saline|Normal saline will be used as the placebo comparator.
224199844|NCT02384239|DRUG|Palbociclib|Given orally (PO)
223749264|NCT04411433|DRUG|Favipiravir (3600 mg + 1600 mg)|"Drug: Favipiravir (3600 mg + 1600 mg) Dosage and method of administration: in a regimen of 2x1800 mg (oral) loading dose on day-1 followed by 1600 mg maintenance dose (2x800 mg, 2 times daily) on day-2 to day-5 (5 days in total).~The treatment duration may be extended up to 14 days with the evaluation of principle investigator."
224199845|NCT02384239|DRUG|Tamoxifen|Given orally (PO)
224199846|NCT02384239|DRUG|Fulvestrant|Given by intramuscular (IM) injection.
224199847|NCT05940467|OTHER|Sleep Loss|Participants will undergo periods of sleep loss in a laboratory setting and be monitored hourly for changes in indicators of arterial stiffness (i.e., pulse wave velocity).
224199848|NCT01299272|DRUG|LY2216684|
224199849|NCT01299272|DRUG|Placebo|
224199850|NCT01299272|DRUG|SSRI|Participants should have been on their SSRI for at least 8 weeks prior and were to continue on their stable dose throughout the study.
224199851|NCT02501655|DEVICE|phase 1 - jet nebulizer|Aerosol generators diethilene penta-acetic triamine technetium (99mTc-DTPA) with radioactivity of 1 millicuries (Noble et al., 2007) mixed with 0.9% saline solution with a total volume of 4 ml using jet nebulizer (NS - mark) and 8l/min of the oxygen
224199852|NCT02501655|DEVICE|Phase 2- mesh nebulizer|Aerosol generators diethilene penta-acetic triamine technetium (99mTc-DTPA) with radioactivity of 1 millicuries (Noble et al., 2007) mixed with 0.9% saline solution with a total volume of 2 ml using vibrating mesh inhaler with valved chamber adapter (Aerogen Solo with Ultra Adapter, Aerogen Ltd).
224199853|NCT00633295|DRUG|AMN107- NILOTINIB|The dose of nilotinib will be 400 mg bid.
224199854|NCT04095546|OTHER|routine psychotherapy for Borderline Personality Disorder (BPD)|Routine psychotherapy as treatment for patients with Borderline Personality Disorder
223507504|NCT02636491|DEVICE|MD-Logic-Automated Insulin Delivery System|"Subjects will undergo 60 hours at home under MD-Logic control and continuing with their regular routine life. At evening of the first intervention day patients will switch to MD-Logic control. Patients will be asked to connect study sensor and pump to the computer using the MD-Logic software. After the activation of the MD-Logic system, basal insulin dosing and correction boluses will be fully automated and controlled by the MD-Logic system except to meal boluses. Patients will be encouraged to measure capillary blood glucose at least 4 times a day, before each meal and before bed time. After the third night the patient will turn the closed-loop controller OFF, this will automatically save the log file. The patient will return to his regular insulin treatment."
223507505|NCT02636491|DEVICE|MiniMed Paradigm® Veo™ System|Subjects use 60 hours at home their conventional insulin pump and continuing with their regular Routine life. During this therapy the Insulin pump operating separately and are not controlled by the MD-Logic System.
223507506|NCT00419432|OTHER|Routine Observational Analysis (prior to procedure)|Controls will undergo the standard orthopaedic surgery using the information from the physical examination and observational analysis of the gait alone.
224199855|NCT01054469|PROCEDURE|TAP block placement with placebo|20 ml of normal saline (placebo)
224199856|NCT01054469|PROCEDURE|Placement of block with ropivacaine|20 ml of 0.5% ropivacaine hydrochloride
224199857|NCT03308123|OTHER|Observational study, not interventional|Not an intervention study
224199858|NCT06356038|PROCEDURE|intra-operative phrenic nerve infiltration|patients received the intra-operative infiltration of phrenic nerve by the surgeon who injected 10 ml of Ropivacaine 0.75% (the same procedure routinely adopted in our clinical practice for local analgesia at the level of the intercostal space) in the peri-neurotic pericardial fat, near the diaphragm. Infiltration is made with a deflated lung, after pulmonary resection and chest tube insertion.
224199859|NCT05226013|DRUG|Polyglycol lated urate oxidase for injection|Single dose escalation
224199860|NCT05226013|DRUG|Placebo|Placebo
224199861|NCT00464308|DRUG|Esomeprazole|20mg once daily for 28days - 1 placebo tab/cap \& 1 active tab/cap daily
224199862|NCT00464308|DRUG|Rabeprazole|20mg once daily for 28days - 1 placebo tab/cap \& 1 active tab/cap daily
224199863|NCT00464308|DRUG|Esomeprazole|40mg once daily for 28days - 1 placebo tab/cap \& 1 active tab/cap daily
224199864|NCT01513759|DRUG|recombinant tissue plasminogen activator|Participants will receive 24 mg of r-tPA delivered via the EkoSonic Endovascular Device.
223601022|NCT06152588|OTHER|Time restricted eating|"3 months (12 weeks) strict TRE intervention: Participants will be instructed to reduce their eating window by minimum 3 hours compared to habitual eating, with an eating window below 10 hours. The timing of the eating window is self-selected but should be placed between 6 am and 8 pm. Diet during the eating window is ad libitum with no further dietary restrictions.~9 months (40 weeks) individually adjusted TRE intervention: An individual plan will be made based on participants' experiences during the strict TRE. Different choices of individual adjustment and support will be provided, including 1) eating window adjustments and the possibility of 'days off', 2) provision of a list of allowed calorie and caffeine free beverages that can be consumed outside the window, 3) continued opportunity to participate in peer-support group meetings, 4) extra phone calls with a project worker to discuss challenges or strategies to continue with TRE etc., and 5) further involvement of relatives."
223601023|NCT04054375|DRUG|Prednisone|Subjects will be asked to take weekly GC oral prednisone dosed based on weight (1mg/kg for patients who weigh less than or equal to 70 kg and 0.75 mg/kg for patients who weigh more than 70 kg). Subjects will also be instructed to take their weekly prednisone on Mondays after their last meal between 7 and 9 PM
223601024|NCT03364738|BIOLOGICAL|rhPTH(1-84)|Participants will receive rhPTH(1-84) SC injection in the thigh (alternate thigh every day) QD.
223601025|NCT01894932|BEHAVIORAL|Mindfulness-based cognitive Group therapy|In this study, groups of Mindfulness-based cognitive psychotherapy, will based on Segal, Williams \& Teasdale (2002)'s work to redesigned an eight-week group course which adapted the local Taiwanese culture and add the appropriate revision of the content in a more easy to understand learning materials available to patient. The group would lead by 2 clinical psychologist and each session is about 2 hours.
223601026|NCT01894932|BEHAVIORAL|psycho-physiological stress regulation group|Physical and psychological stress regulation group in eight weeks, mainly to provide understanding of physical and mental effects of stress factors, self-conceptualization of stress and psychosomatic symptoms, physiological adjustment (relaxation, diet, exercise), psychological adjustment (positive primary, secondary assessment, cognitive identification), adjust negative thoughts, learn coping by using new choice. The group would lead by 2 clinical psychologist and each session is about 2 hours.
223601027|NCT00550966|BEHAVIORAL|Psychoeducative program in fibromyalgic patients|Multi-component program including information about the illness, counselling about physical exercise and training in autogenic relaxation. The intervention consists on nine 2 hour sessions delivered during a two month period. The pharmacological treatment prescribed by the physician is maintained in both groups.
223601028|NCT00766714|DEVICE|Cook K-SOFT-5100 catheter|A Cook K-SOFT-5100 catheter was used for embryo transfer in human IVF/ICSI
223601029|NCT00766714|DEVICE|Frydman classical catheter|A Frydman classical catheter was used for embryo transfer in human IVF/ICSI
223749265|NCT04411433|DRUG|Favipiravir (3200 mg + 1200 mg) combined with Hydroxychloroquine|"Hydroxychloroquine Dosage and method of administration: in a regimen of 2x400 mg (oral) loading dose on day-1 followed by 400 mg maintenance dose (2x200 mg oral, 2 times daily) on day-2 to day-5 (5 days in total).~Favipiravir Dosage and method of administration: in a regimen of 2x1600 mg (oral) loading dose on day-1 followed by 1200 mg maintenance dose (2x600 mg, 2 times daily) on day-2 to day-5 (5 days in total). The treatment duration may be extended up to 14 days with the evaluation of principle investigator."
224199865|NCT01513759|DEVICE|EKOS EkoSonic Endovascular System|24 mg of r-tPA will be delivered through the EkoSonic Endovascular System.
223749266|NCT04411433|DRUG|Favipiravir (3200 mg + 1200 mg) combined with Azithromycin|"Azithromycin Dosage and method of administration: in a regimen of 1x500 mg (oral) loading dose on day-1 followed by 250 mg maintenance dose (oral daily) on day-2 to day-5 (5 days in total).~Favipiravir Favipiravir Dosage and method of administration: in a regimen of 2x1600 mg (oral) loading dose on day-1 followed by 1200 mg maintenance dose (2x600 mg, 2 times daily) on day-2 to day-5 (5 days in total). The treatment duration may be extended up to 14 days with the evaluation of principle investigator."
224199866|NCT00090337|PROCEDURE|acupuncture therapy|Patients undergo acupuncture for 20-30 minutes once weekly for 4 weeks
224199867|NCT00090337|PROCEDURE|standard follow-up care|Patients undergo standard care
224199868|NCT03606109|DRUG|Tranexamic Acid (TXA)|One gram of intravenous tranexamic acid (TXA) will be administrated before tourniquet inflation and before closure of the incision, as 1 g has been shown to be a safe amount with minimal side effects
224199869|NCT00619671|DRUG|Rituximab (Rituxan)|Four weekly IV infusions of Rituxan with dosage individually calculated per subject.
224199870|NCT04839133|DEVICE|MyoSuitFeasibility|Participants will absolve feasibility tests with and without wearing a MyoSuit.
224199871|NCT02995928|PROCEDURE|Decompressive craniectomy|Decompressive craniectomy: All patients in the treatment group will receive decompressive craniectomy of at least 12 cm according to institutional guidelines and a published surgical protocol during the clipping surgery within 48 hours form the onset.
224199872|NCT02995928|PROCEDURE|Best medical treatment|Best medical treatment: Best medical treatment is based on American Heart Association/American Stroke Association (AHA/ASA) and European Stroke Organisation (ESO) as published in the current protocol from 2012 and 2013 respectively.
224199873|NCT00820183|OTHER|Quality Improvement plan for Hypertension Control|"Implementation of a plan of quality improvement addressed to health professionals in Primary Health Care Teams. It includes:~Specific training programme on how to diagnose hypertension , and measure blood pressure correctly To send feed back information to primary care health professionals about poorly controlled hypertensive patients An audit will be performed, every 6 months, to see the adhesion to the recommended clinical guidelines , and the information will be diffused among the participant primary health care professionals Each participant primary health care team will have a designated reference person, that will provide support on any doubts on the programme implementation"
224199874|NCT00006397|DRUG|Indinavir sulfate|
224199875|NCT00006397|DRUG|Ritonavir|
224199876|NCT00006397|DRUG|Stavudine|
224199877|NCT00006397|DRUG|Didanosine|
224199878|NCT02069145|DRUG|OMP-54F28 with Sorafenib|
224199879|NCT00718978|PROCEDURE|CSS grafting|grafting of autologous three-cellular cultured skin substitutes (CSS) consisting of cultured keratinocytes, melanocytes and fibroblasts attached to a scaffold of hyaluronic acid (HYAFF11® and HYAFF11p80®) obtained from full-thickness skin biopsies to repair full-thickness loss of substance
224199880|NCT00630994|DRUG|Dacogen|
224199881|NCT03669640|DRUG|RO6889450|Participants will receive a once-daily, oral dose of RO6889450 for 12 weeks.
223749267|NCT04411433|DRUG|Hydroxychloroquine|"Dosage and method of administration for patients with mild possible or confirmed COVID-19 pneumonia (no severe pneumonia symptoms): in a regimen of 2x400 mg (oral) loading dose on day-1 followed by 400 mg maintenance dose (200 mg oral 2 times daily) on day-2 to day-5 (5 days in total).~Dosage and method of administration for patients with uncomplicated possible or confirmed COVID-19: in a regimen of 400 mg (200 mg oral 2 times daily) throughout 5 days (5 days in total)."
223749268|NCT04411433|DRUG|Hydroxychloroquine combined with Azithromycin|"Drug: Hydroxychloroquine combined with Azithromycin Hydroxychloroquine Dosage and method of administration for patients with mild possible or confirmed COVID-19 pneumonia (no severe pneumonia symptoms): in a regimen of 2x400 mg (oral) loading dose on day-1 followed by 400 mg maintenance dose (2x200 mg oral, 2 times daily) on day-2 to day-5 (5 days in total).~Hydroxychloroquine Dosage and method of administration for patients with uncomplicated possible or confirmed COVID-19: in a regimen of 400 mg (2x200 mg oral, 2 times daily) throughout 5 days (5 days in total).~Azithromycin Dosage and method of administration: in a regimen of 1x500 mg (oral) loading dose on day-1 followed by 250 mg maintenance dose (oral daily) on day-2 to day-5 (5 days in total)."
223749269|NCT03127657|DRUG|Cock's comb extract 0.01%|Applied topically twice daily for 12 weeks
223749270|NCT02940171|PROCEDURE|Early Excision of full thickness burn|first excision surgery of full -thickness burn performed within 48 hours from burn injury
223749271|NCT02940171|PROCEDURE|Late Excision of full thickness burn|first excision surgery of full -thickness burn performed after 48 hours from burn injury
223749272|NCT04157946|DIAGNOSTIC_TEST|CT|"Patients with ARDS were included. We excluded patients with emphysema, asthma, pneumothorax, or serious conditions of instability: oxygen saturation ≤ 88%; severe shock, ventricular arrhythmia, or myocardial ischemia.~To allow comparison between groups, patients were ventilated in volume control under similar conditions of tidal volume (TV; 6 ml/kg-PBW), plateau pressure (PPlat 30 cmH2O), respiratory rate (18 bit/min) and constant flow. PEEP was adjusted to reach objective PPlat.~Transpulmonary pressures (TP) were measured and a chest CT scan performed during an expiratory and inspiratory pause. Global and regional volumes of lungs were measured using specific software (Volume Analysis Software,Toshiba, Japan). Three regions were identified: basal (from the diaphragm to the carina), middle (from the carina to the aortic arch) and apical (above the aortic arch)."
223749273|NCT00912314|PROCEDURE|PTNS|Monthly PTNS after 12 weeks of weekly PTNS
223749274|NCT02436759|DRUG|RVL-1201|RVL-1201 Ophthalmic Solution 0.1%
223749275|NCT02436759|DRUG|RVL-1201 Vehicle Placebo|RVL-1201 Vehicle Placebo
223749276|NCT01412203|BEHAVIORAL|Action Schools! BC|AS! BC applies a socioecological, whole school approach to promote healthy living within the elementary school context. Schools are provided with the tools and support needed to create customized action plans that promote physical activity (PA) and healthy living across six Action Zones (School Environment, Scheduled Physical Education (PE), Classroom Action, Family and Community, Extra-curricular, School Spirit). Generalist teachers receive training and resources to implement their Action Plan with the ultimate goal of providing students with 150 minutes of PA/week. The model is choice-based; teachers are asked to provide 15 additional minutes of PA/day within the Classroom Action Zone. The activities require minimal equipment and can be performed in the classroom, hallway or on the school playground.
224075271|NCT01820325|DRUG|Buparlisib placebo|Placebo + Carboplatin + Paclitaxel
224075272|NCT01820325|DRUG|Carboplatin|
223507507|NCT00419432|OTHER|Routine Observational analysis supplemented with Gait Lab Information (prior to procedure)|This experimental group will undergo standard orthopaedic surgery using the information from the physical examination, observational AND the gait laboratory analysis data
223507508|NCT00198614|DRUG|Carvedilol versus Metoprolol|
223507509|NCT05496699|BEHAVIORAL|Mckenzie Exercises|"1. Cervical Retraction Exercise in Sitting Position The participant sits on the chair, puts the second and third fingers on his chin and pushes his head posteriorly and inferiorly.~2. Cervical Rotation Exercise in Sitting Position~3. Cervical Retraction Exercise in Supine Position~4. Cervical Rotation Exercise in Supine Position The participant turns his head to the right and left, respectively, while taking his head back in the supine position with his head out of the bed.~5. Cervical Lateral Flexion Exercise~6. Cervical Flexion Exercise in Sitting Position"
223507510|NCT05496699|BEHAVIORAL|Mulligan Exercise|"The exercises to be applied are listed below.~1- C1-C2 Self Mobilization Slip is applied for natural apophyseal cervical right rotation. The belt is put on level C1. At the same time, the participant actively pulls the belt and turns his head to the right. To facilitate the rotation of the belt in C1, pressure is applied to the belt in the same direction as C2 and rotation of the head towards the restricted side is requested. It waits like this for 3 seconds. These movements are done in the painless range."
223507511|NCT06170866|BEHAVIORAL|Socially supported physical activity|Use of a culturally and linguistically tailored intervention that uses mobile health technology plus social support to increase engagement in physical activity in the management of Parkinson´s disease.
223507512|NCT04086615|DEVICE|NMES and exercise supplemented with high BFR|"The BFR-NMES-Exercise training consists of 20-min sessions performed concurrently with NMES and exercise in the clinic 2x a week for a total of 18 in-clinic sessions. Using the Delfi PTS Personalized Tourniquet System for Blood Flow Restriction at 80% of LOP, the participant performs 4 exercise sets of 60 repetitions (5 seconds ea) for 5 minutes, with a 1-minute BFR deflation between sets. The standard exercise rehabilitation protocol for PFPS combines open chain and closed chain quadriceps strengthening exercises: active straight leg raises, quadriceps straightening, step up, and squats. NMES training consists of 20-minute sessions: a 2-min warm-up, 15-min work-out, and a 3-min cool down using the KneeHAB® XP Multipath stimulation system which changes the current pathways between the electrodes for preset periods within each pulse, allowing for higher stimulation intensities that maximizes muscle fibre recruitment and minimizes muscle fatigue."
223601030|NCT04814147|PROCEDURE|Sleeve gastrectomy|Measure of NLRP3 inflammasome preoperative activation level by the expression of NLRP3, IL-1β, IL18 and caspase-1 mRNAs in subcutaneous and visceral adipose tissue. of the epiploon;
223601031|NCT02932748|DIETARY_SUPPLEMENT|Portion Controlled Meals (PCM)|Portion controlled meals provide conveniently packaged, low-energy, high-nutritional content food.
223601032|NCT02932748|BEHAVIORAL|Group Phone (GP)|Weight management program delivered via group conference call.
223601033|NCT02932748|DIETARY_SUPPLEMENT|Conventional Diet|Conventional diet (CD) will consist of a nutritionally balanced, reduced energy, high volume, lower fat (fat= 20-30% energy) diet based on USDA's MyPlate recommendations.
223601034|NCT02932748|BEHAVIORAL|Individual Phone (IP)|Weight management program delivered via individual phone call.
223601035|NCT02932748|BEHAVIORAL|Enhanced Usual Care (EUC)|Weight management topics delivered face-to-face at clinic office every 6 months.
223601036|NCT03245398|DRUG|Treatment with one of the two regimens of mebendazole|Once in the morning and once in the evening for 3 consecutive days
223601037|NCT04543695|COMBINATION_PRODUCT|Concurrent Chemoradiotherapy|"Radiotherapy:~50Gy in 25 fractions to the primary tumor and to mesorectal, presacral,and internal iliac lymph nodes.~Concurrent chemotherapy:~Capecitabine 1650 mg/m2/d"
223601038|NCT04543695|DRUG|XELOX|"Intravenous infusion of oxaliplatin (130 mg/m2 over 2 h) on day 1 and oral administration of capecitabine (1000 mg/m2 twice daily) from day 1 to day 14, is repeated every 3 weeks for 6 cycles.~6 courses，3 weeks per course"
223601039|NCT04543695|DRUG|mFOLFOX|Administration of l-LV (400 mg/m2) and oxaliplatin (85 mg/ m2) by intravenous infusion over 2 h, followed by rapid intravenous infusion (iv) of 5-FU (400 mg/m2) and then slow infusion (civ) of 5-FU (2400 mg/m2 over 46 h), is repeated every 2 weeks for 9 cycles.
223601040|NCT04543695|PROCEDURE|TME|Total mesorectal excision
223601041|NCT02130596|BEHAVIORAL|Acceptance-Based Behavioral Intervention|
223601042|NCT02130596|OTHER|Nutritional Counselling|
223601043|NCT03700489|OTHER|titanium dioxide denture|patients will receive titanium dioxide denture (made from acrylic resin with titanium dioxide nanoparticles ) for 1 month in the initial phase then in the second phase after one month they will receive( rapid heat cured acrylic resin)denture according to the principle of crossover des
223601044|NCT00475904|DRUG|EpiCept-NP-1 Cream|ketamine 4% amitriptyline 2% cream, twice daily for 4 weeks
223601045|NCT00475904|DRUG|Gabapentin Capsules|1800mg/day capsules for 4 weeks
223601046|NCT00475904|DRUG|placebo|placebo cream and caps
223601047|NCT01406197|DRUG|Experimental: Vaginal progesterone|Vaginal progesterone formulation (150 mg micronized progesterone daily)
223601048|NCT01406197|DRUG|Experimental: Topical progesterone|Progesterone will be applied daily (150 mg micronized progesterone)by topical application
223601049|NCT01406197|DRUG|Experimental: Intramuscular progesterone|Preterm labor patients will be injected IM with micronized progesterone (50 mg/day).
223601050|NCT01635881|DEVICE|Emerge™ 1.20 mm PTCA Dilatation Catheter|"The Emerge 1.20 mm device is the next-generation Boston Scientific PTCA dilatation catheter. It is a sterile, single-use, intravascular medical device used to improve lumen diameter.~The catheter consists of a shaft with a balloon near the distal tip. The balloon is designed to provide an inflatable segment of known diameter and length at recommended pressures."
223601051|NCT06473792|OTHER|Probiotic Toothpaste|"Composition: Main - Water, calcium carbonate, calcium glycerophosphate, glycerin, xylitol, sodium bicarbonate, sweet fennel oil (Foeniculum vulgare), carrageenan, maltodextrin, Dental-Lac (Lactobacillus paracasei), potassium sorbate, yucca (Y. filamentosa) powder, stevia leaf extract (Eupatorium rebaudiana bertoni), zinc chloride.~Usage: This is mint flavored toothpaste containing Lactobacillus paracasei which has demonstrated the ability to help address harmful strains of oral flora, and promotes the maintenance of a healthy teeth and gums. The participant will be instructed to brush with it twice daily."
223601052|NCT00939562|DRUG|doxycycline monohydrate tablet|Tablet, 100 mg, Single dose
223601053|NCT00939562|DRUG|doxycycline carragenate tablet|Tablet, 100 mg, Single dose
223601054|NCT03579043|OTHER|Nutritive Sweetener|Participants will receive twelve, 12-ounce cans of a beverage that represents their assigned condition. Participants will be instructed to drink their assigned beverages Tuesday through Thursday, and to consume one beverage at 12pm, the second at 3pm, and the third at 6pm. Participants will be instructed that the beverages need to be consumed within +/- 30 minutes of the instructed time. Participants will be instructed that any other beverage consumed on Tuesday through Thursday should be water.
223512248|NCT04867590|DEVICE|Radiofrequency|"Endoscopic treatment using the HALO® 360 or 90 system is a thermal method for destroying the superficial mucosa. An initial debridement of the mucosal deposits is carried out by application of acetylcysteine in spray form with a spray catheter on the entire mucosal surface to be treated and then rinsed with water after a minute of application time.~For circumferential BEs, a single-use 360 Express® probe is used to make it possible to size the diameter of the esophagus and the treatment used. The length of the treatment area is 5 cm and several points of impact can be achieved by overlapping the catheter at two consecutive heights, with the zone spanned measuring one centimeter, in order to cover the entire pathological area requiring treatment.~For non-circumferential lesions a palette applicator is used in a variety of sizes, and in this context no sizing of the esophagus is required."
223601055|NCT03579043|OTHER|Non-Nutritive Sweetener|Participants will receive twelve, 12-ounce cans of a beverage that represents their assigned condition. Participants will be instructed to drink their assigned beverages Tuesday through Thursday, and to consume one beverage at 12pm, the second at 3pm, and the third at 6pm. Participants will be instructed that the beverages need to be consumed within +/- 30 minutes of the instructed time. Participants will be instructed that any other beverage consumed on Tuesday through Thursday should be water.
223601056|NCT03579043|OTHER|Carbonated Water|Participants will receive twelve, 12-ounce cans of a beverage that represents their assigned condition. Participants will be instructed to drink their assigned beverages Tuesday through Thursday, and to consume one beverage at 12pm, the second at 3pm, and the third at 6pm. Participants will be instructed that the beverages need to be consumed within +/- 30 minutes of the instructed time. Participants will be instructed that any other beverage consumed on Tuesday through Thursday should be water.
223601057|NCT03009734|DRUG|ATx201 dermal formulations 2%|Topical application of ATx201 dermal formulations 2%
223601058|NCT00152308|DEVICE|2% rapamycin-eluting YUKONdes PEARL-stent|
223601059|NCT00152308|DEVICE|1% rapamycin-eluting YUKONdes PEARL-stent|
223601060|NCT00152308|DEVICE|YUKONdes PEARL-stent coated with placebo (ethanol)|
223601061|NCT05370872|DIAGNOSTIC_TEST|Remote functional testing protocol|Clients in the remote functional testing protocol group will be asked to describe their functional capacity limits using a clinician guided motivational interviewing approach and will also be asked to complete a mobility screening protocol to provide the clinician with the opportunity to observe the clients natural movements.
223601062|NCT02750319|DRUG|Amiodarone|
223601063|NCT02750319|DRUG|N-Acetylcysteine|
223601064|NCT02750319|DRUG|Placebo|
224075273|NCT01820325|DRUG|Paclitaxel|
223601065|NCT05716360|DIAGNOSTIC_TEST|Pre-procedural, early and late post-procedural susceptibility weighted imaging and vessel wall imaging with a 3T Magnetic Resonance Imaging Device|Pre-procedural, early and late post-procedural susceptibility weighted imaging and vessel wall imaging with a 3T Magnetic Resonance Imaging Device
223601066|NCT05716360|PROCEDURE|Aneurysm Treatment with Flow-Diversion Therapy|Aneurysm Treatment with Flow-Diversion Therapy
223601067|NCT05716360|PROCEDURE|Aneurysm Treatment with Metalic Bare Stent|Aneurysm Treatment with Metalic Bare Stent
223601068|NCT01147354|DIETARY_SUPPLEMENT|selenium yeast|The patients in this arm took 200 micrograms of selenium yeast daily for 12 weeks.
223601069|NCT01147354|OTHER|placebo capsules|The patients in this arm took one placebo capsule daily for 12 weeks.
223601070|NCT01023360|DRUG|Clopidogrel and proton pump inhibitors|"baseline detection --\> clopidogrel 75 mg PO QD for 1 week --\> clopidogrel 75 mg plus rabeprazole 20mg PO QD for 1 week --\> clopidogrel 75 mg PO QD for 1 week (wash-out phase) --\> clopidogrel 75 mg plus pantoprazole 40mg PO QD for 1 week --\> clopidogrel 75 mg PO QD for 1 week (wash-out phase) --\> clopidogrel 75 mg plus esomeprazole 40mg PO QD for 1 week --\>~1 week washout --\> aspirin 100mg PO QD for 1 week"
223601071|NCT02523781|OTHER|information pamphlet|The intervention group receives the information pamphlet
223601072|NCT04118049|OTHER|BiopHreshTM vaginal probiotic supplement (Good Clean Love, Inc. Eugene, OR) and RestoreTM gel.|BiopHreshTM is a vaginal probiotic supplement that is offered over the counter and contains four different lactobacilli strains (L. crispatus, L. gasseri, L. jensenii, and L. rhamnosus). RestoreTM is a moisturizing personal lubricant that has been on the market for three years. Participants will use 1 probiotic capsule with RestoreTM gel nightly three times weekly.
223601073|NCT04118049|OTHER|Standard Care|Standard care arm is standard care for pessary use. Pessary maintenance will be performed standardly by their provider.
223601074|NCT01847989|DRUG|catridecacog|Single doses of rFXIII administered intravenously (IV) to eight subjects in each of the five dose groups (2, 5, 10, 25 and 50 U/kg).
223601075|NCT01847989|DRUG|placebo|Single doses of placebo administered intravenously (IV) to two subjects in each of the five dose groups (2, 5, 10, 25 and 50 U/kg).
223601076|NCT03629353|PROCEDURE|endotracheal intubation|After preoxygenation with FiO2 1.0 and flow rate of 8 L/min for 3 minutes, the enrolled patients will be intubated with endotracheal tube and maintained oxygenation during surgery.
223601077|NCT03629353|PROCEDURE|high flow nasal cannula|After preoxygenation with 100% oxygen through high flow nasal cannula for 3 minutes, the enrolled patients will be maintained intubationless oxygenation with flow rate of 70 L/min during surgery.
223601078|NCT02156414|PROCEDURE|Radical Prostatectomy|Radical Prostatectomy
223749277|NCT03858491|DRUG|Cobicistat|Cobicistat will be added to the treatment with osimertinib. The initial dose will be 150 mg cobicistat, which equals the dose used in the treatment of HIV-infected patients. If this dose is well tolerated and the increase in exposure of osimertinib is not sufficient, the dose of cobicistat will gradually be escalated to 600 mg per day (150 mg cobicistat, four times per day).
224199882|NCT03669640|DRUG|Placebo|Participants will receive a once-daily, oral dose of placebo matched to RO6889450 for 12 weeks.
224199883|NCT00664417|BIOLOGICAL|Monovalent subvirion H5N1 influenza vaccine|0.5 mL, IM, 2 injections, Formulation 1
224199884|NCT00664417|BIOLOGICAL|Monovalent subvirion H5N1 influenza vaccine|0.5 mL, IM, 2 injections, Formulation 2
224199885|NCT00664417|BIOLOGICAL|Monovalent subvirion H5N1 influenza vaccine|0.5 mL, IM, 2 injections, Formulation 3
224199886|NCT00664417|BIOLOGICAL|Monovalent subvirion H5N1 influenza vaccine|0.5 mL, IM, 2 injections, Formulation 4
224199887|NCT00664417|BIOLOGICAL|Monovalent subvirion H5N1 influenza vaccine|0.5 mL, IM, 2 injections, Formulation 5
223601079|NCT02156414|PROCEDURE|Extended Lymphadenectomy|Extended Lymphadenectomy
223601080|NCT02663830|DRUG|Sildenafil & clomiphene citrate|105 Patients will receive 25 mg sildenafil citrate 6hourly orally (day 6 to the end of the cycle), and clomiphene citrate 100 mg/day (day 2 to 6) orally by the patient, for induction of ovulation
223601081|NCT02663830|DRUG|clomiphene only|105 Patients will receive clomiphene citrate 100 mg/day (day 2 to 6) orally by the patient, for induction of ovulation
223601082|NCT03084835|BEHAVIORAL|Usual Care|Brief cessation counseling
223601083|NCT03084835|BEHAVIORAL|WEB+TXT|Access to Become an Ex website plus text messaging
223601084|NCT03084835|BEHAVIORAL|WEB+TXT+TTS|Access to Become an Ex website plus text messaging plus consult with a trained tobacco treatment specialist
223601085|NCT03970941|OTHER|Cost evaluation|The cost for the hospital of the strategy of management will be evaluated.
223601086|NCT03970941|OTHER|Questionnaire|The quality of life of patients will be measured.
223601087|NCT03422536|BIOLOGICAL|Cetuximab|Given IV
223601088|NCT03422536|DRUG|Ficlatuzumab|Given IV
223601089|NCT02954614|BEHAVIORAL|Active play in after school programs (ASP)|"* A 15 hour training-program for ASP-staff aimed to increase active play and physical activity among children in ASPs. The program includes lectures, guided discussions and practical tasks focusing on increasing the staffs competence in how to support active play and PA among all children in the ASP~* A 8 hour course for local physiotherapists enabling them to guide ASP-staff during parts of the intervention period"
223601090|NCT01771523|PROCEDURE|Thyroidectomy|total thyroidectomy or lobectomy
224199888|NCT00664417|BIOLOGICAL|Monovalent subvirion H5N1 influenza vaccine|0.5 mL, IM, 2 injections, Formulation 6
224199889|NCT00664417|BIOLOGICAL|Monovalent subvirion H5N1 influenza vaccine|0.5 mL, IM, 2 injections, Comparator 1
224199890|NCT00664417|BIOLOGICAL|Monovalent subvirion H5N1 influenza vaccine|0.5 mL, IM, 2 injections, Comparator 2
224199891|NCT00664417|BIOLOGICAL|Physiological saline|0.5 mL, IM, 2 injections
224199892|NCT03035981|OTHER|White rice, low amylose|White and brown rice were tested for differences in gastric emptying rate and appetitive response
224199893|NCT03035981|OTHER|White rice, high amylose|White and brown rice were tested for differences in gastric emptying rate and appetitive response
224199894|NCT03035981|OTHER|White rice, slow|White and brown rice were tested for differences in gastric emptying rate and appetitive response
224199895|NCT03035981|OTHER|White rice, resistant|White and brown rice were tested for differences in gastric emptying rate and appetitive response
224199896|NCT03035981|OTHER|Brown rice, low amylose|White and brown rice were tested for differences in gastric emptying rate and appetitive response
223601091|NCT01771523|DEVICE|use of drain|drain will be used
223601092|NCT04531241|DEVICE|ACUVUE® OASYS 1-DAY|senofilcon A contact lenses made with a novel manufacturing technology
223601093|NCT04531241|DEVICE|ACUVUE® OASYS 1-DAY|senofilcon A contact lenses made with the current manufacturing technology
223601094|NCT06079021|DEVICE|CytoSorb|Application of CytoSorb treatment for 72 hours in patients with ACLF
223601095|NCT00761696|DRUG|IPI-926|Oral daily dosing
223601096|NCT03301610|OTHER|Mobile Education Delivery|Patients will be provided with an iPad on admission to the post-surgical unit and will remain with the patient until discharge. The patient, independently or with the nurse, may use the program at any point during the inpatient care experience. The RN will use the iPad to engage patients in their pain management.
223601097|NCT03301610|OTHER|Standard Verbal and Written Education|Patients will be provided with two pamphlets on pain management on admission to the post-surgical unit. Nurses will follow-up with verbal instruction based on patient need. This will continue through hospital stay. Additional printed education materials are available through the department of patient education and verbal instruction may be tailored based on nursing assessment and patient need.
223601098|NCT05711524|BIOLOGICAL|Traditional Cryoprecipitate|This is the cryoprecipitate already currently being given to patients with a cryo order.
223601099|NCT05711524|BIOLOGICAL|Pathogen-Reduced Cryoprecipitate|This is the pathogen-reduced cryoprecipitate that is intended to be compared to the standard cryoprecipitate.
223601100|NCT06968676|OTHER|Conventional Upper Limb Treatment|Control group (CG) will receive two 60-minute sessions per week for a period of ten weeks (a total of 20 sessions per group). The CG will receive a specific conventional physiotherapy intervention by a physiotherapist with expertise in the care of people with MS. This intervention will be based on conventional physiotherapy exercises \[23\], including shoulder, elbow, wrist and finger joint mobilization, forearm and hand muscle strengthening exercises, gross and fine motor work and functional task practice with the aim of mimicking the movements included in the settings specifically designed for the experimental intervention.
223601101|NCT06968676|OTHER|Experimental intervention with mixed reality|Experimental group will receive the same conventional physiotherapy treatment (40 minutes) in addition to a mixed reality protocol, using Meta Quest 3.0. glasses (20 minutes), by retraining on tasks specifically designed for this project and linked to the specific locations (kitchen, bathroom, living room, bedroom and garden-terrace. The intervention will be carried out by a physiotherapist skilled in the use of the technology. The patient's initial position will be seated facing a table at mid-trunk height, with the elbow at 90° of flexion and the forearm in neutral pronation-supination. The therapist will provide manual assistance as needed, moving to upright-high seated or standing positions as the protocol progresses and as tasks require, and work will be done bilaterally.
223601102|NCT06975566|PROCEDURE|radial artery catheterization|
223601103|NCT06977048|OTHER|Mobile Application-Based Educational Program|"Week 0:~Participants are informed about the study and trained in the use of the mobile application.~The mobile app is installed on their smartphones.~Educational animation videos and modules are watched with the researcher in a predefined order.~Questions about animations are answered.~Videos are downloaded to the participant's phone.~DFU photographs are recorded.~Weeks 1-12:~Participants are instructed to use the app regularly between weeks 5-12.~Video watching days and durations are logged using a tracking form.~Weekly push notifications remind participants to use the app.~Weekly phone calls are made to assess engagement using a structured checklist.~DFU photographs are taken at weeks 8 and 12.~At week 12, data are collected in person, including:~DFU size (length × width) with disposable paper ruler~Metabolic parameters from blood tests~Wagner-Meggitt classification~Re-ulceration assessment"
223601104|NCT06977048|OTHER|Standard care|"Participants provide consent and receive baseline information.~DFU photographs are taken at baseline, week 8, and week 12.~At week 12, the same outcome measures as the intervention group are collected.~After the study ends, participants are provided with access to the mobile application."
223601105|NCT06975917|DRUG|Chemotherapy|Any chemotherapy regimen that is used in the adjuvant setting
223601106|NCT06974500|PROCEDURE|Daily efferent limb stimulation for at least two weeks prior to surgery using saline solution and a thickering agent|"Participants in the intervention group will undergo daily stimulation of the efferent limb for a minimum of two weeks prior to ileostomy closure. The procedure involves the instillation of a solution composed of saline and a thickening agent through the efferent limb of the ileostomy via the inactive orifice. This is performed by the patient at home following specific training and instructions provided during a preoperative consultation.~The stimulation begins the day after the pre-anaesthesia consultation and is carried out once per day. Patients are supported with a structured follow-up, including one physical consultation in the stoma clinic, telephone contact with the research team every 48 hours, and access to an email address for queries. The objective of the intervention is to recondition the excluded colon before the restoration of intestinal continuity in order to reduce postoperative complications."
223601107|NCT06976190|DRUG|MRG003 + Pucotenlimab|MRG003 will be administrated as specified in the protocol. Pucotenlimab will be administrated as specified in the protocol.
223601108|NCT06976190|DRUG|Gemcitabine, Docetaxel, or Capecitabine|"Gemcitabine will be administrated via intravenous infusion at 1000 mg/m2 once on Day 1 and 8 of every 3 weeks (21-day cycle).~Docetaxel will be administrated via intravenous infusion at 75 mg/m2 once on Day 1 of every 3 weeks (21-day cycle).~Capecitabine will be administrated orally at 1000 mg/m2 twice a day for Day 1 to 14 of every 3 weeks (21-day cycle)."
224199897|NCT03035981|OTHER|Brown rice, high amylose|White and brown rice were tested for differences in gastric emptying rate and appetitive response
224199898|NCT03035981|OTHER|Fructooligosaccharide (FOS)|White and brown rice were tested for differences in gastric emptying rate and appetitive response
224199899|NCT03130855|DRUG|inferior alveolar nerve block with 4% articaine|an anesthetic technique using 4% articaine anesthetic solution
224199900|NCT03130855|DRUG|buccal infiltration with 4% articaine|anesthetic technique using 4% articaine anesthetic solution
224199901|NCT01224418|DRUG|Tacrolimus|oral
224199902|NCT01198990|BEHAVIORAL|Group 1|Subjects will be randomized to the small change eating strategy, a physical activity goal and will receive the positive affect/self affirmation component.
224199903|NCT01198990|BEHAVIORAL|Group 2|Subjects will be randomized to the small change eating strategy and a physical activity goal.
224199904|NCT04583384|DIAGNOSTIC_TEST|1H-Spectroscopy MRI|"PRESS asymetric monovoxel  PROBE , TE 144 ms, TR 2500 ms, 768 or 1024 averages"
223749278|NCT00919399|DRUG|Exemestane|25mg a day during 4 months
223749279|NCT00919399|DRUG|tamoxifen|One 20 mg tablet a day started 1 week after the first Aromasine intake
223749280|NCT00978328|DRUG|oxycodone immediate release (OXYRX)|Characteristics of pts. receiving prescription medications containing OXYRX
224199905|NCT03024359|DIETARY_SUPPLEMENT|Extra virgin olive oil|2 liters of extra virgin olive oil will be given to participants to include/use in their daily foods.
224199906|NCT04185207|OTHER|no intervention|There is no intervention.
224199907|NCT06568445|DRUG|Maintenance at initial treatment sequential as-needed therapy with inhaled budesonide-formoterol(Symbicort 160/4.5) ®）|one inhalation twice daily for 4 weeks maintenance, sequential as-needed for symptom relief (no more than 8 inhalations per day) to 24-week.
224199908|NCT06568445|DRUG|as-needed therapy with inhaled budesonide-formoterol (Symbicort 160/4.5) ®）|as-needed for symptom relief (no more than 8 inhalations per day) to 24-week.
224199909|NCT02118818|GENETIC|Next generation sequencing|There will be no intervention. This is an observational trial to examine the differences in genetic variants and gene expression between patients with and without RHD.
224199910|NCT03533608|BEHAVIORAL|Group PE|Participants will engage in twelve 90-minute sessions of Group PE over the course of 6 weeks. Treatment consists of psychoeducation, rationale for treatment, and in vivo exposure to reduce trauma-related avoidance and thereby improve PTSD symptoms.
224199911|NCT00122148|BEHAVIORAL|Feedback on provision of care|
224199912|NCT06700382|DRUG|capecitabine|different methods of treatment for capecitabine
224199913|NCT04872127|DEVICE|proximal embolism protection device|a proximal occlusion Mo.Ma will be used as the embolism protection device during CAS
224199914|NCT04872127|DEVICE|distal embolism protection device|a distal SpiderFX will be used as the embolism protection device during CAS
224199915|NCT03541668|DRUG|Recombinant human urokinase|Patients receive rhPro-UK 35mg,15mg of which is given as a bolus within 3 minutes followed by dlivery of the remaining 20 mg as a constant infusion over a period of 30 minutes.
224199916|NCT03541668|DRUG|Alteplase|Patients receive rt-PA in a dose of 0.9mg per kilogram of body weight(maximum,90 mg),10 percent of which was given as a blous followed by delivery of the remaining 90 percent as a constant infusion over a period of 60 minutes.
224199917|NCT03286426|DIAGNOSTIC_TEST|Pictor|The back of each eye will be imaged with Pictor. Visual acuity and color vision will be checked if patient able to cooperate with exam.
223749281|NCT00277212|DRUG|Lamotrigine + Aripiprazole|"Tablets, Oral, once daily, Phase 1 (all subjects) - up to 24 weeks; Phase 2 - up to 52 weeks~Lamotrigine 100-200 mg/day~Aripiprazole 10-30 mg/day"
223749282|NCT00277212|DRUG|Lamotrigine + Placebo|"Tablets, Oral, once daily, Phase 2 - up to 52 weeks~Lamotrigine 100-200 mg/day~placebo 0 mg/day"
223749283|NCT00902564|DRUG|Escitalopram|Flexible-dosed (5 to 20 mg Oral Tablets Daily)
224075274|NCT02170662|DRUG|Bimatoprost|Bimatoprost 0.03% ophthalmic solution as purchased from the manufacturer will be the active drug.
224075275|NCT02170662|DRUG|Placebo|
224075276|NCT03806127|DRUG|Vibegron|oral administration
224075277|NCT03806127|DRUG|Placebo|oral administration
224075278|NCT00525759|DRUG|5-FU, Epirubicin, Cyclophosphamide, Docetaxel|3 cycles of FEC q3w, followed by 3 cycles of docetaxel q3w FEC: 5FU 500mg/m2 intravenous bolus D1, Epirubicin 100mg/m2 intravenous bolus D1, Cyclophosphamide 500mg/m2 intravenous bolus D1) every 21 days Docetaxel: (100mg/ m2 intravenous infusion) every 21 days
224199918|NCT05241626|DIAGNOSTIC_TEST|AS-OCT|Optical Coherence Tomography (OCT) creates detailed cross-sectional images of the anterior and posterior segments using low coherence interferometry. OCT is a noninvasive, real-time method for evaluating the tear meniscus, total corneal thickness (CT), and corneal epithelial thickness
224199919|NCT01953731|DRUG|Palbociclib|"In period 1, patients will receive a single 125mg oral dose of palbociclib alone. Subjects will undergo palbociclib pharmacokinetic sampling at prespecified time points up to 120 hours post palbociclib dose.~In period 2, subjects will receive 12 daily oral doses of 600mg of rifampin and a single 125mg oral dose of palbociclib on day 8. Subjects will undergo palbociclib pharmacokinetic sampling at prespecified time points up to 120 hours post palbociclib dose."
224199920|NCT01953731|DRUG|Rifampin|In period 2, subjects will receive 12 daily oral doses of 600mg of rifampin and a single 125mg oral dose of palbociclib on day 8. Subjects will undergo palbociclib pharmacokinetic sampling at prespecified time points up to 120 hours post palbociclib dose.
224199921|NCT02255773|BEHAVIORAL|Computerized Tasks|3 computerized tasks completed to assess motivation, learning of goal-directed and habitual behavior, and flexibility in switching between behavior strategies. It should take about 60 minutes to complete all three tasks.
224199922|NCT02255773|BEHAVIORAL|Questionnaires|Completion of 8 questionnaires about mood, fatigue, sleep quality, and other symptoms. It should take about 30 minutes to complete these questionnaires.
224199923|NCT00871104|DRUG|Fosfomycin and imipenem|IV Fosfomycin 2 gr./6 hours and IV Imipenem 1 gr./6 hours adjusted acoording to renal function during 4-8 weeks
224199924|NCT00871104|DRUG|Vancomycin|IV Vancomycin 30 mg/kg twice a day with valley leves higher than 15 mcg/kg
223512249|NCT01016015|BIOLOGICAL|Cixutumumab|Given IV
223512250|NCT01016015|OTHER|Laboratory Biomarker Analysis|Correlative studies
223512251|NCT01016015|DRUG|Temsirolimus|Given IV
223512252|NCT03947021|RADIATION|Computed tomography (CT) scan|A CT scan of thorax and heart will be performed in the CT+BSPM group.
223512253|NCT03947021|DEVICE|Body-surface potential mapping|Measurement of 256-lead body-surface electrocardiogram
223512254|NCT03221296|BEHAVIORAL|Vestibular Training (Intervention Group)|Exercises three times daily, for up to approximately 20 minutes. Changes in functional status and physical status shall be measured at study onset and follow up.
223512255|NCT03917836|DIAGNOSTIC_TEST|endoscopy and histology|diagnostic evaluation of chronic gastritis
223512256|NCT05569889|PROCEDURE|Anterior Cruciate Ligament reconstruction (ACLR)|A comparison between the two groups were done regarding the three following stages: (a) the preparation time of the trolley, which is the time taken by the CNOR to recover from the reserves all the single-packed sterile instruments (SPSI) necessary for the intervention or to recover the CST (b) the opening time of the instruments by the circulating nurse who opens the packages and gives them to the surgical nurse while respecting the sterility of the items, and by the surgical nurse who prepares the table for the intervention, and (c) the sorting time of the waste between plastic and paper at the end of the intervention.
223749284|NCT00322010|PROCEDURE|early PT OT|"1. Passive range of motion exercises for all limbs in patients who remain unresponsive despite sedative interruption (ten repetitions in all cardinal directions).~2. Sessions began with active assisted and active range of motion exercises in the supine position.~3. If tolerated, treatment is advanced to bed mobility activities, including transferring to upright sitting.~4. Sitting balance activities are followed by participation in activities of daily living (ADLs) and exercises that encourage increased independence with functional tasks.~5. The session progresses to transfer training, and finally pre-gait exercises and ambulation.~6. Progression of activities is dependent on patient tolerance and stability.~7. Therapy intervention continues on a daily basis throughout the patient's hospital stay until he/she returns to prior level of function or is discharged."
223601109|NCT06975254|OTHER|"On the basis of routine nursing, the Internet + nursing program based on the FLS model is implemented"|1\) During hospitalization: After the patient is admitted to hospital, the coordinator will establish wechat contact with the patient face to face and establish a good trust relationship with the patient; The coordinator and the doctor will collect the patients' cases together, and then according to the patients' conditions and wishes, the diagnosis and treatment plan will be formulated jointly by multiple disciplines, including medicine, rehabilitation and nutrition management. 2) Before discharge: the coordinator helps the patient to make an appointment for return visit; Issue business cards of the team's online and offline services to patients and guide them to use wechat and online service application procedures (such as Zheli Care and Dr. Nari); 3) After discharge: patients keep in touch with the liaison staff at any time, and any abnormal situation will be contacted by the liaison staff; Team members supervised the patient's medication situation by punching in the mini program
223601110|NCT06975033|OTHER|Video|Participants will watch video.
223601111|NCT06325462|DEVICE|sensors of regional cerebral oxygen saturation (O3 regional oximeter, Masimo Corp, Irvine, CA) FDA Reg No. 3011353843|O3 regional oximetry monitors the regional hemoglobin oxygen saturation of the blood (rSO2) in adult patients, placed on the forehead by noninvasive and continuous combining arterial and venous oxygen saturation signals from near-infrared spectroscopy (NIRS)
223601112|NCT06576401|DRUG|[14C] HDM1002|Administered orally
223601113|NCT05696795|DRUG|Abrocitinib 200 mg|Abrocitinib (Cibinqo) is FDA approved at 200 mg dose once daily for the treatment of atopic dermatitis. It is not currently FDA approved for the treatment of sarcoidosis.
223601114|NCT02023996|RADIATION|89Zr-DFO-trastuzumab|
223601115|NCT02023996|DEVICE|PET imaging|
223601116|NCT06975397|OTHER|EXERCISE TRAINING WITH OR WITHOUT MEDICATION|This training and research project was conducted over eight weeks and started 6 - 8 weeks after natural childbirth. All study participants were included in the exercise program designed for postpartum females. Exercises included four sets that changed every two weeks and were held individually with a physiotherapist three times a week, every two to three days, for 45 minutes each unit. All participants performed breathing exercises, body posture correction, abdominal muscle strengthening exercises (transverse, oblique, and rectus abdominis muscles), and engaged other muscles to improve overall physical fitness.
223601117|NCT06975397|OTHER|kinesio taping|The Kinesiology Tape used in this study has a European quality certificate (CE). Before the exercise program, on the day of the first ultrasound, participants had tapes placed on their abdomens. The tape length for each participant was 20 cm to ensure the ends were located on the lateral edges of the rectus abdominis muscles. Both ends of the tape were simultaneously attached to the abdomen, with two attached from the navel line upwards and one below it Each participant in the tape group was asked to breathe in using the abdominal muscles, and after a maximal stretch of the abdominal integuments, three tapes were attached at 50% tension or without tension. The taping procedure was repeated once per week, with the tapes attached for six days and removed at the end of the 6th day. The placebo and tape groups had a break on the 7th day
223601118|NCT06976658|DRUG|Dorzagliatin|Dorzagliatin 50mg bd
223601119|NCT06976658|DRUG|matched placebo|matched placebo
223601120|NCT06975813|DRUG|masseter muscle|masseter muscle trigger points injection by magnesium sulphate
223601121|NCT06975813|DRUG|masseter and sternocleidomastoid muscle|masseter and sternocleidomastoid muscle trigger points injection by magnesium sulphate
223601122|NCT06974487|DRUG|GZR102 injection|Participants will get a single dose of GZR102 injection （fixed-ratio combination of GZR4 and GZR18）.
223601123|NCT06974487|DRUG|GZR4 injection|Participants will get a single dose of GZR4 injection
223749285|NCT02915653|OTHER|Educational materials on a new diagnostic service|Educational materials on a new diagnostic service
223601124|NCT06974487|DRUG|GZR18 injection|Participants will get a single dose of GZR18 injection
223601125|NCT06974474|DRUG|Guselkumab|Guselkumab
223601126|NCT06975527|OTHER|Breastfeeding guidelines|"All participants will be instructed by the following guidelines:~* Hold the breast so the nipple brushes the center of the infant's lips and wait for the infant to open the mouth.~* Infant's mouth should be opened wide, as with a yawn and should cover the entire areola, or a large amount of the areola.~* Both breasts are used in each feeding, usually 10 to 15 minutes on the first side, followed by burping before beginning the second side.~* Break suction by placing finger in the corner of infant's mouth and quickly remove breast.~* Apply breast massage before breastfeeding.~* The neonate is nursed shortly after birth and approximately every 2 to 3 hours thereafter for a total of 8 to 12 feedings a day.~* Lactating women needs about 8 to 10 glasses of fluids per day while breastfeeding.~* Caffeine consumption should be limited to 2 cups of coffee, tea or cola per day.~* Lactating mother should consume a healthy diet which is varied, balanced, and natural."
223749286|NCT03336216|BIOLOGICAL|Cabiralizumab|specified dose on specified days
223749287|NCT03336216|DRUG|Nab-paclitaxel|specified does on specified days
223749288|NCT03336216|DRUG|Onivyde|specified dose on specified days
223749289|NCT03336216|BIOLOGICAL|Nivolumab|specified dose on specified days
223749290|NCT03336216|DRUG|Fluorouracil|specified dose on specified days
224199925|NCT03196739|DEVICE|Virtual rehabilitation|A total of 10 sessions were held for 30 minutes, 2 to 3 times a week for upper limb rehabilitation using immersive virtual reality under the assistance of an occupational therapist.
224199926|NCT06073041|OTHER|Invitation to adopt|All eligible Prisma Health clinics will be invited to adopt EIMG. Adopting clinics will first be sent an instructional video as a part of a low touch initial onboarding. After 4 months, clinics will then receive an in-depth standardized onboard training.
223749291|NCT03336216|DRUG|Gemcitabine|specified dose on specified days
223749292|NCT03336216|DRUG|Oxaliplatin|specified dose on specified day
223749293|NCT03336216|DRUG|Leucovorin|Specified dose on specified days
223749294|NCT03336216|DRUG|Irinotecan Hydrochloride|Specified dose on specified days
223749295|NCT02166190|PROCEDURE|Radiofrequency Ablation using EndoHPB Probe|Radiofrequency Ablation using EndoHPB Probe
223749296|NCT02166190|PROCEDURE|Stenting only|Stenting only
223749297|NCT06496802|OTHER|no intervention|no intervention
223749298|NCT03239470|BIOLOGICAL|Cohort 1: 1.0 x 10^8 PolyTregs|Each participant will receive a target cell dose of 1.0 x 10\^8 polyclonal Tregs.
223749299|NCT03239470|BIOLOGICAL|Cohort 2: 2.5x10^8 PolyTregs|Each participant will receive a target cell dose of 2.5x10\^8 polyclonal Tregs.
223749300|NCT01457599|PROCEDURE|Computertomography-guided marking of colorectal liver metastases|Computertomography-guided marking of colorectal liver metastases
223749301|NCT02793518|BEHAVIORAL|psychological tests|
223749302|NCT05727228|OTHER|cytology, p16/ki67 dual stain cytology (DS), extended genotyping, DNA methylation, viral load,|p16/Ki67 dual stain cytology, extended genotyping and DNA methylation will be performed from the residual cell-pellet from the HPV-positive screening samples. If no cytology-triage testing is performed as a part of the screening algorithm, a cytology will be performed at inclusion. If any residual material is left after DS, extended genotyping and DNA methylation, it will be stores at -80 degrees for future purposes.
223749303|NCT00218374|DRUG|Gabapentin|Gabapentin initiated up to a daily dose of 2400mg PO x 5 weeks
223749304|NCT04049942|OTHER|Multimodal prehabilitation group|Multimodal prehabilitation strategy includes physical exercise (moderate aerobic exercise combined with resistance exercise and respiratory training ), nutritional suggestion and optimization(whey protein supplement), and psychological therapy, as well as conventional guidance (including preoperative anesthesia assessment, drug treatment recommendations for chronic disease, quit smoking and abstinence). Patients are advised to record daily exercises and adherence to nutritional, psychological and other recommendations. Short message interviews are sent to patients twice a week to optimize adherence and promote feedback.
224199927|NCT03514121|BIOLOGICAL|FPA150|A monoclonal antibody against B7-H4
224199928|NCT03514121|BIOLOGICAL|Pembrolizumab|An anti-PD1 antibody
224199929|NCT05553600|DEVICE|Tampon BR|Modified Regular Absorbency Tampons
224199930|NCT05553600|DEVICE|Tampon CR|Reference Regular Absorbency Tampons
223601127|NCT06975527|OTHER|Aerobic exercise|The participants will be engaged in a supervised moderate aerobic exercise in the form of walking on a treadmill for 40 minutes/ day, 3 days/ week, for 6 weeks beginning 6:8 weeks postpartum. Each exercise session will be divided into 3 phases. The warm-up phase begins with walking at low speed (within resting heart rate) on a treadmill for 5 minutes. The active phase continues for 30 minutes at a moderate intensity of 60 to 70% of maximal heart rate (HRmax). Gradual increase and adjustment of speed will be applied for each woman according to her prescribed intensity based on HRmax. HRmax is calculated by subtracting the age from 220. The program will be terminated with 5 minutes cool-down phase, during which the treadmill speed will be gradually decreased until the heart rate resumes its resting level.
223601128|NCT02613585|OTHER|Permethrin Impregnated Clothing|Uniforms and work clothing treated with permethrin according to proprietary process used by Insect Shield, Inc.
223601129|NCT06842888|DEVICE|Miraπ|"This device has tiny sensors that measure the movement of the healthy fingers and tiny motors that move the affected fingers of the patient.~The device is connected to a specially designed finger mechanism that moves the affected fingers of the patient. This opening mechanism is designed in a way that it prevents the fingers from being forced into any hurting position. If the patient moves the healthy fingers during training, also the fingers of the affected hand are moved by the device at the same time. This creates the effect of mirror therapy for the brain as the patient can see both hands moving."
223601130|NCT06842888|BEHAVIORAL|Mirror Therapy|Current standard of care using MT.
223601131|NCT05795985|DIAGNOSTIC_TEST|calprotectin levels|dosage of calprotectin levels in patients with abdominal pain
223601132|NCT04099121|DEVICE|Ultrasound Imaging|3D ultrasound of the pelvic floor and vaginal cavity will be obtained by using a commercial ultrasound system.
223601133|NCT03565146|DEVICE|PiQo4 Laser System|PiQo4 Laser System for treatment of pigmented lesions
223601134|NCT06866041|PROCEDURE|mpMRI-targeted confirmatory biopsy|mpMRI-targeted confirmatory biopsy after one year from the diagnosis, according to the international guidelines
223601135|NCT04788316|BEHAVIORAL|CBI and Text messaging|A computerized brief intervention (2 sessions) followed by six months of personalized text messaging
223749305|NCT04049942|BEHAVIORAL|Aerobic training group|Aerobic training strategy includes the same guided individualized moderate aerobic exercise as the multimodal prehabilitation group, as well as the conventional guidance. Patients are advised to record daily exercises. Short message interviews are sent to patients twice a week to optimize adherence and promote feedback.
223749306|NCT00922766|DRUG|Dalteparin|Patients prescribed dalteparin for non-ST segment elevated acute coronary syndromes in nursing home patients who will be treated conservatively (without corornary intervention \[PCI\] or coronary artery bypass graft \[CABG\] within 48 hours).
223749307|NCT05250024|DEVICE|UHMWP Cranioplasty|patient specific cranial implant
223749308|NCT05250024|DEVICE|PEEK Cranioplasty|patient specific cranial implant
223749309|NCT00843713|DRUG|raltegravir|For patients assigned to the raltegravir group, subjects will receive raltegravir 400mg to be taken by mouth twice daily for 24 weeks in addition to taking their current HIV medication
223749310|NCT00843713|DRUG|Placebo|For the patient assigned to the placebo group, subjects will take a matching placebo pill 400mg to be taken by mouth twice daily for 24 weeks in addition to taking their current HIV medication
224199931|NCT05553600|DEVICE|Tampon BS|Modified Super Absorbency Tampons
224199932|NCT05553600|DEVICE|Tampon CS|Reference Super Absorbency Tampons
224199933|NCT01493063|OTHER|Physiopathology|Samples of breastmilk and infant serum and questionnaires.
224199934|NCT04149769|DEVICE|Indego Exoskeleton|Regular dosing of Indego Exoskeleton walking.
224199935|NCT04930536|DRUG|Acalabrutinib capsule|The recommended dose of Acalabrutinib is 100 mg given per oral (PO) twice daily
224199936|NCT04329013|OTHER|Left lateral Position during intervention|Left lateral position during EGD
224199937|NCT04329013|OTHER|Prone Position during intervention|Prone position during EGD
223601136|NCT06524427|PROCEDURE|Robot-assisted lobectomy|Patients will receive robot-assisted lobectomy using Da Vinci surgical system
223601137|NCT06524427|PROCEDURE|Video-assisted lobectomy|Patients will receive video-assisted lobectomy
223601138|NCT06626022|DEVICE|MRI|Standard prostate mpMRI.
223601139|NCT06626022|DEVICE|ExactVu|microUltrasound
223601140|NCT06622512|DEVICE|Radial Pressure Wave Therapy|Radial pressure wave therapy (RPWT) is a non-invasive treatment used for musculoskeletal disorders, including knee OA. (Schroeder AN) It involves the application of mechanical energy to stimulate biological responses, RPWT differs fundamentally from focal shock wave therapy (FSWT) in several physical properties, in its point of maximum energy flux density (EFD), and in some clinical applications. RPWT activates cellular pathways involved in tissue regeneration and generates mechanical energy that spreads radially from the point of application, primarily affecting superficial tissues and leading to pain relief and improved function through a process known as mechano-transduction, by enhancing blood flow and stimulating cellular repair processes . (Simplicio CL, Wang CJ)
223601141|NCT06702410|BEHAVIORAL|mental health gap action program intervention guide (mhGAP-IG)|The mhGAP-IG is an evidence-based intervention developed by WHO. It was designed for non-specialists to scale up high quality mental health services. Although more than 90 countries worldwide have implemented mhGAP-IG, this study is the first to evaluated if it works for scaling up CMBDs services in China. Investigators have cultrually adapted the mhGAP-IG according Chinese context.
223601142|NCT03405519|PROCEDURE|Radiotherapy planning using both CT and MRI scans|Patients' radiotherapy will be planned using CT and MRI scans in order to establish the best methodology for planning of radiotherapy for nodal disease
223601143|NCT01716455|DRUG|SSP-004184|
223601144|NCT04412447|DEVICE|Functional Electrical Stimulation|Electrical stimulation of motor-nerves innervating the musculature of the lower limb.
223601145|NCT06077890|OTHER|Digital Rehabilitation|Participants in this arm will undergo an in-person rehabilitation program coordinated by a Physiatrist and will be able to access home-based rehabilitation strategies through dynamic content provided by SIMPLI.REHAB digital tool.
223601146|NCT06077890|OTHER|Conventional Rehabilitation|Participants in this arm will undergo an in-person rehabilitation program coordinated by a Physiatrist and will be given home-based strategies in a printed paper brochure.
223601147|NCT03106467|PROCEDURE|Single-port laparoscopic appendectomy|Single-port laparoscopic appendectomy: A 1.5 cm skin incision is made inside the umbilicus and single port is introduced through it. The appendix is manipulated by a combination of a 5-mm scope, angulated, and straight instruments. The periappendiceal vessels and appendix are ligated and divided. Specimen is delivered via the transumbilical port. Umbilical fascia and skin are routinely closed.
223601148|NCT03106467|PROCEDURE|Three-port laparoscopic appendectomy|Three-port laparoscopic appendectomy: CLA requires the introduction of a 30-degree 5-mm or 10-mm rigid scope through a 0.5 - 1.0 cm intra umbilical incision. Two additional 5-mm incisions are made outside umbilicus. Appendectomy is performed in the same manner as described for the SLA above. The umbilical fascia and skin are routinely closed.
223601149|NCT02333019|BEHAVIORAL|Let's Talk About Sex|Multimedia web site to build parental skills in communicating with their pre-adolescnet child sex and relationships, pregnancy prevention, and risk of sexually transmitted infections.
223601150|NCT02333019|BEHAVIORAL|Websites; preventing teen pregnancy|Two general web sites with information about preventing teen pregnancy
223601151|NCT00395850|DRUG|Disulfiram|Disulfiram at 0, 250, 375, or 500 mg/day for 12 weeks
223601152|NCT02816619|BEHAVIORAL|Personalized Physical Activity coaching program|
224199938|NCT01855321|DRUG|Vitamin D|The cholecalciferol capsule with respect to size and shape and 2) the intervention group will take 1 oral capsule of cholecalciferol 50,000 IU (Bio-Tech Pharmacal, Fayetteville, AR USA) once weekly for 8 weeks followed by 50,000 IU once monthly for 4 months.
224199939|NCT01855321|DRUG|Placebo|The placebo capsule is to be identical to the cholecalciferol capsule with respect to size and shape and 2) the intervention group will take 1 oral capsule of cholecalciferol 50,000 IU (Bio-Tech Pharmacal, Fayetteville, AR USA) once weekly for 8 weeks followed by 50,000 IU once monthly for 4 months.
224199940|NCT01432600|DRUG|Pomalidomide|Pomalidomide at 4 mg by mouth (PO) as outlined in the treatment arms.
224199941|NCT01432600|DRUG|Dexamethasone|Dexamethasone at 40 mg (20 mg) PO as outlined in the treatment arms.
223601153|NCT02816619|BEHAVIORAL|Free practice of physical activity|
223601154|NCT00820872|BIOLOGICAL|trastuzumab|
223601155|NCT00820872|DRUG|carboplatin|
223601156|NCT00820872|DRUG|docetaxel|
223601157|NCT00820872|DRUG|lapatinib ditosylate|
223601158|NCT03973762|DEVICE|DR Grading with CAD|A CAD system is used to make DR grading.
223601159|NCT03973762|OTHER|DR Grading by expert panel|DR Grading by expert panel
223601160|NCT03311347|OTHER|+Gz accelerations and positive pressure breathing|
223601161|NCT00428870|PROCEDURE|Arthroscopic acromioplasty or arthroscopy alone (sham) or conservative treatment (rehabilitation)|
223601162|NCT00351507|DRUG|Vildagliptin|
223601163|NCT01241071|OTHER|myofascial treatment|myofascial release techniques of different muscles implicated in low back pain
223749311|NCT02200848|DRUG|Lenalidomide, Ibrutinib, Rituximab|Dose level -2 Ibrutinib 280 mg; Lenalidomide 2.5 mg; Rituximab 375 mg/m2 Level -1 Ibrutinib 420 mg; Lenalidomide 2.5 mg; Rituximab 375 mg/m2 Level 1 Ibrutinib 420 mg; Lenalidomide 5 mg; Rituximab 375 mg/m2 Level 2 Ibrutinib 420 mg; Lenalidomide 10 mg; Rituximab 375 mg/m2 Level 3 Ibrutinib 420 mg; Lenalidomide 15 mg; Rituximab 375 mg/m2
224311285|NCT03840369|DEVICE|Repetitive Transcranial Magnetic Stimulation to Right Dorsomedial Prefrontal Cortex|Transcranial magnetic stimulation (TMS) works by delivering a magnetic pulse to a focal brain region. TMS has a high degree of safety and has been studied as an intervention for many mental health and neurological conditions. Repetitive TMS (rTMS) delivers pulses at a set time interval in order to modulate neural activity in that region.
223601164|NCT01241071|OTHER|Placebo|A manual sham intervention will be applied to different muscles implicated in low back pain
223601165|NCT06144047|DEVICE|EEG SubQ subcutaneous EEG device|2-channel subcutaneous EEG device
223601166|NCT00964561|DRUG|Ciprofloxacin and Valortim|Days 1-3 400mg IV Ciprofloxacin BID over 60 minutes. Day 4 20mg/kg Valortim IV over 60 minutes.
223601167|NCT00964561|DRUG|Placebo Antibiotic and Valortim|Days 1-3 20mg/kg IV Normal Saline BID over 60 minutes. Day 4 20mg/kg Valortim IV over 60 minutes.
223601168|NCT00964561|OTHER|Placebo Antibiotic and Placebo Valortim|Days 1-3 200mL IV Normal Saline for Placebo Antibiotic over 60 minutes. Day 4 200mL IV Normal Saline for Placebo Valortim over 60 minutes.
223601169|NCT00982202|DRUG|pioglitazone|15mg tablet daily, increase by one pill at one-week intervals based on reported tolerability; maintain best tolerated dose (1 to 3 tablets daily) for \~18months
223601170|NCT00982202|DRUG|Placebo|1 to 3 tablets daily for \~18 months
223601171|NCT03355677|PROCEDURE|Case finding Clinic|Case finding clinic - participants will be reviewed by a respiratory specialist team. Full respiratory history will be taken and physical examination will be preformed. The participant will then complete 3 quality of life and functionality questionnaires the MRC dyspnoea score and the COPD diagnostic questionnaire. They will then be asked to perform FeNO CO and spirometry measurements.
223601172|NCT03355677|PROCEDURE|At Risk Case Clinics|Complex Case Clinic participants will be reviewed by a respiratory specialist team. Full respiratory history will be taken and physical examination will be preformed. The participant will then complete 6 quality of life and functionality questionnaires . They will then be asked to perform FeNO CO and spirometry measurements. Participants inhaler technique will be checked and any errors corrected. Smoking cessation advice and support will be given if necessary. Each participant will be given an individualised self management plan.
223601173|NCT03355677|OTHER|Usual Care|The control surgeries selected by the HHRA will continue with usual care.
223601174|NCT01435967|OTHER|Data collection|Data collected when only the lyophilised formulation of Rotarix was in use (which is considered as baseline) will be specifically compared to data collected post the introduction of the liquid formulation. The results will also be compared to available vaccine coverage data for those rotavirus vaccines being used in Belgium.
223601175|NCT04212689|DEVICE|Game Based Virtual Reality Exercises|A game-based virtual reality device named USE-IT will be added to the rehabilitation program. USE-IT is a technological rehabilitation system designed by the Department of Physiotherapy and Rehabilitation at Hacettepe University. It is a smart gaming device which has been used in patients who suffer from movement loss in their upper extremities due to various neurological and orthopedic reasons.
223601176|NCT04212689|OTHER|Conventional Physiotherapy and Rehabilitation|The conventional physiotherapy and rehabilitation program includes stretching exercises, neurodevelopmental approaches, static positioning, strengthening exercises, Transcutaneous Electrical Nerve Stimulation (TENS), hydrotherapy, cryotherapy.
223601177|NCT02461888|DRUG|Ixazomib|Chemotherapy
223601178|NCT02461888|DRUG|Cyclophosphamide|Chemotherapy
223601179|NCT02461888|DRUG|Dexamethasone|Chemotherapy
223601180|NCT02295605|OTHER|water-based exercises|water-based exercise strengthening protocol for lower limb muscles
223601181|NCT02295605|OTHER|land-based exercises|land-based exercise strengthening protocol for lower limb muscles
223601182|NCT01520025|RADIATION|PET MPI imaging with 18F-Fluorodeoxyglucose|"Exercise Stress Testing. All patients will undergo a symptom-limited exercise treadmill test using the Bruce protocol after a 24 hour high fat, low carbohydrate diet and an overnight fast. Persantine Stress Testing: Subjects who have undergone Persantine stress protocol for the PET or SPECT will follow the same protocol. A high fat, low carbohydrate diet for 24 hours and a 12 hour overnight fast will precede the study stress scan. Anti-anginal medications will be withheld on the morning of the exercise test.~18FDG (370 mBq) will be injected at either peak exercise or within 1 hour of peak.~Patients will be imaged 60 minutes after radiotracer injection in the supine position in a Discovery 690/VCTLYSO PET system (GE Healthcare, Milwaukee, Wisconsin)"
223601183|NCT05575908|PROCEDURE|Digital expert team|A digital team will be appointed based on the participant's answers in the digital screening questionnaire. Members of the team can be specialists in Physical and rehabilitation medicine, psychologist, physiotherapist, social workers, and consultants in the labor- and welfare administration. The general practitioner will also be invited to the meeting.
223601184|NCT04876612|PROCEDURE|Transforaminal epidural steroid injection (TFESI)|Well trained pain physician performs all the fluoroscopy-guided transforaminal epidural steroid injection (TFESI), who is not involved in evaluating study variables. Electrocardiography, noninvasive blood pressure, heart rate, and peripheral oxygen saturation were monitored for all patients before, while, and after conducting procedure. For TFESI, patients are prone positioned, and skin preparation on injection site is done with chlorohexidine. Procedure is conducted under fluoroscopy guidance at the patient's symptom complaining level. After confirming with a contrast medium, 3 ml of 0.1875% ropivacaine and 5 mg of dexamethasone are administered.
223749312|NCT00277069|DRUG|Carboplatin|Carboplatin given at 300mg/m2 IV over 30 minutes day 1, q 21 days
223601185|NCT02652468|DRUG|Fludarabine Phosphate|Fludarabine will be administered by IV over approximately 30 minutes for 4 days.
223601186|NCT02652468|DRUG|Mesna|Given IV over 24 hours starting prior to cyclophosphamide
223601187|NCT02652468|DRUG|Cyclophosphamide|Given IV for 2 days
223601188|NCT02652468|RADIATION|Total nodal irradiation|Undergo total lymphoid irradiation
223601189|NCT02652468|BIOLOGICAL|T Cell-Depleted Hematopoietic Stem Cell Transplantation|Undergo TCR alpha-beta/DC19-depleted hematopoietic stem cell transplant
223601190|NCT02652468|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo TCR alpha-beta/DC19-depleted hematopoietic stem cell transplant
223601191|NCT02652468|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo TCR alpha-beta/CD19-depleted hematopoietic stem cell transplant
223601192|NCT02652468|DRUG|Mycophenolate Mofetil|Given PO
223601193|NCT02652468|DRUG|Tacrolimus|Given PO or IV ONLY if graft cell content is over 1 x 10\^5 cells/kg ideal BW of the patient
223601194|NCT02652468|BIOLOGICAL|Rituximab|Given IV ONLY if graft B cell content exceeds 1 x 10\^5 cells/kg ideal BW of the patient
223601195|NCT02732431|OTHER|Sleep Symptom|Questionnaires, skin allergy test, overnight polysomnography
223601196|NCT03393949|DRUG|Methylprednisolone 1 mg•kg-1|Patients in Group M received methylprednisolone 1mg•kg-1
223601197|NCT03393949|DRUG|isotonic saline 1mg•kg-1|Patients in Group C received isotonic saline 1mg•kg-1
223601198|NCT01620762|DRUG|Cat-PAD|1 dose every 4 weeks
223749313|NCT00277069|DEVICE|Capecitabine|Capecitabine is administered at 1500mg/m2 PO qd in 2 divided doses day 1-14 q 21 days
223749314|NCT00277069|DRUG|Vinorelbine|Vinorelbine: 25mg/m2 IV over 10 minutes day 1, 8 q 21 days
223749315|NCT00802399|PROCEDURE|Partial Lacrimal Punctual Occlusion|Cauterization of the edge of all lacrimal punctum was carried out in all patients
223749316|NCT05381584|PROCEDURE|laparoscopy|laparoscopy will be done under anesthesia for management for cases with blind vagina
223749317|NCT05531435|DRUG|local anaesthetic injection|Local anesthetic injection of articaine 4% + adrenaline 1/100.000 (Septanest, Septodont, Saint Maur des Fossés, France) with 30G - 9 mm needle (DENTAL HI TEC, ZI de l'Appentière, Mazières-en-Mauges, France).
223601199|NCT01620762|DRUG|Placebo|1 dose every 4 weeks
223601200|NCT02836431|DRUG|Dexmedetomidine 1mcg/kg Intranasal|DEX 1 mcg/kg Intranasal
223601201|NCT02836431|DRUG|Dexmedetomidine 2mcg/kg Intranasal|DEX 2 mcg/kg Intranasal
223601202|NCT02836431|DRUG|Dexmedetomidine 1mcg Intravenous|DEX 1 mcg/kg Intravenously
223601203|NCT01298271|DRUG|propranolol|Starting from 20 mg daily, titrated weekly to decrease heart rate more than 25 % of baseline, administrated during the whole study period
223601204|NCT03521479|DRUG|Squaric Acid Dibutyl Ester|Repeat topical application of 2% and 0.5% squaric acid dibutyl ester (SADBE) in subjects with frequent herpes labialis (4 or more episodes in the previous 12 months).
223601205|NCT00057408|DRUG|olanzapine (Zyprexa)|Olanzapine tablets given po at a dosage of 2.5 - 20 mg per day for up to 12 weeks.
223601206|NCT00057408|DRUG|Placebo|Matching Placebo
223601207|NCT00705146|DEVICE|Comfort Cool thumb splint by North Coast Medical|Comfort Cool(TM) splint, a prefabricated neoprene splint, fit according to the participant's size (S, M, M+, L). Participants instructed to wear the splint when symptomatic, during manual tasks, and at night if desired. Used for 4 weeks. Treating therapists did not provide exercises or joint protection education until the final outcome measurement session at 9 weeks.
223601208|NCT00705146|DEVICE|Custom made thermoplastic & neoprene splint|The Hybrid splint was based on Pat McKee's custom-made splint design, fabricated from neoprene and 1.6 mm Rolyan Aquaplast Watercolors (Bollingbrook, IL). Participants were instructed to wear the splint when symptomatic, during manual tasks, and at night if desired. Splint was worn for 4 weeks. Treating therapists did not provide exercises or joint protection education until the final outcome measurement session at 9 weeks.
223601209|NCT02910102|DRUG|RVT-101 35 mg|RVT-101 once daily, oral, 35-mg tablets
223601210|NCT02910102|DRUG|Placebo|Placebo once daily, oral
223749318|NCT02353559|BEHAVIORAL|EASE|EASE includes psychotherapeutic (EASE-psy) and physical symptom control (EASE-phys) components.
223601211|NCT04585607|DEVICE|A medium cut-off dialyzer (Theranova) will be used for HDx.|"A medium cut-off dialyzer used for HDx (Theranova) must be implemented following current clinical practices guidelines and procedures at the hospital. No additional actions are required. General rules will be applied regarding dialysis prescription.~HD with MCO dialyzer (Theranova 400®, Baxter) vs. high-flux dialyzer (eg. Polyflux H, Baxter)"
223601212|NCT04585607|DEVICE|A synthetic high-flux dialyzer (Polyflux)|A synthetic high-flux dialyzer (Polyflux) used for hemodialysis must be implemented following current clinical practices guidelines and procedures at the hospital. No additional actions are required.
223601213|NCT00095173|DRUG|Abatacept|IV infusions, IV, 10mg/kg body weight, every 4 weeks, 6 months (unless a disease flare discontinued the patient earlier).
223601214|NCT00095173|DRUG|Placebo|IV infusions, IV, N/A, every 4 weeks, 6 months.
223601215|NCT00095173|DRUG|Abatacept|Solution, intravenous, Approximately 10 mg/kg fixed dose, based on subject's body weight; 500 mg for subjects weighing \< 60kg; 750 mg for subjects weighing 60 to 100 kg; and 1 gram for subjects weighing \> 100 kg, monthly
223601216|NCT02658773|DRUG|lidocaine-Prilocaine cream|
223601217|NCT02658773|DRUG|placebo cream|
223601218|NCT06300268|DEVICE|AdvaPro Sirolimus Eluting Coronary Stent System|Cardiac Stent
223601219|NCT03777319|DRUG|Spironolactone|Spironolactone will be prescribed for 6 months, after which the family and primary care physician will determine to either remain on spironolactone or transfer to prednisolone.
223749319|NCT06517147|DEVICE|Cryogenx cooling|During the cooling phase of both trials established field based cooling approaches e.g., temperate temperature water spraying (30°C, 5 mL.min-1), and air circulation (electric fan 2 m distance, 1.7 m.s-1 will be implemented. During the CRYOGENX cooling trial, the product will be affixed to the participant's torso in accordance with manufacturer's instructions and they will receive cooling via this intervention in addition to water spraying and air circulation. During the control visit, no intervention will be applied however water spraying and air circulation will be received.
223749320|NCT06517147|DEVICE|Regular cooling|During the cooling phase of both trials established field based cooling approaches e.g., temperate temperature water spraying (30°C, 5 mL.min-1), and air circulation (electric fan 2 m distance, 1.7 m.s-1 will be implemented. During the CRYOGENX cooling trial, the product will be affixed to the participant's torso in accordance with manufacturer's instructions and they will receive cooling via this intervention in addition to water spraying and air circulation. During the control visit, no intervention will be applied however water spraying and air circulation will be received.
223749321|NCT03883204|DRUG|Aripiprazole|Initial dose: 10 mg.
223749322|NCT03883204|DRUG|Risperidone|Initial dose: 2 mg.
223749323|NCT01231581|DRUG|GSK1120212|administered orally starting on day 1 followed by a continuous daily dosing of 2.0 mg
223601220|NCT03777319|DRUG|Prednisolone|Prednisolone will be prescribed for 6 months as the clinical standard of care.
223601221|NCT01622777|DRUG|Rosuvastatin|20 mg daily of oral rosuvastatin for 12 weeks
223601222|NCT01622777|DRUG|Placebo|100 mg of oral placebo with identical appearance, form and size than rosuvastatin, one tablet daily for 12 weeks
223601223|NCT03659877|BEHAVIORAL|Physical activity|Participants will undertake a variety of typical daily physical activities, such as laying down, sitting, walking whilst wearing accelerometers and gas analysis equipment.
223601224|NCT01745042|OTHER|Clinical exams|Physiological and biochemical tests; quality of life questionnaire; body composition measurement
223601225|NCT03676907|PROCEDURE|double layer suturation technique|in our clinic uterine incision is sutured by single layer suturation technique routinely. in this arm, we will use double layer suturation technique which is also accepted as valid suturation technique in obstetrics and gynecology textbooks
223601226|NCT00748319|OTHER|Detection of KIR receptor by RT PCR|Detection on biopsy cutaneous (3mm) and on blood sample of 30 ml
223601227|NCT02356848|BEHAVIORAL|Tailored Intervention (TI)|Participants in this arm will receive a comprehensive intervention based on the Transtheoretical Model and Prospect Theory with the counseling being delivered by health counselors using MI principles.
223749324|NCT01231581|DRUG|Gemcitabine|Intravenous gemcitabine infused over 30 minutes weekly for 7 weeks followed by one week of rest from treatment. Subsequent cycles will consist of 1000 mg/m2 intravenous infusion over 30 minutes on days 1, 8, and 15 followed by 1 week of rest from treatment for each 28-day treatment period.
223749325|NCT01231581|DRUG|Placebo|administered orally starting on day 1 followed by a continuous daily dosing of 2.0 mg
223749326|NCT03508856|DRUG|Ingenol Mebutate (Picato®) 0.015% gel|
223601228|NCT02356848|BEHAVIORAL|Current Practice (CP)|this group will receive calls and mailings focusing on providing education and prevention strategies for health conditions such as colorectal cancer, influenza, insomnia, vision, dementia, and oral disease.
223749327|NCT00889954|BIOLOGICAL|TGFBeta resistant HER2/EBV-CTLs|"Each patient will receive one injection of the TGFBeta resistant HER2/EBV-specific CTLs. Each pt will be followed for 6 weeks after the CTL infusion for evaluation of dose limiting toxicity (DLT).~Patients may receive up to six additional doses of the T cells at 6 to 12 weeks intervals."
223749328|NCT01044602|OTHER|Laboratory evaluations, sleep study|Fasting plasma glucose, liver function tests, chem-7, HOMA-IR, HBA1C, lipid profile, indirect calorimetry.
223749329|NCT01044602|OTHER|Best Medical Management|Standard of care.
223749330|NCT01044602|PROCEDURE|Roux-en-Y gastric bypass surgery|Surgical treatment.
223749331|NCT00576277|DRUG|AV411|
223601229|NCT02537184|PROCEDURE|Oral Clinical conditions|caries incidence assessment dental anxiety assessment
223601230|NCT00016991|DRUG|gefitinib|
223749332|NCT05855564|BEHAVIORAL|mindfulness matters|Classroom program will be provided to primary one students in eight primary schools and they will receive an 8 session mindfulness matters program, developed by Eline Snel, delivered by their teachers. Each session lasts for 30 minutes. The program includes mindfulness exercises, psychoeducation, discussion and sharing activities. For students with special needs, same programs will be delivered by teachers or social workers in small groups and each groups has 4 to 7 students. Program content is consistent with the classroom program.
223749333|NCT02142686|DEVICE|Filling pressure 80|After the hysteroscope is introduced into the uterine cavity, the filling pressure will remain at 80mm Hg.
223749334|NCT02142686|DEVICE|Filling pressure 50|After the hysteroscope is introduced into the uterine cavity, the filling pressure will be reduced to 50mm Hg.
223749335|NCT02142686|DEVICE|Filling pressure 30|After the hysteroscope is introduced into the uterine cavity, the filling pressure will be reduced to 30mm
223749336|NCT03647540|PROCEDURE|fluorescent laparoscopic radical gastrectomy|The gastrectomy for group F would be underwent by the fluorescence laparoscopy. All surgical procedures will be performed by the surgery team ,which is leaded by professor Wang Quan.
223749337|NCT03647540|PROCEDURE|traditional laparoscopic radical gastrectomy|The gastrectomy for group L would be underwent by the laparoscopy.All surgical procedures will be performed by the surgery team ,which is leaded by professor Wang Quan.
223749338|NCT04426565|BEHAVIORAL|motivational enhancement interview|Motivational interviewing is supported by over 200 randomized controlled trials across a range of target populations and behaviors including substance abuse, health-promotion behaviors, medical adherence, and mental health issues.
223749339|NCT04426565|BEHAVIORAL|the individual psychotherapy|It has been demonstrated to be an effective treatment for depression and has been modified to treat other psychiatric disorders such as substance use disorders and eating disorders. It is incumbent upon the therapist in the treatment to quickly establish a therapeutic alliance with positive countertransference of warmth, empathy, affective attunement and positive regard for encouraging a positive transferential relationship, from which the patient is able to seek help from the therapist despite resistance.
223749340|NCT04426565|BEHAVIORAL|the group psychotherapy|Group psychotherapy is a key component of milieu therapy in a therapeutic community. The total environment or milieu is regarded as the medium of therapy, all interactions and activities regarded as potentially therapeutic and are subject to exploration and interpretation, and are explored in daily or weekly community meetings. A form of group therapy has been reported to be effective in psychotic adolescents and recovering addicts.
224199942|NCT01432600|DRUG|Cyclophosphamide|"The dose escalation uses a standard 3x3 design: Ex: If none of the first 3 participants have a DLT, enter 3 participants at the next higher dose level. Once the maximum tolerated dose (MTD) of oral weekly cyclophosphamide in combination with pomalidomide and dexamethasone was determined, investigators proceeded with the second phase of the trial, a randomized phase II study comparing pomalidomide and dexamethasone with pomalidomide, dexamethasone and oral weekly cyclophosphamide delivered at the MTD determined in the phase I study."
224199943|NCT04425642|DRUG|Glucose/Amino acids|If indications for parenteral nutrition appear, it's dose will be calculated according patient's age and weight and will consist of glucose and amino acids solutions. To prevent potential complications of parenteral nutrition, the target dose will be reached by the third day of therapy. It will discontinued, when the patient oral food intake will be more than 60% for three consecutive days.
223601231|NCT03684382|OTHER|NeW-I group|A 5-week intervention offered to parents of children with chronic life-threatening illness using an internet-based narrative approach with life review elements. After completion of the first four weeks of the intervention, participants will receive a 'legacy' document which is a compiled and edited document of their narrative expression during the first four weeks. This legacy document is structured in a manner that enables participants to find a sense of spiritual well-being and hope in their experience of caring for their child through examination of past experiences and achievements as well as future aspirations.
223601232|NCT02089126|DRUG|Gemigliptin/Glimepiride combination|
223601233|NCT04770792|OTHER|2% chlorhexidine gluconate with mineral trioxide aggregate.|2% chlorhexidine gluconate with mineral trioxide aggregate.
223601234|NCT04770792|OTHER|Mineral trioxide aggregate.|Mineral trioxide aggregate.
223601235|NCT05266391|OTHER|subacromial corticosteroid injections|Patients with SAIS whose application of corticosteroid in their injections were the same in terms of type and dose (1 ml betamethasone dipropionate + betamethasone sodium phosphate).
223601236|NCT02484222|DRUG|Fentanyl|Before the end of the procedure, spontaneous respiratory was recovered. All the patients were given 1 mcg/kg fentanyl i.v. after the end of the procedure.
223601237|NCT05861661|OTHER|The study do not include an intervention|The study do not include an intervention
223601238|NCT04715971|DIAGNOSTIC_TEST|portable ultrasound bladder scan|A post-void residual volume was measured using a Verathon BladdersScan BVI 3000.
223749341|NCT04426565|BEHAVIORAL|the family therapy|"According to a 2004 French government study conducted by French Institute of Health and Medical Research, family and couples therapy was the second most effective therapy after Cognitive behavioral therapy. The study used meta-analysis of over a hundred secondary studies to find some level of effectiveness that was either proven or presumed to exist. Of the treatments studied, family therapy was presumed or proven effective at treating schizophrenia, bipolar disorder, anorexia and substance dependence."
223749342|NCT06184425|PROCEDURE|Dural Puncture Epidural technique using pencil-point 25G Whitacre needle|\- DPE technique was performed in the sitting position at the L3/4 or L4/5 interspace via the midline approach using a 17-gauge Touhy needle and a loss of resistance to saline technique, then the dura was punctured with a 25-gauge pencil point Whitacre spinal needles using a needle-through-needle technique, and spontaneous flow of cerebrospinal fluid was confirmed, then the spinal needle was removed and a flexible 19-gauge, spring closed-tip catheter was inserted 5 cm into the epidural space toward the cranial side.
223749343|NCT06184425|PROCEDURE|Dural Puncture Epidural technique using pencil-point 27G Whitacre needle|\- DPE technique was performed in the sitting position at the L3/4 or L4/5 interspace via the midline approach using a 17-gauge Touhy needle and a loss of resistance to saline technique, then the dura was punctured with a 27-gauage pencil point Whitacre spinal needles using a needle-through-needle technique, and spontaneous flow of cerebrospinal fluid was confirmed, then the spinal needle was removed and a flexible 19-gauge, spring closed-tip catheter was inserted 5 cm into the epidural space toward the cranial side.
223749344|NCT03616912|DRUG|Baricitinib|Administered orally.
223749345|NCT03616912|DRUG|Placebo|Administered orally.
223749346|NCT03897400|OTHER|AMH levels in young women with crohn's disease will be considered.|Ovarian Reserve in Young Women of Reproductive Age with Crohn's Disease;Blood will be taken from both the study and control groups and the AMH level will be evaluated.
223749347|NCT04512248|BEHAVIORAL|Quit and Stay Quit Monday Model|Participants randomized to the study intervention will receive: (1) 2 telephone smoking cessation coaching calls; (2) enrollment into SmokefreeTXT; and (3) enrollment in the iquitmonday.org weekly email newsletter. The telephone coaches will ask these participants to identify a future Monday as their quit date and provide coaching to achieve a Monday quit. The coaches will also enter the selected Monday as the patient's quit day when enrolling the patient into SmokefreeTXT.
223749348|NCT02935465|BEHAVIORAL|Mindfulness-Oriented Recovery Enhancement (MORE)|Mindfulness-Oriented Recovery Enhancement (MORE) is a group behavioral intervention that unites mindfulness training, cognitive reappraisal, and positive psychological principles into an integrative intervention strategy targeting mechanisms of pain and opioid misuse.
223749349|NCT02935465|BEHAVIORAL|Support Group|A conventional support group will allow participants to express emotions, share experiences, and receive social support under the guidance of a skilled therapist.
223749350|NCT01414569|DRUG|Dexamethasone|Singe dose preoperatively in 100 ml saline intravenously
223749351|NCT02245256|DRUG|Precedex|infusion of 0.1mcg/kg/hr of precedex
223749352|NCT02245256|DRUG|placebo control|placebo
223749353|NCT01995695|BIOLOGICAL|Live attenuated H7N9 A/Anhui/13 ca influenza virus vaccine|Participants will receive approximately 10\^7.0 focus forming units (FFU) of the live attenuated H7N9 A/Anhui/13 ca influenza virus vaccine. The vaccine will be delivered by an Accuspray nasal spray device (0.25 mL per nostril for a total of 0.5 mL of vaccine).
223749354|NCT01995695|BIOLOGICAL|Inactivated subvirion H7N9 influenza vaccine|Participants will receive 30 mcg of the inactivated subvirion H7N9 vaccine by intramuscular injection.
223749355|NCT02867540|OTHER|MRI enterography|
223749356|NCT04242888|OTHER|pragmatic manual therapies|three of the intervention are novel and the rest of the interventions are in practice but seldom used to treat the shoulder disorder.
223749357|NCT02410499|DRUG|MLN1202 Placebo|MLN1202 placebo-matching solution for SC injection
223749358|NCT02410499|DRUG|MLN1202|MLN1202 solution for SC injection
223749359|NCT06440031|BEHAVIORAL|CaMaPi|CaMaPi is a manually assisted brief psychological intervention that is based on the principles of Cognitive Behaviour Therapy (CBT). The intervention includes psycho-education and a comprehensive cognitive behavioural assessment of the suicidal ideation and self-harm attempt using virtual stories of four young people to be delivered in 8-10 sessions for over three months
223749360|NCT06440031|OTHER|TAU|Treatment as Usual (TAU) is routine care, such as diagnosis, assessment, psychotherapy, monitoring and any form of intervention (e.g., medication prescription) available at the collaborating service.
223749361|NCT00957203|DRUG|Istradefylline|Oral istradefylline (KW-6002) 20 or 40 mg once daily
224311286|NCT03796039|BEHAVIORAL|Standing|Standing for an additional 100 minutes per week; 20 minutes Monday-Friday
223512257|NCT03683199|PROCEDURE|Rhinoplasty|"The cleft lip rhinoplasty will be performed under general anesthesia.~1: 100,000 epinephrine will be infiltrated in the columellar incision and in the septum.~Open approach rhinoplasty will be used. A step ladder incision placed at the patient's columella, and continued with infra-cartilaginous incision.~The columellar skin flap along with the nasal tip skin will be dissected from the lower lateral cartilages.~Harvesting of the septal cartilage, to be used as spreader graft and columellar graft. Correction of the septal deviation.~Lengthening of the columella on the expense of the ala. Correction of the nasal tip by suturing techniques and by cartilage grafts."
223512258|NCT06054880|DRUG|Indigotindisulfonate sodium 0.8%|Experimental contrast dye that is commonly used as a visualization aid in pelvic and abdominal surgeries and for various diagnostic procedures in medical practice.
223512259|NCT06054880|OTHER|Saline injection 0.9%|Placebo
223512260|NCT05330546|PROCEDURE|Densah burs|using Densah burs to prepare implant osteotomy
223512261|NCT05330546|PROCEDURE|Ridge expansion screws|using Ridge expansion screws to prepare implant osteotomy
223512262|NCT04648241|BIOLOGICAL|TBE vaccine 0.5 mL|TBE vaccine 0.5 mL (intramuscular injection).
223512263|NCT04648241|BIOLOGICAL|TBE vaccine 0.25 mL|TBE vaccine 0.25 mL (intramuscular injection).
223512264|NCT02057666|DRUG|Tasquinimod|A patient initially received a 0.25 mg/day dose which was then titrated through 0.5 mg/day (from Day 15) to a maximum of 1 mg/day (from Day 29). If tolerability issues arose at 0.5 or 1 mg/day, patients had their dose reduced to 0.25 or 0.5 mg/day, respectively.
223512265|NCT02057666|DRUG|Placebo|Placebo capsules were identical to tasquinimod capsules in appearance and excipients but excluded the active compound (tasquinimod).
223601239|NCT03406117|DRUG|HAT1|All the participants will have the test product applied to the appropriate test sites by trained study staff. The study was conducted on a mixed population comprising of normal subjects, and patients with atopic dermatitis and active plaque psoriasis.
223601240|NCT03406117|OTHER|Saline Solution|Only for CIT portion of the study. Participant will have product applied topically on site by the trained study staff.
223601241|NCT04001283|DRUG|Sodium Nitrite|Intravenous drug infusion
223601242|NCT04001283|DRUG|0.9% Sodium-chloride|Matched placebo
223749362|NCT02848677|BEHAVIORAL|Nutritional counseling|Nutritional counseling implemented by a dietitian for a low sodium diet rich in fruits, vegetables, low fat dairy foods, and low in processed foods.
223749363|NCT02848677|BEHAVIORAL|usual care|usual care of hypertensive patients.
223749364|NCT06127082|DEVICE|Echocardiography|Do echocardiography to obese patient
223749365|NCT06332716|OTHER|Based on diagnostic and treatment guidelines/expert consensus, as well as clinical treatment experience, it is recommended that no more than 9 drugs be used for drug sensitivity testing each time.|Based on diagnostic and treatment guidelines/expert consensus, as well as clinical treatment experience, it is recommended that no more than 9 drugs be used for drug sensitivity testing each time. The sending doctor can choose from the following relevant treatment drugs and confirm with the responsible researcher for drug sensitivity testing.
223749366|NCT04707261|DRUG|Dapagliflozin|Participants will receive dapagliflozin 10 mg once daily
223749367|NCT04707261|DRUG|Placebo|Participants will receive placebo 10 mg once daily
223749368|NCT02972216|DRUG|Nolbaxol|
223749369|NCT02972216|DRUG|Taxotere|
223749370|NCT02972216|DRUG|cisplatin|
223749371|NCT02967250|DRUG|ursodeoxycholic acid|Subjects will be provided \~50mg/kg/day (based on the use of 250 and 500mg capsules) of UDCA to be divided into 3 equal daily doses and titrated up over \~2 weeks to a stable dose for 4 weeks.
223749372|NCT02782416|OTHER|Examination of latent tuberculosis|
223601243|NCT00153465|BEHAVIORAL|Motivational intervention, parent training|
223601244|NCT00234169|DRUG|VTP195183|"VTP195183: 60mg/m2 orally daily G-CSF: 10mcg/kg/day subcutaneously Provision is made for dose reduction of VTP195183 in the event of unexpected dose-limiting toxicities G-CSF10mcg/kg/day will commence on day 1 and will continue until the peripheral blood (PB) CD34+ count falls below baseline, or below 5 x 106/L, whichever happens first.~Patients will be treated with VTP195183 alone at 60mg/m2/day from day 1 to day 7. On day 8 VTP195183 will be continued and G-CSF10mcg/kg/day will be added. VTP195183 plus G-CSF will continue until the peripheral blood (PB) CD34+ count falls below baseline, or below 5 x 106/L, whichever happens first."
223601245|NCT04218591|OTHER|PRP|Platelet rich plasma
223601246|NCT04218591|OTHER|Placebo|Saline
223601247|NCT04132596|DEVICE|Transcutaneous spinal cord stimulation|Electrical stimulation of the spinal cord via transcutaneous hydrogel electrodes
223601248|NCT04132596|OTHER|Activity Based Therapy|Physical therapy
223601249|NCT05239767|DRUG|NSAID|We will administer oral NSAIDs
223601250|NCT04479124|DIAGNOSTIC_TEST|COVID-19 PCR|Nasopharyngeal samples were analyzed by PCR for the detection of Novel Coronavirus 2019 DNA
223749373|NCT02134132|BIOLOGICAL|Platelet Gel|Application of platelet gel in patients suffering from diabetic foot ulcers.
223749374|NCT02134132|OTHER|Placebo|The patients with Diabetic foot ulcer who receive placebo instead of PL Gel.
223601251|NCT04398550|OTHER|Specific Carbohydrate Diet|Diet restricts all but simple carbohydrates and allows for inclusion of fresh fruits, vegetables, unprocessed meats, and homemade lactose-free cheese and yogurt.
223749375|NCT02510794|DRUG|Ranibizumab|Ranibizumab will be administered at dose of 0.5 mg monthly ITV injections of 10-mg/mL formulation or delivered through the implant with three different formulations.
223749376|NCT01649375|DRUG|Secukinumab (75 mg)|Secukinumab 75 mg s.c.
223749377|NCT01649375|DRUG|Placebo|Placebo
223749378|NCT01649375|DRUG|Secukinumab (150 mg)|Secukinumab 150 mg s.c.
223749379|NCT04257812|DRUG|Ceftolozane/tazobactam|"The dose will be 1g ceftolozane + 0,5 g tazobactam every 8 hours or 2 g ceftolozane + 1 g tazobactam, it´s recommended to use this last dose regimen in patients with pneumonia or septic shock of any focus.~The patients will be followed as it´s done habitually. There will be done infection focus cultures and others according to usual clinical practice. It´ll be determined the clinical response and mortality in the days 14 and 30 after the beginning of the medicine, respectively.~The Ceftolozane-Tazobactam levels determination will always be made in state of equilibrium (after the third dose). Four samples will be collected:~1. Just before the antibiotic infusion.~2. One hour after the antibiotic infusion.~3. Three hours after the antibiotic infusion.~4. Six hours after the antibiotic infusion."
223749380|NCT04982666|OTHER|Whole-Food, Plant-Based Diet|This diet is focused on nutritional needs with natural, minimally-processed plant foods.
223749381|NCT04982666|OTHER|FODMAP Diet|An elimination diet of fermentable, oligosaccharides, disaccharides, monosaccharides and polyols
223749382|NCT04939727|OTHER|OUD-CDS + Suicide Risk Model associated CDS|Access to OUD-CDS + Suicide Risk CDS
223601252|NCT04398550|OTHER|Mediterranean Diet|Diet rich in whole vegetables, fruit, plant-based protein, and olive oil, with moderate amounts of seafood and dairy, and limited in sugar-sweetened goods, red meat, and nutrients like heme and sodium.
223601253|NCT01452581|OTHER|Red blood cell transfusion|Maximal 2 units of packed red blood cells given one at a time on the first postoperative day. Evaluation of primary outcome is done after administration of each unit.
223601254|NCT01452581|DRUG|Voluven|Infusion of up to 2 x 280 ml colloid (6% Hydroxyethyl Starch 130/0.4 in 0.9% Sodium Chloride). 280 ml at a time. Evaluation of primary outcome after each intervention.
223601255|NCT00315016|DRUG|eplerenone|active comparator
223601256|NCT00315016|DRUG|fosinopril|doubling of fosinopril dose
223749383|NCT01124604|DRUG|Tapentadol Hydrochloride|Tapentadol hydrochloride extended release (ER) tablets 25 to 250 milligram (mg) will be administered orally twice daily for 12 weeks. Dose will be adjusted as per Investigator's discretion.
223749384|NCT01124604|DRUG|Placebo|Placebo matched to tapentadol hydrochloride ER tablets 25 to 250 mg will be administered orally twice daily for 12 weeks. Dose will be adjusted as per Investigator's discretion.
223601257|NCT00315016|DRUG|placebo|placebo (double dummy)
223601258|NCT01500304|PROCEDURE|Minimally invasive inguinal lymph node dissection|Operative intervention will be a minimally invasive inguinal lymphadenectomy, which is a three trocar technique to the inguinal dissection, that respects the same anatomic boundaries as the conventional open procedure
223601259|NCT00330681|DRUG|MCI-186|Two ampoules (60 mg) of MCI-186 injection are intravenously administered once a day, for successive 14 days, followed by 14 days observation period (first cycle). Then treatment (10 days' administration during 14 days) - observation (14 days) cycle is repeated five times (2nd-6th cycles).
223601260|NCT00330681|DRUG|Placebo of MCI-186|Two ampoules of placebo injection are intravenously administered once a day, for successive 14 days, followed by 14 days observation period (first cycle). Then treatment (10 days' administration during 14 days) - observation (14 days) cycle is repeated five times (2nd-6th cycles).
223601261|NCT03976206|BIOLOGICAL|Very small embryonic-like stem cell|We carried out the subdermal application of VSELs with a 1-mL syringe (volume, 0.4 mL) coupled to a 30-gauge needle, in the left preauricular area (1-cm2 area), 2 cm distal from the tragus
223601262|NCT04038450|OTHER|No intervention|No interventions separated the groups. Each group reviewed pictures and wrote down their estimated ROM of the joint pictured.
223601263|NCT01195324|DRUG|Canagliflozin/Warfarin|Treatment A: Tablets, oral, canagliflozin 300 mg, once daily for 12 days and canagliflozin 300 mg + warfarin 30 mg, single dose on Day 6 followed 14 days later by Treatment B: Tablets, oral, warfarin 30 mg, single dose on Day 1
223601264|NCT01195324|DRUG|Canagliflozin/Warfarin|Treatment B: Tablets, oral, warfarin 30 mg, single dose on Day 1 followed 14 days later by Treatment A: Tablets, oral, canagliflozin 300 mg, once daily for 12 days and canagliflozin 300 mg + warfarin 30 mg, single dose on Day 6
223601265|NCT04698993|DIAGNOSTIC_TEST|Dräger Antigen Test SARS-CoV-2|Collection of patient samples using the Dräger sample collector with subsequent test reading via the Dräger Antigen SARS-CoV-2 Test
223749385|NCT01856790|DEVICE|ePID closed loop system|Insulin pump controlled by closed loop unit and algorithm
223749386|NCT01856790|DRUG|liraglutide|Liraglutide is a long-acting analog of human glucagon like peptide-1 (GLP-1) that works as a GLP-1 receptor agonist
223512266|NCT06244199|BEHAVIORAL|T2CR Intervention|The T2CR intervention entails two phases. T2CR Phase 1 (Assess and Plan) is a program that occurs during or shortly after hospital discharge that includes completion of a comprehensive risk assessment, development of strategies to address identified risks while restoring function through education regarding living a healthy lifestyle and familiarization and practice of exercise training techniques. T2CR Phase 2 (Implementation and Support) entails a HBCR program that is based on the Promising Practices HBCR but further enriched by insights and strategies developed in T2CR Phase 1 and which also incorporates techniques that maximize the effectiveness and efficiency of exercise training.
223512267|NCT06244199|OTHER|Usual Care|Participants will receive usual care following an acute heart event that is recommended by their providers, which may include Promising Practices Home-Based Cardiac Rehabilitation (aka Usual HBCR) at both sites or site-based CR at VAPHS.
223601266|NCT05248139|DRUG|Intraoperative delivery of medication, Kenalog (Triamcinolone)|Subconjunctival triamcinolone acetonide 4 mg (0.4 mL of 10 mg/mL solution), single-dose injected 6-8 mm inferior to the inferior limbus with a bent 27-gauge needle at completion of cataract surgery.
223601267|NCT05248139|DRUG|Topical post-operative eyedrops, Prednisolone acetate|Standard of care Presnisolone acetate 1% ophthalmic drop taper: 4 times per day for first week, then tapering one drop per week for 3 additional weeks. Discontinued after 4 weeks.
223601268|NCT02578186|DRUG|Diphenhydramine Hydrochloride|30 mL at bedtime
223601269|NCT02578186|DRUG|Placebo|30 mL at bedtime
223601270|NCT04487925|DRUG|A single Gonadotropin-Releasing Hormone (GnRH) antagonist corifollitropin alfa (CFA) stimulation|CFA will be administered in combination with Follitropin beta.
223601271|NCT04487925|DRUG|Up to three modified natural cycles with Follitropin beta.|Follitropin beta in a low dose will be given.
223601272|NCT00527904|DRUG|PN400 (VIMOVO)|Subjects are instructed to take 2 tablets a day, one in the morning and one in the afternoon/evening. The morning tablet should be taken with water, on an empty stomach 30 to 60 minutes before breakfast, or the first meal. The afternoon/evening tablet should be taken with water, on an empty stomach 30 to 60 minutes before dinner. Tablets should be swallowed whole and not broken, crushed or chewed.
223601273|NCT00527904|DRUG|PN 400 (VIMOVO)|500 mg delayed-release naproxen/20 mg immediate release esomperazole dosed twice daily for 12 months
223601274|NCT06514404|OTHER|observational study|Observational study of the effects on anxiety and empathy of personality the situation of start academic year in health sciences
223601275|NCT06191172|BEHAVIORAL|Reminiscence Therapy|Old objects and pictures of old objects that facilitate remembering about weekly topics will be taken to the institution by the researcher, and individuals within the scope of the research will be asked for their own photographs, if any.
223601276|NCT06191172|BEHAVIORAL|Montessori application|Drill toy Matching puzzle Chickpeas, rice sorting Lock, zipper Counting beans Making a tie Taking and pouring food with a scoop
223601277|NCT06191172|BEHAVIORAL|Environmental Layout|Dining place Music Lighting Heat
223601278|NCT06191172|BEHAVIORAL|Application of contrast ergonomic special equipment|White tablecloth Beveled red blue and yellow blue plate Ergonomic yellow and red fork, spoon and cup
223601279|NCT01122615|DRUG|Sunitinib|12.5 to 50 mg orally (PO) daily x 14 days, 7 days off for 21 day cycle.
223601280|NCT01122615|DRUG|Temsirolimus|6 to 25 mg intravenously (IV) over 30 minutes once weekly for 21 day cycle.
223749387|NCT03938194|PROCEDURE|Aquablation|a novel minimally invasive water ablation therapy combining image guidance and robotics for the targeted and heat-free removal of prostate tissue
223749388|NCT01776788|DRUG|insulin lispro injection, exenatide injection|First, Patients in the exenatide group will receive short-term continuous subcutaneous insulin (CSII)therapy. The doses will be titrated every day in order to attain the glycaemic goal which is defined as a fasting capillary blood glucose of less than 6.1 mmol/L and capillary blood glucose at 2 h after each of three meals of less than 8.0 mmol/L. Treatments will be maintained for 2 weeks after the glycaemic target will be reached. Then, patients will Sequential be treated with 5 mcg bid for 4 weeks and then 10 mcg bid for 8 weeks. After interventions will be stopped, patients will be instructed to continue diet and physical exercise only and will be followed-up with glycaemic monitoring monthly
223749389|NCT01776788|DRUG|insulin lispro injection|Patients in the control group will receive insulin with an insulin pump. The doses will be titrated every day in order to attain the glycaemic goal. Treatments will be maintained for 2 weeks after the glycaemic target will be reached. Then interventions will be stop, patients will be instructed to continue diet and physical exercise only and will be followed-up with glycaemic monitoring monthly.
223749390|NCT00733109|PROCEDURE|Excision of the lesion|Surgery with Large Loop Excision of Transformation Zone (LLETZ)
223749391|NCT00733109|OTHER|Follow-up for spontaneous regression of the lesion|Follow-up at last 12 months
223749392|NCT01582997|DRUG|GSK2118436|Dose escalation with GSK2118436 may proceed until the overseas recommended phase III dose.
223507513|NCT04086615|DEVICE|NMES and exercise supplemented with low BFR|"The BFR-NMES-Exercise training consists of 20-min sessions performed concurrently with NMES and exercise in the clinic 2x a week for a total of 18 in-clinic sessions. Using the Delfi PTS Personalized Tourniquet System for Blood Flow Restriction at 20mmHG venous pressure (no blood flow restricted), the participant performs 4 exercise sets of 60 repetitions (5 seconds ea) for 5 minutes, with a 1-minute BFR deflation between sets. The standard exercise rehabilitation protocol for PFPS combines open chain and closed chain quadriceps strengthening exercises: active straight leg raises, quadriceps straightening, step up, and squats. NMES training consists of 20-minute sessions: a 2-min warm-up, 15-min work-out, and a 3-min cool down using the KneeHAB® XP Multipath stimulation system which changes the current pathways between the electrodes for preset periods within each pulse, allowing for higher stimulation intensities that maximizes muscle fibre recruitment and minimizes muscle fatigue."
223507514|NCT00564070|BEHAVIORAL|Enhanced treatment as usual plus adherence training|The single-session life-steps treatment targets informational, problem solving, and cognitive-behavioral steps that are geared toward improving medication adherence and diabetes self-management.
223507515|NCT00564070|BEHAVIORAL|Enhanced treatment as usual plus CBT-AD|The multiple-session CBT treatment is given after completion of the life-steps session. The CBT sessions focus on treatment of depressive symptoms as well as adherence to diabetes self-care.
223507516|NCT05548777|DRUG|Andexanet alfa|Andexanet alfa
223507517|NCT05548777|DRUG|4F-PCC|Four-Factor Prothrombin Complex Concentrate (4F-PCC)
223507518|NCT01018056|DRUG|D-serine|The dosage schedule will be flexible with a maximum dose for each subject being 30 mg/kg/day. In any individual subject, dose escalation may proceed more slowly, or the dose may be reduced if necessary. At the 4 week visit, if an additional dosage increase is prescribed by Dr Singer, the pharmacy will provide an additional vial of capsules labeled as study drug, but containing either 250 or 500 mg tablets of D-serine or placebo; capsule content to be determined by patient's weight. No changes in dosage will be made during the final week of treatment.
223507519|NCT01018056|DRUG|Riluzole|The starting dose of riluzole will be 50 mg for one week; administered as one capsule (50) every morning. Dosage schedules will be flexible. If needed for tic suppression, the dose will be increased weekly by 50 mg and given in BID doses. The maximum dose will be 200 mg/day (administered as 2 capsules BID). In any individual subject, dose escalation may proceed more slowly, or the dose may be reduced if necessary. At the 4 week visit, if an additional dosage increase is prescribed by Dr Singer, the pharmacy will provide an additional vial of 14 capsules labeled as study drug, but containing placebo capsules. No changes in dosage will be made during the final week of treatment.
223507520|NCT01018056|DRUG|Placebo|Placebo tablets will be formulated in look-alike capsules. At the 4 week visit, if an additional dosage increase is prescribed by Dr Singer, the pharmacy will provide an additional vial of 14 capsules labeled as study drug, but containing additional placebo capsules.
223507521|NCT06637384|DRUG|Hyaluronic Acid (HA)|Gengigel Gingival Gel 20ml, Ricerfarma, Milan, Italy
223507522|NCT06637384|DRUG|Corticosteroid Injection|Hydrocortisone Sodium Succinate, Cirin Pharmaceuticals, Pakistan
223507523|NCT03142334|BIOLOGICAL|Pembrolizumab|IV infusion
223507524|NCT03142334|DRUG|Placebo|IV infusion
223507525|NCT06639737|PROCEDURE|preoperative stroke volume optimization|Stroke volume optimization using transthoracic echocardigraphy (sub aortic velocity time integral) before induction of total intravenous anesthesia. Fluids bolus of 250 ml of cristalloids will be successively administered until the sub aortic velocity time integral increase will be \< 10%
223507526|NCT06639737|PROCEDURE|Post induction stroke volume optimization|Optimization of stroke volume following induction of general anesthesia using oesophageal stroke volume measurement. 250 ml bolus of cristalloids succesively administered until the stroke volume increase \<10%
223507527|NCT05922098|OTHER|Texture Modified Foods Manual for chewing dysfunctions in older adult|Texture Modified Foods Manual for chewing dysfunctions (including IDDSI)
223507528|NCT06539260|DRUG|Vitamin D|Take 400 units of vitamin D3, twice daily, for a duration of 3 months.
223507529|NCT06539260|DRUG|Placebo|Take a placebo that is identical in appearance and weight to 400 units of vitamin D3, twice daily, for a duration of 3 months.
223507530|NCT06440746|DRUG|Subcutaneous (SC) injections of OKZ 64 milligrams (mg) every 4 weeks (q4w), one injection of 0.4 millilitre (mL)|Olokizumab is a sterile solution for subcutaneous injection in a 2-mL clear Type I glass vial, containing a target fill volume of 0.5 mL (for withdrawal of no less than 0.4 mL) of olokizumab drug substance at a concentration of 160 milligrams (mg)/mL.
223507531|NCT06440746|DRUG|SC injections of Placebo every 4 weeks (q4w), one injection of 0.4 mL|Placebo (sodium chloride 0.9 %) does not contain any active pharmaceutical ingredients. Placebo will be supplied in 2-mL, 5-mL, or 10-mL ampoules made of low-density polyethylene or polypropylene.
223507532|NCT06248177|DIETARY_SUPPLEMENT|Probiotic|Probiotic capsules
223507533|NCT06248177|DIETARY_SUPPLEMENT|Placebo|Placebo capsules
223507534|NCT02828085|BIOLOGICAL|Nasal swab|Nasal swab will be performed in addition to the routine diagnosis visit in order to determine the diagnosis of infective pericardite with a more specific technique: PCR
223507535|NCT01991535|DEVICE|Spontaneous Ventilation Mode|"Respiratory rate and duration of inspiration are controlled by the patient.~Device model: Stellar 150® (ResMed, Australia)."
223507536|NCT01991535|DEVICE|Controlled Ventilation Mode|"Ventilator maintains the positive end-expiratory pressure until the patient inspires. At that point, the ventilator reaches the support pressure in a predetermined time. The patient fixes the respiratory rate and the duration of inspiration, triggering all the cycles.~Device model: Stellar 150® (ResMed, Australia)."
223749393|NCT04091646|DRUG|Roflumilast Foam 0.3%|Roflumilast foam for topical application.
223749394|NCT04091646|DRUG|Vehicle foam|Vehicle foam for topical application.
223749395|NCT03012113|DRUG|Mirabegron|
223749396|NCT03012113|OTHER|Short term mild cooling|
223749397|NCT03012113|DRUG|Placebo Oral Capsule|
223749398|NCT03068975|DRUG|Alvimopan|Patients who sustained abdominal trauma with resection of bowel and anastomosis will receive Alvimopan ( post operative dose only) and will monitor for post operative ileus.
223749399|NCT03068975|DRUG|Placebo|Patients who sustained abdominal trauma with resection of bowel and anastomosis will receive the Placebo Pill (post operative dose only) and will monitor for post operative ileus.
223749400|NCT02224911|DEVICE|Laser Interstitial Thermal Therapy|
223749401|NCT01889784|DEVICE|Phototherapy through light emitting diode (LED) - 150J|The near-infrared radiation by light emitting diode (LED) will be performed with a cluster multi-diode arranged in an array of 34x18 cm containing 50 LEDs (GaAlAs, 850 nm). The phototherapy will be applied bilaterally on femoral quadriceps and triceps surae muscles during 40 seconds with 3J of total energy for each diode and 150 J of total energy delivery to muscle. Neither subject nor evaluators will known if LED was effective or placebo during data collection. A hidden button in the LED device is employed to ensure the double-blind procedure. This button allows selecting placebo or effective emission of near-infrared radiation while the time display is working. This button will be selected by a researcher who just participated of randomization procedure and LED application and had no access to data collection.
223749402|NCT01889784|DEVICE|Placebo phototherapy - 150J|The near-infrared radiation by light emitting diode (LED) will be performed with a cluster multi-diode arranged in an array of 34x18 cm containing 50 LEDs (GaAlAs, 850 nm). The phototherapy will be applied bilaterally on femoral quadriceps and triceps surae muscles during 40 seconds with 3J of total energy for each diode and 150 J of total energy delivery to muscle. Neither subject nor evaluators will known if LED was effective or placebo during data collection. A hidden button in the LED device is employed to ensure the double-blind procedure. This button allows selecting placebo or effective emission of near-infrared radiation while the time display is working. This button will be selected by a researcher who just participated of randomization procedure and LED application and had no access to data collection.
224075279|NCT00525759|DRUG|5-FU, Epirubicin, Cyclophosphamide, Docetaxel, Zoledronic acid|3 cycles of FEC q3w, followed by 3 cycles of docetaxel q3w FEC: 5FU 500mg/m2 intravenous bolus D1, Epirubicin 100mg/m2 intravenous bolus D1, Cyclophosphamide 500mg/m2 intravenous bolus D1) every 21 days Docetaxel: (100mg/ m2 intravenous infusion) every 21 days Zoledronic acid: 4mg intravenous infusion Day 2, AFTER FIRST CYCLE CHEMOTHERAPY ONLY
224311287|NCT05234372|BEHAVIORAL|mivacunaLA|Based on their stated language preference in the baseline survey, eligible participants in the program received a text message or email twice a week (Monday and Wednesday at noon). The short text messages (\<160 characters in length) provided a link to a 2-3 min video (Monday) and a short educational content around 500 words (Wednesday). Content was organized by week with the following topics: 1) what is COVID-19 and how COVID-19 vaccines works, 2) COVID-19 vaccine myths and facts, 3) COVID-19 vaccine safety and efficacy in children, and 4) how to obtain COVID-19 vaccines in your community. Every week we provided information about how to get vaccines with links to local vaccine sites \& resources.
223601281|NCT05889637|DIAGNOSTIC_TEST|Gastric ultrasound|Patient will be scanned first in the supine position and then in the right lateral decubitus position. The ultrasound probe will be placed in a sagittal plane in the epigastric region at the left subcostal margin and then will be moved past the midline in a fan like manner to the right subcostal region. Qualitative and quantitative assessments will be done.
223601282|NCT00959556|OTHER|laboratory biomarker analysis|
223601283|NCT01154426|OTHER|Diagnostic Laboratory Biomarker Analysis|Correlative studies
223601284|NCT01154426|DRUG|Gemcitabine Hydrochloride|Given IV
223601285|NCT01154426|OTHER|Pharmacological Study|Correlative studies
223601286|NCT01154426|DRUG|Veliparib|Given orally
223601287|NCT05284344|DRUG|Anti-Diabetics|The anti-diabetic treatments include insulin glargine, insulin aspart, GLP-1 receptor agonist, DPP-4 inhibitor, SGLT-2 inhibitor, metformin, sulfonylureas and/or gliclazide. Therapeutic dose of each drug follows recommendation by the treating doctor.
223601288|NCT00003354|PROCEDURE|conventional surgery|
223601289|NCT00003354|PROCEDURE|laparoscopic surgery|
223601290|NCT02337881|DRUG|nifedipen|The protocol for nifedipen in our units consists of 20 mg orally stat, followed by 10 mg orally every 6-8 hours for 48 to 72 hours as needed
223601291|NCT02337881|DRUG|Sildenafil|sildenafil citrate will be administered vaginally in a dose of 25mg at 8 hourly intervals and both medications will be continued for 48-72 hours as indicated.
223601292|NCT00428389|DRUG|Rivastigmine 5 cm^2 transdermal patch|Rivastigmine 5 cm\^2 patch size, loaded with 9 mg and providing 4.6 mg rivastigmine per 24 hours.
223601293|NCT00428389|DRUG|Rivastigmine 10 cm^2 transdermal patch|Rivastigmine 10 cm\^2 patch size loaded with 18 mg and providing 9.5 mg rivastigmine per 24 hours.
224075280|NCT01467492|DRUG|Telaprevir|Tablet
224075281|NCT01467492|DRUG|Ribavirin|Tablet
224075282|NCT01467492|BIOLOGICAL|Pegylated Interferon Alfa-2a|Subcutaneous Injection
224311288|NCT01333774|DRUG|Glucobay (Acarbose, BAYG5421)|Patients treated with acarbose tablets under the real-life setting. Dosing regimen customised to the needs of each participating patient according to the investigators assessment
224311289|NCT04008628|DRUG|Nitrous Oxide|Inhalation of a 50%/50% nitrous oxide/oxygen mixture (Kalinox®)
223601294|NCT04582955|DRUG|Chidamide in combination with chemotherapy|Chidamide, orally,20mg at day 0,4,7,11,21,every 3 weeks; in combination with Docetaxel 75mg/m2,intravenous infusion，at day1 every 3 weeks，and Epirubicin 75mg/m2, intravenous infusion，at day1 every 3 weeks
223601295|NCT02012660|OTHER|Seasonality|The impact of high temperature during summer months on the prevalence of hyponatremia will be explores.
223601296|NCT01500668|DRUG|Botox|Injection of 200 units of Botulinum Toxin A (BOTOX) to a treated limb. Each limb will be divided to two levels - arterial arch and digital arteries (near MCP/MTP) levels. In each level 100 units of Botox will be injected in 6 injection points in the proximity of the arteries.
223601297|NCT01500668|DRUG|Placebo|Injection of 0.5cc of normal saline (0.9% NaCl) to each injection site as in the Active drug arm.
223601298|NCT03585049|OTHER|Vaginal swabs|The protocol includes the secondary use of vaginal swabs that are primarily used for routine diagnostic assessment in a vulvovaginal clinic
223601299|NCT00302913|DRUG|Adjustment of clopidogrel dose|
223749403|NCT01889784|DEVICE|Phototherapy through light emitting diode (LED) - 300J|The near-infrared radiation by light emitting diode (LED) will be performed with a cluster multi-diode arranged in an array of 34x18 cm containing 50 LEDs (GaAlAs, 850 nm). The phototherapy will be applied bilaterally on femoral quadriceps and triceps surae muscles during 80 seconds with 6J of total energy for each diode and 300 J of total energy delivery to muscle. Neither subject nor evaluators will known if LED was effective or placebo during data collection. A hidden button in the LED device is employed to ensure the double-blind procedure. This button allows selecting placebo or effective emission of near-infrared radiation while the time display is working. This button will be selected by a researcher who just participated of randomization procedure and LED application and had no access to data collection.
223749404|NCT01889784|DEVICE|Placebo phototherapy - 300J|The near-infrared radiation by light emitting diode (LED) will be performed with a cluster multi-diode arranged in an array of 34x18 cm containing 50 LEDs (GaAlAs, 850 nm). The phototherapy will be applied bilaterally on femoral quadriceps and triceps surae muscles during 80 seconds with 6J of total energy for each diode and 300 J of total energy delivery to muscle. Neither subject nor evaluators will known if LED was effective or placebo during data collection. A hidden button in the LED device is employed to ensure the double-blind procedure. This button allows selecting placebo or effective emission of near-infrared radiation while the time display is working. This button will be selected by a researcher who just participated of randomization procedure and LED application and had no access to data collection.
223749405|NCT02606591|PROCEDURE|Electroencephalograph|EEG performed at beginning and end of school year.
223749406|NCT02606591|BEHAVIORAL|Cognitive Tests|During the EEG, participant asked to wear headphones and do some simple tests on the computer that measure their abilities to see, hear, and understand information.
223749407|NCT02606591|OTHER|Hair Sample|Participants provide a sample of hair at baseline (near the beginning of school), and follow-up (near the end of school). Sample tested to measure cortisol levels.
223749408|NCT01762943|DRUG|Leuprolide Acetate|All subjects will receive one IM injection (3.75 mg) each month for four months.
223749409|NCT01762943|DRUG|Micronized estradiol|All participants will receive micronized estradiol daily for eight weeks. Estradiol will be started at a dose of 4 mg/day and increased progressively up to 10 mg/day.
223749410|NCT01762943|DRUG|Progesterone|All subjects will receive micronized progesterone daily for eight weeks. Progesterone will be started at 400 mg/day and increased progressively up to 800 mg/day.
223749411|NCT00294164|DRUG|Serostim®|Serostim® will be administered subcutaneously (daily or given on alternate days with matched placebo), at a dose based on body weight measured at Baseline, with a maximum daily dose of 4 mg up to Week 24.
223749412|NCT00294164|DRUG|Placebo|Matching placebo will be administered subcutaneously (daily or given on alternate days with Serostim®), up to Week 24.
223749413|NCT00539838|DRUG|Prednisone|Oral repeating dose
223749414|NCT00539838|DRUG|Immunosuppressive regime (azathioprine, mycophenolate mofetil or methotrexate)|Oral repeating dose
223749415|NCT00539838|DRUG|Methylprednisolone|Intravenous repeating dose
223749416|NCT00539838|DRUG|Ocrelizumab|Intravenous repeating dose
223749417|NCT00539838|DRUG|Placebo|Intravenous repeating dose
224311290|NCT03915028|OTHER|Spa therapy|"The standardized treatment will consist of 4 spa treatments per day for 3 consecutive weeks.~Each day, the patient receives at least four treatments, among which:~* Cure of Drink (in addition to 4 daily cares)~* Bath in running water: Bath~* Bath in running water: Pool at 32 ° C~* Bath with aerobain~* Immersion shower bath~* Shower of high pressure under immersion in swimming pool~* General penetrating shower~* General jet shower~* Local jet shower~* Local mud bath at the feet~* Single poultice~* Multiple poultice~* Compress~* Mobilization pool~* Massages under water"
224311291|NCT01679639|DRUG|aleglitazar|Single dose of aleglitazar in Periods 1, 2, 3
224311292|NCT01679639|DRUG|rifampicin|Single dose in Periods 1 and 2; multiple doses in Period 3
224311293|NCT02927366|DRUG|QCC374|0.03 mg (2 capsules of 0.015 mg) BID 0.06 mg (1 capsule of 0.06 mg) BID 0.12 mg (2 capsules of 0.06 mg) BID
223512268|NCT04925440|DIETARY_SUPPLEMENT|Bifidobacterium longum 1714® strain|Probiotic capsules containing 5 x 10\^9 CFUs, corn-starch and magnesium stearate.
224311294|NCT02927366|DRUG|Placebo Matching|"Placebo matching to QCC374:~0.03 mg BID, 0.06 mg BID and 0.12 mg BID"
223512269|NCT04925440|DIETARY_SUPPLEMENT|Placebo|Capsules containing corn-starch and magnesium stearate only.
223512270|NCT03563612|DEVICE|cpap|application of cpap to the non-dependent lung, during one lung ventilation
223512271|NCT04845971|DIETARY_SUPPLEMENT|Saisei Maf capsules|Dietary supplement name: Colostrum MAF, Saisei MAF immunomodulator. Formulation: 148 mg acid-resistant coated capsules, containing 2.3 mg of enzymatically treated bovine colostrum powder and supplementary ingredients The dietary supplement substances: Active ingredien: Enzymatically treated bovine colostrum powder 2.3 mg 1.6 % Supplementary ingredients: Lactase (Derived from yeast) 0,15 mg 0.1 % HPMC (Hydroxypropyl Methylcellulose) acid-resistant capsule 47 mg 31.8 % Microcrystalline cellulose (Derived from pulp) 98,4 mg 66.5 % Dosage for adults: 2 - 10 capsules daily (stronger version 9 capsules daily) Route of administration: oral Contraindication: allergy to dairy product components Precaution: pregnancy and lactation Storage: Can be stored in at + 5 to +25°C, on dry place for up to two years Manufacturer: Saisei Pharma, Osaka, MORIGUCHI city, OKUBO-cho, 3-34-8. Japan
223512272|NCT00323544|DRUG|zidovudine and lamivudine (Combivir®)|
223512273|NCT00323544|DRUG|emtricitabine and tenofovir DF|
223512274|NCT04726904|PROCEDURE|Sacral neuromodulation in conventional implantation technique|Sacral neuromodulation is implanted with the patients in a prone position, then the insert point of the needle is decided according to anatomical landmarks; afterwards, the lead will be inserted.
223512275|NCT00548561|DRUG|Dexrazoxane|
223512276|NCT00066937|DRUG|Nortriptyline Oral Capsule|Nortriptyline will be titrated up from 25 mg qhs to a maximum dose of 150 mg qhs based on treatment response and side effect profile.
223512277|NCT00066937|DRUG|Benztropine Oral Product|Benztropine will be titrated up from .125 mg qhs to a maximum dose of .750 mg qhs based on treatment response and side effect profile.
223512278|NCT00066937|BEHAVIORAL|CBT|Six in-person, individual sessions of cognitive-behavioral therapy for pain management include relaxation training, pain coping skills training, cognitive therapy for negative and dysfunctional thoughts, and diaries for monitoring relaxation, goals, and negative thinking.
223601300|NCT05864937|OTHER|infertily evaluation|All couples had undergone a standard infertility evaluation, which included medical history, physical examination, and assessment of tubal patency by either hysterosalpingography or laparoscopy and hormonal analysis on cycle day 3. A transvaginal ultrasound scan was performed on the second day of the cycle. On the same day, ovarian stimulation was carried out with recombinant FSH follitropin);rFSH;Gonal-F,MerckSerono,France,orfollitropin ; Puregon, MSD, France), urinary FSH (urofollitropin, Fostimon, France),orhMG(menotropin,Menopur,France)atastarting dose of 75 IU/day from the second day of the cycle.
223601301|NCT04687371|OTHER|Proprioceptive vestibular exercise|To assess effects of proprioceptive vestibular exercises training in patients with peripheral vestibular hypofunctions
223601302|NCT04687371|OTHER|Standard vestibular rehabilitation exercises|To assess effects of standard vestibular rehabilitation exercises in patients with peripheral vestibular hypofunctions
223601303|NCT04687371|OTHER|Controlled|First and last measurement will be taken. There will be no intervention. study will include 9 patients.
223601304|NCT00075556|DRUG|capecitabine|
223601305|NCT00075556|PROCEDURE|conventional surgery|
223601306|NCT00075556|PROCEDURE|neoadjuvant therapy|
223601307|NCT00075556|RADIATION|radiation therapy|
223601308|NCT03671915|DEVICE|Continuous Glucose Monitoring|collection of glucose data
223601309|NCT03671915|DEVICE|External Insulin Pump|Insulin delivery
223601310|NCT03671915|DEVICE|Diabeloop Software (Model predictive control)|Diabeloop software embeds a regulation algorithm to automatically regulate the patient's glycaemia. It takes as input glycaemia value received every 5 minutes from the CGM and patient inputs related to meals and physical activities and it calculates the amount of insulin to be delivered. It sends this information to the pump that automatically delivers this quantity.
223601311|NCT03671915|OTHER|Remote monitoring (Telemedicine)|Remote follow up by care health providers team
223601312|NCT01306383|OTHER|SODIS Bottle|SODIS Bottles used by SODIS group to treat their drinking water
223601313|NCT03610373|BEHAVIORAL|Modular Approach to Therapy for Children (MATCH)|MATCH is a collection of 31 modules that correspond to the treatment procedures included in standard evidence-based treatments for youth depression, anxiety, and behavioral disorders.
223601314|NCT01574885|DEVICE|Halotherapy|The treatment consist of 10 session of micronized iodized salt (sodium chloride) inhalation in a chamber that reproduces the environmental characteristics of a natural salt cave. Each daily session last 30 minutes.
223601315|NCT01574885|DEVICE|Placebo|The treatment consist of 10 sessions in a chamber that emulates the environmental characteristics of a natural salt cave but with no salt emanation. Each daily session last 30 minutes.
223601316|NCT03937492|OTHER|GMI protocol|"This group follow GMI program split in 3 step:~1. left/right descrimination~2. visual motor imagery~3. mirror therapy~Patients perform this exercises 3 times every day and they have checks in therapy al least twice a week."
223601317|NCT03937492|OTHER|Standard Rehabilitation Protocol|"This group follow standard rehabilitation protocol, with active and passive motion of upper limb structure, including hand, wrist, elbow, shoulder.~Patients perform this exercises 3 times every day and they have checks in therapy al least twice a week."
223601318|NCT03296150|BEHAVIORAL|PRESTAGE|PRESTAGE educational program targets the acquisition by the patients and their caregivers of competencies in (1) a better understanding of their disease and (2) their treatment, (3) a better drug management, including both anticancer and supportive treatments, (4) maintenance of a good nutritional status, (5) general health and psychological well being and (6) physical well being. After an individual educational diagnosis, each patient will be proposed an individualized educational program consisting in 1 to 6 of these workshops. An individualized final interview - entitled educational synthesis - will assess patient's skills and satisfaction.
223601319|NCT01534195|DRUG|Prednisolone Sodium Phosphate Ophthalmic Solution 1%|One drop in each eye, four times/day for 8 days.
223601320|NCT01534195|DRUG|Tears Naturale II Ophthalmic Solution|one drop in each eye, four times/ day (QID) for 8 days
223601321|NCT03546114|OTHER|Gender Questionnaire|13-items questionnaire including demographics questions (gender, age, education; naive to osteopathic treatment or not; general gender preferences; specific gender preference in case of low back pain, neck pain, gastrointestinal disorders, musculoskeletal disorders of upper and lower limbs pain; headache; urogenital disorders
223601322|NCT04870372|DRUG|Selegiline|Subjects will receive one Selegiline tablet (5 mg) per day administered at breakfast. The initial dose of Selegiline is 5 mg/day and be up-titrated in 2-week intervals in increments of 5 mg up to 10 mg (which can be taken at breakfast or divided doses of 5 mg each taken at breakfast and lunch) according to the investigator's judgment, based on individual clinical response and tolerability.
223601323|NCT02302872|DEVICE|ARTO System|
223601324|NCT05029739|DEVICE|A PAD-specific smartphone application (e-intervention) developed for patients with Peripheral Artery Disease|See description of the e-intervention group as above.
223601325|NCT03062111|PROCEDURE|ProTouch Laser Enucleation of Prostate (LEP)|Laser enucleation of the prostate is a standard form of treatment for BPH used widely. The ProTouch laser is established to be safe and is newer than the holmium laser.
223601326|NCT03062111|PROCEDURE|Transurethral Resection of Prostate (TURP)|TURP has been considered a gold standard for treatment of BPH in which rigid resectoscopes with bipolar cautery are used to endoscopically resect prostatic tissue.
223601327|NCT02356289|DRUG|Placebo|
223601328|NCT02356289|DRUG|MYK-461|
223601329|NCT03052595|DIAGNOSTIC_TEST|Oral glucose tolerance test|Oral glucose tolerance test to measure glucose and insulin concentrations after oral glucose load
223601330|NCT03052595|DIAGNOSTIC_TEST|Testing of autonomous nervous system function|Autonomous nervous system function will be assessed using a battery of tests (orthostasis, Valsalva manoeuvre, heart rate variability recording, blood hormone levels, ect.)
223601331|NCT03052595|DIAGNOSTIC_TEST|Stroop test|Stroop test will be used to test cognitive function
223749418|NCT03974230|OTHER|Collection of datas|Collection of datas of examination for diagnosis and follow-up of the Fuchs Endothelial Corneal Dystrophy (FECD) including slit lamp results will be performed.
223749419|NCT03974230|BIOLOGICAL|blood sample|Blood sample will be performed (genetic analyses).
223749420|NCT03974230|OTHER|slit lamp examination|Slit lamp examination will be performed.
223749421|NCT04409288|DRUG|Apalutamide|Androgen receptor inhibitor.
223749422|NCT04409288|DRUG|Enzalutamide|Androgern receptor inhibitor
223749423|NCT04145258|DRUG|Aspirin|Two tablets of aspirin 100 mg per day from inclusion (D-0) to end of Week-8 (W-8)
223749424|NCT04145258|DRUG|Placebo of aspirin|Two placebo tablets with the same appearance of aspirin 100 mg per day from inclusion (D-0) to end of Week-8 (W-8)
223749425|NCT04145258|DRUG|WHO TBM treatment|2 months of (R-H-Z-E) + 7 months of (R-H)
223749426|NCT04145258|DRUG|Intensified TBM treatment|2 months of (HDR-L-H-Z-E) + 7 months of (R-H), with HDR=high-dose rifampicin and L=linezolid
223749427|NCT00079924|DRUG|teriparatide|
223749428|NCT00079924|DRUG|aldrenodate|
223749429|NCT00079924|DRUG|raloxifene|
223749430|NCT00581074|BEHAVIORAL|diet (grapefruit or grapefruit juice)|weight loss diet
223749431|NCT03284996|DEVICE|Doppler ultrasonography|Examination of the whole cases \& controls by doppler ultrasound to measure renal resistive index.
223749432|NCT01012687|DRUG|perindopril erbumine|8 mg tablet
223749433|NCT04965545|DIETARY_SUPPLEMENT|low copper diet|All patients with wilson disease should receive low copper diet
223749434|NCT06962826|DRUG|Empagliflozin|Empagliflozin
223749435|NCT06961266|DRUG|JZP441|Administered orally
223507537|NCT01991535|DEVICE|Simulator Ventilation Mode|"Ventilator maintains a continuous positive airway pressure during the entire cycle.~Device model: Stellar 150® (ResMed, Australia)."
223507538|NCT04465305|PROCEDURE|entraped treatment|patients with tarlov cysts treated by entraped and plasty nerve root
223507539|NCT04465305|PROCEDURE|plasty treatment|patients with tarlov cysts treated by plasty nerve root
223507540|NCT01217047|DEVICE|FES Cycling|You will be seated in your own wheelchair in front of the cycle. We will place your legs onto the cycle and secure them with straps. Electrodes (pads that stick to the skin) will be placed on your skin on your legs and buttock. The pads will be connected to a stimulator box through a wire. We will then start the cycle motor and stimulate your leg and buttock muscles with electric current. This will cause your legs to cycle. You will do this for 1 hour.
223507541|NCT01217047|DEVICE|Cycling without FES|You will be seated in your own wheelchair in front of the cycle. We will place your legs onto the cycle and secure them with straps. The cycle is configured to work without FES. We will then start the cycle motor. This will cause your legs to cycle. You will do this for 1 hour.
223507542|NCT01217047|PROCEDURE|Lumbar puncture|The study includes 2 lumbar punctures: one at the beginning of the study and one at the end. During a lumbar puncture a small needle will be inserted into the lower back and a small amount of spinal fluid will be drained (about 1 tablespoon).
223507543|NCT01217047|BEHAVIORAL|Mood assessment|"If you do not already have an account, you will be signed up with Mood24/7 (http://www.mood247.com). This is a free service that texts your mobile phone daily asking you to rate your mood on a scale of 1 (low) through 10 (high). We will not monitor your entries during the study but only at the final visit when we will get a printout of the course of your mood during the study. After completion of the study we will assist you in removing us from your Mood24/7 account and we will no longer have access to your mood reports outside of the study period."
223507544|NCT02583061|OTHER|There is no intervention. An exposure of interest is glucose tolerance status in pregnancy|
223507545|NCT05529173|DRUG|Povidone-Iodine 10%|Nasal swab stick application of Povidone-Iodine 10% prior to surgery
223507546|NCT05529173|DRUG|0.9% NaCl Solution|Nasal swab stick application of 0.9% NaCl Solution prior to surgery
223507547|NCT06567873|OTHER|Gastric Ultrasound Exam|A gastric ultrasound is a simple, fast, non-invasive bedside diagnostic test that provides a qualitative and quantitative assessment of gastric contents. There are no known risks of a gastric ultrasound exam.
223507548|NCT05574764|BEHAVIORAL|Cultivating Awareness and Resilience in Education (CARE)|CARE provides teachers and staff with tools and resources to reduce stress, prevent burnout, enliven teaching, and help students thrive socially, emotionally, and academically. CARE blends instruction with experiential activities, reflection, and discussion.
223507549|NCT06691516|PROCEDURE|horizontal and vertical bone augmentation using computer guided cortical shell technique|Computer-guided cortical shell technique in anterior mandible 3d defect using bone harvesting guide and fixation guides
223507550|NCT06691516|PROCEDURE|free hand cortical shell technique in anterior 3d defect|vertical and horizontal ridge augmentation in anterior mandible using free hand cortical shell technique
223507551|NCT06014892|DEVICE|Snoo smart bassinet|Participants in the intervention arm will be shipped a Snoo bassinet during their third trimester. The bassinet must be returned to the company at 6 months
223507552|NCT06014892|DEVICE|Willow wearable breast pump|Participants in the intervention arm will be shipped a Willow wearable breast pump and milk storage bags during the third trimester, which participants may keep
223507553|NCT06014892|BEHAVIORAL|Maven Clinic on-demand perinatal consultation|Participants in the intervention arm will receive immediate access to Maven Clinic for 24/7 on-demand consultation with perinatal specialists.
223507554|NCT06014892|BEHAVIORAL|Faculty mentor|After enrollment, participants in the intervention arm will be paired with a faculty mentor who is also a mother to discuss issues related to work-family integration during pregnancy and early infancy.
223507555|NCT02192697|DRUG|ASP8273|Oral administration
223749436|NCT06961266|DRUG|Matching Placebo|Administered orally
223749437|NCT04343521|OTHER|Targeted Indoor Residual Spraying (TIRS)|Spraying of insecticide Actellic 300CS will start in May or June extending for 1 to 2 months. Residents will be asked to temporarily leave the house during treatment and wait half an hour to one hour for the product to dry before re-entering the house. Insecticide application will follow strict protocol developed by the Centers for Disease Control and Prevention (CDC), Emory University, and the Universidad Autónoma de Yucatán.
223749438|NCT00629837|BIOLOGICAL|Recomb. Factor VIII (Kogenate FS Liposome, BAY79-4980)|Low dose of BAY 79-4980 \[13mg of liposomes/kg\] then cross over to rFVIII-FS (35 IU/kg reconstituted in 2.5 mL WFI / 1000 IU).
223749439|NCT00629837|BIOLOGICAL|Recomb. Factor VIII (Kogenate FS Liposome, BAY79-4980)|High dose of BAY 79-4980 \[22mg of liposomes/kg\] then cross over to rFVIII-FS (35 IU/kg reconstituted in 2.5 mL WFI / 1000 IU)
223749440|NCT00629837|BIOLOGICAL|Recombinant Factor VIII (Kogenate FS, BAY14-2222)|rFVIII-FS (35 IU/kg reconstituted in 2.5mL WFI /1000 IU) then cross over to low dose of BAY 79-4980 \[13mg of liposomes/kg\]
223749441|NCT00629837|BIOLOGICAL|Recombinant Factor VIII (Kogenate FS, BAY14-2222)|rFVIII-FS (35 IU/kg reconstituted in 2.5mL WFI /1000 IU) then cross over to high dose of BAY 79-4980 \[22mg of liposomes/kg\]
223601332|NCT02558777|OTHER|Multicomponent nurse-led intervention|"Participants in the intervention group received the first intervention in the first 24 hours from admission, and thereafter daily until hospital discharge. The intervention was carried out exclusively by the intervention nurses, and was composed of two main parts, being the first one a risk factor analysis, and the second one the intervention on the risk factors detected (orientation, sensorial deficit, sleep, mobilization, hydration, nutrition, drugs, elimination, oxygenation, pain). Furthermore, the intervention nurses identified the principal caregiver in the first 24 hours from admission, and provided an informative booklet about strategies and recommendations to prevent delirium incidence, including ambient strategies, orientation abilities, and identification of alert signs."
223601333|NCT01320202|DRUG|Soluble Ferric Pyrophosphate (SFP)|Patients to receive 11 micrograms (µg) of iron/ deciliter (dL) of dialysate during dialysis 3 or 4 times/week for up to 18 months.
223749442|NCT00301210|DRUG|Tramadol|oral doses four times per day
223749443|NCT01917201|PROCEDURE|IVUS-guided group|"The randomization on groups was completed in accordance with stents to be implanted: Xience Prime/Xience V, Promus Element, Resolute Integrity, Biomatrix Flex, Nobori, Orsiro. In each group randomization on subgroups of IVUS-guided implantation and non-IVUS in the ratio 2:1 was completed. After randomization it is carried out coronary stenting under IVUS-control: a choice of length and diameter of stent - according to IVUS data. After the completion of implantation and postdilatation of stents the control IVUS is being used. If criteria of optimal implantation were not achieved, additional impact is being made: larger balloon, higher pressure, sufficient time of impact. In case of an additional impact the repeated control IVUS is being completed and the following results are being fixed. After control IVUS the OCT procedure is carried out. During OCT possible problems corresponding to stenting are being fixed. An additional impact based on OCT data is not being used."
223601334|NCT01320202|DEVICE|Standard dialysate|Patients to receive standard dialysate (no iron) during dialysis 3 or 4 times/week.
223749444|NCT01917201|PROCEDURE|Non-IVUS group|"The randomization on groups was completed in accordance with stents to be implanted: Xience Prime/Xience V, Promus Element, Resolute Integrity, Biomatrix Flex, Nobori, Orsiro. In each group randomization on subgroups of IVUS-guided implantation and non-IVUS in the ratio 2:1 was completed. After randomization it is carried out coronary stenting under angiography control. After postdilatation control OCT is carried out. During OCT possible problems corresponding to stenting (malapposed struts, separate beams, a prolapse of fiber, microthrombosis) are being fixed. An additional impact based on OCT data is not being used."
223749445|NCT05679518|BEHAVIORAL|ConquerFear intervention|ConquerFear is a manualized intervention, consists of six individual sessions over 10 weeks. The key goals of this intervention are the following: (1) teach strategies for controlling worry and excessive threat monitoring, (2) modify underlying unhelpful beliefs about worry, (3) develop appropriate monitoring and screening behaviours, (4) encourage acceptance of the uncertainty brought about by a cancer diagnosis, and (5) clarify values and encourage engagement in values-based goal setting (19). Each session will last 60-90 minutes and be delivered by a trained therapist. After each session, participants will be given home-based exercises to practice the skills learned in the sessions. With the uncertainty surrounding the COVID-19 pandemic, instead of face-to-face sessions only, a hybrid mode of intervention delivery will be used by offering participants the choice of face-to-face or online sessions.
223749446|NCT05679518|BEHAVIORAL|CALM intervention|CALM is a semi-structured, manualized, individual psychotherapy intervention designed for patients with advanced cancer. It includes 3-6 individual therapy sessions, with each approximately lasts 45-60 minutes, delivered over 3-6 months. The sessions cover 4 domains: 1) symptom management and communication with health care providers; 2) changes in self and relations with close others; 3) sense of meaning and purpose; and 4) the future and mortality. All modules will be addressed with each patient, but the sequencing and time devoted to each domain can be varied, based on the concerns that are most relevant to each patient.
223749447|NCT05679518|BEHAVIORAL|Basic Cancer Care|Basic Cancer Care intervention for the control arm was developed to help cancer survivors with health maintenance in long-term through providing comprehensive lifestyle guidance. The intervention incorporates relaxation training, dietary and physical fitness consultations with the key goals to (1) teach relaxation techniques, (2) offer personalized diet and physical activity advice, and (3) enhance survivors' perceived control over illness, thereby leading to better adjustment to cancer. Similar to the ConquerFear intervention, Basic Cancer Care intervention consists of 6 individual sessions over 10 weeks. Each session will last 60-90 minutes and be delivered by a trained therapist, a registered dietitian, and an exercise physiologist, respectively. A hybrid mode of intervention delivery will be also used by offering participants the choice of face-to-face or online sessions.
223749448|NCT05344859|BEHAVIORAL|Weekly Automated Health Coaching|This intervention will involve health coaching delivered by Artificial intelligence (AI). The automated health coaching mechanism will be coupled with AI-based responses, and recent advancements have made the voices generated through the AI, almost human-like voices. Every week participants enrolled in automated health coaching intervention will receive a health coaching and goal-setting call that will help guide the participants in managing their Type 2 Diabetes Mellitus. This technology-driven study group will inform us whether trained human coaches are required or if the automated technologies are sufficient to create clinically meaningful HbA1c improvements.
223749449|NCT05344859|BEHAVIORAL|Weekly Human Health Coaching|Every week participants enrolled in human health coaching intervention will receive a health coaching call and goal-setting call from their respective health coaches to guide them in managing their Type 2 Diabetes Mellitus.
223749450|NCT05344859|BEHAVIORAL|Adapted Reward Level|In the adapted reward (gamified) variation, participants will receive 25 cents per day for the first week of daily-monitoring calls, 50 cents per day in the second week, 75 cents per day in the third week, and a dollar per day from the fourth week until the end of the study (Aim 2). In the adaptive variation, missing one day of monitoring (in the past seven days), drops the reward value by one level (example: 75 cents becomes 50 cents), two days of missed calls drop the reward level by two levels, and similarly for three days. In the adaptive variation, participants have to continue to daily monitor their behavior to again build up their reward levels.
223749451|NCT05344859|BEHAVIORAL|Fixed Gamified Reward Level|In our fixed-reward arm, participants will be awarded 25 cents per day for answering the daily monitoring call - this serves simply as a reward for answering the daily calls. It is important that the rewards are for answering the calls and not for the actual values of the responses provided.
223749452|NCT00107198|PROCEDURE|Conventional Surgery|Undergo surgery
223749453|NCT00107198|DRUG|Cyclophosphamide|Given IV
223749454|NCT00107198|DRUG|Doxorubicin Hydrochloride|Given IV
223749455|NCT00107198|DRUG|Prednisone|Given IV or PO
223749456|NCT00107198|RADIATION|Radiation Therapy|Undergo IFRT
223749457|NCT00107198|DRUG|Vincristine Sulfate|Given IV
223749458|NCT01569958|OTHER|transcranial direct current stimulation|transcranial direct current stimulation applied to the motor cortex of both sides (1 mA, 20 minutes) for five consecutive days every month for 12 months
223749459|NCT01569958|OTHER|Sham stimulation|1 mA stimulation for 30 seconds every 900 seconds per session
223749460|NCT02391103|DEVICE|Compex 3 Professional (CefarCompex Medical AB) stimulator|NMES
223749461|NCT02391103|DEVICE|sham-stimulation|no electricity applied
223749464|NCT05676749|BIOLOGICAL|C-TIL051|C-TIL051 given in combination with IL-15 (NKTR-255) and pembrolizumab
223749465|NCT05228288|PROCEDURE|Conventional direct laryngoscopy (CDL)|This procedure is considered the gold standard for endotracheal intubation and is routinely used in the peri-operative setting as well as in intensive care and emergency medicine.
223749466|NCT05228288|PROCEDURE|Video assisted laryngoscopy with Macintosh-shaped blade (M-VAL)|This device is implemented in most german hospitals and used when conventional direct laryngoscopy is not sufficient. By positioning the camera at the tip of the blade, the achievable field of view onto the glottic plane is improved.
223749467|NCT05228288|PROCEDURE|Video assisted laryngoscopy with hyper-angulated blade (H-VAL)|The hyper-angulated blades are often used as a backup instrument when a view of the glottic plane cannot be achieved with the Macintosh blade due to anatomic abnormalities, even with a video-assisted laryngoscope.
223749468|NCT00864877|DEVICE|biodegradable fixation system (Inion OTPS FreedomPlateTM)|
223749469|NCT00815438|PROCEDURE|cholecystectomy.|Patients enrolled in the study will have a flexible transvaginal endoscopy used during laparoscopic cholecystectomy.
223749470|NCT02859051|DEVICE|Humanoid Robot MEDi|Humanoid robot programmed with cognitive-behavioral interventions such as role modeling, teaching coping strategies, positive reinforcement, parent encouragement
224199944|NCT04425642|DRUG|Glucose/Amino acids/Lipids|If indications for parenteral nutrition appear, it's dose will be calculated according patient's age and weight and will consist of glucose, amino acids and lipid emulsions. To prevent potential complications of parenteral nutrition, the target dose will be reached by the third day of therapy. It will discontinued, when the patient oral food intake will be more than 60% for three consecutive days.
224199945|NCT06537206|OTHER|Application Footbath|The foot bath application for the experimental group will be applied with water at 38-40 degrees Celsius for an average of 10 minutes under thermometer control. Immediately afterward, the second physiological parameters will be measured.
223601335|NCT00635882|DRUG|mometasone furoate/formoterol 100/10 mcg|mometasone furoate/formoterol 100/10 mcg twice daily (BID) (two inhalations of MF/F 50/5 from a metered-dose inhaler) for 14 days
223601336|NCT00635882|DRUG|mometasone furoate/formoterol 200/10 mcg|mometasone furoate/formoterol 200/10 mcg twice daily (BID) (two inhalations of MF/F 100/5 from a metered-dose inhaler) for 14 days
223601337|NCT00635882|DRUG|mometasone furoate/formoterol 400/10 mcg|mometasone furoate/formoterol 400/10 mcg twice daily (BID) (two inhalations of MF/F 200/5 mcg from a metered-dose inhaler) for 14 days
223601338|NCT00635882|DRUG|MF DPI 200 mcg|MF DPI 200 mcg twice daily (BID) (one inhalation of MF DPI 200 mcg) for 14 days
223601339|NCT00635882|DRUG|MF MDI 200 mcg|MF MDI 200 mcg twice daily (BID) (two inhalations of MF MDI 100 mcg) for 14 days
223601340|NCT00635882|DRUG|Placebo|MF/F MDI placebo twice daily (BID) (2 inhalations)
223749471|NCT00296933|DRUG|Escitalopram|
223749472|NCT00296933|DRUG|Bupropion XL|
223749473|NCT06225661|BEHAVIORAL|SAFE Intervention|Manualized individual youth and family psychotherapeutic intervention. Weekly individual and family sessions with a therapist for 6 weeks. Participants will continue to receive usual care.
223749474|NCT06225661|BEHAVIORAL|NAV (Telephone Navigation)|Weekly telephone contact with parents regarding participant health care utilization. Referrals to community mental health resources provided as needed. Participants will continue to receive usual care.
223749475|NCT02120950|DRUG|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|Eylea is administered as an intravitreal injection
223749476|NCT02120950|OTHER|Visudyne|Photodynamic therapy is a combined therapy of drug (Visudyne) applied to reinforce the action of a device (laser)
223749477|NCT02424383|DEVICE|PTA (Lutonix® 035 DCB Catheter)|"Percutaneous Transluminal Angioplasty (PTA) will involve the insertion of a catheter into one of the femoral arteries. Once the catheter is in place, a tiny balloon on the end of the catheter will be inflated to press against the narrowing (or blockage) in the artery to try to open the blockage, and allow more blood to flow through the artery. The balloon may need to be inflated several times in order for the narrowed area to open up sufficiently to improve the blood flow. The area will be viewed with specialized x-ray or other imaging devices to see if the artery has opened enough.~The Lutonix® DCB through the blood vessel to the narrowed area to be treated."
223749478|NCT00382954|DRUG|Velcade|velcade (4 original dosing levels with 3 modified dosing levels) I.V. on days 1, 4, 8, 11, 15, 18, 22, and 25 for 4 weeks concurrent with the Idarubicin
223749479|NCT00382954|DRUG|Idarubicin|I.V., 8, or 10 or 12 mg/m\^2 weekly (days 1, 8, 15, and 22) for 4 weeks
223749480|NCT02816060|PROCEDURE|manual therapy|manual therapy with neural exercise will be applied on patients with neck pain
224199946|NCT04835207|OTHER|"1- LDL-C (low-density lipoprotein cholesterol)| and HDL-C(high-density lipoprotein cholesterol) Ratio. 2- Glycemia will be assessed : RBS ( random blood sugar ) . 3- S"|"Blood samples were obtained before PCI, and the following parameters will be measured: 1- LDL-C (low-density lipoprotein cholesterol)\| and HDL-C(high-density lipoprotein cholesterol) Ratio. 2- Glycemia will be assessed : RBS ( random blood sugar ) . 3- S"
223749481|NCT04777162|DRUG|Tislelizumab|For included participants, tislelizumab would be administrated 200mg q3w iv.
223749482|NCT04777162|DRUG|Anlotinib|Patients will be administrated with Anlotinib 12mg p.o. d1-d14 q3w.
223749483|NCT05868486|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223749484|NCT05868486|GENETIC|Genetic Testing for Cancer Risk|Undergo germline testing
223601341|NCT06293768|DEVICE|continuous wireless monitoring system of Vital Signs (Win@Hospital) + continuous system for continuous monitoring of blood sugar (Dexcom G6)(only for diabetic patients)|Patients randomized to the experimental group on discharge or with transfer to the subacute ward will be connected to the system continuous monitoring of Vital Signs(Win@Hospital) continuous system for the continuous monitoring of blood sugar(Dexcom G6)(only for diabetic patients). The system, once applied, does not require the presence of a dedicated person and continuous monitoring in real time. It is set with alerts that are triggered both when the parameters they leave the normal ranges both if the data is not recorded due to technical problems. the data is transmitted in real time on mobile devices in the possession of a doctor and a nurse available 24 hours a day who guarantee the remote control system. Devices. Mobiles also contain the clinical information of each patient.
223601342|NCT06526091|OTHER|Cerebral NIRS monitoring at delivery|Application of cerebral NIRS monitoring immediately after delivery and during optimum cord management
223601343|NCT03576911|DIETARY_SUPPLEMENT|Coenzyme Q10|
223601344|NCT03576911|OTHER|Placebo|
223601345|NCT06393166|DRUG|Sequential AG and mFOLFOX in Combination With Serplulimab Injection and Bevacizumab Injection|Nab-paclitaxel:125 mg/m2, ivgtt, D1, 8 and 15,every 6 weeks for a treatment cycle Gemcitabine hydrochloride: 1g/m2, ivgtt, D1, 8 and 15,every 6 weeks for a treatment cycle 5-FU: 2400 mg/m2 ,ivgtt over 46h, D29-30, every 6 weeks for a treatment cycle Oxaliplatin: 85 mg/m2 ,ivgtt, D29, every 6 weeks for a treatment cycle LV: 400 mg/m2 ,ivgtt over 2h, D29, every 6 weeks for a treatment cycle Serplulimab Injection: 3mg/kg,ivgtt,D1, every 2 weeks for a treatment cycle. Bevacizumab Injection: 5mg/kg,ivgtt,D1, every 2 weeks for a treatment cycle.
223601346|NCT06183333|BEHAVIORAL|Heidelberg Emotion Regulation Training|The four-week intervention program is specifically designed to enhance the participants' emotion regulation. It focuses on developing their skills in accurately recognizing various emotions and effectively applying diverse emotion regulation strategies. To achieve this, the program includes video-based psychoeducation sessions. Alongside these sessions, the program incorporates daily short exercises, each lasting approximately five minutes. These exercises are crafted to help participants practically integrate the concepts and strategies learned from the psychoeducation sessions into their everyday lives. All components of the intervention are accessible through an online platform, ensuring ease of access and flexibility for participants.
223601347|NCT03332446|OTHER|cold water immersion|10 min at 12-15°C
223601348|NCT00825812|DRUG|Sugammadex|After induction of anesthesia an intubation dose of 0.6 mg/kg rocuronium was administered. Maintenance doses of 0.1-0.2 mg/kg rocuronium intravenous (IV) could be administered if necessary. At reappearance of T2 after the last administration of rocuronium, an IV single bolus dose of 2.0 mg/kg sugammadex was administered.
223601349|NCT00825812|DRUG|neostigmine|After induction of anesthesia an intubation dose of 0.6 mg/kg rocuronium was administered. Maintenance doses of 0.1-0.2 mg/kg rocuronium IV could be administered if necessary. At reappearance of T2 after the last administration of rocuronium, an IV single bolus dose of 50 µg/kg neostigmine (combined with 10-20 μg.kg-1 atropine, in a ratio ranging from 2.5:1 to 5:1) was administered.
223601350|NCT05545839|BEHAVIORAL|Transition coaching|Transition coaching sessions (8 sessions), covering paediatric to adult care, self-advocacy, medication management, general health, lifestyle and behaviours, future planning, screening for mood disorders and coping skills.
223601351|NCT04223414|DEVICE|Analgesia Nociception Index (ANI)|"ANI will be used to analyse the autonomic nervous system's response to volume expansion.~ANI will be assessed during surgery, before during and after the volume expansion"
223601352|NCT02371031|DRUG|6-[F-18]-Fluoro-L-3,4,-dihydroxyphenylalanine|
223601353|NCT02371031|DEVICE|PET/MRI|
223601354|NCT02371031|PROCEDURE|Surgical resection (standard of care)|
223601355|NCT00364741|DRUG|Oxygen|During and 2 hours after surgery
223601356|NCT06325865|OTHER|Interview|Interview with ALS patient in which the experiences of unpleasant sensations or pain during study procedures are assessed in a qualitative manner.
223601357|NCT02606058|PROCEDURE|Deferred cord clamping|Deferred cord clamping (for 60 seconds or more with the baby held below or at the level of the placenta)
223601358|NCT01925248|DIETARY_SUPPLEMENT|Whey protein|Whey protein group participants will take supplement drinks that contain whey protein, daily before breakfast and before dinner for 3 months.
223601359|NCT01925248|DIETARY_SUPPLEMENT|Placebo group|Placebo group participants will take supplement drinks that do not contain whey protein, daily before breakfast and before dinner for 3 months.
223601360|NCT02741206|BEHAVIORAL|Bellevue ROSE Intervention|
223601361|NCT02741206|BEHAVIORAL|Psycho-education session and usual, Standard of care Control|Psycho Education and usual, standard of care
223601362|NCT02741206|BEHAVIORAL|One Psycho-education session and usual, standard of care Control|
223601363|NCT03287427|DRUG|TetMYB Vaccine|Weekly intra-dermal injections of either 0.1mg, 0.5mg or 1.0mg on day 1 for week 1 to week 6.
223601364|NCT03287427|DRUG|BGB-A317|3 weekly IV injections of 200mg commencing from Week 4.
223601365|NCT00538070|DIETARY_SUPPLEMENT|Sarcosine|You will receive two grams of sarcosine or placebo per day. Each capsule will contain 500 mg of sarcosine or placebo. You will take two capsules twice per day, once in the morning and once in the evening, every day for six weeks. You can take the pills with or without food. You should continue to take all your other medications throughout the study.
223601366|NCT01658761|PROCEDURE|vitrectomy|Surgery
223601367|NCT02567019|OTHER|blood samples|blood samples will be done for patients patients suffering of periodontal diseases and healthy volunteers
223601368|NCT03851432|DRUG|Janagliflozin plus metformin|Janagliflozin: Tablets, Oral, 25 mg, Once daily, 52 weeks The patient's stable dose of background therapy of metformin should be continued throughout the study.
223601369|NCT03851432|DRUG|Janagliflozin plus metformin|Janagliflozin: Tablets, Oral, 50 mg, Once daily, 52 weeks The patient's stable dose of background therapy of metformin should be continued throughout the study.
223601370|NCT03851432|DEVICE|Placebo plus metformin|Placebo: Tablets, Oral, 25/50 mg, Once daily, 24 weeks The patient's stable dose of background therapy of metformin should be continued throughout the study.
223601371|NCT00658463|DRUG|Rosuvastatin|rosuvastatin 20 mg/day during 6 weeks versus placebo during 6 weeks in a cross-over design
223601372|NCT00658463|DRUG|Placebo|Placebo
223749485|NCT05868486|PROCEDURE|Liquid Biopsy|Undergo liquid biopsy testing
223749486|NCT05868486|PROCEDURE|Magnetic Resonance Imaging of the Whole Body without Contrast|Undergo whole body MRI without contrast
223749487|NCT05868486|OTHER|Survey Administration|Complete surveys
223749488|NCT01888796|DRUG|Linagliptin|
224199947|NCT02437981|DRUG|PrEP|Oral pre-exposure prophylaxis (PrEP) for HIV infection using a daily combination tablet of tenofovir disoproxil fumarate and emtricitabine
224199948|NCT04714684|DEVICE|Fitostimoline proctogel|Medical device for topical use for the treatment of fissures
224199949|NCT04714684|DEVICE|Fitostimoline proctogel + muscle relaxant|medical device for topical use for the treatment of fissures
224199950|NCT00949052|GENETIC|DNA analysis|
224199951|NCT00949052|GENETIC|polymorphism analysis|
223507556|NCT03442465|BEHAVIORAL|Toronto Extremity Salvage Score|Participant-reported outcome score. For lower extremities, this is a 33 item questionnaire containing 32 5 point Likert scale items and 1 open ended response item. For upper extremities, this is a 31 item questionnaire containing 31 5 point Likert scale items and 1 open ended response item. Individual item responses range from 1-5 with higher values indicating a task is easier to complete. A total questionnaire score can also be calculated by taking the sum of the scores minus the number of total items answered, and dividing this by the maximum possible score based on the number of items answered. This results in a range from 0 -100% with higher values indicating greater ability to complete tasks 31. This scoring allows for the fact that some items may not be answered if they do not apply to an individual. It is anticipated that it will take 20 minutes to complete. Scores for the lower extremity and upper extremity may be combined, but we intend to treat them separately for analysis.
223507557|NCT03442465|BEHAVIORAL|Musculoskeletal Tumor Society Score|Clinician-reported global score. For lower extremities, this is a 6 item questionnaire containing 6 point Likert scale items which cover pain, function, emotional acceptance, walking ability, gait, and necessary support. Individual item scores range from 0-5 with higher values indicating greater function, less pain, or more positive emotional acceptance. For upper extremities, this is a 6 item questionnaire containing 6 point Likert scale items which cover pain, function, emotional acceptance, hand positioning, manual dexterity, and lifting ability. Individual item scores range from 0-5 with higher values indicating greater function, less pain, or more positive emotional acceptance. A total questionnaire score which is defined as the sum of the individual items divided by the maximum possible score (5 times the number of items) may also be computed. It is represented as a percentage from 0 - 100%.
223507558|NCT03442465|BEHAVIORAL|Timed Get Up and Go Test|Validated functional measurement, for lower extremities only. The patient is observed and timed while s/he rises from an arm chair, walks 3 meters, turns, walks back, and sits down again. The test predicts the patient's ability to go outside alone safely and quantifies functional mobility. The test requires no special equipment and will take less than one minute to complete.
223507559|NCT03442465|DIAGNOSTIC_TEST|Orthogonal Radiographs|The distance of bone transport is measured, accounting for calibration of the radiographs. The presence of bone regenerate between the transported segment is determined by the presence of continuous calcified callus from the proximal segment to the distal segment. Each of the orthogonal radiographs is used to visualize two cortices: the AP radiographs visualizes the medial and lateral cortices and the lateral radiograph measures the anterior and posterior cortices. Each continuous calcified cortex is counted with a range from 0 to 4 cortices intact.
223507560|NCT03442465|DIAGNOSTIC_TEST|Weight Bearing for lower extremities only|As part of the current standard of care, patients are asked to stand on a scale with the affected lower extremity on the scale and the unaffected extremity on a block which is level with the scale. The patient is asked to place as much weight as possible on the affected extremity and this weight Is recorded. Each patient's total weight is then measured and the percent of weight bearing is calculated as the amount of weight bearing over the total body weight.
223507561|NCT03442465|DIAGNOSTIC_TEST|Range of Motion|As part of the current standard of care, the joints of the affected extremity are assessed for passive range of motion at each follow up visit by the clinician. If surgery is on the femur, the hip and knee joints are assessed for range of motion. Whereas for the tibia, the knee and ankle joints are assessed. These assessments would be measured using a goniometer placed alongside the extremity and recorded for each direction of movement. Hip range of motion includes flexion, extension, abduction, internal rotation and external rotation. Knee range of motion includes flexion and extension. Ankle range of motion includes dorsiflexion and plantarflexion.
223512279|NCT00066937|BEHAVIORAL|Disease MGT|Six in-person, individual sessions of temporomandibular joint disorder (TMD) disease management (MGT) that include information about the jaw and good oral habits, diet, sleep, and general stress management.
223512280|NCT04093284|DEVICE|The needle-free jet injector|Continuous insulin therapy for 9 days
223749489|NCT01888796|DRUG|placebo|
223749490|NCT01829776|BEHAVIORAL|Educational intervention|This is an 8-week comprehensive fall prevention exercise and education program, with one 2-hour session each week, for people with MS, adapted from a similar program for older adults.
223749491|NCT02497027|OTHER|pharmacogenetic testing|pharmacogenetic testing report released to physician at 4 weeks post enrollment
223749492|NCT02497027|OTHER|pharmacogenetic testing|pharmacogenetic testing report released to physician at 12 weeks post enrollment
223749493|NCT05638685|OTHER|Questionnaire|The questionnaire comprises demographics, job or school related questions, screen work questions, the International Physical Activity Questionnaire (IPAQ) and questions about the participant's health.
223749494|NCT00177970|DRUG|intravenous immunoglobulin G (IVIG)|IVIG to be given IV to patients with C-Diff .
223749495|NCT00177970|DRUG|Placebo|Placebo to be given IV to patients with C-Diff
223749496|NCT05235334|DEVICE|MySOLIUS|MySOLIUS is a portable light therapy device that is designed to deliver a small amount of targeted ultraviolet B (UVB) light to trigger the body's natural production of vitamin D.
223749497|NCT03672331|OTHER|Mammogram|Every 1-4 years according to the national/regional guidelines or personalised schedule according to risk assessment
223749498|NCT03672331|OTHER|Ultrasound|As required according to the national/regional guidelines or personalised schedule according to risk assessment
223749499|NCT03672331|OTHER|MRI|As required according to the national/regional guidelines or personalised schedule according to risk assessment
223749500|NCT03672331|OTHER|Tomosynthesis|As required according to the national/regional guidelines or personalised schedule according to risk assessment
224199952|NCT00949052|OTHER|laboratory biomarker analysis|
224199953|NCT00949052|OTHER|medical chart review|
224199954|NCT00949052|OTHER|questionnaire administration|
223601373|NCT00888953|OTHER|Fall risk assessment|Assessment of presence of risk factors (previous falls, self efficacy, balance and gait disorders, weakness, daily living impairment, limb pain, foot problems, dizziness, cognitive impairment, vision impairment, depression, urinary incontinence, heart disease, polimedication and consumption of neuroleptics and psychotropic medication)
223601374|NCT00888953|OTHER|Tailored intervention|Induction of an intervention for each identified risk factor. If is possible the intervention will be directed towards the treatment of the underlying cause.
223601375|NCT04115137|DEVICE|pelvic varicose veins plug embolization|pelvic varicose veins plug embolization
223601376|NCT02779413|DRUG|insulin degludec|Patients will be treated with commercially available Tresiba® FlexTouch® according to routine clinical practice at the discretion of the treating physician.
223601377|NCT00714311|BEHAVIORAL|Transference-Focused Psychotherapy|Outpatient psychotherapy according to the treatment manual, sessions of 50 minutes twice per week
223507562|NCT03767231|DIAGNOSTIC_TEST|Xpert HCV Viral Load Finger-stick Point-of-Care test (Cepheid)|The investigators will randomly assign eligible and consented patients to either to HCV POC VL Group or Reference Group. All participants will take a short survey regarding HCV care and treatment. As part of the investigators' ED HCV Screening and Linkage to Care Program, all participants will receive the standard-of-care clinical laboratory-based HCV RNA viral load testing via whole blood (i.e. patient will receive blood drawn). This standard-of-care HCV viral load testing result will be provided to participant when it is available (usually 1-2 days later). Participants in the HCV POC VL Group will receive the novel POC HCV RNA viral load testing and the result of the novel test will be disclosed to the patients approximately within 1 to 1½ hours of the testing.
223507563|NCT03365908|PROCEDURE|Adductor Canal Nerve Block|An adductor canal nerve block with 15 mL of 0.5% ropivacaine will be performed pre-operatively by Anesthesiology.
223507564|NCT03365908|DRUG|Ropivacaine injection|15 mL of 0.5% ropivacaine will be administered for the adductor canal block
223507565|NCT05432960|BIOLOGICAL|RPH-104|solution for subcutaneous administration 40 mg/mL, 2 mL in the 4-mL glass vial
223507566|NCT05432960|DRUG|Placebo|Normal Saline (0.9% Sodium Chloride solution)
223507567|NCT05783960|OTHER|administration questionary|Questionnaire will be compared to 24h sodium and potassium urinary excretion (reference). A Bayesian network and a multiple regression will be used to validate the questionary
223507568|NCT04702672|DIETARY_SUPPLEMENT|100% wheat (control)|Intake of 250 ml of tap water and 100 g of bread baked with 100% wheat flour (regular commercial available wheat flour). Consumed over maximum 10 minutes at time 0 min after overnight fasting. At one of four visits.
223507569|NCT04702672|DIETARY_SUPPLEMENT|100% Lean-baking barley®|"Intake of 250 ml of tap water and 100 g of bread baked with 100% Lean-baking barley® flour. Consumed over maximum 10 minutes at time 0 min after overnight fasting. At one of four visits.~HIAMBA® are naturally bred in corporation with PlantCarb ApS and researchers at Aarhus and Copenhagen Universities. The wheat flour is standard commercial available flou"
223507570|NCT04702672|DIETARY_SUPPLEMENT|100% regular barley|"Intake of 250 ml of tap water and 100 g of bread baked with 100% regular barley flour and 25% wheat flour. Consumed over maximum 10 minutes at time 0 min after overnight fasting. At one of four visits.~HIAMBA® are naturally bred in corporation with PlantCarb ApS and researchers at Aarhus and Copenhagen Universities. The wheat flour is standard commercial available flour."
223507571|NCT05233917|DIETARY_SUPPLEMENT|Olive oil use|Olive oil, 25-30g/d by day for 6 month
223507572|NCT05233917|DIETARY_SUPPLEMENT|MLCT oil use|MLCT oil, 25-30g/d by day for 6 month
223507573|NCT04072432|DRUG|RBT-3|intravenous administration
223507574|NCT04460794|BEHAVIORAL|Ballet-inspired workouts|8 weeks, delivered by volunteers with a self-directed resource package
223507575|NCT04460794|OTHER|Usual care|Usual care and general recommendations on basic stretching and leg exercises for stroke survivors
223507576|NCT04886609|DEVICE|ORISE gel|To establish if ORISE Gel an effective and feasible submucosal injecting solution during endoscopic resection of large colorectal polyps
223507577|NCT05712889|DRUG|VIP236 (Q3W)|VIP236 will be administered by IV infusion once every 3 weeks, for a 21-day cycle.
223507578|NCT05712889|DRUG|VIP236 (Q2W)|VIP236 will be administered by IV infusion once every 2 weeks, for a 28-day cycle.
223507579|NCT04717908|DRUG|Bedaquiline|400 mg once daily for 2 weeks then 200mg 3 times per week;
223507580|NCT04717908|DRUG|Pyrazinamide|1500 mg daily
223507581|NCT04717908|DRUG|Linezolid|600 mg daily
223507582|NCT04717908|DRUG|Cycloserine|≤50kg 500 mg daily, \>50kg 750mg daily;
223507583|NCT04717908|DRUG|Clofazimine|100 mg daily;
223507584|NCT05257018|DRUG|R-CDOP+intrathecal MTX|"R-CDOP+intrathecal MTX：~* Rituximab 375 mg / m\^2，D1~* Cyclophosphamide 750 mg / m\^2，D2~* Doxorubicin Hydrochloride Liposome Injection 35mg / m\^2，D2~* Vincristine 1.4mg/m\^2 (dose capped at 2 mg)，D2~* Prednisone 50 mg， bid D2-6~* Cycle1-5：Intrathecal MTX 12 mg + DXM 5 mg after chemotherapy （PK patients will be given 24 h after chemotherapy）"
223507585|NCT03847090|DRUG|Reloxaliase|Reloxaliase 2 capsules, orally, with each meal/snack, 3 to 5 times per day
223507586|NCT03847090|DRUG|Placebo|Placebo 2 capsules, orally, with each meal/snack, 3 to 5 times per day
223507587|NCT00428077|BIOLOGICAL|bcr-abl peptide vaccine|Patients will be vaccinated 15 times over 12 months with a vaccine comprised of native and synthetic break-point cluster region-Abelson murine leukemia(BCR-ABL) specific peptides and the immunologic adjuvants, Montanide ISA 51-VG.
223507588|NCT00428077|GENETIC|reverse transcriptase-polymerase chain reaction|"A baseline reverse transcriptase-polymerase chain reaction(RT-PCR) transcript level of BCR-ABL will be determined after enrollment on study. This baseline will be used to measure response to the vaccine. Patients will have 3 quantitative RT-PCR tests for BCR-ABL transcript levels performed on their peripheral blood in the first month after enrolling on study. Peripheral blood samples will be drawn at approximately 1-month prior (about day -30), 2 weeks prior (about day -14), and the day of the first vaccination (day 0). Samples will be analyzed at a central lab and the three values will be averaged to determine a baseline circulating transcript level. During this one-month period, a peripheral blood sample will be analyzed to determine whether patients have a B3A2 or B2A2 junction."
223507589|NCT03362957|DEVICE|Geniculate Artery Embolization|Gel-Bead Microspheres will be used for geniculate artery embolization (GAE) in subjects with knee osteoarthritis.
223507590|NCT03362957|DIAGNOSTIC_TEST|Sham Procedure|Patients will receive a sham procedure, which will include a diagnostic angiogram
223601378|NCT00714311|BEHAVIORAL|treatment by experienced community psychotherapists|Outpatient psychotherapy in private practices or outpatient units of psychiatric hospitals. Licensed psychotherapists with experience and special interest in the treatment of borderline patients are treating according to the method they have learned.
223601379|NCT03368846|DRUG|Varlitinib|\[14C\]-Varlitinib
223601380|NCT05357508|BEHAVIORAL|Intervention brochure|Provide participants with information about their personalized risk for colorectal cancer and appropriate screening recommendations to facilitate their screening option choice.
223601381|NCT05357508|BEHAVIORAL|Control brochure|Provide participants with general information about options for colorectal cancer screening.
223601382|NCT05456620|OTHER|Exercise therapy|"The intervention treatment consists of a progressive 4-stage, criteria-based exercise protocol, in which the amount of tendon compression is limited. This includes:~1. Education: Specific information on the importance of limiting tendon compression during rehabilitation, as well as general information on load management, the importance of active exercise therapy and setting expectations.~2. Orthotic treatment: heel inserts to reduce ankle dorsiflexion during daily activities and sports~3. Physiotherapy: Progressive tendon-loading exercise therapy (4 phases) restricting the amount of tendon compression by limiting dorsiflexion of the ankle and prohibiting stretching"
223601383|NCT05456620|OTHER|Exercise therapy (usual care)|"The control treatment consists of a progressive 4-phase, criteria-based exercise protocol, in which the amount of tendon compression is not limited. This includes:~1. Education: general information on load management, the importance of active exercise therapy and setting expectations.~2. No orthotic treatment.~3. Physiotherapy: Progressive tendon-loading exercise therapy (4 phases) without any restriction around tendon compression and encouraging stretching"
223601384|NCT01959438|DRUG|Sodium selenite (Introselen)|Intravenous infusion daily for each week day during 2 weeks (10 infusions). After that chemotherapy during 6 weeks. Chemotherapy for each patients is the first line treatment, so chemotherapy differs among patients, with respect to which treatment a patient got as first line.
223749501|NCT06502275|BEHAVIORAL|Mobile Health Management Frailty Care Program|"Through the LINE communication software, participants are provided with exercise and nutrition information three times a week, with a total of 36 messages. As well as 6 podcasts of health information and 6 sports videos in total. At weeks 2, 4, and 6, researchers scheduled 5- to 10-minute telephone consultations. Participants can receive guidance through telephone consultations and carry a Xiaomi sports band wearable device to monitor their exercise."
223749502|NCT02438722|DRUG|Afatinib Dimaleate|Given PO
223749503|NCT02438722|BIOLOGICAL|Cetuximab|Given IV
223749504|NCT02438722|OTHER|Laboratory Biomarker Analysis|Correlative studies
223749505|NCT00542152|DRUG|CYCLOSPORINE VS INFLIXIMAB|"* Cyclosporine 2mg/kg/day intravenous for 7 days then Neoral 4mg/kg/day orally for 3 months.~* Infliximab 5mg/kg at weeks 0, 2 and 6"
223749506|NCT02179996|BIOLOGICAL|Three vaccine injections DTP-pertussis-Hib|DTP-pertussis-Hib injections at two, three, four months after birth
223749507|NCT02179996|BIOLOGICAL|Two vaccine injections DTP-pertussis-Hib|DTP-pertussis-Hib injections are administered at two and four months after birth
223749508|NCT00793364|DIETARY_SUPPLEMENT|Stanol ester spread|Stanol ester spread 20 g every day
223749509|NCT00793364|DIETARY_SUPPLEMENT|Placebo spread|Placebo spread 20 g every day
223749510|NCT00793364|DIETARY_SUPPLEMENT|Mediterranean Diet|Mediterranean Diet every day
223749511|NCT05164458|DRUG|IBI 308 injection|IBI308 IV 200mg Q3W Day1
223749512|NCT05164458|DRUG|IBI 389 Injection|IBI 389 IV Q2\~Q3W Day 1
223749513|NCT00001893|DRUG|TNFR:Fc|
223749514|NCT00909779|DRUG|Arformoterol|Arformoterol Tartrate Inhalation Solution 15 mcg twice daily (BID) for a duration of one year
223749515|NCT00909779|DRUG|Placebo|Placebo inhalation solution, twice daily (BID) for a duration of one year.
223749516|NCT04150276|PROCEDURE|ZEEP during awakening|ZEEP will be established 2 min prior to the start of emergence preoxygenation and awakening.
223749517|NCT04150276|PROCEDURE|PEEP during awakening|PEEP will be maintained throughout emergence preoxygenation and awakening.
223507591|NCT04010253|DEVICE|SIMEOX|Instrumental airway clearance by the medical device SIMEOX
223507592|NCT04010253|OTHER|Autogenic drainage|Manual aiway clearance by autogenic drainage
223507593|NCT00609973|DRUG|Ciprofloxacin|Ciprofloxacin 500 mg oral bid for 6 months
223507594|NCT00609973|DRUG|Placebo|Placebo bid for 6 months
223507595|NCT05198362|OTHER|Placebo|Inactive comparator
223507596|NCT05198362|DRUG|Tesomet|Fixed-dose combination
223507597|NCT06054464|DRUG|PC14586|Part 1 and Part 2: Single, oral dose of PC14586 on day 1 and single, oral dose of PC14586 on day 14.
223507598|NCT06054464|DRUG|Rabeprazole|Part 1: Daily oral dose of rabeprazole on days 11-14.
223507599|NCT06054464|DRUG|Famotidine|Part 2: Twice daily oral dose of famotidine on days 11-13. Single, oral dose of famotidine on day 14.
223507600|NCT05688709|BEHAVIORAL|WhatsApp peer support group|YLHIVA assigned to the WhatsApp group will interact with each other and their peer counsellors through one-on-one private communications and on the group chat. The group chat will allow YLHIVA to ask questions, post comments, and reply to one another at any time. We shall share education videos once a week at a time agreed upon with study participants to optimize assimilation of information. In addition, peer counsellor will engage in private WhatsApp calls with youth once a week, to monitor psychosocial state, medication adherence, identify barriers to adherence and counsel YLHIVA. However, youth may initiate in more private communications' when need arises. The peer counsellor will also engage with YLHIVA daily through WhatsApp messages. We will tailor the messages to young people's treatment schedules, clinic appointments, and psychosocial state. Again, youth may text a peer counsellor whenever they wish to do so.
223507601|NCT00601185|PROCEDURE|confocal microscopy in vivo|A dermatologist will perform a shave biopsy according to standard clinical procedures. This study will be carried out after the shave biopsy. The deep surface and the peripheral margins will be imaged on each patient.
223749518|NCT00117559|BEHAVIORAL|Telehealth Treatment|Participants receive a 15-minute telephone call for 8 weeks
223749519|NCT00208962|PROCEDURE|chemotherapy and blood stem cell transplantation|A combination of conventional dose chemotherapy, granulocyte-colony stimulating factor (G-CSF) mobilized HLA-identical related allogeneic PBSC transplant, and post transplant infusions of donor leukocytes.
224199955|NCT00949052|PROCEDURE|assessment of therapy complications|
224199956|NCT00949052|PROCEDURE|evaluation of cancer risk factors|
223749520|NCT00789893|DEVICE|Vaginal Dilator|Participants will be instructed to use the dilators 3 times per week, regardless of frequency of sexual intercourse. At 5 time points, data will be collected to determine vaginal dilator size, grade vaginal stenosis \& assess vaginal symptoms. 1)Baseline: patient self-assessment following consultation up until the end of the first week of radiation 2)Post-radiation: patient self-assessment one month ± 2 weeks follow-up from last day of radiation 3)Post-radiation: 3 month ± 4 weeks follow-up from initiation of dilator use 4)Post-radiation: 6 month ± 4 weeks follow-up from initiation of dilator use 5)Post-radiation: 12 months ± 4 weeks follow-up from initiation of dilator use. At the 1st \& 2nd time points, the nurse will telephone the patient to retrieve her responses. The 1st phone call will occur between the time following consultation up until the end of the first week of radiation, \& the 2nd will be one month ± 2 weeks from last day of radiation.
223749521|NCT04264910|BEHAVIORAL|Calm App|Calm is a subscription-based meditation app which provides guided meditations, sleep stories, soundscapes and calming music. Calm offers 7 Days of Calm for those new to meditation, the daily Calm, a meditation posted daily and a library of unique 10-12 minute meditations with topics related to acceptance, anxiety, self-compassion, and physical pain (to name a few).
223749522|NCT01743287|DRUG|Imotun capsule|Imotun capsule: Avocado-Soya Unsaponifiables 300.03mg/Cap, per oral, a capsule once a day during for 24 weeks
223749523|NCT01743287|DRUG|Imotun capsule placebo|Imotun capsule placebo: per oral, a capsule a day during 24 weeks
223749524|NCT02608931|DRUG|Dronabinol|
223749525|NCT02608931|OTHER|Placebo|placebo
223507602|NCT05610761|BEHAVIORAL|Core stabilization exercises with Kegel exercises|Core stabilization exercise program consists of two phases: teaching the basic movement (contraction of the Transversus abdominis and other muscles with diaphragmatic breathing) and incremental exercises added to the basic movement. The basic movement will be studied before each exercise and then the specified exercises will be added. The physiatrist will teach the exercise program to the patients. The first 6 of the 12 exercises classified according to the degree of difficulty will be performed for 5 weeks, and the next 5 weeks will be moved to the other 6 exercises. The exercises will be performed at least 3 days a week, with 10 repetitions of each movement, and the program will last for 10 weeks. Compliance with the exercise program will be questioned over the phone, and patients will be evaluated with a follow-up form before the study, at the 10th week, and at the 20th week. In addition, the Kegel exercise program specified in the other group will be applied.
223749526|NCT06419387|DEVICE|Self-Therapy Mobile App|Self-Therapy Mobile App includes videos and guidelines for applying EMDR Flash Technique
223749527|NCT06419387|OTHER|Psycho-education Videos|Psycho-education Videos include guidelines for increasing emotion regulation skills.
223749528|NCT03031093|RADIATION|inhalation protocol|technetium labeled diethylenetriaminepenta-acetic acid (99mTc-DTPA) (1mCi) and bronchodilators (fenoterol (2.5 mg) and ipratropium bromide (0.25 mg)) with 0.9% saline solution
223749529|NCT03031093|DEVICE|High Flow Nasal Cannula|aerosol solution of technetium labeled diethylenetriaminepenta-acetic acid (99mTc-DTPA) (1mCi) and bronchodilators (fenoterol (2.5 mg) and ipratropium bromide (0.25 mg)) with 0.9% saline solution (total 1,5 ml) using a vibrating MESH inhaler (Aerogen® Solo, Aerogen Ltd, Galway, Ireland). A High Flow Nasal Cannula will deliver the aerosol at a 30L/min flow of oxigen.
223749530|NCT04418986|PROCEDURE|opposite clear corneal incisions (OCCI)|"Coaxial small incision cataract surgery was performed for all cases using a 2.8 mm keratome placed at steep meridian and 1-mm paracentesis was made 90 degrees apart with a 20-gauge microvitrectomy blade. Surgery was performed with a 30-degree, 0.9-caliper phacoemulsification tip (microtip) with a divide and conquer technique.~In the OCCI group, a single penetrating incision was created with 2.8 mm keratome in the clear cornea, 1.5 mm anterior to limbal blood vessels, centered over the steep meridian and opposite the phacoemulsification incision."
223749531|NCT02653456|DEVICE|RA-308 Excimer Laser and DABRA Catheter|See information already included in arm description
223749532|NCT06146582|BEHAVIORAL|Laguna Coach and App Intervention Group|Behavioral, mental and contextual support was delivered through personal interactions with Laguna Coaches via mobile app, phone, video, or web chat. Care interventions were individualized to best match each participant's needs and strengths. Support will be provided to participants through interactions over approximately 90 days.
223749533|NCT02738333|DRUG|LDV/SOF|90/400 mg FDC tablet administered orally once daily
223749534|NCT02738333|DRUG|SOF|400 mg tablet administered orally once daily
224199957|NCT05712915|OTHER|RRT operation|"A retrospective observational study was conducted at a 990-bed tertiary care referral teaching hospital from April 2014 to December 2020. The RRT implemented in April 2017 as a part-time RRT operating 8 hours on weekdays. In March 2018, operation time was extended to 15 hours on weekdays and finally, extended to 24 hours a day, 7 days a week in February 2019.~Impact of RRT operation on CPR incidence was retrospective analyzed without any prospective intervention."
223507603|NCT05610761|BEHAVIORAL|Kegel exercises|"Kegel Exercises The exercise will start as 2 sets of 10 repetitions in the morning and evening, and after getting used to it, it will be increased to 3 sets of 10 repetitions per day.~The patient, lying on his back with his knees bent, feet slightly apart from each other, will try to lift the breech, urinary tract opening and vagina on the pelvic floor by counting to 5, and should not tighten your abdominal and leg muscles, and should not hold your breath while doing this exercise.~In this way, he will count up to 5 while contracting, then he will relax by counting to 10 (after getting used to it, the holding time will be increased to 10 seconds)."
223507604|NCT01225224|DRUG|peficitinib|oral
223507605|NCT01225224|DRUG|Placebo|oral
223507606|NCT02585180|DEVICE|Endotracheal tubes not allowing SSD|In each participating center, a bundle of VAP prevention will be applied: elevate the head of the bed to 30°-45°, regular oral care, manage patients with sedation algorithm, assess readiness to extubate daily, intermittent control of endotracheal tube cuff pressure
223507607|NCT02585180|DEVICE|Endotracheal tubes allowing SSD|"In each participating center, a bundle of VAP prevention will be applied: elevate the head of the bed to 30°-45°, regular oral care, manage patients with sedation algorithm, assess readiness to extubate daily, intermittent control of endotracheal tube cuff pressure.~In addition, SSD will be realized using a 10 ml syringe at in attending frequency of 2 hours."
223507608|NCT06333652|DRUG|Ravulizumab|Intravenous infusion 100 mg/ml
223507609|NCT06481969|PROCEDURE|Conventional IVF|Conventional In Vitro Fertilization (IVF) procedure and standard assisted reproductive treatments.
223601385|NCT01959438|DRUG|Sodium selenite|Intravenous treatment as described above. Cohorts of 3 patient are given a fixed dose for daily treatment (started with 0.5 mg/m2) and if no grade 3 or 4 toxicity, a new cohort is started on a higher dose. The dose for next cohort is 50% higher than for the former cohort. If grade 3 or 4 toxicity is found in 1 patient, 3 more patients are included on the same dose and if one more patient has serious toxicity it is considered to high a dose and a dose in between the toxic dose and the one before is tested. Thus if 2 patients in 3-6 tested patients has serious toxicity by a certain dose, this dose is to high and the highest dose is considered the earlier tested dose.
223749535|NCT02738333|DRUG|RBV|Capsules administered orally in a divided daily dose according to package insert weight-based dosing recommendations (≤ 60 kg = 600 mg, \> 60 kg to ≤ 80 kg = 800 mg, and \> 80 kg = 1000 mg)
223749536|NCT04979741|OTHER|No interventions|Observational study, no intervention is required
223749537|NCT02658136|OTHER|Cardiac Computed tomography|
223749538|NCT05936866|OTHER|Pelvic floor stretching|Week 1 to 4: Pelvic floor muscles awareness, Breathing exercises , seated pelvic tilts, cat stretches, seated hip openers (2 sets, 8 reps, sustained for 6 seconds) Week 5 to 8: Pelvic floor muscles awareness, Breathing exercises ,seated pelvic tilts, cat stretches, Seated hip openers, Relaxed Frog (2 sets, 8 reps, sustained for 6 seconds) Week 9 to 13: Pelvic floor muscles awareness, Breathing exercises, seated pelvic tilts, cat stretches, Seated hip openers, Relaxed Frog side lying clamshells, mini squats with support (2 sets, 9 reps, sustained for 7 seconds)
223749539|NCT05936866|OTHER|Pelvic floor strengthening|"Week 1 to 4: Pelvic floor muscles awareness, Breathing exercises, 2 Sets of 10 Reps for pelvic floor squeeze and release Seated marching with elastic band with pelvic floor squeeze.~Week 5 to 8: 2 sets x 9 Reps for Pelvic floor squeeze and release, Seated marching with elastic band with pelvic. 2 Sets x 8 Reps for bridging with pelvic floor squeeze, side lying hip circles Week 9 to 13: 2 sets 10 reps for Pelvic floor squeeze-and-release, Seated marching with elastic band with pelvic floor squeeze, pelvic bridging with pelvic floor squeeze, side lying hip circles with pelvic floor squeeze. 2 sets, 8 reps for . side lying Clamshells with resistance band and pelvic floor squeeze and plie squats with pelvic floor squeeze"
223749540|NCT05632549|DRUG|Placebo|Group 1 (n=22) which will receive traditional therapy plus placebo capsule twice daily for 3 months.
223749541|NCT05632549|DRUG|L-Carnitine 500Mg Oral Tablet|Group 2 (n=22) which will receive traditional therapy plus L-carnitine capsules (500 mg twice daily) for 3 months.
223749542|NCT05632549|DRUG|Biotin Capsules|Group 3 (n=22) which will receive traditional therapy plus Biotin capsules (5 mg twice daily) for 3 months.
223749543|NCT05711667|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
223749544|NCT05711667|DRUG|Letermovir|Given PO or IV
223749545|NCT01336075|PROCEDURE|Percutaneous radiofrequency catheter ablation|Percutaneous radiofrequency catheter ablation around the rights and lefts pulmonary veins, with complete circumferential ablation.
223749546|NCT01336075|PROCEDURE|Mini invasive thoracoscopic radiofrequency ablation|Video-assisted thoracoscopic approach for electrical isolation of the pulmonary veins bilaterally and left atrial appendage excision or exclusion.
223749547|NCT00311896|DRUG|Bemiparin|
223749548|NCT00311896|DRUG|Placebo|
223749549|NCT05152888|DRUG|Evolocumab|Evolocumab is a human monoclonal antibody that inhibits proprotein convertase subtilisin-kexin type 9 (PCSK9). Evolocumab was FDA approved in 2015 for the treatment of hyperlipidemia and subsequently approved in 2017 for the prevention of stroke and heart attack. 140mg single use SureClick autoinjector that is administered subcutaneously once every 2 weeks.
223749550|NCT04579042|PROCEDURE|cartilaginous batten graft septoplasty|septoplasty using cartilaginous batten graft in cases with caudal septal deviation
223749551|NCT00080743|DRUG|gefitinib|250 mg po once daily
223749552|NCT00080743|DRUG|tamoxifen citrate|20 mg po once daily
223749553|NCT00080743|DRUG|Placebo|One pill po once daily
223749554|NCT05695521|BIOLOGICAL|CK0803|CK0803 (cryopreserved, allogeneic, cord blood derived T regulatory cells that express neurotropic homing markers) will be administered intravenously
223749555|NCT05695521|OTHER|Excipient|Excipient
223749556|NCT02859233|OTHER|Lack of hyperhydration|
223749557|NCT01212718|DRUG|FUFA|2600/500 mg/m2 i.v. 24 h via port, 1 time weekly for six weeks, than have a break for 2 weeks (=8 weeks for 1 cycle)
223749558|NCT01212718|DRUG|systemic chemotherapy|CPT-11, 80 mg/m2 for 90 minutes and 5 FU/FA 2000/500 mg/m2 iv. 24h via port; 1 time weekly for six weeks, than have a break for 2 weeks
223749559|NCT05450887|DRUG|Obeticholic Acid Tablets（OCA）|Obeticholic Acid：Once a day (QD) by mouth (PO).
223749560|NCT05450887|DRUG|UDCA|UDCA：13\~15 mg/kg/day
223601386|NCT03009968|OTHER|Post-void residual free voiding trial|Will proceed with voiding trial and assess bladder emptying based on voided amount without checking a post-void residual.
223749561|NCT05450887|DRUG|Placebo|Placebo：Once a day (QD) by mouth (PO).
223749562|NCT04914390|DRUG|AT regimen|Doxorubin 60mg/㎡ d1 or Epirubicin 75mg/㎡ d1 and Nab-paclitaxel 260mg/㎡ d1 of Cycles 1-6 (Q3W) of the neoadjuvant phase of the study; IV injection.
223749563|NCT04914390|DRUG|Tislelizumab|200mg on d1 of Cycles 1-6 (Q3W) of the neoadjuvant phase of the study; IV injection.
223749564|NCT04914390|DRUG|Anlotinib|8mg on d1-14 of Cycles 1-5 (Q3W) of the neoadjuvant phase of the study; po. Arotinib is a small molecule multi-target TKI, which exerts its effect by inhibiting angiogenesis, a critical component of tumour growth and metastasis.
223749565|NCT01430013|DRUG|Endostar and CHOPT|Endostar 7.5mg/m2, for iv for continuous 14 days cyclophosphamide, pirarubicin, vincristine, teniposide, prednisone
223749566|NCT05940480|BEHAVIORAL|TCM Daoyin|The TCM Daoyin training program consisted of two 90-min training classes and at least five 30-min at-home practice sessions per week for 16-weeks. All sessions included 10 min of warmup and 10 min of cooldown.
223749567|NCT05940480|BEHAVIORAL|Health education|Health education is provided by doctor and nurse, including work, rest, diet and other basic programs.
223749568|NCT01861496|DRUG|LiPlaCis|LiPlaCis IV every 3 weeks on day 1, day 8
223749569|NCT01498952|DRUG|MEDI-573 (1 of 3 doses)|MEDI-573, a human immunoglobulin G2 lambda (IgG2λ) monoclonal antibody (MAb), is a dual-targeting human antibody that neutralizes insulin-like growth factor (IGF)-I and IGF-II ligands
223749570|NCT01498952|DRUG|Sorafenib|Sorafenib is a tyrosine kinase inhibitor, anti-angiogenic, VEGF inhibitor
223601387|NCT04573608|DRUG|Papacarie|Papacarie was introduced into the cavity using the applicator and left for 40 seconds. A blunt excavator was used to remove the softened dentin. The remaining gel was removed using a cotton pellet. When there was no change in gel color, the cavity was considered caries free. The cavity was then filled with high viscosity glass ionomer cement (GIC) in an encapsulated form (Riva Self-Cure, SDI Limited, Bayswater, VIC, Australia). A mechanical mixer was used to mix the capsule for 10 seconds, the capsule was placed into the applicator to apply the GIC into the cavity. For occluso-proximal cavities, a matrix strip with a wooden wedge was used to provide the appropriate contour of the restoration. A gloved finger was used to apply pressure on the GIC for one minute and occlusion was checked and excess material was removed
223601388|NCT04573608|DRUG|Atraumatic Restorative Treatment|The tooth was cleaned with a wet cotton pellet to remove debris and plaque. Caries was removed using sharp spoon excavators (Darby-Perry #220/221, #17 DE, Hu-Friedy, Chicago, USA), followed by cleaning the cavity using a small wet cotton pellet and finally dried with a dry cotton pellet. The cavity was considered caries-free when a leather-hard texture was reached and the excavator did not stick anymore. GIC was used to restore the cavity using the same technique described for the other group.
223601389|NCT01488201|DRUG|Placebo|
223601390|NCT01488201|DRUG|KHK4827|
223601391|NCT01278797|DRUG|Telmisartan/Amlodipine Combination Tablet|Combination Tablet
223601392|NCT01278797|DRUG|Amlodipine Monocomponent|Active Comparator
223601393|NCT04283591|PROCEDURE|Acupuncture Treatment|Acupuncture Treatment Group will get acupuncture treatment which will be applied to Baihui (DU20), Yintang (EX-HN3) points of the hemiplegic side and bilateral Tai Chong (LR3), Hegu (LI4) points for 4 weeks, twice a week.
223601394|NCT04283591|OTHER|Conventional Rehabilitation Programme|They will continue to receive the conventional rehabilitation programme.
223601395|NCT03556709|DEVICE|Treadmill Ankle Robot Training|This intervention employs the use of an adaptive ankle robot control system, during treadmill walking, over a 6-week intervention period.
223601396|NCT03626961|OTHER|readmission|Readmission after 48 hours
223601397|NCT03626961|OTHER|discharge|Discharge
223601398|NCT04254666|BEHAVIORAL|Physical Literacy & Food Literacy Intervention.|A 12-week intervention designed to expose adolescents with ID to a variety of sports skills and healthy eating concepts to equip them with skills and confidence to participate in sports and make healthy food choices. The program will follow a protocol adapted to meet the needs of a diverse group of children with ID. Sessions will be held 1 time/week for 75 minutes virtually; 35 minutes will focus on sport skills activities with 35 minutes devoted to healthy eating.
223601399|NCT01695434|OTHER|MRI|All subjects will undergo a MRI.
223601400|NCT00025558|BIOLOGICAL|filgrastim|
223601401|NCT00025558|DRUG|carboplatin|
223601402|NCT00025558|DRUG|temozolomide|
223601403|NCT00025558|DRUG|thiotepa|
223749571|NCT02280590|DRUG|Rosuvastatin(Cresnon®)|10mg
223749572|NCT02280590|DRUG|Rosuvastatin(Crestor®)|10mg
223749573|NCT00579826|DRUG|Letrozole|Letrozole 2.5 mg tablet daily. Then optional open label letrozole for another 6 months.
224199958|NCT02980029|DRUG|TVB-2640|TVB-2640 is a potent and reversible inhibitor of the FASN enzyme. TVB-2640 inhibits the β-ketoacyl reductase (KR) enzymatic activity of the FASN enzyme. TVB-2640 is uncompetitive towards both NADPH and acetoacetyl-CoA in inhibiting KR activity.
223601404|NCT00025558|PROCEDURE|autologous bone marrow transplantation|
223601405|NCT00025558|PROCEDURE|peripheral blood stem cell transplantation|
223601406|NCT01574066|PROCEDURE|Chest CT-scan|Patients with a suspicion of acquired pneumonia visiting the emergency department will do a chest CT-scan
223601407|NCT00114855|DRUG|HYPOCOL®|
223601408|NCT01921504|DEVICE|Acupuncture|"Acupuncture treatment~1. Acupuncture rationale 1a) Style of acupuncture: body acupuncture (in accordance with meridian theory)~2. Needling details 2a) Number of needle insertions per subject per session: 9-19 2b) Acupoints: Basic points - Large Intestine(LI)4, Stomach(ST)36, Liver(LR)3, Spleen(SP)4, Conception Vessel(CV)12 Optional points - Gallbladder(GB)21, Small Intestine(SI)14, Pericardium(PC)6, External points of Hand and Neck(EX-HN)5, Stomach(ST)34 2c) Depth: 5 \~ 30mm 2d) Response sought: 'Deqi' 2e) Needle stimulation: Manipulation 2f) Retention time: 15 minutes 2g) Needle type: 25 X 30 mm, sterilized stainless steel needle, Dongbang Inc., Korea"
223601409|NCT04966520|OTHER|Accelerated repetitive intermittent theta-burst transcranial stimulation (iTBS)|"Accelerated iTBS will be used to stimulate the regions of interest of mPFC and L-DLPFC nodes in cancer survivors or patients.~Accelerated iTBS will be administered in a single half-day period to allow for a 50minutes interval between any two treatments to minimize interference effects between treatments. Thus, there will be \~10 minute sessions of stimulation x 2 applications per node x 2 nodes (L-DLPFC, mPFC) = 40 total minutes of daily stimulation - each session delivers 1800 pulses in a 5 Hz triplet burst frequency, 2 second trains with intertrain interval of 8 seconds; triplets occur with 50 Hz frequency, as per standard iTBS protocols for depression treatment. The treatment will be offered for five consecutive days."
223601410|NCT03343626|DRUG|Placebo|Placebo (normal saline (0.9% NaCl) IM injection.
223601411|NCT03343626|BIOLOGICAL|PIZV|Purified inactivated Zika virus vaccine with aluminum hydroxide adjuvant IM injection.
223749574|NCT00579826|DRUG|Placebo|Placebo tablet daily for 6 months then optional open label letrozole for 6 months.
224075283|NCT00769145|DRUG|Ranibizumab|0.5mg subconjunctival dose of ranibizumab 3 days prior to corneal transplantation and at the time of corneal transplantation (total 2 injections).
224075284|NCT01627587|DRUG|GSK221149 750 mg|Treatment A: 750 mg GSK221149 single dose
224075285|NCT01627587|DRUG|Ketoconazole|Treatment B: 400 mg of Ketoconazole single dose
224075286|NCT01627587|DRUG|GSK221149 100 mg|Treatment C: 100mg of GSK221149 single dose
224075287|NCT01627587|DRUG|GSK221149 750 mg Fasted|Treatment D: 750 mg of GSK221149 administered fasted
224075288|NCT01627587|DRUG|GSK221149 750 mg + Food|Treatment E: 750 mg of GSK221149 administered with a high fat meal
224199959|NCT02980029|OTHER|Placebo|Placebo
224199960|NCT01542879|PROCEDURE|WB-DW-MR scan|WB-DW-MR scans will be obtained on a 3T PET-MR system
224199961|NCT01542879|PROCEDURE|18-F-FDG PET scan|
224199962|NCT01542879|DRUG|Ferumoxytol|
224199963|NCT01542879|PROCEDURE|18-F-FDG PET/MR scan|
223601412|NCT02856048|DRUG|Triptorelin (GnRHa) + Chemotherapy|During her chemotherapy, the patient in the experimental arm will have regular injections of Triptorelin (DECAPEPTYL LP 3 mg, IPSEN) in order to preserve her fertility
223601413|NCT00673335|DRUG|letrozole|
223601414|NCT00673335|DRUG|Placebo|
223749575|NCT04189458|OTHER|Multimodal exercise program|Each session includes: beginning ritual (5 min), warm-up (15 min), main section comprising the multimodal exercises (30 min), cool-down (5 min), and finishing ritual (5 min). At the initial stage, the activation of different muscle groups will be performed. The main section (multimodal exercises) will be focused on the specific objectives through sensorimotor and neurocognitive activities and will privilege IPS. This section includes periods ranging 10-15 min of exercises mainly focused on motor stimulation - physical fitness (strength, balance and agility) - alternating with exercises mainly focused on cognitive stimulation - CF (planning ability, solving-problems, IPS, attention and DT performance). At the cool-down the participants will normalize their physiological parameters. Finally, at the finishing ritual the participants sign an attendance sheet regarding the session, including perceived exertion (Borg Scale) and satisfaction (Caregiver Treatment Satisfaction questionnaire).
223749576|NCT04000048|GENETIC|sequencing of the complete exome|Once the pathological diagnosis is confirmed (WHO 2016), a tumor fragment will be selected and frozen for each lobe. DNA extraction will be performed for each fragment. The samples (4 different DNAs per GDBG corresponding to the DNA extracted from each of the 3 lobes and the blood DNA) will be sent to the Montpellier Genomix platform for sequencing of the complete exome.
223749577|NCT04191382|DRUG|Amcenestrant (SAR439859)|Pharmaceutical form: Capsules, Route of administration: Oral
223749578|NCT04191382|DRUG|Letrozole|Pharmaceutical form: Tablets, Route of administration: Oral
223749579|NCT02939963|PROCEDURE|ATC then pressure support 7 cm H2O PEP 4 cm H2O|spontaneous breathing through endotracheal tube with no ventilator support except for ATC, the patient is connected to the ventilator with pressure support 0 cm H2O and PEP 4 cm H2O during 30 minutes then 30 minutes of basal pressure support then 30 minutes with pressure support 7 cm H2O PEP 4 cm H2O
223749580|NCT02939963|PROCEDURE|Pressure support 7 cm H2O PEP 4 cm H2O then ATC|30 minutes with pressure support 7 cm H2O PEP 4 cm H2O then 30 minutes of basal pressure support then 30 minutes with spontaneous breathing through endotracheal tube with no ventilator support except for ATC, the patient is connected to the ventilator with pressure support 0 cm H2O and PEP 4 cm H2O
223749581|NCT05035173|OTHER|Survivorship Clinic Assessments|"Patients will visit in person the Survivorship Clinic at the baseline and end of the study (12-month) at the ORCHID center in the Cork University Hospital (Cork, Ireland).~During these visits, baseline and end of the study assessments will be made. Patients will receive routine standard information, a care plan and resources about survivorship at the baseline visit."
223749582|NCT05035173|OTHER|Survivorship Clinic Nurse Resource|"Patients will receive a Survivorship Personal Treatment Plan by the nurse from the Women's Health Initiative Survivorship Clinic according to the results from the baseline ePROs. In addition to that, each 2 months for a period of 12 months, the patient will be answering ePROs. The nurse will undertake an intervention when needed based as per the Trigger system (developed form ePROs responses) or clinical judgement.~\- ePRO Symptom Survey Instrument (nurse questions): A core list of symptoms/adverse events that are identified including gastrointestinal, attention/memory, pain, fatigue and insomnia, mood-emotional distress/depression, anxiety, fear of cancer recurrence, gynaecological, urinary, sexual issues, hot flashes."
223749583|NCT05035173|OTHER|Survivorship Clinic Dietitian Resource|"Patients will receive Diet Education and Personalised Nutrition Counselling by the dietitian from the Women's Health Initiative Survivorship Clinic at the baseline. In addition to that, each 2 months for a period of 12 months, the patient will be answering ePROs. The dietitian will undertake an intervention when needed as per the Trigger system (developed form ePROs responses) or clinical judgement.~\- ePRO Symptom Survey Instrument (diet questions): nutritional risk (lack of appetite; worry regarding weight loss; worry regarding weight gain), weight, and exercise."
223749584|NCT00446433|DRUG|CC-5013|
223749585|NCT06254742|DRUG|HHPG-19K Injection|first cycle: Auto-HHPG-19K Injection or HHPG-19K Injection second cycle: HHPG-19K Injection or Auto-HHPG-19K Injection
224199964|NCT04931147|DRUG|RXC007|"RXC007 will be administered in the form of oral capsules at selected doses starting at 2 mg to 4 of the 6 participants within each cohort in Part A and Part B. For Part A, dosing frequency is one single dose on one occasion and for Part B, dosing frequency is single doses once daily for 14 days. If required, following dose escalation data review, dosing frequency and duration may be modified in Part B.~All participants in Part C (24) will receive active RXC007 in the form of oral capsules as single doses."
224199965|NCT04931147|DRUG|RXC007 Matching Placebo|"The matching placebo for RXC007 will be administered in the form of oral capsules matched to the number of active RXC007 capsules at each dose level to 2 of the 6 participants within each cohort in Part A and Part B. For Part A, dosing frequency is one placebo dose on one occasion and for Part B, dosing frequency is single placebo doses once daily for 14 days. If required, following dose escalation data review, dosing frequency and duration may be modified in Part B.~There is no placebo intervention for Part C of the study."
224199966|NCT01319747|PROCEDURE|PVI|For catheter ablation, we used irrigated 4mm RF-ablation catheters, at a maximum power of 30-35Watt, an irrigation rate of 20 mL/min. PV isolation was performed by wide circumferential ablation, encircling all ipsilateral PVs.
223601415|NCT03919357|BEHAVIORAL|BMT-i|Passing the BMT-i test
223601416|NCT04051853|DRUG|Sorafenib|Patients will receive sorafenib at a starting dose of 200 mg twice daily. In the absence of toxicity dosage will be gradually escalated up to 400 mg BID.
223601417|NCT04051853|OTHER|Midazolam clearance test|Before start of treatment patients receive a single oral dose of midazolam to phenotype CYP3A4 activity. Blood samples will be taken at several time points to measure sorafenib and midazolam concentrations.
223601418|NCT04051853|OTHER|CYP cocktail clearance test|In a subgroup of 15 patients (in the Academic Medical Center Amsterdam), this test will be replaced by an oral cocktail of subclinical doses of caffeine, midazolam, omeprazole, warfarin and metoprolol and will be repeated after 4 weeks of treatment to assess the influence of sorafenib on cytochrome P450 (CYP) 1A2, 3A4, 2C19, 2C9 and 2D6 activity, respectively.
223601419|NCT02566317|DEVICE|Sit-Stand workstation|Installation of a sit-stand desk at work
223601420|NCT02566317|BEHAVIORAL|Move|A multi-level individual, social, environmental, and organizational intervention targeting increases in light-intensity physical activity in the workplace
223601421|NCT05968768|DRUG|Naxitamab|Naxitamab will be used only in a hospital setting and must be administered under the supervision of a doctor with experience in the use of oncological therapies. The medicinal product must be administered by a healthcare professional prepared to deal appropriately with severe allergic reactions, including anaphylaxis, in an environment that provides immediate, full access to resuscitation. The patient should have 2 well-functioning IV accesses before any naxitamab treatment is initiated. The solution should be administered through a peripheral or central intravenous catheter. Other concomitant intravenous medicinal products should be administered through separate intravenous access. Before the start of each infusion, premedication will be carried out.
223601422|NCT04978584|DRUG|Acalabrutinib|Given PO
223601423|NCT04978584|DRUG|Cyclophosphamide|Given IV
223601424|NCT04978584|DRUG|Doxorubicin Hydrochloride|Given IV
223601425|NCT04978584|DRUG|Lenalidomide|Given PO
223749586|NCT06254014|DRUG|Exendin-4 Fc fusion protein injection|1.2mg, subcutaneous injection in the abdomen, biweekly, 54 weeks of treatment.
223749587|NCT06254014|DRUG|Exendin-4 Fc fusion protein injection|The first dose of 1.2 mg was administered subcutaneously in the abdomen, and after two weeks, the dose was adjusted to 2.4 mg, followed by a continuation of treatment for 52 weeks.
223749588|NCT06254014|DRUG|Placebo|0.6 ml, placebo injection, biweekly subcutaneous abdominal injections for 26 weeks (core treatment period), after which placebo was randomized 1:1 to JY09 (1.2 mg) and JY09 (2.4 mg) continued subcutaneous abdominal injections biweekly for 28 weeks (extended treatment period).
223749589|NCT06538766|OTHER|Strength training with an internal focus of attention|A 4 weeks strength training program of seated calf raises with progressive overload is carried out. A supervisor applies force specific internal focus instruction in three sessions per week with at least 48h rest time. One session consists of 3 series until failure with 75%RM. Rest intervals between series are defined as 2 minutes.
223749590|NCT06538766|OTHER|Strength training with a proprioceptive external focus of attention|A 4 weeks strength training program of seated calf raises with progressive overload is carried out. A supervisor applies force specific proprioceptive external focus instruction in three sessions per week with at least 48h rest time. One session consists of 3 series until failure with 75%RM. Rest intervals between series are defined as 2 minutes.
223749591|NCT06538766|OTHER|Strength training with a visual external focus of attention|A 4 weeks strength training program of seated calf raises with progressive overload is carried out. A supervisor applies force specific visual external focus instruction in three sessions per week with at least 48h rest time. One session consists of 3 series until failure with 75%RM. Rest intervals between series are defined as 2 minutes.
223749592|NCT05100823|PROCEDURE|Nasal cells sampling|Nasal epithelium brushing in intermediate turbinate using a specific curette following a local anesthesia with Xylocaine 5% nebulizer.
223749593|NCT05100823|PROCEDURE|Rectal biopsy sampling|Forceps Biopsy Procedure (Servidoni et al., 2013) Only for volunteer patients included in the Montpellier center.
223749594|NCT05237206|BIOLOGICAL|SUPLEXA|PBMC-derived autologous cellular therapy derived through an ex vivo activation procedure, resulting in a cell mixture comprised predominantly of NK, NK-T, and T cells stored in cryogenic media.
223749595|NCT05433623|PROCEDURE|Surgery|It will be documented if the patient underwent surgery for their vascular issue
223749596|NCT05846516|DRUG|VSV-GP154|VSV-GP154
223749597|NCT05846516|DRUG|ATP150|ATP150
223512281|NCT03483220|DIAGNOSTIC_TEST|MRI brain|"1\. Emotion Regulation Questionnaire (ERQ): A 10-item scale designed to measure respondents' tendency to regulate their emotions in two ways: (1) Cognitive Reappraisal and (2) Expressive Suppression. Respondents answer each item on a 7-point Likert-type scale .~UPPS-P Impulsive Behavior Scale- Short form: The UPPS-P impulsivity scale is a 20-item scale designed to assess five distinct personality traits to impulsive behavior: Negative Urgency, Lack of Perseverance, Lack of Premeditation, Positive Urgency and Sensation Seeking .~Magnetic resonance imaging examination:~The MR examination of brain was done using 1.5T MR scanner (Achieva, Philips Medical Systems, The Netherlands) with a 16 channel head coil without using any sedation."
223749598|NCT05846516|DRUG|ATP152|ATP152
223749599|NCT05846516|DRUG|Ezabenlimab|Ezabenlimab
223601426|NCT04978584|DRUG|Prednisone|Given PO
223749600|NCT05846516|DRUG|ATP162|ATP162
223749601|NCT05067634|DRUG|Xcopri|Age groups 12 to \<18 will enroll once dosing data is received from Cohort I of the PK analysis of YKP3089C039 study. Age groups 6 to \<12 will enroll once dosing data is received from Cohort IIa of the PK analysis of YKP3089C039 study. Age groups 4 to \<6 will enroll once dosing data is received from Cohort IIb of the PK analysis of YKP3089C039 study. Age groups 2 to \<4 will enroll once dosing data is received from Cohort III of the PK analysis of YKP3089C039 study.
223749602|NCT06460519|OTHER|Non-invasive blood pressure measurements|Non-invasive blood pressure measurements to the tension cuff three times in a row on each side (right arm and left arm)
223749603|NCT01748643|DRUG|deep neuromuscular blockade with rocuronium, reversal with sugammadex|after induction of anesthesia, a rocuronium infusion (0.6mg/kg (lean body mass)/h,) is started and titrated to a post tetanic count of 1-2 twitches. At the end of surgery neuromuscular blockade will be reversed with sugammadex 4mg/kg. Patients are extubated when TOF ratio \> 0.9.
223749604|NCT01748643|DRUG|normal neuromuscular blockade reversal with rocuronium, reversal with neostigmine|After induction of anesthesia, top-ups of rocuronium (10mg) are given as needed to maintain a train of four count of 1-2. At the end of surgery neuromuscular blockade will be reversed with neostigmine 50μg/kg and glycopyrrolate 10μg/kg (lean body mass). Patients are extubated when the train of four ratio is \> 0.9.
223601427|NCT04978584|BIOLOGICAL|Rituximab|Given IV
223601428|NCT04978584|BIOLOGICAL|Tafasitamab|Given IV
223601429|NCT04978584|DRUG|Vincristine|Given IV
223601430|NCT05831488|OTHER|Non-Interventional|Non Interventional
223601431|NCT03005132|OTHER|Normal brain tissue|The investigators will extract total protein, DNA and RNA from the samples.
223601432|NCT02475278|BIOLOGICAL|NoV GI.1/GII.4 Bivalent VLP Vaccine|Norovirus GI.1/GII.4 bivalent VLP vaccine adjuvanted with aluminum hydroxide for IM injection
223749605|NCT04079179|DRUG|Cobimetinib|Cobimetinib will be administered at a maximal dose of 60 mg daily for patients \<18 years old and a flat dose of 40 mg daily for patients ≥18 years for 21 days on, then 7 days off, in a 28-day treatment cycle for a total of 12 cycles (approximately 12 months).
223749606|NCT05612633|DRUG|zelavespib|Oral zelavespib 100 mg will be administered once daily
223749607|NCT01966640|BIOLOGICAL|Basophil Activation Test|blood sample for Basophil Activation Test
223749608|NCT04569903|DEVICE|Computer algorithm for ATTR|Patients will be evaluated for the identification of ATTR Amyloidosis through a claims-based algorithm
223749609|NCT02701647|DEVICE|Repetitive transcranial magnetic stimulation (rTMS)|Repetitive TMS (rTMS) is a painless and non-invasive technique for activation of cerebral cortex based on the principle of electromagnetic induction of an electric field in the brain. rTMS will be delivered to the scalp over the leg area of the bilateral motor cortex by using a Magstim Rapid magnetic stimulator. (Magstim Company, Whitland, UK) and 90 mm double cone coil.
223749610|NCT02701647|OTHER|Treadmill training|Participants will proceed to 30 minute of treadmill training after rTMS. A safety harness without body weight support will be provided. 80% of participant's over ground maximum walking speed will be halved and used for warm-up. After warming up, walking speed will be increased by 0.2 km/h every 5 minutes. Progression will be given if patients could tolerate the belt speed with appropriate step length and walk with good stability for 5 minutes. Participants will maintain the maximum speed achieved for the rest of the session or adjusted as needed. Positive verbal feedback will be given to encourage large strides and upright posture during training. The participants will be instructed to walk on treadmill without holding onto the handrails if possible. Participants will perform warm up and cool down exercise to minimize training related-injury.
223749611|NCT01369979|PROCEDURE|Liver vein catheter|Liver vein catheter is placed in the heptic vein via the femoral vein, using fluoroscpoy as guidance.
223749612|NCT02653807|OTHER|mobilization with movement|manual therapy intervention
223749613|NCT02653807|OTHER|osteopathic mobilization|manual therapy intervention
223749614|NCT03042052|DRUG|detrusor infection of Botulinum toxin|detrusor injection
223749615|NCT06542952|OTHER|seizure|epileptic children
223749616|NCT06050252|PROCEDURE|Biopsy Procedure|Undergo tissue biopsy
223749617|NCT06050252|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223749618|NCT06050252|DRUG|Cisplatin|Given IV
223749619|NCT06050252|PROCEDURE|Computed Tomography|Undergo CT scan
223749620|NCT06050252|BIOLOGICAL|Durvalumab|Given IV
223749621|NCT06050252|DRUG|Gemcitabine|Given IV
223749622|NCT06050252|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI scan
223749623|NCT06050252|PROCEDURE|Resection|Undergo surgical resection
223512282|NCT04356443|DEVICE|AirGo Respiratory Monitor|AirGo™ is composed of a wearable, miniaturized recorder unit and a medical grade Holter worn over the floating ribs of patients both at rest and during normal activity. The recorder measures live circumference changes.
223749624|NCT00454987|BIOLOGICAL|Menitorix|Menitorix was only administered to subjects of the group Meningitic+Hiberix group at 40 to 43 months of age.
223749625|NCT00454987|BIOLOGICAL|Infanrix IPV|Infanrix IPV was administered according to the manufacturer's instructions to UK subjects at 40 to 43 months of age.
223749626|NCT06422260|OTHER|Prosthesis superstructure|Prosthesis superstructure for 2 implant supported short span fixed bride constructed from different materials
223749627|NCT02205333|BIOLOGICAL|MEDI6469 Monotherapy|single intravenous (IV) administration of MEDI6469
223749628|NCT02205333|BIOLOGICAL|MEDI6469 Plus Tremelimumab|MEDI6469 in combination with Tremelimumab
223512283|NCT00320580|DRUG|norelgestromin/ethinyl estradiol|
223512284|NCT04545372|OTHER|aerobic exercise|
223512285|NCT04483232|BIOLOGICAL|Ear canal swab|Ear canal swab
223749629|NCT02205333|BIOLOGICAL|MEDI6469 Plus Durvalumab|MEDI6469 in combination with Durvalumab
223749630|NCT02205333|BIOLOGICAL|MEDI6469 plus Rituximab|MEDI6469 in combination with Rituximab
223749631|NCT05272904|PROCEDURE|Quilting|Following mastectomy and/or axillary lymph node dissection, the subcutaneous tissue is sutured to the pectoralis muscle placing multiple rows of running sutures. The suture starts at either end of the scar, running back and forth, creating rows of quilting stiches. The rows are placed transversely from the cranial to the caudal end of the wound with 2-3 cm between them, totalling some three to ﬁve rows for the cranial ﬂap. The caudal ﬂap is quilted with 2-3 rows in a caudal to cranial fashion. A subcutaneous suture followed by a intracutaneous running suture is used to close the skin.
223749632|NCT05272904|PROCEDURE|Conventional wound closure|Following mastectomy, skin is closed using subcutaneous sutures followed by intracutaneous running suture. Depending on the surgeons discretion a vacuum closed suction drain was placed beneath the skin flaps.
223512286|NCT01864096|DRUG|Metformin|One month run-in of 850mg metformin once daily, followed by 850mg twice daily of metformin for 35 months. Total time is 36 months.
223512287|NCT01864096|DRUG|Placebo|One month run-in of placebo tablet once daily, followed by twice daily for 35 months. Total time is 36 months.
223512288|NCT00430664|PROCEDURE|Pleurodesis with either talc or iodopovidone|
223512289|NCT03685240|BEHAVIORAL|SafelyYou Fall Prevention System|Technology + Quality Assurance Services Provided by SafelyYou
223512290|NCT05492903|BEHAVIORAL|COMmunity of Practice And Safety Support for Navigating Pain (COMPASS-NP)|A peer-led and supportive group program (10 weekly sessions) designed to address the needs of HCWs with chronic or elevated pain. The intervention will integrate work-based injury protections with pain education and cognitive-behavioral therapy strategies for pain self-management.
223512291|NCT04063904|DRUG|Mifepristone|One 200 mg pill (oral)
223512292|NCT04063904|DRUG|Misoprostol|Two 400 mcg pills (sublingual)
223512293|NCT00017186|DRUG|epirubicin hydrochloride|
223512294|NCT00017186|DRUG|gemcitabine hydrochloride|
223512295|NCT01760980|DRUG|Reference product (A) Aromasin (Exemestane)|Aromasin tablets will be administered under fasting conditions on two occasions
223512296|NCT01760980|DRUG|Test product (B) Exemestane|Exemestane tablets will be administered under fasting conditions on one occasion
223512297|NCT03028922|DEVICE|creos xenogain|GBR procedure will be performed using creors xenogain bone graft substitute in patients that need horizontal bone augmentation prior to implant placement. The defect should be located in the pre-molar and molar region of the mandible
223749633|NCT05024500|OTHER|ARDSNet table|The setting of the lowest PEEP level and FiO2 match stated by the table to achieve a goal oxygenation.
223749634|NCT05024500|OTHER|Driving Pressure|The setting of the lowest PEEP level by the lowest correspondent driving pressure, which is defined by the difference of plateau pressure, after a modified alveolar recruitment maneuver.
223749635|NCT05024500|OTHER|Electrical Impedance Tomography|The setting of the PEEP level above the intersection of the curves representing relative alveolar overdistention and collapse, after a modified alveolar recruitment maneuver.
223749636|NCT01476696|DRUG|Prasugrel|Administered orally
223749637|NCT04818190|PROCEDURE|Sensory neurotization|The donor nerve is a cutaneous nerve that is identified with the most inferior lateral perforator vessels. The nerve is then dissected for neurotization and divided at the level of the fascia where it is a pure sensory nerve. The recipient intercostal nerve is usually easily identified in the third intercostal space during the dissection of the internal mammary artery and vein. The anterior branch of the third intercostal nerve can usually be found at the junction of the inferior portion of the third rib and the sternum, approximately 80% of the time. The nerve is dissected and transected medially. It is then mobilized to give it the longest length possible in preparation for neurotization. Neurotization is performed by coapting the donor nerve to the third anterior intercostal nerve directly with a 9-0 nylon suture in standard fashion.
223749638|NCT01187927|BIOLOGICAL|Cervarix®|Administered according to the prescribing information in the locally approved label by the authorities.
223749639|NCT04836299|DRUG|Ivermectin|Participants will be randomly assigned to receive a single 600 µg / kg dose of ivermectin or placebo.
223749640|NCT04836299|DRUG|Placebo|Participants will be randomly assigned to receive a single of placebo.
223749641|NCT04087460|BIOLOGICAL|Protein based pneumococcal vaccine(Low dose)|0.2mL,Intramuscular other name:PBPV
223749642|NCT04087460|BIOLOGICAL|Protein based pneumococcal vaccine placebo(Low dose)|0.2mL,Intramuscular other name:PBPV placebo
223749643|NCT04087460|BIOLOGICAL|Protein based pneumococcal vaccine(Middle dose)|0.5mL,Intramuscular other name:PBPV
223749644|NCT04087460|BIOLOGICAL|Protein based pneumococcal vaccine placebo(Middle dose)|0.5mL,Intramuscular other name:PBPV placebo
223749645|NCT04087460|BIOLOGICAL|Protein based pneumococcal vaccine(High dose)|1.0mL,Intramuscular other name:PBPV
224199967|NCT01319747|PROCEDURE|VATS-PVI|A bilateral video-assisted thoracoscopic (VATS) pulmonary vein isolation and left atrial appendage (LAA) excision is performed under general anaesthesia and double-lumen endotracheal ventilation.
223512298|NCT05025371|OTHER|Systemic immune-inflammatory markers|Systemic immune-inflammatory markers used in this study: total neutrophil count, total lymphocyte count, total monocyte count, total platelet count, neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), lymphocyte-to-monocyte ratio (LMR), systemic immune-inflammation index (SII), prognostic nutritional index (PNI)
223512299|NCT04779593|OTHER|Clinical examination|Clinical data will be recorded (general clinical examination, height, weight, blood pressure,heart beat, alcohol and tobacco consumption, antecedent) as well as concurrent medication at each follow-up visit.
223512300|NCT04779593|OTHER|SF36 questionnaire|"At D0, M12 and M24. This 36 item patient reported survey of patient's health is the most commonly used and validated health survey instrument for appraising quality of life.~Items are grouped in 8 scaled scores exploring multiple dimension of global health (vitality, physical functioning, bodily pain, general health, perceptions, physical role functioning, emotional role functioning, social role functioning, mental health).~Scoring will be performed as recommended by the SF-36 instruction manual to create the eight scale scores. Furthermore, these subscales sum to obtain the total SF-36 score and will be summarized into two composite scores (physical and mental quality of life)."
223512301|NCT04779593|OTHER|AIMS2_SF questionnaire|At D0, M12 and M24. The Arthritis Impact Measurement Scales 2 Short Form (AIMS2-SF) is a specific tool to measure changes in global health, pain, mobility and social function in patients with arthritis. It was described in 1992 in patients with rheumatoid arthritis and osteoarthritis and include 26 items that are summarized in scales according to a predefined scoring system: mobility, physical activity (walking, bending, lifting), dexterity, household activity (managing money and medications, housekeeping), social activities, activities of daily living, pain, depression, and anxiety. The French translation has been validated and this questionnaires has been widely used in the rheumatology field to assess quality of life of patients with arthritis. Because HFE related arthropathy is very similar to osteoarthritis this questionnaire is ought to be adequate in this setting.
223512302|NCT04779593|OTHER|WOMAC questionnaire|At D0, M12 and M24. The Western Ontario and McMaster Universities Arthritis Index (WOMAC) is a widely used questionnaires specifically assessing lower limb (hips and knee) osteoarthritis. It measures five items for pain, two for stiffness and 17 for functional limitation and had been translated in French.
223512303|NCT04779593|OTHER|EQ-5D-5L questionnaire|At D0, M12 and M24. The EQ-5D is a standardized instrument which evaluates the generic quality of life (http://www.euroqol.org/). It is a preference-based health-related quality of life measure with one question for each of the five dimensions that include mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The answers given to EQ-5D permit to find 243 health states that can be converted into utility score anchored at 0 for death and 1 for perfect health. EQ-5D is an instrument developed in Europe, widely used in cost-utility analysis. It has been validated in a representative sample of French population.
223512304|NCT04779593|BIOLOGICAL|Blood Sample Complete blood count|Blood Sample Complete blood count at D0, M6, M12, M18 and M24/end follow-up visit
223512305|NCT04779593|BIOLOGICAL|Blood Sample Iron panel|Blood Sample Iron panel (serum ferritin, serum iron and serum transferrin to determine transferrin saturation according to randomization group (at M6, M12 and M18) at D0, M6, M12, M18 and M24/end follow-up visit and at each bloodletting.
223512306|NCT04779593|BIOLOGICAL|Blood Sample Fasting Glucose|Blood Sample Fasting Glucose at D0 and M24/end follow-up visit
223512307|NCT04779593|BIOLOGICAL|Blood sample lipid panel|Blood sample lipid panel (total cholesterol, triglycerides, HDL, LDL) at D0 and M24/end follow-up visit
223512308|NCT04779593|BIOLOGICAL|Blood sample liver panel|Blood sample liver panel (total bilirubin, Alanine Aminotransferase, Alkaline Phosphatase, Aspartate Aminotransferase, Gamma-Glutamyl Transferase) at D0 and M24/end follow-up visit
223601433|NCT01416948|DRUG|Methylphenidate Hydrochloride 20 mg|For patients assigned to the MPH arm of the study, the drug will be initiated at 5 mg bid at week 0, and increased to 10 mg bid at week 4, and finally increased to 20 mg bid at week 8 and then held constant until the major outcome assessment at week 12. The drug will be gradually tapered during weeks 12-14. If adverse events ensue, the subject's dose can be held at the current dose (rather than proceeding with scheduled dose increases) or reduced to the previous dose. Subjects who cannot tolerate the minimum dose (5 mg bid) will be withdrawn from the study.
223601434|NCT01416948|DRUG|Placebo Capsule|For patients randomly assigned to the placebo arm of the study, placebo will be administered BID at Week 0 through Week 12. Matching placebo will be administered to match the taper period.
223601435|NCT01416948|DRUG|Galantamine 12 mg|For patients randomly assigned to the GAL arm of the study, the drug will be initiated at 4 mg bid at week 0, increased to 8 mg bid at week 4, and finally increased to 12 mg bid at week 8 and then held constant until the major outcome assessment at week 12. The drug will be gradually tapered during weeks 12-14. If adverse events ensue, the subject's dose can be held at the current dose (rather than proceeding with scheduled dose increases) or reduced to the previous dose. Subjects who cannot tolerate the minimum dose (4 mg bid) will be withdrawn from the study.
223601436|NCT01103388|DRUG|Rituximab|375 mg/m\^2 by vein (IV) in 4 weekly doses (1 cycle) every 6 months for 4 cycles.
223601437|NCT01740024|BIOLOGICAL|1 (Dose Response Skin Prick Tests)|3 different cat epithelium allergenic extracts at 3 different concentrations, together with a positive and negative control will be tested in every patient in duplicate on the volar surface of the forearm.
223601438|NCT00003346|DRUG|acetaminophen|
223601439|NCT00003346|DRUG|acetylcysteine|
223601440|NCT00003346|DRUG|carmustine|
223601441|NCT03402724|OTHER|echographic|Patients are called for an echographic evaluation in the implanting center in case of the usual care
223601442|NCT03987516|OTHER|Active exercising|Patients allocated to the experimental group were included in an active exercising program adapted to each patient
223749646|NCT04087460|BIOLOGICAL|Protein based pneumococcal vaccine placebo(High dose)|1.0mL,Intramuscular other name:PBPV placebo
223749647|NCT00827970|BEHAVIORAL|Screening for urogenital Chlamydia trachomatis|Receeiving an invitation to be tested for urogenital Chlamydia trachomatis by use of a home-obtained and mailed sample.
223749648|NCT01275274|DRUG|Retinoic acid|Patients will be started at half the recommended dose of retinoic acid for the treatment of acute promyelocytic leukemia (APL), i.e. 22.5mg/m2/day orally in two divided doses, to minimize the risk of adverse events. If there is no decrease in PR3/MPO gene expression to a fold change of \< 2 by quantitative polymerase chain reaction(QT-PCR) technique for PR3 at the end of 4 weeks, the dose will be increased to 45 mg/m2/day in two divided doses for an additional 8 weeks. If the patient shows a decrease in PR3/MPO gene expression to \< 2 at 4 weeks, the patient will remain on the same dose for the remainder of 12 weeks. All patients will be followed for a total of 12 months for safety evaluations and to assess changes in disease activity and the incidence of disease relapse.
223749649|NCT01275274|DRUG|Standard of care|maintenance therapy with azathioprine or mycophenolate mofetil with or without small dose prednisone. Dose, frequency and duration depend on disease activity (partial or complete remission).
223749650|NCT01771146|DRUG|FOLFIRINOX Regimen|6 cycles of FOLFIRINOX prior to surgical resection: Eloxatin® (Oxaliplatin) 85 mg per square meter 2-hour IV infusion Camptosar® (Irinotecan Hydrochloride) 180 mg per square meter 90-minute IV infusion via Y-connector adrucil (Fluorouracil; 5-FU)2400 mg per square meter 46-hour IV infusion
223749651|NCT06301711|BEHAVIORAL|Rehabilitation therapy|"The study lasted 10 days for each patient. During the treatment, All the participants were provided with the rehabilitation therapy, which included routine rehabilitation, cognitive training, swallowing function training and nutrition support.~Particularly, due to dysphagia, the patients enrolled might face difficulty in eating. For patients who were able to finish intake via mouth by compensatory means, the consistency, type, and size of food bolus was arranged. For those who cannot acquire sufficient nutrition through oral intake, the nasogastric tube feeding was provided."
223749652|NCT06301711|PROCEDURE|Stellate ganglion block|Based on the invention above, the patients in the observation group were provided with Stellate ganglion block, using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate ganglion block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
223749653|NCT06301711|DRUG|Lidocaine Hydrochloride|Based on the invention above, the patients in the observation group were provided with Stellate ganglion block, using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate ganglion block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
223749654|NCT02128191|DRUG|Oral ibuprofen|Initial dose of 10 mg/kg of oral ibuprofen, followed by two doses of 5 mg/kg 24 and 48 hours later
223749655|NCT02128191|DRUG|Normal saline|Initial dose of normal saline followed by second and third dose 24 and 48 hours later, at equal volume to ibuprofen arm
223749656|NCT03747432|DRUG|Propofol|Procedural sedation during TAVR procedure using propofol
223749657|NCT03747432|DRUG|Dexmedetomidine|Procedural sedation during TAVR procedure using dexmedetomidine
224075289|NCT04436146|OTHER|laryngeal manual therapies|The laryngeal manual therapy incorporates massaging the laryngeal muscles thus reducing excessive tension in the laryngeal and perilaryngeal musculature in patients with globus .
224075290|NCT00053248|DRUG|arsenic trioxide|
224075291|NCT00053248|DRUG|imatinib mesylate|
224075292|NCT00167635|BEHAVIORAL|cognitive-behavioral|Cognitive-behavioral over 9 weeks
223601443|NCT02618902|BIOLOGICAL|tolerogenic dendritic cells (tolDC)|dose-escalation
223601444|NCT02880098|BIOLOGICAL|Troponin T blood level|assess Troponin T blood level for every child born from the same sample of blood (after clamping the umbilical cord) used for assessment of pH and lactate.
223749658|NCT06488963|OTHER|NatraCure Cold Therapy gloves and socks|These gloves and socks will be adjusted and tied to the child's wrists and ankles. There are sizes suitable for all ages and the dimensions of the gloves and socks can be adjusted with a snap fastener. The gloves and socks contain a soft Lycra lining and four inner gel cold packs to ensure full length cold therapy treatments. When the children wear these gloves and socks, they can still move their fingers and toes easily. In addition, it is a great advantage that the iced gel packs do not touch the child's skin directly.
223749659|NCT02009046|BEHAVIORAL|SEI Classroom Curriculum|Participants receive the 12-session Sexuality Education Initiative (SEI) classroom curriculum. The SEI classroom curriculum covers anatomy, abstinence, contraception and protection, STIs and HIV/AIDS, media messages, gender, relationships, rights and responsibilities, pregnancy, sexuality, peer pressure, negotiation and coercion, and decision making. These sessions are delivered over a two-month period. Each curriculum session is about 45 minutes in length.
223749660|NCT02009046|BEHAVIORAL|Control Classroom Curriculum|Participants receive the 3-session basic control curriculum. The control curriculum includes 3 sessions on sexually transmitted infections, anatomy and birth control delivered over a two- or three-week period. Each curriculum session is about 45 minutes in length.
223749661|NCT02009046|BEHAVIORAL|SEI Curriculum + 3 School Components|Participants receive SEI classroom curriculum and all three school wide components. The peer education/advocacy component recruits, trains and supervises students through an after-school leadership program to serve as resources to peers, organize health events, and refer students to school-based clinic services. The parent education component provides sessions for parents of students, covering reproductive health, teen pregnancy, and parent-teen communication, together with a parent education booklet for widespread use. The clinical services linkages includes health services on campus, including pregnancy/STI testing, contraceptive consultation and prescriptions, condom distribution, counseling, and referrals. It includes training for teachers and staff to distribute condoms as needed.
224199968|NCT01922973|OTHER|Fasting|normal volunteers fast from food on one occasion for 62.5 h; on another occasion fed 3 meals
223512309|NCT04779593|BIOLOGICAL|Blood sample C reactive protein|Blood sample C reactive protein at D0 and M24/end follow-up visit
223512310|NCT04779593|PROCEDURE|Bloodletting - control group|Patients treated with bloodletting according to current guidelines (ferritin alone). Patient will undergo bloodletting with a goal of maintaining a serum ferritin equal or lower than 50 g/L according to current clinical practice guidelines (French and European).A first bloodletting will be performed at inclusion with the same volume as usually performed by the patients.Results of the biological test performed at this visit will guide the time schedule and volume of the next bloodletting according to randomization group. Time schedule and volume of bloodletting will be adjusted to biological results after each follow-up visit.
223512311|NCT04779593|BIOLOGICAL|BioBank|Blood sample will be collected for BioBank at D0, M12 and M24.
223512312|NCT04779593|OTHER|Medico-economical|Medico-economic data will be collected at each follow up visit.
223512313|NCT04779593|PROCEDURE|Bloodletting - experimental group|"Patients treated with bloodletting according to transferrin saturation and serum ferritin. Patients will undergo bloodletting with a goal of maintaining a serum transferrin saturation equal or lower than 50 % and a serum ferritin lower than the upper limit of the normal range (300 g/L for men and 200 g/L for women).A first bloodletting will be performed at inclusion with the same volume as usually performed by the patients.Results of the biological test performed at this visit will guide the time schedule and volume of the next bloodletting according to randomization group. Time schedule and volume of bloodletting will be adjusted to biological results after each follow-up visit."
223512314|NCT00236197|DRUG|rabeprazole sodium|Following a one week single-blind, placebo run-in phase, patients will receive rabeprazole 10 mg orally,placebo once daily, for 14 days during the double-blind, randomized treatment phase. This will be followed by a one week single-blind placebo follow-up phase.
223512315|NCT00236197|DRUG|placebo|Following a one week single-blind, placebo run-in phase, patients will receive placebo orally, once daily, for 14 days during the double-blind, randomized treatment phase. This will be followed by a one week single-blind placebo follow-up phase.
223512316|NCT04330339|BEHAVIORAL|Fasting|Fasting
223512317|NCT05301231|DIAGNOSTIC_TEST|Genomics (DNA Extraction)|"Blood samples for detection of:~Genes for Dyslipidemia BY WES and NGS (4 GWA) (30 cases) Genes polymorphism for NAFLD/NASH BY TaqMan SNP Genotyping Assay on 10 GWAS"
223512318|NCT05301231|DIAGNOSTIC_TEST|Epi-genomics|"* blood samples for detection of Expression profiling of plasma microRNAs~* PCR array to determine the altered miRNAs for 168 plasma miRNAs (12 cases)~* Expression analysis of top 5 altered miRNAs (All)"
223512319|NCT05301231|DIAGNOSTIC_TEST|Proteomics (Glycoproteomics)|blood samples for Identifying glycosylation pattern of five glycoproteins linked with NAFLD/NASH (transferrin, apoC III, haptoglobin, Mac2 binding protein, IgG)
223512320|NCT05301231|DIAGNOSTIC_TEST|Salivary Metabolomics|"Salivary Samples for detecting Salivary Metabolomics~1. Genome analysis (Identification of microbial strains common among Egyptians BY apid RT-PCR (DNA sequencing: 16S rRNA gene amplicons)~2. Microbiome related Metabolites Identification using GC-MS Analysis (the top 5 identified microbial-related metabolites) as metabolomics~3. Meta-genomic assess of three microbiome-related metabolites; lactoferrin, (LPS), (IgA) BY Commercial ELISA kits"
223512321|NCT05301231|BEHAVIORAL|Individualized counselling for behavioural modification|"Individualized counselling for behavioral modification (3 sessions):~Nutritional education, Promotion of physical activities and Cognitive \& Psychological support"
223512322|NCT00951873|DRUG|activated recombinant human factor VII, long acting|Single injection of long acting activated recombinant human factor VII subcutaneously (under the skin). Each treatment dose of 0,1 mg/kg, 0,3 mg/kg and 0,5 mg/kg is assessed for safety before escalating to next dose.
223512323|NCT00951873|DRUG|placebo|Single injection of long acting activated recombinant human factor VII placebo subcutaneously (under the skin). Each treatment dose of 0,1 mg/kg, 0,3 mg/kg and 0,5 mg/kg is assessed for safety before escalating to next dose.
223512324|NCT00951873|DRUG|activated recombinant human factor VII, long acting|Single dose of 0,1 mg/kg long acting activated recombinant human factor VII injected intravenously (into a vein).
223512325|NCT01893762|BIOLOGICAL|Aerobic exercise|Aerobic exercise: 2x30 min on an indoor rowing machine at 75% of Maximum heart rate
223512326|NCT01893762|BIOLOGICAL|Anaerobic exercise|Anaerobic exercise: 3x1000m maximum effort, on an indoor rowing machine
224199969|NCT06329076|DRUG|Losartan|Administration of losartan tablets (50 mg)
223601445|NCT00600210|DRUG|Bevacizumab|Bevacizumab will be delivered intravenously on day -7 at a dose of 10 mg/kg followed by carboplatin AUC 2.0 intravenously. This will allow therapy to start one week before starting radiotherapy to assess the initial tolerability of the combination without having radiation as a confounding factor, to start treatment while the patient's radiation is being planned, and to possibly optimize the tumor vasculature and allow optimal carboplatin delivery by the time chemoradiotherapy starts. Thereafter, bevacizumab will be given intravenously at 10 mg/kg every two weeks. Carboplatin will be given intravenously weekly at AUC 2.0. On weeks where both drugs are given, bevacizumab will be given first since it could help sensitize the tumor cells to carboplatin.
223601446|NCT00600210|DRUG|Carboplatin|Bevacizumab will be delivered intravenously on day -7 at a dose of 10 mg/kg followed by carboplatin AUC 2.0 intravenously. This will allow therapy to start one week before starting radiotherapy to assess the initial tolerability of the combination without having radiation as a confounding factor, to start treatment while the patient's radiation is being planned, and to possibly optimize the tumor vasculature and allow optimal carboplatin delivery by the time chemoradiotherapy starts. Thereafter, bevacizumab will be given intravenously at 10 mg/kg every two weeks. Carboplatin will be given intravenously weekly at AUC 2.0. On weeks where both drugs are given, bevacizumab will be given first since it could help sensitize the tumor cells to carboplatin.
223601447|NCT00600210|RADIATION|Radiation Therapy|"Whole pelvis will be treated to a total dose of 45 Gy in 5 weeks.~Cesium will be used with standard intracavitary systems preferably in two intracavitary applications. An effort should be made to deliver a minimum cumulative external and intracavitary dose to Point A of 85 Gy in 2 insertions."
223601448|NCT01865448|DIETARY_SUPPLEMENT|Omega-3 DHA|Patients take daily 2 tablets of Docosahexaenoic Acid
223601449|NCT01865448|OTHER|Placebo|Patients in control group take daily 2 placebo capsule
223601450|NCT03475485|DEVICE|ID-Capsule- Active|A standard gelatin or HPMC capsule with an embedded ingestible wireless sensor.
223601451|NCT03475485|DEVICE|Wearable Sensor|Subjects will wear an ID-Reader
223749662|NCT02009046|BEHAVIORAL|Control Curriculum + 1 School Component|Participants receive control classroom curriculum and one of the three school wide components, the clinical services linkages. This component includes health services on campus for students, including pregnancy and STI testing, contraceptive consultation and prescriptions, condom distribution, counseling, and referrals. It also includes training for teachers and school staff to distribute condoms to students as needed.
223749663|NCT01646515|DRUG|Placebo|"Capsule, appears identical with udenafil, will be provided by Dong-A pharmaceutical company.~Patients will receive 50 mg of placebo drug two times a day for 4 weeks, and then the dosage will be escalated to 100 mg two times a day for next 8 weeks"
223749664|NCT01646515|DRUG|Udenafil (Zydena)|Udenafil (Zydena), a newly developed PDE-5 inhibitor by Dong-A pharmaceutical company, will be administered to patients in this group, 50 mg two times a day for 4 weeks, and then the dosage will be escalated to 100 mg two times a day for next 8 weeks.
223749665|NCT04242004|DRUG|Docosahexaenoic acid (DHA) capsules|Treatment was provided as 7 omega-3 fatty acid (Lovaza) capsules daily. Each capsule contained 1 g of omega-3 fatty acids with approximately 450 mg of docosahexaenoic acid (DHA).
223749666|NCT04242004|DIETARY_SUPPLEMENT|Soy oil capsules|The placebo was identical looking capsules that contained soy oil
224199970|NCT06329076|DRUG|Placebo|Administration of placebo tablets
224199971|NCT01900392|BEHAVIORAL|Financial incentive|Participants in the direct payment and lottery arms will receive financial incentives as part of the intervention. See arm descriptions for more detail.
224199972|NCT04861831|OTHER|Power Centering for Seniors intervention|Power Centering for Seniors is an innovative East-meets-West intervention (75-minute, twice weekly, supervised group classes over 12 weeks) that integrates Western best practice muscle strength and balance training components with Chinese Tai Chi/Qi Gong to improve mobility and quality of life in older, community-dwelling adults. Home practice is recommended (approximately 30 minutes three times per week on non-course days). The modularly designed course consists of four cycles with six themes repeated in each cycle. Course exercises increase in intensity throughout the twelve-week intervention period. Repetition of cycles and themes prepares participants for continuing their individualized version of the program after the group course intervention is complete. This should lead to long-term practice of the exercises learned in the intervention and to sustained positive effects of the training.
224199973|NCT00457431|PROCEDURE|Mild therapeutic hypothermia|Mild therapeutic hypothermia will be performed by any methods applicable in the hospitals
224199974|NCT00861731|DRUG|simvastatin|simvasatin therapy alone at the dose of 40 mg/day
224199975|NCT00861731|DRUG|EZE/simvastatin|EZE/simvastatin combined therapy at the dose of 10/20 mg/day
224199976|NCT00861731|DRUG|EZE/simvastatin|EZE/simvastatin combined therapy at the dose of 10/40 mg/day
223749667|NCT00142870|DRUG|Bupropion|150 mg, twice a day
223749668|NCT01525147|BIOLOGICAL|YHB1411-2: Level 2|IV infusion
223601452|NCT03475485|DEVICE|Placebo|A standard gelatin or HPMC capsule without an embedded ingestible wireless sensor.
223601453|NCT04141423|DRUG|Tregopil|Insulin Tregopil is recombinant human insulin modified by a single amphiphilic oligomer covalently linked via an amide bond to lysine at position 29 of the B-chain. This alters the physicochemical characteristics of the molecule, leading to enhanced stability and resistance to intestinal degradation following oral administration.
223601454|NCT00227409|DRUG|calcium disodium EDTA (edetate calcium disodium)|
223749669|NCT01525147|BIOLOGICAL|YHB1411-2: Level 3|IV infusion
223749670|NCT01525147|BIOLOGICAL|YHB1411-2: Level 4|IV infusion
223749671|NCT01525147|BIOLOGICAL|YHB1411-2: Level 5|IV infusion
223749672|NCT01525147|BIOLOGICAL|Placebo|IV infusion
223749673|NCT01525147|BIOLOGICAL|YHB1411-2: level 1|IV infusion
223749674|NCT05217251|OTHER|frontal alpha asymmetry in EEG|frontal alpha asymmetry based on EEG monitoring of uterine contractions in the first stage of labor. The power spectra will be log-transformed and averaged across the frontal left (FL) channels (FP1, F3, F7) and frontal right (FR) channels (FP2, F4, F8). A higher power spectrum value indicates lower neural activity. Frontal asymmetry (FA) power scores are calculated as follows, FA = (FR-FL)/(FR+FL). A positive FA value shows greater neural activity in the left frontal lobe than right frontal neural activity (relative left frontal asymmetry), while its negative value shows oppositely.
223749675|NCT04537000|DIAGNOSTIC_TEST|clinical condition score|A score is firstly identified using a clinical condition scale including the concentration of inspired oxygen to maintain the percutaneous oxygen saturation (SPO2)≧95%, the fusion rate of catecholamine drugs to maintain normal blood pressure, the nasopharyngeal temperature and the oxygen saturation of central venous blood. The score was graded as 0, 1 and 2 points according to the patient's clinical condition. The score identified from the scale plus 7 finally makes the clinical condition score. If the score is higher than 10, it will be replaced with 10. That is to say, the highest clinical condition score is 10. If the clinical condition score≦Hb, blood red cell transfusion will not be started. If the clinical condition score\>Hb, blood red cell transfusion will be started, and the volume will be calculated using the following formulation, transfusion volume(ml)=(clinical condition score - Hb)\*body weight \*5.
223749676|NCT00801125|DRUG|natalizumab|
223749677|NCT01153243|DRUG|Ergocalciferol|"Active Comparator: Ergocalciferol~The investigators will give intervention group 12 weeks of Vitamin D (ergocalciferol 50,000 units every week)"
223601455|NCT04205682|DRUG|Cannabidiol|CBD capsules administered BD for 4-days (800-1200 mg/day), placebo day 5
223601456|NCT04205682|DRUG|Placebo|Placebo capsules administered BD for 5 days
223601457|NCT06196606|DRUG|Botulinum toxin type A for injection|Botulinum toxin was injected into the upper esophageal sphincter of each patient
223601458|NCT01199224|DRUG|veliparib|veliparib formulation A
223601459|NCT01199224|DRUG|veliparib|veliparib formulation B
223601460|NCT01199224|DRUG|veliparib|veliparib formulation C
223601461|NCT01199224|DRUG|veliparib|veliparib formulation C
223749678|NCT01153243|DRUG|Placebo pill|The investigators will give control group 12 weeks of 1 placebo pill every week.
224199977|NCT06649591|BEHAVIORAL|Survey|The intervention is an email based survey as described in the study description.
224199978|NCT06562439|BEHAVIORAL|Sickle Cell Collaboration for Child Development|The Sickle Cell Collaboration for Child Development (SCCCD) combines the Parents as Teachers curriculum with experienced occupational therapy to help families and children meet their learning and developmental goals.
224199979|NCT01063439|DRUG|Busulfan, Etoposide, Cytarabine, Melphalan|Busulfan 3.2 mg/kg/d for 2 days Etoposide 400 mg/m2/d for 2days Cytarabine 1 g/m2 for 2 days Melphalan 140 mg/m2 for 1 day
223601462|NCT03487744|OTHER|Osmolite 1.5|Continuous enteral tube feeding according to a standardized calculation via nasojejunal tube.
223601463|NCT03487744|OTHER|Promote without fiber|Continuous enteral tube feeding according to a standardized calculation via nasojejunal tube.
223601464|NCT00952081|DRUG|Clevidipine|Clevidipine (0.5 mg/ml in 20 % lipid solution) will be administered via peripheral vein using syringe pump; drug infusion will be initiated at 5 mg/hr (10ml/h) and titrated to effect up to a maximum rate of 32 mg/hr when SBP exceeds 130 mm Hg. The anesthesiologist will be allowed to administer the alternative antihypertensive treatment (e.g. labetalol, hydralazine) after achieving a maximum clevidipine infusion rate.
223601465|NCT01354717|DRUG|Brand Carac|treatment of actinic keratosis
223601466|NCT01354717|DRUG|Generic 0.5% 5-fluorouracil cream|treatment of actinic keratosis
223601467|NCT01354717|OTHER|Placebo cream|treatment of actinic keratosis
223749679|NCT04867265|PROCEDURE|Mout-to-mouth ventilation|we will record the visibility of chest rising
223749680|NCT04867265|PROCEDURE|Mout-to-mouth ventilation with quantitative analysis|we will record the visibility of chest rising, review the ventilation metrics and evaluate each rescue breath in QCPR Skill Reporter
223749681|NCT03413553|DEVICE|immediate implant|Patient will receive immediate implant alone.
223749682|NCT03413553|BIOLOGICAL|connective tissue graft|patient will receive immediate implant with connective tissue graft and platelet rich fibrin
224199980|NCT03585868|OTHER|Placebo|Beverage with no flavonoids
223601468|NCT00439296|DRUG|ABT-751|"Treatment Course 1:~Oral capsule to be given daily for 21 days at assigned dose.~Treatment Course 2:~ABT-751 will be taken once daily, by mouth, at the assigned dose on days 15-35.~Treatment Course 3:~ABT-751 will be taken once daily, by mouth, at the assigned dose on days 1-21 followed by 1 week of rest."
223749683|NCT03413553|BIOLOGICAL|platelet rich fibrin|patient will recieve immediate implant combined with connective tissue graft and platelet rich fibrin
223749684|NCT02436278|OTHER|4MGS|Usual walking speed measured over 4 metres
223749685|NCT04516083|DIAGNOSTIC_TEST|Mismatch repair instability somatic and germline testing|Each Endometrial Endometrioid adenocarcinoma is routinely stained for MMR mutation to seek for tumor genetic instability. If stains positive, the patient is called in for genetic blood testing to look for the same mutation in the germline.
223749686|NCT01637974|DRUG|INTERCOAT administration|Applying INTERCOAT in the intrauterine cavity at the end of the hysteroscopic surgery
223749687|NCT02159664|OTHER|didgeridoo practice|instrument lessons, 1X/w and daily practice, 20 min /d
223749688|NCT02177448|DRUG|BIBR277 low dose|
224199981|NCT03585868|OTHER|Flavonoids|Flavonoids-enriched cacao beverage
224199982|NCT03585868|DIETARY_SUPPLEMENT|No Flavonoids|Beverage with alkalinized cocoa which eliminates flavonoid content
223601469|NCT00439296|DRUG|Dexamethasone|"In Treatment Course 1 only:~* 10 mg/m2/day divided BID.~* Take dexamethasone by mouth days 1-14."
223601470|NCT00439296|DRUG|PEG-asparaginase|"In Treatment Course 1:~* 2500 IU's/m2/day.~* Intramuscular injection (IM) on days 4, 11 and 18.~In Treatment Course 2:~* 2500 IU's/m2/day.~* Intramuscular injection (IM) on day 15."
223601471|NCT00439296|DRUG|Doxorubicin|"In Treatment Course 1 only:~• 60 mg/m2/day IV over 15 minutes on day 1."
223601472|NCT00439296|DRUG|Cytarabine|"* Given Intrathecally on day 1 of course 1 at the dose defined by age below.~  * 30 mg for patients age 1-1.99~ * 50 mg for patients age 2-2.99~ * 70 mg for patients \>3 years of age~* Omit IT Ara-C on Day 1 if patient received IT therapy prior to study enrollment as part of diagnostic lumbar puncture procedure.~In Treatment Course 2: • 75 mg/m2/day IV on days 2 through 5 and days 9 through 12."
223601473|NCT00439296|DRUG|Methotrexate|"In Treatment Course 1:~• Given Intrathecally on day 15 at the dose defined by age below.~* 8 mg for patients age 1-1.99~* 10 mg for patients age 2-2.99~* 12 mg for patients 3-8.99 years of age~* 15 mg for patients \>9 years of age~In Treatment Course 2:~• Given Intrathecally on day 1, 8, 15 and 22 at the dose defined by age below.~* 8 mg for patients age 1-1.99~* 10 mg for patients age 2-2.99~* 12 mg for patients 3-8.99 years of age~* 15 mg for patients \>9 years of age~In Treatment Course 3:~Intrathecally on day 1 at the age-defined dose"
223601474|NCT00439296|DRUG|Cyclophosphamide|Course 2 only: • 1000mg/m2/day IV over 30 minutes to be given on day 1.
223601475|NCT00439296|DRUG|6-thioguanine|Treatment Course 2 only: • 60 mg/m2/day to be given orally on days 1 through 14.
223601476|NCT06442384|OTHER|Tobacco and non-tobacco e-cigarettes|Participants with no e-cigarette restrictions.
223601477|NCT06442384|OTHER|Tobacco only e-cigarettes|Participants restricted to tobacco flavored e-cigarettes only.
223601478|NCT05111249|DRUG|Branaplam|messenger ribonucleic acid (RNA) splicing modifier. Branaplam was administered as an oral solution once weekly.
223601479|NCT05111249|DRUG|Placebo|Matching placebo oral solution once weekly
223601480|NCT02378688|DRUG|MT-1303|
223601481|NCT02378688|DRUG|Placebo|
223601482|NCT05128578|BEHAVIORAL|Liver Education About Pain (LEAP)|LEAP is a modular 12-week pain self-management intervention with 6 individual sessions and 6 optional group sessions. Individual sessions serve the purpose of individualizing the program to the needs of the patients. Group sessions allow participants to practice skills, set goals with the group, seek social support, and learn together. The purpose of the LEAP program is to make pain better, help patients reach their personal goals (things that may be hard to do because of pain), and add to the care patients' medical team is providing.
223601483|NCT05128578|BEHAVIORAL|Usual Care|"Patients can continue to use other pain management strategies (usual care) in order to mimic real-life conditions."
223601484|NCT05725083|PROCEDURE|Lower thoracic epidural|before induction of anesthesia,first the investigators identify the correct targeted thoracic level. All epidural block will be performed under all aseptic precautions with a 17-gauge Tuohy needle and 19 G flex-tip catheters. Using the loss of resistance to saline technique, catheter will be inserted 4 cm into the epidural space and a suitable test dose will be administered to exclude intravascular or sub-arachnoid injection. Bupivacaine 0.25% of 7.5-12 ml volume will be given bolus through the epidural catheter then continuous infusion of bupivacaine 0.1% will be infused at a rate of 5 ml/h up to 15ml/h .for breakthrough pain patient controlled analgesia (PCA) using nalbuphine 1 mg bolus , 10 min lockout period . The catheter will be removed under complete aseptic precautions after 48 hrs.
223601485|NCT05725083|PROCEDURE|Erector spinae plane block|before induction of anasthesia ,highfrequency linear ultrasound probe will be placed in a longitudinal parasagittal orientation 2.5-3 cm lateral to the T9 spinous process. A 21G 10 cm needle will be inserted using an in plane approach. The tip of the needle will be placed into the fascial plane on the deep aspect of the erector spinae muscle.confirmed by visible fluid spread lifting the erector spinae muscle off the bony shadow of the transverse process on ultrasonographic imaging.Then the catheter placement 5cm into the space under the erector spinae muscle and suitable test dose will be administered . Bupivacaine 0.25% of 7.5-12 ml volume will be given bolus through the catheter then continuous infusion of bupivacaine 0.1% will be infused at a rate of 5 ml/h up to 15 ml/h , for breakthrough pain patient controlled analgesia (PCA) using nalbuphine 1mg bolus,10 min lockout period.The catheter will be removed under complete aseptic precautions after 48 hrs.
223601486|NCT00620724|DRUG|Placebo|Placebo three times daily
223601487|NCT00620724|DRUG|Nifedipine|20 mg of slow-release Nifedipine three times daily
223601488|NCT03009422|DRUG|Local application pentostam|
223601489|NCT03009422|DRUG|intra-lisional pentostam|
223601490|NCT03009422|DEVICE|fractional CO2 laser|
223601491|NCT03965741|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Follow clinical administration
223601492|NCT03965741|DRUG|Apixaban(Eliquis)|Follow clinical administration
223601493|NCT03965741|DRUG|Pradaxa (Dabigatran etexilate)|Follow clinical administration
223601494|NCT06413238|DRUG|curcumin, saffron, Combination of saffron and curcumin and placebo|This study investigates the individual and combined effects of curcumin and saffron on diabetes compared to a placebo group. It will assess the effects on both clinical and laboratory diabetes symptoms within and between groups. Participants will receive either two 500mg curcumin capsules in arm 1, one 15mg saffron capsule with a 500mg starch flour placebo in arm 2, one 500mg curcumin and one 15mg saffron capsule in arm 3, and two 500mg starch flour placebos in arm 4.
223601497|NCT05078398|BEHAVIORAL|POINT Protocol|Patients will receive counseling on risks and benefits of opioids for pain control, asked to choose whether they need opioid prescription when ready for discharge.
223601498|NCT05078398|BEHAVIORAL|Usual care|Will prescribe standardized amount of opioid for postoperative pain without patient input
223601499|NCT02031263|PROCEDURE|bronchial thermoplasty system|Check on the quality of life, emergency room uses, and sudden progress of the disease of the patients before and after the treatment by using bronchial thermoplasty system by using paired t test.
223749689|NCT02177448|DRUG|BIBR277 medium dose|
223749690|NCT02177448|DRUG|BIBR277 high dose|
223749691|NCT02177448|DRUG|Enalapril low dose|
223749692|NCT02177448|DRUG|Enalapril medium dose|
223749693|NCT02177448|DRUG|Enalapril high dose|
223749694|NCT02177448|DRUG|Placebo matching BIBR277|
223749695|NCT02177448|DRUG|Placebo matching enalapril|
223749696|NCT02154555|PROCEDURE|debridement|post-operative debridement at 1 week follow-up visit
224199983|NCT06703268|DRUG|HSK7653 10 mg|HSK7653 10 mg Q2W
223601500|NCT03069157|PROCEDURE|lung recruitment maneuver|lung recruitment manoeuvre will be performed in patients using continuous positive airway pressure( CPAP) (30) cm H2O for (40) seconds after induction of anesthesia then patient will be converted to pressure controlled mode again with PEEP 5 cm H2O
223601501|NCT00557999|OTHER|Application of mechanical ventilation weaning protocol|Application protocol for 8 months in experimental group
223601502|NCT02124694|BEHAVIORAL|HTUG|HTUG is a group psychotherapy...
223601503|NCT03257839|DEVICE|Routine Full-Field Digital Mammography|Routine screening mammography exam, CC + MLO views.
223601504|NCT03257839|DEVICE|Routine Digital Breast Tomosynthesis|Routine screening tomosynthesis exam, CC + MLO views.
223601505|NCT03257839|DEVICE|Automated Whole Breast Ultrasound|Bilateral breast ultrasound performed as an adjunct to mammography.
223601506|NCT04744922|DIETARY_SUPPLEMENT|Extracts of citrus peels standardized in AUR and NAR (phytocomplex).|One capsule a day for 9 months
223601507|NCT00910780|DRUG|Aripiprazole|via oral tablets, everyday
224199984|NCT06703268|DRUG|Daily DPP-4 inhibitor|Daily DPP-4 inhibitor
223601508|NCT00910780|DRUG|Zyprexa|via oral tablets, taken once daily
223601509|NCT00910780|DRUG|Risperdal|via oral tablets, taken once daily
223601510|NCT05701020|OTHER|questionnary|If agreeing to the protocol, ; patients will answered questions about sexual health during the gynecologic consultation
223601511|NCT01043211|DRUG|Lidocaine Hydrochoride Injection, without epinephrine|A standardized 0.2 ml/kg (2 mg/kg) intravenous bolus dose of lidocaine (1%, 10 mg/ml) is given after anesthetic induction but prior to skin incision. Immediately thereafter, lidocaine (1%, 10 mg/ml) will be administered on a standardized 0.3 ml/hr/kg (3 mg/kg/hr, maximum 200 mg/hr = 20 ml/hr) basis using a continuous infusion pump during the surgical procedure. Immediately after skin closure, the lidocaine infusion will be decreased by 50% to 0.15 ml/hr/kg (1.5 mg/kg/hr, maximum 100 mg/hr = 10 ml/hr) and continued for 90 minutes postoperatively. The infusion will be stopped before the patient is discharged from the post-anesthesia care unit (PACU).
223601512|NCT01043211|DRUG|Normal Saline|A standardized 0.2 ml/kg intravenous bolus dose of preservative-free normal saline will be given after anesthetic induction but prior to skin incision. Immediately thereafter, normal saline will be administered on an equal 0.3 ml/hr/kg (maximum 20 ml/hr) basis using a continuous infusion pump during the surgical procedure. Immediately after skin closure, the normal saline infusion will be decreased by 50% to 0.15 ml/hr/kg (maximum 10 ml/hr) and continued for 90 minutes postoperatively. The infusion will be stopped before the patient is discharged from the post-anesthesia care unit (PACU).
223601513|NCT01043211|DRUG|Normal Saline|A standardized 0.2 ml/kg (2 mg/kg) intravenous bolus dose of lidocaine (1%, 10 mg/ml) is given after anesthetic induction but prior to skin incision.
223601514|NCT02756676|PROCEDURE|Multidisciplinary Intensive Rehabilitation Treatment (MIRT)|MIRT consists of a 4-week physical therapy that entails four daily sessions, five days a week, in a hospital setting. The duration of each session is about one hour. The first session comprise cardiovascular warm-up activities, relaxation, muscle- stretching, exercises to improve the range of motion of spinal, pelvic and scapular joints, exercises to improve the functionality of the abdominal muscles, and postural changes in the supine position. The second session includes aerobic exercises to improve balance and gait using a stabilometric platform, treadmill plus, crossover and cycloergometer. The third is a session of occupational therapy to improve autonomy in daily living activities. The last session includes one hour of speech therapy.
223601515|NCT04627363|PROCEDURE|Hepatic arterial infusion chemotherapy|administration of oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries every 6 weeks
223601516|NCT04627363|DRUG|Bevacizumab|15mg/kg intravenously every 3 weeks
223601517|NCT04627363|DRUG|Toripalimab|240mg intravenously every 3 weeks
223601518|NCT04338308|DEVICE|new-DES|with ot without embolic protection device
223601519|NCT04338308|DEVICE|BMS|with ot without embolic protection device
223601520|NCT04005157|PROCEDURE|MWA|Patients diagnosed with early-stage NSCLC and signing the informed consent will undergo MWA with the guidance of ENB.
223601521|NCT04005157|DEVICE|ENB|ENB (LungCare Medical Technologies Ltd., Inc, Suzhou, China)will be used to guide bronchoscope into the accurate location of the lesion during MWA.
223601522|NCT04344275|OTHER|-Scapular endurance test|The resistance of the trapezius and serratus anterior muscles to fatigue was assessed using the scapular muscle endurance test.
223601523|NCT04344275|OTHER|-Muscle strength test|Upper trapezius (UT), middle trapezius (MT), lower trapezius (LT), and serratus anterior (SA) muscle strengths were tested using a hand-held digital dynamometer (Lafayette Manual Muscle Tester, Model 01165).
223601524|NCT02259465|BEHAVIORAL|low FODMAP diet|Participants will attend a one-hour group session on how to follow the low FODMAP diet, run by a dietitian trained in the diet. They will be asked to follow the diet for 7 days while keeping a food diary.
223601525|NCT02259465|DIETARY_SUPPLEMENT|Oligofructose|Participants will supplement their diet with 7 grams of OF twice daily for the week that they follow the low FODMAP diet.
223601526|NCT02259465|DIETARY_SUPPLEMENT|Maltodextrin|Participants will supplement their diet with 7 grams of maltodextrin twice daily for the week that they follow the low FODMAP diet.
223601527|NCT03940729|DRUG|Chlorhexidine Topical|In the Malmö needle exchange program, people who inject drugs (PWID) are repeatedly screened for S aureus colonization during one year. Those colonized will repeatedly shower with chlorhexidine during the following year. The infection frequency will be compared between the two periods.
223601528|NCT00797849|DEVICE|Farabloc Limb Cover|Wear prosthetics, sock or glove laminated with Farabloc
223601529|NCT00797849|DEVICE|Sham Limb Cover|Wear prosthetics, sock or glove laminated with sham material
223601530|NCT02924493|OTHER|Diet low in fermentable carbohydrates (low FODMAP diet)|The participants follow the diet in 4 weeks. They have been provided with some foods (bread, pasta, cereal products), but will by the rest themselves. They have been provided with lists of foods to include and foods to avoid. They have also been provided with suggestions to a 4 week meal plan, based in their individual need for energy.
223601531|NCT03004911|DEVICE|ProFibro (Mobile application)|ProFibro, a mobile Android application in Brazilian Portuguese to promote self-care in patients with fibromyalgia
224199985|NCT06539143|DRUG|Lidocaine|The Paracervical Block with lidocaine for manual vacuum aspiration
224199986|NCT01450150|DEVICE|Transcranial Direct Current Stimulation|20-minute daily sessions of 2 mA tDCS for 15 days (Monday to Friday on three consecutive weeks)
223601532|NCT03004911|DEVICE|Paper booklet|A 64-page booklet with content similar to the mobile application
224199987|NCT01450150|DEVICE|Transcranial Direct Current Stimulation|The tDCS stimulator will be turned on for 30 seconds only, after which it will be gradually decreased and then turned off for the remainder of the 20-minute daily sessions for 15 days (Monday to Friday on three consecutive weeks).
223601533|NCT04911894|DRUG|IBI321|Several dose levels will be evaluated for IBI321 administered as a single agent. IBI321 will be given via IV infusion on Day 1 of each cycle until disease progression or loss of clinical benefit.
223601534|NCT02638324|PROCEDURE|Renal nervous denervation|The heart failure patients will undergo renal nervous denervation if they have not properly responded to medication and biventricular pacing therapy.
224199988|NCT04676386|DIAGNOSTIC_TEST|Primary Immune Response (PIR) test by Biodesix, Inc.|Blood draw for biomarker assessment will be performed at these time-points: pretreatment, start of 3rd cycle and investigator assessed progression. The biomarker analysis will be performed retrospectively.
223601535|NCT03152695|DEVICE|High-intensity focused ultrasound|Local tumor ablation by ArcBlate (EpiSonica, Taiwan) will be performed, and the entire procedure will be monitored by MRI
223601536|NCT04526223|OTHER|comprehensive treatment regimen|"1. Diagnosis MF(includ Post-ET,Post-PV,PMF，MDS/MPN with MF)~2. With at least two month Ruxolitinib treatment prior to transplantation~3. DAC+BF as myeloablative conditioning regimen~4. received Rux at +5d in ASCT and continued to +60d"
223601537|NCT04889508|BEHAVIORAL|Socio-emotional mental training|Core practice: Affect Dyad. In the Affect Dyad (AD), participants perform a 12-minute partner-based exercise which involves contemplating over one difficult situation and one situation which incurred gratitude in the past 24 hours. Both partners take turns speaking about the two situations while the other partner listens in a non-judgmental manner. While the participants elaborate on the situations, they are asked to focus on the bodily experience of the emotions generated during the situation. The goal of the exercise is to enhance coping with difficult emotions, empathic listening, social sharing, acceptance, and gratitude.
223601538|NCT04889508|BEHAVIORAL|Mindfulness-based mental training|Core practice: Breathing Meditation. In this intervention, participants will practice 12-minute basic attention-based mindfulness meditation such as the Breathing Meditation (BM). BM is a 12-minute individual exercise that requires participants to focus their attention on the sensations of breathing. Participants have to sustain their attention to breath for long stretches of time, and have to return their attention to their breath when their mind wanders. The key focus is on training attention and interoceptive body awareness. Other practices participants will be taught is mindfulness on sounds (here the object of attention is not the breath but sounds in the environment).
223749697|NCT03198741|DRUG|Aspirin + clopidogrel|After randomization(6 months±2 weeks after enrollment),receive aspirin 100mg/d + clopidogrel 75mg/d for an additional 6 months. The above treatments between 6 and 12 months are double-blinded.
223749698|NCT03198741|DRUG|Clopidogrel monotherapy|After randomization(6 months±2 weeks after enrollment),receive clopidogrel 75mg/d + placebo (clopidogrel monotherapy group) for an additional 6 months. The above treatments between 6 and 12 months are double-blinded.
223601539|NCT00014079|GENETIC|DNA stability analysis|
223601540|NCT00014079|GENETIC|loss of heterozygosity analysis|
223601541|NCT00014079|GENETIC|microsatellite instability analysis|
223601542|NCT04449627|OTHER|Feeling Good Digital App|Audio based tracks using Jacobson relaxation and mindfullness based cognitive therapy (MBCT) techniques including positive visualisation.
223601543|NCT00872599|DRUG|fenofibrate|Subjects will be randomized to receive either fenofibrate 160 mg/day or matching placebo for five days by mouth.
223601544|NCT00872599|DRUG|Placebo|Subjects will be randomized to receive placebo or fenofibrate for five days by mouth
223601545|NCT04769570|PROCEDURE|interscalene brachial plexus block|Single shot ultrasound guided interscalene brachial plexus block will be performed preoperatively to patients.Patient-controlled analgesia (PCA) with morphine will be used for postoperative analgesia.
223601546|NCT04769570|PROCEDURE|suprascapular nerve block|Single shot ultrasound guided interscalene brachial plexus block and Suprascapular nerve block will be performed preoperatively to patients.Patient-controlled analgesia (PCA) with morphine will be used for postoperative analgesia.
223601547|NCT04769570|PROCEDURE|Group Control|consist of the patient group without any procedure.
223601548|NCT01937260|DRUG|Brodalumab|Group 1 consists of 20 subjects and will receive 2 oral doses of midazolam and a single SC dose of brodalumab. Group 2 consists of 10 subjects and will receive a single SC dose of brodalumab.
223601549|NCT00801229|DRUG|Vyvanse|Vyvanse 30, 50, or 70 mg daily
223601550|NCT00801229|DRUG|Placebo|Placebo 30, 50, 70 mg daily
223601551|NCT02610777|DRUG|Azacitidine|Azacitidine intravenous or subcutaneous formulation.
223601552|NCT02610777|DRUG|Pevonedistat|Pevonedistat intravenous infusion.
223601553|NCT00493259|BEHAVIORAL|Health-Related Quality of Life instrument|Adolescents will fill out questionnaires regarding quality of life and dealing with diagnosis of Insulin Resistance Syndrome
223601554|NCT00493259|BEHAVIORAL|Depression Scale for Children (CES-DC)|questionnaire
223749699|NCT03198741|DRUG|Aspirin monotherapy|After randomization(6 months±2 weeks after enrollment),receive aspirin 100mg/d + placebo (aspirin monotherapy group) for an additional 6 months. The above treatments between 6 and 12 months are double-blinded.
223601555|NCT01460134|DRUG|CDX-1127|"Patients will initially receive a single dose of CDX-1127, followed by a 28-day observation period and a Multi-Dose Phase (one cycle of 4 weekly doses of CDX-1127). All patients with stable disease who do not experience a DLT or start alternate anti-cancer treatments may then be eligible for a Retreatment Phase (up to 4 additional cycles). Patients with confirmed partial response or complete response will be followed for response duration and may be eligible for additional cycles of treatment at the time of relapse/progression.~The dose of CDX-1127 given for the Dose Escalation phase will depend on the cohort each patient is assigned to, and will range between 0.1 and 10.0 mg/kg of CDX-1127."
223601556|NCT01460134|DRUG|CDX-1127|"Patients will receive 4 weekly doses of CDX-1127 followed by an observation period. All patients with stable disease who do not experience a DLT or start alternate anti-cancer treatments may then be eligible for a Retreatment Phase (up to 4 additional cycles). Patients with confirmed partial response or complete response will be followed for response duration and may be eligible for additional cycles of treatment at the time of relapse/progression."
223749700|NCT06672874|DIETARY_SUPPLEMENT|Fermented Papaya Preparation (FPP)|Fermented Papaya Preparation (FPP) is administered in this study as a dietary supplement aimed at assessing its potential benefits for cognitive function and driving performance in older adults. Participants consume FPP as a 3-gram powder dose taken orally three times daily (morning, afternoon, evening) for a total of 8 weeks. FPP is known for its antioxidant and anti-inflammatory properties, which may influence cognitive domains essential for safe driving, such as attention, memory, reaction time, and executive function. This intervention is specifically designed to explore FPP's potential impact on reducing driving errors and improving psychomotor skills in a high-fidelity driving simulation environment.
223749701|NCT00776646|DRUG|hydrochlorothiazide 50 mg tablet|
223749702|NCT05686265|DRUG|Oxygen|Physiological intervention consisting of 1 hour of mild hypoxia (PaO2 9-10 kPa), 1 hour of mild hyperoxia (PaO2 13-14 kPa), and in healthy subjects also 1 hour of an inspired oxygen fraction of 100%.
224199989|NCT01200316|PROCEDURE|Standard of Care|Post surgical patient to sit in a non-rocking chair for at least sixty minutes per day, and ambulating at least three times per day.
223749703|NCT05946538|DIAGNOSTIC_TEST|SARS-COV-2, Influenza and RSV 8-Well MT-PCR Panel|The SARS-CoV-2, Influenza and RSV PCR test is multiplex-tandem polymerase chain reaction (MT-PCR) based on qualitive in vitro diagnostic testing for the detection and identification of pathogens in nucleic acid extracts.
223749704|NCT05946538|DIAGNOSTIC_TEST|BioFire Respiratory Panel 2.1|The BioFire Respiratory Panel 2.1 (RP2.1) is a PCR-based multiplexed nucleic acid test intended for use with the BioFire® FilmArray® 2.0 or BioFire® FilmArray® Torch Systems for the simultaneous qualitative detection and identification of multiple respiratory viral and bacterial nucleic acids in nasopharyngeal swabs (NPS) obtained from individuals suspected of respiratory tract infections.
223749705|NCT01674231|OTHER|Grape in the form of freeze-dried whole grape powder|60g freeze-dried whole grape powder with 296mg polyphenols per day for 4 weeks.
223749706|NCT01674231|OTHER|Grape powder placebo|60g control food (matched for calories, low in polyphenols, and indistinguishable from active intervention) per day for 4 weeks.
223749707|NCT03530475|DIAGNOSTIC_TEST|ultrasound and doppler|"• Ultrasound examination (2D gray scale and color doppler )~1\. Confirming the presence of placenta previa 2,To assess the possibility of concomitant placenta accreta (Sonographic findings that have been associated with placenta accreta (1) Loss of normal hypoechoic retroplacental zone (2) Multiple vascular lacunae (irregular vascular spaces) within placenta, (3) Blood vessels or placental tissue bridging uterine-placental margin, myometrial-bladder interface, or crossing uterine serosa1 (4) Retroplacental myometrial thickness of 1 mm (5) Bladder wall interruption (6) Presence of placental bulge (7) Utero-vesical hypervascularity (8) presence of lacunae feeder vessels.~3\. Assessment of uterine artery Doppler in different cases of placenta previa.~. Documentation of the operative findings during cesarean section and/or cesarean hysterectomy procedures.~Histopathological examination of the hysterectomy specimens to assess the degree of myometrial invasion."
223749708|NCT00924872|OTHER|wheelchair skills training|Five 30-minute training sessions, at a target frequency of 3-5 sessions per week, aimed at improving their power wheelchair skills.
223749709|NCT04721990|DEVICE|Automatic Sound Management 3.0|The investigational front-end features include those within Automatic Sound Management 3.0 (i.e., Ambient Noise and Transient-Noise Reduction, and Adaptive Intelligence). Automatic Sound Management 3.0 will be accessed in the MAESTRO system software. The investigational front-end features within Automatic Sound Management 3.0 will be programmed in the SONNET2EAS processor.
223749710|NCT06454110|DRUG|NM8074|NM8074 will be administered as an intravenous infusion. All subjects will be administered 17 mg/kg of NM8074 intravenously weekly for a total of 15 doses from Day 1 to Day 99 of the Treatment Period.
223749711|NCT00620828|OTHER|Placebo saline injection|20 cc of sterile, injectable saline
223749712|NCT00620828|DRUG|Ropivicaine 0.5%|Ropivicaine
223749713|NCT02918851|BIOLOGICAL|Transfusion of 7-day stored red blood cells|Subjects will donate blood at Week 0 and Week 5 of their participation and receive, at Week 6, back a transfusion of their Week 5 (7-day old) red blood cells.
223749714|NCT02918851|BIOLOGICAL|Transfusion of 28-day stored red blood cells|Subjects will donate blood at Week 2 and Week 5 of their participation and receive, at Week 6, back a transfusion of their Week 2 (28-day old) red blood cells.
223749715|NCT02918851|BIOLOGICAL|Transfusion of 42-day stored red blood cells|Subjects will donate blood at Week 0 and Week 5 of their participation and receive, at Week 6, back a transfusion of their Week0 (42-day old) red blood cells.
223601557|NCT01460134|DRUG|CDX-1127|"Patients will receive four doses of CDX-1127 administered every three weeks followed by an observation period. All patients with stable disease who do not experience a DLT or start alternate anti-cancer treatments may then be eligible for a Retreatment Phase (up to 4 additional cycles). Patients with confirmed partial response or complete response will be followed for response duration and may be eligible for additional cycles of treatment at the time of relapse/progression."
223601558|NCT05474573|DEVICE|Combined ultrasound and fluorescence-guided brain tumor resection|Surgeon intraoperatively assesses extent of tumor resection observing it's fluorescence in microscope and performing sonography
223601559|NCT05474573|DEVICE|Fluorescence-guided brain tumor resection|Surgeon intraoperatively assesses extent of tumor resection observing it's fluorescence in microscope
223601560|NCT02324283|DRUG|desflurane|"Desflurane group: this group of patients receives desflurane as the main anesthetic agent during one-lung anesthesia.~Propofol group: this group of patients receives propofol as the main anesthetic agnet during on-lung anesthesia."
223601561|NCT02324283|DRUG|propofol|Propofol group:this group of patients receives propofol as the main anesthetic agent during one-lung anesthesia.
223601562|NCT01316874|DRUG|Valrubicin, 800 mg|Investigator will be responsible for regulating the use of concomitant medications (systemic and/or topical anticholinergic therapy or topical anesthesia) and other medications.
223749716|NCT00304356|DRUG|Nitazoxanide|500 mg bid
223749717|NCT00285597|DRUG|Ursodeoxycholic Acid|
223749718|NCT03169465|PROCEDURE|open approach|open excision of the bursa and deformity then debridement of Achilles tendon
223601563|NCT06384157|DRUG|INDV-2000|INDV-2000 is a highly potent and selective OX1R antagonist that is being developed as a therapy for the treatment of OUD.
223601564|NCT06384157|OTHER|Placebo|This is a randomized, double-blind, placebo-controlled study.
223601565|NCT02300259|DRUG|LY2623091|Administered orally
223601566|NCT02300259|DRUG|Itraconazole|Administered orally
223601567|NCT02300259|DRUG|Simvastatin|Administered orally
223749719|NCT03169465|PROCEDURE|endoscopic approach|excision of the bursa and deformity then debridement of Achilles tendon through endoscopy
223749720|NCT05463796|OTHER|Samples|"Tissue samples will be collected during a routine visit. Participants will be asked to donate any of the following tissue types:~Blood, Buccal swab (saliva) or mouthwash, Urine, Stool, Biopsy or surgical tissue (i.e., bone marrow),Bodily fluids, Other tissues"
223749721|NCT06008509|PROCEDURE|Gastric echography preoperative|Patients with acute abdomen that are going to surgery, are going to recieve a gastric echography in the surgery room before the start of anesthesia. This procedure include vision of the stomach during supine position and lateral position with curve transductor.
223749722|NCT01045109|DIETARY_SUPPLEMENT|cholecalciferol|4,000 I.U. softgel daily orally for 48 weeks
223749723|NCT01045109|DIETARY_SUPPLEMENT|cholecalciferol|cholecalciferol or vitamin D3 4,000 IU daily for 48 weeks
223601568|NCT02300259|DRUG|Tadalafil|Administered orally
223601569|NCT02300259|DRUG|Diltiazem|Administered orally
223601570|NCT03951272|DEVICE|Lyoplant® Onlay/DURAFORM™ Dural Graft Implant|Lyoplant® Onlay will be used as a dura substitute for the repair of the duramater.The DURAFORM™ Dural Graft Implant will be used in the procedures where the repair or substitution of the patient's dura mater is needed.
223601571|NCT02737475|DRUG|BMS-986178|Specified dose on specified days
223601572|NCT02737475|DRUG|Nivolumab|Specified dose on specified days
223601573|NCT02737475|DRUG|Ipilimumab|Specified dose on specified days
223601574|NCT02737475|BIOLOGICAL|Tetanus vaccine|Specified dose on specified days
223601575|NCT02737475|BIOLOGICAL|DPV-001 vaccine|DPV-001 (UbiLT3 and UbiLT6): Specified dose on specified days
223601576|NCT02737475|DRUG|Cyclophosphamide|Specified dose on specified days
223601577|NCT04867551|DRUG|KDT-3594|oral administration, dose titration
223601578|NCT05048316|BEHAVIORAL|Cognitive-Behavioral Stress Management and Health Education|Participants will attend group sessions with a trained facilitator held over videoconference. Sessions will each last 2 hours and will be held once weekly for 10 weeks. Sessions will include Cognitive-Behavioral Stress Management and health education content.
223601579|NCT06244472|DEVICE|Experiment 1: visual and auditory attention task|We will use the FYNA Research system on 20 healthy volunteers with a visual and auditory attention task to evaluate the system's performance in recording brain signals complex frequency content.
223749724|NCT01712607|OTHER|Preoperative Warm-Up training|Preoperative Warm-Up training
223749725|NCT06064643|OTHER|Online Survey|All participants will be asked to complete an online survey
223749726|NCT06064643|OTHER|Qualitative Interview|30 survey participants will take part in a single one-hour qualitative interview.
223601580|NCT06244472|DEVICE|Experiment 2: language production and rest tasks|We will use the FYNA Research system on 20 healthy healthy volunteers with a language production task to assess the system's functional mapping capabilities and a resting task to assess the system's ability to identify resting networks.
223749727|NCT06064643|OTHER|Bleed Diary|50 participants will complete a 30 day bleed diary
223749728|NCT05702645|PROCEDURE|Biospecimen Collection|Patients undergo saliva/buccal and blood sample collection
223749729|NCT05702645|OTHER|Clinical Evaluation|Undergo a clinical assessment
223749730|NCT05702645|OTHER|Neurocognitive Assessment|Undergo neurocognitive assessment
223749731|NCT05702645|OTHER|Questionnaire Administration|Ancillary studies
223749732|NCT05702645|OTHER|Survey Administration|Ancillary studies
224199990|NCT01200316|PROCEDURE|Rocking Chair Motion|Post surgical patient to rock in a rocking chair in 10-20 minute increments for at least sixty minutes per day, and ambulating at least three times per day.
223601581|NCT06244472|DEVICE|Experiment 3: visuo-motor task|We will use the FYNA Research system in 20 healthy volunteers with a visuo-motor task to evaluate the system's performance in recording brain signals when the subject moves, inducing perturbations that affect the classical system (loss of spatial precision) and the FYNA Research system (low-frequency artifacts).
223601582|NCT06244472|DEVICE|Experiment 4: brain activity at rest|We will be using the FYNA Research system on 20 concussed male athletes volunteers to assess the system's ability to detect modulations in the frequency content of resting brain activity.
223601583|NCT02338986|DRUG|Plasma|Plasma
223601584|NCT02741141|OTHER|New partograph based on the studies of Neal and Lowe|"The partograph designed by Neal and Lowe includes an action line which if crossed permits an active management of labour.~Eventually, the only difference between the two arms is the moment when the active management of labour is started.~The oxytocin is administrated according to the department protocol."
223601585|NCT02741141|OTHER|Classical partograph|Classical partograph used as standard care
223601586|NCT06146829|OTHER|no intervention|no intervention
223601587|NCT00410930|BIOLOGICAL|Subcutaneous immunotherapy - Recombinant birch pollen|
223601588|NCT00654082|DRUG|sildenafil|sildenafil 50 mg tablet by mouth 1 hour prior to anticipated sexual activity, but not more than once daily (QD) for 6 weeks; after 2 weeks on treatment, doses could be escalated to 100 mg or reduced to 25 mg
223601589|NCT00654082|DRUG|placebo|placebo tablet by mouth 1 hour prior to anticipated sexual activity, but not more than once daily (QD) for 6 weeks
223601590|NCT05263557|DIETARY_SUPPLEMENT|Dehydroepiandrosterone (DHEA)|Dehydroepiandrosterone (DHEA) at a dose of 150mg once daily for 7 days.
223601591|NCT05263557|DIETARY_SUPPLEMENT|11-ketoandrostenedione (11KA4)|11ketoandrostenedione (11KA4) at a doses of 150mg once daily for 7 days.
223601592|NCT03688074|BIOLOGICAL|Tezepelumab|Tezepelumab subcutaneous injection
223601593|NCT03688074|OTHER|Placebo|Placebo subcutaneous injection
223601594|NCT03306719|BIOLOGICAL|Blood sampling|Serial blood sampling
223601595|NCT00563459|DRUG|carisbamate|400-1200 mg/day for 12 months
223601596|NCT00563459|DRUG|topiramate|200-400mg/day for 12 months
223601597|NCT00563459|DRUG|levetiracetam|1000-3000mg/day for 12 months
223601598|NCT05213520|OTHER|Alternate Day Intermittent Energy Restriction|It is a dietary intervention designed to alternate between full energy consumption on one day and 40% of daily energy requirement on the following day.
223601599|NCT05213520|OTHER|Reduced Calorie Diet|It is a dietary intervention designed to reduce daily calorie intake by 500-1000 kcal below an individual's daily calorie needs.
223601600|NCT00660179|DRUG|macitentan (ACT-064992)|Tablet, 3 mg dosage, once daily
223749733|NCT00003799|DRUG|fluorouracil|Given IV
223749734|NCT00003799|DRUG|oxaliplatin|Given IV
223749735|NCT00003799|RADIATION|radiation therapy|Undergo radiotherapy
223749736|NCT00003799|DRUG|leucovorin calcium|Given IV
223749737|NCT00003799|PROCEDURE|therapeutic conventional surgery|Undergo surgery
223749738|NCT00335972|DRUG|Remifentanil|Remifentanil will be infused throughout surgery at a rate of 0.1-0.2 µg/kg/min. Propofol will be titrated to maintain a BIS value as close to 45 as clinically practical
223749739|NCT00335972|DRUG|Dexmedetomidine|Dexmedetomidine, 0.5-1 µg/kg, will be infused over 20 minutes, immediately followed by an infusion at a rate of 0.2 µg/kg/hr until the end of surgery (For patients in renal failure, the loading dose will be 0.2 µg/kg). The infusion rate will be reduced as necessary to maintain acceptable blood pressure and heart rate. Propofol will be titrated to maintain BIS as close to 45 as clinically practical.
223749740|NCT03355586|COMBINATION_PRODUCT|Electromagnetic navigation|Electromagnetic navigation combined with use of radial EBUS probe and Rapid On Site Evaluation of Histology for diagnosis of peripheral pulmonary nodules.Controlled by cone beam CT.
223749741|NCT06125288|OTHER|lab investigation and radiation|"1. . Full history taking including~   * Environmental factors such as long term exposure to environmental hazards as bacteria, fungi, chemicals, tobacco smoke and air pollution.~  * Host factors Family history (you have a higher risk of ILD if a close relative has ILD). History of recurrent chest infection. History of exposure to medication such as radiation and chemotherapy. History of Multisystem autoimmune diseases~2. Full examination general and systemic especially chest examination~3. investigation~   * pulse oximetry.~  * lab investigation include complete blood count parameters .~  * radiological investigation including ( echocardiography - MSCT chest - chest -x ray"
223749742|NCT05762900|RADIATION|Ultra-fractionated radiation therapy|5.2Gy per fraction for 5 fractions with an integrated boost of 6Gy per fraction.
223749743|NCT01170806|DRUG|Orlistat|Capsules of 120mg of two commercial formulations of Orlistat (Lipiblock or Xenical) were taken 3 times daily for 7 dayy
223749744|NCT05876741|DIAGNOSTIC_TEST|history taking , vital signs and labaratory investigations|"1. Complete history taking:~   With stress on age, sex, epigastric pain, comorbidities (ischemic heart disease, diabetes, liver cirrhosis, renal failure, malignancy), syncope, disturbed conscious level, blood transfusion, drug history .~2. Clinical examination:~   Pulse, blood pressure, calculating the shock index, pallor, jaundice, cachexia, purpura, ecchymosis, conscious level, abdominal examination.~3. Laboratory investigations:~   * Complete blood count (CBC).~  * Creatinine and blood urea nitrogen (BUN).~  * liver function tests (serum bilirubin, serum albumin, alanine aminotransferase (ALT), aspartate aminotransferase (AST), prothrombin time (PT), prothrombin concentration (PC), and international normalized ratio (INR)).~  * Serum electrolytes and arterial blood gases.~  * Fasting blood sugar.~4. Assessment of risk and predicting outcomes by:~   * Pre-endoscopic Rockall score (pRS).~  * Glasgow-Blatchford score (GBS).~  * AIMS65 score.~  * ABC score.~  * Horibe score."
223749745|NCT01321268|DIETARY_SUPPLEMENT|dietary supplement for cellulite (PUFA, resveratrol, lycopene, beta carotene, lutein)|oral, twice daily in morning and evening for 6 months
223749746|NCT01321268|DIETARY_SUPPLEMENT|Viatmin E|oral, twice daily in morning and evening for 6 months
223749747|NCT05721963|DIAGNOSTIC_TEST|No interventions.|No interventions.
223749748|NCT03902535|OTHER|Comprehensive Geriatric Assessment|Complete comprehensive geriatric assessment
223749749|NCT03902535|OTHER|Quality-of-Life Assessment|Complete quality of life assessment
223749750|NCT03902535|OTHER|Questionnaire Administration|Complete questionnaires
223601601|NCT00660179|DRUG|macitentan (ACT-064992)|Tablet, 10 mg dosage, once daily
223601602|NCT00660179|DRUG|placebo|Matching placebo, once daily
223601603|NCT02255461|DRUG|palbociclib isethionate|Given PO
223749751|NCT05654155|OTHER|auricular acupressure|Auricular acupressure therapy is a well-established treatment strategy whose foundations lie in Traditional Chinese Medicine and is a therapy that is increasingly used in Western medicine.
223749752|NCT01778933|DRUG|EC17|
223749753|NCT03675802|DRUG|misoprostol|giving misoprostol to this group
223749754|NCT03675802|DRUG|dinoprostone|giving dinoprostine
223749755|NCT01844609|BEHAVIORAL|Self Study Journal Club|This Self Study Journal Club will read articles and prepare written answers to the study questions on their own time. The participants will read 24 articles; 12 gynecology and 12 obstetrics, based on monthly journal clubs available online at the Obstetrics and Gynecology website. The first and last article will serve as a basis for the oral and written exam in which they will be tested on comprehension, verbal and written Medical English.
224075293|NCT02950233|DRUG|NMDA active|NMDA active group will involve ketamine (0.5 mg/kg IV bolus pre-incision and 0.1 mg/kg/hr infusion postoperatively up to 24 hours) and oral memantine (5 mg BID \[first week\]; 10 mg BID \[following three weeks\]).
224199991|NCT01200316|BEHAVIORAL|Questionnaire|Beginning on day of surgery till discharge (3-5 days)
223601604|NCT02255461|OTHER|pharmacological study|Correlative studies
223601605|NCT02255461|OTHER|laboratory biomarker analysis|Correlative studies
223601606|NCT04648683|BEHAVIORAL|Individual telehealth mindfulness|Participants who enroll and complete lumbar spine surgery will participate in a one-on-one telehealth-delivered (online with audio and video) mindfulness intervention with a trained mindfulness therapist. The intervention is adapted from mindfulness-based cognitive therapy and includes eight, weekly sessions lasting 75 minutes each (except the first session which lasts 90 minutes).
223601607|NCT04648683|BEHAVIORAL|Group telehealth mindfulness|Participants who enroll and complete lumbar spine surgery will participate in a group-delivered telehealth (online with audio and video) mindfulness intervention with a trained mindfulness therapist. The intervention is adapted from mindfulness-based cognitive therapy and includes eight, weekly sessions lasting 90 minutes each.
224075294|NCT02950233|DRUG|Steroid active|Steroid active group will involve two doses of dexamethasone; 25 mg given prior to starting surgery and 25 mg given on the morning of second postoperative day.
223601608|NCT03154996|DRUG|Topotecan|"Topotecan is a chemotherapeutic agent that is a topoisomerase inhibitor. TPT is administered through an externalized catheter and external microinfusion pump.~Dose: 146 micrometers (uM)"
223601609|NCT03154996|DRUG|Gadolinium|Gadolinium is a widely available MRI contrast agent that is used routinely in clinical practice via IV administration, especially for imaging of intracranial tumors.
224075295|NCT02950233|DRUG|NMDA placebo|NMDA active group will involve normal saline (IV bolus pre-incision and infusion postoperatively up to 24 hours) and oral matching placebo to memantine (1 capsule BID \[first week\]; 1 capsule BID \[following three weeks\]).
224075296|NCT02950233|DRUG|Steroid placebo|Steroid placebo group will involve two doses of normal saline; one dose given prior to starting surgery and one dose given on the morning of second postoperative day.
224075297|NCT00235079|DRUG|Colchicine|Colchicine 0.5mg BID (\>70Kg) or 0.5 once daily for 6 months
224075298|NCT00235079|DRUG|Placebo|Placebo comparator
224075299|NCT05280977|OTHER|POST ISOMETRIC RELAXATION|Group A (Post Isometric Relaxation + Conventional Physiotherapy): This group will receive Muscle Energy Technique in addition to conventional physiotherapy for the treatment of erector spinae tightness. The treatment will be given on alternate days for four weeks with 8 - 10 repetitions of METs per session.
223601610|NCT03154996|DEVICE|Synchromed II infusion pumps|Implanted subcutaneously to facilitate chronic infusion.
223601611|NCT03056339|DRUG|Fludarabine|30 mg/m2 by vein on Days -5 to -3.
223601612|NCT03056339|DRUG|Cyclophosphamide|300 mg/m2 by vein on Days -5 to -3.
223601613|NCT03056339|DRUG|Mesna|300 mg/m2 by vein on Days -5 to -3 before and after the cyclophosphamide dose.
223601614|NCT03056339|BIOLOGICAL|iC9/CAR.19/IL15-Transduced CB-NK Cells|"Infusion of iC9/CAR.19/IL15-transduced CB-NK cells on Day 0 by vein.~Starting dose: 10E5"
223749756|NCT01844609|BEHAVIORAL|Intensive Journal Club|This Intensive Journal Club will read articles and prepare written answers to the study questions along with a fluent English speaker. The participants will read 24 articles; 12 gynecology and 12 obstetrics, based on monthly journal clubs available online at the Obstetrics and Gynecology website. Participants will prepare oral presentations of the studies and answers to the study questions. They will have interactive sessions with this fluent English speaking monitor 3 times a week, one hour sessions for 8 weeks. The first and last article will serve as a basis for the oral and written exam in which they will be tested on comprehension, verbal and written Medical English.
223749757|NCT00446407|OTHER|Collaborative Stepped Care Intervention|Psychoeducation, interpersonal therapy, fluoxetine (20-40 mg/d), adherence management
223749758|NCT00446407|OTHER|Enhanced Usual Care|Screening plus Antidepressants based on practice guidelines
223749759|NCT05383547|DRUG|Bortezomib|Dexamethasone 10mg+ bortezomib (1.3mg /m2 IV) was administered at D1,D4,D8,D11, one month for 1 cycle, for 2 cycles.
223749760|NCT04557657|DRUG|Active bio Activa|Cement that release fluoride
224199992|NCT03667586|BEHAVIORAL|Group cognitive behavioral therapy|Group sessions based on the principles of Cognitive Behavioral Therapy and adjusted for chronic disease patients
223601615|NCT03056339|DRUG|AP1903|If participant has graft-versus-host disease (GvHD) or cytokine release syndrome after the NK cell infusion, they will receive AP1903 0.4 mg/kg administered as an intravenous infusion.
223601616|NCT05236673|DRUG|JARDIANCE®|JARDIANCE® film-coated tablets 10mg
223601617|NCT01048658|DRUG|Sevoflurane|Subject receives Sevoflurane in addition to other standard of care drug regimens for anesthesia with this procedure.
223601618|NCT01048658|OTHER|No Sevoflurane|Subject only standard of care drug regimens for anesthesia with this procedure.
223601619|NCT03529968|PROCEDURE|esophagectomy|Subtotal esophagectomy and proximal gastrectomy with intrathoracic esophagogastric anastomosis. Total gastrectomy and esophageal resection at the level of the azygos vein and Roux-en-Y esophagojejunostomy
223601620|NCT00195533|DRUG|piperacillin-tazobactam|
223749761|NCT04557657|DRUG|Resin Cement|Resin Cement Convinonal
223749762|NCT03274531|BEHAVIORAL|Referral of hypertensive patients to the attending physician|Immediate referral to the treating physician in case of elevated automated office blood pressure measurements
223749763|NCT06209151|OTHER|monitor signs of infection|Prospective observational study of 1040 patients admitted to the ICU without any signs of infection. All patients were subjected to one or more of the most used procedures in ICU (Intubation \& mechanical ventilation, Central line insertion and Urinary catheterization) for at least 48 hours. Then, they were followed for any signs of infection either clinically or laboratorial.
224199993|NCT05001763|DRUG|Prucalopride|Prucalopride, 2mg, tablet. First given 2 days before surgery beginning on POD 1, until defecation or for a maximum of 7 days of postoperative treatment
223601621|NCT00195533|DRUG|glycopeptide|
223601622|NCT03982680|DRUG|Toripalimab|3mg/kg on d1 and d15 q4W\*4cycles，then 3mg/kg q3w for 1 year in total
223601623|NCT03982680|DRUG|Gemcitabine|1250mg/m2 on d1 and d15 q4W\*4cycles
223749764|NCT02605707|DRUG|Intravenous stem cell transplantation|Intravenous injection of autologous endothelial progenitor cells transplantation
223749765|NCT00039754|DRUG|Holmium-166-DOTMP|
223749766|NCT01761656|DRUG|loading dose atorvastatin|For loading dose atorvastatin intervention, patients will be treated with 80 mg atorvastatin (lipitor) 12 hours before PCI and 40 mg atorvastatin (lipitor) 2 hours before PCI and then 20mg/d after PCI.
224199994|NCT05001763|DRUG|Placebo|Glucose, 2mg, tablet.
224199995|NCT00368914|DRUG|sirolimus|
223601624|NCT03982680|DRUG|5- fluorine pyrimidine|400mg/m2 intravenous injection plus 5-FU 2.4g-3.6g/m2 continuous intravenous drip for 48h on d1 and d15 q4W\*4cycles
223601625|NCT05224453|OTHER|Physical training and high protein diet|In addition to the integrated physical training exercises, group A received a high protein diet in the range of 1.1 - 1.3 g/kg protein/ ideal body weight/day (\>1 g/kg aBW/d)
223601626|NCT05224453|OTHER|Physical training and low protein diet|In addition to the integrated physical training exercises, group B received low protein diet in the range of 0.7 - 0.9 g/kg protein/ ideal body weight/day (\<1 g/kg aBW/d)
223601627|NCT02544919|DRUG|SMOF lipid (SMOFLIPID) pre treatment|Experimental Arm
223601628|NCT02075151|PROCEDURE|Bronchial Thermoplasty|Bronchial thermoplasty
223601629|NCT04055909|DRUG|nangibotide low dose|nangibotide 0.3 mg/kg/h
223601630|NCT04055909|DRUG|nangibotide high dose|nangibotide 1.0 mg/kg/h
223601631|NCT04055909|DRUG|placebo|matching placebo
223601632|NCT03770221|BEHAVIORAL|CATCH|Brief, intensive case management service.
223601633|NCT03770221|OTHER|Financial Incentive|Financial incentive for maintaining contact with CATCH service providers.
223601634|NCT05945446|DIAGNOSTIC_TEST|Galectin 3|Women diagnosed with Placenta Accreta Spectrum (PAS) were invited to join the study, providing they had no known systemic diseases (e.g. chronic hypertension, diabetes, hypothyroidism, chronic renal-liver diseases, etc.), autoimmune disorders, multiple pregnancies, or the presence of fetal structural and chromosomal anomalies. They also did not have cholestasis of pregnancy, preterm delivery, or evidence of chronic and active infection.
223601635|NCT00999440|DRUG|Methadone|ECG (QT, QTc, Heart rate), Urine sample (opiates, benzodiazepines, THC, cocaine, amphetamines, methadone-metabolite), Questionnaire PSQI - perceived sleep - self report , Pain indices (severity, duration, cause, etc.) , usage of other medication for pain and other significant disease/disorders, history of drug abuse, age, sex, place of birth and ethnic origin, comorbidity. Follow up after 4weeks, 6months and 1 year will be done. Patients who start with any opiate and then switch to methadone, move to methadone follow up
224199996|NCT00368914|OTHER|laboratory biomarker analysis|
224199997|NCT00368914|OTHER|pharmacological study|
224199998|NCT00368914|PROCEDURE|biopsy|
223601636|NCT02581735|OTHER|Patients with haemophilia|"Using the platform Upatient, patients with hemophilia will register for one year, the prophylactic treatment who receive at home. Likewise, they indicate a replacement therapy as a result of joint bleeds.~At baseline, a month, 6 months and at the end of the study, patients shall complete two questionnaires. The same way in the initial evaluation and end of the study, the clinical joint status will be evaluated with HJHS scale ."
223601637|NCT05580939|OTHER|Intervention group|They use Web-based Simulation Application for 4 weeks
223601638|NCT03374371|DIAGNOSTIC_TEST|high-throughput sequencing|technique of high-throughput sequencing of the markers present in the genome of the S. epidermidis strains responsible for infection in order to help to discriminate the true infections of the contaminations
223601639|NCT05164627|DRUG|Dexmedetomidine|patients will receive Dexmedetomidine infusion (0.2 mcg/kg/hr) from the start of the surgery till the end of it.
223601640|NCT05164627|DRUG|Magnesium Sulphate|patients will receive Magnesium infusion (10 mg/kg/hr) from the start of the surgery till the end of it.
223601641|NCT05164627|DRUG|Normal saline|After patient arrival at the PACU, Paediatric Anaesthesia Emergence Delirium (PAED) scale ,Ramsay sedation scores (RSS), emergence agitation, HR, and mean arterial blood pressure (MAP) were recorded every 5 min during the first 30 min, then every 10 min for the remaining 30 min of the recovery room stay. Patients were then transferred to the ward. All postoperative observations and scores were performed by the same anesthesiologist who was blinded to the group assignment
223601642|NCT03833063|DRUG|botulinum toxin A|glabellar injections with botulinum toxin A
223601643|NCT03833063|DRUG|Placebos|glabellar injections with sodium chloride
223601644|NCT02775448|DRUG|Carduus marianus 6cH|
223601645|NCT02775448|DRUG|Carduus marianus 12cH|
223601646|NCT02775448|DRUG|Carduus marianus 30cH|
223601647|NCT02775448|DRUG|Placebo|
223601648|NCT02775448|BEHAVIORAL|Exercise|aerobic exercise, 30 minutes, daily
223601649|NCT02775448|OTHER|Diet|1600 calories
223601650|NCT05314335|OTHER|Reflexology socks+walking|Patients should wear reflexology socks; Wearing clothes and walking 30 minutes after breakfast and dinner for 30 minutes 3 days a week (Monday, Wednesday and Friday)
223601651|NCT05314335|OTHER|Just walking|Patients will be instructed to walk for 30 minutes, 3 days a week (Monday, Wednesday, and Friday), 30 minutes after breakfast and dinner. Patients will be asked to continue the application for 4 weeks.
223601652|NCT02580461|BEHAVIORAL|A 24 week center-based structured exercise and education program|The intervention will consist of a strength and aerobic exercise program. The exercise program will include twice weekly group resistance exercises classes, twice monthly group education classes, and individual activities to achieve 150 weekly minutes of aerobic activity. The resistance exercise and education classes will be run at a gym space at the University of Calgary. The wait-list control participants will be told not to change their activity levels throughout the 12 weeks of the trial. The wait list control participants will be enrolled into the exercise and education intervention once they have completed 12 weeks of wait-list control. A 12 week maintenance exercise program will be offered to all participants who finish the 12 week exercise and education program. The maintenance exercise program will consist of once weekly resistance group based exercise classes and individual activities to achieve 150 weekly minutes of aerobic physical activity.
223601653|NCT02148055|OTHER|Comparaison between MR and autopsy in the macroscopic evaluation of intra uterine death.|
223749767|NCT01761656|DRUG|conventional dose atorvastatin|For conventional dose atorvastatin intervention, patients will be treated with 20 mg atorvastatin (lipitor) 12 hours before PCI and then 20mg/d after PCI.
223601654|NCT01128244|DIETARY_SUPPLEMENT|Vitamin B6|Subjects will receive vitamin B6 supplementation.
223601655|NCT01128244|PROCEDURE|Infusion of labeled serine, methionine and leucine|Subjects will be given an infusion of the stable isotope labeled amino acids, serine, methionine and leucine prior to vitamin B6 supplementation and after 28 days of B6 treatment. In addition, they will receive a special diet 2 days prior to the infusion and will have weekly weight, blood, and visits to the clinic.
223601656|NCT05260827|OTHER|Heated tobacco product|Sham heated tobacco product
223601657|NCT03326700|PROCEDURE|Inguinal Hernia Repair|Inguinal hernia repair is surgery to repair a hernia in the groin. A hernia is tissue that bulges out of a weak spot in the abdominal wall. The intestine may bulge out through this weakened area. During surgery to repair the hernia, the bulging tissue is pushed back in. The abdominal wall is strengthened and supported with sutures (stitches), and sometimes mesh. This repair can be done with open or laparoscopic surgery.
223601658|NCT03654508|GENETIC|ADRB2-genotype guided treatment|This intervention assesses whether ADRB2 genotype-guided treatment leads to better asthma control after 3 months compared to usual care in children who are uncontrolled despite adherent and adequate use of ICS.
223601659|NCT03654508|OTHER|Randomisation|In the control arm, children will be randomised over double dose ICS or ICS+LABA instead of treatment according to their genotype.
223601660|NCT00939536|DRUG|Zolpidem Tartrate Tablets 10 mg|
223601661|NCT05403671|OTHER|Increasing Exercise and Physical Activity in Those Rehablilitating From Cancer|Intervention includes exercising and relaxation in a group
223601662|NCT01120106|DRUG|levosimendan|patients enrolled in this group will receive a levosimendan continuous infusion at a rate of 0.1 mcg/kg/min
223601663|NCT01120106|DRUG|placebo|saline continuous infusion
223601664|NCT04157803|DIAGNOSTIC_TEST|Acetic acid % spray|"If during a videcolonoscopy a polyp is found with suspicion of tubular, tubulovillious or Serrated adenoma, the endoscopist will proceed to stain it using diffuser and acetic acid at a concentration of 3%. The presence or not of the aceto-whitening reaction will be evaluated, understanding it as the persistence of white staining of the polyp at one minute or three minutes, standing out from the surrounding mucosa.~In case of positive staining it will be considered homogeneous if the staining is uniform on the surface of the polyp or heterogeneous if it is done irregularly."
223749768|NCT00374881|DRUG|Morphine|Morphine
223749769|NCT00374881|DRUG|Morphine|Morphine low dose
223749770|NCT00374881|DRUG|Sorbitol+Phenylephrine|Sorbitol+Phenylephrine
223749771|NCT00374881|DRUG|Sorbitol+Phenylephrine+Morphine|Sorbitol+Phenylephrine+Morphine
223749772|NCT00374881|DRUG|Sorbitol low concentration+Phenylephrine+Morphine|Sorbitol low concentration+Phenylephrine+Morphine
223749773|NCT00788892|DRUG|CPX-351|
223749774|NCT00788892|DRUG|Cytarabine|
223749775|NCT00788892|DRUG|Daunorubicin|
223601665|NCT00644150|BEHAVIORAL|Physician Ai Shi Zi training|This training uses a curriculum developed specifically for Project Ai Shi Zi and includes training in stigma; risk-reduction counseling; and quality HIV/STI diagnosis, treatment, and management. Physician training will consist of multiple components: an orientation workshop on fundamental knowledge and skills of HIV/STI treatment and prevention, a 3-month practice period, a 3-month post-practice seminar on preventive counseling, another 3-month practice period, and a 6-month post-practice seminar on clinical HIV and STI management. The practice periods will promote learning-by-doing to further enhance physicians' abilities to deliver high quality, integrated HIV/STI prevention and treatment. Post-practice seminars will allow participants to share experiences gained during the previous 3-month practice period.
223601666|NCT00644150|DRUG|Standard care|If an STI is confirmed by a lab test, participants will receive standard of care treatment. Gonorrhea will be treated with a single dose of 250 mg of ceftriaxone sodium administered by intramuscular injection. If patients are allergic to ceftriaxone, they will be treated with azithromycin (2 g single oral dose). Chlamydia will be treated with azithromycin (1 g single oral dose).
223601667|NCT00644150|BEHAVIORAL|Patient risk-reduction counseling|On the initial visit, participants will receive HIV/STI risk-behavior counseling from the physician trained in Ai Shi Zi. The process is based on motivational interviewing techniques and will include discussing topics such as partner notification, HIV/STI prevention, and expected difficulties in changing behaviors. This risk-reduction model encourages the HIV/STI-infected or -uninfected person to develop a risk-reduction plan. The objective is to decrease the chance of infection for that individual and for others, too. Patients will develop a list of risk-reduction strategies to follow.
223601668|NCT04171219|BIOLOGICAL|Pembrolizumab|Given IV
223601669|NCT04171219|DRUG|Talabostat Mesylate|Given PO
223601670|NCT05430113|DEVICE|Spinal Cord Stimulator (octopolar Medtronic Vectris Leads)|2-4 leads FDA-approved for treatment of symptoms of refractory pain
223601671|NCT03988764|OTHER|None AHT|No further intervention planned for either group as part of the current study.
223601672|NCT06234254|BEHAVIORAL|Virtual Reality headset with calming scenery|Participants will be immersed in a virtual environment. Calming scenery will be shown via the headset for 20-30 minutes
223601673|NCT04809285|DEVICE|Guardian™ Connect system, InPen™ Basal smart cap, smart insulin pens, and InPen™ Diabetes Management app|Guardian™ Connect system consists of Guardian™ Connect app, Guardian™ Connect transmitter, and Guardian Sensor (3), will be working with InPen™ Basal smart cap and smart insulin pens and InPen™ Diabetes Management app for multiple daily injections. The subject's insulin delivery, sleep, physical activity (as applicable), food intake data, and medication (as applicable) will be collected through applications with meal logging and medication requiring manual entry. In addition, subjects may also participate in optional self-administered insulin injection video capture and upload using a secure cloud-based site and/or monthly menstrual cycle logging using Apple Health and/or cardiac monitoring using BodyGuardian MINI.
223601674|NCT06501703|OTHER|Instruments|instruments used as different techniques in final irrigation after root canal preparation
223601675|NCT06166667|PROCEDURE|Fecal Microbiota Transplant（FMT）|Patients involved in the trial received 20 capsules of Enterobacteriaceae (one course) on days 1, 8, and 15, which were provided by Dongyuan Yikang company. Patients were prohibited from taking antibiotics such as amoxicillin and Cefalexin during the trial.
223601676|NCT06292130|BEHAVIORAL|refresh|A theoretically-grounded, highly individualized tobacco cessation Health-Kit enabled app. Unlike existing tobacco cessation apps, refresh: 1) implements a full range of best practices in tailored health behavior change communications; 2) individualizes messaging based on the patient's clinical context using Health app data obtained through Fast Healthcare Interoperability Resources (FHIR) standard Application Programming Interfaces (API) and behavior change constructs; and 3) provides data and key insights back to the EHR.
223601677|NCT05811169|GENETIC|Next generation sequencing|Next generation sequencing
223601678|NCT04166916|OTHER|Acoustic stimulation|Acoustic stimulation to modulate slow waves.
223601679|NCT04166916|OTHER|SHAM acoustic stimulation|This is the sham-control intervention; only the biosignal will be recorded but no acoustic stimulation will be played.
223601680|NCT06374706|BEHAVIORAL|Morning Walk training for stroke|Assessing the Feasibility of the End-Effector Rehabilitation Robot, Morning Walk Training and investigate the Immediate Post-Adaptation Effect of Morning Walk Training for Symmetrical Walking on the Ground.
223601681|NCT06374706|BEHAVIORAL|Morning Walk training for healthy|Assessing the Feasibility of the End-Effector Rehabilitation Robot, Morning Walk Training and investigate the Immediate Post-Adaptation Effect of Morning Walk Training for Asymmetrical Walking on the Ground.
223601682|NCT06284668|DRUG|normal Saline|Patients undergoing oocyte retrieval were given 5ml 0.9% saline before anesthesia and surgery
223601683|NCT06284668|DRUG|Esketamine|Patients undergoing oocyte retrieval were given esketamine 0.2mg/kg before anesthesia and surgery
223601684|NCT06284668|DRUG|Remimazolam|Patients undergoing oocyte retrieval were given remimazolam 0.2mg/kg before anesthesia and surgery
223601685|NCT05495867|PROCEDURE|implant placement|implant placement in edentulous area
223601686|NCT03409783|DEVICE|ENSO Device|An active ENSO device that delivers neuromodulation therapy.
223601687|NCT03409783|DEVICE|Sham Device|Sham Device
223601688|NCT06774378|BEHAVIORAL|Minds@Work-ADHD-Quality of Life|Minds@Work-ADHD-Quality of Life
223601689|NCT06774378|BEHAVIORAL|Minimal contact|Weekly 15-minute scripted phone calls made individually by a member of the research team to offer minimal support, without any active intervention.
223601690|NCT05707208|DRUG|ST-01|A sustained release lidocaine formulation designed for the treatment of acute and chronic pain.
223601691|NCT05707208|DRUG|1% Lidocaine HCL|Currently approved lidocaine
223601692|NCT05036317|DRUG|Empagliflozin (Jardiance®;|Each tablet contains the active substance of 10 mg empagliflozin as well as the adjuvant lactose-monohydrate and is taken orally once daily in the morning.
223601693|NCT05036317|OTHER|Placebo Control Intervention|Placebo will be provided by Boehringer Ingelheim. It is identical to the interventional product apart from the active compound.
223601694|NCT01038167|DRUG|telaprevir|Tablet, Oral, 750mg, every 8 hours, Day 1-11 of Period 2
223601695|NCT01038167|DRUG|telaprevir|Tablet, Oral, 750mg, every 8 hours, Day 1-13 of Period 2
223601696|NCT01038167|DRUG|cyclosporine|Solution, Oral, 100mg, Day 1 of Period 1
223601697|NCT01038167|DRUG|cyclosporine|Solution, Oral, 10mg, Day 1 and Day 8 of Period 2
223601698|NCT01038167|DRUG|tacrolimus|Capsule, Oral, 2mg, Day 1 of Period 1
223601699|NCT01038167|DRUG|tacrolimus|Capsule, Oral, 0.5mg, Day 8 of Period 2
223601700|NCT04150094|OTHER|Pelvic floor muscle training (PFMT)|Participants will be firstly evaluated and orientated about pelvic floor muscles and pelvic floor muscle training. They will be clarified about the role of pelvic floor muscles in continence mechanisms and will be orientated to perform 8 weeks of PFMT without stimulus, coming once a week to a session supervised by physiotherapist and will be encouraged to perform the exercises at home during the other week days.
223601701|NCT04150094|OTHER|Pelvic floor muscle training + intravaginal vibratory stimulus|Participants will be firstly evaluated and orientated about pelvic floor muscles and pelvic floor muscle training. They will be clarified about the role of pelvic floor muscles in continence mechanisms and will be orientated to perform 8 weeks of PFMT with intravaginal vibratory stimulus. They will need to come once a week to a session supervised by physiotherapist to use the vibration device and will be encouraged to perform the exercises at home during the other week days.
223601702|NCT00004223|DRUG|docetaxel|
223601703|NCT00004223|DRUG|gemcitabine hydrochloride|
223601704|NCT02761343|OTHER|MRI scan|Following the clinically indicated cardiac ablation procedure, a post ablation MRI scan will be performed.
223601705|NCT04985461|DEVICE|dental occlusion ties maxillo-mandibular fixation|"This research study is being done to determine if dental occlusion ties can adequately align and stabilize jaw fractures. The chief goal of jaw fracture repair is to ensure that the teeth align normally. Traditionally, alignment has been accomplished by using steel wires and bars (having the jaw wired). Dental occlusion ties are newer devices similar to cable ties or zip ties that are wrapped around and/or between some of the teeth and secured. This procedure is intended to hold the teeth in similar alignment as wires, yet with less application time and less damage to the gums."
223601706|NCT00000355|DRUG|Buprenorphine|
223601707|NCT03994874|DRUG|PolyCore (Polydextrin, L-Carnitine, D-xylitol)|A single nightly exchange, with 2 liters PolyCore solution, lasting 12-14 hours. Patients should remain on their prescribed heart failure medications and the same dosing schedule for the duration of the study unless investigators determine medically necessary to change.
223601708|NCT04548856|PROCEDURE|Microsurgical clipping|Subjects randomized to surgical therapy will receive treatment from one neurosurgeon expert in surgery for ruptured aneurysms.
223601709|NCT04548856|PROCEDURE|Endovascular embolization|Subjects randomized to endovascular therapy will be treated by one endovascular expert in such treatment. Endovascular treatment will include all modern accepted surgical techniques.
223601710|NCT05766826|OTHER|Coupons for safe water program: Treatment|Randomly selected women in the treatment group will receive coupons for free chlorine solutions to be redeemed at the health facility each month.
223601711|NCT05766826|OTHER|Coupons for safe water program: Control|Randomly selected women in the treatment group will not receive coupons for free chlorine solutions after enrollment.
223601712|NCT04515901|DRUG|2% lidocaine|Viscous lidocaine
223601713|NCT04515901|OTHER|Placebo|Methylcellulose and cherry flavouring
223601714|NCT04698603|DRUG|5 Methoxy N,N Dimethyltryptamine|GH001 administered via inhalation
223601715|NCT05021770|DRUG|Orelabrutinib|150mg or 200mg orally daily
223601716|NCT05021770|DRUG|Orelabrutinib|RP2D
223601717|NCT05021770|DRUG|Thiotepa|30 mg/m2 intravenously every 3 weeks (maximum 6 cycle)
223601718|NCT03132701|DRUG|Magnesium|Mg is administered during anesthesia until 5 minutes before surgery ends
223601719|NCT03132701|DRUG|Saline|Same volume of saline is infused until 5 minutes before surgery ends
223601720|NCT05659927|DRUG|MG-ZG122 Humanized Monoclonal Antibody Injection|Single subcutaneous injection. Subjects with a dose of less than or equal to 2 ml were given one injection, and subjects with a dose of more than 2 ml were given two injections. A group 0.5 ml, B group 1 ml, C group 2 ml, D group 4 ml.
224199999|NCT03422081|DIAGNOSTIC_TEST|arterial doppler ultrasound|doppler ultrasound
224200000|NCT06563050|PROCEDURE|Nebulized lidocaine|Subjects in group A underwent nebulization with 5 mL of 2% lidocaine for 15 minutes by using a jet nebulizer.
223601721|NCT05659927|DRUG|Placebo|Single subcutaneous injection. Subjects with a dose of less than or equal to 2 ml were given one injection, and subjects with a dose of more than 2 ml were given two injections. A group 0.5 ml, B group 1 ml, C group 2 ml, D group 4 ml.
223601722|NCT04857580|DEVICE|CTS Device|Coronary cryotherapy is delivered locally on eligible lesions randomized to the treatment using the CTS System.
223601723|NCT02023957|BEHAVIORAL|Interactive computer-assisted screening (iCAS)|
223601724|NCT04947241|DRUG|PD-1 inhibitor+ Gemcitabine + Cisplatin|"Before surgery, patients will receive therapy as follows:~PD-1 inhibitor: 240mg (day1) , intravenous, Q3W, 2cycles; cisplatin: 80 mg/m2(day1), intravenous , intravenous, Q3W, 2cycles Gemcitabine: 1000mg/m2(day1and day8), intravenous, Q3W, 2cycles"
223601725|NCT05472922|DEVICE|Placement of MiniMizer Gastric Ring|Insertion of MiniMizer Gastric Ring in addition to the normal MGB-OAGB
223601726|NCT05472922|PROCEDURE|Normal MGB-OAGB|No insertion of Minimizer Gastric Ring in addition to the normal MGB-OAGB
223601727|NCT05322720|BIOLOGICAL|EOC202|EOC202 will be SC injection
223601728|NCT05322720|DRUG|albumin-bound paclitaxel|albumin-bound paclitaxel will be Iv injection
224200001|NCT06563050|PROCEDURE|Lidocaine spray|Subjects in group B will underwent 10% lidocaine spray solution will be sprayed 10 times at the oropharynx at 5 s interval.
223601729|NCT06270914|BEHAVIORAL|Inclusive Positive Behavior Interventions and Supports|The intervention is based on the Norwegian manualized program of SW-PBIS, N-PALS (Positiv Atferd, Støttende Læringsmiljø, og Sammhandling). The Norwegian model shares its core components with the original SW-PBIS model. The program's core components constitute: (a) positive behavior support strategies, including positive expectations and classroom rules, which are followed up with positive feedback and encouragement; (b) a system for monitoring student behavior, (c) school-wide corrections using consequences, (c) instruction in classroom management skills for teachers, and (e) strategies for collaboration with parents. These components are implemented through activities at school level and at classroom level.
223601730|NCT01703507|DRUG|Ipilimumab|Given IV
223601731|NCT01703507|RADIATION|Whole-Brain Radiation Therapy (WBRT)|Undergo WBRT
223601732|NCT01703507|RADIATION|Stereotactic Radiosurgery (SRS)|Undergo SRS
223601733|NCT03954821|DEVICE|prefabricated insoles|
223601734|NCT02154919|PROCEDURE|Percutaneous coronary intervention|
223601735|NCT06571266|DRUG|Risankizumab|• Subcutaneous Injection via prefilled syringe
223601736|NCT03600441|DRUG|Abexinostat|Abexinostat tosylate salt is formulated into an oral tablet formulation and is available in 20 mg strength.
223601737|NCT06444581|BEHAVIORAL|Super Skills Schools|Super Skills Structured and manualized intervention with a manual for the therapist and a workbook for the children. The intervention will be administered by Super Skills-trained clinical psychologists. Sessions will take place once a week for twelve weeks, with each session lasting approximately fifty minutes. The program includes emotional education and social skills training. These contents are learned through playful exercises, activities, readings and role-playing. The intervention modality will be face-to-face.
223601738|NCT00407472|DEVICE|ATS-1 needle free device|
223601739|NCT02695693|BEHAVIORAL|TeachTown|TeachTown is an online program for students with autism that uses an applied behavior analysis framework to provide intervention in academic and pre-academic areas
223601740|NCT02695693|BEHAVIORAL|Discrete Trial Training|Discrete trial training is a one-on-one didactic behavioral intervention in which the teacher or therapist uses specific behavioral methods based on principles of operant conditioning, to help students gain skills
223601741|NCT02695693|BEHAVIORAL|Pivotal Response Training|Pivotal response training is a one-on-one child-lead behavioral intervention in which the teacher or therapist uses specific behavioral methods, leveraging the students interests, to help students gain skills
223601742|NCT02695693|BEHAVIORAL|Teaching in Functional Routines|Functional routines are sets of chained behaviors that students are taught that help them complete and manage specific activities in the classroom
223601743|NCT04656457|DEVICE|Treadmill|Treadmill is not used to harness power, but as exercise machines for running or walking in one place. Rather than the user powering the mill, the machine provides a moving platform with a wide conveyor belt driven by an electric motor or a flywheel. The belt moves to the rear, requiring the user to walk or run at a speed matching that of the belt. The rate at which the belt moves is the rate of walking or running. Thus, the speed of running may be controlled and measured
223601744|NCT04656457|OTHER|resisted exercises|Resistance exercises will be involved in this technique are for upper and lower limb (Exercise program including shoulder flexion, abduction and horizontal adduction, elbow extension and flexion, calf raise, leg extension and squatting)
223601745|NCT03574636|DEVICE|OCT guidance|OCT guide stent implantation
223601746|NCT03574636|DEVICE|IVUS guidance|IVUS guide stent implantation
223601747|NCT03574636|DEVICE|QCA|QCA guide stent implantation
223601748|NCT01112787|DRUG|Tazarotene Foam|Tazarotene Foam
223601749|NCT01112787|DRUG|Vehicle Foam|Vehicle Foam
223601750|NCT01112787|DRUG|Sodium Laural Sulfate|Sodium Laural Sulfate
223601751|NCT01112787|DRUG|Distilled Water|Distilled Water
223601752|NCT00297323|DRUG|Topiramate|75 patients over the age of 2 years old with epilepsy.
223601753|NCT05367791|OTHER|POSTUR|Training sessions without any stimulation
223601754|NCT05367791|OTHER|Localised Vibration|Training sessions with localized vibration
223601755|NCT05367791|OTHER|Somatosensory Electrical Stimulation|Training sessions with somatosensory electrical stimulation
223601756|NCT05596604|OTHER|survey- no intervention|survey- no intervention
223601757|NCT04054076|DEVICE|Prefabricated insoles|The participants received prefabricated insoles
223601758|NCT04054076|DEVICE|Soft custom-made insoles|The participants received soft custom-made insoles
223601759|NCT04054076|DEVICE|Hard custom-made insoles|The participants received hard custom-made insoles
223512327|NCT01783873|OTHER|standardized bronchial challenge test (SCL SCL • • GenaSOL ™ GenaSIC ™)|At Visit 1: Patients are selected and they will receive a metacholine challenge test during and outside of work. After randomization, patients undergo a standardized bronchial challenge test (SCL SCL • • GenaSOL ™ GenaSIC ™) to either an wheat flour allergen extract or didecyldimethylammonium chloride or placebo. Each bronchial challenge test is followed by blood sampling at different time points and induced sputum. The immediate bronchial response and late bronchial response will be recorded.
223749776|NCT00251446|DRUG|Vinflunine|320 mg/m2 as a 20-minute IV infusion
223601760|NCT05761990|OTHER|POST ISOMTERIC RELAXATION TECHNIQUE|"POST ISOMETRIC RELAXATION TECHNIQUES~* Stretching the hypertonic muscle to the point when movement resistance is initially felt or just past the point of discomfort.~* For 5 to 10 seconds, a submaximal (10-20%) hypertonic muscle contraction is carried out away from the barrier while resistance is supplied in the other side. To help with this, the individual should breathe in.~* The individual is told to relax while breathing after the isometric contraction. After then, until the next barrier is reached, a gentle stretch is employed to pick up the slack.~* Starting with this new barrier, the procedure is carried out two or three more times."
223601761|NCT05761990|OTHER|NOVEL STRETCHING|"NOVEL STRETCHING The NS will be performed in a supine posture for Group B participants. Participants will be instructed to open their knees while wearing a resistance band around their knees. Participant will be instructed to bridge as high as he can while keeping his shoulders 90 ° abducted and his elbows 90 ° flexed. By lifting the body weight upward, the bridging motion pins the scapula's medial border against the thorax without immediately squeezing or constricting the posterior shoulder bones. This position is thought to provide more flexibility of mobility while causing less discomfort. The subjects were instructed to hold this position while tightening or squeezing their gluteal muscles. They were also instructed to stretch by jerkily turning their shoulders inward as far as possible. Using the second hand, the stretch was pushed forward to the point of mild discomfort while contraction was maintained."
223601762|NCT02094092|OTHER|ProTectis drops (five drops per day) for 21 days|
223601763|NCT02094092|OTHER|Placebo drops (five drops per day) for 21 days|
223601764|NCT02458573|OTHER|continuous epidural analgesia|the continuous epidural analgesia group: epidural analgesia started from induction of anesthesia and continued for 48 h.
223601765|NCT02458573|OTHER|continuous intravenous analgesia|the continuous intravenous analgesia group: intravenous analgesia started from induction of anesthesia and continued for 48 h.
223601766|NCT06135935|OTHER|No-added-sugar ice cream|The initial focus of this clinical trial will be the impact on postprandial glycaemia of 300g of ice cream, since, from a nutrition perspective, the flavored milks and ice creams are very similar in composition.
224200002|NCT06563050|PROCEDURE|Combination of nebulized lidocaine and lidocaine spray|Group C: both nebulization and spray will be performed in the same manner except the number of spray will be 2 instead 10.
223749777|NCT03541824|BEHAVIORAL|Body Acceptance Program|The Body Acceptance Program is a mixed-gender modification of the eBody Project, an online intervention in which cognitive dissonance principals are used to reduce eating pathology.
223749778|NCT06493708|OTHER|Trauma focused psychotherapy: EMDR|14 sessions of psychotherapy with EMDR will be carried out with patients. One session per week, lasting 90 minutes. The first two sessions will be used for the description of the EMDR method and for stabilization, then there will be treatment sessions.
223749779|NCT04097093|OTHER|No intervention|No intervention
223749780|NCT04225299|DRUG|TOOKAD®|TOOKAD® -VTP procedure will consist of an IntraVenous (IV) administration to patients using a 753nm laser light at a fixed power of 150mW/cm and a fixed energy at 200J/cm delivered through transperineal interstitial optical fibers. The needles are positioned in the prostate under ultra sound image guidance
223749781|NCT03021850|PROCEDURE|Flexibility training with or without different thermal modalities|Flexibility training of the hamstring muscles by passive static stretching of the hamstring muscles in 10 30-second repetitions, with a 10-second pause between each repetition associated with or without short-wave heating or cryotherapy
223749782|NCT04408482|DEVICE|Biliary cannulation|Cannulation of biliary duct by sphincterotome
223601767|NCT06135935|OTHER|Conventional products|The overconsumption of sugar-added conventional products leads to an increased risk of poor control of glycaemic levels.
223601768|NCT02677272|OTHER|Appropriateness of NH resident's transfer to ED|
223601769|NCT02664506|BEHAVIORAL|Word repetition after a time delay.|This is a behavioral intervention, Word repetition after a time delay. Individuals listen to words and repeat them after 5 or 10 seconds.
223601770|NCT04370106|OTHER|Social leg program|Usual care as described for the CG will also be provided to the IG. Wound healing measurement, therapeutic adherence measurement, wound recurrence measurement, and questionnaires will be provided by the institute's nurses. After baseline data collection (T0) and random allocation to the intervention group, this usual care will be enhanced by frequenting a social leg program.
223601771|NCT03525691|DEVICE|Low flow Extracorporeal CO2 removal|Low flow Extracorporeal CO2 removal using a 0.67 m² membrane oxygenator (Lilliput 2) and a specific circuit (HP-X) mounted on a RRT monitor (PrismafleX)
223601772|NCT05838157|BIOLOGICAL|prophylactic HPV vaccine(bivalent HPV、quadrivalent HPV、9-valent HPV)|at least one dose of prophylactic HPV vaccine including bivalent HPV (2vHPV)， quadrivalent HPV vaccine (4vHPV)，9-valent HPV vaccine (9vHPV)
223601773|NCT03733613|OTHER|no intervention|no intervention
223601774|NCT03258086|DIAGNOSTIC_TEST|blood sample test|blood sample will be taken from all diabetic children for assessment of vitamin D level
223601775|NCT03040674|PROCEDURE|Cell therapy|Each participant will receive cell therapy with stem cells harvested either from peripheral blood or from bone marrow plus peripheral blood; after harvest, cells are processed and returned to the patient via peripheral circulation on the same day
223601776|NCT00473200|DIETARY_SUPPLEMENT|S-adenosylmethionine|1200 mg daily
224200003|NCT04707066|BEHAVIORAL|Treatment As Usual (TAU)|Treatment As Usual
223601777|NCT00002359|BIOLOGICAL|HIV-1 Immunogen|
223601778|NCT00330005|BEHAVIORAL|Group Psychotherapy|
223601779|NCT05614349|DRUG|Paxlovid|This adaptive platform trial will assess therapeutics for SARS-CoV-2 in out-patient settings. The first intervention arm is Paxlovid.
223601780|NCT05614349|DRUG|Antioxidant|Antioxidant therapy (comprising of selenium, zinc, lycopene, and vitamin C)
223601781|NCT00519272|BEHAVIORAL|Questionnaire|Series of surveys to be completed at the time of diagnosis and within one month after completion of treatment, taking approximately 45 minutes each time.
223601782|NCT05711823|DRUG|Aprepitant in combination with granisetron and dexamethasone|Patients with unresectable hepatocellular carcinoma will receive aprepitant in combination with granisetron and dexamethasone during the therapeutic process of hepatic arterial infusion chemotherapy.
223601783|NCT05711823|DRUG|Granisetron and dexamethasone|Patients with unresectable hepatocellular carcinoma will receive granisetron and dexamethasone during the therapeutic process of hepatic arterial infusion chemotherapy.
223601784|NCT03930602|DRUG|BMS-986165|Participants will receive BMS-986165.
223601785|NCT03930602|DRUG|Fluvoxamine|Participants will receive fluvoxamine.
223749783|NCT01330485|BEHAVIORAL|Affect Regulation Training|The ART is a transdiagnostic, group-based intervention that has been developed to explicitly target emotion regulation skills (e.g., the abilities to be aware of, understand, accept, tolerate and modify negative emotions).
223749784|NCT01330485|BEHAVIORAL|Common Factor Control Condition|The CFC is an active treatment condition designed to control for unspecific effects of psychotherapeutic interventions.
223749785|NCT00271089|PROCEDURE|PBSC Collection|
223749786|NCT00271089|PROCEDURE|Bone Marrow Harvest|
223601786|NCT05871099|PROCEDURE|Hyperthermic Intraperitoneal Chemotherapy (HIPEC)|Experimental group receive HIPEC two times after laproscopic gastrectomy
223601787|NCT00036634|DRUG|Tenofovir DF|Tenofovir DF tablet administered orally once daily
223601788|NCT00036634|DRUG|Tenofovir alafenamide|Tenofovir alafenamide tablet(s) administered orally once daily
223601789|NCT03362749|OTHER|RFA, MWA, cryo and IRE|local tumor ablation
223601790|NCT00749723|DRUG|carboplatin|200 mg/m²/d continuously IV on day 1-4 of each 21-28-day-cycle. Number of cycles: until disease progression, maximum 4 cycles
223749787|NCT00271089|DEVICE|CliniMacs Cell Selection System|
223749788|NCT02299986|OTHER|Ultrasound measurement|Thickness measurement through ultrasound. The investigators will perform daily ultrasound measurements to assess the evolution in thickness during mechanical ventilation
223749789|NCT05196542|PROCEDURE|patients with apical prolapse who will do Sacro hysteropexy using mersilene tape|comparison between standard poly prolene mesh and the poly ester mersilene tape in Sacro hysteropexy surgical procedure
223749790|NCT04826146|DEVICE|Validation of qCON versus BIS|Correlation between qCON and BIS values (main outcome) and qNOX and MOAA/S scale are determined
223749791|NCT00798538|OTHER|Services will be provided at one site|Provision of buprenorphine induction and management, substance abuse counseling and HIV care will be provided at one clinic: the Waterbury Hospital Infectious Disease Clinic..
224200004|NCT04707066|BEHAVIORAL|Collaborative Assessment and Management of Suicidality (CAMS) - Phase 1|Collaborative Assessment and Management of Suicidality
224200005|NCT04707066|BEHAVIORAL|Dialectical Behavior Therapy (DBT) - Phase 2|Dialectical Behavior Therapy
223601791|NCT00749723|DRUG|etoposide|100mg/m²/d continuously IV on day 1-4 of each 21-28 day cycle. Number of cycles: until disease progression, maximum 4 cycles
223601792|NCT00749723|DRUG|temozolomide|150mg/m²/d p.o. on day 1-5 of a 21-28-day-cycle. Number of cycles: until progression or maximum up to 2 years
223601793|NCT00749723|DRUG|thiotepa, carboplatin, etoposide|high dose chemotherapy followed by to autologous stem cell transplantation
223749792|NCT00798538|OTHER|Services remain dispersed; i.e., not centralized to one-location or provider.|Buprenorphine induction, substance abuse counseling, and HIV care will be provided at separate locations: the Community Health Care Van (CHCV), the Yale AIDS Program, and patients' own HIV providers, respectively.
223601794|NCT00749723|DRUG|temozolomide, thiotepa|high dose chemotherapy followed by autologous stem cell transplantation
223601795|NCT00749723|PROCEDURE|autologous stem cell transplantation|autologous stem cell transplantation following HD-chemotherapy
223601796|NCT00749723|DRUG|intraventricular etoposide|prior to systemic chemotherapy as single agent in patients with neoplastic meningitis, in addition to systemic chemotherapy if proven effective in phase II study, intraventricularly age-dependent daily dose (\>3m to \<3y 0.7 mg; \>3y 1.0 mg) for 5 days every 2 two 4 weeks. Number of cycles: at least 3 courses, maximum up to 2 years
223601797|NCT00749723|DRUG|trofosfamide, etoposide|maintenance therapy: trofosfamide and etoposide: 100 mg/m²/d and 25 mg/m²/d, respectively, for 21 days every 4 weeks. Number of cycles: until progression or maximum up to 2 years
223601798|NCT04174690|DEVICE|Force platform|In order to volunteers to be selected for collection a recruitment test will be taken, the volunteer will have to stand on one foot for 5 seconds without additional support. So that the volunteer can go to the balance test on the force platform, he will be dressed with safety equipment (harness), and will also have the attachment of the electrodes.
223601799|NCT02047214|DRUG|TPI 287|TPI 287 is a microtubule inhibitor belonging to the taxane diterpenoid (taxoid) family, and specifically to the abeotaxane class. TPI 287 is an Investigational Drug.
223601800|NCT02047214|DRUG|Bevacizumab|Avastin (bevacizumab) is an FDA approved drug indicated for multiple cancers, including as a single agent for GBM for adult patients with progressive disease following prior therapy. Single agent effectiveness is based on improvement in objective response rate; no data is available demonstrating improvement in disease-related symptoms or survival with bevacizumab.
223601801|NCT02206035|DRUG|Tacrolimus|Patients enrolled in the clinical trial will receive tacrolimus per institutional guidelines at doses to maintain therapeutic levels and continued until at least Day 90 posttransplant.
223601802|NCT02206035|DRUG|Methotrexate|Methotrexate will be dosed at 15 mg/m2 Day +1 and 10mg/m\^2 Days +3, +6 and +11.
223601803|NCT02206035|DRUG|Tocilizumab|Tocilizumab will be administered intravenously at a dose of 8 mg/kg at Day -1.
223601804|NCT06342518|DEVICE|Extracorporeal Shock Wave Therapy (ESWT)|The ESWT group received radial ESWT each session with a total of 2000 pulses at a frequency of 10 Hz. A gel was used at the interface, and the air pressure was set at 1.8 bar per session.
223601805|NCT06342518|DEVICE|Sham ESWT|The Sham-ESWT group received Sham radial ESWT each session, but without actual contact of the applicator. To enhance the illusion of treatment, gel was applied, and the device emitted sound at every shock
223601806|NCT06342518|BEHAVIORAL|Resting Splint , Exercises and ice|Ensuring proper usage of the wrist resting splint by the patient was confirmed during follow-up visits. The physician instructed the patients on stretching and strengthening exercises for wrist extensors, which they were asked to perform three times a day. Application of ice for 20 minutes every 3-4 hours during painful periods was recommended. During follow-up visits patients confirmed that they adherence to exercises and recommendations.
223601807|NCT02059304|DEVICE|Measurement of cervical length with embryo transfer catheter|
223601808|NCT01934010|DRUG|AM-101|AM-101 gel for intratympanic injection
223601809|NCT04609631|BEHAVIORAL|Tai Chi|24-form Tai Chi will be performed for 12 weeks. Each session contains a warm-up period (10 minutes), a Tai Chi period (40 minutes) and a cool-down period (10 minutes).
223601810|NCT04609631|BEHAVIORAL|CBT|CBT will be performed once a week for 12 weeks. Each session lasts for 1 hour.
223601811|NCT02936024|PROCEDURE|Two-Stage GSLO Technique|The patient will initially receive the first stage of the two-stage technique which involves the ligation of testicular vessels laparoscopically, or transection of these vessels using cautery. After the first stage is complete, the patient will be seen approximately 3-6 months later for the second stage. The second stage of the procedure involves free mobilization of the testis and placement/fixation of the testicle in the scrotum.
223601812|NCT02936024|PROCEDURE|One-Stage GSLO Technique|The patient will receive only one surgical procedure during which ligation of testicular vessels is performed, as well as mobilization of the testis and placement/fixation of the testicle in the scrotum.
223601813|NCT06521372|OTHER|Magenta AI image analysis tool|MagentaTM is a non-invasive image analysis tool that utilizes artificial intelligence to evaluate 2-dimensional images of denuded mature MII oocytes. The MagentaTM software has been analyzed retrospectively, by Future Fertility. This data displays that a higher MagentaTM score is associated with a higher chance of blastocyst development. Additionally, the MagentaTM software has been validated in a prospective multi-center study, displaying that a higher MagentaTM score correlates to a higher chance of blastocyst development.
223601814|NCT01709370|DRUG|Letrozole, PD 0332991|
224200006|NCT04707066|BEHAVIORAL|Maintenance/Monitoring - Phase 2|Maintenance/Monitoring
223601815|NCT04625439|BEHAVIORAL|Personality Feedback Self-Management Intervention|The intervention is a personality feedback report that will tell participants whether they scored low (bottom third), average (middle third), or high (top third) on each of the five factor personality characteristics based on gender-matched norms. In addition to a description of general tendencies based on their level of each personality trait, the feedback will include information about how scoring in a given category may relate to an individual's cancer self-management or healthcare decision making. The feedback for each personality trait will include recommendations for how to improve key outcomes.
223601816|NCT00992355|DRUG|Tobramycin 0.3% - Dexamethasone 0.1%|
223601817|NCT00992355|DRUG|Tobramycin 0.3% - Dexamethasone 0.1% plus Ketorolac tromethamine 0.5%|
223749793|NCT03082599|DEVICE|Presbyopia and astigmatism correcting intraocular lens|The Symfony Toric IOL (ZXTx) is an extended depth of focus (EDOF) IOL design to improve the sharpness of vision at near, intermediate and far distances reducing the need of glasses after cataract surgery in patients with astigmatism.
223601818|NCT03356678|DRUG|Pralatrexate|"* Patients treated with pralatrexate due to relapse or refractory disease after primary and/or salvage treatment. Relapse following an autologous stem cell transplant allowed.~* Patients treated with pralatrexate 30mg/m2 once a week for 6 weeks as part of a 7-week cycle. However, modified dose and/or schedule allowed."
223601819|NCT06419088|OTHER|Preoperative individualized education|Based on the identified individual education needs, the researcher implemented audio-visual education to the intervention group in the ward.
223601820|NCT05260268|BEHAVIORAL|TEST Intervention|The TEST intervention will include standard post-transplant care and include additional touchpoints utilizing the Way to Health system. Details on this intervention are included in the study arm description.
223601821|NCT05777395|PROCEDURE|Maitland Oscillatory Mobilization|Maitland Posteroanterior unilateral vertebral pressure and Maitland cervical rotation technique will be used.3 sets of 15 repetitions. Each set is of 30 seconds and each repetition is given for 2 seconds.
223601822|NCT05777395|PROCEDURE|Kaltenborn Sustained Stretch Mobilization|"Kaltenborn sustained stretch mobilizations. 3 sets of 15 repetitions for 3 seconds.~* Frequency: 3 times a week for 2 weeks. 6 sessions in total.~* Mobilizations will be performed in Grade 1 and then progressed to 2 and 3.~* Kaltenborn technique used will be atlas-axis rotation"
223601823|NCT05777395|PROCEDURE|Conventional therapy|Moist heat, TENS, Neck Muscle Stretching, Neck muscle isometrics
223601824|NCT03218436|PROCEDURE|CAP treatment|Treatment with low-temperature argon plasma during colposcopic examination. No general anesthesia required.
223601825|NCT03151330|OTHER|Screened Arm|Woman who are identified as high risk will be advised of potential interventions which will include support through care link(nurse education), cervical surveillance, consider vaginal progesterone, low dose aspirin if not already taking.
223601826|NCT03503760|DEVICE|LIMFA Therapy®|It applies a packages of magneto-electric field sequences having variable geometry, with frequencies and intensities that vary in a range of 0-80 Hertz and 0-100 microTesla, respectively.
223601827|NCT05696886|DRUG|Pethidine|Group A received Pethidine alone in the period between January 2021 and December 2021
223601828|NCT05696886|DRUG|Tramadol with pethidine|Group B got Tramadol with pethidine in the period between January 2022 and December 2022
223601829|NCT03081871|OTHER|Pharmacist-led cardiovascular risk service (CVRS)|CVRS pharmacists will access the study database including patient baseline information obtained from the medical record and patient entered data to make their assessments and recommendations to onsite physicians and onsite clinical pharmacists and individualize their communication with patients. The intervention will provide patient-centered counseling and education to improve medication adherence, lifestyle modifications and/or smoking cessation. The CVRS pharmacist does not make changes to therapy independently but, rather, provides the physicians and on-site pharmacists with action plans and status updates about adherence to Guideline metrics, which should markedly reduce the gaps in guideline-concordant therapy that place patients at risk for CVD events.
223749794|NCT05899907|DRUG|Telitacicept|160mg once a week for 48 weeks
224200007|NCT04707066|BEHAVIORAL|Collaborative Assessment and Management of Suicidality (CAMS) - Phase 2|Collaborative Assessment and Management of Suicidality (CAMS) - Phase 2
223601830|NCT03081871|OTHER|Mobile access to study Personal Health Record|Only subjects assigned to the intervention arm will have access to the mobile app version of the study personal Health Record.
223601831|NCT03081871|OTHER|Web access to study Personal Health Record|Subjects assigned to both the intervention and control arms will have access to the standard website version of the study personal Health Record.
223601832|NCT03489889|DRUG|Ursodeoxycholic Acid 300mg tablet|Cross-over study: Ursodeoxycholic Acid 300mg tablet and after Ursodeoxycholic Acid 300mg capsule
223601833|NCT03489889|DRUG|Ursodeoxycholic Acid 300mg capsule|Cross-over study: Ursodeoxycholic Acid 300mg capsule and after Ursodeoxycholic Acid 300mg tablet
223601834|NCT01851629|BEHAVIORAL|Locomotor Training|Individuals are provided manual assistance for intense, task-specific stepping practice on a treadmill and overground.
223601835|NCT01851629|OTHER|Cross-Sectional Testing (No Intervention)|Individuals with and without spinal cord injury will be evaluated to develop protocols within our laboratory to assess reflexes (spinal tract integrity), walking ability, and whether mirror images during walking enhance or disrupt motor responses during walking.
223601836|NCT00317330|DRUG|Isoniazid|
223601837|NCT00317330|DRUG|Pyrazinamide|
223601838|NCT00317330|DRUG|Rifampin|
223601839|NCT04303572|DRUG|Eloctate ITI|This is a factor VIII-Fc infusion protein.
223601840|NCT04303572|DRUG|Emicizumab|This is a bispecific monoclonal antibody FVIII mimic.
223601841|NCT05533164|DRUG|Rituximab|1000mg rituximab in 250ml NaCl 0.9% intravenously
223601842|NCT05533164|DRUG|Placebo|Placebo in 250ml NaCl 0.9% intravenously
223601843|NCT05889377|PROCEDURE|Socket preservation|Socket preservation will be done after tooth extraction. For each group we will use a bone substitute.
223601844|NCT00274963|DRUG|bendamustine hydrochloride|
223601845|NCT00274963|DRUG|mitoxantrone hydrochloride|
223601846|NCT03266406|DRUG|Hyaluronidase|4ml of retrobulbar LA with addition of 15IU/ml hyaluronidase to 2% lidocaine
223601847|NCT00498589|DRUG|methotrexate|25 mg per week IM or SC during 24 weeks
223601848|NCT00498589|DRUG|placebo|one intramuscular injection per week
223601849|NCT05952206|DEVICE|Angiolite: Sirolimus-eluting stent|The angiolite stent (iVascular, Barcelona, Spain) is a thin-strut cobalt-chromium sirolimus-eluting stent with an open-cell design containing a durable biostable coating composed of three layers - acrylate to ensure adhesion to the metal surface, fluoroacrylate that carries the sirolimus, and a top layer of fluoroacrylate to control drug release.
223601850|NCT05952206|DEVICE|Xience: Everolimus-eluting stent|The Xience stent family (Abbott vascular, California, United States of America), characterized by an L-605 cobalt-chromium (CoCr) is a thin-strut cobalt-chromium everolimus-eluting stent with an open-cell design containing a nonerodable polymer made of PBMA, a reservoir made of a fluorinated copolymer of vinylidene fluoride and hexafluoropropylene monomers. Xience™ stent family includes XIENCE Skypoint™ and XIENCE Sierra™
223749795|NCT05899907|DRUG|Standard of Care|Steroid(≤1mg/kg/d) with or without proper immunosuppressants：CTX, MMF, AZA, CsA, FK 506, HCQ, MTX, LEF, SASP etc.
224200008|NCT03172390|DEVICE|4D Cardiac Magnetic Resonance|4D Cardiac Magnetic Resonance for patients with a ascending aorta dilatation without current indication for surgery for measured parameters of ascending aorta
223601851|NCT05952206|DRUG|1-month DAPT|"DAPT with acetylsalicylic acid + prasugrel or ticagrelor for 1 month. Then, only the same oral P2Y12 inhibitor (clopidogrel, prasugrel, and ticagrelor) up to 12 months.~The type of agent and treatment duration will be selected according to the clinical characteristic of the patient: Acute coronary syndrome or Chronic coronary syndrome and Need for OAC or No need for OAC"
223601852|NCT05952206|DRUG|12-month DAPT (Standard of care)|DAPT with acetylsalicylic acid and prasugrel or ticagrelor up to 12 months. The type of agent and treatment duration will be selected according to the clinical characteristic of the patient: Acute coronary syndrome or Chronic coronary syndrome and Need for OAC or No need for OAC
223601853|NCT04400565|BEHAVIORAL|Recovery group|The researchers designed a recovery group suited to Taiwanese with mental illness, according to content of the Pathways to Recovery (PTR): A Strengths Recovery Self-Help Workbook (Ridgway et al., 2002) and recovery-related literature (Davidson et al., 2005; Ridgway, 2001)
223601854|NCT06540794|OTHER|PEEP TITRATION|Determining the optimal PEEP value that provides the lowest driving pressure using decremental PEEP titration.
223601855|NCT02032225|OTHER|Skin biopsy|
223601856|NCT05759858|OTHER|None of intervention|None of the interventions was applied.
223601857|NCT06970340|BEHAVIORAL|Online MedEd Intern Bootcamp|6 months of online access plus biweekly live sessions
223601858|NCT05799066|DIAGNOSTIC_TEST|Swinging Light test|The swinging light or pen light test with manual pupil measurements is the standard of care test for RAPD. This test consists of a light being shone in one eye for 3 to 4 seconds then shown in the other eye for 3 to 4 seconds, repeating 2 to 3 times. Pupils are measured manually immediately after the light test. Measurements are recorded in patient's medical record.
223601859|NCT05799066|DIAGNOSTIC_TEST|Virtual Reality Head-Mounted Display (VR HMD)|A light is shone from within the VR HMD, pupillary measurements are taken and recorded by the machine learning (ML) algorithm.
223601860|NCT05592379|DRUG|Psilocybin|The IV formulation of psilocybin will be prepared using bulk psilocybin that will satisfy Good Manufacturing Practice (GMP) criteria. The IV psilocybin solution will be prepared under sterile conditions by the University of Wisconsin Pharmaceutical Research Center (PRC).
223601861|NCT05592379|DRUG|Clonidine|Clonidine will be administered orally in a 0.2mg dose
223601862|NCT05592379|OTHER|Saline|The IV placebo (saline) will be prepared under sterile conditions by the University of Wisconsin Pharmaceutical Research Center.
223601863|NCT06109714|OTHER|Goal Directed Fluid Therapy|Fluid administration and hemodynamic management guided with the assistance of Edwards Lifesciences ACUMEN monitor
223601864|NCT04929249|DRUG|Inclisiran|Inclisiran sodium 300 mg/1.5 ml (equivalent to 284 mg inclisiran liquid) in prefilled syringe (PFS).
223601865|NCT06974526|DRUG|Oxandrolone|Absorbable oxandrolone implant (subdermal insertion) Men: 400 mg oxandrolone (two 200 mg oxandrolone implants each) Women: 200 mg oxandrolone (one 200 mg oxandrolone implant)
223601866|NCT06974526|DRUG|Placebo|Absorbable placebo implant (excipients; subdermal insertion) Men: 400 mg placebo (two 200 mg placebo implants each) Women: 200 mg placebo (one 200 mg placebo implant)
223601867|NCT06976281|OTHER|conventional exercise Program|Exercises include shoulder flexion, shoulder abduction, leg extension, and hand grip. Start with 1-3 sets of 12 reps at 30% of 1-repetition maximum, increasing by 10% according to patient endurance. Cycling is a 30-minute chair or bedside cycle ergometer exercise 2 time/weak for 2 consecutive months
223601868|NCT06976281|OTHER|blood flow restriction training|Patients received the same conventional exercise program, which included isometric, aerobic, and resisted exercise individualized for every patient with blood flow restriction by 50% of limb occlusion pressure. Training will be conducted for 2 time/weak for 2 consecutive month
223601869|NCT06816524|DIETARY_SUPPLEMENT|Iron syrup|Iron syrup administered daily from 6 to 10 months of age.
223601870|NCT06816524|DIETARY_SUPPLEMENT|Multivitamin syrup|Multivitamin syrup administered daily from 6 to 10 months of age.
223601871|NCT06816524|BIOLOGICAL|R21-Matrix/M Vaccine (malaria vaccine)|R21-Matrix/M vaccine administered in 3 doses at 7, 8 and 9 months of age.
223601872|NCT06816524|BIOLOGICAL|Measles-Rubella vaccine|Measles-Rubella vaccine administered at 9 months of age.
223601873|NCT06800963|BIOLOGICAL|Intravesical Recombinant Mycobacterium (rMBCG)|19.2e8 Colony-forming unit(s) CFU (1 vial) rMBCG via a urinary catheter in the bladder (ie, intravesical administration)
223601874|NCT04580693|OTHER|PET Scan|PET scan using a tracer that is under a physician sponsored IND.
223601875|NCT05730972|DEVICE|Transcutaneous electrical acupoint stimulation|The patients are taken in the recumbent or sitting position, and the local skin at the acupoints is routinely disinfected. A pair of conductive gel patch, connecting to the Huatuo SDZ-ⅡB portable electronic needle therapy instrument, are respectively affixed to the ipsilateral acupoint group, so as contralateral side.
223601876|NCT05730972|DEVICE|Sham transcutaneous electrical acupoint stimulation|The electroacupuncture instrument has a normal screen display as the Huatuo SDZ-ⅡB portable electronic needle therapy instrument, but could not output current normally.
223601877|NCT05730972|DRUG|Routine palliative treatment|The patients in both groups received routine palliative treatment of tumors, such as chemotherapy, immunotherapy, targeted therapy, drug analgesic therapy, nutrition support, and so on.
223749796|NCT04327219|OTHER|CDED diet|examine the microbial, mucosal and immunological changes of the pouch during one year post IPAA, and examine the impact of the CDED on disease activity and dysbiosis in adults suffering from active pouchitis.
223601878|NCT01349764|DRUG|Vitamin D3|
223601879|NCT01561053|BIOLOGICAL|Albumin 5%|Therapeutic plasma exchange with human albumin 5%
223601880|NCT01561053|BIOLOGICAL|Albumin 20%|Low volume plasma exchange with human albumin 5%
223601881|NCT01561053|BIOLOGICAL|Immunoglobulin|Intravenous human immunoglobulin 5%
223749797|NCT00181012|DRUG|Lidocaine|
223749798|NCT06279871|BIOLOGICAL|ARCT-2303|Self-Amplifying RNA COVID-19 vaccine (Omicron XBB.1.5)
223749799|NCT06279871|BIOLOGICAL|Influenza vaccine|Licensed cell-based influenza vaccine
223749800|NCT06279871|BIOLOGICAL|Influenza vaccine, adjuvanted|Licensed influenza vaccine, adjuvanted
223749801|NCT06279871|OTHER|Placebo|0.9% saline
223749802|NCT00323115|BIOLOGICAL|Autologous Dendritic Cell|Vaccine given by cervical lymph node injection 3 times every other week
223749803|NCT00323115|DRUG|Temozolomide|Radiotherapy (RT) with concurrent temozolomide (TMZ) for 6 weeks before vaccine is SOC
223749804|NCT00323115|PROCEDURE|Radiotherapy|RT is standard of care (SOC) post surgery
223601882|NCT03921177|DIETARY_SUPPLEMENT|Multiple micronutrient supplement|Preconception to 12-weeks gestation: daily (coded) multiple micronutrient supplement containing 15-nutrients (vitamins and minerals) providing an approximate recommended dietary allowance for pregnant women, approximating the UNICEF UNIMAP formulation (UN micronutrient preparation).
223601883|NCT03921177|DRUG|Placebo Oral Tablet|Preconception to 12-weeks gestation: identical tablet
223601884|NCT02130505|DIETARY_SUPPLEMENT|OGTT|Oral glucose tolerance test (OGTT) with 75 g of oral anhydrous glucose
223601885|NCT02161926|OTHER|dietary restrictions|Dietary restrictions during 8 weeks
223601886|NCT05529329|PROCEDURE|overlay|Lithium Disilicate partial coverage of hypo-mineralized defected enamel
223601887|NCT06321939|DIAGNOSTIC_TEST|EBV-DNA next generation sequencing|EBV-DNA next generation sequencing
223601888|NCT05296031|DEVICE|Treatment with Zilver PTX Drug Eluting Stent (DES) in femoropopliteal lesions|Randomized trial comparing drug eluting stent Zilver PTX vs Bare metal stent Zilver Flex in critical limb ischemia and treatment of lesions in femoral and popliteal arteries
223601889|NCT05296031|DEVICE|Treatment with Zilver Flex Bare Metal Stent (BMS) in femoropopliteal lesions|Randomized trial comparing drug eluting stent Zilver PTX vs Bare metal stent Zilver Flex in critical limb ischemia and treatment of lesions in femoral and popliteal arteries
223601890|NCT04098861|DRUG|Latanoprost/Timolol|Latanoprost/Timolol Fixed Combination
223601891|NCT03784807|DIAGNOSTIC_TEST|synovial calprotectin, confocal laser microscopy|Calprotectin will be determined in synovial fluid of patients with septic and aseptic failure of their prosthesis. CLSM will be used to detect presence of microorganisms in synovial fluid. Susceptibility to antimicrobials of bacterial strains isolated from patients with prosthetic joint infections will be assessed using planktonic cells and biofilm associated bacteria
223601892|NCT02122367|OTHER|HES 130/0.4 (VolulyteⓇ, Fresenius Kabi, Canada)|HES 130/0.4 (VolulyteⓇ, Fresenius Kabi, Canada) 6ml/kg of ideal body weight loading
223601893|NCT01973504|DRUG|MP4OX|4.3 g/dL pegylated hemoglobin in balanced lactate-electrolyte solution
223601894|NCT01973504|DRUG|Control|Crystalloid solution IV infusion drip to keep vein open
223601895|NCT01297205|BIOLOGICAL|Human Umbilical Cord Blood Derived-Mesenchymal Stem Cells|Dose A - 10 million cells per kg Dose B - 20 million cells per kg Single intratracheal administration
223601896|NCT03937414|DEVICE|The OSNA assay|SLN was defatted after SLNB. If the node weighed less than 100mg, the node was only assessed by histology postoperatively. If the node weighed more than 100mg, the node was sliced to equal blocks according to the length of short axis: If the length was less than 4mm, the node was sliced into two blocks along the long axis (a, b). Intraoperatively, the block a and b were tested by TIC, and the block a was prepared for OSNA. Postoperatively, the block b was assessed by histology. If the length was more than 4mm, the node was sliced into four blocks (a, b, c, d). Intraoperatively, all blocks (a, b, c, d) were tested by TIC, and the block a and c were prepared for OSNA.
223601897|NCT02353390|OTHER|Oral Water Hydration|Subjects in the hydration group will be allowed up to 15 minutes to drink up to 500 milliliters (mL) of water prior to the vaccines. Subjects will be encouraged to drink the entire 500 mL; however, they are free to drink as much as they want and can finish before the end of the 15-minute period. Subjects will be instructed not to share the water and to not otherwise empty the bottle. As with the control group, subjects will be instructed not to eat or drink anything else for the duration of the study, unless clinically indicated (e.g., as part of management of presyncope or syncope).
223601898|NCT04780464|DRUG|Doxorubicin|60 to 75 mg/m² intravenous, every 3 weeks for max 6 cycles until PD
223601899|NCT04780464|DRUG|Doxorubicin|12 mg/m2 intravenous weekly for a maximum of 450 mg/m2 until PD
223601900|NCT04780464|DRUG|Cyclophosphamide Oral Product|100 mg BD on day 1 to day 7 of each 14 day cycle until PD
223601901|NCT04780464|DRUG|Prednisolone|10-20 mg on day 1 to day 7 of each 14 day cycle until PD
223601902|NCT04780464|DRUG|Prednisone|10-20 mg on day 1 to day 7 of each 14 day cycle until PD for those Countries where Prednisolone in tablets is not available
223601903|NCT02211456|PROCEDURE|Atrial Fibrillation/flutter (AF) or Ventricular Tachycardia (VT) ablation with multi-site pacing protocol|Pacing at several endocardial sites in isolation and individually will be performed, with response to this assessed by LV dp/dt max
223601904|NCT02973308|OTHER|Observer|Observer A and observer B
224200009|NCT01466959|OTHER|citrate dialysate (CD)|Citrasate (CD) is substituted as the dialysate during the patients regular dialysis run 4hours three times weekly for a period of 2 weeks. The only difference between citrasate and the regular dialysate is the lack of acetic acid.
223601905|NCT04199143|DRUG|Nitrous Oxide-Oxygen|The medical product used in this study is a gas for common medical use in various domains including anesthesic, consisting in the equimolar mixture of nitrous oxide and oxygen. Subjects will receive a mixture of 50% N2O / 50% O2 for 1 hour.
223601906|NCT04199143|DEVICE|Tissue Pulsatility Imaging - TPI|Tissue Pulsatility Imaging (TPI) is a variation of ultrasonic Doppler strain imaging we are developing to measure the local expansion and relaxation of the brain tissue over the cardiac cycle to characterize and image perfusion.
223601907|NCT04199143|DEVICE|Magnetic Resonance Imaging - MRI|Structural and Functionnal (including BOLD and ASL) MRI will be aquired in this study
223601908|NCT03879421|PROCEDURE|Accelerated corneal collagen cross linking|This strategy is based on the underlying pathology of the disease. Corneal collagen cross linking (CXL) idea was based on the fact that a photosensitizer substance like riboflavin (vitamin B2) can interact with ultraviolet irradiation (Ultraviolet-A) to strengthen the corneal tissue inter and intrafibrillar collagen bonds thus preventing further thinning, corneal protrusion and reduces corneal irregular astigmatism.
223601909|NCT02274740|DRUG|LIXISENATIDE AVE0010|Pharmaceutical form:solution Route of administration: subcutaneous
223601910|NCT02274740|DRUG|metformin|Pharmaceutical form:tablet Route of administration: oral
223601911|NCT03563365|OTHER|Replenix Power of 3 Cream with resveratrol|Cosmetic product containing Green Tea Polyphenols, Resveratrol, Caffeine USP, Bisabolol Cucumber extract, Chamomile extract, Rosemary extract, Squalane, Soy Phospholipids
223601912|NCT03563365|DRUG|Adapalene and Benzoyl peroxide gel, 0.1%/2.5%|FDA approved topical agent for the treatment of acne
223601913|NCT04672122|DEVICE|Transcranial direct current stimulation|Cathodal tDCS will be applied for 20 mins.
223601914|NCT00328861|DRUG|Natural Killer (NK) Lymphocytes|Thirty minutes infusion of natural killer (NK) cells 2 days after last dose of chemotherapy.
223749805|NCT00323115|BIOLOGICAL|Dendritic Cell Vaccine|Vaccine given cervical lymphnode injection 3 times every other week
223749806|NCT02062918|DEVICE|Abdominal belt|
223749807|NCT06513780|OTHER|Observation|No intervention were made.
223749808|NCT06860516|OTHER|blood draw|a blood draw for testing of HLA-DRB1\*04:01
223749809|NCT00001598|DRUG|Dehydroepiandrosterone|
223749810|NCT02707705|DEVICE|Apply an auricular acupuncture protocol by stimulating specific points of the ear with needles inserted on adhesive tape (Pyonex®).|"Intervention Description :~The auricular acupuncture protocol is based on an anxiolytic triad of three points selected according to the World Health Organization classification. These points are detected and located precisely by a differential detector starting with the right ear, and in the absence of response, the points are searched on the left ear. The detected points are treated by application of adhesive tape with needles of diameter 0.2 mm and length 0.9 mm.~Data collected :~* T0 : anxiety VAS, pain VAS, APAIS, ANI, arterial pressure and cardiac frequency~* T1 : anxiety VAS, pain VAS, APAIS, ANI, arterial pressure, cardiac frequency and side effects~* T2 : anxiety VAS, pain VAS, arterial pressure, cardiac frequency and side effects~* T3 : anxiety VAS, pain VAS, arterial pressure, cardiac frequency and side effects"
223749811|NCT02707705|DEVICE|Apply a device having no real effect|"The three points of the protocol are detected and located precisely by a differential detector starting with the right ear, and in the absence of response, the points are searched on the left ear.The detected points are treated by application of adhesive tape without needle.~Data collected :~* T0 : anxiety VAS, pain VAS, APAIS, ANI, arterial pressure and cardiac frequency~* T1 : anxiety VAS, pain VAS, APAIS, ANI, arterial pressure, cardiac frequency and side effects~* T2 : anxiety VAS, pain VAS, arterial pressure, cardiac frequency and side effects~* T3 : anxiety VAS, pain VAS, arterial pressure, cardiac frequency and side effects"
223749812|NCT02707705|PROCEDURE|Disinfection|The ear is disinfected by applying Chlorhexidine®.
223749813|NCT07057596|DRUG|Tebentafusp|"Patients will receive tebentafusp intravenously (IV) weekly for 6 months with liver directed imaging every 2 months to identify rapid progressors. Tebentafusp will be administered at 20 micrograms on W1D1, 30 micrograms on W2D1, and 68 micrograms once every week thereafter.~After 6 months, patients with complete response (CR) according to RECIST will continue tebentafusp therapy (surgery might be an option if deem appropriate by local PI); while patients achieving partial response or stable disease will be evaluated for tumor resection and will enter into Surgery phase. Surgery will be conducted 7 months (+/- 1 month). If progressioh disease (PD) occurs earlier surgery can happen earlier. After surgery, patients without pCR or R0 surgery will maintain tebentafusp until disease relapse, unacceptable toxicity or patient withdrawal. Patients with pCR and R0 will continue tebentafusp therapy for 1 additional year or until disease relapse, unacceptable toxicity or patient withdrawal."
223749814|NCT02265978|DEVICE|CopeSmart|Participants will use the CopeSmart app at least once per day for four weeks
223749815|NCT06379217|DRUG|[68Ga]Ga-PSMA-11|\[68Ga\]Ga-PSMA-11 will be administered as a single intravenous dose of approximately 150 MBq (4 mCi) to be administered during baseline imaging and approximately 7 weeks after last RLT dose. Administered dose should not be lower than 111 MBq (3 mCi) or higher than 259 MBq (7 mCi)
223749816|NCT06379217|DRUG|[68Ga]GA-DOTA-TATE|\[68Ga\]Ga-DOTA-TATE will be administered as a single intravenous dose to be administered during baseline imaging and approximately 7 weeks after last RLT dose, within a range of 100-200MBq (2.7-5.4 mCi)
223512328|NCT06874985|BEHAVIORAL|Lived experience video campaign|Participants in the selected villages will be shown a two-minute video developed specifically for the Lived Experience Communication Campaign in addition to usual awareness they receive for cancer screening mobilisation. The video will feature personal narratives from cancer survivors and local leaders emphasizing the importance of early detection and screening.
223512329|NCT06400745|DEVICE|CPO Pro IOL|Intraocular lens (IOL) implanted in the eye for the visual correction of aphakia in adult patients with less than 1 diopter of preexisting corneal astigmatism in whom a cataractous lens has been removed. The IOL is intended to mitigate the effects of presbyopia on intermediate and near visual acuity while maintaining comparable distance visual acuity.
223512330|NCT06400745|DEVICE|CPO IOL|Intraocular lens (IOL) implanted in the eye for the visual correction of aphakia in adult patients with less than 1 diopter of preexisting corneal astigmatism in whom a cataractous lens has been removed. The IOL is intended to mitigate the effects of presbyopia on intermediate and near visual acuity while maintaining distance visual acuity.
223512331|NCT06400745|PROCEDURE|Cataract surgery|Extraction of the cataractous lens by phacoemulsification, followed by implantation of the IOL.
223512332|NCT05250726|BIOLOGICAL|MENISC-T|Decellularized, viro-inactivated, freeze-dried and sterile allogeneic graft of meniscus used as interposition at the STT joint
223512333|NCT04921800|PROCEDURE|Anterior Cervical Discectomy & Fusion|Participants are undergoing previously scheduled anterior cervical discectomy \& fusion for single level or multiple level cervical disease
223512334|NCT04921800|DEVICE|Application of ADAM mechanoacoustic skin sensor|Applying the ADAM sensor to the suprasternal notch following surgery to allow for collection of the anatomical data
223512335|NCT05545488|DEVICE|Virtual reality|I had the women wear virtual reality glasses and watch the video they wanted for at least 5, maximum 15 minutes during the examination.
223512336|NCT06761612|BIOLOGICAL|FDA approved mRNA vaccines|This study is non-interventional as participants will have received an FDA approved mRNA COVID-19 vaccine prior to entering the study. The study protocol does not determine or allocate receipt of vaccine
223512337|NCT01733693|DRUG|Buprenorphine|Study participants will be randomly assigned 1:1 to buprenorphine (experimental/intervention) or methadone (active comparator). We will stratify by HIV status to ensure an equal number of HIV-infected participants in each group.
223512338|NCT01733693|DRUG|Methadone|Study participants will be randomly assigned 1:1 to buprenorphine (experimental/intervention) or methadone (active comparator). We will stratify by HIV status to ensure an equal number of HIV-infected participants in each group.
223512339|NCT03188029|DIAGNOSTIC_TEST|adrenocortical function|"Blood samples for cortisol dosage are performed and 24 hours after the sixth session. All blood samples are performed at 9 and collected in normal tube.~Blood samples for glycaemia, sodium, potassium and bicarbonates are performed at the same rate."
223512340|NCT04028960|DRUG|Regular insulin (Humulin-R), intranasal route|Humulin-R insulin is approved by the U.S. Food and Drug Administration (FDA) for the treatment of diabetes.
223601915|NCT00328861|BIOLOGICAL|IL-2|IL-2 720,000 IU/kg/intravenous every 8 hours for up to 5 days.
223601916|NCT00328861|DRUG|Cyclophosphamide|Cyclophosphamide 60 mg/kg/day intravenous on days -8 and -7.
223601917|NCT00328861|DRUG|Fludarabine|Fludarabine 25 mg/m\^2 day intravenous on days -6 through -2.
223601918|NCT04897178|DIAGNOSTIC_TEST|Ultrasound|Routine 2 dimensional Ultrasound used to screen fetuses for congenital anomalies
223601919|NCT00897221|DRUG|Deferiprone oral solution 100mg/mL|Deferiprone oral solution (20 mg/kg/day)
223601920|NCT00897221|DRUG|Deferiprone oral solution 100 mg/mL|Deferiprone oral solution(40mg/kg/day)
223601921|NCT02286232|BEHAVIORAL|Stretching exercise|This program begins with 10 stretches/exercises over 15 minutes on the initial class and incrementally increases by 1 stretch/exercise each session for a total of 21 stretches/exercises over 30 minutes on the 12th session. The program is designed to stretch/exercise the major muscle groups, emphasizing the neck and arms, trunk, and legs. In addition to the stretches, each class will include breathing exercises and guided imagery for relaxation. Classes will be taught by Physical Therapists who are trained to lead classes through the protocol.
223601922|NCT02286232|BEHAVIORAL|Self-care book|The Back Pain Helpbook which provides information on the causes of back pain and advice on exercising, making appropriate lifestyle modifications, and managing flare-ups.
223601923|NCT03323801|DRUG|13-cis retinoic acid|Accutane is used for the treatment of severe acne
223601924|NCT00514371|DRUG|tanespimycin|High dose
223601925|NCT00514371|DRUG|Bortezomib|Mid dose, and low dose
223601926|NCT03728179|COMBINATION_PRODUCT|Low dose irradiation + Nivolumab + Ipilimumab or Cyclophosphamide + Aspirin/Celecoxib|"Low Dose Radiation (RT): RT will be administered as single fractions every 2 weeks (Q2W) from cycle C0 to cycle C4. RT will be delivered to a number of metastatic deposits visible by PET/CT, at the PI's discretion.~Cyclophosphamide: 200mg/m2 will be administered as intravenous infusion (IV) Q2W from cycle C0 to C4.~Nivolumab: 240 mg will be administered as IV Q2W from cycle C1 to C4.~Ipilimumab: 1mg/kg will be administered as IV every 6 weeks (Q6W) from cycle C1 to C4~Aspirin: 300mg will be administered orally daily from cycle C1 to C4. All subjects will receive mandatory gastric prophylaxis with an oral H2 antagonist.~Celecoxib: 200mg will be administered orally twice a day from cycle C1 to C4.~At the end of cycle C4, patients eligible for maintenance will be treated with nivolumab at 240mg Q2W until progression or excessive toxicity; celecoxib will be maintained if the drug is well tolerated"
223601927|NCT00005824|BIOLOGICAL|filgrastim|
223601928|NCT00005824|DRUG|busulfan|
223601929|NCT00005824|DRUG|cyclophosphamide|
223601930|NCT00005824|PROCEDURE|peripheral blood stem cell transplantation|
223601931|NCT03067623|DRUG|PRP|PRP intrauterine infusion
223601932|NCT03067623|DEVICE|Tomcat catheter|PRP intrauterine infusion by means Tomcat catheter
223601933|NCT04331002|DRUG|Zilretta|ZILRETTA is an injectable suspension that delivers 32 mg of triamcinolone acetonide. It is supplied as a single-dose kit containing one vial of ZILRETTA microsphere powder, one vial of 5 mL diluent, and one sterile vial adapter.
223601934|NCT04331002|OTHER|Placebo|5 mL normal saline
223601935|NCT02999412|PROCEDURE|Comprehensive medication review|"* A thorough medication reconciliation, including a patient/carer interview, by a clinical pharmacist.~* The clinical pharmacist performs a comprehensive medication review in collaboration with the ward physician and patient, similar to a level three clinical medication review as earlier described in the literature \[4\]. This includes a structured, critical examination of all of the patient's medications in relation to the patient's conditions, based on information from the patient and the medical record. The objective is to optimise the impact of medications and minimizing the number of medication-related problems. The effects of medication changes will be monitored during the hospital stay by the physician or pharmacist, depending on the specific situation.~* Before discharge, the clinical pharmacist performs another medication reconciliation to check if the patient's prescriptions for medications to be used after hospital stay are consistent with the patient's medical record."
223601936|NCT02999412|PROCEDURE|Comprehensive medication review with active follow-up|"The same as I1 but with the following additions:~* In case of any monitoring needs or necessary subsequent actions to be taken after hospital discharge, the clinical pharmacist and the ward physician send an electronic medication review referral to the patient's primary care physician upon discharge.~* A first phone call to the patient or carer is made by the clinical pharmacist 2-7 days after the patient is discharged depending on health condition and the pharmacist's availability. This phone call aims to ensure that all information has been understood correctly and to find out if any problems, concerns or questions have arisen after discharge.~* A second phone call will be made by the clinical pharmacist approximately 30 days after hospital discharge. This phone call aims to find out how the patient is managing the medication and if any problems, concerns or questions have arisen, and to provide the patient with a motivational boost."
223601937|NCT02999412|PROCEDURE|Usual Care|The control group will receive usual hospital care. According to Swedish legislation, usual care includes medication reconciliation upon admission. Next to that, the law requires a medication report addressing the patient's medication treatment to be given to the patient or carer upon hospital discharge and to be attached to the electronic discharge letter. This report contains a motivation and explanation to the changes in medication treatment that have been made during hospital stay, as well as the patient's updated medication list. These mandatory activities are currently carried out to various degree within the different hospitals and wards. Other activities as described in the interventions above may be carried out to a certain degree as well, but no clinical pharmacist will be involved.
223601938|NCT01616368|BEHAVIORAL|Mindful Eating and Living Course|An eight week course designed to teach mindfulness skills with an emphasis on mindful eating.
223601939|NCT05567926|DIETARY_SUPPLEMENT|Beetroot juice concentrate (140 ml)|A beetroot juice concentrate (140 ml) will be administered to participants in experimental conditions.
223601940|NCT05567926|DIETARY_SUPPLEMENT|Blackcurrant juice (placebo)|140 ml of blackcurrant juice with added appropriate amount of sugar to equalize the carbohydrate value and lemon juice fort the taste.
223601941|NCT02371408|DRUG|ravidasvir hydrochloride|200 mg
223601942|NCT02371408|DRUG|sofosbuvir|400 mg
223601943|NCT02371408|DRUG|ribavirin|1000 mg - 1200 mg per day, weight-based dosing
223601944|NCT00627133|DRUG|levetiracetam|2 gram iv load, 500mg bid
223601945|NCT05641922|DEVICE|BioTraceIO 360|Use of the device for planning, monitoring and assessment of liver tissue ablations
223512341|NCT04028960|DEVICE|SipNose intranasal device|The SipNose device is an aerosol nasal delivery platform that uses pressurized delivery through the discharge of compressed air, resulting in an aerosol that delivers the drug in a narrow plume geometry, which targets the olfactory epithelium in the upper nasal cavity. From the olfactory epithelium, therapeutics rapidly reach the central nervous system, traveling extracellularly along the olfactory nerves. The device is not currently commercially available, but numerous studies have demonstrated its ability to intranasally deliver radiolabeled and therapeutic compounds to the brain.
223512342|NCT05208320|BEHAVIORAL|Adherence|"Patients received interventions as follow:~* The health education syllabus included 4 chapters: (1) introduction to hypertension, (2) complications of high blood pressure, (3) lifestyle management, and (4) SCORE - European High-Risk Chart~* Home health education by Community Health Workers every month for 6 months"
223601946|NCT01500486|DEVICE|NordiFlex PenMate™|Subjects whom will be offered growth hormone (Norditropin NordiFlex®) on prescription as part of normal clinical practice will be asked to evaluate the NordiFlex PenMate™ device.
223601947|NCT01960517|DEVICE|ACS Catheter|
223601948|NCT01454765|OTHER|generation of stem cells|Collected germ cells will be cultured in medium. The germ cell cultures will be infected with reprograming factors. Rare colonies with characteristic stem cell morphologies will be expanded.
223601949|NCT02080299|PROCEDURE|Remote ischemic preconditioning (RIPC)|3 circles of 5 min left upper arm ischemia by inflation of a blood pressure cuff to 200 mmHg and 5 min reperfusion, preceding TAVI procedure.
223601950|NCT02080299|PROCEDURE|Placebo|Prior to TAVI-procedure, the blood pressure cuff remains uninflated for 30 min.
223601951|NCT00082199|DRUG|Aripiprazole|Tablets, Oral, 2-30mg, Once daily, 12 weeks.
223601952|NCT00082199|DRUG|Placebo|Tablets, Oral, Once daily, 12 weeks.
223601953|NCT00147316|DRUG|Alteplase|0.6mg/kg intravenous alteplase with 10% being administered as a bolus followed by continuous infusion of the remainder over 1 hour
223601954|NCT03504631|OTHER|No intervention|no intervention
223601955|NCT02112864|DRUG|Dexamethasone|10 mg (2.5 ml)
223601956|NCT02112864|DRUG|Normal Saline|2.5 mL normal saline
223601957|NCT03370666|OTHER|HFNT|High flow nasal therapy
223601958|NCT03370666|OTHER|NIV|Noninvasive ventilation
223512343|NCT02043860|RADIATION|Total Marrow Irradiation|Subjects in this trial will receive total body irradiation (3Gy) per day for up to four days and as little as one day. Total IMT doses: 3Gy, 6Gy, 9Gy, or 12Gy.
223512344|NCT02043860|PROCEDURE|Autologous Transplant|Subjects will receive standard melphalan 200mg/m\^2 (100mg/m\^2 day-2 and day-1) conditioning with escalating doses of total marrow irradiation prior to autologous stem cell rescue.
223512345|NCT02043860|DRUG|Melphalan|Subjects will receive standard melphalan 200mg/m\^2 (100mg/m\^2 day-2 and day-1) conditioning therapy prior to transplant.
223512346|NCT02043860|DRUG|Filgrastim (G-CSF)|Subjects to begin GCSF 5 μg/kg/d SC or IV on Day 5 and continue until ANC \> 1000/mm\^3 over period of 3 days.
223512347|NCT04264585|BEHAVIORAL|Internet-delivered cognitive behaviour therapy|All clients will receive the same materials, namely the UniWellbeing Course, which was developed at Macquarie University, Australia. The UniWellbeing Course is a transdiagnostic intervention targeting symptoms of depression and anxiety, that has been tailored for use in post-secondary students. It comprises 4 online lessons that provide psychoeducation about: symptom identification and the cognitive behavioural model; thought monitoring and challenging; de-arousal strategies and pleasant activity scheduling; graduated exposure; and relapse prevention. Seven supplementary lessons can also be accessed at any time (e.g., sleep, communication). Materials are presented in a didactic (i.e., text-based with visual images) and case-enhanced learning format (i.e., educational stories demonstrate the application of skills) with 4 lesson summaries and homework assignments that facilitate skill acquisition. Therapists will spend \~15 mins. per week/per client.
223512348|NCT04264585|BEHAVIORAL|Motivational Interviewing|Clients assigned to the ICBT with Motivational Interviewing condition will receive access to the Planning for Change lesson before accessing Lesson 1. They will be presented with five interactive online exercises based on motivational interviewing principles (i.e. values clarification, importance ruler, looking back, confidence ruler, and looking forward). As clients complete the exercises, they are prompted to answer open-ended questions and are provided with written feedback.
223512349|NCT04264585|BEHAVIORAL|Booster Session|"Clients assigned to the ICBT with Booster condition will receive access to a booster session one month after the end of the ICBT course. The booster session will include information about maintaining motivation, a review of the ICBT course content and skills, and information about structured problem solving. Clients will also have access to a Do-It-Yourself guide that summarizes the information in the booster session and includes worksheets for clients to practice the problem-solving skills described in the booster.~This booster session will be self-guided (ie. no therapist support is offered)."
223512350|NCT01101048|DRUG|Placebo|Subjects will be randomized to receive one of 3 doses of AMG 167 or equivalent volume of placebo administered at once every two-week or once every four-week dosing intervals. Postmenopausal women will receive AMG 167 in one of 3 fixed doses, while men will receive AMG 167 in one of 2 fixed doses by injection under the skin.
223512351|NCT01101048|DRUG|AMG 167|Subjects will be randomized to receive one of 3 doses of AMG 167 or equivalent volume of placebo administered at once every two-week or once every four-week dosing intervals. Postmenopausal women will receive AMG 167 in one of 3 fixed doses, while men will receive AMG 167 in one of 2 fixed doses by injection under the skin.
223512352|NCT02032784|DRUG|octreotide|Octreotide 100mg subcutaneous every 8 hours for 5 days
223512353|NCT02032784|OTHER|No Octreotide|No drug
223512354|NCT02113215|PROCEDURE|Stable Isotope Infusion|9-hour infusion of stable isotope tracers
223512355|NCT05791591|DIETARY_SUPPLEMENT|NUV001 - IR|Daily supplementation with 1000 mg of NUV001 (in two administration orally) immediate release gel capsule formulation for 90 days in total
223512356|NCT05791591|DIETARY_SUPPLEMENT|NUV001 - GR|Daily supplementation with 1000 mg of NUV001 (in two administration orally) gastro resistant gel capsule formulation for 90 days in total
223512357|NCT05791591|DIETARY_SUPPLEMENT|Placebo|Placebo containing starch Powder (1000 mg, daily in two administration orally for 90 days)
223512358|NCT06094829|OTHER|Oral cytobrush|Oral epithelial cells will be collected during routine odontology appointments, upon documented non-opposition, via minimally invasive cytobrush sampling of the inner cheek
223749817|NCT06379217|DRUG|[68Ga]Ga-NeoB|\[68Ga\]Ga-NeoB will be administered as a single intravenous dose to be administered during baseline imaging and approximately 7 weeks after last RLT dose.within a range of 150-250 MBq (4.1-6.8 mCi).
223749818|NCT06379217|DRUG|[177Lu]Lu-PSMA-617|\[177Lu\]Lu-PSMA-617 will be administered as an intravenous infusion at a dose of 7.4 GBq (200mCi) (+/- 10%), every 6 weeks for 6 cycles.
224200010|NCT01466959|OTHER|acetic-acid based dialysate (AD)|Acetate based dialysate; AD is the standard dialysate used in hemodialysis runs 4 hours three times weekly. For the study it will be used for a period of 2 weeks and compared to the CD study time period.
223601959|NCT05620264|DIAGNOSTIC_TEST|Tear Sample Probe|Samples will be collected by conjunctival lavage of the affected eye without topical anesthesia. Sterile normal saline will be infused at room temperature into the lower conjunctival sac by gently pulling down the lower eyelid and with a needle-free insulin syringe. After few seconds, the lavage fluid will be aspirated back into the same syringe without the syringe touching the conjunctiva.
223601960|NCT04410406|DRUG|Ivermectin|Ivermectin (IVM) 200 µg/kg
223601961|NCT04410406|DRUG|Diethylcarbamazine|Diethylcarbamazine (DEC) 6mg/kg
223601962|NCT04410406|DRUG|Albendazole|Albendazole (ABZ) 400 mg
223601963|NCT04410406|DRUG|Moxidectin|Moxidectin (Mox) 8 mg
223601964|NCT01540669|DIETARY_SUPPLEMENT|Polydextrose, low dose|4g polydextrose powder will be mixed with beverage and consumed once per day for 2 weeks
223601965|NCT01540669|DIETARY_SUPPLEMENT|Polydextrose, medium dose|8g polydextrose powder will be mixed with beverage and consumed once per day for 2 weeks
223601966|NCT01540669|DIETARY_SUPPLEMENT|Polydextrose, high dose|12g polydextrose powder will be mixed with beverage and consumed once per day for 2 weeks
223601967|NCT01540669|DIETARY_SUPPLEMENT|Placebo powder|Placebo powder will be mixed with beverage and consumed once per day for 2 weeks
223601968|NCT04530864|DRUG|Dextenza 0.4Mg Ophthalmic Insert|All patients will receive pre-surgical ocular surface treatment with intracanalicular sustained release dexamethasone, 0.4 mg
223601969|NCT01964638|PROCEDURE|Targeted Biopsy|
223601970|NCT02177474|BEHAVIORAL|Telephone based peer support|
223601971|NCT04607811|BEHAVIORAL|Gamification with social incentives|Participants will select a step goal that is 33%, 40%, or 50% above their baseline step value. Participants in this group will participate in a game with points and levels to help motivate participants to meet their daily step goal. Additionally, all participants will identify a support partner to receive weekly updates on their performance and offer positive encouragement to help the participant meet their step goal.
223601972|NCT00691184|DRUG|Placebo|0% Terbinafine HCl Nail Lacquer for onychomycosis, twice daily for 28 days.
223601973|NCT00691184|DRUG|Terbinafine Hydrochloride|10% Terbinafine HCl Nail Lacquer for onychomycosis, twice daily for 28 days.
223601974|NCT00691184|DRUG|Terbinafine Hydrochloride|1% Terbinafine Hydrochloride Cream, twice a day for 7 days.
224200011|NCT03286400|DEVICE|CTAG Device with ACTIVE CONTROL|Intent to treat with the CTAG Device with ACTIVE CONTROL in the treatment of aortic diseases as part of routine clinical practice.
223601975|NCT00691184|DRUG|Terbinafine|Terbinafine tablet, 250mg, single dose in groups 1,2 and 3 at end of study.
223601976|NCT01601665|DEVICE|SN6AT6 Intraocular Lens|Acrylic intraocular lens with cylinder power at the IOL plane of 3.75 diopters. Intraocular lenses are implanted during cataract surgery as a replacement for the natural crystalline lens and are intended for long term use over the lifetime of the cataract subject.
223601977|NCT01601665|DEVICE|SN6AT7 Intraocular Lens|Acrylic intraocular lens with cylinder power at the IOL plane of 4.50 diopters. Intraocular lenses are implanted during cataract surgery as a replacement for the natural crystalline lens and are intended for long term use over the lifetime of the cataract subject.
223601978|NCT01601665|DEVICE|SN6AT8 Intraocular Lens|Acrylic intraocular lens with cylinder power at the IOL plane of 5.25 diopters. Intraocular lenses are implanted during cataract surgery as a replacement for the natural crystalline lens and are intended for long term use over the lifetime of the cataract subject.
223601979|NCT01601665|DEVICE|SN6AT9 Intraocular Lens|Acrylic intraocular lens with cylinder power at the IOL plane of 6.00 diopters. Intraocular lenses are implanted during cataract surgery as a replacement for the natural crystalline lens and are intended for long term use over the lifetime of the cataract subject.
223601980|NCT01601665|DEVICE|SN60WF Intraocular Lens|Acrylic aspheric monofocal intraocular lens. Intraocular lenses are implanted during cataract surgery as a replacement for the natural crystalline lens and are intended for long term use over the lifetime of the cataract subject.
223749819|NCT06379217|DRUG|[177Lu]Lu-DOTA-TATE|\[177Lu\]Lu-DOTA-TATE will be administered as an intravenous infusion at a dose of 7.4 GBq (200mCi) (+/- 10%) every 6 weeks for 6 cycles.
223749820|NCT06379217|DRUG|[177Lu]Lu-NeoB|\[177Lu\]Lu-NeoB will be administered as an intravenous infusion at a dose of 9.25 GBq (250mCi) every 6 weeks for 6 cycles
223749821|NCT06379217|DRUG|L-Lysine HCl-L-Arginine HCl, 2.5 %,|sterile solution for infusion Lysine HCl-Arginine HCl, 2.5 % (1L)
223749822|NCT06379217|DRUG|Gonadotropin-releasing hormone (GnRH) analogues|Anatomical Therapeutic Chemical \[ATC\] code L02AE
223749823|NCT06379217|DRUG|GnRH antagonists|abarelix, degarelix, or relugolix
223749824|NCT06379217|DRUG|Antiemetics & antinauseants|ATC code A04A
223749825|NCT06379217|DRUG|Metoclopramide|ATC code A03FA01
223749826|NCT06906822|DRUG|enfortumab vedotin|Enfortumab vedotin 1.25 mg/kg be administered on Days 1,8,22 and 29 of every 6-week cycle by IV infusion given over approximately 30 minutes.
223749827|NCT06906822|DRUG|pembrolizumab|Pembrolizumab 400 mg on day 1 of each 42-day cycle (Q6W)
223749828|NCT07100782|DRUG|Relugolix CT|Study medication will be provided by Sumitomo in pill bottles containing an 84-day supply of relugolix 40mg, estradiol 1mg, norethindrone acetate 0.5mg (Relugolix Combination therapy).
224200012|NCT02260752|PROCEDURE|hysterectomy|surgical removal of the uterus
224200013|NCT02260752|PROCEDURE|Uterine arterial embolization|In uterine artery embolization, doctor uses a slender, flexible tube (catheter) to inject small particles (embolic agents) into the uterine arteries, which supply blood to your fibroids and uterus.the embolic agents are injected into these fibroid blood vessels. The goal is to block the fibroid vessels, starving the fibroids and causing them to shrink and die.
224200014|NCT02260752|PROCEDURE|myomectomy|surgical procedure to remove uterine fibroids, but does not remove uterus
224200015|NCT02260752|DRUG|Medical Therapy|treatment of uterine fibroids with only medications, no procedure or surgery is used
223601981|NCT00268970|DRUG|Satraplatin in combination with Paclitaxel|Paclitaxel 200 mg/m2 IV over 3 hours on day 1. Satraplatin 60 mg/m2 administered by mouth once daily for 5 consecutive days (days 1-5). Satraplatin will be administered within 2 hours following paclitaxel infusion on day 1. Subsequent doses on days 2-5 will be taken at approximately 24 hour intervals.
223601982|NCT00172042|DRUG|Zoledronic acid 4 mg|Zoledronic acid 4 mg in 5 mL concentrated solution prepared with 100 mL calcium free infusion solution (0.9 % sodium chloride or 5% glucose solution).
223601983|NCT05688332|DRUG|Voglibose + Metformin|"In treatment group B, 59 participants will also be randomly assigned to the voglibose 0.2/0.3mg TDS + metformin 500mg BD treatment combination to be taken orally daily, during or immediately after meals with dose titration at day 6 and 12 if the average fasting blood glucose (FBG) level is ≥7 mmol/L (126 mg/dL) and then dosage will be maintained for the remainder of the treatment period Participants in the intervention group initially receiving voglibose 0.2mg + metformin 500mg BD will be dose-titrated to voglibose 0.3mg +metformin 1g BD.~The duration of therapy for each participant will be 12 weeks, which is the minimum period for evaluating the primary endpoint."
223601984|NCT05688332|DRUG|Glibenclamide + Metformin|"The drugs (glibenclamide + metformin), in the control or comparator group will also be taken orally, glibenclamide once a day (OD) before meals, and metformin twice a day (BD) also before meals. These drugs will also be taken with a dose-titration at days 6 and 12 if the average is FBG level will be ≥ 7 mmol/L and the dose will be maintained for the remainder of the study period.~The duration of therapy for each participant will be 12 weeks, which is the minimum period for evaluating the primary endpoint. In this group, participants will initially receive glibenclamide 5mg once daily (OD) + metformin 500mg BD then will be dose-titrated to glibenclamide 10mg OD + metformin 1g BD."
223601985|NCT01748721|BIOLOGICAL|anti-endosialin/TEM1 monoclonal antibody MORAb-004|Given IV
223601986|NCT01748721|OTHER|pharmacological study|Correlative studies
223601987|NCT01748721|OTHER|laboratory biomarker analysis|Optional correlative studies
223601988|NCT02400021|DRUG|Prometrium|
223601989|NCT01770015|PROCEDURE|biological sampling|cutaneous, rectal, nose and mouth swabs to identify potential fungi colonization
223601990|NCT01770015|PROCEDURE|sampling blood|HLA DR antigen, cytokines (IL 6 and 10), B-glucan
223601991|NCT01770015|PROCEDURE|endotracheal aspiration|fungi and bacteria endotracheal aspiration
223601992|NCT02956941|BEHAVIORAL|BCC on Essential Nutrition and Hygiene Actions (ENHAs)|The behavioral change communication (BCC) on micronutrient intake messages will be implemented based on Essential Nutrition and Hygiene Actions (ENHAs) on micronutrient deficiencies prevention and control. BCC intervention training workshop will be given to science teachers by principal investigator/ senior health professional in local language. Interventions will be delivered to students by their science teachers under the supervision of principal investigator/ school director for the consecutive three times.
223601993|NCT01500902|OTHER|EndoPAT testing (non invasive device)|Using the EndoPAT device, we will assess endothelial function.
223601994|NCT01500902|OTHER|WatchPAT testing (non-invasive device)|Using the WATCHPAT device we will assess sleep apnea.
223601995|NCT01771250|BIOLOGICAL|Insulin Peglispro|Daily doses administered SC.
223601996|NCT01771250|BIOLOGICAL|Insulin Glargine|Daily doses administered SC.
223601997|NCT03778450|DRUG|Analgesics, Opioid|"Patients are included in the long-term opioid group if they started an opioid-therapy between 2013 and 2017 and received consecutive prescriptions for opioid medications over a minimum of 3 quarters, over a 60-month period between January 1, 2013, and December 31, 2017. The treatment will be assessed using the ATC codes of opioid~treatment N02AA01, N02AA05, N02AB03, N02AE01, N02AX02, N02AX01, N02AX06) reported in reimbursed medicines to patients."
223601998|NCT03778450|DRUG|Non-Opioid Analgesic|Patients with non-opioid pain medication are included, if they received a medication therapy with anticonvulsants (gabapentin, pregabalin, carbamazepine), antidepressants or non-opioid analgesics (NSAIDs, Metamizole) over a minimum of 3 quarters, over a 60-month period between January 1, 2013, and December 31, 2017. The non-opioid treatment will be assessed using the ATC codes (N03AX12, N03AX16, N03AF01) of treatment reported in reimbursed medicines to patients.
223601999|NCT04674657|DRUG|blood drug concentration|blood drug concentration
223602000|NCT02451462|DRUG|Zoledronic acid|
223602001|NCT00307203|DRUG|bupropion SR|Participants were randomly assigned to receive bupropion SR 150 mg or placebo, once daily for 7 days, then twice daily for 11 weeks.
223602002|NCT00307203|BEHAVIORAL|Cognitive Behavioral Group Therapy|Participants attended a 12-session, 1-hour, weekly smoking cessation group program with 3 to 7 participants led by a psychologist with tobacco treatment specialist training. Subjects set a quit date, and nicotine patches (Habitrol) and nicotine polacrilex gum (Nicorette) were initiated in the fourth week.
223602003|NCT00307203|DRUG|nicotine replacement therapy|Nicotine patch was dosed at 21 mg/d for 4 weeks, 14 mg/d for 2 weeks, and 7 mg/d for 2 weeks, then discontinued. Nicotine gum (2 mg) was distributed for use as needed for craving up to 18 mg/d.
223602004|NCT02925624|PROCEDURE|Pulmonary vein isolation|
223602005|NCT05026203|DRUG|Ketamine Hydrochloride|Ketamine hydrochloride 0.5 mg/kg intravenous administer in 40 minutes per day for 3 consecutive days
223602006|NCT05026203|DRUG|Midazolam|Midazolam
223602007|NCT03006874|DRUG|CJ-12420 100mg QD|CJ-12420 100mg tablets will be orally administered, once daily, for up to 8 weeks. For subjects whose erosive esophagitis is not endoscopically healed at Week 4, subjects will receive additional 4 week treatment of CJ-12420 100mg.
223602008|NCT03006874|DRUG|Esomeprazole 40mg|Esomeprazole 40mg tablets will be orally administered, once daily, for up to 8 weeks. For subjects whose erosive esophagitis is not endoscopically healed at Week 4, subjects will receive additional 4 week treatment of Esomeprazole 40mg.
223602009|NCT03006874|DRUG|CJ-12420 50mg QD|CJ-12420 50mg tablets will be orally administered, once daily, for up to 8 weeks. For subjects whose erosive esophagitis is not endoscopically healed at Week 4, subjects will receive additional 4 week treatment of CJ-12420 50mg.
224200016|NCT02260752|PROCEDURE|endometrial ablation|surgical procedure that destroys uterine lining via a telescope placed inside the uterus
224200017|NCT02260752|PROCEDURE|magnetic resonance guided focused ultrasound|procedure that destroys fibroids while inside an MRI machine
224200018|NCT02260752|PROCEDURE|radiofrequency ablation|procedure that uses heat to destroy uterine fibroids
224200019|NCT05500235|BEHAVIORAL|Smart phone based training|The study team will acquaint headmasters with the Tobacco Free Teachers-Tobacco Free Society (TFT-TFS) program and the smartphone training app. Headmasters will receive six monthly trainings on smartphones, including brief videos followed by quizzes with feedback, discussion forums to promote peer learning, demonstration of techniques, and the ability to review the content as needed. Headmasters will implement TFT-TFS at monthly school meetings with teachers and parents. TFT-TFS consists of four program components: (1) six group discussions with teachers, (2) cessation support and referrals to government resources, (3) posting six thematic tobacco control posters in the school, and (4) implementing a school tobacco policy. These four components incorporate the program's six themes: Teachers as Role Models; Health Effects of Tobacco; Motivation to Quit Tobacco Use; Skills to Quit Tobacco and to Help Others Quit; Dealing with Withdrawal; and Maintenance and Celebration.
223602010|NCT00483938|DRUG|Pegylated-interferon Alfa-2a|Participants will receive pegylated-interferon alfa-2a 180 mcg subcutaneously once in a week for the specified duration.
223602011|NCT00483938|DRUG|Ribavirin|Participants will receive ribavirin 1000 to 1400 mg orally daily for the specified duration.
223602012|NCT03111329|OTHER|No aspiration of gastric residuals|No assessment of gastric residuals will be performed prior to administering 3-hourly feeds with increasing amounts of the feeds given as per a predefined plan
223602013|NCT06128603|PROCEDURE|laparoscopic pancreaticoduodenectomy|laparoscopic pancreaticoduodenectomy was performed for periampullary benign and malignant diseases. Besides, the surgical video was recorded.
223602014|NCT02534246|DEVICE|Ultrasound biopsy needle Echo Tip ProCore|Two passes preformed with Echo Tip ProCore ultrasound biopsy needle (Cook Medical 25 gauge) and two passes will be performed using SharkCore ultrasound biopsy needle (Medtronic \[Beacon\] 25 gauge) from single lesion.
223602015|NCT02534246|DEVICE|Ultrasound biopsy needle SharkCore|
223602016|NCT00894946|PROCEDURE|Lipiodol + IVF|IVF preceded by lipiodol
223602017|NCT00894946|PROCEDURE|IVF|IVF alone
223602018|NCT05360745|DIETARY_SUPPLEMENT|ARACOMPLEX®|ARACOMPLEX® is an authorized food supplement that contains maca extract, vitamin complexes and ions, and that improves the quality of life of the patient.
223602019|NCT05360745|DIETARY_SUPPLEMENT|placebo|Placebo has a composition that makes its weight and organoleptic characteristics are identical to ARACOMPLEX®.
223602020|NCT04382378|DEVICE|neuromuscular electrical stimulation|application of an electric current through electrodes placed on the skin over the targeted musclesto induce skeletal muscle contractions
223602021|NCT05777512|PROCEDURE|Gastric Feeds|The participant will receive nutrition via a nasogastric tube. Gastric feedings will be administered as bolus feeds every 3 hours over 1 hour. Infants who are deemed able to advance oral feedings via mouth during the study period will be permitted to do so, and this will be recorded.
223602022|NCT05777512|PROCEDURE|Jejunal Feeds|The participant will receive nutrition via a nasojejunal tube. Postpyloric feedings will be administered continuously into the jejunum. Infants who are deemed able to advance oral feedings via mouth during the study period will be permitted to do so, and this will be recorded.
223602023|NCT04591444|DRUG|Fluoride Varnish|Following the manufacturer's recommendations, it was not necessary to moisten or dry the treated surface beforehand or afterwards. The product was dispensed and manipulated for 15 s until a homogeneous mixture was obtained, applied with a micro brush, flowing into interproximal areas, and quickly adhering to the tooth surface in the presence of saliva.
223602024|NCT04591444|DRUG|Glass Ionomer Sealant|Following the manufacturer's recommendations, prophylaxis and prior drying of the treated surface was carried out, the product was also dispensed and manipulated for 15 s until a homogeneous mixture was obtained, applied with a micro brush and light-cured for 20 s.
223602025|NCT04591444|OTHER|Placebo Group|4 weeks after the simulation of the treatment application, participants in the placebo group received DH treatment with the product that had the best effect in the first 4 weeks.
223602026|NCT03581838|BEHAVIORAL|Observed eating session|Eating a Jimmy Johns turkey or vegetarian sandwich
223602027|NCT02373644|OTHER|HVLA Thrust Manipulation and DN|HVLA thrust manipulation targeting primarily the lumbar articulations and sacroiliac joint. Up to 10 sessions over 6 weeks. At least one session of dry needling to the lumbo-pelvic muscles and peri-articular ligaments of the SI joint.
223602028|NCT02373644|OTHER|Conventional Physical Therapy|Therapeutic exercise and manual therapy, up to 10 sessions over 6 weeks. Patients may receive interferential current and moist heat.
223602029|NCT01973725|DRUG|Icotinib Hydrochloride|Patients will receive Icotinib Hydrochloride at 125mg/times,oral three times daily for 21 days.
223602030|NCT02218008|DRUG|ALKS 5461|Sublingual tablet, taken once daily (in addition to open-label treatment with a commercially available antidepressant)
223602031|NCT02218008|DRUG|Placebo|Sublingual tablet, taken once daily (in addition to open-label treatment with a commercially available antidepressant)
223602032|NCT02038075|BEHAVIORAL|Brief Cognitive Behavioral Therapy (BCBT)|
223602033|NCT02038075|BEHAVIORAL|Treatment As Usual (TAU)|
223602034|NCT00106353|DRUG|Torisel|60-minute intravenous (IV) infusion once weekly to pediatric subjects with advanced solid tumors. Part 1 is an ascending-dose study to evaluate the safety of IV temsirolimus given once weekly to subjects ages 1 to 21 years with advanced solid tumors disease that is recurrent or refractory to standard therapy or for whom standard therapy is not available. (enrollment completed) Part 2 will be conducted in three groups of children with refractory or relapsed pediatric solid tumors. Subjects with the following tumor types will be enrolled: neuroblastoma, rhabdomyosarcoma, and high-grade gliomas. Subjects will receive IV temsirolimus once weekly until disease progression or unacceptable toxicity.
223602035|NCT02346617|BIOLOGICAL|IFN-γ positive selected T-cells|No intervention
223602036|NCT02110264|DRUG|XR-NTX|Monthly injections of XR-NTX will be administered to participants assigned to either the XR-NTX or XR-NTX+PN groups.
223602037|NCT02110264|BEHAVIORAL|XR-NTX+PN|In addition to long-acting naltrexone (XR-NTX), participants assigned to the XR-NTX+PN condition will meet regularly with a patient navigator to assist in accessing psychosocial services when released from jail.
223602038|NCT02110264|BEHAVIORAL|ETAU|Participants assigned to the ETAU group will receive drug education.
223602039|NCT03477838|DEVICE|FreeStyle LibrePro CGM|a professional CGM device will be worn by the participant for up to 14 days
223602040|NCT00032357|PROCEDURE|Ferritin reduction to 25 ng/ml by phlebotomy|
223602041|NCT00713895|BEHAVIORAL|Expert System|an expert system intervention provided the Pathway-To-Change self-help manual and a series of 3 individualized feedback reports at baseline, 3, and 6 months.
223749829|NCT06910579|DRUG|topical application of oxygenated gel|patients who used oxygenated gel (Blue®m, Wijhe, Netherlands) were trained by the co-investigator (A.H) through real demonstration for topical application of the gel on aphthous ulcers, which entails the application of 1-2 ml of oxygenated gel directly to the ulcer two times per day and this was repeated for 7 days
223602042|NCT00713895|BEHAVIORAL|Standard Self-Help|standard smoking cessation self-help manual
223749830|NCT06910579|DRUG|topical application of Triamcinolone acetonide gel|patients were treated with Kenalog in orabase (Triamcinolone acetonide 0.1% oral paste 5g), four times (i.e., at 8 am, 12 noon, 4 pm, and 8 pm) a day for 7 days at intervention group.
223602043|NCT04649684|DEVICE|Conventional robot-assisted gait training|They got conventional robot-assisted gait training, guidance force given equally to both limbs, and then gradually reduce the degree of guidance force to the extent that the patient is tolerable equally .during 4- week treatment session
223749831|NCT07108725|OTHER|Magnetic Resonance Cholangiopancreatography|Patients who are scheduled for magnetic resonance cholangiopancreatography and have undergone conventional imaging
223749832|NCT07110558|RADIATION|Without prophylactic neck irradiation|Intensity-modulated radiotherapy restricted to the primary tumor, omitting prophylactic neck irradiation.
223749833|NCT07110558|DRUG|PD-1 antibody (Toripalimab)|Toripalimab 240mg every 2 weeks with a total of 2 cycles as neoadjuvant anti-PD-1 immunotherapy; Toripalimab 240mg every 3 weeks with a total of 8 cycles as adjuvant anti-PD-1 immunotherapy after CCRT
223749834|NCT07110558|DRUG|Cisplatin|Cisplatin 100mg/m2(every three weeks), Day 1, Day 22, Day 43 of intensity modulated radiotherapy
223749835|NCT04534348|DEVICE|70% isopropyl alcohol-impregnated catheter caps|Implementation of 70% isopropyl alcohol-impregnated catheter caps in order to assess the number of CLABSI diagnosed during 1 Year
223749836|NCT06930885|DRUG|Cardiovascular Polypill (Valsartan, Atorvastatin, Aspirin)|"Cardiovascular Polypill contains Valsartan, Atorvastatin, Aspirin~1. Valsartan 160 mg + Atorvastatin 40 mg + Aspirin 100 mg~   or~2. Valsartan 160 mg + Atorvastatin 80 mg + Aspirin 100 mg~   or~3. Valsartan 320 mg + Atorvastatin 40 mg + Aspirin 100 mg~   or~4. Valsartan 320 mg + Atorvastatin 80 mg + Aspirin100 mg~   or~5. Valsartan 160 mg + Atorvastatin 20 mg + Aspirin 100 mg\*~   or~6. Valsartan 320 mg + Atorvastatin 20 mg + Aspirin 100 mg\*~   * The use of these formulations of the cardiovascular polypill will be restricted to cases of Statin-Related Muscle Symptoms (SRMS)"
223749837|NCT06930885|DRUG|Colchicine 0.5 mg|Colchicine 0.5 mg once daily
223602044|NCT04649684|DEVICE|Lower CIMT robot-assisted gait training group|They got robot-assisted gait training based on CIMT concept; 100% guidance force is given on the unaffected side and then verbal ques are given not to contract unaffected muscle voluntarily as much as possible are provided, automatically according to the predetermined joint trajectory. In contrast at the affected side, gradually reduce the degree of guidance force to the extent that the patient is tolerable.
223602045|NCT02409771|DEVICE|PRECIZON Presbyopic|Optical correction of aphakia in adults in whom the crystalline lens has been removed and who desire presbyopia correction.
223602046|NCT02389400|DRUG|methotrexate|Single Group Assignment
223749838|NCT06930885|DRUG|Usual Care Group|Patients allocated to the usual care arm will receive standard of care therapies for secondary prevention according to the guidelines. Drugs and doses will be left at the discretion of the treating physicians.
223749839|NCT06930885|DRUG|Colchicine-placebo 0.5 mg|Matching Colchicine-placebo 0.5 mg once daily
223602047|NCT00839761|DIETARY_SUPPLEMENT|iron fortified rice|
223602048|NCT00839761|DIETARY_SUPPLEMENT|iron drops|
223602049|NCT05185050|DIAGNOSTIC_TEST|physical examination and measurement of spinal alignment|physical examination for scoliosis and myofascial pain syndrome, measurement of spinal coronal and sagittal alignment in X-ray, and pain intensity (with Visual analog scale) if necessary (for MPS group)
223749840|NCT07141303|DRUG|The methylprednisolone sodium succinate|Patients will receive intra-arterial methylprednisolone sodium succinate 40mg immediately after the recanalization from thrombectomy in anterior circulation large vessel occlusion. Then, intravenous administration with methylprednisolone sodium succinate 2mg/kg in the next 3 days.
223749841|NCT07141303|DRUG|Placebo|The placebo group patients will receive intra-arterial and intravenous sterile water for injection.
223749842|NCT07164313|DRUG|ZW251|Administered intravenously
223749843|NCT07161622|OTHER|Low-Level Laser Therapy (LLLT)|"Participants received LLLT using a gallium-aluminium-arsenide (Ga-Al-As) diode laser device (BTL-5000, UK). The laser operated at a wavelength of 830 nm and a power output of 100 mW. Irradiation was applied at three sites (anterior capsule, posterior capsule, subacromial area) using a stationary-contact technique for 60-90 seconds each, delivering 4 J/cm² per site. Sessions were administered three times weekly for eight weeks.~Conventional Therapy (for both groups):~15 minutes of moist heat (Chattanooga Hydrocollator)~Pendulum exercises~Passive and active-assisted ROM exercises~Isometric strengthening of rotator cuff and scapular stabilizers~Postural correction training"
223749844|NCT07161622|OTHER|Muscle Energy Technique (MET)|"Participants received MET for major shoulder muscles (internal/external rotators, flexors, extensors). Each contraction was performed at \~20% of maximum effort, sustained for 10 seconds, followed by 5 seconds relaxation, and then passive stretch to new end range. Three to five cycles per muscle group were performed. Sessions lasted \~20 minutes, three times weekly for eight weeks.~Conventional Therapy (same as Arm A):~15 minutes of moist heat~Pendulum exercises~Passive and active-assisted ROM exercises~Isometric strengthening of rotator cuff and scapular stabilizers~Postural correction training"
223602050|NCT03940118|DEVICE|Catheter secretion suctioning|Catheter secretion suctioning with prior nebulization of hypertonic saline
223602051|NCT03940118|COMBINATION_PRODUCT|Secretion suctioning + hypertonic saline|Catheter secretion suctioning with prior nebulization of hypertonic saline
223602052|NCT03940118|DEVICE|Ins-exsufflation|Application of a mechanical insufflation-exsufflation device for respiratory tract secretion suctioning
223602053|NCT03940118|COMBINATION_PRODUCT|Ins-exsufflation + Hypertonic saline|Application of a mechanical insufflation-exsufflation device for respiratory tract secretion suctioning
223602054|NCT05186168|DEVICE|MiniHip Stem|The MiniHip stem is a titanium femoral stem (Ti-6Al-4V) coated with a layer of hydroxyapatite applied over a layer of pure titanium
223749845|NCT07180719|BEHAVIORAL|Dementia anti stigma intervention|The intervention is a train-a-trainer programme contextually developed, for delivery (via demonstrations and role-plays) by lay providers such as community health workers. It includes four sessions that promote: (i) understanding of dementia, (ii) demystifying myths and misconceptions, (iii) empathetic connections using videos of people with dementia and carers (virtual social contact) and (iv) social inclusion through a case vignette and discussions. It is delivered bi-weekly in a group setting and each session ranges between 1.5 to 2 hours.
223749846|NCT07181421|PROCEDURE|Tissue flossing with Therapeutic exercises|"Isometric Knee Extension - Standing Hamstring Curl - Wall Squats - Leg Press Against Wall. The Red TheraBand from Thera Tool (2m \* 5cm \* 1.3mm) will be used. The band will be wrapped starting from the tibial tuberosity and extending to 5 cm above the femoral epicondyle. Care will be taken to ensure that the patella remains uncovered.~* The band will be wrapped with 50% tension and 50% overlap.~* Flossing Duration: The floss band will be kept on for 2 minutes, and during this time, the patient will perform the exercises mentioned above. The number of repetitions for each exercise will depend on the patient's tolerance level, with a reference of 10 repetitions per exercise (based on similar tissue flossing protocols, though adapted for knee OA patients)."
223749847|NCT07181421|PROCEDURE|Therapeutic Exercises|Isometric Knee Extension - Standing Hamstring Curl - Wall Squats - Leg Press Against Wall.
223602055|NCT05186168|DEVICE|Trinity Acetabular Cup System|The Trinity Acetabular System is a modular acetabular cup system consisting of a press fit, titanium alloy shell
223749848|NCT07181109|DRUG|Zilebesiran|Zilebesiran will be administered SC
223602056|NCT00856804|DRUG|thalidomide|Open-label pilot study analyzing the impact of adding thalidomide (200 mg/d)to SOC on 12 weeks virological response in patients with chronic hepatitis C and interferon resistance.
223602057|NCT00015808|DRUG|Idebenone|
223602058|NCT02519595|DRUG|Ketamine IV 1mg/kg|Intervention: Ketamine IV 1mg/kg
223602059|NCT02519595|DRUG|Ketamine IV 1.5mg/kg|Intervention: Ketamine IV 1.5 mg/kg
223602060|NCT02519595|DRUG|Ketamine IV 2mg/kg|Intervention: Ketamine IV 2 mg/kg
223602061|NCT04678388|DRUG|Reference drug|1 Cap., single oral administration under fasting condition
223602062|NCT04678388|DRUG|Test drug 1|1 Tab., single oral administration under fasting condition
223602063|NCT04678388|DRUG|Test drug 2|1 Tab., single oral administration under fasting condition
223602064|NCT02191813|DRUG|Seresis®|
223602065|NCT02191813|DRUG|Placebo|
223602066|NCT06439303|DRUG|Cytisine 1,5 mg|Administration of Cytisine as monotherapy in the treatment of moderate tobacco use disorder or serious
223602067|NCT04028141|DRUG|Procedural sedation with ketofol in a 1 on 4 ratio|"The participant was brought to a zone where advanced life support could be optimally administered and where all necessary drugs and materials for treatment of complications are present. Oxygen saturation, continuous electrocardiogram, intermittent blood pressure measurement (every 2 minutes) and capnography were applied. A 20 gauge intravenous line was inserted. The participant was placed in semi-recumbent position and was given oxygen for at least 3 minutes through a non-rebreather mask unless contra-indications applied.~Ketofol 1 on 4 was prepared by mixing 1ml of ketamine (50mg) and 20ml of propofol (200mg) in a single syringe. It was administrated as a loading dose of 1ml/10kg, corresponding to 0,952mg/kg propofol and 0,238mg/kg ketamine, and followed by titration in aliquots of 0,5ml/10kg every 1 to 2 minutes until desired depth of sedation was achieved, and then every 3-5 minutes to retain the desired depth of sedation. The loading dose was halved if above 65 years."
223602068|NCT03382808|BEHAVIORAL|SEE Training|Participants are first presented with a fixation cross which indicates the beginning of a trial and is immediately followed by a bilateral presentation of a neutral and a fearful image (face) of the same model identity. The fearful expression is always replaced by an arrow pointing to the left or the right which remaines active until the participant indicates via button-press which direction the arrow is pointing to. The model identity, the position of the fearful cue and the arrow probe direction are pseudo-randomized across trials with no more than three identical sequential occurrences on each parameter. Each session consists of 360 trials in total, with 120 distinct trial types and three repetitions. Participants are trained with neutral and 75% fearful expressions only in the first session; the intensity of the fearful cue is successively decreased by 15% at every subsequent session.
223749849|NCT07181109|DRUG|Placebo|Placebo will be administered SC
223749850|NCT07180654|DEVICE|transcranial magnetic stimulation|Subjects will receive a series of 60 10s trains that will be presented over the course of the \~3.5 min session. Each train will consist of 2 s of stimulation with an 8 s ITI. During the 2 s of stimulation, 10, 50 Hz bursts will be repeated at intervals of 200 ms (5 Hz). iTBS will be administered at 100% of the motor threshold (MT).
223749851|NCT07180160|DRUG|QL1706|QL1706 is a single bifunctional MabPair product consisting of two engineered monoclonal antibodies (anti-PD-1 and anti-CTLA-4).
223749852|NCT07180160|DRUG|CDK4/6 inhibitor|palbociclib OR ribociclib OR abemaciclib OR dalpiciclib
223749853|NCT07180160|DRUG|Fulvestrant|SERD
223602069|NCT03382808|BEHAVIORAL|GAZE Training|Participants are first presented with a fixation cross, which indicates the beginning of a trial and is immediately followed by a bilateral presentation of a direct gaze-image (neutral face) and an image of a neutral face (same model identity) displaying deviated gaze. The averted gaze-face is always replaced by an arrow pointing to the left or the right which remaines active until the participant indicates via button-press which direction the arrow is pointing to. The model identity, the position of the fearful cue and the arrow probe direction are pseudo-randomized across trials with no more than three identical sequential occurrences on each parameter. Each session consists of 360 trials in total, with 120 distinct trial types and three repetitions. Participants are trained with direct and 100% averted gaze images only in the first session; the intensity of the deviated gaze cue is successively decreased by 20% at every subsequent session.
223602070|NCT00387036|DRUG|Fluticasone|fluticasone 250 µg/inhalation, 2 inhalations bid. 14 Days of treatment.
223602071|NCT00387036|DRUG|Comparator: Placebo|Placebo /inhalation, 2 inhalations bid. 14 Days of treatment.
223602072|NCT02846441|PROCEDURE|hepatobiliary scintigraphy|99mTc-mebrofenin hepatobiliary scintigraphy with single photon emission computed tomography (SPECT)
223602073|NCT00850538|RADIATION|MRI|1.5T MRI exam of signal knee with knee coil (estimated time: 35 minutes)
223749854|NCT07181057|OTHER|one-meal-a-day (OMAD)|"Arm Title: Morning Meal (08:00)~Intervention: Other: One-meal-a-day (OMAD)~Description: Participants consume a single isocaloric meal at 08:00.~Arm Title: Midday Meal (12:30)~Intervention: Other: One-meal-a-day (OMAD)~Description: Participants consume a single isocaloric meal at 12:30.~Arm Title: Evening Meal (18:00)~Intervention: Other: One-meal-a-day (OMAD)~Description: Participants consume a single isocaloric meal at 18:00."
223749855|NCT07180862|DRUG|BAT3306|One vial of 4 mL of concentrate contains 100 mg of BAT3306
223602074|NCT00850538|PROCEDURE|Primary Total Knee Replacement|Fluid, bone, and meniscus specimens obtained from total joint replacement will be collected.
223602075|NCT02969460|BEHAVIORAL|Neurotrack Virtual Cognitive Health Program|
223602076|NCT03970291|DEVICE|PMD-200|The PMD-200 system is comprised of a console and designated finger probe with 4 sensors. The Sensors are Photoplethysmography (PPG) Galvanic Skin Response (GSR), Accelerometer (ACC) and Thermistor (TMP)
223749856|NCT07180862|DRUG|US-Keytruda®|One vial of 4 mL of concentrate contains 100 mg of pembrolizumab
223749857|NCT07181083|DEVICE|Rheolytic thrombectomy|Rheolytic thrombectomy via AngioJet ZelanteDVTTM Catheter (Boston Scientific Co., USA).
223602077|NCT06258408|DRUG|BB102 tablet|BB102 tablets will be administered orally once daily(QD).
223602078|NCT01760772|DRUG|Exendin-9|Bolus of Ex-9 (7500 pmol/kg) over 1 minute followed by continuous infusion at 750 pmol/kg/min
223602079|NCT01760772|DRUG|GLP-1|Constant infusion of GLP-1 at 0.3 pmol/kg/min
223602080|NCT01760772|OTHER|saline|Constant infusion
223602081|NCT01477489|DRUG|Veliparib|Starting dose of veliparib will be 50 mg taken twice daily and will escalate up to a possible 200 mg twice daily.
223602082|NCT01477489|RADIATION|Standard radiation treatment|Limited to 60 Gy.
223602083|NCT03188510|BIOLOGICAL|LY3074828|Administered SC
223602084|NCT03139344|OTHER|Low-frequency Exercise|The quadriceps/hamstrings will perform exercise via the application of low-frequency electrical stimulation.
223602085|NCT03139344|OTHER|High-frequency Exercise|The quadriceps/hamstrings will perform exercise via the application of high-frequency electrical stimulation.
223749858|NCT07181369|DRUG|GTX-B001|Single infusion of one of up to five dosages of GTX-B001
223749859|NCT07181369|DRUG|Normal Saline|Single infusion of normal saline
223749860|NCT07180290|BEHAVIORAL|Psychotherapy|Session 1 : Introduction and awareness of the sleep-wake link Session 2 : Awareness of day/night habits and behaviors Session 3 : Awareness of sleep/wake rhythms and sleepiness signals Session 4 : Awareness of the night/bed/sleep association Session 5 : Awareness of emotions and thoughts related to sleep Session 6 : Awareness of possible alternatives Session 7 : Awareness of one's relationship to sleep Session 8 : Awareness of future benefits
223602086|NCT03113981|DEVICE|Total Hip Arthroplasty|Implanting THA grafted with PolyNass or not
223602087|NCT01031173|BIOLOGICAL|agalsidase alfa|0.2 mg/kg body weight, administered by an intravenous infusion over 40 minutes, every other week.
223602088|NCT02261766|DEVICE|Holter monitoring and Thumb ECG|5 days holtermonitoring and 30 days 30 seconds twice daily thumb ECG recording
223602089|NCT04254094|OTHER|Neuropsychological scales|Basic Activity of Daily Living (BADL) and Instrumental Activities of Daily Living (IADL), Neuropsychiatric Inventory (NPI), Cornell Scale for Depression in Dementia (CSDD), Clinical Dementia Rating Scale (CDR) and defining dementia criteria. Also as part of this study, an MRI examination at baseline and at 18 months follow-up will be performed in the Bordeaux center
223602090|NCT01989806|DEVICE|Robotic-assisted body weight supported treadmill training (Lokomat V6, Hocoma AG, Switzerland)|
223749861|NCT07181343|DRUG|HS-10374 tablets|From Day 8 to Day 19, participants will orally take HS-10374 Tablets 12 mg（6 mg×2） once daily under fasting conditions
223749862|NCT07181343|DRUG|Drospirenone and Ethinyl Estradiol tablets|On Day 1 and Day 14, participants will orally take one tablet of Drospirenone and Ethinylestradiol Tablets under fasting conditions.
223749863|NCT07180433|DIAGNOSTIC_TEST|FAPI PET/MR|The patients will be injected intravenously with 2 MBq/kg 18F-FAPI, 60 minutes before the PET/MRI acquisition. The PET/MRI examinations will be performed on a Siemens Biograph mMR (Siemens Healthcare, Erlangen, Germany) with software version VE11P. Static PET will be acquired simultaneously with MRI using two protocols; a one bed position protocol in prone position covering the breast and a whole body 4-5 bed position protocol in supine position covering brain to thighs. Total acquisition time of the breast protocol will be approximately 20 minutes. Total acquisition time of the whole-body protocol will be approximately 30 minutes.
224311295|NCT03093389|DRUG|BIA 6-512|The investigational products consisted of capsules containing BIA 6-512 25 mg, 50 mg, 100 mg and 150 mg. Products were administered orally, with approximately 240 mL of water in case of Doses 1 and 13, and at least 150 mL of water in case of Doses 2 to 12. First dose (Dose 1) and last dose (Dose 13) were administered in fasting of at least 8 hours and subject remained fasted until to 2.5 h post-dose. Meals were not served within 1 hour prior and 1 hour after investigational product administration in Doses 2 to 12
223602091|NCT01989806|DEVICE|Passive lower limbs mobilization training (Motomed Vivo 2, RECK, Germany)|
223602092|NCT04414566|DRUG|gemcitabine and cisplatin; docetaxel, cisplatin and fluorouracil|Patients receive GP gemcitabine (1000 mg/m\^2 d1,8) and cisplatin (80mg/m\^2 d1) or TPF docetaxel (60mg/m\^2 on day 1), cisplatin (60mg/m\^2 on day 1) and fluorouracil (600mg/m\^2 on Days 1 to 5) every three weeks for three cycles before the radiotherapy.
223602093|NCT04414566|RADIATION|IMRT|Intensity modulated-radiotherapy (IMRT) is given as 2.0 Gy per fraction with five daily fractions per week for 6-7 weeks to a total dose of 66 Gy or greater to the primary tumor.
223602094|NCT04414566|RADIATION|IMRT and concurrent cisplatin|Intensity modulated-radiotherapy (IMRT) is given as 2.0-2.30 Gy per fraction with five daily fractions per week for 6-7 weeks to a total dose of 66 Gy or greater to the primary tumor, concurrently with cisplatin 100 mg/m\^2 every 3 weeks for 3 cycles.
223602095|NCT03300063|OTHER|Low flow nocturnal oxygen|Nocturnal low-flow oxygen via nasal cannula
223602096|NCT06407531|OTHER|VR-G|Patients watched videos with virtual glasses before undergoing colonoscopy
223602097|NCT02624531|DRUG|Taxane|NACT and Fertility-sparing Treatment Strategy
223602098|NCT02624531|PROCEDURE|radical trachelectomy|NACT and Fertility-sparing Treatment Strategy
223602099|NCT01907425|OTHER|Blood samples|
224311296|NCT03093389|DRUG|Placebo|Matching placebo capsules
223602100|NCT04182672|DRUG|FX006|Subjects will be injected with the 5mL of FX006. This injection may be followed with up to 3mL of ropivacaine (depending on the capacity of the bursa), under ultrasound guidance.
223602101|NCT06496165|DRUG|Remimazolam|Intravenous pump injection. The loading dose will be 0.1mg/kg, the maintenance dose will be 0.1-0.5mg/kg/h, with the target RASS be -2-0
223602102|NCT06496165|DRUG|Propofol|Intravenous pump injection. The loading dose will be 0.5mg/kg, the maintenance dose will be 1-4mg/kg/h, with the target RASS be -2-0
223602103|NCT03150420|DRUG|Sodium Thiosulfate|Intravenous Sodium Thiosulfate Injection (25 grams sodium thiosulfate) to be administered each hemodialysis session (3 times weekly) for 3 weeks
223749864|NCT07181486|DRUG|Live Biotherapeutic Product L. jensenii 1153-1666|"The vaginally administered MucoCept-CVN contains Lactobacillus jensenii 1153-1666, a natural component of the human vaginal microbiota that has been modified to continuously express the potent HIV entry inhibitor modified-cyanovirin-N (mCV-N) right at the site of infection.~MucoCept-CVN is supplied as a prefilled vaginal applicator containing Lactobacillus jensenii 1153-1666, a modified strain of L. jensenii 1153 by integrating a modified cyanovirin-N gene into its chromosome to enhance the strain's ability to inhibit HIV. Each applicator contains 200 mg of MucoCept-CVN powder (1 x 109 CFU), and an inactive preservation matrix."
223749865|NCT07181486|DRUG|Placebo|Each placebo applicator contains 200 mg of placebo powder comprising the same inactive ingredients of the preservation matrix as the study product.
223749866|NCT07181850|OTHER|Standard-of-Care Neoadjuvant Immunochemotherapy (nIT+nCT)|Adults with biopsy-confirmed ESCC received standard neoadjuvant immunochemotherapy before surgery (e.g., camrelizumab with paclitaxel plus cisplatin or carboplatin, typically 2 cycles every 2-3 weeks). Treatments were routine clinical care at participating centers and were not assigned by study protocol; this record captures the exposure for observational modeling of pathological complete response (pCR). Surgery (R0) occurred \~6-8 weeks after therapy.
223749867|NCT07181382|DRUG|Placebo|Matching capsule containing placebo
223602104|NCT03150420|DRUG|Placebo-Normal Saline|Placebo: to be administered each hemodialysis session (3 times weekly) for 3 weeks
223602105|NCT02975258|PROCEDURE|Blood draw|Blood will be drawn for plasma, serum, and peripheral blood mononuclear cells.
223749868|NCT07181382|DRUG|Seralutinib|Capsule containing seralutinib
223749869|NCT07181382|DEVICE|Generic Dry Powder Inhaler|Generic dry powder inhaler for seralutinib or placebo delivery
223749870|NCT07181239|DRUG|CM336 Injection|Specified dose on specified days
223749871|NCT07181239|DRUG|Standard Of Care( SOC)|Specified dose on specified days
223749872|NCT07180563|DRUG|Participants were treated with doxycycline + berberin for chronic endometritis (intervention group).|Diagnosed chronic endometritis according to endometrial biopsy pathology , the specific medication plan for the intervention group was to use doxycycline 100mg, bid + berberin 100mg, tid, continuously for 14 days.
223749873|NCT07180563|DRUG|At present, the commonly used clinical treatment for chronic endometritis is oral doxycycline|11After hysteroscopic diagnosis of chronic endometritis, patients received monotherapy with doxycycline hydrochloride capsules for 14 days.
224075300|NCT05280977|OTHER|POST FACILITATION STRETCHING|"Group B (Post Facilitation Stretching + Conventional Physiotherapy):~This group will receive Post Facilitation Stretching Technique in addition to conventional physiotherapy for the treatment of erector spinae tightness. The treatment will be given on alternate days for four weeks with 8 - 10 repetitions of METs per session."
224075301|NCT05854901|DIAGNOSTIC_TEST|Procalcitonin|blood test, measuring the concentration of PCT in ug/L
224075302|NCT05854901|OTHER|Physician's decision|The physician's decided whether the patient will receive antibiotic treatment or not
224075303|NCT01164085|DRUG|Intravitreal Ketorolac|4mg of intravitreal ketorolac
224075304|NCT00522795|DRUG|PPX with cisplatin and radiation|weekly IV treatment of Paclitaxel Poliglumex and Cisplatin for 6 weeks
224075305|NCT02913157|DRUG|Hydroxychloroquine|Orally administered Hydroxychloroquine
224075306|NCT02770937|OTHER|Virtual reality simulator|The virtual reality simulator group will receive a maximum of 4 hours of training (2 sessions, 2 hours each) using the Simbionix simulator on laparoscopic suturing.
224075307|NCT02770937|OTHER|Box trainer|The box trainer group will receive a maximum of 4 hours of training (2 sessions, 2 hours each) on a box trainer.
224075308|NCT02770937|DEVICE|Simbionix|
224075309|NCT02450487|DRUG|Piroxicam|After extraction of at least one third molar, 100 patients will be treated with Piroxicam (20 mg once daily for 4 days) for pain control, collect the saliva to be genotyped and phenotyped for CYP2C9 (by PCR) and their post-operative notes (pain, swelling, trismus, temperature) will be analyzed. For the pharmacokinetics of piroxicam saliva samples will be collected from 10 of these patients at different times after ingestion of a capsule of 20 mg Piroxicam (before, 1, 2, 3, 4, 5, 6, 8, 11, 24, 48 and 72 hours after ingestion).
224075310|NCT06427551|DRUG|Ropivacaine|The local anesthetic was dosed on the patient's weight (50-59kg: 120mg, 60-61kg: 140mg, 70-79kg: 160mg, ≥80kg: 180mg)
224075311|NCT01790048|DIETARY_SUPPLEMENT|Whey permeate RUSF|"Each child will receive 75 kcal/kg/day (314 kJ/kg/day) of whey RUSF. A ration of sufficient for two weeks based on the subject's weight will be distributed at each visit. Children will be asked to return every two weeks for follow-up, where caretakers report on the child's clinical symptoms, anthropometric measurements are re-assessed, and additional supplementary food is distributed for those that remained wasted.~Whey RUSF contains whey permeate, WPC 80 (contains at least 80% protein), peanut paste, sugar, soy oil, a customized micronutrient premix to account for the minerals in whey permeate, and an emulsifier."
224075312|NCT01790048|DIETARY_SUPPLEMENT|Soy Protein RUSF|"Each child will receive 75 kcal/kg/day (314 kJ/kg/day) of soy RUSF. A ration of sufficient for two weeks based on the subject's weight will be distributed at each visit. Children will be asked to return every two weeks for follow-up, where caretakers report on the child's clinical symptoms, anthropometric measurements are re-assessed, and additional supplementary food is distributed for those that remained wasted.~Soy RUSF contains extruded soy flour, peanut paste, sugar, soy oil, palm oil, a premix containing concentrated minerals and vitamins, an emulsifier and dicalcium phosphate or calcium carbonate (Roche, Mumbai, India). Soy RUSF has no protein from animal sources."
224075313|NCT04635306|DIAGNOSTIC_TEST|Approved GEBT test meal|FDA-approve GEBT test meal
223602106|NCT02975258|OTHER|Questionnaires|The following questionnaires are administered to participants by study personnel: Gingo Asthma Questionnaire (GAQ) and the Asthma Quality of Life questionnaire (AQL).
223749874|NCT07181278|OTHER|Mobile unit with quasi point of care HPV testing and immediate triage + treatment|"A mobile team consisting of one or two midwives and a lab technician with a Genexpert platform visits the health centres on a regular basis.~After informed consent is granted, participants perform a vaginal self-sample, which is immediately analyzed with the Genexpert plateform. Participants who test HPV positive are invited for immediate triage and treatment if required."
223602107|NCT02975258|PROCEDURE|Spirometry|Spirometry is a simple breathing test that measures the amount of air in one's lungs and how well one can move that air by forcefully blowing 3 or more times into a mouthpiece. A series of these maneuvers will be performed under the instruction of a respiratory technician or respiratory therapist.
223602108|NCT02975258|PROCEDURE|Methacholine challenge test|A methacholine challenge is a common test often used to support a diagnosis of asthma. The test consists of inhaling increasing doses of methacholine through a nebulizer to assess how quickly the participant's airways narrow.
223602109|NCT02975258|RADIATION|Quantitative CT scans|There will be a standard chest CT and an abdominal CT. The CT scans capture contiguous volume scans acquired at slice thicknesses of 5.0 mm in the axial plane and reconstructed with 512 x 512 pixel matrices. CT examinations will encompass the entire thorax and the abdomen and will be performed during a breath-hold at end-inspiration. The investigators will measure % of lung tissue below a threshold for emphysema (i.e. -950 Hounsfield units). Measurements have been histologically-verified and give reproducible measurements. The data set is assembled and analyzed with the image data anonymized. If the participant has had a research chest CT scan done recently, only the abdomen CT will be done.
223749875|NCT07181278|OTHER|Centralized screening|Self-collected samples are sent to a reference laboratory for HPV testing. Results are communicated to the participants and HPV positive women are invited to go to the reference centre where triage and treatment (when required) are performed.
224200020|NCT05500235|BEHAVIORAL|In person training|Headmasters will receive three face-to-face trainings, each 60-75 minutes long and held at convenient locations. The study team will introduce headmasters to the TFT-TFS program and teach participants how to use paper-based materials. The trainings will encourage participants to discuss successes and come up with solutions to overcome challenges. Headmasters will implement TFT-TFS at monthly school meetings with teachers and parents. TFT-TFS consists of four program components: (1) 6 group discussions with teachers, (2) cessation support and referrals to government resources, (3) posting six thematic tobacco control posters in the school, and (4) implementing a school tobacco policy. These four components incorporate the program's six themes: Teachers as Role Models; Health Effects of Tobacco; Motivation to Quit Tobacco Use; Skills to Quit Tobacco and to Help Others Quit; Dealing with Withdrawal; and Maintenance and Celebration.
224200021|NCT05179980|OTHER|Assessment|Evaluation of clinical-surgical competencies with a previously validated instrument.
224200022|NCT06411782|DEVICE|Foam roller|In foam roller application, a partitioned FR from the Trigger Point Grid 2.0 brand, measuring 33x14 cm and weighing 0.9 kg, with an inner part made of polyvinylchloride (PVC), will be used. Participants will roll the segmented FR with slight flexion-extension by placing the FR on the SCM muscle to apply FR from the starting point to the end point of that muscle region for the selected SCM muscle, with the person in the side stance position against the wall. This action will consist of 3 sets of 1 minute each, with a 30-second rest period between each set. It will be applied once for each region, including the right and left SCM muscle.
223602110|NCT02975258|PROCEDURE|Urine pregnancy test|All female participants with childbearing potential will be asked to provide a urine sample for pregnancy testing. The result of the pregnancy test must be negative in order for her to be in this research study.
223602111|NCT02975258|PROCEDURE|Adipose biopsy|The doctor will obtain a sample of fat cells from the participant's abdomen. Numbing medicine will be applied. A needle is placed through the skin \& into the fat pad under the skin. A blunt-tip hollow cannula is then used to aspirate fat tissue through the incision.
223602112|NCT02975258|PROCEDURE|Exhaled nitric oxide measurement|The investigators will measure concentrations of exhaled nitric oxide by asking the participant to inhale deeply, and then exhale very slowly into a mouthpiece for between 10-15 seconds.
224200023|NCT06411782|DEVICE|Inspiratory muscle training|Inspiratory muscle training will be done with a resistive exercise device at 80% of MIP max and for 30 breaths.
224200024|NCT06359964|PROCEDURE|Transperineal Biopsy without antibiotics prophylaxis|Transperineal Biopsy without antibiotics prophylaxis
224200025|NCT06359964|PROCEDURE|Transperineal Biopsy with antibiotics prophylaxis|Transperineal Biopsy with antibiotics prophylaxis
224200026|NCT05447559|DRUG|Cefazolin|Intravenous administration of 2 g cefazolin
224200027|NCT05447559|DRUG|Water for injection|Intravenous administration of 10mL sterile water for injection
224200028|NCT06236152|DRUG|Ferrous sulfate|Ferrous Sulphate was given once daily for 4 to 6 weeks to the patients instead of deltacortil.
224200029|NCT06236152|DRUG|Deltacortril|Deltacortil 10mg was given orally once daily for 4 to 6 weeks
224200030|NCT06340087|OTHER|10% Sucrose|10% sucrose corresponding to a regular soft drink
223602113|NCT02083497|OTHER|rigid bandage|
223602114|NCT02083497|OTHER|elastic bands|
223602115|NCT02083497|OTHER|without the use of banding|
224200031|NCT06340087|DRUG|Sucrose+ Hesperetin|Addition of hesperetin increases sweetness of 7% sucrose solution to match sweetness of 10% sucrose solution
224200032|NCT06340087|OTHER|7% Sucrose|7% sucrose to match the caloric content of the sugar-reduced hesperetin intervention
224200033|NCT00171756|DRUG|valsartan/atenolol|
224200034|NCT02802137|DRUG|tafluprost|
224200035|NCT02802137|DRUG|tafluprost and dorzolamide/timolol|
224200036|NCT03852407|DRUG|Thymoglobulin|ATG: 2.5 mg /kg/day on day -2 and -1 (day 0 is allogenic transplantation)
224200037|NCT03852407|DRUG|Melphalan|100mg/m² on day -2
224200038|NCT03852407|DRUG|Fludarabine|30mg/m² on days -6, -5, -4, -3, and -2
224200039|NCT03852407|DRUG|Cyclophosphamid|50 mg/kg on days +3 and +4.
224200040|NCT00514709|BIOLOGICAL|DTaP-HB PRP~T Combined Vaccine|0.5 mL, Intramuscular (IM)
224200041|NCT00514709|BIOLOGICAL|DTaP-HB-PRP~T vaccine|0.5 mL, IM
224200042|NCT00514709|BIOLOGICAL|Oral Polio Vaccine|Oral co-administered with study vaccine.
224200043|NCT01861600|OTHER|S-26 Gold|(13.4 g/L protein) with 100% Fat Blend A
223602116|NCT02343809|OTHER|Actual Diacutaneous Fibrolysis|Diacutaneous Fibrolysis is a non-invasive physiotherapeutic technique applied by means of a set of metallic hooks ending in a spatula with bevelled edges that allow a deeper and more precise application, which could not be achieved manually. The hook is deeply applied following the intermuscular septum between the muscles with an anatomical of functional relationship with the painful structure in order to release adherences between musculoskeletal structures.
223602117|NCT02343809|OTHER|Sham Diacutaneous Fibrolysis|Sham Diacutaneous Fibrolysis is applied at a superficial level. A pinch of skin was held with the thumb of the palpatory hand and the tip of the spatula, without any action taking place on the deep tissular levels.
223602118|NCT02343809|OTHER|Protocolized Physiotherapy|Protocolized physiotherapeutic treatment: Three weeks fo daily stretching exercises, ultrasound and analgesic electrotherapy
223602119|NCT00005120|DRUG|Calanolide A|
223602120|NCT00376857|DRUG|Surgery with and without the aid of Indocyanine Green (ICG)|
223749876|NCT07180745|DRUG|Pioglitazone (PIO)|30 mg orally once daily
223749877|NCT07180745|DRUG|Empagliflozin|10 mg orally once daily
223749878|NCT07180745|DRUG|Statin (Atorvastatin)|20 mg orally once daily
223749879|NCT07180745|DRUG|Empagliflozin plus Statin (Atorvastatin)|Orally once daily of each (10 mg, 20 mg respectively)
223749880|NCT07180745|DRUG|Pioglitazone plus Atorvastatin|Orally once daily of each (30mg and 20mg respectively)
223749881|NCT07181291|PROCEDURE|PVI|pulmonary-vein isolation
223749882|NCT07181629|OTHER|Control|The Personal Information Form, Mini Nutritional Assessment-Short Form (MNA-SF), Zarit Caregiver Burden Scale, Short Form-36 (SF-36) Quality of Life Questionnaire, and the Dysphagia Management Knowledge Form for Stroke Patients administered to caregivers of stroke patients at each interview (at 0, 1, and 3 months).
223749883|NCT07181629|BEHAVIORAL|Dysphagia Management Education|The Personal Information Form, Mini Nutritional Assessment-Short Form (MNA-SF), Zarit Caregiver Burden Scale, Short Form-36 (SF-36) Quality of Life Questionnaire, and the Dysphagia Management Knowledge Form for Stroke Patients administered to caregivers of stroke patients at each interview (at 0, 1, and 3 months). The intervention group received dysphagia management training after the questionnaires were administered at the first meeting.
223749884|NCT07179900|DRUG|QL1706|Apololitovoreli monoclonal antibody (QL1706) 7.5mg/kg intravenous infusion, once every 3 weeks
223749885|NCT07179900|RADIATION|Radiotherapy|41.4-50.4Gy/1.8Gy/23-28F
223749886|NCT07179900|DRUG|Sintilimab|200mg q3w
223749887|NCT07179900|DRUG|Bevacizumab|15mg/kg q3w
223749888|NCT07181928|BEHAVIORAL|Mentalization-Based Therapy (MBT)|MBT is a manualized psychodynamic therapy based on attachment theory, designed to restore adolescents' mentalizing in general and in emotionally stressful situations and relationships. It targets to rebuilt epistemic trust, to successfully mentalize oneself and others.
223602121|NCT01755728|DRUG|Paracetamol|Per gavage paracetamol 15 mg/kg every 6 hours, for up to 7 days.
223602122|NCT01755728|DRUG|Ibuprofen|Per Gavage ibuprofen 10mg/kg x 3/d for up to 5 days Gold standard per literature
223749889|NCT07181928|BEHAVIORAL|Treatment-as-usual-plus (TAU-plus)|The adolescents receive supportive child psychiatric consultations. For the parents the EFST sessions combine mindfulness, theoretical input, and experiential practice. Parents learn and apply four core skills: validation, repair, motivation, and setting boundaries.
223749890|NCT07180888|DIAGNOSTIC_TEST|Echocardiography|diastolic dysfunction in ESKD in hemodialysis by echocardiography
223749891|NCT07180888|DIAGNOSTIC_TEST|Echocardiographic assessment of diastolic dysfunction|non invasive transthoracic echocardiography including doppler and tissue doppler imaging will be used to assess left ventricular diastolic dysfunction parameters in hemodialysis patient
223749892|NCT07181681|DRUG|BG-C0902|Administered by intravenous infusion
223749893|NCT07179653|DRUG|TVAX-008|TVAX-008
223749894|NCT07179653|DRUG|Placebo|Placebo
223602123|NCT01755728|PROCEDURE|Closure of PDA|Open surgery for closure of PDA
223602124|NCT02564809|BEHAVIORAL|Fit Brains Training|These hourly classes will consist of cognitive brain training (Fit Brains by Rosetta Stone) on a mobile device (tablet/iPad). Fit Brains offers 60+ different training games, each targeting one of five cognitive domains - executive functions, memory, concentration/attention, visual-spatial ability, and processing speed. Each game lasts exactly 60 seconds during which individuals aim to answer as many questions correctly. The difficulty of the game increases after each correct answer. Each game has three level of difficulty: 1) novice; 2) intermediate; and 3) advanced.
223749895|NCT07181265|DRUG|Amiodarone Hydrochloride Tablets|Cohort 1: The intervention is for study of drug drug interaction of JMKX003142 when administered with Amiodarone
223749896|NCT07181265|DRUG|Febuxostat Tablets|Cohort 2: The intervention is for study of drug drug interaction of JMKX003142 when administered with Febuxostat Tablets
223749897|NCT07181603|BEHAVIORAL|Resilience Enhancement Training Program|A structured 10-week behavioral training program designed to improve resilience and reduce perceived stress among nursing students. The program includes 10 sessions covering self-awareness, self-regulation, stress and coping strategies, cognitive restructuring, self-compassion, gratitude practice, optimism training, self-esteem, and a wrap-up with evaluation. Each session aims to strengthen coping skills and psychological adaptability.
223749898|NCT05866237|DEVICE|Patient Engagement tool|The study intervention (PET) aims to increase uptake of vaccines that are already recommended through national guidance.The PET will help educate and inform individuals about the benefits of COVID-19 and Flu vaccinations through culturally adapted educational support, including content, design, mode and timing of delivery of messages (text, video or voice messages).
223749899|NCT05113537|DRUG|Abemaciclib|Given Orally
223749900|NCT05113537|DRUG|Lutetium Lu 177-PSMA-617|Given IV
223749901|NCT06312878|OTHER|Describe the anatomy of the IVC in the case of an anatomical variant|Evaluated technique by collecting data from the medical record.
223749902|NCT03568357|PROCEDURE|Reoxygenation|After one minute of full bypass, fraction of inspired oxygen (FiO2) in conservative group was increased at increments of 0.1 per minute to reach an FiO2 target of 40% that was adjusted to maintain an arterial PO2 in the range of 250 mm Hg or less during the bypass, while FiO2 in liberal group was increased at increments of 0.1 per minute to reach a FiO2 target of 80% adjusted to maintain PO2 in the range of 300 mm Hg or more, on the basis of arterial PO2 level measured via a point of care blood gas analyzer.
223749903|NCT01468766|OTHER|Supervised progressive resistance training|2x60 minutes per week for 12 weeks
223602125|NCT02564809|BEHAVIORAL|Exercise + Fit Brains Training|These classes combine aerobic training and cognitive training. The classes will consist of a 15-minute walk prior to cognitive brain training (Fit Brains by Rosetta Stone) on a mobile device (tablet/iPad). Fit Brains offers 60+ different training games, each targeting one of five cognitive domains - executive functions, memory, concentration/attention, visual-spatial ability, and processing speed. Each game lasts exactly 60 seconds during which individual aims to answer as many questions correctly. The difficulty of the game increases after each correct answer. Each game has three level of difficulty: 1) novice; 2) intermediate; and 3) advanced.
223602126|NCT02564809|BEHAVIORAL|Balanced And Tone|These classes will consist of hourly sham training class, hourly classes of sham exercise (e.g., balance, stretching, range of motion), and hourly educational classes.
223749904|NCT01468766|OTHER|Supervised progressive muscle relaxation training (Jacobson method)|2x60 minutes per week for 12 weeks
223749905|NCT01015248|DRUG|Rituximab and Bendamustine|Rituximab 375 mg/m2 iv. day 1 Bendamustine 90 mg/m2 iv. day 1 and 2
223749906|NCT01885091|OTHER|Kinerase|
223602127|NCT03025243|DEVICE|computer aided surgical guide|comparing accuracy of surgical guide of printing layer thickness of 50 micron and 100 micron by superimposition of pre-operative and post-operative CBCT
223602128|NCT03052049|DEVICE|Prostate Artery Embolization|The PAE procedure will be completed on all enrolled patients in Interventional Radiology includes a pelvic/prostate angiogram and embolization with Bead Block microspheres to slow/block blood flow to the prostate.
223602129|NCT03361982|OTHER|Slow Freezing and Thawing|half of the surgically obtained testicular sperm will be frozen for 30 minutes and subsequently thawed prior to performing ICSI
223602130|NCT05271760|PROCEDURE|Single-shot spinal analgesia|The intrathecal medication included 1ml of 0.5% heavy bupivacaine (5 mg) and 25 μg fentanyl, CSF barbotage will do to reach a total volume of 2 ml
223602131|NCT05271760|PROCEDURE|Continuous epidural analgesia|Epidural analgesia is performed using a 16-gauge Tuohy epidural needle using a loss-of-resistance- to-saline technique, upon feeling the loss of resistance an epidural catheter will be introduced cranially through the needle for 5 cm in the L3-L4 epidural space, after negative aspiration for blood or spinal fluid a test dose of 3 ml lidocaine 1.5% with epinephrine 1:200000 will be given via inserted catheter, 10 ml of 0.125 % bupivacaine and 2ug/ml fentanyl will be injected as a loading dose then the solution will infuse in a rate of 6 -14 ml/h.
223602132|NCT05271760|PROCEDURE|Combined spinal-epidural analgesia|"Epidural analgesia is performed using a combined spinal-epidural set. using a loss-of-resistance- to-saline technique, upon feeling the loss of resistance, once epidural space will be detected, 27 G Whitacre spinal needle inserted through Touhy epidural needle, intrathecal injection of 1ml of 0.5% heavy bupivacaine (5 mg) and 25 μg fentanyl, CSF barbotage will do to reach a total volume of 2 ml. Then an epidural catheter will be introduced cranially through the needle for 5 cm in the L3-L4 epidural space, after negative aspiration for blood or spinal fluid.~10 ml of 0.125 % bupivacaine and 2ug/ml fentanyl will be injected as a loading dose then the solution will infuse at a rate of 6 -14 ml/h if needed."
223602133|NCT02913716|DRUG|defactinib|Single oral dose of 400 mg \[14C\]-defactinib
223602134|NCT01366729|DEVICE|TheraTogs|Orthosis facilitating hemiplegic hip extensor and abductor activity. Worn daily from dressing in the morning to undressing at night. May be removed during therapy or afternoon sleep.
224200044|NCT01861600|OTHER|S-26 Gold EF1|(13.4 g/L protein) with 60% Fat Blend A and 40% Betapol fat blend
224200045|NCT01861600|OTHER|S-26 Gold EF2|(13.4 g/L protein) with 60% Fat Blend A and 40% Betapol fat blend, and supplemented with 3.0 g/L oligofructose
224200046|NCT01861600|OTHER|S-26 Gold EF3|(13.4 g/L protein) with 60% Fat Blend A and 40% Betapol fat blend, and supplemented with 5.0 g/L oligofructose
224200047|NCT01861600|OTHER|Human Milk|Human Milk
224200048|NCT03102788|BEHAVIORAL|Rheumatologist-led care.|"Rheumatologist-led care comprises confirmation of diagnosis, information about hand osteoarthritis and symptom modifying medication, and, for some patients, Intra-articular injection of long-acting Corticosteroid.~The rheumatologist may also refer participants to occupational therapy if needed."
223749907|NCT00710320|PROCEDURE|Covered and uncovered anesthesia induction|"We hypothesize that the core temperatures of:~1. the covered group during induction of general anesthesia will be greater by 0.5ºC than the uncovered group during induction of general anesthesia.~2. both groups, covered and uncovered, will be equal during surgery and post-operatively. In other words, due to the active warming procedures during surgery and post-operatively in the PICU, core temperatures of the uncovered group will catch up to the covered group."
223749908|NCT02008448|PROCEDURE|Pulmonary vein isolation|
223749909|NCT02008448|PROCEDURE|Linear Lesion Ablation|
223749910|NCT02008448|DRUG|BT injection|
223749911|NCT03667352|PROCEDURE|Unilateral Scalp Block|Scalp block is provided by injecting local anaesthetic in the scalp at specific areas to block 6 nerves which are responsible for sensory innervation of the scalp - Supraorbital and supratrochlear nerves, Zygomaticotemporal nerve, Auriculotemporal nerve, Greater and lesser occipital nerves.
223749912|NCT03667352|PROCEDURE|Transversus abdominis plane block|The transverse abdominis plane (TAP) block is a peripheral nerve block designed to anesthetize the nerves supplying the anterior abdominal wall (T6 to L1). It is usually accomplished by a single bolus injection into the transversus abdominis plane through the lumbar triangle of Petit and can be accomplished either by blind landmark based technique or alternatively under ultrasound guidance (as in this study).
223749913|NCT03667352|DRUG|Intravenous Fentanyl|Fentanyl is a commonly used opioid drug administered for analgesia in the perioperative period. It may be used as either intermittent bolus administration or continuous infusion or a combination of the two. Usual infusion doses range from 1-2 microgram/kg/hr, which may be titrated based on intraoperative haemodynamics or postoperative patient reported pain scores.
223749914|NCT02674620|OTHER|Aerobic Exercise|Patients are treated with progressive exercise
223749915|NCT02693574|DRUG|Clarithromycin|
223749916|NCT02693574|DRUG|Levofloxacin|
223749917|NCT01660893|DRUG|Tetracaine HCl 3% and oxymetazoline HCl 0.05%|3 unilateral intranasal sprays per dose
223749918|NCT01660893|DRUG|Tetracaine HCl 3%|3 unilateral intranasal sprays per dose
223602135|NCT01366729|DEVICE|Cane walking|All walking activities must take place with cane from waking until sleeping
223602136|NCT01418742|DRUG|Panitumumab, Doxycycline/Placebo|comparison of Doxycyline/Placebo and Panitumumab regarding efficacy of the therapy of panitumumab induced skin toxicity
223749919|NCT01660893|DRUG|Placebo|3 unilateral intranasal sprays per dose
223749920|NCT02759068|BEHAVIORAL|sounds and odors|presentation of sounds and odors
223749921|NCT00771433|BIOLOGICAL|filgrastim|Given subcutaneously
223749922|NCT05886166|OTHER|robot assisted training|Rebless® (H-ROBOTICS, KOREA) is a knee or ankle robot for range of motion (ROM) and strength training that can operate in passive or active mode in knee or ankle flexion and extension. The patients underwent 30 min of robot training using Rebless® with 30 min conventional therapy, 5 days a week for 8 weeks.
223749923|NCT02658890|DRUG|BMS-986205|
223749924|NCT02658890|DRUG|Nivolumab|
223749925|NCT02658890|DRUG|Ipilimumab|
223749926|NCT02242838|DRUG|Telmisartan|
223749927|NCT01462669|DRUG|50mg Ezogabine/retigabine|A single 50mg ezogabine/retigabine tablet will be administered orally with the subject in the fasted state
223749928|NCT01462669|DRUG|100mg Ezogabine/retigabine|A single 100mg ezogabine/retigabine tablet will be administered orally with the subject in the fasted state
223749929|NCT01462669|DRUG|200mg Ezogabine/retigabine|A single 200mg ezogabine/retigabine tablet will be administered orally with the subject in the fasted state
223602137|NCT01418742|DRUG|Panitumumab|mCRC patients receiving panitumumab as EGFR inhibitor.
223749930|NCT01462669|DRUG|400mg Ezogabine/retigabine|A single 400mg ezogabine/retigabine tablet will be administered orally with the subject in the fasted state
223749931|NCT04498793|BIOLOGICAL|Tislelizumab|On Day 1 of the last seven cycles in the neoadjuvant and each cycle in the adjuvant phases of the study for a total of 21 cycles; intravenous (IV) infusion.
223749932|NCT04498793|DRUG|Nab paclitaxel|On Days 1 and 8 of Cycles 1-4 in the neoadjuvant phase of the study; IV infusion.
223749933|NCT04498793|DRUG|Doxorubicin|On Day 1 of Cycles 5-8 of the neoadjuvant phase of the study; IV injection.
223749934|NCT04498793|DRUG|Epirubicin|On Day 1 of Cycles 5-8 of the neoadjuvant phase of the study; IV injection.
223749935|NCT04498793|DEVICE|Cyclophosphamide|On Day 1 of Cycles 5-8 of the neoadjuvant phase of the study; IV infusion.
223749936|NCT00017134|DRUG|fenretinide|
223749937|NCT00017134|PROCEDURE|conventional surgery|
223602138|NCT00122369|BEHAVIORAL|Self-hypnotic Relaxation|A research assistant read to the patient a self-hypnotic relaxation script while displaying empathic attention.
223749938|NCT02734888|OTHER|No drug or device, only a test. The test is called a PET/CT|A single PET/CT scan will be performed
223749939|NCT00992810|PROCEDURE|Lateral-to-Medial Approach|Approach of the needle to administer the brachial plexus nerve block will be done in a lateral-to-medial direction.
223749940|NCT00992810|PROCEDURE|Media-to-Lateral Approach|Approach of the needle to administer the brachial plexus nerve block will be done in a medial-to-lateral direction.
223749941|NCT02484495|OTHER|Program evaluation (impact assessment)|"The program activities include: processed complementary food rations which will be distributed to all children 6-23 months of age, in a grain bank based on bartering of raw materials; enhanced Infant and Young Child Nutrition (IYCN) counselling will be given to the mothers of children 6-23 month of age, using improved Behavior messages based Change Intervention (BCI) on formative research.~Monthly 15 MNPs sachets will be provided to all children 6-23 months of age with the instruction to add them to their complementary food, to enable point-of-use fortification on every alternate day."
224200049|NCT03102788|BEHAVIORAL|Occupational therapist-led care.|Occupational therapist-led care comprises confirmation of diagnosis, information about hand osteoarthritis and symptom modifying medication, teaching of hand exercises and ergonomic working methods, and, for some patients, provision assistive devices and orthoses/splints. The occupational therapist will refer patients to a short rheumatologist consultation if confirmation of diagnosis or intra-articular injections of long-acting Corticosteroid are needed.
223602139|NCT00122369|BEHAVIORAL|Empathic Attention|A research assistant displayed defined behaviors of empathic attention.
223602140|NCT02146391|DRUG|Androxal 25 mg Capsules|
223602141|NCT01189591|DEVICE|Slow-wave deprivation|Using acoustic tones to suppress slow-wave sleep
223602142|NCT00003569|DRUG|cisplatin|
223602143|NCT00003569|DRUG|dimesna|
223602144|NCT00003569|DRUG|paclitaxel|
223602145|NCT00999518|BIOLOGICAL|Tanezumab|1 mg dose given subcutaneously twice at an 8-week interval.
223749942|NCT01587495|DRUG|Ertapenem|Ertapenem will be administered by intravenous infusion per the FDA approved standard of care (1 gram q24 hours). as follows:
223749943|NCT03266068|GENETIC|DNA Analysis of Blood Sample|DNA analysis of the genes possibly involved in IBS.
223749944|NCT03266068|PROCEDURE|Flexible sigmoidoscopy with colonic biopsies|Endoscopy of the subject's lower colon in which biopsies of the lining of the colon will be taken.
223749945|NCT03266068|PROCEDURE|Small bowel and colonic gastrointestinal permeability|A validated scintigraphic method to measure gastric, small bowel and colonic transit will be used.
223749946|NCT03266068|DIAGNOSTIC_TEST|Stool sample analysis|Stool samples will be used to extract supernatants. These supernatants will be studied in using chamber set-up to determine barrier effects on T84 monolayers.
223749947|NCT02280980|OTHER|Oculomotor and Gaze Stability Exercises|Daily oculomotor and gaze stability exercises, twice a day, for three weeks
224075314|NCT03609372|BEHAVIORAL|The STOP-HPV Trial 6: Maintenance|In this period, study team support will be withdrawn after previous bundled intervention (including HPV vaccine communication, performance feedback and provider prompts) was given to reduce MOs and increase HPV vaccination rates.
224075315|NCT00159432|DRUG|Oxaliplatin|
224075316|NCT00159432|DRUG|Bevacizumab|
224075317|NCT00159432|DRUG|Capecitabine|
224075318|NCT05736588|BEHAVIORAL|Elimisha HPV|Elimisha HPV is a multi-level stigma-responsive cervical cancer prevention service delivery model that incorporates stigma-responsive education, peer navigation and a patient-centered delivery strategy, addressing drivers while mitigating harms from stigma.
224200050|NCT06143683|PROCEDURE|Early Mobilization|On post-operative day (POD) 1, active range of motion exercises of the elbow joint will be initiated under the observation and guidance of the physical therapy team. On POD 3, the patient will be transitioned to active as well as active-assisted range of motion exercises. The physical therapy team will provide an exercise sheet handout to patients (Appendix 5) and encourage patients to do the exercise for 10 repetitions, 2 times a day, holding each stretch for 30 seconds. On POD3, patients with non-meshed sheet hand grafts will undergo active range of motion exercises of the hands under the observation and guidance of the physical therapy team. On POD 5, the patient will be allowed to move the extremity as tolerated with no restrictions.
224200051|NCT06143683|PROCEDURE|Late Mobilization|Following surgery, the patient's grafted upper extremity will be immobilized using an elbow flexion blocking splint. From POD 1 to 4, the patient's affected extremity will be kept elevated and immobilized with a flexion blocking splint. On POD 5, the patient will be allowed to move the extremity as tolerated with no restrictions. The physical therapy team will guide the patient on POD5 through range of motion exercises, starting with active, then active assisted, then passive as tolerated.
224200052|NCT00826176|DRUG|Sugammadex|After induction of anesthesia an intubation dose of 0.6 mg/kg rocuronium was to be administered. Maintenance doses of 0.1-0.2 mg/kg rocuronium intravenous (IV) could have been administered if necessary. At 1-2 PTC after the last administration of rocuronium, an IV single bolus dose of 4.0 mg/kg sugammadex was to be administered.
224200053|NCT02543229|DRUG|OPT-302|OPT-302 will be administered by intravitreal injection once every month for 3 months
224200054|NCT02543229|DRUG|Lucentis™|Lucentis™ (0.5 mg) will be administered by intravitreal injection once every month for 3 months
224200055|NCT02406365|DEVICE|Diagnostic imaging aid for one-visit management of cervical lesions|
224200056|NCT01921725|DEVICE|hydrophilic-based dressing (KoCarbonTM)|"BCT Hydrophilic Wound Dressing consists of PET non-woven, activated carbon fiber (ACF) cloth and PE film. The PET non-woven is vapor permeable to allow air exchange for the wound. The absorbent ACF absorbs exudate, bacteria and odor to create an effective barrier. Furthermore, far infrared ray (FIR) emitted from ACF accelerates blood circulation and metabolism to reduce healing period. The PE film helps to minimize wound trauma at dressing changes."
224200057|NCT03593239|OTHER|Tobacco flavored JUUL 1.7% ENDS|Treatment with Tobacco flavored JUUL 1.7% ENDS (10 puffs)
224200058|NCT03593239|OTHER|Tobacco flavored JUUL 5% ENDS|Treatment with Tobacco flavored JUUL 5% ENDS(10 puffs)
224200059|NCT03593239|OTHER|Mint flavored JUUL 1.7% ENDS|Treatment with Mint flavored JUUL 1.7% ENDS(10 puffs)
224200060|NCT03593239|OTHER|Mint flavored JUUL 5% ENDS|Treatment with Mint flavored JUUL 5% ENDS(10 puffs)
224200061|NCT03593239|OTHER|Fruit Medley flavored JUUL 1.7% ENDS|Treatment with Fruit Medley flavored JUUL 1.7% ENDS(10 puffs)
224200062|NCT03593239|OTHER|Fruit Medley flavored JUUL 5% ENDS|Treatment with Fruit Medley flavored JUUL 5% ENDS(10 puffs)
224200063|NCT03593239|OTHER|Crème brulee flavored JUUL 1.7% ENDS|Treatment with Crème brulee flavored JUUL 1.7% ENDS(10 puffs)
224200064|NCT03593239|OTHER|Crème brulee flavored JUUL 5% ENDS|Treatment with Crème brulee flavored JUUL 5% ENDS(10 puffs)
224200065|NCT03593239|OTHER|JUUL 1.7% ENDS 10 puffs vs. ad lib puffs|Treatment with JUUL 1.7% ENDS 10 puffs vs. ad libitum puffs
224200066|NCT03593239|OTHER|JUUL 5% ENDS 10 puffs vs. ad lib puffs|Treatment with JUUL 5% ENDS 10 puffs vs. ad libitum puffs
224200067|NCT00317967|DRUG|Atorvastatin|80 mg pills daily
224200068|NCT00317967|DRUG|Placebo|80 mg pills daily
223507610|NCT06481969|PROCEDURE|Lower abdominal liposuction and preparation of SVF|After lower abdominal liposuction (the liposuction volume is about 100 ml), the preparation and quality inspection of SVF will be completed by a laboratory with good manufacturing practice-approved facilities immediately. The adipose tissue will be cut into pieces of about 1mm3, and the equal volume of 0.1% collagenase I will be added to digest the adipose tissue. The digestion will be terminated after 40 minutes, followed by isolation, filtration, centrifugation, resuspension and dilution to obtain the SVF suspension. The test items, including bacteria, fungi, viruses and endotoxin, will be tested, and the expression of SVF surface markers, including CD45, CD34, CD31, CD11b, CD44, CD73, CD105 and CD90, will be detected by flow cytometry to ensure the quality of the SVF suspension. After about 4 hours of quality control and detection, the SVF suspension will be transported to the operating room on ice in a sealed incubator.
223507611|NCT06481969|PROCEDURE|Ovarian injection|Under ultrasound guidance, the SVF suspension will be injected into patients' bilateral ovaries. SVF with a total amount of (1\~2)×107 cells from autologous fat tissue will be transplanted into each side of ovary. There are 3 injection points on each side of ovary, and 330±10μl SVF suspension will be administered at each point. The administration volume of each ovary will be 1ml in total. After injection, the patients will be required to lie flat for 2 hours to observe whether there would be adverse events.
223507612|NCT05288257|BEHAVIORAL|Learning Module|Safe Cholecystectomy Learning Module
223507613|NCT02868528|GENETIC|chromosome screening with NGS technology|
223507614|NCT00005774|DRUG|Early surfactant|Early surfactant followed by extubation within 30 minutes and application of continuous positive airway pressure (CPAP)
223507615|NCT00005774|DRUG|Standard practice|Surfactant according to current center practice, only after initiation of mechanical ventilation.
223507616|NCT01941056|BIOLOGICAL|multi-CMV epitope modified vaccinia Ankara vaccine|Given IM
223507617|NCT01941056|OTHER|laboratory biomarker analysis|Correlative studies
223507618|NCT02746939|BEHAVIORAL|InSciEd Out Fitness and Nutrition Curriculum|Science curriculum is designed in partnership with 3rd and 4th grade teachers and InSciEd Out scientists. The curriculum is designed to focus on inquiry driven science, and also aims to decrease high risk behaviors that can lead to obesity in the students.
223507619|NCT00543465|DRUG|MK0782|
223507620|NCT05472298|BEHAVIORAL|self-management intervention|lifestyle modification, goal setting, coaching and peer support, problem-solving
224200069|NCT05296369|DRUG|Folic acid|Folic acid was added during the period prior to concurrent chemoradiotherapy
224200070|NCT00752401|DRUG|Cholecalciferol|6800 IU of Cholecalciferol will be administered in the form of Oleovit® D3-drops once a day for one year. Treatment starts on day 5 after kidney transplantation. At serum calcium levels \>2,65 mmol/l vitamin D3 administration will be reduced to 3600 IU per day. If calcium levels persist above 2,85 mmol/l over a period of four weeks vitamin D3 administration will be discontinued and restarted when serum calcium levels declined to ≤ 2,65 mmol/l with only 3600 International Units per day.
223749948|NCT04929652|DRUG|Surufatinib,Camrelizumab,Irinotecan,GM-CSF|"1. Dose climbing stage design (n=12) :~   Surufatinib: Oral, 3w.The initial dose of 250mg/ day (n=6) : If 2 out of 6 patients developed \> DLT in the first treatment cycle, the exploratory dose was 200 mg/ day; if ≤2 out of 6 patients developed DLT, the exploratory dose was 300mg/ day (n=6);At the next dose phase, if 2 out of 6 patients with \> developed DLT, the previous dose was recommended or the study was terminated;If no more than 2 out of 6 patients developed DLT, the dose was the recommended dose；PD-1,200mg, iv,D1, 3w；Irinotecan: 200mg/㎡, iv, D1, 3w；GM-CSF,D2, D3, D4, D5, D6 and D7 in the first week of each cycle ；~2. Dose expansion phase design(n=36):~   1. Surufatinib: Oral, 3w. the dose was set according to the recommended dose in the dose climbing stage;~  2. PD-1(Camrelizumab) : 200mg, iv,D1, 3w;~  3. Irinotecan: 200mg/㎡, iv, D1, 3w;~  4. GM-CSF: continuous administration of D2, D3, D4, D5, D6 and D7 in the first week of each cycle, 5ug/kg once per body weight, once a day, 3w."
223602146|NCT00999518|BIOLOGICAL|Tanezumab|2.5 mg dose given subcutaneously twice at an 8-week interval.
223602147|NCT00999518|BIOLOGICAL|Tanezumab|10 mg dose given subcutaneously twice at an 8-week interval.
223602148|NCT00999518|BIOLOGICAL|Tanezumab|20 mg dose given subcutaneously twice at an 8-week interval.
223602149|NCT00999518|OTHER|Placebo|Placebo dose given subcutaneously twice at an 8-week interval.
223602150|NCT01918059|PROCEDURE|Tissue Adhesive skin closure|The approach to repair will follow standard technique. If eyelid marginal component is present, margin repair will be performed with two 6-0 interrupted silk sutures: one at the gray line and one at the lash line. If the tarsus requires reapproximation, this will carefully be done using interrupted polyglactin vicryl sutures. The superficial skin will then be repaired with tissue adhesive (octyl-2-cyanoacrylate).
223749949|NCT02474199|BIOLOGICAL|darTregs|A single intravenous infusion as described administered over a 20-30 minute interval with close monitoring prior to, during, and after the infusion.
223749950|NCT02474199|DRUG|Acetaminophen|Pre-medication for darTregs infusion. A dose of 15 mg/kg will be administered 30 to 60 minutes prior to the darTregs infusion.
223749951|NCT02474199|DRUG|Diphenhydramine|Pre-medication for darTregs infusion. A dose of 1-2 mg/kg diphenhydramine will be administered 30 to 60 minutes prior to the darTregs infusion.
223749952|NCT02474199|DRUG|Immunosuppression (IS) Withdrawal|"Subjects:1.) who fulfill study eligibility criteria will withdraw IS 2.) enter the study on calcineurin inhibitor (CNI) monotherapy or a CNI-based regimen with either Prednisone or MMF as a second IS medication 3.) will proceed with changes in CNI dosing according to the protocol's CNI withdrawal algorithm.During the last 2 weeks of IS withdrawal (e.g., Step 2 in algorithm -CNI reduced 25%-pre darTregs), a single dose of darTregs will be infused IV. The subject will then, if eligible, proceed with IS withdrawal within 2 weeks after the infusion. Eligible subjects meeting the primary endpoint of 75% reduction in CNI from baseline after darTregs will be offered the opportunity to continue IS withdrawal until complete discontinuation of IS."
223749953|NCT02474199|PROCEDURE|Study Mandated Procedures|Blood draws (venipuncture); collection of peripheral blood mononuclear cells (PBMCs) by a procedure known as leukapheresis or venipuncture; buccal (cheek) swab for HLA typing; liver biopsies (per protocol and for cause).
223749954|NCT00691496|BEHAVIORAL|Behavioral intervention to reduce sexual risk among African-American men who have sex with men|5 week intervention to increase skill level of participants with talking to their social networks and sexual partners about reducing high risk sexual behaviors while preparing a healthy meal
223749955|NCT04113499|PROCEDURE|Direct Endoscopic Intervention|"The necrotic collection is first identified using a linear echoendoscope. A Hot AXIOS stent is utilized in all patients for EUS-guided drainage of the necrotic collection. The necrotic material is sent for gram stain and culture with sensitivities.~For endoscopic necrosectomy, in patients allocated to direct endoscopic necrosectomy group, endoscopic necrosectomy is performed during the same session as the index endoscopic drainage. It is performed using a therapeutic gastroscope and various accessories (see below for further details) for 90 to 120 minutes."
224200071|NCT00752401|DRUG|Placebo|An oral placebo solution matching Cholecalciferol in terms of appearance, smell and taste will be administered once a day for one year. Treatment starts on day 5 after kidney transplantation.
224200072|NCT06079801|DEVICE|Transcranial direct current stimulation (tDCS)|TDCS was delivered by a DC-Stimulator (Newronika, Italy) over both DLPC. The electrodes (35 cm2) were soaked in 0.9% NaCl. The anode was positioned on the left dorsolateral prefrontal cortex and the cathode on the right dorsolateral prefrontal cortex.
223602151|NCT01918059|PROCEDURE|Absorbable suture skin closure|The approach to repair will follow standard technique. If eyelid marginal component is present, margin repair will be performed with two 6-0 interrupted silk sutures: one at the gray line and one at the lash line. If the tarsus requires reapproximation, this will carefully be done using interrupted polyglactin vicryl sutures. The superficial skin will then be repaired with absorbable sutures (surgical gut).
223602152|NCT01918059|PROCEDURE|Non-absorbable suture skin closure|The approach to repair will follow standard technique. If eyelid marginal component is present, margin repair will be performed with two 6-0 interrupted silk sutures: one at the gray line and one at the lash line. If the tarsus requires reapproximation, this will carefully be done using interrupted polyglactin vicryl sutures. The superficial skin will then be repaired with either non-absorbable sutures (6-0 polypropylene).
224200073|NCT06079801|DRUG|anti-CGRP-mAbs|CGRP-mAbs have been the first target-driven treatment to be approved for migraine prevention. Their efficacy and safety have been demonstrated in randomized controlled trials (RCT) as well as, in real-world evidence (RWE) studies
223602153|NCT00496639|PROCEDURE|angioplasty|Balloonplasty of the stenotic lesion at the venous anastomosis of the thrombosed AV graft.
223602154|NCT00496639|PROCEDURE|stent placement|Balloonplasty plus stent deployment at the stenotic lesion at the venous anastomosis of the thrombosed AV graft
223602155|NCT05003596|DRUG|Methylprednisolone Tablet|Subjects will take a quantity 21 4mg tablets over a 6 week taper.
223602156|NCT05003596|OTHER|Standard Mobilization Treatment|standard treatment of hand injuries with focus on mobilization. No anti-inflammatory medications. Pain management via Tylenol or narcotics if deemed necessary.
223602157|NCT02055300|DRUG|LY03005|
223602158|NCT02055300|DRUG|Placebo|
223602159|NCT02055300|OTHER|Meal|
223602160|NCT02055300|DRUG|Pristiq|
223602161|NCT01679886|RADIATION|Rubidium PET|Rubidium PET
223602162|NCT02770300|DEVICE|Arm Light Exoskeleton Rehab Station (ALEx RS)|ALEx RS is a complete system specifically designed to support the rehabilitation of stroke patients. In particular, this system is equipped with a robotic arm exoskeleton conceived for the force assistance, integrated in a Virtual Reality system that allows implementing rehabilitative exercises highly interactive and engaging for the patients. It is proven that the use of this type of devices in rehabilitation can provide high intensive, repetitive, task specific, and interactive treatment of the impaired arm and an objective and reliable mean for monitoring patients' progress.
223602163|NCT02770300|DEVICE|Arm Light Exoskeleton Rehab Station (ALEx RS) - automatically personalized|ALEx RS is a complete system specifically designed to support the rehabilitation of stroke patients. In particular, this system is equipped with a robotic arm exoskeleton conceived for the force assistance, integrated in a Virtual Reality system that allows implementing rehabilitative exercises highly interactive and engaging for the patients. It is proven that the use of this type of devices in rehabilitation can provide high intensive, repetitive, task specific, and interactive treatment of the impaired arm and an objective and reliable mean for monitoring patients' progress. The movements to be performed by the patient are automatically decided by the exoskeleton.
223602164|NCT05905731|BIOLOGICAL|TCR-T|"Stage-1: Patients will receive three biweekly HBV-TCR T cell infusions at escalating doses, ranging from 1 x 10\^5 cells/kg to 5 x 10\^6 cells/kg bodyweight (by IV infusion). Patients are to remain on existing HBV NUC treatment.~Stage-2: Patients will receive three biweekly HBV-TCR T cell infusions at maximum dose as determined in Stage-1 study. Patients are to remain on existing HBV NUC treatment."
223602165|NCT00544427|DEVICE|Optical coherence tomography|Optical coherence tomography imaging
223749956|NCT04113499|PROCEDURE|Step-up Endoscopic Intervention|"The necrotic collection is first identified using a linear echoendoscope. A Hot AXIOS stent is utilized in all patients for EUS-guided drainage of the necrotic collection. The necrotic material is sent for gram stain and culture with sensitivities.~In patients allocated to the step-up endoscopic interventions group, endoscopic necrosectomy is not performed at the time of the index intervention, however it is performed when clinically indicated during the follow-up period (6 months from index intervention)."
223749957|NCT00458653|BIOLOGICAL|Dendritic Cell Tumor Fusion|"Post-Transplant (Groups A and B): Given under the skin every four weeks for three doses.~Pre-Transplant (Group B): Injected under the skin in upper part of leg or arm prior to stem cell collection for ASCT"
223749958|NCT06301100|OTHER|Dual energy CT after routine simulation|Dual energy CT after routine simulation
223749959|NCT03090100|DRUG|Guselkumab|Participants will receive 1 injection of active guselkumab at Weeks 0, 4, 12, 20, 28, 36, and 44.
223749960|NCT03090100|DRUG|Placebo|Participants will receive 1 injection of placebo at Weeks 0, 4, 12, 20, 28, 36, and 44 and 2 injections of placebo at Weeks 1, 2, 3, 8, 16, 24, 32, and 40.
223749961|NCT03090100|DRUG|Secukinumab|Participants will receive 2 injections of active secukinumab at Weeks 0, 1, 2, 3, 4 and every 4 weeks (q4w) thereafter through Week 44.
223749962|NCT05828277|DRUG|repotrectinib (TPX-0005)|Oral repotrectinib (TPX-0005)
223749963|NCT05925491|DRUG|Pembrolizumab|Pembrolizumab administration in combination with chemotherapy for 3 cycles, followed by standard of care
223749964|NCT05925491|DRUG|Cisplatin|Cisplatin 75mg/mq in combination with pembrolizumab 200 mg and docetaxel 75 mg/mq every three weeks (Q3W) for 3 courses.
224200074|NCT04430101|PROCEDURE|Minimally invasive stabilization of Lisfranc injuries|Patients with positive weightbearing radiographs will be operated by minimally invasive stabilization (eg, isolated homerun screw)
223749965|NCT05925491|DRUG|Docetaxel|Docetaxel 75 mg/mq in combination with pembrolizumab 200 mg and cisplatin 75 mg/mq every three weeks (Q3W) for 3 courses.
223749966|NCT05925491|DRUG|Carboplatin|Carboplatin AUC 5 alternative to Cisplatin if toxicities occur.
223749967|NCT02047799|DIETARY_SUPPLEMENT|Calcitriol|Subjects whom were enrolled for 6 weeks of treatment with a daily dose of Calcitriol (1000 UI)
223749968|NCT02047799|DIETARY_SUPPLEMENT|Control|Subjects whom were enrolled for 6 weeks of treatment with a daily dose of Placebo
224075319|NCT05079490|BEHAVIORAL|motor intervention|gross motor skill intervention combined with fitness training
224075320|NCT01677247|DRUG|Group I (Test) : Glimepiride 4 mg tablet of PT Dexa Medica|In each of the two study periods (separated by a washout of one week) a single dose of test or reference product was administered.
224075321|NCT01677247|DRUG|Group II (Reference) : glimepiride (Amaryl) 4 mg tablet of PT Sanofi Aventis|In each of the two study periods (separated by a washout of one week) a single dose of test or reference product was administered.
224075322|NCT01200784|DRUG|Nicotinamide|dosage
224075323|NCT05366699|PROCEDURE|axillary lymphadenectomy with immediate lymphatic reconstruction (LYMPHA)|lymphatic reconstruction where the cut lymphatic vessels are reconstructed by anastamosing to the veins
224075324|NCT05366699|PROCEDURE|Axillary lymphadenetomy alone|oncologic axillary lymphadenectomy
224075325|NCT05366699|PROCEDURE|axillary lymphadenectomy with soft tissue reinforcement|axillary lymphadenectomy with soft tissue reinforcement(STR)
224075326|NCT06222944|DRUG|Anlotinib|Anlotinib: 12mg PO, QD, D1-14, Q3W;
224075327|NCT06222944|DRUG|TQB2450|TQB2450: 1200 mg, IV, D1, Q3W
224075328|NCT06222944|DRUG|Albumin-Bound Paclitaxel|125mg/m2 IV D1,8，Q3W
224075329|NCT01842503|DRUG|GET 73|300 mg tid on 3 days cycle
224075330|NCT01842503|DRUG|inactive ingredients capsule|3 capsules tid on 3 days cycle
224075331|NCT06282458|DRUG|Enobosarm|Enobosarm is an oral, new chemical entity class, SARM, that has demonstrated tissue-selective, dose-dependent improvement in body composition with increases in muscle mass and reduces fat mass, improves insulin resistance, has no masculinizing effects in women, has neutral prostate effects in men, and no increases in hematocrit. Increases in muscle mass have resulted in improvements in muscle strength and physical function.
224075332|NCT06282458|DRUG|Semaglutide|Semaglutide for Chronic Weight Management
224075333|NCT00796471|DRUG|Paliperidone ER|
224075334|NCT05754918|DEVICE|TnoFs then TFS (Cochlear implant)|Cochlear implant with tonotopy-based fitting without fine structure coding then with fine structure coding
224075335|NCT05754918|DEVICE|TFS then TnoFS (Cochlear implant)|Cochlear implant with tonotopy-based fitting with fine structure coding then without fine structure coding
224075336|NCT03403699|BIOLOGICAL|Generation of inducible pluripotent stem cells|Generation of inducible pluripotent stem cells from peripheral blood cells.
223749969|NCT06438861|DRUG|Vibegron 75mg|Each patient will undergo intradetrusor onabotulinumtoxinA injections of 100U either in the office or in the operating room depending on patient and provider preference. Patients will begin taking vibegron 75mg daily or a placebo pill daily starting the day of their procedure and continue for 3 months.
223749970|NCT06438861|DRUG|Placebo|Each patient will undergo intradetrusor onabotulinumtoxinA injections of 100U either in the office or in the operating room depending on patient and provider preference. Patients will begin taking vibegron 75mg daily or a placebo pill daily starting the day of their procedure and continue for 3 months.
223749971|NCT01438970|DEVICE|ALFApump system|The device described above will be implanted using general anaesthesia. The device will be programmed according to each patient's individual requirements, setting the daily loss of ascitic fluid needed to maintain a stable body weight.
223749972|NCT00159588|DRUG|Betablockers or other preventive drugs based on primary headache type|Several preventive drugs based on each individual regarding type of original headache type (i.e angiotensin II blockers, betablockers, valproate, tricyclic antidepressants or gabapentin)
223749973|NCT06424886|OTHER|Landing error scoring system (LESS)|Each group will perform two training blocks of 10 drop vertical jumping (DVJ) tasks. Knee joint position sense (KJPS), frontal plane projection angle (FPPA), and Landing Error Scoring System (LESS) assessments will be performed before and after the training blocks, and follow-up assessments will be performed 1 week later. The dominant limb of the participants (the side limb they use when kicking the ball) will be taken into account during the measurement.
223749974|NCT01660711|DRUG|5 Fluorouracil|2400 mg/m2 by continuous intravenous infusion over 46 hours
223749975|NCT01660711|DRUG|Leucovorin|400 mg/m2 by IV infusion over 2 hours
223749976|NCT01660711|DRUG|Irinotecan|180 mg/m² IV infusion on Day 1 over 90-120 minutes (infusion via a Y connector during the infusion of leucovorin)
223749977|NCT01660711|DRUG|Oxaliplatin|85 mg/m² IV infusion on Day 1 over 2 hours
223749978|NCT01626261|DEVICE|Magnetic and electric field´s impact on the implant|Examination of magnetic and electric field's impact on the implant regarding: stability detection threshold using different strength of magnetic and electric field
223749979|NCT02727348|PROCEDURE|Sciatic with or without femoral block|Sciatic with or without femoral block performed either with ultrasound and/or nerve stimulator on the patient with 3mg/kg of ropivacaine
223749980|NCT02727348|PROCEDURE|Spinal anaesthesia|Spinal anaesthesia with up to 3mls of 0.5% bupivacaine
223749981|NCT03460587|DEVICE|Telerehabilitation|The Telerehabilitation system will deliver rehabilitation treatment sessions via an in-home internet-connected computer. A major component of the system is the use of games to promote therapeutically relevant movements. The subject will perform daily assigned home-based telerehabilitation games and exercises and 5 minutes of stroke education, all guided by the telerehabilitation system.During some of the sessions, therapists will initiate a videoconference with the subject's telerehabilitation system to discuss progress, issues, and revise treatment plans as needed.
223749982|NCT01571661|DRUG|GSK189075A|20mg, 50mg, 150mg, 500mg, 1000mg or Placebo
223749983|NCT01571661|OTHER|Placebo|Placebo
223749984|NCT00079833|DRUG|Esomeprazole magnesium (Nexium)|
223602166|NCT03617146|BEHAVIORAL|Health coaching|The intervention will seek to help participants express their diabetes emotional needs and to work with them to figure out what can be done to meet those needs. Depending on the unique needs of each participant, the coaching approach for this study will include: improving motivation and self-efficacy for diabetes management using motivational interviewing and appreciative inquiry; building trust and rapport through mindful listening, open-ended inquiry, and perceptive reflections; and expressing empathy through nonviolent communication. Each participant will receive eight individual coaching sessions over a five month period. All coaching sessions will be delivered over the phone (i.e. telecoaching). The coaching intervention will be done by a certified health and wellness coach.
223602167|NCT03617146|OTHER|Diabetes Distress-specific Education|A diabetes distress-specific education that explains what diabetes distress is, why it matters, and its four domains. In addition, the participant is given feedback on his or her distress score and advised on ways to deal with the areas of greatest distress. Participant is linked with resources to overcome any expressed needs. The education is provided by a trained medical assistant.
223602168|NCT04891484|DRUG|Ondansetron group|patients will be injected with 4 mg Ondansetron diluted with normal saline IV 5 minutes before spinal anesthesia
223602169|NCT04891484|DRUG|Saline group|patients will be injected with 10 ml normal saline intravenous 5 min before spinal anesthesia
223602170|NCT00332228|DRUG|depot naltrexone|long-acting depot parenteral formulation of naltrexone
223602171|NCT00332228|BEHAVIORAL|Compliance enhancement (CE)|Compliance enhancement (CE), simulating standard treatment with oral naltrexone
223602172|NCT00332228|DRUG|BNT|behavioral therapy with oral naltrexone maintenance for the treatment of heroin addiction
223602173|NCT01088399|DRUG|Somatropin (rDNA origin)|Dose, frequency and duration are at discretion of attending physician, and determined on an individual basis.
223602174|NCT02825199|DIETARY_SUPPLEMENT|Caffeine|capsule: 300mg caffeine
223602175|NCT02825199|DIETARY_SUPPLEMENT|Non caffeine|capsule: placebo (maize starch)
223602176|NCT03186417|BIOLOGICAL|2 million hMSC/kg|2 million hMSCs/kg infusion
223602177|NCT03186417|BIOLOGICAL|4 million hMSC/kg|4 million hMSC/kg infusion
223602178|NCT03186417|BIOLOGICAL|6 million hMSC/kg|6 million hMSC/kg infusion
223602179|NCT03186417|BIOLOGICAL|placebo|placebo infusion
223602180|NCT02861599|OTHER|proprioceptive therapy|
223602181|NCT02861599|OTHER|speech therapy|
223602182|NCT04832880|DRUG|Baricitinib Oral Tablet [Olumiant]|Baricitinib 4 mg die (2 mg for patients aged \> 75 years) for 10 days.
223602183|NCT04832880|DRUG|Remdesivir|Intravenous remdesivir 200 mg on day 1, followed by remdesivir 100 mg die until day 10
223602184|NCT04832880|DRUG|Dexamethasone|Intravenous dexamethasone 6 mg for 10 days
223602185|NCT06141265|DRUG|Niraparib|The starting dose is 300mg or 200mg QD based on the subject's baseline body weight or baseline platelet count
223602186|NCT06333366|DEVICE|Intra-gastrointestinal monitoring device (PDT)|The PressureDOT(PDT) is an active intra-gastrointestinal device, that is intended to be introduced in the gastrointestinal tract, approximately along whole. The device is battery powered. The signal is wirelessly transmitted through outside the body and received by waist receiver, using an antenna array applied to the skin with a protection guard at the level of the abdomen.
223602187|NCT03752749|OTHER|Prednisolone + Acute Intermittent Hypoxia|Administration of oral prednisolone followed by 15, 60-second bouts of mild hypoxia
223602188|NCT03752749|OTHER|Placebo + Acute Intermittent Hypoxia|Administration of oral matching placebo followed by 15, 60-second bouts of mild hypoxia
223602189|NCT03120715|DRUG|estrogen|The oral estrogen replacement is 4mg per day (2 mg twice daily), 4 days; 6 mg per day, 4 days. Then, the patient's endometrial thickness is evaluated through vaginal ultrasound and if the endometrial thickness is \<7 mm, increasing estrogen by 2 mg is given to patients until the endometrial thickness is \>9 mm.
223749985|NCT04069403|OTHER|Automated Reports on prescription patterns for their patients|de-identified aggregate reports
223749986|NCT06368674|OTHER|Intervention group Case Manager (CM)|The CM will be informed about the discharge plan from the nurse at the geriatric ward, as will the municipality for those with need of home help care. An outline of the intervention has been created with managers from primary care and rehabilitation within primary care and municipality care. Core components in the intervention will be active follow-up of the discharge, rehabilitation and care plans. If there are plans that have not been executed or unmet needs, the CM will take adequate contacts to ensure that actions are made to meet the needs. These contacts can be, e.g. the GP for medical needs, the rehabilitation unit in primary or municipality care for unmet rehabilitation needs, and the home help service for unmet care needs. The CM will have a network of contact persons in hospital, primary and community care, as well as in rehabilitation in primary and community care, in order to facilitate for prompt actions to meet the needs.
223749987|NCT06368674|OTHER|Control Group|The participants in the control group with a planned follow-up by a primary health care centre within the catchment area of the Sahlgrenska University Hospital that does not have CMs designated for active follow up of discharged frail older people. Thus, the participants in the control group will not actively be followed-up after discharge.
223749988|NCT04920123|DEVICE|Neuro-World|Neuro-World is a collection of six games that are developed for cognitive training that focuses on memory and attention.
223749989|NCT00136149|PROCEDURE|Immediate implants|Immediate implants are used.
223749990|NCT06436846|OTHER|Biospecimen sample collection during standard-of-care surgery|Patients in this observational study are undergoing planned surgical resection of their retroperitoneal sarcoma as prescribed by their primary surgeon and treatment team. In addition to removal of the primary tumor, surgeons remove 4 samples of retroperitoneal fat and a sample of subcutaneous fat for further study at the time of the operation.
223749991|NCT05696834|PROCEDURE|Sclerotherapy With Adjuvant Bone Marrow Injection In Management of Aneurysmal Bone Cyst|Sclerotherapy With Adjuvant Bone Marrow Injection In Management of Aneurysmal Bone Cyst
223749992|NCT04173117|DIETARY_SUPPLEMENT|Low energy meal replacement plan (12 weeks)|Low energy meal replacement plan (12 weeks)
223749993|NCT02599181|OTHER|propanol-biphenol: Kodan|WITH-group, the skin is disinfected with an aerosolized alcoholic solutionpropanol-biphenol: Kodan, Schülke \& Mayr, Zurich, Switzerland.
223749994|NCT04537858|DEVICE|Virtual reality therapy first|First day of the protocol with Virtual Reality intervention in the morning and conventional intervention in the afternoon
223749995|NCT04537858|DEVICE|Conventional therapy first|First day of the protocol with conventional intervention in the morning and Virtual Reality intervention in the afternoon
223749996|NCT04220372|DRUG|Tongxinluo|Provided by Shijiazhuang Yiling Pharmaceutical CO., LTD
223749997|NCT04220372|DRUG|Placebo|Provided by Shijiazhuang Yiling Pharmaceutical CO., LTD
223749998|NCT05993611|PROCEDURE|Biopsy|Undergo biopsy
223749999|NCT05993611|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223750000|NCT05993611|BIOLOGICAL|Chimeric Antigen Receptor T-Cell Therapy|Given CD6-CAR Tregs IV
223602190|NCT03120715|DRUG|Low Molecular Weight Heparin|If the endometrial thickness is greater than 9 mm, hCG 10000 IU will be administered via intramuscular injection.And low molecular weight heparin (LMWH) will be injected subcutaneously 4100 IU (WHO) every other day before FET.Then on the next day(D0), progesterone in oil 60 mg will be administered via intramuscular injection. Transfer of thawed embryos will be performed 3 days later(D3).
223750001|NCT05993611|PROCEDURE|Computed Tomography|Undergo CT
224200075|NCT04430101|PROCEDURE|Conservative treatment|Patients with negative weightbearing radiographs will be treated conservatively
223602191|NCT03120715|DRUG|hCG|If the endometrial thickness is greater than 9 mm, Human Chorionic Gonadotropin（hCG） 10000 IU will be administered via intramuscular injection.
223602192|NCT03120715|DRUG|progesterone|on the next day(D0), progesterone in oil 60 mg will be administered via intramuscular injection. Transfer of thawed embryos will be performed 3 days later(D3).
223750002|NCT05993611|PROCEDURE|Echocardiography|Undergo ECHO
223750003|NCT05993611|OTHER|Electronic Health Record Review|Ancillary studies
223750004|NCT05993611|PROCEDURE|Leukapheresis|Undergo leukapheresis
223750005|NCT05993611|PROCEDURE|Lumbar Puncture|Undergo lumbar puncture
223750006|NCT05993611|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI/CT
223750007|NCT05993611|OTHER|Quality-of-Life Assessment|Ancillary studies
223750008|NCT05993611|BIOLOGICAL|Tafasitamab|Given IV
223750009|NCT05993611|PROCEDURE|X-Ray Imaging|Undergo x-ray imaging
224075337|NCT03508310|OTHER|Taking Care of Me Video|The video's conceptual framework incorporates Social Cognitive Theory, Information-Motivation-Behavioral Skills model, and Social Action Theory, which together address cognitive and behavioral factors related to study outcomes. Storylines embedded prevention messages aimed at increasing treatment initiation (n=9), medication adherence (n=35), retention in care (n=22), partner protection (n=12), and communication with health care providers (n=7).
224075338|NCT05607823|OTHER|Core Stabilization Training|Core Stabilization training will be based on dynamic neuromuscular stabilization and consists of three stages. In the first session, it is to teach the simultaneous activation of the transversus abdominis, pelvic floor, multifidus and diaphragm muscles and to improve muscle coordination and proprioception in the entire spinal region. In the second and third phases, exercises will be made more intense to improve muscular endurance and stability. The difficulty of the exercises will be increased by working in different positions, using resistance bands, exercise balls and body weight, and adding movements to the extremities. A total of 10 sessions of treatment program will be applied to the patients for ten weeks, once a week.
223750010|NCT01998048|PROCEDURE|Latarjet|A diagnostic arthroscopy is performed before the Latarjet operation in general anaesthesia. In case of a significant Hill-Sachs defect an additional remplissage procedure may be performed according to surgeons' decision by inserting 1 to 2 more suture anchors according to surgeon's preference into the deepest portion of the Hill-Sachs defect and tying the infraspinatus tendon down to fill the bony defect. Thereafter an open Latarjet operation is performed using standard techniques described by Walch or de Beer. A deltopectoral incision is used. The coracoid process is osteotomized and ventrally prepared to bleeding bone. The coracoid process is then transferred through the middle of the subscapularis and re-attached on to the freshened neck of the glenoid, just medial to the joint line with two screws and washers, according to the surgeon's preference.
223602193|NCT00782483|DEVICE|ThermoVision A20M Infrared Camera|FLIR Systems, Boston, MA. This is a non invasive passive thermal imaging device with less than minimal risk to subjects and staff.
223602194|NCT00782483|DEVICE|ScleroPLUS|Sclerolaser, Candela Corp., Wayland, MA. This laser is approved by the food and drug administration (FDA) for treating PWS lesions and will be used as labeled.
223602195|NCT00782483|DEVICE|3D Digital Camera|3dMD, Atlanta, GA. Approved by the food and drug administration (FDA) for imaging patients and will be used as labeled.
223602196|NCT00774683|DRUG|Raltegravir (Isentress®)|400 mg p.o. BID x 7 days
223602197|NCT05313737|OTHER|Automated message|Automated message via phone call (audiocare)
223602198|NCT05313737|OTHER|Opt-out scheduling|Scheduling via non-automated phone call
223602199|NCT00349778|DRUG|Cyclophosphamide|Cyclophosphamide as a white powder in 100 mg, 200 mg and 500 mg vials, to be dissolved in \~250 mL of saline or D5W and infused IV over 2 hours
223602200|NCT00349778|DRUG|Etoposide|100 mg etoposide as 5 mL solution in clear ampules for injection.
223602201|NCT00349778|DRUG|Melphalan|Melphalan as single-use glass vials of freeze-dried melphalan hydrochloride (equivalent to 50 mg of melphalan), to be reconstituted in 0.9% sodium chloride solution to not greater than 0.45 mg/mL, and administered within 1 hour of constitution.
223602202|NCT00349778|DRUG|Carmustine|Carmustine as a powder for reconstitution in 100 mg vials, to be reconstituted with 3 mL sterile dehydrated ethanol and D5W. Carmustine should be dissolved in 500 mL of 5% dextrose in water (D5W) and infused IV over 2 hours.
223602203|NCT00349778|DRUG|Filgrastim|Filgrastim in vials of 300 µg or 480 µg at a concentration of 300 µg/mL, to be given as a daily subcutaneous injection.
223602204|NCT06071481|DRUG|Arm-2 : 2,00,000 IU Vitamin D3 oral solution , Arm-3: 4,00,000 IU Vitamin D3 oral solution|2,00,000 IU Vitamin D3 oral solution in the form of cholecalciferol 4,00,000 IU Vitamin D3 oral solution in the form of cholecalciferol
223602205|NCT00005030|DRUG|SCH 66336|
223602206|NCT00005030|PROCEDURE|conventional surgery|Exploratory laparotomy and/or resection of hepatic metastases. Patients randomized to no treatment may undergo surgery at any time within 15 days of randomization. Other patients undergo surgery on days 8-15.
223602207|NCT00541853|DRUG|Candesartan|Candesartan upto 8mg
223602208|NCT00541853|DRUG|Candesartan and Cilnidipine|Candesartan upto 8mg per day and Cilnidipine upto 20mg per day
223602209|NCT00541853|DRUG|Candesartan plus non-CCB agents|Candesartan upto 8mg per day and other antihypertensive drugs except CCB and ACEI
223602210|NCT03438136|BEHAVIORAL|Adult Broad Learning Experiment (ABLE)|"This intervention implements six factors from early childhood experiences: individualized scaffolding (having a responsive teacher), forgiving environment (allowing the learner to make and learn from mistakes), growth mindset (believing that abilities can develop with effort), open-minded learning (exploring new experiences), serious commitment to learning (adopting a learning lifestyle), and learning multiple skills simultaneously."
223602211|NCT04594928|DRUG|GLPG3667|GLPG3667 capsules
223602212|NCT04594928|DRUG|Placebo|Matching placebo capsules
223602213|NCT04534270|DRUG|Dapagliflozin|Dapagliflozin will be given 5mg per day (weight≤30kg) or 10mg per day (weight\>30kg), for 12 weeks
223602214|NCT02650102|DRUG|Risperidone|a kind of antipsychotics
223602215|NCT02650102|DRUG|Olanzapine|a kind of antipsychotics
223602216|NCT02650102|DRUG|Quetiapine|a kind of antipsychotics
223602217|NCT02650102|DRUG|Aripiprazole|a kind of antipsychotics
223602218|NCT02650102|DRUG|Ziprasidone|a kind of antipsychotics
223602219|NCT01893775|BIOLOGICAL|Hu-Mik- Beta-1|Hu-Mik-Beta-1 every 3 weeks for a total of 3 doses (given on day 1, week 3 and week 6)
223602220|NCT00595010|BEHAVIORAL|SafeCare|Treatment will be based on an updated version of the SafeCare program, which specifically addresses parenting and discipline associated with child physical abuse. Participants will receive services from Comprehensive Home-Based Services.
223602221|NCT00284362|PROCEDURE|Arthroscopic or open surgery for hallux rigidus|
223602222|NCT02036866|OTHER|Transcutaneous Electrical Nerve Stimulation|The TENS electrodes will be applied on the medial and lateral superior, as well as the medial and lateral inferior, borders of the patella. A continuous biphasic pulsatile current (150 Hz, phase duration 150 µs) will be applied at an intensity that produces a comfortable sensation but not a muscle contraction. The duration of intervention will be 8 hours per day for 1 week.
223602223|NCT02036866|OTHER|Physical Therapy Exercises|Patients will be given detailed verbal and hands-on instruction in a home exercise program. This program will consist of 6 exercises modeled from established protocols focuses on improving lower extremity strength. Patients will be instructed to do the exercises daily and to progress the exercises over the week for a maximum of 30 repetitions per day for 1 week.
223602224|NCT02036866|OTHER|No Intervention|Patients will be instructed to maintain their usual activity level.
223602225|NCT02419820|DRUG|APD791|Temanogrel
223602226|NCT02419820|DRUG|Clopidogrel|Clopidogrel
223602227|NCT02419820|DRUG|Aspirin|Aspirin
223602228|NCT02419820|DRUG|Placebo for APD791|Placebo for APD791
223602229|NCT04932642|BEHAVIORAL|HIIT+RT experimental group|Each experimental group will be compared with their another contrast order session group
223602230|NCT04932642|BEHAVIORAL|RT+HIIT experimental group|Each experimental group will be compared with their another contrast order session group
223602231|NCT03536507|DRUG|ACETAZOLAMIDE oral capsule|Administration of 1x125mg acetazolamide in the morning, 2x125mg in the evening, starting 24 hours before departure to 3'100m
223602232|NCT03536507|DRUG|Placebo oral capsule|Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3'100m
223602233|NCT04937283|PROCEDURE|Segmentectomy with systemic lymph node dissection|Segmentectomy with hilar and mediastinal lymph node dissection is performed. If the tumor located at inter-segment plane and without sufficient resection margin distance, a combined segmentectomy will be performed. Systemic or selective lymph node dissection is mandatory, and nodal sampling is not allowed. At least three stations of mediastinal lymph node from 2R, 4R, 7, 8, 9 for the right side and 5, 6, 7, 8, 9 for the left side, respectively. The distance from the dissection margin to the tumor edge must be evaluated intra-operatively. If the distance is either less than the maximum tumor diameter or 20 mm, the absence of cancer cells in the resection margin must be histologically or cytologically confirmed before finishing surgery.
223602234|NCT04937283|PROCEDURE|Lobectomy with hilar and mediastinal lymph node dissection|Lobectomy with hilar and mediastinal lymph node dissection is performed. Segmentectomy with hilar and mediastinal lymph node dissection is performed. Systemic or selective lymph node dissection is mandatory, and nodal sampling is not allowed. At least three stations of mediastinal lymph node from 2R, 4R, 7, 8, 9 for the right side and 5, 6, 7, 8, 9 for the left side, respectively. The distance from the dissection margin to the tumor edge must be evaluated intra-operatively. If the distance is either less than the maximum tumor diameter or 20 mm, the absence of cancer cells in the resection margin must be histologically or cytologically confirmed before finishing surgery.
223602235|NCT04833595|BEHAVIORAL|Mindfulness practice|Mindfulness is hypothesised to include reflective practice. Therefore, reflective questions are asked in the questionnaire for intervention group but not for control group.
223602236|NCT03044808|DRUG|Lidocaine|
223750011|NCT01998048|PROCEDURE|Bankart|An arthroscopic Bankart operation is performed in general anaesthesia according to current practise (Provencher 2010). The intra-articular findings are recorded and the anteroinferior labrum and the IGHL are mobilized until subscapular muscle fibers can be seen. The IGHL complex is then re-attached to the freshened neck of the glenoid with 2 to 3 suture anchors according to surgeon's preference to re-create labral bumper and capsular tension. In case of a significant Hill-Sachs defect an additional remplissage procedure may be performed according to surgeon's decision by inserting 1 to 2 more suture anchors, according to surgeon's preference into the deepest portion of the Hill-Sachs defect and tying the infraspinatus tendon down to fill the bony defect.
223750012|NCT02062762|BEHAVIORAL|Online-MBSR|8 week mindfulness based stress reduction online
223750013|NCT02062762|BEHAVIORAL|Expressive Writing Online|Online distributed expressive writing intervention as active control
223750014|NCT03267862|OTHER|there was no intervention|patients were observed during routine care on separate times when their eye pressure was different on one day from another.
223750015|NCT04333810|DEVICE|Whoop strap 3.0|WHOOP strap 3.0, a photodiode-based device that tracks sleep duration, resting heart rate, heart rate variability, activity (calories).
223750016|NCT03945812|DRUG|Granulocyte Colony Stimulating Factor|Filgrastim, Amgen, California, USA 300 mg/1.0 mL
223750017|NCT03945812|OTHER|Platelet Rich Plasma Arm|Platelet Rich Plasma Arm
223750018|NCT03945812|OTHER|Saline|Saline 9%
223750019|NCT06116331|OTHER|Data collection|Participants will answer questionnaires and submit stool samples.
223750020|NCT01299831|BEHAVIORAL|72 hour fast|The participants will be fasting 72 hours prior to the start of the study day, drinking water is allowed.
223750021|NCT01299831|BEHAVIORAL|control, 12 hour fast|The 12 hour fast will be used as a basic metabolic control
223750022|NCT01299831|DRUG|Growth hormone|Genotropin bolus(0,005 mg/kg over 20 min.) will be administered at the beginning of the study day after a 12 hour fast.
223750023|NCT01299831|DRUG|Olbetam|"The participants will be fasting 72 hours prior to the start of the study day, drinking water is allowed.~During the last 12 hours of fasting and the study day lipolysis will be inhibited with one tablet of olbetam 250 mg every 4 hours."
223750024|NCT06457555|OTHER|type of parallel data in a convergent parallel hash pattern (near time)|This study is a mixed method research conducted to determine the knowledge levels and experiences of nurses working in adult intensive care units regarding the prevention of pressure sores. In accordance with the purpose of the study, parallel data type in convergent parallel mixed design will be used as the research design. The quantitative phase will be conducted as a descriptive survey, and the qualitative phase will be conducted as a descriptive case study design. In this mixed design, equal priority, parallel timing and combining results during interpretation are planned.
223750025|NCT00516724|DRUG|KU-0059436 (AZD2281)(PARP inhibitor)|oral
223750026|NCT00516724|DRUG|Carboplatin|intravenous injection
223602237|NCT03044808|DRUG|Saline|
223602238|NCT03156374|DEVICE|Test use|Use of home ovulation test to predict ovulation
223750027|NCT00516724|DRUG|KU-0059436 (AZD2281)(PARP inhibitor)|Oral
223750028|NCT00516724|DRUG|Paclitaxel|Intravenous injection
223750029|NCT00516724|DRUG|KU-0059436 (AZD2281)(PARP inhibitor)|Oral
223750030|NCT00516724|DRUG|Paclitaxel + Carboplatin|Intravenous injection
223750031|NCT03253848|OTHER|Simplified Patient Care Strategy|Treatment per Acute Promyelocytic Leukemia (APL) Treatment Guidelines plus discussion between doctors and APL expert
223750032|NCT03253848|OTHER|Laboratory Biomarker Analysis|Correlative studies
223750033|NCT06315569|BEHAVIORAL|Run 3000 meters|Participants in both groups were asked to do two 3,000-meter runs at different intervals
223750034|NCT05352815|DRUG|IcoSema|Participants will receive once weekly IcoSema subcutanously (s.c. under the skin) with or without oral anti diabetic drugs for 52 weeks.
223750035|NCT05352815|DRUG|Insulin icodec|Participants will receive once weekly Insulin icodec subcutanously (s.c. under the skin) with or without oral anti diabetic drugs for 52 weeks.
223750036|NCT02165020|DEVICE|Hyaluronic acid (Macrolane VRF 30®, Q-MED)|"One injection of 3 to 10 cc of hyaluronic acid (Macrolane VRF 30®, Q-MED) introduced in the perirectal fat between the rectum and the prostate in connection with an ultrasound.~The injection is performed under local anesthesia (with Lidocaine) and ultrasound guidance, using a 16 gauge needle."
223750037|NCT05719207|DEVICE|Balloon dilation of eustachian tube|Patients in the intervention group would undergo balloon dilation of the eustachian tube under local anesthetic in clinic. The Stryker XprESS LoProfile ENT dilation system or the Stryker Audion ET dilation system will be used.
223750038|NCT05719207|OTHER|Sham procedure|Patients in the sham group will undergo the motions of an in-office dilation of the eustachian tube, without actually dilating the eustachian tube.
223602239|NCT06094400|OTHER|Meditation|Participants in the intervention group will be furnished with a tablet incorporating a pre-installed Muse Meditation App and a set of headphones. They can choose their preferred immersive soundscape for the meditation session.
223602240|NCT06094400|OTHER|Control|Participants allocated to the control group will similarly wear the portable EEG headband, but they will receive a rest session without any additional intervention
223750039|NCT05402657|PROCEDURE|Frontoparietal Ultrabrief Right Unilateral (UBRUL-FP) electroconvulsive therapy|UBRUL-FP involves ultrabrief right unilateral ECT delivered using a novel frontoparietal montage, where the anterior electrode is shifted frontally to a position above the midpoint of the right eye to avoid temporal lobe stimulation (and reduce memory side effects). UBRUL-FP will be delivered using standard ECT devices.
223750040|NCT05402657|PROCEDURE|Temporoparietal Ultrabrief Right Unilateral (UBRUL-TP) electroconvulsive therapy|UBRUL-TP is the standard form of ultrabrief right unilateral ECT, using the conventional temporoparietal (d'Elia) electrode placement, where the anterior electrode is placed over the right temporal lobe. UBRUL-TP will be delivered using standard ECT devices.
223750041|NCT04371679|OTHER|No interventions planned|No interventions planned. Observational.
223750042|NCT05923853|OTHER|FiO2 titration using electronic alert system|In the intervention arm, arterial oxygen saturation (SaO2) and peripheral oxygen saturation (SpO2) will be initially noted. Based on the correlation between the SaO2 and SpO2 the optimal oxygenation range will be determined. E-alerts will then be used to monitor oxygenation for patients in the intervention arm, based on SpO2 values generated by the patient due to the FiO2 given to the patient through the ventilator. Once an e-alert is sent, the respiratory therapist has 45 minutes for adjusting oxygen. Then the e-alert continues to monitor FiO2 and SpO2 values in this manner for every 45 minute period until the ventilator is attached to the patient.
223750043|NCT02759120|DRUG|Antimicrobial therapy: Co-trimoxazole or Doxycycline|160mg trimethoprim/800mg sulfamethoxazole (double strength co-trimoxazole) twice daily plus folic acid 5 mg daily OR doxycycline 100mg once daily if weight \< 50 kilograms or 100mg twice daily if weight \> 50 kilograms for up to 36 months
223602241|NCT05084898|OTHER|Far-UVC light as an additional method of disinfection|Far-UVC light is a form of ultraviolet light with an extremely short wavelength (222 nm)
223602242|NCT05084898|OTHER|Placebo fluorescent light|"Inactive fluorescent light (no additional disinfection)"
223602243|NCT01900808|DEVICE|Trained operator with M probe.|Trained operator with M probe: non-drug intervention, baseline comparator.
223602244|NCT01900808|DEVICE|Experienced operator with M probe.|Experienced operator with M probe: non-drug intervention, longitudinal comparator.
223602245|NCT01900808|DEVICE|Experienced operator with XL probe.|Experienced operator with XL probe: non-drug intervention, longitudinal comparator.
223750044|NCT02759120|OTHER|No Intervention: Standard of Care|Standard of care
223602246|NCT02653547|OTHER|standard multisite four weeks|Repetitive transcranial magnetic stimulation (Magventure): 1000 stimuli of 20 Hz rTMS over the left DLPFC (110% motor threshold) followed by 1000 stimuli of 1 Hz rTMS over the left temporoparietal cortex (110% motor threshold) followed by 1000 stimuli of 1 Hz rTMS over right temporoparietal cortex (110% motor threshold). Patients continue treatment after two weeks for further two weeks of treatment (20 treatment days).
223602247|NCT02653547|OTHER|high-frequency multisite four weeks|Repetitive transcranial magnetic stimulation (Magventure): 1000 stimuli of 20 Hz rTMS over the left DLPFC (110% motor threshold) followed by 1000 stimuli of 20 Hz rTMS over the left temporoparietal cortex (110% motor threshold) followed by 1000 stimuli of 20 Hz rTMS over right temporoparietal cortex (110% motor threshold). Patients continue treatment after two weeks for further two weeks of treatment (20 treatment days).
223602248|NCT02653547|OTHER|standard multisite two weeks|Repetitive transcranial magnetic stimulation (Magventure): 1000 stimuli of 20 Hz rTMS over the left DLPFC (110% motor threshold) followed by 1000 stimuli of 1 Hz rTMS over the left temporoparietal cortex (110% motor threshold) followed by 1000 stimuli of 1 Hz rTMS over right temporoparietal cortex (110% motor threshold). Patients discontinue treatment after two weeks (10 treatment days).
223602249|NCT02653547|OTHER|high-frequency multisite two weeks|Repetitive transcranial magnetic stimulation (Magventure): 1000 stimuli of 20 Hz rTMS over the left DLPFC (110% motor threshold) followed by 1000 stimuli of 20 Hz rTMS over the left temporoparietal cortex (110% motor threshold) followed by 1000 stimuli of 20 Hz rTMS over right temporoparietal cortex (110% motor threshold). Patients discontinue treatment after two weeks (10 treatment days).
223602250|NCT01704404|DRUG|TD-4208|
223602251|NCT01704404|DRUG|Placebo|
223602252|NCT01390896|DRUG|Fondaparinux Sodium|
223602253|NCT00851617|DEVICE|Threshold® IMT|The IMT group was trained using the threshold IMT device with a 40% MIP load. Each training session consisted of 5 sets with 10 breaths, twice a day
223602254|NCT04632771|OTHER|N/A (observational study)|N/A (observational study)
223750045|NCT02861794|PROCEDURE|Medacta International, GMK Sphere medially stabilized knee|Total Knee Replacement
223750046|NCT04133168|DEVICE|Boston Scientific Cardiac Cryoablation System|"The Boston Scientific Cardiac Cryoablation System is intended for ablation and electrical mapping of the pulmonary veins for pulmonary vein isolation (PVI) in the ablation treatment of patients with paroxysmal atrial fibrillation (PAF).The main devices and components of the system consists of the following:~* POLARx™ or POLARx™ FIT Cryoablation Catheter~* POLARMAP™ Catheter~* POLARSHEATH™~* SMARTFREEZE™ Console~* Diaphragm Movement Sensor (DMS)~* Related Accessories"
223602255|NCT00918099|PROCEDURE|Avaulta mesh|Insertion of a mesh vs conventional repair
223602256|NCT00918099|PROCEDURE|Anterior repair|Conventional repair
223602257|NCT01281540|DRUG|Cisapride|one 10 mg tablet 4 times a day for 8 weeks
223602258|NCT01281540|DRUG|Placebo|one placebo tablet 4 times a day for 8 weeks
223602259|NCT06362018|DIETARY_SUPPLEMENT|Mitopure (Urolithin A)|Mitopure (Urolithin A) is gut microbiome derived postbiotic that has been shown to improve muscle and mitochondrial health
223602260|NCT01946152|DRUG|Dexamethasone|Given PO
223602261|NCT01946152|BIOLOGICAL|Filgrastim-sndz|Given SC
223602262|NCT01946152|OTHER|Laboratory Biomarker Analysis|Correlative studies
223602263|NCT01946152|DRUG|Pomalidomide|Given PO
223602264|NCT03742583|OTHER|Square Knot|Standard square knot
223602265|NCT03742583|OTHER|RHAP Knot|Reversing half-hitch alternating post knot
223602266|NCT05168033|OTHER|Motor imagery training|Mentally imagine to perform rehabilitation exercises or sport-specific tasks without generating actual motor output.
223602267|NCT05168033|OTHER|Classic rehabilitation|Classic rehabilitation after anterior cruciate ligament reconstruction focusing on regaining mobility, stability and strength of the knee joint and return to sport.
223602268|NCT06528301|GENETIC|UB-VV111|UB-VV111 is a gene therapy that generates CD19 CAR T cells in the body.
223602269|NCT06528301|DRUG|rapamycin|Rapamycin is an FDA-approved drug.
223602270|NCT04255862|DRUG|Bimekizumab|Study participants will receive a single-dose of bimekizumab administered subcutaneously in the Treatment Period.
223602271|NCT05902988|DRUG|VLS-1488|VLS-1488 tablets will be given orally.
223602272|NCT03392246|DRUG|Osimertinib|"may stop (or inhibit) the growth of a cancer with a mutation in the EGFR gene"
223602273|NCT03392246|DRUG|Selumetinib|"may enhance the effect of osimertinib to stop (or inhibit) the growth of a cancer with a mutation in the EGFR gene"
223602274|NCT02574273|BEHAVIORAL|Secret Agent Society (SAS) Program|The Secret Agent Society (SAS) intervention involves subjects participating in 9 weekly two-hour therapy groups ('Club meetings') with 3 to 6 other children. The SAS intervention includes a number of components to help children apply the skills that they learn in the session to home.
223602275|NCT02574273|OTHER|Waitlist Group / Treatment As Usual|The wait list control condition includes the treatment participants are already receiving (which may include but is not limited to: individual therapy, group therapy, and/or medication management). Therefore, the wait list control condition consists of treatment which is individually tailored for each participant. Parent and child assessments will be completed at pre and post treatment (Wk 1 and Wk 10) and at 3-month and 6-month follow-up booster visits. The wait-list group will then be given the opportunity to participate in the SAS intervention at their treating clinic.
223750047|NCT04792697|OTHER|Increase morning bright light|Participants will wear Re-Timer bright glasses for 30 minutes each morning upon rising
223750048|NCT04792697|OTHER|Decrease evening blue light|Participants will wear blue light blocker goggles for 2 hours before bed
223750049|NCT04792697|BEHAVIORAL|Sleep Scheduling|Participants will advance their bedtime by 1.5 hours and regularize their wake time
223750050|NCT04792697|BEHAVIORAL|Monitor sleep, mood, and substance use|Participants will complete smartphone-based sleep, mood, and substance use monitoring
223750051|NCT01474044|DRUG|Gastropylor Complex Capsules|3 pills, three times a day, after meal
223750052|NCT01474044|OTHER|Placebo Comparator|Placebo that is same as gastropyloric complex capsules
223602276|NCT06278766|DRUG|ABBV-552|Oral Solution
223602277|NCT00961363|DRUG|Sitagliptin|sitagliptin 100 mg per day
223602278|NCT00961363|DRUG|Placebo|Placebo
223602279|NCT05083429|DRUG|Salmeterol|Salmeterol inhaler dispensing claim is used as the reference
223602280|NCT05083429|DRUG|Tiotropium|Tiotropium dispensing claim is used as the reference
223602281|NCT03128242|DRUG|Oxytocin|intranasal administration of oxytocin (24IU)
223602282|NCT03128242|DRUG|placebo|intranasal administration of placebo (24IU)
223602283|NCT00941915|RADIATION|SBRT Prostate|Five fractions of 7.4 Gy. The total dose will be 37 Gy. A minimum of 36 hours and a maximum of 96 hours should separate each treatment. No more than 3 fractions will be delivered per week. The total duration of treatment will be no shorter than 10 days and no longer than 18 days.
223602284|NCT00431015|DRUG|IPI-504|IV Hsp90 inhibitor
223750053|NCT02657460|BIOLOGICAL|tumor derived microparticles|The main difference between the two treatment groups is the biological coat, which is tumor derived microparticles.
223750054|NCT02657460|DRUG|cisplatin|cisplatin is a traditional drug for lung cancer
223602285|NCT00154440|DRUG|proton pump inhibitor|
223750055|NCT02152501|OTHER|Exercise Energy Expenditure 300 kcal/day|
223602286|NCT00154440|DRUG|clarithromycin|
223602287|NCT00154440|DRUG|amoxicillin|
223602288|NCT00154440|DRUG|metronidazole|
223602289|NCT00154440|PROCEDURE|radiation therapy|
223602290|NCT01051336|DEVICE|TARIS Placebo|
223602291|NCT01051336|PROCEDURE|Sham Procedure|
223602292|NCT01016600|DRUG|Lenalidomide|
223602293|NCT01016600|DRUG|Azacitidine|
223602294|NCT02679755|DRUG|Palbociclib|125 mg/d capsules orally for 3 out of 4 weeks in repeated cycles
223602295|NCT02679755|DRUG|Letrozole|2.5 mg/d tablets orally on a continuous regimen
223602296|NCT04755608|OTHER|Low Intensity Exercises with Blood Flow Restriction|In the exercise protocol, people exercised resistance between 20% and 30% of 1 MaxRepetition with free weight. In addition, blood flow was restricted in 70% of the arterial occlusion pressure of the individual with the help of a cuff during exercise.
223602297|NCT04755608|OTHER|High Intensity Resistant Exercise|People included in the study did resistance exercise with free weight at 70-80% of 1 MT.
223750056|NCT02152501|OTHER|Exercise Energy Expenditure 600 kcal/day|
223750057|NCT03056755|DRUG|Alpelisib|300 mg of alpelisib film-coated tablets administered orally once daily
223750058|NCT03056755|DRUG|Fulvestrant|500 mg of fulvestrant via intramuscular injection administered on Days 1, 15 on Cycle 1 and Day 1 at each cycle thereafter. Cycle=28 days
223750059|NCT03056755|DRUG|Letrozole|2.5 mg of letrozole film-coated tablets administered orally once daily
223750060|NCT03056755|DRUG|Goserelin|3.6 mg of goserelin via injectable subcutaneous implant administered every 28 days. Only for men in Cohort B and premenopausal women.
223750061|NCT03056755|DRUG|Leuprolide|7.5 mg of leuprolide via injectable intramuscular depot administered every 28 days. Only for men in cohort B and premenopausal women.
223750062|NCT04463550|OTHER|Description and analysis|Retrospective, non-interventional study, using clinical, biological, radiological and therapeutic data collected during the initial diagnosis and follow-up.
223750063|NCT04630951|OTHER|Blood Flow Restriction Strength training with low load|Low Load (20-50% 1RM), 4 set of 30/15/15/15 repetitions, 30 seconds resting between sets.
223750064|NCT04630951|OTHER|High Load Strength Training|High Load (60-80% 1RM) 4 sets of 8 repetitions, 2 minutes resting between sets
223750065|NCT06469775|DEVICE|Low intensity shock wave|6 sessions of low intensity shock wave therapy, applied in 15 minute appointments once weekly.
223750066|NCT06469775|COMBINATION_PRODUCT|Control|Standard of care treatment: phosphodiesterase 5 inhibitor therapy, vacuum erectile device, constriction bands, intracorporal injections, and penile implant.
223750067|NCT00969787|DRUG|DWP05195|tablets, oral administration, single and multiple administrations
223750068|NCT05955339|OTHER|NOTES|The intervention will include: (1) a brief training on using the patient portal to access written visit information with assistance in setting up patient portal accounts where necessary (including strategies to share notes with a caregiver), (2) post-visit reminders to use the patient portal to access written visit information.
223750069|NCT05955339|OTHER|AUDIO|The intervention will include: (1) audio recording all visits with the study clinician for six months, (2) training on how to record visits and access visit recordings, and (3) post-visit reminders listen to the visit recordings.
223750070|NCT06203639|OTHER|UR Caregiver|The UR Caregiver app was informed by previous research and developed in collaboration with caregiver partners. The app utilizes cognitive behavioural principles and is consistent with models of stress and coping. The app consists of seven modules. The app is available on IOS and Googe Play store. In addition to the didactic information provided in the app, worksheets are available in each module to practice the strategy/skill provided.
223750071|NCT06203639|OTHER|CLEAR Dementia Care|A subset of participants will be randomly assigned to use the CLEAR Dementia Care app as part of an active control group. The app consists of features that primarily address care-related needs (as opposed to stress management strategies) allowing for a comparison with the UR Caregiver app. The app was developed by the Northern Health and Social Care Trust (Northern Ireland) and is freely available on both IOS and Google Play stores. The CLEAR Dementia Care app provides users with information about dementia (e.g., the different types of dementia, how dementia affects the brain, and symptoms associated with dementia). The app offers suggestions and alternative approaches to various care-related situations through illustrations/images that caregivers may experience.
223602298|NCT03779659|DEVICE|Synapse TENS device|At the time of local anesthetic application the TENS device will be activated and placed on the buccal and lingual alveolar mucosa adjacent to the tooth receiving the restorative treatment using the pad applicator. The tip of the device with the electrodes are placed in a vertical up and down motion for approximately ten seconds. Following this, the level of pain and anxiety are measured using the Wong Baker Scale and Visual Analog Scale. The TENS device is used for achieving localized pain relief at the site of local anesthetic injection prior to injecting the anesthetic agent (such as lidocaine or articaine). Following this, once the clinician ensures that the patient is pain free then local anesthetic injection is given and following that the dental procedures are conducted.
223602299|NCT03779659|DRUG|Topical anesthetic gel|"The local anesthetic gel is typically used for achieving localized pain relief at the site of local anesthetic injection and this is part of standard care that is followed prior to dental procedures.~The amount of local anesthetic used will not exceed the maximum allowable dose, which will be calculated for each patient based on his/her age and weight prior to the dental procedure"
223602300|NCT03245125|BEHAVIORAL|High-intensity interval training|Patients warmed up for 3 min at 30% of peak oxygen consumption (VO2peak). Five 3-minute intervals at 80% of VO2peak and each interval was separated by 3-minute exercise at 40% of VO2peak. The exercise session was terminated by 3-minute cool-down at 30% of VO2peak. All subjects used a EKG and BP monitors as indicators of the assigned exercise intensity. Borg 6-to-20 scale was used to assess the rate of perceived exertion during and after each exercise session. Patients suffering unstable hemodynamic, ischemic cardiac symptoms/signs, and uncontrolled arrhythmia were instructed to immediately terminate exercise training.
223750072|NCT03395158|DIAGNOSTIC_TEST|Implementation of new alert criteria|The intervention is when the prior alert criteria are replaced by the present alert criteria
223750073|NCT04659850|OTHER|low fat, low AGE milkshake|low fat, low AGE milkshake given after an overnight fast
223750074|NCT04659850|OTHER|low fat, high AGE milkshake|low fat, high AGE milkshake given after an overnight fast
223750075|NCT04659850|OTHER|high fat, low AGE|high fat, low AGE milkshake given after an overnight fast
223750076|NCT04659850|OTHER|high fat, high AGE milkshake|high fat, high AGE milkshake given after an overnight fast
223750077|NCT04713124|BEHAVIORAL|R2C-M|R2C-M comprises 12 modules addressing core practice elements and skills from evidence-based cognitive and behavioural interventions. Modules include: (i) self-monitoring, goal setting and behaviour change skills; (ii) identification of strengths and motivational enhancement; (iii) relapse prevention; (iv) psychoeducation and harm reduction; (v) emotion regulation skills; (vi) anger management skills; (vii) urges and cravings management skills; (viii) sleep hygiene skills; (ix) mindfulness skills; (x) interpersonal skills; (xi) anxiety management skills; (xii) depressed mood management skills. The R2C-M workbooks contain psychoeducation and intervention exercises, to facilitate counsellor-delivered exercises within sessions, and between-session practice.
223750078|NCT04713124|OTHER|Self-help booklet|A booklet of information and self-help strategies for methamphetamine use problems.
223602301|NCT00659932|BEHAVIORAL|Immediate Cognitive behavioural therapy (CBT)|The Dealing with Anxiety CBT Group Program comprises 7 group sessions: an initial five hour session followed by 6 three hour sessions over a three month period
223602302|NCT00659932|BEHAVIORAL|Delayed CBT|Commencement of the CBT Group Program is delayed 3 months
223602303|NCT00725049|DEVICE|Dental Implant (Nanotite)|Root form titanium dental implant
223602304|NCT03854838|DRUG|Tolipalimab|Radiation begun the day after the first dose of Toripalimab. Toripalimab (240mg dose every 3 weeks for 7 cycles, one cycle is three weeks) will be administered as an intravenous infusion over 60 minutes.
223602305|NCT03854838|RADIATION|Reirradiation|intensity-modulated radiation therapy (IMRT), 60 Gy 2.2Gy per fraction ,5 fractions per week, for 6 weeks
223602306|NCT06825832|DEVICE|high power laser therapy|The MLS® Laser Therapy device used in this study is M6 (ASA srl -Arcugnano, Italy), equipped with both a robotized multidiode head (up to 3,3W), able to perform automatic scanning treatments, and an MLS® handpiece (up to 1,1W), aimed to perform manual point to point or scanning treatments. Each treatment includes two stages: the scanning of the frontal and dorsal shoulder area of 93 cm2 each with a robotized multidiode head and a point-by-point process with the manual handpiece with 7 points of 3,14 cm2 area.
223750079|NCT02347267|BEHAVIORAL|Caloric and non-caloric SSBS reduction|Isocaloric individualized diet and sweetened caloric and non-caloric beverages restriction
223750080|NCT02347267|BEHAVIORAL|Caloric SSBS reduction|Isocaloric individualized diet and caloric SSBS restriction
223602307|NCT06825832|DEVICE|pulsed electromagnetic field therapy|the PEMF application, with application of low intensity and frequency pulsed electromagnetic fields (PEMF), the portable device PMT QS (ASA Srl, Arcugnano) is used, equipped with Flexa applicators (36 x 21 x 2 cm (L x P x H) - 1.2 kg), programmable frequency from 0.5 to 100 Hz and variable magnetic field intensity from 5% to 100% (from \~2.5 to \~40 Gauss)), two solenoid applicators are placed at the anterior and posterior positions in the patient's shoulders and applied for 25 min at 25 G intensity at a frequency of 50 Hz.
223602308|NCT06825832|OTHER|Exercise|The conventional exercise program for hemiplegic shoulder pain (HSP) is stretching exercise therapy, joint stabilization exercise therapy.
223602309|NCT02451917|DRUG|Glargine insulin|The initial insulin dose for those randomized to IGlar was 80% of the total daily NPH dose that was being discontinued. All of them had pre-prandial Regular insulin switched to Lispro insulin (Humalog™, Lilly, Brazil), at the same dose as in use previously. After 24 weeks, basal insulins were switched; in other words, individuals on IGlar in the first period switched to INPH, and the doses of pre-meal insulin were sustained
223602310|NCT02451917|DRUG|NPH insulin|The same total daily NPH insulin dose was maintained for those randomized to INPH. All of them had pre-prandial Regular insulin (Humulin R™, Lilly, Brazil) switched to Lispro insulin (Humalog™, Lilly, Brazil), at the same dose as in use previously. . After 24 weeks, basal insulins were switched; in other words, individuals on NPH in the first period switched to glargine insulin, and the doses of pre-meal insulin were sustained.
223602311|NCT02038335|DRUG|DMPA|Depot medroxyprogesterone acetate
223602312|NCT02038335|DRUG|NET-EN|Norethisterone enantate
223602313|NCT02038335|DRUG|MPA/E2|Medroxyprogesterone acetate and estradiol cypionate
223602314|NCT02038335|DEVICE|LNG-I|Levonorgestrel subdermal implant
223602315|NCT02038335|DEVICE|ENG-I|Etonogestrel subdermal implant
223602316|NCT02038335|DEVICE|Cu-IUD|Copper IUD
223602317|NCT03666871|BIOLOGICAL|SB-728-T|Autologous CD4+ T cells with ex vivo modification of the CCR5 gene by zinc finger nucleases
223750081|NCT02121288|DRUG|Ticagrelor|Day 1: Loading dose of ticagrelor 180mg (two 90mg tablets) followed by 90mg dose at 12 hours after loading dose. Subject continues to take ticagrelor 90mg twice a day (morning and evening) for 7 days until next visit (Day 7).
223750082|NCT02121288|DRUG|clopidogrel|Day 1: Clopidogrel 75mg oral tablet. Subjects will continue to take clopidogrel 75mg once a day for 7 days until next visit (Day 7/Visit 3). Note: no loading dose is given for the clopidogrel as those subjects are already on chronic dosing.
223750083|NCT03986320|DEVICE|Keeogo™ Dermoskeleton|This device is intended for use in rehabilitation institutions to assist individuals with hemiparesis due to stroke who are able to stand and initiate a step in performing ambulatory functions.
223750084|NCT06200727|PROCEDURE|PRF membrane tamponade surgery in macular hole|A specially formulated PRF membrane, as described previously, was filled into the macular hole to promote fissure repair.
223750085|NCT06200727|PROCEDURE|ILM peeling in macular hole|The treatment of the macular hole was ILM peeling.
223602318|NCT03666871|BIOLOGICAL|Expanded unmodified autologous CD4+ T cells|Autologous CD4+ T cells without ex vivo modification of the CCR5 gene by zinc finger nucleases
223602319|NCT05694455|DIAGNOSTIC_TEST|Starling Stroke Volume (Starling SV)- Passive Leg Raise|All septic patients will have a passive leg raise performed with the assistance of an Starling SV device to look at Stroke Volume change. This will be performed at admission and 4 hours after admission. This intervention will not be performed on healthy controls
223602320|NCT05694455|DIAGNOSTIC_TEST|Microscan Sublingual Microscopy|All septic patients will have sublingual microscopic images performed at admission, 8-16 hours, 48 hours and 72 hours. Control patients will have a sublingual microscope imaging performed after intubation for the elective procedure. This is a process of a 2cm probe tip gently placed on patients' mouth and 3 different images of 5-8 seconds are recorded.
223602321|NCT05694455|DIAGNOSTIC_TEST|Venous Excess Ultrasound Scoring (VExUS)|All septic Patients will have this performed on all patients at admission, 8-16 hours, 48 hours and 72 hours. Ultrasound images and blood flow waves will be collected of the Inferior Vena Cava diameter, hepatic vein, portal vein, renal veins and scored using the Venous Excess Ultrasound (VExUS scale). Healthy controls will not have ultrasound performed
223602322|NCT05694455|OTHER|Urine Collection|The urine assay is collected passively from the patient will be ran through a Dimethylmethylene blue (DMMB assay)- could provide future beneficial information to resuscitation efforts. This will be performed on all septic patients at admission, 8-16 hours, 48 hours and 72 hours. Urine will be collected on healthy controls at time of intubation for elective procedure.
223602323|NCT03032263|DEVICE|Video Laryngoscopy for nasal intubation|The anesthesia provider will use a video laryngoscope to facilitate the nasal intubation for the procedure.
223602324|NCT03032263|DEVICE|Direct Laryngoscopy|These patients will be nasally intubated for their procedure via direct laryngoscopy
223602325|NCT03385148|DRUG|68Ga-Sgc8|underwent a standard routine 18F-FDG PET/CT first, and then injected 10\~20 MBq 68Ga-Sgc8
223602326|NCT02432586|BEHAVIORAL|Intensive Education|Participants will attend a 3 day family-centered, multidisciplinary, intensive education session at our regional diabetes camp, Camp Sweeney. A second 'booster' session will be conducted 6 months later.
223602327|NCT04737278|DRUG|Cunermuspir|"Copper Niacin Chelate, 6.06 mg per capsule Non-medicinal ingredients:~Organic evaporated cane juice powder, hypromellose, titanium dioxide"
223602328|NCT04737278|OTHER|Placebo|same non-medical ingredients and encapsulation as Intervention 1
223602329|NCT05147805|DRUG|Treprostinil Palmitil|Administered by oral inhalation using a Plastiape capsule-based dry powder inhaler.
223602330|NCT05147805|DRUG|Placebo|Administered by oral inhalation using a Plastiape capsule-based dry powder inhaler.
223602331|NCT04227093|DRUG|Acetazolamide|Oral acetazolamide tablets of 250 mg taken twice daily.
223602332|NCT04227093|DRUG|Placebo|Matching placebo tablets taken twice daily.
223750086|NCT06200727|PROCEDURE|PRF membrane grafting in pterygium|Used of autologous PRF membrane to cover the exposed conjunctiva after pterygium excision.
223750087|NCT06200727|PROCEDURE|Autologous conjunctival transplantation in pterygium|Used of autologous conjunctiva to cover exposed sclera after pterygium excision
223750088|NCT06200727|PROCEDURE|autologous PRF membrane grafting in trabeculectomy for glaucoma|Used of autologous PRF membranes to cover the exposed sclera after trabeculectomy for glaucoma.
223602333|NCT00546000|DRUG|Fluticasone propionate 0.05% lotion|Daily applications
223602334|NCT00959595|DRUG|EMLA cream|The study subjects are treated either by 50 g of a local anesthetic agent containing 2.5% Lidocaine and 2.5% Prilocaine (EMLA®, AstraZeneca - Södertälje, Sweden) or a placebo cream, applied to the lower leg. The cream is applied under occlusive bandage (plastic foam and a tube) for 1.5 hours circumferential to the lower leg 10-12 cm distally of the tibial tuberosity and the malleolus at ankle level. Administration of the treatment cream as well as removal after 1,5 hour and at sensory assessment after 1.5 hour and 24 hours, and interviewing the patient about subjective experience from the treatment are performed by an independent research nurse, not involved in the sensory assessment.
223602335|NCT00959595|DRUG|EMLA cream|50g applied according to description of intervention
223602336|NCT05054426|DRUG|Methotrexate|intravenous versus intrathecal methotrexate
223602337|NCT01512095|DRUG|somatropin|A single dose administered subcutaneously (under the skin) on 2 separate dosing visits (treatment periods) separated by a wash-out period
223602338|NCT01512095|DRUG|somatropin|A single dose administered subcutaneously (under the skin) on 2 separate dosing visits (treatment periods) separated by a wash-out period
223602339|NCT03231852|OTHER|Survey|Attitudes and Randomized Trial Questionnaire (ARTQ), Hospital Anxiety and Depression Scale, Perception Survey
223602340|NCT01212393|BEHAVIORAL|reminders|In the intervention group, emergency departments will be provided with poster and pocket cards and, if possible, with a computer decision support system remembering venous thromboembolism prophylactic treatment.
223602341|NCT00889824|DEVICE|balance prosthesis|vibrotactile stimulation
223602342|NCT01736670|DRUG|Triamcinolone Acetonide spray|
223602343|NCT01736670|DRUG|Triamcinolone acetonide cream|
223602344|NCT01736670|DRUG|Alcohol spray|
223602345|NCT04236752|RADIATION|Stereotactic Ablative Body Radiation (SBRT)|
223602346|NCT05833997|PROCEDURE|Monopolar Transurethral resection of bladder tumor|"Patients randomized to Monopolar TURBT will be operated using a 26F continuous-flow resectoscope sheaths and a single-pole working element to exclusive use of the resection. The power will be set to cut in 80w and 60w. The technique that will be performed will be the classic endoscopic resection from the top of the tumor until reaching the base, taking a sample from the base of the lesion (muscle layer). Fragments will be removed through an Ellik evacuator, and the solution used will be 3% glycine. After the procedure, the patient will will be catheterized with a silicon catheter number 22F with three ways and continuous irrigation.~After 30-60 days of the first procedure, all patients diagnosed with a lamina propria invasion in the uro-pathology analysis (T1) will be submitted to a new monopolar TURBT."
223602347|NCT05833997|PROCEDURE|Holmium Laser resection of bladder tumor (HoLEBT)|"It will be used a 24-26F continuous-flow resectoscope sheath with a specific working element to use with a 600µm fiber to Laser Holmium.~Patients will be operated with the Megapulse 70w (Richard Wolf) and laser will be set to deliver the energy of 0,5J and 30-40Hz frequency, 15-20W of final energy. The solution used will be 0,9% saline solution. The resection will start from the base of the lesion, reaching the muscle layer to obtain a sample and resection of the whole tumor, without fragmentation. After this, the morcellation will be performed in the apex of tumor sparing the base with a long nephroscope, and the patient will will be catheterized with a silicon catheter number 22F with three ways and continuous irrigation. The morcellated product will be sent to the pathology lab for detailed analysis."
223602348|NCT00650403|DRUG|Paroxetine hydrochloride 40 mg tablet|40mg, single dose fed
223602349|NCT00650403|DRUG|Paxil® 40 mg Tablet|40mg, single dose fed
223602350|NCT01504412|DRUG|DS-5565|Oral tablets administered twice daily
223602351|NCT01504412|DRUG|DS-5565|Oral tablets administered twice daily
223602352|NCT01504412|DRUG|DS-5565|Oral tablets administered twice daily
223602353|NCT01504412|DRUG|Placebo|DS-5565 placebo oral tablets and pregabalin placebo oral capsules administered 2 times per day
223602354|NCT01504412|DRUG|Pregabalin capsules|Pregabalin oral capsules 150 mg administered twice a day
223602355|NCT01800630|DRUG|Gemcitabine HCl Oral Formulation|
223602356|NCT02312050|DRUG|GCS-100|1 mg, 3 mg, or 9 mg IV push injections
223602357|NCT02312050|DRUG|Placebo|
223602358|NCT03975686|OTHER|neuromuscual realigning exercise|neuromuscular realigning exercise
223602359|NCT01983085|DEVICE|NOx dressing|The NOx dressing should be changed at least every 2 days.
223602360|NCT01983085|DEVICE|Standard of Care|Dressing changed as per normal clinical practice
223602361|NCT02832635|DRUG|TMZ|TMZ 75mg/m2/d from the 1st day to the last day of radiotherapy
223602362|NCT02832635|RADIATION|WBRT with avoidance of hippocampus|Whole brain radiotherapy of 30Gy/10f by IMRT (Intensity Modulation Radiated Therapy), with or without boost. The maximum dose of hippocampus should be no more than 18Gy.
223602363|NCT02832635|RADIATION|WBRT without avoidance of hippocampus|Whole brain radiotherapy of 30Gy/10f by IMRT, with or without boost. The dose of hippocampus is not considered.
223602364|NCT05935332|DRUG|RPT193|RPT193 is an antagonist of the C-C motif chemokine receptor 4 (CCR4) that inhibits CCR4-mediated chemotaxis toward both CCL22 and CCL17
223602365|NCT05935332|OTHER|Placebo|placebo
223602366|NCT04406675|OTHER|neuropsychological test|neuropsychological test
223602367|NCT04730791|DIAGNOSTIC_TEST|Algo(s)rithm/ IASP clinical criteria|IASP clinical criteria for identifying nociplastic pain. The criteria is completed by the healthcare professional and includes questions about the patient's clinical picture.
223602368|NCT04730791|DIAGNOSTIC_TEST|Pressure Pain Threshold|The pain pressure threshold (PPT) is used to measure pain sensitivity in body areas. The test quantifies the minimum amount of pressure in a given area, during an increasing skin pressure stimulus, which is capable of altering the feeling of pressure in pain.
223602369|NCT06291480|BEHAVIORAL|Neurologic Music Therapy|Music therapy focused on cognitive and motor rehabilitation after stroke (subacute phase).
223602370|NCT06474312|BEHAVIORAL|Nae Disha|"Nae Disha for Life is a brief, multi-component, psychosocial promotion and resilience tool developed by Emmanuel Hospital Association, New Delhi. The purpose of this research work is to evaluate the feasibility, acceptance, and effectiveness of Nae Disha for Life tool in reducing suicide ideation among youth in Bundelkhand region. This will be implemented among the targeted schools of Nowgong block, Chhatarpur district."
223602371|NCT05637398|DRUG|Colchicine|The active treatment intervention consists of colchicine 0.5 mg twice daily that will be administrated by the investigator
223750089|NCT06200727|PROCEDURE|Amniotic membrane in trabeculectomy for glaucoma|Used of amniotic to cover the exposed sclera after trabeculectomy for glaucoma.
223750090|NCT06200727|PROCEDURE|PRF membrane grafting incorneal ulcer|After surgical debridement of corneal ulcers, autologous PRF membrane was placed over the corneal wound to promote corneal healing
223750091|NCT06200727|PROCEDURE|Amniotic membrane in corneal ulcer|After surgical debridement of corneal ulcers, autologous amniotic membrane was placed over the corneal wound to promote corneal healing
223750092|NCT00278954|BIOLOGICAL|Gammaplex (Intravenous immunoglobulin)|GAMMAPLEX 5g/100 mL, dose is 300-800 mg/kg/infusion every 21 or 28 days, intravenously for 12 months.
223750093|NCT01147861|DRUG|GSK256073|5mg in the AM and 5mg in the PM
223750094|NCT01147861|DRUG|GSK256073|10mg in the AM
223750095|NCT01147861|DRUG|GSK256073|50mg in the AM
223750096|NCT01147861|DRUG|GSK256073|25mg in the AM and 25mg in the PM
223750097|NCT01147861|OTHER|Placebo|2 placebo tablets in the AM and 2 placebo tablets in the PM
223750098|NCT02523846|DRUG|morphine|"Investigators use the formula that was published by Pamela Macintyre in her paper entitled Age is the Best Predictor of Postoperative Morphine Requirements. The estimation for the first 24-hour morphine requirement after surgery is calculated as: 100 - age (year).~So, half of the total 24-hour morphine requirement will be infused over 24 hours.~e.g. background morphine infusion= (100-Age)/ 2/ 24 (mg/hour)"
223750099|NCT02523846|BEHAVIORAL|Patient re-education|A similar leaflet will be used to re-educate patient at 4 hour after surgery. The correct method to initiate IV-PCA dose, possible side effects and addiction issue will be explained again and re-emphasized
224200076|NCT03823339|DRUG|Insulin degludec/liraglutide|Patients will be treated with Insulin degludec/liraglutide (Xultophy®) at the treating physician's discretion and independent from the decision to include the patient in the study.
223602372|NCT02444052|DEVICE|Zimmer Puros Cancellous Allograft|Right side will have an extraction followed by an allogenic bone graft zimmer puros followed by implant placement.
224200077|NCT01340703|PROCEDURE|vitrectomy without laser or gas tamponade|vitrectomy without laser or gas tamponade
223602373|NCT02444052|DEVICE|Nobel Biocare Creos Cancellous Allograft|Left side will have an extraction followed by an allogenic bone nobel biocare creos graft followed by implant placement.
223602374|NCT04276519|PROCEDURE|Physiotherapeutic, non-invasive position-induced opening of the intervertebral foramen|Opening of the mechanical interface of the nerve root, neurodynamics
224200078|NCT01502917|DRUG|Radioactive iodine-labeled monoclonal antibody omburtamab|Prior to treatment children will be pre-medicated with super-saturated potassium iodide \& liothyronine to prevent thyroid uptake of the therapeutic radioisotopes. The proposed intervention is a surgical procedure using interstitial infusion of the radiolabeled monoclonal antibody 124I-omburtamab into the brain stem tumor. This will be performed by stereotactic placement of a small caliber infusion cannula into the tumor followed by a slow infusion (CED) of 124I-omburtamab. Following treatment, these children will be monitored during inpatient hospitalization with clinical evaluations \& PET/CT or PET/MRI scans of the brain \& other organs. Clinical observations, intensive care unit monitoring, routine blood \& interval imaging studies (MRI \& PET/CT or PET/MRI scans) will be performed at predetermined time points. If the PET/CT scan happens to fall on a weekend or holiday, the scan may be done before or after at the discretion of the Study PI. This will not affect dosimetry interpretation.
223602375|NCT02837185|PROCEDURE|Botulinum Toxin injection|Botulinum toxin injection for cervical dystonia subjects (as part of clinical care)
223602376|NCT02837185|OTHER|Physiological measures|These include TMS and EMG measurements
223602377|NCT04694560|OTHER|Treatment Free Observation|Participants without evidence of clinical relapse will remain off therapy and continue serial monitoring through end of study at 24 cycles. Participants with clinical relapse will continue to be monitored off therapy through 24 cycles or until meeting criteria for treatment per iwCLL criteria. If participants experience clinical relapse requiring treatment, radiology assessment, disease assessment, and testing for resistance mutations will be performed. Participants will be observed for an additional 12 cycles following start of reintroduction of therapy.
223750100|NCT03406858|BIOLOGICAL|HER2Bi-Armed Activated T Cells|Given IV
223750101|NCT03406858|OTHER|Laboratory Biomarker Analysis|Correlative studies
223750102|NCT03406858|BIOLOGICAL|Pembrolizumab|Given IV
223750103|NCT05271955|DEVICE|"e-GOLIAH"|"Usual care plus electronic tablet with games application e-GOLIAH (Gaming Open Library for Intervention in Autism at Home)"
223750104|NCT05271955|BEHAVIORAL|Usual care|Usual care which combines speech therapy, psychomotor, educational or psychological care with a developmental and / or behavioral orientation and a school life support during schooling.
223750105|NCT01865279|DRUG|insulin degludec|Ascending single doses - 5 dose levels. Escalation to next dose level will be performed following evaluation of safety data.
223750106|NCT01865279|DRUG|placebo|Ascending single doses - 5 dose levels
224200079|NCT01502917|RADIATION|External Beam Radiotherapy|Standard radiation therapy is given 4-6 weeks prior to study entry.
223750107|NCT01865279|DRUG|insulin degludec|A single dose corresponding to that of isophane human insulin
223750108|NCT01865279|DRUG|isophane human insulin|A single dose of 0.4 IU/kg is administered to subjects with type 1 diabetes while a single dose of 0.6 IU/kg is administered to subjects with type 2 diabetes
224200080|NCT06566508|DRUG|Calcium Hydroxide Intracanal medication|Calcium Hydroxide Intracanal medication
223750109|NCT06387914|DEVICE|Stimulation ON|Neurostimulation of the periaqueductal gray matter and sensory thalamus at a level with potential to provide pain relief
223750110|NCT06387914|DEVICE|Stimulation Pseudo-ON|Neurostimulation of the periaqueductal gray matter and sensory thalamus S at a low level, not designed to provide pain relief
223750111|NCT06358105|PROCEDURE|Simulator-based training|A two-day training program will be performed before starting their cath lab period as interventional cardiology fellows
223750112|NCT06358105|PROCEDURE|Standard training|Standard master-apprentice training interventional cardiology fellows' program during their cath lab period
223750113|NCT06276959|DIAGNOSTIC_TEST|intraoral scanning|The patients underwent intraoral scanning using an iTero Element 5D imaging system (Align Technology, San Jose, CA, USA). This imaging system uses near-infrared light with a wavelength of 850 nm and provides multiple layers of data in a single scan, including a three-dimensional (3D) model, two-dimensional (2D) color images, and NIRI mapped to the 3D model
223602378|NCT04966507|DRUG|Listerine Antiseptic Mouthwash Product|COOL MINT LISTERINE® Antiseptic Mouthwash will be used as the 'active' study drug condition. This is a commercially available, over the counter mouthwash product. Active ingredients for this product include Eucalyptol 0.092%, Menthol 0.042%, Methyl salicylate 0.060%, Thymol 0.064%. This product also contains 21% alcohol. Participants will be asked to rinse and gargle their mouth with 20mL of mouthwash daily.
223602379|NCT04966507|DRUG|Biotene Mouthwash|Biotène Rinse is designed with a moisturizing formula to help relieve dry mouth symptoms and is specifically designed to have a pH similar to saliva. This is a commercially available, over the counter mouthwash product. Biotène Mouthwash Ingredients include: Purified Water, Propylene Glycol, Hydrogenated Starch Hydrolysate, Poloxamer 407, Hydroxyethylcellulose, Sodium Benzoate, Flavor (Peppermint Oil), Benzoic Acid, Disodium Phosphate, Zinc Gluconate, Lactoferrin, Lysozyme, Lactoperoxidase, Potassium Thiocyanate, Aloe Vera Gel, Calcium Lactate, Glucose Oxidase. Participants will be asked to rinse and gargle their mouth with 20mL of mouthwash daily.
223602380|NCT05477680|DEVICE|Navigation-guided surgery|Surgeon removes brain lesions and assesses brain shift with neuronavigation
223750114|NCT06276959|DIAGNOSTIC_TEST|clinical oral examination|Under illumination in the dental unit, a UVE of the proximal surfaces of the patient's entire dentition was conducted by clinicians using a mouth mirror, dental probe, and an air-water syringe. Visual and tactile methods were performed according to the guidelines of the American Dental Association. Clinicians assessed the soundness of the proximal surfaces based on the presence of discoloration, surface alterations, or cavitation.
223750115|NCT06276959|DIAGNOSTIC_TEST|cone-beam computed tomography|All enrolled patients underwent CBCT scans because clear aligner treatment required real root/bone visualization features. We would like to clarify that due to the retrospective cross-sectional nature of this study, the patients involved were not subjected to radiation beyond what was initially necessary for their orthodontic treatment.
223750116|NCT06317753|BEHAVIORAL|Aerobic Exercise|Participants allocated to the Aerobic condition will be following a 4 month-intervention aerobic exercise protocol of 3 weekly interleaved sessions with a 50 minutes duration
223750117|NCT06317753|BEHAVIORAL|Agility-Cognitive Exercise|Participants allocated to the Agility-Cognitive condition will be following a 4 month-intervention agility-cognitive exercise protocol of 3 weekly interleaved sessions with a 50 minutes duration
223750118|NCT06317753|BEHAVIORAL|Stretching/relaxation|Participants allocated to the stretching control condition will be following a 4 month-intervention protocol of 1 weekly session with a 50 minutes duration
223750119|NCT02419742|DRUG|Carboplatin|TCH regimen: Carboplatin dose = Target Area Under Curve (AUC) (6 milligrams\*milliliter/minute \[mg\*mL/min\]) multiplied by (Glomerular Filtration Rate \[GFR\] + 25). Carboplatin will be administered as IV bolus every 3 weeks for 6 cycles (Cycles 1 to 6).
223750120|NCT02419742|DRUG|Cyclophosphamide|AC-TH regimen: Cyclophosphamide 600 mg/m\^2 IV bolus every 3 weeks for 4 cycles (Cycles 1 to 4).
223750121|NCT02419742|DRUG|Docetaxel|AC-TH regimen: Docetaxel 100 mg/m\^2 IV infusion every 3 weeks for 4 cycles (Cycles 5 to 8). TCH regimen: Docetaxel 75 mg/m\^2 IV bolus every 3 weeks for 6 cycles (Cycles 1 to 6).
223750122|NCT02419742|DRUG|Doxorubicin|Participants will receive Doxorubicin 60 mg/m\^2 administered as I.V. bolus injection over 5 to 15 minute every 3 weeks for 4 cycles for AC-TH regimen.
223750123|NCT02419742|DRUG|Paclitaxel|AC-TH regimen: Paclitaxel 175 mg/m\^2 IV infusion every 3 weeks for 4 cycles (Cycles 5 to 8).
223750124|NCT02419742|DRUG|Trastuzumab|AC-TH regimen: For weekly administration, 4 milligrams per kilograms (mg/kg) loading dose on Day 1 of Cycle 5, followed by 2 mg/kg on Day 8 of Cycle 5 and 2 mg/kg every week for 4 cycles (up to Cycle 8). For 3 weekly administration, 8 mg/kg loading dose on Day 1 of Cycle 5, followed by 6 mg/kg every 3 for 4 cycles (up to Cycle 8). From Day 1 of Cycle 9, 6 mg/kg will be administered every 3 weeks up to Cycle 22. TCH regimen: For weekly administration, 4 mg/kg loading dose followed by 2 mg/kg weekly from Cycles 1 to Cycle 6. For 3 weekly administration, 8 mg/kg loading dose followed 6 mg/kg every 3 weeks from Cycles 1 to 6. From Cycle 7, 6 mg/kg every 3 weeks up to Cycle 18. All administrations will be intravenous (IV) infusion.
223750125|NCT00390325|DRUG|Sorafenib Tosylate|Given PO
223750126|NCT06404632|BEHAVIORAL|Lev-g|Lev-g includes three sessions + a booster session using psychoeducation, motivational interviewing, and applied behavioral analyses. Lev-g is done in groups to enable support and tips from others.
224200081|NCT06566508|DRUG|Leddermix Intracanal medication|Leddermix Intracanal medication
223602381|NCT05878054|OTHER|Proactive, integrated and personalised care|During the intervention patients receive proactive, integrated and personalised care. An intake consultation using Positive Health tool, or a similar method, the needs of each patient is assessed. In a multidisciplinary meeting with the GP, mental health care practice nurse, a social worker and the patient, a personalised care plan is made. The personal is executed and a care coordinator maintains proactive contact with the patient. Clinical follow-up will be done via a second multidisciplinary meeting.
223750127|NCT01280214|DRUG|Triamcinolone|Subconjunctival and peribulbar, 40 mg/ml, 3 monthly injection
223750128|NCT06045806|BIOLOGICAL|idecabtagene vicleucel|Specified dose on specified days
223750129|NCT06045806|DRUG|Lenalidomide|Specified dose on specified days
223750130|NCT06045806|DRUG|Fludarabine|Specified dose on specified days
223750131|NCT06045806|DRUG|Cyclophosphamide|Specified dose on specified days
224200082|NCT06566508|DRUG|Asiaticoside Intracanal medication|Asiaticoside Intracanal medication
224200083|NCT06057233|DIAGNOSTIC_TEST|mqMRI and GABA-MRS|multiparametric quantitative MRI (mqMRI) and of GABA-edited magnetic resonance spectroscopy (GABA-MRS)
224200084|NCT02881970|DRUG|autologous cord blood stem cell|Injection of 5.107 / kg autologous mononuclear cells from umbilical cord blood
223750132|NCT06124716|OTHER|Enhanced COACH CDS Tool|CDS tool with features to promote high blood pressure management
223750133|NCT06124716|OTHER|Usual Care COACH CDS Tool|CDS tool with limited features to promote high blood pressure management
223750134|NCT05877092|DEVICE|implants with overdentures|two implants with bar attachment placed in interforaminal of the mandible mandible of the participants, the patients were delivered conventional upper complete denture constructed from heat cured acrylic rein, but in implanted mandibular arch they were received complete overdenture constructed from heat cured acrylic resin for Group I, and complete thermoplastic denture was constructed for Group II.
224200085|NCT01687400|DRUG|decitabine|
224200086|NCT03932747|OTHER|pre- Hydratión skin|Measurement of hydration of the skin.
223750135|NCT01758185|BIOLOGICAL|recombinant hepatitis b vaccine|0.5ml intramuscular
223750136|NCT01758185|BIOLOGICAL|Aleph influenza vaccine|0.5ml intramuscular
223602382|NCT02974257|DRUG|Thiamine|Thiamine 500mg IV twice daily for 2 days
223602383|NCT02974257|OTHER|placebo|100mL normal saline IV every 12 hours for 2 days
223602384|NCT05130151|BEHAVIORAL|Youth Health SMS|The intervention is comprised of an automated two-way text messaging and interactive voice recognition service that provides sexual reproductive health (SRH) and HIV prevention information. The proposed intervention will add PrEP information and mental health and alcohol use screeners to the platform with the goal of promoting linkage to HIV clinics and to phone-based mental health counseling for symptomatic participants.
223602385|NCT06583707|PROCEDURE|Dry needling with and without ultrasound guidance|The dry needling technique involves inserting a sterile needle to stimulate a myofascial trigger point with the aim of reducing pain and increasing range of motion and quality of life. This technique can be performed using ultrasound guidance, which allows us to visualize the needle at all times, but it can also be done using anatomical landmarks. In the placebo dry needling technique, the needle will remain stationary in the subcutaneous tissue.
223602386|NCT05140460|BEHAVIORAL|Cultural Pride Reinforcement for Early School Readiness (CPR4ESR)|The intervention entails distribution of a children's book with a cultural pride theme and the cultural pride parent book-sharing guide. Intervention participants select and receive a developmentally appropriate (baby, toddler, or preschool) book that features African American, Latino, Asian or diverse cultural pride perspectives.
223602387|NCT05140460|BEHAVIORAL|Reach Out and Read (ROR)|The control condition involves distribution of a standard ROR book and book-sharing advice. Distributed books are developmentally appropriate (baby, toddler, or preschool).
223602388|NCT04543227|BEHAVIORAL|Opioid Use 90-Days Post Treatment|Survey conducted 90-days post treatment to determine use of opioid medications in relation to burn or knee arthroscopy pain
223602389|NCT05097495|PROCEDURE|Only NNS|"Before the procedure, the Premature Infant Comfort Scale shall be filled out.~Procedure steps for the control group:~* Materials shall be prepared (napkins, non-sterile gloves, pacifier)~* Hands shall be washed; gloves shall be worn.~* The infant shall be given a NNS just before the procedure and continue until the 5th minute after the procedure.~* The diapers shall be changed.~* Hands shall be washed after the procedure.~* The Premature Infant Comfort Scale shall be assessed during, shortly after, and 5 minutes after the procedure."
223602390|NCT05097495|PROCEDURE|NNS Combined with Breast Milk|"* Before the procedure, the Premature Infant Comfort Scale shall be filled out.~* Materials shall be prepared (napkins, non-sterile gloves, pacifier, breast milk, cup)~* Hands shall be washed; gloves shall be worn.~* The cylindrical part of a pacifier shall be in touch with breast milk for 5 seconds. The infant shall be given the pacifier, combined with breast milk, just before the procedure and continue until the 5th minute after the procedure.~* The diapers shall be changed.~* Hands shall be washed after the procedure.~* The Premature Infant Comfort Scale shall be assessed during, shortly after, and 5 minutes after the procedure."
223602391|NCT03029923|BEHAVIORAL|Experimental: Behavioral Activation Treatment for Cardiac Smokers (BAT-CS)|All participants will receive one hour of standard smoking cessation counseling during their hospitalization for an acute coronary syndrome. Participants will be randomized 1 week after discharge. Those assigned to BAT-CS condition will receive 5 more counseling sessions over the 12 weeks after discharge. The first will be up to one hour and will be conducted in person. The next 4 sessions will occur by phone and will take about 30 minutes. Post-discharge sessions will be focused on smoking cessation and mood management using behavioral activation techniques. Participants will be offered the nicotine patch if medically cleared.
223750137|NCT04974112|OTHER|Apply SGA and NRS2002|Special researchers appointed by the research unit apply SGA and NRS2002 and other data measurement tools to collect patient information
223750138|NCT00070265|DRUG|oxaliplatin|Given IV
223750139|NCT00070265|DRUG|capecitabine|Given orally
223750140|NCT00070265|PROCEDURE|therapeutic conventional surgery|Undergo surgical resection
223750141|NCT00070265|OTHER|laboratory biomarker analysis|Correlative studies
223750142|NCT00102700|DRUG|ARQ 501 in combination with gemcitabine|
223750143|NCT05333627|BEHAVIORAL|Wellbeing Course for Students (Fast Track)|The core Fast-Track lesson includes information on managing their cycle of symptoms, motivation, and an overview of strategies that can be used to manage symptoms of depression and anxiety. After the core lesson, clients can access three additional Do-It-Yourself guides that focus on thought challenging, controlled breathing/activity planning, and behavioural activation/relapse prevention. These materials are able to be accessed out of sequence on a schedule that suits their needs. With optional therapist support, therapists will respond to any messages that clients send once per week. Therapists will not message clients on weeks where the client does not send a message.
223750144|NCT05333627|BEHAVIORAL|Wellbeing Course for Students (5 weeks)|The 5-week course consists of four lessons that provide psychoeducation about: symptom identification and the cognitive behavioural model, thought monitoring and challenging, controlled breathing and pleasant activity scheduling, graded exposure, and relapse prevention. With optional therapist support, therapists will respond to any messages that clients send once per week. Therapists will not message clients on weeks where the client does not send a message.
224200087|NCT03932747|OTHER|post- Hydratión skin|Measurement of hydration of the skin.
224200088|NCT04475068|PROCEDURE|Lateral Position (left and right lateral decubitus)|Prior to initiating the protocol, patients will be sedated deeply with sedatives and opioids and paralyzed. Patients will be evaluated in 5 positions sequentially: 1) Supine 2) Left lateral 3) Supine 4) Right lateral 5) Supine. The side with the least ventilation evaluated by EIT will define which side will start the sequence. Each step will last 30 minutes. Aeration measured by Electric Impedance Tomography (EIT) and lung ultrasound, distribution of the lung ventilation and perfusion measured by EIT, ventilator and hemodynamic parameters, esophageal pressure, and blood gas analysis will be recorded at the end of each step. Continuous monitoring of blood pressure, heart rate and saturation of arterial blood (SpO2) will be carried out during all steps of the protocol to assess the tolerance to the procedure.
224200089|NCT06145880|DIAGNOSTIC_TEST|Artificial intelligence tool for transthoracic echocardiography|Pre-defined cohorts will be used to train the artificial intelligence tool for transthoracic echocardiography to improve the diagnosis of PH on TTE.
224200090|NCT02995265|DEVICE|Exoskeleton Program|Subjects will wear the exoskeleton device at each physiotherapy session to work on improving mobility and walking ability.
223602392|NCT03029923|BEHAVIORAL|Smoking cessation plus Health and Wellness|All participants will receive one hour of standard smoking cessation counseling during their hospitalization for an acute coronary syndrome. Participants will be randomized 1 week after discharge. Those assigned to the Smoking cessation plus Health and Wellness condition will receive 5 more counseling sessions over the 12 weeks after hospital discharge. The first will be up to one hour and will be conducted in person. The next 4 sessions will occur over the phone and will take about 30 minutes. Post-discharge sessions will be focused on smoking cessation and didactic health and wellness education. Participants will be offered the nicotine patch if medically cleared.
223602393|NCT02381015|GENETIC|Genetic Risk Score: Number Format|Genetic Risk Score: Number + Pictograph Genetic risk score based on validated panel of 46 single nucleotide polymorphisms previously identified to be associated with Prostate Cancer risk by Genome Wide Association Studies, presented to subjects as a number.
223602394|NCT02381015|GENETIC|Genetic Risk Score: Number + Pictograph|Genetic Risk Score: Number + Pictograph Risk information conveyed as either a number or a number + pictograph, depending on randomization group.
223602395|NCT02381015|BEHAVIORAL|Family History: Number Format|Family History: Number Format Risk information conveyed as either a number or a number + pictograph, depending on randomization group.
223750145|NCT05333627|BEHAVIORAL|Wellbeing Course (8 weeks)|The 8-week course consists of five lessons that provide psychoeducation about: symptom identification and the cognitive behavioural model, thought monitoring and challenging, controlled breathing and pleasant activity scheduling, graded exposure, and relapse prevention. With optional therapist support, therapists will respond to any messages that clients send once per week. Therapists will not message clients on weeks where the client does not send a message.
223750146|NCT04434131|DRUG|Convalescent Plasma|Study subjects will receive 1 unit (200mL) of SARS-CoV-2 convalescent plasma collected from a single donor who recovered from COVID-19.
223750147|NCT06182826|PROCEDURE|Core Stability protocol|5 Minutes Warm up Hamstring stretch Back Extensor Stretch Hip Flexor Stretch Jumping Rope Stair Stepping Mountain Climbers Curl Up Side Planks Bird Dog Frequency: 3 sessions per week for six weeks. Time Duration: Approx. 30 to 45 minutes
223750148|NCT06182826|PROCEDURE|Routine exercise therapy|5 Minutes Warm up Hamstring stretch Back Extensor Stretch Hip Flexor Stretch Jumping Rope Stair Stepping Mountain Climbers Frequency: 3 sessions per week for six weeks. Time Duration: Approx. 30 to 45 minutes
223750149|NCT03768596|BEHAVIORAL|Nudge|Influenza Vaccine Prescription Form accompanied on the back of telephone numbers of occupational health centers of different hospitals where interns are likely to be on probation.
223750150|NCT03768596|OTHER|vaccination form|a form about vaccination
223750151|NCT01135758|DRUG|Ketamine|Administration of a subanaesthetic dose of Ketamine, intravenously (0.5 mg/kg)
223750152|NCT03851042|DEVICE|Virtual Reality Head set in PACU|Use of VR headset to determine post op satisfaction in PACU, decreased pain reduction and opioid consumption
223750153|NCT03851042|OTHER|No intervention|Routine post laparoscopic hysterectomy management (no VR headset)
223602396|NCT02381015|BEHAVIORAL|Family History: Number + Pictograph|Family History: Number + Pictograph Risk information conveyed as either a number or a number + pictograph, depending on randomization group.
223750154|NCT04236804|DEVICE|Flowly (TMC-CP01)|TMC-CP01 is a device designed specifically for pain management and is tailored for low back pain. The treatment utilizes virtual reality and biofeedback to train patients to auto-regulate themselves and improve their pain over time guidelines.
223750155|NCT06214156|BIOLOGICAL|T3011|T3011 will be given intratumorally， Q2W；
223750156|NCT05115110|DRUG|RO7204239|"RO7204239 will administered every 4 weeks (Q4W) by subcutaneous (SC) injection into the abdomen.~RO7204239 will be investigated at low- and high-dose in Part 1."
223750157|NCT05115110|DRUG|Placebo|Placebo will be administered Q4W by SC injection into the abdomen.
223750158|NCT05115110|DRUG|Risdiplam|Risdiplam will be administered orally once daily (QD) for the duration of the study.
223750159|NCT03870828|DIAGNOSTIC_TEST|Bronchoalveolar lavage and taking bronchial mucosa samples|"Regional anesthesia and sedation with use of lidocaine and midazolam will be performed, according to anesthesia protocols applied in respective endoscopy units. Intravenous cannula will be inserted prior to BF. During endoscopy, the patient will be monitored according to safety protocols applied in respective endoscopy units.~Bronchoalveolar lavage will be performed in the bronchus from the middle robe of right lung or the lingula of left lung (B4, B5). Localization will be chosen based on HRCT results and will be recorded in patient's medical history. Sterile solution of 0, 9% NaCl will be instilled. 200 ml fluid will be applied with a syringe in portions of 25 ml or 50 ml. It is recommended that minimum 60 % of the lavage fluid is retrieved."
223750160|NCT03870828|DIAGNOSTIC_TEST|6minute walk test|a submaximal exercise test which entails measurement of distance walked over a span of 6 minutes. Blood pressure, pulse oximetry are measured directly before and after the test. The participant is also periodically asked about their dyspnea sensation
223750161|NCT03870828|DIAGNOSTIC_TEST|Arterial blood gas|If SpO2 is measured to be \< 92%, an artery (radial or femoral) is punctured in order to take a sample of arterial blood. Then, the artery is compressed in order to prevent bleeding/ hematoma.
223750162|NCT03870828|PROCEDURE|Blood drawing|A vein will be punctured in order to take a blood sample for further tests
223750163|NCT06567626|OTHER|Decision Support Tool (DECIDE-CAD)|DECIDE-CAD is a decision support tool - designed using mixed methods through this study - which aims to enable shared decision making with people who are considering revascularisation options for coronary artery disease.
223750164|NCT06169813|OTHER|Nicotine Replacement Therapy (NRT)|NRT (daily patches and lozenges). NRT strength will be according to the established dosing guidelines for tobacco treatment. NRT is the standard of care in tobacco treatment and helped reduce CPD in prior trials
223750165|NCT06169813|OTHER|E-Cigarette (EC)|EC with single-use pods. Nicotine - 48 mg/ ml (4.8% nicotine) concentration.
223602397|NCT02779049|OTHER|Blood examination|blood sampling
223602398|NCT02084550|DIETARY_SUPPLEMENT|Vaminolac|Vaminolac with an amino acid content corresponding humane breast milk.
223602399|NCT02084550|OTHER|Saline|Intravenous isotonic saline with a sodium chloride content of 9mg/ml.
223602400|NCT00657163|DRUG|fluoxetine|fluoxetine per os 20 mg daily
223750166|NCT06169813|BEHAVIORAL|Counseling|Each participant will receive up to 5-motivational counseling sessions. The first session will also include orientation of EMA/EMI texting.
223602401|NCT00657163|DRUG|placebo|placebo per os daily
223750167|NCT06113133|DIAGNOSTIC_TEST|measurement of oxygen uptake|oxygen uptake is obtained during a maximal exercise test
223750168|NCT04452331|OTHER|Open Access Audio|Patient obtains secure access to an audio recording of the medical encounter post-visit that is accessible from any internet enabled device.
223750169|NCT04452331|OTHER|No Access, Patient and Provider Aware of Recording|Patient does not obtain access to audio recording but both patient and provider are aware visit is being recorded.
223750170|NCT04452331|OTHER|No Access, Provider Unaware of Recording|Patient does not obtain access to audio recording and provider is unaware visit is being recorded.
223750171|NCT05071183|DRUG|TPX-0005|Oral TPX-0005 capsules
223750172|NCT05071183|DRUG|Trametinib|Oral trametinib tablets
223750173|NCT02969824|BEHAVIORAL|Supervised Aerobic Exercise|The AE protocol will consist of eight sessions that proceed in a stepwise fashion in terms of duration and intensity over 11 days. Exercise will be performed on the Velotron Pro stationary cycle ergometer (RacerMate Inc., WA, USA), which will be digitally connected to a heart rate monitor and programmed to monitor the wattage of the bike based on the participant's heart rate. Exercise duration (15min-20min) and intensity (60%-75% max HR) will increase over the intervention period. For the remotely supervised sessions, exercise intensities and heart rate will be monitored via FitBit.
223602402|NCT06011837|DEVICE|Altered Auditory Feedback|Mumble Melody is an application that leverages Altered Auditory Feedback (AAF). During AAF, a person's speech is altered in near-real time. Mumble Melody modulates the user's voice and plays it back to them while they are speaking. Included are Unaltered (raw voice), Whisper (voiceless sound), Reverb (cathedral sound), and Harmonized (robotic sound) voice transformations.
223602403|NCT03921931|OTHER|White light stimulation|Stimulation of the retina with white light
223750174|NCT01904708|OTHER|Acute Moderate Intensity Exercise|Moderate intensity exercise by walking on a treadmill at 75% of max heart rate.
223750175|NCT00003075|DRUG|Fenretinide|Oral Fenretinide daily for 6 months with 3 days of rest every month.
223750176|NCT00003075|OTHER|Placebo|Oral placebo daily for 6 months with 3 days of rest every month.
223750177|NCT03638310|PROCEDURE|intratympanic application of gentamicin|under local anesthesia is gentamicin instilled through tympanic membrane to tympanic cavity
224200091|NCT02995265|OTHER|Usual Care Program|Subjects will receive hands-on physiotherapy to improve their mobility and walking ability. Physiotherapy session will be tailored to subject individually by their therapist.
224200092|NCT00665704|BEHAVIORAL|Tobacco Tactics website|Pilot test the Tobacco Tactics website tailored to the needs of veteran smokers
223602404|NCT00002203|DRUG|Lamivudine/Zidovudine|
223602405|NCT00002203|DRUG|Lamivudine|
223602406|NCT00002203|DRUG|Zidovudine|
223750178|NCT03638310|PROCEDURE|microsurgical removal of vestibular schwannoma|surgery under general anesthesia
223750179|NCT02256761|DRUG|BIRT 2584 XX - multiple escalating dose|
223750180|NCT02256761|DRUG|Placebo|
223750181|NCT02256761|DRUG|BIRT 2584 XX - single dose|
223750182|NCT02256761|OTHER|high caloric meal|30 minutes prior to the second drug administration after a one week wash-out period, a standardised high fat, high caloric meal was served
224200093|NCT00437710|PROCEDURE|cell therapy, bone marrow derived stem cell|
224200094|NCT05033379|BEHAVIORAL|Control|Importance of sleep
224200095|NCT05033379|BEHAVIORAL|Resilience coaching|Arena Strive
223602407|NCT05196191|BIOLOGICAL|VIAGENEX Max|Collagenous membrane derived from umbilical cord
223602408|NCT05196191|PROCEDURE|Hibiclens wash|Antiseptic skin cleanser
223750183|NCT00324467|DRUG|Cyclophosphamide|"Dose: 750 mg/m\^2 Administration: IV infusion day 1 over 20-60 minutes Schedule: Cycle 1, 2, 3, 4, 5\*, 6\* (Week 1, 4, 7, 10, 14, 17)~\* Cycles 5 and 6 of R-CHOP will be administered only to patients with a negative mid-treatment PET scan"
223750184|NCT00324467|DRUG|Doxorubicin|"Dose: 50 mg/m\^2 Administration: IV Push day 1 Schedule: Cycle 1, 2, 3, 4, 5\*, 6\* (Week 1, 4, 7, 10, 14, 17)~\* Cycles 5 and 6 of R-CHOP will be administered only to patients with a negative mid-treatment PET scan"
223750185|NCT00324467|DRUG|Vincristine|"Dose: 1.4 mg/m\^2 Administration: IV Push day 1 Schedule: Cycle 1, 2, 3, 4, 5\*, 6\* (Week 1, 4, 7, 10, 14, 17)~\* Cycles 5 and 6 of R-CHOP will be administered only to patients with a negative mid-treatment PET scan"
223750186|NCT00324467|DRUG|Prednisone|"Dose: 45 mg/m\^2 Administration: IV infusion day 1 (or day 2) over 90 minutes-8 hours Schedule: Cycle 1, 2, 3, 4, 5\*, 6\* (Week 1, 4, 7, 10, 14, 17)~\* Cycles 5 and 6 of R-CHOP will be administered only to patients with a negative mid-treatment PET scan"
223750187|NCT00324467|DRUG|Ondansetron|Premedication for R-CHOP Dose: 8 mg Route: PO Schedule: 15 min pre-CHOP chemotherapy
223750188|NCT00324467|DRUG|Dexamethasone|Premedication for R-CHOP Dose: 12 mg Route: PO Schedule: 15 min pre-CHOP chemotherapy
223750189|NCT00324467|DRUG|Diphenhydramine|Premedication for R-CHOP Dose: 50 mg Route: PO Schedule: Prior to rituximab and then q 4h during rituximab infusion
223750190|NCT00324467|DRUG|Acetaminophen|Premedication for R-CHOP Dose: 650 mg Route: PO Schedule: Prior to rituximab and then q 4h during rituximab infusion
223750191|NCT00324467|DRUG|Ifosfamide|R-ICE Chemotherapy Schedule (cycles repeated every 3 weeks) Dose: 5000 mg/m\^2 (total dose per cycle) Administration: In 3 equally divided doses IV infusion days 1,2,3, over 2 hours Schedule: Cycle 1, 2, 3, 4 (Week 14, 16, 20, 23)
223750192|NCT00324467|DRUG|Mesna (IV)|R-ICE Chemotherapy Schedule (cycles repeated every 3 weeks) Dose: 5000 mg/m\^2 (total dose per cycle) Administration: In 3 equally divided doses IV infusion days 1,2,3 (with ifosfamide) over 2 hours Schedule: Cycle 1, 2, 3, 4 (Week 14, 16, 20, 23)
223750193|NCT00324467|DRUG|Mesna (oral)|R-ICE Chemotherapy Schedule (cycles repeated every 3 weeks) Dose: 2 g Administration: PO 2h and 4h after ifosfamide infusion on days 1,2,3 Schedule: Cycle 1, 2, 3, 4 (Week 14, 16, 20, 23)
224200096|NCT03016104|DEVICE|Magpro X100 + Option|In addition to treatment as usual (TAU), participants were supposed to receive ten sessions of MST in four weeks, with three sessions per week in the first two weeks and two sessions per week in the following two weeks.
224200097|NCT03016104|DEVICE|ThymatronSystem Ⅳ Electroconvulsive System|In addition to treatment as usual (TAU), participants were supposed to receive ten sessions of modified ECT in four weeks, with three sessions per week in the first two weeks and two sessions per week in the following two weeks
224200098|NCT03016104|OTHER|treatment as usual (TAU)|Participants will engage in their inpatient treatment program as-usual.
224200099|NCT04179578|PROCEDURE|Crura plastic|Closure of hiatus with a running suture
223602409|NCT01449006|DRUG|Maraviroc|Maraviroc oral tablet. Dosage: 150 mg twice daily, 300 mg twice daily, or 600 mg twice daily. Dosing will be dependent on the participant's background HAART therapy, and will be in accordance with the product information sheet.
223602410|NCT05415007|BEHAVIORAL|GOLD Program|Participant will receive a 2-hour interventional session
223602411|NCT05415007|BEHAVIORAL|Treatment as usual (TAU)|Participant will receive treatment-As-Usual which consist of information about diagnosis routinely-disseminated by personnel and providers.
223602412|NCT03350815|DRUG|150 mg open-label secukinumab|All patients in Treatment Period 1 received 150 mg s.c. injection open-label secukinumab.
223602413|NCT03350815|DRUG|150 mg double-blinded secukinumab|Treatment Period 2 Patients who achieved responder status entered Treatment Period 2 and continued to receive 150 mg s.c. (1 s.c. injection of secukinumab 150 mg)
223602414|NCT03350815|DRUG|300 mg double-blinded secukinumab|Treatment Period 2 300 mg (2 s.c. injections of the 150 mg dose)
223602415|NCT02586870|DEVICE|Intravascular Ultrasound|
223602416|NCT05610527|OTHER|Proposed study design and randomization scenarios|Present hypothetical study scenarios and assess willingness to be randomized based on the adapted 7-item Attitudes to Randomized Trials Questionnaire
223602417|NCT05610527|OTHER|Repeated measures of validated Inflammatory Bowel Disease Patient Reported Outcome Instruments|We will electronically administer Ulcerative Colitis (UC) and Crohn's Disease validated PRO instruments, including the daily symptom modules and weekly quality of life modules for 12 weeks to all 200 participants
223602418|NCT05610527|OTHER|Inflammatory marker collection and assessment for correlation with PRO responses and menstrual timing|In an Aim 3 sub study of 30% of participants, we will collect inflammatory markers commonly used to assess disease activity and risk of relapse in inflammatory bowel disease patients, including weekly blood samples of high sensitivity c-reactive protein (13 total) and monthly ferritin, albumin, and WBC, as well monthly stool specimens (4 total) for fecal calprotectin
223602419|NCT00863499|DRUG|Short Acting Methylphenidate|Dosage: 5 mg twice daily (before breakfast and lunch) with gradual increments of 5 to 10 mg weekly. Daily dosage above 60 mg is not recommended.
223602420|NCT00863499|DRUG|Long Acting Methylphenidate|Dosage: 9 to 20 mg once daily in the morning (with or without food) with gradual increments of 9 to 20 mg weekly. Daily dosage above 60 mg is not recommended.
223602421|NCT01866358|PROCEDURE|Intraosseous infusion|Using intraosseous infusion for resustation in this group
223602422|NCT01866358|PROCEDURE|Umbilical vein infusion|Using umbilical vein infusion for resustation in this group
223602423|NCT03053570|DEVICE|Cryoballoon|use Cryoballoon to isolation the Pulmonary Vein
223602424|NCT03053570|DEVICE|Radiofrequency Energy(Contact Force)|use Radiofrequency Energy(Contact Force) to isolation the Pulmonary Vein
223602425|NCT00237497|DRUG|Ramelteon|Ramelteon 8 mg, tablets, orally, once daily for up to 28 nights.
223602426|NCT00237497|DRUG|Zopiclone|Zopiclone 7.5 mg, tablets, orally, once daily for up to 28 nights.
223602427|NCT00237497|DRUG|Placebo|Placebo-matching tablets, orally, once daily for up to 28 nights.
223602428|NCT05355662|OTHER|Age|The study was retrospective and did not involve the application of interventions.
223602429|NCT03336294|RADIATION|SRM P31|All the volunteers involved in the CAMUS study will perform during the SRM P31 a quadricipital physical task at 70% 1-RM.
223602430|NCT06841328|PROCEDURE|Stem cells|The administration of stem cell or stem cell-derived exosome therapy as a regenerative treatment for gonadal failure in both men and women. The intervention involves a single intra-gonadal injection (testicular or ovarian) of adipose-derived stem cells (ADSCs) or exosomes.
223602431|NCT04386941|PROCEDURE|Xpeeda Fibre Laser Vaporesection of the Prostate|"Both interventions are currently used standard of care treatments for the Holmium laser enucleation of the prostate (HoLEP) for patients with bothersome lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH).~Holmium Xpeeda side firing fibre was introduced and it stands apart from other available technologies as a combination of power and efficiency, which minimizes vaporization time. This technology seems to revolutionize utilization of the Holmium power and delivering more energy directly to the tissue, due to its capability of being in contact with the tissue."
223602432|NCT04386941|PROCEDURE|Greenlight XPS Vaporization of the Prostate|The introduction of the Xcelerated Performance System (XPS) 180W in 2010 with the MoXy fibers represents the highest-powered system currently in use for this type of laser.11 It encourages the adoption of the enucleation principle, making it a real contender to HoLEP in treating large adenomas. Despite the fact that large prostates often require more energy and longer operative time, the XPS system has reduced the operative time and number of fibers required in these situations.
223602433|NCT05213702|DEVICE|Renal Calyx punture with traditional free hand or ANT-X device|ANT-X device is a software-controlled automated electromechanical arm. It is developed to provide needle guidance for surgeon in MIS. This aims to reduce the surgery time taken and also minimize the radiation withstand by both surgeon and patient. ANT-X device is actually a Delta parallel robot implementing inverse kinematics to achieve effector's movement. Parallel structures excel in their great stiffness and high positioning accuracy. Most of the main components of ANT-X robot are made up of medical grade Polyether ether ketone (PEEK) material. PEEK is preferred to build the robot because it is radiolucent and lightweight while being able to provide relatively high material strength. The device is intended for use together with C-arm fluoroscope (fluoroscopy/CT technology). The fluoroscopy technology is used to provide image guidance for the needle
223602434|NCT00139048|BEHAVIORAL|Decision Aid|
223602435|NCT06114199|BEHAVIORAL|Produce Prescription Program (PPRx) Standard|Participants will receive biweekly deliveries of 20 lbs (\~50 servings) of fresh produce (8-10 different kinds of produce) plus standard nutrition education materials consisting of nutrition education infographics inside of the produce prescription boxes as well as online videos, recipes, and nutrition tips accessed via Quick Response (QR) code.
223602436|NCT06114199|BEHAVIORAL|Smartphone App|Participants will be given access to a smartphone app that allows women to interact with an artificial intelligence (AI) chatbot to obtain real-time cooking suggestions.
223750194|NCT00324467|DRUG|Carboplatin|"R-ICE Chemotherapy Schedule (cycles repeated every 3 weeks) Dose: 5 x (25+CrCl\*) (maximum dose 800 mg) Administration: IV infusion day 1 over 1 hour Schedule: Cycle 1, 2, 3, 4 (Week 14, 16, 20, 23)~\*Carboplatin is dose via the Calvert formula with an AUC of 5, maximum dose 800 mg per cycle.~Estimate Creatinine Clearance (CrCl)"
223602437|NCT01191177|DRUG|Lovaza (omega-3-acid ethyl ester)|supplied as 1gram transparent soft-gelatin capsules filled with yellow oil, dosage is 1gram per kilogram of body weight per day, not exceeding 4grams per day until normalization of liver function test
223602438|NCT01191177|DIETARY_SUPPLEMENT|Corn oil|1 gram per kilogram body weight per day, not exceeding 4 grams
223750195|NCT00324467|DRUG|Etoposide|R-ICE Chemotherapy Schedule (cycles repeated every 3 weeks) Dose: 100 mg/m\^2 Administration: IV infusion day 1,2,3 over 30 minutes Schedule: Cycle 1, 2, 3, 4 (Week 14, 16, 20, 23)
223750196|NCT00324467|DRUG|Rituximab|R-ICE Chemotherapy Schedule (cycles repeated every 3 weeks) Dose: 375 mg/m\^2 Administration: IV infusion day 1 (or day 2 or day 3) over 90 minutes-8 hours Schedule: Cycle 1, 2, 3, 4 (Week 14, 16, 20, 23)
223750197|NCT00324467|DRUG|Ondansetron|Premedication for R-ICE Dose: 8 mg Route: PO Schedule: 15 min pre-chemotherapy daily
223750198|NCT00324467|DRUG|Dexamethasone|Premedication for R-ICE Dose: 8 mg Route: PO Schedule: 15 min pre-chemotherapy daily
223750199|NCT00324467|DRUG|Diphenhydramine|Premedication for R-ICE Dose: 50 mg Route: PO Schedule: Prior to rituximab and then q 4h during rituximab infusion
223750200|NCT00324467|DRUG|Acetaminophen|Premedication for R-ICE Dose: 650 mg Route: PO Schedule: Prior to rituximab and then q 4h during rituximab infusion
223750201|NCT00324467|OTHER|PET Scan|Investigations: 18F-FDG-PET scan Timing: After 4 cycles of R-CHOP (days 21-28) and after 4 cycles of R-ICE (days 28-35)
223750202|NCT01759108|DRUG|Rebamipide|Patients will be randomized 1:1 to receive either 300mg/d (100mg x3/day) of rebamipide or placebo for 12 weeks together with their usual therapy.
223750203|NCT01371474|DRUG|Paroxetine|
223750204|NCT02981823|PROCEDURE|hip replacement|The patients undergo hip replacement with the collum femoris preserving stem suffered from periprosthetic fractures.
223750205|NCT05228522|BEHAVIORAL|Lifestyle Intervention|16-week family-focused intervention that includes nutrition education, behavioral change skills training, and physical activity.
223750206|NCT02133950|PROCEDURE|elective cryopreservation of available embryos after PGD|no elective fresh embryo transfer; freeze all
223750207|NCT02133950|PROCEDURE|PGD and elective fresh embryo transfer plus cryopreservation of supernumerary available embryos after PGD|PGD and elective fresh embryo transfer plus cryopreservation of supernumerary available embryos after PGD
223750208|NCT01229423|DRUG|bimatoprost 0.03%|One drop of bimatoprost 0.03% (LATISSE®) applied evenly to each upper eyelid in the evening. Treatment is once daily for up to 40 weeks.
224200100|NCT05255354|DEVICE|ClonoSEQ|Cancer clonotype sequences are identified in diagnostic 'ID' samples and then sequence frequencies are measured in follow up samples.
223750209|NCT06453629|DEVICE|Floreo VR|12 week VR program to help children with ASD to reduce the core symptoms of Autism
223750210|NCT06453629|DEVICE|VR Control|12 week program administered in VR
223750211|NCT06453629|DEVICE|VR Control Crossover|If opt in, this group will crossover at the end of 12 weeks to the Floreo VR program
223750212|NCT05580081|BEHAVIORAL|i-CAN|online support and consultation to providers
223750213|NCT06171776|DRUG|RetroMTA|calcium silicate lining material work as dentin substitute
223750214|NCT06171776|DRUG|TheraCal|calcium silicat material light cured
223750215|NCT06171776|DRUG|Fuji IX|filling material bonded chemically to the tooth structure
223750216|NCT01232920|DRUG|Methotrexate|All methotrexate doses will be taken orally once per week in a divided dose (half in the morning, half in the evening), and should be taken with food. For the first two weeks, a loading dose of 15 mg/week orally will be administered to assess tolerability. After two weeks, the dose will be ramped up to 25 mg/week until the end of follow-up or until treatment failure due to intolerability, adverse events, or of lack of efficacy. If the study ophthalmologist decides to reduce the study treatment dose due to intolerability, the dose will be reduced to 20 mg per week while maintaining masking. If side effects persist and the study ophthalmologist wishes to reduce the dose a second time, the dose will be reduced to 15 mg per week.
223750217|NCT01232920|DRUG|Mycophenolate mofetil|Mycophenolate mofetil will be taken twice daily on an empty stomach. For the first two weeks, a loading dose of 500 mg/BID orally will be administered to assess tolerability. After two weeks, the dose will be ramped up to 1 g/BID until the end of follow-up or until treatment failure due to intolerability, adverse events, or lack of efficacy. If the study ophthalmologist decides to reduce the study treatment dose due to intolerability, the dose will be reduced to 750 mg/BID while maintaining masking. If side effects persist and the study ophthalmologist wishes to reduce the dose a second time, the dose will be reduced to 500 mg/BID.
223750218|NCT05224674|DEVICE|Extracorporeal Shock Wave Therapy (ESWT)|The ESWT device is product of Elettronica Pagani, Italy.
223750219|NCT04608903|DIETARY_SUPPLEMENT|L-sulforaphane 1%|Administration of 4g L-sulforaphane per day, for 2 months
223750220|NCT04608903|DIETARY_SUPPLEMENT|Placebo Group|Administration of 4g corn starch colored with chlorophyll, per day, for 2 months
223750221|NCT06846710|DRUG|HS-20118|Single and multiple ascending doses of HS-20118 orally
223750222|NCT06846710|OTHER|HS-20118 placebo|Single and multiple ascending doses of HS-20118-matched placebo orally
223750223|NCT05221606|BEHAVIORAL|Nurse AMIE|Supportive Care Platform (behavioral interventions that are offered based on answers to daily symptom rating questions). Interventions offered include walking, balance, strength exercise, guided relaxation, mindfulness, CBT, DBT, soothing music.
223750224|NCT05221606|BEHAVIORAL|Usual Care|Binder of written supportive care materials
223750225|NCT02563678|DRUG|Hyperbaric Oxygen|Hyperbaric oxygen therapy
223750226|NCT02563678|OTHER|Hyperbaric Air/Oxygen|Breathing air inside a hyperbaric chamber, then breathing oxygen inside a hyperbaric chamber
223750227|NCT02563678|OTHER|Normobaric oxygen|Breathing 100% oxygen at normal, atmospheric pressure
223750228|NCT05682261|DIETARY_SUPPLEMENT|UNIMMAP-MMS|The study participants in this arm will receive the United Nations International Multiple Micronutrient Antenatal Preparation-Multiple Micronutrient Supplements (UNIMMAP-MMS) containing 15 micronutrients including 30 mg of iron and 400 µg of folic acid.
224200101|NCT04920162|OTHER|Biospecimen into patients who had skin diseases|Collect of blood samples without DNA into patients who had a vitiligo or a melanoma at day 0 until 1 year after their treatment
224200102|NCT03394404|DEVICE|ECG-I mapping and PVI|ECG-I mapping and PVI
224200103|NCT03032575|BEHAVIORAL|SEARCH010/RV254|
223602439|NCT05509426|BEHAVIORAL|Cognitive Rehabilitation|This cognitive rehabilitation will be tailored to each participant's cognitive status while maintaining a systematic treatment approach to attention and memory, following a study treatment manual. The intervention will include (i) restitution strategies to retain memory and attention functions including strategies to improve encoding and retrieval, (ii) compensation strategies, including internal mnemonics, use of external devices and ways of coping with attention and memory problems, (iii) the importance of errorless learning. The emphasis will be on identifying the most appropriate strategies to help individuals overcome their cognitive problems and in providing participants with a range of techniques, which they can adapt and use according to their needs. This is group based intervention that will take place remotely using MS Teams.
223750229|NCT05682261|DIETARY_SUPPLEMENT|IFA|The study participants in this arm will receive iron-folic acid supplements with 30 mg of iron and 400 µg of folic acid.
223602440|NCT04984486|DEVICE|dental implant|"The procedure used to accomplish its intended use is as follows :~* The recipient implant site is prepared using a drilling sequence, then the implant is placed at the crestal level~* After a period of osseointegration of the implant, a transgingival healing screw is placed to allow the healing of soft tissues. After this healing phase, the final prosthesis will be loaded on the implant."
223602441|NCT00001212|DRUG|prednisone|
223602442|NCT00001212|DRUG|cyclophosphamide|
223602443|NCT00001212|DRUG|cyclosporin A|
223602444|NCT05681065|DEVICE|TeNDER tool|"The TeNDER intervention consists of the use of the TeNDER technological tool. It is a web application that integrates all the functionalities of biosensors to facilitate patient self-monitoring, caregiver care and monitoring and management in the daily work of healthcare professionals. Each participant will use the sensor that suits their needs:~Sleep quality detector; Position sensor; Smart band; Smart watch; Microphone and speaker; rgb (real sense) sensor; Binary door and window sensor; Environmental sensor."
223602445|NCT00318799|DRUG|EV/DNG (Qlaira, BAY86-5027, SH T00658ID)|per cycle (28 days): Days 1-2: 3.0 mg EV; Days 3-7: 2.0 mg EV + 2.0 mg DNG; Days 824: 2.0 mg EV + 3.0 mg DNG; Days 25-26: 1.0 mg EV; Days 27-28: Placebo
223602446|NCT00318799|DRUG|SH D01155E|per cycle: Days 1-21: 0.03 mg EE + 0.15 mg LNG; Days 22-28: Placebo
223750230|NCT05682261|OTHER|Placebo|The study participants in this arm will receive placebo made of sugar (lactose anhydrous).
223750231|NCT04979169|BEHAVIORAL|Text Messaging|A series of theory-informed text messages encouraging them to contact their primary care provider and the UR LCS Program's Patient Navigator to coordinate screening, along with contact information to do so.
223602447|NCT05230472|DRUG|Simvastatin|simvastatin 60 mg tab
223602448|NCT03376737|DRUG|Apatinib|Apatinib (250 mg/d) + Pemetrexed (500 mg/m2)
223602449|NCT00350688|RADIATION|Helical tomotherapy IMRT|Helical tomotherapy IMRT
223602450|NCT02092792|DRUG|DLYE5953A|Escalating doses of DLYE5953A
223602451|NCT02092792|DRUG|DLYE5953A|Administration of DLYE5953A at the recommended phase II dose (RP2D)
223750232|NCT05794152|OTHER|Standardized breakfast|Participants will be provided with a standardized breakfast on a morning of the days they wear a continuous glucose monitoring (CGM) device.
223750233|NCT05794152|OTHER|Standardized snack|Participants will be provided with a standardized snack 2 hour after they have the standardized breakfast.
223750234|NCT05794152|OTHER|Standardized lunch|Participants will be provided with a standardized lunch 2 h after they have the standardized snack.
223750235|NCT03970590|BEHAVIORAL|CTC Intervention|"An integrated peer narrative-based intervention (VIEW \> SELECT \> GET), beginning with VIEW In-person viewing of VA Stories narratives, followed by SELECT a favorite Veteran\] Storyteller, and then GET favorite Storyteller narrative-aligned text messages over 6 months"
223750236|NCT03970590|BEHAVIORAL|Control|6-month HTN management assessment text messages without narrative component
223750237|NCT03840083|BEHAVIORAL|Sleep|Participants will sleep (either a mid-day nap or normal overnight sleep)
223750238|NCT01206179|BIOLOGICAL|cell injection|Injection of mesenchymal cells in fractured zone
223750239|NCT06216691|OTHER|Coach-guided smartphone delivered CBT program.|All eligible participants will be enrolled in an 8-week coach-guided smartphone delivered CBT program. The full duration of the program, with follow-up interview, will be 9 weeks.
223750240|NCT02674971|BEHAVIORAL|Common components of intervention|12-week standard lifestyle intervention for obesity, which consists of weekly meetings. Each meeting will last 60 minutes, with participants attending group meetings specific for their condition. In all meetings, participants will be weighed, homework assignments will be verbally reviewed, and a behavioral lesson will be presented. Basic behavioral lessons, will be similar to those that have been successfully used in the Diabetes Prevention Program (DPP) and Look AHEAD. Topics to be covered in the meetings will focus on the dietary prescriptions and dietary information for each condition, the physical activity goal, energy balance, and behavioral strategies. Each session will conclude with reminding participants of their dietary and physical activity goals, and having participants self-monitor these behaviors every day and implement the behavioral strategies discussed in the session.
223750241|NCT06104059|DEVICE|Nociception level index (NOL™)|If a NOL value \>25 persists for \>1 minute a bolus of iv fentanyl 0.5mcg/kg will be given and reassessment of the NOL value will continue every 5 minutes. If NOL index value: 10-25 is not reached within 10 minutes, fentanyl 0.5mcg/kg iv is re-administered.
223750242|NCT06104059|OTHER|Fentanyl|Bolus doses of iv fentanyl 0.5 mcg/kg will be administered based on the judgment of the anesthesiologist in charge.
223602452|NCT01015781|PROCEDURE|Progressive Tinnitus Management|"The program follows a five-level progressive intervention model that addresses the various needs of tinnitus patients in a systematic and hierarchical manner-from initial contact with a VA provider through long-term treatment. The five levels of progressive intervention are: 1) Triage; 2) Audiologic Evaluation; 3) Group Education; 4) Interdisciplinary Evaluation; 5) Individualized Support"
223602453|NCT01015781|PROCEDURE|Wait List Control|VA audiologists typically (a) perform an audiologic evaluation; (b) fit hearing aids if necessary; and (c) provide basic information about tinnitus in the form of one-time, one-on-one informational counseling and/or a tinnitus handout. We therefore will provide these procedures for subjects who are randomized to receive usual care. Usual care subjects also can be referred for other clinical services as deemed appropriate.
223602454|NCT02837029|OTHER|Laboratory Biomarker Analysis|Correlative studies
223602455|NCT02837029|BIOLOGICAL|Nivolumab|Given IV
223602456|NCT02837029|RADIATION|Yttrium Y 90 Glass Microspheres|Given IA
223602457|NCT00398567|DRUG|HKI-272|HKI-272 by mouth
223602458|NCT00398567|DRUG|trastuzumab|trastuzumab 4 mg/kg IV as a loading dose followed by trastuzumab 2 mg/kg weekly thereafter
223602459|NCT06304623|BIOLOGICAL|Autologous adipose-derived SVF IV administration|Subjects received an intravenous injection of autologous adipose-derived SVF.
223750243|NCT03136003|DRUG|DDAVP|The participant will take either 1 or 2 nasal sprays of IN DDAVP (known as Octostim® in Canada). After receiving IN DDAVP, the participant will rest for 30 minutes.
223750244|NCT03136003|BEHAVIORAL|Exercise|The participant will exercise on a stationary cycle-ergometer using the previously-validated, progressively-incremental Godfrey protocol. Per the Godfrey protocol, the participant starts cycling on the calibrated cycle-ergometer with an initial exercise load dependent on their height. The workload is increased every minute in standard increments also based on the participant's height. All participants will exercise until they complete 3-minutes of cycling at 85% of their maximum predicted heart rate or exhaustion (whichever is first). Upon completion of planned exercise, work load is decreased to zero watts and participants will continue cycling at this cool-down rate for an additional 3-minutes, before getting off the ergometer.
223750245|NCT06484712|DEVICE|Stochastic Resonance (SR)|The system consists of six linear isolated stimulators (STMISOLA, Biopac Systems, Inc., Goleta, USA). The SR signal (Gaussian White Noise, zero mean) will be generated through a 16 bit PCI 6733 National Instruments multifunction data acquisition card by a custom LabView program. The stimulation sites include the ankle, lateral soleus, peroneus longus, and tibialis anterior muscles and the hip.
223750246|NCT05900440|OTHER|Ultrasound with Artificial Inteligence Engabled|Participants shall be randomized 1:1 to receive personal access to a handheld ultrasound device with artificial intelligence vs a device with no artificial intelligence. The groups shall not cross over in which intervention they received.
223750247|NCT05900440|OTHER|Ultrasound without Artificial Intelligence Enabled|Participants shall be randomized 1:1 to receive personal access to a handheld ultrasound device with artificial intelligence vs a device with no artificial intelligence. The groups shall not cross over in which intervention they received.
223602460|NCT02397538|DRUG|Fimasartan|
223602461|NCT02397538|DRUG|Amlodipine|
223602462|NCT02397538|DRUG|Rosuvastatin|
223602463|NCT01969695|DRUG|ABT-199|ABT-199 continuous once daily dosing
223602464|NCT04108611|PROCEDURE|hemodiafiltration with endogenous re infusion (HFR)|hemodiafiltration with endogenous re infusion (HFR) for cases 2
223602465|NCT03484247|OTHER|Infraclavicular brachial plexus block|Infraclavicular block will be performed with ultrasound guidance and peripheric nerve stimulator. Local anesthetic will be administered after aspiration, via peripheric nerve needle according to mentioned technique ( https://www.nysora.com/)
223602466|NCT03484247|OTHER|axillary brachial plexus block|Axillary nerve block will be performed with ultrasound guidance and peripheric nerve stimulator. Local anesthetic will be administered after aspiration via peripheric nerve needle according to mentioned technique ( https://www.nysora.com/)
223602467|NCT02034877|BIOLOGICAL|13-valent Pneumococcal conjugate vaccine|1 dose (0.5 mL/ pre-filed syringe) of 13vPnC administered at visit 1
223602468|NCT02034877|PROCEDURE|Blood sample collection|10 mL of blood will be collected just before and approximately 1 month after vaccination.
223602469|NCT05408715|OTHER|Natural History Study|Longitudinal assessment of symptoms and development of complications in type II collagen disorders
223750248|NCT06023576|OTHER|antihypertensive medications|"One or more of the following medications may be used in both randomization groups to achieve SBP goals:~* Angiotensin converting enzyme inhibitors (ACEI)~* Angiotensin receptor blockers (ARBs)~* Beta-blockers (BB)~* Thiazide-type diuretics~* Calcium channel blockers~* Aldosterone antagonists~* Alpha1-receptor blockers.~* Direct vasodilators~* Loop diuretics"
224200104|NCT05301452|RADIATION|Intravascular Irradiation of Blood (ILIB)|The laser treatment will be performed by a speech therapist and will have the following parameters: wavelength of 808 nm. It will be done twice a week for 8 weeks, in 20-minute sessions.
223602470|NCT00526591|DRUG|Everolimus|Patients will receive arm-specific dosage of Everolimus daily continuously for 8 week
223602471|NCT00526591|PROCEDURE|conventional surgery|Radical prostatectomy with bilateral pelvic lymphadenectomy will be performed within 10 days of the completion of week 8 on RAD-001 (Everolimus).
223602472|NCT05104125|DRUG|ASC40 25mg|25mg of ASC40 orally once daily for 12 weeks.
223602473|NCT05104125|DRUG|ASC40 50mg|50mg of ASC40 orally once daily for 12 weeks.
223602474|NCT05104125|DRUG|ASC40 75mg|75mg of ASC40 orally once daily for 12 weeks.
223602475|NCT05104125|DRUG|Placebo|Placebo orally once daily for 12 weeks.
223602476|NCT05624580|DRUG|NNC0582-0001|Participants will receive single dose of any of the six dose levels of subcutaneous NNC0582-0001 in a sequential manner with the dose increasing between cohorts.
223602477|NCT05624580|DRUG|Placebo|Participants will receive single dose of subcutaneous injection of placebo matched to NNC0582-0001.
223602478|NCT01057186|DIETARY_SUPPLEMENT|Alfacalcidol; phosphate.|Individual dosage form and dosage depending on phenotype and underlying cause.
223602479|NCT01057186|DRUG|Sevelamer|Pills. Individual dosage depending on clinical symptoms/phenotype.
223602480|NCT04138446|OTHER|Altitude exposure in climate chamber|Altitude exposure in a climate chamber will consist of hypobaric hypoxia similar to the conditions found at 3000m asl and 5000m asl.
223602481|NCT03524014|OTHER|Only advice for diagnosis and prevention|Only advice for diagnosis and prevention
223602482|NCT01731366|OTHER|Whole grain|Whole grain diet: Participants consume more than 75g of whole grain per day (corresponds to the whole grain intake of the 90th percentile of the population)
223602483|NCT01731366|OTHER|Refined grain|Refined grain diet: Participants consume less than 10 g of whole grain per day (corresponds to the whole grain intake below the 10th percentile of the population)
223602484|NCT06403267|DRUG|NoNO-42|a single dose sterile 20 ml vial containing lyophilized powder for reconstitution containing 300 mg of NoNO-42 active ingredient.
223602485|NCT06457425|DRUG|Flonoltinib 50mg|Flonoltinib 50mg, QD
223507621|NCT04168710|DRUG|ESP block with bupivacaine|Each participant randomized to the ESP block group will receive an ultrasound guided single shot injection of 20cc of 0.25% bupivacaine in the plane between the transverse process of the spine and the erector spinae muscle.
223507622|NCT04168710|OTHER|Saline control/sham injection|Each participant randomized to the ESP block group will receive an ultrasound guided single shot injection of 20cc of normal saline in the plane between the transverse process of the spine and the erector spinae muscle.
223507623|NCT02794779|DRUG|Oxytocin|Intravenous bolus infusion of oxytocin 3UI followed by re-asessment of uterine tone by obstetrician after 3 minutes. Infusion stops when uterine tone is adequate and is repeated if inadequate to the maximum of 9UI (3 bolus infusions). If uretine tone is inadequate after 9UI then other methods for preventing bleeding will be used.
223507624|NCT02553070|OTHER|Survey|Pharmacy students will be asked to participate in a short (5-7 minutes) survey (see below) that contains 21-short cases involving an exposure to a pharmaceutical or non-pharmaceutical agent. All cases involve children less than 19 years of age. Participants will be asked to indicate their year in pharmacy school (1st or 2nd) and their gender (female/male).
223507625|NCT00294788|BIOLOGICAL|Fluvax|
223507626|NCT00294788|DRUG|PCC® (Lactobacillus fermentum VRI 003)|
223507627|NCT00113126|DRUG|Treatment interruption|
223507628|NCT04919343|BEHAVIORAL|BBC Education Tiny Happy People videos|This intervention involves regular texting of BBC Education Tiny Happy People videos to parents
223507629|NCT04919343|BEHAVIORAL|Physical health control intervention|This intervention involves regular texting of publicly available videos about supporting infant physical and dental health to parents
223507630|NCT03888079|DRUG|Local anesthetic|1% or 2% lidocaine with 1:100,000 epinephrine, augmented by intravenous sedation and analgesia
223507631|NCT03888079|DRUG|general anesthetic|Endotracheal intubation, intravenous narcotic agents, and inhaled agents
223507632|NCT00001818|DRUG|Hydroxyurea|
223507633|NCT04281719|OTHER|Mobile Application (working name: Bright Path)|The Bright Path web-based mobile application is designed to target co-occurring problems, enhance patient treatment engagement, and contribute to lasting improvements in teens' mental health. The central hypothesis is that developmentally tailored mobile applications that incorporate evidence-based treatment principles can facilitate increased patient engagement in and between sessions, thus, improving the efficiency, efficacy, and reach of treatments for this highly vulnerable population.
223507634|NCT00191152|DRUG|gemcitabine|1000 mg/m2, intravenous (IV) day 1 and day 8 every 21 days until disease progression
223507635|NCT00191152|DRUG|docetaxel|75 mg/m2, intravenous (IV), every 21 days until disease progression
223507636|NCT00191152|DRUG|capecitabine|1000 mg/m2, by mouth (PO) twice a day (BID), days 1-14, every 21 days until disease progression
223507637|NCT04828525|DRUG|Dexamethasone|adjuvant dexamethasone treatment
223507638|NCT04828525|DRUG|normal saline|placebo
223507639|NCT03360968|PROCEDURE|Variable-PS|Variable-PS mode switched on for 1 hour
223507640|NCT03360968|PROCEDURE|SPN-CPAP/PS|SPN-CPAP/PS mode switched on for 1 hour
223507641|NCT03360968|PROCEDURE|Variable-PS|Variable-PS mode switched on for 1 hour
223602486|NCT06457425|DRUG|Flonoltinib 100mg|Flonoltinib 100mg, QD
223602487|NCT06457425|DRUG|Ruxolitinib|For patients with platelet counts between 100×10\^9/L and 200×10\^9/L, the recommended starting dose is 15 mg twice daily (bid). For patients with platelet counts \>200×10\^9/L, the recommended starting dose is 20 mg bid. For patients with platelet counts between 50×10\^9/L and \<100×10\^9/L, the recommended maximum starting dose is 5 mg bid.
223602488|NCT06334718|BEHAVIORAL|Interviews and simulation|Work package 1: interview study Work package 2: simulated cardiac arrest study with AED delivered by drone following a simulated emergency (999) call.
223602490|NCT05945524|OTHER|Bone marrow sampling|Bone marrow sampling collected at 12 weeks after initiation treatment (day 1 cycle 4)
223602491|NCT05989230|BEHAVIORAL|Emotional Awareness and Expression Therapy|The goal of EAET is to increase awareness of uncomfortable emotions that are often linked to stressful past experiences (e.g., anger, sadness, fear) and learn adaptive ways to experience and express those emotions, in a safe and controlled environment. Core treatment components include pain education, drawing associations between the experience of pain and emotion, and experiencing and expressing emotions via imaginary, in vivo, and real life exposures. EAET will be delivered via 8, 60-minute, weekly psychotherapy visits.
223602492|NCT05396248|BEHAVIORAL|Memory Retraining Exercises|Memory retraining exercises will be administered on a laptop computer twice a week for five weeks (10 training sessions).
223602493|NCT05396248|BEHAVIORAL|Placebo Control Memory Exercises|Placebo control memory exercises will be administered on a laptop computer twice a week for five weeks (10 training sessions).
223602494|NCT04282668|DRUG|TAS1440|Form: Capsule or Tablet Route of Administration: Oral
223602495|NCT04282668|DRUG|TAS1440 + ATRA|Form: Capsule or Tablet Route of Administration: Oral
223602496|NCT06471218|DRUG|SHR-1918; SHR-1918 Placebo|SHR-1918/SHR-1918 Placebo,two administration
223602497|NCT03906071|BIOLOGICAL|Nivolumab|Nivolumab is an antibody directed at the programmed death receptor-1 (PD-1), blocking its interaction with PD-L1 and PD-L2.
223602498|NCT03906071|DRUG|Sitravatinib|Sitravatinib is a small molecule inhibitor of receptor tyrosine kinases.
223602499|NCT03906071|DRUG|Docetaxel|Docetaxel is an anti-neoplastic agent that acts by disrupting the microtubular network in cells.
223602500|NCT03750227|PROCEDURE|Conventional Surgery|Undergo surgery
223602501|NCT03750227|OTHER|Questionnaire Administration|Ancillary studies
223602502|NCT03750227|RADIATION|Stereotactic Radiosurgery|Undergo stereotactic radiosurgery
223602503|NCT03750227|PROCEDURE|Computed Tomography|Undergo CT
223602504|NCT03750227|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223602505|NCT03750227|PROCEDURE|Biospecimen Collection|Undergo blood sample, tissue and CSF sample collection
223602506|NCT02700386|COMBINATION_PRODUCT|Adjuvant Hypofractionated Radiation|Hypofractionation is the delivery of radiotherapy in single daily doses greater than the 180-200 cGy. Hypofractionation, through use of larger doses per fraction and fewer total treatments, is a method of shortening overall treatment time in breast cancer therapy.
224200105|NCT05301452|RADIATION|Placebo Intravascular Irradiation of Blood (ILIB)|The photobiomodulation procedure will be simulated, but with the laser turned off. It will be done twice a week for 8 weeks, in 20-minute sessions.
223507642|NCT02587286|OTHER|Gather app|Participants in the intervention group will receive the Gather Health software free for the duration of the study. Their medication and BG testing goals will be entered into the system and they will receive automated reminders. Their data will be regularly reviewed by study staff and feedback provided.
223602507|NCT05328596|BEHAVIORAL|CBT-treatment|Cognitive Behavioral Treatment for Gaming Disorder.
223602508|NCT05328596|BEHAVIORAL|Wait list control|No intervention
223602509|NCT04168372|OTHER|High fructose, fructose labeled meal|Liquid meal containing high fructose (16% of energy), labeled with 2-13C fructose
223602510|NCT04168372|OTHER|High fructose, pyruvate labeled meal|Liquid meal containing high fructose (16% of energy), labeled with 2-13C pyruvate
223602511|NCT04168372|OTHER|Low fructose, fructose labeled meal|Liquid meals containing low fructose (6% of energy), labeled with 2-13C fructose
223602512|NCT04168372|OTHER|Low fructose, pyruvate labeled meal|Liquid meal containing low fructose (6% of energy), labeled with 2-13C pyruvate
223602513|NCT05949957|BEHAVIORAL|LvL UP App|LvL UP App: A Smartphone-based conversational agent-delivered holistic lifestyle intervention. The intervention group will receive several digital coaching sessions focus on 3 pillars: diet, physical activity, and mental well-being to promote health literacy and promote healthy lifestyles. The app includes practical exercises per pillar (e.g., journaling, slow-breathing exercises, lifehacks).
223602514|NCT05949957|BEHAVIORAL|HAPPY App|HAPPY App: Each subject will use the HAPPY App that aims to:(1) deliver health promotion information (guided by Singapore Health Promotion Board's resources), and (2) display health data collected (e.g., body mass index, blood pressure, OGTT results) that help them monitor own health and prevent T2D.
223602515|NCT05949957|BEHAVIORAL|Oura Ring And Oura App|Oura ring and Oura App: Each subject will receive an Oura ring, i.e., an activity-tracking wearable that collects lifestyle data (physical activity, sleep and heart rate (as a proxy for stress) that will be synced with Oura App
223602516|NCT06448026|DRUG|Cemiplimab|Given by IV
223602517|NCT06448026|DRUG|Cetuximab|Given by IV
223507643|NCT03148639|BEHAVIORAL|Avatar therapy|Patients will receive 6 sessions of avatar therapy consisting of 45 minute (1 session per week). The therapy will consist in prompting patients to enter in a dialogue with their persecutor to better regulate their emotional responses. Over the course of the therapy, the character of the avatar will progressively become under patients' control. More precisely, the avatar's speech and tone will gradually be changed by the therapist to echo patients' improved ability to regulate their emotions. That is, the avatar will progressively change from being abusive to becoming helpful and supportive. By doing so, the therapy will seek to reinforce patients' feeling of empowerment over their voices.
223507644|NCT03148639|OTHER|Treatment-as-usual|Treatment as usual will consist of typical or atypical antipsychotic medication and regulars appointments with psychiatrists and others care team members for a period of 6 weeks.
223507645|NCT00140114|DRUG|Misoprostol (Cytotec®)|50 micrograms of sublingual or vaginal misoprostol every 4 hours for a maximum of 5 doses
223507646|NCT03399123|OTHER|Tidal volume|After General anesthesia, patients that during volume control mode of mechanical ventilation in experimental group, we take low tidal volume.
223507647|NCT00114777|DRUG|Cyclosporin A|tablet, oral, 1st month target: 150-300 ng/mL, after 1st month target: 100-250 ng/mL, daily, 36 months, 100-250 ng/mL, daily, 84 months
223507648|NCT00114777|DRUG|Belatacept Less Intensive Regimen (LI)|solution, IV, 10mg/kg: Days 1 and 5, Weeks 2, 4, 8 and 12, then 5 mg/kg every 4 weeks, q 4 weeks, 36 months months, 5 mg/kg every 4 weeks, q 4 weeks, 84 months
223507649|NCT00114777|DRUG|Belatacept More Intensive Regimen (MI)|solution, IV, 10mg/kg: Days 1 and 5, Weeks 2, 4, 6, 8, 10,12, 16, 20, and 24, then 5 mg/kg every 4 weeks, q 4 weeks, 36 months, 5 mg/kg every 4 weeks, q 4 weeks, 84 months
223507650|NCT05895500|DRUG|Injection for SC administration (120mg/syringe)|Injection
223507651|NCT05895500|DRUG|Tablet (50mg/tablet), oral|Tablet
223507652|NCT02298491|DRUG|H.P. Acthar Gel|80 IU subcutaneously daily for 10 days then followed by 80 IU subcutaneously three times per week through Month 12
223507653|NCT04448080|DEVICE|Micropulse Transscleral Laser Therapy for Glaucoma (MP-TLT)|Intraocular pressure will be lowered by Micropulse Transscleral Laser Therapy for Glaucoma (MP-TLT) in patients with a diagnosis of glaucoma
223507654|NCT04219774|PROCEDURE|Endovascular intervention|Endovascular angioplasty of the occluded carotid using balloon angioplasty and reconstruction with stents: coronary stents distally (Rebel, Boston Scientific; Vision, Abbott Vascular) and carotid stents proximal (Acculink and Xcat, Abbott Vascular) Patients will stay on their aspirin 325 mg and clopidogrel 75 mg
223507655|NCT04219774|DRUG|Aspirin and Clopidogrel (maximal medical Therapy)|Best Medical Management: daily dual antiplatelet therapy (aspirin: 325 mg p.o. qd and Clopidogrel: 75 mg p.o. qd), optimization of systolic blood pressure (120 -140 mmHg), and smoking cessation.
223507656|NCT01986322|BIOLOGICAL|DTP/HB/Hib vaccine|Dosage equal to 0.5 mL administered intramuscularly
223507657|NCT01986322|BIOLOGICAL|DTP/HB and Hib vaccine|Dosage equal to 0.5 mL administered intramuscularly
223507658|NCT02717715|BEHAVIORAL|Home base stroke rehabilitation|The intervention consists of physiotherapy exercises targeting functional and physical capacity.
223507659|NCT03090295|DEVICE|Palpation and Accuro|Identify placement for spinal
223507660|NCT01334853|OTHER|No drug will be used|Biomarker
223507661|NCT01334853|OTHER|No drug will be used|Biomarker
223602518|NCT05055323|DRUG|Pyrvinium Pamoate|Given PO
223602519|NCT06378957|DRUG|D-Limonene|Oral Limonene administered via capsule
223602520|NCT06378957|DRUG|Delta-9-THC|Oral delta-9-THC in ethanol vehicle administered via capsule
223602521|NCT06378957|DRUG|Placebo|Placebo (cellulose) administered via capsule
223602522|NCT05842863|BEHAVIORAL|Dialectical Behavior Therapy|Dialectical Behavior Therapy (DBT) is a treatment program that helps teens reduce suicidal and self-harm behaviors by teaching them coping skills for managing negative emotions. DBT includes weekly individual therapy, weekly multifamily skills group, and 24/7 telephone-based skills coaching from the therapist.
223750249|NCT06023576|DIAGNOSTIC_TEST|Blood pressure measurement|Home BP Monitoring (HBPM)-Throughout the study period, patients will perform HBPM at baseline, month 6, and month 12 (end of treatment). At each of these timepoints, HBPM will be performed for 7 days with 2 morning and 2 evening readings for each day (measured 1-min part).
223750250|NCT06023576|DIAGNOSTIC_TEST|Echocardiogram|At baseline, month 6, and month 12
223750251|NCT06023576|OTHER|Symptom-limited cardiopulmonary exercise test|Consecutive patients in each treatment group who meet the eligibility criteria for exercise testing will be offered to participate in CPET at the time of consent. Patients who agree will undergo CPET (baseline, 6 months, and 12 months) until the target accrual of 33 patients per group is met.
223750252|NCT06023576|OTHER|Quality of Life Measures|FACT-B, Fatigue Symptom Inventory (FSI), Patient Reported Outcomes Measurement Information System (PROMIS) Global Health Scale, Godin Leisure Time Exercise Questionnaire (GLTEQ),PROMIS Medication Adherence Scale. Given baseline, 3 months and 12 months.
223750253|NCT06023576|DIAGNOSTIC_TEST|Biomarkers|Research blood samples will be collected at baseline, 3 months, and 6 months
223750254|NCT02836600|DRUG|LY3039478|Administered orally
223602523|NCT05842863|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|Cognitive Behavioral Therapy for Insomnia (CBTI) is a type of counseling that helps people improve sleep by changing their sleep behaviors and thinking about sleep. In CBTI, people learn about sleep regulation, factors that influence quantity and quality of sleep, and specific techniques to optimize sleep. In this study, CBTI will be delivered using a self-guided online program called Firefly.
223602524|NCT05613257|DEVICE|Distal targeting jig|Patients in this arm will have an assistive targeting device used for interlocking screw placement. The targeting device is attached to the nail proximally or distally (for antegrade or retrograde nailing, respectively) to guide screw placement through the other end of the intramedullary device.
224200106|NCT05301452|PROCEDURE|Orofacial Myofunctional Therapy|"Myofunctional therapy will be performed by a speech therapist specialized in the area. It will consist of 1 weekly session, where the functions of breathing, chewing and swallowing will be evaluated and addressed.~The following exercises will be indicated: nasal hygiene, inflated cheeks with the tip of the tongue on the palate, lingual sweep, tongue thrust against the palate, tongue touch on the last molars, chewing of soft solids and bolus assembly (20 minute therapy session)."
224200107|NCT00436397|RADIATION|radiation therapy|
224200108|NCT01408056|DRUG|Timolol 0.5% Gel Forming Solution (GFS)|"Dose-based escalation schedule for topical application:~4-8 kg: Day 0-7: 1 drop every other day; Day 7-14: 1 drop daily; Day 14 - Day 60: 1 drop twice per day~8-12 kg: Day 07: 1 drop daily; Day 7-14: 1 drop twice per day; Day 14 - Day 60: 2 drops twice per day"
223602525|NCT05613257|PROCEDURE|Free-hand/perfect circles technique|"Patients in this arm will have no assistive targeting device use and the surgeon will use a free-hand technique for the placement of interlocking screws. With this technique, fluoroscopic images are taken such that the interlocking holes of the intramedullary device are perfect circles and indicate that a screw introduced in the same plane that the fluoroscopic image was taken would seat perpendicularly to the intramedullary device. This is the most commonly employed technique for interlocking screw placement through intramedullary devices."
223602526|NCT05380505|BEHAVIORAL|Racially Congruent Ads|Facebook food ads that are racially congruent.
223602527|NCT05380505|BEHAVIORAL|Racially Incongruent Ads|Facebook food ads that are racially incongruent.
223602528|NCT06071650|BEHAVIORAL|Exercise to a Heart Rate (HR) Zone|Participants prescribed moderate intensity aerobic exercise using personalised heartrate zones with a goal of sustaining an intensity level by maintaining their heartrate above 50 percent of their heartrate reserve level for their prescribed duration
224200109|NCT01408056|DRUG|Mupirocin 2% Ointment|Topical application twice per day for 60 days
224200110|NCT04798430|DRUG|lerodalcibep|PCSK9 inhibitor
224200111|NCT03953768|DEVICE|Vagal nerve stimulation (VNS)|Implantation with vagal nerve stimulator for epilepsy
224200112|NCT05957913|DRUG|Truvada (tenofovir/emtricitabine)|Doses and route of administration of the study drug will be kept the same as for the FDA-approved indication of HIV-1 prevention in healthy individuals. The study drug is not FDA-approved for the treatment of multiple sclerosis.
224200113|NCT04800822|DRUG|PF-07284892|PF-07284892
224200114|NCT04800822|DRUG|lorlatinib|lorlatinib
224200115|NCT04800822|DRUG|binimetinib|binimetinib
223602529|NCT00192816|BEHAVIORAL|reaction to pain|
223602530|NCT04054141|DEVICE|Mag Stim|rTMS
223602531|NCT01647893|DRUG|CTB-001|IV bolus or IV infusion
223602532|NCT03653143|BEHAVIORAL|JASPER|JASPER is a therapist and parent-mediated intervention that (1) targets the foundations of social communication, (2) uses naturalistic behavioral strategies to increase the rate and complexity of social communication and (3) includes parents as implementers of the intervention to promote generalization across settings and to ensure maintenance. This intervention is individualized and centered around two key developmental domains critical for social communication function: joint engagement and joint attention.
223602533|NCT00783614|DRUG|Aspirin 325mg|Patients randomized to Aspirin 325mg po daily versus placebo pill daily
223602534|NCT00783614|DRUG|Antiretroviral therapy (ART)|Patients randomized to start ART immediately or defer use for 1 month
223750255|NCT04534010|DEVICE|NACgraft|Patients requiring reconstruction of their nipple and areola have a NACgraft surgically implanted on their breasts. A NACgraft is a novel decellularized cadaveric implant derived from human nipples.
223750256|NCT06447493|OTHER|Osteopathic Manipulative Treatment-Spencer's Technique (Modified)|Combination OMT approach utilizing Muscle Energy Technique (MET), Articulatory Technique (ART), and Myofascial Release (MFR). It is a series of direct OMT addressing the barrier of somatic dysfunction (SD) with the goal of restoring neurovascular balance and improved motion of the shoulder girdle and glenohumeral joint. Utilizing these three OMT techniques, the practitioner attempts restoration of glenohumeral joint motion using shoulder extension, flexion, circumduction with compression, circumduction with distraction, abduction, adduction, external rotation, internal rotation, and distraction in abduction. The study uses a modified version of the Spencer technique, done in the seated position for patient comfort, as well as adding to the treatment sequence: latissimus dorsi, pectoralis minor-major, serratus anterior, and rhomboid major-minor. Adding these muscles into treatment will help to address and correct sternoclavicular joint SD, acromioclavicular joint SD, and scapular SD.
223750257|NCT06447493|OTHER|Rest|10 minute rest period.
223750258|NCT02532647|DRUG|Remimazolam|
224311297|NCT06000943|OTHER|Low vs Intermediate vs High surgical risk stratified according with SAPT/DAPT/OAC and OAC+SAPT|"All patients undergoing TAVR will be stratified according with surgical risk level and all combination of antithrombotic therapy at discharge~Low risk (SAPT vs DAPT and OAC vs OAC+SAPT) Intermediate risk (SAPT vs DAPT and OAC vs OAC+SAPT) High risk (SAPT vs DAPT and OAC vs OAC+SAPT)"
224311298|NCT02472223|DRUG|Betadine 5%|"One time in-office administration (4-5 drops) of Betadine 5% limited to 2 minutes, followed by saline lavage.~Betadine 5% exposure to the ocular surface is limited to 2 minutes in-office administration, followed by saline lavage per labeling instructions."
224311299|NCT02472223|DRUG|Artificial Tears|One time in-office administration (4-5 drops) of artificial tears limited to 2 minutes, followed by saline lavage.
223602535|NCT05426070|BEHAVIORAL|Strength training-based exercise|Participants will take part in two group-based Zoom exercise sessions and two individual exercise sessions per week for three months. Exercise sessions will include a combination of various aerobic (e.g., jogging in place, high knees) and muscle strengthening exercises (e.g., burpees, push-ups, lunges, body weight squats) designed to keep heart rate in the 60-85% range of maximum heart rate. Participants will choose from a variety of options for their two individual sessions (e.g., online exercise video, jogging or walking outside, prescribed exercise session listed on the website, or any other exercise) and modifications for each exercise will be made depending on the participant's ability and current fitness and strength level. Participants will be instructed to stop exercising if problems occur and will receive training and handouts on how to recognize problems such as angina and myocardial infarction.
223602536|NCT00694018|OTHER|Education and standard care|Educational program for individuals with chronic back pain.
223602537|NCT00694018|BEHAVIORAL|Internet mediated enhanced pedometer intervention|Enhanced pedometer for uploading step information and website that provides step goals and feedback, tailored motivational messages and an online community.
223602538|NCT04618289|DIETARY_SUPPLEMENT|Vitamin D3-fortified fruit juice supplement|Vitamin D3-fortified fruit juice supplement
223602539|NCT01331980|DEVICE|Peripheral quantitative computed tomography (pQCT)|A pQCT scan of the non-dominant radius at the 4% and 65% sites will be conducted at a single study visit
223750259|NCT02532647|DRUG|Midazolam|
223750260|NCT02532647|DRUG|Placebo|
224200116|NCT04800822|BIOLOGICAL|cetuximab|cetuximab
224200117|NCT04800822|DRUG|encorafenib|encorafenib
223750261|NCT05153369|BEHAVIORAL|Enhanced Care|Enhanced care aims to educate participants about bipolar disorder using a didactic approach, in addition to teaching and practicing DBT skills in an applied and relevant manner based on the participant's needs. Participants will receive a total of four sessions (approx. 60 minutes in duration), to occur once a month, at a minimum. The content will be split up into psychoeducation (2 sessions) and selected DBT skills (2 sessions). Psychoeducation will be specific to youth bipolar disorder, covering topics such as symptoms of depression and hypo/mania, medications used to treat bipolar disorder, the role of biology and the environment in emotions, and vulnerability and protective factors to emotion dysregulation and mood episodes. The content of skills sessions will be individualized and based on participant needs and goals (e.g., learning and applying skills to optimize their overall functioning, address problem behaviors and/or stressors, and/or maintain commitment to treatment).
224200118|NCT04223622|BIOLOGICAL|ASC secretome|The osteochondral explants isolated from arthroplasty patients will be induced to an OA phenotype and treated with ASC secretome (either complete conditioned medium or extracellular vesicles) in order to investigate its therapeutic potential.
224200119|NCT03731325|BEHAVIORAL|Episodic Future Thinking Group|"Participants in the Episodic Future Thinking (EFT) Group will train with EFT throughout the entire study. As part of the training, research staff will help participants create cues. Cues are descriptions of future events the participant can vividly imagine as happening right now.~Participants will be instructed to think about the EFT cues they created to help them focus on the future and importance of reaching their weight-loss goals. Participants will be instructed to use their EFT cues at least once per day, but will be encouraged to use their cues with every eating and physical activity decision."
224311300|NCT04702438|BEHAVIORAL|ICT activities|Family interventions using ICT to promote family communication, sharing happiness with family members, and well-being in the community.
224311301|NCT02969681|DRUG|ascorbic acid|1.5g/kg/day, D1-3, every 2 weeks
224311302|NCT02969681|DRUG|Chemotherapy|"* mFOLFOX6~* Oxaliplatin 85 mg/m² d1 concurrent with~* Leucovorin 400 mg/m², followed by~* Bolus 5FU 400 mg/m² , followed by~* Infusional 5FU 2400 mg/m² over 46 hours, every 2 weeks~with or without bevacizumab 5mg/kg, every 2 weeks"
223602540|NCT01331980|DEVICE|Dual X-ray absorptiometry (DXA)|A total body DXA scan will be conducted at a single study visit
223750262|NCT05153369|BEHAVIORAL|DBT Skills Training|In DBT Skills Training, participants will only receive skills training and can choose to do this individually and/or with their individual family unit by including their parent(s) and/or sibling(s). Participants will receive 20-25 sessions (approx. 60 minutes in duration), to occur at least biweekly. Skills training will include the five standard youth DBT modules: psychoeducation about DBT and bipolar disorder, mindfulness, distress tolerance, emotion regulation, interpersonal effectiveness, and walking the middle path. The primary focus of the skills training is to impart knowledge and acquire and strengthen pragmatic skills to replace dysfunctional behaviors. If participants choose to include their family members, they will be encouraged to coach one another in effective use of skills.
224200120|NCT04846920|DRUG|Belzutifan|40 mg tablet administered orally at a dose of 160 mg, 200 mg, or 120 mg.
224200121|NCT02902757|PROCEDURE|Computed Tomography|Undergo FDG PET/CT
224200122|NCT02902757|RADIATION|Fludeoxyglucose F-18|Undergo FDG PET/CT
224200123|NCT02902757|PROCEDURE|Positron Emission Tomography|Undergo FDG PET/CT
224200124|NCT04943913|BIOLOGICAL|Tumor Infiltrating Lymphocytes (TIL)|Adoptive transfer of 1x10\^9-5x10\^10 autologous TILs to patients i.v. in 30-120 minutes.
224311303|NCT00855179|DRUG|Red vine leaf extract (AS 195)|Antistax film-coated tablet 360 mg
224311304|NCT00855179|DRUG|Placebo|Placebo tablets identical to those containing Anstistax 360 mg
224311305|NCT05023837|DRUG|Pembrolizumab 100 MG Injection|Pembrolizumab iv 200mg q21d
224311306|NCT04699851|BEHAVIORAL|Tailored recommendations|Tailored informations delivered by email about health prevention behavior in a pandemic based on the answers in the survey.
224311307|NCT04699851|BEHAVIORAL|General recommendation|The control group will receive general recommendations by email about health prevention in a pandemic.
223602541|NCT01564732|DEVICE|Standard-LAGB|The laparoscopic adjustable gastric banding (LAGB) procedure is a safe, effective, and durable treatment option for refractory morbid obesity and its related health consequences.5 This minimally invasive technique is now a popular approach for bariatric surgery, and it offers obvious advantages such as decreased operating time, shorter hospital stay (often same day surgery), and favorable complication rates as compared with other bariatric procedures.
223750263|NCT05153369|BEHAVIORAL|Dialectical Behavior Therapy Full Intervention|The DBT full intervention is based on Miller et al.'s DBT for suicidal youth, with modifications for youth with BD. DBT will be conducted over 1 year with approximately 40-50 sessions. Sessions will alternate between individual and skills training sessions. Family involvement in skills training will be strongly encouraged, however will be up to the participant to decide. Participants in Level 3 will complete diary cards tailored for this population, assessing daily mood, suicidality, sleep, and medication adherence. Participants will report use of specified DBT skills on the diary card, and individualized treatment goals will be incorporated into the diary card (e.g., alcohol use). In addition, Level 3 will include skills coaching by phone (via phone and/or text). These brief, structured calls and/or texts function to promote skills generalization by helping the participant and any participating family member(s) use skills to achieve goals and solve problems.
223750264|NCT01014429|DRUG|NMS-1286937|Single Arm, dose escalation study. No. of cycles: until progression or unacceptable toxicity develops.
223750265|NCT03980769|DRUG|Thiotepa|Given IV
223602542|NCT01564732|DEVICE|Plicated-LAGB|"At the time of LAGB placement, plication sutures can be placed along the body \& greater curvature of the stomach to tighten and cinch up the stomach in a sleeve-like orientation. It was recently reported that this modified technique of plicated LAGB could result in lower band slippage complication rates and faster, early weight loss."
223602543|NCT03139123|OTHER|Hemodynamic monitoring during passive leg raising|Measurement of hypotensive episodes related to preload dependance.
223602544|NCT01159015|DRUG|KetoNaph|Ophthalmic Solution administered BID for 6 weeks
223602545|NCT01159015|DRUG|Vehicle|Vehicle of KetoNaph ophthalmic solution administered bid for six weeks
223602546|NCT01247961|DRUG|Dexamethasone acetate|10 mg intravenous given as single administration with optional repeat dose after 36 hours.
223602547|NCT01247961|OTHER|Placebo|Normal saline
223602548|NCT04054986|DIAGNOSTIC_TEST|F-Var3 PET/CT|Participants will undergo up to 5 serial F-Var3 PET/CT scans within 25 minutes of the injection of 18F-Var3, 30, 60, 120 and 240 minutes after injection of the 18FVar3.
223602549|NCT04054986|OTHER|Blood draw|Collection of blood for research tests before the injection, 30, 60, 120 and 240 min after the injection.
223602550|NCT01497301|BEHAVIORAL|Group Visits|"During group visits, there will be discussions regarding the basic pathophysiology of diabetes, the ABCs to Better Diabetic Care as defined by the ACP Diabetes Care Guide, setting goals, nutrition, exercise, diabetic medications, and complications of diabetes. Patients will have blood drawn to measure hemoglobin A1C and lipids. They will be educated on self glucose monitoring so they will undergo finger sticks to measure their own glucose. BP measurements, monofilament foot exams, and urine collection for microalbumin will also occur during the study. They may also receive immunizations. A consent form for participation in the group visits, including undergoing the above procedures will be reviewed at our first group visit and signed by all participants."
223602551|NCT03056742|BIOLOGICAL|Stempeucel(R)|Ex vivo cultured adult bone marrow derived allogeneic mesenchymal stem cells
224200125|NCT03366142|DRUG|Ustekinumab|0.75 mg/kg or 45 or 90 mg via subcutaneous injection for 5 doses (second dose 4 weeks after first, subsequent doses every 12 weeks thereafter).
224200126|NCT05854745|BEHAVIORAL|HBB Virtual Training|HBB Virtual Training (Intervention): The 2nd edition HBB training course focuses on preparation for birth, routine care for all babies, the Golden Minute, and continued ventilation with normal or slow heart rate. The one-day virtual training will be delivered remotely to participants via Zoom. Facilitators and training materials will be the same in both the control and intervention arms.
224200127|NCT05854745|BEHAVIORAL|HBB In-person Training|HBB In-Person Training (Control): The 2nd edition HBB training course focuses on preparation for birth, routine care for all babies, the Golden Minute, and continued ventilation with normal or slow heart rate. The one-day in-person training will be delivered in person. Facilitators and training materials will be the same in both the control and intervention arms.
224200128|NCT04587635|DIETARY_SUPPLEMENT|PHGG|PHGG
224200129|NCT04587635|DIETARY_SUPPLEMENT|Placebo|Maltodextrin
223602552|NCT00542607|DRUG|levocetirizine dihydrochloride|
223602553|NCT05154318|PROCEDURE|Pericapsular Nerve Group Block|Nerve block targeting major hip joint sensory nerves.
223602554|NCT05154318|PROCEDURE|Fascia iliaca compartment block|Routine nerve block for hip fracture surgery.
224200130|NCT01970280|DRUG|Enoxaparin|
223602555|NCT05267119|PROCEDURE|Swab|The scalp was swabbed with five strokes which were performed each in a vertical, horizontal, left diagonal, and right diagonal direction. The swab was moved back and forth for 10 times
223602556|NCT00248586|BEHAVIORAL|Standard CBT (S-CBT)|Standard CBT (S-CBT) is a skills-based training program delivered to patients in 10 weekly, 1-hour sessions.
223602557|NCT00248586|BEHAVIORAL|Minimal contact CBT (MC-CBT)|Minimal contact CBT (MC-CBT) covers the same range of procedures featured in S-CBT but relies extensively on self study materials.
223602558|NCT05900232|DIAGNOSTIC_TEST|Anti _KU antibodies|aim of the work is to determine the relationship between Anti\_Ku antibodies and SLE manifestations the study will include 60 SLE cases diagnosed by SLICC criteria and the activity of SLE will be calculated by SELDAI criteria, which is tool composed of 24 clinical and laboratory variables.
223602559|NCT05876468|DEVICE|Continuous anterior chest compression|"Patients with severe to moderate ARDS who were placed in prone position by the attending physician :~* First CACC : the applied pressure is equal to the one observed in the prone position~* Second CACC : The applied pressure is set at 60 - 80 cmH20"
223750266|NCT03980769|DRUG|Treosulfan|Given IV
223750267|NCT03980769|DRUG|Fludarabine Phosphate|Given IV
223750268|NCT03980769|BIOLOGICAL|Rabbit Anti-Thymocyte Globulin|Given IV
223750269|NCT03980769|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo HCT via infusion
223750270|NCT03980769|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
223750271|NCT03980769|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
223750272|NCT03980769|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223750273|NCT03980769|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223750274|NCT02211131|DRUG|Talimogene Laherparepvec|Talimogene laherparepvec will be administered by intralesional injection into the injectable cutaneous, subcutaneous, and nodal tumors initially at a dose of 10\^6 plaque forming units (PFU)/mL at day 1 of week 1 followed by a dose of 10\^8 PFU/mL at day 1 (±3 days) of week 4, 6, 8, 10 and 12 or until all injectable tumors have disappeared, or intolerance of study treatment or in the opinion of the investigator, immediate surgical resection or any other treatment for melanoma is warranted, whichever occurs first.
223750275|NCT02211131|PROCEDURE|Immediate surgical resection of melanoma lesion(s)|Surgical resection of melanoma tumor lesion(s) will be performed after randomization any time during weeks 1 to 6.
223750276|NCT01820416|RADIATION|Low-level Laser Therapy|Portable unit containing two laser diodes producing 532 and 635 nm wavelengths. Both diodes produced energy levels of 7.5 mw (class IIIb). Beams from both diodes were dispersed through lenses to create parallel line-generated beams, rather than spots. The 532 nm light was constant, and the 635 nm light was pulsed, with frequencies of 15 and 33 Hz. The pulsing alternated between frequencies every 30 seconds.
223750277|NCT01820416|OTHER|Placebo Comparator: Disabled Laser|Portable unit containing two DISABLED laser diodes. Same protocol was followed as for the Experimental (radiation) group, except that the disabled diodes produced no radiation.
223750278|NCT06158191|BEHAVIORAL|Lifestyle modification program|Participants will take part in a lifestyle modification program focused on physical activity and diet.
223750279|NCT04877249|BEHAVIORAL|Split-belt treadmill training|1\. Split-belt gait training without or with any resistance, 2. Facilitating the knee extension during the terminal swing phase of gait cycle to identify the impact on the propulsive force generation of paretic leg
223602560|NCT02399774|DEVICE|Leboride|"1. Post-partum primi and multiparous women whom are interested in breastfeeding and have not begun yet. This arm will be randomized into 2 groups~   1. Intervention group: participants will receive the dental device and be instructed to use it during breastfeeding.~  2. Control group: participants will not receive any device for breastfeeding pain control~2. Post-partum women that have already begun breast feeding, will receive the dental device and each woman will be serve as her own control (breastfeeding before and after the use of the dental device."
223602561|NCT06241105|DRUG|Lenvatinib+Toripalimab.|Adjustment of Medication Dosage: Throughout the course of treatment, adjustments should be made exclusively to the dosage of the drug Lenvatinib.The starting dosage for lenvatinib is 8 mg, administered orally once a day for a period of four weeks. If no adverse reactions are observed, the dosage can be escalated to 12 mg for individuals weighing over 60 kg. However, if the patient experiences intolerable side effects, the dosage should be decreased back to 8 mg.For individuals weighing less than 60 kg, the maximum dosage is 8 mg per day. Should adverse reactions become intolerable, the dosage may be decreased to 4 mg per day.Withdrawal from the study if still intolerable.
223602562|NCT04696679|OTHER|Patient Quality of life assessment|Other: Patient questionnaire about quality of life assessment and their determinants during the confinement-deconfinement period of Covid-19 pandemic in France
223602563|NCT04696679|OTHER|Control group Quality of life assessment|Other: Patient questionnaire about quality of life assessment and their determinants during the confinement-deconfinement period of Covid-19 pandemic in France relationships with teachers, schoolwork, and self-esteem)
223602564|NCT01979952|DRUG|Matching Placebo|twice daily dosing
223602565|NCT01979952|DRUG|Nintedanib|gelating capsule
223602566|NCT03661333|BEHAVIORAL|Dialectical behavioral therapy|DBT will be conducted over 1 year, and divided into two modalities: skills training, conducted in 60 minute biweekly family meetings and individual therapy conducted in 60 minute biweekly sessions. Family skills training proceeds as follows: psychoeducation about DBT and bipolar disorder, mindfulness skills, emotion regulation skills, distress tolerance skills, interpersonal skills, and walking the middle path skills. Individual therapy sessions aim to aid the adolescent in applying skills in their daily lives. We adopt the standard DBT hierarchy of treatment targets, whereby the individual therapist selects behaviors to focus on based on the following priorities: 1) decreasing life-threatening behaviors, 2) decreasing therapy-interfering behaviors, 3) decreasing quality-of-life interfering behaviors, and 4) increasing behavioral skills. Therapists will be available to participants and their participating family members by cell phone for in-vivo skills coaching between sessions.
223750280|NCT02952339|BIOLOGICAL|RSV LID ΔM2-2 1030s vaccine|10\^5.0 PFU; administered as nose drops
223750281|NCT02952339|BIOLOGICAL|Placebo|Administered as nose drops
223750282|NCT00696852|BEHAVIORAL|Mindfulness Meditation|The yoga and mindfulness classes will combine specific techniques of meditation, simple yoga postures, and breathing exercises.
224200131|NCT01757418|DRUG|Immune Globulin Intravenous (IVIG)|A single dose of intravenous immune globulin or saline placebo administered within 24 hours of hospital presentation. The maximum dose in Phase I was 800 mg/kg. The dose for Phase II is 400mg/kg.
224200132|NCT01757418|OTHER|Normal saline|A single dose of normal saline administered within 24 hours of hospital admission for uncomplicated pain crisis.
223750283|NCT00696852|BEHAVIORAL|Yoga|The yoga and mindfulness classes will combine specific techniques of meditation, simple yoga postures, and breathing exercises.
223750284|NCT00696852|BEHAVIORAL|Exercise, Relaxation, and Health Education|The Exercise, Relaxation and Health Education program will consist of a 90 min group session that will include simple relaxation (such as progressive muscle relaxation) and light stretching exercises, group support, and discussions of various health topics and on stress reduction.
223750285|NCT00003752|DRUG|bexarotene|
223750286|NCT05504941|DIAGNOSTIC_TEST|Diagnostic, cerebral Digital Subtraction Angiography (DSA)|The DSA is the goldstandard for the visualization of brain vessels. For performing a diagnostic cerebral DSA, the femoral artery of the patient will be punctured in the groin. Over this arterial access a catheter will be advanced under fluoroscopy guidance to the target vessel in the brain. After navigation to the targeted brain vessel, contrast media will be injected over the catheter into the vessel. The efflux of the contrast media will be monitored and visualized with fluoroscopy. The additional radiation to the patient due to the DSA will be approx. 1.1 mSv. The duration of the DSA will be 15 to 20 minutes.
224200133|NCT02530320|DRUG|Palbociclib|Palbociclib will be administered orally at a dose of 125 mg/day, until disease progression, unacceptable adverse side effects or study end.
223750287|NCT02126956|DRUG|ACT-128800|ACT-128800 was supplied as a powder mix in hard gelatin capsules for oral administration. The capsules contained a co-precipitated mixture of non-radiolabeled and 14C-labeled ACT-128800 formulated at a dose strength of 40 mg with a maximum radioactive content of 102 μCi (3.79 MBq).
223750288|NCT03162978|OTHER|HIIT + POE|Subjects will participate in high-intensity interval training (HIIT) with an additional treatment component to increase positive outcome expectations (POE) of exercise.
223750289|NCT03162978|OTHER|HIIT only|Subjects will participate in high-intensity interval training (HIIT) only.
223602567|NCT05421481|OTHER|home visit, health education, mobile application, group walk, message|"Home visit: Elderly individuals will be visited once at home. During the home visit, training will be given on the slide about physical activity. A brochure will be provided for general health promotion awareness. Counseling will also be provided during the home visit process.~Google Fit Application: During the home visit, the application will be downloaded to the phone of the elderly, and a document will be given about the use of the application after the usage is explained. The researcher will support those who have problems with the application in the following weeks.~Group walking: The walk, which will be done once, will be done in a light paced manner, and the purpose of the walk is to see the number of steps in the mobile application and to increase their motivation with the group.~Message: Message content For your health, you should exercise at least 30 minutes a week for a total of 150 minutes. will be."
223602568|NCT02813239|OTHER|hCG|Oocyte maturation with hCG
223602569|NCT02813239|OTHER|hCG + GnRH agonist|Oocyte maturation with hCG + GnRH agonist
223602570|NCT05851820|OTHER|comparison of outcomes/exposure|analysing if diabetes mellitus have an impact on the primary outcomes: hospital stay, admission to the ICU, death.
223602571|NCT04379206|DIAGNOSTIC_TEST|HIV self-test kit|fingerprick and oral fluid HIV self-tests with optional on-site or hotline staff assistance
223602572|NCT04379206|OTHER|Graphical User Interface|Gamification or neumorphism user interface
223602573|NCT04489199|OTHER|Questionnaire and semi-structured interview|questionnaire submitted by telephone 3 months, 6 months, 1 year, 5 years, and 10 years after the stroke/TIA. interview duration 20 to 40 minutes
223602574|NCT06149871|BEHAVIORAL|Physical activity|resistance, aerobic, and flexibility exercises
223602575|NCT05375448|OTHER|Neural mobilisation|"Participants will perform an active femoral nerve mobilisation technique. The treatment will be performed at home.~Patients will receive a video model to perform the exercise during the 8 weeks of treatment. The treatment should be performed 10 repetitions twice a day, with one set recommended in the morning and one in the evening.~The treatment will be monitored by telephone and if there are any doubts, the session will be carried out together with the patient."
223602576|NCT03560089|DEVICE|Serious game|Serious game with movements
223602577|NCT03560089|DEVICE|Placebo serious game|Serious game without movement
223602578|NCT06490133|DIETARY_SUPPLEMENT|Polyhpenol extract|Three capsules in fasting conditions 15 minutes prior breakfast
223602579|NCT06490133|DIETARY_SUPPLEMENT|Placebo|Three capsules in fasting conditions 15 minutes before breakfast
223602580|NCT05254431|BEHAVIORAL|Exercise|"Novel Moderate Intensity Interval Exercise~The Experimental Design is a randomized trial of moderate intensity interval training (5-minute intervals at 50% VO2peak 3 times weekly for 12 weeks) in Veterans with COPD and OSA compared with standard of care controls"
223602581|NCT05462574|OTHER|No Intervention|No Intervention
223750290|NCT04493060|BIOLOGICAL|Dostarlimab|Given IV
223602582|NCT04517344|OTHER|Initial Flow Rate|Patients placed on High Flow Nasal Cannula by treating physician will be randomized to initial flow rates of 1 L/kg/min, 1.5 L/kg/min, or 2 L/kg/min
223602583|NCT05438576|OTHER|Digital stethoscope electrocardiogram|Digital stethoscope artificial intelligence enabled electrocardiogram (AI-ECG). An artificial intelligence algorithm which analyses ECG data and generates prediction probabilities for a diagnosis of cardiomyopathy.
223602584|NCT01028846|DRUG|Diazoxide|4 mg/kg body weight total dosage administered orally
223602585|NCT01028846|DRUG|Placebo|Oral saline
223602586|NCT00391612|DEVICE|Exhale® Drug-Eluting Stent|Bronchoscopic procedure in which up to six Exhale Drug-Eluting Stents are placed in the lungs; total procedure time is 1 to 2 hours
223602587|NCT00391612|DEVICE|Sham control|5-10 minute bronchoscopic procedure in which the lungs are examined and a bronchial lavage is performed; the bronchoscope is then retracted to a point above the carina and below the vocal folds for the remained of the time; total procedure time is about 1-2 hours
223602588|NCT03466736|DIAGNOSTIC_TEST|[18F]flutemetamol PET scan|Each subject will receive an amyloid PET scan with \[18F\]flutemetamol
223602589|NCT05431504|DRUG|Dalpiciclib in combination with endocrine therapy by Physicians choice|"Dalpiciclib 150 mg orally once daily for 3 weeks, followed by 1 week off in each 4-week cycle.~Endocrine therapy including but not limited to fulvestran, tanastrozole, letrozole or exemestane In regular doses"
223602590|NCT06583330|DRUG|Low Molecular Weight Heparin (dalteparin)|All patients initiated low molecular weight heparin for drug prevention within 24 hours after surgery. The prevention course for the experimental group patients was 14 days, while the prevention course for the control group patients was 28 days. Low molecular weight heparin is administered subcutaneously once daily at a dose of 0.3ml.
223602591|NCT06583902|DRUG|Intravenous iron|Patients with an absolute deficiency (ferritin ≤100 μg/L) or functional deficiency (ferritin ≤ 300 μg/L with transferrin saturation ≤20%) receive iron supplementation, through a single administration of an iron preparation for intravenous use administered according to the doses present in the technical data sheet.
223602592|NCT06583902|OTHER|Retrospective case-control analysis|the only routine clinical data collection (Hb, iron status, direct and indirect Coombs test, IL6, erythropoietin dosage, number of units of blood components possibly transfused)
223750291|NCT04493060|DRUG|Niraparib|Given PO
223750292|NCT05492110|DEVICE|Coronary sinus reducer|The Neovasc coronary sinus reducer is an hourglass-shaped stainless steel device inserted percutaneously into the coronary sinus and currently indicated for the treatment of refractory angina.
223750293|NCT05492110|OTHER|Sham-procedure|Implantation procedure with no device implanted
223750294|NCT05492110|DIAGNOSTIC_TEST|Invasive coronary physiology|Invasive coronary physiology assessment as part of REMEDY-MECH mechanistic substudy
223750295|NCT04165070|BIOLOGICAL|Pembrolizumab|IV infusion
223750296|NCT04165070|DRUG|Carboplatin|IV infusion
223750297|NCT04165070|DRUG|Paclitaxel|IV infusion
223602593|NCT06584162|DRUG|Vedolizumab Injection|"Based on therapeutic drug monitoring, patients could be de-escalated based on a pharmacokinetic model:~Dosing interval Trough Target 20 mg/L~Adjust dosing interval to:~2 weeks \< 33 mg/L 2 weeks 2 weeks 33 - 46 mg/L 3 weeks 2 weeks ≥ 46 mg/L 4 weeks 3 weeks \< 20 mg/L 2 weeks 3 weeks 20 - 29 mg/L 3 weeks 3 weeks ≥ 29 mg/L 4 weeks 4 weeks \< 13 mg/L 2 weeks 4 weeks 13 - 20 mg/L 3 weeks Version number: 6.1, 24-06-2024 22 of 44 4 weeks ≥ 20 mg/L 4 week"
223750298|NCT04165070|DRUG|Pemetrexed|IV infusion
223750299|NCT04165070|BIOLOGICAL|Vibostolimab|IV infusion
223750300|NCT04165070|BIOLOGICAL|Boserolimab|IV infusion
223750301|NCT04165070|BIOLOGICAL|MK-4830|IV infusion
223750302|NCT04165070|BIOLOGICAL|MK-0482|IV Infusion
223750303|NCT04165070|BIOLOGICAL|Ifinatamab Deruxtecan (I-DXd)|IV infusion
223750304|NCT04165070|BIOLOGICAL|HER3-DXd|IV Infusion
223750305|NCT05414045|PROCEDURE|Autologous testicular tissue transplantation of prepubertal frozen testicular tissue|"Freezing testicular tissue of prepubertal boys is a method for preserving spermatogonial stem cells (SSCs).~If the patient has a childwish on adult age and in case no spermatozoa are found in the ejaculate, the investigators will perform autologous testicular tissue transplantation with the primary objective being to restore spermatogenesis and fertility."
223750306|NCT00971347|OTHER|Extra sugar-free chewing gum sticks|90 minutes chewing per day after meals; mid-morning and mid-afternoon; 1 to 2 hours after dinner; and in response to hunger, cravings, preoccupation with eating, or negative feelings in general throughout the day.
223750307|NCT00971347|BEHAVIORAL|nutrition brochure|one-time at baseline visit
223750308|NCT04553432|DEVICE|Amniotic membrane Omnigen[TM]|17mm circular disk of processed amniotic tissue donated by mother after birth with a 6mm laser cut aperture to allow unimpeded vision https://www.nu-vision.co.uk/omnigen
223750309|NCT04553432|DEVICE|Bandage soft Contact Lens OmniLenz[R]|18mm soft silicone-hydrogel contact lens https://www.nu-vision.co.uk/omnilenz
223750310|NCT02939560|DEVICE|NeuroStar® TMS device (Neuronetics, Atlanta, GA)|Participants in this study arm will be evaluated before and after receiving rTMS. Outcome measures will include social skills rating scales, depression rating scales and cognitive tasks while undergoing functional magnetic resonance imaging (fMRI).
223750311|NCT04606576|OTHER|Placebo|Fish Oil
223750312|NCT04606576|DRUG|ORMD-0801 QD|Oral Insulin once per day
223750313|NCT04606576|DRUG|ORMD-0801 BD|Oral Insulin, twice per day
223750314|NCT05398432|OTHER|motivational interview|"After the pre-test data were applied to all patients, before starting the motivational interview seans, the patients were informed about the interview intervals, duration, and how many times they would be held. In the second week, motivational interview seans were started with the patients. seans with patients took place during the hemodialysis seans. A total of 6 seans were held, one seans per week. After the first seans of the self-care supported motivational interview, the Self-Care and Adaptation to Disease Training Guide prepared by the researcher in line with the literature was given to the experimental group. Self-care training was given in the first, second and third seans. Motivational interviews were conducted in the fourth, fifth and sixth seans. Motivational interviewing techniques were used for patients to realize their self-care activities. seans were held individually with the patients and each seans lasted approximately 15-20 minutes."
223750315|NCT06389747|OTHER|BFR technique|For BFR application, Airbands brand, wireless, automatic training cuffs will be used. During application, it will be ensured that the device module faces forward and the cuff will be fixed in the correct position by wrapping the band around the metal ring. There will be a space between the skin and the cuff that can fit two fingers. The cuff will then be paired via Bluetooth with the Airbands app installed on the phone. BFR cuffs will be placed proximal to the biceps brachii muscle and pressure will be applied. The cuff will be inflated to automatically detect limb pressure. BFR application with 80% pressure to one group of participants and 20% pressure to the other group will be applied simultaneously with the exercise.
223602594|NCT06583889|DRUG|Heparin|The patients randomized to standard medical care will receive (or continue) either any type of body-weight adjusted low molecular weight heparin in therapeutic dose, or intravenous adjusted dose unfractionated heparin (aPTT value kept within 1 time the normal value), according to the existing international guidelines.
223750316|NCT05608421|BEHAVIORAL|1MoreStep|Cognitive behavioral intervention to reduce HIV and IPV stigma.
223602595|NCT06583889|PROCEDURE|Endovascular treatment|Standard endovascular techniques to mechanically remove clot material, such as mechanical thrombectomy and/or balloon angioplasty and/or local application of alteplase or urokinase within the thrombosed sinuses.
223750317|NCT05608421|BEHAVIORAL|1MoreStepControl|This is an equal attention control group.
223750318|NCT01170494|DRUG|ergocalciferol 2000 IU orally, daily|ergocalciferol 2000 IU orally, daily
223750319|NCT01170494|DRUG|ergocalciferol 25000 IU oraly every 2 weeks|ergocalciferol 25000 IU oraly every 2 weeks
223750320|NCT01170494|DRUG|ergocalciferol 50000 IU orally every 4 weeks|ergocalciferol 50000 IU orally every 4 weeks
223750321|NCT01170494|DRUG|ergocal1000 IU & cholecal 1000 IU orally daily|ergocalciferol 1000 IU and cholecalciferol 1000 IU orally every day
223750322|NCT01170494|DRUG|cholecalciferol 2000 IU orally daily|cholecalciferol 2000 IU orally everyday
223750323|NCT01170494|DRUG|Cholecalciferol 25000 IU orally every 2 weeks|Cholecalciferol 25000 IU orally every 2 weeks
223750324|NCT01170494|DRUG|Cholecalciferol 50000 orally every 4 weeks|Cholecalciferol 50000 orally every 4 weeks
223750325|NCT01170494|DRUG|placebo orally everyday|placebo orally everyday
223750326|NCT02443142|DRUG|Ibuprofen|Ibuprofen 800 mg orally three times per day for two days for study subjects who are randomized to the ibuprofen arm.
223750327|NCT02443142|DRUG|Acetaminophen|Acetaminophen 1000 mg orrally three times per day for two days for subjects who are randomized to the acetaminophen arm.
223750328|NCT00755131|OTHER|Exercise-based Cardiac Rehabilitation program|Trained patients attend the exercise training protocol for 6 months on hospital ambulatory-based regimen 3 times/week. Training sessions are supervised under continuous electrocardiography monitoring by a cardiologist, a physiotherapist and a graduate nurse. Each session is preceded by a 5-min warming-up and followed by a 5-min cooling-down. Exercise is performed for 30 min on a bicycle ergometer with the target of 60-70% of the peak oxygen consumption achieved at the initial symptom-limited cardiopulmonary exercise test. Exercise protocol is performed with a gradual increase in exercise workload until the achievement of the predefined target.
223750329|NCT03340025|DEVICE|PICO Single Use Negative Pressure Wound Therapy System|Class II negative pressure wound therapy powered suction pump
223750330|NCT03340025|DEVICE|xeroform gauze|traditional surgical dressing of xeroform gauze and padding
223602596|NCT04281381|DIAGNOSTIC_TEST|Cross-sectional imaging|MRI with gadolinium contrast will be the imaging modality of choice. In patients with contraindications to MRI who instead undergo baseline evaluation by CT scan, tumor evaluation will be by serial CT scans with IV contrast throughout the study period.
223602597|NCT01966835|BEHAVIORAL|High intensity aerobic interval training|The intervention consists of a total of 18 moderate-to-high intensity aerobic interval training sessions (20-30 minutes/session) spread over a maximum of eight weeks (2-3 times/week) as shown in Table 1. The training sessions are performed on bicycle ergometers (Kettler) and supervised by physiotherapists. Each session is built up by brief periods of high-intensity aerobic exercise (70-80 %) separated by recovery periods of lower-intensity (40-50%). Each session is introduced by a 5-minute warm-up and ends with a 5-minute cool-down (equivalent to 40-50% watt max). The absolute exercise intensity/workload (watt) is determined individually for each participant based on the watt max test performed at baseline.
223602598|NCT00544336|OTHER|questionnaire administration|no intervention
223602599|NCT00544336|OTHER|survey administration|no intervention
223602600|NCT00544336|PROCEDURE|quality-of-life assessment|no intervention
223602601|NCT05971927|BEHAVIORAL|Simulation education|Randomly assigned experimental group students performed eight different vaginal examination scenarios in the laboratory on the fetal monitoring and labor progress model set for cervical dilatation, cervical effacement, presenting fetal part, presence of amniotic membrane and fetal descent. The researchers repeated the vaginal examination scenario and informed the students about the evaluation results after each student had performed the vaginal examination scenario prepared by the researchers. This process continued until the experimental group students completed eight different vaginal examination scenarios.
223602602|NCT05159570|DIETARY_SUPPLEMENT|Ketone ester|Commercially available ketone supplement
223602603|NCT05159570|DIETARY_SUPPLEMENT|Placebo drink|Isocaloric placebo
223602604|NCT03941717|OTHER|Mindfulness-Based Condition|Each script for the mindfulness-based intervention was slightly modified to fit the context of a venipuncture, and begins with instructions to take deep breaths. Both scripts aim to cultivate present moment awareness of experiences, curiosity, nonjudgement, and acceptance of experiences as they unfold. In particular, the scripts ask that the participant visualize their worries and feelings as a cloud in the sky, and probes for curious thoughts about these experiences. The temporary nature of sensations is described, and the participant is asked to keep this openness and curiosity during the venipuncture.
223750331|NCT01366339|DRUG|Oral methylnaltrexone|
223750332|NCT01366339|DRUG|Oral placebo|
223750333|NCT01630512|BEHAVIORAL|Mindfulness-Based Cognitive Therapy (MBCT)|The intervention consists of 8 weekly individual sessions of MBCT. Each session will be administered individually and will last 45 to 60 minutes.
223750334|NCT01630512|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|The intervention consists of 8 weekly individual sessions of CBT. Each session will be administered individually and will last 45 to 60 minutes.
223750335|NCT03205410|PROCEDURE|remote ischemic preconditioning|The remote ischemic preconditioning protocol described before began after anesthesia induction, and was completed prior to the start of surgery.
223750336|NCT03205410|PROCEDURE|no - remote ischemic preconditioning|The sham - remote ischemic preconditioning protocol described before began after anesthesia induction, and was completed prior to the start of surgery.
224311308|NCT01675843|PROCEDURE|Intrauterine insemination (IUI)|The male semen is obtained then processed by swim up technique and then introduced into the uterus by special catheter.
224311309|NCT06402617|PROCEDURE|Pulmonary vein isolation|Standard clinical radio-frequency ablation isolation of pulmonary veins
224311310|NCT06402617|DIAGNOSTIC_TEST|RETRO-Mapping without adjunctive ablation|RETRO-Mapping performed using research equipment and software, but without any adjunctive ablation
224311311|NCT06402617|PROCEDURE|Adjunctive ablation guided by RETRO-Mapping|Radio-frequency ablation using a European conformity (CE)-marked ablation catheter of sites of focal activation identified by RETRO-Mapping
224311312|NCT02913092|BEHAVIORAL|Electronic sensor and OW education|MDI sensor-generated alerts will be relayed via app platform on participant's phone and responded to (e.g. outreach worker contacts the patient for a missed dose) in real-time to the intervention group. Outreach worker will also assess intervention group participants' need for further asthma education and provide education over the phone
224311313|NCT01676415|DRUG|Prednisone|"Three-week course of a broad-spectrum antibiotic Amoxicillin/Clavulanate at a daily dosage of 875mg twice daily~If the subject is allergic to Penicillin and its derivatives or has had an adverse reaction to Amoxicillin/Clavulanate, a three-week course of clarithromycin instead~Antihistamines if an appropriate history of atopy is obtained~Systemic prednisone: Starting dose of 40mg for five days followed by a taper decreasing by 10mg every 5 days~Following completion of the oral corticosteroid: Course of topical mometasone until the end of the study"
224311314|NCT01676415|DRUG|Topical mometasone|"Three-week course of a broad-spectrum antibiotic Amoxicillin/Clavulanate at a daily dosage of 875mg twice daily~If the subject is allergic to Penicillin and its derivatives or has had an adverse reaction to Amoxicillin/Clavulanate, a three-week course of clarithromycin instead~Antihistamines if an appropriate history of atopy is obtained~Standing course of topical mometasone at the standard dose of 2 sprays to each nostril once daily and will remain on the topical mometasone until the end of the study."
223750337|NCT03491995|DRUG|Quadruple therapy|Moxifloxacin, omeprazole sodium bicarbonate, nitazoxanide, doxycyclin
223750338|NCT03491995|DRUG|Classic treatment|Omeprazole, amoxycillin, clarithromycin
223750339|NCT06802029|GENETIC|Whole Genome Sequencing Analysis|Laboratory blood analysis
223750340|NCT03063892|DRUG|Tranexamic Acid (TXA)|Tranexamic acid is an antifibrinolytic used to control bleeding
223750341|NCT03063892|DRUG|Saline solution|Saline solution is used as the placebo comparator
223750342|NCT04773158|BEHAVIORAL|Clinical Decision Support|The intervention clinic sites will be provided access to a Clinical Decision Support System (CDSS) that incorporates the Rome IV criteria for evidence-based care recommendations for functional gastrointestinal disorders (FGIDs)
223750343|NCT00017147|DRUG|carmustine|"40 mg/m\^2 IV over 1 hour on day 1 of each cycle 6 hours after O6-BG dose for experimental arm with O6=BG.~200 mg/m\^2 IV over 1 hour on day 2 of each cycle for the active comparator arm."
223750344|NCT00017147|RADIATION|radiation therapy|5 days/week using one fraction per day and a dose of 180 cGy per fraction. Initial target volume is dose of 5040 cGy in 28 fractions with boost target volume of 1080 cGy in 6 fractions.
223750345|NCT00017147|DRUG|O6-Benzylguanine|120 mg/m\^2 IV over 1 hour on day 1 of each cycle
223750346|NCT03035123|BEHAVIORAL|Therapeutic education|Interventional arm
223750347|NCT02420691|OTHER|Laboratory Biomarker Analysis|Correlative studies
224200134|NCT00297882|DRUG|1. Artemether-Lumefantrine (AL)|Artemether-Lumefantrine(Co-Artem)=Artemether, 2mg/kg x 2(12h apart) and Lumefantrine, 12mg/kgx2 (12h apart).
223602605|NCT03941717|OTHER|Unfocused attention Condition|Each script for the unfocused attention task instructs participants to allow their mind and thoughts to roam. The aim is to encourage the participant to continue thinking and mind wandering as they typically would.
223602606|NCT01407666|PROCEDURE|paravertebral blocks|use bilateral thoracic paravertebral blocks for pain control
223602607|NCT04278976|OTHER|Implementation of CoBaTrICE|"The implemention of CoBaTrICE will include the three following essential elements:~1. Training the trainers. In order to provide high quality feedback to guide development of competence, tutors will receive a course in formative assessment, debriefing techniques, and effective feedback.~2. Workplace-based assessment (WbA) to promote learning and to guarantee that the predefined competences and skills are effectively acquired. Current Wb observation methods such as mini-clinical examination exercise, direct observation of procedural skills and multisource-feedback 360º will be used.~3. The use of an electronic portfolio specifically created as a personal collection of training documents that includes the record of formative assessments, activities, and the levels of competence achieved. The portfolio will help monitor progress of trainee's skills development and learning experiences contributing to an effective assessment, self-reflection and control of the learning process."
223602608|NCT01511068|DRUG|Leukine|Participants will receive inhaled rhGM-CSF (Sargramostim, Leukine) at the dose of 250 mcg one time per week for 12 weeks. Following an interim safety evaluation, participants may be entered into a second 12 week treatment period where participants will receive either 250 mcg or 500 mcg once weekly. At the end of any treatment period, participants will be followed for 12 additional weeks in the absence of inhaled rhGM-CSF to evaluate safety and efficacy.
223602609|NCT03616509|DRUG|Growth hormone|12 months on Growth hormone, initial dose 0,2 mg per day, then adjusted by insulin like growth factor (IGF-1) level
223602610|NCT03616509|DRUG|Placebo|2 months on placebo, sodium chloride 0,9% injections
223602611|NCT00465088|DRUG|Niacin ER/Simvastatin Tablets|Up to 2000 mg/40 mg at bedtime
223602612|NCT00465088|DRUG|atorvastatin|40 mg at bedtime
223602613|NCT06512168|BEHAVIORAL|AAC Generative Language Intervention|Aided AAC Language Input/Output Intervention
223602614|NCT02716623|OTHER|CR diet|Diet consists of meals lower in carbohydrates but does not restrict the number of calories that participants can consume.
223602615|NCT02716623|BEHAVIORAL|Exercise|Participants will be asked to undergo specific exercise schedule. Exercise will be tracked using a fitness device.
223602616|NCT04035239|DEVICE|BGS goggles|BGS goggles use for 3-6 weeks
223602617|NCT04191317|OTHER|Pain Neuroscience Education and gradual exposure|Education covering the pathophysiology of apin and exercises based on the gradual exposure principle
223602618|NCT04191317|OTHER|Pilates and postural education|Postural education and pilates exercises
223602619|NCT02813161|BIOLOGICAL|cellular and tissue based therapy|
223602620|NCT02813161|DEVICE|negative pressure wound therapy|
223750348|NCT02420691|OTHER|Pharmacological Study|Correlative studies
223750349|NCT02420691|DRUG|Ribociclib|Given PO
223750350|NCT00528723|DRUG|salbutamol 100 mcg|To be used as needed for symptom relief
224200135|NCT00297882|DRUG|2. Amodiaquine-Artesunate (AQ-AS)|Amodiaquine-Artesunate (0H),D1(24H),D2(48H)= Artesunate 4mg/kg and Amodiaquine at 10mg/kg
223602621|NCT02813161|PROCEDURE|debridement|
223602622|NCT02813161|PROCEDURE|advanced wound therapy|
223602623|NCT02813161|DIETARY_SUPPLEMENT|Nutritional screening|
223602624|NCT02813161|DEVICE|off-loading|
223602625|NCT02813161|DEVICE|Hyperbaric oxygen Therapy|
223602626|NCT01067144|DRUG|Gabapentin|1200 mg Gabapentin preoperative dose, 300 mg of Gabapentin 3-times a day postoperative doses for 72-hour post-surgical period.
223602627|NCT01067144|DRUG|Lorazepam (active control)|0.5 mg Lorazepam (active control) given pre-operatively in a single dose.
223602628|NCT01067144|DRUG|Placebo (inactive)|2 capsules of inactive placebo given 3-times a day post-operatively for the 72-hour post-surgical period.
223602629|NCT00973687|DRUG|Ora Sweet|A pharmaceutical suspending vehicle and flavouring agent added to the dexamethasone. All arms received the same amount of dexamethasone based on the child's weight, only in different volumes.
223602630|NCT00973687|DRUG|Dexamethasone|
223602631|NCT05971537|DRUG|antibiotic lock|"In the intervention arm, in addition to the appropriate IP antibiotics, an antibiotic-lock will be prepared by the same antibiotics. We will follow the suggested data used in hemodialysis catheter for the concentration of different antibiotics to prepare the locking solution . Some commonly used antibiotics for the treatment of PD peritonitis with their suggested concentrations in the antibiotic-lock are quoted as below:~Cefazolin 10mg/mL Ceftazidime 10mg/mL Vancomycin 10mg/mL Gentamicin 5mg/mL Tienam 50mg/mL"
224200136|NCT01170767|DRUG|Avastin|Intravitreal injection of bevacizumab at a concentration of 1.25 mg per injection. One injection per month at the maximum and between 3 and 12 injection in the whole study.
224200137|NCT01170767|DRUG|Lucentis|Intravitreal injection of ranibizumab at a concentration of 0.50 mg per injection. One injection per month at the maximum and between 3 and 12 injection in the whole study.
224200138|NCT03534635|DRUG|Pembrolizumab|Pembrolizumab monotherapy at 200 mg every 3 weeks for 2 years maximum.
224200139|NCT03534635|DRUG|Pembrolizumab - additional treatment|Patients may be retreated for one year of additional pembrolizubmab therapy (200 mg every 3 weeks).
224311315|NCT00587990|BIOLOGICAL|Lower dose mesenchymal stem cell (MSC) injection|Participants will receive between 10 and 20 intramyocardial injections of 2 million MSCs per 0.25-0.5 cubic centimeter (cc) for a total of 2 x 10\^7 cells. The injections will be administered following completion of CABG surgery.
223602632|NCT05971537|DRUG|conventional IP antibiotics|In the control arm, appropriate IP antibiotics are to be continued. The dosage and duration of antibiotics will fully follow the recommendation from the latest International Society for Peritoneal Dialysis (ISPD) peritonitis guidelines
223602633|NCT06160934|BEHAVIORAL|T1D Parent Check-in|The Type 1 Diabetes (T1D) Parent Check-in is an innovative, 3-session, T1D-specific intervention for parents of newly diagnosed children and adolescents that can be delivered via telehealth. The T1D Parent Check-in is an adaptation of The Parent Check-In, a brief, prevention-based parenting intervention developed by Grolnick, Levitt, Caruso, \& Lerner (2021). The T1D Parent Check-in is designed to promote parenting skills on dimensions of autonomy support, structure and involvement that facilitate children's adjustment and motivation, and integrates skills from cognitive-behavioral therapy, customized to be highly relevant to families with a child 6-12 months from new diagnosis of T1D. The intervention is intended to promote diabetes-related resilience and positive psychological and medical outcomes among families of children with T1D.
223602634|NCT02978196|PROCEDURE|Injection of 99mTc-NM-01|Patient is injected with micro-dose of 99mTc-NM-01
223602635|NCT02978196|PROCEDURE|Injection of 68Ga-NM-01|Patient is injected with micro-dose of 68Ga-NM-01
223602636|NCT04182243|OTHER|Evaluation of job satisfaction in emergency health care providers by questionnaire|
223602637|NCT04215900|BEHAVIORAL|High-speed yoga multi-directional yoga|The yoga training will be performed over a 4-month period where classes will be held two times per week. Each session will include a warm-up, speed and balance training section, and cooldown phase. The yoga program will include four separate progressions with the first four weeks serving as a familiarization phase, where the participants will be introduced to the poses and proper technique will be demonstrated. The second four-week phase will emphasize a speed component used to target improvements in aerobic capacity. The same poses previously learned will be used. The final two phases will increase in intensity maintaining the speed element and include skill-based training, where the participants will be asked to complete each pose moving as quickly as possible in response to visual and auditory cues.
223602638|NCT00475709|DEVICE|Trifecta Aortic Heart Valve|Surgical replacement of the aortic valve with the Trifecta Aortic Heart Valve.
223602639|NCT00010283|DRUG|beclomethasone dipropionate|
223602640|NCT04583527|DEVICE|ALV1 System|The ALV1 system is designed to create a controlled size interatrial shunt via a proprietary intra-cardiac catheter. There is no temporary or permanent implant used to create or maintain the interatrial shunt. The therapy is intended to be delivered in a single procedure administered under general anesthesia in a cardiac catheterization laboratory.
223602641|NCT01732315|BEHAVIORAL|Email Notification|This study will use a targeted email reminder/recall intervention that addresses specific aspects of adolescent under-immunization.
223602642|NCT00555672|DRUG|5-fluorouracil|5- fluorouracil is given as 4000 mg/m\^2 total dose over 96 hr continuous infusion of a 21 day chemotherapy cycle. Each 21 day cycle is repeated until progression of disease or unacceptable toxicity is observed.
223602643|NCT00555672|DRUG|cisplatin|Cisplatin is given 80 mg/m\^2 through a vein on day 1 every 21 days. Each 21 day cycle is repeated until progression of disease or unacceptable toxicity is observed.
223602644|NCT00555672|DRUG|sunitinib malate|sunitinib is given orally 37.5mg /day for 14 days followed by 7 days of drug free period. Each 21 day cycle is repeated until progression of disease or unacceptable toxicity is observed.
223602645|NCT03079089|DRUG|Sequential Packaging (SET)|Sequential chemotherapy: - Thiotepa 5 mg/kg/day for 1 day (D-13) -Cyclophosphamide 400 mg/m²/day for 4 days (J-12 to J-9)- Etoposide 100 mg/m²/day for 4 days (J-12 to J-9) Repos days J-8 and J-6 Reduced-intensity conditioning (RIC)-Fludarabine 30 mg/m²/day for 5 days (J-5 to D-1)- Busulfan IV 3.2 mg/kg/day for 2 days (J-5 and J-4)- Anti-lymphocyte serum (Thymoglobuline) 2.5 mg / kg / day for 2 days (J-3 and J-2)
223602646|NCT03079089|DRUG|Transfusion graft|Graft of peripheral stem cells is preferred at DO
223750351|NCT00528723|DRUG|BDP/salbutamol HFA pMDI|Patients assigned to BDP/salbutamol HFA pMDI will receive 2 puffs twice daily (morning and evening), for a total daily dose of BDP 1000 mcg/salbutamol 400 mcg, plus 2 puffs twice daily of alternative CFC placebo
223750352|NCT00528723|DRUG|BDP/salbutamol CFC pMDI|Patients assigned to BDP/salbutamol CFC pMDI will receive 2 puffs twice daily (morning and evening), for a total daily dose of BDP 1000 mcg/salbutamol 400 mcg, plus 2 puffs twice daily of alternative HFA placebo
223750353|NCT01620073|OTHER|HIV counseling and testing|Male partner HIV counseling and testing
223750354|NCT03002012|DRUG|Sertraline|sertraline 400mg/day
223602647|NCT03079089|DRUG|Prevention of GVHD|"* Cyclophosphamide 50mg/ kg/day on days D + 3 and D + 5 - Cyclosporine A (CSA; 3 mg / kg / day IV from D+6)~* Mycophenolate mofetil (MMF; 30 mg/kg/ day, maximum x2 1g / day from day J+6)"
223602648|NCT03079089|DRUG|Care supports|According to the protocols of each center
223602649|NCT03079089|DRUG|Lymphocyte injection of prophylactic donor (PDLI)|"According to the protocols of each center. In the absence of clinical indication against-disease (GVHD), phasing MMF between days D + 35 and D + 56, then phasing APF between D + 62 and D + 90~\- PDLI: 3 injections from the D + 120 patients who discontinued immunosuppressive therapy for ≥ 1 month and having no active GVHD or history of acute GVHD grade\> II."
223602650|NCT03632772|DRUG|Solifenacin 5Mg|We compared the safety and therapeutic efficacy between Solifenacin and Mirabegron in men with benign prostate hyperplasia and having overactive bladder symptoms immediately after Transurethral Resection of the Prostate.
223602651|NCT03632772|DRUG|Mirabegron 50 MG|We compared the safety and therapeutic efficacy between Solifenacin and Mirabegron in men with benign prostate hyperplasia and having overactive bladder symptoms immediately after Transurethral Resection of the Prostate.
223602652|NCT04759157|BEHAVIORAL|Couples-based treatment|Couples will attend 3, video based sessions for couples-based treatment
223602653|NCT04759157|OTHER|Standardized education|Patients will receive standardized educational materials
223750355|NCT03002012|DRUG|Placebo Oral Tablet|matched placebo tablet
223750356|NCT03002012|DRUG|Fluconazole|Standard of Care Fluconazole per World Health Organization and Ugandan Guidelines (800mg/day x 2 weeks, 400mg/day x10 weeks, 200mg through 6 months).
224311316|NCT00587990|GENETIC|Placebo|Participants will receive between 10 and 20 placebo injections that consist of phosphate buffered saline (PBS) and 1% human serum albumin (HSA).
223750357|NCT06113198|BIOLOGICAL|rMenB+OMV NZ|3 doses of rMenB+OMV NZ vaccine administered intramuscularly on Day 1, Day 61, and any day between Day 241 - Day 391.
223750358|NCT04814576|BEHAVIORAL|Collaborative cares|The intervention consists of the co-design and implementation of therapeutic activities by the nurse and the mental health day hospital users following a collaborative care model. For this purpose, the participatory action research (PAR) method will be used and semi-structured interviews and focus groups will be used as data collection techniques.
223750359|NCT03167879|BEHAVIORAL|safer conception counseling|Multi-component counseling to help HIV-affected couples to make an informed decision about childbearing, and to provide counseling to use contraception or safer conception methods, depending on whether the couples chooses to seek or prevent pregnancy after initial consultation.
223750360|NCT03636347|DRUG|Placebo Oral Tablet|twice daily administration
223750361|NCT03636347|DRUG|Alvelestat oral tablet - dose 1|twice daily administration
223750362|NCT03636347|DRUG|Alvelestat oral tablet - dose 2|twice daily administration
223750363|NCT02129985|DRUG|Exenatide|Exenatide (10 ug/bid for 3 months)
223750364|NCT02129985|DRUG|Metformin|Metformin 850 mg/bid for 3 months
223750365|NCT06231212|DRUG|ECa 233|Intervention groups are separated into group A and group B. Group A takes capsules containing 250 mg of ECa 233 and group B takes capsules containing 500 mg of ECa 233.
223750366|NCT06231212|DRUG|Ibuprofen|Ibuprofen group was given capsules containing 200 mg of ibuprofen
223750367|NCT06231212|OTHER|Placebo|Placebo-controlled group received capsules containing 250 mg of lactose
224200140|NCT03665246|BEHAVIORAL|Integrated Mothers and Babies Course|The Integrated Mothers and Babies Course/Early Childhood Development (iMBC/ECD) will be implemented along side normal C-PrES programming (key MNCHN behaviors). The iMBC curriculum is a prevention model based on cognitive behavioral therapy with the aim of supporting pregnant women and mothers with children under two years of age to become more resilient, decrease risk for future depression, and manage daily stressors effectively. In addition, the updated version of the iMBC is integrated with selected early childhood development (ECD) messages. The integration of these messages is intended to increase mothers' knowledge of the stressors associated with pregnancy and parenting young children and promote early stimulation behaviors and bonding to support child development.
224200141|NCT04484805|DEVICE|ICE Condition|Experimental socket integrated with a heat spreader. An ICE Unit (includes TEC) is attached to the socket.
223750368|NCT03897179|DEVICE|INVSENSOR00032 and INVSENSOR00033|Investigational pulse oximeter device
223750369|NCT00854945|DRUG|ON 01910.Na|1800 mg/day as a 24-hour continuous intravenous infusion administered three times a week every 2 weeks
223750370|NCT04710706|OTHER|Colonoscopy insertion technique used during procedure|Each arm is using a different colonoscopy insertion technique: either water-alone colonoscopy or water-CO2 colonoscopy.
223750371|NCT05552677|OTHER|Multicomponent Training|Participants will perform a multicomponent training that explores strength, aerobic and balance capacities with load progression every 15 days. The sessions will last 60 minutes each, being held three times a week with a day of rest in between. The intervention will last 12 weeks
223750372|NCT01923415|PROCEDURE|No intervention, skin biopsy|All participants will have 2 adjacent 4 mm punch biopsies collected from uninvolved and involved skin (a total of 4 biopsies).
223750373|NCT01923415|PROCEDURE|No intervention, blood collection|Blood for serum analyses will be taken from all participants, blood for DNA analysis only from subjects who consent to this separately.
223750374|NCT01923415|PROCEDURE|No intervention, urine collection|Urine will be collected from all participants.
223750375|NCT00704535|DRUG|Ezetimibe|1 tablet of 10 mg once daily
223750376|NCT05156866|DRUG|TORL-2-307-ADC|antibody drug conjugate
223750377|NCT01480076|DRUG|Fampridine|Supplied as a 10 mg twice daily tablet and taken twice daily. Doses must be spaced at least 12 hours apart.
223750378|NCT04508790|DRUG|Dexamethasone|Given PO
223750379|NCT04508790|DRUG|Leflunomide|Given PO
223750380|NCT04508790|DRUG|Pomalidomide|Given PO
223750381|NCT04053101|DEVICE|PET CT|Every patient undergoing a PET CT at the time of diagnosis of muscle invasive bladder cancer from January 2005 to December 2017 in Bordeaux (Institut Bergonié and University Hospital).
223750382|NCT02503332|DRUG|Pegcetacoplan|
223750383|NCT02503332|OTHER|Sham Procedure|
223750384|NCT05457257|DRUG|olaparib|300 mg (2x 150 mg tablets) twice daily
223750385|NCT05457257|DRUG|enzalutamide|160 mg (4 x 40 mg capsules) once daily
223750386|NCT05457257|DRUG|abiraterone acetate|1,000 mg (4 x 250 mg tablets) once daily
223750387|NCT05457257|DRUG|Prednisone|5mg(5mg x 1 tablet) twice daily
223750388|NCT05138133|DRUG|Anifrolumab|Anifrolumab intravenous infusion (IV)
223750389|NCT05138133|DRUG|Placebo|Placebo intravenous infusion (IV)
223750390|NCT05968690|DRUG|Propranolol|Propranolol will be administered to patients in all cohorts.
224200142|NCT04484805|DEVICE|Sham Condition|Experimental socket integrated with a heat spreader. A Sham Unit (excludes TEC) is attached to the socket.
224200143|NCT05873959|BIOLOGICAL|HAV implantation|HAVs already implanted under humanitarian aid program to repair or reconstruct arteries following an extremity life- or limb-threatening traumatic injury.
224311317|NCT00587990|BIOLOGICAL|Higher dose MSC injection|Participants will receive between 10 and 20 intramyocardial injections of 20 million MSCs per 0.25-0.5 cc for a total of 2 x 10\^8 cells. The injections will be administered following completion of CABG surgery.
223750391|NCT05968690|DRUG|Naltrexone|Naltrexone will be administered to patients in cohorts 2, 3, and 4.
223750392|NCT06339073|DEVICE|mechanical ventilation|Abdominal trauma patients were treated with mechanical ventilation according to their conditions.
223750393|NCT04139707|DEVICE|Caring4Dementia|A mobile application administered for 30 days, which provides people caring for a person living with dementia with a useful and intuitive tool targeting communication skills.
223750394|NCT04139707|OTHER|White Paper|The White Paper group will receive a white paper (hard copy and electronically) on the principles of communicating efficiently with persons living with dementia.
223750395|NCT06452095|DEVICE|Hyperbaric Oxygen therapy|The SECHRIST INDUSTRIES mono-place Hyperbaric Chambers OR Sigma Series mono-place Hyperbaric Chambers
224200144|NCT06405152|OTHER|Chart review|Retrospective Chart Review
224200145|NCT06402513|DRUG|Ravagalimab|Subcutaneous Injection
223602654|NCT05380440|BEHAVIORAL|Families Actively Improving Relationships (FAIR)|FAIR is a behavioral intervention for the treatment of parental substance abuse and child neglect for families involved in the child welfare system. This project will adapt the existing FAIR intervention for prevention. FAIR involves four major treatment components, supported by ongoing purposeful engagement : (1) Substance use treatment including contingency management and positive reinforcement, frequent urinalysis, relationship building, day planning, healthy environments and peer choices, and refusal skills; (2) Mental health treatment including cognitive behavioral therapy, developing healthy coping skills, emotion regulation skills, exposure therapy, and referral for medication management; (3) Parent management training including parenting skills, nurturing and attachment, reinforcement, emotion regulation, supervision, structure, non-harsh discipline, and nutrition; and (4) Resource building and provision of ancillary supports including assistance with housing and employment.
223602655|NCT05380440|BEHAVIORAL|Standard Case Management and Referral|Parents will be referred for a substance abuse and mental health assessment with possible resulting treatment. Child Welfare treatment plans typically include a series of recommendations, including parenting classes, securing safe housing, psychosocial treatment (e.g., domestic violence), accessing self-sufficiency services (e.g., food stamps, WIC), securing employment or education, and meeting court dates and requirements.
223602656|NCT06528431|DRUG|Clinical tapering strategy|Clinical Tapering strategy : Adalimumab injections will be progressively spaced out according to DAS28 assessment every 3 months
223602657|NCT06528431|DRUG|Step Wedge trial|Step Wedge trial : At baseline, all the patients will receive in this study the standard adalimumab dosing regimen. At subsequent time points (steps), patients will begin the intervention of interest, here the tapering adalimumab strategy. The time at which a patient begins the intervention will be randomized. We fixed the time steps duration to 3 months that corresponds the frequency of there commended follow-up of RA patients
223602658|NCT01479361|DRUG|Atovaquone 750 mg twice daily|
223602659|NCT01479361|DRUG|Atovaquone 1500 mg twice daily|
223602660|NCT00921791|DEVICE|HBPM|Automatic oscillometric device for home blood pressure measurement and usual care.
223602661|NCT00921791|DEVICE|HBPM and Pharmaceutical care|Automatic oscillometric device for blood pressure measurement at home and consultations with the pharmacists
223602662|NCT00921791|BEHAVIORAL|Pharmaceutical care|consultations with the pharmacists
223602663|NCT00921791|OTHER|Usual care|Consultation with the physician.
223602664|NCT06360848|OTHER|surgery|SURGICAL TREATMENT OF PSEUDARTHROSIS OF THE HUMERUS
223602665|NCT04259008|OTHER|Manganese omission|Participants randomized to the experimental intervention arm will not receive added manganese in their parenteral nutrition.
223602666|NCT04259008|OTHER|"5 mCg/kg/day manganese from Multitrace-4 Neonatal."|"5 mCg/kg/day manganese from Multitrace-4 Neonatal."
223602667|NCT01415401|DRUG|Brinzolamide 1% / timolol 0.5% maleate fixed combination|
223602668|NCT02899091|BIOLOGICAL|CB-AC-02|"Stage1:~① Group1: CB-AC-02 administration on day 0~② Group2: CB-AC-02 administration on day 0 and on week 4 (repeated injection)~Stage2~① Arm1: K-MMSE 20\~26 CB-AC-02 administration on day 0 and on week 4 (repeated injection)~② Arm2: K-MMSE 10\~19 CB-AC-02 administration on day 0 and on week 4 (repeated injection)"
223602669|NCT02899091|BIOLOGICAL|Placebo|"Stage2:~Placebo administration on day 0 and on week 4 (repeated injection)"
223602670|NCT02397148|RADIATION|Computed Tomography|imagery with ionizing radiation
223602671|NCT02397148|RADIATION|Cone Beam Computed Tomography|imagery with ionizing radiation
223750396|NCT06297278|BEHAVIORAL|Moderate Intensity Exercise|Participants randomized to the active (moderate intensity) exercise condition will complete a 3-minute warm-up at low speed on a treadmill. Speed and incline will be increased in 3-minute increments until moderate-intensity exercise, defined as participants staying within a zone of 60-80% AAMHR with the target being to attain and maintain 70-75% AAMHR while briskly walking and/or jogging depending on current fitness status, is reached for a total of 30 min.
223750397|NCT00837655|DRUG|Sevelamer|sevelamer tablets, 800 mg (Renagel(r), Genzyme Inc). The initial daily dose of sevelamer will be 2400 mg (800 mg x 3). After the first week of treatment the dose will be increased to 4800 mg. If treatment with sevelamer is well tolerated and if a phosphate concentration of \<1.8 mmol/l is not obtained, the dose may be increased further. The maximum daily dose of sevelamer will be 9600 mg. If a patient experiences side effects, the dose of sevelamer will be reduced to the highest acceptable dose, and, if a phosphate concentration of \<1.8 mmol/l is not obtained, the treatment will be supplemented with calcium carbonate in a dose tolerated by the patient.
223750398|NCT00837655|DRUG|Calcium carbonate|Calcium carbonate tablets, 250 mg (Kalcidon, Abigo AB). Calcium carbonate will be prescribed at the dose given prior to the washout period. The dose will be adjusted weekly to obtain a serum phosphate concentration \<1.8 mmol/l.
223750399|NCT02746562|PROCEDURE|Freeze all|Freezing of all blastocyst stage embryos with thawing and transfer in a subsequent natural cycle
223602672|NCT03746717|DEVICE|occlusive wound closure|skin closure with a commercially available wound closure product consisting of a synthetic adhesive mesh and cyanoacrylate based skin glue
223602673|NCT03746717|DEVICE|conventional wound closure|wound closure with surgical staples
223602674|NCT01860313|BEHAVIORAL|Web-based interactive education|An educational program for training teachers and educators to better recognize mental health problems in adolescents and children
223602675|NCT01860313|BEHAVIORAL|Text and Video-based education|This group received the material that composed the web-based education environment without any kind of interactivity. This material was composed by some videos about children mental health and a support text.
223602676|NCT02465372|BEHAVIORAL|CSPAP|Comprehensive School Physical Activity Program.
223602677|NCT00119470|PROCEDURE|EUS-FNA|
223602678|NCT00119470|PROCEDURE|Conventional Surgical Technique|
223602679|NCT06268938|PROCEDURE|Canal wall down tympanomastoidectomy|Mastoid cavity obliteration by in canal wall down tympanomastoidectomy tympanomastoidectomy in cholesteatoma surgery
223750400|NCT03350360|BEHAVIORAL|Attention Control Training|Attention control training teaches participants that the emotional salience of cues (i.e., threatening or neutral) is not related to successful completion of the computerized response task, and thus, teaches participants to ignore irrelevant threat-related contingencies (Badura-Brack et al., 2015).
223602680|NCT02923856|DEVICE|The results of clarithromycin susceptibility test of H. pylori isolates|According to the results of antibiotic susceptible testing, patients who were resistant to clarithromycin were belonged into clarithromycin resistance group.Patients who were sensitive to clarithromycin were belonged into the 7days/10days/14days treatment groups.
223602681|NCT02923856|DEVICE|Computer generated random number, randomly assigned into groups|The patients with clarithromycin sensitive. Computer generated random number,randomly assigned into 7days/10days/14days treatment groups.
223750401|NCT03350360|BEHAVIORAL|Comparison Task|Neutral- neutral stimuli prior to response task
223750402|NCT01837628|DRUG|Lidocaine Gel|
223750403|NCT01837628|DRUG|Paraffin Oil|
223750404|NCT00000644|DRUG|Clarithromycin|
223750405|NCT03836963|BEHAVIORAL|cognitive training|Cognitive training consists of a set of computerize games played on an iPad at home. Training will include 4 sessions/week for 8 weeks. Each session will take 30min. Total hours of training is 16 hours.
223750406|NCT03836963|BEHAVIORAL|active control cognitive training|The active control consists of a set of computerized games played on an iPad. Training will include 4 sessions/week for 8 weeks. Each session will take 30min. Total hours of training is 16 hours.
223750407|NCT03836963|BEHAVIORAL|memory strategy training|the participant's prospective memory strategies will be developed with researchers. Participants will be engage in the strategies daily; this will take only a few minutes a day to accomplish.
223750408|NCT03836963|BEHAVIORAL|memory strategy training|the participant's prospective memory strategies will be developed with researchers. Participants will be engage in the strategies daily; this will take only a few minutes a day to accomplish.
223602682|NCT02923856|DEVICE|The result of 13C-urea breath test of patient in 7days/10days/14days treatment groups|The intervention focused on the results from the result of 13C-urea breath test at 8 weeks after treatment in patients. All patients were taking 75mg 13C-urea and analysis with a modified isotope ratio mass spectrometer to determine the 13CO2 content.The successful treatment groups were patients with negative in 13C-urea breath tests.The failed treatment of H. pylori groups were patients with positive in 13C-urea breath tests after the standardized triple therapy treatment.
223750409|NCT03548402|BEHAVIORAL|Acceptance and Commitment Therapy (ACT)|ACT is based on the theory that rigid attempts to control internal states, thoughts and feelings, and other forms of experiential avoidance contribute to symptom development and maintenance of anxiety and self-injury.
223750410|NCT02916563|DEVICE|Blood Glucose Monitoring System Altitude Performance|Performance as assessed against a reference method at an altitude of approximately 10,000 feet.
223750411|NCT03608514|DRUG|Experimental|Patients in this arm of the study will receive intravenous infusion (IVi) terlipressin by rate 1-2µg/kg/min.
223750412|NCT03375021|DRUG|CX717 200 mg|CX717 200 mg capsules BID
223750413|NCT03375021|DRUG|CX717 800 mg|CX717 4 X 200 mg capsules BID
223750414|NCT03375021|DRUG|Placebo|Placebo 200 mg or 800 mg capsules BID
223750415|NCT02149173|PROCEDURE|Computed Tomography|Undergo F-18 FES PET/CT
223750416|NCT02149173|PROCEDURE|Computed Tomography|Undergo FDG PET/CT
224200146|NCT03290976|OTHER|Acupuncture|"Acupuncture treatments will be patient-tailored, with the acupuncture points (acu-points) to be selected by the acupuncturist at each treatment session, in accordance with the dynamic of the patient's symptoms, concerns and expectations. At the same time, acupuncturists will be required to choose at least 5 of the following 11 acupoints, which are to be incorporated into their treatment regimen:~Lower limb points: Liver (LIV) 3, Spleen (SP) 4, SP6, Stomach (ST) 36, Gallbladder (GB) 34, Kidney (KID) 3, LIV8, Web (Bafeng) points Upper limb points: Large Intestine (LI) 4, LI 11, LI10, Pericardium (PC) 6, Triple Warmer (TW) 3/4/5"
223750417|NCT02149173|DRUG|F-18 16 Alpha-Fluoroestradiol|Undergo F-18 FES PET/CT
223750418|NCT02149173|DRUG|Fludeoxyglucose F-18|Undergo FDG PET/CT
223750419|NCT02149173|OTHER|Laboratory Biomarker Analysis|Correlative studies
223602683|NCT01503086|PROCEDURE|Cognitive Assessment|Ancillary studies
223602684|NCT01503086|OTHER|Computer-Assisted Cognitive Training|Receive computer-assisted cognitive training
223750420|NCT02149173|PROCEDURE|Positron Emission Tomography|Undergo F-18 FES PET/CT
223750421|NCT02149173|PROCEDURE|Positron Emission Tomography|Undergo FDG PET/CT
223750422|NCT01733446|OTHER|Continuation of High Frequency Jet Ventilation (HFJV)|In Group B, after cessation of anesthetic infusions, High Frequency Jet Ventilation (HFJV) will continue through the endotracheal tube. Patient will be extubated when awake. Respiratory Inductance Plethysmography (RIP) and Transcutaneous carbon dioxide (PtcCO2) measurements will continue for the duration of emergence.
223750423|NCT02625090|DRUG|UCB0942|"* Active Substance: UCB0942~* Pharmaceutical form: Film-coated tablet~* Concentration: 25 mg, 100 mg or 200 mg~* Route of Administration: oral"
223750424|NCT06482021|DEVICE|Low-intensity extracorporeal shock wave|Acetylcholine iontophoresis• The Iontophoresis comprises of electric impulses from a low voltage galvanic current stimulation unit to drive ions (Ach) (1%) into soft tissue structures.
223750425|NCT02858219|DRUG|Botulinum Toxin Type A|
223750426|NCT02858219|OTHER|Saline solution|
223750427|NCT02858219|OTHER|Indexes|Visual Analogic Scale (VAS), Female Sexual Function Index (FSFI), Dermatology Life Quality Index (DLQI)
223750428|NCT04338438|DRUG|Apatinib Mesylate tablets combined with S-1 capsules|Apatinib Mesylate tablets combined with S-1 capsules, p.o.
223602685|NCT01503086|PROCEDURE|Psychosocial Assessment and Care|Ancillary studies
223602686|NCT01503086|OTHER|Quality-of-Life Assessment|Ancillary studies
223750429|NCT02467556|DRUG|Morphine, memantine|Morphine up to 30 mg per day orally and memantine up to 40 mg per day orally if tolerated for 10 weeks.
223750430|NCT02467556|BEHAVIORAL|Psychological intervention|To help patients shift perspective from pain and CRPS-symptoms, to increase body awareness, to create vivid imagenary, to increase the use of a CRPS hand with mindfulness exposure exercises, to increase flexibility in behavioral repertoire, to explore the fusion of emotions, automatic cognitions and learned responses and to help patients to integrate new skills in their lives.
223750431|NCT02467556|OTHER|Physiotherapy intervention|Graded motor imagenary with group and individual weekly sessions with daily practices at home.
223750432|NCT00647127|DRUG|Buprenorphine|Buprenorphine: 20microg/h
223750433|NCT00647127|DRUG|Fentanyl|Fentanyl: 25microg/h
223750434|NCT00647127|DRUG|Placebo|Placebo: '5microg/h' (not active drug, it is just called '5microg/h')
223750435|NCT02076828|DRUG|Ferro Sanol® sp|The children with IDA that included in Fe-S (Ferro Sanol® sp.)(Group I) were treated with a therapeutic dose Ferro Sanol® sp as 6 mg/kg/day in the first 2 months and followed by maintenance treatment at a dosage of 2 mg/kg/day for the next 2 months.
223750436|NCT02076828|DRUG|Santafer® sp.|The children with IDA that included in Fe-OH-PM (Santafer® sp.)(Group II) were treated with a therapeutic dose Santafer® as 6 mg/kg/day in the first 2 months and followed by maintenance treatment at a dosage of 2 mg/kg/day for the next 2 months.
223750437|NCT02076828|DRUG|Ferro Zinc® sp|The children with IDA that included in Fe-Zn (Ferro Zinc® sp.)(Group III) were treated with a therapeutic dose Ferro Zinc® sp. as 6 mg/kg/day in the first 2 months and followed by maintenance treatment at a dosage of 2 mg/kg/day for the next 2 months.
223750438|NCT03970863|DIAGNOSTIC_TEST|Prostate Health Index|Use Prostate Health Index for the follow-up after focal therapy.
223750439|NCT03000699|BEHAVIORAL|Cognitive Bias Modification|Training paragraphs describe scenarios designed to be ambiguous at the outset and to resolve in a positive direction, with the intention of establishing a learning contingency between the ambiguity at the beginning of the scenario and the positive resolution that becomes clear towards the end of the statement.
223750440|NCT04396093|BEHAVIORAL|psychological support|specific questionnaires administration: EORTC QLQ 30, EORTC- PAN 26, HADS, Millon Clinical Multiaxial Inventory
223602687|NCT01503086|OTHER|Questionnaire Administration|Ancillary studies
223602688|NCT01870505|DRUG|BYL719|
223602689|NCT01870505|DRUG|Letrozole|
223602690|NCT01870505|DRUG|Exemestane|
223602691|NCT03667469|PROCEDURE|Laparoscopic one anastomosis gastric bypass|Laparoscopic surgical bariatric procedure with creation gastric pouch. A jejunal loop was created about 200 cm from the ligament of Treitz and anastomosed to the gastric pouch.
223602692|NCT03667469|DIETARY_SUPPLEMENT|Hypocaloric diet therapy|Hypocaloric diet therapy with energy restriction (-500 kcal/d)
223602693|NCT04067609|DRUG|Dexamethasone|subjects will receive a single administration of either 0.1 mg/kg of intravenous dexamethasone in 90mL of normal saline
223602694|NCT04067609|OTHER|placebo|100mL of normal saline (placebo)
223602695|NCT04765202|PROCEDURE|AG Tx|Control treatment that is meshed autograft alone applied to a burn area.
223602696|NCT04765202|BIOLOGICAL|SOMA Tx|Meshed autograft applied to the burn area and covered with StrataGraft.
223602697|NCT06565221|DEVICE|Heat and negative pressure|Heat and negative pressure applied to the feet
223602698|NCT06855355|DIETARY_SUPPLEMENT|Clostridium butyricum MIYAIRI 588|A butyrate-producing probiotic, has demonstrated potential anti-inflammatory and anti-tumorigenic effects.
223602699|NCT06976489|DRUG|PA-111|PA-111 1Tab., Per Oral
223602700|NCT06975709|OTHER|Questionnaire and Physical Exam|"The diagnostic questionnaires will be administered and the participants' responses will subsequently be analyzed, evaluating the presence of temporomandibular disorders (DTMs) in patients with sleep disorders.~The questionnaires will be administered to patients with a previous diagnosis of sleep disorder carried out at a specialist centre, consecutively belonging to the outpatient clinics of both centers U.O of Neurology-Sleep Disorders Center and U.O of Dentistry."
223602701|NCT04459468|DRUG|Lipiodol|Lipiodol TACE procedure
223750441|NCT02439320|DRUG|Lasmiditan 100 mg|
223750442|NCT02439320|DRUG|Lasmiditan 200 mg|
223750443|NCT02439320|DRUG|Placebo (matches lasmiditan doses)|
223750444|NCT01433510|DRUG|Grazax|1 tablet/day - pre and co-seasonal
223750445|NCT03169946|PROCEDURE|RCT with CHX-MTZ,OFD|Endodontic treatment using chlorhexidine metronidazole combination as an intracanal medicament along with open flap debridement .
223750446|NCT03169946|PROCEDURE|RCT with CHX,OFD|Endodontic treatment using chlorhexidine as an intracanal medicament along with surgical periodontal therapy in form of open flap debridement.
223750447|NCT02928510|PROCEDURE|Biospecimen Collection|Undergo biospecimen collection
223750448|NCT02928510|PROCEDURE|Colonoscopy|Undergo colonoscopy
223750449|NCT02928510|PROCEDURE|Colposcopic Biopsy|Undergo colposcopic biopsy
223750450|NCT02928510|DRUG|Idelalisib|Given PO
223750451|NCT02928510|OTHER|Laboratory Biomarker Analysis|Correlative studies
223750452|NCT02928510|OTHER|Pharmacological Study|Correlative studies
223750453|NCT02928510|PROCEDURE|Physical Examination|Undergo physical examination
223602702|NCT06548373|DIAGNOSTIC_TEST|Artificial Intelligence-assisted Point-of-Care Echocardiography|"A wireless, AI-guided handheld ultrasound probe will be used on adult male patients who present with a clinical indication for peri-anesthesia point-of-care echocardiography examination.~Residents will document personal interpretation of the completed point-of-care ultrasound (POCUS) examination, important clinical findings, and assessment of whether obtaining a formal echocardiogram is warranted on an exam assessment form. The residents will complete 11 examinations with 10 specific scans each. The first 10 examinations will be AI-guided, and the final 11th examination will be done via a standard (non-AI guided) ultrasound system to gauge the resident's growth in point-of-care echocardiography skill."
223602703|NCT06594198|DEVICE|Cerebral monitor|The study procedure consists of monitoring the values of 3 cerebral parameters: SctO2, bcSEF and ANI measured by the ARGOS sensor. These 3 parameters will be recorded and compared after the intervention with 3 parameters considered as standard: SctO2 measured by the INVOS 7100 cerebral oximeter, the bispectral index (BIS) measured by the BIS monitor and the ANI measured by the MDoloris monitor. These 3 reference parameters are once again usually monitored and recommended for all cardiac surgery.
223602704|NCT02687139|DRUG|18F-DCFPyL|
223750454|NCT02928510|PROCEDURE|Sigmoidoscopy|Undergo sigmoidoscopy
223750455|NCT01238614|OTHER|CHICA PSF plus JIT|
223750456|NCT01238614|OTHER|CHICA maternal depression PSF|
223750457|NCT01238614|OTHER|Control|
223750458|NCT02972632|DRUG|Vortioxetine|Vortioxetine tablet
223750459|NCT02245841|DRUG|H.P. Acthar Gel|80 U (1 mL) of H.P. Acthar gel via subcutaneous injection twice weekly for 24 weeks
223750460|NCT04362917|OTHER|There is no intervention|There is no intervention
223750461|NCT01936935|OTHER|Low-fat dairy|2 servings/d of 2% non-flavored, unsweetened milk + 1 serving/d sweetened low-fat yogurt
223750462|NCT01936935|OTHER|Sugar-sweetened beverages|2 servings/d of non-diet soda + 1 serving/d of non-dairy pudding
223750463|NCT04609410|PROCEDURE|Neuromuscular blockade|Neuromuscular blockade will be achieved via rocuronium intravenous administration and level will be monitored with train of four/post tetanic count monitoring
223602705|NCT02687139|PROCEDURE|PET/CT|Positron Emission Tomography - Computed Tomography (PET/CT)
223602706|NCT01224366|DRUG|Vildagliptin|
223602707|NCT01224366|DRUG|Placebo|
223602708|NCT06658132|DRUG|0.5~1ug/kg/min remifentanil combined with 0.2~0.5mg/kg/h esketamine for the physiological testing phase of DBS surgery.|Throughout the first and third stages of surgery, all patients receive a traditional induction of anesthesia. Fifteen minutes before the second stage of surgery (MER and clinical assessment), when the burr hole is ready, the propofol and sevoflurane infusion is discontinued, and patients receive 0.5\~1ug/kg/min remifentanil combined with 0.2\~0.5mg/kg/h esketamine. On completion of the second stage of surgery, the interventional drug is discontinued and propofol combined with sevoflurane is resumed until the end of the third stage.
223602709|NCT05949268|DEVICE|Small bowel capsule endoscopy|Patients with gastrointestinal bleeding receive small bowel capsule endoscopy after bleeding could not be located in gastroscopy or colonoscopy.
223602710|NCT05854368|PROCEDURE|Additional blood collection as part of a blood sampling performed during routine care or specific for the research if not part of routine care.|Collection of an additional blood volume (9 mL) as part of a blood sampling performed during routine care or specific for the research if not part of routine care.
223602711|NCT05854368|PROCEDURE|Blood collection|Blood sample collection (10 mL)
223602712|NCT01707082|DRUG|PF-06282999|Tablet, 10 mg, every 8 hours, 14 days
223750464|NCT01202825|DRUG|TMC647055|One single dose as oral solution, doses from 100 mg up to a maximum of 3000 mg increasing in sessions I through VI.
223750465|NCT01202825|DRUG|Placebo|Oral solution given in session XI every 12 hours, in session XII every 12 or 8 hours. Doses and regimen will be determined based on outcome of previous sessions.
223750466|NCT01202825|DRUG|TMC647055|Oral solution given in session XIII, treatment arm 1 during 10 days at a dose of 1000 mg every 12 hours.
223750467|NCT01202825|DRUG|TMC647055|In sessions VIII through X, oral solution given once daily, every 12 hours or every 8 hours on 6 consecutive days. Doses are based on outcome of previous sessions.
223602713|NCT01707082|DRUG|Placebo|Tablet, 0 mg, every 8 hours, 14 days
223602714|NCT01707082|DRUG|PF-06282999|Tablet, 30 mg, every 8 hours, 14 days
223602715|NCT01707082|DRUG|Placebo|Tablet, 0 mg, every 8 hours, 14 days
223602716|NCT01707082|DRUG|PF-06282999|Tablet, 100 mg, every 8 hours, 14 days
223602717|NCT01707082|DRUG|Placebo|Tablet, 0 mg, every 8 hours, 14 days
223602718|NCT01707082|DRUG|PF-06282999|Tablet, 250 mg, every 8 hours, 14 days
223750468|NCT01202825|DRUG|Placebo|One single dose as oral solution, selected dose ranging between 100 and 3000 mg in session VII
223750469|NCT01202825|DRUG|TMC435|Oral capsule given in session XIII, in treatment arm 1 during 10 days and in treatment arm 2 during 6 days at a dose of 150 mg once daily.
223750470|NCT01202825|DRUG|Placebo|One single dose as oral solution, selected dose ranging between 100 and 3000 mg in session VII
223750471|NCT01202825|DRUG|TMC647055|One single dose as oral solution, selected dose ranging between 100 and 3000 mg in session VII
223750472|NCT01202825|DRUG|Placebo|In sessions VIII through X, oral solution given once daily, every 12 hours or every 8 hours on 6 consecutive days. Doses are based on outcome of previous sessions.
223750473|NCT01202825|DRUG|TMC647055|Oral solution given in session XI every 12 hours, in session XII every 12 or 8 hours. Doses and regimen will be determined based on outcome of previous sessions.
223750474|NCT03806439|OTHER|Radical cystectomy.|Adult patients undergoing radical cystectomy.
223750475|NCT02030379|BEHAVIORAL|QPL-CT|Use the QPL-CT to prioritize questions
223750476|NCT01960946|DIETARY_SUPPLEMENT|Modified Citrus Pectin (MCP) vs placebo|5 grams by mouth three times a day
223750477|NCT03720912|BEHAVIORAL|Online Learning Modules|The modules will include information about common family management skills: social support, problem solving, communication, and supportive behavior change strategies.
223602719|NCT01707082|DRUG|Placebo|Tablet, 0 mg, every 8 hours, 14 days
223602720|NCT01707082|DRUG|PF-06282999|Tablet, 350 mg every 8 hours or 500 mg every 12 hours, 14 days
223602721|NCT01707082|DRUG|Placebo|Tablet, 0 mg, every 8 or 12 hours, 14 days
223602722|NCT01707082|DRUG|midazolam|Tablet, 7.5 mg, single dose on Period 1 Day 1 and Period 2 Day 14
223602723|NCT01707082|DRUG|PF-06282999|Tablet, dose to be determined (determined in Part A), every 8 or 12 hours, 14 days
223602724|NCT01707082|DRUG|midazolam|Tablet, 7.5 mg, single dose on Period 1 Day 1 and Period 2 Day 14
223602725|NCT01707082|DRUG|PF-06282999|Tablet, dose to be determined (determined in Part A), every 8 or 12 hours, 14 days
223602726|NCT04520724|DIETARY_SUPPLEMENT|plant fiber|The patients with NAFLD (study and control group) will receive low-processed rolls with an 12 g plant fiber content twice daily, which would be a convenient for easy replenishment of the amount of vegetable fiber (act as prebiotic) in the diet. The intervention will be preceded by a 21 day wash-out period during which subjects will be asked to avoid foods containing large amount of fiber.
223602727|NCT04520724|DIETARY_SUPPLEMENT|maltodextrin bar|The patients with NAFLD (placebo group) will receive maltodextrin bars twice daily, which would be a convenient and easy-to-eat snack replacing the second breakfast and afternoon tea. The bars must be eaten with 180 ml of water or unsweetened liquid. The intervention will be preceded by a 21 day wash-out period during which subjects will be asked to avoid foods containing large amount of fiber.
223602728|NCT03114384|OTHER|Creation and detection of patient-respirator asynchronies|The provocation of leaks on the Ventilation circuit and expiratory trigger modulation will generate a number of asynchronies between the subject and the respirator
223602729|NCT06155539|OTHER|No intervention|No intervention
223602730|NCT05107622|OTHER|FMUD+Probiotic|Full-mouth ultrasonic periodontal debridement associated with administration of probiotic formulation (Lactobacillus paracasei 28.4) twice a day for 30 days.
223602731|NCT05107622|OTHER|FMUD+Placebo|Full-mouth ultrasonic periodontal debridement associated with administration of placebo formulation twice a day for 30 days.
223750478|NCT05831202|DEVICE|The SEAL™ Saccular Endovascular Aneurysm Lattice System|All adult subjects between 22 and 80 years of age and presenting with an unruptured or ruptured saccular Wide Neck intracranial aneurysm with less or equal to 19 mm in its equatorial width (2mm-19mm range) that in the opinion of the Principal Investigator (PI) requires treatment and suitable candidate for intrasaccular flow diversion treatment, who meet all eligibility criteria, will be considered for study enrollment.
223602732|NCT02305238|DRUG|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|Aflibercept 2mg is intravitreally injected.
223602733|NCT01019369|DRUG|Medroxyprogesterone 17-Acetate|Depot medroxyprogesterone acetate, SC, every 12 weeks for 1 year
223602734|NCT01019369|DRUG|Medroxyprogesterone 17-Acetate|Depot medroxyprogesterone acetate, SC, every 12 weeks for 1 year
223602735|NCT02513472|DRUG|Eribulin Mesylate|Eribulin Mesylate will be administered as a 1.4 milligram per square meter (mg/m\^2) IV (intravenous) infusion on Day 1 and Day 8 of each 21-day cycle in the presence of clinical benefit until intercurrent illness, unacceptable toxicity, or disease progression occurs, or until the participant withdraws consent.
223602736|NCT02513472|DRUG|Pembrolizumab|Pembrolizumab will be administered as a 200 milligram (mg) IV infusion on Day 1 of each 21-day cycle in the presence of clinical benefit until intercurrent illness, unacceptable toxicity, or disease progression occurs, or until the participant withdraws consent.
223602737|NCT03156439|DRUG|BIS-001 ER|BIS-001 ER is an extended release formulation of the nutritional supplement Huperzine A.
223602738|NCT04367090|DRUG|Docetaxel, trastuzumab|Docetaxel and trastuzumab once per cycle
223602739|NCT04367090|DRUG|Pyrotinib|Pyrotinib 400/320 mg orally daily
223602740|NCT04683445|DRUG|Eribulin|Eribulin，1.4mg/m2，Intravenous infusion，d1，d8，3-week cycle
223602741|NCT04683445|DRUG|Trastuzumab|Trastuzumab，8mg/kg for the first dose，6mg/kg for the following dose，Intravenous infusion，3-week cycle
223602742|NCT04683445|DRUG|pertuzumab|Pertuzumab，，840mg for the first dose，420mg for the following dose，Intravenous infusion，3-week cycle
223602743|NCT04683445|DRUG|Pyrotinib|Pyrotinib，400mg，oral，every day
223602744|NCT04683445|DRUG|Pembrolizumab|Pembrolizumab，200mg，Intravenous infusion，3-week cycle
223602745|NCT04683445|DRUG|Camerlizumab|Camerlizumab，200mg，Intravenous infusion，3-week cycle
223602746|NCT01380834|DRUG|control group|Group 2(control group): 42 patients will have placebo/normal saline in paravertebral space, same amount, and injection at incision sites for all four insufflation ports with ropivacaine 0.5%.
223602747|NCT01380834|DRUG|treatment group|Group 1( treatment group ): 42 patients will have six paravertebral nerve blocks with ropivacaine 0.5 %, and incisional administration of placebo / normal saline at all four laparoscopic ports.
223602748|NCT01418079|DEVICE|O2 MedTech cerebral oximeter (Oxygen desaturation)|Reduction in blood oxygen saturation by sequential reduction in inspired gas composition. Steps are of 6 minutes duration with reduction in pulse oximeter oxygen saturation from 100 to 70%.
223602749|NCT02088021|DEVICE|Portico Transcatheter Aortic Valve|Placement of the SJM Portico aortic valve with a ALC delivery system
223602750|NCT00049712|BIOLOGICAL|etaracizumab|
223602751|NCT04310566|DEVICE|JJVC Investigational Multifocal Contact Lens (senofilcon A c3)|TEST
223602752|NCT04310566|DEVICE|Dailies Total 1® Multifocal Contact Lens|CONTROL
223602753|NCT02657447|DRUG|Betalutin with lilotomab dose 1|15 MBq/kg b.w. Betalutin (lutetium (177Lu) lilotomab satetraxetan) single injection, with lilotomab pre-dosing, dose 1
224200147|NCT03290976|OTHER|"Multi-modality (Acupuncture plus)"|"A number of additional CIM treatment modalities will be added to the acupuncture treatment in this arm of the study, in accordance with the practitioners available at each of the participating study centers. These will include one of more of the following:~* Manual-movement therapies - e.g. acupressure/reflexology, self- and caregiver-practiced acupressure~* Mind-body therapies - e.g. relaxation/imagery method, Anthroposophic music therapy The multimodal CIM treatment regimen will be re-evaluated at each session, and adapted according to the concerns and expectations of the patients, as well as the recommendation of the treating CIM practitioner."
223602754|NCT02657447|DRUG|Betalutin with lilotomab dose 2|15 MBq/kg b.w. Betalutin (lutetium (177Lu) lilotomab satetraxetan) single injection, with lilotomab pre-dosing, dose 2
223602755|NCT03554447|DRUG|Escitalopram 20 mg tablet plus Pentoxifylline 400Mg Tablet|Selective serotonin reuptake inhibitor plus phosphodiesterase inhibitor with anti-inflammatory properties
223602756|NCT03554447|DRUG|Escitalopram 20 mg tablet + Placebo|Selective serotonin reuptake inhibitor plus placebo
223602757|NCT04720742|DRUG|Analytical Treatment Interruption + bNAbs infusion|The participant will perform an Analytical Treatment Interruption (ATI) of up to 18 months of duration. During the first 8 months, the participants will be infused once per month with a combination of the broadly neutralizing antibodies (bNAbs) 3BNC117 and 10-1074
223602758|NCT04165499|COMBINATION_PRODUCT|Combination of Plant Extracts (BSL_EP026)|Each participant will consume 2 capsules daily, in the morning and in the evening.
223602759|NCT04165499|COMBINATION_PRODUCT|Control|Each participant will consume 2 capsules daily, in the morning and in the evening.
223602760|NCT03076294|DEVICE|TMS|Repetitive TMS involves application of electric currents in the patient's cortex by a magnetic field applied to the scalp of the patient through an eight-coil connected to a magnetic stimulator (MagStim Rapid² magnetic stimulator-UK). In a small percentage of patients, it may cause minimal discomfort with a mild headache sensation, which usually disappears after a few seconds. Depending on the parameters, rTMS can increase or decrease corticomotor excitability and by the connection of the motor cortex with the thalamus, influencing pain control. The patients will respond to an adverse effects questionnaire and will report the perception of real or sham stimulation.
223602761|NCT03076294|OTHER|Manual therapy (MT)|This intervention uses manual contact for diagnosis and treatment, its practitioners use an enormous amount of manual techniques to preserve the homeostasis through the recovery of dysfunctions, which may cause limitations in the physiological movements, in the accessory movements of the joints (WHO , 2010).
223602762|NCT04565951|BEHAVIORAL|VA S.A.V.E.|The intervention is called VA S.A.V.E. It is an online video-based training tailored to veterans and their close supports. It is free, brief (24 minutes), and includes three scripted role plays.
223602763|NCT04565951|BEHAVIORAL|Sham intervention|"A sham training consisting of information unrelated to suicide prevention but relevant to transitioning veterans and their loved ones."
223750479|NCT02735161|OTHER|Muscle strength training|Two different muscle strength training protocols will be compared; one exercise session with high load/low repetitions (4 sets x 5RM) versus one exercise session with low load/high repetitions (2 sets x 25RM). Both session will be conducted at four different exercises; seated leg press, chest press, cable lat pull down and seated rowing.
223750480|NCT02735161|OTHER|Endurance exercise training|Two different endurance exercise training protocols will be compared; one exercise sessions is interval training with high intensity (85-95% of HRmax) versus one of moderate intensity (70-75% of HRmax) with longer duration.
223750481|NCT00100243|DRUG|Plenaxis|
223750482|NCT02196285|BIOLOGICAL|Double viral (MR) vaccine|Measles and Rubella vaccine, as single arm
223750483|NCT01835743|DEVICE|Erchonia HPS Laser|The Erchonia HPS Laser is administered to the subject's heel 6 times across 3 consecutive weeks, 2 times each week, for 10 minutes of treatment time per administration.
223750484|NCT01835743|DEVICE|Placebo Laser|The Placebo Laser is administered to the subject's heel 6 times across 3 consecutive weeks, 2 times each week, for 10 minutes of treatment time per administration.
223750485|NCT02999256|DIETARY_SUPPLEMENT|Montmorency Tart Cherry Juice|
223750486|NCT02999256|OTHER|Placebo|
223750487|NCT03532997|OTHER|ELOS|"The investigators aim to introduce patients with advanced cancer to supportive care resources, including specialty palliative care, through a novel web-based application called ELOS (stands for extra layer of support) in a prospective cohort study."
223750488|NCT06200675|OTHER|Compassion-based intervention|Participants assigned to this intervention will be asked to engage in one brief compassion-focused exercise, where they will be asked to be asked to connect to their inner compassionate self. They will be asked to stay connected to that feeling while rereading what they wrote about their feelings of shame and imagining it was someone else who wrote it. Participants will then be asked to write a compassionate response to themselves. Participants will then be asked to reread this response while remaining connected to their compassionate self.
223750489|NCT06200675|OTHER|Logic-based intervention|Participants assigned to this intervention will be asked to engage in one brief (10-15 minute) online logic-based exercise that was adapted from a CBT thought record. Participants will be asked to reread what they wrote about their feelings of shame and chose a thought central to their shame to use for this exercise. Participants will be asked to generate evidence for and against their chosen thought, and then generate a more balanced thought. After the exercise, participants will be asked to reread their newly generated more balanced thought.
223750490|NCT06200675|OTHER|Placebo control condition|"Participants assigned to this intervention will be asked to listen to an audio recording of The Hobbit and then re-read what they wrote about their feelings of shame. They will then be asked to write a reflection about the thoughts and feelings arising from doing so. They will then be asked to re-read what they wrote in this reflection."
223602764|NCT02748928|DEVICE|UltraShape Power|Tissue selectivity is achieved by a proprietary knowledge of ultrasound parameters ensuring specific destruction of the fat cells only within the target area. All other types of tissue, such as blood vessels, muscles and peripheral nerves remain intact. There are no thermal effects. Fat cell destruction is achieved by ultrasound-induced mechanical effects during a very short exposure time
223602765|NCT04067414|BIOLOGICAL|BZ019|"Subjects will be enrolled in three dose-groups:~Dose 1: 1×10\^6/kg CAR+ cells; Dose 2: 3×10\^6/kg CAR+ cells; Dose 3: 6×10\^6/kg CAR+ cells."
223602766|NCT03301298|DRUG|SXC-2023|Oral capsule
223602767|NCT03301298|DRUG|Placebo oral capsule|Placebo given as oral capsule.
223750491|NCT02823275|OTHER|Functional mobilisation|functional mobilisation
223602768|NCT00429169|DRUG|Paroxetine|Dosage will be 25 mg every day for 2 weeks, then 37.5 mg every day for 2 weeks, and then optional increase to 50 mg every day for the remainder of treatment.
223602769|NCT00429169|DRUG|Bupropion|Dosage will be 150 mg every day for 2 weeks, then 300 mg every day for 2 weeks, and then optional increase to 450 mg every day for the remainder of treatment.
223602770|NCT02186145|DRUG|Association of metronidazole; nystatin and dexamethasone|
223602771|NCT02186145|DRUG|Flagyl|Vaginal cream of metronidazole and nystatin
223602772|NCT00066027|DRUG|20 mg doxycycline hyclate|Subjects in the LDD group took 20 mg doxycycline hyclate tablets twice daily for two years
223602773|NCT00066027|DRUG|Placebo|Subjects in the placebo group took a placebo look-alike twice daily for two years.
223750492|NCT02823275|OTHER|Short term plaster cast fixation|2 weeks cast immobilisation
223602774|NCT01652131|OTHER|Tetrastarch (130/0.4)|
223602775|NCT02296255|BIOLOGICAL|Cervarix®, GlaxoSmithKline|3 doses (0,1,6 months) of Cervarix®, GlaxoSmithKline
223602776|NCT04238507|DEVICE|Guedel airway|Following induction of GA, air:O2 flows will be set at 0:10L, the Adjustable Pressure Limiting (APL) valve set to 50cm water pressure, and the reservoir bag filled. The learner will perform BMV with a Guedel airway placed by the anesthesiologist, while the anesthesiologist ensures that the reservoir bag is filled between breath attempts by using the oxygen flush.
223602777|NCT04238507|DEVICE|USASK airway|Following induction of GA, air:O2 flows will be set at 0:10L, the Adjustable Pressure Limiting (APL) valve set to 50cm water pressure, and the reservoir bag filled. The learner will perform BMV with a USASK airway placed by the anesthesiologist, while the anesthesiologist ensures that the reservoir bag is filled between breath attempts by using the oxygen flush.
223602778|NCT01711645|BIOLOGICAL|Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed onto aluminum phosphate|55 postpartum subjects receive a single intramuscular (IM) 0.5 mL dose of Adacel® (Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed).
223750493|NCT04126395|DIAGNOSTIC_TEST|Movement Assessment Battery for Children 2(M-ABC-2)|The M-ABC-2 is a motor performance test for children aged 3 trough 16 years of age. We will use Dutch-Flemish norms.
223602779|NCT01548066|DRUG|Valproic Acid|spray 7.2% of sodium valproate on scalp twice a day (morning and evening) for 24 weeks
223602780|NCT01548066|DRUG|Control placebo|spray vehicle without sodium valproate on scalp twice a day (morning and evening) for 24 weeks
223602781|NCT05320003|DIAGNOSTIC_TEST|Inky foot analysis|Inky foot analysis to confirm the diagnosis of pes planus
223750494|NCT04126395|DIAGNOSTIC_TEST|Developmental Coordination Disorder - Questionnaire (DCD-Q)|The DCD-Q is a brief parent questionnaire designed to screen for the presence of DCD in children aged 5 trough 15 years of age. We will use Dutch norms.
223602782|NCT05320003|DIAGNOSTIC_TEST|Evaluation of plantar pressure with pedobarography|Evaluation of plantar pressure distribution by pedobarography in individuals with pes planus
223602783|NCT05320003|DIAGNOSTIC_TEST|Balance assessment with computerized posturography|Evaluation of fall risk with computerized posturography
223602784|NCT03878784|DRUG|Imigran|All patients will undergo this intervention on one of two study days
223602785|NCT03878784|OTHER|Isotonic Saline|All patients will undergo this intervention on one of two study days
223602786|NCT00662116|DRUG|alagebrium|200 mg (two 100 mg tablets) two times daily for 24 weeks
223602787|NCT00662116|DRUG|placebo|placebo tablets - two tablets taken twice daily
223602788|NCT05628909|PROCEDURE|PPV with SO tamponade|Patients randomized into silicone oil group were received pars plana vitrectomy surgery with silicone oil tamponade and without internal limiting membrane peeling. And silicone oil tamponade was removed at least 12 months after the primary surgery with completely resolved of foveoschisis.
223602789|NCT05628909|PROCEDURE|PPV with fovea-sparing ILMP and gas tamponade|Patients randomized into gas group 1 were received pars plana vitrectomy surgery with fovea-sparing internal limiting membrane peeling and gas tamponade.
223602790|NCT05628909|PROCEDURE|PPV with gas tamponade|Patients randomized into gas group 2 were received pars plana vitrectomy surgery without internal limiting membrane peeling and gas tamponade.
223602791|NCT02327494|DRUG|neuromuscular blockade|to determine the influence on oxygantion saturation parameters of the administration of neuromuscular blockade drug, rocuronio, to provide intense neuromuscular blockade during laparoscopic colorectal surgery
223602792|NCT02109809|RADIATION|total nodal irradiation|Undergo TLI
223602793|NCT02109809|OTHER|laboratory biomarker analysis|Correlative studies
223602794|NCT02109809|OTHER|questionnaire administration|Ancillary studies
223602795|NCT01041521|DRUG|Lovaza|Lovaza at a dose of 4g per day with each 1g capsule containing approximately 465 mg of eicosapentaenoic acid (EPA) and 375 docosahexaenoic acid (DHA) for 24 months
223602796|NCT06204081|DEVICE|CSO_without cueing|The sole is worn without using the cueing application
223750495|NCT04126395|DIAGNOSTIC_TEST|Social Responsiveness Scale 2 (SRS-2)|The SRS-2 is a parent questionnaire designed to identify social impairments associated with ASD in children 4 trough 18 years of age. We will used Dutch norms.
223750496|NCT04126395|OTHER|Retrospective Video Analysis|Retrospective video analysis will be used to explore motor development in children with DCD, DCD+ASD and controls.
223750497|NCT01339728|PROCEDURE|far-infrared ray|The duration of far-infrared ray is 20 minutes.
223750498|NCT02894177|PROCEDURE|tcPCO2 measurement|tcPCO2 continuous monitoring during spontaneous breathing trials
223602797|NCT06204081|DEVICE|CSO_cueing|The sole is worn with using the cueing application
223602798|NCT03691662|DRUG|DE-117 Ophthalmic Solution|Topical DE-117 Ophthalmic Solution once daily and Vehicle once daily for 3 months
223750499|NCT04713098|DEVICE|Peripheral Nerve Stimulation|ACTIVE peripheral nerve stimulation with a percutaneously inserted lead and wearable stimulator (SPR Therapeutics, Cleveland, Ohio) that generates electric current for 14 days
223750500|NCT04713098|DEVICE|Sham|SHAM peripheral nerve stimulation with a percutaneously inserted lead and wearable stimulator (SPR Therapeutics, Cleveland, Ohio) that does not generate electric current for 14 days
223750501|NCT02927379|DRUG|Dexmedetomidine|local anesthetic wound infiltration with with 20 ml of bupivacaine 0.5 % diluted in 20 ml saline plus dexmetedomidine in two divided doses i.e. 20 ml is administered on each side of incision
223750502|NCT02927379|DRUG|Ketamine|local anesthetic wound infiltration with with 20 ml of bupivacaine 0.5 % diluted in 20 ml saline plus ketamine in two divided doses i.e. 20 ml is administered on each side of incision
223750503|NCT02927379|DRUG|Bupivacaine|local anesthetic wound infiltration with with 20 ml of bupivacaine 0.5 % diluted in 20 ml saline only in two divided doses i.e. 20 ml is administered on each side of incision
223750504|NCT02701972|DEVICE|BACE Device|Implanted BACE device
223750505|NCT03850873|DRUG|TQB3616|TQB3616 administerde days 28 of a 28-day schedule,doses ranging from 20m，40mg，60mg，80mg，100mg，120mg once daily
223750506|NCT02812316|DEVICE|HI-BRITE Large Diameter Rigid Gas Permeable Contact Lens|Approximately At least one hundred and forty (140) subjects (280 eyes) will be enrolled in this study at approximately two (2) clinical sites in Taiwan. All subjects will be fitted for and dispensed study lenses by each Investigator.
224075339|NCT05607823|OTHER|Orofacial Manual Therapy|As orofacial manual therapy, soft tissue (intraoral and extraoral trigger point therapy and myofascial release of painful muscles) and joint mobilization (caudal and ventro-caudal traction, ventral and mediolateral translation), muscle energy technique, fascia mandibularis release, occipital release and ligamentous treatment was planned.
223602799|NCT03691662|DRUG|Timolol Maleate Ophthalmic Solution 0.5%|Topical Timolol Maleate Ophthalmic Solution 0.5% twice daily for 3 months
223602800|NCT05254249|DRUG|Lactobacillus Plantarum IS-10506|Indonesian original probiotic, given in capsule form with a dose of 2 x 1010 CFU
223602801|NCT05254249|OTHER|Placebo|Placebo is an empty drug, given in capsule form with a dose of 2x1 sachets
223602802|NCT02978950|OTHER|Duplex ultrasound surveillance|bilateral lower extremity venous duplex
223602803|NCT02978950|OTHER|No ultrasound surveillance|will have daily exam and history as per normal clinical routine
223602804|NCT01746173|DRUG|Cyclophosphamide|
223602805|NCT01746173|DRUG|Doxorubicin|
223602806|NCT01746173|DRUG|Vincristine|
223602807|NCT01746173|DRUG|Etoposide|
223602808|NCT01746173|DRUG|Prednisone|
223602809|NCT01746173|DRUG|Filgrastim|
223602810|NCT01746173|DRUG|Plerixafor|
223602811|NCT01746173|PROCEDURE|Stem Cell Collection|
223602812|NCT01746173|DRUG|Palifermin|
223602813|NCT01746173|DRUG|Gemcitabine|
223602814|NCT01746173|DRUG|Busulfan|
223602815|NCT01746173|DRUG|Melphalan|
223602816|NCT01746173|PROCEDURE|Stem Cell Transplant|
223602817|NCT03401268|DRUG|subcutaneous immunoglobulin|24 patients demonstrating hypogammaglobulinemia post allogeneic HCT will be started on ScIG for a total of 6 months. Tolerability of the intervention will be assessed with qualitative questionnaires, as well as a financial analysis regarding the intervention.
223750507|NCT04483713|BEHAVIORAL|Educational Workshop|"The workshop proposes a review of all stages of EBP which includes approaches to clinical care based on science and the quality of evidence, with the ultimate goal of promoting safe and quality care.~The workshops comprise one for each group with a total workload of six (6) hours divided into two days, lasting three hours each day. The first day will be a theoretical approach and the second day a practical approach.~The workshops with theoretical content and practical classes will be held in rooms of Albert Einstein Hospital.~All participants of both educational strategies will answer the same questionnaires."
223750508|NCT04483713|BEHAVIORAL|Educational Workshop plus J. H. N. EBP Guide Tools|"In addition to the workshop. It will follow the same molds as the case of group Educational Workshop plus the Johns Hopkins Nursing Evidence-based Practice guide tools since the beginning of this practical class, when the participant will receive a description of a problem as a basis for elaborating their clinical question, and thus, move on to the next stage.~The tools will be offered in the case of this group: question development, evidence level and quality guide, research evidence assessment tool, individual evidence tool, evidence synthesis and recommendation tool, action planning tool and tool dissemination."
223750509|NCT03685084|DRUG|AAI101 i.v.|600 mg, 1 g, 2 g, 4 g, 1 g (every 6h), 2 g (every 6h)
223750510|NCT03685084|DRUG|Saline 0.9% infusion|Vehicle infusion
223750511|NCT03685084|DRUG|Piperacillin i.v.|piperacillin 3 g i.v.
223750512|NCT03685084|DRUG|Cefepime i.v.|cefepime 1 g i.v.
223602818|NCT03771274|DEVICE|Tecnis ZLB00 & Symfony IOL|The Symfony IOL will be implanted in the dominant eye while the Tecnis ZLB00 will be implanted in the non-dominant eye.
223602819|NCT05557305|DEVICE|Videogame therapy|There will be 5 video game-type applications for virtual therapy, each with a specific therapeutic objective, which will be administered by trained personnel, depending on the characteristics of each patient.
223602820|NCT05557305|OTHER|Conventional therapy|Occupational therapy with different play materials
223602821|NCT04033783|OTHER|6MWT - accompanied|Assessor walks behind the patient
223602822|NCT04033783|OTHER|6MWT - not accompanied|Assessor does not walk behind the patient
223602823|NCT02646813|PROCEDURE|Intraluminal Placement|Pt. will have Arndt Endobronchial Blocker placed intraluminally
223602824|NCT02646813|PROCEDURE|Extraluminal Placement|Pt. will have Arndt Endobronchial Blocker placed extraluminally
223602825|NCT02917395|DEVICE|echocardiography|Tow echo examination, few hours apart, that includes strain rate will be done to each patient. The first, after taking the regular medical treatment excluding disopyramide and the last one after taking the disopyramide.
223602826|NCT01710631|DRUG|eszopiclone 3 mg|eszopiclone 3 mg (comprised of either two 1.5 mg tablets, or one 1 mg tablet and one 2 mg tablet).
223602827|NCT01710631|DRUG|placebo|placebo
223602828|NCT01718444|DRUG|Progestin|
223602829|NCT01718444|DRUG|Clomiphene Citrate|
223602830|NCT01371552|DEVICE|delefilcon A contact lens|Investigational, silicone hydrogel, single vision contact lens worn on a daily disposable basis for 3 days in Part 1 and one week in Part 2.
223602831|NCT01371552|DEVICE|filcon II 3 contact lenses|Commercially marketed, silicone hydrogel, single vision contact lens worn on a daily disposable basis for 3 days in Part 1.
223602832|NCT01371552|DEVICE|narafilcon A contact lenses|Commercially marketed, silicone hydrogel, single vision contact lens worn on a daily disposable basis for 3 days in Part 1.
223750513|NCT03553407|DEVICE|Low Level Laser - Pulse|The laser will be applied at a single point in contact, perpendicular to the surface of the tooth in a region that presents healthy enamel, towards the pulp chamber. The laser chosen was the low power diode laser with the following protocols: Group 1 (880nm, 30mW, 3.6 J / cm², 25 Hz) and Group 2 (880nm, 30mW, 3.6 J / cm²), after 10 minutes we will ask to the patient again from 0 to 3 the level of pain, to then proceed to the anesthetic phase.
223750514|NCT03553407|DEVICE|Low Level Laser - continuous|The laser will be applied at a single point in contact, perpendicular to the surface of the tooth in a region that presents healthy enamel, towards the pulp chamber. The laser chosen was the low power diode laser with the following protocols: Group 1 (880nm, 30mW, 3.6 J / cm², 25 Hz) and Group 2 (880nm, 30mW, 3.6 J / cm²), after 10 minutes we will ask to the patient again from 0 to 3 the level of pain, to then proceed to the anesthetic phase.
223750515|NCT03553407|DEVICE|Low Level Laser - placebo|placebo will be applied at a single point in contact, perpendicular to the surface of the tooth in a region that presents healthy enamel, towards the pulp chamber. The laser chosen was the low power diode laser with the following protocols: Group 1 (880nm, 30mW, 3.6 J / cm², 25 Hz) and Group 2 (880nm, 30mW, 3.6 J / cm²), after 10 minutes we will ask to the patient again from 0 to 3 the level of pain, to then proceed to the anesthetic phase.
223602833|NCT01750723|DRUG|Acetazolamide|1 g diluted in 10 ml saline, i.v. bolus injection.
223602834|NCT04078581|OTHER|Questionnaire and fecal sample collection|Questionnaire and fecal sample collection in order to select donors for FMT.
223602835|NCT02133092|OTHER|No intervention|This is an observational study. The children hospitalized with lower respiratory tract infection (LRTI) with a laboratory confirmed RSV infection will be monitored for maximum 7 days or until hospital discharge.
223602836|NCT02718092|DEVICE|Plastic Stent|Subjects who are randomized to this arm will receive a plastic stent
223602837|NCT02718092|DEVICE|Axios Fully Covered Self Expanding Metal Stent|Subjects who are randomized to this arm will receive the Axios FCEMS
223602838|NCT00958646|OTHER|Osteopathic Manipulation|Standardized rib raising protocol
223602839|NCT00958646|OTHER|Placebo|Light touch control procedure
223602840|NCT05684029|DEVICE|Near-infrared devices|This device can emit and collect near-infrared light of a specific wavelength. The parathyroid glands in the specimen appear as a high-brightness image in the device, to find the parathyroid gland that may be accidentally removed from the specimen.
223602841|NCT05684029|DIAGNOSTIC_TEST|PTH test strip|The PTH test strip is to detect the PTH in the specimen by immunocolloidal gold technology to determine whether it is parathyroid.
223602842|NCT01359501|DRUG|Chinese medical treatment-LCH1|Start to take the powder of Chinese herb-LCH1 3g\*BID just after the 1st chemotherapy, and Stop 2-3 weeks after the final cycle of chemotherapy.
223602843|NCT01359501|DRUG|Placebo|Start to take the powder of Placebo 3g\*BID just after the 1st chemotherapy, and stop 2-3 weeks after the final chemotherapy.
223602844|NCT04107207|DIETARY_SUPPLEMENT|Ginger Kombucha|Craft Ginger Kombucha, a fermented black tea
223602845|NCT04107207|DIETARY_SUPPLEMENT|Ginger Water|Placebo
223750516|NCT06093412|PROCEDURE|unilateral epidural anesthesia|The patients received unilateral epidural anesthesia
223602846|NCT05476029|DIAGNOSTIC_TEST|Blood samples and alveolar lavage fluid were collected|Blood samples and alveolar lavage fluid were collected for exosome sorting and identification, differential miRNAs, and analysis of serum oxidation and inflammatory indicators.
223602847|NCT01291407|DRUG|S-1|S-1,30mg/m2/d,peroral BID,in treatment days concurrently with radiation therapy in a standard manner.
223750517|NCT06093412|PROCEDURE|combined lumbar and epidural anesthesia|The patients received combined lumbar and epidural anesthesia
223602848|NCT01291407|DRUG|S-1|S-1,40mg/m2/d,peroral BID,in treatment days concurrently with radiation therapy in a standard manner.
223750518|NCT04912934|PROCEDURE|A survey form was applied to individuals included in the study face-to-face.|This study was completed with a descriptive, cross-sectional and relational screening model
223750519|NCT01909596|DEVICE|Neutral customized foot orthoses|Foot orthoses with arch support and without lateral inclination
223750520|NCT01909596|DEVICE|6° lateral customized foot orthoses|Foot orthoses with arch support above insoles with lateral inclination set at 6°
223750521|NCT01909596|DEVICE|10° lateral customized foot orthoses|Foot orthoses with arch support above insoles with lateral inclination set at 10°
223750522|NCT00178841|DRUG|Rosiglitazone and Bexarotene|rosiglitazone added to bexarotene capsules
223750523|NCT04076995|OTHER|Water Intake|Increased water intake during the 11 h protocol
223602849|NCT01291407|DRUG|S-1|S-1,50mg/m2/d,peroral BID,in treatment days concurrently with radiation therapy in a standard manner
223602850|NCT01291407|DRUG|S-1|S-1,60mg/m2/d,peroral BID,in treatment days concurrently with radiation therapy in a standard manner.
223602851|NCT01291407|DRUG|S-1|S-1,70mg/m2/d,peroral BID,in treatment days concurrently with radiation therapy in a standard manner.
223602852|NCT01291407|DRUG|S-1|S-1,80mg/m2/d,peroral BID,in treatment days concurrently with radiation therapy in a standard manner.
223602853|NCT02328027|DRUG|99mTc-rhAnnexin V-128|1 single intravenous bolus administration of 250 MBq, at Day 1 and at Day 42.
223602854|NCT01357252|DRUG|vildagliptin|
223602855|NCT01357252|DRUG|Placebo|
223602856|NCT01545440|DRUG|lebrikizumab|subcutaneous dose every 4 weeks
223602857|NCT01545440|DRUG|lebrikizumab|subcutaneous dose every 4 weeks
223602858|NCT01545440|DRUG|lebrikizumab|subcutaneous dose every 4 weeks
223750524|NCT01251380|BIOLOGICAL|Botulinum toxin type A|Intramuscular (IM) injection on day 1 of each treatment cycle.
223750525|NCT01650662|DRUG|Cyclosporine A|In the CsA group, at least 5 min before balloon inflation and stenting, patients will receive an intravenous bolus injection of 2.5 mg/kg of CsA. In the control group, patients will receive only recommended treatments. CsA will be dissolved in normal NaCl 0.9% solution (final concentration 25 mg/ml) and injected slowly (over 20-30 seconds) via a catheter positioned in an antecubital vein at least 5 min before PCI, to allow for distribution of the drug.
223750526|NCT06416696|DRUG|Toripalimab|"1. Radiotherapy: Both external beam and brachytherapy, with radiation therapy techniques, target delineation, prescribed doses, and organ-at-risk constraints following established guidelines.~2. Chemotherapy: The preferred regimen is cisplatin at a dose of 40mg/m\^2 administered intravenously once weekly for 5-6 cycles; for patients intolerant to cisplatin or with renal impairment, carboplatin (AUC=2) may be considered, also administered once weekly.~3. Toripalimab concurrent immunotherapy: Following the regimens of phase III RCTs such as JUPITER-02, JUPITER-06, CHOICE-01, NEOTORCH, and RENOTORCH, Toripalimab is administered at a fixed dose of 240mg per infusion, given intravenously once every 3 weeks for three doses.~4. The concurrent chemoradiotherapy and immunotherapy phase does not exceed 8 weeks in duration."
223750527|NCT02122536|DRUG|Xeomin to right side of face in half of the subjects; Xeomin to left side of face in the other half of subjects|Subjects were randomized to which side of the face would be treated with Xeomin.
223750528|NCT02122536|DRUG|Botox to right side of face in half of the subjects (randomized); Botox to the left side of the face in the other half of subjects|Subjects were randomized to which side of the upper face would be treated with Botox
223750529|NCT01167231|DRUG|Acarbose (Glucobay, BAYG5421)|Patients treated with acarbose tablets under the real-life setting. Dosing regimen customised to the needs of each participating patient according to the investigators assessment
223750530|NCT05067296|OTHER|By TVS|Uses of TVS to diagnosis of Cesarean section niche in patients with abnormal uterine bleeding
223750531|NCT05776121|DRUG|ZB001 for injection|Dose Cohort1 (3 mg/kg) ZB001 four IV injections
223750532|NCT05776121|DRUG|ZB001 for injection|Dose Cohort2 (10 mg/kg) ZB001 four IV injections
223602859|NCT01545440|DRUG|placebo|subcutaneous dose every 4 weeks
223602860|NCT04995549|DEVICE|Cutiscan® CS 100|Repeated measures on healthy volunteers skin (forearm) are performed using Cutiscan® CS 100 device
223602861|NCT00930228|DRUG|Flutamide|Flutamide, 250 mg capsule for oral administration, twice a day for 4 weeks (or menstrual cycle length in normally-cycling controls)
223602862|NCT00930228|DRUG|Placebo|Placebo, for oral administration, twice a day for 4 weeks (or menstrual cycle length in normally-cycling controls)
223602863|NCT02922179|DRUG|Long- and intermediate- acting insulins|alone or in combination with metformin, short-acting insulin, or second-generation sulfonylurea
223602864|NCT03304873|DRUG|Retapamulin|Retapamulin is a topical antibiotic ointment. The ingredients include retapamulin and white petrolatum as the vehicle. The composition is 10mg retapamulin per 1g of ointment (1%).
223602865|NCT03304873|DRUG|Placebo Ointment|The placebo that will be used is triple-purified pharmaceutical-grade petrolatum.
223602866|NCT03114631|BIOLOGICAL|Dendritic cells pulsed with tumor lysate|
223602867|NCT03114631|BIOLOGICAL|Dendritic cells pulsed with MUC-1/WT-1 peptides|
223602868|NCT03319212|DEVICE|senofilcon A contact lenses|Senofilcon A Daily Disposable Contact Lenses
223602869|NCT04734301|DEVICE|Intravaginal Electrical Stimulation (2 times/week)|IVES sessions were performed two times in a week, for 10 weeks. Every session lasted 20 minutes. The intervention comprised a 20-sessions treatment program of ES. The stimulation parameters were frequency at 10 Hz, a 5-10s work-rest cycle and 100 ms pulse width. The symmetric biphasic pulse wave could be delivered over a range of 0-100 mA. The intensity was controlled according to patients' discomfort level feedback.
224200148|NCT06488469|BEHAVIORAL|Psychological Interventions for children and adolescents|"Psychological Interventions for children and adolescents:~* Behavioral modifications using Functional Analysis and Parent Management Techniques~* Illness Management behavior - Motivational Interviewing, Cognitive Therapy to identify thinking errors posing challenges to self-management, Behavioral Modification to enhance self-management of illness, Solution focused therapy to manage identified barriers in illness -management~* Managing emotional problems- Cognitive Behavioral Therapy techniques~Psychological Interventions for Parents/ Caregivers:~* Parent management techniques- Identification of problem behaviors/deficit~* Education on Dysfunctional attitude and their effects Psycho-education for Children could be delivered best in Combined with Health Education and Nutritional education leading to dietary modifications.~* Individualized Treatment targets and Resetting targets"
223602870|NCT04734301|DEVICE|Intravaginal Electrical Stimulation (5 times/week)|IVES performed in the same way as Group 1, except for frequency of treatment. IVES sessions were performed five times in a week, for 4 weeks. Every session lasted 20 minutes. The intervention comprised a 20-sessions treatment program of ES. Stimulation parameters were the same as Group 1.
224200149|NCT04484987|OTHER|9 hours daily eating window|Participants assigned to the TRE group will have to consume all their daily meals and snacks during a 9-hour window for 12 weeks.
224200150|NCT04484987|OTHER|15 hours daily eating window|Participants assigned to the control group will have to consume all their daily meals and snacks during a 15-hour window for 12 weeks.
224200151|NCT03944798|OTHER|Frequency: Every 3 Months|every 3 months
224200152|NCT03944798|OTHER|Frequency: Every 6 Months|every 6 months
224200153|NCT03944798|OTHER|Imaging Modality: Chest Radiograph (CXR)|Chest radiograph (CXR)
224200154|NCT03944798|OTHER|Imaging Modality: Chest CT|Chest computed tomography (CT)
224200155|NCT01016925|PROCEDURE|tunnelized perineural catheter|the catheter will be tunneled 2-3 cm subcutaneously.
223602871|NCT01737216|DRUG|Zoledronic acid plus EP/TP|Drug:EP/TP+Zoledronic acid EP(VP-16 100mg/m2 d1-3;DDP 60-75mg/m2 d1) every 4 weeks, for 4-6 cycles TP(PTX 135-175mg/m2 d1;DDP 60-75mg/m2 d1) every 3 weeks, for 4-6 cycles Zoledronic acid 4mg d1 every 3 months until bone metastasis, 4mg d1 every 1 month until progression
223602872|NCT01737216|DRUG|EP/TP|Drug:EP/TP EP(VP-16 100mg/m2 d1-3;DDP 60-75mg/m2 d1) every 4 weeks, for 4-6 cycles TP(PTX 135-175mg/m2 d1;DDP 60-75mg/m2 d1) every 3 weeks, for 4-6 cycles
223602873|NCT00250276|BIOLOGICAL|Cervarix™|GSK Biologicals' vaccine against human papillomaviruses 16 and 18.
223602874|NCT00201942|PROCEDURE|PET scan|
223602875|NCT06156241|BIOLOGICAL|Stem Cell|Stem cells derived from human cord tissue.
223602876|NCT05037617|DRUG|Continuation or discontinuation of oxytocin during the active first stage of labor (≥6 cm dilation).|"At the intervention site (Foothills Medical Centre), for participants who consent to being part of the trial, once a patient is found to be \>= 6 cm dilation, the study medication will be initiated. Pharmacy will make up identical vials of oxytocin or saline, which will be numbered according to the random allocation sequence created by the study statistician.~The intervention will be continued until delivery unless contractions decrease to less than 2 in 10 minutes or if no further cervical dilation is noted 4 hours after discontinuation."
223602877|NCT02267161|OTHER|Psychometric scales for infants at 3 years of age|WPPSI-III, VINELAND, CBCL, NEPSY
223602878|NCT04591847|DRUG|Vitamin D 2|Vitamin D2 20000IU 1 tab oral weekly
223602879|NCT04591847|DRUG|Placebo drug|Placebo drugs 1 tab oral weekly
223602880|NCT00465777|BEHAVIORAL|Guideline adherence and financial incentive|
223602881|NCT00286871|DRUG|Neoral|
223602882|NCT00286871|DRUG|Tacrolimus|
223602883|NCT00761722|DRUG|azacitidine|"Arm 1:~Cycle 1 (PK Phase) - Subjects will receive a single SC dose of 75 mg/m2 on Days 1 and 15. Single oral doses of a given formulation of azacitidine will be administered in increasing doses on Days 3 and 5, and at doses calculated to deliver 80% and 120% of the SC exposure, up to a maximum dose of 600 mg on Days 17 and 19.~Cycles 2 and beyond - (Treatment phase) Oral azacitidine will be administered in a dose calculated to deliver 100% of the SC exposure up to a maximum of 600 mg on days 1 - 7 of a 28 day cycle.~Arm 2:~All Cycles - Oral azacitidine will be administered a maximum of 600 mg on Days 1 - 7 of a 28 days cycle."
223602884|NCT01546688|DRUG|Zonisamide at targeted daily doses of 100-500 mg/day|Each group received 2 doses a day (in the morning and evening) during the Titration Period, once a day (in the evening) or BID during the Maintenance Phase, comprising 25 mg, 50 mg, or 100 mg of ZNS capsules
223602885|NCT01546688|DRUG|Placebo administered to match targeted daily doses of 100-500 mg/day|matching placebo
223602886|NCT05665803|PROCEDURE|Pediatric rotary files|Mechanical preparation of primary tooth canals with pediatric rotary files
223602887|NCT05665803|PROCEDURE|Manual flare files|Mechanical preparation of primary tooth canals with manual flare files
223602888|NCT04448769|BIOLOGICAL|Anti-SARS-CoV-2 IgT seropositivity|"Each inhabitant who agrees to participate will have to :~* sign the consent form after receiving complete information~* complete a questionnaire exploring sociodemographic (gender, age, professional activity...), medical (anthropometric measures, health problems, smoking...), potential contacts with COVID-19 and symptoms.~* take a blood sample for the dermination of anti-SARS-CoV-2 IgT seropositivity of the individuals tested in the population of the Grand Nancy Metropolitan area (GNM)."
223602889|NCT04241406|DEVICE|Transcutaneous spinal cord stimulation|Electrodes are placed over the back for a 10 minutes in the same manner as experimental groups, but will be applied a sham electrical stimulation increasing current intensity during 30 second and decrease intensity subsequentl
223602890|NCT02518633|DEVICE|Continuous positive airway pressure devices|overnight use of CPAP device
223602891|NCT00648700|DRUG|Levothyroxine Sodium Tablets 300 μg|2x300mcg, single dose fasting
223602892|NCT00648700|DRUG|Levothroid® Tablets 300 μg|2x300mcg, single dose fasting
223602893|NCT00544037|DRUG|Interferon beta-1b (Betaseron, BAY86-5046)|Standard Therapy for Multiple Sclerosis
223602894|NCT04771637|DRUG|Dexmedetomidine|The loading dose with 0.5 μg/kg, maintenance dose with 0.5 μg/kg of Dexmedetomidine is used to observe the effect on the electrolyte and quality of recovery of the patients
223602895|NCT04771637|DRUG|Dexmedetomidine|The loading dose with 1.0 μg/kg, maintenance dose with 0.25 μg/kg of Dexmedetomidine is used to observe the effect on the electrophysiology and quality of recovery of the patient
223750533|NCT02473315|OTHER|cryotherapy|"The treatment arm :Whole body cryotherpy (WBC) (20 sessions of 3 minutes at a temperature of -110 degrees Celsius, on the basis of two sessions a day, spread over two weeks).~The control arm : Whole body cryotherpy (WBC) (20 sessions of 1 minute at a temperature of -60 degrees Celsius, on the basis of two sessions a day, spread over two weeks)."
223750534|NCT02085187|OTHER|Telemedicine training and counselling|"Training and counselling by the physiotherapist consisted of 3 weekly sessions, lasting 30-45 minutes, over a 3 week period, i.e. a total of 9 supervised sessions. Heart rate and oxygen saturation were monitored during the exercise training. This included thoracic mobilization exercises, cardio training, strength training and breathing exercises. The training intensity was progressed continuously.~There were 1-2 sessions with the occupational therapist, which consisted of training and counselling on energy conservation techniques. The first session was 60 minutes long and included assessment, counselling and training. This session was delivered in the second week of the intervention. The intervention concluded in the third week, with sessions of 30 minutes as required."
223750535|NCT03038815|DEVICE|VACOped|restriction of ankle joint motion
223750536|NCT03038815|DEVICE|Ortho Tri|restriction of ankle joint motion
223602896|NCT04771637|DRUG|Dexmedetomidine|The loading dose with 1 μg/kg, maintenance dose with 0.5 μg/kg of Dexmedetomidine is used to observe the effect on the electrophysiology and quality of recovery of the patients
223602897|NCT04771637|DRUG|Normal saline|Normal saline is used to observe the effect on the electrophysiology and quality of recovery of the patients
223602898|NCT04057846|DEVICE|EUS guided transgastric drainage|Whenever possible, randomisation and intervention shall be postponed until 4 weeks after onset of pancreatitis in line with international guidelines. All procedures in this study shall be performed by three experienced endoscopists (PNS, EFH, SN), who all have an extensive experience in endoscopic ultrasound (EUS-) guided drainage of pancreatic collections and the use of self-expanding stents. They have together performed more than 300 endoscopic, transmural drainage and debridement procedures in patients with WON since 2005. Endosonography-guided, transgastric drainage of the WONs shall be performed using a curve-linear echoendoscope (endoscope: Olympus GF-UCT180; ultrasound scanner: Hitachi Arietta 850 or Olympus EU-ME2). All collections shall be treated by single tract transmural cystogastrostomy (single-gate technique). T
223602899|NCT04949074|OTHER|saliva sampling|when the patient goes to the laboratory for a covid 19 diagnostic from a routine nasopharingeal sample, an additionnal sample of saliva is asked
223602900|NCT02313974|PROCEDURE|Renal Biopsy|
223602901|NCT03372174|DEVICE|Maintaining mechanical ventilation during surgery|dead space ventilation using tidal volume of 2.5 mL/kg/pbw (predicted body weight) with 5-7 cm H2O Positive end-expiratory pressure
223602902|NCT03372174|DEVICE|Absence of mechanical ventilation during surgery|absence of mechanical ventilation (and no Positive end-expiratory pressure) by disconnecting the tracheal tube from the ventilator
223602903|NCT01811186|DRUG|Oxycodone/naloxone|Oxycodone/naloxone titration
223602904|NCT06130462|DIAGNOSTIC_TEST|Aluminum|Different concentrations of aluminium added to the blood test in vitro
223602905|NCT06130462|DIAGNOSTIC_TEST|Tetanus toxoid|Used as control substance
223602906|NCT01092052|DRUG|NMS-1116354|Oral daily administration for 14 consecutive days followed by 7 days of rest
223602907|NCT05065853|DIAGNOSTIC_TEST|urine self-sampling group|collection of urine and vaginal samples
223602908|NCT05065853|DIAGNOSTIC_TEST|clinician-collected cervical sample group|A clinician takes a smear from cervix according to standard routine
223602909|NCT01979458|DEVICE|PSE|
223602910|NCT00378261|PROCEDURE|Use of an Electronic Data Capture System by patients and physicians to assess patient-physician interactions & therapeutic decisions & outcomes in RA subjects.|
223602911|NCT04213716|COMBINATION_PRODUCT|silver nano particulate solution mixed with calcium hydroxide powder|1ml of nanosilver solution 30ppm concentration mixed with 100 mg of calcium hydroxide powder used as intracanal medication
223602912|NCT04213716|COMBINATION_PRODUCT|conventional calcium hydroxide|1ml of distilled water mixed with 100 mg of calcium hydroxide powder and used as intracanal medication after root canal retreatment
223602913|NCT00306540|DRUG|Quetiapine Fumarate|oral flexible dose
223602914|NCT00306540|DRUG|quetiapine fumarate placebo|oral 0 mg
223750537|NCT02447133|DEVICE|3D OCT-1 Maestro|OCT Machine used for diagnostic purposes
223750538|NCT03054870|DRUG|Xe-133|Xe-133 ventilation scintigraphy
223750539|NCT03054870|DRUG|Technegas|Technegas ventilation scintigraphy
223750540|NCT05990400|DRUG|Finasteride|finasteride topical 0,1%
224200156|NCT05101473|OTHER|Exercise Therapy|The overall framework will consist of two supervised exercise sessions per week of 30-60 min duration for 12 weeks in order to be able to result in the physiological adaptions that are needed to improve the health of the individual participant.
224200157|NCT02141373|DEVICE|Glubran 2|
223602915|NCT05623657|OTHER|Trunk Stabilization Exercise Training Group|The adolescents in this group who are involved in archery sports will be given 40 minutes of exercise training 2 days a week for 8 weeks. Exercise training will be applied as 5-10 minutes warm-up, 15-30 minutes trunk stabilization exercises, 5-10 minutes cooling down, and stretching exercises. The number of repetitions and difficulty levels of the exercises will gradually increase in the 3rd and 6th weeks.
223602916|NCT05623657|OTHER|Game Based Exercise Program Group|At least 4 different games selected from Xbox 360 Kinect® games will be applied to adolescents practicing archery sports in this group for a total of 40 minutes with the physiotherapist. The games will be selected from games that include movement patterns similar to the exercises of the trunk stabilization exercise group. Game-based exercise training is planned to be performed twice a week for a total of 8 weeks.
223602917|NCT01448499|DRUG|Clozapine|escalating dose of clozapine up to 900 mg/day
223602918|NCT01448499|DRUG|Amisulpride|escalating dose of amisulpride up to 800 mg/day
223602919|NCT01448499|DRUG|Clozapine+Amisulpride|augmentation of clozapine with amisulpride
223602920|NCT02300740|DIETARY_SUPPLEMENT|Nicotinamide riboside|NIAGEN, ChromaDex
223602921|NCT01670773|DRUG|CAT-1004|
223602922|NCT01670773|DRUG|Salsalate + DHA|
223602923|NCT01670773|DRUG|Placebo|
223750541|NCT05990400|DRUG|Minoxidil|minoxidil topical 5%
223750542|NCT05693285|OTHER|No intervention|No intervention
224200158|NCT06370039|DRUG|INV-102|INV-102 Ophthalmic Solution
224200159|NCT06370039|DRUG|Vehicle|Vehicle Ophthalmic Solution
223602924|NCT03669289|OTHER|enhanced model of primary care|The SCHOOL STARS model of care includes pre-visit planning, standardized visit content, post-visit care coordination, and coordination between primary care and school.
223602925|NCT00688272|DRUG|Ciprofloxacin|Given 500mg BID x 6 days
223602926|NCT00688272|DRUG|Eltrombopag|Given QD x 6 days
223750543|NCT06516276|DEVICE|Mobile App M.I.O|This mobile app provides patients with access to various resources and therapies focused on nutrition, exercise, and emotional well-being. The main objective is to measure the quality of life of the app users through validated questionnaires in a randomized health education study to evaluate whether a substantial improvement in their well-being is achieved.
223750544|NCT03398720|DRUG|HTI-1066 dose level 1|Starting dose level
223750545|NCT03398720|DRUG|HTI-1066 dose level 2|2nd dose level
223750546|NCT03398720|DRUG|HTI-1066 dose level 3|3rd dose level
223750547|NCT03398720|DRUG|HTI-1066 dose level 4|4th dose level
223750548|NCT02822469|OTHER|Manual Therapy Treatment|"Treatment starts with 10 deep breathing movements for global relaxation. The anterior and posterior neck muscles, shoulder girdle and subdiaphragmatic will be addressed with myofascial techniques repeated 10 times in each stroke. The cervical spine will be pulled in the longitudinal direction. The draw will be held 1 time, lasting 1 minute. The thoracic region will receive mobilization technique in the anteroposterior direction,10 repeated movements involving all thoracic segment.~The treatment will be applied previously trained therapists, 4 weeks, 2 times a week, totaling eight sessions. The treatment time per session is about 25 minutes."
223750549|NCT02822469|DEVICE|Placebo Ultrasound|A detuned pulsed ultrasound will be applied to regions of the muscles around the shoulder girdle and anterior posterior cervical, for 25 minutes (2.5 minutes in each zone ). The device will be used with the internal cables disconnected for the placebo effect . However, you can handle it and adjust the doses and alarms as it is connected in order to simulate clinical practice and increase the credibility of the use of this device in the voluntary . The placebo treatment will be applied by previously trained therapists. Treatment will have 4 weeks, 2 times a week, totaling eight sessions.
223750550|NCT03448965|DIAGNOSTIC_TEST|random blood sugar|do random blood sugar at 0 hour - 2 hours- 4 hours and after 6 hours
223750551|NCT06822907|BIOLOGICAL|Early intervention|"In this arm, patient will receive unique dose of the PCV-20 vaccine (Prevnar 20) as soon as possible and until 72h after apyrexia.~The Prevenar 20 will be used Prevenar 20 will be injected by intramuscular route. The preferred site of injection is the deltoid muscle of the upper arm in adults."
223750552|NCT06822907|BIOLOGICAL|Delayed intervention|"In this arm, from 15 days and until 58 days after fever resolution (i.e after the first day with a body temperature \< 37.5°C without paracetamol use in the 6 previous hours) (whether or not the patient has been discharged) in the absence of fever, the patient will receive unique dose of the PCV-20 vaccine (Prevnar 20).~The Prevenar 20 will be used Prevenar 20 will be injected by intramuscular route. The preferred site of injection is the deltoid muscle of the upper arm in adults."
223750553|NCT05787314|BEHAVIORAL|Low Glycemic Index Diet|"1. Participants who came to the hospital for control and were interested in the study contacted the study researchers and eligibility was determined through face-to-face interviews. Potential participants were invited to a screening visit to verify eligibility.~2. The LGID program was initiated as an outpatient treatment in patients who applied to a dietitian. 3) Medium and high GI carbohydrates (GI \> 55) were excluded from the diet and only low GI (GI \< 50) foodstuffs were allowed. 4) A list of low glycemic index foods were given to the patients. In addition, a list of foods to avoid (medium and high glycemic index) is provided."
223750554|NCT02495311|PROCEDURE|myomectomy or adenomyomectomy|
223602927|NCT00688272|DRUG|Placebo|Given QD x 6 days
223750555|NCT04027738|OTHER|PRP|The patients received a single 3-ml injection of PRP. Approximately 10-mL of venous blood was drawn from each patient and centrifuged using an Arthrex autologous conditioned plasma (ACP) kit (a low-leukocyte ACP system), spun at a speed of 1500 rpm for 5 minutes. The platelet concentration obtained was approximately 2-3 times greater than the baseline platelet concentration.
223750556|NCT06122090|DRUG|Bimatoprost|Bimatoprost will be delivered with laser
223750557|NCT06122090|DRUG|Saline|Saline control will be delivered with laser
223602928|NCT06420180|PROCEDURE|hip arthroscopy|"CT rotational profile Will be used for measurement of LL rotational abnormality.~MRI will be evaluated for the presence of labral tears, chondral lesions, ligamentum teres pathology, and other soft-tissue disorders."
223602929|NCT05416736|PROCEDURE|The bladder stimulation technique|The bladder stimulation technique consists of two consecutive maneuvers. In the first maneuver, the bladder is stimulated by tapping the suprapubic region for 30 seconds at a frequency of 100 touches per minute. In the second maneuver, circular massage is applied to the paravertebral region for 30 seconds. The two stimulation maneuvers will be repeated alternately for 3 minutes (180 seconds) until micturition begins. Maneuvers will be performed by the researcher. Infants in both groups will be held under the armpit by a parent, male infants will be held in the drooping legs, and female infants will be held in the hip flexion position.
223602930|NCT05416736|PROCEDURE|Steril urine bag|Steril urine bag are attached to the genital area to collect urine samples
223602931|NCT01800136|DEVICE|Repetitive Transcranial Magnetic Stimulation and Transcranial Direct Current Stimulation|Five sessions of HF-rTMS or tDCS applied daily during 5 consecutive days
223602932|NCT01219062|DRUG|morphine|periarticular infiltration with 0.25% Bupivacaine for 20 ml.
223602933|NCT01219062|OTHER|control|the patients will be received spinal anesthesia with 0.5% Isobaric Bupivacaine and postoperative pain control by intravenous (IV) Patient - control Analgesia (PCA)
223602934|NCT01219062|DRUG|Bupivacaine|the patients will be received spinal anesthesia and periarticular tissue infiltration with 0.25% Bupivacaine and postoperative pain control by IV PCA
223750558|NCT04112017|DEVICE|YVOIRE Y-Solution 360|Hyaluronic acid
223750559|NCT05774158|OTHER|Physiotherapy assessment|Of the individuals included in the study; Information about age, height, body weight, type of congenital heart disease, surgical history, drug use, comorbid chronic disease, education level and occupation will be obtained. Functional Capacity, Peripheral Muscular Strength, Hand Grip Strength, Fatigue, Physical Activity Level, Quality of Life, Social Participation, Depression Anxiety Stress Level and Physical Activity Barriers will be evaluated
223750560|NCT00917709|OTHER|Imaging with IBVM|in vivo molecular imaging of presynaptic molecular target of cholinergic systems with \[123I\]-iodobenzovesamicol
223750561|NCT00917709|OTHER|Imaging with DATSCAN|in vivo molecular imaging of presynaptic molecular target of dopaminergic systems (DAT) with DATSCAN
223750562|NCT00917709|BEHAVIORAL|neuropsychological evaluation|neuropsychological evaluation using neuropsychological tests
223750563|NCT01626807|BEHAVIORAL|Walking School Bus|Children will have the option of walking to and/or from school with study staff who are trained in Safe Routes to School methods.
223602935|NCT05969340|DIAGNOSTIC_TEST|ultra-high-resolution CT-scan|Use of ultra-high-resolution CT-scan to detect otoconia in the posterior canal BPPV
223750564|NCT03972280|BIOLOGICAL|Recombinant anti-granulocyte colony-stimulating factor (G-CSF) receptor monoclonal antibody|Recombinant anti-G-CSF receptor monoclonal antibody is a preservative-free, sterile liquid formulation that is suitable for intravenous infusion
223750565|NCT01428180|DRUG|Indomethacin|3 doses of 0,2mg/kg every 12h (first week of life) or every 8h (after first week of life)
223750566|NCT01428180|PROCEDURE|Surgical Ligation|In nonresponders to medical treatment with persistent hemodynamically relevant patent ductus arteriosus surgical ligation is performed.
223750567|NCT01428180|DRUG|Ibuprofen|3 doses every 24h; first dose 10mg/kg, second and third dose 5mg/kg
223750568|NCT04179695|OTHER|Consulting with PARKINSUN as communication aid-tool|Participating patients visit their general practitioner or neurologist with PARKINSUN at 1 months, 4 months, 7 months
223602936|NCT03369236|DRUG|Danicopan|Danicopan was administered as an oral tablet.
223602937|NCT03369236|DRUG|Placebo|Matching placebo was administered as an oral tablet.
223602938|NCT02248636|DRUG|Cholinesterase inhibitor|This group receives a half-dose of their previous cholinesterase inhibitor medication (in overencapsulated form) for two weeks, then receives placebo.
223602939|NCT02248636|DRUG|Sham discontinuation|This group receives their previous dose of cholinesterase inhibitor medication, but in overencapsulated form
223602940|NCT03942939|OTHER|Primary Robotic-Assisted Total Knee Arthroplasty with a short tourniquet time|Primary Robotic-Assisted Total Knee Arthroplasty with a short tourniquet time. Short tourniquet time is defined in this study as the release of the tourniquet after the initial exposure, resulting in a total tourniquet time of only 10-15 minutes.
223602941|NCT03942939|OTHER|Primary Robotic-Assisted Total Knee Arthroplasty with the use of a tourniquet|Primary Robotic-Assisted Total Knee Arthroplasty with the use of a tourniquet
223602942|NCT03806608|PROCEDURE|Crestal|Subjects will be included with the absence of 2-4 teeth in the posterior region of the maxilla or mandibular. Twenty patients will be recruited. Two implant placement depths, equicrestal and subcrestal, were randomly assigned to two sites of each patient with a predefined randomization tables (one crestal implant and one subcrestal implant).
223602943|NCT03806608|PROCEDURE|Subcrestal|Subjects will be included with the absence of 2-4 teeth in the posterior region of the maxilla or mandibular. Twenty patients will be recruited. Two implant placement depths, equicrestal and subcrestal, were randomly assigned to two sites of each patient with a predefined randomization tables (one crestal implant and one subcrestal implant).
223750569|NCT04179695|OTHER|Consulting without PARKINSUN as communication aid-tool|Participating patients visit their general practitioner or neurologist without PARKINSUN at 1 months, 4 months, 7 months
223750570|NCT04136925|OTHER|questionnaire|questionnaire before and after race
223750571|NCT00362908|BEHAVIORAL|Moderate Fat and Moderate Carbohydrate Diet|40% allowable fat diet (less than or equal to 7% saturated fat) consumed for 1 or 5 months
223750572|NCT00362908|BEHAVIORAL|Low Fat and High Carbohydrate Diet|20% fat diet (less than or equal to 7% saturated fat) consumed for 1 or 5 months
223750573|NCT02687984|DRUG|RBP-7000|A single subcutaneous injection with doses of RBP-7000 containing 120 mg risperidone and either a low, high, or intermediate molecular weight PLGH polymer.
223602944|NCT05293925|BEHAVIORAL|announcement of cessation of treatment|"The first 40 outpatients for whom an announcement to stop anti-tumour treatments is made at the Institut Curie Paris, in a conventional oncology consultation or in Palliative Care Day Hospital.~Categorical variables will be described by numbers and percentages. Quantitative variables will be described by the mean, standard deviation, median of the distribution as well as the minimum, maximum and interquartile range and compared by a Student's t test or a Wilcoxon test according to the normality of the variables."
223750574|NCT06850168|DEVICE|SVL|Dispensed to one eye in Year 1
223750575|NCT06850168|DEVICE|SVL with passive red-light emission|Dispensed to the contralateral eye in Year 1.
223750576|NCT06850168|DEVICE|MCL|Dispensed to one eye in Year 2 (if used SVL with passive red-light emission in Year 1).
223750577|NCT06850168|DEVICE|MCL with passive red-light emission|Dispensed to the contralateral eye in Year 2 (if used SVL in Year 1).
223750578|NCT03207932|PROCEDURE|Central vein catheterisation|ultrasound guided versus landmark central vein catheterisation
223750579|NCT04227821|OTHER|Vasopressor and/inotrope therapy|In pediatric patients admitted to the pediatric intensive care, with the persistent hemodynamic instability after fluid resuscitation, the vasopressor and/or inotrope therapy will be initiated
223750580|NCT03414463|BEHAVIORAL|TREAT|A 4-week one-to-one intervention between the clinical RA (cRA) and participant. Comprised of eight sessions, it involves psycho-educational lessons and skill-building exercises to achieve objectives based on the characteristics of alexithymia.
223750581|NCT02864849|DRUG|Oxaliplatin|
223750582|NCT02864849|DRUG|Capecitabine|
223750583|NCT02864849|RADIATION|Intensity modulated radiotherapy|
223750584|NCT02864849|PROCEDURE|Total mesorectal excision|
223750585|NCT04650477|PROCEDURE|Fixation while forearm in extension-pronation position|Fixation was performed after tenodesis in the extension-pronation position, which is the anatomically most suitable position of the biceps tendon.
223750586|NCT04311099|DRUG|Active drug|Injection of Ropivacaine
223750587|NCT04311099|DRUG|Placebo|Injection of Saline solution
223750588|NCT04311099|PROCEDURE|Injection of Ropivacaine - Ultrasound-guided transverse abdominal plane block|Lateral ultrasound-guided transverse abdominal plane block 40 ml ropivacaine 2 mg / ml
223750589|NCT04311099|PROCEDURE|Injection of Ropivacaine - Laparoscopic assisted transverse abdominal plane block|Laparoscopic assisted subcostal transverse abdominal plane block 40 ml ropivacaine 2 mg / ml
223750590|NCT04311099|PROCEDURE|Injection of placebo - Ultrasound-guided transverse abdominal plane block|Lateral ultrasound-guided transverse abdominal plane block with saline solution
224311318|NCT01381315|PROCEDURE|Injection of isotope|On the day of surgery, if the radioactive SLN cannot be located using the gamma probe prior to incision, lymphazurin or methylene blue dye will be used in the breast in the subareolar plexus at the discretion of the surgeon for assistance in identifying the sentinel nodes. This contingency, expected to occur \<3% of the time, will be used since locating the SLN for staging is of greater importance than the study. If radioactive isotope is sufficient to identify the sentinel node draining from the breast, then the blue dye will be injected dermally in the upper inner arm along the bicipital groove of the ipsilateral arm in order to locate the draining lymphatics from the arm. No more than 5cc of blue dye will be injected in any of the above mentioned scenarios.
224311319|NCT01381315|PROCEDURE|Axillary lymph node dissection|The one-year lymphedema rate among subjects undergoing axillary lymph node dissection with or without sentinel lymph node biopsy is ≥ 0.13. With our sample size of 58 subjects undergoing ALND, we will reject that hypothesis in favor of the alternative-that the lymphedema rate is \<0.13 for subjects undergoing ALND-if lymphedema is confirmed in three or fewer (ie, 0, 1, 2, or 3) subjects.
223750591|NCT04311099|PROCEDURE|Injection of placebo - Laparoscopic assisted transverse abdominal plane block|Laparoscopic assisted subcostal transverse abdominal plane block with saline solution
223750592|NCT05356702|OTHER|Brain Health Assessment|Research interventionists, who will be trained and licensed health practitioners (e.g., social workers), will ask participants about changes in memory or thinking and daily function, screen for depression, and administer a standard cognitive screening test. They will use a standardized note template to document results in the participant's EHR. Research interventionists will notify participants and PCPs if follow-up is recommended.
223750593|NCT06529406|DRUG|Ozanimod|De-escalation of anti-CD20 treatment using ozanimod.
223750594|NCT04368247|DIAGNOSTIC_TEST|Skin Fluorescent Imaging|Application of reagents, then imaging and scoring
223750595|NCT06557889|DRUG|Pembrolizumab + Cisplatin/Carboplatin + 5-FU|"* 4 cycles of combination treatment: 4 cycles of pembrolizumab (200 mg IV on Day 1 of each 3-week cycle) in combination with chemotherapy with platinum salts (cisplatin (100 mg/m2 IV on Day 1 of each 3-week cycle) or carboplatin (AUC 5 IV on Day 1 of each 3-week cycle), at the investigator's choice) and 5-FU (1000 mg/m2/day IV continuous from Day 1-4 of each 3-week cycle).~* Maintenance phase: pembrolizumab is continued as monotherapy for up to 24 months of treatment in total (from the first injection of cycle 1)."
223750596|NCT02676505|BEHAVIORAL|Coached pushing group|It includes 217 patients who are admitted in active stage of labor (cervical dilatation 4cm at least) to labor delivery ward. They are coached by the nurse to use closed-glottis and pushing three to four times during each contraction immediately when cervical dilation reached 10 cm and to continue pushing using this method with each contraction until birth. The nurse counts to 10 during each pushing effort to assist the woman in holding her breath for at least 10 seconds.
223750597|NCT02676505|BEHAVIORAL|uncoached pushing group|It includes 217 patients who are admitted early in active stage of labor (cervical dilatation 4cm at least) to labor delivery ward at 10-cm cervical dilation where they remain until they feel the urge to push or the second stage had lasted 2 hours (whichever came first)., they are encouraged to bear down with contractions without holding their breath (open-glottis) for no more than 6-8 seconds and continue bearing down no more than three times with each contraction until birth. .
223602945|NCT01364311|DIETARY_SUPPLEMENT|Vitamac® Tag and Nacht capsules|"Vitamac® Tag und Nacht Kapseln: Dosage 1 capsule Vitamac® Tag per day ingested in the morning, 1 capsule Vitamac® Nacht per day ingested in the evening.~Vitamac® Tag: Lutein 12mg, Vitamin C 300mg, Zinc 10mg, ginkgo biloba 10mg, Flavinoids 25mg, Fishoil 300mg, administered for 12 weeks Vitamac® Nacht: Zeaxanthin 5mg, Vitamin E 60mg, Copper 1mg, Selen 20µg, Ginkgo Biloba 10mg, Flavinoids 25mg, Alpha Lipon acid 150mg), administered for 12 weeks"
223602946|NCT03969186|BEHAVIORAL|Intervention|Telehealth intervention monitoring weight and medication adherence accompanied by a weekly phone call to monitor symptoms.
223602947|NCT01153724|DRUG|BI 1744|10 mcg solution for oral inhalation
223602948|NCT01153724|DRUG|Fluconazole|400 mg capsule
223602949|NCT03334812|BIOLOGICAL|LNA043|LNA043 Single dose
223750598|NCT00951028|BEHAVIORAL|Cognitive behavioral therapy (CBT) for adherence and depression (CBT-AD)|12 therapy sessions delivered over 4 months, using cognitive behavioral strategies to target depressive symptoms and adherence to HIV medications
223602950|NCT03334812|BIOLOGICAL|placebo to LNA043|placebo to LNA043 single dose
223750599|NCT00951028|BEHAVIORAL|Life-steps adherence treatment|Single-session adherence treatment that targets informational, problem solving, and cognitive-behavioral steps geared toward improving HIV medication adherence and self-management
223750600|NCT00951028|BEHAVIORAL|Information and supportive psychotherapy (ISP) for adherence and depression (ISP-AD)|12 therapy sessions delivered over 4 months, providing education and support that target depressive symptoms and adherence to HIV medications.
223750601|NCT01154218|DRUG|crizotinib|"Treatment A (Reference 1): a 250 mg single dose of crizotinib administered in a fasted state as 1 × 50-mg IRT and 2 × 100-mg IRTs.~Treatment B (Reference 2): a 250 mg single dose of crizotinib administered in a fasted state as 1 × 50-mg PIC and 2 × 100 mg PICs.~Treatment C (Test for BE, Reference for Food Effect): a 250 mg single dose of crizotinib administered in a fasted state as 1 × 250-mg CIC.~Treatment D (Test High Fat): a 250 mg single dose of crizotinib administered with a high-fat meal as 1 × 250-mg CIC"
223750602|NCT05933928|OTHER|Simulation-based electronic fetal monitoring training|"Practices will be carried out with the students in the intervention group with the NOELLA Birth Simulator, which is a high-reality simulator located in the Simulation laboratory of the Department of Midwifery of the Faculty of Health Sciences of Hamidiye. A simulator will be practiced with a separate scenario including early, late, variable deceleration, reactive, sinusoidal and non-reactive trace interpretation and intervention."
223750603|NCT01643993|OTHER|hCG at the Time of Embryo Transfer|hCG will be included in the 20 microliters of media inserted during a mock embryo transfer immediately prior to actual embryo transfer.
223750604|NCT01643993|OTHER|Control|Patients will have 20 microliters of media inserted during a mock embryo transfer immediately prior to actual embryo transfer.
223750605|NCT00589953|DRUG|Erythropoietin|"5 of first 10 subjects (Group 1): 400 units/kg/dose once daily for 7 days 5 of next 10 subjects (Group 2): 800 units/kg/dose once daily for 7 days 20 of next 30 subjects (Group 3): 1000 units/kg/dose once daily for 7 days administered i.v. over 1 hour.~The volume of the study drug will be 1 mL in a 1 mL Tuberculin syringe to be administered over 1 hour."
223602951|NCT04223908|OTHER|observational : questionnaries for assessment of health burden|The French IN-FOCUS study was designed to capture current and retrospective data in FCS or MCS. Patients were called by the participating centers and were proposed to answer a paper questionnaire or to connect to a web-based questionnaire The questionnaire was divided into sections specifically assessing various domains of their experience: demographic data, signs, symptoms and complications of the disease, healthcare circuit, management, relationship with healthcare providers, and burden of the disease on daily life. (Details are available as supplementary material S1). The questionnaire focused on symptoms because the interest of quality of life assessment tools is debated in rare diseases with episodic manifestations. Indeed, most of these tools refer to a limited recall period.
223602952|NCT01605110|DRUG|Hyperbaric oxygen treatment|Patients that volunteer to participate in this study will be exposed to two treatments (one before surgery; one after surgery) of 100% oxygen at 2.0 atmospheres absolute (ATA) inside mono-place chambers for 90 minutes (at depth).
223602953|NCT01605110|DRUG|Air sham|Patients that volunteer to participate in this study will be exposed to two treatments (one before surgery; one after surgery) of medical grade air (21%oxygen; sham) at 1.2 ATA inside mono-place chambers for 90 minutes.
223602954|NCT03850535|DRUG|Idasanutlin|Participants will self-administer idasanutlin tablets by mouth (PO) once daily (QD) for 5 days of each 28-day treatment cycle for up to 2 cycles of induction, up to 4 cycles of consolidation, and 12 cycles of maintenance, according to the study's protocol.
223602955|NCT03850535|DRUG|Cytarabine|Cytarabine will be administered for 7 days of each 28-day cycle for up to 2 cycles of induction treatment at a dose of 200 milligrams per meter squared (mg/m\^2) of body surface area, once daily (QD) by intravenous (IV) infusion. At the investigator's discretion, cytarabine will also be administered as part of chemotherapy consolidation at a dose of 1.5 g/m\^2 QD as IV infusion for 5 days of each 28-day cycle and for up to 4 cycles of treatment.
223602956|NCT03850535|DRUG|Daunorubicin|Daunorubicin will be administered for 3 days of each 28-day cycle for up to 2 cycles of induction treatment at a dose of 60 mg/m\^2 QD as IV infusion.
223602957|NCT03850535|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplant (Allo-HSCT)|After induction treatment, participants who achieve remission will either receive chemotherapy consolidation treatment or undergo Allo-HSCT (as per local guidelines) at the investigator's discretion.
223602958|NCT04314674|DRUG|%3 HS bolus|After head fixation %3 HS bolus 3 ml/kg will be administered
223602959|NCT04314674|DRUG|%3 HS infusion 20 ml/h|After head fixation %3 HS 20 ml/h infusion will be administered
223602960|NCT04314674|DRUG|20% mannitol|After head fixation %20 mannitol 0.6 ml/kg will be administered
223602961|NCT00426543|DRUG|MabThera (rituximab)|1000 mg infusion twice with 14 days interval
223602962|NCT00426543|DRUG|Rituximab, Mabthera|1000 mg Rituximab infusion in 500 ml isotonic sodiumchloride twice with 14 days interval
223750606|NCT00589953|DRUG|Saline placebo|Saline vehicle at a volume of 1 mL given over 1 hour intravenously once a day for the first seven days of life.
223750607|NCT00563953|DRUG|Liposomal pegylated doxorubicine|Four cycles of liposomal pegylated doxorubicine at 35 mg/m² IV combined with cyclophosphamide at 600 mg/m² on Day 1 every 4 weeks, and followed by paclitaxel 80 mg/m²/week for 12 weeks before surgery.
224200160|NCT04992091|OTHER|constructive debriefing|Constructive debriefing was applied to an interventional group Traditional debriefing was applied on noninterventional group
224200161|NCT02014428|DIETARY_SUPPLEMENT|Hyaluronic acid|
224200162|NCT02014428|DRUG|Placebo|
223602963|NCT03295617|PROCEDURE|Thoracoscopy|Thoracoscopy surgery
223602964|NCT01600989|OTHER|blood sampling|Blood samples will be taken at ICU admission, and 24h and 48h after admission, and at time of resolution of sepsis
223602965|NCT01600989|OTHER|blood sampling|Blood samples will be taken twice at a 7 day interval
223602966|NCT02731443|PROCEDURE|Epilepsy surgery|Epilepsy surgery is a procedure that removes an area of the brain where seizures originate.
223602967|NCT02731443|PROCEDURE|Depth electrodes insertion|Depth electrodes are inserted for monitoring/mapping the subsurface levels of the brain for the surgical treatment of epilepsy.
223602968|NCT02491606|DRUG|Tafenoquine|Tafenoquine 200mg and 400 mg
223750608|NCT00129129|BIOLOGICAL|GSK Biologicals' Haemophilus influenza type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine 792014 vaccine|Primary phase: 3 IM doses Booster phase: 1 IM dose
223750609|NCT00129129|BIOLOGICAL|ActHIB|Primary phase: 3 IM doses Booster phase: 1 IM dose
223750610|NCT00129129|BIOLOGICAL|Pediarix|Primary phase: 3 IM doses
223750611|NCT00129129|BIOLOGICAL|Prevnar|Primary phase: 3 IM doses Booster phase: 1 IM dose
223750612|NCT00129129|BIOLOGICAL|Menomune|Primary phase: 1 SC dose
223750613|NCT00881933|OTHER|Cyclophosphosphamide, TBI|fludarabine (30 mg/m2 once daily i.v. on days -7, -6, -5, -4, -3, \& -2) (if body weight \< 10 kg or if age \< 1 year: 1.33 mg/kg) cyclophosphamide (60 mg/kg once daily i.v. on days -9, \& -8) total body irradiation (3G on days -1)
223750614|NCT03345589|DRUG|18-22mg/kg/d Ursodeoxycholic|18-22mg/kg/d Ursodeoxycholic
223750615|NCT03345589|DRUG|13-15mg/kg/d Ursodeoxycholic|13-15mg/kg/d Ursodeoxycholic
223750616|NCT05470699|PROCEDURE|Computed Tomography|Undergo PET/CT
223750617|NCT05470699|OTHER|Fluorine F 18 Piflufolastat|Given IV
223750618|NCT05470699|DEVICE|Positron Emission Tomography|Undergo PET/CT
223750619|NCT01647633|OTHER|Calcium Glycerophosphate Nasal Spray Wash|Nasal wash two to six times per day
223750620|NCT02958150|DRUG|Dexmedetomidine|
223750621|NCT02958150|PROCEDURE|Standard Clinical Practice|
223750622|NCT03688750|OTHER|no intervention|
223750623|NCT00820157|PROCEDURE|Cytoreductive Surgery|Cytoreductive Surgery followed by TACE for MNHCC
223750624|NCT00820157|PROCEDURE|TACE|TACE alone or TACE followed by downstage resection for MNHCC
223750625|NCT03812887|DIAGNOSTIC_TEST|Photopatchtesting|Photopatchtesting to the sunscreen series and extended series, irradiated at both 24 and 48 hours
224200163|NCT00556972|DEVICE|Fecal Incontinence Management System|The device is intended to remedy fecal incontinence.
223750626|NCT02736045|DEVICE|emWave|Our approach will be to test the impact of this intervention through a smartphone application, emWave software, which will be provided to all our subjects. emWave is a tool that reduces stress by allowing individuals to be less reactive, think clearly, and make good decisions, especially under pressure. Fifty medical residents with high burnout symptoms will be randomized to receive an 8-week intervention (emWave - computer based resilience training program).
223602969|NCT02491606|OTHER|Placebo|Placebo
223602970|NCT00429533|DRUG|Dapsone|
223750627|NCT00159055|BIOLOGICAL|CMV vaccine|
223750628|NCT04087252|BIOLOGICAL|tumor neoantigen|tumor neoantigens
223750629|NCT00002504|BIOLOGICAL|aldesleukin|
223750630|NCT00002504|BIOLOGICAL|recombinant interferon alfa|
223750631|NCT01028157|BEHAVIORAL|STARS: Sistas Talking About Real Solutions|The intervention consisted of 2, 4-hour workshops. The first workshop focused on enhancing ethnic/gender pride, self-esteem, realizing values/setting goals, healthy/unhealthy relationships, partner violence, HIV/STD knowledge, heightening awareness of HIV susceptibility, safer-sex options/skills. The second workshop covered realistic choices in sexual decision making, consistent/proper condom use, setting limits/boundaries, communication styles, and condom skills negotiation. Participants received 3-hour booster sessions at 6- and 9-months to reinforce materials from the initial intervention. Bi-monthly phone calls and quarterly mailings were used to reinforce workshop material and facilitate retention.
223750632|NCT01028157|BEHAVIORAL|General Health & Nutrition|Participants in this condition received a 2 hour group session which consisted of general health information and women's health brochures facilitated by a trained health educator. The control group received bi-monthly phone calls and quarterly mailings for retention purposes only, with no intervention material provided.
223750633|NCT05792228|OTHER|nurse-led standardized intervention|Once the patient in the intervention group decided to undergo cisplatin-based chemotherapy, the nurses would assess the risk factors associated with chemotherapy-induced nausea and vomiting (CINV) and reported to the physicians. During the chemotherapy, nurses would provide education on prevention and control of CINV using web-based approaches. All patients received standard antiemetic regimen, which included Aprepitant, 5-Hydroxytryptamine3-receptor antagonists, and Dexamethasone. If the physician's prescription was not accordance with the standard antiemetic regimen, nurse would remind the physician to adjust the prescription. Patients were recommended to eat small and frequent meals slowly. Overly spicy, fatty, and sweet foods should be avoided. Music relaxation therapy was performed for 60 min each time, once a day, and 3 times in the whole chemotherapy cycle. Follow-up was delivered until the 5th day after chemotherapy.
223750634|NCT01583335|BEHAVIORAL|Lifestyle habits, including sleep and stress|The intervention group was offered up to 10 individual consultations focusing on improving diet, physical activity and sleep habits and reducing stress. Moreover, the intervention group was offered participation in monthly cooking classes and playing arrangements
223750635|NCT01907477|OTHER|Samples taken at the clinical hematology unit|
223750636|NCT00142675|BEHAVIORAL|Physical Activity|
223750637|NCT05074238|OTHER|Zinc containing suncreen|"The study participant will be randomized via a randomization tool within the REDCap database as to which half of the wound (A or B) the patient will be asked to apply zinc containing sunscreen for the duration of the study."
223750638|NCT06369168|DEVICE|auricular acupuncture|two auricular acupuncture methods are compared with each other and with no treatment
223602971|NCT01555333|DRUG|arbaclofen|A flexible dose titration will be utilized. Orally disintegrating tablets
223602972|NCT01742806|DEVICE|bio-absorbable felt(NEOVEIL®)|To cover bio-absorbable felt over the lymphadenectomy area (hepatoduodenal ligament, #5 and 12/gastroduodenal artery, #6/ pancreas head /suprapancreatic area, #7,8 and 9)
223602973|NCT00003864|DRUG|carboplatin|
223602974|NCT00003864|DRUG|docetaxel|
223750639|NCT06967181|BIOLOGICAL|CVM150|CVM150- Live PIV5-based MuV vaccine expressing the MuV (Iowa strain/2006) F and HN proteins formulated in 1x sucrose phosphate glutamate (\[SPG\]; sucrose, KH2PO4, K2HPO4 and L-glutamic acid) buffer.
223750640|NCT06967181|BIOLOGICAL|CVM26|CVM26: A live, attenuated MuV vaccine based on Iowa strain genetically edited to remove the V and SH protein expression. Formulated in 1x sucrose phosphate glutamate (\[SPG\]; sucrose, KH2PO4, K2HPO4 and L-glutamic acid) buffer.
223750641|NCT06967181|OTHER|Placebo|Placebo: 0.9% normal sterile saline (purchased commercially).
223750642|NCT02724475|PROCEDURE|LA|Ultrasound-guided puncture to the front of the thrombus with a power of 30 watts and pulse time of 0.3-0.4 seconds with 1 second interval until the thrombus was totally eliminated
223750643|NCT02724475|PROCEDURE|3D-CRT|γ-knife treatment with radiation dose of 48-63 Gy/6-9 times
223750644|NCT05232240|DIAGNOSTIC_TEST|blood pressure variability measured by ambulatory 24-hour blood pressure monitoring|The ambulatory 24-hour blood pressure monitoring will be performed at baseline and one year after the enrollment. Various blood pressure variability characteristics will be obtained from these examinations.
223602975|NCT02547558|PROCEDURE|Arterial blood gases|Measured through radial arterial catheter
223602976|NCT02547558|PROCEDURE|Cardiac Output|Measured through bioimpedance: FloTrac pressure transducer (FloTrac sensor; Edwards Lifesciences) using the third-generation (3.01) FloTrac software for continuous CO display.
223602977|NCT02547558|PROCEDURE|Vital signs|As measured in clinical practice
223602978|NCT02547558|PROCEDURE|Exhaled breath|Were recorded using a pneumotachograph (CPX/D; Med Graphics, St. Paul, MN, U.S.A.).
223602979|NCT02547558|PROCEDURE|Spirometry|In a daily calibrated spirometer.
223602980|NCT02547558|DRUG|Indacaterol|Indacaterol Breezhaler@ 300 mcg (1 inhalation)
223602981|NCT01438606|BIOLOGICAL|VSV-Indiana HIV gag vaccine|Administered IM in both deltoids at baseline and Week 8. Dose will vary depending on which group the participant is enrolled in.
223602982|NCT01438606|BIOLOGICAL|Placebo injection (normal saline)|Administered IM in both deltoids at baseline and Week 8.
223602983|NCT01824433|DRUG|venlafaxine|venlafaxine 75-225mg qd
223750645|NCT05195463|OTHER|Exercise intervention|Women with diastasis recti abdominis will do core stabilization exercises for the transversus abdominis muscle with 10 repetitions 3 days a week for 8 weeks. The exercises include diaphragmatic breathing exercises, core stabilization exercises for the transversus abdominis muscle, and pelvic floor contractions
223750646|NCT05195463|OTHER|Exercise intervention by wearing abdominal corset|In this group, in addition to the first group, core stabilization exercises will be performed by wearing an abdominal corset. Participants will be asked to wear their corsets while performing their exercises.
223602984|NCT01824433|DRUG|fluoxetine|fluoxetine 20-60mg qd
223602985|NCT03701919|DRUG|Botulinum toxin pyloroplasty|Intraoperative laparoscopic injection of Botulinum toxin into the pylorus immediately following sleeve gastrectomy
223602986|NCT03701919|DRUG|Normal saline pyloric injection|Intraoperative laparoscopic injection of normal saline into the pylorus immediately following sleeve gastrectomy
223602987|NCT00242099|PROCEDURE|Monitoring - blood samples drawn to test for HHV-6 and HHV-7|
223602988|NCT00524472|OTHER|Hyperinsulinemic-normoglycemic clamp|Patients will be randomized to receive the hyperinsulinemic-normoglycemic clamp titrating the blood glucose to 80-110 mg/dL.
223602989|NCT00524472|OTHER|insulin at the standard of care levels|Subjects will be administered insulin at the standard of care levels established by the participating institution.
223602990|NCT02508428|DEVICE|Hip Replacement with crosslinked Marathon polyethylene|Comparison of Marathon and Enduron polyethylene
223602991|NCT02508428|DEVICE|Hip Replacement with noncrosslinked Enduron polyethylene|
223602992|NCT04833296|DRUG|Ropivacaine|all patients will receive interscalene block using same volume of ropivacaine but in different concentrations
223602993|NCT02430116|PROCEDURE|Ischemic postconditioning|In the Treat group, the procedure involved 5 min before opening the ascending aorta, aortic unclamping for 30 s, and cross-clamping for 30 s for three cycles, after which the ascending aorta was completely opened.
223602994|NCT00209300|DRUG|Pentasa|
223602995|NCT02210975|DEVICE|LES-Stimulation Device|
223602996|NCT04554771|DRUG|Tocilizumab 20 Mg/mL Intravenous Solution|tocilizumab 8 mg/kg with a maximum of 800 mg intravenously on day 1, 15 and 29 of standard of care neoadjuvant chemoradiation
223750647|NCT05195463|OTHER|Corset intervention|Participants included in this group will be required to wear only this corset all day (except for the bathroom) for 8 weeks.
223750648|NCT02532296|BEHAVIORAL|Transition Coach (TC)|"TC reviews patient's medical record to understand current admission and the medical/psycho-social history. TC makes introductory hospital visit(s) with patient to establish rapport and to define post-discharge needs.~Starting in-house and continuing after discharge, TC helps patient set transition goals to maximize healthcare outcomes. Post-discharge, TC offers a voluntary face-to-face visit with patient along with weekly outreach calls, which are designed to assist patient with goal setting and attainment, medical system navigation; medication management; medical follow-up; transportation; use of community resources; and self-care.~Intervention lasts 30 days post-discharge; afterwards TC seeks to handoff to an outpatient care team member, to ensure continuity of care."
223750649|NCT02532296|BEHAVIORAL|Control|Receives usual hospital-based care, discharge preparation, transitional care and outpatient care.
223750650|NCT06481514|OTHER|Interpretation of the CTG using FRI score|At each of the components of the score will be assigned a score of 1 if the variable evaluated is considered normal, 0 if classified as abnormal. To encourage a simplified clinical interpretation of the different scores obtained (score from 1 to 8) they will be classified into 3 risk categories: Score 5-8: green zone, Score 3-4: zone yellow, Score 1-2: red zone. An FRI of 1-2 (red zone) is to be considered as anomalous
223602997|NCT04554771|DRUG|Paclitaxel|Paclitaxel 50 mg/m2 will be given intravenously on days 1, 8, 15, 22 and 29
223602998|NCT04554771|DRUG|Carboplatin|Carboplatin AUC = 2 will be given intravenously on days 1, 8, 15, 22 and 29
223750651|NCT06481514|OTHER|Classic interpretation of the CTG|evaluate the CTG of group B patients according to the usual internal management protocols
223750652|NCT06043076|DEVICE|TMS|Active iTBS will be applied using a butterfly figure-of-eight C-B60 coil connected to MagPro R30 stimulator with add-on Theta Burst option (MagVenture A/S, Farum, Denmark).
223602999|NCT04554771|RADIATION|External beam radiotherapy|External beam radiotherapy will be delivered to a total dose of 41.4 Gy in 23 fractions of 1.8 Gy, 5 fractions per week starting the first day of the first cycle of chemotherapy
223603000|NCT04031989|DEVICE|CorVista Capture|The CorVista System is a medical device system that is being developed to collect phase signals from patients to support the development and testing of machine learned algorithms developed by CorVista Health. Data collected with the CorVista System during this study will not be used to guide treatment.
223603001|NCT02748070|DRUG|Prednisone|
223603002|NCT02748070|DRUG|Flonase|
223603003|NCT03842241|DEVICE|Non-custom made foot orthoses|Foot orthoses is an orthotic devices which are used to support arch and rear-foot and put it in a good alignment.
223603004|NCT05426941|BEHAVIORAL|Music Imagery|Up to 30 participants will be randomized to receive 8 weekly Music Imagery sessions over 8-12 weeks.
223603005|NCT05426941|BEHAVIORAL|Music Listening|Up to 15 participants will be randomized to independent music listening.
223603006|NCT02785068|DRUG|MM-151|Oligoclonal antibody
223603007|NCT02785068|DRUG|nal-IRI|Nanoliposomal irinotecan
223750653|NCT06043076|DEVICE|Sham|Sham iTBS will be applied using acoustic stimulation of a second coil behind the participant's head
223603008|NCT02785068|DRUG|Leucovorin|folinic acid
223603009|NCT02785068|DRUG|5-FU|Chemotherapy
223603010|NCT00928694|DRUG|fenofibrate (U.S. formulation)|Single dose of 160 mg fenofibrate U.S. formulation (Tricor®) in one of two treatment periods.
223603011|NCT00928694|DRUG|fenofibrate (UK formulation)|Single dose of 160 mg fenofibrate UK formulation (Supralip®) in one of two treatment periods.
223603012|NCT02215304|DIETARY_SUPPLEMENT|Bifidobacterium longum ssp infantis R0033|"12 weeks intervention study: A run-in period of two weeks, 8 weeks of intervention (from weeks 2 to 10) and two weeks after intervention finishing time.~During the 8 weeks of intervention participants will intake one daily dose of the product which contains 3\*10E9 colony forming units (CFU)"
224311320|NCT06118606|OTHER|Case-manager led multidisciplinary follow-up after intensive care|Early in-hospital follow-up in survivors of intensive care with an increased risk of psychological/physical sequelae. The follow-up is led by a case-manager reassessing the patient after ICU discharge for psychological/physical rehabilitation needs. The CM will discuss patient needs with concerned specialists in a multidisciplinary team, leading to the establishment of a personal rehabilitation plan, communicated to the patient and next-of-kin. The CM will keep track of the patient during hospital stay and ensure primary care rehabilitation (if needed) is established once the patient is discharged from the hospital. The CM will contact the patient weekly to follow up on well-being and primary care activities until 12 weeks after discharge.
224311321|NCT02754856|BIOLOGICAL|Durvalumab|Given IV
223603013|NCT02215304|DIETARY_SUPPLEMENT|Lactobacillus helveticus R0052|"12 weeks intervention study: A run-in period of two weeks, 8 weeks of intervention (from weeks 2 to 10) and two weeks after intervention finishing time.~During the 8 weeks of intervention participants will intake one daily dose of the product which contains 3\*10E9 colony forming units (CFU)"
223603014|NCT02215304|DIETARY_SUPPLEMENT|Bifidobacterium bifidum R0071|"12 weeks intervention study: A run-in period of two weeks, 8 weeks of intervention (from weeks 2 to 10) and two weeks after intervention finishing time.~During the 8 weeks of intervention participants will intake one daily dose of the product which contains 3\*10E9 colony forming units (CFU)"
224311322|NCT02754856|OTHER|Laboratory Biomarker Analysis|Correlative studies
223750654|NCT04503759|OTHER|NanoBone Bone Graft Substitute|Synthetic, biodegradable bone grafting material that is composed of non-sintered nanocrystalline hydroxyapatite (HA) which is embedded in a silica gel matrix (amorphous SiO2). The ratio of HA/SiO2 has been chosen to optimize the rate of biodegradation for treatment of osseous defects in human bone. NanoBone does not contain any components of animal or human origin, eliminating the possibility of transmission of infection or disease.
223750655|NCT03817385|DEVICE|repetitive TMS|rTMS x 10 times
223750656|NCT03817385|DEVICE|robotic GT|robotic gait training for 20 times
223750657|NCT02882854|DRUG|Guanfacine|Patients will receive 1 mg of guanfacine to take orally.
223750658|NCT02882854|DRUG|Placebo|Patients will receive a placebo containing no drug that appears similarly to guanfacine to take orally.
223603015|NCT02215304|DIETARY_SUPPLEMENT|Placebo|"12 weeks intervention study: A run-in period of two weeks, 8 weeks of intervention (from weeks 2 to 10) and two weeks after intervention finishing time.~During the 8 weeks of intervention participants will intake one daily dose of the product which contains 3\*10E9 colony forming units (CFU)"
223603016|NCT01315444|DRUG|Stop PPI gradually|
223603017|NCT01315444|DRUG|Stop PPI gradually|
223603018|NCT00534976|DRUG|Comparator: montelukast sodium|"Patients 4-5 years: 4 mg Montelukast chewable tablet daily~Patients 6-14 years: 5 mg chewable tablet daily"
223603019|NCT00534976|DRUG|Comparator: Comparator: placebo (unspecified)|"Patients 4-5 years: 4 mg Pbo chewable tablet daily~Patients 6-14 years: 5 mg Pbo chewable tablet daily"
223603020|NCT03799939|DEVICE|Intervention group|Polyvinylidene fluoride mesh (Dynamesh IPST) is used on intraperitoneal onlay position to prevent parastomal hernia.
223603021|NCT04364152|BEHAVIORAL|Dual-task walking training|Participants will be instructed to perform both motor and cognitive dual-task walking during exercise training. For example, for motor dual-task walking, the participants may be instructed to throw and catch a ball while walking. As for cognitive dual-task walking, the participants may be instructed to name animals or perform calculation while walking.
223603022|NCT01281033|PROCEDURE|Manual Thrombectomy|In patients in the thrombus-aspiration group, this step is followed by the advancing of the 6-French Export Aspiration Catheter (Medtronic; crossing profile, 0.068 in.) into the target coronary segment during continuous aspiration.
223603023|NCT01281033|PROCEDURE|AngioJet Rheolytic Thrombectomy (RT) System|The AngioJet Rheolytic Thrombectomy (RT) System consists of a drive unit console, disposable pump set, and disposable catheter. Thrombectomy is accomplished by the introduction of a pressurized high velocity saline stream through directed orifices in the catheter distal tip so that thrombus is entrained (Bernoulli effect), dissociated into small particles, and evacuated from the body through the catheter and associated tubing. The pump set consists of a high pressure pulsatile pump which is used to generate the flow necessary for the dissociation and evacuation of thrombus, an effluent bag for the collection and storage of thrombus debris, and associated tubing.
223603024|NCT05972746|DEVICE|Telemonitoring with electronic alerts|Patients assigned to this group will receive standard care plus a telemonitoring program.
223603025|NCT05972746|OTHER|Standard of care|Standard of care
223603026|NCT06183073|PROCEDURE|caudal block|bupivacaine 0.25% in a dose of (1 ml / kg)
223603027|NCT06183073|DRUG|Dexmedetomidine|dexmedetomidine 1μg/ kg.
223603028|NCT06183073|PROCEDURE|TAP|analgesia
223750659|NCT04288648|DIAGNOSTIC_TEST|ultrasound examination|ultrasound examination of pelvic floor muscle will be conducted. In addition questionnaires regarding demographic characteristics and SUI will be performed.
223750660|NCT03722550|OTHER|Starter Infant Formula, Follow-up Formula, and Growing-up Milk Supplemented With a Blend of Five Human Milk Oligosaccharides|Study formulas are administered orally, ad libitum, from enrollment until 15 months of age
223750661|NCT03722550|OTHER|Breast-feeding|Exclusive Breast-feeding up to 4 months of age
223750662|NCT03722550|OTHER|Standard Starter Infant Formula, Follow-up Formula, and Growing-up Milk|Standard Study formulas are administered orally, ad libitum, from enrollment until 15 months of age
223603029|NCT06183073|DRUG|Bupivacain|bupivacaine 0.25% in a dose of (0.5 ml / kg
223750663|NCT03272607|OTHER|Deprescribing opportunities|An electronic intervention that identifies potentially inappropriate medications (PIMs) and generates instructions for safe discontinuation, which is presented to the treating physician for their consideration.
223750664|NCT00425867|BEHAVIORAL|PAR1 polymoprhisms and placental invasion|
223750665|NCT01278485|DRUG|Sulphonylurea|SU administered according to usual practice.
223750666|NCT01278485|DRUG|Metformn|Metformin administered according to usual practice.
223750667|NCT00491010|PROCEDURE|radiofrequency catheter ablation|
223750668|NCT00625976|BEHAVIORAL|Graded exposure in vivo|Graded exposure in vivo according to the protocol of de Jong et al. (2005)
223750669|NCT00625976|BEHAVIORAL|Physiotherapy|Physiotherapy according to the protocol of Oerlemans, Oostendorp, de Boo and Goris (1999)
223750670|NCT03192943|DRUG|BMS-986205|Specified dose on specified days
224311323|NCT02754856|PROCEDURE|Therapeutic Conventional Surgery|Undergo liver surgery
223603030|NCT05793242|DEVICE|Hypervolt|HyperVolt Percussive Massage Device: this will be performed by a physical therapist while the participant is prone. The physical therapist will apply a vibrating device to the back of the thigh with moderate pressure while continuously moving the device for 5 minutes.
223603031|NCT05793242|DEVICE|Body Tempering|Body Tempering:this will be performed by a physical therapist while the participant is prone. The physical therapist will apply a moderately heavy metal device to the back of the thigh while continuously moving the device for 5 minutes.
223603032|NCT05793242|DEVICE|Dry cupping|Dry Cupping: This will be performed by a physical therapist while the participant is prone. The physical therapist will apply several negative pressure devices to the back of your thigh for 5 minutes.
223750671|NCT03192943|BIOLOGICAL|Nivolumab|Specified dose on specified day
223750672|NCT03558243|PROCEDURE|Patent Hemostasis arm|Patent hemostasis with TR BAND
223750673|NCT03558243|PROCEDURE|ULTRA arm|Patent hemostasis protocol plus ipsilateral ulnar compression
223750674|NCT03558243|DEVICE|Hemostatic disc arm|StatSeal disc plus TR Band
223750675|NCT02273895|DRUG|Scopolamine|0.3 mg/mL, intravenously, once
223750676|NCT03297385|DRUG|Enzalutamide|Men with localized prostate cancer will undergo an additional set of targeted tumor biopsies and will be subsequently treated with 3 months of enzalutamide. The prostatectomy specimen will be additionally sampled, ex vivo.
223750677|NCT03434847|OTHER|Education|Participants who receive perioperative educational to address their expectation about their postoperative pain will have improved pain-related postoperative outcomes.
223750678|NCT02266459|DEVICE|Microwave technology (Medfield Diagnostics)|A microwave measurement will be performed. The procedure will take approximately 15 minutes (the duration of the actual measurements is \< 1 minute) and will not interfere with the patient's standard of care at the Stroke Unit.
223750679|NCT00763347|DRUG|SYR-619|SYR-619 12.5 mg, tablets, orally, once daily for up to 12 weeks.
223750680|NCT00763347|DRUG|SYR-619|SYR-619 50 mg, tablets, orally, once daily for up to 12 weeks.
223603033|NCT05793242|OTHER|Static stretching|Participants will perform a static stretch on their lower extremity. This stretch will be performed by having the participant loop a strap around their heel and grasping it with both hands followed by pulling the strap to raise the fully extended leg into hip flexion. The participant will be instructed to lift the leg until they reach their maximal tolerable point and then to hold the position for 30 seconds. They will then lower the extremity to the table and rest for 15 seconds This self-stretch sequence will be performed for 7 cycles so that the total intervention was equal to the intervention time of the other group (5 minutes).7
224311324|NCT02754856|BIOLOGICAL|Tremelimumab|Given IV
224311325|NCT05567146|BEHAVIORAL|Experimental group|"It is planned to use the social media platform WhatsApp application to carry out the study. technique of gamification will have content in the form of points, ranking, penalties and rewards, which are the basic principles of gamification.~Studies have shown that these contents are effective techniques to increase the interest, encouragement, motivation and purpose of the participants."
223750681|NCT00763347|DRUG|SYR-619|SYR-619 100 mg, tablets, orally, once daily for up to 12 weeks.
223603034|NCT03422965|DIAGNOSTIC_TEST|Optical Coherence Tomography Angiography|Optical Coherence Tomography Angiography images capture.
223603035|NCT03422965|DIAGNOSTIC_TEST|Blood test|Blood test, systemic markers
223603036|NCT03422965|DIAGNOSTIC_TEST|Urine test|Urine test, systemic markers
223750682|NCT00763347|DRUG|SYR-619|SYR-619 200 mg, tablets, orally, once daily for up to 12 weeks.
223750683|NCT00763347|DRUG|Placebo|SYR-619 placebo-matching tablets, orally, once daily for up to 12 weeks.
223750684|NCT00763347|DRUG|Alogliptin|Alogliptin 25 mg, tablets, orally, once daily for up to 12 weeks.
223750685|NCT02965274|DRUG|Torrent's Fluoxetine Tablets|
223750686|NCT02965274|DRUG|Warner Chilcott LLC's Sarafem Tablet|
223750687|NCT00368654|DRUG|Methotrexate|Initial dose 5 mg, then 15 mg per week
224311326|NCT00530218|DRUG|Ganciclovir|Following the first CMV-positive blood culture on day 21 or later, or the first two consecutive CMV-positive PCR tests on day 21 or later, 5mg/kg/bid x 7 days of Ganciclovir is given intravenously, followed by oral Ganciclovir 1000 mg tid 7 days per week x 5 weeks
224311327|NCT01342900|DEVICE|connected to the InSpectra Monitor|
224311328|NCT06476951|BEHAVIORAL|Parent-Child Physical Activity Program|The program includes online education, parent-child games, parent-child dancing, and other parent-child physical activity activities.
223750688|NCT00368654|DRUG|Raptiva|Raptiva, initial dose 0.7 mg/kg, then 1.0 mg/kg
223750689|NCT05552768|PROCEDURE|Bone level-driven placement|The objective of this study will be to determine if implants placed according to the soft tissue-driving implant placement paradigm, i.e. 4 mm below the tissue margin will have different clinical performance as compared to the bone level-driven placement paradigm.
223750690|NCT05552768|PROCEDURE|Biological width-driven placement guidelines|Biological width-driven placement guidelines
223750691|NCT03774433|BEHAVIORAL|Laddr|"Laddr is an integrated, personalized, web-based self-regulation assessment and behavior change system. It integrates tools that have been shown to be effective for a wide array of behavioral phenomena ranging from substance use and abuse, mental health, risk-taking, chronic pain management, medication adherence, diet, exercise, diabetes and other chronic disease management, and smoking. The organizational structure, functionality and content within Laddr's system centrally embrace these fundamental aspects of behavior change; thus, the Laddr platform is not diagnosis-specific but rather enables integrated care for any combination of individuals' goals, needs, and preferences."
223750692|NCT03403959|DEVICE|light therapy|6 weeks morning treatment with bright light therapy in own home.
223750693|NCT00108160|DRUG|Mupirocin Ointment [Treatment]|The impact of the treatment arm versus placebo arm on development of new (recurrent) S. aureus infection will be assessed as the primary end point. Change in S. aureus strains (MSSA versus MRSA) will be assessed as the secondary end point.
224311329|NCT03477903|DRUG|TAK-954|TAK-954 infusion
224311330|NCT03477903|DRUG|Metoclopramide|Metoclopramide infusion
224311331|NCT03477903|DRUG|Normal Saline|0.9% sodium chloride for injection
224311332|NCT04766164|BEHAVIORAL|Survey|Data will be obtained via self-report from participants via a one-time Qualtrics survey.
224311333|NCT04378738|BEHAVIORAL|survey|all people in the cohort
224311334|NCT01031030|DRUG|cyclophosphamide|
223750694|NCT00108160|DRUG|Polyethylene Glycol Ointment [Placebo]|The impact of the treatment arm versus placebo arm on development of S. aureus re-infections will be assessed as the primary end point. Change in S. aureus strains (MSSA versus MRSA) will be assessed as the secondary end point.
223750695|NCT01285245|DRUG|kineret|once daily 100 mg of kineret subcutaneously for 8 days
223750696|NCT00680433|DRUG|Ketamine|Ketamine IV will be administered after the administration of the normal anaesthetic agents for ECT.
223750697|NCT00680433|DRUG|Saline|Saline (placebo) will be administered after the normal anaesthetic agents in ECT.
223750698|NCT05025111|DEVICE|Entia Liberty|Home monitoring device
223750699|NCT03817242|PROCEDURE|Tympanoplasty using tragal cartilage graft|tympanoplasty type I is performed using tragal cartilage in arm 1
223750700|NCT03817242|PROCEDURE|Tympanoplasty using temporalis fascia graft|tympanoplasty type I is performed using temporalis fascia in arm 2
223750701|NCT00731770|DRUG|Advair 250|1 puff bid inhaled
223750702|NCT00731770|DRUG|Placebo- matched|1 puff bid inhaled
223750703|NCT00731770|DRUG|Placebo|Placebo 1 puff bid inhaled
223750704|NCT00731770|DRUG|Advair 250 - matched|i puff bid inhaled
223750705|NCT03184350|RADIATION|Adjuvant pelvic proton radiation|Patients will receive a dose of 45-50.4 Gray in 1.8 Gray fractions 5-6 times per week using active raster-scanning pencil beam proton radiation
224200164|NCT03752021|PROCEDURE|Myometrial Sampling|"A myometrial sample will be obtained at the time of cesarean delivery. Sample will be obtained from the superior edge of the existing lower uterine segment incision and will be 2 inches in length and 0.5 inches in width. The uterine incision will be repaired in a standard two-layer closure. If a classical cesarean (vertical) uterine incision is deemed necessary and is performed by the surgical team, a sample of the same size will be taken parallel to the incision at the existing edge. The classical uterine incision will be closed utilizing the standard layered technique.~Placenta and gestational membrane tissue will be obtained after placental delivery. The entire placenta and attached gestational membranes will be collected if not being sent for pathologic review"
224200165|NCT02116309|DRUG|Rectal Indomethacin|
224200166|NCT02116309|DRUG|Epinephrine|
224200167|NCT03557073|BEHAVIORAL|Postoperative phone call|The intervention is a phone call on the day following surgery.
224200168|NCT05671731|DIETARY_SUPPLEMENT|Beneo Synergy 1|
224200169|NCT05671731|BEHAVIORAL|Project FUN|Project FUN, a culturally tailored online nutrition and physical activity program is based on the Health Promotion/ Transtheoretical Model. It includes 8 modules offered in a password-protected learning management system along with a workbook also used to assure intervention completion.
224200170|NCT02185820|DRUG|Carfilzomib|
224200171|NCT02185820|DRUG|Pomalidomide|
224311335|NCT01031030|DRUG|epirubicin hydrochloride|
223603037|NCT06223126|OTHER|Combined oral contraception|Women, who want to start taking birth control pills will get a prescription for oral contraception at the discretion of their own attending physician
223603038|NCT06223126|OTHER|Discontinuation of a combined oral contraception|Cessation of the use of combined oral contraceptives
223603039|NCT03797456|DRUG|ICP-022|ICP-022 (tablets, 50 mg) is given orally at the dose of 150 mg/day from day 1 to day 28 of each cycle for up to a total of 6 cycles or until progression.
223750706|NCT05057442|OTHER|Proprioception assessment, functionality assessment|Proprioception assessment, functionality assessment
223750707|NCT04690504|OTHER|dim light melatonin onset (DLMO)|A series of saliva samples will be collected and assayed for melatonin so that the timing of melatonin secretion onset can be determined.
223750708|NCT02694237|BEHAVIORAL|Model|Each participant will receive an informed consent discussion with the aid of an anatomic knee model.
223750709|NCT02694237|BEHAVIORAL|Knee Anatomy Video|Each participant will hear a scripted informed consent discussion while they watch a knee anatomy video orated by an interviewer.
223750710|NCT02694237|BEHAVIORAL|Verbal|Each participant will receive a verbal informed consent discussion without a visual aid.
223750711|NCT01517672|BEHAVIORAL|Cognitive Trauma Therapy for Battered Women (CTT-BW)|10 individual sessions of this form of cognitive therapy, with a trained therapist.
223750712|NCT03076957|DRUG|CKD-516 Tablet|CKD-516 PO for 5 consecutive days and 2 days off in Combination with Irinotecan inj.
223750713|NCT01035944|DEVICE|HemCon Dressings and HemCon ChitoGauze; chitosan-based.|Perform debridement of chronic wounds using HemCon chitosan-based dressings and HemCon ChitoGauze both at bedside and in the Operating Room (OR) settings. Control for both settings will be gauze and saline dressings.
223750714|NCT01035944|DEVICE|Gauze and saline dressings.|Control for both settings will be gauze and saline dressings.
223750715|NCT05823623|DRUG|Inetetamab|Patients with HER2-positive metastatic breast cancer after progression on trastuzumab are enrolled and receive treatment.
223750716|NCT05823623|DRUG|Pyrotinib|Patients with HER2-positive metastatic breast cancer after progression on trastuzumab are enrolled and receive treatment.
223750717|NCT05823623|DRUG|Oral Vinorelbine Tartrate|Patients with HER2-positive metastatic breast cancer after progression on trastuzumab are enrolled and receive treatment.
223750718|NCT00206869|BEHAVIORAL|exercise|
223750719|NCT00206869|BEHAVIORAL|heat|
223750720|NCT00206869|PROCEDURE|red light illumination|
223750721|NCT05837416|DRUG|blue®m Gel|Oxygen will be released after application Oxygen Releasing Oral Gel (blue®m gel) creating a partially high oxygen pressure (pO2), which aids in restoring the micro-environment for a healthy oral cavity
223750722|NCT05837416|DRUG|NBF GINGIVAL GEL®|Anti-oxidant gel (Nano-emulsion complex propolis and vitamin C - NBF GINGIVAL GEL®) is a nano bio fusion gel containing propolis, nano vitamin C, E and herb extract
224200172|NCT02185820|DRUG|Dexamethasone|
224200173|NCT02139020|OTHER|Plasma samples|Plasma samples at baseline (and one whole blood sample) and at every radiological evaluations
224200174|NCT01169662|DIETARY_SUPPLEMENT|Vegetable/fruit juice|450ml active juice, 45ml no added sugar fruit squash (for flavour)
224200175|NCT01169662|DIETARY_SUPPLEMENT|Placebo juice|50 ml No Added Sugar fruit squash, 45 ml Pressed Apple Juice, 405ml with water.
224311336|NCT01031030|DRUG|fluorouracil|
224311337|NCT01031030|DRUG|methotrexate|
224311338|NCT01031030|OTHER|laboratory biomarker analysis|
224311339|NCT01031030|PROCEDURE|adjuvant therapy|
223603040|NCT02358226|BEHAVIORAL|Soccer League (SL)|Participants will be invited to attend soccer practice in the late afternoons, roughly 2-3 times per week. Competitive games will be held on Saturdays so that friends and family may attend. Using a mobile phone application, coaches will regularly record information on participants' arrival and departure times, sportsmanship, volunteering in the community, the results of saliva tests for drugs and alcohol. The SL intervention arm will last for one year.
223750723|NCT05837416|DRUG|COE-PAK™|It is non eugenol periodontal dressing. It is supplied in two tubes, the contents of which are mixed immediately before use. One tube contains zinc oxide, oil, a gum, and lorothidol. The other tube contains liquid coconut fatty acids thickened with colophony resin and chlorothymol
223750724|NCT01742507|DEVICE|Resolute Integrity Stent|Resolute Integrity Stent
223750725|NCT01742507|DEVICE|Biomatrix stent|Biomatrix stent
223750726|NCT04803669|PROCEDURE|Intrument-assisted soft tissue mobilization technique|This technique; It is applied with the help of a tool made of stainless steel. The instrument is rubbed on the skin at an angle of about 30 degrees, creating a massage-like effect on the soft tissue (2 sessions per week and 5 minutes per session, 8 sessions in total for 4 weeks).
223750727|NCT04803669|PROCEDURE|Conventional Treatment|Hotpack, TENS, Ultrasound and Exercise will be applied as conventional treatment methods.
223750728|NCT06520930|BEHAVIORAL|breathing exercise therapy|Description: The breathing exercises to be applied were taught to each pregnant woman face to face with one-on-one training. The taught practice was then repeated by the pregnant woman and the researcher together. In the next step, pregnant women were asked to perform the application themselves. In this way, it was determined whether individual breathing exercise practices were performed correctly and effectively. After the one-on-one training was completed, the pregnant women were divided into groups of maximum six people and breathing exercise exercises were performed 7 days a week, once a day and once a week face-to-face for 8 weeks. Each session lasted approximately 45 minutes. For 8 weeks, a short reminder message was sent to pregnant women every morning to ensure that they did not interrupt their daily breathing exercise practices, and they were called in the evening to check whether they had performed the application correctly and whether they had any problems.
223750729|NCT03384550|BEHAVIORAL|Self-regulation coaching|Short (2-5 min.) dialogue with the digital coach who provides information relevant for behavioral self-regulation, such as a goal reminder, the distance between the current step count and the goal and strategies to increase daily steps. Participants are randomized to self-regulation coaching or control (no coaching) on a daily basis.
223750730|NCT03384550|BEHAVIORAL|Planning|A dialogue with the digital coach who prompts the participant to either formulate action plans (when and where the participant can go for a walk) or coping plans (strategies to respond to barriers for increasing daily steps) for the upcoming week. Participants are randomized on a weekly basis to action planning, coping planning or control (no planning).
223750731|NCT03384550|BEHAVIORAL|Financial Incentives|Participants receive CHF 1 ($1) for each day they meet a personalized adaptive step goal.
223750732|NCT03384550|BEHAVIORAL|Charity Incentives|Participants donate CHF 1 ($1) to a charity of choice for each day they meet a personalized adaptive step goal.
223750733|NCT05584865|OTHER|Digital occluar prosthesis|Each patient will receive the full digital fabricated ocular prosthesis. DICOM data from the Computerized Tomography (CT) will be imported into Materializes Interactive Medical Image Control System (MIMICS) software++++ tool for visualizing and segmenting medical images (such as CT and MRI)
223750734|NCT05584865|OTHER|Conventional occluar prosthesis|An accurate impression of the patient's eye socket will be obtained to prepare a suitable wax mod. The wax model will be flasked and processed into heat cured acrylic resin of the same colour of the sclera of the other healthy eye of the patient
223750735|NCT06264206|DIAGNOSTIC_TEST|Killer-cell immunoglobulin-like receptors (KIRs) testing|patients were tested for KIRs, and based on the divided in the 2 arms. Patient from ARM KIR AA received immunomuodulatorc treatment.
223750736|NCT05768152|DEVICE|RLRL|RLRL will be performed twice per day with an interval of at least 4 hours, each treatment last 3 minutes, in addition to single vision spectacles with power for correcting distance refraction.
223750737|NCT00578942|DRUG|Campath Purged Non-myeloablative ASCT|"Preparative regimen: Begins on day -5 and consist of 4 days of daily fludarabine at 30 mg/m2/d infused over 30 minutes, cyclophosphamide 500 mg/m2/d infused over 1 hour, 5 days of Campath-1H at 20 mg/d in 250 ml of D5 normal saline or normal saline infused over 3 hours.~Subject Evaluation will occur 2-3 times per week by physical exam for toxicity through day 45."
223750738|NCT03263416|OTHER|Dedicated and coordinated follow-up|"* Coordinated follow-up performed by a dedicated nurse with consultations (before treatment initiation and during treatment) and a telephone follow-up during treatment period~* Pharmaceutical conciliation before treatment initiation made by the Center Pharmacist~* Completion of QLQ-C30 and GIRERD questionnaires"
223750739|NCT03263416|OTHER|Standard follow-up|\- Completion of QLQ-C30 and GIRERD questionnaires
223750740|NCT05264194|OTHER|Suturing technique|The technique (subcuticular or transcutaneous) that will be used to close skin post-surgery.
223750741|NCT05725512|DRUG|Prednisolone|Prednisolone tablets (20 mg daily for 6 weeks, 10 mg daily for 1 week, 5 mg daily for 1 week) or identical placebo tablets for 8 weeks
223750742|NCT05725512|DRUG|Placebo|Placebo identical to prednisolone tablets
223750743|NCT01249612|OTHER|Thermotherapy|Knee joint icing
223750744|NCT01249612|OTHER|Thermotherapy|Elbow joint icing
223750745|NCT01065519|DEVICE|Xience V everolimus eluting stent|Xience V everolimus eluting stent
223603041|NCT02358226|BEHAVIORAL|Soccer League/Vocational Training (SL-V)|In addition to the SL intervention, participants will gain access to vocational training. The Vocational Training will take place through the Silulo or Zenzele programs based in Khayelitsha for a period of 6 months. These programs offer practical and market-related training in computer skills, woodwork, or welding. The SL-V intervention arm will last for one year; with six months dedicated to soccer and six months dedicated to vocational training.
223603042|NCT06186986|DRUG|Brentuximab vedotin|5 Participants will receive unlabeled brentuximab and 20 participants will receive 89ZR-Brentuximab.
223603043|NCT00490074|BIOLOGICAL|DNA-C|1.0mg per ml of DNA HIV-C vaccine 2x2 ml IM
223603044|NCT00490074|BIOLOGICAL|NYVAC-C|NYVAC-C 1 ml IM
223750746|NCT01065519|DEVICE|Biolimus A9-eluting Biomatrix stent|Biolimus A9-eluting Biomatrix stent
223603045|NCT04859374|BEHAVIORAL|Mindfullness|Behavioral approach (mindfulness) delivered on line and smart phone for 6 weekly sessions
223750747|NCT00433563|RADIATION|Once daily radiotherapy|Standard of care chemotherapy (cisplatin/etoposide) + once daily radiotherapy
223603046|NCT04859374|DRUG|treatment as usual (TAU) (pharmacological)|Any pharmacological therapy used for managing chronic pain or chronic migraine
223750748|NCT00433563|RADIATION|Twice daily radiotherapy|Standard of care chemotherapy (cisplatin/etoposide) + twice daily radiotherapy
223750749|NCT00255593|DRUG|rituximab|
223750750|NCT04713826|DRUG|BAY2586116|160 µg, nasal spray administration.
223603047|NCT02929238|OTHER|Polypropylene Suture Right Side|Suture Description: The suture used in this study will be a sterilized polypropylene suture and individually crossed in the base of the wound. Polypropylene is commonly used for commercially available implanted meshes. The polypropylene suture is intended for single use only and the individual suture will be packaged and purchased sterile.
223750751|NCT04713826|DRUG|Placebo|Placebo matching BAY2586116, nasal spray administration.
223750752|NCT02897674|DIETARY_SUPPLEMENT|Palm olein|two thirds of the 30% fat calories will come from palm olein
223750753|NCT02897674|DIETARY_SUPPLEMENT|Interesterified palm olein|two thirds of the 30% fat calories will come from interesterified palm olein
223603048|NCT02929238|OTHER|Polypropylene Suture Left Side|Suture Description: The suture used in this study will be a sterilized polypropylene suture and individually crossed in the base of the wound. Polypropylene is commonly used for commercially available implanted meshes. The polypropylene suture is intended for single use only and the individual suture will be packaged and purchased sterile.
223603049|NCT05820984|OTHER|SPIRIT checklist plus usual practice|"Peer reviewer will be reminded of the following 10 CONSORT items (including a short description):~Outcomes (12) Sample size (14) Recruitment (15) Allocation implementation (16 c) Blinding (17 a) Data collection methods (18 a) Data collection methods - retention (18 b) Statistical methods (20 a) Population analysed (20 c) Access to data (29)"
223603050|NCT05820984|OTHER|Usual practice|Peer review as it is usual practice at the journal
223750754|NCT02897674|DIETARY_SUPPLEMENT|soybean oil|two thirds of the 30% fat calories will come from soybean oil
223750755|NCT00600938|DRUG|Core Study: Deferasirox|20 mg/kg/day once daily (od) for 2 weeks, followed by 30 mg/kg/day od for 1 week and a subsequent continuation of 40 mg/kg/day
223750756|NCT00600938|DRUG|Core Study: Deferoxamine|50 mg/kg/day to 60 mg/kg/day infused subcutaneously in 8- to 12-hour intervals administered 5 to 7 days/week
223750757|NCT00600938|DRUG|Extension: deferoxamine to deferasirox|40 mg/kg deferasirox once daily administered 30 minutes before taking food.
223750758|NCT00600938|DRUG|Extension: deferasirox to deferoxamine|DFO at a target range of 50 mg/kg/day to 60 mg/kg/day via subcutaneous (sc) infusion lasting a period of 8 to 12 hrs administered for 5 to 7 days per week,
223603051|NCT02123576|DRUG|Pentoxyfylline|
223603052|NCT02123576|DRUG|Placebo|
223603053|NCT02123576|DRUG|AMO Therapy|Albumin, midodrine and octreotide therapy (standard of care for HRS)
223750759|NCT00600938|DRUG|Deferasirox|
223750760|NCT00600938|DRUG|Deferoxamine|
223750761|NCT04894396|DEVICE|Aetrex L2305 Premium Memory Foam Orthotics W/ Metatarsal Support|An Orthotic insole to be inserted into shoes. Features Aetrex Arch Support to help biomechanically align the body \& help prevent common foot pain such as Plantar Fasciitis, Arch Pain and Metatarsalgia. For medium to high arches with forefoot pain, featuring a cupped heel to cushion and stabilize the back of foot and a metatarsal pad to redistribute weight to relieve ball-of-foot discomfort. With 43% more memory foam in the forefoot for those experiencing foot discomfort or fatigue.
223750762|NCT04894396|DEVICE|Aetrex L2300 Premium Memory Foam Orthotics|An Orthotic insole to be inserted into shoes. Features Aetrex Arch Support to help biomechanically align the body \& help prevent common foot pain such as Plantar Fasciitis, Arch Pain and Metatarsalgia. With 43% more memory foam in the forefoot for those experiencing foot discomfort or fatigue.
223750763|NCT01365390|OTHER|Data collection (Retrospective)|For the retrospective part of the study, the parent(s)/ legally acceptable representative(s) of the subjects will be interviewed to collect information on factors potentially related to risk for middle ear diseases. The medical records of the subjects will also be reviewed and all acute otitis media related problems that occurred during the last year prior to enrolment (for subjects aged 1 to \< 6 years) or since birth (for subjects aged \< 1 year) will be recorded in the electronic case report form.
223750764|NCT01365390|OTHER|Data collection (Prospective)|For the prospective part of the study, the enrolled subjects will be followed up for a period of 1 year starting from the consent date, during which the parent(s)/ legally acceptable representative(s) will be asked to bring the subject for a visit each time they notice symptoms of acute otitis media or respiratory tract infection in the subject. In case AOM is diagnosed by the investigator, detailed information on the signs, symptoms, severity, course and treatment will be recorded. The parent(s)/ legally acceptable representative(s) of the subjects will also be required to fill up a parental quality of life questionnaire and an Otitis Media-6 children's quality of life questionnaire.
223750765|NCT03803280|PROCEDURE|ERAS program|ERAS pathway according to the Spanish Via RICA
223750766|NCT04751149|PROCEDURE|Removal of Urinary Catheter|Urinary catheter will be removed in aeseptic conditions. Before the removal a urinary culture will be obtained from the catheter.
223750767|NCT04500184|OTHER|cardiac rehabilitation|rehabilitation performed by professional trainers
223603054|NCT02477189|PROCEDURE|Silicone Block|
223603055|NCT01930721|PROCEDURE|episiotomy|incision angle of episiotomy will be 60 degrees.
223750768|NCT03079323|RADIATION|PART-trial|Elective radiation to the para-aortic lymph nodes 45 Gy / 1.8 Gy
223750769|NCT00855491|PROCEDURE|Phaco|AcrySof Single-Piece IOL
223750770|NCT04056195|DRUG|SKI-O-703|The SKI-O-703 capsules will contain 100 mg of drug substance.
223750771|NCT04056195|DRUG|Placebo oral tablet|Placebo capsules are filled with microcrystalline cellulose.
223750772|NCT05948202|BEHAVIORAL|Pivotal Response Treatment|Group-based parent training to teach parents behavioral strategies based on principles of learning to motivate their child.
223603056|NCT01930721|PROCEDURE|episiotomy|incision angle of episiotomy will be 40 degree before cutting.
223603057|NCT05781464|PROCEDURE|Traditional chest physiotherapy|"Postural drainage: the patient is positioned in postural drainage so that gravity had the maximum effect on the lung segment that needed to be drained, all lung zones are emphasised in positional initiatives for babies.~Percussion is the rhythmic striking of the chest wall with cupped hands for 1 to 2 minutes at a time.~Vibration is performed by placing fingers on the chest wall over the segment being drained and isometrically contracting the forearm and hand muscles to produce a vibratory motion.~Vibration is accomplished either through manual vibratory motion of the therapist's fingers on the infant's chest wall or through the use of a mechanical vibrator ( Foreo vibrator)."
223603058|NCT05781464|PROCEDURE|Prolonged slow expiration technique|The therapist places one hand on the thorax below the suprasternal notch and the other hand over the upper abdomen while the neonate is supine. Both hands will have hypothenar contact with the thorax and abdomen. At the end of the expiratory phase, the therapist places a compression force with both hands. Compression at the end of expiration with hypothenar eminence is kept for 2 or 3 breathing cycles. This technique is repeated several times, with a rest time between applications of about 5 or 10 spontaneous breaths.
223603059|NCT00934128|DEVICE|Vapotherm|Deliver air in and out of the lungs, warmed, filtered for bacteria, and then delivered through the nose using a tube under the nostrils.
223603060|NCT00934128|DEVICE|BIPAP|Air given through a mask, and amount can be set to different levels allowing more air in and out of lungs without using as much effort as regular breathing.
223603061|NCT03811301|DEVICE|BrainConnexion|A 4.4mm by 4.2mm electrode array is placed onto the surface of the motor cortex which is then connected to a miniaturized neural recording microsystem that transmits signals wirelessly to control an external assistive device. Neural signals are recorded at least once every week for 12 months or longer.
223603062|NCT02834247|DRUG|TAK-659|TAK-659 Tablets.
223603063|NCT02834247|DRUG|Nivolumab|Nivolumab intravenous infusion.
223603064|NCT02346461|DRUG|ManNAc|At doses of 3 g and 6 g twice daily for a total dose of 6 and 12 g per day.
223603065|NCT02346461|DRUG|ManNAc|At doses of 6 g twice daily (12 g per day).
223603066|NCT00406601|DRUG|Sorafenib (BAY-43-9006)|800 mg/die orally on a continuous basis
223603067|NCT02750852|PROCEDURE|Total hip arthroplasty, blood loss analysis|Data analysis about blood loss in total hip replacement
223603068|NCT03933813|OTHER|Iron Sucrose|Venofer (Iron Sucrose Injection USP) is a brown, sterile, aqueous, complex of polynuclear iron (III)-hydroxide in sucrose for intravenous use.
223603069|NCT04803266|RADIATION|Internal mammary node irradiation|Regional nodal irradiation including internal mammary node irradiation along with breast or chest wall irradiation after breast-cancer surgery
223603070|NCT04803266|RADIATION|No internal mammary node irradiation|Regional nodal irradiation not including internal mammary node irradiation along with breast or chest wall irradiation after breast-cancer surgery
223603071|NCT02621307|DIETARY_SUPPLEMENT|Salba|
224200176|NCT04392882|BEHAVIORAL|Legume enriched diet group|"* Replacing 1/3 refined rice intake with legumes three times per day~* Vegetable intake at least six units (30-70 g/unit) per day for sufficient dietary fiber intake~* Regular 30-min walk after dinner each day"
224200177|NCT02206100|DRUG|PER977|reversal of edoxaban-induced anticoagulation
224200178|NCT02206100|DRUG|Placebo|Reversal of edoxaban-induced anticoagulation
224200179|NCT02206100|DRUG|enoxaparin|
224200180|NCT00645606|BIOLOGICAL|Rituximab|rituximab :500 mg/m² every 8 weeks during 2 years
224200181|NCT05696665|OTHER|conventional therapy|Patients will be kept on conventional therapy and no added drugs will be given
224200182|NCT05696665|DRUG|Saffron and Chamomile|Patients will be given saffron and chamomile in capsule formulation twice daily
223603072|NCT02621307|DIETARY_SUPPLEMENT|Flax|
223603073|NCT02621307|DIETARY_SUPPLEMENT|Control|
223603074|NCT00389844|BEHAVIORAL|Exercise Trainer component of the Exercise Plus Program|With the exception of the routine care group, the exercise trainers visited each of the participant in their homes twice a week for two months, once a week for four months, and once a month for six months.
223603075|NCT00389844|BEHAVIORAL|Plus component (motivation) of the Exercise Plus Program|Motivation only
224200183|NCT05696665|DRUG|Crocin and Apigenin|Active ingredients of saffron(Crocin) and Chamomile(Apigenin) will be given in capsule formultaion once daily
223603076|NCT00389844|BEHAVIORAL|Exercise Plus Program (exercise + motivation)|Exercise plus motivation
223603077|NCT00799266|DRUG|Zoledronic acid|intravenous infusion
223603078|NCT00799266|DRUG|Placebo|intravenous infusion
223603079|NCT01966822|DRUG|Dolutegravir, 50mg every 24 hours|Dolutegravir, 50mg every 24 hours
223603080|NCT01966822|DRUG|Protease Inhibitor/ritonavir|Protease Inhibitor/ritonavir
223603081|NCT02669342|DEVICE|Radiance™ Clear Sharklet® Silicone Foley Catheter|
223603082|NCT02669342|DEVICE|Silicone Foley Catheter|
223603083|NCT05508022|BEHAVIORAL|Breathing exercise|Before the enema is applied, breathing exercises will be applied to the participants in the intervention group.
223603084|NCT02883374|DRUG|Chidamide|
223603085|NCT02535325|RADIATION|3-Dimensional Conformal Radiation Therapy|Undergo 3-D conformal RT
224200184|NCT00848965|DRUG|Fluticasone propionate|Corticosteriod, with anti-inflammatory effects
224200185|NCT00848965|DRUG|Placebo|Placebo comparator
224200186|NCT03710824|DRUG|Nintedanib|diagnosed IPF patients initiating treatment with nintedanib
224200187|NCT04898517|PROCEDURE|Pancreaticoduodenectomy with the CONDUCTJE-ST technique|"The termed technique connexion pancreatic duct to the jejunum stented (CONDUCTJE-ST) in pancreaticoduodenectomy is a novel technique, modification of the pre-existing ones, whose effectiveness lies in the fact that it is not an anastomosis in the strict sense but rather a simple connection for restoring pancreatic juice flow from the pancreatic remnant towards the intestine."
224200188|NCT04661917|DRUG|BAY2327949|60 mg of BAY2327949 (2 tablets of 30 mg, orally) once daily for 28 days.
223750773|NCT01034449|OTHER|allogeneic transplant|ex vivo amplification of a unit of placental blood for transplantation
223750774|NCT03054662|OTHER|Education|Education of patients and caregivers about haemophilia and carriers of haemophilia.
223750775|NCT03054662|DIAGNOSTIC_TEST|Improve biological diagnosis and follow-up of haemophilia|train the laboratory to the diagnosis ans follow-up un haemophilia
224200189|NCT04661917|DRUG|Placebo|Matching placebo orally once daily for 28 days.
224200190|NCT02329834|DRUG|Fursemide Injection Solution for subcutaneous administration (80 mg)|Furosemide Injection Solution, 10mL of undiluted buffered furosemide solution (8mg/mL)
224200191|NCT02329834|DRUG|Furosemide Injection, USP|Furosemide Injection, USP (10mg/mL), 80 mg by intravenous administration.
224200192|NCT02475109|DRUG|PAN-90806 Ophthalmic Solution|
224311340|NCT06551415|DRUG|Dabigatran Etexilate 150mg|100 CVT patients will receive dabigatran 150mg Bid for 6 months. We will assess the Proportion of subjects who have partial or complete venous recanalization by Day 180 the rate of drug hemorrhagic complications using the PLATO bleeding definition, and the rates of patients who achieved a favorable outcome with (mRS = 0-2) after one week and after 180 days in a face-to-face interview in the outpatient clinic, Proportion of subjects with recurrent venous thromboembolism (any thrombosis at a new site, including cerebral venous thrombosis in a separate location from the index event) at Day 180 or the end of anticoagulation, whichever is sooner, rates of a composite of pulmonary embolism, DVT, myocardial infarction, and death due to vascular events after 180 days of follow-up, the MoCA, HIT-6 by 180 days, the rate of treatment-related adverse effects assessed by a follow-up questionnaire
223603086|NCT02535325|DRUG|Cisplatin|Given IV
223603087|NCT02535325|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
223603088|NCT02535325|DRUG|Methoxyamine|Given PO
223603089|NCT02535325|DRUG|Methoxyamine Hydrochloride|Given PO
223603090|NCT02535325|DRUG|Pemetrexed|Given IV
223603091|NCT02535325|DRUG|Pemetrexed Disodium|Given IV
223603092|NCT01779232|DRUG|Danazol|100 mg day for 4 monthh in women with diagnosed endometriosis before IVF
223603093|NCT01779232|DRUG|placebo|administered daily like the active comparator
223603094|NCT00954993|DRUG|Vaniprevir|Period 1: Vaniprevir 600 mg twice daily on Days 1-3 and a single dose of Vaniprevir 600 mg on Day 4. Period 2: Vaniprevir 300 mg twice daily on Days 1-3 and a single dose of Vaniprevir 300 mg on Day 4. There was at least a 30-day (up to approximately 140-day) washout interval between periods 1 and 2.
223603095|NCT03112265|BEHAVIORAL|Modular Approach to Therapy for Children with Anxiety, Depression, Trauma, and Conduct Problems|MATCH-ADTC is designed for children aged 6-15. Unlike most evidence-based treatments (EBTs), which focus on single disorder categories (e.g., anxiety only), MATCH is designed for multiple disorders and problems encompassing anxiety, depression, post-traumatic stress, and disruptive conduct, including the conduct problems associated with ADHD. MATCH is composed of 33 modules-i.e., specific treatment procedures derived from decades of research on EBTs. The various modules can be organized and sequenced flexibly to tailor treatment to each child's characteristics and needs.
223603096|NCT03112265|OTHER|Monitoring and Feedback System|For each child, the web-based MFS system provides weekly monitoring of the MATCH modules used and the child's treatment response, in two forms (a) changes on the Behavior and Emotions Survey and (b) changes in severity of the top treatment concerns identified by youths and caregivers. At the end of treatment, the MFS provides a complete record of modules used, and child treatment response, across all the weeks of treatment.
223603097|NCT03112265|BEHAVIORAL|Treatment as usual|Treatment in the UC condition will use the procedures therapists and their supervisors consider appropriate and believe to be effective.
223603098|NCT04548466|DEVICE|PEP bottle|
223603099|NCT02227004|DIAGNOSTIC_TEST|Perform MRI in patients with pacemaker or ICD|Perform MRI in patients with pacemaker or ICD
223603100|NCT05482828|DRUG|JGT (Jaeumgeonbi-Tang) tablet|JGT tablet (composed of 19 herbs), 24 g daily (single dose=8 g), t.i.d. for 28 days
223750776|NCT03054662|DRUG|Implement haemostatic non substitutive care of haemophilia|Implement the use of DDAVP and antifibrinolytics in patients with haemophilia and symptomatic carriers
223750777|NCT03054662|OTHER|Implement non haemostatic care of haemophilia|Implement regular physiotherapy, develop dental care, promote the regular use of pain killers
223750778|NCT02853240|PROCEDURE|Muscle biopsy|A biopsy (specifically done for the study) of a muscle that has already been injected with botulinum toxin before inclusion of the patient in the study will be performed, taken during a planned surgery (for tendon transfer or muscle lengthening). A biopsy of a muscle that has never been injected with botulinum toxin may be performed during surgery. No biopsy will be made on a member that would not require surgery. Thus sampling will be conducted on a muscle requiring a surgery: 2 to 3 millimeters will be taken on 10 mm muscle before transfer or lengthening.
224200193|NCT02129257|DRUG|AFLIBERCEPT|
223603101|NCT05482828|DRUG|Placebo tablet|Corn starch tablet, 24 g daily (single dose=8 g), t.i.d. for 28 days
223603102|NCT01061359|DRUG|Epirubicin: Observational Study|Observational: Chemotherapy
223750779|NCT04794790|DRUG|Buprenorphine/naloxone|Buprenorphine/Naloxone induction via a standard dose protocol
223750780|NCT05797493|DRUG|Atezolizumab|Upfront chemo-immunotherapy
223750781|NCT00549562|DRUG|Paliperidone ER|Starting dose is 3 mg per day. Can be titrated up to a maximum dose of 9 mg per day.
224200194|NCT02129257|DRUG|Irinotecan|
224200195|NCT02129257|DRUG|5-Fluorouracil|
224200196|NCT02129257|DRUG|Folinic Acid|
224200197|NCT03146819|DEVICE|iTotal PS Knee Replacement System|Total Knee Replacement systems (Patient Specific)
224200198|NCT03146819|DEVICE|Off-the-Shelf Knee Replacement System|Total Knee Replacement systems (Off-the-shelf)
224200199|NCT02041182|BEHAVIORAL|Pre-Visit Questionnaire|
224200200|NCT06568757|OTHER|Wet Cupping|Wet cupping therapy will be applied once using disposable plastic vacuum cups to a total of 4 areas, which are recommended areas for headaches; cervical spine C7 (DU14 acupuncture point), bilateral T2-4 lateral spine (BL41-42 acupuncture point) and suboccipital region (FengFu DU-16 acupuncture point).
224200201|NCT06568757|OTHER|No intervention|No treatment will be applied to individuals and the routine medical treatment program will continue.
224200202|NCT02406066|DRUG|metyrapone & oxazepam|6 subjects will receive active study drug (a low dose combination of metyrapone \& oxazepam) and 2 subjects will receive placebo.
224200203|NCT02406066|DRUG|metyrapone & oxazepam|6 subjects will receive active study drug (a medium dose combination of metyrapone \& oxazepam) and 2 subjects will receive placebo.
224200204|NCT02406066|DRUG|metyrapone & oxazepam|6 subjects will receive active study drug (a high dose combination of metyrapone \& oxazepam) and 2 subjects will receive placebo.
224200205|NCT02406066|DRUG|Placebo|Each cohort will have 2 subjects receiving placebo
223603103|NCT01182155|PROCEDURE|Exhaled Breath Sampling|Standard of care
223603104|NCT00062179|DRUG|carboplatin|Carboplatin: dosed at an AUC of 6 by the Calvert Formula 3 cycles of carboplatin 21 days apart
223603105|NCT00062179|DRUG|celecoxib|Celecoxib: 400 mg po BID celecoxib 3-7 days before first dose of chemotherapy
223603106|NCT00062179|DRUG|paclitaxel|Paclitaxel: 225 mg/m2 by 3-hour intravenous infusion 3 cycles of paclitaxel 21 days apart
223603107|NCT00062179|OTHER|Placebo|placebo 3-7 days before first dose of chemotherapy
223603108|NCT04230915|OTHER|Intraoperative nerve monitoring|This group will determine as those who were administered 0.3 mg/kg rocuronium,
223603109|NCT02930902|DRUG|Gemcitabine Hydrochloride|Given IV
223603110|NCT02930902|OTHER|Laboratory Biomarker Analysis|Correlative studies
223603111|NCT02930902|DRUG|Nab-paclitaxel|Given IV
223603112|NCT02930902|DRUG|Paricalcitol|Given IV
223603113|NCT02930902|BIOLOGICAL|Pembrolizumab|Given IV
223603114|NCT02930902|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgical resection of tumor
223603115|NCT03488966|BEHAVIORAL|Mindfulness Based Eating and Awareness Training|Eight sessions of Mindfulness Based Eating and Awareness Training (MB-EAT) will be delivered once per week over the course of 8 weeks, following an introductory session. The treatment uses general mindfulness meditation and eating meditation to help participants bring greater awareness and understanding to their relationship with food. Homework consists of weekly mindfulness exercises.
223603116|NCT00629863|DRUG|cisplatin|
223603117|NCT00629863|DRUG|fluorouracil|
223603118|NCT00629863|OTHER|questionnaire administration|
223603119|NCT00629863|PROCEDURE|diagnostic endoscopic procedure|
223603120|NCT00629863|PROCEDURE|neoadjuvant therapy|
223603121|NCT00629863|PROCEDURE|quality-of-life assessment|
223603122|NCT00629863|PROCEDURE|therapeutic conventional surgery|
223603123|NCT00629863|PROCEDURE|therapeutic endoscopic surgery|
223603124|NCT00629863|PROCEDURE|ultrasound imaging|
223603125|NCT00629863|RADIATION|radiation therapy|
223603126|NCT00629863|RADIATION|radioisotope therapy|
223603127|NCT03571126|DRUG|Olanzapine|Dexamethasone (10mg/d) (Days1-3) Tropisetron (4mg or 4.48mg or 5mg /d) (Days1-3) Olanzapine (10mg/d) (Days1-4)
223603128|NCT03571126|DRUG|Placebos|Dexamethasone (10mg/d) (Days1-3) Tropisetron (4mg or 4.48mg or 5mg /d) (Days1-3) Placebos (Days1-4)
223603129|NCT04094974|DEVICE|ANSiscope|Heart rate variability will be assessed using ansiscope before surgery
223603130|NCT04724863|PROCEDURE|Angioscan|"The study procedure foresees to take images during a deep breath as well as deep exhalation. This second measurement does not require the administration of an additional amount of contrast material. However, the exposure time to ionising radiation is doubled. The examination uses helical acquisition in fast mode. The duration of the helix is of the order of 2 seconds in the inspiration phase, then there is a delay of 5 seconds of machine time (half-turn) and again 2 seconds of exposure in the expiration phase, i.e. 4 seconds of actual exposure to ionizing radiation, the time of image taking and 9 seconds the total time of the examination."
223603131|NCT06390683|OTHER|Rewilding|Yards of the assisted living centers will be modified with berry bushes, fruit trees, perennial yard plants, meadow flowers, cultivation boxes, organic mulch materials, decaying deadwood, leaf compost and organic plant growing media with high microbial diversity.
223603132|NCT04951752|DRUG|Ropivacaine injection|Transmuscular quadratus lumborum block - active
223603133|NCT02772744|DRUG|Daclatasvir 60 MG Oral Tablet [Daklinza]|Daclatasvir (60 MG) is a potent, pan-genotypic inhibitor of the HCV NS5A protein
223603134|NCT02772744|DRUG|Sofosbuvir 400 MG Oral Tablet [Sovaldi]|Sofosbuvir (400 MG) is a nucleotide analogue HCV NS5B polymerase inhibitor
223603135|NCT02772744|DRUG|Ribavirin Oral Product|Ribavirin (twice-daily) dosed according to body weight (\<75 kg, 1000 mg daily; ≥75 kg, 1200 mg daily)
223603136|NCT04046146|DRUG|Indocyanine Green|A trained physician will inject 0.1 ml of Indocyanine Green into the web spaces of the hands in both upper extremities. Subjects may have up to five study visits to confirm feasibility, safety, and reproducibility.
223603137|NCT04046146|DEVICE|MultiSpectral Imaging System|Once the Indocyanine Green is injected, the contrast is expected to fluoresce underneath the MultiSpectral Imaging System. Multispectral video and still images will be recorded at the study visits.
223603138|NCT04364295|DEVICE|Spinal Surgery with SeaSpine product|Implanted with SeaSpine spinal or orthobiologic product
223603139|NCT01669772|DRUG|DA-9701 and placebo|Prescribe 30mg of DA-9701(motilitone) t.i.d for 1 week and then crossover to placebo.
223603140|NCT01669772|DRUG|Placebo and DA-9701|Administer placebo 1 tablet t.i.d for 1 week. After 1 week of washout, crossover to 30mg of DA-9701 t.i.d. for 1 week.
223603141|NCT01361100|DEVICE|Oncoral® test|The patient rinses his oral cavity for 2 minutes. Then he screws lid back onto a beaker. The investigator holds the beaker straight so that the end of the aspiration mouth is dipped into the liquid. Then, the investigators takes 2 tubes and pushes them one after the other down on the opening of the beaker. The tubes should fill by themselves. The tubes can't be kept more than eleven days and are send to the Clinident Institute for the analysis.
223603142|NCT02363621|DRUG|Ranibizumab 0.3 mg|Ranibizumab 0.3 mg Patient will receive intravitreal injection of Ranibizumab 0.3 mg
223603143|NCT02363621|DRUG|Aflibercept 2.0 mg|Patient will receive intravitreal injection of Aflibercept 2.0 mg
223603144|NCT00003727|BIOLOGICAL|filgrastim|
223603145|NCT00003727|BIOLOGICAL|recombinant interferon alfa|
223603146|NCT00003727|BIOLOGICAL|sargramostim|
223603147|NCT00003727|BIOLOGICAL|therapeutic autologous lymphocytes|
223603148|NCT00003727|DRUG|carmustine|
223603149|NCT00003727|DRUG|cyclophosphamide|
223603150|NCT00003727|DRUG|etoposide|
223603151|NCT00003727|DRUG|gemcitabine hydrochloride|
223750782|NCT06281847|GENETIC|CCTx-001|Frozen CAR T-cells suspensions in media containing dimethyl sulfoxide (DMSO)
223750783|NCT03425929|DRUG|Oxytocin|Intranasal administration, 24 international units (IU) oxytocin.
223750784|NCT03425929|DRUG|Placebo|The placebo nasal sprays contain identical ingredients except for the peptide itself.
223750785|NCT06469008|DRUG|BL-B16D1|Administration by intravenous infusion for a cycle of 3 weeks.
223750786|NCT05093231|DRUG|Pembrolizumab|Pembrolizumab is a highly selective immunoglobulin G4-kappa humanised monoclonal antibody against Programmed cell death protein 1 (PD-1) receptor. It was generated by grafting the variable sequences of a very high-affinity mouse antihuman PD-1 antibody onto a human IgG4-kappa isotype with the containing a stabilizing Serine 228 to Proline Fc mutation.
223750787|NCT05093231|DRUG|Olaparib|Olaparib is a potent inhibitor of polyadenosine 5'diphosphoribose polymerase (PARP) developed as a monotherapy as well as for combination with chemotherapy, ionising radiation and other anti-cancer agents including novel agents and immunotherapy.
224200206|NCT01550354|DRUG|administration of propofol|intravenous administration of propofol 2 mg/kg before intubation
224200207|NCT01550354|DRUG|administration of alfentanil|intravenous administration of alfentanil 14 μg/kg before intubation
224200208|NCT01550354|DRUG|administration of rocuronium|Intravenous administration of rocuronium 0.3 mg/kg before intubation
224200209|NCT02525575|BEHAVIORAL|Project Life Force Group Treatment|"PLF, a 12-session, group psychotherapy intervention, combines Dialectical Behavioral Therapy (DBT) skill based and psychoeducational approaches, to enhance suicide safety planning development and implementation. Veterans revise their plans over several weeks while learning distress tolerance, emotion regulation, and friendship building/interpersonal skills to incorporate into their safety plans and also receive lessons on gun safety and minimizing access to lethal means. Sessions are augmented with 1) training in the use of a suicide safety planning mobile App to promote accessibility and maximize implementation, and 2) didactic information to bolster recovery, including fostering improved connection with the treatment team, and Veteran's family. Importantly, the group format mitigates loneliness and fosters increased belongingness, both key risk factors for suicide."
224200210|NCT03825887|DRUG|Nalbuphine|"Nalbuphine (Group B): Patients will be started on the same dose of 10 mcg / kg / hour as a background and 10mcg bolus dose with lock-out 20 minutes having the maximum allowed dose up to 40mcg /kg/ hour.~Any patient will continue to complain of pain rating 4-6 on VAS after reaching the maximum designated dose (which is 40 mcg/kg/hour) will be transferred to the ICU for close monitoring according to the internal hospital guidelines and getting him/her out of the study.~There is no drug shifting at any part of the study."
224200211|NCT03825887|DRUG|Morphine|"morphine (Group A): Patients will be started on the same dose of 10 mcg / kg / hour as a background and 10mcg bolus dose with lock-out 20 minutes having the maximum allowed dose up to 40mcg /kg/ hour.~Any patient will continue to complain of pain rating 4-6 on VAS after reaching the maximum designated dose (which is 40 mcg/kg/hour) will be transferred to the ICU for close monitoring according to the internal hospital guidelines and getting him/her out of the study.~There is no drug shifting at any part of the study."
223750788|NCT05644262|DRUG|T2:C100|"The active study intervention, T2:C100, is an oral combination of tetrahydrocannabinol (THC) and cannabidiol (CBD) in a digestible oil. T2:C100 is a full spectrum oral solution with five non-reactive ingredients: delta-9-tetrahydrocannabinol (THC), cannabidiol (CBD), a pharmaceutical grade medium chain triglyceride (MCT) oil, and two flavoring agents (lemon and peppermint).~During the double-blind treatment period, participants will receive 1mL study drug (T2:C100) twice daily for Baseline - Day 7 (approximately 1 week), and then will increase to 2mL study drug twice for the remainder of the double-blind treatment period (Day 7 - Week 12 (approximately 11 weeks)).~Participants who enter the Open Label Extension will receive 1mL study drug (T2:C100) twice daily for Week 12 - Week 13 (approximately 1 week), and will then increase to 2mL study drug twice daily for the remainder of the Open Label Extension (Week 13 - Week 26 (approximately 23 weeks))."
223750789|NCT05644262|DRUG|Placebo|"Matching placebo in a digestible oil. The placebo contains only three non-reactive ingredients: medium chain triglyceride (MCT) oil and two flavoring agents (lemon and peppermint).~During the double-blind treatment period, participants will receive 1mL placebo twice daily for Baseline - Day 7 (approximately 1 week), and then will increase to 2mL placebo twice for the remainder of the double-blind treatment period (Day 7 - Week 12 (approximately 11 weeks))."
223750790|NCT05366803|BEHAVIORAL|Physical Activity|The PA intervention will consist of a multimodal activity program of aerobics, balance, strength, flexibility. The intervention will involve encouraging participants to increase all forms of PA throughout the day and to decrease sedentary time, such as sitting. This may include activities such as leisure sports, gardening, use of stairs instead of escalators, leisurely walks with friends, and less use of remote control devices.The intervention is conducted primarily by mail with website support and resources available.
223750791|NCT06914271|COMBINATION_PRODUCT|Kendall Exercise|The Kendall Exercises focus on correcting posture, strengthening the core, and re-educating muscles to improve spinal alignment and reduce pain .These exercises primarily target specific muscles and joint actions to help patients regain their range of motion.
224200212|NCT03349203|DRUG|Icotinib|Patients with EGFR-mutant stage IIIB or oligometastasis Non-small Cell Lung Cancer which can be potentially radical treated by surgery are arranged to receive Icotinib with a dose of 125 mg three times per day by mouth for 8 weeks as neoadjuvant therapy before surgery and 2 years as adjuvant therapy or till progressive disease or unaccepted toxicity.
223603152|NCT00003727|DRUG|melphalan|
223603153|NCT00003727|PROCEDURE|bone marrow ablation with stem cell support|
223603154|NCT00003727|PROCEDURE|in vitro-treated peripheral blood stem cell transplantation|
223603155|NCT00002357|DRUG|HBY 097|
223603156|NCT00002357|DRUG|Zidovudine|
223603157|NCT04279535|DRUG|Topical Ascorbic Acid|Twice daily application of 300 microliters of 30% ascorbic acid solution with a small cuticle brush.
223603158|NCT04564157|DRUG|Carboplatin|"Structure: The cis-diamino (cyclobutan-1, 1 dicarboxilate) plating. Stability: 24 hours at ambient temperature in 5% glucose, glucosaline or physiologic saline. It is recommended not to dilute with chlorinated solutions for this could affect the carboplatin.~Route of administration: Intravenous infusion.~Guidelines of Carboplatin administration: According to the standard of each center."
223603159|NCT04564157|DRUG|Paclitaxel|"Structure: A diterpene whose composition is: 5b, 20-epoxy-1, 2a, 4,7b, 10b, 13a-hexa-hidroxytax-11-en 9 one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)- N-benzoyl-3-phenylisoserine.~Stability: Concentrations of 0.3-1.2 mg/ml in 5% dextrose or normal saline have demonstrated chemical and physical stability for more that 27 hours at ambient temperature (25ºC approximately). The intact vial must be stored between 15º and 25ºC.~Guidelines on Paclitaxel administration: Paclitaxel must be administered by infusion over 3 hours in dextrose (D5W) or normal saline (NS). The concentration must not exceed 1.2 mg/ml."
223603160|NCT04564157|DRUG|Nivolumab|"Structure: Nivolumab is a soluble protein consisting of 4 polypeptide chains.~Route of administration: Intravenous infusion.~Product Description: Nivolumab (BMS-936558-01) Injection drug product is a sterile, non-pyrogenic, single-use, isotonic aqueous solution formulated in 10 mg/ml.~Storage Conditions: It must be stored at 2 to 8 degrees Cº and protected from light and freezing.~Guidelines: The administration of nivolumab infusion must be completed within 24 hours of preparation.The dose of Nivolumab for the adjuvant treatment is 360 mg administered as an intravenous infusion over 30 minutes every 3 weeks (+/-3 days) for 4 cycles.~For the maintenance adjuvant treatment the dose is nivolumab 480 mg Q4W (+/-3 days) over 30 minutes for 6 months (6 cycles).~Subjects should be carefully monitored during nivolumab administration to follow infusion reactions.~Doses of nivolumab may be interrupted, delayed, or discontinued depending on how well the subject tolerates the treatment."
223750792|NCT06914271|COMBINATION_PRODUCT|Kabat Exercises|The principle of the Kabat exercises is based on a series of neuromuscular facilitation techniques that emphasize dynamic movement patterns, flexibility, and coordination to enhance functional mobility and alleviate pain.
223750793|NCT06672445|DRUG|ARO-ATXN2 Injection|single dose of ARO-ATXN2 by intrathecal (IT) administration
223750794|NCT06672445|DRUG|Placebo|calculated volume to match active treatment by IT administration
223750795|NCT05410873|DRUG|MitoQ Compound|Mitoquinol mesylate
223750796|NCT05410873|DRUG|Placebo|Placebo
223750797|NCT05903378|OTHER|Relational touch practice|Relational touch practice during the first bedside session. Touch in care aims to improve the patient's perception of potentially painful or anxiety-provoking acts of care. It is based on techniques of skin contact, developing and deepening.
223750798|NCT06783309|DRUG|CNP-103|CNP-103
223750799|NCT06783309|DRUG|Placebo|0.9% sodium chloride for injection
223750800|NCT06774027|PROCEDURE|Specimen collection|Blood specimens will be collected during regular clinical visits for correlative and exploratory analysis
223750801|NCT06774027|DRUG|Non-Investigational Antibody-Drug Conjugates (ADC)|ADC given under usual care for the treatment of cancer
223750802|NCT06774027|OTHER|Medical Record Review|Prospective and retrospective medical chart reviews will be conducted to obtain data for analysis.
223750803|NCT06810934|BIOLOGICAL|CoTend-BXBB (SARS2-30404)|Ad35-vectored SARS-CoV-2 RBD (XBB.1.5) vaccine
223750804|NCT06810934|BIOLOGICAL|CoTend-s3BXBB (SARS2-17032)|Ad35-vectored s3-SARS-CoV-2 RBD (XBB.1.5) vaccine
223750805|NCT06810934|BIOLOGICAL|Placebo|Sterile sodium chloride 0.9% for injection, preservative free
223750806|NCT07174232|OTHER|Russian current and muscle energy techniques|The participants will have the electrodes placed on their biceps and triceps muscles for the Russian current treatment and were positioned comfortably, typically in a supine or seated position, depending on the muscle group being targeted. This positioning ensured stability and allowed for the effective application of the MET .
223750807|NCT07174232|OTHER|Russian Current|The participants will have the electrodes placed on their biceps and triceps muscles for the Russian current treatment. For the biceps, one electrode will be placed on the middle of the muscle, about halfway between the shoulder and elbow, while the second electrode will be placed slightly above it, closer to the shoulder
223750808|NCT07180537|BEHAVIORAL|Creating Health Online Course|Immediate access to an online audio and video course with education about strategies to grow and improve resilience, diet quality, exercise, stress reduction and self-care
223750809|NCT07180537|BEHAVIORAL|Delayed access to Creating Health Online Course|Delayed access (12-week delay) to an online audio and video course with education about strategies to grow and improve resilience, diet quality, exercise, stress reduction and self-care
223750810|NCT07181317|OTHER|Questionnaires|"Assessment of stress and anxiety and quality of life after myocardial infarct:~* Stress score: Perceived Stress Scale-4 (PSS-4)~* Anxiety score: Generalized Anxiety Disorder-7 (GAD-7)~* Depression score: Patient Health Questionnaire-9 (PHQ-9)~* Quality of life scores: European Quality of Life-5 Dimensions (EQ-5D) and 12-Item Short-Form General Health Survey (SF-12)"
223750811|NCT07181317|OTHER|Major events|Collection of information related to major events occurring since inclusion in the WAMIF study
223750812|NCT07179731|PROCEDURE|subcostal transversus abdominis plane block|Under ultrasound guidance, 30 ml of bupivacaine is injected along the fascia of transversus abdominis muscle.
223750813|NCT07179731|PROCEDURE|External Oblique Intercostal Plane Block|Under ultrasound guidance, 30 ml of bupivacaine is injected between the fascias of external oblique and intercostal muscles.
223750814|NCT07179731|PROCEDURE|external oblique intercostal plane block and subcostal transversus abdominis plane block combination|The combination of the two blocks will be applied in 15 ml of volume for each.
223750815|NCT02485912|BIOLOGICAL|ChAd3-EBO Z|This is a viral vectored vaccine using a chimpanzee adenovirus as a vector encoding a Zaire strain Ebola glycoprotein
223750816|NCT02485912|BIOLOGICAL|MVA-EBO Z|This is a viral vectored vaccine using a modified vaccinia Ankara virus as a vector encoding a Zaire strain Ebola virus glycoprotein
223750817|NCT02674178|PROCEDURE|Invitro fertilization|"All participants underwent long protocol. Daily SC injection of Triptorelin 0.1 mg started at day 21 of the cycle prior to stimulation cycle and continued till the day of hCG injection. Gn stimulation started in a starting dose of 150-300 IU/day depending on patients age and previous gonadotropin response. then the dose was adjusted according to ovarian response monitored by serum E2 and ultrasound evaluation. All patients were followed up by Transvaginal ultrasound scan daily or on alternate days~Triggering by HCG 10000 IU IM when at least 2 follicles reached a mean diameter of 18 mm \[18\]~Ovum pick-up (OPU) was done 34-36 hours after hCG injection Transfer of cleaving embryos was done on day 3 after oocyte retrieval"
223750818|NCT06075485|OTHER|Ketocal|ketogene diet
223750819|NCT01331148|DRUG|Vitamin D|10,000 IU/caplet, patients receiving 240,000 IU to 600,000 IU cumulative Vitamin D dose based on weight.
223750820|NCT01331148|OTHER|Placebo|placebo with daily calcium/Vitamin D soft chews
223603161|NCT06164665|DRUG|Pioglitazone 15mg|Pioglitazone (PIO) will be administered as a 15 mg oral dose per day for 5 days
223603162|NCT06164665|OTHER|Placebo|100% microcrystalline cellulos
223603163|NCT03012048|DEVICE|Silver-impregnated ceramic tablet|"A silver-impregnated ceramic disk used for drinking water treatment that was developed by engineers at the University of Virginia. When the ceramic disk is placed in a household water storage container, silver diffuses through the porous ceramic into the water at a release rate that is effective for continual disinfection of waterborne pathogens while remaining below the silver drinking water standard. The disk is effective for daily treatment of 10 to 15 liters for at least six months.~This intervention was removed from the study in July 2017 (approximately at 1 year of follow-up)."
223603164|NCT03012048|DEVICE|Silver-impregnated ceramic water filter|"Silver-impregnated ceramic water filter are well-developed, tested, and widely-used devices. In addition to mechanically removing pathogens, the filter is treated with silver to reduce live pathogens that pass through the filter and to provide residual disinfectant to reduce risk of recontamination after treatment.~This intervention was replaced with ceramic filters without silver in Dec 2017 (approximately at 1.5 years of follow-up)."
223603165|NCT03012048|DEVICE|Safe-storage water container|The safe-storage water containers used in this study are plastic buckets with a spigot, purchased locally.
223603166|NCT06114888|DIAGNOSTIC_TEST|MeMed BV + Usual Care|We will aim to have blood drawn for MeMed BV testing within 24 hours of the first dose of IV antibiotics. We will then aim to have test results back within 24 hours of sampling.
223603167|NCT06114888|OTHER|Usual Care Alone|Usual care can involve oxygenation support, ventilatory support, intravenous fluids, and antibiotics, or any combination of these.
223603168|NCT05873998|DIAGNOSTIC_TEST|Slow pressure-volume curve|Patients will be sequentially subjected to a slow pressure-volume curve and a lung recruitment maneuver
223603169|NCT06532279|OTHER|Best Practice|Receive usual symptom management
223603170|NCT06532279|PROCEDURE|Biospecimen Collection|Undergo collection of blood, serum, and/or plasma samples
223603171|NCT06532279|DRUG|Cisplatin|Given cisplatin
223603172|NCT06532279|PROCEDURE|Computed Tomography|Undergo CT
223603173|NCT06532279|RADIATION|Image Guided Radiation Therapy|Undergo image-guided radiation therapy
223603174|NCT06532279|RADIATION|Intensity-Modulated Radiation Therapy|Undergo intensity-modulated radiation therapy
223603175|NCT06532279|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223603176|NCT06532279|DRUG|MnSOD Mimetic BMX-001|Given SC
223603177|NCT06532279|DRUG|Placebo Administration|Given SC
223603178|NCT06532279|OTHER|Questionnaire Administration|Ancillary studies
223603179|NCT04784143|DRUG|Midomafetamine|120 mg midomafetamine HCl followed by a supplemental dose of 60 mg
223603180|NCT04784143|BEHAVIORAL|Psychotherapy|Manualized psychotherapy performed by therapist team
223603181|NCT05484739|OTHER|Water Spray|Participants will receive water spraying on their body throughout the climate chamber exposure.
223603182|NCT05484739|OTHER|Fan|Participants will be exposed to a fan throughout the climate chamber exposure.
223603183|NCT05484739|OTHER|Water Spray and Fan|Participants will receive both water spraying and a fan throughout the climate chamber exposure.
223603184|NCT05484739|OTHER|Control|Participants will NOT receive either water spray or a fan exposure.
223603185|NCT03974945|DEVICE|Passive-elastic prosthetic foot|The investigators will measure the biomechanics (motion, forces, and muscle activity) and metabolic rates while subjects walk using their own passive-elastic prosthesis with and without visual feedback of peak propulsive force targets.
223603186|NCT03974945|DEVICE|Powered ankle-foot prosthesis|The investigators will measure the biomechanics (motion, forces, and muscle activity) and metabolic rates while subjects walk using a battery-powered ankle-foot prosthesis with and without visual feedback of peak propulsive force targets.
223603187|NCT06794619|DIETARY_SUPPLEMENT|Placebo|Placebo
223603188|NCT06794619|DIETARY_SUPPLEMENT|Dietary Supplement with actives|Dietary Supplement containing probiotic and prebiotic ingredients
223603189|NCT06507943|BEHAVIORAL|Promotora Home Visit|For each participating family, Promotora home visits will be scheduled 6-8 weeks apart, with in-person or virtual visits conducted per the family's preference. The visits will begin with a survey which will evaluate concerns related to asthma for the child and the family, including their asthma control (via the ACT), their home environment (via screening for environmental exposures), and quality of life for the child. These surveys will be available in both online or physical forms for potential connectivity concerns, and Promotoras will have IPads for the online forms. The Promotoras, who have received specialized asthma training, will then address concerns raised by families, using the Clinical Pathway which will have resources for asthma-related concerns that are raised.
223603190|NCT06184503|DRUG|Velmanase Alfa|Lamzede® (velmanase alfa, henceforth referred to as Lamzede) is a recombinant human lysosomal alpha-mannosidase product developed as an intravenous enzyme replacement therapy (ERT) for the treatment of alpha-mannosidosis.
223750821|NCT01156285|OTHER|Filling in a patient questionnaire|Filling in a patient questionnaire
223750822|NCT03228134|DRUG|Ke Chuan Liu Wei Granule|Traditional Chinese Medicine
223603191|NCT03274414|DRUG|Cisplatin|Cisplatin should be administered on day 1 (+/- 3 days) of the start of radiotherapy and then every 3 weeks (unless there is a delay for safety concerns such as neutropenia) for a total of 3 cycles. 100 mg/m\^2 (dose reductions after the first cycle allowed for toxicity)
223750823|NCT03228134|DRUG|Yang He Ping Chuan Granule|Traditional Chinese Medicine
223750824|NCT03228134|OTHER|Ke Chuan Liu Wei Granule placebo|Placebo
223750825|NCT03228134|OTHER|Yang He Ping Chuan Granule placebo|Placebo
223750826|NCT00864474|DRUG|CELSENTRI® Tablets|"CELSENTRI ® Tablets 150mg, depending on the Investigator prescription. Frequency and duration are according to Package Insert as follows. The usual adult dosage is 300 mg twice daily. Maraviroc must be used in combination with other anti-HIV drugs. The dosage may be adjusted according to co-administered medical products. Maraviroc can be taken with or without food."
223750827|NCT05508113|OTHER|ozone autohemotherapy|After autologous blood is mixed with ozone in vitro, the blood is injected into the patient through intravenous infusion
224200213|NCT05381025|DIETARY_SUPPLEMENT|Kava (Piper methysticum) extract|Each dose (3 capsules) contains kavalactones (225 mg) and silicified microcrystalline cellulose.
223750828|NCT04119089|OTHER|Gastric ultrasound|"A first gastric ultrasound will be performed in the supine and the right lateral (RLD) decubitus position, allowing a qualitative analysis of the gastric contents (empty, liquid, solid, solid-liquid). The antral area will also be measured in both positions. The volume of gastric fluid content will be calculated according to the following formula: volume (ml) = -7,8 + (0,035 x antral area in RLD (mm²)) + 0,127 x age (month).~This examination will be immediately followed by the aspiration of gastric contents through the nasogastric tube used for enteral feeding, into 50-ml syringes, by a nurse blinded to the result of the first ultrasound examination. A second antral ultrasound examination will then be performed, by the same investigator blinded to the volume aspirated.~The occurrence of regurgitation and / or vomiting occurring within the 12 hours before and after the examination will be recorded."
223750829|NCT06017661|DIETARY_SUPPLEMENT|Nutridrink Skin Repair with a mixture of plant extracts rich in polyphenolic compounds|2 times a day
223750830|NCT06017661|DIETARY_SUPPLEMENT|Nutridrink Skin Repair|2 times a day
223750831|NCT06200181|DRUG|Olanzapine|Given by PO
223750832|NCT06200181|DRUG|Olanzapine|Given by PO
223750833|NCT06200181|DRUG|Placebo|Given by PO
223750834|NCT06529991|DEVICE|Occipivot suboccipital pillow self-myofascial release|"Subjects will be instructed in the use of the Occipivot suboccipital pillow and how it should feel. They will be supervised as it is placed. Once verbal verification is obtained regarding the feel and placement of the wedge, the treatment time will begin and continue for 5 minutes."
223750835|NCT06957860|OTHER|Piezotome|Four Intra-lift diamond tips were used for drilling the osteotomy, increasing diameters till a final diameter of 2.8 mm is reached for placement of 3.5 mm diameter and 10-12 mm length implant.
223750836|NCT06957860|OTHER|Densah burs|implant drilling procedures will be done using the surgical drills of the supplier kit of densah burs. Surgical drills of increasing diameters will be used till a final drill diameter of 3 mm for placement of a 3.5 mm diameter.
223603192|NCT03274414|RADIATION|Adjuvant Proton Radiotherapy|"Proton therapy treatment will follow the National Cancer Institute's Guidelines for the Use of Proton Radiation Therapy in NCI-Sponsored Cooperative Group Trials. Proton therapy techniques may include passively scattered or scanning or pencil beam technology."
223603193|NCT03274414|PROCEDURE|Endoscopic Resection|In brief, an endoscope is used and two surgeons perform the intervention in a binostril manner. Tumor is generally resected with an emphasis on identification of the attachments in the paranasal sinuses, nasal cavity, or skull base.
223603194|NCT03274414|DRUG|cisplatin and etoposide|If the final surgical pathology report shows SNUC, at the discretion of the treating medical oncologist, the patient will receive an addition of etoposide chemotherapy to cisplatin chemotherapy. The dose of cisplatin will be decresed from 100 mg/m2 to 60 mg/m2. Cisplatin should be administered on days 1-2, 21-22 and 42-43 at a dose of 60 mg/m2 and Etoposide should be administered at days 1-3, 21-23, and 42-44 at a dose of 120 mg/m2.
223603195|NCT01744548|BEHAVIORAL|tCBT treatment|The UP comprises 4 main treatment components: 1) psychoeducation about emotions and behaviour; 2) changing misappraisals about probabilities and consequences of negative experiences; 3) preventing avoidance of negative emotion triggers; and 4) modifying emotion-driven behaviours (e.g. hypervigilance, withdrawal). The manualised tCBT intervention will be adapted in order to account for a United Kingdom (UK) audience (as the manual was developed in the United States) and older people (as the manual was developed for working-age people).
223603196|NCT06845527|OTHER|Gut microbiome testing|Gut microbiome testing for the characterization of the patient gut microbiome
223603197|NCT03867357|DRUG|GnRH agonist|Zoladex is a gonadotropin-releasing hormone agonist, or GnRH-A. It is an implant that is injected under the skin (subcutaneously). The implant gradually dissolves and releases the drug over the time between injections. There are two dosages of Zoladex: Zoladex 10.8 mg, which is injected once every 3 months, and Zoladex 3.6 mg, which is injected once a month.
223603198|NCT03310814|OTHER|Personalized nutrition|Receives individualized nutrition information
223603199|NCT02502942|BEHAVIORAL|Upper Airway Muscle Exercise|Patients will use an individualized oral retainer device for upper airway muscle training exercises daily for 20 minutes each day (10 minutes in the morning and 10 minutes in the afternoon/evening) for 6 weeks.
223603200|NCT02502942|BEHAVIORAL|Sham Exercise|Patients will be given an individualized oral retainer device and instructed to do deep breathing exercise twice daily for 6 weeks.
223750837|NCT06957834|DRUG|Eflornithine hydrochloride cream|Eflornithine hydrochloride cream at 11.5% applied twice daily
223750838|NCT06957834|DRUG|Hydroquinone cream|Hydroquinone 2% cream, applied twice daily
223750839|NCT04770896|DRUG|Atezolizumab|Atezolizumab will be administered by intravenous (IV) infusion at a fixed dose of 1200 mg on Day 1 of each 21-day cycle until unacceptable toxicity or loss of clinical benefit as determined by the investigator.
223750840|NCT04770896|DRUG|Lenvatinib|Lenvatinib will be administered once daily by mouth each day of every 21-day study treatment cycle. Participants with a baseline body weight of \< 60 kg will receive a daily dose of 8 mg. Participants with a baseline body weight of ≥ 60 kg will receive a daily dose of 12 mg.
223750841|NCT04770896|DRUG|Sorafenib|Sorafenib will be administered at a dose of 800 mg per day, i.e. two tablets of 200 mg swallowed by mouth twice daily (equivalent to a total daily dose of 800 mg) each day of every 21-day study treatment cycle.
223750842|NCT04542707|PROCEDURE|joint manipulation|Thrust manipulation to the spine, hand, and foot
224200214|NCT04286438|DRUG|Bentracimab (PB2452) Infusion|"Bentracimab (PB2452) 18 g Intravenous Infusion over a 16 hour duration.~In subjects with potential drug interaction from recent concomitant use of moderate or strong CYP3A inhibitors with ticagrelor, the active treatment period may be 24 hours and 10 min if receiving the 36g infusion.~In patients presenting with intracranial hemorrhage (ICH), brain imaging within 2 hours of initiation of study drug and at least one follow-up brain imaging performed 12-24 hours post completion of PB2452."
224200215|NCT05398458|PROCEDURE|Lymphocele excision and space obliterated by pedicle Gracilis muscle only flap|By this procedure it has helped in reduction and complete resolution of the lymphocele with no recurrence in the past 2 years
223750843|NCT04542707|PROCEDURE|Exercise|Strength training, bike aerobic training, and yoga exercise
223750844|NCT04542707|DEVICE|Soft tissue massage|Graston tool
223750845|NCT05717140|BIOLOGICAL|Aerosol Sargramostim|Given via inhalation with nebulizer
223750846|NCT05717140|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
223750847|NCT05717140|PROCEDURE|Computed Tomography|Undergo CT
223603201|NCT03461640|OTHER|Community-based doula support for labour|CBDs will be recruited, trained and employed by non-profit organization MIRA. Women allocated to receive CBD support will be contacted by an either a Somali, Arabic-, Russian- or Tigrinya-speaking CBD as appropriate, and arrangements made for them to meet twice prior to the birth to get to know each other and discuss the woman's wishes regarding support in labour and what the CBD can offer. Each woman will then contact her CBD when she goes into labour and the CBD will attend hospital with her and stay with her throughout her labour and birth, in addition to any other support people she may have, such as her partner.
223603202|NCT03461640|BEHAVIORAL|Standard labour support|"Standard labour support by health care providers only. Women allocated to the comparison arm of the trial will receive standard intrapartum care as provided at their chosen hospital of birth. That is emotional, information and instrumental support from a helping nurse or a midwife or in some cases a doctor. The support includes caring actions, such as comforting, massage, information and presence.~Note: Women partner and/or other support people to accompany throughout her childbirth will be allowed, regardless of their trial allocation."
223603203|NCT01299181|DRUG|Atorvastatin|80mg once daily orally
223750848|NCT05717140|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223603204|NCT02761122|PROCEDURE|Human biological samples|"* Blood sample~* Skin or mucosal brushing~* Skin or mucosal biopsy"
223603205|NCT04273893|RADIATION|SBRT with additional treatment planning dose optimization|Lung SBRT 50-60Gy in 5 fractions with standard of care planning and additional treatment planning dose optimization criteria to minimize decrease in lymphocyte count beyond dosimetric criteria from RTOG 0915/0813 SBRT trials.
223603206|NCT04273893|RADIATION|SBRT with standard of care planning only|Lung SBRT 50-60Gy in 5 fractions with standard of care planning (no additional dose optimization beyond SOC)
223603207|NCT04273893|DIAGNOSTIC_TEST|Blood Draws|CBC w/ Diff and additional blood analysis for all participants in both groups. Blood draws will prior to treatment, end of treatment, 4 weeks after treatment, and 6 months after treatment.
223603208|NCT05946564|DRUG|Pioglitazone (ACTOS®)|Patient will be randomize in the intervention group receive treatment by pioglitazone (30 mg/day orally) for 26 weeks on top of a SOC immunosuppressive treatment.
223603209|NCT05946564|DRUG|Placebo of Pioglitazone|Patient will be randomize in the intervention group receive treatment by placebo of pioglitazone (30 mg/day orally) for 26 weeks on top of a SOC immunosuppressive treatment.
223603210|NCT03657290|DRUG|vadadustat|Vadadustat Tablets
223603211|NCT02497729|PROCEDURE|Written Checklist|Use of a written checklist pre and peri-intubation
223603212|NCT02497729|PROCEDURE|Head of Bed Up|Raising the patient's head of bed to 25 degrees
223603213|NCT00225498|DRUG|ziprasidone vs risperidone or olanzapine|ziprasidone target dose is 160 mg/day risperidone target dose is 4 mg/day olanzapine target dose is 20 mg/day
223603214|NCT04577430|DRUG|Dexmedetomidine|The loading dose with 0.5 μg/kg, maintenance dose with 0.5 μg/kg of Dexmedetomidine is used to observe the effect on the electrophysiology of the patients' hearts
223603215|NCT04577430|DRUG|Dexmedetomidine|The loading dose with 1 μg/kg, maintenance dose with 0.5 μg/kg of Dexmedetomidine is used to observe the effect on the electrophysiology of the patients' hearts
223603216|NCT04577430|DRUG|Dexmedetomidine|The loading dose with 1 μg/kg, maintenance dose with 1 μg/kg of Dexmedetomidine is used to observe the effect on the electrophysiology of the patients' hearts
224200216|NCT06263543|DRUG|Sacituzumab govitecan|IV infusion of 10 mg/kg on Days 1 and 8 of each continuous and consecutive 21-day cycles. The first infusion will last approximately 3 hours and subsequent infusions will last 1-2 hours if prior infusions were well tolerated.
224200217|NCT01016366|DRUG|Lu AA24493|Vials with solution for i.v. injection. 325mcg Lu AA24493 dosed 3 times per week for two weeks. Vials will be supplied in concentrations ready for injection.
224200218|NCT01016366|DRUG|Placebo|Vials with solution for i.v. injection. Placebo dosed 3 times per week for two weeks.
224200219|NCT01471652|DRUG|Nutraceutical supplements|"1. CoEnzyme Q10: oral gel capsule bid~2. Acetyl L-carnitine: oral capsule bid~3. Alpha Lipoic Acid: oral tablet qd~4. Docosahexaenoic acid: oral gel capsule bid"
224200220|NCT01471652|DRUG|Placebo|"Capsule form to imitate the following nutraceuticals:~1. Placebo 1: oral gel capsule bid~2. Placebo 2: oral capsule bid~3. Placebo 3: oral tablet qd~4. Placebo 4: oral gel capsule bid"
223603217|NCT04577430|DRUG|Normal saline|Normal saline is used to observe the effect on the electrophysiology of the patients' hearts
223603218|NCT01036321|DRUG|Purified isoflavones|Soy-based isoflavone concentrate with methyl cellulose blend filler - Take 2 capsules daily
223603219|NCT01036321|DRUG|Methyl cellulose blend|Placebo - Take 2 capsules daily
223603220|NCT03919474|DIAGNOSTIC_TEST|microvascular markers|follow up of microvascular biomarkers during patient follow up
223603221|NCT01425125|DRUG|Tolvaptan in euvolemic hyponatremia|This arm will test the effectiveness of tolvaptan in treating the hyponatremia of patients with euvolemic hyponatremia.
223603222|NCT01351116|RADIATION|EBR plus HDRIB|EBR of 20 Gy in 5 daily fractions over one week plus HDRIB of 14 Gy in 2 fractions over two weeks
223603223|NCT01351116|RADIATION|EBR|EBR of 20 Gy in 5 daily fractions over one week
223603224|NCT03456232|OTHER|High-flux hemodialysis|High-flux hemodialysis using diffusion, ultrafiltration and convection principle to remove harmful substances in the blood and excessive water.
223603225|NCT03456232|OTHER|Hemodiafiltration|Hemodiafiltration is a combination of hemodialysis and hemofiltration with two modes of treatment advantages, both by diffusion and convection principle to remove harmful substances in the blood.
223603226|NCT00838240|DRUG|clofarabine|Given IV
223603227|NCT00838240|DRUG|cytarabine|Given IV
223603228|NCT00838240|DRUG|idarubicin|Given IV
223603229|NCT01942174|BIOLOGICAL|Prevenar 13|Vaccination at the beginning of the study (day 0)
223750849|NCT05717140|OTHER|Medical Device Usage and Evaluation|Use Aerogen Solo nebulization device
223750850|NCT05717140|BIOLOGICAL|Nivolumab|Given IV
223750851|NCT04517552|DRUG|[11C]-CS1P1|Participants will receive a single intravenous bolus injection of 6.0 - 20.0 mCi (222-740 MBq) of the investigational radiotracer \[11C\] CS1P1. Participants will then undergo a \[11C\] CS1P1 PET/CT scan.
223750852|NCT06333262|DRUG|Pirtobrutinib|"Initial treatment:~\- Pirtobrutinib 200 mg by mouth (PO) daily from Cycle 1 Day 1 until the end of Cycle 12. Each cycle is 28 days.~Re-treatment:~-Pirtobrutinib 200 mg PO daily continuously"
223750853|NCT06333262|DRUG|Obinutuzumab|"Obinutuzumab is given intravenously from Cycle 7 to Cycle 12, for total 6 cycles during initial treatment only.~Initial treatment:~\- Obinutuzumab intravenous (IV) following the standard schedule from Cycle 6 through Cycle 12 (total 6 cycles: 100 mg on Cycle 6 Day 1, 900 mg on Cycle 6 Day 2, 1000 mg on Cycle 6 Day 8 and Cycle 6 Day 15, 1000 mg on Day 1 of Cycle 7 through Cycle 12)."
223750854|NCT04409821|BEHAVIORAL|Tele-delivered psychological intervention|The intervention consists of two (or one, if preferred by caregivers) weekly tele-sessions during the ICU stay, lasting up to 30 minutes, and two sessions in the month after discharge from or death in the ICU. Sessions will be conducted via phone-calls or video-conferencing. Therapists will 1) validate caregivers' subjective experience, 2) normalize and psychoeducate about emotional reactions, and 3) offer emotion regulation drawing on contemporary cognitive treatment packages of decentering, acceptance and emotion tolerance. Sessions for bereaved caregivers will include psycho-education about grief, assessment of risk for adverse outcomes and information about available support, if needed. The intervention will be performed based on an intervention manual. The content of the intervention will be continually adapted and tailored to the needs of the participating caregivers by involving all caregivers in co-creating the intervention trough brief post-session interviews.
223750855|NCT05062629|GENETIC|Whole Genome Sequencing|Whole Genome Sequencing
223750856|NCT06780969|BEHAVIORAL|Green Mother Training|Poster education
223507662|NCT05771623|DEVICE|Iontophoresis drug delivery device|"Botulinum toxin type A (Botox Allergan ®, Irvine, CA, USA) is used. 100 U vacuum-dried powder in a single-use vial for reconstitution diluted in 2mL of sterile, preservative-free 0.9% saline to constitute a solution at a concentration of 4 U/0.1 mL) is being administered once a month for a total period of three months.~The dose will be adjusted to 2.5 U/cm2 of the scar. The dose shouldn't exceed 100 units per session.~This can be done through the Iontophoresis drug delivery device. Traditional PT: Stretching, deep friction massage and pressure therapy (2 times per week for 3 months)."
223507663|NCT05771623|BEHAVIORAL|Traditional physical therapy|Traditional PT: Stretching, deep friction massage and pressure therapy (2 times per week for 3 months).
223507664|NCT03238872|BEHAVIORAL|Cognitive Behavioural Therapy|
223750857|NCT00060996|DRUG|Remodulin® (treprostinil sodium) Injection|
223750858|NCT00393679|DRUG|amodiaquine-artesunate (ASAQ)|A fix-dose combination tablet containing artesunate-amodiaquine in three different dosages, to be used according to patient age and weight: 25mg/67.5mg; 50mg/135mg; 100mg/270mg
223750859|NCT00393679|DRUG|dihydroartemisinin-piperaquine (DHAPQ)|DHAPQ tablets contain either 20/160mg or 40/320mg of dihydroartemisinin (DHA) and piperaquine phosphate (PQ) respectively.
223750860|NCT00393679|DRUG|artemether-lumefantrine (AL)|Tablets containing 20 mg of Artemether and 120 mg of Lumefantrine.
223750861|NCT00393679|DRUG|Lapdap (Chlorproguanil-Dapsone) + artesunate (AS)|"Lapdap tablets contain 15/18.75mg or 80/100mg of Chlorproguanil Hydrochloride and Dapsone, respectively. Arsumax® tablets contain 50mg Artesunate.~TO BE NOTED: following GlaxoSmithKline decision to discontinue the clinical development of the fixed-doses combination of Lapdap (Chlorproguanil-Dapsone) and artesunate, the Lapdap plus Artesunate arm was immediately discontinued in this study, on 17th February 2008. A formal amendment has been submitted to all the concerned ECs and competent authorities.The leading EC approval was obtained on 2nd June 2008."
223750862|NCT02373358|BEHAVIORAL|Group yoga intervention|Participants will participate in 6 90-minute yoga groups designed to promote themes related to trauma recovery (safety \& boundaries, strength \& power, assertiveness, intuition, trust, \& community) using mindfulness, breath work, and physical yoga poses.
223750863|NCT04891939|OTHER|Health education lessons (Smart-Kid's program)|The intervention is designed for all students, including never-smokers and students at high risk for smoking. Therefore, some contents are intended to influence those high-risk youth within the larger student audience by targeting the stages of the smoking acquisition process including, preparation, initiation, experimentation, regular use, and addiction (Mayhew et al., 2000). The intervention is also focused on addressing risk factors for smoking initiation and continue use (Hansen et al., 2015; So \& Yeo, 2015). These risk factors are, therefore, grouped into four major groups namely; personal factors, behavioral factors, environmental factors and sociodemographic factors
223507665|NCT03238872|OTHER|Treatment as usual|
223507666|NCT06162234|OTHER|observational|none (observational study)
223507667|NCT05428228|OTHER|TP1|Participants will be administered TP1 during one of the experimental visits.
223507668|NCT05428228|OTHER|TP2|Participants will be administered TP2 during one of the experimental visits.
223507669|NCT05428228|OTHER|Placebo|Participants will be administered placebo during one of the experimental visits.
223507670|NCT00746720|DRUG|Etoricoxib 60 mg|film coated tablet 60 mg (orally), 120 mg (= 2 tablets a 60 mg) once daily, on day one post surgery
223507671|NCT00746720|DRUG|Placebo for Etoricoxib 60 mg|film coated tablet (orally), two tablets once daily, on day one post surgery
223507672|NCT00746720|DRUG|Etoricoxib 60 mg|film coated tablet (orally), 120 mg (= 2 tablets a 60 mg) once daily, two hours before and 24 hours after surgery
223507673|NCT00746720|DRUG|Placebo for Etoricoxib 60 mg|film coated tablet (orally), 2 tablets once daily, two hours before and 24 hours after surgery
223507674|NCT03447145|DRUG|TQ-B3203|dose escalation, 2/4/6/10/14/18mg/m2
223507675|NCT00333307|DRUG|recombinant human relaxin|
223507676|NCT02106559|DRUG|porfimer sodium|Given IV
223507677|NCT02106559|PROCEDURE|therapeutic conventional surgery|Undergo tumor resection and/or radical pleurectomy
223507678|NCT02106559|DRUG|photodynamic therapy|Undergo PDT
223750864|NCT04891939|OTHER|School Health and Education Program (SHEP)|The SHEP is the usual health and education program been done in all schools, and also has tobacco control component. This is will be used as the control for the intervention.
223507679|NCT04710433|DEVICE|Non-invasive Neuromodulation|Sacral nerve stimulation via two adhesive electrodes (single current).
223507680|NCT04710433|OTHER|Medical and Behavioral Therapy|Behavioral Therapy consists of toilet training, an active and healthy lifestyle. Doses of medical options are applied weight-adjusted.
223507681|NCT00629239|DRUG|AZD4818|Dry Powder, inhalation, b.i.d., 4 weeks
223507682|NCT00629239|DRUG|Placebo|
223507683|NCT00793065|OTHER|Electronic health record (EHR)|Computer-based system that allows physicians to access and manage patient records electronically.
223750865|NCT05817136|DIAGNOSTIC_TEST|Eko DUO|Acquisition of a single-lead ECG via patients self-examine themselves twice a week for 12 months.
223750866|NCT03135041|DIETARY_SUPPLEMENT|Fiber-containing dietary supplement|Effects of fiber-containing dietary supplement on weight loss during energy restriction
223750867|NCT03135041|DIETARY_SUPPLEMENT|Placebo|Effects of placebo supplement on weight loss during energy restriction
223603230|NCT01942174|BIOLOGICAL|Pneumo23 / Pneumovax|Vaccination 2 months later the beginning of the study NB : Vaccine Pneumo23 has been replaced by equivalent vaccine Pneumovax in September 2017 because of the stop of commercialization of Pneumo23 in France by the pharmaceutical company
223603231|NCT01942174|DRUG|Methotrexate - Immediate|concerning immediate group, methotrexate is Initiated in the same time that the antipneumococcal vaccination by prevenar 13
223603232|NCT01942174|DRUG|Methotrexate - Delay|"For period group, methotrexate is Initiated \& month after the antipneumococcal vaccination by prevenar 13"
223750868|NCT05140577|OTHER|Maximal voluntary isometric strengthening|The subject is asked to perform a maximum voluntary isometric force work against a wall during 5 seconds
223750869|NCT02376946|DEVICE|ActiPatch(TM)|Assigned by randomization, this study group will be comprised of subjects that receive the PEMF ActiPatch(TM) treatment for postoperative management of pain and edema.
223750870|NCT02376946|DEVICE|Placebo|Assigned by randomization, this control group will be comprised of the subjects that receive a placebo patch as treatment for postoperative management of pain and edema.
223750871|NCT03961100|DRUG|Entrectinib 600 mg (T1)|Test formulation 1 (T1): Multi-particulate formulation 1: entrectinib film-coated mini-tablets
223750872|NCT03961100|DRUG|Entrectinib 600 mg (T2)|Test formulation 2 (T2): Multi-particulate formulation 2: entrectinib film-coated mini-tablets
223750873|NCT03961100|DRUG|Entrectinib 200 mg (R)|Reference formulation (R): entrectinib hard capsules
223750874|NCT03961100|DRUG|Entrectinib 200 mg (T)|Test formulation (T): entrectinib HPMC capsules
223507684|NCT00793065|OTHER|Medical Home redesign|Implementation of NCQA Level III Medical Home
223507685|NCT03309059|DEVICE|water and soap|Use of soap and water in the area and subsequent diaper placement disposable.
223507686|NCT03309059|DEVICE|zinc oxide|Use of soap and water sanitation and application of zinc oxide.
223507687|NCT03309059|DEVICE|Non-Irritant Barrier Film|Use of soap and water hygiene and application of Non Irritant Barrier Film.
223507688|NCT06309329|BEHAVIORAL|Strength at Home Parents|Strength at Home parents is an 8 week trauma-informed and cognitive behavioral tele-health group intervention that aims to improve parenting behaviors and overall parent-child and family functioning among U.S. military Veterans with post-traumatic stress disorder symptoms
223507689|NCT06309329|BEHAVIORAL|VA treatment as usual|VA treatment as usual includes referral to the online resources at veterantraining.va.gov/parenting .
223603233|NCT04808141|DEVICE|Digital program|Patients in the digital intervention group will benefit from an 8-week program composed of therapeutic exercise, education and cognitive behavioural therapy (CBT) program provided by SWORD Health. These patients will be referred to SWORD Health by the investigator who identified the candidate. SWORD Health will then assign a physical therapist to each patient. The physical therapist will contact the patient for onboarding and will manage the case.
223603234|NCT04808141|OTHER|Conventional physical therapy|Patients in this group will benefit from a 8-week program consisting of two 30 min face-to-face physical therapy sessions per week in an outpatient clinic setting, for a total of 16 sessions. The program will follow the protocol outlined in Annex 3, which can however be adapted by the physical therapist to the specific needs of the participant. Participants in this group will be considered as dropouts if they: a) choose to abandon the study; b) miss four consecutive scheduled physical therapy sessions.
223603235|NCT00381693|DRUG|azacitidine|
223603236|NCT06237400|DRUG|ZG19018|ZG19018 Given by PO (mouth)
223603237|NCT02598297|DRUG|Ruxolitinib|5 mg tablet for oral use
223750875|NCT02990169|DEVICE|CATS tonometer prism|IOP tonometer prism for assessment of intraocular pressure
223750876|NCT02990169|DEVICE|Goldmann Tonometer prism|IOP tonometer prism for assessment of intraocular pressure
223750877|NCT00004888|DRUG|pegylated liposomal doxorubicin hydrochloride|Given IV
223750878|NCT00004888|DRUG|docetaxel|Given IV
223750879|NCT00004888|BIOLOGICAL|trastuzumab|Given IV
223507690|NCT05901961|DRUG|Whitfield solution|The patient will receive 60 mL of Whitfield solution. They will be instructed to apply 0.5 mL of the solution to the lesion twice daily for a consecutive period of 8 weeks.
223507691|NCT05901961|DRUG|Zinc oxide nanoparticles solution|The patient will receive 60 mL of 1% Zinc oxide nanoparticles solution. They will be instructed to apply 0.5 mL of the solution to the lesion twice daily for a consecutive period of 8 weeks.
223507692|NCT05901961|DRUG|Combined Whitfield and Zinc oxide nanoparticles solution|The patient will receive 60 mL of combined Whitfield and Zinc oxide nanoparticles solution. They will be instructed to apply 0.5 mL of the solution to the lesion twice daily for a consecutive period of 8 weeks.
223603238|NCT02598297|DRUG|Ruxolitinib Placebo|5 mg placebo tablet for oral use
223603239|NCT04677010|OTHER|Cycle exercise|10 weeks of cycle exercise on a cycle ergometer with motor.
223603240|NCT02766712|PROCEDURE|Pace During 1st Half of Lesion|
223603241|NCT02766712|PROCEDURE|Pace During 2nd Half of Lesion|
223750880|NCT00004888|OTHER|laboratory biomarker analysis|Correlative studies
223750881|NCT02579265|DRUG|Smoflipid 20% (investigational lipid for parenteral nutrition)|"Dose: The targeted maximal dose is 3.0 g/kg/day. In patients already receiving parenteral nutrition (PN) before starting study treatment, the dose will either stay at 3.0 g/kg/day or be increased by 1.0 g/kg/day steps to a maximum of 3.0 g/kg/day.~Smoflipid 20% will be infused over 20 - 24 hours, as per hospital policy, at a weight based infusion rate.~Smoflipid 20% will be infused into a central or a peripheral vein."
223750882|NCT02579265|DRUG|Intralipid® 20%|"Dose: The targeted maximal dose is 3.0 g/kg/day. In patients already receiving parenteral nutrition (PN) before starting study treatment, the dose will either stay at 3.0 g/kg/day or be increased by 1.0 g/kg/day steps to a maximum of 3.0 g/kg/day.~Intralipid® 20% will be infused over 20 - 24 hours, as per hospital policy, at a weight based infusion rate.~Intralipid® 20% will be infused into a central or peripheral vein."
223750883|NCT00433056|OTHER|STI|CD4 guided treatment interruption
223750884|NCT00433056|DRUG|stable HAART|continuous therapy
223750885|NCT01548131|BEHAVIORAL|Psychoeducative group therapy|6 sessions during pregnancy and 1 after childbirth
223750886|NCT03567837|OTHER|Fructose + Glucose Beverage|The intervention is an oral sugar challenge with blood sampling over three hours.
223750887|NCT03087968|DRUG|GS-4997|Experimental drug
223750888|NCT03087968|DRUG|Prednisolone|Control drug that is also administered with the Experimental drug, GS-4997. This drug is used in both arms.
223750889|NCT03087968|DEVICE|HepQuant SHUNT Test|"The HepQuant SHUNT Liver Diagnostic Kit is intended for use in the quantitative detection of 13C-cholate and d4-cholate in blood serum, collected after the intravenous administration of 13C-cholate and the oral ingestion of d4-cholate. The device is indicated to assess the severity of liver disease.~For use by health care professionals. Administer the test under a physician's supervision. The HepQuant Analytical Testing Laboratory must analyze the serum samples."
223750890|NCT03087968|DRUG|Placebo|Placebo
223750891|NCT02174848|DRUG|Deferiprone oral solution|Deferiprone oral solution at a dosage of up to 15 mg per kilogram of body weight, twice a day
223750892|NCT01339351|BEHAVIORAL|Therapeutic Group by Teleconference|10 sessions
223750893|NCT00322192|BEHAVIORAL|Conventional UK Physical therapy|
223750894|NCT00322192|BEHAVIORAL|Increased intensity of UK conventional physical therapy|
223750895|NCT00322192|BEHAVIORAL|UK conventional physical therapy plus functional strength training|
223750896|NCT06377397|DRUG|Antibiotics|"In experimental arm, intravenous antibiotics as per the written down empirical antibody policy of the unit will be administered selectively to those newborn infants who later develop clinical signs of sepsis according to a predefined repertory of clinical signs.~In active comparator arm, intravenous antibiotics as per the written down empirical antibody policy of the unit will be administered pre-emptively to all newborn infants from enrollment even if they do not have any clinical signs of sepsis at enrollment"
223750897|NCT05616858|BEHAVIORAL|Complex exercise program|Stretching exercise, aerobic exercise, strengthening and balancing exercise
223750898|NCT05457374|PROCEDURE|PVE|Portal vein embolization (PVE) mainly embolizes the portal vein of the resected liver lobe, causing the non-tumor lobe to proliferate, and after tumor lobectomy, the volume of the non-tumor lobe proliferates so that patients with hepatocellular carcinoma that could not be directly surgically resected are given the opportunity to be surgically resected
223750899|NCT05457374|PROCEDURE|LVD|Combining PVE and Hepatic Vein Embolization (HVE) in the same procedure
223750900|NCT05595512|BEHAVIORAL|Naser Al-Husban|depressive symptoms within 6 months of delivery
223750901|NCT04421911|DRUG|Ketoprofen topical|Ketoprofen topical for 21days
223750902|NCT04421911|DRUG|Diclofenac Topical|Diclofenac topical for 21days
223750903|NCT01074164|OTHER|Standard-of-care treatment for AD|Subjects will receive standard of care treatment for atopic dermatitis, including moisturizers and topical corticosteroids, per their dermatologist.
223750904|NCT01074164|DEVICE|Accu-patch pellet|The accu-patch pellets will be applied to the LI11 pressure point, located on the left arm lateral to the antecubital fossae, for 10 minutes, 3 times a week for 1 month.
223750905|NCT02229318|DIETARY_SUPPLEMENT|FruitiVits|Daily administration of FruitiVits dietary supplement
223750906|NCT03365596|OTHER|Conventional therapy|According to the status of a patient, optimized therapy will be applied.
223750907|NCT05422781|DRUG|ITI-3000|ITI-3000 is a DNA vaccine (L-H LT S220A) which contains sequences for both LAMP1 and LTS220A, the truncated form of the LT antigen of MCPyV with a detoxifying serine to alanine mutation at position 220
223750908|NCT02220270|DEVICE|ASD and PDA closure|
223750909|NCT01301872|OTHER|check biomarker :RAGE|We will check RAGE for all patients who have ARDS included in our study
224200221|NCT00781482|DRUG|eszopiclone, zolpidem, placebo|In random order, each subject will receive one study drug per visit over three visits. Visits will occur about 1 week apart. Each subject will eventually receive eszopiclone 3 mg., zolpidem 10 mg., and a placebo. PET scans will be done 1-2 hours after each dose.
223507693|NCT02298569|BEHAVIORAL|multi-pronged program to improve early postpartum discharge|"Better team integration and changes to promote interprofessional collaboration and communication between healthcare providers involved in pre- and post-natal care in a perinatal network.~Transition optimization: all involved healthcare professionals will complete a specific form during pregnancy and hospitalization to coordinate support safe process, and to improve quality transitions to outpatient midwives and pediatrician. A check-list will be completed by the mother to assess whether she agrees to early discharge and that she is aware of its conditions Implementation of best practices about early discharge after delivery to improve safety of early discharge particularly for neonates at risk (jaundice and dehydration)."
223507694|NCT00715897|PROCEDURE|Hyperbaric Oxygen Therapy (HBOT)|8-week, 5 times a week administration of 100% O2 for 90 minutes at a pressure of 2 ATA.
223507695|NCT01851369|DRUG|TRC102|Methoxyamine hydrochloride (TRC102) has been shown to potentiate the activity of temozolomide by preventing base excision repair (BER) and allowing cleavage of TRC102 bound deoxyribonucleic acid (DNA), which will cause DNA strand breaks in cancer cells. We hypothesize that oral TRC102 can be safely co-administered with Temozolomide (TMZ) and would potentiate DNA damage caused by TMZ resulting in antitumor responses.
223750910|NCT05413252|OTHER|Practice Facilitation|Practices will be assigned a practice facilitator who will support practices in implementing all practice redesign components associated with TBC for HTN management.
223750911|NCT03796780|DIETARY_SUPPLEMENT|Extra-Virgin Olive Oil|Daily consumption of 25 mL Extra-Virgin Olive Oil in adjunct to medical treatment for 6 weeks
223750912|NCT03796780|DIETARY_SUPPLEMENT|Refined Olive Oil|Daily consumption of 25 mL Refined Olive Oil in adjunct to medical treatment for 6 weeks
223750913|NCT04881357|OTHER|test mouth rinse (Lacer Oros Acción Integral - new formula, Barcelona, Spain).|The experimental group will use three times daily a provided manual toothbrush with a sodium fluoride dentifrice, followed by the use of the test mouth rinse (Lacer Oros Acción Integral - new formula, Barcelona, Spain).
223750914|NCT04881357|OTHER|control group|The control group will use three times daily a provided manual toothbrush with a sodium fluoride dentifrice, followed by the use of the control mouth rinse (Lacer Oros Acción Integral - new formula, without active ingredients, Barcelona, Spain).
223750915|NCT04931056|DEVICE|Titanium Facial Plates|The Facial Plating System provides a comprehensive titanium fixation solution for maxillofacial surgery procedures. More than twenty-five different plating options in two systems, the 1.5 mm and 2.0 mm with a variety of instruments, and high torque screws, including meshes, are part of this system. Plates and screws are made of commercially pure titanium per ASTM F-67, Titanium 6Al 4V Alloy per ASTM F-136.
223750916|NCT04931056|DEVICE|Titanium Mandibular Plates|"The Mandibular Plating System provides a comprehensive titanium fixation solution for mandibular surgical procedures. Several plating options, a variety of instruments, and high torque screws with various plate shapes are part of this system.~Plates in the Mandibular Plating System have profiles of various thicknesses. Screws are available in self-tapping, locking and non-locking varieties, and in various sizes between 2.0 mm and 2.3 mm in diameter, and 5 mm to 18 mm in length."
223750917|NCT04931056|DEVICE|Add-on Condyle|The Add-On Condyle is intended to be implanted in the human jaw to replace the mandibular condyle to functionally reconstruct the temporomandibular joint on a temporary basis for patients undergoing ablative tumor surgery requiring the removal of the native mandibular condyle. This device is not for permanent implantation, traumatic injuries, or for treatment of temporomandibular joint disease.
223750918|NCT04931056|DEVICE|HTR-PEKK|The HTR-PEKK implants are fabricated from polyether-ketone-ketone (PEKK) via selective laser sintering (SLS), a 3D manufacturing technique. The laser sintering machine builds the implant in layers as dictated from a stereolithographic (STL) file of the approved implant. The HTR-PEKK implants are designed individually for each patient to replace bony voids in the facial anatomy using a patient's own CT imaging data. The implant is made to fill an existing or planned void (where appropriate) using computer-aided design technology for anatomy enhancement, correction of trauma injuries, and/or to correct congenital defects in the craniofacial bone.
223750919|NCT00615277|DIETARY_SUPPLEMENT|Omega-3 fatty acids|600 mg EPA 120mg DHA daily, 16 weeks
223750920|NCT00644969|DRUG|placebo|Randomization 2:1 treatment to placebo
223750921|NCT00644969|DRUG|varenicline (CP-526,555)|One week of titration up to 1mg bid and 11 weeks of dosing at 1mg bid
223750922|NCT05279586|DRUG|lactulose|all interventions are used in secondary prophylaxis in cirrhotic patients
223750923|NCT05279586|DRUG|colistin|all interventions are used in secondary prophylaxis in cirrhotic patients
223750924|NCT04998591|BEHAVIORAL|Fasting|fasting for 7 days (caloric intake \<500 kcal in liquid form)
223750925|NCT05883904|DRUG|Fedratinib|Fedratinib administered after AIFA reimbusement approval
223750926|NCT04918212|DEVICE|Fabulous Stent Graft System|All patients received endovascular surgery using fabulous stent graft system
223507696|NCT01851369|DIAGNOSTIC_TEST|CT scan|CT scans will be performed at baseline, and repeat scans will be performed every 2 cycles (every 3 cycles for participants on study more than one year).
223507697|NCT01851369|OTHER|Lomotil|If diarrhea develops and does not have an identifiable cause other than study drug administration, anti-diarrheal's such as Lomotil (diphenoxylate hydrochloride (HCl) 2.5 mg + atropine sulfate 0.025 mg/tablet) dosed according to package insert or loperamide 4 mg by mouth (po) after the first unformed stool with 2 mg po every 2 hours as long as unformed stools continue (4 mg every 4 hours while asleep). No more than 16 mg of loperamide should be taken in during a 24-hour period.
223507698|NCT01851369|OTHER|Prochlorperazine|If a participant develops nausea/vomiting, an anti-emetic such as prochlorperazine may be given.
223507699|NCT01851369|OTHER|Metoclopramide|If a participant develops nausea/vomiting, an anti-emetic such as metoclopramide may be given.
223507700|NCT01851369|OTHER|5-HT3 antagonist|If a participant develops nausea/vomiting, an anti-emetic such as 5-HT3 antagonist may be given.
223507701|NCT01851369|OTHER|Aprepitant|If a participant develops nausea/vomiting, an anti-emetic such as aprepitant may be given.
223507702|NCT01851369|PROCEDURE|Biopsy|Tumor biopsies will be optional during the escalation phase.
223507703|NCT03066076|DRUG|Antithyroid Drug|Antithyroid drug
223507704|NCT03066076|PROCEDURE|Total thyroidectomy|Operation
223507705|NCT04920292|DRUG|Oxfendazole|Oxfendazole is a benzimidazole anthelminthic drug.
223507706|NCT04920292|DRUG|Placebo|The placebo tablet is made using the same non-active ingredients and matches the investigational tablet.
223507707|NCT00928005|BEHAVIORAL|Weight loss diet|The weight loss diet will follow the American Diabetes Association guidelines and be nutritionally balanced with a reduced saturated fat content.
223507708|NCT00928005|BEHAVIORAL|Weight loss diet plus exercise|The supervised exercise training sessions will take place three times a week for 6 months. Each session will last 1 to 1 ½ hours and will include aerobic exercise and weight training.
223507709|NCT02046200|DRUG|Ivermectin|Ivermectin is a semi-synthetic macrocyclic lactone used worldwide as a broad-spectrum antiparasitic avermectin.
223507710|NCT02046200|DRUG|Placebo|Matched placebo
223507711|NCT02046200|DRUG|Alcohol|
223507712|NCT03753503|BEHAVIORAL|exercise|exercised three times a week in the 8-week HIIT program
223507713|NCT03753503|BEHAVIORAL|conventional physical therapy|
223507714|NCT03865251|DEVICE|Kinesiology tape|Application for 0%, 50%, and 100% of maximal KT stretch to the calf muscle during lying and standing positions
223507715|NCT02453191|DRUG|Talimogene Laherparepvec|Talimogene Laherparepvec
223507716|NCT02453191|RADIATION|Radiotherapy|Concurrent Preoperative Radiation. External Beam Radiation Therapy (EBRT) will be given at the standard dose for resectable soft tissue sarcomas. according to the NCCN sarcoma guidelines.
223507717|NCT05528666|OTHER|High Efficacy Therapy (HET)|HET include alemtuzumab, ofatumumab, ocrelizumab, natalizumab, cladribine, fingolimod and ozanimod.
223507718|NCT05528666|OTHER|Non High Efficacy Therapy (Non-HET)|Non-HETs include molecules classified as with moderate or modest efficacy such as: interferons, glatiramer acetate, dimethyl fumarate and teriflunomide.
223507719|NCT04599257|DEVICE|BTL-899|The device applicator combines high-intensity focused electromagnetic procedure and radiofrequency energy to induce visible muscle contractions along with heating of the subcutaneous fat.
223507720|NCT00007501|BIOLOGICAL|Varicella-zoster vaccine|Immunization with 0.5 ml, live, attenuated (Oka/Merck) varicella-zoster vaccine.
223507721|NCT00007501|BIOLOGICAL|Placebo|Placebo vaccine
223507722|NCT03902990|OTHER|Dual task|The patients in the dual task group received cognitive tasks during treadmill training sessions.
223750927|NCT00001445|BIOLOGICAL|HIV-1 Immunogen|
223750928|NCT00654277|DRUG|Ondansetron|ODT, 8 mg, single-dose
223750929|NCT00654277|DRUG|Zofran|ODT, 8 mg, fasting conditions
223750930|NCT00414804|DEVICE|Precision SCS|Precision Spinal Cord Stimulation (SCS) Therapy
223750931|NCT00414804|PROCEDURE|Nerve Blocks and PT|Pain therapy utilizing Nerve Blocks with Physical Therapy
223750932|NCT03244865|DEVICE|LaborView Electronic Fetal Monitor|"Per LaborView directions, electrode application sites will be prepared to reduce skin impedance, electrodes will be applied to the maternal abdomen and FHR data acquired for comparison with CTG data obtained through the traditional monitoring system. The comparison will be performed off-line.~Nothing is required of the subjects. They will be non-invasively monitored for one to several hours. The information obtained will not be used for medical decision-making and there is no significant risk to the patient or her fetus."
223750933|NCT06076694|DRUG|TNP-2198|Group A, TNP-2198 capsules 400mg(4 capsules),BID, 14days Group B, TNP-2198 capsules 600mg(6 capsules),BID, 14days Group C , TNP-2198 capsules 600mg(6 capsules),TID, 14days Group D, TNP-2198 capsules 600mg(6 capsules),TID, 7days
223750934|NCT06076694|DRUG|Rabeprazole Sodium|Group A,Group B,Control group: Rabeprazole sodium enteric-coated tablets 20 mg, BID, 14days Group C :Rabeprazole sodium enteric-coated tablets 20 mg, TID, 14 days Group D : Rabeprazole sodium enteric-coated tablets 20 mg, TID, 7 days
223750935|NCT06076694|DRUG|Amoxicillin|Group A,Group B,Control group: Amoxicillin capsules 1g, BID, 14days Group D : Amoxicillin capsules 1g, TID, 7 days
223750936|NCT01901003|DRUG|Lorazepam|
223750937|NCT01901003|OTHER|no premedication|
223750938|NCT01901003|DRUG|Placebo (microcrystalline celluloses)|
223750939|NCT04774978|DEVICE|TTE|Transthoracic echocardiography
223750940|NCT06361628|BEHAVIORAL|multicomponent intervention on vaccination awareness|Educational sessions to create awareness on HPV and MMR (were addressed) vaccination that is culturally sensitive health information and provided in an easily understandable manner by trained health promoters (and healthcare professionals) to underserved communities. Support for navigation and access to vaccines.
223750941|NCT05527431|DEVICE|high flow nasal cannula|high flow nasal cannula
223750942|NCT05527431|DEVICE|noninvasive ventilation|noninvasive ventilation
223750943|NCT05005390|DEVICE|TTIP ventilation|In TTIP ventilation, an endotracheal tube is inserted via the nostril or oral cavity and subsequently advanced until the tip of the tube reaches approximately the level of the glottis.
223507723|NCT03902990|OTHER|Treadmill Training|Standard treadmill training
223507724|NCT03902990|OTHER|Standard exercise programme|Standard exercise programme for Parkinson Disease
223507725|NCT02172599|BEHAVIORAL|Sit-stand workstation provision|The research compares the effects of a sit-stand workstation only and a multi-component sit-stand workstation intervention including individual and organisation-level approaches, with usual office-based working practice (no sit-stand workstation) over 12 months.
223507726|NCT01413646|DIETARY_SUPPLEMENT|Walnut Supplementation|Eight weeks of walnut supplementation
223507727|NCT01413646|DIETARY_SUPPLEMENT|No walnut supplementation|Eight weeks without walnut supplementation
223507728|NCT00353574|DRUG|Darusentan|Darusentan capsules administered orally once daily
223507729|NCT04623060|OTHER|Combination of Low-volume interval treadmill training and Resistance Training|"Low-volume interval training (LV-ITT) protocols included a 5 min warm-up (30%-50%VO2peak) up to 20min of LV-ITT and a 5 min cooling down (30%-50% VO2peak). The LV-ITT will repeat 60s bursts of fast treadmill walking at maximum tolerate speed (0% incline), alternate with pre-specified recovery periods about 4 minutes according to protocol. Each time the participants completed a burst successfully, treadmill speed will be increased by 0.1 mph for the next burst. The recovery periods will be 4 minutes. The intervention will be conducted for about 30 minutes.~Resistance training will be conducted by using a horizontal leg press machine. They are encouraged to focus on an explosive concentric movement and a controlled eccentric movement such that the time on each phase was in the ratio 1:2."
223507730|NCT01520714|DEVICE|Medtronic 4195 active fixation LV lead and Medtronic passive fixation LV lead|1:1 randomization between Medtronic active fixation 4195 LV lead and another FDA approved passive fixation Medtronic LV lead. Fluoroscopic images will be taken at implant in a supine position and again at 3 month follow-up in different postural positions with capture thresholds of the LV lead taken at each postural position.
223507731|NCT04275414|DRUG|Bevacizumab Injection|Bevacizumab 500mg + normal saline (NS) 100ml, ivdrip ≥90min
223507732|NCT02614664|DEVICE|NIRS|Cerebral oxygenation monitor which is standard of care for this surgery.
223507733|NCT01213771|PROCEDURE|Preoperative preparation 2010|Preoperative optimisation Supportive care LEAN in patient pathways
223507734|NCT04331379|DEVICE|Nasal Elevator|A device aiming to elevate the clefted nostril extraorally and fixed on the forehead.
223507735|NCT04331379|DEVICE|Taping Alone|Horizontal tape alone.
223507736|NCT02526394|BIOLOGICAL|Meningococcal vaccine|Meningococcal vaccination
223507737|NCT02526394|DRUG|Pertussis containing vaccine|Pertussis containing vaccination
223507738|NCT00183391|DRUG|Atomoxetine|Participants will be randomly assigned to receive either methylphenidate or atomoxetine for either 2 or 5 weeks, depending on how soon they respond to the treatment. After the 2- or 5-week period, participants will be crossed-over to receive whichever medication they did not receive in the first part of the study.
223507739|NCT00183391|DRUG|Methylphenidate|Participants will be randomly assigned to receive either methylphenidate or atomoxetine for either 2 or 5 weeks, depending on how soon they respond to the treatment. After the 2- or 5-week period, participants will be crossed-over to receive whichever medication they did not receive in the first part of the study.
223750944|NCT05005390|DEVICE|Mask Ventilation|In mask ventilation, a mask is placed over the nose and mouth.
223750945|NCT01347138|OTHER|case management|confirmation of hospital visit date, checking the adverse effect and treatment compliance
224075340|NCT05607823|OTHER|Conventional Physiotherapy|Conventional physiotherapy consists of home exercise and patient education. Patient education consists of parafunctional behaviors, habits, a diet with soft food, and posture education. The exercises consist of exercises for the mandible, cervical and thoracic region and breathing. All movements are planned to be done at home 3 times a day, every day of the week.
224075341|NCT05807035|BIOLOGICAL|Radvax|Vaccine extracted from patient's own tumour tissue formulated with polysaccharide adjuvant
224075342|NCT06323616|PROCEDURE|MAC adjustment to PSI between 25 and 50|According to SedLine monitoring, the depth of anesthesia will be adjusted by changing the amount of sevoflurane so that the PSI median value is between 25 and 50.
223603242|NCT01222780|DRUG|Marqibo|Marqibo® intravenously (IV) over 60 minutes (+ 10 minutes) every 7 days (+ 3 days) for 4 consecutive weeks (day 1, 8, 15, 22) for a 28-day treatment cycle
223603243|NCT00345865|DRUG|carmustine|Day -6, 300 mg/m\^2 over 2 hour
223603244|NCT00345865|DRUG|cyclophosphamide|"NHL with radiation: Cyclophosphamide 60 mg/kg intravenous (IV) over two hours daily x 2 days.~HL without radiation: Cyclophosphamide, Days - 6 through -3, 1.5 gm/m\^2 over 2 hours daily x 4 days.~Cyclophosphamide will be dosed based on actual body weight (ABW) unless the patient is 20% or more of ideal body weight (IBW). If more than 20% of ideal body weight, an adjusted ideal body weight (AIBW) will be used for dosing."
223603245|NCT00345865|DRUG|etoposide|"NHL without radiation and cyclophosphamide: Etoposide 100 mg/m2 IV over 2 hours twice daily on Day -5 through -2.~HL without radiation: 150 mg/m\^2 intravenously over 4 hours every 12 hours for 6 total doses on Days -6 through -4."
223603246|NCT00345865|PROCEDURE|peripheral blood stem cell transplantation|Day 0 infuse PBSC. All patients will have PBSC collected by leukapheresis. Mobilization will be done with G-CSF alone (filgrastim) or using ifosfamide/carboplatin/etoposide and with or without rituximab. Leukapheresis is to begin on Day 5.
223603247|NCT00345865|RADIATION|irradiation therapy|"Patients undergo total body irradiation (TBI) twice daily on days -4 to -1.~* \> 1000 cGy to whole lung, kidney, or abdominal bath.~* \> 3000 cGy to spinal cord, myocardium, mediastinum, lumbar periaortic lymph nodes.~* \> 3600 cGy to whole brain."
223603248|NCT00345865|BIOLOGICAL|G-CSF|"Day 5: Begin G-CSF 5μg/kg/day subcutaneously (SQ) rounded to the nearest vial size.~Continue G-CSF until absolute neutrophil count (ANC) \> 1500/μl x 3 consecutive days.~If ANC falls \<1000/μL, restart G-CSF."
223603249|NCT00345865|DRUG|Cytarabine|100 mg/m\^2 over one hour BID on days -6 through -2 of BEAM conditioning regimen.
223603250|NCT05651867|DEVICE|EPIONE device|The EPIONE device is a user controlled, stereotactic accessory intended to assist in the planning and manual advancement of one or more instruments, as well as in verification of instrument position during Computed Tomography (CT) guided percutaneous procedures.
223603251|NCT00005024|DRUG|carboplatin|
223603252|NCT00005024|DRUG|cyclophosphamide|
223603253|NCT00005024|DRUG|doxorubicin hydrochloride|
223603254|NCT00005024|DRUG|granisetron hydrochloride|
223603255|NCT05771740|DEVICE|Stemoscope (bluetooth sound amplifier)|The bluetooth device will be placed in six locations on the front and six locations on the back of the chest and sound recordings stored for each location.
223603256|NCT02553395|DEVICE|Phenacite (Test) contact lens|
223603257|NCT02553395|DEVICE|comfilcon A contact lens|
223603258|NCT03114332|PROCEDURE|Subcutaneous Drain|A closed drainage system for the subcutaneous tissue was used (Redivac) through a separate stab wound. Drains were left in place for 24 h or until drainage was less than 50 ml.
223603259|NCT02159976|DRUG|Pantoprazole|Pantoprazole 40mg bid
223603260|NCT02159976|DRUG|Amoxicillin|Amoxicillin 1000mg bid
223603261|NCT02159976|DRUG|Clarithromycin|Clarithromycin 500mg bid
223603262|NCT02159976|DRUG|Metronidazole|Metronidazole 500mg tid
223603263|NCT02159976|DRUG|Tetracycline|Tetracycline 1000mg bid
223603264|NCT02159976|DRUG|Bismuth|Bismuth 600mg bid
224200222|NCT04712968|BEHAVIORAL|Regular exposure to morning daylight|"Participants are asked to stay outside in morning daylight for minimum 30 minutes each day before 1 pm for 6 weeks. A specific plan for individual outdoor possibilities for daylight exposure is made (e.g. a walk, a stay in a park or in their garden, a bike trip). Furthermore a detailed instruction to the personal light tracker LYS Button and the matching LYS Insight app is provided. The LYS Insight app gives the user access to real-time insight of light stimulus. Further, the participants receive psycho-education on the connection between exposure to morning daylight and antidepressant effect. All participants in this group receive the intervention as add-on to usual treatment, which may comprise prescribed antidepressants, psychotherapy, including psycho-education and psychiatric care."
223603265|NCT04576026|BEHAVIORAL|mental fatiguing task|a 30-minute computerized Stroop test will be used to induce mental fatigue before exercise intervention
223603266|NCT04576026|BEHAVIORAL|45 - minute simulated soccer game|an intermittent running protocol using intensities and speeds seen in soccer will be used to simulate the physiological demands of the sport
223603267|NCT04576026|BEHAVIORAL|cognitive function|The Stroop test and a complex reaction time test will be used to assess cognitive function during exercise.
223603268|NCT05044858|PROCEDURE|Midpoint transverse process block group|After marking the level of the incision by surgeon (commonly T5- T6) The patient will be situated in the lateral position, the block area will be sterilized with povidine-iodine, and high -frequency linear ultrasound probe will be placed oblique parasagittally 3 cm lateral to the spinous process at the level of skin incision. 100-mm short bevel echogenic needle (Contiplex, B.Braun, Germany) will be inserted in plane from cranial to caudal direction. The desired end point of the needle tip will be the midpoint of the line between the posterior border of transverse process and the pleura titrated bolus of 20 ml of 0.25% bupivacaine and dexamethazone 8 mg will be injected at the target site. At end of the surgery general anaesthesia will be stopped with reversal of muscle relaxation and awakening of patient
223603269|NCT05044858|PROCEDURE|Sham group|"General anesthesia will be induced with the same protocol and MTP block will be done but with injection of placebo (2 ml normal saline) instead of local anesthetic .~On arrival to the PACU postoperative Numerical Rating scale at rest and coughing will be recorded, analgesia will be maintained with intravenous paracetamol 1 g every 8 h and required additional rescue analgesia (morphine) at any time will be calculated."
223603270|NCT00933868|DRUG|Magnesium Chloride|An infusion of magnesium chloride will be given over 4 to 10 minutes in patients breathing 100% oxygen
223603271|NCT00933868|DRUG|Placebo|A saline placebo will be given as an infusion (six infusions over a three week period) in a double blind manner with the active test agent
223603272|NCT03060278|BEHAVIORAL|Self-help materials|Self-help smoking cessation materials.
223603273|NCT03060278|DRUG|nicotine patch|Participants who smoke \>10 cigarettes per day will receive 4 weeks of 21 mg, 2 weeks of 14 mg and 2 weeks of 7 mg nicotine patches. Participants who smoke \< 10 cigarettes per day will receive 6 weeks of 14 mg and 2 weeks of 7 mg nicotine patches.
223603274|NCT03060278|OTHER|Smartphone-delivered automated treatment|Tailored video clips, text and graphical messages delivered automatically each week to the participant.
223603275|NCT03060278|BEHAVIORAL|Counseling|Proactive phone counseling with a Certified Tobacco Treatment Counselor
223507740|NCT04651374|DEVICE|geko T3|The device stimulates the peroneal nerve.It will be applied for the entire duration of ICU stay and replaced once every 24 hours.
223507741|NCT05163535|DRUG|VM-1500A-LAI|VM-1500A (parent drug of elsulfavirine) IM injection dosage form
223507742|NCT05163535|OTHER|ELPIDA®|Elsulfavirine capsules
223507743|NCT02636322|DRUG|Cyclophosphamide|Given IV
223507744|NCT02636322|DRUG|Doxorubicin Hydrochloride|Given IV
223507745|NCT02636322|DRUG|Etoposide|Given IV
223507746|NCT02636322|DRUG|Ibrutinib|Given PO
223507747|NCT02636322|DRUG|Lenalidomide|Given PO
223507748|NCT02636322|DRUG|Prednisone|Given PO
223507749|NCT02636322|BIOLOGICAL|Rituximab|Given IV
223507750|NCT02636322|DRUG|Vincristine Sulfate|Given IV
223507751|NCT00512044|PROCEDURE|Local anesthesia (pudendal block)|local anesthesia as indicated
223507752|NCT00512044|PROCEDURE|general anesthesia (spinal and general)|general according to guidelines
223507753|NCT02326090|DRUG|cis-UCA ophthalmic solution 1.0%|
223507754|NCT02326090|DRUG|cis-UCA ophthalmic solution 2.5%|
223507755|NCT02326090|DRUG|Placebo ophthalmic solution|
223507756|NCT03922971|OTHER|Option 1: National comparison|Ability to view center's rate compared with all others.
223507757|NCT03922971|OTHER|Option 2: National comparison with benchmarking|Ability to view center's rate compared with the others with a similar patient comorbidity profile and in addition to viewing option 1.
223507758|NCT00649571|DRUG|Doxycycline Monohydrate Tablets (100 mg|100mg, single dose fasting
223507759|NCT00649571|DRUG|Adoxa Tablets 100 mg|100mg, single dose fasting
223507760|NCT00647023|DRUG|metformin|1000 mg metformin x 2 daily during 8 months
223507761|NCT02696577|DRUG|Low dose aspirin|
223507762|NCT02696577|DRUG|Omega 3|
223507763|NCT05192083|BEHAVIORAL|Self-management and Support|A smartphone-based self-management support programme includes a 30-min face-to-face or online session at baseline, 3 phone calls and 2-month mobile messages
223507764|NCT02336503|DRUG|BBI-4000 Gel, 5%|BBI-4000 Gel, 5%
223507765|NCT02336503|DRUG|BBI-4000 Gel, 10%|BBI-4000 Gel, 10%
223507766|NCT02336503|DRUG|BBI-4000 Gel, 15%|BBI-4000 Gel, 15%
223507767|NCT02336503|DRUG|Vehicle|Placebo, BBI-4000 Gel, 0%
223507768|NCT03978208|DRUG|ATB-346 low dose|Double blind comparison of orally administered ATB-346 versus placebo in osteoarthritis patients
223507769|NCT03978208|OTHER|Placebo|Double blind comparison of orally administered ATB-346 versus placebo in osteoarthritis patients
223507770|NCT03978208|DRUG|ATB-346 mid-dose|Double blind comparison of orally administered ATB-346 versus placebo in osteoarthritis patients
223507771|NCT03978208|DRUG|ATB-346 standard dose|Double blind comparison of orally administered ATB-346 versus placebo in osteoarthritis patients
223507772|NCT04697992|DRUG|vitamin c 20%|one eye was treated with vitamin c 20% + microneedling a session was done every 2 weeks a total of 4 sessions (other eye was placebo treated with saline + microneedling).
223507773|NCT04697992|DRUG|Tranexamic acid 5mg/ml|one eye was treated with tranexamin acid 5 mg/ml + microneedling a session was done every 2 weeks a total of 4 sessions (other eye was placebo treated with saline + microneedling)
223507774|NCT04867330|OTHER|Toxicities reduced treatment arm|Two cycles Toripalimab+docetaxel+cisplatin induction chemotherapy followed by reducing radiation dose(60Gy/30Fx) and omitting concurrent cisplatin chemotherapy when responses to induction chemotherapy are ≥ 50% Partial Response(PR)
223507775|NCT04744532|DRUG|Bosutinib (Phase 1 part)|Subjects will receive 100 mg, 200mg, 300mg or 400 mg of bosutinib once daily, orally.
223507776|NCT04744532|DRUG|Bosutinib (Phase 2 part)|Subjects will receive 200mg/day or 300mg/day of bosutinib once daily, orally.
223507777|NCT02460380|DRUG|Vitamin D3|Women allocated to vitamin D arm received one capsule 50.000 IU of vitamin D3 once weekly for eight weeks.
223507778|NCT02460380|OTHER|Placebo|Women in the placebo arm received once capsule of placebo once weekly for eight weeks
223507779|NCT01146444|OTHER|UV A and B irradiation|UV irradiation
223507780|NCT01183286|BEHAVIORAL|CFFONE|A password-protected, secure website, which can be accessed via a web capable cell phone. The website contains age appropriate medical and behavioral information, disease management tools and social networking features for adolescents and young people who have Cystic Fibrosis.
223507781|NCT01183286|BEHAVIORAL|CF website|A CF-related educational website which has some areas of CF information and services relevant to adolescents.
223507782|NCT00395512|DRUG|Alogliptin|Alogliptin tablets.
223507783|NCT00395512|DRUG|Pioglitazone|Pioglitazone tablets.
223507784|NCT00395512|DRUG|Placebo|Matching placebo tablets.
223507785|NCT03303066|DRUG|FG-4592|Oral
223507786|NCT03303066|DRUG|Placebo|Oral
223507787|NCT00682838|BEHAVIORAL|Self-management|Self-management
223507788|NCT00682838|BEHAVIORAL|Telemonitored care|Telemonitored care
223507789|NCT01986751|DRUG|Clonidine|
223507790|NCT01986751|DRUG|ropivacaine|
223507791|NCT00581789|DRUG|erlotinib, sunitinib|erlotinib 150mg PO daily + sunitinib 25mg PO daily (level 1) or 37.5mg PO daily (level 2)
223507792|NCT02388789|OTHER|active movement|same as arm description
223507793|NCT02912520|DRUG|Anti-Bacterial Agents|administration of any antibiotic substance(s) over the course of 2 weeks
223507794|NCT01478087|DEVICE|Mysorba|Subjects will undergo one cycle of five immunoadsorption (IA) treatment sessions over two weeks.
223507795|NCT03566550|DIAGNOSTIC_TEST|MRI scans|Repeated MRI scans imaging digestion of standard meals
223507796|NCT00485849|DRUG|Atomoxetine Hydrochloride|
223507797|NCT02618187|DRUG|SER-287|
223507798|NCT02618187|DRUG|Placebo|
223507799|NCT02618187|DRUG|Placebo Pre-Treat|
223507800|NCT02618187|DRUG|Vancomycin Pre-Treat|
224075343|NCT06233656|BEHAVIORAL|Acceptance and commitment therapy (ACT)|Participants assigned to the ACT group will receive 8 weekly individual ACT sessions guided by a coach for one hour per week over 8 weeks through Zoom videoconferencing.
224075344|NCT05206357|DRUG|Epcoritamab|Subcutaneous Injection (SC)
224075345|NCT05030311|DRUG|LOU064 25 mg (b.i.d)|LOU064 25 mg was administered by oral route twice a day (b.i.d) as a tablet.
224075346|NCT05030311|DRUG|Placebo|Placebo
223750946|NCT02134873|OTHER|sucrose|Sucrose will be administered by a research nurse experienced in neonatal intensive care using a standardized procedure and timing consistent with policies in the participating units, including: (a) administering sucrose 2 minutes prior to the heel lance to ensure peak effects; (b) giving the total volume of sucrose drop by drop via syringe on the anterior surface of the tongue, as tolerated, over a period of up to 1 minute to allow for individual infant swallowing rates and to ensure analgesic effects are sustained during the heel lance procedure; and (c) offering a pacifier for non-nutritive sucking (NNS) immediately following sucrose administration.
223750947|NCT02597556|DRUG|Albendazole|A single 400mg dose of Albendazole administered at 0, 3, 6, 9, and 12 months.
223603276|NCT02914574|OTHER|PowersTM strap|The powers strap aims to decrease knee varus through supporting femoral abduction and external rotation. Participants will wear the Powers strap while performing functional tasks (running, squatting, single leg step down).
223603277|NCT00394706|DEVICE|Impedance Threshold Device (ITD)|Use of Impedance Threshold Device (ITD)
223603278|NCT00394706|DEVICE|Sham ITD|Sham ITD
223603279|NCT00394706|OTHER|Analyze early|Upon EMS arrival at the scene of a non-traumatic cardiac arrest, an assessment of the cardiac rhythm is done to determine whether a defibrillatory shock is required.
223603280|NCT00394706|OTHER|Analyze later|Upon EMS arrival at the scene of a non-traumatic cardiac arrest, three minutes of CPR is given prior to the assessment of the cardiac rhythm to determine whether a defibrillatory shock is required.
223603281|NCT04270799|DIAGNOSTIC_TEST|Machine Learning Classification|Patient's scans will be used as input into in-house software to extract multiple radiomics features. These features will be used to develop a risk-signature which can predict malignancy risk. Patient scans will also be used as input into deep learning/convolutional neural network models to perform automated imaging classification.
223603282|NCT04846322|DIAGNOSTIC_TEST|PD4ED 3-step intervention (ED assessment, outpatient assessment, Brain health plan)|"1. ED assessment for suspected dementia.~2. positive ED patients referred for outpatient clinic cognitive impairment assessment.~3. positive clinic patients referred to primary care with brain health patient plan."
223603283|NCT02466282|DEVICE|Angiography-guided PCI with bioresorbable vascular scaffold|Everolimus-eluting bioresorbable vascular scaffold (Absorb, Abbott Vascular, Santa Clara, CA, USA) was made from a bioabsorbable polylactic acid backbone which is coated with a more rapidly absorbed polylactic acid layer that contains and controls the release of the antiproliferative drug, everolimus. PCI will be performed with BVS under conventional coronary angiography without any other intravascular imaging modality.
223603284|NCT02466282|DEVICE|optical coherence tomography-guided PCI with bioresorbable vascular scaffold|Everolimus-eluting bioresorbable vascular scaffold (Absorb, Abbott Vascular, Santa Clara, CA, USA) was made from a bioabsorbable polylactic acid backbone which is coated with a more rapidly absorbed polylactic acid layer that contains and controls the release of the antiproliferative drug, everolimus. For optimized PCI, both conventional coronary angiography and optical coherence tomography can be used before and after stent implantation. OCT study should be checked at the final post-procedure and stent implantation is optimized.
223603285|NCT01649934|BEHAVIORAL|Implementation Intention|Implementation Intentions are a series of what/when/where statements that a participant will make to create automatic cues to complete a behaviorally advantageous action.
223750948|NCT02597556|DRUG|Placebo|Matching placebo tablet administered at 0, 3, 6, and 9 months. At month 12, all participants will receive a single dose of 400mg Albendazole.
223750949|NCT00666757|DRUG|duloxetine|30-120 milligrams (mgs) orally daily for 12 weeks
223750950|NCT00666757|DRUG|fluoxetine|20-80 mgs orally daily for 12 weeks
223750951|NCT00666757|DRUG|citalopram|20-40 mgs orally daily for 12 weeks
223750952|NCT00666757|DRUG|paroxetine|20-50 mgs orally daily for 12 weeks
223750953|NCT00666757|DRUG|sertraline|50-200 mgs orally daily for 12 weeks
223750954|NCT06072547|OTHER|Access to all varieties of on! 4mg nicotine pouches (Berry, Citrus, Cinnamon, Wintergreen, Mint, Coffee, and Original)|Access to all varieties of on! 4mg nicotine pouch products (Berry, Citrus, Cinnamon, Wintergreen, Mint, Coffee, and Original), throughout the trial.
223750955|NCT06072547|OTHER|Access to Original on! 4mg nicotine pouches|Access to non-flavored (i.e., Original) 4mg on! nicotine pouch products throughout the trial.
223603286|NCT01649934|BEHAVIORAL|Contact Clinic|Participants will be asked to sign a form indicating their need to contact the recommended clinics to make their appointments.
223603287|NCT03737539|DIAGNOSTIC_TEST|Multigene methylation detection|Colorectal tumor-specific plasma ctDNA methylation markers detection
223603288|NCT01469273|DRUG|Mutaflor® Suspension|Application of Mutaflor-Suspension on 10 consecutive days.
223603289|NCT04684069|DEVICE|Long-axis syringe free in-plane|Long-axis syringe-free in-plane catheter placement
223603290|NCT04684069|DEVICE|Short-axis out-of-plane|Short-axis out-of-plane catheter placement
223750956|NCT06072547|OTHER|Non-Flavored then complete flavor on! nicotine pouches|Access to non-flavored (i.e., Original) on! 4mg nicotine pouch products during the first 3 weeks and then access to all varieties (Berry, Citrus, Cinnamon, Wintergreen, Mint, Coffee, and Original) of on! 4mg nicotine pouch products during the rest of the trial
223750957|NCT02975921|DRUG|Povidone-Iodine|Intrapleural administration of Povidone-Iodine
223750958|NCT05398978|OTHER|e-Registration and mHealth|Registration to the electronic database Counseling through voice calls for facility delivery Text messages to promote facility delivery
223750959|NCT02980965|DRUG|letrozole, leuprorelin, fluorouracil, epirubicin, cyclophosphamide, docetaxel|Postmenopausal patients were treated with letrozole 2.5mg/day p.o until complement of neoadjuvant chemotherapy before surgery, while premenopausal ones received letrozole 2.5mg/day p.o and a subcutaneous injection of the GnRH-a, leuprorelin, as concomitant treatment with neoadjuvant chemotherapy (fluorouracil 600mg/m2 IV, epirubicin 90mg/m2 IV and cyclophosphamide 600mg/m2 IV on day 1 at 3-weekly intervals for 3 cycles followed by docetaxel 100mg/m2 IV on day 1 at 3-weekly intervals for 3 cycles; or epirubicin 90mg/m2 IV and cyclophosphamide 600mg/m2 IV on day 1 at 2-weekly intervals for 4 cycles, followed by docetaxel 80mg/m2 IV on day 1 at 2-weekly intervals for 4 cycles), letrozole was delivered after 1 week of first dose of leuprorelin injection.
224075347|NCT05030311|DRUG|LOU064 25 mg (b.i.d) as a tablet.|LOU064 25 mg was administered by oral route twice a day (b.i.d) as a tablet in open label phase.
224075348|NCT02484417|BIOLOGICAL|RSV A2|Intranasal inoculation of healthy volunteers with 10\^5 or 10\^6.3 plaque forming units (PFU) of RSV A2.
223750960|NCT02980965|DRUG|fluorouracil, epirubicin, cyclophosphamide, docetaxel|Patients received fluorouracil 500mg/m2 IV, epirubicin 90mg/m2 IV and cyclophosphamide 500mg/m2 IV on day 1 at 3-weekly intervals for 3 cycles followed by docetaxel 100mg/m2 IV on day 1 at 3-weekly intervals for 3 cycles; or epirubicin 90mg/m2 IV and cyclophosphamide 600mg/m2 IV on day 1 at 2-weekly intervals for 4 cycles, followed by docetaxel 100mg/m2 IV on day 1 at 2-weekly intervals for 4 cycles.
223603291|NCT05185999|DRUG|Icodextrin/Dextrose|Single 8 hour dwell of a 500mL intraperitoneal sodium-free 30% Icodextrin / 10% Dextrose solution
223603292|NCT06113055|DRUG|L-serine|Active comparator
223750961|NCT05547321|DRUG|OMTX705|The investigational product is OMTX705 administered as monotherapy.
223603293|NCT06113055|DRUG|Placebo|Placebo comparator
223603294|NCT06165328|DIAGNOSTIC_TEST|CT and colonoscopy|All patients were admitted and worked up as inpatient cases. A blood test was obtained and a CT whole abdomen was performed for all patients in the evening. On the next day, all patients were prescribed for bowel preparation in the morning, then subsequently underwent colonoscopy in the afternoon.
223603295|NCT03369249|BEHAVIORAL|Link2CARE|The Link2CARE intervention consists of 4 sessions. Session 1 consists of a one-on-one meeting with a Health Coach, during which participants will be offered an oral rapid HIV test and STI test. Sessions 2, 3, and 4 are group-based. During these sessions, participants will engage in discussions and activities regarding sexual and substance use risk behaviors.
223603296|NCT02003534|DRUG|0.15% Brimonidine Tartrate|0.15% Brimonidine Tartrate (Alphagan® P) 1 drop in the affected eye 3 times daily for 3 months.
223603297|NCT02133885|DRUG|Minocycline Group|These subjects will start with minocycline for 16 weeks, followed by a washout period for 3 weeks, then will receive a placebo for 16 weeks, followed by a washout period for 3 weeks, then will finish with minocycline for 16 weeks.
223603298|NCT02133885|OTHER|Placebo Group|These subjects will start with placebo (tablet looking just like minocycline) for 16 weeks, followed by a washout period for 3 weeks, then will receive minocycline for 16 weeks, followed by a washout period for 3 weeks, then will finish with placebo for 16 weeks.
223603299|NCT00640497|BIOLOGICAL|IT-Combination|The treatment consists of a standard dose of 4 infusions of IT-combination (4 mg/m2), given 48-hours apart over a 4-hour period. The IT-combination is a combination of two immunotoxins. One immunotoxin is a mAb anti-CD3 conjugated to recombinant ricin A chain and the other immunotoxin is a mAb anti-CD7 conjugated to recombinant ricin A chain.
223603300|NCT04429191|BIOLOGICAL|Humanized anti-CD117 Monoclonal Antibody (JSP191)|Procedure: single intravenous infusion of JSP191 antibody
223603301|NCT01817023|RADIATION|SIB-IMRT|SIB-IMRT was given to the patients with regimen of 69.96Gy-73.92Gy to the gross target volume, 60Gy to the high risk clinical target volume, 50Gy to the low risk clinical target volume
223603302|NCT01817023|DRUG|Cisplatin|Cisplatin 100mg/m2 was delivered at d1,d22 and d43 to the CCRT group patients during radiotherapy.
223603303|NCT03094741|OTHER|CancerLife|CancerLife is a mobile digital solution that allows patients to broadcast their health status inside a private invitation only group, text, email or publicly in Facebook or Instagram. By doing, so the patient collects his/her own patient-reported outcomes data and then share this data with their doctor or care team.
223603304|NCT05878535|DRUG|Metformin|Metformin 850 mg oral tablets. Prescribed: Once daily PO with meals and 200 mL of water. The dose can be up-titrated to 1500-2000 mg divided q8-12hr with meals in enrolled diabetic patients as a monotherapy or combined with sulfonylurea.
223603305|NCT05878535|DRUG|Placebo|Placebo oral tablets. Prescribed: Once daily PO with meals and 200 mL of water.
223603306|NCT05139784|OTHER|Biosampling|Collection of blood and stool specimens; and collection of lymph node specimens for the group undergoing surgical lymphadenectomy.
223603307|NCT00117260|DRUG|Seasonale (levonorgestrel and ethinyl estradiol)|
223603308|NCT06535620|OTHER|red wine with alcohol|200 ml of red wine - Demi sec Bordeaux wine 'La Dorni' (alcohol content at 20ºC of 10.1% - Alves \& Martins Bebidas Especiais LTDA - Bandeirantes, Parana - Brazil)
223603309|NCT06535620|OTHER|red wine without alcohol|200 ml of red wine without alcohol - Demi sec Bordeaux wine 'Casa Navaronne' (alcohol content at 20ºC of 0.23% - Alves \& Martins Bebidas Especiais LTDA - Bandeirantes, Parana - Brazil)
223603310|NCT01862523|BIOLOGICAL|Capsaicin|Thirty-three\* well-characterized IR patients will be recruited and screened for participation in this study with nasal capsaicin spray (0,1 mmol/l ) using the treatment regimen described by van Rijswijk et al. (1 x 5 applications in one day, with 1 hour between each application)
223603311|NCT01862523|BIOLOGICAL|diluent|diluent
223603312|NCT05020080|OTHER|Operant conditioning of motor evoked potentials|MEPs elicited by TMS will be applied at the hot spot for the wrist extensor carpi radialis. During training trials, participants will be asked to increase the size of their MEP response. During assessment trials, a physical therapist or occupational therapist will rate the functional level of arm impairment using FMA and ARAT.
223603313|NCT01947751|PROCEDURE|CVC exchange|CVC exchange when related infection is suspected
223750962|NCT05547321|DRUG|Pembrolizumab|The investigational product is OMTX705 administered in combination with pembrolizumab.
223750963|NCT03171350|DIAGNOSTIC_TEST|ellume.lab Group A Streptococcus Test|ellume.lab Group A Streptococcus Test is a rapid diagnostic test intended to be used as an aid in the diagnosis of Group A Streptococcus in symptomatic patients. The sample type used is a throat swab.
223750964|NCT02427867|OTHER|Remote ischemic preconditioning|
223750965|NCT02427867|OTHER|no ischemic preconditioning|
223750966|NCT00613028|DRUG|Temo + Avastin|Patients have progressed/had gr3/\> toxicity related to etoposide, with no had progression/gr 3/\> toxicity related to temozolomide, will only be considered for bevacizumab and temozolomide. Bevacizumab intravenously at dose 10mg/kg every other wk. For patients on bevacizumab and temozolomide, temozolomide administered on continuous dosing schedule at 50mg/m2/day.
223750967|NCT00613028|DRUG|VP-16 + Avastin|Patients have progressed/had gr3/\> toxicity related to temozolomide, but have not progressed/gr3/\> toxicity related to etoposide,considered only for bevacizumab and etoposide. Bevacizumab intravenously at dose 10mg/kg every other wk. Patients on bevacizumab and etoposide, etoposide once daily at 50mg/m2/day first 21 days of each 28-day cycle.
223603314|NCT01947751|DRUG|CVC maintenance|CVC maintenance and adding antibiotic therapy when related infection is suspected, waiting for the cultures to take the decision of changing CVC
223750968|NCT00880529|DEVICE|ON-Q bupivicaine administration|continuous subcutaneous bupivicaine drip
223750969|NCT00880529|DRUG|IV opioid administration|Patient controlled analgesia with IV narcotics
223750970|NCT04227184|DRUG|Trospium|Drug to treat overactive bladder
223750971|NCT04227184|DRUG|Placebo oral tablet|Placebo tablet containing no active drug
223750972|NCT02681549|DRUG|Pembrolizumab plus Bevacizumab|Pembrolizumab will be administered on day 1 of every cycle until disease progression or withdrawal from study. Bevacizumab will be administered in addition to pembrolizumab on day 1 of cycles 1, 2, 3, and 4 (or alternative cycles if bevacizumab is held during these cycles). Three weeks constitutes one cycle.
223750973|NCT03318991|PROCEDURE|Laser prostatectomy|Patients with symptomatic benign prostate obstruction (BPO) will be assigned under randomisation to treat with GreenLight laser or thulium laser.
223750974|NCT05202847|PROCEDURE|pulsed radiofrequency ablation to modifined points group|Point 1 place 10mm higher than the boundary between Femur's medial epicondyle and shaft. The 2nd point is targeted 20mm above the patella. Point 3 is targeted 10mm above the femur lateral epicondyle and shaft boundary. At point 4, find the boundary position between the tibia epicondyle and the shaft in the AP view and move it superolateral by 10 mm to target the central part of the medial shaft of the tibia and perform the main touch. Point 5 targets the center of the fibular head.
223750975|NCT05202847|PROCEDURE|pulsed radiofrequency ablation to conventional points group|Under AP view X-ray fluoroscopy, enter the cannula into the tunnel view until reaching the bone, reaching the border of the shaft and epicondyle, then stop the cannula tip at the anterior 2/3 junction in the lateral view. A total of three target points are the boundary position between the femur medial epicondyle and the shaft, the boundary position between the femur lateral epicondyle and the shaft, and the boundary position between the tibia meidal epiconcyle and the shaft. Subsequent procedure will be proceed same as Arm 1
223750976|NCT00344383|DRUG|Norgestimate/Ethinyl Estradiol tablet|
223750977|NCT06143332|OTHER|Aerobic exercise training|Aerobic exercise training on a cycle ergometer
223750978|NCT03674866|DRUG|Insulin degludec|Participants are treated with Tresiba® (insulin degludec) under conditions of routine care.
223603315|NCT04253002|BEHAVIORAL|Robinson's Culturally Adapted Coping with Stress Course (A-CWS)|Participants randomized to the experimental condition will take part in the Adapted Coping with Stress Course (A-CWS). The A-CWS is a 15-session, cognitive-behavioral group intervention designed to develop and enhance African American youths' skills to adaptively cope with stress, using standard cognitive-behavioral strategies such as relaxation training and cognitive restructuring. Emphasis is given to the identification of individual and contextual factors associated with suicide risk and the unique day-to-day experiences of the youth, providing options for adaptive coping (e.g., positive thinking) that are culturally consistent. The A-CWS is structured and manualized to allow its transportability to service providers working in similar environments with similar youth.
223603316|NCT04253002|BEHAVIORAL|Standard Care Control Condition|Students meeting criteria for study inclusion and randomized into the standard care condition will be referred to the school-based health center (SBHC) mental health provider for case management. Standard care may range from (1) brief intervention by the SBHC mental health provider to (2) outside referral to local community service providers; these determinations will be made by the SBHC mental health team.
223603317|NCT04120961|DRUG|prolonged continuous use of bivalirudin|prolonged continuous use of bivalirudin 4 hours after elective PCI (dose: 0.75 mg/kg bolus plus 1.75 mg/kg per hour)
223603318|NCT04120961|DRUG|bivalirudin use during ePCI|bivalirudin use during ePCI (0.75 mg/kg bolus plus 1.75 mg/kg per hour)
223603319|NCT03271502|PROCEDURE|Total intravenous anesthesia|Total intravenous anesthesia with propofol and remifentanil
223603320|NCT03271502|PROCEDURE|Inhalation anesthesia|Inhalation anesthesia with sevoflurane and remifentanil
223603321|NCT00972725|BIOLOGICAL|GSK Biologicals' HIV vaccine (732461)|1 dose intramuscular injection
223603322|NCT00972725|DRUG|Chloroquine|One dose of 300 mg
223603323|NCT02506192|DRUG|Modified-Release Prednisone|Modified-Release Prednisone oral tablets (2x5mg) daily for 8 weeks
223603324|NCT02506192|DRUG|Placebo|Placebo oral tablets (2x5mg) daily for 8 weeks
223603325|NCT03549377|BEHAVIORAL|Deception|Participants will be deceived during delayed gratification task.
223750979|NCT00271479|BIOLOGICAL|A, C, Y, W135 meningococcal polysaccharide vaccine|
223750980|NCT00952341|DRUG|aprepitant|Day 1: Oral aprepitant 125 mg prior to administration of cisplatin; Days 2 and 3: Oral aprepitant 80 mg
223750981|NCT00952341|DRUG|Comparator: Placebo to aprepitant|Day 1: Placebo to oral aprepitant 125 mg prior to administration of cisplatin; Days 2 and 3: Placebo to oral aprepitant 80 mg
223750982|NCT00952341|DRUG|dexamethasone|Day 1: Oral dexamethasone 10.5 mg prior to administration of cisplatin; Days 2, 3, and 4: Oral dexamethasone 7.5 mg
223603326|NCT00694668|BEHAVIORAL|Cognitive Behavioral treatment|Brief cognitive behavioral therapy (12 sessions)
223603327|NCT00694668|BEHAVIORAL|Mindfulness based cognitive therapy|9 sessions MBCT in a group-format (up to 8 persons)
223603328|NCT02548338|PROCEDURE|argon plasma coagulation|On the first group we use the regular electric scalpel to perform the surgery , and on the second group we use the argon plasma coagulation scalpel to perform the procedure.
223603329|NCT04853719|DRUG|Rivaroxaban 2.5 Mg Oral Tablet|oral anticoagulants plus antiplatelet agent
223603330|NCT03936257|OTHER|Breastfeeding|Infants were breastfed during 3 months minimum. Data on growth and tolerance were collected. 10 out of 40 infants take a blood test to metabolome analysis
223603331|NCT03936257|OTHER|Conventional BIO Infant formula|Infant were fed during 6 months with a conventional BIO infant formula. Data on growth and tolerance were collected. 10 out of 40 infants take a blood test to metabolome analysis
223750983|NCT00952341|DRUG|granisetron|Day 1: IV granisetron 3 mg prior to administration of cisplatin
223750984|NCT00952341|DRUG|dexamethasone|Day 1: oral dexamethasone 6 mg prior to the administration of cisplatin; Days 2 and 3: oral dexamethasone 3.75 mg
223750985|NCT00024089|DRUG|gefitinib|
223750986|NCT03570866|DIAGNOSTIC_TEST|Positron emission tomography and computed tomography|Preoperative staging of early stage intermediate and high-risk endometrial cancer with positron emission tomography and computed tomography.
223750987|NCT03570866|PROCEDURE|Surgical treatment|Surgical treatment of early stage intermediate and high-risk endometrial cancer by usual practice: peritoneal cytology, total abdominal hysterectomy, bilateral salpingo-oophorectomy, systematic pelvic and para-aortic lymphadenectomy.
223750988|NCT04573036|DRUG|HRS4800 tablets|single oral administration
223603332|NCT03936257|OTHER|TrueGreen BIO infant formula|Infant were fed during 6 months with the TrueGreen BIO infant formula. Data on growth and tolerance were collected. 10 out of 40 infants take a blood test to metabolome analysis
223750989|NCT04573036|DRUG|Placebo tablets|single oral administration
223750990|NCT06450171|OTHER|GRAIL Galleri Test|A multi-cancer early detection (MCED) blood test.
223750991|NCT06343311|BIOLOGICAL|EB103|EB103 is an autologous T-cell therapy whereby a subject's own T cells are transduced with a lentiviral vector expressing the EB103 transgene.
223750992|NCT03051048|PROCEDURE|Reperfusion|
223750993|NCT03293251|PROCEDURE|Trabeculectomy with MMC|glaucoma surgeries
223750994|NCT02826681|DRUG|Injectafer® (Ferric Carboxymaltose - FCM)|Intravenous Iron
223750995|NCT02826681|DRUG|Placebo (Normal Saline)|Normal Saline Solution
224200223|NCT03588312|PROCEDURE|Aortoplasty using autologous pericardial patch|hypoplastic aortic arch repair using a glutaraldehyde treated, autologous pericardial patch.
223750996|NCT03679910|DIAGNOSTIC_TEST|CEMIP , CA19-9 ,CEA|CEMIP: Cell migration inducing protein CA19-9: Carbohydrate antigen 19-9 CEA: Carcinoembryonic antigen
223750997|NCT03679910|DIAGNOSTIC_TEST|A) CBC . B) RBG. C)KFT. D) LFT.|A)CBC: Complete blood count. B)RBG: Random blood glucose. C)KFT: Kidney function tests. D)LFT: Liver function tests.
223750998|NCT03343184|PROCEDURE|SEE Strategy and Incremental Restoration|37% phosphoric acid will be applied during 30 seconds, only in enamel in 50 teeth. This acid will be removed using water, the cavity will be air-dried, and then, the adhesive will be brushed during 20 seconds in the cavity, will be air-dried during 5 seconds, and photoactivated during 10 seconds with Light Emission Diode (LED) light. Then, the Filtek Z350XT composite will be used in increments of no more than 2 mm, using the incremental restoration technique, and each increment will be photoactivated for 40 seconds.
223750999|NCT03343184|PROCEDURE|SEE Strategy and Bulk Fill Restoration|37% phosphoric acid will be applied during 30 seconds, only in enamel in 50 teeth. This acid will be removed using water, the cavity will be air-dried, and then, the adhesive will be brushed during 20 seconds in the cavity, will be air-dried during 5 seconds, and photoactivated during 10 seconds with Light Emission Diode (LED) light. Then, the Filtek Bulk Fill composite will be used in increments of 4 mm, using the bulk restoration technique, and photoactivated for 40 seconds.
224075349|NCT03142321|DRUG|Vedolizumab 300 MG Injection [Entyvio]|Vedolizumab Injection
224075350|NCT03042468|DRUG|177Lu-PSMA-617|177Lu-PSMA-617 \[50mCi (1.85GBq) - 300mCi (11.1GBq)\] intravenous X2 doses, 2 weeks apart (Visit 1 and 2)
224075351|NCT03042468|DRUG|68Ga-PSMA-HBED-CC|68Ga-PSMA-HBED-CC \[5 ±2mCi or 185 ±74MBq\] intravenous during screening and at 12 weeks with standard imaging
224075352|NCT06278207|DRUG|Finerenone (BAY 94-8862)|10 mg or 20 mg daily
223603333|NCT03077230|BEHAVIORAL|Pre/Post Test of a Lung Cancer Screening Decision Aid|After completing the baseline survey, the research team member will ask each participant asked to view the lung cancer screening decision aid on a tablet. The following areas regarding lung cancer screening: What is lung cancer?, Why is lung cancer a problem?, What is screening?, What is low-dose CT screening, Recommended frequency of screening, Screening factors, lung cancer risks and benefits (magnitude of benefit, harms, false positive, invasive procedures, radiation, stress/anxiety), Summary, Values Clarification, Screening Choice, and Smoking cessation messaging for current smokers OR positive reinforcement for former smokers.
224075353|NCT04827355|DEVICE|External Upper Esophageal Sphincter (UES) Compression Device|External Upper Esophageal Sphincter (UES) Compression Device fit to manufacturer guidelines.
224075354|NCT04827355|DEVICE|Sham Device|External Upper Esophageal Sphincter (UES) Compression Device fit to pressure known not to provide treatment.
224075355|NCT03286842|DRUG|Olaparib|Patients will be administered olaparib orally, twice daily at 300 mg. Two (2) 150 mg olaparib tablets should be taken at the same time each morning and evening of every day, approximately 12 hours apart.
224075356|NCT03036137|DEVICE|Transcranial Direct Current Stimulation|Anodal stimulation of the temporoparietal left area with an cathode over the right dorsolateral prefrontal cortex. Stimulation will be applied for 20 minutes at 2 mA.
224075357|NCT03036137|DEVICE|Sham Transcranial Direct Current Stimulation|Sham tDCS sessions will last 20 minutes
224075358|NCT05398315|BEHAVIORAL|Empathic Statements/Reflections|Presence of Empathic Statements
224075359|NCT05398315|BEHAVIORAL|Narrator Backstory|Presence of a narrator backstory
224075360|NCT05398315|BEHAVIORAL|Male Narrator|Presence of a male narrator
224075361|NCT05398315|BEHAVIORAL|Female Narrator|Presence of a female narrator
224075362|NCT05398315|BEHAVIORAL|MI Techniques|Presence of MI techniques
224075363|NCT03178487|DRUG|Upadacitinib|Tablet
224075364|NCT03178487|DRUG|Placebo|Tablet
224075365|NCT00004900|BIOLOGICAL|filgrastim|
224075366|NCT00004900|DRUG|anastrozole|
224075367|NCT00004900|DRUG|carboplatin|
224075368|NCT00004900|DRUG|cisplatin|
224075369|NCT00004900|DRUG|cyclophosphamide|
224075370|NCT00004900|DRUG|etoposide|
224075371|NCT00004900|DRUG|thiotepa|
224075372|NCT00004900|PROCEDURE|peripheral blood stem cell transplantation|
224075373|NCT00004900|RADIATION|radiation therapy|
224075374|NCT05373147|BIOLOGICAL|αPD1-MSLN-CAR T cells|The safety and efficacy of αPD1-MSLN-CAR T cells will be assessed in a standard 3+3 dose escalation approach. Four doses of CAR T cells will be evaluated in this study: 1×10\^5 CAR+ T cells/kg, 3×10\^5 CAR+ T cells/kg, 1×10\^6 CAR+ T cells/kg, and 3×10\^6 CAR+ T cells/kg.
224075375|NCT01453855|DRUG|Travoprost ophthalmic solution, 0.003%|
224075376|NCT01453855|DRUG|Travoprost ophthalmic solution, 0.004%|
224075377|NCT06301880|DRUG|The topical application of a vasodilator on the LIMA graft|Patients were randomly assigned to receive the topical application of one of three agents: milrinone (Baxter Pharmaceuticals, Ahmedabad, India) 10 mg in 20 ml of dextrose 5%, nitroglycerin (Caspian Tamin Pharmaceutical, Guilan, Iran) 10 mg in 20 ml of normal saline, or normal saline (0.9% sodium chloride solution) as control.
224075378|NCT04103437|DIAGNOSTIC_TEST|Maximal incremental running test|"Maximal incremental running test with measures of metabolic, spatio-temporal parameters and video recording with camera in the frontal plane.~video recording of frontal view, metabolic and spatio-temporal measures of three (self-selected speed, + and - 20 percentage of self-selected speed) 6 minutes running test monthly (12 months) follow-up questionnaire"
224200224|NCT02005302|DRUG|1,25(OH)2 Vitamin D3|Oral 1,25(OH)2 Vitamin D3 by 0.25 microgram once daily at start and regulate the dose according to the changes of blood levels of 25(OH)Vit D, calcium, phosphorus, and intact parathyroid hormone.
224200225|NCT02005302|DRUG|Vitamin D2|Oral Vit D2 1.25mg(50,000 unit) once weekly as a start and maintain 1.25mg(50,000 unit) once monthly according to the blood 25(OH)vitamin D level.
223507801|NCT02614768|DEVICE|Glucose Sensor|"The investigational intervention is CGM monitoring using four different CGM systems. Three of the four CGM devices which are used will be CGM systems which have received conformité européenne (CE) certification (Dexcom G4 Platinum, Medtronic MiniMed 640G system, Abbott FreeStyle Libre Flash). The SPIDIMAN sensor will be used for the first time in human subjects, does not yet have received CE certification and will be given an identifying label in addition to being labelled for investigative use only."
223507802|NCT04576949|DRUG|Cytisinicline|film-coated oral tablets containing 3 mg cytisinicline
223507803|NCT04576949|DRUG|Placebo|film-coated oral tablets containing matched placebo
223507804|NCT04576949|BEHAVIORAL|Behavioral support|Behavioral support sessions by a qualified study site staff member will be participant-driven and will include direct engagement with the subject about their attempt to quit smoking. Each session will last approximately 10 minutes.
223507805|NCT00052715|DRUG|poly ICLC|
223507806|NCT05511480|BEHAVIORAL|Interference through learning of a competing motor skill.|Interference through the learning of a competing motor skill.
223507807|NCT05511480|BEHAVIORAL|No interference|No interference through the continuation of learning same motor skill
223507808|NCT04188509|DRUG|Voxelotor|All participants will receive voxelotor once daily (QD), administered orally as tablets, dispersible tablets, or a powder for oral suspension formulation (powder formulation packaged as stick packs).
223507809|NCT00279513|DRUG|Traumeel S|
223507810|NCT05311982|DEVICE|DLPFC-R (F4) TDCS|direct current brain stimulation- The study was developed through a triple-blind, crossover, randomized, placebo-controlled clinical trial (dummy tDCS). Participants were randomized into three groups receiving unilateral tDCS in DLPFC-L F3 (Block A), combined tDCS in DLPFC-L (F3) and DLPFC-R (F4) simultaneously (Block B) or sham-tDCS (Block C) with equal electrode configuration guaranteed blindness. After the procedures, each participant received the following intervention in the order ABC, BCA or CAB with a period of 1 week between each one. Each block took 3 weeks, organized into: 1) Assessment; 2) Application of stimulation; 3) Reassessment and washout week. Adding 1 more week of final evaluation, the study totaled the period of 10 weeks. During this period, patients were instructed to continue their behavioral/educational treatment and medication routines.
223507811|NCT05311982|DEVICE|DLPFC-L (F3) and DLPFC-R (F4) TDCS|DLPFC-L (F3) and DLPFC-R (F4) (Bock B)
223507812|NCT05311982|DEVICE|sham-tDCS|sham-tDCS (Block C) with equal electrode configuration guaranteed blindness
223507813|NCT04202783|OTHER|Exosomes|Focused ultrasound delivery of intravenously-infused exosomes
223507814|NCT05708378|OTHER|Rocker board training|Patients will perform 24 sessions (4 times per week over 6 weeks) and effects will be measured before treatment, at 3rd and after 6th week.
223507815|NCT05708378|OTHER|Stable surface training|Patients will perform 24 sessions (4 times per week over 6 weeks) and effects will be measured before treatment, at 3rd and after 6th week.
223507816|NCT00100750|DRUG|Gemcitabine Hydrochloride|Given IV
223507817|NCT00100750|DRUG|Tipifarnib|Given PO
223507818|NCT00100750|OTHER|Laboratory Biomarker Analysis|Correlative studies
223507819|NCT04841798|OTHER|[11C]SL25.1188 PET radiotracer|Monoamine oxidase B (MAO-B) occupancy before and after medication treatment using \[11C\]SL25.1188 PET
223507820|NCT03673228|BEHAVIORAL|Comprehensive Relapse Prevention Intervention|"This intervention consists of 4 components:~1. Visit Prior to Discharge: counselor from research team will visit patient at hospital bedside to provide counseling~2. Follow up calls after discharge: 6 proactive counseling calls and initiate unlimited reactive calls to their counselor, at days 1,3,7,14,30,an 60 days after hospital visit~3. Text messaging support: patients will be registered in NCI's Smokefree TXT while in the hospital and will receive multiple daily messages, designed for someone who has already quit~4. Caregiver support: 10 minute training session to the caregiver on how to help patient prevent relapse by increasing self efficacy, maintaining motivation and dealing with high risk situations"
223507821|NCT03673228|BEHAVIORAL|Standard Treatment Counseling|Participants will receive two 10 minute counseling calls from the staff of the preoperative counseling program during the first month after the hospital discharge
223507822|NCT03673228|DRUG|Nicotine Replacement Therapy (NRT)|Patients in both arms will be encouraged to receive NRT
223507823|NCT02084186|OTHER|herb-partitioned moxibustion|Ignited moxa cones are placed upon herbal cake. Herbs are smashed into powder. Every 2.8g medicine powder mix with 3g millet wine and then be pressed into herbal cakes which are 28mm in diameter and 7mm in high with a specific mould. Then the herbal cake with a moxa cone will be fixed on Tianshu and Shangjuxu.
223507824|NCT02084186|OTHER|bran-partitioned moxibustion|Ignited moxa cones are placed upon bran cake. Every 2.8g bran powder mix with 3g millet wine and then be pressed into bran cakes which are 28mm in diameter and 7mm in high with a specific mould. Then the bran cake with a moxa cone will be fixed on Tianshu and Shangjuxu.
223507825|NCT00467467|DRUG|Alfuzosin Hydrochloride|
223507826|NCT00033475|BIOLOGICAL|therapeutic allogeneic lymphocytes|
223507827|NCT00051142|DRUG|Travoprost|
223507828|NCT00051142|DRUG|Latanoprost|
223507829|NCT05264675|PROCEDURE|primary suture|Primary suture of the EPL-tendon
223507830|NCT05264675|PROCEDURE|EIP-transfer|transfer of the EIP-tendon to the EPL-tendon
223603334|NCT04703764|DRUG|HSG4112|Once-daily, 14-day multiple oral administration
223603335|NCT04703764|DRUG|Placebo|Once-daily, 14-day multiple oral administration
223603336|NCT00529425|DRUG|Ropivacaine|
224200226|NCT02005302|DIETARY_SUPPLEMENT|low protein diet|Using nutritious software to make meals recipes and give dietary guidance for patients to reach the DPI goal of 0.6g-0.8g/kg/d.
223603337|NCT03523767|BIOLOGICAL|S.typhi Injection|0.5 ml of S.typhi injection
223603338|NCT03523767|BIOLOGICAL|Normal Saline Injection|0.5 ml of normal saline injection
223603339|NCT03162822|BEHAVIORAL|Behavioral Intervention|The behavioral intervention has the parents develop an if-then plan for dealing with conflict and negativity, using strategies to downregulate their own negative emotions.
223751000|NCT03343184|PROCEDURE|SET Strategy and Incremental Restoration|no conditioning, the adhesive system will be used in 50 teeth, according to the manufacturer's instructions, in the self-etching mode. The adhesive system will be brushed during 20 seconds in the cavity, will be air-dried during 5 seconds, and photoactivated during 10 seconds with Light Emission Diode (LED) light. Then, the Filtek Z350XT composite will be used in increments of no more than 2 mm, using the incremental restoration technique, and each increment will be photoactivated for 40 seconds.
223751001|NCT03343184|PROCEDURE|SET Strategy and Bulk Fill Restoration|no conditioning, the adhesive system will be used in 50 teeth, according to the manufacturer's instructions, in the self-etching mode. The adhesive system will be brushed during 20 seconds in the cavity, will be air-dried during 5 seconds, and photoactivated during 10 seconds with Light Emission Diode (LED) light. Then, the Filtek Bulk Fill composite will be used in increments of 4 mm, using the bulk restoration technique, and photoactivated for 40 seconds.
223751002|NCT00351260|PROCEDURE|Coronary Angioplasty|
223751003|NCT04471636|DEVICE|Withings ScanWatch|The smart watch is capable of recording SpO2, ECG, and heart rate.
223751004|NCT01370226|BEHAVIORAL|CBI|"The multimedia, interactive Computer Brief Intervention (CBI) condition will be delivered using tablet computers. The content and format will be easily negotiated by participants. The 30-minute interventions are designed to address the primary target behavior of alcohol use, and will include a tailored review of participants' goals/values, feedback regarding their present alcohol use patterns and consequences (either actual experiences or potential based on risk behaviors), developing a discrepancy between their alcohol use and ability to meet goals and values through a decisional balance exercise, and formulation of a change plan tailored for each participant."
223751005|NCT01370226|BEHAVIORAL|TBI|"Participants receive a 30-minute intervention session with a Master's-level clinician. The interventions are designed to address the primary target behavior of alcohol use, and will include a tailored review of participants' goals/values, feedback regarding their present alcohol use patterns and consequences (either actual experiences or potential based on risk behaviors), developing a discrepancy between their alcohol use and ability to meet goals and values through a decisional balance exercise, and formulation of a change plan tailored for each participant."
224200227|NCT02005302|DIETARY_SUPPLEMENT|normal protein diet|Using nutritious software to make meals recipes and give dietary guidance for patients to reach the DPI goal of more than 0.8g/kg/d.
223603340|NCT03162822|OTHER|Cognitive Intervention|The cognitive intervention has parents come up with reasons why their children do things they don't like, until they come up with benign attributions for those behaviors.
223603341|NCT03162822|OTHER|Interpretation Bias Intervention|"The Interpretation Bias intervention has parents look at morphed facial expressions and determine whether the face is happy or angry. Positive feedback is given for rating the faces as happy and negative feedback is given for rating the faces as angry."
223603342|NCT03162822|OTHER|Evaluative Conditioning|The Evaluative Conditioning intervention presents parents with pictures of ambiguous child faces (conditioned stimuli) and pairs them with positive word descriptors (unconditioned stimuli; e.g., sweet; cooperative).
223603343|NCT03238690|DEVICE|Controlled Cardiac Reloading through LVAD Speed Adjustment|LVAD speed is reduced at a fixed rate according to the particular LVAD device model implanted. LVAD speed reduction adjustments will be performed at visits occurring every 2 - 3 weeks, up to a total of 8 visits. Reduction of LVAD speed will continue until the soonest of: minimum operating setting as recommended in the LVAD Operator's manual is reached; the minimum setting tolerated by the subject is reached; the subject completes 8 visits; or until the subject receives a heart transplant.
223603344|NCT00437814|DRUG|Ketamine, effect on intracranial pressure|
223603345|NCT01664182|BIOLOGICAL|Bevacizumab|Given IV
223603346|NCT01664182|DRUG|Pazopanib Hydrochloride|Given PO
223603347|NCT01664182|DRUG|Sorafenib Tosylate|Given PO
223751006|NCT00946426|OTHER|Clamp|Insulin sensitivity, Hepatic glucose production, Evaluation of inflammation, Socioeconomic status, Ethnicity and family history
223751007|NCT03930888|DIETARY_SUPPLEMENT|Dietary supplement|Patients with preoperative nutritional support with special nutritional supplements vs. patients without special nutritional support.
223751008|NCT00455507|DRUG|Istradefylline|Two 10 mg KW-6002 tablets orally once daily for 12 weeks
223751009|NCT00455507|DRUG|Istradefylline|Two 20 mg tablets orally once a day for 12 weeks
223751010|NCT00455507|DRUG|Placebo|Two placebo tablets orally once daily for 12 weeks
223751011|NCT05757687|DEVICE|Omega device|"The ProArc Medical Omega system is a prostatic reshaping device. The Omega System is comprised of two main components: Omega Delivery Device and Omega Implant.~The delivery system uses a diathermy electrode to perform a circular and superficial incision through the urethral wall into the prostate tissue, into which the arc-shaped permanent implant is placed. The implant is made up of commonly used surgical implantable nitinol material, coated with Parylene coating. The implant expands the obstructed area, reducing the fluid obstruction through the prostatic urethra."
223751012|NCT05696691|DRUG|Ketamine Hydrochloride|100mg IM ketamine to be administered in conjunction with CRP. The ketamine injection will be administered first. Participants will be observed and have vital signs monitored for the first 45 minutes after administering medication in the ED, observing for immediate reactions. Afterwards, participants will continue to be monitored for potential late-term side effects on the inpatient unit. Ketamine will be given only after initial standard of care (SOC) treatment and screening studies have been initiated.
224200228|NCT02668445|OTHER|Standard meal containing low or high carbohydrate content|
224200229|NCT02416505|BEHAVIORAL|Verbal+Anatomic Model|
224200230|NCT02416505|BEHAVIORAL|Verbal+Video|
223603348|NCT01664182|DRUG|Sunitinib Malate|Given PO
223603349|NCT01664182|BIOLOGICAL|Trebananib|Given IV
223603350|NCT02144857|DRUG|etanercept|50 mg
223603351|NCT02144857|DRUG|ustekinumab|45 mg
223603352|NCT02144857|DRUG|cyclosporine|Cyclosporine 2.5-3 mg/kgr
223603353|NCT02144857|DRUG|Secukinumab|300 mg
223603354|NCT02144857|DRUG|Apremilast|30mg
223603355|NCT05170763|DRUG|PA9159 nasal spray solution, 10 μg one day treatment|Single dose of PA9159 (5 μg/nasal spray) is delivered intranasally through a metered-dose mechanical spray pump, one spray each in the left and right nostril.
223603356|NCT05170763|DRUG|PA9159 nasal spray solution, 20 μg one day treatment|Single dose of PA9159 (5 μg/nasal spray) is delivered intranasally through a metered-dose mechanical spray pump, two sprays each in the left and right nostril.
223603357|NCT05170763|DRUG|PA9159 nasal spray solution, 40 μg one day treatment|Single dose of PA9159 (10 μg/nasal spray) is delivered intranasally through a metered-dose mechanical spray pump, two sprays each in the left and right nostril.
223603358|NCT05170763|DRUG|PA9159 nasal spray solution, 80 μg one day treatment|Single dose of PA9159 (10 μg/nasal spray) is delivered intranasally through a metered-dose mechanical spray pump, four sprays each in the left and right nostril.
223603359|NCT05170763|DRUG|PA9159 nasal spray solution, 20 μg 7-day treatment|Repeated doses of PA9159 (5 μg/nasal spray) or Placebo is delivered intranasally through a metered-dose mechanical spray pump, two sprays each in the left and right nostril.
223603360|NCT05170763|DRUG|PA9159 nasal spray solution, 40 μg 7-day treatment|Repeated doses of PA9159 (10 μg/nasal spray) is delivered intranasally through a metered-dose mechanical spray pump, two sprays each in the left and right nostril.
223603361|NCT05170763|DRUG|Placebo, the same intranasal spray solution without PA9159 active ingredient|Placebo is delivered intranasally through a metered-dose mechanical spray pump with the same volume as the corresponding PA9159 dose group
223751013|NCT05696691|BEHAVIORAL|Crisis Response Plan|"Crisis Response Plan is a brief, empirically-validated, Cognitive-Behavioral Therapy-based one-time therapy, and its administration typically takes 30-60 minutes. It begins with a narrative assessment (allowing patients to tell their story) and concludes with collaboratively constructed plan that outlines strategies for the patient's self-management of future acute suicidal crises. Patients who engage in CRP are given an index card to keep with them that summarizes the emotional management strategies that they collaboratively generate with the CRP provider."
223751014|NCT06250972|DRUG|Gemcitabine, Nab-paclitaxel, Irinotecan|continuing chemotherapy using the previous regimen until disease progression
223751015|NCT06250972|RADIATION|Intensity-Modulated Radiation Therapy (IMRT)|Receive Intensity-Modulated Radiation Therapy (IMRT) after about 2\~6 cycles of chemotherapy.
223751016|NCT02492269|DRUG|Dexmedetomidine|
223751017|NCT02492269|DRUG|Placebo|
223751018|NCT02567955|BIOLOGICAL|Immunogenicity two doses of Gardasil-9|Subjects will receive two standard doses of Gardasil-9 (0.5 ml)
223751019|NCT02567955|BIOLOGICAL|Immunogenicity Cervarix and Gardasil-9|Subjects will receive a standard dose of Cervarix (0.5 ml) and a standard dose of Gardasil-9 (0.5 ml)
223751020|NCT06801912|BEHAVIORAL|Behavior Change Technique Package|"Behavior Change Technique 1: Goal setting (Behavior) (BCT 1.1). Goal setting for behavior is defined as setting a goal for the behavior to be achieved.~Behavior Change Technique 2: Action planning (BCT 1.4). Action planning is defined as detailing the plan of where, for how long, and at what time taking medication is going to be performed.~Behavior Change Technique 3: Self-monitoring of behavior (BCT 2.3). Self-monitoring of behavior is defined as monitoring and recording behavior.~Behavior Change Technique 4: Prompts/Cues (BCT 7.1) This BCT is defined as prompt rehearsal and repetition of the behavior in the same context repeatedly, so that the context elicits the behavior."
223751021|NCT06009263|OTHER|Conventional treatment|"Application of ultrasound and transcutaneous electrical nerve stimulation TENS for mechanical low back pain."
223751022|NCT06009263|OTHER|Open chain segmental control|"Application of open chain segmental control exercises As well as, application of ultrasound and transcutaneous electrical nerve stimulation TENS for mechanical low back pain."
223751023|NCT06009263|OTHER|Closed chain segmental control|"Application of closed chain segmental control exercises As well as, application of ultrasound and transcutaneous electrical nerve stimulation TENS for mechanical low back pain."
223603362|NCT01004289|PROCEDURE|Postconditioning|Primary angioplasty and stenting followed by brief episodes of ischemia-reperfusion performed during the first minutes of reperfusion
223603363|NCT01004289|PROCEDURE|Primary angioplasty and stenting without additional intervention|Primary angioplasty and stenting without additional intervention.
223751024|NCT04390477|DIETARY_SUPPLEMENT|Probiotic|Oral daily capsule containing probiotic strains with maltodextrin as excipient, administrated for 30 days.
223751025|NCT05169385|BEHAVIORAL|Parent SMART|Parent SMART experimental intervention
223751026|NCT05169385|BEHAVIORAL|Treatment as Usual|Residential treatment as usual
223751027|NCT06562296|OTHER|Amnion-Intermediate-Chorion|Dehydrated human placental multilayer allograft from derived donated human tissue. AIC contains amnion and chorion layers as well as basement membrane and trophoblast.
223751028|NCT06562296|OTHER|Amnion-Chorion-Amnion|Dehydrated human placental trilayer allograft derived from donated human tissue.
223603364|NCT02919046|BIOLOGICAL|GD2-targeted CAR-T cells|This study have only one arm that is CAR-T experimental arm. Firstly all participators will be attended the screening, who passed the screening for the treatment of CAR-T cells, the CAR-GD2-modified T cells can recognize and kill tumor cells in the body，follow-up 35 months.
223603365|NCT02177188|DEVICE|LBNP Lower Bodi Negative Pressure Chamber|
223603366|NCT05059509|BIOLOGICAL|FB825|FB825, 5mg/kg, by 1 hour IV infusion on Day 1
223603367|NCT04030572|DRUG|Clonidine Pill|0.1 mg tabs, one by mouth daily at bedtime for one week
223603368|NCT03660761|DRUG|apatinib|The patient was given a daily dose of apatinib 500mg (or based on weight). For adult, the dose of apatinib was prescribed with 425 mg or 500 mg per day and four weeks for a cycle. The dosage was modified to 250 mg if patients experienced ≧grade 2 hematologic adverse events, hand and foot syndrome, proteinuria, fecal ocular blood, or grade 3/4 hypertension, or other grade 3/4 adverse events. Apatinib was administrated until disease progression, unacceptable toxicity or death.
223603369|NCT03660761|DRUG|temodar|dose-dense temozolomide (100 mg/m2 , 7 days on with 7 days off ) , 28d
223751029|NCT06562296|PROCEDURE|Standard of Care|Standard of care is to establish a clean, healthy wound bed and optimize the wound environment to have the best chance of healing the wound. This is achieved through wound cleansing, debridement, offloading and moisture balance.
223751030|NCT04661748|DEVICE|real time alarm of deviating vital signs|Intervention consists of actively alerting staff personnel if physiologic vital signs, deviates from certain thresholds
223751031|NCT01413360|DRUG|High dose vitamin C|Vitamin C, 3g per day (tid), with meal, per oral with water 100mL
223751032|NCT00521768|BEHAVIORAL|Prolonged exposure|
223751033|NCT04045496|DRUG|JAB-3312|JAB-3312 will be supplied as 0.25 mg and 1.0 mg capsules.
223751034|NCT06370156|DRUG|Adalimumab|To suggests the role of TWEAK and the effectiveness of different treatments like adalimumab and methotrexate in managing plaque psoriasis and psoriatic arthritis.
223751035|NCT06630806|DRUG|SAR446523|Pharmaceutical form: Powder for solution for injection; Route of administration: Subcutaneous (SC)
223751036|NCT06216041|DRUG|IMM-H014|"SAD and MAD adopt sentinel method which 2 healthy subjects first will receive IMM-H014, and if are evaluated to be tolerable, the remaining 8 subjects will be randomly assigned to receive IMM-H014 and placebo in a ratio of 3:1(10 in per experimental Cohort)."
223751037|NCT06216041|DRUG|Placebo|"SAD and MAD adopt sentinel method which 2 healthy subjects first will receive IMM-H014, and if are evaluated to be tolerable, the remaining 8 subjects will be randomly assigned to receive IMM-H014 and placebo in a ratio of 3:1(10 in per experimental Cohort)."
223751038|NCT06216041|DRUG|IMM-H014 ( FE)|"FE part is divided into two groups: 8 subjects will receive IMM-H014 and 2 subjects will receive placebo In group A .All 8 subjects will receive IMM-H014 in group B. Group A adopts sentinel method .The treatment in food effect consists of 2 periods."
223751039|NCT06216041|DRUG|Placebo ( FE)|"FE part is divided into two groups: 8 subjects will receive IMM-H014 and 2 subjects will receive placebo In group A .All 8 subjects will receive IMM-H014 in group B. Group A adopts sentinel method .The treatment in food effect consists of 2 periods."
223751040|NCT06316856|DRUG|Autologous CD5 CAR T-cells|Peripheral blood mononuclear cells for the production of CD5 CAR T-cells from patients.
223751041|NCT06316856|DRUG|Previous stem-cell transplantation (SCT) donor-derived CD5 CAR T-cells|Peripheral blood mononuclear cells for the production of CD5 CAR T cells are collected from previous SCT donors.
223751042|NCT06316856|DRUG|Newly matched donor-derived CD5 CAR T-cells|Peripheral blood mononuclear cells for the production of CD5 CAR T cells are collected from newly matched donors.
223751043|NCT04682626|DIETARY_SUPPLEMENT|Soft gelatin capsules each contains 50 000 IU VD3 (cholecalciferol) equivalents to 1.25 mg.|Soft gelatin capsules each contain 50 000 IU VD3 (cholecalciferol) equivalents to 1.25 mg.
223751044|NCT04415281|DEVICE|THOR® laser system|We chose the THOR® laser system given because their active treatment arm uses both coherent laser and monochromatic LED light. Therefore, we will use three types of active probes in this investigation including, A) Single Laser 810 NM 200 mw; B) Laser Cluster of 810 NM equivalent to 1 WATT and; C) LED Cluster, 34 X 660nm at 10 mw and 35 850nm, 30mw 1390mw total. As detailed in Table 3. We propose to use these three PBM probes in concert for the treatment of TMD pain. Laser A (Single Diode Laser) is designed for isolated trigger points and superficial muscles. Laser B (Cluster Laser) is designed for a more diffuse treatment area,targeting analgesia, anti-inflammatory, and deep tissue repair. Laser C (LED Cluster) is purportedly designed for the presence of diffuse inflammation.
223751045|NCT04415281|DEVICE|sham THOR® laser system|sham THOR® laser system
223751046|NCT05694546|BEHAVIORAL|Community Health Worker Post-Discharge Intervention|Clients will be offered a community-based follow-up from a community health worker after hospital discharge.
223751047|NCT03350854|BEHAVIORAL|Patient Preference in Treatment Decision Making|The roles are divided into two active roles, a collaborative (or shared) role, and two passive roles in the Patient Preference scale questionnaire. Once the questionnaire is administered, the patient will then proceed to original surgical appointment. The provider is informed of the patient's preferred role and has a discussion with them patient about this in the intervention group, but not in the control group.
223751048|NCT04682184|DRUG|Propranolol|Administered orally.
223751049|NCT04682184|DRUG|Pseudoephedrine|Administered orally.
223751050|NCT04682184|DEVICE|Wearable Biosensor Patch Device|Biosensor patch device attached to the chest and worn throughout the trial with replacement of biosensor every 7 days.
224200231|NCT03253601|BEHAVIORAL|Strategy Training|Strategy training is a form of meta-cognitive instruction that trains individuals with stroke-related cognitive impairments to identify and prioritize problematic daily activities, identify the barriers impeding performance, generate and evaluate their own strategies to address barriers, and apply these skills through iterative practice.
224200232|NCT04861766|DEVICE|STYLAGE® L|Injection in both NLFs
224200233|NCT04861766|DEVICE|Active Comparator|Injection in both NLFs
224200234|NCT00775827|DRUG|fenofibrate 160 mg tablets|
224200235|NCT03862469|PROCEDURE|Individualized laboratory test|Laboratory test administered between 6 and 2 days prior to the subsequent menstrual cycle.
224200236|NCT00561600|DEVICE|ASR™-XL Modular Acetabular Cup System|The ASR™-XL Modular Acetabular Cup System treatment device is comprised of a metal acetabular cup, a unipolar femoral head and a taper sleeve adapter.
224200237|NCT00561600|DEVICE|Pinnacle™ acetabular shell|The Pinnacle™ shells are cementless, titanium alloy cups with Porocoat® porous coating and HA DuoFix™ coating. There are various different liners available for use with the Pinnacle™ Acetabular Cup System. For the purpose of this investigation, the CoCrMo ULTAMET® 28mm or 36 mm metal liners will be used.
224200238|NCT02012751|DEVICE|Nevus doctor program|The Nevus doctor program supplies a diagnostic category of pigmented skin lesions based on dermatoscopy images.
223751051|NCT00749372|OTHER|T2* Cardiac and Liver MRI|Patients will undergo an MRI of the heart and liver.
223751052|NCT05506852|BEHAVIORAL|Web-based training strategy|"Participants will undergo a web-based training protocol where they will play an online game that simulates a breakfast environment and will perform everyday activities as cooking and setting tables in a multi-tasking fashion. Participants will learn to play the game using specific strategies, in order to optimize the performance."
224200239|NCT05102162|DRUG|Cefepime, Meropenem, or Piperacillin/Tazobactam|A 1:1 randomization scheme based on the infusion duration (continuous over 24 hours or intermittent over 30 minutes) with stratification based on the beta-lactam prescribed (cefepime, meropenem, or piperacillin/tazobactam)
224200240|NCT05102162|DRUG|Cefepime, Meropenem, or Piperacillin/Tazobactam|A 1:1 randomization scheme based on the infusion duration (continuous over 24 hours or intermittent over 30 minutes) with stratification based on the beta-lactam prescribed (cefepime, meropenem, or piperacillin/tazobactam)
224200241|NCT04918095|DEVICE|CareCOPD Platform|The subjects will be provided with CareCOPD devices for home monitoring of airway impedance, medication use, and symptoms data.
223751053|NCT05506852|BEHAVIORAL|Web-based regular training (no strategy)|"Participants will undergo a web-based training protocol where they will play an online game that simulates a breakfast environment and will perform everyday activities as cooking and setting tables in a multi-tasking fashion. Participants will learn to play the game under regular game instructions."
223751054|NCT01589445|DRUG|Pioglitazone hydrochloride|77 patients were treated with pioglitazone hydrochloride (B001) for 3 months.Biomedical parameters were measured each month.
223751055|NCT01589445|DRUG|Metformin hydrochloride|After the treatment with pioglitazone(001) for 3 months first and then patients were on one month washout period;in the washout period they were given metformin tablet 850mg once daily,then treated with 002 (metformin) for further 3 months. The same biomedical measurements were assayed.
224200242|NCT05393635|BIOLOGICAL|ITIL-168|"ITIL-168 is a cell therapy product derived from a participant's own TILs. A portion of tumor is resected to make a personalized ITIL-168 product. If appropriate, participants may receive bridging therapy after recovering from the tumor resection during ITIL-168 manufacturing. Once ITIL-168 has been made, the participant is treated with up to 5 days of lymphodepleting chemotherapy including cyclophosphamide and fludarabine, followed by a single infusion of ITIL-168, and up to 8 doses of IL-2.~Drug: Pembrolizumab Participants will receive 1 dose of pembrolizumab following tumor resection prior to receiving ITIL-168, and additional doses for up to a year after ITIL-168 infusion."
223751056|NCT03559179|OTHER|Opioid Wizard|The Opioid Wizard is an OUD clinical decision support tool for primary care providers.
223751057|NCT05962229|DRUG|(S)-Nicotine|Participants will spend 8 hours in the hospital research ward and will vape e-liquid containing 100% (S)-nicotine. They will vape following a standardized session, followed by a 4 hour abstinence period. Participants will then vape as they wish (ad libitum) for 90 minutes.
223751058|NCT05962229|DRUG|(R)- nicotine|Participants will spend 8 hours in the hospital research ward and will vape e-liquid containing 100% (R)-nicotine. They will vape following a standardized session, followed by a 4 hour abstinence period. Participants will then vape as they wish (ad libitum) for 90 minutes.
223751059|NCT05962229|DRUG|Racemic nicotine|Participants will spend 8 hours in the hospital research ward and will vape e-liquid containing 50% (R)-nicotine and 50% (S)-nicotine. They will vape following a standardized session, followed by a 4 hour abstinence period. Participants will then vape as they wish (ad libitum) for 90 minutes.
223751060|NCT03148418|DRUG|Atezolizumab|Atezolizumab will be administered as a monotherapy or atezolizumab with other agent(s) as per parent protocol. Dosing regimen will continue in accordance with the parent study or at equivalent dose (if applicable) and at the same schedule as the parent study, or switch to a fixed atezolizumab dose of 1200 mg every 3 weeks (Q3W).
224200243|NCT01165424|DRUG|mometasone furoate|"MFNS 50 μg spray device~* 3 to 11 years: one spray per nostril once daily (100 μg/day) in the morning.~* 12 to 15 years: 2 sprays per nostril once daily (200 μg/day) in the morning."
224200244|NCT06264765|OTHER|scalp block|The scalp block will be performed by the anesthesiologist 10 minutes before the pin head holder application (PHHA). Supraorbital and supratrochlear nerves will be blocked bilaterally with 6 ml of 0.5% bupivacaine injected vertically into the skin above the eyebrow midline. Auriculotemporal nerves will be blocked bilaterally by injecting 4 ml of 0.5% bupivacaine 1.5 cm anterior to the ear at the tragus level. The needle will be inserted perpendicular to the skin and the fascia will be injected deeply and superficially while the needle is withdrawn. Postauricular branches of the greater auricular nerves will be blocked bilaterally with 2 ml of 0.5% bupivacaine injected 1 cm posterior to the ear, between the bone and skin, at the level of the tragus. The greater, lesser, and third occipital nerves run along the upper nuchal line approximately halfway between the occipital prominence and the mastoid prominence.
223507831|NCT05500846|DEVICE|The Visual Ice Cryoablation System|Currently, the standard surgical treatment option for localized prostate cancer is total prostatectomy, which removes the entire prostate organ. However, total prostatectomy is invasive and postoperative urinary incontinence, sexual dysfunction and local recurrence remain clinical challenges even with the introduction of robotic assistance techniques. Cryotherapy has been approved as one of the other surgical treatment options for localized prostate cancer in the USA and Europe, but not in Japan. This clinical trial aims to expand the indication of cryotherapy equipment, which has already been approved for insurance for renal cancer, to prostate cancer in Japan. In this clinical trial, Focal Therapy will be performed by targeting a single localized prostate cancer lesion visualized by MRI. By targeting cancer lesions in a minimally invasive manner, we aim to achieve both control of cancer lesions and maintenance of quality of life.
223507832|NCT04480580|DIAGNOSTIC_TEST|SARS-CoV-2 Ab|Patient test for specific antibodies for SARS-CoV-2
223507833|NCT01163500|DIETARY_SUPPLEMENT|Coenzyme Q10|coenzyme Q10 supplements 60 mg/day and 150 mg/day
223507834|NCT01163500|OTHER|Placebo|Placebo controlled (dextrin)
223507835|NCT06501261|BEHAVIORAL|CALM psychotherapy|psychotherapy sessions
223507836|NCT04195477|BEHAVIORAL|vDPP|virtual Diabetes Prevention Program
223507837|NCT01063881|DRUG|Dapoxetine|Starting dose is one 30-mg tablet taken approximately 1-3 hours prior to sexual activity, may be increased after 4 weeks to 60mg, taken for 12 weeks. The maximum recommended dosing frequency is once every 24 hours.
223507838|NCT00186797|PROCEDURE|Allogeneic stem cell transplant|
223507839|NCT00186797|DRUG|Fludarabine, Cyclophosphamide|
223507840|NCT06169670|DEVICE|Viality|"Viality is a lipoaspirate wash system designed to be used in the operating room in conjunction with, and attached to, a user-provided liposuction cannula, a vacuum source, and a waste canister.~Viality is to be used to filter and wash aspirated, harvested autologous adipose tissue for aesthetic body contouring. The system should be used with a legally marketed vacuum or aspirator apparatus as a source of suction. If harvested fat is to be re-implanted, the harvested fat is to be used without any additional manipulation. Viality is not intended to process autologous adipose tissue other than for aesthetic body contouring uses."
223507841|NCT01084720|DRUG|V0034 CR|
223507842|NCT00205062|PROCEDURE|PET-CT|
223507843|NCT01851512|DRUG|T-R (Test-Reference drug)|
223507844|NCT01851512|DRUG|R-T (Reference-Test drug)|
223507845|NCT02527083|DRUG|Propofol|
223507846|NCT02527083|DRUG|Sevoflurane|
223507847|NCT02527083|DRUG|Remifentanil|
223507848|NCT02527083|DRUG|Ketamine|
223603370|NCT04014985|OTHER|An extensive biological assessment|To study the morphology of red blood cells, the markers of oxidative stress and the signaling pathway of IFGF1.
223603371|NCT05704790|OTHER|Cognitive Compensatory Training|The intervention will include 5 weekly sessions (60-90 minutes each) of cognitive compensatory training (CCT) delivered virtually by a pediatric neuropsychologist.
223603372|NCT05292131|DRUG|bimekizumab|Study participants will receive a single dose of bimekizumab (BKZ) administered subcutaneously in the Treatment Period.
223603373|NCT03198494|OTHER|Acoustic 1Hz Stimulation|1Hz acoustic pulses delivered during sleep via headphones
223603374|NCT03198494|OTHER|Sham Background Noise|Background Noise used as a control
223603375|NCT05882214|DIETARY_SUPPLEMENT|β-nicotinamide Mononucleotide|After an 8-hour overnight fast, the participants ingested β-nicotinamide Mononucleotide capsules with a single morning dose of 1000mg. The purity of β-nicotinamide Mononucleotide capsules was no less than 97% according to high-performance liquid chromatography analysis.
223603376|NCT05882214|DIETARY_SUPPLEMENT|Maltodextrin|After an 8-hour overnight fast, the participants ingested maltodextrin capsules with a single morning dose of 1000mg.
223603377|NCT04438889|OTHER|Non-interventional|Only routine clinical data, which has already been recorded in the patient's medical chart, will be documented. Any other data assessments (e.g. quality of life analyses such as EQ-5D and QLQ-C30 have been approved by the Ehtikkommission für das Bundesland Salzburg and are optional.
223603378|NCT06170853|OTHER|Exercise with augmented reality glasses|Three days a week (12 weeks in total), each session will be 60 minutes in total, and moderate exercise will be done with AR glasses.
223603379|NCT05658484|DRUG|Dimethyl fumarate|Administered as specified in the treatment arm.
223751061|NCT03148418|DRUG|Bevacizumab|Bevacizumab will be administered as directed per the parent study.
223751062|NCT04404738|PROCEDURE|MicroPort® robot-assisted laparoscopic surgery|In this group, patients undergoing robot-assisted laparoscopic surgery in urology will be performed by Microport® Surgical System
223751063|NCT04404738|PROCEDURE|da Vinci robot-assisted laparoscopic surgery|In this group, patients undergoing robot-assisted laparoscopic surgery in urology will be performed by da Vinci Surgical System
223751064|NCT02373787|DEVICE|creos xenoprotect|Implant placement with simultaneous bone augmentation
223751065|NCT02373787|DEVICE|Bio-Gide|resorbable collagen membrane
223751066|NCT02891707|DEVICE|Rehabilitative Lower-limb Orthopedic Accommodating-feedback Device (ReLOAD)|"The study will use a novel piece of technology, the ReLOAD, which is a data collector system that uses instrumented insoles, custom, miniature (1x1) microcontroller with accelerometer, gyroscopes, and geomagnetic sensors connected to a Bluetooth transceiver to collect and transmit gait kinematic data to mobile devices, such as an iPad and iPod. When a person walks or performs a specific activity, the ReLOAD system captures the movement, which can then be stored locally within the mobile device and/or encrypted and sent to a secured central server. This allows the patient or provider to access clinically relevant biomechanical data to help guide rehabilitation."
223751067|NCT01578889|BIOLOGICAL|HIV-MAG vaccine|Participants assigned to receive the HIV-MAG vaccine will receive 3 mg of the vaccine with bupivacaine, alone or admixed with one of three doses of the IL-12 pDNA adjuvant.
223751068|NCT01578889|BIOLOGICAL|IL-12 pDNA adjuvant|Participants assigned to receive the IL-12 plasmid (IL-12 pDNA) adjuvant will receive one of three doses (total of 250 mcg, 1000 mcg, or 1500 mcg) of the adjuvant admixed with the HIV-MAG vaccine.
223603380|NCT06389851|DIETARY_SUPPLEMENT|Experimental: Case Group - Tomato-free diet|Nutritional intervention without tomatoes and sauce
223603381|NCT06389851|DIETARY_SUPPLEMENT|Experimental: Case group - Diet enriched with tomatoes|Nutritional intervention enriched with tomatoes and souce
223603382|NCT06645470|OTHER|Standard Medical Care (SMC)|Standard Medical Care will continue to receive their regular standard clinical care during the 6-month intervention period of this study.
223751069|NCT01578889|BIOLOGICAL|VSV HIV gag vaccine|Participants assigned to receive the VSV HIV gag vaccine will receive a total dose of 1x10\^8 plaque-forming units (PFUs) administered as 5x10\^7 PFU in 1 mL by IM injection in both the left and right deltoids at Month 6.
223751070|NCT01578889|BIOLOGICAL|Placebo|Placebo will consist of sodium chloride for injection, USP 0.9%.
224200245|NCT06264765|OTHER|Incisional infiltration|Incisional infiltration: 20 ml of 0.5% bupivacaine will be infiltrated by the surgeon into the PHHA points and surgical incision areas 10 minutes before PHHA. Two
224200246|NCT06334627|BEHAVIORAL|Pre-Primary Intervention|School readiness intervention
224200247|NCT06357065|OTHER|Active transport educational program based on the ecological model|The intervention is structured according to the following units: Unit I: benefits of physical activity on health and healthy habits in schoolchildren; Unit II: Active Transportation: Experiences from other countries; Unit III: Analysis of the environmental characteristics of the school environment of each establishment; and Unit VI: Road safety for pedestrians and cyclists. This last topic will be broken down considering analysis and prevention of accidents with automobiles, pedestrian regulations, signaling, and cyclist safety. The sessions of the last month of intervention (November) will include practical walking activities in the school environment (outside the school). Depending on the possibilities of each school, cycling sessions will be included.
223603383|NCT06645470|BEHAVIORAL|Monitoring Contacts|Participants will receive contacts with the research staff at weeks 6, 12, and 18.
223603384|NCT06645470|BEHAVIORAL|Aerobic Training|Aerobic Training will be supervised exercise. It will occur on 3 days per week and will progress to 50 minutes per session (150 minutes per week). The intensity of the exercise will progress from 60%±5% to 70%±5% of age-predicted maximal heart rate (if taking beta-blocker medication intensity will progress from a Rating of Perceived Exertion of 11-13 to 12-14 based on the 6-20 Borg scale). While walking will be the preferred mode of exercise, alternative forms of cardiovascular exercise (upright cycling, elliptical, etc.) are allowed to accommodate any physical limitations that may be present for a participant. Heart rate will be monitored throughout these exercise sessions.
223751071|NCT01578889|DEVICE|Ichor Medical Systems TriGrid™ Delivery System (TDS) electroporation (EP) device|The HIV-MAG vaccine, IL-12 pDNA adjuvant, and placebos for IL-12 pDNA adjuvant/HIV-MAG vaccines will be delivered IM into the deltoid by the Ichor Medical Systems TDS EP device.
224200248|NCT06362707|DRUG|Fasudil|A ROCK inhibitor approved for treating vasospasms following subarachnoidal bleeding in Japan and China. Dosage: Participants will undergo a 2-week titration period at 60 mg daily before escalating to a maintenance dose of 120 mg daily.
223751072|NCT01675687|BEHAVIORAL|Follow Up Support|inputs will be based on elements derived from cognitive behavioural therapy, acceptance and commitment therapy, mindfulness and awareness training
223751073|NCT04615611|DRUG|salbutamol|inhalation of salbutamol
223751074|NCT04615611|DRUG|Placebo|administration of placebo
223751075|NCT06297174|DRUG|Racecadotril 100 mg Capsules|Racecadotril 100 mg Capsules (test drug)
223751076|NCT06297174|DRUG|HIDRASEC®|HIDRASEC® (reference drug)
223751077|NCT05517499|DRUG|Dexamethasone|Randomized clinical trial
223603385|NCT06645470|BEHAVIORAL|Resistance Training|Resistance Training will be supervised exercise. It will occur 3 days per week and includes 8 exercises performed in a prespecified order. Week 1-2 sessions focus on familiarization to acclimate the participant to the equipment, proper form, to establish initial weight (load) for training, and with performing multiple sets per day. For Weeks 3-8, participants will engage in 2 sets per exercise with the weight adjusted to elicit muscle fatigue in 8-12 repetitions per set. This progresses to 3 sets per exercise from Week 9 until the end of the intervention period. When 12 repetitions for a specific exercise can be achieved, the resistance will increase for that exercise at the next session. There is a 90 second rest period between each set of an exercise. Heart rate will be monitored throughout these exercise sessions.
223603386|NCT06645470|OTHER|Nutrition Education|A single counseling session to discuss the dietary recommendations when taking an obesity medication.
223603387|NCT05141721|DRUG|GRT-C901|A patient-specific neoantigen cancer vaccine administered via intramuscular (IM) injection as prime and single boost at a dose of 1x10\^12 viral particles 2 times over the course of the first year.
223603388|NCT05141721|DRUG|GRT-R902|A patient-specific neoantigen cancer vaccine boost, administered via IM injection at a dose of 30ug 4 times over the course of the first year.
223603389|NCT05141721|DRUG|Atezolizumab|Atezolizumab will be administered via intravenous (IV) infusion at a dose of 1680 mg once every 4 weeks.
223603390|NCT05141721|DRUG|Ipilimumab|Ipilimumab will be administered via subcutaneous (SC) injection at a dose of 30 mg with the first dose of GRT-C901 and GRT-R902.
223603391|NCT05141721|DRUG|Fluoropyrimidine plus leucovorin|Fluoropyrimidine (infusional 5-FU or capecitabine) and leucovorin administered as maintenance therapy per standard of care.
223603392|NCT05141721|DRUG|Bevacizumab|Bevacizumab administered as maintenance therapy per standard of care.
223603393|NCT05196022|OTHER|Cochlear implant|G2 will receive a cochlear implant during the study
224200249|NCT06362707|DRUG|Placebo|Placebo tablets that look identical to the fasudil tablets and will follow the same dosing schedule as participants receiving fasudil.
224200250|NCT01292291|OTHER|biologic sample preservation procedure|
223751078|NCT05700682|DEVICE|Shoulder/Hip/Knee Embolization with Embozene Microspheres|Fluoroscopically-guided arterial embolization of synovitis in the painful shoulder, hip or knee.
223751079|NCT04541433|DRUG|AZD9833|AZD9833 taken orally
223751080|NCT05845879|OTHER|delivery|delivery
223751081|NCT01425554|OTHER|Doppler sonography of internal jugular veins|Doppler sonography of internal jugular veins
223751082|NCT01425554|OTHER|Magnetic resonance venography of internal jugular veins|Magnetic resonance venography of internal jugular veins
223751083|NCT01425554|OTHER|Air-plethysmography of the neck|Air-plethysmography of the neck
223751084|NCT01425554|OTHER|Catheter venography of internal jugular veins|Catheter venography of internal jugular veins
223751085|NCT01116297|DEVICE|Imaging with S-FLARE imaging system|Tissue oxygenation measurements during plastic surgery using the S-FLARE system.
224200251|NCT01292291|OTHER|laboratory biomarker analysis|
223751086|NCT00703885|DRUG|0.25 mg alprazolam|"0.25 mg alprazolam PO (liquid) to be administered 1 hour prior to fMRI scan~Note that subjects receive all 3 treatments in randomized order (cross-over study), approximately 7-10 days apart."
223751087|NCT00703885|DRUG|1.0 mg alprazolam|"1 mg alprazolam PO (liquid) will be administered 1 hour prior to fMRI scan~Note that subjects receive all 3 treatments in randomized order (cross-over study), approximately 7-10 days apart."
223751088|NCT00703885|DRUG|placebo|"Placebo (liquid) to be administered 1 hour prior to fMRI scan~Note that subjects receive all 3 treatments in randomized order (cross-over study), approximately 7-10 days apart."
223751089|NCT03823053|OTHER|Home Based Traditional Scoliosis Exercise|Program will include posture exercises, strengthening exercises of interscapular muscle and limb, diaphragmatic breathing exercises and stretching exercises for lumbar extensor, hip flexor, hamstring, pectoral muscles. Exercises will be applied 1 sets of 10 repetitions and once a day.
223751090|NCT03823053|OTHER|Home Based Core Stabilization Training|Program will include posture exercises, strengthening exercises of interscapular muscle and limb, diaphragmatic breathing exercises and stretching exercises for lumbar extensor, hip flexor, hamstring, pectoral muscles. In addition, the training group received core stabilization exercises for multifidus, transversus abdominis, diaphragm,erector spines, rectus abdominis, internal and external obliques, quadratus lumborum, gluteus maximus, and pelvic floor muscles.Exercises will be applied 1 sets of 10 repetitions and once a day.
224200252|NCT01292291|OTHER|study of socioeconomic and demographic variables|
224200253|NCT01292291|PROCEDURE|diffusion-weighted magnetic resonance imaging|
224200254|NCT01292291|PROCEDURE|dynamic contrast-enhanced magnetic resonance imaging|
224200255|NCT01292291|PROCEDURE|multiparametric magnetic resonance imaging|
224200256|NCT01292291|PROCEDURE|quality-of-life assessment|
224200257|NCT01292291|PROCEDURE|transperineal prostate biopsy|
224200258|NCT01292291|PROCEDURE|transrectal prostate biopsy|
224200259|NCT01292291|PROCEDURE|ultrasound-guided prostate biopsy|
224200260|NCT02181673|DRUG|Placebo|Participants will receive intravenous infusions of placebo at Weeks 0, 4, 12 and 20 in treatment Group 1 and intravenous infusions of placebo at Week 24 to maintain the blind in treatment Group 2.
224200261|NCT02181673|DRUG|Golimumab|Participants will receive intravenous infusions of golimumab 2mg/kg at Weeks 0, 4 and thereafter every 8 weeks up to Week 52 in treatment Group 2 and intravenous infusions of golimumab (2mg/kg) at Weeks 24, 28 and thereafter every 8 weeks up to Week 52 in treatment Group 1.
224200262|NCT02550509|DEVICE|ultrasound echogenicity|ultrasound echogenicity to patient with stroke
224200263|NCT02550509|DEVICE|elastography|elastography to patient with stoke
224200264|NCT04539106|DRUG|intravitreal injection of Ranibizumab|intravitreal injection of 0.25 mg/0.025 ml ranibizumab with a 30-gauge needle 1.5mm from limbus
223751091|NCT01100242|DRUG|Velcade and Sorafenib|Velcade will be administered intravenously; sorafenib will be self-administered on an outpatient basis. At least 2 courses will be administered to each patient unless there is early progression of disease or unacceptable toxicity. Repeated courses may be given to patients who benefit from the treatment (complete or partial remission or stabilization of disease)
223751092|NCT06195397|OTHER|Evidence-Based Education intervention|A total of 12 hours of Evidence-Based Education intervention was applied to students in the intervention group, spread over 7 sessions.
223751093|NCT01100099|DIETARY_SUPPLEMENT|Gluten challenge.|The study population consists of 50 HLA-DQ2+ patients on a gluten free diet, both celiacs and uncertain celiacs. The patients will undergo a oral gluten challenge with four slices of bread daily for three days. Before challenge blood samples will be drawn for tetramer staining of gluten-specific T-cells. The analysis is done at the Institute of Immunology at Rikshospitalet, using FACS analysis. Small intestinal biopsies will be examined for morhological changes and inflammatory gene expression. These procedures with blood samples and biopsies will be repeated after gluten challenge. Registration for clinical symptoms and personality traits will be done by standardised and validated forms. A dietist will perform an interview of the patients.
223603394|NCT04733053|OTHER|Diet plus exercise|"The diet program has two phases: 1) intensive weight loss through a ketogenic very low calorie diet VLCD, and 2) transition from ketogenic VLCD onto a healthy eating plan for weight maintenance. Meal replacements will be provided to participants free of charge from the start of the trial to a maximum of 14 weeks (12 weeks for the ketogenic diet and 2 weeks for transition). If a participant does not wish to transition off the ketogenic diet after 14 weeks but wants to continue or if they wish to recommence the ketogenic diet any time after week 14 they will need to purchase meal replacements themselves at their own cost.~Participants will be encouraged to aim to lose at least 10% body weight."
223603395|NCT04733053|OTHER|Exercise|The trial coordinator will have provided participants with educational material about OA, handouts of home exercises including photographs and descriptions, a logbook for recording home program completion and resistance exercise bands ahead of their first appointment. Physiotherapists will prescribe 5-6 strengthening exercises from a pre-determined list to be performed at home three times/week, including two quadriceps exercises, one each for hip abductors, hamstrings and calf, and any other as appropriate. Review and modification will occur at each consultation to maintain moderate intensity (effort of ≥5 out of 10 (hard) on a modified Borg Rating of Perceived Exertion scale). The physiotherapist will also prescribe a personalised physical activity plan in collaboration with the participant that is supported and progressed over time.
223603396|NCT06136897|PROCEDURE|Biopsy Procedure|Undergo biopsy
223603397|NCT06136897|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
223603398|NCT06136897|PROCEDURE|Echocardiography Test|Undergo ECHO
223603399|NCT06136897|BIOLOGICAL|Pertuzumab|Given IV
223603400|NCT06136897|PROCEDURE|Radiologic Examination|Undergo radiologic evaluation
223603401|NCT06136897|BIOLOGICAL|Trastuzumab|Given IV
223603402|NCT05428631|DEVICE|Implantation of the CARDIOMEMS™ HF device|The initial routine workup includes a nephrological evaluation: mGFR with Iohexol before fitting the CARDIOMEMS™ HF device, renal echo-Doppler, urinary sedimentation, etiological assessment of severe Chronic Kidney Disease, NT-ProBNP, impedancemetry, urinary ionogram, weight, anemia assessment, and correction of possible iron and/or vitamin deficiency and a cardiology evaluation: blood pressure, heart rate, clinical data, biology (Complete Blood Count, iono, urea, creatinine, total bilirubin, ferritin, CST), echocardiography (Left Ventricle Ejection Fraction, E/A, E/e', indexed volume of the left atrium, Tricuspid Annular Plane Systolic Excursion, Tissue Doppler S-wave, surface area of the right atrium, Systolic Pulmonary Artery Pressure, Right Atrial Pressure). The device will be implanted in the selected patients by Pr François Roubille at Montpellier University Hospital within 1 month of the pre-inclusion visit. It will monitor their pulmonary artery pressure.
223751094|NCT03857087|DRUG|Gallium Ga 68-labeled PSMA-11|Given IV
223751095|NCT03857087|PROCEDURE|Magnetic Resonance Imaging (MRI)|Given PET/MRI
223751096|NCT03857087|PROCEDURE|Positron Emission Tomography (PET)|Undergo PET/MRI
223751097|NCT02032147|DRUG|NGF group|This group will be treated with NGF 18u per day im for 60 days
223751098|NCT02609022|BIOLOGICAL|CV-MG01|"3 consecutive subcutaneous injections of CV-MG01. The three injections are planned for each patient on Days 1, 29 (+/- 3 days) and 85 (+/- 7 days), respectively.~Two dose levels: low and high dose."
223751099|NCT02609022|BIOLOGICAL|Placebo|3 consecutive subcutaneous injections of placebo. The three injections are planned for each patient on Days 1, 29 (+/- 3 days) and 85 (+/- 7 days), respectively.
223751100|NCT03688412|DEVICE|Cook lead extraction devices|The Cook lead extraction devices are mechanical devices that encompass a full variety of devices required for percutaneous removal of CIED leads, indwelling catheters and foreign objects.
223751101|NCT06080386|DIAGNOSTIC_TEST|UDFF|quantification of liver fat: UDFF (lipid fraction derived from ultrasound) from one of the probes of an ultrasound system
223751102|NCT00370253|DRUG|Terlipressin|1mg/4 h per day
223751103|NCT00370253|DRUG|Noradrenalin|0,1 mcg/kg/min
223751104|NCT01451775|DRUG|Empagliflozin|high dose of empagliflozin after overnight fasting for at least 10 h
223751105|NCT01451775|DRUG|Empagliflozin|low dose empagliflozin after overnight fasting for at least 10 h
223751106|NCT01451775|DRUG|Empagliflozin|high dose of empagliflozin after a standardised high fat breakfast
223751107|NCT00191828|DRUG|olanzapine|
223751108|NCT06496126|DEVICE|Cerasmart 270 (GC Coop, Tokyo, Japonya)|Hybrid Ceramic Block
223751109|NCT06496126|DEVICE|EverX Flow (GC Coop, Tokyo, Japonya)|Fiber Reinforced Composite Resin
223751110|NCT06496126|DEVICE|: G-CEM ONE (GC Coop, Tokyo, Japonya)|Universal Self Adhesive Resin Cement
223751111|NCT06496126|DEVICE|G-Premio Bond (GC Coop, Tokyo, Japonya)|Universal Adhesive
223751112|NCT06496126|DEVICE|G-ænial A'CHORD|Conventional Composite Resin
223603404|NCT03785405|DRUG|sacubitril/valsartan|"Target dose 3.1 mg/kg bid~Formulations:~Tablets (50, 100, 200 mg) Granules \[12.5 mg (4 granules), 31.25 mg (10 granules), in capsules\] Liquid (1 mg/ml, 4 mg/ml, prepared from tablets)"
223603405|NCT06532565|DRUG|GS-2121|Tablet administered orally
223603406|NCT06532565|DRUG|Zimberelimab|Administered intravenously
223603407|NCT06635980|PROCEDURE|Biopsy of Breast|Undergo breast biopsy
223603408|NCT06635980|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223603409|NCT06635980|PROCEDURE|Breast Surgery|Undergo breast surgery
223603410|NCT06635980|DRUG|Chemotherapy|Receive SOC chemotherapy
223603411|NCT06635980|PROCEDURE|Computed Tomography|Undergo CT
223603412|NCT06635980|PROCEDURE|Contrast Enhanced Digital Mammography|Undergo CEDM
223603413|NCT06635980|RADIATION|Hypofractionated Radiation Therapy|Undergo hypofractionated radiotherapy
223603414|NCT06635980|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223603415|NCT06635980|PROCEDURE|Positron Emission Tomography|Undergo PET
223603416|NCT06635980|OTHER|Survey Administration|Ancillary studies
223603417|NCT06635980|PROCEDURE|Tissue Collection|Undergo tissue collection
223603418|NCT06635980|PROCEDURE|Ultrasound Imaging|Undergo ultrasound
223751113|NCT01488097|DRUG|sebelipase alfa|Sebelipase alfa is a recombinant human lysosomal acid lipase.
223751114|NCT04407910|COMBINATION_PRODUCT|AIRFLOW® Master device +Opalescence Xtra Boost.|Prophylaxis techniques for pre-bleaching treatment
223751115|NCT04407910|COMBINATION_PRODUCT|rubber-cup+Opalescence Xtra Boost.|Prophylaxis techniques for pre-bleaching treatment
223751116|NCT03999411|DRUG|Nicoderm C-Q Transdermal Product|6 weeks of GlaxoSmithKline Nicoderm CQ (NRT)
223751117|NCT03999411|BEHAVIORAL|Adherence to Antiretroviral Therapy Counseling|Brief counseling on adhering to antiretroviral therapy with self-help materials.
223751118|NCT03999411|BEHAVIORAL|Behavioral Smoking Cessation Counseling|One time face-to-face smoking cessation counseling and 2 follow-up phone calls.
223751119|NCT03999411|BEHAVIORAL|"Crave-to-Quit app"|"Evidence-based mindfulness smoking cessation smartphone app (Crave-to-Quit) adapted from an in-person mindfulness training relapse prevention smoking cessation intervention."
223751120|NCT03999411|BEHAVIORAL|"vDOT emocha app"|"Video Directly Observed Therapy (vDOT) smartphone app (emocha) that allows participants to take a video of themselves taking medication to ensure adherence."
223751121|NCT02016482|BIOLOGICAL|Adalimumab|
223603419|NCT03705559|DRUG|Vaporized Marijuana|Active Marijuana administered through vaporizer
223603420|NCT03705559|DRUG|Opioid Agonist|Active Opioid Agonist administered intranasally
223603421|NCT03705559|DRUG|Placebo|Experimental, non-therapeutic administration of inactive opioid or marijuana dose(s)
223603422|NCT03559647|DRUG|Atezolizumab|Atezolizumab will be administered per the Summary of Product Characteristics (SmPC) from the European Medicines Agency (EMA).
223751122|NCT02016482|OTHER|Placebo|
223751123|NCT03441633|DRUG|apixaban|current or new medication
223751124|NCT03441633|DRUG|dabigatran|current or new medication
223751125|NCT03441633|DRUG|VKA|current or new medication
223751126|NCT03441633|DRUG|rivaroxaban|current or new medication
223751127|NCT03990896|DRUG|Talazoparib|"Talazoparib is a study drug that inhibits (stops) the normal activity of certain proteins called poly (ADP-ribose) polymerases also called PARPs. PARPs are proteins (made from genes which are part of DNA) that are found in all normal and cancer cells that are involved in the repair of DNA. PARPs are needed to repair mistakes that can happen in DNA when cells divide. If the mistakes are not repaired, the defective cell will usually die and be replaced. Cells with mistakes in their DNA that do not die can become cancer cells."
223751128|NCT05446402|COMBINATION_PRODUCT|Geologie Acne Regimen - one side of face|"Geologie is an over-the-counter cosmetic acne regimen with three products. The regimen also has three levels over the course of three months, in which the nighttime lotion is switched to a stronger formula each month. The Geologie Clear System regimen for acne prone skin includes:~1. Clarifying Gel Cleanser - SA Formula (2% Salicylic Acid)~2. Brightening Day Cream - SPF 15 (5% Azelaic Acid, 2% Hyaluronic Acid, 1%Niacinamide)~3. Repairing Night Cream -~   1. Level 1 (0.05% Retinol, 3% Niacinamide, 2% Hyaluronic Acid)~  2. Level 2 (0.2% Retinol, 3% Niacinamide, 2% Hyaluronic Acid)~  3. Level 3 (0.3% Retinol, 3% Niacinamide, 2% Hyaluronic Acid)"
223751129|NCT05446402|COMBINATION_PRODUCT|Proactive Acne Regimen - other side of face|"ProActiv is an over-the-counter cosmetic regimen with three products. The~Proactiv Solution 3-Piece System regimen includes:~1. Renewing Cleanser (Active ingredient: 2.5% Benzoyl Peroxide)~2. Revitalizing Toner (Glycolic Acid)~3. Repairing Treatment (Active ingredient: 2.5% Benzoyl Peroxide)"
224075379|NCT04103437|DIAGNOSTIC_TEST|Metabolic and movement analysis of running|Running analysis of three six minutes running test (self-selected speed, + and - 20% of the self-selected speed) by video recording with camera in the frontal plane, and acquisition of the metabolic and spatio-temporal parameters
224075380|NCT04103437|OTHER|Questionnaires|Monthly follow-up questionnaire (12 months) about training habits and injuries
223603423|NCT00583063|DRUG|sunitinib|25 mg daily (oral dosing)
223603424|NCT00583063|DRUG|rapamycin|4 mg daily (oral dosing)
223603425|NCT02584270|DEVICE|Palatal Augmentation Prosthesis (PAP)|The palatal augmentation prosthesis, or PAP can improve speech and swallowing functions through reshaping the palatal contours. This may improve the contact between the tongue and hard palate as a person speaks or eats. It is meant to be created after adequate healing in patients with adequate motivation for improvements in their speech and swallowing. Regular wear and articulation therapy are necessary for this therapy to be effective.
223603426|NCT02584270|OTHER|Articulation Therapy|Subjects will receive the standard of care speech and articulation therapy in either arm.
223603427|NCT04027751|DRUG|Tropisetron|Investigators administrated intravenously Tropisetron 5mg before anesthesia induction
223603428|NCT04027751|DRUG|Placebos|Investigators administrated intravenously 0.9% saline solution as a placebo
223603429|NCT04923568|DEVICE|EaseVRx|Participants will experience 2 sessions of the EaseVRx device for chronic pain
223603430|NCT04891523|DIETARY_SUPPLEMENT|Probiotics-O (Burgerstein)|Topical oral treatment with the probiotic Streptococcus salivarius K12 (BIOTICS-O, Burgerstein) in form of a lozenge, daily, during 3 weeks.
223603431|NCT04891523|OTHER|Placebo [inactivated Probiotics-O (Burgerstein)]|Topical oral treatment with the placebo \[inactivated probiotic Streptococcus salivarius K12 (BIOTICS-O, Burgerstein)\] in form of a lozenge, daily, during 3 weeks.
223603432|NCT03357016|OTHER|Training programs|High Intensity Interval Training program (HIIT) vs. Moderate Intensity Continuous Training program (MICT) vs. High Intensity Interval Training program + Resistance Training program (HIIT+RT)
223603433|NCT05727813|DEVICE|cryoablation|cryoablation of breast cancer smaller than 2 cm
223603434|NCT05373264|DRUG|Hydrochlorothiazide 25 mg|An oral capsule containing 25mg of hydrochlorothiazide
223603435|NCT05373264|DRUG|Placebo|A matching oral capsule containing placebo
223603436|NCT01581398|DRUG|Ypeginterferon alfa-2b|sc, qw, 24 weeks.
223603437|NCT01581398|DRUG|Pegasys|sc, qw, 24 weeks.
223603438|NCT01581398|DRUG|Ypeginterferon alfa-2b|sc, qw, 48 weeks.
223603439|NCT01581398|DRUG|Pegasys|sc, qw, 48 weeks.
223603440|NCT02195375|DRUG|Flutiform 500/20 µg BID|
223603441|NCT02195375|DRUG|Flutiform 250/10 µg BID|
223603442|NCT02195375|DRUG|Seretide Accuhaler 50/500 µg BID|
223603443|NCT05234957|PROCEDURE|Bilateral Lateral Rectus Recession|Symmetric bilateral lateral rectus muscle recession involves equal recession of both lateral rectus muscles. Asymmetric bilateral lateral rectus muscle recession involves recession of the lateral rectus muscle by 2mm more in the non-dominant eye.
223603444|NCT04930900|DRUG|ARS-1 with URTI|ARS-1
223603445|NCT04930900|DRUG|ARS-1 without URTI|ARS-1 without URTI
223603446|NCT06206161|BEHAVIORAL|Indicated Prevention, Clinical Staff|Standard brief intervention eligibility criteria involving indicated prevention (i.e., brief interventions delivered to high-risk drinkers only). BIs delivered by standard SBIRT workforce involving school nursing or clinical staff.
223603447|NCT06206161|BEHAVIORAL|Selective Prevention|Expanded brief intervention eligibility criteria involving selective prevention in addition to indicated prevention (i.e., brief interventions delivered to current drinkers with and without risky alcohol use).
223603448|NCT06206161|BEHAVIORAL|Expanded Paraprofessional Workforce|Brief interventions delivered by expanded SBIRT workforce involving school nursing or clinical staff and trained paraprofessionals.
223603449|NCT03109639|DEVICE|Conventional EUS FNA needle|Participants randomised to Group A will undergo tissues acquisition using the Conventional EUS FNA needle and then crossed over to receive the experimental Acquire EUS- FNB device.
223603450|NCT03109639|DEVICE|Acquire FNB device|Participants randomised to Group B will undergo tissue acquisition using the experimental Acquire EUS FNB device and then crossed over to receive the conventional EUS FNA needle
223603451|NCT00034086|DRUG|Lopinavir/Ritonavir|
223603452|NCT00034086|DRUG|Lamivudine/Zidovudine|
223603453|NCT00034086|DRUG|Tenofovir disoproxil fumarate|
223603454|NCT00034086|BIOLOGICAL|Pneumococcal Vaccine, Polyvalent (23-valent)|
223603455|NCT00034086|DRUG|Lamivudine|
223603456|NCT00034086|DRUG|Stavudine|
223603457|NCT00034086|DRUG|Zidovudine|
223603458|NCT00034086|DRUG|Didanosine|
223603459|NCT00034086|BIOLOGICAL|Lyme Disease Vaccine Recombinant OspA|
223603460|NCT00034086|BIOLOGICAL|Haemophilus B Conjugate Vaccine|
223603461|NCT05206760|PROCEDURE|Brain biopsy|Biopsy of brain tissue
223603462|NCT04590573|BEHAVIORAL|Cognitive behavioural couple therapy (CBCT), Emotion focused couple therapy (EFCT), Wait-list control (Control)|5 sessions in CBCT, EFCT and Control (3 hours per session), 6-8 pairs of couples per group and around 7 groups will be held.
223603463|NCT05109624|PROCEDURE|prolonged prone position ventilation|patients mechanically ventilated with SARS COV 2 will be subjected to a longer than usual period of prone position ventilation
223603464|NCT02134444|BEHAVIORAL|Experimental group|Experimental group will receive a game-based exercise program delivered at home. This includes provision of a head-mounted motion mouse. This provides a treatment tool applied to gaze control, and allows incorporation of balance exercises. It also allows many different therapeutic exercises to be coupled to a wide range of inexpensive commercial computer games. Participants will attend 3 clinical sessions during which time the home therapy programs will be established and training in the use of the motion mouse and games will be provided. The treating physiotherapist will attend the participant's home to ensure proper set-up and operation of the computer applications. Participants will be asked to perform their respective home programs four times per week for 20 minutes per session.
223603465|NCT02134444|BEHAVIORAL|Control group|Control group will receive a vestibular exercise program which will include the Herdman gaze stabilization exercises and balance training program. This program is presently a standard of vestibular care. Participants will attend an out-patient physical therapy clinic once a week for 12 weeks. The program also includes a 20 minute home exercise program prescribed 4 times per week.
223603466|NCT03825302|DIAGNOSTIC_TEST|Methacholine challenge|Methacholine inhalation challenge will be administered to both male and females with asthma
223603467|NCT03825302|DIAGNOSTIC_TEST|Mannitol challenge|Mannitol inhalation challenge will be administered to both male and females with asthma
223603468|NCT05605912|OTHER|Control|Participants perform five one-hour conventional training sessions at the Sint Maartenskliniek in which they perform functional exercises. After the conventional training program, the control group will receive a recommendation for physical activity at home for six weeks.
223603469|NCT05605912|DEVICE|Myosuit|Participants perform five one-hour Myosuit training sessions at the Sint Maartenskliniek in which they perform functional exercises and learn to don, doff and use the device for standing, walking, climbing the stairs and sit-to-stand transitions. After the clinical Myosuit training program, participants receive the Myosuit at their disposal at home and a recommendation for physical activity at home for six weeks.
223603470|NCT06248333|DEVICE|STN-DBS ON|Stimulation ON
223603471|NCT06248333|DEVICE|STN-DBS OFF|Stimulation OFF
223603472|NCT05394831|DRUG|JIN-A02|PO, QD
223603473|NCT06433479|DRUG|Dapagliflozin 10 mg per day for 3 months after initial catheter ablation|Dapagliflozin 10 mg per day for 3 months after initial catheter ablation
223603474|NCT02881762|DRUG|Maraviroc|Participants will receive 4 weeks of maraviroc (dosing based on concomitant HIV antiretroviral regimen). Serial measurements of HCV viral load will be obtained before, during, and after maraviroc exposure. Study duration will be approximately 12 to 16 weeks.
223603475|NCT00795236|DRUG|Melatonin|One 0.5 mg tablet of melatonin will be taken by subjects who are free-running and willing to enter the intervention phase of the study. These subjects will take melatonin until entrainment status is confirmed or throughout the duration of the study.
223603476|NCT02856204|OTHER|Cytology Specimen Collection Procedure|Undergo collection of blood
223603477|NCT02856204|OTHER|Laboratory Biomarker Analysis|Correlative studies
223603478|NCT03269058|DRUG|Dapagliflozin|Dapagliflozin 10 mg daily per os
223603479|NCT03269058|DRUG|Placebos|Placebo of Dapagliflozin per day per os
223751130|NCT05836402|DIETARY_SUPPLEMENT|Low carbohydrate diet intervention|"Patients will receive a study kit. The kit will contain the following:~* Instruction sheet containing medical food instructions and food journal and a web link to the weekly online journal~* A 30-day supply of the medical food, KetoCitra, developed by Santa Barbara Nutrients, Inc. KetoCitra® is a ready-to-mix powder to be dissolved in water and taken twice per day with meals. KetoCitra® contains BHB, citrate, and a blend of minerals (potassium, calcium, magnesium) and is flavored with natural lemon flavor and stevia natural sweetener. KetoCitra® is sugar- and sodium-free and is intended to support the metabolic switch aimed for with the low-carbohydrate diet by providing exogenous BHB (Package insert)"
223507849|NCT05351034|DEVICE|Anorectal manometry|Anorectal manometry in diagnosis of Functional anorectal disorders
223507850|NCT03749863|PROCEDURE|Serial PRP injections|Autologous platelet-rich plasma will be injected into the vocal fold mucosa in a serial fashion, once per month for a total of 4 injections.
223507851|NCT01981928|DRUG|ASP7962|Oral
223507852|NCT01981928|DRUG|Placebo|Oral
223507853|NCT01446653|BEHAVIORAL|Motivational Interviewing plus feedback|Provides an MI + feedback intervention supplemented with video and brochures-based information
223507854|NCT01446653|BEHAVIORAL|Video|Video arm will provide information via documentary video
223507855|NCT01446653|BEHAVIORAL|Informational Brochure|Informational Brochures are given to participants following baseline assessment.
223507856|NCT06132997|PROCEDURE|Thoracoscopy procedure|is a minimally invasive endoscopic procedure utilized by pulmonologists to evaluate, diagnose, and treat pleural pathologies of the lung, mainly pleural effusions.
223507857|NCT06132997|PROCEDURE|Chest tube thoracostomy|Insert chest intercostal tube without thoracoscopy
223507858|NCT00005922|BEHAVIORAL|Partial schedule of pharmacotherapeutic reinforcement|Dose of 0.1% of Aristocort A on 1-2 of every 4 days for a period of up to 14 weeks.
223507859|NCT00005922|DRUG|Dose control for Arm B|Dose of 0.025-0.05% of Aristocort A 2 times per day for a period of up to 14 weeks.
223507860|NCT00005922|OTHER|Standard pharmacotherapeutic protocol|Full dose of Aristicort A (0.1%) 2 times per day for a period of up to 14 weeks.
223507861|NCT01666405|DEVICE|Urgent(R) PC Neuromodulation System|The Urgent PC Neuromodulation System (Uroplasty, Inc., Minnetonka, MN, USA), device, is an easily administered neuromodulation system designed to deliver retrograde access to the sacral nerve through percutaneous electrical stimulation of the tibial nerve. This method of treatment is referred to as percutaneous tibial nerve stimulation (PTNS).
223507862|NCT00576342|DRUG|AL-3862+timolol ophthalmic suspension|
223507863|NCT00576342|DRUG|Dorzolamide+timolol ophthalmic solution|
223507864|NCT01489358|BIOLOGICAL|VRC-CHKVLP059-00-VP|VRC-CHKVLP059-00-VP is a VLP vaccine that consists of the E1, E2 and capsid proteins of the Chikungunya Virus
223507865|NCT03434366|DRUG|ketamine and dexmedetomidine|intranasal ketamine and dexmedetomidine for treatment for autism spectrum disorder
223507866|NCT03434366|DRUG|ketamine|intranasal ketamine for treatment for autism spectrum disorder
223507867|NCT03434366|DRUG|Saline|intranasal saline for treatment for autism spectrum disorder
223507868|NCT02730286|OTHER|observational study|application of several standard instruments in patients with rheumatoid arthritis
223507869|NCT00736476|BIOLOGICAL|H.pylori vaccines|1 dose of H.pylori vaccine at 0, 1, and 2 months
223507870|NCT00736476|BIOLOGICAL|Placebo Vaccine|Placebo Vaccine at 0, 1, and 2 months
223507871|NCT02845180|PROCEDURE|Adipose Allograft Extracellular Matrix (AAM) Injection|Injection followed by surgery
223507872|NCT04043104|DRUG|AAV2hAQP1: 1 x 10^11 vg/gland (single gland)|Intra-parotid administration of AAV2hAQP1 via Stensen's duct to a single parotid gland at a dose level of 1 x 10\^11 vg/gland
223507873|NCT04043104|DRUG|AAV2hAQP1: 3 x 10^10 vg/gland (both glands)|Intra-parotid administration of AAV2hAQP1 via Stensen's duct to both parotid glands at a dose level of 3 x 10\^10 vg/gland
223507874|NCT04043104|DRUG|AAV2hAQP1: 3 x 10^11 vg/gland (single gland)|Intra-parotid administration of AAV2hAQP1 of via Stensen's duct to a single parotid gland at a dose level of 3 x 10\^11 vg/gland
223507875|NCT04043104|DRUG|AAV2hAQP1: 1 x 10^11 vg/gland (both glands)|intra-parotid administration of AAV2hAQP1 via Stensen's duct to both parotid glands at a dose level of 1 x 10\^11 vg/gland
223507876|NCT04043104|DRUG|AAV2hAQP1: 1 x 10^12 vg/gland (single gland)|Intra-parotid administration of AAV2hAQP1 via Stensen's duct to a single parotid gland at a dose level of 1 x 10\^12 vg/gland
223603480|NCT05017467|DRUG|undefinedCentella Asiatica Extract|"All patients were asked about scar hypertrophy, scar tenderness, and pillar pain.~The scar assessment was performed using the Vancouver Scar Scale (VSS) at the one, three and 6 months after surgery.~Patients were asked to complete pre- and postoperative functional evaluations. The VAS score and QuickDASH test was used"
223603481|NCT01821859|DRUG|Abraxane|Abraxane will be infused at a dose of 220 mg/m² in 20 mL normal saline per 100 mg vial over 30 minutes. This will follow the Bevacizumab infusion.
223603482|NCT01821859|DRUG|Bevacizumab|Bevacizumab will be infused at a dose of 10 mg/kg in 100 mL normal saline over 30 minutes ± 10 minutes. It is given first, prior to the Abraxane infusion.
223507877|NCT04043104|DRUG|AAV2hAQP1: 3 x 10^11 vg/gland (both glands)|Intra-parotid administration of AAV2hAQP1 via Stensen's duct to both parotid glands at a dose level of 3 x 10\^11 vg/gland
223507878|NCT04043104|DRUG|AAV2hAQP1: 3 x 10^12 vg/gland (single gland)|Intra-parotid administration of AAV2hAQP1 via Stensen's duct to a single parotid gland at a dose level of 3 x 10\^12 vg/gland
223507879|NCT04043104|DRUG|AAV2hAQP1: 1 x 10^12 vg/gland (both glands)|Intra-parotid administration of AAV2hAQP1 via Stensen's duct to both parotid glands at a dose level of 1 x 10\^12 vg/gland
223507880|NCT05581264|BEHAVIORAL|Diabetes Self-Management Education Program|diabetes self-management education and counseling program with follow-up via phone for the intervention group for 24 weeks
223507881|NCT00502515|DRUG|SSR180575|Oral, once daily dosing
223507882|NCT00502515|DRUG|Placebo|Oral, once daily dosing
223507883|NCT05845190|OTHER|aerobic exercises|aerobic exercises in form of walking on treadmill
223507884|NCT05845190|OTHER|resistance exercises|60% of One-repetition maximum 3 sets ( 8 to 12 ) repetitions
223507885|NCT02018809|BEHAVIORAL|Medication Adherence Partner|
223507886|NCT02018809|DEVICE|Electronic pill bottle|This device can remotely track medication taking and will be used by subjects to store once-a-day statin medication already prescribed pre-trial.
223751131|NCT02872116|DRUG|Nivolumab|Specified dose on specified days
223751132|NCT02872116|DRUG|Ipilimumab|Specified dose on specified days
223751133|NCT02872116|DRUG|Oxaliplatin|Specified dose on specified days
223751134|NCT02872116|DRUG|Capecitabine|Specified dose on specified days
223751135|NCT02872116|DRUG|Leucovorin|Specified dose on specified days
223751136|NCT02872116|DRUG|Fluorouracil|Specified dose on specified days
223603483|NCT05383456|DIAGNOSTIC_TEST|Diagnostic Test|Standard diagnostic tests.
223603484|NCT05383456|DRUG|HIV Anti-retroviral Background Therapy|"All participants are required be on continuous HIV Anti-retroviral Background Therapy.~No intervention on drug is part of the Study."
223603485|NCT00203424|DRUG|Erlotinib + Bevacizumab|Erlotinib every day for 24 weeks and Bevacizumab every 3 weeks for a total of 8 doses
223603486|NCT04741919|PROCEDURE|Yag Laser peripheral Iridotomy|Laser peripheral iridotomy will be performed using neo-dynium:yttrium:aluminium-garnet laser after pretreatment with 2% pilocarpine and brimonidine 0.15%. Superior LPIs will be placed between the 11- and 1-o'clock positions such that they were covered completely by the upper eyelid; nasal/temporal LPIs will be placed between the 2- and 4-o'clock positions or the 8- and 10-o'clock positions such that they were completely clear of the lid margin. Preference will be given to iris crypts, avoiding iris vessels when possible. Laser peripheral iridotomies will be performed in both eyes during the same visit and will be confirmed to be patent after the procedure. Intraoperative data collected will include initial per-shot laser energy in milli joules, number of laser shots, and total laser energy in millijoules. All the patients will be treated with flurometholone 0.1% eye drops QID for 5 days after surgery.
223603487|NCT05844267|BEHAVIORAL|Experimental led booster breaks|Participants in this group will receive interventions in the form of active breaks, administered by professionals in the relevant field, such as Physical Education teachers, for a period of 12 weeks. The active breaks will comprise exercises of light-to-moderate intensity, based on the guidelines provided by the Chilean safety association (ACHS), with an average duration of 14-16 minutes per day from Monday to Friday. The exercise types and progression will be elaborated in our protocol and published as supplementary material.
223603488|NCT05844267|BEHAVIORAL|Experimental unled computer-prompts|"Participants in this group will receive interventions in the form of active breaks, facilitated through an application called Ponte de pie por tu salud, proposed by the Chilean Ministry of Health. This off-line application will be configured to generate breaks every hour, lasting for 2 minutes per break, over the course of 8 hours. This ensures that an average of 14-16 minutes of active breaks are accumulated throughout the day. Our research team will install the application on the participants' work computers and collect data from these computers weekly. At the end of the intervention period, the application will be uninstalled if necessary."
223603489|NCT05796895|BEHAVIORAL|Videogame|Children will be provided with the videogame for eight weeks, through which they will be taught symptom management strategies. Children and their parents will be telephoned every week by a nurse to inquire whether children performed the strategies taught to them and if they have any health concerns. Children and parents can also call the nurse educator if they have any questions. Their queries/concerns will be responded to by the nurse educator in consultation with the clinical health experts (doctors and nurses) in the research team.
223603490|NCT05796895|BEHAVIORAL|WhatsApp|Children will be provided with weekly WhatsApp messages on healthy behaviors. Children and their parents will be telephoned every week by a nurse to inquire whether they have any health concerns. Children and parents can also call the nurse educator if they have any questions. Their queries/concerns will be responded to by the nurse educator in consultation with the clinical health experts (doctors and nurses) in the research team.
223603491|NCT01053988|DRUG|FF/GW642444 Inhalation Powder|Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA) for COPD
223603492|NCT01053988|DRUG|FF Inhalation Powder|Inhaled Corticosteroid (ICS)
223603493|NCT01053988|DRUG|GW642444 Inhalation Powder|Long Acting Beta Agonist(LABA)
223603494|NCT01053988|DRUG|Placebo|Placebo
223603495|NCT01922271|DRUG|NVA237|NVA237 44 µg inhalation capsules once daily, delivered via single-dose dry-powder inhaler (SDDPI)
223603496|NCT01922271|DRUG|Tiotropium|Tiotropium 18 μg once daily delivered via HandiHaler® device.
223603497|NCT01922271|DRUG|Placebo to NVA237|Placebo to NVA237 once daily, delivered via single-dose dry-powder inhaler (SDDPI).
223751137|NCT03883932|BEHAVIORAL|Fatherhood Focused FVEP (F3)|F3 is designed to focus specifically on the importance of fathering within a cognitive-behavioral intervention.
223751138|NCT03883932|BEHAVIORAL|Family Violence Education Program (FVEP)|FVEP is a court-mandated program intended to treat those arrested for intimate partner violence (IPV).
223751139|NCT00944151|PROCEDURE|TAP Catheter and Infusion of Study Solution|Subject will be randomized to one of two groups: Saline infused TAP catheter following surgery for 0-2 days or ropivacaine infused TAP catheter following surgery for 0-2 days. All patients will be given a single injection of ropivacaine prior to surgery. Research staff will follow all patients for two days following surgery or while they have TAP catheter in.
223751140|NCT01460433|PROCEDURE|Genital and rectal swabbing|Subjects swabs their genitals and rectum daily. The amount of HSV shed over the previous 24 hours is measured and the daily HSV shed rate is calculated.
223751141|NCT04420156|OTHER|No intervention administered.|Eye exams are standard of care and would be performed regardless of participation in this study.
223751142|NCT03588221|PROCEDURE|four sets of hand hygiene measurements per participant|"1. Six-step hand hygiene technique with an application time of 30 seconds~2. Six-step hand hygiene technique with an application time of 15 seconds~3. Three-step hand hygiene technique with an application time of 30 seconds~4. Three-step hand hygiene technique with an application time of 15 seconds"
223751143|NCT03342742|BEHAVIORAL|Weight Loss|Weight loss behavioral intervention via one of two strategies.
223751144|NCT04383210|DRUG|Seribantumab|Anti-HER3 monoclonal antibody
223751145|NCT02367703|PROCEDURE|laparoscopic hysterectomy|
224075381|NCT01797211|DIETARY_SUPPLEMENT|Mediterranean diet|Patients underwent administration of Mediterranean diet and olive oil, or Mediterranean diet and not-fried fish, or Mediterranean diet and nuts.
224075382|NCT03915223|PROCEDURE|leg fracture|Surgical leg fracture with injection of solumedrol (steroidal anti-inflammatory drug) or physiological serum
224200265|NCT00860054|DIETARY_SUPPLEMENT|Different amount of phytosterols are added into diets|Diets with 59, 400, or 2000 mg of phytosterols daily for 4 weeks were given to each subject, in random order.
223603498|NCT01922271|DRUG|Placebo to tiotropium|Placebo to tiotropium once daily delivered via HandiHaler® device
223603499|NCT01922271|DRUG|Salbutamol|Used as resuce medication
223603500|NCT04385459|OTHER|Coronary artery disease|Exposure
223603501|NCT05933668|BIOLOGICAL|YK0901 cells|On day 0, the TCR-T cells will be administered one time. Drug: Fludarabine + Cyclophosphamide+Oxaliplatin Fludarabine: 25mg/m²/day×3days Cyclophosphamide: 300mg/m²/day×3 days Oxaliplatin：100mg×1day Drug: IL-2 After 18-24 hours of infusion of YK0901 cells, the patients will be given a small dose of IL-2 subcutaneously, 500,000 IU/time, twice a day (interval 10-12 hours), for 14 days.
223603502|NCT01103570|PROCEDURE|cholecystocholangiography|a central venous pressure catheter was introduced through the anterior abdominal wall subcostally in a direction parallel to the gallbladder bed under direct vision so that it emerges close to the gall bladder. Then the catheter was advanced into the fundus of the gall bladder . The dye was prepared by diluting 20ml of 76% urografin with 20ml normal saline in a 50ml syringe
223603503|NCT01103570|PROCEDURE|cystic duct cholangiography|Then a 14G cannula was introduced through the anterior abdominal wall subcostally, (size 4F), was introduced through this cannula. The catheter was inserted into the cystic duct no more than 1 cm, by a grasper Then a 50ml syringe with the diluted urografin dye, as above, was attached to the catheter and cholangiography was performed by slowly injecting the dye under control of C-arm image intensifier.
223603504|NCT06412783|DIAGNOSTIC_TEST|blood test|performing blood tests on the participants for specific markers.
223603505|NCT03276897|OTHER|Nutriage SPF 30 day cream and Nutriage night cream (Difa Cooper S.p.a, Italy)|A fixed quantity of both cosmetic products was applied for an uninterrupted period of 3 months, on the face included the submental area (day cream at the morning and the night cream at the evening), preferentially always at the same hour, with a mild massage
223603506|NCT00013741|BEHAVIORAL|Tailored Education Messages|
223603507|NCT01824355|DEVICE|Ninja 3 PLUS Investigational BG Monitoring System|Untrained subjects with diabetes performed self Blood Glucose (BG) tests with capillary fingerstick and palm blood using the Ninja 3 PLUS Investigational BG Monitoring System. Study staff tested subject fingerstick blood. All BG results were compared to a reference laboratory glucose method.
223507887|NCT03518203|DRUG|Eculizumab|Eculizumab will be administered as intravenous infusion (IV) over 60 minutes. The dosage form will be 300 mg single-use vials each containing 30 mL of 10 mg/mL sterile, preservative-free solution.
223507888|NCT01129895|BEHAVIORAL|Health promotion|In each intervention clinic 5 workshops on the initiation of health prevention projects in each clinic will be organized by the intervention team and than the clinic will be followed by the intervention team for 6 months.
223507889|NCT00129558|DRUG|PT-523 for Injection|
223507890|NCT05558254|OTHER|Robert - intervention to enhance muscle strength|"Intervention:~Training will be conducted with the robot ROBERT®. 3 times a week for 8 weeks the patient will conduct 60 repetitions of hip flexion of one leg. The patient is lying supine. ROBERT is attached to the patient's lower leg. The physiotherapist guides the patient's leg in hip flexion and ROBERT record the movement. The ROBERT is attached to the patient's lower leg and thereby eliminating the gravity of the leg. The physiotherapist guides the patient's leg in hip flexion and ROBERT record the movement. ROBERT is set in active or guided mode and will be individually adjusted. When practice starts the patient get visual feedback to the range of movement of the hip flexion plus the amount of repetitions conducted and persisting."
223507891|NCT00002370|DRUG|Itraconazole|
223507892|NCT01270867|DEVICE|Mechanical Thrombectomy|Each arm will use either Merci or Trevo as the primary Mechanical Thrombectomy device.
223507893|NCT03511066|DRUG|CT-P27 90 mg/kg|Influenza A treatment drug.
223507894|NCT03511066|DRUG|CT-P27 45 mg/kg|Influenza A treatment drug.
223507895|NCT03511066|DRUG|Placebo|Placebo.
223507896|NCT05755945|OTHER|eHealth Application|"Custom phone application that integrates data from smart watch. Subjects will complete daily To-Do-Lists where data will be collected on if they had a headache in the past 24 hours, severity of headache, and any analgesics used to treat the headache."
223507897|NCT06293859|OTHER|Probiotic oat flakes|2 x 10\^9 cfu/g Lactococcus cremoris immobilized on oat flakes
223507898|NCT06293859|OTHER|Conventional oat flakes|Commercial oat flakes
223507899|NCT01509209|DRUG|Pseudoephedrine / Levocetirizine|tablet, BID everyday
223507900|NCT05807893|DRUG|Serplulimab combined with bevacizumab and first-line chemotherapy|Serplulimab combined with bevacizumab and first-line chemotherapy
223507901|NCT05905055|DRUG|co-administration of cefepime and nacubactam|2 g cefepime and 1 g nacubactam every 8 hours for at least 5 days and up to 14 days via IV infusion over a period of 60 minutes
223507902|NCT05905055|DRUG|co-administration of aztreonam and nacubactam|2 g aztreonam and 1 g nacubactam every 8 hours for at least 5 days and up to 14 days via IV infusion over a period of 60 minutes
223507903|NCT05905055|DRUG|BAT|Dosage of BAT will be based per site's standard of care
223507904|NCT03562637|BIOLOGICAL|adagloxad simolenin combined with OBI-821|In the neoadjuvant and adjuvant phases of the study for a total of 100 weeks; subcutaneously injections.
223507905|NCT03562637|DEVICE|Globo H IHC Assay|The Globo H IHC assay will be used to identify eligible patients who may clinically benefit from the OBI-822 treatment, defined by Globo H expression.
223507906|NCT03562637|OTHER|Standard of care treatment|Standard of care treatment consisting of observation alone, adjuvant capecitabine or platinum monotherapy over a 100 week period.
223507907|NCT02362412|DRUG|FK949E|A tablet containing 50 mg or 150 mg of quetiapine taken orally.
223507908|NCT04421768|BEHAVIORAL|cervical exam training|Each nurse will then examine 1 sets of 10 high-fidelity silicone task trainers approximately three per week for a maximum of 20 sessions (200 repetitions total). For each set of 10 exams, the estimates will recorded on an answer sheet. A cumulative summation analysis will be performed on each participant. When an individual nurse achieves competence her training will be suspended
223507909|NCT05103566|DEVICE|gammaCore|Participants will receive two 2-minute non-invasive stimulations to the cervical branch of the vagus nerve (nVNS) three times daily with gammaCore, an FDA cleared device for the acute treatment and prevention of migraine and cluster headache. Intervention will begin within 72 hours post-rupture and end at 10 days post-rupture or discharge, whichever occurs first. The dosing regimen is supported by preclinical models and clinical data.
223603508|NCT06206915|DRUG|XZ120 injection|in Part One：XZ120 monotherapy, IV, no less than 60min, Q3W dose escalation study: 4 dose group (0.75 mg/m2, 1.5 mg/m2, 2.25 mg/m2, 3.0 mg/m2) Dose expansion study: MTD dose
223603509|NCT03897660|DIETARY_SUPPLEMENT|Omega-3 + vitamin K2 (TG form of omega-3)|"The intervention is a randomized double bond cross over design testing the pharmacokinetics of a monoglyceride formulation compared to a triglyceride and an ethyl ester form.~Treatments are randomly assigned on days 0, 7 and 14 of the clinical study. Blood samples will be collected at time 0, 1, 2, 4, 5, 6, 8, 9, 10, 12 and 24 hours. Each participant will perform all three treatments, with a minimum of 6 days between treatments. A questionnaire will document the side effects felt by participants during the omega-3 supplement taking day."
223603510|NCT03897660|DIETARY_SUPPLEMENT|Omega-3 + vitamin K2 (EE form of omega-3)|"The intervention is a randomized double bond cross over design testing the pharmacokinetics of a monoglyceride formulation compared to a triglyceride and an ethyl ester form.~Treatments are randomly assigned on days 0, 7 and 14 of the clinical study. Blood samples will be collected at time 0, 1, 2, 4, 5, 6, 8, 9, 10, 12 and 24 hours. Each participant will perform all three treatments, with a minimum of 6 days between treatments. A questionnaire will document the side effects felt by participants during the omega-3 supplement taking day."
223751146|NCT05695716|DEVICE|CSI pVAD System|The CSI percutaneous ventricular assist device (pVAD) is being investigated as a temporary left ventricular system intended to support and/or provide hemodynamic stability during high-risk percutaneous coronary interventions.
223751147|NCT01318031|DRUG|Period 1|Subjects will receive a single 45 mg dose of PF-00299804 on Day 1 of Period 1.
223751148|NCT01318031|DRUG|Period 2|Subjects will receive a single 30 mg tablet of paroxetine once daily for 3 days (Days 1 to 3). Then, subjects will be co-administered a 45 mg single dose of PF-00299804 plus a single dose of 30 mg paroxetine on Day 4. Single 30 mg doses of paroxetine will be administered once daily for 6 days (Days 5-10).
223751149|NCT00417807|DRUG|Imatinib mesilate|
223751150|NCT00844272|BEHAVIORAL|Psychoeducation|"Group-therapeutic intervention with 12 sessions plus 5 update sessions with 24-week therapy duration and/or 12 sessions plus 10 update sessions with 48-week therapy duration Module I: Create understanding, resources, problems and solutions Module II: Information on hepatitis C infection Module III: Information on treatment Module IV: Specific information on depression and withdrawal symptoms under interferon The meetings take a minimum of 60 min. time, should be once weekly. The group size should lie between 6 and 12 participants.~The group leaders are trained in performance of the psycho-education."
223751151|NCT05628077|OTHER|No intervention|No intervention
223751152|NCT03089606|DIAGNOSTIC_TEST|FDG PET/CT scan|18F-fluorodeoxy glucose (FDG) positron emission tomography (PET) with intravenous (IV) contrast images are obtained before and at the end study treatment (pembrolizumab infusion).
223751153|NCT03089606|DIAGNOSTIC_TEST|C11-AMT PET scan|11C-methyl-L-tryptophan (C11-AMT) positron emission tomography (PET) images are obtained before study treatment (pembrolizumab infusion).
223751154|NCT03089606|DRUG|Pembrolizumab|200 mg Pembrolizumab IV administered over 30 minutes on day 1. Repeat every 3 weeks for 4 cycles, until progression, or subject withdrawal for other reasons
223751155|NCT03089606|DIAGNOSTIC_TEST|CT scan|Computerized tomography (CT) images are taken without IV contrast before the treatment (pembrolizumab infusion) and with IV contrast 3 months after the treatment start.
223751156|NCT01482247|DIETARY_SUPPLEMENT|L-Arginine|Dietary Supplement
223751157|NCT01482247|DIETARY_SUPPLEMENT|Placebo Supplement|Dietary Supplement
223751158|NCT06067386|OTHER|Dissemination of a selective reporting for antibiotic susceptibility testing|For each E. coli positive urine culture analyzed by LabOuest, GPs will receive an antibiotic susceptibility testing report, with the list of antibiotics restricted according to four E. coli susceptibility profiles, with an emphasis on narrower-spectrum antibiotics. The selected antibiotic susceptibility testing was developed following a targeted literature review and consultation with a steering committee including GPs, biologists and infectiologists. At the GP's request, a full antibiogram can be provided.
223751159|NCT06067386|OTHER|Standard antibiotic susceptibility testing report|GPs will receive a standard antibiotic susceptibility testing report for each E. coli positive urine culture.
223751160|NCT04540289|DRUG|Optimal Medical Therapy (OMT)|"Patients will be treated according to Optimal Medical Therapy defined by the following guidelines:~1. 2019 ESC guidelines for the diagnosis and management of chronic coronary syndromes~2. 2016 ESC guidelines for the management of acute and chronic heart failure"
223751161|NCT04540289|DEVICE|Implantable cardioverter-defibrillator (ICD)|"An ICD consists of an electronic medical device and electrode leads. The surgery can be performed in local anaesthesia, but a short general anaesthesia is required if the ICD has to be tested giving the patient an electric shock. Besides the possibility to shock during arrhythmias the ICD can potentially terminate ventricular tachycardias by rapid pacing for short periods (small bursts of pacing).~The subcutaneous defibrillator is an established and valid alternative to the conventional ICD for the preven-tion of SCD. According to current guidelines, the subcutaneous defibrillator should be considered as an alternative to transvenous defibrillators in patients with an indication for an ICD when pacing therapy for bradycardia support, cardiac resynchronisation or antitachycardia pacing is not needed."
223751162|NCT03963115|DRUG|Epinephrine or normal saline|epinephreine or normal saline coated syringe before drawing allergen for injection.
223507910|NCT06964438|DEVICE|Neuromuscular Electrical Stimulation|Neuromuscular Electrical Stimulation training twice daily (30 minutes per session), during postoperative days 1-4. The training will be carried out using a handheld device. Training will be carried out by the participant themselves, with researcher supervision until independently able to do so.
223507911|NCT06964438|DIETARY_SUPPLEMENT|Protein supplement drink|"Whey protein isolate drink, to provide a total of 60 g protein per day (2 x30 g).~The supplement will be provided in a powder form to participants. Participants will be asked to consume the supplement around the time of NMES training."
223507912|NCT06963294|DRUG|Ketamine|Ketamine will be administered as an intravenous infusion at 0.1 mg/kg/hour during surgery
223507913|NCT06964724|PROCEDURE|Mechanical thrombectomy|Mechanical thrombectomy with stent retriever
223507914|NCT03528850|OTHER|Telemedicine evaluation|Weekly virtual visits and daily biometric readings of blood pressure, weight, oxygen saturation and pulse
223507915|NCT00810745|PROCEDURE|starr|stapled transanal rectal resection
223507916|NCT04518670|DEVICE|Comaneci Embolization Assist Device|assist in the coil embolization of wide-necked intracranial aneurysms with a neck width ≤ 10 mm.
223603511|NCT03897660|DIETARY_SUPPLEMENT|Omega-3 + vitamin K2 [MaxSimil (MAG form of omega-3)]|"The intervention is a randomized double blind cross over design testing the pharmacokinetics of a monoglyceride formulation compared to a triglyceride and an ethyl ester form.~Treatments are randomly assigned on days 0, 7 and 14 of the clinical study. Blood samples will be collected at time 0, 1, 2, 4, 5, 6, 8, 9, 10, 12 and 24 hours. Each participant will perform all three treatments, with a minimum of 6 days between treatments. At each blood draw time points, a questionnaire will be administered to the particpant to monitor if they experiencec side effects with the dietary supplement they ingested in the morning."
223751163|NCT02708147|OTHER|Physiotheraphy + Conventional treatment|The experimental group will receive 5 physiotherapy sessions at home or in a physical therapy office. The respiratory techniques follow a flowchart which begins with saline instillation into the nose and nasopharyngeal cleaning techniques. Then to clear the lung slow inspiratory and slow and forced expiratory techniques will be used. The application of vibration is also included on the flowchart. During the sessions, educational information will also be provided.
223751164|NCT02708147|OTHER|Conventional treatment|Medication and observation by a physician/paediatrician. Only evaluations will be made at baseline and on the 3th, 5th and 21st days and an interview 30 days after.
223751165|NCT02872779|PROCEDURE|Blood sampling for free mutant DNA analysis|Blood sampling for Patients Treated for Metastatic Colorectal cancer
223603512|NCT03892746|DEVICE|Active tDCS + task oriented practice|Participants in this arm will receive active tDCS(2mA) to the motor cortex(targeting the triceps) of the weaker upper limb for 2 30 minute cycles during each 2 hour upper limb training session. While receiving tDCS the participant will be performing task oriented practice for the weaker upper limb. Participants will receive these interventions for 15 sessions over several weeks up to 8 weeks.
223603513|NCT03892746|DEVICE|Sham tDCS + task oriented practice|Participants in this arm will receive sham tDCS(0mA) to the motor cortex(targeting the triceps) of the weaker upper limb for 2 30 minute cycles during each 2 hour upper limb training session. While receiving tDCS the participant will be performing task oriented practice for the weaker upper limb. Participants will receive these interventions for 15 sessions over several weeks up to 8 weeks
223603514|NCT05703581|PROCEDURE|TRIANGLE operation|dissection the region composed of common hepatic artery (CHA), superior mesenteric artery (SMA) and superior mesenteric vein (SMV)
223603515|NCT06852859|PROCEDURE|Transurethral resection of the prostate|Thermocoagulation is used in contrast to the other methods
223603516|NCT06852859|PROCEDURE|Transurethral vaporization of the prostate|Heat is used to vaporize prostate
223603517|NCT06852859|PROCEDURE|GreenLight laser enucleation of the prostate|laser is used in contrast to the other methods
223603518|NCT05490030|DRUG|TNO155|Single oral dose of TNO155 on Day 1
223603519|NCT06419504|OTHER|SAP block group|US-guided SAP block is performed approximately 30 minutes before the surgery in patients undergoing breast cancer surgery in a separate regional anesthesia room with standard anesthesia monitoring.
223603520|NCT06419504|OTHER|PECS II block group|US-guided PECS II block is performed approximately 30 minutes before the surgery in patients undergoing breast cancer surgery in a separate regional anesthesia room with standard anesthesia monitoring.
223603521|NCT06419504|OTHER|ESP block group|US-guided ESP block is performed approximately 30 minutes before the surgery in patients undergoing breast cancer surgery in a separate regional anesthesia room with standard anesthesia monitoring.
223603522|NCT06419504|OTHER|Control group|No intervention
223603523|NCT01865643|DEVICE|GlideScope|The GlideScope is used to assist with difficult tracheal intubation.
223751166|NCT04427774|DRUG|Surufatinib plus Sintilimab|Surufatinib will be given orally. Sintilimab will be given intravenously
223751167|NCT00178035|DRUG|paroxetine|
223751168|NCT00178035|BEHAVIORAL|One night of Total Sleep Deprivation|
223751169|NCT01678417|DRUG|131I-rituximab|
223751170|NCT01376271|DRUG|Paroxetine|
223751171|NCT00922883|DRUG|Eltrombopag|
223751172|NCT04976634|DRUG|Pembrolizumab|Pembrolizumab 400 mg administered Q6W via IV infusion
223603524|NCT03475589|DRUG|apatinib|Patients with advanced (stage IV) gastric cancer, non-small-cell lung cancer (NSCLC), breast cancer or ovarian cancer will be included in this study to receive apatinib treaetment starting from 250 mg Qd and closely monitored for ADRs during apatinib treatment, with dosage adjustment performed as needed to make the treatment tolerable to the patients.
223603525|NCT03854513|DEVICE|dialysis machine|A machine used in dialysis that filters a patient's blood to remove excess water and waste products when the kidneys are damaged
223603526|NCT02588404|DRUG|LHRH therapy|These patients will be treated with LHRH agonist as standard therapy.
223751173|NCT04976634|DRUG|Belzutifan|Belzutifan 120 mg administered QD via oral tablet
223751174|NCT04976634|DRUG|Lenvatinib|Lenvantinib dose for HCC is 8 mg QD for body weight \<60 kg and 12 mg QD for body weight ≥ 60 kg administered via oral capsule. For all other tumors, the lenvatinib dose is 20 mg QD administered via oral capsule
223751175|NCT06970925|DIETARY_SUPPLEMENT|Sucrosomial Iron (SI)|The Sucrosomial Iron (SI) you may receive is a considered a supplement, so it has not been approved by the U.S. Food \& Drug Administration (FDA) for sale. However, it is available for over-the-counter purchase. Sucrosomial Iron (SI) has been developed by PharmaNutra.
223751176|NCT04022772|OTHER|Best Practice|Receive standard of care
223751177|NCT04022772|OTHER|Medical Chart Review|Ancillary studies
223751178|NCT04022772|OTHER|Quality-of-Life Assessment|Ancillary studies
223751179|NCT04022772|OTHER|Questionnaire Administration|Ancillary studies
223751180|NCT04022772|PROCEDURE|Supportive Care|Participate in PACK Health program
223751181|NCT00083681|DRUG|Thalidomide|
223751182|NCT00083681|DRUG|Dexamethasone|
223751183|NCT00083681|DRUG|Cytoxan|
223751184|NCT00083681|DRUG|Etoposide|
223751185|NCT00083681|DRUG|Cisplatin|
223751186|NCT00083681|DRUG|G-CSF|
223751187|NCT03303378|DRUG|melatonin (Helsinn Chemical Co, Biasca, Switzerland)|"Patients will receive a total intravenous melatonin (Helsinn Chemical Co, Biasca, Switzerland) dose of 11.61 mg (aproximately 166 μg/kg). The dose will be distributed in a volume of 500 ml of an isotonic and sterile solution of 100 μM melatonin during 150 min with a drip rate of 4.2 ml/min.~The temporal distribution of perfusion will be: 30 min previous to percutaneous revascularization and remainder doses in a subsequent 120 min (1 h during the angioplasty +60 min post-intervention)."
223603527|NCT04406649|DRUG|Dihydroergotamine|Dihydroergotamine is a semi-synthetic derivative of ergotamine tartrate.
223603528|NCT04763941|DIAGNOSTIC_TEST|CDR assessment face-to-face|The assessment of the CDR is administered once by a psychologist with the patient and his caregiver.
223603529|NCT04806737|DRUG|Teriflunomide Oral Tablet|The study will be conducted with two treatment groups in the form of a 2:1 parallel group comparison and will serve to compare oral treatment with 14 mg/d teriflunomide vs. placebo in subjects with well-controlled coeliac disease undergoing gluten challenge. The screening period will be up to 8 weeks, followed by a 7-day run-in treatment period with a loading dose of teriflunomide followed by a 6 day therapeutic maintenance dose, an initial 4-week treatment-free follow-up period and a 6 month closing follow-up.
223603530|NCT02576795|BIOLOGICAL|valoctocogene roxaparvovec|Adeno-Associated Virus Vector-Mediated Gene Transfer of Human Factor VIII in Severe Hemophilia A
223603531|NCT04742361|DRUG|[18F]PSMA-1007|diagnostic radiopharmaceutical for PET scan
223603532|NCT05650905|DEVICE|Dynamic Vessel Analyzer (DVA)|Retinal neurovascular coupling, Retinal vessel diameters and Retinal oxygen saturation will be assessed using the DVA
223603533|NCT05650905|DEVICE|Fourier domain optical coherence tomography (FDOCT)|Retinal blood velocities and Retinal blood flow will be assessed using the FDOCT
223603534|NCT05650905|DEVICE|Optical coherence tomography (OCT)|Retinal nerve fiber layer thickness, Central retinal thickness and Retinal vessel density will be assessed using the OCT
223603535|NCT05650905|DEVICE|Laser Speckle Flowgraphy (LSFG)|Normalized blur and Relative flow volume will be assessed using the LSFG
223603536|NCT05650905|DIAGNOSTIC_TEST|Proteomics and Metabolites in Plasma, tear fluid and finger sweat|Proteomics and Metabolites in Plasma, tear fluid and finger sweat will be assessed using a Blooddraw, filter paper and Schirmer-test
223603537|NCT06967792|DEVICE|Terahertz (THz) scanning using THz Imaging system.|The Terahertz (THz) scanning system is non-invasive and non-contact. It is a prototype developed by Institute of Materials Research and Engineering (IMRE), A\*STAR, Singapore and is performed for the purpose of research. THz scanning will provide safety data in human and the measurement of cornea hydration status. Each THz scan will take approximately 1 second. Real-time data will be generated when participants are positioned in front of the device.
223603538|NCT02712528|DRUG|remifentanil-based|
223751188|NCT03303378|DRUG|Placebos|The temporal distribution of perfusion will be: 30 min previous to percutaneous revascularization and remainder doses in a subsequent 120 min (1 h during the angioplasty +60 min post-intervention).
223603539|NCT02712528|DRUG|sevoflurane-sufentanil balanced|
223751189|NCT05397054|BEHAVIORAL|Education|\- Education: Education about risk of high sodium intake, type of sodium, nutrition ingredients
224200266|NCT01588678|DRUG|DS-3078a|DS-3078a will be administered as oral capsules once daily and will be supplied in 5, 20, 50, and 150 mg capsules.
224200267|NCT01145872|BEHAVIORAL|Mindfulness Based Cognitive Therapy|
224200268|NCT01145872|BEHAVIORAL|Health Enhancement Program|
224200269|NCT00433771|DEVICE|WallFlex™ Biliary Fully Covered Metal Stent placement|Implantable metal biliary stent intended for use in the palliative treatment of biliary strictures produced by malignant neoplasms. The stent is fully covered with a polymer to reduce the potential for tumor ingrowth into the stent.
223507917|NCT01541254|DEVICE|Low profile Visualized Intraluminal Device (LVIS and LVIS Jr.)|Low profile Visualized Intraluminal Device (LVIS and LVIS Jr.)
223507918|NCT04381377|DRUG|azoximer bromide|Investigational medicinal product
223507919|NCT04381377|OTHER|Placebo|Placebo
223507920|NCT02512445|BEHAVIORAL|Trauma Informed Guilt Reduction Therapy|Trauma focused therapy
223507921|NCT02512445|BEHAVIORAL|Supportive Care Therapy|Supportive therapy
223507922|NCT05768711|DRUG|Venetoclax|Combination of Azacitidine and Venetoclax
223507923|NCT00656812|DRUG|Rituximab|375 mg/m2 on day 1 of a 21-day treatment cycle
223603540|NCT01897948|OTHER|Milk-based beverage without DHA|
223603541|NCT01897948|OTHER|Milk-based beverage with DHA at mid level|
223603542|NCT01897948|OTHER|Milk-based beverage with DHA at high level|
223751190|NCT05397054|BEHAVIORAL|Reformulation|\- Reformulation: Dietary recommendation in low sodium intake
223751191|NCT05397054|BEHAVIORAL|Environmental change|\- Environmental change: Encourage about low sodium intake in community
223751192|NCT05397054|DEVICE|Salt meter|\- Used salt meter: at least 3 times/wk
224200270|NCT04208165|OTHER|ultrasound-guided nerve block PVB|Thoracic paravertebral block guided by ultrasound device which allows visualizing the surrounding anatomy and placement of the needle at the target location in real time.
224200271|NCT04208165|OTHER|ultrasound-guided nerve block TAB|Transverse abdominis plane block guided by ultrasound device which allows visualizing the surrounding anatomy and placement of the needle at the target location in real time.
224200272|NCT01069458|OTHER|The high protein diet group and the low fat diet group|The High Protein Diet Group was advised to have 25 energy percent from protein, 55 energy percent from fat, 20 energy percent from carbohydrate in the diet and the Low Fat Diet Group was advised to have 30 energy percent from fat, 20 energy percent from protein, 50 energy percent from carbohydrate in the diet.
223507924|NCT00656812|DRUG|2-CdA|0.1 mg/kg s.c. on days 1 - 4 of a 21-day treatment cycle
223507925|NCT06289218|DEVICE|interferential current|IFC plus exercise
223507926|NCT06289218|OTHER|kinesio taping|KT plus exercise
223507927|NCT06289218|OTHER|exercise|exercise only
223507928|NCT04622319|DRUG|DS-8201a|Administered initially as an intravenous (IV) infusion at a dose of 5.4 mg/kg on Day 1 of each 21-day cycle
223507929|NCT04622319|DRUG|T-DM1|Administered initially as an intravenous (IV) infusion at a dose of 3.6 mg/kg on Day 1 of each 21-day cycle
223507930|NCT06195163|DRUG|Transdermal Gel in Sachet Dosage Form|Transdermal testosterone gel application prior to ovarian stimulation in the study group.
223507931|NCT06195163|DRUG|No pretreatment|No pretreatment prior to the ovarian stimulation in the control group.
223507932|NCT05103332|DRUG|Indapamide|Indapamide administered orally
223751193|NCT05397054|BEHAVIORAL|standard treatment|standard treatment
223751194|NCT01519453|BEHAVIORAL|Home Based Asthma Education|4 home based and 3 phone based sessions with community asthma outreach worker to provide families with asthma education
223507933|NCT05103332|DRUG|Amlodipine|Amlodipine administered orally
223507934|NCT05103332|DRUG|Olmesartan|Olmesartan administered orally
223507935|NCT05103332|DRUG|Placebo|Placebo administered by SC injection
223507936|NCT05103332|DRUG|Zilebesiran|Zilebesiran administered by SC injection
223507937|NCT06351189|DEVICE|Observation|Patients will be filmed in sitting position in the NETTI DYNAMIC chair, either in static mode or dynamic mode for a period of 3 hours each time.
223507938|NCT05611047|OTHER|Clinical assessment|MS history and MS treatments and Expanded Disability Status Scale (EDSS) score will be recorded
223507939|NCT05611047|OTHER|Classical cognitive evaluation of several domains:|Information processing speed (IPS) Working memory (WM) Executive functions (EF) Episodic memory (EM) Premorbid intelligence quotient (IQ) Multidomain or complex task
223507940|NCT05611047|OTHER|Ecological evaluation|Virtual reality task : Urban DailyCog©
223507941|NCT05611047|BEHAVIORAL|Patent reported outcomes (PRO's)|"Patent reported outcomes (PRO's) : Beck Depression Inventory (BDI), European Quality of Life-5 Dimensions (EQ-5D-5L) for Health-Related Quality of Life (HRQOL), Multiple Sclerosis Impact Scale-29 Items (MSIS-29), French version of the Modified Fatigue Impact Scale (EMISEP) and State trait anxiety inventory (STAI).~Subjective cognitive deficits: Perceived Deficits Questionnaire (PDQ) and Cognitive Activities Questionnaire (DCAQ)"
223507942|NCT05611047|OTHER|Telerehabilitation : active procedure|The Cognitive rehabilitation (CR) consists of weekly 45 minutes online individual session with the unblinded Speech Therapist.
223507943|NCT05611047|OTHER|Telerehabilitation : comparator procedure|Once per week over a 12-week period completed by daily online exercises performed by the patient 4 days a week.
223507944|NCT02478788|DRUG|mixed amphetamine salts-extended release (MAS-XR)|MAS-XR is a psychostimulant medication composed of amphetamine and dextroamphetamine, has been systematically studied in adolescents with ADHD, and is FDA-approved for the treatment of ADHD in adolescents.
223507945|NCT02478788|DRUG|Placebo|Pills with no medication in it
223507946|NCT03870321|OTHER|Core training|"In the first week different types of abdominal exercises will be performed: standard, with trunk rotation, extension of the back raising the upper extremity of the body and legs, extension of the back raising one arm and the contralateral leg. In the same way, the subject will raise from the quadruped position one arm and the contralateral leg on each side, and we will ask for the exercise of the front plate, positioning itself in a position of four support points: feet and elbows. When performing the rear bridge exercise the subject will raise the trunk resting on both feet, while in the lateral bridge exercise will be done with support on the right and left side. All exercises will be done for 30 seconds, in 3 series).~During the next three weeks we will continue with the same training, but for each week we will increase 10 seconds per exercise."
223507947|NCT02218268|DRUG|Pre-meal bolus|Long acting insulin as scheduled per usual routine PLUS rapid/ short acting (bolus) prior to Boost
223507948|NCT02218268|DRUG|No meal bolus|Long Acting insulin as scheduled per usual routine (given once daily)
223507949|NCT04469530|DRUG|Sirolimus|Sirolimus is given at a dose of 2 mg/m2 once daily. The amber oral dose syringe should be used to withdraw the prescribed amount of sirolimus oral solution from the bottle. The solution can be drunk or administered at once to assure delivery of all of the medication. It is safe for administration through a nasogastric or G-tube. For tablets, the tablet should not be crushed, split, or otherwise altered. As with the liquid dosing form, the tablets should be given within two hours each day and should be at consistent intervals with regard to meals.
223507950|NCT04469530|DRUG|Cyclophosphamide|"A synthetic antineoplastic drug chemically related to the nitrogen mustards. The drug is administered orally daily, in the formulation appropriate for age.~The solution should be diluted in 20-30 ml of appropriate liquid before administration through nasogastric (NG) tube or gastrostomy (G) tube, with adequate flushing after administration to prevent obstruction of the feeding tube."
223507951|NCT04469530|DRUG|Etoposide|A semisynthetic derivative of podophyllotoxin which functions as mitotic inhibitor but does not interfere with microtubular assembly. The drug is administered orally daily, in the formulation appropriate for age.
223507952|NCT04469530|DRUG|Celecoxib|The drug is administered orally daily, in the formulation appropriate for age.The solution is safe for administration through a nasogastric or G-tube.
223507953|NCT04419142|PROCEDURE|Total infrapatellar fat pad excision|Exposure for total knee arthroplasty (TKA) commonly includes total excision of the infrapatellar fat pad (IPFP). The rationale behind this is to obtain improved access to the lateral tibial plateau allowing a more accurate bone cut, baseplate placement and easier management of soft tissue interposition in the bone and cement interface. However, there is growing concern that as the IPFP is a highly vascularized and innervated fibrous adipose tissue filling the anterior compartment of the knee, its complete excision may have a detrimental effect on knee biomechanics and ultimately, TKA outcome. The reason for this effect has been suggested to be patellar tendon (PT) scarring and shortening via ischemic contracture following impaired vascularization, maintenance and biological repair of the tendon.
223507954|NCT04419142|PROCEDURE|Partial infrapatellar fat pad excision|It has been suggested in the literature that partial infrapatellar fat pad excision instead of total excision would diminish the potential negative effect on patellar tendon and knee biomechanics. However, there is only limited data in the literature and choice of total/partial infrapatellar fat pad excision in TKA remains debatable.
223751195|NCT01709695|DRUG|Guanfacine Hydrochloride XR|Weekly adjustments based on parent ratings of symptoms, side effects, and health status per vital signs up to 4mg maximum dose
223751196|NCT01709695|DRUG|Placebo|Weekly adjustments based on parent ratings of symptoms, side effects, and health status per vital signs up to 4mg maximum dose
223751197|NCT00911261|DRUG|Oxymorphone Extended Release|"* Study Medication: Oxymorphone ER 5 mg, 10 mg, 20 mg, and 40 mg tablets~* Rescue Medication: Oxymorphone IR 5 mg and 10 mg tablets~* Treatment will consist of up to 12 months of dosing with Oxymorphone ER."
223751198|NCT02802592|DRUG|Epogen|1:1 randomization to either the Epogen arm or Placebo(Normal Saline) arm
223751199|NCT02802592|DRUG|Normal Saline|1:1 randomization to either the Epogen arm or Placebo(Normal Saline) arm
223751200|NCT04650802|DEVICE|Gait training|Participants receive five weeks individual robotic gait training in LOPES II, targeting paretic propulsion (60 minutes, two time a week). The robotic gait training is complemented with daily home exercises (15 minutes/day) focusing on increasing strength and practice of learned strategies in daily life.
223751201|NCT02220933|DRUG|MD1003 100mg capsule|
223751202|NCT02220933|DRUG|Placebo|
223751203|NCT04341142|DIAGNOSTIC_TEST|Serological tests will be applied on patients blood sampling|Application of tests on patients' serum
223751204|NCT00418132|DRUG|Thalidomide|Thalidomide at a dose of 50 mg/day. The dose will be increased to 100 mg/day at Week 2, then to 200 mg/day at Week 4, and finally to 300 mg/day at Week 6.
223751205|NCT00418132|DRUG|Placebo thalidomide|Participants will receive placebo thalidomide. The placebo dose will be increased through to Week 6.
223751206|NCT04830787|OTHER|no intervention|there is no intervention, we just chose patients diagnosed with hypertrophic cardiomyopathy and underwent CAG, and patients without hypertrophic cardiomyopathy as control ,the two groups are matched with age, gender and hypertension.
223751207|NCT06497114|OTHER|ABILHAND-Kids questioner|questioner
223751208|NCT03741660|DIETARY_SUPPLEMENT|konjac glucomannan|Konjac-mannan fiber-enriched biscuits (0.7 g/412KJ \[100kcal\] of glucommanan)
223751209|NCT03741660|DIETARY_SUPPLEMENT|wheat bran|Wheat bran (hard red wheat bran) fiber enriched biscuits
223751210|NCT02368795|DEVICE|Pancreatic Stent|A 5-Fr, 4-cm-long stent (Endoflex) with a single duodenal pigtail is used for pancreatic duct stenting
223751211|NCT02368795|DRUG|Indomethacin|Indomethacin 100 mg suppository ten minutes before ERCP
223751212|NCT02368795|DRUG|Isosorbide Dinitrate|Sublingual Isosorbide dinitrate 5 mg before ERCP
223751213|NCT02368795|DRUG|Ringer's lactate|IV Ringer's lactate serum with a dose of 6 cc/kg/h during the procedure and 20 cc/kg after ERCP as a bolus dose and 3 cc/kg/h for the next 8 hours.
223751214|NCT01144442|DRUG|Hyperthermic intraperitoneal chemotherapy with Carboplatin|Carboplatin at a dose of 1000mg/m\^2 will be added to the perfusate once circulating levels reach 1000-1500cc/minute. The circulation of the chemotherapy impregnated perfusate will be performed for 90 minutes.
223751215|NCT01144442|OTHER|Isotonic saline (perfusate)|The HIPC infusion will be performed with a closed abdomen technique. The perfusate will be isotonic saline heated to 40-42° Celsius.
223751216|NCT01144442|PROCEDURE|Surgery|"The abdominal incision will be performed in a vertical fashion extending from the supra-pubic region to around the umbilicus.~If cytoreductive surgery is required, it will be performed at this time and proceed in standard approach."
223751217|NCT01144442|DRUG|Carboplatin|The scheduled systemic chemotherapy is paclitaxel 175mg/m2 and carboplatin AUC 6 every 3 weeks for 6 total cycles.
223751218|NCT01144442|DRUG|Paclitaxel|The scheduled systemic chemotherapy is paclitaxel 175mg/m2 and carboplatin AUC 6 every 3 weeks for 6 total cycles.
224200273|NCT06126770|BEHAVIORAL|The social norm intervention|"The intervention will target Married adolescent girls, their spouses, and elderly/influential community members. Thirty-six 2-hour weekly sessions will be conducted with MAGs. The session topics will be categorized into two broad headings: i) Health and life skills sessions covering, for example topics such as sex and gender, rights, marriages, SRHR, and ii) Business and entrepreneurship sessions.~Spouses of the MAGs will receive 20 2-hour bi-weekly sessions. A total of three 2-hour couples sessions will be held. Elderly women and influential community members will have three 2-hour bi-monthly sessions. In addition, MAGs with leadership qualities will be identified and trained to conduct campaigns and activism. They will also receive training on income generating."
223507955|NCT06560905|DRUG|68Ga-PSMA|This is an imaging radionuclide tracer and is in chemical form. Up to 200 MBq. Route of administration is Intravenous.
223507956|NCT03651336|DEVICE|ARGOS-IO Sensor Pressure System|The ARGOS-IO Pressure sensor have been additionally implanted during local routine working procedures for cataract surgery in Patients with Primary Open Angle Glaucoma (POAG) and indicated cataract surgery in previous studies ARGOS-01 and ARGOS-02
223507957|NCT04791020|DRUG|Lidocain topical + paracervical blockade|5mL of lidocaine gel applied topically to cervix previous to clamping and paracervical blockade
223507958|NCT04791020|DRUG|Lidocaine topical|5mL of lidocaine gel applied topically to cervix previous to clamping, No paracervical blockade will be applied.
223751219|NCT04119856|OTHER|Affiliation with the outgoing lung team|"The work of the outgoing lung team takes place in the patient's home and involves the following:~* The outgoing lung team teaches the patients, relatives and primary care staff about symptoms, treatments and instructions related to COPD.~* The patients, relatives and primary care staff can contact the outgoing lung team by telephone day and night.~* The patients report symptoms and measurements to the outgoing lung team using telemedicine as patient reported outcomes.~* The outgoing lung team initiates appropriate treatment by telephone or a home visit. The outgoing lung team always consults a doctor from the Department of Respiratory Diseases and Allergy before initiating treatment.~* The outgoing lung team initiates acute consultations at Department of Respiratory Diseases and Allergy based on patient reported outcomes, home visit or telephone call."
223751220|NCT02344030|DEVICE|channeled blade|In a randomised trial we measure the time for ventilation by means of endtidale CO2 Curve
223751221|NCT02344030|DEVICE|standard blade|In a randomised trial we measure the time for ventilation by means of endtidale CO2 Curve
223507959|NCT02051283|OTHER|RFA|RFA
223507960|NCT06549374|OTHER|blood sampling|"After informing eligible patients (or their trusted support person, relative/guardian/curator where applicable) and in the absence of any opposition, they are included in the research.~Blood samples from an arterial catheter already in place will be taken every day from D1 to D7, then every 72 hours until discharge from intensive care, or until D28. For each of these samples, a maximum volume of 4 ml will be collected in a heparinized tube. Samples will not be taken if the hemoglobin level is below 7g/dl. For patients undergoing controlled surgery, the D1 sample will be taken as soon as possible after induction of anaesthesia.~Patients will be monitored until discharge from intensive care, or until D28 at the latest. Apart from the blood samples included in this study, all other examinations will be carried out as part of routine management. Data will be collected exclusively from medical records."
223751222|NCT04092790|DEVICE|Virtual Gate Device (VGD)|A VGD will be applied to one randomly-assigned lower limb. The VGD will be operated constantly (apart from times that the patient is being bathed or undergoing investigations or procedures) providing intermittent stimulations for a maximum of 10 days.
223751223|NCT03978585|DEVICE|high tone external muscle stimulation|Participants receive self-administered home based high tone therapy for 8 weeks for 30 minutes daily after device instruction
223751224|NCT03978585|DEVICE|transcutaneous electrical nerve stimulation (TENS) therapy|Participants receive self-administered home based TENS therapy for 8 weeks for 30 minutes daily after device instruction
223751225|NCT01682590|PROCEDURE|Renal Remplacement Therapy|"Investigators of each center will have the choice of the RRT technique based on their usual practice: intermittent hemodialysis, intermittent hemodiafiltration, continuous hemodialysis, continuous hemofiltration, continuous hemodiafiltration (typically the continuous techniques in the acute phase, followed by intermittent techniques after stabilization).~In case of life threatening conditions within the 48 hours after randomisation (hyperkalemia, metabolic acidosis or pulmonary edema) the RRT will be initiated as soon as possible.~In case of improvement of renal function within the 48 hours after randomisation (defined as the return of spontaneous urine output \> 1000ml/24 hr or \>2000ml/24hr with diuretics), RRT is not mandatory."
223751226|NCT02182531|DRUG|Epinastine|
223751227|NCT02182531|DRUG|Pseudoephedrine|
223751228|NCT02182531|DRUG|Epinastine + Pseudoephedrine combination|
223751229|NCT05103215|DRUG|Lidocaine HCl 2%|Intravenous injection of 1.5 mg/kg lidocaine at induction of anesthesia and continuous infusion of 1.5 mg/kg/h (ideal body weight) through the maintenance period to one hour after operation.
223751230|NCT05103215|DRUG|Normal saline|Intravenous injection of 1.5 mg/kg normal saline at induction of anesthesia and continuous infusion of 1.5 mg/kg/h (ideal body weight) through the maintenance period to one hour after operation.
223751231|NCT03238638|DRUG|Pembrolizumab|Both cohorts will receive pembrolizumab at a flat dose of 200mg every 3 weeks.
223603543|NCT03830346|OTHER|Instrument-assisted|instrument-assisted soft tissue mobilization techniques (applied with the subject in prone position. The technique lasted 20 seconds in a parallel direction and 20 seconds in a perpendicular direction on the posterior shoulder and scapula muscles. While the dominant hand was used to hold the instrument, the other hand was used to tighten the skin medially to ensure an even area of treatment) and post-isometric horizontal adduction stretches (carried out with the subject in the supine position, passively adducting the arm horizontally until the first motion barrier and performing active horizontal abduction for 5 seconds at 25% of force. The arm was then taken to the new motion barrier, repeating this process three times).
223603544|NCT02675010|OTHER|ENDOSCOPIC GASTRIC BIOPSIES FROM ANTRUM AND BODY|ENDOSCOPIC GASTRIC BIOPSIES FROM ANTRUM AND BODY
223603545|NCT04210622|DEVICE|Catheter mapping and ablation with the Sphere-9 Catheter and Affera Mapping and Ablation System|Catheter mapping and ablation with the Sphere-9 Catheter and Affera Mapping and Ablation System
223603546|NCT06209736|DRUG|OMS906 study drug|OMS906 study drug dose 5mg/kg IV administration at 4-week internals
223603547|NCT06370819|DRUG|NNC0519-0130|NNC0519-0130 will be administered subcutaneously.
223751232|NCT03238638|DRUG|epacadostat|Both cohorts will receive epacadostat. Patients in cohort 1 will take 300mg of epacadostat by mouth twice per day. Cohort 2 will take 300mg of epacadostat every 6 weeks.
223751233|NCT06233487|DIAGNOSTIC_TEST|Repeat hip ultrasound measurements|See earlier
223751234|NCT00100126|DRUG|Amoxicillin Pulsatile Release Multiparticluate Sprinkle|
223751235|NCT01150123|BIOLOGICAL|Group B streptococcus (GBS) vaccine- low dose|
223751236|NCT01150123|BIOLOGICAL|Group B streptococcus (GBS) vaccine- High dose|
223751237|NCT01150123|BIOLOGICAL|Placebo- Saline|
223751238|NCT01977170|BIOLOGICAL|Hib/PRP-T vaccine|Hib liquid vaccine
223751239|NCT02788968|OTHER|MRI|"Conventional reasoning tasks in both  with and without cognitive conflict and realized during an MRI"
223751240|NCT04116138|DIETARY_SUPPLEMENT|Salovum|Egg yolk powder enriched for anti secretory factor
223751241|NCT02486042|DRUG|Omegaven|Infants will receive nutritional supplementation with omega-3 fatty acids (omegaven).
223603548|NCT04427072|DRUG|Capmatinib|400 mg, capmatinib tablets, administered orally twice daily
223603549|NCT04427072|DRUG|Docetaxel|Docetaxel 75 mg/m\^2 by intravenous infusion every 21 days
223603550|NCT02284087|DEVICE|PAS|
223603551|NCT05232864|DRUG|Secukinumab|300 mg solution for subcutaneous (s.c.) injection in a 2mL Pre-Filled Syringe (PFS)
223603552|NCT06976125|DEVICE|Decision Aid-prediction model|"ER physician will input the necessary de-identified data into the decision aid application.~The decision aid determines if the patient has a high or low likelihood of having a positive urine culture. The patient with high likelihood of positive culture, will be prescribed empiric antibiotics per the UH guidelines for treating UTI in the ambulatory setting. Patients with a low likelihood of having a positive culture, will be discharged without antibiotics.~Study team members will give the patient a handout describing what will happen in the event of a positive or negative culture.~The culture call-back team, consisting of clinical pharmacists, will be notified."
223603553|NCT06975241|DIETARY_SUPPLEMENT|EPA 2.4g/day|EPA from fish oil will be supplemented to an equal number of males and females for 12 weeks.
223603554|NCT06974708|OTHER|Home Healthcare Virtual Simulation Training System|Interactive Virtual Occupational Safety Training Software Program for Home Healthcare Workers and Agencies
223603555|NCT06976749|DEVICE|myobrace appliance|functional appliance
223751242|NCT02486042|DIETARY_SUPPLEMENT|Standard lipids (primarily omega-6 fatty acids)|Infants will receive nutritional supplementation with standard intralipid, composed primarily of omega-6 fatty acids.
223751243|NCT00298207|BEHAVIORAL|Walking (behavior)|
223751244|NCT02441933|DRUG|taxane plus carboplatin|"Doxorubicin (60 mg/m2) IV + cyclophosphamide (600 mg/m2) IV every 3 weeks for 4 cycles followed by taxane plus carboplatin for 4 cycles The taxane plus carboplatin regimen can be selected based on the investigator's discretion from among the following two regimens.~* Docetaxel (75 mg/m2) IV plus carboplatin (AUC 5) IV every 3 weeks for 4 cycles~* Paclitaxel (80 mg/m2) IV weekly for 12 doses plus carboplatin (AUC 5) IV every 3 weeks for 4 cycles"
223751245|NCT02441933|DRUG|Taxane|"Doxorubicin (60 mg/m2) IV + cyclophosphamide (600 mg/m2) IV every 3 weeks for 4 cycles followed by taxane for 4 cycles The taxane regimen can be selected at the investigator's discretion from among the following two regimens.~* Docetaxel (75 mg/m2) IV every 3 weeks for 4 cycles~* Paclitaxel (80 mg/m2) IV weekly for 12 doses"
223751246|NCT04241497|BEHAVIORAL|Home-based rehabilitation|1 supervised exercise session at the hospital; 3 weeks of supervised home-based exercise training (3x/week); 9 weeks of unsupervised home-based exercise training (3x/week)
223751247|NCT06086028|OTHER|Wrist worn sensor|Biostrap collects biometrics such as the following: (1) sleep pattern/ quality; (2) steps, activity, calories; (3) heart rate/ HRV; (4) respiratory rate. Participants will be randomly assigned to one of two groups.
223751248|NCT06078033|BIOLOGICAL|Mobilization with movement|Sustained neutral apophyseal glide (SNAG) mobilization with movement applied to targeted vertebra while patients performed their painful movement.
223603556|NCT06976749|DEVICE|Twin block|functional appliance
223603557|NCT06976385|DIETARY_SUPPLEMENT|White tea|White tea mouth rinse applied topically twice daily.
223603558|NCT06976385|DIETARY_SUPPLEMENT|Wheat grass solution|wheat grass solution mouth rinse applied topically twice daily.
223603559|NCT06975215|DEVICE|Concomitant embolization|This will include EVAR, following the standard pathway of care, associated with embolization. The decision to perform side-branch embolization or aneurysm sac embolization will be left to each participating centre/physician.
223603560|NCT06975215|PROCEDURE|EVAR|Endovascular aortic aneurysm repair
223603561|NCT06976671|DRUG|Bevacizumab|intra-articular bevacizumab
223751249|NCT06078033|BIOLOGICAL|Sham mobilization with movement|Manual contact (without any pressure) applied to targeted vertebra while patients performed their painful movement.
223751250|NCT02530450|DEVICE|continuous glucose monitoring (CGM)|All subjects in Groups 1 and 2 wore the CGM device at time points 0, 3 months, and 6 months. Group 1 did not review CGM data at time 0, but did review CGM data at time point 3 months and 6 months. Group 2 reviewed CGM data at all time points.
223751251|NCT02831166|PROCEDURE|Transradial primary percutaneous coronary intervention|Transradial coronary angiography will be performed by the Judkins technique using 6 French diameter sheaths and pre-molded catheters for selective catheterization of left and right coronary arteries. Primary percutaneous coronary intervention with stent deployment will be indicated when a culprit lesion is identified, with high probability of angiographic success, being ideally performed immediately after coronary angiography Procedures will be performed according to recommendations of current guidelines. To achieve hemostasis in the transradial approach, a radial compression device will be applied, to maintain patent antegrade flow.
223751252|NCT02831166|PROCEDURE|Transfemoral primary percutaneous coronary intervention|Transfemoral coronary angiography will be performed by the Judkins technique using 6 French diameter sheaths and pre-molded catheters for selective catheterization of left and right coronary arteries. Primary percutaneous coronary intervention with stent deployment will be indicated when a culprit lesion is identified, with high probability of angiographic success, being ideally performed immediately after coronary angiography Procedures will be performed according to recommendations of current guidelines. A vascular closure device will be used to achieve hemostasis in the transfemoral approach, preceded by systematic performance of femoral angiography and maintaining absolute bed rest for 60 minutes.
223751253|NCT01825382|DEVICE|iBGStar meter|Subjects will receive iBGStar meter and iPhone to use as meter during the study.
223751254|NCT00566150|DRUG|Levetiracetam|Flexible dose up to 2500mg per day, for 6 weeks.
223751255|NCT00566150|DRUG|Placebo|Flexible dose up to 2500mg per day, for 6 weeks.
223751256|NCT02347189|DEVICE|Melody Transcatheter Pulmonary Valve PB1016|
223751257|NCT05084573|DRUG|Liposomal bupivacaine|Single bolus injection 10mL 1.33% LB
223751258|NCT05084573|DRUG|Standard bupivacaine|Single bolus 10mL 0.25% SB + continuous 300mL 0.2% SB @5mL/hr
223751259|NCT03394482|DRUG|Lu AF35700 5 mg clinical formulation|Lu AF35700 tablets 5 mg oral single dose
223751260|NCT03394482|DRUG|Lu AF35700 5 mg commercial formulation|Lu AF35700 tablets 5 mg oral single dose
223751261|NCT03394482|DRUG|Lu AF35700 10 mg clinical formulation|Lu AF35700 tablets 10 mg oral single dose
223603562|NCT06976983|DEVICE|Portable ergonomic helmet for real tSMS|Unlike repetitive magnetic stimulation (rTMS), tSMS is attracting considerable interest because it is more manageable and easy to apply. It is a method applicable through a portable ergonomic helmet that shifts the paradigm of non-invasive brain stimulation (NIBS) from a center-based therapeutic model to a home-based one.
223603563|NCT06976983|DEVICE|portable ergonomic helmet for placebo tSMS|Unlike repetitive magnetic stimulation (rTMS), tSMS is attracting considerable interest because it is more manageable and easy to apply. It is a method applicable through a portable ergonomic helmet that shifts the paradigm of non-invasive brain stimulation (NIBS) from a center-based therapeutic model to a home-based one.
223603564|NCT06974578|PROCEDURE|phacoemulsification|cataract extracton with phacoemulsification
223603565|NCT06974578|DEVICE|CTR|insertion of capsualr tension ring
223603566|NCT06974578|DEVICE|hydrophilic IOL|implantation of hydrophilic IOL
223603567|NCT06974578|DEVICE|Hydrophobic IOL|insertion of hydrophobic IOL
223603568|NCT06976866|PROCEDURE|implant surgery|surgery
223603569|NCT06976593|DIAGNOSTIC_TEST|Functional Exercise Testing and Muscle Oxygen Saturation Measurement|Participants will complete three physical performance tests: (1) the 6-Minute Walk Test (6MWT), (2) the 30-Second Sit-to-Stand Test, and (3) a submaximal treadmill test. Muscle oxygen saturation (SmO2) will be continuously monitored during the tests using near-infrared spectroscopy (NIRS) devices placed on the intercostal, quadriceps, and triceps surae muscles. Additional variables such as heart rate, perceived exertion, respiratory pressures, pulmonary function, and fatigue will be assessed during or after the tests.
223603570|NCT06976333|DIAGNOSTIC_TEST|Tumor-infliltrating lymphocyte (TIL) percentage|TIL percentage was calculated as the area occupied by lymphocytes divided by the cancer area, expressed as a percentage \[%\]
223603571|NCT06976333|DIAGNOSTIC_TEST|Grey level co-occurrence matrix (GLCM)|The GLCM is a second-order statistical method for texture feature extraction. Structured images typically contain numerous pixel pairs with co-occurring low- and high-intensity values. After GLCM calculation, different weights were applied to each matrix element to derive two measures: M1 and M2, representing areas with low and high intensities, respectively. Lower M1 and higher M2 values characterized more structured images with distinct TIL patterns.
223603572|NCT06976333|DIAGNOSTIC_TEST|Fractal dimension (FD)|Quantification of the complexity of TIL
223751262|NCT03394482|DRUG|Lu AF35700 10 mg commercial formulation|Lu AF35700 tablets 10 mg oral single dose
223751263|NCT03394482|DRUG|Lu AF35700 20 mg clinical formulation|Lu AF35700 tablets 20 mg oral single dose
223751264|NCT03394482|DRUG|Lu AF35700 20 mg commercial formulation|Lu AF35700 tablets 20 mg oral single dose
223603573|NCT06974851|DRUG|HRS9531|HRS9531
223603574|NCT06974851|DRUG|HRS9531placebo|HRS9531placebo
223603575|NCT04493203|DRUG|Nivolumab|Nivolumab is a human IgG4 monoclonal antibody that blocks PD-1. It is a type of Immunotherapy and works as a checkpoint inhibitor, blocking a signal that prevents activation of T cells from attacking the cancer.
223603576|NCT04493203|DRUG|Axitinib|Axitinib (AG013736; trade name Inlyta) is a small molecule tyrosine kinase inhibitor.Its primary mechanism of action is thought to be vascular endothelial growth factor receptor 1-3, c-KIT and PDGFR inhibition, this, in turn, enables it to inhibit angiogenesis (the formation of new blood vessels by tumours)
223603577|NCT05723263|BEHAVIORAL|Standard Pay-it-forward|400 men who have sex with men (MSM) at 4 clinics will be enrolled. The standard pay-it-forward arm will include free point-of-care gonorrhea testing, as well as a passive community engagement component (such as viewing postcards and materials written by others encouraging gonorrhea/chlamydia testing).
223603578|NCT05723263|BEHAVIORAL|Community Engaged Pay-it-forward|400 MSM at 4 clinics will be enrolled. The community engaged pay-it-forward arm will include free point-of-care gonorrhea testing, as well as an active community engagement component (such as multi-stakeholder co-creation activities to develop essential components of the intervention and implementation strategies; writing postcards; designing fans with stickers; sending out testing promotion messages on social media; and opportunity to donate to support others)
223603579|NCT05723263|OTHER|Control arm|400 MSM at 4 clinics will be enrolled. The control arm will include a fee-based point-of-care gonorrhea testing (approximately 20 U.S. Dollars (USD) per test) and no community engagement component
223603580|NCT06169982|DRUG|LY3209590|Administered SC
223603581|NCT05154773|BEHAVIORAL|Kidney donation and transplant information made easy|Same as arm description
223751265|NCT06229496|COMBINATION_PRODUCT|Gemcitabine 800mg/m2 + Nab-paclitaxel 100mg/m2 + S-1 (dose according to BSA)|Dose escalation study-dose level 1
223751266|NCT06229496|COMBINATION_PRODUCT|Gemcitabine 800mg/m2 + Nab-paclitaxel 125mg/m2 + S-1 (dose according to BSA)|Dose escalation study-dose level 2
223751267|NCT06229496|COMBINATION_PRODUCT|Gemcitabine 1000mg/m2 + Nab-paclitaxel 125mg/m2 + S-1 (dose according to BSA)|Dose escalation study-dose level 3
223751268|NCT03187457|OTHER|Metronidazole|Women with Bacterial Vaginosis treated with Metronidazole for 5 days
223751269|NCT03187457|OTHER|Control: no treatment|Healthy women without Bacterial Vaginosis
223603582|NCT06974799|DIAGNOSTIC_TEST|Fatty acids measurement|Serum analysis for metabolomic biomarker identification
223603583|NCT06976034|DEVICE|Optical Transmission Tomography (OTT)|Multiple imaging sessions added by research using the systems described (OTT) will be carried out by two different operators at different positions during these sessions.
223603584|NCT06976034|DEVICE|Optical Coherence Tomography (OCT)|Multiple imaging sessions (OCT) already used in standard of care will be performed by two different operators at different positions during these sessions.
223603585|NCT06976034|DEVICE|Specular Microscopy (SM)|Multiple imaging sessions (SM) already used in standard of care will be performed by two different operators at different positions during these sessions.
223603586|NCT06975345|OTHER|Multicomponent intervention. Hip flexors stretching, Strengthening exercises and education and medical treatment (Medication and medical counselling)|"Hip flexors stretching (Adaptation from Evjenth and Hamberg)~Strengthening Exercise~* Deep squats~* Flexo-extension of the ankle on a step over the head of metatarsal bones~* Plank~* Strengthening knee flexors and hip extensors~* Lunges with a stick behind the patient back~Education Pain relieving positions identified will be taught to the patient to use when they feel their pain.~Identifying and learning to avoid pain positions or activities that increase pain.~When the pain occur self stretching of hip flexors on the couch or the chair must be done"
223751270|NCT01866514|PROCEDURE|proximal humerus intraosseous vascular access|The arm receiving the IO needle is positioned with the arm abducted to shoulder level (in position required for surgery), with the arm rotated inward, into the optimal position, with the palms faced down. Deeply palpate the humerus until the junction of the humeral shaft and the humeral head, the surgical neck is identified; the insertion site is in the surgical neck. With the 45mm IO needle placed perpendicular to the plane of the skin, the IO needle is inserted into the surgical neck using a slightly superior angle of insertion and the needle is inserted to the hub. The stylet will be removed and an EZ-Connect primed with 2% preservative-free lidocaine will be attached to the catheter hub. Aspirate return will be attempted to confirm needle placement within the medullary cavity.
223751271|NCT01866514|DRUG|2% preservative-free lidocaine|
223751272|NCT01866514|DEVICE|EZ-IO|
223751273|NCT01277952|DEVICE|Deep Brain Stimulation|Brain pace maker, implanted in the brain
223751274|NCT03293732|BIOLOGICAL|DCB07010|A protein based adjuvant originated from prokaryotic organism.
223751275|NCT03293732|BIOLOGICAL|HA antigens|HA antigens from three strains of influenza virus ( 7.5 μg of HA each strain).
223751276|NCT01478126|DRUG|N(2)-L-Alanine L-Glutamine dipeptide|Intravenous infusion of glutamine in total dose of 2 g/kg/day (rate=2\*weight/24 ml/h). Infusion starts in operating room and ends next day after the surgery.
223751277|NCT01478126|DRUG|Placebo|Intravenous infusion of 0,9% solution of NaCl, rate=2\*weight/24. Infusion starts in operating room and ends next day after the surgery.
223751278|NCT04368988|BIOLOGICAL|SARS-CoV-2 rS - Phase 1|Alternating intramuscular (deltoid) injections of SARS-CoV-2 rS (0.6 mL) on Days 0 and 21.
223751279|NCT04368988|BIOLOGICAL|SARS-CoV-2 rS/Matrix-M Adjuvant - Phase 1|Alternating intramuscular (deltoid) injections of SARS-CoV-2 rS mixed with Matrix-M adjuvant (0.6 mL) on Days 0 and 21.
223751280|NCT04368988|OTHER|Normal saline solution (NSS), Placebo - Phase 1|Alternating intramuscular (deltoid) injections of placebo (0.6 mL) on Days 0 and 21.
223751281|NCT04368988|OTHER|Normal saline solution (NSS), Placebo - Phase 2|Intramuscular (deltoid) injections of placebo (0.5 mL).
223751282|NCT04368988|BIOLOGICAL|SARS-CoV-2 rS/Matrix-M Adjuvant, Day 0 - Phase 1|Intramuscular (deltoid) injection of SARS-CoV-2 rS mixed with Matrix-M adjuvant (0.6 mL) on Day 0.
223751283|NCT04368988|OTHER|Normal saline solution (NSS), Placebo, Day 21 - Phase 1|Intramuscular injection of placebo (0.6 mL) in alternate deltoid on Day 21.
223751284|NCT04368988|BIOLOGICAL|SARS-CoV-2 rS/Matrix-M Adjuvant - Phase 2|Intramuscular (deltoid) injections of SARS-CoV-2 rS co-formulated with Matrix-M adjuvant (0.5 mL).
223751285|NCT05004155|DIAGNOSTIC_TEST|24 hour pH & impedance monitoring|24 hour pH impedance monitoring will be done on healthy subjects so that normative data specific to indian population can be generated.
223751286|NCT04891900|DRUG|TQB2450/Anlotinib hydrochloride/Oxaliplatin/Capecitabine|"Initial treatment (6 cycles)：~1. TQB2450：1200 mg , Day 1 ivgtt ,once every 3 weeks~2. Anlotinib: 10 mg/day orally ，from days 1 to 14 in a 21-day cycle~3. Oxaliplatin: 130 mg / m2, Day 1 ivgtt ,once every 3 weeks~4. Capecitabine: 1000 mg / m2, orally, twice a day (once in the morning and once in the evening), from days 1 to 14 in a 21-day cycle Maintenance treatment：~1）TQB2450: 1200 mg , Day 1 ivgtt , once every 3 weeks 2）Anlotinib: 10 mg/day orally , from days 1 to 14 in a 21-day cycle"
223751287|NCT04087187|DRUG|Treatment A|Subject will be given AZD5718 Dose A tablet once daily
223751288|NCT04087187|DRUG|Treatment B|Subjects will be given AZD5718 Dose B tablet once daily
223751289|NCT04087187|DRUG|Treatment C|Subjects will be given AZD5718 Dose C tablet once daily
223751290|NCT04404855|OTHER|NGS + Antibiotic Recommendation|NGS results in addition to recommended antibiotic therapy made by infectious disease pharmacist
223751291|NCT04404855|PROCEDURE|Standard of Care treatment|Subjects will have a standard of care urine culture and prophylactic antibiotic prescribed per routine care.
223603587|NCT06975345|DRUG|Medical treatment.|A medical doctor will prescribe the treatment following the standard of care in Polish public health services. Treatment will consist of medication and counseling.
223603588|NCT04668872|RADIATION|Y90 TARE|Y90 TARE will be performed as standard of care (SOC)/clinically indicated: 1) in a lobar or sub-lobar fashion (depending on tumor involvement and location; also targeting the tumor as selective as possible and sparing as much as possible of non-involved liver parenchyma), for participants with extensive bilobar disease or 2) in a radiation segmentectomy approach, intending to deliver 190 Gy radiation dose to target tumor: for patients with limited liver metastatic disease, not amenable for surgery or ablation.
223603589|NCT04668872|DIAGNOSTIC_TEST|PET/CT|Following 90Y TARE, participants will receive a PET/CT or PET/MRI scan to measure the dose administered to the target tumor(s) and uninvolved hepatic parenchyma.
223603590|NCT04668872|DIAGNOSTIC_TEST|PET/MRI|Following 90Y TARE, participants will receive a PET/CT or PET/MRI scan to measure the dose administered to the target tumor(s) and uninvolved hepatic parenchyma.
223603591|NCT06074159|BEHAVIORAL|In-clinic report-back|Investigators measure whether report-back from a clinician improves environmental health literacy, including leading to greater shifts in exposure-reducing health behaviors
223603592|NCT02093962|DRUG|TH-302 combination with pemetrexed|"400 mg/m2 of TH-302 will be administered by IV infusion over 30 - 60 minutes on Day 1 and Day 8 of a 21-day cycle.~Pemetrexed (500 mg/m2) will be administered as an IV infusion on Day 1 two - four hours after TH-302 administration."
223603593|NCT02093962|DRUG|Matched placebo in combination with pemetrexed|"Matched placebo will be administered by IV infusion over 30 - 60 minutes on Day 1 and Day 8 of a 21-day cycle.~Pemetrexed (500 mg/m2) will be administered as an IV infusion on Day 1 two - four hours after placebo administration."
223603594|NCT03930121|OTHER|Anodal transcranial direct current stimulation (tDCS) combined with speech-language therapy (SLT, including naming therapy and communicative-pragmatic therapy)|Two daily sessions of intensive SLT combined with tDCS of the left primary motor cortex (M1)
223751292|NCT03209063|DIAGNOSTIC_TEST|polymerase chain reaction|diagnostic test as Polymerase chain reaction for detection of Prothrombin gene and methylenetetrahydrofolate reductase gene polymorphisms
223751293|NCT00735878|DRUG|ABT-751 and Carboplatin|This primary objective of this Phase 1/2 study is to evaluate the DLT and MTD of escalating oral doses of ABT-751 given BID on Day 1 of each cycle for 7 days in combination with carboplatin given on a 21-day schedule. The carboplatin dose is fixed at AUC 6 and will be administered on Day 4 during the first cycle to facilitate the pharmacokinetic analysis. During the subsequent cycles both agents will be administered on Day 1. ABT-751 is administered at the following dose levels using the Simon rapid dose escalation model: 100, mg, 125 mg, 150 mg, 175 mg and 200 mg BID.
223751294|NCT00386087|DRUG|Enzastaurin Hydrochloride|
223751295|NCT00994240|PROCEDURE|Electrodessication & Curettage|Electrodessication \& Curettage 1 or 3 cycles
223603595|NCT05814328|OTHER|Transitional Care|Targeted inhospital intervention of GMT for patient aged 75 ans more with TRST score ≥2 with a follow-up after ED discharge. Transitional Care is defined by a geriatric team having intervention strategies linked to community care: home visits with community professionals and/or multidisciplinary clinical meetings and/or shared professionals and/or shared information systems.
223751296|NCT02662881|DEVICE|PerFuse Percutaneous Decompression System|Core decompression with PerFuse
223751297|NCT02662881|DEVICE|BioCUE Platelet Concentration System|PRP injection through the PerFuse cannula into core decompression site
223751298|NCT04754776|BIOLOGICAL|ChAdOx1 RVF|Single dose of ChAdOx1 RVF
223751299|NCT03320564|DIAGNOSTIC_TEST|F-18 FDG PET|Repeat scan performed by specially trained staff to reduce risk of repeat infiltration.
223751300|NCT05190198|OTHER|Proprioceptive neuromuscular facilitation|"* Weight shifting in each direction (anteriorly, posteriorly, and lateral side) combined with side-to-side head movements (5 times for each direction).~* One-legged stance with slight knee flexion of another leg for 15 seconds (5 times for each leg).~* One-legged stance with increasing knee flexion of the other leg for 15 seconds (5 times for each leg).~* Standing on a balance pad with shifting weight (anteriorly, posteriorly, and lateral side) 10 times in each direction.~* In standing position, moving the weight left and right maximally.~* In standing position, moving the weight forward and backward maximally.~* In standing position, moving both heels of feet up and down.~* In standing position, bending and stretching both knees by squatting as much as possible."
223751301|NCT05190198|OTHER|conventional therapy|"(Dorsiflexion, planter flexion, eversion and inversion) 10 repetitions for each movement.~(A) Sit to stand (5 times). (B) Standing with shifting Weight anteriorly, posteriorly, and sideway (5 times for each direction). (C) Functional reach sideway and anterior for touching targets set by the therapist (5 times for each direction). (D) Standing on heels for 20 seconds (5 times). (E) Standing on toes for 20 seconds (5 times).~(A) Spot marching (2 min). (B) Walking over the heels, toes, lateral border of feet with the preferred speed (6 min). (C) Tandem walking in a straight line (2 min)."
224200274|NCT01188759|DRUG|Voriconazole|"For Children aged 2-11 years and adolescents aged 12-14 years weighing \<50 kg:~Voriconazole 9 mg/kg IV load q12h x 24h, then 8 mg/kg IV q12h, with option to switch to oral voriconazole at 9 mg/kg q12h (maximum 350 mg) after 7 days.~For adolescents aged 12-17 years, excluding 12-14-year-olds weighing \<50kg:~Voriconazole 6 mg/kg IV q12h x 24h, then 4 mg/kg IV q12h, with an option to switch to oral voriconazole at 200 mg q12h after 7 days.~Voriconazole therapy is to be given for 6-12 weeks."
224200275|NCT01188759|DRUG|Anidulafungin|"Anidulafungin 3 mg/kg IV load q24h x 24h (maximum 200 mg), then 1.5 mg/kg q24h (maximum 100 mg).~Anidulafungin therapy is to be given for 2-4 weeks in combination with voriconazole."
223603596|NCT06976905|PROCEDURE|Total laparoscopic hysterectomy|Hysterectomy by laparoscope using uterine manipulator or myoma screw as a manipulator of large uterus
223603597|NCT06975111|DRUG|Metformin|Metformin will be given to participants who have a elevated HbA1c and also for weightloss.
223603598|NCT06975111|DRUG|semaglutide|Overweight women and women with obesity will take Semaglutide for weight-loss
223603599|NCT06975111|DRUG|Anti-hypertensives|a. Antihypertensives, with the goal of maintaining blood pressure at 130/80 or lower per ACC guidelines19. Per current clinical guidelines and standard of care, hypertension will be treated first with monotherapy using either an angiotensin converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB), a calcium channel blocker, or a thiazide diuretic provided that are no contraindications.
223603600|NCT06975111|DRUG|Lipid Lowering Medication|. First line agents will be generic statin medications (atorvastatin or rosuvastatin)whichever is covered by the participant's health insurance), barring contraindication to their use.
223603601|NCT06975111|BEHAVIORAL|Life style intervention|will simply be followed and given preventive advice (maintenance of a normal BMI and physical activity, moderation in salt intake, and no more than 1 alcoholic drink per day). They will be provided with a wearable activity monitor. This advice will be based on guidelines by the American Heart Association and the Menopause Society.
223603602|NCT06975111|DRUG|Fezolinetant|Women with menopausal symptoms will be treated with hormone therapy (estrogen and progesterone) if appropriate, or with a neurokinin receptor antagonist (Fezolinetant). This can be treatment for women in any arm of the study as well as an arm by its self.
223603603|NCT06975111|DRUG|Hormonal therapy|Participants will be treated with estrogen and/or progesterone for treatment of hot flashes in women during the study.
223603604|NCT06974669|DRUG|oral steroid-dexamethasone|this study is the first according to the best of our knowledge assessing the value of adding mini oral pulse steroid therapy to non cultured epidermal suspension in treatment of stable acral and difficult to treat vitiligo
223603605|NCT06974669|PROCEDURE|non cultured epidermal suspension|this is the best surgical technique for surgical treatment of vitiligo that would be done for both arms
223603606|NCT00870987|BIOLOGICAL|DNA vaccine prime|2 mg total dose (1 mg per construct in a volume of 1 mL)
223603607|NCT00870987|BIOLOGICAL|adenovirus type 5 vaccine boost|2 x 1010 particle units (pu) (1 x 1010 pu per each of 2 constructs including CSP and AMA1 respectively)
223603608|NCT03812315|COMBINATION_PRODUCT|Propolis chewing gum|Children who will use chewing gum will be instructed to chew a gum for 20 minutes once after breakfast and another before bed time for two weeks.
223603609|NCT03812315|COMBINATION_PRODUCT|Propolis mouthwash|Children who will use mouthwash will be instructed to rinse with 10 ml for 60 seconds twice daily once after breakfast and another before bedtime for two weeks.
223603610|NCT06009835|OTHER|Recommended treatment plan|Develop a final treatment plan based on DOTr/DOTA test results, MTB consultation expert opinions, and drug accessibility
223603611|NCT03427723|DEVICE|Accuvein®400|The intervention comes down to the randomization of the standard treatment versus Accuvein for peripheral intravenous cannulation
223603612|NCT03427723|OTHER|Standard care|The intervention comes down to the randomization of the standard treatment versus Accuvein for peripheral intravenous cannulation
223603613|NCT06356922|DRUG|Experimental drug [177Lu]Lu-PentixaTher|Injection of \[177Lu\]Lu-PentixaTher
223603614|NCT06975995|DIETARY_SUPPLEMENT|Yi'en Yuan Honey Fermented Drink|The oral postbiotics product used in the trial is called Yi'en Yuan Honey Fermented Drink. The product is made from water, edible brown sugar, and honey as raw materials. It is fermented by a mixture of plant lactic acid bacteria and coagulating Bacillus, and then inactivated at high temperature. The product meets the food and beverage standard. Participants will receive the product for 150ml per day.
223751302|NCT01760512|PROCEDURE|Gastric bypass|Gastric bypass
223603615|NCT06974890|OTHER|Shuttle Balance Training|Shuttle balance training is a form of dynamic balance exercise that uses a shuttle system-often a platform or track with resistance bands or gliders-to help improve stability, coordination, and strength. In children, this type of training plays a significant role in enhancing gait, balance, and posture by engaging core and lower limb muscles in controlled, functional movements. It encourages proprioceptive development, helping children become more aware of their body's position in space, which is crucial for maintaining upright posture and walking efficiently. Through repetitive and playful activities, shuttle balance training can aid in correcting abnormal gait patterns, improving postural alignment, and boosting confidence in physical activities.
223603616|NCT06974890|OTHER|Baseline Treatment|"Baseline treatment sets a foundation for managing the patient's condition effectively. It ensures that the patient receives appropriate care based on current medical knowledge and guidelines, with the goal of improving health outcomes and quality of life. Duration of session will be 45 min and 3 sessions per week.~Control Group Considerations: Clarifying how participants assigned to the control group will receive standard care or placebo intervention to maintain ethical standards and enable comparison with the intervention group."
223751303|NCT05497492|DRUG|propofol|single administration of propofol
223751304|NCT05497492|DRUG|propofol and sufentanil|administration of propofol and sufentanil in combination
223751305|NCT05497492|DRUG|propofol and esketamine|administration of propofol and esketamine in combination
223751306|NCT05497492|DRUG|propofol and lidocaine|administration of propofol and lidocaine in combination
224200276|NCT01188759|DRUG|Voriconazole|"For Children aged 2-11 years and adolescents aged 12-14 years weighing \<50 kg:~Voriconazole 9 mg/kg IV load q12h x 24h, then 8 mg/kg IV q12h, with option to switch to oral voriconazole at 9 mg/kg q12h (maximum 350 mg) after 7 days.~For adolescents aged 12-17 years, excluding 12-14-year-olds weighing \<50kg:~Voriconazole 6 mg/kg IV q12h x 24h, then 4 mg/kg IV q12h, with an option to switch to oral voriconazole at 200 mg q12h after 7 days.~Voriconazole therapy is to be given for 6-12 weeks."
223751307|NCT00860782|BEHAVIORAL|Parent Educational Support|Parents will attend 45-minute educational sessions that will focus on providing them with information regarding SCD and how they can best help their child perform better in school.
223751308|NCT01886183|OTHER|Virtual Reality Training|The participants of the study will be trained 8 balance games during 14 sessions
223751309|NCT01886183|OTHER|Physical Therapy|Patients of the control group will be trained with balance exercises.
223751310|NCT00352846|DRUG|Zoledronic Acid|4 mg/m\^2 by vein over 30 Minutes at baseline and 6 months.
223751311|NCT00352846|DRUG|Vitamin D|400 mg by mouth daily
223751312|NCT00352846|DRUG|Calcium Carbonate|1200 mg by mouth daily
223751313|NCT05735301|PROCEDURE|Endovascular|"Endovascular therapy, as an adjunct to standard stroke therapy, may be beneficial for a very select population of patients who present with an acute ischemic stroke and have a proven large, proximal occlusion on imaging.~Endovascular therapy includes any one or more of the following:~Intra-arterial thrombolytic therapy, aspiration, stent retrieval, or a combination of multiple mechanical devices.Remedial measures after failed thrombectomy are permitted by pharmacologic arterial thrombolysis or intravenous infusion of antiplatelet drugs, such as tirofiban or rt-PA"
223751314|NCT05735301|DRUG|Drug|best drug conservative therapy could be uesd in patients who with no indication of surgery
223751315|NCT01344187|DRUG|riboflavin solution|0.12% riboflavin ophthalmic solution
223751316|NCT01344187|DRUG|placebo solution|0.0% riboflavin ophthalmic solution
223751317|NCT01344187|DEVICE|KXL System|30 mW/cm2
223603617|NCT06975332|RADIATION|Local, targeted therapy with alpha emitter [225Ac]Ac-DOTA-SP (TAT)|Local, targeted therapy with alpha emitter \[225Ac\]Ac-DOTA-SP (TAT) administered to the post-resection cavity or tumour via Rickham reservoir using induced diffusion.
224200277|NCT04869475|DRUG|Arsenic trioxide|This is a single-arm study with all patients receiving arsenci trioxide.
223507961|NCT06100042|DRUG|BDP/FF/G|"BDP/FF/G is an extrafine single inhaler triple therapy available in two dosage strengths:~* Medium strength (MS) containing 100 µg of beclomethasone dipropionate, 6 µg of formoterol fumarate dihydrate and 10 µg of glycopyrronium (as 12.5 µg glycopyrronium bromide);~* High strength (HS) containing 200 µg of beclomethasone dipropionate, 6 µg of formoterol fumarate dihydrate and 10 µg of glycopyrronium (as 12.5 µg glycopyrronium bromide)."
223603618|NCT06976931|DRUG|YY2201|This is a multicenter, open-label, dose-escalation phase I study. participants will receive one single target dose of YY2201 on Cycle 0 Day 1 (C0D1) to observe safety and collect PK blood samples up to 48 h post-dose. On the third day after the first dose (Cycle 1 Day 1, C1D1), subjects will start to receive multiple doses of YY2201 orally twice daily (approximately 12 h interval) for 3 days followed by 4 days off in a 21-days treatment cycle.
223603619|NCT06976996|DRUG|normal saline|normal saline (0.15 ml/kg)
223603620|NCT06976996|DRUG|esketamine|esketamine (0.15 mg/kg)
223603621|NCT06976996|DRUG|propofol|propofol (2 mg/kg)
223603622|NCT06976996|DRUG|etomidate-ciprofol (EC) mixture|etomidate-ciprofol (EC) mixture (0.2 ml/kg)
223603623|NCT06976996|DRUG|ciprofol|ciprofol (0.5 mg/kg)
223603624|NCT06976996|DRUG|etomidate-propofol (EP) mixture|etomidate-propofol (EP) mixture (0.2 ml/kg)
223603625|NCT06078059|BIOLOGICAL|Knee aspiration + UCB-MSCs|Knee aspiration and the application of cultered allogeneic umbilical cord blood-derived mesenchymal stromal stem cells (UCB-MSCs).
223751318|NCT00788827|BIOLOGICAL|Autologous CD34+ stem cells|Up to 5 x 10 log 8 of autologous stem cells on a single occasion
223751319|NCT02331147|OTHER|Offloading|Patient will be offloaded in a diabetic camboot after treatment
223751320|NCT02331147|OTHER|Dressing Application|Application of a non-adherent dressing, a moisture retentive dressing, and a multi-layer compression dressing.
223751321|NCT05211713|DEVICE|Opp|Opp is a universal mental health promoting mobile application for adolescents aged 13-25 years.
223603626|NCT06078059|OTHER|Knee aspiration|Knee aspiration
223603627|NCT00465452|DRUG|Continuous Release Dopamine Agonists|Continuous Release Dopamine Agonists
223603628|NCT03375489|OTHER|Telehealth Palliative Care|"Teleconference meeting with the palliative care team. Palliative care is a medical specialty focused on lessening (or palliating) patients' symptoms and helping patients and their families cope with a serious illness."
223751322|NCT02233244|DRUG|CTX-4430|
223751323|NCT02233244|DRUG|Midazolam|
223751324|NCT01218555|DRUG|Lenalidomide|Lenalidomide (10mg, 15mg, 20mg or 25mg) once daily by mouth, every day of each 28-day cycle.
223751325|NCT01218555|DRUG|Everolimus|5mg or 10mg of everolimus administered once daily by mouth on a once daily continuous dosing schedule for 28 days.
223751326|NCT00464425|PROCEDURE|Electroacupuncture|EA using sharp needles placed at various acupoints; electrical stimulation at 50 Hz applied to the needles
224200278|NCT05919069|DRUG|AZD2693|Subcutaneous administration of AZD2693 single dose in participants with hepatic impairment
223507962|NCT04906421|DRUG|TVB-2640|Oral dose, tablet
223507963|NCT04906421|OTHER|Placebo|Oral dose, tablet
223507964|NCT02084342|DRUG|tranexamic acid and sodium chloride injection|10mg/kg, IV (in the vein) for 30min, before incision. then at 1mg/kg/h, IV pump, until the surgery is over.
223751327|NCT00464425|PROCEDURE|Sham Acupuncture|Acupuncture using blunt-tip needles placed 15 mm away from acupoints; no electrical stimulation used
223751328|NCT00464425|OTHER|No Acupuncture|Control
223751329|NCT02242708|BEHAVIORAL|Alternative nostril breathing|The experimental groups will do alternative nostril breathing twice a week (20 minutes/time) for 3 months.
224200279|NCT06163209|DIAGNOSTIC_TEST|Nasal Ultrasonography|"Ultrasonography of the external nose will be performed with the use of a high-resolution transducer (Clarius L20HD3 8-20 MHz) and a 3mm-thick disposable gel pad, according to the following protocol:~1. Sagittal plane, along the most prominent part of nasal dorsum.~2. Transverse plane, level of nasion.~3. Transverse plane, level of intercanthal line.~4. Transverse plane, level of rhinion.~5. Along inferior border of the right nasal bone.~6. Along inferior border of the left nasal bone.~7. Along medial part of the right orbital rim below frontomaxillary suture.~8. Along medial part of the right orbital rim below frontomaxillary suture.~9. Along the line connecting right frontomaxillary suture and the tip of the nose.~10. Along the line connecting left frontomaxillary suture and the tip of the nose.~At each location the transducer position will be adjusted until it is held perpendicular to the bone surface and a single image will be saved for further assessment."
223603629|NCT03375489|OTHER|In-person Palliative Care|"In-person meeting with the palliative care team. Palliative care is a medical specialty focused on lessening (or palliating) patients' symptoms and helping patients and their families cope with a serious illness."
223751330|NCT05643261|OTHER|Muscle and technique training|The strength training consists of three exercises (clam shell, side plank, calf raises) with an progressive overload after two to three weeks to ensure a continuous muscle stimulation. The technique training consists of different cutting variations with a focus on forefoot landings and conscious control of the knee to avoid high knee valgus movement and KAM respectively.
223751331|NCT03266991|DRUG|Rifapentine|Treatment with weekly rifapentine and isoniazid as Directly Observed Therapy in 12 weeks
223603630|NCT06975202|OTHER|No intervention|No intervention
223603631|NCT04283097|DRUG|KPG-818|The 4 planned dose level (cohorts) of KPG-818 will be explored: 2, 3, 4 and 5mg. Each dose of KPG-818 will be administered orally with approximately 240 ml of water daily, and used as a single agent in subjects with selected hematological malignancies (or in combination with dexamethasone weekly for MM), according to specific dosing schedule in each treatment cycle until disease progression, unacceptable toxicity, the subject withdraws, or any other study withdrawal criterion is met. The treatment of study is divided into 6 cycles.
223603632|NCT03897673|DIETARY_SUPPLEMENT|Early Iron|iron syrup for the first three months (84 days) and placebo syrup for the fourth month
223603633|NCT03897673|DIETARY_SUPPLEMENT|Delayed Iron|placebo syrup for the first month (28 days) and iron syrup for the second, third, and fourth months
223603634|NCT05370443|BEHAVIORAL|Life Skills education program|"The World Health Organization (WHO), describes life skills as abilities for adaptive and positive behaviour that enables individuals to deal effectively with the demands and challenges of everyday life. Life Skills Education includes activities that support critical and creative thinking, coping with emotions and stress, self-awareness and empathy, decision-making and problem-solving, communication skills, and interpersonal relations."
223603635|NCT04140045|OTHER|Water intake|Water intake will be manipulated in both arms to create a hypohydrated state and a euhydrated state, post-exercise
223603636|NCT06660082|PROCEDURE|Experimental treatment: Head movements|"These are gaze stabilisation exercises under vHIT control, between post-operative days 1 to 6.~The patient sits facing a wall 2 metres away. The investigator places the vHIT device on the participant's head and ensures that it fits properly.~This is followed by an initial calibration phase (the patient must follow a laser dot with his eyes).~Then comes stimulation phase: the investigator, standing behind the patient, places his hands on the sides of the patient's lower jaw, which he is asked to clench. The investigator asks the subject to stare at a visual target on the wall in front of the patient. The investigator then performs a series of low-amplitude, high-speed head movements in the plane of the lateral canals and on the side of the vestibular deficit.~The patient is encouraged to resume fixation of the visual target as quickly as possible.~For each treatment session, patients should perform a minimum of 10 impulses and a maximum of 30 impulses on the deafferented side. Each"
223603637|NCT06660082|PROCEDURE|Sham treatment: only eye movements|"These are visually guided saccade exercises under vHIT device control but without head movements (saccade module), between post-operative days 1 to 6.~For this sham treatment, the modalities are identical to the experimental treatment session, up to the calibration phase described above.~For the stimulation phase, the investigator, standing behind the patient, places his hands on the sides of the patient's lower jaw, which he is asked to clench. The investigator asks the subject to stare at a visual target on the wall in front of the patient. The target then jumps horizontally to trigger visually guided saccades or slides horizontally to trigger an eye-tracking movement. The investigator stabilises the patient's head to prevent any head movement. The patient is encouraged to resume or maintain fixation of the visual target as quickly as possible.~A minimum of 5 horizontal saccade sequences and 5 horizontal eye-tracking sequences will be performed. Each training session lasts approxi"
223603638|NCT03591315|DIAGNOSTIC_TEST|resting state fMRI|Define the visual resting state network.
223603639|NCT03591315|DIAGNOSTIC_TEST|visual tasking state fMRI|Using visual task stimulation to identify the activation characteristic of primary visual cortex.
223603640|NCT03591315|DIAGNOSTIC_TEST|diffusion tensor imaging|Define the integrity of white matter fibers in the visual pathway.
223603641|NCT03591315|DIAGNOSTIC_TEST|automated visual field|Identify the existence and type of visual field defect.
223751332|NCT03266991|DRUG|Isoniazid|Treatment with daily isoniazid in 6 months
223751333|NCT05228392|OTHER|listening to music|listening to lullaby or other music types
223751334|NCT03667365|PROCEDURE|aortic valve replacement|aortic valve replacement surgical or transcatheter aortic valve replacement (will be decided by the heart team before randomization)
223751335|NCT03667365|OTHER|strict clinical surveillance|strict clinical surveillance strategy
223751336|NCT02213393|DIETARY_SUPPLEMENT|Protein enriched products|The intervention group receives CwC protein enriched products. After discharge the intervention group receives CwC products delivered at home for 12 weeks.
223751337|NCT02213393|DIETARY_SUPPLEMENT|Usual menu|The control group receives the usual menu, which is energy and protein rich in this elderly patient group. After discharge the control group receives regular products, no protein enrichment, at home for 12 weeks.
223751338|NCT01527682|DRUG|Latanoprost, Dorzolamide|"* Latanoprost 0.005% ophthalmic solution given once a day at nighttime (9.00 PM)~* Dorzolamide 2% ophthalmic solution given three times a day as a monotherapy, two times a day if in combination with latanoprost"
223507965|NCT02084342|DRUG|normal saline|100ml, IV for 30min,before incision.
223507966|NCT02084342|DRUG|desmopressin acetate injection|0.3μg/kg dissolved in 100ml NS，IV for 30min，before incision.
223507967|NCT00000335|DRUG|Morphine|
223507968|NCT02602197|DRUG|Paracetamol|After anesthetic induction, the first I.V bolus injections of 1 gr paracetamol (total amount of 100 ml) were given during 15 minutes and then repeated every 6 h until 24 h postoperative period.
223507969|NCT02602197|DRUG|Dexketoprofen|After anesthetic induction, the first I.V bolus injections of 50 mg Dexketoprofen (premixed with 0.9 % sodium chloride to total amount of 100 ml) were given during 15 minutes and then repeated every 8 h until 24 h postoperative period.
223507970|NCT00669344|DRUG|Exelon (rivastigmine)|Capsules, twice daily orally. Dosage starts at 1.5mg bis diem to 4.5mg bis diem.
223507971|NCT00669344|DRUG|Placebo|Capsule, twice daily orally. Dosage starts at 1.5mg bis diem to 4.5mg bis diem.
223751339|NCT03889769|DIAGNOSTIC_TEST|OSNA test|Analysis of lymph node with OSNA
223751340|NCT03630809|BIOLOGICAL|HER2 DC1 Vaccine|Ultrasound (US) guided intranodal delivered vaccines will be administered at each participating site by a radiologist experienced in ultrasound guided procedures along with the principal investigator or his/her designee. Each dose will consist of between 1.0-2.0 x 10\^7 cells and will be injected into 1 right and 1 left normal groin lymph nodes.
223603642|NCT03591315|DIAGNOSTIC_TEST|visual acuity|Assess the visual acuity by using ETDRS scales.
223603643|NCT06706219|DRUG|Sacituzumab tirumotecan plus pembrolizumab|"Participants meeting the inclusion criteria will receive pembrolizumab 200 mg IV on D1, Q3W + SKB264 4mg/kg IV on D1, D15 and D29，Q2W for 12 weeks as induction therapy.~Subjects who receive radical radiotherapy will undergo 8 cycles of pembrolizumab 200 mg IV on D1, Q3W; For those receiving surgical treatment, pembrolizumab is selected for adjuvant therapy for pCR patients, and SKB264 combination with pembrolizumab is selected non-PCR patients."
223751341|NCT02595086|PROCEDURE|Laparoscopic PPG|Laparoscopy assisted pylorus-preserving gastrectomy with D1+ lymphadenectomy (exclude lymph node station No. 5) in Japanese classification.
223751342|NCT02595086|PROCEDURE|Laparoscopic DG|Laparoscopic distal gastrectomy with D1+ lymphadenectomy in Japanese classification.
223603644|NCT01350245|RADIATION|Total Body Irradiation (TBI)|Total body irradiation is given in 8 fractions over 4 days (total dose of 12 Gy).
223603645|NCT01350245|BIOLOGICAL|Donor Lymphocyte Infusion (DLI)|After TBI, the patients will receive a dose of 2 x 10e8 of their donor's T cells. After this infusion, the patients will have 2 rest days.
223603646|NCT01350245|DRUG|Cyclophosphamide|Cyclophosphamide is administered 2 days after the DLI to help tolerize the donor T cells. It is given at a dose of 60 mg/kg/d for 2 days
223603647|NCT01350245|DRUG|Mycophenolate Mofetil (MMF)|Started the day before the transplant to prevent graft versus host disease (GVHD)
223603648|NCT01350245|DRUG|Tacrolimus|Started the day before the transplant to prevent graft-versus-host disease (GVHD)
223603649|NCT01350245|DEVICE|Hematopoietic stem cell transplantation (HSCT)|"One day after the cyclophosphamide is finished, the patients will receive a CD34 selected-donor stem cell product. This is the day of transplant.~The CliniMACS® Plus Instrument will be used for the selection of human CD34+ hematopoietic stem and progenitor cells in human allogeneic hematopoietic stem cell transplantation."
223603650|NCT04351724|DRUG|Chloroquine or Hydroxychloroquine|Hydroxychloroquine 200mg 2-0-2 on day 1 followed by 200mg 1-0-1, or Chloroquine 250mg 2-0-2, as available
223603651|NCT04351724|DRUG|Lopinavir/Ritonavir|Lopinavir/Ritonavir 200mg/50mg 2-0-2
223603652|NCT04351724|OTHER|Best standard of care|best standard of care
223603653|NCT04351724|DRUG|Rivaroxaban|2.5mg 2-0-2 or 10mg 1/2-0-1/2, as applicable
223603654|NCT04351724|DRUG|Thromboprophylaxis|as local standard, most likely to be low molecular weight heparin
223603655|NCT04351724|DRUG|Candesartan|starting dose 4mg once daily, titrated to normotension
223603656|NCT04351724|DRUG|non-RAS blocking antihypertensives|This excludes angiotensin converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (AT-blockers, sartans) and includes alpha-receptor antagonists, calcium antagonists, amongst others
223603657|NCT04351724|DRUG|Remdesivir|200mg on day 1, thereafter 100mg for a total of 5-10 treatment days, according to local standards
223603658|NCT04351724|DRUG|Asunercept 400mg|asunercept 400mg once per week, up to 4 doses in total
223603659|NCT04351724|DRUG|Asunercept 100mg|asunercept 100mg once per week, up to 4 doses in total
223603660|NCT04351724|DRUG|Asunercept 25mg|asunercept 25mg once per week, up to 4 doses in total
223603661|NCT04351724|DRUG|Pentaglobin|7ml/kg/day for 12h for 5 days
223603662|NCT06842901|DEVICE|Portable Rehabilitation (PoRi) device|Once the calibration is complete, the device moves the fingers to close and open the hand for a total of 20 minutes.
223603663|NCT02104947|DRUG|idarucizumab|idarucizumab
223751343|NCT02038582|OTHER|POC CD4 Testing|Point of Care CD4 testing
223751344|NCT02038582|OTHER|CD4 Referral|Referral to CD4 testing
223751345|NCT02038582|BEHAVIORAL|Lay Counselor Follow-up|Follow-up from a lay counselor
223751346|NCT02038582|BEHAVIORAL|Clinic Accompaniment|Accompaniment to the clinic by a counselor
223751347|NCT02038582|BEHAVIORAL|Clinic Referral|Referral to clinic
223603664|NCT05998577|DEVICE|ESM and Traqq|Two telephone applications: ESM is a psychosocial diary and Traqq is a food diary to measure abdominal pain as well as possible triggerfactors (i.e. diet, stress, anxiety)
223603665|NCT02610452|OTHER|Clown therapy|"The clowns intervene by twos: a game takes place.~1. The game requires the active presence of a number of potential players in the room (patient, family, caregivers) and takes into account body position, emotional state, the general atmosphere.~2. The clowns initiate a game proposal: provisional staging of clown characters based on imagination/improvisation which engages a physicality and a basic emotional state.~3. The original game proposal is adjusted according to mutual empathy with those present.~4. The game is developed on the model of theatrical improvisation: an original creation that has scenic quality comparable to that of a complete representation. Improvisation time varies depending on the condition of the person, his/her desire to participate, choosing the main theme.~5. The final stage of the game is preparing all actors for separation: restitution of roles, revisiting the paths traveled."
223751348|NCT02038582|BEHAVIORAL|SMS Reminder|SMS reminder for male circumcision
223751349|NCT02038582|BEHAVIORAL|Circumcision Promotion|Promotion of male circumcision at the time of HIV testing
223751350|NCT02038582|OTHER|POC VL|POC VL testing for HIV infected persons on ART
223751351|NCT02038582|OTHER|Laboratory based VL assay|Laboratory based viral load testing for HIV infected persons on ART
223507972|NCT03180372|DEVICE|Hybrid Fractional Laser|Consecutive and coincident fractional 2940 nm and 1470 nm lasers
223507973|NCT00922051|DEVICE|Transcutaneous electrical nerve stimulation (TENS)|
223507974|NCT00922051|DEVICE|Transcutaneous electrical nerve stimulation (TENS)|Placebo
223507975|NCT01125748|DRUG|Omalizumab|Omalizumab was supplied as a sterile, white, preservative-free, lyophilized powder in single-use vials that was reconstituted with sterile water for injection.
223507976|NCT01125748|DRUG|Placebo|Placebo contained the same ingredients as the omalizumab formulation, excluding omalizumab.
223603666|NCT00883441|OTHER|Insecticide treated curtains and insecticide treated covers|The study is comparing the introduction of two new vector control tools (insecticide treated curtains and insecticide treated covers) through two different distribution strategies. These tools are curently not in use in the routine programmes of the concerned countries.
223603667|NCT00145574|DRUG|colesevelam HCl|Tablets
223507977|NCT01125748|DRUG|Asthma therapies|Participants could receive 1 or more of the following medications as concomitant asthma therapy: Inhaled corticosteroids; long acting beta-agonists; zafirlukast or other leukotriene receptor antagonist; zileuton or other 5-lipoxygenase enzyme inhibitors; oral, inhaled, and/or nasal anticholinergic therapy; mast-cell stabilizers; theophyllines; chronic oral corticosteroids, defined as a minimum dose of oral prednisone of 2 to 40 mg/day or 5 to 80 mg every other day.
223507978|NCT01641432|BEHAVIORAL|Tonic and Phasic Attention Training|"The Tonic and Phasic Alertness treatment task (TAPAT) consist of two consecutive rounds of a 12-minute continuous performance task in which continually varying, rich visual (e.g., scenes, objects, faces) or auditory stimuli (tones or complex sounds) are briefly displayed and participants are required to respond via a button press when they see a non-target item (90% of trials) or withhold button-press responding when the item is a pre-determined target item (10% of trials). Presentation of the target item is non-predictive and infrequent, disallowing the development of an executive strategy. Participants simply sustain attention to the task over a prolonged period of time (tonic attention), ignoring distractions, and inhibiting the pre-potent motor response when they see a target item (phasic attention).~Following the 24 minutes of TAPAT treatment participants will undergo one additional computer-based cognitive exercise, Multiple Object Tracking (MOT), for an additional 12 minutes."
223507979|NCT01641432|BEHAVIORAL|Active Comparator|Computer games chosen from a list of progressive visual/audiovisual games from the top-100 game list: sporcle.com. Training duration will be similar to that of experimental training.
223507980|NCT00839826|DRUG|Rivaroxaban (BAY59-7939)|2,5 mg bid,5 mg bid,10mg bid, 20 mg bid, 20 mg tid, 30 mg bid, dose escalation trial
223507981|NCT00839826|DRUG|Enoxaparin|40 mg bid
223507982|NCT01028391|DRUG|Sitagliptin 100 mg q.d.+ Pioglitazone 45 mg q.d.|Patients will receive combination therapy with blinded sitagliptin 100 mg q.d. (q.d. = once daily) and open-label pioglitazone 45 mg q.d. during the up to 30 week extension study. Sitagliptin 100 mg q.d. and pioglitazone 45 mg q.d. will be administered as oral tablets.
223603668|NCT00145574|DRUG|placebo|Matching Tablets
223603669|NCT04846465|OTHER|Screening in picture archiving and communication system (PACS) .|Screening in picture archiving and communication system (PACS) , the images of the participants who underwent computed tomography (CT) of the femur and acetabulum.
223603670|NCT06233097|DRUG|Esomeprazole magnesium dihydrate-Test product|Esomeprazole magnesium dihydrate 40 mg tablets Manufactured by: Cipla Limited, India
223603671|NCT06233097|DRUG|Esomeprazole magnesium dihydrate-Reference product|Esomeprazole magnesium dihydrate 40 mg tablets Manufactured by: AstraZeneca AB, Kingdom of Sweden
223603672|NCT02021955|BEHAVIORAL|guideline treatment recommendations|Primary care clinicians receive guideline concordant treatment recommendations for their patients discharged from hospital for a COPD exacerbation.
223603673|NCT04673578|DRUG|Celecoxib|Selective COX-2 inhibitor; nonsteroidal anti-inflammatory drug (NSAID)
223603674|NCT04673578|OTHER|Placebo|Microcrystalline cellulose
223603675|NCT00053144|DRUG|cytarabine|
223603676|NCT00053144|DRUG|irinotecan hydrochloride|
223603677|NCT01279603|DRUG|GO-203-2c|GO-203-2c Injection is a non-preserved, sterile, ready-to-use liquid dosage form provided in a glass vial with rubber closure and crimp seal. Injection will be added to the contents of an intravenous bag (of 0.9% NS, D5W or sterile water) to a final concentration of between 0.03 - 0.3 mg/ml (preferable in 100 mls or greater) and administered as a single agent intravenously over 60 minutes. A treatment cycle will consist of a daily IV dose administered for 21 consecutive days followed by a 7 day rest.
223603678|NCT05636761|DIAGNOSTIC_TEST|Heart rate variability|Collection and Analysis of Heart Rate Variability
223603679|NCT06480318|DEVICE|TENS|The device is portable and battery-powered to preserve the patient functional activity. The device has two channels and the parameters of each channel can be adjusted independently of the other. The device contains a power supply, amplifier and electrodes to give a warning. The power supply and amplifier are located within the TENS device. Electrodes are connected to the device via cables. The current produced in the power supply is increased in the amplifier and reaches the electrodes. The device is self-gel to facilitate the transmission of current between the electrodes made of carbon silicon alloy and the skin surface. In the research, a dual-channel, four-electrode (5 cm x 5cm) TENS device will be used. TENS application will be applied every 12 hours, twice and for 20 minutes, 24 hours after the surgery.
223603680|NCT04440657|BEHAVIORAL|Self-Assured Parenting program|Parents will receive parenting education for 10 weeks
223603681|NCT00001317|DRUG|interferon-gamma|
223603682|NCT03727906|OTHER|No pre-sleep arousal manipulation|As with the pre-sleep arousal up- and down-regulation nights, the participant will sleep in comfortable sound-proof and temperature-controlled bedroom and will go to bed and wake up at his/her self-reported usual school-week times. On this night, pre-sleep activities include watching television or reading a book.
223603683|NCT03727906|OTHER|pre-sleep arousal down-regulation|"On the low pre-sleep arousal night, about 30 min before lights-out, a 20 min session of relaxation-driven Virtual Reality (VR) + slow breathing will be conducted. Adolescents will be instructed to perform slow diaphragmatic breathing and to let the VR immersion guide them through this relaxation process."
223603684|NCT03727906|OTHER|pre-sleep arousal up-regulation|"On the high pre-sleep arousal night, an anticipatory stress procedure from the Trier Social Stress Test (TSST) will be used to elicit stress-induced ANS activation in the pre-sleep period. About 30 min before lights-out participants will be told that the following morning they will need to prepare and give a 5-min speech in front of a panel of assessors who will judge their performance and ask questions. Participants will be shown the testing room (set up with chairs, video camera, microphone)."
223603685|NCT03002714|OTHER|Exercise|
223603686|NCT01366885|DRUG|Vitamin D3|5000 IU D3 capsule oral/day for entire pregnancy. 7000 IU D3/day during breastfeeding. If not breast feeding, baby gets 400 IU D3/day. Baby increased to 1000 IU D3/day at one year of age.
223751352|NCT04931433|DRUG|Lignocaine|Group A will receive 1.5mg/kg IV lignocaine bolus prior to induction followed by 2mg/kg/hour of lignocaine infusion throughout surgery until wound closure in which the infusion will be halved to 1mg/kg/hour until the end of surgery. The same rate will be infused in the recovery room for another half an hour before participant is discharge.
223751353|NCT04931433|DRUG|Normal saline|Group B will receive saline of similar volume and rate as Group A
223751354|NCT01083212|DRUG|AZD1656|Single dose,oral tablet
223751355|NCT01083212|DRUG|Gemfibrozil|Oral tablet bid on day 1 - 5.
223751356|NCT01083212|DRUG|Placebo|Oral tablet bid on day 1-5
224200280|NCT06163209|DIAGNOSTIC_TEST|Computed Tomography Scan of the Face|"A standard computed tomography scan of the face will be performed and the following areas will be assessed by an experienced radiologist:~1. Bony part of the nasal septum~2. Left nasal bone - part proximal to the intercanthal line~3. Right nasal bone - part proximal to the intercanthal line~4. Left nasal bone - part distal to the intercanthal line~5. Right nasal bone - part distal to the intercanthal line~6. Frontal process of the left maxilla~7. Frontal process of the right maxilla"
224200281|NCT02585375|DRUG|Preservative-free latanoprost 50µg/ml|
223507983|NCT01028391|DRUG|Pioglitazone 45 mg q.d. + Sitagliptin 100 mg placebo q.d.|Patients will receive placebo to match sitagliptin 100 mg q.d. (blinded) and open-label pioglitazone 45 mg q.d. during the up to 30 week extension study. The placebo to match sitagliptin 100 mg q.d. (blinded) and open-label pioglitazone 45 mg q.d. will be administered as oral tablets.
223603687|NCT02681289|OTHER|Early goal directed neuromotor therapy|Early goal directed neuromotor therapy (NGDT) is referred to as 'task-oriented' and is built on contemporary system theories of motor control. The development and learning of new skills occur in an interaction between the child, the task to be performed and the particular environment in which the activity takes place.
223603688|NCT05386693|PROCEDURE|Ilioinguinal nerve block|Local anesthetic injection of the ilioinguinal nerve. This is performed in the outpatient clinic.
223603689|NCT00858637|DRUG|MCI-196|Tablets of 3 g to 12 g/day (3 times a day) with dose escalation design during 16 weeks of Active Comparison Phase, and 4 weeks of fixed dose during Withdrawal Phase (Week 16 to Week 20)
223751357|NCT05572112|DEVICE|Venous access port implantation|Venous access port implantation
223751358|NCT00763165|DRUG|Triclosan|Brush twice daily
223751359|NCT00763165|DRUG|Fluoride|Brush twice daily
223751360|NCT00763165|DRUG|Fluoride|Brush twice daily
223751361|NCT05887882|BIOLOGICAL|Universal Donor (UD) Transforming growth factor beta imprinting (TGFβi) Natural Killer (NK) Cells|The TGFβi NK cell product will be manufactured in the Cell Therapy Laboratory at Nationwide Children's Hospital and given via infusion.
223751362|NCT05887882|PROCEDURE|Implantation|Undergo placement of Ommaya reservoir
223751363|NCT05887882|PROCEDURE|Magnetic Resonance Imaging (MRI)|Imaging procedure
223507984|NCT01028391|DRUG|Metformin|Patients not meeting specific glycemic goals during the 30-week extension study will receive open-label metformin at a dose determined by the investigator.
223507985|NCT06462872|OTHER|observational study|It is an observational study
223507986|NCT00477022|DEVICE|Vasotrain-447|
223507987|NCT01817478|OTHER|microbiologic sample|
223507988|NCT05922280|OTHER|subtalar and talo-crural mobilization|"Traction, Antero Posterior (AP) and Postero Anterior (PA) Maitland Grade III oscillatory mobilizations of 2Hz with 120 oscilations per minute, 3 sets for 5 minutes with 1 min of rest between sets at subtalar and talocrural joint would be performed. The mobilization would be large amplitude rhythmic oscillations from the joint mid into end-range muscle spasm/stiffness (translation taken to tissue resistance). Duration will be 20 minutes with 2 sessions per week, total 12 sessions would be performed on each patient in the total period of 6 weeks.~Patients will be guided to follow self foot care examination given by IWGDF Guidelines."
223507989|NCT05922280|OTHER|International Working Group of the Diabetic Foot care guidelines|"Patients will continue their usual activities according to International Working Group on Diabetic Foot (IWGDF) guidelines including the measures of inspecting the feet, self- examination for callus, pre-ulcerative signs or deformity. They will be restrict barefoot walking in-door and outdoors. To wash their feet daily with careful drying, to use emollients to prevent dryness and cut their nails straight across. Monitor the foot skin temperature for inflammation, wear orthotic insoles for preventing abundant callus.~Patients will perform active ROM exercises 5 times per week for duration of 30 minutes for 6 weeks:Ankle pumps, Supination and Pronation, Drawing score from 0 to 9, Leg Flexion and Extension"
223507990|NCT05833932|DRUG|Suhexiang Pill|Suhexiang Pill is an approved traditional Chinese patent medicine.
223507991|NCT01408498|DRUG|Testosterone|Topical administration of testosterone gel. Participants receive a one-time, single dose of 10 g of 1% testosterone gel.
223507992|NCT05466253|PROCEDURE|Fixed Orthodontic treatment|All the patients will receive the indicated periodontal surgical treatment. and the patients will then be randomly divided into two groups - test group and control group Orthodontic treatment will be started in the test group (EARLY)10 days after periodontal surgery whereas the control group will receive orthodontic intervention (DELAYED) 3 months after periodontal surgery.
223507993|NCT01227395|DRUG|Azithromycin|"Inhibition of onset: Perorally administer 1200mg of azithromycin (potency) once a week to adults.~Treatment: Perorally administer 600mg of azithromycin (potency) once a day to adults."
223507994|NCT00593255|DRUG|soluble human insulin|
223507995|NCT00593255|DRUG|insulin aspart|
223751364|NCT05887882|OTHER|Quality-of-Life Assessment|Ancillary studies
223751365|NCT00031889|DRUG|Exemestane|Exemestane
223751366|NCT00031889|DRUG|Exemestane+bicalutamide|Exemestane as in arm I and oral bicalutamide once daily
224200282|NCT02585375|DRUG|Preserved latanoprost 0.005%|
224200283|NCT03073291|BEHAVIORAL|Responsible Marijuana Vendor Training|Employees at retail recreational marijuana stores assigned to the the responsible marijuana vendor training will register them on TrainToTend online training program, create a user profile, and complete the training within four weeks from initial registration. Personnel who complete the training will receive a certificate of completion. New hires at the stores during the trial will be registered and complete the training within four weeks of commencing work. Separate versions of the training will be available reflecting differences in the laws/regulations on recreational marijuana sales in Colorado, Oregon, and Washington State and the content will be reviewed and approved by state regulators.
223751367|NCT03463746|DEVICE|LYRA® gait trainer|The EG will get standard individual physical therapy (5x/week, 45min) whereby three sessions of electromechanical-assisted gait training on LYRA® gait trainer.
223751368|NCT03463746|DEVICE|Standard individual physical therapy|The CG will get standard individual physical therapy (5x/week, 45min) without any instrument-based locomotion therapy (i.e. treadmill training, electromechanical/robot-assisted gait training).
223751369|NCT03843879|PROCEDURE|Transversus Abdominis Plane Block|Single-injection transversus abdominis plane block with 30 mL of 0.25% Bupivacaine with 1:400,000 epinephrine
223751370|NCT03843879|DRUG|Intravenous Lidocaine|Continuous intravenous lidocaine infusion
223751371|NCT01660854|BIOLOGICAL|Heterologous challenge|challenge by the bites of 5 Plasmodium falciparum infected mosquitoes.
223751372|NCT01660854|DRUG|Malarone treatment|Three days: 4 tablets 250/100mg per day
223751373|NCT05213923|PROCEDURE|ED Sepsis Tracking Sheet|Implementation of an ED Sepsis Tracking Sheet. This sheet will track time of patient presentation, time of High-Acuity Medical Response (HAMR) page, time of bilateral 18g or larger IV access, time of initial lactate, time two sets of blood cultures were sent, time antibiotics were administered as well as which antibiotics and what dose, time initial IV fluid bolus was completed, time repeat lactate was sent, timing of post-IV-fluid bolus vital signs, as well as the presence of persistent hypotension following this IV fluid bolus and whether or not vasopressors were applied.
223751374|NCT01093911|BIOLOGICAL|CDP7657|Ascending single doses of CDP7657
223751375|NCT01093911|OTHER|Placebo|Placebo: 0.9% sodium chloride aqueous solution
223751376|NCT05044455|BEHAVIORAL|Cognitive Behavioural Therapy (CBT)|A 9 week CBT group, 2 hours weekly, is delivered by trained Peer facilitators to mothers randomized to this arm.
223751377|NCT01586819|DRUG|Botulinum Toxin|"The botulinum toxin will be injected into the wrinkles crow's feet. The injections will take about 10 minutes to complete."
223751378|NCT01586819|PROCEDURE|Chemical Peel Only|After cleansing the face with a pre-treatment cleansed composed of water and alcohol, the Jessner's peel solution \[a combination of resorcinol (14g), salicylic acid (14g), and lactic acid (85%) in ethanol (95%)\] will be applied to the entire face with a large cotton swab. The mixture will be left in place for a few minutes, and then the face will be wiped clean with water. Next, the TCA peel \[35% Trichloroacetic acid\] will be applied around the eyes. After leaving in place for a few minutes, cool, iced washcloths will be applied and the face will be wiped clean with water. Wound care regimen will consist of dilute acetic acid and either Aquaphor or petroleum jelly.
223751379|NCT05696912|GENETIC|Ex-vivo approach concerning 25 patients|Ex-vivo approach concerning 25 patients with blood sample in PAXgene tubes or skin biopsy and RNA-Seq analysis
223751380|NCT05696912|GENETIC|In-vitro approach concerning 25 patients|In-vitro approach concerning 25 patients without specific samples needed for analysis in minigene or luciferase assay
223751381|NCT00433823|DRUG|Atorvastatin, Ezetimibe|
223751382|NCT01544751|DRUG|Low dose metformin|500 mg twice a day
223751383|NCT01544751|DRUG|Metformin|1000 mg twice a day
223751384|NCT01544751|DRUG|Atorvastatin|20 mg/day
223751385|NCT01359254|DRUG|Melphalan|Melphalan is given daily for 2 days, overlapping with the completion of fludarabine.
223751386|NCT01359254|DRUG|Fludarabine|Fludarabine is given through the vein daily for 5 days.
223751387|NCT01359254|DRUG|Antithymocyte Globulin (ATG)|ATG is given every other day for 4 days.
223751388|NCT01359254|DRUG|Busulfan|Busulfan is given daily for 4 days.
223751389|NCT01359254|DRUG|Total Body Irradiation (TBI)|TBI is given twice on the last day.
223751390|NCT01203228|OTHER|Reduced Intensity Conditioning|"Busilvex®:~6.4 mg/kg IBW i. v. day -7: 0.8 mg/kg IBW x 4 (2 hour infusion every 6 hours) day -6: 0.8 mg/kg IBW x 4 (2 hour infusion every 6 hours)~or (if i.v.-application is not available)~Busulfan:~8.0 mg/kg BW p. o.: day -7: 4.0 mg/kg BW day -6: 4.0 mg/kg BW~plus:~Fludarabine:~5 x 30 mg/m² BS i. v.: day -7: 30 mg/m² BS day -6: 30 mg/m² BS day -5: 30 mg/m² BS day -4: 30 mg/m² BS day -3: 30 mg/m² BS"
223751391|NCT01203228|OTHER|Myeloablative conditioning|"Busilvex®:~12.8 mg/kg IBW i. v.; day -9: 0.8 mg/kg IBW x 4 (2 hour infusion every 6 hours) day -8: 0.8 mg/kg IBW x 4 (2 hour infusion every 6 hours) day -7: 0.8 mg/kg IBW x 4 (2 hour infusion every 6 hours) day -6: 0.8 mg/kg IBW x 4 (2 hour infusion every 6 hours)~or (if i.v.-application is not available):~Busulfan:~16.0 mg/kg BW p. o.; day -9: 4.0 mg/kg BW day -8: 4.0 mg/kg BW day -7: 4.0 mg/kg BW day -6: 4.0 mg/kg BW~plus:~Cyclophosphamide:~120 mg/kg BW i. v.; day -4: 60 mg/kg BW day -3: 60 mg/kg BW"
223751392|NCT04896710|DEVICE|SD Biosensor|Nasal swab SD biosensor to be self administered
223751393|NCT01571895|DRUG|DF2156A|DF2156A is a novel small molecule that inhibits the biological activity of the CXC ligand 8 \[CXCL8; formerly interleukin (IL)-8\] through inhibition of the activation of CXCL8 receptors: CXCR1 and CXCR2. This specific inhibitor stems from a program of drug design of molecules intended to modulate chemokine action.
223751394|NCT01296295|BEHAVIORAL|Lifestyle counseling and spirometry|The patients of the intervention group will be given a brief structured smoking cessation advice by their primary care physician combined with a detailed and structured discussion of the spirometry results.
223751395|NCT01296295|BEHAVIORAL|Smoking cessation advice|Brief smoking cessation advice
223751396|NCT04390594|DRUG|Nafamostat Mesilate|"Nafamostat mesilate continuous intravenous injection. Daily dose ranging between 0.1 mg/kg/h and 0.2 mg/kg/h, based on the severity and underlying disease of the clinical trial participant.~Administration for 10-14 days based on the severity and underlying disease of the clinical trial participant"
223751397|NCT01457885|DRUG|Clofarabine/Busulfan x 4|"* Clofarabine IV dose level: 40 mg/m2/day x 5 days~* Busulfan IV dose level: 3.2 mg/kg daily x 4 days"
223751398|NCT01457885|PROCEDURE|Peripheral blood stem cell transplant|Peripheral blood stem cell transplant, after pre-conditioning drug treatment
223751399|NCT01024907|RADIATION|proton beam radiation therapy|Undergo radiation
223751400|NCT01024907|PROCEDURE|quality-of-life assessment|Ancillary study
223751401|NCT01024907|OTHER|questionnaire administration|Ancillary study
223751402|NCT03379207|OTHER|Blood samples|Blood samples for research purpose, taken whenever possible during blood sampling for routine purpose
223751403|NCT03379207|OTHER|Tracheal Aspirates|Only for mechanically ventilated participants.
223751404|NCT03379207|OTHER|Surplus of Broncho-alveolar lavage fluid|Only if performed for diagnosis purpose by the treating investigator : indication left at his discretion
223603690|NCT00858637|DRUG|Placebo of Simvastatin|Tablets once a day, for 16 weeks of Active Comparison Phase, and 4 weeks of fixed dose during Withdrawal Phase (Week 16 to Week 20)
223603691|NCT00858637|DRUG|Simvastatin|Tablets of 10 mg to 40 mg/day (once a day) with dose escalation design during 16 weeks of Active Comparison Phase, and 4 weeks of fixed dose during Withdrawal Phase (Week 16 to Week 20)
223603692|NCT00858637|DRUG|Placebo of MCI-196|Tablets 3 times a day for 16 weeks of Active Comparison Phase, and 4 weeks of fixed dose during Withdrawal Phase (Week 16 to Week 20)
223603693|NCT00289081|DEVICE|Total Knee Replacement|Rotating Platform (RP) Cruciate Retaining Knee implant
223603694|NCT00289081|DEVICE|Total knee replacement|Rotating Platform (RP) Cruciate Substituting Knee implant.
223603695|NCT05813002|OTHER|standard neural mobilization|is a movement-based intervention aimed at restoring the homeostasis in and around the nervous system.
223603696|NCT05813002|OTHER|Distal to proximal neural mobilization|is a distal to proximal movement-based intervention aimed at restoring the homeostasis in and around the nervous system.
223603697|NCT05813002|OTHER|proximal to distal neural mobilization|is a proximal to distal movement-based intervention aimed at restoring the homeostasis in and around the nervous system.
223603698|NCT02642380|DRUG|Dexamethasone (4 cycles)|dexamethasone 40mg daily for 4 consecutive days every 14 days for 4 courses
223751405|NCT03745092|DEVICE|normobaric oxygen|Normobaric oxygen (NBO) is a routine adjuvant hyperoxygenation intervention supplied by facemask (such as Venturi mask), with one atmosphere pressure (1ATA=101.325kPa).
223751406|NCT03745092|DEVICE|room air|The patient had a rest with lying, sitting or walking, did not performed with NBO intervention.
223751407|NCT02227342|BIOLOGICAL|Fecal Microbiota Transplant|serial FMT
223751408|NCT03979638|DRUG|BLU-5937|Four escalating doses of BLU-5937 administered BID over the course of the study
223751409|NCT03979638|DRUG|Placebo|Matching placebo for BLU-5937
223603699|NCT02642380|DRUG|Dexamethasone (1 cycle)|dexamethasone 40mg daily for 4 consecutive days
223603700|NCT03931694|DEVICE|e-DOL|e-health program (smartphone and web platform)
223603701|NCT02487004|DEVICE|hemodialysis|
223603702|NCT03263338|BEHAVIORAL|Mobile Sleep and Growth Study|The intervention is designed to test if sleep tips delivered by text messages can aid with reaching time in bed targets. And if additional motivational text messages can further aide with reaching time in bed targets.
223603703|NCT04083157|BIOLOGICAL|Intradermal hepatitis B vaccine with imiquimod|Intradermal hepatitis B vaccine with topical imiquimod pretreatment
223751410|NCT04255355|OTHER|Pelvic alignment and forceful expiration|"The participant will be in supine with feet flat on a wall and the knees and hips flexed to 90 degrees. A standard 5 ball will be placed between the knees. The participant will hold a standard 9-inch balloon in the mouth with one hand. The subject will be instructed to isometrically contract the hamstrings to lift the ischium off the table while maintaining a posterior pelvic tilt. In this position, subject will be instructed to perform isometric hip adduction by squeezing the ball placed between the knees. The subject will then be instructed to breathe in through the nose and blow the air out into the balloon with full exhalation to activate the transverse and oblique abdominals. The participant will hold the breath for 3 seconds while maintaining hamstring contraction, adductor contraction, and transverse and oblique abdominal contraction. This process will be repeated four times. This exercise will be performed once daily under the supervision of the therapist for 5 days."
223751411|NCT04255355|OTHER|Pelvic repositioning exercise|The participant will be positioned supine with their feet flat on a wall and the knees and hips flexed to 90 degrees. The subject will be instructed to isometrically contract the hamstrings to allow the ischial tuberosities to lift off the table while also maintaining a posterior pelvic tilt. The tailbone should be slightly lifted off the table, the abdominal muscles should be relaxed, and the low back should be flat on the table. While maintaining the posterior pelvic tilt, the subject will be instructed to perform isometric hip adduction by squeezing the ball that is placed between the knees. The subject will hold for 3 seconds and then relax. This process will be repeated four times. This exercise will be performed daily under the supervision of the therapist for 5 days.
223751412|NCT04255355|OTHER|Diaphragmatic breathing exercise|For diaphragmatic breathing exercise, the subject will be in supine position. The investigator places both hands around the participant's lower ribs and abdominal area. The investigator applies slight manual resistance to the chest and abdominal wall during inhalation phase of breathing.The participant is instructed to apply outward pressure against the investigator resistance and to raise the chest and abdominal wall simultaneously with inhalation. Then participants performs a full exhalation and hold his/her breath for 3 seconds before breathing in again. This process is repeated for 4 breathing cycles. Participants will perform this exercise once a day under investigator supervision.
223507996|NCT00593255|DRUG|insulin NPH|
223507997|NCT03964129|PROCEDURE|Avance Nerve Graft with Autologous BMAC|The Avance Nerve Graft will be inserted in the area of nerve injury. Between 40 to 60 ml of Bone Marrow Aspirate from the anterior or posterior iliac crest of the pelvis will be harvested. Using SmartPrep centrifuge and 60 ml BMAC kit, 7 to 10 ml of final BMAC will be obtained. Of the 7 to 10 ml of final BMAC that is yielded, half (3.5 to 5 ml) of the final concentrate, will be injected on top of the Avance Nerve Graft following coaptation. The second half (3.5 to 5 ml) of the final concentrate will be inserted into a sterile tube containing culture media and shipped overnight to Cleveland Clinic Lerner Research Institute for cell processing and colony assay to confirm that the BMAC indeed contains autologous bone marrow stem cells.
223507998|NCT01090206|DIETARY_SUPPLEMENT|Vitamin D and calcium|Doses will be based on Vitamin D levels
223507999|NCT00668408|OTHER|LTOT (oxygen therapy)|Patients on LTOT will receive oxygen for at least 15 hours/day from the liquid oxygen systems at a flow rate adjusted to raise resting SaO2 between 93 and 96% and / or PaO2 between 65 and 80 mmHg every day for 3 years.
223603704|NCT04083157|BIOLOGICAL|Intramuscular hepatitis B vaccine with aqueous cream|Intramuscular hepatitis B vaccine with topical aqueous cream pretreatment
223603705|NCT00888342|DRUG|supplementary oxygen|Supplementary oxygen 2 L/min if SpO2 \< 90%. If SpO2 \< 90 % the oxygen dose is titrated until SpO2 reads 88-92%. For patients on LTOT the oxygen dose is doubled for intervention.
223603706|NCT00888342|DRUG|zopiclone|5 mg sedative given approximately 1 hour before sleep
223603707|NCT00888342|OTHER|alcohol|5 mg alcohol/kg body-weight approximately 1 hour before sleep
223603708|NCT01898013|DRUG|Pregnenolone|
223603709|NCT01898013|DRUG|Placebo|
223603710|NCT05547308|DEVICE|3D myoelectric prosthetic device|All subjects will use the 3D Prosthetic device and complete a variety of quality of life questionnaires.
223603711|NCT05351866|DEVICE|CBT-based mobile intervention for depression|SparkRx is a 5-week program divided into levels intended to be completed weekly. SparkRx is a behavioral activation program. Participants are instructed to complete a weekly Patient Health Questionnaire (PHQ)-8 assessment and participant symptom check (PSC) in the mobile app. Tasks in the mobile app progress in a linear fashion (i.e., each task must be completed to progress to the next task).
223603712|NCT05351866|DEVICE|Mobile control with education about depression|The control mobile application will consist of 5 weeks of educational content about depression. Participants will be instructed to complete a weekly Patient Health Questionnaire (PHQ)-8 assessment and PSC in the mobile app.
223751413|NCT01064492|DRUG|PF-04620110|The three treatments are A) a single dose of 5 mg PIC under fasted condition; B) a single dose of 5 mg tablet under fasted condition: and C) a single dose of 5 mg tablet under fed condition.
223751414|NCT04130399|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|Patients will receive 5 fractions of SBRT delivered over a five-day period. Treatment may be delivered over 2 weeks, provided that the patient receives at least 2 fractions per week.
223751415|NCT04130399|DRUG|FOLFIRINOX|Participants in this trial will receive neoadjuvant and adjuvant FOLFIRINOX chemotherapy for 6 cycles (1 cycle = 14 days) per routine guidelines
223751416|NCT05112380|OTHER|Performing Xco endurance test|The subjects will perform the test two times, with 7-10 days between the two sessions
223751417|NCT02576028|OTHER|Fascial Manipulation® (FM)|Fascial Manipulation® (FM) is a manual therapy that focus on the deep muscular fascia. This technique considers the fascia as a three-dimensional continuum. The mainstay of this manual technique lies in the identification of specific localised areas of the fascia, defined Center of Coordination (CC), where the gliding of the subcutis should be preserved to avoid biomechanical in-coordination of the surrounding muscles. The method is performed by applying a deep friction over the CCs that result more altered at the clinical palpation
223751418|NCT02576028|OTHER|standard active exercises|two sessions of 45 minutes of active exercises
223751419|NCT00272571|PROCEDURE|External counter pulsation therapy|
223751420|NCT02620514|BEHAVIORAL|Education and Reminders|Participants with inflammatory bowel disease (IBD) will complete health-literacy surveys to assess medication adherence. Participants will be provided education materials, and will receive scheduled educational reminder phone calls and text messages at 2,6,12, and 24 weeks from the baseline assessment.
223751421|NCT02620514|BEHAVIORAL|Educational Visit|Participants with inflammatory bowel disease (IBD) will complete health-literacy surveys to assess medication adherence.Participants will undergo one scheduled visit with a nurse practitioner or physician for education about inflammatory bowel disease (IBD) after the baseline assessment.
223751422|NCT02620514|BEHAVIORAL|Medication Educational Visit|Participants with inflammatory bowel disease (IBD) will complete health-literacy surveys to assess medication adherence. Participants will undergo one scheduled visit with a nurse practitioner or physician to discuss medication side effects and medication inadequacy after the baseline assessment.
223751423|NCT02620514|BEHAVIORAL|Financial Support|Participants with inflammatory bowel disease (IBD) will complete health-literacy surveys to assess medication adherence. Participants will receive information about patient assistance programs, copay cards, and a scheduled meeting with a social worker or financial advisor.
223751424|NCT03465332|OTHER|Doctor's questionnaire|The survey of physicians will be performed using doctor's questionnaire, which will be developed by lung specialists who are not participating in the survey.
223751425|NCT03465332|OTHER|Subject file|All subject-based data will be obtained by retrospective evaluation of subject files available at the treating lung specialist.
223751426|NCT00713336|DRUG|ZD4054|ZD4054 10mg Tablet
223751427|NCT00713336|DRUG|Moxifloxacin|400 mg capsule
223751428|NCT00713336|DRUG|ZD4054 Placebo|3 tablets
223751429|NCT00713336|DRUG|Moxifloxacin placebo|1 capsule
223751430|NCT00713336|DRUG|ZD4054 Placebo|2 tablets
223603713|NCT05311787|PROCEDURE|esophagectomy with simultaneous reconstruction|Subtotal resection of esophagus and simultaneous reconstruction by gastric pull-up or colon conduit
223603714|NCT01957410|DRUG|Ketamine|During Cohorts 1 and 2, a single ketamine 0.5 mg/kg dose will be given as a continuous IV infusion over 40 minutes by use of an electronic syringe infusion pump. The predefined dose and infusion rate/duration should not be adjusted. If a patient is unable to tolerate the study medication, the infusion should be stopped. Within 1 week of completion of the open-label treatment phase, participants can receive a single dose of ketamine 0.5 mg/kg administered as an IV infusion over 40 minutes during an optional open-label treatment phase.
223603715|NCT01957410|DRUG|Placebo|During Cohort 2, a single placebo dose will be given as a continuous IV infusion over 40 minutes by use of an electronic syringe infusion pump. Within 1 week of completion of the double-blind treatment phase, participants can receive a single dose of ketamine 0.5 mg/kg administered as an IV infusion over 40 minutes during an optional open-label treatment phase.
223751431|NCT00713336|DRUG|ZD4054|30mg tablet
223751432|NCT00713336|DRUG|ZD4054|10mg tablet
223751433|NCT01416727|OTHER|Emergency Psychiatry Immersion Course|A two-day simulation-based training course covering assessment of self-harm, capacity, managing aggression, working with the emergency team and medical emergencies in the psychiatric hospital
223751434|NCT01416727|OTHER|Observed SKills in the Emergency Room|For four weeks, participants will be accompanied by a senior psychiatric registrar or consultant psychiatrist, who has received training in giving feedback, during their on-call duties. Each participant will receive between 8-12 hours of 1:1 training.
223751435|NCT03341195|BEHAVIORAL|SMS messages and automated calls|The intervention consists of SMS and automated calls based messages
223751436|NCT01983579|PROCEDURE|Intraocular anti-VEGF injection|
223751437|NCT01983579|DEVICE|SENSIMED Triggerfish|
223751438|NCT04248933|BEHAVIORAL|Peer-Delivered Behavioral Activation (Peer Activate)|The Peer Activate intervention consisted of weekly one-hour BA sessions led by a peer recovery specialist (PRS) for up to 12 weekly sessions, with the first five being the core treatment sessions and content, and the subsequent seven designed to reinforce core content. In these sessions, participants received individualized support in learning skills to assist in their retention and persistence in methadone treatment and were guided through exercises aimed at incorporating substance-free, rewarding activities into their daily life.
223751439|NCT04010721|DEVICE|Experiment 1|Stimulation of one electrode at a time
223751440|NCT04010721|DEVICE|Experiment 2:|Stimulation in groups of 4, 8 and 12 electrodes
224200284|NCT05090046|OTHER|Trauma exposure|Exposure to the Canterbury earthquake sequence and other relevant psychological trauma
223603716|NCT03761342|BEHAVIORAL|Multiple Traffic Light Label|The United Kingdom's Multiple Traffic Light label has repeatedly demonstrated effectiveness and has been widely implemented in Europe. The label shows how much calories, fats, saturated fats, sugar and salt are present in a product, with associated traffic light signals for high (red), medium (amber) and low (green) percentages for each attribute.
224200285|NCT06401317|DRUG|Saline Hypertonic Solution|Ultrasound-guided intra-articular injection of 0.25ml of 0.9% saline solution.
223508000|NCT00668408|OTHER|Pharmacological therapy of COPD and CHF|"Optimal pharmacologic treatment will include :~* Long (LABD, salmeterol, formoterol, tiotropium) - as well as short-acting (SABD, Salbutamol, terbutaline, ipratropium)bronchodilators (beta-2 agonists, anticholinergics)~* Inhaled steroids (ICS, beclomethasone, fluticasone, budesonide always associated with LABD)~* Beta-blockers~* Diuretics~* Angiotensin-converting enzyme (ACE) inhibitors alone or in associations with diuretics~* Statins and any other treatment required for associated co-morbidities (eg insulin and/or anti-diabetic drugs, other antihypertensive, etc).~The treatment of the deseases will follow the international guidelines."
223603717|NCT03761342|BEHAVIORAL|Nutri-Score Label|In late 2017, France began voluntary implementation of one FOP label, termed Nutri-Score, adapted from its predecessor, the 5-colour Nutrition Label. Consumer acceptability and understanding of the NS label has been demonstrated in several studies. It provides a letter score as a composite grade of a product's nutrition quality from A (best) to E (worst).
223603718|NCT02322970|DEVICE|transcranial Doppler|Comparison of non invasive intracranial pressure (through use of transcranial Doppler ) vs invasive monitoring (through insertion of intracerebral catheters) with the purpose of comparing these two techniques in terms of specificity and sensitivity.
223603719|NCT05118399|DRUG|Bupivacaine Injection [Marcaine]|Bupivacaine injection \[Marcaine\] is the standard treatment used in our hospital.
223603720|NCT05118399|DRUG|Bupivacaine Liposome 13.3 MG/ML [Exparel]|Bupivacaine liposome is a multivesicular formulation of bupivacaine that allows rapid absorption and prolonged release of bupivacaine.
223603721|NCT01481077|DRUG|Latanoprost-PPDS|Sustained release for 12 weeks
223603722|NCT05266677|OTHER|blend of glycerides at certain proportions|combination of glycerides in specific proportions in a liquid oral supplement
223603723|NCT05266677|OTHER|glycerides used in current formulas|glycerides used in current formulas in a liquid oral supplement
223603724|NCT04677504|DRUG|Atezolizumab|Atezolizumab will be administered intravenously at a fixed dose of 1200 mg on Day 1 of each 21-day cycle.
223603725|NCT04677504|DRUG|Bevacizumab|Bevacizumab will be administered at a dose of 15 mg/kg intravenously on Day 1 of each 21-day cycle after atezolizumab.
223603726|NCT04677504|OTHER|Placebo|Placebo matching bevacizumab will be administered intravenously on Day 1 of each 21-day cycle after atezolizumab.
223603727|NCT04677504|DRUG|Cisplatin|Cisplatin will be administered intravenously at a dose of 25 mg/m\^2 on Days 1 and 8 of each 21-day cycle for Cycles 1-8.
223603728|NCT04677504|DRUG|Gemcitabine|Gemcitabine will be administered intravenously at a dose of 1000 mg/m\^2 on Days 1 and 8 of each 21-day cycle for Cycles 1-8.
223603729|NCT00082914|BIOLOGICAL|denileukin diftitox|
223603730|NCT05466357|PROCEDURE|Excision of pituitary tumor outside pseudocapsule|Dedicated high-resolution magnetic resonance imaging (MRI) protocols have been proposed to detect pituitary adenoma and accurately guide surgical removal. To accomplish complete PA removal and minimize the impact on pituitary functions, intraoperative navigation was used to identify the tumor pseudocapsule. Depending on different tumor sizes and pseudocapsule development, investigators adopted different resection strategies. The suspicious tissue was sent to the pathology department for histopathology intraoperatively. Long-term postoperative follow-up imaging and endocrine data were used to evaluate tumor prognosis before and after operation. Standardized management and established biobank is critical for pituitary adenomas.
223603731|NCT03182907|BIOLOGICAL|Bezlotoxumab|A single intravenous (IV) infusion of 10 mg of bezlotoxumab per kg body weight. Dose may then be changed based on results from initial 12 participants.
223603732|NCT03182907|DRUG|Placebo|A single IV infusion of placebo for bezlotoxumab consisting of either 0.9% sodium chloride or 5% dextrose.
223603733|NCT03182907|DRUG|Antibacterial drug treatment (ABD)|ABD will be administered for 10-21 days including the duration of ABD prior to the screening visit, during the screening period, and after the infusion of study treatment, per institutional guidelines, at the investigator's discretion. ABD is defined as the receipt of oral metronidazole, oral vancomycin, intravenous (IV) metronidazole concurrent with oral vancomycin, oral fidaxomicin, or oral fidaxomicin concurrent with IV metronidazole.
223603734|NCT04161261|PROCEDURE|Electrical Stimulation|To measure the facial nerve stimulation threshold for one mid-array and one apical electrode of the implant using the pulse-train stimuli
223603735|NCT02183233|DRUG|Eschscholtzia Californica|
223603736|NCT02183233|DRUG|Eschscholtzia Californica Placebo|
223603737|NCT02513576|OTHER|physiotherapy exercises|Consisted of trunk stabilization exercises.The exercises were undertaken for 15 minutes every day for tree weeks. Patients were the contract their abdominal muscles with an emphasis on the transverse abdominal. Patients were to contract their abdominal muscles in a supine,sitting and stand up position.
223603738|NCT04044742|DRUG|Resiniferatoxin|Receiving Resiniferatoxin injection
223603739|NCT04044742|DRUG|Placebo|Receiving Placebo injection
223603740|NCT03897855|OTHER|Post Traumatic Stress Disorder|"The test Think / No-Think"
223603741|NCT05914207|BEHAVIORAL|Lifestyle modifications|Written suggestions on lifestyle modifications including duration of sleep, meal frequency, reduce screen time, exercise duration, food to avoid.
223751441|NCT04010721|DEVICE|Experiment 3|Stimulation total duration from 10 to 600 ms
224200286|NCT06401317|DRUG|Triamcinolone Acetonide|Ultrasound-guided intra-articular injection 0.25ml (10 mg) of triamcinolone.
224200287|NCT06389825|OTHER|Healthy diet|28-day fully controlled dietary intervention during which participants will receive a diet that reflects the recommendations of Canada's Food Guide.
224200288|NCT05418517|PROCEDURE|Tracheostomy|temporary tracheostomy insertion
224200289|NCT05418517|PROCEDURE|Overnight intubation|Patient who had overnight intubation
223603742|NCT05914207|OTHER|Vestibular rehabilitation exercise|Each participant will be taught simple home-based vestibular rehabilitation exercise, which needs to be repeated
223751442|NCT04196946|DRUG|25 mcg fentanyl|Before operation each patient was informed about the use of patient controlled analgesia system and visual pain scale (VPS) for pain scoring. In operating room all patient was monitored using electrocardiography (ECG), noninvasive blood pressure. Before spinal anesthesia 10-15 ml/kg intravenous serum saline infusion was started. Group I received 10 mg hyperbaric bupivacaine (2 cc) and 25 mcg fentanyl (0.5 cc).
223603743|NCT03747640|DEVICE|Self Transcranial Direct Current Stimulation (tDCS)|tDCS with a constant current intensity of 2 milliamps (mA) will be applied for 20 minutes per session daily for 2 weeks (Monday to Friday) via the Soterix 1x1 tDCS mini-CT Stimulator device (Soterix Medical Inc., New York; 6.5 inches long, 3 inches wide, 0.7 inches thick) with headgear and 5x7 cm saline-soaked surface sponge electrodes.
223603744|NCT03747640|BEHAVIORAL|mindfulness-based meditation|The meditation intervention will be delivered by a recorded device that participants will be given together with the tDCS. All meditation instruction recordings will be done by an experienced mind-body intervention specialist and installed in a user-friendly MP3 player.
223751443|NCT04196946|DRUG|250 mcg alfentanil|Before operation each patient was informed about the use of patient controlled analgesia system and visual pain scale (VPS) for pain scoring. In operating room all patient was monitored using electrocardiography (ECG), noninvasive blood pressure. Before spinal anesthesia 10-15 ml/kg intravenous serum saline infusion was started. Group II received 10 mg hyperbaric bupivacaine (2 cc) and 250 mcg alfentanil (0.5 cc) intrathecally.
223751444|NCT04391387|PROCEDURE|prone position|a position with the patient lying face down with arms bent comfortably at the elbow and padded with the armboards positioned forward
223751445|NCT03569332|OTHER|Alarm|"1. Alarm is provided from 9am to 9pm.~2. Alarm is active every 50 minutes if the exercise goal(10 times/hour) hasn't satisfied."
223751446|NCT03569332|OTHER|Nurse's dashboard|"1. Wireless data transmission system~2. The practicing rate of participants on study group is sent to Nurse's Dashboard.~3. It is only to display."
223751447|NCT04874974|BEHAVIORAL|Metacognitive and Defusion Training|Module I will give a brief introduction into the rational of the therapy and explain the terms cognitive biases and relational responding and their role in the development of psychological problems (psychosis) in a simple language and with the help of examples and small exercises. The principle of metacognition and cognitive defusion in psychotherapy will be made clear. An outlook on the procedures and the goals of the group therapy will be given. Module II will include interventions adapted from the MCT manual (Moritz et al., 2017) and Module III with consist of defusion strategies taken from the ACT group manual (Dambacher et al., 2020) and existing studies on ACT and psychosis (Bach et al., 2013; Gaudiano \& Herbert, 2006).
223751448|NCT01422863|BEHAVIORAL|Lifestyle Intervention|Participants undergo 3 months of monitored exercise, consisting of aerobic and resistance training (3 days per week for 1 hour). Participants will also meet with a registered dietician, who will prescribe an American Heart Association low fat diet. The goal is to achieve a 1-2 lb weight loss per week.
223751449|NCT05004376|BEHAVIORAL|Text Messaging|Text messages based on behavioral theory to encourage scheduling colorectal cancer screening.
223603745|NCT03747640|DEVICE|Sham Self Transcranial Direct Current Stimulation (tDCS)|For sham stimulation, the electrodes will be placed in the same positions as for active stimulation, but the stimulator will only deliver 2 mA current for 30 seconds.
223603746|NCT03747640|BEHAVIORAL|sham meditation|For sham meditation, the participants will be instructed, approximately every 2-3 minutes, to take deep breaths as we sit in meditation. Time spent giving instructions in the sham meditation intervention will be matched to time spent in the mindfulness intervention.
223603747|NCT06279507|DRUG|Sodium Hyaluronate|Sodium hyaluronate 2% (40 mg/2 mL), with molecular weight of 1-2 million dalton Other active ingredient : Mannitol 0.5% Preparation : Pre-filled syringe
223603748|NCT06279507|DRUG|Normal Saline|0.9% sodium chloride 2 mL prepared in plastic syringe
223751450|NCT01087047|DEVICE|Acoustic reflection method|An acoustic reflection device gives the longitudinal cross-sectional area profile along airways. It is based on the analysis of a planar acoustic wave propagating in a rigid duct connected to airway.
223751451|NCT04026607|DIETARY_SUPPLEMENT|Protein Supplementation|Participants will continue to ingest the standardized diet; however, supplements will be consumed twice daily (25g per serving x 2 servings/day or 50g supplemental protein/day)
223751452|NCT02038595|RADIATION|PET imaging|
223751453|NCT05184374|DRUG|Gonadorelin|GnRH pump pulse subcutaneous injection of gonadorelin in a month
223751454|NCT06162156|OTHER|Back massage|For the intervention group, massage will be given to the participant's back area by the researcher for 20 minutes, 12 hours after the cesarean birth. Preliminary data forms will be filled out by the participant before the massage. One hour after the massage, 'Visual Analog Scala' and 'Physiological Parameter Form' data will be filled in again. The final data forms will be filled out by the participant 24 hours after the cesarean birth, that is, 12 hours after the back massage.
223751455|NCT04666064|DIAGNOSTIC_TEST|Covid19 RT-PCR|patients admitted to ER for suspicion of COVID-19 infection will have a SARS-CoV-2 RT-PCR test
223751456|NCT04666064|OTHER|lung ultrasound|patients admitted to ER for suspicion of COVID-19 infection who has a SARS-CoV-2 RT-PCR test and for whom the emergency doctor decide to perform a lung ultrasound
224200290|NCT02623530|OTHER|Educational intervention|"Control Group: An educational intervention focusing on first aid for the development of skills and dispositions of critical thinking. For this group will be taught the contents of first aid through the Methodology of PBL without the support MEAPC.~Experimental Group: An educational intervention focusing on first aid for the development of skills and dispositions of critical thinking. For this group will be taught the contents of first aid through Methodology PBL, supported by the MEAPC."
223603749|NCT06279507|DRUG|Triamcinolone Acetonide 10mg/mL|10 mg of triamcinolone acetonide will be injected to all participants before the specified intervention
223603750|NCT02735954|OTHER|Marijuana|This is an observational study looking at the effects of marijuana on health, including lung health and sleep.
223603751|NCT03801603|BEHAVIORAL|HPV vaccination training and education|1\) Training of providers and clinic staff on the importance of providing a strong HPV vaccination program and 2) HPV vaccination education for parents and the community.
223603752|NCT01265303|DEVICE|Prolonged telemetric Full Disclosure ECG recording.|Continuous Full Disclosure Telemetric ECG monitoring lasting 14 days
223603753|NCT06121024|PROCEDURE|Interventional Bronchoscopy|Bronchoscopy offers vital information when evaluating patients suffering from tracheal stenosis. It enables direct visualisation which identifies the lesion, determines its location and extent of airway involvement, highlights vascularity and fragility, allows for tissue diagnosis and enables the operator to assess the extent of mucosal infiltration and airway compression caused by the tumour. The technique facilitates assessment of stenosis diameter for suitable stent selection. In addition to enabling diagnostic bronchoscopy, rigid bronchoscopy offers therapeutic options such as dilatation, cryotherapy and stenting for tracheal stenosis patients. Our clinical setting employs rigid bronchoscopy for interventional procedures with both diagnostic and therapeutic aspects.
223603754|NCT04836884|PROCEDURE|Percutaneous Vascular Anomaly/Malformation Biopsy|US-guided percutaneous vascular anomaly core needle biopsy of up to 10 cores using an 18-gauge co-axial core needle biopsy device at the time of clinically indicated sclerotherapy, embolization or ablation treatment.
223603755|NCT00637962|BIOLOGICAL|HIV glycoprotein CN54gp140 (vaccine)|vaginal immunisation with 100ug CN54gp140 antigen in gel on 9 occasions in one menstrual cycle
223603756|NCT00637962|BIOLOGICAL|Carbopol 974|vaginal immunisation with Carbopol 974 P 0.924%; benzyl alcohol 1.09%; sodium hydroxide 0.176%; and purified water 97.81%. alone on 9 occasions in one menstrual cycle
223751457|NCT02586896|BEHAVIORAL|Strengths-based Case Management (SBCM)|The six case management sessions for the proposed trial are based on those described in manuals developed by Dr. Rapp for two clinical trials, one supported by National Institute on Drug Abuse (NIDA) and another by the Centers for Disease Control (CDC). Each session is guided by specific objectives that promote linkage with and retention in substance abuse treatment, particularly pharmacotherapy for opioid dependence in a specialty or primary care setting. Objectives from the earlier trials will be adapted to fit the specific context of this trial, linking with and staying in treatment following an emergency department visit. Initiation of the relationship between client and case manager begins immediately following random assignment and termination takes place when either (1) six sessions have occurred; (2) ninety days have elapsed; or (3) clients discontinue involvement.
223751458|NCT02586896|BEHAVIORAL|Screening, Assessment, and Referral (SAR)|"The research assistant will provide these participants with an information sheet listing treatment (including both specialty treatment centers and primary care clinics that provide buprenorphine) and self-help resources in their community. The referral sheet includes names, addresses, and phone numbers of local addiction treatment agencies. Because the emergency department does not currently screen or refer systematically, the SAR condition represents a level of care significantly higher than treatment as usual. Participants will also receive an informational pamphlet about drug use and its consequences, addiction, and treatment."
223751459|NCT01166477|DRUG|Lopinavir and ritonavir|The patients will take Kaletra (lopinavir200mg/ritonavir50mg)two tablets bid
223751460|NCT01166477|DRUG|Triple therapy with ritonavir|The patients will continue to take their usual triple therapy, as established in the summary of product characteristics
223751461|NCT03075670|DRUG|N9-GP|A single dose of 50 IU/kg for intravenous (i.v.) injection
223751462|NCT03075670|DRUG|ALPROLIX®|A single dose of 50 IU/kg for intravenous (i.v.) injection
223751463|NCT03747965|BIOLOGICAL|Mesothelin-directed CAR-T cells|Cells will be infused one day after the completion of conditioning regimen of paclitaxel and cyclophosphamide
223603757|NCT03460912|DEVICE|Bipolar and monopolar probes (SPESS MEDICA S.r.l. Via Buccari 16153 Genova (GE), Italy) administered to all participants.|Bipolar and monopolar probes (SPESS MEDICA S.r.l. Via Buccari 16153 Genova (GE), Italy) administered to all participants.They compared each others(bipolar vs monopolar) via amplitudes and latency values.
223603758|NCT05150717|DRUG|[14C]-Jaktinib|Subjects will receive single dose of orally \[14C\]-Jaktinib on Day 1.
223603759|NCT03416452|DEVICE|vibratory cueing device|ankle brace with vibrator that provides electric stimulus
223603760|NCT03416452|DEVICE|Mobile Gait Trainer|standard rolling walker that has a battery operated sensor attached to the side, designed to detect footsteps
223603761|NCT02983864|BEHAVIORAL|BASICS|A one session intervention focused on reducing drinking with motivational interviewing
223603762|NCT02983864|BEHAVIORAL|Integrated BASICS|A one session intervention focused on reducing drinking and sexual behavior while drinking
223751464|NCT00589316|PROCEDURE|Allogeneic Bone Marrow Transplantation|Given via central line
224200291|NCT05879796|DRUG|cis-platinum|chemotherapeutics
224200292|NCT05879796|RADIATION|radiation|"External beam radiotherapy was performed using IMRT/VMAT radiotherapy with pelvic and/or extended field irradiation at a total dose of 45-50.4 Gy;1.8-2.0 Gy/f,25 -28 f. In patients with pelvic lymph node metastasis, para-aortic lymph node metastasis, and retroperitoneal lymph node metastasis, local lesions were simultaneously boosted to 60 Gy. In FIGO stage IIIB, simultaneous or late course boost to 60 Gy was given parametrially.~Brachytherapy: High dose rate (HDR) afterloading brachytherapy was used, with a total dose of 30-40 Gy and a cumulative dose of 80-85 Gy at point A/HRCTV D90; if the tumor diameter was ≥ 4 cm, the cumulative dose of ≥ 87 Gy at point A/HRCTV D90. Brachytherapy combined with external beam radiation therapy was completed within 8 weeks."
223603763|NCT02983864|BEHAVIORAL|Relaxation|A one session intervention focused on increasing relaxation skills
223603764|NCT02983864|BEHAVIORAL|Integrated Bystander|A one session intervention focused on reducing sexual assault with a focus on the role of alcohol
223603765|NCT00759421|DRUG|Sertindole|12 to 20 mg daily after initial up-titration, encapsulated tablets, orally, 84 days
223603766|NCT00759421|DRUG|Olanzapine|10 to 20 mg daily after initial up-titration, encapsulated tablets, orally, 84 days
224200293|NCT05879796|DRUG|Envafolimab Injection|PD-L1 antibody
224200294|NCT05879796|DRUG|Recombinant Human Endostatin Injection|angiogenesis inhibitors
224200295|NCT00832286|DRUG|Ciprofloxacin|Licensed medication, dose: 500 mg every 12 hours for 3 days.
224200296|NCT02892435|DEVICE|incisional negative pressure wound therapy|positioning incisional negative pressure therapy over closed wound.
224200297|NCT02892435|DEVICE|conventional dressing|positioning conventional dressing
224200298|NCT04189536|OTHER|SMS Intervention|Delivery of text messages will use the Rip Road Mobile platform.
224200299|NCT00000549|DRUG|estrogen replacement therapy|
223603767|NCT05063682|BIOLOGICAL|EGFRvIII-specific hinge-optimized CD3 ζ-stimulatory/41BB-co-stimulatory Chimeric Antigen Receptor autologous T-lymphocytes|ICV administration
223603768|NCT00567411|DRUG|brimonidine 0.1%|1 drop, 1 hour prior to selective laser trabeculoplasty (SLT)
223603769|NCT00567411|DRUG|Apraclonidine 0.5%|1 drop applied 1 hour prior to SLT
223603770|NCT00112125|DEVICE|OPTIMIZER System|
223603771|NCT00982839|PROCEDURE|Syringe Conditioning|A syringe will be used to inflate the balloon at the end of the probe which is inside of the rectum.
223603772|NCT00982839|PROCEDURE|Barostat Conditioning|A barostat machine will be used to inflate the balloon at the end of the probe which is inside of the rectum.
223603773|NCT01600937|BEHAVIORAL|Theoretical & practical exercise counseling|2 sessions/ per wk for 1 month
223603774|NCT01921764|BEHAVIORAL|Workplace physical exercise|
223603775|NCT01921764|BEHAVIORAL|Home physical exercise|
223603776|NCT03668093|OTHER|ICCM|comprehensive system for caries management
223603777|NCT03668093|OTHER|CAMBRA|Caries risk assessment model
223603778|NCT04292613|OTHER|"The Effect of Hemiplegic Shoulder Pain on Balance, Upper Extremity Function and Quality of Life"|"The Effect of Hemiplegic Shoulder Pain on Balance, Upper Extremity Function and Quality of Life"
224200300|NCT00000549|DRUG|hormone replacement therapy|
223603779|NCT00128115|DRUG|MK0677|
223603780|NCT01325805|BEHAVIORAL|Structured Weight Loss Program|Those patients randomized to the structured weight loss group will have a formal evaluation and counseling a medical endocrinologist specializing in weight management. The structured weight loss program will consist of meeting with a dietician who will guide them on following a hypocaloric diet with a calorie deficit of 750kcal/day. The weight loss goal will be to lose 1-1.5 pounds/week. The participants will receive teaching utilizing the American Diabetes Association Exchange Lists and will receive sample meal plans. In addition, participants will be seen by the dietitian once a week for a month, then every 2 weeks for 2 months, then once per month for 3 months. Patients randomized to the study group will continue in the structured weight loss program for 6 months.
223603781|NCT01325805|BEHAVIORAL|Routine Weight Loss Counseling|Participants randomized to the routine weight loss counseling group will receive the ACOG Patient Education pamphlets on obesity.
223603782|NCT00523081|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|Half the teens in the study will also meet with a research counselor for five to nine individual, weekly sessions that last about 50 minutes each. Whether a teen attends the weekly counseling sessions is decided by chance, like flipping a coin. If teens are assigned to these sessions, they will learn ways to deal with stress and feel better. If teens take part in the counseling sessions, the study counselor will also talk to the teen's doctor from time to time to help plan for the best possible care.
223603783|NCT00523081|BEHAVIORAL|Active control|Teens in the active control arm will keep seeing their doctor as usual. Teens and a parent are interviewed briefly over the phone to see if they are appropriate for the study. If they qualify for the study, there is an hour-long interview with teen over the telephone and a 30 minute interview with the parent. They will be interviewed six more times in the next two years.
224200301|NCT00000549|DRUG|estrogens|
224200302|NCT00000549|DRUG|progestins|
223603784|NCT03154437|BIOLOGICAL|Emicizumab|Participants will receive emicizumab at a loading dose of 3 milligrams per kilogram (mg/kg) per week subcutaneously (SC) for 4 weeks, followed by a maintenance dose of 1.5 mg/kg per week SC thereafter. Treatment with emicizumab will continue until unacceptable toxicity, withdrawal of consent, participant or physician decision to discontinue treatment, death, the participant is able to obtain commercial drug after emicizumab becomes commercially available, or the sponsor decides to discontinue emicizumab clinical development, whichever occurs first.
224200303|NCT02189200|DIETARY_SUPPLEMENT|oat bran - 40g|oat bran - 40g per day
223603785|NCT03458156|BIOLOGICAL|SLE group|The patients will be assigned to systemic lupus erythematosus (SLE) group, receiving umbilical cord mesenchymal stem cell transplantation.
223603786|NCT03458156|BIOLOGICAL|LN group|The patients will be assigned to lupus nephritis (LN) group, receiving umbilical cord mesenchymal stem cell transplantation.
223603787|NCT03458156|OTHER|the control group|The patients will be assigned to the control group.
223603788|NCT02975674|DEVICE|MT-12 dental implant|Placement of the MT-12 dental implant with Morse taper implant-abutment connection
223603789|NCT02975674|DEVICE|CON.INT dental implant|Placement of the CON.INT dental implant with internal hexagon implant-abutment connection
224200304|NCT02189200|DIETARY_SUPPLEMENT|refined rice flour- 40g|refined rice flour - 40g per day
224200305|NCT04911075|DRUG|85% TCA Solution|"* TCA is an acetic acid analogue solution (CCl3COOH) which is formed from the reaction of acetic acid (CH3COOH) with chlorine (3Cl2).~* High concentrations (85 percent) of this solution can penetrate deeply into the epidermis-dermis layer and cause cells necrosis.~* This solution (1-2 milliliter) will be applied to participants cervical tissue (ectocervix and endocervix) using cotton swab for 1-3 minutes."
224200306|NCT01578018|OTHER|Measure DCAM levels in blood|Measure DCAM levels in blood
224200307|NCT01578018|OTHER|DCAM levels in blood|DCAM levels in blood
224200308|NCT03861533|OTHER|survey|Cross-Reference
223603790|NCT04703491|BEHAVIORAL|Interactive and full-featured intervention|Participants will go through an automated program. Participants will learn and practice the techniques of CBT through multimedia elements. They will play games based on Cognitive Bias Modification (CBM) paradigms, practice mindfulness, and chat with an automated empathic chatbot.
223603791|NCT04703491|BEHAVIORAL|Feature-limited CCBT|Participants will be going through an automated program. Participants will learn and practice the techniques of CBT in a plain-text format with reduced features
223603792|NCT04703491|OTHER|Waitlist control|Participants will be put on a waitlist for a period of 6 weeks.
223603793|NCT01629758|BIOLOGICAL|Denenicokin|
224200309|NCT03733418|DRUG|540,000 IU vitamin D3|This intervention was administered as part of VIOLET parent study. A single dose of 540,000 IU vitamin D3 was administered within 2 hours of randomization time.
224200310|NCT03733418|DRUG|Placebo|Placebo that matched the vitamin D3 color was provided.
224200311|NCT02230332|DRUG|Alendronate|
223751465|NCT00589316|DRUG|Cyclophosphamide|Given IV
223603794|NCT01629758|BIOLOGICAL|Nivolumab|
223603795|NCT04560387|BEHAVIORAL|Physician-lead complex program of weight-reducing interventions|A structured motivational and goal directed program will be used for weight reduction involving physicians, nutritionists, educators and physiotherapists. Initially, based on the input data provided by the patient an individual nutritional plan will be designed with the aim of reducing caloric intake by 10%. Low-intensity aerobic exercise for 30 min will be prescribed 3-times a week with the aim of increasing the frequency to 5-times a week and participants will be offered the possibility to participate in regular physiotherapist-lead group exercises. Patients will be required to maintain a diet and physical activity diary. Regular reviews will be scheduled every 3-6 months according to the actual weight loss.
223603796|NCT04560387|PROCEDURE|Bariatric surgery - sleeve gastrectomy|Bariatric surgery will be performed based on actual medical indication and independently of patient's participation in the study. Sleeve gastrectomy was selected as the currently most frequent restrictive type of bariatric surgery with a proven efficacy on weight reduction, metabolic status and low-grade inflammation
223751466|NCT00589316|DRUG|Fludarabine Phosphate|Given IV
223751467|NCT00589316|RADIATION|Iodine I 131 Monoclonal Antibody BC8|Given IV (dosimetry dose) or via central line (therapeutic dose)
223751468|NCT00589316|OTHER|Laboratory Biomarker Analysis|Correlative studies
223751469|NCT00589316|DRUG|Mycophenolate Mofetil|Given IV or PO
223751470|NCT00589316|DRUG|Tacrolimus|Given IV or PO
223751471|NCT00589316|RADIATION|Total-Body Irradiation|Undergo TBI
223751472|NCT05094219|OTHER|No intervention will be offered|No intervention will be offered
223751473|NCT04220411|DRUG|AR100DP1|topical ointment
223751474|NCT03156478|BEHAVIORAL|Digital lifestyle intervention group|Intervention with digital application for lifestyle changes
223751475|NCT03156478|BEHAVIORAL|Combined digital and face-to-face lifestyle intervention group|Intervention with digital application and group meetings for lifestyle changes
223751476|NCT02487212|DRUG|0.05% Clobetasol propionate|0.05% Clobetasol propionate was rubbed for 2 minutes on one side of the scar immediately after treated with fractional Erbium: YAG (2,940-nm) laser. The treatment was done in every 2 weeks for 4 sessions
223751477|NCT02487212|DRUG|Petrolatum gel|Petrolatum gel was rubbed for 2 minutes on the other side of the scar immediately after treated with fractional Erbium: YAG (2,940-nm) laser.The treatment was done in every 2 weeks for 4 sessions
223751478|NCT02487212|DEVICE|Fractional Erbium:Yag (2,940-nm) laser|The parameter of the laser was 28 J/cm2, 5% spot density, 1 pass for the whole scar. The treatment was done in every 2 weeks for 4 sessions
223751479|NCT02028988|DRUG|Enzalutamide|
223751480|NCT02028988|RADIATION|External Beam Radiation|
223603797|NCT00446173|DRUG|Busulfan|130 mg/m\^2 IV Daily Over 3 Hours x 4 Days
223751481|NCT02680639|DEVICE|BiPAP Synchrony ventilator|The BiPAP Synchrony ventilator will be used to determine Expiratory Positive Airway Pressure (EPAP). The ventilator will be used with varying pressure supports and oscillations depending on what arm of the study the participant is in.
223751482|NCT05744349|PROCEDURE|K-wires Fixation of Pediatric Shaft Both Bone Forearm Fractures|After administration of anesthesia, surgery will be performed with the patient supine on the operating table and fracture will be analyzed with an image intensifier. In radius, the wire will be inserted by surgical drilling through Lister's tubercle or the radial styloid while in ulna, the wire will be inserted through the tip of the olecranon.
223751483|NCT01063595|BIOLOGICAL|Octaplas LG|Octaplas LG was composed of human coagulation-active plasma treated with solvent/detergent for 1-1.5 hours to remove enveloped viruses, eg, HIV, HBV, and HCV. An additional manufacturing step, involving an affinity ligand gel, removed prion proteins. Octaplas LG was provided frozen in pyrogen free plastic bags.
223751484|NCT01063595|BIOLOGICAL|Octaplas SD|Octaplas SD was composed of human coagulation-active plasma treated with solvent/detergent for 4-4.5 hours to remove enveloped viruses, eg, HIV, HBV, and HCV. Octaplas SD was provided frozen in pyrogen free plastic bags.
223751485|NCT01663415|DRUG|Enzalutamide|oral
223751486|NCT03152370|DRUG|E7046|oral administration
223751487|NCT03152370|RADIATION|Long Course Chemoradiotherapy (LCRT)|pelvic radiotherapy
223751488|NCT03152370|RADIATION|Short Course Radiotherapy (SCRT)|pelvic radiotherapy
223751489|NCT03152370|DRUG|capecitabine|chemotherapy
223751490|NCT03152370|DRUG|folinic acid/5-FU/oxaliplatin (mFOLFOX-6)|chemotherapy
223751491|NCT00492310|BEHAVIORAL|yoga|vinyasa yoga
223751492|NCT00492310|BEHAVIORAL|cognitive therapy|cognitive behavioral therapy once weekly
223603798|NCT00446173|DRUG|Cyclophosphamide|60 mg/kg IV Daily Over 4 Hours x 2 Days
223751493|NCT00492310|BEHAVIORAL|yoga|vinyasa yoga twice weekly with smoking cessation once weekly
223751494|NCT00492310|BEHAVIORAL|wellness|wellness program with smoking cessation
223751495|NCT03454984|DRUG|Guadecitabine|30/m2/day SubCutaneous for 5 days (Cycle = 28 days). total of 10 cycles
223751496|NCT02976974|OTHER|Manual therapy|Application of different manual therapy techniques through posterior and inferior humeral head slides, as well as scapular movements. Also, rotator interval stretching will be done.
223751497|NCT02976974|OTHER|Therapeutic exercise|"* Shoulder extension: Elastic bands.~* Shoulder flexion: Elastic bands~* Shoulder external rotation: Elastic bands.~* Scapulothoracic stability: Movement of scapular adduction guided by the physiotherapist, keeping the position for few seconds ; standing push up on the wall.~* Thoracic column movements: Flexion-extension"
223751498|NCT03976063|DRUG|Nifedipine|Loading dose: Oral Nifedipine 20 mg prolonged-release at T0 and T0.5 (i.e. 30 min), total=2x20 mg Maintenance dose: Oral Nifedipine 20 mg prolonged-release at T3, then 1 pill every 8 hr for 48 hr (i.e. T11, T19, T27, T35 and T43, total=6x20 mg)
223751499|NCT03976063|DRUG|Placebo of Nifedipine|Oral Placebo of Nifedipine 20 mg, at T0, T0.5, T3, T11, T19, T27, T35 and T43
223751500|NCT03027895|DEVICE|Lumen-apposing metal stent (LAMS)|Endoscopic Ultrasound-guided Drainage of WON with LAMS
223751501|NCT03027895|DEVICE|Double pigtail plastic stent (DPPS)|Endoscopic Ultrasound-guided Drainage of WON with DPPS
223751502|NCT00851799|DRUG|Emtricitabine/tenofovir disoproxil fumarate|"200 mg emtricitabine/300 mg tenofovir disoproxil fumarate taken orally daily. A combination drug of two nucleoside reverse transcriptase inhibitors (NRTIs).~Other Name: TDF/FTC"
223751503|NCT00851799|DRUG|Ritonavir|"100 mg taken orally once daily. A protease inhibitor (PI).~Other Name: RTV"
223751504|NCT00851799|DRUG|Atazanavir|"300 mg taken orally once daily. A protease inhibitor (PI).~Other Name: ATV"
223751505|NCT00851799|DRUG|Raltegravir|"400 mg taken orally twice daily. An integrase inhibitor (INI).~Other Name: RAL"
223751506|NCT00851799|DRUG|Darunavir|"100 mg taken orally once daily. A protease inhibitor (PI).~Other Name: RTV"
223751507|NCT00118976|DRUG|Lisinopril|
223751508|NCT00392431|DRUG|amiodarone|
223751509|NCT01852266|BIOLOGICAL|RSV cps2 Vaccine|10\^5.3 plaque forming units (PFUs) of RSV cps2 vaccine will be administered as nose drops (0.25 mL per nostril, for a total of 0.5 mL).
223751510|NCT01852266|BIOLOGICAL|Placebo Vaccine|Placebo vaccine will be administered as nose drops (0.25 mL per nostril, for a total of 0.5 mL).
223751511|NCT04702490|DRUG|MET409 Active|MET409 Active (50mg)
223751512|NCT04702490|DRUG|MET409 Placebo|MET409 Placebo (50mg)
223751513|NCT04702490|DRUG|Empagliflozin|Empagliflozin (10mg)
223751514|NCT06502743|DRUG|Nesuparib|Nesuparib 150mg or 100mg, QD, PO
223751515|NCT06502743|DRUG|Pembrolizumab|Pembrolizumab 400mg, IV, Q6W
223751516|NCT01001442|DRUG|BT062|intravenous administration
223751517|NCT03774589|PROCEDURE|Magnetic Compressive Anastomosis|The magnetic compressive anastomosis will be used to complete the anastomosis during bilioenteric anastomosis.
223751518|NCT03774589|PROCEDURE|Manual Anastomosis|A handsewn technique will be used to complete the anastomosis during bilioenteric anastomosis.
223751519|NCT05478070|DEVICE|Dexcom G6|Continuous glucose monitor
223751520|NCT02522390|OTHER|Research activities|"Measurements are primarily based on do-it-yourself non-invasive or minimally invasive methods. Participants upload collected data to the Personal Health Portal.~The measurements are divided into required and optional measurements. The required measurements mainly include routine methodology (e.g. weight, blood pressure, blood glucose); the latter also include methods under development that will be fine-tuned along the project. Which additional measures will be offered to participants is dependent on if funding or in-kind sponsoring is available. Participants will receive measurement kits for these analyses at-home and will be responsible for collection, labeling and shipment of samples themselves. After analysis the resulting data are uploaded to the user accounts."
223751521|NCT01321775|DRUG|Bevacizumab,Trastuzumab,Paclitaxel,Cyclophosphamide,Myocet|"Neo-adjuvant doses (12 weeks):~Bevacizumab: 15mg/Kg every 3 weeks Trastuzumab: 4 mg/Kg (First dose) - 2mg/Kg every week. Paclitaxel: 80mg/m2 every week.~Adjuvant doses:~Trastuzumab: 8mg/Kg(first dose)- 6mg/Kg every 3 weeks (At least 9 months) Cyclophosphamide: 600mg/m2 every 3 weeks (9 months) Doxorubicin Liposomal: 50mg/m2 every 3 weeks (3 months)"
223751522|NCT00187746|DRUG|Adefovir dipivoxil|Subjects will be given a single oral dose of 10 mg of adefovir dipivoxil
223751523|NCT02753699|DRUG|Alisporivir|Intervention of interest; follow-up after ALV-active study
223751524|NCT04720196|DEVICE|Active repetitive transcranial magnetic stimulation|High frequency rTMS over the primary motor area to induce the long term potentiation of primary motor areas for the muscles of upper extremity.
223751525|NCT04720196|DEVICE|Sham repetitive transcranial magnetic stimulation|Sham stimulation to mimic the high frequency rTMS over the primary motor area.
223751526|NCT06730347|BIOLOGICAL|Lorigerlimab|Bispecific DART protein binding PD-1 and CTLA-4
223751527|NCT05630859|BIOLOGICAL|NgG low dose investigational vaccine|Two doses of NgG low dose investigational vaccine, administered intramuscularly.
223751528|NCT05630859|BIOLOGICAL|NgG medium dose investigational vaccine|Two doses of NgG medium dose investigational vaccine, administered intramuscularly.
223751529|NCT05630859|BIOLOGICAL|NgG high dose investigational vaccine|Two doses of NgG high dose investigational vaccine, administered intramuscularly.
223751530|NCT05630859|BIOLOGICAL|Placebo|Two doses of placebo, administered intramuscularly.
223751531|NCT05630859|BIOLOGICAL|NgG HTD investigational vaccine|Two doses of NgG HTD investigational vaccine, administered intramuscularly.
223751532|NCT05630859|BIOLOGICAL|NgG below HTD investigational vaccine|Two doses of NgG below HTD investigational vaccine, administered intramuscularly.
223751533|NCT01519882|OTHER|Placebo|"Placebo patches size equivalent to 4, 6 \& 8 mg/24 h. Daily application of Placebo patches starting at 4 mg/24 h. Dose will be up-titrated weekly by increments of 2 mg/24 h until optimal or maximal dose is reached. Maximal dose is 16 mg/24 h.~Optimal or maximal dose will be maintained for 4 Weeks followed by a de-escalation by 2 mg/24 h every other day."
223751534|NCT01519882|OTHER|Rotigotine|"Rotigotine patches of 4,6 \& 8 mg/24 h. Daily application of Rotigotine patches starting at 4 mg/24 h. Dose will be up-titrated weekly by increments of 2 mg/24 h until optimal or maximal dose is reached. Maximal dose is 16 mg/24 h.~Optimal or maximal dose will be maintained for 4 weeks followed by a de-escalation by 2 mg/24 h every other day."
223751535|NCT00827879|BEHAVIORAL|Strength at Home Couples Group|A multiple site randomized trial will compare 10 sessions of PF-RET to 10 sessions of a supportive group therapy. PF-RET focuses on 1) deployment stress and traumatic experiences impacting intimate relationships; 2) communication between intimate partners; 3) conflict and anger management; and 4) closeness and intimacy.
223751536|NCT00827879|BEHAVIORAL|Supportive Group Therapy|A general support group designed to enhance support for healthy relationship building.
223751537|NCT06151704|RADIATION|High intensity laser therapy|The subject will receive high-intensity laser therapy in a prone position with a cushion under the abdomen and eye protection. The laser scanner, 50 cm from the skin, will target the area from the 12th ribs to the upper iliac crest, 4.2 cm lateral to the spine. The sciatic, tibial, and peroneal nerves will also be irradiated. A GaAlAs laser device will be used, with a power of 1.6 watts and a wavelength of 808nm. The initial dose will be 10 joules/cm², with an increment of 2 joules after every three sessions. The final dose will be 16 joules/cm².
224200312|NCT02230332|DRUG|Placebo|
224200313|NCT04382599|BEHAVIORAL|Text warning with square background|The warning message is in white text on a black square background
224200314|NCT04382599|BEHAVIORAL|Text warning with octagon background|The warning message is in white text on a black octagon background
224200315|NCT04382599|BEHAVIORAL|Icon warning|The warning message in in white text on a black background, below an icon that conveys the topic the warning is about
224200316|NCT04382599|BEHAVIORAL|Graphic warning|The warning message in in white text on a black background, below a graphic that conveys the topic the warning is about
224200317|NCT02140801|DRUG|Ticagrelor|Plain, round, yellow, filmcoated tablet, 90 mg
223751538|NCT06151704|OTHER|Motor control exercise|Motor control exercise is defined as an exercise to increase control and coordination of the spine and pelvis. Normally, Motor control exercise increases the weak deep trunk muscles, such as transversus abdominis and multifidus, and reduces the overactive large external trunk muscles, such as rectus abdominal and erector spinae muscles. . All subjects participate in a foundational treatment regimen involving motor control exercises: isolated and combined contractions of the transverse abdominis and multifidus muscles in various positions. Contractions will initially be performed up to a maximum of 10 repetitions per movement, with each contraction sustained for a duration of 10 seconds. Commencing from the third week, the subject should be capable of comfortably executing 10 repetitions, sustaining the contraction for 10 seconds, and progressively increasing the intensity.
223751539|NCT06571175|DIAGNOSTIC_TEST|High frame rate echocardiography|Conventional transthoracic echocardiography will be performed, with added 3D-imaging and acquisitions with high frame rate. The data from these patients will be anonymized and transferred for post-hoc analysis in dedicated computer software (GE Vingmed, EchoPac 2.6) and in validated machine learning algorithms.
223751540|NCT06571175|DIAGNOSTIC_TEST|MRI|Cardiac MRI will be performed. In all patients without contraindications, a gadolinium-based contrast agent will be given.
223751541|NCT06571175|DIAGNOSTIC_TEST|Blood test|Conventional brachial venous blood samples will be drawn. Hematocrit value {in %} will be used to calculate CMR-derived exttracellular volume (ECV)
223751542|NCT06571175|DIAGNOSTIC_TEST|ECG and Holter-ECG|ECG/Holter-ECG will be performed, and the findings will be related to the imaging findings.
223751543|NCT06571175|DIAGNOSTIC_TEST|6 min walking test|6 MWT will be performed, and the findings will be related to findings from CMRI/echocardiography.
223751544|NCT05191680|DRUG|Apalutamide Oral Tablet [Erleada]|Apalutamide is a selective Androgen Receptor (AR) inhibitor that binds directly to the ligand-binding domain of the AR.
223751545|NCT05191680|DRUG|Placebo|Placebo to match apalutamide
223751546|NCT06348524|DRUG|Ferumoxytol injection|ferumoxytol will assess patency of coronary arteries
223603799|NCT00446173|DRUG|G-CSF|10 mcg/kg Subcutaneously Once Daily
223603800|NCT00446173|DRUG|GM-CSF|250 mcg/kg Subcutaneously Once Daily
223603801|NCT05852236|OTHER|Assigned Interventions|Pressure ulcer care package application.
223603802|NCT04839549|DRUG|Dextenza 0.4Mg Ophthalmic Insert|Dextenza 0.4Mg Ophthalmic Insert
223603803|NCT04839549|DRUG|Fluoromethalone .01%|Fluoromethalone .01%
223603804|NCT03268291|OTHER|Standard outpatient observation|Outpatient management according to Ministry of health standards
223603805|NCT03268291|BEHAVIORAL|"Communicational program Trust"|"The developed program is based on the experience of international research studies and includes the following sections:~daily seminars with patients going to be discharged about the benefits of adherence to therapy; distribution of printed materials; service for the regular informing of the patients which is motivating to remain adherence to medications by automated contact management systems (SMS, e-mail), as well as calls from contact center operators; questioning of participants of the program for general adherence to therapy, reasons for refusal, change of therapy / drug, complaints and other. The questioning is carried out through telephone interviewing by contact center operators and automatic collection of electronic forms through aggregator services."
223603806|NCT02487862|BEHAVIORAL|Stress Reduction Protocol|Stress Reduction Protocol
223603807|NCT05825391|DRUG|Adjustment of Antiplatelet Drugs|The maximum platelet aggregation rate induced by arachidonic acid (AA-MPA)≥20%, give aspirin 200mg qd. The maximum platelet aggregation rate induced by adenosine diphosphatase (ADP-MPA)≥36.4% for flow diversion, give ticagrelor 60mg bid. ADP-MPA≥42.9% for stent-assisted coil embolization，give ticagrelor 60mg bid. ADP-MPA\<20%, give clopidogrel 37.5mg qd. The timing of drug adjustment should be at least 1 day before stent implantation, and the LTA testing should be performed again 48 hours after the drug adjustment. For patients whose ADP-MPA does not reach the normal range, a second antiplatelet drug adjustment should be performed: ticagrelor overdose: reduce to 45mg bid; ticagrelor resistance, increase to 90 mg bid.
223603808|NCT01879943|DEVICE|PillCam Colon 2|PillCam® COLON 2 capsule endoscopy is a minimally invasive tool for direct visualization of the colon, including identifying the occurrence of polyps.
223603809|NCT01879943|PROCEDURE|Colonoscopy|Standard colonoscopy is the standard against which capsule endoscopy is compared.
223603810|NCT02022436|DRUG|Contrast Ultrasound|Definity® is the contrast agent that will be administered by intravenous injection by a registered nurse during the ultrasound (contrast enhanced ultrasound (CUS). The purpose is to assist in identifying differences in AAA characteristics based on gender and AAA stability and growth.
223603811|NCT04741490|DRUG|Camrelizumab|PD-1antibodies，200mg ivgtt Q3W
223603812|NCT04741490|RADIATION|radiotherapy|45-55Gy/1.8～2.0Gy
223603813|NCT04994548|PROCEDURE|Endosocpic resection of early esophageal tumor|under general anesthesia, by mucosectomy or endoscopic submucosal dissection
223751547|NCT00920114|BIOLOGICAL|blood sample|
223751548|NCT06604039|DEVICE|Central venous catheter|Placement of a medical device to gain entry into the bloodstream, typically through a vein or artery, for the purpose of administering fluids, medications, blood products, or for hemodialysis
223751549|NCT06593522|DRUG|AMG 193|Film-coated tablet
223751550|NCT05656768|OTHER|Constant Routine Protocol|A constant routine protocol is used to directly examine markers of circadian rhythmicity (e.g., melatonin and core body temperature). A constant routine protocol requires an individual to remain in a dimly lit room, in a constant semi-recumbent posture, and remain awake for more than 24 hours. It is one of two gold-standard research protocols for examining circadian rhythms in humans.
223603814|NCT00267852|OTHER|as clinical practice|Dosage, form, frequency and duration as per ordinary clinical practice
223603815|NCT01894438|BEHAVIORAL|Mediterranean lifestyle|Counseling will be based on the goal setting theory. Motivational and behavioral strategies will be also used. In the Mediterranean lifestyle group culinary practices, seasonality, and locality of food products, socialization during meals, rest during the day, as well as the adoption of an active living will be additionally addressed.
224200318|NCT02140801|DRUG|Clopidogrel|Orange brown capsule, containing one 75 mg clopidogrel tablet (cut into 2 halves)
224200319|NCT05029167|OTHER|Restrictive PaO2|Patients are randomized to a PaO2 target of 9-10 kPa (open-label).
223603816|NCT01894438|BEHAVIORAL|Mediterranean Diet|Counseling will be based on the goal setting theory. Motivational and behavioral strategies will be also used. In the Mediterranean diet group, all food groups of the Mediterranean diet will be targeted.
223603817|NCT03294850|PROCEDURE|Bariatric surgery|Subjects enrolling in the study who are undergoing bariatric surgery as part of their medical care will be studied
223603818|NCT03294850|DEVICE|HepQuant SHUNT Dual Cholate Liver Diagnostic Kit|For the experimental group, the device will be used to monitor the effect of bariatric surgery on liver function. For the active comparator group, the device will be used for the assessment of baseline liver function.
223603819|NCT06195410|OTHER|kangaroo care application|In the study, the mother applied kangaroo care to her premature baby for 65 minutes, and after a 24-72 hour washout period, the father applied kangaroo care for 65 minutes.
223603820|NCT05750550|OTHER|Instrument Assisted Soft Tissue Mobilization|With the IASTM device, application will be made over the skin to the triceps surae muscle and plantar fascia for 15 minutes. The application will be made in the prone position. Massage oil will be used to reduce tissue friction before the application.
223751551|NCT05991557|PROCEDURE|peroneus longus autograft|Peroneus longus tendon graft will be harvested with a longitudinal skin incision at 2 to 3 cm (2 finger-breadths) above and 1 cm (1 finger-breadth) behind the lateral malleolus, followed by superficial fascia incision in line with skin incision followed by incision of the tendon sheath proximal to the retinaculum. The peroneus longus and peroneus brevis tendons will be then identified. The tendon division location marked at 2 to 3 cm above the level of the lateral malleolus.The peroneus longus tendon will be exposed on its posterolateral surface through the incision after carefully incising the fascia
223751552|NCT06987474|DEVICE|Unity DX and SMARTCataract DX (SCDX) Biometer|Unity DX is a CE-marked, noninvasive, noncontact instrument that generates a 3D model of the eye using hyper parallel optical coherence tomography (HP OCT), aberrometry, and topography. The current version of SCDX software will be used in this study.
223751553|NCT06987474|DEVICE|IOLMaster 700 Biometer|The IOLMaster 700 Biometer is a CE-marked, noninvasive, noncontact instrument that captures optical biometry. Data will be collected using standard clinical assessments.
223751554|NCT06987474|DEVICE|Argos with Alcon Image Guidance Biometer|The Argos with Alcon Image Guidance biometer is a CE-marked, noninvasive, noncontact instrument that will capture optical biometry. Data will be collected using standard clinical assessments.
223751555|NCT06818006|PROCEDURE|Transcatheter Aortic Valve Replacement (TAVR) with surgical oversight|Transcatheter Aortic Valve Replacement (TAVR) with surgical oversight
223751556|NCT06818006|PROCEDURE|Transcatheter Aortic Valve Replacement (TAVR) without surgical oversight|Transcatheter Aortic Valve Replacement (TAVR) without surgical oversight
223751557|NCT06988241|OTHER|positional release|All participants in group (A) will receive the same program of group B added to positional release . In order to make the positional release , the therapist will pick up the trigger points by palpation in the upper trapezius muscle by pincer palpation method and distinguished with dots on the skin. Participants will be made supine lying and relaxed by maintaining the cervical spine in a neutral position. Lateral flexion of subject's head toward the side of a tender point, the therapist grasps the subject's forearm and abducts shoulder to approximately 90° and adds slight flexion or extension to fine-tune.The most comfortable position achieved will be held for 90 seconds and after that passive return of the body part to an anatomically neutral position will be maintained for 5 minutes. All participants will be treated three times per week for 4 consecutive weeks and will be instructed to maintain their normal activities while avoiding any undue stress to the neck.
223751558|NCT06988241|OTHER|Posture correction|Posture correction advices during lactation + posture correction exercises
223751559|NCT06664762|BEHAVIORAL|Left lateral position intervention|Patients will be randomized and asigned to start and remain in left lateral position during the colonoscopy
223751560|NCT06664762|BEHAVIORAL|Supine position intervention|Patients will be randomized and asigned to start and remain in supine position during the colonoscopy
223603821|NCT00039663|DRUG|Pravastatin|
223603822|NCT00039663|DRUG|Gemfibrozil|
223751561|NCT06663345|PROCEDURE|Transversus Abdominis Plan Block (TAPB), Lateral Quadratum Lumborum (QLB-1) Block|Following the acquisition of informed consent prior to surgery, 2 mg of intravenous midazolam will be administered to patients who volunteer. These patients will be monitored in the preoperative preparation room. Bilateral TAP or QLB-1 block will be performed, and this block is routinely applied for postoperative pain in our hospital.
223751562|NCT06985654|DRUG|Lactated Ringers|A bolus of Lactated Ringers (15mL/kg of ideal body weight) will be given to patients prior to anesthesia induction.
223603823|NCT00039663|DRUG|Rosiglitazone|
223603824|NCT01351155|DEVICE|Skin protective dressing device|Application of one the three indicated devices (3 active arms) to prevent NIV-induced skin injury
223603825|NCT02619643|DEVICE|Transcranial Magnetic Stimulation (Magstim)|
223751563|NCT06594315|DRUG|Deuterated Glucose|Given orally
223751564|NCT06594315|PROCEDURE|Magnetic Resonance Imaging (MRI)|Imaging procedure performed at University of California, San Francisco
223751565|NCT06594315|PROCEDURE|Blood Sample|Capillary blood from the fingertip
223751566|NCT06594315|PROCEDURE|MR spectroscopy (MRS)|Imaging procedure performed at University of California, San Francisco
223603826|NCT02505113|DRUG|Montelukast|Montelukast (10mg, q.d., p.o.)
223603827|NCT03154749|DRUG|DCb (docetaxel/carboplatin) versus EC followed by D (epirubicin/cyclophosphamide followed by docetaxe)|All eligible patients were randomly assigned at a 1:1 ratio to the experimental arm (docetaxel (75 mg/m2 administered intravenously every 3 weeks) plus carboplatin (AUC 6 mg/mL per min, intravenously every 3 weeks) for six cycles) or the standard treatment arm (epirubicin (90 mg/m2) plus cyclophosphamide (600 mg/m2), both administered intravenously every 3 weeks for four cycles, followed by docetaxel (100 mg/m2) administered intravenously every 3 weeks for four cycles).
223603828|NCT00364143|DRUG|IHL-305 (irinotecan liposome injection)|
223603829|NCT00470925|DRUG|123-I MZINT injection and SPECT imaging|SPECT imaging uses the single photon emissions from radioactive compounds that are (most commonly) injected into a patient and are metabolized by specific organs or body systems. SPECT imaging is performed by using a gamma camera to acquire multiple 2-D images (also called projections), from multiple angles. A computer is then used to apply a tomographic reconstruction algorithm to the multiple projections, yielding a 3-D dataset. This dataset may then be manipulated to show thin slices along any chosen axis of the body, similar to those obtained from other tomographic techniques, such as MRI, CT, and PET. The resulting SPECT images reflect body/organ function as opposed to specific anatomy of other imaging modalities such as CT or MRI
223603830|NCT05409898|DEVICE|smart wearable device|screening masked hypertension with smart wearable devices
223603831|NCT05599243|DRUG|Dutasteride|The application will be made locally (spray for topical application on the scalp) Application: 1 mL (6 sprays) once a day. Each 1mL of formulation has approximately 1.5mg of Dutasteride (more precisely it would be 1.4835mg when considering density).
223603832|NCT05599243|OTHER|Placebo|Vehicle excipient
223603833|NCT01217372|DIETARY_SUPPLEMENT|Lemon supplementation|60 ml of lemon juice twice daily (an amount expected to provide 6 grams or 92 mEq of citric acid per day)
223603834|NCT04757545|OTHER|HM-PRO|"The intervention group will have a predetermined consultation appointment planned to assess medical status and symptom control. Seven days prior to the scheduled visit, the patient will receive an electronic invitation via RedCap to complete and send PRO data (HM-PRO). Prior to each appointment PRO data will be evaluated by a nurse from an algorithm deciding one of three tracks for the patients:~1. Worsening in symptoms results in a nurse-led telephone consultation within two days guided by the symptom management manual.~2. Minor changes in patient's symptom assessment result in a nurse-led telephone consultation within seven days using the symptom management manual.~3. Patients that are completely stable in the symptom assessment will receive an electronic answer via min-SP (electronic patient journal) regarding the results and a new appointment, including PRO-data prior to this."
223603835|NCT00870545|BEHAVIORAL|Telephone support groups|There was one intervention. Participants were enrolled in one of 14 telephone groups (each with a trained Group Leader and 6 participants) will focus on education, training in and practice of coping skills and cognitive restructuring (identifying and re-shaping negative and destructive thoughts), and support through 12 hour-long structured sessions. The content, modeled on Soldier BATTLEMIND, targets readjustment concepts based on the letters of BATTLEMIND, including Bonds, Adding and subtracting family roles, Taking control, Talking it out, Loyalty and commitment, Emotional balance, Mental health and readiness, Independence and interdependence, Navigating the system, Denial of self and a concluding session entitled Moving forward.
223603836|NCT04248088|BEHAVIORAL|Gentle Stretching and Education|60 minutes of gentle stretching twice weekly for 6 months
223603837|NCT03162237|OTHER|Porcine islets|"Porcine islets: 10000IEQ/Kg;~Tacrolimus: 0.087mg/kg, Bid;~mycophemo-latemofetil (MMF): 1g x 2/d;~NULOJIX(belatacept): Day 1 (prior to transplantation), Day 5, Week 2, Week 4, Week 8, Week 12 10mg/kg"
223603838|NCT03162237|OTHER|Autologous Treg|Autologous Treg: 2x10\^6/Kg
223603839|NCT04230213|DRUG|PF-06410293|SC injection
223603840|NCT04230213|DRUG|adalimumab|SC injection
223603841|NCT01160913|PROCEDURE|Continuous wound infusion|
223603842|NCT01160913|PROCEDURE|Continuous wound|
223603843|NCT04481360|DEVICE|CT of the chest|Degree of affection on the lung infected by COVID19
223751567|NCT05431959|OTHER|balneotherapy|immersion in Lake Hévíz, 36℃ sulphur, carbonate, calcium, magnesium, hydrogen carbonate and very light radon-content thermal-mineral water 15 times in 3 weeks 30-minute therapy sessions. The total mineral substance of the water is 754 mg/l.
223751568|NCT06198556|DRUG|HRS-1167 tablets; rifampicin|HRS-1167 tablets single oral dose of HRS-1167 or co-administered with rifampicin.
223751569|NCT06985355|DRUG|MHB046C|IV administration of MHB046C Q3W; Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and confirmed disease progression.
223603844|NCT01394913|DRUG|Reumatocept (etanercept)|50mg each week for 30 weeks
223603845|NCT01394913|DRUG|Enbrel (etanercept)|50mg each week for 30 weeks
223603846|NCT04230824|DIETARY_SUPPLEMENT|Pre-workout plus and Protein recovery plus|products consumed prior and after exercise
223603847|NCT04230824|OTHER|Placebo|placebo product consumed prior and after exercise
223603848|NCT04230824|OTHER|6-week resistance training program|participants will complete a moderate-intensity warm-up, a full-body resistance training workout (2 x per week) and an interval training session (1 x per week)
223603849|NCT00216216|DRUG|Pemetrexed|Pemetrexed 500 mg/m2 IV q 3 weeks
223603850|NCT04499989|DRUG|INH|3 vaginal tablet of isonicotinic acid hydrazide self inserted 12 hours before IUD insertion.
223603851|NCT04499989|DRUG|Placebo Comparator|3 vaginal tablet of Placebo Comparator self inserted 12 hours before IUD insertion
223603852|NCT04883034|PROCEDURE|adductor canal block in outpatient clinic|perform adductor canal block in outpatient clinic for patient post total knee arthroplasty
223603853|NCT04883034|DRUG|Analgesics, etoricoxibe|anaelgetic oral intake
223603854|NCT02859441|DRUG|Ranibizumab|Intravitreal injections of the commercially-available 10 mg/mL formulation of ranibizumab. Ranibizumab is formulated as a sterile solution (pH 5.5) with histidine, trehalose and polysorbate 20. The vial contains no preservative. Each vial contains 0.5 mL of 10 mg/mL ranibizumab aqueous solution. The intravitreal injection volume of ranibizumab is 50 microliter, which correlates to 0.5 mg of dry ranibizumab.
223751570|NCT06494449|OTHER|Higher protein|An acute mixed meal containing higher protein
223751571|NCT06494449|OTHER|Lower protein|An acute mixed meal containing lower protein
223751572|NCT06663553|PROCEDURE|TU-LESS|patients in TU-LESS group will receive transumbilical laparoendoscopic single-site surgery (TU-LESS) for hysterectomy
223751573|NCT06663553|PROCEDURE|vNOTES|patients in vNOTES group will receive transvaginal natural orifice transluminal endoscopic surgery (TU-LESS) for hysterectomy
223751574|NCT00310583|DRUG|Pregabalin|
223751575|NCT05868629|OTHER|Non-investigational|Participants obtaining commercial (non-investigational) dabrafenib plus trametinib (i.e. solid formulation or liquid formulation, if approved and commercially available locally) per local guidance or patient access program
223751576|NCT04166721|DRUG|Atezolizumab|Immunotherapy
223751577|NCT04365556|BEHAVIORAL|TASC Intervention|All participants receive Step 1 of the intervention. Participants who have adherence below or at 68% will step up to Step 2 or Step 3 after the third or fourth month in the study.
223751578|NCT06995508|OTHER|Best Practice|Given standard of care symptom management
223603855|NCT02859441|DRUG|E10030|E10030 is not a commercially available drug product, and will be provided by Ophthotech Corp. The drug product is provided as a sterile aqueous solution of E10030 at a concentration of 30 mg (oligo weight)/mL. The solution contains monobasic sodium phosphate monohydrate and dibasic sodium phosphate heptahydrate as buffering agents as well as sodium chloride as a tonicity adjuster. The intravitreal injection volume of E10030 is 50 microliter, which correlates to 1.5 mg of dry E10030.
223603856|NCT03252002|DRUG|BAY1101042|Single oral dose of 10 mg, 20 mg, 30 mg, 40 mg, 50 mg or optionally 5 mg BAY 1101042 (given as 5 mg MR tablets) or corresponding placebo followed by once daily dosing for 7 days
223603857|NCT03252002|DRUG|Placebo|Single dose on Day 1 (00d) and once daily for 7 days from Day 3 (02d) until Day 9 (08d)
223603858|NCT06444802|DRUG|Linezolid|Linezolid dosing will be adapted according to a model informed precision dosing (TDMx)
223603859|NCT00411814|DRUG|GSK679586|Active Drug
223603860|NCT00411814|DRUG|Placebo|Saline
223603861|NCT03256318|OTHER|No intervention|No intervention; surveys/questionnaires only
223603862|NCT00912457|DRUG|donepezil|donepezil 5 mg/day for 14 days followed by donepezil 10 mg/day for 14 days
223603863|NCT00912457|DRUG|placebo|placebo 1 p/day for 28 days
223603864|NCT03876899|DIETARY_SUPPLEMENT|Evening Primrose Oil|botanical oil derivative from the seeds of Evening Primrose (Oenothera biennis),1,300 milligrams t.i.d.
223603865|NCT03876899|DIETARY_SUPPLEMENT|Placebo|Pill
223603866|NCT04236739|DRUG|Instant MSC Product accompanying Autologous Chondron Transplantation|Application of a mixture of allogenic MSC's and autologous chondrons with a fibrin cell carrier (Tisseel®) in the cartilage defect of the knee during one surgical procedure.
223603867|NCT00006208|DRUG|Efavirenz|
223603868|NCT00006208|DRUG|Emtricitabine|
223603869|NCT00006208|DRUG|Stavudine|
223603870|NCT00006208|DRUG|Didanosine|
223751579|NCT06995508|DRUG|Olanzapine|Given PO
223751580|NCT06995508|OTHER|Questionnaire Administration|Ancillary studies
223751581|NCT06529835|DEVICE|NeuroSpan Bridge|"The implant is used to connect peripheral nerve discontinuities. It is designed to be an interface between the nerve and surrounding tissue and to create a conduit for axonal growth across a nerve gap.~The NeuroSpan Bridge is a novel scaffold to support regeneration that mimics the natural bio- architecture, providing multiple channels that are strictly linear so that axonal position is accurately maintained across the full length of the scaffold - over any length - to re-enter the distal nerve stump."
223751582|NCT06529835|DEVICE|NeuroGen Nerve Guide|The NeuraGen Nerve Guide is a resorbable implant for the repair of 0.5-1.0cm peripheral nerve discontinuities. NeuraGen Nerve Guide provides a protective environment for peripheral nerve repair after injury. It is designed to be an interface between the nerve and surrounding tissue and to create a conduit for axonal growth across a nerve gap. The semi-permeable type 1 collagen membrane allows for controlled resorption, appropriate nutrient diffusion and retention of representative Nerve Growth Factor.
223751583|NCT06529835|DEVICE|Nerve Autograft|A nerve autograft is a surgical procedure that involves transplanting a segment of a patient's own sensory nerve tissue to repair a damaged peripheral nerve injury measuring 1.1-3.0cm. It is designed to be an interface between the nerve and surrounding tissue and to create a conduit for axonal growth across a nerve gap
223751584|NCT07006142|OTHER|Modified Fasting Guidelines|Patients will follow a full-liquid diet 48 hours prior to their procedure, clear liquid diet 24 hours prior to their procedure, and nothing by mouth (NPO) after midnight on the day of their procedure
223751585|NCT07066852|RADIATION|x ray|we performed pelvis ap and frog leg x ray to child in 6 month and 1 age
223751586|NCT07066852|DIAGNOSTIC_TEST|ultrasound|we will perform ultrasound in 6 week and 3 month
223751587|NCT05231473|OTHER|Nurse Enhanced Recovery After Surgery participation|Bellvitge University Hospital will include the NEC participation along Enhanced Recovery After Surgery program.
223751588|NCT07070206|BEHAVIORAL|The health professionals in the capacity building arm will receive in-service training about culturally customized maternal nutrition education.|The health professionals in the routine capacity building arm will receive in-service training given through the health are system.
223751589|NCT07089628|OTHER|Assessment|There is no intervention in this study. Participants will only undergo assessments.
223751590|NCT06913400|COMBINATION_PRODUCT|Stereopsis Recovery|This prospective longitudinal observational study aims to assess stereopsis recovery in strabismic patients at one month and three months post-corrective surgery
223751591|NCT07102979|DRUG|Ursodeoxycholic Acid (URSO)|Ursodeoxycholic acid (UDCA) was administered orally at a dose of 10 mg/kg/day for 6 months.
223751592|NCT07102979|DRUG|Simvastatin|Simvastatin was administered orally at a dose of 40 mg/day for 6 months.
224200320|NCT05029167|OTHER|Low normal MAP|The patients are randomized to receive a Phillips M1006B blood pressure measuring module, offset by +10 %. All patients will target a MAP of 70, but due to the offset module, the patients will target an actual blood pressure of 63 mmHg.
224200321|NCT05029167|OTHER|Liberal PaO2|Patients are randomized to a PaO2 target of 13-14 kPa (open-label).
224200322|NCT05029167|OTHER|High normal MAP|The patients are randomized to receive a Phillips M1006B blood pressure measuring module, offset by -10 %. All patients will target a MAP of 70, but due to the offset module, the patients will target an actual blood pressure of 77mmHg.
223603871|NCT05352425|DEVICE|MobiusHD|The MobiusHD® device is a nickel-titanium device that is implanted in the internal carotid sinus using a minimally invasive approach.
223603872|NCT05370833|DEVICE|transcranial direct current stimulation|Anodal, 2mA, tDCS session applied on M1 for 20 minutes.
223751593|NCT07101523|BEHAVIORAL|mHealth|"The intervention was carried out over a period of 8 consecutive weeks and was delivered through a mobile application specifically developed for this project, called IDHEApp, which incorporated gamification elements to enhance user engagement and motivation. Participants in the experimental group received a structured mHealth-based program aimed at promoting healthier behaviors in three primary domains: physical activity, sedentary behavior reduction, and dietary improvement. Objective data on physical activity and sedentary behavior were collected using a smartwatch device (Fitbit Versa 3), which was worn by all participants in both the experimental and control groups throughout the study. However, only participants in the experimental group received a daily personalized behavioral challenge targeting one of the following domains:~1. Increasing physical activity (e.g., Walk an additional 1,000 steps today);~2. Reducing sedentary behavior (e.g., Stand up and move for at least 5 minut"
223751594|NCT07109076|OTHER|skin-to-skin contact|Uninterrupted skin-to-skin contact between the neonate and the mother will be initiated immediately and maintained for at least 15 minutes following cesarean birth.
223751595|NCT07109076|OTHER|routine care|Current routine neonatal care following cesarean section includes delayed umbilical cord clamping. Afterward, the newborn is dried by a midwife, dressed, briefly shown to the mother, and then handed over to the father.
223751596|NCT07110259|OTHER|DeepGEM-guided Molecular Testing and Treatment|Artificial intelligence-based mutation prediction using DeepGEM to guide clinical decision-making for molecular testing and therapy selection.
223751597|NCT07110259|OTHER|Standard Diagnostic Pathway|DeepGEM is used for eligibility screening, but its results are withheld. Clinicians manage patients per standard diagnostic and treatment practices.
223751598|NCT07109999|OTHER|None-placebo|This study is an observational study, and no interventions will be implemented.
223751599|NCT07110701|OTHER|Retention of the fissure sealants evaluated|Following classification system was employed for the retention evaluation of the sealants: 1 = complete retention; 2 = partial loss; or 3 = complete loss.
223751600|NCT07109973|BEHAVIORAL|Culturally Adapted Cognitive Behavioural Therapy (CA-CBT)|CA-CBT is an 8-week manualized therapy program based on core CBT principles, adapted for Arab and Asian adolescents in the UAE. Adaptations followed the Southampton Adaptation Framework (SAF-CaCBT) and the PEN-3 model, including culturally relevant metaphors, integration of religious/spiritual beliefs, family involvement, and emphasis on academic and familial stressors. Sessions were delivered weekly for 60 minutes by trained therapists, with support in English, Arabic, and Tagalog.
223751601|NCT07109973|OTHER|Treatment-as-Usual (TAU)|Participants in the TAU group received standard care available within their community. This included optional access to school counselors, general practitioners, or local mental health clinics. No structured psychotherapy or manualized intervention was provided by the research team. This arm served as a pragmatic comparator to evaluate the added value of the Culturally Adapted Cognitive Behavioural Therapy (CA-CBT) intervention.
223751602|NCT07109622|DIETARY_SUPPLEMENT|LN18178|400 mg, One capsule to be consumed in the morning after breakfast for 12 weeks.
223751603|NCT07109622|DIETARY_SUPPLEMENT|Placebo|One capsule to be consumed in the morning after breakfast for 12 Weeks
223603873|NCT02037906|RADIATION|Escalating Energy SWL|Dose escalation, 1500 SW at 18 kv, followed by 1500 SW at 20 kv and the following 1500 SW at 22 kv.
223603874|NCT02037906|RADIATION|Constant Energy SWL|Constant dose at 20 kv
223603875|NCT02037906|RADIATION|Reduction Energy SWL|Dose reduction, 1500 SW at 22 kv, followed by 1500 SW at 20 kv and the following at 18 kv.
223603876|NCT04480632|BIOLOGICAL|Convalescent plasma|ABO compatible convalescent plasma obtained from from recovered COVID-19 patients
223603877|NCT02848391|OTHER|Environmental|hypobaric flight simulation
223603878|NCT01580202|DRUG|Entecavir|Entecavir 0.5mg daily per os
223603879|NCT01580202|DRUG|Lamivudine|lamivudine 100mg daily per os
223603880|NCT00214058|DRUG|Carboplatin|
223603881|NCT00214058|DRUG|Docetaxel|
223603882|NCT05271448|OTHER|Continue ACEI or ARBs ( Enalapril , Ramipril , Valsartan , Candesartan, Losartan )|Randomized to continue on prescribed ACE1 or ARBs ( Enalapril 5, 10, 20 mg // Ramipril 2.5 , 5 mg // Valsartan 80 , 160 mg // Candesartan 8, 16 mg // Losartan 50 mg )
224075383|NCT04655664|DIAGNOSTIC_TEST|not currently consumed vitamin D supplements regularly|The tests carried out were examination of 25 (OH) D and 1.25 (OH) D levels of serum and saliva, examination of demographic data, and other anthropometries. The examination was carried out by taking 5 mL of blood and 2 mL of saliva, and then checking the serum and saliva levels of 25 (OH) D and 1.25 (OH) D. Before the examination, the research subjects were asked not to consume food or drink for at least 90 minutes before being examined. Centrifugation was carried out (2500 g, 10 minutes) and the product immediately stored at -20 oC. In the serum examination, after the blood was drawn, centrifugation was carried out and the product stored at -20 oC for further determination of the levels of 25 (OH) D and 1.25 (OH) saliva.
223603883|NCT05271448|OTHER|Hold ACEI or ARBs|"Angiotensin converting enzyme inhibitor or angiotensin receptor blocker held at least 24 hours pre-cardiac catheterization and restarted 48-72 hours post-catheterization (after creatinine measurement)~Other Name: Includes all ACEI inhibitors or ARBs"
223603884|NCT01462396|DEVICE|CD34+ cells selected with the Miltenyi Clinimacs machine|Haploidentical allogeneic stem cell transplant following sub-myeloablative conditioning and cell selection using the Miltenyi Clinimacs device
223603885|NCT05024708|OTHER|Cardiac exercises and tests|Rest ECG, rest echocardiography, cardio-pulmonary exercise test, exercise echocardiography, holter ECG monitor (48 yours), rest CMR, exercise CMR (ergocycle)
223603886|NCT00571805|DRUG|varencline|2.0 mg/day varencline (1.0 mg BID)
223603887|NCT00571805|DRUG|placebo|matching placebo
223603888|NCT06077942|DEVICE|FX Artificial Shoulder Prosthesis|Humelock II Anatomic Shoulder System, Humelock II Reversible Shoulder System, Humelock Reverse Shoulder System, Humeris Shoulder System, Easytech Anatomical Shoulder System, PRCT II Fracture Plate, V-135
223603889|NCT04198077|DRUG|Oxygen|Administered via invasive or non-invasive mechanical ventilation with fraction of inspired oxygen between 0.21 and 1.0
223603890|NCT01799824|BIOLOGICAL|ANT-1403|
223603891|NCT01799824|BIOLOGICAL|placebo|
223603892|NCT05367843|DRUG|PRIME-2-CoV_Beta|Intramuscular (IM) injection
223751604|NCT07108530|OTHER|Integrated IAV/MA Chemotherapy and Allo-HSCT Protocol for Adult AML|This intervention is distinguished by its risk-adapted, time-compressed, and economically tiered design. It integrates two induction options-IAV (idarubicin + cytarabine + venetoclax) for patients with better economic resources and DAV (daunorubicin + cytarabine + venetoclax) for those with limited resources-followed by consolidation with either the MA regimen (liposomal mitoxantrone + intermediate-dose cytarabine) or intermediate-dose cytarabine alone. Eligible patients proceed directly to allogeneic hematopoietic stem cell transplantation (allo-HSCT) with a FA-BuCy/ATG conditioning regimen and a novel GVHD prophylaxis strategy using anti-CD25 monoclonal antibody combined with delayed oral cyclosporine. The entire treatment is designed to be completed within four months from diagnosis. This protocol is unique in its combination of liposomal chemotherapy, venetoclax-based induction, and tailored transplant strategies.
223751605|NCT07108530|DRUG|First Induction (IAV or DAV Regimen)|"* IAV Regimen:Intravenous Idarubicin (Ida): 6 mg/m²/day on days 1-3 (total cumulative dose ≤ 40 mg)，Intravenous Cytarabine: 100 mg/m²/day on days 1-7，Oral Venetoclax: 8-day schedule（100 mg on day 4, 200 mg on day 5, and 400 mg/day on days 6-11）~* DAV Regimen：Intravenous Daunorubicin (D): 60 mg/m²/day on days 1-3，Intravenous Cytarabine: 100 mg/m²/day on days 1-7，Oral Venetoclax: 8-day schedule（100 mg on day 4, 200 mg on day 5, and 400 mg/day on days 6-11）"
223751606|NCT07108530|DRUG|Consolidation Therapy Options: MA or Intermediate-Dose Cytarabine Regimen|"* MA Regimen (Liposomal Mitoxantrone + Intermediate-Dose Cytarabine):Liposomal Mitoxantrone: 10 mg/m²/day on days 1-2.Cytarabine: 1 g/m² every 12 hours for 3 days (days 1-3).~* Intermediate-Dose Cytarabine Regimen:Cytarabine: 1 g/m² every 12 hours for 3 days (days 1-3)."
223751607|NCT07108530|OTHER|Subsequent Treatment Plan for Transplant-Eligible Patients|"Patients eligible for allogeneic hematopoietic stem cell transplantation (allo-HSCT) should proceed directly to transplant after the above two treatment cycles（The requirement before transplantation is that minimal residual disease should be negative).~* Conditioning Regimen: FA + BuCy (Fludarabine + Busulfan + Cyclophosphamide). For haploidentical transplantation, ATG (antithymocyte globulin) is added.~* Donor Selection Priority:~  1. HLA-matched sibling donor (MSD)~ 2. Matched unrelated donor (MUD)~ 3. Haploidentical donor (Haplo) Selection should consider donor age, health status, and other clinical factors."
223751608|NCT07108530|OTHER|Allogeneic Stem Cell Transplantation Protocol|"Conditioning Regimen: FA-BuCy/ATG~* Fludarabine: 30 mg/m²/day on days -8 to -6~* Cytarabine: 1 g/m²/day on days -8 to -6~* Busulfan: 2.4 mg/kg/day on days -5 to -3~* Cyclophosphamide: 30 mg/kg/day on days -4 to -3~* ATG (Antithymocyte Globulin): 7.5 mg/kg total dose, administered from day -5 to -2"
223751609|NCT07108530|OTHER|GVHD Prophylaxis Regimen|"GVHD Prophylaxis~* Recombinant Humanized Anti-CD25 Monoclonal Antibody: 50 mg on days +1 and +4.~* The GVHD prophylaxis regimen consists of cyclosporine, mycophenolate mofetil (MMF), and short-course methotrexate (MTX).Cyclosporine (CsA):Initiated as a continuous 24-hour intravenous infusion at a dose of 2 mg/kg/day, starting from day -9 before transplantation.Once the patient can tolerate oral intake, cyclosporine is switched to oral administration at a dose of 3-5 mg/kg/day, divided into two daily doses.The target therapeutic trough concentration of cyclosporine should be maintained between 150-250 μg/L.~* Delayed Oral Cyclosporine Protocol:Continue IV infusion until day +20, even if GI symptoms resolve.Switch to oral only if no acute GVHD occurs.If grade II-IV acute GVHD develops, continue IV CsA."
224200323|NCT00552812|DEVICE|Stent therapy of aortic coarctation|Transcatheter delivery of a metallic stent to enlarge region of aortic narrowing caused by the coarctation.
224200324|NCT00080925|BIOLOGICAL|filgrastim|
224200325|NCT00080925|BIOLOGICAL|graft-versus-tumor induction therapy|
223603893|NCT03981627|DRUG|ADO09 formulation|Subcutaneous injection of ADO09 formulation
223603894|NCT03981627|DRUG|NovoRapid®|Subcutaneous injection of insulin aspart
223603895|NCT00724633|OTHER|Lowering the dialysate sodium|Please see above
223603896|NCT05095350|BIOLOGICAL|Probiotic powder|Probiotic powder containing 10 strains from Lactobacillus and Bifidobacterium genus.
223603897|NCT05095350|BIOLOGICAL|Placebo powder|Placebo powder containing maltodextrin and no probiotics.
223603898|NCT03666221|DRUG|Nimotuzumab|Drug: Nimotuzumab Radiation: Intensity Modulated Radiation Therapy
223603899|NCT03275038|BEHAVIORAL|Tai-Chi exercise|Behavioral: Tai-Chi exercise
223603900|NCT03275038|BEHAVIORAL|Aerobic exercise|Behavioral: Aerobic exercise
223603901|NCT01548196|PROCEDURE|Standard Percutaneous nephrolithotomy|Percutaneous nephrolithotomy
223603902|NCT01301170|PROCEDURE|dry needling|The needling will take place bilaterally at both the suboccipital region and the paravertebral muscles between C4 and T4. The needling will take place with the patient in the prone position. Following all needle placement, they will rotated clockwise till the point that tension on the needle is felt by the therapist. This will create more tension between the needle and tissue fibers, after which the needles were removed.
223603903|NCT03002883|BEHAVIORAL|Usual Care|"Participant provided Quit Kit water bottle with small cessation aids (eg. sunflower seeds) and educated about student health as a cessation resource"
223603904|NCT03002883|BEHAVIORAL|Brief Motivational Interviewing|Peer educator conducts brief motivational interviewing about smoking cessation and participant goals
223603905|NCT03002883|BEHAVIORAL|Direct referral to quitline|Peer educator educates about state quitline services and gets verbal consent to use quitline's direct referral web portal for quitline to contact participant in 1-2 business days about free counseling services to make a quit plan
223603906|NCT05222126|PROCEDURE|Ultrasound-guided Hydrodissection (HD) with 5 cc 5% Dextrose|The median nerve will be defined at the proximal entrance of the carpal tunnel (scaphoid-pisiform plane). Under the ulnar approach with the in-plane technique, first it was planned to hydrodissect the median nerve from the retinaculum superiorly and then from the flexor tendons inferiorly, using 5 cc of 5% dextrose.
223603907|NCT05222126|PROCEDURE|Ultrasound-guided Hydrodissection (HD) with 5 cc Normal Saline|The median nerve will be defined at the proximal entrance of the carpal tunnel (scaphoid-pisiform plane). Under the ulnar approach with the in-plane technique, first it was planned to hydrodissect the median nerve from the retinaculum superiorly and then from the flexor tendons inferiorly, using 5 cc normal saline.
223603908|NCT05222126|PROCEDURE|Ultrasound-guided Hydrodissection (HD) with 10 cc 5% Dextrose|The median nerve will be defined at the proximal entrance of the carpal tunnel (scaphoid-pisiform plane). Under the ulnar approach with the in-plane technique, first it was planned to hydrodissect the median nerve from the retinaculum superiorly and then from the flexor tendons inferiorly, using 10 cc 5% dextrose.
223751610|NCT07108530|OTHER|Subsequent Consolidation Therapy for Transplant-Ineligible Patients|"1. Consolidation Therapy (Two Cycles)~   * Option A Intermediate-Dose Cytarabine-Based Regimen：Liposomal Mitoxantrone: 10 mg/day on days 1-2 (dose-reduced).Cytarabine: 1 g/m² every 12 hours for 3 days (days 1-3).~  * Option B VA Regimen (Venetoclax + Azacitidine)：Venetoclax (V): Dose-escalation starting at 100 mg on day 1, increasing to 400 mg/day by day 6, continued through day 14.Azacitidine (A): 75 mg/m²/day subcutaneously or intravenously on days 1-7.~  * Treatment Cycle:Each regimen is administered for two cycles with a 3-week interval between cycles, followed by maintenance therapy.~2. Maintenance Therapy After Two Consolidation Cycles~   * Pegylated Interferon α-2b (Long-acting Interferon): 180μg subcutaneously every two weeks.~Continued until disease progression or unacceptable toxicity occurs."
223751611|NCT07110363|DRUG|BT02|monoclonal antibody injection with intravenous administration every 2 or 3 weeks
223751612|NCT07110038|DRUG|Avelumab|Avelumab, 1,200 mg IV
223603909|NCT05222126|PROCEDURE|Ultrasound-guided Hydrodissection (HD) with 10 cc Normal Saline|The median nerve will be defined at the proximal entrance of the carpal tunnel (scaphoid-pisiform plane). Under the ulnar approach with the in-plane technique, first it was planned to hydrodissect the median nerve from the retinaculum superiorly and then from the flexor tendons inferiorly, using 10 cc normal saline.
223603910|NCT03203434|DIAGNOSTIC_TEST|Urinary volatile organic compound analysis|
223603911|NCT01001793|DEVICE|Levacor Ventricular Assist Device|Surgical procedure
223603912|NCT05840536|DRUG|Furosemide plus Chlorothiazide|"Patients will receive lasix infusion starting at 5mg/hr along with a bolus dose of chlorothiazide 250mg at the initiation of the protocol. The lasix infusion can be titrated to 10mg after 12hrs based on volume of diuresis. This arm will also receive 250mg bolus doses of chlorothiazide every 12hrs for the duration of the study.~Intravenous (IV) lasix infusion at 5mg/hr plus IV boluses of diuril every 12 hrs."
223603913|NCT05840536|DRUG|Furosemide|Patients will receive furosemide infusion at 5mg/hr along with an initial bolus dose of furosemide equal to twice their home oral dose. The furosemide infusion can be increased to 10mg/hr after 12hrs based on urine output. This arm will receive bolus doses of furosemide every 12hrs equal to twice their home oral dose until completion of the protocol.
223603914|NCT05137769|BEHAVIORAL|Body Scan|The body scan is a core element of mindfulness-based stress reduction. Participants will listen to a 20-minute audio guide instructing them to focus on sensations in the body, place attention on one area of the body at a time, and progressively move attention throughout areas of the body.
223603915|NCT02199561|BIOLOGICAL|Fecal Microbiota Transplant|Fecal transplant processed from routinely screened universal donor
223603916|NCT00241592|DRUG|Cannabis|
223603917|NCT04649177|DEVICE|Ocular surface optical coherence tomography|EYEdeal Scanning technology enables rapid measurement of the corneal and scleral topography which provides data for an automated sequence to fit PROSE devices
223603918|NCT02340910|PROCEDURE|Short Duration|During each WBV repetition, subjects will stand on the vibration platform of the WBV device with knees slightly bent (approximately 30 degrees flexion). The subject will hold the handrails for balance and the WBV device will be turned on. The subject will receive a total of 6 minutes of WBV at a frequency of 50 Hz.
223603919|NCT02340910|PROCEDURE|Long Duration|"During each WBV repetition, subjects will stand on the vibration platform of the WBV device with knees slightly bent (approximately 30 degrees flexion). The subject will hold the handrails for balance and the WBV device will be turned on. The subject will receive a total of 12 minutes of WBV at a frequency of 50 Hz.~Interventions will occur for a total of 20 sessions over 4 consecutive weeks ."
223603920|NCT01985425|DRUG|Colchicine 0.6 mg|
223603921|NCT01985425|DRUG|Placebo Colchicine|
223603922|NCT01428531|DRUG|Fondaparinux Sodium|
223603923|NCT02797782|OTHER|Detection of anti HBs antibody titer|All samples will be analyzed for anti HBs antibody titer using ELISA kits.
223603924|NCT02272712|BEHAVIORAL|Cognitive Behavioural Therapy|psychoeducation about insomnia, relaxation training, sleep restriction, stimulus control, hypnotic tapering under direction of a physician, cognitive therapy, sleep hygiene
223603925|NCT01957202|DRUG|FF/levocabastine|FF/levocabastine (25mcg/50 mcg) will be supplied as intranasal aqueous microsuspension in an amber glass bottle fitted with a white top actuated plastic metering atomising spray pump filled with a uniform white suspension. Two sprays in each nostril in the morning in a fasted state will be administered.
223603926|NCT01957202|DRUG|FF|FF (25mcg) will be supplied as intranasal aqueous microsuspension in an amber glass bottle fitted with a white top actuated plastic metering atomising spray pump filled with a uniform white suspension. Two sprays in each nostril in the morning in a fasted state will be administered.
223603927|NCT01957202|DRUG|levocabastine|levocabastine (50mcg) will be supplied as intranasal aqueous microsuspension in an amber glass bottle fitted with a white top actuated plastic metering atomising spray pump filled with a uniform white suspension. Two sprays in each nostril in the morning in a fasted state will be administered.
223751613|NCT07110038|DRUG|enfortumab vedotin|Enfortumab vedotin, 1.25 mg/kg IV
223751614|NCT07108712|OTHER|Magnetic Resonance Imaging (MRI)|Magnetic Resonance Imaging (MRI) Scanner: All imaging will be performed using a 1.5 tesla MRI scanner to ensure high resolution and signal-to-noise ratio.
223751615|NCT07110103|DRUG|golidocitinib with PD-1 inhibitors|"Dose escalation: 75/150mg golidocitinib with PD-1 inhibitors as maintenance treatment after 4 cycles of PD-1 inhibitors and chemotherapy.~Dose expansion: Selected dose (75mg or 150mg) of golidocitinib with PD-1 inhibitors as maintenance treatment after 4 cycles of PD-1 inhibitors and chemotherapy."
223751616|NCT07109908|BEHAVIORAL|Wiping Bath|"The babies in this group were given the first bath in the form of wiping baths. The bathing application was carried out by the midwife working in the unit and experienced in bathing newborns.~The newborn's clothes except the diaper are removed, the newborn is wrapped in a towel, the newborn's face and body are wiped clean with a skin cleanser and cotton cloth compatible with the baby's skin, the diaper is removed and the genital area is wiped, the baby's body is wiped with a cloth moistened with water (37-39 oc), the body is dried, the baby's body is wrapped in a dry towel, the baby's head is washed with a shampoo compatible with the baby's skin, the baby's head is dried and a hat is put on, The newborn was dressed in clothes."
224200326|NCT00080925|BIOLOGICAL|rituximab|
224200327|NCT00080925|BIOLOGICAL|therapeutic allogeneic lymphocytes|
224200328|NCT00080925|DRUG|cyclophosphamide|
224200329|NCT00080925|DRUG|cyclosporine|
224200330|NCT00080925|DRUG|cytarabine|
223751617|NCT07109908|BEHAVIORAL|Wrapping Bath|"The first bath of the babies in this group was in the form of a wrap-up bath, in which the baby was wrapped and placed in the bathtub. The bathing application was carried out by the midwife working in the unit and experienced in bathing newborns.~The newborn's clothes were removed, the newborn was wrapped in a towel, the newborn was slowly immersed in water wrapped in a towel in a bathtub with a maximum of 7 cm of water at the appropriate temperature (37-39 oC), the towel was gently opened and the baby's body was gently cleaned with a suitable cleansing product and a cotton swab, including the torso, legs and genital area, the baby's head was wetted and washed with a shampoo compatible with the baby's skin, the baby's head was rinsed by pouring water from the hairline, The baby's torso was gently removed from the bathtub and rinsed, the newborn baby was dried and then dressed in clothes."
223751618|NCT07109908|BEHAVIORAL|Showering Bath|"The first bath of the babies in this group was in the form of a shower bath. The bathing application was carried out by the midwife working in the unit and experienced in bathing newborns.~The newborn's clothes are removed, the newborn's body is soaked with water at the appropriate temperature (37-39 oC) under running water, the body is washed with the appropriate skin cleanser and cotton cloth, the head is washed with the appropriate shampoo for the baby's skin, the whole body is rinsed under running water, the whole body is dried with a towel and the clothes are dressed."
223751619|NCT07110025|OTHER|designed physical therapy program|a one-hour physical therapy program, focusing on abdominal and back muscle activation and improving balance during standing. The program includes exercises like supine on wedges, prone on wedges, weight shifting, and balance training.
223751620|NCT07110025|OTHER|core stabilization exercise with neuromuscular electrical stimulation|The text describes various exercises for children to improve their physical abilities. These exercises include bridging, crab, plank, superhero, wheelbarrow walk, and kneeling on balls. The placement of electrodes on the gluteus maximus and rectus abdominis muscles is determined using anatomical landmarks. The electric current is generated using a biphasic symmetrical waveform with pulse width and intensity, and the stimulus frequency is adjusted to 35 Hz. The neuromuscular electric stimulation mode is used in a Synchronous mode.
223751621|NCT07103551|BIOLOGICAL|Platelet-rich plasma|Platelet-rich plasma used during clear aligner therapy for acceleration of Orthodontic Tooth Movement
223751622|NCT07109921|BEHAVIORAL|Structured Early Rehabilitation Nursing Program|A protocolized, phased program. Phase 1 (unconscious): passive range of motion and repositioning. Phase 2 (awake/stable): respiratory training (deep breathing, incentive spirometry), bed mobility (bridging, rolling), and progressive mobilization (sitting at edge of bed). Phase 3 (active): in-place stepping and supervised ambulation. Psychological support was provided throughout. Safety criteria were monitored continuously.
223751623|NCT07109921|OTHER|Usual Care|Standard ICU management for SAP as directed by the primary ICU team. Rehabilitation was discretionary, typically limited to passive range of motion exercises by bedside nurses if deemed necessary.
223603928|NCT01957202|DRUG|Placebo|Placebo will be supplied as intranasal aqueous microsuspension in an amber glass bottle fitted with a white top actuated plastic metering atomising spray pump filled with a uniform white suspension. Two sprays in each nostril in the morning in a fasted state will be administered.
223603929|NCT05639296|OTHER|Discovery learning (DL)|"DL makes the trainee practice before giving them instruction, Do-Then-Tell, thereby promoting their ability to use and build upon their existing knowledge."
223603930|NCT01456169|DRUG|Azilsartan medoxomil/placebo|Azilsartan medoxomil and placebo to chlorthalidone combination tablets
223603931|NCT01456169|DRUG|Azilsartan medoxomil - chlorthalidone|Azilsartan medoxomil and chlorthalidone fixed dose combination tablets
223603932|NCT05550935|DEVICE|High-flow Nasal Cannula|HFNC is a device that, in this study, will give the maximum flow (60 L/min), with minimum adjusted temperature (31°C) and FiO2 of 21% or room air.
223603933|NCT01671033|BEHAVIORAL|Biofeedback|Patients with panic disorder practice muscle relaxation with temperature biofeedback monitor, and send the temperature data to server via internet every day. Therapist gives comments and suggestions on line. Patients also have to complete some self-rating scales on browser every day or every week.
223603934|NCT01671033|BEHAVIORAL|Muscle Relaxation|Patients with panic disorder practice muscle relaxation via internet every day. Therapist gives comments and suggestions on line. Patients also have to complete some self-rating scales on browser every day or every week.
223603935|NCT03120130|BIOLOGICAL|Amblyomin-X|Intravenous drug administration, with different doses in each cohort
223603936|NCT01888224|DRUG|Isotretinoin|Isotretinoin Capsules,40 mg
223603937|NCT05547126|DEVICE|Transcranial direct current stimulation|"It is currently known that Transcranial Direct Current Stimulation (tDCS) can modulate cortical activity, being considered an important resource in the treatment of sequelae resulting from stroke.~Cognitive motor dual-task training (CMDT) is a type of cognitive rehabilitation training at the same time as exercise rehabilitation therapy."
223603938|NCT02398604|DRUG|Allo-hMSCs|Allogeneic Human Mesenchymal Stem Cells
223603939|NCT02398604|DRUG|Placebo|Placebo
223603940|NCT04355403|DEVICE|Hyalo Gyn gel in prefilled applicators|One vaginal application of Hyalo Gyn gel every 3 days to a total of 12 consecutive weeks.
223751624|NCT07109102|OTHER|Moderate-intensity eccentric cycling|"* This group will perform eccentric cycling exercise twice per week for ten weeks using the Cyclus2 standard eccentric ergometer.~* The intensity will start at 60% of the peak power output (PPO) of the incremental concentric cycling test.~* The intensity will progressively increase by 5% of PPO every 2 weeks (60%-80% PPO)."
224200331|NCT00080925|DRUG|doxorubicin hydrochloride|
224200332|NCT00080925|DRUG|etoposide|
224200333|NCT00080925|DRUG|fludarabine phosphate|
224200334|NCT00080925|DRUG|prednisone|
224200335|NCT00080925|DRUG|vincristine sulfate|
224200336|NCT00080925|PROCEDURE|peripheral blood stem cell transplantation|
224200337|NCT04120701|DRUG|mFOLFOX6|Patients receive adjuvant chemotherapy every 2 weeks during 6 months: FOLFOX6m (5-FU, leucovorin and oxaliplatin).
223603941|NCT04517565|DIAGNOSTIC_TEST|Brain magnetic resonance imaging|Brain magnetic resonance imaging (MRI) will be done using multiple sequences to evaluate presence, type and severity of brain abnormalities in enrolled subjects.
223751625|NCT07109102|OTHER|High-intensity eccentric cycling|"* This group will perform eccentric cycling exercise twice per week for ten weeks using the Cyclus2 standard eccentric ergometer.~* The intensity will start at 80% of the peak power output (PPO) of the incremental concentric cycling test.~* The intensity will progressively increase by 5% of PPO every 2 weeks (80%-100% PPO)."
223603942|NCT04517565|BEHAVIORAL|Neuro-psychology testing|Participants will undergo age-appropriate neuro-psychology testing to assess motor, language and other neuro-cognitive functions potentially affected by Sturge-Weber syndrome.
223603943|NCT05021146|OTHER|usual care and topical essential copaiba oil|All subjects will receive daily interdisciplinary - multimodular -treatment during their hospital stay including a daily 30 minute massage therapy. Both experimental groups and the placebo group patients continue to use topical treatment in the first half of the follow up period (90 days).
223603944|NCT05021146|OTHER|usual care and placebo treatment|All subjects will receive daily interdisciplinary - multimodular -treatment during their hospital stay including a daily 30 minute massage therapy. Both experimental groups and the placebo group patients continue to use topical treatment in the first half of the follow up period (90 days).
223603945|NCT05021146|OTHER|usual care|All subjects will receive daily interdisciplinary - multimodular -treatment during their hospital stay.
223603946|NCT00412243|DRUG|Clofarabine|40 mg/m\^2 Daily for 3 Days
223603947|NCT00412243|DRUG|Cyclophosphamide|Beginning dose 200 mg/m\^2 every 12 hours for 3 days
223603948|NCT02859103|DRUG|Desvenlafaxine|Patients will be provided 50mg dose of desvenlafaxine for 1 week titrated up to 100mg dose of desvenlafaxine for 7 weeks.
223603949|NCT00935311|DRUG|ABT-712 Extended-release|ABT-712 extended-release tablet
223603950|NCT00935311|DRUG|Hydrocodone/Acetaminophen Immediate-release|Hydrocodone/acetaminophen immediate-release tablet
223603951|NCT00935311|DRUG|Placebo|Placebo tablet
223603952|NCT04336072|BEHAVIORAL|RFPP|
223603953|NCT04336072|BEHAVIORAL|TFCBT|
223603954|NCT00729625|DEVICE|robotic device|"The device has a small air muscle that when activated will slowly lift their fingers and wrist from your resting wrist position. This device is classified as a non-significant risk device by the FDA (see attached letter dated 1-15-05). The patient should not experience any pain or discomfort during this stretching activity. If they do experience any pain or discomfort they can activate a stop switch located on the control box with their unimpaired hand."
223751626|NCT07109102|OTHER|Moderate-intensity concentric cycling|"* This group will perform concentric cycling exercise twice per week for ten weeks using the Lode Excalibur sport ergometer.~* The intensity will start at 60% of the peak power output (PPO) of the incremental concentric cycling test.~* The intensity will progressively increase by 5% of PPO every 2 weeks (60%-80% PPO)."
223603955|NCT01593124|DRUG|Imiquimod|Participants first have sampling in the follicular and luteal phases of the menstrual cycle. Then participants receive 4 doses of HEC placebo gel in the luteal phase. Finally, participants are randomized to the order of IMiquimod, 2 doses vaginally, in the luteal phase and nonoxynol-9, 4%, 4 doses vaginally in the luteal phase.
223603956|NCT01593124|OTHER|Placebo|Participants first have sampling in the follicular and luteal phases of the menstrual cycle. Then participants receive 4 doses of HEC placebo gel in the luteal phase. Finally, participants are randomized to the order of IMiquimod, 2 doses vaginally, in the luteal phase and nonoxynol-9, 4%, 4 doses vaginally in the luteal phase.
223603957|NCT01593124|DRUG|Nonoxynol-9|Participants first have sampling in the follicular and luteal phases of the menstrual cycle. Then participants receive 4 doses of HEC placebo gel in the luteal phase. Finally, participants are randomized to the order of IMiquimod, 2 doses vaginally, in the luteal phase and nonoxynol-9, 4%, 4 doses vaginally in the luteal phase.
223603958|NCT04498442|BEHAVIORAL|Simha Kriya|Simha-Kriya involves deep breathing exercises and meditation. It is the practice of extending the breath, expanding our lung capacity and mental concentration and energizing the body. Simha Kriya, when practiced intentionally will unite the mental, physical, and spiritual body through the breath. For the purpose of this study we advocate practice of Simha Kriya at least once a day.
223603959|NCT04498442|BEHAVIORAL|Reading a Book|Reading a book regularly promotes knowledge enhancement, reduces stress and enhances memory among other benefits. Reading a book is often inculcated into mindfulness research due to it's impact on the personality and attitude. The simple act of reading a book can have a significant impact on their attitudes and can help them cope better with stress. For the purpose of this study, we advocate reading any book/ journal of participants choice routinely for 15 minutes each day. Reading a book could potentially be substituted with sitting idle for 15 minutes if participants wishes to.
223603960|NCT01561521|DRUG|AKF-1|1 drop AKF-1 0.025% in each eye at 2 separate times during a 14 day period
223603961|NCT01561521|DRUG|AKF-1|1 drop AKF-1 0.035% in each eye at 2 separate times during a 14 day period
223603962|NCT01561521|DRUG|AKF-1|1 drop 0% in each eye at 2 separate times during a 14 day period
223603963|NCT05878847|DIETARY_SUPPLEMENT|Q-actin|idoBR1 is an iminosugar amino acid isolated from fruits of certain cucumbers, Cucumis sativus (Cucurbitaceae), which has been shown to have anti-inflammatory activity. IminoTech Inc in the USA has produced a quality-controlled cucumber extract containing measured idoBR1 (Q-actin™) that has given good results in osteo-arthritis from oral use.
223603964|NCT05878847|DIETARY_SUPPLEMENT|Placebo|Placebo
223603965|NCT05478083|DRUG|Leuprorelin|Treatment consist of leuprorelin 3.75 mg once monthly for the first 3 months followed by 3-monthly injections of 11.25 mg. The direct start group will use leuprorelin for 36 months. The delayed start group will use standard of care in the first 18 months.
223603966|NCT00960492|DRUG|XL184|XL184 will be administered daily as a single oral agent supplied as 25- and 100-mg capsules
223603967|NCT00960492|DRUG|temozolomide|TMZ will be supplied as 5-, 20-, 100-, 250-, 140-, and 180-mg capsules. The starting dose will be 75 mg/m2/day given daily with concurrent RT for 6 weeks
223603968|NCT00960492|DRUG|temozolomide|TMZ will be supplied as 5-, 20-, 100-, 250-, 140-, and 180-mg capsules. The starting dose will be 200 mg/m2/day given for 5 consecutive days and repeated every 28 days.
223751627|NCT07108374|OTHER|Implementation strategies to increase use of transfusion recommendations|Five implementation strategies will be employed in this study to enhance use of the blood transfusion recommendations. These include 1) building consensus, 2) provider education, 3) identifying and empowering champions ,4) use of computerized clinical decision support tools, and 5) provide quantitative metric-based feedback. Strategies 1-3 will occur prior to initiation of CCDS tools. All patients admitted to the PICU following the date of CCDS tool initiation will be considered to be part of the post-implementation phase. The investigators will collect data from the EHR on CCDS use and conduct provider surveys and interviews following CCDS tool initiation. Surveys and interviews will be both be conducted at 6 and 12 months post-CCDS tool initiation. Process and outcomes measures will be assessed before an after use of the implementation strategies.
223603969|NCT00960492|RADIATION|Radiation Therapy|Subjects will receive RT consisting of fractionated focal irradiation administered using 1.8-2 Gy/fraction, daily for 5 days/week for 6-7 weeks, for a total dose of up to 60 Gy.
223603970|NCT00960492|DRUG|temozolomide|TMZ will be supplied as 5-, 20-, 100-, 250-, 140-, and 180-mg capsules.
223603971|NCT03045523|DRUG|GLPG2222 150 mg q.d.|GLPG2222 150 mg administered as a ready-to-use oral suspension, once daily (q.d.) for 29 days
223603972|NCT03045523|DRUG|GLPG2222 300 mg q.d.|GLPG2222 300 mg administered as a ready-to-use oral suspension, once daily (q.d.) for 29 days
223603973|NCT03045523|DRUG|Placebo|Placebo administered as a ready-to-use oral suspension, once daily (q.d.) for 29 days
223751628|NCT07110428|PROCEDURE|NCgroup|The patients in this group received oxygen therapy via nasal cannula at a flow rate of 5 L/min, with an oxygen concentration of 100%. An end-tidal carbon dioxide (ETCO2) monitoring catheter was placed at the nostril opening to monitor ETCO2, observe whether the waveform was regular, and record the values.
223751629|NCT07110428|PROCEDURE|SJOVgroup|Gently insert an appropriately sized WNJ tube into one nostril of the subject. Connect one port of the tube to a jet ventilator (Twinstream), with the following SJOV (Synchronized Jet Ventilation) parameters: Driving pressure (DP): 15 psi (1 bar ≈ 15 psi) Respiratory rate: 15 breaths per minute Inspiratory-to-expiratory ratio (I:E): 1:2 Fraction of inspired oxygen (FiO₂): 100% Connect the other port to an end-tidal carbon dioxide (ETCO₂) monitoring catheter to observe the ETCO₂ waveform for regularity and record the numerical values.
223751630|NCT02890589|DEVICE|SYNERGY stent|"Coronary angiography will assess the presence of at least one eligible coronary lesion requiring stent implantation before revascularization by angioplasty.~Stent will be implanted according to manufacturer's and competent authority recommendations."
223751631|NCT02890589|DEVICE|ABSORB (Everolimus-eluting Bioresorbable Vascular Scaffold)|"Coronary angiography will assess the presence of at least one eligible coronary lesion requiring stent implantation before revascularization by angioplasty.~Stent will be implanted according to manufacturer's and competent authority recommendations."
223751632|NCT06923098|PROCEDURE|PET-CT guided biopsy|PET-CT guided biopsy of lung lesions
223751633|NCT06923098|PROCEDURE|CT guided biopsy|CT guided biopsy of lung lesions
223751634|NCT06923969|OTHER|balneotherapy|
223603974|NCT05781074|DRUG|Sintilimab|a PD-1 immune checkpoint inhibitor
223751635|NCT07108946|OTHER|Black background|Changing the background color during scanning to evaluate its effect on scan quality .
223751636|NCT07108946|OTHER|White background|Changing the background color during scanning to evaluate its effect on scan quality .
223751637|NCT07108946|OTHER|Participant own skin as a background|Changing the background color during scanning to evaluate its effect on scan quality .
223751638|NCT07108868|BIOLOGICAL|CAR-T cells targeting CD19 and CD22|"Using the 3+3 design, the following dose levels will be assessed:~Dose level 1: 0.5x10e6 CAR-transduced T cells/kg; Dose level 2: 1x10e6 CAR-transduced T cells/kg; Dose level 3: 2x10e6 CAR-transduced T cells/kg; Dose level 0: 0.25x10e6 CAR-transduced T cells/kg"
223751639|NCT07108517|BEHAVIORAL|IC-Growth ACT-Based Support Program|IC-Growth Psychosocial Group Intervention is a structured, manualized program designed to enhance post-traumatic growth (PTG) in adults diagnosed with breast, colorectal, or head and neck cancer. The intervention is delivered in small groups (8-10 participants) over 6-8 weeks, with weekly 90-minute sessions led by trained health psychologists. The program integrates evidence-based therapeutic approaches, including Acceptance and Commitment Therapy (ACT), mindfulness, cognitive restructuring, narrative exercises, and interpersonal support-building, with the goal of improving psychological flexibility, resilience, quality of life, and overall well-being.
223751640|NCT06917079|DRUG|BBO-11818|Participants will receive assigned dose of BBO-11818 orally (PO)
223751641|NCT06917079|DRUG|Pembrolizumab|Patients will receive IV pembrolizumab
223751642|NCT06917079|DRUG|Platinum chemotherapy (cisplatin or carboplatin)|Patients will receive IV platinum chemotherapy (cisplatin or carboplatin)
223751643|NCT06917079|DRUG|Pemetrexed|Patients will receive IV pemetrexed
223751644|NCT06917079|DRUG|Cetuximab|Patients will receive IV cetuximab
223751645|NCT06506877|BEHAVIORAL|Implementation of Cognitive Risk Calculator (RC) and Brief Assessment of Cognitive Health (BACH)|Enrolled providers will have access to two cognitive screening tools during the active phase. The first tool is a Cognitive Risk-Calculator (RC), integrated into the Electronic Health Record, to help providers identify patients who are at high risk of exhibiting cognitive decline. The second tool is a computerized cognitive screening tool, the Brief Assessment of Cognitive Health (BACH), which patients complete independently. Results are automatically entered into the patient's medical record, along with patient-specific flags for concerns about depression and/or sleep disorder. The purpose of these tools is to facilitate cognitive screening and treatment for factors that may be contributing to cognitive decline.
223751646|NCT05573555|DRUG|ARV-471|Daily oral dosages of ARV-471 continuously, dose escalation/de-escalation in Phase 1b until RP2D determined, cycles lasting 28 days
223751647|NCT05573555|DRUG|Ribociclib|Daily oral dosages of ribociclib consecutively for 21 days followed by 7 days off treatment, cycles lasting 28 days
223603975|NCT05781074|DRUG|Lenvatinib|Lenvatinib capsules
223603976|NCT05781074|PROCEDURE|Cryoablation|Cryoablation is performed under US or CT guidance per Investigator decision
223603977|NCT02342223|DEVICE|Voluma|
223603978|NCT03101254|DRUG|LY3022855|LY3022855 is a colony-stimulating factor-1 receptor (CSF-1R) inhibitor
223603979|NCT03101254|DRUG|Vemurafenib|Vemurafenib is a BRAF inhibitor that works by blocking altered BRAF proteins from stimulating the growth of melanoma cancer cells
223751648|NCT04328207|OTHER|No Financial Incentive|Standard of care eye health education
223603980|NCT03101254|DRUG|Cobimetinib|Cobimetinib works by blocking a protein called MEK that has been known to promote melanoma growth
223603981|NCT01200368|BIOLOGICAL|13-valent pneumococcal conjugate vaccine (13vPnC)|0.5 mL per dose, 4 doses
223603982|NCT01200368|BIOLOGICAL|diphtheria, tetanus, and acellular pertussis vaccine (DTaP)|0.5 mL per dose, 4 doses
223603983|NCT01200368|BIOLOGICAL|7-valent pneumococcal conjugate vaccine (7vPnC)|0.5 mL per dose, 4 doses
223751649|NCT04328207|BEHAVIORAL|Financial Incentive|Patients who are referred for an in-person follow-up exam will receive a financial incentive once the referral visit is completed.
223751650|NCT06944002|DIETARY_SUPPLEMENT|Milk product|The participants will abstain from consumption of any dairy product for ten days and subsequently drink milk for seven consecutive days (700 ml per day), while concomitant consumption of other dairy products is also allowed.
223751651|NCT06937177|DRUG|TCMCB07|TCMCB07 is will be provided in single-use vials for subcutaneous administration
223751652|NCT06937177|DRUG|Placebo|Matching placebo
223751653|NCT07144111|DRUG|Inavolisib|Participants will receive a single oral dose of inavolisib
223751654|NCT07150143|OTHER|Exercise|Each exercise session lasts 50 minutes, consisting of a 10-minute warm-up, 30 minutes of stabilization exercises, and a 10-minute cool-down. Stabilization exercises are selected from an exercise pool according to the individual's needs, with progression ensuring throughout the program. The exercises will be administered face-to-face twice a week for eight weeks, and participants will be provided with illustrated brochures and instructed to perform a one-hour home exercise program daily.
223751655|NCT07150143|OTHER|Connective tissue massage|Connective tissue massage will be applied, starting from the basic regions and gradually incorporating other regions.
223751656|NCT07150143|OTHER|Infrared therapy|Infrared therapy will be applied for 20 minutes
223751657|NCT07150143|OTHER|Continuous ultrasound|Continuous ultrasound will be applied to the right and left sides for 7 minutes each at an intensity of 2 W/cm².
223751658|NCT07150143|OTHER|Conventional TENS|20 minutes of conventional TENS will be administered to the painful area.
223751659|NCT07167212|OTHER|Diaphragm Training|The diaphragm serves dual roles in respiration and postural control, yet its contribution is often overlooked in core stability exercise (CSE) programs for low back pain (LBP) rehabilitation. Abdominal hollowing, or the 'tummy tuck,' targets TrA and lumbar multifidus. Diaphragmatic breathing (DB) increases intra-abdominal pressure, contributing to lumbar stability. The intervention included four progressive weeks: Week 1-Supine and Crocodile breathing; Week 2-Supine and Crocodile with TheraBand; Week 3-Seated and 90/90/90 breathing; Week 4-Seated and 90/90/90 with TheraBand. Supine emphasized diaphragmatic expansion with resistance at the thoracolumbar junction; Crocodile focused on lateral rib expansion; Seated required upright posture with rib control; 90/90/90 integrated deep breathing with resisted stabilization. This study evaluates DB combined with CSE on pain, disability, muscle activity, and sleep quality in chronic LBP.
223603984|NCT01200368|BIOLOGICAL|DTaP|0.5 mL per dose, 4 doses
223603985|NCT01200368|BIOLOGICAL|DTaP|0.5 mL per dose, 4 doses
223603986|NCT05232331|DIETARY_SUPPLEMENT|Intake of nitrate rich vegetables|Nutritional intervention for 10 weeks to increase the consumption of vegetables rich in nitrate. At the beginning of the NSPT on visit 1 (week 2), the first of 5 nutritional interventions will begin with the objective of consuming \~ 350 mg of nitrate daily from vegetables
223603987|NCT00411372|DRUG|fluticasone propionate/salmeterol 250/50mcg combination, salmeterol 50mcg|
223603988|NCT05981482|DIAGNOSTIC_TEST|OxVPS|Comparing a new screening tool, the Oxford visual perception screening, to the gold standard, Rivermead Perceptual Battery Assessment.
223603989|NCT03202719|BIOLOGICAL|Bivalent oral poliovirus vaccine (bOPV) at 6,10 and 14 weeks of age|bOPV at 6, 10 and 14 weeks of age
223603990|NCT03202719|BIOLOGICAL|Inactivated poliovirus vaccine (IPV) at 14 weeks and 18 months of age|IPV at 14 weeks and 18 months of age
223603991|NCT03202719|BIOLOGICAL|Inactivated poliovirus vaccine (IPV) at 14 weeks, 18 weeks and 18 months of age|IPV at 14 weeks, 18 weeks and 18 months of age
223751660|NCT07167212|OTHER|Myofascial Release Technique|The myofascial release technique for the diaphragm was performed with the participant lying supine and limbs relaxed. The therapist, positioned at the head, placed the pisiform, hypothenar, and last three fingers bilaterally under the seventh to tenth rib costal cartilages, forearms aligned toward the shoulders. During inspiration, gentle traction was applied cephalad and slightly laterally, accompanying rib elevation. On exhalation, pressure was directed inward along the costal margin to maintain resistance. With each breath, traction was gradually deepened to improve release. The maneuver consisted of two sets of 10 deep breaths with a 1-minute rest between sets. Figure 1 illustrates the manual diaphragm release technique (source: author's photo). This method, adapted from Rocha et al. (2015), emphasizes progressive traction and controlled resistance to facilitate diaphragmatic mobility and rib cage expansion.
223751661|NCT05864053|DRUG|Ketamine|Ketamine will be administered over a 45-minute period.
223751662|NCT05864053|DRUG|(2R,6R)-hydroxynorketamine|(2R,6R)-Hydroxynorketamine hydrochloride will be administered over a 45-minute period.
223751663|NCT05864053|DRUG|Saline|Saline will be administered over a 45-minute period.
223603992|NCT03202719|BIOLOGICAL|Inactivated poliovirus vaccine (IPV) at 14 weeks and 9 months of age|IPV at 14 weeks and 9 months of age
223603993|NCT03202719|BIOLOGICAL|Inactivated poliovirus vaccine (IPV) at 6 weeks and 9 months of age|IPV at 6 weeks and 9 months of age
223603994|NCT03202719|BIOLOGICAL|Inactivated poliovirus vaccine (IPV) at 6 and 14 weeks of age|IPV at 6 and 14 weeks of age
223603995|NCT01330329|BEHAVIORAL|Standard behavioral treatment|Participants receive a standard behavioral weight loss program similar to that used in other large trials such as Look AHEAD and the Diabetes Prevention Program. Individuals will come to weekly group meetings for 6-months and will be instructed to reduce caloric intake, increase physical activity, and self-monitor their weight, eating, and exercise behaviors.
223603996|NCT01330329|BEHAVIORAL|SBT + technology system (SBT+FIT)|Participants will receive a standard behavioral weight loss program and will also be asked to use the Body Media FIT system as part of their weight loss intervention. Individuals will come to weekly group meetings for 6-months and will be instructed to reduce caloric intake, increase physical activity, and self-monitor their weight, eating, and exercise behaviors. Participants in this group will also wear an armband that measures energy expenditure and they will log their food intake on the internet.
223603997|NCT02849119|PROCEDURE|Laparoscopic or robotic partial nephrectomy|Laparoscopic or robotic partial nephrectomy of a small renal masses (T1a) through transperitoneal or retroperitoneal approach
223603998|NCT04475120|DRUG|liposomal lactoferrin|oral and intra-nasal formulation
223603999|NCT04475120|DRUG|SOC therapy|oral administration
223604000|NCT00351910|DRUG|Quetiapine|
223604001|NCT00351910|DRUG|Amitriptyline|
223604002|NCT00351910|DRUG|Bupropion|
223604003|NCT00351910|DRUG|Citalopram|
223604004|NCT00351910|DRUG|Duloxetine|
223604005|NCT00351910|DRUG|Escitalopram|
223604006|NCT00351910|DRUG|Fluoxetine|
223604007|NCT00351910|DRUG|Paroxetine|
223604008|NCT00351910|DRUG|Sertraline|
223604009|NCT00351910|DRUG|Venlafaxine|
223604010|NCT01854034|DRUG|AUY922|AUY922 administered intravenously once a week at 70mg/m2
223604011|NCT02036125|DEVICE|Ultrasound|Subjects will receive an ultrasound guided injection of 40 mg of methylprednisolone.
224200338|NCT06034301|DEVICE|Medication Reminder App|"If the participant is randomized to the intervention group, they will:~1. receive a brief education session and be handed a flyer about the importance of medication adherence.~2. get training on how to use the medication reminder app and participant will be given a user guide on how to use the app~3. demonstrate their understanding on an iPad using the teach back method~4. install and set up the medication reminder app on their phone~5. receive a MEMS cap and be given instructions on how to use it with their blood pressure medication. Study team members will use a participant ID to log into the MEMS cap application; no identifiable information will be entered."
223604012|NCT02036125|DRUG|methylprednisolone|Subjects will receive a blind injection of 40 mg of methylprednisolone.
223604013|NCT05648292|BEHAVIORAL|Neuropsychological tests and psychological questionnaires|"* The clinical group will complete:~  * the BCcogSEP: a comprehensive neuropsychological examination~ * the IAM and I WILL BE tasks; experimental neuropsychological tasks to assess autobiographical memory, future thinking and personal identity~ * A series of questionnaires including the BRIEF COPE, the Connor Davidson Resilience Scale, the Satisfaction with Life Scale and the Hospital Anxiety and Depression Scale, which respectively assess coping strategies, resilience, life satisfaction and anxiety/depression~* The control group will complete:~  * the IAM and I WILL BE tasks; experimental neuropsychological tasks to assess autobiographical memory, future thinking and personal identity~ * A series of questionnaires including the BRIEF COPE, the Connor Davidson Resilience Scale, the Satisfaction with Life Scale and the Hospital Anxiety and Depression Scale, which respectively assess coping strategies, resilience, life satisfaction and anxiety/depression"
223604014|NCT06029049|DRUG|Modified Time Principle Induction (MTPI) with rocuronium|Participants will be induced using lidocaine 1 mg/kg IV, an opioid such a fentanyl (1-2 mcg/kg) IV, followed by 0.6 mg/kg IV rocuronium, and IV propofol with dosage at the discretion of the care team, administered within 10 seconds of rocuronium and the intubation will be performed with a C-MAC
223604015|NCT06029049|DRUG|RSI succinylcholine|Participants will be induced as per routine care using lidocaine 1 mg/kg IV, an opioid such a fentanyl (1-2 mcg/kg) IV, propofol 1-2 mg/kg IV, and succinylcholine 1mg/kg IV, and the intubation will be performed with a C-MAC
223604016|NCT00287508|DEVICE|Carotid artery stenting with filter (interventional)|
223604017|NCT02016651|BEHAVIORAL|Right side position|Enrolled infants are positioned on their back or right side. Tracheal aspirate is assessed for pepsin concentration as an index of aspiration.
223604018|NCT06467903|DEVICE|SW as medical devices(comperator) to evaluate the retinal image of the patient's eye (to identify if the patient has DR or if the patient is healthy) .|second AI medical device to evaluate the retinal image of the patient's eye. two AI as MD will be evaluating the retinal image
223604019|NCT04119180|DRUG|Ketamine 50 MG/ML|Ketamine injectable solution in a concentration of 50.0 mg/mL via oral route; dose of 4.0 mg/kg maximum 100.0 mg
223604020|NCT04119180|DRUG|Midazolam Hcl 2Mg/Ml Syrup|Midazolam oral solution in a concentration of 2.0 mg/mL via oral route; dose of 0.5 mg/kg, maximum 5.0 mg when associated with ketamine;
223604021|NCT04119180|PROCEDURE|Protective stabilization|The legal guardian or accompanying person appointed by the legal guardian should sit in the dental chair with the child and contain leg and arm movements. A dental assistant keeps the child's head contained during care.
223604022|NCT02221674|DRUG|Tapentadol|
223604023|NCT05227430|OTHER|Educational video tutorials|Educational video tutorials (Hysterectomy, Bilateral salpingo-oophorectomy, Bilateral salpingectomy)
223604024|NCT04672707|DRUG|Bromhexine Hydrochloride Tablet|32 mg
223604025|NCT04672707|DRUG|Bromhexine Hydrochloride Tablet|48 mg
223604026|NCT04672707|DRUG|Bromhexine Hydrochloride Tablet|64 mg
223604027|NCT04672707|DRUG|Bromhexine Hydrochloride Tablet|80mg
223604028|NCT06555575|DRUG|Ubiquinone 200 Mg Oral Capsule|By mouth three times daily for three months
223604029|NCT06555575|DRUG|Ubiquinol 100 MG Oral Capsule|By mouth three times daily for three months
223604030|NCT06092047|BIOLOGICAL|UTAA09 cells for infusion|Intravenous injection, dosage:1-10×10\^8 CAR+ γδT cells, Cell concentration: 2×10\^7 cells/mL.
223604031|NCT06092047|DRUG|Fludarabine|30 mg/m\^2/day×4 days
223604032|NCT06092047|DRUG|Cyclophosphamide|1000 mg/m\^2/day×3 days
224200339|NCT05242146|DRUG|GB5121|Capsule containing GB5121
223604033|NCT06506487|BEHAVIORAL|Doll Therapy|Doll therapy involves the use of lifelike dolls to provide comfort and reduce behavioral and psychological symptoms in people with dementia. The therapy includes activities such as holding, dressing, and interacting with the dolls under the guidance of trained caregivers.
224200340|NCT06700486|PROCEDURE|SOCKET SHIELD|in implant dentistry
224200341|NCT06700486|PROCEDURE|Immediate implant and sticky bone|in implant dentistry
224200342|NCT01556646|DRUG|Tolvaptan|15 to 30mg qd titrated to sodium concentration
224200343|NCT03317925|PROCEDURE|Renal Transplantation|Kidney transplantation and biomarkers that can identify injury after transplant.
223604034|NCT04468919|BEHAVIORAL|BCI-FIT multi-modal access|Adding a personalized multi-modal access protocol to customize a BCI-FIT access method configuration for each individual end user, based on a combination of user characteristics, clinical expertise, user feedback, and system performance data in the software.
223604035|NCT04468919|BEHAVIORAL|BCI-FIT adaptive signal modeling|Adding a BCI-FIT adaptive signal modeling that employs transfer learning and on-line model adaptation techniques with noisy labels in the software of this brain-computer interface to eliminate the need for data collection exclusively for model calibration, as well as to address model drift issues associated with drowsiness, fatigue, and other human and environmental factors.
223604036|NCT04468919|BEHAVIORAL|BCI-FIT active querying|Adding BCI-FIT active querying techniques which are software-based optimal action control policies in the brain-computer interface developed with active and reinforcement learning techniques in order to perform efficient user intent inference to improve the entire speed-accuracy trade-off curve for alternative communication.
223604037|NCT04468919|BEHAVIORAL|BCI-FIT language modeling|Adding vocabulary and location information (called partner and environmental input) to the language models in the brain-computer interface from a user's communication partner.
223604038|NCT06101030|DEVICE|Signal On|InSee monitor patient signals are on.
223604039|NCT04891809|DRUG|Isatuximab-Irfc 20 MG/ML [Sarclisa]|Induction: 10mg/kg on day 1,8,15,22 in cycle 1, subsequently on day 1, 15; every 28 days (q28 days) Maintenance: 10mg/kg, day1, q28 days until progression or intolerance but for a maximum of 24 cycles from start of maintenance
223604040|NCT04891809|DRUG|Lenalidomide|"Induction: 25mg\*, day 1-21, every 28 days (q28 days); Maintenance: 5-10mg, day 1-21, q28 days (according to individual tolerance) until progression or intolerance but for a maximum of 24 cycles from start of maintenance~\*) for patients with moderate renal impairment (30≤ GFR (MDRD formula) \< 50 mL/min) starting dose is 10 mg"
223604041|NCT04891809|DRUG|Dexamethasone Oral|"Induction:~Patients aged \<75 years: 40mg, once weekly; Patients aged ≥75 years: 20mg, once weekly"
223604042|NCT05588648|DRUG|Vactosertib|Vactosertib is given twice a day, five days on and two days off in four-week cycles. Vactosertib is a transforming growth factor-beta (TGF-β) type 1 receptor inhibitor.
223604043|NCT06086626|DRUG|Cefiderocol|Administered via intravenous (IV) infusion
223604044|NCT06086626|DRUG|Standard of Care|Antibiotics selected by the investigator based on the participant's symptoms, in accordance with local standards
223604045|NCT03829449|DRUG|rVA576|The study population will consist of patients who have completed participation in clinical trials under other Akari protocols and who wish to continue to receive rVA576 (Coversin).
223604046|NCT02557542|OTHER|One Stop Vein Clinic|Same day diagnosis and treatment
223604047|NCT02557542|DEVICE|Radiofrequency ablation|Venous ablation
223604048|NCT02557542|DEVICE|Endovenous laser ablation|Venous ablation
223604049|NCT02557542|DRUG|Foam sclerotherapy (Polidocanol or Sodium Tetradecyl Sulphate)|Venous ablation
223604050|NCT04390880|DRUG|18F-DCFPyL|Study participants will receive intravenous administration of 18F-DCFPyL and undergo a PET/CT imaging study. Patients may be reenrolled in the study, if 18F-DCFPyL PET/CT is performed for subsequent management decision.
223751664|NCT07169929|OTHER|Measurement of fetal transverse thalamic diameter by 2dimensional abdominal ultrasound|"All pregnant women attending the feto-maternal unit with gestational age from 18 weeks to 36 weeks in the obstetrics and gynecology department in the faculty of medicine Cairo university Using curvilinear 2D transabdominal ultrasound probe of ultrasound machine either Voluson E10 GE or Nuewa I9 Elite Mindray.~The investigators will take all the biometry (Biparietal diameter, head circumference, abdominal circumference, femur length and trans-cerebellar diameter) and exclude any congenital anomalies in the scan.~Transverse thalamic diameter is to be measured by 2D ultrasound at the standard axial trans-cerebellar plane. A guitar shape representative structure is presented to demarcate the thalamic diameter.~Calculate the gestational age using transverse thalamic diameter from this equation Transverse thalamic Diameter( in mm)=0.912 x Gestational age in weeks -1.134) ( Sridar P, et al 2020)"
223751665|NCT07173790|OTHER|Patient-Reported Outcomes Survey|Participants will complete validated questionnaires including EORTC QLQ-C30, EQ-5D-5L, and disease-specific modules (QLQ-CLL17, QLQ-NHL). Responses will be used to assess quality of life and psychological distress during watchful waiting.
223751666|NCT07173855|DRUG|Magnesium sulfate administration|Magnesium sulfate is used in both arms for magnesium replacement.
223751667|NCT07173855|DRUG|Magnesium oxide|In the higher-target arm, magnesium oxide 420mg po q12h x 2 is one of the options available for magnesium replacement when magnesium levels lie between 0.75 and 0.95mmol/L.
223604051|NCT05880771|OTHER|Immediate Implant Placement|Tooth extraction followed by immediate implant placement. One group will have Allograft graft in the buccal gap, the other will have Xenograft graft.
223604052|NCT05600543|DEVICE|Lumbar belt|"All subjects (LBP group and healthy group) wear the belt during the two visits to perform differents tests.~The invistigator will ask the LBP patients to wear the lumbar belt between the two visits (for 4 weeks, for 4 to 8 hours per day)"
223604053|NCT05600543|DEVICE|Lombaskin lumbar belt and the Lyne Up percko postural T-shirt.|Lombaskin lumbar belt and the Lyne Up percko postural T-shirt could be worn during the third addtional visit proposed to the healthy subject.
223604054|NCT05042076|DRUG|BK-specific T cells from Donor Lymphocytes|"Naturally occurring, allogeneic donor lymphocytes derived from a leukapheresis, enriched for BK-specific CD4+ and CD8+ T cells~Suspension of BK-specific T cells in approximately 7 mL (5-10 mL range for volume of IMP) of 0.9% NaCl with 2.5% HSA at a cell dose of: ≥ 300 and ≤ 5,000 BK virus-specific CD3+ T cells/kg body weight (BW).~IV bolus injection; IV push of IMP over approximately 2-4 minutes, resulting in an infusion rate of approximately 3 mL/min."
223604055|NCT03976882|DRUG|Hetrombopag|Hetrombopag
223604056|NCT03976882|DRUG|Placebo|Placebo
223604057|NCT02914405|DRUG|Nivolumab|Nivolumab is a soluble protein consisting of 4 polypeptide chains, which include 2 identical heavy chains consisting of 440 amino acids and 2 identical light chains. Molecular weight is 146,221 daltons.
223751668|NCT07173855|DRUG|Magnesium glucoheptonate|Magnesium glucoheptonate 30mL po q12h x 2 is an oral option for magnesium replacement in the higher-target arm.
223751669|NCT07175831|BEHAVIORAL|Low-Intensity Continuous Training|Participants ran continuously for 30 minutes at 50% of their MAS without rest.
223751670|NCT07175831|BEHAVIORAL|Moderate intensity Interval training|Participants ran continuously for 30 minutes at 70% of their MAS without rest.
223751671|NCT07175831|BEHAVIORAL|High-Intensity Interval Training|Participants ran at 105-110% of their MAS for 15-second intervals, covering a pre-calculated distance during each bout. After each 15-second sprint, they rested passively for 15 seconds and returned to their starting point. This was repeated continuously for 5 minutes, constituting one set. A total of four 5-minute sets were completed, interspersed with 2,5-minute passive rest periods, yielding a total exercise time of 30 minutes.
223751672|NCT07180329|DIETARY_SUPPLEMENT|Myrin P Fort|Patient took Myrin P Fort
223751673|NCT07180329|DIETARY_SUPPLEMENT|Zn + Se supplemented cookies|patients took Zn + Se supplemented cookies
223751674|NCT07180329|DIETARY_SUPPLEMENT|Zn + Se + Myrin P Fort|"patients took Zn + Se~\+ Myrin P Fort"
223751675|NCT07180823|DEVICE|Bronchoscopy with Lung Vision navigation system|The procedure begins with inspection of the airways up to the subsegmental branches using a flexible bronchoscope. During the procedure, augmented fluoroscopy will be used as a guidance tool, which is already in use at our operating unit as part of normal clinical practice, and will be combined with radial ultrasound using a mini probe. Once the peripheral lesion has been located, a cytological and histological sample will be taken using a needle and/or forceps and/or cryoprobe under augmented fluoroscopic guidance and with R-EBUS, as per normal current clinical practice. If atypical cells or malignant tumour cells are found during the extemporaneous cytological examination, the FM, acquired specifically for the study, will be positioned to mark the pulmonary nodule. A coil-tailed FM will be used. Enhanced fluoroscopy will be used via the LungVision system.
223751676|NCT07180186|DRUG|Mesalamine|Patients with ulcerative colitis in remission treated with oral mesalamine.
223751677|NCT07180186|DRUG|Probiotics (Bacillus Clausii)|Patients with ulcerative colitis in remission treated with probiotics (Bacillus Clausii).
223751678|NCT07180186|DRUG|Mesalamine and probiotics (Bacillus Clausii)|Patients with ulcerative colitis in remission treated with oral mesalamine and probiotics (Bacillus Clausii).
223751679|NCT07181018|OTHER|Trial within cohort (TWIC)|"Educational intervention based on a protocol specifically developed for the TWINS.PL cohort, aimed at activating and engaging the participant in the intervention process.~Intervention group: Phenotypically concordant participants from the TWINS.PL STUDY cohort, randomized to receive an educational intervention designed to actively engage them in modifying selected health-relevant endpoints.~Control group: The co-twin of the participant randomized to the intervention arm, serving as the control.~1. TWINS-TWIC HL: Research Question: Does participation in a structured, participant-activating educational intervention program influence health literacy indicators among participants of the TWINS.PL study? Study Design: A randomized controlled trial embedded within a prospective observational twin cohort (TWiC study in a twin cohort).~2. TWINS-TWIC DIET Research Question: Does participation in a structured, participant-activating educational intervention focused on dietary habits influence the"
223751680|NCT07179705|DEVICE|Hypotensive prediction index|The HPI, developed by Edwards Lifesciences and integrated into the HemosphereⓇ hemodynamic monitoring system, is an algorithm-based tool that predicts hypotensive events before they occur, allowing earlier intervention. While this tool has shown benefit in surgical and post-operative settings, it has not been tested in ICU patients undergoing dialysis.
223604058|NCT02914405|DRUG|Ch14.18/CHO|APN311 (ch14.18/CHO) is manufactured in a Good Manufacturing Practice (GMP) compliant facility of Polymun Scientific, Austria according to a state of the art aseptic manufacturing process based on a characterized and stable Chinese Hamster Ovary (CHO) cell line. After propagation of the working cell bank (WCB) in small volume vessels/bioreactors, manufacture is carried out in a 2500 L stirred tank reactor utilizing components which are free of material of animal or human origin.
223604059|NCT01464177|RADIATION|Stereotactic hypofractionated RT 5x5Gy|"Stereotactic hypofractionated radiation therapy delivered as follows:~* Gross tumor volume (GTV) equals enhancement area in T1 contrast enhanced MRI.~* Planning tumor volume (PTV) equals GTV plus 3mm margin.~* The dose of radiation will be 25Gy delivered in 5 fractions.1 fraction per day, non consecutive days in a maximum period of 10 working days.~* RT to begin in a maximum of 2 weeks after randomization"
223604060|NCT01464177|RADIATION|Stereotactic hypofractionated RT 5x7Gy|"Stereotactic hypofractionated radiation therapy delivered as follows:~* Gross tumor volume (GTV) equals enhancement area in T1 contrast enhanced MRI.~* Planning tumor volume (PTV) equals GTV plus 3mm margin.~* The dose of radiation will be 35Gy delivered in 5 fractions.1 fraction per day, non consecutive days in a maximum period of 10 working days.~* RT to begin in a maximum of 2 weeks after randomization."
223604061|NCT06641791|RADIATION|Standard Radiotherapy (SRT)|2400 cGy in 3 fractions - day 0/7/21, OR, 2500 cGy in 5 fractions over 1 week
223604062|NCT06641791|RADIATION|Stereotactic Body Radiotherapy (SBRT)|4500 cGy in 5 fractions (twice a week to primary and nodal GTV, OR, 4000 cGy in 5 fractions twice a week if organs at risk.
223604063|NCT06643403|DRUG|Oxygen 100% Gas for Inhalation|"SAUERSTOFF medizinisch, Messer GmbH, Industriestrasse 5, 2352 Gumpoldskirchen, Austria~Dose:~min. 95.5%, breathing for max. 45 minutes"
223604064|NCT04384029|OTHER|Covid-19 + patients|all the patients hospitalized in Geneva and SARS-Cov2 positive
223604065|NCT04713163|DRUG|covid19 vaccine|Vaccine
223604066|NCT05081232|DEVICE|MLG (Multi-Layered Perinatal Issue Allograft) Allograft|"MLG allografts contains more than 450 bioactive proteins including growth factors and cytokines known to modulate inflammation and promote tissue healing.~MLG is supplied as sterile sheets having dimensions of 2cm x 2cm and a thickness of approximately 0.8-1.0mm thick.~Participants receiving MLG will have it placed around the neurovascular bundle. Placement of the graft should not take over 5 minutes of time to impact overall surgical time length significantly."
223604067|NCT04723017|OTHER|Retrospective analysis cohort|We analyze pre-existing data base and develop machine-learning-based system that predicts the risk of hypoxemia
223604068|NCT04723017|OTHER|Prospective validation cohort|We validate our model to predict the risk of hypoxemia to prospective cohort
223751681|NCT07179705|DEVICE|Standard of care monitoring|"Standard of Care~* Monitoring via conventional invasive BP and clinical judgment~* Use of physical exam, CVP, PPV, and response-based decisions (fluid bolus, vasopressors)"
224200344|NCT00002373|DRUG|Maribavir|
223604069|NCT01814475|DRUG|A: Fludarabine + Busulphan|Fludarabine 30 mg/m2/d, day -8 to day-3 and Busulphan (Busilvex) 0,8 mg/Kg/i.v. dose x 4 doses on days -5,-4 and x 2 doses on day -3, total dose 8 mg/Kg) prior allogenic transplant (day zero)
223604070|NCT01814475|DRUG|B: Fludarabine + Thiotepa|Fludarabine 30 mg/m2/d day -8 to day -3 Thiotepa 6 mg/Kg for 2 doses ( days -4, -3) prior allogeneic transplant (day zero)
223751682|NCT07180836|OTHER|No Intervention (Observational Study)|This is an observational, cross-sectional study. Patients with suspected or confirmed hemoglobinopathies were evaluated for prevalence and hematological characteristics using laboratory investigations, without any experimental treatment or therapeutic intervention applied.
223751683|NCT07181772|BEHAVIORAL|virtual escape room|Triage training will be taught to students in the experimental group for the first time through a virtual escape room game.
223751684|NCT07181772|BEHAVIORAL|with Power point education|The control group was trained using the traditional method using power point.
223751685|NCT07180056|DRUG|CDK4/6 inhibitor|abemaciclib OR ribociclib
223751686|NCT05254327|DRUG|BMX-001|Loading dose of 28 mg per subject, followed by maintenance doses of 14 mg per subject twice per week.
223751687|NCT00857922|OTHER|tissue and data repository|Tissue and data will be maintained in a repository for study from consenting subjects.
223604071|NCT01688375|DRUG|Ursodeoxycholic Acid|UDCA administration will begin twenty-four hours after endoscopic or surgical procedure and will last fourteen days. UDCA dose will be administered at 750 mg/day, divided into three doses.
223604072|NCT05900544|OTHER|System implementation of patient-centered incidental findings report|For three lung cancer screening programs a system level implementation for a patient-centered incidental findings report
223604073|NCT05468437|BEHAVIORAL|Telenutrition|Nutrition education and individualized nutrition counseling will be done with a Registered Dietitian via video-conferencing with iPad FaceTime, which is aimed to decrease the risk of complications like obesity, high cholesterol, or diabetes, and explore associations between bowel and bladder function and nutrition. The telenutrition counseling consists of 6 sessions that are scheduled approximately 2 weeks apart. The first session will last approximately 1 hour, while sessions 2-6 will last approximately 30mins. During these sessions, the Registered Dietitian will share nutrition education tailored towards people with SCI. You will be involved in developing personal nutrition goals and the dietitian will help you address barriers to meeting your goals and provide individualized feedback to improve and maintain your nutrition. Telenutrition appointments will maintain privacy and will not be recorded.
223618059|NCT02920892|OTHER|Language Intervention|"All subjects will begin an intensive language intervention 2 months after starting treatment with AFQ056 or placebo and will continue the intervention through the end of the study.~The language intervention will be administered by a trained language specialist through a combination of in clinic visits and at home synchronous video conferencing sessions. The intervention will subsequently be delivered to the parent by a speech-language clinician through weekly clinician coaching, homework, and feedback sessions.~The language intervention is designed to help parents learn and use verbally responsive interactional strategies more frequently and effectively throughout the course of their daily interactions with their children."
223751688|NCT04439318|DRUG|Trametinib Dimethyl Sulfoxide|Given PO
223751689|NCT00699972|DRUG|E2007 (perampanel)|8 mg perampanel in a 1:1:1 ratio, 125 subjects/arm. All subjects will take a maximum of 6 tablets daily for the duration of the study and will be up-titrated weekly in 2-mg increments to their randomized dose.
223751690|NCT00699972|DRUG|E2007 (perampanel)|12 mg perampanel in a 1:1:1 ratio, 125 subjects/arm. All subjects will take a maximum of 6 tablets daily for the duration of the study and will be up-titrated weekly in 2-mg increments to their randomized dose.
223751691|NCT00699972|DRUG|Placebo|Placebo in a 1:1:1 ratio, 125 subjects/arm. All subjects will take a maximum of 6 tablets daily for the duration of the study.
223751692|NCT00160316|DRUG|0.5 Mg Estradiol and 2.5 Mg Dydrogesterone|p.o. daily
223751693|NCT00126295|DEVICE|'What you need to know about stroke' education package|
223751694|NCT03057145|DRUG|Prexasertib|LY2606368 is a checkpoint kinase 1 (CHK1) inhibitor that is being developed as a treatment for patients with advanced cancer
223751695|NCT03057145|DRUG|Olaparib|Olaparib is a poly (ADP-ribose) polymerase (PARP) inhibitor.
223751696|NCT01945385|BEHAVIORAL|Video intervention|Brief 7 minute video of physician describing LARC methods followed by two patient testimonials about their own postabortal LARC experience.
223751697|NCT06492811|DRUG|GAT@F nanoenzyme hydrogel complex|The wound condition was recorded by taking photos each time the dressing was changed. The diabetic wound was routinely treated with a dressing change, after which GAT@F nanoenzyme hydrogel complex was applied externally and a secondary dressing - medical surgical gauze was added. According to existing clinical data, it is recommended to use no more than 10ml per dressing change.
223751698|NCT03425812|DRUG|To withdraw NSAIDs therapy|NSAIDs therapy will be withdrew after washout period.
223751699|NCT03425812|DRUG|To continue NSAIDs therapy|NSAIDs therapy will be continued.
223751700|NCT01485315|BIOLOGICAL|SAGM (Saline-Adenine-Glucose-Mannitol) blood transfusion|One unit prestorage, leuko-depleted SAGM blood at haemoglobin at 9.0 g/dl (5.6 mM) or less at point-of-care testing
223751701|NCT01485315|BIOLOGICAL|SAGM (Saline-Adenine-Glucose-Mannitol) blood transfusion|One unit prestorage, leuko-depleted SAGM blood at haemoglobin 7.0 g/dl (4.3 mM) or less at point-of-care testing
223751702|NCT04898751|DRUG|Immune checkpoint inhibitor (ICI)|Immune checkpoint inhibitors included were targeting either PD-1, PD-L1 or CTLA-4, and had received FDA approval at the time of study (ATC classification): Ipilimumab (L01XC11), Nivolumab (L01XC17), Pembrolizumab (L01XC18), Durvalumab (L01XC28), Avelumab (L01XC31), Atezolizumab (L01XC32), and Cemiplimab (L01XC33).
223751703|NCT03509675|DRUG|Ibuprofen suspension 5mg/100ml|Non-Steroidal Anti-inflammatory Topical Rinse will be used for Symptomatic OLP patients.
223751704|NCT03509675|DRUG|Placebos|Placebo
223751705|NCT03689361|COMBINATION_PRODUCT|MRI|Routine MRI with all the sequences performed for the management of acute neurological deficit in the Toulouse Neuro Vascular Unit (diffusion, FLAIR, T2 \*, vascular sequences (AngioRM and TOF) and perfusion).
223751706|NCT03689361|DIAGNOSTIC_TEST|MRI control|MRI with all the sequences performed for the management of acute neurological deficit in the Toulouse Neuro Vascular Unit (diffusion, FLAIR, T2 \*, vascular sequences (AngioRM and TOF) and perfusion)
223751707|NCT03689361|OTHER|telephone consultation|telephone consultation
223751708|NCT03898349|OTHER|Annie text messaging system|Annie text messaging system for patient self-management of HCV treatment including medication, lab, and appointment reminders, and motivational messages.
223751709|NCT03898349|OTHER|Annie text messaging system with Usual implementation|"Three comparison sites received usual implementation of the automated text messaging system Annie only, which involves an orientation/training meeting and the option of attending twice-monthly Annie clinical adoption calls"
223751710|NCT03898349|OTHER|Annie text messaging system with Augmented implementation|"Four facilities received the automated text messaging system Annie and our augmented implementation strategy. These facilities had regular facilitation calls, a site visit to assist with implementation, and were given the toolkit, in addition to receiving usual implementation assistance"
223751711|NCT03606681|DRUG|Calcium Hydroxide|After cleaning the caries with partial removal (non-exposed pulp), cavity disinfected with sodium hypochlorite then indirect pulp capping agent was applied to cavity and restoration was finished in the same session.
223604074|NCT05370014|BEHAVIORAL|Integrating Community-based Intervention Under Nurse Guidance with Families (iCINGS FAM)|The intervention consists of two planning sessions with the dyad (over 2 weeks) followed by eight topic-guided sessions delivered the RN-CHW team over 12 weeks (weekly the first 4 weeks, then bi-weekly) (Table 3). Key components of these televisits include COVID-19 risk mitigation, chronic disease management, medication adherence, family functioning/support, and community and health systems resource identification and referral with ongoing goal planning. The RN-CHW will meet weekly for progress review, follow up planning, and setting up anticipatory guidance for the next session with the dyads. The RN and CHW will also review IC or survivor dissatisfaction and other issues that require more immediate attention. RN-CHW planning will be assessed to make sure each televisit remain topic focused yet incorporates flexibility to suit the needs of each dyad.
223751712|NCT03606681|DRUG|Mineral Trioxide Aggregate|After cleaning the caries with partial removal (non-exposed pulp), cavity disinfected with sodium hypochlorite then indirect pulp capping agent was applied to cavity and restoration was finished in in the same session.
223751713|NCT03606681|DRUG|TheraCal LC|After cleaning the caries with partial removal (non-exposed pulp), cavity disinfected with sodium hypochlorite then indirect pulp capping agent was applied to cavity (2 milimeter layer) and polymerized and restoration was finished in in the same session.
223751714|NCT01991119|DRUG|Propafenone|
223751715|NCT01991119|DRUG|Dronedarone|
223604075|NCT03667092|BIOLOGICAL|non-drug intervention type|8 peripheral blood samples (8x5ml) will be obtained at different times ; before, during and after treatment
223604076|NCT02627989|DRUG|Diflucortolone valerate (Nerisona)|Potency Class II (classified as Very Strong class in Japan) topical corticosteroids
223604077|NCT02627989|DRUG|Diflucortolone valerate (Texmeten)|Potency Class II (classified as Very Strong class in Japan) topical corticosteroids
223604078|NCT00245037|BIOLOGICAL|therapeutic allogeneic lymphocytes|A population of lymphocytes therapeutically administered to a recipient individual who is genetically distinct from a donor of the same species.
223604079|NCT00245037|DRUG|busulfan|"Busulfan is an alkylating chemotherapeutic agent which has been used in many high dose and reduced intensity regimens prior to allogeneic or autologous hematopoietic stem cell transplants. It is active in a wide variety of malignancies and in high-doses it is myeloablative.~IV busulfan is available and diluted and administered per package insert guidelines."
223604080|NCT00245037|DRUG|cyclosporine|"Cyclosporine is a cyclic polypeptide immunosuppressive agent. It blocks the calcium-dependent calcineurin-mediated nuclear localization of nuclear factor of activated T cells (NFAT) following T-cell activation, thereby inhibiting transactivation of key T-cell response genes including Interleukin 2 (IL-2) and Interleukin 4 (IL-4).~\- Starting on day -3, Cyclosporine (CSP) is given at a dose of 4.0 mg/kg p.o. b.i.d."
223604081|NCT00245037|DRUG|fludarabine phosphate|"Fludarabine's active metabolite 2-fluoro-ara-A is an antimetabolite that inhibits DNA primase, DNA polymerase alpha and ribonucleotide nuclease.~* Dosing: Days -4, -3 and -2: Fludarabine 30 mg/m2/day IV. Total dose equals 90 mg/m2.~* Monitoring: Fludarabine level is not monitored.~* Dose Adjustments: There are no provisions for fludarabine dose adjustments."
223604082|NCT00245037|DRUG|mycophenolate mofetil|"Mycophenolate mofetil (MMF) is the morpholinyl ethyl ester of mycophenolic acid (MPA) and reversibly inhibits inosine monophosphate dehydrogenase, particularly the type II isoform that is more prominent in activated lymphocytes. As a result of the inhibition of de novo purine synthesis, proliferation of B- and T-lymphocytes is blocked and antibody production is inhibited.~* Related Donors: MMF will be given daily at 15mg/kg q 12 hrs until day +28, then stop without tapering. Doses will be rounded to the nearest 250 mg (capsules are 250 mg).~* Unrelated Donors: MMF will be given daily at 15mg/kg q 8 hrs until day +28, then given daily at 15mg/kg q 12 hours until day +56, then stop without tapering. Doses will be rounded to the nearest 250 mg (capsules are 250 mg)."
223604083|NCT00245037|PROCEDURE|peripheral blood stem cell transplantation|"Bone marrow transplantation (BMT) and peripheral blood stem cell transplantation (PBSCT) are procedures that restore stem cells that have been destroyed by high doses of chemotherapy and/or radiation therapy. There are three types of transplants:~* In autologous transplants, patients receive their own stem cells.~* In syngeneic transplants, patients receive stem cells from their identical twin.~* In allogeneic transplants, patients receive stem cells from their brother, sister, or parent. A person who is not related to the patient (an unrelated donor) also may be used."
223751716|NCT01023581|DRUG|Alogliptin|Alogliptin tablets.
223751717|NCT01023581|DRUG|Metformin|Metformin capsules
223751718|NCT01023581|DRUG|Alogliptin Placebo|Alogliptin placebo-matching tablets.
223751719|NCT01023581|DRUG|Metformin Placebo|Metformin placebo-matching capsules.
223751720|NCT00803881|OTHER|nasal lavage and sputum collection|non-invasive longitudinal assessment of pathogen colonization in both airway levels
223751721|NCT02515409|DEVICE|HHHFNC|After the treatment with CPAP fails, the participants will use HHHFNC as a treatment for OSAS.
223751722|NCT02515409|DEVICE|CPAP|CPAP, as a first line treatment in OSAS.
223751723|NCT02280174|DRUG|linagliptin|linagliptin 5 mg/d for12 weeks
223751724|NCT03791866|OTHER|Nutrition|Enteral nutrition
223751725|NCT06163248|OTHER|Chrono nutrition|An integral nutritional strategy involving timing, order and distribution of macronutrients
223751726|NCT06163248|OTHER|Standard|Conventional nutritional strategy involving isocaloric distribution with no specific timing
223751727|NCT03095066|DRUG|Placebo|Administered as capsules
223604084|NCT00245037|RADIATION|Total Body Irradiation (TBI)|"TBI is a form of radiotherapy used primarily as part of the preparative regimen for haematopoietic stem cell (or bone marrow) transplantation. As the name implies, TBI involves irradiation of the entire body, though in modern practice the lungs are often partially shielded to lower the risk of radiation-induced lung injury.~* Toxicities: At the dosage used, side effects are not expected. Nevertheless, there may be fever, alopecia, parotitis, diarrhea, reversible skin pigmentation, mucositis and late effects including cataract formation, pulmonary damage, carcinogenesis, and sterilization.~* Dosing: TBI will be given in one 200 cGy fraction from linear accelerator at a rate of 15-19 cGy/min."
223604085|NCT00245037|DRUG|Granulocyte colony-stimulating factor (G-CSF)|"Granulocyte colony-stimulating factor (G-CSF or GCSF) is a colony-stimulating factor hormone. G-CSF is also known as colony-stimulating factor 3 (CSF 3).~It is a glycoprotein, growth factor and cytokine produced by a number of different tissues to stimulate the bone marrow to produce granulocytes and stem cells. G-CSF then stimulates the bone marrow to release them into the blood.~* Toxicities: At the dosage used, the most common side effect will be medullary bone pain.~* Dosing: 5 mcg/kg/day given per institutional standards (on approximately days 10-15 or not at all)."
223604086|NCT00245037|DRUG|Phenytoin|This drug is used to prevent seizures while on chemotherapy.
223604087|NCT00245037|DRUG|Methotrexate|Methotrexate is used to treat severe psoriasis (a skin disease in which red, scaly patches form on some areas of the body) that cannot be controlled by other treatments.
223604088|NCT04786795|DRUG|Compound Azintamide Enteric-coated Tablets|the experimental group takes Compound Azintamide Enteric-coated Tablets.They were registered before medication and on days 14 and 28 after medication, and gastrointestinal symptoms were assessed at each follow-up visit
223604089|NCT04786795|DRUG|Oryz-aspergillus Enzyme both Pancreatin Tablet and Ursodeoxycholic Acid Tablets|the control group takes Oryz-aspergillus Enzyme both Pancreatin Tablet and Ursodeoxycholic Acid Tablets. They were registered before medication and on days 14 and 28 after medication, and gastrointestinal symptoms were assessed at each follow-up visit
223604090|NCT04734067|OTHER|Immune checkpoint inhibitors(ICIs) therapy|Patients with malignant tumors who first received ICIs
223604091|NCT03031366|OTHER|3d roadmap guidance|TIPS was established using 3d roadmap
223604092|NCT03031366|OTHER|conventional TIPS procedure|conventional TIPS procedure using wedged hepatic venography
223604093|NCT02246426|OTHER|Computerized plasticity-based adaptive cognitive training|Computerized plasticity-based adaptive cognitive training for a total maximum of 40 treatment sessions, 3-5 times weekly, 40-60 minutes per session.
223604094|NCT02246426|OTHER|Commercially available computerized training|Commercially available computerized training for a total maximum of 40 treatment sessions, 3-5 times weekly, 40-60 minutes per session.
223751728|NCT03095066|DRUG|AVP-786-28|28 mg of d6-DM and 4.9 mg of Q
223751729|NCT03095066|DRUG|AVP-786-42.63|42.63 mg of d6-DM and 4.9 mg of Q
223751730|NCT01723163|BEHAVIORAL|Abstinence Reinforcement Therapy (ART)|Veterans randomized to the intervention will receive cognitive-behavioral telephone counseling (TC), a tele-medicine clinic for access to nicotine replacement (NRT), and mobile contingency management (mCM)
223751731|NCT01723163|BEHAVIORAL|Telephone Counseling and NRT|Veterans randomized to the control group will receive cognitive-behavioral telephone counseling (TC) and a tele-medicine clinic for access to nicotine replacement (NRT)
223751732|NCT00751816|DRUG|systemic chemotherapy|
223751733|NCT00751816|OTHER|survey administration|will be administered before, during, and after medical intent-to-cure treatment to describe head and neck cancer survivors' physical and functional well-being.
223751734|NCT00751816|PROCEDURE|adjuvant therapy|
223751735|NCT00751816|PROCEDURE|management of therapy complications|
223751736|NCT00751816|PROCEDURE|musculoskeletal complications management/prevention|
223751737|NCT00751816|PROCEDURE|physical therapy|weekly visits coordinated with adjuvant treatment as part of standard care
223751738|NCT00751816|RADIATION|radiation therapy|
223604095|NCT00032981|BEHAVIORAL|Behavior Therapy|
223751739|NCT03549702|DRUG|Povidone iodine 1% solution|irrigation of subcutaneous tissue with Povidone-Iodine prior to skin closure
223751740|NCT04111094|DIAGNOSTIC_TEST|No intervention|No intervention
223751741|NCT00382811|DRUG|phenoxodiol|400mg phenoxodiol three times daily in 28 day cycles.
223604096|NCT05376176|DRUG|STN1010904 ophthalmic suspension 0.03% BID|0.03% STN1010904 ophthalmic suspension BID
223751742|NCT00382811|DRUG|carboplatin|AUC=2 weekly in 28 day cycles
223751743|NCT00382811|DRUG|placebo|every 8 hours daily in 28 day cycles
223751744|NCT03483935|OTHER|Microwave treatment|Microwave energy delivered using the microwave instrument, SWIFT, manufactured by Emblation and CE marked for dermatology applications.
223751745|NCT03571087|DRUG|HL140 5/10|"1\) Treatment(W0\~W8), Extension(W9\~W20): 6Tab./q.d. HL140 5/10(Rosuvastatin5mg/Ezetimibe10mg) : ●♤♡□△◇~●: HL140 5/10mg, ♤: HL140 10/10mg placebo, ♡: HL140 20/10mg placebo, □: Crestor Tab.5mg placebo, △: Crestor Tab. 10mg placebo, ◇: Crestor Tab. 20mg placebo"
223751746|NCT03571087|DRUG|HL140 10/10|"1\) Treatment(W0\~W8), Extension(W9\~W20): 6Tab./q.d. HL140 10/10(Rosuvastatin10mg/Ezetimibe10mg) : ○♠♡□△◇~○: HL140 5/10mg placebo, ♠: HL140 10/10mg, ♡: HL140 20/10mg placebo, □: Crestor Tab. 5mg placebo, △: Crestor Tab. 10mg placebo, ◇: Crestor Tab. 20mg placebo"
223751747|NCT03571087|DRUG|HL140 20/10|"1\) Treatment(W0\~W8), Extension(W9\~W20): 6Tab./q.d. HL140 20/10(Rosuvastatin20mg/Ezetimibe10mg) : ○♤♥□△◇~○: HL140 5/10mg placebo, ♤: HL140 10/10mg placebo, ♥: HL140 20/10mg, □: Crestor Tab. 5mg placebo, △: Crestor Tab. 10mg placebo, ◇: Crestor Tab. 20mg placebo"
223751748|NCT03571087|DRUG|Rosuvastatin 5mg → HL140 5/10|"1. Treatment(W0\~W8): 6Tab./q.d. Rosuvastatin 5mg : ○♤♡■△◇~   ○: HL140 5/10mg placebo, ♤: HL140 10/10mg placebo,♡: HL140 20/10mg placebo, ■: Crestor Tab. 5mg, △: Crestor Tab. 10mg placebo, ◇: Crestor Tab. 20mg placebo~2. Extension period(W9\~W20): 6Tab./q.d. HL1405/10(Rosuvastatin5mg/Ezetimibe10mg) : ●♤♡□△◇~   * HL140 5/10mg, ♤: HL140 10/10mg placebo, ♡: HL140 20/10mg placebo, □: Crestor Tab. 5mg placebo, △: Crestor Tab. 10mg placebo, ◇: Crestor Tab. 20mg placebo"
224200345|NCT06388265|OTHER|Trifold information|Additional detailed and written information about the procedure will be given to the participants
223508001|NCT01673945|DEVICE|EUS-guided fine needle aspiration|Each patient will undergo examination with the CLA-EUS or the FV-EUS, which will be selected based on the randomization process. FV-EUS will be performed using the newly available FV -EUS scope (TGF-Y0001-UC) that is compatible with last generation Aloka alpha 10. First, search of the presumed lesion will be performed and once visualize, its characteristics (size, echogenicity, margins, etc) will be recorded on data collection sheet. Fine needle aspiration will be performed under EUS guidance using a 19- ,22- or a 25-gauge fine needle or procore needles depending on endoscopist's preference
223751749|NCT03571087|DRUG|Rosuvastatin 10mg → HL140 10/10|"1. Treatment(W0\~W8): 6Tab./q.d. Rosuvastatin 10mg : ○♤♡□▲◇~   ○: HL140 5/10mg placebo, ♤: HL140 10/10mg placebo, ♡: HL140 20/10mg placebo, □: Crestor Tab. 5mg placebo, ▲: Crestor Tab. 10mg, ◇: Crestor Tab. 20mg placebo~2. Extension period(W9\~W20): 6Tab./q.d. HL140 10/10(Rosuvastatin10mg/Ezetimibe10mg) : ○♠♡□△◇~   * HL140 5/10mg placebo, ♠: HL140 10/10mg, ♡: HL140 20/10mg placebo, □: Crestor Tab. 5mg placebo, △: Crestor Tab. 10mg placebo, ◇: Crestor Tab. 20mg placebo"
223751750|NCT03571087|DRUG|Rosuvastatin 20mg → HL140 20/10|"1. Treatment(W0\~W8): 6Tab./q.d.Rosuvastatin 20mg : ○♤♡□△◆~   ○: HL140 5/10mg placebo, ♤: HL140 10/10mg placebo, ♡: HL140 20/10mg placebo, □: Crestor Tab. 5mg placebo, △: Crestor Tab. 10mg placebo, ◆: Crestor Tab. 20mg~2. Extension period(W9\~W20): 6Tab./q.d. HL140 20/10(Rosuvastatin20mg/Ezetimibe10mg) : ○♤♥□△◇ ○: HL140 5/10mg placebo, ♤: HL140 10/10mg placebo, ♥: HL140 20/10mg, □: Crestor Tab. 5mg placebo, △: Crestor Tab. 10mg placebo, ◇: Crestor Tab. 20mg placebo"
223751751|NCT03732053|OTHER|GPR Intervention Research group|The research intervention consisted in the reappointment of three GPR therapeutic postures.
223751752|NCT02534831|PROCEDURE|Soft tissue manual therapy protocol|The STMTP consisted of a pre-determined set of seven (7) soft tissue techniques delivered as part of a single treatment session lasting approximately 30 minutes. The techniques and their respective durations were: suboccipital release (5 minutes), anterior thoracic myofascial and sternum release (5 minutes), anterior cervical myofascial release (5 minutes), costal ligament balance (5 minutes) and muscular energy technique (MET) to the following muscles - scalenes (1 minute and 40 seconds), pectoralis minor (1 minute and 40 seconds) and latissimus dorsi and serratus anterior (1 minute and 40 seconds)
223751753|NCT02347566|BEHAVIORAL|Physical activity enhancing programme|COPD patients performing pulmonary rehabilitation will wear the DirectLife activity monitor with set targets and feedback. They will have access to a web coaching programme. Their physical activity targets will be updated on a weekly basis in order to enhance their physical activity.
223751754|NCT02347566|OTHER|Usual care|COPD patients performing pulmonary rehabilitation will wear the DirectLife activity monitor without set targets and/or feedback. They will not have access to a web coaching programme.
223751755|NCT01963390|DRUG|Testosterone Therapy|In this observational study we will be enrolling testosterone deficient men who intend to undergo testosterone therapy.
223508002|NCT04650945|OTHER|isCGM group|As previously described
223508003|NCT02722291|DEVICE|Trayner Pinhole Glasses (Trayner Glasses, Ivybridge Devon, U.K.)|
223508004|NCT01325766|OTHER|Yoga|Yoga 2 sessions per week for 8 weeks
223508005|NCT02025036|DRUG|Capecitabine(Aibin)|capecitabine(Aibin)：625mg/m2, bid d1-5; q1w, po,5 weeks in total
223508006|NCT02025036|DRUG|Oxaliplatin(Aiheng)|Oxaliplatin(Aiheng)：65mg/m2，d1，8, 22, 29,I.V.
223508007|NCT02025036|RADIATION|Radiotherapy|concurrent radiotherapy： 50Gy in total，2 Gy/d，5d/w，Until disease progression or unacceptable toxicity
223508008|NCT01398475|DRUG|LY3009104|Administered orally
223508009|NCT01341041|BIOLOGICAL|chlorine dioxide|one time wash with 50ppm CD solution
223508010|NCT01341041|BIOLOGICAL|saline|one time wash with 50-100 cc normal saline
223508011|NCT05367830|BEHAVIORAL|the Bone@BC app|The bone@BC app is a diary for patients with breast cancer that they can use if they want to.
223508012|NCT00683384|DRUG|Etanercept (Enbrel)|
223508013|NCT06466265|DRUG|DNP002|Anti-CEACAM6 monoclonal antibody
223508014|NCT03888274|DEVICE|ClearUP Sinus Pain Relief|Microcurrent Device Treatment
223508015|NCT03334266|BEHAVIORAL|Family Spirit Nurture (FSN)|The FSN home-visiting module consists of 36 60-minute lessons delivered by trained local FHCs, from 28 weeks gestation to 18 months postpartum. The lessons focus on three key content domains: 1) promotion of optimal breastfeeding, complementary and responsive feeding across early childhood; 2) promotion of healthy infant/toddler diet and physical activity, as well as reduced screen time and sedentary lifestyle; and 3) promotion of maternal psychosocial well-being, optimization of healthy food/beverage availability and identification/creation of safe play spaces in the home environment.
223508016|NCT03334266|OTHER|Injury Prevention Education (IPE)|The control group will receive Injury Prevention Education (IPE). The IPE home-visiting module consists of 8 30-minute lessons delivered by trained local Family Health Liaisons (FHL), from 28 weeks gestation to 18 months postpartum. Injury prevention lessons focus on injury prevention topics relevant to the participating communities, including: motor vehicle safety for mothers and children; preventing scald burns; fire safety; child-proofing a home; preventing falls; preventing poisonings; and preventing animal bites.
223508017|NCT03334266|OTHER|Optimized Standard Care (OSC)|OSC will be available to both in the FSN intervention and control groups. OSC consists of transportation assistance to prenatal and well-baby clinic visits as recommended by the Indian Health Service (IHS) and American Academy of Pediatrics (AAP) and rescue services through linkages to community agencies as needed.
223508018|NCT02926612|OTHER|Next Generation Genomic Sequencing|DNA and RNA are extracted from biospecimens, amplified, sequenced, and then compared to known microbe databases, allowing for quantitative identification of non-host organisms
223508019|NCT00120874|BEHAVIORAL|Individualized management of AD including caregiver training|Individualized management program: consists of home visits to get the patient exercising, doing enjoyable activities and cognitive stimulation, educational sessions for caregivers on coping with difficult situations and a caregiver support group to help with questions and emotional concerns.
223508020|NCT00120874|DRUG|Memantine|Patients receive 10 milligrams of memantine twice daily.
223508021|NCT03975114|DRUG|Chemotherapy|Any approved first line chemotherapy regimen at Investigators' choice
223508022|NCT03975114|DRUG|Durvalumab|Durvalumab 1500 mg iv Q4w until progressive or unacceptable toxicity or patient's refusal
223508023|NCT03975114|DRUG|Tremelimumab|Tremelimumab 75 mg iv Q4w for 4 administrations (4 months)
223508024|NCT02130141|DIETARY_SUPPLEMENT|Dark chocolate|Mildly hypertensive subject will replace their usual snacks with with 50 g dark chocolate daily for a period of 8 weeks.
223508025|NCT02130141|OTHER|Dietary counselling|Usual snacks are limited.
223508026|NCT00425139|BEHAVIORAL|Re-Mission|
223508027|NCT00922389|PROCEDURE|will receive G-CSF and peripheral blood derived mononuclear cells|Multiple intra muscular implantation of mononuclear stem cells derived from peripheral blood after G-CSF (granulocyte colony-stimulating factor)mobilization in either of two individual dose ranges which would be given to equal number of subjects.
223508028|NCT00922389|DRUG|G-CSF|5 micrograms/kg/day for 4 days by subcutaneous route
223508029|NCT00922389|DRUG|Standard Therapy|Any thing directed to improve blood perfusion in the limb example.Heparin,Antiplatelet agents etc
223508030|NCT00845000|DRUG|SCH 420814 10 mg|one 10-mg capsule, orally, at hour 0 of treatment period
223508031|NCT00845000|DRUG|SCH 420814 100 mg|single oral dose of four SCH 420814 25-mg capsules at hour 0 of treatment period
223508032|NCT00845000|DRUG|Placebo|Placebo capsule, oral, at hour 0 of treatment period
223508033|NCT00845000|DRUG|Levodopa|levodopa intravenous (IV) infusion (1 mg/kg body weight) was beginning 1 hour after study drug administration and continued for 2 hours
223508034|NCT00845000|DRUG|Carbidopa|one 25-mg table, orally, at hours 0, 2 and 4 of each treatment period
223508035|NCT03407586|DIAGNOSTIC_TEST|Point-of-care STI testing|All participants underwent point-of-care STI testing (GeneXpert), and if diagnosed with a STI were offered immediate therapy, and expedited therapy, if indicated.
223508036|NCT04994236|DRUG|Hepatic artery infusion chemotherapy with FOLFOX regimens (oxaliplatin, fluorouracil, and leucovorin)|The FOLFOX regiments were given via hepatic artery catheterization, including oxaliplatin 85 mg/m2, leucovorin 400 mg/m2, fluorouracil bolus 400 mg/m2, followed by fluorouracil infusion 2400 mg/m2 for 46 hours. If no severe adverse events occurred, the treatment will be repeated every 3 weeks.
223508037|NCT03107000|PROCEDURE|Trabeculectomy|Incisional surgery for glaucoma
223508038|NCT03107000|PROCEDURE|Phako-trabeculectomy|Incisional surgery for glaucoma plus cataract
223508039|NCT03022214|DIETARY_SUPPLEMENT|Placebo|Microcrystalline cellulose capsules x 5 morning and night with meals for two days prior to exercise test and 5 capsules taken on the morning of the test with the first meal
223604097|NCT05376176|DRUG|STN1010904 ophthalmic suspension 0.1% BID|0.1% STN1010904 ophthalmic suspension BID
223604098|NCT05376176|DRUG|Placebo (Vehicle) BID|Placebo (vehicle) BID
223604099|NCT05822180|DRUG|NANOS1 , argent colloïdal ,|orally, during 5 day
223604100|NCT01151371|DEVICE|narafilcon B contact lens|Silicone Hydrogel Daily Disposable Contact Lenses
223604101|NCT01151371|DEVICE|nelfilcon A contact lens|Conventional Hydrogel Daily Disposable Contact Lenses
223604102|NCT01151371|DEVICE|lotrafilcon B contact lens|Silicone Hydrogel Monthly Replacement Contact Lenses
223604103|NCT06965361|DRUG|carboplatin|carboplatin use due to its effectiveness in increasing pathological complete remission (pCR) rates and improving survival outcomes
223604104|NCT06965361|DEVICE|carboplatin|used in the treatment of triple-negative breast cancer (TNBC) due to its effectiveness in achieving pathological complete response (pCR) and breast-conserving surgery (BCS) rates.
223604105|NCT05956652|DEVICE|Hydra Transcatheter Aortic Valve System|The Hydra device is self-expanding transcatheter aortic valve consists of a self-expanding nitinol frame and three bovine pericardial leaflets in supra-annular position.
223604106|NCT06967701|BEHAVIORAL|Exercise program|Participants will receive a free Garmin smartwatch and a free program membership providing exercise coaching + personalized feedback about the relationship among their insulin, carbohydrates, exercise, sleep, and blood sugar.
223604107|NCT06967701|BEHAVIORAL|Self-monitoring|Wear a fitness watch and keep daily health diary
223604108|NCT06969469|DIETARY_SUPPLEMENT|Give the Placebo and test article|"Phase 1: The subjects take 2 capsules (500 mg/capsule)/Placebo after dinner every day for 14 days.~Phase 2: The subjects take 2 capsules (500 mg/capsule)/test article after dinner every day for 28 days."
223604109|NCT02877303|BIOLOGICAL|Blinatumomab|Given IV
223604110|NCT02877303|DRUG|Cyclophosphamide|Given IV
223604111|NCT02877303|DRUG|Cytarabine|Given IT and IV
223604112|NCT02877303|DRUG|Dexamethasone|Given PO
223604113|NCT02877303|DRUG|Doxorubicin Hydrochloride|Given IV
223604114|NCT02877303|BIOLOGICAL|Inotuzumab Ozogamicin|Given IV
223604115|NCT02877303|OTHER|Laboratory Biomarker Analysis|Correlative studies
223604116|NCT02877303|DRUG|Mercaptopurine|Given PO
223604117|NCT02877303|DRUG|Methotrexate|Given IT, IV, and PO
223604118|NCT02877303|BIOLOGICAL|Ofatumumab|Given IV
223604119|NCT02877303|DRUG|Prednisone|Given PO
223604120|NCT02877303|BIOLOGICAL|Rituximab|Given IV
223604121|NCT02877303|DRUG|Vincristine Sulfate|Given IV
223604122|NCT06967662|PROCEDURE|Selective plasma adsorption of extracellular DNA|Selective plasma adsorption of extracellular DNA using NucleoCor® sorption columns (Pocard Ltd., Russia) on the Spectra Optia™ Apheresis System (Terumo Blood and Cell Technologies, USA). NucleoCor® is a sorption column for plasma adsorption containing porous spherical agarose beads with a ligand that selectively binds extracellular DNA. This medical device has a Registration Certificate No. РЗН 2022/18982 in Russian Federation. Participants will receive selective plasma adsorption of extracellular DNA twice: once during the tumor removal surgery (the procedure will be initiated at the time of pancreatic tumor mobilization and will be stopped an hour after removal of the organ complex) and once on the day after the surgery.
223604123|NCT06968312|OTHER|Cognitive Processing Therapy + Hexadecanal|Cognitive Processing Therapy is a protocolized, trauma-focused, CBT type treatment for PTSD.
223604124|NCT06968312|OTHER|Hexadecanal - Molecule Distribution in the Therapy room|Distribution of a naturally secreted molecule from body odor (Hexadecanal).
223604125|NCT02618148|DRUG|ESTROGEN HERBALS 21|"Applies to the following strengths:~17β-estradiol 1.5mg/24 hours x 21 days, stop drinking for 7 days. Progesterone 5 mg/24 hours x 10 days, stop drinking for 7 days. Garlic oil 30mg/24 hours x 28 days. Enzyme nattokinase 300 FU x 24 hours x 28 days."
223751756|NCT03164499|BEHAVIORAL|Individual counselling on lifestyles|Individual standardized counselling on healthy diet, daily physical activity, stress management, smoking cessation, and moderation in alcohol consumption.
223751757|NCT03164499|BEHAVIORAL|Additional group counselling on lifestyles|"Group sessions focusing on cardiovascular risk, diet and moderation in alcohol consumption, physical activity and stress management, and smoking cessation will be held in health centres for four consecutive weeks. Each session will last 60-90 minutes, and will be led by two trained nurse practitioners. Ten participants will assist each group. During each session, attendance will be recorded and printed educational materials related to the topic addressed will be distributed.~Follow-up calls to reinforce lifestyle modification and record the barriers to behaviour change found will be performed 6 and 9 months after enrolment."
223604126|NCT02618148|DRUG|ESTROGEN HERBALS 28|"Applies to the following strengths:~17β-estradiol 1.5mg/24 hours x 28 days. Garlic oil 30mg/24 hours x 28 days. Enzyme nattokinase 300 FU x 24 hours x 28 days."
223604127|NCT00764062|DRUG|Amoxicillin|Amoxicillin :drug
223751758|NCT03532464|DRUG|azithromycin|The route of administration is oral. It is administered at a dose of 1 g (4 tablets), as a single dose with or without food.
223751759|NCT03532464|DRUG|doxycycline|The patients in the doxycycline group take one tablet of 100 mg twice a day for seven days.
223751760|NCT02397863|DRUG|Cannabidiol (Epidiolex)|Daily dosage up to 25 mg/kg/day with an optional up titration to a maximal daily dosage up to 50 m/kg/day until End of Treatment.
223751761|NCT03952169|DIETARY_SUPPLEMENT|Lactobacillus paracasei dietary supplement|a commercial probiotic dietary supplement
223751762|NCT03952169|OTHER|Placebo controls|placebo with a similar appearance to probiotics supplement
223604128|NCT04683653|RADIATION|Hypofractionated Radiation|Radiation treatment in which the total dose of radiation is divided into large doses and treatments are given less often. Hypofractionated radiation therapy is given over a shorter period of time (fewer days or weeks) than standard radiation therapy.
223604129|NCT04683653|OTHER|Clinical Follow-Up and Assessments|"At each visit, the subject will be evaluated for any signs of their endometrial cancer or symptoms returning (clinical disease recurrence) and any negative side effects associated with their prior radiation treatment. Study participants will also be asked to fill out a survey regarding bowel/urinary habits and quality of life questionnaires (known as the EPIC questionnaire) during these visits. The data collected during these clinical follow up visits will be used to determine how effective hypofractionated/shortened whole radiation therapy is for treating endometrial cancer."
223604130|NCT06177067|DRUG|Revumenib|Given by mouth (capsule or liquid solution) or liquid solution by Nasogastric tube (NG) or Gastrostomy tube (G-tube)
223604131|NCT06177067|DRUG|Venetoclax|Given by mouth (tablet)
223604132|NCT06177067|DRUG|Azacitidine|Given intravenously (IV) infusion
223604133|NCT06177067|DRUG|intrathecal (IT) chemotherapy|Given intrathecal (IT)
223604134|NCT06177067|DRUG|Cytarabine|Given intrathecal (IT) as part of intrathecal (IT) chemotherapy.
223604135|NCT06177067|DRUG|Methotrexate|Given intrathecal (IT) as part of intrathecal (IT) chemotherapy.
223604136|NCT03724890|DRUG|M3814|Participants received M3814 twice daily (BID) continuously starting from Day 1 until progressive disease (PD) or unacceptable toxicity.
223604137|NCT03724890|DRUG|M3814|Participants received M3814 concomitantly with RT once (QD) daily starting Day 1 for 5 days per week for 2 weeks in total.
223604138|NCT03724890|DRUG|Avelumab|Participants received avelumab once every 2 weeks (Q2W) starting from Day 1 until PD or unacceptable toxicity.
223604139|NCT03724890|RADIATION|Radiotherapy|Participants received radiotherapy at the dose of 3 grays (Gy) per day starting Day 1 for 5 days per week for 2 weeks.
223751763|NCT06190561|DRUG|PF-07940367|Participants to receive a single dose of PF-07940367 product II 150 mg by mouth
223751764|NCT06190561|DRUG|PF-07940367|Participants to receive a single dose of PF-07940367 product I 150 mg by mouth
223751765|NCT05728164|BEHAVIORAL|Cinematic Simulation|Comprehensive videos from specific films will be selected as films fitting the needs of participants and the established objectives. The films comprehensively develops several characters enriching the values of positive emotions, resilience and empathy. The intervention film videos will be delivered on 5 sessions for each group (2 sessions per week).
223751766|NCT02567461|DRUG|Edoxaban 60 mg|Patients will receive randomized treatment for 10±2 days, in order to achieve steady-state anticoagulant effects. Afterwards, patients randomized to any of the edoxaban groups (arms 1 and 2) will stop aspirin therapy. Study treatment will be administered for other 10±2 days.
223751767|NCT02567461|DRUG|Edoxaban 30 mg|Patients will receive randomized treatment for 10±2 days, in order to achieve steady-state anticoagulant effects. Afterwards, patients randomized to any of the edoxaban groups (arms 1 and 2) will stop aspirin therapy. Study treatment will be administered for other 10±2 days.
223751768|NCT02567461|DRUG|Clopidogrel 75 mg|Patients will receive randomized treatment for 10±2 days, in order to achieve steady-state anticoagulant effects. Afterwards, patients randomized to any of the edoxaban groups (arms 1 and 2) will stop aspirin therapy. Study treatment will be administered for other 10±2 days.
223751769|NCT02567461|DRUG|Aspirin 81 mg|Patients will receive randomized treatment for 10±2 days, in order to achieve steady-state anticoagulant effects. Afterwards, patients randomized to any of the edoxaban groups (arms 1 and 2) will stop aspirin therapy. Study treatment will be administered for other 10±2 days.
223751770|NCT02850536|BIOLOGICAL|anti-CEA CAR-T cells|Gene modified patient T cells
223751771|NCT03751215|PROCEDURE|Cataract surgery|During cataract surgery the patient is implanted with the monofocal IOL Clareon in one eye and the monofocal IOL AcrySof in the contralateral eye
223751772|NCT06212102|DRUG|Progestin primed ovarian stimulation|HMG ( 300IU) was used during the follicular phase of ovarian stimulation (FPS) and during the luteal phase of ovarian stimulation (LPS). Progestin (dydrogesterone) 30 mg/day was used to prevent premature LH surge during the FPS and LPS.
223751773|NCT06212102|DRUG|GnRH antagonist|HMG ( 300IU) was used during the follicular phase of ovarian stimulation (FPS) and during the luteal phase of ovarian stimulation (LPS). Flexible GnRH antagonist protocol (Cetrorelix acetate) (0.2 mg) was used to prevent premature LH surge during the FPS and LPS.
223604140|NCT06043063|PROCEDURE|Topical lidocaine|Topical anesthetic
223604141|NCT06043063|PROCEDURE|EMLA cream|Topical anesthetic
223604142|NCT06043063|PROCEDURE|Periurethral block|5 cc 1% lidocaine or 0.25% bupivacaine at 3 and 9 o'clock (periurethral tissues) to depth of 1.5 cm using 25G needle
223604143|NCT02314221|DEVICE|Exoskeletal-assisted walking (ReWalk, Ekso)|The WALK arm will consist of supervised exoskeletal-assisted walking training, three sessions per week (4-6 h/week) for 36 sessions (12 weeks) and usual activities for their second 12-week period.
223751774|NCT06377293|OTHER|Dialysis-specific therapeutic diet|A healthy diet for dialysis patients
223751775|NCT05828446|DEVICE|MRI|To compare the diagnostic performance of US+/- Constrast-enhanced US and AMRI for HCC detection in an at-risk population
223751776|NCT03436979|DEVICE|NeuGuide™ System|The NeuGuide™ device is indicated for anchoring sutures to ligaments of the pelvic floor.
223751777|NCT01391390|DRUG|Melatonin|10mg/day, 12-week treatment
223751778|NCT01391390|DRUG|Placebo|10mg/day, 12-week treatment for TD
223751779|NCT04011527|PROCEDURE|Rotational Atherectomy in Coronary Lesion/s|
223751780|NCT03231787|DIAGNOSTIC_TEST|Platelet function assay|"Plateletworks is an in vitro diagnostic screening assay for the determination of % platelet aggregation or % platelet inhibition.~It will be used to measure platelet function after withdrawal of the antiplatelet agent.~If there are more than 80,000 functional platelets, the patient will be operated on within the next 24 hours."
223751781|NCT06484998|BEHAVIORAL|Dental anxiety level and child's compomer colors selection|Patients without any syndromes or systemic disorders, without mental retardation, who needed restorative treatment for primary molars were included in the study. The examination forms of 275 patients requiring restorative treatment of primary teeth were analysed at the session they came for restorative treatment. To determine the child's anxiety, the Modified Child Dental Anxiety Scale-faces version was administered to the children before restorative treatment. The children were asked to choose from a scale consisting of 9 colours (pink, blue, gold, silver, orange, yellow, green, purple, white) for the compomer restoration color selections. The patients were asked what their favourite color was after the compomer restoration color selection so that the previous question would not have any effect on the child's restoration color selection.
223751782|NCT01725425|OTHER|Control|The control is designed to determine average mood.
223751783|NCT01725425|OTHER|Increase Portion Size|The purpose is to determine whether a change in mood will occur.
223751784|NCT01725425|OTHER|Decrease Portion Size|The purpose is to determine whether a change in mood will occur.
223751785|NCT01725425|OTHER|Mixed Portions|The purpose is to determine if a change in mood will occur.
223751786|NCT02255370|DRUG|Curcumin|subjects will be randomized into two arms; they will be given either placebo or curcumin 3g/d per os plus thiopurines during 6 months in a double-blind manner. Rutggerts endoscopic score at 6 months will be the main judgment criteria
223751787|NCT06201754|OTHER|Measure air quality|Measure air quality, including PM2.5、PM10
223751788|NCT03875378|DRUG|Transdermal estrogen|Transdermal estradiol (0.045mg)/levonorgestrel (0.015mg) weekly patch
223604144|NCT06975462|COMBINATION_PRODUCT|SHR-A1811 and radiotherapy|SHR-A1811:4.8mg/kg radiotherapy: 800cGY\*5
223604145|NCT06974812|DRUG|IBI3014|12 mg/kg D1 IV Q3W
223604146|NCT06974812|DRUG|IBI3014|6 mg/kg D1 IV Q3W
223604147|NCT06974812|DRUG|IBI3014|1 mg/kg D1 IV Q3W
223604148|NCT06974812|DRUG|IBI3014|15 mg/kg D1 IV Q3W
223604149|NCT06974812|DRUG|IBI3014|9 mg/kg D1 IV Q3W
223604150|NCT06974812|DRUG|IBI3014|3 mg/kg D1 IV Q3W
223604151|NCT06783413|BEHAVIORAL|Intervention group (Laughter Yoga)|Laughter yoga is a practice that includes physical laughing exercises and breathing techniques. Sessions will be conducted as group therapy with a trained guide. The intervention will be applied to evaluate changes in participants' fatigue, sleep quality and psychological well-being.
223751789|NCT03875378|DRUG|Placebos|Placebo weekly patch
223751790|NCT00076687|BIOLOGICAL|botulinum toxin Type A|botulinum toxin Type A 240 U injection on Day 1, Week 12, Week 18
223751791|NCT00076687|BIOLOGICAL|botulinum toxin Type A|botulinum toxin Type A 360 U injection at Day 1, Week 12, Week 18
223751792|NCT00076687|DRUG|saline|Saline injection at Day 1, Week 12, Week 18
223751793|NCT05953428|OTHER|Opioid Sparing Anesthesia Protocol (OSA)|OSA protocol will include boluses of dexmedetomidine and ketamine at anesthesia induction, followed by a ketamine infusion that will continue until PACU discharge. Another bolus of ketamine will be administered upon surgical incision and another dexmedetomidine bolus will be given at surgical closure to reduce the use of opioids.
223751794|NCT05953428|OTHER|Opioid Based Anesthesia Protocol (OBA)|The OBA group will be administered a saline infusion at the same rate of the ketamine infusion (only while in the PACU) up until PACU discharge so that surgeons, patients, and PACU nurses will be blinded. The OBA group will be administered fentanyl 100 mcg IV for anesthesia induction followed by 50 mcg IV boluses when heart rate or systolic blood pressure is 20% above baseline throughout the case.
223751795|NCT04193722|DRUG|Hyperbaric oxygen therapy|Hyperbaric oxygen therapy in a multiperson hyperbaric oxygen chamber. Standard hyperbaric oxygen therapy provided as reimbursed by insurers.
223751796|NCT04196140|DEVICE|Omnipod Horizon™ Automated Glucose Control System|The Omnipod Horizon™ Automated Glucose Control System will provide automated insulin delivery
223751797|NCT06180447|BIOLOGICAL|Hepatitis B vaccine, rabies vaccine, HPV vaccine, influenza vaccine|Exposure was defined as use of the vaccine 90 days before the last menstrual period and during pregnancy.
223751798|NCT05042947|DEVICE|double-loop clips|a new ligation method using the double-loop clips (D-L clips) technique
223751799|NCT05042947|DEVICE|Titanium Clip|the Titanium Clip
223751800|NCT05355415|DEVICE|Adaptive optics imaging|Adaptive optics scanning laser ophthalmoscopy (AOSLO) and adaptive optics - optical coherence tomography (AO-OCT) retinal imaging
223751801|NCT03760796|DEVICE|Corrie Health Digital Platform|The Corrie Health Digital Platform consists of the Corrie smartphone app for heart attack recovery which is paired with an Apple Watch and Bluetooth-enabled, iHealth blood pressure monitor.
223751802|NCT05039008|OTHER|Blood flow restriction|The intervention protocol will be carried out under the same environmental conditions and, as far as possible, at the same time. The intervention will last 4 weeks, with a periodicity of 3 weekly sessions. In total there will be 12 sessions that will last between 15 and 30 minutes depending on the number of joints affected.
223604152|NCT06783413|OTHER|Control group|Participants in the control group will continue to receive their current standard of care and will not receive any additional interventions.
223604153|NCT02123823|DRUG|Everolimus|10mg dose
223604154|NCT02123823|DRUG|Exemestane|Fixed dose at 25mg
223751803|NCT02029001|DRUG|Nilotinib (400 mg BID)|Patient with advanced pigmented villonodular synovitis and tumors with mutations of ABL1, KIT, PDGFRA, PDGFRB, DDR1, DDR2, CSF1R, or amplification/translocation of the genes and/or of the ligands.
223751804|NCT02029001|DRUG|Everolimus (10 mg QD)|Patients whose tumor harbors mutations or amplification of the PIK3CA, PIK3R1, AKT1, AKT2, mTOR, RICTOR, RAPTOR genes, or with TSC1, TSC2 or PTEN loss (defined as complete loss of both gene copies OR loss of one copy + mutation on the other copy or loss of one copy + loss of expression using immunohistochemistry).
223751805|NCT02029001|DRUG|Sorafenib (400 mg BID)|Patients whose tumor harbors mutations of VEGFR1-3, PDGFRB, FLT3, BRAF (other than V600 mutations), CRAF, HRAS, KRAS or RET or amplification/translocation of the genes and/or of the ligands.
223751806|NCT02029001|DRUG|Lapatinib (1500 mg QD)|Patients whose tumor harbors mutations or amplifications of HER2
223751807|NCT02029001|DRUG|Pazopanib (800 mg QD)|Patients whose tumor harbors mutations of VEGFR1-3, PDGFRA, PDGFRB or KIT\* or amplification /translocation of the genes and/or of the ligands.
223751808|NCT02029001|DRUG|Olaparib (300 mg BID)|"ATM, BAP1 et BRIP1 Mutation only if double hit documented; BRCA2, BRCA1, RAD51C, PALB2, RAD51D Mutation; BRCA1, BRCA2, ATM and BAP1 Loss; BRCA1, BRCA2, ATM and BAP 1 : mutation and heterozygote deletion. except for patients eligible to olaparib's available labels and reimbursements in France.~NOTE : only prostate cancer with RECIST 1.1 evaluable disease are eligible until the French price and reimbursement"
223751809|NCT02029001|COMBINATION_PRODUCT|Durvalumab + Tremelimumab|Any molecular types of tumor (which are known to be immunogenic or with high mutation load), except lung, urothelial and head and neck or CNS tumors, or patients who fulfill conditions to receive any other MTT of the MOST Plus study.
223751810|NCT06644144|OTHER|No Interventions|No intervention so not applicable.
223751811|NCT05669820|DIETARY_SUPPLEMENT|Salovum|Salovum is an eggyolkpowder derived from hens fed with SPC (specially processed cereals) and contains increased amounts of the endogenous protein antisecretory factor.
223751812|NCT05669820|DIETARY_SUPPLEMENT|Placebo egg yolk powder|Egg yolk powder derived from hen fed with normal feed.
223751813|NCT06543849|PROCEDURE|Target Temperature Management Treatment|Target Temperature Management Treatment
223751814|NCT04720976|DRUG|JAB-3312|JAB-3312 will be administered orally, variable dose.
223751815|NCT04720976|DRUG|Binimetinib|Binimetinib will be administered orally.
223751816|NCT04720976|DRUG|Pembrolizumab|Pembrolizumab will be administered as an intravenous infusion.
223751817|NCT04720976|DRUG|Sotorasib|Sotorasib will be administered orally.
223751818|NCT04720976|DRUG|Osimertinib|Osimertinib will be administered orally.
223751819|NCT05243654|DRUG|Metformin|Metformin 1000mg XR OD + standard-of-care MDT
223751820|NCT05243654|DRUG|Placebo|Placebo + standard-of-care MDT
223751821|NCT04627701|DEVICE|Omega|Omega Implantation
223751822|NCT03788096|BEHAVIORAL|Peer Support with Motivational Interviewing|Mentors will trained in motivational interviewing and will conduct weekly telephone calls with participants randomized to the PS-PICS peer support intervention arm.
223751823|NCT03788096|BEHAVIORAL|Usual Care Group|Usual care.
223604155|NCT02123823|DRUG|BI 836845|1000 mg, recommended dose per Phase Ib part. Human monoclonal antibody. Dose escalation in Phase Ib. 2 dose levels (high or low) depending on the dose cohort explored
223604156|NCT06064682|OTHER|standard of care biopsy|Image-guided or surgical biopsy of the lesion that is suspected to be osteosarcoma in a patient with localized disease (Group 1)
223604157|NCT06064682|OTHER|standard of care biopsy|Image-guided or surgical biopsy or excision of the lesion that is suspected to be recurrent or metastatic osteosarcoma (Group 2).
223604158|NCT05176808|BEHAVIORAL|Early Achievements- Parent Coaching Intervention|Children, along with a caregiver, will be randomized into one of two conditions to receive parent coaching guided by NDBI principles.
223751824|NCT06576063|DEVICE|Lumoral Treatment|Home-use of photodynamic antibacterial dual-light device, used with a marker substance (indocyanine green)
223751825|NCT06576063|BEHAVIORAL|Standard oral hygiene methods|Best available standard oral self-care hygiene methods performed at home and instructed by oral healthcare professionals, supported by professional cleaning at the oral healthcare clinic
223751826|NCT05664490|BEHAVIORAL|Youth Friendship Bench SA|The intervention includes: 5 individual counseling sessions; one optional in-person or WhatsApp-based group counseling session; optional remote counseling sessions; and optional one-way SMS messages to provide reminders about upcoming visits. During the initial session, participants will meet with the trained counselor to discuss mental health challenges, identify problems in their life that affect their mental health and PrEP use, generate alternative solutions, make decisions about the alternatives, and collaboratively decide on a plan to implement the solutions. During follow-up counseling sessions, participants will discuss progress in implementing solutions to address the problems they identified in prior sessions with the lay counselor. They will also discuss any other mental health challenges and problems in their life that affect their mental health and PrEP use which they would like to address.
223604159|NCT06503653|DIAGNOSTIC_TEST|syncope channel|"The procedures and investigations proposed for the etiological diagnosis of low-risk or neither high nor low syncope and included in the study are those recommended by the European Society of Cardiology.~No additional procedures, invasive or non-invasive explorations or blood sampling not provided for as part of routine care will be offered or carried out as part of the study.~The only change in practice for patients included in the syncope pathway The only change in practice concerns the grouping of patients included in the syncope pathway into a single day at a day hospital within 10 days of their emergency consultation."
223751827|NCT06338189|OTHER|The 5Ad Diet|Participants are to follow the 5Ad diet.
223751828|NCT06338189|OTHER|The Low FODMAP Diet|Participants are to follow the active phase of the Low FODMAP diet.
223751829|NCT03999190|DRUG|NPA radiotracer|"\[11C\]NPA radiotracer, 2 injection per subject~Antagonist (\[11C\]raclopride) and agonist (\[11C\]NPA) radiotracer will be used sequentially to measure binding potential (BPND) under baseline conditions and 3-hours following oral administration of 0.5 mg/kg amphetamine in the same 30 medication free subjects with schizophrenia (MF-S) and 30 healthy control subjects (HC)."
223604160|NCT06503653|DIAGNOSTIC_TEST|routine care|"The procedures and investigations proposed for the etiological diagnosis of low-risk or neither high nor low syncope and included in the study are those recommended by the European Society of Cardiology.in routine care, medical examinations are carried out by specialists such as cardiologists who do not practice in hospitals"
223604161|NCT04964947|DRUG|Tobramycin Injection|80 milligrams of tobramycin diluted in 40 milliliters of normal saline
223604162|NCT06975280|BEHAVIORAL|Trauma - Focused Cognitive Behavioral Therapy|TF-CBT is a comprehensive, evidence-based, short-term therapeutic protocol aimed at reducing trauma-related symptoms in children and adolescents aged 3-18. The protocol consists of 12 double sessions conducted with both the child and their caregiver. Developed for children who have experienced sexual abuse and multiple traumas, TF-CBT has since been successfully applied to a variety of traumatic experiences. Core components of the protocol include psychoeducation, relaxation techniques, emotional regulation, cognitive processing, trauma narrative, in vivo exposure, conjoint child/caregiver sessions, and safety planning. The intervention is culturally informed and flexible to meet individual needs. Adjustments have been made in the context of unaccompanied minors (UAMs), where caregiver involvement is not feasible, due to specific circumstances in accommodation centers and Supportin Greece.
223508040|NCT03022214|DIETARY_SUPPLEMENT|Intervention|"Daily capsules will be divided into two servings, one serving to be taken in the morning with breakfast, and one serving to be taken in the evening with dinner. Each serving containing 5 capsules, as follows:~* EnduraCell broccoli sprout powder: 3 capsules~* Bulk Powders Green tea extract: 1 capsule~* Bulk Powders Cinnamon Bark Extract: 1 capsule taken for two days prior to exercise test and 5 capsules taken on the morning of the test with the first meal"
223618060|NCT03306966|DEVICE|Endoscopic Linear Cutter Stapler and Reloads (Frankenman)|The Single Use Endoscopic Linear Cutter Stapler and Reloads from Frankenman received CE-mark in April 2013. It is used to staple and simultaneously divide tissue from the central line.
223618061|NCT02474563|DRUG|Bortezomib|Participants receiving Bortezomib 1.3 milligram per square meter (mg/m2) will be observed in this study.
223618062|NCT02474563|DRUG|Melphalan|Participants receiving Melphalan 9 mg/m\^2 will be observed in this study.
223508041|NCT05138640|OTHER|Not applicable. The study is designed as an observational cohort study|Not applicable. The study is desigend as an observational cohort study
223508042|NCT03897192|DRUG|Bevacizumab|Anti-vascular endothelial growth factor (VEGF)
223508043|NCT04428593|DRUG|Treamid 5 mg|The volunteers received the study drug once, and then continued daily intake for 14 days after a 6-day break.
223618063|NCT02474563|DRUG|Prednisone|Participants receiving Prednisone 60 mg/m\^2 will be observed in this study.
223618064|NCT04486235|BEHAVIORAL|Brief waiting room pamphlet|An experiential pamphlet including brief assessment questions and recommended questions for the participant to ask their physician based on their responses. Areas covered in the pamphlet include patients' knowledge of weight status and implications of weight, confidence in physicians' abilities to treat weight, stage of change for weight-related behaviors, and comfort in discussing their weight.
223618065|NCT01715168|DRUG|DOXIL/CAELYX|
223618066|NCT01715168|DRUG|ATI-0918|
223618067|NCT00451672|DRUG|bromocriptine|
223618068|NCT00495729|DRUG|SB-649868|Subjects will receive SB-649868 5 mg, 25 mg tablets orally 1 hour prior to simvastatin administration.
223618069|NCT00495729|DRUG|Placebo|Subjects will receive matching placebo tablets to SB-649868 orally 1 hour prior to simvastatin administration.
223618070|NCT00495729|DRUG|Simvastatin|Subjects will receive Simvastatin 10 mg tablets orally.
223618071|NCT00213512|DRUG|Mabthera|
223618072|NCT01009658|DIETARY_SUPPLEMENT|Monosodium glutamate|Oral intake of 2.0 g of monosodium glutamate on the examination day and 0.6 g of sodium chloride on the other examination day.
223618073|NCT01009658|DIETARY_SUPPLEMENT|Sodium chloride|Oral intake of 0.6 g of sodium chloride on the examination day and 2.0 g of monosodium glutamate on the other examination day.
223618074|NCT02604381|DIETARY_SUPPLEMENT|Glucosamine Sulfate Potassium Chloride/Standardized Ginkgo Biloba Extract|
223618075|NCT02604381|OTHER|Placebo|
223618076|NCT05058807|OTHER|Whole body vibration group|"Experimental Group will receive WBV training and balance exercises under the supervision of a physical therapist by using a vibration platform. Balance exercises include:~Double leg stance with eyes open and eyes closed 10 Reps \* 3 minutes Tandem walk for 3 minutes Sideways walk for 3 minutes Single leg stance for 1 minute with 5 Reps, with 30 sec rest interval~WHOLE BODY VIBRATION:~The patient stood on the platform with his/her feet barefoot shoulder width and stared at the front, delivered on a side alternating vibration platform in an intermittent way: five repetitions of 1 min vibration followed by a 1 min rest. The vibration frequency and amplitude were 20 Hz and 3.0 mm respectively.~These outcomes will be evaluated at baseline, and after 4 week and at 8th week"
223618077|NCT05058807|OTHER|Tai Chi group|"Control group will receive Balance exercises include:~Double leg stance with eyes open and eyes closed 10 Reps \* 3 minutes Tandem walk for 3 minutes Sideways walk for 3 minutes Single leg stance for 1 minute with 5 Reps ,with 30 sec rest interval Yang style Tai chi exercise which consist of 10 positions. 1. Hold the ball ward off 2: Grasping the sparrows tail left; 3.Grasping the sparrows tail Right;; 5.Repulse Monkey; 6. Part wild horse's Mane; 7.Brush knee Twist step; 8.Lift kick left; 9.Lift kick Right; 10.Cross hands with double leg stance~1st and 2nd week will last for 5reps, 3rd and 4th week will last for 10reps,5th and 6th week will last for 15reps,7th and 8th week will last for 20reps, starting with 10 minutes warming- up and ending with 10 minutes cool-down. These outcomes will be evaluated at baseline, and after 4 week and at 8th week"
223618078|NCT01092728|DRUG|Dasatinib|100 mg daily.
223618079|NCT01092728|PROCEDURE|Surgical Resection|Complete surgical resection of tumor(s).
223618080|NCT00646685|PROCEDURE|surgical technique: duct-to-duct biliary reconstruction|surgical reconstruction
223618081|NCT00646685|PROCEDURE|surgical technique: roux-en-y biliary reconstruction|surgical reconstruction
223618082|NCT00721396|BIOLOGICAL|rMenB+OMV NZ|
223618083|NCT00721396|BIOLOGICAL|combined diphtheria,tetanus,pertussis+polio+Hepatitis B+Haemophilus influenzae B vaccine|
223618084|NCT00721396|BIOLOGICAL|Pneumococcal vaccine|
223604163|NCT06975280|BEHAVIORAL|Treatment as Usual (TAU)|The Treatment as Usual (TAU) approach involves routine clinical management and psychological support, without the use of a structured therapeutic framework. This intervention consists of general, non-specific support provided by clinical staff, including informal counseling and monitoring of the child's psychological well-being. Unlike more structured therapeutic protocols, TAU does not follow a predefined set of interventions or techniques, allowing for a flexible and individualized approach, though lacking the formal therapeutic focus of interventions like TF-CBT.
223604164|NCT06976047|BEHAVIORAL|Tell-Show-Do|"The inferior alveolar nerve block will be administered utilizing a combination of the Tell-Show-Do technique and verbal distraction. Initially, the procedure will be explained to the child in simple, age-appropriate language to reduce fear and foster understanding (Tell). This will be followed by a demonstration of the materials and sensations involved, using models or non-threatening demonstrations on the child's hand (Show). Once the child appears comfortable, the actual administration of the nerve block (Do) will proceed exactly as explained, maintaining consistency between the explanation and the action. Throughout the process, verbal distraction will be continuously employed, engaging the child in non-procedural conversation, offering positive reinforcement, and using calming, encouraging language."
223604165|NCT06976047|BEHAVIORAL|Visual distraction|"The child's attention will be distracted before anesthesia by asking the child to participate in the activity and attempt to catch the light. The dentist, using a thumb sleeve placed on their finger, will perform various hand movements. The light in the thumb sleeve is controlled by pressing a battery that turns the light on and off. The child is instructed to catch the light, creating the illusion of passing it from one hand to the other and eventually swallowing it into the oral cavity. Once the child appears comfortable, the actual administration of the nerve block will proceed."
223604166|NCT06976047|BEHAVIORAL|Sensory distraction|During the application of local anesthesia, the child will be provided with a Pop-it toy as a form of sensory distraction. The child will be briefly instructed on how to use the toy, with a simple explanation of the method of play, encouraging active engagement throughout the anesthetic procedure.
223604167|NCT06976047|BEHAVIORAL|Visual and sensory distraction|"The child's attention will be distracted before anesthesia by asking the child to participate in the activity and attempt to catch the light. The dentist, using a thumb sleeve placed on their finger, will perform various hand movements. The child is instructed to catch the light, creating the illusion of passing it from one hand to the other and eventually swallowing it into the oral cavity. During the application of local anesthesia, the child will be provided with a Pop-it toy as a form of sensory distraction. The child will be briefly instructed on how to use the toy, with a simple explanation of the method of play, encouraging active engagement throughout the anesthetic procedure."
223604168|NCT06976840|DEVICE|Intermittent theta burst stimulation|Aimed at potentiating the stimulation target.
223604169|NCT06976840|DEVICE|Sham theta burst stimulation|No effect is expected on stimulation target
223604170|NCT06976840|DEVICE|Continuous theta burst stimulation|Aimed at depotentiating the stimulation target
223604171|NCT06081920|BIOLOGICAL|IBI363|IBI363 monotherapy
223751830|NCT03999190|DRUG|Raclopride radiotracer|"\[11C\]raclopride radiotracer, 2 injections per subject~Antagonist (\[11C\]raclopride) and agonist (\[11C\]NPA) radiotracer will be used sequentially to measure binding potential (BPND) under baseline conditions and 3-hours following oral administration of 0.5 mg/kg amphetamine in the same 30 medication free subjects with schizophrenia (MF-S) and 30 healthy control subjects (HC)."
223751831|NCT03999190|DRUG|Dextroamphetamine|Dextroamphetamine, one oral administration of 0.5 mg/kg per subject Antagonist (\[11C\]raclopride) and agonist (\[11C\]NPA) radiotracer will be used sequentially to measure binding potential (BPND) under baseline conditions and 3-hours following oral administration of 0.5 mg/kg amphetamine in the same 30 medication free subjects with schizophrenia (MF-S) and 30 healthy control subjects (HC).
223751832|NCT00325754|DEVICE|E-Cylinder|Portable Oxygen Therapy Delivered Via An E-Cylinder Mounted On A Wheeled Cart
223751833|NCT00325754|DEVICE|Lightweight Cylinder|Ambulatory Oxygen Therapy Delivered Via A Carbon-Wrapped Aluminum Cylinder
223751834|NCT00555607|DRUG|prednisolone|Prednisolone oral tablets (10 mg active ingredient per tablet) once a day at a dose of 0.5mg/kg bodyweight, during 14 days.
223751835|NCT04361981|OTHER|Deep Venous Disease Diagnostic|Clinical and/or echographic diagnosis of Deep Venous Disease in a patient with COVID-19 infection
223751836|NCT00982709|BEHAVIORAL|Aerobic vs. Agility Training|High Intensity 4x's per week for 4 weeks with a physical therapist.
223751837|NCT05659810|DRUG|Gabapentin 300mg|Preoperative gabapentin before spinal anesthesia
223751838|NCT01334723|DRUG|Adherent with 5-alpha-reductase inhibitor (5ARI) therapy|Patient with BPH who are adherent to 5ARI therapy (Adherence will be calculated using a medication possession ratio (MPR); 3 MPR threshold values of 70%, 75%, and 80% will be evaluated.)
223751839|NCT01334723|DRUG|Non-adherent to 5ARI therapy|Patients with BPH non-adherent to 5ARI therapy (Adherence will be calculated using a MPR; 3 MPR threshold values of 70%, 75%, and 80% will be evaluated.)
223751840|NCT02174068|DRUG|paracetamol 1000 mg per os, nefopam 60mg per os, paracetamol 1000 mg + nefopam 60 mg per os|
223508044|NCT04428593|DRUG|Treamid 15 mg|The volunteers received the study drug once, and then continued daily intake for 14 days after a 6-day break.
223508045|NCT04428593|DRUG|Treamid 50 mg|The volunteers received the study drug once, and then continued daily intake for 14 days after a 6-day break.
223508046|NCT04428593|DRUG|Placebo|The volunteers received the study drug once, and then continued daily intake for 14 days after a 6-day break.
223508047|NCT04002427|DRUG|Intravenous Infusion|30 µg \[14C\]AZD7594 containing 6.7 kBq (180 nCi) carbon-14 (14C) as a 1 hour infusion.
223508048|NCT04002427|DRUG|Inhaled dose|A single inhalation on one occasion.
223508049|NCT03572114|DIAGNOSTIC_TEST|3Tesla MRI|"1. A previously validated multi-parameter mapping protocol sensitive to neuromelanin and iron content~2. Iron mapping and micro-bleed detection: QSM (quantitative susceptibility mapping), a fully flow-compensated, susceptibility-weighted gradient-echo sequence (5 minutes).~3. 1-mm isotropic anatomical MPRAGE (magnetization-prepared rapid gradient-echo)~4. conventional FLAIR sequence"
223508050|NCT03572114|BEHAVIORAL|Burke-Fahn-Marsden Dystonia Rating scale|internationally standardized examination/quantification of dystonia
223508051|NCT03572114|BEHAVIORAL|MDS-United Parkinsons Disease Rating Scale, Part III|most recent, internationally standardized examination/quantification of bradykinesia / rigidity according to the Movement Disorder Society
223751841|NCT01912144|OTHER|Coffee|
223751842|NCT05771233|OTHER|Prevention|"First, an anamnesis is performed to collect information on illnesses, previous and current injuries, medication, sports practice outside of dance, diet, sleep hours and, where appropriate, information on menstruation.~Subsequently, an individual pre-intervention assessment of each participant is carried out, where personal data is collected, motor, elasticity and flexibility, muscle strength and stability tests are performed.~After the initial assessment, group sessions are stablished, divided by classes according to the type of specialty of 6th grade dance. The first session is focused on teaching the different exercises and the importance of muscle strengthening, the subsequent sessions are focused on the correction of the exercises, the resolution of doubts and the incorporation of progressions regarding strength and stabilization.~At the end of the intervention, each participant is re-evaluated and results are compared."
223751843|NCT04924036|DRUG|glycopyrronium cloths|Qbrexza is an anticholinergic indicated for topical treatment of axillary hyperhidrosis in adults and pediatric patients 9 years of age and older
223751844|NCT04924036|DRUG|Placebo|Placebo for this study are cloths that look like the qbrexza cloths but do not have any active ingredient.
224311341|NCT06551415|DRUG|Apixaban 5MG|100 CVT patients will receive apixaban 5mg Bid for 6 months. We will assess the Proportion of subjects who have partial or complete venous recanalization by Day 180 the rate of drug hemorrhagic complications using the PLATO bleeding definition, and the rates of patients who achieved a favorable outcome with (mRS = 0-2) after one week and after 180 days in a face-to-face interview in the outpatient clinic, Proportion of subjects with recurrent venous thromboembolism (any thrombosis at a new site, including cerebral venous thrombosis in a separate location from the index event) at Day 180 or the end of anticoagulation, whichever is sooner, rates of a composite of pulmonary embolism, DVT, myocardial infarction, and death due to vascular events after 180 days of follow-up, the MoCA, HIT-6 by 180 days, the rate of treatment-related adverse effects assessed by a follow-up questionnaire.
223751845|NCT04733651|DRUG|Hospital standard of care for COVID-19|Standard care for COVID-19 as per the hospital guidelines
223751846|NCT04733651|DRUG|Isoquercetin|Daily 1000 mg Isoquercetin as 4 capsules
224200346|NCT05269615|DRUG|Valsartan 80 mg|The well-established angiotensin II receptor blocker (ARB) valsartan will be used in the present study to selectively block AT1 receptors. Valsartan is a generic medication widely used in hypertensive patients since 1996 as well as safely applied in physiological studies comprising healthy individuals.1-3 A minimal valsartan dose of 80 mg known to acutely reduce circulating EPO levels in healthy individuals will be provided 4 hours before starting Study 1 to optimize AT1 blockade according to valsartan's half-life.1-3 The same dose of valsartan (80 mg) will be provided 4 hours before each ET session in Study 2. The participants will be randomly allocated in a 1:1 ratio to valsartan or placebo. Valsartan and placebo tablets will be indistinguishable in taste, smell, appearance and dosage. The protocol will be developed in a double-blind manner in that both participants and investigators will be blinded toward the intervention condition.
224200347|NCT05269615|DRUG|Placebo|The participants will be randomly allocated in a 1:1 ratio to valsartan or placebo. Valsartan and placebo tablets will be indistinguishable in taste and smell. The protocol will be developed in a double-blind manner in that both participants and investigators will be blinded toward the intervention condition.
224311342|NCT02199886|DRUG|BIBH 1|labeled with eight to ten millicurie of 131I
224311343|NCT02308566|PROCEDURE|Minimized Extracorporeal Circulation (MECC)|This group of patients receives surgical aortic valve replacement using MECC.
224311344|NCT02308566|PROCEDURE|Conventional Extracorporeal Circulation (CECC)|This group of patients receives surgical aortic valve replacement using CECC.
224311345|NCT04445597|OTHER|Sampling of tissue|In all groups of participants, tissue from the nasal cavity and olfactory system will be surgically removed
223508052|NCT03572114|BEHAVIORAL|Beck Depression Inventory|internationally standardized examination to quantify traits of anxiety and depression
223508053|NCT03572114|BEHAVIORAL|MoCA: Montreal Cognitive Assessment:|internationally standardized examination to quantify cognition, frequently used in studies of dystonia and parkinsonism
223751847|NCT04773444|BEHAVIORAL|Eccentric cycling training|"1. Performed exercise training 5 days a week for 6 weeks on an eccentric ergometer.~2. Each training session: 3 min at 30% of maximal workload (Wmax) for warmed up and cold down and 30 min the main training phase.~3. Intensity: Firstly, set at 45% Wmax, and progressively increased 5% per week"
223751848|NCT04773444|BEHAVIORAL|Concentric cycling training|"1. Performed exercise training 5 days a week for 6 weeks on an eccentric ergometer.~2. Each training session: 3 min at 30% of maximal workload (Wmax) for warmed up and cold down and 30 min the main training phase.~3. Intensity: Firstly, set at 45% Wmax, and progressively increased 5% per week"
223751849|NCT05109663|DRUG|SKLB1028|SKLB1028, capsule, oral
224311346|NCT03389815|DRUG|WX-0593 Tablets|tablets, dosage ranged from 30 mg to 300 mg, quaque die（QD）
224311347|NCT00616070|DRUG|Difluprednate|Difluprednate
224311348|NCT00616070|OTHER|Placebo|Vehicle
223508054|NCT00335621|DRUG|Inhaled Tiotropium|
223508055|NCT01807104|PROCEDURE|Anterior Approach / Posterior Approach|compare results of total hip arthroplasty performed through either an anterior or posterior surgical approach
223508056|NCT01807104|PROCEDURE|Anterior versus Posterior Approach for total hip replacement|Compare results of total hip arthroplasty performed through either an anterior or posterior surgical approach
223508057|NCT02137681|DRUG|Rituximab|Rituximab was given intravenously at a dose of 375mg/m(2) weekly for 2 consecutive weeks (Day 1, 8) in 2 cycles arm; or 4 consecutive weeks (Day 1, 8, 15, 22) in standard 4 cycles arm
223508058|NCT03084679|OTHER|Aerobic exercise in treadmill|30-40min of aerobic exercise in treadmill. The aerobic intensity will be established by heart rate levels that corresponded to anaerobic threshold up to 10% below the respiratory compensation point obtained in the cardiopulmonary exercise test. This intensity corresponded to 60-72% peak V̇o2. During the exercise sessions, when a training effect will be observed, as indicated by a decrease by 8 to 10% in heart rate, the treadmill velocity or inclination will be increased to return to the target heart rate levels.
223508059|NCT03084679|OTHER|Local strengthening exercises|15 min of local strengthening exercises will be performed in major muscle groups (legs, arms and trunk muscles): three series of each exercise, 12-15 repetitions.
223508060|NCT03084679|OTHER|Stretching exercises|5-min stretching exercises will be performed in major muscle groups (legs, arms and trunk muscles)
223508061|NCT00443326|DRUG|AMG 714|Dosing Regimen is 6 Doses over 3 Months
223604172|NCT05061862|DEVICE|cardiac implantable electronic devices (CIEDs)|Subjects will be implanted with various cardiac implantable electronic devices and followed according to their standard of care. Medical imaging will be collected at various stages of the implant procedure and/or non-invasive diagnostic collection at follow-up visits, as applicable.
223604173|NCT03453489|OTHER|Carbon C 11 Alpha-methyltryptophan|Undergo AMT-PET
223604174|NCT03453489|OTHER|Laboratory Biomarker Analysis|Correlative studies
223604175|NCT03453489|PROCEDURE|Positron Emission Tomography|Undergo AMT-PET
223604176|NCT03453489|DRUG|Telotristat Etiprate|Given PO
223604177|NCT02989584|DRUG|Atezolizumab|
223604178|NCT02989584|DRUG|Gemcitabine|
223604179|NCT02989584|DRUG|Cisplatin|
223604180|NCT06253923|DRUG|Amantadine Hydrochloride|MR-301 is an I.V. formulation for the treatment of TBI. The active ingredient is amantadine hydrochloride (HCl).
223604181|NCT06253923|DRUG|Placebo|The placebo for this study is 0.9% Sodium Chloride IV Solution.
223604182|NCT05773222|DRUG|Apixaban|Single Group Assignment
223604183|NCT04827992|DRUG|Medical Marijuana|Patients in this group can choose what type, how much, and when to use medical marijuana to use.
223604184|NCT04827992|BEHAVIORAL|Prescription Opioid Taper Support (POTS)|Prescription Opioid Taper Support (POTS), a manualized behavioral prescription opioid taper support intervention developed by consultant, will be offered weekly to all participants to support behavioral self-management of pain and structured, voluntary taper of COT dose.
223604185|NCT05286346|DRUG|Tenofovir disoproxil 245mg|1 tablet q.d. for 48 weeks
223604186|NCT05286346|DRUG|Tenofovir disoproxil fumarate 300mg|1 tablet q.d. for 48 weeks
223604187|NCT06554743|BEHAVIORAL|Default Veg|Received a plant-based meal as the default option on the event RSVP form that required participants to pre-select their meal choice
223604188|NCT06554743|BEHAVIORAL|Default Meat|Received a meal with meat as the default option on the event RSVP form that required participants to pre-select their meal choice
223604189|NCT03201861|DRUG|Paclitaxel, Cisplatin|weekly paclitaxel and cisplatin
223604190|NCT03201861|DRUG|EC to docetaxel or paclitaxel|Standard adjuvant chemotherapy recommended by guideline
223604191|NCT06975774|DRUG|Purified Protein Derivative of BCG（BCG-PPD）|Thirty subjects were randomized, double-blinded to perform a homogeneous double-arm BCG-PPD skin test.
223604192|NCT06482112|DRUG|Efinopegdutide|SC injections in dose-escalation regimens potentially including doses of 2 mg, 4 mg, 7 mg, and 10 mg in all arms and 15 mg in the Efinopegdutide Q2W 15 mg arm
223604193|NCT06975839|DRUG|Metformin|local application of metformin gel after surgical removal of lower third molar tooth
224200348|NCT01776060|OTHER|generation of 'omic markers of disease progression|Aside from first in disease sampling, the serial, biannual collection of samples from PPMS patients would not only permit the identification of 'omic profiles that can be compared and contrasted to those from RRMS patients in a parallel study, but it would also allow the generation of 'omic markers of disease progression.
224200349|NCT03759301|DRUG|Growth Hormones Somatropin Recombinant|Growth Hormones Somatropin Recombinant 4 IU/day subcutaneous from the 2nd day of the cycle and stopped 1 day before ovum pickup
224200350|NCT03759301|DRUG|Placebo saline solution|same volume as growth hormone ampule used
223508062|NCT06538493|BEHAVIORAL|JUMPSTART-ANAI|"Patient questionnaire about experiences, preferences, and concerns regarding ACP followed by feedback form with tips for initiating ACP conversation with provider at next clinical visit."
223508063|NCT01374464|OTHER|Interscalene brachial plexus block|"4 different administrations of levobupivicaine will be applied:~1. High Volume, High Concentration = 15mls of 0.75% levobupivicaine~2. High Volume, Low Concentration = 15mls of 0.5% levobupivicaine~3. Low Volume, High Concentration = 5mls of 0.75% levobupivicaine~4. Low Volume, Low Concentration = 5mls of 0.5% levobupivicaine"
223508064|NCT05067270|DRUG|Sodium Citrate|Administered SC infusion.
223508065|NCT05067270|DRUG|Treprostinil|Administered SC infusion.
223508066|NCT05067270|DRUG|Humalog diluent|Administered SC infusion.
223508067|NCT05067270|DRUG|Magnesium Chloride|Administered SC infusion.
223508068|NCT00469027|BIOLOGICAL|eNOS transfected EPCs will be delivered via a PA line|incremental dosing over 3 days
223508069|NCT04309630|PROCEDURE|intercostal block|pain control by intercostal block
223508070|NCT04309630|PROCEDURE|erector spina plane block|pain control by erector spina plane block
223508071|NCT03591796|DEVICE|HFOV|Ventilated infants were randomized to HFOV
223508072|NCT03591796|DEVICE|CMV|Ventilated infants were randomized to CMV.
223508073|NCT07044375|BEHAVIORAL|Going Places|Going Places is a community driven intervention to increase transportation self-efficacy among low-income youth, enabling access to community-based programs that promote physical activity and improve long term cardiometabolic health. The intervention incorporates a multi-level approach that includes 1) workshops on navigating local transportation systems; 2) field trips and participatory assets mapping activities; and 3) youth transportation advocacy.
223508074|NCT07046715|DRUG|DA-5222|single dose administration (DA-5222 one tablet once a day)
223508075|NCT07046715|DRUG|DA-5222-R1|single dose administration (DA-5222-R1 one tablet once a day)
223508076|NCT07046715|DRUG|DA-5222-R2|single dose administration (DA-5222-R2 one tablet once a day)
223604194|NCT06975839|DRUG|non metformin gel|local application of placebo gel after surgical removal of lower third molar tooth
223604195|NCT06974513|BEHAVIORAL|cognitive experiments' session|The aim of this unique session of cognitive experiments is to study the auditory localization performance in patients with a first episode of psychosis. Results of this Arm 1 will be compared to those of Arm 2.
223604196|NCT05858892|OTHER|usual care|usual care(rehabilitation program)
223604197|NCT00585520|DRUG|Progesterone|200mg BID for 5 days
223604198|NCT00585520|DRUG|Placebo|Placebo
223604199|NCT03562494|BIOLOGICAL|VY-AADC02|Adeno-associated viral vector serotype 2 encoding human aromatic L-amino acid decarboxylase (AAV2- hAADC) infusion into the brain
223604200|NCT03562494|OTHER|Sham (Placebo) Surgery|Bilateral partial burr/twist holes without dura penetration
224200351|NCT06536868|DRUG|Tislelizumab|Tislelizumab infusion will be administered for 2 years (200mg, day1, Q3W).
224200352|NCT06536868|DRUG|Etoposide|Etoposide intravenous infusion will be administered during the induction phase (100mg/㎡, day1-3 Q3W for 4 cycles).
223604201|NCT05476783|DRUG|TB006|Clear to slightly opalescent, sterile solution for injection
223604202|NCT06665035|BIOLOGICAL|TDV|TDV SC injection.
223604203|NCT06665035|OTHER|Placebo|Placebo SC injection.
223604204|NCT03960177|DRUG|Glucarpidase|Given IV
223604205|NCT03960177|OTHER|Quality-of-Life Assessment|Ancillary studies
223604206|NCT05941741|RADIATION|Intensity Modulated Radiation Therapy|All target volumes will be outlined slice by slice on the axial contrast-enhanced CT with MR fusion images in the treatment planning system. The target volumes are defined in accordance with the International Commission on Radiation Units and Measurements Reports 83. The prescribed dose is 70-72 Gy to PTVp (Planning target volume of the primary tumor), 64-70 Gy to PTVn (Planning target volume of the lymph node), 60- 64Gy to PTV1 (High-risk planning target volume), and 54-58 Gy to PTV2 (Low-risk planning target volume) in 30-32 fractions.
223604207|NCT05941741|DRUG|Chemotherapy|Induction chemotherapy: gemcitabine and cisplatin, Q3W, 3 cycles Concurrent chemotherapy: cisplatin, Q3W, 2-3 cycles
223604208|NCT05941741|BIOLOGICAL|Immune checkpoint inhibitor|Cadonilimab: 10mg/kg, Q3W, 3 cycles
223604209|NCT05941741|RADIATION|Low-dose radiotherapy|Low-dose radiotherapy will be performed to study group, with the use of IMRT.
223604210|NCT03953300|BIOLOGICAL|Benralizumab|Benralizumab: 30 mg/mL solution for injection in accessorized prefilled syringe (APFS) will be administered subcutaneously (SC) every 4 weeks for the first 3 doses - Weeks 0, 4 and 8, and then every 8 weeks - Weeks 16, 24, 32, 40.
223604211|NCT03953300|BIOLOGICAL|Placebo|Matching placebo will be administered subcutaneously with accessorized prefilled syringe (APFS) every 4 weeks for the first 3 doses - Weeks 0, 4 and 8, and then every 8 weeks - Weeks 16, 24, 32, 40.
223604212|NCT06975124|DEVICE|transcutaneous auricular vagus nerve stimulation|Ear clip electrodes attached to the left cymba conchae to target vagus nerve branches.
223604213|NCT06975124|DEVICE|Sham condition|Electrode placement attached on the left earlobe.
223604214|NCT06976164|PROCEDURE|The standard antenatal care.|Antenatal Protocol.
223604215|NCT06976164|PROCEDURE|Foot reflexology.|A manual therapy technique.
223604216|NCT06974838|DEVICE|intermittent theta burst stimulation|stimulatory protocol
223604217|NCT06974643|OTHER|Thoracic epidural block|Patients will preoperatively receive an awake thoracic epidural block.
223604218|NCT06974643|OTHER|Paravertebral block|Patients will preoperatively receive a paravertebral block.
223604219|NCT06337032|DRUG|F/TAF (High Dose Tablet)|200/25 mg fixed-dose combination (FDC) tablet administered orally
223604220|NCT06337032|DRUG|F/TAF (Low Dose Tablet)|200/10 mg FDC tablet administered orally
223508077|NCT07046715|DRUG|DA-5222-R3|single dose administration (DA-5222-R3 one tablet once a day)
223508078|NCT07046091|BEHAVIORAL|20-minute mindfulness-based breathing exercise|Mindfulness-based approaches help to focus attention and teach individuals strategies for coping with challenging situations, accepting experiences, building self-confidence, and disengaging. Mindfulness-based practices increase an individual's level of awareness and distance them from current or potential stress factors. In recent years, non-pharmacological complementary and integrative interventions have become more widely used in disease management. Studies supporting the use of mindfulness-based interventions, particularly for the management of acute and chronic pain, have demonstrated biological and psychological improvements. In this study, the aim of the 20-minute mindfulness-based breathing exercise program is to reduce dyspnea and fatigue levels and improve sleep quality in heart failure patients who face many challenging situations. After a pre-test, the experimental group will receive the mindfulness-based breathing exercise program. The program will last for 6 weeks, with e
223508079|NCT07046091|BEHAVIORAL|Control (Standard treatment)|No intervention would be applied to patients in this group and only pre-test and post-test data would be collected.
223508080|NCT07044609|DRUG|Clonidine extended release oral suspension|The study is blinded and the active clonidine extended-release oral suspension will look just like the placebo comparator.
223508081|NCT07044609|DRUG|Placebo|Placebo suspension
223508082|NCT07044986|OTHER|no intervention|no intervention
223508083|NCT07045259|OTHER|The Neuromuscular Exercise Training program|The Neuromuscular Exercise Training program will be carried out in groups of 5 people for 45 minutes/2 days/8 weeks. The exercise program will consist of warm-up, loading and cooling phases. The warm-up phase will consist of flexibility exercises, mini squat and roll down etc. exercises to prepare the individual for exercise. The loading phase will consist of a cognitive-based neuromuscular exercise program aiming to provide stabilization, increase in balance, neuroplasticity and motor control and is planned to include strengthening exercises, stabilization exercises, balance-proprioceptive exercises and neuromuscular control exercise training with visual feedback. The exercises will progress gradually from easy to difficult with increasing repetition and set numbers.
223508084|NCT07045259|OTHER|Exergaming Exercise Training|In our study, Xbox 360 Kinect game console and Kinect sensor will be used within the scope of Exergaming. Exergaming program will be carried out in groups of 5 people for 45 minutes/ 2 days/ 8 weeks. It will consist of warm-up, loading and cooling phases. The games to be used for the Exergaming program were selected from games that include locomotor and cognitive repetitive tasks. Just Dance, a movement-based dance/rhythm game accompanied by dance choreography, will be preferred in the warm-up phase. In the loading phase, games such as Reflex Ridge, River Rush, Ralleyball from Microsoft Kinect Adventures game series for lower extremity functions; Bowling, Table Tennis, Swim Out, Fruit Ninja from Microsoft Kinect Sports game series for upper extremity functions will be included. As the sessions progress, game levels will be gradually made more difficult, progressing from easy to difficult.
223508085|NCT07045324|DEVICE|Vagus Nerve Stimulation (nVNS)|Arm 1 (Vagus Nerve Stimulation (nVNS)) is an experimental intervention, as it tests a novel approach (non-invasive vagus nerve stimulation) for trigger point treatment.
223508086|NCT07045324|PROCEDURE|Ischemic Compression|Arm 2 (Ischemic Compression) is an active comparator, as it uses a standard treatment (trigger point massage) commonly applied for myofascial pain.
223508087|NCT07045324|BEHAVIORAL|Exercise (Control)|Arm 3 (Exercise (Control)) is explicitly labeled as the control group in your document, using a standard exercise program, which aligns with an active comparator (since it's an active intervention rather than a placebo or no intervention).
223604221|NCT06337032|DRUG|F/TAF (Lowest Dose Tablet)|120/15 mg FDC tablet administered orally
223604222|NCT06337032|DRUG|F/TAF (High Dose TOS)|60/7.5 mg tablet for oral suspension (TOS) administered orally
223604223|NCT06337032|DRUG|F/TAF (Low Dose TOS)|30/3.75 mg TOS administered orally
223751850|NCT04381845|DIAGNOSTIC_TEST|COVID19 immunization testing|serological COVID19 test with confirmation at J15 during hospitalization
223604224|NCT06337032|DRUG|F/TAF (Lowest Dose TOS)|15/1.88 mg TOS administered orally
223604225|NCT06337032|DRUG|E/C/F/TAF|150/150/200/10 mg tablet administered orally
223604226|NCT06337032|DRUG|E/C/F/TAF (Low Dose)|90/90/120/6 mg tablet administered orally
223604227|NCT06337032|DRUG|Cobicistat (High Dose)|150 mg tablet administered orally
223604228|NCT06337032|DRUG|Cobicistat (Low Dose)|90 mg tablet administered orally
223604229|NCT06337032|DRUG|Cobicistat (TOS)|30 mg TOS administered orally
223604230|NCT06337032|DRUG|B/F/TAF (High Dose)|50/200/25 mg FDC tablet administered orally
223604231|NCT06337032|DRUG|B/F/TAF (Low Dose)|30/120/15 mg FDC tablet administered orally
223604232|NCT06337032|DRUG|B/F/TAF (High Dose TOS)|15/60/7.52 mg TOS administered orally
223604233|NCT06337032|DRUG|B/F/TAF (Low Dose TOS)|7.5/30/3.76 mg TOS administered orally
223604234|NCT06337032|DRUG|B/F/TAF (Lowest Dose TOS)|3.76/15/1.88 mg TOS administered orally
223604235|NCT06337032|DRUG|3rd ARV Agent|A 3rd antiretroviral (ARV) agent administered as defined by the investigator, according to the prescribing information. A 3rd ARV agent may include: boosted atazanavir (ATV), boosted lopinavir (LPV/r), boosted darunavir (DRV), unboosted efavirenz (EFV), unboosted nevirapine (NVP), unboosted raltegravir (RAL), or unboosted dolutegravir (DTG), or any other unspecified agent that is available in a participant's country
223604236|NCT06337032|DRUG|Nucleos(t)ide reverse transcriptase inhibitors (NRTI)|NRTIs administered as defined by the investigator, according to the prescribing information. NRTIs may include zidovudine (ZDV), stavudine (d4T), didanosine (ddI), abacavir (ABC), tenofovir disoproxil fumarate (TDF), tenofovir alafenamide (TAF), lamivudine (3TC), or emtricitabine (FTC)
223604237|NCT06337032|DRUG|ATV|Administered according to the prescribing information
223604238|NCT06337032|DRUG|DRV|Administered according to the prescribing information
223604239|NCT06337032|DRUG|Lopinavir Boosted with ritonavir (LPV/r)|Administered according to the prescribing information
223604240|NCT05010603|GENETIC|Blood Draw|Collection of blood samples for genetic testing
223604241|NCT05010603|OTHER|Late Onset Alzheimer's Disease (LOAD) Neuropsychological Battery Test|Memory Test
223604242|NCT04200417|PROCEDURE|Chemoembolization|Chemoembolization will be performed via the artery (bronchial, non-bronchial systemic, or pulmonary) that shows the greatest tumor enhancement on angiography. Chemoembolization will be performed using a lipiodol / mitomycin emulsion, followed by spherical particles.
223751851|NCT00559546|DRUG|montelukast|10 mg montelukast tablet each evening for 3 weeks or placebo for 3 weeks in cross-over manner
223751852|NCT03412084|BEHAVIORAL|Stand up and move more|4 week behavioral intervention involving the development and implementation of action plans
223751853|NCT00218673|BEHAVIORAL|Peer mentor intervention|groups sessions, 8
223604243|NCT04200417|DRUG|Mitomycin C|Mitomycin (5mg/m\^2,maximum mitomycin dose 20 mg) will be dissolved in lipiodol at 2 mg/ml on the day of procedure.
223604244|NCT04200417|DRUG|Lipiodol|Mitomycin (5mg/m\^2,maximum mitomycin dose 20 mg) will be dissolved in lipiodol at 2 mg/ml on the day of procedure.
223604245|NCT04200417|DRUG|Embospheres|Embospheres are non-resorbable spherical microspheres (trisacryl gelatin) that are FDA-approved for embolization of hypervascular tumors.
223604246|NCT05380349|DRUG|combinations of up to 3 FDA approved drugs from a panel of compounds|personalized drug combinations
223604247|NCT03106324|DRUG|Revlimid (lenalidomide)|Treatment with first line Revlimid containing regimen as prescribed in routine clinical practice
223604248|NCT01985919|OTHER|Obtaining human tissue for basic research or biospecimen bank|
223604249|NCT00219505|PROCEDURE|acupuncture|
223604250|NCT06350123|DRUG|Balcinrenone/dapagliflozin 15 mg/10 mg and matching placebo for dapagliflozin 10 mg|1 capsule of balcinrenone/dapagliflozin 15 mg/10 mg and 1 tablet of matching placebo for dapagliflozin 10 mg once daily, oral use
223751854|NCT02725047|OTHER|Cryotherapy|Crushed ice (1kg) inside a plastic bag (24x34x0,08 cm). The positioning of the plastic bags will cover the entire knee surface (Anterior, lateral and posterior region). After the positioning of the ice bags, they will be fixed with an elastic bandage (compression). To protect the skin against frost bites, all the knee surface will be covered with a moistened operative field (45x50x0,01 cm, 100% cotton)
223751855|NCT02725047|OTHER|Placebo - Sand|Sand (1kg) inside a plastic bag (24x34x0,08 cm). The positioning of the plastic bags will cover the entire knee surface (Anterior, lateral and posterior region). After the positioning of the sand bags, they will be fixed with an elastic bandage (compression). Also, all the knee surface will be covered with a moistened operative field (45x50x0,01 cm, 100% cotton) to mimic the experimental group.
223604251|NCT06350123|DRUG|Balcinrenone/dapagliflozin 40 mg/10 mg and matching placebo for dapagliflozin 10 mg|1 capsule of balcinrenone/dapagliflozin 40 mg/10 mg and 1 tablet of matching placebo for dapagliflozin 10 mg once daily, oral use
223604252|NCT06350123|DRUG|Dapagliflozin 10 mg and matching placebo for balcinrenone/dapa gliflozin|1 tablet of dapagliflozin 10 mg and 1 capsule of matching placebo for balcinrenone/dapagliflozin once daily, oral use
223604253|NCT05408091|DRUG|TRL345, a human monoclonal antibody|Anti-Human Cytomegalovirus (HCMV) IgG1κ Human Monoclonal Antibody
223604254|NCT01635855|DEVICE|Belotero®|Hyaluronic acid dermal filler
223604255|NCT06393647|OTHER|Frailty scale forms (Frailty Scale Version 9, Quality of Life Scale Short Form-36)|In our study, we aim to investigate the relationship between frailty status assessed using frailty scale forms (Frailty Scale Version 9, Quality of Life Scale Short Form-36) and preoperative levels of Albumin/Creatinine, B12, Folate, Ferritin, Sedimentation Rate, and CRP in patients undergoing gastrointestinal malignancy surgery.
223604256|NCT06340672|OTHER|Augmented Reality Enhanced Preoperative Counseling|For patients undergoing AR enhanced preoperative counseling, headset-based AR holograms of standardized patient anatomy through AnatomyX as well as patient specific anatomy through SurgicalAR will be projected to assist the surgeon in educating the patient throughout preoperative counseling.
223604257|NCT06340672|OTHER|Standard preoperative counseling|Control patients will undergo standard preoperative counseling.
223751856|NCT01801150|DEVICE|CPAP nasal treatment|Treatment with titred CPAP nasal during the nighttime
224311349|NCT03172663|DEVICE|pure tone audiometry|for estimate the type and degree of hearing loss
223604258|NCT06284772|OTHER|Questionnaire and fecal sampling|The participants will be mailed a fecal collection kit and a 20-page health questionnaire. This questionnaire will include the similar questions concerning health, lifestyles, and diet as in 2002.
223751857|NCT03198377|DEVICE|TENS: Randomized frequency modulation|"Transcutaneous application of Conventional TENS current over the course of the superficial radial nerve in the right forearm for a 20 minutes session. The intensity of the current will increase until participants report a strong but comfortable sensation, just Transcutaneous application of Conventional TENS current over the course of the superficial radial nerve in the right forearm for a 20 minutes session. The intensity of the current will increase until participants report a strong but comfortable sensation, just below motor threshold. Currents parameters are:~Frequency modulation: randomized pattern (from 80 to 120 Hz) Pulse width 200 microseconds"
223751858|NCT03198377|DEVICE|TENS: Scan 6/6 of frequency modulation|"Transcutaneous application of Conventional TENS current over the course of the superficial radial nerve in the right forearm for a 20 minutes session. The intensity of the current will increase until participants report a strong but comfortable sensation, just below motor threshold. Currents parameters are:~Frequency modulation: Scan of frequency from 80 to 120 Hz in 6/6 mode (frequency sweep from 80 Hz to 120 Hz in 6 seconds and from 120 to 80 Hz in 6 secons) Pulse width 200 microseconds"
223751859|NCT03198377|DEVICE|TENS: Fixed frequency|"Transcutaneous application of Conventional TENS current over the course of the superficial radial nerve in the right forearm for a 20 minutes session. The intensity of the current will increase until participants report a strong but comfortable sensation, just below motor threshold. Currents parameters are:~Fixed frequency at 100 Hz Pulse width 200 microseconds"
223751860|NCT03198377|DEVICE|Sham Stimulation|Electrodes are placed over the course of the superficial radial nerve in the right forearm for a 20 minutes in the same manner as experimental groups, but will be applied a sham electrical stimulation increasing the current intensity of an unconnected channel.
223751861|NCT02418195|DRUG|ketamine|IV infusion of ketamine 0.5mg/kg at a rate of 40mL over 40 minutes
223751862|NCT01242956|BEHAVIORAL|verum group|video-based training after stroke
223751863|NCT01242956|BEHAVIORAL|Placebo group|non-video group
223751864|NCT03255343|DEVICE|IMDENDRIM|In situ and intra tumoral injection of non removal nanodevice IMDENDRIM
223751865|NCT00731887|PROCEDURE|Blood and urine testing|complete blood count, routine chemistries, liver function test, retinol binding protein, transferrin, prothrombin time, partial thromboplastin time, fibrinogen, Vitamin A and Zinc, Insulin Growth Factor levels and binding proteins, cytokines (interleukins 1, 6, 12), insulin, thyroid hormones, cortisol, 25-hydroxyvitamin D, and osteocalcin.
223751866|NCT01512953|DRUG|Lansoprazole|Lansoprazole 30 mg once a day
223751867|NCT00225381|DEVICE|connection of measuring device to anesthesia circuit|same as name
223751868|NCT00225381|PROCEDURE|drawing of blood sample through an arterial line, placed according to clinical criteria by primary anesthesia team|same
223751869|NCT00225381|PROCEDURE|changing operating room bed position (head down and up position)|same
223751870|NCT00225381|PROCEDURE|adding PEEP during anesthesia|same
223751871|NCT00225381|PROCEDURE|placement of esophageal Doppler for cardiac output measurements|same
223751872|NCT00225381|DEVICE|Humidity sensor|Small conventional anesthesia T piece including tiny 2 thermometer inside
223751873|NCT00225381|DEVICE|A mixing chamber (bymixer)|2 mixing chambers (bymixers) composed of 2 arms where one arm serves as a mixing (passive) arm for the measurement of mixed gas fraction. The bymixer is made of conventional anesthesia supplies and does not influence dead space nor circuit resistance.
223751874|NCT00225381|DEVICE|Pneumotachometer cuvette|The pneumotachometer cuvette is used by many anesthesia monitors to measure gas flow.
223604259|NCT06284772|OTHER|Health examination|This examination will include measurements for anthropometrics, cognition (MoCA, Stroop, DSST), and blood pressure. The participants will undergo blood draw for laboratory analyses of CMD risk factors, such as blood lipids, glucose metabolism (fasting glucose, HbA1c, and fasting insulin), liver enzymes (GGT, ALT, and AST), inflammation (hs-CRP), and cardiac markers (proBNP and hs-TnI). We will perform ultrasound imaging for hepatic fibrosis.
223604260|NCT05484219|DEVICE|Functional navigation|Surgeon removes brain tumor or vascular malformation and assesses location of motor areas with functional navigation and intraoperative neuromonitoring
223604261|NCT03190460|OTHER|Cognitive Training|Web-based cognitive training intervention targeting specific cognitive tasks. Subjects complete 3 training sessions per week with at least 24 hours in between sessions.
223604262|NCT03190460|OTHER|Technology-based Education|Subjects complete 16 web-based educational modules on healthy aging content. Following each module, subjects complete a learning reflection.
223604263|NCT05870865|DRUG|ASN008|ASN008 topical gel applied twice daily.
223604264|NCT05870865|OTHER|ASN008 Matching Vehicle|The ASN008 matching vehicle formulation matches the formulation of each ASN008 topical gel dose, but contains no ASN008.
223604265|NCT06251115|DRUG|QY-1-T|QY-1-T is a TCR-T drug targeting HBV-related HCC
223604266|NCT04551807|PROCEDURE|Modified natural cycle|This treatment protocol is defined as a modified natural cycle as the participant will be instructed to (1) administer human chorionic gonadotropin (hCG) to assist with timing of the embryo transfer and (2) supplement the luteal phase with a low dose of progesterone.
223604267|NCT04551807|PROCEDURE|Programmed cycle|This protocol is designated as programmed because the endometrial development occurs only in association with administration of estradiol and progesterone. No ovulation occurs due to suppression of follicle development by the estradiol and the timing of the transfer is based on the number of days elapsed following initiation of exogenous progesterone.
223604268|NCT06674525|DRUG|626|Single subcutaneous injection
223604269|NCT06674525|DRUG|Placebo|Single subcutaneous injection
223751875|NCT00225381|DEVICE|Mass spectrometer sampling port|Designed for the anesthesia tubing and connected at the airway opening. it has small volume (3 mL) and do not influence circuit resistance.
223751876|NCT03689166|DIETARY_SUPPLEMENT|Probiotic|Reduce preterm birth with this dietary supplement
223751877|NCT03689166|OTHER|Placebo|Placebo
223751878|NCT04249037|DRUG|bictegravir/emtricitabine/tenofovir alafenamide (BIC/F/TAF)|A 30 day supply of Bictegravir 50mg/Emtricitabine 200mg/Tenofovir Alafenamide 25mg will be provided to the rapid start arm.
224311350|NCT03051932|DRUG|Ofiramev® (IV Acetaminophen)|Post -op pain medication
223751879|NCT04249037|DRUG|Standard initiation of antiretroviral therapy (ART)|Standard initiation of ART at the discretion of provider + new diagnosis package with laboratory evaluations and social work referral.
223604270|NCT04203004|PROCEDURE|HOPE with cytokine filtration by CytoSorb|Cytokine filtration during HOPE
223604271|NCT01768195|DRUG|Entecavir prophylaxis|"Entecavir 0.5mg daily from day 1 of immunochemotherapy and/or chemotherapy to 12 months after completing immunochemotherapy and/or chemotherapy.~In patients with low load of hepatitis B virus DNA(≤2000 IU/ml), rituximab will be administrated at the beginning of entecavir prophylaxis. And in patients with high load of hepatitis B virus DNA(\>2000 IU/ml), rituximab will be administrated when hepatitis B virus DNA decreased to the level of 2000 IU/ml after entecavir prophylaxis."
223604272|NCT01480310|DRUG|MCAF5352A|may receive up to 3 subcutaneous doses of MCAF5352A
223604273|NCT01480310|DRUG|Placebo|may receive up to 3 subcutaneous doses of placebo
223751880|NCT06367465|DRUG|Glecaprevir-pibrentasvir|Glecaprevir-pibrentasvir 100 mg / 40 mg 3 tab orally (PO) once daily for 56 days.
223751881|NCT01912846|BEHAVIORAL|Interactive advance care planning|"The facilitator will begin each course of intervention by assessing the patient's and his/her family caregiver's readiness for engagement in ACP independently.~Providing participant-centered care tailored to the specific needs of participants at each stage of readiness for engagement in ACP.~Facilitating EOL care discussions throughout the dying process.~A workbook and a video decision aid that briefly describes ACP to enhance participants' understanding of the essential elements in ACP."
223751882|NCT01912846|BEHAVIORAL|Attention usual care|a consistent master prepared nurse on the study team will provide the attention portion of the care. The initial meeting will occur before the patient discharges from hospital and the usual care nurse will give patients and family caregivers a workbook and a video with educational materials on how to manage common symptoms and a comprehensive list of resources available, including patient support organizations, support and financial assistance through the social work department..
223751883|NCT05112692|DRUG|Dydrogesterone Tablets|first arm will be coadministered gonadotrophins with 20mg dydrogesterone till day of trigger second arm will be subjected to fixed GnRH antagonist protocol then will do Freeze All in both arms then frozen embryo transfer next cycle
223751884|NCT05112692|DRUG|cetrorelix 0.25mg|In the fixed GnRH antagonist protocol, daily s.c. administration of Cetrotide 0.25 mg will be initiated at 6th day of stimulation. HMG (150-225IU) will be administered daily from menstrual cycle day 3.
223751885|NCT05112692|DRUG|human menopausal gonadotropin|(150-225IU) will be administered daily from menstrual cycle day 3 till day ot trigger
223751886|NCT05112692|DRUG|triptorelin 0.1 mg|When the dominant follicles reach a diameter of 18mm, the final stage of oocyte maturation will be induced with injections of 100µg of triptorelin s.c combined with 1000IU of hCG i.m
223751887|NCT05112692|DRUG|human chorionic gonadotropin|When the dominant follicles reach a diameter of 18mm, the final stage of oocyte maturation will be induced with injections of 100µg of triptorelin s.c combined with 1000IU of hCG i.m
223751888|NCT05112692|PROCEDURE|cryopreservation|All of the follicles greater than 10mm in diameter will be aspirated. The oocytes are inseminated approximately 4-6hours after follicular aspiration by a conventional IVF method or intracytoplasmic sperm injection, based on the sperm quality On day 3, high quality embryos are cryopreserved by means of vitrification
223751889|NCT05112692|DRUG|Estradiol Valerate and progesterone|Endometrium will be prepared using step-up oral estrogen protocols. On day 14 of estrogen administration, endometrial thickness will be assessed and serum progesterone level will be measured, with cycles to be cancelled according to the arbitrary thresholds of 7.0 mm and 1.5 ng/mL, respectively. Progesterone administration will be started on the morning (am) of day 15, with the start date of progesterone and the day of blastocyst cryopreservation used to coordinate the day of FET
223751890|NCT03687203|DIAGNOSTIC_TEST|Functional Activities Questionnaire|The FAQ is an economic and easy to apply activity of daily living scale. We aim to validate the prognostic value of novel FAQ scores, which differentiate cognitive- from motor-driven activity of daily living function.
223751891|NCT04129788|DRUG|Bisacodyl 5 milligram|three doses taken, one per day on three consecutive days
223751892|NCT04129788|DRUG|Placebo oral tablet|three doses taken, one per day on three consecutive days
223751893|NCT06204458|OTHER|mild hyperthermia group|The hyperthermia treatment is carried out in a cycle of two treatments per week, with at least one day in between, over a period of two weeks, according to the manufacturer's instructions. For better tolerability, the application takes place under administration of 10L/min oxygen. According to the guidelines, the rectal (possibly vaginal) temperature (as body core temperature), heart rate and oxygen saturation (Sp02) are continuously determined during the hyperthermia treatment. During the treatment, continuous supervision by trained personnel is guaranteed, and a doctor is on call.
223751894|NCT06204458|OTHER|sham group|Within the application, patients in the Sham group will undergo a hyperthermia application with virtually no overheating. To achieve this, the patients are positioned on the hyperthermia device in the same way as the intervention group. An insulating foil applied beforehand prevents direct irradiation with water-filtered infrared-A radiation. This prevents an increase in temperature. Due to the insulating blanket and the natural heat from the device and body, patients in the Sham group experience a gentle warmth that cannot be compared with regular whole-body hyperthermia and an increase in core body temperature of around 1.5°C. The number of treatments, the lighting conditions and procedures including 10L/min oxygen supply, is equal to the treatments in the intervention group.
223604274|NCT04174196|DRUG|CC-486|Participants will be treated with CC-486 and lenalidomide for 6 cycles
223604275|NCT04174196|DRUG|Lenalidomide|Participants will be treated with CC-486 and lenalidomide for 6 cycles
223604276|NCT04174196|RADIATION|Radiation Therapy|Radiation therapy will be initiated to the plasmacytoma after cycle 2
223604277|NCT06600581|BIOLOGICAL|IMM01-STEM|IMM01-STEM is an allogeneic cell-free secretome product derived from partially differentiated human stem cells derived from a pluripotent embryonic stem cell line that was established from a single donor IVF discarded blastocyst. The cells are cultivated in bioreactors and the product of their secretion is collected, purified and concentrated to a standardized formulation. The secretome contains a mixture of molecules related to immunomodulation, growth, and extracellular matrix remodeling. This intervention is given 2mL twice a week.
223604278|NCT06600581|OTHER|Placebo|Saline. This intervention is given 2mL twice a week.
224311351|NCT03051932|DRUG|Placebo IV administration|Post -op pain
223604279|NCT06600581|BIOLOGICAL|IMM01-STEM alternating with placebo (saline)|This intervention consists of IMM01-STEM given once a week and placebo given one a week. IMM01-STEM is an allogeneic cell-free secretome product derived from partially differentiated human stem cells derived from a pluripotent embryonic stem cell line that was established from a single donor IVF discarded blastocyst. The cells are cultivated in bioreactors and the product of their secretion is collected, purified and concentrated to a standardized formulation. The secretome contains a mixture of molecules related to immunomodulation, growth, and extracellular matrix remodeling.
223604280|NCT05803720|BEHAVIORAL|Provider Intervention on Addressing Intersectional Stigma and Medical Mistrust in Patients with HIV|The intervention will consist of psychoeducation and skills-building for HIV care providers to gain knowledge and skills needed to address intersectional stigma and medical mistrust with patients. The intervention will be online and conducted in groups.
223604281|NCT06170372|DRUG|200 ppm Nitric Oxide|NO will be supplemented at 200-ppm concentration 3 times a day for 30 min until the pneumonia resolves, but no more than 7 days
223604282|NCT06170372|DRUG|Sham treatment|Oxygen-air mixture without NO 3 times a day for 30 min until the pneumonia resolves, but no more than 7 days
223604283|NCT06129903|OTHER|referral to the Memorial Sloan-Kettering Cancer Center (MSK) Department of Psychiatry and Behavioral Sciences.|The primary intervention in this study is referral to the Memorial Sloan-Kettering Cancer Center (MSK) Department of Psychiatry and Behavioral Sciences. This study will not dictate specific psychiatry interventions beyond providing the referral.
223604284|NCT06672003|DIAGNOSTIC_TEST|4 meter walking speed and hand grip strength|4 meter walking seconds are noteed for each of participants
223604285|NCT06671821|DRUG|HRS-7535|HRS-7535
223604286|NCT06921538|DEVICE|AscenZ-IV neuromodulation device|AscenZ-IV neuromodulation device is a novel treatment modality that utilizes 2 non-invasive neuromodulation technologies - tPCS and TENS - concurrently within a device. The home-based, non-invasive AscenZ-IV Stimulator therapy has been shown to improve spasticity and motor function
223604287|NCT06921993|DIAGNOSTIC_TEST|LUNG ULTRASOUND|"All subjects randomly assigned to the investigational arm will undergo lung ultrasound (LUS) .~Ultrasound still images and ultrasound clips will be acquired according to the study protocol. Detailed methodology of the ultrasound examination and parameters is provided as appendix to the study protocol"
223604288|NCT03922893|OTHER|Family History Information|The family history ascertainment focuses on self-reported family history of first-, second-, and third-degree family members, including types of malignancies/ pre-malignant lesions and age at diagnosis.
223604289|NCT03922893|GENETIC|ORAGENE|Approximately 2-4mL of saliva may be collected in specialized Oragene DNA Self-Collection Kit tubes or buccal swab-based collection devices.
223604290|NCT03922893|GENETIC|Blood|For select participants, 1-2 tubes of blood will be drawn for DNA and RNA analysis
223604291|NCT03922893|OTHER|Skin Biopsy|In certain circumstances, for Memorial Sloan Kettering participants and their family members, it may be necessary to obtain a skin biopsy.
223604292|NCT03711760|BEHAVIORAL|telepsychology|CBT delivered by telepsychology
223604293|NCT05399212|DRUG|FPT-20|FPT-20 should be used regularly, the daily maintenance dose is 1 tablet once a day(\>6 to 12 months) until the therapeutic purpose is achieved.
223604294|NCT06684587|BEHAVIORAL|Exercise Program|In this 10-week intervention, participants will be given strengthening exercises and neuromuscular re-education exercises.
223604295|NCT06684587|BEHAVIORAL|Mindful Exercise|In this 10-week intervention, mindfulness meditation will be integrated with strengthening and neuromuscular exercises recommended for knee osteoarthritis.
223604296|NCT06863194|DRUG|Probiotic Supplementation (Lactobacillus plantarum)|"Participants in this group will receive Lactogemikan (Probiotic Supplement), which contains 10 billion CFU of Lactobacillus plantarum per tablet. The dose is one tablet daily for 6 months.~This probiotic is intended to modulate gut microbiota, reduce systemic inflammation, and decrease uremic toxins (indoxyl sulfate) in CKD patients. The intervention will be compared to a placebo to evaluate its effectiveness in slowing CKD progression and improving metabolic and inflammatory markers."
223604297|NCT06863194|DRUG|Placebo Tablets|"Participants in this group will receive an inert placebo tablet that is identical in appearance, taste, and packaging to the probiotic supplement but contains no active probiotic ingredients. The dose is one tablet daily for 6 months.~The placebo serves as a control to compare the effects of the probiotic intervention. Both groups will undergo identical monitoring and follow-up assessments to determine whether the probiotic has a significant effect on kidney function, inflammation, and gut microbiota composition."
223604298|NCT05943548|BEHAVIORAL|Omuyambi|HIV testing, referral, care linkage, and medication adherence support
223604299|NCT05943548|BEHAVIORAL|Control|HIV Testing and referral
223604300|NCT04838236|OTHER|MASP app + NRT|MASP is a mobile intervention that targets anxiety sensitivity among African American smokers (Mobile Anxiety Sensitivity Program for Smoking: MASP). Our intervention is framed within the cultural context of interoceptive stress among African American smokers, which is supported by theory, empirical evidence, and characteristics of this group. The MASP app employs a variety of features to educate its users on how to deal with stress, anxiety, and nicotine withdrawal symptoms. The app contains a series of on-demand features, including a coping toolkit, stress management trainings, and a series of educational videos. MASP also utilizes Ecological Momentary Assessments (EMAs) to gather information, and provide personalized messages to users in real time.
223604301|NCT04838236|OTHER|QuitGuide app + NRT|Quitguide is a smartphone-based National Cancer Institute (NCI) app for standard mobile smoking cessation treatment. The app contains features that allows its' users to better understand their smoking patters, and build skills needed to becomes and stay smoke free. The app allows users to track their cravings, and delivers motivational messages to users for each craving they track.
223604302|NCT06705257|DIAGNOSTIC_TEST|Studying the effects of varying levels of PEEP using Electrical impedance tomography|Feasibility of using EIT, to study the effect of varying levels of PEEP/Continous distending pressure on lung recruitment as measured by changes in functional lung scores and silent spaces in preterm infants (\<32 weeks) who are on mechanical ventilation or receiving primary or post extubation CPAP support.
223604303|NCT00998088|OTHER|erythropoietin and cell saver|weekly 40.000 IU s.c. for 4 weeks pre-operatively; use of cell saver includes intra- and post-operative drainage and reinfusion
223604304|NCT00998088|DRUG|erythropoietin|weekly 40.000 IU s.c. for 4 weeks pre-operatively
223604305|NCT00998088|DEVICE|OrthoPAT|for intra- and post-operative re-infusion of autologous wound blood
223604306|NCT00998088|DEVICE|Post-operative drain device|For post-operative re-infusion of unwashed wound blood
223604307|NCT00998088|OTHER|Erythropoietin and OrthoPAT|weekly 40.000 IU s.c. for 4 weeks pre-operatively
223604308|NCT00998088|OTHER|Erythropoietin and drain device|weekly 40.000 IE s.c.for 4 weeks pre-operatively; drain use in post-operative period
223604309|NCT00998088|DEVICE|OrthoPAT|For intra- and post-operative reinfusion of autologous blood
223604310|NCT06977022|DEVICE|Chest wall reconstruction|Extended resection of chest wall tumors with subsequent biodegradable polycaprolactone (PCL) 3D-printed rib prosthetic reconstruction
223604311|NCT06876233|BEHAVIORAL|Wellth App|Participants will be eligible to receive $30 at the end of four consecutive 30-day periods ($120 in total) if they demonstrate complete medication adherence through the Wellth app (i.e. taking a daily picture of their pills in their hand and submitting it through the Wellth app). Photos must be submitted within a 2-hour window around a specific time of day chosen by the participant and set at the start of each 30-day period. They will lose $2 (from their $30 total) for every day they miss a medication check-in within their pre-set 2-hour window with the Wellth app. The Wellth app will also provide reminders at the end of the day if participants have not yet completed their daily check-in.
223604312|NCT06876233|BEHAVIORAL|Action Planning|"Participants will learn about habits and the importance of contextual cues for triggering their AH pill taking, and be asked to complete an electronic worksheet with a detailed description of their personalized contextual cue in terms of its: 1) location (e.g., where in the participant's house or office does this cue occur); 2) time of day; 3) preceding action (e.g., I usually go to the bathroom before making coffee); and 4) a visual cue (e.g., my coffee cup will trigger pill taking)."
223604313|NCT06876233|BEHAVIORAL|Wellth + Cue|Participants will be eligible to receive $30 at the end of four consecutive 30-day periods ($120 in total) if they submit daily evidence of their medication adherence habit using the Wellth app (i.e. one photo that provides evidence of pill-taking and one photo that provides evidence of their contextual cue, which participants will select and specify on their comprehension survey at the start of the study). Photos must be submitted within a 2-hour window around a specific time of day chosen by the participant and set at the start of each 30-day period. They will lose $2 (from their $30 total) for every day they miss a medication check-in (plus evidence of their contextual cue) within their pre-set 2-hour window with the Wellth app. The Wellth app will also provide reminders at the end of the day if participants have not yet completed their daily check-in.
223604314|NCT06727357|DRUG|Chemotherapy|in according to institutional guidelines
223604315|NCT06727123|OTHER|motivational interviewing|Motivational interviews will be conducted with diabetic patients for 6 months. Patients will be trained before starting the interviews.
223604316|NCT06727123|OTHER|Control|No application will be made. Routine follow-ups will be made.
223604317|NCT06725238|OTHER|Acute-to-chronic glycemic ratio|This ratio could be related to diabetic foot ulcer
223604318|NCT06725589|OTHER|metabolic disease|metabolic disease
223604319|NCT06390007|DEVICE|Sham press needle|The plester used is a round plaster that resembles the shape of an acupuncture press needle.
223604320|NCT06390007|DEVICE|Press needle acupuncture|Press needle acupuncture is a modality of acupuncture using tiny and very thin needles.
223604321|NCT06726746|DEVICE|Fractional CO2 laser|". Using the following settings with the internal handpiece: square pattern with Deep Mode, fractional density of 5% and energy level of 50 mJ and fluence of 283 J/cm2. The handpiece will be inserted into the vagina (up to 10 cm) The handpiece will be positioned with contact to the vagina and will be rotated to apply 12 pulses at each 1-cm marking (application of laser energy at 3-10-cm depths) until the distal end of the vaginal probe reaches the introitus.~The laser application will be performed on an outpatient basis without local anesthesia in outpatient clinic."
223604322|NCT06726499|DEVICE|Spherical CRT|Contact lens for myopia progression
223604323|NCT06726499|DEVICE|Toric CRT|Contact lens for myopia progression
223604324|NCT06726213|OTHER|Walk and talk|An hour long walk at a slow pace lead by a trained walking leader.
223604325|NCT06727292|DIETARY_SUPPLEMENT|Food supplement|Instant drink in a powder form presented in a sachet to be disolved in a glass of water (200 ml).
223604326|NCT06727292|DIETARY_SUPPLEMENT|Placebo|Instant drink in powder form in a sachet to be disolved in a glass of water (200ml)
223604327|NCT06725134|BEHAVIORAL|Therapy dog presence|A trained therapy dog will be present during the child's dental appointment. The dog will be in the operatory as the child enters the room and will lie on the child during injection of local anesthesia.
223604328|NCT06725134|BEHAVIORAL|Standard-of-care basic behavior guidance|Basic behavior guidance as defined by the American Academy of Pediatric Dentistry includes strategies to help children cope through potentially stressful dental procedures. These strategies include tell-show-do, positive reinforcement, parental presence, and nitrous oxide/oxygen analgesia, among others.
223604329|NCT05379673|OTHER|Oxygen Gas for Inhalation|Oxyhemoglobin saturation (SpO2) higher than 96% vs SpO2 between 90% and 94%.
223604330|NCT07048132|DIAGNOSTIC_TEST|Headache Screening Questionare|"The Headache Screening Questionnaire (HSQ) is a 10-item tool developed to screen for migraine and tension-type headache (TTH), based on the ICHD-3 beta criteria.~Each item reflects a diagnostic criterion for migraine or TTH. Participants complete the HSQ and are also evaluated by a neurologist for diagnosis.~A score of 6 or higher suggests probable migraine or probable TTH."
223604331|NCT07046702|DIAGNOSTIC_TEST|68Ga-MY6349|Each subject receives a single intravenous injection of 68Ga-MY6349 and undergoes PET/CT imaging within the specified time.
223604332|NCT05604989|DRUG|Probiotic Combination Cap/Tab|The Perfect Probiotics® capsule will be given as an intervention, which is composed of mostly Lactobacillus acidophilus \& Bifidobacterium lactis.
223604333|NCT05604989|DRUG|intravitreal Anti-VEGF injection|Intravitreal anti-VEGF injection treatment in the neovascular AMD patients.
223604334|NCT06742281|BIOLOGICAL|CVXGA (CVXGA50)|CVXGA is a recombinant parainfluenza virus type 5 (PIV5) engineered to express SARS-CoV-2 S gene from the KP.2 strain.
223604335|NCT06742281|BIOLOGICAL|COMIRNATY®|COMIRNATY® (COVID-19 vaccine, mRNA) suspension for injection, for intramuscular use, 2024-2025 Formula (BioNTech Manufacturing GmbH \[Mainz, Germany\] and Pfizer Inc. \[New York, NY\]) will be used as the comparator vaccine for this study.
223751895|NCT02656108|PROCEDURE|Ommited controlled cord traction|No controlled cord traction and no fundal pressure. placenta will be allowed to deliver physiologically
224311352|NCT06979206|OTHER|Application of Binarual Beat|The binaural beat audio file consists of pure tones at 431 Hz in the left ear and 432 Hz in the right ear, delivered via earphones continuously until the end of anesthesia.
223604336|NCT05747027|PROCEDURE|Laparoscopic abdominal ventral rectopexy|Laparoscopic abdominal ventral rectopexy is an established surgical technique used to restore rectal support in women with obstructive defecatory syndrome (ODS). It is the most common surgery used to treat ODS. It involves a series of small cuts in the abdomen and the use of mesh to hold the rectum in the correct position.
223604337|NCT05747027|PROCEDURE|Transvaginal sacrospinous rectopexy|Transvaginal sacrospinous rectopexy is an innovative procedure which has shown to be safe and effective in the treatment of stool entrapment. This is a mesh-free and vaginal route procedure.
223604338|NCT05724641|DIAGNOSTIC_TEST|MRI perfusion imaging using ASL's non-invasive technique|Patients will undergo through an MRI-scan using the ASL MRI sequence, as described per protocol.
223604339|NCT06893666|OTHER|Play based therapy|Experimental group was given pay based therapy. Total of 4 sessions were given each session of 40min.
223604340|NCT06893666|OTHER|Child centered play therapy|Control group was given child centered play therapy. Total of 4 sessions were given each session of 40min.
223604341|NCT06893068|DEVICE|AI-based clinical intelligent management system|The clinical intelligent management system, integrated with AR glasses and powered by a multimodal foundational model, is designed to improve the quality of outpatient care at community health service centers.
223604342|NCT06067269|DRUG|Apalutamide|Given PO
223604343|NCT06067269|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
223604344|NCT06067269|PROCEDURE|Computed Tomography|Undergo PSMA-PET/CT
223751896|NCT02656108|PROCEDURE|controlled cord traction|active management of third stage of labor in the form of uterine massage with controlled cord traction
223751897|NCT03684915|DEVICE|Rotary files|using rotary files in cleaning root canals of infected primary molars
223751898|NCT03493984|OTHER|Ginger exosomes|Naturally occurring plant exosomes from ginger
223751899|NCT03493984|OTHER|Aloe exosomes|Naturally occurring plant exosomes from aloe
223751900|NCT03493984|OTHER|Placebo|Exosome placebo tablet
223751901|NCT03524807|DEVICE|Electrophysiologic therapy|Pelvic floor electrophysiological therapy is used after common gynecologic surgery to record anal exhaust time and micturition time after surgery and endometrium recovery of intrauterine adhesions.For intrauterine adhesions patients, Drug: Aspirin(low dose of Aspirin after operation)Device: intrauterine balloon (insert intrauterine balloon after operation)
223751902|NCT03307733|BEHAVIORAL|walking and behavour change techniques|a Fitbit pedometer with individualised step targets and partaking in a closed Facebook group
224200353|NCT06536868|DRUG|Carboplatin or Cisplatin|Carboplatin or Cisplatin intravenous infusion will be administered during the induction phase (Carboplatin AUC5, Q3W for 4 cycles; Cisplatin 75mg/㎡, Q3W for 4 cycles).
224200354|NCT06536868|RADIATION|Thoracic radiotherapy|IMRT 30-45Gy/10-15f
223604345|NCT06067269|OTHER|Gallium Ga 68 Gozetotide|Undergo PSMA-PET/CT
223604346|NCT06067269|RADIATION|Guided Stereotactic Body Radiation Therapy|Undergo guided SBRT
224200355|NCT04482101|OTHER|Root canal obturation|Root canal filling
224200356|NCT05869019|OTHER|education|Premature baby care training will be provided.
224200357|NCT03469141|DEVICE|Pressure Relief Monitoring System|Biofeedback provided to the intervention group via the smartphone app will include: Visual (e.g., phone notification bar) and auditory reminders if PR (pressure relief) is not performed as scheduled, Real-time feedback during performance of PR maneuvers to ensure adequate PR (e.g., the app will indicate if the duration of PR is sufficient), and Aggregate counts of daily PR activity.
224200358|NCT01036594|DRUG|Ketoconazole|200mg during first week of study (run-in phase), then 400mg po tid
223604347|NCT06067269|PROCEDURE|Multiparametric Magnetic Resonance Imaging|Undergo multiparametric MRI
223604348|NCT06067269|PROCEDURE|Positron Emission Tomography|Undergo PSMA-PET/CT
223604349|NCT06067269|OTHER|Questionnaire Administration|Ancillary studies
223604350|NCT07051850|DRUG|Bispecific antibody|It uses a dual targeting mechanism to enhance specificity and immune activation. It is an off-the-shelf treatment, and doesn't require a manufacturing process of patient cells.
223604351|NCT07051850|DRUG|Antibody-Drug Conjugate|It is a targeted therapy consisting of a monoclonal antibody linked to a cytotoxic drug. The antibody binds to a specific antigen on cancer cells, delivering the cytotoxic agent directly to the tumor, minimizing systemic toxicity.
223604352|NCT07051850|DRUG|Monoclonal antibody|Monoclonal antibodies are lab-engineered antibodies that target specific antigens expressed on cancer cells. These commonly target CD20 (rituximab or obinutuzumab) to mediate immune destruction.
224200359|NCT01036594|DRUG|Hydrocortisone|"Hydrocortisone 20mg po qam and 10mg po qpm~If participant has ≥30% PSA decline at 12 week evaluation, treatment continues until progressive disease (by RECIST criteria OR by PSAWG criteria) is documented. After that, drug will be discontinued. If participant has \<30% PSA decline, patient goes off study."
224200360|NCT01036594|DRUG|Dexamethasone|"Dexamethasone 0.5mg po bid~If ≥ 30% PSA decline (Prostate-specific antigen) at 12 week evaluation, administration starts when disease progression (by RECIST criteria OR by PSAWG criteria) is documented."
224200361|NCT05914987|OTHER|Targeted Therapy|Approved interventions based on the subject's genomic profile will be provided to investigators for consideration for anti-tumor therapy.
224200362|NCT05095896|OTHER|ITP patients|ITP patients were enrolled in this study based on Chinese consensus of ITP.12 Patients were excluded as (1) receiving platelet transfusion within 7 days or ITP-related medication within 3 months (2) treated with lipid-lowing agents, including statins, fibrates, niacin, bile sequestrant resins, ezetimibe and so on.
224311353|NCT06982872|DIAGNOSTIC_TEST|artificial intelligence|Different AI assisted diagnostic systems are used to diagnose lesions.
223604353|NCT07051850|DRUG|Proteasome Inhibitor|It blocks the activity of proteasomes, which role is degrading damaged proteins. This disruption induces apoptosis in cancer cells. Common agents include bortezomib and carfilzomib.
224311354|NCT06981767|DIETARY_SUPPLEMENT|Topical Bromelain|A natural enzyme-based formulation derived from pineapple, bromelain in orabase is being investigated for its anti-inflammatory and wound-healing properties. As a non-steroidal alternative, it offers a potentially safer treatment option with minimal side effects.
223604354|NCT07051850|DRUG|IMiD treatment|Immune modulatory drugs modulate the immune response by enhancing T-cell and NK cell activty to disrupt tumor progression. Common drugs include lenalidomide and thalidomide.
223604355|NCT07051850|DRUG|CAR-T Therapy|It uses the patient's own T cells, and requires a manufacturing process to modify and expand T cells before infusion. It directly targets B cell specific antigens, such as CD19 or CD20.
224200363|NCT05784311|DRUG|Cefuroxime|1500mg IV cefuroxime thrice daily during five days.
224200364|NCT05784311|DRUG|Metronidazole|500mg IV metronidazole thrice daily during five days.
224200365|NCT05773053|DRUG|NT 201|Clostridium botulinum neurotoxin type A (150 kiloDalton \[kD\], free of complexing proteins) powder for solution for injection.
223618085|NCT02205996|DRUG|Insulin (Humulin S)|Using insulin and glucose infusions (hyperinsulinaemic clamps), blood glucose levels were stabilised over 1 hour to reach 5 mmol/L and maintained at that level for 1 hour, then gradually reduced over 1 hour to 2.8 mmol/L and maintained at that level for 1 hour. Blood samples were collected at times 0 (baseline), 2 hours (euglycaemia), 4 hours (hypoglycaemia) and at 24 hours after the clamp studies.
223618086|NCT02205996|DEVICE|Euglycaemic Hypoglycaemic Insulin clamp|
224200366|NCT05773053|DRUG|NT 201 Placebo|NT 201 Matching-placebo.
224200367|NCT01576731|DRUG|Tenofovir, Emtricitabine, Lopinavir/r|Combination drug
224200368|NCT01576731|DRUG|Tenofovir, Emtricitabine, Raltegravir|Combination drug
224200369|NCT02233465|PROCEDURE|IPOM Mesh-repair parastomal hernia|Safety study for mesh-repair of parastomal hernia
223618087|NCT01521130|DRUG|Levetiracetam|Medication doses are defined on a mg/kg basis. Dosage form, frequency and titration schedule is based on accepted clinical practice.
223618088|NCT02253225|OTHER|Functional Magnetic Resonance Imaging (fMRI)|Imaging will be performed on a 3T Siemens Trio scanner. Each MRI scanning session will last no more than 90 minutes.
223618089|NCT03546621|DRUG|Myrcludex B|2 mg, once daily, subcutaneously
223618090|NCT03546621|DRUG|Myrcludex-B|5 mg, once daily, subcutaneously
223618091|NCT03546621|DRUG|Myrcludex-B|10 mg, once daily, subcutaneously
223618092|NCT03546621|DRUG|Tenofovir|tenofovir disoproxil 245 mg, equivalent to tenofovir disoproxil fumarate 300 mg
223618093|NCT01096836|OTHER|macronutrient and energy manipulation|
223618094|NCT00226590|DRUG|Gemcitabine|Induction Chemotherapy.
223618095|NCT00226590|DRUG|Carboplatin|Induction Chemotherapy. Weekly Carboplatin and Paclitaxel During Thoracic Radiation Therapy.
223618096|NCT00226590|DRUG|Paclitaxel|Weekly Carboplatin and Paclitaxel During Thoracic Radiation Therapy.
223618097|NCT00226590|PROCEDURE|Radiation|Radiation Therapy will begin on day 57 if there has been adequate hematologic recovery from Induction Chemotherapy.
223618098|NCT06136429|PROCEDURE|Transcatheter aortic valve replacement|Device: Transcatheter Heart Valve System (Silara SR)
223618099|NCT01054105|DRUG|Iloprost|Iloprost inhalation, 2.5 - 5mcg, 6 times per day
223618100|NCT06045312|OTHER|education|Comparison of the effectiveness of peer or adult education to adolescents with asthma
223618101|NCT01111708|PROCEDURE|Close Rectal Dissection - IPAA|Comparison between conventional IPAA and Close Rectal IPAA and INRA after (sub)total proctocolectomy for Ulcerative colitis
223618102|NCT05384340|DIETARY_SUPPLEMENT|Beetroot juice rich in nitrate|On the first day, an acute test will be carried out with beet juice rich in nitrate, in which two units of juice will be provided, totaling 140 ml (800 mg of nitrate) for each protocol. That is, each participant will receive 2 units of juice bottles. From the second to the seventh day, participants will receive 6 units of vials of the juice corresponding to the first intervention on the first visit to the laboratory and will drink one vial a day for a week. Of the 8 units (100%), six bottles (75%) will be provided for the participants to take home. On the seventh day of the intervention, the participants will return to the laboratory for the consumption of the seventh and last bottle of juice. Between one protocol and another, a 7-day washout interval will be given for the purification of the compounds provided by the protocols.
223618103|NCT02365649|DRUG|Placebo|Oral Dosing
223618104|NCT02365649|DRUG|ABT-494|Oral Dosing
223618105|NCT03591926|DRUG|SM04646|"Nebulized, inhaled solution; single dose concentration dosed once per day for 12 weeks; dosing pattern will follow a 2 weeks on, 2 weeks off regimen, wherein subjects will dose 5 consecutive days of each 7 day on week."
223618106|NCT04142034|BEHAVIORAL|the iAmHealthy Behavioral Intervention|"iAmHealthy Behavioral Intervention Arm~Child/caregiver pairs in the iAmHealthy behavioral intervention arm will receive:~* usual care at their clinic for all issues, including overweight and obesity;~* a monthly newsletter that focuses on general child health. The child/caregiver pairs will receive six newsletters (one per month) during the six month intervention period (same newsletter provided to the newsletter-only intervention participants);~* weekly group sessions for the first three months, followed by monthly group sessions during the next three months, for a total of 15 group sessions. The trial's iAmHealthy behavioral intervention psychologist or social worker (one team per clinic) will deliver these group sessions via an electronic tablet that the trial sponsor will supply;~* 11 hours of individual homework sessions with the iAmHealthy behavioral intervention dietician"
223618107|NCT04142034|BEHAVIORAL|Newsletter only arm|Newsletter arm participants will receive a monthly newsletter on maintaining a healthy weight through diet and exercise
223618108|NCT04142034|OTHER|Consecutive Recruitment|Recruitment of study participants through identifying potential participants through their medical records
223618109|NCT04142034|OTHER|Traditional Recruitment|Recruitment of potential participants through flyers and advertisements
223618110|NCT04024488|BEHAVIORAL|TI-CBT Intervention Arm|"TI-CBT teaches techniques and ways to manage distress through psychosocial health education, cognitive restructuring, and mastery of trauma, which refers to the process by which survivors of psychological trauma work through the traumatic experience in a meaningful way, and are able to move on with life. TI-CBT addresses both the trauma of learning one has HIV and the trauma associated with managing a chronic and stigmatized illness. The intervention highlights links between HIV and traditional gender roles, gender inequities, and gender based violence. Finally, the relaxation training teaches youth strategies to relax and these are integrated at the beginning and end of each session. TI-CBT Youth and Caregiver Intervention Manuals are distributed to sites for translation, backtranslation, and cultural adaptation in preparation for the Randomized Trial."
224200370|NCT01135901|BEHAVIORAL|Behavioural change programme|The programme consists of a introductory course, organised physical activity 2-3 times a week, meetings every 3rd month with lectures and theme nights, and organising self-help groups.
224311355|NCT06981767|DRUG|0.1% topical triamcinolone acetonide|A corticosteroid-based standard treatment for OLP, triamcinolone acetonide in orabase is used for its strong anti-inflammatory and immunosuppressive effects. It serves as the conventional treatment versus novel therapy in this study
223604356|NCT07061392|OTHER|standardized-patient simulation|"Intervention Arm (Group M) Participants randomized to Group M (n = 45 enrolled; 43 analyzed) first completed baseline assessments of meaningful learning self-awareness , perceived learning, and stoma-care skill , as well as a 10-item demographic survey. They then attended a two-hour didactic session-covering stoma indications, types, perioperative care, evidence-based practices, complications, and the stoma-care nurse's role-delivered by a certified stoma-care nurse in small groups.~Immediately following the lecture, each nurse participated in a two-hour hands-on simulation with a trained standardized patient. The standardized patient had been prepared with a realistic stoma moulage (transparent drape and egg-biscuit mixture) and received two hours of role-training. Simulation sessions adhered to INACSL Standards (pre-briefing, in-scenario, observation, and debrief"
223604357|NCT07061392|OTHER|a low-fidelity Prestan 2000 adult CPR mannequin modified with a play-dough stoma model|"Control Arm (Group K) Participants randomized to Group K (n = 45 enrolled; 44 analyzed) underwent the identical sequence of baseline assessments and the same two-hour didactic session as Group M. For the practical component, they performed stoma-care simulation on a low-fidelity Prestan 2000 adult CPR mannequin modified with a play-dough stoma model.~Hands-on practice was structured in small groups over two hours and included:~Pre-briefing: Overview of objectives and materials.~In-scenario: Individual stoma-care performance on the mannequin, guided by the certified stoma-care nurse with cueing as needed.~Observation: Peers observed from a separate area with scenario summaries.~Debriefing: Reflection and feedback using the PEARLS framework to consolidate learning and discuss transfer to clinical practice.~Immediate post-training assessments using the same three scales captured outcomes in meaningful learning self-awareness, perceived learning, and stoma-care skill level."
223604358|NCT06811922|BEHAVIORAL|GBE (Ghya Bharaari Ekatra) intervention|"Ghya Bharaari Ekatra (Marathi for Take a flight together) intervention~The intervention consists of six sessions. Each session will cover one of 6 major modules to enhance transformation of motivation: 1) You, Me, and Us: Spending Meaningful Time Together, 2) I'm a Champion: I Can't Be Broken and I don't Accept Defeat! 3) Building Communication and conflict management strategies, and 4) Empowerment of the Couple: Planning Ahead, 5) Sexual communication and the sexual relationships, and 6) A Lens into Domestic Violence. The sessions will be audio-recorded and include a combination of didactics, interactive discussions, media use, and role play. The expected durations of sessions are 2 hours.~GBE will be delivered to a total of 500 dyads."
223604359|NCT06811922|BEHAVIORAL|Ethical standard of care|Ethical standard of care includes information on IPV and mental and reproductive/sexual health resources) to prevent IPV experience. This intervention will be delivered to a total of 350 dyads.
223604360|NCT06784375|BEHAVIORAL|Unblinded CGM/Nutrition Therapy|Personalized nutrition counseling based on CGM data
223604361|NCT06784375|BEHAVIORAL|Blinded CGM/Nutrition Therapy|Standard nutrition education which does not incorporate CGM data
223604362|NCT06784375|BEHAVIORAL|Unblinded CGM/No Nutrition Therapy|CGM and general diabetes education (no nutrition education)
223604363|NCT06784375|BEHAVIORAL|Blinded CGM/No Nutrition Therapy|General diabetes education (no nutrition education)
223604364|NCT07056751|DEVICE|Air negative ion intervention study|The observation group received air negative ion intervention every night for one week before entering the plateau (from 22:00 to 06:00). Before entering the plateau, they were in Putian City, China, where the temperature was about 28°C, humidity was about 68%, and the concentration of negative ions was approximately 800/cm³. The air negative ion converter used was the Mi Energy ET-21 model from RELTEC Medical Devices Corporation. Air negative and positive ion concentrations were measured using an ion detector (NKMH-103, HOKUTO, Japan) to ensure that each participant's room had a negative ion concentration of around 100,000/cm³.
223604365|NCT07056751|DEVICE|No air negative ion intervention|No air negative ion intervention
223604366|NCT05376267|DEVICE|Therapeutic Hypothermia|"Participants will receive therapeutic hypothermia for the assigned number of hours with controlled rewarming,~A zero hour cooling duration (normothermia) treatment arm will be opened for enrollment if there is not an increase in the treatment effect across the durations. Alternatively, longer durations (84 or 96 hours) will be opened for enrollment if the treatment effects are increasing (rather than plateauing or decreasing) through 72 hours."
224311356|NCT06981767|COMBINATION_PRODUCT|Combination of Topical Bromelain and Triamcinolone Acetonide in Orabase|This novel formulation combines the enzymatic, healing properties of bromelain with the anti-inflammatory property of triamcinolone. It is designed to provide enhanced therapeutic effects through synergistic action, potentially reducing the required corticosteroid dose while improving clinical outcomes.
223604367|NCT06526819|DRUG|SMP3124LP|Liposomal encapsulation formulation of SMP-3124
224200371|NCT03387267|DEVICE|Dysphagia Detection System|The Nestle Health Sciences (NHSc) Dysphagia Detection System (DDS) is a portable, non-invasive device designed for use at the bedside. The investigational DDS has 3 basic components: Sensor Unit (suspended on a necklace), Sensor Fixation and a personal computer (PC) for collecting data. The Sensor Unit consists of a dual-axis accelerometer in a plastic housing that is attached to the front of a patient's neck just below the thyroid cartilage by the single-use, disposable fixation unit. The Sensor Unit is connected via a cable to an A/D converter which then connects via cable to the PC. The PC collects the examination data, which is then sent to dedicated application software (installed at the CRO), which interprets the acceleration data and displays the examination result.
224200372|NCT00941681|DRUG|CK-1827452|50 mg MR CK-1827452 BID for 10 days
224200373|NCT00941681|DRUG|CK-1827452|37.5 mg IR CK-1827452 TID for 10 days
224311357|NCT06981676|DIETARY_SUPPLEMENT|DHA and EPA|Women will receive daily supplementation of LCPUFAs (DHA and EPA) from first trimester until delivery
224311358|NCT06982833|OTHER|Trunk restraint|Participants were seated in a chair with a standard sitting height of 26 centimeters. After completing the 9-Hole Peg Test with their trunks free on a table of appropriate height so that their trunks would not flexion, they were secured to the chair crosswise in front of their chest with the help of a non-elastic but firm enough belt that would not cause discomfort to the person. Participants completed the 9-DPT with their trunks constrained.
223604368|NCT06714851|DIETARY_SUPPLEMENT|Chondractiv Move|The dietary supplement under study (Chondractiv Move) is a combination of 2 active ingredients: Hydrolyzed chicken cartilage and Rosehip extract at the dose of 1580 mg/day.
223604369|NCT06714851|OTHER|Placebo|Placebo contains 100% maltodextrins as non-active agent at the dose of 1800 mg/day.
223604370|NCT06748950|OTHER|LCHF Ketogenic Diet|Low Carbohydrate, Moderate Protein, High Fat (LCHF) Ketogenic Dietary Intervention for 12 weeks
223604371|NCT06748950|OTHER|Diet-as-Usual (DAU)|Participant's usual diet
223604372|NCT06895629|BEHAVIORAL|PRO-MAMAS (Promoting participation, health and wellbeing through meaningful maternal-role activities after stroke)|PRO-MAMAS - a novel occupational therapy intervention program to promote participation, health and wellbeing of older mothers with chronic stroke.
223604373|NCT06897241|OTHER|Resistant starch|Participants will consume 80 grams of carbohydrates from resistant starch during the meal challenges and two times daily during the 14-day intervention period
223604374|NCT06897241|OTHER|Slow digestible starch|Participants will consume 80 grams of carbohydrates from slow digestible starch during the meal challenges and two times daily during the 14-day intervention period
223604375|NCT06897241|OTHER|Rapid digestible starch|Participants will consume 80 grams of carbohydrates from rapid digestible starch during the meal challenges and two times daily during the 14-day intervention period
223604376|NCT03828019|BIOLOGICAL|Adalimumab (ADA)|Adalimumab is a fully-human monoclonal antibody to TNF-α, which is approved by the U.S. FDA for the treatment of non-infectious intermediate, posterior, and panuveitides in adults and children 2 years of age and older.
223604377|NCT03828019|DRUG|Conventional immunosuppression (CON)|The study ophthalmologist will select amongst the permissible drugs (methotrexate, mycophenolate mofetil or azathioprine for antimetabolites; cyclosporine or tacrolimus for calcineurin inhibitors) taking into account the side effect profile of each drug with respect to subject's clinical situation.
223751903|NCT05865288|DRUG|Oxytocin nasal spray|Intranasal OT will be performed using a spray containing 24IU (12IU administered to each nostril), sorbitol, benzyl, alcohol glycerol, distilled water. Dosage and administration method was determined by standard OT studies instructions and guidelines. The substance will be prepared immediately after randomization by an external preparation and delivered and stored until administration under required conditions. The nasal spray will be self administered, with the nursing staff supervising for proper administration of substance, after training and guiding the patient, and for supervision of side effects.
223751904|NCT05723562|BIOLOGICAL|Dostarlimab|Dostarlimab will be administered.
223751905|NCT01363596|OTHER|Creighton Model System in conjunction with Natural Procreative Technology (NPT)|Patients will learn the Creighton Model System to chart their fertility biomarkers, and this information will then be used by their physician in conjunction with Natural Procreative Technology (NPT) to evaluated and treat infertility or history of spontaneous abortion.
223751906|NCT00783042|DRUG|Rosuvastatin|40 mg, tablet, oral, once daily for 1 (double blind) +2 months (open).
223751907|NCT00783042|DRUG|Placebo|Tablet, oral, once daily for 1 month (double blind)
223751908|NCT01883401|DIETARY_SUPPLEMENT|Freeze-dried strawberries|25g or 50g freeze-dried strawberries reconstituted in water
223751909|NCT01883401|DIETARY_SUPPLEMENT|Dietary fiber|4g or 8g dietary fiber blended in water
223751910|NCT06008964|OTHER|Ylang Ylang oil with inhalation|Ylang Ylang OIL WILL BE INHALED
223751911|NCT06008964|OTHER|Lavender oil with inhalation|LAVENDER OIL WILL BE INHALED
223751912|NCT02383446|DEVICE|Elan foot prosthesis|The research group will perform a gait analysis test (on a computerized treadmill) using their own non-computerized hydraulic foot, while in-socket pressures are measured. The prosthetic foot will then be replaced by a computerized prosthetic foot for one month, following which, the measurements will be repeated. Gait factors will be examined (spatio-temporal data, center of pressure movement) and internal loads inside the residuum will be evaluated. Comparison will also include patient's satisfaction and his ability to move around, evaluated by dedicated questionnaire.
223751913|NCT05325567|PROCEDURE|Mini open incision CTR|two techniques commonly used for carpal tunnel release are being compared to determine if one vs. the other provides superior patient outcomes.
223751914|NCT01289847|BIOLOGICAL|Gammaplex|GAMMAPLEX 5g/100 mL, dose is 300-800 mg/kg/infusion every 21 or 28 days, intravenously. The total duration of treatment with GAMMAPLEX will be 12 months with a 3 month follow-up.
223751915|NCT05876273|DEVICE|Neural-net Artificial Pancreas|NAP is a neural-net implementation of the previously tested UMPC algorithm (below).
224200374|NCT00941681|DRUG|CK-1827452|100 mg MR CK-1827452 BID for 10 days
224200375|NCT02179385|BEHAVIORAL|Health Coaching|
223604378|NCT07052305|DRUG|NT-I7|Provided by NeoImmune Tech
224311359|NCT06982014|BEHAVIORAL|cilinical simulation|he experimental group will interact with standardized patients (using moulage techniques) who exhibit signs of physical violence. This approach provides a realistic environment for students to assess the physical manifestations of violence and practice their recognition skills in a controlled, yet lifelike, setting.
223604379|NCT07052305|BIOLOGICAL|CAR T-cell therapy|Will be given on day 0
223604380|NCT07065474|OTHER|education material|For students in Grades 6 to 7, the intervention comprises a coloring book that integrates storytelling and coloring assignments designed to explain key concepts related to ARF and RHD. In addition, students in these grades will watch video sessions that cover the symptoms, causes, prevention, and treatment of ARF and RHD. These videos serve to visualize the information introduced in the books. Complementing these materials, the intervention includes interactive classroom sessions facilitated by the trained field team, during which students will participate in guided discussions and activities to enhance their understanding and retention of health messages. For students in Grades 8 to 9, the intervention uses a more advanced format tailored to older adolescents. These students will receive an activity book that includes heart anatomy coloring assignments and games such as puzzles, scrambled words, and maze runs that incorporate facts and concepts about RHD.
223604381|NCT07066280|DRUG|Skin Repairing Cream|Skin Repairing Cream containing natural weak-acid
223604382|NCT07066280|OTHER|Cetaphil® Moisturizing Cream as Inactive Control|Cetaphil® Moisturizing Cream
223604383|NCT07064720|DRUG|Dexmedetomidine with Mannitol|receive 1 mcg/kg of dexmedetomidine added to 0.4 mcg/kg of mannitol
223751916|NCT05876273|DEVICE|University of Virginia Model Predictive Control|A previously tested artificial pancreas control algorithm, based on a differential-equation model of the human metabolic system in diabetes.
223751917|NCT02051036|PROCEDURE|Moxibustion|"In the moxibustion treatment group, 5 moxibustion points (bilateral SP6, LV3 and unilateral CV4) will be heated with indirect moxibustion (KangHwa, Korea).~The moxa pillars will be removed when the patient feel hotness and require to remove them.~The moxibustion will be conducted repeatedly unless patients feel the sense of heat up to seven times per session."
223751918|NCT03226262|DEVICE|FFRangio|"FFRangio is a non-invasive image-based software device that provides physicians with a quantitative analysis of functional significance of the coronary lesion, similar to invasive FFR (Fractional Flow Reserve), and a qualitative three-dimensional model of the demonstrated coronary arteries, during routine PCI procedure. The CathWorks FFRangio software device is able to perform all required processing and calculations, based only on angiography images and hemodynamics information that are acquired during the coronary catheterization procedure.~The CathWorks FFRangioTM technology does not require any additional use of invasive devices, or any additional vasodilation treatment, as required by other known FFR techniques."
223751919|NCT04839614|OTHER|CONCURRENT LAPAROSCOPIC HYSTERECTOMY AND WEIGHT LOSS SURGERY-Referral|See arm description
223751920|NCT03278964|PROCEDURE|Orbital decompression|
223751921|NCT00532285|DRUG|Paclitaxel/Gemcitabine|Treatment will be delivered in the outpatient setting. Each three-week cycle consists of paclitaxel 80 mg/m2 (day 1, 8) and gemcitabine 1200 mg/m2 (day1, 8).Patients will receive four cycles of therapy unless there is any evidence of no response (SD or PD) or unacceptable toxicity defined as unpredictable, irreversible, or Grade 4, or noncompliance by patient with protocol requirements.
223751922|NCT06353503|PROCEDURE|autologous bone marrow aspirate concentrate|local knee joint injection of autologous bone marrow
223751923|NCT04839159|OTHER|Blood sampling|Blood sampling at the age of 6 and 12 months, 2-3-4 years
223751924|NCT04839159|OTHER|Blood sampling|Blood sampling before any new sickle cell disease treatment as determined by a physician according to the standard of care to which the hospital adheres
223604384|NCT07064720|DRUG|Mannitol (20%)|receive 0.5 g/kg of mannitol
223604385|NCT07066982|BIOLOGICAL|CD146/HER2 CAR-T cells|"The intervention in this clinical trial involves a novel approach using CD146/HER2 Chimeric Antigen Receptor T (CAR T) cells combined with chemotherapy. The goal is to assess safety and efficacy in patients with specific hematologic malignancies.~Treatment Regimen:~Patients in the trial will undergo the following regimen:~Fludarabine Phosphate (Days -4 to -2): IV administration of fludarabine phosphate over 30 minutes on days -4 to -2. It's part of the preparatory regimen to enhance the body's response to CAR T-cell therapy.~Cyclophosphamide (Day -2): IV cyclophosphamide over 60 minutes on day -2.~BCMA/GPRC5D Chimeric Antigen Receptor T Cells (Day 0): IV administration of investigational therapy, CD146/HER-2 CAR T cells, over 10-20 minutes on day 0.~Additional Doses: Eligible patients responding well to the initial CD146/HER-2 CAR-T cell infusion without unacceptable side effects and sufficient CAR-T cell availability may receive 2 or 3 additional doses."
223604386|NCT07065396|PROCEDURE|Virtual reality|The VR intervention will take place in a quiet room. The participant will be installed in a seated position, wearing a virtual reality headset that includes an audio device playing sounds. The eyes are covered by a mask featuring a screen showing calming 3D VR images (e.g. beach landscapes), designed by our team. The intervention lasts 20 minutes. The hypnotic suggestions with auditory and visual calming stimulations will help the person to focus on the present moment, to reduce anxiety and painful sensations.
223604387|NCT07065396|PROCEDURE|Cranial nerve non-invasive neuromodulation (CN-NINM)|During each intervention including CN-NINM, this latter will be applied for 20 minutes, with the help of a portable stimulator comprising a network of 18 electrodes, directly on the tongue of the participants. The participants will hold the CN-NINM in place by pressing their tongue upwards. The CN-NINM will generate high-frequency pulses (50 µsec to 150 Hz), and the intensity of the stimulus will be set by each participant to a comfortable level of sensation, similar to the sensation in the mouth of a soft drink.
223604388|NCT07065396|PROCEDURE|Placebo CN-NINM|In this study, we will have a control intervention which will be placebo CN-NINM. For placebo CN-NINM, participants will wear the device such as the real CN-NINM group, without having experienced the tingling sensation beforehand, so they will not know what the CN-NINM potential effect is.
223604389|NCT07066462|OTHER|Fatigue Exercise Protocol with Biosignal Monitoring|Participants will complete two fatiguing exercises, including static bicycling and dumbbell squats. During each exercise, surface electromyography (sEMG), electroencephalography (EEG), and heart rate (HR) will be recorded to analyze fatigue levels.
223604390|NCT07066904|DIAGNOSTIC_TEST|Standard echocardiography|Routine ultrasound examination with standardized recordings for the study, incorporating volumetric assessment techniques
223604391|NCT07066904|DIAGNOSTIC_TEST|2D phase-contrast magnetic resonance imaging|A cardiac MRI will be performed on a 1.5 Tesla system, including a biventricular function study with a series of short-axis slices, three long-axis slices, a 2D phase-contrast acquisition orthogonal to the aortic root. Additionally, standard T1 mapping sequences will be acquired on three short-axis slices, 15 minutes after the injection of 0.2 mmol/kg of body weight of gadolinium, for myocardial and blood T1 measurements.
223751925|NCT03552575|DRUG|sacubitril/valsartan|Sacubitril is a prodrug neprilysin inhibitor used in combination with valsartan to reduce the risk of cardiovascular events in patients with chronic heart failure (NYHA Class II-IV) and reduced ejection fraction.
223751926|NCT03552575|DRUG|Valsartan|is an angiotensin II receptor antagonist (commonly called an ARB, or angiotensin receptor blocker), that is selective for the type I (AT1) angiotensin receptor.
223751927|NCT00805974|BIOLOGICAL|Biological examinations (blood and urinary).|
223751928|NCT01485562|DRUG|Misoprostol|4 tablets of 200 mcg misoprostol administered sublingually if the woman experiences a PPH after child birth
223751929|NCT01485562|OTHER|placebo|4 tablets, administered sublingually if the woman experiences a PPH
224311360|NCT06982014|OTHER|Educational Video Viewing|"The control group will watch a film titled Gözlerimde Al (translated as Take My Eyes), which addresses the issue of gender-based violence. The film aims to provide insights into the emotional and physical effects of violence against women and encourages reflection on how to recognize such violence in real-life scenarios."
224311361|NCT06983964|GENETIC|CD19 CART|"Dose group dosage unit (CAR+T cells/kg) Acceptable dose range Expected sample size (± 30%, CAR+T cells/kg)~1. 0.5 × 106 0.4 × 106\~0.6 × 106 3-6 cases~2. 1.0 × 106 0.7 × 106\~1.3 × 106 3-6 cases~3. 2.0 × 106 1.4 × 106\~2.6 × 106 3-6 cases Dose escalation rule The enrollment starts from dose group 1, and if no DLT occurs in the 3 subjects included, they will be transferred to the next dose group. If one of the three subjects in a certain dose group develops DLT, three additional subjects will be added to the group for cell infusion at the same dose. If there is ≥ 1 case of DLT in the 3 additional cases, it will be reduced to the previous dose group. If there are only 3 subjects in the previous dose group at this time, an additional 3 subjects need to be added for the trial; If there are already 6 subjects in the previous dose group, the trial ends and this dose is the maximum tolerated dose (MTD)."
224311362|NCT06981624|OTHER|No heparin|Hemostasis achieved using a dual-artery compression device without administration of heparin after trans-radial diagnostic catheterization
223604392|NCT07066904|DIAGNOSTIC_TEST|4D flow magnetic resonance imaging|A sagittal 4D flow acquisition lasting between 6 and 10 minutes of free breathing to cover all four cardiac chambers is added to the 2D acquisition.
223604393|NCT07066904|DIAGNOSTIC_TEST|Cardiac ultrafast ultrasound imaging|Ultrafast sequences are added to the standard echocardiography acquisition.
223604394|NCT07065994|DEVICE|Virtual Reality Glasses Application|The day before the surgery, you will be shown a video of nature images with relaxing music for 10-15 minutes using virtual reality glasses.
223604395|NCT07065539|DRUG|GnRH-a-1M|Pre-treatment with one dose GnRH agonist before endometrial preparation.
223604396|NCT07065539|DRUG|GnRH-a-2M|Pre-treatment with two doses GnRH agonist before endometrial preparation.
223604397|NCT07065539|DRUG|GnRH-a+LE-1M|Pre-treatment with one dose GnRH agonist, along with daily 2.5 mg letrozole for 28 days before endometrial preparation.
223604398|NCT07065539|DRUG|GnRH-a+LE-2M|Pre-treatment with two doses GnRH agonist, along with daily 2.5 mg letrozole for 28 days since the first injection of GnRH agonist before endometrial preparation.
223604399|NCT07067073|OTHER|Anti-Dynamic Line Cream|Topical cream (Formula# 899675 44A) applied to the full face and neck twice daily for 8 weeks. Participants apply 1 g each time in the morning and evening after cleansing, with massage on wrinkle-prone areas. Used after a 2-week wash-out period with standard skincare.
223604400|NCT07066839|DIETARY_SUPPLEMENT|LipoMicel Chrysin|A maximum single oral dose of 1000 mg chrysin
223604401|NCT07066839|DIETARY_SUPPLEMENT|Non-Micellar Chrysin|A maximum single oral dose of 1000 mg chrysin
223604402|NCT07066839|DIETARY_SUPPLEMENT|Standard/Unformulated Chrysin|A maximum single oral dose of 1000 mg chrysin
223604403|NCT07065825|PROCEDURE|robot-assisted partial nephrectomy|Robotic-Assisted Partial Nephrectomy (RAPN) is a minimally invasive surgical procedure performed with the help of a robotic system to remove a kidney tumor while preserving as much healthy kidney tissue as possible. It is commonly used to treat small to medium-sized kidney tumors. Thanks to the precision of robotic technology, RAPN offers faster recovery, less postoperative pain, and fewer complications compared to traditional open surgery.
223604404|NCT07066436|DRUG|MRI contrast-enhancing agents|"1. Ferumoxytol will be injected as an off-label MRI contrast agent at a dose of 4 mg/kg body mass. For safety (in accordance with prior research), ferumoxytol will be diluted 1:4 in saline, and administered slowly over at least 15 minutes, with patient monitoring during and post injection.~2. ImmunoMRI will be performed using an iron sensitive fat-suppressed, fast spoiled gradient echo T2\* mapping sequence. At each time point (i.e. pre-treatment and post-treatment), T2\* mapping will be performed before and \~24h after ferumoxytol injection."
223604405|NCT07066787|BEHAVIORAL|psychological group|fill the psychological section
223604406|NCT07066787|DIAGNOSTIC_TEST|somatic|fill the somatic section
223604407|NCT07066059|DRUG|Shouhui Tongbian Capsules|2 pills twice daily from admission to the night before surgery, then resuming after bowel sound recovery and oral intake postoperatively, with a 3-day post-discharge regimen
223604408|NCT07065383|DRUG|Semaglutide administration plus dietary counselling and physical activity encouragement|Semaglutide administration plus dietary counselling and physical activity encouragement
223604409|NCT07065383|DRUG|Semaglutide plus a personalised and supervised program of resistance and endurance training|Semaglutide administration plus a personalised and supervised program of resistance and endurance training.
223604410|NCT07064798|DEVICE|Paxman Limb Cryocompression System|An investigational device designed to provide controlled cooling and compression to participant limbs during chemotherapy administration. The device is comprised of a control unit, connecting hose, and two limb wraps. The customizable limb wraps delivers continuous-flow cooling-and-compression to participant extremities
223604411|NCT07065097|OTHER|A multimodal intervention in which they worked on self-esteem, self-concept and body image and nutrition.|A multimodal intervention in which they worked on self-esteem, self-concept and body image and nutrition.
223604412|NCT07066072|DEVICE|Tecar therapy (TECAR: Capacitive and Resistive Energy Transfer).|the Tecar therapy (TECAR: Capacitive and Resistive Energy Transfer) will be assigned to TECAR group
223604413|NCT07066072|OTHER|standard pharmacological therapy in sickle cell disease like hydroxyurea,paracetamol,ibubrofen and blood transfusion if needed|this is the standard medical care assigned to control group
223604414|NCT07066423|OTHER|Ai prediction photo of the patients|Ai prediction photo generated by specially designed ai model to help patients see how they will look after orthodontic extraction and retraction
223604415|NCT07066423|PROCEDURE|Fixed orthodontic brackets with premolars extraction|Subjects will undergo orthodontic fixed brackets treatment, four premolar extractions from the mandibular and maxillary arches, followed by anterior segment retraction. This treatment will achieve dental alignment, profile, and facial enhancement.
223604416|NCT07066800|BEHAVIORAL|Mindfulness-Based Online Training Program|"A 4-week web-based mindfulness program developed by the research team, designed to improve attention, emotional regulation, and mental health in adults with a history of maltreatment.~* The intervention includes:~  * Weekly educational videos (5-10 minutes each)~ * Weekly mindfulness practice videos (5-10 minutes each)~ * Assigned home practices each week~ * Optional support via KakaoTalk channel for Q\&A and participant engagement~* Weekly themes include:~  * Breathing and muscle relaxation~ * Mindfulness breathing meditation~ * Body scan meditation~ * Mindful walking"
224311363|NCT03077555|DRUG|Zoely|quick start of combined hormonal contraception containing 1.5 mg estradiol /2.5 mg nomegestrol acetate
223604417|NCT07066137|DEVICE|CAREN|"The interventions include proprioceptive stimuli combined with specific rehabilitation protocols, such as Tabata training, plyometric training, and visual-cognitive-motor enhancement with the S.V.T.A. method.~Healthy subjects and athletes (about 50) will participate in intensive aerobic and anaerobic training, including sensory-motor-cognitive training and exercises on the CAREN platform. Another 25 participants will have TMS/tDCS and music therapy added to their regimen.~Regarding neurological patients, 50 participants will undergo posture and gait rehabilitation using the CAREN platform, while 25 will receive non-invasive neuromodulation to enhance their rehabilitation outcomes. This arm of the study focuses on the recovery of motor and cognitive functions.~This study uses the CAREN system as a tool for physical rehabilitation in neurological and healthy participants. The device is not being investigated for new indications and the study is conducted entirely in Italy."
223751930|NCT06050551|PROCEDURE|uniportal VATS|"1. elective uniportal VATS lung resection, pleural tumor removal or mediastinal lymph node biopsy, etc.~   (exclude the bil. operation, extended wound length over 5 cm, conversion to thoracotomy or multiportal VATS procedure, surgeon's decision for exclusion during operation.)~2. thoracoscopic internal costal nerve block with 10 mL of 1% Ropivacaine at the end of the operation,~3. routinely prescribed with oral Tramadol 37.5mg and Acetaminophen 325mg four times a day postoperatively and intravenous morphine as extra dose if need."
223604418|NCT07066137|OTHER|Control group|"the control group is typically the group that does not receive the experimental treatment or intervention, serving as a baseline to compare the effects of the intervention. However, in the context you're describing with healthy subjects and athletes, here's how it's structured:~Healthy subjects and athletes (around 50 participants) will undergo:~Intensive aerobic and anaerobic training Sensory-motor-cognitive training~Additionally, 25 of these participants will receive:~Transcranial Magnetic Stimulation (TMS) Transcranial Direct Current Stimulation (tDCS) Music therapy This approach allows for a comparison between the effects of the physical and cognitive training alone versus the enhanced effects when combined with neuromodulation (TMS, tDCS) and music therapy. This design will help in assessing the added value of these interventions on performance"
223604419|NCT06660173|DRUG|Maridebart Cafraglutide|Solution for subcutaneous injection.
223604420|NCT06660173|DRUG|Placebo|Solution for subcutaneous injection.
223604421|NCT05996185|DRUG|Mogamulizumab|Mogamulizumab is a humanized monoclonal antibody directed against C-C chemokine receptor 4 (CCR4) with potential anti-inflammatory and antineoplastic activities. Mogamulizumab selectively binds to and blocks the activity of CCR4, which may inhibit CCR4-mediated signal transduction pathways and, so, chemokine-mediated cellular migration and proliferation of T cells, and chemokine-mediated angiogenesis.
223604422|NCT05996185|DRUG|DA-EPOCH Protocol|EPOCH is an intensive chemotherapy regimen intended for treatment of aggressive non-Hodgkin's lymphoma.
223604423|NCT07065526|BEHAVIORAL|Emodin|Following the pre-test in the first encounter, the participants were administered the first EFT lasting 30-40 minutes by the first author, who is a certified EFT facilitator, followed by the CPS. Afterwards, a total of 4 sessions of EFT were administered at 1-week intervals. The CPS was applied before and after each EFT. After the last EFT session, SUE, PSQI and MENQOL post-tests were administered.
223604424|NCT07066527|COMBINATION_PRODUCT|The addition of sodium hyaluronate to poly (cinnamyl alcohol-RRB- produces a more stable foam|According to the study, the half-life of 1% poly (cinnamyl alcohol-RPol(POL) foam with a liquid-to-gas ratio of 1:4 was 142.8(64.32) seconds, in this study, the half-life of the foam made from 1% POL containing 0.05% hyaluronic acid (HA) was 390.4(613.06) seconds, human blood contains a certain amount of HA, according to the literature reported that 0.05% concentration of HA injected into human blood is safe, so this more stable foam preparation method was patented, and published in international journals.
223604425|NCT07065630|DRUG|Volrustomig|500mg or 750mg (cycles 1-2) and 250mg thereafter IV day 1.
223604426|NCT07065630|DRUG|Carboplatin|100mg/m2 IV day 1 and day 8.
223604427|NCT07065630|DRUG|Paclitaxel|AUC 5 IV day 1
223604428|NCT06756230|OTHER|Pulmonary Rehabilitation|"8 weeks, 2 sessions per week,~Aerobic training will be provided as treadmill walking. It will be performed either downhill or on a flat treadmill, depending on the group.~Warm-up and stretching exercises~Resistance exercises will be performed with a load equivalent to 50% of 1 maximum repetition. 10 repetitions will be performed in sets, one set in each session. Based on the differences in the general condition of the patients, different workloads and modifications will be used when creating an exercise program for each patient. Resistance exercises will focus on both upper and lower extremity muscles."
223604429|NCT06756230|OTHER|Downhill Walking|Treadmill exercise will be applied for 30 minutes in the target heart rate range of 60-80% intensity. The target heart rate method will be used to determine the exercise intensity. Blood pressure, heart rate and Borg Perceived Exertion Scale scores will be monitored during the exercises. Downhill walking training will continue with a constant -10% incline.
223751931|NCT04851795|OTHER|supervised physical exercise sessions|Participants assigned to the supervised exercise group will perform a supervised routine of approximately 30 minutes, 2 days per week (Monday and Wednesday at the Txagorritxu hospital, and Tuesday and Thursday at the Santiago hospital from 7:15 to 7:45 and from 15:15 to 15:45).
223751932|NCT04851795|OTHER|unsupervised physical exercise|For the non-supervised group, we will propose climbing the stairs from floor 0 to floor 7 three times during the working day and doing planks and stretching exercises outside of work. For the latter, an educational session will be given at the beginning of the study to explain how to perform them correctly.
223751933|NCT00729339|DRUG|mosapride for the first month and placebo for the 2nd month|lansoprazole 30 mg once per day for 2 months mosapride 5 mg thrice per day, for the first month placebo thrice per day, for the second month
224311364|NCT03077555|DRUG|Meliane ED|quick start of combined hormonal contraception containing 20 mcg ethinyl estradiol /75 mcg gestodene
224311365|NCT03441932|PROCEDURE|Fiberoptic endoscopic evaluation of swallowing (FEES)|"Subjets within the two groups will after than have FEES with videotaping of pharyngeal phase after giving subjects a standardised food consisting of thin Puree."
224311366|NCT04053920|BEHAVIORAL|Low Load Resistance exercise|leg extension, leg press, leg curl and calf press
224311367|NCT04053920|BEHAVIORAL|High Load Resistance exercise|leg extension, leg press, leg curl and calf press
224311368|NCT00525551|DRUG|Acetylcysteine|150 mg / kg body weight. Drug is dissolved in NaCl to a final volume of 300 mL. This volume is infused starting one hour prior to surgery, and continued 1 hour after the end of surgery.
224311369|NCT00525551|DRUG|Placebo (NaCl)|300 mL 0.9% NaCl
223751934|NCT00729339|DRUG|placebo for the first and mosapride for the second month|lansoprazole 30 mg once per day for 2 months placebo thrice per day, for the first month mosapride 5 mg thrice per day, for the second month
223751935|NCT02533336|DRUG|abamectin and fenpyroximate|
223751936|NCT06219681|BEHAVIORAL|Active neurofeedback|The session will be done on an individual basis. The active group will receive neurofeedback training from the repetitive negative thinking (RNT) related brain functional connectivity.
223751937|NCT06219681|BEHAVIORAL|Sham neurofeedback|The session will be done on an individual basis. The sham group will receive neurofeedback training from an artificially generated random feedback signal.
224311370|NCT00426361|BIOLOGICAL|Boostrix ® Polio|One dose of vaccine administered intramuscularly
223604430|NCT06756230|OTHER|Treadmill Walking without incline|Treadmill exercise will be applied for 30 minutes in the target heart rate range of 60-80% intensity. The target heart rate method will be used to determine the exercise intensity. Blood pressure, heart rate and Borg Perceived Exertion Scale scores will be monitored during the exercises. Traditional walking training will initially involve walking with a neutral incline.
223751938|NCT01720433|PROCEDURE|intervention|The patient was placed in the Trendelenburg position (30°) and two manual lung inflations to a maximum pressure of 60 cm H2O for five seconds, with the valves on the operative ports fully open.
223604431|NCT03400176|DRUG|VAY736|Experimental
223751939|NCT04648865|DRUG|LY3537031|Administered SC.
223751940|NCT04648865|DRUG|Placebo|Administered SC.
224200376|NCT01213004|PROCEDURE|respiration correlated CT scan|Thoracic malignancies (study group 1): Patients to be treated for gastro-esophageal junction (GEJ) malignancy undergo an implantation procedure of two or three radiopaque markers several days prior to treatment simulation, which are used to correct patient position at treatment. At treatment simulation, patients receive a standard CT scan followed by an RCCT scan. In cases of GEJ malignancy, oral contrast is administered prior to the standard CT scan; this is done at the treating physician's discretion. The standard CT is used to design the radiation treatment plan, where as the RCCT is used to define a volume that encompasses the motion extent of the tumor with breathing and is transferred to the standard CT.
223604432|NCT03400176|DRUG|ibrutinib|Approved medication
223604433|NCT05719675|BEHAVIORAL|Intervention|"The general outline of the intervention is divided into three phases:~1. Dispositional alteration, where the aim will be to obtain precise information on the barriers that patients encounter in carrying out their treatment and thus focus the issues to achieve an awareness of the disease by altering some of the factors that give rise to the realization of behaviors that interfere with treatment adherence.~2. Alteration of one's own behavior, focused on the development of healthy habits that are consistent with the indications of the health team for the proper management of the disease.~3. Alteration of the behavior of others, focused on the development of skills in the participants so that they are able to modify the behavior of other people close to them through health promotion strategies."
223604434|NCT06920641|OTHER|Tagatose|"Sachet containing 10g tagatose to be dissolved in 250ml water and taken once daily on Days 1-28 of a 4-week dosing period.~(1 of 2 dosing periods separated by a 4-week washout)"
223604435|NCT06920641|OTHER|Placebo|"Sachet containing 10g sucrose to be dissolved in 250ml water and taken once daily on Days 1-28 of a 4-week dosing period.~(1 of 2 dosing periods separated by a 4-week washout)"
223604436|NCT06913387|COMBINATION_PRODUCT|Lipid Based Artificial Tears|30 participants received lipid-based artificial tears (Recuro) in this study arm. The intervention involved the administration of RECURO EYE DROPS, which contain Sodium carboxymethylcellulose 0.5%. Participants were instructed to instill 1-2 drops in each eye, three times daily (morning, afternoon, and evening) throughout the 6-week trial period.
223751941|NCT05904717|DRUG|PXS-4728 (A)|Participants will receive once daily (QD) for period of 12 weeks
223751942|NCT05904717|DRUG|Matching Placebo (B)|Participants will receive once daily (QD) for period of 12 weeks
223751943|NCT05319444|DEVICE|Off-brand Waterpik®|"Study staff will use the Waterpik® device and brush for approximately two to five minutes on the participant's scalp until all scale and other debris appears to be resolved. Their scalp will then be rinsed and gently dried with a towel.~The off-label design utilizes the Waterpik® device, but with adjustments optimized for scalp health. The device settings are adjustable during the treatment, ranging from settings of 2-10. Study staff plan to utilize the setting of 10 unless the participant indicates discomfort. Investigators attached a small Losophy brush in replacement of the Waterpik® toothbrush. The small Losophy brush was connected to the device via PVC heat shrink and a hole was drilled on the brush in order to deliver water while simultaneously utilizing the brush on the scalp."
223751944|NCT02550496|DEVICE|Dermoscopy|
223751945|NCT02822989|DEVICE|Vagus nerve stimulation|Patients will receive transcutaneous stimulation of the auricular branch of the left vagus nerve for 5 minutes daily for 4 consecutive days. The device is a handheld electrical pulse generator and a pair of electrodes to be placed at the ear for stimulation. The specific target at the ear will be the auricular branch of the vagus nerve which innervates the skin of the ear canal. Electrodes will be placed near/at the entrance to the canal of the ear to provide stimulation to the auricular branch.
224200377|NCT01213004|PROCEDURE|respiration correlated CT scan|Abdominal malignancies (study group 2): Patients undergo an implantation procedure of two or three radiopaque markers several days prior to treatment simulation. At treatment simulation, patients receive a standard CT scan followed by an RCCT scan. Intravenous contrast is administered prior to the standard CT; this is done at the treating physician's discretion.
224311371|NCT00426361|BIOLOGICAL|GSK Biologicals' HPV-16/18 L1 AS04 vaccine (Cervarix TM)|Three doses of vaccine administered intramuscularly, with the second and third dose give one month and six months after the first dose respectively
223604437|NCT06913387|COMBINATION_PRODUCT|Aqueous Based Artificial Tears|30 participants received aqueous-based artificial tears (Softeal) in this study arm. The intervention involved the administration of SOFTEAL EYE DROPS, which contain Hydroxypropylmethyl Cellulose 0.3%. Participants were instructed to instill 1-2 drops in each eye, three times daily (morning, afternoon, and evening) throughout the 6-week trial period.
223604438|NCT03399474|DRUG|Lidocaine Hydrochloride 2%|Lidocaine Hydrochloride 2%
223604439|NCT03399474|DRUG|Dexmedetomidine 0.5 ug/kg|pecedex
223604440|NCT03399474|DRUG|Dexmedetomidine Injection 0.25 ug/kg|pecedex
224311372|NCT06606639|DIETARY_SUPPLEMENT|Caffeine|acute caffeine intake (3 mg/kg)
224311373|NCT06606639|DIETARY_SUPPLEMENT|Placebo|Acute placebo intake (3 mg/kg of maltodextrin)
223604441|NCT00119821|BEHAVIORAL|Weight Reducing Diet|Behavioral intervention
223604442|NCT00119821|BEHAVIORAL|Exercise|Moderate exercise implemented plus behavioral intervention.
223751946|NCT02822989|DEVICE|Sham vagus nerve stimulation|Patients will receive sham transcutaneous stimulation of the auricular branch of the left vagus nerve for 5 minutes daily for 4 consecutive days. Sham stimulation will be performed in the identical manner as true transcutaneous stimulation except that the patient will not receive electrical stimulation of the vagus nerve.
223751947|NCT03464006|OTHER|Online Support Module|The online support module is a computer software program which helps patients monitor factors related to their peripheral artery disease
223751948|NCT03464006|OTHER|Standard of Care|The normal care that patients receive at the institution.
223751949|NCT02984358|OTHER|Animal protein based diet|
223604443|NCT00119821|BEHAVIORAL|Smoking Cessation|"Nicotine Patch in dosages given based on number of cigarettes per day smoked. 21 mg patch, 14 mg patch, 7 mg patch for total of 6 weeks duration of therapy.~NRT gum is being provided to assist with relapse prevention. At the randomization visit the participant is given one (1) box of 2mg NRT gum, which consists of (110) pieces. The participant may request up to two (2) more boxes, for a maximum of three (3) boxes per participant."
223604444|NCT03180970|DRUG|1.2% Lugol's solution|1.2% Lugol's solution will be sprayed on the lesion suspected early esophageal squamous neoplasia .Then the lesions will be treated with endoscopic submucosal dissection(ESD).
223604445|NCT03180970|DRUG|1.0% Lugol's solution|1.0% Lugol's solution will be sprayed on the lesion suspected early esophageal squamous neoplasia .Then the lesions will be treated with endoscopic submucosal dissection(ESD).
223604446|NCT03180970|DRUG|0.8% Lugol's solution|0.8% Lugol's solution will be sprayed on the lesion suspected early esophageal squamous neoplasia .Then the lesions will be treated with endoscopic submucosal dissection(ESD).
223604447|NCT03180970|DRUG|0.6% Lugol's solution|0.6% Lugol's solution will be sprayed on the lesion suspected early esophageal squamous neoplasia .Then the lesions will be treated with endoscopic submucosal dissection(ESD).
223604448|NCT03180970|DRUG|0.4% Lugol's solution|0.4% Lugol's solution will be sprayed on the lesion suspected early esophageal squamous neoplasia .Then the lesions will be treated with endoscopic submucosal dissection(ESD).
223604449|NCT01262534|OTHER|Clinical profile of patients|Comorbidities and associated type of treatments will be collected.
223604450|NCT01262534|OTHER|Patient Preferences about treatment|Patient Benefit Index (PBI), for treatment to record patient preferences regarding psoriasis treatment.
223604451|NCT01262534|OTHER|Quality of Life|The Quality of Life will be assessed by 2 questionnaires (SF-36 questionnaire, to analyze the overall quality of life of patients, and Dermatology Life Quality Index (DLQI), to analyze the quality of life of patients, in dermatological terms).
223604452|NCT03107494|DEVICE|Gala Airway Treatment System|The Gala Airway Treatment system is a device-based, energy delivery system that delivers high frequency short duration energy to the airway epithelium and sub-mucosal tissue layers. The energy is delivered via a proprietary catheter through the bronchoscope. In this study, 2 treatment sessions will be delivered 1 month apart. The right lung is treated at the first treatment session and the left lung is treated at the second treatment session. A third bronchoscopy will be performed 3 months following the second treatment session where treatment is not delivered but a cryo-biopsy will be taken from the airway sites that have been treated during the two previous bronchoscopic treatment session to evaluate the effect of the treatment on the airways producing excessive mucous. Subjects will be required to submit to several tests during the study including two CT scans (lung), respiratory function tests, exercise testing.
223604453|NCT06351059|DIAGNOSTIC_TEST|InModi acoustic emission analysis|All diagnosis tests
223751950|NCT02984358|OTHER|Low-nucleotide mycoprotein based diet|
223751951|NCT02984358|OTHER|High-nucleotide mycoprotein based diet|
223751952|NCT04424238|BEHAVIORAL|m-health management|Patients in intervention group received additional WeChat group management when conducted standard clinic prenatal care.
223751953|NCT05698966|OTHER|we will use reduced dose of acceptable corticosteroids treatment for preterm birth|the two different group will differ in the doses of corticosteroids
223751954|NCT05562973|DRUG|Psilocybin|Participants will receive three psilocybin sessions, at least two weeks apart.
223751955|NCT01419548|DRUG|ABT-888|
223751956|NCT01419548|DRUG|Carboplatin|
223751957|NCT01419548|DRUG|Paclitaxel|
223751958|NCT01814306|DEVICE|Supreme LMA|Use Supreme LMA to compare efficay with Proseal LMA in prone position insertion
223751959|NCT01814306|DEVICE|Proseal LMA|Use Proseal LMA to compare efficay with Supreme LMA in prone position insertion
223751960|NCT01611987|OTHER|MStep|Participant will meet with instructor twice to learn how to exercise safely. Exercises will be demonstrated and practiced under the direct supervision of the instructor. Written details and pictures will be made. Variety in exercise will be encouraged to promote long-term adherence. Stretching, strengthening and relaxation exercises will be given. Persons will be given Thera Band® to facilitate resistance exercise training and instructed how to progress. Equipment such as Nordic Walking Poles, stationary bicycle, BOSU®, or exercise balls will be available. Rather than having a fixed rigid prescription, the aim is to get people to intuitively adjust the amount of resistance so they feel they are working without causing harm, they are not doing the same boring activity, week in week out.
223751961|NCT01611987|OTHER|General guideline approach|Individuals in the control condition will meet with the exercise instructor on two occasions during the first two weeks to review key components of public health guidelines for physical activity and health. In brief, the general guidelines for MS are (i) aerobic and endurance exercise for 30 minutes per session, 3 times per week at an intensity of 60% to 75% of heart rate peak; (ii) weight training for weak muscles, 2 days per week, on non-endurance days, 8 to 15 repetitions per exercise; and (iii) stretching daily with active or passive range of motion exercises, or attendance at Yoga or Tai Chi classes.
223751962|NCT03695731|PROCEDURE|cold induced activation of brown adipose tissue|cold exposure wearing a cold life jacket
223751963|NCT06030843|DRUG|Empagliflozin 10 MG|Empagliflozin 10 MG
223751964|NCT06030843|DRUG|Placebo|Matching placebo containing Lactose content (0.26 gram)
224311374|NCT06612957|PROCEDURE|Repair of uterine cicatricial diverticulum|Cut off the uterine cicatricial diverticular tissue in the lower portion of the uterus, and restore normal uterine muscle tissue.
224311375|NCT00004025|BIOLOGICAL|aldesleukin|
224311376|NCT00004025|BIOLOGICAL|dendritic cell-gp100-MART-1 antigen vaccine|
223751965|NCT02181062|BEHAVIORAL|Walking Intervention|"4-week series of twice-weekly 1-hour group-based case-manager-led interactive sessions.~The intervention will provide the knowledge necessary to improve stroke risk factors. Case manager group leaders will teach that seeing a healthcare provider regularly and monitoring blood pressure prevents strokes; all participants will be provided with the National Institute on Aging booklet, How to Talk to your Doctor and the contact information for their healthcare provider.~Participants will be given a pedometer and be trained to use it to measure steps, with the goal of reaching 10,000 steps each day.~The intervention will utilize attribution retraining to teach seniors that stroke risk factors including sedentary lifestyle should not be attributed to old age."
223751966|NCT01324388|BIOLOGICAL|LY2189265|Administered subcutaneously
223604454|NCT03430232|DRUG|Placebo|Short infusion of the solution for intravenous administration, Sodium Chloride 0.9%
223751967|NCT01324388|DRUG|Metoprolol|Administered orally
223751968|NCT01324388|DRUG|Lisinopril|Administered orally
223604455|NCT03430232|DRUG|STR-324 Dose Level 1|Short infusion of a solution for intravenous administration
223604456|NCT03430232|DRUG|STR-324 Dose Level 2|Short infusion of a solution for intravenous administration
223604457|NCT03430232|DRUG|STR-324 Dose Level 3|Short infusion of a solution for intravenous administration
223604458|NCT03430232|DRUG|STR-324 Dose Level 4|Short infusion of a solution for intravenous administration
223604459|NCT03430232|DRUG|STR-324 Dose Level 5|Short infusion of a solution for intravenous administration
223604460|NCT03430232|DRUG|STR-324 Dose Level 6|Short infusion of a solution for intravenous administration
223604461|NCT03430232|DRUG|STR-324 Dose Level 7|Short infusion of a solution for intravenous administration
223604462|NCT03430232|DRUG|STR-324 Dose Level 8|Short infusion of a solution for intravenous administration
223604463|NCT03430232|DRUG|STR-324 Dose Level A|Long infusion of a solution for intravenous administration
223604464|NCT03430232|DRUG|STR-324 Dose Level B|Long infusion of a solution for intravenous administration
224311377|NCT06981988|DRUG|Linperlisib ； Rituximab|Linperlisib ； Rituximab
223604465|NCT03430232|DRUG|STR-324 Dose Level C|Long infusion of a solution for intravenous administration
223604466|NCT03430232|DRUG|Placebo|Long infusion of the solution for intravenous administration, Sodium Chloride 0.9%
223604467|NCT05998174|OTHER|Faecal Microbiota Transplantation|treatment with capsules
223604468|NCT00206440|DRUG|esomeprazole|nexium
223604469|NCT00206440|OTHER|Placebo|Placebo 1 pill daily Cycle 1 Days 1-5 and Cycle 2 Days 1-5
223604470|NCT03998969|DRUG|Pantoprazole|Pantoprazole 40mg tablet
223604471|NCT03998969|DRUG|DA-5204|DA-5204 tablet
223604472|NCT03998969|DRUG|Placebo|Film-coated tablet manufactured to mimic DA-5204
223604473|NCT03870412|DRUG|PEG-rhG-CSF|The test drug PEG-rhG-CSF was administered prophylactically to elderly lymphoma patients who met the inclusion/exclusion criteria 24-72 hours after chemotherapy.
223604474|NCT01298765|DRUG|BEMA Buprenorphine|buccal soluble film; applied to the buccal mucosa twice daily
223604475|NCT03815565|PROCEDURE|continuous femoral block|infusion of anesthetic by PCA pump
223604476|NCT04152798|PROCEDURE|Laparoscopic hiatal hernia repair with ProGrip™ mesh|Suturing of the right and left diaphragmatic crura using 3 to 4 interrupted nonabsorbable stitches with additional reinforcement of crura repair with ProGrip™ mesh
223604477|NCT04152798|PROCEDURE|Laparoscopic primary posterior crural repair|Posterior cruroraphy will be performed with 3 to 4 interrupted non-absorbable sutures
223604478|NCT02302391|OTHER|PK analysis|Quantification of Serum Levels and subsequent pharmacokinetic (PK) modelling.
223604479|NCT00952393|DRUG|Pharmacokinetic|Subject receives 150 mg of compound formulated with hypomellose and Pharmcokinetics is determined
223604480|NCT06388798|OTHER|Education|Psychoeducational training
223604481|NCT06284733|DEVICE|Whole-body vibration plus conservative care|Whole-body vibration (WBV) is a therapeutic method that exposes the entire body to mechanical oscillations while the patient stands or sits on a vibrating platform. This method was used in rehabilitation to improve muscle function, joint stability, balance control and to reduce the risk of falling.
223604482|NCT06284733|OTHER|conservative care|"1. Stretching and ROM exercises daily to make sure that the patient can straighten hip; this makes walking, and even lying in bed, more comfortable.~2. Resting hip on a pillow, as this promotes a hip flexion contracture~3. A pillow between legs, as this lengthens the inner thigh muscle that helps to keep legs together while walking, and shortens the outer thigh muscles so that walking and standing with feet apart.~4. Regular skin care.~5. Regular prosthetic care."
223604483|NCT02249039|DRUG|intermittent IV CLON|Mechanically ventilated infants and children receive intravenous intermittent Clonidine instead of dexmedetomidine
223604484|NCT06354478|DRUG|Dexmedetomidine Hydrochloride 0.5 MG/ML|Will be used either alone or in combination of gabapentin
223604485|NCT06354478|DRUG|Gabapentin|Will be used either alone or in combination of Dexmedetomidine
223604486|NCT06479941|OTHER|antibiotic treatment|AT: Mother-infant cohort with antibiotic treatment group CS: Mother-infant cohort (Prophylactic antibiotics therapy) ND: Mother-infant cohort (Natural delivery)
223604487|NCT06301932|PROCEDURE|Open liver resection|The definitions of liver resection and the type of hepatectomy were aligned with the anatomic classification of the Brisbane 2000 Terminology
223604488|NCT03723109|PROCEDURE|Induction of anesthesia|Standardized TCI and RSI anesthesia induction
223604489|NCT05182268|PROCEDURE|endoscopic ear surgery|a ear surgery via endoscopic
223604490|NCT05182268|PROCEDURE|microscopic ear surgery|a ear surgery via microscopic
223604491|NCT05758428|DRUG|Ensifentrine|14 Subjects enrolled will use one 3 mg/2.5 mL ampule for the 3 mg dose, subjects will receive a 3 mg ensifentrine single dose, followed by 3 mg repeated dose (twice daily, BID). On the dosing day (Day 1), subjects will receive a single dose of 3 mg ensifentrine. On Day 4, subjects will receive multiple doses of 3 mg ensifentrine BID for 3 days (Day 4 to Day 6), and a morning dose will be administered on Day 7.
223751969|NCT01324388|DRUG|Placebo|Administered subcutaneously
223751970|NCT02087527|DRUG|Dexamethasone|IV Dexamethasone 0.15 mg/kg every 6 hours for 48 hours
223751971|NCT02087527|DRUG|Normal Saline|IV normal saline every 6 hours for 48 hours
223751972|NCT04089787|OTHER|Intervention|Shortened antibiotic treatment of 5 days
224311378|NCT06990620|COMBINATION_PRODUCT|TACE+AK112|TACE+AK112 (PD-1/VEGF bi-antibody, 20mg/kg, ivgtt, Q3W)
223751973|NCT04089787|OTHER|Control|Antibiotic treatment of 7 days or longer at the discretion of the treating physician
223751974|NCT01405963|DRUG|Placebo|Administered in a 1-hour intravenous infusion
223604492|NCT05758428|DRUG|Ensifentrine|14 subjects will be enrolled in this cohort, then randomly assigned to one of 2 treatment sequences (6mg and 1.5mg single dose). Subjects will 2 different dose levels of study drug. Two 3 mg/2.5 mL ampules will be needed for the 6 mg dose (5 mL total volume) and the 1.5 mg dose will be achieved using an appropriate dilution protocol described in the pharmacy manual.
223604493|NCT00274677|DRUG|Placebo|Experimental treatment arm
223751975|NCT01405963|BIOLOGICAL|Tezepelumab|Administered in a 1-hour intravenous infusion
223751976|NCT00403247|DIETARY_SUPPLEMENT|Capsule with folate, Vitamin B12 & pyridoxine|
223751977|NCT00403247|OTHER|placebo|placebo capsule
223751978|NCT03887000|OTHER|magnesium|Fibromyalgia patients taking either magnesium or placebo according to the randomized plan
223751979|NCT03887000|OTHER|placebo|Fibromyalgia patients taking either magnesium or placebo according to the randomized plan
223751980|NCT00396045|DRUG|Revlimid (CC-5013)|
223751981|NCT05137561|PROCEDURE|PSMA PET guided prostate biopsy|PSMA PET-guided prostate biopsy from PSMA avid prostatic lesion will be done.
223751982|NCT05137561|PROCEDURE|MRI directed TRUS guided prostate biopsy|TRUS guided MR directed Cognitive fusion prostate biopsy based on the PIRADS scoring
224311379|NCT06989632|DEVICE|We want to know the work and sport activities that our patients are able to undertake after a total lumbar disc replacement|
224311380|NCT04837755|DIAGNOSTIC_TEST|Cytokine measurements|The serum concentrations of multiple cytokines are measured.
224311381|NCT02889055|DEVICE|patient requiring the MIRUS (mechanical ventilation)|
224311382|NCT00902031|DRUG|Docusate Sodium, Sennoside|"Docusate sodium: given in capsule form (100 mg/capsule), at a dosage of 200 mg, taken twice daily for 10 days.~Sennoside: will be given in tablet form (8.6 mg), 1-3 tablets taken 1-3 times daily for 10 days."
223604494|NCT00274677|DRUG|lamotrigine|Experimental treatment
223751983|NCT00155337|PROCEDURE|photodynamic therapy|
223604495|NCT00766051|OTHER|The intervention group: Neurophysiologically Based Occupational Therapy Intervention (NBOTI)|This study included a pre-feeding, feeding, and postural-respiratory protocol, given per the attending physician's order. The interventions were given daily when possible, and the infants FiO2 and heart rate, along with stress behaviors, were monitored prior to, during, and after the NBOTI. The intervention included parent education for feeding, handling, and interaction with their infant, along with nursing training during the feeding session. The occupational therapy investigator partnered with the parents and when the parents were not available, she partnered with the nursing staff.
223604496|NCT03401671|DRUG|Lanadelumab|SC injection of 300mg in 2mL (150 mg/mL) solution of lanadelumab will be administered as a single dose injection in the abdomen.
223604497|NCT06120439|COMBINATION_PRODUCT|PECS II combined with intercostal nerve blockade;|The patient was in a supine position, and under ultrasound guidance, the needle tip was first placed in the plane between the pectoralis major and minor muscles, and 10ml of 0.3% ropivacaine was injected. The needle was then advanced into the space between the pectoralis minor and serratus anterior muscles, and 20ml of 0.3% ropivacaine was injected. Intercostal nerve blockade: The range of intercostal blockade was determined based on the location of the breast surgery. The needle was inserted into the intercostal space from the posterior axillary line, and 3ml of 0.3% ropivacaine was injected into each intercostal space.
223604498|NCT06120439|COMBINATION_PRODUCT|General anesthesia with laryngeal mask|The C Group underwent general anesthesia induction using TCI propofol 3-3.5μg/ml, TCI remifentanil 1-2ng/ml, sufentanil 0.3μg/kg iv, midazolam 0.05mg/kg iv, and rocuronium 0.6mg/kg iv after loss of consciousness. After muscle relaxation, the laryngeal mask was inserted, and mechanical ventilation was performed with a tidal volume of 6ml/kg. Anesthesia maintenance included propofol 3-4μg/ml and remifentanil 1-2ng/ml.
223751984|NCT05481177|DRUG|Ivabradine|Ivabradine is a drug approved to treat tachycardia in volunteers with heart failure. This study is to determine benefit of ivabradine treatment in postural orthostatic tachycardia syndrome (POTS) in participants with Long haul Covid.
223751985|NCT02832310|PROCEDURE|valsalva maneuver|the effects of valsalva maneuver on arterial pressure
223751986|NCT05707117|OTHER|Tendon neuroplastic training (TNT)|Subjects will attend physical therapy for three non-consecutive days per week for a total 4 consecutive weeks. Exercise would involve isolated flexion, extension with a dumbbell. This exercise would be paced with external audio/visual cue on smart phone using proMetronome app. Patients will listen to the sound and track the movement of metronome with the eyes. Pace of metronome will be set at 20 beats per minute such that each beat will be 3 sec apart. This will allow a 3sec concentric and 3 sec eccentric phases.4 sets of 8 repetitions would be completed with a 2-minute rest between each set. Exercise will begin with 3 pounds weight, but it would be made sure that this wouldn't cause pain during exercise (more than 5/10), gradual progression in weight to 5 pounds after 2nd weeks.
223751987|NCT05707117|OTHER|group B Conventional treatment|Subjects assigned to this group will undergo static stretching of Extensor carpi radialis brevis and myofascial release for 4 weeks, 3 sessions a week. Myofascial release technique will be applied for 5 minutes and 2 reptations per session
223604499|NCT03007602|OTHER|Upper Extremity Aerobic Exercise|"Range of maximal heart rate is being followed by a polar band during supervised session each week.~Aerobic exercise is being trained for 30 min-per/day, 3 days/week, 6 weeks. All sessions are being performed by a physiotherapist at cardiopulmonary rehabilitation department."
223751988|NCT00947973|BEHAVIORAL|Challenging Horizons Program (CHP) after-school model|Interventions delivered by a counselor 2 days a week as an after-school program. Interventions will strengthen skills in materials organization, homework management, studying, note taking, and socialization.
223751989|NCT00947973|BEHAVIORAL|Challenging Horizons Program (CHP) consultation model|Interventions delivered by a mentor (e.g., a teacher or school counselor) as needed, with expert consultation available
224311383|NCT00902031|DRUG|Sennoside + Placebo|"Sennoside: will be given in tablet form (8.6 mg), 1-3 tablets taken 1-3 times daily for 10 days.~Placebo: will be taken in capsule form, similar in size, shape, and color to docusate, taken twice daily for 10 days"
224311384|NCT02446327|OTHER|Blood sampling for biomarker assessment|
224311385|NCT02478320|DRUG|Ilorasertib|200 mg administered by mouth twice daily on Days 1, 8, and 15 of each 28-day cycle.
223604500|NCT03259061|DEVICE|Flexible fiberoptic nasopharyngoscopy|"1. Flexible fiberoptic nasopharyngoscopy (FFN) allows direct transnasal observation of the anatomy and dynamic activity of the velopharyngeal sphincter. Such observations can be recorded for permanent documentation by coupling FFN to a video camera with simultaneous audio recording. Numerous published reports discuss the advantages of FFN as a clinical method for evaluating velopharyngeal function during speech (10).~2. Cephalometric analysis, is the clinical application of cephalometry. It is analysis of the dental and skeletal relationships of a human skull and is frequently used by dentists, orthodontists, and oral and maxillofacial surgeons as a treatment planning tool.~Cephalometric analysis can also be applied for assessing the velopharyngeal structure and function. More specifically, velopharyngeal function in terms of its shape and mobility was analyzed quantitatively on the basis of cephalometric principle"
223751990|NCT00176592|DRUG|Betaseron|Betaseron 250 micrograms injected SQ every other day
223751991|NCT00176592|DRUG|Copaxone|Copaxone 20 mg injected SQ every day (glatiramer acetate)
223751992|NCT02596269|DRUG|Nefopam|120 mg of nefopam is included in the i.v. PCA with with 100 ml solution containing 1250 µg fentanyl. a bolus of 1 ml with an 8-min lockout time was set, without any background continuous infusion. After the end of surgery, and if the goal VRS score was achieved at PACU, PCA device was turned on and the patient was encouraged to use the pre-set bolus dose, until 24h after the end of surgery.
223751993|NCT02596269|DRUG|Saline|i.v. PCA with with 100 ml solution containing 1250 µg fentanyl. a bolus of 1 ml with an 8-min lockout time
223604501|NCT06272123|OTHER|no intervention|no intervention
223751994|NCT05749042|DRUG|Sintilimab|Concurrent Chemoradiotherapy Based of Cisplatin Plus Sintilimab.
223751995|NCT05749042|RADIATION|Radiotherapy|Concurrent Chemoradiotherapy Based of Cisplatin
223604502|NCT02233023|DRUG|Pramipexole|
223604503|NCT02233023|DRUG|Bromocriptine and other dopamine agonists|
223604504|NCT05712954|OTHER|music group|music
223604505|NCT05712954|OTHER|video group|video
223604506|NCT00959738|PROCEDURE|Diverting loop ileostomy with rod|Diverting loop ileostomy with rod
223604507|NCT00959738|PROCEDURE|diverting loop ileostomy without rod|diverting loop ileostomy without rod
223604508|NCT03302247|BIOLOGICAL|Nivolumab|Monoclonal antibody against non small cell lung cancer
223751996|NCT00625677|BIOLOGICAL|NeisVacC (Meningococcal C conjugate vaccine)|Dosage
223751997|NCT00625677|BIOLOGICAL|Menjugate (Meningococcal C conjugate vaccine)|Dosage
223751998|NCT02437019|DRUG|PCI-32765 (Ibrutinib)|Participants will receive PCI-32765 (ibrutinib) 420 mg (three 140-mg capsules) oral once daily continuously on a 28-day cycle.
223751999|NCT06327958|OTHER|Cormack-Lehane (C&L)|There is no distinguishing feature of the C\&L and POGO scores required to provide the best laryngoscopic view from other interventions in this or any other clinical trial.
223752000|NCT06327958|OTHER|POGO score|There is no distinguishing feature of the C\&L and POGO scores required to provide the best laryngoscopic view from other interventions in this or any other clinical trial.
223752001|NCT05641233|RADIATION|Stereotactic radiotherapy|Preoperative radiotherapy delivered in a single fraction of 12 Gy focussed on 4cm pancreas at the intended (i.e. future) anastomotic site.
223752002|NCT01103687|BIOLOGICAL|Ad26.ENVA.01 (rAd26)|5 x 10\^10 virus particles (VP) vaccine delivered intramuscularly (IM)
224311386|NCT03673319|PROCEDURE|Dry needling with positives expectation|"DN procedure: is a very effective form of treatment used to treat neck-shoulder pain and it is expected to reduce your perception of pressure pain"
224311387|NCT03673319|PROCEDURE|Dry needling with neutral expectation|"DN procedure: is a form of treatment used to treat neck-shoulder pain that has unknown effects on your perception of pressure pain"
224311388|NCT04834843|OTHER|Observational study, no intervention|Observational study, no intervention
223604509|NCT03302247|DRUG|Nivolumab+Gemcitabine|Gemcitabine is added to the Nivolumab treatment
223604510|NCT05651672|DRUG|Pemigatinib|13.5mg, po, 2 weeks on/1 week off, Q3W
223604511|NCT03240770|DEVICE|VPro5 device|Use of the VPro5 device for 5 minutes a day
223604512|NCT03240770|OTHER|Deviation from Standard Tray Wear Time (14 Days)|Patients reduced Tray Wear Time Interval (14 Days)
223604513|NCT06525090|OTHER|no intervention-child-administered questionnaires|The implementation of the research was started after getting approval from Mugla Sıtkı Kocman University Health Sciences Ethics Committee and TR Ministry of National Education Research, Competition and Social Activity. The purpose of the study was explained by the researchers to the administrators of the schools where the study was conducted and planning was made with the school administration. The data were collected in 15-20 minutes from the students who agreed to participate in the study during the course hours deemed appropriate by the administration. The purpose of the study and how to fill in the measurement tools was explained to the students, and it was stated that the research data would be kept confidential and used only by the researcher. The self-administered questionnaires were filled out on the paper. Verbal consent was obtained from the students participating in the study and written informed consent was obtained from their parents.
223604514|NCT06525584|DRUG|Ketamine Hcl 50Mg/Ml Inj|ketamine infusion at a dose of 0.1 mg/kg/hour for 16 hours
223752003|NCT01103687|BIOLOGICAL|Placebo Vaccine|Placebo vaccine delivered IM
223752004|NCT00973024|DRUG|JNJ-42160443 3 mg|JNJ-42160443: type=exact number, unit=mg, number= 3, form=solution for injection, route=Subcutaneous use or Placebo: form=solution for injection, route=Subcutaneous injection. One inj of 3 mg of JNJ-42160443 or matching placebo every 4 wks for up to 104 wks.
223752005|NCT00973024|DRUG|JNJ-42160443 1 mg|JNJ-42160443: type=exact number, unit=mg, number= 1, form=solution for injection, route=Subcutaneous use or Placebo: form=solution for injection, route=Subcutaneous injection. One inj of 1 mg of JNJ-42160443 or matching placebo every 4 wks for up to 104 wks.
223752006|NCT00973024|DRUG|JNJ-42160443 6 mg/3mg|JNJ-42160443: type= exact number, unit= mg, number= 3 and 6, form=solution for injection, route= Subcutaneous use or Placebo: form= solution for injection, route= Subcutaneous injection. 1 inj of 6 mg of JNJ-42160443 on Day 1 followed by 1 inj of 3 mg or matching placebo every 4 wks for up to 104 wks.
223752007|NCT00973024|DRUG|JNJ-42160443 10 mg|JNJ-42160443 10 mg: type=exact number, unit=mg, number= 10, form=solution for injection, route=Subcutaneous use or Placebo: form=solution for injection, route=Subcutaneous injection. One inj of 10 mg of JNJ-42160443 or matching placebo every 4 wks for up to 104 wks.
223752008|NCT00973024|DRUG|Matching Placebo|Form= solution for injection, route= subcutaneous. Matching placebo given as a subcutaneous (SC) (under the skin) injection (inj) once every 4 weeks (wks).
223752009|NCT03289507|DIETARY_SUPPLEMENT|Treatment1|Longvida Capsule formulation A
223752010|NCT03289507|DIETARY_SUPPLEMENT|Treatment2|Longvida Capsule formulation B
223752011|NCT03289507|DIETARY_SUPPLEMENT|Treatment3|Curcuma longa extract of Rhizomes
223752012|NCT02335723|DEVICE|Alteco LPS Adsorber|"Alteco® LPS Adsorber is a Class IIa medical device developed in accordance with existing international standards. Alteco® LPS Adsorber does not contain any pharmaceutical or toxic components.~Alteco® LPS Adsorber is used for the adsorption of LPS as endotoxins. The capturing component is a specially designed synthetic peptide developed for adsorption of endotoxin. The capturing component has high affinity to Lipid A, i.e. a constant component in the endotoxin molecule, which ensures efficient reduction of endotoxins from different bacterial species."
223752013|NCT02335723|DEVICE|Placebo|Exactly the same as Alteco LPS Adsorber but no peptide component has been attached to the matrix (i.e. there is no adsorber functionality)
223752014|NCT02484963|DRUG|Zolpidem|
223604515|NCT06525584|DRUG|Ketamine Hcl 50Mg/Ml Inj|ketamine infusion at a dose of 0.3 mg/kg/hour for 16 hours
223752015|NCT02484963|DRUG|placebo|
223752016|NCT01649531|PROCEDURE|1 Implant|
223604516|NCT06525584|OTHER|Control|Without ketamine
223604517|NCT04090242|DEVICE|BD Diabetes Care Application (for mobile devices) PLUS use of BD Nano Pen Needle|Subjects in the Intervention Group will be instructed to use the DC-App and switch from their current pen needle to the BD Nano 2nd Gen Pen needle during their participation in the study. The app is intended to be used as a patient education tool and data logger to augment the diabetes care team.
223604518|NCT00002138|DRUG|Tecogalan sodium|
223604519|NCT01969630|DEVICE|PEB|Paclitaxel eluting balloon angioplasty plus provisional nitinol stent implantation
223604520|NCT01969630|DEVICE|PES|Systematic Paclitaxel eluting stent angioplasty
223604521|NCT02371603|DRUG|GSK1278863 25 mg Tablet|A round, biconvex, white film coated tablet to be taken orally in the fasted state in the morning
223604522|NCT02371603|DRUG|Pioglitazone 15 mg Tablet|"White to off-white, round, convex, non scored tablet with ACTOS on one side, and 15 on the other, to be taken orally in the fasted state in the morning"
223604523|NCT02371603|DRUG|Rosuvastatin 10 mg Tablet|"Pink, round, biconvex, coated tablets. Debossed CRESTOR and 10 on one side, to be taken orally in the fasted state in the morning"
223752017|NCT01649531|PROCEDURE|2 Implants|
223752018|NCT02743650|DIETARY_SUPPLEMENT|Sodium bicarbonate|The initial dose of sodium bicarbonate is 0.3 mEq/kg/d. If a subject meets the protocol criteria, the dose will be increased to 0.6 mEq/kg/d.
223752019|NCT01253759|PROCEDURE|TTT + ICG-based PDT|
223752020|NCT01209442|DRUG|Bevacizumab|Bevacizumab will be administered at 10 mg/kg on day 1 and day 15. Four to six weeks following completion of concurrent IMRT, TMZ and bevacizumab, patients will receive 6 cycles of Bevacizumab.
223752021|NCT01209442|DRUG|Temozolomide|Patients will be treated with hypofractionated IMRT (60 Gy in 10 Fx) and daily temozolomide at 75 mg/m2 qd concurrent with IMRT. Four to six weeks following completion of concurrent IMRT, TMZ and bevacizumab, temozolomide will be given at 150-200 mg/m2 qd on days 1-5 of each cycle.
223752022|NCT01209442|RADIATION|RT (Radiation Therapy)|Patients will be treated with hypofractionated IMRT (60 Gy in 10 Fx)
223752023|NCT03604640|OTHER|Physical Training|Physical exercise program and health education
223752024|NCT01894152|DEVICE|XIENCE PRIME Everolimus Eluting Coronary Stent System (EECSS)|Subjects receiving XIENCE PRIME Everolimus Eluting Coronary Stent System (EECSS)
223752025|NCT01708174|DRUG|LDE225|Sonidegib for oral suspension was supplied in amber glass bottles. Sonidegib oral suspension was combined with the supplied reconstitution vehicle to a final concentration of 50 mg/mL.
223752026|NCT01708174|DRUG|TMZ|Temozolomide capsules were obtained locally by the Investigator
223604524|NCT02371603|DRUG|Trimethoprim 100 mg Tablet|"White, round, scored, convex tablet, debossed 93 above the score and debossed 2159 below the score on one side and plain on the other, to be taken orally as two tablets once in the morning and once in the evening"
223604525|NCT05050864|PROCEDURE|venous sinus stenting|The placement of a vascular endoprosthesis (stent) is an interventional neuroradiology procedure aimed, by venous approach (percutaneous puncture), to restore the diameter of a venous sinus. It requires 6 months of antiplatelet aggregation. The aim is to allow better venous drainage from the brain to increase the absorption of cerebrospinal fluid
223604526|NCT05050864|PROCEDURE|Neurosurgical internal ventricular shunt|The internal ventricular shunt consists of the introduction of a catheter from a lateral ventricle into the atrium or peritoneum. It is associated with a valve whose opening pressure is adjustable. The goal is that cerebrospinal fluid can be absorbed extra-cranial
223604527|NCT05910008|PROCEDURE|O-Arm Stereotactic imaging|Prior to electrode implantation, O-ARm stereotactic imaging (Magnetic Resonance Imaging)
223604528|NCT05910008|PROCEDURE|Standard Stereotactic imaging|Prior to electrode implantation, standard stereotactic imaging (Magnetic Resonance Imaging)
223604529|NCT00550693|DEVICE|Chlorhexidine-impregnated foam dressing|Patients during the intervention period had this foam dressing applied around their central venous catheter. This was replaced once a week as recommended by the package insert unless the dressing was soiled, bloody, or fell off.
223604530|NCT02930915|DEVICE|Hand-held laser scanner|The laser scanning is non-intrusive and the scan can be completed in approximately 15 minutes. The scanning process involves the patient sitting in a chair while a researcher performs the scan. As a precautionary measure we require the patient to wear an eye mask as although the scanner is CE marked and completely safe . The process can be completed in stages (e.g. 3 x 5 minutes) with a break of 2-3 minutes between each session. The laser scanner will then be moved around the patient to obtain a set of 3D points forming the surface of the patient's head. We believe the laser scanning to be the most accurate way to acquire the surface of the patient's face / head and we wish to compare the models we obtain with surfaces rendered from the patient's CT data set.
223604531|NCT00001094|DRUG|Lamivudine/Zidovudine|
223752027|NCT01632969|BEHAVIORAL|The The Family Assessment of Treatment at the End of life (FATE ) survey|Study candidates will be contacted by mail with an initial contact letter with information explaining the study, and then will receive a follow-up phone call to discuss their participation in the study no later than 1 month following the posting of the initial contact letter. If a family member or next-of-kin chooses to participate, verbal informed consent will be obtained over the phone and a one-time telephone interview will be conducted.
223752028|NCT00641407|DRUG|NPL insulin|Starting dose 10 IU bedtime and then titration
223752029|NCT00641407|DRUG|Insulin glargine|10 IU bedtime and then titration
223604532|NCT00001094|DRUG|Nelfinavir mesylate|
223604533|NCT00001094|DRUG|Saquinavir|
223604534|NCT00001094|DRUG|Delavirdine mesylate|
223604535|NCT03153995|PROCEDURE|soft tissue expansion|"Three surgeries will be carried out for group I patients:~* Soft tissue expansion (1st surgery); at baseline~* Alveolar ridge augmentation (2nd surgery); after five weeks~* Implant surgery (3rd surgery); after six months"
223604536|NCT00195663|BIOLOGICAL|Adalimumab|
223604537|NCT00195663|DRUG|Methotrexate|
223604538|NCT00195663|BIOLOGICAL|Adalimumab placebo|
223604539|NCT00195663|DRUG|Methotrexate placebo|
223604540|NCT04455945|PROCEDURE|Open Rectal cancer surgery|Open sphincter preserving surgery for rectal cancer
223604541|NCT04455945|PROCEDURE|Laparoscopic Rectal cancer surgery|Laparoscopic sphincter preserving surgery for rectal cancer
223604542|NCT03214406|DRUG|Arm & Hammer Advance White Brilliant Sparkle (Test product)|20% sodium bicarbonate
223604543|NCT03214406|DRUG|Crest Cavity Protection Regular Toothpaste (Negative Control)|Negative control
223604544|NCT00604695|DRUG|Tenecteplase|Intracoronary injection of IV tenecteplase.
223604545|NCT00604695|DRUG|Sterile Saline|Intracoronary injection of IV sterile saline
223604546|NCT04030793|DEVICE|Individualized transcranial direct current stimulation|Based on tDCS stimulation, individualized stimulation during 30 minutes with sitting position.
223604547|NCT04030793|DEVICE|Conventional transcranial direct current stimulation|Conventional tDCS stimulation during 30 minutes with sitting position.
223604548|NCT01098305|DRUG|Varenicline|Participants will be randomized to receive varenicline or placebo for 12 weeks. The dosing regimen consistent with FDA guidelines will be used: Day 1-Day 3 (0.5mg once daily); Day 4-Day 7 (0.5mg twice daily); and Day 8-Day 84 (1.0mg twice daily).
223604549|NCT01098305|BEHAVIORAL|Counseling|All participants will be provided with a structured behavioral counseling program, involving 6 counseling sessions by a trained NDDTC counselor. This will be a manual-based intervention and revised as needed for cultural relevance and sensitivity by Dr. Stigler. The intervention is designed to enhance awareness of the harmful effects of smokeless tobacco, assist the person in developing skills to quit and avoid relapse, and instruct the smokeless tobacco user on medication adherence, as recommended by experts in the field.
223752030|NCT00075582|PROCEDURE|conventional surgery|Some patients may undergo second-look surgery
223752031|NCT00075582|DRUG|dactinomycin|Given IV
223752032|NCT00075582|DRUG|cyclophosphamide|Given IV
223752033|NCT00075582|DRUG|vincristine sulfate|Given IV
223752034|NCT00075582|RADIATION|radiation therapy|Undergo radiotherapy
223604550|NCT04560075|BEHAVIORAL|Text2Connect|The T2C intervention aims to increase mental health self-efficacy though psychoeducation, self-monitoring of symptoms and stressors, and cues to action for college-bound youth.
223604551|NCT04560075|BEHAVIORAL|Psychoeducational Videos (PE) Only|Participants in this group will receive psychoeducation through the PE video library.
223604552|NCT03447847|OTHER|Water|1 liter of water in meals; 1 liter out of meals
223604553|NCT02964442|OTHER|Capsinoids|12 mg of Gel capsules
223604554|NCT02964442|OTHER|Cold Stimulus|Cooling vest maintain at 14 degree Celsius
223604555|NCT01100775|DRUG|Galantamine|A lead-in 3 days of 4mg/ twice a day of galantamine (or placebo) followed by 8 mg (or placebo) on the 4th day, the day of testing.
223604556|NCT01100775|DRUG|Placebo|Subjects will be randomly assigned to the two possible order of administration: the drug and then placebo, or the placebo and then drug. Subjects will be given a lead-in 3 days of 4mg/ twice a day of galantamine (or placebo) followed by 8 mg (or placebo) on the 4th day, the day of testing.
223604557|NCT02536924|BEHAVIORAL|Waiting Room Intervention|The waiting room intervention is called RESOLVE (Relaxation SOLving problem and cognitive errors), which is a short film.
223604558|NCT02536924|BEHAVIORAL|Treatment as usual.|The patient will receive treatment as usual.
223604559|NCT00325390|DRUG|clopidogrel (SR25990C)|
223604560|NCT05504993|OTHER|Frequency of AECOPD|No intervention has been applied. 92 COPD patients divided into 2 groups according to their comorbidity level. Than these groups were compared for their AECOPD frequency
223604561|NCT03803384|OTHER|Oxygen therapy|Oxygen supply during ESWT, once with the prescribed constant oxygen flow and once using an auto-regulated oxygen flow system setting the SpO2 target at 92%.
223604562|NCT01716780|OTHER|Intervention|"Patients allocated to the intervention group will undergo prospective, proactive, integrated, structured pain treatment according to recent guidelines on cancer pain care"
223604563|NCT04924998|DRUG|current treatment of AL-CM|current treatment of AL-CM
223604564|NCT01162915|BIOLOGICAL|Autologous bone marrow-derived mesenchymal stem cells.|Intrathecal infusion of a single dose of ex vivo expanded MSC.
223604565|NCT03910114|DRUG|Magnevist|GBCA enhancement
223604566|NCT03910114|DRUG|Dotarem|GBCA enhancement
223604567|NCT03910114|DRUG|Gadovist|GBCA enhancement
223604568|NCT04623814|OTHER|Food|HEC113995 20mg will be taken orally fasted or with food
223752035|NCT05045144|COMBINATION_PRODUCT|RSVPreF3(120 μg)|A single dose of RSVPreF3(120 μg) combined with Sodium Chloride (NaCl) was administrated intramuscular (IM). There were used 3 different lots of RSVPreF3(120 μg), one for each individual group (RSV lot1 Group, RSV lot2 Group and RSV lot3 Group) considered under RSV pooled Group.
223752036|NCT05045144|COMBINATION_PRODUCT|Flu Quadrivalent influenza vaccine (15 μg HA)|A single dose of Flu Quadrivalent influenza (15 μg HA) vaccine was administrated intramuscular (IM).
223752037|NCT05045144|COMBINATION_PRODUCT|Placebo|One dose of placebo, administered intramuscularly in the deltoid region of the right arm, at Day 1.
223752038|NCT01920919|DRUG|Dexamethasone|
223752039|NCT01920919|DRUG|Placebo|
223752040|NCT03668626|OTHER|Family-centered intervention program (FCIP)|This program included in-hospital intervention, after-discharge intervention and neonatal follow-up. Five sessions of in-hospital intervention emphasized modulation of the NICU, teaching of child developmental skills, feeding support, massage, interactional activities and parent support and education. The 7-session after-discharge intervention consisted of 4 clinic visits and 3 home visits with specific care in modulation of home environment, teaching of child developmental skills, feeding support, teaching of interactional activities, and parent support and education.
223752041|NCT02385084|DRUG|LY2409021|Administered orally
223752042|NCT04357015|DRUG|intravenous tranexamic acid|The tranexamic acid (TXA) group will receive a single bolus IV injection of 15 mg/kg of TXA 20 minutes before surgical incision
223752043|NCT04357015|DRUG|intravenous carbetocin|The carbetocin group will receive a single bolus IV injection of 100 mcg of carbetocin 20 minutes before surgical incision
223752044|NCT04357015|DRUG|placebo|the placebo group will be given a normal saline IV bolus 20 minutes before surgical incision
223752045|NCT05113615|DRUG|Tiotropium Bromide|respimat inhaler 2.5mcg/puff
223752046|NCT05113615|DRUG|Matching placebo|matching placebo Respimat inhaler
223752047|NCT03221920|OTHER|Very Low Carbohydrate Diet|1 : 4 ratio of carbohydrate to fat of the total daily calories intake
223752048|NCT00366600|DRUG|neratinib|HKI-272
223604569|NCT04623814|DRUG|HEC113995|HEC113995 will be taken orally fasted (HEC113995 10mg）or with food (HEC113995 20mg and 40mg） for 10 days
223604570|NCT04623814|DRUG|placebo|The placebo will be administered fasted or with food for 10 days.
223604571|NCT04682535|OTHER|Social relationships|Exposure to social interactions with spouse, friends, and family. Perceived loneliness, emotional strain, and emotional support.
223604572|NCT03227666|BEHAVIORAL|Exercise|The intervention group will perform three supervised group training sessions a week, consisting of 30 minutes of balance training for 4 weeks.
223604573|NCT01196832|PROCEDURE|blood sample|blood sample for fibrocytes analysis
223604574|NCT01196832|PROCEDURE|Clinical and functional evaluation|Plethysmography, Carbon monoxide capacity of transfer , arterial gaz
223604575|NCT01061502|DEVICE|Procellera (Bioelectric Wound Dressing)|Dressing used on one-half of the donor graft site. Dressing changes every 5-7 days, more frequently if needed
223604576|NCT01061502|DEVICE|Opsite (Transparent Adhesive Dressing)|Semi-occlusive wound dressing placed on one-half of the skin graft donor site. Dressing change every 5-7 days, more frequently if needed.
223752049|NCT06427356|BEHAVIORAL|PREVAIL Interdisciplinary Team|Patient meets simultaneously with an interdisciplinary team (IDT) five pain specialists and develops an individualized treatment plan based on Whole Health. Participants receive five months of coaching calls then return six months later for a follow-up visit with the IDT.
223752050|NCT00632255|DRUG|Imatinib|Conventional therapy with imatinib
223752051|NCT05719805|DRUG|Mavacamten|Specified dose on specified days
223752052|NCT04725760|DEVICE|BrainPort Vision Pro|"Ten hours of training over 3 to 5 days, followed by autonomous use of the device.~It will be recommended that the subject use the BrainPort® Vision Pro device for at least 5 hours per month for a period of 12 months."
223752053|NCT02171260|DRUG|Eribulin Mesylate|Eribulin mesylate will be administered intravenously on Days 1 and 8 of each 21-day cycle.
223604577|NCT05018078|BIOLOGICAL|Coronavirus vaccine|Coronavirus vaccine was inoculated on day 0 and day 25±3, respectively
223752054|NCT01797289|OTHER|Lung CT or V/Q scanning in patients with a high pre-test clinical probability of PE and/or a positive D-dimer|
223752055|NCT00145873|DRUG|nesiritide, continuous infusion|
223752056|NCT03571542|OTHER|pulmonary function|The aim of this study is to assess the respiratory function thanks to pulmonary function tests in renal transplanted children in France.
223752057|NCT05180214|DRUG|Bupivacain|analgesic
223752058|NCT05180214|DRUG|Ketorolac|analgesia
223752059|NCT02574130|DRUG|Amikacin|400 mg, nebulizer, every 12 hours, 10 days
223752060|NCT02574130|DRUG|Placebo|placebo 4 ml, nebulizer, every 12 hours, 10 days
223752061|NCT04318509|DIETARY_SUPPLEMENT|GMPOWER|(casein) glycomacropeptide protein substitute for the dietary management of PKU from the age of 3 years
223752062|NCT01527279|DRUG|antazoline|Patients assigned to antazoline group will be administered antazoline in boluses of 50mg diluted to 10cm3 every 5 minutes up to cumulative dose of 250mg or conversion of AF to SN. Drug administration will also be stopped in case of serious adverse event or conversion of AF to different supraventricular arrhythmia. BP will be measured before every injection.
223752063|NCT01527279|DRUG|0.9% saline|Patients assigned to control group will be administered 0.9% saline in boluses of 10cm3 every 5 minutes up to cumulative volume of 50cm3, conversion of AF to SN or in case of serious adverse event or conversion of AF to different supraventricular arrhythmia. BP will be measured before every injection.
223752064|NCT00399009|DEVICE|AutoSuture Premium Plus CEEA/Ethicon Proximate ILS|
223752065|NCT00188019|PROCEDURE|diagnosis methods|
223752066|NCT00323492|DRUG|Truvada|Truvada + NNRTI or PI.
223752067|NCT00323492|DRUG|Current HAART regimen|Maintain baseline regimen
223604578|NCT06447402|DRUG|Normal saline|5 mL of normal saline will be nebulised in the control arm
223604579|NCT06447402|DRUG|Amphotericin B deoxycholate|2 mL of the above reconstituted amphotericin B solution will be obtained in a sterile syringe and transferred into the drug chamber of a nebulizer. Three mL of distilled water will be added to 2 mL of the reconstituted amphotericin B (5 mL liquid in the chamber ensures complete and easy nebulization of all the contents)
223604580|NCT03634254|OTHER|Satisfaction survey of communication quality:|a conversation from phone call to survey primary caregivers of AAC users in New Taipei City who think the users communication quality
223604581|NCT05091125|DIAGNOSTIC_TEST|Diagnostic performance of the S100B protein dosage|Dosage of the S100B protein in patients with mild head trauma with complication risks
223604582|NCT04984577|DRUG|Compound Edaravone Injection-Low dose|Compound Edaravone Injection 30mg/dose (Edaravone 30mg, Taurine 600 mg), one dose every 12 hours, continue for 14 days
223604583|NCT04984577|DRUG|Compound Edaravone Injection-High dose|Compound Edaravone Injection 50mg/dose (Edaravone 50mg, Taurine 1000 mg), one dose every 12 hours, continue for 14 days
223604584|NCT04984577|DRUG|Edaravone Injection|Edaravone Injection 30mg/dose, one dose every 12 hours, continue for 14 days
223604585|NCT04984577|DRUG|Placebo injection|Placebo injection, one dose every 12 hours, continue for 14 days
223604586|NCT04887987|OTHER|Pilates training + active PBMT|Participants will be submitted to a supervised 8-wk mat Pilates exercise program (2 x/week) and will receive active PBMT on the lumbar region 10 min before and after (totaling 20 min) each workout.
223752068|NCT02824250|BEHAVIORAL|MBSR|Mindfulness-Based Stress Reduction (MBSR) is an 8-week classroom based program of mindfulness meditation and gentle yoga.
223752069|NCT01092533|DRUG|Myfortic|Myfortic 360 mg BID (during week 1) Myfortic 720 mg BID (from week 2 on) Maintenance dose Decortin 5mg/d
223752070|NCT01092533|DRUG|Decortin|Maintenance dose 5 mg/d
223752071|NCT05114135|DEVICE|Osteo3 ZP Putty|Transforminal Interbody Fusion at one spinal level (L2-S1) with instrumented posteriorlateral fusion on at least the contralateral side to the TLIF approach.
223752072|NCT05049070|DIAGNOSTIC_TEST|Mobile medical application to self administer a subjective refraction test|GoEyes is a software as a medical device and mobile medical application, which is downloaded to a smartphone and is a self-administered subjective refraction test that measures the refractive error of the user's eyes in the home environment without any contact or help from health care professionals
223752073|NCT05049070|DIAGNOSTIC_TEST|Standard of care refraction test|Standard of care subjective manifest refraction test performed by a healthcare professional
223752074|NCT03905460|DIAGNOSTIC_TEST|Point-of-care ultrasound|Focused ultrasound of the heart, lungs and pleurae
223752075|NCT01466387|BIOLOGICAL|Typhoid Vi Polysaccharide Vaccine|One dose of typhoid Vi polysaccharide vaccine.
223604587|NCT04887987|OTHER|Pilates training + sham PBMT|Participants will be submitted to a supervised 8-wk mat Pilates exercise program (2 x/week) and will receive sham PBMT on the lumbar region 10 min before and after (totaling 20 min) each workout.
223604588|NCT04887987|OTHER|Multicomponent training + active PBMT|Participants will be submitted to a supervised 8-wk multicomponent exercise program (3 x/week) and will receive active PBMT on the lumbar region imediately before each workout.
223604589|NCT04887987|OTHER|Multicomponent training + sham PBMT|Participants will be submitted to a supervised 8-wk multicomponent exercise program (3 x/week) and will receive sham PBMT on the lumbar region imediately before each workout.
223752076|NCT01466387|BIOLOGICAL|Yellow Fever Vaccine|One dose of yellow fever vaccine.
223604590|NCT03964324|DIAGNOSTIC_TEST|Fractioned Exhaled Nitrogen Oxide measurements|Measurements of Fractioned Exhaled Nitrogen Oxide obtained by blowing into a mouthpiece. The NIOX VERO machine will be used for these measures.
223604591|NCT04552808|DRUG|Yimitasvir Phosphate|Cohort A: On the first day, 100 mg of Yimitasvir phosphate was given in a single dose on fasted by each subjects
223604592|NCT04552808|DRUG|Yimitasvir Phosphate|Cohort B: were subjects with moderate liver function impairment. On the first day, 100 mg of Yimitasvir phosphate was given in a single dose on fasted by each subjects.
223752077|NCT01466387|BIOLOGICAL|Japanese Encephalitis Vaccine|Two doses of Japanese Encephalitis Vaccine.
223752078|NCT01466387|BIOLOGICAL|Rabies Vaccine|Three doses of Rabies vaccine.
223752079|NCT01466387|BIOLOGICAL|MenACWY-CRM Vaccine|One dose of MenACWY-CRM vaccine.
223752080|NCT05602987|PROCEDURE|enema|receiving enema at the night before anal surgery
224200378|NCT05573646|OTHER|Dual-task training|Participants will receive a one-hour online group-based dual-task training session twice a week for 12 weeks, giving a total intervention time of 24 hours. A co-design approach will be adopted to develop the training components in the dual-tasks. For the cognitive training component, arithmetic operation, verbal fluency, and upper limb/ finger movements are included. For the physical training component, we select chair-based exercises are included. A group-based training mode led by a facilitator will be adopted. During the session, participants will be asked to turn on their camera so that they can see and interact with each other. They will also have their audio on as they will have to participate in the cognitive tasks by voicing out their answers.
224200379|NCT05573646|OTHER|Attention Control|Participants will receive eight one-hour online group-based interactive education on health topics other than exercise and cognitive health.
223604593|NCT04552808|DRUG|Yimitasvir Phosphate|Cohort C: Cohort C are healthy subjects, cohorts C and D, should be matched in terms of sex, age, and body mass index (BMI). On the first day, 100 mg of Yimitasvir phosphate was given in a single dose on fasted by each subjects.
223604594|NCT04552808|DRUG|Yimitasvir Phosphate|Cohort D: were subjects with severe liver function impairment. On the first day, 100 mg of Yimitasvir phosphate was given in a single dose on fasted by each subjects.
223604595|NCT00442221|DRUG|Sumatriptan and Naproxen sodium|
223752081|NCT05602987|PROCEDURE|no enema|no enema before anal surgery
223752082|NCT04471389|OTHER|Incidence and risk factors of hypertension|During the follow-up period, General information(age, sex, BMI, blood pressure, the history of drink and smoke, medical history, etc). Blood biochemistry parameters（Lipid, hsCRP levels, etc）and other laboratory examination parameters(arterial stiffness, IMT, FMD) will be collected.
224200380|NCT03664024|DRUG|Pembrolizumab|Pembrolizumab, 200 mg, Day 1 of each 21-day cycle (Q3W), intravenous infusion (IV), standard of care in most countries
223752083|NCT02522208|DRUG|BiDil XR|fixed combination capsule
223752084|NCT02522208|DRUG|BiDil Immediate Release (IR)|fixed combination tablet
223752085|NCT00907985|DRUG|Placebo|Single dose of placebo will be provided.
223752086|NCT00907985|DRUG|Vofopitant|Vofopitant (GR205171) will be provided as 5 milligram single dose capsule administered orally. It will be available as swedish orange, size 0 capsules.
223752087|NCT00907985|DRUG|Lamotrigine|Lamotrigine will be provided as 25 milligrams or 100 milligrams single dose dispersible tablet administered orally.
223752088|NCT02488603|BEHAVIORAL|Decision aids (tamoxifen-related educational materials in brochure or mobile app)|Decision aids (tamoxifen-related educational materials in brochure or mobile app)
223752089|NCT02488603|DRUG|tamoxifen|
223752090|NCT00374296|DRUG|MGCD0103|MGCD0103 administered orally three-times per week
224200381|NCT03664024|DRUG|Pemetrexed|Pemetrexed, 500 mg/m\^2 infusion, standard of care, Q3W, IV
224200382|NCT03664024|DRUG|Carboplatin|Carboplatin AUC 5 mg/mL/min, IV infusion, Day 1 of each 21-day cycle for 4 cycles (Cycles 1 - 4). Investigator's choice of either cisplatin or carboplatin.
223752091|NCT04868279|BEHAVIORAL|Web-Based Interactive Nurse Support Program Based on Health Promotion Model|Nursing education will be given on healthy behaviors such as nutrition, exercise, health responsibility and stress management according to the health promotion model. The researcher will make phone calls with the intervention group for 6 months (12 times in total), twice a month. During telephone interviews, individuals will be talking about the use of the website, the points that are not understood or need to be emphasized, their application of health promotion behaviors, the obstacles they experience during the application and the suggestions for this.
223752092|NCT03159481|BEHAVIORAL|Usual Care + Health Promotion Intervention|Telephone sessions for approximately 5-6 weeks to enhance empowerment and skills for managing medication adherence.
223508088|NCT07045805|DRUG|QL1706 combined with paclitaxel and bevacizumab|"Phase 1:~Plan to enroll 6 subjects to receive QL1706 7.5 mg/kg, paclitaxel 150 mg/m², and bevacizumab 7.5 mg/kg, d1, Q3W. Subjects will undergo a 3-week Dose-Limiting Toxicity (DLT) evaluation period.~If ≥2 DLTs occur among the 6 subjects, QL1706 5 mg/kg will be selected as the Recommended Phase 2 Dose (RP2D) for Phase 2.~Otherwise, QL1706 7.5 mg/kg will be the RP2D for Phase 2.~Phase 2:~Plan to enroll 54-60 subjects. Starting from Cycle 1, QL1706 will be administered intravenously at the RP2D determined in Phase 1. Subjects will receive:~QL1706 (RP2D) Paclitaxel 150 mg/m² Bevacizumab 7.5 mg/kg All agents administered on day 1 of each Q3W cycle. Treatment Duration for All Subjects: Continues until disease progression, intolerable toxicity, withdrawal of informed consent, death, or initiation of new antitumor therapy-whichever occurs first."
223604596|NCT02721095|OTHER|KCl plus 0.9%NaCl|comparison of KCl plus 0.9%NaCl and KCl plus 0.45%NaCl for correction of hypokalemia
223752093|NCT02437955|OTHER|Ferrous sulfate fortified bread with tea|Fasting subjects will be served a wheat roll fortified with labelled ferrous sulfate and stable isotopes
223752094|NCT02437955|OTHER|ferrous sulfate fortified bread with water|Fasting subjects will be served a wheat roll fortified with labelled ferrous sulfate and stable isotopes
223752095|NCT02437955|OTHER|Ferrous fumarate fortified bread with tea|Fasting subjects will be served a wheat roll fortified with labelled Fe Fumarate and stable isotopes
223604597|NCT02721095|OTHER|KCl plus 0.45%NaCl|comparison of KCl plus 0.9%NaCl and KCl plus 0.45%NaCl for correction of hypokalemia
223604598|NCT00296920|DEVICE|Deep Brain Stimulation|
223604599|NCT02815644|DRUG|empagliflozin/linagliptin FDC|empagliflozin/linagliptin fixed-dose combination (FDC) film-coated tablet
223604600|NCT03663335|BIOLOGICAL|CFZ533 - MMF - CS|Comparison with standard of care immunosuppression
223604601|NCT03663335|DRUG|Tacrolimus - MMF - +/- corticosteroids|Standard of care immunosupprevive regimen
223604602|NCT02777489|DRUG|Perindopril|Perindopril Bluepharma 8 mg tablets, daily, during approximately 12 weeks
223604603|NCT01180296|DRUG|oral micronized progesterone|oral micronized progesterone = 400 mg oral micronized progesterone nightly from 16 to 34 weeks
223604604|NCT01180296|DRUG|Identical Placebo tablet|Identical Placebo tablet = placebo taking nightly from 16 to 34 weeks
223604605|NCT05015270|DIAGNOSTIC_TEST|Medications or percutaneous coronary intervention|In this study, we will for the first analyze the correlation of proteins concentration with coronary artery disease burden. Next, the prediction of proteins for one-year clinical events will be further analyzed
223752096|NCT02437955|OTHER|Ferrous fumarate fortified bread with water|Fasting subjects will be served a wheat roll fortified with labelled Fe Fumarate and stable isotopes
223752097|NCT03486093|DEVICE|"Training and retraining to GAVECELT bundle recommendations plus port protector"|"Physicians and nurses of RICU have been trained and retrained to GAVECELT bundle recommendations concerning the management of CVC. The bundle includes: hand hygiene and precautions for protection and safety, adequate insertion site, echo-guided placement of central venous line, use of clorexidine 2% for skin disinfection of insertion site chosen and subsequent continuous or discontinuous disinfection of exit site, use of suture-less devices, use of transparent semi-permeable dressing whenever applicable and immediate removal of catheter when no longer needed.~After the first training meeting, the use of Curos® Disinfecting Port Protector for needleless valves port-protector has been introduced."
224200383|NCT03664024|DRUG|Cisplatin|Cisplatin, 75 mg/m\^2, IV infusion, Day 1 of each 21-day cycle for 4 cycles (Cycles 1 - 4). Investigator's choice of either cisplatin or carboplatin.
224200384|NCT04981782|OTHER|No study specific intervention, regular care.|Chiropractic care (regular care)
224200385|NCT01615757|DRUG|Ara-c|IV formulation, administered as a 2 hr infusion in 1 pint of normal saline, BD on D1,3,5 at 3 gm/m2 /dose
223604606|NCT02396355|DEVICE|Investigational BD FACSPresto System|Blood samples will be tested on the BD FACSPresto system for CD4 absolute count (CD4Abs), %CD4, and Hb concentration.
223604607|NCT02396355|DEVICE|BD FACSCalibur flow cytometer|Blood samples will be tested on the predicate, currently marketed device. For CD4Abs and %CD4 measurement, the BD FACSCalibur flow cytometer will be used with BD Multiset software version 1.1 or later and BD Tritest CD3/CD4/CD45 reagent with Trucount tubes.
223604608|NCT02396355|DEVICE|Sysmex hematology analyzer KX-21|Blood samples will be tested for hemoglobic concentration on the predicate, currently marketed Sysmex hematology analyzer KX-21
223604609|NCT00169208|DRUG|rituximab|375 mg/m² IV, D1 each cycle during 4 cycles
223604610|NCT00169208|DRUG|fludarabine|40 mg/m²/day IV , D1 each cycle during 4 cycles
223604611|NCT00169208|DRUG|mitoxantrone|10 mg/m² IV, D2-3-4 each cycle during 4 cycles
224200386|NCT01615757|DRUG|Ara-c|IV formulation, administered as a 2 hr infusion in 1 pint of normal saline, BD on D1,3,5 at 2 gm/m2 /dose
224200387|NCT04024722|PROCEDURE|In Vitro Fertilization|Patients suitable for research with poor ovarian response will receive treatment including laparoscopic surgery, resection, and transplantation of ovarian tissue in the same operation to improve the chances of success of in vitro fertilization and pregnancy. Participants will be assessed for surgical incisions and fertility assessment up to two weeks after treatment, including general physical examination, US pelvic examination, and blood tests for a hormonal profile to determine the initiation of ovarian stimulation and IVF. Patients will be monitored from 2 weeks to 1 year after treatment (once a week in the first two months and one month for one year after surgery), which will include a general physical examination, a US test, and blood tests for the hormonal profile at the IVF clinic.
224200388|NCT01851343|OTHER|Bone Marrow Stromal Cell (BMSC) Infusion|Subjects will receive 4 weekly BMSC infusions and be monitored for AEs as well as for clinical improvement and mucosal healing.
223604612|NCT00778908|RADIATION|Late-course accelerated hyperfractionated IMRT|"1. IMRT target definition: PTV1=Gloss tumor PTV; PTV2=High risk area containing subclinical disease; PTV3=Low risk area containing subclinical disease~2. IMRT delivery scheduling: (1) Six-week treatment: PTV1=60Gy/30fractions, PTV2=57Gy/30fractions,PTV3=54Gy/30fractions.(2) Concomitant boost to PTV1 as a second daily treatment for the last 10 treatments of the Six-week treatment: PTV1=12Gy/10fractions.(3) PTV3 will be treated with conventional radiotherapy technique separately."
223604613|NCT00778908|DRUG|Concomitant cisplatin chemotherapy|cisplatin:40mg/m2 weekly infusion for 6 weeks
223604614|NCT00778908|RADIATION|Conventionally fractionated IMRT|IMRT target definition: PTV1=Gloss tumor PTV; PTV2=High risk area containing subclinical disease; PTV3=Low risk area containing subclinical disease IMRT delivery scheduling: (1) Seven-week treatment: PTV1=70Gy/35fractions, PTV2=63Gy/35fractions,PTV3=55.8Gy/31fractions.(2) PTV3 will be treated with conventional radiotherapy technique separately.
223604615|NCT05818267|DRUG|Regorafenib|The drug dose that taken by the subject is gradually increased to the maximum dose tolerated by the patient according to individualization. Specifically, the initial dose of 80 mg/day was gradually increased to 120 mg/day (80 mg/day in the first week, 120 mg/day in the second week, and a maximum tolerated dose of 160 mg/day). The maximum tolerated dose is 160 mg/day. The dose is administered once daily in a 4-week cycle (3 weeks of dosing and 1 week of rest) and the maximum dose achieved in the first treatment cycle is maintained.At the discretion of the investigator, regorafenib may be delayed or discontinued. Dose adjustments and interruptions due to toxicity are made according to the recommendations specified in the protocol.
223604616|NCT00379067|DRUG|Tamsulosin OCAS|Adrenoceptor antagonist
223604617|NCT00379067|DRUG|Placebo|placebo
223604618|NCT01511081|RADIATION|SBRT (stereotactic body radiotherapy)|50 Gy (RBE) in 4 daily treatments of stereotactic body radiotherapy (SBRT). Each treatment taking about 30-45 minutes per day.
223604619|NCT01511081|RADIATION|SBPT (stereotactic body proton therapy)|50 Gy (RBE) in 4 daily treatments of stereotactic body proton therapy (SBPT). Each treatment taking about 30-45 minutes per day.
223604620|NCT00038558|DRUG|Filgrastim SD/01|
223604621|NCT00038558|DRUG|Adriamycin|
223604622|NCT00038558|DRUG|Bleomycin|
223604623|NCT00038558|DRUG|Vinblastine|
223604624|NCT00038558|DRUG|DTIC|
223604625|NCT03600532|BEHAVIORAL|Teachable Moment Brief Intervention (TMBI)|Behavioral intervention informed by Collaborative Assessment and Management of Suicidality and Dialectical Behavior Therapy/Cognitive Behavior Therapy to assist in positive recovery trajectory following a suicide attempt.
223604626|NCT05009290|DRUG|SHR3680|"Treatment group: SHR3680 240 mg orally once daily before or after breakfast, 28 days per cycle for a total of 12 treatment cycles (6 cycles before and 6 cycles following radical prostatectomy).~Goserelin acetate sustained-release depot: 10.8 mg administered subcutaneously into the anterior abdominal wall once every 3 cycles (12 weeks) for a total of 12 cycles."
223604627|NCT05009290|DRUG|Placebo|"Treatment group ：Placebo 240 mg orally once daily before or after breakfast, 28 days per cycle for a total of 12 treatment cycles (6 cycles before and 6 cycles following radical prostatectomy).~Goserelin acetate sustained-release depot: 10.8 mg administered subcutaneously into the anterior abdominal wall once every 3 cycles (12 weeks) for a total of 12 cycles."
223604628|NCT04138290|DEVICE|Predictix Antidepressant Software tool|Predictix Antidepressant is a stand-alone software tool based on a patients' genetic panel, clinical, demographic and behavioral inputs, intended to support a clinician in choosing the most suitable antidepressant treatment/s for an individual patient diagnosed with Major Depressive Disorder.
223618111|NCT04024488|BEHAVIORAL|Discussion Control Arm|Each youth discussion control group session will be led by IYL and each caregiver discussion control group will be led by adult study staff. Discussion topics will be selected by youth and caregivers in the group as applicable. Discussion Control group session will take place at a separate time from TI-CBT youth group sessions in attempt to minimize contamination. To note, participant and caregiver group sessions are always held separately.
223618112|NCT06491602|DIAGNOSTIC_TEST|renal biobsy|analsis of renal biobsy and decide grade of renal affection
223618113|NCT01324661|BEHAVIORAL|Ostracism|Participants would received the ball of a computerized ball-tossing game once or twice in the beginning and then never again for the duration of the game.
223618114|NCT01366001|DRUG|ALKS 33-BUP|Sublingual administration, ALKS 33 + buprenorphine, administered once daily for 10 consecutive days.
223618115|NCT01366001|DRUG|ALKS 33|Sublingual administration, ALKS 33 administered once daily for 10 consecutive days.
223618116|NCT01366001|DRUG|Placebo|Sublingual administration, Placebo administered once daily for 10 consecutive days.
223618117|NCT03824041|DIETARY_SUPPLEMENT|Aronia full spectrum - half dose|Powdered whole fruit obtained from aronia berries (Aronia melanocarpa)
223618118|NCT03824041|DIETARY_SUPPLEMENT|Aronia full spectrum - full dose|Powdered whole fruit obtained from aronia berries (Aronia melanocarpa)
223618119|NCT03824041|DIETARY_SUPPLEMENT|Placebo|Identical formulation as the treatment consisting of colored maltodextrin using artificial colors.
223618120|NCT02843906|PROCEDURE|Lombar Punction|cerebrospinal fluid testing at screening and M36
223618121|NCT02843906|RADIATION|Magnetic Resonance Imaging (MRI)|MRI done at screening and M36
223618122|NCT02843906|RADIATION|Positron-Emission Tomography (TEP) /(FDG)|TEP/FDG done at screening and M36
223618123|NCT02843906|OTHER|Psychiatric tests|
223618124|NCT02843906|OTHER|Neuropsychological Tests|done at screening, M12, M24 and M36
223618125|NCT02843906|GENETIC|Apolipoprotein (ApoE) detection|ApoE detection done at screening
223618126|NCT00583336|DEVICE|ShuntCheck|Thermal dilution test for CSF flow
223618127|NCT05647590|PROCEDURE|Chemotherapy|3 months of platinum doublet chemotherapy (cDDP / CBDCA + Pemetrexed, NVB)
223618128|NCT05647590|PROCEDURE|Radiotherapy (RT) + Stereotactic Body Ratio Therapy (SBRT)|"* RT to primary tumor + SBRT to all oligometa (max. 10 intra / extracranial lesions, intracranial SD / PR)~* SBRT V \< 100 ml, if technically possible fractionation RT (40 - 50 Gy / 16 - 20 fractions), SBRT (30 Gy / 1 fraction, 50 - 60 Gy / 3 - 5 fractions) 3 - 6 weeks … maintenance"
223618129|NCT05647590|PROCEDURE|Maintenance chemotherapy|Maintenance chemotherapy will follow 3-6 weeks after RT.
223618130|NCT06005181|BEHAVIORAL|Music listening|Daily music listening
223618131|NCT06005181|BEHAVIORAL|Piano training|Daily piano practice
224200389|NCT02292407|DEVICE|LigaSure Precise instrument|LigaSure Precise instrument is used during Axillary Lymph Node Dissection Technique: Dead space closure Technique: Omission of postoperative drain
224200390|NCT05343793|OTHER|Enhanced Monitoring and Feedback (EMF)|Enhanced Monitoring and Feedback consists of performance data (reach, adoption, effectiveness, implementation) gathered and reported by the program on a quarterly basis. Data summaries for each program and in comparison to the entire sample, will be reflected back to participants, via dashboards, within one-month of data submission.
223604629|NCT05226299|BIOLOGICAL|Supra-threshold and progressive doses of diluted capsaicin via a dosimeter-controlled nebulizer|Participants will be exposured to increasing doses of aerosolized capsaicin (a known cough stimulant) through a dosimeter-controlled nebulizer, while implementing behavioral cough suppression strategies. The concentration of capsaicin will increase incrementally as tolerated, as long as participants are still able to suppress cough. Individual doses will never exceed 1000 micromolar. Cumulative doses per session will never exceed 2000 micromolar. Participants will attend 12 treatment sessions and be given up to 12 exposures per treatment session. Participants will be encouraged to use cough suppression strategies outside of treatment sessions as much as possible to attempt to suppress cough.
223604630|NCT05226299|BIOLOGICAL|Saline|Participants will be repeatedly exposed to a saline through a dosimeter-controlled nebulizer during treatment sessions. Participants will attend 12 treatment sessions and be given up to 12 exposures per treatment session.
223604631|NCT04326049|DEVICE|LLETZ with videocolposcope|Loop procedure using a videocolposcope in order to see and remove the abnormal cervical tissue
223604632|NCT04326049|DEVICE|LLETZ with binocular colposcope|Loop procedure using a binocular colposcope in order to see and remove the abnormal cervical tissue
223604633|NCT06523244|PROCEDURE|PHOTODYNAMIC THERAPY|Respective photosensitive dye solution is applied on to the surgical site, including all the root surfaces. Vacuum suction is used to remove the excess dye from the site and to prevent ingestion of the dye solution The dye is activated with 810nm diode laser with continuous wave frequency and power of 0.3 W with 400 µm fiber tip for 20 seconds/spot. After this, the area is irrigated with saline.
223604634|NCT03364309|DRUG|Ixekizumab|Administered SC
223604635|NCT03364309|DRUG|Placebo|Administered SC
223604636|NCT04747587|OTHER|Reaching Session|"Two x 45 minutes sessions of reaching tasks. Patients in the stroke group will perform the task with the paretic arm using a weight reduction system, allowing movement in the horizontal plane.~Subjects in the control group will perform the task with the randomly selected arm weighted at 80% of their maximum voluntary shoulder torque"
223604637|NCT01850407|BEHAVIORAL|Education Counseling|
223604638|NCT03413709|OTHER|Family Formation Program|The sample for the treatment group for the impact evaluation will only include fathers who are receiving the full 240 hour FFP program (and not the abbreviated 80 hour program). The treatment group will receive FSC's Family Formation Program, which is a six week, 240 hour program implementing a set of curricula focusing on responsible parenting, healthy relationships, and economic stability and mobility.
223604639|NCT02430883|PROCEDURE|Retrograde Intrarenal Surgery|endoscopic treatment of kidney stones with flexible renoscopy
223604640|NCT01882504|DRUG|gevokizumab|
223604641|NCT04014569|DEVICE|MPSA Algorithm|Insulin dosing will be adjusted using the MPSA Algorithm
223604642|NCT03145948|DRUG|ABBV-553|It is administered orally.
223604643|NCT03145948|DRUG|Placebo|It is administered orally.
223604644|NCT05268952|OTHER|Liquid biopsies|Blood/urine sampling and scans are done at regular intervals
223604645|NCT05268952|OTHER|Scans (CT, gallium-68 DOTATE/TOC/NOC PET-CT)|Scans will be done at regular intervals
223604646|NCT05995236|DRUG|PSMA radionuclide therapy|Collect clinical data related to treatment of PSMA-positive metastatic castration-resistant prostate cancer treated with PSMA radionuclide therapy
223604647|NCT03482492|DRUG|Tramadol|Tramadol iv
223604648|NCT03482492|DRUG|Paracetamol|Paracetamol iv
223604649|NCT00810992|BEHAVIORAL|Nutritional and behavioral program A|Recommendation for nutrition and behavior for patients with coronary artery disease according to the German Society of Nutritional Medicine and the International Task Force for the Prevention of Coronary Artery Disease
223604650|NCT00810992|BEHAVIORAL|Nutritional and behavioral program B|Recommendation for nutrition and behavior for patients with coronary artery disease according to the system of the Traditional Tibetan Medicine
223604651|NCT03676140|DRUG|Albendazole on Day 1|Albendazole 400 mg oral tablet Single Dose Treatment on D1
223618132|NCT02386982|DRUG|HMS5552|
223618133|NCT04014283|DIETARY_SUPPLEMENT|Selenium supplementation or placebo treatment|Patients from this group will receive selenium supplement to achieve optimal selenium level
223618134|NCT04014283|OTHER|Diet modification|Patients from this group will have modified diet over the course of the study. Diet modification is aimed to lower selenium concentration in blood.
223618135|NCT04014283|OTHER|Selenium supplementation or placebo treatment and diet modification|In this group patients will receive supplement, placebo or diet modification. The goal is to raise selenium concentration in blood
223618136|NCT02418052|PROCEDURE|neck flexion|After the cervical esophagogastric anastomoses is completed and the skin incision is closed, the patient's occiput will be lifted, and then the neck will be maintained in flexing position by an assistant. The underside of the chin will be fixed to the anterior chest wall with two stout nylon sutures by the surgeon. The neck will be fixed in the neutral flexing position for 7 to 10 days after surgery.
223618137|NCT02586623|DRUG|Droxidopa capsules|100, 200 or 300 mg
223618138|NCT02586623|DRUG|Placebo capsules|
223618139|NCT01844336|DEVICE|PBASE system 1.1 + CT100 (active treatment)|
223618140|NCT01844336|DEVICE|PBASE system 1.1 + CT100 (placebo treatment)|
223618141|NCT03631342|OTHER|VCV20|controlled volume ventilation mode under constant flow of 20 Lpm. The inspired volume was progressively increased until the Pmax reached 40cmH2O.
223618142|NCT03631342|OTHER|VCV40|volume controlled ventilation mode under constant flow of 40 Lpm. The inspired volume was progressively increased until the Pmax reached 40cmH2O.
223618143|NCT03631342|OTHER|PCV|controlled ventilation mode, 1 second inspiratory time. The inspiratory pressure was increased every 5 cmH2O, until reaching the maximum pressure of 40 cmH2O.
223752098|NCT03486093|BEHAVIORAL|"Training and retraining to GAVECELT bundle recommendations"|"Physicians and nurses of RICU have been trained and retrained to GAVECELT bundle recommendations concerning the management of CVC. The bundle includes: hand hygiene and precautions for protection and safety, adequate insertion site, echo-guided placement of central venous line, use of clorexidine 2% for skin disinfection of insertion site chosen and subsequent continuous or discontinuous disinfection of exit site, use of suture-less devices, use of transparent semi-permeable dressing whenever applicable and immediate removal of catheter when no longer needed."
223604652|NCT03676140|DRUG|Ivermectin on Day 1|Ivermectin 200 µg/kg oral tablet Single Dose Treatment on Day 1
223604653|NCT03676140|DRUG|Diethylcarbamazine on day 1|Diethylcarbamazine 6 mg/kg oral tablet Single Dose Treatment on Day 1
223604654|NCT03676140|DRUG|Azithromycin on Day 1|Azithromycin 30mg/Kg oral tablet Single Dose Treatment On Day 1
223604655|NCT03676140|DRUG|Azithromycin on Day 8|Azithromycin 30mg/Kg oral tablet Single Dose Treatment On Day 8
223752099|NCT02918149|OTHER|Palpation Landmark Technique|"Clinician will follow routine palpation landmark technique procedure for LP, such as identification of anatomic landmarks by palpation (i.e., superior borders of the posterior iliac crest lies in parallel with L4 spinous process). Palpation will be followed by blind stick of the appropriate inter-spinous process space. The study member will have 2 attempts to complete the LP. A successful attempt is obtaining cerebrospinal fluid."
223604656|NCT00167310|DRUG|Eicosapentaenoic acid (omega-3 fatty acid)|2 g of Eicosapentaenoic acid in 4 x 500 mg capsules daily for baseline, 1 month, 2 months and 4 months
223604657|NCT00167310|DRUG|Placebo|2 g of Placebo (soy bean oil) in 4 x 500 mg capsules daily for baseline, 1 month, 2 months and 4 months
223604658|NCT02720406|DRUG|Intravenous ketamine0.5mg/kg|Intravenous ketamine 0.5mg/kg after anesthesia and before surgery.
223604659|NCT02720406|DRUG|Nebulized Ketamine 1mg/kg|Nebulized Ketamine 1mg/kg given by nebulizer before anesthesia.
223604660|NCT02720406|DRUG|Nebulized Ketamine 2mg/kg|Nebulized Ketamine 2mg/kg given by nebulizer before anesthesia.
223604661|NCT02720406|DRUG|saline placebo|Saline 0.9% given by nebulizer before anesthesia and iv after anesthesia and before surgery.
223604662|NCT00365040|PROCEDURE|Prk with mitomycin vs Lasik|
223604663|NCT06197620|OTHER|Thread embedding acupuncture and standard therapy|In the treatment, thread embedding acupuncture was performed using a needle containing polydioxanone (PDO) thread at the EX-B2 acupuncture point (12.5 mm lateral to the spinous process) at the level of the 1st lumbar vertebra with an insertion angle perpendicular to the skin surface. All patients are also given standard therapy after surgery in the form of intravenous Paracetamol 1000 mg, 3 times a day.
223604664|NCT05504005|DEVICE|Multi-channel Microspatial Offset Raman Scattering Spectroscopy (mμSORS) for Noninvasive Blood Glucose Detection|Blood glucose of participants were measured by venous plasma and multi-channel microspatial offset Raman scattering spectroscopy (mμSORS). The two measurements were collected synchronously and analyzed.
223752100|NCT02918149|DEVICE|Ultrasound-Assisted Technique LP|"Clinician will use an ultrasound-assisted technique to perform the LP. The Phillips CX50 ultrasound machine is an FDA approved device and will be used in accordance with its approved labeling. Spinal ultrasound will be performed using a linear high-frequency transducer to locate and mark the termination of the conus medullaris, the narrowing of the spinal canal, and the midline to delineate a safe zone. The study team member will have 2 attempts to complete the LP. A successful attempt is obtaining cerebrospinal fluid."
223752101|NCT03014323|DRUG|Galantamine|Galantamine 4 mg twice a day for 4 weeks
223752102|NCT03014323|DRUG|Placebo|Placebo 1 capsule twice a day for 4 weeks
223752103|NCT05441527|DEVICE|MI Paste, then, Biotene Dry Mouth Gel|1 milliliter of product will be applied daily to the intaglio (i.e., underside) of the patient's removable prosthesis and seated intraorally.
223752104|NCT05441527|DEVICE|Biotene Dry Mouth Gel, then, MI Paste|1 milliliter of product will be applied daily to the intaglio (i.e., underside) of the patient's removable prosthesis and seated intraorally.
223752105|NCT05083793|DRUG|Pregabalin 150mg|The effect of pregabalin on post-operative pain
223604665|NCT04954157|DIAGNOSTIC_TEST|Phase-1: Breath Holding Test|In this phase of the study, each subject will be asked to hold their breath for up to 60 seconds or until they can longer hold it. While they are holding their breath, subjects will be hooked up to a monitor that will measure their Peripheral oxygen saturation (SpO2) respiratory rate (RR), and heart rate (HR).
223604666|NCT04954157|DIAGNOSTIC_TEST|Phase 2: 6-Minute Walk Test (6MWT)|In this phase of the study, each subject will be asked to walk for 6 minutes in their hospital room or hallway. Their rate of perceived exertion will be measured while also hooked up to a monitor that will measure their Peripheral oxygen saturation (SpO2) respiratory rate (RR), and heart rate (HR).
223604667|NCT05921799|PROCEDURE|Blood specimen collection|Routinely collect citrate blood and native blood from patients as required by their condition.
223604668|NCT03540199|BIOLOGICAL|Activated CIK and CD3-MUC1 Bispecific Antibody in Treating Kidney Cancer|CIK cells was activated by PD-1 inhibitor and bispecific antibody of anti-CD3/MUC1
223752106|NCT05083793|OTHER|Placebo|patients will receive placebo one hour before operation
224200391|NCT05343793|OTHER|NIATx/MAT Academy|This two-day workshop will provide participating clinics with rationale, clinical practice and program integration with MOUD (Day 1), and an overview of NIATx principles and tools (Day 2).
223604669|NCT03540199|PROCEDURE|cryotherapy|the maximum tumor length≥2 cm，cool down the lesion,result in degeneration, necrosis or loss of the lesion.
223604670|NCT04921904|DRUG|Abemaciclib|150mg dose administered orally twice daily every day
223604671|NCT04921904|DRUG|Ramucirumab|8mg/kg iv every 2 weeks until evidence of disease
223604672|NCT00795301|DRUG|Capecitabine, Cetuximab, Oxaliplatin|
223604673|NCT04320901|DEVICE|Ligasure|Ligasure™ Maryland Jaw Laparoscopic Sealer/Divider 37cm
223604674|NCT04320901|DEVICE|Harmonic|Harmonic ACE 7+
223604675|NCT01665391|DRUG|fresolimumab|1 mg/kg total body weight administered intravenous (IV)
223604676|NCT01665391|DRUG|fresolimumab|4 mg/kg total body weight administered intravenous (IV)
223604677|NCT01665391|DRUG|Placebo|Placebo administered to match active treatment group
223604678|NCT01294969|DRUG|AL-4943A|Once daily topical ocular allergy medication used for 7 days
223752107|NCT05068128|OTHER|Flow MRI|"4 flow acquisitions based on the 2D cine phase contrast sequence (present on all MRI systems) will be performed.~This sequence requires a cardiac synchronization by a plethysmograph put on the patient's finger.~32 cardiac phases are reconstructed per acquisition. The processing of the flow MRIs and the analysis of the flow curves of the LCS and blood during the cardiac cycle will be performed using the Amiens software.~Parameters measured via flow MRI are:~\- Cerebral vascular flow, intracranial LCS dynamic volume, extracranial LCS dynamic volume"
223752108|NCT05068128|OTHER|PERFUSION TEST|"The test will be performed will include:~* Inserting a needle into the lumbar space, Ommaya reservoir or valve pre-chamber, as appropriate~* Connect the needle to the pressure transducer via saline filled manometer lines connected via a 3-way valve. The other end of the 3-way connection will be connected to a saline~* Recording of the opening pressure for 10 minutes~* The infusion test is terminated either when the pressure stabilizes again on a new plateau, or when the average pressure exceeds 40 mmHg, or in case of adverse effects or symptoms such as headache, nausea/vomiting or visual disturbances.~* At the end of the test, a depletion of 30 to 50 mL of CSF will be performed.~* The pressure recording during the test is then used to calculate the parameters of the mechanical properties of the CSF circulation and reported to the neurosurgeon ordering the test."
223604679|NCT06203769|DRUG|14-day antibiotic therapy|The studied intervention will be 14-day antibiotic therapy after removal of infected material
223604680|NCT06203769|DRUG|28-day antibiotic therapy|The comparator arm will be 28-day antibiotic therapy after removal of infected material
223752109|NCT00827255|DRUG|Cyclosporine Ophthalmic Emulsion 0.05%|One drop two times a day approximately 12 hours apart
223752110|NCT00897988|GENETIC|gene expression analysis|
223604681|NCT01178203|DRUG|Placebo|Placebo
223604682|NCT01178203|DRUG|Tramadol|Tab, 100mg in 6, 12 and 24 hours after root canal treatment
223604683|NCT01178203|DRUG|Novafen|325 mg in 6, 12 and 24 hours after root canal treatment
223604684|NCT01178203|DRUG|Naproxen|Tab, 500 mg in 6, 12, and 24 hours after root canal treatment
223604685|NCT00667849|DEVICE|Exogen 4000+|Low-intensity pulsed ultrasound (LIPUS)
223604686|NCT00667849|DEVICE|Sham|sham device identical to active device with the exception of administration of ultrasound
223604687|NCT01895959|DRUG|Euflexxa|Euflexxa will be injected weekly for 3 consecutive weeks on the knee joint.
223604688|NCT01895959|DEVICE|Magnetic Resonance Imaging (MRI)|MRI of the knee will be acquired during baseline (a week prior to the treatment), follow up visit 1 (1 week after treatment) and follow up visit 2 (3 months after treatment).
223604689|NCT03543137|DRUG|Nicotine Prototype Mini lozenge|A single dose of a prototype nicotine 4mg lozenge will be placed in participants mouth, occasionally moving it side to side. Allowing it to slowly dissolve and try to minimize swallowing. Participants will be instructed not to chew lozenge. The lozenge should be completely dissolved.
223752111|NCT00897988|GENETIC|mutation analysis|
223752112|NCT00897988|GENETIC|polyacrylamide gel electrophoresis|
223752113|NCT00897988|GENETIC|polymerase chain reaction|
223752114|NCT00897988|GENETIC|protein expression analysis|
223752115|NCT00897988|GENETIC|reverse transcriptase-polymerase chain reaction|
223752116|NCT00897988|OTHER|flow cytometry|
223604690|NCT03543137|DRUG|Nicorette Mini Lozenge|A single dose of a 4 mg nicotine polacrilex mini lozenge (Nicorette Minis) will be placed in participants mouth, occasionally moving it side to side. Allowing it to slowly dissolve and try to minimize swallowing. Participants will be instructed not to chew lozenge. The lozenge should be completely dissolved.
223604691|NCT06040853|DRUG|Tranexamic acid intravenous administration|Participants will be given 15mg/kg tranexamic acid before the incision in ten minutes, 100 mg/h will continue until the end of the surgery.
223604692|NCT06040853|DRUG|Saline|Participant was given intravenous 100 ml saline
223752117|NCT00897988|OTHER|immunoenzyme technique|
223752118|NCT00897988|OTHER|immunologic technique|
223752119|NCT00897988|OTHER|laboratory biomarker analysis|
223752120|NCT00897988|OTHER|pharmacological study|
223752121|NCT02064010|DRUG|SNC-102|Acamprosate calcium (SNC-102) tablet, administered orally for 4 weeks
223752122|NCT02064010|DRUG|Placebo|Placebo tablet, administered orally for 4 weeks
223752123|NCT05870033|DEVICE|Electromyography (EMG) measurement|Electromyography (EMG) measurement of m. quadriceps femoris and semitendinosus muscle during static functional tasks
223752124|NCT02158390|BEHAVIORAL|Jasper-EMT with words and AAC|"Jasper-EMT with words and AAC~A therapist plus parent implemented social communication intervention which include use of the iPad for a mode of communication. A total of 6 hour long workshops with the parent and 42 hour long intervention sessions with the child occur; half include the parent as therapist and occur in the home. The treatment lasts approximately 4 months."
223752125|NCT01085799|BEHAVIORAL|Health Education Intervention|This is a health hygiene education strategy which encourages the pro-active role of both teachers and students and changes in attitudes and practices with the aim of keeping the level of parasite infection low, through increased knowledge.
223604693|NCT00465023|PROCEDURE|Proton Beam Radiation|Once a day, 5 days a week (Monday-Friday) for 3 weeks.
223604694|NCT00995423|DEVICE|CoroflexTM Please|highly flexible CoroflexTM Please-Stent
223604695|NCT00995423|DEVICE|Paclitaxel-eluting stent|Paclitaxel-eluting stent
223604696|NCT04247295|DEVICE|Traditional Cast|Application of a traditional cast
223604697|NCT04247295|DEVICE|Woodcast|Application of a woodcast
223604698|NCT03116256|DIETARY_SUPPLEMENT|Very low calorie diet (VLCD)|All participants (including exercise group) will be using full daily meal replacement during the 6-week interventional period. The total meal supplement is 600 kcal/day.
223604699|NCT03116256|OTHER|High intensity interval training (HIIT)|Participants in this group will be having HIIT session three times per week under close medical supervision. This involves 60 sec high intensity cycling at 95-125% Watt Max, with 90s recovery, repeated 5 times, with 2 minutes warm up and cool down.
223604700|NCT03116256|OTHER|Resistance exercise training (RET)|The exercise format will be 2 sets of 12 repetitions at 70% 1-RM for each resistance regime, with 1-2 minutes rest between sets after a prescribed warm-up 3 sessions/week. The resistance regimes are: (3 upper body)chest press, latissimus pull down, seated lever row; (3 lower body) leg extension, leg curl, leg press. Participants will be alternating between upper and lower body exercise during each training session.
223604701|NCT02366156|DIETARY_SUPPLEMENT|Placebo|Three placebo capsules consumed prior to breakfast each day for 4 weeks
223604702|NCT02366156|DIETARY_SUPPLEMENT|Low Dose Grape Blend|Three low dose grape blend capsules consumed prior to breakfast each day for 4 weeks.
223604703|NCT02366156|DIETARY_SUPPLEMENT|High Dose Grape Blend|Three high dose grape blend capsules consumed prior to breakfast each day for 4 weeks.
223604704|NCT00118950|DRUG|Metformin|Tablet Metformin 500 mg; Dosage: 1000 mg two times daily. Duration: Four months.
223604705|NCT00118950|DRUG|Repaglinide|Tablet Repaglinide 1 mg; Dosage: 2 mg three times daily. Duration: Four months.
223604706|NCT00118950|DRUG|Placebo-Metformin.|Tablet Placebo (corresponding to 500 mg Metformin). Dosage: 2 tablets two times daily. Duration: Four months.
223604707|NCT00118950|DRUG|Placebo-Repaglinide.|Tablet Placebo (corresponding to 1 mg Repaglinide). Dosage: 2 tablets three times daily. Duration: Four months.
223604708|NCT00118950|OTHER|Diet-only.|Diet-only treatment. Duration: One month.
223752126|NCT05540834|DRUG|Alteplase|The enzyme tissue plasminogen activator that cleaves plasminogen to form plasmin.
223752127|NCT01599273|DRUG|subconjunctival triamcinolone injection|Patients are randomized into two groups: Injection (Group 1) and observation-only controls (Group II). In Group I, patients were treated with 1-3 injections of 20 mg triamcinolone acetate using a 30-gauge needle into the subconjunctival region of the lid between the conjunctiva and Muller's muscle. Injections were stopped after 1-2 injections if both swelling and retraction resolved completely, or if one eye scored 0 and the contralateral eye scored 1, and there existed no patient concern after physician inquiry regarding function and cosmetic appearance.
223752128|NCT01808430|PROCEDURE|VATS for confirmed non-small cell lung cancer (NSCLC)|Video-Assisted Thoracoscopic Surgery for NSCLC patients
223752129|NCT03895983|PROCEDURE|Percutaneous primary coronary intervention|Percutaneous primary coronary intervention
223752130|NCT03829748|PROCEDURE|Intermittent aspiration|Endoscopic ultrasound is done for the localization of the lesion and to localize the site of puncture.Prior to the puncture of the lesion the stylet is removed and a vacuum syringe is prepared with 10 cc of vacuum allowing the generation of continous pressure inside and connected to the end of the needle. Once the lesion is punctured 15 movements in and out of the lesions will be made while the syringe is opened and closed on and off for a total of 3 times each pass. A total of 4 passes will be done in each lesion.
223752131|NCT03921697|DEVICE|Werable sensors|Parkinson Disease Patients monitored by werable sensors
223752132|NCT03125434|OTHER|EOS full-spine, MRI, gait analysis|full-spine stereoradiography, high-resolution spine muscle MRI and 3D gait analysis will be performed
223752133|NCT02609334|DRUG|CRD007|One single dose given 3 hours prior to Mannitol challenge
223752134|NCT02609334|OTHER|Placebo|One single dose given 3 hours prior to Mannitol challenge
223752135|NCT01542385|PROCEDURE|Stent|Percutaneous coronary intervention: reperfusion with a thrombectomy catheter or a small balloon angioplasty catheter, followed by coronary stenting
223752136|NCT00896337|DEVICE|Epic™ Nitinol Stent System|The Epic™ Nitinol Stent System is comprised of two components: the implantable nitinol endoprosthesis and the stent delivery system.
223604709|NCT01760343|BIOLOGICAL|Berinert|Berinert is a plasma-derived C1 esterase inhibitor (human), supplied as a freeze-dried powder for reconstitution.
223604710|NCT01760343|BIOLOGICAL|CSL830|CSL830 is a formulation of Berinert.
223604711|NCT01052077|DRUG|OPC-34712|Tablets, Oral, 1 - 3 mg OPC-34712
223604712|NCT01052077|DRUG|Placebo|Placebo
223604713|NCT01052077|DRUG|ADT|
223604714|NCT00202956|DRUG|Bugusan|
223604715|NCT00520156|DEVICE|Continuous positive airway pressure (CPAP)|Patients diagnosed with obstructive sleep apnea (OSA) will be offered standard of care treatment of CPAP (patients given oral appliances for OSA are excluded from our study). Note: our study is a survey-based and observational study following patients who are being evaluated for sleep disorders. Those patients diagnosed with OSA would be offered CPAP or possibly an oral appliance regardless of whether they are entered into our study or not.
223604716|NCT04534322|DRUG|Melphalan Flufenamide|Melphalan flufenamide (melflufen) is an investigational peptide-drug conjugate (PDC) that targets aminopeptidases and rapidly releases alkylating agents into tumor cells.
223604717|NCT04534322|DRUG|Dexamethasone|Dexamethasone, a synthetic adrenocortical steroid, is a white to practically white, odorless, crystalline powder. It is stable in air. It is practically insoluble in water.
223752137|NCT00896337|DRUG|Anti-platelet therapy|Investigators must prescribe concomitant anti-platelet medication consistent with current clinical practice. Anti-platelet therapy should be administered preprocedure and continued throughout participation in the trial.
223752138|NCT00896337|DRUG|Anti-coagulation therapy|Anti-coagulation therapy must be administered during the procedure consistent with current clinical practice.
223752139|NCT04498728|OTHER|Mobile Health Application for Remote Monitoring|The use of the CATCH application (CATCH App), and any data and images obtained from the use of the CATCH App, will all be performed as standard of care for patients at Children's Mercy Kansas City, and will be for the clinical treatment of patients. Data will be collected for the repository for all patients submitting data through the use of the CATCH App. Clinical care team will follow the patients after discharge home from the hospital.
223752140|NCT05752110|DRUG|Ketamine|0,5mg/kg single dose Ketamine (0.05ml/kg) intravenously administered
223752141|NCT05752110|OTHER|Saline|0.09% Saline (0.05ml/kg) intravenously administered
223752142|NCT04083807|BIOLOGICAL|TISSEEL Lyo|The dose to be applied is governed by variables including the type of surgical intervention, the size of the affected area and the mode of intended application, and the number of applications.. The guideline for sealing surfaces is one package of Tisseel Lyo 2 ml (i.e. 1 ml sealer protein solution plus 1 ml thrombin solution) is sufficient for a surface of at least 10 cm2.
223752143|NCT04083807|PROCEDURE|Manual compression with surgical gauze pads|Surgical 4x4 inches gauze pads
223752144|NCT03854422|DEVICE|left position|colonoscopy will be performed in 3 different locations. Left position, the patient will be in the left-side position during the entire colonoscopy
223752145|NCT03854422|DEVICE|left supine position|Colonoscopy in the Left supine position
223752146|NCT03854422|DEVICE|dynamic position|Colonoscopy in the Dynamic position
223752147|NCT03686410|BEHAVIORAL|Web-based Therapeutic Educational Intervention|"The subjects assigned to this group will follow a web-based therapeutic educational intervention on pain and poor sleep quality.~All the subjects assigned to this intervention will have free access to the website from any device with internet access and will be able to consult it as many times as they wish during the intervention. The intervention will last for four weeks."
223752148|NCT03686410|OTHER|Conventional Treatment|"The subjects assigned to this condition will continue with their usual treatment is based on the recommendations of the clinical practice guideline for the treatment of fibromyalgia Guide of Fibromyalgia developed by the Department of Health of the Generalitat de Catalunya and the Servei Català de Salut."
223752149|NCT04070131|OTHER|Horse-Assisted Rehabilitation|One hour weelky session of hippotherapy.
223752150|NCT00139828|DRUG|human coagulation Factor IX|
223752151|NCT01124643|BIOLOGICAL|Replagal|0.2 mg/kg administered intravenously \[IV\] every other week
223752152|NCT00977132|DRUG|Valproic aicd|"Treatment with VPA starts at day1, the dose ist slowly increase according to the following scheme~day morning dose midday dose evening dose contents of 1 tablet~1+2 0 0 1 500 mg~3+4 ½ 0 1 500 mg~5+6 1 0 1 500 mg~7+8 1 ½ 1 500 mg~9+10 1 1 1 500 mg~11+12 1 1 1 500 mg~In the morning of day 13 trough level of VPA will be checked. The target range will be 50-110 µg/l. The dose of VPA will be adjusted depending on the trough level. In the first eight weeks of therapy weekly controls of VPA levels are required. Thereafter, VPA levels will be checked every four weeks."
223508089|NCT07048405|OTHER|Cooling|Participants will undergo cold exposure during the baseline and final visits (2.5 hours each visit), as well as throughout the 10-day cold acclimation period (2 hours per day). This will be achieved using water-perfused blankets set to individualized temperatures, selected to elicit comparable physiological responses across participants.
223752153|NCT00977132|DRUG|Lenalidomide|"5 mg/day, continuous therapy~Dosing will be in the morning at approximately the same time each day. Capsules may be taken before or after a meal.~Only one cycle of study drug (28 days) will be supplied to the patient every four weeks"
223508090|NCT07048405|PROCEDURE|Biopsies|"Under local anesthesia, biopsies will be obtained from the following sites:~* Brown adipose tissue from the supraclavicular (collarbone) region, guided by computed tomography (CT).~* White adipose tissue from the abdominal (periumbilical) area.~* Skeletal muscle from the outer thigh, specifically the vastus lateralis.~These biopsies will be performed both before and after the 10-day cold acclimation protocol."
223508091|NCT07048405|RADIATION|Injection of 18F-FDG|Intravenous injection of 18F-FDG will be performed after 2 hours of cold exposure. This will be followed by a 30min dynamic total PET/CT scan while cold exposed using water-perfused blankets. These procedures will take place before and after the 10 day-cold acclimation protocol.
223508092|NCT07048405|OTHER|Indirect calorimetry|Participants will rest quietly while oxygen consumption and carbon dioxide production are continuously recorded using a indirect calorimeter. These data will be used to calculate energy expenditure and respiratory exchange ratio. This procedure will take place before and after the 10 day-cold acclimation protocol.
223508093|NCT07048405|OTHER|Electromyogram|Skin surface electrodes will be placed on major skeletal muscles to measure shivering and muscle activity during both warm and cold conditions. This procedure will take place before and after the 10 day-cold acclimation protocol.
223508094|NCT07048405|OTHER|Core and skin temperature monitoring|"Participants will ingest an electronic capsule that wirelessly and continuously monitors core body temperature. This procedure will be conducted before and after the 10-day cold acclimation protocol.~Additionally, wireless temperature sensors will placed at multiple standardized sites on the body to measure skin temperature. This procedure will be performed before, during, and after the 10-day cold acclimation protocol."
223508095|NCT07055581|DRUG|Induction Durvalumab +etoposide/platinum +Radiochemotherapy+ durvalumab maintenance|"Drug: Durvalumab~Induction Phase: Durvalumab (1500mg D1 IV Q3W) combined with EP \[cisplatin or alternatively Carboplatin (AUC 5-6 D1) and Etoposide (100 mg/m² (BSA) D1-3) once every 3 weeks\] for minimum two cycles prior to thoracic radiotherapy Consolidation Phase: Durvalumab (1500 mg once every 4 weeks) until PD or unacceptable toxicities or for a maximum of 24 months, whichever occurs first.~Drug: Chemotherapy Concomitant chemoradiotherapy consists of further four cycles Etoposide (100 mg/m² D1-3), cisplatin (75 mg/m² D1) /carboplatin (AUC 5-6 D1) q3w~Radiation: Thoracic Radiotherapy Radiotherapy to the primary tumor is recommended to start with the 3rd cycle of EP, which can be delayed appropriately per investigator's decision. 60±6 Gy, 1.8-2 Gy/d or 45±1.5 Gy (1.5 Gy per fraction twice daily, with 4 hours or more between fractions) or other biologically equivalent regimens will be delivered."
223508096|NCT07056361|DEVICE|Direct cortical stimulation and deep brain stimulation of motor thalamus|All participants enrolled will undergo implantation of deep brain stimulation electrode leads for treatment of movement disorders. In addition to standard-of-care subcortical mapping using micro-electrode recording (MER) and macrostimulation mapping during DBS placement, cortical local field potentials (LFPs) will be simultaneously recorded from primary motor (M1) and somatosensory (S1) cortical areas by placement of a temporary strip electrode (1X6) in the subdural space. The strip electrode over M1 will be used to produce motor evoked potentials to contralateral hand muscles from direct cortical stimulation (DCMEPs). Cortical and subcortical LFPs will be obtained alongside electromyographic (EMG) data while the patient performs contralateral upper extremity movement tasks and a variety of articulation exercises.
223508097|NCT07056439|DRUG|HRS-1738 Injection|HRS-1738 injection.
223508098|NCT07056738|DIAGNOSTIC_TEST|imaging|OCT, OCTA, RNFL-OCT, fundus autofluorescence, fundus imaging, flaremeter, fundus and slit lamp examination
223508099|NCT00575302|DRUG|Gonal-f®: follitropin alpha|Gonal-f®: follitropin alpha, administration of 300 U
223508100|NCT00575302|DRUG|Gonal-f®: follitropin alpha|Gonal-f®: follitropin alpha, administration of 450 U
223508101|NCT00862589|OTHER|GLP-1 infusion|physiological effect of GLP-1
223508102|NCT02994680|DEVICE|Three-burner LPG stove|The intervention arm will receive a three-burner LPG stove upon enrollment. The control arm will receive the stove one year after enrollment.
223508103|NCT02994680|OTHER|Delivery of LPG tanks|One year supply of LPG fuel, in the form of delivery of 20 kg tank that holds 10 kg of LPG. Delivered to homes.
223508104|NCT02994680|OTHER|Vouchers for LPG tanks|One year supply of LPG, in the form of vouchers to obtain a free LPG tanks from a distribution center. (Beginning one year after enrollment, for one year)
223752154|NCT05544838|DEVICE|LMA insertion with standard technique|"Standard LMA insertion technique; LMA held like a pen and index finger placed at the junction of LMA tube and cuff. Index finger used to press LMA against hard palate and posterior pharyngeal wall until definite resistance felt at the base of hypopharynx. LMA then held with non- dominant hand and index finger removed.~Rotational LMA insertion; LMA inserted like guedel airway insertion: LMA proximally grasped close to anaesthesia circuit attachment. Insertion was conducted with LMA cuff facing towards nose, hard palate and then advanced into the base of hypopharynx until resistance was felt. At this point, LMA rotated at 180 degree anti-clockwise and LMA tube black line positioned and confirmed on the nasal side."
223752155|NCT04903405|OTHER|No intervention|No intervention is involved in this study
223752156|NCT04851899|DIETARY_SUPPLEMENT|Phaeosol low dose|1 Phaeosol softgel of 440mg/day and 1 placebo softgel of 500mg/day (look like softgel of Phaeosol product) + 1 capsule of 440mg/day of natural stimulant Subjects were instructed to take the study supplement or placebo once daily for 1 months (±2 days). The first and the last doses will be administered at the clinical site during Visit 2 (Experiment 1) and Visit 3 (Experiment 2, respectively).
223752157|NCT04851899|DIETARY_SUPPLEMENT|Phaeosol high dose|2 Phaeosol softgels of 440mg/day + 1 capsule of 440mg/day of natural stimulant. Subjects were instructed to take the study supplement or placebo once daily for 1 months (±2 days). The first and the last doses will be administered at the clinical site during Visit 2 (Experiment 1) and Visit 3 (Experiment 2, respectively).
223752158|NCT04851899|DIETARY_SUPPLEMENT|Placebo|2 placebo softgels of 440mg/day (look like softgel of Phaeosol product) + 1 capsule of 500mg/day containing Microcellulose (look like capsule of natural stimulant). Subjects were instructed to take the study supplement or placebo once daily for 1 months (±2 days). The first and the last doses will be administered at the clinical site during Visit 2 (Experiment 1) and Visit 3 (Experiment 2, respectively).
223752159|NCT01541137|DRUG|Diclofenac|oral diclofenac 75 mg, a 44-hour iv-infusion of diclofenac 150 mg/24h, oral diclofenac 75 mg x 2, IV-PCA programmed with morphine boluses of 2-3 mg and a lock-out time of 5-15 minutes
223752160|NCT01541137|DRUG|parecoxib/ valdecoxib|oral valdecoxib 40 mg, a 44-hour iv-infusion of parecoxib 80 mg/24h, IV-PCA programmed with morphine boluses of 2-3 mg and a lock-out time of 5-15 minutes
223752161|NCT01541137|DEVICE|patient controlled epidural analgesia|epidural catheter, epidural loading dose of 1 ml/10 kg of 0.15% bupivacaine with fentanyl 6 µg/ml. Thereafter a continuous infusion was started at 1 ml/10 kg/h. In the PACU PCEA-patients could take incremental doses of 3 ml with a 8-15 min lock-out time
223752162|NCT03762382|DRUG|TFV/LNG IVR|TFV/LNG IVR is an intravaginal ring that releases approximately 8-10 mg/day of TFV and approximately 20ug/day of LNG to be used for 90 continuous days.
223752163|NCT03762382|DRUG|TFV IVR|TFV IVR is an intravaginal ring that releases approximately 8-10mg/day of TFV to be used for 90 continuous days.
223604718|NCT06025409|DRUG|Leuprolide Acetate 11.25 MG/ML|Subcutaneous injection
223604719|NCT05155774|DEVICE|Twin block|Twin Block orthodontic appliance for treating patients with Angle class II molar relationship and a large horizontal overjet, often in combination with an incomplete lip closure
223604720|NCT03512379|DEVICE|TIANJI Robot|A robotic system for spinal surgery
223604721|NCT03512379|DEVICE|Fluoroscopy|For fluoroscopy-based free hand surgery
223604722|NCT03512379|DEVICE|Navigation|For navigation-assisted spinal surgery
223604723|NCT03288922|PROCEDURE|Limited BF OL-HDF with SHF|"The new modality Limited BF OL-HDF with SHF were performed using Fresenius 5008 hemodiafiltration machine. The prescribed blood flow rate was 300 ml/min and the total dialysis fluid flow rate was 800 ml/min which included pre-filter substitution rate of 150 ml/min. The super high-flux dialyzer was PES-17Dα from Nipro Corporation, Japan which contains 1.7 m2 hollow fiber polyethersulfone membrane (ultrafiltration coefficient 80 ml/h/mmHg; urea clearance 267 ml/min, Qb 300 ml/min and Qd 500ml/min). The patients were received this treatment thrice-a-week for 2 week before entering the wash-out period and crossover to another arm."
223604724|NCT03288922|PROCEDURE|High-efficiency OL-HDF|"The controlled modality High-efficiency OL-HDF were performed using Fresenius 5008 hemodiafiltration machine. The prescribed blood flow rate was 400 ml/min and the total dialysis fluid flow rate was 800 ml/min which included post-filter substitution rate of 100 ml/min. The standard high-flux dialyzer that was used was HF80s from Fresenius Medical Care, Germany contains 1.8 m2 hollow fiber polysulfone membrane (ultrafiltration coefficient 55 ml/h/mmHg; urea clearance 248 ml/min, Qb 300ml/min and Qd 500 ml/min). The patients were received this treatment thrice-a-week for 2 week before entering the wash-out period and crossover to another arm."
223604725|NCT01775605|DRUG|Synera|Synera Pain Patch
223752164|NCT03762382|DRUG|Placebo IVR|Placebo IVR is an intravaginal ring containing no active experimental ingredients to be used for 90 continuous days.
223752165|NCT03215329|PROCEDURE|abdominal or vascular surgery|Intermediate or high risk abdominal or vascular surgery
223752166|NCT04620083|OTHER|Integrative Learning Program for Old People with Dementia|The program included modalities for reality orientation, daily living skills training, reminiscence therapy, multisensory stimulation, fall prevention program, mindfulness activities, Meridian exercise, brain health program (Four Arts of the Chinese Scholar which referred to zither, go, calligraphy and painting) and health education. It was also agreed that case managers, caregivers, and participants were free to choose these treatments or could be assigned to a treatment regime on a 'mix and match' basis to suit their personality traits for improving their abilities to meet their own needs. This program was developed by the team using Delphi technique.
224200392|NCT05343793|OTHER|NIATx-Internal Facilitation (NIATx-IF)|Internal facilitators will receive training (in-person or online) on how to provide coaching within their organization. For 9-months, Internal Facilitators (IFs) will: a) support teams to harness resources toward systemic change and improvement; b) employ a range of concepts and tools to provide individualized support to teams; c) help teams to practice and hone their skills to optimize performance, and d) focus on team relationships and communications.
223604726|NCT00002847|BIOLOGICAL|aldesleukin|
223604727|NCT00002847|BIOLOGICAL|recombinant interferon alfa|
223604728|NCT00002847|PROCEDURE|conventional surgery|
223604729|NCT03172572|PROCEDURE|Minimally invasive pancreatoduodenectomy|Laparoscopic, robot-assisted, or hybrid resection
223604730|NCT03172572|PROCEDURE|Open pancreatoduodenectomy|Open resection
223604731|NCT02465203|DRUG|Previous treatment in DEB025 study|Follow-up after DEB025 active study
223752167|NCT03322215|DRUG|Palbociclib|75-125 mg capsule orally once daily for 21 consecutive Days followed by 7 Days of treatment.
224200393|NCT05343793|OTHER|NIATx-External Facilitation (NIATx-EF)|For 9-months, organizations in the NIATx-EF study arm will work with one of 4 experienced consultant NIATx External Facilitators (EFs). The EF meets with clinic staff to plan change projects, review ongoing change efforts, discuss successes, and offer guidance on planning future change projects using PDSA cycles. The EF makes a 1-day site visit during the 1st quarter of the implementation period and leads monthly 1-hour phone calls.
223604732|NCT03779087|DRUG|10d TL quadruple therapy|esomeprazole 40 mg bid., tripotassium dicitrate bismuthate 300mg qid, tetracycline 500 mg qid, levofloxacin 500 mg qd.
223604733|NCT03779087|DRUG|10d AL quadruple therapy|esomeprazole 40 mg bid., tripotassium dicitrate bismuthate 300mg qid, amoxicillin 500 mg qid, levofloxacin 500 mg qd.
223604734|NCT03689816|PROCEDURE|sleeve gastrectomy|sleeve gastrectomy
223604735|NCT03689816|PROCEDURE|gastric bypass|gastric bypass
223604736|NCT05526898|DEVICE|SyntrFuge System|Microsized Adipose Tissue
223604737|NCT05526898|DRUG|Triamcinolone Injection|Corticosteroid
223604738|NCT05819320|OTHER|observe pattern of mucocutaneous manifestations in chronic kidney disease patients|"1. To study the patterns of mucocutaneous disorders in Chronic Kidney Disease patients .~2. Comparison of the patterns of mucocutaneous manifestations and their correlation with the different stages of Chronic Kidney Disease"
223604739|NCT02387554|DRUG|HGP0904|
223604740|NCT02387554|DRUG|HGP0608|
223604741|NCT02387554|DRUG|HGP1405|
223604742|NCT06394245|OTHER|Progressive muscle exercises|The initiative was made with the Turkish Psychologists Association's Progressive Relaxation Exercises audio recorded. PGE consists of a recording of breathing exercises and progressive muscle stretching exercises, with music in the background that will relax the patient. The first part of the recordings takes approximately 10 minutes. It continues and includes information about the definition of relaxation exercise, its purpose, benefits and points to consider when starting the exercises, correct breathing in the appropriate position and what the environment should be like. The second part consists of how to contract and relax certain muscles in our body, which takes approximately 25-30 minutes, and the steps to exit this process after the relaxation session is over.
223604743|NCT00042991|DRUG|gefitinib|Given orally
223604744|NCT00042991|RADIATION|radiation therapy|Undergo standard brain irradiation
223604745|NCT00042991|OTHER|pharmacological study|Correlative studies
223604746|NCT00042991|OTHER|laboratory biomarker analysis|Correlative studies
223752168|NCT03322215|DRUG|Fulvestrant|500 mg intramuscularly Days 1 and 15 of cycle 1, and then on Day 1 of each subsequent 28-days cycle.
223752169|NCT03322215|DRUG|Capecitabine|Oral tablet 500 - 1,250 mg/m2 twice Daily, for 2 weeks followed by 1 week of rest.
223604747|NCT05312294|BIOLOGICAL|Flu-M [inactivated split influenza vaccine] without preservative|Solution for intramuscular injection, 0.5 ml
223604748|NCT05312294|BIOLOGICAL|Flu-M [inactivated split influenza vaccine] with preservative|Solution for intramuscular injection, 0.5 ml
223604749|NCT02223806|BEHAVIORAL|Uterine Tonus Assessment by Midwife|Uterine tonus assessment every 15 minutes for 2 hours.
223604750|NCT02223806|BEHAVIORAL|Patient self-assessment of uterine tonus|Uterine tonus assessment by patient every 15 minutes for 2 hours.
223604751|NCT04188145|DRUG|Fluoropyrimidine|"Option 1: Capecitabine 1250 mg/m2 twice daily (i.e. 2500 mg/m²/d) (D1 to D14, D1 = D22) For frail patients according to investigator evaluation capecitabine dose may be reduced to 1000 mg/m2 twice daily (2000 mg/m²/d).~Or Option 2: Capecitabine 625 mg/m2 twice daily (i.e. 1250 mg/m²/d) (D1 to D21, D1 = D22) Or Option 3: LV5FU2 simplified (folinic acid 200 mg/m² (or Elvorin 400 mg/m²) IV during 2h followed by 5-FU bolus IV of 400 mg/m² during 10 min and IV continuous 5-FU at 2400 mg/m² during 46h). (D1=D15)."
223604752|NCT04188145|DRUG|Bevacizumab|"Option 1 and Option 2 : D1 bevacizumab 7.5 mg/kg IV (D1=D21). See smPCs for infusion time of bevacizumab.~Or Option 3: D1 bevacizumab 5 mg/kg IV (D1=D15). See smPCs for infusion time of bevacizumab"
223604753|NCT03770117|PROCEDURE|Prehabilitation|Participants who underwent Prehabilitation will have their CT scans analysed.
223604754|NCT03770117|PROCEDURE|Standard Procedure|Patients who underwent a panctratoduodenectomy and did not receive any Prehabilitation will have their CT scans analysed and compared.
223604755|NCT05506527|OTHER|Sensorimotor program and plyometric exercise|"Children in study group A will receive combined plyometric exercises (vertical paradigm) and sensorimotor program~\- Children of the study group B will receive sensorimotor program alone."
223604756|NCT04072887|DRUG|QBW251|QBW251 oral capsules (450, 300, 150, 75 and 25 mg) of identical appearance to ensure blinding administered twice a day (b.i.d) for 24 weeks
223604757|NCT04072887|DRUG|Placebo|Placebo oral capsules administered twice a day for 24 weeks
223604758|NCT04072887|DRUG|COPD maintenance background therapy|Combination of fluticasone furoate, vilanterol and umeclidinium bromide
223604759|NCT00988572|OTHER|Vestibular rehabilitation|The intervention program comprises of vestibular rehabilitation, at group sessions, twice a week for 9 weeks. The program is described in detail in table 1. Vestibular rehabilitation aims to facilitate rearrangement and recruitment of the control capacities of the vestibular system, by letting the patient be exposed to unstable body positions, such as standing on foam and performing head, trunk or eye-movements.
223604760|NCT03939936|OTHER|Psoriatic measurements|Psoriasis Area and Severity Index (PASI) was performed baseline and after 8 weeks. Saliva samples were taken from patients for the evaluation of proinflammatory cytokine baseline and after 8 weeks.
223752170|NCT02704078|DEVICE|EBUS-TBNA|EBUS-TBNA - Patients in the Active comparator arm shall undergo mediastinal lymph node aspiration transtracheally using the EBUS scope
223752171|NCT02704078|DEVICE|EUS-B-FNA|EUS-B-FNA - Patients in the experimental arm EUS-B-FNA shall undergo mediastinal lymph node aspiration transesophageally using the EBUS scope
223752172|NCT00002115|DRUG|Adefovir|
223752173|NCT02363725|DRUG|Colchimax®|
223752174|NCT02363725|DRUG|Conventional treatment|
224200394|NCT04180371|DRUG|BT5528|Participants will receive a 60-minute intravenous infusion of BT5528 once a week (Days 1, 8, 15, and 22) or every other week (Days 1 and 15) on a 4-week cycle at the selected dose.
224200395|NCT04180371|DRUG|Nivolumab|Participants will receive nivolumab at 480mg intravenous infusion every 4 weeks.
223752175|NCT02803307|DRUG|TLC599|Single dose via intra-articular injection
223604761|NCT03939936|OTHER|Non-surgical periodontal treatment|Non-surgical periodontal treatment was performed baseline and after 8 weeks. Saliva samples were taken from patients for the evaluation of proinflammatory cytokine baseline and after 8 weeks.
223604762|NCT03939936|OTHER|saliva samples|Saliva samples were taken from patients for the evaluation of proinflammatory cytokine baseline and after 8 weeks.
223604763|NCT03193736|DEVICE|MINIject implant|"MINIject implant is used to reduce intra-ocular pressure (IOP) in the eye through a minimally-invasive Glaucoma surgical intervention.~The intervention is to be performed as stand-alone surgery."
223604764|NCT00423449|DRUG|vorinostat|Dose escalation study: vorinostat 300-500 mg capsules once daily for 7-14 days in continuous cycles of 21 days
223604765|NCT00423449|DRUG|Gemcitabine|Dose escalation study: Gemcitabine 1000-1250 mg/m2 will be given for 2 days in each 21 day cycle
223604766|NCT00423449|DRUG|Platinum-based agent|Cisplatin IV 75 mg/m2 will be given for 1 day in each 21 day cycle or carboplatin dosed according to renal function.
223604767|NCT02697435|OTHER|Patient-Centered Care|Patient-centered care will be directed by geriatricians who have been trained to assess and treat 11 conditions that commonly affect chronic low back pain. Treatments may involve behavioral components, physical therapy, or medical treatments such as cortisone shots, depending on the patient's needs.
223604768|NCT02697435|OTHER|Imaging-Directed Care|Imaging-Directed Care will allow patients to follow-up their initial imaging with whatever course they (and/or their doctor) chose, should they chose to follow any course at all.
223604769|NCT01670435|DRUG|Ciprofloxacin (BAYQ3939)|Patient treated with Ciproxan as a first line treatment in daily clinical practice
223604770|NCT03433352|DRUG|Methimazole Pill|Patients who developed GD received methimazole treatment
223604771|NCT03433352|DRUG|Propylthiouracil Pill|Patients who developed GD received propylthiouracil treatment
223604772|NCT05165758|OTHER|Self-assessment questionnaires|Subjects will pass the SF-36 score (mental health items) and the EPICES index
223604773|NCT00344422|DRUG|Vincristine, DOXIL (doxorubicin HCl liposomal injection), and Dexamethasone (VDD) vs. Vincristine, Doxorubicin and Dexamethasone (VAD)|
223604774|NCT00305149|PROCEDURE|interim therapy scintigraphy study gallium scan or PET/CT|
223752176|NCT03858946|PROCEDURE|Simple trapeziectomy|A curvilinear incision is made over the base of the 1. metacarpal towards the tendon of the extensor pollicis brevis in the distal part of the anatomical snuffbox. The joint is opened as widely as possible and the trapezium is dissected free in a proximal direction until the articulation with the scaphoid is reached. Then trapezium is removed taking care not to damage tendon of the flexor carpi radialis. The joint capsule is closed and skin sutured in the usual manner. At the completion of the procedure two small shame incision are made (1 cm each) involving only epidermis on the volar aspect of the palm and forearm. Each of them will be closed with one stitch
223752177|NCT03858946|PROCEDURE|Weilby|The first part of the surgical procedure is identical to simple trapeziectomy. In addition, the tendon sheath of the first extensor compartment is divided. After this, a strip consisting of approximately one-third of flexor carpi radialis tendon is dissected using two small incisions on the volar aspect of the wrist and distal forearm. The distally based tendon strip is tunneled to its insertion on the second metacarpal bone. Then the strip of tendon is winded around the abductor pollicis longus tendon and the rest of the tendon at least twice, pulling those tendons together into the space created after excision of the trapezium. The tendons are sutured together with non-absorbable sutures while the skin is sutured in the usual manner
223752178|NCT03389464|BEHAVIORAL|computer-based confrontation with dysfunctional beliefs|"Patients will be presented with a virtual agent confronting them with their dysfunctional core beliefs (e.g. You are worthless). Participants will be instructed to contradict these virtual agents (e.g. That's not true, I'm a wonderful person)."
223752179|NCT02678676|OTHER|No Intervention|Participants who previously received Pioglitazone in the PROactive study (NCT00174993).
223752180|NCT02678676|OTHER|No Intervention|Participants who previously received pioglitazone-matching placebo in the PROactive study (NCT00174993).
223752181|NCT00747435|DEVICE|Electric Acoustic System|Combination of a cochlear implant and a hearing aid
223752182|NCT06327399|DRUG|Dexmedetomidine infusion|patients will receive Dexmedetomidine infusion dose of 1 mcg/kg over 10 min before induction.
223604775|NCT00305149|PROCEDURE|"interim gallium or PET/CT"|
223752183|NCT06327399|DRUG|Dexmedetomidine bolus|patients will receive Dexmedetomidine bolus dose of 0.3 mcg/kg over 60 seconds.
223752184|NCT06327399|DRUG|Atropine Sulfate|If heart rate falls below 45 bpm, rescue dose (500 mcg) of atropine will be given.
223752185|NCT06327399|DRUG|Ephedrine|If mean blood pressure decreases below 50 mmHg, boluses of 10 mg ephedrine will be given
223752186|NCT06327399|DRUG|Propofol|Propofol 20 mg boluses till loss of contact
223752187|NCT00385242|PROCEDURE|Positron emission tomography: FDG viability imaging|FDG PET viability imaging
223752188|NCT00385242|OTHER|PET imaging|PET viability imaging
224200396|NCT00638118|DRUG|Fexofenadine|
223604776|NCT03325036|DIAGNOSTIC_TEST|Serum levels of immunologic profiles|Serum levels of immunologic profiles before and after chemoradiotherapy
223604777|NCT04008251|GENETIC|Second generation humanized CAR-T cells|Patients receive humanized CD19 CAR-T cells transduced with a lentiviral vector on days 0/1/2 in the absence of disease progression or unacceptable toxicity.
223604778|NCT00053872|DRUG|cisplatin|
223604779|NCT00053872|DRUG|lomustine|
223604780|NCT00053872|DRUG|vincristine sulfate|
223604781|NCT00053872|PROCEDURE|adjuvant therapy|
223604782|NCT00053872|RADIATION|radiation therapy|
223604783|NCT02860572|OTHER|follow-up without intervention|
223604784|NCT02860572|OTHER|fluid bolus|
223604785|NCT02178696|OTHER|Placebo, identified as placebo to participants|White tablets
223604786|NCT02178696|DRUG|Celexa or other antidepressant as clinically indicated|Open label s-citalopram, 20 mg start up dose, increasing to 40 mg as clinically indicated; If prior non-response to this medication is noted by the patient, alternative treatments may include another first-line antidepressant:fluoxetine 20 mg; paroxetine up to 60 mg; sertraline up to 200 mg; bupropion up to 300 mg
223604787|NCT02178696|OTHER|"Placebo, identifed to participants as Active medication"|Blue Capsule
223604788|NCT01273324|DEVICE|ADM Cup|ADM Cup
223604789|NCT05814952|GENETIC|LX103 Injection|Qualified subjects will receive a single unilateral intravitreal injection of LX103 at Day 0 in the trial.
223752189|NCT00109395|DRUG|Lorazepam|Intravenous dosage forms, administered at dose and frequency per protocol in order to achieve adequate sedation as measured by the Comfort score
223752190|NCT00109395|DRUG|Midazolam|Intravenous dosage forms, administered at dose and frequency per protocol in order to achieve adequate sedation as measured by the Comfort score
223752191|NCT00109395|DRUG|Lorazepam CI|Intravenous dosage forms, administered at dose and frequency per protocol in order to achieve adequate sedation as measured by the Comfort score
223752192|NCT00267722|DRUG|Visilizumab|
223752193|NCT05403879|PROCEDURE|fixation of greater tuberosity fractures|deltopectoral approach for shoulder, then open reduction and fixation of displaced greater tuberosity fractures using hooked Kirshner wires
223604790|NCT00240500|BIOLOGICAL|Engerix™-B|In the primary study, subjects received HBV (10 milligram) vaccine according to a 0, 1 and 2 month schedule with a booster dose at Month 12. Subjects in the 5-dose vaccination regimen received a booster dose of HBV vaccine at Month 60.
223752194|NCT05209022|DIETARY_SUPPLEMENT|Beetroot juice|140 mL of beetroot juice or beetroot juice placebo
223752195|NCT00302133|DRUG|Naltrexone hydrochloride|Naltrexone hydrochloride 50 mg capsule daily for 12 weeks
223752196|NCT00302133|OTHER|Placebo|Placebo arm
223752197|NCT06254053|OTHER|zirconia reinforced glass ionomer|Restorative material
223604791|NCT04371666|DRUG|Pamrevlumab|Pamrevlumab per dose and schedule specified in the arm description
223604792|NCT04371666|DRUG|Placebo|Matching placebo per schedule specified in the arm description
223604793|NCT04371666|DRUG|Corticosteroids|Systemic deflazacort or equivalent potency of corticosteroids administered orally
223752198|NCT06254053|OTHER|Glass ionomer cement|Restorative material
223752199|NCT01988116|DRUG|Oral Calcitriol 0.5 mcg once daily for 6 weeks|
223752200|NCT01988116|DRUG|Placebo|
223752201|NCT03437109|DIAGNOSTIC_TEST|Laboratory tests|Testosterone HSBG Hb1Ac LH
223752202|NCT02418858|PROCEDURE|Deep Brain Stimulation surgery|Deep Brain Stimulation surgery awake vs. asleep
223604794|NCT03473899|DEVICE|rESWT|"rESWT will be performed as follows:~* Nine rESWT sessions~* Three sessions per week~* rESWT device: Swiss DolorClast (Electro Medical Systems, Nyon Switzerland), EvoBlue handpiece, 15 mm applicator~* 2500 rESWs per session, with energy density between 0.12 and 0.16 mJ/mm\^2, depending on what the patient tolerates~* rESWs applied at 15 Hz~* Application of rESWs in prone position, with the patient lying on an examination table~* Exact location of the application of rESWs determined by clinical and ultrasonographic examinations~* Treatment of both the side of injury and the entire affected muscle (from distal to proximal in order to relax the affected muscle)~* No use of local anesthesia.~In addition, patients will receive a specific rehabilitation program."
223604795|NCT03473899|DEVICE|Sham-rESWT|"Sham-rESWT will be performed as rESWT described in Arm rESWT + RP, but with a specially designed placebo EvoBlue handpiece that looks and sounds like the EvoBlue handpiece of the Swiss DolorClast, but does not generate radial shock waves. This is achieved by blocking the projectile shortly before it strikes the metal applicator. The placebo EvoBlue handpiece will not emit any radial shock wave energy.~In addition, patients will receive a specific rehabilitation program."
223604796|NCT06070909|DEVICE|The EMG activations|The EMG activations of the middle trapezius, posterior deltoid and infraspinatus muscles in the dominant limb were recorded during exercises in standing external rotation (SER), side-lying position (SDER), scapular plane (SPER) and muscle architecture-based (MABER) positions
223604797|NCT01781559|DIETARY_SUPPLEMENT|phenolic acid|phenolic acid
223604798|NCT00801398|DRUG|Oxymorphone IR|Open-label, 2 part, ascending dose, single and multiple dose q4-6 hrs up to 48 hrs
223752203|NCT05016388|OTHER|Collaborative Multidimensional Model (CMD)|The teams enrolled in the CMD intervention will have a 22-hour training that integrates current knowledge of depression with skills for the management of functional variables, interpersonal, social, emotional regulation, and history of biographical adversity from childhood considering the trauma informed care paradigm. After the training, the PHC teams will implement the depression treatment according to a collaborative model.
223752204|NCT05016388|OTHER|Standard Model (SM)|The teams enrolled in the SM intervention will have a 22-hour training that integrates the current national clinical guide for Depression in Chile. This guide offers a staggered treatment according to the severity of the depression. After the training, the PHC teams will implement the depression treatment according to the SM.
223604799|NCT05665907|OTHER|Questionnaire BRIEF (Behavioral Rating Inventory of Executive Function)|Questionnaire BRIEF (Behavioral Rating Inventory of Executive Function)
223752205|NCT00511693|BEHAVIORAL|centralized osteoporosis coordinator|The regional osteoporosis coordinator will phone fracture patients and counsel them about their risk of osteoporosis, reiterating messages in the print material. The coordinator will also follow-up with family physicians by phone and send them a patient-specific reminder that informs them that their patient has experienced a fracture and they are at high risk for future fracture. As part of the reminder, a set of evidence-based recommendations about appropriate BMD testing and treatment based on the recent Canadian guidelines will be included. If the patient does not have a family physician, the regional osteoporosis coordinator will facilitate referral to the MOP.
223752206|NCT00511693|BEHAVIORAL|fall prevention|Fracture patients from hospitals receiving falls prevention advice will also be called by the osteoporosis regional coordinator. The patient will receive educational material and telephone counseling regarding fall prevention. During the call, patients will be encouraged to visit their family physician for fracture follow-up. They will not receive counseling or educational materials about osteoporosis at this time. Patients in the falls prevention group will receive the physician and patient osteoporosis program six months post-fracture.
223752207|NCT04745403|DRUG|mRNA HBV/TCR T-cells|"Study Infusion~The first dose of mRNA HBV-TCR T-cells at dose 1x10e5/kg BW will be infused on Day 0, and subsequently incremental doses on Day 14 and 28, up to the dose of 5-10x10e6/kg BW."
223752208|NCT05629832|PROCEDURE|mechanical ventilation strategy guided by transpulmonary pressure|Mechanical ventilation parameters adjust guided by transpulmonary pressure monitoring. For pressure assist control or volumn assit control mode; inspiratory pressure or volumn setting needs to maintain Ppeak less than 25 cm H2O; PEEP was set at such a level that expiratory Ptp stayed between 0 and 5 cm H2O.
223752209|NCT00457938|OTHER|low-fat diet ( Still recruiting )|This study will compare 10% fat versus 35% fat diets in terms if effect on liver fat, triglycerides adn other metabolic parameters.
223752210|NCT00457938|OTHER|Diet|10 % versus 35 % fat in diet
223604800|NCT01835730|DRUG|PE0139 Injection|
223604801|NCT01835730|DRUG|Placebo|
223604802|NCT01022099|PROCEDURE|Implantation of a Total Knee Arthroplasty|"In all patients a cemented, unconstrained, cruciate-retaining TKA with a rotating platform (ScorpioTM PCS, Stryker Orthopaedics, Mahwah, NJ) was implanted. No patellar resurfacing was performed. A medial parapatellar approach with a femur-first preparation was done in all cases.~The Stryker Navigation System, Knee Navigation Software V3.1 (Stryker Orthopaedics, Mahwah, NJ) was used for computer-assisted implantation.~The conventional implantation was performed with femoral intramedullary and tibial extramedullary standard alignment guides."
223604803|NCT05826847|PROCEDURE|Prone Positioning|Prone positioning will be performed according to ICU local protocol with trained provider teams.
223604804|NCT05826847|PROCEDURE|Thoracoabdominal Binding|Thoracoabdominal binding will be used in semi-recumbent position (supine at 45º) and titrated to obtain a 20-30% decrease in chest wall compliance and 1-3 cm H2O increase in end-expiratory gastric pressure during steady-state breathing
223604805|NCT05826847|PROCEDURE|Control|ARDS patients at spontaneous breathing onset on pressure support ventilation mode in supine position at 45º degrees, performed under standard PEEP according to ARDSNet strategy and individualized PEEP applied in random order.
223604806|NCT00861471|DRUG|Docetaxel|"One treatment cycle is defined as 21 days.~Docetaxel: 70 mg/m\^2 (60 mg/m\^2 was tested in Phase I as well), Intravenous, every 21 days."
223604807|NCT00861471|DRUG|Imatinib Mesylate|"One treatment cycle is defined as 21 days.~Imatinib Mesylate: 24-36 hours after Docetaxel, 600 mg (400 mg was tested in Phase I as well), orally, daily x 14 days."
223604808|NCT04043078|OTHER|Exercise|The exercise regime will include daily upper limb aerobic (hand bike) and inspiratory muscle training (POWERbreathe) and upper body strength training every second day until discharge.
223752211|NCT03602469|DRUG|Bupivacaine|Ultrasound-guided suprascapular nerve block will be performed using 7 mL of 0.5% bupivacaine plus 3 mL of 0.9% saline
223604809|NCT02157077|DRUG|Aflibercept|Intravitreal Injection
223604810|NCT05686564|DRUG|ALXN1840|bis-choline tetrathiomolybdate
223604811|NCT01445080|OTHER|Laboratory Biomarker Analysis|Correlative studies
223752212|NCT03602469|DRUG|Bupivacaine-magnesium|Ultrasound-guided suprascapular nerve block will be performed using 7 mL of 0.5% bupivacaine plus magnesium sulfate 10% (3 ml) (total 10mL)
223604812|NCT01445080|OTHER|Pharmacological Study|Correlative studies
223604813|NCT01445080|DRUG|Sorafenib Tosylate|Given orally
223604814|NCT04787354|DRUG|Oxaliplatin|Oxaliplatin: 130 mg/m2/day
223604815|NCT04787354|DRUG|Capecitabine|Capecitabine: 2,000 mg/m2/day
223604816|NCT02757118|DRUG|Intravenous Crystalloid|crystalloid is administered to maintain stroke volume variation \< 15 during volume controlled ventilation (8 ml/kg tidal volume) of O2/air mixture
223752213|NCT03602469|DRUG|Propofol|Using propofol 1.5-2.5 mg/kg
223752214|NCT03602469|DEVICE|Ultrasound|Ultrasound-guided suprascapular nerve block
223752215|NCT03602469|DRUG|Sevoflurane|Sevoflurane 0.7-1.5 MAC in 40% oxygen
223604817|NCT02757118|DRUG|Intravenous HES|HES is administered to maintain stroke volume variation \< 15 during volume controlled ventilation (8 ml/kg tidal volume) of O2/air mixture
223604818|NCT01398748|DRUG|Intranasal glutathione - (in)GSH|Intranasal glutathione-Tripeptide glutathione 100 mg/ml. 1 ml 3x per day TID X 12 weeks at 2100mg in 15 participants
223604819|NCT01398748|DRUG|Intranasal glutathione - (in)GSH|Intranasal Glutathione-Tripeptide glutathione - 200mg/ml. 1 ml 3x per day TID X 12 weeks at 4200mg in 15 participants
223604820|NCT01398748|DRUG|Saline Intranasal Delivery|Saline administration 1ml 3x/day 12 weeks in 15 participants
223752216|NCT03602469|DRUG|Rocuronium|Rocuronium 0.6 mg/kg
223752217|NCT03904238|BEHAVIORAL|Cognitive-Behavior Therapy for Hypersomnia (CBT-H)|"The CBT-H intervention consists of 6 weekly sessions that are conducted either individually or in small groups. Each session is expected to last about 45 to 60 minutes and will be delivered a study therapist using live videoconferencing or in-person. The treatment package consists of cognitive and behavioral modules that include education about hypersomnia, coping skills training, emotion regulation regarding the perceived limitations of living with chronic hypersomnia (e.g., I cannot live a full life because of my illness), and behavioral techniques using scheduled naps, sleep hygiene, and regularizing sleep schedules at night which are on the current optional recommendations for hypersomnia."
224200397|NCT06701175|PROCEDURE|Nerve Block|anterolateral geniculate nerve block
223604821|NCT00445770|DRUG|Etanercept|10 mg twice weekly, subcutaneous injection for 52 weeks
223604822|NCT00445770|DRUG|Etanercept|25 mg, twice weekly, subcutaneous injection for 52 weeks
223604823|NCT00445770|DRUG|Methotrexate|up to 8 mg per week, oral dosing for 52 weeks
223604824|NCT05407155|COMBINATION_PRODUCT|bevacizumab plus nab-paclitaxel and platinum|Bevacizumab is given as 15mg/kg every 3 weeks. Nab-paclitaxel is given as 260 mg/m2 every 3 weeks for 4 cycles at most. Platinum includes caboplatin or cisplatin, which is chosed by phycisians. Carboplatin was calculated using AUC equals 5 for 4 cycles at most, and cisplatin was given as 75mg/m2 for 4 cycles at most. Bevacizumab is given untill disease progression or intolerated toxicities.
223604825|NCT00979771|DRUG|GSK706769|100 mg GSK706769 twice daily orally (BID) for 28 days
223604826|NCT00979771|DRUG|Placebo|GSK706769 matched-placebo twice daily orally (BID) for 28 days
223604827|NCT03857542|DRUG|Pilocarpine HCl Ophthalmic Solution|Pilocarpine HCl ophthalmic solution 1.25%, one drop in each eye, once daily, for up to 30 days.
223604828|NCT03857542|OTHER|Vehicle|Vehicle, one drop in each eye, once daily, for up to 30 days.
223604829|NCT00370565|DRUG|Inhaled Human Insulin|
223752218|NCT01342510|DRUG|Magnesium Sulfate|We propose studying Lidocaine 50 mg in a 10 cc syringe, Magnesium sulfate 0.25 g (2 mOsmol) in a 10 cc syringe, 0.9% saline in a 10 cc syringe, Lidocaine 50 mg and 0.25 g (2 mOsmol) magnesium sulfate in a 10 cc syringe for pretreatment of propofol related pain on injection.
223752219|NCT01342510|DRUG|Lidocaine|We propose studying Lidocaine 50 mg in a 10 cc syringe, Magnesium sulfate 0.25 g (2 mOsmol) in a 10 cc syringe, 0.9% saline in a 10 cc syringe, Lidocaine 50 mg and 0.25 g (2 mOsmol) magnesium sulfate in a 10 cc syringe for pretreatment of propofol related pain on injection.
224200398|NCT06701175|PROCEDURE|Portal Anesthesia|portal anesthesia
224200399|NCT01291069|DRUG|Tadalafil Citrate|If allocated to the treatment arm, the patient will be given tadalfil citrate, 0.8-1 mg/kg/day in 1 daily dose. Maximum dose 40 mg. All patients will receive either study drug or placebo for a total of 20 days.
224200400|NCT01291069|DRUG|Sugar pill|If allocated to the placebo arm, the child will be given a similar appearing medication; the placebo will be a mixture of Ora-Sweet® and Ora-Plus® in a 1:1 ratio. All patients will receive drug for 20 days
224200401|NCT02120482|DEVICE|Combined apheresis|Semiselective immunoadsorption combined with membrane filtration
224200402|NCT01696227|DRUG|Nissle 1917|Uropathogens will be challenged to share the same in vitro environment with Nissle 1917.
224200403|NCT02413723|DEVICE|Videolaryngoscope|McGrath Mac videolaryngoscope will be use for first attempt of intratracheal intubation.
224200404|NCT02413723|DEVICE|Standard laryngoscope|Macintosh laryngoscope will be use for first attempt of intratracheal intubation.
224200405|NCT01813682|OTHER|treatment group1|fe-1 group with TPN of iron supplementation of 200μg/kg/d.
223604830|NCT03274856|DRUG|GLWL-01|Oral administration of 3 capsules, twice a day
223604831|NCT03274856|DRUG|Placebo|Oral administration of 3 capsules, twice a day
223604832|NCT03121703|OTHER|lumbar stabilization exercise|lumbar stabilization exercise
223604833|NCT03121703|OTHER|trunk muscle strengthening exercise|trunk muscle strengthening exercise
223604834|NCT01714401|DRUG|Salbutamol 2,5 mg|20 min nebulization of 2.5 mg of salbutamol
223604835|NCT01714401|DRUG|Salbutamol 5mg|20 min nebulization of 5 mg of salbutamol
223604836|NCT06300073|DEVICE|Experimental: U-shaped Power Toothbrush|Twice daily brushing for 30 seconds with fluoride toothpaste
223604837|NCT06300073|DEVICE|Placebo Comparator: Soft Manual Toothbrush|Twice daily brushing for 2 minutes with fluoride toothpaste
223604838|NCT02260947|DRUG|PF-06273340|PF-06273340 50 mg
223604839|NCT02260947|DRUG|PF-06273340|PF-06273340 400 mg
223604840|NCT02260947|DRUG|Pregabalin|Pregabalin 300 mg
223604841|NCT02260947|DRUG|Ibuprofen|Ibuprofen 600 mg
223604842|NCT02260947|DRUG|Placebo|Matching Placebo
223618144|NCT03631342|OTHER|PCV+Tins|controlled ventilation and inspiratory pressure was increased every 5 cmH2O until the maximum pressure was 40 cmH2O. The inspiratory time was gradually increased until the inspiratory flow reached the baseline. Concomitantly, the respiratory rate was decreased to allow the expiratory flow also to reach the baseline, to avoid self-PEEP.
223618145|NCT03631342|OTHER|PSV|ventilatory mode with pressure support, with progressive increases of 5 cmH2O at inspiratory pressure, until reaching Pmax of 40 cmH2O. The expiratory sensitivity was adjusted by 25% for all patients.
223618146|NCT06278792|PROCEDURE|Diuretic protocol|Nurse-led natriuresis-guided protocol based on a bedside urinary sodium result
223618147|NCT06278792|PROCEDURE|Standard of Care|Diuretic therapy at the discretion of the physician
223618148|NCT00704366|DRUG|AZD0530|oral, tablet, once daily, dose will be variable
223618149|NCT03624842|DRUG|Trappsol (R) Cyclo (TM)|
223618150|NCT05041335|OTHER|wet heparinzed suction|Needle flushed with 5000 Units in 10mL of heparin
223618151|NCT05041335|OTHER|Microsieve|A microsieve used for tissue preparation
223618152|NCT05041335|OTHER|No heparin flush|The needle not prepped
223618153|NCT05041335|OTHER|No microsieve|The tissue is placed into formalin
223618154|NCT02338544|DRUG|0.1% Adapalene / 2.5% Benzoyl peroxide|Epiduo® gel containing 0.1% adapalene + 2.5% benzoyl peroxide dispensed from a pump.
223618155|NCT01788917|DIETARY_SUPPLEMENT|Linseed oil|Dietary supplement: 10 mL linseed oil per day
223618156|NCT05705466|DRUG|Navtemadlin|Navtemadlin is an experimental MDM2 anticancer drug taken by mouth.
223618157|NCT05705466|DRUG|Navtemadlin Placebo|Navtemadlin placebo is a placebo that is the same in appearance to navtemadlin drug taken by mouth.
223618158|NCT05705466|DRUG|Pembrolizumab|Pembrolizumab is a humanized antibody used in cancer immunotherapy that will be administered intravenously
223618159|NCT04487106|DRUG|Azacitidine|Given IV or SC
223618160|NCT04487106|DRUG|Trametinib|Given PO
223618161|NCT04487106|DRUG|Venetoclax|Given PO
223618162|NCT00003419|PROCEDURE|antiviral therapy|
223618163|NCT00391300|PROCEDURE|bioelectric field imaging|
223618164|NCT00391300|PROCEDURE|biopsy|
223618165|NCT00391300|PROCEDURE|histopathologic examination|
223618166|NCT01603589|PROCEDURE|Coronary artery bypass grafting with the use of minimal invasive extracorporeal circulation|We use a prototype AHEPA (modular type IV) circuit comprised of the standard and a standby accessory. Components of the standard circuit include: aortic cannula, three-stage venous cannula, coated tubing, a centrifugal pump, a new-generation membrane oxygenator with integrated arterial filter, a venous air removal device, a soft coated bag and pulmonary artery as well as aortic root vent. In addition, there is a standby hard-shell reservoir in parallel to the venous line, so as to convert the closed system to an open one. The standby component is bridged to the main circuit with an afferent line which is connected just before the VARD sending blood to the hard-shell reservoir and an efferent that re-directs it back to the VARD. A cell-saver device is added to the circuit for collecting shed blood and washing red blood cells for autotransfusion.
223618167|NCT01603589|PROCEDURE|Coronary artery bypass grafting under conventional extracorporeal circulation|A standard open CPB circuit is used, consisting of uncoated PVC tubing, a hard-shell venous reservoir, a microporous membrane oxygenator (Dideco, Mirandola, Italy) and a roller pump (Stöckert S3, Munich, Germany). The circuit contains a 40 μm arterial line blood filter (Dideco, Mirandola, Italy) and it is primed with 1500 mL of a balanced crystalloid/colloid solution (1000 mL of Ringer's solution, 200 mL of mannitol 20%, and 300 mL of hydroxyethyl starch 6%). Cardiotomy as well as sump sucker are integrated to the circuit.
223618168|NCT03887013|DRUG|Trimetazidine|Trimetazidine is given as 20mg every time and three times per day (Tid) or 20mg every time and two times per day (when renal function is declined).
223618169|NCT00778115|DRUG|Loperamide HCl 2 mg and simethicone 125 mg tablets|
223618170|NCT00376792|DRUG|docetaxel|
223618171|NCT00376792|OTHER|active surveillance|
223618172|NCT00376792|PROCEDURE|adjuvant therapy|
223618173|NCT02910466|DRUG|rhPTH(1-84)|Participants will receive 25, 50, 75, and 100 microgram (mcg) of rhPTH(1-84) subcutaneous injection to the thigh via a multidose pen injector device once daily for 36 months. The dose will be individualized based on Albumin-corrected Serum Calcium (ACSC) and 24-hour calcium urinary excretion to achieve a serum calcium level in the lower half of the normal range.
223618174|NCT04037865|DRUG|PF-06651600|PF-06651600 50 mg oral tablets will be administered on Days 1 to 10
223752220|NCT01342510|DRUG|Control|We propose studying Lidocaine 50 mg in a 10 cc syringe, Magnesium sulfate 0.25 g (2 mOsmol) in a 10 cc syringe, 0.9% saline in a 10 cc syringe, Lidocaine 50 mg and 0.25 g (2 mOsmol) magnesium sulfate in a 10 cc syringe for pretreatment of propofol related pain on injection.
223752221|NCT01342510|DRUG|Lidocaine/Magnesium|We propose studying Lidocaine 50 mg in a 10 cc syringe, Magnesium sulfate 0.25 g (2 mOsmol) in a 10 cc syringe, 0.9% saline in a 10 cc syringe, Lidocaine 50 mg and 0.25 g (2 mOsmol) magnesium sulfate in a 10 cc syringe for pretreatment of propofol related pain on injection.
223752222|NCT06256042|PROCEDURE|Occlusal splint|a stabilizing maxillary acrylic occlusal splint was made, flat, total and adjusted in central relation (RC).
223752223|NCT06256042|PROCEDURE|Arthrocentesis|The patient then underwent arthrocentesis of the temporomandibular joint itself, following the Nitzan technique.
223752224|NCT03480997|COMBINATION_PRODUCT|Albuterol Sulfate and Ipratropium Bromide|
223752225|NCT03480997|COMBINATION_PRODUCT|Albuterol Sulfate|
223752226|NCT06202742|BEHAVIORAL|cognitive behavioral therapy for insomnia|Online meeting, weekly for 8 weeks, to deliver CBTI by psychologist/ psychiatrist
223752227|NCT06202742|BEHAVIORAL|Health education|Online meeting, weekly for 8 weeks, to deliver general health knowledge
223752228|NCT01449526|DEVICE|B&L Investigational Contact Lens|Lenses will be worn on a daily wear basis for 3 months, new lenses dispensed monthly.
223752229|NCT01449526|DEVICE|B&L PureVision Contact Lens|Lenses will be worn on a daily wear basis for 3 months, new lenses dispensed monthly.
223752230|NCT04750837|PROCEDURE|debridement of the wound|The edges and the floor of the wound were firstly debrided, and any callosities around the wound were removed. This was repeated if needed when callosities around the wound reappeared. By this technique, the chronic wound was transformed into an acute one
223752231|NCT04750837|BIOLOGICAL|platelet rich plasma|Part of activated PRP was injected around the wound and under the base of the wound, while another portion of PRP was left over the floor of the wound and let to coagulate and form a gel.
223604843|NCT01808235|BEHAVIORAL|Oral Health Intervention|The dental hygienist will assess the IMD's tooth brushing technique and will provide specific feedback on the tooth brushing technique, including areas of the dentition missed in brushing. The IMDs will be given a powered toothbrush that records time, date and duration of toothbrushing activity, along with the direction and extent of motion of the toothbrushing activity. In addition, use of interdental cleaning aids will be recommended. The dental hygienist will review the findings from the oral health evaluation with the IMDs and caregivers, and provide detailed feedback on treatment and prevention of the oral health conditions and symptoms. The dental hygienist or study coordinator will call subjects by telephone biweekly to monitor oral hygiene practices and to provide coaching, if needed. Oral hygiene technique assessments will be conducted again three months after the first visit, and once more three months later, at the end of the intervention.
223604844|NCT04859816|OTHER|Metabolic test|Iv and oral administration of stable isotope tracers during fasting and a high-fat liquid mixed meal
223604845|NCT04859816|OTHER|DXA-scan|Dual energy X-ray Absorptiometry scan of whole-body fat
223604846|NCT04859816|OTHER|MRS|Magnetic resonance spectroscopy of liver fat content
223604847|NCT04859816|OTHER|Feces collection|4-day feces collection
223604848|NCT04503720|DEVICE|CLoWI|Patients will receive a continuous wound infusion with ropivacaine and normal saline in the PCA pump.
223752232|NCT04750837|PROCEDURE|conventional dressing|The wound was irrigated by normal saline, covered by vaseline gauze then sterile dressing. Repeated dressing every two days till 20 weeks, if the wound failed to heal at that time
223752233|NCT04350151|BEHAVIORAL|no intervention|no intervention
223752234|NCT02282956|DRUG|Ropivacaine 0,75%|Ropivacaine injection
223752235|NCT02282956|PROCEDURE|posterior tibial nerve block|ultrasound guided posterior tibal nerve block
224200406|NCT01813682|OTHER|treatment group2|fe-2 group with TPN of iron supplementation of 400μg/BW (BW=birth weight)
224200407|NCT03961932|DRUG|Linzagolix|A single dose of 200 mg linzagolix (2 tablets of 100 mg) will be administered orally under fasting conditions
224200408|NCT00953589|DRUG|ribavirin|Ribavirin - oral administration Subjects with body weight \< 65 kg: 800 mg/day Subjects with body weight 65-85 kg: 1000 mg/day Subjects with body weight 86-105 kg: 1200 mg/day Subjects with body weight \> 105 kg: 1400 mg/day
224200409|NCT00227591|DRUG|lenalidomide|Given orally (PO)
223752236|NCT02282956|DRUG|morphine and droperidol|i.v PCA
223752237|NCT01538862|DRUG|Granulocyte Colony Stimulating Factor (GCSF)|G-CSF 10mcg/kg/d SQ for 7 days
223752238|NCT04470999|OTHER|Leukapheresis|Blood collection and PBMC collection via apheresis machine will be conducted
224200410|NCT00227591|DRUG|prednisone|Given PO
224200411|NCT00227591|OTHER|laboratory biomarker analysis|Correlative studies
224200412|NCT01779466|DRUG|Desmopressin|
223604849|NCT04503720|DEVICE|PCA|Patients will receive a continuous wound infusion with normal saline and morphine in the PCA pump.
223752239|NCT06284785|PROCEDURE|Bariatric surgery|Patients included in our obese patient group are all scheduled to undergo bariatric surgery
223752240|NCT02978742|BEHAVIORAL|Adaptive Recovery Record App|Participants will use the Recovery Record smartphone app, which is a meal monitoring tool, that incorporates discrete reminders, motivational tools, social support, summative feedback, and coping skill suggestions. Participants will also receive tailored, algorithm-generated content in a structured manner that mimics the progression of psychotherapy (e.g., checking in with users, reminding them of their reasons for wanting to recover, and working towards goals) over the course of 8 weeks.
224200413|NCT01779466|DRUG|Placebo (not active)|
223604850|NCT00675220|DRUG|insulin aspart|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
224200414|NCT03865550|DRUG|Isotonic saline|Placebo
224200415|NCT03865550|DRUG|Ketamine Injectable Solution|Active comparator
224200416|NCT02651246|OTHER|data collection|
224311389|NCT03222752|DEVICE|Cranial Electrotherapy Stimulation|Alpha-Stim® AID microcurrent and cranial electrotherapy stimulator will be used. Daily one hour cranial electrotherapy stimulation (CES) treatment using ear clip electrodes with current set at fixed level of 100 uA (a subsensory current level), 0.5 Hertz will be used for active CES treatment group for 6 weeks. For the sham group the Alpha-Stim® AID ear clips will not emit electricity.
223752241|NCT02978742|BEHAVIORAL|Standardized Coaching|Coaches (dietitians or mental health clinicians) will review patients' logs daily and participants will receive one communication of standardized feedback each day through the app based on their food records. A standardized feedback manual to be used by coaches has been developed by co-investigators (two PhD psychologists and one psychiatrist), and all feedback will be monitored for consistency and quality by co-investigators.
223604851|NCT04688255|BEHAVIORAL|MSTEP|Aerobic exercise that is advanced weekly
223752242|NCT00363454|DRUG|Triciribine Phosphate Monohydrate|8 Cycles @ 28 days. Level 1: 15 mg/m\^2; Level 2: 25 mg/m\^2; 35 mg/m\^2; 45 mg/m\^2.
223752243|NCT00199290|DRUG|Trafermin (genetical recombination)|
223752244|NCT05471050|DRUG|TAC|Tacrolimus is given at a dose of 0.03mg/kg·d, and the dose is adjusted to maintain the trough concentration of tacrolimus at approximately 3-5 ng/mL for 12 weeks.
223752245|NCT05471050|DRUG|Danazol|Danazol is given at 200mg bid for 12 weeks.
223752246|NCT01400516|DRUG|Teriparatide|20 μg, subcutaneous injection, 1 injection per day
223752247|NCT01400516|DRUG|calcium citrate|1000 mg of calcium citrate
223752248|NCT01400516|DRUG|Vitamin D|800 IU of Vitamin D
223752249|NCT01400516|DRUG|TNF antagonist|TNF antagonist as prescribed in clinical practice (such as etanercept or adalimumab)
223752250|NCT01412866|BEHAVIORAL|EDSS with CO feedback and health checklist|Web-based electronic decision support system with CO feedback and health-checklist
223752251|NCT01412866|BEHAVIORAL|EDSS with health checklist feedback alon|Web-based electronic decision support system (EDSS) with health-checklist feedback alone (without CO feedback)
223752252|NCT02190799|BIOLOGICAL|Convalescent plasma|Convalescent plasma from patients who recently recovered from MERS-CoV, HCWs who had potential exposure and subjects who are willing to donate plasma and have their blood tested for anti MERS-CoV serology and RT-PCR after obtaining their consent
223752253|NCT01500642|BIOLOGICAL|Slit One|slit one sublingual immunotherapy 200 stu
223752254|NCT01500642|BIOLOGICAL|Slit One|slit one vestibular immunotherapy 200 stu
223752255|NCT01500642|BIOLOGICAL|Slit One ragweed|slit one 400 stu dose ragweed (sublingual doubled immunotherapy)
223752256|NCT02280135|BIOLOGICAL|Intravitreal injection of Autologous bone marrow Stem Cell|"We will proceed to the injection of 0.1 ml of the suspension with the autologous MNC of BM avoiding coincide with conjunctival and scleral hole and perpendicular to the sclera.~After the injection, a dry, sterile dressing will be placed to prevent reflux. Immediately, the perception of light, the movement of the central retinal artery, the venous pulse and the color of the papilla will be evaluated. If necessary, anterior chamber paracentesis will be performed.~After injection, the patient will remain with closed eyes and sitting, waiting for cells will be deposited on the bottom of the eyeball and for 3 days will instill tropicamide collyrium every 12 hours."
223752257|NCT02280135|OTHER|Subconjunctival injection of saline|"In the control eye, will make a subconjunctival injection of 0.1 ml saline. To realize contralateral injection gloves and all surgical materials will change, trying extreme measures of sterility.~After injection, the patient will remain with closed eyes and sitting, waiting for cells will be deposited on the bottom of the eyeball and for 3 days will instill tropicamide collyrium every 12 hours."
224200417|NCT06289010|BEHAVIORAL|Family-Focused Treatment for Childhood-Depression (FFT-CD)|"This intervention includes 12 one-hour, in-person sessions. FFT-CD was designed to help families gain skills to combat depression and create ways of interacting that protect the child from the negative sequelae of stress. Within a broad psychoeducational framework, interpersonal factors impacting youth depression and the interplay of mood and interpersonal interactions are emphasized. Participants are taught to identify Upward Spirals - positive interactions fueling positive moods leading further upward - and Downward Spirals - negative interactions fueling negative moods leading further downward. The treatment rationale is to stop downward spirals and to start upward spirals; this idea provides a foundation for skills building to help the child and family better navigate stress. Handouts, role-playing, behavioral rehearsal, and homework assignments are all used to help shape behaviors."
223752258|NCT00128921|DRUG|VELCADE™|"Patients will receive two cycles of VELCADE™ (1.3 mg/m2, 1.0 mg/m2 or 0.7 mg/m2) on days 1, 4, 8, and 11, on a 21 day cycle. No growth factors or bisphosphonates will be allowed during study treatment. Bone markers will be measured:~Days 1, 4, 8, 11: Pre-dose, post-dose, and every 2-4 hours for 8 hours Days 2-3, 5-7, 9-10, 12-21: every 24 hours, beginning with the immediate post-dose sample (+/- 2 hours) Other laboratory and radiologic studies will be performed as detailed in the Study Calendar.~Patients will complete the study after two cycles of VELCADE™. However, if a patient continues to receive VELCADE™ as part of his/her treatment for relapsing MM, routine bone markers may be monitored for the duration of VELCADE™ treatment as clinically indicated."
223752259|NCT01132495|OTHER|Stenting plus OMT|FFR guided PCI, plus OMT
223752260|NCT01132495|OTHER|OMT|OMT alone
223752261|NCT01132495|OTHER|Standard of care|FFR \> 0.80; treatment according to local practice
223752262|NCT02204748|DEVICE|DePuy Attune posterior stabilizing fixed bearing knee system|
223752263|NCT03007758|PROCEDURE|open ventral hernia repair|An open retromuscular ventral hernia repair involves an incision through your abdominal wall, most often through a prior surgery scar. The contents of the hernia, which may include intestine or fatty tissue, are returned into the abdominal cavity. The posterior (inner-most) layer of the abdominal wall is separated from the muscle and closed, which closes the abdominal cavity. Mesh is then placed over that closed layer, which is outside of the abdominal cavity, but below the abdominal muscles. The anterior (outer-most) layer of the abdominal wall is then closed over the mesh, which closes the hernia.
223604852|NCT04688255|BEHAVIORAL|Stretching|Stretching exercises that are advanced weekly
223604853|NCT00451256|DRUG|AVI-5126|
223604854|NCT03969095|BEHAVIORAL|Tongue Pressure Resistance Training|2 supervised sessions per week: Each session will be a maximum of one hour in length and will include: 1) 20 repetitions of maximum isometric presses (MIPs) with rapid rise in pressure at the anterior location. 2) 15 regular saliva swallows with the IOPI bulb in place. 3)15 effortful saliva swallows with the IOPI bulb in place. 4) 10 generalization tasks with mildly thick liquid and IOPI.
223604855|NCT03058692|BIOLOGICAL|Influenza Multimeric-001 Vaccine|The M-001 vaccine consists of 3 repetitions of 9 conserved linear epitopes that are prepared as a single recombinant protein. The M-001 vaccine is expected to protect against existing as well as future seasonal and pandemic virus strains.
223604856|NCT03058692|OTHER|Placebo|Placebo is saline injection
223752264|NCT03007758|PROCEDURE|robotic ventral hernia repair|A robotic retromuscular ventral hernia repair involves a similar separation of the layers of the abdominal wall, similar mesh placement, and similar closure of the hernia defect. The surgical robot is a tool that allows your surgeon to place long, narrow instruments through small incisions in order to perform surgery from the inside of your abdomen. Rather than one longer incision in the middle of your abdomen, four to six small incisions, about 1 inch, are made along the outer part of your abdomen between the rib cage and hip.
223604857|NCT03058692|BIOLOGICAL|Quadrivalent Recombinant Seasonal Influenza Vaccine|Quadrivalent Inactivated Influenza Vaccine (IIV4) for intramuscular injection is indicated for active immunization against influenza disease caused by influenza virus subtypes A and type B present in the vaccine.
223604858|NCT02736201|DEVICE|Capacitive diathermy (T-CaRe®)|The instrumental manual therapy with the switched on capacitive diathermy electrode (IMT+ T-CaRe® on; n = 10) and the instrumental manual therapy with the switched off capacitive diathermy electrode (IMT+ T-CaRe® off; n = 10) will be bilaterally treated for 4 weeks (1 treatment per week during 10 minutes) in the lumbopelvic region.
223604859|NCT02736201|OTHER|Instrumental manual therapy|Bilateral longitudinal massage in the lumbar region (110 mm; 5 minutes in each side)
223604860|NCT00841334|BEHAVIORAL|ACTION|Overweight/obese adolescents enrolled in ACTION will meet with SBHC providers over a 6 month period in one school year. SBHC providers will use Motivational Enhancement Therapy to motivate overweight/obese adolescents to adopt strategies for improving nutrition and physical activity.
223604861|NCT00841334|BEHAVIORAL|Usual care|Overweight/obese adolescents in the second arm will receive a well child check with usual anticipatory guidance.
223604862|NCT01759797|BIOLOGICAL|intra venous injection of stem cell|Intra venous injection of mesenchymal stem cell
223604863|NCT04012541|PROCEDURE|active dental procedure|scaling and root planing
223604864|NCT04012541|DRUG|post-myocardial infarction management|aspirin, clopidogrel, ticagrelor
223604865|NCT04012541|RADIATION|basic periodontal examinations|panorama radiograph : full mouth periapical radiograph
223604866|NCT04081922|PROCEDURE|Erector spinae plane block|Using ultrasound, place the needle in the erector spinae fascia plane at T7-8 level. Then, 0.25% ropivacaine 0.5 ml is injected to confirm the needle location. After checking the location, 0.25% ropivacaine 0.5 ml/kg is administered. This procedure is repeated at contralateral side.
223752265|NCT05145829|DIAGNOSTIC_TEST|Diagnostic Test: Sentinel node mapping using MRI|Sentinel lymph node mapping in melanoma patients using a magnetic tracer and MRI
223752266|NCT05210686|OTHER|subgingival re-instrumentation|subgingival re-instrumentation (control)
223752267|NCT05151263|DRUG|Acetyl Salicylate|Aspirin is an effective antiplatelet agent, exhibiting its action by irreversibly inhibiting platelet cyclooxygenase-1 enzyme, thus preventing the production of thromboxane A2 (TXA2). It has been used in the primary and secondary prevention of thromboembolic vascular events
223752268|NCT05151263|DIAGNOSTIC_TEST|Optical Platelet Aggregation test|The evaluation of platelet aggregation was performed using an optical aggregometer (AggRAM, using fresh citrated blood. Platelet-rich plasma was obtained by centrifugation of the citrated blood at 190 g for 5 min. The platelet count was adjusted to 200,000 to 300,000 platelets/mm3. Platelet-rich plasma (250 μl) was deposited in each equipment channel, and the activators adenosine diphosphate, epinephrine, collagen, and arachidonic acid were used according to the manufacturer's instructions. aspirin resistance was defined as platelet aggregation ≥ 20% with arachidonic acid and ≥70% with adenosine diphosphate.
223752269|NCT00918021|DRUG|olanzapine|normal dosage of olanzapine (the same dosage as on hospital ward)
223752270|NCT00918021|DRUG|placebo|placebo
223752271|NCT00082433|DRUG|Ixabepilone + Capecitabine|Ixabepilone lypholized powder/Diluent for solution for injection/Tablets, IV/Oral, 40 mg/m2 + Capecitabine 2000 mg/m2, Ixabepilone on Day 1 and Capecitabine twice daily Days 1-14 of 21 day cycle
223752272|NCT00082433|DRUG|Capecitabine|Tablet, Oral, 2500 mg/m2, Capecitabine twice daily Days 1-14 of 21 day cycle
223752273|NCT00162565|DRUG|beta-blocker treatment|beta-blocker treatment
223604867|NCT05852067|DEVICE|pcTBS of M1|Prolonged continuous theta-burst stimulation (pcTBS) was administered to the left M1 at 80% RMT, consisting of a burst of 3 pulses given at 50 Hz repeated every 5 Hz. A total of 1,200 pulses were delivered with the TMS coil positioned in a posterior-anterior (PA) direction parallel to the midline
223604868|NCT05852067|DEVICE|SHAM stimulation|The Sham stimulation was delivered using the same pcTBS protocol, with the coil being flipped 90◦to the scalp so that the magnetic field would be delivered away from the scalp
223604869|NCT03476148|DEVICE|Home Rehabilitation using Interactive device|Rehabilitation is performed using interactive motion tracking augmented reality device. 6 exercises are included in one-day rehabilitation program. Each exercise is recorded in aspect of compliance, completion.
223604870|NCT03476148|OTHER|Inpatient Rehabilitation|Patients are given the exercises in the setting of inpatient rehabilitation
223604871|NCT04130321|DIETARY_SUPPLEMENT|Camu camu|3 capsules of camu camu powder (500 mg / capsule) daily during 12 weeks
223604872|NCT04130321|DIETARY_SUPPLEMENT|Placebo|3 capsules of placebo daily during 12 weeks
223604873|NCT00571974|DEVICE|PDL-585, ScleroPLUS laser|PDT Treatment; emits light with 585 nm wavelength in pulses of 1.5 milliseconds in sections of 5 mm diameter to target the lesion and surrounding tissue
223604874|NCT00571974|DRUG|5-Aminolevulinic Acid (Levulan KerastickTM)|Topically administered; incubation time 60-180 minutes; single dose (345 mg of active 5-ALA in 1.5 ml solution); soaked onto white gauze and applied to lesion, covered with sterile Xeroform gauze
223604875|NCT00571974|PROCEDURE|Fluorescence Diagnosis Imaging|FD Image taken prior to PDL-585 usage
223604876|NCT01105208|DRUG|Cephalexin suspension (Optocef, BAYO5448 )|Single dose of 500 mg / 10 mL
223604877|NCT01105208|DRUG|Cephalexin suspension (Keflex)|Single dose of 500 mg / 20 mL
223604878|NCT04791436|DIAGNOSTIC_TEST|Gustatory and olfactory function test|The gustatory and olfactory function will be tested by using the combined Burghart Screening 12 test containing smelling sticks and taste strips (Fa. MediSense, Groningen, Netherlands). Evaluation of taste and smell is performed by offering the sticks/strips and demand a forced multiple choice.
223604879|NCT04791436|DIAGNOSTIC_TEST|Molecular assessment of saliva|Saliva samples will be taken for molecular biological determination of the oral microbiome. The microbiome is determined at the Institute for Medical Microbiology by 16s-rRNA gene analysis with Next Generation Sequencing and bioinformatics.
223604880|NCT00312026|DRUG|efalizumab|
223752274|NCT06372353|OTHER|Baduanjin Exercise|Baduanjin exercise training program was applied to the subjects in the exercise group, 3 days a week, 5 minutes each with warm-up and cool-down exercises, for a total of 24 sessions, 60 minutes each, under supervision, online, via the ZOOM application, for 8 weeks. In addition, the patients did the exercises unsupervised at home once a week. The patients' first sessions were held in the hospital
223752275|NCT00443586|BEHAVIORAL|Developmental Screening|Child participants were screened for sensory and developmental problems and referred for further evaluation and treatment at ages 12 and 24 months of age
223604881|NCT01867502|DRUG|MET + Vildagliptin Group|"Vidagliptin group will receive 50mg of this drug twice a day during 12 weeks added to usual metformin.~For the glicemic control evaluation will be used the capilar glycemia at home. The adjustments will be done by the researcher coordinator."
223604882|NCT01867502|DRUG|MET + Glibenclamide Group|"The initial dose of glibenclamide group will be 5mg / day during the first week of study, later it will increase to 10 mg / day (2 x 5mg). With the control the dose may be adjusted, reaching the maximum dose allowed, which is 20 mg / day.~For the glycemic control evaluation will be used the capillar glycemia at home. The adjustments will be done by the researcher coordinator."
223752276|NCT00443586|BEHAVIORAL|Screening plus Transportation|Child participants were screened for sensory and developmental problems and referred for further evaluation and treatment at 12 and 24 months of age; their mothers were provided with free transportation for prenatal and well-child care through child age 2.
223604883|NCT01698814|DRUG|AL-4943A Ophthalmic Solution|
223604884|NCT01698814|DRUG|AL-4943A Ophthalmic Solution Vehicle|Inactive ingredients used as placebo
223604885|NCT05241093|DRUG|HYML-122; cytarabine|HYML-122 is administered orally consecutive with 400mg bid or 600mg bid or dose adjusted by DMC judgement in each 28-day treatment cycle. cytarabine is administered by intravenous infusion with 100mg/m2 or dose adjusted by DMC judgement once daily on the first to 7th day of each treatment cycle. Upon completion of each 28-day treatment cycle, patients may continue to receive HYML-122 and cytarabine if they are benefit from the treatment and the toxicity is tolerable.
223604886|NCT00252070|BEHAVIORAL|Functional Exercise for People with Arthritis (FEPA)|
223604887|NCT06362317|DRUG|Toripalimab|Toripalimab 240mg, intravenous infusion every 3 weeks until disease progression or occurrence of intolerable toxicity.
223604888|NCT06362317|DRUG|Lenvatinib|When the body weight is ≥60 kg, the dosage of Lenvatinib is 12mg qd, when body weight \< 60kg the dosage is 8mg qd.
223604889|NCT06362317|DRUG|Gemox Chemotherapy（Gemox or GC）|"Chemotherapy drugs: GC regimen is preferred, and if patients cannot tolerate it, GEMOX regimen is used.~Gemcitabine + oxaliplatin (GEMOX) regimen chemotherapy: every 21 days (3 weeks), 1000 mg/m2 of gemcitabine was administered intravenously for more than 30 min on the 1st and 8th day, and 100 mg/m2 of oxaliplatin was administered intravenously for 2h on the 1st day Gemcitabine + cisplatin (GC) regimen chemotherapy: 1250 mg/m2 was administered intravenously for 30 min on day 1 and day 8, respectively, and 100 mg/m2 was administered intravenously for 2 hours after gemcitabine treatment on day 1."
223604890|NCT01186991|DRUG|Onartuzumab|Onartuzumab will be administered as intravenous (IV) infusion at a dose of 10 milligrams per kilogram (mg/kg) on Day 1 and Day 15 of each 28-day cycle. The dose of onartuzumab will be based on the participant's weight at screening and will remain the same throughout the study.
223604891|NCT01186991|DRUG|Bevacizumab|Bevacizumab will be administered as IV infusion at a dose of 10 mg/kg on Day 1 and Day 15 of each 28-day cycle. The dose of bevacizumab will be based on the participant's weight at screening and will remain the same throughout the study.
223604892|NCT01186991|DRUG|Paclitaxel|Paclitaxel will be administered as IV infusion at a dose of 90 milligrams per meter-squared (mg/m\^2) on Day 1, Day 8, and Day 15 of each 28-day cycle.
223604893|NCT01186991|DRUG|Bevacizumab Placebo|Placebo matching to bevacizumab will be administered as IV infusion on Day 1 and Day 15 of each 28-day cycle.
223604894|NCT01186991|DRUG|Onartuzumab Placebo|Placebo matching to onartuzumab will be administered as IV infusion on Day 1 and Day 15 of each 28-day cycle.
223752277|NCT00443586|BEHAVIORAL|Screening, Transport, Prenatal Visits|Child participants were screened for sensory and developmental problems and referred for further evaluation and treatment at 12 and 24 months of age; their mothers were provided with free transportation for prenatal and well-child care through child age 2, and were provided an average of 9 home visits by nurses during pregnancy.
223752278|NCT00443586|BEHAVIORAL|Screen, Transport, Prenatal/Inf Visits|Child participants were screened for sensory and developmental problems and referred for further evaluation and treatment at 12 and 24 months of age; their mothers were provided with free transportation for prenatal and well-child care through child age 2, and were provided an average of 9 home visits by nurses during pregnancy and 23 during the child's first two years of life.
223604895|NCT04734717|DIAGNOSTIC_TEST|Neurology test|movement examination of patients with covid19 disease
223604896|NCT03501732|BEHAVIORAL|Values Affirmation|Experimental Group selects two values and describes why they are important
223604897|NCT03501732|BEHAVIORAL|Risk Feedback|Experimental and comparator conditions both receive normative feedback in domains of risk
223604898|NCT02826343|DRUG|Xenon129 MRI imaging|subjects will receive at baseline and 3 month post Advair intervention (See next intervention)
223604899|NCT02826343|DRUG|Gadolinium MRI|subjects will receive at baseline and 3 month post Advair intervention (See next intervention)
223752279|NCT02313753|BEHAVIORAL|CLASP|
223604900|NCT02826343|DRUG|Advair (250mcg/50mcg) one puff twice a day|subjects will receive for 3 month duration between baseline and 3 month post Xenon129 MRI imaging and Gadolinium MRI.
223604901|NCT03353844|BEHAVIORAL|Intradialytic exercise|intradialytic exercise which start and finish in first hour of hemodiafiltration session
223604902|NCT01975363|DIETARY_SUPPLEMENT|curcumin|Participants will be randomized to either 50 mg BID or 100 mg BID NEC for a 3 month treatment period.
223604903|NCT01975363|OTHER|Biomarker analysis|Breast adipose tissue and plasma samples will be obtained at baseline and 3 months for biomarker analyses. Breast adipose tissue samples will be obtained via fine needle aspiration. Plasma samples from the baseline blood draw will be assessed for curcumin/COG and also stored at -80°C for biomarker analyses.
223604904|NCT01975363|OTHER|Assessment of Dietary Intake|Food frequency questionnaires will be obtained at 0 months and 24-hour dietary recalls will be obtained at 1, 2 and 3 months of the study.
223604905|NCT01975363|OTHER|Daily Log|All participants will complete a daily log on the date and time of NEC administration, potential adverse events, and medications.
223604906|NCT01776034|BEHAVIORAL|SystemCHANGE Group Lifestyle counseling|
223604907|NCT01776034|BEHAVIORAL|Phone Lifestyle Counseling|
223604908|NCT02505659|BEHAVIORAL|Preoperative re-education|Preoperative re-education (behavior): 8 re-education sessions of 30 to 40 minutes, 2 times a week, for 4 weeks
223604909|NCT02737579|PROCEDURE|XFM guidance|X-ray images and MRI roadmaps are aligned, during the medically indicated catheterization procedure, both conventional X-ray and investigational XFM images are displayed side-by-side. The operator may choose to be guided by either.
223604910|NCT04014062|COMBINATION_PRODUCT|INTP5|INTP5: A proposed pegfilgrastim biosimilar to US Neulasta.
223604911|NCT04014062|COMBINATION_PRODUCT|US Neulasta|US Neulasta: FDA-approved pegfilgrastim innovator product.
223604912|NCT02477124|DEVICE|transvaginal digital colposcope (TVDC)|TVDC is a miniature colposcope used to obtain images of cervical tissue.
223604913|NCT02477124|OTHER|Standard of care screening|Standard of care screening varies from institution to institution but is either visual inspection with the naked eye, colposcopy, or visual inspection with a camera or microscope
223604914|NCT05425329|DIETARY_SUPPLEMENT|I3.1|Capsule containing bacterial strains Lactobacillus plantarum (CECT7484 and CECT7485) and Pediococcus acidilactici (CECT7483) at a ratio of 1:1:1.
223604915|NCT05425329|DIETARY_SUPPLEMENT|Placebo treatment|Capsule containing maltodextrin.
224200418|NCT00552656|DEVICE|Firebird(TM) Sirolimus-Eluting Stent|balloon expandable stent that made of stainless steel.The length is from 13mm-33mm,and the diameter from 2.5mm-4.0mm
224311390|NCT03222752|DEVICE|Sham Cranial Electrotherapy Stimulation|The sham treatment will be using a sham Alpha-Stim AID which will look and sound exactly like the active treatment but will deliver no current.
223604916|NCT03469648|PROCEDURE|Air-Test|The Air Test simply consisted in breathing room air for 5 min during anesthesia while measuring peripheral oxygen saturation by Pulse oximetry
223604917|NCT02637583|DRUG|PCV13|Intramuscular injection of 13-valent pneumococcal conjugate vaccine once
223604918|NCT02637583|DRUG|PPV23|Intramuscular injection of 23-valent pneumococcal polysaccharide vaccine once
223604919|NCT04450940|BEHAVIORAL|PACV survey|
223604920|NCT04450940|BEHAVIORAL|Placebo survey|
223604921|NCT03038126|OTHER|CCHT|Veterans Administration (VA) CCHT program available to veterans with difficult to manage chronic conditions and employing an established guideline-based CKD DMP, augmented laboratory monitoring, and decision support from the VA Renal Inter-disciplinary Safety clinic (RISC).
223604922|NCT03038126|OTHER|Usual care|Standard clinical care
223604923|NCT03847935|PROCEDURE|surgery|A1 pulley release of finger
223604924|NCT03847935|PROCEDURE|corticosteroid injections|corticosteroid injection to A1 pulley
223604925|NCT03847935|OTHER|Hand Therapy|orthosis fabrication, therapeutic exercise for range of motion to digits, ice massage, nodule massage, patient education,
223604926|NCT03847935|OTHER|Modality Hand Therapy|orthosis fabrication, therapeutic exercise for range of motion to digits, ice massage, nodule massage, patient education, plus modalities such as ultrasound, iontophoresis
223604927|NCT01635595|PROCEDURE|Subtotal esophagectomy and gastric pull up|Subtotal esophagectomy and gastric pull up and radical thoracic (2,3,4R,7,8,9)and abdominal (15,16,17,18,19,20) lymphadenectomy
223604928|NCT01635595|PROCEDURE|Subtotal esophagectomy at the azygos vein, total gastrectomy|Subtotal esophagectomy at the azygos vein, total gastrectomy and esophagojejunostomy and radical thoracic (2,3,4R,7,8,9) abdominal (15,16,17,18,19,20) lymphadenectomy.
223604929|NCT01831167|OTHER|dynamic light|
223604930|NCT04011657|OTHER|Compulsory CDSS|Compulsory CDSS use with prospective review feedback in patients prescribed with piperacillin tazobactam or carbapenems
223604931|NCT00808119|DRUG|RTI-336 (CTDP 31862)|The RTI-336 drug product is formulated as hard, white, gelatin capsules. The dosage levels are 0.3, 1.0, and 3.0 mg (Cohort 1) and 6.0, 12.0, and 20.0 mg (Cohort 2). Subjects will receive a single dose of the study drug on study day 1.
223604932|NCT01980329|DRUG|Maraviroc|
223604933|NCT05076201|BEHAVIORAL|Patients with completed rehab|The main objective is to measure the level of cocaine craving, 6 months after the end of their detoxification treatment (outpatient or full hospitalization), in patients with a diagnosis of moderate to severe dependence (DSM 5) to cocaine and co-addiction, or not, to alcohol and / or psychostimulants. To evaluate cocaïne craving,the questionnaire CCQ-Brief will be used.
224311391|NCT02257294|DRUG|Alteplase|Single treatment consisting of a single slow infusion administration after reperfusion with aspiration thrombectomy ± angioplasty but before stenting during primary PCI.
223752280|NCT02313753|BEHAVIORAL|SAFE|
223604934|NCT01724866|DRUG|SPI-2012|SPI-2012 SC injection.
223604935|NCT01724866|DRUG|Pegfilgrastim|Pegfilgrastim SC injection, per manufacturer's Prescribing Information.
223604936|NCT01724866|DRUG|Docetaxel|Docetaxel given based on standard dose for chemotherapy.
223604937|NCT01724866|DRUG|Cyclophosphamide|Cyclophosphamide given based on standard dose for chemotherapy.
224200419|NCT04156438|DEVICE|Low tidal volume ventilation|Conventional ventilation strategy for patient with ARDS
224200420|NCT04156438|DEVICE|Airway pressure release ventilation|Experimental ventilation protocol for patients with ARDS
224200421|NCT02659657|DRUG|Interleukin-2|Interleukin-2 (IL-2), 0.4×10E+6/M2/d, 3 times a week (separated by at least 1 day between injections) until day +90 (+/- 7 days)
224200422|NCT00357734|DRUG|Gefitinib|ZD1839 at a daily dose of 250 mg or 500 mg depending on final dose in parent trial
224200423|NCT00389168|DRUG|Irbesartan|Titrated to 300 mg od, 48 weeks.
224200424|NCT00389168|DRUG|Atenolol|Titrated to 100 mg od, 48 weeks.
224200425|NCT02057549|DRUG|Haloperidol|Intravenous dose of haloperidol 5 mg.
224311392|NCT02257294|OTHER|Placebo|Single treatment consisting of a single slow infusion administration after reperfusion with aspiration thrombectomy ± angioplasty but before stenting during primary PCI.
224311393|NCT00200759|DRUG|Cranberry juice and capsules|
224311394|NCT04617054|DRUG|AB-106|600mg QD for each subjects.
224311395|NCT03255655|DEVICE|Intense Therapeutic Ultrasound Treatment - ITU|
224311396|NCT05940155|DIAGNOSTIC_TEST|RT PCR test of COVID 19|diagnostic test by naso-pharyngel swab to confirm the diagnosis of covid-19 at moderate and severe cases.
224311397|NCT03040323|DRUG|Lumason 60.7Mg Powder for Injection|Lumason 60.7Mg Powder for Injection injected prior to ultrasound-guided biopsy
223604938|NCT06288048|PROCEDURE|Experimental: Deep Dry Needling (DDN), Ischemic Compression, Cold Spray with Stretching + MFT|"Experimental:~Target: Proximal third of m. Brachioradialis (BR) Patient position: Seated Therapist position: Same side as needle insertion Needle insertion direction: Lateral-to-medial towards clinician\&#39;s finger Needle type: AguPunt® Barcelona, Spain Technique: Seek three local twitch responses in m. Brachioradialis (BR) Alternative for no responses: 10 needle insertions and withdrawals at 1 Hz frequency~Ischemic Compression (IC):~Applied using sphygmomanometer on seated subject\&#39;s arm Pressure: Increased until ischemic pain (approx. 200 mmHg) Duration: Maintained for 90 seconds~Combined with three applications of Cryos Phyto Performance 400 ml cold spray synchronized with m. Brachioradialis (BR) stretching:~Stretching: Passive sustained mobilization with elbow extension and forearm pronation for 10 seconds~Mirror Therapy (MFT):~Setup: Patient seated with forearms resting on bed Mirror: 35 x 35 cm, covering punctured side at 45-degree angle for hand visualization"
223604939|NCT06288048|PROCEDURE|Deep Dry Needling (DDN), Ischemic Compression, Cold Spray with Stretching|The intervention protocol in this study will target individuals experiencing Post-needling pain associated with lateral elbow pain. It will comprise a series of treatments including Deep Dry Needling (DDN) focused on the proximal third of the m. Brachioradialis (BR), conducted with the patient seated and the therapist positioned on the same side as the needle insertion. Following DDN, ischemic compression (IC) will be applied using a sphygmomanometer on the seated subject\&#39;s arm, along with three applications of cold spray synchronized with m. Brachioradialis (BR) stretching. The intervention will not conclude with Mirror Therapy (MFT).
223604940|NCT03824002|DRUG|Dulaglutide|Diabetes therapy with dulaglutide and various combinations of insulin, metformin, glinides
223752281|NCT04289116|BEHAVIORAL|We Test|This design tests the added benefits of adjunct intervention components delivered prior to receipt of CHTC-Assertive Communication Training (ACT) videos viewed by the couple separately and individually delivered Motivational Interviewing-based Communication Skills Training (MI-CST). These target the development of communication skills necessary to participate fully in HIV prevention and sexual safety discussions inherent to CHTC.
223752282|NCT04289116|BEHAVIORAL|IHTC|Individual HIV Testing and Counseling
223752283|NCT03034993|BEHAVIORAL|Text Messaging|"Subjects will receive text messages with reminders of their upcoming outpatient health care appointments at the Boston Health Care for the Homeless Program (BHCHP) clinic. The text message will indicate the time of the appointment and the location (e.g. Remember appointment Friday March 15 at 10am in the Yawkey building). Appointment reminder text messages will be sent 3 days ahead and again 1 day ahead of the appointment date. Medication related texts will be sent every other day and will be educational and motivational (e.g. Keep taking medications that way the doctor prescribed them, even if feeling fine). Mood related texts will also be sent every other day and ask about mood on a 1 to 5 scale. The participant will text back a response."
223752284|NCT00005833|DRUG|R115777|300mg P.O. BID.
223752285|NCT05009810|DIETARY_SUPPLEMENT|astaxanthin 4 mg|They will take astaxanthin 4 mg 1 capsule once daily for 2 months.
223752286|NCT05009810|DIETARY_SUPPLEMENT|astaxanthin 6 mg|They will take astaxanthin 6 mg 1 capsule once daily for 2 months.
223752287|NCT05009810|DIETARY_SUPPLEMENT|Placebo|They will take placebo 1 capsule once daily for 2 months.
223752288|NCT01796197|DRUG|Trastuzumab|
223752289|NCT01796197|DRUG|Pertuzumab|
223752290|NCT01796197|DRUG|Paclitaxel|
223752291|NCT01796197|DRUG|Doxorubicin|
223752292|NCT01796197|DRUG|Cyclophosphamide|
223752293|NCT01796197|PROCEDURE|Mastectomy|
223604941|NCT03824002|DRUG|Aspart insulin|Diabetes therapy with various combinations of insulin, metformin, glinides but without dulaglutide
223604942|NCT03824002|DRUG|Glargine|Diabetes therapy with various combinations of insulin, metformin, glinides but without dulaglutide
223604943|NCT03824002|DRUG|Metformin|Diabetes therapy with various combinations of insulin, metformin, glinides but without dulaglutide
223604944|NCT03824002|DRUG|Repaglinide|Diabetes therapy with various combinations of insulin, metformin, glinides but without dulaglutide
223604945|NCT01424501|BIOLOGICAL|GSK Biologicals' investigational TB vaccine GSK 692342|Intramuscular injection, 2 doses
223604946|NCT01424501|BIOLOGICAL|Placebo|Intramuscular injection, 2 doses
223752294|NCT01796197|RADIATION|Radiation Therapy|
223752295|NCT05721248|OTHER|Cessation of anti-HER2 treatment|Cessation of anti-HER2 treatment with standard treatment described as trastuzumab (Herceptin) with or without pertuzumab (Perjeta) continued as long as it is working or significant side effects occur.
223752296|NCT03733171|DRUG|PLATELET RICH PLASMA|PRP was injected in 1-2 ml by multiple injections into and circumferentially around the ulcer until bleeding stopped using a 25-G retractable, standard sclerotherapy needle
223752297|NCT03733171|DRUG|diluted epinephrine|diluted epinephrine was injected in 1-2 ml by multiple injections into and circumferentially around the ulcer until bleeding stopped using a 25-G retractable, standard sclerotherapy needle
223752298|NCT03733171|DEVICE|hemoclips|diluted epinephrine was injected followed by application of hemoclips
223752299|NCT01380184|DRUG|ridaforolimus|4 enteric-coated tablets, each containing 10 mg ridaforolimus, orally (total daily dose: 40 mg)
223752300|NCT01660828|OTHER|remote ischemic preconditioning (RIPC)|RIPC protocol which consist of three 5-min cycles of bilateral forearm ischemia
223752301|NCT00016952|DRUG|fluorouracil|
223752302|NCT00016952|DRUG|irinotecan hydrochloride|
223752303|NCT00016952|DRUG|leucovorin calcium|
223752304|NCT01076907|OTHER|Warm water|Warm water loading of sigmoid colon when spasms occur and waiting for them to subside.
223752305|NCT01076907|OTHER|Control|Air will be used instead of warm water for unsedated colonoscopy.
223752306|NCT06333327|DEVICE|Pulmonary vein isolation with the multielectrode radiofrequency balloon catheter|Pulmonary vein isolation with the multielectrode radiofrequency balloon catheter
223752307|NCT04097821|DRUG|Ruxolitinib|5 mg tablets for oral use
223752308|NCT04097821|DRUG|Siremadlin|10 mg, 20 mg, or 40 mg capsules for oral use
223752309|NCT04097821|DRUG|Crizanlizumab|100 mg/10 mL concentrate for infusion for intravenous use
223752310|NCT04097821|DRUG|Sabatolimab|100 mg/mL or 400 mg/4 mL concentrate for infusion for intravenous use
223752311|NCT04097821|DRUG|Rineterkib|100 mg capsule for oral use
223752312|NCT04097821|DRUG|NIS793|700 mg/7 mL concentrate for infusion for intravenous use
223752313|NCT04243538|BEHAVIORAL|I-HoME|I-HoME will consist of two components: (1) synchronous live video interactions between patients/CGs and a hospice nurse; and (2) educational videos.
223752314|NCT04300972|DIAGNOSTIC_TEST|Body/weight adaption|contrast media dose is adapted to weight and body type
223752315|NCT04300972|DIAGNOSTIC_TEST|Standard dose|a fixed amount of contrast media is used, independently of weight and body type
223752316|NCT03688763|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia (CBT-i)|CBT-i is an evidence-based treatment for insomnia. Participants will receive CBT-i via online program (Sleepio).
223752317|NCT03510117|BEHAVIORAL|Mindfulness|Mindfulness
223604947|NCT01980095|DRUG|RHB-105|"The intended dose is RHB-105 (12.5 mg rifabutin, 250 mg amoxicillin, and 10 mg omeprazole capsules) 4 capsules every eight hours, equivalent to a total daily dose of:~* Rifabutin 150 mg~* Amoxicillin 3000 mg~* Omeprazole 120 mg~Subjects will take study drug every 8 hours with food for 14 consecutive days."
223604948|NCT01980095|DRUG|Placebo|Subjects will take 4 placebo capsules every 8 hours with food for 14 days.
223604949|NCT00640848|DRUG|almorexant|1 dose of 400 mg in two treatment sequences
223604950|NCT00640848|DRUG|almorexant|1 dose of 200 mg in two treatment sequences
223604951|NCT00640848|DRUG|almorexant|1 dose of 100 mg in two treatment sequences
223604952|NCT00640848|DRUG|almorexant|1 dose of 50 mg mg in two treatment sequences
223604953|NCT00640848|DRUG|almorexant|1 dose of 1000 mg in two treatment sequences
223604954|NCT03148041|OTHER|health education program|"Intensive health education program for intervention group: 1.The introductory 30 minute Arabic lecture for increase level of the awareness of the participants regarding stroke. Lecture from the USA National Stroke Association, 2011, will be used. The lecture includes the following issues about stroke (1) definition; (2) signs and symptoms; (3) risk factors; (4) treatment; and (5) prevention.~2\. Self-help materials will involve health education brochures regarding stroke and will be distributed for all participants at the time they are attending the lecture. The brochures which will be used for this study will be collected from the World Stroke Day 2016 Brochures, the Arabic version.~The routine care for control group: different lecture and brochures will be used"
223604955|NCT00002399|DRUG|Posaconazole|
223604956|NCT00002399|DRUG|Fluconazole|
223604957|NCT03079063|BIOLOGICAL|Eptacog alfa, biosimilar|Either a single dose of eptacog alfa biosimilar 30 μg/kg and one single dose of NovoSeven 30 μg/kg, or vice versa, with doses separated by a washout period. Then, in an open follow up phase of 12 months, for every bleeding episode eptacog alfa biosimilar 30 μg/kg, on demand, for one of more days until resolution of bleeding, based on the Investigator's decision - or - prophylaxis with eptacog alfa biosimilar, with dose, frequency, and duration of treatment based on the Investigator's decision. The modality of treatment (on demand or prophylaxis) will be decided by the Investigator.
223604958|NCT03079063|BIOLOGICAL|Novoseven|Either a single dose of eptacog alfa biosimilar 30 μg/kg and one single dose of NovoSeven 30 μg/kg, or vice versa, with doses separated by a washout period.
223604959|NCT03223337|DRUG|Daprodustat (GSK1278863)|Daprodustat (GSK1278863) 6 mg tablet will be given to all subjects as a single dose via oral route. Daprodustat (GSK1278863) is a 9.0 millimeter (mm) round, compound radius, white film coated tablet.
223604960|NCT00531869|BEHAVIORAL|biases towards products|
223604961|NCT01382238|DRUG|Dolutegravir 50 mg tablet|Dolutegravir is an experimental drug in the integrase inhibitor class for the treatment of HIV.
223604962|NCT01382238|DRUG|Dolutegravir 50 mg oral granules|Dolutegravir is an experimental drug in the integrase inhibitor class for the treatment of HIV.
223752318|NCT00044343|DRUG|lapatinib|
223752319|NCT03159728|BEHAVIORAL|Educative intervention:|"* In the induction of the new group members are present, including caregivers who start the program and those who coordinated.~* In Module I: to strengthen the knowledge of the situation and the people involved in care.~* In Module II: to strengthen the value in the caregiver through decision making, skill and social support to back it up.~* In Module III: or end, after analyzing that uneasy caregiver, patience is reviewed through the meaning of family care and self."
223752320|NCT01730183|OTHER|Bone marrow derived stem cells|Intrathecal administration of autologous bone marrow derived stem cells upto a cell dose of equal or greater than 10(8)BMMNCs.
223752321|NCT06968988|DRUG|Zanzalintinib|Zanzalintinib will be supplied by Exelixis, Inc.
223752322|NCT06968988|DRUG|Ipilimumab|Ipilimumab will be commercially sourced.
223752323|NCT06968988|DRUG|Nivolumab|Nivolumab will be commercially sourced.
223604963|NCT01362608|DRUG|Canakinumab, ACZ885|Canakinumab and placebo matching to triamcinolone acetonide
223604964|NCT01362608|DRUG|Triamcinolone acetonide|Triamcinolone acetonide 40 mg and placebo matching to canakinumab
223604965|NCT00726414|DRUG|Quinine Sulfate 2 x 324 mg Capsules|Quinine Sulfate (2 x 324 mg capsules) administered after an overnight fast of at least 10 hours.
223604966|NCT00726414|DRUG|Quinine Sulfate 2 x 324 mg Capsules|Quinine Sulfate (2 x 324 mg capsules) administered 30 minutes after a standardized, high fat breakfast.
223604967|NCT03403439|DRUG|BI 1015550|Reference and Test Treatment
223604968|NCT03403439|DRUG|itraconazole|Test treatment
223604969|NCT01679132|DEVICE|BAROSTIM NEO System and Medical Management|"Experimental: Device and Medical Management~Subjects have been implanted with the BAROSTIM NEO System and receive optimal medical management, including drugs to be determined by the subject's physician. Drug types include: Loop Diuretics; Thiazide Diuretics; Potassium-sparing Diuretics; Aldosterone receptor blockers; Beta-blockers; Beta-blockers with intrinsic sympathomimetic activity; Combined alpha- and beta-blockers; ACE inhibitors; Angiotensin II antagonists; Calcium channel blockers- non-Dihydropyridines; Calcium channel blockers- Dihydropyridines; Alpha1-blockers; Central alpha2-agonists and other centrally acting drugs; Direct vasodilators."
223752324|NCT05386108|DRUG|Elacestrant|300 mg, 400 mg
223752325|NCT05386108|DRUG|Abemaciclib|100 mg, 150 mg
223752326|NCT06974968|BIOLOGICAL|Allogeneic Human Induced Pluripotent Stem Cell (iPSC)-Derived Motor Neuron Progenitor Cells|"Description:~XS228 Cell Injection is an investigational, allogeneic cell therapy product composed of motor neuron progenitor cells (MNPCs) derived from human induced pluripotent stem cells (iPSCs). This advanced therapy medicinal product (ATMP) is being developed for the treatment of spinal cord injury (SCI) and represents a novel approach in regenerative medicine."
223752327|NCT06974968|OTHER|Placebo|Standard rehabilitation protocols
224311398|NCT03040323|DRUG|Placebos|Placebos injected prior to ultrasound-guided biopsy
223752328|NCT03393156|BEHAVIORAL|Internet-based metacognitive therapy|Internet-based metacognitive therapy on a safe internet platform. Treatment is divided into ten modules, each containing homework assignments . The participants will be assigned a therapist that they can contact through a message system in the platform and expect answer within 24 hour
223752329|NCT00719836|DRUG|SB1518|SB1518 taken orally daily for 28 consecutive days in a 28-day cycle
223604970|NCT00877240|BEHAVIORAL|Behavioral intervention-to determine the effectiveness of a general intervention on healthy living habits of IDF staff|the program consists of 3 times a week of physical activity, nutrition advice, weight lodd program, stress workshop and smoking cessation workshop
223752330|NCT02180516|DRUG|Meloxicam|
223752331|NCT02180516|DRUG|Other Non Steroidal Anti-Inflammatory Drugs (NSAIDs) except etodolac|
223752332|NCT05500378|OTHER|Head extension and rotation movement|Active exercise of the head
223752333|NCT06573476|BEHAVIORAL|PRC supported text + AI driven CSDH-enhanced text|"In interventional Arm-1, PRC-supported text check-ins to participants (3x/week) will be provided by PRC study staff in addition to automated AI-driven texts. The PRC will personalize text check-ins to participants based on: (a) baseline CSDH needs (e.g., food insecurity, legal aid); (b) initial intake visit in primary care or challenges with service entry; and (c) content outlined in the CSH training addressing emerging participant challenges."
223752334|NCT06573476|BEHAVIORAL|AI driven CSDH-enhanced text only|In interventional Arm-2, participants will receive the AI-driven CSDH-enhanced text messaging only. Participants in this arm will not receive text support from the PRC.
223752335|NCT06573476|BEHAVIORAL|Treatment as Usual (TAU)|In Arm-3, the control group, individuals randomized to the control arm will receive treatment as usual (i.e., verbal instructions and NYC Dept of Health pamphlets detailing access to OUD and social services). No services will be provided except for social/clinical service referrals given at the end of each REDCap visit.
223752336|NCT05028621|DIAGNOSTIC_TEST|Genetic testing|Genetic testing of blood or tissue sample and limited medical information sent to an outside company. Database will link genome sequence data with human trait information, including cancer and other diseases, to be sent to participant's physician.
223604971|NCT00863005|DRUG|K201|Cream
223604972|NCT00863005|DRUG|K201|
223604973|NCT00491933|PROCEDURE|Quantiferon-TB Gold assay|
223604974|NCT00491933|PROCEDURE|Tuberculin skin test|
223604975|NCT01336140|DRUG|Aminophylline|75 mg of intravenous aminophylline
223604976|NCT01336140|DRUG|Placebo|Matching 0.9 Normal Saline (sterile salt water)administered intravenously.
223604977|NCT05015569|DEVICE|COVR Medical Garment|"COVR undergarments are available in a Half Short design for unilateral lower extremity procedures and a Bilateral (brief) style garment designed for bilateral lower extremity procedures. Either style may be worn for upper extremity, trunk, spine procedures, etc. where an undergarment would be preferred along with a standard hospital gown. The garments are available in a variety of sizes. The COVR garments can be released at the hip(s)/waistline for improved access to the lateral hip and include retractable panels for procedural access to the groin and genitals if needed by the care team."
223604978|NCT05015569|OTHER|Standard Patient Gown|The standard patient gown is provided to all patients in a hospital setting.
223604979|NCT01978041|OTHER|Meal prepared with non fluoridated water|Ingestion of a typical brazilian meal (rice, beans, meat, french beans, carrots, gelatin and juice) prepared with purified water containing a fluoride dose of 0.8 ug of fluoride/kg body weight (resulting of the natural fluoride concentration in foods).
223604980|NCT01978041|OTHER|Meal prepared with fluoridated water|Ingestion of a typical brazilian meal (rice, beans, meat, french beans, carrots, gelatin and juice) prepared with fluoridated water (1 ug of fluoride/mL), to provide a total intake of approximately 12 ug of fluoride/kg body weight.
223752337|NCT06052969|DEVICE|Pulse NanoMED System|The Pulse NanoMED System is comprised of iron nanoparticles and a small, portable, magnetic Workstation.
223752338|NCT05429892|BEHAVIORAL|Smoking cessation counseling and food delivery|"The community health workers will delivery three 30-minute sessions during intervention months 1 through 6 (1,3,6 months) to provide interpersonal level support for smoking cessation. The community health workers will conduct real-time video motivational counseling to clients. The community health workers will implement the 5As (Ask, Advise, Assess, Assist, Arrange) and support smokers in quitting, if ready, and build confidence toward quitting if they are uncertain about change.~Smokers enrolled in the TRTsocialmot1 arm will be provided with food boxes or grocery store gift card at 1,3, and 6 months. Healthy meal preparation instructions will be included and delivery by project staff and will reduce transportation barriers to food access rural counties.~Participants will receive educational materials at 1, 3, and 6 months."
223752339|NCT05429892|BEHAVIORAL|Smoking cessation counseling|"The community health workers will deliver three 30-minute sessions during intervention months 1 through 6 (1,3,6 months) to provide interpersonal level support for smoking cessation. The community health workers will conduct real-time video motivational counseling to clients. The community health workers will implement the 5As (Ask, Advise, Assess, Assist, Arrange) and support smokers in quitting, if ready, and build confidence toward quitting if they are uncertain about change.~Participants will receive educational materials at 1, 3, and 6 months."
223752340|NCT05429892|BEHAVIORAL|Food delivery|"Smokers enrolled in the TRTsocial2 arm will be provided with food boxes or grocery store gift card at 1, 3, and 6 months Healthy meal preparation instructions will be included and delivery by project staff and will reduce transportation barriers to food access rural counties.~Participants will receive educational materials."
223752341|NCT04134923|DRUG|[11C] Pittsburgh Compound-B (PIB)|Participants will receive a single intravenous bolus injection of 6.0 - 20.0 mCi (222-740 MBq) of the investigational radiotracer \[11C\] PIB. Participants will then undergo a \[11C\] PIB PET/CT scan conducted in the Center for Clinical Imaging Research (CCIR) facility.
224311399|NCT06299852|DRUG|Trastuzumab emtansine|SRT for metastatic foci
224311400|NCT04428333|DRUG|Feladilimab|Humanized anti-inducible T cell co-stimulatory receptor (ICOS) immunoglobulin G4 (IgG4) monoclonal antibody (mAb)
223604981|NCT01978041|OTHER|Non fluoridated water|Ingestion of purified water with addition of fluoride to provide a total intake of approximately 0.8 ug of fluoride/kg body weight, which represented the same fluoride ingestion dose of the experimental phase with meal prepared with non fluoridated water.
223604982|NCT01978041|OTHER|Fluoridated water|Ingestion of fluoridated water (1 ug F/mL), to provide a total intake of approximately 12 ug of fluoride/kg body weight.
223604983|NCT01978041|OTHER|Meal prepared to provide a fluoride dose of 60 ug F/kg|Ingestion of a typical Brazilian meal (rice, beans, meat, french beans, carrots, gelatin and juice) prepared with non-fluoridated water, with sodium fluoride solution added to the juice to provide a total intake of approximately 60 ug of fluoride/kg body weight.
223604984|NCT01978041|OTHER|Meal prepared to provide a fluoride dose of 120 ug F/kg|Ingestion of a typical Brazilian meal (rice, beans, meat, french beans, carrots, gelatin and juice) prepared with non-fluoridated water, with sodium fluoride solution added to the juice to provide a total intake of approximately 60 ug of fluoride/kg body weight.
223604985|NCT05115032|DEVICE|Vestibular retraining with dynamic posturography|12 sessions, twice per week, of rehabilitation exercises last about 20 minutes, using CDP and interactive visual feedback
223604986|NCT05115032|BEHAVIORAL|At-home rehabilitation exercises|6 weeks of daily rehabilitation exercises involving nodding and shaking of the head
223604987|NCT03814408|BIOLOGICAL|RP-L102|CD34+ enriched cells from subjects with Fanconi anemia subtype A transduced ex vivo with lentiviral vector carrying the FANCA gene, PGK-FANCA-WPRE
223604988|NCT02697318|DRUG|Timolol maleate 0.5% ophthalmic solution|
223604989|NCT00971139|BEHAVIORAL|Access to an OPPC service|Access to an Internet-based messaging system where patients can ask questions and receive advice and support from care providers at the hospital and social counsellors
223604990|NCT02002741|DRUG|Paracetamol|Ibuprofen 3 doses administered q24h + Paracetamol 12 doses administered q 6h
223604991|NCT02002741|DRUG|Placebo|Ibuprofen 3 doses administered q24h + Placebo : 12 doses administered q 6h
223604992|NCT05334628|PROCEDURE|Preoperative Erector spinae plane block|Erector spinae plane block will be performed unilaterally, under US guidance, before the surgical operation, after the induction of anesthesia, and when the patient is placed in the lateral decubitus position.
223604993|NCT05334628|PROCEDURE|Postperative Erector spinae plane block|Erector spinae plane block will be performed unilaterally, under US guidance, after the surgical operation, under general anesthesia, and when the patient is placed in the lateral decubitus position.
223604994|NCT02638649|PROCEDURE|Lung ultrasound|At each call, the paramedic will initially evaluate the patient clinically conducting a standard history and physical exam. The paramedic will then use the portable U/S machine to look for the presence of either unilateral or bilateral B-lines indicating possible pneumonia (in the case of unilateral B-lines) or pulmonary edema (in the case of bilateral B-lines). The paramedic will then document the presence or absence of B-lines for each lung on the prehospital study sheet. The paramedic will then use the U/S to evaluate for the presence of pleural effusions, lung sliding and pericardial effusion.
223604995|NCT02638649|DEVICE|ultrasound|
223604996|NCT03226834|DEVICE|MUSIC CARE|Musicotherapy session using one of the U musical sequences of MUSIC CARE among the preselected music styles
223604997|NCT03226834|OTHER|PERSONAL PLAY-LIST|Musicotherapy session using the patient's play-list composed by the patient with her favourite songs
223604998|NCT03676244|DEVICE|immediate implant in defected anterior maxillary esthetic zone|"Patients indicated for immediate implant placement with presence of partial or complete loss (type 2 sockets) of labial bone plate.~Use of GBR (mix of autogenous bone graft and xenograft in combination to absorbable collagen membrane) and healing abutment at the same time of extraction then place implant palatally engaging the side walls of the socket, leaving a buccal gap.~construct custom two-piece screw retained healing abutment then remove custom healing abutment and fit and place the collagen membrane for GBR , the membrane should cover the defect 2 mm circumferentially and extend to the level of free gingival margin, Place bone graft material buccal to the implant surface ,replace custom healing abutment."
223604999|NCT00193817|PROCEDURE|Two field vs Three field lymphadenectomy|
223752342|NCT06095141|DRUG|Cisplatin|Cisplatin 25 mg/m2, ivgtt, 30 min, D1, 8. The administration of other chemotherapeutic agents including gemcitabine, nab-paclitaxel, fluorouracil, irinotecan, capecitabine is applied according to the National Comprehensive Cancer Network (NCCN) guideline. PARP inhibitor will be recommended to patients with platinum-sensitive metastatic PDAC after six months of cisplatin based regimen.
223752343|NCT03490513|DRUG|anastrozole (1 mg/day)|Participants will take Anastrozole 1mg per day, attend behavioral classes conducted by a dietitian, receive instruction on how to loss 10% of their body weight and participate in a supervised exercise training program.
223605000|NCT02155777|DRUG|OrthoNovum 1/35|
223605001|NCT00624273|DRUG|Sildenafil therapy|oral use
223605002|NCT03499184|DIETARY_SUPPLEMENT|P Flor locally delivered|Locally delivered Lactobacillus reuteri 1.2 CFU per gram
223605003|NCT03499184|DIETARY_SUPPLEMENT|P Flor systemically administered|Systemically administered Lactobacillus reuteri 1.2 CFU per gram
223605004|NCT03499184|DRUG|Amoxil 500 mg Oral Capsule|Systemically administered Amoxil 500 mg thrice daily
223605005|NCT03499184|DRUG|Flagyl 400 mg Tablet|Systemically administered Metronidazole 400 mg twice daily
223605006|NCT00601497|DEVICE|InterX 5000|20-30 minute device sessions on the following schedule: 3 times per week for 3 weeks, then 2 times per week for 3 weeks, then 1 time per week for 2 weeks.
223605007|NCT00354393|DRUG|Cisplatin|
223605008|NCT00354393|DRUG|Methotrexate|
223605009|NCT00354393|DRUG|Vinorelbine ditartrate|
223605010|NCT00354393|PROCEDURE|Adjuvant therapy|
223605011|NCT00354393|PROCEDURE|Conventional surgery|
223605012|NCT00354393|PROCEDURE|Neoadjuvant Therapy|
223605013|NCT00354393|RADIATION|3-dimensional conformal radiation therapy|
223605014|NCT00354393|RADIATION|Intensity-modulated radiation therapy|
223605015|NCT05855369|DEVICE|Trigeminal Nerve Stimulation (TNS)|Non-invasive, pain-free, low-level electrical stimulation to the forehead to modulate the trigeminal nerve and enhance smell function through activation of the highly connected olfactory-intranasal trigeminal brain circuits.
223605016|NCT05855369|OTHER|Active Smell Training (ST)|Sniffing various higher intensity odorant chemicals while performing odor-related cognitive tasks. 16 odorant chemicals will be used for training including: 2 phenyl ethanol, eugenol, lemon, eucalyptus, cinnamon, peppermint, coffee, mandarin, lavender, vanilla, lilac, ginger, chocolate, thyme, banana, and bacon.
223752344|NCT03490513|DRUG|Placebo|Participants will take a placebo tablet every day, attend behavioral classes conducted by a dietitian, receive instruction on how to loss 10% of their body weight and participate in a supervised exercise training program.
223752345|NCT03532295|DRUG|Epacadostat|-All BID doses will be taken in the morning and evening, approximately 12 hours apart
223752346|NCT03532295|DRUG|Bevacizumab|-The first infusion will be over the course of 90 minutes; if tolerated, the second infusion will be over the course of 60 minutes; if tolerated, all subsequent infusions will be over 30 minutes
223605017|NCT05855369|OTHER|Placebo Smell Training (PBO)|Sniffing the same lower intensity odorant chemicals (i.e. N-butanol and 2-phenyl ethanol) over the course of the trial and performing no odor-related cognitive tasks.
223605018|NCT05362032|DEVICE|Biopsy|Undergo transrectal MRI-targeted biopsy
223605019|NCT05362032|PROCEDURE|Endorectal Magnetic Resonance Imaging|Endorectal MRI
223605020|NCT05690555|OTHER|Preoperative and Postoperative Pelvic Floor Physical Therapy (PFPT)|"Patients will present to see the physical therapist 3 weeks and 6 weeks postoperatively. The following interventions will be performed:~3 weeks:~* Subjective assessment of bowel and bladder function~* Visual and external palpation and assessment of external pelvic floor region~* Intravaginal pelvic floor assessment~* Pelvic floor muscle dynamics and coordination assessment~* Instruction of pelvic floor coordination and lengthening~* Discussion of dilator program and progression~* Home program with instructions~  6 weeks:~* External scar assessment and treatment if tissue healing allows~* Instruction to patient of scar mobilizations~* Intravaginal pelvic floor assessment and treatment if indicated~* Review of pelvic floor lengthening and coordination~* Review and progression of dilator program if appropriate~* Assessment of current bowel/bladder symptoms; home program and instructions to address these symptoms"
223605021|NCT05690555|OTHER|No Pelvic Floor Physical Therapy (PFPT)|"Patients will present to see the physical therapist 3 weeks postoperatively. The following interventions will be performed:~Subjective assessment of bowel and bladder function. Visual and external palpation and assessment of external pelvic floor region. Intravaginal pelvic floor assessment. Pelvic floor muscle dynamics and coordination assessment. Review of pelvic floor anatomy and function."
223605022|NCT05690555|OTHER|Postoperative PFPT|Preoperative Diaphragmatic breathing Discuss dilator positioning/introduce dilator program External pelvic floor assessment Teach pelvic floor coordination Current bowel/bladder symptoms; home program and instructions 3 weeks Assessment of bowel and bladder function Visual and external palpation and assessment of external pelvic floor region Intravaginal pelvic floor assessment Pelvic floor muscle dynamics and coordination assessment Instruction of pelvic floor coordination and lengthening Discussion of dilator program and progression Home program with instructions 6 weeks External scar assessment and treatment if tissue healing allows Instruction to patient of scar mobilizations Intravaginal pelvic floor assessment and treatment if indicated Review of pelvic floor lengthening and coordination Review and progression of dilator program if appropriate Current symptoms; home program and instructions
223605023|NCT06367699|BEHAVIORAL|Usual Care|Parent/guardian and adolescent participants will not receive the ECA-HPV system intervention. A survey will be given via REDCap to the parent/guardian and adolescent participants at baseline, after the first well child clinic visit, and after the second well child clinic visit to assess self-reported vaccination attitudes and behaviors. Adolescent participants will receive usual care.
223605024|NCT06367699|BEHAVIORAL|ECA-HPV App with Clinic Notification and Adolescent Functions Disabled|Parent/guardian participants will interact with the ECA-HPV smartphone-based system over a period of \~16 months. The ECA-HPV is designed to interact with parents/guardians to increase vaccine acceptability prior to the clinic visit. A survey will be given via REDCap at baseline, after the first well child clinic visit, and after the second well child clinic visit to both the parent/guardian and adolescent to assess self-reported vaccination attitudes and behaviors. Parent/guardian participants will also be asked questions about the ECA-HPV app. The clinic notification and adolescent functions of the complete ECA-HPV app are disabled. Adolescent participants will receive usual care.
223605025|NCT06367699|BEHAVIORAL|ECA-HPV App with Clinic Notification Function Enabled|Parent/guardian participants will interact with the ECA-HPV smartphone-based system over a period of \~16 months. The ECA-HPV is designed to interact with parents/guardians to increase vaccine acceptability prior to the clinic visit. A survey will be given via REDCap at baseline, after the first well child clinic visit, and after the second well child clinic visit to both the parent/guardian and adolescent to assess self-reported vaccination attitudes and behaviors. Parent/guardian participants will also be asked questions about the ECA-HPV app and the clinic notification feature. The clinic notification is enabled on the parent/guardian ECA-HPV app, however, the adolescent does not have access to the adolescent ECA-HPV app. Adolescent participants will receive usual care.
223605026|NCT06367699|BEHAVIORAL|ECA-HPV App with Adolescent Function Enabled|Parent/guardian participants will interact with the ECA-HPV smartphone-based system over a period of \~16 months. The ECA-HPV is designed to interact with parents/guardians to increase vaccine acceptability prior to the clinic visit. A survey will be given via REDCap at baseline, after the first well child clinic visit, and after the second well child clinic visit to both the parent/guardian and adolescent to assess self-reported vaccination attitudes and behaviors as well as ECA-HPV app use and satisfaction. The adolescent function is enabled, however, the clinic notification function is disabled. Thus, the ECA-HPV system app will have an adolescent-facing feature for adolescent participants to engage with the agent. Adolescent participants will receive usual care and will be able to engage with the adolescent version of the ECA-HPV app throughout the duration of the study.
223752347|NCT03532295|RADIATION|Radiation therapy|-The gross tumor maximum diameter (to be irradiated) to be \</= 6 cm in the first 6 patients. If more than 1 target is irradiated, then the sum of all the target maximum diameters should be \</= 6 cm. No more than 3 separate targets for RT is allowed.
223752348|NCT03532295|DRUG|Retifanlimab|-Will be supplied by Incyte
223752349|NCT03388190|DRUG|Nivolumab|"FLOX: Intravenous oxaliplatin 85 mg/m2 on day 1; bolus 5-fluorouracil 500 mg/m2 and bolus Leucovorin on days 1 and 2; IV administration every 2 weeks.~Nivolumab: 240 mg flat dose; IV administration every 2 weeks."
223752350|NCT03388190|DRUG|FLOX|FLOX: Intravenous oxaliplatin 85 mg/m2 on day 1; bolus 5-fluorouracil 500 mg/m2 and bolus Leucovorin on days 1 and 2; IV administration every 2 weeks.
223752351|NCT05984823|OTHER|Home based body weight type exercises with blood flow restriction|"The participant will be asked to complete blood flow restricted exercises described below three times per week for 6 weeks.~Exercise protocol: Two tourniquets will be placed around the upper part of each thigh, these tourniquets will be inflated to an individualised and maintained for the duration of each exercise (including the inter-set rest period) but deflated during the 5 min rest in between. Five Body weight Exercises will be performed: Sitting knee extensions, standing knee raise, Heel-toe raises, Bilateral, mini-squat behind a chair, and Chair rise/sit to stand."
223752352|NCT05984823|OTHER|Home based body weight type exercises|The participant will be asked to complete body weight exercises for three times per week for 6 weeks. These exercises include: Sitting knee extensions, standing knee raise, Heel-toe raises, Bilateral, mini-squat behind a chair, and Chair rise/sit to stand.
223752353|NCT06551701|OTHER|Pharmacist call|Pharmacists will call patients and their providers to discuss benefits of statin use
223752354|NCT03511976|BEHAVIORAL|Tier 1 Classroom Management|The primary teacher for each participating student will receive consultation related to implementing Tier I management strategies at a classroom level for all students including the target child (see Appendix C). Consultation will be provided by trained study personnel and the strategies will be implemented by the general education teacher (i.e., the end user of the intervention)
223752355|NCT03511976|BEHAVIORAL|Daily Report Card (DRC)|Students in the RTI DRC condition will receive Tier II strategies, namely an individualized DRC. Behavioral consultants will meet with teachers to identify appropriate behavioral targets and establish a DRC according to established protocol (see our website for an example http://ccf.fiu.edu/for-families/resources-for-parents/printable- information/). Consultants will also meet with parents to develop a plan for reinforcing the DRC at home using a hierarchical menu of rewards/privileges that will be provided contingent on meeting daily goals.
223752356|NCT03511976|BEHAVIORAL|Enhanced DRC (DRC-E)|"In this condition, students who did not show sufficient response to the Phase 1 DRC will receive additional and more intensive Tier II supports.~Following student assignment to RTI-E, the teacher will have meet with one of the consultants to complete a functional behavior analysis (FBA) to identify remaining target behaviors and ascertain their function. The consultant and teacher will then use the completed FBA to develop a treatment plan for an enhanced DRC (DRC-E).~Tier II enhancements will be chosen to directly map on to the functions of the target behaviors as outlined in the FBA."
223752357|NCT03511976|DRUG|Stimulant|Students will receive either a long-acting methylphenidate preparation or a long-acting mixed amphetamine salts preparation based on parent consultation with the study physician. The prescribed medication will be taken daily.
223752358|NCT04964102|BEHAVIORAL|Workshop of Enhancing Interpersonal Effectiveness, Emotional Regulation and Clinical Communication Skills|Workshop of Enhancing Interpersonal Effectiveness, Emotional Regulation and Clinical Communication Skills
223752359|NCT03999710|RADIATION|Radiation Therapy|Treatment will consist of 60 Gy in 30 fractions to fields encompassing gross tumor and lymph nodes.
223752360|NCT03999710|DRUG|Durvalumab|A dose of 1500mg (for patients \>30kg in weight) will be administered using an IV bag containing 0.9% (w/v) saline or 5% (w/v) dextrose, with a final durvalumab concentration ranging from 1 to 15 mg/mL, and delivered through an IV administration set with a 0.2- or 0.22- μm filter.
223752361|NCT04960787|OTHER|Educational Intervention|Watch online educational videos
223605027|NCT06367699|BEHAVIORAL|ECA-HPV App with Clinic Notification and Adolescent Functions Enabled|Parent/guardian participants will interact with the complete ECA-HPV smartphone-based system over a period of \~16 months. The ECA-HPV is designed to interact with parents/guardians to increase vaccine acceptability prior to the clinic visit. A survey will be given to parent/guardian participants via REDCap at baseline, after the first well child clinic visit, and after the second well child clinic visit to both the parent/ guardian and adolescent to assess self-reported vaccination attitudes and behaviors as well as ECA-HPV app use and satisfaction and questions about the clinic notification feature. The complete ECA-HPV app includes the parent version and adolescent versions of the ECA-HPV app. Both versions have the clinic notification feature enabled. Adolescent participants will receive usual care and can engage with the adolescent version of the ECA-HPV app throughout the study.
223605028|NCT05327686|BIOLOGICAL|Avelumab|Given IV
223605029|NCT05327686|DRUG|Axitinib|Given PO
223605030|NCT05327686|PROCEDURE|Biospecimen Collection|Undergo collection of blood
223605031|NCT05327686|PROCEDURE|Bone Scan|Undergo bone scan
223605032|NCT05327686|DRUG|Cabozantinib|Given PO
223605033|NCT05327686|PROCEDURE|Computed Tomography|Undergo CT
223605034|NCT05327686|BIOLOGICAL|Ipilimumab|Given IV
223752362|NCT04960787|BEHAVIORAL|Patient Navigation|Meet with CENTS counselor and PAF case manager
223605035|NCT05327686|DRUG|Lenvatinib|Given PO
223605036|NCT05327686|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223605037|NCT05327686|BIOLOGICAL|Nivolumab|Given IV
223605038|NCT05327686|BIOLOGICAL|Pembrolizumab|Given IV
223605039|NCT05327686|RADIATION|Stereotactic Ablative Radiotherapy|42 Gy in 3 fractions
223605040|NCT03827057|BEHAVIORAL|Reconsolidation of Traumatic Memories (RTM)|"RTM is a trauma-focused, but not cognitive behavioral, therapy: it involves brief exposure to the trauma memory, but does rely on conscious responses to correct the symptoms of PTSD. RTM was first used to treat phobias in the 1970s, and has more recently been refined to focus on reconsolidation to update long-term memories, reconfiguring the salience structure of the original memory, and incorporating those changes into the overall memory structure. Reconsolidation is a neural mechanism for updating long-term memory, inserting new information that contradicts an essential element of the memory, which makes it possible to change the emotional tone and salience of the memory. It is hypothesized that RTM can thereby achieve quicker, greater, and more durable responses than with traditional exposure therapies."
223605041|NCT03827057|BEHAVIORAL|Prolonged Exposure (PE)|PE is a trauma-focused cognitive behavioral therapy (TFCBT) that depends on exposure to the feared stimulus as a central effector of change, utilizing extinction, which theorizes that if a trigger that previously elicited a fear response is presented enough times without reinforcement, the response fades. Previous researchers have shown that extinction involves the creation of a new blocking memory which prevents expression of the original fear memory. While PE has more evidence to support its efficacy in PTSD than other approaches, and a majority achieve a clinical response (e.g., decrease in CAPS score of 10 or more), many do not achieve complete remission of symptoms, and the blocking memory may be fragile, so subsequent triggers may result in relapse.
223605042|NCT05437562|PROCEDURE|Ewing Below Knee Amputation|Ewing Below Knee Amputation
223605043|NCT05437562|PROCEDURE|Standard Below Knee Amputation|Standard Below Knee Amputation
223752363|NCT04960787|OTHER|Quality-of-Life Assessment|Ancillary studies
223752364|NCT04960787|OTHER|Questionnaire Administration|Complete questionnaires
223752365|NCT06521567|DRUG|Cobolimab|Cobolimab will be administered
223752366|NCT06521567|DRUG|Dostarlimab|Dostarlimab will be administered
223605044|NCT04502966|BIOLOGICAL|Dupixent®|An initial dose of 600 mg (two 300 mg injections), followed by 300 mg administered every other week (biweekly), by subcutaneous injection.
223605045|NCT04502966|BIOLOGICAL|Grazax®|"One Grazax® tablet daily, by sublingual administration.~Grazax® is formulated as a freeze-dried oral lyophilisate/orally disintegrating tablet for oromucosal use. The active pharmaceutical ingredient is a standardized allergen extract derived from extraction and purification of grass pollen from timothy grass (Phleum pratense). The biological activity of the allergen is expressed in Standardized Quality Tablet units (SQ-T) units. The Grazax® dosage is one oral lyophilisate (75,000 Standardized Quality Tablet units (SQ-T) or approximately 2800 Bioequivalent allergy units (BAU), a measure of Phleum pratense SQ total biological potency defined by the FDA."
223605046|NCT04502966|DRUG|Dupixent® Placebo|"Two subcutaneous injections of Placebo (for Dupilumab) as a loading dose followed by a single injection administered every other week.~Dupixent® placebo is a subcutaneous injection whose composition is identical to the active Dupixent®, with the exception of the active pharmaceutical ingredient."
223605047|NCT04502966|DRUG|Grazax® Placebo|"One tablet of Placebo (for Grazax®) daily, by sublingual administration.~Grazax® placebo is a tablet whose composition is identical to the active Grazax® tablet with the only exception being exclusion of the active pharmaceutical ingredient, Phleum pratense Standardized Quality Tablet (SQ-T) units."
223752367|NCT03747874|DIAGNOSTIC_TEST|ventilatory polygraphy|we put a ventilatory polygraphy device on the patient in the evening, they come back home to sleep while the device is recording ventilatory parameters and they come back the morrow to give the device back
223752368|NCT03402009|BEHAVIORAL|Apps|Apps and weblinks to coach self-guided meditation.
223752369|NCT03402009|BEHAVIORAL|EEG neurofeedback|Device provides feedback based on EEG readings.
223752370|NCT06018883|DRUG|Ascorbate|Vitamin C 900 mg/day, three times a day, orally.
223752371|NCT06018883|DRUG|Nab paclitaxel|Nab-paclitaxel (120 mg per square meter of body-surface area) on days 1, 8, and 15 every 4 weeks
223752372|NCT06018883|DRUG|Gemcitabine|Gemcitabine (1000 mg per square meter) on days 1, 8, and 15 every 4 weeks
223752373|NCT02776917|DRUG|Cirmtuzumab + Paclitaxel|Cirmtuzumab and paclitaxel may be administered until disease progression or unacceptable toxicity. Cirmtuzumab or paclitaxel may be continued alone if the other drug is discontinued due to toxicity.
223752374|NCT06563765|OTHER|FAP-targeting PET/CT imaging will be performed on the enrolled patients.|FAP-targeting PET/CT imaging will be performed on the enrolled patients.
223752375|NCT06997042|PROCEDURE|Terminolateral anastomotic technique|Suturing the vein and artery of the arteriovenous fistula with a terminolateral anastomotic suture.
223752376|NCT06997042|PROCEDURE|Piggyback anastomotic technique|Suturing the vein and artery of the arteriovenous fistula with a piggyback anastomotic technique.
223752377|NCT06402825|BEHAVIORAL|Fit-for-Fertility program|Women in the intervention group had to delay fertility treatments for 6 months and were offered the interdisciplinary lifestyle intervention, which was provided for a maximum of 18 months or until the end of a pregnancy that occurred. The lifestyle intervention consisted of individual meetings with a dietitian and a kinesiologist trained in motivational interviewing, combined with 12 educational group sessions during the first 6 months. Details of the lifestyle intervention are presented in the previously published protocol (Duval et al., 2015).
223752378|NCT00721773|DRUG|Benazepril|Patients with hypertension will take 10-20mg benazepril per day, antihypertensive agents other than ACE inhibitors and ARBs will be allowed. Doses are adjusted appropriately to achieve and maintain the target blood pressure of 120-140/70-90 mmHg.
223752379|NCT00721773|DRUG|Valsartan|Patients with hypertension will take 80-160mg valsartan per day, antihypertensive agents other than ACE inhibitors and ARBs will be allowed. Doses are adjusted appropriately to achieve and maintain the target blood pressure of 120-140/70-90 mmHg.
223752380|NCT00721773|DRUG|Benazepril+Valsartan|Patients with hypertension will take 10-20mg benazepril plus 80-160mg valsartan per day, antihypertensive agents other than ACE inhibitors and ARBs will be allowed. Doses are adjusted appropriately to achieve and maintain the target blood pressure of 120-140/70-90 mmHg.
223752381|NCT00721773|DRUG|Control|Patients in the control group will administer antihypertensive agents, except ACE inhibitors and ARBs. Doses are adjusted appropriately to achieve and maintain the target blood pressure of 120-140/70-90 mmHg.
223752382|NCT06861920|DRUG|Naproxen Sodium 550mg|Participants will receive Naproxen Sodium 550 mg oral tablet, administered twice daily for the first 48 hours of their menstrual period, for 1-year. Naproxen Sodium is a nonsteroidal anti-inflammatory drug (NSAID) used for pain relief and inflammation reduction. 550 mg naproxen sodium is the highest FDA-approved starting dosage, equivalent to 500 mg naproxen; the sodium formulation quickens absorption.
223752383|NCT06861920|DRUG|Placebo|Participants will receive a placebo oral tablet, identical in appearance to Drug X, administered twice daily for the first 48 hours of their menstrual period, for 1-year. The placebo contains inactive ingredients with no known therapeutic effect.
223752384|NCT06861920|DRUG|Extended Release Acetaminophen (650 mg)|Participants may take extended release acetaminophen 650mg oral tablet as needed for breakthrough menstrual pain. Participants will be instructed to take 1 dose of acetaminophen after 2 hours of taking a dose of either naproxen sodium or placebo, only if needed for pain relief. They are able to take an additional dose of acetaminophen after 2 more hours have elapsed for continued breakthrough symptoms. Use of rescue medication will be monitored and recorded.
223752385|NCT07011810|BIOLOGICAL|Axatilimab|Given IV
223752386|NCT07011810|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223752387|NCT07011810|OTHER|Questionnaire Administration|Ancillary studies
223752388|NCT07011810|PROCEDURE|Skin Biopsy|Undergo optional skin biopsy
223752389|NCT07011810|PROCEDURE|Skin Measurement|Undergo optional skin flexibility assessment
223752390|NCT06684379|DRUG|Placebo comparator|A single dose of saline solution 0.9% for infusion
223752391|NCT06684379|DRUG|PRS CK STORM|A single dose of PRS CK STORM (dose A) for infusion
223752392|NCT06684379|DRUG|PRS CK STORM|A single dose of PRS CK STORM (dose B) for infusion.
223752393|NCT07016035|OTHER|mPCOSQ-F and SF-36|Questionnaires
223752394|NCT07015762|DRUG|IBI3002|Participants with AD will receive IBI3002 at the corresponding dose and dosing interval.
223752395|NCT07015762|DRUG|Placebo|Participants with AD will receive placebo at the corresponding volume and dosing interval.
224311401|NCT04428333|DRUG|Pembrolizumab|Humanized anti- programmed cell death receptor1 (anti-PD-1) IgG4 mAb
223752396|NCT06689566|DIETARY_SUPPLEMENT|genistein|the patients will receive genistein 250mg BID orally for complete 3 months. Afterwards, there will be 3 months washout period. Patients would then be followed for outcome measurement.
223752397|NCT07017972|DEVICE|AI evaluation of embryos|AI evaluation of embryos inside a time-lapse incubator.
223752398|NCT06681376|OTHER|Comfort menu and cart|"The comfort menu and cart will be implemented after the pre-intervention data collection phase is completed. The menu will list the items available on the cart and will be presented to eligible patients in printed or digital format (on a tablet). The cart will be placed in an easily accessible area within the ED. Approximated retail prices have been previously reported.~Comfort Cart Contents:~* Hot and cold packs;~* Extra blanket and pillow;~* Face towel;~* Gloves and hat;~* Personal hygiene kit;~* Items for distraction;~* Items to enhance communication.~Comfort Menu Options:~* Physiotherapy assessment;~* Conversation with chaplain, concierge, or social worker;~* List of resources for older adults needing community services;~* Home care assistance."
223752399|NCT03072615|DIAGNOSTIC_TEST|Stiffness measurement|Transient Elastopgraphy (TE) or Shear-Wave-Elastography
223752400|NCT06626048|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|Digital cognitive behavioral therapy for insomnia (CBT-I) is a behavioral (psychotherapeutic) intervention for insomnia disorder. Participants will complete digital CBT-I online using the Sleep Healthy Using the Internet (SHUTi) program.
223752401|NCT06626048|DEVICE|Passive Body Heating (PBH)|Passive body heating (PBH) is a body-based treatment that participants will complete using a sauna blanket, which is similar in form factor to an adult-sized sleeping bag (head is not within the heated area). Participants will complete at least three 15-minute PBH sessions per week. Participants will complete PBH sessions in the sauna blanket placed on the floor or on a couch (i.e., not in their bed) at a setting of Level 6, 1-2 hours before bed.
223752402|NCT07015346|DRUG|Rotigexole 8 mg|Rotigotine 8 mg
223752403|NCT07015346|DRUG|Neupro ® 8 mg|Rotigotine 8 mg
223752404|NCT04057040|DRUG|PTG-300|Active
223752405|NCT04057040|DRUG|Placebo|Placebo
223752406|NCT05425524|PROCEDURE|Care Bundle|Treatment step by step we have 5 steps STEP 1: Leptospirosis suspected case STEP 2: Investigations STEP 3: Antibiotics within 1 hour after Hemocultures were taken STEP 4: Intravenous Fluid STEP 5: Stage-Base Management of AKI (KDIGO)
223752407|NCT06627452|OTHER|Dynamic Neuromuscular Stabilization Training|Patients will be taught how to perform exercises in different developmental positions both manually and verbally by the DNS therapist. In the DNS concept, proper breathing patterns are important alongside stabilization, and elastic bands will be used to regulate intra-abdominal pressure (IAP) and teach correct breathing. The elastic band will be secured around the chest just below the ribcage, and the patient will be asked to expand the elastic band in all directions while inhaling, thereby regulating the IAP. After teaching IAP guidance, exercises will be conducted in developmental positions with IAP regulation. The exercises will be conducted twice a week under the supervision of a physiotherapist, and three days at home, with sessions lasting approximately 30 minutes, for a total of five days a week over a period of 12 weeks.
223752408|NCT06627452|OTHER|Pelvic Floor Muscle Training|Pelvic floor exercises involving both slow and fast muscle contractions will be taught to patients through vaginal palpation. During fast contractions, patients will be instructed to quickly contract and relax their pelvic floor muscles. During slow contractions, patients will be asked to gradually squeeze their pelvic floor muscles, hold for 10 seconds, and then slowly relax. Each set of pelvic floor exercises will consist of 10 fast contractions and 10 slow contractions. Patients will perform pelvic floor exercises twice a week with a physiotherapist and three days at home. The exercises will be done in sets throughout the day, lasting approximately 30 minutes, and will be conducted over a period of 12 weeks.
223752409|NCT06461351|OTHER|Inaticabtagene autoleucel Injection|Inaticabtagene autoleucel Injection
223752410|NCT05084768|DIAGNOSTIC_TEST|Donor-derived cell-free DNA|As mentioned previously
223752411|NCT06714435|OTHER|Intermittent hypoxia|Intermittent hypoxia during 6 hours in daytime
223752412|NCT06714435|OTHER|Normoxia|Normoxia during 6 hours in daytime
223752413|NCT00849160|DRUG|darunavir|darunavir/r 800/100 mg once daily by oral route, 48 weeks of treatment
223752414|NCT07041918|DEVICE|The study is entirely designed to analyze product performance (analyze only results from whole blood and derived from the PRP tubes), and no interventions will be performed.|The study will evaluate and analyze only the results obtained from whole blood in the hemogram test and the results derived from the PRP tubes. The main objective is to measure the performance of the Vacusera PRP Tube and Vacusera PRP Tube with Gel in obtaining platelet-rich plasma. The study is entirely designed to analyze product performance, and no interventions will be performed.
223605048|NCT05195541|DRUG|CU-20401|Subcutaneous injection in the subcutaneous fat area，0.2ml
223605049|NCT06455852|BIOLOGICAL|oral cholera vaccine or typhoid conjugate vaccine|One group of participants will receive a 2 dose oral cholera vaccine, the other set will receive a typhoid conjugate vaccine
223752415|NCT07042139|PROCEDURE|No reduction|No reduction
223752416|NCT07042139|PROCEDURE|Closed Reduction|Closed reduction
223752417|NCT07042139|OTHER|Casting|Dorsal cast
223752418|NCT06887465|DEVICE|Non-invasive Blood Pressure Monitor|Application of the VeriTrack non-invasive blood pressure monitor
223752419|NCT07039656|DRUG|Toripalimab|Participants will receive Toripalimab (240 mg IV) Q3W for 17 cycles (cycle length=21 days).
223752420|NCT07039656|DRUG|Cisplatin-based chemotherapy|Cisplatin\[75 mg/m\^2 IV Q3W\]/carboplatin\[AUC 5 IV Q3W\]+paclitaxel\[260 mg/m\^2 IV Q3W\] or cisplatin\[75 mg/m\^2 IV Q3W)\]/carboplatin\[AUC 5 IV Q3W\]+ pemetrexed\[500 mg/m2 IV Q3W\],dependent on tumor histology. Participants will receive Chemotherapy for 3-4 cycles
223605050|NCT05757557|DRUG|Sham treatment|Sham treatment: Oxygen-air mixture without NO after intubation, during CPB, and for six hours after surgery.
223605051|NCT05757557|DRUG|80-ppm NO|NO will be supplemented at 80-ppm concentration to cardiac surgery patients perioperatively after trachea intubation, during CPB, and for six hours after surgery.
223605052|NCT06796452|OTHER|Ribs Mobilization|Three sets of 6-8 repetitions in each session and conventional(Baseline) Physical therapy Treatment.
223605053|NCT06796452|OTHER|Conventional treatment|"* Hot pack for 8 min~* Maitland Generalized Cervical Mobilizations (6-8 REPS,3 sets)~* Isometric Strengthening Exercise"
223605054|NCT06797128|PROCEDURE|One Anchor|Participant will receive one standard anchor
223605055|NCT06797128|PROCEDURE|Two Mini Anchors|Participant will receive two mini anchors
224311402|NCT04428333|DRUG|Placebo|Sterile normal saline
224311403|NCT04428333|DRUG|Platinum based chemotherapy|Cisplatin/carboplatin
224311404|NCT04428333|DRUG|Fluorouracil (5FU)|5-fluorouracil
224311405|NCT04853992|DRUG|LEO 152020|LEO 152020 is a small drug molecule which can block the histamine 4 receptor (H4R). LEO 152020 is a tablet for oral administration.
224311406|NCT04853992|DRUG|LEO 152020 placebo|LEO 152020 placebo is a tablet for oral administration. LEO 152020 placebo contains the same excipients in the same concentration as the LEO 152020 tablet, except the medical ingredient, LEO 152020.
223605056|NCT04506502|DEVICE|The ZELTIQ System|The MMS device will be used to perform the treatments.
223605057|NCT05576818|DRUG|Lactobacillus acidophilus 10 billion colony forming unit (CFU) and prebiotic fibers|Two sachets daily of synbiotic preparation containing Lactobacillus acidophilus 10 billion colony forming unit (CFU) and prebiotic fibers
223605058|NCT06794021|DIETARY_SUPPLEMENT|Dietary Supplement with Proprietary Herbal Extract Blend and GABA|Eligible subjects will receive active product to take daily for seven days
223605059|NCT06794021|OTHER|Placebo|Eligible subjects will receive Placebo to take daily for seven days
223605060|NCT02983461|DRUG|Sildenafil|Sildenafil, 20mg x 3 times a day for 10 weeks
223605061|NCT02983461|DRUG|Placebo|Placebo oral tablet, 3 times a day for 10 weeks
223605062|NCT06275386|DEVICE|Paclitaxel Drug-coated balloon|Percutaneous coronary intervention of the actual CTO body with a paclitaxel drug-coated balloon.
223605063|NCT05475522|DEVICE|Ultrasound guided brain tumor resection|Surgeon intraoperatively assesses extent of tumor resection using ultrasound
223605064|NCT05475522|DEVICE|5-aminolevulinic acid fluorescence-guided brain tumor resection|Surgeon intraoperatively assesses extent of tumor resection observing it's fluorescence in microscope
223605065|NCT05411120|OTHER|Western Diet|Western Diet is by high intakes of pre-packaged foods, refined grains, red meat, processed meat, high-sugar drinks, candy and sweets, fried foods, conventionally-raised animal products, butter and other high-fat dairy products, and low intakes of fruits, vegetables, whole grains.
223605066|NCT05411120|OTHER|CLEAN-MED|Mediterranean like diet is a high consumption of vegetables, oil and moderate consumption of protein, with no processed foods.
223752421|NCT06732349|DIAGNOSTIC_TEST|Urinary tubular test panel|The urinary tubular test panel will be applied to urine samples that are collected as part of the routine outpatient follow-up. Its predictive power for CKD progression will be assessed. The results of the tubular test panel will not influence the treatment of the patients. They will remain under standard outpatient treatment throughout the study.
223605068|NCT05446220|BEHAVIORAL|Lifestyle intervention|Dietary advise and/or advise on physical activity monitored by pedometer
223605069|NCT05384015|DRUG|Lenvatinib|"Lenvatinib is an oral, potent multiple receptor tyrosine kinase (RTK) i that selectively inhibits VEGF-driven VEGFR2 phosphorylation and suppressed proliferation and tube formation in human umbilical vein endothelial cell models. Antitumor activity of lenvatinib in vivo has been shown in numerous xenograft animals. These results suggest that lenvatinib may be a novel anticancer therapy through inhibition of angiogenesis and may be useful as either monotherapy or in combination with other anticancer drugs.~Part 1 (safety run-in) and Part 2:~The study intervention consists of:~Dose: 8 mg (induction) and 20 mg (maintenance) Dose Frequency: Once daily Dose formulation: Capsule Route of administration: Oral Treatment duration: 4 cycles (induction) and no treatment duration limit (maintenance)."
223752422|NCT06788834|BEHAVIORAL|Multimodal prehabilitation Program|"A tailored intervention will be prescribed if specific physical, nutritional or psychological impairments will be identified during the assessment phase.~Based on the data obtained during the multimodal assessment, different domains and levels of care will be prescribed, focusing on exercise training, and/or nutrition optimization, and/or distress-coping techniques. Different combinations of three domains will be utilized to maximize their synergistic anabolic effects. The duration of the program will be set at a minimum of three weeks."
223752423|NCT06469164|DRUG|BNT331|Vaginal insert
223752424|NCT06469164|OTHER|Placebo|Vaginal insert
224311407|NCT05027243|PROCEDURE|bilateral temporomandibular joint arthroscopy|The TMJ arthroscopy was performed with a 1.9-mm arthroscope including a video system, with a 2.8-mm outer protective cannula. Briefly, for TMJ arthroscopy level 1, the authors used the classic puncture with an entry point 10 mm anterior and 2 mm below the Holmlund-Hellsing (H-H) line. A second puncture with a 21-G needle was performed 30 mm anterior and 7 mm below the H-H line to wash the joint with 250-300 ml Ringer solution. After washing the joint, 1.5-2 cc of hyaluronic acid was injected into it. For level 2 TMJ arthroscopy, the second puncture was substituted by a 2.8-mm outer protective cannula with a sharp trocar until the joint was reached. The 2.8-mm cannula was used for (1) intra-articular coblation and/or (2) intrasynovial medication. Antibiotic and non-steroidal anti-inflammatory drugs were routinely prescribed. Patients were instructed to follow a soft diet for 3 days after surgery and 5 physiotherapy and 3 speech therapy exercise sessions after intervention.
224311408|NCT05027243|DRUG|Xeomin® (Merz)|For tenderness grade 2, 155U of Incobotulinum toxin A was injected in the masticatory muscles and for tenderness grade 3 195U of Incobotulinum toxin A was injected. The authors used Xeomin® (Merz) in all patients.
224311409|NCT03582826|BEHAVIORAL|Nutritional counselling|Behavioral nutritional counselling delivered via the Internet.
224311410|NCT03582826|BEHAVIORAL|Stress-reduction counseling|The psycho-behavioral intervention includes administering questionnaires and monthly maintenance psychological support delivered via the Internet.
224311414|NCT03761680|DIETARY_SUPPLEMENT|MEDPass mode of administration|Allocation of 50 ml of ONS four times per day distributed with the medication rounds
224311415|NCT03761680|DIETARY_SUPPLEMENT|Control Intervention|Patients receive ONS between meals or at their request as usual
223605070|NCT05384015|DRUG|Pembrolizumab|"Pembrolizumab is a potent humanized immunoglobulin G4 (IgG4) monoclonal antibody (mAb) with high specificity of binding to the programmed cell death 1 (PD-1) receptor, thus inhibiting its interaction with programmed cell death ligand 1 (PD-L1) and programmed cell death ligand 2 (PD-L2).~Part 1 (safety run-in) and Part 2:~Dose: 200 mg Frequency: Day 1, Q3W Route: Intravenous Treatment Period: Up to 35 cycles or until reaching a discontinuation criterion"
223752425|NCT06736522|BEHAVIORAL|Leadership, Engagement, and youth Action Program with Mindfulness|The Leadership, Engagement, and youth Action Program with Mindfulness intervention (LEAP) was designed and co-created with youth to improve youth well-being by enhancing leadership opportunities and by developing mindfulness in day-to-day life. LEAP seeks to foster these improvements in youth and to increase youth mental, emotional, and behavioral health. Youth voice is incorporated into the intervention, with facilitators leading the first 7 sessions, and youth leading the remainder.
223752426|NCT06736522|BEHAVIORAL|EnvisionIT|Participants in this arm will receive 14 sessions of EnvisionIT training, focused on preparing students with essential skills including digital literacy through competency in information technology, financial literacy, English language arts skills, and college and career readiness. All sessions will be delivered by facilitators trained in EnvisionIT.
223752427|NCT07044843|OTHER|Oxygen|SSOT and sham air (5l/min) will be applied with the oxygen concentrator EverFloTM via nasal cannula during training
223752428|NCT07044843|OTHER|Standard ambiant air will be breathed during endurance training.|ambiant air
223752429|NCT06745518|DRUG|TS-172|oral administration of TS-172 20\~60 mg/day
223605071|NCT05384015|DRUG|Etoposide|"Standard first-line treatment for the vast majority of patients with SCLC, regardless of stage, involves combination chemotherapy with etoposide plus cisplatin or carboplatin.~Pharmacotherapeutic group: Cytostatics, plant alkaloids and other natural products, derived from podophyllotoxin. Mechanism of action :The main effect of etoposide appears to be in the late S and early G2 phase of the cell cycle, in mammalian cells.~Part 1 (safety run-in) and Part 2:~Dose: 100 mg/m2 Frequency: Day 1-3, Q3W Route: Intravenous Treatment Period: 4 cycles"
223752430|NCT06745518|DRUG|Placebo|oral administration of placebo
223752431|NCT07109479|DEVICE|Intravascular Lithotripsy|study group will receive the investigational devices (Single-Use Coronary Forward Intravascular Lithotripsy Catheter combined with the Intravascular Lithotripsy Therapy Device) for calcified lesion pre-treatment.
224311416|NCT02269163|BIOLOGICAL|Immune Globulin Intravenous|Gammargard, Gammaplex,Gamunex, or Octogam IGIV Product
224311417|NCT02269163|BIOLOGICAL|Prometic's Immune Globulin Intravenous 10%|Liquid formulation of Prometic Immune Globulin Intravenous 10% (human) in 50 mL vials containing 100 mg/mL of immunoglobulin G (IgG)
223605072|NCT05384015|DRUG|Carboplatin|"Pharmacotherapeutic group: Other antineoplastic agents, platinum compounds.~Carboplatin, like cisplatin, binds to DNA to produce inter- and intra-strand cross-links cells exposed to carboplatin. DNA reactivity has been linked to cytotoxicity.~Part 1 (safety run-in) and Part 2:~Dose: AUC5 Frequency: Day 1, Q3W Route: Intravenous Treatment Period: 4 cycles"
223605073|NCT04040088|PROCEDURE|Computed Tomography|Undergo PET/CT
223752432|NCT07109479|DEVICE|Rotational Atherectomy|control group will receive the control device (Coronary Rotational Atherectomy System)
223752433|NCT06896422|DRUG|Glutathione|Glutathione is administered as an adjunct intervention to the PD-1 inhibitor plus chemotherapy regimen.
223752434|NCT06896422|DRUG|PD1 Inhibitor|e.g. pembrolizumab, camrelizumab, sintilimab, tislelizumab, toripalimab
223752435|NCT06896422|DRUG|Chemotherapy|Platinum-based doublet chemotherapy
223752436|NCT06227767|OTHER|spinal stabilization exercise|The exercise program will be implemented in the hospital under the supervision of a physiotherapist for 6 weeks, and the next 6 weeks will be followed as a home program. The first group will be given an exercise program 2 days a week, the second group will be given an exercise program 4 days a week. The exercise program is planned to be 40 minutes and the first 5 minutes of the program will be warm-up and the last 5 minutes will be cool-down exercises.
223752437|NCT06588738|DRUG|ESK-001|ESK-001
223752438|NCT06588738|DRUG|Placebo|Placebo
223752439|NCT06588738|DRUG|Apremilast|Apremilast
223752440|NCT07063836|PROCEDURE|VST|"atraumatic extraction to the hopeless teeth will be performed using periotomes followed by conventional forceps under local anesthesia.A small incision (1 cm) is made on (vestibular area) near the base of the extracted teeth, extending slightly towards neighboring teeth.Using special instruments from the VST kit, the gum tissue is carefully dissected to expose the underlying bone and an immediate implant is placed using a surgical guide. the augmentation is done using A mixture of bone chips harvested from the surgical site (autogenous bone) and a bone-grafting material (deproteinized bovine bone mineral) is used to fill any gaps and support the implant, especially in the labial bone wall (labial plate).~A special 0.6 mm thick membrane is inserted through the access incision. the vestibular incision is then sutured and the provisional is inserted."
223752441|NCT07063836|PROCEDURE|contour augmentation and early implant placement|"Teeth extraction : minimally invasive adjacent teeth extraction under anesthesia using periotome and forceps.~the empty sockets will be filled with a special collagen material (BioPlug) to aid healing for 4 to 8 weeks.~flap elevation : a full-thickness flap will be carefully raised using a crestal incision extended one tooth mesial and distal to the extraction location, then connected with two vertical incisions extended through the sulcus forming a trapezoid flap.~Implants Insertion: The two implant is then placed into the prepared sockets using surgical guide.~Bone Grafting: Any bone deficiencies are addressed by grafting. This involves placing a layer of (autogenous bone) directly on the two implants' surface, followed by a layer of a bone-grafting material (Demineralized Bone Matrix).~Membrane Placement: A double-layered collagen membrane is used to cover the grafted area.~Flap Closure: The previously lifted flap is repositioned and sutured back in place."
223752442|NCT06734234|DRUG|GSK4771261|GSK4771261 will be administered.
223752443|NCT06734234|DRUG|Placebo matching GSK4771261|Placebo matching GSK4771261 will be administered.
223752444|NCT07083050|DEVICE|Volume stable collagen matrix|Volume stable collagen matrix obtained from porcine collagen after proprietary cross-linking by device manufacturer
224311418|NCT03296384|OTHER|Clinical and environmental evaluation|For schizophrenic's patients, specific assessment will be perform
224311419|NCT01026155|OTHER|Respiratory muscle training|Respiratory muscle endurance training by means of isocapnic voluntary hyperpnoea
224311420|NCT03337165|BIOLOGICAL|tolerogenic dendritic cells|dose-escalation
223605074|NCT04040088|DRUG|Gallium Ga 68-DOTATATE|Given IV
223605075|NCT04040088|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
223605076|NCT01378767|DIETARY_SUPPLEMENT|Krill oil supplementation|During a 21-day Daniel Fast, group one supplemented with krill oil capsules (two grams per day) while group two supplemented with a placebo (coconut oil capsules at two grams per day).
223605077|NCT03526146|BEHAVIORAL|Behavioral: Preventing Loss of Independence through Exercise (PLIE)|PLIE is an integrative exercise program that focuses on training procedural memory for the ability to perform the movements that are most needed for daily function (e.g., transitioning safely from sitting to standing) while increasing mindful body awareness and encouraging social connection. It combines elements from a wide range of Eastern and Western exercise modalities, including occupational therapy, physical therapy, yoga, tai chi, Feldenkrais, Rosen Method, dance movement therapy and mindfulness meditation.
223605078|NCT03769558|OTHER|Non-Interventional|Non-Interventional
223605079|NCT05138029|DRUG|Ranibizumab Injection [Lucentis]|The visual acuity and the thickness of the center of the macula were reviewed at 1 day, 7 days, 1 month, 3 months, and 6 months after the operation to compare the effect of the operation, and observe the cornea, anterior chamber, vitreous cavity, and intraocular pressure.
223605080|NCT05138029|PROCEDURE|Inner limiting membrane stripping|The visual acuity and the thickness of the center of the macula were reviewed at 1 day, 7 days, 1 month, 3 months, and 6 months after the operation to compare the effect of the operation, and observe the cornea, anterior chamber, vitreous cavity, and intraocular pressure.
223605081|NCT05138029|DRUG|Dexamethasone intravitreal implant|The visual acuity and the thickness of the center of the macula were reviewed at 1 day, 7 days, 1 month, 3 months, and 6 months after the operation to compare the effect of the operation, and observe the cornea, anterior chamber, vitreous cavity, and intraocular pressure.
223605082|NCT03262168|OTHER|Exercise Programme|Complete background demographics, Sniff Nasal Inspiratory Pressure (study group one only), grip strength, muscle strength, PHQ-9 and GAD-7 questionnaires.
223605083|NCT02124213|DRUG|30 mg PF-06412562|Subject will receive a single dose of 30 mg PF-06412562
223605084|NCT02124213|DRUG|PF-06412562|The dose will be selected based on the results obtained for Cohort 1. This Cohort is optional.
223605085|NCT02124213|DRUG|PF-06412562|"The dose will be selected based on the results obtained for Cohort 1 and Cohort 2.~This Cohort is optional."
223605086|NCT03835299|BEHAVIORAL|Fear Intervention|Coping information related to the fear that was identified by the participant will be presented via a computer tablet.
223605087|NCT03571555|BEHAVIORAL|Sentebale Psychosocial Programme|Residential interventions (camps) for the young people, and community based support (clubs) for the young people and the caregivers.
223605088|NCT05556668|DEVICE|Percutaneous placement of biodegradable biliary stents|Benign biliary strictures treated with polydioxanone (PPDX) stents (Ella-DV biliary stent, ELLACS, Hradec Králové, Czech Republic). The stents are implanted using a percutaneous transhepatic cholangiography. Before stent implantation, balloon bilioplasty is be performed.
223605089|NCT05096065|DRUG|Leuprolide Oral Tablet - 120 mg - QD- Treatment A|"If the subject during Treatment A meets the pharmacodynamic success criterion (estradiol level \<20 pg/mL on Treatment Day 29 of the First Treatment Cycle), in the Second Treatment Cycle, she will be assigned Treatment B - 80 mg (2 x 40 mg tablets) (QD), with food-intake restrictions.~If the subject during Treatment A fails to meet the pharmacodynamic success criterion (i.e., if estradiol level ≥20 pg/mL on Treatment Day 29 of the First Treatment Cycle), then she will be switched to the Second Treatment Cycle with Treatment D - 60 mg (BID) with food intake restrictions."
223605090|NCT05096065|DRUG|Leuprolide Oral Tablet - 80 mg - QD - Treatment B|"If the subject on Treatment B meets the pharmacodynamic success criterion (estradiol level \<20 pg/mL on Treatment Day 29 of the Second Treatment Cycle), then she will be switched to the Third Treatment Cycle with Treatment C - 60 mg (QD) with food-intake restrictions.~If the subject on Treatment B does not meet the pharmacodynamic success criterion (i.e., if estradiol level ≥20 pg/mL on Treatment Day 29 of the Second Treatment Cycle), then she will be switched to the Third Treatment Cycle with Treatment E - 40 mg (BID) with food intake restrictions."
223605091|NCT05096065|DRUG|Leuprolide Oral Tablet - 60 mg - QD - Treatment C|For up to 29 consecutive days with food-intake restrictions
223605092|NCT05096065|DRUG|Leuprolide Oral Tablet - 60 mg - BID - Treatment D|"If the subject on Treatment D fails to meet the pharmacodynamic success criterion (i.e., if estradiol level ≥20 pg/mL on Treatment Day 29 of the Second Treatment Cycle), she will be discontinued from the study following completion of the Second Treatment Cycle.~If the subject during Treatment D meets the pharmacodynamic success criterion (estradiol level \<20 pg/mL on Treatment Day 29 of her Second Treatment Cycle), then she will be switched to the Third Treatment Cycle with Treatment E - 40 mg (BID) with food intake restrictions."
223605093|NCT05096065|DRUG|Leuprolide Oral Tablet - 40 mg - BID - Treatment E|For up to 29 consecutive days with food-intake restrictions
223605094|NCT02305771|DEVICE|Electroencephalography|
224311421|NCT02702479|OTHER|High Fructose Corn Syrup|An intervention in which calories from HFCS are substituted isocalorically for sucrose in the diet
223605095|NCT02305771|DEVICE|MRI|
223605096|NCT03401255|OTHER|Partosure test|To perform the analysis, a sample of cervicovaginal secretions is collected using a vaginal swab provided in the PAMG-1 Detection Test Kit.After removing the swab from its packaging, hold the swab in the middle of the stem and carefully insert the end of the swab into the vagina over a length of 5-7cm (using a speculum). Is not necessary for sampling), when the patient is lying down.Remove the swab from the vagina after 30 seconds. Once the swab has been removed, immediately place the end in the solvent vial provided for this purpose, then rinse the swab by repeating several rotations for 30 seconds. The strip is removed as soon as two bands are clearly visible in the test area, or after 5 minutes.Two bands in the test area indicate a positive result, while a line in the test area indicates a negative result. It is not recommended to read or interpret results beyond 10 minutes of immersion.
223605097|NCT01136408|DRUG|Dabigatran etexilate|Dabigatran etexilate 110 mg capsule, twice a day, oral administration
223605098|NCT01136408|DRUG|Dabigatran etexilate|Dabigatran etexilate 150 mg capsule, twice a day, oral administration
223605099|NCT01136408|DRUG|Warfarin|Dose-adjusted warfarin based on target INR values
224311422|NCT02702479|OTHER|Sucrose|An intervention in which calories from sucrose are substituted isocalorically for HFCS in the diet
224311423|NCT03506984|DEVICE|Threshold Inspiration Muscle Training Device|Threshold based trainer is a small handled device.It includes a mouthpiece and a calibrated spring loaded valve. The valve control a constant inspiratory pressure training load and the patient must generate a suffient inspiratory pressure in order for the inspiratory valve to be opened and allow the air to be inhaled. The amount of resistance can be adjusted by varying the compression of the spring-loaded valve. Adjustment from 9cmH2o to 41cmH2o.
223605100|NCT01090193|PROCEDURE|Whipple operation,Hepaticojejunostomy|Whipple operation, Hepaticojejunostomy
223605101|NCT02828436|DEVICE|Precision Spectra System|Spinal Cord Stimulation
223605102|NCT02828436|BEHAVIORAL|Exercise Intervention|Standard Exercise
223605103|NCT00270062|DRUG|epoetin alfa|
223605104|NCT05490576|RADIATION|[18F] PI-2620 Tau Ligand|Tau binding ligand
223605105|NCT01485328|DRUG|AMARGOL®|per oral solution, 40 mL single dose
223605106|NCT04220554|OTHER|Improved support by health-care professionals|Improved support to patients prescribed topical antipsoriatic drugs
223752445|NCT07083050|PROCEDURE|Autologous Connective Tissue Graft from the Hard Palate|Autologous connective tissue surgically harvested from the hard palate and transplanted in the area of gingival recession
223752446|NCT07084064|BEHAVIORAL|Families Moving Together|The Families Moving Together intervention was co-designed with community leaders and caregivers to address these barriers and promote physical activity co-participation among families. This evidence-based curriculum consists of six progressive lessons aimed at helping families learn, practice, and sustain an active lifestyle. The goals of this study are to increase community awareness of the importance of physical activity, create changes in parent and child physical activity, and increase parent physical activity knowledge and self-efficacy for promoting family physical activity.
223752447|NCT07086235|DRUG|self-assembling peptide|According to the instructions of the manufacturer, the lesion will be treated with etch solution (Super Etch, SDI Ltd, Bayswater, Victoria, Australia) for 30 seconds to open up the pores to the subsurface lesion and subsequently will be washed and dried. Curodont Repair Fluoride Plus brush will be rehydrated with 0.05 ml of sterile water and a single drop of the resulting solution will be immediately applied to the lesion surface. Moisture control will be ensured until the Curodont Repair Fluoride Plus solution will be no longer visible (approximately two minutes).
223752448|NCT07086235|DRUG|S-PRG Barrier Coat|According to the instructions of the manufacturer, after mixing one drop of activator with base, a thin film coating will be applied to the WSL area then will be left undistributed for 3 seconds and finally will be light cured for 10 seconds using LED light-curing unit.
223752449|NCT05525156|DRUG|aspirin enteric coated tablet 75 mg|blister packaged enteric coated tablet of 75 mg aspirin taken once daily for 24 weeks in addition to the conventional antiretroviral drugs
223752450|NCT05756790|BEHAVIORAL|Motivational Interviewing|Counseling
223752451|NCT05756790|BEHAVIORAL|Motivational Interviewing plus Breathalyzer|Counseling plus mobile breathalyzer/ app
223752452|NCT07087366|PROCEDURE|ERAS protocol|Procedure: ERAS protocol
223752453|NCT07087626|OTHER|Arterial Blood Gas Analysis|Arterial blood gas analysis will be performed at predefined time points: at rest during the preoperative period, before induction and preoxygenation during the perioperative period, two minutes after induction but prior to intubation, within the first 30 minutes in the PACU during the postoperative period, and at the 72nd postoperative hour in the ward
223752454|NCT07090681|DEVICE|Active Control Placebo|In this intervention, participants underwent magnetic stimulation at the neck level with a TMS coil. Ten minutes after, they received a high frequency temporal interference stimulation with an overlapping sinusoidal wave at 2KHz, without any interferent pattern.
223752455|NCT07090681|DEVICE|tTIS|In this intervention, participants underwent magnetic stimulation at the neck level with a TMS coil. Ten minutes after, they received active transcranial temporal interference stimulation with a patterned stimulation (intermittent theta-burst) generating temporal interference in the striatum; see Wessel et al., 2023, Nat Neurosci. for details
223752456|NCT07090681|DEVICE|tTIS + TMS|In this intervention, participants underwent cerebellar magnetic stimulation at the level of a predefined individual point in the inferior left cerebellar hemisphere with a TMS coil, receiving a total of 600 pulses organised in an intermittent theta-burst pattern. Ten minutes after, they received active transcranial temporal interference stimulation with a patterned stimulation (intermittent theta-burst) generating temporal interference in the striatum; see Wessel et al., 2023, Nat Neurosci. for details
223752457|NCT03889912|DRUG|Cemiplimab|Each patient will receive intralesional injections of cemiplimab every week (QW), or at less frequent dosing into the lesion at the assigned dose level for 3-12 weeks prior to scheduled surgery
223752458|NCT07084493|DEVICE|CBD stent either a 7-Fr and 7 cm or a 10-Fr and 7-cm OR double-pigtail stent|prophylactic CBD stent either a 7-Fr and 7 cm or a 10-Fr and 7-cm double-pigtail stent
223752459|NCT07084493|DEVICE|biliary stent|prophylactic CBD stent either a 7-Fr and 7 cm or a 10-Fr and 7-cm double-pigtail stent
224311424|NCT03506984|DEVICE|Electronic Bicycle Ergometer|Electronic Bicycle equipped with electronic break, display screen, adjustable seat, handle bar and foot straps will be used in High interval intensity training.
223605107|NCT00002984|DRUG|cisplatin|Cisplatin will be given at a dose of 100 mg/m2 at a concentration of 1 mg/ml over one hour on Day 1 and 29 for a total of 2 courses
223605108|NCT00002984|DRUG|fluorouracil|5-FU will be given at 500 mg/m2 in 1 liter D5 1/2 by continuous infusion every 12 hours for a total of 8 doses (Total 1.0 g/m2/day X 4 days) on Days 1-4 and 29-32 for a total of 2 courses
223605109|NCT00002984|DRUG|paclitaxel|30 mg/m2 - 45 mg/m2 given weekly. The dose each subject receives will depend on when they enter the study
223605110|NCT00002984|PROCEDURE|surgical procedure|Surgical resection should take place approximately 4 weeks following completion of the chemotherapy.
223605111|NCT00002984|RADIATION|radiation therapy|The dose of radiation to the tumor and nodal area will be 4500 cGy given as 180 cGy fractions daily, Monday through Friday, for 5 weeks
223605112|NCT05615740|DIAGNOSTIC_TEST|Optical coherence tomography (OCTA)|OCTA can detect the passage of individual blood elements (mostly erythrocytes) through capillaries and larger vessels in real-time
223605113|NCT04615039|DEVICE|PROFEMUR® Preserve Classic Femoral Stem|Single study group of subjects, either newly or previously implanted with the PROFEMUR® Preserve Classic Femoral Stem combined with any type of polyethylene and ceramic acetabular shells, acetabular liners and femoral heads.
223605114|NCT00655616|DRUG|Montelukast Placebo|"Seretide 100 Accuhaler 1 dose twice daily plus 1 tablet daily of placebo montelukast~Seretide 250 Accuhaler 1 dose twice daily plus 1 tablet daily of placebo montelukast~Seretide 500 Accuhaler 1 dose twice daily plus 1 tablet daily of placebo montelukast~Doses of montelukast or placebo: up to 6 years 4 mg once daily; 6-14 years 5 mg once daily; 15 years and above 10 mg once daily"
223752460|NCT05703763|DIAGNOSTIC_TEST|Applanation tonometry|"Applanation tonometry will be used to measure arterial stiffness in these segments, bilaterally:~* Superficial temporal artery to frontal temporal artery~* Common carotid artery to superficial temporal artery"
223752461|NCT05703763|DIAGNOSTIC_TEST|Standardized GCA assessment|Clinical assessment, blood test review, high-resolution temporal artery ultrasound using a 24mHz probe.
223605115|NCT00655616|DRUG|Salmeterol, Montelukast|"Flixotide Accuhaler 50 micrograms per blister, 1 blister dose twice daily plus 1 tablet daily of montelukast~Flixotide Accuhaler 100 micrograms per blister; 1 blister dose twice daily plus 1 tablet daily of montelukast~Flixotide Accuhaler 250 micrograms per blister; 1 blister dose twice daily plus 1 tablet daily of montelukast~Flixotide Accuhaler 500 micrograms per blister; 1 blister dose twice daily plus 1 tablet daily of montelukast~Doses of montelukast or placebo: up to 6 years 4 mg once daily; 6-14 years 5 mg once daily; 15 years and above 10 mg once daily"
223605116|NCT04421482|OTHER|Standard room temperature (RTS) feeding of milk/formula|Standard room temperature (RTS) milk/formula will be given for an entire feeding (15-20 minutes).
223605117|NCT04421482|OTHER|Cold temperature (CS, at 4-9°C) of milk/formula|If the infant shows signs of dysphagia cold temperature (CS, at 4-9°C) milk/formula will be given for an entire feeding (15-20 minutes).
223605118|NCT01013194|OTHER|Human Fetal Liver Cell Transplantation|"Human Fetal Liver Cell Transplantation. Cell source: Non-purified and non-selected fetal liver cells from fetuses aborted between the 16th and 26th week of gestation.~Infusion technique: Isolation and incannulation of the femoral artery.Splenic artery infusion under radiological guidance.~Cell infusion: between 5 and 10x10\^8 cells. Number of sessions: up to 2."
223605119|NCT05604027|DIAGNOSTIC_TEST|Visual Analogue Scale|Clinical criteria and rating system for nociplastic pain affecting the musculoskeletal system and PainDETECT scale to determine pain type SF-36 Quality of Life Scale, Roland Morris Disability Questionnaire, Pain Catastrophizing Scale, and Visual Analog Scale to determine the effects
223605120|NCT03736941|OTHER|Patients with venous leg|The medical device Venotrain® Ulcertec will be prescribed according to the indications supported by the Health Insurance and used according to the recommendations of the manufacturer. It will be dispensed in town pharmacies. After inclusion, follow-up visits are scheduled at 4, and 16 weeks (± 1 week) as well as an end-of-study visit, not later than 20 weeks after enrollment or in case of premature termination. follow-up.
223605121|NCT03010319|DEVICE|PriMatrix Dermal Repair Scaffold|Application of PriMatrix to ulcer
223605122|NCT03010319|DEVICE|Secondary Dressings|Dressings to ensure moist wound environment
223605123|NCT03010319|DEVICE|Offloading device|Offloading device to decrease pressure to wound area
223605124|NCT02128724|DRUG|BKM120|Buparlisib is a highly specific inhibitor of phosphatidylinositol 3-kinase (PI3K). Buparlisib is supplied as 10mg and 50mg hard gelatin capsules.
223605125|NCT02644317|DEVICE|Modified shoe inserts|For experimental arm: wear modified shoe inserts and shoes for balance test.
223605126|NCT02780492|OTHER|Set of assessment tools|
223605127|NCT03897556|DIETARY_SUPPLEMENT|Guarana herb|The intervention is a functional food bar produced in a licensed commercial kitchen that contains guarana powder as well as dates, raisins, oats, spirulina, walnuts, flour, coconut butter, soybean oil, xanthan gum and chocolate chips.
223605128|NCT03897556|OTHER|Usual Care|Participant will receive 'usual-care' for cancer survivors. At the end of the study, after completing the Final Visit, they will receive 21 guarana energy bars to thank them for being in the study.
223605129|NCT03550274|DEVICE|App-based exercise rehabilitation|"App-based exercise rehabilitation available on any mobile device and/or tablet using Android or iOS operating systems. The app Injurymap© is hosting the exercise program. The app requires user-registrations and a monthly paid subscription fee to access the exercise program. The participants in this study will not be charged for using the app.~The exercise program consists of three phases with increasing difficulty. Each phase consists of several categories of exercise types. The categories are 1) mobility, 2) stability/balance, 3) strength and 4) stretching. Within each phase, there can be more than one exercise for each category. This makes it possible to adjust the difficulty of the exercises depending on user-feedback."
223605130|NCT03368586|DEVICE|Flash Glucose Monitoring|The camp comprised a structured daily routine with five fixed meals: breakfast, lunch, afternoon snack, dinner and evening snack. Capillary blood glucose (BG) values were measured in parallel with unmasked Flash Glucose (FG) measurements using the FGM reader's built-in glucometer at breakfast, lunch and dinner. Additional measurements were taken before snacks, between the meals or overnight and BG was measured only in cases of low (\<4.0 mmol/L) or high (\>15.0 mmol/L) FG values or when symptoms were discordant with sensor readings. Sensor-related issues were documented and a questionnaire assessing satisfaction and usability of the FGM was completed by patients and caregivers at study completion.
223752462|NCT05703763|DIAGNOSTIC_TEST|Repeat applanation tonometry (optional)|Repeat index test at month 6 and at disease relapse.
223752463|NCT02513407|BEHAVIORAL|Behavioral Dietary Intervention|Attend healthy nutritional education session
223752464|NCT02513407|OTHER|Educational Intervention|Attend EML educational session
223752465|NCT02513407|BEHAVIORAL|Exercise Intervention|Attend exercise educational session
223752466|NCT02513407|BEHAVIORAL|Exercise Intervention|Receive fitness tracker
223752467|NCT02513407|OTHER|Laboratory Biomarker Analysis|Correlative studies
223752468|NCT02513407|OTHER|Questionnaire Administration|Ancillary studies
223752469|NCT05592678|OTHER|Donepezil|Donepezil is administered as a standard of care treatment by the subject's provider.
223752470|NCT07101679|DRUG|LICSBR|Participating patients will receive the GnP regimen every 21 days (nab-paclitaxel 125mg/m² ivgtt on days 1 and 8 + gemcitabine 1000mg/m² ivgtt on days 1 and 8, repeated every 21 days) combined with serplulimab (200mg ivgtt Q3W). In the second cycle, patients will receive SBRT targeting the primary tumor and/or retroperitoneal lymph nodes: 6.6Gy×5 fractions, 7Gy×5 fractions, or 8Gy×5 fractions, administered every other day with radiotherapy completed in 5 sessions (specific selection determined by investigators based on lesion size and organs at risk \[OAR\] assessment).
223752471|NCT07104773|DEVICE|Control Lens (omafilcon A)|15 minutes of daily wear
223752472|NCT07104773|DEVICE|Test Lens (stenfilcon A)|15 minutes of daily wear
223752473|NCT04379999|DRUG|Atorvastatin 20mg|No history of colorectal cancer and no colorectal adenomas within 5 years.
223752474|NCT04379999|DRUG|Atorvastatin 20mg AND Aspirin 325 mg|History of colorectal cancer and/or history of colorectal adenomas within 5 years.
223605131|NCT06492590|BEHAVIORAL|Multicomponent intervention|Multicomponent intervention based on psycho-education and physical rehabilitation.
223605132|NCT05287425|DRUG|Gentamicin Ophthalmic|4 drops daily in both eyes for 7 ± 1 days
223605133|NCT05287425|DRUG|Ciprofloxacin Ophthalmic|4 drops daily in both eyes for 7 ± 1 days
223752475|NCT07108452|OTHER|A mobile application that uses AI to deliver behavioral nudges that encourage healthy food choices.|As a mobile application for assessing dietary intake, the app provides a daily report of food intake- a core function that both the gamified and limited app versions have. The gamified version has the added functionality of delivering behavioral nudges that encourage healthy food selections.
223605134|NCT05287425|DRUG|Povidone Ophthalmic|4 drops daily in both eyes for 7 ± 1 days
223605135|NCT05287425|DRUG|Povidone and Benzalkonium Chloride Ophthalmic|4 drops daily in both eyes for 7 ± 1 days
223605136|NCT05817305|OTHER|Medical history and functional evaluation|During each session, physical parameters are measured and data on medical history and physical activity are collected. To assess cardiorespiratory fitness, all patients complete a submaximal, moderate, and perceptually regulated treadmill walking test (1k-TWT). Patients unable to complete the test at a walking speed ≥ 3.0 km/h perform the test over 500m or 200m.
223605137|NCT05817305|OTHER|Health education|Patients receive recommendations for risk factor management as well as continuous motivational counselling in order to develop and maintain a stable active lifestyle.
223605138|NCT06425341|DRUG|HRS-5635 Injection|HRS-5635 Injection low dose administered by subcutaneous injection
223605139|NCT06425341|DRUG|HRS-5635 Injection|HRS-5635 Injection medium dose administered by subcutaneous injection
223605140|NCT06425341|DRUG|HRS-5635 Injection|HRS-5635 Injection high dose administered by subcutaneous injection
223605141|NCT06425341|DRUG|HRS-5635 Injection|HRS-5635 Injection lowest dose administered by subcutaneous injection
223605142|NCT06425341|DRUG|HRS-5635 Injection (low dose) and Peg-IFN-α|HRS-5635 Injection (low dose) and Peg-IFN-α, administered by subcutaneous injection
223605143|NCT06425341|DRUG|HRS-5635 Injection (high dose) and Peg-IFN-α|HRS-5635 Injection (high dose) and Peg-IFN-α, administered by subcutaneous injection
223605144|NCT06425341|DRUG|Peg-IFN-α|Peg-IFN-α, administered by subcutaneous injection
223605145|NCT03329092|DRUG|ATM-AVI|"(Creatinine clearance \> 50 mL/min) 6500 mg ATM/2167 mg (loading dose, extended loading dose and maintenance dose) by iv infusion on Day 1 followed by a total daily dose of 6000 mg ATM/2000 mg AVI~(Creatinine clearance 31 - 50 mL/min) 4250 mg ATM/1417 mg AVI on Day 1 (loading dose, extended loading dose, maintenance dose) followed by total daily dose 3000 mg ATM/1000 mg AVI~(Creatinine clearance 16 - 30 mL/min) 2700 mg ATM/900 mg AVI on Day 1 (loading dose, extended loading dose maintenance dose), followed by total daily dose 2025 mg ATM/675 mg AVI"
223605146|NCT03329092|DRUG|MTZ|For cIAI only; 500 mg/100 mL metronidazole iv infusion over 1hr q8h
223605147|NCT03329092|DRUG|MER|"Where pathogen initially not suspected of being MER-resistant:~(Creatinine clearance \> 50 mL/min) 1000 mg meropenem by 30 min iv infusion q8h~(Creatinine clearance 26 - 50 mL/min) 1000mg meropenem by 30 min iv infusion q12h~(Creatinine clearance 16 - 25 mL/min) 500 mg meropenem by 30 min iv infusion q12h~Where pathogen initially suspected of being MER-resistant (Creatinine clearance \> 50 mL/min) 2000 mg meropenem by 180 min iv infusion q8h~(Creatinine clearance 26 - 50 mL/min) 2000 mg meropenem by 180 min iv infusion q12h~(Creatinine clearance 16 - 25 mL/min) 1000 mg meropenem by 180 min iv infusion q12h"
223605148|NCT03329092|DRUG|COL|"Loading dose 9 million IU by 30 -60 min iv infusion (6 million IU where weight \< 60 kg) followed by one of the following maintenance doses:~(Creatinine clearance \> 50 mL/min) after a 12h interval, commence maintenance dosing 9 million IU daily in 2 or 3 divided doses by 30 -60 min iv infusions.~(Creatinine clearance 31 - 50 mL/min) After a 24 hr interval, commence maintenance dosing of 6 million IU daily in 2 divided doses by 30 -60 min iv infusion~(Creatinine clearance 21 - 30 mL/min) After a 24 hr interval, commence maintenance dosing 5 million IU daily in 2 divided doses by 30 -60 min iv infusion~(Creatinine clearance 16 - 20 mL/min) after a 24 hr interval, commence maintenance dosing 4 million IU daily in 2 divided doses by 30 -60 min iv infusion"
223752476|NCT07108452|OTHER|Limited app version for dietary assessment only|This app version provides a daily report of energy and nutrient intake- available to those randomized to the control group
223752477|NCT07109687|OTHER|HIIT GROUP|Participants will perform a 31-minute protocol on a cycle ergometer consisting of 1-minute high-intensity intervals at 90% of peak workload (W peak) and low-intensity intervals at 30-40% of W peak, twice a week for 8 weeks.
223752478|NCT07109687|OTHER|MICT|Moderate intensity continous exercise
223605149|NCT05786508|OTHER|Partners4Pain program|"Partners4Pain is a self-management program of evidence based complementary and integrative health approaches for pain including pain education, mindfulness, cognitive behavioral approaches, and neck/back specific exercises.~The intervention program will include nine, 90-minute group sessions that occur weekly for 9 weeks"
223605150|NCT05786508|OTHER|Key to Wellbeing program|"Keys to Wellbeing is a general health and wellbeing education program addressing topics such as keeping socially connected, finding meaning and purpose, addressing mental health, and keeping physically fit. The program was designed to control for time, attention, and many other key contextual factors (e.g., program format, materials).~The intervention program will include nine, 90-minute group sessions that occur weekly for 9 weeks"
223605151|NCT05969067|PROCEDURE|Tunneling Technique during RA SCP|As described in the intervention arm above
223752479|NCT07108270|BIOLOGICAL|Dostarlimab|Dostarlimab will be administered.
223752480|NCT07108270|DRUG|Carboplatin|Carboplatin will be administered.
223752481|NCT07108270|DRUG|Paclitaxel|Paclitaxel will be administered.
223752482|NCT07108400|PROCEDURE|ultrasound-guided injections of hyaluronic acid plus high-power laser therapy|Received two ultrasound-guided injections of hyaluronic acid into the coxo-femoral joint, 10 sessions of physical therapy specifically targeting hip OA (5 sessions/week for two weeks) lasting 45 minutes, and 10 sessions of active high-power laser therapy using a diode laser.
223752483|NCT07108400|PROCEDURE|"ultrasound-guided injections of hyaluronic acid plus sham high-power laser therapy"|"Received two ultrasound-guided injections of hyaluronic acid into the coxo-femoral joint, 10 sessions of physical therapy specifically targeting hip OA (5 sessions/week for two weeks) lasting 45 minutes, and 10 sessions of sham high-power laser therapy using a diode laser, due to the presence of a light pointer and an acoustic signal of the device, which made it impossible to distinguish the active treatment from the sim-ulated one."
223605152|NCT05969067|PROCEDURE|Dissection Technique during RA SCP|As described in the intervention arm above
223605153|NCT06359210|BEHAVIORAL|Responder Monthly Behavior Change Discussion Sessions|Monthly behavior change discussion sessions (3 total) for 12 weeks.
223605154|NCT06359210|BEHAVIORAL|Incomplete Responder Monthly Behavior Change Discussion Sessions|Monthly behavior change discussion sessions (3 total) for 12 weeks.
223605155|NCT06359210|BEHAVIORAL|Incomplete Responder Monthly Behavior Change Discussion Sessions + Bi-Weekly Exercise Sessions|Monthly behavior change discussion sessions (3 total) for 12 weeks and attend bi-weekly (every other week) exercise classes that mirror the exercises completed in their respective community-based exercise program.
223605156|NCT05833438|DRUG|VEN+AZA-5|Up to 6 cycles: Azacitidine (AZA) 75 mg/m2, d1-5 of each 28 day cycle (SC) in combination with Venetoclax (VEN): 400 mg daily (orally)
223605157|NCT04426318|BEHAVIORAL|Healthy Minds Program Foundations Training|The HMP is a novel, smartphone-based app that provides a series of guided meditation practices on four primary constituents of well-being: Awareness, Connection, Insight, and Purpose. The program is unique in several ways. First, all program elements are introduced with a summary of the scientific evidence supporting its constituent elements (e.g., Awareness and well-being). Second, in addition to standard sitting meditation practices found in many meditation-based behavioral interventions, the HMP offers active practices in which participants can develop the same skills but while embedding practice into activities they already do in their normal daily routine.
223605158|NCT05350644|OTHER|Primary exposure variable|"1. Specific activated CD8+ T-cell transcriptome signature in biopsies is associated with better treatment outcome~2. Specific activated CD8+ T-cell transcriptome signature in blood is associated with better treatment outcome"
223605159|NCT05350644|OTHER|Other (exploratory) exposure variables|Specific transcriptomic signatures in intestinal biopsies and peripheral blood mononuclear cells (PBMCs) of IBD patients can work as a predictive biomarker for the tumor necrosis factor inhibitors (TNFi) treatment response
223605160|NCT04239235|BEHAVIORAL|CRAFT|CRAFT is an evidence-based and non-confrontational approach for teaching friends/family members strategies to help their loved one reduce/refrain from using substances. It focuses on improving the lives of both the friends/family members and the individual struggling with substance use.
223605161|NCT02081313|OTHER|Biopsy|
223605162|NCT02081313|OTHER|Blood sample|
223752484|NCT07110493|DEVICE|Transcranial Magnetic Stimulation (TMS)|Single-pulse TMS is applied to specific areas of the visual cortex to non-invasively induce the perception of phosphenes (brief flashes of light). Stimulation is delivered using a TMS device, with the operator controlling the intensity and frequency parameters to a level equal to the phosphene-evoking threshold. During stimulation, participants are seated comfortably and asked to report the location of perceived phosphenes on a monitor and a physical grid, helping to map the cortical visual field.
223752485|NCT07110493|DEVICE|Electroencephalography (EEG)|Continuous brain electrical activity is recorded using a 128-channel gel-based EEG system (Skoltech). The EEG cap is fitted to the participant's head to capture neural responses with high temporal resolution throughout the session. The collected data is used to analyze brain activity changes, including the P300 component and other event-related potentials, to identify neural correlates of phosphene perception and the effects of TMS.
223752486|NCT07110493|DEVICE|Eye-Tracking|Eye movements are continuously monitored using a Tobii Defusion 2 eye-tracker (Skoltech) operating at 60 Hz. This device provides high-accuracy measurements of gaze fixation and saccades. Participants are instructed to fixate their gaze on one of five predetermined points on a screen (center, top, bottom, left, right), with the fixation point being determined randomly for each trial. The eye-tracking data is analyzed to assess the influence of gaze position on phosphene localization and to study any stimulation-induced changes in eye movement patterns.
223752487|NCT07108673|DIAGNOSTIC_TEST|MRI|structural MRI imaging and behavioral testing (e.g. Barratt Impulsiveness scale) both performed by skilled physicians.
223752488|NCT07108829|DEVICE|Renal Artery Radiofrequency Ablation Clamp|This device is a clamp used during a laparoscopic surgical procedure. It is placed on the external surface (adventitia) of the renal artery and is connected to a radiofrequency generator. It delivers targeted radiofrequency energy to ablate the renal sympathetic nerves.
223752489|NCT07108582|DRUG|no NSAID|no NSAID but a placebo with identical galenic formulations to maintain blindness at all times during participation in the study
223752490|NCT07108582|DRUG|protocol for administering NSAIDs already used in routine care|"* 100 mg ketoprofen LP orally administered 30 minutes before surgery,~* 50 mg ketoprofen intravenously at the end of surgery~* then 100 mg ketoprofen LP PO twice a day for 7 days following surgery"
223752491|NCT07109167|DRUG|Benmelstobart combined with gemcitabine and cisplatin|Benmelstobart 1200mg, intravenous infusion on Day 1;Gemcitabine 1000mg/m², intravenous infusion over 30 minutes on Day 1 and Day 8;Cisplatin 25mg/m², intravenous infusion on Day 1 and Day 8. Maintenance dose of study medication: Benmelstobart 1200mg, intravenous infusion on Day 1;Gemcitabine 1000mg/m², intravenous infusion over 30 minutes on Day 1 and Day 8
223752492|NCT07109115|DIETARY_SUPPLEMENT|Vitamin C (Ascorbic Acid)|Subjects will be supplemented with the following vitamin C doses: 0mg, 200mg, 500mg, 1000mg.
223752493|NCT07108556|BEHAVIORAL|Mindfulness VR-Typical|Participants first experience mindfulness exercise with virtual reality incorporated, then another mindfulness exercise with only audio-guidance as typically delivered without the technology
223752494|NCT07108556|BEHAVIORAL|Mindfulness Typical-VR|Participants first experience mindfulness exercise with only audio-guidance, then another mindfulness exercise with virtual reality incorporated
224075384|NCT04655664|DIAGNOSTIC_TEST|consumed vitamin D supplements regularly|The tests carried out were examination of 25 (OH) D and 1.25 (OH) D levels of serum and saliva, examination of demographic data, and other anthropometries. The examination was carried out by taking 5 mL of blood and 2 mL of saliva, and then checking the serum and saliva levels of 25 (OH) D and 1.25 (OH) D. Before the examination, the research subjects were asked not to consume food or drink for at least 90 minutes before being examined. Centrifugation was carried out (2500 g, 10 minutes) and the product immediately stored at -20 oC. In the serum examination, after the blood was drawn, centrifugation was carried out and the product stored at -20 oC for further determination of the levels of 25 (OH) D and 1.25 (OH) saliva.
223605163|NCT04395079|BIOLOGICAL|Durvalumab|Given IV
223605164|NCT04395079|RADIATION|Internal Radiation Therapy|Undergo brachytherapy
223605165|NCT04395079|BIOLOGICAL|Tremelimumab|Given IV
223752495|NCT07109934|DEVICE|deep breathing exercises, chest mobilization:|The patients were instructed to engage in deep and gentle inspired breathing, maintain it for 3 seconds, and then exhale gently via the mouth while seated in a semi-sitting posture. During expiration, the patients were instructed to cough twice with maximum efficiency (patients were instructed to maintain a cushion in the incision area during coughing). Thereafter, the patient was provided with an incentive spirometer to be utilized 5 to 10 times daily at intervals of 2 hours. The chest mobilization was conducted five times each set, with three sets assigned to each session Individual participants independently performed chest mobilization under the guidance of a physiotherapist for the first time. The chest mobilization technique involves pulling the arms upwards to their maximum extent while inhaling appropriately during arm movement.
223752496|NCT07109232|OTHER|Position the patient|In addition, prior to the operation and throughout the PCNL procedure, hemodynamic measurements were obtained while patients were positioned in the supine, lithotomy, and prone positions, as necessitated by the surgical protocol.
223752497|NCT06912802|OTHER|Non-Intervention|Non-Intervention study
223752498|NCT07109440|DIAGNOSTIC_TEST|FAPI PET/CT|Patient will undergo FAPI PET/CT Prior to surgery
223605166|NCT03574779|DRUG|Niraparib|Niraparib is a potent, orally active PARP1 and PARP2 inhibitor being developed as a treatment for participants with tumors that harbor defects in the homologous recombination deoxyribonucleic acid (DNA) repair pathway or that are driven by PARP-mediated transcription factors.
223605167|NCT03574779|BIOLOGICAL|TSR-042|TSR-042 is a humanized monoclonal antibody that binds with high affinity to Programmed cell death protein 1 (PD-1) resulting in inhibition of binding to programmed death receptor ligands 1 and 2 (PD-L1 and PD-L2).
223605168|NCT03574779|BIOLOGICAL|Bevacizumab|Bevacizumab is an Food Drug and Administration (FDA) approved antiangiogenic recombinant humanized monoclonal Immunoglobulin (Ig) G1 antibody against the vascular endothelial growth factor protein, which has been shown to be efficacious against a variety of different cancer types, including colon cancer, lung cancer, glioblastoma, and renal-cell carcinoma.
223605169|NCT03574779|DRUG|Carboplatin|Carboplatin will be infused intravenously over 60 minutes at the prescribed dose of area under the concentration versus time curve of 5 to 6 mg/milliliters (mL) per minute on Day 1 of every 21-day cycle
223605170|NCT03574779|DRUG|Paclitaxel|Paclitaxel will be administered intravenously over 180 minutes at the prescribed dose of 175 mg/meter square (m\^2) on Day 1 of every 21-day cycle
223605171|NCT04985500|PROCEDURE|ESP block|peripheral nerve block
223605172|NCT04985500|PROCEDURE|PIF block|peripheral nerve block
223605173|NCT04985500|PROCEDURE|Ultrasound|Ultrasound guidance
223752499|NCT07110545|OTHER|Acupuncture|Application of acupuncture on specific acupoints
223752500|NCT07108972|PROCEDURE|Transabdominal pre-peritoneal laparoscopic inguinal hernia repair|laparoscopic inguinal hernia repair surgical technique that it's main principal is placing the mesh pre-peritoneally through transabdominal approach
223752501|NCT07108972|PROCEDURE|Totally extraperitoneal laparoscopic inguinal hernia repair|laparoscopic inguinal hernia repair surgical technique that it's main principal is placing the mesh pre-peritoneally through extraperitoneal approach
223752502|NCT07110649|DEVICE|Virtual Reality Rehabilitation Group|Conducted in three progressive stages using VR games: improving ROM, strengthening shoulder muscles, and simulating game scenarios.
223752503|NCT07110649|OTHER|Traditional Rehabilitation Group|Used conventional physical therapy methods based on established rehabilitation programs.
223752504|NCT07109258|DRUG|Dexamethasone (Decadron) 8mg IM injection|one dose of IM dexamethasone sodium phosphate 8 mg (2 mL) given at the start of labour induction
223752505|NCT07109258|DRUG|Misoprostol 25 mcg|vaginal misoprostol 25 μg tablets every 6 h, up to 4 tablets, for a maximum duration of 24 h.
223752506|NCT07109258|DRUG|Both Misoprostol 25 mcg & Dexamethasone 8mg IM injection|one dose of IM dexamethasone sodium phosphate 8mg (2mL) with the first dose of vaginal misoprostol 25 μg tablets that will be given every 6 h, up to 4 tablets, for a maximum duration of 24 h.
223752507|NCT05588843|DRUG|SAR443122|oral capsule
223752508|NCT05588843|DRUG|Placebo|oral capsule
224311425|NCT03480386|BEHAVIORAL|Home Based Pulmonary Rehabilitation|Twice daily exercise routine six days a week of 3 minutes of personal breathing, 5 exercises with 10 reps each, and 6 minutes of walking with weekly health coach calls.
223605174|NCT04985500|DRUG|Bupivacain|10-20 mL of 0.25% bupivacaine
223605175|NCT06005844|DIAGNOSTIC_TEST|Cerebellar Cognitive-Affective Syndrome Scale|The CCASS will be administered by a neuropsychologist starting with version 1A. An alternative version (1B, 1C or 1D) will also be administered. An interval of approximately 30 minutes should be observed between the two administrations. In order to assess the inter-rater reliability of the scale, a second neuropsychologist will be present in the room and will independently evaluate (i.e., blind to his/her colleague's rating) patient's responses. The choice of alternative version (i.e., 1B, 1C, or 1D) will be randomized.
223605176|NCT02588261|DRUG|naquotinib mesilate|Participants received ASP8273 300 mg orally once daily on an empty stomach (no food for at least 2 hours before and 1 hour after taking drug) at approximately the same time every day.
223605177|NCT02588261|DRUG|Erlotinib|Participants received erlotinib 150 mg orally once daily on an empty stomach (no food for at least 2 hours before and 1 hour after taking drug) at approximately the same time every day. At the beginning of the trial, prior to site initiation and shipment of study drug supplies, each investigator selected either erlotinib or gefitinib to be utilized for all participants randomized to the comparator arm at their site.
223752509|NCT07110454|DEVICE|Previous receipt of the Minder System (implantable continuous electroencephalographic (EEG) monitoring (iCEM) system)|The Minder System consists of an implanted device containing an electrode lead and telemetry unit. The electrode lead contains four electrodes that are placed under the patient's scalp to record electrical activity (EEGs) from both sides of the brain. The electrode lead is connected to the telemetry until that continuously transmits these signals to the external Minder devices to remotely show EEGs for clinician review.
223752510|NCT06924593|DEVICE|Trans-Carotid Artery Occlusion Shunt System|To evaluate the Safety and Efficacy of the Trans-Carotid Artery Occlusion Shunt System for Carotid Artery Revascularization during Endovascular Treatment
223752511|NCT06923254|OTHER|7.0T MRI-Scan|7.0T MRI-Scan
223605178|NCT02588261|DRUG|Gefitinib|Participants received gefitinib 250 mg was taken orally once daily with water, with or without food, at approximately the same time every day. At the beginning of the trial, prior to site initiation and shipment of study drug supplies, each investigator selected either erlotinib or gefitinib to be utilized for all participants randomized to the comparator arm at their site.
223605179|NCT06281236|DRUG|Prednisolone|Prednisolone according to the participant's pre-trial dose, symptoms and inflammatory biomarkers.
223605180|NCT06281236|DRUG|SPI-62|SPI-62 administered once daily.
223605181|NCT01749150|DRUG|danoprevir + ritonavir|125 mg danoprevir + 100 mg ritonvir fixed-dose combination tablet, orally b.i.d., 12 weeks
223605182|NCT01749150|DRUG|danoprevir + ritonavir|125 mg danoprevir + 100 mg ritonvir fixed-dose combination tablet, orally b.i.d., 24 weeks
223605183|NCT01749150|DRUG|peginterferon alfa-2a [Pegasys]|180 mcg sc weekly, 12 weeks
223605184|NCT01749150|DRUG|peginterferon alfa-2a [Pegasys]|180 mcg sc weekly, 24 weeks
223752512|NCT06928337|DEVICE|AI evaluation of oocytes.|AI evaluation of oocytes inside a time-lapse incubator.
223605185|NCT01749150|DRUG|ribavirin [Copegus]|1000-1200 mg orally daily in divided doses, 12 weeks
223605186|NCT01749150|DRUG|ribavirin [Copegus]|1000-1200 mg orally daily in divided doses, 24 weeks
224200426|NCT02057549|DRUG|Conventional Therapy|Conventional Therapy includes hydration via IV fluids, pain control with analgesics (usually opiates) frequently requiring multiple doses, also antiemetics (often requires multiple doses and different agents in attempts to control nausea and vomiting within this population), in addition to electrolytes abnormalities corrections as needed.
223605187|NCT03213288|DIETARY_SUPPLEMENT|Delphinidin type anthocyanins|Bilberry extract containing Delphinidin type anthocyanins
223605188|NCT03213288|DIETARY_SUPPLEMENT|Cyanidin type anthocyanins|Black rice extract containing Cyanidin type anthocyanins
223605189|NCT03213288|DIETARY_SUPPLEMENT|Placebo|No anthocyanins
223605190|NCT05082246|OTHER|Conscious Breathing|During the Conscious Breathing session, participants will be asked to sit comfortably and with gently closed eyes. Participants will be guided through several different kinds of breathing techniques, where the will focus will be on the expansion of the chest or abdomen, releasing all tension from the body, and visualizing breathing light into the body.
223605191|NCT05082246|OTHER|Heartfulness Meditation|During the Heartfulness Meditation session, participants will be asked to sit comfortably and with gently closed eyes. Starting with the feet and working towards the head, participants will be asked to relax each part of the body. Then participants will focus on the heart and imagine it filled with light and love. Participants will sit in this relaxed state for a few minutes to allow all stress and cares to be released.
223605192|NCT05082246|OTHER|Emotional Freedom Technique|"During the Emotional Freedom Technique session, participants will be asked to tap lightly on several acupressure points while saying a variety of statements regarding pain, anxiety, depression or stress. As participants tap on the acupressure points, participants will repeat phrases of affirmation and acceptance, and also talk through how pain, anxiety, depression or stress may cause distress but can learn to release these feelings. participants will be given a picture of where each of the acupressure points lie on the face, chest or head, and will also be given a script of what to say while tapping on each acupressure point. In addition, participants will be given a description of what each acupressure point means - its associated organ and what emotion that point helps to release."
223605193|NCT01761019|DRUG|Taclonex Topical Suspension|topical medication for psoriasis
223752513|NCT07108322|OTHER|Intraoral scanning|Adigital impression with intraoral scanning
223752514|NCT01285804|OTHER|Cuffed ETT|Kimberly Clark
223752515|NCT01285804|OTHER|Uncuffed ETT|Kimberly Clark
223752516|NCT05010928|COMBINATION_PRODUCT|mouthwash with tea|Using tea as a base, supplemented with licorice to make mouthwash to relieve stomatitis.
223752517|NCT04259112|PROCEDURE|high pressure|High-pressure pneumoperitoneum is defined as intra-abdominal pressure 12-15 mmHg.
223752518|NCT04259112|DRUG|deep neuromuscular block|Deep neuromuscular block is defined as PTC 1-2.
223752519|NCT04259112|PROCEDURE|low pressure|Low-pressure pneumoperitoneum is defined as intra-abdominal pressure 7-10 mmHg.
223752520|NCT04259112|DRUG|moderate neuromuscular block|Moderate neuromuscular block is defined as TOF twitch 1-2.
223752521|NCT06483971|DIAGNOSTIC_TEST|Oral Isotretinoin|20 mg/kg/day that affects sebaceous glands and is used to treat severe acne Frequency: Once daily
223752522|NCT06483971|COMBINATION_PRODUCT|Antibiotics|250 mg on laternate day/3 months Frequency: Once or twice daily
223605194|NCT03781778|OTHER|Dietary Intervention (resistant starch)|Eat foods with resistant starch
223605195|NCT03781778|OTHER|Dietary Intervention (regular starch)|Eat foods with regular corn starch
223605196|NCT03781778|OTHER|Questionnaire Administration|Ancillary studies
223752523|NCT00661076|DRUG|adefovir dipivoxil|10mg po daily for 96 weeks (arm 1) or 48 weeks (arm 2)
223752524|NCT00661076|DRUG|peginterferon alfa-2a [Pegasys]|180 micrograms weekly for 48 weeks
223752525|NCT01166685|DEVICE|Everolimus-eluting stent|Everolimus-eluting stent
223752526|NCT01166685|DEVICE|Bare-metal stent|Bare metal stent
223752527|NCT01166685|DEVICE|Biodegradable Polymer-DES|drug-eluting stent with bioabsorbable polymer
223752528|NCT02449239|BIOLOGICAL|Vicinium|Intravesical administration
223752529|NCT03821558|OTHER|Exercise training|Patients to be randomized to the 'interval training group' or 'continuous training group' will undergo exercise training sessions with different intensity levels.
223752530|NCT03222843|DRUG|Hetrombopag Olamine|once daily
223752531|NCT03222843|DRUG|matching placebo|once daily
223752532|NCT06164132|OTHER|Evaluation|Evaluation through PCOS Phenotypes, measurements of Body weight, height, waist and hip circumferences, Dual-energy X-ray absorptiometry, and Sonographic examination.
224200427|NCT02701660|DEVICE|electronic medication dispenser (medido)|Automated dispense of medication through an electronic dispenser
224200428|NCT04867980|DRUG|ACP-196|Participants will receive a single oral dose of 100 mg ACP-196 (1 x 100 mg capsule) on Day 1 (Treatment A) and 400 mg ACP-196 (4 x 100 mg capsules) on Day 1 (Treatment B) according to the randomization scheme.
224200429|NCT04867980|DRUG|Moxifloxacin 400 mg|Participants will receive a single oral dose of 400 mg moxifloxacin (1 x 400 mg tablet) on Day 1 (Treatment C) according to the randomization scheme.
223605197|NCT02287467|BIOLOGICAL|Intravenous hyperimmune immunoglobulin (IVIG)|Administered intravenously (IV) at a dose of 0.25 g/kg (up to a maximum of 24.75 g, corresponding to approximately 100 kg actual body weight)
223605198|NCT02287467|BIOLOGICAL|Placebo for IVIG|Administered IV as 500 mL of normal saline
223605199|NCT04775641|OTHER|questionnaire|questionnaire
223605200|NCT01517555|DRUG|liraglutide|Administered as a subcutaneous injection. Initial dose 0.6 mg daily, adjusted to 1.2 mg daily in week 2 and escalated to 1.8 mg daily in week 3
223605201|NCT01517555|DRUG|placebo|Administered as a subcutaneous injection. Given as daily volume of 100 mcl, 200 mcl and 300 mcl respectively
223605202|NCT01517555|DRUG|paracetamol|One single dose of 1 g. Tablet
223605203|NCT04270968|DEVICE|extra-corporeal shock wave therapy|Extracorporeal Shock Wave Therapy (ESWT) has been introduced efficiently for more than twenty years as a treatment modality in orthopedic and musculoskeletal disorders. ESWT has mechanical and cellular impacts on tissues regeneration and pain management through cavitation bubbles, acoustic micro streaming, and hyper-vascularity that can directly affect tissue calcifications, and modulate cell activity.
223752533|NCT00763074|BEHAVIORAL|Standard life style modification for type 2 diabetes|"Two session of education for exercise and diet.~\----------- Exercise: 30min/day x 4/week Diet: ideal body weight x 30\~35kcal/day"
223752534|NCT00763074|BEHAVIORAL|Diet restriction|"Education for diet and exercise every 2 weeks~\----------- Dietary calorie restriction: reduce their usual intake by -500kcal/day"
223752535|NCT00763074|BEHAVIORAL|Exercise|"Education for diet and exercise every 2 weeks~\----------- Exercise: more than 60min/day of exercise with moderate activity level twice per day"
223605204|NCT04270968|DRUG|topical none steroidal anti-inflammatory drug|participants received 1% topical diclofenac gel on the tender points 3 times /day for 4 weeks.
223605205|NCT03316638|DRUG|W0101 - Cohort A1|Administered once every 2 weeks
223605206|NCT03316638|DRUG|W0101 - Cohort A2|Administered every 3 weeks
223605207|NCT03316638|DRUG|W0101 - Expansion Phase|Administered according to the recommended dose for expansion
223605208|NCT02770924|DEVICE|AT LISA TRI TORIC|phacoemulsification with IOL implantation
223752536|NCT00763074|BEHAVIORAL|Diet and exercise|"Education for diet and exercise every 2 weeks~\----------- Exercise education like as exercise group and diet education like as diet group"
223752537|NCT03339609|DIAGNOSTIC_TEST|Uroflow|Isolated uroflow measurement
223752538|NCT03339609|DIAGNOSTIC_TEST|Uroflow/EMG|Uroflow measurement with superficial EMG testing of the pelvic floor
223752539|NCT03339609|DIAGNOSTIC_TEST|US|Ultrasound of post void residual urine
223752540|NCT02189564|BEHAVIORAL|Feedback about good performance|
223752541|NCT02189564|BEHAVIORAL|Feedback about good performance + money|
223752542|NCT02189564|BEHAVIORAL|Feedback about average performance|
223752543|NCT05437289|DRUG|AZD7442 IM|In cohort 1, participants will be randomized to receive 300 mg AZD7442 (150 mg AZD8895 and 150 mg AZD1061) administered sequentially as direct gluteal IM injections.
223752544|NCT05437289|DRUG|Placebo IM|In cohort 1, participants will be randomized to receive placebo with dose match to AZD7442 in the same cohort administered sequentially as direct gluteal IM injections.
223752545|NCT05437289|DRUG|AZD7442 IM|In cohort 2, participants will be randomized to receive 600 mg AZD7442 (300 mg AZD8895 and 300 mg AZD1061) administered sequentially as direct gluteal IM injections.
223752546|NCT05437289|DRUG|Placebo IM|In cohort 2, participants will be randomized to receive placebo with dose match to AZD7442 in the same cohort administered sequentially as direct gluteal IM injections.
223752547|NCT05437289|DRUG|AZD7442 IV|In cohort 3, participants will be randomized to receive 300 mg AZD7442 (150 mg AZD8895 and 150 mg AZD1061) mixed in IV bag co-administered as a single IV infusion.
223752548|NCT05437289|DRUG|Placebo IV|In cohort 3, participants will be randomized to receive placebo with dose match to AZD7442 in the same cohort as a single IV infusion.
223752549|NCT05437289|DRUG|AZD7442 IV|In cohort 4, participants will be randomized to receive 600 mg AZD7442 (300 mg AZD8895 and 300 mg AZD1061) mixed in IV bag co-administered as a single IV infusion.
223605209|NCT02770924|DEVICE|AT LISA TRI|phacoemulsification with IOL implantation
223605210|NCT04473027|DIAGNOSTIC_TEST|Blood sample collection|Whole venous blood of participants will be collected in EDTA tubes (max. 10 mL) at baseline, before start of first immunotherapy round. The Belgian Red Cross will perform serological blood group diagnostics, and molecular RBC typing.
223605211|NCT03441386|BEHAVIORAL|Physical Exercise Session|
223605212|NCT00445185|BIOLOGICAL|Henogen HB vaccine|Month 12, 24 and 36
223605213|NCT00445185|BIOLOGICAL|Fendrix vaccine|Month 12, 24 and 36
223605214|NCT02652156|DRUG|Bupivacaine|60 ml Bupivacaine 0.25% will be drawn via 60 ml Syringe. The syringe will be connected and a 10ml flush syringe containing 10ml 0.9% Normal Saline (NS) will be connected to the end of an IV extension set via a 3-way stopcock and Luer lock connections. The Bupivacaine 0.25% syringe will be connected to the stopcock. The distal end of the IV connection will be connected to the injection needle. The entire setup will be flushed with 0.9% NS via flush syringe. The TAP space will also be located under ultrasound guidance and verified by using the 0.9% NS flush syringe. Once in the TAP space, 30 ml Bupivacaine 0.25% will be injected into the TAP space. This dose will be decreased to 25 ml for patients under 70 kg. The process will be repeated on the opposite side TAP block.
223605215|NCT02652156|DRUG|Exparel®|20 ml Exparel (266 mg) will be drawn into a 20 ml syringe. A 20 ml Bupivacaine 0.25% syringe and the syringe containing the Exparel solution will be connected to the end of an IV extension set via a 3-way stopcock. The IV connection will be connected to the injection needle. The setup will be flushed with the Bupivacaine syringe. The TAP space will be located under ultrasound guidance. 133mg of Exparel will be injected into the TAP space. After injection, the syringe will be exchanged for the Bupivacaine syringe and 20ml Bupivacaine injected into the space. The process will be repeated on the opposite side TAP block.
223752550|NCT05437289|DRUG|Placebo IV|In cohort 4, participants will be randomized to receive placebo with dose match to AZD7442 in the same cohort as a single IV infusion.
223752551|NCT06310577|DEVICE|Leak-free bronchoscope adapter|Bronchoscopy using both a standard adapter and a leak-free adapter will be performed.
223752552|NCT00779012|BIOLOGICAL|Infliximab|Remicade 5 mg/kg, given as an intravenous infusion over a 2-hour period followed by additional 5 mg/kg infusion doses at 2 and 6 weeks after the first infusion, then every 6 to 8 weeks (maximum 9 infusions).
223752553|NCT04460222|PROCEDURE|Rotational Thromboelastometry to guide blood product transfusion pre invasive procedure|"Rotational Thromboelastometry will be performed pre procedure and blood component will be transfused if~* EXTEM CT more than 80 sec then FFP will be transfused at 15 ml/kg MCF less than 35 mm then Platelet will be transfused at 10 ml/kg~* FIBTEM MCF less than 7 mm then Cryoprecipitate will be transfused at 5 ml/kg"
223752554|NCT04460222|PROCEDURE|Conventional transfusion methods to guide blood product transfusion pre invasive procedure|Transfusion will be given If INR: 1.5 - 2.5 FFP will be transfused at 10 ml/kg If Platelet Count is 20,000/mm3-50,000/mm3 Platelet will be transfused at 10 ml/kg If Fibrinogen \< 80 mg/dl Cryoprecipitate will be transfused at 5 ml/kg
223752555|NCT04115943|OTHER|Treatment protocol for neck pain|The protocol to be used in the study is in accordance with the latest guidelines for the treatment of neck pain associated with limited mobility for patients in the chronic phase. The followed techniques will be performed: i) manual therapy - manipulation or mobilization of the upper cervical spine, manipulation or mobilization of the cervical, cervicothoracic and thoracic regions, manual cervical traction, release of the cervical muscles and muscles of the scapulothoracic region; ii) exercises - strengthening and resistance exercises for the muscles of the scapular girdle, coordination, proprioception and postural training of the cervical and scapulothoracic regions.
223752556|NCT04115943|OTHER|Protocol for release of tongue muscles|. The aim is the relaxation of the suprahyoid muscles (mylohyoid, geniohyoid, digastric and stylohyoid) as well as the cervical fascia of the anterior region and soft tissues of the region of the pharynx and larynx.
223752557|NCT01657110|OTHER|Tea tree oil|Pea-sized amount of tea tree oil medicated gel (containing 200mg/g tea tree oil) applied to the face twice daily for 12 weeks.
223752558|NCT03430804|OTHER|Bishop score calculation of modified Bishop score in numbers by digital vaginal examination|Measurement of cervical length by transvaginal ultrasound and digital examination of Bishop score in 320 parturients undergoing labour induction at term
223752559|NCT01847391|DRUG|GS-6615|GS-6615 tablet(s) administered orally once daily
223752560|NCT01847391|DRUG|Placebo|Placebo tablet(s) to match GS-6615 administered orally once daily
223752561|NCT00950534|DRUG|INSULIN GLARGINE (HOE901)|The dose of insulin glargine will be titrated toward a fasting plasma glucose (FPG) target of 5.5 mmol/L. Treatment with oral antidiabetic drugs (OADs) prescribed before study entry may continue (except Sitagliptin, Acarbose, Rosiglitazone)
223605216|NCT02652156|DRUG|Ropivacaine|40 ml Bupivacaine 0.25% will be drawn via two 20ml Syringes. A Bupivacaine 20ml syringe will be connected to an IV extension via a 3-way stopcock and Luer lock. The IV will be connected to an injection tuohy needle and flushed with NS. The TAP space will be located using ultrasound guidance. 15 ml Bupivacaine 0.25% will be injected. A catheter will be threaded through the tuohy needle into the TAP space. 5ml Bupivacaine 0.25% will then be injected. The catheter will be secured via standard technique. The process will be repeated for the opposite side. Patients will receive a filled ON-Q system. The ON-Q system contains Ropivacaine 0.2%. The pump will run at 7 ml/hr. per side.
223605217|NCT04287387|DRUG|Glucophage 500Mg Tablet|0.5g three times daily
223605218|NCT04287387|DRUG|Acarbose Tablets|50mg three times daily
223605219|NCT04287387|DRUG|Sitagliptin tablet|100mg once daily
223605220|NCT04287387|DRUG|Dapagliflozin Tablet|10mg once daily
223605221|NCT04287387|DRUG|Pioglitazone Tablets|30mg once daily
223605222|NCT04287387|DRUG|Glimepiride Tablets|2mg once daily
223605223|NCT00342849|DRUG|Succimer|Succimer (2,3-meso-dimercaptosuccinic acid) is an orally active dithiol compound that is a relatively specific chelating agent for heavy metals, especially lead, arsenic and mercury. The drug undergoes limited absorption in the gastrointestinal tract and then is rapidly metabolized to mixed disulfides which are eliminated in the urine. Blood levels decline slowly with an apparent elimination half-life of about 48 hours in adults.
223605224|NCT00342849|DRUG|Placebo|
223605225|NCT04031859|DRUG|acetylsalicylic acid|It's a VTE risk stratification tool or procedure that will be used after total knee replacement (TKR) to help surgeons in choosing the tailored VTE prophylaxis according to patients' specific VTE risk, this tool will stratify the TKR-patient in one of three risk-groups: Low high risk who will be prescribed Aspirin upon hospital discharge as extended VTE prophylaxis post TKR surgery, or moderate high risk group who will be prescribed oral anti coagulant (like rivaroxaban) as extended prophylaxis, and the last group is very high risk group who will be prescribed parenteral anticoagulant ( like Enoxaparin) plus compression devices.
223605226|NCT05564455|OTHER|Biometry with Kane formula|Kane formulae for intraocular lens (IOL) power calculation in cataract patients
223605227|NCT05564455|OTHER|Biometry with SRK-T formula|Sanders Retzlaff Kraff theoretical (SRK T) formulae for intraocular lens (IOL) power calculation in cataract patients
223605228|NCT00002695|GENETIC|DNA stability analysis|
223605229|NCT00002695|GENETIC|microsatellite instability analysis|
223605230|NCT00002695|GENETIC|mutation analysis|
223605231|NCT00002695|OTHER|laboratory biomarker analysis|
223605232|NCT04405973|DEVICE|vv-ECMO|vv-ECMO required in severe COVID-19 ARDS
223752562|NCT00950534|DRUG|Oral Anti Diabetics (OAD)|Patients treated with the usual standard of care (OAD dose titration, addition of a second or third OAD or referral to an endocrinologist) until optimal doses are reached to maintain a FPG of 5.5 mmol/L
223752563|NCT05558228|DEVICE|FloPatch FP120|FloPatch FP120 is an FDA 510(k) cleared device indicated for the non-invasive assessment of blood flow in the carotid artery by medical professionals, such as physicians and nurses. FloPatch uses ultrasound and the Doppler effect to assess blood flow.
223605233|NCT04513548|DRUG|Ligelizumab|One injection every four weeks
223605234|NCT04513548|DRUG|Placebo|One injection every four weeks
223752564|NCT05175599|OTHER|Water Birth|The water birth group will use a tub of a water to labor and give birth.
224200430|NCT04867980|DRUG|Placebo|Participants will receive a single oral dose of ACP-196 matching placebo (4 x 100 mg matching placebo capsules) and moxifloxacin matching placebo (1 x 400 mg matching placebo tablet) on Day 1 (Treatment D) according to the randomization scheme.
224311426|NCT02517086|OTHER|therapeutic exercises|The applied therapeutic exercises involve shoulder movements including flexion, extension, abduction, adduction, internal and external rotation in isolated or combined movements, with ten repetitions of each movement, associated with the music, and stretching movements finalizing the sequence of movements.
223605235|NCT03709004|OTHER|Pacifier|Pacifier given to mom.
223605236|NCT05697562|PROCEDURE|Rubber band ligatures (RBL)|This instrumental technique is realized during consultation. A rubber band is applied on top of each hemorrhoidal complex via a proctoscope. This banding causes an ulceration which heals with resulting fibrosis. The patient can receive a maximum of 3 RBL during each session, which can be repeated up to 3 times at a 6 weeks interval.
223605237|NCT05697562|PROCEDURE|Superior Rectal Artery Embolization (SRAE)|"This technique is realized under local anesthesia during a one-day hospitalization. The interventional radiologist will perform the procedure in the angiography room. After local anesthesia right femoral artery puncture is performed and a 4 F or 5 F introducer sheath is placed using the Seldinger technique. With an appropriate 4 or 5 F catheter the superior rectal artery is catheterized. With a microcatheter the different branches are selectively occluded with microcoils. The endpoint of embolization is reached when all SRA branches above the pubic ramus are embolized, with cessation of flow distally or a static column of contrast.~The procedure can be repeated with addition of the embolization of the middle rectal wall artery (MRA) in case of failure after 12 weeks."
223605238|NCT05697562|PROCEDURE|Doppler-Guided Hemorrhoidal Artery Ligation (DG-HAL)|The procedure is performed in lithotomy position with a modified proctoscope including a Doppler transducer (THD device) under anesthesia during a one-day hospitalization. This transanal Doppler guidance enables accurate detection and targeted suture ligation of the SRAs Following gel lubrication, the proctoscope is inserted through the anal canal reaching the low rectum, about 6-7 cm from the anal verge. After identification of the best place for artery ligation, the Doppler system is turned off. The artery will be directly ligated with a Z-stitch at the site of the best Doppler signal.
223605239|NCT06209827|BEHAVIORAL|Intervention for reducing benzodiazepines long-term use.|"Comprehensive, multicomponent intervention utilizing education and support for benzodiazepines.~Family doctor, nurse, community pharmacist and social workers: carried out informative discussion with the patient with by providing educational material. They informed patients about the advantages, disadvantages and alternatives to benzodiazepines including a descending benzodiazepines schedule to minimize withdrawal symptoms. It briefly explained the professionals' concerns about the continued use of benzodiazepines and offers possible solutions.~If the patient requested a withdrawal, he/she was referred to the doctor."
223605240|NCT00936000|DIETARY_SUPPLEMENT|Protandim|The dosage of Protandim will be 1350 mg per day given p.o. in two equally divided doses
223605241|NCT02593942|DRUG|Remifentanil|0.1-0.5 mcg/kg/min infusion
223605242|NCT02593942|DRUG|Propofol|75-200 mcg/kg/min infusion
223752565|NCT04700748|RADIATION|Brain metastases radiation|Brain metastases radiation according to clinical practice.
223605243|NCT01071421|DEVICE|abbreviated polysomnography|Both groups will be studied with in-hospital respiratory polygraphy during the sleep. The group A will be studied with another respiratory polygraphy in the home one month after the resolution of CAP. Some questionnaires to measure the sleepiness (Epworth test), FOSQ test, in-home sleepiness questionnaire and symptoms questionary will be obtained in Group A and B
223605244|NCT00108862|OTHER|Strategy: Immediate ART|The intervention is the strategy of initiating antiretroviral therapy (ART) after approximately 2 weeks of rifampin (RIF)- or other rifamycin-based TB treatment according to in-country national TB treatment guidelines. The study-provided ART is efavirenz (EFV) 600 mg (1 tablet orally), emtricitabine (FTC) 200 mg (1 capsule orally), and tenofovir disoproxil fumarate (TDF) 300 mg (1 tablet orally) daily. Substitutions with other locally available U.S. Food and Drug Administration (FDA)-approved or tentatively approved antiretrovirals that are compatible with TB treatment may be used at the discretion of the site investigator. The TB treatment will be supplied and monitored by the host country TB control program.
223605245|NCT00108862|OTHER|Strategy: Deferred ART|The intervention is the strategy of initiating ART either after 8-12 weeks of RIF- or other rifamycin-based TB treatment according to in-country national TB treatment guidelines. The study-provided ART is EFV 600 mg (1 tablet orally), FTC 200 mg (1 capsule orally), and TDF 300 mg (1 tablet orally) daily. Initiation outside of these windows, on a case by case basis, is permitted at the discretion of the site investigator. Substitutions with other locally available U.S. FDA-approved or tentatively approved antiretrovirals that are compatible with TB treatment may be used at the discretion of the site investigator. The TB treatment will be supplied and monitored by the host country TB control program.
223605246|NCT06144554|DEVICE|Omnipod 5|"The Omnipod 5 System consists of a tubeless insulin Pod and the Omnipod® 5 App, installed on a designated Controller or compatible Android smartphone. The Omnipod 5 System works with the Dexcom G6® Continuous Glucose Monitoring System to continuously adapt and automatically deliver insulin according to personal needs.~Every two weeks while on the Omnipod 5 system, participants will receive a push notification to complete assessments including any severe hypoglycemia or diabetic ketoacidosis events experienced since the prior assessment."
223752566|NCT05125939|OTHER|Comparison of ADR|The investigators will compare ADRs using traditional screening-restricted definition and combined screening, surveillance, and diagnostic indication (i.e., overall-non-FIT indication). The impact of addition of FIT+ indication into the overall indication (i.e., overall-FIT indication) on ADR will also be evaluated.
223752567|NCT05537376|BEHAVIORAL|SUicide Prevention by Peers Offering Recovery Tactics|Following the completion of a comprehensive mental health evaluation by a licensed VA provider, which includes a suicide safety plan, if a Veteran is having active thoughts of suicide or made a suicide attempt in past three months, they may be eligible for SUPPORT. In SUPPORT, the Peer Specialist and Veteran co-create a personalized suicide-focused recovery plan (SUPPORT Plan) in flexible, 50-minute weekly encounters. The SUPPORT Plan includes modules that focus on valuing recovery, building a hope kit and daily plan, setting recovery goals, and looking ahead to enhance the Veteran's safety plan. Learning strategies are incorporated into each module to promote salience and recall of intervention material. The Peer Specialist works closely with the Veteran's treatment team and uses the most recent safety plan in the Veteran's chart to help complete the SUPPORT Plan as well as reinforce the usage of the Veteran's safety plan.
223752568|NCT03893799|DRUG|RBT-1|Single intravenous administration
223752569|NCT03087370|OTHER|No intervention|No intervention
223752570|NCT06146036|BEHAVIORAL|HIIT snacks|Cycling Exercise. 3 times per day 6 x 1 min at approximately 85-95% of HRmax
223752571|NCT06146036|BEHAVIORAL|Sprint snacks|Cycling Exercise. 3 times per day one ''all out'' sprint
223752572|NCT06146036|OTHER|Control|No exercise, sedentary.
223605247|NCT03534141|DEVICE|Esophageal cooling/warming device|The EnsoETM (formerly known as Esophageal Cooling Device) is a non-sterile multilumen silicone tube placed in the esophagus for the purpose of cooling or warming a patient while allowing gastric decompression and drainage. It is placed in a manner identical to a standard orogastric tube, which is standard equipment for liver transplant surgery. It is removed at the end of surgery. Control of the patient's temperature is achieved by connecting the EnsoETM to an external heat exchanger (Gaymar Medi-Therm III or similar system). The Medi-Therm III is a standard device used in operating rooms for warming patients with a conductive table warming pad. The Medi-Therm III circulates temperature-controlled water through a closed-loop system via the two outer lumens of the EnsoETM. Water temperature ranges from 4°C - 42°C.
223605248|NCT03534141|OTHER|Mild hypothermia|Cooling will be initiated after induction of anesthesia and maintained throughout the anhepatic phase of liver transplantation. In all feasible cases the surgeon will cover the peritoneal surface over the right kidney, which is exposed during the operation, with ice-cold sponges to enhance cooling of the renal parenchyma. After blood flow is completely restored to the liver, the esophageal cooling device and other standard measures (forced-air, fluid, and table warmers, plus a heated anesthesia circuit) will be used to actively re-warm the patient (expected warming rate ≥ 1 deg C/hour). The goal is to achieve normothermia by case end.
223605249|NCT03534141|OTHER|Normothermia|After induction of anesthesia, the esophageal cooling/warming device and standard warming measures will be used to maintain normothermia throughout the operation.
223605250|NCT05225857|DRUG|AGA2118|"Part 1 - SAD study: SAD participants in various cohorts will receive various single dose of AGA2118 via either SC or IV.~Part 2 - MAD study: MAD participants in various cohorts will receive various multiple doses of AGA2118 Q4W via SC."
223605251|NCT05225857|DRUG|Placebo|"Part 1 - SAD study: SAD participants in various cohorts will receive a single dose of placebo via either SC or IV.~Part 2 - MAD study: MAD participants in various cohorts will receive multiple doses of placebo via SC."
223605252|NCT06064695|DEVICE|Whole-body Electrical Muscle Stimulation Exercise|This is a fitness device that delivers whole-body electrical muscle stimulation in conjunction with exercise programs using an iPad App. The stimulation suit (fitted shorts/shirt, vest, leg straps, arm straps) will be donned with the assistance of trained research personnel. Muscle groups stimulated include biceps, triceps, pectorals, abdominals, periscapular musculature, paraspinal musculature, gluteus musculature, quadriceps, and hamstrings. The stimulation level of each individual muscle group can be tailored to participant responses and tolerance (i.e. stimulation of the quadriceps and biceps can occur at different settings). While the participant is following along with the video, a qualified health care professional will be monitoring and adjusting the stimulation levels based on participant responses; rate of perceived exertion will also be monitored to ensure safe moderate intensity levels are maintained.
223605253|NCT03071822|DRUG|cisplatin|PIGLETs
223605254|NCT03071822|DRUG|ifosfamide|PIGLETs
223605255|NCT03071822|DRUG|gemcitabine|PIGLETs
223605256|NCT03071822|DRUG|L-asparaginase|PIGLETs
223605257|NCT03071822|DRUG|etoposide|PIGLETs
223752573|NCT06530654|BEHAVIORAL|Distraction by dentist|Dental treatment is carried out with tell-show-do technique as a behavioural guidance technique.
223752574|NCT06530654|BEHAVIORAL|Distraction by cartoon movie|Dental treatment is carried out with showing cartoon movie as a passive distraction during the treatment.
223752575|NCT06530654|BEHAVIORAL|AG-active distraction group|The active distraction group is treated and interacting with the designed application
223752576|NCT05372276|OTHER|Assessment 1|Mental Toughness Questionnaire in Sport
223752577|NCT05372276|OTHER|Assessment 2|Sport Imagery Questionnaire
223752578|NCT05372276|OTHER|Assessment 3|The Pittsburgh Sleep Quality Index
223605258|NCT03071822|DRUG|dexamethasone|PIGLETs
223605259|NCT02630914|DEVICE|The AtriCure Synergy Ablation System|The AtriCure Synergy Ablation System will be used on all patients for AF ablation.
223752579|NCT05372276|OTHER|Assessment 4|The Perceived Stress Scale (PSS)
223752580|NCT05829759|BEHAVIORAL|Tele-B6|Participants will be part of the Tele-B6 intervention that includes six group sessions delivered over the course of six weeks. Survey assessments for the intervention group (first phase) will be conducted at enrollment (baseline), 2 months (immediate post-intervention survey), 4 months (interim-survey, post-intervention), and 6 months (endline).
223752581|NCT05829759|BEHAVIORAL|Delayed intervention (waitlist control)|Wait-list control participants will be assigned to a group for initiation of the full intervention beginning at month 4 after their enrollment (i.e., beginning after they, and their corresponding intervention group, have completed their intervention and two follow-up surveys). Wait-list control participants will complete surveys at enrollment (baseline), 2 months (pre-intervention), 4 months (preintervention), 6 months (immediate post-intervention), and 8 months (post-intervention).
223752582|NCT06579144|DRUG|Efanesoctocog alfa|Recombinant coagulation factor VIII Fc-von Willebrand Factor-XTEN fusion protein (rFVIIIFc-VWF-XTEN)
223752583|NCT04747340|BEHAVIORAL|Training for Awareness Resilience and Action (TARA)|See arm-description
224200431|NCT03217916|DIAGNOSTIC_TEST|Elisa assay of podocyte glycoprotein in urine|"Biomarkers evaluated in urine specimens including podocyte glycoproteins nephrin and podocalyxin, All biomarkers were measured by ELISA. Assay information for sources of ELISA kits, standard cure range, sample dilution factors, etc.~All assays will be performed following the manufacture's instructions. All specimens will be measured in duplicate.~Personnel who performed the assays of analyteswere blinded to the clinical information."
224200432|NCT02267616|DEVICE|Etonogestrel Implant|Subdermal arm implant
223752584|NCT04747340|OTHER|Standard treatment|See arm-description
223752585|NCT04296006|BEHAVIORAL|Money|Three money values offered as alternatives to cocaine.
223752586|NCT04296006|DRUG|Cocaine HCl|3 mg/70 kg is available as an alternative to money.
223752587|NCT03314584|DEVICE|Transcranial Magnetic Stimulation|Active-repetitive transcranial magnetic stimulation (rTMS) at the left motor cortex.
223752588|NCT03314584|DEVICE|Sham Transcranial Magnetic Stimulation|Sham rTMS will consist of the same parameters as active, however, the subject will not receive the actual magnetic stimulation to the left motor cortex due to the use of a double sided Active/Sham coil used specifically for research studies.
224200433|NCT05934682|PROCEDURE|Surgery|All children submitted to surgery will be followed until hospital discharge or 30 days postoperatively.
223605260|NCT04521244|OTHER|Thrust joint lumbar manipulation|Moist Hot pack of 14/15' over lumbar region for 15 mins. Hydro collator Temperature according to standardized hot pack is 40-45οC.Bilateral Thrust Manipulation of Lumbar Spine from L1-L5 Baseline Algometer for springing force tolerance and Lumbar Inclinometry using dual inclinometer for lumbar flexion, extension and goniometer for lumbar side bending.These pre and post intervention values were mentioned in questionnaire. The participants were administered with thrust and non-thrust manipulation of the lumbar spine and data was collected again immediately after the interventions without any delay.
223605261|NCT04521244|OTHER|Lumbar mobilization|Moist Hot pack of 14/15' from L1 where ribcage ends up to the region of gluteal folds for 15 mins. Non Thrust Manipulation for 30 seconds Using Kaltenborn grade 3 (Stretch rotation mobilization).Baseline Algometer for springing force tolerance and Lumbar Inclinometry using dual inclinometerfor lumbar flexion, extension and goniometer for lumbar side bending. These pre and post intervention values were mentioned in questionnaire. The participants were administered with thrust and non-thrust manipulation of the lumbar spine and data was collected again immediately after the interventions without any delay.
223752589|NCT03314584|DIAGNOSTIC_TEST|Magnetic resonance imaging (MRI)|Brain imaging will be done via MRI prior to the first rTMS/Sham TMS session. Imaging will allow investigators to target specific areas in the brain.
223752590|NCT06134817|DEVICE|Embozene Color-Advanced Microspheres.|"Embozene Microspheres are spherical, tightly calibrated, biocompatible, nonresorbable, hydrogel microspheres coated with an inorganic perfluorinated polymer. The microspheres are intended to occlude vasculature for the purpose of blocking blood flow to a target tissue.~In the study, the abnormal vessels will be embolized with 100 μm Embozene Microspheres solution under direct fluoroscopic visualization to prevent reflux and non-target embolization. Multiple geniculate arteries may be embolized until neovascularity is no longer seen."
223752591|NCT05098132|DRUG|STK-012|pegylated alpha/beta-biased engineered interleukin-2
223752592|NCT05098132|DRUG|pembrolizumab|anti-PD-1 humanized monoclonal antibody
223752593|NCT05098132|DRUG|pemetrexed|antifolate chemotherapy
223752594|NCT05098132|DRUG|carboplatin|platinum chemotherapy
223752595|NCT04435015|DRUG|Camostat Mesylate|Participants will be given Camostat mesylate three times daily.
223752596|NCT04435015|DRUG|Microcrystalline Cellulose, NF|Participants will be given Microcrystalline Cellulose (placebo) three times daily.
223605262|NCT05187039|OTHER|Electrical impedance tomography during anesthesia|Thoracic electrical impedance tomography measurements ( min each) will be performed at the following time points: before induction of the anaesthesia; before the surgical procedure when the induction is terminated and recruitment manoeuvers have been performed; after the termination of the surgical procedure; before transport to the Post anaesthesia Care Unit (PACU); before the discharge from the PACU after 2 hours of monitoring. An additional thoracic EIT-measurement will be performed before discharge at home. For this, resulting potential differences are measured, and impedance distribution sampled at 30 Hz will be calculated. Relative change in poorly ventilated lung regions (silent spaces) and end-expiratory lung impedance (EELI) and measures of ventilation inhomogeneity will be calculated using customised code (Matlab R2021a, The MathWorks, Nattick, Massachusetts, USA).
223605263|NCT00517361|DRUG|carboplatin|AUC 6 in 250mL saline IV over 30 minutes
223605264|NCT00517361|DRUG|bevacizumab|15mg/kg in 100mL saline IV over 60 - 90 minutes
223605265|NCT02564185|OTHER|Usual practice|
223605266|NCT02564185|OTHER|Education program|
223605267|NCT04146662|DIAGNOSTIC_TEST|Faecal immunochemical test|Faecal immunochemical test (FIT) and urine volatile organic compounds (VOC) analysis.
223605268|NCT05503342|OTHER|Mobile Application|Use of the cell phone application to include information about asthma symptoms which had returned with guidance on self-management.
223605269|NCT05503342|OTHER|Asthma control assessment|Asthma control assessment questionnaire application in paper format
223605270|NCT00894868|DRUG|vildagliptin|
223605271|NCT00894868|DRUG|placebo of vildagliptin|
223605272|NCT04200690|OTHER|Interdisciplinary management|"The intervention in this trial consists of the combined efforts of the interdisciplinary team in the combined clinic arm.~The interdisciplinary team consists of dermatologists, gastroenterologists, rheumatologists, nurses, psychologists, dieticians, social workers, physiotherapists, and secretaries. Treatment will be individualized based on clinical, biomarker, phenotypic, and psychosocial characteristics. The medical treatment will follow local, national and international guidelines."
223752597|NCT05673486|COMBINATION_PRODUCT|PENG Block|"With the patient in the supine position, the ultrasound probe is placed on a transverse plane over the anterior superior iliac spine (ASIS). Once the ASIS is identified, the transducer is aligned with the pubic ramus and rotated at approximately 45 degrees, parallel to the inguinal crease. The transducer is then slid medially along this axis until the anterior inferior iliac spine (AIIS), iliopubic eminence (IPE), and the psoas tendon is clearly identified, serving as anatomic landmarks.~Sliding the probe distally or gently tilting the caudal will expose the head of the femur. Returning to the initial starting position, a needle is inserted in-plane, from lateral to medial, in the plane between the psoas tendon and the pubic ramus. 100 mg of ropivacaine is then deposited in this plane, lifting the psoas tendon."
223752598|NCT05673486|COMBINATION_PRODUCT|Multimodal analgesia|Multimodal analgesia is administered to patients as follows : 2-3 mg of morphine (2mg if patient's weight \<60kg; 3mg if patient's weight \>60kg) + Paracetamol 1g/8h and Nefopam 20mg/8h. Frequency of morphine administration depends on the assessed pain.
223752599|NCT04302389|BEHAVIORAL|myWW App, Virtual Workshops, and Private Facebook Group|The 6-month intervention includes the use of WW's mobile app, weekly virtual workshops, and a private online community. Participants are given a personalized food plan based on expert healthy eating guidelines and the latest nutritional science, an activity plan designed to promote regular physical activity and techniques to help shift members towards a helpful mindset for lasting change all within the WW app. Participants will attend weekly virtual workshops led by an expert WW Coach. The coach will help with goal setting, overcoming setbacks, and follow-up on progress toward goals each week. Participants will be encouraged to participate in a private Facebook group that gives participants an opportunity to receive motivational support from each other. Participants can post about their journey through photos, videos, and comments.
223752600|NCT05987423|DRUG|Satralizumab|Satralizumab will be administered by SC injection.
223752601|NCT05987423|DRUG|Placebo|Placebo will be administered by SC injection
223605273|NCT04200690|OTHER|Usual-care management|Usual care will be carried out by HCPs that are not otherwise involved in the trial. In usual care the patients will not be offered an interdisciplinary patient-centered care as described, but only attend their usual disease-specific departments at the usual appointments.Treatment will be prescribed as felt appropriate according to local, national and international guidelines by the treating physicians with no set protocol and no restrictions.
223605274|NCT01685697|PROCEDURE|Mask ventilation with a Laerdal face mask|Mask leak will be measured using a respiratory function monitor. Mask ventilation will be analyzed over a period of 5 minutes. The mean mask leak will be compared to the intervention group.
223605275|NCT01685697|PROCEDURE|Mask ventilation with a F&P face mask|Mask leak will be measured using a respiratory function monitor. Mask ventilation will be analyzed over a period of 5 minutes. The mean mask leak will be compared to the control group.
223752602|NCT03250026|BEHAVIORAL|Workplace convergence dialogue|Work place contact as a convergence dialogue between the employer and employee with the Rehab Coordinator as a guide
223752603|NCT03250026|BEHAVIORAL|Care Manager|Regular contact Care Manager during around 12 weeks
223752604|NCT02855437|DEVICE|IVR (Phone call)|IVR will auto dial participants at a schedule time. Participants complete questions using their phone keypad. Participants can also call the IVR to complete surveys if they experience a flare. The IVR will be programmed to call the patient weekly for 26 weeks to complete a weekly Gout Flare Survey and Patient Reported Outcomes Survey. Consistent with the published gout flare self-report definition, gout flare ascertainment questions will include whether the recent flare is similar to past flares, the number of swollen joints and the number of warm joints. Pain at rest during the attack will be assessed on a 0-9 scale. Further questions will include peak pain, timing of attack and duration of attack if completed. We will capture patient reported outcome measures (e.g. pain, fatigue, sleep) using instruments from NIH PROMIS. Following completion of 26 week IVR period participants will crossover to RheumPro arm.
223752605|NCT02855437|DEVICE|RheumPro (Smartphone application)|"RheumPRO will be programmed to notify participants weekly for 26 weeks via a scheduled pop-up to complete Gout Flare and Patient Reported Outcomes Surveys. Participants self-navigate through the survey questions using their smartphone. If participants do not complete the Gout Flare or Patient Reported Outcomes surveys RheumPro will generate 2 more pop-ups at the same time over the proceeding 2 days (eg. Tuesday 4 PM, Wednesday 4 PM). Participants can also open the RheumPro application on their smartphone and complete surveys or if they experience a flare on a day they are not scheduled to complete a survey. Following completion of 26 week RheumPro period participants will crossover to IVR arm."
223752606|NCT05262556|DRUG|NP-101 (TQ Formula)|Oral, five 600mg tabs daily every three weeks for four cycles (21-day cycle), then maintenance for an additional 12 weeks for a total of six cycles.
223752607|NCT05262556|DRUG|Nivolumab (3mg/kg)|Intravenously on Day 1 every three weeks for four cycles (maximum dose 360mg once every 3 weeks), then 240mg maintenance every two weeks for six cycles for a total of six months of treatment.
223752608|NCT05262556|DRUG|Ipilimumab (1mg/kg)|Intravenously on day 1 of each (21-day) cycle for a total of four cycles only.
223752609|NCT00602147|OTHER|laboratory biomarker analysis|Blood or cheek cells wil be collected.
223752610|NCT01984775|DRUG|GSK2894512 cream|GSK2894512 is a white to off-white cream that will be applied topically in 3 different concentrations (0.5% \[5 milligram (mg)/gram (g)\], 1% \[10 mg/g\], and 2% \[20 mg/g\]).
223752611|NCT01984775|DRUG|Vehicle cream|Vehicle cream does not contain any active pharmaceutical ingredient.
223752612|NCT01984775|DRUG|Positive control|Positive control contains sodium lauryl sulfate solution 0.1% (1 mg/g).
223752613|NCT01984775|DRUG|Negative control|Negative control contains petrolatum.
223752614|NCT03264287|PROCEDURE|3 times per week therapeutic frequency|Participants will receive acupuncture, moving cupping and ear-tapping procedure 3 times per week over the 6 weeks period.
223752615|NCT03264287|PROCEDURE|1 time per week therapeutic frequency|Participants will receive acupuncture, moving cupping and ear-tapping procedure 1 time per week over the 6 weeks period.
223752616|NCT06493214|BEHAVIORAL|Physical activity|Participants will be asked to complete three eight-minute InPACT at Home exercise videos per day, five days a week, for 12 weeks.
223752617|NCT04613024|DRUG|Topamax|Experiment randomized group will be prescribed Topamax before and after surgery with follow up at regular interval
223752618|NCT04613024|DRUG|Gabapentin|Control group will be prescribed gabapentin after surgery with follow up at regular interval
224200434|NCT06509542|BEHAVIORAL|Objective assessment of upper limb use during activities in ecological situation|Twenty-five patients will be recorded performing three activities during their rehabilitation: getting dressed, preparing a meal, and eating a meal. The movements of their upper limbs will be tracked using wrist-worn accelerometers and video cameras.
224200435|NCT01418365|DRUG|Metronidazole + MMX Mesalazine/mesalamine placebo|Metronidazole 750 mg twice daily + MMX Mesalazine/mesalamine placebo once daily for 3 days orally, then Metronidazole 750 mg single dose + MMX Mesalazine/mesalamine placebo single dose on Day 4 orally
223605276|NCT01156103|BEHAVIORAL|America SCORES, Bay Area|After-school program promoting physical activity via soccer 3 days/week
223605277|NCT01435213|DRUG|Atipamezole|Administration of a single dose of 5-150 micrograms of atipamezole as an intravenous infusion
223605278|NCT01435213|DRUG|Atomoxetine|A single dose of 1.2 mg/kg of atomoxetine administered orally
223605279|NCT01435213|DRUG|Ketamine|A single dose of ketamine (approximately 60 mg) administered as an intravenous infusion
223605280|NCT01435213|OTHER|Cold pressor test|30-45 min cold pressor test of the foot
223605281|NCT01435213|DRUG|Insulin|Insulin administered as an intravenous infusion to induce hypoglycemia
223605282|NCT01435213|DRUG|Placebo|A single dose of placebo (capsules) administered orally
223605283|NCT04321434|OTHER|Hyperoxia|
223605284|NCT04321434|OTHER|Normoxia|
223605285|NCT04321434|DEVICE|laser Doppler|laser Doppler
223605286|NCT04459871|BIOLOGICAL|recombinant human Thrombin(CHO cell)|2 rhThrombin, dissolved in 5mL sterile saline and mixed, the final solution contains 1000IU/mL rhThrombin solution (clear and transparent liquid).
223605287|NCT04459871|BIOLOGICAL|placebo|placebo, dissolved in 5mL sterile saline and mixed, the final solution contains 1000IU/mL rhThrombin solution (clear and transparent liquid).
223605288|NCT05276258|DEVICE|cryoSPHERE Ablation|The cryoSPHERE probe will be introduced through a thoracoscopic port and placed inferior to each rib level and 2cm lateral and away from the sympathetic chain when clearly visible or 4cm lateral and away from the spine when the sympathetic chain is not visible. Levels to be ablated are intercostal spaces 3-9. Each intercostal nerve will undergo cryogenic ablation of -70 degrees Celsius for 120 seconds. The probe will be firmly pushed against the nerve for 120 seconds and will only be released from the nerve when the probe has thawed. Axons within the intercostal nerve that send pain signals will be destroyed distal to the cryoablation site. However, the tubules structures (epineurium, perineurium, and endoneurium) of the nerve will remain intact, allowing the axons to regenerate and nerve function to resume after one to three months.
223752619|NCT05289323|DRUG|Neostigmine Methylsulfate|0.5 mg ampule (1 ml) will be diluted in 4 ml dextrose 5% to make a solution of 100 μg/ml, 0.2 ml of this solution will be added to 2.5 ml of hyperbaric bupivacaine 0.5 % used for intrathecal injection.
223752620|NCT05289323|DRUG|Dextrose 5%/Nacl 0.9% Inj|one ml of normal saline 0.9 % will be mixed with 4 ml dextrose 5 % in the five-milliliter syringe. 0.2 ml of this mixture will be prepared at a one-milliliter identical syringe.
223752621|NCT02306512|PROCEDURE|H&E|Sample will be stained with H\&E according to standard procedures
223752622|NCT02306512|PROCEDURE|IHC MART-1|Samples will be stained with immunohistochemistry antibody: MART-1 according to standard procedures.
223752623|NCT02306512|PROCEDURE|IF MART-1|Samples will be stained with immunofluorescence antibody: MART-1 according to standard procedures.
223752624|NCT02306512|PROCEDURE|IF cocktail|The fluorescent primary antibodies may include HMB-45, SOX10, Ki-67 and MART-1. However other markers will be considered to make the most visually remarkable cocktail; these may include S-100, MiTF, lamin and nestin. Primary antibodies will be tagged with secondary antibodies labeled with fluorescent signals. A fluorescent organelle stain and/or 4',6-diamidine-2-phenylindol (DAPI) may also be used to enhance cellular architecture.
223752625|NCT06639126|DIETARY_SUPPLEMENT|Wild thyme extract|All patients will be randomized (1:1) to receive the active thyme extract (600 mg/capsule/day or 600 mg/capsule/day of microcrystalline cellulose) in the form of capsules, administered orally and daily for 2 months
223752626|NCT06639126|OTHER|Placebo|600 mg/day microcrystalline cellulose
223752627|NCT06038799|BEHAVIORAL|Caregiver Skills Training (CST)|The investigators are comparing the relative efficacy of CST between a CST group led by clinicians trained and supervised remotely versus a group led by clinicians trained an supervised face-to-face.
223752628|NCT06356883|DRUG|IA Carboplatin + IA Caelyx|Intraarterial infusion of carboplatin combined with liposomal doxorubicin
223752629|NCT06356883|DRUG|IA Carboplatin + IA Etoposide Phosphate|Intraarterial infusion of carboplatin combined with etoposide phosphate
223752630|NCT04214288|DRUG|AZD9833|Dosage formulation: AZD9833 tablets will be administered orally.
223752631|NCT04214288|DRUG|Fulvestrant|Dosage formulation: Fulvestrant will be administered via intramuscular (IM) injection.
223752632|NCT06164587|DRUG|K8|sustained released bio-erodible intravitreal implants
223752633|NCT04094701|OTHER|Control Group Regimen|Norco (hydrocodone-acetaminophen) 5mg-325mg, 30 total pills. This is the standard of care prescribing procedure for pain management after hip arthroscopy.
223752634|NCT04094701|OTHER|Opioid reduced regimen|Tylenol extra strength (1000 mg, three times daily for 10 days following surgery), Gabapentin (300 mg at night for 10 days following surgery) and Norco (hydrocodone-acetaminophen) 5mg-325mg, 5 total pills
223752635|NCT06051461|DIETARY_SUPPLEMENT|Oral lipid emulsions|The oral lipid emulsions will contain water, sucrose, emulsifier, flavouring, and the corresponding fat (50 g/m2 of body surface area): milk cream (SFAs) or refined olive oil (MUFAs) with or without a dose of omega-3 PUFA, which will consist of 920 mg of EPA and 760 mg of DHA (ω3-LCPUFAs).
223752636|NCT03754894|DEVICE|ready made plastic stent application|full / partial thickness apically repositioned flap with paracrestal lingual incision will be performed for implant placement followed by healing abutment placement covered by ready-made plastic stent.
223752637|NCT03754894|PROCEDURE|simple interrupted sutures|full / partial thickness apically repositioned flap with paracrestal lingual incision will be performed for implant placement followed by healing abutment placement and securing the flap with simple interrupted sutures
223752638|NCT05217849|BEHAVIORAL|Tai Chi|Tai Chi is an ancient Chinese form of exercise/martial art that involves a series of movements performed in a slow, focused manner and accompanied by deep breathing.
223752639|NCT05217849|BEHAVIORAL|Preventing Loss of Independence through Exercise (PLIE)|PLIE is a gentle, mindful movement exercise program that integrates elements of Eastern and Western exercise modalities to develop mindful body awareness and enhance social connection.
224200436|NCT01418365|DRUG|Metronidazole + MMX Mesalazine/mesalamine|Metronidazole 750 mg twice daily + MMX Mesalazine/mesalamine 4.8 g once daily for 3 days orally, then Metronidazole 750 mg single dose + MMX Mesalazine/mesalamine 4.8 g single dose on Day 4 orally
224200437|NCT00493701|BEHAVIORAL|High Fat Diet|Daily eating
224200438|NCT00493701|BEHAVIORAL|Low Fat Diet|Life style eating habits
223752640|NCT05217849|BEHAVIORAL|Health and Wellness Education|This on-line class will consist of hour-long lectures/talks about various topics related to healthy aging and wellness.
223752641|NCT04434768|BIOLOGICAL|UMSC01|There will be one dose of IV administration in patients with acute ischemic stroke, or one dose of IV administration followed by low or high doses of IA infusion for acute ischemic stroke with or without bridging therapy (i.e. Intravenous rt-PA thrombolysis or intraarterial thrombectomy) with 12 months of follow up after the first treatment.
223752642|NCT06790173|BEHAVIORAL|Strategy training for physical activity|STPA is a home-based rehabilitation that guides stroke participants to implement strategy training for addressing barriers to physical activity engagements. Participants learn and practice meta-cognitive strategies (to set a goal, to make a plan, to do the plan, to check the performance of the plan) throughout the intervention period.
223752643|NCT06790173|BEHAVIORAL|Physical activity|PA program consists of a warm-up for 5 minutes, an aerobic exercise program for 30-40 minutes, a multicomponent exercise program (resistance and balance training) for 10-20 minutes, and finally, a cooling down program for 5 minutes.
224200439|NCT00984646|DRUG|Prevascar|Intradermal Prevascar, 5ng/100μl/linear cm of wound site or margin administered once just prior to wounding and once 24 h later
224200440|NCT00984646|DRUG|Prevascar|Intradermal Prevascar, 50ng/100μl/linear cm of wound site or margin administered once just prior to wounding and once 24 h later
223605289|NCT05276258|DRUG|Bupivacaine|A long needle will be introduced through a thoracoscopic port, and in each intercostal space (1-11), 1ml of liposomal bupivacaine will be injected onto the intercostal nerves to induce intercostal nerve blockage.
223605290|NCT00117039|DRUG|Aranesp®|
223605291|NCT02848534|BIOLOGICAL|neutrophil to lymphocyte ratio|value of the neutrophil to lymphocyte ratio in the diagnosis of bacterial infections
223752644|NCT06790173|OTHER|Education|Stroke-related information and knowledge that includes stroke subtypes and their etiology, risk factors of primary and secondary stroke, healthy lifestyles, common sequala, and adaptive skills for impaired functions are provided.
223752645|NCT03932409|DRUG|Pembrolizumab|"prior to VCB: 200mg IV given one week (7 days) before radiation~after VCB: 200mg IV on day 1 of a 21 day cycle prior to chemotherapy"
223605292|NCT05642520|PROCEDURE|Oval section abutment of 2.9 mm|The choice of the diameter to be used as recommended by the manufacter, was determined by the mesiodistal width between the two adjacent natural teeth, in order to maintain at least 1.5mm between the implant and the adjacent tooth. When said the distance was between 5.9 and 6.3 mm, a 2.9 mm implant was placed. Implant designs are made of a titanium and zirconium alloy (Roxolid®) with a SLActive® surface (Institut Straumann AG, Basel, Switzerland).
223605293|NCT05642520|PROCEDURE|Circular section abutment of 3.3 mm|The choice of the diameter to be used as recommended by the manufacter, was determined by the mesiodistal width between the two adjacent natural teeth, in order to maintain at least 1.5mm between the implant and the adjacent tooth. When said the distance was between 6.4 and 7.1 mm, a 3.3 mm implant was placed. Implant designs are made of a titanium and zirconium alloy (Roxolid®) with a SLActive® surface (Institut Straumann AG, Basel, Switzerland).
223605294|NCT02795585|OTHER|QFR (observational)|QFR assessment by Medis Suite, Medis medical imaging B.V., The Netherlands
223605295|NCT04381169|DRUG|Lactated Ringer Solution|Comparison of aggressive versus moderate Lactated Ringer-based fluid resuscitation
223605296|NCT00669708|DEVICE|cooling compound (ph5 Eucerin)|application twice daily to the skin
223752646|NCT03932409|RADIATION|Vaginal cuff brachytherapy (VCB)|Treatment should commence within 12 weeks of the surgery/hysterectomy
223752647|NCT03932409|DRUG|Paclitaxel|after VCB, Paclitaxel IV on days 1,8 and 15 of a 21 day cycle for 3 cycles
223752648|NCT03932409|DRUG|Carboplatin|after VCB, Carboplatin IV on day 1 of a 21 day cycle for 3 cycles
223752649|NCT05749094|DIAGNOSTIC_TEST|Optic nerve sheath ultrasound|The patients are examined in a supine relaxed position. The probe is gently placed on the closed eyelid with a standard ultrasound gel and adjusted to a suitable angle to display the optic nerve entry into the eyeball. Measurements are done 3mm distal to the posterior aspect of the ocular globe. Ultrasosonographic 14L5 probe is used with a safe thermal index, mechanical index and intensity limit. All patients will also undergo a bedside fundoscopic examination. Official ophthalmology consultation will be requested in patients with visual symptoms or abnormal fundoscopy.
223752650|NCT05749094|DIAGNOSTIC_TEST|Standardized GCA assessment|Clinical assesment, blood test review, temporal/axillary artery ultrasound
223752651|NCT05801679|DRUG|Sugammadex|Fifteen minutes after ICU arrival, subjects will be administered sugammadex (2 mg/kg assuming a twitch count of 2-4 of 4 or 4mg/kg assuming a twitch count less than 2 of 4) by the anesthesia provider. Five minutes after administration, a quantitative neuromuscular monitor (TetraGraph, Senzime, Uppsala, Sweden) will be applied and the TOF ratio will be recorded.
223752652|NCT05801679|OTHER|Placebo|Fifteen minutes after ICU arrival, subjects will be administered placebo (2 mg/kg assuming a twitch count of 2-4 of 4 or 4mg/kg assuming a twitch count less than 2 of 4) by the anesthesia provider. Five minutes after administration, a quantitative neuromuscular monitor (TetraGraph, Senzime, Uppsala, Sweden) will be applied and the TOF ratio will be recorded.
223752653|NCT06364553|DEVICE|Esophageal self-expandable metal stent|The Leufen Esophageal aixstent ® (Leufen Medical GmbH) is indicated for the treatment of malignant esophageal strictures and postoperative stenosis. It is comprised of two components: an implantable metallic stent and the delivery system. After the procedure, the stent remains at the intended location, within the patient while the delivery system is removed.
223752654|NCT04415606|DEVICE|QuikClot Control+|Non-absorbable, sterile, X-ray detectable non-woven dressing impregnated with kaolin.
223752655|NCT05002127|DRUG|Evorpacept (ALX148)|IV Q2W
223752656|NCT05002127|DRUG|Trastuzumab|IV Q2W
223752657|NCT05002127|DRUG|Ramucirumab|IV Q2W
223752658|NCT05002127|DRUG|Paclitaxel|IV Days 1, 8, and 15 of a 28-day cycle
224200441|NCT00984646|DRUG|Prevascar|Intradermal Prevascar, 250ng/100μl/linear cm of wound site or margin administered once just prior to wounding and once 24 h later
224200442|NCT00984646|DRUG|Prevascar|Intradermal Prevascar, 1000ng/100μl/linear cm of wound site or margin administered once just prior to wounding and once 24 h later
223605297|NCT06530199|PROCEDURE|Enamel matrix derivative|connective tissue graft and Enamel matrix derivative in the defect area
223605298|NCT05974930|DEVICE|IVUS imaging for primary PCI guidance|Eagle Eye Platinum Intravascular ultrasound (IVUS) will be used to assess intra-coronary plaque, thrombus or stenosis in patients with STEMI. The device is FDA- and EMA-approved and routinely used in clinical practice. Quantitative and qualitative IVUS parameters will be collected and recorded for all participants to be correlated with clinical, imaging and angiographic outcomes of interest.
223605299|NCT00004030|DRUG|VX-853|
223605300|NCT00004030|DRUG|pegylated liposomal doxorubicin hydrochloride|
223605301|NCT00640965|DRUG|DP-VPA|DP-VPA dose escalation to 900mg, then continued for 8 weeks
223605302|NCT00640965|DRUG|DP-VPA Placebo|Matching Placebo to Active, dose escalation, then continued for 8 weeks
223605303|NCT00726232|DRUG|Ruxolitinib|Ruxolitinib was administered orally and supplied as 5 mg and 25 mg tablets.
224200443|NCT00984646|DRUG|Prevascar|Intradermal Prevascar, 25ng/100μl/linear cm of wound site or margin administered once just prior to wounding and once 24 h later
223605304|NCT05341115|DRUG|Leuprorelin Acetate Depot 3M|Leuprorelin Acetate Depot 3M SC injections.
223605305|NCT05501704|DRUG|Tamoxifen|Taken orally
223605306|NCT05501704|DRUG|Anastrozole|Taken orally
223605307|NCT05501704|DRUG|Degarelix|Subcutaneous (under the skin) injection
223605308|NCT05501704|DRUG|Abemaciclib|Taken orally
223605309|NCT06104904|BEHAVIORAL|MAPP|Behavioral intervention based on exposure therapy strategies.
223605310|NCT05637593|BEHAVIORAL|Upper-limb movement training with the aid of RAS|"Three target bowls, labeled as the left, middle, and right target bowl, will be placed on the table at an equal distance from the main bowl. The distance between a target bowl and the main bowl is set at 30 cm. Wooden beads with a diameter of 2 cm will be put in target bowls. The main bowl will be placed in front of the patient.~Patients will be asked to listen to the RAS sound, use the right hand to take one bead at a time from the left target bowl to the main bowl, repeat this movement for the middle and right target bowls, and keep repeating this order. They should keep their movements consistent with the sound of the RAS, with one RAS sound corresponding to one pick-up movement.~Each daily training will consist of three rounds separated by two 5-minute breaks. Each round will consist of four consecutive sessions (for each session: 2-minute training followed by a 30-second break). The training will last for a total of 21 days."
223605311|NCT05637593|BEHAVIORAL|Upper-limb movement training without the aid of RAS|"Three target bowls, labeled as the left, middle, and right target bowl, will be placed on the table at an equal distance from the main bowl. The distance between a target bowl and the main bowl is set at 30 cm. Wooden beads with a diameter of 2 cm will be put in target bowls. The main bowl will be placed in front of the patient.~Patients will be asked to use the right hand to take one bead at a time from the left target bowl to the main bowl, repeat this movement for the middle and right target bowls, and keep repeating this order. They are asked to execute the task as fast as possible.~Each daily training will consist of three rounds separated by two 5-minute breaks. Each round will consist of four consecutive sessions (for each session: 2-minute training followed by a 30-second break). The training will last for a total of 21 days."
223605312|NCT02898896|BIOLOGICAL|blood test|Additional 21 ml of blood will be collected
223605313|NCT04364360|DIETARY_SUPPLEMENT|Sulforaphane extract|2x BroccoMax® capsules day, giving a total daily dose of 30 mg of Sulforaphane Glucosinolate Per day
223752659|NCT05379478|DIAGNOSTIC_TEST|Laboratory assessment of antibody profiles|Antibody profiles will be determined on submitted plasma samples
223752660|NCT03581240|DRUG|eflornithine HCl|"In this study subjects without CNS disease will receive oral difluoromethylornithine (DFMO) at a dose of 500 to 1000 mg/m2 BID~Subjects with CNS disease will receive a dose of 2500 mg/m2/dose BID in order to facilitate crossing into the CNS."
223752661|NCT05989607|OTHER|Lower sugar flavored water|A commercially available low sugar flavored water (2.88kcal/100ml; 0.57(sugar) +0.03 (stevia)=0.60g/100ml; sodium 7.9mg/100ml).
223752662|NCT05989607|OTHER|Plain Water|Commercially available bottled, spring water.
223752663|NCT06104124|DRUG|Dazodalibep|IV infusion
223605314|NCT00133601|BEHAVIORAL|Cognitive Behavioral Therapy|CBT-I including sleep restriction, stimulus control, sleep hygiene instructions and one session of cognitive therapy devoted to catastrophic thoughts about the consequences of insomnia.
223605315|NCT05094648|OTHER|high flow nasal therapy|effect of high flow nasal therapy in covid 19 patients who pass and who need non invasive
223605316|NCT04064060|DRUG|Luspatercept|Luspatercept (ACE-536), an erythroid maturation agent, is a recombinant fusion protein consisting of a modified form of the extracellular domain (ECD) of the human activin receptor type IIB (ActRIIB) linked to the human immunoglobin G 1 (IgG1) Fc domain. ActRIIB receptor and its ligands are members of the transforming growth factor-β (TGF-β) superfamily. Members of the TGF-β superfamily ligands, through their binding to activin receptors, are involved in modulating the differentiation of late-stage erythrocyte precursors (normoblasts) in the bone marrow. Luspatercept for injection is formulated as a sterile, preservative-free, lyophilized cake/powder. Luspatercept for injection is available in 25 mg and 75 mg vials and when reconstituted with water for injection, each consists of 50 mg/mL luspatercept in a 10 mM citrate buffer-based solution
223605317|NCT00195091|DRUG|Tetrathiomolybdate|"Induction with Tetrathiomolybdate (TM) Tetrathiomolybdate 40 mg. p.o. TID with meals and tetrathiomolybdate 60 mg at bedtime for a total of 4 doses (180 mg) per day.~Induction goal Total tetrathiomolybdate dose per day = 180 mg until serum ceruloplasmin (Cp) level decreases to 5-15mg/dL.~When target Cp window is reached, then the maintenance phase begins.~Maintenance with Tetrathiomolybdate Total tetrathiomolybdate dose per day = 100 mg~Tetrathiomolybdate 40 mg p.o. BID with meals and tetrathiomolybdate 20 mg at bedtime."
223605318|NCT05396911|BEHAVIORAL|UP2UTobacco|The universal prevention program was designed as a group intervention to include components of effective tobacco control programs for youth and young adults. The intervention lasts approximately 45 minutes and is delivered in a classroom setting, utilizing a Socratic teaching style and evoking participation using the principles of motivational interviewing. UP2UTobacco targets all tobacco products with the goals to enhance motivation for youth to quit tobacco or remain tobacco-free, reduce intentions to use tobacco, promote peer discussions around the impact of using tobacco, and correct cognitive misperceptions around tobacco use.
223605319|NCT01201720|PROCEDURE|Plasma exchange with albumin|Realization of 6 plasma exchange with albumin in 11 days
223605320|NCT03083301|OTHER|Medical Files data extraction|Medical Files data extraction
223605321|NCT06090565|DRUG|Cefixime|Two 400 mg tablets will be administered orally to equal a 800 mg dose.
223752664|NCT06104124|DRUG|Placebo|IV infusion
223752665|NCT05421897|DRUG|Dinutuximab with Chemotherapy|Rapid infusion of dinutuximab in 4 hours or less
223752666|NCT01794806|PROCEDURE|Tooth extraction and grafting with allograft|Alveolar ridge preservation using a bone grafting material (allograft) and a synthetic dPTFE (dense Polytetrafluoroethylene) barrier membrane
223752667|NCT01794806|PROCEDURE|Tooth extraction|Minimally traumatic single-rooted tooth extraction
223752668|NCT04896658|DRUG|Belantamab Mafodotin, Cyclophosphamide and Dexamethasone|Study drug
223752669|NCT05087056|COMBINATION_PRODUCT|MenABCWY vaccine|Two doses of the MenABCWY vaccine, administered intramuscularly in the deltoid region of the non-dominant arm, on a 0-, 24-month schedule in the ABCWY-24 Group, and a 0-, 48-month schedule in the ABCWY-48 Group.
223752670|NCT05087056|COMBINATION_PRODUCT|Placebo|Single dose of Placebo (saline solution in pre-filled syringe), administered intramuscularly in the deltoid region of the non-dominant arm, at Day 1441 in the ABCWY-24 Group, and at Day 721 in the ABCWY-48 Group.
223752671|NCT06433596|OTHER|Platelet-rich plasma|3 injections of 10 cc of autologous Platelet Rich Plasma (PRP), weeks 1, 5 and 9
223752672|NCT06433596|OTHER|Shock waves therapy|6 sessions of focal shock waves, 1 per week
223752673|NCT06433596|OTHER|Placebo PRP|3 injections of 10 cc of saline solution, weeks 1, 5 and 9
223752674|NCT06433596|OTHER|Sham shock waves therapy|6 sessions of sham shock waves, 1 per week
223752675|NCT05553054|OTHER|Quantification of IV drugs wastage|"Drugs are prescribed depending on physician discretion.~Specific collection bins are provided to ICU. Healthcare teams discard syringes labelled with name and dilution which have been used to prepare drugs into these bins. After 24 hours of collection, bins are analyzed by investigators."
223752676|NCT00826800|DRUG|FOLFOX and bevacizumab|The patient will receive six treatments, two weeks apart. On each treatment day you will get Oxaliplatin, 5-FU,Leucovorin. On the first four treatments you will also get Bevacizumab (Avastin). These drugs are given through a Mediport. They will be given in an outpatient chemotherapy unit. Each tx will take about 4 hours. A pump for the 5-FU is worn around your waist. This drug is given over 2 days. Part II: Colon Cancer Surgery is standard practice, and is not a research procedure.Part III: Post-operative Re-Evaluation and Recovery The doctor will decide on the type of chemotherapy based on how the patient responded to the first chemotherapy. The plan will be for the patient to get 6 more doses of FOLFOX, without any further bevacizumab, unless your doctor finds a reason to do otherwise.
223752677|NCT05914779|OTHER|No use of antibiotics|Subjects will be randomized into antibiotics and no antibiotics groups based on inclusion and exclusion criteria
223752678|NCT05914779|OTHER|with antibiotics treatment|with antibiotics treatment
223605322|NCT06090565|DRUG|Doxycyclin|One 100 mg tablet will be administered orally twice a day for 7 days
223605323|NCT06090565|DRUG|Ceftriaxon|Dose of 1 g intramuscular one time
223605324|NCT06090565|DRUG|Azithromycin|Four 500 mg tablets will be administered orally to equal a 2 g dose.
223605325|NCT02726412|PROCEDURE|Acute vs elective|non-intverention study
223605326|NCT02466763|PROCEDURE|Cochlear implant surgery|Surgical placement of a cochlear implant device.
223605327|NCT00856765|DEVICE|Drug eluting balloon|Percutaneous transluminal coronary balloon angioplasty catheter eluting paclitaxel
223605328|NCT00856765|DEVICE|Bare metal stent|Bare metal stent
223605329|NCT00856765|DEVICE|Drug eluting stent|Paclitaxel eluting stent
223605330|NCT02212041|OTHER|disposable electronic cigarettes|"Participants will receive e-cigs free of charge during 6-week. Each week for 6 weeks, participants will receive enough e-cigs to cover 150% of their usual weekly cigarette smoking rate. We will encourage participants to use the e-cigs whenever they would usually smoke a cigarette.~During a 4-week post-distribution period, we will assess e-cig and cigarette use and other measures when e-cigs are not being freely provided and participants must purchase them on their own. The Week 10 session at the end of this period includes assessment of total nicotine intake, nicotine dependence, subjective and reinforcing effects of e-cigs and cigarettes, attitudes toward e-cigs, motivation to quit and self-efficacy for smoking cessation. At the Week 24 follow-up session we will again collect these measures to determine if any changes observed during the intervention phases have been maintained."
223605331|NCT03667157|DRUG|every week IVMP therapy|12 pulses of intravenous methylprednisolone (IVMP) in every week schedule (for the first 6 weeks 0.5g IVMP per week, for the next 6 weeks 0.25g IVMP per week; cumulative dose 4.5g) according to EUGOGO recommendations
223605332|NCT03667157|DRUG|very high doses IVMP therapy|3 pulses of intravenous methylprednisolone (IVMP) (1.0g/day for 3 consecutive days; cumulative dose 3.0g) according to EUGOGO recommendations
223752679|NCT00976742|BEHAVIORAL|Endurance exercise training|
223752680|NCT03774953|DIETARY_SUPPLEMENT|Protein and vitamin supplementation|The intervention group will receive 1.5 g protein/kilo/day during hospitalization and a standard dose of 27 g protein/day in 60 days after discharged together with a daily dose of vitamin/mineral supplement
223752681|NCT02706509|DRUG|Tramadol|patient will receive oral Tramadol 50 mg an hour before IUD insertion
223752682|NCT02706509|BEHAVIORAL|Verbal anesthesia|patient will receive full explanation about the procedure for five minutes before IUD insertion
223752683|NCT02706509|DEVICE|Jaydess|Patient will go through an insertion of Jaydess intrauterine device.
223752684|NCT06223074|OTHER|IV Methylprednisolone administration|Group 1 will receive 1g methylprednisolone IV for 3 or 5 days, according to the severity of the relapse
223605333|NCT02931552|BEHAVIORAL|Nuevo Amancer-II Stress Management Program|Participant meets weekly with a trained interventionist called a Compañera (a peer who has had breast cancer) to complete a structured 10-week program designed to develop cognitive and behavioral skills to manage stress and distress, improve communication with family and clinicians, and increase knowledge of self-management after breast cancer.
223752685|NCT06223074|DRUG|Nasal Methylprednisolone (MT)|Group 2 will receive the dose intranasal equivalent to 1g of methylprednisolone for 3 or 5 days according to the severity of the relapse
223605334|NCT03084692|BEHAVIORAL|Therapeutic Yoga and Resistance Exercise|Combined Program of Yoga and Resistance Exercise
223605335|NCT03766659|DIAGNOSTIC_TEST|MOSE|EUS-FNB with MOSE
223605336|NCT03766659|DIAGNOSTIC_TEST|ROSE|EUS-FNA with ROSE
223605337|NCT06330168|DRUG|bupivacaine-calcitonin-fentanyl|pre-induction single shot thoracic paravertebral block using 20 mL 0.25% bupivacaine, 100 micrograms of fentanyl (2ml), and 100 IU of calcitonin (1ml).
223605338|NCT06330168|DRUG|Bupivacaine-fentanyl|pre-induction single shot thoracic paravertebral block using 20 mL 0.25% bupivacaine, 100 micrograms of fentanyl (2ml), and 1 ml saline 0.9%.
223752686|NCT03806166|OTHER|Shorter Systemic Antibiotics|Reduced duration of post-operative systemic antibiotic therapy
223752687|NCT03806166|OTHER|Standard treatment|Standard duration of systemic antibiotic treatment
223752688|NCT02269280|DRUG|Azacitidine (AZA) Days 1 - 3|Azacitidine 75 mg/m2 by vein or subcutaneously daily for 3 days (days 1-3) approximately every 28 days.
223752689|NCT02269280|DRUG|Decitabine (DAC)|Decitabine 20 mg/m2 by vein for 3 days (days 1-3) approximately every 28 days.
223752690|NCT02269280|OTHER|Best Supportive Care (BSC)|Participants receive standard of care as chosen by study doctor. Best supportive care for transfusion-independent participants only.
223605339|NCT05788094|DRUG|Dihydroartemisinin-piperaquine plus tafenoquine (450 mg adult dose)|"* Dihydroartemisinin-Piperaquine will be purchased as Duo-Cotecxin® Beijing Holley-Cotec Pharmaceuticals Co., Ltd, China). One tablet contains 40 mg of dihydroartemisinin and 320 mg piperaquine (i.e. a 1:8 ratio). A weight-based regimen containing a total dose of approximately 7 mg/kg DHA and 55 mg/kg piperaquine given in 3 divided doses once daily.~* Tafenoquine KODATEF® 150 mg film-coated tablets will be purchased from Biocelect (Suite 5.02, Level 5, 139 Macquarie Street, Sydney NSW, 2000 Australia), 450 mg (4 1/2 tablets) will be given."
223605340|NCT05788094|DRUG|Chloroquine plus Tafenoquine (450 mg adult dose)|"* Chloroquine will be dosed as a 25 mg/kg base given in divided doses of 10 mg/kg orally on days 0 and 1, and in 5 mg/kg dose on day 2. Tablets will be obtained from Government Pharmaceutical Organization (GPO) in Bangkok, Thailand and supplied as 250 mg tablets (155.3 mg base).~* Tafenoquine KODATEF® 150 mg film-coated tablets will be purchased from Biocelect (Suite 5.02, Level 5, 139 Macquarie Street, Sydney NSW, 2000 Australia), 450 mg (4 1/2 tablets) will be given."
223605341|NCT05788094|DRUG|Artemether-Lumefantrine plus Tafenoquine (450 mg adult dose)|"* Artemether-Lumefantrine will be given at a standard dose of 20/120 mg twice daily for three days. (AL will be purchase from Novartis Pharma Services AG- Lichtstrasse 35, CH-4056 Basel, Switzerland.)~* Tafenoquine KODATEF® 100 mg film-coated tablets will be purchased from Biocelect (Suite 5.02, Level 5, 139 Macquarie Street, Sydney NSW, 2000 Australia), 450 mg (4 1/2 tablets) will be given."
223605342|NCT04658043|OTHER|Intervention on socioemotional functioning|"A culturally sensitive intervention based on the train the trainer (or coach the coach) model for enhancing the social adaptive functioning of young children (aged 3-6) with ASD in China, via providing training for parents"
223605343|NCT00003512|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|"Patients With Recurrent or Refractory Waldenstrom's Macroglobulinemia will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
223752691|NCT02269280|DRUG|Azacitidine (AZA) Days 1 - 5|Azacitidine 75 mg/m2 by vein or subcutaneously daily for 5 days (days 1-5) approximately every 28 days.
223752692|NCT05820893|DRUG|Resistant Potato Starch|MSPrebiotic (MSPrebiotic Inc, Carberry, Manitoba, Canada). MSPrebiotic is an unmodified resistant starch derived from potatoes (Solanar tuberosum). It consists of 20% amylose and 80% amylopectin forming granules the stomach and small intestine are unable to digest allowing for absorption in the colon. MSPrebiotic is consumed by mixing 10g into cold or room temperature foods or beverages; it is not to be heated. Participants will be instructed to take MSPrebiotic 2 or more hours before or after consuming any medications.
223752693|NCT05303753|OTHER|fermented dairy protein with prebiotic fiber|During the intervention period, the participant will consume a new product and will reduce the amount of protein in their normal diet reflecting the protein content of the new product.
223752694|NCT05642416|DRUG|Continuous Infusion of ropivacaine|Continuous infusion of ropivacaine
223752695|NCT05642416|DRUG|Intermittent bolus of ropivacaine|Intermittent bolus of ropivacaine
223752696|NCT06322836|PROCEDURE|Duble current electro cardioversion|Instead of the regular clinical treatment, in this study direct-current electrical cardioversion (DC-ECV) will be performed at the patient's home and will be carried out by well-trained and certified advanced practice providers (APP) on site, i.e. nurse practitioner or physician assistant, supported by an EMS ambulance team containing an ambulance nurse and ambulance driver, both trained advanced life-support (ALS) professionals.
223752697|NCT06244615|DEVICE|Verum (WO 6607)|Mouth and throat rinse and gargle solution
223752698|NCT06244615|DEVICE|Placebo (WO 6608)|Mouth and throat rinse and gargle solution
223752699|NCT01650207|PROCEDURE|acupuncture|"All participants were received regular rehabilitation program, and received different interventions.~treatment frequency: 20 minutes per session, once daily, 5 times a week for 2 weeks"
223752700|NCT01650207|PROCEDURE|TENS|
223752701|NCT01650207|PROCEDURE|sham acupuncture|
223752702|NCT03890549|DIAGNOSTIC_TEST|SnoreLab (smart phone application for snoring recording)|The investigators selected 3 appropriate downloadable smart phone applications for snoring recording and make validation with the golden standard of polysomnography.
223752703|NCT04922320|BEHAVIORAL|Patient Priorities Care|A facilitator will schedule a PPC facilitation encounter 2-3 weeks before an upcoming PCP visit. The facilitator conducts a structured assessment using a written conversation guide that begins with general questions establishing what is most important to Veterans about their health and moves toward establishing specific goals (actionable outcomes), and what patients are willing/not willing to do to achieve these goals (care preferences). The result is a structured patient priorities report delivered to PCPs designed to facilitate changes in the patient's care plan to align it with his/her priorities. In the subsequent visit, the PCP will use one or more of the established PPC decisional strategies to align care with patients' priorities. Education for PCPs about the facilitation process, the patient priorities report, and the decisional strategies occurs prior to the PCP seeing any intervention patients. The PCP will document changes in care made to achieve the identified priorities.
223605344|NCT03604796|DRUG|Rectal Solution|Rectal acetaminophen at 15 mg/kg x 4/day for three days
223605345|NCT03604796|DRUG|Intravenous Infusion|Loading dose of 15 mg/kg IV acetaminophen followed by a continuous infusion at a rate of 2.5 mg/kg/hr for 72 hours
223605346|NCT00684775|COMBINATION_PRODUCT|Work Plus Naltrexone Contingency|"Vivitrol, an extended-release depot formulation of naltrexone, was used. Participants were offered an inpatient opioid detoxification and oral naltrexone induction. Participants who complete the oral naltrexone induction (N=40) were randomly assigned to one of two groups. Both groups will be invited to work in the Therapeutic Workplace and will be prescribed depot naltrexone for 6 months. Participants in the Work Plus Naltrexone Contingency condition earned access to working and earning salary by taking depot naltrexone injections once per month."
223752704|NCT04922320|OTHER|Usual Care|PCPs will not be alerted when an encounter involves a UC group participant. UC participant visits will appear the same as all other unenrolled patient encounters. PCPs will be trained to address the needs of UC participants based on their typical approach without the use of a facilitator or explicit process for identifying patient priorities. UC participants will not receive any additional preparation
223752705|NCT01990495|OTHER|Exercise training|Subjects will participate in a center-based and home exercise training program for 3 months.
223752706|NCT01990495|OTHER|Usual Care|This group will serve as control subjects. They will receive only usual clinical care.
223752707|NCT01747109|DEVICE|PREOXYFLOW|"Patients randomized in PREOXYFLOW group will received a four minutes preoxygenation period with Nasal High Flow Therapy (HFT) Optiflow ® (60 l/mn FIO2 = 1) before orotracheal intubation under laryngoscopy after crash induction"
224075385|NCT05979571|OTHER|Mobile health app|Breastfeeding knowledge and promotion information will be delivered through the AmiBreastfeed app platform
224075386|NCT00211146|DRUG|epoetin alfa|
223752708|NCT01747109|PROCEDURE|STANDARD FACE MASK|"Patients randomized in STANDARD FACE MASK group will received a four minutes preoxygenation period with a standard face mask (15 l/mn) before orotracheal intubation under laryngoscopy after crash induction. Each hospital involved in this study will use the standard face mask as per its usual practice (no specific trademark requested by this protocol)"
223605347|NCT05906433|DRUG|Kenalog with bupivacaine Injection|Indications, relevant for this study include Kenalog injection for knee pain from osteoarthritis or inflammatory arthritis. A single injection to a patient who has no known allergies to anesthetic or corticosteroids would be administered during a scheduled clinical visit.
223605348|NCT05723471|OTHER|Adaptative Physical Activity|12 weeks of a collaborative program of customized, adaptative and supervised physical activity by sports instructor
223605349|NCT05463406|OTHER|The PLUS algorithm|Combination of a clinical prediction score and LUS, and if needed PCT measurement
223605350|NCT05463406|OTHER|Usual care|Management as usual
223605351|NCT06516159|DIAGNOSTIC_TEST|MBI-C Scale in French|"The original version has 34 items, divided into 5 areas:~* a reduction in motivation, interests and initiative~* the appearance of mood disorders~* dysregulation of impulse management~* loss of conventions and societal norms~* the abnormal development of strongly held beliefs and sensory experiences~The items are rated based on the occurrence of the severity of the disorders in the previous six months on a scale of 0 to 3.~This scale is completed by a member of the healthcare team on the basis of information collected from the relative (informant) either in person but also by telephone The score varies between 0 and 102. The higher the score, the more psychological and behavioral symptoms are present.~The test lasts 10 minutes."
223605352|NCT04526145|BEHAVIORAL|Stress and emotion management|Group intervention led by a nurse and dietitian to address stress, emotion management and healthy lifestyle for African American women with hypertension. The weekly sessions will include:how to manage stress during Covid-19, taking blood pressure, interpersonal relationships skills, mindful awareness, restful sleep, physical activity, and healthy eating.
223605353|NCT05982496|DRUG|FES|16-alpha-18F-fluoro-17-beta-estradiol(FES) is a radiolabeled form of estrogen binding to functionally active ER which will be used as radiotracer for the PET/MRI exam
223605354|NCT05982496|PROCEDURE|PET/MRI A|An additional FES PET/MRI will be performed before surgery.
223605355|NCT05982496|PROCEDURE|PET/MRI B|Two additional PET/MRI will be performed before and after induction ET.
223605356|NCT05982496|PROCEDURE|PET/MRI C|Two additional PET/MRI will be performed before and after two cycles of neoadjuvant chemotherapy.
223605357|NCT05982496|PROCEDURE|PET/MRI D|Two additional PET/MRI will be performed before and after two cycles of systemic therapy.
223605358|NCT05982496|GENETIC|Translational analysis|Selected cases of heterogeneous tumors on imaging will be also investigated on pathology, imaging, genomic and radiomic levels.
223605359|NCT05802862|DRUG|Insulin Degludec and Insulin Aspart|administered subcutaneously, once a day
223605360|NCT02197663|PROCEDURE|acupuncture(44mm in length and 32-gauge)|"The whole course of the acupuncture contains 24times(about 3 months). The acupoints are fixed and located over head and limbs.~The whole course of the sham acupuncture contains 24times(about 3 months). The acupoints are fixed and 1cm away from meridian and no acupoints over head were chosen."
223605361|NCT00983320|DRUG|quetiapine|flexible dosage (50 to 300 mg)
223605362|NCT00983320|DRUG|placebo|placebo
223605363|NCT04471506|OTHER|interval training|Ixercise program in form of a cycling protocol which will be comprised 5 minutes of warming up before exercise initiation and another 5 minutes for cooling down by the end of the exercise session in the form of slow pedaling (50% of PHR). The work interval also will be consisted of 8-12 cycling intervals (60s cycling work interval with 120s of passive rest or low-intensity cycling (70% of PHR) between work intervals that progressively will be reduced until reaching 90s by the end of the exercise program).
223605364|NCT04471506|OTHER|diet recommendations|the control group will follow diet recommendations for 12 weeks
223605365|NCT04471506|OTHER|mindfulness breathing|Mindful breathing is a exercise that involves using breathing as an object of attention. 15-minute mindful breathing intervention will be adapted. It consists of the following three steps: (a) adopt a physical posture, (b) establish a mindfulness anchor, and (c) maintain mindfulness
223605366|NCT00632619|BEHAVIORAL|Group-based behavior therapy|Group-based behavior therapy with a parenting class will include 12 weeks of sessions that focus on reducing oppositional and aggressive behaviors. Children will participate in 12 weeks of social skills training integrated with a cognitive behavioral therapy (CBT) component to target mood symptoms. Parents will learn ways to identify and address their child's mood problems, communicate better with their child, and work with school staff to address academic and behavioral problems.
223605367|NCT00632619|DRUG|Stimulant medication therapy|All participants will be stabilized on an FDA-approved stimulant medication for 2 to 6 weeks prior to therapy assignment.
223605368|NCT00632619|BEHAVIORAL|Community-based psychosocial treatment|Participants will receive referrals to community-based psychosocial treatments that will focus on ADHD symptoms and management of aggression.
223605369|NCT05541575|OTHER|VR films|A new virtual reality course for home care workers to experience the view of dementia people with BPSD and the relative feelings.
223752709|NCT02121483|DRUG|empagliflozin medium dose|
223752710|NCT02121483|DRUG|empagliflozin high dose|
223752711|NCT02121483|DRUG|empagliflozin low dose|
223752712|NCT02912026|DRUG|IV F901318|Metabolic profile AUC 0 to infinity
223752713|NCT02912026|DRUG|Oral F901318|Metabolic profile AUC 0 to infinity
223752714|NCT00385528|BEHAVIORAL|Multi-faceted psychiatric intervention|
223752715|NCT05292560|OTHER|Training in positivity|The University of Twente developed an evidence-based positive psychology app that is aimed at increasing mental well-being and resilience (Training in positivity; TiP). TiP consists of a 3-week structured intervention, in which participants do two exercises every week for 6 days, aimed at increasing resilience and mental well-being. An exercise takes an average of 15 minutes per day.
224075387|NCT02163473|PROCEDURE|Septic patients|The investigators will draw two sets of blood samples. One at baseline, 10 mL, and another, 24 hours later, 10 mL, for a total of 20 mL.
224075388|NCT02163473|PROCEDURE|Healthy Control|The investigators will draw 10 mL, once, during baseline for a total of 10 mL among the healthy control group.
223605370|NCT00566852|DRUG|Memantine|Patients began taking memantine(by mouth) while receiving radiation therapy. Patients continued taking memantine for 24 weeks or until doctor thinks it is in their best interest to stop. They started with 5 mg once a day. After a week dose increased to 5 mg twice a day. At week 3, dose increased to 10 mg in the morning and 5 mg in the evening. Weeks 4-24, dose was 10 mg twice a day.
223605371|NCT00566852|OTHER|Placebo|Patients began taking placebo(by mouth) while receiving radiation therapy. Patients continued taking placebo for 24 weeks or until doctor thinks it is in their best interest to stop. They started with 5 mg once a day. After a week dose increased to 5 mg twice a day. At week 3, dose increased to 10 mg in the morning and 5 mg in the evening. Weeks 4-24, dose was 10 mg twice a day.
223605372|NCT00566852|RADIATION|Whole brain radiation therapy|Whole brain radiation therapy (WBRT) once a day (2.5Gy), five days a week (Monday to Friday) for three weeks, for total fifteen treatments and 37.5 Gy
223605373|NCT01378442|OTHER|fitness training program|"Experimental: high level training group. The experimental group received training for 40 min per day 3 times a week for 12 weeks. The hVCT program consisted of a 5-min warm-up exercise, twenty repetitions of sitting-to-standing movements, cycling for 20 min, and a cool-down exercise for 5 min.~Experimental: low level training group. The experimental group received training for 40 min per day 1-2 times a week for 12 weeks. The program consisted of a 5-min warm-up exercise, twenty repetitions of sitting-to-standing movements, fitness training for 20 min, and a cool-down exercise for 5 min.~Control:The control group will not receive fitness training program but maintain the usual life style."
223605374|NCT04079816|DEVICE|INVSENSOR00025|Noninvasive pulse oximeter sensor
223605375|NCT00785473|DIETARY_SUPPLEMENT|cholecalciferol|cholecalciferol capsules, 20,000 IU weekly for 2 years and calcium carbonate 500 mg daily
223605376|NCT00785473|DIETARY_SUPPLEMENT|calcium carbonate|calcium carbonate 500 mg daily for 2 years
223605377|NCT01434849|DRUG|topical 0.5% Timolol maleate|topical 0.5% Timolol aqueous solution, 1-2 drops to cover the hemangioma, twice daily
223605378|NCT01434849|DRUG|Control (placebo) group|Aqueous placebo, 1-2 drops to cover the hemangioma, twice daily
223605379|NCT00638495|DRUG|Nalfurafine Hydrochloride (TRK-820)|TRK-820 2.5, 5 and 10 microg is to be administered orally once daily, after supper in principle, for 28 days.
223605380|NCT00638495|DRUG|Placebo|Placebo is to be administered orally once daily, after supper in principle, for 28 days.
223605381|NCT06069414|OTHER|Type of anesthesia induction|Patients will receive inhalatory or intravenous anesthesia at their choice; both groups will be evaluated with lung ultrasound after induction to detect ultrasonografic signs of atelectasis
223752716|NCT05738941|PROCEDURE|radiofrequency ablation|17-G length-adjustable electrode (RITA RF Electrode;) a 200-W RF generator is going to be used,under CT fluoroscopic guidance. The type of the electrode and the length of the active tip will be selected according to the size, location, and shape of the tumor, as well as the operator preference.ablation will be performed with 100 W energy for 30 seconds. The number of electrodes placed, ablation time per electrode, total ablation time, and total energy delivered to targets, as well as the temperature of the lesions, will be recorded. For lesions less than 3 cm, surgery was performed with one electrode , and for lesions of 3 cm or more, two or more electrodes were used . The procedure may be followed by injection of bone cement through the same working cannula, and a long working time will be delivered (STABILIT, Merit Medical Systems, Inc.) for the optimal filling of the bone lesion
223752717|NCT05738941|PROCEDURE|angioembolization|"Use a 4- or 5-French diagnostic catheter for the initial angiogram and either continue to use this catheter for embolization where the feeding vessel is large or add a standard 2.3- to 2.5-French microcatheter as a coaxial technique .~\- Injection of embolizing material in the feeding vessels using gel foam , PVA or histoacryl according to the nature of the bony lesion"
223605382|NCT04137731|DEVICE|Interferential Current Therapy|IFC treatment after Total Knee Arthroplasty
223605383|NCT04057430|DEVICE|GumChucks|GumChucks® is an innovative flossing system resembling mini nunchucks. The two-handle design eliminates the need to wrap the floss around fingers, and a proper flossing technique is facilitated by the nature of its curved shaped.
223605384|NCT04057430|DEVICE|String floss|Traditional string floss used in this study was Oral-B Glide® Pro-Health Original Floss
223605385|NCT00192413|BIOLOGICAL|Cold-adapted influenza vaccine trivalent (CAIV-T)|Liquid CAIV-T vaccine for this study consisted of 3 cold-adapted, attenuated, reassortant strains, representing the HA and NA antigens of the A/New Caledonia/20/99 (H1N1), A/Panama/2007/99 (H3N2), and B/Victoria/504/2000 influenza strains. The vaccine contained no preservatives and had a pH of 7.2 ± 0.5.
223605386|NCT00192413|BIOLOGICAL|Trivalent Inactivated Vaccine (TIV)|Commercially available TIV, inactivated influenza vaccine (Split Virion) BP (Aventis Pasteur MSD, Lyon, France) was administered IM according to the manufacturer's dosing instructions (one 0.5-mL IM dose for adults).
223605387|NCT01435486|DRUG|Caffeine citrate|Single stat dose (25 mg per kilogram of body weight) of intravenous caffeine citrate (25mg caffeine citrate equal to 12.5mg caffeine base).
223605388|NCT01435486|DRUG|Normal saline|Placebo with an equivalent volume of normal saline.
223605389|NCT02457468|DEVICE|coflex|
223752718|NCT05447364|DRUG|Pregabalin 75mg|1 tab of Pregabalin Brillior 75 mg and 1 tab of Placebo
223752719|NCT05447364|DRUG|Pregabalin 150mg|2 tabs of Pregabalin Brillior 75 mg
223752720|NCT01816828|BEHAVIORAL|Gay Poz Sex|Gay Poz Sex is a community-driven, peer-facilitated program for HIV+ gay and bisexual men. This eight week program is offered to small groups of 5-8 men and provides information about sexual health, the legal context of HIV non-disclosure and uses motivational interviewing to support each individual in setting and achieving a personal goal.
223752721|NCT01816828|OTHER|Wait List/Standard of Care|Participants are given referrals to existing resources in the community. Referrals and uptake will be tracked.
223752722|NCT01420289|DEVICE|High pressure intermittent pneumatic compression (HPIPC)|Apply therapy for 45 minutes twice daily
223752723|NCT01420289|BEHAVIORAL|Excercise|Treadmill walking 45 minutes once daily
223752724|NCT03601221|OTHER|Sample collection|Collection of one sampling pouch from each blood donor
223752725|NCT04127916|DRUG|Bendamustine|To investigate the efficacy and safety of bendamustine plus rituximab in patients with mantle cell lymphoma.
223752726|NCT01928862|DRUG|Prepopik® ½ Sachet x 2 (9-12 years)|
223752727|NCT01928862|DRUG|Prepopik® 1 Sachet x 2 (9-12 years)|
223752728|NCT01928862|DRUG|Oral polyethylene glycol (PEG) based preparation (9-12 years)|
223752729|NCT01928862|DRUG|Prepopik® 1 Sachet x 2 (13-16 years)|
223752730|NCT01928862|DRUG|Oral polyethylene glycol (PEG) based preparation (13-16 years)|
223752731|NCT01360658|DRUG|Intravenous immunoglobulins|Single administration of 2 g/kg intravenous immunoglobulins over 2 days
223605390|NCT04746820|OTHER|single-center prospective pilot study|"fNIRS will be compared to evoked potentials in an experimental group consisting of unconscious neuro-intensive care patients and in a control group consisting of healthy, conscious subjects.~To compare fNIRS with evoked potentials there are two test phases:~1. The cerebral response to a somatosensory stimulus (peripheral nerve stimulation) is measured by fNIRS and SSEP~2. The cerebral response to an auditory stimulus is measured by fNIRS and AEP"
223605391|NCT00310817|BIOLOGICAL|MenACWY-CRM conjugate vaccine, adjuvanted|
223605392|NCT00310817|BIOLOGICAL|MenACWY polysaccharide vaccine|
223752732|NCT00145665|PROCEDURE|FLT-PET scan|PET scan using FLT
223605393|NCT00310817|BIOLOGICAL|MenACWY-CRM conjugate vaccine, unadjuvanted|
223605394|NCT01702246|DRUG|Simvastatin|40 mg, orally, once daily for 3 months
223605395|NCT03225378|OTHER|Fluid loading of 500 mL of crystalloid solution|Infusion of 500 mL of crystalloid solution in less than 15 minutes
223605396|NCT03225378|OTHER|Passive Leg Raising test|This intervention is done before the fluid loading in order to predict fluid responsiveness.
223605397|NCT02290977|RADIATION|Scheduled interval TACE - RT|RT will be administered at 2 weeks after TACE in HCC combined PVTT
223605398|NCT02523378|BEHAVIORAL|Edmonton Symptom Assessment Scale|Participants complete the symptom survey alone, or with the help of a research nurse or assistant.
223605399|NCT02523378|BEHAVIORAL|Interview|After completion of the symptom questionnaire, participants asked if they preferred completing the questionnaire alone, or if they preferred to have a nurse help them answer the questions.
223605400|NCT01587040|DRUG|SAR245408|Pharmaceutical form: capsule or tablet Route of administration: oral
223605401|NCT01587040|DRUG|SAR245409|Pharmaceutical form: capsule or tablet Route of administration: oral
223605402|NCT04667741|OTHER|Post-dialysis recovery group|Before the hemodialysis session, the patients were asked by the investigators how long it took them to recover from a dialysis session, taking the last treatment month into account.
223605403|NCT04886778|DIETARY_SUPPLEMENT|Low-carbohydrate diet|Participants will be instructed to maintain a daily dietary energy intake of less than 1600 kcal.Based on the low-carbohydrate diet model, the proportion of daily intake of carbohydrate was about 30%, and this ratio was up to 30%, 40% of protein and fat respectively.Participants should choose unprocessed whole grains, potatoes, vegetables, meat, fish, eggs, soy products, sugar-free dairy products, designated varieties of low-GI fruits and nuts, etc. as breakfast, and avoid processed meats and high-fat red meat and poultry skins. Standard nutritious meal instead of daily lunch and dinner meals, that is to say, participants should take one nutritional bar for lunch and dinner (310 kcal totally, provided by Guangzhou Nanda Fett Nutrition and Health Consulting Co., Ltd.), and avoid starchy foods. Other food varieties are required to be the same as breakfast. Plant oil is the main cooking oil, and participants will be instructed to drink 2L water every day.
223605404|NCT04886778|DIETARY_SUPPLEMENT|Probiotic compound preparations|The probiotic compound preparation，named Junyi Yili® Probiotics，is made of Lactobacillus reuteri, Lactobacillus gasseri, Lactobacillus acidophilus and Bifidobacterium lactis, and resistant dextrin contained water-soluble dietary fiber. The subjects will take this probiotic compound preparations with purified water after three meals every day, 1 sachet each time.
223605405|NCT04886778|DIETARY_SUPPLEMENT|Placebo|Placebo is made of resistant dextrin which contained water-soluble dietary fiber. The subjects were taken this placebo with purified water after three meals every day, 1 sachet each time.
223605406|NCT00432341|BIOLOGICAL|botulinum toxin type A|200 Units at Visit 1 (Day 1)
223605407|NCT00432341|BIOLOGICAL|botulinum toxin type A|500 Units at Visit 1 (Day 1)
223605408|NCT00933998|OTHER|Metanx® (Oral L-methylfolate, Methylcobalamin and Pyridoxal 5'-phosphate)|One pill twice a day for 2 weeks. Then one pill a day until 12 month study is up.
223605409|NCT00970437|BEHAVIORAL|Cognitive Behavioral Analysis System of Psychotherapy|Duration of intervention per patient: 20 weeks acute treatment (n=24 sessions) followed by 28 weeks of continuation treatment (n=8 sessions) Follow-up per patient: 48 weeks after randomisation
223752733|NCT01731522|BEHAVIORAL|EF condition|
223752734|NCT04649164|BEHAVIORAL|Peer mentor support and caregiver intervention|Sixteen-week modular curriculum with printed/online workbook, additional resources, and weekly phone discussion with Lewy Body Dementia peer mentor.
223752735|NCT04649164|OTHER|Focus group to provide feedback on educational materials and mentoring program|Participation in a 2-3 hour focus group to review pilot and revised materials and provide feedback
223752736|NCT03168464|DRUG|Ipilimumab|Ipilimumab (3mg/kg) is given concurrently (+/- 24hrs from first RT dose) with radiation therapy on Day 1 of the study. On day 22 the combined treatment of ipilimumab plus nivolumab will start (nivolumab 240mg q 2 weeks, ipilimumab 1mg/kg q 6 weeks), and administered until evidence of progression.
223752737|NCT03168464|DRUG|Nivolumab|On day 22 the combined treatment of ipilimumab plus nivolumab will start (nivolumab 240mg q 2 weeks, ipilimumab 1mg/kg q 6 weeks), and administered until evidence of progression.
224200444|NCT00984646|DRUG|Prevascar|Intradermal Prevascar, 125ng/100μl/linear cm of wound site or margin administered once just prior to wounding and once 24 h later
223605410|NCT00970437|BEHAVIORAL|System of Supportive Psychotherapy|Duration of intervention per patient: 20 weeks acute treatment (n=24 sessions) followed by 28 weeks of continuation treatment (n=8 sessions) Follow-up per patient: 48 weeks after randomisation
223605411|NCT05385003|DIETARY_SUPPLEMENT|anserine|During the study period, subjects are instructed to take one capsule of anserine daily for a total of 3 months. Aside from the prebiotic supplement, all participants are instructed to continue their normal routine and not make any changes to their exercise habits but reduce purine intake.
223605412|NCT05385003|DIETARY_SUPPLEMENT|Sunflower peptide|During the study period, subjects are instructed to take one capsule of Sunflower peptide daily for a total of 3 months. Aside from the prebiotic supplement, all participants are instructed to continue their normal routine and not make any changes to their exercise habits but reduce purine intake.
224200445|NCT00984646|DRUG|Prevascar|Intradermal Prevascar, 500ng/100μl/linear cm of wound site or margin administered once just prior to wounding and once 24 h later
223605413|NCT05385003|DIETARY_SUPPLEMENT|Placebo control|During the study period, subjects are instructed to take one capsule of placebo control daily for a total of 3 months. Aside from the probiotic supplement, all participants are instructed to continue their normal routine and not make any changes to their exercise habits but reduce purine intake.
223752738|NCT03168464|RADIATION|Radiation therapy|Ipilimumab (3mg/kg) is given concurrently (+/- 24hrs from first RT dose) with radiation therapy on Day 1 of the study.
223605414|NCT05039944|DRUG|SI-B001|In Arm\_A, B and C, the intravenous infusion dose of SI-B001 was single drug RP2D selected in phase I (Q2W); In Cohort\_D, E, and F, SI-B001 was divided into two doses, the high dose was the single drug RP2D selected in phase I clinical trial, and the low dose was the second low dose of single drug RP2D, both of which were administered by intravenous infusion.
223605415|NCT05039944|DRUG|Irinotecan|Administration by intravenous infusion, 180 mg/m2 Q2W.
223605416|NCT05039944|DRUG|FOLFIRI Protocol|FOLFIRI is administered intravenously at the standard dose recommended by the guidelines(Q2W).
223752739|NCT03433664|DEVICE|CO2 laser|Fractional CO2 laser treatment using the DeepFX setting hand piece (Ultrapulse, Lumenis), performed under general anaesthetic at 4-6 week intervals. All treatments consisted of a single pass of 300Hz, 5% density and 50mJ energy with minimal overlapping
223605417|NCT05039944|DRUG|FOLFOX Protocol|FOLFOX is administered intravenously at the standard dose recommended by the guidelines(Q2W).
223605418|NCT03081650|DEVICE|Airvo Humidifier|
223605419|NCT03485235|PROCEDURE|D&C|Dilatation and curettage
223605420|NCT03485235|PROCEDURE|ICSI|Intra Cytoplasmic Sperm Injection
223605421|NCT06970158|OTHER|AI-Designed Passive Plate Therapy|A removable passive orthopedic plate designed using an AI-assisted digital workflow based on intraoral scan data. The design process is automated via a Blender-based software plugin that identifies anatomical landmarks and generates a custom-fit plate. The plate is 3D printed using biocompatible material and fitted shortly after birth. It is worn continuously until primary surgical repair, typically around 4 months of age. The intervention aims to reduce cleft width prior to surgery without requiring traditional impressions or extensive manual design effort.
223605422|NCT05209438|DEVICE|Cereset Research|Cereset Research The upgraded platform for medical research using the HIRREM technology has been rebranded as Cereset Research® (CR). This system uses the same core technology and algorithms to echo brainwaves in real-time using audible tones, as with HIRREM. The CR system also includes 64-bit processing architecture for faster feedback, the use of 4 sensors, and the use of standard protocols (with flexibility regarding the length and sequencing of the standard protocols), all done with eyes closed. Four sensors are applied to the scalp at a time. However, only two sensors are actively echoing feedback. The software automatically switches from one sensor pair to the other when needed. This reduces the number of sensor placement changes needed, resulting in shorter session time and fewer interruptions.
223605423|NCT05059535|DRUG|standard pain relievers|Knee arthroscopy will be performed ansd patients will receive standard pain relievers in confomtity with the current practice
223752740|NCT02053753|DRUG|Denosumab CP4|Denosumab produced by a process referred to as CP4, administered subcutaneously.
223752741|NCT02053753|DRUG|Denosumab CP2|Denosumab produced by a process referred to as CP2, administered subcutaneously.
223752742|NCT04722796|DEVICE|TAVR with Venus A plus using supra-annular sizing and THV implantation technique (Hangzhou solution)|Transcatheter aortic valve replacement (TAVR) with Venus A plus using supra-annular sizing and THV implantation technique (Hangzhou solution)
223752743|NCT04722796|DEVICE|TAVR with Venus A plus using annular sizing and THV implantation technique|Transcatheter aortic valve replacement (TAVR) with Venus A plus using annular sizing and THV implantation technique (Traditional sizing strategy)
223752744|NCT01969812|DEVICE|Evie Slow-release Insemination Device|
223752745|NCT01969812|OTHER|Traditional Intrauterine Insemination|
223752746|NCT03352921|OTHER|clinical pilates exercises|servikal, deep flexor muscles, posture exercsises
224200446|NCT00984646|DRUG|Prevascar|Intradermal Prevascar, 2000ng/100μl/linear cm of wound site or margin administered once just prior to wounding and once 24 h later
223752747|NCT03352921|OTHER|home exercises program|stretching, strengthening, and posture exercises to reduce functional disability, to relieve the pain and to provide postural straightening.
223752748|NCT05210166|DEVICE|Active tSCS and Lokomat|"A symmetrical biphasic 30 Hz current of 1 ms pulse-width with an electro-stimulator will be applied.~For the stimulation intensity, the maximum intensity tolerated by the patient will be selected. The intensity will be increased in case of habituation to the current."
223752749|NCT05210166|DEVICE|Sham tSCS and Lokomat|The protocol and device of sham tSCS combined with Lokomat will be the same as active tSCS except for the stimulus intensity, which will be set at the sensory threshold, maintained for 30 seconds and then slowly will be decreased to zero, being this intensity maintained for the remaining 20 minutes of stimulation.
223752750|NCT03183414|OTHER|echocardiographic measurements|echocardiographic parameters of the RV, measured with TEE and the right ventricular ejection fraction (thermodilution)
223752751|NCT00640705|DRUG|diclofenac sodium|15 mg (1%) topical patch; measuring 7 cm by 10 cm; applied once daily
223752752|NCT00640705|DRUG|Matching placebo patch|Matching placebo patch, containing identical constituents to the active comparator except for diclofenac sodium; measuring 7 cm by 10 cm; applied once daily
224200447|NCT00984646|DRUG|Placebo|Intradermal Placebo, 100μl/linear cm of wound site or margin administered once just prior to wounding and once 24 h later
224200448|NCT02391194|DRUG|AVB-620|
224200449|NCT05897931|OTHER|Connective tissue massage|Connective Tissue Massage will be applied by starting from the lumbosacral region, continuing from the lower thoracic region, and finishing by applying it to the scapular region, interscapular region, and cervico-occipital region.
224200450|NCT05897931|OTHER|Kinesio Tape Application|"Taping will be applied to the levator scapula and upper trapezius muscles in a Y shape, with 25% tension and while the participants were in an upright position. Again in the same position, this time the C shaped taping technique will be adhered with 50% tension from the middle fibers of the trapezium to the last rib."
223605434|NCT06080061|RADIATION|Hypofractionated accelerated radiation therapy|Hypofractionated accelerated radiation therapy
223605435|NCT05638087|DRUG|Dexamethasone|Dexamethasone Oral Suspension
223605436|NCT05638087|DRUG|Placebo Control|Placebo Oral Mix
223605437|NCT04275973|DEVICE|Lower limb prostheses|"Standard commercially available prostheses for participants with lower-limb amputation.~Specific prostheses will be determined at the time of the study, but they will include prostheses that are fully passive such as energy storage-and-return (ESR) feet, ESR feet with mobilized ankles such as passive hydraulic ankles (PHA), and ESR feet with microprocessor-controlled ankles (MPA)."
223605438|NCT04275973|DEVICE|Orthoses for Drop-foot|Standard commercially-available orthoses or standard-of-care custom orthoses as well as standard commercially-available electrical stimulation neuro-orthoses.
223605439|NCT04275973|DEVICE|Footwear|Different footwear will be used.
223605440|NCT05499533|PROCEDURE|implant site preparation|a hole were created in the edentulous ridge area before implant placement
223605441|NCT06352645|DEVICE|Bixdo Ultra Compact Water Flosser|Use of water flosser, in addition to standard tooth brushing, twice a day for 8 weeks.
223605442|NCT06352645|DEVICE|Manual toothbrush|For those in the control group, they will be asked to use only the study-provided manual toothbrush, twice a day for 8 weeks.
223605443|NCT06468618|BEHAVIORAL|DREAMS Program Video and Care Kit|A pediatric, circadian health program comprised of an introductory video to sleep experiences for stem cell transplant recipients, strategies to improve sleep, and a Sleep and Circadian Care Kit which includes ear plugs, a white noise machine, an eye mask, a lightbox, and kit instructions. Actigraph, Fitbit, and tablet will be provided to participant and family.
223605444|NCT06665347|OTHER|Progressive muscle relaxation|The participants will receive progressive muscle relaxation for 8 weeks. The muscles of the hand, arm, face, shoulder and neck, chest, abdomen, back, thigh and hip, legs and feet will be contracted and relaxed in sequence. The contraction time is 5 seconds (s), and the relaxation time is 10s.
223605445|NCT06665347|OTHER|Yoga|The participants will receive yoga for 30 minutes/session, 3 sessions/week for 8 weeks. The session will begin with 5 minutes for warming up. Twenty minutes of wind relieving position (pavanmuktasana), corpse position (savasana), standing side stretch position, seated forward bend (paschimothanasana), cobra position (bhujangasana), and chair position (utkatasana). Five minutes of cooling down.
223605446|NCT05092009|OTHER|Tissue and blood|Tissue and blood will be derived from patient during a standard of care procedure
223605447|NCT06974006|OTHER|Devices: Kardia Mobile 6L; Omron M7 BP ; Beurer PO30; Datospir Peak-10; NUTRILAB BIA 101 BIVA® PRO; JAMAR® Smart.|Use of the Kardia Mobile 6L portable device to assess electrocardiogram; Omron M7 BP for blood pressure; Beurer PO30 for oxygen saturation; Datospir Peak-10 for peak flow; NUTRILAB BIA 101 BIVA® PRO for body composition; questionnaires for the nutritional status (Mini-Nutritional Assessment, Malnutrition Universal Screening Tool), JAMAR® Smart for handgrip strength; The Short Physical Performance Battery for frailty status and fall risk; the Geriatric Depression Scale to evaluate depression status; the Fried's frailty phenotype to assess the frailty status; the International Physical Activity Questionnaire for the physical activity levels; SARC-F to identify older adults at risk of sarcopenia; and the Timed-Up and Go for mobility, walking ability and fall risk.
223605448|NCT06968442|PROCEDURE|Venipuncture|Simple blood collection
223605449|NCT06668454|PROCEDURE|Surgical resection followed by preoperative chemoimmunotherapy for oligometastatic esophagogastric cancer|Surgical resection followed by preoperative chemoimmunotherapy for oligometastatic esophagogastric cancer
223605450|NCT04607837|DRUG|Etrasimod|Etrasimod 2 mg tablet by mouth, once daily up to 52 weeks of treatment
223605451|NCT04607837|DRUG|Placebo|Etrasimod matching placebo tablet by mouth, once daily up to 52 weeks of treatment
223605452|NCT06260943|BEHAVIORAL|Target Navigation Pilot Program|Participants will meet with a navigator, in either English, Spanish or Creole, biweekly, in person or virtually, until the first treatment appointment and every three months after. Each session will last approximately one hour; depending on the needs identified, patients will be connected to appropriate institutional or community-based resources.
223605453|NCT06184438|DRUG|Micronized purified flavonoid fraction(Daflon 1000mg)|Received Micronized purified flavonoid fraction(Daflon 1000mg) BID after surgery from day to day 7
223605454|NCT06184438|DRUG|Placebo|Received placebo after surgery.
223605455|NCT06975930|PROCEDURE|Percutaneous Coronary Intervention (PCI)|"Patients with Aortoostial coronary lesion undergoing PCI will be blindly randomized into 2 groups Conventional group: patients who will undergo 2D convnetional angiography Aorto-ostial coronary stenting.~Floating Wire group: Patients who will undergo Aorto-ostial coronary stenting with Floating wire technique."
223605456|NCT06976957|DEVICE|MyPlan / Movisalud App|Those patients in experimental arm will be followed through a mobile app that offers different functionalities designed to improve clinical-patient communication, empower the patient in the management of his disease and treatment, detect symptoms early and individualize the interventions of professionals thanks to the patient records on the platform
223605457|NCT06974825|DRUG|BGM0504 Administered SC|5 milligrams (mg) BGM0504 administered subcutaneously (SC) once a week.
223605458|NCT06974825|DRUG|BGM0504 Administered SC|Experimental: 10 mg BGM0504 10 mg BGM0504 administered SC once a week.
223605459|NCT06974825|DRUG|BGM0504 Administered SC|Experimental: 15 mg BGM0504 15 mg BGM0504 administered SC once a week.
223605460|NCT06974825|DRUG|Semaglutide Administered SC|"Active Comparator: 1 mg Semaglutide~1 mg semaglutide administered SC once a week"
223605461|NCT06974825|DRUG|Placebo Administered SC|Placebo Comparator: Placebo Placebo administered SC once a week.
223605462|NCT06975228|BEHAVIORAL|TRUST|Six-session psychological intervention focussing on values and imagery Session 1: Assessment, formulation and psychoeducation Session 2: Values and values-based goals Session 3-5: Harnessing imagery to pursue values and imagery focussed strategies to change negative beliefs about self and others Session 6: Review
223605463|NCT04857502|DRUG|99mTc-based PSMA Imaging and Surgery Agent|Given via IV injection
223605464|NCT04857502|PROCEDURE|Computed Tomography|Undergo SPECT/CT
223605465|NCT04857502|PROCEDURE|Single Photon Emission Computed Tomography|Undergo SPECT/CT
224075389|NCT05323435|BIOLOGICAL|Recombinant two-component COVID-19 vaccine (CHO cell)|Before reconstitution: Lyophilized powder for reconstitution in single-use vials After reconstitution with BFA03 adjuvant: Milk-white solution with no visible foreign matter
224075390|NCT05323435|BIOLOGICAL|COVID-19 Vaccine (Vero Cell), Inactivated|Milky-white suspension.Stratified precipitate may form which can be dispersed by shaking
224200451|NCT00730366|DRUG|sulfadoxine-pyrimethamine|Sulfadoxine-pyrimethamine given as intermittent therapy, at the dosage of 1500/75 mg per administration (3 tablets), Twice during pregnancy
223752753|NCT05806294|BEHAVIORAL|Digital Metabolic Rehabilitation|Digital Metabolic Rehabilitation combines two programs: The Canadian Health Advanced by Nutrition and Graded Exercise Protocol (CHANGE) and My Viva Plan (MVP). All participants receive free access to MVP and attend group video conferencing sessions with health professionals. After the 60-minute initial assessments with the dietitian and the kinesiologist, each participant has an individualized diet and exercise plan based on the intervention protocol built in MVP. Participants are split into groups of 20 based on physical ability and stage of COPD. Intervention has 3 phases. In phase 1, weekly videoconferences with the kinesiologist and dietitian and monthly sessions with psychologist and respiratory therapist are held for the first 3 months. Phase 2 lasts from months 4 to 6 and has biweekly videoconferences with health professionals. Phase 3 starts in month 6 and has monthly group sessions with health professionals.
223605466|NCT06975540|OTHER|Multidomain physical exercise|The intervention includes a daily intake of two 200-mL of Meritene nutritional supplements (199 Kcal, 16g of protein, 25g of carbs, 3.6g of fats, and enriched with vitamins and minerals/bottle) plus a supervised and personalized multicomponent exercise program. Multicomponent exercise program (MEP) includes endurance, strength, coordination, balance, and flexibility exercises. The sessions last 65 min a day, 3 days/week for 24 weeks. All the sessions are supervised and delivered in groups by sports scientists.
223605467|NCT06975306|PROCEDURE|autologous bone grafts|group will be treated with autologous bone graft for BTB ACLR
223605468|NCT06975306|OTHER|Demineralized bone matrix (DBM)|Demineralized bone matrix (DBM) is a biologic allograft product derived from bone tissue that has undergone a process of demineralization to remove inorganic mineral components while retaining the organic matrix, including proteins and growth factors.
223605469|NCT06975488|PROCEDURE|LASER Lithotripsy ( Fragmentation modality)|Group-A patients will be treated with fragmentation modality utilizing Holmium YAG laser.
223605470|NCT06975488|PROCEDURE|LASER lithotripsy (Dusting Modality)|Group-B patients will be treated with dusting modality utilizing Holmium YAG laser.
223752754|NCT06424262|DEVICE|CI622D|A dexamethasone-eluting Slim Straight electrode
223752755|NCT06424262|DEVICE|CI622|A standard Slim Straight electrode
223752756|NCT01565330|DRUG|florbetapir F 18|single dose IV injection
223752757|NCT06231550|DRUG|FC084CSA tablets|"FC084CSA accelerated doses at 100mg QD, and then started the conventional 3+3 design from 200mg QD."
223752758|NCT02089061|DRUG|BMS-919373|
223752759|NCT02089061|DRUG|Rosuvastatin|
223752760|NCT02089061|DRUG|Atorvastatin|
223605471|NCT06976788|OTHER|Tomography exam|Brain imaging examination
223605472|NCT06976151|DRUG|Non-steroidal anti-inflammatory drugs (NSAID)|The participants will receive non-steroidal anti- inflammatory drugs (NSAID), Diclofenac 20 mg/ day for 3 consecutive menstrual cycles.
223605473|NCT06976151|OTHER|Transcutaneous Electrical Acupoint Stimulation (TEAS)|"The participants will receive transcutaneous electrical acupoint Stimulation (TEAS). These acupoints will include large intestine 14 (LI4) , gall bladder 34 (GB34), large intestine 11 (LI11), Gall bladder 39 (GB39) and stomach 36 (ST 36). The session will be applied for 30 minutes / 3 days/ week, in addition to Diclofenac 20 mg/ day for 3 consecutive menstrual cycles.~."
223605474|NCT06578663|OTHER|conventional physical therapy|including transcutaneous electrical nerve stimulation (TENS) and an exercise therapy program (stretching exercises, both hip and knee strengthening, balance, and stability exercise)
223752761|NCT05804383|DRUG|BMS-984923|Capsules
223752762|NCT05804383|DRUG|Placebo|Capsules
223752763|NCT03636750|DRUG|HB002.1T|HB002.1T is a Vascular Endothelial Growth Factor Receptor Decoy
223752764|NCT02697162|DEVICE|Antiseptic-coated catheter|Antiseptic-coated hydrophilic intermittent urinary catheter with octenidine chloride
223752765|NCT02697162|DEVICE|Hydrophilic catheter|Hydrophilic intermittent urinary catheter
223752766|NCT02697162|DRUG|Octenidine chloride|Antiseptic
223752767|NCT00889343|DRUG|Sorafenib|2x200 mg filmcoated tablets BID on day 2-12 of a 14-days cycle, oral
223752768|NCT00889343|DRUG|Placebo|2 filmcoated tablets BID, day 2-12 of a 14-days cycle, oral
223605475|NCT06578663|OTHER|Electrical Dry Needling|In electrical dry needling, needle electrodes are used to deliver an electric current to the taut muscle band or the pain-generating trigger point. Low-frequency currents are thought to improve the physiological effects of the therapy by using electrical stimulation to enhance certain physiological reactions and achieve a speedier analgesic and anesthetic effect than that obtained with standard dry needling.
223752769|NCT00889343|DRUG|Oxaliplatin or Irinotecan|Oxaliplatin 100 mg/m2 intravenous infusion on day 1 of 14-days cycle, Irinotecan 180 mg/m2 intravenous infusion on day 1 of 14-days cycle
223752770|NCT00889343|DRUG|Leucovorin|400 mg/m2 intravenous infusion on day 1 of a 14-days cycle
223752771|NCT00889343|DRUG|5-Fluorouracil|400 mg/m2 intravenous bolus infusion on day 1, 2400 mg/m2 46 hour intravenous infusion on day 1 to 2 of a 14-days cycle
223752772|NCT02456831|OTHER|Experimental Infant Formula 1|method A phytate reduction and 5% protein hydrolysis
223752773|NCT02456831|OTHER|Experimental Infant Formula 2|method A phytate reduction and 10% protein hydrolysis
223752774|NCT02456831|OTHER|Experimental Infant Formula 3|method B phytate reduction and 5% protein hydrolysis
223752775|NCT02456831|OTHER|Active Comparator: Control Infant Formula|Ready-to-Feed (RTF) Soy Infant Formula
223752776|NCT00401765|DRUG|CNTO 328|Patients will receive 6 mg/kg CNTO 328 in treatment phase of cohort 1A and cohort 1B; 9 mg/kg CNTO 328 in treatment phase of cohort 2; and 12 mg/kg CNTO 328 in treatment phase of cohort 3.
223752777|NCT00401765|DRUG|Docetaxel|Patients will receive 75 mg/m2 docetaxel in run-in phase of cohort 1A, cohort 2, and cohort 3; and in treatment phase of cohort 1A, cohort 1B, cohort 2, and cohort 3.
223752778|NCT02023151|DRUG|Omalizumab|
223752779|NCT04064294|DRUG|Intravenous Infusion|Intravenous levodopa given 1.0 to 1.5 mg/kg/hr from 0930 - 1130 on a single visit day.
223752780|NCT01400867|DRUG|Ceftaroline fosamil|"Subjects ≥ 6 months old: 12 mg/kg IV for subjects weighing ≤ 33 kg and 400 mg for subjects weighing \> 33 kg will be infused over 60 (± 10) minutes every 8 hours (q8h) (± 1 hour)~Subjects \< 6 months old: 8mg/kg infused over 60 (± 10) minutes every 8 hours (q8h) (± 1 hour)"
224200452|NCT00730366|DRUG|Chloroquine|Chloroquine tablets 100 mg. First administration of 1500 mg given over three days, followed by weekly doses of 300 mg/week
224200453|NCT04530227|DRUG|Biological: Camrelizumab|PD-1
224200454|NCT04530227|DRUG|Pemetrexed|chemotherapy
223605476|NCT06578663|OTHER|Glucosamine sulfate iontophoresis|Galvanic current mode will be used to deliver the cream through the skin. One gram of GS will be placed on positive electrode (being positively charged using Trans-arthral electrode placement technique) for administration of Iontophoresis \[40mA-min (2mA x 20minutes)\].
223605477|NCT01407198|DRUG|Nilotinib|Orally, daily 200 - 400 mg BID
223605478|NCT01407198|RADIATION|Radiation therapy|External beam radiation will be delivered at 1.8 Gy per day, 5 days per week (excluding holidays)for a total of 28 fractions over a 6 weeks period.
223605479|NCT06575647|DRUG|Tafenoquine|"Tafenoquine KODATEF® 100 mg film-coated tablets will be purchased from Biocelect (Suite 5.02, Level 5, 139 Macquarie Street, Sydney NSW, 2000 Australia).~Tafenoquine will be given as follows,~\>10 kg to ≤ 20 kg - 150 mg (1 tab), \>20 kg to ≤ 35 kg - 300 mg (2 tabs), \> 35 kg - 450 mg (3 tabs)"
223605480|NCT05650879|DRUG|ELVN-002|capsule
223605481|NCT05650879|DRUG|Fam-Trastuzumab Deruxtecan-Nxki|intravenous
223605482|NCT05650879|DRUG|Trastuzumab emtansine|intravenous
223605483|NCT05216263|DRUG|Atogepant|Oral Tablet
223605484|NCT06363240|DEVICE|Broadband Light|Broadband Light treatment
223605485|NCT05499871|BEHAVIORAL|Gait retraining intervention|Participants will receive a training to modify their footstrike pattern toward a more forefoot strike and increase their cadence by 7.5%.
223605486|NCT05499871|DEVICE|Transition to minimalist footwear.|Participants will receive a running minimalist footwear.
223605487|NCT05893381|DRUG|[177Lu]Lu-PSMA I&T|The radiopharmaceutical 177Lu-PSMA-I\&T will be administered, by slow intravenous injection, in 2 cycles of treatment at 6-8 weekly intervals at a dosage of 7.4 GBq.
223605488|NCT05893381|RADIATION|Stereotactic Radiotherapy|Ablative stereotactic radiation on the metastatic sites. Delivered in a 1 to 5 fractions regimen, depending on the target size and the surrounding normal tissue constraints,
223605489|NCT04346654|DRUG|Eltrombopag|Eltrombopag is for oral use and comes in 25, 50 and 75 mg tablets. Prescribed dose is taken once daily.
223605490|NCT04346654|DRUG|Dexamethasone|Dexamethasone is for oral use and comes in 8 mg tablets. Prescribed dose is taken once daily.
223605491|NCT05470374|PROCEDURE|Intraoperative sonography|ultrasound scanning of brain to search tumor remnants
223605492|NCT05836259|GENETIC|TN-201|TN-201 is a recombinant adeno-associated virus serotype 9 (AAV9) containing Myosin Binding Protein C (MYBPC3) transgene. It is a single (one-time) intravenous dose.
223605493|NCT04797455|BEHAVIORAL|DBT-Based Parenting Intervention|The intervention will consist of 4 individual telehealth parent sessions, to be completed within one month after the teen discharges from the inpatient hospital or within one month of linkage to care whatever comes first . Sessions will be 60-90 minute in length and will be offered weekly. Therapists may see parents more than once a week if needed, as long as the total number of sessions does not exceed 4.
224200455|NCT04530227|DRUG|Nab-paclitaxel|chemotherapy
224200456|NCT04712058|DRUG|Bictegravir / Emtricitabine / Tenofovir Alafenamide Oral Tablet [Biktarvy]|Biktarvy will be administered on the same day of diagnosis. The daily dosing will be continued for 48 weeks.
223605494|NCT04797455|BEHAVIORAL|Treatment as usual|No parenting intervention provided beyond standard practices on the adolescent psychiatric inpatient unit.
223605495|NCT06627205|BEHAVIORAL|Sleep Restriction Therapy|Therapist led sleep restriction therapy sessions.
223605496|NCT05759949|DRUG|RLY-5836|RLY-5836 is a mutant-selective, oral PI3Kα inhibitor.
223605497|NCT05759949|DRUG|Fulvestrant|Fulvestrant (500 mg) is administered IM into the buttocks (gluteal area) slowly (1 to 2 minutes per injection) as 2×5 mL injections, 1 in each buttock, on Cycle 1 Day 1, Cycle 1 Day 15, and Day 1 of each subsequent cycle.
223605498|NCT05759949|DRUG|Palbociclib|Palbociclib 125 mg once daily is taken orally in combination with RLY-5836 and fulvestrant for 28-day cycles that include 21 days of treatment followed by 7 days off treatment.
223605499|NCT05759949|DRUG|Ribociclib|Ribociclib 600 mg once daily is taken orally in combination with RLY-5836 and fulvestrant for 28-day cycles that include 21 days of treatment followed by 7 days off treatment.
223605500|NCT05759949|DRUG|Abemaciclib|Abemaciclib 150 mg BID will be taken orally in combination with RLY-5836 and fulvestrant for 28-day cycles.
223605501|NCT06726304|BEHAVIORAL|Baby Carrier Intervention|Mothers in the intervention group will have the opportunity to choose between two different soft ergonomic baby carriers and will receive instructions on how to use the carrier of their choice. Infants will be placed chest-to-chest in the carrier, supported by the mother's upper torso for a prescribed amount of time during the period of six weeks.
223605502|NCT06722014|BEHAVIORAL|STAMP + CBT|A mobile health, smartphone application that provides tailored multi-media, cancer pain psycho-education and pain management coping skills using algorithm-based technology to provide in the moment symptom monitoring and feedback.
224200457|NCT04893915|BIOLOGICAL|Cytokine-induced memory-like NK cells|Cell product processing is performed at the Siteman Cancer Center Biological Therapy Core or another FACT-accredited cellular therapy production facility that can manufacture the product per the IND CMC.
224200458|NCT04893915|DRUG|Fludarabine|-Lymphodepleting regimen
224200459|NCT04893915|DRUG|Cyclophosphamide|-Lymphodepleting regimen
224200460|NCT04893915|PROCEDURE|Donor Leukapheresis|-Apheresis will be performed via peripheral IVs or central line, as determined by the apheresis team.
223605503|NCT06722014|BEHAVIORAL|Digital Cancer Pain Education Packet|Packet including Articles from the Association for Clinical Oncology and the National Cancer Institute and the pain and medication monitoring form.
223605504|NCT03491787|DEVICE|Ultrasound guidance|The ultrasound guidance was used to obtain intraosseous access
223618175|NCT05416905|DEVICE|STN-DBS|"The patients will be treated with deep brain electrode placement of STN target under local and general anesthesia. Switching the system on: the stimulator will be switched on 3 weeks after surgery to allow time for the brain edema and stun effect to wear off. Postoperative medication: The subject taking medication in the past will continue the medication. If the subject with no medication before, will be required not to take medication related to dystonia."
224200461|NCT04893915|DRUG|Interleukin-2|-IL-2 will start approximately 2-4 hours after the NK cell infusions.
224200462|NCT06207045|PROCEDURE|limb elevation|limb elevation more than 45 degrees
223605505|NCT04748289|DEVICE|ICU Cockpit software testing|"the ICU Cockpit Software Platform is intended to be used for monitoring of patient characteristics and vital physiological parameters in patients at the Neurointensive Care Unit of the University Hospital Zurich.~Furthermore, three different applications for prognostication and prediction of complications will be tested:~1. ICU Cockpit COVID-19 for remote monitoring of isolated patients,~2. ICU Cockpit Stable State for a comprehensive visualization of vital parameters and as additional aid in early detection of imminent critical complications~3. ICU Cockpit Cerebral Ischemia for the prediction of delayed DCI in patients with subarachnoid hemorrhage (SAH)."
223605506|NCT06757764|DRUG|Aspirin|"Aspirin 100mg qd (21days)~* In case of stenting, aspirin will be added to cilostazol and clopidogrel until 90 days after stenting.~* Route: per oral. IMP can be taken with or without food.~* Frequency: once daily (qd)"
223605507|NCT06757764|DRUG|Clopidogrel|"Clopidogrel 75mg qd (180days)~* Route: per oral. IMP can be taken with or without food.~* Frequency: once daily (qd)"
223605508|NCT06757764|DRUG|Cilostazol|"Cilostazol SR 100mg x 2cap (180days)~* Route: per oral. IMP can be taken with or without food.~* Frequency: once daily (qd)"
223605509|NCT06757764|DRUG|Placebo|"Placebo x 2cap (180days)~* Route: per oral. IMP can be taken with or without food.~* Frequency: once daily (qd)"
223605510|NCT07061483|BEHAVIORAL|Experimental (Gratitude Journaling)|60-Day Gratitude Journaling With Guided Prompts
223605511|NCT07061483|BEHAVIORAL|Control (journaling without gratitude)|60-Day Journaling Without a Gratitude Focus
223605512|NCT01073202|DRUG|ursodeoxycholic acid|13-15mg/kg/day, 250mg/capsule, given twice per day, within the first 4 weeks after liver transplantation
223605513|NCT01073202|DRUG|identical-appearing placebo|13-15mg/kg/day, 250mg/capsule, given twice per day, within the first 4 weeks after liver transplantation
223605514|NCT07065565|PROCEDURE|non-intubated tracheal and carinal reconstruction|non-intubated tracheal and carinal reconstruction
223605515|NCT07065565|PROCEDURE|intubated tracheal and carinal reconstruction|intubated tracheal and carinal reconstruction
223605516|NCT07066592|BEHAVIORAL|Prehabilitation education provided via mobile compatible website|The prehabilitation education delivered through a mobile-compatible website was developed specifically for patients who are candidates for stem cell transplantation. Through this platform, patients can easily and quickly access accurate information on managing potential symptoms during the transplant process, as well as guidance on nutrition and exercise aimed at improving their quality of life.
223752781|NCT01400867|DRUG|Vancomycin +/- Aztreonam or Cefazolin +/- Aztreonam|"Vancomycin 15mg/kg IV over 60 minutes (or a maximum of 10mg/min whichever is longer) +/- Aztreonam 30 mg/kg IV every 8 hours over 60 minutes (for infections involving gram negative pathogen suspected or confirmed)~Cefazolin 75mg/kg IV divided every 8 hours over 60 minutes (for sites that do not empirically cover for MRSA) +/- Aztreonam 30 mg/kg IV every 8 hours over 60 minutes (for infections involving gram negative pathogen suspected or confirmed"
223752782|NCT01400867|DRUG|Cephalexin or Clindamycin or Linezolid|"Possible oral switch on or after study day 4.~Cephalexin: 25 mg/kg q6h PO or Clindamycin: 10 mg/kg q8h PO or Linezolid 600mg q12h (cohort 1) or 10 mg/kg q8h (cohorts 2,3 and 4) PO."
223752783|NCT06328790|OTHER|Multidisciplinary Rehabilitation Training|34 Patients will attend the in-person 5-day rehabilitation program (2 h/day) followed by a 12-weeks telemedicine program (1 h/week).
223752784|NCT06328790|BEHAVIORAL|Cross-sectional study on patients with FMD and patients with structural/organic diseases|Each subject will undergo behavioural, neurophysiological, and Magnetic Resonance Imaging (MRI) tests exploring the motor, exteroceptive and interoceptive domains.
223752785|NCT06328790|BEHAVIORAL|Cross-sectional study on patients with FMD and healthy controls (HC)|Each subject will undergo a set of behavioural, neurophysiological, and Magnetic Resonance Imaging (MRI) tests exploring the motor, exteroceptive and
223605517|NCT07064772|OTHER|First Rib Mobilization|Participants in the mobilization group will receive either a seated or supine three stage progressive muscle energy technique (MET) plus a singular high-velocity, low-amplitude thrust (HVLAT) mobilization technique directed to their first rib on their symptomatic side based on the discretion of the treating physical therapist.
223605518|NCT07064772|OTHER|Sham Comparator|Participants in the sham mobilization (control) group will be placed in a supine, hook-lying position identical to the mobilization group; however, they will be instructed to inhale and exhale 3 times using diaphragmatic breathing (avoiding upper chest recruitment) as the physical therapist gently rests his or her hand over the area of the upper trapezius muscle just proximal to the first rib to simulate a sham mobilization hand placement. Therefore, physical therapists will not use any significant compressive force to the musculature, perform any tactile cueing for upper chest breathing, perform any mobilizations, nor perform any HVLAT techniques to participants in the sham mobilization group.
223605519|NCT07066774|DIAGNOSTIC_TEST|Tru-cut Biopsy with 14 G Needle|Each participant underwent Percutaneous Tru-cut Biopsy with 14G tru-cut needle in a single session procedure. There are no studies to our knowledge to compare samples from the same tumor
223752786|NCT03001921|OTHER|No intervention|Registration of all HD patients in the First Affiliated Hospital of Sun Yat-sen University and other hospital which have signed the contract in China.
223752787|NCT04431362|BEHAVIORAL|Self-selected music|Participants will be given iPods and headphones to listen to their music
223752788|NCT03450707|DRUG|Thiamine 500 mg IV|Thiamine hydrochloride (vitamin B1) 500mg IV will be given every 12 hours for 5 doses in the experimental arm.
223752789|NCT03450707|OTHER|Placebo|100mL of intravenous normal saline will be given every 12hours for 5 doses in the placebo arm
223752790|NCT02302196|PROCEDURE|Autologous Fat Grafting of the Breast|In fat grafting, fat tissue is removed from other parts of the body; usually thighs, belly, and buttocks by liposuction. The tissue is then processed and injected into the breast area to reconstruct or recreate the breast. The fat will be removed from by a narrow surgical instrument (cannula) through a small incision. Then the fat will be prepared in a specific way before being replaced back in the body. This preparation may include washing, filtering, and centrifugation (spinning) of the fat. The fat is then placed into the desired area of the breast using either a smaller cannula or needle.
224200463|NCT03710759|OTHER|Assistive autogenic Drainage|Assistive autogenic Drainage : All the 3 components of Autogenic drainage was given passively to the patients. By placing the hands on the child's chest, the therapist manually increases the expiratory flow to achieve the different lung volume breathing.
224200464|NCT01950052|DIETARY_SUPPLEMENT|Diet group 800 Kcal diet|Pre-operative liver shrinking diet of 800 kcal is administered for 4 weeks
223605520|NCT07066774|DIAGNOSTIC_TEST|Tru-cut Biopsy with 16G tru-cut needle|Each participant underwent Percutaneous Tru-cut Biopsy with 16 tru-cut needle in a single session procedure. There are no studies to our knowledge to compare samples from the same tumor
223605521|NCT07066774|DIAGNOSTIC_TEST|Tru-cut Biopsy with 18G tru-cut needle|Each participant underwent Percutaneous Tru-cut Biopsy with 18G tru-cut needle in a single session procedure. There are no studies to our knowledge to compare samples from the same tumor
223605522|NCT07065682|DRUG|Aloevera + dutasteride|Dutasteride 0,5 mg/day + Aloe Vera Extract 380 mg/day
223605523|NCT07065682|DRUG|Dutasteride (0.5mg)|Control
223605524|NCT07066241|DEVICE|Virtual Reality Glasses|The Effect of Virtual Reality on Stress, Pain Levels and Vital Signs in Patients with Hyperthyroidism Undergoing Fine Needle Biopsy
223605525|NCT07065435|DRUG|Disitamab Vedotin (RC48)|A HER2-targeted antibody-drug conjugate comprising a humanized anti-HER2 monoclonal antibody linked via a cathepsin-cleavable MC-VC-PAB linker to the microtubule inhibitor MMAE (drug-to-antibody ratio ≈4). Administered intravenously at 2.0 mg/kg every 2 weeks.
223605526|NCT07065435|DRUG|Bevacizumab|A recombinant humanized monoclonal antibody that binds vascular endothelial growth factor (VEGF) to inhibit tumor angiogenesis. Administered intravenously at 7.5 mg/kg every 2 weeks in combination with RC48.
223605527|NCT07065435|DRUG|Pyrotinib|An irreversible pan-HER tyrosine kinase inhibitor targeting HER1, HER2, and HER4, inhibiting downstream PI3K/Akt and MAPK signaling. Administered orally at 320 mg once daily (post-meal) in combination with RC48.
223605528|NCT07066878|PROCEDURE|treatment received in the group of patients suffering from malignant lesions of the head and neck.|This protocol focuses on a retrospective, single-center analysis, analyzing the factors that influence survival as the main objective, and secondarily the development of complications and the quality of life based on the treatment received in the group of patients suffering from malignant lesions of the head and neck.
223605529|NCT07065071|OTHER|Mentalization-Based Therapy|Group MBT that takes place as part of treatment as usual within Derbyshire Healthcare NHS Foundation Trust's Older Adult Community Mental Health Team's service.
223605530|NCT07065578|OTHER|STAR condition 1|"* Basic module: HF information and doing symptom awareness exercises.~* Low version Module 1: Symptom awareness exercises 2 times in 1 week, and written feedback HF nurse~* Low version Module 2: Coaching in symptom management response and choose symptom response option to experiment with. Written feedback from HF nurse~* Low version Module 3: Instruction and doing symptom management experiments for 2 weeks + keep logs; Written feedback HF nurse"
223752791|NCT02302196|OTHER|Control Arm|Retrospective chart review for women who have undergone standard breast reconstruction for lumpectomy.
223752792|NCT02635464|BIOLOGICAL|hUC-MSCs+Injectable collagen scaffold+CABG|Patients underwent Coronary Artery Bypass Surgery (CABG) with 10\^8 allogeneic human umbilical cord mesenchymal stem cells (hUC-MSCs) in collagen scaffold injecting in the infarct region.
223605531|NCT07065578|OTHER|STAR condition 2|Basic module: aims to improve the participant's illness perceptions and standardize HF knowledge at the start of the intervention and doing exercises.- Low version Module 1: Symptom awareness exercises 2 times in 1 week, and written feedback HF nurse - Low version Module 2: Coaching in symptom management response and choose symptom response option to experiment with. Written feedback from HF nurse - High version Module 3: Instruction and doing symptom management experiments for 2 weeks + keep logs; Verbal feedback HF nurse
223605532|NCT07065578|OTHER|STAR condition 3|Basic module: aims to improve the participant's illness perceptions and standardize HF knowledge at the start of the intervention and doing exercises.- Low version Module 1: Symptom awareness exercises 2 times in 1 week, and written feedback HF nurse - High version Module 2: Coaching in symptom management response and choose symptom response option to experiment with. Verbal feedback from HF nurse - High version Module 3: Instruction and doing symptom management experiments for 2 weeks + keep logs; Verbal feedback HF nurse
223605533|NCT07065578|OTHER|STAR condition 4|Basic module: aims to improve the participant's illness perceptions and standardize HF knowledge at the start of the intervention and doing exercises.- Low version Module 1: Symptom awareness exercises 2 times in 1 week, and written feedback HF nurse - High version Module 2: Coaching in symptom management response and choose symptom response option to experiment with. Verbal feedback from HF nurse - Low version Module 3: Instruction and doing symptom management experiments for 2 weeks + keep logs; Written feedback HF nurse
223605534|NCT07065578|OTHER|STAR condition 5|Basic module: aims to improve the participant's illness perceptions and standardize HF knowledge at the start of the intervention and doing exercises.- High version Module 1: Symptom awareness exercises 6 times in 2 weeks, and verbal feedback HF nurse - Low version Module 2: Coaching in symptom management response and choose symptom response option to experiment with. Written feedback from HF nurse - Low version Module 3: Instruction and doing symptom management experiments for 2 weeks + keep logs; written feedback HF nurse
223752793|NCT02635464|BIOLOGICAL|hUC-MSCs+CABG|Patients underwent Coronary Artery Bypass Surgery (CABG) with 10\^8 allogeneic human umbilical cord mesenchymal stem cells (hUC-MSCs) injecting in the infarct region.
223752794|NCT02635464|PROCEDURE|CABG|Patients underwent CABG alone.
223752795|NCT03930706|OTHER|Longer administration of estradiol (Progynova®)|All women included will take exogenous hormone with daily administration of Estradiol Valerate (Progynova®), the standard dose used will be 6 mg/day (Cobo et al., n.d.). On day 7 of endometrial preparation patients will be examined with vaginal ultrasound and blood test, to evaluate the endometrial thickness and the hormones levels. In both arms the FET will take place after 6 days of Progesterone supplementation (600 mg per day, vaginal administration of Utrogestan®) According to embryo quality after warming, embryo transfer to the uterine cavity will be performed on day 5 of development under ultrasound guidance whenever possible. Following embryo transfer, luteal support will be continued with vaginally administered P (Utrogestan®). All patients 12 days after the FET will undergo the pregnancy test (blood test to evaluate hCG).
224075391|NCT02213809|BEHAVIORAL|Case method education in COPD|In case method a rich narrative describing of a real-life situation (teaching case) is presented, in which the learning group must make a decision or solve a problem. The teaching case provide information, but neither analysis nor conclusions. The analytical work of explaining the relationships among events in the case, identifying options, evaluating choices and predicting the effects of actions is the work done by students during the discussion.
224200465|NCT03334201|OTHER|Western Diet|high fat (40%), high sugar (25%) and low fiber (15g/day)
224200466|NCT03334201|OTHER|Non-Western Diet|low fat (25%), low sugar (15%), high fiber (30g/day)
223605535|NCT07065578|OTHER|STAR condition 6|Basic module: aims to improve the participant's illness perceptions and standardize HF knowledge at the start of the intervention and doing exercises.- High version Module 1: Symptom awareness exercises 6 times in 2 weeks, and verbal feedback HF nurse - Low version Module 2: Coaching in symptom management response and choose symptom response option to experiment with. Written feedback from HF nurse - High version Module 3: Instruction and doing symptom management experiments for 2 weeks + keep logs; Verbal feedback HF nurse
223605536|NCT07065578|OTHER|STAR condition 7|Basic module: aims to improve the participant's illness perceptions and standardize HF knowledge at the start of the intervention and doing exercises.- High version Module 1: Symptom awareness exercises 6 times in 2 weeks, and verbal feedback HF nurse - High version Module 2: Coaching in symptom management response and choose symptom response option to experiment with. Verbal feedback from HF nurse - Low version Module 3: Instruction and doing symptom management experiments for 2 weeks + keep logs; Written feedback HF nurse
223605537|NCT07065578|OTHER|STAR condition 8|Basic module: aims to improve the participant's illness perceptions and standardize HF knowledge at the start of the intervention and doing exercises.- High version Module 1: Symptom awareness exercises 6 times in 2 weeks, and verbal feedback HF nurse - High version Module 2: Coaching in symptom management response and choose symptom response option to experiment with. Verbal feedback from HF nurse - High version Module 3: Instruction and doing symptom management experiments for 2 weeks + keep logs; Verbal feedback HF nurse
223605538|NCT07065318|BEHAVIORAL|LV-HIIT (Low-Volume High-Intensity Interval Training)|30-sec intervals at 85-100% peak workload, 30-sec rest at 40%, total 20-30 min.
223605539|NCT07065318|BEHAVIORAL|MICT (Moderate-Intensity Continuous Training)|Continuous cycling at 60-80% peak workload for 20-30 min.
223605540|NCT07065318|DEVICE|Ergometer cycle|Electronically Ergometer cycle custo ec5000, CustoMed used for all exercise sessions. Calibrated before each trial.
223605541|NCT07065877|DRUG|vit D mixed with xenograft|Topical application of vitamin D solution mixed with xenograft in the jumping gap around immediate implant
223605542|NCT07065877|DRUG|only xenograft without vit D|grafting the jumping gap with xenograft only around immediate implant
223605543|NCT07064733|OTHER|Music Therapy|"The music therapy intervention consists of listening sessions using specially recorded handpan music, designed to promote relaxation and reduce anxiety in pregnant women. The handpan is a melodic percussion instrument known for its soothing and harmonic sound qualities.~Participants will listen to a 30-minute handpan music recording at home, in a quiet and dimly lit room, while resting in a semi-fowler or left lateral position. The sound volume will be kept below 60 decibels to ensure comfort and prevent overstimulation. Sessions will be scheduled three times per week, in the morning and evening, over a two-week period.~Before each session, participants will be reminded by phone and instructed to measure their blood pressure immediately prior to and at 0, 30, and 60 minutes after the music listening. The therapy aims to create a calming environment that encourages positive thoughts and bonding with the fetus."
223605544|NCT07064733|OTHER|warm water foot bath therapy|"The warm water foot bath therapy involves soaking the participant's feet in water heated to 37-40°C for 10-15 minutes per session. This therapy is designed to promote relaxation, improve peripheral circulation, and reduce anxiety symptoms.~Participants will perform the foot bath in a safe and comfortable setting, ensuring water temperature is monitored with a thermometer before each session. After soaking, feet should be thoroughly dried to prevent slipping, and participants are advised to have a companion nearby when standing up to avoid falls.~The intervention will be applied three times weekly, in the morning and evening, over a two-week period. Blood pressure measurements will be taken immediately before and at 0, 30, and 60 minutes after each session."
223605545|NCT07065942|DRUG|Lactulose oral solution|Oral, 30 mL once daily administered during breakfast.
223605546|NCT07065942|DRUG|Live Combined B. Subtilis and E. Faecium Enteric-coated Capsules|Oral, 2 tablets (500 mg per tablet) three times daily (TID).
223605547|NCT07065175|DRUG|Kangfupen (liquid dressing) retention enema administration|"Dosage: 50 mL per administration, once daily Duration: 3-6 months of continuous therapy~Procedure:~Enema depth determined by colonoscopy-identified lesion location Administered as retention enema (minimum 30-minute retention time)"
223605548|NCT07064759|BIOLOGICAL|4D-150 IVT (3E10 vg/eye)|If randomized to the 4D-150 treatment arm, 4D-150 will be administered at the assigned dose level as a single dose IVT injection on Day 1
223605549|NCT07064759|BIOLOGICAL|EYLEA® (aflibercept) Injection 2 mg (0.05mL)|Eylea (aflibercept) will be administered at applicable visits
223605550|NCT07065656|DEVICE|Vapotherm high velocity therapy (HVT) 2.0 (Vapotherm, Inc, Exeter, NH)|Oxygen therapy will be given via the Vapotherm high velocity therapy (HVT) 2.0 (Vapotherm, Inc, Exeter, NH) using a small-bore cannula, with a flow rate of up to 45 L/min, starting temperature of 37oC and FiO2 of up to 1.0.
223605551|NCT07065656|DEVICE|Respironics Vision V60|Ventilation will be performed with the Respironics Vision V60 (Philips Healthcare, Murrysville, PA) using an oronasal mask of appropriate size, with FiO2 (up to 1.0), inspiratory (IPAP 12 to 20 cmH2O) and expiratory (EPAP 5 to 10 cm H2O) pressures titrated to alleviate patient's respiratory distress.
223605552|NCT07066488|BEHAVIORAL|Acceptance and Commitment Therapy (ACT)|Acceptance and Commitment Therapy methods were focused on promoting Values clarification, Acceptance, Cognitive defusion, Committed action and Flexible attention to the present moment, and included methods such as the Garden Metaphor or defusion training.
223605553|NCT07066943|BEHAVIORAL|MINDxYOU|The online program MINDxYOU is based on the principles of 'third wave' psychotherapies and it is an online program particularly addressed at healthcare providers which will both monitor and support the individual's mental health. The program is self-administered and will be delivered via the Internet and available via smartphone, tablet, and personal computer.
223605554|NCT07065604|PROCEDURE|Non-intubated VATS for mediastinal neoplasm|Non-intubated VATS for mediastinal neoplasm
224200467|NCT02365701|DRUG|Motilitone 30mg|30mg of Motilitone in tablet form, to be taken 3 times daily for 4 weeks
224200468|NCT02365701|DRUG|Placebo|Placebo, in tablet form, to be taken 3 times daily for 4 weeks. The placebo is the same formulation as Motilitone except that it does not contain the active pharmaceutical ingredient.
224200469|NCT06644729|PROCEDURE|Arthroscopic Rotator Cuff Repair|Arthroscopic Rotator Cuff Repair
224200470|NCT06135129|DEVICE|Sonoelastography|Sonoelastography (SE) is a new ultrasound-based method measure the stiffness or elasticity of tissues, has no hazards on poatients.
224200471|NCT00003726|BIOLOGICAL|lepirudin|lepirudin
224200472|NCT01754805|DRUG|peficitinib|oral
223605555|NCT07065604|PROCEDURE|Intubated VATS for mediastinal neoplasm|Intubated VATS for mediastinal neoplasm
224200473|NCT01754805|DRUG|methotrexate|oral
224200474|NCT03626246|OTHER|Kidney disease|"Being part of this study you agree to participate in all these interventions:~Genetic:~• Blood sample~Procedure/Surgery:~• Bone and muscle biopsies.~Radiation:~* Bone density (DXA)~* Thoracic and lumbar spine plain films.~* HRpQCT: high-resolution peripheral quantitative computed tomography~Other:~* Completing medical history, physical activity level, and dietary questionnaires for calcium and vitamin D.~* Measure levels of Advanced Glycation End products (AGEs) in the skin."
224200475|NCT02894541|DRUG|CKD-519 100mg|
224200476|NCT02894541|DRUG|CKD-519 200mg|
224200477|NCT02894541|DRUG|CKD-519 100mg|
224200478|NCT02894541|DRUG|CKD-519 200mg|
224200479|NCT06041100|DEVICE|Exoskeleton|Use a passive assistive hip exoskeleton (alQ, Imasen Electrical Industrial Co., Ltd.) for 30 minutes daily during moderate to intensive activities over a period of 12-weeks. The exoskeleton is designed to aid hip flexion and as such its primary role is to improve gait by increasing step length and improving speed. The amount of time the exoskeleton has been used will be weekly monitored through phone calls and two gait sessions will be conducted to measure the development.
223605556|NCT07064967|DIAGNOSTIC_TEST|Magnetoencephalography|Participants will undergo magnetoencephalography scan in both resting and tasking state.
223605557|NCT07064889|DRUG|Dexamethasone|Dexamethasone, 40 mg/d, for 4 days (The 4-day course of dexamethasone was repeated in the case of lack of response by day 10)
223605558|NCT07064889|DRUG|Upadacitinib|Upadacitinib 15mg qd for 12 weeks
224200480|NCT04679649|OTHER|Manual spinal mobilisation physiotherapy|Manual spinal mobilisation is a physiotherapy technique to improve spinal mobility by gently applying pressure manually on the each segmental vertebrae by hands-on treatment of a physiotherapist.
224200481|NCT04065997|DEVICE|HeartWare Ventricular Assist Device|The HVAD is an implantable centrifugal rotary blood pump that is implanted in the pericardial space and is designed to provide up to 10 L/min of blood flow from the left ventricular to the aorta. The HVAD System is comprised of three major components: the HVAD (pump) with inflow and outflow conduits, a Controller (microprocessor unit that controls the operation of the HVAD), and power sources (AC and DC power adapters that provide power to the Controller and implanted HVAD).
224200482|NCT05395845|BIOLOGICAL|platelets rich plasma|local ingection of platelets rich plasma
223605559|NCT07065812|OTHER|Surgical team familiarity|Surgical team familiarity: the degree of collaboration within the surgical team is statistically described based on data regarding team personnel and composition, which is used to calculate the Intraoperative Familiarity Score (IFS)-the core component of this study. The specific methodology includes IFS=（X1+X2+X3+X4+X5+X6…）/ N N=nCr=n!/r!(n-r)! Here, X represents the number of times a pair of team members has worked together over a specified period (this process is repeated for all possible pairings in the team), and N is the total number of possible pairwise combinations in the team.
223605560|NCT07065812|OTHER|Composition and Dynamics of the Surgical Team|"Basic indicators reflecting surgical team personnel and composition:~1. Number of surgical, anesthesia, and nursing team members participating in procedures: are obtainable via the Anesthesia Information Management System (AIMS).~2. Shift changes among surgical, anesthesia, and nursing teams during individual procedures: can be tracked through the AIMS.~3. Gender ratio within surgical, anesthesia, and nursing teams: will be derived from the Hospital Information System (HIS)."
223605561|NCT07065279|DRUG|JY231 Injection|Patients were enrolled and given a single dose of JY231 injection intravenously, hospitalized for observation over the following month, and followed up for observation over the following 2 years.
223605562|NCT07065864|DIETARY_SUPPLEMENT|Ketone ester|Standardized light meal, questionnaires, blood measurements (finger stick), resting physiology and steady state submaximal exercise (6 minutes each at 40, 50, and 60% of the peak power achieved at VO2max) at simulated 4500m after consuming the ketone ester or placebo (in randomized order).
223605563|NCT07065864|OTHER|Placebo|steady state submaximal exercise (6 minutes each at 40, 50, and 60% of the peak power achieved at VO2max) at simulated 4500m after consuming the ketone ester or placebo
223605564|NCT07067047|BEHAVIORAL|Nursing Decision Support System|A behavioral intervention involving a nurse-led decision support system designed to manage fluid volume overload in heart failure patients. The intervention guided nursing care planning, monitoring, and evaluation during hospitalization and through home follow-up visits.
224200483|NCT04125498|OTHER|Osteopathic treatment|Manual treatment that aims to release myofascial tensions
224200484|NCT04125498|OTHER|Placebo treatment|Similar to OMT without pressure
224200485|NCT04125498|OTHER|Self-massage|Women will be instructed to perform self-massage at home once a day for 5 minutes.
224200486|NCT02905695|DRUG|Chirocaine|
224200487|NCT02905695|OTHER|Placebo|
224200488|NCT06466369|DRUG|Tadalafil|tadalafil 2.5 mg, 5 mg
224200489|NCT00714025|DRUG|RAD001|RAD001 10mg, daily, PO
224200490|NCT02222168|DRUG|BI 409306|film-coated tablet
224200491|NCT01572610|DRUG|RTA 402|once a day, oral administration
223605565|NCT07064837|OTHER|Conecta Familia|The Conecta intervention is a Spanish language contraceptive need screening and referral process that includes a screener and referral to social needs navigation bundled with developmental screener in 0-12 month old pediatric well visit for written completion by the mother of the patient
223605566|NCT07064837|OTHER|Contraceptive need survey|brief survey describing demographic information and contraceptive need, use, and experience
223605567|NCT06915571|OTHER|Plantar Fascia Stretching.|It consists of participants who will undergo plantar fascia stretching.
224200492|NCT04698018|DRUG|Faster Aspart|Administered s.c. (subcutaneously, under the skin) of the lower abdomen using a pen-injector.
224200493|NCT04698018|DRUG|Novo Rapid|Administered s.c. (subcutaneously, under the skin) of the lower abdomen using a pen-injector.
224200494|NCT04846049|OTHER|Comprehensive Care|"1. Comprehensive Geriatric Assessment (3 visits with a geriatrician alternating with 3 primary provider visits over 6 months)~2. Care Planning with Interdisciplinary Team~3. Care coordination~4. Co-management with Primary care~5. Social work needs assessment~6. Patient-centered telehealth using phone, home telehealth, patient portal, Video~7. Transportation provided for all visits~8. Referral to Geriatric primary care clinic and mental health per Veteran need~9. Goals of Care and Veteran preferences conversation~10. Educate primary care providers about HNHR population, home and community based services, collaboration"
223752796|NCT00481195|DRUG|Armodafinil|Patients were randomly assigned to begin oral treatment with armodafinil, which was titrated to 150 mg/day (3 tablets). Armodafinil was titrated up to the target dosage of 150 mg/day (daily dose was administered each morning). Patients began taking blinded armodafinil at a dose of 50 mg/day (1 tablet) on the day following the baseline visit. Doses were increased by 50 mg/day (1 tablet) to a dose of 100 mg/day on Day 2 and 3, and then again by 50 mg /day on day 4 for a target dose of 150 mg/day. Following titration, patients continued taking 150 mg/day of armodafinil for the duration of the study. If a patient was unable to tolerate (recurrent or persistent adverse events) the study drug, 1 reduction in dosage (ie, minimum dosage 100 mg/day \[2 tablets\]) was allowed. The dosage could not be increased after it was decreased.
223752797|NCT00481195|DRUG|Placebo|Patients were randomly assigned to begin oral treatment with placebo, which was titrated to 3 tablets. Placebo tablets matching the 50 mg armodafinil tablet were used in a manner identical to that of the armodafinil tablets. Study drug was titrated up to the target dosage of 3 tablets / day (daily dose was administered each morning). Patients began taking blinded study drug at a dose of 1 tablet daily on the day following the baseline visit. Doses were increased by 1 tablet to a dose of 2 tablets/day on Day 2 and 3, and then again by 1 tablet /day on day 4 for a target dose of 3 tablets/day. Following titration, patients continued taking 3 tablets/day of study drug for the duration of the study. If a patient was unable to tolerate (recurrent or persistent adverse events) the study drug, 1 reduction in dosage (ie, minimum dosage 2 tablets/day) was allowed. The dosage could not be increased after it was decreased.
223752798|NCT05715567|OTHER|Re-EValuating the Inhibition of Stress Erosions (REVISE) Trial (NCT03374800)|Following the intervention of the Re-EValuating the Inhibition of Stress Erosions (REVISE) Trial (NCT03374800)
223605568|NCT06915571|OTHER|Graston Technique|It consists of participants who will underwent graston technique application.
223605569|NCT07065266|OTHER|Binary pain questionnaire|Post-operative questionnaire that asks if pain is 'tolerable' or 'intolerable'
223605570|NCT07065266|OTHER|Numerical Pain Rating Scale (NPRS)|Standard 10-point pain scale used post-operatively to assess pain
223605571|NCT07066826|DRUG|Huperzine A Controlled-Release Tablets|During the trial, the patients should take huperzine A controlled-release tablets in the morning
223605572|NCT07066826|DRUG|Donepezil hydrochloride tablets|During the trial, the patients should take donepezil hydrochloride tablets before going to bed in the evening
223605573|NCT07066826|DRUG|Huperzine A controlled-release tablets placebo; Donepezil hydrochloride tablets placebo|During the trial, the patients should take huperzine A controlled-release tablets placebo in the morning and donepezil hydrochloride tablets placebo before going to bed in the evening
223605574|NCT07065786|OTHER|Generative model|Prospectively enroll pretreatment imaging data from patients with unresectable hepatocellular carcinoma undergoing TACE in combination with immunotherapy plus targeted therapy. Utilize a generative model to create virtual images that represent optimal treatment responses, and compare these virtual images with actual treatment response images collected during follow-up to evaluate the reliability of the generative model.
223605575|NCT07065201|DEVICE|Mobile application for preoperative patient guidance|The mobile application provides patients with tailored information during the preoperative period until seven days after surgery. 1) Before the preoperative outpatient clinic visits, patient will receive information regarding the preoperative screening process and an overview of available anesthesia techniques through videos embedded in the app. 2) After approval for surgery and during the period leading up to the day of surgery, they will receive instructions concerning medication adjustment, lifestyle modifications, fasting rules, and hygiene measures.
223605576|NCT07065201|DEVICE|Mobile application and standard care|Patients in the control group will be asked to download the same mobile app but they will not receive the same tailored information as those in the intervention group. Instead, they will be provided with standard preoperative information and instructions. In addition, they will be asked to fill out the same questionnaire as the intervention group.
223605577|NCT07065032|DRUG|ZT002 Injection|Q2W, subcutaneous injection
223605578|NCT07065032|DRUG|ZT002 Injection|Q2W, subcutaneous injection
223752799|NCT04828954|OTHER|Immobilization for 2-weeks postoperative|Non-removable thumb spica plaster postoperative splint immobilization worn for 2 weeks
223752800|NCT04828954|OTHER|Immobilization for 6-weeks postoperative|Non-removable postoperative thumb spica splint immobilization worn for 2 weeks (+/- 3 days), to be transitioned to thumb spica cast for an additional 4 weeks (Total of 6 weeks immobilization)
223605579|NCT07065032|DRUG|ZT002 Placebo|Participants will receive the same volume as the study drug in each cohort.
223605580|NCT07064993|OTHER|Observation|Routine monitoring and observation
223605581|NCT07064993|PROCEDURE|Experimental|Administration of tramadol and dexmethasone to arthroscopy solution
223605582|NCT06900205|DRUG|Esketamine|loading dose:intravenous infusion of 0.25mg/kg esketamine after induction of aneshtesia; postoperative intravenous analgesia:1.5ug/kg sufentail+1mg/kg esketamine diluted into 100ml will be provided to the patients after surgery at a rate of 2ml/h for 48h.
223605583|NCT06900205|DRUG|0.9 % saline|loading dose:intravenous infusion the same volume of 0.9% saline as the other group after induction of aneshtesia; postoperative intravenous analgesia:1.5ug/kg sufentail diluted into 100ml will be provided to the patients after surgery at a rate of 2ml/h for 48h.
224075392|NCT02213809|BEHAVIORAL|Traditional education in COPD|Traditional education in this study means that the teacher mainly speaks to the group. Although short cases may be used for illustration, the main focus is not that the group shall solve problems from a narrative case.
224075393|NCT01239160|DEVICE|Flexitouch System|"A segmental, programmable, gradient pneumatic compression device. It consists of a controller and garment set. The garments are constructed of nylon and have 27-32 chambers, depending upon garment size. The pressure setting is variable between normal and increased. The device is intended to be used for 60 minutes per day"
224075394|NCT01239160|DEVICE|Hydroven FPR|The FH is an intermittent sequential external pneumatic compression system. The garment contains 3 compression chambers. The pressure range of the compressor device is 30-100 mmHg. It is intended to be used for 60 minutes per day.
224075395|NCT02288338|DRUG|1 (Lipitor®)|atorvastatin calcium 40mg, Lipitor® 40mg will be administered to healthy volunteers during 7days
224075396|NCT02288338|DRUG|1 (Ezetrol®)|After 11days withdrawal period, ezetimibe 10mg, Ezetrol® 10mg will be administered to healthy volunteers during 7days
224200495|NCT04846049|OTHER|Standard Care|No intervention or treatment will be provided.
224200496|NCT03505606|DIAGNOSTIC_TEST|Visual acuity tests|Participants to have visual acuity tested with the three modified vision tests.
224200497|NCT00739206|DRUG|SAR97276A|Dose based on body weight
224200498|NCT02287142|PROCEDURE|Brachial plexus nerve block|All arms of the study comparing the three different blocks are receiving the same single injection bolus of ropivacaine 0.5% prior to surgery. We will then record and compare pain scores in PACU and opioid requirement.
224200499|NCT01826032|DEVICE|CPAP|CPAP treatment every night plus standard care for OSA: lifestyle, and sleep hygiene counselling
224200500|NCT01826032|OTHER|Standard care for OSA|sleep higiene and dietary counseling
223605584|NCT07065162|OTHER|Subtle Touch Technique|3 cycles of ACBT along with subtle touch technique for 15 minutes 3 times daily for 8 weeks, in addition to the standard COPD care and medication.
223605585|NCT07065162|OTHER|Active Cycle of Breathing Technique|3 cycles of ACBTs technique for 15 minutes 3 times daily for 8 weeks, along with standard COPD care and medication.
223605586|NCT07064681|PROCEDURE|Surgery with and without the aid of Indocyanine Green (ICG)|Enrolled patients will receive surgery and be follow up for 2 years
223605587|NCT06853444|DRUG|ESG206|Administered via intravenous (IV) infusion
223605588|NCT06853444|DRUG|ESG206|Administered via intravenous (IV) infusion
223605589|NCT06853444|DRUG|ESG206|Administered via intravenous (IV) infusion
223605590|NCT06853444|DRUG|ESG206|Administered via intravenous (IV) infusion
223605591|NCT06772064|DRUG|Rifaximin (drug)|Rifaximin 0.4g bid for 2 weeks
223605592|NCT05715242|BEHAVIORAL|Core Behavioral Weight Loss Intervention|All participants will receive a 10-week core behavioral weight loss treatment consisting of: self-monitoring weight, steps, and food intake; behavioral lessons; action plans; and tailored feedback. The intervention will be delivered remotely via email and digital tools (such as a smart scale, Fitbit activity tracker, and Fitbit app).
223605593|NCT05715242|BEHAVIORAL|Easier Step Goal|Participants will receive an easier daily step goal.
223605594|NCT05715242|BEHAVIORAL|Harder Step Goal|Participants will receive a more challenging daily step goal.
223605595|NCT05715242|BEHAVIORAL|Easier Calorie Goal|Participants will receive an easier daily calorie goal.
223605596|NCT05715242|BEHAVIORAL|Harder Calorie Goal|Participants will receive a more challenging daily calorie goal.
224200501|NCT05965232|DIAGNOSTIC_TEST|Fibroscan|"Performing FibroScan :~The patient is positioned supine, with the right arm in maximum abduction to clear the intercostal spaces.The measurement itself is performed on the right lobe of the liver via the intercostal (intersection of the mid-axillary line and the xiphoid process) using a dedicated probe (3.5 MHz) after application of a conduction gel to the skin. FibroScan® examinations are carried out by personnel trained in the use of the device.This training is specific and validated by the device's manufacturer manufacturer, EchosensTM (Paris). Ten valid measurements at the same measurement point in the right liver must be be performed, with an interquartile range/median ratio ≤ 30 (required only if the elastometry value is \> 7.1 KPa."
224200502|NCT00540982|DRUG|indocyanine green|0.5 mg/kg will be administered by IV push to determine clearance
224200503|NCT00540982|DRUG|lidocaine|1 mg/kg will be administered to determine metabolic capacity
224200504|NCT00540982|DRUG|vinorelbine ditartrate|Varying doses ranging from 30 mg/m2 to 7.5 mg/m2 will be administered based upon liver function
223605597|NCT05715242|BEHAVIORAL|Easier Eating Window Goal|Participants will receive an easier daily eating window goal.
223605598|NCT05715242|BEHAVIORAL|Harder Eating Window Goal|Participants will receive a more challenging daily eating window goal, akin to time-restricted eating.
223605599|NCT05715242|BEHAVIORAL|Easier Red Zone Food Goal|Participants will receive an easier daily Red Zone Food goal.
223605600|NCT05715242|BEHAVIORAL|Harder Red Zone Food Goal|Participants will receive a more challenging daily Red Zone Food goal.
223605601|NCT06661798|PROCEDURE|orthognathic surgery|Mandibular setback, Maxillary advancement, Bilateral sagital split osteotomy
223605602|NCT06661798|PROCEDURE|USG examination|Comparison of blood flow in the mental foramen before and 1week, 1 month and 3 month after orthognathic surgery using ultrasound examination
223605603|NCT06661798|PROCEDURE|Subjective evaluation - Neuro-sensitivity tests|Direction determination, two-point separation, pinprick, and brush tests, along with neurosensitivity VAS and pressure VAS, were applied to the patients. These tests were performed before surgery (T0), seven days after surgery (T1), one month after surgery (T2), and three months after surgery (T3).
223618176|NCT05416905|DEVICE|GPi-DBS|The patients will be treated with deep brain electrode implantation of GPi target under local and general anesthesia. Except that the surgical target was GPi, the operation process, stimulator switch-on time, and postoperative medication were the same as those in the STN-DBS group.
223618177|NCT05177614|DIETARY_SUPPLEMENT|Upper-level multiple micronutrient-fortified bouillon cube|80 µg/g Folic acid 1.2 µg/g Vitamin B12 3 mg/g Zinc (ZnO) 4 mg/g Iron (FePP/citric acid/trisodium citrate) 200 µg/g Vitamin A (retinyl palmitate) 30 µg/g Iodine (KIO3)
223618178|NCT05177614|DIETARY_SUPPLEMENT|Lower-level multiple micronutrient-fortified bouillon cube|28.8 µg/g Folic acid 0.288 µg/g Vitamin B12 1.68 mg/g Zinc (ZnO) 1.3 mg/g Iron (FePP/citric acid/trisodium citrate) 96 µg/g Vitamin A (retinyl palmitate) 30 µg/g Iodine (KIO3)
223618179|NCT05177614|DIETARY_SUPPLEMENT|Iodine-fortified bouillon cube|30 µg/g Iodine (KIO3)
223618180|NCT04816474|BEHAVIORAL|Online education and Phone Counseling Service|Online education total of 6 times for 6 weeks. Phone Counseling Service total of 6 times for 6 weeks
223618181|NCT04154475|DIETARY_SUPPLEMENT|yogurt diet|500 g yogurt/day
223618182|NCT04154475|DIETARY_SUPPLEMENT|dairy diet|500 g non-yogurt dairy products
223618183|NCT04154475|DIETARY_SUPPLEMENT|standard diet|500 g soya-yogurt
223618184|NCT01163526|PROCEDURE|CT perfusion|
223618185|NCT00965250|DRUG|IMC-12|20 mg/kg intravenously once every three weeks
223618186|NCT04184570|OTHER|Observational Trial|Observational Trial
223618187|NCT04387513|PROCEDURE|Cardiac surgery|Cardiac surgery, if indicated, delayed or not by neurological complications
223618188|NCT00549315|DEVICE|Valiant Endoluminal Stent-Graft Stent-Graft Balloon Catheter|VALIANT stent-graft endoprosthesis is inserted by the Xcelerant Delivery System via a surgical cutdown (e.g., external iliac artery, femoral artery, common iliac artery conduit, etc.) approach. The insertion method depends on each patient's anatomy and is determined by the Clinical Investigator.
224075397|NCT02288338|DRUG|1 (Lipitor®, Ezetrol®)|After 11days withdrawal period, atorvastatin calcium 40mg, Lipitor® 40mg and ezetimibe 10mg, Ezetrol® 10mg will be administered to healthy volunteers during 7days
224075398|NCT02288338|DRUG|2 (Ezetrol®)|ezetimibe 10mg, Ezetrol® 10mg will be administered to healthy volunteers during 7days
224075399|NCT02288338|DRUG|2(Lipitor®, Ezetrol®)|After 11days withdrawal period, atorvastatin calcium 40mg, Lipitor® 40mg and ezetimibe 10mg, Ezetrol® 10mg will be administered to healthy volunteers during 7days
224075400|NCT02288338|DRUG|2 (Lipitor®)|After 11day withdrawal period, atorvastatin calcium 40mg, Lipitor® 40mg will be administered to healthy volunteers during 7days
224075401|NCT02288338|DRUG|3(Lipitor®, Ezetrol®)|atorvastatin calcium 40mg, Lipitor® 40mg and ezetimibe 10mg, Ezetrol® 10mg will be administered to healthy volunteers during 7days
223605604|NCT07066085|DEVICE|Serial Blood Count Study|"A new home monitoring device called Athelas One (or Athelas Home) was granted an FDA 510K Class 2 clearance for evaluation of white blood count (WBC) and absolute neutrophil count (ANC).~The device uses a drop of blood on a slide to measure the WBC and ANC. The drop of blood is obtained using a lancet that comes with the device, it is just like how diabetics do with a glucose monitoring device. The process will be done once a day for 42 days (6 weeks) unless the drop is not placed on the slide correctly. If there is an issue with the first attempt, the process could be done again to obtain the WBC and ANC results.~The Athelas device is intended for use by patients with neutropenia or patients at risk of neutropenia. The device is indicated for use by patients and caregivers within home settings with results viewable by health care professionals."
223618189|NCT04528160|OTHER|Pain neuroscience education and exercise|PNE will be conducted in line with international guidelines and will cover the neurophysiology of pain, transition from acute to chronic pain and the nervous system ability to modulate the pain experience. Exercise will included genera exercise delivered at moderate intensity.
223618190|NCT04528160|OTHER|Usual Care|Usual care delivered at primary care for older adults with pain.
223618191|NCT02221869|DRUG|Xyrem|
223618192|NCT00066677|DRUG|rhuMAB-VEGF|
223618193|NCT00066677|DRUG|docetaxel|
223618194|NCT05774301|BEHAVIORAL|simulation-based training|the training will include a theoretical \& practical parts
223618195|NCT02108249|DEVICE|Annex™ Adjacent Level System|
223618196|NCT04332107|DRUG|Azithromycin|Participants will be shipped a single 1.2 g dose of oral azithromycin
223618197|NCT04332107|DRUG|Placebos|Participants will be shipped a dose of matching placebo
223618198|NCT02348593|DRUG|JZP-110|
223618199|NCT02348593|DRUG|Placebo oral tablet|
223618200|NCT00001118|DRUG|Enfuvirtide|
223618201|NCT05742477|DRUG|Antibiotic|role of antibiotics in treatment of neonatal sepsis
223618202|NCT00879385|DRUG|Dacogen™ (decitabine)|"Dacogen™ (decitabine) is a FDA approved drug (NDA - 021790) for the treatment of myelodysplastic syndromes (MDS) including previously treated and untreated, de novo and secondary MDS (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia).~Decitabine will be given on this study at 45 mg/m2 IV over 2 hrs"
223618203|NCT00879385|DRUG|Vectibix® (panitumumab)|"Vectibix® (panitumumab) is a FDA approved drug (BLA-125147) indicated as a single agent for the treatment of EGFR-expressing metastatic colorectal carcinoma with disease progression on or following fluoropyrimidine, oxaliplatin, and irinotecan chemotherapy regimens. Approval is based on progression-free survival; no data demonstrate an improvement in disease-related symptoms or increased survival.~DRUG DESCRIPTION Vectibix® (panitumumab) is a recombinant, human IgG2 kappa monoclonal antibody that binds specifically to the human epidermal growth factor receptor (EGFR). Panitumumab has an approximate molecular weight of 147 kDa. Panitumumab is produced in genetically engineered mammalian (Chinese Hamster Ovary) cells.~Panitumumab will be given on this study at 6 mg/kg, IV over 1 hr"
223618204|NCT04608565|DEVICE|Remote biomonitoring sensor device|Same as described in arm descriptions. Safety was ensured by getting radiant warmer and multichannel probe examined and services by the biomedical engineering department; calibration certificates were obtained and these were used routinely in care of other neonates. An adverse event reporting and resolution protocol for the wearable sensor devices to capture number and severity of adverse events; individual clinical management and feedback for changes into device design. Adverse events recorded were: dermatitis, infection, thermal injury, radiation injury, device leak/burst and others.
223618205|NCT05775770|DRUG|Insulin|insulin therapy
223618206|NCT05217277|DIAGNOSTIC_TEST|Humans ELISA kits|"ELISA (enzyme-linked immunosorbent assay) is a plate-based assay technique designed for detecting and quantifying soluble substances such as peptides, proteins, antibodies, and hormones.~The saliva of the patients included in the study will be examined with ELISA kits after they are taken."
223618207|NCT00871871|DRUG|Hydrochlorothiazide (HCTZ)|HCTZ 50 mg (two 25 mg capsules) once daily for 4 weeks per treatment period.
223618208|NCT00871871|DRUG|Comparator: Placebo to HCTZ|Placebo to HCTZ two 0 mg capsules once daily for 4 weeks per treatment period
223618209|NCT00871871|DRUG|Isosorbide mononitrate (ISMN)|ISMN 60 mg extended release capsule once daily for 4 weeks per treatment period
223618210|NCT00871871|DRUG|Comparator: Placebo to ISMN|Placebo to ISMN 0 mg capsule once daily for 4 weeks per treatment period
223618211|NCT03952013|OTHER|To explore health literacy levels in patients hospitalized for acute neuro-cardiovascular diseases i.e. stroke, myocardial infarction, or heart failure|All patients included and followed within one of the three cohorts studies: LOOP-HF, HIBISCUS-STEMI and HIBISCUS-STROKE who accepted to participate in the study, will be contacted by phone (attempted calls are set to 3 to reach the patient), mail or during a consultation, to answer to a health literacy questionnaire. The patient will participate in the study only once. The estimated duration is therefore estimated at 1 day for each patient and two month for the study. Thanks to the many following periods within the cohorts (6 months, 1 year and 18 month), we will measure health literacy at different times of the care.
223618212|NCT02093793|DEVICE|PRECISION SCS Adapted for High-Rate SCS|Comparison of spinal cord stimulation parameters
223618213|NCT01808196|DRUG|Losartan Potassium|The dose of study drug is dependent on body weight and tolerance but did not exceed 100 mg.
223618214|NCT05676112|DRUG|nintedanib|nintedanib
223618215|NCT05676112|DRUG|pirfenidone|pirfenidone
223618216|NCT05297591|OTHER|assessment of UL function and prognostic factors|clinical assessments and questionnaires
223752801|NCT03343483|BEHAVIORAL|Volunteering|"Volunteers provide non-medical caregiving for frail seniors-care receivers-to help them maintain their independence and improve their well-being. Friendly visiting is the primary service provided. Structured, intensive training is provided prior to placement. The target expectation is of interactions in person and/or by telephone for at least 16 hours per month. On-going training (booster sessions) as well as volunteer support groups, and educational activities are provided. Participants not interested in serving as peer companions are allowed other volunteer options as long as the activities are deemed 'social' by the volunteer coordinator and are options routinely provided as part of the AmeriCorps Senior RSVP Program. COVID update: due to physical distancing requirements, volunteer placements have transitioned to remote friendly calling/letter writing or activities that can be conducted with physical distancing, such as delivery for Meals on Wheels."
223605605|NCT07066085|DEVICE|Athelas Home device|"A new home monitoring device called Athelas One (or Athelas Home) was granted an FDA 510K Class 2 clearance for evaluation of white blood count (WBC) and absolute neutrophil count (ANC).~The device uses a drop of blood on a slide to measure the WBC and ANC. The drop of blood is obtained using a lancet that comes with the device, it is just like how diabetics do with a glucose monitoring device. The process will be done once a day for 42 days (6 weeks) unless the drop is not placed on the slide correctly. If there is an issue with the first attempt, the process could be done again to obtain the WBC and ANC results.~The Athelas device is intended for use by patients with neutropenia or patients at risk of neutropenia. The device is indicated for use by patients and caregivers within home settings with results viewable by health care professionals."
223605606|NCT06906185|BEHAVIORAL|Calm Moms-V|Calm Moms-V is the trauma-informed treatment developed and refined by the PI and being tested in the current study. Calm Moms-V is an online treatment program for trauma-exposed pregnant Veterans designed to target anxiety, stress, low mood, and trauma-related symptoms using empirically supported CBT techniques. Calm Moms-V includes four sessions and a booster session closer to delivery/postpartum. Sessions 1-4 are designed to be completed across four weeks (one session delivered each week). Each session is self-paced and designed to take approximately 45 minutes to complete.
223605607|NCT06906185|BEHAVIORAL|Care As Usual|"The control condition will be Care As Usual (CAU). CAU at SLVHCS involves participation in available services chosen by the patient with input from their providers. Further, for all pregnant Veterans that use VHA maternity benefits, CAU includes routine phone calls (throughout pregnancy and up to one-year postpartum) conducted by the site MCC to coordinate maternity benefits, facilitate additional services, and arrange for specific supplies (e.g., breast pump). Further, the SLVHCS MCC mails each pregnant Veteran enrolled in VHA a welcome packet that includes national, local, and VHA MH and physical health resources that may be useful to them during the perinatal period. Veterans in the CAU condition will be assessed at the same intervals as those in the active condition."
223605608|NCT06903936|OTHER|Group 1: GNB (GENICULAR NERVOUS NERVOUS BLOCK) group:|6 ml of solution consisting of 5 ml 2% lidocaine hydrochloride and 1 ml 40 mg triamcinolone acetonide will be injected equally into the superomedial, inferomedial and superolateral genicular nerve branches using a 23G (0.6\*60mm) needle under ultrasound guidance.
223605609|NCT06903936|OTHER|Group 2: PT (PHYSICAL THERAPY) group|Group 2: PT (PHYSICAL THERAPY) group: In the PT group, all interventions will be performed with the patient supine and knees in extension. First, superficial heating will be applied using a hotpack for 20 minutes, followed by therapeutic ultrasound in continuous mode at a frequency of 1 MHz and 1.5 Watt/cm2 for 5 minutes to achieve deep thermal effects. Then traditional transcutaneous electrical nerve stimulation (TENS) will be applied for 15 minutes for a total of 15 sessions.
223605610|NCT06903936|OTHER|Group 3: Exercise group|Group 3: Control group: For 3 weeks, exercise therapy will be applied by the patient. Knee range of motion exercises, quadriceps strengthening exercises, hamstring stretching exercises will be taught to the patients by the doctor and they will be asked to do them every day, 2 times a day, 10 repetitions for a total of 3 weeks. The use of NSAIDs will be restricted during the treatment period.
223605611|NCT02623075|BIOLOGICAL|Influenza vaccine|Blood samples will be collected at research study visits at 0 and 30 days (+/- 2 days) post-IIV4 (influenza vaccine). Collection will be as follows: 45-50 ml blood at each visit (not to exceed more than three visits over a two month period).
223752802|NCT03343483|BEHAVIORAL|Life Review|Subjects will complete a self-guided life review exercise over 12 months. Subjects will complete one section of the life review (with the self-help book) each month and send 'assignments' once per month to an email 'counselor' who will respond with supportive comments within three days.
223752803|NCT03047109|DRUG|Phenylephrine|30 patients will receive Phenylephrine 30 µg/minute by syringe pump infusion for 30 minutes.
223752804|NCT03047109|DRUG|Ephedrine|30 patients will receive Ephedrine 3 mg/ minute by syringe pump infusion for 30 minutes.
224200505|NCT00540982|OTHER|high performance liquid chromatography|Used to determine plasma concentrations of vinorelbine
224200506|NCT00540982|OTHER|intracellular fluorescence polarization analysis|Used to determine concentration of lidocaine metabolic capacity
224200507|NCT00540982|OTHER|liquid chromatography|Used to determine concentrations of vinorelbine and its metabolites
224200508|NCT00540982|OTHER|mass spectrometry|Used to determine concentrations of vinorelbine and its metabolites
224200509|NCT00540982|OTHER|pharmacological study|Determination of concentrations of vinorelbine and its metabolites
224200510|NCT02087865|DRUG|donepezil HCL|
224200511|NCT02087865|DRUG|Placebo|
224200512|NCT01164280|OTHER|Pulse Rate Change|Different pulse rate settings of the implantable neurostimulator
224200513|NCT03781817|DRUG|Intravenous Ketamine|Subject randomized to IV Ketamine arm will receive IN Normal Saline at induction. After 8 minutes subjects will receive IV Ketamine (10 mg/mL) at a dose of 1.5 mg/kg. Level of sedation will be scored at the 15 minutes from induction to determine if adequate sedation has been achieved.
224200514|NCT03781817|DRUG|Intranasal Ketamine|Subject randomized to IN Ketamine arm will receive IN Ketamine (100 mg/mL) at a dose of 9 mg/kg at induction. After 8 minutes subjects will receive IV Normal Saline. Level of sedation will be scored at the 15 minutes from induction to determine if adequate sedation has been achieved.
224200515|NCT01392469|DRUG|Imatinib|Film coated tablets, oral administration
224200516|NCT01392469|DRUG|Sildenafil|Oral Administration
224200517|NCT01392469|DRUG|Bosentan|Oral Administration
224200518|NCT04945980|DIETARY_SUPPLEMENT|Ground beef|Ground beef naturally low in monounsaturated fatty acids or naturally high in monounsaturated fatty acids
223752805|NCT04146064|OTHER|Breathprint analysis and patient-reported outcomes|"Breathprint analysis: Patients will be providing breathprint samples into the eNose device at baseline and every 12 weeks thereafter as long as on immunotherapy treatment.~Questionnaires will be completed at the same timepoints."
223752806|NCT04758377|PROCEDURE|Magnetic resonance imaging (MRI)|Serial MRI scans of patients with acute cervical SCI to quantify hemorrhage.
223752807|NCT03500146|DRUG|Anticholinergic|Patients prescribed medication for OAB
223752808|NCT03500146|PROCEDURE|PTNS|Patients prescribed PTNS for OAB
223752809|NCT04846725|OTHER|Data collection|"Collect in medical records :~* Filter's retrieval rate~* Complications of vena cava filters~* Predictive factors of attempted inferior vena cava filters retrieval: age, the distance between the patient's home and the hospital, the indication or not given by the therapeutic medicine department, patients referred by external structures, patients whose filter was installed during the medical on-call period, the absence of a written request for filter placement, the presence of active neoplasia at the time of filter placement, a peri-surgical context."
223605612|NCT06913075|DRUG|GnRH agonist downregulation|Triptorelin Acetate 3.75mg for two consecutive dosage at 30 days interval
223605613|NCT06913075|DRUG|GnRH agonist and Letrozole|Triptorelin Acetate 3.75mg for two consecutive dosages at 30 days interval) + Letrozole (5 mg once daily for a total of 21 days during the second depot - letrozole stops when Estrogen priming starts
223605614|NCT06917014|PROCEDURE|360°|reset the proximal and distal part of the niche, widely 360° coagulation to restore and change the shape and size of niche, and ultimately improve symptoms of patients.
223605615|NCT06917014|PROCEDURE|traditional|reset the proximal part of the niche, and coagulation to restore and change the shape and size of niche, and ultimately improve symptoms of patients.
223605616|NCT03265457|OTHER|Specular microscopy|Comparison between corneal Endothelial count in patients with pseudoexfoliation syndrome and age matched group
223605617|NCT06917989|OTHER|Relaxation Exercise|Jacobson muscle relaxation technique
223605618|NCT06917989|OTHER|Virtual Reality Application|Virtual Reality Application will be done using virtual reality glasses
223752810|NCT01505608|DRUG|TPI 287|Subjects will receive six cycles of intravenous (IV) TPI 287 at a dose of 125 mg/m2 on Days 1, 8 and 15 of a 28-day cycle.
223752811|NCT01505608|DRUG|Temozolomide|Oral (PO) Temozolomide at a dose of 100mg/m2 on days 1-5 of each 28 day cycle
223752812|NCT01505608|DRUG|Irinotecan|Intravenous (IV) Irinotecan at a dose of 10mg/m2 on days 1-5 and 8-12 of each 28 day cycle.
223752813|NCT02699944|DEVICE|ECG Vest Optimization|As part of a standard and clinically indicated CRT optimization procedure utilize an ECG Vest as one modality for collecting information to determine best device programming.
223752814|NCT00004804|DRUG|interferon alfa|
223752815|NCT01865162|OTHER|ketogenic diet|Treatment will consist of ketogenic diet. KD will consist of 4:1 \[fat\] : \[protein+carbohydrate\] weight ratio with 1600 kcal restriction. The diet will be supplemented with vitamins, calcium, phosphorus, zinc and selenium supplements to meet the requirements of US Dietary Reference Intakes (DRI) standard.
223752816|NCT06099977|PROCEDURE|Binaural sound|Binaural sound: Binaural sound will be applied.
223752817|NCT06099977|PROCEDURE|Placebo|Only headphone without sound will be applied.
223752818|NCT00203970|BEHAVIORAL|Observation|Using a data abstraction form, we wish to gather the following information: 1) Patient demographics 2) identity of the attending, residents, and interns caring for the patient 3)whether the patient had any absolute or relative contraindications for receiving LMWH 4) how the patient was treated for his/her condition
223605619|NCT06917989|OTHER|Patient Education|Participants will be informed about oral care, food consumption, nutrition and sleeping position.
223605620|NCT06919380|DRUG|MSC-exos Nebulization Therapy|"The intervention in this study, Nebulized MSC-exos for Anti-MDA5+ RP-ILD Treatment, is distinguished by its use of mesenchymal stem cell-derived exosomes (MSC-exos) for direct pulmonary delivery via nebulization. This targeted approach aims to modulate immune responses and reduce inflammation specific to lung diseases, offering a novel therapeutic strategy. This method stands out for its potential to provide a safer and more effective treatment for RP-ILD compared to traditional therapies."
223605621|NCT06922344|DRUG|Fluconazole|Oral fluconazole prescribed to group A
223605622|NCT06922344|DRUG|Itraconazole|Oral itraconazole prescribed to Group B
223605623|NCT06920602|DEVICE|AI-empowered voice-interactive chatbot|Participants will interact with the chatbot on a daily basis to record their migraine experiences. They will be asked to initiate a conversation with the chatbot whenever they experience a migraine attack and provide the required information, including the date and time of the attack, presence of aura, migraine intensity, accompanying symptoms, triggers, and medication use. The chatbot will engage participants in a conversation to collect these data points and store them securely within the chatbot system.
223605624|NCT06920602|DEVICE|Paper migraine diary|Participants will manually document their migraine experiences on the paper migraine diary, including the date and time of the attack, presence of aura, migraine intensity, accompanying symptoms, triggers, and medication use.
223605625|NCT06920602|DEVICE|Paper migraine diary|Participants will manually document their migraine experiences on the paper migraine diary, including the date and time of the attack, presence of aura, migraine intensity, accompanying symptoms, triggers, and medication use.
223752819|NCT00963261|BEHAVIORAL|psycho-oncological intervention|stepped care treatment program with different elements (patient information, exercise, psychoeducation, individual and group therapy, psycho-pharmacology)
223752820|NCT04318496|OTHER|Press Tack Acupuncture|PYONEX Φ0.20×0.6 mm made by Seirin Corporation
223752821|NCT04318496|OTHER|Press Tack Placebo|PYONEX placebo sticker made by Seirin Corporation
223752822|NCT06376253|DRUG|[68Ga]Ga-EVS459|Radioligand imaging agent
223752823|NCT06376253|DRUG|[177Lu]Lu-EVS459|Radioligand therapy
223752824|NCT01399242|DRUG|Certican|Patients' therapy will be replaced from tacrolimus-based to everolimus-based immunosuppression. Everolimus will be introduced on day 1 at dose of 2 mg/day (1mg bid), and then everolimus trough levels will be obtained from day 3 onwards until C0 reaches the target for three consecutive days. Through levels will be adjusted to achieve 6-10ng/ml. Thereafter, if the target level was reached, the measurement will be performed weekly for 4 weeks and every 2 weeks until 8 weeks after conversion.In parallel, the tacrolimus dose will be reduced by 50% on day 1 and another 25% on day 7. The Tacrolimus will be withdrawn on day 14 if the target levels of everolimus are obtained.EC-MPS will be unchanged until day 14 after conversion.
223752825|NCT02259361|DRUG|Sustained-release oral dalfampridine|One Sustained-release oral dalfampridine; 10 mg tablet, twice daily, taken 12 hours apart (one tablet in the morning and one tablet in the evening) taken for 14 consecutive days.
223752826|NCT02259361|DRUG|Placebo|Placebo, 10 mg tablet, twice daily, taken 12 hours apart (one tablet in the morning and one tablet in the evening) taken for 14 consecutive days.
223752827|NCT00253383|OTHER|counseling intervention|
223752828|NCT00253383|OTHER|educational intervention|
223752829|NCT00253383|PROCEDURE|psychosocial assessment and care|
223752830|NCT00253383|PROCEDURE|quality-of-life assessment|
223752831|NCT02479256|DRUG|Clomiphene citrate|Women will receive one tablet of clomiphene citrate oral tablets 50 mg (Clomid®, aventis/Egypt) twice daily 12 hours apart (total dose 100 mg daily) from the 3rd day of the menses for 5 days, for only one menstrual cycle.
223752832|NCT02479256|DRUG|Tamoxifen Placebo|Women will receive one tablet of placebo of tamoxifen oral tablets twice daily 12 hours apart from the 3rd day of the menses for 5 days, for only one menstrual cycle.
223752833|NCT02479256|DRUG|Tamoxifen|Women will receive one tablet of tamoxifen oral tablets 10 mg (Tamoxifen®, amriya/Egypt) twice daily 12 hours apart (total dose 20 mg daily) from 3rd day of the menses for 5 days, for only one menstrual cycle.
223752834|NCT02479256|DRUG|Clomiphene citrate placebo|Women will receive one tablet of placebo of clomiphene citrate twice daily 12 hours apart from 3rd day of the menses for 5 days, for only one menstrual cycle.
223605626|NCT06920602|DEVICE|AI-empowered voice-interactive chatbot|Participants will interact with the chatbot on a daily basis to record their migraine experiences. They will be asked to initiate a conversation with the chatbot whenever they experience a migraine attack and provide the required information, including the date and time of the attack, presence of aura, migraine intensity, accompanying symptoms, triggers, and medication use. The chatbot will engage participants in a conversation to collect these data points and store them securely within the chatbot system.
223605627|NCT02915978|DRUG|Fentanyl|Fentanyl delivered via sublingual spray
223752835|NCT00908726|DRUG|propofol|Each subject received both propofol formulations in a crossover fashion separated by a 7-day washout period, and the order of the drug administration was randomized. Subjects received both propofol formulations (Lipid emulsion propofol: Diprivan® and Microemulsion propofol: AquafolTM) during 60 min. The infusion rate was assigned according to a nonblinded, randomized design to 1.5, 3, 6, or 12 mg/kg/hr.
223752836|NCT06470412|OTHER|Control group|Participants receive supplement prescriptions from a physician based on current standard practices, which include biochemical markers, genetic data, and metabolic profiles.
223752837|NCT06470412|OTHER|AI-Guided Group|Participants receive supplement prescriptions determined by GenAIS, an AI system which considers genetic data, metabolic profiles, biochemical markers, and patient history.
223752838|NCT06373497|DIAGNOSTIC_TEST|18-F-NaF Cardiac PET/MRI and|All eligible subjects will receive 18-F-NaF Cardiac PET/MRI at baseline and 6 months after the completion of radiotherapy where the heart is in the treatment field
223752839|NCT06373497|DIAGNOSTIC_TEST|CT Angiogram|All eligible subjects will receive CT Angiogram at baselin
223752840|NCT04033601|BEHAVIORAL|Non-pharmacological intervention|The non-pharmacological intervention will comprise sleep hygiene education, exercise training and relevant modules of cognitive behavioral therapy.
223605628|NCT02915978|DRUG|Placebo|Matching placebo delivered via sublingual spray
223605629|NCT03605914|DRUG|diclofenac|The non-steroidal anti-inflammatory drug (NSAID) used in this study is diclofenac.
223605630|NCT03605914|DRUG|Norco|The opioid used in this study is Norco. Norco is a combination medication that contains both an opioid pain reliever (hydrocodone) and a non-opioid pain reliever (acetaminophen).
223605631|NCT03262636|DRUG|Indocyanine Green|Indocyanine Green
223752841|NCT05774834|OTHER|No intervention|No intervention
223752842|NCT04809324|PROCEDURE|Gross examination of the resection specimen|measurement of the surgical margin by the operating surgeon using sterile scale, margins \<7mm will be revised on table
223752843|NCT04809324|PROCEDURE|Frozen section|frozen section evaluation of the specimen by the pathologist
223752844|NCT03975647|DRUG|tucatinib|300mg given twice per day by mouth (orally)
223752845|NCT03975647|DRUG|placebo|Given twice per day orally
223752846|NCT03975647|DRUG|T-DM1|3.6 mg/kg given into the vein (IV; intravenously) every 21 days
223605632|NCT06945263|PROCEDURE|Rectus Sheath Block|Bilateral rectus sheath blocks using an in-plane ultrasound-guided technique with 0.25% bupivacaine with epinephrine 1:200 000 at 0.8 mL/kg (half of total volume per side) up to a maximum of 20 mL prior to the incision.
223752847|NCT05957796|DEVICE|"Novel Snaps Eye Shield"|"Using a novel eye shield, Snaps manufactured in Morgantown, WV by Intermed Labs after cataract surgery that has a different adhesive mechanism that utilizes adhesive and snap-on attachments to the shield."
223752848|NCT05957796|OTHER|Standard Alcon Eye Shield|Use normal Alcon eye shield with tape to adhere to shield to eye postop.
223752849|NCT05788458|DRUG|Bupivacain|"The blocks will be performed in supine position under complete aseptic condition. The site to be blocked will be painted with 5% povidone iodine followed by 70% ethyl alcohol and draped. Linear high-frequency ultrasound probe (7 -15 mhz) (General Electric; GE, LOGIQ E) will be initially placed in a transverse plane over the anterior superior iliac spine (ASIS) and then alignes to identify the following landmarks: Anterior inferior iliac spine, ilio-pubic eminence, iliopsoas muscle and tendon, the femoral artery, and Pectineus muscle. Point of injection will be musculo-fascial plane between the psoas tendon and ilio-pubic eminence."
223752850|NCT05446883|DRUG|QL1706|Intravenous Infusion
223752851|NCT05446883|DRUG|Placebo|Intravenous Infusion
223752852|NCT05446883|DRUG|Paclitaxel injection|Intravenous Infusion
223752853|NCT05446883|DRUG|Cisplatin/Carboplatin|Intravenous Infusion
224200519|NCT01736527|DRUG|LE Gel|Single drop of LE Gel 0.5% administered to the study eye on visit 2
224200520|NCT00250965|DRUG|intravenous magnesium|Subjects will be randomized prior to surgery (1:1) to receive 5 g magnesium or placebo (saline) bolus by the anaesthesiologist upon removal of the crossclamp. On postoperative days 1 through 4, subjects will receive either IV MgSO4 (5g in 250 ml normal saline) or IV placebo (250 ml normal saline) infusion over 4 hours daily.
223752854|NCT06278324|DEVICE|Nasal Spray HSV Treatment|Nasal treatment with the nasal spray Humer Stop Virus for 7 days, 2-3 puffs per nostril, 3-4 per day, space applications 4 hours apart.
223752855|NCT02514837|DEVICE|RTM|Both the internal temperature and skin temperature will be measured non-invasively through the skin using the RTM device
224311427|NCT02517086|OTHER|elastic compression|exercises for upper limb will be performed for an hour associated with the use of elastic compression. Elastic compression will be effected through a clamp brand compression of 30-40 mmHg according to the measures of voluntary member.
223605633|NCT06945263|DRUG|Local Anesthetic at the Umbilical Port Site|0.25% bupivacaine with epinephrine 1:200 000. Total dose of 0.8 mL/kg (maximum 20 mL) at the umbilical port site.
223605634|NCT06945263|DRUG|Intravenous Dexamethasone|Intravenous Dexamethasone delivered concurrent to the RSB. Total dose of 150 mcg/kg up to a maximum of 8 mg.
223605635|NCT06945263|DRUG|Local Anesthetic at the Incision Site|The remaining volume of local anesthetic (0.2 mL/kg) can be infiltrated at each of the incision sites at the discretion of the surgeon up to a maximum of 10 mL.
223605636|NCT04811482|BEHAVIORAL|TCIT-CALM (Teacher-Child Interaction Training-CALM)|This intervention is designed to treat early childhood anxiety. It is an adaptation of parent-child interaction therapy (PCIT), in which teachers rather than parents are targeted as the therapeutic agent of change. The intervention follows the procedures of the CALM protocol, in which caregivers are taught play therapy skills to support and address anxious behaviors and avoidance.
223605637|NCT02275156|BIOLOGICAL|Evolocumab|Administered by subcutaneous injection
223605638|NCT03257683|DRUG|Ranolazine|Study group will receive additional therapeutic dosing of drug.
223752856|NCT04663581|OTHER|Left Sided Colonoscopy|Starting colonoscopy with the patient in left decubitus
223752857|NCT04663581|OTHER|Right Sided Colonoscopy|Starting colonoscopy with the patient in right decubitus
223752858|NCT05004233|BIOLOGICAL|Blood collection before antiplatelet treatment|Blood sample (17ml) will be collected in the neurovascular department to be processed for platelet ultrastructural analysis before the onset of an antiplatelet treatment
223752859|NCT05004233|BIOLOGICAL|Blood collection after antiplatelet treatment|"A follow-up will be carried out 5 to 8 days after the initiation of the treatment.~A blood test will be taken in the NeuroVascular Unit"
224075402|NCT02288338|DRUG|3 (Lipitor®)|After 11day withdrawal period, atorvastatin calcium 40mg, Lipitor® 40mg will be administered to healthy volunteers during 7days
224075403|NCT02288338|DRUG|3 (Ezetrol®)|After 11day withdrawal period, ezetimibe 10mg, Ezetrol® 10mg will be administered to healthy volunteers during 7days
224075404|NCT02288338|DRUG|4 (Lipitor®)|atorvastatin calcium 40mg, Lipitor® 40mg will be administered to healthy volunteers during 7days
224075405|NCT02288338|DRUG|4(Lipitor®, Ezetrol®)|After 11days withdrawal period, atorvastatin calcium 40mg, Lipitor® 40mg and ezetimibe 10mg, Ezetrol® 10mg will be administered to healthy volunteers during 7days
224075406|NCT02288338|DRUG|4 (Ezetrol®)|After 11day withdrawal period, ezetimibe 10mg, Ezetrol® 10mg will be administered to healthy volunteers during 7days
224200521|NCT04642040|OTHER|Pulmonary Rehabilitation|Positioning,breathing techniques (diaphragmatic breathing, alternate breathing, and pursed-lip breathing),respiratory muscle exercises, joint ROM exercises, early-mobilization and progressive ambulation, peripheral muscle strengthening exercises
224200522|NCT00511329|DRUG|somatropin [rDNA origin] for injection|Genotropin will be started at 0.3 mg/kg/week administered by daily subcutaneous injection. Doses will be increased by weight at each visit. Additionally, we will monitor IGF-1 levels at month 3, and 6 and adjust the Genotropin dose to maintain IGF-1 levels in the 50th -75th percentile for ages.
224200523|NCT00557986|PROCEDURE|Primary surgery|Primary breast surgery before systemic therapy
224200524|NCT00648739|DRUG|Samalizumab|Samalizumab is a humanized anti-CD200 monoclonal antibody.
224200525|NCT03042338|BEHAVIORAL|CET: Central Executive Training|CET: Central Executive Training
224311428|NCT02517086|OTHER|functional compressive bandaging|exercises for upper limb will be performed for an hour associated with the use of functional compressive bandaging. The functional compressive bandaging will be held with the volunteer sitting with ipsilateral upper limb resting on the support surgery. After hydration member a cotton mesh is used to prevent friction density 1cm strip of foam on the member to be wrapped. Elastic bandages of cotton will be involved 5 cm, 10 cm, 15 cm from the fingers to the axillary region multilayered
223605639|NCT03779815|DRUG|[18F]Florbetaben|"* Drug: \[18F\]Florbetaben~* \[18F\]Florbetaben PET/CT Imaging for detecting amyloidosis in multiple myeloma~* Other name: Neuraceq~* Amount: 300 MBq ± 20% bolus, 10mL intravenously"
223605640|NCT03392818|OTHER|The measured distance|To measure the distance between the upper edge of the thyroid cartilage to the upper edge of the sternum add the distance from the upper edge of the sternum to the carina calculated according to the chest CT scans as a guide to the placement of Uniblocker without the aid of Fiberoptic bronchoscope.
223605641|NCT03392818|OTHER|formula|Calculate the depth of intubation according to the formula of 0.1977\* patient's height - 4.2423
223605642|NCT03392818|DEVICE|Fiberoptic bronchoscope|The intubation of Uniblocker under the guidance of Fiberoptic bronchoscope
223605643|NCT00200668|DRUG|FDG = fluorodeoxyglucose|
223605644|NCT00902707|DRUG|Mucinex 1200mg|Compared to Placebo
223605645|NCT00902707|DRUG|Placebo|Compare to active Mucinex
223605646|NCT02343406|DRUG|Depatuxizumab mafodotin|Adults: intravenous administration (1.25 mg/kg or 1.0 mg/kg body weight) over 30 to 40 minutes once every 2 weeks until one of the treatment withdrawal criteria was met. The dose was 1.25 mg/kg in the original protocol (Version 1) and Version 2, Amendment 1, and was lowered to 1.0 mg/kg in protocol Version 3, Amendment 2. Pediatric participants: Intravenous administration (1.0 mg/kg body weight for those who were 6 to 17 years old at the date of first dose, or 1.3 mg/kg for those who were 0 to 5 years old) over 30 to 40 minutes or as directed by the guidelines once every 2 weeks until one of the treatment withdrawal criteria was met, for a maximum of one year. If used in combination with temozolomide, depatuxizumab mafodotin was dosed on Day 1 and Day 15 of the TMZ cycle (assuming a standard regimen of 200 mg/m\^2/day for 5 days of each 28-day cycle; for other TMZ schedules, timing of the depatuxizumab mafodotin dosing schedule were to be discussed with the medical monitor).
224200526|NCT03042338|BEHAVIORAL|CET: Comparison Executive Training|CET: Comparison Executive Training
223605647|NCT02343406|DRUG|Temozolomide|Capsules administered orally, 150 mg/m\^2 on Days 1-5 for the first 28-day cycle, with dose escalation to 200 mg/m\^2 in subsequent cycles in case of adequate tolerance until one of the treatment withdrawal criteria was met.
223605648|NCT02343406|DRUG|Lomustine|Capsules administered orally, 110 mg/m\^2 on Day 1 of every 42-day treatment period. Treatment continued until one of the treatment withdrawal criteria was met, for a maximum of one year.
223605649|NCT02816528|BEHAVIORAL|Training program|Physicians will be given informations regarding antibiotic consumptions and bacterial resistance in their activity area every 3 months during 12 months.
223605650|NCT04216576|OTHER|Paper Drug Diary|Participants will receive and use a paper Drug Diary and a paper medication calendar.
223605651|NCT04216576|OTHER|OhMD APP|Participants will receive multiple text messages regarding administration over time on medication self-management over the course of 3 cycles of medication
223605652|NCT05510336|PROCEDURE|Arthrocentesis|Injection of lactated ringer solution in the TMJ to wash out inflammatory mediators and help reducing anterior disc displacement with reduction
223752860|NCT04606979|DEVICE|1x1 Low Intensity Transcranial Direct Current Stimulation (tDCS)|"tDCS will be delivered through a pair of identical square rubber electrodes (size 35 cm2), placed in rectangular saline-soaked sponges. For the stimulation of M1, electrodes will be placed over C3 or C4 according to the 10-20 EEG system, matching with the M1 contralateral to the performing dominant hand. The reference electrode will be positioned on F1 or F2, ipsilateral to the dominant hand.~The current stimulation will be slowly ramped up from 0 mA to 2 mA in one minute. For the anodal tDCS condition, this intensity will be maintained for the duration of the SRT-task (approximately 20 minutes). This will result in a current density of 0,057 mA/cm2. For the sham tDCS condition - unbeknown to the subject - stimulation will be gradually decreased towards 0 mA immediately after the one-minute ramp-up. During the last block of the SRT-task, this gradual ramping-up and -down of the current stimulation will be repeated to optimize the process of blinding of participants."
223752861|NCT02404350|BIOLOGICAL|Secukinumab|Anti IL-17a monoclonal antibody
223752862|NCT05993676|BEHAVIORAL|MeT4VeT mobile phone app: control|The control/ sham comparator arm of the Mental Health Toolkit for Veterans (MeT4VeT) smart phone app contains only signposting information around support services available to military veterans
223752863|NCT05993676|BEHAVIORAL|MeT4VeT mobile phone app: intervention|"The Mental Health Toolkit for Veterans (MeT4VeT) smart phone app has been developed through careful and close collaboration with military veterans and key providers of veterans' mental healthcare services. The aim of this app is to provide both a degree of education to support military veterans' understanding of mental health and foster self-recognition and management of mental health symptoms whilst also encouraging those who need it to seek more formal support.~The elements of the app have been chosen for inclusion as they represent the intersection between:~1. Core components of cognitive behavioural therapy, the theoretical framework underwriting the app~2. Behaviour change constructs"
223752864|NCT01972672|DRUG|Icaritin|Icaritin 600 mg orally, twice daily for a total daily dose of 1200 mg
223752865|NCT03149250|DIAGNOSTIC_TEST|Aggregometry, Monitoring of plasmatic hemostasis|Multiple Electrode Aggregometry using the Multiplate system Coagulation factor analyses (FXIII, FVIII, vWF) Parameters of conventional coagulation testing (aPTT, INR, Platelet count)
224075407|NCT02288338|DRUG|5 (Ezetrol®)|ezetimibe 10mg, Ezetrol® 10mg will be administered to healthy volunteers during 7days
224075408|NCT02288338|DRUG|5 (Lipitor®)|After 11day withdrawal period, atorvastatin calcium 40mg, Lipitor® 40mg will be administered to healthy volunteers during 7days
224311429|NCT06207214|OTHER|Self-help book for university students.|"The intervention being tested, is a self-help book for university students based on Acceptance and Commitment Therapy. The book was published in 2021 and is called The Unbreakable Student: 6 Rules for Staying Sane at University. The book is by Dr Nic Hooper.~The self-help book will be posted in paper form to all participants. There are 8 chapters in the book and participants will be given eight weeks to read the book at home (with a suggestion of reading one chapter per week)."
223605653|NCT02451124|DEVICE|non-endoscopic inflatable balloon for the esophagus|Undergo non-endoscopic brushing of the esophagus using a non-endoscopic inflatable balloon for the esophagus
224075409|NCT02288338|DRUG|5 (Lipitor®, Ezetrol®)|After 11days withdrawal period, atorvastatin calcium 40mg, Lipitor® 40mg and ezetimibe 10mg, Ezetrol® 10mg will be administered to healthy volunteers during 7days
224075410|NCT02288338|DRUG|6(Lipitor®, Ezetrol®)|atorvastatin calcium 40mg, Lipitor® 40mg and ezetimibe 10mg, Ezetrol® 10mg will be administered to healthy volunteers during 7days
224075411|NCT02288338|DRUG|6 (Ezetrol®)|After 11days withdrawal period, ezetimibe 10mg, Ezetrol® 10mg will be administered to healthy volunteers during 7days
224075412|NCT02288338|DRUG|6 (Lipitor®)|After 11day withdrawal period, atorvastatin calcium 40mg, Lipitor® 40mg will be administered to healthy volunteers during 7days
223605654|NCT02451124|OTHER|Questionnaire Administration|Ancillary studies
223605655|NCT02451124|OTHER|Laboratory Biomarker Analysis|Correlative studies
223605656|NCT02451124|PROCEDURE|esophagogastroduodenoscopy|Standard of care, patients digestive tract scoped post balloon brushing
223605657|NCT00262899|BEHAVIORAL|counseling intervention|
223605658|NCT00262899|OTHER|educational intervention|
223605659|NCT00262899|PROCEDURE|psychosocial assessment and care|
223605660|NCT00273429|DRUG|timolol maleate 0.5%|
223605661|NCT00273429|DRUG|dorzolamide/timolol maleate fixed combination|
223605662|NCT00273429|DRUG|latanoprost 0.005%|
223605663|NCT00273429|DRUG|placebo|
223605664|NCT00268541|BEHAVIORAL|Physical activity|
223605665|NCT01324362|DRUG|Placebo|Twice daily dosing
223605666|NCT01324362|DRUG|Placebo|Twice daily dosing
223605667|NCT01324362|DRUG|FP 100mcg|Twice daily dosing
223605668|NCT01324362|DRUG|FP 250mcg|Twice daily dosing
223605669|NCT01324362|DRUG|FP 500mcg|Twice daily dosing
223605670|NCT01324362|DRUG|FSC 100/50mcg|Twice daily dosing
223605671|NCT01324362|DRUG|FSC 250/50mcg|Twice daily dosing
223605672|NCT01324362|DRUG|FSC500/50mcg|Twice daily dosing
223605673|NCT05463250|DEVICE|Smartwatch|Wearing a smartwatch and having access to its data
223605674|NCT04585841|DRUG|Cannabidiol|Patients will receive cannabidiol in the period of time they receive chemotherapy.
223605675|NCT00196456|PROCEDURE|photosensitisation|
223605676|NCT00004050|BIOLOGICAL|Leuvectin|Leuvectin injected intratumorally followed by prostatectomy
223605677|NCT00958165|DEVICE|CardioFocus EAS-AC|PVI for PAF
223605678|NCT01189981|BEHAVIORAL|Lifestyle counseling|One health conversation at baseline
223605679|NCT01189981|BEHAVIORAL|eHealth intervention|SMS based encouragements to intensive exercise
223605680|NCT02799498|DEVICE|Auto-injector device|Single 50 mg subcutaneous dose of liquid etanercept (ENBREL®) in a 1.0 ml pre-filled syringe administered via an auto-injector device manufactured by Scandinavian Health Limited (SHL)
223605681|NCT02799498|OTHER|Etanercept (ENBREL®) via Manual injection|Single 50 mg subcutaneous dose of liquid etanercept (ENBREL®) in a 1.0 ml pre-filled syringe administered via manual injection (reference treatment) to compare to the auto-injection
223605682|NCT02799498|DRUG|Etanercept (ENBREL®)|Single 50 mg subcutaneous dose of liquid etanercept (ENBREL®) in a 1.0 ml pre-filled syringe administered via an auto-injector device manufactured by Scandinavian Health Limited (SHL)
223605683|NCT02017925|BEHAVIORAL|exercise intervention|Undergo pulmonary rehabilitation
223605684|NCT02017925|PROCEDURE|pulmonary complications management/prevention|Undergo pulmonary rehabilitation
223752866|NCT03731533|BEHAVIORAL|WellStart|"1. Five weekly automated text messages linked to an online article on health and wellness.~2. Five weekly automated health coach motivational text message to smart phone. Optional back and forth text with their health coach is available.~3. Daily Option to participate and post comments or questions in online discussion forum moderated by health coaches.~4. Three group (up to 20 participants) health coach online visits (60 minutes).~5. Two online group visits with a dietitian in groups of 10-12 participants.~6. Three one-on-one online visits with a Physician Advisor to review progress, review any changes in medications by the primary medical provider (PCP), review biometrics and lab results, review safety guidelines and symptoms (30 minutes)."
223605685|NCT02017925|PROCEDURE|quality-of-life assessment|Ancillary studies
224075413|NCT03995264|PROCEDURE|Ultrasound -guided cannulation|radial artery cannulation using the ultrasound
224075414|NCT03995264|PROCEDURE|Palpation -guided cannulation|radial artery cannulation using the palpation
224200527|NCT02712359|OTHER|Blood sample collection|A blood sample (\~5mL) will be collected from all subjects at each cross-sectional survey (Year 8 and Year 10).
224200528|NCT00003652|DRUG|cisplatin|
224200529|NCT00003652|DRUG|fluorouracil|
224200530|NCT00003652|PROCEDURE|neoadjuvant therapy|
223605686|NCT02017925|OTHER|questionnaire administration|Ancillary studies
223605687|NCT02085304|PROCEDURE|Gross total resection and Gliadel(R) wafers implanted|Complete removal of tumor and implant of Gliadel(R) wafers that are small, dime-sized wafers designed to deliver the chemo drug, carmustine, directly into the cavity made when the brain tumor was removed.
223605688|NCT02085304|RADIATION|GammaKnife(R) stereotactic Radiosurgery|GammaKnife® (GK) radiosurgery dose of 15 Gy in one fraction to the resection cavity margin
223605689|NCT02085304|RADIATION|Standard fractionated radiation therapy|standard fractionated RT of 60 Gy in 30 fractions (over approximately six weeks)
223605690|NCT02085304|DRUG|Temozolomide|temozolomide 75 mg/m2 daily for 42 days, will be administered to all patients beginning within 24 hours of GK/RT initiation as is routine clinical care. There will be a one month drug holiday following the 42 days before adjuvant chemotherapy begins. Adjuvant temozolomide administered 5 days monthly at 150-200 mg/m2/day will be administered for 12 months as is routine clinical care.
223605691|NCT04659525|DRUG|Evolocumab|In the intervention arm evolocumab 140 mg subcutaneous every 2 weeks will be administered for 24 weeks to high cardiovascular risk haemodialized statin intolerant patients with hypercholesterolemia
224075415|NCT04146610|DRUG|an antibody drug conjugate|Multiple dose grouping
224075416|NCT04781816|DRUG|SAR443122|Pharmaceutical form: Capsule Route of administration: Oral
224200531|NCT00003652|RADIATION|radiation therapy|
223605692|NCT04659525|DRUG|Ezetimibe|Ezetimibe 10 mg daily will be administered for 24 weeks to high cardiovascular risk haemodialized statin intolerant patients with hypercholesterolemia in both the placebo arm (plus placebo) and in the intervention arm (plus evolocumab)
223605693|NCT04659525|DRUG|Placebo|In the placebo arm placebo subcutaneous every 2 weeks will be administered for 24 weeks to high cardiovascular risk haemodialized statin intolerant patients with hypercholesterolemia
223605694|NCT04070612|OTHER|Blood sample|A blood sample of 2 times 2 to 5 ml additional maximum
223605695|NCT04551950|DRUG|M7824|Participants received bintrafusp alfa until confirmed disease progression, death, unacceptable toxicity and study withdrawal maximum of 2 years (at the discretion of the Investigator).
223605696|NCT04551950|DRUG|Carboplatin|Carboplatin was administered intravenously as per standard of care.
223605697|NCT04551950|DRUG|Paclitaxel|Paclitaxel was administered intravenously as per standard of care.
223605698|NCT04551950|DRUG|Bevacizumab|Bevacizumab was administrated as indicated for standard of care.
223605699|NCT04551950|DRUG|Cisplatin|Cisplatin was administered intravenously as per standard of care.
223605700|NCT04551950|RADIATION|Radiotherapy|Participants received radiotherapy as per standard of care.
223605701|NCT03501940|PROCEDURE|Computed Tomography|Undergo 18F-DCFPyL PET/CT
223605702|NCT03501940|RADIATION|Fluorine F 18 DCFPyL|Given IV
223605703|NCT03501940|OTHER|Laboratory Biomarker Analysis|Correlative studies
224075417|NCT04781816|DRUG|Placebo|Pharmaceutical form: Capsule Route of administration: Oral
224075418|NCT03174483|DRUG|Hypertonic saline|nasal spray
224075419|NCT03174483|DRUG|Fluticasone Nasal|nasal spray
224075420|NCT00144183|DRUG|Nevirapine (NVP)|Nevirapine 200mg once daily for 14 days followed by 200mg twice daily thereafter for the remainder of the treatment period. Combivir®, one tablet twice daily.
224075421|NCT00144183|DRUG|Zidovudine (ZCV)|
224075422|NCT00144183|DRUG|3TC|
224075423|NCT03322059|BEHAVIORAL|Experimental|Participants will receive a fitbit and lifestyle counseling to increase steps. Weekly newsletter for first 6 weeks, bi-weekly for remaining weeks with behavioral content designed to increase physical activity (e.g., barriers, SMART goals). They will also receive a donation to a cancer charity of their choice if they meet daily step goals.
224075424|NCT03322059|BEHAVIORAL|Control|Participants will receive a fitbit and lifestyle counseling to increase steps. Weekly newsletter for first 6 weeks, bi-weekly for remaining weeks with behavioral content designed to increase physical activity (e.g., barriers, SMART goals).
223752867|NCT04848935|DEVICE|CURATE.AI|CURATE.AI will be utilised to provide personalised training intensity recommendations (low, medium or high) to the patients during the digital cognitive test battery DI session. The difficulty of each task will be modulated by CURATE.AI by adjusting the frequency of critical events that demand evaluation and/or response.
223752868|NCT02119065|PROCEDURE|positron emission tomography|Undergo PET/CT scan
223752869|NCT02119065|PROCEDURE|computed tomography|Undergo PET/CT scan
224200532|NCT05068700|DEVICE|Integrated Pulmonary Index|Medtronic Capnostream 35p monitoring parameter
224200533|NCT05068700|DEVICE|Standard capnography monitoring|Medtronic Capnostream 35p monitoring parameter
224200534|NCT05808907|OTHER|Questionnaire|A novel TAVI PROMs questionnaire will be created by us and used for this study.
224200535|NCT04942561|DEVICE|Samsung Gear VR|Participants 13 -21 years old can use the Samsung Gear VR. The VE is mobile based (Samsung with the Gear VR) and has active matrix LCDs with high pixel resolution, creating a bright, vibrant color and a quality image. Participants will engage with BearBlast (appliedVR™), a multi-sensory VR game in which users travel on a pre-set path through a colorful, highly-interactive 3-D environment filled with animated landscapes, buildings, and clouds, during which the user's gaze controls the direction of a firing cannon to knock down teddy bears. The VR game is equipped with a head-tracking system, enabling the player to look around the VE. Therefore, the child will be receiving distraction via 3-D visual and auditory sensory, thus supplying a multi-sensory immersive experience. While wearing these glasses, the children only can see the HMD screen so that the immersion and presence will be increased. The VR glasses will be sanitized before every use to minimize chance of infection.
224311430|NCT00574912|DRUG|Placebo|single dose of Placebo injected s/c at 8am and monitor blood glucose over 24 hours
224200536|NCT04942561|DEVICE|Merge VR|Participants 10-21 years can use the Merge. The VE to be used in this study is mobile based (Pixel with the Merge) and has active matrix LCDs with high pixel resolution, creating a bright, vibrant color and a quality image. Participants will engage with BearBlast (appliedVR™), a multi-sensory VR game in which users travel on a pre-set path through a colorful, highly-interactive 3-D environment filled with animated landscapes, buildings, and clouds, during which the user's gaze controls the direction of a firing cannon to knock down teddy bears. The VR game is equipped with a head-tracking system, enabling the player to look around the VE. Therefore, the child will be receiving distraction via 3-D visual and auditory sensory, thus supplying a multi-sensory immersive experience. While wearing these glasses, the children only can see the HMD screen so that the immersion and presence will be increased. The VR glasses will be sanitized before every use to minimize chance of infection.
224200537|NCT01261650|DEVICE|transcranial direct current stimulation|
224200538|NCT01261650|DEVICE|sham treatment|
223752870|NCT05042882|DIETARY_SUPPLEMENT|Early enteral nutrition|Enteral nutrition via nasojejunal tube
223752871|NCT03880721|PROCEDURE|Microwave abaltion|Use microwave ablation to treat hepatocellular carcinoma
223752872|NCT06227507|BEHAVIORAL|Front-of-package label|Participants will identify the healthfulness of three packaged foods, each displayed with front-of-package labels as specified by their assigned group.
223752873|NCT01959152|DEVICE|HiRes™ 90K Advantage implant with HiFocus™ Mid-Scala electrode|
223752874|NCT00464828|PROCEDURE|Internal jugular vein cannulation|
223752875|NCT00464828|DEVICE|ultrasound|
223752876|NCT00600756|DRUG|Quetiapine XR|Oral, once daily, tablets of 400 mg to 800 mg
224200539|NCT00564486|DRUG|IV Placebo|IV, every 6 hours for 24 hours (4 doses total)
224200540|NCT00564486|DRUG|IV Placebo|IV, every 4 hours for 24 hours (6 doses total)
224200541|NCT00564486|DRUG|IV Acetaminophen|IV, every 6 hours for 24 hours (4 doses total)
224200542|NCT00564486|DRUG|IV Acetaminophen|IV, every 4 hours for 24 hours (6 doses total)
224200543|NCT05645263|OTHER|dieting Coca-cola|The patients all dieted Coco-cola to treat gastric phytobezoars, 250ml-500ml/2 h till to sleeping time according to the health conditions and life habits. Pay more attention to the stools and assess if the bezoars had excreted. The dieting Coco-cola period of group A is 3 days, group B is 5 days and group C is 7 days.
224200544|NCT02415634|OTHER|RECAP|"Patients will receive an information pack at ICU discharge called the RECAP. This pack will include~* Part 1: A critical care discharge summary (UCCDIP) (Bench and Day, 2012)~* Part 2: A rehabilitation goal setting care plan~* Part 3: A patient communication forum~* Part 4: Useful supports and contact information~* Part 5: Tailored exercise programme~The patient will have a consultation with the ICU physiotherapist before ICU discharge once weekly thereafter for 3 weeks . The focus of the session will be to discuss goal attainment and associated challenges.~The ICU therapist will meet once weekly with the patient's primary physiotherapist to provide clinical support if necessary, in determining the patient's needs post critical care."
224200545|NCT02415634|OTHER|Control|Participants allocated to the control group will receive standard physiotherapy intervention post ICU discharge
224200546|NCT01246102|DRUG|AT13387|Treatment will be administered as a 1-hour IV infusion on 2 consecutive days of every week for 3 weeks, followed by a 1-week period without drug administration.
224311431|NCT00574912|DRUG|Insulin Glargine 0.5 u/kg body wt SC|8 weeks later, a differing dose (0.5, 1.0, 1.5, 2.0 u/kg body wt.) of Insulin Glargine and monitoring over a 24 hour period each separated by 8 weeks (5 separate study visits)
224311432|NCT00574912|DRUG|Insulin Glargine 1.0 u/kg body wt SC|
224311433|NCT00574912|DRUG|Insulin Glargine 1.5 u/kg body wt SC|
224311434|NCT00574912|DRUG|Insulin Glargine 2.0 u/kg body wt SC|
223752877|NCT00600756|DRUG|Risperidone|Oral, once daily, tablets of 2 mg to 6 mg
223752878|NCT00144586|DRUG|MRA(Tocilizumab)|8mg/kg/4 weeks
223752879|NCT00013117|BEHAVIORAL|Telephone specialist consultation|
223752880|NCT05933161|DEVICE|Freestyle Libre 3 Continuous Glucose Monitor (CGM)|Subjects will be provided a Freestyle Libre 3 CGM for monitoring of blood glucose levels throughout participation in the study (approximately 3 months). CGM data will be uploaded to the LibreLink app on a weekly basis for review of glucose control and consultation with a diabetes-trained provider for any values outside of normal ranges. Adjustments to diet and medication therapy (antihyperglycemic therapy) will be made during consultations to improve episodes of hypoglycemia or severe hyperglycemia that were observed.
223752881|NCT06355427|DRUG|[18F]F-FAPI PET-CT|\[18F\]F-FAPI PET-CT in addition to regular CT and MRI, prior to participants undergoing surgery
223752882|NCT01767922|DIETARY_SUPPLEMENT|Extramel 10 mg - 140 UI SOD|"Subjects took one capsule of Extramel® 140 IU, or its corresponding placebo, daily over 12 weeks.~Each volunteer was seen for the 3 visits:~* visit V1, so-called inclusion visit (D0),~* visit V2 at 28 days, tolerance of +/- 3 days, (D28) and~* visit V3 at 84 days, tolerance of +/- 3 days, (D84)."
223752883|NCT01767922|DIETARY_SUPPLEMENT|Placebo - Excipient only|
223752884|NCT06559111|DEVICE|2-week casting followed by 4-week bracing|Participants in the bracing group had a cast for 2 weeks after the surgery followed by ankle brace for 4 weeks.
223752885|NCT06559111|DEVICE|6-week casting|Participants in the casting group had a cast for 6 weeks after the surgery.
223752886|NCT05844852|DEVICE|P200TE|The P200TE provides OCT imaging including retinatopography and ONH (optic nerve head) scans.
223752887|NCT05384184|PROCEDURE|Tumor /metastases removal|Tumor /metastases removal
223752888|NCT05585034|BIOLOGICAL|XmAb®808|Monoclonal bispecific antibody
223752889|NCT05585034|BIOLOGICAL|Keytruda® (pembrolizumab)|Monoclonal antibody
223752890|NCT02049242|PROCEDURE|triple tourniquet|"Triple tourniquet consist of two tourniquet applied both infundibulopelvic ligaments and one uterine isthmus to occlude the left and right ovarian vessels and to occlude the uterine arteries. For this purpose, a small opening is made in the avascular place of the broad ligament on either side of the uterine isthmus superior to the uterine vessels. A pediatric Foley catheter is threaded through the two holes and tied tightly anteriorly around the cervix at the level of the internal os.~Through the same openings in the broad ligament each side a Foley catheter looped around the infundibulopelvic ligament lateral to the fallopian tube and ovary."
224200547|NCT04457323|DRUG|Metoprolol|S-Metoprolol XR 25 mg and 50 mg Film Coated Tablets
224200548|NCT04457323|DRUG|Metoprolol|Beloc® (Metoprolol) Zok 50 mg and 100 mg Controlled Release Film Tablets
223508105|NCT06173648|DEVICE|Laser and ICG solution.|Intervention consists of addition of a combined laser absorption solution and infrared diode laser. The solution is introduced into the prepared pulp chamber and root canals, allowed to dwell for 1 minute, followed by exposure to the laser energy delivered via a fiber optic introduced into the root canal, and while activating the laser at 2.5 watts of optical output with a pulse duration of 100 msec and a pulse gap of 300 msec, the solution and residual structures in the root and pulp chamber are exposure over the course of 30 seconds, moving and relocating the fiber tip throughout the canals and chamber during that time. The laser is halted and a wait time of 30 seconds is applied. The laser fiber is then reintroduced and another 30 second exposure, repeating the same settings and technique.
224200549|NCT02387723|BIOLOGICAL|Allogeneic adipose derived stem cells (CSCC_ASC)|Culture expanded allogeneic adipose derive stem cells (CSCC\_ASC)
223508106|NCT07056387|OTHER|A nurse-led community-based sailing programme|A nurse-led community-based sailing programme is validated by an expert panel including professionals from various fields, such as a registered nurse, academia, and qualified sailing instructors, delivered in a group of 6 participants, incorporating experiential learning, with the aid of materials including dinghies with Universal design, safety boats, buoys, buoyancy aids, supplementing with a waterproof sailing booklet. The intervention is developed and facilitated by a registered nurse (principal investigator).
223508107|NCT07056387|OTHER|Crafting activities|Participants in the attention control group will participate in crafting activities. Activities match the time and attention dedicated by the intervention group. Activities are designed to have no impact on resilience.
223508108|NCT01852136|DEVICE|BD NEXT 31G x 5 mm pen needle|Each pen needle type will be used for approximately one week. Subjects will use their current pen injector device.
223508109|NCT01852136|DEVICE|BD NEXT 31G x 8mm pen needle|Each pen needle type will be used for approximately one week. Subjects will use their current pen injector device.
223508110|NCT01852136|DEVICE|BD NEXT 32G x 4mm pen needle|Each pen needle type will be used for approximately one week. Subjects will use their current pen injector device.
223508111|NCT00757900|BIOLOGICAL|MUTAGRIP|Purified polyvalent vaccine for active immunisation against influenza.The vaccine is an inactivated split virus mixture of different group A and B viral strains. One 0.5 ml dose, intramuscular route.
223508112|NCT03362593|DRUG|MEDI7219|Experimental Drug
223508113|NCT03362593|DRUG|Placebo|Placebo
223508114|NCT03362593|DRUG|Formulation without Active Drug|Formulation without Active Drug
223508115|NCT04077359|DIAGNOSTIC_TEST|CT|the CT consist of four phases; non-enhanced, corticomedullary, nephrographic and excretory phase.
223508116|NCT06134700|PROCEDURE|Laparoscopic Surgery|"* Surgery will then proceed at either 8 - 10 or 12 - 15 mmHg pneumoperitoneum pressure depending on study group the patient falls into~* Port Placement~* Reflection of colon~* Isolation of ureterogonadal packet~* Upper pole dissection~* Hilar dissection~* Vessel clipping and division~* Dissection of kidney~* Delivery through either Pfannenstiel or iliac fossa incision"
223508117|NCT01365572|DEVICE|Xiene V stent, Endeavor Resolute stent|for each lesion, randomized either Xience V stent or Endeavor Resolute stent
223508118|NCT04853875|DRUG|Tetracycline, Metronidazole, Bismuth subcitrate|52 participants (Group A) are randomly assigned to receive intraluminal eradication of H. pylori with medicament containing Tetracycline, Metronidazole, and Bismuth subcitrate
223508119|NCT04853875|DRUG|Amoxicillin, Metronidazole, Clarithromycin|52 participants (Group B) are randomly assigned to receive intraluminal eradication of H. pylori with medicament containing Amoxicillin, Metronidazole, and Clarithromycin
224200550|NCT04700813|DIAGNOSTIC_TEST|search for rare pathogenic mutations|search for rare pathogenic mutations causing diabetes type 2
223508120|NCT06271980|OTHER|ENCORE|A panel of microRNA, whose expression level is tested in macro-dissected formalin-fixed and paraffin-embedded (FFPE) samples derived from the primary tumor.
223508121|NCT06211790|DRUG|Anlotinib, Everolimus and Tislelizumab|Anlotinib (PO, QD), Everolimus (PO, QD) and Tislelizumab (IV, Q3W)
224200551|NCT03191435|DEVICE|Inspiratory muscle training.|Patients will perform the inspiratory muscle training using a moderate load of 30% of maximal inspiratory pressure (MIP 30%). The training will be conducted at home in a period of 30 minutes, 7 times a week, during 12 weeks. During inspiratory muscle training, individuals will attend Hospital de Clinicas de Porto Alegre once a week to the supervision of the way the exercise is being performed. Furthermore, load in the device (powerbreathe) will be adjusted for the individual to use next week.
224311435|NCT02958423|DEVICE|Transcranial DCS Healthy Volunteers|The DC stimulator manufactured by NeuroConn (Germany) will be used to deliver anodal direct current stimulation over the right primary motor cortex of healthy volunteers
223605704|NCT03501940|PROCEDURE|Positron Emission Tomography|Undergo 18F-DCFPyL PET/CT
223605705|NCT03167021|OTHER|Survey|This observational and transversal study will be conducted as a survey using the REDCap software and the response to this survey will be done online, in real time, with an automatic, secure and centralized data collection (CHU Clermont-Ferrand).
223605706|NCT00014833|OTHER|No intervention|No intervention
223605707|NCT06015087|OTHER|fasting diet|A total of 50 patients with breast cancer will be randomly devided in intervention and control group. Intervention group will follow a 60 hours fasting diet (36h prior and 24h after chemotherapy infusion), low in calories, mainly plant based, and the Mediterranean Diet in the meantime between chemotherapy cycles. Control group will receive only standard of care. Nutritional counseling and dietary records will be performed by registered dietitian. Adherence to the Mediterranean Diet will be estimated with MedDietScore. Grade of toxicity will be estimated by using the National Cancer Institute Common Terminology Criteria for Adverse Events. All participants will be encourange to continue usual physical activity.
223605708|NCT04443309|DRUG|Camrelizumab|Camrelizumab 200mg,iv,d1,q2w
223605709|NCT04443309|DRUG|Lenvatinib|Lenvatinib 8mg (\<60kg) or 12mg (≥60kg),po,d2,qd
223605710|NCT05848427|OTHER|LUSZ P|LUSZ protocol applied to WOSS in-hospitalized Covid-19 patients: a Corticosteroid Therapy-enhanced Standard Care (CTSC), a standard care enhanced by corticosteroid (methylprednisolone) treatment.
223605711|NCT00407303|DRUG|Obatoclax mesylate|30 mg, 45 mg
223605712|NCT00407303|DRUG|Bortezomib|1.0mg/m2, 1.3 mg/m2
223605713|NCT02277912|DEVICE|navigated rTMS of motor cortex|Navigated repetitive transcranial magnetic stimulation of the motor cortex ( 10 Hz ) ,5 daily sessions per week for two weeks.
223752891|NCT02049242|PROCEDURE|Single tourniquet|Single tourniquet is tourniquet applied uterine isthmus to occlude the uterine arteries. For this purpose, a small opening is made in the avascular place of the broad ligament on either side of the uterine isthmus superior to the uterine vessels. A pediatric Foley catheter is threaded through the two holes and tied tightly anteriorly around the cervix at the level of the internal os.
223752892|NCT05368545|DRUG|High intensity lipid lowering|Two different regimens of drugs with different effects on LDL lowering
223752893|NCT06473480|DEVICE|Abbott FreeStyle Libre System 2 Plus|The sensor is placed subcutaneously at the back of the participant's upper arm with one insertion and measures the subcutaneous glucose concentration.
224200552|NCT03191435|DEVICE|Placebo inspiratory muscle|Patients will perform the inspiratory muscle training using a very low load of 2% of maximal inspiratory pressure (MIP 2%). The training will be conducted at home in a period of 30 minutes, 7 times a week, in the course of 12 weeks. During inspiratory muscle training, individuals will attend Hospital de Clinicas de Porto Alegre once a week to the supervision of the way the exercise is being performed.
223605714|NCT02277912|DEVICE|navigated rTMS of somatosensory cortex 2|Navigated repetitive transcranial magnetic stimulation of the secondary somatosensory cortex ( 10 Hz ), 5 daily sessions per week for two weeks
223605715|NCT02277912|DEVICE|SHAM rTMS with SHAM block|Repetitive SHAM transcranial magnetic stimulation of the motor cortex ( 10Hz) 5 daily sessions per week for two weeks.
223605716|NCT03579810|OTHER|Investigational|"The educational intervention helped to increase the knowledge of attitudes, and habits of healthy lifestyle in children, parents and teachers and it was based on health promotion models and social cognitive theory, to be articulated with the Institutional Educational Project through the pedagogical component that integrates three areas, physical activity, healthy eating, and the knowledge of the body and the heart with the dynamics of the educative community.~The program covered self-care of the body and heart, healthy diet, and physical activity"
224311436|NCT02958423|DEVICE|Transspinal DCS Healthy Volunteers|The DC stimulator manufactured by NeuroConn (Germany) will be used to deliver anodal direct current stimulation over the D10 spinal process of healthy volunteers
224311437|NCT02958423|DEVICE|Transcranial DCS CPP patients|The DC stimulator manufactured by NeuroConn (Germany) will be used to deliver anodal direct current stimulation over the right primary motor cortex of CPP patients
223605717|NCT03579810|OTHER|Control|The control group did not receive an educational intervention in areas of physical activity, healthy eating, and the knowledge of the body and the heart. Instead, children received the standard curriculum in health and physical activity of the national Ministry of Education.
223605718|NCT04180332|DIAGNOSTIC_TEST|Blood sample|5ml of venous blood was taken from the ante cubital vein from each of the study subjects
224311438|NCT02958423|DEVICE|Transspinal DCS CPP patients|The DC stimulator manufactured by NeuroConn (Germany) will be used to deliver anodal direct current stimulation over the D10 spinal process of CPP patients
224311439|NCT03456154|DRUG|Botox Injectable Product|60u will be used at 3 sites of masseter muscle, on each side of the face
224311440|NCT03456154|DEVICE|Occlusal splint|In this group patients will receive an occlusal splint which will be worn everyday for 6 months at night.
223605719|NCT03360474|BEHAVIORAL|Delirium Screen|Patients who screen positive for delirium will be assessed for pain, electrolyte imbalances,infection, the use of deliriogenic medications and any issues will be resolved. Those with persistent delirium following all other intervention will be treated with antipsychotic medication.
223605720|NCT01354119|PROCEDURE|Aortic stent-graft|Early intervention with aortic stent-graft
223605721|NCT05695274|BEHAVIORAL|Progressive muscle relaxation exercise|Experimental group Fibromyalgia patients will be provided with progressive relaxation exercises twice a week. Progressive relaxation technique includes stretching and relaxing the bigmuscle groups (hands, arms, neck, shoulders, face, chest, abdomen,hip, feet andfingers) in the human body on purpose. When steps ofProgressive Relaxation Exercises are analyzed, it is observed thatlearning how to take correct and deep breaths is the most impor-tant step towards learning relaxation.
223605722|NCT03702036|DRUG|molibresib|molibresib 20 mg will be supplied for compassionate use for the identified individual subject.
223605723|NCT00166439|DRUG|Oxaliplatin, Cytosine Arabinoside, Dexamethasone With Rituxan (ROAD)|"rituximab 375 mg/m2 IV Weekly x 4 1 cycle only~dexamethasone 40 mg PO/IV Days 2-5 q 21 days 2 cycles~oxaliplatin 130 mg/m2 IV Day 2 q 21 days 2 cycles~cytosine arabinoside 2000 mg/m2 x 2 doses IV Days 2-3 q 21 days 2 cycles~pegfilgrastim 6 mg SQ Day 4 q21 days 2 cycles"
223605724|NCT05942599|BIOLOGICAL|Cryopreserved BE CAR33 T Cells (BE752TBTTBCAR33PBL)|Single-dose intravenous infusion (weight-based dosing) of a banded dose of CAR33+ T cells/kg. BECAR33 Total duration of treatment: 28 days follow up: 12 months
223605725|NCT04326582|OTHER|Observation|Determine of percentage of each type of arthritis in children, it's prognosis and outcome of treatment in comparison with international guidelines
223605726|NCT05463016|DEVICE|Experimental Group 1: Color Correcting Lenses|Color Correcting Lenses
223605727|NCT05463016|DEVICE|Placebo Group 1: Placebo Lenses|Placebo Lenses
223605728|NCT05463016|DEVICE|Placebo Group 1 Crosses over to become Experimental Group 2: Color Correcting Lenses|Color Correcting Lenses
223605729|NCT05463016|DEVICE|Experimental Group 1 Crosses over to become Placebo Group 2: Placebo Lenses|Placebo Lenses
223605730|NCT05463016|DEVICE|Color Correcting Lenses in Subjects with Normal Color Vision|Color Correcting Lenses
223605731|NCT00406536|DIETARY_SUPPLEMENT|Lym-X-Sorb powder|Lym-X-Sorb is an organized matrix of lyso phosphatidylcholine (LPC), free fatty acid (FFA) and monoglyceride formulated at 20wt% with flour and sugar. A dosage contains 32 grams of powder and is consumed with food twice a day (6 to 11.9 years old) or three times per day (12 to 17.9 years old) for 18 months.
223605732|NCT00406536|DIETARY_SUPPLEMENT|Placebo powder|The placebo is composed of soybean oil, sunflower oil, fully hydrogenated cottonseed oil and flax seed oil dispersed at 16wt% on flour and sugar. The placebo is \>99% triglycerides with no trans fatty acids. The fatty acid composition and caloric content is designed to match the active supplement (Lym-X-Sorb). A dosage contains 32 grams of powder and is consumed with food twice a day (6 to 11.9 years old) or three times per day (12 to 17.9 years old) for 18 months.
223605733|NCT04575207|DIAGNOSTIC_TEST|caFFR|caFFR is a new index of physiological assessment of coronary artery stenosis severity, based on angiographic images. Through two-dimensional analysis and three-dimensional reconstruction of two coronary angiography image series with an angle-off \> 30 degrees, combined with fluid mechanics, TIMI frame counting method, and optimized CFD algorithm, the pressure drop from coronary ostium to every point in the vessel can be obtained, and then the caFFR value of each point in the vessel can be computed. The cutoff value in this trial is caFFR ≤ 0.80 for myocardial ischemia.
223605734|NCT04575207|DIAGNOSTIC_TEST|FFR|FFR is a widely used, pressure-based functional assessment index of coronary stenoses obtained with an intracoronary pressure wire fitted with pressure sensors. The pressure wire passes through the stenosis and directly measures the pressure distal to the stenosis. FFR value can be obtained by combining the pressure at the coronary ostium and the distal pressure to the stenosis. The cutoff value in this trial is FFR ≤ 0.80 for myocardial ischemia.
223605735|NCT00496288|RADIATION|Prophylactic radiation to the contralateral breast|The contralateral breast will be treated with 2 tangent fields, using 1.8-2 Gy/fx to a total dose of 50-50.4 Gy. The whole breast will be treated according to traditional guidelines and as described in the RTOG/NSABP B39 study. The heart should be maximally blocked for left sided breasts, included lung tissue should be reduced to minimum. No overlapping field is allowed on the skin between the two breast fields in the midline. Maximal dose should not exceed 110%
223605736|NCT05613023|RADIATION|SBRT|Stereotactic Body Radiotherapy
223605737|NCT00615992|DRUG|Tiotropium|
223605738|NCT02518373|BIOLOGICAL|G17DT|G17DT is a therapeutic immunogen, formulated as a white, sterile, semi-viscous, water-in-oil emulsion (30:70 weight for weight). It was manufactured and supplied by Nova Laboratories Ltd., in glass ampoules containing 0.5 mL at a concentration of 1.25 mg/mL, as a single dose to be administered by intramuscular injection.
223605739|NCT02518373|DRUG|Omeprazole|Proton pump inhibitor used in the treatment of dyspepsia, peptic ulcer disease, gastroesophageal reflux disease, laryngopharyngeal reflux, and Zollinger-Ellison syndrome.
223605740|NCT03802591|DRUG|CS1001 monoclonal antibody|Participant will receive CS1001 monoclonal antibody by intravenous infusion every 3 weeks(Q3W), for up to 24 months
223605741|NCT03802591|DRUG|CS1001 placebo|Participant will receive CS1001 placebo antibody by intravenous infusion every 3 weeks(Q3W), for up to 24 months
223605742|NCT03802591|DRUG|Oxaliplatin|Administered as an IV infusion on Day 1 Q3W
223605743|NCT03802591|DRUG|Capecitabine|Administered by oral, twice a day on Day 1 - Day 14 of each cycle.
223605744|NCT01802125|OTHER|laboratory biomarker analysis|Correlative studies
223605745|NCT04685525|BEHAVIORAL|Mycobiome Supporting Diet|MSD takes combines elements from several diets (e.g., Paleo, low-carbohydrate, vegetarian, and Mediterranean) and excludes elements of these diets that have been specifically proven to increase pathogenic fungi in the human gut.
223605746|NCT02819791|OTHER|Optimized conventional therapy alone|Patients will benefit from a traditional follow-up as provided for this type of patients at 3 months and 1 year
223605747|NCT02819791|BEHAVIORAL|Optimized conventional therapy with therapeutic education|"The objectives of this therapeutic education program involve:~* learning objectives and acquisition of knowledge and self-care skills making the patient more autonomous and facilitating its adherence.~* the objectives of acquiring coping skills ( self-confidence , stress management , setting projects ) to improve their quality of life .~* the development objectives respects the relevant criteria of quality , realism and principle of educational progress."
223605748|NCT02219074|DEVICE|Sebacia microparticle and laser treatment|
223605749|NCT02219074|DEVICE|Vehicle and laser treatment|
224311441|NCT01008982|DRUG|LimphoStat-B|subjects will receive 10 mg/kg belimumab, in solution for infusion, monthly
223752894|NCT06473480|DEVICE|Abbott Freestyle Libre Pro|The sensor is placed subcutaneously at the back of the participant's upper arm with one insertion and measures the subcutaneous glucose concentration.
223752895|NCT03396614|DIAGNOSTIC_TEST|CTTC scan, cardiac MRI, ECG, 6 minute walking test, echocardiogram|CTTC scan, cardiac MRI, ECG, 6 minute walking test, echocardiogram
223752896|NCT02934906|PROCEDURE|Standard clinical treatment, including intravenous immunoglobulin and/or platelet transfusion|Observational study.
223752897|NCT05907096|BIOLOGICAL|ARGX-117|Intravenous administration of ARGX-117
223752898|NCT05907096|OTHER|Placebo|Intravenous administration of placebo
223752899|NCT02319031|DRUG|Daclatasvir|
223752900|NCT02319031|DRUG|Sofosbuvir|
224311442|NCT02116426|BIOLOGICAL|Blood work in the ambulance|Blood sample for copeptin and troponin HS testing is taken during ambulance care.
224311443|NCT02116426|BIOLOGICAL|Blood work upon arrival in the emergency room|Blood in drawn for copeptin and troponin HS testing upon arrival in the emergency room.
224311444|NCT02116426|BIOLOGICAL|Blood work at 3 hours post-arrival in the emergency room|Blood is drawn for troponin HS testing 3 hours after the patient's arrival in the emergency room.
224311445|NCT03715075|PROCEDURE|Caesarean Section|Caesarean Section
223752901|NCT02319031|DRUG|Ribavirin|
223752902|NCT02168010|DRUG|Analgecine|Analgesic drug under test
223752903|NCT02168010|DRUG|Neurotropin|Analgesic drug as positive control
223752904|NCT02168010|DRUG|Placebo|Blank tablet as placebo.
223752905|NCT03435965|DIAGNOSTIC_TEST|AmnioQuickDuo+|AmnioQuickDuo+ kit for detection of PROM
223752906|NCT03521258|DEVICE|Dehydrated Human Amnion/Chorion Membrane|
223752907|NCT03521258|PROCEDURE|Flap-Based Reconstructive Surgery|Standard of Care surgical intervention
223752908|NCT04525612|DIAGNOSTIC_TEST|68Ga-BNU-PSMA|Each patient receive a single intravenous injection of 68Ga-BNU-PSMA, and undergo PET/CT scan within specified time.
223752909|NCT06003530|BIOLOGICAL|hOMSC200|Human Oral Mucosal Stem Cells
223752910|NCT06003530|OTHER|Placebo|Animal component-free, defined cryopreservation medium with 5% DMSO
223752911|NCT02759666|DRUG|SHR3162|SHR3162 capsule(s) is administered orally QD.
223752912|NCT04692961|DEVICE|Elastography|Use elastography to evaluate the stiffness of lower leg muscle after peroneal artery-based free flap harvested
223752913|NCT00439556|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic hematopoietic stem cell transplantation
223752914|NCT00439556|BIOLOGICAL|Anti-Thymocyte Globulin|Given IV
224311446|NCT00375349|PROCEDURE|Ultrasound to demonstrate existence of fatty liver|
224311447|NCT02854111|OTHER|ice cream|The ice cream was made by nutritionists in Ramathibodi Hospital. It consisted of cornstarch, milk, sucrose, milk powder, egg yolk, and banana which contained carbohydrate 73.9 g, fat 27.7 g, protein 18.9 g for a total of 620.9 kcal with a cost of 35 bahts. The time for complete ingesting 75-g glucose and ice cream was 5 and 15 minutes, respectively.
223508122|NCT06466044|BEHAVIORAL|Auricular acupressure in concha area|The method of pressing beans on auricular points is based on the meridian theory and viscera theory in the basic theory of traditional Chinese medicine, combined with the knowledge of modern medical anatomy, and from the perspective of syndrome differentiation and treatment, relevant auricular points are selected, and appropriate stimulation such as kneading, pressing, pinching and pressing is given to the seeds of Vaccaria seed attached to the concha auricularis, so that the auricular points can produce acid, numbness, swelling and pain slowly and continuously. For therapeutic purposes.
223508123|NCT06466044|BEHAVIORAL|Auricular acupressure in earlobe|The auricular point pressing bean method is based on the meridian theory and viscera theory in the basic theory of traditional Chinese medicine, combined with the knowledge of modern medical anatomy, and from the perspective of syndrome differentiation and treatment, the relevant auricular points are selected, and the seeds attached to the ear lobe, which is the least innervated part of vagus nerve, are given appropriate stimulation such as kneading, pressing, pinching and pressing, so that the auricular points produce acid, numbness, swelling and pain slowly and continuously. For therapeutic purposes.
223508124|NCT06713317|DRUG|HLB3-002|Recombinant Hyaluronidase
223508125|NCT06713317|DRUG|0.9% NaCl|0.9% Normal saline
223508126|NCT06499948|DRUG|Treatment with Spironolactone followed by Dapagliflozin followed by their combination|After titrating the renin-angiotensin-system inhibitor dose, patients will receive 25 mg of Spironolactone once daily for 4 weeks. Spironolactone will be stopped after 4 weeks. The first treatment period will be followed by 4 weeks of wash-out. After the first wash-out period, treatment with Dapagliflozin will be started. Patients will receive 10 mg of Dapagliflozin once daily for 4 weeks. Dapagliflozin will be stopped after 4 weeks. The second treatment period will be followed by 4 weeks of wash-out. After the second wash-out period, treatment with both Spironolactone 25 mg and Dapagliflozin will be started. Patients will receive 25 mg of Spironolactone once daily in combination with 10 mg of Dapagliflozin daily for a duration of 4 weeks. Spironolactone and Dapagliflozin will be stopped after 4 weeks. The third treatment period will be followed by 4 weeks of wash-out, after which the study will be finalized.
223508127|NCT06499948|DRUG|Treatment with Dapagliflozin followed by Spironolactone followed by their combination|After titrating the renin-angiotensin-system inhibitor dose, patients will receive 10 mg of Dapagliflozin once daily for 4 weeks. Dapagliflozin will be stopped after 4 weeks. The first treatment period will be followed by 4 weeks of wash-out. After the first wash-out period, treatment with Spironolactone will be started. Patients will receive 25 mg of Spironolactone once daily for 4 weeks. Spironolactone will be stopped after 4 weeks. The second treatment period will be followed by 4 weeks of wash-out. After the second wash-out period, treatment with both Spironolactone and Dapagliflozin will be started. Patients will receive 25 mg of Spironolactone once daily in combination with 10 mg of Dapagliflozin daily for a duration of 4 weeks. Spironolactone and Dapagliflozin will be stopped after 4 weeks. The third treatment period will be followed by 4 weeks of wash-out, after which the study will be finalized.
223508128|NCT06756139|PROCEDURE|cognitive behavioural therapy mobile application|The CBT mobile application enables patients to conduct cognitive therapy independently.
223508129|NCT06756139|DRUG|Flupentixol and Melitracen Tablets|patients take Flupentixol and Melitracen Tablets
223508130|NCT05546931|BEHAVIORAL|Coaching application|A digital application for providing education and support for home-based blood pressure monitoring.
223752915|NCT00439556|DRUG|Bortezomib|Given IV
223752916|NCT00439556|DRUG|Carmustine|Given IV
223752917|NCT00439556|DRUG|Cytarabine|Given IV
223752918|NCT00439556|DRUG|Etoposide|Given IV
223752919|NCT00439556|BIOLOGICAL|Filgrastim|Given SC
223752920|NCT00439556|DRUG|Melphalan|Given IV
223752921|NCT00439556|DRUG|Methotrexate|Given IV
223752922|NCT00439556|BIOLOGICAL|Rituximab|Given IV
223752923|NCT00439556|DRUG|Tacrolimus|Given IV and PO
223752924|NCT02871739|BEHAVIORAL|Webinar|1 hour online, interactive webinar that covers shared decision making skills in clinical encounters.
223752925|NCT02871739|BEHAVIORAL|DA viewing|Participants will receive 3 decisions aids to review.
223752926|NCT02871739|BEHAVIORAL|SPI feedback|Rating of shared decision making skills and opportunities for improvement based on transcript of a standardized patient interaction
223752927|NCT02307006|DRUG|Ceftaroline|Surgical prophylaxis
223752928|NCT02307006|DRUG|Cefazolin / Vancomycin|Standard of care surgical prophylaxis
223752929|NCT02189421|DEVICE|ultra-slim upper endoscope|Direct peroral cholangioscopy by using an ultra-slim upper endoscope without assisting accessories
224311448|NCT02854111|OTHER|75 g-glucose|The 75-g glucose is used for standard oral glucose tolerance test.
223605750|NCT03311789|DRUG|PD-1 inhibitor + Gemcitabine + Cisplatin|Gemcitabine: 1000mg/m2 on day 1 and 5 every 3 weeks. Cisplatin: 75mg/m2 on day 1 every 3 weeks. PD-1 inhibitor: Nivolumab 3mg/kg, or SHR-1210 200mg.
223605751|NCT06284512|DIAGNOSTIC_TEST|Sonography, color fundus photography|Patients will undergo routine diagnostic imaging (Sonography, color fundus photography)
223605752|NCT02462018|DEVICE|WalkAide|"Patiants with hemiplegic or asymmetric diplegic CP will use WalkAide device for 4 months .First month for adjustment and three months of daily using of the device.~For each patient two assessments will be conducted: at baseline and at post-intervention follow-up.~During the assessments each child will go through:~A. Medical interview and neurological and physical therapist examination. B. Motor function tests: 6 min walk test, Gross motor function measure (GMFM) ,Timed up and down stairs test (TUDS), walking on a ramp ,with and without the FES device.~C. Gait analysis test with and without FES device. D. Parents will be requested to complete questionnaires on the frequency of falling.~E. On the second assessment parents wiil be requested to complete a questionnaire about the compliance to the FES."
223605753|NCT04289792|DRUG|nab-Paclitaxel+Gemcitabine|Drug: nab-Paclitaxel 125 mg/m2 IV over approximately 30-45 min on Days 1 and 15, followed by gemcitabine 1000 mg/m2 IV infusion over approximately 30 min on Days 1 and 15 of each 28-day cycle for 6 cycles.
223605754|NCT04289792|RADIATION|split-course SBRT|Radiation: During the first 1 and 2 cycles of chemotherapy, SBRT was given as a single irradiation of 10 Gy ⅹ 4 times (Days 2 and 16 of each 28-day cycle).
223605755|NCT03862235|DIAGNOSTIC_TEST|Cardiovascular Magnetic Resonance|The patients underwent to CMR examination on a Philips Achieve 1.5 device. Images were acquired coupled to the electrocardiogram and during respiratory pause, in four chambers, short axis and long axis of the left ventricle, in the same exact location in different sequences. A gradient - echo sequence (steady-state free precession) was used to evaluate cardiac function (functional evaluation). We will also evaluate T1 weighted images (T1 -relaxation times) and T2, performed sequentially, through spin-echo pulse (black-blood), triple inversion recovery sequence, for the morphological evaluation
223605756|NCT03862235|DIAGNOSTIC_TEST|Transthoracic echocardiography|The images were collected by the Vivid E9. The patients were submitted to one-dimensional (M-mode), two-dimensional (B-mode), and three-dimensional (three-dimensional) echocardiographic studies. The images obtained were associated with pulsed, continuous and color Doppler.
223605757|NCT06009328|OTHER|fundamental movement skills|measured by test of gross motor development
223605758|NCT05797636|DEVICE|transcranial magnetic stimulation|"The study intervention is modulation of cortical excitation to inhibition (E/I) balance in the dorsolateral prefrontal cortex (dlPFC) by means of 2 trains of spaced continuous theta burst stimulation (cTBS) using a transcranial magnetic stimulation device. As prior work (Huang et al 2005; Chung et al. 2018) has shown that cTBS reliably decreases the cortical E/I ratio with diverse cortical targets, the Investigators expect to replicate a reduction in E/I balance when applied. The mechanism of action is thought to be an increase in inhibitory neurotransmission across diverse timescales. The endpoint of this stimulation will be a decrease in the local E/I ratio that should last at least 60 minutes post-stimulation (Chung et al., 2018).~In separate sessions, all participants will receive stimulation to either the dorsolateral prefrontal cortex (dlPFC) or to the angular gyrus (AG). The Investigators will contrast the effects of dlPFC cTBS with control cTBS to the AG."
223605759|NCT00856297|BIOLOGICAL|MenACWY-CRM conjugate vaccine|
223605760|NCT00856297|BIOLOGICAL|Licensed comparator|
223605761|NCT00028327|DRUG|Lamivudine/Zidovudine|
223752930|NCT00849966|DRUG|Celebrex suspension|"Patients will be randomized to receive celecoxib suspension 6 mg/kg one hour prior to their scheduled surgery. In addition the patient will receive seven weight-based doses of celecoxib (3 mg/kg) to be administered every 10-12 hours while the child is awake; the first dose being administered the evening of surgery.~All participants will receive undergo and post surgery anesthetic treatment according to the usual standards of practice at CHEO."
223752931|NCT00849966|DRUG|Placebo|"Patients will be randomized to receive placebo by mouth one hour prior to their scheduled surgery. In addition the patient will receive seven weight-based doses of the placebo to be administered every 10-12 hours while the child is awake; the first dose being administered the evening of surgery.~All participants will receive undergo and post surgery anesthetic treatment according to the usual standards of practice at CHEO."
223752932|NCT03321669|PROCEDURE|Capsule endoscopy|Ingestion of capsule endoscopy for the diagnosis of small bowel lesions
223752933|NCT01899599|DRUG|PankoMab-GEX|start dose 500mg at C0D1, maintenance dose 1700mg at CxD1, Number of Cycles: until progression or unacceptable toxicity develops.
223508131|NCT05546931|OTHER|WebMD|Smartphone-based application for health education and/or monitoring.
223508132|NCT05546931|BEHAVIORAL|Home-based blood pressure monitoring|Device for measuring blood pressure at home with blue tooth connectivity for automated collection.
224311449|NCT00469911|PROCEDURE|Magnetic Resonance Spectroscopy|Magnetic Resonance Spectroscopy is a noninvasive procedure that provides detailed body images on any plane.
224311450|NCT00469911|PROCEDURE|Ex vivo heart biopsy|Heart transplant patients will have their normal clinical routine heart biopsy
223508133|NCT06332573|OTHER|Onco-sexology support|Initiation of onco-sexology support before the introduction of systemic oncology treatment
223508134|NCT06332573|OTHER|Onco-sexology support|Initiation of onco-sexology support after the introduction of systemic oncology treatment (2-3 months after the start of treatment).
223508135|NCT06623188|OTHER|Auricular neuromodulation|3 neuromodulation sessions over 12 weeks
223508136|NCT06623188|OTHER|Sham auricular neuromodulation|3 neuromodulation sessions over 12 weeks
223508137|NCT04820257|BEHAVIORAL|Home based exercise|Exercise at home and behavioural change to increase daily exercise
223508138|NCT04551131|DRUG|Ruxolitinib|Given orally (PO) or per nasogastric tube (NGT) twice a day for 8 weeks
223508139|NCT04551131|DRUG|Dexamethasone|Given intravenously (IV) or orally (PO) twice a day for 8 weeks
223508140|NCT04551131|DRUG|Etoposide|Given intravenously (IV) once a week for 8 weeks
223508141|NCT06917508|DRUG|EDP-323|Subjects will receive EDP-323 once daily on Days 5-15
223508142|NCT06917508|DRUG|Midazolam|Subjects will receive midazolam once daily on Days 1 and 12
223508143|NCT06917508|DRUG|Caffeine|Subjects will receive caffeine once daily on Days 1 and 12
223508144|NCT06917508|DRUG|Rosuvastatin|Subjects will receive rosuvastatin once daily on Days 2 and 13
223605762|NCT00028327|DRUG|Nelfinavir mesylate|
223605763|NCT00028327|DRUG|Efavirenz|
223605764|NCT00028327|DRUG|Lamivudine|
223605765|NCT00028327|DRUG|Zidovudine|
223605766|NCT05515835|DEVICE|body composition analysis|Patients will undergo body composition analysis using bioelectical impedance method before anesthesia.
223605767|NCT01392547|DRUG|vatreptacog alfa (activated)|1-3 doses per bleeding episode
223605768|NCT01392547|DRUG|eptacog alfa (activated)|1-3 doses per bleeding episode
223605769|NCT01735266|OTHER|Air colonoscopy|Colonoscopy will be performed with conventional air insufflation during colonoscope insertion.
223752934|NCT01899599|DRUG|Placebo|start dose matching 500mg at C0D1, maintenance dose matching 1700mg at CxD1, Number of Cycles: until progression or unacceptable toxicity develops.
223605770|NCT01735266|OTHER|Water exchange colonoscopy|Water exchange method (The air pump was turned off before colonoscopy. During colonoscope insertion, residual air in lumen was suctioned and 37°C water was infused into lumen to obtain lumen visualization) was used in whole or left colon. Air was insufflated until cecum was reached or appendix opening was seen.
223605771|NCT01042925|DRUG|XL147 (SAR245408)|administered orally once daily as tablet(s)
223605772|NCT01042925|BIOLOGICAL|trastuzumab|administered by IV once every 3 weeks
223605773|NCT01042925|DRUG|paclitaxel|administered by IV once every week
223605774|NCT02754921|PROCEDURE|percutaneous dilatational tracheostomy using Ultra-Perc|Procedure difficulties and complications faced while doing percutaneous dilatational tracheostomy using Ultra-Perc
223605775|NCT02754921|PROCEDURE|Percutaneous dilatational tracheostomy using Ciaglia Blue Dolphin|Procedure difficulties and complications faced while doing percutaneous dilatational tracheostomy using Ciaglia Blue Dolphin
223605776|NCT01718457|DEVICE|Endobarrier|
223605777|NCT06492434|BEHAVIORAL|Peer decision coaching|Peer Decision Coaching is a brief, personalized intervention grounded in evidence-based decision- and peer support principles. During the intervention, a trained peer specialist supports the young person in identifying a decision related to community participation that they need to make, such as whether to work or go to school, helping them address decision-making needs, and assisting them with developing and implementing a decision-making plan. Ultimately, the intervention aims to support young people in pursuing their community participation interests and goals.
223605778|NCT00267215|DRUG|Lumiracoxib|
223605779|NCT04867668|BEHAVIORAL|Anti-vaping and anti-smoking digital advertising|Delivery of social media based advertising to prevent vaping and smoking among young adults ages 18-24.
223605780|NCT03771651|DRUG|Aspirin 81 mg|Subjects will take aspirin daily for 14 days leading up to surgery to determine whether it impacts inflammation of fallopian tubes.
223605781|NCT00615017|DRUG|AZD9773 (CytoFab)|intravenous infusions
223605782|NCT00615017|OTHER|Placebo|Placebo
223605783|NCT00806988|PROCEDURE|Mitral Valve Repair|"Surgical techniques for mitral valve repair may need to be adjusted at the discretion of the surgeon, as based on intra-operative findings that may not be previously recognized in the pre-operative evaluation. The common elements for mitral annuloplasty planned as part of this study include the following:~1. All procedures will be performed with cardiopulmonary bypass (CPB) and with moderate hypothermia. Cannulation will be central with aortic cannulation for arterial inflow from the cardiopulmonary bypass circuit. Right atrial or bicaval (inferior and superior vena cava) drainage cannulas will be employed.~2. The heart will be arrested with cardioplegia.~3. A complete annular ring shall be placed unless specifically contraindicated by intra-operative findings. Additional repair of the mitral apparatus itself will be based on intra-operative findings."
223605784|NCT00806988|PROCEDURE|CABG|CABG will be performed using standard surgical techniques. Conduit selection and harvesting methods will not be prescribed, except that utilization of the left internal mammary artery (LIMA) is recommended when a left anterior descending (LAD) graft is indicated. The technical details of bypass grafting will not be prescribed. Complete revascularization will be performed, within the judgment of the surgical investigator.
223605785|NCT01550536|BEHAVIORAL|Resistance and aerobic exercise|Following baseline measurements, sedentary women were enrolled in a 16-week exercise training program at the YMCA in La Jolla, CA. Exercise occurred 3 times per week, for 1.5 hours each time. Exercise consisted of stretching, 20 minutes of aerobic exercise on elliptical machines, and 3 sets of 10-12 repetitions to failure for each of ten weight lifting exercises: abdominal crunch, arm curl, arm extension, chest press, lat pull-down, leg curl, leg extension, leg press, seated row, and trunk extension. Women started at 65-75% of 1-repetition-maximum, and resistance was increased as necessary to maintain the number of sets and reps and to continue to work to failure. Exercise was monitored by a TechnoGym electronic key system, and trainers instructed and supervised subjects in the gym.
223605786|NCT04658329|DRUG|Antiretroviral|Study the response to antiretroviral treatment (clinical, immuno-virological) and contribute to the identification of the antiretroviral strategies and combinations most suited to the particularities of the infection.
223605787|NCT06060795|DIAGNOSTIC_TEST|Electro-conductance measurement|Interventions are done to diagnose Autonomic Nervous system Troubles
223605788|NCT02310412|BIOLOGICAL|INTERCEPT treated platelets|
223605789|NCT02534545|DEVICE|Doctormate® (200mmHg)|Limb ischemia was induced by Renqiao Remote Ischemic Conditioning Device (Doctormate®) inflating tourniquets to 200mmHg.
223605790|NCT02534545|DEVICE|Doctormate® (60mmHg)|Limb ischemia was induced by Renqiao Remote Ischemic Conditioning Device (Doctormate®) inflating tourniquets to 60mmHg.
223605791|NCT01429493|RADIATION|Conventional Radiotherapy|Conventional radiotherapy will be used (8 Gy/ 1 fraction).
223605792|NCT01429493|RADIATION|Biological image-guided radiotherapy with conventional dose.|Biological image-guided radiotherapy on the positron emitting tomography (PET) positive lesion with conventional dose (8Gy/ 1 fraction) will be used.
223605793|NCT01429493|RADIATION|Biological image-guided SBRT with dose-escalation.|Biological image-guided stereotactic body radiotherapy (SBRT) with dose-escalation on the PET positive lesion will be used.
223605794|NCT06429150|BIOLOGICAL|CAR-T cells|Infusion of multi-CAR-T cells
223752935|NCT03166280|DRUG|Sofosbuvir 400 mg|treatment for hepatitis c by sofosbuvir (Sovaldi) 400 mg/day
223752936|NCT03166280|DRUG|Daclatasvir 60 mg/day|treatment for hepatitis c by Daclatasvir 60 mg/day
223752937|NCT05819164|DEVICE|Masimo oximeter|During this period, the Masimo oximeter Radical 7 was used for SpO2 reading
223752938|NCT05819164|DEVICE|Nellcor oximeter|During this period, the Nellcor oximeter N-600 was used for SpO2 reading
223605795|NCT02908126|DRUG|Oxytocin|Oxytocin drug
223605796|NCT00938678|DRUG|Pegfilgrastim Hospira|Subjects in both treatment groups will have safety assessments and will be followed for all adverse and serious adverse events.
223605797|NCT00938678|DRUG|Neulasta (Amgen)|Subjects in both treatment groups will have safety assessments and will be followed for all adverse and serious adverse events.
223752939|NCT05819164|DEVICE|Nonin oximeter|During this period, the Nonin oximeter was used for SpO2 reading
223752940|NCT01642238|DRUG|Ticagrelor + ASA + Bivalirudin|Single loading dose of Ticagrelor (180 mg given as two 90 mg tablets), plus single dose of ASA (one 81 mg tablet) + bivalirudin administered as 0.75 mg/kg IV bolus followed by 1.75 mg/kg/hour for 1 hour.
223752941|NCT01642238|DRUG|Clopidogrel + ASA + Bivalirudin|Single loading dose of Clopidogrel (600 mg given as two 300 mg tablets), plus single dose of ASA (one 81 mg tablet) + bivalirudin administered as 0.75 mg/kg IV bolus followed by 1.75 mg/kg/hour for 1 hour.
223752942|NCT01725191|OTHER|Laboratory Biomarker Analysis|Correlative studies
223752943|NCT01725191|OTHER|Pharmacological Study|Correlative studies
223752944|NCT01725191|DRUG|Tivantinib|Given PO
223752945|NCT05464004|OTHER|Nintendo Wii balance board|"Experimental group was given Nintendo Wii balance board therapy in combination with conventional physical therapy for 16 sessions/8 weeks~Control group was conventional physical therapy which include stretching of the hamstrings, quadriceps and calf muscles. strengthening of the lower limb. Balance exercises include walk in parallel bar"
223752946|NCT01845285|DEVICE|Aortic Valve Replacement|Transthoracic Echo (TTE),CT Scan (ECG triggered, contrast enhanced),Aorto-Iliac Angiogram,Peripheral Evaluation,Coronary Evaluation,12 lead ECG,Arrhythmia Assessment, New York Heart Association (NYHA) functional status, Modified Rankin Score Assessment (mRS) if symptomatic for stroke, Current Cardiac Medications, Transthoracic echo (TTE)
223752947|NCT02086942|DRUG|Bortezomib|Induction therapy：1.6mg/m2 or 1.3mg/m2 SC,Days 1, 6, 11, 16 of each 28 day cycles,4 cycle Intensive therapy：1.6mg/m2 or 1.3mg/m2 SC,Days 1, 6, 11, 16 of each 28 day cycles,5 cycles.
223752948|NCT02086942|DRUG|cyclophosphamide|Induction therapy：300mg/m2 VD Days 1-3 of each 28 day cycles,4 cycles. Intensive therapy：300mg/m2 VD Days 1-3 of each 28 day cycles,5 cycles. Maintenance treatment with CP: 200mg PO Days 1-14 of each 28 day cycles,12 cycles.
223752949|NCT02086942|DRUG|Dexamethasone|Induction therapy：40 mg/d VD Days 1,6,11,16 of each 28 day cycles,4 cycles Intensive therapy：40 mg/d VD Days 1,6,11,16 of each 28 day cycles,5 cycles.
223752950|NCT01514968|DRUG|cyclosporine|Single oral dose
223752951|NCT01514968|DRUG|danoprevir|Single oral dose
223752952|NCT01514968|DRUG|ritonavir|Single oral dose
223752953|NCT01991171|OTHER|Kinesio Taping|Kinesiotaping intervention is based upon the use of specific elastic tapes (known as Kinesio Tex Gold) that are applied with a certain amount of tension fixed to the skin of patients with the target muscles in a stretched position. The tapes will be placed over the quadriceps muscle.
223752954|NCT06277934|DRUG|RGT001-075|Administered orally
223752955|NCT06277934|DRUG|Placebo|Administered orally
223752956|NCT05291364|DRUG|Group 1|Is formed of 20 patients had splanchnic plexus block with 4.5 ml ethanol 96% + 1.5 ml of lidocaine 10 mg/ml + 2 μg/kg dexmedetomidine diluted in 0.9% sterile saline (total volume 12 ml) on each side
224311451|NCT06633471|DRUG|Two test formulations for the treatment of DED are being compared against the approved OTC formulation (Systane Ultra) and saline (placebo).|Rain and Mist are the test formulations. Systane Ultra is an approved OTC formulation. Saline is the placebo.
223605798|NCT05804669|DRUG|atumelnant|Atumelnant is an orally active investigational agent which antagonizes the action of ACTH at its receptor administered as oral tablets.
223605799|NCT02685306|BIOLOGICAL|Bavituximab|12 weekly doses of bavituximab given on Days 1, 8,15,22,29, 36, 43, 50, 57, 64, 71, 78
223605800|NCT02685306|DRUG|Taxane|12 weekly doses of taxane on Days 1, 8,15,22,29, 36, 43, 50, 57, 64, 71, 78
223605801|NCT00257699|DRUG|Metronidazole placebo|
223605802|NCT00257699|DRUG|ciprofloxacin placebo|
223752957|NCT05291364|DRUG|Group 2|Is formed of 20 patients had splanchnic plexus block with 4.5 ml ethanol 96% + 1.5 ml of lidocaine 10 mg/ml diluted in 0.9% sterile saline (total volume 12 ml) on each side.
223752958|NCT02086929|DRUG|Trazodone|
223752959|NCT02086929|DRUG|Venlafaxine|
223752960|NCT06089720|DEVICE|Zinc oxide nanoparticle coated orthodontic molar tubes (experimental)|nine orthodontic patients each one will receive 2 coated zinc oxide nanoparticle molar tubes in split-mouth manner and will assess for antimicrobial effect on s. mutans \& lactobacillus after two weeks, in addition to evaluation of bond failure rate after three months.
224311452|NCT01789827|OTHER|Laboratory Biomarker Analysis|Correlative studies
224311453|NCT01789827|PROCEDURE|Radionuclide Imaging|Undergo technetium Tc 99 hydrazinonicotinamide-tricine-linked interleukin-2 scintigraphies
223605803|NCT00257699|DRUG|ciprofloxacin|500 mg bid po
223605804|NCT00257699|DRUG|metronidazole|250 mg bid po / 250 mg tid po / 500 mg bid po depending on body weight
223605805|NCT05597774|OTHER|Inspiratory + expiratory muscle training group|Participants will perform an inspiratory and expiratory muscle training including warm-up, recovery between intervals and return to calm.
223605806|NCT05597774|OTHER|Inspiratory + expiratory muscle training sham group|Participants will perform an inspiratory and expiratory muscle training including warm-up, recovery between intervals and return to calm.
223605807|NCT05597774|OTHER|Exercise training program|Participants will perform a cardiovascular exercise program including warm-up, recovery between intervals and return to calm by cycloergometer.
223605808|NCT00842556|DRUG|Dapagliflozin|Tablets, Oral, 20 mg, Single Dose
223605809|NCT00842556|DRUG|Glimepiride|Tablets, Oral, 4 mg, Single Dose
223605810|NCT00842556|DRUG|Sitagliptin|Tablets, Oral, 100 mg, Single Dose
223752961|NCT06089720|DEVICE|orthodontic molar tubes (control)|nine orthodontic patients each one will receive two uncoated molar tubes in split-mouth manner and will assess for antimicrobial effect on S. mutans \& lactobacillus after two weeks, also, evaluation of the bond failure rate after three months period.
224311454|NCT01789827|BIOLOGICAL|Technetium Tc 99 Hydrazinonicotinamide-Tricine-linked Interleukin-2|Undergo technetium Tc 99 hydrazinonicotinamide-tricine-linked interleukin-2 scintigraphies
224311455|NCT02149329|DRUG|Discontinuation of imipenem-cilastatin or meropenem|Discontinuation of imipenem-cilastatin or meropenem after 3x24 hours irrespective of presence of fever.
223605811|NCT01181466|DEVICE|AeriSeal System|The AeriSeal System will be Administered at 3 to 4 Pulmonary Subsegments During a Single Treatment session.
223605812|NCT04930523|OTHER|Elongation Longitudinaux Avec Decoaption Osteo Articulaire|"Pre physiotherapy treatment~Gym (treadmill ,cycling,vibrator) according to ability and condition of patient Shortwave diathermy SWD for atleast 10 mins Decompression treatment i.e. Neuro-oxy motorized lumbar spinal decompression therapy for 25 minutes.~Post physiotherapy treatment~Conventional Tens and infrared heat for 10 minutes at low back region. TENS is modality to reduce pain and tension,by stimulating large diameter afferent fiber .IR give superficial heat for circulation and relaxation of muscles.~No exercises or walk were guided for home (till 24 hrs) Low back exs guided i.e knee to chest, pelvic rolling, bridging, SLR, pirformis exs is guided for home plan along with precautions.~No exertion ,drive carefully Avoid stairs climbing ,twisting ,bending ,weight lifting"
223605813|NCT04930523|OTHER|Decompression|"Pre physiotherapy treatment~Gym (treadmill ,cycling, vibrator) according to ability and condition of patient Shortwave diathermy SWD for at least 10 minutes. ELDOA positions are guided and performed by patients before decompression Low back exercises guided i.e. knee to chest, pelvic rolling, bridging, SLR, piriformis exercises is guided for home plan along with precautions.~Decoarctation of (C0/C1/C2),(C4/C5),(C5,C6),(C6/C7),(T4/T5),(T6/T7),(T8,/T9),(L4/L5),(L5/S1) Neuro-oxy motorized lumbar spinal decompression therapy for 25 minutes. Post physiotherapy treatment Tens and infrared heat for 10 minutes at low back region. TENS is modality to reduce pain and tension, by stimulating large diameter afferent fiber .IR give superficial heat for circulation and relaxation of muscles.~ELDOA exercises(positions)are guided for home plan after session (after 24 hrs) No exertion ,drive carefully Avoid stairs climbing, twisting bending, weight lifting"
223605814|NCT03853135|DIAGNOSTIC_TEST|measurement of serum endocan|measurement of serum levels of endocan
223605815|NCT04001413|DRUG|MEDI0457|MEDI0457 is an investigational drug that will be administered with the Cellectra Device in this study
223605816|NCT04001413|DRUG|Durvalumab|Durvalumab is an investigational drug in this study.
223605817|NCT02610686|DRUG|Chloroquine|efficacy of chloroquine for the treatment of Plasmodium vivax infections
223605818|NCT03461107|OTHER|No intervention|
223605819|NCT03094117|OTHER|News items with spin|Interpretation of news items with spin
223605820|NCT03094117|OTHER|News items without spin|Interpretation of news items without spin
223605821|NCT04327791|DRUG|Baloxavir|administered PO once
223605822|NCT04327791|DRUG|Placebos|administered PO once
223605823|NCT03072264|BEHAVIORAL|Body in Mind Training (BMT)|Session 1 - Stop; Session 2 - Intention; Session 3 - Attention; Session 4 - Scientist Myself; Session 5 - Self-Compassion; Sessions 6, 7, 8 - Practice.
223605824|NCT03072264|DRUG|Fluoxetine|In this group, individuals will consult with a psychiatrist weekly and will receive fluoxetine in a dosage of 20 to 60mg/dia according to clinical response.
223605825|NCT03072264|BEHAVIORAL|Quality of Life Group|Session 1 - Psychoeducation; Session 2 - Substance Use; Session 3 - Sleep; Session 4 - Physical Exercise; Session 5 - Healthy Eating; Sessions 6, 7,8 - discussions.
223605826|NCT01493401|PROCEDURE|Midurethral slings (MUS)|Retropubic, Transobturator, and Single incision MUS can be used.
223605827|NCT02722200|DRUG|hydrocortisone|Hydrocortisone will be used as the steroid of choice because it is bio-identical to cortisol and is subject to the same metabolism as cortisol.
223605828|NCT02722200|OTHER|saline|Saline will be used as the placebo comparator. It will be administered in the same manner as the active drug.
223605829|NCT04775953|DRUG|Cefazolin|Cefazolin is a semisynthetic cephalosporin analog with broad-spectrum antibiotic action due to inhibition of bacterial cell wall synthesis. Cefazolin (2 g will be administrated intravenously (IV) every 8 hours for 4-6 weeks)
223605830|NCT04775953|DRUG|Dalbavancin|A second-generation lipoglycopeptide antibiotic synthesized from a fermentation product of Nonomuraea species
223605831|NCT04775953|DRUG|Daptomycin|Daptomycin (USA) or Cubicin (Spain) is a cyclic lipopeptide antibiotic that inhibits gram-positive bacteria. Daptomycin (6-10 mg/kg will be administrated intravenously (IV) daily for 4-6 weeks
223605832|NCT04775953|DRUG|Nafcillin|Nafcillin is a semi-synthetic antibiotic related to penicillin. Nafcillin (2 g will be administrated intravenously (IV) every 4 hours for 4-6 weeks)
223605833|NCT04775953|DRUG|Oxacillin|Oxacillin is an antibiotic used in resistant staphylococci infections. Oxacillin (2 g will be administrated intravenously (IV) every 4 hours for 4-6 weeks
223605834|NCT04775953|DRUG|Vancomycin|Vancomycin is a glycopeptide antibiotic product of the organism Amycolatopsis orientalis. Vancomycin (dose per local standard of care × 4-6 weeks)
223605835|NCT00855959|DRUG|Budesonide|Inhalation powder, inhalation, twice daily, 4 weeks followed by Suspension for nebulisation, inhalation, once or twice daily, 6 weeks
223605836|NCT00855959|DRUG|Pulmicort Turbuhaler|Pulmicort Turbuhaler 200 µg, Dry powder inhaler, budesonide 200 µg/dose, 112 doses/Turbuhaler
223605837|NCT05541146|COMBINATION_PRODUCT|Intraperitoneal chemotherapy|Patients will undergo intraperitoneal chemotherapy with Paclitaxel (4 cycles) associated with systemic chemotherapy. After treatment, patients will be reassessed and if there is a peritoneal response, they will undergo gastrectomy
223605838|NCT02813889|DEVICE|SmarToyGym|"We aim to develop a SmarToyGym where sensitized, wireless toys are strategically hung and placed within reach of infants to elicit toy-oriented body and arm/hand movements. Each toy will be equipped with sensors capable of measuring the infant's grasping actions such as squeezing, pinching, tilting, etc.~A low-cost 3D motion capture system will be used to collect video data and the infants' reaching and body kinematics in response to the toys. A pressure mat will be used to measure postural changes to detect weight shifts, rolling, crawling and other movements away from the initial posture."
223605839|NCT02917785|DEVICE|Karman curettage|
224311456|NCT00527865|DRUG|DAS181|DAS181 is formulated as dry powder and packaged in capsules containing DAS181. The delivered dose of DAS181 dry powder at each fill size is 0.5 mg, 1.0 mg, 2.25 mg, and 4.5 mg.
224311457|NCT00527865|DRUG|Placebo|Capsules containing 10.5 mg of lactose will be supplied as placebo.
224311458|NCT01659086|BIOLOGICAL|Investigational H9N2 vaccine GSK2654911A|2 or 3 doses of GSK2654911A (different formulations) followed by 1 or 0 dose of saline placebo respectively, depending in the treatment group. All doses to be administered intramuscularly (IM) in deltoid region of arm.
224311459|NCT01659086|BIOLOGICAL|Investigational H9N2 vaccine GSK2654909A|2 or 3 doses of GSK2654909A followed by 1 or 0 dose of saline placebo, respectively (treatment 5). All doses to be administered IM in deltoid region of arm.
223508145|NCT06932471|DRUG|MY008211A tablets|MY008211A tablets Participants will receive MY008211A at a dose of 400 mg orally b.i.d
223752962|NCT06548191|BEHAVIORAL|Time-restricted eating|Fasting (abstinence from calorie-containing food or drink) during 14 h at night, with no caloric consumption after 8 pm to align with circadian rhythms
223752963|NCT06283797|DEVICE|OmniPod 5|Participants will be trained to use OmniPod 5 to treat type 1 diabetes for 1 year
223752964|NCT06283797|DEVICE|Dexcom G6|Participants will use Dexcom G6 for continuous glucose monitoring
223752965|NCT06283797|OTHER|PAID questionnaires|At visits 3, 7 and 11, parents/guardians and patients aged between 8 and 17 will complete diabetes-related problem questionnaires (PAID-PR, PAID-Peds)
223752966|NCT01758380|DRUG|Vildagliptin|Patients will be instructed to take Vildagliptin tablets at a fixed dose of 50 mg twice daily (double blind therapy)
223752967|NCT01758380|DRUG|Gliclazide|Patients will be instructed to take Gliclazide capsules at an equivalent dose to previous sulfonylurea in multiples of 80mg only (double blind therapy)
223752968|NCT01758380|DRUG|Metformin|Patients in both arms will take Metformin at a dose between 1500mg-2500mg per day, in an open label fashion
223752969|NCT01758380|DRUG|Placebo to Gliclazide|Patients will be instructed to take the Gliclazide matching placebo capsules at an equivalent dose to previous sulfonylurea in multiples of 80mg only (double blind therapy)
224200553|NCT02195921|OTHER|single point Zhongwan(CV12) plus antiemetic drug|"All participants were supine in the hospital bed. A disposable sterile acupuncture needle (ø 0.30 × 40 mm, Hwato) was inserted vertically at approximately 20-30 mm until De Qi (sensation of soreness, numbness, distension, etc. around the acupoint) was reported by the participants. Then, the needle handle was clamped via a metal clip to connect to the positive electrode of the electric acupuncture apparatus (Huatuo, SDZ-V model, Suzhou Medical Appliance). Another reference electrode was placed 1 cm above the CV12 acupoints of the stimulation point, where no acupoints or meridians passed through. A dilatational wave at a frequency of 2/10 Hz and a current intensity at the highest level tolerated by the patient, with a maximum intensity no more than 10 mA, were used to deliver the EA stimulation. People in the intervention groups were offered a standardized 30-minute EA session once daily from the 1st day of the four-day chemotherapy cycle."
224311460|NCT01659086|BIOLOGICAL|Placebo|1 dose of saline placebo administered intramuscularly (IM) in deltoid region of arm.
224311461|NCT04445363|DRUG|Jaktinib hydrochloride cream|Jaktinib hydrochloride cream/placebo applied topically in the morning and in the evening, administered continuously for 24 weeks
224311462|NCT04445363|DRUG|Placebo|Dose extension: Placebo
223508146|NCT03181009|DRUG|Omalizumab|All subjects will receive omalizumab, stored and prepared according to the investigator brochure. Subjects greater or equal to 4 yrs receive 150 mg. Subjects less than 4 yrs receive 75 mg.
223508147|NCT03181009|DRUG|Food Flour Allergens|The subject's allergens will be introduced after receiving the third omalizumab dose.. Subjects will return to clinic to escalate the dose of their allergens until 300 mg (group A) vs. 1200 mg (group B) total protein daily dose is reached. There will be equivalent allergen protein portions depending on test allergen per each subject's history. Subjects will be randomized 1:1 to either group A or group B after meeting eligibility criteria. All subjects and study personnel will be blinded to group A vs B. Research staff will administer food flour to the subject orally in an age-appropriate food vehicle.
223508148|NCT06951048|OTHER|Group I (Neural Mobilization)|"Participants will undergo a neural mobilization program targeting the sciatic, femoral, and tibial nerves. Exercises are designed to promote nerve sliding through specific movement patterns and are performed bilaterally. Each nerve mobilization is applied in 4 sets of 10 repetitions, three times per week on non-consecutive days, with 30-second rest intervals.~Sciatic nerve: Performed in side-lying; ankle dorsiflexion with neck extension followed by dorsiflexion release and neck flexion.~Femoral nerve: In side-lying; simultaneous movements of the hip, knee, and neck in flexion and extension.~Tibial nerve: In supine; coordinated ankle, toe, and cervical spine movements with controlled hip/knee positioning."
223508149|NCT06951048|OTHER|Group II (Neural Mobilization + Dynamic Stretching)|Participants in this group will engage in the same neural mobilization protocol applied in Group I, combined with a structured dynamic stretching program targeting lower extremity flexibility and neuromuscular performance. The dynamic exercises include active straight leg raises (SLR), vertical jumps, and 10-meter sprints. Each activity will be performed in three sets of ten repetitions, aiming to enhance muscular activation, mobility, and functional readiness.
223508150|NCT06951048|OTHER|Group III (Dynamic Stretching Only)|This group will engage exclusively in a dynamic stretching protocol comprising active straight leg raises (SLR), vertical jump exercises, and 10-meter sprint drills. Each exercise will be performed in three sets of ten repetitions, focusing on enhancing lower extremity mobility, muscle activation, and functional movement capacity without any neural mobilization intervention.
223508151|NCT06949111|RADIATION|radiotherapy|Radiotherapy: Administer three-dimensional conformal/intensity-modulated/TOMO radiotherapy with a conventional fractionation schedule of 36-41.4 Gy in 20-23 fractions (1.8 Gy per fraction).
223508152|NCT06949111|DRUG|CAPOX|4 cycles, Oxaliplatin 130 mg/m², Capecitabine 825 mg/m²
223508153|NCT06949111|DRUG|Capecitabine|Administer Capecitabine at a dose of 825 mg/m², twice daily, orally on radiotherapy days
223508154|NCT06949111|DRUG|Iparomlimab and Tuvonralimab Injection|IV, 5 mg/kg every 3 weeks
223508155|NCT05894564|DRUG|Fluvoxamine|"Fluvoxamine is a round golden 50 mg tablet that is scored on both sides - one side has APO and the other side has F50 with a partial bisect. All packaging will be labeled to indicate that the product is for investigational use, administered at a dose of 50 mg, twice daily for 10 days."
223508156|NCT05894564|OTHER|Placebo|Each study arm will contain a placebo comparator. Placebo will look similar to study drug and will be administered via the same route of administration and dose. However, placebo will be an inactive substance, containing no study drug.
223605840|NCT03845127|DEVICE|Revivent TC Ventricular Enhancement System|Anchors that are implanted into the left ventricle to reshape and reduce the size and increase the efficiency of the pumping chamber.
223605841|NCT03845127|DRUG|GDMT|Guideline Directed Medical Therapy
223605842|NCT00368641|DRUG|Extraneal|Periotneal Dialysis
223605843|NCT04668885|DRUG|CPX-351|"Induction phase: CPX-351 15 mg/m\^2 on days 1 and 3 of each 28-day cycle for up to a total of 6 cycles in the absence of unacceptable toxicity~Maintenance phase: CPX-351 7.5 mg/m\^2 on days 1 and 3 for two cycles alternating with 15 mg/m\^2 for one cycle. Participants may receive up to 12 cycles of maintenance phase in the absence of unacceptable toxicity."
223605844|NCT03633110|BIOLOGICAL|GEN-009 Adjuvanted Vaccine|GEN-009 Adjuvanted Vaccine consists of GEN-009 Drug Product mixed with Hiltonol (poly-ICLC, adjuvant) and is administered by subcutaneous injection.
223605845|NCT03633110|DRUG|Nivolumab|Nivolumab is a PD-1 checkpoint inhibitor approved by the FDA to treat the tumor types in this study.
223605846|NCT03633110|DRUG|Pembrolizumab|Pembrolizumab is a PD-1 checkpoint inhibitor approved by the FDA to treat the tumor types in this study.
223605847|NCT05065359|DRUG|Rodatristat Ethyl 300 mg BID|Tablets, oral, 300 mg, BID 14 days
223605848|NCT05065359|DRUG|Rodatristat Ethyl 600 mg BID|Tablets, oral, 600 mg, BID 14 days
223605849|NCT05065359|DRUG|Placebo|Tablets, oral, 0 mg, BID for 14 days
223605850|NCT02379169|DIETARY_SUPPLEMENT|Sea buckthorn oil & lutein|Standardised sea buckthorn seed and pulp oil complemented with lutein
223605851|NCT02379169|DIETARY_SUPPLEMENT|Placebo|Triglycerides of medium chain fatty acids
223605852|NCT00381758|DRUG|Methylphenidate Extended Release Capsules|
223605853|NCT06499493|OTHER|Myofascial induction in gastrocnemius muscle|A 3-pass shallow leg gliding technique was applied first, followed by 5 minutes of the deep myofascial calf induction technique described by Pilat.
223605854|NCT05402670|OTHER||
223605855|NCT03787121|PROCEDURE|care management pathways|different care management pathways, including thyroidectomy, iode 131, hormonal treatment and type of follow up
223605856|NCT00555880|DRUG|Midodrine hydrochloride|one dose, 10-30mg, given orally
223605857|NCT00555880|DRUG|Placebo|Placebo
223605858|NCT02385747|PROCEDURE|hystroscopy|Detailed hysteroscopic examination under general anesthesia Once the cavity entered, a panoramic view of the uterine cavity then systematic; first the fundus, then anterior, posterior and lateral walls of the uterus consecutively, ending by visualization of the uterine -tubal junctions, The thickness, colour, aspect and vasculature of the mucous membrane lining the uterine cavity was observed and recorded. If there is any intrauterine pathology detected; the shape, size and site were estimated.
224311463|NCT03688438|DEVICE|Closed-Incision Negative-Pressure Therapy|A foam or gauze dressing is put directly on the wound. This foam acts as a filter to keep any large particles (such as blood clots or dead, sloughed off tissue) from clogging the vacuum system. A clear, occlusive, adhesive film covers and seals the dressing and wound, creating an airtight seal. A drainage tube leads from under the adhesive film and connects to a portable vacuum pump. This pump removes air pressure over the wound. The pump is programmed for strength of suction, amount of time it is to be applied and if it is to be intermittent or continuous. A chamber on the pump collects drainage and moisture is drawn away from the wound site.
224311464|NCT02235038|BEHAVIORAL|Low carbohydrate diet|Composition (by proportion of calories) : 15% carbohydrate, 65% fat, 20% protein
223605859|NCT03058926|OTHER|Data Management and Monitoring|"Clinical Research Support Center's Data Management and Multicenter Study Support (MCSS) teams responsible for monitoring protocol and regulatory compliance for all consortium studies.~MCSS responsible for maintaining and tracking IRB approval and regulatory documents from each site throughout the life of the study."
223605860|NCT03833726|PROCEDURE|Experimental: LED group|5 Sessions of 8 minute 405 nm Blue Light Emitting Diode, LED, with a power of 1.66 W / m2, 7 days apart.
223605861|NCT03833726|PROCEDURE|Sham Comparator: Control|5 Sessions of 8 minute with device off and heated gel, 7 days apart.
223605862|NCT01340586|DRUG|Apixaban|Tablets, Oral, 5 mg, Once, 4 days
223605863|NCT01340586|DRUG|Apixaban|Tablets, Oral, 5 mg, Twice, 15 days
224200554|NCT02195921|OTHER|single point Zusanli(ST36) plus antiemetic drug|"A disposable sterile acupuncture needle (ø 0.30 × 40 mm, Hwato) was inserted vertically at approximately 20-30 mm until De Qi (sensation of soreness, numbness, distension, etc. around the acupoint) was reported by the participants. Then, the needle handle was clamped via a metal clip to connect to the positive electrode of the electric acupuncture apparatus (Huatuo, SDZ-V model, Suzhou Medical Appliance). Another reference electrode was placed 1cm below ST36 acupoints of the stimulation point, respectively, where no acupoints or meridians passed through. A dilatational wave at a frequency of 2/10 Hz and a current intensity at the highest level tolerated by the patient, with a maximum intensity no more than 10 mA, were used to deliver the EA stimulation. People in the intervention groups were offered a standardized 30-minute EA session once daily from the 1st day of the four-day chemotherapy cycle."
224200555|NCT02195921|OTHER|Zusanli(ST36)and Zhongwan(CV12) plus antiemetic drug|Stimulating both Zusanli(ST36)and Zhongwan(CV12)
224200556|NCT02195921|DRUG|only antiemetic drug|received routine antiemetic treatment
224200557|NCT03497000|PROCEDURE|OCTA-guided Photodynamic therapy|Half-dose photodynamic therapy using verteporfin under the guidance of OCTA
224311465|NCT02235038|BEHAVIORAL|Moderate carbohydrate diet|Feeding study. Composition (by proportion of calories): 40% carbohydrate, 40% fat, 20% protein
224200558|NCT03497000|PROCEDURE|ICGA-guided Photodynamic therapy|Half-dose photodynamic therapy using verteporfin under the guidance of ICGA
223605864|NCT01186185|DRUG|Fludrocortisone|Fludrocortisone 0.2 mg by mouth daily for 30 days
223605865|NCT02859259|DRUG|BMS-663068 (1 tablet at 600 mg)|BMS-663068 (1 tablet at 600 mg). A single dose of BMS-663068 administered orally as specified.
223605866|NCT02859259|DRUG|BMS-663068 (4 tablets at 150 mg each tablet)|BMS-663068 (4 tablets at 150 mg each tablet). A single dose (4 tablets) of BMS-663068 administered orally as specified.
223605867|NCT03671213|DEVICE|Calypso Knee System (Implantable Shock Absorber)|The Calypso Knee System is an extra-capsular knee implant designed to fill the therapeutic gap between conservative care and more invasive surgical interventions for knee osteoarthritis.
223752970|NCT01758380|DRUG|Placebo to Vildagliptin|Patients will be instructed to take Vildagliptin matching placebo tablets at a fixed dose of 50 mg twice daily (double blind therapy).
223752971|NCT00299013|DRUG|COLAL-PRED®|COLAL-PRED 40, 60 or 80mg oral capsule, once daily for 8 weeks.
223752972|NCT00299013|DRUG|Prednisolone|Prednisolone 40mg oral tablets, once daily, dose tapering weekly (40,40,30,20,15,10,5,0mg) over 8 weeks.
223752973|NCT00727753|DRUG|Ranibizumab|ranibizumab (0.5 mg) will be injected intraocular
223752974|NCT00727753|DRUG|Bevacizumab|Bevacizumab (1.25 mg) will be injected intraocular
223752975|NCT00727753|OTHER|No treatment|No treatment
223752976|NCT04962646|PROCEDURE|Carbon dioxide flooding|Once the thoracic cavity is opened a flow of carbon dioxide of 5L/min will be initiated into the surgical wound and proceed until there is no connection between the cardiac or aortic cavity and surrounding air.
223752977|NCT06171178|DRUG|ASP1012|Intravenous (IV) infusion
223752978|NCT06171178|DRUG|Pembrolizumab|IV infusion
223752979|NCT04012944|DEVICE|Cordella™ Pulmonary Artery Sensor System|"The Cordella PA Sensor System comprises seven subsystems that operate together to take daily Pulmonary Artery Pressure (PAP) readings at a patient's home and transmit the results to a care provider for evaluation.~1. Cordella Sensor~2. Cordella Delivery System~3. myCordella Patient Reader~4. Reader Dock~5. Cordella Calibration Equipment (CalEQ)~6. myCordella Hub~7. Cordella Data Analysis Platform (CDAP)."
223752980|NCT00624676|DRUG|Lipo Hydroxy Acid|Twice a day
223605868|NCT02804126|PROCEDURE|TAP (transversus abdominis plane block)|ultrasound-guided regional block between abdominal wall muscles to treat acute postoperative pain. Stimuplex Ultra 360 needle will be used and 0.25% bupivacaine administered (0.2 mL/kg).
223605869|NCT02804126|PROCEDURE|QL (quadratus lumborum block)|ultrasound-guided regional block between abdominal wall muscles to treat acute pain, similar to transversus abdominis plane block, but with distribution of local anesthetic towards paravertebral space. Stimuplex Ultra 360 needle will be used and 0.25% bupivacaine administered (0.2 mL/kg).
223752981|NCT00624676|DRUG|5% benzoyl peroxide gel|Once a day
223605870|NCT02804126|DRUG|Bupivacaine|In both groups (TAP\&QL) 0.25% bupivacaine will be given (0.2 mL/kg)
223752982|NCT01075698|DRUG|Non-ARB (standard therapy)|Blood pressure lowering therapy except ARB
223752983|NCT01075698|DRUG|ARB (Telmisartan)|Telmisartan 20-80 mg/day
223752984|NCT03519568|BIOLOGICAL|EV71 (inoculation vaccine)|EV71 vaccine 0.5ml per dose, Wuhan Biological Products Co., Ltd., Wuhan, Hubei Province, China 10μg HepB 0.5ml per dose, Wuhan Biological Products Co., Ltd., Wuhan, Hubei Province, China 30ug MPSV-A 0.5ml per dose, Wuhan Biological Products Co., Ltd., Wuhan, Hubei Province, China MR 0.5ml per dose, Beijiing Biological Products Co., Ltd., Beijing, China JE-L 0.5ml per dose, Chengdu Biological Products Co., Ltd., Chengdu,Sichuan Province, China
223752985|NCT05316831|BIOLOGICAL|PCV13|Pneumococcal polysaccharides conjugated to CRM197 carrier protein
223605871|NCT02804126|DEVICE|Needle|Ultrasound-guided, Stimuplex ultra 360 needle will be used in the study
223605872|NCT02804126|DRUG|Paracetamol|Intravenous paracetamol will be used (1.0 gram), up to 4 grams per day
223752986|NCT05316831|BIOLOGICAL|PPSV23|Pneumococcal polysaccharides
223752987|NCT01085097|DRUG|Laquinimod|Laquinimod will be administered per dose and schedule specified in the arm description.
223752988|NCT01085097|DRUG|Mycophenolate Mofetil|Mycophenolate Mofetil (MMF) will be administered per dose and schedule specified in the arm description.
223752989|NCT01085097|DRUG|Prednisolone/Prednisone|Prednisolone/Prednisone will be administered per dose and schedule specified in the arm description.
224200559|NCT02492152|DEVICE|Study group|Dianatal
223605873|NCT02804126|DRUG|Metamizol|Intravenous metamizol will be used (1.0 gram), up to 4 grams per day
223605874|NCT02804126|DRUG|Ketoprofen|Intravenous ketoprofen will be used (0.1 gram), up to 200 milligrams per day
223605875|NCT02804126|DRUG|Morphine|Intravenous morphine (5 mg) will be given when pain exceeds 40 mm in VAS (maximum 2 doses per day)
223605876|NCT00748670|DEVICE|Fixture MicroThread (Micro-Macro)|Fixture MicroThread (Micro-Macro) Ø 3.5 and 4.0 mm in lengths of 9, 11, 13, 15 and 17 mm.
223752990|NCT01085097|DRUG|Placebo|Placebo matching to laquinimod will be administered per schedule specified in the arm description.
223752991|NCT01085097|DRUG|Methylprednisolone|Methylprednisolone (MP) will be administered per dose and schedule specified in the arm description.
223752992|NCT02570061|BEHAVIORAL|telephone|information given at the primary contact by phone, or at a scheduled later time
223752993|NCT02570061|BEHAVIORAL|consultation face-to-face|information given at a scheduled consultation at the hospital
223752994|NCT05336474|DIAGNOSTIC_TEST|Ultrasonographic upper airway measurements|Ultrasonographic upper airway measurements: Epiglottis-skin distance, Hyoid bone-skin distance, Anterior commissure-skin distance and Thickness of tounge
223752995|NCT03615807|PROCEDURE|Surgical debridement (if needed)|Surgical debridement
223752996|NCT03615807|DIAGNOSTIC_TEST|Microbiological sampling|Microbiological sampling
223752997|NCT03615807|PROCEDURE|Revascularisation (if needed).|Revascularisation (if needed).
223752998|NCT03615807|DEVICE|Off-loading|Off-loading by Special shoes
223752999|NCT03615807|BEHAVIORAL|Patient's education and instructions|Patient's education and instructions by specialized nurses
223753000|NCT03615807|PROCEDURE|Wound debridement|Regular wound debridement by specialized nurses
223753001|NCT03615807|DRUG|Antibiotic duration|Systemic antibiotic duration according to the study arms
223753002|NCT05889598|OTHER|Ballistic Resistance Lower Body Strength Training|The exercise programme involves two supervised sessions per week at University. Each session will involve 30-40 minutes of exercise, comprising warm-up , two main exercises: a hack squat and calf raise using a hack squat machine, and core exercises. After a warm-up period involving 5 minutes cycling and one set of 5 conventional repetitions at 40%1RM, the ballistic training group will complete eccentric phase hack squat exercise in approximately 3 seconds and the concentric phase as fast as possible with throwing type contractions. If participants can, participants will be allowed to take off in the concentric phase. To maintain high velocity in this group, lower loads will be used compared to the conventional group. The load will be decided according to regular maximal muscular strength test (1RM) to use of the correct weight for training (in proportion to the strength). Participants will start off using light weights and these will increase as participants become stronger.
224200560|NCT05847309|OTHER|Delayed extubation|Patients randomized to delayed extubation, will be extubated 6-12 hours after endovascular treatment under general anesthesia.
223605877|NCT06796491|OTHER|Post Isometric relaxation|Group A will receive Post Isometric Relaxation (PIR) Patient applied the sub-maximal contraction almost 20%. Isometric contraction was held for 10 seconds and then slight stretch for 30 seconds was maintained.4 contractions per treatment with 3 seconds rest between each contraction. This protocol continues 3 days/week for 4 weeks conventional treatment Hot pack for 10 minutes Pelvic bridging: The subjects will be asked to lie supine and with knee flexed and then raise the pelvis upward till the comfort then hold that position for 5 sec and repetitions were 10 times Cat and camel: The subjects will be requested to prone kneel and then take a deep breath from nose while making hump in the back (cat) and breathe out from mouth while curving the spine (camel) for 5 second 10 times repetitions
223605878|NCT06796491|OTHER|Post Facilitation stretch|Group B will receive Post Facilitation Stretch (PFS) Isometric contraction was held for 10 seconds and then slight stretch for 30 seconds was maintained. 4 contractions per treatment with 3 seconds rest between each contraction. This protocol continues 3 days/week 4 weeks. for hamstring flexibility conventional treatment Hot pack for 10 minutes Pelvic bridging: The subjects will be asked to lie supine and with knee flexed and then raise the pelvis upward till the comfort then hold that position for 5 sec and repetitions were 10 times Cat and camel: The subjects will be requested to prone kneel and then take a deep breath from nose while making hump in the back (cat) and breathe out from mouth while curving the spine (camel) for 5 second 10 times repetitions
223605879|NCT02275741|BIOLOGICAL|prophylactic vaccine (tetanus, diphtheria, pertussis, poliomyelitis, influenza, hepatitis A, hepatitis B, tick-borne encephalitis, meningococcal, pneumococcal)|Publically recommended protective vaccines in MS patients, vaccination applied according to the manufacturers description
223605880|NCT00971074|DRUG|Hylan G-F 20|6 ml intra-articular injection given once. The injection takes approximately 15 seconds.
223605881|NCT00971074|OTHER|Sham Injection|A needle will be inserted through the knee capsule but no medication will be injected.
223605882|NCT05947617|DRUG|VIX001|"This study utilizes a dose-escalation design with three arms or cohorts to evaluate the safety, tolerability, preliminary efficacy, and dose effect of VIX001, an amniotic fluid product, in patients with Post-Acute COVID-19 Syndrome (PACS) associated with neurological symptoms of cognitive impairment.~In all arms, the intervention will be administered at baseline and participants will be assessed at specified timepoints for safety, cognitive impairment, pain, activity, and quality of life. The primary objective is to evaluate the safety of VIX001, while the secondary objectives include assessing its potential efficacy and patient-reported outcomes."
223605883|NCT03564652|DIETARY_SUPPLEMENT|Balanced energy-protein (BEP)|Lactating women in the intervention arms will receive approximately 800 Kcal/day and around 16-21 gram of protein in a day in the form of ready-to-use supplement.
223605884|NCT03564652|DRUG|Azithromycin|A single prophylaxis dose of 20 mg/kg in suspension form, reconstituted by trial staff before dose administration by the same.
223605885|NCT02030522|BEHAVIORAL|Accelerated Resolution Therapy (ART)|"The ART protocol will be delivered in 2-5 sessions. Imaginal Exposure (IE) will be used whereby service members and veterans will be asked to recall (verbally or non-verbally) details of the traumatic event(s) while focusing their attention on physiological sensations, thoughts, and emotions. This short period of exposure to the memory will be followed by identification and diminishment of the emergence of any uncomfortable emotional or somatic symptoms. Imagery Rescripting (IR) will be used to change (replace) negative traumatic images to positive images. The service member/veteran will imagine and play out an affectively-driven solution to change sensory components of the memory, as if they were the director of the movie of the memory they are working on."
223753003|NCT05889598|OTHER|Conventional Resistance Lower Body Strength Training|The exercise programme involves two supervised sessions per week at Loughborough University. Each session will involve 30-40 minutes of exercise, comprising warm-up , two main exercises: a hack squat and calf raise using a hack squat machine, and core exercises. After a warm-up period involving 5 minutes cycling and one set of 5 conventional repetitions at 40% of 1RM, the conventional training group will complete eccentric and concentric phases of hack squatting exercises for approximately 3 seconds each, with appropriate breathing techniques. The load will be decided according to regular maximal muscular strength test (1RM) to use of the correct weight for training (in proportion to the strength). Participants will start off using light weights and these will increase as participants become stronger.
223753004|NCT00035854|DRUG|Zyvox® / Linezolid|
223753005|NCT00554437|BEHAVIORAL|UW Falls Prevention Program|The intervention model is of a community-based multifactorial intervention that links participants to existing medical care and service networks. The intervention used an algorithm based on the University of Wisconsin Falls Prevention Clinic, designed to identify predisposing factors for falls; induce risk reduction changes in medical conditions, medications, behavior, physical status, and home environment through recommendations to participants and their physicians; and make sure these changes are long-lasting through follow-up and linkages to other care networks.
223753006|NCT01066988|OTHER|ORB Ocular Emulsion|lubricant eye drop
223753007|NCT01066988|OTHER|SootheXP Emollient (Lubricant) Eye Drops|lubricant eye drop
223753008|NCT06372288|DEVICE|Transcranial Magnetic Stimulation|Transcranial Magnetic Stimulation (TMS using Intermittent theta burst stimulation (iTBS)
223753009|NCT06372288|DEVICE|Sham Transcranial Magnetic Stimulation|Participants will not receive intermittent theta burst stimulation during the sham-TMS sessions
223753010|NCT06140095|DRUG|Evolocumab|See arm description
223753011|NCT00324064|PROCEDURE|GHRH/arginine stimulation testing|GHRH(Geref) 1mcg/kg IVP followed by Arginine 10% solution 0.5mg/kg (maximum of 30 Gm) infused over 30 minutes. Labs drawn 6 times over 2 hours.
223753012|NCT04391790|PROCEDURE|Cystectomy and modified urinary conduit|The modified retrosigmoid conduit is extended aorund 5 cm, so the left ureter does not have to cross under the mesentery wheras the presumed more robust ileal segment does.
224200561|NCT05847309|OTHER|Early extubation|Patients randomized to early extubation, will be extubated \< 6 hours after endovascular treatment under general anesthesia.
224311466|NCT02235038|BEHAVIORAL|High carbohydrate diet|Feeding study. Composition (by proportion of calories): 60% carbohydrate, 20% fat, 20% protein
224311467|NCT00275938|DRUG|interferon alpha 2b plus ribavirin|
224311468|NCT00275938|DRUG|interferon alpha 2b plus placebo|
224311469|NCT00003638|BIOLOGICAL|Detox-B adjuvant|
224311470|NCT00003638|BIOLOGICAL|THERATOPE STn-KLH vaccine|
224311471|NCT00003638|BIOLOGICAL|keyhole limpet hemocyanin|
224311472|NCT00003638|DRUG|cyclophosphamide|
223753013|NCT04391790|PROCEDURE|Cystectomy and standard urinary conduit ad modum Bricker|The conduit is constructed using approximately 15 cm of terminal ileum and placed in the right side of the abdomen. In order for the left ureter to reach the conduit, it is mobilized behind the sigmoideum to the conduit.
223605886|NCT01870115|DIETARY_SUPPLEMENT|Fiber Pill|This fiber pill has been manufactured to mimic the pill that contains the dietary supplements melatonin (M), strontium citrate (S), vitamin D3 (D) and vitamin K2 (K) in appearance but does not contain the supplements
223605887|NCT01870115|DIETARY_SUPPLEMENT|Melatonin, Strontium citrate, Vitamins D3 and K2|Each pill has been manufactured to contain the dietary supplements 2.5mg melatonin (M), 225mg strontium citrate (S), 1000IU vitamin D3 (D) and 30mcg vitamin K2 (K)
223605888|NCT01569620|BEHAVIORAL|Best clinical practices plus culturally targeted print materials|This intervention arm includes best clinical practices (or usual care at MSSM) and the culturally relevant print materials developed for this study.
223605889|NCT01569620|BEHAVIORAL|Best clinical practices plus standard print materials|This intervention arm includes best clinical practices (or usual care at MSSM) and the standard CRC screening print materials developed by the Centers for Disease Control (CDC).
223605890|NCT01569620|BEHAVIORAL|Best clinical practices alone|This intervention arm includes best clinical practices (or standard/usual care at MSSM) and no additional print materials.
223605891|NCT05078372|DRUG|ropivacaine and midazolam intraarticular administration|Patients undergoing ACL reconstruction with hamstring autograft who will receive ropivacaine and midazolam epidural administration for anesthesic technique for the procedure, and intraarticular administration of those drugs.
223605892|NCT05078372|DRUG|ropivacaine and midazolam epidural administration|Patients undergoing ACL reconstruction with hamstring autograft who will receive ropivacaine and midazolam epidural administration for anesthesic technique for the procedure
223605893|NCT03158324|DRUG|OPB-111077|Receive 600 mg of OPB-111077 on a 4 days-on, 3 days-off per week in 28-day cycles till disease progression or intolerable toxicity
223605894|NCT02517541|DEVICE|SenSura Mio Convex Soft|SenSura Mio Convex Soft is a CE marked ostomy product manufactured by Coloplast
223605895|NCT00941317|DEVICE|Pathformer (micro-drilling device)|The micro-drilling device drills the nail with a prespecified diameter drill bit and to a prespecified depth in the nail, using skin impedance (also referred to as equivalent resistivity level) as a feedback mechanism for stopping the drilling intervention at a preset trigger level value.
223753014|NCT05078853|DEVICE|Point of care assay for thyroglobulin (POC-Tg) evaluation of a suspected cervical lymph node|"FNA Clinic: When a bloody material is seen in the needle, 100 µL of 0.9% saline is drawn via the needle into the syringe. The aspirate is then transferred into an Eppendorf tube. 40 µL is aspirated from the Eppendorf tube and dripped into the middle of the sample well of the POC-Tg kit. Two drops of the buffer are then dispensed into the middle of the sample well. The result of the POC-Tg is obtained and documented after 10 minutes. To compare the accuracy of the POC-Tg kit to the formal immunoassay for Tg, 0.9% saline is added to the aspirate that was left in the Eppendorf tube to a final volume of 0.6 mL. This volume is transferred into a gel containing tube and sent to the clinical laboratory that performs Tg measurement.~Operating room: When an indeterminate or suspicious LN is found, the LN is dissected and evaluated by both the formal evaluation and the POC-Tg. Following dissection of the LN, the ex-vivo POC-Tg is conducted as described above."
224075425|NCT01789970|DRUG|Hydrocodone ER|"During the open-label, titration period, all participants were administered hydrocodone ER tablets at dosages of 15, 30, 45, 60, or 90 mg every 12 hours to identify a dosage deemed successful for managing their pain.~Hydrocodone ER was taken by participants randomized to the hydrocodone ER treatment arm during the double-blind treatment period at the dose level identified during the titration period.~Participants were instructed to take tablets with a glass of water on an empty stomach at least 1 hour before or 2 hours after eating."
224075426|NCT01789970|DRUG|Placebo|"Placebo matching the active drug dose identified during the titration period was taken by participants randomized to the placebo treatment arm during the double-blind treatment period.~Participants were instructed to take intervention with a glass of water on an empty stomach at least 1 hour before or 2 hours after eating."
224075427|NCT04904289|OTHER|All intervention of real world|We analyzed all data we can obtain from our databases
224075428|NCT00104897|DRUG|tanespimycin|
223605896|NCT02083536|RADIATION|Low Dose Fractionated Whole Abdominal Radiation Therapy|A single fraction of LDFWART will be given 6-8 hours after the start of morning administration of Docetaxel for 6 cycles (the time of the start Docetaxel will be counted as the frame of reference for when the LDFWART can be given).
223605897|NCT02083536|DRUG|Docetaxel|Chemotherapy will consist of 6 cycles of Docetaxel. Each cycle will follow standard of care and will be scheduled every 3 weeks ± 3 days. Chemotherapy should be administered in the morning to allow 6-8 hours before Radiation Therapy. On Day 1 of each cycle, chemotherapy will consist of Docetaxel 60 mg/m² infused intravenously over 30-60 minutes (with premedication of dexamethasone 10 mg given IV 30-60 minutes prior to docetaxel administration).
223605898|NCT00699608|DRUG|GSK1755165; placebo; zopiclone|Subjects receive either 3mg GSK1755165, matching placebo or 7.5mg zopiclone
223605899|NCT01426672|OTHER|Monovision Correction (with the help of glasses or contact lenses)|
223605900|NCT00566462|DRUG|perampanel|2 mg/d for 14 days followed by 4 mg/d for 14 days
223605901|NCT00566462|DRUG|placebo|Matching placebo for for 14 days followed by 4 mg/d for 14 days
224311473|NCT01199679|PROCEDURE|Mucosectomy|Endoscopic mucosal resection in the upper GI tract.
223605902|NCT02245945|DRUG|TFV 1% vaginal gel|Tenofovir 1% gel is supplied as a clear, transparent, viscous gel packaged in pre-filled single use applicators. Each applicator contains 4.0 mL of tenofovir gel (equal to 4.4 gm) at a concentration of 1% (weight for weight) formulated in purified water with edetate disodium, citric acid, glycerin, methylparaben, propylparaben and hydroxyethylcellulose, and is pH adjusted to 4-5.
223605903|NCT02245945|DRUG|HEC Placebo Gel|Placebo gel contains hydroxyethylcellulose (HEC) as the gel thickener, purified water, sodium chloride, sorbic acid and sodium hydroxide. The gel is isotonic and formulated at a pH of 4.4. Each pre-filled applicator will contain approximately 4 mL of placebo gel for delivery.
223605904|NCT01929382|DRUG|interferon gamma 1b|Standard therapy vs dose titration
223605905|NCT03827603|DRUG|Ibrutinib|Ibrutinib and rituximab combination for the treatment of steroid refractory AIC (warm type AIHA and PRCA) with underlying CLL.
223753015|NCT03676881|DEVICE|Computerized cognitive battery: Cognigram (CG)|is a validated, computerized battery of cognitive tasks based on card games, developed by Cogstate Ltd. This technology includes four tasks, with a total duration of 10-15 minutes. The subject is asked to answer each task by pressing either 'D' or 'K' keyboard buttons. The technology supports the measurement of attention/vigilance, processing speed, concentration, visual working memory and visual recognition memory. The software will run on a computer supplied by the Bruyère Research Institute, in a private test room. The RA will be present during the testing session, reading out loud the batteries standardized instructions and doing the practice trials with the participants. After the practice trials, the RA will not give any feedback or support.
223753016|NCT03676881|DEVICE|The NeuroCatch™ Platform (NCP)|the NCP includes 6 stimulus sequences specifically designed to elicit desired brain responses. Each sequence contains both the oddball task and semantic word-pair task, and lasts 6 minutes. In our protocol, two sequences will be used. For the setup, EEG electrodes are placed on the participant's scalp, and the EEG signal quality is ensured by gently abrading the skin beneath each of the electrodes. A conductive gel is then placed between the skin and the electrode. Most electrodes are contained in an elastic cap, which is worn by the participants, but some electrodes are attached to the skin with adhesive. This part of the session takes around 10 minutes. EEG scan will commence once the setup is completed. Two auditory scans of 6 minutes each, separated by a one-minute break, will be administered. The total time of EEG testing for participants, including setup, will be of ≈25 minutes.
223753017|NCT03062956|DRUG|MYK-491 or placebo|Oral suspension
223753018|NCT01900028|PROCEDURE|Pharmacokinetic sampling|Blood samples taken pre and post dosing with olaparib+/- itraconazole
223753019|NCT01900028|DRUG|Olaparib tablet dosing|Olaparib tablets: Part A 100mg od, days 1 and 9 only. Part B 10x300mg doses over 5 days (300mg bd).
223753020|NCT01900028|DRUG|Itraconazole|Itraconazole 200mg od Part A days 5 to 11 only
223753021|NCT04028245|DRUG|Spartalizumab|Spartalizumab at 400 mg weeks x 2 doses prior to radical nephrectomy Infusion
223753022|NCT04028245|DRUG|Canakinumab|Canakinumab 300 mg IV Q4 weeks x 2 doses prior to radical nephrectomy Infusion
223753023|NCT01498640|BIOLOGICAL|Collagenase clostridium histolyticum|up to three 0.58 mg injections
224075429|NCT01065974|BEHAVIORAL|Behavior Therapy|Weight loss using CBT and continued CBT during weight loss maintenance.
224075430|NCT01065974|DIETARY_SUPPLEMENT|Meal Replacements|Weight loss using CBT and meal replacements.
224075431|NCT01065974|BEHAVIORAL|Nutritrol|To make widespread nutritional changes to participants personal food environments.
224311474|NCT01199679|PROCEDURE|Rubber Band Ligation|Endoscopically ligate esophageal varices at or above the gastroesophageal junction or to ligate internal hemorrhoids.
224311475|NCT02629354|DRUG|Ibuprofen|
224311476|NCT02629354|DRUG|Caffeine|
223508157|NCT03882801|DRUG|Gefapixant|In Periods 1 and 2 (7 days each) participants receive 4 tablets (180 mg) of gefapixant (MK-7264) QHS.
223508158|NCT03882801|DRUG|Placebo|In Periods 1 and 2 (7 days each) participants receive 4 tablets of placebo QHS.
223508159|NCT06380400|BEHAVIORAL|Foot bath|Pregnant women were given footbaths for 20 minutes during the active phase of the first stage of labour (after cervical dilatation of 4 cm) and 20 minutes during the transitional phase of the second stage of labour (cervical dilatation of 9 cm). Pregnant women who completed two footbath sessions were assessed for pain using the visual comparison scale. In addition, the data collection process will be completed by applying the Birth Comfort Scale after the two stages of labour.
223508160|NCT06369662|DIAGNOSTIC_TEST|Flow cytometric immunophenotyping|CD155 expression by flow cytometric immunophenotyping
223508161|NCT06369662|DIAGNOSTIC_TEST|Complete blood count|Complete blood count with peripheral blood smear examination
223508162|NCT06369662|DIAGNOSTIC_TEST|Bone marrow aspiration|Bone marrow aspiration at both diagnosis and follow up of patients
223508163|NCT06369662|DIAGNOSTIC_TEST|Cytogenetic testing|Karyotyping or AML fluorescence in situ hybridization (FISH) panel for diagnosis and risk stratification of AML patients
223508164|NCT06369662|DIAGNOSTIC_TEST|FLT3-ITD using High resolution melting curve (HRM) analysis|Detection of FLT3-ITD mutation in AML patinets
223508165|NCT06324578|DIAGNOSTIC_TEST|AT Testing|Analysis of blood specimens and neck ultrasonography
223508166|NCT04574505|DIETARY_SUPPLEMENT|Eufortyn Colesterolo Plus|Food supplement combination containing bergamot (Vazguard®) phytosomal polyphenolic fraction associated with standardized artichoke extract (Pycrinil®, Cynara Cardunculus L) and Cynara scolimus, associated with high coenzyme Q10 bioavailability(Q10 phytosome® Ubiqsome) and zinc.
223508167|NCT04574505|DIETARY_SUPPLEMENT|Placebo|Placebo
223508168|NCT02117154|DEVICE|6-day Continuous Glucose Monitoring System|performed 3 times on a patient, one month apart
224075432|NCT00927771|DRUG|azelaic acid gel|azelaic acid 15% gel twice a day for 6 months
224075433|NCT00927771|DRUG|hydroquinone cream|hydroquinone 4% cream twice a day for 6 months
224075434|NCT01121393|DRUG|Gemcitabine+Cisplatin|Gemcitabine d1,8, Cisplatin d1, 21 days as a course, up to 6 courses.
224311477|NCT02629354|DRUG|Ibuprofen|
223508169|NCT06348212|DIETARY_SUPPLEMENT|Lactobacillus paracasei PS23|2 caps daily use
223508170|NCT06348212|DIETARY_SUPPLEMENT|microcrystalline cellulose|2 caps daily use
223508171|NCT04607785|DRUG|Miswak mouthwash group|Twice daily for seven days for two months
223508172|NCT04607785|DEVICE|Chlorhexidine gluconate mouthwash|Twice daily for seven days for two months
223508173|NCT04026451|DEVICE|Sedation guided by SEF95 (10-13 Hz) from SedLine® monitor|Dosage of propofol and fentanyl will be guided by SEF95 value between 10-13 Hz. If SEF95 is lower than 10 Hz, the infusion rate of propofol and fentanyl will be diminished; if SEF95 is higher than 13 Hz, the infusion rate of propofol and fentanyl will be increased; and if SEF95 is between 10-13 Hz, then the infusion rate will be kept.
223508174|NCT04026451|BEHAVIORAL|Sedation guided by SAS scale (1-2)|Dosage of propofol and fentanyl will be guided by SAS to keep a value of 1-2. If SAS is higher than 1-2, then the infusion rate of propofol and fentanyl will be increased; and if SAS is 1-2, then the infusion rate of propofol and fentanyl will be maintained.
223508175|NCT04026451|DRUG|Deep sedation with propofol andfentanyl|Propofol and fentanyl will be infused to reach a score in the SAS of 1-2
223508176|NCT04026451|PROCEDURE|Mechanical Ventilation|Critically ill patients will be ventilated mechanically following the clinical indication.
224311478|NCT00086827|DRUG|romidepsin|Given IV
223605906|NCT05440422|DRUG|anifrolumab|This is a double blind placebo-controlled study to characterize whether blocking type I IFN receptor signaling with anifrolumab will lead to improvements in vascular function, decreases in vascular inflammation and modulation of biomarkers of vascular risk in patients with SLE.
223605907|NCT05440422|OTHER|Placebo|non-active substance comprised of 25 mM histidine/histidine-HCl, 50 mM lysine-HCl, 130 mM trehalose, and 0.05% (w/v) polysorbate 80, with a pH of 5.9.
223605908|NCT03078556|DRUG|Dolutegravir|Single dose of DTG 50 mg tablet along with 3TC (EPIVIR) tablet will be given to randomized subjects in parts 1 and 2 with 240 mL of room temperature water. DTG will be a white, film coated, round tablet engraved with SV 572 on one side and 50 on the other side.
223605909|NCT03078556|DRUG|Lamivudine|"Single dose 3TC (commercial name: EPIVIR) 300 mg tablet along with DTG tablet will be given to randomized subjects in parts 1 and 2 with 240 mL of room temperature water.\<br\>3TC will be gray, diamond shaped tablet, engraved GX EJ7 on one side and plain on the other side."
223753024|NCT02037542|BEHAVIORAL|Diet and exercise|Upon enrollment, the patient will be asked to meet with a dietitian to assess the individual patient's current diet and exercise routines. In the first session, the dietitian will provide individual counseling and together with the patient devise weight loss / exercise strategies that fit the patients' lifestyle. Following the initial assessment, patients will embark on a weekly program, with weekly meetings lasting 30min - 1h. Patients will be asked to record meal portions weekly in a Food Log (Appendix B), according to the established goal. At each meeting, the dietitian will review the Food Log with the patient and evaluate progress.
223753025|NCT06293157|PROCEDURE|Transpedicular spinal stabilization - carbon fibers-based implants|Transpedicular stabilization with carbon fiber and PEEK-based implants in one of the two possible variants - first involves a large skin incision and separation of the back extensor muscles; second is associated with minimally invasive, which is percutaneous procedure that allows the stabilization with implants without the need to detach the muscles, using only a small skin incision.
223753026|NCT06293157|PROCEDURE|Transpedicular spinal stabilization - titanium implants|Transpedicular stabilization with titanium implants in one of the two possible variants - first involves a large skin incision and separation of the back extensor muscles; second is associated with minimally invasive, which is percutaneous procedure that allows the stabilization with implants without the need to detach the muscles, using only a small skin incision.
223753027|NCT06293157|RADIATION|Stereotactic body radiotherapy|Spinal tumors will be treated with stereotactic body radiotherapy at a dose of 5x5 Gy (25 Gy in a total dose); either prior to or post-surgical treatment, accordingly the allocation to one of the study arms.
224200562|NCT03476837|BEHAVIORAL|Treatment|The CHWs will go to the homes of the WCGs who enroll in the study and will use a culturally-adapted motivational interviewing protocol, educational messages pilot tested during the formative research phase, and biofeedback based on the child's saliva sample and WCG's carbon monoxide. Saliva samples will be collect from one child in the home at baseline and final. Baseline saliva data and carbon monoxide monitoring will be used to develop feedback that aims to motivate WCGs to implement and sustain comprehensive smoke free policies. The intervention will last 6 months. We will measure changes in primary and secondary outcomes at multiple assessment points.
224200563|NCT03476837|BEHAVIORAL|Control|Following baseline assessment, at 1, 3, and 6 months, WCGs in the control group will educational materials in the mail. Final follow-up assessments will occur at 12 months.
223605910|NCT03078556|DRUG|Dolutegravir + Lamivudine FDC Formulation 1|Single dose of DTG 50 mg combined with 3TC 300 mg in a FDC formulation 1 tablet will be administered to randomized subjects in treatment periods 1 and 2 (under fasted state) of Part 1 and the first 16 subjects in treatment period 3 (under fed) of Part 1 with 240 mL of room temperature water. \&lt;br\&gt;FDC formulation 1 tablets will be oval, biconvex, white, film coated tablet engraved 'SV H7I' on one face.
223605911|NCT03078556|DRUG|Dolutegravir + Lamivudine FDC Formulation 2|Single dose of DTG 50 mg combined with 3TC 300 mg in a FDC formulation 2 tablet will be administered to randomized subjects in treatment periods 1 and 2 (under fasted state) and the first 16 subjects in treatment period 3 (under fed) of Part 2 with 240 mL of room temperature water. \&lt;br\&gt;FDC formulation 2 tablets will be oval, biconvex, white, film coated tablet engraved 'SV 13N' on one face.
224200564|NCT00952432|DRUG|Carbamazepine|Carbamazepine 200mg, 1/2 tablet, TID for 1 month
223605912|NCT00449124|DRUG|Placebo|Injections of 0.5 mL of normal saline solution (0.9% NaCl).
224200565|NCT00952432|PROCEDURE|Acupuncture|Acupuncture
224200566|NCT01070407|BIOLOGICAL|Ad6NSmut; AdCh3NSmut|2 doses Ad6NSmut 5 x 10\^8vp at weeks 0 and 4 and 1 dose AdCh3NSmut 2.5 x 10\^10vp at week 24.
224200567|NCT01070407|BIOLOGICAL|Ad6NSmut; AdCh3NSmut|2 doses Ad6NSmut 5 x 10\^9vp at weeks 0 and 4 and 1 dose AdCh3NSmut 2.5 x 10\^10vp at week 24.
224200568|NCT01070407|BIOLOGICAL|Ad6NSmut; AdCh3NSmut|2 doses Ad6NSmut 2.5 x 10\^10vp at weeks 0 and 4 and 1 dose AdCh3NSmut 2.5 x 10\^10vp at week 24.
224311479|NCT00086827|OTHER|laboratory biomarker analysis|Correlative studies
224311480|NCT00611273|DEVICE|GFX|The GFX system employs minimally invasive technique utilizing Bi-polar (radio frequency) RF technology. GFX ablates nerves activating the muscles that cause glabellar furrowing.
224311481|NCT01841476|DRUG|POL6326|
224311482|NCT01912027|PROCEDURE|Open Latarjet technique|
223605913|NCT00449124|BIOLOGICAL|TG4040|Modified vaccinia virus Ankara encoding hepatitis C virus (HCV) proteins NS3, NS4, and NS5B administered by subcutaneous injection into the thigh. Dosages: TG4040 10\^6 PFU, TG4040 10\^7 PFU and TG4040 10\^8 PFU.
223605914|NCT04555564|PROCEDURE|Technicium 99 MAA infusion|4mci of Technicium 99 MAA will be infused into the bronchial artery via a catheter prior to a standard therapy (bronchial artery embolization). The patient will undergo nuclear medicine imaging following this intervention to quantify MAA distribution within the lung tumor and adjacent lung tissue.
223605915|NCT03502473|DEVICE|UltraShape Power device|"UltraShape Power is a non-invasive focused ultrasound device, approved by the FDA (160896K;170370K); CE; Israeli Ministry of Health. The UltraShape Power system works by emitting acoustic waves of focused ultrasonic energy (200 ± 30 KHz frequency) that converge into a confined focal volume underneath the skin, thereby, targeting only subcutaneous fat at a controlled depth. Unlike traditional ultrasound technology, UltraShape Power's energy transmits pulsed ultrasound, allowing control over temperature elevation. The system comprised of two main parts:~* The Main console~* Transducer"
224311483|NCT01912027|PROCEDURE|Arthroscopic Latarjet techniques|
223605916|NCT06123000|PROCEDURE|Modified Widman Flap (MWF)|At buccal and lingual/palatal side, a full thickness incision parallel to the long axis of the tooth will be performed. In case of buccal or lingual pockets deeper than 2 mm, this initial incision will be placed approximately 1 mm apically to the free gingival margin. All soft tissues will be removed from the bony surface of intrabony defects. In case of incomplete adaptation between the flaps and the teeth or between the buccal and lingual flaps, the flaps will be thinned, and an amount of bone removal will be performed. Only osteoplasty will be allowed, while these patients will not receive ostectomy.
223605917|NCT06123000|PROCEDURE|Fiber Retention Osseous Resective Surgery (FibReORS)|At the buccal sites, internally beveled incisions will be positioned at intra-sulcular or extra-sulcular level based on the apico-coronal dimension of the keratinized tissue. A split thickness flap beyond the MGJ will be then elevated. Vertical releasing incisions will be used to augment surgical access as needed. At lingual site split-full-thickness flap was used positioning an extra-sulcular internally beveled primary incision, while at the palatal area, the thinned palatal flap technique will be performed.
224200569|NCT01070407|BIOLOGICAL|AdCh3NSmut; Ad6NSmut|2 doses AdCh3NSmut 5 x 10\^8vp at weeks 0 and 4 and 1 dose Ad6NSmut 2.5 x 10\^10vp at week 24.
224200570|NCT01070407|BIOLOGICAL|AdCh3NSmut; Ad6NSmut|2 doses AdCh3NSmut 5 x 10\^9vp at weeks 0 and 4 and 1 dose Ad6NSmut 2.5 x 10\^10vp at week 24.
223605918|NCT05718856|DRUG|TPO-RAs|After enrollment, all subjects receive TPO-RAs treatment. The initial dose of eltrombopag, hetrombopag and avatrombopag administration were the same as described in arm description. Complete blood count including platelet count was done once a week. The dose of TPO-RAs was adjusted according to the subject platelet count during the period from week 1 to week 24. If the platelet count \>250×10\^9/L, the TPO-RAs will stop until the platelet count \<100×10\^9/L.
223605919|NCT05718856|DRUG|TPO-RAs combining anti-CD 20 monoclonal antibody|"After enrollment, all subjects receive TPO-RAs treatment. The initial dose of eltrombopag, hetrombopag and avatrombopag administration were the same as described in arm description.The dose of TPO-RAs was adjusted according to the subject platelet count during the period from week 1 to week 24.~Subjects in TPO-RAs combining anti-CD 20 monoclonal antibody treatment group received single dose infusion of Rituximab 375 mg/m2 within 14 days after enrollment. Subjects weighing less than 30kg will be given Rituximab 100 mg once a week for four times. Ortuzumab at 1000mg/ dose is also recommended for subjects weighing 45kg or greater.~Ps.Participants in the TPO-RAs monotherapy group who have platelet count \< 20×10\^9/L or significant skin and mucosal bleeding at the end of 12 weeks of treatment will be given a single dose of Rituximab 375mg/m2 or Ortuzumab at 1000mg/ dose if weighing 45kg or greater."
223605920|NCT04121702|PROCEDURE|Cardiac Rehabilitation|Implementation of a physical exercise program (PEP) with tele-monitoring
223605921|NCT00087334|DRUG|capecitabine|
223605922|NCT00087334|DRUG|gefitinib|
223605923|NCT00087334|DRUG|oxaliplatin|
223605924|NCT02682732|PROCEDURE|FDG-PET/CT guided bone marrow sampling|(Fluorodeoxyglucose positron-emission tomography) FDG-PET/CT guided bone marrow sampling will be used to obtain two different samples from avid and dim bone marrow areas.
223605925|NCT01817426|DRUG|Infliximab|
223605926|NCT01817426|OTHER|Placebo|
223605927|NCT03371693|DEVICE|HIPEC|Patients consenting to this protocol will undergo their scheduled surgical procedure. After cytoreductive surgery (CRS) to a residual disease ≤ 2.5 mm, a single dose of lobaplatin (30 mg/m2) will be administered in normal saline via intraperitoneal hyperthermic perfusion using the closed-abdomen technique. HIPEC will be continued for 60 minutes in the hyperthermic phase (43℃±0.5℃). And HIPEC will be repeated at the 3 and 5 day after the day of CRS plus HIPEC.
223605928|NCT03371693|DEVICE|CRS|cytoreductive surgery (CRS) to a residual disease ≤ 2.5 mm.
223605929|NCT03371693|DEVICE|IVCT|platinum-based intravenous chemotherapy
223605930|NCT01908478|DRUG|Veliparib|
223605931|NCT01908478|DRUG|Gemcitabine|
223605932|NCT01908478|RADIATION|Intensity modulated radiation therapy|
223605933|NCT02085694|DRUG|Lactobacillus brevis CD2|
223605934|NCT02057172|DRUG|HM11260C|HM11260C is a novel long-acting form of CA Exendin-4 (an Exendin-4 analogue)
223605935|NCT02057172|DRUG|liraglutide|Liraglutide is a GLP-1 agonist.
223605936|NCT02057172|DRUG|Placebo|Placebo
223605937|NCT04306510|DRUG|TEGSEDI|SC injection.
224200571|NCT01070407|BIOLOGICAL|AdCh3NSmut; Ad6NSmut|2 doses AdCh3NSmut 2.5 x 10\^10vp at weeks 0 and 4 and 1 dose Ad6NSmut 2.5 x 10\^10vp at week 24.
224200572|NCT01070407|BIOLOGICAL|Ad6NSmut; AdCh3NSmut|1 dose Ad6NSmut 2.5 x 10\^10vp at week 0 and 1 dose AdCh3NSmut 2.5 x 10\^10vp at week 8.
224200573|NCT01070407|BIOLOGICAL|AdCh3NSmut; Ad6NSmut|1 dose AdCh3NSmut 2.5 x 10\^10vp at week 0 and 1 dose Ad6NSmut 2.5 x 10\^10vp at week 8.
224200574|NCT01070407|BIOLOGICAL|AdCh3NSmut; Ad6NSmut|1 dose AdCh3NSmut 7.5 x 10\^10vp at week 0 and 1 dose Ad6NSmut 7.5 x 10\^10vp at week 8.
224311484|NCT04422782|OTHER|For each routine sample, an additional tube will be collected to measure the osmotic pressure in the blood and urine|Interventional research protocol involving the human person category 2 at risk and minimal constraints
223605938|NCT04961112|DEVICE|Cranial Electrotherapy Stimulation|Participants will receive cranial electrotherapy stimulation stimulation on one of two separate visits (within-subjects).
223605939|NCT04961112|DEVICE|Sham Cranial Electrotherapy Stimulation|Participants will receive sham stimulation on one of two separate visits (within-subjects).
223605940|NCT04720417|DRUG|Defactinib Hydrochloride|Given PO
223605941|NCT04720417|DRUG|Raf/MEK Inhibitor VS-6766|Given PO
223605942|NCT04720417|PROCEDURE|Biopsy|Undergo tumor biopsy
223753028|NCT04253288|OTHER|Morbidity Mortality Review (MMR)|"* Standardization of Morbidity Mortality Review (MMR) in radiotherapy centers~* National database from MMR board meetings which include clinical , radiation technique and biological parameters of intrinsic radiosensitivity of patients"
224200575|NCT04625907|DRUG|Irinotecan|antineoplastic enzyme inhibitor
224200576|NCT04625907|DRUG|Actinomycin D|Antineoplastic agent that is a polypeptide antibiotic
224200577|NCT04625907|DRUG|Doxorubicin|An anthracycline topoisomerase inhibitor isolated from streptpmyces peucetius var. casesius
224200578|NCT04625907|DRUG|Ifosfamide|chemotherapeutic agent chemically related to the nitrogen mustards and is a synthetic analog of cyclophosphamide
224200579|NCT04625907|DRUG|Vincristine|anti neoplastic vinca alkaloid agent
224200580|NCT04625907|DRUG|Vinorelbine|vinca alkaloid with a role as an antineoplastic agent
223605943|NCT06500715|DEVICE|Acupuncture|Acupuncture will be administered bilaterally on points PC6, LI 4, CV6, SP6, SP10 and ST36 on the first day of each cycle (d1), prior to administration of chemotherapy; and on d8, each session lasting between 30 to 45 minutes. Patients will continue from d1 to d8 with press-tack acupuncture needles on points PC 6, LI4, SP 6 and ST 36. On d8, patients will again undergo acupuncture, and continue with self-acupressure on the same points as the press-tack needles, until the next chemotherapy cycle.
223605944|NCT04770116|DEVICE|Auditory Stimulation|The device records biosignals and precisely plays tones to enhance sleep slow waves.
223605945|NCT02312817|OTHER|Mailed Outreach Invitation|"Individuals randomized to Group 2 will receive:~1. Mailed outreach invitation to complete HCC screening ultrasound and alpha-fetoprotein (AFP) blood test.~2. Live phone calls 2 to 4 weeks after the mailed invitation to facilitate HCC screening completion. Up to three attempts will be made. All communications will use standard English or Spanish scripts.~3. Centralized process to promote guideline-appropriate follow up testing with CT or MRI or referral to GI Clinic."
223605946|NCT02312817|OTHER|Mailed Outreach Invitation and Patient Navigation|"Individuals randomized to Group 3 will receive:~1. Mailed outreach invitation to complete HCC screening ultrasound and alpha-fetoprotein (AFP) blood test.~2. Live phone calls 2 to 4 weeks after the mailed invitation to facilitate HCC screening completion and address patients' self-reported barriers to HCC screening (e.g., it does not apply to me). Up to three attempts will be made. All communications will use standard English or Spanish scripts.~3. Centralized navigation to promote screening completion (i.e., appointment reminder phone calls from patient navigator) and guideline-appropriate follow up testing with CT or MRI or referral to GI Clinic."
223605947|NCT04662554|DEVICE|1-mm Resolution Clinical PET camera|1-Millimeter Resolution Clinical PET System in Head and Neck Cancer (HNC) Imaging
223605948|NCT05547048|BEHAVIORAL|Decision Aid|Decision aid for PrEP tailored for justice-involved women with opioid use disorder
223605949|NCT05547048|COMBINATION_PRODUCT|Athena strategy|eHealth for integrated PrEP/medications for opioid use disorder + decision aid
223605950|NCT06073652|OTHER|Control 1st age starter infant formula|A standard bovine milk-based term infant formula.
223605951|NCT06073652|OTHER|Experimental 1st age starter infant formula|Same content as Control formula plus supplemented with a HMO blend and a probiotic
223605952|NCT04299282|DEVICE|CanGaroo|CIED ECM envelope
223753029|NCT06558474|BEHAVIORAL|Liberal post-dilatation strategy during PCI|"A liberal post-dilatation strategy for stent optimization during PCI will be implemented in multiple centers in the Netherlands.~This include an increase of post-dilatation use of at least 20% per operator, or a percentage of post-dilatation of at least 85%.~Operators will be asked to enforce a very low threshold for post-dilatation in general, with a mandatory HPNC post-dilatation for the following indications:~* In case of any calcification~* Delta of ≥ 0.5mm between the distal and proximal reference diameter of the treated coronary segment~* Stent length \>24 mm~* Signs of incomplete stentframe-deployment on angiography or StentBoost~* In case of CTO~* In case of bifurcation PCI (Left main and non-left main)~  * Proximal Optimisation Technique (POT) with NC balloon~ * Final Kissing Balloon dilatation (FKB) with preferentially first sequential high-pressure inflations and final low pressure kiss both with NC balloons"
223753030|NCT03178747|DIAGNOSTIC_TEST|Methylene blue|working solution methylene blue
223753031|NCT03178747|DIAGNOSTIC_TEST|Giemsa stain|working solution Giemsa stain (Wolbach's modification)
223605953|NCT04075981|DRUG|Botulinum Toxin Type A Injection [Xeomin]|Before the main stage of the surgery, botulinum toxin will be injected into the entire visible area of the 4 major epicardial fat pads, during extra corporal circulation and before aortic cross clamping in order to reduce the time of ischemia.
223753032|NCT02635516|DEVICE|Near-Infrared Phototherapy|"The In Light Wellness Systems Near-Infrared Phototherapy Device (manufactured by In Light Wellness Systems, Inc.) contains alternating rows of 402 red (640 nm) and infrared (880 nm) light-emitting diodes embedded in 2 neoprene pads. One pad circles the skull, providing 720 Joules/min, and the other pad covers the top of the head, providing 360 joules/min. For each treatment session, the A setting on the 3-port controller is utilized, which runs approximately 6.7 min of 73 Hz, 587 Hz, and 1175 Hz in an automated sequential manner. No other interventions were utilized."
223753033|NCT05800470|OTHER|fNIRS-based neurofeedback with motor imagery|A multichannel wearable fNIRS (NIRSport2, NIRx Medical Technologies LLC, Glen Head, NY, USA) will be used to detect the cortical activity in SMA. The HbO concentration will be processed and displayed as a visual feedback during MI training.
223753034|NCT05800470|OTHER|Kinesthetic motor imagery|Prior to each task, participants will watch a video of a person executing balance tasks and walking tasks. The balance tasks will include static and dynamic standing tasks such as sit-to-stand, tandem stance, standing on a balance board, reaching out to different directions and single leg stance. The walking tasks consists of tandem walking, crossing obstacles, sideward walking, backward walking, and turning. The participants will be asked to kinesthetically imagine movements in the first-person perspective, and the researcher will give the explicit instruction encouraging them to focus on the feeling (i.e. tactile, proprioceptive and kinesthetic sensations). Each MI session consists of 10-min of balance tasks and 10-min of walking tasks.
224200581|NCT04625907|DRUG|Cyclophosphamide|Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent
224200582|NCT04625907|DRUG|Temozolomide|oral antineoplastic alkylating agent
224200583|NCT04625907|RADIATION|radiotherapy|Ionising radiation
224200584|NCT04625907|DRUG|Regorafenib|Oral multi-kinase inhibitor that targets a broad range of angiogenic, stromal and oncogenic kinases, including vascular endothelial growth factor receptors (VEFGR) 1, 2 and 3, tyrosine kinase with immunoglobulin and epidermal growth factor homology domain 2 (TIE2), platelet-derived growth factor receptor (PDGFR), fibroblast growth factor receptors (FGFR), c-KIT, RET, RAF-1 and BRAF (wild-type and V600E mutant).
224200585|NCT03015207|DRUG|NNC0194-0499|
223605954|NCT04075981|OTHER|Drug placebo|All patients from the control group will receive placebo. Before the main stage of the surgery, during extra corporal circulation and before aortic cross clamping, the placebo will be injected into the entire visible area of the 4 major epicardial fat pads as follows (1 mL at each fat pad).
223605955|NCT05653115|PROCEDURE|Bariatric surgery|Bariatric surgery
224200586|NCT03015207|DRUG|Placebo|
224200587|NCT03862807|DRUG|Patisiran|Patisiran was administered via IV infusion.
224200588|NCT03144115|DRUG|Oxytocin|
224200589|NCT03144115|DRUG|Placebos|
224311485|NCT00561704|DRUG|losartan|losartan, 100mg daily,
223753035|NCT05800470|OTHER|Motor training|The tasks for balance and gait training are similar to those during the MI training. The difficulty of the tasks will be modified individually for each participant. The researcher will ensure the safety.
223753036|NCT05852431|DRUG|Pegozafermin|Subcutaneous injection
223753037|NCT05852431|DRUG|Placebo|Subcutaneous injection
223753038|NCT04242615|OTHER|Prognostic score|
223753039|NCT00210054|DRUG|denufosol tetrasodium (INS37217)|
223753040|NCT00415233|BIOLOGICAL|recombinant thyroid-stimulating hormone|Recombinant thyroid stimulating hormone (rhTSH) should be given at a dose of 0.9mg by intramuscular injection on two consecutive days before ablation.
223753041|NCT00415233|RADIATION|Radiodine ablation without rhTSH|Patients in this group do not receive rhTSH pre ablation.
223753042|NCT06003010|BEHAVIORAL|Yoga|6 yoga videos to be done 2-3x a week for 6 weeks before and after surgery.
223753043|NCT01514695|DRUG|Midazolam|Starting with 1mg intravenously in all patients. More can be added at the discretion of the physician as needed for sedation.
223753044|NCT01514695|DRUG|Fentanyl|100mcg intravenously given in 2mL syringe at start of procedure
223753045|NCT01514695|OTHER|Placebo|One dose of saline (2ml)
223753046|NCT05891509|PROCEDURE|Minimally Invasive Hematoma Evacuation|Procedure of minimally invasive hematoma evacuation PLUS best medical therapy
223753047|NCT05891509|OTHER|Best Medical Therapy|Best medical therapy
223605956|NCT06099561|BEHAVIORAL|National specialized medical care unit for severe self-harm behaviour-Consultation model|Extensive assessments. Consultation and training for existing treatment providers and caregivers. Network-meetings for providers and caregivers.
223605957|NCT04587050|DIAGNOSTIC_TEST|Human papillomavirus testing|HPV test from cervical sample using Cepheid GeneXpert HPV
223753048|NCT05434520|PROCEDURE|Preoperative biliary drainage (ERC og PTC-aided)|Placement of biliary stent (plastic, covered SEMS, uncovered SEMS) endoscopic by ERC or placement of plastic catheter by PTC
223753049|NCT02110342|DRUG|[14C] PF-04449913|Single oral dose of 100 mg PF-04449913 + 100µCi of \[14C\] PF-04449913
223753050|NCT06418841|PROCEDURE|Computer-Assisted Paramedian Approach Technique|Computer-Assisted Paramedian Approach Technique
223753051|NCT06418841|PROCEDURE|Conventional Midline Approach Technique|Conventional Midline Approach Technique
223605958|NCT04587050|DIAGNOSTIC_TEST|Cervical cytology|Cervical cytology
223605959|NCT04587050|DIAGNOSTIC_TEST|HPV serology|HPV type specific serology (16/18) using ELISA from serum samples
223605960|NCT02468726|DEVICE|NER1008 enema|NER1008 enema administered to cleanse the bowel bewteen 1 and 3 hours prior to flexible sigmoidoscopy
223605961|NCT02468726|DRUG|Fleet|Fleet enema administered to cleanse the bowel bewteen 1 and 3 hours prior to flexible sigmoidoscopy
223605962|NCT00004052|BIOLOGICAL|QS21|
223605963|NCT00004052|BIOLOGICAL|bcr-abl peptide vaccine|
223605964|NCT05716932|PROCEDURE|Dual focal laser and intravitreal Ranibizumab injection|Direct and perilesional focal laser followed by a single intravitreal 0.5 mg ranibizumab (Lucentis, Genentech, Inc., South San Francisco, CA, USA) injection
223753052|NCT05631405|DRUG|Dexamethasone|Patients treated with dexamethasone
223753053|NCT05631405|DRUG|Placebo|Patients treated with placebo
223753054|NCT00780325|DRUG|CG100649 (2 mg)|CG100649 capsules: 2 mg, single oral administration (Part 1); CG100649 capsules: dose to be determined, single oral administration (the single CG100649 dose level used in Part 3 will be determined by part 1 and 2).
223753055|NCT00780325|DRUG|Celecoxib|Celecoxib (Celebrex®) capsules: 200 mg; single oral administration (Part 1 and 3)
223753056|NCT00780325|DRUG|Placebo capsules|Placebo capsules: 198 mg silicified microcrystalline cellulose + 2 mg talc, multiple oral administrations (Part 1 and 3)
223753057|NCT00780325|DRUG|Naproxen|Naproxen (Naprosyn®) tablets: 500 mg, single oral administration (Part 3)
223605965|NCT04778826|PROCEDURE|Lymphadenectomy|radical bloc dissection of all mediastinal lymph node stations
223605966|NCT06104111|DIETARY_SUPPLEMENT|Vitamin D3|Vitamin D3 bolus at days 0, 28 and 56. Blood samples taken at days 0, 1, 28, 29, 56, 57 ad 84
223605967|NCT00390039|DRUG|Intranasal Morphine|MNS075 7.5mg q1h PRN
223605968|NCT00390039|DRUG|Placebo|IN Placebo q1h PRN
223605969|NCT00390039|DRUG|IV morphine|IV morphine 7.5mg q3h PRN
223605970|NCT00390039|DRUG|Placebo|IV Placebo q3h PRN
223605971|NCT00390039|DRUG|Intranasal morphine|MNS075 15mg q3h PRN
223605972|NCT00390039|DRUG|Placebo|IN Placebo q3h PRN
223753058|NCT00780325|DRUG|Acetazolamide|Acetazolamide (generic, immediate release) tablets: 250 mg, single oral administration (Part 3)
223753059|NCT00780325|DRUG|CG100649 (8 mg)|CG100649 capsules: 8 mg, single oral administration (Part 1); CG100649 capsules: dose to be determined, single oral administration (the single CG100649 dose level used in Part 3 will be determined by part 1 and 2).
223753060|NCT06220708|OTHER|dance movement therapy|Our DMT program was adapted from an integrated somatic dance and visual arts program previously applied to the older population (Hsu, 2023). The intervention was scheduled in the afternoon and lasted for approximately 2 h. As previously recommended, rhythmic and contralateral movements on both sides of the body were emphasized in this study to enhance coordination and stimulation between the left and right cerebral hemispheres (Phillips-Silver and Trainor, 2007). The experimental groups were then subdivided into six groups. Balloons half-filled with water were used as the game in this study to guide individual and grouping rhythms and movements. Additionally, painting was incorporated to help participants understand their bodies and psychological states (Tjasink et al., 2023). Finally, group discussions and mutual support, along with verbal sharing after the DMT exercise, were encouraged.
223753061|NCT06220708|OTHER|yoga training|The yoga program included breathing exercises, Asanas, eye focus, body lock, and meditation. Participants were instructed to adjust their positioning based on their skill level to mitigate the risk of injury. The yoga intervention was scheduled at 2 pm and lasted for approximately 2 h.
223753062|NCT03471533|DIETARY_SUPPLEMENT|nutraceutical: experimental product|84 days of consumption
223753063|NCT03471533|DIETARY_SUPPLEMENT|placebo|84 days of consumption
223753064|NCT02578927|DIETARY_SUPPLEMENT|GT+Ex|In this session the volunteers ingested capsules with 2g of powder green tea before exercise
223753065|NCT02578927|DIETARY_SUPPLEMENT|PL+Ex|In this session the volunteers ingested capsules with 2g of placebo before exercise
223753066|NCT02578927|DIETARY_SUPPLEMENT|Green Tea|In this investigation the volunteers ingested capsules with 2g of powder green tea before the rest similar to the exercise time
223753067|NCT05627531|BEHAVIORAL|Narrative Medicine|Intervention group completes pre- and post-intervention measures, composition book and guided reading, discussion, and writing with narrative medicine coordinator.
223753068|NCT06385145|DRUG|PEG-rhGH with new preparation (T)|A single subcutaneous injection of PEG-rhGH with new preparation
223753069|NCT06385145|DRUG|PEG-rhGH with present preparation (R)|A single subcutaneous injection of PEG-rhGH with present preparation
223753070|NCT04430010|BEHAVIORAL|BEST in CLASS|BEST in CLASS is a Tier-2 evidence based program (EBP) that has demonstrated effectiveness at reducing children's Disruptive Behavior Problems (DBPs) and risk for Emotional and Behavioral Disorders (EBDs)
223753071|NCT04017936|DRUG|Anakinra|Active Treatment
223753072|NCT01161992|GENETIC|Genetic Analysis|Perform Genome Wide Association Studies.
223753073|NCT02438202|DEVICE|Thymatron IV device (Somatics)|Patients will be treated with a modified routine ECT/maintenance ECT series.
223753074|NCT05908786|DRUG|Atezolizumab|Atezolizumab will be administered at a dose of 1200 mg by IV infusion on Day 1.
223753075|NCT05908786|DRUG|Bevacizumab|Bevacizumab will be administered at a dose of 15 mg/kg by IV infusion on Day 1.
223753076|NCT05908786|DRUG|Tiragolumab|Tiragolumab will be administered at a dose of 600 mg by IV infusion on Day 1.
223753077|NCT05908786|DRUG|Tobemstomig|Tobemstomig will be administered at a dose of 600 mg by IV infusion on Day 1
223753078|NCT00870571|DRUG|AMLODIPINE (as BESILATE) TABLETS 10 mg , single dose|A: Experimental Subjects received EMCURE PHARMACEUTICALS LTD. formulated products under fed conditions
223753079|NCT00870571|DRUG|NorvasC® 10 mg Tablets|B: Active comparator Subjects received Pfizer Labs Division of Pfizer Inc. formulated products under fed conditions
223753080|NCT00651573|PROCEDURE|Blood transfusion at hematocrit value less than 24%|transfusion
223753081|NCT00651573|PROCEDURE|Blood transfusion at hematocrit value less than 28%|transfusion
223753082|NCT01524692|DRUG|Dovitinib (TKI258)|500 mg orally on a 5-days on/2-days off schedule each week of a 4-week (28-day) cycle. Treatment will continue until progression as defined by RECIST, unacceptable adverse events, patient refusal to continue on study, or physician's decision to withdraw the patient.
224200590|NCT01302288|PROCEDURE|Per oral endolumenal myotomy|patient cohort having flexible endoscopic submucosal esophageal partial myotomy
223605973|NCT01295957|BEHAVIORAL|reminiscence therapy|24 bi-weekly sessions of reminiscence therapy, lasting one hour each one, over a period of 12 weeks. The latter refers to the use of images, sentences or memorabilia which help to focus on specific segments of the life history of an individual, and stimulates the emergence of affect-laden personal recalls, which are later verbalized in the context of guided conversations12. The term story life is intended to highlight samples of meaningful events of the subject's life rather than a historically structured biography13. Three main variables contributed to reminiscing: individuality, evaluation and structure.
223605974|NCT01295957|BEHAVIORAL|comparison group|The control group was administered counseling and informal social contacts in bi-weekly sessions of one hour, common subjects addressed by comparison group were social security incomes, diets, family visits.
223605975|NCT01295957|OTHER|control|advise and informal counseling
223605976|NCT01101789|PROCEDURE|triclosan coated suture for surgical wound closure|triclosan coated suture for surgical wound closure
223605977|NCT01101789|PROCEDURE|regular sutures for surgical wound closure|
223605978|NCT04359160|DEVICE|Orthense, Orthense, Digikare Inc. Blagnac, France|Mobile-app follow-up care, with questions and score
223605979|NCT04359160|OTHER|Questionnaire|Paper questionnaire follow-up, with questions and score
223605980|NCT02353715|DRUG|Enzalutamide|
223605981|NCT02353715|DRUG|Abiraterone acetate|
223605982|NCT02353715|DRUG|Sipuleucel-T|
223605983|NCT04797572|DEVICE|Free Margin Cusp Sizer|The free margin cusp sizer will be used during aortic valve repair and sparing procedures as a caliper to measure the aortic valve free margin length.
223753083|NCT03984591|DRUG|Eplerenone|Eplerenone according to guidelines
223753084|NCT03984591|DRUG|Spironolactone|Spironolactone according to guidelines
223753085|NCT01970111|DRUG|KPS-0373, High dose|
223753086|NCT01970111|DRUG|KPS-0373, Low dose|
223753087|NCT06532513|OTHER|Family-Centered Goal-Oriented Physiotherapy and Rehabilitation Application|Family centered goal-oriented physiotherapy and rehabilitation applications aim to enhance the functional level of severely affected children with dyskinetic cerebral palsy children through individualized activities conducted by family members at home. The program focuses on specific goals determined collaboratively by the family, physiotherapists, and physician, with regular monitoring and assessments to track progress.
223753088|NCT04533373|PROCEDURE|DIEP Flap Neurotization|"We will be performing breast reconstruction using tissue from the patient's abdomen and transferring it to the chest wall to repair the mastectomy defect. Sensory function is restored by using the nerve that supplies the skin of this abdominal tissue (i.e the new source) that is being transferred and attaching it to a nerve in the chest wall."
223753089|NCT03993678|DRUG|IP-001|Dose and route: Immediately (within 15 - 30 min) after thermal ablation, IP-001 will be injected in and around the ablated lesion. The amount of IP-001 injected depends on the dose level.
223753090|NCT03993678|DEVICE|Thermal Ablation|"The medical device includes a laser unit. The system continuously measures the temperature of the tissue, guiding the user to perform precise and safe treatments.~Treatment time: 30 min"
224311486|NCT05009914|PROCEDURE|cardiac denervation|Excision of Marshall ligament and Waterstone fat pad during CABG.
223753091|NCT04770012|DRUG|Placebo|patients randomized to placebo study group will be dispensed placebo capsules to be taken daily for the duration of the treatment
223753092|NCT04770012|DRUG|aspirin|patients randomized to aspirin study group will be dispensed aspirin capsules to be taken daily for the duration of the treatment
223753093|NCT04770012|DRUG|Clopidogrel|patients randomized to clopidogrel study group will be dispensed clopidogrel capsules to be taken daily for the duration of the treatment
224200591|NCT00003861|OTHER|laboratory biomarker analysis|
224200592|NCT04362761|DRUG|ELX/TEZ/IVA|Fixed-dose combination (FDC) tablet for oral administration.
224200593|NCT04362761|DRUG|IVA|Tablet for oral administration.
223605984|NCT05600244|PROCEDURE|PENG block Technique|A linear probe will be used. Puncture will be performed in a lateromedial direction until the needle tip reached the plane between the iliopsoas tendon and periosteum and between the anterior inferior iliac spine and iliopubic eminence. After a negative aspiration test, 30 ml of bupivacaine 0.25% will be injected in the plane beneath the iliopsoas muscle
223605985|NCT05600244|PROCEDURE|Lumbar ESPB Technique|Using the out-plane technique, a 22G/80-mm block needle will be advanced until it reached the transverse process. 0.5-1 ml of the prepared local anesthetic solution, 30 ml bupivacaine 0.25% will be administered leading to hydrodissection to confirm the correct location. The needle will be repositioned by pulling back a few millimeters if resistance occurs when administering local anesthetic . All local anesthetic will be administered to this location between the transverse process and the erector spinae muscle
223753094|NCT06821867|DEVICE|PN + HA (Newest)|"PN+HA (Newest) is a viscoelastic, sterile, single-use gel for intradermal use. PN+HA is a medical device containing the combination of polynucleotides (10 mg/ml) and hyaluronic acid (10 mg/ml).~PN+HA is administered using a fine needle (usually 30 G) by injecting the solution into the dermis. Depending on the medical assessment, different injection techniques such as linear threading, serial punctures, crosslinked, radial fanning or mixed can be used. The injection site must consist of healthy skin. PN+HA can also be administered by means of non-invasive techniques (iontophoresis, electroporation, hydroelectrophoresis, etc.). In all these cases, thoroughly cleanse and disinfect the area to be treated before application. Then remove the disinfectant with sterile saline."
223753095|NCT00310531|DRUG|Menostar (Estradiol, BAY86-5435)|Menostar (estradiol transdermal delivery system (SHP00577E), 0.014 mg/day)
223753096|NCT00310531|DRUG|Raloxifene|Raloxifene tbl. (60 mg/day)
223753097|NCT05306418|DRUG|Mim8|"For treatment part 1, all participants will start on once-weekly treatment and continue on this regimen until week 26. For treatment part 2, starting at week 26, all participants will be offered the choice to remain on once-weekly or switch to once-monthly dosing.~Mim8 will be injected with a thin needle into the skin"
223753098|NCT00457782|DRUG|KW-2478|Daily intravenous KW-2478 for 5 days in 14-day cycles, ascending dose cohorts
223753099|NCT05749575|DRUG|Chidamide Plus Toripalimab Plus Paclitaxel|Each participant receives chidamide plus toripalimab plus paclitaxel
223753100|NCT03922451|DRUG|piperacillin-tazobactam|Administered for infection treatment or prophylaxis per hospital protocol
224200594|NCT05595161|BEHAVIORAL|Bright Bodies|The Bright Bodies intensive, family-based lifestyle intervention uses group sessions including nutrition education, behavior modification, and exercise to improve weight and weight-related outcomes among children and adolescents with obesity.
224200595|NCT00684645|DRUG|SUTENT|SUTENT® hard gelatin capsules containing 12.5 mg, 25 mg or 50 mg equivalent of sunitinib malate; daily dosage of 50 mg for 4 consecutive weeks followed by a 2-week rest period. Sutent is administered until disease progression or occurrence of unacceptable toxicity.
224200596|NCT04729504|BEHAVIORAL|Adapted Project BRAVE|A culturally and linguistically adapted Project BRAVE is web-based single session intervention that is about 30 minutes in length. The session is designed to focus on targeting child anxiety symptoms in the multilingual and diverse families in Miami-Dade.
223605986|NCT05600244|PROCEDURE|Transmuscular QLB-t block Technique|A convex transducer will be placed in the transverse plane on the flank of the patient cranial to the iliac crest. The 4th lumbar vertebral transverse process, erector spinae muscles, psoas muscle, transverse abdominis muscle, internal and externa oblique muscles, and the quadratus lumborum muscle will be identified. A 15 cm 22G insulated needle will be inserted on the posterior corner of the transducer. 30 ml bupivacaine 0.25% will be administered between the quadratus lumborum and psoas muscles into the fascial plane.
223605987|NCT01035619|DRUG|moxidectin|Single Dose Moxidectin 4 mg
223605988|NCT00255788|DRUG|everolimus|
223605989|NCT00609570|DIETARY_SUPPLEMENT|NanoGreens|fruits and vegetables
223605990|NCT00609570|DIETARY_SUPPLEMENT|Whey protein|Whey
223605991|NCT00609570|DIETARY_SUPPLEMENT|Calcium pills|CA
223753101|NCT03922451|DRUG|Cefazolin|Administered for infection treatment or prophylaxis per hospital protocol
223753102|NCT00369512|DRUG|Erlotinib|Erlotinib therapy for 2 weeks (150 mg po qd)(for those who are enrolled before surgery is done), surgery/biopsy up to 8 weeks recovery, radiation/Erlotinib therapy for 6 weeks (150mg po qd).
223753103|NCT04007523|BEHAVIORAL|Family Support System|Family members and/or caregivers of patients will receive pagers, and alerts will provide recommendations for daily delirium screening and therapeutic activities. Protocols with associated activities will be provided to family members.
223753104|NCT04007523|BEHAVIORAL|HELP Support System|A postoperative page will be sent, on behalf of participants, to the on-call HELP staff. The page will request early evaluation and enhanced therapeutic protocols for delirium prevention.
223753105|NCT02608554|BEHAVIORAL|Taichi|The program of Taichi training consisted of 60 minutes exercise sessions, 3 days per week for 12 weeks, based on their original level of physical activity. Each session comprised 40 minutes of Taichi training plus a 10-minute warm-up and cool-down. The Taichi training was instructed by the same experienced Taichi instructors who were qualified in the teaching of Taichi. The 24 forms of simplified Taichi recommended as the popular health sport by the General Administration of Sport of China were applied.
223753106|NCT02608554|BEHAVIORAL|Self-monitored exercise|Exercise was self-monitored and consisted of brisk walking, cycling, jogging, or any other aerobic exercise for 60 mins. 3 days per week for 12 weeks.
224200597|NCT01771627|DRUG|varenicline|Given PO
224200598|NCT01771627|DRUG|nicotine patch|
223618217|NCT02290015|OTHER|Acupuncture|All treatments were performed by the same acupuncturist, who is a medical doctor with more than eight years of clinical and research experience in ACP for tinnitus. Acupoints described as being effective for tinnitus were selected according to TCM theory. Basic points that are manipulated in ACP include GV 20 (Baihui), TE 17 (Yifeng), GB 8 (Shuaigu), SI 19 (Tinggong), GB 2 (Tinghui), TE 21 (Ermen), VC 23 (Lianquan), GB 20 (Fengchi), TE 2 (Yemen), TE 5 (Waiguan), SI 2 (Qiangu), GB 43 (Xiaxi) and GB 41 (Zulinqi). However, several secondary (accessory) acupoints were also added according to TCM and the etiological diagnosis of tinnitus: GV 4 (Mingmen), KI 3 (Taixi), BL 23 (Shenshu), BL 19 (Danshu), BL 18 (Ganshu) and CV 4 (Guanyuan).
223753107|NCT04652479|DRUG|Avexitide|Avexitide (exendin 9-39) is a competitive antagonist of GLP-1 at its receptor
223753108|NCT04879004|DRUG|Ropivacaine injection|Effect of continuous ESPB performed with Ropivacaine 0,375% infusion, in patients undergoing elective laparoscopic colectomy.
223618218|NCT03035799|OTHER|Paleolithic diet|Paleolithic diet
224311487|NCT05641090|OTHER|Nordic walking in water|Nordic walking in water will be based on nordic walking in water at temperature 34◦C. Nordic walking in water will be conducted at moderate intensity (40-60% heart rate reserve). The program was exercised 60 minutes include warm-up and cool down. At first 6 weeks, The exercise intensity was 40-50% heart rate reserve and it will be increased 50-60% heart rate reserve. The training program will be performed 3 times per week for 12 weeks.
223508177|NCT04252118|BIOLOGICAL|MSCs|3 times of MSCs(3.0\*10E7 MSCs intravenously at Day 0, Day 3, Day 6).
223508178|NCT01389284|DRUG|Naproxen Sodium ER (BAYH6689)|660 mg Naproxen Sodium extended release tablet, orally administered once daily for 24 hours
223508179|NCT01389284|DRUG|Naproxen Sodium IR (Aleve, BAYH6689)|220 mg Naproxen Sodium instant release tablet, orally administered 3 times daily (TID) for 24 hours
223508180|NCT01389284|DRUG|Naproxen Sodium ER Placebo|Matching placebo of 660 mg Naproxen Sodium ER for 24 hours
223508181|NCT01389284|DRUG|Naproxen Sodium IR Placebo|Matching placebo of 220 mg Naproxen Sodium IR (Aleve) for 24 hours
223508182|NCT01144351|DRUG|ELND002|
223508183|NCT01144351|DRUG|Placebo|
223508184|NCT00476788|DEVICE|Omnipod Insulin Management System|Initiation of insulin pump therapy within three months of the diagnosis of type 1 diabetes mellitus
223618219|NCT03035799|OTHER|General Healthful Diet|General Healthful Diet
223618220|NCT01366989|DEVICE|Radiographic evaluation of previously implanted patients|Radiographs of the ankle
223618221|NCT04187495|DRUG|MAX-40279-01|"Part 1: Dose escalation, MAX-40279-01 twice daily with dose modifications based on tolerability criteria.~Part 2: Dose expansion, Recommended doses from Part 1.~For each dose level, a single dose of MAX-40279-01 will be first administered orally followed by 1 day observation, then continuous treatment will start 4 weeks treatment (per cycle)."
223618222|NCT04657874|OTHER|Bromelains and Escin Oral Tablet|Supportive care after oral surgery
223618223|NCT04657874|OTHER|Placebo|Oral tablet without the active principle
223618224|NCT00479713|DRUG|ezetimibe (+) simvastatin|ezetimibe/simvastatin 10/20mg. The treatment duration will be 6 weeks.
223618225|NCT00479713|DRUG|Comparator : rosuvastatin calcium|rosuvastatin 10mg. The treatment duration will be 6 weeks.
223618226|NCT00479713|DRUG|Comparator: Placebo (unspecified)|rosuvastatin 10mg Placebo. The treatment duration will be 6 weeks.
223618227|NCT00479713|DRUG|Comparator: Placebo (unspecified)|ezetimibe/simvastatin 10/20mg Placebo. The treatment duration will be 6 weeks.
223618228|NCT04963400|DIAGNOSTIC_TEST|Analysis of hs-cTnT serum concentration at hospitalization|Analysis of the hs-cTnT serum concentration in the blood drawn at the day of hospitalization
223618229|NCT04963400|DIAGNOSTIC_TEST|Analysis of hs-cTnT serum concentration after discharge|Analysis of the hs-cTnT serum concentration in the blood drawn after discharge (60 days after hospitalization)
223618230|NCT00271102|PROCEDURE|anterior vaginal repair (colporrhaphy)|vaginal repair
223618231|NCT00271102|PROCEDURE|abdominal paravaginal defect repair|abdominal repair
223618232|NCT03216408|DRUG|Neuronox|
223618233|NCT03216408|DRUG|Botox|
223618234|NCT02664662|OTHER|tailored education|Tailored rehabilitated education is which fit for each breast cancer patients after surgery in clinic. We design three of tailored books for experimental group. Each patients will be tailored by three principles. First, the educated times and hours are depended on patients physical function and learning ability. Second, the material is depended on each patient's life experience. Finally, the educated content is depended on patient's operation method.
223618235|NCT02226718|OTHER|Administration of questionnaire|
223618236|NCT05100615|PROCEDURE|surgery|applying the graft inside bony defect after surgery
223618237|NCT00200330|BEHAVIORAL|Behavioral weight loss treatment|
223618238|NCT00200330|BEHAVIORAL|Behavioral and home environment weight loss treatment|
223618239|NCT03863509|BEHAVIORAL|Cigarettes|smokes daily
223618240|NCT03863509|BEHAVIORAL|E-Cigarettes|E-cigarette usage \>/= 5 days/week
223618241|NCT00141102|DRUG|Celecoxib|Participants are assigned to one of two groups in parallel for the duration of the study
223618242|NCT00141102|DRUG|Diclofenac + Omeprazole|Participants are assigned to one of two groups in parallel for the duration of the study
223618243|NCT02952885|DRUG|Pegvisomant|Study medications will be prescribed as per clinical practice with PEGV being added, or optimally dosed, at the Month 0 visit. Subjects who are naïve to PEGV should start their injections from 10 mg twice a week to 10 mg daily if used as combination therapy or 10 to 20 mg daily if used as monotherapy. Maximum dosing should not exceed 40mg/day. Dosing of PEGV can be adjusted as per clinical judgement to meet the normalization of IGF-1 levels (\<1.0 ULN) in increments of 5-10mg/day. In the event of a reduction in IGF-1 below the LLN, the dose of PEGV could be decreased by 5-10 mg/day.
223618244|NCT03067246|DEVICE|VBM Intubating Laryngeal Tube|The position of the VBM Intubating Laryngeal Tube will be assessed using a fibreoptic scope following balloon inflation of the cuff. Seal pressure will be assessed with the presence of the inflated cuff. Endotracheal intubation through the intubating laryngeal tube with a size 7 VBM reinforced tube will be assessed using a fiberoptic scope.
223618245|NCT03067246|DEVICE|I-Gel|The position of the I-Gel will be assessed using a fibreoptic scope. The seal pressure will be assessed with the specified design of the I-Gel in the absence of a cuff. Endotracheal intubation through the I-Gel with a size 7 reinforced endotracheal tube will be assessed using a fiberoptic scope.
223618246|NCT03549221|DRUG|0.6 mg 1:1000 epinephrine (0.6 ml)|In group 1, the multimodal anesthetic cocktail consisted of 100 mg Levobupivacaine (0.5%, 20 mL) 30 mg ketorolac (1 ml) and 0.6 mg 1:1000 epinephrine (0.6 ml). In group 2, the multimodal anesthetic cocktail consisted of 100 mg Levobupivacaine (0.5%, 20 mL) and 30 mg ketorolac (1 ml). Both groups were mixed with a 0.9% normal saline solution to a total volume of 100 ml.
223618247|NCT05455476|BEHAVIORAL|CBT for Loneliness|CBT delivered over the course of 8, \~45 minute sessions delivered via telehealth more centrally focused addressing factors contributing to loneliness and social isolation.
223618248|NCT05455476|BEHAVIORAL|CBT for Chronic Pain|CBT delivered over the course of 8, \~45 minute sessions delivered via telehealth broadly focused on increasing quality of life despite being in pain.
223618249|NCT00853866|DRUG|reboxetine|single dose of 4mg reboxetine 80 minutes before assessment of Jebsen Taylor test
223605992|NCT03956966|DRUG|TQL block with saline|"drug: saline 21 ml 0.9% normal saline administered on each side as bilateral TQL blocks Drug: fentanyl With induction of general anaesthesia, fentanyl (1 microgram.kg) will be given. Intraoperatively, fentanyl boluses (0.5 microgram.kg) will be given in case of increase in intraoperative mean arterial blood pressure or heart rate of more than 20% of baseline for longer than 5 minutes.~Drug: Paracetamol Paracetamol infusion (15 mg.kg) will be given by intravenous infusion after induction of general anesthesia. Postoperatively, 1 g of paracetamol will be given by intravenous infusion to all cases every 8 hours.~Drug: Ketorolac analgesia In PACU Ketorolac 30 mg ampoule will be given by intravenous infusion to all cases Drug: Nalbuphine Nalbuphine boluses 0.1 mg. /kg will be given as rescue analgesia if VAS is more than3.~Device: ultrasound-guided nerve block Transmuscular quadratus lumborum block, ultrasound-guided"
223753109|NCT03389009|DIAGNOSTIC_TEST|Ultrasound Biomicroscopy of anterior segment of the eye|5150 Vumax (Sonomed, USA) under standard illumination
223618250|NCT00853866|DRUG|Placebo|placebo, 80 min before assessment of Jebsen Taylor test
223618251|NCT00853866|DEVICE|tDCS verum|20 minutes of 1 mV transcranial direct current stimulation with 5x5 cm electrodes with active electrode over the primary motor representation of the stroke hemisphere and reference electrode over the contralateral supraorbital area Application during assessment of Jebsen Taylor test
223753110|NCT03872089|OTHER|Infrared Thermography|Measurements of the temperature of the plantar arch by thermal imaging (Infrared Thermography)
223753111|NCT03784885|BIOLOGICAL|AD07010|A protein based adjuvant
223753112|NCT03784885|BIOLOGICAL|Inactivated trivalent influenza vaccine|Inactivated trivalent seasonal influenza vaccine
223753113|NCT03906045|DRUG|BGF-MDI|Budesonide, Glycopyrronium and Formoterol Fumarate.
223753114|NCT03352323|DRUG|Oxymetazoline|RLD
223753115|NCT02547610|DEVICE|The imaging biomarkers determined by MR-PET|Combining PET and MRI, namely MR/PET, has the benefit of evaluating tissue metabolism with PET and at the same time evaluating tissue morphology/functional information with MR.
223753116|NCT02197806|DRUG|AGN-199201|1 to 2 drops of AGN-199201 ophthalmic solution in the eye(s) as per protocol.
223753117|NCT02197806|DRUG|AGN-190584|1 to 2 drops of AGN-190584 ophthalmic solution in the eye(s) as per protocol.
223753118|NCT02197806|DRUG|AGN-199201 Vehicle|1 to 2 drops of AGN-199201 vehicle in the eye(s) as per protocol.
223753119|NCT03487861|DIAGNOSTIC_TEST|observational(urinary biomarker for kidney allograft fibrosis)|After an informed consent is obtained, urine specimens will be collected prospectively before kidney transplantation (if available) and 3rd and 7th day, 1st, 3rd, and 6th month post-transplant. About 35\~50ml of urine sample is collected from each patient. For each urine specimen, 0.5 ml of a protease inhibitor mixture (5mM 4-(2-animoethyl) benzensulfonyl fluoride hydrolchloride, 2 μM Leupeptin-hemisulfate, and 3.3 mM Sodium azide) is added. To remove urinary sediments including whole cells, large membrane particles, and other debris, urine specimens are centrifuged at a rate of 4000 rpm for 15 minutes at 4 ℃. An aliquot of supernatant is stored at -80 ℃ until use. Urinary biomarkers including transglutaminase 2 are quantified using ELISA or CBA. In addition, urinary exosomes are isolated and analyzed. When a for-cause biopsy is done for some patients, the correlation between biomarkers and pathologic diagnosis will be assessed.
223753120|NCT03477227|DEVICE|Short stocking|Patients in the experimental group will be asked to wear new type of compression stockings for four weeks post-operatively
223753121|NCT03477227|DEVICE|Usual stocking|Patients in the control group will be asked to wear usual type of compression 2 class stockings for four weeks post-operatively
223753122|NCT00448474|BEHAVIORAL|Mailed Arthritis Self-Management Education|
223753123|NCT02283047|BEHAVIORAL|DIET|Lifestyle intervention through hypocaloric diet
223753124|NCT02283047|BEHAVIORAL|DIET & MODERATE CONTINUOUS TRAINING|Lifestyle intervention through hypocaloric diet and exercise at moderate intensity (60-80%peakHR) continuous mode, and high volume (45 min).
223753125|NCT02283047|BEHAVIORAL|DIET & HIGH VOLUME HIIT|Lifestyle intervention through hypocaloric diet and exercise at high intensity (80-95%peakHR) interval mode, and high volume (45 min).
223753126|NCT02283047|BEHAVIORAL|DIET & LOW VOLUME HIIT|Lifestyle intervention through diet and exercise at high intensity (80-95%peakHR) interval mode, and low volume (20 min).
223753127|NCT05544786|DRUG|Nirmatrelvir/ ritonavir|Single oral dose of nirmatrelvir/ritonavir tablets under fasted condition
223753128|NCT05544786|DRUG|Nirmatrelvir/Ritonavir|Single oral dose of nirmatrelvir/ritonavir mixed in water under fasted condition
223753129|NCT05544786|DRUG|Nirmatrelvir/Ritonavir|Single oral dose of nirmatrelvir/ritonavir mixed in infant formula under fasted condition
223753130|NCT05544786|DRUG|Nirmatrelvir/ritonavir|Single oral dose of nirmatrelvir/ritonavir mixed in vanilla pudding under fasted condition
223753131|NCT05544786|DRUG|Nirmatrelvir/ritonavir|Single oral dose of nirmatrelvir/ritonavir mixed in vanilla pudding under fed condition
223753132|NCT03065244|DRUG|IVIG|Subjects randomized to this arm will receive IVIG 2g/kg over 10-12 hours
223753133|NCT03065244|DRUG|Infliximab|Subjects randomized to this arm will receive infliximab 10 mg/kg over 2 hours
223753134|NCT01907672|PROCEDURE|Rapid Diagnostic Test|Rapid Diagnostic Test for Malaria carried out to direct antimalarial dispensing. No antimalarials for negative tests, antimalarials for positive tests
223753135|NCT02755324|BIOLOGICAL|male Schistosoma mansoni cercariae|Viable male Schistosoma mansoni cercariae of the Puerto Rican strain
224200599|NCT03315325|BIOLOGICAL|Human kisspeptin-10 (metastin 45-54)|Kisspeptin-10 (metastin 45-54, Calbiochem, Darmstadt, Germany) is a potent HPG-axis stimulator and control reproduction.
223618252|NCT00853866|DEVICE|tDCS sham|30 seconds of 1 mV transcranial direct current stimulation with 5x5 cm electrodes with active electrode over the primary motor representation of the stroke hemisphere and reference electrode over the contralateral supraorbital area Application during assessment of Jebsen Taylor test
224200600|NCT03486327|DRUG|BR55|A novel targeted ultrasound contrast agent
224200601|NCT02755727|PROCEDURE|Platelet Rich Plasma Injection|See Arms
224200602|NCT02755727|PROCEDURE|Open Surgical Release|See arms
224200603|NCT05180682|OTHER|Gait Training|"the physical therapist will provide different protocol at different weeks in the following way.~first week: first fitting and initial Gait training second week: Specific Gait Training third week: Advance Gait Training fourth week: Functional Training"
224200604|NCT03126682|DRUG|Wellbutrin SR 300Mg Extended-Release Tablet|Wellbutrin SR 300Mg Extended-Release Tablet
223753136|NCT03163082|OTHER|Cognitive Intervention|The cognitive intervention has partners come up with reasons why their partners do things they don't like, until they come up with benign attributions for those behaviors.
223753137|NCT03163082|BEHAVIORAL|Behavioral Intervention|The behavioral intervention has partners develop an if-then plan for dealing with conflict and negativity, using strategies to downregulate their own negative emotions.
223753138|NCT03163082|OTHER|Interpretation Bias|"The Interpretation Bias intervention has partners look at morphed facial expressions and determine whether the face is happy or angry. Positive feedback is given for rating the faces as happy and negative feedback is given for rating the faces as angry."
223753139|NCT03163082|OTHER|Evaluative Conditioning|The Evaluative Conditioning intervention presents partners with pictures of ambiguous adult faces (conditioned stimuli) and pairs them with positive word descriptors (unconditioned stimuli; e.g., generous; loving).
223605993|NCT03956966|DRUG|TQL block with Bupivacaine|"Drug: saline~1mL 0.9% normal saline administered on each side as bilateral TQL blocks drug: Bupivacaine 20 ml Bupivacaine hydrochloride 0.25% administered on each side as bilateral TQL blocks Drug: fentanyl With induction of general anaesthesia, fentanyl (1 microgram.kg) will be given. Intraoperatively, fentanyl boluses (0.5 microgram.kg) will be given in case of increase in intraoperative mean arterial blood pressure or heart rate of more than 20% of baseline for longer than 5 minutes.~Drug: Paracetamol 15 mg.kg will be given by intravenous infusion after induction of general anesthesia. Postoperatively, 1 g of paracetamol will be given to all cases every 8 hours.~Drug: Ketorolac In PACU Ketorolac 30 mg ampoule will be given by intravenous infusion to all cases Drug: Nalbuphine Nalbuphine boluses 0.1 mg. /kg will be given as rescue analgesia if VAS is more than 3.~Device: ultrasound-guided nerve block Transmuscular quadratus lumborum block"
223753140|NCT03717480|DEVICE|ClinicMACs|The Reagent System will remove certain cells (called T-Cell Receptor (TCR) α/β positive T-cells) that are thought to cause GVHD from donor product before it is given to participants
223753141|NCT00187460|BEHAVIORAL|Publicly released hospital cardiac report cards|Participating hospital corporations were randomized to either early feedback or delayed feedback (21 months later) in the form of publicly released hospital report cards of performance on a set of cardiac process-of-care quality indicators.
223753142|NCT05259007|DIETARY_SUPPLEMENT|propolis solved in lactic acid solvent|propolis given as a dietary supplement which was solved in a lactic acid solvent.
223753143|NCT05259007|DRUG|Amoxicillin-Clarithromycin-Lansoprazole|H pylori eradication treatment
223753144|NCT05259007|OTHER|IV saline 0.9%|Physiological serum solution is given as a placebo
223753145|NCT05259007|OTHER|Lactic acid|given to determine if the improvement of the symptoms are due to propolis or the solvent
223753146|NCT05275647|DRUG|BOTOX 100U in normal saline|LESW with 3000 shocks, frequency of 3 pulses per second, and maximum total energy flow density 0.25 mJ/mm2 , and followed by intravesical BoNT-A 100U instillation in 30ml normal saline retained in the bladder for 2 hours, every one week for 4 times.
223753147|NCT05275647|DRUG|Normal saline|LESW treatment with 3000 shocks, frequency of 3 pulses per second, and maximum total energy flow density 0.25 mJ/mm2 , and followed by intravesical instillation of 30ml normal saline retained in the bladder for 2 hours after LESW application, every one week for 4 times.
223753148|NCT05486221|OTHER|Extensive cardiologic work-up|Specific 3D and 2D echocardiography measuring left ventricule and left atrial dimensions as well as longitudinal strain. 30 day prolonged ECG monitoring.
223753149|NCT01591876|OTHER|Intradialytic aerobic exercise|Participants in the intervention group will undertake moderate intensity aerobic exercise. Exercise modality will be recumbent cycling during the first two hours of haemodialysis sessions. Exercise prescription is set using a graded exercise test and anchored to a perceived level of exertion using the BORG scale. Training stimulus is maintained by the participant by increasing the cycling resistance when perceived exertion drops by one point at the current resistance level. Adherence and training volume is recorded during the intervention period.
223753150|NCT01591876|OTHER|Progressive Muscle relaxation|This is a sequence of stretching and relaxation of the major muscle groups of the body. Participants are initially given detailed information regarding the technique and then provided with a recorded version which they listen to for 30-40 minutes during dialysis sessions. Participants in this group are offered the exercise programme at the end of three months.
223753151|NCT03603444|OTHER|No intervention are provided|
223753152|NCT03647865|PROCEDURE|Osseous Genioplasty|Surgical Procedure that cuts the chin and reposition it in the correct place
223753153|NCT01147705|DRUG|Allopurinol|Participants will be given blinded medication and asked to take one tab/day for the first six weeks (100mg strength for two weeks then 300mg strength for four weeks) followed by two tabs/day for the remaining 18 weeks
223753154|NCT01147705|DRUG|Placebo|Same appearance/dosing as active drug.
223753155|NCT02245074|OTHER|Sputum induction|The sputum induction will be performed by repeated nebulizations of 3% saline hypertonic solution. Cellularity and cell profiles were analysed as previously recommended.
223753156|NCT00199355|DRUG|Istradefylline (KW-6002)|
223753157|NCT00277433|OTHER|Buccal Swab|collection of buccal swab
223753158|NCT04573595|DEVICE|Blood Pressure Measurement|The purpose of this study is to provide supporting documentation for Noninvasive blood pressure measurement accuracy claims for Fresenius 5008S BPM Module and Cuffs on the intended population(s). The same arm sequential method with dual observer auscultation will be used to collect data.
223753159|NCT01066754|DRUG|Fexofenadine|Fexofenadine Hydrochloride 180 mg Tablets
223753160|NCT02190812|DEVICE|Forearm supporter|The forearm supporter be use in tennis elbow.
224200605|NCT03770182|DEVICE|NEUROLITH|transcranial pulse stimulation (TPS)
223753161|NCT02190812|DEVICE|Grip ball|
224200606|NCT05801094|DRUG|QL1604|QL1604 3 mg/kg Q3W
224200607|NCT02682069|DEVICE|MolecuLight i:X Imaging Device|The intended use of the device is to assist clinicians during care and management of patients with chronic wounds by screening for the presence of potentially harmful bacteria levels. The device will be used as part of the current clinical wound assessment process which may include examination for characteristic signs and symptoms of infection. The device can capture and document either an image or video of the chronic wound where the presence of florescent bacteria appears under violet light illumination. This information can be used to guide a clinician to inspect, sample, debride or further evaluate areas within or around a wound where fluorescent bacteria are present.
223753162|NCT02861703|BEHAVIORAL|Online lifestyle intervention|Online, computer-mediated interactive group-based lifestyle intervention addressing thoughts, feelings, behaviours related to eating, physical activity, and other psychosocial issues related to breast cancer survivorship (e.g., mood, body image, existential issues, social support).
223753163|NCT06243887|OTHER|Enhanced Recovery After Surgery (ERAS) protocol in minimal invasive esophagectomy|Enhanced Recovery After Surgery (ERAS) refers to patient-centered, evidence-based, multidisciplinary team developed pathways for a surgical specialty and facility culture to reduce the patient's surgical stress response, optimize their physiologic function, and facilitate recovery.
223753164|NCT06243887|OTHER|standard of care approaches in minimal invasive esophagectomy|standard of care approaches other than ERAS
223753165|NCT04448405|BEHAVIORAL|Questionnaire for evaluation of confinement on deviant sexual fantasies|Questionnaire for evaluation of confinement on deviant sexual fantasies. Population already followed for deviant fantasies
223753166|NCT00056563|DEVICE|Bilateral Deep Brain Stimulation|The DBS site (STN or GPi) will be assigned on a random basis at the time the patient enters the surgical phase of the trial.
223753167|NCT00056563|OTHER|best medical therapy|"Participants will initially be randomized to DBS or to 6 months of best medical therapy. BMT participants will then proceed into the surgical phase of the trial. Effective 08/05/05, randomization to the BMT arm has been discontinued since the study has sufficient information to compare the outcomes of DBS and BMT patients at 6 months."
223605994|NCT03956966|DRUG|TQL block with Bupivacaine and dexamethasone|"Drug: dexamethasone~1 mL dexamethasone 4mg administered on each side as bilateral TQL blocks drug: Bupivacaine 20 ml Bupivacaine hydrochloride 0.25% administered on each side as bilateral TQL blocks Drug: fentanyl With induction of general anaesthesia, fentanyl (1 microgram.kg) will be given. Intraoperatively, fentanyl boluses (0.5 microgram.kg) will be given in case of increase in MBP or HR of more than 20% of baseline for longer than 5 minutes.~Drug: Paracetamol Paracetamol infusion (15 mg.kg) will be given by intravenous infusion after induction of general anesthesia. Postoperatively, 1 g of paracetamol will be given by intravenous infusion to all cases every 8 hours.~Drug: Ketorolac In PACU Ketorolac 30 mg ampoule will be given by intravenous infusion to all cases Drug: Nalbuphine Nalbuphine boluses 0.1 mg. /kg will be given as rescue analgesia if VAS is more than 3.~Device: ultrasound-guided nerve block Transmuscular quadratus lumborum block"
223605995|NCT02984917|PROCEDURE|Anterior transversalis fascia approach|Patients will undergo inguinal hernia repair via the anterior transversalis fascia approach.
223753168|NCT03168152|RADIATION|Microwave Ablation (MWA)|MWA will typically be administered in one ablation session during which time up to 2 tumors are treated.
223753169|NCT03168152|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|SBRT will be administered in five fractions of up to 10 Gy per fraction. SBRT will be administered 5-15 days per tumor.
223753170|NCT02782533|DEVICE|Deep Brain Stimulation V3|
223753171|NCT02922907|DIETARY_SUPPLEMENT|arabinoxylan rice bran|a proprietary product derived from rice bran treated with extracts from three mushrooms
223753172|NCT02922907|DIETARY_SUPPLEMENT|Placebo for arabinoxylan rice bran|inactive product
223753173|NCT03891420|DRUG|Galidesivir|Galidesivir IV infusion
223753174|NCT03891420|DRUG|Placebo|Placebo IV infusion
223753175|NCT03444922|OTHER|Placebo|Ingestion of Placebo
223753176|NCT03444922|OTHER|BPA 4 ug/kg BW|Oral BPA ingestion of 4 ug/kg BW
223753177|NCT03444922|OTHER|BPA 50 ug/kg BW|Oral BPA ingestion of 50 ug/kg BW
223753178|NCT02401880|DRUG|Linagliptin|22 subjects will receive Linagliptin for 30 days
223753179|NCT02401880|OTHER|Placebo|22 subjects will receive Placebo for 30 days
223753180|NCT02401880|DRUG|Empagliflozin|44 subjects will receive Empagliflozin for 60 days
223753181|NCT05533047|PROCEDURE|TURP|Bipolar and monopolar transurethral resection of the benign prostatic hyperplasia
223753182|NCT01774786|DRUG|5-Fluorouracil|Participants will receive 5-fluorouracil 800 milligrams per meter square (mg/m\^2)/24 hour IV infusion for 120 hours (Days 1-5) q3w for 6 cycles.
223753183|NCT01774786|DRUG|Capecitabine|Participants will receive capecitabine 1000 mg/m\^2 orally twice daily, evening of Day 1 to morning of Day 15 (28 doses) q3w for 6 cycles.
223753184|NCT01774786|DRUG|Cisplatin|Participants will receive cisplatin 80 mg/m\^2 IV q3w for 6 cycles.
223753185|NCT01774786|DRUG|Pertuzumab|Participants will receive pertuzumab 840 mg IV q3w until disease progression, occurrence of unacceptable toxicity, or withdrawal from the study for another reason.
223753186|NCT01774786|DRUG|Placebo|Participants will receive placebo (matched to pertuzumab) IV q3w until disease progression, occurrence of unacceptable toxicity, or withdrawal from the study for another reason.
224200608|NCT04715880|PROCEDURE|Paravertebral block/Intercostal Block (PVB/ICB) group|A paravertebral catheter will be placed by surgeon into pleural cavity and will not be loaded with bolus dose. At the end of surgery the (consultant anaesthesiologist) will perform intrathoracic unilateral intercostal nerve block two level above and two level below and at site of incision with 4 ml per level of 0.25 % bupivacaine followed by continuous infusion with 0.25 % bupivacaine at 6-8 ml/hour through catheter placed in paravertebral space.
224311488|NCT05641090|OTHER|No exercise intervention|This group wasn't receive intervention program. The participants in this group will do following a physician who treat them. They can exercise according to the physician recommend.
223753187|NCT01774786|DRUG|Trastuzumab|Participants will receive 8 mg/kg IV initial dose on Day 1, followed by 6 mg/kg IV q3w until disease progression, occurrence of unacceptable toxicity, or withdrawal from the study for another reason.
223753188|NCT04459312|DIAGNOSTIC_TEST|Antibody test (SARS-CoV2)|Antibody test
223753189|NCT03099447|OTHER|ocular electroacupuncture|During intervention period, patients will continue to keep medications for primary condition. Patient's skin located in the extraocular muscles projection area is routinely disinfected. A diameter of 0.20 mm and length of 25 mm needle is inserted slowly. Piercing depth is about 20mm. The electropuncture apparatus is used, each group of electrodes are distinguished with different colors of wires to generate current stimulations of current 1.0\~1.5 milliampere (mA), voltage 9 volt(V), frequency 1.5 hertz (Hz), and duration of 40 minutes.
223753190|NCT03099447|OTHER|ocular acupuncture|During intervention period, patients will continue to keep medications for primary condition. Patient's skin located in the extraocular muscles projection area is routinely disinfected. A diameter of 0.20 mm and length of 25 mm needle is inserted slowly. Piercing depth is about 20mm.The duration of intervention is 40 minutes.
224200609|NCT04715880|PROCEDURE|Paravertebral Block (PVB) group|A paravertebral catheter will be placed by the surgeon before closure of thoracotomy wound. The catheter will be introduced percutaneously through 18 gauge needle into the pleural cavity. The tip of catheter will be loaded by anaesthesiologist with 0.25 % isobaric bupivacaine with 20 ml followed by continuous infusion with bupivacaine 0.25 % at 6-8 ml per hour
224200610|NCT03347929|DRUG|Naproxen 500 Mg|10 days treatment with Naproxen 500 mg twice daily
223605996|NCT02984917|PROCEDURE|Preperitoneal space approach|Patients will undergo inguinal hernia repair via the preperitoneal space approach.
223605997|NCT03223116|PROCEDURE|Radiofrequency delivery|Radiofrequency to the gastroesophageal junction
223605998|NCT00870012|DRUG|Lepicol probiotic & prebiotic formula|NAFLD patients treated with Lepicol probiotic and prebiotic formula for 24 weeks.
224200611|NCT03347929|DRUG|Placebo|10 days treatment with Placebo1 tablet twice daily
223605999|NCT00870012|OTHER|Simple lifestyle advice|NAFLD patients treated with lifestyle advice.
224200612|NCT03052374|BEHAVIORAL|VID-KIDS Intervention Program|"Investigators created VID-KIDS for mothers with PPD to improve sensitivity and positive responsiveness towards their infants. Video-feedback has the advantage of being visually concrete yet distant because the action and the feedback are not concurrent; this helps mothers maintain an element of objectivity that may minimize guilty feelings associated with potential perceived lack of parenting skills. Video-feedback interventionists are trained by investigators with manualized modules. Including: Introduction to Video-feedback; NCAST Keys to Caregiving Program; Infant Engagement and Disengagement Cues; Video-feedback Intervention Protocol; Overview of Behaviours of Interest; Case Studies; and Examples of Strengths-Based Feedback. VID-KIDS intervention follows an 8-step protocol."
223606000|NCT04861935|DEVICE|ultrasound evaluation|ultrasound evaluation of normal patients and patients who have a sacral dimple
223606001|NCT05330832|DIAGNOSTIC_TEST|Thrombodynamics test|Thrombodynamics test is a global hemostasis test that allows to register the dynamics of fibrin clot formation in time and space. It requires whole blood samples from included patients.
223606002|NCT00321451|BEHAVIORAL|Cognitive behavioral therapy for insomnia|4 biweekly outpatient sessions with sleep psychologist
223606003|NCT00321451|BEHAVIORAL|Pseudo-desensitization procedure|4 biweekly outpatient visits with sleep psychologist
223606004|NCT00321451|OTHER|Usual care|3 outpatient visits with study physician
223606005|NCT02178761|DEVICE|drug-eluting balloon|angioplasty completed with drug-eluting balloons
224311489|NCT03169712|BEHAVIORAL|Cognitive Behavioral Therapy for PTSD|Trauma-focused CBT protocol elaborated by Marchand and Guay from the Trauma Studies Centre at Louis-H. Lafontaine Hospital in Montreal and adapted from Foa, Hembree and Rothbaum (2007)
224311490|NCT03169712|BEHAVIORAL|Imagery Rehearsal Therapy|IRT protocol published by Nappi and collaborators (2010)
223606006|NCT02178761|DEVICE|biodegradable vascular scaffold stent|Stenting with biodegradable vascular scaffold stents
223508185|NCT01845415|BEHAVIORAL|Social Marketing Campaign|The campaign will involve distribution of posters throughout the communities promoting awareness of the consequences of fall injuries and encouraging people to go to an website that provides safety information and injury stories.
223508186|NCT01845415|BEHAVIORAL|Intervention components|Doctors and nurses in these communities will perform health education to parents of 1 through 4 year olds around the risks of falls in the home when these parents visit the doctor for regular visits. Also, several parenting classes in these communities will be modified to include educational videos and discussion of these issues
223508187|NCT04633304|DEVICE|EndoAVF System for endovascular AV fistula creation|AV fistula creation
223508188|NCT03532490|DRUG|Roflumilast 500 Mcg Oral Tablet|The first two weeks the participant will take one tablet every other day. If well tolerated, participant will take one tablet every day.
223508189|NCT03532490|DRUG|Placebo oral capsule|The first two weeks the participant will take one tablet every other day. If well tolerated, participant will take one tablet every day.
223606007|NCT02178761|DEVICE|Apex™ PTCA Dilatation Catheter|plain old balloon angioplasty alone
223508190|NCT00409227|DRUG|Alpha blocker-alfuzosin|P.O. alfuzosin 10 mg once a day
223508191|NCT00409227|DRUG|placebo|placebo once a day for 3 months or stone free
223508192|NCT04421664|DRUG|Hydroxychloroquine|200mg tablet; 800 mg orally once, followed in 6 to 8 hours by 600 mg, then 600mg once a day for 4 consecutive days
223508193|NCT04421664|DRUG|Placebo oral tablet|4 placebo tablets once, followed in 6 to 8 hours by 3 tablets, then 3 tablets once-a-day for 4 consecutive days
223508194|NCT03548415|DRUG|IONIS-GHR-LRx|IONIS GHR-LRx administered subcutaneously.
223508195|NCT03548415|DRUG|Placebo|Placebo administered subcutaneously.
223508196|NCT02914678|OTHER|Fentanyl|Change in protocol from 2 to a total of 3 μg/kg fentanyl per transport
223508197|NCT04138082|OTHER|Exposition to high-dB soundtrack|Already stated
223606008|NCT02178761|DEVICE|Stent System|stenting with either bare-metal stents or drug-eluting stents
223606009|NCT01073449|PROCEDURE|In-hospital follow-up of cardiac device|Electrical measures taken during normal follow-up and clinical status of the patient
223606010|NCT00195286|DRUG|piperacillin/tazobactam|
223606011|NCT04107532|OTHER|Virtual Reality Therapy and Imagination Exposure Therapy|Virtual Reality Therapy and Imagination Exposure Therapy
223606012|NCT03932695|DIETARY_SUPPLEMENT|Low dose milk peptide|what is the effect of milk peptides 1400mg on postprandial glycemia after a meal rich in carbohydrates (75g)
223606013|NCT03932695|DIETARY_SUPPLEMENT|High Dose milk peptide|what is the effect of milk peptides 2800mg on postprandial glycemia after a meal rich in carbohydrates (75g)
223606014|NCT03932695|DIETARY_SUPPLEMENT|Placebo|what is the effect of placebo on postprandial glycemia after a meal rich in carbohydrates (75g)
223606015|NCT02223338|DRUG|Ciprofloxacin|Use of topical ciprofloxacin 4x daily for 3 days after intravitreal injection using standard aseptic techniques with Povidone-Iodine is a common practice intervention in the United States, and is thought by some to reduce the risk of post-injection endophthalmitis.
223606016|NCT02223338|DRUG|Standard Aseptic Technique|Patients in this group will have received Povidone-Iodine Only following injections of anti-VEGF agents at least 3 times in the last 6 months.
223606017|NCT00496080|DEVICE|Doppler-Guided Uterine Artery Occlusion Device (DUAO)|Investigational transvaginal clamp inserted one time for 6 hours.
223508198|NCT01803737|BEHAVIORAL|Standard Behavioral Weight Loss Intervention (SBWL)|Included changing eating behaviors, increasing physical activity, and attending regular group weight loss meetings.
223508199|NCT01803737|BEHAVIORAL|Campaign Intervention (CI)|Included changing eating behaviors and increasing physical activity, however participants will not attend regular meetings. Instead they will attend two weekly meetings at weeks 0 and 12. During the weeks they are not scheduled to attend in-person weekly meetings (weeks 1-11), they will receive education materials via e-mail. They will also have the opportunity to earn points towards prizes by reporting diet and physical activity behaviors, and body weight via e-mail.
223606018|NCT03349125|BEHAVIORAL|Collar On|
223606019|NCT03349125|BEHAVIORAL|Collar Off|
223606020|NCT03636789|OTHER|Neurological consultation|study of horizontal, vertical, reflex and voluntary saccades, and of horizontal and vertical ocular pursuit by a BrainTracker eye-oculography system
223606021|NCT05725980|DIAGNOSTIC_TEST|Cephalometric analysis|Cephalometric analysis will be performed evaluating upper airways landmarks.
223606022|NCT02931032|PROCEDURE|Sampling of dental plaque / infected dentine|A sample of dental plaque / infected dentine will be taken during routine dental treatment and cultivated in a lab. The headspace above the culture will be sampled and analyzed in GC-MS for the detection of unique volatile organic compounds emitted by the plaque components.
223508200|NCT04558853|DRUG|autologous NK cells|Autologous ex vivo expanded and activated NK cells
223508201|NCT03123562|COMBINATION_PRODUCT|Stem cell transplantation|Transplantation of Autologous Bone Marrow Mononuclear Cells
223606023|NCT01675518|DRUG|ASP7991|oral
223606024|NCT01675518|DRUG|Placebo|oral
223606025|NCT05318703|BEHAVIORAL|tai ji quan|cognitively enhanced tai ji quan exercise
223606026|NCT05318703|BEHAVIORAL|Stretching|Stretching exercise
223606027|NCT00909506|DRUG|Placebo|"Control: Receive placebo pill once every evening on 1\~2 weeks.~Receive placebo pill in every morning and evening on 3\~24 weeks (twice a day)."
223606028|NCT00909506|DRUG|Metformin|"Metformin 500 mg/d: Receive oral metformin 500 mg dose once daily on 1\~2 weeks.~Receive placebo pill in every morning and oral metformin 500 mg in every evening on 3\~24 weeks."
223606029|NCT00909506|DRUG|Metformin|"Metformin 1000 mg/d : Receive oral metformin 500 mg dose once daily on 1\~2 weeks. (Dose-escalate)~Receive oral metformin 500 mg in every morning and evening on 3\~24 weeks (metformin 500 mg \* twice a day = 1000 mg per day)."
223606030|NCT00570310|DRUG|Comparator: pregabalin|pregabalin (up to 600 mg/day by mouth (po)). Duration of Treatment: 6 Weeks
223606031|NCT00570310|DRUG|Comparator: Placebo (unspecified)|pregabalin Pbo (up to 600 mg/day by mouth (po)). Duration of Treatment: 6 Weeks
223606032|NCT05189119|DIAGNOSTIC_TEST|non invasive ventilation|invasive mechanical ventilation session in the BIPAP Mode with a pressure support (PS) level of 5cmH2O, a positive end expiratory pressure (PEEP) level of 5 cmH2O and an inspiratory fraction of oxygen (FiO2) allowing a pulse saturation (SpO2) of at least 92% for a one minute and followed by an increase of the PS level to 30cmH2O.The plethysmographic PAR (PAR) was calculated based on the following formula: PARpleth= PP30 / PP5
223508202|NCT03824054|PROCEDURE|colorectal resection|Surgery includes laparoscopic resection of all visible endometriosis, including resection of the affected bowel with primary anastomosis
223508203|NCT01529112|DRUG|Lenvatinib|
223508204|NCT01529112|DRUG|Lenvatinib matched placebo|
223508205|NCT01529112|DRUG|BSC|
223508206|NCT03765359|DRUG|metforminhydrochloride|metformin 500 mg tablets and insulin
223508207|NCT03765359|DRUG|Placebo Oral Tablet|Placebo tablets mimic metformin 500 mg tablets and insulin
223508208|NCT03279068|OTHER|Teaching and EFM Paper|Data will be collected for patients receiving EFM without pattern interpretation as the first phase of the study, as this is the current practice at Ayder Hospital. Then, the second phase will involve a week of teaching sessions regarding interpretation and management of EFM as per ACOG and FIGO guidelines. For the third phase of this study, paper will be provided for the use of EFM with pattern interpretation for all patients receiving EFM.
223606033|NCT01751009|DIETARY_SUPPLEMENT|Vitamin A supplements|Sprinkles with Vitamin A
223606034|NCT01751009|DIETARY_SUPPLEMENT|Sprinkles without Vitamin A|Active comparator
223606035|NCT00887549|DRUG|pemetrexed|Induction Therapy: 500 milligrams per square meter (mg/m\^2), intravenous, day 1 of each 21 day cycle for the first 4 cycles; Maintenance Therapy: 500 milligrams per square meter (mg/m\^2), intravenous, day 1 of each 21 day cycle until progression or unacceptable toxicity occurs
223606036|NCT00887549|DRUG|cisplatin|Induction Therapy: 75 mg/m\^2, intravenous, day 1 of each 21 day cycle for the first 4 cycles
223508209|NCT01506336|DRUG|masitinib|masitinib 12 mg/kg/day
223508210|NCT01506336|DRUG|sunitinib|sunitinib 50 mg/day
223508211|NCT00558480|DRUG|Vitamin A|Vitamin A capsules, as retinol palmitate 200,000 IU at enrollment, 3 and 6 months
223508212|NCT00558480|DRUG|Vitamin A placebo|Vitamin A placebo at enrollment, 3 and 6 months
223508213|NCT03859856|OTHER|hormone panel and ultrasonography|Blood sampling on the 3rd day of menstrual cycle for the measurement of serum FSH, LH, E2 and AMH hormone levels and ultrasonography for antral follicle count and ovarian volume measurement will be done.
223508214|NCT05414253|DEVICE|Parallel Assignment|Single-centre randomized, parallel design, clinical trial with a 2 week follow-up
223508215|NCT04928066|DRUG|Iguratimod|Iguratimod tablet，25mg, po, twice per day (Bid) prescribed at the beginning and adjusted due to patient response. Then may titer down until the endpoint.
223606037|NCT03647826|BEHAVIORAL|Mind Power Intervention|The intervention has a total sample of 110 schoool classes, which are devided in two arms: Mind Power Intervention Group 1 or Mind Power Intervention Group 2
223606038|NCT05435664|BEHAVIORAL|Progressive relaxation exercise|It consists of sessions involving deep breathing and stretching and relaxing the body.
223508216|NCT04928066|DRUG|Tofacitinib|Tofacitinib,5mg, po, twice per day (Bid) prescribed at the beginning and adjusted due to patient response. Then may titer down until the endpoint.
223508217|NCT04928066|DRUG|Pred|Pred, 0-10mg, po, once per day (Qd) prescribed if needed and adjusted due to patient response.
223753191|NCT03099447|OTHER|sham acupuncture|During intervention period, patients will continue to keep medications for primary condition. Patient's skin located in the extraocular muscles projection area is routinely disinfected. A diameter of 0.20 mm and length of 25 mm sham needle set is stick onto insertion area without piercing into the skin. The duration of intervention is 40 minutes.
223606039|NCT00856063|DRUG|atomoxetine (or placebo)|Each child will be randomized to receive either ATMX or placebo in the 1st crossover phase followed by the alternative drug condition in the 2nd crossover phase. The study drug (ATMX or placebo) will be administered BID and will be titrated blindly based on clinical response and tolerability. ATMX will be initiated at 0.5 mg/kg/day for 3 days. Based on clinical response, ATMX dose will be titrated to 0.8 mg/kg/day during week 1, 1.4 mg/kg/day during week 2, and a maximum of 1.8 mg/kg/day during week 3, unless serious untoward effects intervene.
223606040|NCT00988988|DRUG|AGEE cream|AGEE cream is a creatine ethyl ester based product (an amino acid) that can be purchased over-the-counter without a prescription and is not FDA controlled. It will be used immediately after injection and repeated as needed.
223606041|NCT00988988|DRUG|1% Steroid Cream|comparing to AGEE cream or placebo. 1% steroid cream is available over the counter. To be used immediately after injection and as needed.
223606042|NCT00988988|DRUG|topical placebo cream with no active ingredients|Cream to be applied immediately after injection and repeated as needed.
223753192|NCT03556579|DEVICE|senofilcon A with new UV blocker|Test Lens
223753193|NCT03556579|DEVICE|senofilcon A|Control Lens
223753194|NCT02965703|DRUG|Aspirin|Given PO
223753195|NCT02965703|PROCEDURE|Biospecimen Collection|Undergo collection of blood, urine, stool, and rectal swab samples
223753196|NCT02965703|OTHER|Placebo Administration|Given PO
223753197|NCT02965703|OTHER|Questionnaire Administration|Ancillary studies
223753198|NCT02965703|PROCEDURE|Rectal Biopsy|Undergo rectal biopsy
223753199|NCT04203628|DIAGNOSTIC_TEST|Xpert MTB/Rif Ultra on stool samples|"The Xpert MTB/Rif Ultra will be performed on stool samples processed using four different processing methods:~* Standard sucrose flotation method~* Optimized sucrose flotation~* Stool processing kit (SPK)~* Simple One-step method (SOS)"
223753200|NCT04203628|DIAGNOSTIC_TEST|Xpert MTB/Rif Ultra on respiratory sample|The Xpert MTB/Rif Ultra will be performed on gastric aspirate or expectorated sputum
223753201|NCT04395209|OTHER|assesment|muscle strength assessment in stroke individuals
223753202|NCT02641769|BIOLOGICAL|Stem Cell Transplantation|intervention with transplantation of autologous purified stem cells
223753203|NCT04563169|OTHER|Video consultation|The first video consultation with a nurse was planned one week after start with CPAP. Three focus points were discussed during the consultations: 1) adherence (\>6 hours per night); 2) rest AHI \< 5 (or \<10 if age \>70), and 3) (improvements in) complaints. If these objectives were achieved after one week, a new consultation was planned three weeks later (four weeks after start). As long as these objectives were not achieved, video consultations were planned weekly (until after four weeks).
223753204|NCT02378363|OTHER|Write, draw and interview|Child should write, draw cancer signifiance and after, they were interview by a school nurse about cancer signifiance.
223753205|NCT00962507|DRUG|everolimus|Beginning with 5 mg every other day Monday, Wednesday or Friday for a 28 day cycle. Dose escalation will be determined by the toxicities associated with treatment.
223753206|NCT00962507|DRUG|panobinostat|10 mg every Monday and Thursday of a 28 day cycle. Dose escalation will be determined by the toxicities associated with treatment.
223753207|NCT00962507|OTHER|laboratory biomarker analysis|Pre-study, day 1 and day 26 samples to evaluation how the study drugs work in vitro (in a test tube).
223753208|NCT00962507|OTHER|pharmacological study|Pre-study, day 1 and day 26
223753209|NCT00768144|DRUG|Sunitinib|
223753210|NCT02268786|OTHER|Preimplantation Genetic Screening by NGS|The VeriSeq PGS takes advantage of next-generation sequencing (NGS) technology to provide comprehensive, accurate screening of all 24 chromosomes for selection of euploid embryos.
223753211|NCT04432311|BEHAVIORAL|Binge Focused Therapy (BFT)|The BFT group will be provided Binge Focused Therapy, a group-based, guided-self help intervention. Participants in this group will attend three online group sessions spread over six weeks (Week 1, Week 2, and Week 6) and complete homework between sessions. Following Session 3, there is a four week period where participants complete self-guided check-ins once per week to monitor continued progress and/or signs of relapse.
223753212|NCT04432311|BEHAVIORAL|CBT Unguided Self Help (CBT USH)|The CBT USH group will be provided with the book, Overcoming Binge Eating by C. Fairburn, which is a well-established self-help book used to help individuals understand binge eating and control binge eating behaviours. After participants receive the book, they will have 10 weeks to read it and work through the exercises provided in the book.
223753213|NCT00744627|DRUG|Vortioxetine|Encapsulated vortioxetine immediate-release tablets.
223753214|NCT00744627|DRUG|Placebo|Vortioxetine placebo-matching capsules
224311491|NCT03547076|DIAGNOSTIC_TEST|Focused ultrasound diagnostics|"Patients first be examined by nurses using a pocket-sized imaging device. Secondly, by a General Practitioner using the pocket-sized imaging device. Thirdly, reference echocardiography will be performed by cardiologist using a high-end echocardiographic scanner. Only tools (ultrasound equipment and dedicated software) approved for clinical practice will be used.~The focused ultrasound examination includes three standard apical views (4-chamber, 2-chamber and long axis) with and without color Doppler, in addition to recordings from both pleural cavities and the inferior vena cava. The reference imaging includes the same recordings, but in addition all other chambers and valves are assessed (grey scale, color Doppler, pulsed wave and continuous wave Doppler and tissue Doppler)."
224311492|NCT04720131|DRUG|Camrelizumab|Camrelizumab was administered 200mg iv every 3 weeks.
223753215|NCT04251221|DRUG|Oral Alcohol Challenge|Subjects will drink an alcohol dose designed to achieve a BAL of 0.08
223753216|NCT05225142|PROCEDURE|Modified minimally invasive surgery|Surgical intervention alone
223753217|NCT05225142|PROCEDURE|Modified minimally invasive surgery with enamel matrix derivative|Surgical intervention with local application of regenerative biomaterial
223753218|NCT05225142|PROCEDURE|Modified minimally invasive surgery with enamel matrix derivative and bone replacement graft|Surgical intervention with local application of regenerative biomaterial and bone replacement graft
223606043|NCT03348280|DIAGNOSTIC_TEST|Blood draw|Blood will be drawn to isolate monocytes after 2 weeks off of blood pressure lowering medications.
223753219|NCT05492565|DRUG|Tenofovir Disoproxil Fumarate 300 MG Oral Tablet|Pre-exposure prophylaxis with coformulated Tenofovir Disoproxil Fumarate 300mg/Emtricitabine 200mg oral QD to prevent HIV infection
223606044|NCT05715164|DEVICE|E-cigarettes device plus liquid|The four basic care counseling sessions will be held over the course of 48 weeks with the supply of e-cigarettes and liquid. Every 12 weeks, a standard care counseling session will be offered, and it will be followed by a study visit to track any alterations in the user's physical or mental health as well as any side effects from using e-cigarettes.
223606045|NCT05715164|DRUG|Nicotine Pouches|The four basic care counseling sessions will be held over the course of 48 weeks with a supply of nicotine pouches. Every 12 weeks, a standard care counseling session will be offered, and it will be followed by a study visit to track any alterations in the user's physical or mental health as well as any side effects from using nicotine pouches.
223606046|NCT05715164|OTHER|Basic care counseling about smoking cessation|The four basic care counseling sessions will be held over the course of 48 weeks. Every 12 weeks, a standard care counseling session will be offered, and it will be followed by a study visit to track any alterations in the user's physical or mental health.
223606047|NCT00352001|DRUG|azacitidine|Azacitidine subcutaneously once daily on days 1-5 or days 1-5 and 8-12. Treatment repeats every 28 days for up to 7 courses in the absence of relapse (after achieving complete or partial remission), disease progression, or unacceptable toxicity.
223606048|NCT00352001|DRUG|lenalidomide|Oral lenalidomide once daily on days 1-14 or days 1-21.Treatment repeats every 28 days for up to 7 courses in the absence of relapse (after achieving complete or partial remission), disease progression, or unacceptable toxicity.
223606049|NCT01372566|DEVICE|Harvest PRP Separation System|Platelet-rich plasma (PRP) is a blood-derived therapy that consists of platelets and growth factors. PRP can be formed by drawing blood from a vein and spinning it at a high speed in a specialized device called a centrifuge.
223606050|NCT01372566|OTHER|Sterile Saline injection|Sterile Saline will be injected multiple times in a different area of the arm (Part 1) or on the opposite side of the face from where the platelet rich plasma is injected.
223606051|NCT00756249|DRUG|Lu AA24493 (CEPO)|0.005 - 50.0 mcg/kg body weight, IV, within 12-48 hrs from symptom onset
223606052|NCT00756249|DRUG|Placebo|Vials with solution for IV infusion
223606053|NCT06206525|OTHER|Initial insulin dosing using the calculator|Participants will receive initial insulin doses by the calculator on hospital admission.
223753220|NCT02320500|BEHAVIORAL|Standard Physiotherapy|standard of care physiotherapy once every 2 weeks for 8 weeks
223606054|NCT00024180|DRUG|romidepsin|
223606055|NCT00900666|DRUG|placebo|A total of 2 cc sterile normal saline: will be injected in 0.5 cc aliquots into 4 different injectate sites within the rectus femoris (with EMG guidance) of the involved limb.
223606056|NCT00900666|DRUG|botulinum toxin A (BTX-A)|200 Units BTX-A reconstituted with 2 cc sterile normal saline in 100:1 ratio. Teflon-coated EMG guidance for confirmation of injection into the Rectus femoris muscle in addition to utilizing standardized injection landmarks, the solution will be injected in 0.5 cc aliquots into 4 different injectate sites within the muscle.
223606057|NCT02807207|DRUG|A: pacritinib|Treatment A
223606058|NCT02807207|OTHER|B: Placebo|Treatment B
223606059|NCT02807207|DRUG|C: moxifloxacin|Treatment C
223606060|NCT05421208|DIAGNOSTIC_TEST|Levels of inflammatory cytokine ( IL-6) in post-COVID-19 POTS and controls|Inflammatory and immune profile of post-COVID-19 POTS patients. Reduced PNS activity (vagal tone) in relation to persistent inflammation.
223606061|NCT05421208|DIAGNOSTIC_TEST|Levels of inflammatory cytokine ( IL-6) in controls|Inflammatory and immune profile of healthy controls. Controls are the subjects who recovered from COVID-19 infection with no sequelae.
223753221|NCT02320500|OTHER|Myofascial-specific therapy|Once every 2 weeks for 8 weeks (includes trigger point injections if deemed 'necessary' by chronic pain physician)
223753222|NCT04628676|DRUG|tranexamic acid|Tranexamic acid is added to the irrigation fluid used in arthroscopic shoulder surgery.
223753223|NCT04628676|DRUG|Epinephrine|Epinephrine is added to the irrigation fluid used in arthroscopic shoulder surgery.
223753224|NCT02903186|BEHAVIORAL|SMS|This is an intervention using short mobile messages (SMS)
223753225|NCT03745144|DRUG|Cladribine|Participants received cladribine once-daily for 5 consecutive days in treatment period 1 and 2.
223606062|NCT05421208|DIAGNOSTIC_TEST|Effect on inflammation after chronic PNS stimulation|Inflammatory biomarkers after restoring PNS function in post-COVID-19 POTS patients, by chronic transcutaneous vagus nerve stimulation (tVNS) in post COVID-19 POTS patients
223753226|NCT03745144|DRUG|Placebo|Participants received placebo matched to cladribine once-daily for 5 consecutive days in treatment period 1 and 2.
223753227|NCT03745144|DRUG|Microgynon®|Participants received Microgynon® tablet once daily for 21 days in treatment period 1 and 2. Participants received Microgynon® for 21 days, starting on the first day of the menstrual cycle in Run-in period.
223753228|NCT03295708|DIETARY_SUPPLEMENT|fish oil capsule|N-3 PUFAs is a kind of essential fatty acid,however the formation is too slow. Studies show that intakes of N-3 PUFAs is associated with MDD.It have to be got from food like deep-sea fishes. EPA and DHA are crucial for the body.Although studies have shown that reduced N-3 PUFAs were correlated with MDD, and patients with an elevated rate of N-6 PUFAs /N-3 PUFAs or a low level of DHA may be at higher odds for suicide. Trials on whether N-3 PUFAs is effective in the treatment of MDD is still controversial, which might be affected by several factors, such as dose, duration etc.. Now there is no large-scale randomized controlled clinical trial in determining the effects of N-3 PUFAs add-on in treatment of MDD.
223753229|NCT03295708|DIETARY_SUPPLEMENT|soybean oil capsule|placebo capsule
223606063|NCT03472950|DRUG|Ranolazine 500 MG|Ranolazine is an FDA approved drug for angina (ongoing chest pain or pressure that is felt when the heart does not get enough oxygen).
223606064|NCT03472950|DRUG|Ranolazine 1000 MG|Ranolazine is an FDA approved drug for angina (ongoing chest pain or pressure that is felt when the heart does not get enough oxygen).
223753230|NCT00665977|DRUG|Thermosmart & placebo|a Fisher \& Paykel 604 CPAP machine with Thermosmart™ heated humidity set at their prescribed pressure. Subjects will also be given nasal steroid placebo (purified water) and instructed to deliver two sprays in each nostril daily
224075435|NCT01121393|DRUG|BIBW 2992|starting dose is 40 mg, in the event of no or minimal drug-related adverse events after one course, the dose will be increased to 50mg. in the event of certain drug related Adverse Event (AE), dose reduction will be increments of 10 mg, with the lowest dose being 20mg.
223618254|NCT06411873|DIETARY_SUPPLEMENT|Control Group|Composition of formula per 100 mL : energy (100 kcal), protein (3 g), carbohydrate (13.54 g), lipids (3.93 g), protein energy ratio/PER 12%, osmolarity (310 mOsm/L), renal solute load/RSL (27.5 mOsm/100 kcal)
223618255|NCT06411873|DIETARY_SUPPLEMENT|Intervention Group|Composition of formula per 100 mL : energy (105.5 kcal), protein (4.35 g), carbohydrate (13.54 g), lipids (3.93 g), protein energy ratio/PER 16.5%, osmolarity (333.5 mOsm/L), renal solute load/RSL (27.7 mOsm/100 kcal)
223753231|NCT00665977|DRUG|Placebo Device & Nasacort|Visit 3 will be identical to visit 2, with the exception being the crossover of double-blind treatment. Subjects will now receive the Fisher \& Paykel 604 CPAP machine with traditional heated humidity and a deactivated Thermosmart™ tube set to their prescribed pressure. Subjects will also be given the nasal steroid Nasacort AQ (triamcinolone acetonide) at a dosage of 220 mcg. They will be instructed to deliver two sprays in each nostril daily. Once again, phone follow-up will be made 7-10 days after the visit to assess compliance with study procedures and adverse events.
223753232|NCT00665977|DEVICE|Placebo Arm|"To enter into the single-blind placebo phase, subjects will be setup with a Fisher \& Paykel 604 CPAP unit with a heated humidifier and deactivated Thermosmart™ tube, thus, only traditional heated humidity will be available. The deactivated unit will still appear to function with intact heated humidity settings. The CPAP machine will be set to the patient's prescribed pressure. Subjects will also be given a nasal steroid spray placebo and instructed to deliver one spray in each nostril daily."
223753233|NCT01673035|BEHAVIORAL|CBT, exposure and response prevention|This intervention entails different exercises aimed exposure to health anxiety stimuli.
223618256|NCT05676502|DEVICE|AIRVO 2|Patients with chronic obstructive pulmonary disease and chronic respiratory failure use Nasal High Flow therapy during daytime sessions of 1.5 h.
223753234|NCT01673035|BEHAVIORAL|BSM, stress management and applied relaxation|BSM, this intervention comprises structured exercises aimed at reducing stress and controlling the anxiety response. One main component is applied relaxation.
223753235|NCT02770586|DIAGNOSTIC_TEST|Breast PET|imaging of the breast using the Breast PET system
223753236|NCT06160063|BEHAVIORAL|Education intervention|Board game was created in line with current literature. In each interview, it is expected that the child's negative behaviors will be transformed into positive behaviors.
223753237|NCT05832333|BIOLOGICAL|VaxigripTetra®|Suspension for injection Injection intramuscular
223753238|NCT00864747|DRUG|Propranolol Hydrochloride Extended Release Capsules 160 mg|A: Experimental Subjects received Actavis formulated products under non-fasting conditions
223508218|NCT02846454|OTHER|inulin|Investigate the satiating effects of consuming 4g/d inulin in 2 daily doses of 2g
223618257|NCT04186767|DIETARY_SUPPLEMENT|Very Low Carb Ketogenic Diet|Patients will be submitted to very low-calorie ketogenic dietary intervention (VLCK) according to the recommendations of the Pronokal® Method program including lifestyle and physical activity guidelines. The ketogenic stage (phase 1-3) consists of a VLCD diet (600-800 kcal / d), with low carbohydrate intake and lipids. The amount of high biological value proteins ranges from 0.8 to 1.2 g / kg of body weight / day. This first stage (ketogenic) is maintained until the patient reaches the goal of reducing the target weight by 80% to be reduced, being variable in time, according to the response of each patient. After this period, it evolved to a non-ketogenic stage, initiating the hypocaloric diet (800 to 1500 Kcal), with progressive introduction of other food groups, reducing weight more slowly. The maintenance stage consists of a balanced diet, ranging from 1500 to 2000 Kcal.
223618258|NCT03025984|BEHAVIORAL|Texting|patient adherence to her recommended care regimen after intervention of a text message reminder and education system
223618259|NCT06666088|OTHER|Cognitive stimulation and Strength training|"The experimental group will participate in a 12-week program to enhance cognitive functions and physical strength through twice-weekly sessions of 45 minutes to 1 hour. Cognitive stimulation activities will improve memory, attention, processing speed, and executive functions through memory games, recall exercises, and tasks that promote focus and quick thinking. Each session will be led by a neuropsychology or occupational therapy professional who will tailor activities to individual needs.~Strength training will also occur twice a week, focusing on exercises that strengthen major muscle groups, improve balance, and enhance coordination. Participants will use light weights, resistance bands, and bodyweight exercises, with modifications based on their physical levels. A specialized trainer will supervise the program, progressively adjusting exercise intensity to ensure safety and optimize benefits."
223508219|NCT02846454|OTHER|arabinoxylan|Investigate the satiating effects of consuming 4g/d arabinoxylan in 2 daily doses of 2g
223618260|NCT06577597|DRUG|GSK3923868|Participants will receive single dose of GSK3923868.
223618261|NCT06577597|DRUG|Placebo|Participants will receive single dose of Placebo.
223508220|NCT00252148|BIOLOGICAL|ADMVA|experimental HIV vaccine, MVA vector expressing HIV clade C env, gag, pol, nef, and tat
223508221|NCT03607695|OTHER|Gait training|Walking on a treadmill and receiving audio cues to improve gait
223508222|NCT06433063|DIAGNOSTIC_TEST|F-MISO PET|Evaluation of tumor hypoxia with F-MISO PET
223508223|NCT01304719|BEHAVIORAL|Computer Assisted Healthy Families America Home Visitation|Computer modules added to home visitation protocol for Healthy Families America
223508224|NCT01304719|BEHAVIORAL|Healthy Families America Home Visitation|Healthy Families America Home Visitation Treatment as Usual
223508225|NCT00884598|DRUG|cilengitide|
223508226|NCT00884598|OTHER|pharmacological study|
223508227|NCT00884598|RADIATION|radiation therapy|
223508228|NCT05963919|OTHER|6-minute walk test|Functional capacity will be assessed with the 6-minute walk test (6MWT). 6MWT will be performed in accordance with the criteria of the American Thoracic Society. The 6MWT distance will be recorded in meters.
223508229|NCT05963919|OTHER|Pulmonary function test|"Pulmonary function test will be performed with a spirometer (COSMED Pony FX (COSMED; Italy) by ATS/ERS criteria. Forced expiratory volume in 1 second (FEV1) and peak expiratory volume (PEF) parameters will be measured. The results will be recorded both as a percentage of measured values and expected values."
223508230|NCT05963919|OTHER|Respiratory muscle strength test|Respiratory muscle strength will be measured in accordance with ATS/ERS criteria using an electronic, mobile, (MicroRPM, Micro Medical; UK) intraoral pressure measuring device. Maximal inspiratory pressure (MIP) and maximal expiratory pressure (MEP) values will be recorded. Three measurements will be repeated for each maneuver and the highest value recorded as cmH2O.
223606065|NCT05829109|DRUG|Fecal Microbiota Transplant (FMT)|"The intervention consists of the following steps:~* Step 1: Vancomycin 125 mg orally every 6 hours and metronidazole 250 mg orally every 6 hours for 5 days.~* Step 2: Bowel preparation with 10 ounces of magnesium citrate.~* Step 3: Two FMT doses will be administered via enema one week apart using stool from donors with a durably healthy pouch."
224311493|NCT04720131|DRUG|apatinib|"Apatinib A safety-run-in was conducted in the first cycle to identify the recommended dose of Apatinib, the initial dose was administered 250mg orally daily every 3 weeks (Day 1-14 of a treatment cycle) The dose of Apatinib increase and reduction was 250 mg orally q.d. and 250 mg orally q.o.d. every 3 weeks respectively according to the number of doses limiting toxicity events (DLTs) in the initial group.~The final dose of Apatinib for the extension stage was detemained by the result of safety-run-in stage."
223606066|NCT02608463|BEHAVIORAL|painDETECT Questionnaire|This self-report questionnaire consists of 7 questions that address the quality of neuropathic pain syndromes. The first 5 questions ask about the gradation of pain, question 6 asks about the pain course pattern and question 7 asks about radiating pain. There are 4 additional questions (not counted in the total score) which asks the subject to rate their pain now and over the last 4 weeks and to mark on a body chart if there is pain radiating into other parts of the body.
223606067|NCT02608463|BEHAVIORAL|Pain Catastrophizing Scale|The PCS is a 13-item self-report scale. It asks subjects to reflect on past painful experiences, and to indicate the degree to which they experienced each of 13 thoughts or feelings when experiencing pain, on 5-point scales with the end points (0) not at all and (4) all the time. The PCS yields a total score and three subscale scores assessing rumination, magnification, and helplessness.
223606068|NCT02608463|BEHAVIORAL|Pain Intensity Scale, Pain Interference Scale, Pain Behavior Scale|"The 3-item, self-report Pain Intensity assesses how much a person hurts. The first 2 items assess pain intensity over the past 7 days; the last item asks subject to rate pain intensity right now. The 4-item, self-report Pain Interference measures the consequences of pain on relevant aspects of subject's life. It includes impairment in subject's social, cognitive, emotional, physical, \& recreational activities. It also incorporates items about sleep and enjoyment of life. It assesses pain interference over the past 7 days.~The 7-item, self-report Pain Behavior measures behaviors that typically indicate to others that an individual is experiencing pain. Measures include observations (sighing, crying), behaviors (resting, guarding, facial expressions, asking for help), \& verbal reports of pain. It assesses pain interference over the past 7 days.~All three scales, derived from the Patient Reported Outcomes Measurement Information System (PROMIS), are not disease specific."
223606069|NCT02608463|BEHAVIORAL|Beck Depression Inventory|The BDI is a widely used instrument that has been used in both clinical and non-clinical setting measuring depressive symptoms. It is a 21 item questionnaire with 4-5 responses for each question. Responses are coded 0-3 for the 4 point scales. The 5 point scales include an additional 2a and 2b response code. The symptom categories reflect overt behavioral manifestations of depression. The instrument has both a high degree of reliability and validity (Beck, Ward, Mendelson, Mock \& Erbaugh, 1961).
223606070|NCT02608463|BEHAVIORAL|Visual Analogue Scale|100 mm line scale that is subject administered to subjectively rate current pain symptoms. The subject will be instructed to draw a single vertical line that best describes current state.
223606071|NCT02608463|BEHAVIORAL|Patient's Global Impression of Change Scale & Clinical Global Impression-Global Improvement Scale|"The PGIC gives a global rating of change in symptoms, activities, emotion, and overall quality of life related to the subject's pain condition. This is a self-rated scale.~The CGI-I gives a global rating of the improvement/change in the symptoms since the last study visit. This is administered by the MD."
223606072|NCT02608463|DEVICE|Transcranial Magnetic Stimulation|Subjects will undergo daily repetitive transcranial magnetic stimulation (rTMS), defined as Monday through Friday, for a total of 10 consecutive sessions. rTMS will be applied using the NeuroStar TMS Therapy System through a figure-8 coil connected to a magnetic stimulator, which provides a biphasic pulse. The coil is applied to the primary motor cortex, M1, contralateral to the painful side. The optimal stimulus site, motor hot spot, will be determined according to visual detection of muscle twitches, and a resting motor threshold is defined as the minimal intensity necessary to induce at least one visible muscle twitch. An rTMS session consists of 10 trains at 90% intensity of resting motor threshold (one train, 100 pulses at 10 Hz; intertrain interval, 50s).
223606073|NCT01318408|DRUG|Levetiracetam|Titration of Keppra will start at 250 mg by mouth twice daily for three days. Then 500 mg by mouth twice daily for three days. Then 750 mg by mouth twice daily for the duration of the study, or for as long as treatment is necessary. This titration schedule is subject to change based on subject's tolerability.
223606074|NCT00377858|DRUG|Insulin lispro mid mixture (MM)|Patient specific adjusted dose, three times a day (TID), subcutaneous (SC) injection x 36 weeks
223606075|NCT00377858|DRUG|Insulin glargine|Patient specific adjusted dose, every day (QD), subcutaneous (SC) injection x 36 weeks
223606076|NCT06519604|DRUG|Human insulin enteric coated capsules in dose 16mg|Single oral administration of human insulin enteric coated capsules in dose 16mg
223606077|NCT06519604|DRUG|Human insulin enteric coated capsules in dose 8mg|Single oral administration of human insulin enteric coated capsules in dose 16mg
223606078|NCT06519604|DRUG|Human Insulin Injection in dose 5IU|Single subcutaneous administration of Human Insulin Injection in dose 5IU
223606079|NCT06127719|OTHER|questionnaires|before surgery, patients are asked to fill out the questionnaires as stated in the outcome measures paragraph
223606080|NCT03631758|OTHER|Evidence-based information|Evidence-based information on mammography such as blog posts, plain language evidence summaries and web resource ratings (quality-appraised online resources).
223606081|NCT03631758|BEHAVIORAL|Patient Decision Aid|Patient Decision Aid for breast cancer screening decision
223606082|NCT03631758|OTHER|Sham information|Educational information not specific to mammography or cancer screening
223606083|NCT05370053|DIAGNOSTIC_TEST|ELF Test|Patients receive ELF testing (a blood draw) and their hepatologist receives the result within a week.
223753239|NCT00864747|DRUG|INDERAL® LA 160 mg Capsules, single dose|B: Active comparator Subjects received Wyeth Pharmaceuticals formulated products non-under fasting conditions
223606084|NCT01543074|DIETARY_SUPPLEMENT|BSE placebo|2 pills = 0 micromoles of Sulforaphane/day
224311494|NCT04720131|DRUG|Capecitabine|Capecitabine was administered 1000mg/m2 orally, b.i.d. every 3 weeks (Day 1-14 of a treatment cycle)
223606085|NCT01543074|DIETARY_SUPPLEMENT|Garlic oil|1 pill = 30 mg garlic oil/day
223606086|NCT01543074|DRUG|BSE|2 pills = 200 micromoles of Sulforaphane/day
223606087|NCT01543074|DIETARY_SUPPLEMENT|Garlic Oil Placebo|1 pill = 0 mg garlic oil/day
223606088|NCT04034004|BEHAVIORAL|Mindfulness|A well-validated brief meditation-based mental training regimen \[four sessions; 20 min/session\] is used to teach patients to independently practice closing their eyes and take a deep breath every few minutes.
223606089|NCT04034004|DRUG|Naloxone|A 0.15 mg/kg bolus dose of naloxone (Naloxone hydrochloride, Amphastar Pharmaceuticals, Inc., Rancho Cucamonga, California) in 25ml normal saline will be administered over 10 minutes. The investigators also will administer a supplementary IV infusion dose of 0.1mg/kg/hour naloxone immediately after bolus infusion will cease till the end of the experiment.
223606090|NCT04034004|OTHER|Saline|A 0.15 mg/kg bolus dose of saline in 25ml normal saline will be administered over 10 minutes. The investigators also will administer a supplementary IV infusion dose of 0.1mg/kg/hour saline immediately after bolus infusion will cease till the end of the experiment.
223606091|NCT04034004|BEHAVIORAL|Meditation|A well-validated brief meditation-based mental training regimen \[four sessions; 20 min/session\] is used to teach patients to independently practice closing their eyes and take a deep breath every few minutes.
223606092|NCT05413161|BIOLOGICAL|ADL-018|150 mg/mL, Solution for injection in PFS
223606093|NCT05413161|BIOLOGICAL|US-licensed XOLAIR|150 mg/mL, Solution for injection in PFS
223606094|NCT05413161|BIOLOGICAL|EU-Approved XOLAIR|150 mg/mL, Solution for injection in PFS
223606095|NCT00945256|OTHER|Aerobic Exercise|45 minuties of treadmill walking was completed at 40% VO2 peak
223606096|NCT00945256|DRUG|Sodium Nitroprusside|Sodium Nitroprusside was given in a constant infusion for 180 minutes at a rate of 0.114 ug/kg/min
223606097|NCT00945256|DIETARY_SUPPLEMENT|Amino Acid Drink|7.5 gram Amino Acid drink
223606098|NCT04438317|PROCEDURE|Pleural drainage procedure with Seldinger procedure|Pleural drainage using Seldinger technique.
223606099|NCT04438317|PROCEDURE|Pleural drainage procedure with surgical-like technique|Pleural drainage using Surgical-like technique.
223606100|NCT03519633|DRUG|Sugammadex|Reversal of deep NMB
223606101|NCT03519633|DRUG|Neostigmine|Reversal of moderate NMB
223606102|NCT05844475|PROCEDURE|Conventional Free Gingival Graft Approach (FGG)|Conventional Free Gingival Graft Approach involving palatal soft tissue harvesting
223606103|NCT05844475|PROCEDURE|Buccal Strip Graft with a collagen matrix (bSG + CM)|A small strip of keratinized gingiva is harvested from the buccal gingiva of a site showing abundant keratinized gingiva, and combined with a xenogeneic collagen matrix
223606104|NCT01991236|BEHAVIORAL|Video|Educational video discussing risks and benefits of chronic use of systemic corticosteroids.
223606105|NCT01991236|BEHAVIORAL|Standard Script|Standard scripted discussion of risks and benefits of chronic corticosteroid usage read to patients.
223606106|NCT00666406|DRUG|Antihemophilic Factor (Recombinant) - Plasma/Albumin Free Method (rAHF-PFM)|Infusion of 50 +/- 5 IU/kg bodyweight
224311495|NCT00683631|OTHER|TheraSphere HUD|TheraSphere is FDA approved under a Humanitarian Use Device. It is considered a brachytherapy device that delivers intra-arterial radiation therapy using yttrium-90 microspheres directly to liver tumors.
223606107|NCT00666406|DRUG|Recombinant Factor VIII (rAHF)|Infusion of 50 +/- 5 IU/kg bodyweight
223606108|NCT01502228|DRUG|150-Water|Patients will be imaged immediately before, and between 14-28 days after initiation of Sunitinib therapy, in the single bed position using the Siemens Biograph 64 TruePoint system located in the clinical facilities of the I.U. Cancer Center. Administer 15O-water at 50 mCi/dose, IV.
223753240|NCT04668950|DRUG|Fluvoxamine|Up to 200mg per day (2 capsules per day) as tolerated, for approximately 15 days
224311496|NCT02292173|DRUG|Trametinib|"Dose Escalation:~Level 1: 1 mg daily. Level 2: 1.5 mg daily. Level 3: 1.5 mg daily. Level 4: 2 mg daily.~Dose Expansion:~Maximum Tolerated Dose (MTD)"
223606109|NCT01502228|DRUG|62Cu-ethylglyoxal bis|Imaging with 62Cu-ETS will be done immediately following imaging with 150-water. Patients will be imaged immediately before, and between 14-28 days after, initiation of Sunitinib therapy using the Siemens Biograph 64 TruePoint system located in the clinical facilities of the I.U. Cancer Center. Administer 62Cu-ETS in the range of 20-25 mCi/Dose, IV.
223606110|NCT01502228|PROCEDURE|Positron Emission Tomography|PET Scan
223606111|NCT01502228|DRUG|Sunitinib|
223606112|NCT04175028|DEVICE|Transcranial Direct Current Stimulation|In tDCS, electrodes are applied on the scalp to transmit direct current at low current amplitudes.
223606113|NCT00584519|OTHER|non-interventional|non-interventional
223606114|NCT06648772|DRUG|Roflumilast Cream 0.3%|Roflumilast Cream 0.3%
223606115|NCT06648772|DRUG|Vehicle cream|Vehicle cream
223606116|NCT03954080|DEVICE|Intraspinal-optimal stim therapy|During the trial, percutaneous lead(s) will be implanted, following standard clinical practices, in the posterior epidural space with the final lead position located in the optimal area to provide pain relief by stimulating neural tissue in order to create paresthesia(s) only on the painful dermatome(s). During Intraspinal-Optimal Stim, a set of electrodes in the stimulation lead(s) will deliver a charge-balanced, pulsed electrical signal with stimulation parameters (frequency, pulse width, and amplitude) within the FDA approved specifications of the commercially available external neurostimulator. These will be adjusted to produce paresthesia coverage of the painful area. Patients that will report equal or greater than 50% reduction in pain, relative to baseline pain, may undergo permanent implantation of a commercially available neurostimulator (INS). This will require a surgical intervention to implant stimulation leads, INS and anchoring hardware followed by therapy programming.
223606117|NCT02542826|OTHER|Pulmonary Rehabilitation|Patients will participate in 3 exercise training sessions/wk for a period of 7-12 wks at one of 4 sites in Quebec. Each training session will include 30-45 min of aerobic training (cycling and/or treadmill walking) at a target intensity of 80% of the maximal heart rate achieved during a symptom-limited incremental cycle exercise test performed prior to the pulmonary rehabilitation program; and 20-30 min of strength training exercises.
223753241|NCT04668950|DRUG|Placebo|Will take 2 capsules per day as tolerated for approximately 15 days
223753242|NCT06418503|OTHER|Balance Training|Participants will complete 16 sessions of balance training (30 min. each) over one month.
223606118|NCT02037334|DEVICE|Pregnolia System|No intervention is done except for measuring the stiffness of the cervix in pregnant women
223606119|NCT04488926|DIETARY_SUPPLEMENT|micronized and ultra-micronized Palmitoylethanolamide (mPEA and umPEA, 300mg + 600mg) microgranules|Micronized and ultra-micronized Palmitoylethanolamide is on the market in Italy as a Food for Special Medical Purposes
223606120|NCT04488926|OTHER|Placebo microgranules 1800mg|Placebo was prepared to be indistinguishable from color and flavor from the Product
223606121|NCT04488926|DRUG|Standard Therapy|(antidepressants, anticonvulsants, muscle relaxants, weak opiates, etc..) consolidated for at least 3 months
223606122|NCT04488926|DRUG|Rescue Drug|Use as needed allowed
223606123|NCT00291603|DEVICE|FX-class of dialyser|
223606124|NCT04007263|DRUG|Placebo|Placebo via 30 minute infusion once daily for 5 days
223606125|NCT04007263|DRUG|NP10679|NP10679 25 mg via 30 minute infusion once daily for 5 days
223606126|NCT02503228|PROCEDURE|Standard of care osteochondral and or meniscal allograft transplantation|Standard of care osteochondral and or meniscal allograft transplantation
223606127|NCT05765123|DIAGNOSTIC_TEST|Oral glucose tolerance test|A drink containing 75g of glucose together with 150mg carbon-13 sodium acetate in 300ml water
223753243|NCT06418503|OTHER|EMG-Biofeedback Training|Participants will complete 16 sessions of EMG-biofeedback balance training (30 min. each) over one month.
224200613|NCT01534429|PROCEDURE|Quantitative Sensory Testing|Quantitative Sensory Testing and Neurophysiologic Testing to be done Pre-operatively and at 3 and 6 months post-operatively.
224200614|NCT05259748|BEHAVIORAL|Psychoeducation Based on the Transtheoretical Model on Healthy Lifestyle Behaviors|Healthy lifestyle behaviours psychoeducation programme, based on the Transtheoretical Model, with 6 sessions (healthcare responsibility, nutrition, physical activity, spiritual development, interpersonal relationships, stress management) was applied to the intervention group for 6 weeks as three days in the weekdays and two sessions in a day. Psychoeducation was carried out by the researcher on the same day but within different time zones. Each psychoeducation session took 90-120 minutes with the breaks taken considering the participants' mood. After completing six sessions, the behavioural change identification form and Healthy Lifestyle Behaviors Scale II were applied to the intervention group again.
224200615|NCT02350439|DRUG|Adenosine infusion at 200μg/Kg/min|Assessment of fractional flow reserve (FFR) under high adenosine intravenous infusion dose (200mg/kg/min)
224200616|NCT03425773|BIOLOGICAL|BVAC-B|Autologous B cell and monocyte presenting HER2/neu antigen
224200617|NCT03065517|DEVICE|VillageWhere App|VillageWhere is a mobile phone app for use on both Android and iOS platforms by youth with conduct disorders and their parents.
224200618|NCT03065517|DEVICE|Attention-Control Placebo App|Mobile phone app for use on both Android and iOS platforms.
224200619|NCT06247579|OTHER|Dietary polystyrene microplastics from disposable plastic tableware|Microplastic release from the daily use of disposable plastic materials (e.g., plastic boxes) when holding hot food or drink.
224200620|NCT02513095|DRUG|Dantrolene sodium for injectable suspension|Ryanodex will be administered as a rapid IV push as a single doses of 2 mg/kg or as 1 mg/kg.
224200621|NCT02786810|DRUG|Sulfur hexafluoride type-a lipid microspheres|Used as a contrast to enhance renal ultrasound
224200622|NCT05427214|DEVICE|Halcyon 4.0 system|During each of the 1 or more imaging sessions, no more than 6 images total will be acquired. Only 5 images total across all of the imaging sessions will be used toward the study endpoint.
224200623|NCT06567418|DRUG|alirocumab 75mg/2week|patients continually prescribed or stopped alirocumab treatment during the follow-up visit, which depend on physician's clinical decision and patient preference
224200624|NCT06567418|DRUG|statin ± ezetimibe|patients will be censored at initiation of alirocumab during the follow up visit
223606128|NCT00653588|DRUG|Rosuvastatin|40mg
223606129|NCT00653588|DRUG|Atorvastatin|80mg
223606130|NCT06020781|DRUG|bupivacaine and dexmedetomidine.|patient will receive Ultrasound -guided Supraclavicular brachial plexus block with 20 ml bupivacaine 0.5% + 1 μg/kg dexmedetomidine.
223606131|NCT06020781|DRUG|bupivacaine only|patient will receive Ultrasound -guided Supraclavicular brachial plexus block with 20 ml bupivacaine 0.5% without additives
223606132|NCT06020781|DRUG|bupivacaine|patient will receive Ultrasound -guided Supraclavicular brachial plexus block with 30 ml bupivacaine 0.5% without additives as a control group.
223606133|NCT05877144|PROCEDURE|Nerve-Sparing Prostatectomy|Undergo nerve-sparing prostatectomy per standard of care
223606134|NCT05877144|OTHER|Medical Device Usage and Evaluation|Receive LiSWT
223606135|NCT05877144|PROCEDURE|Duplex Ultrasound|Undergo DDUS
223606136|NCT05877144|OTHER|Survey Administration|Ancillary studies
223606137|NCT05877144|PROCEDURE|Nerve-Sparing Prostatectomy|Undergo nerve-sparing prostatectomy per standard of care
223606138|NCT05877144|PROCEDURE|Sham Intervention|Receive sham LiSWT
223606139|NCT05877144|PROCEDURE|Duplex Ultrasound|Undergo DDUS
223606140|NCT05877144|OTHER|Survey Administration|Ancillary studies
223606141|NCT06577506|BEHAVIORAL|Deaf Diabetes Can Together|10-week diabetes self-management telehealth intervention for deaf adults with diabetes.
223606142|NCT02526004|DRUG|Ceftazidime|
223606143|NCT02526004|DRUG|Tobramycin|
223606144|NCT06268964|DRUG|Trimebutine|Prescription of trimebutine at pediatric dosage (15 mg/kg/day), divided into 2 daily doses, for 8 weeks.
223606145|NCT06268964|DIETARY_SUPPLEMENT|Lactobacillus rhamnosus|Prescription of Lactobacillus rhamnosus 5 billion CFUs in chewable tablets, a single dose (night) for 8 weeks.
223606146|NCT06268964|OTHER|Placebo|Prescription of a placebo, 250 mg microcrystalline cellulose tablets, a single dose (night) for 8 weeks.
223606147|NCT05706220|DIAGNOSTIC_TEST|Eye tracking|Eye tracker will be used to evaluate eye movements
223606148|NCT05706220|DIAGNOSTIC_TEST|Microperimetry|Perimetric examination with Expert Exam strategy Microperimetry be used for fixation test
223606149|NCT05706220|DIAGNOSTIC_TEST|Optical coherence tomography (OCT)|Macular Cube 512x128 or 200x200 scan. OCT will be used to analysis of retinal nerve fiber layer, ganglion cell complex and ganglion-cell/inner plexiform layer
224200625|NCT04205864|DRUG|Thrombi-Gel|Thrombin gel Matrix applied on pelvic lymphadenectomy areas after lympadenectomy
224200626|NCT04205864|PROCEDURE|Conventional Pelvic lymphadenectomy|Conventional Pelvic lymphadenectomy
224200627|NCT00030602|BIOLOGICAL|PSA prostate cancer vaccine|
223753244|NCT02064881|DRUG|Metformin glycinate|All patients are going to begin the treatment with one tablet orally at night, 30 minutes before dinner (1 tablet of 620 mg glycinate metformin or one 500 mg tablet of metformin hydrochloride) and the dose will be administrated every 3 days to complete the dose of 2 tablets in the morning 30 minutes before breakfast and 2 tablets in the evening 30 minutes before dinner (1240 mg metformin glycinate every 12 hours or 1000 mg metformin hydrochloride every 12 hrs) .
223606150|NCT05706220|DIAGNOSTIC_TEST|Visual processing speed test|"Visual processing speed test will be used for assessing subject visual stimulus search and reach times.~Thirty-two different everyday visual stimuli divided in four complexity groups that were presented along 8 radial visual field positions at three different eccentricities."
223606151|NCT04999436|BEHAVIORAL|APOL1 Counseling Training Program|The APOL1 counseling training program is designed for transplant nephrologists who evaluate live kidney donor candidates of African ancestry who are at risk for having APOL1 risk variants and kidney failure post-donation. The training program aims to increase transplant nephrologists' practical knowledge, self-efficacy, and skills in counseling live donor candidates about APOL1 in a culturally competent manner. The program will include training in: current APOL1 data; the value of APOL1 testing and meaning of positive test results for living donor clinical evaluation; risks of having two APOL1 gene variants on the donor's kidney health; how to engage in shared decision making about donation; how to address cultural concerns about genetic testing; and how to protect donor candidates' privacy and confidentiality with APOL1 test results. The APOL1 counseling training program will be delivered by a genetic counselor through webinars and other interactive modalities and last 2-4 hours.
223606152|NCT05621551|DRUG|Dapagliflozin|The patients is required to receive dapagliflozin(10mg, q.d.) at least for 3 days until 24 hours before the surgery. Then dapagliflozin will be discontinued and recovered as soon as the patient is able to take oral diet postoperatively. Dapagliflozin wil be ceased five days after surgery.
223606153|NCT06617936|DRUG|neoadjuvant therapy:Tislelizumab With Recombinant human endostatin combined with Chemotherapy|neoadjuvant therapy : Tislelizumab: 200mg, ivgtt, day 1 ; Recombinant Human Endostatin Injection (Endostar),210mg was pumped intravenously for 3 consecutive days; Pemetrexed (Non-squamous NSCLC) or Nab-paclitaxel(Squamous NSCLC):Pemetrexed: 500 mg/m\^2, ivgtt, day 1. Nab-paclitaxel: 260mg/m\^2, ivgtt, day 1.; Carboplatin:Carboplatin was given dosed to an area under the serum concentration-time curve (AUC) of 5 ivgtt on day 1 ; every 21 days for 1 cycle,2-4 cycles; (If the preoperative neoadjuvant did not reach 4 cycles, the treatment with ralizumab combined with recombinant human endostatin injection and chemotherapy for 1-2 cycles can be continued after surgery, and the total cycle of chemotherapy before and after surgery is up to 4 cycles)
223606154|NCT06617936|PROCEDURE|surgery|Patients who are discussed by the MDT panel to evaluate surgical resection will undergo surgery.Surgery must be done within the 4th-6th week from day 1 the last cycle of neoadjuvant treatment.
223606155|NCT06617936|DRUG|Adjuvant therapy:Tislelizumab and Recombinant Human Endostatin Injection (Endostar)|Adjuvant therapy Tislelizumab: 200mg, ivgtt, day 1 of each 21-day cycle, 17 cycles at most. Recombinant Human Endostatin Injection (Endostar):210mg was pumped intravenously for 3 consecutive days, every 21 days for 1 cycle,17 cycles at most.
223606156|NCT06617936|OTHER|Standard Treatment|Patients assessed by the MDT panel as inoperable for surgical treatment will be selected by the investigator for a standard treatment protocol determined by the MDT discussion
223606157|NCT04477759|RADIATION|50 Gy Radiation Therapy|Ionizing radiation
223606158|NCT04477759|RADIATION|55 Gy Radiation Therapy|Ionizing radiation
223606159|NCT04477759|RADIATION|60 Gy Radiation Therapy|Ionizing radiation
223606160|NCT04477759|DRUG|Concurrent Atezolizumab|Atezolizumab (1,680 mg) will be given to all subjects by intravenous injection every 4 weeks following the initiation of radiation treatment up to 1 year from radiation fraction 1.
223606161|NCT04477759|DRUG|Adjuvant Atezolizumab|Atezolizumab (1,680 mg) will be given to all subjects by intravenous injection every 28 days following the initiation of radiation treatment up to 1 year.
223606162|NCT06494358|OTHER|liquid biopsies and surgery specimen analysis|liquid biopsies and surgery specimen analysis
223618262|NCT05548244|BEHAVIORAL|Behavioral Activation Therapy|Participants will be seen for a maximum of 16 sessions of therapy focused on increasing rewarding behaviors (16 individual therapy sessions of 1-hour, 2 of which include the BSIS component) over 16 weeks. BA intervention includes monthly booster sessions offered throughout 6-month follow up. If needed, two extra sessions will be allowed during treatment.
223618263|NCT05548244|BEHAVIORAL|Baseline assessment procedures|Completion of the K-SADS and CDRS-R to assess MDD, and the Wechsler Abbreviated Scale of Intelligence - 2nd Edition to assess IQ.
223753245|NCT02064881|DRUG|Metformin Hydrochloride|All patients are going to begin the treatment with one tablet orally at night, 30 minutes before dinner (1 tablet of 620 mg glycinate metformin or one 500 mg tablet of metformin hydrochloride) and the dose will be administrated every 3 days to complete the dose of 2 tablets in the morning 30 minutes before breakfast and 2 tablets in the evening 30 minutes before dinner (1240 mg metformin glycinate every 12 hours or 1000 mg metformin hydrochloride every 12 hrs)
223753246|NCT01089439|DRUG|Nitric oxide by inhalation INOMAX|"Nitric oxide by inhalation INOMAX 800 ppm~40 ppm during 24 hours then 20 ppm during 24 hours then 10 ppm during 24 hours"
223753247|NCT01089439|DRUG|Placebo|placebo
223753248|NCT06528522|DIAGNOSTIC_TEST|Clinical Measurements and Saliva Sample Collection|"Saliva samples will be collected from all participants, and comprehensive clinical parameters will be meticulously documented. The Plaque Index (PI) and Gingival Index (GI) will be measured at four sites per tooth. Full-mouth probing depth (PD) and clinical attachment level (CAL) will be recorded in detail for each tooth at six sites. The percentage of bleeding areas will be assessed within 20 seconds post-probing using a binary scoring system to indicate presence or absence. All clinical parameters will be recorded by a calibrated periodontologist utilizing manual probing techniques.~Following collection, saliva samples will be stored at -80°C until subsequent analysis. Concentrations of IL-39, IL-41, IL-1β, and TNF-α in the saliva samples will be quantified using specific enzyme-linked immunosorbent assay (ELISA) kits."
223753249|NCT00945581|OTHER|Experimental Nutritional Powder Formula|Powder twice a day
224200628|NCT00030602|BIOLOGICAL|incomplete Freund's adjuvant|
224200629|NCT00489008|PROCEDURE|Stereotactic Body Radiation Therapy (SBRT)|"Cohorts 1 \& 2: 50 gray (GY) with 12.5 GY per Fraction for 4 treatments~Cohort 3: 40 GY with 10 GY per Fraction for 4 treatments"
223606163|NCT06049303|OTHER|Paraffin wax bath therapy and Maitland joint mobilization techniques|"In group A Patients will be treated with paraffin wax bath 20 minutes (before any physical therapy treatment)~* (Apply a few drops of olive oil into the skin of the area. Dip/pour knee joint area into the wax and leave it in for a few seconds until a layer forms over the area. Wait for the wax to dry. Repeat this process until you have at least 10 layers of wax area to be treated.)~* Joint mobilization technique (8-12 glides at knee joint, mobilization grade-I and grade-II will be used for pain management and relaxation, while grade III for improvement in the PROM at knee joint) will be given 4 times a week for 6 weeks (The patient will be positioned in supine lying with the knee slightly flexed and a prop placed under the distal femur. The stabilizing hand will be used to prop the distal femur and the mobilizing hand is placed over the proximal tibia just below the tibial tuberosity. The mobilization itself will be performed by a force perpendicular to the line of the tibia.)"
223606164|NCT06049303|OTHER|Maitland knee joint mobilization|"Group B will have (8-12 glides at knee joint, mobilization grade-I and grade-II will be used for pain management and relaxation, while grade III for improvement in the PROM at knee joint) 4 times a week for 6 weeks.~Mobilization procedure will be same as above"
223606165|NCT00260624|DRUG|Escitalopram (Lexapro)|
223753250|NCT00945581|OTHER|Placebo comparator|Powder twice a day
223753251|NCT04461782|DIETARY_SUPPLEMENT|Lactobacillus plantarum|Oral food supplement
223753252|NCT00901758|DRUG|IV Nitroglycerin|IV injection, initial does of 1mL, with further doses of 1-3mL, up to a recommended maximum of 10mL.
223753253|NCT00901758|DRUG|Normal saline|IV injection, initial does of 1mL, with further doses of 1-3mL, up to a recommended maximum of 10mL
223753254|NCT06215404|OTHER|Liberal group|Fluid challage to keep stroke volume variation \< 10%
223753255|NCT06215404|OTHER|restrictive group|Fluid challage to keep stroke volume variation \< 18%
223753256|NCT02790970|DEVICE|PReDicT Test|PReDicT Test, when completed 7-9 days after starting antidepressant treatment, is able to predict a patient's subsequent response to that antidepressant treatment 4-6 weeks later
223753257|NCT02790970|OTHER|Treatment as Usual|Patients treated by the clinician conventionally using signs and symptoms to determine treatment changes or medication changes.
223753258|NCT05810090|PROCEDURE|Total knee arthroplasty|patient who received a TKA in our hospital
223753259|NCT00355862|DRUG|CNI, MMF, Steroids, Aza etc. (mTOR inhibitor free)|center specific therapeutic regimen without mTOR inhibition
223753260|NCT00355862|DRUG|Sirolimus|Sirolimus based immunosuppression
223753261|NCT00550095|DRUG|valsartan|
223753262|NCT04662801|BEHAVIORAL|Behavioral Weight Loss (BWL)|All participants will receive twelve weeks of BWL treatment.
224200630|NCT03145038|DRUG|Vericiguat(BAY1021189, high-dose pediatric-formulation)_fed|Vericiguat high-dose pediatric formulation (fed; American breakfast), 10 mg given as 20 x 0.5 mg mini tablets
223606166|NCT02843672|PROCEDURE|Triple Weil´s Osteotomy|"A 10mm longitudinal incision is made with a No.15 blade in the second intermetatarsal space immediately behind the dorsal interdigital fold, parallel to the extensor tendon. An intra-articular osteotomy in the metatarsal head is performed angled 45º relative to the long axis of the metatarsal and in a dorsal-distal to proximal-plantar direction. A second osteotomy is performed perpendicular to the metatarsal shaft,.The osteotomy is fastened with a 2.0mm snap-off screw.~Once all the osteotomies are completed, the incisions are closed with a 2/0 monofilament suture."
223606167|NCT02843672|PROCEDURE|Distal metatarsal minimally invasive osteotomy|A 5mm longitudinal incision is made with a MIS blade No.64 in the intermetatarsal space immediately behind the dorsal interdigital fold, parallel to the extensor tendon. Under fluoroscopy vision, an extra-articular osteotomy in the metatarsal neck is performed angled 45º relative to the long axis of the metatarsal and in a dorsal-distal to proximal-plantar direction. The osteotomies scheduled preoperatively are performed, repeating the same procedure for each ray needing an osteotomy. Once all are completed, the incisions are closed with a 4/0 monofilament suture.
223753263|NCT04662801|BEHAVIORAL|Early Responder: BWL continued|Participants categorized as experiencing early weight loss at the end of the first month of treatment will continue with BWL for the remainder of treatment.
223753264|NCT04662801|COMBINATION_PRODUCT|Early Non-responder: BWL continued with medication added|Participants categorized as not experiencing early weight loss at the end of the first month of treatment will continue BWL plus a weight loss medication (Naltrexone Bupropion) for the remainder of treatment.
223606168|NCT06964165|DRUG|Niraparib|Niraparib will be administered
223606169|NCT06964165|DRUG|Carboplatin|Carboplatin will be administered
223606170|NCT06964165|DRUG|Paclitaxel|Paclitaxel will be administered
223753265|NCT01004588|DIETARY_SUPPLEMENT|Protein drink|total of 15 g protein/d in a protein drink consumed every morning after breakfast during 24 weeks
223753266|NCT01004588|DIETARY_SUPPLEMENT|placebo drink|subjects consume a placebo drink every morning after breakfast over a period of 24 weeks.
223753267|NCT01883427|DRUG|Placebo|placebo containing saline+glucose
223753268|NCT01883427|DRUG|Glucose oxidase|a hydrogen peroxide producing enzyme that creates an acidous environment to which rhinoviruses are sensitive.
223753269|NCT04697693|DRUG|Escitalopram|The participant will be begun on either escitalopram 10mg or duloxetine 30mg. Subjects will begin escitalopram 10mg, continue this dosage for 4 weeks, then if the HRSD \>7 at Week 4, he/she will have their dosage increased to 20mg for the remainder of the 8 week study.
223753270|NCT04697693|DRUG|Duloxetine|Participants who have not responded to or not tolerated escitalopram in the current depressive episode will be started on duloxetine. They will take 30mg for the first 2 weeks, then, contingent on clinical assessment that the 30mg dose is sufficiently well tolerated, be increased to 60mg for the remaining 6 weeks of the study.
223753271|NCT02733536|DEVICE|Standard endotracheal tube|1\) Direct laryngoscopy using a Macintosh laryngoscope with size 3 blade (Mercury Medical, Clearwater, FL, USA) with a conventional 7.0 mm internal diameter (ID) tracheal tube
223753272|NCT02733536|DEVICE|C-MAC|C-MAC introduced with a h size 3 blade.
223753273|NCT02719132|DRUG|Dapagliflozin|Dapagliflozin, 10 mg
223753274|NCT02719132|DRUG|Metformin|Metformin, up to 2500 mg
224200631|NCT03145038|DRUG|Vericiguat(BAY1021189, high-dose pediatric-formulation)_fasted|Vericiguat high-dose pediatric formulation (fasted),10 mg given as 20 x 0.5 mg mini tablets
224200632|NCT03145038|DRUG|Vericiguat(BAY1021189, low-dose pediatric-formulation)_fed|Vericiguat low-dose pediatric-formulation (fed; American breakfast), 2.5 mg given as 25 x 0.1 mg mini tablets
223606171|NCT04043039|PROCEDURE|Palatal wound bandage with PRF|palatal wound will be protected by a quadruple layer of Platelet Rich Fibrin obtained by folding on itself 2 Platelet Rich Fibrin membranes
223606172|NCT04043039|PROCEDURE|Palatal wound bandage with Gelatine Sponge|palatal wound will be protected by gelatine sponge
223753275|NCT02427321|DEVICE|Video recording of flexible cystoscopic examination|The video feed from the flexible cystoscopic examination will be recorded for all participants in the study. Proof-of-concept device will record high-definition video in a lossless format to a computer hard-drive from any existing cystoscopy equipment
224200633|NCT03145038|DRUG|Vericiguat(BAY1021189,10 mg IR film-coated tablets,intact)_fed;American breakfast|10 mg IR tablet, intact (fed; American breakfast)
223606173|NCT05383716|DRUG|Pembrolizumab|Two to four cycles of neoadjuvant chemotherapy in combination with pembrolizumab will be administered before surgery, followed by another one to two cycles of chemotherapy plus pembrolizumab after surgery (4 cycles neoadjuvant/adjuvant chemotherapy in total ) then use pembrolizumab monotherapy for up to 1 year.
223606174|NCT01407757|GENETIC|DNA analysis|
223606175|NCT01407757|GENETIC|gene expression analysis|
223606176|NCT01407757|OTHER|laboratory biomarker analysis|
223606177|NCT01407757|OTHER|pharmacogenomic studies|
223606178|NCT03221244|DEVICE|VR Treatment|Distractors
223606179|NCT03221244|DEVICE|VR Active Control|No distractors
223606180|NCT04211441|DEVICE|Catheter mapping and ablation with the Sphere-9 Catheter and Affera Mapping and Ablation System|Catheter mapping and ablation with the Sphere-9 Catheter and Affera Mapping and Ablation System
223606181|NCT03758534|OTHER|No intervention|This is a retrospective chart review study.
223606182|NCT02000297|PROCEDURE|Allogenic bone graft|Patients in this arm is treated with allogenic bone graft to fill the bone defect created with medial open wedge high tibial osteotomy
223606183|NCT02000297|PROCEDURE|Synthetic bone substitute (geneX®)|Patients in this arm is treated with synthetic bone substitute (geneX®) to fill the bone defect created with medial open wedge high tibial osteotomy
223606184|NCT03643627|DRUG|SYNT001|single IV infusion
223606185|NCT03643627|DRUG|Placebo|single IV infusion
223606186|NCT03939975|DRUG|pembrolizumab or nivolumab or JS001|ICIs therapy of nivolumab (3 mg/kg, per 2 weeks) or pembrolizumab (2 mg/kg, per 3 weeks) or JS001 (240mg, per 3 weeks) was performed until the off-treatment criteria were met. For participants with stable disease or atypical progression to ICIs therapy, thermal ablation of radiofrequency ablation or microwave ablation was performed addtionally.
223606187|NCT05730413|DRUG|Bisoprolol|Bisoprolol dose was divided to be taken as 2.5 mg twice per day from hospital admission to discharge.
223753276|NCT06219460|OTHER|Ventilation using two types of face masks|ventilation using two types of face mask
223753277|NCT04318782|DEVICE|Pharmacodynamic thrombectomy|Pharmacodynamic thrombectomy using AngioJet ™ PE Thrombectomy Catheter
223753278|NCT04059146|OTHER|Pain Education and Exercise|Participants will be randomly assigned to a pain education group, following biopsychosocial model, or standard of care education, following biomedical model. The goals of the pain education intervention are for patients to 1) address fear of movement and pain catastrophizing specific to AT, 2) learn about the neurophysiology of pain, 3) develop coping skills, and 4) promote exercise participation through pacing. This program enables patients to have a conceptual change in their understanding of what causes pain, gain greater control over the psychological aspects of pain, and reduce the perceived threat of chronic pain. Participants will be given weekly online exercises to promote engagement with the material, give individual feedback to participants, and assess understanding. In person sessions with the physical therapist will reinforce self-learning and application to a home exercise program.
224200634|NCT03145038|DRUG|Vericiguat(BAY1021189,10 mg IR film-coated tablets,crushed)_fed;American breakfast|10 mg IR tablet, crushed (fed; American breakfast)
223606188|NCT05730413|DRUG|Bisoprolol|Bisoprolol was taken as 5 mg per day from hospital admission till discharge.
223606189|NCT03700567|OTHER|low temperature contrast|UAP patients undergoing PCI were performed with low temperature contrast. The investigators used thermal insulation equipment to keep contrast at 5℃. The EKG and blood pressure were monitored during the PCI procedure. After PCI, the investigators monitored levels of myocardial injury biomarkers for 3 days every 8 hours.
223606190|NCT00335296|DEVICE|PFx catheter|
224200635|NCT03145038|DRUG|Vericiguat(BAY1021189,10 mg IR film-coated tablets,intact)_fed;Continental breakfast|10 mg IR tablet, intact (fed; Continental breakfast)
224200636|NCT00836238|BEHAVIORAL|Interview|Physical Function and Symptom Assessment Interviews
224200637|NCT00836238|OTHER|Physical Function Tests|3 physical function tests.
224200638|NCT04527159|DRUG|Fluoraphat Pro / VivaSens|desensitizing agents for treatment of dentinal hypersensitivity
223606191|NCT02661243|DEVICE|Biohorizons Laser-lok bonelevel dental implants|Insertion of Biohorizons Laser-lok bonelevel dental implants to replace missing (pre)molars or to stabilize a denture
223606192|NCT04298957|PROCEDURE|Cone biopsy|Cone biopsy if transformation Zone (TZ) 2 or TZ 3
223606193|NCT00907504|DRUG|CP-751,871|CP-751,871 20mg/kg every 3 weeks
223606194|NCT00907504|DRUG|Cisplatin|Cisplatin 80 mg/m2 every 3 weeks
223606195|NCT00907504|DRUG|Gemcitabine|Gemcitabine 1,250 mg/m2 Day1+8 of evey 3 week-cycle
223606196|NCT00907504|DRUG|Cisplatin|Cisplatin 80 mg/m2 every 3 weeks
223606197|NCT00907504|DRUG|Gemcitabine|Gemcitabine 1,250 mg/m2 Day1+8 of evey 3 week-cycle
223606198|NCT01546662|DIETARY_SUPPLEMENT|E-RH-06|Capsules, 1 capsule/ 2 capsule, twice daily for 12 weeks
223606199|NCT01546662|DIETARY_SUPPLEMENT|Placebo|1/ 2 capsules, twice daily for 12 weeks
223606200|NCT03084003|DIETARY_SUPPLEMENT|Almonds|
223606201|NCT03084003|DIETARY_SUPPLEMENT|Graham crackers|
223606202|NCT02732782|OTHER|Isometric exercise|
223606203|NCT02732782|OTHER|Eccentric exercise|
223606204|NCT03890744|DRUG|ModraDoc006/r|Treatment with twice daily once weekly (BIDW) ModraDoc006 (oral docetaxel) 10mg tablets in combination with ritonavir 100mg tablets
223606205|NCT00420069|DEVICE|MRTX device|device for ventilation
223606206|NCT02440685|DRUG|ASN002 Dose Escalation|Multiple ascending doses of ASN002 assigned by cohort
223606207|NCT02440685|DRUG|ASN002 RD|Recommended dose of ASN002 from Part A
223606208|NCT04887519|OTHER|No Intervention|This is a non-interventional study.
223606209|NCT05293184|OTHER|Observational study only|
223606210|NCT02434562|OTHER|Serum (with or without urine) samples|
223606211|NCT04289311|BEHAVIORAL|Voice Crisis Alert V2|An mHealth intervention (app) with multiple components for self-management behavior development. Components include: electronic educational information, symptom monitoring and tracking, communication with a provider, health history entry and storage (including medication adherence).
223606212|NCT00369213|DEVICE|Additional spermicidal lubricant to condoms|
223606213|NCT03321422|OTHER|No intervention Observational study|follow up of the function of the hip after lateral shelf acetabuloplasty by harris hip score and WOMAC score
223606214|NCT01514201|RADIATION|3-Dimensional Conformal Radiation Therapy|Undergo 3D-CRT
223606215|NCT01514201|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
223606216|NCT01514201|OTHER|Laboratory Biomarker Analysis|Optional correlative studies
223606217|NCT01514201|OTHER|Pharmacological Study|Correlative studies
223606218|NCT01514201|DRUG|Temozolomide|Given PO
223606219|NCT01514201|DRUG|Veliparib|Given PO
223606220|NCT02352844|DRUG|Everolimus|
223606221|NCT00398099|DRUG|MK0826, ertapenem sodium / Duration of Treatment: 14 Days|
223753279|NCT04059146|OTHER|Standard Education and Exercise|The comparison group will be given education based on standard of care resources that primarily utilize a biomedical model, which assumes that AT pain is primarily caused by tissue damage. The videos, handouts, and exercises will be equivalent to the pain education group in terms of time and learning requirements.
223753280|NCT01978028|DRUG|ferric carboxymaltose|
223753281|NCT01978028|DRUG|placebo|
223753282|NCT04909775|DRUG|Tislelizumab|200 mg per cycle, IV on day 1 of 3-week
223753283|NCT04909775|DRUG|Cisplatin|70mg/m2 IV on Day 1 of 3-week, for 4 cycles. Dose fractionation is permissible.
223753284|NCT04909775|DRUG|Gemcitabine|1000mg/m2, Day 1 and Day 8 of 3-week, for 4 cycles
223753285|NCT04038515|DRUG|Nicotine 0 mg/mL|E-liquid containing no nicotine (0 mg/mL nicotine) will be self-administered via e-cigarettes. This will be administered in 5 flavor conditions (1 unflavored, 2 menthol, and 2 fruit conditions).
223753286|NCT04038515|DRUG|Nicotine 6 mg/mL|E-liquid containing low nicotine (6 mg/mL nicotine) will be self-administered via e-cigarettes. This will be administered in 5 flavor conditions (1 unflavored, 2 menthol, and 2 fruit conditions).
223753287|NCT04038515|DRUG|Nicotine 12 mg/mL|E-liquid containing medium nicotine ( 12 mg/mL nicotine) will be self-administered via e-cigarettes. This will be administered in 5 flavor conditions (1 unflavored, 2 menthol, and 2 fruit conditions).
223753288|NCT04038515|DRUG|Nicotine 24 mg/mL|E-liquid containing high nicotine ( 24 mg/mL nicotine) will be self-administered via e-cigarettes. This will be administered in 5 flavor conditions (1 unflavored, 2 menthol, and 2 fruit conditions).
223753289|NCT04038515|OTHER|'Menthol' flavor|E-liquid containing 'menthol' flavor will be self-administered via e-cigarettes. This will be administered in 4 nicotine conditions (0, 6, 12, 24 mg/mL nicotine).
223753290|NCT04038515|OTHER|'Menthol/Mint' flavor|E-liquid containing 'menthol/mint' flavor will be self-administered via e-cigarettes. This will be administered in 4 nicotine conditions (0, 6, 12, 24 mg/mL nicotine).
223753291|NCT04038515|OTHER|'Green Apple' flavor|E-liquid containing 'green apple' flavor will be self-administered via e-cigarettes. This will be administered in 4 nicotine conditions (0, 6, 12, 24 mg/mL nicotine).
223753292|NCT04038515|OTHER|'Watermelon' flavor|E-liquid containing 'watermelon' flavor will be self-administered via e-cigarettes. This will be administered in 4 nicotine conditions (0, 6, 12, 24 mg/mL nicotine).
223753293|NCT04038515|OTHER|'Unflavored'|E-liquid containing no additional flavor (i.e., 'unflavored') will be self-administered via e-cigarettes. This will be administered in 4 nicotine conditions (0, 6, 12, 24 mg/mL nicotine).
223606222|NCT05888181|OTHER|Mobile app-based self-management intervention|"The self-management program, accessible via a smartphone app, comprises several components. First, the app contains an RA-specific educational program presented as videos in 16 weekly modules. Second, the app provides patients with tailored lifestyle advice, both as part of the educational program and in the form of personalized messages from a certified health coach. Third, the study app includes remote monitoring features underpinned by goal-setting principles. For instance, participants can use the app to log daily steps and physical activity, as well as their diet, sleep, and mental health. Personal goals, as well as physical challenges and meditation or mindfulness exercises, can be set up within the app to encourage behavioral change.~Finally, patient-reported disease burden can be monitored within the study app via the RAID instrument. Based on random allocation to one of both intervention groups, the RAID will be prompted either weekly (group A) or monthly (group B)."
223606223|NCT04647968|PROCEDURE|Primary closure of tracheo-cutaneous fistula|This procedure will follow protocoled steps. It consists of a sutured closure of the tracheotomy following local anesthesia, done at bedside.
223606224|NCT04647968|PROCEDURE|Secondary closure of tracheo-cutaneous fistula|This procedure will follow protocoled steps. It consists of removing the tracheotomy canula and applying ointment and an Elastoplast on the site, which will be changed regularly until full healing of the wound.
223606225|NCT06383416|OTHER|Neck pain by VAS|chronic neck pain will be assessed by visual analogue scale. Patients will fill out quality of life questionnaire and headache disability index.
223606226|NCT02421718|RADIATION|Radiotherapy|
223606227|NCT03124836|DEVICE|Pulse Oximeter Sensor|
223753294|NCT06151587|DRUG|QLM3004 Concentration 1|"Low dose of QLM3004 Ophthalmic Solution~1 drop in each eye at bedtime"
223753295|NCT06151587|DRUG|QLM3004 Concentration 2|"Medium dose of QLM3004 Ophthalmic Solution~1 drop in each eye at bedtime"
223753296|NCT06151587|DRUG|QLM3004 Concentration 3|"High dose of QLM3004 Ophthalmic Solution~1 drop in each eye at bedtime"
223753297|NCT06151587|OTHER|Placebo|Vehicle
223753298|NCT04694313|DEVICE|OPM|Simultaneous MEG SQUID + SEEG acquisition followed by a simultaneous MEG OPM + SEEG acquisition.
223753299|NCT04445428|BIOLOGICAL|oral polio vaccine + information|Bivalent OPV (GSK), 0.1 ml administered orally on a sugar lump
223753300|NCT04445428|BEHAVIORAL|Information|Advice regarding how to protect oneself from COVID-19
223753301|NCT02455271|DRUG|Eszopiclone|The usual dosage of eszopiclone is 2 mg per dose for adults and 1 mg per dose for elderly participants, taken orally before bedtime. The dosage may be adjusted according to the participant's symptoms, but a single dose should not exceed 3 mg in adults and 2 mg in elderly participants.
223606228|NCT04890288|PROCEDURE|Interventional randomized controled trial (RCT) comparing two oxygenation methods to reduce desaturation during intubation vs standard of care.|Demonstrate that airway management supported by oxygen supplementation (either HFNC or low flow oxygen) can prevent significant desaturation (SpO2 \> 85%) among patients in pediatric intensive care units (PICU) and neonatal intensive care units (NICU).
223606229|NCT00003154|DRUG|aminocamptothecin colloidal dispersion|120 hour continuous infusion of aminocamptothecin colloidal dispersion (AC/CD) once a week for 2 weeks, followed by 1 week of rest. Patients are assessed after every 2 courses of therapy. Treatment with aminocamptothecin continues indefinitely if there is tumor shrinkage or stable disease and no significant toxicity is experienced. Patients are followed every 3 months.
223606230|NCT00646425|DRUG|Basiliximab|40 mg basiliximab administered as short iv infusion once every 2 weeks for 3 doses and at Weeks 8 and 12 for a total of 5 doses
223606231|NCT00646425|DRUG|Placebo|Placebo to match basiliximab
223606232|NCT01902329|DRUG|HMA|azacitidine 75 mg/m2 for 7 days or decitabine 20mg/m2 for 5 days
223606233|NCT01902329|DRUG|SGN-CD33A|Given intravenously on Day 1 or Days 1 and 4 every 3 weeks (SGN-CD33A Monotherapy) or given intravenously on the final HMA dosing day every 4 weeks (SGN-CD33A+HMA)
223606234|NCT03054649|DEVICE|HARMONI® Modular Intraocular Lens System|Two-component system consisting of a base and a separate optic that allows for an intraoperative exchange of the optic only without direct manipulation of the capsular bag
223606235|NCT03054649|PROCEDURE|Intraoperative optic exchange|Removal of one optic and replacement with another during cataract surgery for the purpose of improving refractive outcomes
223606236|NCT03852667|BEHAVIORAL|Pain Neuroscience Education|The PNE intervention consisted of 2 sessions of 30 minutes. In the first session, the main goal is to explain the patient why pain is important and why people can't live without it. Besides it is explained why objective findings such as x-rays, MRI, CT scans, etc. often lack significant findings despite the pain that the patient experiences. This first session of pain education might help the patient understand that pain is necessarily a result from tissue damage. Furthermore, the session explains the right approach to conquer pain and to avoid going down in this vicious circle of low back pain. The second session of PNE, is a revision of the first session, continuing on what was unclear from the first session.
224200639|NCT06079437|PROCEDURE|Cheer|Maximum isometric contraction was performed with cheering.
223606237|NCT03852667|OTHER|Exercise therapy|The exercise therapy varies form analytical exercises in the first sessions, to functional and sports related exercises near the following sessions. The first session focuses on the lumbar neuromuscular control of the patients: first a voluntary contraction of the Transversus Abdominis muscle, the Multifidus muscle and the pelvic floor muscles is learned. When the subject is able to maintain the combined contraction for 10 times, the exercises evolve to more complicated tasks. In the final stage, more functional and sport specific tasks will be exercised.
223606238|NCT00756990|DRUG|Depot Naltrexone|228mg of injectable naltrexone
223606239|NCT02595619|DEVICE|RRT plus ECCO2R|Patients with acute kidney injury will be treated with Renal replacement therapy associated to extracorporeal carbon dioxide removal in a single treatment
223606240|NCT02563236|OTHER|Parabolic flight|
223606241|NCT05842148|OTHER|Study and recording of post-surgical clinical and pathological data of patients diagnosed with breast cancer undergoing unilateral or bilateral conservative oncoplastic surgery.|Control and review of pathological parameters (oncological radicality resection volume, locoregional extension / TNM / multifocality and tumor biological profile).
223606242|NCT05842148|OTHER|Study and recording of any associated post-surgical complications (of patients diagnosed with breast cancer undergoing unilateral or bilateral conservative oncoplastic surgery.|Control and review of post-surgical complications (dehiscence, liponecrosis, infection, seroma, hematoma, fibrosis, scar hypertrophy).
223606243|NCT05842148|OTHER|Study and recording of aesthetic and functional post-surgical results related to the quality of life, as data perceived by the surgeon (technical analysis), and by the patient.|Control and review of technical analysis by the surgeon, and of psychosocial well-being, physical discomfort, adverse effects of radiotherapy by the patient collected through the administration of a questionnaire.
223606244|NCT02534909|BIOLOGICAL|LFG316|"LFG316 20 mg/kg was administered to all patients enrolled in the study:~* Treatment Periods 1 to 3: LFG316 20 mg/kg as i.v. infusion every 2 weeks~* Treatment Period 4: LFG316 20 mg/kg as i.v. infusion every 2 weeks for 4 weeks (total 2 infusions)."
223606245|NCT02534909|DRUG|LNP023|Treatment Period 4: LNP023 200 mg b.i.d. for approximately 20 weeks. Four capsules (each 50 mg) were administered each time study medication was taken.
223606246|NCT01389869|BIOLOGICAL|Sniffing emotional tears|A band-aid soaked 100μl of emotional tears will be applied just below nostrils.
223606247|NCT01389869|BIOLOGICAL|Sniffing trickled saline|A band-aid soaked 100μl of trickled saline will be applied just below nostrils.
223606248|NCT01389869|BIOLOGICAL|Sniffing fasting plasma|A band-aid soaked 100μl of own fasting plasma will be applied just below nostrils.
223606249|NCT01389869|BIOLOGICAL|Sniffing postprandial plasma|A band-aid soaked 100μl of own postprandial plasma will be applied just below nostrils.
223606250|NCT01804881|BEHAVIORAL|Lifestyle counseling|Six week program to address problematic eating
224200640|NCT06079437|PROCEDURE|The cold pressure test|Maximum isometric contraction was performed with the cold pressure test.
224200641|NCT02248428|DRUG|Clarithromycin|500mg orally daily on days 1-28,repeated every 28 days
224200642|NCT02248428|DRUG|Thalidomide|Thalidomide 100-200mg orally per night on days 1-28,repeated every 28 days
224200643|NCT02248428|DRUG|Cyclophosphamide|300mg/m\^2 intravenously daily on day 1-3,repeated every 28 days
224200644|NCT02248428|DRUG|Dexamethasone|40 mg orally weekly on days 1,8,15,22,repeated every 28 days
224200645|NCT00107809|DRUG|Modafinil|
224200646|NCT05324254|DEVICE|Weighted blanket|A weighted blanket is a blanket with extra weight sewn in for added pressure to the body.
224200647|NCT00845377|BEHAVIORAL|Comprehensive psychosocial support for depressed elderly|The model includes a psychiatric nurse as a care manager, a multiprofessional team with a physiotherapist, psychologist and psychiatrist. Each participant receives individually tailored services such as therapeutic groups, conversation groups, physical exercise, music therapy, art therapy and nutritional counseling
224200648|NCT03337776|OTHER|WhatsApp message|WhatsApp message will be sent to invite subjects to participate in CRC screening
223606251|NCT01625000|DRUG|MP-214 3mg|Patients who meet eligibility criteria will be administered a once daily oral 3mg of MP-214 for six weeks.
223606252|NCT01625000|DRUG|MP-214 6mg|Patients who meet eligibility criteria will be administered a once daily oral 6mg of MP-214 for six weeks.
223606253|NCT01625000|DRUG|MP-214 9mg|Patients who meet eligibility criteria will be administered a once daily oral 9mg of MP-214 for six weeks.
223753302|NCT05300295|BEHAVIORAL|Mentoring Program|The Autism Mentorship Program is a psychosocial intervention that pairs adults and adolescents with autism spectrum disorder (ASD) in one-to-one mentoring relationships. AMP involves weekly meetings in an afterschool setting and targets the socio-emotional health and social connectedness of adolescents and adults with ASD.
223753303|NCT01599507|DRUG|FG-4592|TIW dosing, capsule
223753304|NCT01599507|DRUG|Placebo|TIW dosing, capsule
223753305|NCT01453283|DRUG|Trabectedin (ecteinascidin-743, ET-743, YONDELIS [R])|
223753306|NCT01484574|BIOLOGICAL|Allogeneic Mesenchymal Stem Cells|Single intramuscular administration of low dose of stem cells
223753307|NCT01484574|BIOLOGICAL|Allogeneic Mesenchymal Stem Cells|Single intramuscular administration of intermediate dose of stem cells
223753308|NCT00108056|DRUG|Enzastaurin (LY317615) monohydronchloride|
223753309|NCT01951339|DRUG|Sitagliptin|100 mg sitagliptin
223753310|NCT01951339|DRUG|Glimepiride|"Active Comparator~2mg glimepiride"
223753311|NCT01951339|DRUG|Placebo|2 mg placebo once daily
223753312|NCT01951339|DRUG|Placebo|100 mg placebo once daily for three months
224200649|NCT03337776|OTHER|Telephone call|Telephone call will be made to invite subjects to participate in CRC screening
223606254|NCT01625000|DRUG|Risperidone 4mg|Patients who meet eligibility criteria will be administered a once daily oral 4mg of risperidone for six weeks.
223606255|NCT01625000|DRUG|Placebo|Patients who meet eligibility criteria will be administered a once daily oral dose of placebo for six weeks.
223606256|NCT05126888|DRUG|SCI-110|SCI-110 - a softgel capsule containing Dronabinol and Palmitoylethanolamide (PEA) in the following doses: 2.5mg Dronabinol+400mg PEA, 5mg Dronabinol+400mg PEA and 10mg Dronabinol+400mg. Maximum dose 20mg Dronabinol and 800mg PEA a day.
223606257|NCT05126888|OTHER|Placebo|Pill that matches in taste, odour and appearance to SCI-110 active pills
223606258|NCT01443702|DRUG|Lapis Judaicus|2 g capsule per day.
223606259|NCT01443702|DRUG|Placebo|2 g capsule per day.
223606260|NCT00904904|DRUG|Indomethacin ophthalmic solution|Indomethacin 0.1% eye drops administered pre-cataract surgery and for 4 weeks post-cataract surgery
223606261|NCT00904904|DRUG|Ketorolac Ophthalmic Solution|Ketorolac 0.5% eye drops administered pre-cataract surgery and 4 weeks post-cataract surgery
223753313|NCT05133687|DRUG|Bupivacaine Hydrochloride|Recruited children will be randomly assigned to one of three groups in a 1:1:1 ratio; (Group 0.8-G), (Group 1.2-G) and (Group G).
223753314|NCT03190070|DIETARY_SUPPLEMENT|Ingestion of protein|Oral protein load as a physiological stimulus to temporarily increase glomerular filtration rate
223753315|NCT04457609|DRUG|Oseltamivir|Current standardized treatment for Covid-19
223753316|NCT04457609|DRUG|Azithromycin|Current standardized treatment for Covid-19
223753317|NCT04457609|BIOLOGICAL|Umbilical Cord Mesenchymal Stem Cells|Adjuvant therapy on top of current standardized treatment (Oseltamivir + Azithromycin)
223753318|NCT04280367|DIAGNOSTIC_TEST|Standardised semi-structured talk|Comprehensive assessment of at-risk mental states (CAARMS) will be used.
223753319|NCT04280367|DIAGNOSTIC_TEST|Autistic spectre disorder screening|Autism-spectrum quotient (AQ) auto-questionnaire will be used.
223753320|NCT04280367|DIAGNOSTIC_TEST|Anxiety measuring|An inventory for measuring clinical anxiety: Beck Anxiety Inventory (BAI); Liebowitz Social Anxiety Scale.
223753321|NCT00338910|DRUG|Budesonide 2 single doses, Metronidazole multiple-dose|Budesonide 3 mg single oral dose on Day 1 and Day 9. Metronidazole 750 mg b.i.d. from Day 2 until Day 8, Metronidazole 750 mg once daily (in the morning) on Day 9.
223753322|NCT04574804|OTHER|Online training program in weight management for osteoarthritis|"An evidence based online education training program for physiotherapists in weight management for osteoarthritis. Training modules cover the following topic areas:~1. Overweight and obesity and osteoarthritis~2. Overview of weight regulation, overweight and obesity~3. Examining weight stigma in physiotherapy and personal beliefs about weight~4. Communication approach for addressing weight management~5. Interventions for weight management~6. Health behaviour change support~These 6 e-learning modules comprise the online training program, access to which comprises the study intervention."
223753323|NCT05829928|DIAGNOSTIC_TEST|Infectious Disease Testing|Participants will undergo infectious disease testing.
223606262|NCT06397573|RADIATION|Reirradiation|Ablative reirradiation of 50 Gy in 5 fractions (5 sessions) that will occur once per day, either for 5 days in a row, or every other day.
223606263|NCT05681806|DIETARY_SUPPLEMENT|Carnipure AAS|A combination of a low dose of Carnipure crystalline (L-carnitine tartrate) and lipid multi-particulate (LMP) creatine monohydrate
223606264|NCT05681806|DIETARY_SUPPLEMENT|Creatine Monohydrate|5g creatine monohydrate
223606265|NCT03165916|DEVICE|Bard 5 Fr diameter feeding tube|A pediatric feeding tube is used as a stent over which biliary anastomosis is performed. This is not a permanent stent and generally migrates out on its own.
223753324|NCT05829928|PROCEDURE|Gonadal Tissue Removal|Removal of gonadal tissue will be done through a surgical procedure.
223753325|NCT00587886|BEHAVIORAL|Questionnaire|The main questionnaire will cover established risk and protective factors for endometrial and ovarian cancer, as well as other possible risk factors. This includes: menstrual history; pregnancy history; use of hormones for menopausal symptoms or other reasons; smoking history; height and weight; use of oral contraceptives and other methods of birth control; family history of cancer; medical history; demographic characteristics. We will also collect dietary data using the Gladys Block questionnaire, to which we have added a supplement to measure consumption of phytoestrogens. We will also obtain a buccal sample from each respondent as the source of DNA for genetic analysis.
224200650|NCT05174273|BIOLOGICAL|Fecal Microbiota Transplantation|FMT is a technique in which intestinal microbiota are transferred from a healthy screened donor to a patient, with the goal being to introduce or restore a stable microbial community in the gut.
224311497|NCT02292173|DRUG|Sorafenib|"Dose Escalation:~Level 1: 200 mg twice daily. Level 2: 200 mg twice daily. Level 3: 400 mg twice daily. Level 4: 400 mg twice daily.~Dose Expansion:~Maximum Tolerated Dose (MTD)"
223606266|NCT00577824|DRUG|exenatide|subcutaneous injection, 5mcg, twice a day
223606267|NCT00577824|DRUG|exenatide|subcutaneous injection, 10mcg, twice a day
223606268|NCT00577824|DRUG|placebo|subcutaneous injection, volume equivalent to 5mcg or 10mcg exenatide, twice a day
223606269|NCT02750488|DRUG|BAY987517|50 μl/ cm2 of the test article is applied directly to two sites on the skin and covered with the appropriate patch. Twenty-four (24) hours later, the patches are removed. The test sites are lightly wiped with a dry cloth/tissue and 3μl/ cm2 of test article is reapplied directly to the skin of the test site designated for irradiation, and lightly spread over the test site. Forty-eight (48) hours later the procedure is repeated to the same test sites. This process is repeated twice weekly for a total of six exposures.
223606270|NCT02750488|OTHER|Untreated skin|One site is patched without treatment as control
223753326|NCT00587886|BEHAVIORAL|Questionnaire|"The main questionnaire will cover established risk and protective factors for endometrial and ovarian cancer, as well as other possible risk factors. This includes: menstrual history; pregnancy history; use of hormones for menopausal symptoms or other reasons; smoking history; height and weight; use of oral contraceptives and other methods of birth control; family history of cancer; medical history; demographic characteristics. We will also collect dietary data using the Gladys Block questionnaire, to which we have added a supplement to measure consumption of phytoestrogens. We will also obtain a buccal sample from each respondent as the source of DNA for genetic analysis.~We will conduct interviews mainly by telephone but also in person (at home or another convenient place)if the participant prefers."
223753327|NCT01356654|DEVICE|Application of Transcranial direct current stimulation (TDCS)|Application of TDCS for 20 minutes, 4 times a week for 4 weeks.
223753328|NCT01356654|DEVICE|Transcranial Direct current stimulation|Application of true TDCS for 20min, 4 times a week for 4 weeks.
223753329|NCT06015503|DRUG|PLB1004|PLB1004 is a capsule in the form of 80mg and 40mg.
223753330|NCT06977737|DRUG|ATTR-01|Intravenous injection
223753331|NCT06135376|BEHAVIORAL|comprehensive multi-component interventions|It is a combination of educational and behavioral interventions. 4 PHCCs will be randomized to 2 groups: 2 PHCCs will receive single intervention and 2 PHCCs will receive all 4 interventions.
223753332|NCT06476886|BEHAVIORAL|Intensive Crisis Intervention (ICI)|ICI is a brief (Average Length of Stay \[ALOS\]: M±SD=4.5±1.4 days), intensive family-centered, skills-based alternative to traditional inpatient psychiatric care. Adolescents participate in 2-3 individual sessions and 1-2 family sessions daily. Based on the cognitive-behavioral model of suicidality, ICI emphasizes that learned, maladaptive cognitive, behavioral, and affective responses to stressors contributing to suicidal behavior can be changed. Master's-level clinicians facilitate this process by engaging adolescents and their families in developing more effective coping skills when faced with potential triggers to suicidal crises.
223753333|NCT06476886|BEHAVIORAL|Adolescent Psychiatric Inpatient Unit (APIU)|APIU provides comprehensive assessment and treatment services to children and adolescents with significant psychiatric difficulties and to their families using a multidisciplinary approach. Symptoms and behaviors that led to admission are targeted through a milieu-based model of care and therapeutic group programming. The multidisciplinary treatment team includes a child and adolescent psychiatrist, often in collaboration with an advanced practice provider, psychologist, psychiatric nursing staff including trained mental health specialists, behavioral healthcare clinicians, care managers, rehabilitative care staff, teachers, and parent partners. Average length of stay is 9-11 days. An individualized treatment plan is developed by the entire treatment team, including the patient and caregivers, and includes initial planning for discharge with the primary treatment goal being stabilization of acute psychiatric symptoms. Programming is based on a trauma-informed biopsychosocial approach.
223606271|NCT02535143|OTHER|Test Cavity Preparation|Subjects will be asked to prepare a cavity 2mmx 2mmx 2mm in an acrylic block using an airotor and a tungsten carbide bur prior to consuming the test drink
223753334|NCT05409118|DEVICE|Alto Abdominal Stent Graft System|Endovascular Abdominal Aneurysm Repair (EVAR) using commercially available, FDA approved endovascular graft systems implanted.
223753335|NCT05409118|DEVICE|FDA Approved EVAR AAA Graft Systems|FDA approved comparator of choice
223753336|NCT03369210|DRUG|red blood cell transfusion trigger|patients receive a RBC unit with different target ranges for the post-transfusion Hb levels
223753337|NCT02722447|DRUG|rivaroxaban|Rivaroxaban 20 mg for 6 weeks
224200651|NCT06653660|OTHER|Clinical examination|For the aim of the present study, we will follow-up children born alive in the TIMOUN cohort at peripubertal age. Questionnaires will be administered to parents on the child's health and lifestyle. Stature-weight anthropometric and cardio-dynamic measurements of the child will be obtained. Scores on three cognitive tests will be obtained. Furthermore, steroid hormones and chlordecone in the child's peripheral blood will be determined.
223606272|NCT02535143|DRUG|Taurine|250 ml of commercially available taurine containing energy drink to be administered three hours after the last meal and half an hour prior to performing the second test cavity
223753338|NCT02722447|DRUG|Placebo|Placebo for 6 weeks
223753339|NCT06610448|DEVICE|ABPMPro|This is an upper arm, cuff-based intermittent ambulatory BP device. This device has an internal activity and body position sensor which gathers information about sleep-wake estimation.
223753340|NCT06610448|DEVICE|Spacelabs Ambulatory Blood Pressure Monitoring|This is an upper arm cuff-based device with tubing for continuous ambulatory BP monitoring with a unique activity sensor that correlate with patient movement activity with blood pressure changes.
224200652|NCT01937546|PROCEDURE|Primary delivery of anterior shoulder|
223606273|NCT02535143|OTHER|Post intervention test cavity|Subjects will be asked to prepare a cavity 2mmx 2mmx 2mm in an acrylic block 30 minutes after consuming the intervention drink using an airotor and a tungsten carbide bur prior to consuming the test drink
223606274|NCT02535143|DIETARY_SUPPLEMENT|Carbonated Apple Juice|250ml of commercially available carbonated apple juice to be administered three hours after the last meal and half an hour prior to performing the second test cavity
224200653|NCT01937546|PROCEDURE|Primary delivery posterior shoulder|
224200654|NCT00249327|BEHAVIORAL|education|
224200655|NCT02525627|DEVICE|Trident cup, X3 inserts, 28 mm head|Orthopaedic implant
224200656|NCT02525627|DEVICE|Trident cup, X3 inserts, 40 mm head|Orthopaedic implant
224200657|NCT02525627|DEVICE|Symax stem|Orthopaedic implant
224200658|NCT02525627|DEVICE|Accolade TMZF stem|Orthopaedic implant
223606275|NCT05100914|OTHER|Couple-based family nursing|Spouses were taught the following rehabilitation movements: hand squeeze, wrist, and elbow flexion and extension, pendulum exercise, finger wall-climbing exercise, hair combing, wall pushup, pulley exercise, and turning around exercise. Arm rehabilitation begins within 48 hours postoperatively, and each movement should be incrementally increased in terms of exertion and repetition until the patient reaches 10 repetitions, 2-3 times daily, for one month. Spouses must support patients' wrist and elbow joints and maintain the arms perpendicular to the body. Spouses were instructed that if women experience negative emotions during the rehabilitation movements, spouses can express support to his wife through body language, such as kissing, holding hands, touching, or hugging.
223606276|NCT00362648|BIOLOGICAL|RotaTeq™ - Rotavirus Vaccine, Live, Oral, Pentavalent|2.0 mL oral dose of RotaTeq™. 14 week treatment period
223606277|NCT00362648|BIOLOGICAL|Comparator: Placebo|Arm 2: Placebo. 14 week treatment period
223606278|NCT04828278|DIETARY_SUPPLEMENT|Arginine|Bonded Arginine Silicate
223606279|NCT04828278|DIETARY_SUPPLEMENT|Placebo|Maltodextrin
223606280|NCT06537726|DIAGNOSTIC_TEST|Secondary electrospray ionization high-resolution mass spectrometry (SESI-HRMS)|Identify volatile biomarkers of IFI by analyzing the breath metabolome of patients with proven or probable IFI according to the criteria outlined by EORTC/MSG and controls.
223753341|NCT06610448|DEVICE|Aktiia Blood Pressure|This is a wrist cuff-based device which uses an optical sensor (photoplethysmography sensor) to gather data from the arteries under the skin surface. Aktiia has an upper arm cuff device which is used for calibration once every month to provide a baseline blood pressure reading.
223606281|NCT05737654|OTHER|Exercise with augmented reality glasses|Two days a week (12 weeks in total), each session will be 60 minutes in total, and moderate exercise will be done with AR glasses.
223753342|NCT06610448|DEVICE|LiveMetric|This is a wrist cuff-based applanation tonometry continuous ambulatory BP device. This device has automatic self-calibration and comes in various sizes.
223753343|NCT06610448|DEVICE|Bpro|This is a wrist cuff-based wireless oscillometric, continuous ambulatory BP device. It has applanation tonometry at the wrist with Pulse wave analysis. This device needs calibration with a brachial cuff BP measurement.
223753344|NCT06991296|DIETARY_SUPPLEMENT|SPM Active®|Participants will take two SPM Active® soft-gel capsules orally each day (total 2 g/day of specialized pro-resolving mediators) for 12 weeks (± 2-4 days). Capsules are provided by Metagenics and contain monohydroxylated n-3 PUFA derivatives (14-HDHA, 17-HDHA, 18-HEPE).
223753345|NCT06340737|DRUG|CD22CART Infusion|Dosing and Administration Participants will be hospitalized to receive treatment with CD22CART, if not previously hospitalized, and will remain hospitalized for approximately 5 to 7 (±2) days. Patients may be discharged once all AEs have resolved to Grade 1 or better, or at the discretion of the treating physician. Participants may be discharged with non critical and clinically stable or slowly improving toxicities (e.g., renal insufficiency, cytopenias) even if \> Grade 1, if deemed appropriate by the investigator.
223753346|NCT02152254|DRUG|Targeted Therapy Based on Molecular Profiling|Molecular profiling results are used to assign targeted therapy. Patients receive targeted therapy by participating in a Phase I or a Phase II clinical trial. If a clinical trial is not available, and a commercially available targeted therapy exists (Food and Drug Administration \[FDA\]-approved for another indication), patients can receive the FDA-approved drug.
223753347|NCT02152254|DRUG|Standard-of-Care Therapy|Standard-of-care treatment regimen will be left to the discretion of the treating physician.
223753348|NCT06745531|DRUG|TS-172 20~60 mg/day|oral administration of TS-172 20\~60 mg/day
223753349|NCT06745531|DRUG|Placebo|oral administration of placebo
223753350|NCT06687980|DRUG|Dupilumab|Pharmaceutical form: Solution for injection Route of administration: subcutaneous injection
223753351|NCT06687980|DRUG|Placebo|Pharmaceutical form: Solution for injection Route of administration: subcutaneous injection
223753352|NCT06754904|PROCEDURE|Omitting TLND|Omitting TLND in patients who achieve an MPR in the index node following neoadjuvant ipilimumab and nivolumab.
223753353|NCT06754904|PROCEDURE|Index node procedure|Index node procedure
223753354|NCT05906537|DRUG|SKB410 for injection|SKB410 for injection is administered every 2 weeks (q2w) until radiographic disease progression (PD), intolerable toxicity, death, or discontinuation of treatment, whichever occurs first.
223753355|NCT06902740|DRUG|Recaticimab and Statin|Recaticimab (450mg every 12 weeks subcutaneously) combined with rosuvastatin 10mg qn or atorvastatin 20mg qn
223753356|NCT06902740|DRUG|Statin|Rosuvastatin 10mg qn or atorvastatin 20mg qn
223753357|NCT05086887|DIAGNOSTIC_TEST|Malaria diagnostic tests (RDT and PCR) and serology for malaria and other parasitic diseases|All individuals are tested. Individuals with demonstrated parasitic disease are referred to the Infectious diseases or Pediatric clinic for evaluation and treatment.
223753358|NCT07109362|DRUG|mild sedation|In this experiment, all subjects were administered remimazolam via a TCI pump until they reached a state of mild sedation, as indicated by a MOAA/S score of 4.
223606282|NCT05074940|DRUG|Amivantamab|Patients will receive amivantamab at 1050mg weekly for the first cycle and biweekly thereafter (1400mg for patients ≥80kg).
223606283|NCT03983304|DEVICE|The ZELTIQ EMS System|The Zeltiq EMS device will be used to perform treatments for abdominal and gluteal toning.
223606284|NCT00799435|DRUG|Exenatide|5 μg of exenatide subcutaneously twice a day for 4 weeks, followed by 10 μg of exenatide subcutaneously twice a day for an additional 8 weeks
223606285|NCT04137458|BIOLOGICAL|Biological analysis|Blood and salivary samples will be taken at inclusion and a psychiatric assessment will be carried out
223606286|NCT03885024|OTHER|Retention Video|Participants assigned to the retention training arm will watch a brief training video that will include information on how to retain peers in clinical trials.
223606287|NCT01518374|DRUG|Florbetapir F 18|370 MBq (10 mCi)
223606288|NCT05332847|DEVICE|POC-US|Point Of Care Ultrasonography (POCUS) is a rapidly evolving bedside modality in which ultrasonography is utilized as a part of the bedside physical examination and the patients' clinical assessment
223606289|NCT01737125|RADIATION|Magnetic Resonance Imaging (MRI)|"* spatial high-resolution MRI multiplanar acquisition in T1 and T2 anatomical sequences~* MRI acquisition in movements with dynamic sequences BEAT-IRT ( dynamic TrueFISP)"
223606290|NCT06577792|PROCEDURE|Lobectomy-First|During the surgical treatment for patients with NSCLC, thoracic surgeons should perform lobectomy first, and then perform lymphadenectomy next.
223606291|NCT06577792|PROCEDURE|Lymphadenectomy-First|During the surgical treatment for patients with NSCLC, thoracic surgeons should perform lymphadenectomy first, and then perform lobectomy next.
223606292|NCT04300309|DRUG|artemether:lumefantrine (2.5 mg:30 mg)|Two oral dispersible tablets twice daily for three consecutive days. Each tablet contained artemether-lumefantrine 2.5 mg:30 mg.
223606293|NCT03035331|PROCEDURE|Cryosurgery|Undergo cryosurgery
223606294|NCT03035331|BIOLOGICAL|Dendritic Cell Therapy|Given IT
223606295|NCT03035331|OTHER|Laboratory Biomarker Analysis|Correlative studies
223606296|NCT03035331|BIOLOGICAL|Pembrolizumab|Given IV
223606297|NCT03035331|BIOLOGICAL|Pneumococcal 13-valent Conjugate Vaccine|Given by injection
223606298|NCT03035331|OTHER|Quality-of-Life Assessment|Ancillary studies
223606299|NCT06974188|OTHER|AI-risk Stratification|With the results being disclosed as 'high-risk' or 'low-risk' in the experimental arm, clinicians have to adhere to a specific 'high-risk' and 'low-risk' management protocol for participants.
223606300|NCT06483854|DIAGNOSTIC_TEST|HIV counseling and testing from a traditional health practitioner|Healer provided HIV counseling and testing services offered to clients
223606301|NCT06799390|DEVICE|Auricular Vagus Nerve Stimulation|Transcutaneous auricular vagal nerve stimulation
223753359|NCT03190278|BIOLOGICAL|UCART123v1.2|Allogeneic engineered T-cells expressing anti-CD123 Chimeric Antigen Receptor Biological/vaccine: CLLS52 A monoclonal antibody that recognizes the CD52 antigen Other Names: Alemtuzumab
224311498|NCT00664131|OTHER|Neurological Examination/Questionnaires|See Detailed Description section for description of treatment plan.
223606302|NCT06799390|DEVICE|Sham Auricular Vagus nerve Stimulation|Transcutaneous auricular vagal nerve ear clip applied without current
223606303|NCT06575660|BEHAVIORAL|Mental health support session|a single AI-VR mental health support session using the XAIA application
223606304|NCT02362464|BIOLOGICAL|Multi-epitope (ME) T-cell Receptor Alternate Reading Frame Protein (TARP) vaccine|dose of 20 x 10\^6 viable cells multiepitope TARP dendritic cell vaccine given intradermally at weeks 3, 6, 9, 12, 15 and 24.
223606307|NCT06976021|DIAGNOSTIC_TEST|Baseline 89-Zr Pembrolizumab Immuno PET-CT|Diagnostic imaging with novel radiotracer - drug (Pembrolizumab) labeled with zirconium-89
223606308|NCT06976021|DIAGNOSTIC_TEST|Proteomic assay|Assessment of the proteomic profile before and periodically after treatment
223606309|NCT06976021|DIAGNOSTIC_TEST|Follow-up 89-Zr Pembrolizumab Immuno PET-CT|Diagnostic imaging with novel radiotracer - drug (Pembrolizumab) labeled with zirconium-89 after radiotherapy performed in patients who are not treated with immunotherapy
223606310|NCT06975553|DEVICE|endotracheal intubation-type end-tidal carbon dioxide sampling tube|In addition to routine monitoring (ECG, NIBP, and SpO2), an endotracheal intubation-type end-tidal carbon dioxide sampling tube is used for end-tidal carbon dioxide IPI monitoring.
223606311|NCT06974552|PROCEDURE|microbead-filled support surfaces|Patients will undergo a preoperative pressure injury risk assessment. After the induction of general anesthesia, a multilayer silicone wound dressing will be applied to the shoulder area. The shoulder will then be supported using microbead-filled support surfaces. This support surface will remain in place throughout the duration of the surgery.
223606312|NCT06974552|PROCEDURE|Jel support surfaces|Patients will undergo a preoperative pressure injury risk assessment. After the induction of general anesthesia, a multilayer silicone wound dressing will be applied to the shoulder area. The shoulder will then be supported using jel support surfaces. This support surface will remain in place throughout the duration of the surgery.
223606313|NCT06974747|DIETARY_SUPPLEMENT|Imunoglukan P4H® chewable tablets|IMG® 50 mg + Zinc 5 mg + Vitamin D 10 μg in 1 tablet
223606314|NCT06974747|DIETARY_SUPPLEMENT|Placebo chewable tablets|Zinc 5 mg + Vitamin D 10 μg in 1 tablet
223618264|NCT03063450|DRUG|Nivolumab|Nivolumab at a dose of 240mg as a 30-minute IV infusion, on Day 1 of every 14 day treatment cycle
223618265|NCT03063450|OTHER|Placebo|Placebo consisting of sterile 0.9% sodium chloride as a 30-minute IV infusion, on Day 1 of every 14 day treatment cycle
223618266|NCT03254199|DRUG|FLX-787-ODT (orally disintegrating tablet)|FLX-787-ODT taken three times daily for 28 days
223618267|NCT03254199|DRUG|Placebo ODT|Placebo ODT taken three times daily for 28 days
223618268|NCT06579950|OTHER|Cool roof|Cool roofs are a sunlight reflecting roof coating that can reduce indoor temperature. Cool roofs have high solar reflectance (reflecting the ultraviolet and visible wavelengths of sunlight, reducing heat transfer to the surface of a roof) and high thermal emittance (radiating absorbed solar energy).
223618269|NCT04315233|DRUG|Ribociclib|Ribociclib Dose Level 0 (starting dose) 200mg QD Dose Level 1A 400mg QD on Days 8-28 Dose Level 1B 200mg QD Dose Level 2 400mg QD on Days 8-28
223618270|NCT04315233|DRUG|Belinostat|"Belinostat Dose Level 0 (starting dose) 600mg/m2 daily for 5 days Dose Level 1A 600mg/m2 daily for 5 days Dose Level 1B 1000mg/m2 daily for 5 days Dose Level 2 1000mg/m2 daily for 5 days~\*Administration on 5 consecutive days is preferred. Administration within 7 days allowed as needed to accommodate holidays and infusion schedules."
223618271|NCT06807151|PROCEDURE|Extracorporeal Treatment|Extracorporeal treatments in our study included hemoperfusion and continuous veno-venous hemodiafiltration.
223618272|NCT03644875|DEVICE|etacoat|Etacoat is a HPMC formulation intended to be used in ophthalmic anterior segment cataract surgery.
223618273|NCT06311292|DEVICE|Volara System|Intrapulmonary percussive ventilation for mobilizing mucus.
223618274|NCT06347978|DEVICE|Deep Brain Stimulation|"Subjects will be randomized to either ON-OFF (Stimulation-Sham) or OFF-ON (Sham-Stimulation) arms. Patients in the ON-OFF arm will first be treated for up to 12 weeks with the parameters identified during the DBS optimization phase until the washout period. Patients in the OFF-ON will have their devices turned off and will not have their device switched on (activated) until the crossover point.~After completion of the first phase of the trial, patients will undergo another washout phase until they are within 20% of their pre-treatment Y-BOCS II score or 4 weeks have passed, whichever comes first. The purpose of the washout is to eliminate any residual effect of stimulation in the ON group.~Patients will then be advanced to the crossover phase. The participants who were initially randomized to the ON-OFF arm will be moved onto the sham (OFF) period, and the participants who were initially randomized to the OFF-ON group will be moved onto stimulation (ON) period for up to 12 weeks."
223618275|NCT05247086|DEVICE|Negative pressure therapy|After surgical wound closure we will apply negative pressure therapy
223606315|NCT06974539|DIAGNOSTIC_TEST|Multiparametric ultrasound with contrast (Sonovue and Optison)|Participants will receive 3D mpUS using both Sonovue and Optison contrast agents during a single transrectal imaging session.
223606316|NCT06128369|DRUG|Dexamethasone Ophthalmic Suspension|Ophthalmic Suspension,1.5% \[15 mg/mL\] Subjects will dose 1 drop of OCS-01 in the study eye once daily for 14 days, beginning 1-day post-surgery in the operated eye (administration of first dose will be performed in the clinic on Day 1).
223606317|NCT06128369|OTHER|Vehicle of OCS-01|inert vehicle of OCS-01 ophthalmic suspension Subjects will dose 1 drop of OCS-01 in the study eye once daily for 14 days, beginning 1-day post-surgery in the operated eye (administration of first dose will be performed in the clinic on Day 1).
223606318|NCT06771921|DRUG|GEN1078|Specified dose on specified days.
223606319|NCT07065006|DIAGNOSTIC_TEST|Qor-40 test (The recovery quality test)|Scale of postoperative recovery quality at first 24th hour. Minimum score is 40=bad ,maximum score is 200=good
223753360|NCT07108426|BEHAVIORAL|Educational Intervention via Telemedicine|A structured educational program delivered remotely through WhatsApp®, including a 30-minute online lecture and daily dissemination of educational content (videos, texts, and practical guidance) on hospital hyperglycemia and glycemic management strategies.
223753361|NCT02988791|DIETARY_SUPPLEMENT|probiotic (BIfidobacterium, BB-12®)|probiotic (Bifidobacterium, BB-12®)
223753362|NCT02988791|DIETARY_SUPPLEMENT|Placebo|Placebo
223753363|NCT00373516|DRUG|Vehicle (Placebo) applied BID|
223606320|NCT07065006|OTHER|Calculation of postoperative opioid consumption|Postoperative opioid consumptions on the pca (patient controlled analgesia) device of the patients will be recorded in Postoperative 30.min,1.,6.,12.,24. Opioid consumptions on the pca device of the patients will be recorded in 30.min,1.,6.,12.,24. hours.
223606321|NCT07063290|DEVICE|the COMBO Endoscopy Oropharyngeal Airway|Using the COMBO Endoscopy Oropharyngeal Airway for oxygenation.
223606322|NCT07066930|PROCEDURE|Magneto-Dynamic Ridge Expansion|A ridge expansion technique using the Magnetic Mallet device. Controlled magneto-dynamic impulses are applied to split the alveolar ridge and compact bone prior to immediate implant placement.
223606323|NCT07066930|PROCEDURE|Osseodensification with Versah Drills|"A ridge expansion method using Versah drills (Densah burs) in osseodensification mode. The drills densify bone without removing it, enhancing bone density and implant stability.~Arm Assignment: Versah Osseodensification (Active Comparator arm)"
223606324|NCT04988880|OTHER|Multiple Sclerosis Expert Patient Program of Catalonia|It is intended to constitute 12 groups of patients (6 with relapsing and 6 for progressive MS; one of each type per unit). The study will be conducted virtually due to the current pandemic situation. Throughout 9 sessions (1 per week for 9 sessions), participants in the group will share knowledge and lived experiences on all aspects related to MS and their self-management. In each session there is a theoretical part to focus on the topic, conducted by the EP. Immediately afterwards, the EP will encourage interaction, facilitating the expression of doubts, questions or experiences about the contents. Its resolution will be sought among the group, resulting in empowerment and control over the health situation. The knowledge acquired will be based on the information provided by the EP and on the knowledge resulting from the life experiences regarding MS of all the people involved. In all sessions, a healthcare professional will act as an observer, providing help and support to the EP.
223606325|NCT07065734|DEVICE|NWPT group|Patients submitted to negative pressure wound therapy
223606326|NCT05178303|DRUG|SB-1121(1)|The daily maintenance, SB-1121(1) dose is to take 2 times a day, 1 tablet each time.
223606327|NCT05178303|DRUG|SB-1121(2)|The daily maintenance, SB-1121(2) dose is to take 2 times a day, 1 tablet each time.
223606328|NCT06927583|OTHER|sensory integration therapy|sensory integration therapy include 2 categories that comprised of 9 strategies.
223753364|NCT00373516|DRUG|QRX-101 75 mcg/g ointment applied QD|
223753365|NCT00373516|DRUG|QRX-101 75 mcg/g ointment applied BID|
223753366|NCT01743261|OTHER|multidisciplinary intervention|Multidisciplinary intervention Instruments of governance are the diagnostic-therapeutic rehabilitation pathways (DTRP), the Quality system and product standards; Medical care process with result-oriented autonomy Technology support of vital signs.
223753367|NCT01743261|OTHER|usual care|"specific pathology. access is determined by clinical stability. the instruments of governance are guidelines and consensus and the rehabilitation programme is focused on functional and cognitive areas.~the medical care process is governed by hierarchy. The technology in this model is limited to a specific specialty"
223753368|NCT05328492|DEVICE|iVAPS-AE|Patients randomised to this intervention will commence home NIV in iVAPS-AE mode according to the clinical operating procedures used at the Respiratory and Sleep Science Department. Patients will follow a NHS standard care pathway as described in the study protocol.
223753369|NCT05328492|DEVICE|ST-mode|Patients randomised to this intervention will commence home NIV in ST-mode according to the clinical operating procedures used at the Respiratory and Sleep Science Department. Patients will follow a NHS standard care pathway as described in the study protocol.
223753370|NCT00956410|BIOLOGICAL|CAD106|
223753371|NCT00003739|BIOLOGICAL|filgrastim|
223753372|NCT01870622|PROCEDURE|Flow waves|Flow waves will be used to confirm correct tube placement in newborn infants.
223753373|NCT01870622|PROCEDURE|ECO2|ECO2 will be used to confirm correct tube placement in newborn infants.
223753374|NCT03989297|RADIATION|Radiation|Consecutive patients who were pathologically diagnosed with NPC and treated with radiation at the Kiang Wu Hospital.
223606329|NCT06927583|OTHER|Traditional Speech therapy|Control group was given traditional speech therapy .total number of 5 sessions give t o each participant that comprised of 30 minutes.
224311499|NCT00107510|BIOLOGICAL|pegfilgrastim|
224311500|NCT00107510|DRUG|carboplatin|
224311501|NCT00107510|DRUG|docetaxel|
223606330|NCT06923410|DEVICE|AI model|The clinical intelligent AI system is equipped with an AI agent doctor, enabling patients to conduct self-consultations and receive care anytime and anywhere without the need for a real doctor.
223606331|NCT06904963|DEVICE|Motivation for oral hygiene through oral scanner|The oral scanner is used to create a digital model of the patient's mouth with which the operator will provide personalized oral hygiene instructions.
223606332|NCT07065370|DEVICE|Group I ( volume-controlled ventilation with tidal volume 6-8ml/kg (predicted body weight) with respiratory rate 12-14 cycle/minute.|Volume-controlled ventilation with tidal volume 6-8ml/kg (predicted body weight) with respiratory rate 12-14 cycle/minute.
223606333|NCT07065370|DEVICE|Group II: (volume-controlled ventilation with tidal volume 6-8ml/kg )|group received volume-controlled ventilation with tidal volume 6-8ml/kg predicted body weight with respiratory rate 18-20 cycle/minute
223606334|NCT07066670|BEHAVIORAL|Strain Counterstrain with Routine Physical Therapy|This intervention involves applying the Strain Counterstrain (SCS) technique in combination with standard physical therapy. SCS targets tender points through passive positioning to reduce muscle tension and pain. The patient is positioned in a position of comfort for 90 seconds while monitoring the tender point. This is followed by gradual return to neutral. Routine physical therapy includes electrotherapy (TENS, IR, ultrasound), strengthening (short arc quads, terminal knee extension), and stretching exercises. The therapy is administered 5 days per week over 8 weeks.
223606335|NCT07066670|BEHAVIORAL|Muscle Energy Technique with Routine Physical Therapy|This intervention combines Muscle Energy Technique (MET) with routine physical therapy. MET involves voluntary muscle contractions against resistance, followed by stretching to restore range of motion and relieve pain. Techniques include post-isometric relaxation and slow eccentric isotonic stretching, particularly targeting hamstring and quadriceps tightness. Routine physical therapy includes electrotherapy (TENS, IR, ultrasound), as well as structured strengthening and stretching exercises. The intervention was delivered 5 days a week for 8 weeks.
223606336|NCT06902636|BEHAVIORAL|Geriatric trauma care program|The experiment group will implement the Geriatric trauma care program (GTCP) and routine care. The GTCP will be implemented by a nurse practitioner and equipped with digitalized educational material, including six units of intervention for older adults with traumatic injuries who live alone.
223606337|NCT06907147|DEVICE|Multi-Organ Denervation Gemini System|After angiography according to standard procedures, subjects are treated with renal denervation followed by hepatic denervation.
223606338|NCT06158815|OTHER|proprioceptive neuromuscular facilitation exercise|The basic principle of Proprioceptive Neuromuscular Facilitation exercises, which is defined as facilitating the responses of the neuromuscular mechanism by stimulating the proprioceptors, is that the movements in the human body have a rotational and oblique character and that a greater response can be obtained with movement against maximum resistance. It is aimed to achieve improvement in strength and movement ability through hand contacts, visual and verbal stimuli.
223606339|NCT02741765|BEHAVIORAL|Sham rTMS|Subjects will participate in daily sessions of sham-rTMS
223606340|NCT02741765|OTHER|Real rTMS|Subjects will participate in a combination of rTMS
223753375|NCT04776967|PROCEDURE|Hyperbaric Compression Profile|A total of 4 randomized hyperbaric treatment compression profiles (accepted standards of care) will be alternated over the patients course of treatment on a daily basis daily to the prescribed treatment depth.
223753376|NCT04865757|DEVICE|Space Flap|A space flap is formed out of Palacos®, adjusted to the skull surface with temporal augmentation
223753377|NCT04124172|DEVICE|Real rTMS (Magstim)|See arm description
224200659|NCT01382680|DEVICE|Guidewire|Use of a guidewire at ERCP for cannulating a stenosis of the biliary tract and for applying a therapeutic device (stent, dilation catheter, others)
223606341|NCT02741765|BEHAVIORAL|Supervised aerobic exercise|
223753378|NCT04124172|DEVICE|Sham rTMS|See arm description
223753379|NCT00947297|DRUG|HPN-100|HPN-100 is a triglyceride that has a similar mechanism of action as NaPBA. It is a liquid with minimal taste and odor. Three teaspoons of HPN-100 (\~17.4 mL) delivers equivalent of PBA that 40 tablets of NaPBA do.
223753380|NCT06486571|OTHER|Electromyography recording with HD-sEMG|Measurement of muscle electrical signal with HD-sEMG sensors, training of a pattern recognition classifier for hand gesture recognition, verification and comparison with state of the art.
223753381|NCT06486571|OTHER|Transcutaneous Electrical Nerve Stimulation (TENS)|Application of TENS by means of non-invasive superifical electrodes on the stump skin of the participants to restore multimodal somatotopical sensations of mechanoception, nociception and thermoception.
223753382|NCT00132340|DEVICE|Electrodes|
223753383|NCT03056131|DEVICE|Diacutaneous Fibrolysis|Diacutaneous Fibrolysis is a non invasive physiotherapeutic technique applied by means a set of metallic hooks having the advantage of allowing a deeper and more precise application, which could not be achieved manually
223753384|NCT06363084|DRUG|Nimotuzumab|Nimotuzumab (400mg) was given weekly
223753385|NCT00322335|BIOLOGICAL|Haemophilus influenzae type b- and meningococcal (vaccine)|Intramuscular injection into the thigh as primary vaccination at 2, 4 and 6 months of age (group HibMenC) and as booster dose at 14 months of age (groups HibMenC and group NeisPoo).
223753386|NCT00322335|BIOLOGICAL|Infanrix™ penta|Intramuscular injection into the thigh as primary vaccination at 2, 4 and 6 months of age
223753387|NCT00322335|BIOLOGICAL|Infanrix™ hexa|Intramuscular injection into the thigh as primary vaccination at 2, 4 and/or 6 months of age (groups NeisPoo and MenCCRM) and/or as booster dose at 14 months of age (group MenCCRM).
223753388|NCT00322335|BIOLOGICAL|Engerix-B|Intramuscular injection into the thigh as a birth dose
223753389|NCT00322335|BIOLOGICAL|NeisVac-C™|Intramuscular injection into the thigh as primary vaccination at 2 and 4 months of age.
223753390|NCT00322335|BIOLOGICAL|Infanrix™ IPV/HIB|Intramuscular injection into the thigh as primary vaccination at 4 months of age
223753391|NCT00322335|BIOLOGICAL|Meningitec™|Intramuscular injection into the thigh as primary vaccination at 2, 4 and 6 months of age
223753392|NCT02384824|PROCEDURE|Primary Percutaneous Intervention|angiography, manual aspiration thrombectomy and antiplatelet therapy
223753393|NCT00013130|BEHAVIORAL|Provision of health status information to patients provider|
223753394|NCT05833503|BEHAVIORAL|Integrative Couple Treatment for Addiction (ICT-A)|Couple-based intervention called Integrative Couple Treatment for Addiction (ICT-A).
223753395|NCT05833503|BEHAVIORAL|Treatment individual as usually offered|Individual-based treatment as usually offer by the specialized centres in addiction.
224200660|NCT02416167|DRUG|FYU-981|
224200661|NCT02416167|DRUG|Placebo|
224200662|NCT03746080|DRUG|Plerixafor|Plerixafor will be administered via infusion at 400 micrograms per kilogram per day for four weeks beginning one week before the end of radiation
224200663|NCT03746080|DRUG|Temozolomide|Temozolomide (TMZ) will be administered concurrently with the radiation for 42 days and 6-12 cycles of monthly adjuvant Temozolomide (TMZ) after completion of Plerixafor infusion.
224200664|NCT03746080|RADIATION|Whole-Brain Radiotherapy (WBRT)|Undergo Whole brain radiotherapy (WBRT) - Radiotherapy consists of 30 Gy in 15 fractions of whole brain radiations
223753396|NCT01686243|OTHER|epidural needle placement with echogenic 17G Tuohy needles (Pajunk TuohySono)|Anesthesiologist will place epidural with aid of ultrasound and placement with echogenic 17G Tuohy needles (Pajunk TuohySono)
223606342|NCT07066319|BEHAVIORAL|Gait Training with Proprioceptive Neuromuscular Facilitation (PNF)|A physiotherapeutic intervention combining structured gait training with Proprioceptive Neuromuscular Facilitation (PNF) techniques. Sessions include rhythmic initiation, diagonal movement patterns, and resistance-based facilitation to enhance lower limb motor control and balance in stroke survivors. Delivered 3 times/week for 12 weeks, 45 minutes per session.
223606343|NCT07066319|BEHAVIORAL|Gait Training with Conventional Physiotherapy|A rehabilitation protocol integrating traditional gait training (step drills, overground walking) with conventional physiotherapy exercises focused on lower limb strength, range of motion, and postural balance. Conducted over 12 weeks, 3 sessions per week, 45 minutes each.
223606344|NCT07066319|BEHAVIORAL|Combined PNF and Conventional Physiotherapy (without direct gait training)|This intervention blends Proprioceptive Neuromuscular Facilitation (PNF) with conventional physiotherapy, excluding dedicated gait tasks. It includes rhythmic stabilization, functional mobility drills, and resistance-based exercises aimed at improving neuromuscular re-education, balance, and independence. Delivered 3 times/week for 12 weeks, 45 minutes per session.
223606345|NCT05331209|OTHER|Acupuncture|Weekly acupuncture treatments, for 8 weeks (8 treatments)
223606346|NCT05331209|OTHER|Acupuncture-Acupressure|Weekly acupuncture, for 8 weeks, with daily self-acupressure by the patient at home.
223606347|NCT04752332|DRUG|Abemaciclib|Administered orally.
223606348|NCT04752332|DRUG|Standard Adjuvant ET|Administered according to label instructions.
223606349|NCT04752332|DRUG|Placebo|Administered orally.
223606350|NCT06914778|OTHER|Blood draw for the laboratory assessment|Blood plasma collection for for lipidomic and metabolomic analysis
223606351|NCT06914778|OTHER|Urine sample|Urine sampling for aqueous metabolomics
223606352|NCT06920576|DRUG|Esketamine|Intravenous esketamine 0.25 mg/kg was administered 10 min before induction of anaesthesia, followed by continuous pumping at 0.25 mg/(kg-h) until the end of the operation.
223753397|NCT01686243|OTHER|standard epidural placement|Anesthesiologist will place epidural within standard practice, with standard needles.
223753398|NCT00983281|DRUG|Hextend|IV fluid resuscitation to restore euvolemia after traumatic injury and surgery.
223753399|NCT02110992|DRUG|Docetaxel|Docetaxel 15mg/m2 IV, given days 1, 8, and 15 during SBRT
223753400|NCT02110992|RADIATION|Stereotactic Radiation|SBRT will be given over 5 fractions separated by \> 48 hours. Dose will be determined based upon dose escalation schedule and will range from 25-40 Gy.
223753401|NCT00502697|BEHAVIORAL|Targeted Nurse Home Visits|Advanced practice nurses provide targeted behavioral interventions during home visits. These visits were in addition to regularly scheduled conventional prenatal and postpartum clinic care. Specific protocols guided nurse interventions related to tobacco use, substance use and misuse, stress management, dental health, maternal infections, perinatal depressive symptoms, family violence, reproductive life plans and continuity of care. Home visits were continued in the postpartum period (through 18 months post-delivery) with a continued focus on risk factors identified during the prenatal period and internatal health care.
223753402|NCT00502697|OTHER|Conventional prenatal/postpartum care|Women in this group received conventional prenatal care and postpartum clinic care.
223753403|NCT05224492|DRUG|Sulforaphane|40 mg of Sulforaphane powder once daily.
223606353|NCT06920576|DRUG|Magnesium sulfate|Intravenous magnesium sulphate 30 mg/kg was administered within 10 min before induction of anaesthesia, followed by continuous pumping at 30 mg/(kg-h) until the end of the operation
223606354|NCT06920576|DRUG|Saline|Pumping equal volumes of saline over the same time period
223606355|NCT04161781|DRUG|18F-BMS-986229 Injection|Single injection prior to scan
223606356|NCT04161781|DRUG|IV 18F-BMS-986229|370 MBq administered intravenously prior to scan
223606357|NCT04161781|DIAGNOSTIC_TEST|PET/CT Scan|Whole-body PET/CT (80 mA)
223753404|NCT05224492|OTHER|Placebo|Placebo
223753405|NCT00610532|DRUG|phenytoin|intravenous phenytoin (15 mg/kg) single dose
223753406|NCT00610532|DRUG|phenytoin and probenecid|intravenous phenytoin (15 mg/kg) single dose and oral probenecid 2000 mg single dose
223753407|NCT02804503|BEHAVIORAL|Calorie Labels|Participants were asked to order food from the assigned menu as if they were having lunch in a fast food restaurant.
223753408|NCT02804503|BEHAVIORAL|Exercise Labels|Participants were asked to order food from the assigned menu as if they were having lunch in a fast food restaurant.
224200665|NCT03746080|RADIATION|Radiation Therapy|Radiotherapy consists of 30 Gy in 15 fractions
224200666|NCT00759226|DRUG|Gemcitabine|Gemcitabine 1000 mg/m2 (30 min)
224200667|NCT00759226|DRUG|Cisplatin|Cisplatin 30 mg/m2 (90 min)
224200668|NCT00759226|DRUG|5-FU|5-FU 750 mg/m2 (24h CI)
224200669|NCT00759226|DRUG|Folinic Acid|Folinic Acid 200 mg/m2 (30 min)
224200670|NCT01473589|DRUG|Teriparatide|Administered by SC injection
224200671|NCT01473589|DRUG|Placebo|Administered by SC injection
224311502|NCT00107510|PROCEDURE|conventional surgery|
223753409|NCT02804503|BEHAVIORAL|No Labels|Participants were asked to order food from the assigned menu as if they were having lunch in a fast food restaurant.
223753410|NCT04382638|COMBINATION_PRODUCT|RCO group|Patients in the experimental group will receive RCO fabrication with standard level of care for bracing, which consists of education on general exercises for spinal movement, strengthening, and balancing. These patients will attend study assessments at baseline, 3 months, 6 months, 12 months and every year until they reach skeletal maturity or if surgical intervention is required.
224200672|NCT01473589|DIETARY_SUPPLEMENT|Calcium supplementation|Administered orally
224200673|NCT01473589|DIETARY_SUPPLEMENT|Vitamin D supplementation|Administered orally
224200674|NCT05566730|BEHAVIORAL|CT-MICART App|App designed with the goal of treating CUD in African American adults
224200675|NCT05566730|BEHAVIORAL|Control|App designed with the goal of treating CUD in African American adults, with participants just tracking their use of cannabis and not receiving treatment videos
224311503|NCT02837614|DRUG|dexamethasone acetate|1 milliliter of dexamethasone (4milligram) administered in the deltoid muscle before commencement of surgical procedure
223606358|NCT03465995|DEVICE|NKI i-PAS Diagnostic Protocol|"The NKI i-PAS:~The NeuroKinetics i-PAS system is a mobile assessment device with an integrated display for eye tracking with the following properties: a head mounted display, a sampling rate of 100 frames per second, eye tracking in the horizontal, vertical and torsional axes, and pupil area measurement with a spatial resolution less than 0.1 o. The testing protocol includes: optokinetic tracking, smooth pursuit horizontal, smooth pursuit vertical, saccade random horizontal, saccade random vertical, saccade predictive horizontal, antisaccade (horizontal), self-paced saccade, saccade and reaction times, visual reaction time, auditory reaction time, gaze horizontal, light reflex, subjective visual (vertical) and subjective vertical horizontal. Several quantitative measures are computed from the data acquired in each test, and these measures are then employed in a multivariate diagnostic assessment."
223606359|NCT00048347|DRUG|AVONEX|30µg IM every week for 12 weeks
223606360|NCT02450513|DRUG|Adalimumab|160 mg at week 0, 80 mg at week 2 and 40 mg every two weeks onwards
223606361|NCT00484978|PROCEDURE|Stereotactic Radiosurgery|
223606362|NCT03908814|DRUG|Whole Human Anti-PD-L1 Antibody Injection (LDP)|Dose escalation study evaluating six dose levels (0.1, 0.3, 1, 3 , 10and 20 mg/kg) of LDP.
223606363|NCT01523509|DEVICE|Radiographic contrast agent. Sodium Iodide.|Application of Sodium Iodide contrast topically to tooth immediately followed by radiograph.
223606364|NCT03193710|DRUG|Propofol|Propofol will be used for anesthesia maintenance in the total intravenous anesthesia group.
223606365|NCT03193710|DRUG|Sevoflurane|Sevoflurane will be used for anesthesia maintenance in the inhalation anesthesia group.
223606366|NCT03193710|DRUG|Remifentanil|Remifentanil will be used for analgesia in both groups.
223606367|NCT05630677|DRUG|AZD5055 solution for infusion|Subjects will receive a single dose intravenous infusion of AZD5055 as 20-minute infusion on Day 1 of the respective period in overnight fasted state.
223606368|NCT05630677|DRUG|AZD5055 oral suspension|Subjects will receive single dose of AZD5055 oral suspension on Day 1 of the respective period in overnight fasted state.
223606369|NCT05630677|DRUG|AZD5055 film-coated tablet|Subjects will receive single oral dose of AZD5055 film-coated tablets on Day 1 of the respective period in overnight fasted state.
223606370|NCT05630677|DRUG|AZD5055 film-coated tablet|Subjects will receive single oral dose of AZD5055 film-coated tablets on Day 1 of the respective period in fed state (either a high fat meal or low-fat meal calorie standard breakfast)
223753411|NCT04382638|DEVICE|TLSO group|Patients in the experimental group will receive TLSO fabrication with standard level of care for bracing, which consists of education on general exercises for spinal movement, strengthening, and balancing. These patients will attend study assessments at baseline, 3 months, 6 months, 12 months and every year until they reach skeletal maturity or if surgical intervention is required.
223753412|NCT02871843|DRUG|RRx-001 dose escalation with TMZ + RT|Dose escalation of RRx-001. Dose levels of 0.5, 1.0, 2.0 and 4.0 mg, once weekly.
223606371|NCT05630677|DRUG|Rabeprazole, Delayed-release tablet|Subjects will receive oral doses of rabeprazole twice daily 3 days prior to AZD5055 single dose and 4 days after the AZD5055 single dose including the day that AZD5055 is dosed under fasted conditions \[Study Day 10 to 18\].
223606372|NCT05630677|DRUG|Rabeprazole, Delayed-release tablet|Subjects will receive oral doses of rabeprazole twice daily prior to AZD5055 single dose under fed conditions (low-fat standard breakfast) and then continued for 2 days.
223606373|NCT03460561|PROCEDURE|Thoracic epidural block (TEA)|Under complete aseptic precautions and before induction of GA, thoracic epidural catheter was inserted using a 17 gauge, Tuohy epidural needle by a midline approach. T9-T10 interspace was chosen for the injection after skin infiltration by 5 mL of lidocaine 1%. The epidural space was identified by the loss of resistance technique then the catheter was introduced 2 cm into the epidural space, and epidural test dose of 3 mL of lidocaine 2% with 1:200,000 adrenaline was injected to exclude vascular or subarachnoid position.
223606374|NCT03460561|PROCEDURE|Rectus sheath block (RSB)|"Under aseptic technique, the rectus muscle was imaged with the ultrasound probe, A broadband (5-12 MHz) linear array probe of Sonosite ™ 3000 ultrasound (FUJIFILM, Sonosite EDGE II -UAS) in a transverse orientation at or immediately above the level of the umbilicus, with an imaging depth of 4-6 cm.~Inserting the needle: An 18G Tuohy needle was introduced few millimeters from the probe using an in plane technique in an angle of 45 degrees to the skin. (posterior rectus sheath and fascia transversalis). Under direct vision, the needle tip was advanced to the desired position where 20 mL of (levo-bupivacaine 0.25% Fentanyl 30 μg) were injected causing hydro dissection of the rectus muscle away from the posterior rectus sheath. The technique is repeated on the opposite side."
223606375|NCT04967027|DEVICE|ASCLU-300 TTF|BM treated by continuous TTFields treatment (ASCLU-300, approved by Chinese FDA)
223606376|NCT03818451|DIETARY_SUPPLEMENT|Co-ultraPEALut (Glialia)|Co-ultraPEALut is administered to moderate traumatic brain injured patients for 180 days
223606377|NCT02240602|DRUG|Oxycodone, 1.00 mg dose|Intravenous oxycodone is provided as patient-controlled analgesia after surgery with bolus dose of 1.00 mg.
223606378|NCT02240602|DRUG|Oxycodone, 0.03 mg/kg dose|Intravenous oxycodone is provided as patient-controlled analgesia after surgery with bolus dose of 0.03 mg/kg.
223606379|NCT02240602|DRUG|Oxycodone, 0.02 mg/kg dose|intravenous oxycodone is provided as patient-controlled analgesia after surgery with bolus dose of 0.02 mg/kg.
223753413|NCT02871843|RADIATION|Radiation|Conformal or intensity-modulated radiotherapy (60 Gy in 2 Gy fractions) given 5 days a week for 30 fractions (about 6 weeks)
223753414|NCT02871843|DRUG|Fixed dose Temozolomide (75 mg/m2)|Oral temozolomide 75 mg/m2 daily for 6 weeks
223753415|NCT02871843|DRUG|TMZ Maintenance|TMZ maintenance at 150-200 mg/m2
223753416|NCT04689087|COMBINATION_PRODUCT|TTFields|For patients with relapsed GBM, before receiving electric field treatment, the patient can be re-operated, and TTFields+BPC chemotherapy is used after surgery
223753417|NCT05857605|OTHER|Exercise for Knee Osteoarthritis|Standard physical therapy exercise instructions based on Arthritis Foundation guidelines for physical activity specific to individuals with knee osteoarthritis.
223606380|NCT05789563|OTHER|Hypoxia and Smartwatch model|Breathing mixtures of O2 (14 %, 12 %, 10 %) balanced with N2 and monitoring SpO2 by one of the smartwatch models on left wrist and by pulse oximeter on left index finger.
223606381|NCT02058563|BIOLOGICAL|Priorix®|1 dose administered as a subcutaneous (SC) injection.
223606382|NCT02058563|BIOLOGICAL|Merck's M-M-R®II, Measles, Mumps, and Rubella Virus Vaccine|1 dose administered subcutaneously.
223606383|NCT04420663|DIAGNOSTIC_TEST|Pleural Manometry|Recording pleural pressure during therapeutic thoracocentesis using a simple water manometer.
223606384|NCT06329206|DRUG|GH2616 Tablets|GH2616 tablets will be given orally
223606385|NCT01999725|DRUG|EDP-788|EDP-788 Capsules and matching placebo capsules. EDP-788 Liquid Suspension and matching placebo. All interventions are given as single doses
223606386|NCT01999725|DRUG|Placebo|Matching placebo capsules or matching suspension
223606387|NCT02481817|PROCEDURE|Endoscopic dilation of subglottic stenosis|This is accomplished with rigid instruments or inflatable balloons.
223606388|NCT02481817|PROCEDURE|Endoscopic resection of the stenosis|This is accomplished with C02 lasers and paired with prolonged medical therapy after surgery.
223606389|NCT02481817|PROCEDURE|Tracheal Resection|Resection of the affected tracheal segment with end-to-end anastomosis
223753418|NCT05857605|DEVICE|Compact seated elliptical exercise machine- Cubii JR-1|Compact seated elliptical machine exerice program in conjunction with standard physical therapy exercise instructions based on Arthritis Foundation guidelines for physical activity specific to individuals with knee osteoarthritis.
223753419|NCT02041130|DEVICE|Renal Denervation|
223753420|NCT03613506|DRUG|Captopril 12.5 Mg|Taking captopril 12.5mg b.i.d for two months before radiotherapy.
223753421|NCT00214955|DRUG|ORAVESCENT Fentanyl Citrate|
223753422|NCT01545817|DRUG|Pazopanib followed by everolimus|All patients received Pazopanib (800 mg once daily orally continuous dosing) until disease progression then second line everolimus (10 mg once daily orally continuous dosing)
223753423|NCT06319599|BEHAVIORAL|Routine therapy|During the treatment, All the participants are provided with the routine therapy, which included routine rehabilitation, cognitive training.
223606390|NCT04039217|DRUG|Biktarvy|Participants will be given two doses of the oral fixed dose combination anti-HIV medication Biktarvy (BIC/FTC/TAF) separated by 24 hours. The first dose is given in the clinic and participants are instructed to take the second dose at home, 24 hours after the first dose.
223753424|NCT06319599|PROCEDURE|Stellate ganglion block|The percutaneous approach via the paratracheal route was used for Stellate ganglion block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
223753425|NCT06319599|DRUG|Lidocaine hydrochloride|Based on the invention above, the patients in the experimental group were provided with Stellate ganglion block , using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). Once a day, totally 10 days.
223753426|NCT06319599|BEHAVIORAL|placebo injection|The percutaneous approach via the paratracheal route was used for Stellate ganglion block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
224200676|NCT03178474|OTHER|JINLINGGUAN Infant formula,PRO-KIDO™ I-PROTECH®|JINLINGGUAN Infant formula,PRO-KIDO™ I-PROTECH®: a type of Phase I infant formula for 0-6 month infants, with a trademark of PRO-KIDO™ I-PROTECH®. The formula contains both OPO structured lipid and α+β patented protein (patent number: ZL200810241156.3).It was produced by Inner Mongolia Yili Industrial Group Co.Ltd.,China
224200677|NCT03178474|OTHER|TOFER Infant formula,TOFER®|TOFER Infant formula,TOFER®: a type of Phase I infant formula for 0-6 month infants, with a trademark of TOFER®. The formula was characterized by (1) Moderate digestible small-molecule protein; and (2) BID® complex probiotics. It was produced by Inner Mongolia Yili Industrial Group Co.Ltd.,China
223606391|NCT01833572|DRUG|Gefitinib|Eligible participants will be given orally gefitinib 250mg daily before surgery for 42 days or until disease progression or unacceptable toxicity. Best supportive care is allowed in this period.
224200678|NCT03178474|OTHER|Breast milk|Breast milk: Human breast milk, provided and fed by the corresponding infant's mother
224200679|NCT04196439|PROCEDURE|continuous epidural analgesia|injection of local anaesthetic into epidural space
223606392|NCT04864951|DIAGNOSTIC_TEST|Colli-Pee urine collection device|first-void urine is collected using Colli-Pee and subsequently analyzed using Anyplex™ II HPV HR Detection from Seegene.
223606393|NCT04864951|OTHER|Survey|Subjects are asked to complete a survey that includes questions about sexual orientation, hormone therapy, gender reassignment surgery, number of sexual partners, HPV vaccination, and smoking
223753427|NCT01536639|DRUG|biphasic insulin aspart 30|Administered by subcutaneous injection. The physician determined the starting dose and frequency, as well as later changes to either dose or frequency, if any
223753428|NCT05724004|RADIATION|SBRT/SRS/radiation therapy|Consolidation radiation therapy (SBRT/SRS/moderately hypofractionated radiation therapy)
223753429|NCT05878613|DEVICE|treadmill training with KT group (TTKT group)|The area to be taped will be cleaned with an alcohol swab, and the I-shaped elastic KT was applied to the four trunk muscles from their insertion to their origin. Patients will then undergo treadmill walking with easy speed control for 20 minutes. The training will be immediately stopped if the subject complain of fatigue during treadmill training; training will be resumed after sufficient rest.
223753430|NCT05878613|DEVICE|treadmill training without KT group (TT group)|General treadmill training without taping will be carried out for the same time as the gait training of the experimental group, and the treadmill speed will also be a comfortable speed in the same manner as in the experimental group.
223753431|NCT02059928|DEVICE|Intraosseous Device|
223753432|NCT00571259|DRUG|Heparin 1000U/mL|A volume sufficient to fill the catheter length will be instilled in both catheter ports post dialysis
224200680|NCT04196439|PROCEDURE|supra-inguinal fascia iliaca compartment block|ultrasound guided injection of local anaesthetic into fascia iliaca compartment
224200681|NCT04440631|OTHER|no intervention, observational only|no intervention, observational only
223606394|NCT04386694|DEVICE|Active PBMT/sMF|The PBMT/sMF will be irradiated in the lower thorax and neck areas, with the patients in supine position. PBMT/sMF application time will be 60 seconds per site. The dose used in the lower thorax will be 31.50 J per site, a total of 6 sites will be irradiated, totalizing a dose of 189J. In addition, the dose used in the neck area (bilaterally) will be 31.50J per site, a total of 1 site (bilaterally) will be irradiated, totalizing a dose of 31.50J (bilaterally). PBMT/sMF will be applied using the direct contact method with light pressure on the skin.
223606395|NCT04386694|DEVICE|Placebo PBMT/sMF|The placebo PBMT/sMF will be irradiated in the lower thorax and neck areas, with the patients in supine position. PBMT/sMF application time will be 60 seconds per site. The dose used for applications during the treatment will be 0 Joules (J) per site. The sounds and signals emitted from the device as well as the information displayed on the screen will be identical, regardless of the type of treatment (active or placebo). PBMT/sMF will be applied using the direct contact method with light pressure on the skin.
223606396|NCT02597387|DRUG|Mitoxantrone HCL Liposome Injection|
223606397|NCT04522141|BEHAVIORAL|Self-control intervention|Participants will wear a Fitbit for 8 weeks to record their daily activity data. The first week of the study will provide a baseline measurement of activity. Across the 8 weeks, participants receive daily reminders to wear their Fitbit. After the baseline week, participants will also receive interventional components that target self-control via the smartphone application MindHike. This intervention should help them achieve their activity goals. The self-control intervention teaches strategies how to potentiate desirable impulses and how to avoid undesirable impulses in daily life.
223753433|NCT00571259|DRUG|4% Sodium Citrate with Gentamicin 320 mcg/mL|A volume sufficient to fill the catheter length will be instilled in both catheter ports post dialysis
223753434|NCT01007461|DRUG|Sodium Sulfide (Na2S) for Injection|IK-1001 is Na2S administered as an isotonic solution for intravenous (IV) injection or continuous infusion. IK-1001 will be administered as a 3-hour continuous IV infusion started \> 5 minutes but \< 20 minutes (approximately) prior to coronary artery reperfusion.
223753435|NCT01007461|DRUG|Placebo|0.9% Sodium Chloride (NaCl) will be administered in the same manner as the experimental drug.
223753436|NCT02915549|OTHER|Progressive Feeding without MEF|This group will receive feeding volumes of 20-24ml/kg/d of day 1 of feeding followed by the study intervention of daily volume increases in increments of 24-25ml/kg/d as tolerated until full enteral feeding is achieved.
223753437|NCT02915549|OTHER|Progressive Feeding with MEF|This group will receive minimal enteral feeds (MEF) with volumes of 20-24ml/kg/d for 4 days followed by daily increases in increments of 24-25ml/kg/d as tolerated until full enteral feeding is achieved.
223753438|NCT02327429|BEHAVIORAL|A Chinese menu plan for type 2 diabetes|The intervention is a menu plan, recipes and tips on healthy eating delivered one-on-one between the participant and the facilitator. There will be 4 such one-on-one meetings. The goal is to facilitate behaviour change that results in a healthier diet.
223753439|NCT04174729|DEVICE|handgrip strength|First, the hand measurements of each volunteer were evaluated, followed by the measurement of handgrip strength using the Jamar® dynamometer. And later the tests were performed using the system that contains the 5 devices to quantify the hand strength.
223753440|NCT04174729|DEVICE|Door handle device|To evaluate the cylindrical grip movement, a door handle was used, which evaluated the full force in the range of motion.
223753441|NCT04174729|DEVICE|Tap device|To evaluate the spherical grip movement, a tap was used, which evaluated the full force in the range of motion.
223753442|NCT04174729|DEVICE|Door pull handle|To assess the hook grip movement, a door pull handle was used, which assessed the full force in the range of motion
223753443|NCT04174729|DEVICE|Linear Switch device|To evaluate the pulp-pulp pinch movement, a switch was used, which evaluated the full force in the movement of the movement.
223753444|NCT04174729|DEVICE|Door Key device|To assess the pulp-side pinch movement, a door key was used, which evaluated the full force in the range of motion.
223753445|NCT04535596|OTHER|Exercise|12 week long strength training exercises for knee
223753446|NCT04076644|DEVICE|TMS treatment|TMS using either a standard 10hz 20min or 3 min theta burst protocol
223753447|NCT03372148|DIAGNOSTIC_TEST|pHRMi|Pharyngeal High Resolution Manometry and Impedance swallowing function evaluation
223753448|NCT04886167|DRUG|AbobotulinumtoxinA|Injection of platysmal bands.
223753449|NCT05124639|BEHAVIORAL|Group self-management support program for anxiety disorders|The group SMS manualized program for anxiety disorders (https://monrelief.ca) aims at improving self-management capabilities through weekly 2.5-hours sessions with 10-15 patients over a 10-week period.This trial will focus solely on the virtual format of the program. The SMS program covers the following themes: getting to know your anxiety; building self-awareness; reconsidering your lifestyle habits; adopting a problem-solving method; avoidance and exposure; acceptance and committed action; seeing things differently; managing your emotions; receiving support from others; and consolidating your toolkit.
223753450|NCT01034917|DRUG|Etravirine 400 mg dissolved in water every 24 hours|Switch from the PI to Etravirine 400 mg dissolved in water every 24 hours
223753451|NCT01034917|DRUG|Continue with the same antiretroviral regimen|Continue with the same antiretroviral regimen
223753452|NCT03552159|BEHAVIORAL|Behavioral activation|Activity scheduling, monitoring, review and re-scheduling
223753453|NCT03552159|OTHER|Psychoeducation|Education on dementia, caregiving stress, event scheduling and communication skills
223753454|NCT03684200|OTHER|Copenhagen adductor exercise|The active player is supported on one forearm on the floor and the upper arm is resting along their side. The supporting partner places their hands at the ankle and the knee of the upper leg. The active partner raises their body from the floor and adducts both legs in a three second movement until the body reaches a straight line. The body is then lowered to the ground in a three second movement, the foot of the lower leg touches the ground before performing another repetition.
223753455|NCT00589108|DEVICE|Sigma Knee System|Sigma Knee System (mobile-bearing knee with the P.S. polyethylene insert)
223753456|NCT00589108|DEVICE|Sigma Pressfit Condylar Posterior Cruciate Substituting System with a metal back tibial tray|Sigma Pressfit Condylar Posterior Cruciate Substituting System with a metal back tibial tray (fixed-bearing knee with the metal backed tray)
223753457|NCT00589108|DEVICE|Sigma Pressfit Condylar Posterior Cruciate Substituting System all polyethylene tray|Sigma Pressfit Condylar Posterior Cruciate Substituting System (fixed bearing with an all polyethylene tray)
223753458|NCT00002794|DRUG|carboplatin|
223606398|NCT04522141|BEHAVIORAL|Control condition|Participants will wear a Fitbit for 8 weeks to record their daily activity data. The first week of the study will provide a baseline measurement of activity. Participants in this condition receive daily reminders to wear their Fitbit through the MindHike smartphone application. Participants in the control group will be matched with the self-control intervention group for how much contact they have with the app and the researchers.
223606399|NCT02048085|DRUG|Ticagrelor|For ticagrelor arm, randomized STEMI patients with a history of fibrinolysis within last 24-48 and undergoing PCI will be loaded with ticagrelor 180 mg prior to PCI followed by maintenance dose of 90 mg bid.
223606400|NCT02048085|DRUG|Clopidogrel|For clopdigrel arm, randomized STEMI patients with a history of fibrinolysis within last 24-48 and undergoing PCI will be loaded with clopidogrel 300 mg prior to PCI followed by maintenance dose of 75 mg QD
223606401|NCT03508609|BIOLOGICAL|CLBS16|GCSF-mobilized autologous CD34 cells
223606402|NCT04563962|BEHAVIORAL|Contingency Management-ART|Participants in this arm will participate in a Contingency Management intervention where rewards are linked with demonstrated adherence to tenofovir-based ART or PrEP.
223606403|NCT04563962|BEHAVIORAL|Contingency Management-Methamphetamine|Participants in this arm will participate in a Contingency Management intervention where rewards are linked with demonstrated abstinence from methamphetamine use.
223606404|NCT05633173|PROCEDURE|Ultrasound-guided erector spinae plan block|Ultrasound-guided erector spina plan block was performed for patients in group E for postoperative analgesia. The patients were placed in the lateral decubitus position and the linear ultrasound probe was placed longitudinally into the sterilized area 1-2 cm lateral to the spinous process of the L1 vertebra. After visualizing the erector spina muscle and the transverse process, the transverse process was reached by pushing forward the 22 gauge, 50 mm needle in the direction from cranial to caudal. Hydrodissection was performed with 1 ml of saline for confirmation. 0.5 mL kg-1 dose of 0.25% bupivacaine was injected under the erector spina muscle at the level of the 1st lumbar vertebra by aspiration every 2 mL.
223606405|NCT05633173|PROCEDURE|Ultrasound-guided caudal block|The patients in group C underwent ultrasound guided caudal block for postoperative analgesia. By placing the patients in the lateral decubitus position, the linear ultrasound probe was placed longitudinally on the sterilized area on the midline of the sacrum, and access was provided with a 2.5 cm 22 gauge needle on the dorsal skin of the sacral hiatus at a 90° position. The sacrococcygeal ligament was crossed, the needle was oriented approximately 25° and advanced approximately 2 to 3 mm to reach the sacral canal. When it was understood that the sacral hiatus had been entered, 0.5 mL kg-1 0.25% bupivacaine was injected by aspirating every 2 mL after the location was confirmed with the negative aspiration method.
223606406|NCT00555217|DRUG|losartan|50 or 100mg/day
223606407|NCT00555217|DRUG|lisinopril|10, 20 or 40 mg/day
223606408|NCT05860153|DRUG|Levetiracetam|Group with oral levetiracetam at a dose of 15-20 mg/kg/day
223606409|NCT05860153|DRUG|Diazepam|Group with diazepam at a dose of 0.3 mg/kg/dose
223753459|NCT00002794|DRUG|vincristine sulfate|
223753460|NCT02707614|PROCEDURE|Robotic vs open prostastectomy|robotic minimal invasive surgery
223753461|NCT04651959|DRUG|AVICOD 200 MG Film Tablet|AVICOD is containing 200 mg favipiravir manufactured by Pharma Plant,Turkey.
223753462|NCT04651959|DRUG|AVIGAN 200 MG Film Tablets|AVIGAN is containing 200 mg favipiravir manufactured by Toyama, Japan
223753463|NCT03256552|DRUG|Glycopyrronium MDI 28.8 micrograms|Glycopyrronium MDI 28.8 micrograms
223753464|NCT03256552|DRUG|Glycopyrronium MDI 14.4 micrograms|Glycopyrronium MDI 14.4 micrograms
223753465|NCT03256552|DRUG|Glycopyrronium MDI 7.2 micrograms|Glycopyrronium MDI 7.2 micrograms
223753466|NCT03256552|DRUG|Placebo MDI|Placebo Inhalation Aerosol
223753469|NCT06270459|DEVICE|HMAN Robot|The HMAN is certified as a CE class 2A upper limb rehabilitation robot suitable for hospital, clinic and home-based use in 2020 by Health Sciences Authority, Singapore. It has since been employed in post-stroke neurorehabilitation therapy and assessment of sensorimotor functions in stroke patients.
223753470|NCT06196671|DRUG|H101|H101 15x10\^11vp intratumorally injection starts at day 1.
223753471|NCT06196671|DRUG|Camrelizumab|Camrelizumab will be administered at 200 mg i.v. every 3 weeks at day 2.
223753472|NCT04576117|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
224200682|NCT05752344|OTHER|Counseling|Professional Counseling is an activity that aims to improve the client's quality of life. Supporting his strengths and his ability to self-determination, Counseling offers a space for listening and reflection in which to explore difficulties, related to evolutionary processes, transition phase, states of crisis and reinforcement of the ability to choose or change.
223753473|NCT04576117|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223606410|NCT01653990|DRUG|moxifloxacin|oral dose of 400mg moxifloxacin
223606411|NCT01653990|DRUG|moxifloxacin-placebo|Oral dose of a pill of moxifloxacin-placebo
223753474|NCT04576117|OTHER|Quality-of-Life Assessment|Ancillary studies
223753475|NCT04576117|OTHER|Questionnaire Administration|Ancillary studies
223753476|NCT04576117|DRUG|Selumetinib Sulfate|Given PO
223753477|NCT04576117|DRUG|Vinblastine Sulfate|Given IV
223753478|NCT04221295|BEHAVIORAL|Exercise Group|Previously described in the arm/group descriptions.
223753479|NCT06390046|DRUG|TIVA versus Inhalation|comparing TIVA with genera anesthesia with inhalation agent
223753480|NCT05630235|DRUG|CBD/CBD-A|Participants will be administered a one-time dose of 204.6 mg of CBD/CBD-A orally.
223753481|NCT05630235|OTHER|Placebo|The placebo equivalent of the CBD/CBD-A dose administered orally.
223753482|NCT06001346|BEHAVIORAL|ActiveCBT|Participants will complete a standardized 30-minute aerobic exercise session on a stationary bicycle prior to therapy. Supervised exercise sessions will consist of steady-state exercise at a moderate intensity corresponding to a '13' or 'somewhat hard' rating of perceived exertion. Continuous monitoring of heart rate, resistance/load, and RPE will occur throughout exercise. To closely match the groups, participants will also view 30-minute nature videos while exercising.
224200683|NCT01819467|DEVICE|Seprafilm|Seprafilm will be placed onto the uterine incision and the anterior midline of the uterus following the primary cesarean section
224200684|NCT03676816|PROCEDURE|vaginal self sampling|This is a prospective, non-inferiority trial comparing two methods of collection using a US Food and Drug Administration- cleared 90-minute rapid nucleic acid amplification assay, the Xpert CT/NG assay. Any adult female patient admitted to the Emergency Department at Community Regional Medical Center felt by the provider to require gonorrhea/chlamydia endocervical testing may be entered in the study.
223606412|NCT00976833|OTHER|Standardized Rehabilitation|3 component Rehabilitation approach, Passive Range of Motion, Physical Therapy and Progressive Resistance Training
223606413|NCT00976833|OTHER|Usual Care|Usual Physical Therapy care
223606414|NCT03863808|BEHAVIORAL|Cognitive Behavioural Therapy|"Following assessment a one on one session will be given comprising education cognitively targeting false ideas and beliefs on the nature of pain, differentiating nociception due to a painful stimulus and the transition of such a stimulus to a centrally sensitized experience due to misinformation, maladaptive behaviour and fear avoidance. Upon completion of the session assessment using the NPQ will be done to assess the understanding of the patient and further address any shortcomings in future exercise sessions.~Another SEMG recording of the Flexion Relaxation phenomenon will be upon completion of the educational session and a SEMG biofeedback session will begin to help the patient regain their sense of control over their body and function.~After the SEMG biofeedback session a graded exposure exercise program of strengthening and functional training starting from the least feared movements to the most over 10 sessions over 5 weeks."
223606415|NCT03863808|OTHER|Strengthening exercises|Strengthening exercises in a gradual manner to the Multifidus and Transversus Abdominis muscles.
223606416|NCT02741427|OTHER|Conventional toothpaste|The participants should brush their teeth with conventional toothpaste for 90 seconds, twice per day, during two weeks.They should place a pea-size amount of toothpaste on their toothbrushes, use dental floss, but not mouth rinse.
223606417|NCT02741427|OTHER|Whitening toothpaste|The subjects should brush teeth with whitening toothpaste containing blue pigment for 90 seconds, twice per day, during two weeks.They should place a pea-size amount of toothpaste on toothbrushes, use dental floss, but not mouth rinse.
223606418|NCT02741427|OTHER|10% carbamide peroxide|"The subjects should dispense the bleaching gel at night into the trays (maxillary and mandibular) and to insert them to cover at least the anterior teeth for a period of 4 h per day, over a 2-week period. Both arches should be bleached at the same time. During the period of bleaching, volunteers should receive the same toothpaste used by G1, in other words, without whitening agents, to standardize their oral hygiene regimen"
223606419|NCT03680183|DRUG|Entecavir 1Mg Oral Tablet|The anti-HBV treatment includes a anti-HBV antibiotics and a drug of protecting liver cells or decrease alanine aminotransferase (ALT) or aspartate transaminase (AST)
223606420|NCT04659473|OTHER|Online survey|This study aims to apply a rapid online survey to determine the Spanish situation in this third wave of the pandemic.
223606421|NCT04771702|DEVICE|Edmon|Exhaled air will be analyzed for propofol
223606422|NCT01963156|BEHAVIORAL|Prescription synchronization|"Each patient's medication that has the greatest quantity of pills on hand after randomization will be defined as the index medication and partial supplies will be provided for all other eligible medications in order to synchronize all of a patient's medication. Prescribers will be contacted for a new prescription to ensure all eligible medications are on the same renewal schedule.~Randomization will occur within strata of whether patients are enrolled in the ReadyFill@Mail program. Once synchronized, patients who are not enrolled in the ReadyFill@Mail program will initiate their own refills. Patients who are enrolled in the ReadyFill@Mail program will have their refills automatically filled, however patients may disenroll from ReadyFill@Mail at any time, in which case they will initiate their own refills. Patients may disenroll in whole or in part from the program at any point."
223606423|NCT00397436|PROCEDURE|UV Irradiation|UV irradiation
223606424|NCT04036929|DRUG|Estrogen-bazedoxifene|Conjugated estrogens 0.45 mg-bazedoxifene acetate 20 mg.
223606425|NCT04036929|DRUG|Placebo oral tablet|Placebo oral tablet
223606426|NCT05056506|PROCEDURE|EPLBD|Endoscopic papillary large balloon dilation for Choledocholithiasis
223606427|NCT05056506|PROCEDURE|ELPBD+ESD|Endoscopic papillary balloon dilation combined with limited endoscopic sphincterotomy for Choledocholithiasis
223606428|NCT01618006|DRUG|Aspirin|Aspirin 81mg po daily x 7days or end of hospitalization. First dose administered on post op day 1.
223606429|NCT01618006|DRUG|Aspirin|Aspirin 325mg po daily x 7days or end of hospitalization. First dose administered on post op day 1.
223606430|NCT01618006|DRUG|Aspirin|Aspirin 81mg po four times daily x 7days or end of hospitalization. First dose administered on post op day 1.
223606431|NCT01868477|DRUG|Deferasirox DFX, DT|provided as dispersible tablets for oral use in 125 and 250, 500 mg
223606432|NCT01868477|DRUG|Erythropoietin alpha|
223606433|NCT01868477|DRUG|Deferasirox DFX, FCT|provided as film-coated tablet for oral use in 90, 180, 360 mg strengths
223606434|NCT01135095|RADIATION|low-dose imaging|"The study is designed to assess the validity of a low dose (\~5mSv) Tc99m one day protocol using D-SPECT standard protocol as the comparators.~D-SPECT cardiac scanner the D-SPECT system uses a solid-state detector, made of an alloy of Cadmium, Zinc, and Telluride, eliminating the need for thick crystals and large photomultiplier tubes. As a result, the system is significantly miniaturized, and ergonomically optimized to both user and patient"
223606435|NCT05505864|BEHAVIORAL|Health Action Process Approach (HAPA)|Health Action Process Approach (HAPA) using action planning and coping strategies to create health behaviour change
223606436|NCT05510674|DIAGNOSTIC_TEST|OWL-EVO1|EVOC probe
223606437|NCT03920943|OTHER|Measurement of temperature using non-invasive means|The study intervention will involve paramedics using the TAT device to measure temperature non-invasively,the first measurements made at least 5 minutes after insertion of the temperature probe (control measurement #1), and also prior to departure from the sending facility (control measurement #2). Once the patient is in the transport vehicle and the vehicle in motion for at least 10 minutes, the paramedics will measure the patient's temperature non-invasively using the TAT. If the transport time exceeds 1 hour, additional measurements taken at 1 hour intervals for the duration of transport (up to a total of 8 hours).
223606438|NCT04387578|DEVICE|fixed orthodontic appliance and arch wires|leveling and aligning stages in orthodontics
223606439|NCT03057860|OTHER|No study intervention|
223753483|NCT06001346|BEHAVIORAL|CalmCBT|Participants will view one of 8 standardized 30-minute nature videos while resting quietly prior to therapy. These are emotionally neutral videos and will allow for participants in both groups to have the same amount of attention and contact time.
223606440|NCT05260762|DIETARY_SUPPLEMENT|Arabinoxylan|Dietary fiber product
223606441|NCT05260762|DIETARY_SUPPLEMENT|Control|Potato starch
223753484|NCT05400278|OTHER|No intervention|No intervention
223606442|NCT04059120|OTHER|Experimental group whit specific stretching|The intervention involves a reality of physical, physical, different exercise, similar to the realist of high-performance athletes. However, this is the physical load, which is reduced with specific exercises of stretching and with it the factors that determine the syndrome of overtraining
223606443|NCT04059120|OTHER|Control group whit out specific stretching|The intervention involves a reality of physical, physical, different exercise, similar to the realist of high-performance athletes. However, this is the physical load, which is reduced less than specific exercises of stretching and with it the factors that determine the syndrome of overtraining
223606444|NCT02528786|OTHER|No Intervention|No study drug will be administered in this study.
223606445|NCT01076387|PROCEDURE|open radical cystectomy|Open radical cystectomy, pelvic lymph node dissection and open urinary diversion.
223606446|NCT01076387|PROCEDURE|robotic-assisted radical cystectomy|Robotic radical cystectomy, pelvic lymph node dissection and open urinary diversion. Robotic radical cystectomy is routinely performed by robotically trained and experienced minimally invasive surgeons.
223606447|NCT01821703|DRUG|LY3045697|Administered as oral solution
223606448|NCT01821703|DRUG|Placebo|Administered as oral solution
223606449|NCT01821703|DRUG|Spironolactone|Administered as capsule
223606450|NCT01821703|DRUG|Placebo|Administered as capsule
223606451|NCT01453608|DRUG|Ferinject (ferric carboxymaltose)|Subjects will receive Ferinject (ferric carboxymaltose) intravenously on Day 0
223606452|NCT01453608|DRUG|Placebo (saline)|Subjects will receive Placebo (saline) intravenously on Day 0
223606453|NCT05417087|DRUG|Vortioxetine Hemihydrobromide Orally Disintegrating Tablets|Vortioxetine Hemihydrobromide Orally Disintegrating Tablets 20 mg equivalent to 20 mg of Vortioxetine
223606454|NCT05417087|DRUG|Vortioxetine Hydrobromide Tablets|Vortioxetine Hydrobromide Tablets 20mg
223606455|NCT00903305|OTHER|medical chart review|
223606456|NCT00903305|OTHER|questionnaire administration|
223606457|NCT00903305|PROCEDURE|fatigue assessment and management|
223606458|NCT00903305|PROCEDURE|psychosocial assessment and care|
223606459|NCT00903305|PROCEDURE|quality-of-life assessment|
223606460|NCT03524638|OTHER|Visbiome|Colorectal surgery plus administration of Visbiome on post-operative day 2.
223606461|NCT03524638|PROCEDURE|Colorectal Surgery|Colorectal surgery alone
223753485|NCT00003217|BIOLOGICAL|filgrastim|
223753486|NCT00003217|DRUG|cyclophosphamide|
223753487|NCT00003217|DRUG|cytarabine|
224200685|NCT03676816|PROCEDURE|provider-performed endocervical sampling|provider-performed endocervical sampling is the gold standard for both gonorrhea and chlamydia. The provider takes a endocervical sample which will get sent to the laboratory as the standard care in comparison to the device being studied.
224200686|NCT02021019|PROCEDURE|Renal Denervation|Renal Denervation
223606462|NCT03483415|DRUG|Morphine Sulfate|Intravenous morphine infusion with PCA: Solution was concentration of 0.5 mg/mL. Loading dose of 1 mg, 0.5 mg of bolus dose and 20 min of locking time.
223606463|NCT03483415|DRUG|Bupivacaine|Ultrasound guided Long thoracic nerve blockage with 5 ml % 0.25 bupivacaine
223606464|NCT00367835|DRUG|SPD503 (Guanfacine hydrochloride)|Subjects will start at 1mg tablet each morning and will subsequently be titrated (in 1 mg weekly increments) to optimal dose based upon tolerance and response to investigational product (not to exceed 4 mg/day).
223606465|NCT00367835|DRUG|Placebo|Placebo
223606466|NCT03320135|PROCEDURE|Enamel matrix derivative proteins|Open flap debridement to enamel matrix derivative to treat proximal furcation involvements.
223606467|NCT03320135|PROCEDURE|Open Flap debridement|Open flap debridement will be performed to decontaminate the proximal furcation involvements.
223606468|NCT04374006|DRUG|Dienogest|1mg/kg BW/day based on the study by Katayama et al. A DNG in 0,5% carboxymethylcellulose suspension was given orally with metal sound daily 0,2-0,4 mL per day
223606469|NCT04374006|DRUG|Propolis|The propolis contains 20 mg in each ml. So, each rat we given 0,2 ml for 50mg/kg propolis treatment and 0,4 ml for 100mg/kg propolis treatment
223606470|NCT04374006|OTHER|placebo|we gave 0,2 ml to each rat everyday to negative control groups, and we gave no treatment to sham groups
223606471|NCT01459744|BEHAVIORAL|Communication training for cardiologists.|"Communication training: a 90 minute workshop to discuss ways to improve communication in patients with serious illness.~Reminders to Cardiologists. Cardiologists will receive reminders to prompt them to have conversations relating to ICD management with patients enrolled in the study.~Audit and feedback. Cardiologists will receive feedback on their rates of conversation as well as data on patient/family satisfaction with their communication skills."
223606472|NCT01459744|OTHER|Control arm|Cardiology grand rounds will be held at usual care sites on the importance of advance care planning.
223606473|NCT02659436|OTHER|Verbal-linguistic CBT|Participants will receive 4 sessions of individual therapy focused on traditional cognitive restructuring and exposure therapy.
223753488|NCT00003217|DRUG|dexamethasone|
223753489|NCT00003217|DRUG|doxorubicin hydrochloride|
223753490|NCT00003217|DRUG|methotrexate|
223753491|NCT00003217|DRUG|vincristine sulfate|
223753492|NCT05694650|BEHAVIORAL|Focus Group|Participants can meet with an interviewer alone. The focus group should take about 1 hour and will be held in person at MD Anderson, by telephone, or online using a video conferencing app called Zoom
223753493|NCT05694650|BEHAVIORAL|Interview|Participants can meet with an interviewer alone. The interview should take about 1 hour and will be held in person at MD Anderson, by telephone, or online using a video conferencing app called Zoom
224200687|NCT03666819|DEVICE|Carbon Dioxide Fractional Laser|Undergo CO2RE laser therapy
224200688|NCT03666819|OTHER|Questionnaire Administration|Ancillary studies
224200689|NCT05354141|BIOLOGICAL|ExoFlo|Intravenous administration of bone marrow mesenchymal stem cell derived extracellular vesicles
223606474|NCT02659436|OTHER|Imagery-based CBT|Participants will receive 4 sessions of individual therapy focused on imagery-based cognitive work and behavioural experiments.
223606475|NCT03296943|COMBINATION_PRODUCT|Essential oil|To inhale the essential oil in an air-conditioned room, the container was flipped over to soak the roll-on cap that was then rolled-on circularly at the right mid-palm of the subject at 2 centimeter in diameter for 5 cycles.
223606476|NCT03296943|COMBINATION_PRODUCT|Perfume|To inhale the perfume in an air-conditioned room, the container was flipped over to soak the roll-on cap that was then rolled-on circularly at the right mid-palm of the subject at 2 centimeter in diameter for 5 cycles.
223606477|NCT03296943|BEHAVIORAL|Cue-induced inhalants craving|Exposing individuals with a set of 12 pictures for one-minute (e.g., 5 second display per picture) every five minutes for three sets in total followed by another three sets of neutral/relaxing pictures of nature.
223753494|NCT06193746|DEVICE|non-invasive laser therapy|(diode laser, continuous output, in skin contact mode, 0.005W,0.2cm,beam spot area 0.03cm2, 288j/cm ,1800s) in the morning session, we measured lipid profile and kidney function before and after treatment to measure improvement
223753495|NCT02239250|DEVICE|Water filter and cookstove|"The Vestergaard Frandsen Lifestraw Family™ 2.1 is a point-of-use water treatment system.Water is poured through a 20 micron pre-filter into a 6L influent water tank.This water then filters through a 0.20 micron hollow-fiber ultrafiltration membrane into a 5.5L storage container.Water is then poured through a plastic tap, which prevents re-contamination.This system filters up to 18,000L of water.The system exceeds the WHO's highly protective standard for household water treatment technologies.The EcoZoom™ Spartan stove concentrates the combustion process while channeling airflow to completely burn the fuel provided.The stove has a ceramic combustion chamber within a steel housing, which is topped with a cast iron stove.The stove includes a rack for placing firewood and a pot skirt that improves the thermal efficiency.The cookstoves and filters will be delivered together at no cost to participating households.Households will receive instructions on how to operate these devices."
223753496|NCT02710604|DRUG|CMX157|tablet
223753497|NCT02710604|DRUG|TDF|300mg tablet
223753498|NCT05549193|OTHER|Exercises Training|"Pelvic Floor Muscle Training: For slow contractions, it was asked to contract in 5 seconds gradually, wait at a maximum of 5 seconds and gradually relax in 5 seconds. For fast contractions, it was asked to contract at a maximum of 2 seconds and then to relax. 10 fast + 10 slow contractions were accepted as 1 set exercise. (10 sets x Every Day x 6 weeks)~Transversus Abdominus: Patients were in the crook lying position and were asked to contract their abdominal muscles strongly and statically. 15 repetitions were carried out, each consisting of contraction for 10 s and relaxation for 20 s. 2 sets of 15 repetitions were done.~Internal Obliquus Abdominus: Patients were in the crook lying position and were asked to contract their abdominal muscles strongly and statically and then try to touch the furthest point of their legs with their fingertips for 15 repetitions consisting of contraction for 10 s followed by relaxation for 20 s. The sequence was then repeated on the other leg."
223606478|NCT03345537|OTHER|Non interventional study|Non interventional study - only data collected and one blood sample additional
223753499|NCT01713868|BEHAVIORAL|Safe Sleep Nursery Education|Nursery-based program for safe sleep
223753500|NCT01713868|BEHAVIORAL|Breastfeeding Nursery Education|Nursery-based program to promote breastfeeding
223753501|NCT01713868|BEHAVIORAL|Breastfeeding Mobile Health Messaging|Mobile messaging to provide multiple short culturally competent videos to promote breastfeeding delivered via email.
223753502|NCT01713868|BEHAVIORAL|Safe Sleep Mobile Health Messaging|Mobile messaging to provide multiple short culturally competent videos to promote safe sleep practices delivered via email.
223753503|NCT06329154|DEVICE|Extracorporeal shock wave therapy|The experimental group received extracorporeal shock wave therapy combined with conventional rehabilitation therapy. The control group was only given conventional rehabilitation therapy. According to the patient's tolerance and the specific condition, extracorporeal shock wave therapy was performed twice a week, 2000-3000 times each time, energy parameters of 2.5-3.5Bar, 8-15Hz, treatment interval \> 1 day, consecutive 4 weeks. Conventional rehabilitation therapy included medium frequency electricity, ultrasound, ultrashort wave, laser and wax therapy. Routine rehabilitation was given once a day, 5 times a week for 4 weeks.
223753504|NCT06329154|OTHER|conventional rehabilitation therapy|Conventional rehabilitation therapy included medium frequency electricity, ultrasound, ultrashort wave, laser, and wax therapy (same as the control group). Routine rehabilitation was given once a day, 5 times a week for 4 weeks.
223753505|NCT05516251|DEVICE|Transcutaneous Supraorbital Nerve Stimulator|SNS devices (DJTT-Ib, Hengyang Dajing Medical Instrument Technology Co., Ltd.) Stimulation electrodes are placed on the bilateral forehead, covering the supratrochlear and supraorbital nerves. The stimulus parameters are set as follows: pulse width 300 μsec, frequency 60 Hz, pulse duration μsec, increasing current peaked at 14 min with 16 mA. Patients receive SNS treatment daily for 20 min, no lease than 5 per week, last for 4 weeks.
223753506|NCT05516251|DRUG|Topiramate 25Mg Tab|Topiramate 25Mg Tab (Tuotai Pian, Xian Janssen Pharmaceutical Ltd.) are prescribed to participates by one neurologist. Participates are asked to take 25mg oral per day in a fixed time usually in the morning.
223753507|NCT05268471|DEVICE|Positional device (PD)|OSA treatment with PD for 6 months
223753508|NCT05268471|DEVICE|Continuos Positive Airway Pressure (CPAP)|OSA treatment with CPAP for 6 months
224200690|NCT05354141|OTHER|Intravenous normal saline|Placebo
224200691|NCT01729546|DEVICE|7 Blood glucose monitoring systems|
224200692|NCT06080503|RADIATION|LT-SABR|42.5 Gy in 5 fractions Low-risk: twice/week Moderate-risk: weekly
224200693|NCT06080503|RADIATION|IMRT|63 Gy in 28 fractions (T1) 65.25 Gy in 29 fractions (T2)
224200694|NCT00000423|BEHAVIORAL|Social support group|
224200695|NCT00000423|BEHAVIORAL|Social support and education group|
224200696|NCT06510114|DRUG|methylprednisolone(daily scheme)|0.5 g methylprednisolone i.v. daily for 5 consecutive days, followed by oral prednisone for 6 months. Oral prednisone started at 40 mg/day for 4 weeks and then the dose was tapered by 5 mg/day every 2-4 weeks.
224200697|NCT06510114|DRUG|methylprednisolone(weekly scheme)|0.5 g methylprednisolone i.v. weekly for 6 weeks and then the dose was tapered by 0.25 g/week over the following 6 weeks.
224200698|NCT03140527|DRUG|PTI-801|Active
224200699|NCT03140527|DRUG|Placebo|Placebo
224200700|NCT03140527|DRUG|PTI-808|Active
224200701|NCT03140527|DRUG|Placebo|Placebo
223606479|NCT04227132|DEVICE|Adaptive computer game training|Patients sit in front of a computer monitor and play the adaptive videogame with a joystick. The game requires to orient and move inside a maze, and it includes phases that engage multitasking abilities. The level and speed of the game is adapted online to patients' performance.
223753509|NCT03709264|DRUG|Amino Acids|Patients randomized to experimental arm receive a continuous infusion of a balanced mixture of amino acids in a dose of 2 g/kg ideal body weight/day (to a maximum 100 g/day) from the operating room admission up to either death, start of RRT, ICU discharge or 72 hours after treatment initiation, trough a central venous line
223753510|NCT03709264|DRUG|Placebos|Placebo: standard treatment
223753511|NCT00741884|DRUG|Varenicline Controlled Release 1.2 mg|Varenicline CR tablet 1.2 mg BID for 7 weeks
223753512|NCT00741884|DRUG|Varenicline Controlled Release 1.8 mg|Varenicline CR tablet 1.8 mg BID for 7 weeks
223753513|NCT00741884|DRUG|Varenicline Controlled Release 2.4 mg|Varenicline CR tablet 2.4 mg BID for 7 weeks
223753514|NCT00741884|DRUG|Varenicline Immediate Release 1 mg|Varenicline IR tablet 1 mg BID for 7 weeks
223753515|NCT00741884|DRUG|Placebo|Placebo BID for 7 weeks
223753516|NCT00178659|OTHER|Blood/saliva samples for protein/molecular analysis|Bloods samples - healthy volunteers(1 time) head injury subjects (5 times). Blood and/or saliva samples mild TBI patients (2 times) and healthy volunteers (2 times)
223753517|NCT02398552|DRUG|Sunitinib|altenative schedules of sunitinib as first line therapy in metastatic renal cell carcinoma patients.
223753518|NCT00423306|DRUG|Darinaparsin|420 mg/m2 of Darinaparsin given twice weekly for three weeks, followed by one week of rest, for up to 6 months
223753519|NCT00003256|DRUG|alvocidib|
224200702|NCT01357382|OTHER|Low carbohydrate diet|restrict carbohydrate consumption to \< 20 grams / day while not restricting their caloric intake. Participants will be encouraged to consume vegetables with low carbohydrate content every day including 2 cups of salad greens and 1 cup of vegetables 'that grow above the ground' increase their salt intake by consuming two cups of broth , ½ teaspoon of salt, or tablespoons of salt daily
223606480|NCT04227132|DEVICE|Standard computerized training|Patients sit in front of the computer monitor and perform simple computerized exercises using a keyboard to respond. Exercises are organized into modules according to the trained cognitive functions. Patients will perform four different modules that are designed for neglect rehabilitation. The level of exercises adapts periodically based on patient's performance.
223753520|NCT03289728|OTHER|Stress single photon emission CT (SPECT) or Stress ultrasound with dobutamine (DSE)|"Stress single photon emission CT (SPECT) or Stress ultrasound with dobutamine (DSE), performed using standard protocol.~Patients with ≥ moderate ischemia observed by SPECT (≥ 10% of the myocardium or transient ischaemic dilatation or reduced post-stress ejection fraction (EF)) or abnormal movements of the myocardial walls observed during a stress echocardiogram (≥ 3/17 segments) will benefit from coronary angiography. Depending on the results of coronary angiography and on the coronary anatomy and other clinical and para-clinical considerations (territory of myocardial ischemia) revascularisation will be performed (REVASC). Patients with \< moderate ischemia will receive medical treatment only (MT)."
223753521|NCT03289728|PROCEDURE|Cornorary angioplasty|Participants randomized to the SCA group, will benefit from a coronary angiography within 24 to 72 hours after the diagnosis of NSTEMI; without any preliminary ischemia imaging.
223753522|NCT00353743|DRUG|placebo|placebo
223753523|NCT00353743|DRUG|doxycycline plus metronidazole|doxycycline 200mg/day plus metronidazole 500mg/day up to 10 days of treatment (additional to the hospital treatment)
223753524|NCT01195805|DRUG|Spironolactone|1 tablet twice a day for 28 days
223753525|NCT01195805|OTHER|Placebo|1 tablet twice a day for 28 days
223753526|NCT01195805|DRUG|Amiloride|1 tablet twice a day for 28 days
223753527|NCT06482931|OTHER|Quality of life questionnaires|Patients will be asked to fill in two quality of life questionnaires: PACT-Q and EQ-5D-5L.
223753528|NCT02498093|BEHAVIORAL|Maximal strength training|
223753529|NCT02498093|BEHAVIORAL|conventional rehabilitation|
223753530|NCT03026257|DEVICE|Lotrafilcon B contact lenses with added wetting agent|Silicone hydrogel contact lenses
223753531|NCT03026257|DEVICE|Samfilcon A contact lenses|Habitual silicone hydrogel contact lenses
223753532|NCT03026257|DEVICE|POLYQUAD/ALDOX-preserved contact lens solution with added wetting agent|Multi-purpose disinfecting solution for contact lens care
223753533|NCT03026257|DEVICE|Hydrogen peroxide-based contact lens solution with added wetting agent|Solution for contact lens cleaning and disinfecting
223753534|NCT03026257|DEVICE|Senofilcon C contact lenses|Habitual silicone hydrogel contact lenses
223753535|NCT03026257|DEVICE|Senofilcon A contact lenses|Habitual silicone hydrogel contact lenses with a replacement pair issued after 2 weeks
223606481|NCT04701736|DEVICE|Picture Medication Calendar|
223753536|NCT03026257|DEVICE|Comfilcon A contact lenses|Habitual silicone hydrogel contact lenses
223753537|NCT03026257|DEVICE|Habitual Multi-Purpose Solution (HMPS)|Multi-purpose solution for contact lens care according to participant's habitual brand, used per manufacturer's instructions
223753538|NCT01530971|DRUG|Supplemental 3LPM oxygen via canula|Parturients will receive supplemental oxygen (3LPM) via nasal canula
223753539|NCT00649064|DRUG|Ziprasidone|Ziprasidone 40 mg capsules twice daily for the first 7 days followed by flexible dosing between 40 and 80 mg twice daily for the remaining 5 weeks.
223753540|NCT04489030|OTHER|Magnifying narrow-band imaging endoscopy|During endoscopy, gastric mucosal patterns would be examined by magnifying narrow-band imaging.
223753541|NCT02613533|OTHER|Intra-ocular pressure measurement (IOP)|Subjects will be given 10ml/kg of water over 15 min prior to laser peripheral iridotomy (LPI) surgery and Intra-ocular pressure (IOP) is tested every 15 min before and after surgical procedure
223753542|NCT02366832|PROCEDURE|Cryoablation|Subjects who respond to lidocaine nerve block will undergo CT guided cryoablation of the affected nerve stump with a 17g Galil Medical Ice Sphere cryoablation needle.
223606482|NCT03865641|DEVICE|Virtual reality rehabilitation|Task-specific training has been shown to be more effective when tasks were ordered in a random practice sequence using repetition and positive feedback. VR is an interactive and enjoyable intervention. VR creates a virtual rehabilitation scene in which the intensity of practice can be systemically manipulated.
223606483|NCT04119193|DEVICE|Novel smartphone application for blood pressure measurement|Continuous blood pressure measurements will be compared between the new application and the reference method (invasive radial arterial line) during 5 minutes of recordings.
223606484|NCT01497249|DIETARY_SUPPLEMENT|A dietary fiber (FCHO)|15 g twice per day in beverage
223606485|NCT01497249|DIETARY_SUPPLEMENT|Placebo|Placebo drink
223606486|NCT03514875|DIETARY_SUPPLEMENT|MitoQ|MitoQ is a mitochondria-targeting antioxidant, which should improve NO bioavailability, and therefore vasodilation
223606487|NCT03514875|DIETARY_SUPPLEMENT|Placebo|A placebo will be used in a double blinded, randomized, cross-over design
223606488|NCT04338971|DEVICE|IpsiHand Therapy|The IpsiHand system utilizes a Brain-Computer Interface (BCI) to enable operation of a robotic hand exoskeleton worn on the hand and wrist as participants are guided through a rehabilitation program on a tablet. Participants will complete 12 weeks of hometherapy with the IpsiHand system. Motor function of their impaired upper extremity will be evaluated at baseline, at 4-week intervals, and 12 weeks completion of IpsiHand use.
223606489|NCT02091843|PROCEDURE|DBS of the Basolateral Nucleus of the Amygdala|
223606490|NCT02091843|DEVICE|Medtronic Activa PC DBS of the Basolateral Nucleus of the Amygdala|
223606491|NCT02818049|PROCEDURE|Bronchoalveolar Lavage|BAL was performed in accordance with current practice. Patients are oxygenated with FiO2=1 at least 5 min before the start and 4 h after the procedure. Blood pressure, central venous pressure, heart rate and breathing are monitored by a monitor. O2 saturation (SpO2) is monitored continuously by pulse oximetry.
223753543|NCT02366832|DEVICE|17g Galil Medical Ice Sphere cryoablation needle|Under CT guidance, the corresponding nerve will be targeted with a 17g probe. Two freeze-thaw cycles will be undertaken. The probe will be removed and a final scan obtained.
223753544|NCT02218333|DIETARY_SUPPLEMENT|Milk|4 dl milk will be consumed daily with breakfast and supper for 12 weeks
223753545|NCT02218333|DIETARY_SUPPLEMENT|Placebo|
223753546|NCT03650010|PROCEDURE|Total ankle replacement|total ankle prosthesis through a lateral or an anterior approach
223753547|NCT04380857|DRUG|Dexamethasone ophthalmic insert 0.4 mg|intracanalicular dexamethasone insert
223606492|NCT06137599|OTHER|Capillary analysis|Samples taken between 2 and 6 months after the presumed events. A pre-analytical treatment of the hair (washing, fragmentation), followed by detection by high-resolution mass spectrometry is carried out by an expert laboratory to search for both GHB and psychoactive drugs.
223753548|NCT04380857|DRUG|Topical Prednisolone Acetate Ophthalmic Drops|"Topical Prednisolone acetate ophthalmic drops per standard of care:~Every two hours on day of procedure, then four times a day for the first week, then two times a day for the second week, then discontinue"
223753549|NCT03372512|DIAGNOSTIC_TEST|Bioimpedance spectroscopy|Fluid overload will be assessed by bioimpedance spectroscopy
223753550|NCT04126928|DIAGNOSTIC_TEST|Screening using DMFT and PUFA, orthopantomogram is taken and assessed using PAI, comprehensive clinical examination to diagnose pulpal and periapical conditions.|
223753551|NCT04654533|OTHER|COSC|"COSC is professional development program for early childcare providers adapted from the Circle of Security-Parenting (COSP) model. It is a manualized intervention that leverages research on attachment relationships combining psycho-education with a mentalization-based approach. The model uses pre-produced video vignettes of secure and problematic caregiver-child interactions to illustrate how caregivers' may struggle in meeting children's' attachment needs.~Participants are invited to reflect on how they meet and perhaps still not meet the needs of the children in their care with a particular focus on the challenging or 'difficult' children.~The COSP manual has been translated into Danish (Cooper, Hoffman and Powel, 2020, translated by Pedersen, Kronendorf von Wowern, Lier, \& Smith-Nielsen), and the additional COSC material has been translated into Danish for the purpose of this study."
223606493|NCT05485285|OTHER|visual analog scale|Data collection was carried out at all stages of treatment: medical and nursing brigade, military mobile hospital, military medical clinical center, during rehabilitation, within 12 months of the injury.
223753552|NCT05060393|BEHAVIORAL|Mindfulness-based cognitive therapy|Mobile application, mindfulness-based therapy
223606494|NCT03483545|COMBINATION_PRODUCT|Follitropin delta and HP-hMG|Follitropin delta dose will be determined by AMG and weight in Kg. Highly purified human menopausal gonadotrophin will be determined by follitropin delta dose and body weight in Kg
223606495|NCT06077032|DRUG|garlic extract (15%) solution|•Group 1: will apply Vaseline over the normal skin surrounding the lesion(s) then a cotton soaked with garlic extract (15%) solution will be applied under occlusion with a plastic tape for one hour and then washed by tap water daily for 6 weeks.
223753553|NCT03132051|DRUG|steroid injection|ultrasound-guided steroid injection using 1ml of 10 mg (10mg/ml) triamcinolone acetonide
223753554|NCT00200954|DIETARY_SUPPLEMENT|Probiotic bacteria|3 x 10e9 CFU of a mixture of probiotic bacteria, once daily to the pregnant mothers last 6 weeks of pregnancy.To their offspring during the first year of life.
223753555|NCT00200954|DIETARY_SUPPLEMENT|Placebo|The placebo consists of the carrier of the probiotic bacteria mixture, i.e. rice starch and maltodextran
223753556|NCT00378313|DRUG|gemcitabine, epirubicin, paclitaxel|
223753557|NCT06019975|DIAGNOSTIC_TEST|FDG-PET|Brain FDG-PET
223753558|NCT03010787|DRUG|V565|single ascending dose of V565
223753559|NCT03010787|DRUG|V565|Multiple dose
223753560|NCT03010787|DRUG|Placebo|Single and multiple dose
223753561|NCT03010787|DRUG|V565|Open-label single dose
223753562|NCT03010787|DRUG|V565|Open-label single ascending dose
223753563|NCT00973791|DRUG|Ringer's Lactate|Ringer's Lactate 8 ml/kg was given intravenously before or after spinal anesthesia in cesarean section
223753564|NCT00973791|DRUG|Six percent hydroxyethyl starch|Hydroxyethyl starch (6%) was given before or after spinal anesthesia in cesarean section
223753565|NCT06358456|DRUG|Artificial tear|Application of low viscosity artificial tears (Artelac EDO). The active ingredient is hypromellose (1.92 mg per 0.6 ml container).
223606496|NCT06077032|DRUG|topical chlorhexidine (2%) solution|•Group 2: will apply Vaseline over the normal skin surrounding the lesion(s) then a cotton soaked with topical chlorhexidine (2%) solution will be applied under occlusion with a plastic tape for one hour and then washed by tap water daily for 6 weeks.
223606497|NCT06077032|DRUG|Saline|•Group 3: (control) will use normal saline 0.9% as a placebo (they will be treated later on after completion of the study using any of the standard therapies for non-genital warts).
223753566|NCT06358456|OTHER|No artificial tears|Before artificial tear application, 2 baseline measurements were taken of the cornea without any intervention
223753567|NCT06375057|PROCEDURE|laparoscopic cholecystectomy|A blood sample is taken the day after surgery
223606498|NCT00601549|PROCEDURE|Laparoscopic surgery|Laparoscopic surgery
223606499|NCT00601549|PROCEDURE|Traditional open surgery|Open surgery
223753568|NCT00838201|DRUG|Denosumab|60 mg SC of Denosumab will be administered on study day 1, month 6, month 12, and month 18
223753569|NCT02558790|DRUG|L-Threonic Acid Magnesium Salt (L-TAMS)|
223753570|NCT05111132|DIAGNOSTIC_TEST|Fluid challenge (cristalloïd, NaCl 0,9%)|A fluid challenge according to group will be administrated by infusion pump
223753571|NCT03424837|BEHAVIORAL|ASCENT|"ASCENT includes the following components:~* Survivorship care plan created through the ASCENT tool~* Online tool which assesses health care needs and facilitates receipt of care~* A national-level navigator who helps the participant to access support services~* Periodic reminders for the participant to pursue recommended survivorship care"
223753572|NCT03638817|DRUG|Eltrombopag|"Eltrombopag will be prescribed at doses recommended in primary immune thrombocytopenia (50, 25 or 75 mg), starting 4 weeks before the procedure and stopped 2 days before. PC will be administrated prophylactically if the platelet count is \< 80 G/L or per/post-operatively in case of bleeding of undetermined cause.~Antifibrinolytics will be authorized and low molecular weight heparin prescribed if indicated for the prophylaxis of postoperative venous thrombosis according to the standard dose and duration, , irrespective of the platelet count"
223753573|NCT00232908|DRUG|ARV regimen|As prescribed
223753574|NCT00232908|DRUG|enfuvirtide [Fuzeon]|90mg sc bid for 12 weeks
223753575|NCT05731401|OTHER|Explanations of the cause of pain|"When analyzing the responses to the question Why do you think you have or have had this pain? two themes emerged from the data: 'explanations associated with damage', and 'explanations not associated with damage'.~The themes were sub-classified into sub-themes, according to the type of explanation"
223753576|NCT02450214|DRUG|Saline|50 mL syringe will be infused at 0.3 mL/Kg in bolus and then 0.15 mL/Kg/h 100 mL flask will be infused at 1mL/Kg in bolus for 30 min and then 0.25mL/Kg/h
223753577|NCT02450214|DRUG|Ketamine|50 mL syringe will be infused at 0.3 mL/Kg in bolus and then 0.15 mL/Kg/h 100 mL flask will be infused at 1mL/Kg in bolus for 30 min and then 0.25mL/Kg/h
223753578|NCT02450214|DRUG|Ketamine + magnesium|50 mL syringe will be infused at 0.3 mL/Kg in bolus and then 0.15 mL/Kg/h 100 mL flask will be infused at 1mL/Kg in bolus for 30 min and then 0.25mL/Kg/h
223753579|NCT05932186|PROCEDURE|Interscalene brachial plexus block combined with general anesthesia|"Baseline diaphragmatic assessment will be performed before the nerve block in the sitting position. Interscalene block will be done as follows. US probe will be placed slightly lower to the level of the cricoid cartilage, followed by scanning of the neck to search for C5 and C6 nerve roots enclosed between the anterior and middle scalene muscles. The needle will be introduced in-plane from lateral to medial through the middle scalene muscle until the tip enters the brachial plexus sheath between the C5 and C6 roots, where LA will be injected.~Patients will be transported to the operation room where general anaesthesia will be induced with tracheal intubation Fentanyl (0.5 μg/kg) will be given to maintain the heart rate and mean blood pressure 20% lower than preinduction values. Intravenous 1 gram paracetamol and 8 mg dexamethasone will be given to all patients as part of multimodal analgesia"
223753580|NCT05932186|PROCEDURE|Upper trunk brachial plexus block combined with general anesthesia|"Baseline diaphragmatic assessment will be performed before the nerve block in the sitting position like the the ISB group~Upper trunk will be visualized distal to the convergence of the C5 and C6 nerve roots but proximal to the departure of the suprascapular nerve (This nerve is a small hypoechoic circle that depart the lateral aspect of the upper trunk and courses posterolateral under the omohyoid muscle). The needle will be introduced in-plane from lateral to medial under the deep cervical fascia and through a very small portion of the middle scalene muscle, until the needle tip lies adjacent to the upper trunk, LA will be distributed below and above the upper trunk. Scanning for the upper trunk can be started from the supraclavicular fossa and moving proximal or opposite to cricoid cartilage and moving distal.~The following steps will be done as in the ISB group"
223606500|NCT01885624|BIOLOGICAL|TAB08|monoclonal antibody
223753581|NCT01387321|DRUG|BYL719|
223753582|NCT06481956|DRUG|Ribociclib Oral Tablet|Patients with advanced breast cancer with at least one evaluable lesion and histologically proven invasive breast cancer were eligible for inclusion. Histopathologically positive for HER2 (IHC 3+, or IHC 2+ with fluorescence in situ hybridization (FISH) positive, either primary or metastatic. Patients with advanced breast cancer must have previously received first-line therapy or initial rescue therapy and have been treated with trastuzumab against HER2.
223753583|NCT00763659|DIETARY_SUPPLEMENT|Lutein/ Zeaxanthin + Omega-3-FA|20mg Lutein, 2mg Zeaxanthin, 510 mg Omega-3-FA; daily supplementation about one year
223606501|NCT04009395|OTHER|Pregnant Women qualitative interviewing|one-on-one in depth interviewing of pregnant African migrant women living in the UK on the barriers and facilitators to healthy eating in pregnancy.
223606502|NCT04009395|OTHER|Midwives qualitative interviewing|one-on-one interviewing/focus group discussions with midwives on their perspectives regarding the provision of healthy eating advice to pregnant African migrant women living in the UK.
223606503|NCT06229327|BEHAVIORAL|THERAPEUTICGAMES|THERAPEUTICGAMES
223606504|NCT03761810|DRUG|S6G5T-3|Once a day topical cream
223606505|NCT03761810|DRUG|S6G5T-8|Once a day topical cream
223606506|NCT01179152|DRUG|Budesonide turbuhaler, Budesonide+Formoterol turbuhaler|Budesonide 200 mcg turbuhaler or Budesonide+Formoterol 160mcg turbuhaler
223606507|NCT04792411|BEHAVIORAL|Prehabilitation|Multimodal, tailored prehabilitation programme
223606508|NCT03229733|DEVICE|Kinect|Receive Kinect games training for 30 minutes. There are 3 sections for 1 week; the intervention period will be 8 weeks
223753584|NCT00763659|DIETARY_SUPPLEMENT|Lutein/ Zeaxanthin + Omega-3-FA|10mg Lutein, 1mg Zeaxanthin, 255 mg Omega-3-FA; daily supplementation about one year
223753585|NCT00763659|DIETARY_SUPPLEMENT|Placebo|0 mg Lutein, Zeaxanthin, Omega-3-FA
223753586|NCT03898765|DIAGNOSTIC_TEST|Dry blood spot screening|Dry blood spot measurement of biomarker for screening biliary atresia
223753587|NCT05789836|OTHER|Nursing care|Involving the mother in nursing care
223753588|NCT05425290|BEHAVIORAL|Single-session emotion regulation training|The single-session emotion regulation skills training will blend psychotherapeutic approaches that emphasize effective ER. First, participants will be taught to adopt a detached (i.e., 'distanced') and nonjudgmental attitude towards an emotional situation. Detachment, or 'distancing' as it will be introduced to participants, will be taught by examining the situation with objectivity or putting spatial or temporal distance between the current moment and the situation. Second, research participants will be taught reframing. Specifically, they will be introduced to the relationship between thoughts and emotions and how to find interpretations that are less upsetting in order to be more effective when upset. Participants will identify elements of a situation that they did not pay attention to or information that was missing, and to reframe their thoughts based on the full picture. The emotion regulation training is expected to take approximately 30-45 minutes.
223753589|NCT05371600|DRUG|Midazolam|midazolam IV at 0.04 mg/kg
223753590|NCT05371600|OTHER|Saline|an equal volume of saline IV
223753591|NCT05897879|BIOLOGICAL|Nasopharyngeal swab|"For hospitalized patients :~Nasopharyngeal swab (1 aspiration or 2 swabs (1 in each nostril))~For ambulatory patients :~Deep nasal swab: 2 swabs (1 in each nostril), or 1 swab only for children for whom taking 2 swabs is complicated."
223753592|NCT05897879|BIOLOGICAL|Blood samples|For hospitalized patients : 3 to 7.5 ml For ambulatory patients: Fingertip blood sampling
223606509|NCT03229733|BEHAVIORAL|Traditional occupational therapy|Patients will receive individually tailored conventional training consisting of the similar movement and dose by using the traditional equipment, such as climbing bar.
223606510|NCT01574651|DRUG|QVA149|QVA149 110/50µg, once daily (q.d.) is administered via a single-dose dry powder inhaler
223606511|NCT01574651|DRUG|Placebo to tiotropium|Placebo to tiotropium capsules daily (q.d.) for inhalation, delivered via proprietary inhaler (Handihaler®). Placebo tiotropium inhalation capsules were matched in size and color to tiotropium 18 μg q.d. inhalation capsules
223606512|NCT01574651|DRUG|Placebo to formoterol|Placebo to formoterol capsules twice daily (b.i.d) delivered via Aerolizer® device. Placebo formoterol inhalation capsules were equally matched in size, shape and color to formoterol 12 μg b.i.d. inhalation capsules.
223606513|NCT01574651|DRUG|Tiotropium|Tiotropium 18µg, once daily is administered via the manufacturer's proprietary inhalation device.
223606514|NCT01574651|DRUG|Formoterol|Formoterol 12µg, twice daily is administered via the manufacturer's proprietary inhalation device.
223606515|NCT01574651|DRUG|Placebo to QVA149|Placebo to QVA149 is administered via a single-dose dry powder inhaler. Placebo QVA149 inhalation capsules were equally matched in size, shape and color to QVA149 110/50 μg q.d. inhalation capsules
223606516|NCT03887221|DRUG|Safinamide 50 mg|Safinamide 50mg film-coated tablets will be administered to subjects in Cohort 1. The subjects will receive the tablets orally in the morning, at 8:00±1hour, under fasting conditions, with 240 mL (total volume) of still mineral water. A mouth-and-hand check will be performed immediately after dosing to ensure treatment compliance.
223606517|NCT03887221|DRUG|Safinamide 100mg|Safinamide 100mg film-coated tablets will be administered to subjects in Cohort 2. The subjects will receive the tablets orally in the morning, at 8:00±1hour, under fasting conditions, with 240 mL (total volume) of still mineral water. A mouth-and-hand check will be performed immediately after dosing to ensure treatment compliance.
223753593|NCT03878316|DRUG|Instranasal Oxytocin|Intranasal Oxytocin - concentrated formulation - 35 IU per dose
223753594|NCT00943228|DRUG|mycophenolate mofetil|High dose 4gms daily
223606518|NCT04454242|OTHER|Expiratory muscle trainig|This exercise will be used to strengthen forced expiratory muscles.
223606519|NCT00138775|DRUG|D-serine|
223606520|NCT02092025|DRUG|Azilsartan|Azilsartan tablets
223606521|NCT03308253|DEVICE|Stimulan Rapid Cure|Calcium sulfate dissolvable beads
223606522|NCT03308253|DRUG|Vancomycin|0.5 g Vancomycin per patient
223606523|NCT03308253|DRUG|Tobramycin|120 mg tobramycin per patient
223606524|NCT03308253|OTHER|Standard of Care|Standard of care provided at Hamilton General Hospital consisting of dressings for the wound.
223606525|NCT01478308|DRUG|Metformin hydrochloride|Metformin is administered orally, with food. Metformin tablets contain 500mg, 850mg, or 1000mg of metformin hydrochloride. Tablets contain inactive ingredients including pofidone and magnesium stearate. The coating for 500mg and 850mg tablets contains hypromellose. Metformin is an antihyperglycemic agent which decreases hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization.In this study, Metformin will be given 850 mg orally, with food, once daily for 1 week starting the week before first docetaxel infusion, and thereafter 850 mg twice daily.
223753595|NCT05228470|DRUG|Elranatamab|BCMA-CD3 bispecific antibody
223753596|NCT02795390|DRUG|Chinese herbal medicine|
223753597|NCT02795390|DRUG|Placebo|
223753598|NCT00842660|DRUG|Gemzar (gemcitabine)|Gemzar(gemcitabine) Hcl has 2'deoxy-2,2'-difluorouridine monohydrochloride
223753599|NCT02311439|DRUG|FOLFIRINOX + CRT|"Induction 4 times chemotherapy, FOLFIRINOX regimen, consisted of Oxaliplatin at a dose of 85 mg/m2 D1, 2-hour I.V + Irinotecan 180 mg/m2 D1 90-minute I.V. + Leucovorin 200 mg/m2 2- hour I.V, D1,2 + (5-FU) dosed at 400 mg/m2, administered as an intravenous bolus on day 1 and day 2, followed by a continuous intravenous infusion of 600 /m2 over a 20- hours period on day 1 and day 2. Treatment will be administered every 2 weeks. G-CSF will be administrated according to the need.~In non-progressed cases, will be followed by consolidation concurrent radiotherapy with capecitabine 625 mg/m2 BID.~Radiotherapy :~A fractionated dose of 50.4Gy /28 fractions/15 MeV photon energy generated by Dual-energetic Linear Accelerator."
223753600|NCT03427359|DRUG|cisplatin, capecitabine|Experimental arm patients received 3 cycles of induction chemotherapy (cisplatin 80mg/m2, day 1; oral capecitabine 1000mg/m2 twice daily from day1-14, repeated every 3 weeks) followed by concomitant cisplatin (100mg/m2,day1,every 3 weeks) for a total of 2 cycles with radiotherapy.
223753601|NCT02342340|OTHER|Navy Beans (cooked)|One time consumption of 3/4 cup of cooked navy beans.
224311504|NCT02837614|DRUG|submucosal dexamethasone injection|Local anesthesia was achieved using 2% lignocaine hydrochloride and 1:100 000 adrenaline and a standard technique was followed to block Inferior alveolar, lingual and long buccal nerve in all patients. In Group B patients, 1 ml of dexamethasone was administered in submucosa. Investigators divided 1 ml Dexamethasone is into 0.4 milliliter, 0.3 milliliter and 0.3 milliliter parts. Following the local anesthesia, each part of dexamethasone was injected submucosally in the buccal, lingual and retromolar region around the tooth to be extracted. Bone removal done around the tooth using a round bur under copious 0.9% normal saline irrigation and tooth elevated. The flap was sutured using three simple interrupted 3-0 black braided silk suture. All patients were given amoxicillin 500 milligram every 8 hours orally for 5 days, and 500 milligram of paracetamol postoperatively.
224311505|NCT02837614|PROCEDURE|Third molar surgery|Surgical access was gained through standard Terrence Ward's incision to raise a full thickness mucoperiosteal flap. Bone removal done around the tooth using a round bur under copious 0.9% normal saline irrigation. The tooth sectioned at cemento-enamel junction whenever required and a Coupland elevator is used to elevate tooth or fragmented tooth out of socket. The socket examined for any debris and sharp bony margins smoothened. The empty socket was irrigated copiously and flap was sutured using three simple interrupted 3-0 black braided silk suture.
224311506|NCT02837614|DRUG|Amoxicillin and paracetamol|Amoxicillin 500 milligram every 8 hours orally for 5 days, and 500 milligram of paracetamol postoperatively (every 6 hours 1 tablet for 2 days).
223753602|NCT02342340|OTHER|Red Kidney Beans (cooked)|One time consumption of 3/4 cup of cooked red kidney beans.
223753603|NCT02342340|OTHER|Pinto Beans (cooked|One time consumption of 3/4 cup of cooked pinto beans.
224311507|NCT02293369|PROCEDURE|Cuff closure via vaginal route|Vaginal cuff will be closed via vaginal route during total laparoscopic hysterectomy.
224311508|NCT02293369|PROCEDURE|Cuff closure via laparoscopic route|Vaginal cuff will be closed via laparoscopic route during total laparoscopic hysterectomy.
224311509|NCT05204836|DRUG|Zoledronic Acid Injection|5 mg / 100 mL intravenous infusion
223606526|NCT01478308|DRUG|Docetaxel|Docetaxel will be administered 75 mg/m2 as one hour infusion on day 1 every 21 days.
223606527|NCT01478308|DRUG|Prednisone|Prednisone will be given 5mg orally twice daily which is the standard regimen with docetaxel
223606528|NCT02161055|DRUG|Insulin|"Insulin dose was selected in accordance with the Yale Insulin Infusion Protocol.~• Amount of insulin (u) = \[fasting blood glucose (mmol/L) × 18-100\] × 10 × body weight (kilogram) × 0.6 ÷ 1000 ÷ 2"
223606529|NCT02145065|DRUG|Local drug delivery via microcrystalline paclitaxel balloon coating (PAK,Balton, Poland)|
223606530|NCT02145065|DEVICE|Plain balloon angioplasty, uncoated balloon (Neptun, Balton, Poland)|
223606531|NCT02562859|DRUG|500 mg GLPG1837 as oral suspension|A single dose of 500 mg GLPG1837 administered as oral suspension
223606532|NCT02562859|DRUG|500 mg GLPG1837 as oral tablet|A single dose of 500 mg GLPG1837 administered as oral tablet
223606533|NCT02399657|DRUG|Intravitreal dexamethasone 0.7mg implant|Ozurdex at day 0 (fixed), 5 months (fixed), 10 months pro re nata or 11 months pro re nata
223606534|NCT02164266|DRUG|Placebo|Matching placebo daily oral administration
223606535|NCT02164266|DRUG|RO6799477|Daily oral administration of RO6799477
223606536|NCT05695144|DEVICE|tDCS active stimulation combined with rTMS sham stimulation|"Active tDCS positive stimulation: left dorsolateral prefrontal cortex (DLPFC) or BeamF3 method; negative stimulation: right frontal, 2mA, 20 mins stimulation, 1 time/day, 5 consecutive days, weekend suspension, lasting 4 weeks, total 20 times.~Sham stimulation rTMS: Parameters such as stimulation site, current intensity, and stimulation time are kept consistent, keeping the coil facing outward."
223753604|NCT02342340|OTHER|Black Beans (cooked)|One time consumption of 3/4 cup of cooked black beans.
223753605|NCT02342340|OTHER|Lentils (cooked)|One time consumption of 3/4 cup of cooked lentils.
223753606|NCT02342340|OTHER|White Rice|One time consumption of 3/4 cup of cooked white rice.
223753607|NCT05929092|PROCEDURE|Umbilical Cord Blood Transplantation|Compared with peripheral blood stem cell transplantation (PBST), UCBT has a higher transplantation rate, as cord blood stem cells are more primitive. Since the first successful umbilical cord blood transplantation (UCBT) in a child with severe Fanconi anemia reported by Gluckman et al. in France in 1988, cord blood has been widely used as a graft source of hematopoietic stem cells for the treatment of hematological diseases. The first sibling UCBT for leukemia was performed successfully by Professor Yongping Song in China, who played a pioneering role in the development of UCBT for leukemia in China. On the basis of previous research, the TFBC regimen (TBI/Flu/Bu/Cy) combined with UCBT is safe and feasible for the treatment of patients with high-risk malignant hematological diseases, which has enormous potential to improve patient outcomes.
223753608|NCT03725189|DEVICE|PPG during exercise|PPG use for pulse waveform evaluation of healthy exercise group
224075436|NCT06221020|DIAGNOSTIC_TEST|Malnutrition Universal Screening Tool|"The Malnutrition Universal Screening Tool (MUST) is a commonly used tool for assessing the nutritional status of adult patients. It is designed to identify early whether a patient is at risk of malnutrition or is already malnourished, enabling timely intervention and treatment. MUST includes three main assessment criteria:~Body Mass Index (BMI):~Degree of Weight Loss: This assesses the patient's weight change over the past three months, with grading based on the extent of weight loss.~Effect of Illness on Dietary Intake: This evaluates the impact of illness on the patient's dietary intake, with grading based on the reduction in dietary intake.~By combining the grades from these three assessment indicators, a final MUST score is obtained to determine the patient's nutritional status and level of risk. Based on the MUST score, patients can be categorized as low risk, medium risk, or high risk for malnutrition."
224311510|NCT05204836|DRUG|Placebo|100 mL intravenous infusion
224311511|NCT03619681|DRUG|KN026|Patient will be intravenously administrated with one dose of KN026. dosing interval may be adjusted during the study based on emerging data from this trial and/or from other trial.
223606537|NCT05695144|DEVICE|rTMS active stimulation combined with tDCS sham stimulation|"Sham stimulation tDCS: Parameters such as stimulation site, current intensity, and stimulation time are kept consistent, keeping the switch off.~Active rTMS: stimulation site: left dorsolateral prefrontal cortex (DLPFC); consisting of a total of 3000 pulses per session at 10Hz (4 seconds on and 16 seconds off) at 110% resting motion threshold (RMT), 40 pulses per string; total 75 strings; 1 time/day, 5 consecutive days, weekend suspension, total 20 times. Resting motor thresholds (RMT) were measured before the start of each day of treatment."
223606538|NCT05695144|DEVICE|tDCS active stimulation combined with rTMS active stimulation|"Active tDCS positive stimulation: left dorsolateral prefrontal cortex (DLPFC) or BeamF3 method; negative stimulation: right frontal, 2mA, 20 mins stimulation, 1 time/day, 5 consecutive days, weekend suspension, lasting 4 weeks, total 20 times.~Active rTMS: stimulation site: left dorsolateral prefrontal cortex (DLPFC); consisting of a total of 3000 pulses per session at 10Hz (4 seconds on and 16 seconds off) at 110% resting motion threshold (RMT), 40 pulses per string; total 75 strings; 1 time/day, 5 consecutive days, weekend suspension, total 20 times. Resting motor thresholds (RMT) were measured before the start of each day of treatment."
223606539|NCT05695144|DEVICE|tDCS sham stimulation combined with rTMS sham stimulation|"Sham stimulation tDCS: Parameters such as stimulation site, current intensity, and stimulation time are kept consistent, keeping the switch off.~Sham stimulation rTMS: Parameters such as stimulation site, current intensity, and stimulation time are kept consistent, keeping the coil facing outward."
223606540|NCT03451123|DRUG|FET PET/MRI|FET PET/MRI scan before and after surgery
223606541|NCT06141876|DRUG|APEX-002-A02|Active
223606542|NCT06141876|OTHER|Placebo|placebo
223606543|NCT05495165|OTHER|Therapeutic education for patients in nutrition|Stakeholders give preventive therapeutic education recommandations in their specific expertize
223606544|NCT00391950|DRUG|Zoledronic acid|
223753609|NCT02117375|DEVICE|spinal cord MRI follow-up|Evaluation : focal lesions (number, volume, localisation), atrophy, parameters from Diffusion Tensor Imaging and parameters from Magnetization Transfer Ratio
223753610|NCT02117375|OTHER|clinical follow-up|Relapses, treatments, global disability,walking performance, upper limbs motor performance, sphincter disturbances and walking difficulty
223753611|NCT02117375|OTHER|brain MRI follow-up|
223753612|NCT04445558|DIETARY_SUPPLEMENT|oral nutritional supplementation|Adjunction of oral nutritional supplementation
223753613|NCT04445558|DIETARY_SUPPLEMENT|intradialytic parenteral nutrition|Adjunction of intradialytic parenteral nutrition
223753614|NCT02985632|DRUG|BMS-986141|
223753615|NCT06231303|GENETIC|DNA extraction and PCR amplification|"Microbial community genomic DNA extraction from fecal samples will be done using extraction kit in accordance with the manufacturer's instructions. The DNA extract will be checked on a 1% agarose gel, and the DNA concentration and purity will be determined using the NanoDrop 2000 UV-vis spectrophotometer.~The hyper-variable region V3-V4 of the bacterial 16S rRNA gene will be amplified with the primer pair 338F (ACTCCTACGGGAGGCAGCAG) and 806R (GGACTACHVGGGTATCTAAT) on a PCR thermocycler. PCR amplification of the 16S rRNA gene will performed as follows:~Initial denaturation at 95 ℃ for 3 min. 27 cycles of denaturing at 95 ℃ for 30 s, annealing at 55 ℃ for 30 s, and extension at 72 ℃ for 45 s.~Final extension step at 72 ℃ for 10 min and incubation at 10 ℃. The PCR product will then be used to quantify different bacterial species in stool samples of patients and controls using real time PCR."
223753616|NCT00703547|DRUG|GSK586529 capsules|GSK586529 will be provided as white gelatin capsule with a dose of 3 milligrams.
223606545|NCT04136730|BEHAVIORAL|Home-based|Resistance exercise carried out unsupervised at home
223606546|NCT02908750|DRUG|Fexofenadine tablet dosing|Fexofenadine (P-gp substrate) 120mg taken once daily on Days 1 in Treatment Period 1 and Day 1 and Day 39 in Treatment Period 2
223753617|NCT00703547|DRUG|GSK586529 tablets|GSK586529 will be provided as a yellow film-coated tablets for oral administration at three different strengths 10 milligrams, 60 milligrams and 120 milligrams.
223753618|NCT00703547|DRUG|Placebo|Placebo tablets and capsules will be provided to subjects.
223753619|NCT02479152|DEVICE|LUCAS2 AD|LUCAS™ 2AD with compressions like the standard LUCAS™ 2 but added decompressions above the initial start position.
223753620|NCT00165490|DRUG|Cetuximab|Given once per week on weeks 1-8 and restarted 4 weeks after surgery, once weekly for 6 months.
223753621|NCT00165490|DRUG|Cisplatin|Given once per week on weeks 1, 2, 4,and 5.
223753622|NCT00165490|DRUG|Irinotecan|Given once per week on weeks 1, 2, 4,and 5.
223606547|NCT02908750|DRUG|Osimertininb tablet dosing|Osimertininb 80 mg taken once daily on Day 1 and Days 4 to 41 in Treatment Period 2
223606548|NCT05419544|BEHAVIORAL|Holy Quran Recital effect|The intervention group, listened to holy Quran recitation for 10 minutes twice a day 4 hours a part (10 am and 2 pm) for 2 consecutive days (usually the 2nd and the 3rd day post-operative) after extubation and gaining alertness. We have chosen Surah Al-Rehman because it is considered as the most rhythmic surah of the Quran and the recitation of Qari Abdul Basit is very soothing and effective as he has recited from the deep of the heart. The listing was by a disposable head phones for an I pad for each hospital. The control group received usual care by their nurses.
223606549|NCT02395614|DRUG|Chlorhexidine irrigation|\- 0.05% chlorhexidine solution (IrriSept®) commercially prepared in 450 ml bottles will be used to irrigate one breast pocket. Each patient will receive triple antibiotic solution on one breast and the CHG on the other breast.
223753623|NCT00165490|DEVICE|Radiation therapy|Once daily for 28 treatments (5 1/2 weeks)
224311512|NCT02553031|DEVICE|The imaging biomarkers determined by MR-PET|This study will explore the potential value in proper therapeutic decision and clinical outcome prediction by using integrated MR-PET system and advanced MR techniques in patients with colorectal cancer.
224311513|NCT02099682|DRUG|Lansoprazole|Lansoprazole Capsules 15/ OD Tablets
223606550|NCT02395614|DRUG|triple antibiotic irrigation|"-triple antibiotic solution will contain 1 g of cefazolin, 50,000 U of bacitracin, and. Each patient will receive triple antibiotic solution on one breast and the CHG on the other breast.~80 mg of gentamicin in 500 mL of NS. If the patient is allergic to either component - the allergen will not be used in the solution - to irrigate one breast pocket"
223753624|NCT00165490|PROCEDURE|Surgery|Surgery performed 4-8 weeks after chemoradiation therapy.
223753625|NCT04628312|OTHER|Static footprint|The static footprint will measure the plantar pressures and surface area of the back of the foot, midfoot and forefoot. Subjects were instructed to stand barefoot on the force platform, participants were instructed to remain in a relaxed standing posture with feet shoulder-width apart and positioned 30 degrees from the midline.
223753626|NCT05620576|DRUG|LY3857210|Administered orally
223753627|NCT05620576|DRUG|Placebo|Administered orally
223753628|NCT04702087|DIETARY_SUPPLEMENT|OLEP|omega 3 (500 mg), leucine (2,5 g), probiotic Lactobacillus paracasei PS23
223753629|NCT04702087|COMBINATION_PRODUCT|Placebo|Isocaloric formula
223753630|NCT02755376|BIOLOGICAL|Cartistem(TM)|ACL reconstruction and injection of Cartstem(TM), human cord blood derived mesenchymal stem cell under arthroscopy.
223753631|NCT02755376|BIOLOGICAL|hyaluronic acid|ACL reconstruction and injection of hyaluronic acid under arthroscopy.
223753632|NCT02755376|PROCEDURE|ACL reconstruction only|ACL reconstruction only without any injection under arthroscopy
223753633|NCT02464202|OTHER|stereolithography tooth replica|Tooth replica will be made and used for preparing the receiving tooth socket during autotransplantation
223753634|NCT03817619|DRUG|Zepatier whole tablet|Single-dose ELB/GZR as a whole tablet in a fasted state.
223753635|NCT03817619|DRUG|Zepatier crushed tablet|Single-dose crushed ELB/GZR in a fasted state.
223753636|NCT03367143|DRUG|Lenalidomide|
223753637|NCT03367143|DRUG|Ifosfamide|
223753638|NCT03367143|DRUG|Carboplatin|
223753639|NCT03367143|DRUG|Etoposide|
223753640|NCT02721316|OTHER|Supported with intensive nursing follow post hospitalization|Intensive nursing follow post - hospitalization
223606551|NCT03228212|DEVICE|CONTROL|ACUVUE OASYS
223753641|NCT02262481|DRUG|dydrogesterone|
223753642|NCT02262481|DRUG|placebo|
223753643|NCT01510119|DRUG|Hydroxychloroquine|
223606552|NCT03228212|DEVICE|TEST|senofilcon A with new UV blocker
223606553|NCT04861376|DRUG|Pueraria lobata|The dose of Pueraria lobata granules is one sachet per day, 1.5g per sachet, which equivalent to 15g of the original drug.
223606554|NCT04861376|DRUG|Pueraria thomsoni|The dose of Pueraria thomsoni granules is one sachet per day, 1.5g per sachet, which equivalent to 15g of the original drug.
223606555|NCT04861376|OTHER|Placebo|The placebo group will take the same dose as the other two groups.
223606556|NCT01674777|DRUG|ASP1941|oral
223606557|NCT00030862|DRUG|cisplatin|
223606558|NCT00030862|DRUG|irinotecan hydrochloride|
223606559|NCT06043973|DRUG|almonertinib|The specific treatment regimen is as follows: Non-squamous NSCLC: almonertinib (110 mg/d) plus anlotinib (12mg/d) is started on the first day of each treatment cycle and administered every three weeks until disease progression or intolerable toxicity. Anlotinib was given for two weeks, followed by one week off.
223606560|NCT05247281|DIAGNOSTIC_TEST|Culture-based treatment|Medications to treat prosthetic joint infection will be chosen based on results of traditional cultures alone
223753644|NCT01510119|DRUG|RAD001|
223753645|NCT00355186|PROCEDURE|intracoronary bone marrow cells infusion|"intracoronary bone marrow cell infusion via a OTW balloon; Stop-flow-technique as previously described"
223753646|NCT03721419|DEVICE|High Flow High Humidity device|High Flow High Humidity device has a flow generator built into the body of unit and can deliver flows between 10 to 60 Liters per minute (LPM) with oxygen bled in as needed in order to deliver specified Fraction of inspired Oxygen (FiO2)
223753647|NCT03721419|DEVICE|Low Flow High Humidity device|Standard high humidity trach collar utilizing venturi device bleed in
223753648|NCT02769416|OTHER|Data and sample repository|Subjects with spinal cord and/or traumatic brain injury, family members and healthy volunteers will provide data and samples.
223753649|NCT02029651|DEVICE|E-glove system|Novel rehabilitation system using game for upper extremity rehabilitation for patients with stroke
223753650|NCT02029651|PROCEDURE|Conventional occupational therapy|conventional occupational therapy
223753651|NCT02811939|DRUG|Active Dronabinol|20 mg capsule of Dronabinol will be administered orally
223753652|NCT02811939|DRUG|Active Pregnenolone|1.79 mg/kg of Pregnenolone will be administered sublingually (under the tongue)
223753653|NCT02811939|DRUG|Placebo Dronabinol|Control: Placebo pill (no active cannabinoids) administered orally
223753654|NCT02811939|DRUG|Placebo Pregnenolone|Control: Placebo given sublingually (under the tongue)
223753655|NCT00983554|DRUG|Anastrazole|Arimidex 1mg daily
223753656|NCT00983554|DRUG|Testosterone|Testim 10g daily
223753657|NCT00983554|DRUG|Dutasteride|Avodart 2.5mg daily
224311514|NCT05141331|DEVICE|piezoelectric|Comparing Piezoelectric split-crest technique versus expansion using Hand Driven Ridge Expanders in treatment of Maxillary Narrow Ridges
223606561|NCT05247281|DIAGNOSTIC_TEST|Next Generation Sequencing (NGS) with Culture|Medications to treat prosthetic joint infection will be chosen based results of NGS and culture
223606562|NCT03222401|DRUG|1 mg/kg single infusion of F598|1 mg/kg single infusion of F598
223606563|NCT03222401|DRUG|3 mg/kg single infusion of F598|3 mg/kg single infusion of F598
223606564|NCT03222401|DRUG|10 mg/kg single infusion of F598|10 mg/kg single infusion of F598
223606565|NCT05711472|OTHER|birth ball exercise|birth ball exercise used in childbirth
223606566|NCT00741442|DRUG|RDEA806|Uricosuric agent for the treatment of gout
223753658|NCT00983554|DRUG|GnRH antagonist|Acyline 300 µg/kg subcutaneous injections every 2 weeks
223753659|NCT02622828|BEHAVIORAL|Participant-identified community based activity|The Canadian Occupational Performance Measure (COPM) is a client-centered outcome measure designed to detect changes in performance and satisfaction in occupations that the individual has self-identified as being important and difficult to perform. The COPM will be used to set self-identified, community-based activities as treatment goals.
223753660|NCT01855295|DIETARY_SUPPLEMENT|Protein Supplement|During the treatment phase, study subjects are advised to increase protein intake to 1.2 g/kg/day for 12 weeks. In addition to any protein supplementation the participant is on, supervised supplementation on each dialysis session is provided. Each participant receives 45 grams of liquid protein supplement (Provide Sugar Free produced by Provide Nutrition LC) at each dialysis treatment for additional 12 weeks for total study duration of 24 weeks.
223753661|NCT03171454|PROCEDURE|Delayed Intrauterine Balloon therapy|D-IUB dilatation therapy group will be performed using a (size 12-14fr) Foley catheter and according to the methodology published in the literature. This will be prepared by cutting the catheter tip protruding beyond the balloon. Once the catheter has reached the fundus, 5mls of saline will be slowly instilled into the balloon under ultrasound guidance.
223753662|NCT03171454|PROCEDURE|immediate Intrauterine Balloon therapy|At the conclusion of the surgery, in the immediate balloon group: a Foley-catheter will be immediately inserted into the uterine cavity and the balloon will be distended with 4-5mls of saline under ultrasound guidance and the balloon will stay in situ for 7 days.
223753663|NCT03303833|OTHER|No intervention, observational study.|
224311515|NCT03874286|DIAGNOSTIC_TEST|Liver Transplant|Patients will obtain a research blood draw and a liver biopsy at 4 months and 12 months post transplant. Liver biopsies are routinely performed in the liver transplant population. We will be obtaining a liver biopsy at this particular time point to compare the biopsy results with the peripheral blood results.
223606567|NCT00741442|DRUG|Placebo|Matching Placebo.
223606568|NCT01807299|DIETARY_SUPPLEMENT|Omega 3|Capsules of omega 3, 1000mg / capsules. Administered 3 times a day.
223606569|NCT01807299|OTHER|Physical Training|
223606570|NCT00543335|DRUG|Sorafenib|Starting dose 200 mg PO (by mouth) Daily
223606571|NCT00543335|PROCEDURE|Radiation Therapy|45 Gy total in 15 radiation treatments: 3 Gy per day, 5 days a week for 3 weeks
224311516|NCT06731101|DRUG|Bupivacaine + Lidocaine +dexamethasone|Sonar guided block of Stellate Ganglion By Bupivacaine + Lidocaine
223606572|NCT00630435|DRUG|Premarin®/MPA formulation A|
224311517|NCT06731101|DRUG|Tryptizole + Librax|Tryptizole + Librax
223606573|NCT00630435|DRUG|Premarin®/MPA formulation B|
223606574|NCT00630435|DRUG|Premarin®/MPA formulation C|
223606575|NCT00630435|DRUG|Premarin®/MPA currently marketed product|
223606576|NCT01984918|OTHER|SMS reminder|A text message reminder via Short Message Service (SMS) will be sent to remind subjects 7-10 days before his colonoscopy appointment
223606577|NCT01984918|OTHER|Non-SMS reminder|No Stext message reminder via Short Message Service (SMS) will be sent
223606578|NCT03759691|BEHAVIORAL|Structured interview|Interview contains questions about stroke knowledge and help-seeking behaviour on the day the stroke occured.
223606579|NCT00811174|DRUG|Octagam 10%|300-600 mg/kg every 21 (+/- 3 days) to 28 days (+/- 3 days)
223606580|NCT06230939|OTHER|Examination|"Individual characteristics of the patients (gender, age, height, body weight, marital status, education level, dominant extremity, smoking and alcohol consumption habits, use and type of assistive device, how many years the assistive device has been used) and disease-related (year of diagnosis, disease duration Information (such as CV, family history, medications used, surgeries) will be questioned. HYE and UPDRS will be used for disease staging and grading. PFS-16 will be used to evaluate fatigue and MMSE will be used to evaluate sleep. In addition, Timed Up and Go (TUG) will be applied for lower extremity performance evaluation. All evaluations will be collected in a single meeting using the face-to-face interview method."
223606581|NCT01938040|DRUG|ibuprofen|single preoperative dose prior to surgery
223606582|NCT01938040|OTHER|sugar water/placebo|single preoperative dose prior to surgery
223606583|NCT06202495|DEVICE|Laser and Fluoride|topic application of amino-fluoride gel (Elmex Dental Gel, Colgate-Palmolive company, New York, 300 Park Ave, United States) in association 980nm diode laser (doctor smile wiser by Lambda s.p.a. Via dell'Impresa, 1, 36040 Brendola VI, Italy) 1.5 W, pulsed mode 2 mm from tooth surface
223606584|NCT06202495|OTHER|Fluoride|topic application of amino-fluoride gel (Elmex Dental Gel, Colgate-Palmolive company, New York, 300 Park Ave, United States)
223606585|NCT05589610|DRUG|EQ101|EQ101, 2 mg/kg, once weekly dosing, for a total of 24 doses
223606586|NCT03685227|OTHER|Yoga Nidra|This is a mind/body technique. Specifically, it is a guided meditation, performed while lying down.
223606587|NCT05927844|DRUG|XH-30002 capsule|receive the study drug until the investigator assessed no longer benefit, toxic intolerance, withdrawal of consent, loss of follow-up, or death, whichever occurred first
223606588|NCT05927844|DRUG|Afatiinb tablet|receive the study drug until the investigator assessed no longer benefit, toxic intolerance, withdrawal of consent, loss of follow-up, or death, whichever occurred first
223606589|NCT02607618|DRUG|Iclaprim|Experimental treatment
223606590|NCT02607618|DRUG|Vancomycin|Active comparator
223606591|NCT02720341|DEVICE|ARMin|single sessions of about one hour each
223606592|NCT03168828|DRUG|Trospium-Releasing Intravesical System (TAR-302-5018)|TAR-302-5018 is a passive, nonresorbable trospium-releasing intravesical system whose primary mode of action is the controlled release of trospium into the bladder over a 42-day period.
223606593|NCT00655538|DRUG|Placebo|po daily for 36 weeks
223606594|NCT00655538|DRUG|dalcetrapib|600mg po daily for 36 weeks
223606595|NCT04452630|OTHER|Infectious Disease and Cardiology Clinical Consultations|Infectious Diseases and Cardiology Clinical Consultations at 1 month and 12 months of recovery from an episode of Covid-19
223606596|NCT02451943|DRUG|Olaratumab|Administered IV
223606597|NCT02451943|DRUG|Doxorubicin|Administered IV
223606598|NCT02451943|DRUG|Placebo|Administered IV
223606599|NCT00211016|DRUG|doripenem|
223606600|NCT06322199|BEHAVIORAL|ASSIP (Attempted Suicide Short Intervention Program) flex|"ASSIP is a specific therapy for patients after a suicide attempt. The brief therapy ASSIP consists of 3-4 sessions of approximately 50 min. each. ASSIP flex delivers ASSIP in the patient's personal environment as an outreach home treatment. The structure of the ASSIP is the same as in the regular ASSIP, but the program is delivered in the patient's environment.~Session 1: A narrative interview is conducted, in which the patient is asked to tell her personal story, which led to the suicidal crisis. The narrative is video-recorded.~Session 2: Using video playback of the recorded narrative, patient and therapist explore further details of the suicidal process.~Session 3: A case conceptualization focusing on the patient's vulnerability and the trigger of the suicidal crisis is formulated in writing. A list of safety strategies for the prevention of future suicidal behavior is developed jointly with the patient.~Regular letters are sent to patients over a period of 2 years."
223606601|NCT03148327|DRUG|Durvalumab (MEDI 4736)|Early studies has shown to possibly reduce the growth of certain types of lung cancer
223606602|NCT03148327|RADIATION|Radiotherapy|Stereotactic Body Radiation Therapy (SABR)
223606603|NCT05294913|BEHAVIORAL|Contextualized Wish-Outcome-Obstacle-Plan (WOOP) intervention|This intervention will ask students to identify socio-culturally integrated academic or personal goals, so that students may be able to better strategize obstacle-overcoming to attain their future academic aspirations and modulate negative emotions or environments and associated physiological responses.
223606604|NCT05294913|BEHAVIORAL|Placebo|The placebo control group will receive a 5- to 10-minute online goal-setting video tutorial and confirm that they have completed it by filling out an online check-list.
223606605|NCT01494792|DEVICE|In Vitro Diagnositc aid for diagnosis|
223606606|NCT03351647|BIOLOGICAL|Evaluation of biological predictive factors of clinical response to ustekinumab|The clinical response is defined as a decrease in the Crohn's Disease Activity Index (CDAI) score ≥ 100 points or a decrease in the HBI score ≥ 3 points.
223753664|NCT01735656|DEVICE|Resolute stents|zotarolimus-eluting Resolute stents made by Medtronic Vascular, Inc (http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/DeviceApprovalsandClearances/Recently-ApprovedDevices/ucm294951.htm).
223606607|NCT01003847|DRUG|fenofibrate, fatty acid, placebo|fenofibrate 160 mg, fatty acids 2 gm, placeob 8 weeks of treatment
223606608|NCT00000424|PROCEDURE|Tidal lavage vs. sham lavage of the knee|
223753665|NCT03592433|BEHAVIORAL|I Can PIC|Participants will be shown (on a computer or via email link) a website called I Can PIC. I Can PIC provides health insurance education, suggests ways to learn about the costs of cancer care and follow-up, shows resources to help offset the high costs of care, and helps individuals estimate (based on national data) how much they might spend on health insurance in the upcoming year.
223753666|NCT06197594|OTHER|Proprioceptive neuromuscular facilitation techniques|Proprioceptive neuromuscular facilitation techniques
223753667|NCT06197594|OTHER|Rebound Therapy|Rebound Therapy
223753668|NCT03126994|DEVICE|PhysioWave Cardiovascular Analyzer|Measurement of Pulse Wave Velocity, Pulse Rate, Body Weight and BMI
223753669|NCT03126994|DEVICE|AtCor XCEL PWA & PWV|Measurement of Pulse Wave Velocity and Pulse Rate
223753670|NCT03126994|DEVICE|Detecto SOLO|Measurement of Body Weight and BMI
223753671|NCT02130063|DRUG|iron isomaltoside 1000 (Monofer®)|
223753672|NCT02130063|DRUG|iron sucrose (Venofer®)|
223753673|NCT02780804|DRUG|Entinostat|Given PO
223753674|NCT02780804|OTHER|Laboratory Biomarker Analysis|Correlative studies
223753675|NCT02780804|OTHER|Pharmacological Study|Correlative studies
223753676|NCT05677620|RADIATION|Pharyngeal Computed Tomography|To assess the presence of a possible level/level of collapse, a pharyngeal CT with cephalometry will be performed, and a standard classification system, VOTE, will be used. After obtaining said CT, the dentist will place the recording in MCP and perform a new CT scan of the pharynx with cephalometry and with the MCP recording set intraorally to assess whether this position reduces or eliminates the collapse from UA.
223753677|NCT05677620|DRUG|Drug-Induced Sleep Endoscopy (Propofol)|The DISE technique will be performed by an otorhinolaryngologist (ENT) with a nasopharyngoscope in a operating room. This technique is complemented with bite registration (MCP). Artificial sleep will be induced by intravenous administration of propofol through an infusion system controlled by an anesthesiologist (2.0-3.0 mcg/mL). The following variables will be continuously monitored: electrocardiography, oxygen saturation, and bispectral index (BIS). In this phase of the DISE, the upper airways will be evaluated during sleep with the MCP positioned intra-orally.
223753678|NCT05677620|DEVICE|Mandibular Advancement Device|A duo-block, titratable, and customized MAD (NOA®; Orthoapnea) will be fitted for each patient who starts treatment with MAD. The MAD consists of two CAD/CAM polyamide intraoral devices (one for the upper and one for the lower arch). The adaptation period takes place over one month. After this adaptation, patients will undergo a new PSG using MAD.
223606609|NCT06244667|PROCEDURE|facet median block with prilocain|facet median block with prilocain
223753679|NCT04855643|DEVICE|home-based active tDCS|Anode and cathode electrodes will be placed over the left and right dorsolateral prefrontal cortexes, respectively, with the use of the Omni-Lateral-Electrode system. Caregivers will set up and administer tDCS for participants with ADRD at home. tDCS will be applied for 30 min at an intensity of 2mA, with 30 s ramping up and down. All sessions will be remotely supervised by trained research staff.
223753680|NCT04855643|DEVICE|home-based sham tDCS|For sham stimulation, electric current will be applied only in the first 30s tDCS. All sessions will be remotely supervised by trained research staff.
223753681|NCT00802022|DEVICE|spinal cord stimulation|The intervention is spinal cord stimulation and will be used for 2 weeks trial stimulation. After clinical successful pain relief (50% of more pain reduction)a definite spinal cord system will be implanted.
223753682|NCT01921829|DRUG|Protocolized Diuretic Strategy|"The Protocolized Diuretic Strategy will administer diuretics according to an algorithm based on based on the stepped pharmacologic care arm used by the CARRESS-HF trial investigators. This algorithm targets a relatively aggressive goal diuresis of urine output (UO) 3-5 L/day with diuretics intensified in a stepped fashion using both loop diuretics given by intravenous (IV) bolus followed by IV continuous infusion (furosemide or alternative loop diuretic at equivalent dose), with or without concomitant thiazide diuretic (oral (PO) metolazone or IV chlorothiazide)."
223753683|NCT03621228|DEVICE|MindfulGarden|MindfulGarden (MG) is an interactive digital technology that combines use of a smart television with sensors to intelligently generate content based on patient voice and gesture input, triggering a multi-layered visual 'garden' on-screen to arrest and de-escalate anxiety and aggression in treatment of hospitalized elderly diagnosed with hyperactive delirium.
223753684|NCT01715818|DRUG|Placebo|matching aleglitazar placebo tablet orally daily
223753685|NCT01715818|DRUG|aleglitazar|150 mcg orally daily
223753686|NCT04476030|DRUG|SAGE-217|Oral capsules
223606610|NCT06244667|PROCEDURE|facet median block with lidocaine|facet median block with lidocaine
223606611|NCT02420704|PROCEDURE|Embryo transfer|For fresh cycles, embryos were transferred 3-5 days after oocyte retrieval; For frozen thawed cycles, embryos were transferred 3-5 days after starting to use progesterone based on the stage of cryopreservation.
223606612|NCT01793766|DEVICE|Brain modulation|Brain modulation using Eldith/Neuroconn transcranial Direct Current Stimulation device
223606613|NCT01793766|DEVICE|Sham modulation|
223753687|NCT04476030|DRUG|Matching Placebo|Oral capsules
223753688|NCT04476030|DRUG|Sertraline|Oral tablets
223753689|NCT04476030|DRUG|Escitalopram|Oral tablets
223753690|NCT04476030|DRUG|Citalopram|Oral tablets
223753691|NCT04476030|DRUG|Duloxetine|Oral capsules
223753692|NCT04476030|DRUG|Desvenlafaxine|Oral tablets
223606614|NCT05813457|OTHER|PRESTO Early Identification Program|"The program combines :~1. A population-based information component (information campaign aimed at the general population).~2. A training component for the LPAs (Front Line Actors: general practitioners, school and university medicine, pharmacists, teenagers school and university medicine, pharmacists, teenagers' homes, association networks, SAMU, firemen, etc.).~3. Facilitated access to care for FPE patients in the form of a pivot mobile team that can directly meet the patient at the request of the LPA, initiate care and ensure the relay within a the relay within 4 weeks to the existing specialized psychiatric structures on the site (CMP, CATTP (CMP, CATTP, day hospital, hospitalization unit, child and adolescent psychiatry services) adolescent psychiatry services)"
223606615|NCT02029911|DEVICE|Aurora Endometrial Ablation System|Ablation of the endometrial lining of the uterus using the Aurora System
223606616|NCT02857608|DRUG|Lymphoseek|
223606617|NCT03785704|DRUG|Xinmailong Injection|Xinmailong injection is extracted, separated, purified and refined from Periplaneta americana. It is the second class of new drugs and the only small molecular bioactive peptide preparation approved by the State Pharmaceutical Administration (P.R.China) for the prevention and treatment of heart failure. Its main constituents include complex nucleoside bases and binding amino acids.
223606618|NCT01002651|DIETARY_SUPPLEMENT|wheat bran extract|soft drink comprising high WBE dose and natural flavor and coloring agent, ingestion after breakfast and after dinner
224075437|NCT06221020|DEVICE|TIB Olfactory Test Device|Olfactory testing is conducted on patients undergoing pituitary tumor surgery via nasal endoscopy using the TIB Olfactory Test Device (TIBSIT). This testing aims to compare olfactory (sense of smell) outcomes before and after the surgery. The olfactory tests are performed preoperatively and then again at the 3-month postoperative mark to assess any changes or impacts on the sense of smell due to the surgery.
224075438|NCT06221020|DIAGNOSTIC_TEST|Apfel Score for Postoperative nausea and vomiting|"Nausea and Vomiting Risk Scale: Apfel Score~Risk Factors: Female; Smoking habit; History of postoperative nausea and vomiting or motion sickness; Use of opioid painkillers post-surgery (Each risk factor scores 1 point; minimum score is 0; maximum score is 4)~Score Probability of Postoperative Nausea and Vomiting~0 - 10%~1. \- 21%~2. \- 39%~3. \- 61%~4. \- 79%"
224200703|NCT03356431|OTHER|Supervised group exercise|"* Quadriceps muscle isometric contraction in sitting position 1 set of 3-3 reps × 1 min hold.~* Isotonic quadriceps contraction with resistance band 3 sets of 10 reps x 1min hold.~* Isotonic hamstring contraction with resistance band 3 sets of 10 reps x 1min hold.~* Sit to stand exercise during 1 min.~* Dynamic stepping exercise (walking up and down one step/stair during 1 min).~* Standing calf stretch 3 x 20 sec.~* Standing quadriceps stretching 3 x 20 sec.~* Supine hamstring stretching 3 x 20 sec."
223606619|NCT01002651|DIETARY_SUPPLEMENT|placebo|soft drink with natural flavor and coloring agent, without WBE, ingestion after breakfast and after dinner
223606620|NCT00483470|BIOLOGICAL|Hepatitis A vaccine AVAXIM 80U|0.5 mL, Intramuscular
223606621|NCT00483470|BIOLOGICAL|Hepatitis A vaccine (HAVRIX 720)|0.5 mL, Intramuscular
223606622|NCT03373149|DRUG|Growth hormone/HPuFSH/GnRH antagonist|"Growth hormone (Somatropin, Sedico, Egypt) \[4 IU/day\] and highly purified urinary FSH (HPuFSH) (Fostimon,IBSA, Switzerland) \[300 IU/day\] will be started on cycle day 3 and will be continued until and including the day of human chorionic gonadotropin (HCG) administration. Starting from cycle day 8, the dose of HPuFSH will be adjusted individually according to ovarian response which will be monitored using transvaginal ultrasound and serum estradiol (E2).~GnRH antagonist (Cetrorelix acetate) (Cetrotide; Serono International S.A., Geneva, Switzerland) 0.25 mg S.C. once daily will be started when the leading follicle is 14 mm in mean diameter and will be continued until and including the day of HCG administration."
223618276|NCT00821652|DRUG|NY-ESO-1 protein; Montanide ISA®-51 VG; Resiquimod|Part I: a cohort of 3 patients to receive a subcutaneous vaccination of 100µg NY-ESO-1 protein emulsified in 1.25mL Montanide ISA®-51 VG (day 1) followed by topical resiquimod 1000 mg of the 0.2% gel on days 1, and 3. If no DLT observed, we will proceed to cohort 2 with Resiquimod dosing on days 1,3 and 5. If DLT is found in the second cohort, the trial will proceed to Part II; with the limited dosing for days 1 and 3 only, as used in the first cohort. If no DLT is found in second cohort, the trial will proceed to Part II with Resiquimod dosing for days1, 3 and 5.
223618277|NCT00821652|DRUG|NY-ESO-1 protein; Montanide ISA®-51 VG; Resiquimod/placebo|Part II: Eligible patients will be randomized to receive a subcutaneous vaccination of 100µg NY-ESO-1 protein emulsified in 1.25mL Montanide ISA®-51 VG (day 1) followed by topical placebo gel (Arm A) or topical resiquimod gel (Arm B) on days 1, 3 and 5; or resiquimod dosing regimen established in Part I. The cycles will be repeated every 3 weeks for a total of 4 cycles (on Study week 1, 4, 7 and 10). All procedures may occur within + 3 days of the planned date.
223618278|NCT05548946|OTHER|PID-5-BF+M and LPFS-BF 2.0 (self-report questionnaires)|"All participants will be asked to fill in the PID-5-BF+M and the LPFS-BF 2.0 to examine personality disorders as defined by the AMPD and ICD-11.~PID-5-BF+M consists of 36 self-report items. It has 18 facet scales and 6 domain scales (Anankastia, Negative Affectivity, Antagonism, Disinhibition, Psychoticism and Detachment).~The LPFS-BF 2.0 has 12 items, measuring 4 domains of personality functioning (identity, intimacy, self-direction and empathy)."
223618279|NCT05548946|OTHER|Secondary Questionnaires (self-report and informant questionnaires)|"The patients fill in a standard test battery during the first weeks of their admission in the institutions, including questionnaires and interviews. The research team will analyze the results retrospectively.~This includes:~YSQ- SF16 (Young \& Brown, 1994; Pauwels et al., 2018) GPS (van Alphen et al., 2006) HoNOS 65+ (Burns et al., 1999) HAP 2.0 (Barendse \& Thissen, 2006) SCL-90-R (Derogatis, 1983; Dutch version: Arrindell, \& Ettema, 1975, 1986, 2005) ADP-IV (Schotte \& De Doncker, 1998) CERQ (Garnefski et al., 2007) UCL (Scheurs et al., 1994; 1988) BIS/BAS Scales (Carver \& White, 1994) EC Scale of the ATQ (Rothbart et al., 2000) BSI (Derogatis, 1975; Dutch version: Beurs, 2008) SIPP-SF (derived from the SIPP-118; Verheul et al., 2008) SMI (Young et al., 2008) WHO-5 (Dutch version: WHO, 1998) SQ3-SF (Young \& Brown, 2005) SCID-5-P (First et al., 2017; Dutch translation: Arntz et al., 2017)"
223753693|NCT03395366|OTHER|Multifaceted Educational / Cognitive Behavioral Intervention|The intervention includes 8 to 12 one-on-one sessions over a 12-week period, run by a licensed social worker (LSW) with experience delivering therapy. Curriculum will introduce education relevant for self-management and consists of prepared slides, handouts \& worksheets. The education was designed based on slides developed and published online by the national kidney foundation and the national kidney disease education program. The curriculum was designed to be understandable by all potential subjects, including those with low literacy levels. Sessions will incorporate behavior-based activities designed to deliver education about and improve upon medication adherence, diet, exercise, and coping. These activities, based around CB strategies such as cognitive restructuring and behavior shaping, will include review of self-management logs, goal setting, creation of treatment plan, problem-solving techniques, reinforcing techniques, and coping with ESRD.
223753694|NCT05159245|DRUG|Alectinib|ALK
223753695|NCT05159245|DRUG|Cobimetinib|MEK1, MEK2
223606623|NCT03373149|DRUG|HPuFSH/GnRH antagonist|"Highly purified urinary FSH (HPuFSH) (Fostimon,IBSA, Switzerland) \[300 IU/day\] will be started on cycle day 3 and will be continued until and including the day of human chorionic gonadotropin (HCG) administration. Starting from cycle day 8, the dose of HPuFSH will be adjusted individually according to ovarian response which will be monitored using transvaginal ultrasound and serum estradiol (E2).~GnRH antagonist (Cetrorelix acetate) (Cetrotide; Serono International S.A., Geneva, Switzerland) 0.25 mg S.C. once daily will be started when the leading follicle is 14 mm in mean diameter and will be continued until and including the day of HCG administration."
223606624|NCT00825188|DRUG|eplerenone, amlodipine|Eplerenone 25mm qd versus amlodipine 5mg qd x 4weeks the Eplerenone 50mg qd versus amlodipine 10mg qd x 4weeks
223606625|NCT00825188|DRUG|eplerenone|Eplerenone 25-50mg daily x 8 weeks
223606626|NCT00825188|DRUG|eplerenone|eplerenone 25- 50 mg daily for 8 weeks
223606627|NCT00825188|DRUG|amlodipine|amlodipine 5-10mg daily for 8 weeks
223606628|NCT00040170|BIOLOGICAL|MVA-MUC1-IL2|
223606629|NCT05155813|DEVICE|WatchPAT|FDA-approved portable home sleep testing device worn on the wrist.
223606630|NCT03113994|DRUG|Rosuvastatin Calcium|10mg Rosuvastatin, daily for 12 months
223606631|NCT03113994|DRUG|Placebo Oral Tablet|Placebo, daily for 12 months
223606632|NCT03113994|DIETARY_SUPPLEMENT|Coenzyme Q10|100mg CoQ10, daily for 12 months
223606633|NCT03113994|DIETARY_SUPPLEMENT|Calcium Carbonate|1250mg Calcium Carbonate, daily for 12 months
223606634|NCT03113994|DIETARY_SUPPLEMENT|Vitamin D|2000IU Vitamin D, daily for 12 months
223606635|NCT03202342|OTHER|Water|Water, 300 ml, at room temperature
223606636|NCT03202342|OTHER|Glucose|Water containing 50 g glucose, 300 ml, at room temperature
223606637|NCT03202342|OTHER|Ethyl butyrate|Water containing ethyl butyrate (pineapple flavour) 300 ml, at room temperature
223606638|NCT03202342|OTHER|Glucose + ethyl butyrate|Water containing 50 g glucose and ethyl butyrate (pineapple flavour) 300 ml, at room temperature
223753696|NCT05159245|DRUG|Vismodegib|Hedgehog
223753697|NCT05159245|DRUG|Trastuzumab+Pertuzumab|HER2
223753698|NCT05159245|DRUG|Entrectinib|NTRK/ ROS1, ALK
223753699|NCT05159245|DRUG|Atezolizumab|PD-L1
223753700|NCT05159245|DRUG|Vemurafenib|BRAF V600
223753701|NCT05159245|DRUG|Regorafenib|KIT/BRAF, RET
223753702|NCT05159245|DRUG|Apalutamide|AR
223753703|NCT05159245|DRUG|Abemaciclib|CDK4/6
223606639|NCT03202342|OTHER|Glucose + ethyl butyrate 0 C|Water containing 50 g glucose and ethyl butyrate (pineapple flavour) 300 ml, at 0 degrees centigrade
223606640|NCT03594682|OTHER|Intervention/treatment|"experimentalgroup initial dose：~1. 250mg qod~2. 250mg qd/500mg qd by turn~3. 500mg qd control group： 750mg qd"
223606641|NCT06504810|OTHER|light|light level
223606642|NCT01101035|DRUG|Febuxostat|Febuxostat tablets
223606643|NCT01101035|DRUG|Allopurinol|Allopurinol tablets
223606644|NCT00210782|DRUG|topiramate, phenytoin|
223606645|NCT06337695|BIOLOGICAL|Vedolizumab|300 mg IV at weeks 0, 3, 6, 14, and 22
223606646|NCT06337695|BIOLOGICAL|Placebo|300 mg IV at weeks 0, 3, 6, 14, and 22
223606647|NCT02802839|DEVICE|Virtual Reality|
223753704|NCT05159245|DRUG|Tepotinib|MET ex14
223753705|NCT05159245|DRUG|Dabrafenib|RAF
224075439|NCT06221020|DIAGNOSTIC_TEST|The American Society of Anesthesiologists (ASA) Physical Status Classification|"ASA I: A normal, healthy patient with no systemic disease. ASA II: A patient with mild systemic disease. ASA III: A patient with severe systemic disease that limits activity but is not incapacitating.~ASA IV: A patient with severe systemic disease that is a constant threat to life.~ASA V: A moribund patient not expected to survive without the operation. This project involves collecting data from adult patients aged 20 to 75 years old who are classified as ASA I to III grade."
223606648|NCT00226057|DRUG|Raptiva|Open Label
223606649|NCT01694381|DRUG|M5|single point mutant of serine protease prourokinase
223606650|NCT01694381|DRUG|C1-inhibitor|a protease inhibitor belonging to the serpin superfamily.
223606651|NCT06063694|DEVICE|Synthetic electrospun fiber matrix|Electrospun fiber matrices have long been investigated as an innovative construct for use in tissue engineering and regenerative medicine research due to their ability to mimic the structure and scale of native tissue. Clinical studies have demonstrated clinical efficacy in treating both chronic and acute wounds. There is strong evidence to support the application of a synthetic electrospun fiber matrix will generate favorable wound healing and reduce infection rates when used to augment transmetatarsal amputation.
223606652|NCT00890747|DRUG|sunitinib malate|Given PO
223606653|NCT00890747|OTHER|pharmacological study|Correlative studies
223753706|NCT05159245|DRUG|Trametinib|MEK1, MEK2
223753707|NCT05159245|DRUG|Dabrafenib+Trametinib|RAF, MEK1, MEK2
223753708|NCT05159245|DRUG|Pemigatinib|FGFR2
223753709|NCT04411342|DIAGNOSTIC_TEST|Albumin creatinine ratio|normal range of albumin in urine in patients with type 2 diabetes
223753710|NCT00445510|DRUG|GSK256066|
223606654|NCT00890747|OTHER|laboratory biomarker analysis|Correlative studies
223606655|NCT03558919|DRUG|Mirabegron 25mg|
223606656|NCT03558919|DRUG|Solifenacin Succinate 5 MG|
223606657|NCT03157375|DEVICE|Intraocular Lens Implantation|
223606658|NCT06835647|DEVICE|Investigational Fetal Monitor|Investigational Fetal Monitoring Device Device is a multi-parameter maternal fetal monitor that is intended to monitor, store, display, transmit, and generate alarms for non-invasive and invasive clinical parameters of pregnant women and fetuses (singleton and twin), during the antepartum, intrapartum, and postpartum period.
223606659|NCT06835647|DEVICE|Ultrasound Imaging Device|The Ultrasound imaging device is a general-purpose diagnostic ultrasound system for use in measurement, display and analysis of the human body and fluid.
223606660|NCT00776854|DEVICE|Noveon laser|870 and 930nm wavelengths
223606661|NCT01172626|DRUG|valproate sodium|oral administration,15-30mg/kg,daily
223606662|NCT01172626|GENETIC|Polymorphism Analysis|Analysis of genetic polymorphisms of the drug metabolic enzymes involving in the deactivation and elimination of Valproate sodium
223606663|NCT01172626|OTHER|Pharmacokinetic analysis|laboratory analysis of concentration of Valproate sodium and 4-ene-Valproate in plasma
223606664|NCT00277771|BEHAVIORAL|Standard behavioral treatment (SBT) for weight loss|Participants attend group sessions where they learn about healthy eating and exercise. They are asked to self-monitor all calories consumed (food and drink) and all calories expended through exercise. Standard paper diaries are used for self-monitoring.
223606665|NCT00277771|BEHAVIORAL|SBT for weight loss using a PDA|Participants attend group sessions where they learn about healthy eating and exercise. They are asked to self-monitor all calories consumed (food and drink) and all calories expended through exercise. Personal Digital Assistants (PDAs) are used for self-monitoring.
223606666|NCT00277771|BEHAVIORAL|SBT for weight loss using a PDA with feedback messages|Participants attend group sessions where they learn about healthy eating and exercise. They are asked to self-monitor all calories consumed (food and drink) and all calories expended through exercise. Personal Digital Assistants with a customized feedback program are used for self-monitoring.
223606667|NCT01681160|OTHER|procedure:maggot therapy|each times in maggot therapy continued for three days.wound assessment was done before and after any intervention
223753711|NCT04945434|DEVICE|S53P4 bioactive glass (BonAlive)|Surgical implantation of S53P4 in a bone defect created during debridement for chronic osteomyelitis.
223753712|NCT05455983|BIOLOGICAL|covid19 vaccines|different types of (COVID-19) vaccination
223753713|NCT05439356|DRUG|Colchicine|Oral colchicine will be initiated with a dose of 1mg per day (one tablet of 0.5mg initially followed by another tablet of 0.5 mg at least four hours later) on days 1 through 3, and continuing with 0.5 mg (one tablet) per day on days 4 through 90.
223753714|NCT05439356|DRUG|Placebo colchicine|Oral placebo colchicine will be initiated with a dose of 1mg per day (one tablet of 0.5mg initially followed by another tablet of 0.5 mg at least four hours later) on days 1 through 3, and continuing with 0.5 mg (one tablet) per day on days 4 through 90.
223753715|NCT05526872|OTHER|Best Practice|Receive usual care
223753716|NCT05526872|BEHAVIORAL|Health Education|Receive educational materials
223606668|NCT01681160|OTHER|conventional therapy|patients receive ordinary treatment for diabetic foot
223753717|NCT05526872|OTHER|Interview|Ancillary studies
223753718|NCT05526872|OTHER|Planned Notification|Receive planned reminders to schedule mammogram
223606669|NCT06237959|DIETARY_SUPPLEMENT|Keranat™|300 mg/capsule(proso millet and wheat extract 600 mg/day)
223606670|NCT06237959|DIETARY_SUPPLEMENT|placebo|300 mg/capsule(600 mg/day as placebo)
223606671|NCT04058041|PROCEDURE|Neural Mobilization|neural exercise Will be performed in the patients
223606672|NCT04058041|PROCEDURE|Surgery|open or endoscopic surgery will be permed in the patients with tunnel carpal syndrome
223606673|NCT04058041|PROCEDURE|Surgery and neural mobilization|following the surgery patients will be treat with neural mobilization exercises.
223606674|NCT05374239|OTHER|Multi-component implementation intervention|The multiple-component implementation intervention will comprise of 3 key components: (1) education, (2) operational process, and (3) audit and feedback
223606675|NCT00681629|DRUG|Quetiapine XR|400-800 mg, oral, bid
223606676|NCT00681629|OTHER|Integrated Care Program (ICP)|Integrated care program (ICP), this is a legally based integrated care program covered by a contract according to §§ 140 a-d SGB-V (SGB: social security code); The ICP is not exclusively designed for this phase IV trial. Participation in the ICP is possible anytime for each patient in whom the services are covered by the individual health insurance.
223606677|NCT03160339|BIOLOGICAL|PXVX0047 Vaccine|PXVX0047 is a live Adenovirus Type 4 (Ad4) / Adenovirus Type 7 (Ad7) vaccine for single-dose oral administration. The Ad4 and Ad7 strains in PXVX 0047 are unattenuated strains propagated in A549 human adenocarcinomic alveolar basal epithelial cells.
223753719|NCT05526872|OTHER|Survey Administration|Ancillary studies
223753720|NCT03015051|DRUG|Oxygen|
223753721|NCT05994729|DIAGNOSTIC_TEST|Invasive Physiological Assessment of Coronary Circulation|After 2 months long rule-in phase required to exclude the unsuitable patients, study population will undergo RDN as indicated to treat resistant or difficult to control hypertension; 12 months after RDN, they will undergo invasive physiological study, comprehensive of Coronary Flow Reserve, Index of Microvascular Resistance, Mean Transit Time. These data will be then compared to the baseline ones obtained during the screening phase.
223753722|NCT06273176|PROCEDURE|Awake mapping under local anesthesia|During an awake craniotomy, the patient is awake and cooperative during the resection of the tumor while the surgeon uses electro(sub)cortical mapping to prevent damage to eloquent areas.
223753723|NCT06273176|PROCEDURE|Asleep mapping under general anesthesia|During asleep mapping under general anesthesia, the surgeon uses electro(sub)cortical mapping with evoked potentials (MEPs, SSEPs or continuous dynamic mapping) to prevent damage to eloquent areas.
223753724|NCT06273176|PROCEDURE|Resection under general anesthesia without mapping|During resection under general anesthesia without mapping, the surgeon does not use any intraoperative stimulation mapping techniques to identify eloquent areas.
223753725|NCT05369910|BEHAVIORAL|Light exposure (Flash)|Light exposure (Flash) is administered for one hour on 7 consecutive days. During the light exposure, participants are seated 120 cm in front of a white curtain that is illuminated by an LED light source (Dawe stroboscope type 1214B, 5 Hz).
223753726|NCT05369910|BEHAVIORAL|Light deprivation (Dark)|Light deprivation (Dark) is administered for one hour on 7 consecutive days. During the Dark intervention, participants are seated in a room in complete darkness.
223606678|NCT03160339|BIOLOGICAL|Teva Ad4/Ad7 Vaccine|Teva Ad4/Ad7 is a live Adenovirus Type 4 (Ad4) / Adenovirus Type 7 (Ad7) vaccine for single-dose oral administration. The Ad4 and Ad7 strains in Teva Ad4/Ad7 are unattenuated strains propagated in WI-38 human diploid fibroblast cells.
223606679|NCT02588235|DRUG|Ezetimibe and Atorvastatin|atorvastatin (20 mg/day）plus ezetimibe（10 mg/day）
223606680|NCT02588235|DRUG|Atorvastatin|atorvastatin (20 mg/day）
223606681|NCT01764711|DRUG|Cosyntropin administration|After 30 minutes of rest in the seated position, participants will be given cosyntropin intravenously. Blood samples will be taken 30 minutes pre-drug administration, 30 minutes post and 60 minutes post drug administration.
223606682|NCT00002092|DRUG|Cimetidine|
223606683|NCT00031473|DRUG|Virazole (Ribavirin) Inhalation Solution|
223606684|NCT05089643|DRUG|Anlotinib|Before breakfast, anlotinib hydrochloride capsule was taken on an empty stomach, once a day, 1 tablet (10mg) each time.Continuous oral administration for 2 weeks stopped for 1 week, that is, 3 weeks (21 days) as a treatment cycle, until disease progression or adverse reactions become intolerable.In case of missing medication, confirm that the time before the next medication is less than 12 hours, no refill.
223753727|NCT00002882|BIOLOGICAL|Aldesleukin (IL-2)|Infusion for a total of 96 hours on days 1-4
223606685|NCT05089643|DRUG|Capecitabine|Capecitabine tablets 1000 mg/m2, twice a day, within 30min after meals, were taken orally for 2 consecutive weeks and stopped for 1 week, i.e., 3 weeks (21 days) as a treatment cycle until disease progression or adverse reactions became intolerable.
223606686|NCT01186302|OTHER|Type of provider|Different types of clinicians have different types of medical training. This study tested whether midlevel providers were as safe and effective in administering medical abortion as doctors. All types of providers underwent the same training in medical abortion and used the same medical abortion regimen.
223606687|NCT04403451|BEHAVIORAL|True North|Love Notes, Financial Stability, Jobs
223753728|NCT00002882|BIOLOGICAL|Recombinant Interferon Alfa (IFN-A)|"IFN-A Therapy Groups:~Schedule A: IV IFN-A induction 5 times a week for 4 weeks followed by subcutaneous IFN-A maintenance 3 times a week for 48 weeks.~Schedule B: Subcutaneous IFN-A 3 times a week for 52 weeks~Adjuvant Biochemotherapy Group: IFN-A is given subcutaneously on days 1-5"
223753729|NCT00002882|DRUG|Cisplatin|IV Days 1-4
223753730|NCT00002882|DRUG|Dacarbazine|IVPB on day 1
223753731|NCT00002882|DRUG|Vinblastine|IVPB on days 1-4
223753732|NCT00002882|PROCEDURE|Adjuvant Therapy|Patients receiving adjuvant radiotherapy will start adjuvant systemic therapy within 8 weeks from lymphadenectomy and a week after completion of and recovery from radiotherapy.
223753733|NCT01542515|PROCEDURE|Meniscal allograft arthroplasty of the carpometacarpal joint of the thumb|"The surgical procedure will involve the use of human meniscal allograft tissue that will be provided by industry. The meniscus will be contoured into a T shape. The T-shaped meniscus allograft is then inserted into the arthritic thumb CMC joint and secured with two suture anchors."
223753734|NCT02927028|OTHER|Chewing|"On the first visit, the random nut treatments will include chewing walnuts, almonds and pistachios. The chewing conditions will include: 1) 5 g nuts alone, 2) 5 g nuts with 5 ml water, 3) 5 g nuts with 5 ml apple juice, 4) 5 g nuts with 5 g plain yogurt, 5) 5 g nuts with 5 g sweet yogurt.~On visits 2 and 3 the treatments of either 28 g of walnuts or walnut butter will be presented."
223753735|NCT02646696|OTHER|Sensory Challenge Protocol|Measurement of electrodermal activity in response to sensation
223753736|NCT04377607|OTHER|File scanning|RBC, HGB, HCT, MCH, MCV, MCHC, WBC values will be noted in the hemogram test performed at the time of initial admission
224200704|NCT03356431|OTHER|Home-based exercise|"* Quadriceps muscle isometric contraction in sitting position 1 set of 3-3 reps × 1 min hold.~* Isotonic quadriceps contraction with resistance band 3 sets of 10 reps x 1min hold.~* Isotonic hamstring contraction with resistance band 3 sets of 10 reps x 1min hold.~* Sit to stand exercise during 1 min.~* Dynamic stepping exercise (walking up and down one step/stair during 1 min).~* Standing calf stretch 3 x 20 sec.~* Standing quadriceps stretching 3 x 20 sec.~* Supine hamstring stretching 3 x 20 sec."
224200705|NCT01320176|BIOLOGICAL|Investigational HIV vaccine dose A|The vaccine will be administered by intramuscular route into the deltoid muscle preferentially of the non dominant arm at Month 0 and Month 3
224314247|NCT02546466|PROCEDURE|Functional Star-shape taping (SFT)|For the SFT procedure, four tapes will be applied in the form of an elastic ''I'' with the aim of facilitating muscle activation. The taping will be applied when the participant is in a seated position. The taping will be positioned covering the entire lumbar region and lower part of the thoracic region (T11, T12), and placed first at the center and then on the ends (Castro-Sanchez et al. 2012).The tension of the taping was 25%, this protocol being recommended by the Kinesio taping manual to facilitate muscle activation (Castro-Sanchez et al. 2012; Kase et al. 2003). The participant will remain for on week with FT.
223606688|NCT05921435|DRUG|CKD-341, D958|A single dose of 1tablet under fasting condition
223606689|NCT01793623|OTHER|atrial tissue|retrieval of discarded atrial tissue
223606690|NCT05531981|OTHER|detect HPV E7 ctDNA|Peripheral blood was collected from the patients, and the copy number of HPV E7 gene in ctDNA was accurately detected by ddPCR
223606691|NCT01285934|BIOLOGICAL|Autologous Hematopoietic Stem Cell Transplantation|All participants randomized to the transplant arm wil undergo Autologous Hematopoietic Stem Cell Transplantation
223606692|NCT01285934|DRUG|intensive insulin therapy|The control arm will be either CSII via an insulin pump or intensive subcutaneous insulin therapy with multiple insulin injections (at least 4/day) utilizing a long acting background insulin and pre-meal rapid acting insulin.
223606693|NCT00681889|DRUG|Ranibizumab|10 Patients will receive treatment (Ranibizumab)
223606694|NCT03275324|DEVICE|Capnostream20p|Observational study of patients connected to the Capnostream20p monitor.
223606695|NCT06351449|OTHER|The patch under study is photographed using the SkinCam®|Unlike standard care, the patch under study is photographed using the SkinCam® and not a standard camera. The shooting and photographic remain similar to that of standard care, with only the camera used being changed.
223606696|NCT05547568|PROCEDURE|Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy|
223753737|NCT01421784|OTHER|cine MRI|Rapid Cine-MRI for Monitoring Moving and Deforming Tumors
223606697|NCT04257526|BEHAVIORAL|Diet and lifestyle advice following a positive FIT test and diagnostic colonoscopy.|Participants will be recruited during CRC screening and will be included if they have a positive faecal immunochemical test (FIT) and are diagnosed with adenomas but are CRC negative during the colonoscopy. Participants receive evidence-based diet and lifestyle advice intervention with 'usual care'.
223606698|NCT05726006|OTHER|No Intervention in This study|No Intervention in This study
223606699|NCT01717872|DEVICE|Laryngoscope blade|The POGO score will be used to assess the percent of the glottis that can be seen with each of the blades lifting and not lifting the epiglotis
223606700|NCT04627155|DRUG|LY03003|Rotigotine,extended-release microspheres
223606701|NCT02214290|DRUG|Caffeine|A 200 mg caffeine tablet was given to subject to examine the drugs effect on arterial function.
223606702|NCT02214290|DRUG|Placebo|A 750 mg placebo capsule (maltodextrin) was given to subjects to examine the effect of the drug on arterial function.
223606703|NCT02214290|DIETARY_SUPPLEMENT|L-citrulline|L-citrulline was used to examine the effect of the supplement on arterial function.
223606704|NCT05159518|DRUG|PRT2527|PRT2527 will be administered by intravenous infusion
223606705|NCT01615016|OTHER|Minimally invasive endotracheal surfactant application|"What are the planned trial interventions?~1. MISurf: Minimally invasive intratracheal surfactant application without mechanical ventilation by feeding tube device~2. InSurE: Surfactant application by InSurE strategy (Intubation - surfactant - extubation sequence).~Both interventions will be performed by intervention teams. For the MISurf intervention, it was decided to use the minimally invasive method via feeding tube exclusively due to concerns about possibility of airway injury with the iv cannula device.~Surfactant Two porcine derived surfactant products have been used in the published trials for minimal invasive surfactant application, Curosurf© and Survanta©. Due to safety reasons we will use these products also in our pilot study however, only the latter is currently available in Canada. Hence we will use Survanta© 100 mg/kgBW, equivalent to 4 ml/kgBW per dose.19,20,26"
223606706|NCT06023706|DRUG|Capsaicin 179 Mg Cutaneous Patch|1 patch applied once for 1 hour
223753738|NCT01277939|BEHAVIORAL|Therapeutic Education System (TES)|Therapeutic Education System (TES) is an interactive, computer-based, psychosocial treatment program. TES is theoretically grounded in evidence-based psychosocial treatments (Community Reinforcement Approach and Cognitive Behavioral Therapy).
223753739|NCT01277939|BEHAVIORAL|Standard Care|Psycho-educational and psycho-social approaches to substance use disorders (commonly offered in prison settings) delivered by counselors in group formats.
224314248|NCT02546466|PROCEDURE|Sham Functional Taping (Sham-FT)|For the Sham-FT procedure, a single bandage 20 cm in length was positioned horizontally, passing through the spinous process of the second lumbar vertebra (Castro-Sanchez et al. 2012). The tension of the taping was 25%, this protocol being recommended by the Kinesio taping manual to facilitate muscle activation (Castro-Sanchez et al. 2012; Kase et al. 2003). The participant will remain for on week with FT.
223606707|NCT06023706|DRUG|Capsaicin low concentration patch (capsaicin 0,04%, 3,2 mg/cm2)|1 patch applied once for 1 hour
223606708|NCT01510158|DRUG|Lesinurad|Tablets, 200 mg once daily (qd)
223606709|NCT01510158|DRUG|Lesinurad|Tablets, 400 mg qd
223606710|NCT01510158|DRUG|Placebo|Tablets, Placebo qd
223606711|NCT01510158|DRUG|Allopurinol|Tablets, ≥ 300 mg QD (≥ 200 mg qd for subjects with moderate renal impairment)
223606712|NCT01510158|DRUG|Allopurinol|Tablets, ≥ 300 mg QD (≥ 200 mg qd for subjects with moderate renal impairment)
223606713|NCT01510158|DRUG|Allopurinol|Tablets, ≥ 300 mg QD (≥ 200 mg qd for subjects with moderate renal impairment)
223606714|NCT05303818|DRUG|Rivaroxaban 10 MG|Patients in post-operative colonic cancer will receive rivaroxaban 10mg/daily for 28 days after surgery
223606715|NCT06514001|DRUG|AMDX-2011P|AMDX-2011P single bolus injection intravenous for diagnostic review
223606716|NCT01067274|DRUG|Vesanoid (ATRA)|45 mg/m2/day in two divided doses from D8 to D28
223606717|NCT01067274|DRUG|AZACITIDINE (VIDAZA)|75 mg/m2/12h SC from D1 to D5
223606718|NCT01067274|DRUG|CYTARABINE|Cytarabine : 60 mg/m2/12h SC from D1 to D5
223606719|NCT00068614|BIOLOGICAL|HER-2/neu peptide vaccine|
223606720|NCT03782701|DRUG|Brimonidine tartrate ophthalmic solution 0.025%|One time dosing of brimonidine tartrate ophthalmic solution 0.025% (1 drop applied to ocular surface)
223606721|NCT03782701|OTHER|Sterile balanced saline solution|One time dosing of sterile balanced saline solution (1 drop applied to ocular surface)
223606722|NCT04593758|DRUG|CPI-613 + Hydroxychloroquine|"dosing regimen was 600mg hydroxychloroquine PO followed 2 hours later by 2,000 mg/m2 of CPI-613 by central IV infusion over 2 hours followed by 600 mg hydroxychloroquine PO 12 hours following the initial dose daily on days 1 through 5 of every 28 days.~Starting dose of 80% of the maximum tolerated (MTD) identified in patients ≥ 45 kg for patients \< 45 kg"
223606723|NCT04542954|OTHER|Optimized Management of Covid-19 Positive Kidney Transplant Recipients: Single Center Experience from the Middle East|Optimized Management of Covid-19 Positive Kidney Transplant Recipients: Single Center Experience from the Middle East
223606724|NCT03545438|BIOLOGICAL|LIB003|LIB003 or placebo
223606725|NCT04633382|COMBINATION_PRODUCT|Enhanced recovery after biliary tract surgery|Patients with malignant and benign diseases of the bile ducts, who have formed various types of anastomosis in two options for managing the postoperative period: traditional and based on the principles of enhanced recovery after surgery
223606726|NCT04770038|BEHAVIORAL|Dialectical Behavior Therapy (DBT)|Evidence-based psychotherapy for the treatment of Borderline Personality Disorder
223753740|NCT03225612|DEVICE|Mitralign Percutaneous Tricuspid Valve Annuloplasty System (PTVAS)|Mitralign Percutaneous Tricuspid Valve Annuloplasty System (PTVAS) is delivered by a percutaneous transcatheter procedure. The Trialign PTVAS procedure utilizes catheters and wires to deliver up to two sets of pledgeted sutures across the tricuspid annulus near the septal/posterior and the posterior/anterior commissures. Each set of implants is pulled together to plicate the posterior tricuspid annulus.
223753741|NCT02555995|DEVICE|OCT scan (as yet unnamed)|OCT scan (as yet unnamed) of the eye with investigational device; newly developed sparse OCT retina scanner by Artorg Center Bern and Berner Fachhochschule Biel
223753742|NCT03666169|OTHER|Survey|Survey
223753743|NCT05973916|OTHER|Comprehensive intervention|"cleaning of patients' rooms will be subjected to a comprehensive intervention, consisting of: 1) a patient's unit commando team for daily and for terminal cleaning, 2) all lights in patients' room are VYV led lights, and 3) in each room, a QleanAir Scandinavia® filtering machine will be placed."
223753744|NCT02752191|DRUG|ferumoxytol|ferumoxytol as an MRI contrast agent infused over several minutes
223753745|NCT02752191|DRUG|gadofosveset|gadofosveset as an MRI contrast agent injected over several seconds
223753746|NCT02965443|DRUG|Dapagliflozin 10 mg + Saxagliptin 5 mg|24 weeks intervention with Dapagliflozin 10 mg + Saxagliptin 5 mg
224311518|NCT04001127|OTHER|High Intensity Functional Training|"The exercise intervention for this study will be HIFT, defined as a style of training that incorporates functional, multimodal movements, performed at relatively high intensity, and designed to improve parameters of general physical fitness and performance. The program design and template will be based on the principles of the HIFT program called CrossFit®. CrossFit is described as a strength and conditioning program that focuses on constantly varying functional movements, performed at a relatively high intensity. CrossFit training includes a variety of elements from gymnastics (e.g., floor, bar and ring exercises), weightlifting exercises (e.g., squats, cleans, snatches and presses with a barbell, dumbbell or kettlebell), and cardiovascular activities (e.g., running or rowing)."
223606727|NCT01347242|GENETIC|Autologous CD34 positive cells transduced with a lentiviral vector containing human WAS gene|transplantation of patient's autologous CD34+ cells transduced with lentiviral vector containing human WAS gene
223606728|NCT01442714|DRUG|Azacitidine|Azacitidine is a chemical analogue of the cytosine nucleoside used in DNA and RNA. Azacitidine is thought to induce antineoplastic activity via two mechanisms; inhibition of DNA methyltransferase at low doses, causing hypomethylation of DNA, and direct cytotoxicity in abnormal hematopoietic cells in the bone marrow through its incorporation into DNA and RNA at high doses, resulting in cell death
223606729|NCT01442714|DRUG|Lenalidomide|Lenalidomide has been used to successfully treat both inflammatory disorders and cancers. In vitro, lenalidomide has three main activities: direct anti-tumor effect, inhibition of angiogenesis, and immunomodulatory role. In vivo, lenalidomide induces tumor cell apoptosis directly and indirectly by inhibition of bone marrow stromal cell support, by anti-angiogenic and anti-osteoclastogenic effects, and by immunomodulatory activity.
223606730|NCT03641170|BEHAVIORAL|Physical activity|Interval walking performed after each main meal.
223606731|NCT03641170|BEHAVIORAL|Inactivity|Inactivity after each main meal.
223606732|NCT03641170|OTHER|Fixed diet.|Participants will receive a fixed diet through out the intervention period and control period.
223606733|NCT06173154|OTHER|Care system to prevent ID|The caregivers of this unit receive training about iatrogenic dependency and how prevent it. They set up this prevention and the research compare evolution of dependence hospitalized patients.
223606734|NCT06173154|OTHER|Routine care|standard care without any specific system in place
223606735|NCT06440629|DRUG|Therapeutic drug monitoring (TDM) of adalimumab|"In the TDM-group, the adalimumab dose will be adjusted according to the following algorithms in order to keep the drug level within the therapeutic range:~* Serum drug level within therapeutic range : keep dose~* Low drug levels, ADAb undetectable or low levels : Decrease dosing interval by one week to a maximum of 40 mg/week~* Low drug levels, ADAb high levels : Switch to another therapy~* High drug levels : Increase dosing interval by one week up to a maximum of 6 weeks"
223606736|NCT05841810|OTHER|mHealth Outreach|Community outreach using mHealth messaging will be led by community weavers via SMS and voice messages about COVID-19 vaccines and preventive care engagement in languages spoken by patients (i.e., Spanish, Arabic, Vietnamese).
223606737|NCT05841810|OTHER|Care Coordination|Inclusive of standard of care coordination with added focus on completing outstanding preventive care practices. Care coordination will be focused on collaborative problem-solving and case management to help patients schedule and attend recommended annual preventive health care, including a routine physical exam, recommended preventive screenings and COVID-19 vaccination
223606738|NCT03314987|DIETARY_SUPPLEMENT|L-carnosine|a naturally occurring di-peptide
223606739|NCT03314987|OTHER|placebo|an identically appearing supplement
223753747|NCT02965443|DRUG|Placebo 1 10 mg + Placebo 2 5 mg|24 weeks intervention with Placebo 1 10 mg + Placebo 2 5 mg
223753748|NCT01536496|BIOLOGICAL|Blood product transfusion based on conventional coagulation tests.|Transfusion of blood products.
223753749|NCT01536496|BIOLOGICAL|Blood product transfusion based on rapid thrombelastography (r-TEG) results.|Transfusion of blood products.
224311519|NCT00699062|DRUG|singular|The participants randomized into this arm will receive singular 10mg q.n. plus combine therapy with inhaled ICS+LABA
223753750|NCT02256891|DEVICE|PRFM|
223753751|NCT02256891|PROCEDURE|Double Row|
223753752|NCT01748786|BEHAVIORAL|Mindfulness Emotion Regulation|12 on-line modules provide didactic information and practice instructions re: mindfulness meditation for pain and distress
223753753|NCT01748786|OTHER|Health Education|12 on-line modules that provide information regarding health behaviors, but no information regarding how to put behaviors into practice
223753754|NCT06106971|DRUG|Sodium tetradecyl sulfate|Subjects receive sodium tetradecyl sulfate via balloon-occluded retrograde transvenous obliteration at 3 to 5 days after initial hemostasis of acute gastric variceal bleeding.
223753755|NCT06106971|DRUG|Cyanoacrylate|Subjects receive endoscopic cyanoacrylate injection at 3 to 5 days after initial hemostasis of acute gastric variceal bleeding then receive repeated endoscopic cyanoacrylate injection at 1-month intervals until obliteration of gastric varices.
223753756|NCT01344447|DRUG|Gadobutrol (Gadovist, BAY86-4875)|A single bolus injection of approx. 0.1mmol/kg
224311520|NCT00699062|DRUG|placebo|The participants allocated into this arm will receive placebo 10mg,q.n plus combine therapy with inhaled ICS+LABA
224311521|NCT03483727|DEVICE|SIMMAXMARCHERYAN|Digital cognitive aid during the management of simulated combat wounded.
224311522|NCT00159627|DRUG|KW-3902IV|
223753757|NCT04586803|DRUG|SHR4640|Subjects were randomly divided into the group A, B, C, D, E and F. On D1, D8 and D15, six groups of subjects were respectively given A version or C version or D version of SHR4640 tablet.
223753758|NCT02034526|DEVICE|DDDR-60|DDDR, lower pacing rate 60 bpm, RR activated (low-moderate)
223753759|NCT02034526|DEVICE|DDD-40|DDD, lower pacing rate 40 bpm, RR function off
224311523|NCT01470768|OTHER|Amino Acid-based Formula with high DHA and ARA|
223606740|NCT03765541|DRUG|Dexamethasone|"In combination with intensive chemotherapy amsacrine-cytarabine:~* Induction (1 cycle): 10 mg/12h from Day 1 to Day 3 of cycle (2 infusions/24h, slow IV \[10 minutes\])~* Consolidation (3 cycles): 10 mg/12h from Day 1 to Day 3 of each cycle (2 infusions/24h, slow IV \[10 minutes\])~In combination with azacitidine:~* Cycle 1: 20 mg/24h from Day 1 to Day 3 of cycle (1 infusion/24h, slow IV \[10 minutes\]).~* Subsequent cycles: 20 mg/24h on Day 1 of each cycle (1 infusion/24h, slow IV \[10minutes\])."
223606741|NCT03765541|DRUG|Amsacrine|"* Induction (1 cycle): 200 mg/m2/24h from Day 1 to Day 3 of cycle (slow IV \[3 hours\])~* Consolidation (3 cycles): 200 mg/m2/24h on Day 1 of each cycle (slow IV \[3 hours\])"
223606742|NCT03765541|DRUG|Cytarabine|"Patients \< 60 years of age:~* Induction (1 cycle): 3 g/m2/12h from Day 1 to Day 4 of cycle (2 infusions/24h, slow IV \[2 hours\])~* Consolidation (3 cycles): 3 g/m2/12h from Day 1 to Day 3 of each cycle (2 infusions/24h, slow IV \[2 hours\]) Note: If the investigators believe that there is an undue risk for the safety of a patient under 60 years of age with comorbidity in receiving a dose level of 3 g/m2/12h, the dose may be reduced to 1 g/m2/12h"
223606743|NCT03765541|DRUG|Azacitidine|75 mg/m2/24h from Day 1 to Day 7 of each cycle \[or from Day 1 to Day 5 and from Day 8 to Day 9 of each cycle\] (SC)
223606744|NCT05930093|DIETARY_SUPPLEMENT|Placebo|Placebo matching LivPhcD cap.
223606745|NCT05930093|DIETARY_SUPPLEMENT|2 cap.LivPhcD/per day|2 caps. LivPhcD cap. after meal, once a day
223606746|NCT05930093|DIETARY_SUPPLEMENT|4 cap.LivPhcD/per day|4 caps. LivPhcD cap. after meal, BID
223606747|NCT05930093|DIETARY_SUPPLEMENT|6 cap.LivPhcD/per day|6 caps. LivPhcD cap. after meal, TID
223753760|NCT06026891|DRUG|MG-K10/Placebo|MG-K10 Humanized Monoclonal Antibody Injection
223753761|NCT02533271|RADIATION|Short-course radiotherapy with neoadjuvant chemotherapy|Short-course radiotherapy with 4 cycles of neoadjuvant chemotherapy
223753762|NCT02533271|RADIATION|Long-term chemoradiotherapy|Standard chemoradiotherapy
223753763|NCT00724516|DEVICE|Novel Breast Compression Paddle|Instead of using the regular wire localization mammography compression paddle, a new breast compression paddle will be used. The new breast compression paddle is similar to a tennis racquet. It consists of crossing plastic strings that are strung tightly in a frame. The needle/wire can be inserted anywhere between the strings.
223753764|NCT04218058|PROCEDURE|reduction of zygomatic arch in zygomaticomaxillary complex fracture|ultrasound guided reduction of zygomatic arch
223753765|NCT03094754|PROCEDURE|nevi excision|After general anesthesia, nevi excision in children is performed.
223753766|NCT01991158|DRUG|High dose of methotrexate|Methotrexate 3.0g/Kg, intravenous drip D1
223753767|NCT01991158|DRUG|Gemcitabine|Gemcitabine 1g/m2 intravenous drip D1,D8
223753768|NCT01991158|DRUG|Pegaspargase|Pegaspargase 2500U/m2 intramuscular injection (IM) D1
223606748|NCT05230524|DEVICE|DiamondTemp™ Ablation System|Pulmonary vein isolation will be performed with the DiamondTemp™ Ablation System
223753769|NCT01991158|DRUG|Dexamethasone|Dexamethasone 20mg/d intravenous drip D1, po D2-3
223753770|NCT01742338|DRUG|Low Dose Corticosteroids|
223753771|NCT01742338|DRUG|High Dose Corticosteroids|
223753772|NCT03249779|DEVICE|Scrambler|Scrambler Therapy is a specific form of electrical stimulation which has also been utilized in chronic neurogenic pain11. This modality of therapy differs from TENS in that the goal is to mediate the patient's perception of pain, rather than masking the peripheral pain signal. The results of this modality of treatment may be longer-lasting than TENS, presumably via reduction in central signal generation. Scrambler therapy works through C fibers to retrain the peripheral sensation in the area being treated. Further description of this technology is available at: International Patent PCT/IT2007/000647 and U.S. Patent No. 8,380,317. Literature search does not yield prior studies regarding efficacy of Scrambler therapy in treating RLS
223753773|NCT05410327|OTHER|Chokeberry (Aronia melanocarpa) juice|A water-infused chokeberry (Aronia melanocarpa) juice will be used as the intervention. The brand being used is called 'Superberries'.
223753774|NCT01442363|DRUG|BLI-1300 low dose|topical ointment
223753775|NCT01442363|DRUG|BLI-1300 high dose|topical ointment
223753776|NCT01442363|DRUG|placebo|topical ointment
223606749|NCT04914533|DEVICE|Luminance RED Low Level Laser Therapy Device|Low Level Laser Therapy (LLLT) sometimes known as Low Level Light Therapy or Photobiomodulation (PBM) is a low-intensity light therapy. The effect is photochemical not thermal. The Luminance RED Device is specifically designed to make it easy to issue LLLT to canker sores.
223606750|NCT03769259|BEHAVIORAL|Brief Cognitive Behavioral Therapy (BCBT)|Participants in BCBT receive 12 outpatient individual psychotherapy sessions scheduled on a weekly or biweekly basis, with the first session lasting 90 minutes and subsequent sessions lasting 60 minutes. BCBT was is delivered in three sequential phases. In phase I (5 sessions), the therapist identifies patient-specific factors that contribute to and maintain suicidal behaviors, provides a cognitive-behavioral conceptualization, collaboratively develops a crisis response plan, and teaches basic emotion regulation skills. In phase II (5 sessions), the therapist applies cognitive strategies to reduce beliefs and assumptions that serve as vulnerabilities to suicidal behavior. In phase III (2 sessions), a relapse prevention task is conducted.
223753777|NCT05044806|OTHER|Ultrasound-guided remote ischemic conditioning|Before conducting RIC, Doppler ultrasound was used to measure the total occlusion pressure (TOP) of brachial artery, which was then determined as the cuff inflation pressure during RIC. The RIC program encompasses four main components of (1) three cycles of remote ischemic pre-conditioning which will be delivered right after the eligibility check and informed consent form signature before PCI; (2) one cycle of remote ischemic per-conditioning, which will be delivered during PCI; (3) three cycles of remote ischemic post-conditioning, which will be delivered within 10 min after PCI; and (4) two sessions per day of remote ischemic post-conditioning which will start on post-operative day 1 and last till hospital discharge. The remote ischemic pre- and post-conditioning share the RIC protocol, which comprises three 3 min cycles of RIC with 3 min intervals of reperfusion in between, while only one single 3 min cycle will be delivered for the remote ischemic per-conditioning.
224200706|NCT01320176|BIOLOGICAL|Investigational HIV vaccine dose B|The vaccine will be administered by intramuscular route into the deltoid muscle preferentially of the non dominant arm at Month 0 and Month 3
224311524|NCT01470768|OTHER|Amino Acid-based Formula with lower DHA and ARA|
224311525|NCT04810130|OTHER|Soccer Kicking|Subjects assigned to the soccer kicking arm will complete 10 soccer kicks in 10 minutes.
223606751|NCT03769259|BEHAVIORAL|Present-Centered Therapy (PCT)|Participants in PCT will receive will include 12 outpatient individual psychotherapy sessions scheduled on a weekly or biweekly basis, with the first session lasting 90 minutes and subsequent sessions lasting 60 minutes. PCT consists of (1) psychoeducation about the typical symptoms and features associated with suicidal thoughts and behaviors among military personnel; (2) normalization of symptoms; (3) experience of receipt of support and feedback from a licensed professional; and (4) positive interpersonal interactions.
223606752|NCT03769259|BEHAVIORAL|Treatment as Usual (TAU)|"All participants will receive the following interventions or procedures, regardless of treatment assignment:~* Suicide risk assessment using the Columbia Suicide Severity Rating Scale~* VA's safety planning intervention, which include Military Crisis Line contact information and lethal means access reduction~* Caring contacts and outreach~* Psychotropic medication, group therapy, substance abuse counseling, and other mental health interventions provided routinely as a part of treatment as usual"
223606753|NCT05462860|OTHER|Suprathel®|Application of standard of care dressing.®
223606754|NCT02751580|OTHER|Telemedicine|Attend a virtual visit via the JeffConnect telehealth app
223606755|NCT02751580|OTHER|Questionnaire Administration|Ancillary studies
223606756|NCT06535958|BEHAVIORAL|OHI|All patients (test and control) will be instructed to brush the implants twice daily to remove supragingival biofilms with a low-abrasive dentifrice and to use specific cylindrical or conical brushes in the interproximal area. Patients will be indicated to brush under, around, and in the peri-implant crevice circumferentially. In those cases with no access for proper OHI, prosthesis will be modified.The interproximal brush device used will be chosen for the patient individually, according to the interproximal space available, the thicker brush that can be used comfortably will be the selected one. It will be previously tested on the patient and its use will be taught, patients should demonstrate proficiency
223606757|NCT06535958|PROCEDURE|OHI+PMPR|Supra- and sub-gingival debridement of the implant surface, the implant neck, and the abutment will be carried out by means of a combination of ultrasonics with a plastic tip and plastic curettes . Finally, the prosthetic components will be polished with a rubber cup
223606758|NCT01898429|DEVICE|SCC DBS|Deep Brain Stimulator
223606759|NCT00149903|DRUG|Mycophenolate sodium (enteric coated)|
223606760|NCT05705427|DRUG|Tenofovir Disoproxil Fumarate 300 MG|Pregnant women in the experimental arm will receive TDF daily beginning in the 3rd trimester of pregnancy and continuing through 1 month postpartum.
223606761|NCT05705427|BIOLOGICAL|Hepatitis B monovalent vaccine|All infants born to women in the study will receive a birth-dose hepatitis B vaccine.
223606762|NCT05705427|DRUG|Placebo|Pregnant women in the placebo arm will receive a placebo pill daily beginning in the 3rd trimester of pregnancy and continuing through 1 month postpartum.
223606763|NCT04829916|DRUG|RMC-035|Multiple dosing during 48 hours following cardiac surgery
223606764|NCT04829916|DRUG|Placebo|Multiple dosing during 48 hours following cardiac surgery
223606765|NCT03020706|DRUG|Magnesium Sulfate, Injectable|magnesium sulphate intravenous administration during general anesthesia
223606766|NCT02630303|DEVICE|LED-RL Phototherapy|"The maximum recommended starting dose (MSRD) (160 J/cm2) will be administered to Group 1's LED-RL phototherapy randomized subjects and the LED-RL dose will be escalated in subsequent groups using the classical method for dose escalation as described by Spilker: starting with dose (X) increased by an equal amount (in this instance: X=160 J/cm2, 2X=320 J/cm2, 3X=480 J/cm2, 4X=640 J/cm2). Common expected procedure side effects are mild and temporary, including warmth, redness (erythema) and swelling (edema). The maximally tolerated dose (MTD) is defined as the dose level below the dose producing unacceptable but reversible toxicity and is considered the upper limit of subject tolerance.~All subjects will receive total of nine LED-RL phototherapy, three times per week for three consecutive weeks."
223606767|NCT02630303|DEVICE|Mock Therapy|"Mock therapy will be administered to mock therapy randomized subjects using the mock therapy unit and only generates warmth and does not emit LED-RL.~All subjects will receive total of nine mock therapy procedures, three times per week for three consecutive weeks."
223606768|NCT04233541|DIAGNOSTIC_TEST|Fall assessment|Through a comprehensive geriatric assessment carried out by our geriatrician led multidisciplinary team we gather information about fall recalls consistent with the definition of landing on the floor or ground.
223606769|NCT03106636|BEHAVIORAL|KEEP-P|The KEEP-P program is a low-cost, manualized, group-based intervention for caregivers of preschool aged children. This trial is evaluating 2 versions of the intervention. KEEP-P is a basic version that employs a curriculum of 12 weekly psychoeducational caregiver support groups Across four waves of data collection (baseline, post-intervention, and 12 and 18 months post-baseline), we will examine the extent to which this intervention condition shows improved parenting, reduced rates of disrupted placements, and improved child outcomes.
223606770|NCT03106636|BEHAVIORAL|KEEP-P+|The KEEP-P program is a low-cost, manualized, group-based intervention for caregivers of preschool aged children. This trial is evaluating 2 versions of the intervention. KEEP-P+ is an augmented version that consists of the caregiver support groups with extended curriculum including information about recent findings in early brain development and the elements of the Filming Interactions to Nurture Development video coaching program. Across four waves of data collection (baseline, post-intervention, and 12 and 18 months post-baseline), we will examine the extent to which this intervention condition show improved parenting, reduced rates of disrupted placements, and improved child outcomes.
223606771|NCT04890470|DRUG|Oxytocin|intranasal administration of oxytocin (24 IU)
223606772|NCT04890470|DRUG|Vasopressin|intranasal administration of vasopressin (20 IU)
223606773|NCT04890470|DRUG|Placebo|intranasal administration of placebo
223606774|NCT00974623|DEVICE|Bone graft substitute, autograft or allograft|spine fusion surgery utilizing any commercially available bone graft substitute(s), autograft or allograft
223606775|NCT00830466|DRUG|Laser and rapamycin versus laser alone|Laser and rapamycin versus laser alone
223606776|NCT01915173|DRUG|Supplement|Abies nigra 4C, Carbo vegetabilis 4C, Nux vomica 4C, and Robinia pseudoacacia 4C
223606777|NCT01915173|DRUG|Placebo|Lactose tablets
223606778|NCT01915173|BEHAVIORAL|Expanded Interview|
223606779|NCT01915173|BEHAVIORAL|Standard Interview|
224311526|NCT04810130|OTHER|Soccer Heading (Frontal)|Subjects assigned to the soccer heading (frontal) arm will complete 10 frontal soccer headers (ball headed directly back to launch direction) in 10 minutes. Soccer balls will be projected at 10-17.5 m/s from approximately 10-15 m with a JUGS ball launcher.
223753778|NCT05044806|OTHER|Traditional remote ischemic conditioning|The RIC program encompasses four main components of (1)three cycles of remote ischemic pre-conditioning which will be delivered right after the eligibility check and informed consent form signature before PCI; (2)one cycle of remote ischemic per-conditioning, which will be delivered during PCI; (3)three cycles of remote ischemic post-conditioning, which will be delivered within 10 min after PCI; and (4) two sessions per day of remote ischemic post-conditioning which will start on post-operative day 1 and last till hospital discharge. The remote ischemic pre- and post-conditioning share the RIC protocol, which comprises three 3 min cycles of upper limb ischemia on the arm that is opposite to the PCI side with 3 min intervals of reperfusion in between delivered by an automated cuff inflation/deflation device, while only one single 3 min cycle will be delivered for the remote ischemic per-conditioning. The pressure applied during cuff inflation is 20 mmHg above systolic blood pressure.
223753779|NCT05044806|PROCEDURE|Percutaneous coronary intervention|Percutaneous coronary intervention (PCI) will be performed by a cardiologist or doctor who specializes in the heart to open coronary arteries that are narrowed or blocked by the buildup of atherosclerotic plaque. PCI requires cardiac catheterization, which is the insertion of a catheter tube, and live x rays helping to guide the catheter into the heart to inject special contrast dye that will highlight the blockage. To open a blocked artery, another catheter will be inserted over a guidewire, a balloon will be inflated at the tip of that catheter, and a small mesh tube called a stent may be put in the artery to help keep the artery open. After PCI, the catheters will be removed, the opening on the wrist or groin will be closed and bandaged.
223606780|NCT05599971|DRUG|intralesional combined digoxin and furosemide|15 patients will receive intralesional combined digoxin and furosemide, with maximum 5 warts per session. 0.2 mL of lignocaine (20 mg/mL) will be used as a local analgesic and after few minutes, 0.1 mL of combined digoxin and furosemide solution will be slowly injected into the base of each wart. Selected patients will receive one session every 2 weeks till complete clearance or up to 5 sessions.
223606781|NCT05599971|DRUG|intralesional injection of 5- Fluorouracil|15 patients will receive intralesional injection of 5- Fluorouracil (50mg/ml) in full concentration into the wart using a 27- gauge insulin syringe till the entire lesion begins to puff up. The maximum dose injected per session will be 2ml of 5-FU. Selected patients will receive one session every 2 weeks till complete clearance or up to 5 sessions.
223606782|NCT05599971|OTHER|intralesional saline|15 patients will receive intralesional saline. Selected patients will receive one session every 2 weeks till complete clearance or up to 5 sessions.
223606783|NCT05668598|DIAGNOSTIC_TEST|ecological MAI test|"Neuropsychological assessment will be realize to determine presence or absence of neurodegenerative disease.~Study test is ecological MAI."
223606784|NCT03421912|OTHER|Cicaplast Balm B5|The patients have to do 2 to 3 applications per day on the face, on lesions and in poultice in the evening in case of painful crack on the fingers
223606785|NCT03421912|OTHER|Dexeryl|The patients have to do 2 to 3 applications per day on the face, on lesions and in poultice in the evening in case of painful crack on the fingers
223606786|NCT02152761|DRUG|bimagrumab|Bimagrumab was administered as intravenous infusion starting on Day 1 until week 20.
223606787|NCT02152761|OTHER|placebo|Matching placebo was administered as intravenous infusion starting on Day 1 until week 20.
223606788|NCT04343755|BIOLOGICAL|Convalescent Plasma|Fresh or frozen plasma will be infused one time to hospitalized patients with COVID-19 infection
223606789|NCT03079895|BEHAVIORAL|Thrive|Thrive is an online self-help tool designed to assess for depressive symptoms and give therapeutic suggestions based on Cognitive Behavioral Therapy principals.
223606790|NCT01255618|DEVICE|INVOS 5100|Near-infrared range and has been used in newborn infants since 1985. Fibre-optic bundles or optodes are placed either on opposite sides of the tissue being interrogated (usually a limb or the head of a young baby) to measure transmitted light, or close together to measure reflected light. Light enters through one optode and a fraction of the photons is captured by a second optode and conveyed to the measuring device. NIRS uses a frequency band between 650 nm and 1000 nm and relies on three important phenomena: (1) human tissue is relatively transparent to light in the near-infrared region of the spectrum; (2) pigmented compounds known as chromophores absorb light as it passes through biological tissue; and (3) human tissues contain substances whose absorption spectra at near-infrared wavelengths are well defined and depend on their oxygenation status.
223606791|NCT06392334|OTHER|Biopsy|Biopsy of lung tissue
223606792|NCT01494077|OTHER|Laboratory processing for results|There is no intervention. Extra fluid that is normally discarded will be processed.
223606793|NCT02639442|DEVICE|ClearRing™|
223753780|NCT04916795|DRUG|Vupanorsen|80 mg subcutaneous injection
223753781|NCT04916795|DRUG|Vupanorsen|80 mg subcutaneous injection
224311527|NCT04810130|OTHER|Soccer Heading (Oblique)|Subjects assigned to the soccer heading (oblique) arm will complete 10 oblique soccer headers (ball headed 90° to the right from ball launch direction) in 10 minutes. Soccer balls will be projected at 10-17.5 m/s from approximately 10-15 m with a JUGS ball launcher.
224311528|NCT02929186|BEHAVIORAL|Opt-In Outreach|Subjects will receive a communication (mail or electronic) describing the importance of colorectal cancer screening with the option to elect to receive a home FIT kit or report prior screening.
223606794|NCT03755882|DEVICE|ACUVUE® DEFINE™ Vivid Style|TEST Lens
223606795|NCT03755882|DEVICE|LACELLE™ Sparkling Brown|CONTROL Lens
223606796|NCT05639140|OTHER|Data collection|Neuropsychological assessment, FM-1OO, brain MRI, electroencephalogram and biomarker datas will be collected
223606797|NCT01011140|BEHAVIORAL|Survey|10-15 minute online survey to assess palliative care physicians' attitudes, beliefs and practice patterns related to parenteral hydration at the end of life in Latin America and Spain.
223606798|NCT04679194|BIOLOGICAL|Mana 312|"Mana 312 is a cellular product comprised of expanded T cells derived from allogeneic donor leukocytes that have been stimulated with monocyte derived dendritic cells pulsed with tumor-associated antigen (TAA) peptide mixes for 3 antigens: Wilms Tumor gene 1 (WT 1), the preferentially expressed antigen of melanoma (PRAME), and Survivin.~Each Mana 312 product is specifically matched for an individual subject and will be manufactured from leukocytes from the same donor who provided stem cells to that subject for their current allogeneic hematopoietic stem cell transplantation (HSCT)."
223606799|NCT05184634|OTHER|PHYSICAL ACTIVITY LEVELS|Determination of physical activity levels of MetS individuals
223606800|NCT05184634|OTHER|DEPRESSION LEVELS|To determine the depression levels of MetS individuals
223606801|NCT05184634|OTHER|FATİGUE SEVERİTY|To determine the severity of fatigue of MetS individuals
223606802|NCT05184634|OTHER|QUALITY OF LIFE|To determine the quality of life of MetS individuals
223606803|NCT02292446|DRUG|Ruxolitinib|supplied as 5 mg, 10 mg and 20 mg tablets to be taken orally
223606804|NCT05900908|DEVICE|Gamma Tile-Surgically Targeted Radiation Therapy (STaRT)|GammaTiles are a permanently implanted radiation device consisting of Cs-131 seeds positioned within a collagen tile
223606805|NCT05900908|RADIATION|Stereotactic Radiation Therapy|External Beam Radiation Therapy
223606806|NCT00224588|DRUG|Ketamine (or placebo : isotonic saline solution)|
223606807|NCT04848272|DRUG|Lanadelumab|Monoclonal antibody that targets active plasma kallikrein
223606808|NCT04848272|OTHER|Saline control|Saline control
223606809|NCT03506997|DRUG|Pembrolizumab|Pembrolizumab 200mg given as a 30 minute intravenous (IV) infusion, on day 1 of each 3 week cycle. Patients may continue with pembrolizumab treatment as long as they remain free from intolerable toxicity for a maximum of two years, if in the Investigator's opinion they are receiving clinical benefit, and/or they do not meet any discontinuation criteria.
223606810|NCT05663463|DRUG|Fluzone High-Dose - 2 doses|2 doses of the High-Dose (HD) influenza vaccine separated by 4-6 weeks For 2023-2024 influenza season the influenza quadrivalent HD vaccine was used. For 2024 -2025 influenza season the influenza trivalent HD vaccine will be used.
223606811|NCT05663463|DRUG|Fluzone High-Dose - 1 dose of HD|1 dose of the High Dose (HD) influenza vaccine, followed by a placebo injection 4-6 weeks later For 2023-2024 influenza season the influenza quadrivalent HD vaccine was used. For 2024 -2025 influenza season the influenza trivalent HD vaccine will be used.
223606812|NCT01311609|OTHER|Systane|Systane Lubricant Eye Drops \[1-2 Drops in each eye four times daily (QID)\]
223606813|NCT05722548|DRUG|Indomethacin suppository|100mg of Indomethacin Suppository sigle dose at the time of induction of anesthesia
223606814|NCT05722548|OTHER|Standard Medical Treatment|Standard Medical Treatment
223606815|NCT04524234|DIAGNOSTIC_TEST|Echocardiography|Echocardiography for assessment of cardiac function
223753782|NCT03507712|PROCEDURE|Symmetrical IO weakening|Bilateral IO Myectomy / Bilateral equal graded IO Recession
223753783|NCT03507712|PROCEDURE|Asymmetrical IO weakening|IO Myectomy in one eye - IO Recession in the fellow eye / Bilateral IO Recession (different amounts) in each eye
223606816|NCT02124681|DRUG|Hydroxychloroquine|Hydroxychloroquine sulfate 400mg/d PO for 13±1 weeks
223606817|NCT02124681|OTHER|Placebo|Placebo PO for 13±1 weeks
223606818|NCT02538601|BEHAVIORAL|CBT-A|"CBT-A was an 8-session (1.5 hours/session) group treatment for quitting smoking comprised of an optimized protocol that incorporated all elements of the CBT-S treatment plus skills for reducing PTSD/anxiety symptoms and improving tolerance to withdrawal. The CBT-A intervention included skills based on a transdiagnostic approach: (1) repeated interoceptive exposures to feared bodily sensations (e.g., dizziness, racing heart); (2) corrective information about anxiety and cognitive restructuring of catastrophic misinterpretations of somatic sensations (e.g., I will lose control.); and (3) use of graduated in-vivo exposure to feared and avoided situational experiences related to anxiety, WTC-related PTSD triggers, and smoking (e.g., going to lower Manhattan; driving without smoking)."
223606819|NCT02538601|BEHAVIORAL|CBT-S|CBT-S was an adapted group-based CBT smoking cessation treatment delivered in 8 sessions (1.5 hours/session) based on the most recent clinical practice guidelines from the United States Department of Health and Human Services (USDHHS), Treating Tobacco Use and Dependence. Standard cessation elements included psychoeducation on reasons for smoking and barriers to quitting, enlisting social support, monitoring and tapering cigarette use, and counseling regarding high-risk smoking situations and unhelpful ways of thinking about smoking and abstinence. The treatment was similar to protocols used in other smoking cessation research.
223606820|NCT02735148|OTHER|Body Weight Supported Treadmill Training|"There were three intervention arms in this study,~1. Body Weight Supported Treadmill Training,~2. Conventional Training and~3. Combined Training."
223606821|NCT03372967|BIOLOGICAL|Vaccine administration by a pharmacist|Administration, number and types, of vaccines by a pharmacist
223606822|NCT03372967|BEHAVIORAL|Unmet vaccination needs identified and met|Identification of unmet vaccination needs and having those needs met
223606823|NCT03372967|BEHAVIORAL|Vaccination forecast review and patient education|Pharmacist review of the vaccination forecast and patient education on his/her vaccine needs
223606824|NCT02735668|OTHER|Shoulder Conventional Exercises|"The protocol consists in:~• Flexibility and Strengthening Exercises of the shoulder muscles conventionally performed in shoulder pathology treatment:~* Mobilisation Joint Exercises.~* Isometrics and Resisted Exercises (elastic bands)."
223606825|NCT02735668|OTHER|Multimodal Physiotherapy|"The protocol consists in:~* Dry Needling in active myofascial trigger points related to shoulder joint (optimal hygiene and disinfection before and after needling). Special care in muscles located in the arm in women with axillary node dissection.~* If Upper Limb Neural Tension Test is positive, neurodynamic techniques will be included."
223606826|NCT02735668|OTHER|Scapular exercises|"The protocol consists in:~Scapula-focused exercises: based on evaluation of scapular dyskinesis and Kinetic Medial Rotation Test as well as inherent characteristics of each woman, individualized scapular exercises were prescribed based on a motor control approach with emphasis on obtaining a neutral scapular orientation."
223606827|NCT02735668|BEHAVIORAL|Therapeutic Education|"The protocol consists in:~Therapeutic Education about chronic shoulder pain using a slide show, anatomical models, providing information and analysis of real clinical cases."
223606828|NCT04407988|DRUG|Pyrotinib Maleate plus Letrozole|pyrotinib(400 mg once daily) + Letrozole (2.5 mg once daily)
223606829|NCT03599791|DRUG|Azelastine Hydrochl./Fluticasone Prop. 0.137/0.05 MG/ACTUAT|Dymista Nasal spray suspension
224311529|NCT02929186|BEHAVIORAL|Opt-Out Outreach|Subjects will receive a communication (mail or electronic) describing the importance of colorectal cancer screening with the option to choose not to receive a home FIT kit or report prior screening. A FIT kit will otherwise be sent to the subject as a default.
224311530|NCT02646852|DRUG|PLX038|
224311531|NCT03086382|DRUG|Lacosamide (LCM) tablet|Treatment A: Single dose of Lacosamide (LCM) 200 mg given as 2 tablets of LCM 100 mg
224311532|NCT03086382|DRUG|Lacosamide (LCM) syrup|Treatment B: Single dose of Lacosamide (LCM) 200 mg given as syrup
223606830|NCT03599791|DRUG|Azelastine Hydrochloride 0.137 MG/ACTUAT|AZEP Nasal spray solution
223606831|NCT03599791|DRUG|Fluticasone Propionate 0.05 MG/ACTUAT|Fluticasone propionate nasal spray suspension
223606832|NCT00106327|BEHAVIORAL|Exercise|6 months of supervised treadmill exercise or strength training, three times per week, followed by a 6 month home-based program.
223606833|NCT00106327|BEHAVIORAL|Diet|11 nutrition education sessions
223606834|NCT04803851|DRUG|Anlotinib plus AK105|Anlotinib： a multi-kinase inhibitor AK105： an anti-PD-1 antibody
223606835|NCT01366599|DRUG|HEC or MEC|Any HEC or MEC, including aprepitant
223606836|NCT01810003|DIETARY_SUPPLEMENT|High DHA|10 week supplementation period
223753784|NCT05655611|OTHER|first rib mobilization|To perform the first rib mobilization, the patient remained lying supine with the head in the examiner's right hand. Examiner then palpated the left first rib and passively side-bended the patient's head to the left to relieve any muscular tension on the first rib. Patient was then asked to take a deep breath in and out. During exhalation, the examiner applied pressure to depress the first rib, holding it in place at the end of the exhalation. Then, holding the first rib in place, the patient was asked to inhale and exhale deeply again. The examiner continued applying pressure to hold the first rib in a position of relative depression during inhalation, and further depressed the first rib as able during exhalation. This process was repeated three times in two sets, for a total of six first rib depression mobilizations.
223753785|NCT05655611|OTHER|muscle energy technique|Muscle energy technique for glenohumeral joint restricted abduction-The therapist stood in front of the patient, then placed one hand over the top of the subject's involved shoulder. The therapist cups the glenohumeral joint to palpate for motion and the subjects are directed to press the elbow towards their body. Muscle energy technique was applied for five repetitions per set, five sets per session, one session per day, three days a week for three weeks with each repetition maintained for the duration of 7-1 seconds.
223753786|NCT03790826|DEVICE|cystoscopy|Comparison of bladder mucosa via cystoscopy.
223753787|NCT02286193|BEHAVIORAL|Patient clinical encounters with Community Resource Specialist (CRS)|CRS will work with patients to create goals, develop action plans and link to community resources to support goals
223753788|NCT02204891|DIETARY_SUPPLEMENT|Probiotics in SIBO|Mixture of the four probiotics in one capsule. One capsule twice daily for 30 days
223753789|NCT02204891|DIETARY_SUPPLEMENT|Probiotics|One capsule twice daily for 30 days
223753790|NCT01041872|DRUG|Propofol Astrazeneca plain|Propofol with saline is administered using a closed-loop algorithm which permits to reach a Bispectral Index target of 50. The blinded syringe contains 45 ml of propofol and 5 ml of saline.
223753791|NCT01041872|DRUG|Propofol Astrazeneca plus lidocaine|Propofol with lidocaine 1¨% is administered using a closed-loop algorithm which permits to reach a Bispectral Index target of 50. The blinded syringe contains 45 ml of propofol and 5 ml of lidocaine.
223753792|NCT01041872|DRUG|Propofol-lipuro B. Braun plain|Propofol with saline is administered using a closed-loop algorithm which permits to reach a Bispectral Index target of 50. The blinded syringe contains 45 ml of propofol and 5 ml of saline.
223753793|NCT01041872|DRUG|Propofol-lipuro B. Braun plus lidocaine|Propofol with lidocaine 1¨% is administered using a closed-loop algorithm which permits to reach a Bispectral Index target of 50. The blinded syringe contains 45 ml of propofol and 5 ml of lidocaine.
223753794|NCT01041872|DRUG|Propofol Fresenius plain|Propofol with saline is administered using a closed-loop algorithm which permits to reach a Bispectral Index target of 50. The blinded syringe contains 45 ml of propofol and 5 ml of saline.
223753795|NCT01041872|DRUG|Propofol Fresenius plus lidocaine|Propofol with lidocaine 1¨% is administered using a closed-loop algorithm which permits to reach a Bispectral Index target of 50. The blinded syringe contains 45 ml of propofol and 5 ml of lidocaine.
224311533|NCT03805711|DEVICE|HLT® Transcatheter System|Transcatheter aortic valve replacement using The HLT® Transcatheter System (HLT System) in patients with symptomatic heart disease due to severe aortic stenosis who are judged by the Heart Team to be at Intermediate or High Risk for aortic valve replacement surgery (Heart Team agrees that the risk of 30-day mortality is ≥ 3%).
223606837|NCT01810003|DIETARY_SUPPLEMENT|High EPA|10 week supplementation period
223606838|NCT01810003|DIETARY_SUPPLEMENT|Placebo|10 week supplementation period
223606839|NCT04267835|PROCEDURE|MIDCAB|Surgery: MIDCAB
223606840|NCT04267835|PROCEDURE|thoracotomy OPCABG|Surgery: thoracotomy OPCABG
223606841|NCT00214513|BEHAVIORAL|Home-based exercise training|
223606842|NCT02968342|DEVICE|Vaginal progesterone 8%|vaginal self application
223606843|NCT03516422|PROCEDURE|ULTRASOUND DEBRIDEMENT|Low-frequency ultrasound SonicOne O.R. (Misonix, New York, US) generates ultrasound waves with 22.5 kHz frequency. Each probe is attached to a set of irrigation solution (saline 0.9%), they transform electric energy into mechanical vibrations to induce tiny particles of water from irrigation fluid. Absorbent pads are positioned to catch excess saline. With SonicOne set at continuous mode with minimum pump flow, the debridement will begin at most distal aspect of ulcer with the hand piece in constant motion until entire ulcer surface has been debrided until as much necrotic tissue has been removed. Peri-wound skin will be cleansed using gauze and sterile normal saline and dry. Packing material will be applied (Acticoat®) into wound cavity.
223606844|NCT03516422|OTHER|STANDARD CARE GROUP|The subject positioned so absorbent pads are in position to catch irrigation solution. The saline bottle will be held 10-15 cm from wound bed, and squeezed to spray all surfaces of wound in a sweeping motion, from clean to dirty area of wound. Irrigation will be repeated as necessary to remove exudate, slough, and debris from the wound until the solution draining from the wound is clear. Peri-wound skin will be cleansed using gauze and sterile normal saline and dry. Packing material will be applied (Acticoat®) into the wound cavity, undermining, or tunnel to fill the dead space without causing the wound to stretch or bulge or be packed tightly. Packing should be in contact with entire wound base and edges. Dressings changed once every 3 days by the patient's care provider.
223606845|NCT02473900|DRUG|HIP1403|Oseltamivir 75mg
223606846|NCT02473900|DRUG|HGP0919|Oseltamivir phosphate 75mg
223606847|NCT06345625|DIAGNOSTIC_TEST|Cognition|"1. The CatchU® app quantitatively and objectively measures the ability to integrate visual-somatosensory information using reaction time test data.~2. Digit Symbol Substitution test assesses processing speed and attention by requiring individuals to match symbols with corresponding numbers within a specified time frame.~3. Trail Making Test part 1 and 2: assesses cognitive flexibility, visual attention, and task-switching by having individuals connect numbered circles in sequence (part 1) and then alternate between numbers and letters (Part 2).~4. Go/No Go test measures an individual's ability to inhibit a prepotent response (No-Go) and execute a response when required (Go). This test provides insights into executive functioning, particularly inhibitory control."
223606848|NCT06345625|DIAGNOSTIC_TEST|Sensory function|"1. Cervical Sensorimotor control will be measured through a wireless wearable sensor 3D-cervical trainer by Sensamove on the placed on the head of the participant. The 3DCT registers cervical position sense by the Head Repositioning Accuracy test where the subject must relocate the head to the previously memorized (neutral) head position with the eyes closed and the joint position error degrees are registered. Cervical movement sense is examined using 'The Fly'-test where the subject ought to follow a movement pattern displayed on the screen in front of them. The movement of the neck-head unit is there upon tracked by the 3DCT and projected on the screen.~2. Vestibular function will be assessed through 3D-video Head Impulse Testing (vHIT), examining the state of the three semicircular canals by delivering the vestibulo-ocular reflex (vor) gain and vor gain asymmetry.~3. For the assessment of static and dynamic visual acuity, functional Head Impulse Testing (fHIT) will be used."
223606849|NCT06345625|DIAGNOSTIC_TEST|Frailty|Frailty will be assessed using the Fried criteria, comprising 5 categories (each accounting for 1 point if scored positive): Unintentional weight loss (interview), weakness (grip strength with hand-held dynamometer), poor endurance and energy (two statements of the CES-D Depression Scale), slowness (walking speed over 15ft through gait analysis) and low physical activity level (Minnesota Leisure Time Activity questionnaire)(Fried et al., 2001).
223606850|NCT06345625|OTHER|Biomechanical movement analysis|Markers will be placed on the predefined anatomical locations and surface electrodes for electromyography will be applied at the predefined muscle locations following the SENIAM-guidelines. The Microsoft HoloLens 2 is fixated on the participant's head which will, on one hand, provide the cue to the participant for the head movement and on the other hand track eye and head movements. A safety harness is attached to the body and the ceiling of the lab. At the start of the trial, the subject will see a projection by the HoloLens 2 on the real environment moving to the left; right; upward; downward (cue in randomized order) which the participant is ought to follow with eyes and head. First while standing still and second while walking the 10-meter overground walkway at a self-preferred walking speed.
223606851|NCT06345625|OTHER|Screening|"The researcher will visit the possible participants (at their home, community centre, etc.) and after written consent on screening procedure is provided, the tests for eligibility will be performed.~1. Interview: asking about age (years), gender (male/female), medical history and the number of falls in the last 12 months .~2. Timed Up-and-Go (TUG) to check walking ability. TUG is a sensitive and specific measure for identifying risk for falls (Shumway-Cook et al., 2000)."
223753796|NCT03881137|OTHER|Geriatric assessment with management|"A multicomponent intervention, carried out in cooperation between hospital and community services, based on a geriatric assessment (GA) followed by individually adapted measures targeting identified needs.~The GA and the start of the intervention will be handled by a PhD student (geriatrician) or project cancer nurse at start of RT. Pre-planned guidelines will be followed. Contribution from relevant hospital professionals will be sought according to needs. Then the intervention will be offered in the primary health care taking advantage of existing services, e.g. home care, rehabilitation services, exercise groups etc. A community-based coordinating nurse will follow the patients with weekly contacts throughout RT and to end of intervention 8 weeks post-RT. To ensure that each patient's intervention is properly adjusted to changing needs, repeated clinical assessments will be performed by the end of RT and 4 weeks post-RT."
223753797|NCT02646579|PROCEDURE|Spinal and Peripheral Dry Needling|Participants will be positioned lying flat and the relevant spinal level will be treated using a Seirin L- type 50 mm needle. The needle will be inserted to a depth no greater than three-quarters length of the needle for 30 seconds using a vertical pistoning technique and then statically up to 10 minutes.
223753798|NCT02646579|PROCEDURE|Peripheral Dry Needling|Participants will be positioned lying flat and the relevant peripheral points will be treated using a Seirin L- type 50 mm needle. The peripheral treatment site(s) will be determined by the physical therapist's palpation of active or latent trigger points or tender points. The needle will be inserted to a depth no greater than three-quarters length of the needle for 30 seconds using a vertical pistoning technique and then statically up to 10 minutes.
223753799|NCT02639481|BEHAVIORAL|Standard physiotherapy|Classical standard physiotherapy, including measures to verticalize patients by means of orthesis, classical tilt tables, or castings
223753800|NCT02639481|DEVICE|Erigo®Pro group without FES|Use of the Erigo®Pro device to verticalize patients to above 60° while performing robotic stepping leg movements. FES ist not used.
223753801|NCT02639481|DEVICE|Erigo®Pro group with FES|Use of the Erigo®Pro device to verticalize patients to above 60° while performing robotic stepping leg movements. FES is applied during then whole treatment session, providing electrical stimulation to the muscles of the upper and lower leg, synchronous to the robotic stepping movements
223753802|NCT00446719|DRUG|Rellidep|2000 mg P.O. daily for 8 weeks
223753803|NCT01492452|OTHER|standardized guidelines for nursing|Information was provided regarding the preoperative preparation of the child, the same conditions and in the postoperative period, as well as information relating to housing and food for the parents. The conventional orientation took about 15 minutes.
223753804|NCT00003724|PROCEDURE|surgical procedure|
223753805|NCT02507414|OTHER|Blood samples|15 arterial blood samples (pre-, intra- and one day postoperatively); no more than 180ml in total over two days.
223753806|NCT02507414|OTHER|Measurement of microcirculation|Measurement of microcirculation with Laser Speckle Contrast Imaging (non-touch setup with no side effects); continuous measurement of the microvascular blood flow on the forehead up to 60 minutes starting one minute before the surgical procedure.
223753807|NCT02507414|OTHER|Head down tilt|"At three different time points the participants will be head down tilted in 20 degrees.~End of surgery (A) One hour postoperatively (B) 18 hours postoperatively (C)"
223753808|NCT04507932|DRUG|68Ga-FAPI|Intravenous injection of one dosage of 74-148 MBq (2-4 mCi) 68Ga-FAPI. Tracer doses of 68Ga-FAPI will be used to image lesions of inflammatory bowel disease by PET/CT.
223753809|NCT05956769|DRUG|Tranexamic Acid|Tranexamic acid injection 10 mg/kg and infusion 2 mg/kg/hr
223753810|NCT05956769|DIAGNOSTIC_TEST|thromboelastography|thromboelastography (TEG6)
223753811|NCT05956769|DRUG|Placebo|Normal saline injection
224311534|NCT03515590|OTHER|Emulsion with solid droplets|This will be a 500 mL beverage emulsion in which the droplets are crystalline. It will have identical composition to the other intervention, i.e. in one the lipid droplets are solid (i.e. crystallized) and the other in which they remain liquid will be introduced at least 7 days apart. The differences in physical state will be achieved simply by changing the temperatures the emulsions are held at. The emulsion will contain 10 % of the lipid palm stearin with 0.4% of the emulsifier sorbitan monostearate (Span60).
224311535|NCT03515590|OTHER|Emulsion with liquid droplets|This will be a 500 mL beverage emulsion in which the droplets are liquid. It will have identical composition to the other intervention, i.e. in one the lipid droplets are solid (i.e. crystallized) and the other in which they remain liquid will be introduced at least 7 days apart. The differences in physical state will be achieved simply by changing the temperatures the emulsions are held at. The emulsion will contain 10 % of the lipid palm stearin with 0.4% of the emulsifier sorbitan monostearate (Span60).
224311536|NCT04941118|DRUG|Injection of dextrose, local anesthetic and saline to the myofascial trigger point|An injection of 5 ml of 5% dextrose prolotherapy using 2.5 ml 10% dextrose, 1 ml 2% local anesthetic (lidocaine), 1.5 ml 0.9% saline will be administered to the active group from at least 10 trigger points.
223606852|NCT06345625|OTHER|Follow up|Participants are followed up for 12 months. They fill in a fall diary and telephone reminders will be performed monthly to encourage participants to complete and return their diaries.
223606853|NCT06097026|PROCEDURE|Alveolar recruitment maneuver|Progressive pressure increase on the ventilator to recruit collapsed alveoli and improve pulmonary ventilation.
223753812|NCT03060772|DRUG|Pioglitazone|Participants will take 30 mg of pioglitazone once daily for a total of two to four weeks for those randomized to therapy, until the next bronchoscopy is performed. Participants will receive 14 to 28 tablets of active pioglitazone, which is enough to complete the minimum 14-day course of therapy.
223753813|NCT02781103|OTHER|Guided imagery plus active tDCS|The subject will be positioned in the sitting/reclining position in a quiet room with the lights dimmed. The tDCS device and audio headphones will be placed on the subject's head. The tDCS device to be used is the Soterix Medical 1X1 device using 2.0 mA of current. The electrodes that will be used will be standard sponge electrodes. The subject will listen to a scripted guided imagery CD specifically developed for women with chronic pelvic pain through the audio headphones. The guided imagery plus active tDCS arm will have tDCS for 20 minutes concurrently with Guided Imagery.
223753814|NCT02781103|OTHER|Guided imagery plus Sham tDCS|The subject will be positioned in the sitting/reclining position in a quiet room with the lights dimmed. The tDCS device and audio headphones will be placed on the subject's head. The tDCS device to be used is the Soterix Medical 1X1 device using 2.0 mA of current. The electrodes that will be used will be standard sponge electrodes. The subject will listen to a scripted guided imagery CD specifically developed for women with chronic pelvic pain through the audio headphones. The sham arm will have 30 seconds of tDCS, but after 30 seconds the device will be turned off. The device will remain in place until the subject has listened to 20 minutes of the guided imagery CD.
223753815|NCT05583188|DEVICE|Aliya Pulsed Electric Fields (PEF) ablation|Patients will undergo PEF ablation
223753816|NCT05583188|DRUG|Nivolumab plus Platinum Doublet Chemotherapy|If EGFR/ALK mutation negative, patients will receive standard of care dosing of three cycles of nivolumab at a dose of 360 mg every three weeks along with a platinum-based chemotherapy doublet (cisplatin or carboplatin plus pemetrexed for adenocarcinoma, cisplatin or carboplatin plus docetaxel, paclitaxel, or gemcitabine for squamous NSCLC) post-PEF ablation followed by resection.
223753817|NCT05583188|DRUG|Standard of care neoadjuvant therapy|Patients not eligible for neoadjuvant nivolumab plus chemotherapy will receive standard of care systemic therapy post-PEF ablation followed by resection.
223606854|NCT06097026|DRUG|Nitric Oxide|Administer nitric oxide upon arrival from cardiac surgery and assess cardiac and pulmonary function afterwards.
223606855|NCT01403155|BIOLOGICAL|INO-3401 + EP|All subjects will receive 0.9mg/mL of study vaccine (INO-3401 DNA plasmid vaccine)at Day 0 and Month 3.
223606856|NCT04359199|RADIATION|Radiation Therapy|Routine radiation dosing (approximately 70 Gy in 35 fractions over 6.5 weeks) to the head and neck for the treatment of head and neck cancer
223606857|NCT04359199|DRUG|Cetuximab|Cetuximab is an epidermal growth factor receptor (EGFR) inhibitor used for the treatment of head and neck cancer
223606858|NCT04359199|DRUG|Chemotherapy|Cisplatin is a chemotherapy medication used to treat a number of cancers, including head and neck cancer
223753818|NCT05583188|OTHER|Surgical Resection|Patients not eligible for systemic therapy will receive definitive surgery without neoadjuvant therapy as per institutional standard of care post-PEF ablation.
223753819|NCT03961542|OTHER|Chewing|Eligible patients are randomized to receive either routine care (control group) or routine care in addition to a chewing gum intervention for five days (beginning with the second study day, i.e. the day after baseline examination): sugar-free, fruit or mint flavoured gum chewed three times daily for 20 minutes before each meal. Routine care includes standard dietary and lifestyle advice for 30 minutes following our local recommendations as well as an advice on capillary blood glucose measurement (fasting as well as 1h after starting each meal). Capillary blood glucose profiles are reevaluated seven days after starting the blood glucose monitoring. Study visits will be scheduled at screening (visit 1, where eligible patients were randomized) as well as seven days later (visit 2).
223753820|NCT02644707|DIETARY_SUPPLEMENT|L-selenomethionine|The group will be randomized to receive organic selenium in the form of L-selenomethionine at the dose of 200mcg daily (intervention group) for 6 months
224311537|NCT04941118|DRUG|Local anesthetic and saline injection to the myofascial trigger point|A total of 5 ml of solution created by using 4 ml of 0.9% saline and 1 ml of 2% local anesthetic (lidocaine) will be administered to the control group, with at least 10 trigger points.
223753821|NCT02644707|OTHER|Placebo|The group will be randomized to receive placebo (control group) for 6 months
223753822|NCT02932904|DRUG|Vortioxetine|Vortioxetine Overencapsulated Tablet
223753823|NCT02932904|DRUG|Paroxetine|Paroxetine Overencapsulated Tablets.
223606859|NCT04359199|DRUG|Immunotherapy|"Keytruda or Pembrolizumab is a highly selective humanized monoclonal IgG4 antibody directed against the PD-1 receptor on the cell surface.~Opdivo or Nivolumab is a targeted therapy. It is a human programmed death receptor-1 (PD-1) blocking antibody.~Imfinzi or Durvalumab is an anti-cancer (antineoplastic) drug. This medication is classified as an Anti-PD-L1 monoclonal antibody."
223606860|NCT00554450|DRUG|Dapagliflozin|Tablets, Oral, once daily
223606861|NCT01822457|DEVICE|Nike FuelBand (NFB)|The Nike Fuel Band (NFB) is a wrist-worn sensor with a built-in accelerometer for motion quantification. It is programmed to estimate the number of steps taken per day, and also predict energy expenditure in units known as Nike Fuel. Accompanying software allows the user to set daily targets and monitor their activity through a graphical user interface.
223606862|NCT02340065|PROCEDURE|standard colonoscopy|examination of the colon with a conventional colonoscope
223606863|NCT02340065|PROCEDURE|Endocuff-assisted colonoscopy|examination of the colon with Endocuff-assisted colonoscopy
223606864|NCT00091234|DRUG|gemtuzumab ozogamicin|
223753824|NCT02932904|DRUG|Placebo|Vortioxetine Placebo-matching Capsules.
223753825|NCT01881659|OTHER|HPV screening|Women who signed informed consent will be screened with HPV testing.
223753826|NCT03976427|BEHAVIORAL|Guided Imagery|The guided imagery exercise asks participants to think about positive associations with healthy foods and imagine their future healthy selves.
223753827|NCT00337103|DRUG|Eribulin Mesylate|1.4 mg/m\^2 intravenous (IV) infusion given over 2-5 minutes on Days 1 and 8 every 21 days
223753828|NCT00337103|DRUG|Capecitabine|Capecitabine 2.5 g/m\^2/day administered orally twice daily in two equal doses on Days 1 to 14 every 21 days
223753829|NCT05532943|BIOLOGICAL|Allogeneic umbilical cord mesenchymal stem cells|UMSC01 cells will be IV infusion followed by IT infusion with 12 months of follow up after treatment.
223753830|NCT05532943|BIOLOGICAL|Control group|Normal saline will be IV infusion followed by sham-IT infusion with 12 months of follow up after treatment.
223753831|NCT05197842|DRUG|BDB-001 injection|Intravenously administered
223606865|NCT03691597|DIAGNOSTIC_TEST|improved patient satisfaction ,marginal integrity, shade match and gingival health|"For both groups N.Awill make a recall visit after6 months and after 12 months:~1. Patient satisfaction will be performed according to questionnaire after One year.Questionnaire will contain several questions that evaluate patient satisfaction.~2. The color will be measured using spectrophotometer Vita easy shade in the same delivery visit ,after 6months and after one year .~3. Images will be captured using digital handheld light microscope (Celestron 5 Megapixel Resolution, USA) that is fixed on a film holder on a specific distance for the standardization of all the images will be captured by the microscope for all the patients.(22)~4. Images will be analyzed using imageJ software to measure marginal gap.~5. Gingival health will be measured using G"
223606866|NCT04258826|DRUG|LY3154207|LY3154207 administered orally.
223606867|NCT04258826|DRUG|Placebo|Placebo administered orally.
223753832|NCT05197842|DRUG|Cyclophosphamide|Intravenously administered
223753833|NCT05197842|DRUG|Glucocorticoids|Orally administered
223753834|NCT01577758|DRUG|MLN0264|MLN0264 30-minute infusion on Day 1 of each treatment cycle
223753835|NCT03981133|BEHAVIORAL|offer a pacifier|offer a pacifier to normal newborn infants the first days of life
223753836|NCT03981133|BEHAVIORAL|no pacifier|not to offer a pacifier at 15 days of life
223753837|NCT05497843|DRUG|Chiauranib|50mg, orally once daily
223753838|NCT05785065|DRUG|Mycophenolate Mofetil|"The participant will receive 500 mg to 1000 mg twice daily of mycophenolate mofetil administered orally for 96 weeks.~The dose scheduling will be as follow:~Weeks 1 and 2: 500 mg twice a day Weeks 3 and 4: 750 mg twice a day Weeks 5 to 96: 1000 mg twice a day"
223753839|NCT05785065|OTHER|Placebo|"The participant will receive 500 mg to 1000 mg twice daily of placebo administered orally for 96 weeks.~The dose scheduling will be as follow:~Weeks 1 and 2: 500 mg twice a day Weeks 3 and 4: 750 mg twice a day Weeks 5 to 96: 1000 mg twice a day"
223753840|NCT00702117|DRUG|flecainide|2 mg/kg iv in 10 minutes
223753841|NCT00702117|DRUG|ajmaline|1 mg/kg iv in 10 minutes
223753842|NCT00702117|DRUG|procainamide|10 mg/kg iv in 10 minutes
223753843|NCT01142310|DRUG|Lamotrigine|Lamotrigine will be initiated at 25 mg/day and upwardly titrated to a dose of 400 mg/day over 10 weeks.
223753844|NCT01142310|DRUG|Placebo|
223753845|NCT05662579|OTHER|Exercises|"There will be 2 reevaluations of the participants, similar to the initial: at the end of the exercise protocol and in a follow-up of 12 weeks after the end of the protocol.~The contraction phase of each exercise will be 2 concentric seconds, 1 isometric second and 2 eccentric seconds, followed by 1 second of rest; there will be approximately 90 seconds of rest between each set of 10 repetitions, time the other member will be exercising.~At the beginning and at the end of each session, the participants will be asked to point out the pain they feel in the hip at that time. In each of the 8 sessions, the physiotherapist will take note of the presence, lateral pain in the hip at the beginning and end of the therapy (by VAS), number of repetitions performed in each exercise (for the group that will do core exercises, it will be noted the time in seconds of each exercise) and any adverse events. Each series of exercises will be repeated 3 times, all performed bilaterally."
223753846|NCT05820347|DEVICE|Artificial Intelligence Estimation of Muscle Pressure during Mechanical Ventilation|Estimation of inspiratory muscle pressure by an artificial intelligence algorithm integrated in the mechanical ventilator (FlexiMag, Magnamed, Brazil).
223753847|NCT04762134|DRUG|Doxycycline Hyclate|STI PrEP arm: doxycycline capsules 100mg orally daily for 12 months STI PEP arm: doxycycline 200mg orally once within 24-72 hours following each sexual encounter deemed at risk (i.e. condomless anal or oral sex), to a maximum of six pills (i.e. 600 mg total) per week
223753848|NCT02578654|OTHER|Strategies to improve HIV care engagement|"Additional HIV care team daily inpatient round and three telephone calls to remind the upcoming clinic appointment. These interventions are specifically added on routine care during the post-intervention period. The routine care does not include the additional round and the three telephone calls and is assessed during the pre-intervention period."
223753849|NCT06038201|PROCEDURE|LAMS placement for cholecystostomy|The EUS-guided cholecystostomy entails placing a 10 mm x 10 mm or 10mm x 15mm Electrocautery-Enhanced LAMS for direct cholecystoscopy with a transnasal gastroscope. Then, the cholecystostomy will be performed with an echoendoscope, assisted by fluoroscopy to allow the puncturing of the gallbladder form either the duodenal bulb (cholecysto-duodenoscopy) or the gastric antrum (cholecysto-gastrostomy). Subsequently, from the most optimal anatomic point it will be tutored with a 10mmx10mm or 10mm x 15mm LAMS to create anastomosis between the structures. Then, the stone clearance will be performed by endoscopy (basket catheters) or by cholangioscopy (mechanical lithotripsy with or without basket catheters).
223753850|NCT06038201|PROCEDURE|Laparoscopic cholecystectomy|A laparoscopic biliary exploration along with an elective laparoscopic cholecystectomy will be performed by experienced laparoscopic surgeons (over 100 laparoscopic procedures yearly) by three or four-trocar technique with transection of the cystic duct and artery.
223753851|NCT01642017|DRUG|Pazopanib|Pazopanib will be administered orally at the starting dose of 400 mg/day in 28-days cycles ; barring limiting toxicities the dose of pazopanib will escalate in several steps (a maximum of 3 dose levels are defined : 400, 600 and 800 mg/day). The pazopanib will be administered at the same dosa until disease progression.
223753852|NCT03984422|OTHER|Smartphone application|use of smartphone application during 2 weeks to 3 months to collect frequency and duration of crises, RCS, photography of finger.
223753853|NCT03095456|DRUG|Revefenacin|Revefenacin administered via nebulization.
223753854|NCT03095456|COMBINATION_PRODUCT|Spiriva Handihaler®|Spiriva Handihaler® contains Spiriva (also known as Tiotropium) and is administered via HandiHaler® device.
223753855|NCT03095456|DRUG|Placebo for Revefenacin|Placebo administered as double blind, double dummy via nebulization.
223753856|NCT03095456|DRUG|Placebo for Spiriva Handihaler®|Placebo administered as double blind, double dummy via Spiriva HandiHaler®.
223606868|NCT04870502|DRUG|Controlled ovarian stimulation by Combined Clomiphene Citrate and Ubiquinol Versus hMG|In group A, controlled ovarian stimulation (COS) was done by Clomiphene Citrate (Fertab® 50 mg tablets, Zynova. SITCO Pharma.) as 150 mg (3 tablets) daily for 5 days (from 2nd day till 6th day of the cycle) together with Ubiquinol (active form of Coenzyme Q10) starting from 2nd day till the day of human Chorionic Gonadotropin (hCG) triggering in a dose of 100 mg capsules orally once daily, immediately after meal (Nutraquinol®; Jamjoom Pharma Nutraceuticals). In group B, Human Menopausal Gonadotropins (hMG) (Merional® 75 I.U. vials, IBSA.) IM was given from 2nd day of the cycle in a dose ranging from 75 to 225 IU according to the patient's response. Patients were instructed not to take any non-study drugs during the whole study period.
223606869|NCT00472901|DRUG|Afamelanotide (CUV1647)|16mg implant
223606870|NCT06147141|BEHAVIORAL|Online Peer Companion Intervention|Ordinary children would be paired with ASD children before the interventions. Dyads in the OPCI would have a total of 12 sessions within two months, each lasting 30-60 minutes. The longest interval between two sessions couldn't exceed two weeks. Researchers would recommend a series of companion themes for children to choose from (e.g., daily sharing and drawing). Ordinary children and ASD children need to discuss activities that are of mutual interest before each session. A researcher assistant would be online to ensure the normal development of the interventions and be responsible for video recording of the exchanges at the beginning of each session. Except for extreme circumstances, he or she would turn off the video and sound throughout the process and withdraw soon. During the interventions, parents would play a supporting role when children express needs without over-involvement.
223753857|NCT02151448|BIOLOGICAL|DC vaccine|Administered on Monday of each cycle: 1 intranodal ultrasound-guided injection (target dose of 3 x 10e6 cells in 0.5 mL) + 1 intradermal injection (target dose of 3 x 10e6 cells in 0.5 mL)
223753858|NCT02151448|DRUG|Celecoxib|Administered at 200 mg, once a day orally, starting the day of the first DC vaccine through week 4/cycle 2. Participants will not take celecoxib while receiving standard of care chemotherapy as instructed by their local oncologist. Celecoxib will continue starting week 20/cycle 3 and continue until the Friday of the last day of the CKM administration, cycle 4. Administered at 400 mg, 200 mg twice a day orally, on days participants receive vaccine and CKM.
223753859|NCT02151448|DRUG|Interferon Alfa-2b|Intravenous infusion over 20 minutes: doses tested in Phase 1 portion (5, 10, or 20 MU/m2) will determine the Phase 2 dose. Administered on the Tuesday of each CKM cycle.
223753860|NCT02151448|BIOLOGICAL|rintatolimod|Intravenous infusion of 200 mg on Wednesday and Friday only of the CKM regimen. The protocol allows for de-escalation to 100 mg if attributable adverse effects are observed.
223753861|NCT00886431|OTHER|embryo vitrification|Ultra rapid cooling of embryos by immersion in liquid nitrogen. The formation of potentially damaging ice crystals is prevented by briefly incubating the embryos in high concentrations of a mix of cryoprotectants.
223753862|NCT05338190|DRUG|Combination of Rituximab with subcutaneous belimumab|Belimumab 200 mg subcutaneous weekly (i.e., every 7 days ±1 day) starting from day 0 through week 24 with 1 g intravenous of Rituximab 7 days and 21 days after the randomization.
223753863|NCT05338190|DRUG|Combination of Rituximab with subcutaneous placebo|Placebo subcutaneous weekly (i.e., every 7 days ±1 day starting from day 0) starting from day 0 through week 24 with 1 g intravenous of Rituximab 7 days and 21 days after the randomization.
223753864|NCT04237428|BIOLOGICAL|CD19 CAR-T cells infusion|"Biological: CD19 CAR-T cells infusion Biological: CD19 CAR-T cells infusion. Pretreatment: patients enrolled in this study will receive cyclophosphamide or fludarabine plus cyclophosphamide. CD19 CAR-T cells infusion are allowed within 2 weeks after treatment.~CD19 CAR-T cells infusion: 30-60 minutes before infusion, H1 anti-histamine agents are applied (acetaminophen 30mg,po.; promethazine 25mg,i.v. ; diphenhydramine 0.5-1mg/kg, no more than 50mg.). Non-physiological doses of corticosteroids are not applied for patients during treatment or recovery unless a life-threatening emergency occurs. CD19 CAR-T cells are infused into patients for one time, the number of infused CD19 CAR-T cells are 0.5-4×10\^6/kg."
224311538|NCT01909830|DRUG|Arm A : Gemcitabine + Pemetrexed|"Gemcitabine: 1000 mg/m2 by intravenous infusion over an exact period of 30' (preferably by a pump to guarantee a constant speed of infusion) on day 3 of each cycle repeated every 14 days.~Pemetrexed: 150 mg/m2 by intravenous continuous infusion over an exact period of 8h on day 1 of each cycle repeated every 14 days."
223753865|NCT02479711|OTHER|composite restoration|The tooth will be isolated with cotton rolls and the caries will be removed. Enamel and dentin conditionings were performed with a self-etching adhesive system (Adhese One F, Ivoclar Vivadent, Liechtenstein). Bulk fill composite (Tetric EvoCeram® , Ivoclar Vivadent, Liechtenstein) will be injected in a single bulk increment of less than 4 mm to fill the preparations. The material was condensed with a flat instrument. Once set, it will be polished with finishing cups (Enhance® , Dentsply , Milford, USA). An interproximal strip will be used to finish the final contour.
223606871|NCT06147141|BEHAVIORAL|Wait-List|Dyads in the WLG would only participate in preliminary training and measurement during the implementation of the intervention. After completing the post-test, this study will implement the same online peer companionship intervention.
223606872|NCT01290757|DRUG|Dabigatran etexilate|150 mg Capsugel (T)
223606873|NCT01290757|DRUG|Dabigatran etexilate|150 mg Qualicaps (R)
223606874|NCT05599737|RADIATION|Integrated boost|Integrated boost based on the dominant intra-prostatic lesion delineated on multi-parametric Magnetic Resonance Imaging and 68Ga-Prostate Specific Membrane Antigen Positron Emission Tomography
223606875|NCT06527781|DRUG|PD5K3|Six dose levels will be evaluated. intravenous injection
223606876|NCT06527781|DRUG|Placebo|intravenous injection
223606877|NCT06527781|DRUG|Pegaspargase|Six dose levels will be evaluated. intramuscular injection
223606878|NCT00759161|DRUG|AN2728|AN2728 Ointment, 5%, twice daily for 4 weeks
223606879|NCT00759161|DRUG|AN2728 Ointment Vehicle|AN2728 Ointment Vehicle, twice daily for 4 weeks.
223606880|NCT02637765|BEHAVIORAL|Increased Physical Activity|Patients will receive a program of increased physical activity starting from 5000 steps/day up to 12000 steps/day after 8 weeks and an 8-week recreational program of brisk walking/running (3 times a week).
223753866|NCT02479711|OTHER|glass ionomer cement|The tooth will be isolated wit cotton rolls and the caries will be removed. The dentist will mix and handle the materials in accordance with the manufacturers' instructions. The material was condensed with a flat instrument. Once set, it will be polished. An interproximal strip will be used to finish the final contour. G-Coat Plus (GC, America) will be applied to the surface and margins of the restoration.
223753867|NCT00343057|OTHER|Patients' questionnaire|
223753868|NCT00906191|DRUG|SAM-531|
223753869|NCT03827278|DRUG|Voriconazole|"6mg/kg bid, was given on the first day, followed by intravenous 4mg/kg bid for 6 days, followed by oral Valconazole 200mg bid for at least 6 months.~Amphotericin B sequential itraconazole group (intravenous amphotericin, dose 0.7 - 1.0 mg / kg / d, 14 days, then changed oral itraconazole 200 mg bid for 10 weeks, after which 100 mg bid maintenance Until CD4+ T cells are greater than 100 cells/L for at least 6 months"
223753870|NCT02788110|OTHER|Noninvasive neurally adjusted ventilatory assist (NIV NAVA)|Neurally adjusted ventilatory assist (NAVA) is a mode of ventilation that uses a functional naso/orogastric tube with embedded electrodes which detect diaphragmatic contractions (called the Edi signal). NAVA uses this Edi signal to synchronize ventilator support to the patient's own respiratory efforts and to support these efforts as needed.
223753871|NCT02788110|OTHER|Nasal intermittent positive pressure ventilation (NIPPV)|"Nasal intermittent positive pressure ventilation (NIPPV) or noninvasive pressure control ventilation (NIV PC) is a mode of ventilation delivering unsynchronized puffs of air or breaths to a baby through nasal cannulae."
223753872|NCT01256593|DRUG|Pregabalin (Lyrica) capsule|"Lyrica® Capsules depending on the investigator prescription. Frequency and duration are according to Package Insert as follows. The usual adult dosage for oral use begins at 150 mg/day of pregabalin in twice daily, and should be gradually increased to 300 mg/day over 1 week or more and should be orally administered twice daily. Dosage should be adjusted, depending on age or symptoms. However, the daily maximum dose should not be beyond 600 mg, and should be orally administered twice daily."
223753873|NCT04414553|BEHAVIORAL|Community Active and Healthy Families|"Community-AHF will consist of eight, semimonthly 2-hour group appointments. Community-AHF sessions will target two areas: 1) Practical information regarding importance of healthy behaviors, and 2) Problem-solving skills to overcome barriers to improving diet and increasing physical activity and other related healthy behaviors. Each session covers specific objectives, includes a number of complementary activities and provides participants with take-home materials to facilitate behavior change.~Community-AHF will be delivered by a nurse and a Community Health Worker (CHW) trained by a consultant nutritionist and study investigators. The CHW will contact families between group sessions to discuss challenges and successes regarding lifestyle changes."
223753874|NCT03287388|PROCEDURE|No Rocuronium|Phase 1: The patient will undergo a routine MRI-abdomen without neuromuscular blockade: TOF ratio =1.
223606881|NCT03329846|DRUG|BMS-986205|specified dose on specified day
223606882|NCT03329846|BIOLOGICAL|Nivolumab|Specified dose on specified day
223606883|NCT03329846|DRUG|Placebo|Specified dose on specified day
223606884|NCT00479336|DRUG|OPC-41061 7.5mg|7.5mg, 1 tablet a day
223606885|NCT00479336|DRUG|OPC-41061 placebo|placebo, 1 tablet a day
223606886|NCT00479336|DRUG|OPC-41061 15mg|15mg, 1 tablet a day
223606887|NCT00479336|DRUG|OPC-41601 30mg|30mg, 1 tablet a day
223606888|NCT02158871|BEHAVIORAL|Beyond Silence|Pilot data from initial phases of the project and best practice principles in contact based education and adult learning theory informed curriculum design. The six in-person sessions use workplace-based vignettes to prompt reflection and discussion, build mental health literacy, reduce stigma, and promote communication and coping skill development. The virtual sessions use a secure online discussion board for participants to explore relevant online resources. All sessions will be co-led by trained peer educators; employees who have personally experienced mental ill health and recovery and are viewed as credible leaders within the organization. They will be recruited and trained to effectively teach the content, share personal experiences, and facilitate discussion.
223753875|NCT03287388|DRUG|Rocuronium (moderate NMB)|Phase 2: Rocuronium will be titrated to a moderate NMB (TOF 1-3), monitored by TOF-watch. When an adequate moderate NMB is achieved, the patient will undergo a second MRI-abdomen.
223753876|NCT03287388|DRUG|Rocuronium (deep NMB)|Phase 3: The patient receives a bolus of 1.2 mg/kg rocuronium (adjusted to ideal body weight), to assure a deep or intense NMB (PTC 0-1). Then the patient will undergo the final, third MRI scan of the abdomen.
223753877|NCT03719313|DRUG|Lonafarnib|Lonafarnib (LNF) 50 mg BID
223753878|NCT03719313|DRUG|Ritonavir|Ritonavir (RTV) 100 mg BID
223753879|NCT03719313|DRUG|PEG IFN-alfa-2a|PEG IFN alfa-2a 180 mcg QW
223753880|NCT03719313|DRUG|Placebo Lonafarnib|Placebo
223753881|NCT03719313|DRUG|Placebo Ritonavir|Placebo
223753882|NCT05300165|DIETARY_SUPPLEMENT|Beer|A daily beer will be consumed by the participants during a total of 6 weeks, changing every 2 weeks from alcohol-free lager beer, lager beer and dark beer
223753883|NCT03800498|OTHER|DASH Education|DASH health education about general knowledge of DASH diet Plan and lifestyle modification
223606889|NCT02158871|BEHAVIORAL|Mental Health First Aid (MHFA)|MHFA is a standardized, twelve-hour educational program designed to teach participants how to recognize the early warning signs of mental illness, how to provide initial help to someone in a mental health crisis, and how to support people who are developing mental health problems. It is an evidence-based approach that originated in Australia, but is being implemented across Canada, under the leadership of the Mental Health Commission of Canada. Leadership of the MHFA will be provided by an employee in each organization who has been trained through the 5-day national MHFA instructor training program. The instructor does not share any personal experiences regarding mental health issues.
223606890|NCT03066193|DRUG|Dronabinol and Palmitoylethanolamide|Participants will receive Dronabinol which will be slowly titrated in the first week of the study. They will be followed for a total of 12 weeks; in addition, participants will receive the PEA in a standing dose of 400mg. They will be followed for a total of 12 weeks.
223606891|NCT03718026|OTHER|The timed 360° turn test|"* The timed 360° turn test: Each participant turns around in place in a standing position for both sides.~* Berg Balance Scale: It has 14 items, each of which is scored from 0 (i.e, severely impaired balance) to 4 (i.e., no balance impairment).~* Timed Up and Go test: It requires individual to stand up from an armed chair, walk 3m, turn around, walk back to the armed chair, and sit down again.~* Functional Reach Test: It measures the maximum distance an individual is able to reach forward beyond arm's length in the standing position when maintaining a fixed base of support.~* One-leg stance test: Individuals were asked to stand on either their left or right leg.~* Four square step test: It requires an individual to step over obstacles in various directions including forward, backward, and sideways."
223606892|NCT04995536|BIOLOGICAL|CpG-STAT3 siRNA CAS3/SS3|Given intratumorally
223606893|NCT04995536|RADIATION|Radiation Therapy|Undergo radiation therapy
223753884|NCT03162601|PROCEDURE|Neurovascular percutaneous intervention|Patient will receive one extra CACT scan while they are receiving percutaneous neurovascular intervention.
223753885|NCT06068569|BIOLOGICAL|GamCovidVac vector vaccine for the prevention of COVID-19 (with altered antigenic profile)|Two intramuscular injections of the GamCovidVac vector vaccine for the prevention of COVID-19 (with altered antigenic profile) will be performed. 1st injection - component I, 2nd injection - component II.
223753886|NCT00838227|DRUG|modafinil|Modafinil up to 400 mg daily will be added to a stable antipsychotic regimen
223753887|NCT04223882|BEHAVIORAL|Management of Stress|"Psychoeducation:~Coronary artery disease, Percutaneous Coronary Intervention, traditional risk factors and emotional stress.~Stress: physiology, triggers, triad (thinking, emotion, action).~Skills training:~Identify warning signs - signs and symptoms; Monitoring of irrational automatic thoughts generating alternative interpretations of situations or unrealistic thinking patterns (Dysfunctional Thinking Records Sheet).~Self-control for stress management:~Assertiveness training, problem solving. Thought-stopping technique, designed for dysfunctional thoughts, such as, I won't do it, It won't work.~Stress Relief / Control Techniques:~Diaphragmatic Breathing: Expansion of the abdomen rather than the chest when breathing.~Progressive Muscle Relaxation: Maximize tension and alternately relax the muscles (legs, abdomen, chest, arms and face)."
223753888|NCT04223882|OTHER|Usual care|outpatient medical appointments
223753889|NCT06485700|OTHER|Peer Delivery of Medications|Door-to-door peer delivery of medications within patients' communities will be implemented.
223753890|NCT06485700|OTHER|Health Information Technology (HIT) Platform|The HIT platform provides: 1) tailored counseling strategies through decision support; 2) teleconsultation support for clinician-peer-patient interactions; 3) medication refill tracking to enhance accountability of the peer delivery process; and 4) analytics to improve medication supply chain by generating patient-level drug consumption data.
223753891|NCT02941679|DRUG|HCP1202|Hanmi Pharmaceutical. Co., Ltd.
223753892|NCT02941679|DRUG|HGP1011|Boehringer Ingelheim
223753893|NCT02941679|DRUG|HCP0910|GlaxoSmithKline
223606894|NCT02118974|PROCEDURE|Hysterectomy|Hysterectomy
223606895|NCT02021643|DRUG|Sofosbuvir|Sofosbuvir 400 mg tablet administered orally once daily
223606896|NCT02021643|DRUG|RBV|Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)
223606897|NCT02021643|DRUG|PEG|Pegylated interferon alfa-2a (Peg-IFNα-2a) 180 µg/0.5 mL pre-filled syringe administered subcutaneously once a week
223606898|NCT03331900|DRUG|COR388|Administered as oral capsule
223606899|NCT03331900|DRUG|Placebo|Administered as oral capsule
223753894|NCT04503564|DEVICE|coil-reinforced soft polymer indwelling cannula|This is a prospective, non-randomized, home-use feasibility study of device performance, usability, tolerability, and safety of the Capillary Biomedical, Inc. (CapBio) Achilles infusion set for continuous subcutaneous insulin infusion (CSII or insulin pump therapy) in up to 20 participants diagnosed with type 1 diabetes mellitus (T1DM).
223753895|NCT06114784|DIAGNOSTIC_TEST|Metagenomics|Clinical metagenomics is used to evaluate pathogens
223753896|NCT03376672|DRUG|Ixazomib|All patients will have similar induction and consolidation treatment with the same regimen.
223753897|NCT03376672|DRUG|Lenalidomide|All patients will have similar induction and consolidation treatment with the same regimen.
223753898|NCT03376672|DRUG|Dexamethasone|All patients will have similar induction and consolidation treatment with the same regimen.
223753899|NCT02781870|PROCEDURE|LiquiBand Fix8 glue fixation|Patients will be operated in a standard procedure to receive the 3D ENDOLAP visible with LiquiBand® Fix 8™ glue fixation.
223753900|NCT02781870|PROCEDURE|No-fixation|Patients will be operated in a standard procedure to receive the 3D ENDOLAP visible without glue fixation.
223753901|NCT05368987|DEVICE|Transcranial magnetic stimulation (TMS)|Research subjects will undergo non-invasive TMS, with a frequency of 20Hz and intensity of 120% of their resting motor threshold (rMT) at varying time points and locations.
223753902|NCT05368987|BEHAVIORAL|Fear Conditioning and Extinction Paradigm|"Participants will undergo a 3-day experimental paradigm. On day 1, participants will undergo a resting-state and structural scans in the fMRI scanner. The data from this scan will be used to determine the specific location of the TMS target for each participant. And participants will be aversively conditioned to two cues in the fMRI scanner. Task based and resting-state scans will occur on this day.~On day 2, subjects will undergo extinction training outside of the scanner where one of the conditioned cues will be paired with TMS in a temporally and anatomically specific manner. A resting-state scan will occur before and after inside the scanner.~On day 3, conditioned cues will be presented during the extinction recall phase of the study. This phase will be conducted in the fMRI scanner. Task-based and resting-state scans will occur on this day."
223753903|NCT04180761|DRUG|intraoperative hyperthermic intraperitoneal chemotherapy (HIPEC)|single dose application of hyperthermic intraperitoneal chemotherapy (HIPEC) at 42.5°C for 60 minutes after the gastrectomy
223753904|NCT06394544|DIETARY_SUPPLEMENT|Brazil Nut|The intervention, for each participant, is estimated to last a total period of six months , which will be divided into three two-month stages, with data collection after each stage. Volunteers will be monitored to control possible side effects, doubts and check compliance. In addition, the telephone number and an email will be made available for contact during business hours, for possible clarifications.
223606900|NCT06162780|DIAGNOSTIC_TEST|ultrasonic cardiography (UCG)|Trans-thoracic echocardiography (TTE) is performed in the resting position. Trans-esophageal echocardiography (TEE) is performed under surface anaesthesia with bupivacaine or intravenous anaesthesia. We comprehensively assess the severity of mitral regurgitation according to American Society of Echocardiography (ASE) guideline.
223753905|NCT00145925|DRUG|Perindopril-indapamide|
223606901|NCT06162780|PROCEDURE|TEER|Two commercial cliping systems are available for clinical use: the G3 MitraclipTM and the G4 MitraclipTM (Abbott), DragonflyTM (Dejin), which will be introduced to the Chinese market in 2024, with the specific choice determined by the operator. The patient receives general anaesthesia (intravenous and endotracheal). The operator performs the procedure according to the recommended surgical steps in the product manual, guided by X-ray and trans-esophageal echocardiography. Postoperative MR ≤2+ is considered successful, and if the result is unsatisfactory, 1-2 additional clips are given.
223606902|NCT05154110|OTHER|stretching on whole body vibration|"SSubjects will be refrained from maximum-effort or new routines for exercise the day before each treatment.Static stretching of hamstring on whole body vibration will include Pre- and post-test active and passive ROM for the both legs, with subjects first undergoing a 5-minute warm-up on a stationary bicycle. The traditional static stretch consisted of a supine active knee extension on whole body vibration (WBV) at 30 Hz at the high amplitude setting will be performed. The stretch will be held at the point of the onset of discomfort 3 times each for 30 seconds, with a 20-second rest period between each stretch. Participants will stretch for 4 days per week for 4 weeks. Active hamstring ROM will be measured via active knee extension using a goniometer with the leg in 90° of hip flexion, with the opposite leg extended. Passive ROM will be measured via clinician-assist ted knee extension with the leg in 90° of hip flexion."
223753906|NCT00145925|DRUG|Gliclazide MR-based glucose lowering|
223753907|NCT06563401|OTHER|prognosis of adult-onset t1d|We are comparing mortality and vascular outcomes in adult-onset T1D to T2D and diabetes-free people
223753908|NCT04227236|OTHER|E-based virtual facilitator training for Making Proud Choices|Participants complete the Making Proud Choices (MPC) facilitator training using an e-based virtual trainer on a computer. Making Proud Choices! (MPC) is an evidence-based pregnancy and HIV/STI risk-reduction program for youth. The facilitator training prepares educators to effectively deliver the MPC curriculum.
223753909|NCT04227236|OTHER|In-person facilitator training for Making Proud Choices|Participants complete the Making Proud Choices (MPC) facilitator training using the standard in-person training method. Making Proud Choices! (MPC) is an evidence-based pregnancy and HIV/STI risk-reduction program for youth. The facilitator training prepares educators to effectively deliver the MPC curriculum.
223753910|NCT02747836|OTHER|Ultrasound of the wrist|using sound waves to create images capturing the movement of the SSCT and flexor tendon and transformation of the median nerve in the wrist
223753911|NCT05835479|DRUG|Co-Trimoxazole|Oral co-trimoxazole or Intravenous (IV) co-trimoxazole for infusion. Anti fungal medication
223753912|NCT05835479|DRUG|Rezafungin Acetate / Co Trimoxazole|"Rezafungin for infusion. Intravenous anti fungal therapy~Oral co-trimoxazole or Intravenous (IV) co-trimoxazole for infusion. Anti fungal medication"
223753913|NCT04301414|DRUG|BMS-986218 and Degarelix|BMS-986218 20mg IV every 2 weeks x 2 doses starting 3 weeks prior to radical prostatectomy plus degarelix 240mg subcutaneous (SQ) x1 dose 2 weeks prior to radical prostatectomy.
223606903|NCT05154110|OTHER|strength training|In second group, strength training will be done for 4 days per week for 4 days. Subjects will have 5 minutes warm up. In 1st week, the protocol will be Nordic hamstring curl (NHC) with bend (3 sets of 8 reps), Prone hamstrings curl (4 sets of 12 reps/leg), Physio-ball leg curl (3 sets of 8 reps), Glute bridge (2 sets of 50 s/leg). In 2nd to 4th week, the protocol will be NHC with bend (3 sets of 12 reps) Prone hamstrings curl (3 sets of 14 reps/leg) Physio-ball leg curl (3 sets of 10 reps) Glute bridge (2 sets of 50 s/leg). There will be 30 seconds rest between each set and 1 minute rest between each exercise . Pre and post AROM and PROM will be measured. Active hamstring ROM will be measured via active knee extension using a goniometer with the leg in 90° of hip flexion, with the opposite leg extended. Passive ROM will be measured via clinician-assisted knee extension with the leg in 90° of hip flexion.
223606904|NCT05523336|OTHER|observation|observation and prospective data collection
223606905|NCT03122210|DEVICE|Automated oxygen administration|In the control group, usual oxygen administration and titration is planned
223606906|NCT01946217|OTHER|questionnaire administration|Ancillary studies
223606907|NCT05659823|DRUG|Bupivacaine-fentanyl-morphine elective group|Guideline recommended analgesia in elective caesarian section.
223606908|NCT05659823|DRUG|Bupivacaine-fentanyl elective group|Current analgesia in elective caesarian section.
223606909|NCT05659823|DRUG|Bupivacaine-fentanyl emergency group|Current analgesia in emergency caesarian section.
223753914|NCT04301414|DRUG|Degarelix|Degarelix 240mg SQ x1 dose 2 weeks prior to radical prostatectomy
223753915|NCT01510678|BEHAVIORAL|Increase Fruits and Vegetables|Children will be encouraged to consume 1 cup/day and 1.5 cups/day of whole fruit, and 1.5 cups/day and 2 cups/day of vegetables for children aged 6 to 8 years and 9 to 12 years, respectively. Children will gradually work towards these goals. Parents will also work towards F\&V goals, with 2 cups/day of whole fruit and 2.5 cups/day of vegetables. Both parent and child will self-monitor these behaviors. As one barrier to consuming F\&Vs is perceived cost of these foods, information regarding lower-cost options for F\&Vs will be included in the manual.
223606910|NCT02768779|OTHER|Hair analysis|Within the laboratory, experimental factors controlling IR-MALDESI response to key ARVs representing various drug classes will be systematically evaluated using the design of experiments (DOE) statistical approach (41,127) for an unbiased optimization of IRMALDESI response to each of the ARVs and their major metabolites. The goal will be to achieve a lower limit of quantification (LLOQ) below clinically relevant hair strand concentrations.
223606911|NCT00043511|BIOLOGICAL|pGA2/JS2 Plasmid DNA Vaccine|
223606912|NCT00697931|BIOLOGICAL|Recombinant MPL- adjuvanted hepatitis B vaccine|Intramuscular injection, 3 doses
223753916|NCT01510678|BEHAVIORAL|Decrease Snack Foods|This condition will reduce intake of SFs (i.e., candy, cookies, cakes, ice cream, chips, nuts) to \< 3 servings/week (for children aged 6 to 12 years, the solid fats and added sugar energy limit is 840 kcals/week and the DECREASE goal will help with meeting this limit). Children and parents will gradually work towards meeting these goals and self-monitor these behaviors.
223606913|NCT00697931|BIOLOGICAL|Engerix™-B|Intramuscular injection, 3 doses
223606914|NCT00988078|DRUG|Placebo|Capsule (without biologic action) administered three times a day for six months
223606915|NCT00988078|DRUG|Metformin|Metformin 500mg three times a day for six months
223606916|NCT04854551|DRUG|Naltrexone|Naltrexone is an opioid antagonist with primary action at the mu opioid receptor.
223606917|NCT04854551|OTHER|Placebo|Placebo will be used to control for expectancy effects
223606918|NCT02631551|DRUG|GSP 301 NS|FDC of olopatadine HCl and mometasone furoate: 2 sprays in each nostril twice daily for 14 days
223606919|NCT02631551|DRUG|Olopatadine HCl NS|2 sprays in each nostril twice daily for 14 days
223606920|NCT02631551|DRUG|Mometasone furoate NS|2 sprays in each nostril twice daily for 14 days
223606921|NCT02631551|DRUG|GSP 301 Placebo NS|2 sprays in each nostril twice daily for 14 days
223606922|NCT05821244|BEHAVIORAL|Exercise Timing Groups|Individualized resistance training program, consisting of twice weekly training sessions supervised via telehealth with a cancer exercise trainer.
223606923|NCT02949726|DRUG|Indocyanine Green (ICG)|"Near-infrared Fluorescence Lymphatic Imaging (NIRFLI) using Indocyanine Green (ICG) is used to visualize lymphatic vessel anatomy and function."
223753917|NCT01510678|BEHAVIORAL|Increase Fruits and Vegetables and Decrease Snack Foods|Will combine the goals of the increase and decrease conditions.
223753918|NCT00231348|DRUG|Nefazodone|
223753919|NCT03611868|DRUG|Phase 1b: APG-115+pembrolizumab|"dose escalation of APG-115 in combination with label dose of pembrolizumab, Four dose levels of APG-115 will be tested: 50, 100, 150, and 200 mg. APG-115 will be administrateddose escalation of APG-115 in combination with label dose of pembrolizumab, Fourfour dose levels of APG-115 will be tested: 50, 100, 150, and 200 mg. APG-115 will be administrated orally every other day (QOD) for consecutive 2 weeks (ie. dosed at Day 1, 3, 5, 7, 9, 11, and 13), with one week dosing off as there are cycles every 3-weeks a cycle. Pembrolizumab is administrated following FDA approved label dose, i.e., 200 mg intravenous infusion at Day 1 of every 3 weeks as a cycle.~Phase II: Combination of APG-115 at 150 mg (RP2D) and pembrolizumab or APG-115 monotherapy alone."
223753920|NCT05222932|BIOLOGICAL|TILT-123|TNFalpha and IL-2 coding oncolytic adenovirus TILT-123
223753921|NCT05222932|DRUG|Avelumab|Anti-PDL1 antibody
223753922|NCT02375191|DRUG|fentanyl|
223753923|NCT02375191|DRUG|dexmedetomidine|
223753924|NCT02375191|DRUG|Ropivacaine|
223606924|NCT02949726|DEVICE|Near-infrared Fluorescence Lymphatic Imaging (NIRFLI)|"Near-infrared Fluorescence Lymphatic Imaging (NIRFLI) using Indocyanine Green (ICG) is used to visualize lymphatic vessel anatomy and function."
223606925|NCT04543877|DIETARY_SUPPLEMENT|Inulin|Consume 12 grams/day of inulin for 5 weeks (Day 9 - 43).
223606926|NCT04543877|DIETARY_SUPPLEMENT|Maltodextrin|Consume 12 grams/day of maltodextrin for 5 weeks (Day 9 - 43).
223606927|NCT04543877|BIOLOGICAL|Ty21a Typhoid Fever Vaccine|All participants will receive the vaccine. One capsule is swallowed on alternate days, e.g. days 30, 32, 34, and 36 for a total of 4 capsules.
223606928|NCT01935635|BIOLOGICAL|HPDCs-T immune therapy|HPDCs-T immune therapy:one time every 2 weeks during 12 weeks to 36 weeks, IV (in the vein), about 2\*105-1\*106 cells per time,total 12 times;
223606929|NCT04341714|OTHER|Satisfaction evaluation|Assessement of satisfaction of the telephone consultation
223606930|NCT05170451|DRUG|CBD|Topical CBD 50 mg/ml applied in 1mL amounts twice daily
223606931|NCT05170451|OTHER|Control|Topical shea butter applied in 1mL amounts twice daily
223606932|NCT02444949|DRUG|endostar|
223606933|NCT02444949|RADIATION|intensity modulated radiation|
223606934|NCT02444949|DRUG|cisplatin|
223606935|NCT04353739|BEHAVIORAL|Self-Management for HIV-positive Asian Pacific Americans|Developed upon the results of our prior studies involving familial relations among APA HIV+ populations, the family-informed self-management intervention has been fully manualized and has eight modules: (1) psycho-education, (2) cognitive-behavioral management skills training, (3) preparation for disclosure, (4) family relations and support management, (5) anxiety and depressive symptom management, (6) brief mindfulness training, (7) symptom reduction, and (8) the Life-Steps program.
223606936|NCT00349817|BEHAVIORAL|web-based learning, didactic lecture and role-play|
223606937|NCT01405300|DIETARY_SUPPLEMENT|Control|34.8 g dextrose, 150 g heavy whipping cream, 39g chocolate syrup, 15 g sunflower oil, 22 g safflower oil, 27 g powdered egg whites, 9.6 g of fiber supplement, water and crushed ice. It will deliver \~1200 kcal.
223606938|NCT01405300|DIETARY_SUPPLEMENT|Peanut|34.8 g dextrose. 137 g heavy whipping cream, 39g chocolate syrup + 3 oz peanuts with skin. It will deliver \~1200 kcal.
223606939|NCT04112303|DRUG|SOF/VEL|Tablets administered orally once daily
223606940|NCT01022658|DRUG|Insulin|For diabetes treatment: metformin continued with insulin (according to arms)
223606941|NCT01373658|DEVICE|Yinyi stent|subjects with Yinyi stent implantation
223606942|NCT02285335|DIETARY_SUPPLEMENT|GINST|The study is designed with using GINST either 500mg/capsule or 1000mg/capsule, two capsules at once, three times a day for 12 weeks.
223606943|NCT03106064|BEHAVIORAL|Promoting independence in self-care|The intervention will consist of an twice daily walking training, plus privileging trips to the toilet by walking (with support devices or with support from people) and all daytime meals seated (not in bed). Attending of the particular and unexplored characteristics of the proposed intervention, namely the use of the toilet and meals, the proposed intervention extends throughout the 24 hours of the day, seven days a week.
223606944|NCT03106064|OTHER|Usual Care|Usual hospital care
223753925|NCT05938751|BEHAVIORAL|TEAm_YOUNG ADULTS program|The TEAm\_YOUNG ADULTS program is an intervention to develop self-determination in young adults with autism. It consists of 20 1.5h weekly sessions. The intervention is conducted by two facilitators with expertise in autism and self-determination promotion. Groups are formed by 4 to 6 participants. The program can be applied online or in person. The first five sessions address specific characteristics and support needs of people with autism. The next ten sessions are focused on the development of self-determination. The last five sessions are focused on working with others and the closure of the group. The individual goals of every participant are considered in the beginning of the group and a weekly follow-up of goals is conducted.
223753926|NCT03969992|DRUG|AeroFact|Aerosolized SF-RI 1
223753927|NCT03969992|OTHER|nCPAP|nCPAP (nasal continuous positive airway pressure) alone
223753928|NCT01841151|BEHAVIORAL|SCP training|
223753929|NCT01841151|BEHAVIORAL|Live Z-score training|
223753930|NCT01841151|BEHAVIORAL|WM training|
223753931|NCT00914862|DRUG|Ramelteon|Ramelteon tablets, orally for one day only.
223753932|NCT01141881|DRUG|Tissue Plasminogen Activator,bevacizumab ,follow up|25 microgram in 0.05 cc,1.25 mg in 0.05 cc,nothing
223753933|NCT00929682|DRUG|Randomization between two referenced treatments|"Levobupivacaine 0.568 mg.mL-1 and sufentanil 0.45 g.mL-1, 20 mL epidurally for induction, then by a patient-controlled regimen with 5-mL self-administered boli in addition to a continuous infusion of 5 mL.hr-1.~Same protocol, with levobupivacaine 1.136 mg.mL-1 and sufentanil 0.45 g.mL-1."
223753934|NCT03317431|OTHER|mechanical ventilation|mechanical ventilation protocol: tidal volume 6-8 ml/kg, positive end-expiratory pressure 5 cmH2O, oxygen concentration 40%; respiratory rate 10-15/min, inspiratory/expiratory ratio 1:1.5.
223753935|NCT02356692|DEVICE|enfilcon A|Test lens
223753936|NCT02356692|DEVICE|senofilcon A|Control lens
223753937|NCT03960151|DRUG|Rolapitant|Rolapitant 180mg PO, Days 1 and 5
223753938|NCT03960151|DRUG|Palonosetron|Palonosetron 0.25 mg IV, Days 1,3, and 5.
223753939|NCT03960151|DRUG|Olanzapine|Olanzapine 10 mg PO PM, Days 2,3,4,5,6-8
223753940|NCT03960151|DRUG|Dexamethasone|Dexamethasone 20 mg AM, Days 1,2 and 3
223606945|NCT01855737|DRUG|Warfarin|Prescribe warfarin to the patients who are needed.
223606946|NCT03355846|DRUG|Centella|after meals twice a day for 15 days
223606947|NCT03355846|DRUG|Proctocella|after hygiene treatment for 4 weeks;
223753941|NCT03317171|DIETARY_SUPPLEMENT|Flavonoids, DHA, EPA|oral administration
223606948|NCT03355846|DRUG|Flavonil® cps|after meals twice a day for 15 days
223606949|NCT03355846|DRUG|Flavonil® Cream|"treatment for 4 weeks;~."
223606950|NCT03355846|DRUG|Rectalgan Mousse|for 4 weeks
223753942|NCT03317171|DIETARY_SUPPLEMENT|placebo compound|oral administration
223606951|NCT05703321|BEHAVIORAL|preoperative fasting|Fasting for 6 hours is required for the patients regarding the preparation of the operation and preparation for anesthesia
223606952|NCT04569292|OTHER|No intervention on patients|No intervention on patients
223606953|NCT01137032|DRUG|Pandel Cream 0.1%|A thin coat of cream will be applied and rubbed into the affected areas, as well as normal skin, twice daily for 21 days
223753943|NCT00062582|DRUG|Roflumilast|
223753944|NCT03897790|OTHER|Transcranial Doppler (DTC)|Evaluation of Vasoconstrictor Vasoreactivity with Transcranial Doppler
223753945|NCT03769272|PROCEDURE|Measurement of electrical delay during LV lead placement|Measurement of electrical signal in the heart during implantation of CRT, by positioning the lead in different places in the heart.
223753946|NCT04330742|DRUG|lactated ringers|the intervention is one liter fluid bag of lactated ringers which is routinely used as a fluid coload for spinal anesthesia. All patients will receive the same amount of fluids however this will be paused at various time points in order to perform the echocardiogram.
223753947|NCT02371707|DRUG|Idalopirdine 60 mg formulation A (test)|Tablet for oral use, single dose
223753948|NCT02371707|DRUG|Idalopirdine 60 mg formulation B (reference)|Tablet for oral use, single dose
223753949|NCT05751330|PROCEDURE|Transcatheter ablation of cardiac ganglionated plexi|"The ablative procedure involves applying radiofrequency deliveries in the two~Right atrium anatomical sites close to the two main ganglionic plexuses of the right atrium:~* Inferior-posterior area (site of first ablation) corresponding to the right inferior atrial ganglion located between the inferior vena cava, coronary sinus ostium and near the atrioventricular node~* Upper-posterior area (site of second ablation) corresponding to the right superior atrial ganglion located between the superior vena cava and the posterior surface of the right atrium"
223753950|NCT02567071|OTHER|perineal impregnated swab|After planned C-section birth, newborns will suck on previously impregnated swab by perineal and vaginal mother secretions.
223606954|NCT04218409|DRUG|OxyCODONE 5 mg Oral Tablet|Oral oxycodone 5 mg orally
223606955|NCT04218409|DRUG|Oxytocin nasal spray|Intranasal oxytocin administration (48 IU)
223606956|NCT04218409|OTHER|Placebo Oxycodone|Oxycodone 0 mg orally
223606957|NCT04218409|OTHER|Placebo oxytocin|Intranasal placebo administration
223606958|NCT04218409|DRUG|OxyCODONE 2.5 mg Oral Tablet|Oral oxycodone 2.5 mg orally
223753951|NCT02567071|OTHER|clean swab|After planned C-section birth, newborns will suck on clean swab.
223753952|NCT02979743|BEHAVIORAL|Occupational therapy|
223753953|NCT02979743|OTHER|Occupational therapy puls acupuncture and massage methods|
223753954|NCT02139566|BEHAVIORAL|Video consent (high-tech)|Consent provided by an animated video with captions
223606959|NCT05419232|OTHER|Short Message Service (SMS) + Website Link Strategy|The intervention we are evaluating is the effectiveness of a participant receiving a SMS + Website Link as a vaccine uptake strategy
223606960|NCT05419232|OTHER|Phone Call with Peer Strategy|The intervention we are evaluating is the effectiveness of a participant having a phone call with a peer as a vaccine uptake strategy
223606961|NCT06212024|BEHAVIORAL|Mentalization Based Treatment-early|MBT-early is an early intervention program for young people at risk for developing BPD that has been developed as an adaptation of MBT, an empirically supported treatment for BPD. MBT-early is a time-limited intervention that has been designed for early-stage BPD and focuses on improving personality functioning. MBT-early is a two-phase treatment that integrates interventions at the individual, family, and context level. MBT-early provides a combination of treatment modalities, including individual and family sessions, case management, and treatment reviews. Interventions are tailored to the specific needs of the young person and his/her family. The treatment consists of 16 weekly individual sessions, 3 family sessions, and case management. The initial treatment phase (16 weeks) is followed by a booster period (6 months) with 4 booster sessions. Since MBT-early involves a flexible approach, this standard package may be downscaled in cases of rapid improvement, or upscaled when needed.
223606962|NCT02595255|OTHER|No intervention|No intervention
223606963|NCT02879825|DEVICE|Cardiac MRI|"Group-A patients, with mitral valve prolapse but no mitral regurgitation, will undergo specifically for research purposes a cardiac MRI, 24-hour external loop recording and exercise ECG on top of regular echocardiography evaluation.~Realization of these examinations will be performed according to recommendations for patients with mitral regurgitation (groups B, C and D)"
223606964|NCT05636852|DRUG|Altropane (123I) Injection|Each participant received a single intravenous (IV) administration of 5 millicuries (mCi) (185 megabecquerels \[MBq\]) of Altropane (123I) Injection on Day 1. Altropane SPECT images were acquired for 30 minutes starting 15 to 20 minutes after administration with Altropane. These images were visually interpreted by 5 expert independent blinded readers.
223753955|NCT02139566|BEHAVIORAL|Video consent (low-tech)|This consent is a video production of the informed consent information, taped using a staff member with basic video equipment.
223753956|NCT02139566|BEHAVIORAL|FAQ format consent|"This consent modality will present the basic information from the informed consent in an interactive, frequently asked questions format. Upon clicking each question, the participant will be shown a short text response to that question."
223753957|NCT02139566|BEHAVIORAL|Standard consent|The standard consent form will present the full informed consent document in a scrolling text window within the browser window. Participants will be asked to review the document online.
223753958|NCT02139566|BEHAVIORAL|PDF informed consent document|A PDF of the full consent document will be available for download, through hyperlink on the consent page. This is provided for video (low-tech), video (high-tech), FAQ format, and standard informed consent.
223753959|NCT00855140|OTHER|Acupuncture|Acupuncture, derived from the TCM literature, specific for insomnia
223753960|NCT05918991|BEHAVIORAL|Daily Report Card|Behavioral consultants will meet with teachers to review daily report card implementation and effective classroom management. The consultant collaborates with the teacher to identify specific behavioral goal targets for the student's DRC based on a review of teacher ratings and teacher description of key problem behaviors. After establishing the initial DRC, the consultant will review procedures with the teacher for scoring the DRC and, importantly, providing the student with effective and consistent performance feedback. The consultant will also make a plan with the teacher to review DRC progress and revise the DRC as needed. Consultants will also meet with parents to develop a plan for reinforcing the DRC at home. The DRC will be implemented for 18 weeks. The behavioral consultants will be available to teachers and parents throughout the duration of the intervention to assist with implementation and adjustment of target behaviors and goals.
223753961|NCT05918991|OTHER|Language Intervention|The intervention protocol to be provided in each grade level will include 18 weeks of 20-25 minutes of small-group intervention 4 days per week, for a total of 72 lessons. The fifth day per week will be allocated to make-up lessons for students absent earlier in the week to maximize opportunity for each participant to receive the full dosage of lessons. Half of these lessons in each grade will be allocated to Language in Motion implementation and the other half to Dialogic Reading. Dialogic Reading is designed to increase vocabulary knowledge through shared reading of picture books. The content involves reading of 9 children's books with 108 targeted vocabulary words. Language in Motion is designed to increase syntax and grammar knowledge using science manipulatives. Daily lessons are highly scripted to introduce primary syntax targets through narrative text. Manipulation props are used to reinforce syntax targets and basic science topics.
223753962|NCT04360018|OTHER|Alcohol beverage|High-proof alcohol (e.g., Everclear) will be mixed with orange juice in an approximately 1:3 ratio and split evenly into two drinks. After splitting the orange juice into two cups, a small amount (approx. 6 ml) of high-proof alcohol will be floated on top of the beverage.
223753963|NCT04360018|OTHER|Placebo beverage|The final drink will have the same volume of liquid as the alcohol beverage.
223753964|NCT05227794|BEHAVIORAL|Compassion Cultivation Training (CCT)|CCT is a secular, empirically supported 8-week program that integrates meditation practices, interactive discussions, and educational lectures to improve self-compassion and other-oriented compassion, emotion and stress management, and happiness and well-being. It includes a weekly 2-hour educational lecture with discussion and in-class exercises, a recommendation of 15-30 minutes of daily meditation, and real-world assignments to practice compassion. The program is taught by a certified instructor with more than 5 years experience.
223753965|NCT05227794|BEHAVIORAL|Mindfulness-Based Stress Reduction (MBSR)|MBSR is among the most studied mindfulness-based interventions in the literature and is a secular, 8-week psycho-educational group-based intervention. The program structure (slightly modified to match CCT) includes a weekly 2-hour class, a prescription of 15-30-minutes of daily mindfulness practice, and a one-day optional retreat (6 hours) between week six and seven. The program is taught by a certified instructor with more than 5 years experience.
223606965|NCT05959460|OTHER|Deuterium dose-to-mother method for assessing breastfeeding|Exclusive breastfeeding practice was compared between maternal recall and the deuterium dose-to-mother method.
223606966|NCT01103583|DRUG|Hydroxyurea|500 mg/die per os for two years
223606967|NCT01103583|OTHER|placebo|500 mg/die per os for two years
223606968|NCT04208555|DRUG|Boric Acid Vaginal Suppository|Boric acid vaginal suppository (600 mg/day) for 14 days
223606969|NCT04208555|DRUG|Terconazole Vaginal Suppository|Terconazole 80 mg vaginal suppository daily for 6 days
223606970|NCT02460809|DEVICE|Transcranial direct current stimulation (tDCS)|Transcranial direct current stimulation (tDCS) uses two surface electrodes placed on the scalp. These electrodes pass a low voltage current and modulate membrane potentials of underlying neurons.
223606971|NCT01646281|DRUG|Vernakalant|10-minute infusion of 3 mg/kg vernakalant, followed by a 15 minute observation period. If the patient is still in atrial fibrillation, an additional 10-minute infusion of 2 mg/kg vernakalant will be given.
223606972|NCT01646281|DRUG|Flecainide|10-minute infusion of 2 mg/kg (maximal 150 mg)
223606973|NCT00398697|DRUG|Perifosine|
223606974|NCT00398697|DRUG|Gemcitabine|
223606975|NCT01076036|DEVICE|CorPath 200|CorPath™ 200 robotically-assisted percutaneous coronary intervention
223606976|NCT01076036|DEVICE|CorPath 200|CorPath PCI - robotic-assisted percutaneous coronary intervention
223606977|NCT03698227|DRUG|Olaratumab|iv infusion
223606978|NCT03698227|DRUG|Dexrazoxane|iv infusion
223753966|NCT00956904|DEVICE|3-D TRUS navigation software during T-RALP|A new solution for guiding the surgeon in RALP is image-guided navigation using transrectal ultrasound (TRUS). A TRUS-guided intraoperative navigation system using a robotic ultrasound probe manipulator (TRUS Robot) has been developed. The research is a pilot clinical trial of the TRUS Robot and three-dimensional (3-D) navigation software to test its image-guidance ability of helping the surgeon during RALP. This is a dual robot approach, a Tandem-RALP (T-RALP). The TRUS Robot allows a steady holding as well as remote manipulation of the TRUS probe. In addition, the TRUS Robot can track the accurate position of TRUS probe which allows 3-D reconstruction of the images.
223606979|NCT03698227|DRUG|Doxorubicin|iv infusion
223606980|NCT00183105|BEHAVIORAL|Brief Intervention (adaptation of motivational interviewing)|
223606981|NCT00005857|BIOLOGICAL|trastuzumab|
223606982|NCT00005857|DRUG|docetaxel|
223753967|NCT06131554|BIOLOGICAL|batch 1 of Group ACYW135 Meningococcal Conjugate Vaccine (CRM197) (MCV4)|1 dose of Menhycia (0.5ml) on Day 0, Intramuscular injection
223753968|NCT06131554|BIOLOGICAL|batch 2 of MCV4|1 dose of Menhycia (0.5ml) on Day 0, Intramuscular injection
223753969|NCT06131554|BIOLOGICAL|batch 3 of MCV4|1 dose of Menhycia (0.5ml) on Day 0, Intramuscular injection
223753970|NCT06131554|BIOLOGICAL|Meningococcal (Groups A, C, Y, and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine|1 dose of Menactra (0.5ml) on Day 0, Intramuscular injection
223753971|NCT03139149|PROCEDURE|Adhesiolysis|"Method of video laparoscopic operation:~* Open access in the left upper quadrant of the anterior abdominal wall,~* Installation of trocars, depending on the prevalence of the adhesion process~* Assessment of the peritoneal adhesion index~* Detection of the asleep gut~* Detection of obstacle area~* Removing the obstacle without trying to completely eliminate the adhesion process in the abdominal cavity~If there is no possibility to eliminate the cause of intestinal obstruction laparoscopically laparotomy is performed."
223606983|NCT05007756|RADIATION|UVB Challenge|UVB challenge will be administered dermally through Lumera Phototherapy System.
223606984|NCT05985486|BEHAVIORAL|Diet|A reduced calorie diet which uses frozen meals purchased at the store and focuses on increasing fruits and vegetables associated with brain health.
223606985|NCT05985486|BEHAVIORAL|Health Education|Monthly health education sessions delivered remotely.
223606986|NCT02346175|DRUG|SHR3824|
223606987|NCT02346175|DRUG|Placebo|
223606988|NCT06161129|DEVICE|Lenses|The filter lenses will be worn by participants for one month all day.
223606989|NCT03391934|DRUG|Cetuximab + FOLFIRI|Cetuximab 400 mg/m2 will be administered in the first dose and 250 mg/m2 will be administered in the next doses every week. Irinotecan will be administered 180 mg/m2 biweekly. Leucovorin will be administered 400 mg/m2 biweekly.Fluorouracil will be administered 400 mg/m2 push, and 2400 mg/m2 as 46-h infusion biweekly.
223606990|NCT01167374|RADIATION|Carbon Ion Radiotherapy|Increasing Dose of Carbon Ion Radiotherapy 4 x 10 Gy E to 4 x 14 Gy E
223606991|NCT03936153|DRUG|abexinostat|abexinostat tablet
223606992|NCT00695526|DIETARY_SUPPLEMENT|cranberry|cranberry extractive in powder product (by Triarco Industries, Inc. NJ, USA) and encapsulated in dose of 500mg/capsule (by Topo digital tech co., Taiwan). By one capsule after each of three meals per day.
223606993|NCT00726635|BEHAVIORAL|Cognitive intervention|The intervention will last one hour and will include cognitive technique (self-talk). The technique will be demonstrated to the woman, practiced with her, and taped so as to encourage further practice at home.
223606994|NCT00726635|OTHER|Control group|A one hour conversation with a nurse
223606995|NCT00726635|OTHER|psycho-physiological intervention|The intervention will last an hour and will include a psycho-physiological intervention (relaxation and guided imagery). The technique will be demonstrated to the woman, practiced with her, and taped so as to assure further practice at home
223606996|NCT01561235|OTHER|Dose-reponse effect of protein on appetite and appetite-regulating hormones|3-arm meal study for investigation of the mechanisms responsible for the satiating effects of protein in three isocaloric test meals with a protein content of 14, 25 or 50 E% protein. A possible 4-h dose-response effect of protein was investigated on a number of appetite-regulating hormones/peptides, together with changes in subjective appetite sensations and sensory desires were evaluated and ad libitum energy intake.
223606997|NCT04034784|DEVICE|Discrete(TM)|A designated volume of Discrete(TM) (according to cohort) is applied intraperitoneally
223606998|NCT04034784|OTHER|Control Lactated Ringer's Solution (Control LRS)|A designated volume of LRS (according to cohort and equivalent to volume of Discrete(TM)) is applied intraperitoneally
223606999|NCT00985868|DRUG|multikinase inhibitor AT9283|
223607000|NCT00985868|OTHER|enzyme-linked immunosorbent assay|
223607001|NCT00985868|OTHER|immunohistochemistry staining method|
223607002|NCT00985868|OTHER|laboratory biomarker analysis|
223607003|NCT00985868|OTHER|pharmacological study|
223753972|NCT03139149|RADIATION|X-ray diagnostics|X-ray of the thoracic (1) and abdomen (2-5 times) with water soluble contrast.
223753973|NCT03139149|RADIATION|Computer tomography|Computer tomography of abdomen with iv contrast
223753974|NCT03139149|PROCEDURE|Ultrasound|Ultrasound of the abdomen (2 times)
223753975|NCT03139149|OTHER|General and biochemical blood test|General blood test and biochemical blood test 2 times a day
223753976|NCT01456104|BIOLOGICAL|Langerhans-type dendritic cells (a.k.a. Langerhans cells or LCs)|Patients will receive a total of 5 vaccinations, comprising a primary immunization followed by four boosters at 3 week intervals with a window of ± 4 days. Vaccines will be dosed at 10x106 LCs per vaccine x 5.
223753977|NCT01805024|DRUG|Omigapil|Cohort 1 0.02 mg/kg/day Cohort 2 0.08 mg/kg/day Cohort 3a 0.04 mg/kg/day Cohort 3b 0.06 mg/kg/day
223753978|NCT00400647|DRUG|Enteric-coated Mycophenolate sodium (EC-MPS)|
223753979|NCT00400647|DRUG|Mycophenolate mofetil|
223753980|NCT03149107|DRUG|N-Acetylcysteine|N-Acetylcysteine (2000 mg/d, 1000 mg in the morning/evening, oral intake). Will be applied continously over 26 weeks parallel to the psychological intervention (IPPI or PSM).
223753981|NCT03149107|DRUG|Placebo|Will be applied continously over 26 weeks (oral intake of capsules) parallel to the psychological intervention (IPPI or PSM).
223753982|NCT03149107|BEHAVIORAL|IPPI (Integrated Preventive Psychological Intervention)|IPPI (Integrated Preventive Psychological Intervention): 21 sessions, the first 20 sessions are scheduled weekly, the last session two weeks after session 20. Single blinded (statistician \& rater)
223753983|NCT03149107|BEHAVIORAL|PSM (Psychological stress management)|PSM (Psychological stress management): 11 sessions; the first 10 sessions will be offered biweekly, the last one 2 weeks after session 10. Single blinded (statistician \& rater).
223753984|NCT05167162|DIAGNOSTIC_TEST|State-Trait Anxiety Questionnaire|"The scale measures ordinally (1 to 5) the values observed during exposure to anxiety patterns during exercise, such as higher repetitions, greater weight gain or longer exercise duration, as follows:~1. Not at all~2. Little~3. Sometimes~4. Almost always~5. Always"
223753985|NCT05167162|DIAGNOSTIC_TEST|Rating of Perceived Exertion|"The scale measures in ordinal form (1 to 6) the perceived effort during the exercise as follows:~1. No pain~2. Little pain~3. Moderate~4. Severe~5. Very strong~6. Unbearable"
223753986|NCT05167162|DIAGNOSTIC_TEST|Motor coordination tests|"The motor coordination tests are divided into three:~1. Jumping with 2 feet together.~2. Throwing 2 balls from a given distance and space.~3. Proprioception turns"
223753987|NCT05167162|PROCEDURE|Physiotherapeutic intervention|Participants received one session per week, until a total of 20 sessions were completed: Group 1 (n=20) received the muscle compression treatment. Group 2 (n=20) received the manual massage treatment. Group 3 (n=20) received the hydrotherapy treatment and group 4 (n=20) received the active recovery treatment.
223753988|NCT05167162|OTHER|Data Analysis|The usual descriptive parameters (mean and standard deviation) of the sample were calculated. The distribution and analysis of the other data were performed by means of a nonparametric test (Mann-Whitney U test) comparing the groups. A confidence level of 95% was established, considering a value of p\<0.05 as statistically significant.
223753989|NCT05957783|OTHER|Cerebral palsy Gait analysis technique|Visual gait analysis in cerebral palsy new technique
223753990|NCT02599753|DRUG|18-FDTBZ|"During this study, participants will receive a single i.v. administration of approximately 370MBq (10 mCi) 18F- DTBZ immediately prior to imaging. The dosage of DTBZ is 10 nmole. The effective dose in human body is about 5.6 mSV.~The proposed dose for this study is based on the investigators' phase I study. At the proposed human dose of 10 mCi, the whole body effective dose (ED) will be approximately 680 mrem. The estimated human ED is expected to be comparable to or below the range of other approved brain imaging agents, such as 18F-FDG (Lin 2010)."
223753991|NCT02364310|DEVICE|Baroreceptor stimulation with Barostim Neo TM|
223753992|NCT03519971|DRUG|Durvalumab|Durvalumab IV (intravenous infusion)
223753993|NCT03519971|OTHER|Placebo|Placebo IV (intravenous infusion)
223753994|NCT03519971|DRUG|Cisplatin/ Etoposide|Cisplatin/ Etoposide, as per standard of care
223753995|NCT03519971|DRUG|Carboplatin/ Paclitaxel|Carboplatin /Paclitaxel, as per standard of care
223753996|NCT03519971|DRUG|Pemetrexed/ Cisplatin|Pemetrexed / Cisplatin, as per standard of care
223753997|NCT03519971|DRUG|Pemetrexed/ Carboplatin|Pemetrexed / Carboplatin , as per standard of care
223753998|NCT03519971|RADIATION|Radiation|5 fractions/ week for \~6 weeks (±3 days) (Total 60 Gy)
223753999|NCT06024603|DIAGNOSTIC_TEST|Drug Sensitivity Test (DST)|Refractory cancer tissue will be collected from participants and subjected to single-drug testing while DNA is simultaneously sent for targeted gene sequencing. Drug sensitivity scores from the tests will become available for a final list of therapeutic options ranked best in order of preference together with suggested doses and schedules.
223754000|NCT05331378|DEVICE|Test myopia control lenses|A myopia control spectacle lenses (test lenses) will be given to 1 arm to wear for 12 months.
223754001|NCT05331378|DEVICE|Single vision lenses|A single vision spectacle lenses (control lenses) will be given to 1 arm to wear for 12 months.
223754002|NCT06276491|BIOLOGICAL|XmAb541|Monoclonal bispecific antibody
223754003|NCT01828047|DEVICE|orthogonal polarization spectral (OPS) imaging|orthogonal polarization spectral (OPS) imaging allows noninvasive observation of human microcirculation in all accessible tissue surfaces
223754004|NCT01113632|DRUG|Ofatumumab|IV infusion once weekly for a total of 8 weeks. Patients will visit the study center once weekly to receive their IV infusion of ofatumumab. To reduce the possibility of infusion reactions, the first dose of ofatumumab will be administered at a dose of 300 mg. If the initial 300 mg dose of ofatumumab is well tolerated, without occurrence of any infusion-associated AEs of ≥ grade 3, subsequent doses of ofatumumab (i.e., Week 2 through Week 8) will be at a dose of 2000 mg.
223754005|NCT04654117|OTHER|Consultee-centered administrative consultation|The consultee-centered administrative consultation model expressly focuses on supporting providers to increase EBP implementation within their specific setting.
223754006|NCT05183737|DIETARY_SUPPLEMENT|Microcapsules with turmeric and propolis|Participants will receive microcapsules containing 0.250 milligrams of turmeric 95% curcumin and 0.250 milligrams of green propolis, twice a day for 12 weeks
223754007|NCT00386867|DRUG|800 mcg misoprostol via oral or buccal administration|
223754008|NCT02237846|BIOLOGICAL|Human umbilical cord tissue-derived mesenchymal stem cells|
223754009|NCT04766242|OTHER|Spiritual healing|"The spiritual healing will be based on an assessment of the total health situation of the individual patient. Spiritual healing will mainly consist of a treatment where the healers hold their hands for some time at different parts of the patient's body, known as power points, outside the patients clothing. The consultation might also include possible life-style advice. The treatments will last for 45-60 minutes each time."
223754010|NCT04766242|OTHER|Usual care|The care the general practitioner (GP) prescribe when the patients are diagnosed with moderate depression.
223754011|NCT04418596|RADIATION|bi-planer radiography (EOS), Conventional radiography (Hip+pelvis)|low dose radiation medical imaging to visualise the hip joint and lumbo-pelvic complex specifically.
223754012|NCT05926167|DIAGNOSTIC_TEST|blood tests drawn days 1, 8, 22 and 90 of the study|Blood tests related to Factor VIII activity that are not a part of standard of care
223754013|NCT05171972|DRUG|Ofatumumab|This investigator-initiated study will be carried out secondary to the discussion of treatment with Ofatumumab and thus our study will not influence or impact the determination of the suitability for candidates to commence therapy with Ofatumumab. This decision will be made by the patient's physician as part of the patient's standard care, and will occur independently of this study. Patients to be enrolled in this longitudinal study will only be asked if they would like to take part if their clinician independently chooses Ofatumumab as a treatment option.
223754014|NCT06779318|DRUG|S-1|Tegafur, Gimeracil, and Oteracil Potassium (S-1) 40-60 mg per dose, orally (p.o.), twice daily (BID), from Day 1 to Day 28, with a 6-week cycle, for a total of 8 cycles; or from Day 1 to Day 14, with a 3-week cycle, for a total of 16 cycles.
223754015|NCT06060665|DRUG|Seladelpar 10 mg|Administered orally
223754016|NCT06060665|DRUG|Placebo|Administered orally
223754017|NCT03403816|BEHAVIORAL|Before School Physical Activity Program|BOKS is a before school physical activity program offered at no cost to participating families that focuses on engaging elementary and middle school students in physical activity, skill development and brief nutrition education sessions that prepare them for a day of learning. The BOKS curriculum includes 12 weeks of instruction and 40 minutes of structured kid-friendly activities that include warm-ups, skill of the week, running, relay and obstacle course activities and nutritional tips. The BOKS team provides training for BOKS leaders free of charge each month. BOKS is currently being used in more than 1,800 schools in the US and Canada.
223754018|NCT06427018|OTHER|No intervention.|Observational study with no intervention.
223607004|NCT02445872|DRUG|Aprepitant|Aprepitant:The first day, one 125 mg capsule will be administered per oral, 1 hour before chemotherapy. Thereafter one 80 mg capsule will be repeated daily between 8 to 10 a.m. during days 2 to 3
223607005|NCT02445872|DRUG|Palonosetron|
223607006|NCT02445872|DRUG|Dexamethasone|
223607007|NCT03547310|BEHAVIORAL|MyoBeatz|Training of the patient's muscle coordination, strength and ability to separately contract muscles, while holding up patient motivation. The patient is expected to follow a protocol of 4 weeks of training.
223607008|NCT02304523|DRUG|CDFR0612|Preparation 500mL is a mixture of CDFR0612 150mL and water 350mL. A total of 2L (Preparation 1L and additional water 1L) will be administrated divided into two in evening before and in early morning at that day of colonoscopy.
223607009|NCT02304523|DRUG|CDFR0613|Preparation 500mL is a mixture of CDFR0613 150mL and water 350mL. A total of 2L (Preparation 1L and additional water 1L) will be administrated divided into two in evening before and in early morning at that day of colonoscopy.
223754019|NCT01821534|OTHER|No Intervention|No treatment (intervention) was administered.
223754020|NCT04641611|OTHER|Bicaval cannulation|Cannulation of SVC and IVC through right atrium in patients undergoing CABG. with snares applied
223754021|NCT04641611|OTHER|Cavoatrial cannulation|Cannulating the right atrium and Inferior vena cava with a 2-stage cannula
223754022|NCT05264155|BEHAVIORAL|GameBus (mHealth app)|Using the mHealth app GameBus, participants could track their performance on 2 social leaderboards: a leaderboard displaying the individual scores of participants and a leaderboard displaying the average scores per department. To score points on these leaderboards, a participant was given a set of 6 tasks that, upon completion, were rewarded with points. In this study, 3/6 tasks were either updated generically (for the control group) or personalized (for the treatment group). By means of the mobile app, users could manually register that they had performed a task. Alternatively, users could use an activity tracker to automatically track their efforts. The activity trackers that were supported included Google Fit, Strava, and a GPS-based activity tracker. Finally, GameBus provided a set of features for social support: a newsfeed showed when other participants had scored points, and participants could like and comment on each other's healthy achievements as well as chat with each other.
223754023|NCT02306629|BIOLOGICAL|Epratuzumab sc|Active substance: Epratuzumab, Pharmaceutical form: Solution for injection, Route of Administration: Subcutaneous,
223754024|NCT02306629|BIOLOGICAL|Epratuzumab iv|Active substance: Epratuzumab, Pharmaceutical form: Solution for Infusion, Route of Administration: Intravenous,
223754025|NCT01408979|DRUG|Magnesium sulfate 12 hours|Magnesium sulfate, 1g/h, (10% solution), for 12 hours
223754026|NCT01408979|DRUG|Magnesium sulfate 24 hours|Magnesium sulfate, 1g/h, (10% solution), for 24 hours
223607010|NCT02304523|DRUG|Coolprep Powder|Preparation 500mL is a water solution of Coolprep Powder A and B. A total of 3L (Preparation 2L and additional water 1L) will be administrated divided into two in evening before and in early morning at that day of colonoscopy.
223607011|NCT02896283|RADIATION|Low-level laser therapy|Low-level laser therapy with the following parameters: Wavelength:660 nanometer, power: 200 mW, continuous mode, tme of irradiation: 32 seconds
223607012|NCT02896283|RADIATION|Turned-off laser|Laser device is turned-off. All parameters are like experimental group, however the laser in turned-off.
223607013|NCT05662956|DRUG|Venetoclax in combination with azacitidine and CAG|"Induction:~VA regimen：~Drug: Venetoclax orally once daily (100 mg d1, 200 mg d2, 400 mg d3-21);~Drug: Azacitidine 75 mg/m2 subcutaneously once daily on days 1-7.~CAG regimen：~Drug: Cytarabine 10mg/m2 subcutaneously q12h on days 1-7;~Drug: Aclacinomycin 12-14mg/m2 on days 1,3,5,7;~Drug: Granulocyte colony-stimulating factor 5ug/kg on days 0-8, discontinue if WBC \>20×10\^9/L；~Consolidation:~Drug: Cytarabine 3g/m2 q12h on days 1-3."
223607014|NCT01124279|DRUG|AMG 853|Single dose administration of AMG 853 in tablet form to healthy adult subjects
223607015|NCT01997424|DEVICE|Controlled Attenuation Parameter (CAP), Echosens, Paris, France|
223607016|NCT01997424|DEVICE|FibroScan, Echosens, Paris, France|
223754027|NCT00725218|DRUG|Saline|Saline 5 ml injection 10 min prior to propofol administration.
223607017|NCT04430569|DRUG|Alteplase|Alteplase single intravenous infusion of 0.6 mg/kg of estimated bodyweight with a maximum of 50 mg given over 15 minutes.
223607018|NCT04430569|DRUG|Placebo|Placebo single intravenous infusion of 0.6 mg/kg of estimated bodyweight with a maximum of 50 mg given over 15 minutes.
223607019|NCT05720390|OTHER|Quinine|Quinine, which is a bitter compound, extracted from the bark of the cinchona tree and has been shown in our previous studies to lower blood glucose in doses of 300-600 mg, will be 'active' in this condition.
223607020|NCT05720390|OTHER|L-leucine|L-leucine, which is a branched-chain amino acid, and one of the building blocks of protein, therefore is part of our daily diet, will be 'active' in this condition.
223607021|NCT05720390|OTHER|Combination of quinine and L-leucine|In this condition, both quinine and L-leucine will be administered as 'active'.
223754028|NCT00725218|DRUG|Flurbiprofen Axetil|Flurbiprofen Axetil 50 mg in 5 ml injection 10min prior to propofol administration.
223754029|NCT04680689|DIAGNOSTIC_TEST|128 Multislice CT coronary angiography|128 Multislice CT coronary angiography with the evaluation of coronary stenosis, the plaque vulnerability markers ( necrotic core, low attenuation plaque, spotty calcifications, napkin ring sign, positive remodeling), asses polar maps of the myocardium
223754030|NCT04680689|DIAGNOSTIC_TEST|2D Cardiac Transthoracic Echocardiography|2D Cardiac Transthoracic Echocardiography with the evaluation of the cardiac cavity dimensions
223754031|NCT04680689|DIAGNOSTIC_TEST|Laboratory Blood tests|Laboratory tests for evaluations the level of inflammatory biomarkers ( hs-CRP, MMP, IL6 and NT-pro-BNP), complete blood count, biochemestry
223754032|NCT01337219|DRUG|Tobramycin|
223754033|NCT04544293|DRUG|Molgramostim|Molgramostim 300 µg nebulizer solution
223754034|NCT04544293|DRUG|Placebo|Matching placebo nebulizer solution
223754035|NCT04544293|DRUG|Molgramostim Open-label|Molgramostim 300 µg nebulizer solution
223754036|NCT04903249|BEHAVIORAL|Core Exercise Promotion Intervention|"Participants are instructed to increase weekly time spent exercising to \>90 minutes over 12 weeks. Exercise will be defined as activities that use large muscle groups, increase heart rate and breathing rate, and are performed intentionally for the purpose of exercise (as opposed to physical activities of daily living, e.g., housework). Participants complete a videoconferencing visit with the study team and are given task and safety related information pertaining to exercise for survivors of cancer. Participants engage in exercise-related goal-setting and action planning and are provided activity trackers to monitor their activity levels over the 12-week study period."
223754037|NCT03893604|DEVICE|tDCS|20 minutes of anodal tDCS (C3/FP2) 2mA or sham
223754038|NCT00152750|DRUG|APO-clonidine|
223754039|NCT01470742|DRUG|XELOX|D1-14 Capecitabine 1000mg/m2 bid D1 Oxaliplatin 110mg/m2 + D5W 250ml over 2hr every 3weeks
223754040|NCT01470742|DRUG|XELODA|Capecitabine 1000mg/m2 bid D1-14 every 3weeks
223754041|NCT04982055|DRUG|Nadroparin (intravenous Infusion)|Intravenous route of administration over a 4-hours infusion of nadroparin 3800 IU
223754042|NCT04982055|DRUG|Nadroparin (subcutaneous group)|Subcutaneous route of administration of nadroparin 3800 IU
223754043|NCT04681482|DRUG|Apixaban|Anticoagulant medication used to treat and prevent blood clots and to prevent stroke in people with nonvalvular atrial fibrillation.
223754044|NCT00642668|DRUG|methoxy polyethylene glycol-epoetin beta|1.2 mcg/kg administered subcutaneously (sc) monthly for 36 weeks (initial recommended dose)
223754045|NCT03608774|DRUG|Azithromycin|Azithromycin monohydrate is a macrolide antibacterial drug, FDA-approved in the US for the treatment of Chlamydia trachomatis (CT) in dose 1 gram (4 capsules of 250 mg), administered orally as a single dose.
223754046|NCT03608774|DRUG|Doxycycline|Doxycycline hyclate is an antibacterial drug synthetically derived from oxytetracycline, FDA-approved in the US for the treatment of Chlamydia trachomatis (CT) as a course of 100 mg (1 capsule), administered orally twice daily for 7 days.
223607022|NCT05720390|OTHER|Control|In the condition, where quinine is 'active', control for L-leucine (5 ml oraplus and 95 ml saline) will be administered. In the condition, where L-leucine will be 'active', control for quinine (10 ml distilled water) will be administered.
223607023|NCT06050135|OTHER|Roadmap to Parenthood|web-based decision support
223607024|NCT06050135|OTHER|Informational Booklet|web-based informational booklet about young adult cancer survivorship
223607025|NCT05192616|DEVICE|Covered stent implantation|Percutaneous transluminal angioplasty (PTA) with iCover covered stent for the treatment of de novo aorto-iliac occlusive lesions
223607026|NCT06042920|DRUG|Deucravacitinib|Specified dose on specified days
223607027|NCT06042920|DRUG|Placebo|Specified dose on specified days
223607028|NCT04871412|DIETARY_SUPPLEMENT|Vitamin D3 Drops|1,000 - 10,000 units daily based on serum levels for the duration of the study
223607029|NCT04871412|DIETARY_SUPPLEMENT|Coriolus Versicolor|1.5g twice daily for the duration of the study
223607030|NCT04871412|DIETARY_SUPPLEMENT|Trident SAP 66:33 Lemon|3g once daily for the duration of the study
223607031|NCT04871412|DIETARY_SUPPLEMENT|Probiotic Pro12|12 billion colony forming units daily during the peri-operative period (approximately 1 month pre and post-surgery)
223607032|NCT04871412|DIETARY_SUPPLEMENT|Provitalix Pure Whey Protein|1 scoop (22g) once daily during the peri-operative period (approximately 1 month pre and post-surgery) and during any adjuvant chemotherapy and radiation treatments
223607033|NCT04871412|DIETARY_SUPPLEMENT|Theracurmin 2X|1.2g twice daily after the peri-operative period. including during adjuvant chemotherapy and radiation
223754047|NCT03608774|OTHER|Placebo|Azithromycin placebo (4 capsules), administered orally as a single dose; Doxycycline placebo (1 capsule), administered orally twice daily for 7 days.
223754048|NCT03390881|OTHER|Fasting condition|Subjects will fast over the whole experimental period (480 min)
223607034|NCT04871412|DIETARY_SUPPLEMENT|Green Tea Extract|700 mg twice daily after the peri-operative period. Will not be given during adjuvant radiation or chemotherapy treatments.
223607035|NCT04871412|OTHER|Nutrition Recommendations|Based on the Mediterranean diet and lower glycemic index foods
223607036|NCT04871412|OTHER|Physical Activity Recommendations|150 minutes moderate intensity aerobic exercise per week plus the addition of a resistance exercise program on 2 of those days
223607037|NCT04871412|BEHAVIORAL|Psychological Recommendations|Activities with the intention of actively improving the participant's mental and emotional health
223607038|NCT06341556|DRUG|Zanubrutinib|Patients diagnosed with mantle cell lymphoma who have achieved remission (CR or PR) by first-line immunochemotherapy, will be treated with Zanubrutinib monotherapy for 2 years (or until PD, intolerable toxicity, death, withdrawal, or study termination).
223607039|NCT03965143|DEVICE|3D talar augmentation|Patients with an avascular necrosis of the body if the talar bone will undergo a 3D custom talar augmentation with or without concomitant ankle arthroplasty
223607040|NCT04981652|DIETARY_SUPPLEMENT|Whole Milk|Participants will consume twice daily whole milk beverages in addition to a standardized diet.
223607041|NCT04981652|DIETARY_SUPPLEMENT|Skim Milk|Participants will consume twice daily skim milk beverages in addition to a standardized diet.
223607042|NCT04981652|DIETARY_SUPPLEMENT|Almond Beverage|Participants will consume twice daily almond beverages in addition to a standardized diet.
223607043|NCT02500953|DRUG|ASP3325|
223607044|NCT02500953|DRUG|Placebo|
223754049|NCT03390881|OTHER|Sugar condition|After a 2-h fasting state, subjects will ingest every hour a drink containing 70% carbohydrate, 15% fat and 15% protein and providing 1.5 X hourly resting energy requirement.
223754050|NCT03390881|OTHER|Fat condition|After a 2-h fasting state, subjects will ingest every hour a drink containing 70% fat, 15% carbohydrate and 15% protein and providing 1.5 X hourly resting energy requirement.
223607045|NCT02655549|BIOLOGICAL|Px563L, RPA563, or placebo|Two intramuscular injections
223607046|NCT06457841|BEHAVIORAL|Direct Interpersonal Exchange|Simulated a negative personally relevant interpersonal experience that is received directly from a perpetrator, commonly experienced in everyday lives
223607047|NCT06457841|BEHAVIORAL|Vicarious Interpersonal Exchange|Hearing or observing a negative personally relevant interpersonal experience that is reported by another person of the same background
223607048|NCT06457841|BEHAVIORAL|Daily Hassles|Day-to-day stressors associated with school, work, finances
223607049|NCT06821620|DIETARY_SUPPLEMENT|Breakfast|Breakfast in one condition will be high carbohydrate and in the other protein enriched
223607050|NCT00303225|DRUG|Vaccine: SIGA-246|
223607051|NCT00779493|DIETARY_SUPPLEMENT|curcumin|curcumin 900mg twice daily by mouth
223607052|NCT00779493|DIETARY_SUPPLEMENT|placebo|placebo capsule to simulate 900mg curcumin capsule
223607053|NCT04563195|DRUG|tibulizumab (LY3090106)|subcutaneous injections of 300mg every 2 weeks over a period of 12 weeks
223607054|NCT05905367|DRUG|Fentanyl|Symptom-inhibited IV fentanyl induction
223607055|NCT05905367|DRUG|Methadone|Opioid agonist therapy (OAT) with methadone at starting doses established by symptom-inhibited IV fentanyl induction
223607056|NCT05905367|DRUG|Slow-release oral morphine|Opioid agonist therapy (OAT) with SROM at starting doses established by symptom-inhibited IV fentanyl induction
223607057|NCT05822622|OTHER|echocardiography|to determine finding of heart failure with preserved ejection fraction and non alcoholic fatty liver disease
223607058|NCT05505006|DRUG|Ferric Carboxymaltose Injection|Anemic patients with ID will receive i.v. iron. Dosage will be based on Hb level and patient body weight.
223607059|NCT05505006|DRUG|Folic acid|Anemic patients with folate deficiency will receive folic acid 5 mg per day for 1 month
223607060|NCT05505006|DRUG|B12|Anemic patients with B12 deficiency will receive B vitamin complex 1 tablet per day for 1 month
223754051|NCT01177540|DRUG|Decitabine|5 day priming with decitabine followed by Induction Chemotherapy of ADE (daunorubicin, cytarabine, etoposide).
223754052|NCT01177540|DRUG|Decitabine|Induction Chemotherapy of ADE (daunorubicin, cytarabine, etoposide) only
223607061|NCT05035732|RADIATION|18F-fluciclovine|IV
223607062|NCT03977103|BIOLOGICAL|High dose irradiation conditioning + Treg/Tcon|High dose irradiation based conditioning regimens followed by infusion of donor regulatory and conventional T cells and purified CD34+ hematopoietic stem cell transplantation
223607063|NCT05715216|DRUG|Nivolumab|Given by IV (vein)
223607064|NCT05715216|DRUG|Etigilimab|Given by IV (vein)
223754053|NCT01793727|DEVICE|Glidescope videolaryngoscope|
223754054|NCT00360464|DRUG|Azithromycin SR|
223754055|NCT06386835|PROCEDURE|Collagen Paste|Collagen paste injection
223754056|NCT06386835|PROCEDURE|Mucosal advancement|Mucosal advancement flap
223754057|NCT01296256|DRUG|Bendamustine-EAM|Bendamustine 200 mg/m2 starting dose on day -7 and -6 Etoposide 200 mg/m2 from day -5 to day -2 Ara-C 400 mg/m2 from day -5 to day -2 Melphalan 140 mg/m2 on day -1
223754058|NCT01112852|DRUG|pantoloc 40 mg|pantoloc iv. infusion per day
223754059|NCT01112852|DRUG|somatostatin or terlipressin|Somatostatin 6mg in 500 cc 5% dextrose, 250μg slow bolus IV infusion followed by 250μg per hour (6mg/ 24 hours) or Terlipressin 2mg bolus was instituted on enrollment followed by 1mg per 6 hours for 5 days. The use of either somatostatin or glypressin was at the discretion of doctors in charge.
223754060|NCT01999595|DEVICE|Control TENS|Control TENS was the application of electrical stimulation via skin with no current
223754061|NCT01999595|DEVICE|Sham TENS|"Sham TENS was the application of electrical stimulation via skin with no current on the participant, who was told TENS is at a turn-on level whether or not you feel it"
223754062|NCT01999595|DEVICE|High frequency TENS with large pads|High frequency TENS was delivered on large electrodes
223754063|NCT01999595|DEVICE|Low frequency TENS with large pads|Low frequency TENS was delivered on large electrodes
223754064|NCT01999595|DEVICE|High frequency TENS with small pads|High frequency TENS was delivered on small electrodes
223754065|NCT01999595|DEVICE|Low frequency TENS with small pads|Low frequency TENS was delivered on small electrodes
223754066|NCT01969903|DRUG|Precedex injection|
223754067|NCT03193411|DEVICE|Visumax femtosecond laser|
223754068|NCT03193411|DEVICE|Moria M2 microkeratome (MK)|
223754069|NCT02910167|DRUG|Hyoscine n-butylbromide|Hyoscine n-butylbromide 10 mg
223754070|NCT02910167|DRUG|Paracetamol|Paracetamol 500 mg
223754071|NCT02910167|DRUG|Hyoscine n-butylbromide|Hyoscine n-butylbromide 10 mg
223754072|NCT02910167|DRUG|Paracetamol|Paracetamol 500 mg
223754073|NCT06215963|DEVICE|App for Independence-O (A4i-O)|A4i-O is a digital health platform designed to support individuals with opioid use disorders. A4i-O will focus on providing education on treatment options, recovery navigation, social activation and connections to a range of resources. It aims to assist with fostering self-management and recovery through identifying risks for relapse, navigating urges/cravings, coping with shame/guilt, avoiding relapse, moving forward after relapse, and lived experiences. Daily wellness and goal attainment check-ins to highlight mental health trajectories will be prompted. With appropriate consent from both the client and provider, a provider dashboard is accessible to the client's provider prior to their appointment, generating a summary of day-to-day wellness ratings, responses to reminders, goal progressions, and other self-reported measures from the platform.
223754074|NCT00006481|DRUG|Biafine cream|
223754075|NCT00006481|PROCEDURE|quality-of-life assessment|
223754076|NCT00006481|RADIATION|radiation therapy|
223754077|NCT06371742|OTHER|Liquid ingestion during labour|An assessment of the volume capacity of the water glasses was carried out using duly certified 50mL syringes in order to calibrate and control the correct measurement of the amount of water ingested. Water is measured using a graduated cup, which is pre-existing in the BP service, since its water intake policy is governed by the formula 1ml/kg/h of clear liquids (water or tea).
223754078|NCT03561493|OTHER|zumba exercise|Participants will engage in 16 classes of 60-minute Zumba® fitness for two consecutive menstrual cycles (an 8-week period, twice weekly). Each class was one hour in length and a recovery period of at least 48 h was taken between classes. Each session will be initiated with low-intensity movements for the ﬁrst 5 min, followed by an increasing intensity throughout the workout. At the end of the training session, the intensity will be gradually reduced. The Zumba sessions will be supervised by three certiﬁed Zumba instructors, each responsible for regular sessions per week.
223754079|NCT00592566|DRUG|Dexamethasone, desmopressin|200 mg of dexamethasone IV infusion OD for 3 days or 0.3 microgram/ kg of desmopressin in 50 ml of saline, as a 30- minute infusion
223754080|NCT03832374|OTHER|Descriptive|
223754081|NCT02202733|OTHER|Cooking|The aim is to test the feasibility of a skill-based cooking intervention to reduce the consumption of foods prepared away from home for the evening meal (e.g., pre-prepared frozen foods, restaurant foods, fast food, take-out), energy intake from evening meals, and parent/child weight status.
223754082|NCT05492669|DRUG|Lidocaine Hydrochloride, Injectable|In the lidocaine group, at the end of the induction of general anesthesia, a bolus injection of lidocaine 1.5 mg/kg, calculated using the patient's ideal body weight and given as an infusion over 10 minutes, followed by a continuous infusion of lidocaine at 1.5 mg/kg per hour for the whole surgical procedure and will be discontinued at the end of surgery. Postoperative pain management during the first 72 postoperative hours will involve the use of a PCIA device, which will contain lidocaine 30mg/kg, sufentanil 2 μg/kg, granisetron 12 mg diluted to 200 mL in 0.9 % normal saline.
223607065|NCT04983355|DIETARY_SUPPLEMENT|Fish Hydrolysate|"The participants take 4 capsules/day of the study product. Two capsules should be consumed orally every morning with breakfast and/or with a glass of (plain, not sparkling) water and not with fruit juice or hot food/drink while ingesting the capsules; and two capsules should be consumed orally every evening with their dinner and/or with a glass of water.~Participants receiving the fish hydrolysate the fourth first weeks will then receive the placebo during another 4 weeks. A wash-out period of 4 weeks is included between each phase of supplementation."
223607066|NCT04983355|DIETARY_SUPPLEMENT|Placebo|"The participants take 4 capsules/day of the study product. Two capsules should be consumed orally every morning with breakfast and/or with a glass of (plain, not sparkling) water and not with fruit juice or hot food/drink while ingesting the capsules; and two capsules should be consumed orally every evening with their dinner and/or with a glass of water.~Participants receiving the Placebo the fourth first weeks will then receive the fish hydrolysate during another 4 weeks. A wash-out period of 4 weeks is included between each phase of supplementation."
223754083|NCT05492669|DRUG|0.9% normal saline|In the placebo group, the same volume of normal saline will be administered during anesthesia. The postoperative PCIA device will contain sufentanil 2 μg/kg, granisetron 12 mg diluted to 200 mL in 0.9% normal saline solution with a total volume of 200 ml.
223754084|NCT03526419|DRUG|Bupivacaine liposome|blood and milk samples will be obtained from those subjects after TAP block
223754085|NCT03496142|PROCEDURE|Transperineal prostate biopsy|Puncture of 12 to 30 percutaneous prostate core biopsies through the perineum with a transrectal ultrasound probe guidance. The procedure would be performed with the Artemis (Eigen) device allowing topographic recording of the puncture and MRI / ultrasound image fusion in order to target the MRI suspected lesion.
223754086|NCT03496142|PROCEDURE|Transrectal prostate biopsy|Patient would undergo 12 to 30 transrectal prostate core biopsies through the rectum with a transrectal ultrasound probe guidance. The procedure would be performed with the Artemis (Eigen) device allowing topographic recording of the puncture and MRI / ultrasound image fusion in order to target the MRI suspected lesion.
223754087|NCT05608876|DRUG|Tigilanol Tiglate|Tigilanol tiglate is a novel, short-chain diterpene ester in clinical development for intratumoural treatment of a wide range of solid tumours.
223754088|NCT03005821|OTHER|Chinese pediatric massage therapy + usual care|
223754089|NCT03005821|OTHER|Sham massage therapy + usual care|
223754090|NCT01936116|DEVICE|sonohysterography with inflated catheter in uterine cavity|during the procedure of sonohysterography balloon catheter is inflated in the uterine cavity
223754091|NCT01936116|DEVICE|sonohysterography with inflated catheter in cervical cavity|During the procedure of sonohysterography balloon catheter is inflated in the cervical canal
223754092|NCT03913091|DRUG|Liposomal Bupivacaine|Liposomal Bupivacaine Plus 0.5% Bupivacaine HCL
223754093|NCT03913091|DRUG|0.5% Bupivacaine HCL|0.5% Bupivacaine HCL for Interscalene Nerve Block (ISB)
223754094|NCT03146442|BEHAVIORAL|Breakfast|For 6 months, the participants will either skip breakfast or will habitually consume a NP or HP breakfast every day.
223607067|NCT05971069|PROCEDURE|Group1|Entire fluorescence defect on the Lt. lobe of liver → Preservation of the aberrant left hepatic artery
223607068|NCT05971069|PROCEDURE|Group2|Partial fluorecence defect on the Lt. lobe of liver → Ligation of the aberrant left hepatic artery
223607069|NCT05971069|PROCEDURE|Group3|No fluorescence defect on the Lt. lobe of liver → Ligation of the aberrant left hepatic artery
223607070|NCT01922908|BIOLOGICAL|MSC Infusion|Allogeneic bone marrow derived mesenchymal stem cells given in one dose 3-10 days after stroke symptom onset
223607071|NCT01922908|BIOLOGICAL|Placebo Comparator|Normal saline
223607072|NCT06127589|BEHAVIORAL|Brief cessation advice (AWARD)|Ask about smoking history, Warn about the high risk of smoking, Advise to quit as soon as possible, Refer to the smoking cessation services, and Do it again (if the smokers refuse to set a quit date).
223754095|NCT04400903|DEVICE|Activity Monitor|Undergo HRV monitoring via WHOOP device
223754096|NCT04400903|OTHER|Quality-of-Life Assessment|Ancillary studies
223754097|NCT04400903|OTHER|Questionnaire Administration|Complete questionnaires
223754098|NCT05960396|BEHAVIORAL|Diet intervention|investigators use different diet intervention to observe the changes of biochemical indicators, body composition, Gut microbiota, metabonomics, etc. for patients with MAFLD during different periods
223754099|NCT06617975|OTHER|Balneotherapy program in rheumatology indication|"At least 4 balneotherapy sessions per day, 6 days a week during 3 consecutive weeks that may include: 1 whirlpool bath per day, 1 poultice application per day, 1 bath with immersion showers in a pool per day, a local jet shower every other day, a penetrating shower every other day.~Alternative treatments may replace penetrating shower or local jet shower, or other care, e.g., collective jet shower or steam bath. 10-minute air diffusion baths are taken in individual tubs at 37°C. Mud is applied 10 minutes as a poultice to both knees (minimum 2 per knee, 52°C), if necessary, to other painful osteoarthritis areas. 10-minute collective pool bathing takes place in a thermal pool equipped with jet stations immersed in water at 32°C. 3-minute local jet shower is applied to the predefined area using thermal water at 37°C. 10-minute penetrating showers are delivered by an affusion ramp on the patient lying down and directed on the area defined, using thermal water at 37°C."
223754100|NCT06355895|DIETARY_SUPPLEMENT|Standardized high-carbohydrate meal|8 ounces of Ensure® nutritional protein shake or a similar meal
223754101|NCT05637437|BEHAVIORAL|Peer supported diabetes self-care intervention|"Participants in the intervention group will attend a multi-faceted 8 weeks peer supported diabetes self-care intervention through digital communication.~* Weekly group video telephony meeting facilitated by trained peer supporters.~* Support and assistance through instant messaging services between peer supporters and participants."
223607073|NCT06127589|DRUG|Nicotine Replacement Therapy (NRT)|1-week sampling of Nicotine Replacement Therapy (NRT) will be provided to support quit attempt. Full pharmacological treatment (12-week) will be available if needed.
223607074|NCT06127589|BEHAVIORAL|Instant messaging Support (IM)|Chat-based mHealth personalized psychosocial and behavioural counselling (smoking cessation and SHS exposure reduction messages will be derived from previously tested interventional studies) using baseline children health and biofeedback data to support quitting throughout the intervention period of 3 months.
223607075|NCT06127589|BEHAVIORAL|Financial Incentive (FI)|A financial incentive (vouchers) of HK$ 500 will be provided for biochemically validated smoking abstinence at 3- and 6-month follow-up. Considering a possibly low engagement rate of the smokers in mHealth-based support (17% in our previous trial, non-engagement mostly due to busy work), additional HK$ 200 will be provided for participants who actively engaged in the mHealth counselling (defined by have discussed quitting process for \>2 times) at 3-month follow-up.
223607076|NCT06127589|BEHAVIORAL|Self-help smoking cessation booklet|A well-designed self-help booklet will be provided to guide and provide detailed information on smoking cessation. The contents include information about the benefits of quitting, smoking and diseases, methods to quit, how to handle withdrawal symptoms, declaration of quitting, etc.
223607077|NCT06127589|BEHAVIORAL|Environmental assessment derived intervention|"In a selected subgroup of 50 families with an additional signed consents, four home visits will be done to: 1. Setup an indoor air quality (IAQ) monitor to collect 24hr air quality data (2 weeks), 2. Collect the monitor for data retrieval, 3. Setup the monitor at 6 months follow-up (2 weeks), 4. Collect the monitor for data retrieval.~Environmental assessment derived intervention, including results interpretation and health advice, will be provided via phone calls for the 50 families within 1 week after the data collection."
223607078|NCT01221350|DIETARY_SUPPLEMENT|Lipoic acid|Lipoic acid 600 mg dose (two 300 mg capsules) once daily in the morning. All patients continued their asthma treatments given by their primary care physician also they were allowed to use rescue medication on demand consisting in inhaled salbutamol. During basal and 8 weeks visits spirometry with bronchodilator challenge, sputum induction and quality of life questionnaires and asthma control test were performed.
223754102|NCT05637437|OTHER|Usual care|Participants in the control group will receive the usual care of the hospital.
223754103|NCT02241499|RADIATION|Radiation therapy|Radiotherapy at a dose of 4 Gy will be given to a total dose of 20 Gy, treatment duration 5 days.
223754104|NCT02241499|DRUG|Oxaliplatin and fluorouracil.|Oxaliplatin at a dose of 85 mg/m2 and will be given on day 1, infusion (44 hours) of fluorouracil will be given for 4 cycles, cycle length 14 days.
223754105|NCT03904888|PROCEDURE|r-TAPP|Robot-assisted repair
223754106|NCT03904888|PROCEDURE|l-TAPP|Laporoscopic repair
223754107|NCT03904888|PROCEDURE|local anesthetics|local anesthetics will be administred
223754108|NCT04449432|BEHAVIORAL|GROWell (Interactive Obesity Treatment Approach)|Personalized messaging via cell phone to support healthy eating behaviors during pregnancy and through 6 months postpartum
223754109|NCT04449432|BEHAVIORAL|Attention Support Control|Personalized messaging via cell phone to support healthy behaviors during pregnancy and through 6 months postpartum
223607079|NCT01221350|DIETARY_SUPPLEMENT|Placebo|Placebo (two capsules filled with 300 mg vehicle) once daily in the morning during 60 days. All patients continued their asthma treatments given by their primary care physician also they were allowed to use rescue medication on demand consisting in inhaled salbutamol. During basal and 8 weeks visits spirometry with bronchodilator challenge, sputum induction and quality of life questionnaires and asthma control test were performed
223607080|NCT01444846|DRUG|SPI-1005 Low dose|Oral capsules, 200 mg ebselen, twice daily, 4 days
223607081|NCT01444846|DRUG|SPI-1005 Middle dose|Oral capsules, 400 mg ebselen, twice daily, 4 days
223607082|NCT01444846|DRUG|SPI-1005 High dose|Oral capsules, 600 mg ebselen, twice daily, 4 days
223607083|NCT01444846|DRUG|Placebo|Oral capsules, 0 mg ebselen, twice daily, 4 days
223607084|NCT02624453|DRUG|Fluconazole|Pre-emptive fluconazole therapy at 800mg/day for two weeks, then 400mg/day for eight weeks, and then 200mg/day thereafter till CD4 count goes beyond 200cells/ml
223607085|NCT02624453|DRUG|Antiretroviral therapy|First line anti-retroviral therapy according to Cameroon national guidelines for the management of HIV/AIDS
223607086|NCT02524002|DIETARY_SUPPLEMENT|Accel Gel|Accel Gel by PacificHealth Labs in Matawan, NJ.
223607087|NCT02524002|DIETARY_SUPPLEMENT|Usual clear diet|Usual clear liquids
223607088|NCT03491111|OTHER|Respiratory muscle training for EMT+IMT|2 times per day and 5 day per week, 6 weeks, training with breathing trainer.
223607089|NCT03491111|OTHER|Regular Rehabilitation|Regular Rehabilitation: 2-3 times a week, 6 weeks.
223607090|NCT03491111|OTHER|Respiratory muscle training for EMT|5 sets, 5 repetition with one or two minute of rest between sets, twice per day, 5 days per week, training with breathing trainer.
223607091|NCT00590863|DRUG|SSRI + placebo|Participants will take escitalopram (10 - 20 mg/day)+ placebo (1 to 3 pills per day). Medications taken orally. Participants will take escitalopram plus placebo for up to 28 weeks. Dosages were adjusted as need at each clinic visit.
223607092|NCT00590863|DRUG|Escitalopram + Bupropion SR|Participant will take Burpopion SR (150 to 450 mg/day) + Escitalopram (10 to 20 mg/day) for up to 28 weeks. Medications taken orally. Bupropion SR was blinded, and escitalopram was given open label. Dosages were adjusted as need at each clinic visit.
223607093|NCT00590863|DRUG|Venlafaxine XR + Mirtazapine|Participants will take Venlafaxine XR (75 to 225 mg/day) + Mirtazapine (15 to 45 mg/day) for up to 28 weeks. Medications taken orally. Venlafaxine XR was blinded, and mirtazapine was given open label. Dosages were adjusted as need at each clinic visit.
223754110|NCT04477304|BEHAVIORAL|Opioid Naive, OR|Visits where the order is for an included opioid and there is no prior opioid prescription with a start date of greater than 1 day and less than 91 days and clinician is on the clinic list as a treating member of the clinic
223754111|NCT04477304|BEHAVIORAL|At-risk for long-term use, OR|Visit where the order is for an included opioid, there is a prior opioid prescription with a start date greater than 1 day and less than 91 days, and there is no prior opioid prescription with a start date greater than 90 days and clinician is on the clinic list as a treating member of the clinic
223607094|NCT05194800|OTHER|Virtual Mirror Therapy|Subjects will be offered the use of a Virtual Reality headset therapy game. Fiducial markers will be placed on the residual limb for tracking via front facing cameras on the Oculus Quest 2 and the sound limb movements will be duplicated (flipped for chirality) and mapped onto the residual limb to provide the appearance of their residual limb. The software will direct the subjects through a series of guided movements, stretches, and visualization exercises which last a total of 15 minutes. Afterwards the subjects will be given 5 minutes of unstructured time in the program to perform any of exercises or movements they desire in order to attempt to relieve their phantom limb pain.
223607095|NCT00305487|DRUG|Ciclesonide nasal spray|
223607096|NCT03688516|BEHAVIORAL|Manipulation of valence and modality|mnemic task with a phase of encoding negative, positive and neutral stimuli, will be proposed followed by an immediate recovery phase, composed of a recall task followed by a recognition task
223607097|NCT03688516|BEHAVIORAL|Spatial and recognition memory|mnemic task with a phase of encoding negative, positive and neutral stimuli, will be proposed followed by an immediate recovery phase, composed of a recall task followed by a recognition task
223607098|NCT03688516|BEHAVIORAL|Source and content memory|mnemic task with a phase of encoding negative, positive and neutral stimuli, will be proposed followed by an immediate recovery phase, composed of a recall task followed by a recognition task
223607099|NCT03838081|BEHAVIORAL|Spielberger State Anxiety Inventory (STAI-S),|STAI is one of the most frequently used scales in anxiety research, although it is not a specific scale for dental anxiety
223754112|NCT04477304|BEHAVIORAL|Long-term opioid recipient|Total opioid doses are at least 50 MME per day, there are two or more prior opioid prescriptions with two different start dates both greater than 1 day and less than 91 days, and there is a prior opioid prescription with a start date greater than 90 days and less than 181 days and clinician is on the clinic list as a treating member of the clinic
223754113|NCT06995430|BIOLOGICAL|rMenB+OMV NZ vaccine|1 dose in the Primed group or 2 doses in the Naive group.
223754114|NCT02795195|RADIATION|Carbon ion radiotherapy (CIRT)|Five dose levels (51GyE, 54GyE, 57GyE, 60GyE, 63GyE) are planned within the Phase I part. And the started dose level will be 54GyE. Daily fraction of 3 GyE will be delivered for all dose levels. After the recommended dose (RD), i.e., maximal tolerated dose, is determined or if the treatments to 63 GyE are safely delivered, the recommended dose (or 63 GyE) will be the prescribed dose in the Phase II part of the study.
223754115|NCT07004686|DEVICE|MGRNOX index-guided analgesia|After anesthesia induction, the remifentanil plasma target concentration was adjusted intraoperatively to maintain the MGRNOX index between 30 and 50,but MAP and HR also were considered .In case the MGRNOX index was below 30 for more than 1 minute, remifentanil target-controlled infusion levels were lowered in steps of 0.5 ng/ml , whereas in case of a value greater than 50 for more than 1 minute, remifentanil target-controlled infusion levels were increased in steps of 0.5 ng/ml.
223607100|NCT03838081|BEHAVIORAL|Dental Fear Scale (DFS)|DFS is a scale developed by Kleinknecht used to determine dental fear in different dimensions. This is a Likert-type scale with a score of 1-5. It has 20 items. It examines the level of fear in terms of dentist avoidance, somatic symptoms of fear, and fear of various applications in dentistry practice
223607101|NCT03838081|BEHAVIORAL|Modified Dental Anxiety Scale (MDAS)|MDAS was developed by Humphris et al. by adding a question related to injection. The scale consists of five-point Likert-type rating with five options. The scoring in this scale varies between 5 and 25
223607102|NCT03838081|BEHAVIORAL|Visual Analog Scale (VAS)|"VAS is ideal for evaluating situations that cannot be measured using digital and oral information. In the present study, a scale comprising 100-mm closed-end line was used to measure the anxiety level. One end of the scale was labeled as no anxiety and the other end as maximum anxiety imaginable"
223607103|NCT03715244|PROCEDURE|Spinal anesthesia with short-acting local anesthetics|Spinal anesthesia in patients with duration of surgery \< 90 minutes
223607104|NCT03715244|PROCEDURE|General anesthesia (current standard)|General anesthesia in patients with duration of surgery \< 90 minutes
223607105|NCT03827525|BEHAVIORAL|Cognitive and Behavioral Therapy|9 sessions of Cognitive and Behavioral Therapy will be realised with the patient by a clinical psychologist. They will last between 1h and 1h30.
223607106|NCT02735343|DRUG|Compazine|Compazine 10mg with diphenhydramine 25 mg IV
223754116|NCT07004686|DEVICE|Standard Clinical Care|After anesthesia induction, if hypertension (MAP \> 100 mmHg) or tachycardia (heart rate \> 90 bpm) persists for more than 2 minutes, remifentanil target-controlled infusion levels were increased in steps of 0.5 ng/ml.If there is no response to remifentanil or the MAP and HR exceed a certain threshold, then urapidil or esmolol will be administered.For hypotension (50 mmHg \< MAP ≤ 60 mmHg) persisting for more than 2 minutes, remifentanil target-controlled infusion levels were lowered in steps of 0.5 ng/ml (lowest target plasma concentration that was allowed is 1 ng/ml), and 4μg of norepinephrine were given. If MAP ≤ 50 mmHg, remifentanil target-controlled infusion levels were lowered in steps of 0.5 ng/ml(lowest target plasma concentration that was allowed is 1 ng/ml), and 8μg of norepinephrine were given.
223754117|NCT07109323|DRUG|BCMA CART|Bcma-cart was reinfused at a dose of 1.0-2.0 × 10 \^ 6 / kg on day +3 (± 1 day) after autologous hematopoietic stem cell reinfusion.
223754118|NCT07109310|DIAGNOSTIC_TEST|RTImodel001|This model was developed through transcriptome sequencing combined with machine learning to predict the risk of disease progression and clinical outcomes of respiratory tract infections
223754119|NCT07108608|BEHAVIORAL|Written Exposure Therapy|Written Exposure Therapy is a brief, evidenced based intervention for PTSD. WET is generally delivered individually across 5 sessions in which the therapist guides the patient through writing exercises. Across exposure sessions, participants experience habituation so that their symptoms decrease by the end of treatment. WET has an established evidence base in general outpatient psychotherapy for PTSD, but has not been adapted or tested in residential SUD treatment settings. Further, the investigators have adapted WET for this setting based on stakeholder and expert feedback.
223754120|NCT07108608|BEHAVIORAL|Treatment as Usual|Treatment as Usual will include a variety of standard care services offered in short term residential treatment. For example, participants receiving TAU will participate in individual case management/general counseling sessions focused on substance use disorder and its consequences, group based psychoeducation sessions, group based counseling sessions (e.g., relapse prevention planning), individual services with a medical provider and pharmacotherapy (e.g., for withdrawal, relapse prevention, or co-occurring conditions)
223754121|NCT06867484|RADIATION|Intensity modulated radiation therapy (IMRT)|40 Gy total in 15 consecutive weekday sessions to the partial breast
223754122|NCT04866771|OTHER|Transcranial Direct Current Stimulation (tDCS)|Noninvasive brain stimulation
223754123|NCT04866771|OTHER|Sham tDCS + anodal tDCS|Fake noninvasive brain stimulation or anodal noninvasive brain stimulation
223754124|NCT07009951|DEVICE|Virtual reality|VR headset provides an immersive environment, such as natural landscapes accompanied by relaxing music. The use of VR will begin at least five minutes before the start of the procedure to allow the patient to acclimate. The headset will remain in use throughout the entire procedure, unless complications arise (e.g., nausea or significant discomfort).
223754125|NCT07023978|OTHER|Some movements in the qigong study called Ba Duan Jin, which will be applied to pregnant women, will be arranged for pregnant women and explained in detail. These are very slow, movements|Ba Duan Jin Qigong
223754126|NCT07022041|DIAGNOSTIC_TEST|conductivity and dieletric constant|collecting blood samples and directly measuring plasma conductivity and dielectric constant using microwave probes already validated for non-invasive glucose monitoring.
223754127|NCT07027644|DEVICE|Dry Cupping Therapy|The patients receive dry cupping therapy for 10 min on the marked trigger point using a plastic set with a hand vacuum pump
223754128|NCT07027644|OTHER|Integrated Neuromuscular Inhibition Technique|The patients receive the Integrated Neuromuscular Inhibition Technique, which consists of ischemic compression, strain-counterstrain, and muscle energy techniques.
223754129|NCT07027644|OTHER|stretching and strengthening exercises|The patients receive stretching and strengthening exercises
223754130|NCT07027644|OTHER|combined integrated neuromuscular inhibition, dry cupping and stretching and strengthening exercises|the patients recive all the three interventions
223754131|NCT06687967|DRUG|Dupilumab|Pharmaceutical form: Solution for injection Route of administration: subcutaneous injection
223754132|NCT06687967|DRUG|Placebo|Pharmaceutical form: Solution for injection Route of administration: subcutaneous injection
223754133|NCT06742736|DRUG|BGF|BUDESONIDE/GLYCOPYRRONIUM/FORMOTEROL
223754134|NCT07058324|DIETARY_SUPPLEMENT|Prebiotic fiber|Chicory root-derived prebiotic fiber
223754135|NCT07058324|DIETARY_SUPPLEMENT|Placebo control|Maltodextrin
223754136|NCT06776731|OTHER|Oxygen|Standard supplemental Oxygen therapy (5l/min) will be applied with an oxygen concentrator via nasal cannula during endurance training.
223754137|NCT06776731|OTHER|Room Air (placebo)|Room air (5l/min) will be applied with an oxygen concentrator via nasal cannula during endurance training.
223754138|NCT06813742|DRUG|18F-MFBG|Patients with pheochromocytoma malignancies receive 5.55 MBq/kg of 18F-MFBG intravenously followed by PET/CT or PET/MR after 60min of injection.
223754139|NCT04586699|DEVICE|Medi1TMS|rTMS theta-burst protocol paired with a consistent attention-to-breath task
223754140|NCT04586699|DEVICE|Medi2TMS|rTMS theta-burst protocol paired with an intermittent deep breathing task
223754141|NCT01515527|DRUG|Cladribine|"Induction cycle: 5 mg/m2 by vein on days 1 - 5 for up to 2, 28 day cycles.~Consolidation cycle: 5 mg/m2 by vein on days 1 - 3 of cycles 2, 5, 6, 9, 10, 13, 14, 17, and 18."
223607107|NCT02735343|DRUG|Ketamine|Ketamine 0.3 mg/kg along with ondansetron 4 mg IV
223607108|NCT00311883|DRUG|hydroxychloroquine|
223607109|NCT06236386|OTHER|VR Experience|VR headset and video experience.
223607110|NCT04635917|OTHER|Personalized diet|Participants in this group will receive tailored nutrition counseling from a dietitian. To facilitate meeting these dietary goals, participants will be provided with nuts, fruits, and vegetables.
223607111|NCT04635917|OTHER|Conventional dietary advice|Participants in the CD group will receive non-personalized, conventional dietary advice by a dietitian based on the MyPlate guidelines.
223607112|NCT06149078|DIAGNOSTIC_TEST|serum uric acid|to detect the relaton ship of serum uric acid with sevwrity of knee osteoarthritis
223607113|NCT02411019|BIOLOGICAL|GX-188E|In phase II study, 72 patients were assigned to two dose groups (1mg and 4mg) and were administered three times with GX-188E by electroporation during an entire period of study. After the final administration, the follow-up will be conducted to investigate safety and efficacy aspects.
223607114|NCT05637801|DEVICE|Sensory Stimulation System (GS120) - Active|Sensory Stimulation System (GS120) - Active settings
223607115|NCT05637801|DEVICE|Sensory Stimulation System (GS120) - Sham|Sensory Stimulation System (GS120) - Sham settings
223607116|NCT05929287|PROCEDURE|Tablet-based CT|This group will perform digital CT tasks.
223607117|NCT05929287|PROCEDURE|Paper-and-pencil CT group|This group will perform paper-and-pencil CT tasks.
223607118|NCT04449510|OTHER|Electronic Cigarette|E-cigarette Device: The delivery device will be a variable wattage all-in-one device with operating wattage of 7.0 - 75.0 W. The device will be set at 10 watts for the study visits.
223607119|NCT06559826|DRUG|Ketamine|Following screening and baseline assessments, individuals randomized to KAP will undergo a preparatory session prior to the first day of dosing. Participants will complete a sequence of four to five intramuscular (IM) ketamine assisted therapy sessions.
223607120|NCT06559826|BEHAVIORAL|Psychotherapy|Each week following KAP, there will be a separate 60-minute integration session 1-6 days afterwards. Integration sessions will focus on processing experiences and material that emerged in KAP sessions (such as assimilating challenging experiences, making meaning of experiences and imagery, working through memories and emotions, and exploring emerging relational patterns) as well as strengthening insights. Within one week of the completion of all KAP sessions, there will be one additional integration session focused on consolidating the insights and improvements gained from KAP treatment.
223607121|NCT04891133|DRUG|Baricitinib|4 mg baricitinib (2 tablets of 2 mg) once daily
223607122|NCT04891133|DRUG|Placebo|4 mg placebo (2 tablets of 2 mg) once daily
223607123|NCT04444466|DRUG|UCB8600|Study participants will receive UCB8600 in a pre-specified sequence during the Treatment Period.
223754142|NCT01515527|DRUG|Cytarabine|"Induction cycle: 20 mg subcutaneously twice daily on days 1-10 for up to 2, 28 day cycles.~Consolidation cycle: 20 mg subcutaneously twice daily on days 1 - 10 of cycles 2, 5, 6, 9, 10, 13, 14, 17, and 18."
223754143|NCT01515527|DRUG|Decitabine|Consolidation cycle: 20 mg/m2 by vein over 1 to 2 hours on days 1-5 of cycles 3, 4, 7, 8, 11, 12, 15, and 16.
223754144|NCT06682754|OTHER|Stress|All participants will perform a baseline test in which they will first be asked to visualize low-arousal IAPS images for three minutes while seated in a chair, and then get up, walk to a table with two bottles, transfer liquid from one bottle to the other, return to the starting chair and sit down again. Subsequently, they will perform an experimental test, where they will repeat the same movements as in the baseline test after visualizing high-arousal IAPS images for three minutes. In addition, IAPS images will continue to be projected in the background while participants perform the described motor tasks.
223754145|NCT06591780|OTHER|Clinical Evaluation|"A clinical evaluation occurs at the first study session. The clinical evaluation assesses walking function and mobility, lower extremity, sensation, health-related quality of life (HRQoL) and foot function.~Session 2 will be a dynamometer-based evaluation of passive ankle stiffness and a 3-dimensional gait analysis to evaluate baseline biomechanics. During Session 3, real-time biofeedback conditions will be used to measure the immediate effects on walking function."
223607124|NCT04444466|OTHER|Placebo|Study participants will receive Placebo in a pre-specified sequence during the Treatment Period matching UCB8600.
223607125|NCT04339673|PROCEDURE|masseteric nerve block|regional bloc of masseter
223607126|NCT04339673|PROCEDURE|trigger point injection|trigger point injection with local anesthetic
223607127|NCT04339673|PROCEDURE|dry needling|needling with acupuncture needles of trigger points in masseter
223607128|NCT01493973|DRUG|Epoetin alfa|Epoetin alfa will be administered s.c. at 1200 IU/Kg every 12 weeks
223607129|NCT01493973|DRUG|Placebo|Placebo
223607130|NCT05710042|DEVICE|Revivent TC System|The Revivent TC System is indicated for patients suffering from symptomatic heart failure referred for treatment of left ventricular antero-septal aneurysms/scars that are contiguous and includes both anterior and septal components.
223607131|NCT03243357|PROCEDURE|TF Adaptive (First Apical Binding File)|"Procedure: TF Adaptive System NiTi (Nickel titanium) Endo File System (SybronEndo) The root canal instrumentation will be performed by the TF Adaptive features Adaptive Motion (Elements Motor).~Procedure: Instrumentation based on protocol of First Apical Binding File The enlargement of the root canal will be performed with three files larger than the diameter of the previously established initial apical file."
223607132|NCT03243357|PROCEDURE|TF Adaptive (Control)|"Procedure: TF Adaptive System NiTi (Nickel titanium)Endo File System The root canal instrumentation will be performed by the TF Adaptive features Adaptive Motion (Elements Motor).~Procedure: Instrumentation based on manufacturer's protocol The enlargement of the root canal will be performed according to the manufacturer's directions."
223607133|NCT00135889|DRUG|Femoral perineural infusion|
223607134|NCT05178602|BEHAVIORAL|Tai Chi Intervention Group|Tai Chi intervention group: routine treatment and tai Chi exercise,5 times a week.
223607135|NCT05622565|DIAGNOSTIC_TEST|Various modalities of ocular fundus imaging|Through various modalities of ocular fundus imaging, combining with clinical data and the experience of clinicians to diagnose different fundus diseases.
223607136|NCT05154526|OTHER|Manual Therapy|Manual Therapy: High velocity-low amplitude technique
223607137|NCT05154526|OTHER|Exercise Program|Exercise program
223607138|NCT05919888|DRUG|Povidone-Iodine|Applied to skin incision.
223607139|NCT05919888|DEVICE|SURGX Wound Gel|Applied to skin incision.
223607140|NCT06352749|BEHAVIORAL|Advice to increase physical activity and reduce sedentary behavior|After the baseline assessments, all participants will receive individualized counseling for following physically active lifestyle and reducing sedentary behaviors. Participants will be encouraged to increase the physical activity time and intensity, and to hourly break the sedentary time while at home. The recommendations will be transmitted verbally and through written material.
223607141|NCT06352749|BEHAVIORAL|Online Physical Exercise|"This intervention will entail:~Strength training of upper and lower limbs. Familiarization phase will include 2-3 exercises of 1-2 series and 8-12 repetitions per session. During the acquisition phase, 2-3 exercises of 2-3 series and 8-12 repetitions at a higher velocity. The resting time between sets will be of 1-3 minutes.~Balance exercises will include proprioception, agility and weight transfer exercises. Difficulty will progressively increase by reducing the base of support, by including multidirectional displacements, walking on tiptoe or heels, body-weight transfer, dynamic exercises modifying the centre of gravity, and stressing postural muscles and by sensorial reductions.~Flexibility exercises: Static stretching maintained during 20-30s carried out at the end of each session.~All the sessions will be supervised online by trained physiotherapists or sports physiologists."
223607142|NCT06352749|BEHAVIORAL|Face-to-Face Exercise|"This intervention will entail:~Strength training of upper and lower limbs. Familiarization phase will include 2-3 exercises of 1-2 series and 8-12 repetitions per session. During the acquisition phase, 2-3 exercises of 2-3 series and 8-12 repetitions at a higher velocity. The resting time between sets will be of 1-3 minutes.~Balance exercises will include proprioception, agility and weight transfer exercises. Difficulty will progressively increase by reducing the base of support, by including multidirectional displacements, walking on tiptoe or heels, body-weight transfer, dynamic exercises modifying the centre of gravity, and stressing postural muscles and by sensorial reductions.~Flexibility exercises: Static stretching maintained during 20-30s carried out at the end of each session.~All the sessions will be supervised face-to-face by trained physiotherapists or sports physiologists."
223754146|NCT06591780|OTHER|Plantar Pressure Biofeedback Gait Training|Participants will complete a 3-dimensional gait evaluation prior to training, after a 6-minute control bout without biofeedback, and following three 6-minute biofeedback training bouts (total 18-minutes). Individualized biofeedback targets will be calculated from each participant's immediate biofeedback session to best minimize plantar pressure whilst maintaining or enhancing propulsion. Audio-visual biofeedback is provided using a screen placed in front of the treadmill and a speaker. For plantar pressure biofeedback, a visual display of a foot with a colored heat map represents the current plantar pressure, in addition to bar graphs representing real-time movement of plantar pressure in specific areas of the foot. A target is provided using the heat map colors of red and target line on the bar graph. Participants are informed that the target is a measurement of the pressure under their foot, and their goal is to decrease pressure to achieve their target
223607143|NCT05028452|OTHER|Internet based support|Carer eSupport is designed to prepare informal caregivers for caregiving, to decrease caregiver burden and prevent a deteriorated health.
223607144|NCT05349357|OTHER|Sliding Neural mobilization|Sliding neural mobilization to femoral, sciatic and tibial nerve
223607145|NCT05349357|OTHER|Tensioner Neural mobilization|Tensioner neural mobilization to femoral, sciatic and tibial nerve
223607146|NCT05349357|OTHER|Stretching exercises|Stretching exercises
223607147|NCT05349357|DEVICE|TENS|TENS
223607148|NCT02204072|DRUG|BI 836845|
223607149|NCT02204072|DRUG|Enzalutamide|
223607150|NCT02204072|DRUG|Enzalutamide|
224311539|NCT06739993|BEHAVIORAL|Resonance frequency breathing with heart rate variability biofeedback training|During training, a ball that expands (breathe in) and shrinks (breathe out) on the screen specified the breathing frequency goal to a value of six cycles per minute (five seconds inspiration, five seconds expiration). The HRV was visualized by new symbols varying in color depending on the respectively measured values, which appeared every ten seconds. When the participants achieved the specified breathing frequency, resulting in an increased sinus arrhythmia, the symbols appearing on the smartphone display were green. When the participants did not achieve the specified breathing frequency, the symbols appeared in yellow (non-significant deviation), orange (significant deviation), or red (very significant deviation). The participants were instructed to adjust their breathing frequency to reach emergence of as many green symbols as possible for the entire training session.
224311540|NCT06739993|BEHAVIORAL|Anti-Stress program|The mobile system eSense Pulse from Mindfield Biosystems is used for the digital anti-stress program. To do this, the participants put on a chest strap with a sensor and can start training via the eSense app. The anti-stress program is carried out using a procedure generated for the study. During the anti-stress program units, the participants receive application-related information and tips to better understand the topic of stress, identify stressors in their own lives and reduce stress. The active control intervention of the anti-stress program was selected to investigate the effect of a specific stress level reduction without the direct modulation of physiological mechanisms of action as with HRV-BF-RFA.
223607151|NCT03319134|DEVICE|active anodal HD-tDCS|1\) active anodal HD-tDCS with memory task
223607152|NCT03319134|DEVICE|sham HD-tDCS|2\) sham HD-tDCS with memory task
224311541|NCT06901336|DRUG|[14C]-STX-478|oral administration
223607153|NCT03319134|DEVICE|active cathodal HD-tDCS|3\) active cathodal HD-tDCS with memory task
223607154|NCT02428569|BEHAVIORAL|PREPARED Decision Support|The PREPARED DVD presents patient and health care provider testimonials that characterize the pros and cons of different kidney replacement treatment options, including in-center hemodialysis, home hemodialysis, peritoneal dialysis, kidney transplant, and conservative management (i.e., no dialysis or transplant). The PREPARED book reinforces differences between the treatments by showing (in lay language) summaries of scientific evidence on treatment outcomes associated with each kidney replacement option.
223607155|NCT05888987|BIOLOGICAL|PCR multiplex by FilmArray|PCR multiplex by FilmArray system on corneal swabbing sample
223607156|NCT05710549|DEVICE|high-density electroencephalography (hdEEG)|EEG will be recorded with a 257-channel EEG system (Geodesic Sensor Net, MegStim). An EEG net is applied at once on the head with evenly spaced sensors that provide full scalp coverage, including the cheek, Ag/Ag-Cl electrodes that are interconnected by thin rubber bands and contain small sponges soaked with saline water that touches the participant's scalp surface directly. Net application takes about 10 min to derive impedances to \<30 kOhms. EEG is recorded with 1 kHz and band-pass filtered between 0.1-200 Hz. Vertex electrode Cz is used as an acquisition reference.
223607157|NCT05710549|DEVICE|Transcranial alternating current stimulation (tACS)|tACS will be delivered by a battery-driven current stimulator Starstim SS32 (Neuroelectrics) through surface Ag/AgCl electrodes placed into holes of a neoprene cap corresponding to the international 10/20 EEG system. Gel (Parker Lab, Inc.) will be applied to optimize signal conductivity and lower impedance.
223607158|NCT06975150|DRUG|HK-660S 100mg|Administered orally
223607159|NCT06975150|DRUG|HK-660S 200mg|Administered orally
223607160|NCT06975150|DRUG|Placebo|Administered orally
223607161|NCT06976814|OTHER|Neuro muscular electrical stimulation|electrical stimulation to facial nerve to improve facial palsy
223607162|NCT06976814|OTHER|Beckmann's oral motor exercises|Oral motor exercises to improve facial palsy.
223607163|NCT06975514|DRUG|YZJ-1139|YZJ-1139 20mg tablets, once daily in the evening
223607164|NCT06975514|DRUG|Zolpidem|Zolpidem 10mg tablets, once daily in the evening
223607165|NCT05500963|DEVICE|Transcutaneous electrical nerve stimulation|Electrical stimulation applied over selected leg muscle will activate sensory receptors that will transmit signals back into the central nervous system.
223607166|NCT06285396|DRUG|Ephedrine|Ephedrine in solution, at applicable concentrations based on literature.
223607167|NCT06285396|DRUG|Phenylephrine|Phenylephrine, at applicable concentrations based on literature.
223607168|NCT06285396|DRUG|Norepinephrine|Norepinephrine, at applicable concentrations based on literature.
223607169|NCT06285396|DRUG|Oxytocin|Oxytocin, at applicable concentrations based on literature.
223607170|NCT06603012|BEHAVIORAL|GET Up PD|"* The exercise training prescription involves performing 3 days per week and include (a) aerobic exercise: 30+ minutes of moderate-intensity walking (≥100 steps/min) monitored by a waist-worn pedometer, and (b) resistance training: 1-3 sets, 8-12 repetitions of 5-10 exercises targeting lower and upper body, and core muscle groups using elastic bands.~* Other components of the GET Up PD program include appropriate exercise equipment (pedometer, resistance bands), one-on-one coaching sessions via Zoom, action-planning via calendars, logbooks for self-monitoring, and SCT-based newsletters."
223607171|NCT06603012|BEHAVIORAL|Stretching and Flexibility|"* The training will involve the same frequency, duration, timeline, behavior change content, and interactions with behavioral coach as the GET Up PD program, and account for activity, social-contact, and attention.~* Other components of the Stretching and Flexibility program include appropriate exercise equipment (yoga mat), one-on-one coaching sessions via Zoom, calendars, logbooks and newsletters similar to the GET Up PD program."
223607172|NCT06584357|OTHER|Biomarker Data Collection|During this study, a sample of your blood will be collected and you will have a PET scan taken of your brain. Blood sample results will be compared to PET scan pictures to understand how well the markers in the blood predict whether there is amyloid in the brain. Blood samples will also be collected that contain your genes. These genetic samples will also be compared to PET scans to help researchers understand how different people react to medicines and to understand the genetic causes of AD. Some of the samples will be stored for future analysis.
223754147|NCT06591780|OTHER|Propulsion Biofeedback Gait Training|Participants will complete a 3-dimensional gait evaluation prior to training, after a 6-minute control bout without biofeedback, and following three 6-minute biofeedback training bouts (total 18-minutes). Individualized biofeedback targets will be calculated from each participant\&#39;s immediate biofeedback session to best minimize plantar pressure whilst maintaining or enhancing propulsion. Audio-visual biofeedback is provided using a screen placed in front of the treadmill and a speaker. For propulsion biofeedback, a visual display with a marker represents the current propulsion (peak AGRF) and a target provided to modulate propulsion. Participants are informed that the marker is a measurement of how hard they are pushing the ground backward, and their goal is to push-off more to achieve their target.
223754148|NCT07080905|GENETIC|CSL222 (Adeno-associated viral vector serotype 5 [AAV5]-hFIXco-Padua)|Administered as a single IV infusion.
223754149|NCT06268340|PROCEDURE|ECochG monitored CI surgery incl. corrective action guide|Interventional surgery with surgeon having access to intra-operative ECochG monitoring feedback to deploy ECochG based corrective action guide
223607173|NCT06584357|RADIATION|MK6240|Each participant will be assessed using either one of two radioactive tau PET tracers: Flortaucipir or MK6240. Flortaucipir is FDA approved while MK6240 is not and is being used in this study as an investigational radioactive drug.
223754150|NCT06268340|PROCEDURE|Routine CI surgery without ECochG monitoring|Routine CI surgery with access to ECochG monitoring by surgeon
223754151|NCT04088071|DEVICE|Catheter ablation|Ablation RF technologies (e.g., THERMOCOOL SMARTTOUCH®, THERMOCOOL SMARTTOUCH® SF).
223754152|NCT00209677|DRUG|Gemcitabine|
223754153|NCT00209677|DRUG|S-1|
223754154|NCT06622759|PROCEDURE|CTG|Connective Tissue Graft has been widely used around implants to increase either the thickness of the soft tissues or the width of keratinized tissues. It is considered the gold standard for soft tissue grafting. The main drawbacks are the donor morbidity and the limit amount of intraoral donor sites. In this study it will be used in the test 1 group in order to compare its clinical results with the other groups.
223754155|NCT06622759|PROCEDURE|Collagen Matrix|Collagen matrix has been used in several studies in order to evaluate its clinical properties over the last years. In this study, the graft will be placed buccally at the time of implant placement in the aesthetic zone in order to assess its clinical and radiographic properties in terms of buccal bone resorption and soft tissue augmentation. Histological assessment and Patient Reported outcomes will also be evaluated.
223607174|NCT06391489|BEHAVIORAL|HOBSCOTCH-PACS|HOme-Based Self-management and COgnitive Training CHanges lives (HOBSCOTCH) HOBSCOTCH is a home-based self-management program to treat cognitive symptoms and improve quality of life, while minimizing the barriers of access to care. The program is based on Problem Solving Therapy (PST) and teaches problem solving strategies and compensatory mechanisms to help manage cognitive dysfunction and enhance quality of life. HOBSCOTCH-PD is an adaptation of the HOBSCOTCH program for people with PD and incorporates education about Parkinson Disease and cognition into the education module.
223607175|NCT00581906|RADIATION|DCE-MRI, DW-MRI and MRS|Pts undergo DCE-MRI, DW-MRI or 1\^H-MRS studies on either the 1.5T scanner or the 3T MRI scanners. Patients will be grouped based on their treatment: group one will include pts who undergo surgery (we will no longer accrue pts in this group) \& group two will include pts who undergo chemoradiation therapy.Pts who undergo surgery will have pretreatment DCE-MRI, DW-MRI \&/or 1H-MRS studies on the GE 1.5T or 3T MRI scanner. Pts who participate in chemo-radiation therapy protocols will have pretreatment DCE-MRI, DW-MRI \&/or 1H-MRS studies on the 3T Philips MRI scanner in the radiation oncology suite \& will undergo additional recommended weekly DW-MRI including IVIM studies at the same MRI scanner during the course of treatment. Pts will undergo two recommended DCE-MRI studies (unless contraindicated) when possible. 1st intra-treatment DCE-MRI is recommended between the 1st \& 2nd weeks of treatment \& the 2nd intra-treatment DCE-MRI is recommended between the 3rd \& 4th weeks of treatment.
223607176|NCT06580561|BEHAVIORAL|Personalized exercise coaching|"This is a 6-session personalized exercise coaching program (delivered over 8 weeks).~All participants will complete six 30-minute scheduled online or phone sessions with a health coach as part of a manualized personalized exercise program (once per week for the first four sessions and then once every two weeks for the remaining two sessions)."
223607177|NCT06580561|BEHAVIORAL|Cognitive behavioral therapy for Insomnia|"This is a 6-week course of automated, digitally delivered cognitive behavioral therapy for insomnia delivered by the online program Sleepio. The weekly sessions will last approximately 15-20 minutes.~Session content comprises evidence-based cognitive and behavioral techniques including Stimulus Control Therapy and Sleep Restriction Therapy, sleep hygiene education, and relaxation exercises."
223607178|NCT04954859|DRUG|Bepirovirsen|No study drug will be administered in this study. Eligible participants who received prior treatment with bepirovirsen in the parent studies will be included.
223607179|NCT04954859|DRUG|Placebo|No study drug will be administered in this study. Eligible participants who received prior treatment with placebo in the parent studies (209668, 202009, and 219288) will be included to maintain the blind in the still ongoing parent studies.
223607180|NCT06982183|DRUG|Propranolol|An administration of a 40-mg propranolol capsule immediately after tarantula exposure
223607181|NCT06982183|DRUG|Hydrocortisone|An intramuscular administration of 62.5 mg/1 ml of hydrocortisone immediately after tarantula exposure
223607182|NCT06982183|DRUG|Morphine|An intramuscular administration of 5 mg/1 ml of morphine immediately after tarantula exposure
223607183|NCT06982183|DRUG|Placebo (oral)|An administration of a placebo capsule after tarantula exposure
223607184|NCT06982183|DRUG|Placebo (IM)|An intramuscular administration of 1 ml of saline immediately after tarantula exposure
223607185|NCT04209205|DRUG|AIN457 6 mg/kg i.v.|AIN457 6 mg/kg delivered by i.v. infusion
223607186|NCT04209205|DRUG|Placebo|Matching placebo to AIN457 i.v. infusion
223607187|NCT04209205|DRUG|AIN457 3 mg/kg|AIN457 3 mg/kg delivered by i.v. infusion
223607188|NCT05244564|OTHER|Motion-assisted, Multi-modular Memory Desensitization and Reconsolidation (3MDR)|"Walk and talk therapy, walking on a treadmill while talking with a therapist about self-chosen pictures representative of one's trauma; 3MDR also includes some features of virtual reality exposure therapy (VRET) and Eye Movement Desensitization and Reprocessing (EMDR) therapy."
223607189|NCT06996665|OTHER|High-flow device flow rate setting|To evaluate the feasibility of diaphragmatic speckle tracking, images acquired under three different high-flow settings (low, medium, and high) will be compared with those obtained under the clinically applied flow rate previously used for each patient.
223607190|NCT06996665|OTHER|PEEP titration through different approaches|To investigate the clinical value of diaphragmatic speckle tracking, this study compares PEEP titrated by ultrasound-based assessment with PEEP determined by conventional P/F ratio tables, and analyzes differences in clinical outcomes between the two groups.
223754156|NCT06622759|PROCEDURE|Control group|In the control group, the implant will be placed without any kind of soft tissue graft in order to compare this treatment modality that many clinicians apply at the clinical practice.
223754157|NCT07084077|OTHER|Narratology education module|At RCSI Dublin, mentioned by James Joyce in Dubliners, a one-week student-choice module Narrative Medicine: lessons from Irish writers and storytellers was offered to those in the second of our five-year undergraduate medical degree program, i.e., students were 18-months into the curriculum, had limited communication skills training, and no real-world clinical exposure. The module used close reading, group viewing, small-group workshops, and whole-group discussions to foster narrative competence. A medically-trained narratology-expert facilitated students' interrogation of classic and award-winning non-healthcare themed works by Irish writers and storytellers, i.e., directors and/or producers.
223754158|NCT07095959|PROCEDURE|vein of Marshall ethanol infusion|After PFA, the coronary sinus venography will be acquired in search of VOM ostium. Then an over-the-wire balloon will be sent into the VOM and deflated with 4-6 atm. Selective VOM venography will be performed, followed by injection of 10ml 95% ethanol into the VOM.
223754159|NCT07095959|PROCEDURE|PVI using pulsed field ablation|Bilateral pulmonary vein antrum ablation using a pulsed field ablation
223754160|NCT06906341|DRUG|Relacorilant 150 mg once daily (QD)|Relacorilant is administered as capsules for oral dosing on the day before, the day of, and the day after nab-paclitaxel infusion.
223607191|NCT06996210|DEVICE|Acupuncture|The needles will be inserted to 12.5-30 mm in acupoints through adhesive pads. Needles will be lifted, thrusted and twirled gently for 3 times to achieve deqi sensation and manipulated every ten minutes.
223607192|NCT06996210|DEVICE|sham acupuncture|The needle will be inserted to 2-3mm in sham Baihui acupoint. For the remaining sham acupoints, needles will be inserted into the pad and reaching the skin. Needles will be lifted, thrusted and twirled gently for 3 times to simulate the effect of the needle tip penetrating the skin.
223607193|NCT06999304|DEVICE|Intermittent theta burst stimulation|MagVenture TMS Therapy active coil with theta burst stimulation. Resting motor threshold: 80%; Intermittent theta burst - Number of pulses per session: 1200 pulses; Inter-train interval: 8 seconds; Pulse frequency in burst: 50 Hertz; Continuous theta burst - Number of pulses per session: 1800 pulses; Pulse frequency in burst: 50 Hertz
223754161|NCT06906341|DRUG|Nab-paclitaxel 80 mg/m^2|Nab-paclitaxel is administered as intravenous (IV) infusion on Days 1, 8, and 15 of each 28-day cycle.
223754162|NCT06906341|DRUG|Bevacizumab 10 mg/kg|Bevacizumab is administered as IV infusion on Days 1 and 15 of each 28-day cycle.
223754163|NCT07098559|BEHAVIORAL|Creative drama|This intervention is unique in its integration of the Bystander Intervention Model with creative drama techniques to enhance empathy, self-efficacy, and active intervention behaviors among middle school students witnessing peer bullying. Unlike traditional anti-bullying programs that rely on lectures or cognitive-based approaches, this study uses experiential learning and role-playing scenarios to simulate real-life bullying situations and encourage emotional engagement and behavioral change.
223754164|NCT07109037|OTHER|Conventional exercise therapy|"Conventional exercise therapy includes four exercises: the little swallow flying exercise, the hip bridge exercise, back muscle stretching, and relaxation. It is performed once a day, 45 minutes ."
224311542|NCT02851693|DEVICE|Optical Coherence Tomography (OCT) with Vivosight|OCT used is Vivosight for diagnosis
224311543|NCT02851693|DEVICE|Optical Coherence Tomography (OCT) with Skintell|OCT used is Skintell for diagnosis
223754165|NCT07109037|OTHER|Suspension training and conventional exercise therapy|Suspension training alternates with conventional exercise therapy. It is conducted every other day, 45 minutes each time, 2-3 times a week for four consecutive weeks. Elastic ropes for suspension training are chosen based on patients' body mass: single - strand for those with body mass ≤ 30 kg and double - strand for those with body mass \> 30 kg. Suspension slings are placed on the head, lower back, and pelvis, and non-elastic rope slings on the ankles. Lower the lifting bed so that the vertical distance from the ankles to the bed surface is about 25-30 cm.
223607194|NCT06999928|BEHAVIORAL|Enhanced Mentor Mother Strategy|The enhanced Mentor Mother strategy introduces a structured approach to differentiated PMTCT support, led by trained peer counselors/Mentor Mothers (MM). Mentor Mothers will be trained on how to perform risk stratification, and they will use a standardized form to identify and document psychosocial and clinical risk factors. Based on these, MMs then deliver tailored interventions, including additional counseling, community outreach, and referrals. Fidelity assessments and a process of audit and feedback will be used to further refine the strategy, which builds on national differentiated service delivery guidelines and integrates into routine care without requiring added clinic staff.
223607195|NCT06676540|OTHER|Neurodevelopmental Therapy (NDT) and Eccentric Exercise Training Group (NDT+EE)|Including Functional Eccentric Exercises Applied to Individuals with Cerebral Palsy
223607196|NCT06676540|OTHER|Neurodevelopmental Therapy (NDT)|This application includes rehabilitation methods frequently used in pediatric rehabilitation.
223607197|NCT07001449|BEHAVIORAL|Pain Neuroscience Education with Communication Training|"This intervention includes individualized physiotherapy based on a Pain Neuroscience Education (PNE) framework delivered by physiotherapists who completed the full Algo(S)Therapy training program. The training includes education in the neurophysiology of pain, clinical reasoning for chronic musculoskeletal pain management, and structured communication skills development (e.g., motivational interviewing, empathy, active listening). The intervention is delivered twice per week over 5 weeks (10 sessions total)."
223607198|NCT07001449|BEHAVIORAL|Pain Neuroscience Education without Communication Training|"A structured PNE program focusing on the neurophysiology and clinical management of chronic musculoskeletal pain. Delivered by physiotherapists trained only in the scientific modules of the Algo(S)Therapy program. Does not include communication skills training. Includes 10 sessions (2/week for 5 weeks), alongside standard physiotherapy care."
223607199|NCT07001449|BEHAVIORAL|Usual Physiotherapy Treatment|"Usual care based on medical referral and physiotherapy assessment. Delivered by physiotherapists who have not received training in Pain Neuroscience Education or communication techniques. No components of the Algo(S)Therapy program are included."
223607200|NCT06867991|DRUG|Ofatumumab combined with daratumumab|All participants will begin acute first-line therapy prior to randomization, and participants who were receiving oral or intravenous corticosteroids at baseline will need to taper their doses according to a standard taper schedule starting 4 weeks after randomization (week 4). Patients will be randomly assigned to receive ofatumumab followed by daratumumab or ofatumumab followed by repeated intravenous globulin. The ofatumumab group will receive subcutaneous ofatumumab at weeks 0, 1, 2, 4, 8, 12, 16, 20, and 24, while the ofatumumab-daratumumab group will receive daratumumab intravenously (on the second day of ofatumumab) in addition to ofatumumab, with a dose of 8 mg/kg at weeks 0, 1, 2, and 4, and a dose of 4 mg/kg at weeks 8, 12, 16, 20, and 24. The study will investigate the effects of up to 24 cycles of daratumumab.
223607201|NCT06867991|DRUG|Ofatumumab|All participants were started on acute first-line therapy before randomization, and participants who were receiving oral or intravenous glucocorticoids at baseline were required to taper their doses according to a standard taper schedule starting 4 weeks after randomization (week 4). Ofatumumab was administered subcutaneously at weeks 0, 1, 2, 4, 8, 12, 16, 20, and 24 in the ofatumumab group.
223607202|NCT06867991|DRUG|Repeated intravenous immunoglobulin/plasma exchange therapy|Repeated intravenous immunoglobulin/plasma exchange therapy
223607203|NCT06491238|BEHAVIORAL|Light Intensity Exercise|12 weeks light intensity strength and endurance NeuroWell exercise program, specifically developed for individuals with neurological disorders or injuries. Participants have the intensity goals descripted in the experimental arm.
223607204|NCT06491238|BEHAVIORAL|Moderate Intensity Exercise|12 weeks moderate intensity strength and endurance NeuroWell exercise program, specifically developed for individuals with neurological disorders or injuries. Participants have the intensity goals descripted in the experimental arm.
223607205|NCT06883630|DRUG|RC148 plus Carboplatin and Paclitaxel/pemetrexed|RC148; Carboplatin; Paclitaxel; pemetrexed
223607206|NCT06883630|DRUG|RC148|RC148 Monotherapy
223607207|NCT06725979|DEVICE|maxillary expansion using hyrax expander|The rapid expansion of the upper jaw will be performed using palatal expander with hyrax screw, which will be activated 2x a day, until the needed width is reached (according to the cast analysis).
223607208|NCT06885424|OTHER|No additional intervention administered in this long term follow-up study|Safety follow-up for A2 Bio GT products administered in a previous interventional study
223607209|NCT06720090|BEHAVIORAL|Light therapy|5 weeks of light therapy administered via wearable light therapy glasses worn for 1 hour each morning after awakening.
223607210|NCT04586452|DIAGNOSTIC_TEST|AAA Group (Aim 3A)|"The primary goal is to relate preoperative 64Cu-DOTA-ECL1i AAA uptake with CCR2+ cell activity in AAA tissue collected at the time of open repair. We will image AAA patients pre-operatively and collect tissue at the time of open repair in an attempt to demonstrate ex-vivo tissue corroboration of our imaging findings (n=20, 10 women and 10 men).~Participants with AAA will undergo routine clinical evaluation including ultrasound, CT scan and scheduling of open surgical repair. We will record age and tobacco use. If a renal function blood test has not been performed within the past 90 days, we will draw \~2 teaspoons of blood for a creatinine test. A contrast dye will be used for the CT portion of the PET-CT scan. Those having open surgery, their PET/CT imaging will be within 7-14 of the surgery and if available, collection of discarded aortic tissue at the time of surgery."
223607211|NCT04586452|DIAGNOSTIC_TEST|Non-AAA Group|We will determine the retention of 64Cu-DOTA-ECL1i in abdominal aorta of non-AAA volunteers (n=10, 5 women and 5 men). This group of participants will have a documented absence of AAA by screening ultrasound that was previously obtained as part of standard care. Both men and women, above the age of 40, with or without active tobacco use will be considered for participation.
223754166|NCT07109375|DRUG|pegunigalsidase alfa|Pegunigalsidase alfa is 2 mg/mL concentrate for solution and is administered via intravenous infusion every two weeks.
223607212|NCT04586452|OTHER|Ex Vivo Human AAA Specimens (Aim 2A)|The primary objective of this sub-aim is to assess the sensitivity and specificity of 64Cu-DOTA-ECL1i binding to ex vivo to human AAA specimens from the Washington University Vascular Surgery Biobank (VS-BB). We will first perform a histopathological evaluation of human AAA specimens (n=75, including samples from this study) and categorize them based on clinical status (e.g, diameter) and degree of inflammation. We will consider healthy, nonatherosclerotic aorta (n=25) as negative controls, and non-aneurysmal aortas (n=25) from patients that have undergone surgery for aortoiliac occlusive disease as positive controls.
223607213|NCT04586452|OTHER|Relationship between radiotracer and CCR2 (Aim 2B)|The objective of this sub-aim is to better understand the relationship between the levels of CCR2+ inflammatory cells and the inflammatory and clinical status of AAA, to gain insight into the importance of proinflammatory monocytes/macrophages in the development of AAA disease at the time of elective AAA repair. We will correlate the level of MMP expression and activity, as well as cytokine profiles, of each specimen, with the associated histopathological features. The relationship between 64Cu-DOTA-ECL1i binding and CCR2 expression in tissues with different degrees of disease severity will be evaluated using Pearson or Spearman correlation coefficients. This will allow us to speculate as to how tracer uptake will perform in vivo and what that uptake represents in regard to disease severity.
223607214|NCT04586452|DIAGNOSTIC_TEST|AAA Group (Aim 3B-Reproducibility)|We will demonstrate consistent 64Cu-DOTAECL1i uptake by performing repeated imaging studies in a separate group of non-surgical AAA patients (n=20, 10 women and 10 men). Completion of this sub-aim will provide support for the use of 64Cu-DOTA-ECL1i PET for evaluating AAA disease in a reliable fashion. These participants will have another PET/CT imaging study performed 10-14 days after the first PET/CT in order to determine the ability to reproduce the uptake results of Cu-64-DOTA-ECL1i. The physician will assess the participant's willingness and eligibility to have a second PET/CT scan.
223754167|NCT07109765|DRUG|Secukinumab|secukinumab 300 mg weekly for five weeks, followed by 300 mg monthly subcutaneous injection
223754168|NCT07108478|DEVICE|Transcatheter aortic valve and recyclable delivery system|In this study, the transcatheter aortic valve and its recycling delivery system were VitaFlow Liberty®, a TAVR product independently developed by Shanghai Minimally Invasive Cardiovascular Treatment Co., Ltd. (approved and marketed by NMPA). This product is equipment/consumables routinely purchased by hospitals. For routine clinical use, it is designed for transcatheter aortic valve implantation. The valve is delivered to the intended implantation site via the peripheral artery by retrograde flow through the delivery system, realizing the delivery, positioning and release of the valve. Under the supervision of medical imaging equipment, the valve is delivered to the lesion site of the aortic valve, and marked by the diseased aortic annulus, to release the valve and relieve the stenosis at the lesion site, thereby ensuring smooth aortic flow, improving cardiac function and achieving therapeutic purposes.
223754169|NCT07108569|OTHER|Lutetia|Lutetia is an AI-based training plattform
223754170|NCT07109947|DRUG|Letrozole 2.5mg|to determine the effect of Letrozole as a premedication before misoprostol treatment used to induce missed miscarriage.
223607219|NCT07066696|BEHAVIORAL|Mindfulness and Compassion Program|"The CUIDA2 program is an adaptation of the manual The practice of compassion. Kindness with others and with oneself (2019) by Dr. Javier García Campayo. It comprises a total of 9 sessions of approximately 50 minutes (one class).~This program is structured in 3 modules: Module I mindfulness, module II compassion and module III convergence of the previous elements. Each module includes group dynamics, short meditation practices adapted to the trainees and the explanation of the main theoretical contents through exercises and stories."
223607220|NCT07066696|BEHAVIORAL|Relaxation|The active control group is composed of a relaxation program consisting of 9 sessions. The sessions will be given weekly (once a week) and have an estimated duration of 50 minutes. Different breathing practices and exercises and relaxation techniques such as visualization, Jacobson's progressive relaxation and Schultz's autogenic relaxation will be used.
223607221|NCT07065916|BEHAVIORAL|Modified Constraint Induced Movement Therapy|Constraint Induced Movement Therapy and Bimanual Therapy
223607222|NCT07066007|BEHAVIORAL|First Aid Education Programme|A six-module behavioral education program for parents, designed to improve first aid knowledge, application skills, and self-efficacy. Delivered face-to-face in three 120-minute sessions using theoretical lectures, demonstrations, and case-based simulations.
223607223|NCT07065760|DEVICE|Endovascular Aneurysm Repair with Physician Modified Endograft|The surgeon will make an incision to access the femoral artery and insert a thin wire to guide the catheter to the juxtarenal aortic aneurysm. The main graft will be modified by hand to match the participant's anatomy, then reloaded and guided through the artery to the aorta. Once in place, the graft will be deployed, and additional stents will be inserted into vital arteries that supply the kidneys and bowels. Two smaller grafts will be placed into the iliac arteries.This allows blood to flow to the target organs and legs, protecting the aneurysm from rupture. All catheters will then be removed, leaving the graft in place, and the incisions will be closed.
223607224|NCT07066748|PROCEDURE|group P:pressure support ventilation mode|Group P: Weaning trial will be done for patients using PSV 8 cmH2O without ATC
224311544|NCT05587569|DEVICE|Treatment of metatarsus adductus and hallux valgus with the Adductoplasty™ Procedure in combination with the Lapiplasty® Procedure|Patients 14 years of age or older with symptomatic metatarsus adductus and hallux valgus will be eligible to participate based on the inclusion/exclusion criteria established in the study protocol. Anticipated study duration will be 5 years post index procedure.
223607225|NCT07066748|PROCEDURE|group A:automatic tube compensation (ATC).|Group A: Weaning trial will be done for patients using PSV 0 cmH2O with 100% automatic tube compensation (ATC).
223607226|NCT07065461|OTHER|200 g serving of white chocolate-based confection product|200 g serving of white chocolate-based confection product
223607227|NCT04843904|DRUG|Venetoclax|Tablet, taken by mouth
223607228|NCT04843904|DRUG|Obinutuzumab|Given as an infusion into the vein (intravenous, IV).
223607229|NCT04843904|DRUG|Rituximab|Given as an infusion into the vein (intravenous, IV).
223607230|NCT06768515|OTHER|No interventtion|to enhance the understanding of the factors associated with the number of organs retrieved from patients admitted to the ICU for organ donation
223607231|NCT06020443|PROCEDURE|Low Dose chest CT Scan for Lung Cancer Screening|Low dose CT scans will be performed for three years
223607232|NCT03197376|BIOLOGICAL|Pneumosil|10-Valent Pneumococcal Conjugate Vaccine
223607233|NCT03197376|BIOLOGICAL|Synflorix|Pneumococcal conjugate vaccine (Non-Typeable Haemophilus influenzae (NTHi) protein D, diphtheria or tetanus toxoid conjugates) adsorbed
223607234|NCT06383260|BEHAVIORAL|Behavioral diagnostic|Diagnosing the behavioral pattern
223607235|NCT04357483|DRUG|flowable thrombin containing collagen hemostat matrix|A 5 ml flowable hemostat matrix (CollaStat®) was applied to the stump or anastomosis site after pancreatectomy.
223607236|NCT04357483|DRUG|thrombin coated L-dopa contained collagen patch|A 5x2.5cm sized thrombin coated L-dopa contained collagen patch (CollaSeal®) was applied to the stump or anastomosis site after pancreatectomy.
223607237|NCT01123395|DRUG|colchicine 0.6 mg tablet|One Colcrys® 0.6 mg intact tablet taken by mouth
223607238|NCT01123395|DRUG|colchicine 0.6 mg tablet|One Colcrys® 0.6 mg tablet dissolved in apple juice
223607239|NCT00032734|DRUG|satavaptan (SR121463B)|
223607240|NCT01680744|OTHER|Hypothermia|The intervention will take place after consent for donation and research has been obtained and hemodynamic stability has been achieved (mean arterial blood pressure \> 60 mmHg for more than one hour without an increase in vasopressors). Organ donors in the experimental group will either be actively warmed or allowed to spontaneously reach a body temperature of 34 °C.
223607241|NCT02059603|PROCEDURE|Electroacupuncture|
223607242|NCT02059603|PROCEDURE|Fast-track program|
223607243|NCT04325620|DRUG|HIP1601|HIP1601
223607244|NCT04325620|DRUG|HGP1805|Placebo of HIP1601
223754171|NCT07109128|BEHAVIORAL|The T1D Talks: A Virtual Group for Teens and Tweens with T1D|The T1D Talks intervention is an 11 session, virtual (online), group intervention. The T1D Talks intervention teaches developmentally appropriate emotion regulation (ER) skills and facilitates practicing these skills via role-plays and in-session experiences that are meant to elicit strong emotions. The investigators adapted the content and situations of an established intervention to be relevant for youth with T1D (e.g., practicing ER skills while role playing situations like telling parents about high blood glucose numbers or telling a coach about needing to take a time out from a game because of a low blood glucose level). The intervention also provides basic diabetes education about risky situations (e.g., how physical activity can affect blood glucose).
223754172|NCT07110337|DEVICE|Receipt of the Minder System (implantable sub-scalp continuous electroencephalographic (EEG) monitoring (iCEM) system)|The Minder System consists of an implanted device containing an electrode lead and telemetry unit. The electrode lead contains four electrodes that are placed under the patient's scalp to record electrical activity (EEGs) from both sides of the brain. The electrode lead is connected to the telemetry unit that continuously transmits these signals to the external Minder devices to remotely show EEGs for clinician review.
223754173|NCT06923280|DRUG|Pegylated Interferon-alpha (IFN)|pegylated interferon-alpha 180 μg once weekly for 24 weeks
223754174|NCT06924255|DRUG|Xanomeline and Trospium Chloride|accelerated titration of Xanomeline and Trospium Chloride
223754175|NCT06924255|DRUG|Xanomeline and Trospium Chloride|slow titration of Xanomeline and Trospium Chloride
223754176|NCT00694759|DRUG|pioglitazone|30 mg for 2 weeks, then 45 mg daily
223754177|NCT00694759|DRUG|metformin|500mg twice daily for 1 week, then 1000 mg twice daily
223754178|NCT00694759|DRUG|placebo|capsule twice daily
223607245|NCT00603122|BEHAVIORAL|ascent protocol|ascent protocol for the two groups has different acclimatization time
223607246|NCT03219346|OTHER|oral care program|Oral care (sputum and special needs of people cleaning teeth) time for three days a week (with swallowing treatment time before), once a day, each about 10 minutes of oral care program.
223607247|NCT05538143|OTHER|Comprehensive ED syncope/presyncope management tool|This is a data-only, prospective observational cohort study to validate the performance metrics of the Canadian Syncope Risk Score in a diverse population of patients evaluated in community EDs of a U.S. integrated health care system.
223607248|NCT01998308|DRUG|Crespine gel|50 Knees will have single injection of Crespine gel
223607249|NCT01998308|DRUG|Intragel|50 Knees will have single injection of 2 ampules of Intragel
223754179|NCT05687240|BEHAVIORAL|Qigong/Tai Chi|Participants will engage in 8 weeks of gentle movement/mindfulness videos provided in a daily text prompt, asking that this be practices most days of the week. A choice of practice video links will be provided, ranging from 10-30 minutes in length, and later confirmation texts will be employed to document if practiced, and what length was chosen.
223754180|NCT05687240|BEHAVIORAL|Heart rate variability biofeedback|"Randomized participants will be coached to practice a breathing technique that focuses attention on the sensations in the heart area, slowing and deepening the breath, and activating through memory or imagery a positive emotion. This practice is used along with a feedback device that provides information on achievement of the heart rate variability target, coherence that represents a neurocardiac state associated with vagal tone, or balance."
223607250|NCT01998308|DRUG|Crespine plus gel|50 Knees will have single injection of Crespine Plus Gel
223607251|NCT01998308|DRUG|Monovisc|50 Knees will have single injection of Monovisc
223607252|NCT02221388|DRUG|BI 671800 HEA, 200 mg tablets|
223607253|NCT02221388|DRUG|BI 671800 HEA EC, 200 mg tablets|
223607254|NCT02221388|DRUG|BI 671800 HEA, 50 mg tablets|
223607255|NCT02221388|DRUG|BI 671800 ED, 100 mg capsules|
223607256|NCT02221388|OTHER|Standard meal|
223607257|NCT03691571|DEVICE|Esophageal Cooling|The EnsoETM is a non-sterile multi-lumen silicone tube placed in the esophagus for the purpose of cooling or warming a patient while simultaneously allowing gastric decompression and drainage.
223607258|NCT03691571|DEVICE|Control|Standard of care involves standard temperature probe monitoring.
223607259|NCT03135938|PROCEDURE|Grading Inferior Oblique Anterior Transposition surgery|in the grading group, IO muscle of the eye with more severe DVD will be sutured at the level of IR insertion and IO muscle of the eye with lower magnitude of DVD will be sutured 2mm posterior to the sclera to consider the preoperative DVD difference between the two eyes.
223607260|NCT03135938|PROCEDURE|Classic Inferior Oblique Anterior Transposition surgery|in the classic group, IO muscle will be sutured to the sclera at the level of inferior rectus (IR) insertion at its temporal border, without considering the asymmetric DVD between the two eyes
223607261|NCT00003968|DRUG|bryostatin 1|
223607262|NCT02831517|DRUG|BIIB074|Administered as specified in the treatment arm
223607263|NCT02831517|DRUG|Placebo|Matched Placebo
223607264|NCT03240094|OTHER|Nutritional telemonitoring|Participants receive a weighing scale, pedometer and television channel in order to perform self measurements and receive guidance on nutrition and physical activity. Nurses use a website in order to receive telemonitoring measurements and decide about proper follow-up. In case of risk of undernutrition, nurses provide personal advice to optimize nutritional status of the participant.
223607265|NCT00121186|DRUG|fludarabine phosphate|30 mg/m\^2 on days -6 to -2 (2-6 days before transplant).
223607266|NCT00121186|DRUG|melphalan|70 mg/m\^2 on days -3 and -2 (2-3 days before transplant).
223607267|NCT00121186|DRUG|methotrexate|5 mg/m\^2 on days 1, 3, and 7 post-transplant.
223607268|NCT00121186|DRUG|tacrolimus|0.03 mg/kg bid on days -3 to 100 post-transplant.
223607269|NCT00121186|PROCEDURE|allogeneic bone marrow transplantation|if donor bone marrow stem cells are harvested
223754181|NCT03434756|OTHER|Propioceptive training of the abdominal wall muscles|At the beginning, patients will be in a supine position, the lower edge of the StabilizerTM will be placed between the posterior superior iliac spines, aligned with the sacral base. Abdominal manoeuvre will be developed by the patients until they reach 40 mmHg and hold steadily for 10 seconds. Prior the examination, each subject practiced the abdominal manoeuvre three times with an ultrasound image feedback.
223754182|NCT04453917|BIOLOGICAL|Collection of blood and urine|Collection of blood (47 mL) and urine (5 mL) at PML diagnosis and 1, 3 and 6 months after, for analysis of immune checkpoint molecules expression, detection of antiviral immune responses and virological analyses.
223754183|NCT04453917|BIOLOGICAL|Spinal tap|Spinal tap for monitoring of JC viral load at PML diagnosis and 1, 3 and 6 months after, and collection of CSF (2 mL) for virological analyses.
223754184|NCT04453917|DIAGNOSTIC_TEST|Brain MRI|Brain MRI at at PML diagnosis and 3 and 6 months after
223754185|NCT04453917|BIOLOGICAL|Neurological evaluation|Neurological evaluation at PML diagnosis and 1, 3 and 6 months after
223754186|NCT03222375|DEVICE|SQUED™ series 28.1 home-use|"Semiconducting QUantum Excitonic Device - artifificial active medium, where the processes of self-organization lead to creation and converter of Autowaves energy.~Some autowaves have the properties of quasi-particles!"
223607270|NCT00121186|PROCEDURE|peripheral blood stem cell transplantation|if donor peripheral blood stem cells are harvested
223607271|NCT03004352|OTHER|retrograde flow|Two pneumatic cuffs were placed on the experimental arm, one on the lower forearm, and the other on the upper arm. Two cuffs were simultaneously inflated for 20 minutes. The distal cuff was inflated to 75 mm Hg and the proximal cuff was inflated to 40 mm Hg. The contralateral (control) arm was cuff free during this intervention.
223607272|NCT03004352|OTHER|oxygen|Supplemental 100% oxygen administered through a nasal cannula.
223754187|NCT06232525|PROCEDURE|transobturator tape operation (TOT)|TOT surgery: With an 18 French Foley urinary catheter, the sling passes through the skin in the groin, the obturator foramen, the back of the adductor longus tendon, and the midurethral vaginal incision; extends 1 cm below the midpoint of the urethra, the tape is held in place without sutures by its interface with the patient's tissue. After the mesh is placed, the incision in the suburethral midline is closed.
223754188|NCT06232525|PROCEDURE|urethral ligament plication|Urethral ligament plication: With an 18 French Foley urinary catheter, a vertical incision of approximately 3 cm is made in the anterior-lateral wall sulcus of the vagina on the right and left lines, 2 cm laterally from the midline, with the urethral meatus remaining in the midline, and external urethral ligaments on both sides inferolateral to the urethra, sutured in the midline by using 2-0 or 3-0 polyester sutures on both sides separately. The incised anterior vaginal tissue is closed one by one with 2-0 rapid Vicryl.
223754189|NCT05026463|PROCEDURE|Inspiratory support level|Inspiratory support is the pressure delivered by the ventilator during pressure support ventilation.
223754190|NCT05083442|DEVICE|Low Level Laser Therapy|Non-surgical cosmetic treatment which can be used by individuals intending to reduce size of the mid-section
223754191|NCT05083442|OTHER|Sham (placebo)|Use of sham (placebo) option
223754192|NCT06376019|PROCEDURE|solitary Implant loading with ball attachment|ball attachment will be attached to the dental implant on the day of implant placement
223754193|NCT06376019|PROCEDURE|splinted Implant loading with intra oral welding|Titanium bar will be welded to the dental implant on the day of implant placement
223754194|NCT06376019|PROCEDURE|complete denture|Mucosa supported conventional complete denture will be fabricated without supporting implants
223754195|NCT03292081|DEVICE|OFDI|PCI under OFDI guidance
223754196|NCT03292081|DEVICE|IVUS|PCI under IVUS guidance
223607273|NCT02486393|PROCEDURE|Parotid surgery|Surgery of the parotid gland tumours
223607274|NCT01397942|OTHER|Diet intervention|The participants in the two experimental arms will each have to consume 500 g of vegetables and cabbages daily.
223607275|NCT06060054|DIAGNOSTIC_TEST|Device measurements|Overnight device measurements
223607276|NCT00186901|DRUG|Calcium carbonate (Tums), vitamin D|Calcium carbonate 100mg/day (Tums), vitamin D 800 units/day
223607277|NCT00186901|OTHER|Placebo|Placebo
223607278|NCT04079075|OTHER|Cognitive training|"This comprises training using using the cogweb software, both in person and remotely:~i) in person training: 30-minute sessions, supervised by a trained nurse, twice weekly .~ii) remote training: unsupervised 30-minute sessions, to be performed at home at the participants will."
223607279|NCT04079075|BEHAVIORAL|Physical activity|This is based on 60-minute sessions including aerobic, resistance, agility/balance and flexibility exercises, directed by a physical education teacher and supervised by a nurse, twice weekly.
223754197|NCT01515800|BEHAVIORAL|Text message reminder|Receive text message
223754198|NCT00762398|DEVICE|Masimo hemoglobin-meter|Placing a probe on the finger
223754199|NCT00762398|BIOLOGICAL|drawing blood sample|drawing a blood sample less that 0.5 mL each time, for around 10-12 times along the surgery (depends on surgical time)
223754200|NCT04695938|DIAGNOSTIC_TEST|MRI|MRI examination with Black Bone, and ultrashort/zero echo time MRI techniques
223754201|NCT00102232|PROCEDURE|supplementation with phosphatidylcholine|
223754202|NCT02531412|DRUG|Spironolactone|After a major surgery event a time 0, 24h and 48h
223754203|NCT02531412|DRUG|Placebo|After a major surgery event a time 0, 24h and 48h
223754204|NCT04760158|OTHER|Exercise|Participants of this study exercised strengthening and stretching 3 days a week for 6 weeks
223754205|NCT03155009|DRUG|Alectinib|600 mg orally BID with food
223607280|NCT04079075|BEHAVIORAL|Nutrition education|"This is based on monthly 180-minute sessions, directed by a nutritionist, comprising:~i) Presentation and discussion of healthy and easy to cook recipes by the nutritionist; ii) Preparation of healthy meals by the participants, followed by a period of social interaction between the participants while consuming the meals prepared."
223607281|NCT04079075|BEHAVIORAL|Adaption to memory loss|This is based on monthly 30-minute sessions, directed by a psychologist or a nurse, who will provide strategies that participants may use in their daily life to cope with memory loss.
223607282|NCT04079075|DIAGNOSTIC_TEST|Diagnosis of hearing impairment|Before implementing the sessions of cognitive training, physical activity, nutrition education and adaption to memory loss, an audiologist will perform an audiogram to all participants. Those with auditive performance inferior to the reference values will be referred for a medical appointment with an otolaryngologist.
223607283|NCT02888288|BEHAVIORAL|Mental Health Intervention|Includes a standard format of greetings, review of last session content, homework discussion, new topic, assigning homework and ends with a fun activity, relaxation or game. First session is a joint session with youth and caregivers. Topics include common stresses and worries experienced by HIV+ youth; relaxation and coping techniques; cognitive behavioral triangle; story of finding out HIV status and if willing, to discuss this in an individual session, peer group session, and with caregiver; identify circles of support; discuss stigma and how to disclose HIV status to others; consider values, hopes and dreams for the future, and how to use this information to live positively with HIV. ART adherence is woven into case examples and discussions.
223607284|NCT02888288|BEHAVIORAL|Standard of Care|Standard of Care includes enhanced ART adherence based on clinic protocols and monthly HIV teaching sessions prior to adolescent clinic.
223607285|NCT02955537|OTHER|MI-BP|MI-BP includes the following components: 1) Home blood pressure monitoring 2) Physical activity monitoring 3) Sodium intake self-monitoring 4) Physical activity and sodium intake goal setting 5) Educational messaging via push notification and in-app messaging 6) motivational messaging 7) tailored messaging relevant to individual participants and 8) medication reminders.
223754206|NCT00909948|OTHER|Fludarabine and total body irradiation|The patients in the second cohort will receive fludarabine 30 mg/m2/day on days -4 to -2 and 200 cGy TBI on day 0.
223607286|NCT00718705|DRUG|Josamycin|josamycin with posology of 2 grams per day by oral way during 10 days
223607287|NCT00718705|DRUG|Placebo|Placebo with posology of 2 grams per day by oral way during 10 days
223754207|NCT00909948|RADIATION|Total body irradiation|Patients will receive 200 cGy TBI on day 0,4-6 hours prior to HCT.
223754208|NCT05652166|OTHER|telephone interview|telephone call to parents to know the information given following the ingestion of foreign body by their child
223754209|NCT04197570|DRUG|Opioid Anesthetics|see arm/group description
223754210|NCT04197570|DRUG|Non Opioid Analgesics|see arm/group description
223754211|NCT00977067|DRUG|GDC-0152|Intravenous escalating dose
224311545|NCT06677554|DRUG|Addition of ultrasound with contrast injection (SonoVue®)|Addition of contrast evaluation with SonoVue® injection (5 min including 1 min of acquisition) within the diagnostic strategy
224311546|NCT06677554|OTHER|Standard Care (in control arm)|No addition of ultrasound with contrast
223607288|NCT05130749|OTHER|Questionnaire|The questionnaire's first section asked for demographic information such as gender, age, the name of the primary healthcare centre, and level of education. The second section comprised sources of knowledge on COVID-19; respondents replied on a scale of 1 least used (1), occasionally (2), more frequently (3), and most used (4). The third section had six items pertaining to nurses' infection prevention and control methods with reference to COVID-19, and respondents replied on a scale of yes (2), occasionally (1), and no (0). Permission to use the questionnaire has been requested from the author and is awaited.
223607289|NCT02771197|DRUG|Fludarabine|
223607290|NCT02771197|DRUG|Melphalan|
224311547|NCT06895577|DRUG|neoadjuvant SCRT followed by Sintilimab plus CAPOX|SCRT (a total of 25 Gy in 5 days) followed by sintilimab (3mg/kg intravenous drip on day 1; every 3-week cycle for two cycles) combined with CAPOX (oxaliplatin 130 mg/m2 intravenous infusion over 2 h on day 1, capecitabine 1000 mg/m2 orally twice daily from day 1-14, in every 3-week cycle for two cycles) 1 week later.
224311548|NCT06891677|BEHAVIORAL|Internet-Based Cognitive Behavioral Therapy (CBT) with ACT and COPD Education|Participants receive an internet-based cognitive behavioral therapy (CBT) intervention combined with education specifically developed for COPD. The CBT program includes Acceptance and Commitment Therapy (ACT) components. The intervention lasts 8-10 weeks and consists of several online modules. Modules cover topics such as coping strategies, mindfulness techniques, disease knowledge, and symptom management. Participants complete the modules at home via a secure online platform, with regular support and feedback from trained healthcare professionals. The program aims to improve mental health, reduce anxiety and depression, enhance COPD knowledge, and help participants manage symptoms and daily life more effectively.
223607291|NCT02771197|DRUG|Pembrolizumab|
223754212|NCT00499096|BEHAVIORAL|Chronic care model for Bipolar Disorder|The behavioral intervention is based on the Chronic Care Model (CCM) where patients receive information on managing bipolar symptoms and health habits in a group self-management session (up to 6 weekly sessions). The Care Manager then follows up with patients via phone contacts for 12 months following the intervention. The providers receive information on guidelines for care.
223754213|NCT01067768|OTHER|Daily review|"Daily nursing review of the urinary catheter´s indication. If the patient meets at least one of the entries to stay with bladder catheter, the nurse will record collection in the format but will not contact the health team. If there aren´t indication in the medical record, she contacts at the attending physician and said: Doctor, I didn´t find record in the history of the indication of the urinary catheter, can we withdraw?. If the physician reported the indication, will be recorded in the format without additional comments.~The attending physician decides withdraw or no withdraw the urinary catheter"
223754214|NCT03387813|DEVICE|CardioMEMS™ HF System|The CardioMEMS™ HF System is comprised of a lead-less, battery-less pressure sensor permanently implanted in the PA, which remotely transmits PA pressure measurements from the patient's home to a secure website. Healthcare professionals are able to access these measurements and associated waveforms to remotely guide individualization of medical management for their patients with chronic HF.
223754215|NCT06096714|DRUG|Nicotine|Nicotine will be infused using a pump.
223754216|NCT06096714|OTHER|Saline|Saline with be used to compare Nicotine, Saline will be infused using a pump
223607292|NCT05138627|OTHER|oral cryotherapy|Ice application protocol developed by the researcher by scanning the literature was prepared by taking the opinions of 5 faculty members who are experts in their fields. Also, the chamber of physics engineers and the chamber of chemical engineers' opinion was taken for the necessary corrections or improvements regarding the chemical/physical structure of the ice and the method applied. In the content of the protocol, materials, preparation before intraoral ice application (written and visual), steps of intraoral ice application (written and visual), termination of intraoral ice application, recording of intraoral ice application, and situations to be considered are explained in detail respectively.
223607293|NCT01794260|DRUG|Cream from Zingiber cassumunar Roxb. extract|
223607294|NCT01794260|DRUG|Placebo cream|
223607295|NCT02155920|DRUG|Everolimus|The recommended dose of Everolimus is 4.5 mg/m2/dose, once daily for up to 2 years, until disease progression or unacceptable toxicity occurs.
223607296|NCT02085109|DIETARY_SUPPLEMENT|Fat milkshake|
223607297|NCT02085109|DIETARY_SUPPLEMENT|Theobromine|
223607298|NCT01802710|BEHAVIORAL|Psychological support|
223607299|NCT01802710|OTHER|No intervention|
223607300|NCT02682992|DEVICE|Low Level Laser Therapy|Patients will receive LLLT three times per week concurrently with chemoradiotherapy. LLLT may be delivered either immediately prior to or after the patient's daily fraction of radiotherapy. Patients will be treated extra-orally with a THOR® LED cluster for one minute along the buccal mucosa on each side and intraorally for one minute to the tongue and soft palate. During each LLLT treatment session a thorough oral exam will be performed to identify any areas of mucositis. If the patient should develop intraoral lesions they will be targeted directly with the intraoral probe for one minute to each site of mucositis. The laser settings to be used are as follows: frequency 2.5 Hz; wavelength 660 nm; and power 75 mW, for an energy of 4.5 J.
223607301|NCT00291486|DRUG|Capecitabine|Capecitabine was administered orally at doses between 1000 and 1500 mg/m2/day depending on assigned dose level for 14 days per 21-day cycle. Daily doses were rounded to the nearest 150 mg.
223754217|NCT04037020|OTHER|Chocolate|Participants will be asked to taste commercially available chocolate varying in sugar, fat and percent cocoa (extreme dark (90%), dark (70%), milk (38%), and white (0%)).
223754218|NCT06218407|COMBINATION_PRODUCT|Computerized Chemosensory-Based Orbitofrontal Cortex Training (CBOT) short burst paradigm|The CBOT device is designed to stimulate intensive neural activity in the medial orbitofrontal regions over long periods of time.
223754219|NCT06218407|COMBINATION_PRODUCT|Computerized Chemosensory-Based Orbitofrontal Cortex Training (CBOT) long burst paradigm|The CBOT device is designed to stimulate intensive neural activity in the lateral orbitofrontal regions and networks over long periods of time.
223754220|NCT06218407|COMBINATION_PRODUCT|Computerized Chemosensory-Based Orbitofrontal Cortex Training plus beta caryophyllene (CBOT-Plus)|CBOT device enhanced with BCP.
223754221|NCT06218407|COMBINATION_PRODUCT|Computerized Chemosensory-Based Orbitofrontal Cortex Training (CBOT)|CBOT device administering continuous olfactory stimuli (i.e., not programmed for short or long burst), and without BCP enhancement.
223754222|NCT04327999|DRUG|Artificial Tears|Self-Administered - utilizing eye drop preservative free vials
224311549|NCT06911398|OTHER|Articulate Medical Intelligence Explorer (AMIE)|AMIE is an AI system for having clinical conversations with patients
223607302|NCT00291486|DRUG|131I-huA33 (131-Iodine on humanised monoclonal antibody A33)|All patients received a dose of 5 mg huA33 conjugated to 5-8 mCi 131I. The therapy dose of 131I-huA33 comprised a constant protein dose of 10 mg/m2 huA33 regardless of dose level. The 131I-huA33 therapy dose was determined by the assigned dose level (i.e. 20, 30 or 40 mCi/m2 131I).
223607303|NCT03618862|BIOLOGICAL|Blood sampling|Peripheral venous blood collection of 56 mL during a sampling required by routine monitoring of human immunodeficiency virus infection.
223607304|NCT03323177|DIETARY_SUPPLEMENT|Gender specific nutritional standardized formula|Patients will continue to consume the study formula until final height: gender specific powder added to water containing about 25% of recommended DRI for calories, high protein (25% of calories) and multi vitamin and mineral (255-100%) of DRI for recommended daily allowance (RDA) or adequate intake
223607305|NCT03323177|OTHER|Follow-up only|Patients who are reluctant to continue to consume the study formula will come to follow-up visits only without any intervention until final height is reached
223754223|NCT03943563|DIAGNOSTIC_TEST|Dixon sequences acquisition|Dixon sequences acquisition
223754224|NCT01293240|DEVICE|lotrafilcon B contact lens|Commercially marketed, silicone hydrogel contact lens worn bilaterally on a daily wear basis for up to 30 days with a two week and four week evaluation visit.
223754225|NCT03903354|OTHER|Incidence of infections within 7 days postoperatively|Measure blood glucose concentration intraoperatively and evaluate incidence of infections 7 days after surgery
223754226|NCT04828668|DIETARY_SUPPLEMENT|Targeted Wellness Formula C™ Sublingual Drops - 1200mg - 30 mL (Formula C)|Hemp seed oil
223754227|NCT03666078|PROCEDURE|cesarean delivery|women delivered by cesarean section
224311550|NCT04874675|DRUG|diclofenac / acetaminophen /codeine|routine pain medication used post extraction of third molars
224311551|NCT04874675|DRUG|ibuprofen/acetaminophen/codeine|routine pain medication used post extraction of third molars
223754228|NCT03394768|OTHER|No additional intervention|Patients will be treated as per department protocols and no additional intervention will be performed
223754229|NCT05578781|BEHAVIORAL|Music Therapy|Music Therapy is a music session with a live therapist and has been shown to reduce pain and anxiety. If effective the music medicine in this RCT will be used help design a full R01 study
223754230|NCT05578781|BEHAVIORAL|Music Medicine|Music Medicine is an audio recorded music therapy session that will be played for the participant. This will be the same music session that will be played live in the music therapy session.
223754231|NCT05578781|BEHAVIORAL|Control group|Control group will listen to an audio recording of text being spoken by the board certified music therapist
224311552|NCT04313049|DEVICE|JACO2|Performing tasks using joystick control
224311553|NCT04313049|DEVICE|VOCAL CONTROL|Performing tasks using vocal control
223754232|NCT02389504|OTHER|Dynamic Exertional Physical Therapy|By contrast, the dynamic exertion protocol includes the treadmill running aspect, but also incorporates other exercises that involve lateral movement (e.g., side lunges, lateral speed training exercises) as well as planar changes (e.g., burpees, squat thrusts) . Recovery on these exercises is measured based on time subjects are able to tolerate the exertion without symptom increase. Across all exertion protocols additional measures of subjective physical effort and objective measurement of heart rate are taken.
224311554|NCT06943196|OTHER|Structured physical activity break|"The structured physical activity breaks in classroom will include 5-30 minutes physical activities sequenced as: Week 1,4,7: 5-mintue stretch break, 5-minute marching in place, 30-sec jumping an invisible rope, 30-sec Flap arms like a bird, 5-minute mirror each other's actions and guess, 5-minute hop on one foot/ jump on both feet, draw on board, guess the color, make a circle and play a game of throw a ball in class. Week 2,5,8: 5-minute stretch break, 2-3 laps throughout the classroom, jumping in and out a circle on command, rock-paper-scissors-jump, paint or sketch on book, guess the animal, up-down-stop-go opposites, make a circle and play a game of throw a ball and clap in class.~Week 3,6: 5-minute stretch break, 30-sec balance on one foot, 30-sec hopping, 5-jumping jacks, 5-claps turn around and guess the shape, play a game on board or notebook, make a circle and play a game of throw a ball and jump in class."
224311555|NCT06537388|PROCEDURE|Ventilation type|Type of ventilation used during the EBUS procedure, either HFJV or IPPV
224311556|NCT06940310|BEHAVIORAL|Daily load-velocity-based training intensity adjustment.|At the beginning of the training session, the one-repetition maximum (1RM) will be estimated based on the individual's load-velocity relationship, using the general velocity associated with the 1RM for the exercises included in the session. Additionally, during the training sessions, intensity will be monitored, and load will be adjusted in real time by movement velocity.
224311557|NCT06940310|BEHAVIORAL|Training intensity prescription based on an initial 1RM estimation using load-velocity relationship|In the first training session, the one-repetition maximum (1RM) will be estimated based on the individual's load-velocity relationship, using the general velocity associated with the 1RM for the exercises included in the session. This 1RM will be used to prescribe exercise intensity throughout the intervention.
223607306|NCT00681733|DRUG|Pioglitazone|Pentoxifylline 1200mg/day in 3 divided doses. Pioglitazone 30 mg/day in single dose
223607307|NCT00681733|DRUG|Pioglitazone|30 mg OD
223607308|NCT00681733|DRUG|Pentoxifylline|1200 mg/d
223607309|NCT01732016|OTHER|Normobaric hypoxia chamber|
223607310|NCT00881816|DRUG|Liposomal paclitaxel plus capecitabine|All Patients will receive liposomal paclitaxel (with a dose of 60mg/m2,3h,ivgtt,at d1,8,15) and capecitabine (with a dose of 1600mg/m2,bid,po.,at d1-14),each cycle for 4 cycles.
223607311|NCT04836845|DEVICE|Focus extracorporeal shock wave therapy|Focus extracorporeal shock wave therapy, device: Electronica, Pagani, Italy
223607312|NCT04836845|DEVICE|Radial extracorporeal shock wave therapy|Radial extracorporeal shock wave therapy, device: Electronica, Pagani, Italy
223607313|NCT04836845|DEVICE|Sham extracorporeal shock wave therapy|Sham extracorporeal shock wave therapy, device: Electronica, Pagani, Italy
223607314|NCT02303028|DRUG|Topotecan and Pazopanib|Low-dose metronomic Topotecan and Pazopanib will be escalated as per the dose escalation schema.
223607315|NCT01246336|OTHER|collection of exhaled breath|no intervention
223607316|NCT06054139|OTHER|Refeeding Syndrome|Patients who developed Refeeding Syndrome despite proper nutrition while receiving treatment in the ICU
223607317|NCT04918511|DRUG|OPD5|OPD5 solution for i.v. infusion
223607318|NCT01590160|DRUG|Ganetespib|IV, Using dose from Phase I
223754233|NCT02389504|OTHER|Standard Exertional Physical Therapy|Standard treadmill running, monitoring heart rate
223754234|NCT03726008|BEHAVIORAL|Perinatal health promotion program and regular prenatal care|Regular prenatal care and perinatal health promotion program including health promotion during pregnant period, health promotion during the ritual of Tso-Yueh-Tzu, health promotion during postpartum period, newborn care
223754235|NCT06114758|DRUG|Cytotec 200Mcg Tablet|the admistiration of 400 Mcg rectal cytotec while starting the surgery, just before the patient is covered
223607319|NCT02121249|DEVICE|Renaissance, Mazor Robotics Ltd, Caesare, Israel|Renaissance (Mazor Robotics Ltd, Caesare, Israel) is the name of the robot
223607320|NCT02121249|PROCEDURE|free hand technique|"No specific device is necessary in the free hand technique"
223607321|NCT01099397|OTHER|Oral glucose tolerance test|For assessment of dysglycemia, 75 grams of glucose solution by mouth at 3 PEAR study visits for all enrolled participants: baseline, single drug therapy assessment, and dual drug therapy assessment.
223607322|NCT05463523|DEVICE|A Real-time Augmented Reality Device with Artificial Intelligence Integration|Patients are diagnosed and treated with the assistance of artificial intelligence, augmented reality and new optical imaging technology, which is different from traditional model.
223607323|NCT02717039|PROCEDURE|Blood Draw|A one time blood draw of 150 milliliters will be performed using a vein in the participants arm. Existing venous access will be used for the blood draw in preference of new venipuncture.
223607324|NCT00959205|DEVICE|CARTO 3D|CARTO (3D Electroanatomic imaging)
223607325|NCT00959205|DEVICE|Angiography|Conventional fluoroscopically guided activation mapping
223607326|NCT04379401|DEVICE|Cardiac Resynchronization Therapy (ON vs. OFF)|This study involves study participants, who already received cardiac resynchronisation therapy implantation for clinical reasons. CRT is authorized for medical use by Swissmedic in Switzerland and all implanted devices are CE-approved.
223607327|NCT02676934|DEVICE|End tidal control module in Aisys anesthesia workstation|THE USE OF AUTOMATED CONTROL OF END TIDAL SEVOFLURANE CONCENTRATION TO MAINTAIN ANESTHESIA DURING DONOR HEPATECTOMY
223607328|NCT04168099|DRUG|Cefotaxime|Cefotaxime IV
223607329|NCT04168099|DRUG|Gemifloxacin|Gemifloxacin oral
223754236|NCT06114758|DRUG|Transamine|1 gram intravenous slow infusion intraoperatively as we start the laparatomy
223754237|NCT05261984|PROCEDURE|Resistance exercise|Knee extensions in flywheel inertia machine in four sets of 10 repetitions.
223754238|NCT05261984|DIETARY_SUPPLEMENT|Oral protein supplementation|24 grams of hydrolyzed whey protein.
223754239|NCT00790439|DRUG|Low Molecular Weight Sulfated Dextran|Inhibitor of instant blood-mediated inflammatory reaction
223607330|NCT03421106|BEHAVIORAL|Intervention Food Pantries|Food pantries will receive consulting services to transform their food offerings and environment in order to influence client health behaviors.
223607331|NCT03421106|OTHER|Control Food Pantries|Normal food pantry use
223607332|NCT04478604|OTHER|applied forms to pregnant women|
223607333|NCT05458804|DEVICE|VR training|A musical game called Beat Saber was used to conduct training sessions. The participant's task was to cut through the blocks of various colors in his direction to the rhythm of music, using two virtual swords. The swords were controlled by the player with controllers of different colors. Blocks had to be cut with a sword whose color matches the block and in the right direction which is indicated by an arrow on the block. The training session consisted of 4 music tracks with different paces and intensities of objects. In addition, during the song, the participant had to avoid objects-objects that randomly appeared in the game scenario - forcing the whole body to move.
223754240|NCT00790439|DRUG|Heparin|Anticoagulant
223754241|NCT00790439|DRUG|Mycophenolate Mofetil|Cell proliferation inhibitor, Transplantation (immunosuppressive)
223754242|NCT00790439|DRUG|Sirolimus|Cell proliferation inhibitor, immunologic (immunosuppressive)
223754243|NCT00790439|DRUG|Tacrolimus|Calcineurin inhibitor
223754244|NCT00790439|DRUG|Cyclosporine|Calcineurin inhibitor, immunosuppressant
223754245|NCT00790439|DRUG|Daclizumab|Monoclonal IL-2 receptor blocker
223754246|NCT00790439|DRUG|Basiliximab|Monoclonal IL-2 receptor blocker
223754247|NCT00790439|BIOLOGICAL|Allogeneic Pancreatic Islet Cells|
223754248|NCT01746212|PROCEDURE|One-level or two-level anterior lumbar interbody fusion|Patients electing to receive a one-level or two-level, anterior approach only (incision through the front), lumbar interbody fusion in order to treat degenerative disc disease (at one or two levels in the spine), and meeting all other inclusion criteria, are eligible for enrollment into the study.
223754249|NCT01746212|BIOLOGICAL|InQu Bone Graft Extender and Substitute mixed with BMAC|Surgeries utilizing InQu Bone Graft Extender and Substitute during the anterior lumbar interbody fusion surgical procedure will be elected for inclusion. InQu will be mixed with BMAC (bone marrow aspirate concentrate), which will be prepared using the SmartPRep2 centrifuge. Patients opting to use a grafting alternative will not meet inclusion criteria, and will not be eligible to enroll in this study.
223754250|NCT01746212|DEVICE|Synthes Spinal Instrumentation|Synthes Spinal Instrumentation will be used during surgery as spinal stabilization.
224200707|NCT01441401|DRUG|gabapentin|According to Japanese Package Insert: For infants and children aged 3 to 12 years, a daily dosage of 10 mg/kg of gabapentin should be administered orally in 3 divided doses on the first day of treatment, and an effective dosage of 20 mg/kg should be administered to them in 3 divided doses on day 2. From day 3 on, infants aged 3 to 4 years should be maintained on the dosage of 40 mg/kg, and children aged 5 to 12 years on the dosage of 25 to 35 mg/kg administered orally in 3 divided doses, respectively (the maximum daily dosage: 1800 mg). Though the maintenance dosage may be adjusted depending on the patient's condition, the maximum daily dosage should be 50 mg/kg. At any time point, dosage should not exceed that the dosage for adults and children aged 13 years.As for children aged 13 years or over is as same as administration for adult.
224200708|NCT04419701|PROCEDURE|periarticular infiltration|"The cocktail will be injected at the following 7 anatomical zones as follows:~Zone 1: medial retinaculum Zone 2: medial collateral ligament and medial meniscus capsular attachment Zone 3: posterior capsule Zone 4: lateral collateral ligament and lateral meniscus capsular attachment Zone 5: lateral retinaculum Zone 6: patellar tendon and fat pad Zone 7: cut ends of quadriceps muscle and tendon Injection at zones 2, 3, and 4 will be administered after making the tibial and femoral cuts and ligament balancing. At zones 1, 5, 6, and 7, the injection will be administered after implant placement."
224311558|NCT06940310|BEHAVIORAL|Traditional training with intensity prescription based on 1RM testing.|The traditional training group will follow a training program using the traditionally employed methodology for assessing and prescribing training intensity in breast cancer survivors. This methodology is based on an initial 1RM estimation conducted through a 1RM test, which will be used to prescribe the training load throughout the intervention.
223607334|NCT01511016|DRUG|"Human recombinant leptin (metreleptin)"|Metreleptin was administered at a dose of 0.02 mg / kg body weight for two months, followed by a dose of 0.04 mg / kg for two more months.
223754251|NCT05996107|DRUG|Ribociclib|400 mg daily with a possibly dose reduction to 200 mg daily if required
223754252|NCT05996107|RADIATION|Postoperative Radiation Therapy|50 Gy in 25 fractions or 42.56 Gy in 16 fraction +/- 10 Gy boost including comprehensive nodal
223754253|NCT03792672|DRUG|TAK-653|TAK-653 tablets.
223607335|NCT01511016|DRUG|Placebo|Placebo was administered at a dose of 0.02 mg / kg body weight daily by subcutaneous injection for two months, followed by 0.04 mg / kg for two more months.
223607336|NCT01900743|DRUG|Regorafenib|Regorafenib (160 mg/d) once daily for three weeks on / one week off plus Best Supportive Care (BSC)until progression (according to RECIST 1.1), intolerance or consent withdrawal.
223607337|NCT01900743|DRUG|Placebo|Placebo plus BSC until progression (according to RECIST 1.1) or unacceptable toxicity. Patients who have received placebo may be offered open-label regorafenib (cross-over option) after objective tumor progression
223754254|NCT03792672|DRUG|Placebo|TAK-653 placebo-matching tablets.
223754255|NCT03792672|DRUG|Ketamine|Ketamine intravenous infusion.
223754256|NCT02846207|DRUG|Yiqi huoxue|Buyang Huanwu demolition, which includes: Astragalus 60g, Radix Paeoniae Rubra 15g, ligusticum wallichii 12g, angelica sinensis 20g, earthworm 12g, flos carthami 12g and peach seed 12g. Oral administration, twice one day, for 12weeks.
223754257|NCT02846207|DRUG|Yiqi group|Astragalus 60g.Oral administration, twice one day, for 12weeks.
223754258|NCT02846207|DRUG|Huoxue group|Radix Paeoniae Rubra 15g, ligusticum wallichii 12g, angelica sinensis 20g, earthworm 12g, flos carthami 12g and peach seed 12g. Oral administration, twice one day, for 12weeks.
223754259|NCT02846207|DRUG|placebo|Dextrin,oral administration, twice one day, for 12weeks.
223754260|NCT01408121|OTHER|Genotyping and platelet reactivity testing with the VerifyNow P2Y12 assay|All patients will undergo genotyping and platelet reactivity testing with the VerifyNow P2Y12 assay, at least 6 hours after receiving a thienopyridine loading dose but before hospital discharge.
223754261|NCT01271868|BIOLOGICAL|IB1001|
223754262|NCT00125866|BEHAVIORAL|Flavonoid rich or flavonoid depleted chocolate drink|
223607338|NCT02397044|PROCEDURE|Implant surgery|Compare surgical protocols
223607339|NCT03920930|PROCEDURE|Late local infiltration analgesia|Patient receive an infiltration of local anaesthetics around the knee directly after total knee replacement for postoperative pain control.
223607340|NCT03920930|PROCEDURE|Early local infiltration analgesia|The local infiltration analgesia is applied in a total of 4 steps during the preparation of the knee joint: 1. after the skin incision, 2. after the capsule incision, 3. after complete exposure of the knee joint, 4. when the posterior knee capsule is reached.
223754263|NCT05424536|OTHER|Bone measurement by DXA and ultrasound|Measurement will be performed at radius and at tibia (ultra-distal and distal). For all the sites plus femoral neck, one measurement will be performed by DXA to get reference values of thickness and BMDs. For the distal positions and additional measurement will be performed by an innovative ultrasound device that estimates cortical thickness and porosity.
223754264|NCT06291714|DEVICE|GDT-based hemodynamic management based on Clearsight device|Intraoperative use of a HPI-guided hemodynamic goal-directed protocol based on the non-invasive measurement of HPI (Clearsight system)
223754265|NCT02562651|DRUG|Doxycycline|Doxycycline bid for the first 7 days after primary anterior STEMI
224200709|NCT04419701|PROCEDURE|genicular nerve block|The genicular arteries will be identified near the periosteal areas, which are the junctions of the epicondyle and the shafts of the femur and tibia, and confirmed by color Doppler ultrasound. genicular nerve block target points should be next to each genicular artery because the superior lateral, superior medial, and inferior medial genicular artery traveled along each genicular nerve.After using color Doppler to confirm the genicular artery, the needle will be inserted in the plane of the ultrasound probe in the long-axis view.
223607341|NCT01303198|DEVICE|APAP - Therapy|automatic positive pressure therapy
223607342|NCT01025830|DRUG|Triomune|Stavudine (40mg) Lamivudine (150mg) Nevirapine (200mg)All twice a day
223607343|NCT01025830|DRUG|Zerit/Epivir/Viramune|Stavudine (40mg) Lamivudine (150mg) and Nevirapine (200mg) All taken twice daily.
223607344|NCT03642730|DEVICE|TransThoracic Echocardiography imaging|ultrasound scanning
223607345|NCT01229306|PROCEDURE|Ablation|Ablation of atrial fibrillation
223607346|NCT05843929|DIAGNOSTIC_TEST|LSCI|"1. A technician delivers a service at the home of the patient, who may be subject to different risk of ulcer, with the aim to analyse his/her foot through an integrated set of measurement technologies, based on:a-the piezoelectric insole that replaces missing pain sensation;b- Laser speckle contrast imaging technique (LSCI) that measures the blood flow;c- the multi points temperature device.~2. Data collected by the technician are sent via internet~3. On the basis of the clinical evaluation and doctor's report on points of foot sensitivity, a 3D model of the foot is created and used by the chiropodist;~4. Using the 3D model of the foot, the chiropodist uses a 3D Editor to design the 3D Model of the insole to enable the production of a tailored insole for the patient shoes~5. The final manufactured insole is then delivered to the patient;~6. A check survey is periodically carried out by the technician to scan the diabetic foot status progress"
223607347|NCT03866564|DIAGNOSTIC_TEST|Echocardiography|Cardiac ultrasound to measure left ventricular systolic function.
223607348|NCT03866564|DIAGNOSTIC_TEST|Neuropsychological Testing|Standard clinical testing designed to establish or exclude the presence of cognitive dysfunction.
223607349|NCT03866564|DIAGNOSTIC_TEST|Quantitative Sensory Testing|Clinically accepted quantitative assessment of chronic pain burden.
223607350|NCT03866564|DIAGNOSTIC_TEST|Nocturnal Polysomnography|Routine overnight sleep study to measure apnea-hypopnea index.
223607351|NCT06273397|DRUG|Acetazolamide 250 MG|Acetazolamide 250mg orally per day plus furosemide as per protocol. The intervention is administered on the day of hospital admission and for two consecutive mornings. The total intervention consists of 3 doses. The intervention is discontinued on the third morning. The calculation of the congestion score is performed every morning until the third morning. If complete decongestion is achieved, the primary outcome will be considered fulfilled.
223607352|NCT06273397|DRUG|Metolazone 2.5 MG|Metolazone 2.5mg orally per day plus furosemide as per protocol. The intervention is administered on the day of hospital admission and for two consecutive mornings. The total intervention consists of 3 doses. The intervention is discontinued on the third morning. The calculation of the congestion score is performed every morning until the third morning. If complete decongestion is achieved, the primary outcome will be considered fulfilled.
223607353|NCT06273397|DRUG|Furosemide Injection|Intravenous furosemide in a double daily dose. The dosage is determined by a predefined table based on the admission renal function and the outpatient dose prior to admission. In general terms, for patients with an estimated glomerular filtration rate above 60 ml/min/1.73m² or those experiencing heart failure debut, the dose will be 1x the outpatient dose. For those with a glomerular filtration rate below 60 ml/min/1.73m², the dose will be 2x the outpatient dose. The dosing protocol for this arm also serves as guidance for furosemide in the intervention arms.
223607354|NCT05749328|DIETARY_SUPPLEMENT|Carbohydrate|To ensure the safety of the trial, preoperative gastric ultrasound measurements will be performed on all patients to assess their gastric volume. See above for other details
223607355|NCT04926246|DRUG|R1: Reference Product X|under fasted conditions
223607356|NCT04926246|DRUG|T1: Test Product M|under fasted conditions
223607357|NCT04926246|DRUG|T2: Test Product N|under fasted conditions
223754266|NCT02562651|OTHER|Standard care for STEMI|Invasive and medical treatment for STEMI according to guidelines
223754267|NCT05400616|PROCEDURE|Microbiome Transplant|A raw microbiome, is collected from a donor without any sinonasal health problems, as a nasal lavage.
223754268|NCT05400616|PROCEDURE|Placebo|Normal saline.
223754269|NCT05526326|DEVICE|Transplant with normothermic machine perfused (NMP) donor liver|The enrolled recipient will receive a DBD or DCD donor liver that underwent normothermic machine perfusion with the OrganOx metra®
223754270|NCT01185873|DRUG|danoprevir|Repeated oral doses
223754271|NCT01185873|DRUG|ritonavir|Repeated oral doses
223607358|NCT04926246|DRUG|T3: Test Product O|under fasted conditions
223607359|NCT04926246|DRUG|T4: Test Product O|under fed conditions
223607360|NCT04926246|DRUG|R2: Reference Product Y|under fasted conditions
223607361|NCT04926246|DRUG|T5: Test Product P|under fasted conditions
223754272|NCT05372120|DRUG|ICP-192|ICP-192 is a round, uncoated tablet, 4mg, 5mg. It is administered orally at the dose of 20 mg/day from day 1 to day 21 of each cycle until progression
224200710|NCT04410627|OTHER|HoPE Website|Educational website focused on hospice care
223754273|NCT00806884|OTHER|Physiotherapy Musculoskeletal Treatment|Other: Physiotherapy Musculoskeletal Treatment Specific, gentle oscillatory mobilisations to the rib cage and thoracic spine of the subjects to improve joint alignment and mobility, and to reduce pain. Treatment of specific muscle dysfunction or tight muscle groups to further optimise muscle length and biomechanical relationships in the area , leading to improved efficiency of recruitment and improved power output. Postural education and awareness discussions to improve the subject's own joint alignment and ability in a functional manner. A short programme to reinforce the progress during the treatment sessions may be given.
223754274|NCT00806884|OTHER|Control group measurements|None other than control group measurements
223754275|NCT01379742|DEVICE|RapidStrand seeds for use with 18g needle|Rapidstrand seeds are standard size and are used with 20 g needles
223754276|NCT01379742|DEVICE|ThinStrand|ThinStrand seeds are smaller in diameter and used with 20g needles
223754277|NCT00461695|BIOLOGICAL|Vaccination against TBEV (FSME Immun CC)|Intramuscular injection into the left (or right) deltoid muscle of 0.5 ml FSME Immun CC for adults (2.4 ug of formalin inactivated TBEV antigen) at time point 0, after 4 weeks and after 24 weeks.
223754278|NCT00918515|DRUG|AZD3043|intravenous solution given once as intravenous infusion over 30 minutes
223754279|NCT03387449|DEVICE|Bimanual Arm Training|Device-based bimanual-to-unimanual training will be provided with the Bimanual Arm Trainer (BAT, Mirrored Motion Works, NC). The device provides bimanual-to-unimanual training of simultaneous shoulder external rotation and elbow extension, and independent training of pronation-supination and grasp and release of each hand. Range of motion and speed are recorded during training and feedback and motivation are provided through age-appropriate gaming modules.
223754280|NCT00165412|PROCEDURE|breast MRI|Repeated once a year for three years
223607362|NCT04926246|DRUG|T6: Test Product P|under fed conditions
223607363|NCT04926246|DRUG|T7: Test Product Q|under fasted conditions
223607364|NCT04926246|DRUG|R3: Reference Product Z|under fasted conditions
223607365|NCT04926246|DRUG|T8: Test Product S|under fasted conditions
223607366|NCT04926246|DRUG|T9: Test Product S|under fed conditions
223607367|NCT04926246|DRUG|T10: Test Product U|under fasted conditions
223607368|NCT02134470|DRUG|Testosterone supplementation|Low-dose testosterone supplementation will be facilitated by using hormone patches. For pharmacokinetic aspects circadian profiles of saliva/blood/urine will be measured under native conditions and under exogene hormone application. In addition, cross-reactivity of a standardized exercise bout and hormone application will be of further interest.
223607369|NCT02487030|DRUG|LDV/SOF|90/400 mg FDC tablet administered orally once daily
223607370|NCT02487030|DRUG|RBV|Tablets administered orally in a divided daily dose based on weight (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
223607371|NCT06260553|DRUG|tislelizumab and metronomic oral vinorelbine|tislelizumab 200mg intravenous drip once every three weeks; Oral Vinorelbine 40mg three times a week for three weeks and Q28d for one course.
223607372|NCT04673539|DIAGNOSTIC_TEST|Spanish version of the Brief-BESTest in stroke patients|Adaptation and validation of the Spanish version of the Brief-BESTest in stroke Patients
223607373|NCT05805891|DRUG|bortezomib|bortezomib 2mg/week subcutaneous injection
223607374|NCT00264537|DRUG|Placebo injections|SC injections
223607375|NCT00264537|DRUG|Placebo capsules|Placebo capsules will be filled with microcrystalline cellulose (Avicel PH 102).
223754281|NCT00165412|PROCEDURE|Mammogram|Repeated once a year for three years
223754282|NCT02772562|BIOLOGICAL|PROSTVAC-V/F|"0.5 ml containing at least 2 x 108 Infectious Units (Inf.U) PROSTVAC-V given on day 1.~0.5 ml containing at least 1 x 109 Inf.U PROSTVAC-F given on days 15, 28, 57, 85, 113, 141."
223754283|NCT00006478|BIOLOGICAL|autologous tumor cell vaccine|
223754284|NCT00006478|BIOLOGICAL|keyhole limpet hemocyanin|
224200711|NCT00339066|DRUG|Sertraline|
224200712|NCT03300726|DIAGNOSTIC_TEST|CSF analysis|CSF analysis for tau, p-tau181, Abeta42, and CSF levels of markers of synaptic injury
224200713|NCT03300726|RADIATION|Functional MRI|Functional MRI during resting state and semantic memory task activation
223754285|NCT00006478|BIOLOGICAL|sargramostim|
223754286|NCT00006478|PROCEDURE|adjuvant therapy|
223754287|NCT06306456|DRUG|GH21|Oral, 15mg BIW/6mg QD
223754288|NCT06306456|DRUG|Tagrisso|Oral, 80mg QD
224200714|NCT06319573|OTHER|Counseling Supported by Univfy® Report|The intervention consists of patients being counseled with the Univfy® PreIVF report during their second consultation. They will also be asked to fill in the same anonymous online questionnaire.
223607376|NCT00264537|DRUG|Methotrexate capsules|Methotrexate capsules will be filled with microcrystalline cellulose (Avicel PH 102) and a 2.5 mg methotrexate tablet.
223607377|NCT00264537|BIOLOGICAL|Golimumab 50 mg injections|SC injections
223607378|NCT00264537|BIOLOGICAL|Golimumab 100 mg injections|SC injections
223607379|NCT00932867|DRUG|Kinzal/Pritor (Telmisartan, BAY68-9291)|Patients under daily life treatment receiving Pritor according to local drug information.
223607380|NCT00627341|BEHAVIORAL|Food Exposure Therapy and Ritual Prevention with Motivational Enhancement for Relapse Prevention in Anorexia Nervosa (AN-EX/RP)|AN-EX/RP will consist of in-session exposures to feared eating situations without using avoidance behaviors as well as formal motivational interviewing techniques.
224200715|NCT06319573|OTHER|Standard Counseling|Patients in this group will be counseled as per standard care during their second consultation. They will be asked to complete an anonymous online validated questionnaire (see below) to assess their responses to the anonymous online questionnaire after consultation.
223607381|NCT00627341|BEHAVIORAL|Cognitive behavioral therapy (CBT)|CBT for anorexia nervosa sessions will focus on behaviorally normalizing eating patterns throughout the day and on cognitively addressing dysfunctional thinking that promotes disordered eating.
223607382|NCT00851929|DRUG|Ambrisentan|ambrisentan 5 mg/day for month month, then 10 mg/day for 3 additional months
224200716|NCT04513873|DEVICE|Equipment to divert the focus of children|The equipment was placed in an area where the children would be able to see easily during the blood collection process. It was turned on as soon as the children sat on to the chair where the process would take place to divert the focus of the children at the equipment.
223607383|NCT05297513|DRUG|ActiveMatrix|All patients will receive weight based prophylactic antibiotics i.e. Ancef, vancomycin, or clindamycin. Drains will be used in fusion cases only. Intrawound vancomycin will be used for all instrumented cases.No negative pressure devices will be used. Anatomic layers will be closed in similar, standard fashion for all cases. For those randomized to the treatment group, the ActiveMatrix product will be administered on top of the dura mater and again on the closed fascia. Those in the control group, will forgo this step.
223607384|NCT02468349|OTHER|Telemedicine|Participants enrolled will be randomised 1:1 to either telemedicine arm or standard care arm.
223607385|NCT04205617|OTHER|produce prescription and nutrition education|Participants will receive diabetic appropriate groceries, diabetes education classes led by volunteer doctors and nurses, cooking demonstrations, shared meals, 1:1 and group coaching by dietitians.
223607386|NCT04678947|BEHAVIORAL|Baxter Retching Faces (BARF) scale|"* Pictorial scale that was developed for use by pediatric patients in self-reported assessments of nausea severity~* A patient will respond by choosing a picture or a number on the scale that best represents how they feel. The patient may speak or simply point to their response. While the numbers 0-2-4-6-8-10 are listed alongside the pictures, patients are also allowed to choose in between or odd numbers. If a patient is unwilling to participate, the patient's parent or guardian may serve as their proxy and choose a number for them, based off of their symptoms.~* The BARF scale has 6 faces with assigned scores ranging from 0 to 10 with a score difference of 2 between each face (a higher score indicates more nausea)."
223607387|NCT05186506|DRUG|Ensatinib|225 mg administered once daily orally for two years.
223607388|NCT05186506|DRUG|chemotherapy|"Pemetrexed : Participants will receive 500 mg/m\^2, day 1 , Q21D , until completion of treatment period (4 cycles), recurrence of disease, unacceptable toxicity, withdrawal of consent, or death, whichever occurs first.~Cisplatin :Participants will receive 75 mg/m\^2, day 1 , 21 days/cycle, Q21D , until completion of treatment period (4 cycles), recurrence of disease, unacceptable toxicity, withdrawal of consent, or death, whichever occurs first.~Paclitaxel: Participants will receive 175 mg/ m\^2, day 1 , 21 days/cycle, Q21D , until completion of treatment period (4 cycles), recurrence of disease, unacceptable toxicity, withdrawal of consent, or death, whichever occurs first.~carboplatin AUC= 5 mg/ mL/min, intravenously guttae, day 1 ,Q21D ，until completion of treatment period (4 cycles), recurrence of disease, unacceptable toxicity, withdrawal of consent, or death, whichever occurs first."
223607389|NCT04519281|DRUG|IV of vitamin C|administration of high-dose of IV vitamin C perioperatively
223607390|NCT04730531|PROCEDURE|Local infiltration with 0.25% bupivacaine and epinephrine|The local infiltration will occur in 2 stages, separated by 30 minutes. The first dose will be injected just prior to the final tightening of set screws, decortication, and bone grafting, and will occur via multiple small volume injections 1 centimeter apart into the paraspinal musculature. The second injection will occur at an interval of 30 minutes following deep fascial closure and similarly consist of multiple small volume injections at 1 centimeter intervals into the subcutaneous tissue and skin.
223607391|NCT04730531|PROCEDURE|Placebo of equal volume injectable saline|An equal volume of injectable saline will be used in the exact 2 stages as the treatment group. The first dose will be injected just prior to the final tightening of set screws, decortication, and bone grafting, and will occur via multiple small volume injections 1 centimeter apart into the paraspinal musculature. The second injection will occur at an interval of 30 minutes following deep fascial closure and similarly consist of multiple small volume injections at 1 centimeter intervals into the subcutaneous tissue and skin.
223607392|NCT05413720|OTHER|two additional blood samples specific to research|proportion of activated monocyte cells (CD14+CD16+ phenotype) within monocytes in the acute phase
223607393|NCT04578067|BEHAVIORAL|Lifestyle intervention|on physical activity and healthier eating
223607394|NCT03217994|DRUG|gel HP|gel of hygrogen peroxide for teeth bleaching
223607395|NCT05128201|RADIATION|consolidative radiotherapy|local consolidative radiotherapy for all metastatic lesion (30-45Gy/3-8F)
223607396|NCT03621657|DRUG|Low Dose FMT Capsule DE|5 FMT Capsule DE along with antibiotic; followed by five capsules FMT Capsule DE x 7 days post-antibiotic course.
223607397|NCT03621657|DRUG|Single Dose FMT Capsule DE|30 pill FMT Capsule DE treatment x 1, 48-72 hours following completion of antibiotic treatment.
223607398|NCT03621657|DRUG|Placebo oral capsule|Five capsules per day along with antibiotic; followed by five capsules per day for seven days post-antibiotic treatment.
223607399|NCT00999544|DRUG|Aprepitant 0mg|Aprepitant 0mg, p.o. pretreatment
223607400|NCT00999544|DRUG|Aprepitant 40mg|Aprepitant 40mg, p.o. pretreatment
223607401|NCT00999544|DRUG|Aprepitant 200mg|Aprepitant 200mg, p.o. pretreatment
223607402|NCT00999544|DRUG|Oxycodone 0mg, p.o.|Oxycodone 0mg, p.o.
223607403|NCT00999544|DRUG|Oxycodone 20mg, p.o.|Oxycodone 20mg, p.o.
223607404|NCT00999544|DRUG|Oxycodone 40mg, p.o.|Oxycodone 40mg, p.o.
223607405|NCT00999544|DRUG|Oxycodone 0mg, IN|Oxycodone 0mg, IN
223607406|NCT00999544|DRUG|Oxycodone 15mg, IN|Oxycodone 15mg, IN
223607407|NCT00999544|DRUG|Oxycodone 30mg, IN|Oxycodone 30mg, IN
223607408|NCT02601404|DEVICE|Bioresorbable scaffold (BRS)|The implantation procedure of an Absorb™ is similar to a metallic stent.
223607409|NCT00112632|DRUG|imatinib mesylate|
223607410|NCT00112632|PROCEDURE|conventional surgery|
223607411|NCT00112632|PROCEDURE|neoadjuvant therapy|
223607412|NCT01827150|DRUG|Redbull, energy drink|A can of 250 mL of the energy drink Redbull will be administered randomly to the subjects
223607413|NCT00574717|PROCEDURE|Spectacles|Infants will receive spectacles with 3.00D of under-correction relative to the spherical equivalent in each eye as measured by the cycloplegic retinoscopy performed at baseline. They will also receive the full amount of measured astigmatism in their glasses. Changes in spectacle lens power will be made as needed at follow-up visits to keep the level of under-correction within 0.50D of the target 3.00D. A program of visual engagement is also provided to encourage the normal development and use of accommodation. Treatment will continue for 15 months (until 18 months of age) or until the infant reaches a spherical equivalent refractive error of +3.00D or less hyperopia.
223607414|NCT03196804|DRUG|LC28-0126|LC28-0126
223607415|NCT03196804|DRUG|Placebo|Placebo
223607416|NCT04958369|DEVICE|Ultrasound-guided axillary venous access|Venous access is obtained through ultrasound-guided axillary vein puncture and Seldinger technique.
223607417|NCT04958369|DEVICE|Cephalic venous access|Venous access is obtained through cephalic vein cut-down.
223607418|NCT03415204|OTHER|acupuncture|acupuncture for post operative pain
223607419|NCT00199121|DRUG|Zidovudine (drug)|
223607420|NCT02688244|PROCEDURE|Irrigation|Irrigation of the abdominal cavity with at least 300ml of normal saline using the power suction/irrigator
223754289|NCT02768675|DEVICE|LOADPRO|The Intellirod LOADPRO sensor is a single-use, disposable instrument for the intra-operative measurement of posterior instrumented, spine rod strain.
223754290|NCT06493552|DRUG|SEphB4-HSA|A recombinant protein comprised of the soluble form of human receptor EphB4 fused to human serum albumin.
223754291|NCT06493552|DRUG|Pembrolizumab|Antibody to human PD-1.
223754292|NCT06493552|DRUG|Gemcitabine|A chemotherapy drug used to treat various types of cancer.
223754293|NCT06493552|DRUG|Cisplatin|A type of chemotherapy drug called an alkylating agent used to treat various types of cancer.
223754294|NCT06493552|DRUG|Enfortumab vedotin|Nectin-4-directed antibody and microtubule inhibitor conjugate.
223754295|NCT00265824|DRUG|bevacizumab|bevacizumab 7.5mg/kg every 3 weeks until disease progression or limiting toxicity
223754296|NCT00265824|DRUG|bevacizumab, erlotinib|bevacizumab 7.5mg/kg and oral erlotinib 150 mg/day continuously Cycles every 3 weeks until disease progression or limiting toxicity
223754297|NCT00855088|DRUG|darunavir|Healthy male volunteers will take darunavir 600 mg orally twice daily for 15 doses (8 days)
223754298|NCT00855088|DRUG|Ritonavir|Healthy male volunteers will take ritonavir 100 mg orally twice daily for 15 doses (8 days)
223754299|NCT00855088|DRUG|Etravirine|Healthy male volunteers will take etravirine 200 mg orally twice daily for 15 doses (8 days)
223754300|NCT03243812|BIOLOGICAL|Blood sampling|Blood sampling will be performed to assess hematological and hemorheological parameters
223754301|NCT03243812|OTHER|Maximum Voluntary Contraction (MVC) test force|Maximum Voluntary Contraction (MVC) test force will be performed before and after a localized muscle endurance test
223754302|NCT03243812|OTHER|Localized muscle endurance test|Subject will perform 4 series of 20 submaximal dynamic contractions at 50% of the MVC interspaced with 1 min recovery.
223754303|NCT03243812|OTHER|Self-paced six-minute walk test|Self-paced six-minute walk test will be conducted according to the guidelines of the American Thoracic Society
223754304|NCT00189748|DRUG|Tacrolimus|
223754305|NCT03583996|COMBINATION_PRODUCT|HepQuant SHUNT Liver Diagnostic Test|One time testing using the HepQuant SHUNT Liver Diagnostic Test kit (the combination product) in subjects with CLD and undergoing a standard of care EGD. The SHUNT test will be completed prior to the EGD. Each subject will receive an IV push dose of 13C Cholate mixed with Albumin simultaneously with an oral dose of d4 Cholate
223754306|NCT00164242|DRUG|Galantamine|
223754307|NCT04534764|DEVICE|etafilcon A with cosmetic pattern|TEST
223754308|NCT04534764|DEVICE|1-Day Acuvue DEFINE Vivid Style|CONTROL
223754309|NCT04796246|OTHER|Leap Motion Controller|Training with the Leap Motion Controller instrument will be carried out first for 5 minutes, for a presentation and interaction of the virtual immersion with it, in the initial meeting. After the second meeting, the attendance protocol will be 16 sessions, this time being distributed as: first game lasting 7 minutes, second and third games lasting 6 minutes each and the last game lasting 8 minutes, totaling 27 minutes of intervention. Between games it was adopted about 2 minutes of rest.
223754310|NCT04796246|OTHER|Conventional Physiotherapy|The conventional physiotherapy intervention will be based on the same activities developed (MMSS movements) of the IG: - First, attach pins with magnets with moving disc and after 1 minute and 25 seconds remove flower petals from inside a tube. The movements performed will be fine motricity, related to the tweezers handling (thumb and forefinger), alternating hands after 2 minutes and 30 minutes of play; - Hitting your hands on suddenly raised rulers, performing bilateral flexion / extension movements of the wrist simultaneously and alternating hands after 2 minutes and 30 minutes of play.
223754311|NCT05369858|DRUG|[14C] SKLB1028|A single 150 mg oral dose of \[14C\] SKLB1028 containing approximately 120 microcurie of \[14C\] SKLB1028
223754312|NCT05302375|OTHER|iPath*D|Online pathway from screening to treatment for depression in cancer patients.
223754313|NCT03161483|DRUG|CC-220|CC-220
223754314|NCT03161483|OTHER|Placebo|Placebo QD PO
223754315|NCT01523548|DRUG|Carbon Monoxide|150 ppm x 3 hours once weekly (week 1) 150 ppm x 3 hours twice weekly (week 2) 150 ppm x 3 hours three times a week (week 3-16)
223754316|NCT05766306|DIETARY_SUPPLEMENT|Probiotic Blend|Participants will be taking 1 sachet a day, 3 billion CFU.
223754317|NCT05766306|DIETARY_SUPPLEMENT|Placebo|Participants will be taking 1 sachet a day.
223754318|NCT05318144|OTHER||
223754319|NCT03224702|DRUG|M6495|Subjects will receive M6495 on Day 1
223754320|NCT03224702|DRUG|Placebo|Subjects will receive placebo matched to M6495 on Day 1
223754321|NCT02767427|DEVICE|Chlorhexidine Wipes|(Standard of Care) Chlorhexidine wipes are a commonly used pre-operative skin cleansing measure, designed to reduce bacterial load on the skin of the surgical site.
223754322|NCT02767427|OTHER|No intervention|Chlorhexidine wipes will not be used though it is a commonly used pre-operative skin cleansing measure.
223607421|NCT02688244|PROCEDURE|No irrigation|Suction only, using suction device
223607422|NCT01387126|DIETARY_SUPPLEMENT|Novel fibre supplement|The full dose of the study intervention is 15 grams per day.
223607423|NCT05889715|OTHER|Green Wellness Program: Plants-2-Plate|A 6-month, intensive interprofessional program focused on a WFPB predominant eating pattern
223607424|NCT00013520|DRUG|Abacavir sulfate, Lamivudine and Zidovudine|
223607425|NCT00013520|DRUG|Atazanavir|
223607426|NCT00013520|DRUG|Lamivudine/Zidovudine|
223607427|NCT00013520|DRUG|Abacavir sulfate|
223607428|NCT00013520|DRUG|Efavirenz|
223607429|NCT00013520|DRUG|Nevirapine|
223607430|NCT00013520|DRUG|Lamivudine|
223607431|NCT00013520|DRUG|Stavudine|
223607432|NCT00013520|DRUG|Zidovudine|
223607433|NCT00013520|DRUG|Didanosine|
223607434|NCT02222610|DRUG|0.5 mg ranibizumab|
223607435|NCT02222610|PROCEDURE|Targeted Retinal Photocoagulation (TRP)|TRP to areas of retinal ischemia
223607436|NCT04683835|DEVICE|Neurosteer Aurora system|The system is composed of hardware and software modules that facilitate the capture and interpretation of electrophysiological data as well as enable viewing the processed data in real time and offline. An electrode patch is attached on the subject's forehead to capture the electrophysiological signal. The signal is sent via low energy Bluetooth to an EEG Monitor. The signal is then sent via Wi-Fi to the cloud where the data is stored on a HIPAA compliant server. Data analysis performed in the cloud transforms the electrophysiological signal into easily readable data of brain activity, which is accessible via any web interface
223607437|NCT06062979|DRUG|rilpivirine/cabotegravir|WWH is currently providing Cabenuva treatment as a treatment option for eligible patients. The purpose of the proposed study is to use an observational, prospective cohort design to further investigate the delivery of Cabenuva among two subpopulations of WWH patients.
223607438|NCT02936635|DRUG|tirasemtiv|Oral
223607439|NCT02697266|OTHER|No intervention|This is an observational study.
223607440|NCT04950361|OTHER|talocalcaneal coalition|patients with talocalcaneal coalition
223607441|NCT00956371|DRUG|ONO-7746|5mg, 10mg, 20mg, 50mg, 100mg, 200mg, 400mg, 800mg, 1200mg QD/1 day
223607442|NCT00956371|DRUG|ONO-7746|5mg, 10mg, 20mg, 50mg, 100mg, 200mg, 400mg, 800mg, 1200mg QD/1 day
223607443|NCT02407223|DRUG|Group 1: Placebo|Participants will receive placebo SC at Weeks 0, 4, 16, and 20. At Week 24, all participants (except those who early escaped) will crossover to receive ustekinumab 45 or 90 mg SC at Weeks 24 and 28 followed by every 12 weeks up to Week 52. At Week 16, participants in placebo group with \< 10% improvement from baseline in both total back pain and morning stiffness measures at Week 12 and 16 will enter early escape to receive ustekinumab 45 mg or 90 mg at Weeks 16, 20, and 28 followed by every 12 weeks up to Week 52. At Week 52, participants who achieved inactive disease by ASDAS (ESR) \<1.3 at both Week 40 and 52 will be re-randomized to receive placebo or ustekinumab every 12 weeks up to Week 88. At Week 52, participants who did not achieve inactive disease by ASDAS (ESR) \<1.3 at Week 40 or 52 will continue with ustekinumab every 12 weeks up to Week 88.
223607444|NCT02407223|DRUG|Group 2: Ustekinumab 45 mg|Participants will receive ustekinumab 45 mg subcutaneously at Weeks 0 and 4, followed by every 12 weeks through Week 52. At Weeks 20 and 24, participants will receive placebo subcutaneously to maintain the blind. At Week 52, participants who achieved inactive disease by ASDAS (ESR) \<1.3 at both Week 40 and Week 52 will be re-randomized to receive either placebo or ustekinumab 45 mg every 12 weeks in a blinded fashion. At Week 52, participants who did not achieve inactive disease by ASDAS (ESR) \<1.3 at Week 40 or Week 52 will continue receiving ustekinumab 45 mg every 12 weeks through Week 88.
223607445|NCT02407223|DRUG|Group 3: Ustekinumab 90 mg|Participants will receive ustekinumab 90 mg subcutaneously at Weeks 0 and 4, followed by every four weeks through Week 52. At Weeks 20 and 24, participants will receive placebo subcutaneously to maintain the blind. At Week 52, participants who achieved inactive disease by ASDAS (ESR) \<1.3 at both Week 40 and Week 52 will receive either placebo or ustekinumab 90 mg every 12 weeks in a blinded fashion. At Week 52, participants who did not achieve inactive disease by ASDAS (ESR) \<1.3 at Week 40 or Week 52 will continue receiving ustekinumab 90 mg every 12 weeks through Week 88.
223607446|NCT06263374|BEHAVIORAL|Motor imagery of the jaw|Fifty individuals who have undergone orthognathic surgery of the mandible alone or concurrently with the maxilla will be randomly assigned to the experimental group, which involves practicing motor imagery in addition to a self-rehabilitation program and physiotherapy. Patients will be guided to visualize three sets of jaw movements three times a day. Adherence to the program will be monitored by the physiotherapist. The program has been standardized across all participating centers as the study is multicentric.
223607447|NCT06263374|BEHAVIORAL|Control task (Sudoku or Crossword puzzle)|Fifty individuals who have undergone orthognathic surgery of the mandible alone or concurrently with the maxilla will be randomly assigned to the control group, which involves practicing a control task (completion of Sudoku or crossword puzzles) in addition to a self-rehabilitation program and physiotherapy. Patients will be instructed to engage in the task for approximately 10 minutes per day, equivalent to the duration of motor imagery practice in the group 1. Adherence to the program will be monitored by the physiotherapist. The program has been standardized across all participating centers, as the study is multicentric.
223607448|NCT01845935|DEVICE|Percutaneous Image-guided Cryoablation (FPRPR3508 IceRod® PLUS Needles)|Treatment consists of a percutaneous cryoablation performed under anesthesia and imaging control.
223607449|NCT05904561|RADIATION|low level laser therapy|"comparing between the effect of low level laser therapy (LLLT) and pulsed ultrasound on post-partum carpal tunnel syndrome. All interventions that were pre-specified to be administered as part of the protocol, even if a particular intervention is not of interest"
223607450|NCT01056939|DEVICE|Neurally adjusted ventilatory assist, i-Servo, Maquet Nordic (Solna, Sweden)|Treatment with neurally adjusted ventilatory assist
223607451|NCT01056939|DEVICE|Control (PC- or PRVC- ventilation), i-Servo, Maquet Nordic (Solna, Sweden)|Treatment with PC or PRVC ventilation.
223607452|NCT05628142|RADIATION|Pelvic CT Scan|Pelvic CT-Scan between 6-12 months post-op
223607453|NCT05011812|DRUG|PBI-0451 Dose 1|Dose level 1 of PBI-0451
223607454|NCT05011812|DRUG|PBI-0451 Dose 2|Dose level 2 of PBI-0451
223607455|NCT05011812|DRUG|PBI-0451 Dose 3|Dose level 3 of PBI-0451
223754323|NCT03818165|BIOLOGICAL|CAR2 Anti-CEA CAR-T cells|doses will be delivered by hepatic arterial infusions using pressure enhanced delivery device (PEDD)
223754324|NCT00354445|DRUG|pegaptanib sodium (Macugen)|
223754325|NCT04128683|DRUG|amisulpride|Dopamine D2 antagonist to test how it affects brain response and behavior to prediction error and reversal tasks during functional magnetic resonance imaging (fMRI).
223754326|NCT04128683|DRUG|bromocriptine|Dopamine D2 receptor agonist test how it affects brain response and behavior to prediction error and reversal tasks during functional magnetic resonance imaging (fMRI).
223754327|NCT04128683|DRUG|Placebo|Placebo pill with no active drug ingredients
223754328|NCT05984355|OTHER|Individual interviews|Discussion between the searcher and the participant about representations and acceptability about a potential application and captors which suggest a Walking itinerary
223754329|NCT01544530|OTHER|Cold isotonic fluid and central venous hypothermia catheter|20-30ml/kg of isotonic crystalloid resuscitation fluid will be used for induction. Hypothermia (32-33 degrees C) will be sustained until organ procurement using an FDA approved central venous catheter connected to an external temperature regulating system
223607456|NCT05011812|DRUG|PBI-0451 Dose 4|Dose level 4 of PBI-0451
223607457|NCT05011812|DRUG|Ritonavir|Ritonavir will be co-administered with the study drug in Treatments J and K
223607458|NCT05011812|DRUG|Midazolam|Midazolam will be co-administered with the study drug in Treatment L
223607459|NCT05011812|DRUG|Placebo|Placebo to match
223607460|NCT05011812|DRUG|PBI-0451|Dose level of PBI-0451 with a projected exposure
223607461|NCT05011812|DRUG|PBI-0451 Dose 5|Dose level 5 of PBI-0451
223607462|NCT03552666|DIETARY_SUPPLEMENT|vitamin D3|
223607463|NCT02582645|PROCEDURE|open window technique|palatally impacted canine will be exposed and left without traction for a maximum of 9 months
223607464|NCT02582645|PROCEDURE|closed window technique|palatally impacted canine will be exposed, an attachment will be bonded, and then the canine will be covered with palatal tissue; traction of the canine will be initiated within 2 weeks following surgery
223607465|NCT02507323|DRUG|ticagrelor|A platelet aggregation inhibitor
223754330|NCT03608488|DIETARY_SUPPLEMENT|Vitamin D|Vitamin D3 50.000 IU/per week, for 8 weeks
223754331|NCT03608488|OTHER|Exercise|Core stability, balance exercises
223754332|NCT00881946|DRUG|GSK21110183|Starting Dose = 25mg once daily with dose escalation until unacceptable toxicity develops
223754333|NCT04448899|DRUG|Ivabradine Oral Tablet|Ivabradine 5 mg twice daily and doses (2.5, 5, 7.5 mg) were to be adjusted upwards or downwards at every visit according to HR at rest and tolerability plus their standard treatment.
223754334|NCT04448899|DRUG|Blacebo plus standard treatment|Blacebo plus standard treatment
223754335|NCT03998553|PROCEDURE|IN VITRO MATURATION AND OOCYTE ACTIVATION|This study aims to fine-tune the in vitro maturation (IVM) technique to achieve nuclear mature oocytes, i.e., to mature the oocytes up to the metaphase II stage. In addition, an artificial oocyte activation (AOA) will be carried out to check the cytoplasmic maturation of the oocytes, avoiding the generation of potentially viable embryos.
223754336|NCT03062475|BEHAVIORAL|lifestyle intervention with dietary and exercise recommendation|"With the dietary intervention we aimed to promote a healthy pattern of eating but not necessarily to restrict energy intake.For example we suggested exchanging carbohydrate-rich foods with a medium-to-high glycaemic index for those with a lower glycaemic index to reduce the glycaemic load, and restricting dietary intake of saturated fat.~With respect to advice on physical activity, we focused on incremental increases in walking from a pedometer assessed, or encourage them to do moderate cycling during pregnancy."
223754337|NCT00980551|DRUG|subtenon Carboplatin|Available in 50mg, 150mg, 450 mg, 600mg vials. It is provided as a premixed aqueous solution or lyophilized powder for injection given on day 1/week 10 (cycles 1-3).
223754338|NCT00980551|DRUG|Topotecan Hydrochloride|Each vial contains topotecan hydrochloride equivalent to 4 mg of topotecan as free base. Given intravenously on days 1-5 of each week (cycles 1-6).
223754339|NCT00980551|DRUG|Vincristine|Each vial contains vincristine sulfate, 1 mg; mannitol, 100 mg; sterile water for injection; Acetic acid and sodium acetate are added for pH control. Given intravenously on day 1/week 1 (cycles 1-6).
223754340|NCT00980551|DRUG|Filgrastim|Supplied as a clear solution in 300 mcg/ml 1 ml or 1.6 ml vials and prefilled syringes containing 300mcg/0.5mL or 480mcg/0.8mL. Given intravenously on day 6 of each week (cycles 1-6).
223754341|NCT02127632|DEVICE|Endotracheal Tube|ETT:Ruschelit, Teleflex Medical Snd. Bhd. Malaysia. Ref:112482
223754342|NCT02127632|DEVICE|Laryngeal Mask Airway-Supreme|"Before LM-S was inserted, to lubricate the surface in contact with the palate a water-based K-YTM gel (Johnson \& Johnson Ltd. Maidenhead, UK) without local anesthetic was applied to completely cover the LM-S cuff. Depending on the patient's body weight For \<50 kg, no. 3 Between 50-70 kg, no. 4 Between 70-100 kg, no. 5 LM-S (The Laryngeal Mask Company Limited, Singapore) was inserted.~Other Names:~LM-S (The Laryngeal Mask Company Limited, Singapore) serial number: 175030 lot: hmabw7"
223754343|NCT05102188|COMBINATION_PRODUCT|Assessment of sleep and related factors|Eligible participants will be invited to fill out several forms and wear a watch-like device on their wrist (an accelerometer) for 7 days to assess their sleep habits. They will also be asked to sleep at home with a watch-like device attached to a sleeve which covers their index finger (an oximeter) for one night to assess whether they may have a sleep problem like sleep apnea.
223607466|NCT02507323|DRUG|prasugrel|a thienopyridine class inhibitor of platelet activation and aggregation
223607467|NCT02507323|DRUG|Placebo|placebo
223607468|NCT00074334|BIOLOGICAL|TGFa-PE38 immunotoxin|
223607469|NCT00074334|PROCEDURE|conventional surgery|
223607470|NCT02611726|OTHER|Acupuncture|Acupuncture
223607471|NCT04804683|GENETIC|Genetic dissection of Fibromuscular Dysplasia|Blood sampling for genetic analysis aiming at unraveling the genetic basis of Fibromuscular Dysplasia
223607472|NCT04804683|OTHER|Search for diagnostic and prognostic biomarkers of Fibromuscular Dysplasia|Blood/urine and in rare cases tissue sampling aiming at identifying biomarkers of Fibromuscular Dysplasia
223607473|NCT03481335|OTHER|CHAP-P Sessions|Residents of intervention communities (barangays) aged 40+ are openly invited to attend CHAP-P sessions. At CHAP-P sessions, trained local volunteers (Barangay Health Workers, or BHWs) collect consent, measure blood pressure, collect other physical measurements, and conduct a survey to determine clients' risk of diabetes. Based on the findings, BHWs provide education and/or referrals. CHAP-P sessions are held twice a month, and clients are encouraged to continuing attending for ongoing follow-up and monitoring.
223607474|NCT05577338|BEHAVIORAL|Theory of Mind psychotherapy|a semi-structured, multidomain, tailored group psychotherapy
223607475|NCT05577338|BEHAVIORAL|health education|disease-related health knowledge
223607476|NCT04657471|OTHER|revised HOME-CoV score|"Educational lectures, posters, and pocket cards showing and explaining the revised HOME-CoV score are communicated to participating Emergency Departments.~For included patients, the physician-in-charge calculates the revised HOME-CoV. Patients with a score \<2 qualified for home treatment. They qualified otherwise for hospitalization. For patients with a score \> 4, hospitalization in a unit allowing monitoring of vital parameters is recommended. However, the physician-in-charge can overrule the qualification for home treatment or for hospitalization in case of major medical or social reasons. A justification explaining the cause of overruling is required."
223607477|NCT04864639|OTHER|Transition of Care Model|Participants with diabetes, Hispanic/Latinos, adults will receive newly developed discharge instructions.
223607478|NCT00004561|BEHAVIORAL|exercise|
223607479|NCT01459445|DRUG|Metformin, Ethinylestradiol 30µg-Drospirenone|Metformin: 1700 mg /day (twice per day)-6 months; EE30µg-drospirenone: 1 tb/day, 21 days/month, 6 months
223607480|NCT05342558|DRUG|Fluticasone Furoate/Vilanterol 100/25 mcgs|Dry powder inhaler with 30 blisters. 100/25mcgs a day for 24 weeks.
223607481|NCT05342558|DRUG|Umeclidinium/Vilanterol 62.5/25 mcgs|Dry powder inhaler with 30 blisters. 62.5/25mcgs a day for 24 weeks
223607482|NCT04395807|DEVICE|Helmet CPAP|Start-up air flow 40 L/min. Start-up PEEP 5 cmH2O. Max PEEP 20 cmH2O. Oxygen flow / FiO2% according to 92% SpO2 target. Titrations at physician's choice.
223607483|NCT04395807|DEVICE|HFNC|Start-up air flow 30 L/min. Max air flow 60 L/min. Oxygen flow / FiO2% according to 92% SpO2 target. Titrations at physician's choice.
223607484|NCT00858026|OTHER|Breastmilk|Exclusively breastfed babies
223607485|NCT00858026|OTHER|Standard milk|Weaning babies fed with the standard formula
223607486|NCT00858026|OTHER|Fermented milk|Weaning babies fed with the fermented formula
223607487|NCT03969914|PROCEDURE|PEEP changes|All patients will be ventilated with a tidal volume of 6 ml/kg before the RRI assessment. Further, three level of PEEP (5, 10 and 15 cmH2O) will be randomly set. For each levels of PEEP, the RRI will be evaluated
223607488|NCT00905463|PROCEDURE|Lung transplantation|Lung transplantation
223754344|NCT04345952|BEHAVIORAL|Calm Meditation Mobile App|The Calm Meditation Mobile App will be used to deliver the meditation intervention to study participants. The Calm app is downloaded onto the participant's smartphone.
223754345|NCT01222975|DRUG|Risperidone|orally disintegrating tablets
223754346|NCT04238728|DEVICE|Silverlon|silver nylon dressing will be applied daily
223754347|NCT01489072|DRUG|Remifentanil|Bolus dose of intravenous remifentanil 0.25 mcg/kg given once before emergence of general anesthesia
223607489|NCT06054100|DRUG|Colchicine Tablets|Colchicine oral tablets loading dose of 1mg every 12 hrs for 1 day, followed by 0.5 mg BID for 3 months
223607490|NCT02309944|PROCEDURE|Standard Wound Closure|The standard surgical closure consists of closure of the fascia with a looped polydioxanone (PDS) suture in a running fashion either in with the use of a mass closure technique or a Smead Jones closure at the discretion of the operating surgeon, closure of the subcutaneous space if \>2 cm deep, followed by staple or suture closure of the skin.
223607491|NCT02309944|DEVICE|Prevena™ Incision Management System|At the close of surgery, the Prevena™ Incision Management System will be placed over the closed incision. It will be removed on post-operative day 2 or 3 as clinically indicated and prior to the patient's discharge from the hospital.
223607492|NCT03049917|BEHAVIORAL|Financial incentive|Conditional cash transfer upon HIV testing
223607493|NCT01480622|DRUG|TDF tablets|"White, almond-shaped, film-coated tablets, one side with the markings GILEAD and 4331"
223607494|NCT02921672|OTHER|Mediterranean Diet|Diet consisting of fruits, vegetables, grains, dairy, olive oils, seafood, and nuts. It is low in red meat and solid fats.
223607495|NCT03947177|BEHAVIORAL|GMIT|Six 30-minute sessions delivered virtually in a group format. Each week a group facilitator will elicit adolescents' feedback on important topics related to substance use and provide experiential activities to help adolescents explore their beliefs and practice making healthy choices.
223607496|NCT03947177|BEHAVIORAL|GMIT+|Six 30-minute sessions delivered virtually in a group format. Each week a group facilitator will elicit adolescents' feedback on important topics related to substance use and provide experiential activities to help adolescents explore their beliefs and practice making healthy choices. Parents and/or guardians will virtually participate in parent-only support group sessions.
223607497|NCT03742765|BEHAVIORAL|Incentivizing planning|Participants receive bonus incentives for planning their workouts
223607498|NCT03742765|BEHAVIORAL|Incentivizing exercise|Participants receive bonus incentives for exercising
223607499|NCT04050059|DRUG|EMLA cream|EMLA cream (5g tube Aspen pharma trading limited) will be applied topically in dose of 2.5 grams (half tube of cream) and area will be covered with tegaderm dressing. Application of EMLA will at least stay for 30 minutes before spinal needle insertion
223607500|NCT04050059|DRUG|2% lidocaine|In 2% lidocaine group infiltration (Xylocaine 2% Barrett Hodgson Pakistan Pvt limited), skin and subcutaneous tissue will be infiltrated with 3 ml of 2% lidocaine (dose of 60 mg) before spinal needle insertion
223607501|NCT00771199|DRUG|Transdermal Therapeutic System (TTS)-Fentanyl|Participants will receive 1 transdermal patch of TTS-fentanyl containing 12 micrograms per hour (mcg/h) for 28 days. Dose can be increased or decreased as per Investigator's discretion up to 100 mcg/h.
223607502|NCT04614727|COMBINATION_PRODUCT|polymeric nano calcium fluoride containing varnish NANO SEAL|It consists of four components Silicone polymer provides excellent adhesion to enamel and dentine, with transparent formula. NANO-fluoroapatite flows into enamel micro cracks \& seals it, penetrating into the dentinal tubules closing them eventually. As for the NANO-calcium fluoride it behaves as a fluoride reservoir, provides gradual and long-term fluoride release. The fourth component Amine fluoride (Olaflur) provides immediate fluoride ion release and accelerates natural remineralization.
223607503|NCT03332381|BEHAVIORAL|Attention training technique|Attention training involves modifying metacognitive control and enhancing attention flexibility so that people can refrain from responding to intrusions with extended processing.
224200717|NCT04076982|DIETARY_SUPPLEMENT|mung bean protein|Participants were instructed to consume the test foods in the morning hours and to keep a record of the days the foods were consumed on a study calendar which was returned to investigators at the final visit and used to track protocol adherence.
223607504|NCT03332381|BEHAVIORAL|Mindful self-compassion|Self-compassion involves not avoiding painful or distressing feelings. Instead these experiences are held in awareness with kindness, understanding, and a sense of shared humanity.
223607505|NCT02232022|DEVICE|Reveal LINQ Insertable Cardiac Monitor|
223607506|NCT00478842|DEVICE|Deep brain stimulation|Deep brain stimulation
223607507|NCT02947386|OTHER|Laboratory Biomarker Analysis|Correlative studies
223607508|NCT02947386|BIOLOGICAL|Nimotuzumab|Given IV
223607509|NCT02947386|BIOLOGICAL|Nivolumab|Given IV
223607510|NCT06525779|DEVICE|Use of macintosh laryngoscope|The requirement of external laryngeal manipulation recorded in use of macintosh vs mcGrath laryngoscope in double lumen tube insertion
223607511|NCT06525779|DEVICE|Use of mcGarth laryngoscope|Use of mcGarth laryngoscope
223607512|NCT01922713|OTHER|white maize and a corn oil capsule|\~ 0 ug RAE/d
223607513|NCT01922713|OTHER|orange maize and a corn oil capsule|\~600 ug RAE/d
223607514|NCT01922713|OTHER|white maize and a vitamin A capsule|600 ug RAE/d
223607515|NCT01218581|DRUG|received oral letrozole (2.5 mg/day)and goserelin subcutaneosly (3.6 mg/month)|
223607516|NCT05229185|DEVICE|DeXtreme training (error-enhancement)|15-20 min DeXtreme - 15 min conventional therapy - 15-20 min DeXtreme
223607517|NCT06157866|OTHER|Electroacupuncture|During the treatment sessions the acupuncturist will insert needles in several locations aimed to reduce the patient's fibromyalgia pain. A low-amplitude, sub-sensory electrical current will be activated by the acupuncturist.
223607518|NCT06157866|BEHAVIORAL|Cognitive Training|Cognitive training with a pain specialist.
223607519|NCT06157866|BEHAVIORAL|Education Training|Education training with a pain specialist.
223607520|NCT04973072|BEHAVIORAL|One large reward treatment|Participants will be awarded S$300 for reaching the PBF goal at the end of 12 weeks.
223607521|NCT04973072|BEHAVIORAL|Small wins treatment|The cash rewards that participants will receive are capped by $300 and depend on which IGs they achieve and whether they maintain their progress at the end of the 12 weeks. Specifically, given the PBF goal, the Loss Target (LT) is the difference between the initial PBF measured at the first visit and the PBF goal, i.e., LT = initial PBF - PBF goal. Then, the IG1 is to achieve 25% of the LT, the IG2 is to achieve 50% of the LT, and the IG3 is to achieve 75% of the LT. Participants will earn $75 credits to their accounts on the programme website for reaching each intermediate goal. Also, when they miss IG1 and/or IG3, they can earn the previous missing $75 credits if they reach the IG2 and the LT. At the end of the 12 weeks, they will lose some or all the credits that they have accumulated if they fail to maintain the progress, and they will only receive the corresponding amount in cash
223607522|NCT04945759|DEVICE|Isokinetick Exercise, Aussie Current, Russion Current, Plasebo Electirical Stimulasyon|Evaluation and treatment will be done with the Cybex humac device.
223607523|NCT01478971|DRUG|Epoetin|Commercially available epoetin alfa administered weekly, twice weekly, or thrice weekly at an initial starting dose, frequency of administration, and mode of administration (intravenous \[IV\] or subcutaneous \[SC\]) individually determined for each participant using the site's usual standard of care. Subsequent dose adjustments or dose holds may have been made in order to maintain a hemoglobin concentration of \<11 g/dL.
223607524|NCT01478971|DRUG|Peginesatide|Administered as a once monthly intravenous (IV) or subcutaneous (SC) injection. The initial dose of peginesatide injection was based on the final weekly dose of epoetin administered in the SCP; subsequent doses may have been adjusted in order to maintain hemoglobin concentrations at \<11 g/dL.
223607525|NCT05940116|DRUG|HS-20117|"Phase Ia: patients will receive HS-20117 starting at 400 mg, and subsequent cohorts will test escalating doses, if tolerated, until a maximum tolerated dose (MTD) or maximum applicable dose (MAD) is defined.~Phase Ib: patients will receive HS-20117 at MED or MAD"
223607526|NCT04399395|DRUG|Naltrexone/bupropion|Approved drug for obesity treatment
223607527|NCT04399395|OTHER|Lifestyle|Lifestyle
223754348|NCT01489072|DRUG|Remifentanil|Bolus dose of intravenous remifentanil 0.5 mcg/kg given once before emergence of general anesthesia
223607528|NCT05307354|OTHER|Tibial Nerve Mobilization|The person performing tibial nerve mobilization will start mobilization by keeping the lower extremity in a horizontal position, with the patient's hip and knee in 45° flexion and ankle in neutral position. Then, in order to mobilize the tibial nerve better, the patient will bring the patient's toes to the extension position, the ankle to the dorsiflexion and eversion position, and the knee joint to the extension to provide appropriate stabilization. Finally, while the patient is in this position, mobilization will be completed by plantar flexion of the distal ankle and flexion of the toes to allow the nerve to slide further distally. This mobilization technique will be performed by an experienced physician/physiotherapist twice a week for 4 weeks, and the patients will be given 5 sets of 10 cycles with a 1-minute rest period in each set.
223607529|NCT05307354|OTHER|Foot-ankle range of motion exercises|In exercise program, foot-ankle joint range of motion exercises will be given. In our study, all exercises will be explained and performed once under the supervision of a physiotherapist, and then the participants will be asked to do all exercises with 10 repetitions, 3 times a day, for four weeks, without the supervision of a physiotherapist.
223607530|NCT00584012|DRUG|Lovastatin|Given PO
223607531|NCT00584012|DRUG|Docetaxel|Given IV
223607532|NCT01525615|DEVICE|Respimat inhaler|Respimat inhaler
223607533|NCT01525615|DRUG|tiotropium+olodaterol (low dose)|2.5 µg tiotropium + 5 µg olodaterol
223607534|NCT01525615|DRUG|tiotropium + olodaterol (high dose)|5 µg tiotropium + 5 µg olodaterol
223607535|NCT01525615|DEVICE|Respimat inhaler|Respimat inhaler
223607536|NCT01525615|DEVICE|Respimat inhaler|Respimat inhaler
223607537|NCT01525615|DRUG|placebo to tiotropium+olodaterol|comparator
223607538|NCT06362096|DRUG|Trastuzumab+pyrotinib+taxene|Trastuzumab (first cycle 8mg/Kg, subsequent 6mg/Kg, iv, q3w) Pyrrotinib \* po, qd, q3w The first cycle 240mg+ montmorillonite powder, the second cycle 320mg+ montmorillonite powder prevention Subsequent cycle 400mg+\* montmorillonite powder used when necessary taxenes
223754349|NCT00793338|DRUG|Sildenafil|Sildenafil 20mg three times a day for 3 months.
223607539|NCT04658004|DRUG|NKG2D CAR T-cells|Each subject receive NKG2D CAR T-cells by intravenous infusion
223754350|NCT02901951|BIOLOGICAL|Engerix-B|Intramuscular administration of single challenge dose of Engerix-B vaccine in the deltoid region of the non-dominant arm.
223754351|NCT05727254|BEHAVIORAL|Agility training|Multi-component (strength, balance, cognition) exercise training.
223754352|NCT05727254|BEHAVIORAL|Exercise recommendations|Participants are being given the standard recommendations how much exercise and what type older adults should do.
223754353|NCT05727254|BEHAVIORAL|Exercise diary|Participants are instructed to write down their physical activity and exercises.
223754354|NCT05389657|BEHAVIORAL|Web-based training|Web-based training will be divided into training modules that will be completed by participants over the course of 6-8 weeks. Training will include didactic training videos, knowledge checks, example sessions, and a library of resources.
223754355|NCT05389657|BEHAVIORAL|Live training|The live training will be delivered by two trainers over the course of two days via Zoom.
223607540|NCT04050618|DEVICE|fanfilcon A test lens|Silicone hydrogel contact lens
223754356|NCT05228275|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
223754357|NCT05228275|OTHER|Survey Administration|Complete survey
223754358|NCT01907828|DEVICE|Renal Artery Ablation|Renal artery denervation using the EnligHTN™ Renal Denervation System
223754359|NCT01907828|DEVICE|Cardiac Ablation|Safire BLU™ Duo or Therapy Cool Path Duo Irrigated Ablation Catheter or Therapy Cool Flex Irrigated Ablation Catheter EnSite Velocity System Agilis NxT Guiding Introducer
223754360|NCT06065826|OTHER|Assessment|All subjects will be assessed for FHP by taking a lateral view picture to calculate the CVA using the Kinovea software. Each subject with FHP will be examined for myofascial trigger points done by the therapist finger to palpate bilaterally on tender nodules in masticatory and neck muscles. Then using a pressure algometer, the PPT value will be scored for each trigger in each muscle bilaterally. Masticatory muscle endurance will be measured by asking the subject to bite on load sensor for as long as the subject can until exhaustion. Using a stopwatch, the time will be recorded in seconds. Using the craniocervical extension endurance test, the subject will lie prone with their head unsupported and with a bubble inclinometer attached to their head. Using a stopwatch, time in seconds will be recorded to test how long the subject can sustain the neck in neutral position. Finally, a smartphone addiction scale will be answered by the subject to identify how much they are addicted to its use.
223754361|NCT03142880|COMBINATION_PRODUCT|hyperbaric ropivacaine|We change the density of ropivacaine solution to make it into an marginally hyperbaric state or into an commonly hyperbaric state.and we hypothesized that the marginally hyperbaric ropivacaine will get a similar efficacy to commonly hyperbaric solutions but a more steadily hemodynamic status.
223754362|NCT00537446|DEVICE|noninvasive positive pressure ventilation|Each subject will undergo 2 hours of high-level noninvasive positive pressure ventilation, with an inspiratory positive airway pressure of 12 cm H2O and an expiratory positive airway pressure of 3 cm H2O.
223754363|NCT00537446|DEVICE|noninvasive positive pressure ventilation|Each subject will undergo 2 hours of low-level noninvasive positive pressure ventilation, with an inspiratory positive airway pressure of 6 cm H2O and an expiratory positive airway pressure of 3 cm H2O.
223754364|NCT01193907|BIOLOGICAL|NVGH Vi-CRM197 12.5 mcg|1 dose of 0.5 mL
223754365|NCT01193907|BIOLOGICAL|NVGH Vi-CRM197 5.0 mcg|1 dose of 0.5 mL
223754366|NCT01193907|BIOLOGICAL|NVGH Vi-CRM197 1.25 mcg|1 dose of 0.5 mL
223754367|NCT01193907|BIOLOGICAL|Vi-polysaccharide vaccine|1 dose of 0.5 mL containing 25 mcg of Vi polysaccharide
223754368|NCT02245243|DRUG|Delafloxacin|Plasma pharmacokinetic parameters: AUC0-t, AUC0 inf, Cmax, Tmax, λz, t1/2, MRTinf, CL, CLnr, Vss, Vz
223754369|NCT06471426|OTHER|Osteopathic Manipulative Treatment|The following methods of evaluation and treatment will be utilized on all subjects: Indirect myofascial release to the cervical region, osteopathic cranial manipulation, sacral articular technique.
223754370|NCT01139528|PROCEDURE|Bouquet pinning of the 5th metacarpal bone|The fracture is reduced under general anesthesia and 2-3 K-pins are introduced in the medullar cavity to keep the fracture in the reduced position
223754371|NCT05656924|DEVICE|digital prosthetic interface technology|Individuals randomized to this group will receive a socket and liner that are manufactured using a novel technique meant to achieve a better distribution of pressure on the residuum. The study is based on the hypothesis that an improvement in pressure distribution on the residuum will enable high adherence to an exercise program meant to improve health status in dysvascular amputees.
223754372|NCT05155228|BEHAVIORAL|Attachment Regulation and Competency|Trauma informed psychotherapy intervention for children with a history of exposure to trauma and their caregivers.
223754373|NCT05155228|BEHAVIORAL|Treatment as usual|Supportive psychotherapy
223754374|NCT01161199|PROCEDURE|Leukapheresis|Blood will be taken by a needle placed in one arm and processed through a machine, which spins the blood so that the white blood cells will be separated out in the machine for purposes of this research and the rest of the blood will be returned through a needle in the other arm.
223754375|NCT01073865|DRUG|ZD9393 (Zoladex) 10.8 mg|10.8 mg (goserelin acetate): one subcutaneous depot injection once every 12 weeks (± 7 days).
223754376|NCT01073865|DRUG|ZD9393 (Zoladex) 3.6 mg|3.6 mg (goserelin acetate): one subcutaneous depot injection once every 4 weeks (± 7 days).
223754377|NCT01839448|BIOLOGICAL|Post-partum oral glucose tolerance test|All patients will have an oral glucose tolerance test at 4 to 12 weeks after the end of pregnancy. Study representatives will contact patients by phone to remind them of the necessity of this test, and its importance for their health.
223754378|NCT03493490|DRUG|Neodolpasse|Patients will receive two infusions containing 75 mg diclofenac and 30 mg orphenadrine citrate 30 minutes after fixation of the graft replacement and with a time interval of 8 hours.
223754379|NCT03493490|DRUG|Diclofenac|Patients will receive two infusions containing 75 mg diclofenac 30 minutes after fixation of the graft replacement and with a time interval of 8 hours.
223754380|NCT03493490|DRUG|Placebo|Patients will receive two physiologic saline infusions 30 minutes after fixation of the graft replacement and with a time interval of 8 hours.
223754381|NCT00621218|DRUG|tretinoin gel 0.05%|Apply tretinoin gel, 0.05% topically once or twice daily to female subjects with rosacea
223754382|NCT00621218|DRUG|vehicle|Apply Atralin Gel vehicle topically once or twice daily to female subjects with rosacea.
223754383|NCT04760717|DRUG|Spironolactone Pill|Participants randomized to the Spironolactone arm will be receiving Spironolactone in addition to their normal routine blood pressure treatment.
223754384|NCT00180024|DRUG|irbesartan (drug)|
223607541|NCT04050618|DEVICE|ocufilcon D control lens|hydrogel contact lens
223607542|NCT04050618|DEVICE|etafilcon A control lens|hydrogel contact lens
223607543|NCT01708512|DEVICE|Ulthera System Treatment|Focused ultrasound energy delivered below the surface of the skin
223607544|NCT04404556|BEHAVIORAL|Diabetes Journey|Web-based telehealth intervention focused on adherence barriers and problem-solving
223607545|NCT04404556|BEHAVIORAL|Enhanced Standard of Care|General education via the T1DToolkit website, as well as 4 phone calls with certified diabetes educators (CDEs) will be provided.
223607546|NCT01217762|DEVICE|IRay|Low voltage stereotactic radiotherapy system
223607547|NCT06555952|DIETARY_SUPPLEMENT|MegaNatural-BP SR 150Mg Tablet|GSE MegaNatural BP
223607548|NCT06555952|OTHER|Placebo Capsule|given in place of GSE MegaNatural BP
223607549|NCT00006116|DRUG|cisplatin|
223607550|NCT00006116|DRUG|gemcitabine hydrochloride|
223607551|NCT02334293|DRUG|Omegaven|Omegaven® fat emulsion will be used as a Compassionate Use treatment for critically ill infants with PN associated liver injury.
223607552|NCT04403412|PROCEDURE|Left atrial appendage closure group|Left atrial appendage closure Left atrial appendage closure is performed using a single endocardial plug devices guided by fluoroscopic guidance and transesophageal echocardiography
223607553|NCT04403412|PROCEDURE|Radiofrequency ablation group|Radiofrequency ablation Each patient with persistent AF receives circumferential pulmonary vein isolation under the 3D electro-anatomical mapping system , and no additional ablation is performed in the extrapulmonary sites unless the patient is diagnosed with atrial flutter before the operation.
223607554|NCT04403412|PROCEDURE|LAAC combined with radiofrequency ablation group|LAAC combined with radiofrequency ablation group Each patient received the same group of patients with simple radiofrequency ablation radiofrequency ablation treatment at the same time, the transcatheter occlusion of left atrial appendage opening
223607555|NCT04184830|DEVICE|non-invasive brain stimulation|
223607556|NCT05031793|OTHER|TCM|TCM include oral chinese herb, laser acupuncture, tuina, nasal steam inhalation.
223607557|NCT05031793|OTHER|Western medicine|Western medicine include nasal spray steroid, oral antihistamine
223607558|NCT00649506|DRUG|Nitrofurantoin Macrocrystals 100 mg Capsules|100mg, single dose fed
223607559|NCT00649506|DRUG|Macrodantin® 100 mg Capsules|100mg, single dose fed
223607560|NCT03777059|DRUG|Atogepant|Atogepant tablet
223607561|NCT03777059|DRUG|Placebo|Placebo-matching atogepant tablets
223607562|NCT02219854|PROCEDURE|Laparoscopic gastrectomy|
223607563|NCT02219854|PROCEDURE|Open gastrectomy|
223754385|NCT01914484|DRUG|Nilotinib|Nilotinib dose will remain fixed at 400mg bid throughout the cycles. BCR-ABL kinase inhibitor
223754386|NCT01914484|DRUG|Ruxolitinib|"In the phase I part of the study, dose escalation will follow a 3+3 study design at either of 3 fixed dose levels (10 mg bid, 15 mg bid or 20 mg bid).~No intra-patient dose-escalation will occur. JAK inhibitor"
223754387|NCT03924830|PROCEDURE|Bulk without surface sealant|Adhese SE self-etch adhesive system will be applied according to the manufacturer's instructions in 53 teeth.Then, the Tetric N-Ceram Bulk fill composite will be used in increments of no more than 4 mm, using the bulk restoration technique, and each increment will be photoactivated for 40 seconds.
223754388|NCT03924830|PROCEDURE|Bulk with Biscover|Adhese SE self-etch adhesive system will be applied according to the manufacturer's instructions in 53 teeth.Then, the Tetric N-Ceram Bulk fill composite will be used in increments of no more than 4 mm, using the bulk restoration technique, and each increment will be photoactivated for 40 seconds. After the restoration is completed, biscover surface sealant will be applied according to the manufacturer's instructions.
223754389|NCT03924830|PROCEDURE|Bulk with Permaseal|Adhese SE self-etch adhesive system will be applied according to the manufacturer's instructions in 53 teeth.Then, the Tetric N-Ceram Bulk fill composite will be used in increments of no more than 4 mm, using the bulk restoration technique, and each increment will be photoactivated for 40 seconds. After the restoration is completed, Permaseal surface sealant will be applied according to the manufacturer's instructions.
223607564|NCT02322437|OTHER|Home treatment|Patients are treated at home whenever possible and appropriate
223754390|NCT00259090|DRUG|Fulvestrant|500 mg intramuscular injection
223754391|NCT00259090|DRUG|Anastrazole|oral tablet
224311559|NCT02551666|OTHER|Balance recovery training|Participants will practice recovering their balance after a perturbation similar to tripping while walking. Each of these 'balance recovery training' sessions will last approximately 30 minutes, and will be performed 3 times per week for 4 weeks.
224311560|NCT02551666|OTHER|Tai Chi exercise|Participants will perform Tai Chi exercises (Yang short form) for 30 minutes, 3 times a week for 4 weeks. Each session will be led by an experienced Tai Chi instructor.
223607565|NCT02322437|OTHER|Treatment As Usual|Patients are treated at a mental hospital
223607566|NCT06834971|DRUG|Colistimethate sodium (CMS)|CMS (colistimethate sodium, 75mg, solubilized in 4 mL 0.9% saline), twice daily. Nebulization will be performed using a vibrating mesh nebulizer (Aeroneb solo, Aerogen, Galway, Ireland) placed in the inspiratory limb of the ventilator tubing, behind the Y-piece, and continued until the nebulizer deposit becomes dry for three consecutive days of mechanical ventilation. To ensure the experiment is conducted under blind conditions, the Nebulizer will be covered by stickers. A filter will be placed on the expiratory limb to protect the ventilator.
223607567|NCT01026012|DRUG|regadenoson|Regadenoson dose of 400 mcg will be infused over 10-20 seconds followed by a saline flush.
223607568|NCT03214575|DEVICE|Conventional method|
223607569|NCT03214575|PROCEDURE|GPS Method|
223607570|NCT03730532|OTHER|Cognitive Behavioural Therapy Guided Self Help|6-week manualised Cognitive Behavioural Therapy Guided Self Help
223607571|NCT03730532|OTHER|Cognitive Analytic Therapy Guided Self Help|6-week manualised Cognitive Analytic Therapy Guided Self Help
223607572|NCT05930652|DIAGNOSTIC_TEST|Psychological tests and psychosocial questionnaires|Assessment of psychological functioning (including well-being, mental health conditions, coping skills), and socio-demographics, academic performance, home, relationships, general health, habits, and attitudes.
223607573|NCT00915863|PROCEDURE|Billroth-II-type reconstruction|surgical procedure
223607574|NCT00915863|PROCEDURE|Isolated Roux-en-Y type reconstruction|surgical procedure
223607575|NCT00763386|DEVICE|NexGen LPS-Flex Fixed Bearing Knee|NexGen LPS-Flex Fixed Bearing femoral component
223607576|NCT00763386|DEVICE|NexGen Legacy Posterior Stabilized Knee|NexGen Legacy Posterior Stabilized femoral component
223754392|NCT04524312|PROCEDURE|Total knee replacement|Participant will undergo total knee replacement performed via anterior parapatellar approach with either Posterior-stabilized or retaining cruciate-retaining with dynamic congruence implant
223754393|NCT04524312|DIAGNOSTIC_TEST|Biomechanics|Participants will be asked to perform biomechanical assesment before and following surgery at baseline, 6-8 weeks and 6-months postoperatively
223754394|NCT04524312|DEVICE|NexGen Ps or Bioimplanti K-MOD implant|Participant are randomly allocated to receive one of the NexGen PS or Biomplanti K-MOD total knee implant for treatment of end-stage knee osteoarthritis.
224311561|NCT05005897|BIOLOGICAL|Cyanocobalamin|Intramuscular injection of 400 µg cobalamin to children with elevated thcy at enrollment
223607577|NCT06408571|OTHER|etiology|As an important part of systems biology, metabolomics mainly detects various metabolites in the sample. Different from nucleic acids, proteins and other biological macromolecules, the relative molecular weight of these metabolites is small, generally within 1000Da, such as amino acids, carboxylic acids, carbohydrates, alcohols, amines, lipids and other special substances. Through qualitative and quantitative analysis of all endogenous low molecular weight metabolites before and after pathophysiology or gene modification stimulation, metabolomics reveals the essential characteristics of life activities and metabolism of the body, and provides guidance for exploring the pathogenesis, early diagnosis, treatment and prognosis of diseases.
223607578|NCT02618265|PROCEDURE|Mobile terminal|multiple strategy including mobile terminal based compliance managment, platelet reactivity modified drug adjustment
223607579|NCT02618265|PROCEDURE|traditional management|aspirin or clopidogrel monotherapy or double treatment for
223607580|NCT02618265|PROCEDURE|website platform management|second prevention based on website platform management
223607581|NCT06184607|OTHER|Distance from contact point to attachment level|A periodontal probe will be used to measure distance between contact point to attachment level in maxillary central incisors
223607582|NCT05519514|DRUG|Cortiment|Budesonide 9 mg prolonged release tablets
223607583|NCT05519514|DRUG|Budesonide|Experimental (Budesonide 9 mg prolonged release tablets)
223607584|NCT06271044|OTHER|With radioiodine treatment|Postoperative radioiodine not given
223607585|NCT06271044|PROCEDURE|With postoperative radioiodine treatment|Postoperative radioiodine given
223607586|NCT04427865|DRUG|prophylactic lactoferrin daily|200 mg oral lactoferrin daily
223607587|NCT01398007|PROCEDURE|Camouflage syringe|Dental anesthesia is administered using the camouflaged syringe.
223607588|NCT00411671|DRUG|Sorafenib|400 mg By Mouth Twice Daily for 28 Days.
223607589|NCT00883961|OTHER|Supervised exercise|The patients will carry out a daily endurance exercise program consisting of walking on a treadmill for 30 minutes at an intensity of about 80% of the maximum heart rate under supervision from study personnel.
223607590|NCT03556163|PROCEDURE|Modified vertical internal mattress sutures + MWF surgery.|Modified vertical internal mattress sutures were given after modified Widman flap surgery.
223607591|NCT03556163|PROCEDURE|Simple loop interrupted sutures + MWF surgery.|Simple loop interrupted sutures were given after modified Widman flap surgery.
223607592|NCT03796637|DRUG|Ataluren|Ataluren will be administered as per the dose and schedule specified in the arm.
223607593|NCT05931926|DEVICE|Fluispotter®|The Fluispotter® has been developed for automated extraction, collection and storage of up to 20 dried venous dried blood spot samples of 3-10 μl over the course of up to 20 hours. The system is attached to the patient through a multilumen microcatheter inserted into a peripheral vein in the arm. The Fluispotter will be inserted in both healthy subjects and patients with adrenal insufficiency.
223607594|NCT02898363|OTHER|Information campaign|During a two-year information program, physicians, mainly general practitioners, carers in and outside institutions, associations and families will be informed on cancer frequency, on cancer particularities and on cancer detection in persons with intellectual disabilities by means of documents, mails and e-mails, meetings and a website providing all available useful information on cancer in persons with intellectual disabilities.
223607595|NCT01173601|DRUG|LY2216684|
223607596|NCT01173601|DRUG|Placebo|
223607597|NCT01173601|DRUG|SSRI|Participants should have been on their SSRI for at least 6 weeks prior and were to continue on their stable dose throughout the study.
223607598|NCT02042521|DRUG|Dietary Supplement|The active evening dietary supplement is taken at 22:00. The active morning dietary supplement is taken at 8:00-8:15. The active evening dietary supplement is taken first. The active morning and evening dietary supplements are taken within 12 hours in time points as specified above.
223607599|NCT02042521|DRUG|Lactose Placebo|This research study involves a placebo dietary supplement that does not have any of or only partial of the active ingredients in the active dietary supplement. The placebo dietary supplement will be given in identical time points to match that of the active dietary supplements.
223754395|NCT02735083|BIOLOGICAL|UCART19 follow-up|UCART19 will not be administered during the study period. Patients who will be rolled-over from the parent study to this long term follow-up study, have previously received UCART19. The roll-over occurs at the end of the parent study, or at any time after UCART19 administration, in case of premature discontinuation from the parent study.
223754396|NCT04253717|OTHER|Motor control exercise program|Structure physical training aimed at strengthening muscles of the lumbo-pelvic-hip core complex in order to improve stabilization and alignment of the spine and pelvis.
223754397|NCT06001658|DRUG|Gemcitabine|Patients will receive treatment on Day 1 and Day 8 of each cycle. Gemcitabine (1000 mg/m2) will be administered IV on Day 1 and Day 8 of each cycle, Q3 weeks with 2 - 4 cycles prior to surgery and then 4-6 cycles after surgery.
223607600|NCT03089021|OTHER|mulligan mobilization|mobilization with movement for spinous process or facet joint.
223607601|NCT03089021|OTHER|maitland mobilization|posterioanterior of spinous process or facet joint.
223607602|NCT03951077|DRUG|Elagolix|Capsule administered orally
223607603|NCT03951077|DRUG|Placebo|Capsule administered orally
223607604|NCT00889512|DRUG|Luveris fixed dose|Luveris 75IU daily throughout ovarian stimulation
223754398|NCT06001658|DRUG|Cisplatin|Patients will receive treatment on Day 1 and Day 8 of each cycle. Cisplatin (25 mg/m2) will be administered IV on Day 1 and Day 8 of each cycle, Q3 weeks with 2 - 4 cycles prior to surgery and then 4-6 cycles after surgery.
223754399|NCT06001658|DRUG|Pembrolizumab|Patients will receive treatment on Day 1 of each cycle. Pembrolizumab (200 mg) will be administered IV on Day 1 of each cycle, Q3 weeks with 2 - 4 cycles prior to surgery and then 4-6 cycles after surgery. Pembrolizumab (400 mg) will be administered IV Q6 weeks up to 4 cycles as maintenance.
223754400|NCT05850936|DRUG|Assigned Interventions: IOP-lowering eye drops|IOP-lowering eye drops Xalacom eyedrops (combination drops, fixed latanoprost with timolol) will be the choice for treatment.
223607605|NCT00889512|DRUG|Luveris increasing dose|Luveris 75IU until estradiol level reaches 250 pg/ml then increasing to 75IU BID for two days, then TID until hCG
223607606|NCT03147352|DEVICE|Hyperbaric oxygen therapy|Hyperbaric oxygen therapy with 100 % oxygen at 1.8 ATA for 2 hours.
223607607|NCT00488540|DRUG|Paracetamol|Suppository
223607608|NCT00488540|DRUG|Placebos|Suppository
223607609|NCT02009488|DRUG|Canagliflozin, 100 mg|One 100 mg capsule taken orally (by mouth) once daily
223754401|NCT04933266|PROCEDURE|Subpectoral plexus block (low dose)|It is one type of peripheral nerve blocks for surgery over the chest. Patients will have an ultrasound scan and nerve block with local anesthetic (LA) agent (0.25% levobupivacaine 10ml) injected 2 target sites through one skin puncture. One at the myofascial plane between the pectoralis major and minor (5ml of LA) and then under direct ultrasound visualization, the needle will be redirected and the remaining 5ml of LA will be injected at the plane between the pectoralis minor and the serratus anterior muscle, close to the origin of thoracoacromial artery from the axillary artery at the level of the third rib.
223754402|NCT04933266|PROCEDURE|Subpectoral plexus block (High dose)|It is one type of peripheral nerve blocks for surgery over the chest. Patients will have an ultrasound scan and nerve block with local anesthetic (LA) agent (0.25% levobupivacaine 20ml) injected 2 target sites through one skin puncture. One at the myofascial plane between the pectoralis major and minor (10ml of LA) and then under direct ultrasound visualization, the needle will be redirected and the remaining 10ml of LA will be injected at the plane between the pectoralis minor and the serratus anterior muscle, close to the origin of thoracoacromial artery from the axillary artery at the level of the third rib.
223754403|NCT04941950|BEHAVIORAL|PlaySmart|PlaySmart is designed to provide players with behavioral skills and knowledge through repetitive and engaging videogame play to target adolescent perception of risk of harm from initiating opioid misuse.
223754404|NCT04941950|OTHER|Video Game Control|Participants in the control group will play another video game with no intended effect similar to PlaySmart.
223754405|NCT03699397|DIAGNOSTIC_TEST|Dry electrode EEG|A single dry electrode electroencephalography (EEG) will be performed in each patient that is included in this study. To do this, the investigators will use the WaveguardTM dry electrode EEG cap and compatible eegoTM amplifier, developed by ANT Neuro B.V. Netherlands and both CE marked as medical devices in the European Union (see appendices 1 and 2). Both products will be used within the intended use as described in the user manuals. The dry electrode cap is put on the patients head and records the EEG signal for several minutes; the amplifier is used to amplify the EEG signal and reduce artefacts.
223754406|NCT03762096|DIETARY_SUPPLEMENT|Trans-resveratrol|1 gram, twice a day by mouth Transmax (Biotivia)
223754407|NCT03762096|DIETARY_SUPPLEMENT|Placebo|Placebo
223754408|NCT06367348|BEHAVIORAL|Mlambe|A combined economic and relationship-strengthening intervention. Sessions consist of incentivized savings accounts, financial literacy training, and relationships skills building, including couple communication.
223754409|NCT05407623|BEHAVIORAL|PAX Good Behavior Game|"PAX GBG is packaged into ten specific tools that the teachers are trained to introduce in in their classroom management practice. The program introduces verbal and visual cues that facilitate prosocial and attentive behaviors One of the core elements of the program is the PAX-game, meaning that the children - while focusing on ordinary school tasks like math - get to play a game in teams where each team tries to make as few classroom rules infractions as possible during a certain period of time. The teams that succeed in achieving predetermined goals get a reward (often a fun and desirable activity) that serves as a reinforcer of prosocial and task-oriented behaviors.~Supervision is performed individually with each teacher and included that the PAX-trainer observes a lecture given by the teacher before each supervision session."
224200718|NCT04076982|OTHER|control biscuit|Participants were instructed to consume the test foods in the morning hours and to keep a record of the days the foods were consumed on a study calendar which was returned to investigators at the final visit and used to track protocol adherence.
224200719|NCT04177173|DRUG|Simvastatin 20 mg|improvement of disease activity
224200720|NCT04177173|DRUG|Methotrexate 10 mg|improvement of disease activity
224200721|NCT00864604|DRUG|Nabumetone 750 mg tablets, single dose|A: Experimental Subjects received Actavis Elizabeth LLC formulated products under fed conditions
224200722|NCT00864604|DRUG|Nabumetone 750 mg tablets, single dose|B: Active comparator Subjects received Teva formulated products under fed conditions
224200723|NCT03877848|DEVICE|Percutaneous Coronary Intervention (PCI)|Patients enrolled to the study will undergo angiography followed by PCI according to current guidelines.
223607610|NCT02009488|DRUG|Canagliflozin, 300 mg|One 300 mg capsule taken orally (by mouth) once daily
223607611|NCT02009488|DRUG|Placebo|One placebo capsule (inactive medication) once daily.
223607612|NCT02297386|DRUG|[18F] DIHYDRO-TESTOSTERONE|
223607613|NCT02297386|DEVICE|PET scan|
223607614|NCT02297386|DEVICE|MRI|
223607615|NCT02297386|OTHER|Blood draw|
223607616|NCT02399709|DRUG|simvastatin|
223607617|NCT02399709|DRUG|Placebo|
223607618|NCT01001117|DEVICE|LensAR laser surgery|Use of laser for cataract surgery
223607619|NCT01001117|DEVICE|Phaco-emulsification cataract surgery|Phaco-emulsification cataract surgery
223607620|NCT02922335|BEHAVIORAL|Multisystemic Therapy for Emerging Adults|MST-EA is a home-based therapy in which therapists work closely with each young adult. Therapists often also work with the young person's family, as appropriate. MST-EA is designed to help young people work on their own behavior. This treatment also involves the use of coaches who help young people develop skills for young adulthood.
223607621|NCT02922335|BEHAVIORAL|Enhanced Treatment as Usual|Standard services that a young person would receive if they have been in trouble with the law and also have a mental illness.
223607622|NCT01395901|DRUG|Palonosetron|Single dose Palonosetron IV 1 mcg/kg (up to a maximum total dose of 0.075 mg)
223607623|NCT01395901|DRUG|Ondansetron|"Single dose Ondansetron IV:~* 0 months to 12 years dose: 0.1 mg/kg for ≤ 40 kg and 4 mg for \>40 kg;~* 13 years to less than 17 years dose: 4 mg"
223607624|NCT01395901|DRUG|Placebo to Ondansetron|
223607625|NCT01395901|DRUG|Placebo to Palonosetron|
223607626|NCT03923790|BEHAVIORAL|Educational Packet|The patient will receive an educational packet.
223607627|NCT03923790|BEHAVIORAL|Phone call at 72 hours by discharge nurse navigator|Patients will receive a phone call at 72 hours by the discharge nurse navigator (standard of care) to assure that they have received their medications and follow-up appointments
223607628|NCT03923790|BEHAVIORAL|Telehealth visit at 7 days, 1 month, 3 months, and 5 months after discharge|A stroke prevention trained nurse practitioner or MD or social worker will review the participant's hospital records and depression, dietary, and sleep apnea screens,will reinforce the care plan based on patient-specific needs.They will counsel patients on salt reduction, the Mediterranean diet, and the importance of diet and exercise for stroke prevention.Along with the pharmacist they will also review the BP data to determine the need for medication adjustment and will discuss the side effects and interactions.The social worker will assess the need for medication assistance and other resources. The care plan will be shared with primary care providers (PCP)and patients will be referred to a PCP if they do not have one. The social worker will also will assist uninsured patients in applying for Texas County Indigent Care programs.
223607629|NCT03923790|BEHAVIORAL|Educational messages every other week|The messages will be sent to the participants cellular phones and will contain one of the following: a reminder to monitor BP, information from about lifestyle and diet for BP reduction, or a message from the pharmacist about medication adherence
223607630|NCT03923790|DIAGNOSTIC_TEST|BP monitoring by QardioARM with periodic transmission of BP data|Participants will be prompted to transmit BP logs through the telemonitoring device every 2 weeks until average BP is \< 130/80, then monthly thereafter. Uncontrolled BP will prompt a call from the pharmacist to discuss medication adherence and the need for further titration.
223607631|NCT05759494|DIAGNOSTIC_TEST|rapid diagnostic test (multiplex PCR filmArray)|"novel diagnostic platform, the FilmArray®, which combines automated sample preparation, nucleic acid extraction and PCR-based detection of 31 separate targets from a single unprocessed sample in one hour. It combines nesting and multiplexing of the PCR (referred to here as nested multiplex or nmPCR) together with DNA melting curve analysis."
223607632|NCT04775485|DRUG|Tovorafenib|Tovorafenib is an oral Type II RAF kinase inhibitor available in 100 mg immediate-release tablet or 25 mg/milliliter (mL) powder for reconstitution.
223607633|NCT00873600|DRUG|chemotherapy|
223607634|NCT00873600|OTHER|medical chart review|
223607635|NCT00873600|OTHER|questionnaire administration|
223607636|NCT00873600|PROCEDURE|adjuvant therapy|
223607637|NCT00873600|PROCEDURE|assessment of therapy complications|
223607638|NCT00873600|PROCEDURE|cognitive assessment|
223607639|NCT00873600|PROCEDURE|psychosocial assessment and care|
223607640|NCT00873600|PROCEDURE|quality-of-life assessment|
223607641|NCT02279667|DRUG|BIA 2-093|oral suspension 50 mg/mL
223607642|NCT02279667|DRUG|BIA 2-093|200 mg tablet
223607643|NCT02279667|DRUG|BIA 2-093|800 mg tablet
224200724|NCT03113201|BEHAVIORAL|Collaborative care|Collaborative care provided by the general practitioner and the care manager. Treatment modalities: Cognitive-behavior Therapy, psychoeducation and medication according to a stepped care model
224200725|NCT03113201|BEHAVIORAL|Consultations-Liaison|Consultation-Liaison provided by general practitioner involving a educational relationship with the Collabri Flex team (care manager and psychiatrist).
224200726|NCT05902767|OTHER|Nuts|"* A mix of nuts containing 1 Brazil nut (\~3g), walnuts (15g), hazelnuts (7g), and almonds (7g) to be consumed daily for 90 days.~* Dietary counselling on how to follow the Australian Dietary Guidelines"
224200727|NCT05902767|OTHER|Control|\- Dietary counselling on how to follow the Australian Dietary Guidelines
223607644|NCT03686293|OTHER|Standardized breakfast|One tablet of paracetamol (500 mg) and a glass of water (150 mL) is consumed followed by a breakfast consisting of white bread, butter, jam, and juice (300 mL) and
223607645|NCT01267305|DRUG|Fondaparinux|2.5mg IH qd(8AM) after operation
223607646|NCT01267305|DRUG|Nadroparin Calcium|4100AxaIU IH qd(8AM) after operation
223607647|NCT01267305|DRUG|Nadroparin Calcium|4100AxaIU IH q12h(8Am,8Pm) after operation
223607648|NCT00713544|DRUG|AZD5672|20 mg oral, once daily
223607649|NCT00713544|DRUG|Etanercept|50 mg, subcutaneous injection, weekly
223607650|NCT00713544|DRUG|Placebo|placebo, oral, once daily
223607651|NCT00713544|DRUG|AZD5672|50 mg oral, once daily
223607652|NCT00713544|DRUG|AZD5672|100 mg oral, once daily
223607653|NCT00713544|DRUG|AZD5672|150 mg oral, once daily
223607654|NCT04799249|DRUG|Trilaciclib|Trilaciclib administered IV over 30mins prior to chemotherapy on Day 1 and Day 8 of each 21-day cycle.
223607655|NCT04799249|DRUG|Placebo|Placebo administered IV over 30mins prior to chemotherapy on Day 1 and Day 8 of each 21-day cycle.
223607656|NCT04799249|DRUG|Gemcitabine|Gemcitabine administered IV on Day 1 and Day 8 of each 21-day cycle.
223607657|NCT04799249|DRUG|Carboplatin|Carboplatin administered IV on Day 1 and Day 8 of each 21-day cycle.
223607658|NCT06303102|OTHER|Manual PT/ Conventional PT Treatment + Segmental and Pursed Lip Breathing Exercise|20 patients will receive conventional physical therapy treatment (hot pack, electrical stimulation, myofascial release, ROM and strengthening exercises) along with segmental and pursed lip breathing exercises.
223607659|NCT06303102|OTHER|Manual PT/Conventional PT Treatment|20 patients will receive conventional physical therapy treatment (hot pack, electrical stimulation, myofascial release, ROM and strengthening exercises).
223607660|NCT02380287|DRUG|humanized monoclonal antibody against human IL-17|
224200728|NCT03469440|OTHER|Continuous central venous oxygenation monitoring|"Central venous oxygen saturation will be targeted higher than 65% in non-cyanogenic patients and 55% in cyanogenic.~* First, isotonic crystalloid, 10 up to 20 mL/kg, will be administered in boluses to achieve continuous central venous oxygen saturation higher than 65% in non-cyanogenic and 55% in cyanogenic.~* Second, if not achieved with fluid administration, will be targeted by initiating and titrating inotropics (dobutamine or milrinone). If the mean arterial pressure is lower than 50 mm Hg will be associated epinephrine.~* If the ScvO2 is lower than 65% in non-cyanogenic and 55% in cyanogenic and the hemoglobin was lower than 8g/dl, red blood cells (20mL/Kg) will be transfused to achieve a hemoglobin level of at least 8g/dL."
223607661|NCT05767840|OTHER|psychological interventions|"mhGap-IG Depression and self-harm module. For participants identified as has having depression, following interventions will be offered depending on nature of the participants.~1. Khushi Aur Khatoon - for the treatment of depression and anxiety~2. Learning through Play Plus - 10-session group intervention that integrates parental information about child development and Cognitive Behavior Therapy~3. Problem management Plus (PM+) - PM+ is for adults suffering from symptoms of common mental health problems , as well as self-identified practical problems.~Cohort identified as having a recent history of self-harm will receive; Culturally Adapted Manual Assisted Problem Solving Intervention (CMAP) - This intervention is a manual-assisted intervention, adapted from a self-help guide called Life After Self-Harm."
223607662|NCT05074160|DEVICE|OCS Liver|Multi-center, observational post-approval registry of adult primary liver transplant recipients who are transplanted with an OCS Liver-perfused DBD or DCD donor liver according to the approved indication and that match the eligibility criteria below.
223607663|NCT04293341|BEHAVIORAL|Transdiagnostic Behavior Therapy|TBT was developed to address transdiagnostic avoidance via the use of four different types of exposure techniques (situational/in-vivo, physical/interoceptive, thought/imaginal, and \[positive\] emotional/behavioral activation). From the transdiagnostic avoidance perspective, the four exposure practices are matched to the type(s) of avoidance experienced by patients based upon their cluster of symptoms/disorders.
223607664|NCT04293341|BEHAVIORAL|Cognitive Processing Therapy for PTSD|CPT is a well established evidence-based psychotherapy for PTSD. CPT focuses on teaching patients to evaluate and change the upsetting thoughts that they have had since their trauma.
223607665|NCT04293341|BEHAVIORAL|Cognitive Behavioral Therapy for MDD|CBT for MDD is a well established evidence-based psychotherapy for depression. CBT for MDD focuses teaching patients how to change their behaviors and challenge their negative thoughts to improve their mood.
223607666|NCT04293341|BEHAVIORAL|Cognitive Behavioral Therapy for Panic Disorder|CBT for Panic Disorder is a well established evidence-based psychotherapy. CBT for Panic Disorder focuses teaching patients how to change their behaviors through exposure practices and challenge their anxious thoughts to reduce their experience of panic attacks and avoidance.
223607667|NCT03384368|DEVICE|fractured level screws-distraction|four pedicle screws were implanted into the upper vertebra and the lower vertebral body of the fractured vertebra. Then, immediate reduction and decompression were achieved by applying distraction of rod. Finally, two additional screws were introduced at fracture level
223754410|NCT05407623|BEHAVIORAL|Count on Me!|"Count on me! is set in adventure game where the child has an avatar that travels thru different worlds/platforms by using their mathematical skills. The child starts of in the home of the avatar, in a house like environment, where the child discovers a magical map that brings the child into a different world called Numberia. During the adventures in Numberia the child learns that it has certain skills, called the mathemagical powers, that will be used to liberate Numberia from the evil Prince Claw that has captured all the beautiful things (e.g., the birds that used to sing in the forest).~Count on me! was developed within a behavior analytic framework using a nonlinear programming process."
223754411|NCT05407623|BEHAVIORAL|Collegial Learning Community|"Collegial learning community is a feasible way of professional learning for teachers according to the five cyclical steps. The teachers go through the first step that is to assess the skill or knowledge gaps for students, using various data sources (for example testing, grades, surveys, student interviews). The second step is to reflect upon what skills the teacher needs to acquire in order to help the students to meet the goals. The third step is to deepen the professional knowledge and skills. The fourth step is engaging the students in the new practice, and in the fifth step to evaluate the impact the new practice has had on student outcomes.~In Collegial learning community teachers take help from their peers in each of these steps in a structured way. For example, way of deepening tacit or procedural knowledge (in step two) is to visit a colleague during class and make observations on their classroom practice."
223754412|NCT06024668|DEVICE|Multiplexing Prism|"Multiplexing prism is designed for spatial vision multiplexing. It allows partial light transmission through the prism allow the observer to simultaneously see the physical world through the prism and see the shifted view from the non-seeing side. It is developed to expand the field of view of individuals with just one eye."
223754413|NCT02530983|OTHER|Mayo Clinic Upper Digestive Disease Survey on Paper|Mayo Clinic patients will be asked to complete the Mayo Clinic Upper Digestive Disease Survey at their one month surgical follow up visit and then every three months for 1 year after surgery, then with each surveillance clinic visit or a minimum of once per year for their lifetime. The questionnaire can be completed at their clinic visit, over the telephone, or by mail. The patient's medical record will also be reviewed to gather any other contributing information.
223754414|NCT02530983|OTHER|Upper Digestive Disease (UDD Monitor) App|"Mayo Clinic and non Mayo Clinic patients can participate by loading the app through the app store. Patient consent will be completed in the app. Patients will be asked to complete questionnaires at their 1.5 month surgical or diagnosis follow up and then every three months for 1 year after their surgery or diagnosis, then with each surveillance clinic visit or a minimum of once per year for their lifetime or as long as they want to participate.~for iOS: https://apps.apple.com/us/app/upper-digestive-disease/id6448756724 for Android: https://play.google.com/store/apps/details?id=com.mayoclinic.uddmobile\&pli=1"
223754415|NCT04203381|DEVICE|GnRH Agonist|Forty participants who are transgender and who have been prescribed a gonadotropin-releasing hormone (GnRH) agonist by their physician will undergo magnetic resonance imaging (MRI), magnetic resonance spectroscopy (MRS), dual-energy x-ray absorptiometry (DXA) and peripheral quantitative computed tomography (pQCT) scans at baseline, at 12 months and at 24 months after initiation of the GnRH agonist therapy. This longitudinal observational study of two cohorts seeks to identify significant changes in bone marrow adiposity and bone density over 24 months. The same assessments will be obtained in 40 healthy control subjects matched for age, race/ethnicity and body mass index, all factors that are known to influence skeletal outcomes. The evaluations of bone marrow adiposity will be correlated with bone density measurements and the assessments of mood (validated anxiety and depression scales) and health-related quality of life, before and after pubertal blockade.
223754416|NCT05862766|DRUG|Isatuximab|The dose will consist of isatuximab 10 mg/kg actual body weight given weekly for the first 4 weeks, followed by 10 mg/kg biweekly for an additional 4 doses. Isatuximab is a clear, colorless to slightly yellow solution. It is supplied as 100 mg/5 mL or 500 mg/25 mL single-dose vials.
223607668|NCT04768621|OTHER|Questionary|Questions about patient health after wintering in Southern and Antarctic French Lands about social and demographics items, psychologic and psychiatric items, sleep disorders, immunological disorders,and endocrinologic disorders, sociological consequences of wintering
223607669|NCT01641601|DEVICE|Outpatient transcervical Foley balloon|A 30 cc transcervical Foley balloon will be placed in the outpatient setting prior to labor induction.
223607670|NCT04977713|OTHER|Acupressure|A researcher sat behind the women to comfortably access the sacral area and be in the appropriate position. The researcher then applied deep rotational pressure on the BL32 points until her nail bed colour changed to prevent any discomfort in the participants
223607671|NCT04977713|OTHER|Shower|During uterine contractions, these participants took a shower while standing, with a researcher on hand to assist her (average time: 20 minutes). The water's temperature was between 22°C and 26°C.
223607672|NCT04577469|DRUG|Maldox tablets|500 mg sulfadoxine / 25 mg pyrimethamine to be given as single dose once under fasting condition
223607673|NCT04577469|DRUG|G-COSPE® tablets|500 mg sulfadoxine / 25 mg pyrimethamine to be given as single dose once under fasting condition
223754417|NCT05862766|PROCEDURE|bone marrow biopsy|Bone marrow biopsy at the time of lung transplantation and at approximately 1 month following completion of therapy. Initial bone marrow biopsy to be performed during the lung transplant operation and to be collected from the sternum by the operating surgeon. Follow-up bone marrow biopsy to be completed by credentialed hematologist during a regularly scheduled follow-up bronchoscopy with standard procedural anesthesia sedation.
223754418|NCT05740787|OTHER|No intervention|Observation only
223607674|NCT00037492|PROCEDURE|home-based sessions/family meetings with trained clinician|
223754419|NCT04598035|DIAGNOSTIC_TEST|Diagnostic Tests|"1. Blood and Urine laboratory tests~2. ECG and blood pressure for cardiovascular measurements~3. Self-report questionnaires about pain"
223754420|NCT05383768|OTHER|preheated conventional bulk-fill resin composite, X-tra fill (VOCO, GERMANY) at 68◦C|"Intervention 1: restoration with one-time preheated conventional bulk-fill resin composite, X-tra fill (VOCO, GERMANY) at 68◦C (Yang et al., 2020).~Intervention 2: Restoration with five time preheated conventional bulk-fill resin composite, X-tra fill (VOCO, GERMANY) at 68◦C (Yang et al., 2020).~Intervention 3: Restoration with ten time preheated conventional bulk-fill resin composite, X-tra fill (VOCO, GERMANY) at 68◦C (Yang et al., 2020)."
223754421|NCT02662127|DEVICE|SIGVARIS® Class 2 - RAL: 23-32.|Below knee graduated elastic compression stocking
223754422|NCT02596594|DEVICE|fetal nutrition port system|Under local anesthesia a subcutaneous pouch for the port capsule was prepared using a pair of scissors. The umbilical vein was punctured with a 18 gauge needle under ultrasound control and the catheter was inserted into the umbilical vein. Note the amniotic cavity remained intact. A 25 gauge port needle was used to enter the port system. The treatment course included daily infusions of AA solution (Fresenius Kabi, Bad Homburg, Germany) with a 10% glucose solution. The investigators limited the volume of the intraumbilical infusion to 10% of the estimated feto-placental blood volume per day. On average, the AA/glucose-infusion was below 50 ml/kg.
223754423|NCT01952756|DRUG|Cilostazol|One tablet (100 mg) twice per day for 12 weeks
223754424|NCT01952756|DRUG|Dummy Placebo|One tablet twice per day for 12 weeks
223754425|NCT03261947|DRUG|TAK-931|TAK-931 hard gelatin capsules
223754426|NCT02059850|BIOLOGICAL|Autologous NY-ESO-1-specific CD8-positive T Lymphocytes|Given IV
223754427|NCT02059850|DRUG|Cyclophosphamide|Given IV
223607675|NCT05158517|DRUG|Subcutaneous vedolizumab|Patients will be switched from IV vedolizumab into subcutaneous vedolizumab
223607676|NCT05185726|BEHAVIORAL|Lidcombe Program|"The LP consists of Stage 1 and Stage 2. Stage 1 aims at reducing the stuttering of the PCWS to (near) zero levels of stuttering. During stage 1, parents learn to provide verbal contingencies during daily, 10-minute practice sessions with their PCWS.~During Stage 1, treatment sessions are scheduled weekly. When the child has typical scores of 0 and 1 on the SR-scale with more 0s than 1s per week for three consecutive weeks, and the stuttering is rated as 0 or 1 during the treatment session, the child can proceed to stage 2.~The maintenance phase starts when the stuttering is reduced to (near) zero stuttering and parents are able to implement the practice sessions when it is necessary (when stuttering relapses). Treatment sessions to monitor if achieved goals are maintained are scheduled with an interval of 2, 2, 4, 4, 8, 8 and 16 weeks."
223754428|NCT02059850|OTHER|Laboratory Biomarker Analysis|Correlative studies
223754429|NCT03967392|DRUG|Xylocaine|TREATMENT
223754430|NCT06110429|DRUG|Lactate, Sodium|Isovolemic and osmotic infusion Comparison of osmotic agent
223754431|NCT06110429|DRUG|Hypertonic saline|Isovolemic and osmotic infusion Comparison of osmotic agent
223754432|NCT03641144|DEVICE|Navigation laser|Navigation laser device is a scanning slit-based instrument.before treatment the surgeon plan laser spots on the screen based on image(infrared, colour, fluorescein angiography)and then apply automated patterns and single spots as appropriate.the device will automatically carry out the plan.
223754433|NCT03641144|DEVICE|Traditional laser|Traditional laser is a slitlamp based instrument.Surgeon operate traditional laer device while watching Participant's image(infrared, colour, fluorescein angiography) and then manually aim at and trigger laser.
223754434|NCT00289809|DRUG|combination of TLC D-99 and Ifosfamide|"* TLC D-99: 40 mg/m2 Day 1 every 3 weeks;~* Ifosfamide: 3000 mg/m2 Day 1, 2, 3 every 3 weeks"
224200729|NCT03469440|OTHER|Standard protocol|The control group will keep the standard therapy to achieve mean arterial pressure higher than 50mmHg, central venous pressure 8 to 12 mmHg, urinay debit higher than 0,5ml/kg/h, hemoglobin higher or equal than 8g/dL, arterial oxygen saturation higher or equal than 92% in non-cyanogenic and 80% cyanogenic, central venous oxygen saturation higher or equal than 65% in non-cyanogenic and 55% in cyanogenic.
224200730|NCT01506986|DRUG|Lansoprazole 30mg, Clarithromycin 500mg, Metronidazole 400mg|All three medications will be taken orally, twice daily, for seven days.
223754435|NCT00228917|BIOLOGICAL|Tritanrix-HepB/Hib-MenAC|Combined Diphtheria, Tetanus, Whole Cell Pertussis, Hepatitis B, Haemophilus influenzae Type b meningococcal AC-tetanus toxoid conjugate Vaccine
223754436|NCT00228917|BIOLOGICAL|Tritanrix-HepB/Hiberix|Combined Diphtheria, Tetanus, Whole Cell Pertussis, Hepatitis B Vaccine, Haemophilus influenzae type b conjugate vaccine
223754437|NCT00228917|BIOLOGICAL|Mencevax-ACWY|Meningococcal Serogroups A, C, W-135 and Y Vaccine
223607677|NCT05185726|BEHAVIORAL|Mini-KIDS|Mini-KIDS for 4-6-year old PCWS consists of four stages: Stage 1 = desensitization, Stage 2 = identification, Stage 3 = modification and Stage 4 = generalization. The program for 2-4-year old child does not include stage 2. SLT and parent(s) are the speech model for the child. They add normal disfluencies and pseudo-stuttering to their speech at first to make sure the child dares to stutter and the child as well as the parent(s) are desensitized for it. Later on in treatment and if necessary, child learn to recognise and alter their stuttering moments. The maintenance phase starts when the child and parent(s) achieved the goals of Stage 4. Usually the stuttering is reduced to (near) zero stuttering. Treatment sessions to monitor if achieved goals are maintained are scheduled with an interval of 2, 2, 4, 4, 8, 8 and 16 weeks.
223607678|NCT05185726|BEHAVIORAL|Social Cognitive Behavioural Therapy|"A parent training is organised for parents with children who stutters who receive SCBT.~The parent training exists of 10 one-hour group evening sessions for parents to discuss and offer education topics about what stuttering is, how stuttering looks like, ...~The program is delivered in 5 phases and each phase takes as long as is necessary for the PCWS (variable): (1) conditioning speaking activities, (2) cognitive training focused on emotions, (3) cognitive training focused on cognitions, (4) emotional training and (5) skill training.~The maintenance phase starts when the child and parent(s) achieved the goals of the 5 phases. During the maintenance sessions, the SLT asks the parent(s) to report about the child and observes the speech of the child."
223754438|NCT04462809|DRUG|Talazoparib|"Talazoparib 1 mg a day (PO) (or 0.75 mg a day) for 2 years, started between 6 to 8 weeks after the end of chemotherapy discontinuation.~Talazoparib will be given for up to 2 years, or less length of time in the case of disease progression,.~unacceptable toxicity despite adequate management,patient decides to withdraw from the study, or general or specific changes in the patient's condition render the patient unacceptable for further treatment."
223754439|NCT00716911|DRUG|ganciclovir|
223607679|NCT01591941|OTHER|Core-PAC|"Core position and control movement strategy (Core-PAC):~Do warm-up prior to 6 weeks of regular soccer training for peak flexion angles and peak abduction moments at the knee during a side-cut (SC) and an unanticipated side-cut (USC) prior to kicking a soccer ball and a side-hop (SH) task."
223607680|NCT02123849|DRUG|Aspirin|Given PO
223607681|NCT02123849|OTHER|Laboratory Biomarker Analysis|Correlative studies
223607682|NCT02123849|OTHER|Placebo|Given PO
223754440|NCT00716911|GENETIC|polymerase chain reaction|
223754441|NCT00716911|OTHER|flow cytometry|
223754442|NCT00716911|OTHER|immunologic technique|
223754443|NCT00716911|PROCEDURE|allogeneic bone marrow transplantation|
223754444|NCT00716911|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
223754445|NCT00716911|PROCEDURE|assessment of therapy complications|
223754446|NCT00716911|PROCEDURE|peripheral blood stem cell transplantation|
223754447|NCT03857984|OTHER|Blood sampling|blood sample before and after a single HD
223607683|NCT03469466|DIAGNOSTIC_TEST|bedside ultrasound|bedside ultrasound imaging of the lungs
223754448|NCT04025996|DIAGNOSTIC_TEST|Cardiac Assessments and Eye Assessments|"Cardiac Assessments, include the following:~* transthoracic echocardiography~* computed tomography of coronary arteries~* position emission tomography computed tomography or single photon emission tomography computed tomography~Eye examinations, include the following:~* pupil dilation~* retinal photography~* dynamic vessel analyser~* IOL master"
223754449|NCT00409617|BIOLOGICAL|adalimumab|Adalimumab 40 mg Every Other Week dosing
223754450|NCT00409617|BIOLOGICAL|adalimumab|Adalimumab 40 mg Every Week dosing if participant experiences a disease flare or is not responding to treatment. A disease flare is defined as an increase of 3 points or more on the HBI compared to the Baseline score and a total HBI score of 7 or higher. Non-response is defined as a decrease by fewer than 3 points in the HBI compared to Baseline.
223754451|NCT04244513|DEVICE|Deep brain stimulation|the HD-DBS arm will be routinely activated after surgery and then stimulated for 6 months(6 months stimulation). The HD-shamDBS arm will be re-launched 3 months after surgery, continued stimulation for 3 months(3 months stimulation), and then entered the open study.
223754452|NCT03917420|DRUG|Tenofovir 300Mg Oral Tablet|Once daily dose of the combo tab x 5 days pre-sampling
223754453|NCT03917420|DRUG|Emtricitabine 200 MG|Once daily dose of the combo tab x 5 days pre-sampling
223754454|NCT02487238|BIOLOGICAL|Fecal Microbiota Enema|Active intervention.
223754455|NCT02487238|BIOLOGICAL|Normal Saline Enema|Placebo comparator.
223754456|NCT03282292|PROCEDURE|Internal jugular vein CVC insertion|Double lumen CVC insertion in the internal jugular vein
223754457|NCT00525668|DRUG|epigallocatechin-gallate (Sunphenon)|200 mg twice daily, after 3 months 400 mg twice daily
223754458|NCT00525668|DRUG|placebo|2 placebo capsules twice daily, after 3 months 4 placebo capsules twice daily
223754459|NCT02758392|DRUG|JNJ-61178104 Intravenous|Participants will receive JNJ-61178104 Intravenously on Day 1.
223754460|NCT02758392|DRUG|JNJ-61178104 Subcutaneous|Participants will receive JNJ-61178104 Subcutaneously on Day 1.
223754461|NCT02758392|DRUG|Placebo|Participants will receive placebo on Day 1.
223754462|NCT02319005|DRUG|Revusiran (ALN-TTRSC)|
223754463|NCT02319005|DRUG|Sterile Normal Saline (0.9% NaCl)|
223754464|NCT01152463|PROCEDURE|thoracic ultrasound|daily thoracic ultrasound evaluation of the chest
223754465|NCT00902642|BEHAVIORAL|an eight day university training course designed to integrating psychosocial factors in clinical practice on a patient level|an eight day university training course on psychosocial factors for physical therapists
223754466|NCT05464654|DRUG|3 g Polynucleotide vaginal suppositories|3 g polynucleotide vaginal suppositories were administered nightly for 6 days.
223754467|NCT05464654|DRUG|Conjugated estrogens cream 1g Tube|Conjugated estrogen cream 1g was applied intravaginally on Monday, Wednesday and Friday for three months.
223754468|NCT03657355|DRUG|ACT-541468|ACT-541468 will be administered as 50 mg tablets for oral use.
223754469|NCT03657355|DRUG|Suvorexant|Suvorexant will be administered as 15 mg over-encapsulated tablets for oral use.
223754470|NCT03657355|DRUG|Zolpidem|Zolpidem will be administered as 10 mg over-encapsulated tablets for oral use.
223754471|NCT03657355|DRUG|Placebo|Matching-placebo will be used.
223754472|NCT03373383|DRUG|Padsevonil|Padsevonil in different dosages.
223754473|NCT03373383|OTHER|Placebo|Placebo will be provided matching Padsevonil.
223607684|NCT00950846|DRUG|Busulfan|"Day -9, -8, -7 and -6~Patients less than or equal to 12 kg: 1.1 mg/kg/dose IV every 6 hours for 16 doses total; patients \>12 kg: 0.8 mg/kg/dose IV every 6 hours for 16 doses."
223607685|NCT00950846|DRUG|Cytoxan|(50 mg/kg/dose) will be given IV on Days -5, - 4, -3, and -2 over 2 hours (can be given over 1 to 4 hours as determined by the treating physician). The total dose to be given over 4 days is 200 mg/kg.
223607686|NCT00950846|DRUG|Fludarabine|40 mg/m2/day IV over 1 hour for patients greater than 10 kg, or 1.3 mg/kg/day for patients less than or equal to 10 kg.
223754474|NCT04499586|COMBINATION_PRODUCT|Radiotherapy Combined With Raltitrexed and Irinotecan|Each cycle lasts 3 weeks. Raltitrexed: 3mg/m2 per week. Irinotecan : 80mg/m2 (UGT1A1\*28 6/6) or 65mg/m2 (UGT1A1\*28 6/7) per week. Radiation: 45-55Gy/25-30Fx
223754475|NCT00656006|DRUG|Albuferon|
223754476|NCT00656006|DRUG|Ribavirin|
223754477|NCT02438748|DEVICE|Repetitive Transcranial Magnetic Stimulation|A non-invasive method of brain stimulation.
223754478|NCT03818516|OTHER|Oral Glucose Tolerance Test (OGTT)|Participants will undergo a fasting blood draw for inflammatory and metabolic markers before a 75gm oral glucose tolerance test (OGTT) and at 1, 2 and 3 hours post-OGTT. Behavioral assessments will also be administered pre- and post-OGTT administration.
223754479|NCT01944995|DEVICE|glasses broadband|
223754480|NCT01944995|DEVICE|nasal CPAP|
223754481|NCT06244069|DIAGNOSTIC_TEST|Temporal arterial biopsy|Collection of 30 ml of peripheral blood in ethylenediaminetetraacetic acid (EDTA) tubes performed at baseline, 6 months, 12 months and in case of flare before month 12. In addition, the temporal artery specimen (at least 5 mm in length) exceeding that used for clinical activity (at least 10 mm in length in accordance with current clinical recommendations) will be digested to use for research purposes (about protocols for collecting, processing, storing and sending biopsy, refer to Standard Operating Procedures, SOP).
223754482|NCT06244069|DIAGNOSTIC_TEST|Whole exome sequencing|"Patients with CHIP will be identified and characterized by using whole exome sequencing from the peripheral blood samples. M-CHIP will be further characterized by:~i) clone dimension as defined by Variant Allele Fraction (VAF); ii) mutations in specific genes such as DNMT3A, Tet methylcytosine dioxygenase 2 (TET2), Additional Sex combs (ASXL1), or Janus kinase 2 (JAK2); iii) multiple mutations.~L-CHIP will be further characterized by:~i) clone dimension as defined by the VAF; ii) mutations in specific genes such as Dual Specificity Phosphatase 22 (DUSP22), FAT atypical cadherin 1 (FAT1), (Histone-lysine N-methyltransferase 2D (KMT2D); iii) multiple mutations; iv) co-occurrence of mutations heralding M- and L-CHIP."
223754483|NCT06244069|DIAGNOSTIC_TEST|Single cell transcriptomics|The investigators will identify actively inflamed arterial biopsies from three treatment-naïve patients without CHIP, and three treatment-naïve patients with CHIP driven by the most relevant gene mutation. Arterial wall Cluster of Differentiation (CD) 45+ leukocytes will be isolated after digestion of arterial tissue and characterized by single cell transcriptomics, with a specific focus on wall infiltrating T cells and macrophages and their subsets (eg: Vascular dendritic cells, Th1, Th2, Th17, Treg, M1- and M2-like,…). Frequencies of these subsets and their genetic expression will be compared between wall-infiltrating leukocytes from GCA patients with or without CH, focusing on histological events supposed to be pathogenic in GCA, or known to be dysfunctional in CHIP.
223754484|NCT04372602|DRUG|Duvelisib|-For patients unable to administer orally, a duvelisib suspension will be administered through a nasogastric/orogastric tube.
223754485|NCT04372602|PROCEDURE|Peripheral blood draw|"* First 10 patients enrolled~* Screening, Day 2, Day 4, Day 8, Day 10, Day 15, and Day 29"
223754486|NCT04372602|DRUG|Placebo|-Provided by Verastem
224200731|NCT01506986|DRUG|Placebo lansoprazole 30mg, clarithromycin 500mg, metronidazole 400mg|Medication to be taken orally, twice a day, for seven days.
223607687|NCT00950846|PROCEDURE|Cord Blood Stem Cell Infusion|The cord blood stem cells will be infused on Day 0.
223754487|NCT04065789|DRUG|Carfilzomib|Carfilzomib on Days 1, 8, 15, of cycle numbers 1-9 and Days 1 and 15 only of cycle numbers 10-18, at a dose of 20 mg/m2 on day 1 of cycle 1; at dose of 56 mg/m2 on all subsequent once weekly dosing days. The quadruple regimen treatment will be administered for 18 cycles.
223754488|NCT04065789|DRUG|Daratumumab|Daratumumab : 16 mg/Kg weekly for 8 weeks, then every 2 weeks for 16 weeks, and then every 4 weeks thereafter. The quadruple regimen treatment will be administered for 18 cycles.
223754489|NCT04065789|DRUG|Lenalidomide|Lenalidomide (25 mg), administered on days 1-21 of 28-day cycle.In frail patients, Lenalidomide dose will be reduced according to 15 mg . The quadruple regimen treatment will be administered for 18 cycles.
223754490|NCT04065789|DRUG|Dexamethasone|Patients will be treated with IV or oral dexamethasone (20 mg for fit and INT-FIT, 10 mg for frail), administered on Days 1-2, 8-9, 15-16, and 22-23 of each 28-day cycle for cycles 1-2 followed by weekly 20 mg dexamethasone on subsequent cycles; In frail patients, dexamethasone will be reduced to 10 mg . The quadruple regimen treatment will be administered for 18 cycles.
224200732|NCT06488417|DIETARY_SUPPLEMENT|Frankincense essential oil + boswellic acid supplement|This supplement contains frankincense essential oil and boswellic acid as its active ingredients.
223754491|NCT03305510|DIAGNOSTIC_TEST|vitamin D is below 20ng/ml|
224200733|NCT06488417|DIETARY_SUPPLEMENT|Frankincense essential oil supplement|This supplement contains frankincense essential oil as its active ingredient.
224200734|NCT05413395|OTHER|topical colloidal oatmeal formulation with a modified plant oil|"Standard-of-care (SOC), over-the-counter (OTC) topical colloidal oatmeal formulation with a modified plant oil (Activated Oil, AO). The AO contains proprietary blends of plant oils that have selective antimicrobial properties."
224200735|NCT05413395|OTHER|topical colloidal oatmeal formulation|Standard-of-care (SOC), over-the-counter (OTC) topical colloidal oatmeal formulation
224200736|NCT04682210|DRUG|Sintilimab|Sintilimab 200mg IV Q3W
224200737|NCT04682210|DRUG|Bevacizumab|Bevacizumab 7.5mg/kg IV Q3W
224200738|NCT05533112|OTHER|Binaural Beat Stimulation|During binaural beats stimulation both ears receive a tone which varies slightly in its frequency. If the left ear is stimulated with a sinusoidal wave of 98 Hz and the right ear with a sinusoidal wave of 108 Hz, the brain will perceive this stimulation as a single tone at the mean frequency of 103 Hz. The amplitude of the perceived tone will fluctuate with a frequency that is equal to the difference of the two initial tones, i.e., 10 Hz
223607688|NCT05809843|DEVICE|hybrid artificial pancreas systems (CSII)|artificial device that adjust the patient's glycemic levels with insulin doses appropriate to the patient's blood glucose
223607689|NCT05041283|OTHER|Chatbot|A artificial-intelligence based chatbot is provided 3 days before colonoscopy to answer questions concerning bowel preparation and colonoscopy conduct.
223607690|NCT05041283|OTHER|Phone call|A phone call is performed every day starting at 3 days before colonoscopy to support bowel preparation.
223607691|NCT01278563|BEHAVIORAL|Low glycemic index diet|dietitian interview and counselling for the low glycemic index diet group
223607692|NCT05408390|OTHER|LPD+LED|Low physical density (LPD) + low energy density (LED) foods. Participants receive breakfast, lunch and snack items engineered to have LPD and LED.
223607693|NCT05408390|OTHER|HPD+LED|High physical density (HPD) + low energy density (LED) foods. Participants receive breakfast, lunch and snack items engineered to have HPD and LED.
223607694|NCT05408390|OTHER|LPD+HED|Low physical density (LPD) + high energy density (HED) foods. Participants receive breakfast, lunch and snack items engineered to have LPD and HED.
223607695|NCT05408390|OTHER|HPD+HED|High physical density (HPD) + high energy density (HED) foods. Participants receive breakfast, lunch and snack items engineered to have HPD and HED.
223607696|NCT01799226|OTHER|Toothpaste without triclosan|this intervention will use a toothpaste without triclosan
223607697|NCT01799226|OTHER|Triclosan|this intervention will use Colgate Total which contains triclosan
223607698|NCT02137824|PROCEDURE|sinus floor elevation|
223754492|NCT04483024|DIETARY_SUPPLEMENT|Collagen hydrolysate and chicken extract|One bottle (68mL) of collagen hydrolysate (2g) in chicken extract taken daily in the morning after meal for 24 weeks
223607699|NCT02987751|DRUG|Glargine + Glulisine|Glargine should be taken 30 minutes before breakfast/dinner, the dose is adjusted as per fasting blood glucose during each visit and Glulisine should be taken 20 minutes before breakfast/dinner, the dose is adjusted as per postprandial blood glucose during each visit
223607700|NCT02987751|DRUG|Premixed analogue insulin (70/30)|Premixed analogue insulin should be taken 30 minutes before breakfast/dinner, the dose is adjusted as per fasting blood glucose during each visit.
223607701|NCT01115868|DRUG|Prevascar 5ng|100uL of 5ng/100uL Prevascar per linear centimetre wound margin injected intradermally.
223607702|NCT01115868|DRUG|Prevascar 25ng|• 100uL of 25ng/100uL Prevascar per linear centimetre wound margin injected intradermally.
223607703|NCT01115868|DRUG|Prevascar 100ng|• 100uL of 100ng/100uL Prevascar per linear centimetre wound margin injected intradermally.
223754493|NCT04966676|DIAGNOSTIC_TEST|cfDNA blood test|Blood sample will be taken for cfDNA testing
223754494|NCT04966676|DRUG|Nivolumab|Antineoplastic agent
223754495|NCT04966676|DRUG|Ipilimumab|Antineoplastic agent
223754496|NCT04966676|COMBINATION_PRODUCT|Platinum-based Chemotherapy|May include carboplatin with gemcitabine, or paclitaxel or pemetrexed
223754497|NCT03063996|PROCEDURE|peripheral IV access procedure|standard of care guided IV access into peripheral vein excluding IJ
223754498|NCT03063996|PROCEDURE|Peripheral IJ access procedure|standard of care guided IV access into IJ
223754499|NCT01219725|BEHAVIORAL|Exercise training|6 months of moderate intensity exercise training 3 times per week
223754500|NCT05564793|DEVICE|Pre-implantation planning|ECGi mapping using the CE marked Amycard 01C device and a contrast enhanced CT
223754501|NCT05564793|DEVICE|Post-implantation assessment|ECGi mapping using the CE marked Amycard 01C device and a non-contrast CT
223754502|NCT06135168|DRUG|PEG-rhGH with new preparation|A single subcutaneous injection of PEG-rhGH with new preparation
223754503|NCT06135168|DRUG|PEG-rhGH with present preparation|A single subcutaneous injection of PEG-rhGH with present preparation
223754504|NCT01633697|BEHAVIORAL|Pranayama|Specific yoga-related breathing method.
223754505|NCT01633697|BEHAVIORAL|Education alone|No special attention to breathing
223754506|NCT02907359|DRUG|Guadecitabine|
223754507|NCT02907359|OTHER|Treatment Choice|"* BSC: according to standard/institutional practice; included RBC or platelet transfusions; growth factors, i.e. erythropoiesis stimulating agents, granulocyte stimulating factors, iron chelating therapy; broad spectrum antibiotics and/or antifungals.~* LDAC: 20 mg/m\^2 SC or IV once daily (QD) for 14 days in 28-day cycles. Other schedules were allowed per institutional practice. Treatment for ≥4 cycles absent disease progression/toxicity. BSC per institutional/standard practice.~* Standard Intensive Chemotherapy: recommended regimen of 7+3 was given as cytarabine 100-200 mg/m\^2/day continuous infusion for 7 days and an anthracycline for 3 days. Anthracyclines per institutional practice included daunorubicin (45-60 mg/m\^2/day) or idarubicin (9-12 mg/m\^2/day) or mitoxantrone (8-12 mg/m\^2/day) by IV infusion. Participants with complete or partial response after IC induction received ≥1 additional cycles with reduced cytotoxic doses then BSC per standard /institutional practice."
224200739|NCT02202902|OTHER|1H magnetic resonance spectroscopy and CMRI|Metabolic status of the patients evaluated by an OGTT (measuring plasma glucose, insulin and plasma nonesterified fatty acids concentrations) and myocardial Imaging and spectroscopy will be performed before and 6 month after treatment
223607704|NCT01115868|DRUG|Prevascar 250ng|• 100uL of 250ng/100uL Prevascar per linear centimetre wound margin injected intradermally.
223607705|NCT02178995|DRUG|Methylphenidate|"Participants with epilepsy will first receive blinded, single-dose capsules which contain either:~Placebo 20mg of methylphenidate or 10mg of methylphenidate.~At each visit, they will receive one capsule and then complete the neurocognitive batteries and neuropsychiatric questionnaires. There will be no medication administered between visits during this time. Following the final randomized visit, interested participants will be prescribed 10mg of methylphenidate twice daily, to be increased to 20mg of methylphenidate twice daily. After four weeks, their scores on the batteries and questionnaires will again be assessed."
223607706|NCT05699824|DRUG|Carvedilol Day2|Carvedilol will be initiated on day 2, at a dose of 3.125mg twice a day (6.25mg/day), along with standard management as per institutional protocol for AVB.
223607707|NCT05699824|OTHER|Standard Medical Treatment|All patients to receive Inj. Terlipressin, 1 mg at 4 hours along with standard management for acute variceal bleed as per institutional protocol. Standard Medical Treatment
223607708|NCT05699824|DRUG|Carvedilol Day6|Carvedilol will be initiated on day 6, at a dose of 3.125mg twice a day (6.25mg/day), along with standard management as per institutional protocol for AVB.
224200740|NCT02202902|OTHER|1H magnetic resonance spectroscopy and CMRI|Metabolic status of the patients evaluated by an OGTT (measuring plasma glucose, insulin and plasma nonesterified fatty acids concentrations) and myocardial Imaging and spectroscopy will be performed before treatment
223754508|NCT05866120|OTHER|Physiotherapy on the ground|Physical therapy will be performed on the ground, in 12 weeks, twice a week. The exercises will be based on a protocol developed by the researchers. This protocol has 15 exercises, aimed at muscle function and extensor musculature. All exercises can be adapted according to the severity of the individual, as well as the progression of these exercises will be made according to the adaptation and ease of individuals throughout the intervention.
223607709|NCT01637155|DRUG|Cholecalciferol|One baseline oral dose of 50.000 UI to determine pharmacokinetics. After 28 days, patients take a period of 90 days of standardization of cholecalciferol based on baseline levels. After this period, patients receive a second oral dose of 50.000 UI to determine a second pharmacokinetics.
223607710|NCT02274792|DRUG|Etanercept|Etanercept produced using the serum free process (SFP)2 was supplied in a single-use 1 mL prefilled syringe for subcutaneous injection.
223607711|NCT05961657|DIAGNOSTIC_TEST|Hemodynamic measurements by USCOM|We will measure cardiac output, cardiac index, and systemic vascular resistance index on 3, 7, and 14 postnatal days using the UltraSonic Cardiac Output Monitor.
223607712|NCT05635513|DEVICE|Owlet OSS V3|A wearable pulse oximeter designed for monitoring infants and children in a home environment
223607713|NCT04080102|OTHER|High Intensity Interval Training|Exercise
223607714|NCT04080102|DIETARY_SUPPLEMENT|Essential Amino Acid|Oral ingestion of a powdered dietary supplement
223607715|NCT04080102|OTHER|High intensity interval training and essential amino acid supplement|Exercise and dietary supplement
223607716|NCT05809193|BEHAVIORAL|Family-Focused Therapy|"After the patient and family are informed, they are included in the therapy group on a voluntary basis. After evaluation by independent evaluators, therapy sessions are started by therapists.~Session 1: Goal Setting, Treatment Overview, Symptoms, Vulnerability Stress Model Session 2: Stress and Coping Skills, Regulation of sleep habits, Relaxation exercises Session 3: Optimizing Family Support; Prevention Plan, Medication adherence Session 4: Overview of Communication Skills; Expressing Positive Feelings, Active Listening Session 5: Making Positive Requests for Change, Communication Clarity Session 6: Expressing Negative Feelings Session 7: Introduction to Problem Solving Skills Session 8 and 9: Problem Solving Skills, Termination of Treatment The same psychometric assessment will be repeated before and after FFT. Intra-group comparisons will be made. Also study groups will be compared using time by group interactions to investigate the differences in therapy response."
223607717|NCT03189160|BIOLOGICAL|PEG-rhGH low dose|PEG-rhGH Injection 0.1 mg/kg/w by subcutaneous injection for 52 weeks.
223607718|NCT03189160|BIOLOGICAL|PEG-rhGH high dose|PEG-rhGH Injection 0.2 mg/kg/w by subcutaneous injection for 52 weeks.
223607719|NCT03189160|OTHER|Non-treatment control group|
223607720|NCT03010033|OTHER|pulmonary rehabilitation|"pulmonary rehabilitation (preoperative part): lower extremity endurance training (using bike ergometer for 3 days, 2 times/day, 15-20min/time) or stair climbing training (3 days, 2 times/day, 30min/time), keep dyspnea index (Borg) score between 5 to 7 points. And inspiratory muscle training (using threshold inspiratory muscle trainer for 3 days, 5 times/day, 2 sessions/time, every session includes 10-20 cycle respirations).~pulmonary rehabilitation (postoperative part): inspiratory muscle training (using threshold inspiratory muscle trainer until hospital discharge, 3-5 times/day, 1 session/time, every session includes 10-20 cycle respirations)."
223607721|NCT02104466|PROCEDURE|Acupuncture|Acupuncture will be delivered in a group setting, in a common space with multiple reclining chairs. The initial acupuncture treatment will include a one-on-one diagnostic interview with one of the study acupuncturists for up to 30 minutes, followed by administration of acupuncture needles retained for 20-40 minutes. For subsequent group acupuncture treatments, participants will have a 10-15 minute diagnostic intake with the acupuncturist, followed by administration of acupuncture needles retained for 20-40 minutes. Eight to twelve needles will be administered in acupuncture points selected based on a treatment manual developed for the study. All treatments will be administered using sterile, disposable, surgical stainless steel acupuncture needles.
223754509|NCT05866120|OTHER|Aquatic physiotherapy|Aquatic physiotherapy will be performed in 12 weeks, twice a week, in shallow water. The exercises will be based on a protocol developed by the researchers. This protocol has 15 exercises, aimed at muscle function and extensor musculature. All exercises can be adapted according to the severity of the individual, as well as the progression of these exercises will be made according to the adaptation and ease of individuals throughout the intervention.
223607722|NCT00476827|DRUG|Bevacizumab|Bevacizumab(Avastin) 15 mg/kg every 3 weeks in combination with Capecitabine (Xeloda), 2 weeks on and 1 week off on a every 3 week cycle. until progression or unacceptable toxicity develops
223607723|NCT00476827|DRUG|Docetaxel|Docetaxel 35mg/m² IV over 60 min days 1, 8, and 15 in combination with avastin 10 mg/kg on days 1 and 15 of a 28-day cycle. until progression or unacceptable toxicity develops
223754510|NCT01060033|DEVICE|MR Spectroscopy|
223754511|NCT01060033|DEVICE|Fat-Saturation and Diffusion-Weighted Imaging|
223607724|NCT00476827|DRUG|CPT-11|CPT-11 (Irinotecan, Camptosar) - Patients being treated with an enzyme inducing antiepileptic drug (EIAED) will receive 340 mg/m² IV; others will receive 125 mg/m² IV 90 min on days 1 and 15, in combination with avastin 10 mg/kg on days 1 and 15 of a 28-day cycle.until progression or unacceptable toxicity develops
223754512|NCT01060033|DEVICE|Dynamic Contrast Enhancement MRI (MR-DCE)|
223754513|NCT01060033|DEVICE|Diffusion Tensor Imaging (DTI)|
223754514|NCT04618120|OTHER|Virtual reality-based exercise|"Virtual reality-based exercises with Microsoft Xbox 360 Kinect and breathing exercises.~Patient education"
223754515|NCT04618120|OTHER|Exercise|Shoulder range of motion, stretching, posture and breathing exercises. Patient education
224200741|NCT04950413|OTHER|Conventional physical therapy program|Infrared, Exercises, Stretching exercise of Suboccepital muscle
224200742|NCT04950413|OTHER|IASTM by M2t blade|A lubricant (Vaseline) will be applied to the skin around the neck area prior to treatment and the M2t blade will be cleaned with an alcohol pad. First, the M2T blade will used to ﬁnd the exact areas of restriction in affected muscles. Then the M2T blade will use at an angle of 45 to apply slow strokes along the muscle. Changes in soft tissue consistency will detected by the clinician through vibrations of the instrument when it slides on areas of irregular fibrosis of the underneath connective tissue. Once an adhesion is discovered, strokes are repeated for 5 min.
223607725|NCT00476827|DRUG|Paclitaxel|Paclitaxel (Taxol)90 mg/m2 IV over 60-90 min days 1, 8, and 15, in combination with avastin 10 mg/kg on days 1 and 15 of a 28-day cycle.until progression or unacceptable toxicity develops
223607726|NCT00476827|DRUG|Vinorelbine Tartrate|Vinorelbine Tartrate (Navelbine®) 25 mg/m² IV over 10 min days 1, 8 and 15 in combination with avastin 10 mg/kg IV on days 1 and 15 of a 28-day cycle. until progression or unacceptable toxicity develops
223607727|NCT00476827|DRUG|Gemcitabine|Gemcitabine (difluorodeoxycytidine, dFdC) 1000 mg/m2 IV on days 1 and 8 in combination with avastin 15 mg/kg IV on day 1 of a 21-day treatment cycle.until progression or unacceptable toxicity develops
223607728|NCT05258149|DEVICE|JJVC Investigational Multifocal Contact Lenses|TEST
223607729|NCT05258149|DEVICE|Dailies Total 1® Multifocal Contact Lenses|CONTROL
223607730|NCT04479332|PROCEDURE|Tracheal intubation and cardiopulmonary resuscitation|Critical patients at the emergency room who require tracheal intubation and/or cardiopulmonary resuscitation will be sequentially allocated to either the resuscitation area or negative pressure isolation room for treatment by the designated medical staff wearing personal protective equipment.
223607731|NCT03370042|PROCEDURE|semilunar coronally positioned flap with free gingival graft|
223607732|NCT03370042|PROCEDURE|semilunar coronally positioned flap alone|
223607733|NCT01912196|DRUG|MSI-195|
223607734|NCT01912196|DRUG|Placebo|
223607735|NCT03590314|DEVICE|Experimental group - robot assisted arm training (Armotion®)|"Passive mobilization and stretching exercises for affected upper limb (10 minutes) followed by robot-assisted exercises (35 minutes). Were selected four types of exercises contained within the Armotion® software:~* Collect the coins~* Drive the car~* Wash the dishes~* Burst the balloons~For increment the difficulty, we have varied the assisted and non-assisted modality, increasing the number of repetitions over the study period."
223607736|NCT03590314|OTHER|Control group - conventional treatment|Upper limb passive mobilization and stretching (10 minutes) followed by exercises (35 minutes) that incorporated single or multi-joints movements for the scapula, shoulder and elbow, performed in different positions (i.e. supine and standing position). The increase of difficulty and progression of intensity were obtained by increasing ROM, repetitions and performing movements against gravity or against slight resistance.
223607737|NCT00227812|DRUG|Bupropion|
223607738|NCT00832416|DRUG|Tramadol Once A Day|One Tramadol Once A Day tablet at randomized dose daily.
223754516|NCT03200678|OTHER|isokinetic assessment|muscle torque assessement
223754517|NCT06045039|OTHER|Stent-balloon-stent (SBS) technique|Patients with coronary bifurcation lesions underwent stent-balloon-stent (SBS) technique. The procedure of this technique is to implant the stent into the side branch at the 1\~2mm, which is away from the opening of the branch, and then implant the stent into the main vessel. The guide wire enters the side branch from the mesh at the distal end of the main vascular stent, and the drug balloon is used to dilate the opening of the side branch, so that the opening area of the side branch is more than 5mm².
223754518|NCT03040635|DRUG|Risdiplam|Single oral doses of Risdiplam will be administered on Day 1.
223754519|NCT03040635|DRUG|Placebo|Single oral doses of Risdiplam matching placebo will be administered on Day 1.
223607739|NCT00832416|DRUG|Placebo|One Placebo tablet daily.
223607740|NCT05549830|OTHER|Patient Positioning|"In the preoperative period, the patient/patient relative will be informed about the possible surgical position and the importance of placing the patient in a different position before and after surgery.~İn the postoperative period, the patient will be placed in a different position compared to during surgery, with repositioning being undertaken every two hours until the first 36th postoperative hour, and the development of pressure injuries will be evaluated at the 36th hour. If no pressure injury has developed in this period, the patient will be placed in the surgical position for a duration that will not exceed 30 minutes, and then repositioning will be applied at two-hour intervals. If pressure injuries have developed, different repositioning techniques will continue to be applied at two-hour intervals."
223607741|NCT03741972|DRUG|iSGTL2|Treatment with empaglifozine 10 mg/day (may be also dapaglifozine 10mg/day depending on clinical trial results)
223607742|NCT00261027|DRUG|Exemestane|
223607743|NCT01761448|DEVICE|Guide Exercise (GEx-)- Training|Both intervention and control group undergo a baseline evaluation and an end evaluation including tests of the clinical routine like cardiopulmonary test (CPX), echocardiography and lactate measurement. They will also answer questionnaires referring to quality of life and the use of the system. During the training phase at home the interventional group will test the supervised training system during endurance training such as running, biking or walking and during resistance training such as performing exercise with rubber bands (at least 3x a week for about 5-6 months according to the generated prescription plan during training at the hospital). They will report their daily activity by diary. The control group will only report their physical activities by diary without using the Gex- System. At the end data are investigated to determine whether the supervised training with the GEx- System will improve the physical capacities ( VO2 peak) of patients.
223607744|NCT01761448|DEVICE|Guided Exercise Training with an easy to wear vest with electrodes to measure ECG, respiration, activity|
223607745|NCT01761448|DEVICE|Control group training without Guided Exercise system at home|
223607746|NCT01278992|DIETARY_SUPPLEMENT|Rhodiola rosea|1 capsule = 182 mg Rhodiola rosea extract standardized to 2.8% total rosavins. Take 2 capsules at start of wakeful period each day. Participants will self-determine need for second dose, of 1 capsule, within 4 hours of the initial dose.
223607747|NCT04950530|DRUG|BIKTARVY 50Mg-200Mg-25Mg Tablet|A three-drug fixed dose combination tablet containing 50mg of bictegravir, 200mg of emtricitabine, and 25mg of tenofovir alafenamide taken once daily, orally
223607748|NCT05887050|DIETARY_SUPPLEMENT|Active|Blend of chromium, amla fruit extract, and citrus bioflavonoids
223607749|NCT05887050|DIETARY_SUPPLEMENT|Placebo|Maltodextrin tablet
223607750|NCT05504044|OTHER|Glucose control|50 g glucose dissolved in 250 mL water
223607751|NCT05504044|OTHER|Bread control|91.4 g white bread
223607752|NCT05504044|OTHER|Almond paste|88.7 g white bread and 15 g almond paste
223754520|NCT03330938|BEHAVIORAL|CBI and Resilience|A combination of CBI techniques (Behavioural activation with positive reinforcement, Deep breathing and muscle relaxation, Cognitive restructuring) + Resilience strengthening (Identifying resilient strengths and potentialities, plus Imagination and projection into the future).
223607753|NCT05504044|OTHER|Almond paste and inulin|88.7 g white bread, 15 g almond paste and 4 g inulin
223607754|NCT05504044|OTHER|Low dose almond paste and inulin|89.6 g white bread, 10 g almond paste and 3.8 g inulin
223607755|NCT05392309|OTHER|Manual ankle rocking training|Group will receive manual ankle rocking training with lower limb exercise and core strengthening of trunk
223607756|NCT05392309|OTHER|Conventional|Group will receive lower limb exercises and core strengthening of trunk. Sessions will be 4 days in a week
223607757|NCT00116220|DRUG|Flutamide (Eulexin) and Lupron or Zoladex|Androgen suppression therapy
223607758|NCT00116220|RADIATION|External Beam Radiotherapy|Once a day, 4-5 days per week for approximately 2 months
223607759|NCT02229188|BEHAVIORAL|Problem Solving Therapy|Problem solving therapy is an evidence based behavioral intervention for late life depression. It consist of 8 weekly session of talk therapy, whereby the therapist helps the patient solve problems that are thought to be causing depressive symptoms.
223607760|NCT02229188|BEHAVIORAL|Evolution|Evo is a video game that has therapeutic elements targeting the cognitive control network. Impairment in this neural network is associated with a specific subtype of late life depression that puts people at risk for poor response to SSRIs. Evo is built from a research grade training paradigm that has shown to induce improvements in this network in healthy older adults
223607761|NCT02229188|BEHAVIORAL|Words|Words is a cognitively challenging crossword/word search type of video game that will serve as the control condition for the second phase of this project
223754521|NCT03330938|BEHAVIORAL|Cognitive-behavioral Intervention|Only CBI techniques (Behavioural activation with positive reinforcement, Deep breathing and muscle relaxation, Cognitive restructuring).
223754522|NCT01624428|DRUG|Varenicline|1 mg bid varenicline titrated over a 2 week period
223754523|NCT01624428|DRUG|Placebo|1 mg bid placebo titrated over a 2 week period
223754524|NCT04154228|DIAGNOSTIC_TEST|PET/MR scan|"Patients will undergo 18F-FDG PET/CT scans before therapy initiation, interim after 2/3 treatment cycles and end of treatment after therapy completion, as part of their routine evaluation, as well as additional follow-up scans, as clinically indicated and requested by referring physicians. Given signed written informed-consent forms, patients will undergo at each time point, immediately after completion of PET/CT, a PET/MR scan, following the same single injection of 18F-FDG. Standard preparation and acquisition protocols for FDG PET imaging will be employed.~PET/MR imaging will include conventional sequences as T1, T2, diffusion weighted imaging, and advanced vascular imaging (DCE-MRI)."
223754525|NCT06390228|PROCEDURE|Major hepatectomy|the extent of liver resection
223754526|NCT02271633|DIETARY_SUPPLEMENT|Sodium nitrate|
223754527|NCT02271633|DIETARY_SUPPLEMENT|Beetroot juice|
223754528|NCT02271633|DIETARY_SUPPLEMENT|Spinach|
223754529|NCT02271633|DIETARY_SUPPLEMENT|Rocket salad|
223754530|NCT00184262|BEHAVIORAL|ERP cognitive therapy|15 exposure and response prevention (ERP) sessions in 3 months with a cognitive therapy rationale
223754531|NCT00184262|BEHAVIORAL|ERP behavioral therapy|15 exposure and response prevention (ERP) sessions in 3 months with a behavioral therapy rationale
223754532|NCT04988347|COMBINATION_PRODUCT|Spirulina platensis|Active treatment with Spirulina platensis in capsules containing 530 mg, 1 capsule orally each 8 hours, for 60 days
223754533|NCT04988347|OTHER|Placebo comparator|Placebo in capsules, 1 capsule orally each 8 hours, for 60 days
223754534|NCT02739269|OTHER|Serum AMH measurement|Serum AMH is measured one month before the IVF treatment
223754535|NCT02739269|OTHER|AFC measurement|Early follicular phase AFC is measured one month before the IVF treatment
223754536|NCT01281748|DRUG|intravenous methylprednisolone|methylprednisolone 0,5 mg/kg every 6 hours for 72 hours, 0,5 mg/kg every 12 hours on days 4 through 6, 0,5 mg/kg daily for day 7 through day 10
223754537|NCT01281748|OTHER|intravenous normal saline solution|50 ml of intravenous normal saline solution every 6 hours for 72 hours, 50 ml every 12 hours on days through 6, 50 ml daily for day 7 through day 10.
223754538|NCT00243308|DRUG|Serine proteinase-1 (Serp-1)|
223754539|NCT01391481|DRUG|Perfluorocarbon|Vaporized PFC Inhalation 100ml/8h for 5 days
223754540|NCT01391481|DRUG|Sterile Water for Injection|Inhalation of Sterile Water for Injection, 100ml/8h for 5 days
223754541|NCT06970353|DRUG|Tunlametinib|Locally advanced or metastatic radioactive iodine refractory NRAS mutant differentiated thyroid cancer
223754542|NCT06970353|DRUG|Tunlametinib+PD-1 mAb|Locally advanced or metastatic NRAS mutant poor-differentiated, undifferentiated thyroid cancer
223607762|NCT02889211|BEHAVIORAL|Gambling Task|
223607763|NCT03173404|PROCEDURE|Hysteroscopy|The hysteroscopy is the visualization of the cervical canal and uterine cavity with a camera. Patients randomized to group I underwent hysteroscopy prior to the IVF cycle.
223607764|NCT01023711|BIOLOGICAL|Inactivated H1N1 vaccine|0.5 ml IM into Deltoid region of arm
223607765|NCT01023711|BIOLOGICAL|Inactivated H1N1 vaccine|0.5 mL IM X 1 dose
223607766|NCT05395741|DRUG|Regorafenib|Patients will receive regorafenib orally at doses adjusted for age, body surface area and pharmacokinetics. Treatment with regorafenib will be continued for up to 1 year or until disease progression, patient death, unacceptable toxicity, or study closure. Pharmacokinetics and safety profile of the investigational product (IP) will be determined throughout the course therapy. In the event of progression or relapse, patients in the control group will have the option to receive the IP along with the standard treatment of the next line.
223607767|NCT01409447|DEVICE|Biphasic osteochondral composite|We had previously developed a biphasic osteochondral composite as the construct for chondrocyte implantation. We further conducted this feasibility study of such device to treat patients with osteochondral lesion of the knee joints.
223607768|NCT05726487|BEHAVIORAL|ACTION Intervention|Participants in the ACTION Intervention arm of the study will have group sessions, physical activity self-monitoring, text-based support for goal setting. Following this intervention participants will be followed for an additional 24-weeks to assess for the maintenance of intervention effects on asthma health outcomes.
223607769|NCT05726487|OTHER|Education Control|Participants in the Education Control arm of the study will receive and individual asthma education session and text messages related to asthma education. Following this intervention participants will be followed for an additional 24-weeks to assess for the maintenance of intervention effects on asthma health outcomes.
223607770|NCT06068426|DIAGNOSTIC_TEST|Transabdominal ultrasound Shear wave elastography|TUS SWE will be performed using a Canon Aplio i800 ultrasound system and a curved 1-6 MHz transducer. 2D SWE will be performed with measurement of shear wave speed in the head, body and tail of the pancreas.
223607771|NCT02461927|DRUG|Ketamine + Naltrexone|Subjects in this arm will receive (1) intravenous ketamine (0.5 mg/kg) once a week for 4 weeks (a total of 4 infusions) and (2) intramuscular naltrexone (380 mg) once a month (a total of 2 injections).
223607772|NCT02461927|DRUG|Ketamine + Placebo|Subjects in this arm will receive (1) intravenous ketamine (0.5 mg/kg) once a week for 4 weeks (a total of 4 infusions) and (2) intramuscular placebo once a month (a total of 2 injections).
223607773|NCT02461927|DRUG|Placebo (psychoactive placebo midazolam) + Placebo|Subjects in this arm will receive (1) intravenous psychoactive placebo midazolam (0.045 mg/kg) once a week for 4 weeks (a total of 4 infusions) and (2) intramuscular placebo once a month (a total of 2 injections).
223607774|NCT04489810|DIETARY_SUPPLEMENT|Placebo|Maltodextrin capsule manufactured to mimic the Elevase® and DE111® capsules
223607775|NCT04489810|DIETARY_SUPPLEMENT|Elevase®|1 capsule containing 350 mg of Elevase®
223607776|NCT04489810|DIETARY_SUPPLEMENT|DE111®|1 capsule containing Bacillus subtilis DE111
223607777|NCT04489810|OTHER|Meal A|Oatmeal porridge - serving of cooked oats containing 50g of carbohydrates (excluding sugars); Wheat cereal - serving of wheat cereal providing 1g of gluten; Water - 125 mL
223607778|NCT04489810|OTHER|Meal B|Refrigerated oatmeal - serving of refrigerated oats containing 50g of carbohydrates (excluding sugars); Wheat cereal - serving of wheat cereal providing 1g of gluten; Water - 125 mL
223607779|NCT06139601|BEHAVIORAL|Virtual single session intervention|A single session, self-paced body empowerment program. The program consists of a single 45-minute self paced, interactive, virtual module.
223607780|NCT06172647|DIAGNOSTIC_TEST|Colonoscopy|Endoscopic exploration of the colon (colonoscopy) for standard clinical practice (study of chronic watery diarrhoea, treatment of colon adenomas or population screening with a positive faecal occult blood test)
223607781|NCT03255317|BEHAVIORAL|Reinforcers|Memes/Gifs: Immediately after completing their daily ecological momentary assessment using the app, each participant is randomized to receive an inspirational or funny meme or gif that is displayed within the app. Life Insights: Immediately after completing both daily active tasks using the app, each participant is randomized to unlock a life insight. Life insights track data provided by the participant, are stored in a virtual library within the app, and are regularly updated with recent data points.
223607782|NCT03255317|BEHAVIORAL|Notifications|Reminder Push Notifications: All participants receive a push notification reminder from the app at 6pm (the time at which data collection opens) to complete their daily data collection activities. Each day, each participant will be randomized to receive either a generic reminder or a reminder that contains more detailed information (e.g., about upcoming incentives). Inspirational Push Notifications: Each day, each participant will be randomized to receive a push notification at 4pm that contains inspirational song lyrics or celebrity quotes.
223607783|NCT05575089|DEVICE|Inspiratory muscle training - Powerbreath|"The device Powerbreath is an inspiratory muscle training used to train respiratory muscles. Currently, it is one of the most used devices for the TMI, a linear load model with continuous application of inspiratory pressure throughout inspiration, in which the inspiratory regulating valve remains open while allowing an unrestricted expiration that generates resistance through a spring or of an electronic valve system, ability to offer greater load during training."
223607784|NCT05575089|OTHER|Aerobic exercise in cycle ergometer|10 face-to-face non consecutive sessions with 30 minutes in a cycle ergometer(divided into three steps: heat 5 minutes; 20 minutes with a comfortable and supportable speed or load ( individually prescribed) and 5 minutes recovery
223607785|NCT05575089|OTHER|Deep breathing exercises|Diaphragmatic exercises ( deep inspirations) associated to raise upper limbs ( 3 times - 10 repetitions each)
223607786|NCT06323109|DEVICE|MRI-UDS; US-UDS; MCUD|Imaging procedures will include a comprehensive protocol of dynamic MRI, 3D ultrasound and MCUD to evaluate and validate this entirely novel methodology.
224200743|NCT04950413|DEVICE|Phonophoresis|It will be consisted of 1 MHz pulsed mode with an intensity set at 1.5 W/cm2 and. A 5 cm2 crystal head with an effective radiating area of 4.0 cm2 ±1.0 wills utilized for 5 Min for each trigger point of neck. lidocine gelwill applied instead of coupling US gel used for transmission.
224200744|NCT04375566|OTHER|Patient Decision Aid|More than 20 IT specialists, 15 doctors and 15 patients
223607787|NCT00051493|DRUG|ALIMTA|
223607788|NCT00051493|DRUG|Carboplatin|
223607789|NCT04484870|DRUG|oral Danshu capsule|Danshu group oral Danshu capsule, 2 tablets per time, 3 times a day (0.45g/ tablets, Sichuan Jishengtang Pharmaceutical Co., Ltd.)
223607790|NCT05484011|BIOLOGICAL|odetiglucan|Odetiglucan is a soluble, β-1,3/1,6 glucan isolated from the cell wall of a proprietary Saccharomyces cerevisiae yeast strain. Odetiglucan acts as a Pathogen-Associated Molecular Pattern (PAMP).
223607791|NCT05484011|BIOLOGICAL|CDX-1140|A fully human agonist anti-CD40 monoclonal antibody
223607792|NCT03449069|DRUG|MSC-AFP|Patients will have a mesenchymal stromal cell coated anal fistula plug placed in their Crohn's perianal fistula tract.
223607793|NCT03418636|BEHAVIORAL|Staying Safe (Ssafe)|Staying Safe motivates and teaches young people who inject drugs (PWID) planning skills and drug use management strategies to enable long-term risk avoidance and the implementation of healthy protective behaviors. Content is presented through guided discussions and role playing exercises, and relies heavily on interactive participation by group members to foster peer-based learning and social reinforcement processes.
223607794|NCT03418636|BEHAVIORAL|Healthy Living|The content of the Healthy Living intervention is based on the DHHS' Eat Healthy, Be Active Community Workshop curriculum, supplemented with basic sleep hygiene education. Science-based dietary and light physical activity guidelines are demonstrated and promoted to help participants develop and maintain a healthy lifestyle.
223607795|NCT03335735|BEHAVIORAL|Loss-framed text message|Participants in the intervention group will receive loss-framed text messages related to drinking and driving on days during the week with a higher likelihood of alcohol consumption (Thursday-Saturday). Loss aversion refers to people's tendency to prefer avoiding losses to acquiring equivalent gains: it's better to not lose $5 than to find $5, so the content of the messages will be related to loss of personal freedom, loss of money, and loss of future employment opportunities due to Driving Under the Influence (DUI) convictions.
223607796|NCT03335735|BEHAVIORAL|Gain-Framed text message|Participants in the intervention group will receive gain-framed text messages related to drinking and driving on days during the week with a higher likelihood of alcohol consumption (Thursday-Saturday). Gain-framed messages have been shown to have a positive effect on preventative healthcare and include content framed in a manner that the participant gains something from taking preventative action. Message content will be related to saving lives, gaining control, and making loved ones happy.
223607797|NCT04707495|DEVICE|Smartphone Application (SPSRS)|"The experimental group receives video-viewing intervention using the SPSRS application, which is a smartphone application. SPSRS is programmed to present 150 ms of positive words after presenting 17 ms of self-confidence-boosting words in videos.~These words are repeated every 5 s. The words to increase self-confidence are can, let us try, good luck, able, and do not worry. These self-confidence-boosting words randomly appear in the four corners of the screen. The positive words are nice, great, fantastic, satisfactory, and enjoyable. These words are displayed at the center of the screen. Interveners use the SPSRS application according to the operating manual. The participants will use an iPhone managed by interveners to watch a pre-determined 10-minute video."
223607798|NCT04707495|DEVICE|Smartphone Application (YouTube)|The control group uses the same iPhone as the experimental group. The control group uses the YouTube application to receive video-viewing intervention. The control group videos do not show confidence-boosting and positive words. The control group watches the same video as the experimental group for 10 min.
223607799|NCT02995317|OTHER|Number of falls based on an one year follow-up|
223607800|NCT00016679|DRUG|1-Octanol|
223607801|NCT04859426|DRUG|DBPR108 tablets|Drug: DBPR108, tablet, oral
223607802|NCT03981679|OTHER|Biological collection|The biological collection will also include samples of blood samples collected before colonoscopy
223607803|NCT04560933|PROCEDURE|Blood sample collection|Blood sample collection
223607804|NCT03623763|DIAGNOSTIC_TEST|Serologic tests of blood samples|Five milliliters of peripheral venous blood will be (after 8-12 hours of fasting) from each participant and will be collected into Human Tube Serum Gel - C/A for ELISA. All blood samples will be collected in August and January. Serum levels of 25(OH) VD and TNF-α, IFN-γ, IL-4 and IL-6 will be detected by ELISA technique
223607805|NCT04260789|DEVICE|Seraph 100,The Microbind Affinity Blood Filter|Treatment with Seraph 100 in one arm
223607806|NCT00004893|BIOLOGICAL|recombinant interleukin-12|
223607807|NCT00622375|DRUG|mesalamine|encapsulated mesalamine granules
223607808|NCT02741596|DRUG|DX-2930|Participants who rollover from the DX-2930-03 study will receive 300 milligram (mg) DX-2930 subcutaneous injection at Day 0 followed by second dose following the first HAE attack and then once in every 2 weeks until the end of the treatment period (up to 924 days). A wash-out period of a minimum of 10 days and a maximum of 18 days is required between subsequent administrations.
223607809|NCT02741596|DRUG|DX-2930|Participants who were not participants in DX-2930-03 will receive 300 milligram (mg) DX-2930 subcutaneous injection once in every 2 weeks until the end of the treatment period (up to 924 days).
223607810|NCT00415129|BIOLOGICAL|A/H5N1 inactivated, split-virion influenza virus|0.5mL, Intramuscular
223607811|NCT00415129|BIOLOGICAL|A/H5N1 inactivated, split-virion influenza virus|0.5mL, Intramuscular
224200745|NCT03080402|DEVICE|Mechanical Perturbation Training|The training program will consist of three stages and subjects will progress through each neuromuscular training stage.The training will consist of double- to single-limb movements with progression of jumping, hopping, and pivoting maneuvers on the perturbation device with an emphasis on proper technique and landing. The initial four sessions will focus on primarily on jumping and hopping maneuvers on double- and single-limb in the sagittal plane. The intermediate four sessions will incorporate additional medial and lateral maneuvers with the plyometric tasks. The final four sessions will incorporate rotational and pivoting activities with the maneuvers. The resultant protocol has been derived and optimized from previous published research studies and prevention techniques.
224200746|NCT00896038|DRUG|Aprepitant|Aprepitant is a neurokinin 1 receptor antagonist shown to have anti-stress actions in preclinical studies, and antidepressant efficacy in human clinical trials
224200747|NCT00896038|DRUG|Placebo|Non-active placebo
224311562|NCT06634433|BEHAVIORAL|Health Personnel Attitude|The intervention consists of a two-phase Training of Trainers Program (TTP) designed for health professionals aimed at enhancing interprofessional education (IPE) skills. Phase 1 includes three days of online theoretical training, focusing on topics such as interprofessional collaboration, communication, and conflict resolution. Phase 2 involves two days of face-to-face practical sessions, where participants engage in scenario-based learning and small group discussions to apply IPE concepts. The effectiveness of the program is assessed through pre-test and post-test evaluations, measuring changes in participants\&#39; knowledge, attitudes, and competencies in interprofessional education.
224311563|NCT04060446|DEVICE|Medical Device|Smoke cigarettes with CReSSMicro topography measurement device and BioRadio device
224311564|NCT04060446|OTHER|Questionnaire Administration|Ancillary studies
223607812|NCT01308086|DRUG|5-Fluorouracil|5-FU 400mg/m2 Bolus and then 22 hours 5-FU 600mg/m2 IV, days 1 \& 2, q2w, for 12 cycles
223607813|NCT01308086|DRUG|Leucovorin|Leucovorin 200mg/m2 IV in 2 hours, days 1 \& 2, q2w, for 12 cycles
223607814|NCT01308086|DRUG|Oxaliplatin|Oxaliplatin 85mg/m2 in 2 hours IV, day 1, q2w, for 12 cycles
224200748|NCT05138900|RADIATION|SBRT|SBRT for central non small cell lung cancer
224311565|NCT04060446|BEHAVIORAL|Tobacco Smoking|Smoke cigarettes
224311566|NCT02293980|DRUG|MK-3795|Oral administration
224311567|NCT02293980|DRUG|Nivolumab|IV infusion
224311568|NCT02293980|DRUG|Cabozantinib|Oral administration
223607815|NCT01308086|DRUG|Capecitabine|Capecitabine 1000 mg/m2 X 2 ,days 1-14, q2w, for 8 cycles
224200749|NCT04666870|OTHER|myopia or not myopia|visual acuity, IOL master biometry, the anterior segment with slit lamp, dilated fundus examination and refraction.
223607816|NCT01308086|DRUG|Oxaliplatin|Oxaliplatin 130 mg/m2 in 2 hours IV, day 1, q2w, for 8 cycles
223607817|NCT01308086|DRUG|5-Fluorouracil|5-FU 400mg/m2 Bolus and then 22 hours 5-FU 600mg/m2 IV, days 1 \& 2, q2w, for 6 cycles
223607818|NCT01308086|DRUG|Leucovorin|Leucovorin 200mg/m2 IV in 2 hours, days 1 \& 2, q2w, for 6 cycles
223607819|NCT01308086|DRUG|Capecitabine|Capecitabine 1000 mg/m2 X 2 ,days 1-14, q2w, for 4 cycles
223607820|NCT01308086|DRUG|Oxaliplatin|Oxaliplatin 130 mg/m2 in 2 hours IV, day 1, q2w, for 4 cycles
223607821|NCT01308086|DRUG|Oxaliplatin|Oxaliplatin 85mg/m2 in 2 hours IV, day 1, q2w, for 6 cycles
223607822|NCT00109824|DRUG|decitabine|Given IV
223607823|NCT00109824|DRUG|valproic acid|Given PO
223607824|NCT00109824|OTHER|pharmacological study|Correlative studies
223607825|NCT00109824|OTHER|laboratory biomarker analysis|Correlative studies
223607826|NCT03958058|DRUG|Anti-borrelial antibiotic therapy|Beside symptomatic therapy, patients received oral doxycycline 100 mg (Doxy®) twice daily or ceftriaxone 2 g (Lendacin®) once daily for 14 days. Antibiotic therapy was left to the discretion of treating physicians. Patients reported the presence of nonspecific symptoms such as headache, fatigue, arthralgia, myalgia.
223607827|NCT03958058|OTHER|No antibiotic.|Patients who received symptomatic therapy (paracetamol, Lekadol®, granisetron, Kytril®, metamizol, Analgin®, parenteral hydration with saline). Patients reported the presence of nonspecific symptoms such as headache, fatigue, arthralgia, myalgia.
223754543|NCT06685042|BIOLOGICAL|CAR T cell|"The investigational medicinal product (IMP) CD19-CAR\_Lenti consists of autologous CD19 Chimeric Antigen Receptor (CAR) transduced CD4/CD8 enriched T cells, derived from a leukapheresis product and processed by using the CliniMACS Prodigy® device (Miltenyi Biotec). CD19-CAR\_Lenti is a suspension of fresh CD4/CD8-enriched CD3+ T cells that have been genemodified with a self-inactivating (SIN) lentiviral vector expressing a CAR directed against human CD19. The SIN lentiviral vector is derived from clinically validated viral vectors described in the literature with a fully characterized sequence."
223754544|NCT00927433|BEHAVIORAL|Psychoeducational intervention for cancer-related fatigue|Patients received education on fatigue management in groups of ten patients over two weeks in three two hour sessions
223754545|NCT01037387|DRUG|Control|Current treatment according to the ATS/ERS guidelines
224200750|NCT02025400|OTHER|eRehab|"Growth in e-Health applications, defined as any computer or Internet application integrated into health services, has resulted in the development of treatment strategies to improve healthcare while reducing costs. The utilization of e-Health to provide a rehabilitative intervention has recently been identified in the cardiac literature as e-rehabilitation or eRehab. This study specifically compares an orthopedic eRehab Internet application to standard outpatient physical therapy as an adjunct in the treatment of non-complicated knee and shoulder disorders."
224200751|NCT02025400|OTHER|Formal Physical Therapy|This intervention involves referral to a licensed physical therapist or supervised ATC-L.
224311569|NCT02293980|DRUG|Bezlutifan|Oral administration
224311570|NCT02339662|DRUG|Gabapentin|muscles pain treatment
223607828|NCT02947646|DEVICE|BabyGentleStick™ ON|experimental intervention
223607829|NCT02947646|DEVICE|BabyGentleStick™ OFF|active comparator
223607830|NCT04301466|DRUG|Qi Zhi Tong Luo capsule|Patients were receiveed Qi Zhi Tong Luo Capsule 4 capsules, 2 times per day for 24 weeks. QZTL capsule, a traditional Chinese medicine. Each capsule was weighted 0.5g.
223607831|NCT04301466|DRUG|Placebos|Patients were allocated to placebo, 4 capsules, 2 times per day for 24 weeks.To preserve blinding, the placebo had an identical taste and appearance to the experimental drugs. Placebo (batch number: 20140805) were produced by Shanxi Zhendong Pharmaceutical Co., Ltd.
223607832|NCT06151444|DRUG|Alpha-Agonist|The maternal systolic blood pressure was consistently maintained above 80% of the preoperative baseline value from the initiation of spinal anesthesia until fetal delivery.
223754546|NCT01037387|DEVICE|NIMV group|Current treatment according to the ATS/ERS guidelines and nocturnal BiPAP (IPAP 10-20 cmH2O,EPAP 4-6 cmH2O).
223754547|NCT02251951|DRUG|nab-Paclitaxel|Abraxane: 150mg/m2 i.v weekly for 3 consecutive weeks followed by a week of rest (28d)
223754548|NCT00923559|OTHER|Treatment as Usual at Child Health Centre|Treatment as usual (TAU) involved scheduled nurse calls at the local Child Health Centre (CHC), with paediatric checkups at 2 and 6 months of age. The nurse is encouraged to promote attachment and to detect postnatal depressions. Mothers might be offered parental groups, infant massage or guidance promoting interaction, as well as appointments with a paediatrician or a child psychiatric psychologist. Within the TAU framework, additional treatment might be initiated by the nurse or the mother. This was registered at the end-point interview.
223607833|NCT06151444|DRUG|α-adrenergic receptor agonist|The maternal systolic blood pressure was consistently maintained above 90% of the preoperative baseline value from the initiation of spinal anesthesia until fetal delivery.
223754549|NCT00923559|OTHER|Mother-Infant Psychoanalytic treatment (MIP)|MIP (Norman, 2001; 2004) is a psychoanalytic method adapted to the requirements of the infant as analysand in the presence of his mother. In the study, the analysts strived to recruit the baby for an emotional interchange, though this did not imply any belief that the infant would understand verbal communication. Rather, the analyst addressed the baby to help him liberate emotions consolidated in symptoms such as screaming, avoiding maternal eye contact, and breast refusal. The analyst took care in enrolling the participant mother. This was to enhance her understanding of the baby's predicament and the nature of their relation, as well as giving her space to vent her own frustration, depression and anxiety.
223754550|NCT02796040|DEVICE|MRI|
223754551|NCT04576611|OTHER|face-to-face protocol|The intervention is based on education (on pain neurophysiology and healthy lifestyle habits) and physical exercise (strength, flexibility, joint mobility and self-massage).
223754552|NCT04576611|OTHER|self-managed protocol|Subjects of this group receive the same intervention content as the other experimental group, but through a mobile application.
223754553|NCT00426582|DRUG|Patupilone|
224200752|NCT00390507|PROCEDURE|Post-tetanic count frequency|
224200753|NCT00185107|DRUG|Colesevelam Hydrochloride|
224200754|NCT00185107|DRUG|Ezetimibe|
224200755|NCT00185107|DRUG|Simvastatin|
224311571|NCT02339662|DRUG|Amitriptyline|muscles pain treatment
224311572|NCT04876105|OTHER|Assesment of treatment preference|Multiple-choice survey questions were created by the researchers based on the studies in the literature regarding the pain and treatment preferences of the participants
223754554|NCT03175328|PROCEDURE|continuous renal replacement therapies|The choice of the method of continuous renal replacement therapy (device setting and anticoagulation method) is left to the discretion of each study site and was prescribed and monitored according to national guidelines.
223754555|NCT00581568|OTHER|Cutaneous Effects of Cryogen Spray Cooling|Cutaneous Effects of Cryogen Spray Cooling
223754556|NCT01951157|DRUG|Docetaxel|Powder for solution for infusion
223754557|NCT01951157|DRUG|Gemcitabine|Powder for solution for infusion
223754558|NCT01951157|DRUG|Lurbinectedin (PM01183)|Powder for concentrate for solution for infusion
223607834|NCT04348266|DEVICE|Radiofrequency ablation (RFA)|Radiofrequency ablation is a device that can generate the heat from radiofrequency for tissue ablation. RFA is a standard treatment for Barrett' esophagus and high grade dysplasia in esophagus.
223607835|NCT05177497|DRUG|SHR-1701|SHR-1701 administered by iv
223607836|NCT05583123|DEVICE|restored abutment (OPZAs)|The restorations will be restored by the OPZAs
223607837|NCT05583123|DEVICE|restored abutment (TPZAs)|The restorations will be restored with the TPZAs with friction-fitted titanium bases.
223607838|NCT05258604|PROCEDURE|argon plasma coagulation|APC Standard APC equipment will be used, consisting of a high-frequency electrosurgical generator (ICC 350; ERBE, Tübingen, Germany), an argon source which is regulated automatically (APC 300) and APC probe.
223607839|NCT05258604|PROCEDURE|endoscopic band ligation|endoscopic band ligation will be carried out using a Saeed Multi-Band Ligator (Cook Medical, WinstonSalem, NC), and ligation bands were placed on the GAVE.
223754559|NCT01200654|DRUG|Linezolid|Dosage of 600 mg discontinuous administration twice a day was about studies in safety volunteers
223754560|NCT04645407|DRUG|Fuzheng Huayu tablet|Fuzheng Huayu tablet (0.4g/tablet, 1.6g/time, 3 times/day, oral; take medicine after meals each time)
223754561|NCT05125328|DRUG|Remifentanil|First start with remifentanil 6.0 ng/ml, and use the up and down method as adjust 0.5 ng/ml of concentration of remifentanil each time. An ANI lower than 30 and hyperdynamics (the increased heart rate and mean blood pressure up 20% of baseline or heart rate\>100bpm and arterial blood pressure\>180/100mmHg) indicates insufficient analgesia, therefore increase it by 0.5 ng/ml; an ANI higher than 30 and stable hemodynamics (the changes of HR and MBP within 20% of baseline or HR\<50bpm and ABP\<90/50mmHg) indicates that analgesia is acceptable, and the next patient will decrease it by 0.5 ng/ml during skull pin fixation.
224200756|NCT03032237|OTHER|Nutritional intervention - protein-rich|"Both groups will receive readymade meals (Sligro) for each day during the 4-week intervention period (28 hot meals in total per participant). They will also receive other food products from FrieslandCampina's assortment to freely consume during the intervention period.~To keep the intervention as close as possible to the real life situation, meals and foods will be home-delivered twice a week as the participants are already used to.~Intervention group will receive protein-rich meals and protein-rich foods and drinks."
224200757|NCT03032237|OTHER|Nutritional intervention - standard|"Both groups will receive readymade meals (Sligro) for each day during the 4-week intervention period (28 hot meals in total per participant). They will also receive other food products from FrieslandCampina's assortment to freely consume during the intervention period.~To keep the intervention as close as possible to the real life situation, meals and foods will be home-delivered twice a week as the participants are already used to.~Control group will receive standard (not protein-rich) meals and standard foods and drinks."
224311573|NCT02354404|BIOLOGICAL|cAd3-EBOZ|cAd3 vaccine vector expressing Ebola glycoprotein from the Zaire strain in single dose vials at 1x10(11) PU/mL.
224311574|NCT02354404|BIOLOGICAL|cAd3-EBO|1:1 ratio of cAd3 vaccine vectors expressing Ebola glycoprotein from the Zaire and Sudan strains filled into single dose vials at 1x10(11) PU/mL of each \[2x10(11) PU/mL total\].
224311575|NCT02354404|BIOLOGICAL|MVA-EbolaZ|MVA vaccine vector that expresses Ebola glycoprotein from the Zaire strain in single dose vials at 3.2 x 10(8) PFU/mL
224311576|NCT04853095|PROCEDURE|Peritoneal fixation (PerFix)|PerFix involves suturing the free end of the peritoneal flap left after RARP + ePLND to the pelvic wall near the symphysis of the pubic bones leaving two lateral openings for directing the lymphatic fluid out of the pelvis to the abdominal cavity.
223607840|NCT06122623|OTHER|Health Education|As previously mentioned, the intervention for this study will be a gaming education program that will be conducted once with each participant. Implementation of the program will occur at different times. Each performance will include a maximum of 60 participants who will be divided into small groups within the same room. Seven to 10 participants will comprise a small group, and each group will have one facilitator. The facilitator will be either a member of the research team or a Health lecturer who will be recruited and trained by the Japanese and Indonesian research teams.
223607841|NCT06119113|OTHER|Evaluation of the wound infection at the 10th day post-op check-up among all groups|Discharge, redness, increased temperature, and dehiscence were accepted as wound infection.
223754562|NCT02436421|OTHER|Best Practice Alert based in the Electronic Medical Record|
223754563|NCT00430560|BEHAVIORAL|cognitive rehabilitation|computer training
223754564|NCT00430560|PROCEDURE|work therapy|opportunity to work in carefully supervised hospital job
223754565|NCT00430560|BEHAVIORAL|work therapy|work therapy
223754566|NCT03398031|DRUG|Magnesium Oxide|After biochemical diagnosis of pregnancy each participant will receive magnesium plus 500 mg tablet once daily till the end of the 1st trimester
223754567|NCT03398031|DRUG|Placebo Oral Tablet|After biochemical diagnosis of pregnancy each participant will receive placebo tablet once daily till the end of the 1st trimester
223754568|NCT05416983|PROCEDURE|Discussion|Attend discussion
223754569|NCT05416983|OTHER|Questionnaire Administration|Complete questionnaire
223754570|NCT01683981|DRUG|L-Citrulline Malate|3 gr per day, oral, for 2 weeks
223754571|NCT06558240|DEVICE|HERADERM Hydrogel Wound Dressing (Sterile)|HERADERM Hydrogel Wound Dressing (Sterile) is a transparent, composite hydrogel dressing. The outer layer is a waterproof and breathable polyurethane film (PU film), which can prevent external bacterial invasion and reduce the risk of infection. The inner layer is A+ polymer hydrogel, which can keep the wound bed in a moist state and reduce the infiltration problem caused by wound exudate.
223754572|NCT05218018|DIETARY_SUPPLEMENT|Lipid drink|100 mls of heavy cream
223754573|NCT03418909|PROCEDURE|Primary Trans Oral Robotic Surgery (TORS)|In the absence of severe mobidity patients with early stage disease (T1-2, N1, M0) were offered TORS, as an alternative to the standard of care (radiotherapy).
223607842|NCT06119113|OTHER|Evaluation of the cosmetic results of the incision line at the 2nd month post-op check-up among all groups|The cosmetic outcome of wound site scar healing was evaluated with two different scales. The Patient and Observer Assessment Scale (POSAS) is a questionnaire developed to assess scar quality. The investigator scores six items: vascularization, pigmentation, thickness, surface roughness, elasticity, and surface area. The participant scores six items: pain, itching, color, thickness, relief, and flexibility. All items are scored on a 10-point multiple scale; A score of 1 is given when the scar characteristic is similar to 'normal skin' and a score of 10 is given when it reflects the 'worst scar'. All items are summed to determine the total scar score; a higher score represents worse scar quality. The Vancouver scar scale (VSS) consists of four variables: vascularity, height (thickness), elasticity and pigmentation. The total score ranges from 0 to 14, with a score of 0 reflecting normal skin.
223607843|NCT06119113|OTHER|Evaluation of the cosmetic results of the incision line at the 6th month post-op check-up among all groups|The cosmetic outcome of wound site scar healing was evaluated with two different scales. The Patient and Observer Assessment Scale (POSAS) is a questionnaire developed to assess scar quality. The investigator scores six items: vascularization, pigmentation, thickness, surface roughness, elasticity, and surface area. The participant scores six items: pain, itching, color, thickness, relief, and flexibility. All items are scored on a 10-point multiple scale; A score of 1 is given when the scar characteristic is similar to 'normal skin' and a score of 10 is given when it reflects the 'worst scar'. All items are summed to determine the total scar score; a higher score represents worse scar quality. The Vancouver scar scale (VSS) consists of four variables: vascularity, height (thickness), elasticity and pigmentation. The total score ranges from 0 to 14, with a score of 0 reflecting normal skin.
223607844|NCT03596203|DEVICE|TransCutaneous Magnetic Stimulator (TCMS)|TCMS coils which are connected to feet and pulse generator. The generator will then be turned on to deliver 50 pulses at a pulse period of 6 seconds and at a pulse intensity of 100% to the bottom of the foot with the TCMS coil.
223607845|NCT05617781|BEHAVIORAL|Questionnary|The primary outcome of this study is to analyze the post-traumatic stress disorder's repercussions on empathy by passing the Interpersonal Reactivity Index (IRI)
223607846|NCT00469703|DRUG|Thalidomide|
223607847|NCT01449435|OTHER|Methacholine challenge testing|Nebulized methacholine administered at the following doses: 0,1 mg/0,4 mg/0,8 mg/1,6 mg
223607848|NCT04838535|DIAGNOSTIC_TEST|Raman spectrum|The wavelength of the follicular fluids were scaned by Raman spectrum
223607849|NCT02859246|DRUG|Mucinex®|Mucinex®
223607850|NCT02218684|DRUG|Telmisartan|
223607851|NCT02218684|DRUG|Lacidipine|
223607852|NCT02218684|DRUG|Placebo|
223607853|NCT00100789|DRUG|gemcitabine|3,000 mg/m2 IV over 30 minutes on days 1 and 15 (q28 days).
223607854|NCT00100789|DRUG|paclitaxel|150 mg/m2 IV over 1 hour on days 1 and 15 (q 28 day cycle), administered after gemcitabine
223607855|NCT01746368|OTHER|The Nurse-Supported Advance Care Planning Intervention|This intervention was a manualized education, support, and guidance session provided by a Registered Nurse that included information about risks, benefits, and alternatives of specific choices. It incorporated an application of the Theory for Enabling Safety.
223607856|NCT01746368|OTHER|Care-as-Usual|The Care-as-Usual was a session with the social worker who explained what the Advance Directive is, and guided the Veteran regarding the process of completing the Advance Directive document, without providing information about risks, benefits, and alternatives of specific choices.
223607857|NCT05280717|BIOLOGICAL|sotrovimab|via IM injection
224311577|NCT04853095|PROCEDURE|Standard of care|ePLND without peritoneal flap fixation
223607858|NCT05280717|BIOLOGICAL|sotrovimab|via IM injection
223607859|NCT05280717|BIOLOGICAL|sotrovimab|via IM injection
223607860|NCT05280717|BIOLOGICAL|sotrovimab|via IM injection
223607861|NCT05280717|BIOLOGICAL|sotrovimab|via IM injection
224311578|NCT02903706|OTHER|Measure of Plasmodium prevalence (PCR)|
223607862|NCT05280717|BIOLOGICAL|sotrovimab|via IV injection
223607863|NCT05280717|BIOLOGICAL|sotrovimab|via IV infusion
223607864|NCT06246110|DRUG|EIK1001|EIK1001 is a Toll like receptor 7/8 (TLR 7/8) agonist
223607865|NCT06246110|DRUG|Pembrolizumab|PD-1 inhibitor
223607866|NCT06246110|DRUG|Paclitaxel|Chemotherapy
223607867|NCT06246110|DRUG|Pemetrexed|Chemotherapy
223754574|NCT03418909|RADIATION|Radio(chemo)therapy|As the standard of care radiotherapy was offered to all of the patients. Patients that qualified for both TORS and radiotherapy were free to choose between the two.
223754575|NCT01429272|DRUG|Minocycline|100 mg po bid for 6 weeks
223754576|NCT01429272|DRUG|Aspirin|81 mg po bid for 6 weeks
223754577|NCT01429272|DRUG|placebo|placebo for minocycline and/or aspirin
224311579|NCT00549575|DRUG|L ARG|Patients received 14 g/day of L-arginine (90 mL syrup, Veyron France Laboratories).
223508231|NCT05963919|OTHER|Lower extremity muscle strength test|The 30-Second Chair Test is administered using a folding chair without arms, with a seat height of 17 inches (43.2 cm). The chair, with rubber tips on the legs, is placed against a wall to prevent it from moving. The participant is seated in the middle of the chair, back straight; feet approximately a shoulder width apart, and placed on the floor at an angle slightly back from the knees, with one foot slightly in front of the other to help maintain balance. Arms are crossed at the wrists and held against the chest. The participant is encouraged to complete as many full stands as possible within 30 seconds. The participant is instructed to fully sit between each stand.
223607868|NCT06246110|DRUG|Carboplatin|Chemotherapy
223607869|NCT01302028|DRUG|ASP1941|Oral
223754578|NCT05337592|DRUG|BI 1815368 formulation 1|BI 1815368 formulation 1
223754579|NCT05337592|DRUG|Placebo|Placebo
223607870|NCT00080301|DRUG|Ixabepilone + Capecitabine|"Ixabepilone - Intravenous Solution, IV 40mg/m², Day 1 every 21 days, Until progression/unacceptable toxicity~Capecitabine (Active Comparator) - Tablet, Oral, 2000 mg/m², Bid Days 1-14 every 21 days, Until progression/unacceptable toxicity"
223607871|NCT00080301|DRUG|Capecitabine|Tablet, Oral, 2500 mg/m², Bid Days 1-14 every 21 days, Until progression/unacceptable toxicity
223754580|NCT05337592|DRUG|BI 1815368 formulation 2|BI 1815368 formulation 2
224311580|NCT00549575|DRUG|Placebo|After double blind randomization, patients received a placebo.
224311581|NCT01707056|OTHER|Black Coffee|Taking Synthroid with 12 ounces of black coffee for 6 weeks.
223754581|NCT00329407|DRUG|Topiramate (Topamax)|Medication Dosing Schedule: Days 1-3 50 mg q PM Days 4-7 50 mg BID Days 8-11 50 mg q AM \& 100 mg q PM Days 12-15 100mg BID Days 16-19 100 mg q AM \& 150 mg q PM Days 20-23 150 mg BID Days 24-27 150 mg qAM \& 200 mg q PM Days 28-70 200 mg BID Days 71-77 150 mg BID Days 78-84 100mg BID Days 85-87 50 mg BID Days 88-91 50 mg qPM
223754582|NCT02374645|DRUG|Volitinib|600mg or 800mg QD: Patients may continue to receive the treatment as long as they are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.
223754583|NCT02374645|DRUG|gefitinib|250mg QD: Patients may continue to receive the treatment as long as they are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.
223754584|NCT00116441|BIOLOGICAL|Therapeutic Cellular Vaccine, GM-CSF Producing|
223754585|NCT04010123|DEVICE|Atherectomy/Thrombectomy|Percutaneous transluminal removal of thrombotic, thromboembolic and atherothrombotic material from fresh, subacute and chronic occlusions of blood vessels in native blood vessels or vessels fitted with stents, stent grafts or native or artificial bypasses.
223754586|NCT00493584|PROCEDURE|Primary Percutaneous Coronary Intervention|Coronary Angiography and PCI using standard protocols and guidelines. Contrast either Iomeron or Visipaque at the operators discretion. Equipment used for the PCI is determined at the operators discretion. All patients undergoing primary PCI receive 10.000 units of Heparin, 600 mg of Clopidogrel and a Glycoprotein IIb/IIIa inhibitor. Patients randomized to standard treatment receive 300 mg of Clopidogrel and 120IU/kg of Dalteparin b.i.d until revascularization. Glycoprotein IIb/IIIa inhibitors or thrombin inhibitors can be given as a supplement at the local hospital at the physicians discretion. All patients receive 300 mg of aspirin upon admission or diagnosis in the ambulance.
223754587|NCT00493584|PROCEDURE|Coronary angiography / Percutaneous coronary intervention|Coronary Angiography and PCI using standard protocols and guidelines. Contrast either Iomeron or Visipaque at the operators discretion. Equipment used for the PCI is determined at the operators discretion. All patients undergoing primary PCI receive 10.000 units of Heparin, 600 mg of Clopidogrel and a Glycoprotein IIb/IIIa inhibitor. Patients randomized to standard treatment receive 300 mg of Clopidogrel and 120IU/kg of Dalteparin b.i.d until revascularization. Glycoprotein IIb/IIIa inhibitors or thrombin inhibitors can be given as a supplement at the local hospital at the physicians discretion. All patients receive 300 mg of aspirin upon admission or diagnosis in the ambulance.
223754588|NCT00978068|DRUG|Lopinavir/Ritonavir (LPV/r)|
223754589|NCT00978068|DRUG|Nevirapine (NVP)|NVP will be used for children \< 3 years of age
223754590|NCT00978068|DRUG|Efavirenz (EFV)|EFV for children ≥3 years of age
223754591|NCT00978068|DRUG|2 nucleoside reverse transcriptase inhibitor (NRTI)|The same NRTI choice strategy will be used for both arms. Lamivudine will be used with all children. The second NRTI will be zidovudine unless the participant has a hemoglobin \< 8 gm/dL, in which case it will be Abacavir. Stavudine will be used in the event that a participant is unable to take Abacavir for safety or other reasons.
223754592|NCT03143699|OTHER|Immediate Feedback|Students will be trained to measure blood pressure in the same way, with a brief 4-hour theoretical-practical intervention. After the training, students will measure the blood pressure of a standardized patient and observers will evaluate them using a checklist. After that, students from the intervention group will receive an immediate feedback based on the previous literature. Briefly, feedback will be based on what was directly observed and will be phrased in non-judgmental language, following the Pendleton model.
223754593|NCT03013556|DRUG|Group A, TDF|TDF for 96 weeks
223754594|NCT03013556|DRUG|Group B:TDF then TDF and Peginterferon alfa-2a|Subjects will be treated by TDF in the first 48 weeks, then will be treated by the combination of TDF and Peginterferon alfa-2a for another 48 weeks
223754595|NCT03013556|DRUG|Group C:TDF and Peginterferon alfa-2a then TDF|Subjects will be treated by the combination of TDF and Peginterferon alfa-2a for the first 48 weeks, then will be treated by TDF for another 48 weeks.
223508232|NCT01333566|BEHAVIORAL|Intervention Group|The study will include one week baseline phase, 6-week intervention phase, and a 3-month follow-up evaluation. Subjects in the intervention group will go through three training sessions during the baseline phase, weekly group exercise sessions once per week and daily home exercises two times each day during the intervention phase, and a follow-up evaluation in three months after the intervention phase.
223508233|NCT01333566|BEHAVIORAL|Placebo Comparator: Control Group|Subjects in the control group will be monitored during the baseline and intervention phase without participating in the interventional exercise. At the end of intervention phase, the subjects will have the option to stop their participation or switch to the intervention group.
223508234|NCT04442750|PROCEDURE|Erector spinae plane block Technique|The patient will be placed in Lateral Decubitus with a surgical side upwards. A curvilinear array ultrasound probe will be placed in a transverse orientation at L4 level to identify the tip of the L4 transverse process. The tip of the transverse process will be centered on the ultrasound screen and the probe will be then rotated into a longitudinal orientation 2-3 cm lateral to vertebral column. The lumbar skin region will be sterilized, local infiltration of the skin and subcutaneous tissue will be applied by 2-3ml of lidocaine 2%. Then, using ultrasound guidance, A 38-mm 22-gauge (22-G, 50-mm 'Stimuplex A'; BBraun, Melsung, Germany) regional block needle will be advanced in plane to the ultrasound beam in a cranial-to-caudal direction until contact will made with the L4 transverse process. Local anesthetic solution will be injected and its type will be selected according to the studied group and patients were placed in a supine position and general anesthesia will be started.
223508235|NCT04442750|PROCEDURE|General anesthesia|"Induction of general anaesthesia will be performed using a regimen of IV 2 μg/kg fentanyl and propofol IV 2 mg /kg. Tracheal intubation will be facilitated using 0.5 mg/kg IV of rocuronium.~Anaesthesia will be maintained with inhaled sevoflurane 1-1.5% in oxygen enriched air (FiO2=0.5). Maintenance doses of rocuronium o.1 m\\kg will be provided every 30 minutes.~Rescue analgesia of fentanyl 1 μg/kg will be given if the mean arterial blood pressure or heart rate rises above 20% of baseline levels.~At the end of surgery, residual neuromuscular blockade will be reversed using neostigmine (0.05 mg/kg) and atropine (0.02 mg/kg), and will extubation be performed after complete recovery of the airway reflexes."
223508236|NCT04442750|DRUG|Bupivacaine 0.5%|The patient will receive 30ml bupivacain 0.5% in erector spinae block
223508237|NCT04442750|DRUG|Bupivacaine 0.375%|The patient will receive 30ml bupivacain 0.375% in erector spinae block
223754596|NCT06182644|DIAGNOSTIC_TEST|FAPI PET/CT|The same group of patients underwent FAPI PET/CT and FDG PET/CT examinations respectively
223607872|NCT04602117|DRUG|Vic-trastuzumab duocarmazine (SYD985) + paclitaxel|"SYD985 (\[vic-\]trastuzumab duocarmazine) an antibody-drug conjugate or ADC being developed by Byondis B.V. (Nijmegen, The Netherlands), consists of the recombinant humanized anti-epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab linked, via a cleavable linker, to the duocarmycin prodrug, seco-duocarmycin-hydroxybenzamide-azaindole or seco-DUBA, which has potent antineoplastic activity.~Eligible patients will receive infusions of SYD985 every three weeks and of paclitaxel weekly."
223607873|NCT03881111|BIOLOGICAL|Pembrolizumab|200 mg administered IV Q3W on Day 1 of each 3-week cycle, up to 35 administrations.
223607874|NCT03881111|DRUG|Placebo|Placebo to pembrolizumab (saline) administered IV Q3W on Day 1 of each 3-week cycle, up to 35 administrations.
223607875|NCT03881111|DRUG|Cisplatin|80 mg/m\^2 administered IV Q3W on Day 1 of each 3-week cycle. Duration of cisplatin treatment will be capped at 6 doses.
223607876|NCT03881111|DRUG|5-FU|800 mg/m\^2/day (4000 mg/m\^2 total per cycle) administered as continuous IV infusion on Days 1 to 5 (120 hours) of each 3-week cycle, or per local standard for 5-FU administration.
223607877|NCT00193921|DRUG|Vinorelbine|IV, 25mg/m2, days 1, 8, 22
223607878|NCT00193921|RADIATION|High dose Radiotherapy|External beam radiation, 40 Gy/20#/5 per week
223607879|NCT00193921|DRUG|Gemcitabine|200mg (flat dose) IV days 1, 8, 15
223607880|NCT00193921|DRUG|Cisplatin|20mg/m2, IV, weekly
223607881|NCT00193921|RADIATION|High Dose Radiotherapy|External beam radiation, 30 Gy/15#/5 per week
223607882|NCT00089037|DRUG|methotrexate|
223607883|NCT00089037|DRUG|sirolimus|
223607884|NCT00089037|DRUG|tacrolimus|
223607885|NCT05337800|BEHAVIORAL|stress managment program|A four-session stress management program will be applied to the experimental group students.
223607886|NCT03654937|BIOLOGICAL|Influenza Vaccination|"Influenza vaccination Influsplit Tetra 2016/2017, GlaxoSmithKline GmbH \& Co. KG, Munich, Germany, batch: AFLBA 152AB."
223607887|NCT06551168|OTHER|Heat exposure|Participants will exercise at home while wearing a clothing ensemble over 19 one hour sessions. They will use validated perceptual scales to guide their effort and thermal sensation.
223754597|NCT03560531|DRUG|ZN-c5|ZN-c5 is a study drug
223754598|NCT03560531|DRUG|Palbociclib|Palbociclib (IBRANCE®) is an approved drug
223508238|NCT04442750|DRUG|Bupivacaine 0.25%|The patient will receive 30ml bupivacain 0.25% in erector spinae block
223508239|NCT02741193|DEVICE|The Magstim Rapid2,|"Transcranial Magnetic Stimulation, which is a microprocessor-controlled machine which delivers both single and repetitive transcranial magnetic stimulation (TMS).~single and repetitive transcranial magnetic stimulation (TMS). TMS will be applied as single pulses to determine motor evoked potentials (MEPs), there will be no modulation of cortical excitability."
223508240|NCT01032343|DIETARY_SUPPLEMENT|Omega-3 PUFA|One capsule (4g omega-3 PUFA) daily for 3 months
223508241|NCT01032343|DIETARY_SUPPLEMENT|Gelatine|One capsule daily for 3 months
223508242|NCT01640535|DRUG|Montelukast + Levocetirizine|Tablet, Montelukast sodium 10 mg + Levocetirizine dihydrochloride 5 mg, Once daily (before bedtime)
223508243|NCT01640535|DRUG|Levocetirizine|Tablet, Matching placebo of Montelukast sodium 10 mg + Levocetirizine dihydrochloride 5 mg, Once daily (before bedtime)
223508244|NCT01640535|DRUG|Montelukast|Tablet, Montelukast sodium 10 mg + matching placebo of Levocetirizine dihydrochloride 5 mg, Once daily (before bedtime)
223607888|NCT06551168|OTHER|Control group|Participants will exercise at home over 19 one hour sessions. They will use heart rate to guide their effort. The exercise will take place in cool conditions
223607889|NCT06175559|COMBINATION_PRODUCT|Healing Town: Embedded Narrative in Interactive Game (Psycho-education Tool) Design|"The narrative-based medication intervention game Healing Town in this study employed a multidisciplinary participatory design approach rooted in narrative theory and behavioral psychology models. The game consists of two perspectives: narrative decision stories and cognitive games. The investigators initially employed participatory design methods to determine the plot and elements within the game, then embedded the conclusions into the therapeutic elements of the game"
223607890|NCT01069965|DRUG|BGP-15 100 mg QD|Two 50 mg BGP-15 capsules by mouth in the morning; and two Placebo capsules by mouth in the evening
223607891|NCT01069965|DRUG|BGP-15 100 mg BID|One 100 mg BGP-15 capsule by mouth in the morning; and one 100 mg BGP-15 capsule by mouth in the evening
223607892|NCT01069965|DRUG|Placebo BID|Two Placebo capsules by mouth in the morning; and two Placebo capsules by mouth in the evening
223607893|NCT01069965|DRUG|BGP-15 200 mg QD|Two 100 mg BGP-15 capsule by mouth in the morning; and two Placebo capsule by mouth in the evening
223607894|NCT01069965|DRUG|BGP-15 200 mg BID|Two 100 mg BGP-15 capsules by mouth in the morning; and two 100 mg BGP-15 capsules by mouth in the evening
223607895|NCT01069965|DRUG|BGP-15 400 mg QD|Two 200 mg BGP-15 capsules by mouth in the morning; and two Placebo capsules by mouth in the evening
223607896|NCT06122974|DEVICE|Drug Eluting Temporary Spur Stent System|The Spur Stent consists of a sirolimus coated stent and balloon that is retrievable after delivery of the sirolimus formulation.
223607897|NCT06122974|DEVICE|Percutaneous Transluminal Balloon Angioplasty|A balloon catheter is inserted across a lesion and inflated to fracture and compress the plaque, creating a larger lumen and improved blood flow through the artery.
223754599|NCT04297137|DIETARY_SUPPLEMENT|Protein ingestion|Ingestion of various sustainable non-animal derived protein sources compared to animal-based milk protein.
223754600|NCT04910009|OTHER|Four sessions of practical privacy education|Two sessions of theoretical, four sessions of practical privacy education
223754601|NCT04153500|OTHER|Anatomy class with Pelvic+ methodology|Teaching of female pelvis anatomy using a interactive training model (Pelvic+ methodology)
223754602|NCT00586183|PROCEDURE|PET scan|The subject will then be positioned in the PET scanner . After optimal positioning of the left ventricle within the field of view, a transmission scan will be performed with either a germanium-68 or CT source for subsequent attenuation correction.
223754603|NCT00721786|BEHAVIORAL|UCSF/SFGH Internet Stop Smoking Study site|Internet stop smoking site in Spanish and English
224311582|NCT01707056|OTHER|Coffee with Milk|Taking Synthroid with 12 ounces of black coffee and 2 ounces of 2% milk for a period of 6 weeks.
224311583|NCT01707056|OTHER|Black Tea|Taking Synthroid with 12 ounces of black tea for a period of 6 weeks.
223607898|NCT06466460|OTHER|Motion based - Virtual cycling|To examine whether the activity of virtual cycling contributes to the improvement of quality of life for individuals with cognitive impairment. (Intervention study)
223607899|NCT02957734|PROCEDURE|Rehabilitation of severely worn dentitions|Patients with severely worn dentition and functional problems are included in this study. Teeth are rehabilitated using indirect composite resin restorations in an increased vertical dimension of occlusion in order to optimize function and esthetics.
223607900|NCT02518971|DRUG|Tamsulosin|0.4 mg daily
223607901|NCT02518971|DRUG|Placebo|one capsule daily
223607902|NCT06130241|PROCEDURE|sentinle lymphnode biopsy|intraoperative sentinle lymphnode biopsy
223607903|NCT02233634|DRUG|Oxygen|Oxygen is provided with a standard medical oxygen mask with reservoir (12L/min) for 3-5 min, assigned to both groups
223607904|NCT02233634|OTHER|Hyperventilation Breath-hold (HVBH)|1 Minute of Hyperventilation (25/min) is followed by a consecutive breath-hold for as long as the subject can comfortably tolerate. Both groups will perform this maneuver
223607905|NCT02233634|OTHER|HVBH with Oxygen|1 Minute of Hyperventilation (25/min) with an oxygen mask mounted (12L/min) is followed by a consecutive breath-hold for as long as the subject can comfortably tolerate. Both groups will perform this maneuver
223607906|NCT06534008|BEHAVIORAL|12-week home-based exercise intervention|All participants will be given the same 12-week distance-based exercise intervention.
223607907|NCT05143034|DIETARY_SUPPLEMENT|TCI66207 Essence|Use it twice a day after washing your face in the morning and evening for a total of 4 weeks.
223607908|NCT05143034|DIETARY_SUPPLEMENT|Placebo Essence|Use it twice a day after washing your face in the morning and evening for a total of 4 weeks.
223607909|NCT02011100|DIETARY_SUPPLEMENT|Carnosine|
223607910|NCT02336230|DRUG|remestemcel-L|Participants were treated with IV remestemcel-L at a dose of 2 x 10\^6 MSC/kg (actual body weight at screening) twice per week for each of 4 consecutive weeks. Infusions were administered at least 3 days apart and no more than 5 days apart for any infusion.
223754604|NCT05864911|DEVICE|the Gastric Bypass Stent System|The Gastric Bypass Stent System is a newly designed endoscopic duodenal-jejunal bypass liner for the treatment of obesity by Hangzhou Tangji Medical Technology Co., Ltd.. It consists of three main parts: a 60-cm polyethylene sleeve fixed into the duodenal bulb by anchors with barbs, a delivery system and a retrieval system. Compared to the Endobarrier, it has several technical adjustments. First, it improved sleeve materials to provide better barrier properties and reduce the breeding of bacteria resulting in hepatic abscess. Second, the barbs on the anchoring system have been modified to reduce duodenal injury. Third, the delivery and retrieval system have been optimized to eliminate the need of fluoroscopic guidance during implantation and explantation.
223754605|NCT01751386|DRUG|Baclofen|
223607911|NCT02524171|BEHAVIORAL|Moral Reconation Therapy (MRT)|MRT is a group-based cognitive-behavioral intervention to restructure antisocial thinking. Patients will receive two groups per week of this intervention for approximately 12 weeks, in addition to the usual care they receive in the mental health residential rehabilitation treatment program.
223607912|NCT06316349|OTHER|Isolated Resistance Training Program|The hip range of motion (ROM) will be fixed at 45 degrees due to the limitation imposed by the femoral insertion of the intra-aortic balloon pump in both lower limbs to allow for a 45-degree knee extension ROM. Four sets of 10 knee extension repetitions will be performed with a 90-second rest interval between sets. The intensity (resistive load) will be set at 60% of the baseline load, calculated using the one-repetition maximum (1RM) test and increased by 10% after every 5 interventions.
223607913|NCT06316349|OTHER|Neuromuscular electrical stimulation|For NMES, two electrodes (area of 5 x 9 cm) will be positioned perpendicular to the muscles of the femoral quadriceps. The parameters of NMES will remain fixed throughout the study: pulsed, biphasic current, with a frequency of 35Hz, pulse width of 1000µs, on-time of 7 seconds (with 3 seconds of rise, 1 second of sustainment, and 3 seconds of descent), and off-time switched off. These settings allow the onset of NMES to be synchronous with the start and end of hip extension for simultaneous execution with resistance exercises and a total of 40 stimulations. The intensity will be gradually adjusted until evoked contractions of grade 4 to 5 (partial muscle recruitment and total muscle recruitment) or the maximum intensity tolerated by the patient is achieved.
223607914|NCT00704886|OTHER|video|video of dementia
223607915|NCT02781675|OTHER|Dietary Intervention|3 wk dietary intervention with prescribed menus and \~50% foods provided.
223607916|NCT02463279|DEVICE|Sinusys Dilation System|Dilation of frontal recess and/or sphenoid sinus ostia
223607917|NCT02535455|BEHAVIORAL|ACES Pilot|This pilot will consist of 5 individual sessions and an innovative bi-directional text message component that uses participant-written positive self-statements informed by the intervention content (e.g., self-compassion, positive self-reappraisal and nonjudgmental acceptance).
223607918|NCT01933490|OTHER|high carbohydrate test meal|
223607919|NCT01933490|OTHER|high carbohydrate test meal after pre-treatment with rapid acting aspart insulin|
223607920|NCT01933490|OTHER|high fructose , low glucose test meal with carbohydrate and caloric content similar to the control meal|
223607921|NCT02669459|DRUG|Imiquimod|12,5 mg imiquimod three times per week during 16 weeks
223607922|NCT02669459|PROCEDURE|LLETZ|surgical treatment for CIN, current gold standard
223607923|NCT01314131|BEHAVIORAL|Stimulation group|"Patients living in nursing home can be enrolled in the study by giving their verbal consent. The trial lasts two weeks for each patients and it will be performed in three parts :~* a cognitive and behaviour assessment : MMSE, BREF, NPI, IA~* an interest questionnaire for patients. It contains 40 questions about activities.~* the intervention : patients will be propose 5 activities. 4 of them are activities that patients are interested in. Each activity have to last 15 minutes and the stimulation is measured by a scale named Observational Measurement of Engagement ."
223607924|NCT02316080|OTHER|Dental bleaching|Home-use or in-office dental bleaching was performed in patients that received different types od desensitizing therapy
223754606|NCT01751386|OTHER|Placebo|
223754607|NCT00012142|DRUG|temsirolimus|
223754608|NCT01471379|DRUG|Milnacipran|50mg Milnacipran PO, BID, for 6 weeks.
223754609|NCT01471379|DRUG|Milnacipran|Milnacipran, 100mg PO, BID, for six weeks
223754610|NCT01471379|DRUG|Milnacipran|Milnacipran, 50mg PO BID for 12 weeks
223754611|NCT01471379|DRUG|Placebo|Inactive pill, identical in shape, size, and appearance to active drug, PO, BID.
223754612|NCT05766930|DEVICE|The novel electrolyzed water spray|Study staff will use the novel electrolyzed water spray device and spray for approximately 2-4 minutes on the participant's diseased area until half a bottle (20-40ml) of water is used. The patients use electrolyzed water to treat the diseased area, two times a day, for 5 days. The trial consists of 5 study visits (day 1-day 5). The relief genital itching evaluation and adverse event assessments will be performed at each visit. Safety analysis will be assessed based on the reports of adverse events during the study.
223754613|NCT02120794|DEVICE|530G Insulin pump|Subjects will use 530G insulin pump with Threshold Suspend (TS) feature for one year.
223754614|NCT04444609|OTHER|Blood tests sputum, nasal lavage and brushing|Venesection, sputum nasal lavage and brushing if appropriate
223754615|NCT00644293|DRUG|azithromycin (Zithromax)|azithromycin 500 mg tablet by mouth once daily for 3 days
223754616|NCT00644293|DRUG|placebo|placebo
223754617|NCT00644293|DRUG|azithromycin SR|azithromycin SR 2.0 g by mouth as an oral slurry for 1 dose
223754618|NCT00644293|DRUG|placebo|placebo
223754619|NCT00411164|DRUG|OROS hydromorphone HCI (slow release)|
223754620|NCT03543592|DIAGNOSTIC_TEST|3 dimensional ultrasonography and Doppler|Three-Dimensional images will be recorded. The volumes will be generated by the automatic rotation of the mechanical transducer 360 degrees. Visualization of the endometrium and myometrium in the three planes will be done to detect endometrial cavity and any lesions. The power Doppler gate will be activated for blood flow mapping of the endometrium and endometrial-myometrial interface (sub-endometrial area). The pulsed Doppler sample volume will be activated to obtain a flow velocity waveform (FVW). Vascularization index (VI), flow index (FI) and vascularization-flow index (VFI) will be automatically calculated from three consecutive FVWs.
223754621|NCT04863755|BEHAVIORAL|DASH|Patients receive DASH diet orientation and recommended to maintain their usual physical activity
223754622|NCT04863755|BEHAVIORAL|DASHPED|Patients receive DASH diet orientation and recommended to increase their usual activity with the use of a pedometer
223508245|NCT03402581|DEVICE|c-mac laryngoscope|type of laryngoscopes
223508246|NCT02567032|DRUG|Oxytocin|40 IU of the oxytocin will be administered intranasally for a one time dose at the beginning of the visit.
223508247|NCT02567032|DRUG|Saline Nasal Spray|40 IU of the saline nasal spray will be administered once at the beginning of the visit.
223508248|NCT00036465|BEHAVIORAL|Treatment regimen change|
223508249|NCT05017402|DRUG|Alglucosidase Alfa|Standard dose: 20-25 mg/kg every other week; Higher dose: \>25 mg/kg every other week.
223508250|NCT05137145|DRUG|Linaclotide|The observation group 1 was given Linaclotide in 1 day combined with 4L of Compound Polyethylene Glycol Electrolyte Powder to clear the intestine, and the observation group 2 was given Linaclotide in 1 day combined with 4L of Compound Polyethylene Glycol Electrolyte Powder to clear the intestine. observation group 3 was given Linaclotide in 3 day combined with 3L of Compound Polyethylene Glycol Electrolyte Powder to clear the intestine. Intestinal cleanliness and the incidence of adverse reactions of patients in each group were compared.
223508251|NCT05137145|DRUG|Compound Polyethylene Glycol Electrolyte Powder|The control group was given Compound Polyethylene Glycol Electrolyte Powder to clear the intestines,
223508252|NCT06035198|OTHER|Stroke|No intervention
223508253|NCT02502383|BEHAVIORAL|ACTION PAC|School-based health center providers will use motivational interviewing to assist students with adopting strategies for improving nutrition and increasing physical activity. All participants will receive annual BMI and other health results discussion with clinical providers. Adolescents with overweight/obesity will meet with providers for 16 sessions over 2 years.
223508254|NCT02502383|BEHAVIORAL|Communication with parents|A letter containing BMI and other health results and obesity prevention recommendations will be sent to parent/guardians.
223508255|NCT06500221|BEHAVIORAL|incentive spirometry|The incentive spirometer is widely used in physical, speech, and respiratory therapy, as well as in preventing postoperative pulmonary infections and improving sputum clearance. Consequently, this study aims to further confirm the role and effectiveness of incentive spirometry in improving lung function, activity endurance, and long-term blood sugar and lipid indices in patients with Type 2 diabetes combined with sarcopenia.
223508256|NCT00366613|PROCEDURE|Cataract surgery with Perfect Capsule and Sodium Chloride|
223508257|NCT01942980|RADIATION|Radiation therapy Brain metastasis in breast cancer|Radiation
223508258|NCT00327431|GENETIC|Cheek swab samples for DNA|
223508259|NCT00477724|BEHAVIORAL|exercise and respiratory therapy|exercise and respiratory therapy for three weeks in-hospital and 15 weeks at home
223508260|NCT00477724|OTHER|sedentary control group|control group with no specific training
223508261|NCT06255938|DIAGNOSTIC_TEST|smears|PCR smears for HPV testing will be performed
223508262|NCT03862053|DRUG|Manuka honey|manuka eyedrops applied to the ocular surface
223508263|NCT04717583|PROCEDURE|Intense pulsed light (IPL) treatment|"After randomization, one side of the face will be treated with IPL using the M22™ Universal IPL device, once every 4 weeks for 3 consecutive times.~Starting from Week 12 (the time point of the primary endpoint), the control side of face will also be treated by IPL if the IPL-treated side shows satisfactory improvement of erythema or telangiectasia by IPL treatment. If the patient was unsatisfied with the improvement in the IPL-treated side at Week 12 visit, no IPL treatment will be given to either side of the face any more."
223508264|NCT01749566|DRUG|maraviroc|Maraviroc administered at standard (300mg po bid) or reduced (300mg po daily) dosing
223508265|NCT02194088|DRUG|Diclofenac and Atropine combination drug|Diclofenac will be associated with a small dose of atropine 1.2mg
223754623|NCT00067678|DRUG|soy protein|
223754624|NCT03777293|DEVICE|ultrasound viscoelasticity|use these devices to do ultrasound examination in chronic liver disease patients
223754625|NCT03550703|BIOLOGICAL|V3-Myoma|Once daily oral pill of V3-Myoma
223754626|NCT02265055|PROCEDURE|transfer early cleavage embryos|transfer early cleavage embryos
223754627|NCT02265055|PROCEDURE|transfer non early cleavage embryo|
223754628|NCT01200797|DRUG|SJG-136|Given IV
223754629|NCT01200797|OTHER|laboratory biomarker analysis|Correlative studies
224311584|NCT01707056|OTHER|Water|Taking Synthroid with water for a period of 6 weeks.
223754630|NCT03048656|OTHER|static posturography|The measurement of the weight distribution and the static posturography was performed on the balance platform Good Balance by Metitur . The device is comprised of the triangular force platform with electronic system and computer software. The body weight distribution was evaluated in the upright standing with eyes open, feet placed 20 cm from each other.The individual stood motionlessly for 15 s, then the measurement was recorded. The static posturography was performed with 3 various positions of feet, both with eyes open and eyes closed. (1) Position : normal standing - an upright standing with feet placed parallel 20 cm apart for 30 s. (2) Position: tandem - a stance with one foot placed ahead of the other. for 20 s. (3) Position: one leg standing: stance on the one leg for 20 s.
223754631|NCT02251795|DRUG|Tipranavir|
223754632|NCT02251795|DRUG|Ritonavir|
223754633|NCT02251795|DRUG|Darunavir|
223754634|NCT02251795|DRUG|Aspirin|single dose on day 2
223754635|NCT02213211|DRUG|Artemether lumefantrine|
223754636|NCT02177279|OTHER|Visit A high wheat bran|
223754637|NCT02177279|OTHER|Visit B normal wheat bran|
223754638|NCT02177279|OTHER|Follow up normal (8days) and high (1day) bran consumption|
223754639|NCT05699083|OTHER|Body Image/Self-Esteem Questionnaires|Pre-operation and post-operation questionnaires to assess factors including but not limited to body image, quality of life, and self-esteem.
223754640|NCT01644175|DRUG|Placebo (for alirocumab)|Solution for injection, one subcutaneous injection in the abdomen, thigh, or outer area of upper arm with a disposable auto-injector (also known as pre-filled pen).
223754641|NCT01644175|DRUG|Alirocumab|Solution for injection, one subcutaneous injection in the abdomen, thigh, or outer area of upper arm with a disposable auto-injector (also known as pre-filled pen).
223754642|NCT01644175|DRUG|Lipid-Modifying Therapy (LMT)|Statin (rosuvastatin, simvastatin or atorvastatin) at stable dose with or without other LMT as clinically indicated.
223754643|NCT01261182|OTHER|In School Feeding|The intervention provides meals consisting of 1049 kcals of energy, 32.6 gm protein, and 24.9 gm fat per child per school day and meet at least two thirds of the child's daily vitamin and mineral requirements, including 99 percent of iron requirements. SFP delivers these nutrients in the form of a fortified corn-soy porridge around mid-morning and beans and maize meal or rice at lunch.
223754644|NCT01261182|OTHER|Take Home Rations|The rations provided in the intervention are equal in size and composition to the food received in the in-school feeding intervention, but are provided to households once per month.
223754645|NCT04174911|DRUG|BOL-DP-o-08|BOL-DP-o-08 sublingual drops
223754646|NCT04174911|DRUG|Placebo|sublingual drops
223754647|NCT04819555|GENETIC|Blood|a blood sample will be taken during hospitalisation for diagnostic confirmation or during the quarterly multidisciplinary consultations scheduled as part of the standard follow-up set up for these patients in the ALS centres of the FILSLAN network. If the genetic status is not yet known, this sample will be taken (1 tube of 7mL EDTA) and then sent within 24-48 hours at room temperature to one of the 3 participating molecular biology laboratories according to the criteria defined in the manual of samples being taken in the 3 laboratories.
223754648|NCT00648596|DRUG|sildenafil|sildenafil 50 mg tablet by mouth 1 hour before sexual activity for 12 weeks; the dose could be increased to 100 mg or decreased to 25 mg.
223754649|NCT00648596|DRUG|placebo|placebo tablet by mouth 1 hour before sexual activity for 12 weeks
223754650|NCT01442870|DRUG|Metformin|Metformin
223754651|NCT04717375|DRUG|SAR444881|Pharmaceutical form: Solution for infusion; Route of administration: Intravenous
223754652|NCT04717375|DRUG|Pembrolizumab|Pharmaceutical form: Solution for infusion; Route of administration: Intravenous
223508266|NCT02194088|DRUG|Placebo|For each capsule of active medication, a capsule of placebo will be provided, identical looking.
223754653|NCT04717375|DRUG|Cetuximab|Pharmaceutical form: Solution for infusion; Route of administration: Intravenous
223754654|NCT04717375|DRUG|Carboplatin|Pharmaceutical form: Concentrate for solution for infusion; Route of administration: Intravenous
223754655|NCT04717375|DRUG|Pemetrexed|Pharmaceutical form: Powder for concentrate for solution for infusion or concentrate for solution for infusion; Route of administration: Intravenous
223508267|NCT03630510|OTHER|Ventilator hyperinflation|The ventilator hyperinflation maneuver with inspiratory time adjustment was performed in the pressure controlled ventilation mode (PCV). The inspiratory pressure was increased gradually every 5 cmH2O until reaching a maximum pressure of 35 cmH2O, according to the tolerance of the patient determined by the absence of cough. PEEP remained unchanged throughout the study. After reaching a maximum pressure of 35 cmH2O (PCV + PEEP level), the inspiratory time was gradually increased until the inspiratory flow reached the baseline. Concomitantly, the respiratory rate was decreased to allow the expiratory flow also to reach the baseline, to avoid self-PEEP. The maneuver was performed for 5 min, followed by tracheal aspiration.
223508268|NCT04242654|PROCEDURE|Handheld fetal doppler ultrasound|Handheld fetal doppler ultrasound will be used to assess heart rate in high-risk neonates.
223508269|NCT01008527|DRUG|CP 870,893|Study drug will be administered open-label as an intravenous solution, followed by observation. Study drug will be supplied as a liquid intravenous solution in vials containing 10 mg/mL of CP870,893. CP 870,893 will be administered at a dosage of 0.01, 0.025 or 0.05 mg/kg at 0.24 mg/mL infused via a syringe pump over 15 minutes, or at 0.1 or 0.2 mg/kg/dose as an i.v. infusion in saline at a concentration of 0.24 mg/mL in an IV bag of up to 100 mL over 30 minutes (controlled by a volumetric pump) for not more than 30 minutes, with a 10 cc flush at the end that should be administered at the same rate as the CP 879,893 infusion.
223508270|NCT01008527|BIOLOGICAL|Peptides|NY-ESO-l 157-165 (165V) and gpl002 80-288 (288V) peptides each at a dose of 0.5 mg will be emulsified with Montanide ISA 51 VG and administered to all patients in the study at Weeks 1,3, 5, 7, 9, 11, 17, 21, 25 33, 41, and 53. Peptides will be administered as a total of 6 deep subcutaneous (s.c.) injections into alternating lower extremities one hour after CP 870,893 infusions.
223508271|NCT01008527|BIOLOGICAL|Oncovir poly IC:LC|The dosage of poly IC:LC chosen for the current trials has been used safely in over one hundred patients with central nervous system (CNS) malignancies enrolled in nitrates and bone turnover (NABT) trials. The injection of 1000 mcg will be made deeply subcutaneously into the same limb as the peptides/Montanide ISA 51 VG, at least 5 cm. proximal to the peptides vaccination site. Poly IC:LC will be administered to all patients in the study at Weeks 1, 3, 5, 7, 9, 11, 17, 21, 25 33, 41, and 53 one hour after CP 870,893 infusion.
223508272|NCT02950974|DRUG|Sterofundin|Fluid loading
224200758|NCT03280563|DRUG|Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 (PD-L1) antibody|Atezolizumab will be given as 840 milligrams (mg) via intravenous (IV) infusion on Days 1 and 15 of each 28-day cycle. This regimen will apply to all arms except when given with entinostat in Stage 1, or exemestane or tamoxifen in Stage 2, in which atezolizumab will be given as 1200 mg via IV infusion on Day 1 of each 21-day cycle.
224200759|NCT03280563|DRUG|Bevacizumab|Bevacizumab will be given as 10 milligrams per kilogram (mg/kg) via IV infusion on Days 1 and 15 of each 28-day cycle in the regimen containing fulvestrant. When given with exemestane or tamoxifen, bevacizumab will be given as 15 mg/kg via IV infusion on Day 1 of each 21-day cycle.
224200760|NCT03280563|DRUG|Entinostat|Entinostat will be given as 5 mg orally once a week on Days 1, 8 and 15 of each 21-day cycle.
224200761|NCT03280563|DRUG|Exemestane|Exemestane will be given as 25 mg orally QD in each 21-day cycle.
224200762|NCT03280563|DRUG|Fulvestrant|Fulvestrant will be given as 500 mg intramuscularly on Days 1 and 15 of Cycle 1 and thereafter on Day 1 of each 28-day cycle.
224200763|NCT03280563|DRUG|Ipatasertib|Ipatasertib will be given as 400 mg orally QD on Days 1-21 of each 28-day cycle.
224200764|NCT03280563|DRUG|Tamoxifen|Tamoxifen will be given as 20 mg orally QD in each 21-day cycle.
224200765|NCT03280563|DRUG|Abemaciclib|Abemaciclib will be given as 150mg twice daily during each 28-day cycle.
224200766|NCT01607398|DRUG|ADOAIR250|250 mcg inhalation, twice daily, from week0 -12.
224200767|NCT01607398|DRUG|Placebo|Placebo inhalation, twice daily, from week0 -12.
224200768|NCT03858920|DEVICE|Fibroscan of Liver|A non-invasive diagnostic device used to measure liver scarring
224200769|NCT03858920|PROCEDURE|Low-dose non-contrast CT|CT scan as part of routine research care
224200770|NCT04965896|OTHER|Control meal|Participants will receive plain white rice (75g of available carbohydrate) alongside a snack with crackers and cheese. The meal is similar in energy and macronutrients to the test meal.
224200771|NCT04965896|OTHER|Nut meal|Participants will receive plain white rice (75g of available carbohydrate) alongside a portion of 30g of nuts. The meal is similar in energy and macronutrients to the control meal.
224200772|NCT00000227|DRUG|Buprenorphine|
224200773|NCT06703827|BEHAVIORAL|The metacognitive training group|The MCT will consist of spending 90 minutes a week in a small online group setting working through a series of workshops. Participants will also be asked to complete homework each week and they will be supported with this. Interviews and questionnaires regarding symptoms and thinking errors will be used before and immediately after the intervention. The participants who attended the group and improved in their symptoms and thinking errors will be invited to an interview asking them what worked for them and how they found the group.
223508273|NCT02950974|DRUG|NSS|Fluid loading
223508274|NCT01011231|PROCEDURE|Gamma Knife Radiosurgery|Patient treatments will be planned with the Gamma Plan software. The dose will be prescribed to the isodose surface which encompasses the target volume within a range of 50-60% based on a local maximum of 100%. Radiosurgery dose will be prescribed based on volume within the prescribed isodose surface (not to exceed 18 cc)
223508275|NCT00458705|DRUG|bortezomib|
223508276|NCT00458705|DRUG|dexamethasone|
223508277|NCT00458705|DRUG|pegylated liposomal doxorubicin hydrochloride|
223508278|NCT00458705|DRUG|thalidomide|
223508279|NCT00337454|DRUG|Dasatinib|Tablets, Oral, 50mg BID, once daily, 24 weeks.
223508280|NCT00337454|DRUG|Dasatinib|Tablets, Oral, 70mg BID, once daily, 24 weeks.
223508281|NCT00337454|DRUG|Dasatinib|Tablets, Oral, 90mg BID, once daily, 24 weeks.
223508282|NCT00337454|DRUG|Dasatinib|Tablets, Oral, 70mg BID, once daily, 24 weeks.
223508283|NCT00337454|DRUG|Dasatinib|Tablets, Oral, 70mg BID, once daily, 12 weeks.
223508284|NCT00337454|DRUG|Dasatinib|Tablets, Oral, 70mg BID, once daily, 12 weeks.
223508285|NCT00392275|DRUG|Ofloxacin 0.3%|
223508286|NCT00392275|DRUG|Ciprofloxacin 0.3%|
223508287|NCT00392275|DRUG|Levofloxacin 0.5%|
223508288|NCT00392275|DRUG|Ofloxacin 400mg|
223508289|NCT00392275|DRUG|Ciprofloxacin 400mg|
223508290|NCT00392275|DRUG|Levofloxacin 250mg|
223508291|NCT04195672|DEVICE|NIPE (MDoloris®) and CBS values|"During different procedures of care with the bed-side nurse, NIPE ware recorded. Monitoring started 15 minutes before care and continuously recorded until 10 minutes after the procedure. Pain assessment was evaluated by the CBS under 3 periods for each patient: 1- before any procedure (T1) representing the baseline, 2- during the procedure of care (T2), and 3- after the procedure (T3). Investigator who performed the CBS was blind to NIPE during the procedure recording.~This study did not change the procedure of care before or after and had no impact on care"
223508292|NCT01951456|BEHAVIORAL|Resistance training|
223508293|NCT01951456|BEHAVIORAL|Health and Wellness|
223508294|NCT04884074|PROCEDURE|Standard Sleeve Gastrectomy plus Anterior Crural Repair|The procedure is performed in a similar fashion as standard sleeve gastrectomy. After gastric mobilization is completed as standard sleeve gastrectomy, the anterior phrenoesophageal ligament is divided and distal 3cm esophagus is mobilized. A Mid-Sleeve tube (40Fr) is inserted per-orally by the anesthetist and the hiatus opening is closed with 2/0 non-absorbable suture over the bougie anterior to the esophagus. The hiatus repair was sized by comfortably placement a dissection forceps adjacent to the esophagus without tension. Sleeve gastrectomy is then performed as the standard technique.
223508295|NCT04884074|PROCEDURE|Standard sleeve gastrectomy (SSG, the control group)|"The procedure is performed in French position with a standard 5-port approach and a pneumoperitoneum not exceeding 15mmHg.~The greater omentum is then completely detached from the greater curvature of stomach using either ultrasonic or bipolar shear device. All adhesion between posterior gastric wall and pancreatic capsule is freed and the cardia is completely free with left crura completely exposed. A Mid-Sleeve tube (40Fr) is inserted per-orally by the anesthetist with its balloon tip reaching the gastric antrum and insufflated with 50cc of air. Sleeve gastrectomy is then performed using laparoscopic linear staplers, starting from a point 5-6cm proximal to the pylorus up cardia at about 1cm lateral to the angle of His, along the Mid-sleeve tube which is lying against the lesser curve of stomach. The staple line is reinforced with absorbable sutures. Distal stomach is anchored at retroperitoneum with non-absorbable stitch."
223607925|NCT02316080|OTHER|Desensitizing therapy|Participants (in T1 and T2) used domestic-use (DU) or in office (IO) desensitizers (D): Control Group; (DU)- experimental dentifrice with 7,5% of Biosilicate micro-particles-(D1); Sensodyne® dentifrice-(D2); (DU)-Odontis RX Sensiblock® dentifrice-(D3); (IO)-Biosilicate micro-particles paste, 1:1-(D4); (IO)-bioglass type 45S5 paste, 1:1 (D6); (IO)-Desensebilize Nano P-(D6).
223607926|NCT00940901|DRUG|sildenafil|sildenafil 50 mg tablet daily for first 8 weeks (phase 1), and then sildenafil 50 mg tablet daily for final 8 weeks (phase 2)
223607927|NCT00940901|OTHER|placebo|placebo 50 mg tablets daily for first 8 weeks (phase 1), and then sildenafil 50mg tablet daily for final 8 weeks (phase 2)
223607928|NCT03491826|BIOLOGICAL|rupture of membrane|
223607929|NCT05676307|BEHAVIORAL|Vestibular Rehabilitation|Cawthorne Cooksey Based Vestibular Rehabilitation Exercises (Oculomotor exercise, Vestibulo-ocular Exercise, posture exercise, balance training, etc)
223607930|NCT00757237|DRUG|Aztreonam for Inhalation Solution (AZLI)|Aztreonam for inhalation solution (75 mg) was administered 3 times a day (TID) for 28 days for each treatment cycle via the PARI eFlow electronic nebulizer.
223754656|NCT00265512|BEHAVIORAL|Telephone Case Monitoring|Telephone Case Monitoring involves telephone delivery of continuing care treatment post intensive outpatient SUD treatment. It includes brief weekly phone calls with a counselor for up to 6 months.
223607931|NCT00757237|DRUG|Tobramycin Inhalation Solution (TIS)|Tobramycin inhalation solution (300 mg) was administered 2 times a day (BID) for 28 days for each treatment cycle via the PARI LC Plus nebulizer with compressor or via another nebulizer compatible with country-specified labeling.
223607932|NCT01534000|PROCEDURE|Cardiac computed tomographic angiography (CCTA)|Patients will (on top of the standard clinical evaluation with a functional-based stress-test) be examined with a Cardiac CT scan. In the control group, the Cardiac CT will be blinded for clinical evaluation and only used retrospectively for research purpose.
223607933|NCT02168907|DRUG|6,8-bis(benzylthio)octanoic acid|Given IV
223607934|NCT02168907|DRUG|bendamustine hydrochloride|Given IV
223607935|NCT02168907|BIOLOGICAL|rituximab|Given IV
223607936|NCT02168907|OTHER|laboratory biomarker analysis|Correlative studies
223607937|NCT03534102|DRUG|Improved Opioid-Tapering Instructions|Applied to first and second experimental groups in the form of discharge instructions and directions from nursing staff.
223754657|NCT00265512|BEHAVIORAL|Continuing Care as Usual|Continuing Care as Usual will include standard group outpatient SUD treatment.
223754658|NCT04222712|DRUG|TRS01 eye drops|Dosed four times a day (QID)
223754659|NCT04222712|DRUG|TRS01 eye drops|Dosed four times a day (QID)
223754660|NCT02881645|BEHAVIORAL|Best practices|Nurses in intensive care units will be trained to the best practices protocol for a period of two-month preceding the trial
224200774|NCT03088280|DRUG|Thymoglobulin|reduced dose (3mg/Kg)
224200775|NCT00001001|DRUG|Zidovudine|
224200776|NCT03925116|OTHER|COntraceptive pathway|alternative way of aiding patients in deciding contraception method
223508296|NCT03963622|OTHER|Respiratory Mechanics|"Different maneuvers based on respiratory mechanics will be assessed at the bedside and will be used to individualize ventilator parameters. Recruitability will be assessed with a one breath decremental PEEP maneuver, and search for airway closure with a low-flow pressure volume or pressure-time curve. If the patient has airway closure, the minimal PEEP will be set at the airway opening pressure to avoid closure. If the patient is considered recruitable, the goal is to set PEEP at or above 15cmH20 to maximize alveolar recruitment, until the plateau pressure reaches the safety limit. Volume control ventilation at 6ml·kg-1 will be used.~Once spontaneous breathing has started, the occlusion pressure (P0.1) will be maintained within targets."
223607938|NCT03534102|BEHAVIORAL|Clinical Patient Educator|Applied to second experimental group in the form of regular calls about weaning off narcotic medications.
223607939|NCT04977284|DEVICE|DS7R, Digitimer, UK|Non-surgical spinal cord stimulation will be applied and electrical activity of muscles will be recorded.
223607940|NCT03738488|DEVICE|3D printing + images|To perform a surgery planification with the combination of the images available and the 3D biomodel in terms of: anticipation of potential complications and the human resources and necessary materials
223607941|NCT03738488|OTHER|Images|To perform a surgery planification with the images available in terms of: anticipation of potential complications and the human resources and necessary materials
223607942|NCT02718729|PROCEDURE|Laparoscopic resection for rectal cancer|Formal curative radical laparoscopic rectal resection.
223754661|NCT06456333|DEVICE|High-density surface electromyography|Electromyographic signals were acquired from the paravertebral muscles in apical vertebral in patients with AIS using SAGA High Density Myoelectrics (TMSi International, New Zealand)
223754662|NCT05121883|DRUG|Edaravone Dexborneol|Edaravone dexborneol (Jiangsu Simcere Pharmaceutical, Co, Ltd) will be initiated within 48 hours of stoke onset at 37.5 mg/dose, once every 12 hours, and continuing for more than 7 days (maximum: 14 days)
223754663|NCT00196079|DEVICE|Coronary stent|
223754664|NCT05697887|DIETARY_SUPPLEMENT|Ketogenic diet|The ketogenic diet (KD) has been shown as an effective alternative for patients with drug-resistant epilepsy
223754665|NCT01113762|DEVICE|articular surface replacement ASR, DePuy|posterolateral incision
223754666|NCT01113762|DEVICE|ReCap/Magnum modular head, Biomet|posterolateral incision
223754667|NCT01113762|DEVICE|Bimetric stem, mallory/head cup, 28 mm ceramic head, Biomet|posterolateral incision
223754668|NCT01113762|DEVICE|28 mm CrCo head, Trilogy CH cup, VerSys Fiber stem,Zimmer)|posterolateral incision
223754669|NCT04993287|OTHER|Non-invasive continuous remote monitoring with structured escalation pathway|Continuous patient monitoring through non-invasive biosensors coupled with machine learning algorithms, with a structured escalation and communication pathway for home health providers and HF care team
223754670|NCT04993287|OTHER|Affective Analysis of Participant Response to Continuous Remote Patient Monitoring|Surveys and interviews with enrolled participants
224200777|NCT06648317|OTHER|FDG-PET|All study participants will undergo 18F-FDG PET/CT scan within 1 week
224200778|NCT06451679|OTHER|Observational|Observational prospective study
224200779|NCT00571909|PROCEDURE|video thorascopic splanchnicectomy (VSPL)|VSPL is a minimally invasive technique using 1-2cm incisions through which a camera and surgical tools are placed inside the thoracic cavity and the idea of the procedure is to cut the pain pathway linking the splanchnic ganglion with pain centers in the hypothalamus
223754671|NCT00819468|DRUG|Teduglutide|Participants will receive 20 mg dose of lypholized powder of teduglutide mixed with sterile water and injected subcutaneously into the abdomen.
223754672|NCT01880112|DRUG|Cefazolin|Cefazolin will be administered as pre-operative prophylaxis in normal weight patients undergoing Cesarean delivery. Tissue and serum levels will be measured at the time of the incision and when the incision is closed.
223754673|NCT02323854|DEVICE|Ablation|Percutaneous antenna will be placed into the target tumor under CT image guidance. Target tumor will be ablated and the antenna will be removed.
223754674|NCT02323854|PROCEDURE|Surgical Resection|The planned surgical resection of the lung tumor will be conducted as scheduled post ablation procedure.
223508297|NCT03963622|OTHER|Standard Ventilation Strategy|Patients randomized to the control arm will receive standard care. The PEEP is adjusted for oxygenation based on a PEEP-FiO2 table, either the low PEEP-FiO2 or the high PEEP-FiO2 table. Volume targeted ventilation with initial VT 6 mL·kg-1 and Plateau pressure at 30 cmH2O or below, targeting PaO2 60-80 or SpO2 90-95%, adjusted as per the protocol. Pressure-support ventilation is at physician's discretion, but recommended when FiO2 \<60%, and is titrated VT 6-8 mL·kg-1.
223508298|NCT00935207|OTHER|Pediatric Pain Diary|Pain diary designed for pediatric patients
223508299|NCT02172261|DRUG|BI 10773|
223508300|NCT02172261|DRUG|Glimepiride|
223508301|NCT05521282|DRUG|Treatment group|Based on the basic treatment, Qianglidingxuan Tablets were given 6 tablets/time, 3 times a day, and warm water was given for 12 weeks.
223508302|NCT05233059|BEHAVIORAL|FitEx|FitEx is an 8 week goal-setting, behavior tracking, physical activity intervention with a low dose of social support which will be delivered virtually.
223508303|NCT05233059|BEHAVIORAL|Weekly Yoga Sessions|30 minutes of optional guided yoga online led by a 500 hour yoga teacher once a week for participants in the walking plus yoga arm. Also accompanied by a yoga based newsletter.
223508304|NCT05233059|BEHAVIORAL|Weekly Movement Sessions|30 minutes of optional guided movement online led by a 500 hour yoga teacher once a week for participants in the walking arm. Also accompanied by a movement based newsletter.
223508305|NCT06000904|OTHER|Exergame-based balance training|For a four-week intervention consisting of three weekly sessions, each lasting 60 minutes. Each training session will include a 5-minute warm-up activity, 40-minute balance exercise, and 15-minute ground walking as a cool-down.
223508306|NCT06000904|OTHER|Upper limb and trunk training|For a four-week intervention consisting of three weekly sessions, each lasting 60 minutes. Each training session will include a 5-minute warm-up activity, 40-minute upper-limb and trunk exercise, and 15-minute ground walking as a cool-down.
223508307|NCT02505672|RADIATION|Chemoradiotherapy for nasopharyngeal carcinoma|Note that this is standard care for NPC and patients are not assigned to different intervention groups. All patients in the study will receive the same treatment (chemoradiotherapy) and will be observed for changes in vestibular function.
223508308|NCT00638391|DRUG|Anastrozole|
223508309|NCT04794478|DEVICE|Dexcom Continuous Glucose Monitoring System|Dexcom Continuous Glucose Monitoring System
223508310|NCT06181058|BEHAVIORAL|escape room game|Participants will be informed about the game (15 minutes). They will complete the game by solving puzzles within the framework of the oncology patient scenario (approximately 30 minutes). There will be a debriefing session at the end of the escape game (15 minutes).
223508311|NCT00209638|DRUG|irinotecan|
223508312|NCT00209638|DRUG|S-1|
223508313|NCT04843839|DRUG|Nepafenac 0.1% Oph Susp|Nepafenac 0.1% eye drops - Allergan : Dosage- 1 drop QID for 6 months
223508314|NCT04843839|DRUG|Refresh Tears 0.5% Lubricant Eye Drops|Refresh Tears 0.5% w/v eye drops - Allergan : Dose- 1 drop QID for 6 months
223508315|NCT02931227|PROCEDURE|temperature obtained by the non-invasive method of zero-heat flux|
223508316|NCT02931227|PROCEDURE|esophageal temperature|
223508317|NCT02931227|PROCEDURE|intracerebral temperature|
223508318|NCT02931227|PROCEDURE|arterial temperature|
223508319|NCT03976141|DIAGNOSTIC_TEST|mri|knee mri
223508320|NCT00306280|DEVICE|Phototherapy|
223508321|NCT02091830|DRUG|Paracetamol and nonsteroidal antiinflammatory drug (NSAID)|
223508322|NCT02091830|OTHER|Physiotherapy|
223508323|NCT02091830|DRUG|Cortisone Injection|
223508324|NCT02091830|OTHER|Others|
223508325|NCT03357445|OTHER|Avantage Reload cup|Patients receiving the Avantage Reload acetabular cup in total hip arthroplasty
223508326|NCT05800626|PROCEDURE|Endoscopic Retrograde Cholangio-Pancreatography (ERCP)|ERCP performed for clinical practice
223508327|NCT05597605|DEVICE|The SHINE SYSTEM|The FUSHO sensor, which is part of the SHINE SYSTEM, is a continuous multi-metabolite monitoring (CMM) sensor which is a miniaturized near-infrared spectrometer that measures the absorption of light in the interstitial fluid to quantify the concentration of multiple metabolites
223508328|NCT00604383|DRUG|ruboxistaurin|32-mg tablet, orally, daily, up to 42 months
223508329|NCT00604383|DRUG|placebo|1 tablet, orally, daily, up to 42 months
223508330|NCT05688657|DEVICE|Lens A|Monthly Replacement Toric Silicone Hydrogel Contact Lens 15 minutes of daily wear
223508331|NCT05688657|DEVICE|Lens B|Daily Disposable Toric Silicone Hydrogel Contact Lens 15 minutes of daily wear
223508332|NCT00163735|DRUG|Administration of wine fined with potential food allergens|
223508333|NCT04998149|DEVICE|Peanut Ball positioning device|Peanut Ball manufactured by Clinton industries at graylinemedical.com https://www.graylinemedical.com/products/clinton-industries-peanut-ball-peanut-ball-40-cm-yellow-8540?\_pos=3\&\_sid=d6e52e63c\&\_ss=r
223508334|NCT06190665|DEVICE|DEB-TACE with visualable microspheres|Drug-eluting Beads Transcatheter Arterial Chemoembolization(DEB-TACE) with visualable microspheres
223508335|NCT06190665|DEVICE|DEB-TACE with PVA microspheres|Drug-eluting Beads Transcatheter Arterial Chemoembolization(DEB-TACE) with polyvinyl alcohol microspheres
223508336|NCT02681042|PROCEDURE|Left atrial appendage closure|The SentreHeart Lariat® device (that is approved for soft tissue ligation) will be used to ligate or close the left atrial appendage as a stand-alone procedure at the participating centers.
223754675|NCT06250062|DRUG|Recombinant humanized IL-17A Monoclonal Antibody（JS005）|Injection
223754676|NCT06250062|DRUG|Placebo（JS005）|Injection
223754677|NCT04657133|DEVICE|Remote ischemic conditioning|RIC is a non-invasive therapy that performed by an electric autocontrol device with cuff placed on arm. RIC procedures consist of five cycles of 5-min inflation (200 mmHg) and 5-min deflation of cuff on one arm. The procedure will be performed once daily for consecutive 7 days after enrollment.
223754678|NCT04657133|DEVICE|Sham remote ischemic conditioning|Sham RIC will be performed by the same electric autocontrol device with cuff placed on arm. Sham RIC procedures consist of five cycles of 5-min inflation (30 mmHg) and 5-min deflation of cuff on one arm. The procedure will be performed once daily for consecutive 7 days after enrollment.
223754679|NCT04657133|DRUG|Standard medication therapy|Standard medication therapy will be performed according to the national and international guidelines.
223508337|NCT02681042|DEVICE|SentreHeart Lariat®|The SentreHeart Lariat® device (that is approved for soft tissue ligation) will be used to ligate or close the left atrial appendage as a stand-alone procedure at the participating centers.
223508338|NCT05928208|DIAGNOSTIC_TEST|no intervention|no intervention
223508339|NCT04297267|DRUG|Gemcitabine|Gemcitabine 1250mg/m2,d1,d8,every 3 weeks
223508340|NCT04297267|DRUG|Cisplatin|Cisplatin 75mg/m2,d1，every 3 weeks
223508341|NCT01122680|DRUG|Tiotropium bromide|inhalation solution, dose of 1.25 mcg (2 puffs of 0.625 mcg)
223508342|NCT01122680|DRUG|tiotropium bromide|inhalation solution, dose of 2.5 mcg (2 puffs of 1.25 mcg)
223508343|NCT01122680|DRUG|tiotropium bromide|inhalation solution, dose of 5 mcg (2 puffs of 2.5 mcg)
223508344|NCT01122680|DRUG|Placebo|placebo inhalation solution
223508345|NCT00225758|DRUG|Lapatinib|1500 mg po daily for 26 weeks or longer
223508346|NCT06274437|DRUG|BND-35|Pharmaceutical form: Solution for infusion; Route of administration: Intravenous
223508347|NCT06274437|DRUG|Nivolumab|Pharmaceutical form: Solution for infusion; Route of administration: Intravenous
223508348|NCT06274437|DRUG|Cetuximab|Pharmaceutical form: Solution for infusion; Route of administration: Intravenous
223508349|NCT04939805|DEVICE|Selective CRP apheresis using the PentraSorb®-CRP system|Selective CRP apheresis as an adjunct to standard of care. Apheresis using the PentraSorb®-CRP system will be performed at day 1, 2 and 3 after PCI.
223508350|NCT01744418|DEVICE|HAVG graft implantation|Patients will be implanted with a Human Acellular Vascular Graft (HAVG) in the forearm or upper arm (arterial anastomosis to the radial or brachial artery, venous anastomosis to either the brachial, cephalic or very central basilica vein) using standard vascular surgical techniques. The graft will be placed in a straight or curved configuration in the first 10 patients. Loop grafts may be permitted in subsequent patients subject to acceptable graft performance at the interim safety review. Placing the graft across the elbow will be avoided.
223508351|NCT06342960|BIOLOGICAL|KYV-101 anti-CD19 CAR-T cell therapy|KYV-101 anti-CD19 CAR-T cell therapy
223508352|NCT06342960|DRUG|Standard lymphodepletion regimen|Standard lymphodepletion regimen
223508353|NCT05220930|OTHER|Foot bath for heel warming|In this study, in line with the literature, the attempt to apply heat with a foot bath will be carried out by immersing both legs of the newborn in a basin filled with 15-20 cm of water at 38-40C, 5 minutes before the heel blood collection, starting just below the knee level. The intervention will be applied while the newborn is held in an upright position on his mother's lap.
223508354|NCT05220930|OTHER|Ineffective heel warming with thermofor|Ineffective heel warming will be applied to the newborns in the control group with a thermofor containing 28C warm water for 5 minutes before the heel blood collection procedure. During the procedure, the general condition of the newborn and the changes in his skin will be observed closely. Heel blood collection will be performed by following the standard procedure steps that are routinely applied in the service.
223508355|NCT06643546|OTHER|theoretical training|received only theoretical breastfeeding training
223508356|NCT06643546|OTHER|model simulation training|theoretical breastfeeding training and model simulation training accompanied by scenarios
223508357|NCT06643546|OTHER|live-simulation|theoretical breastfeeding training and live simulation training with scenarios
223508358|NCT06645262|OTHER|Cryotherapy|cryotherapy, therapeutic exercises, the use of braces, and the Bowen technique.
223508359|NCT05927298|OTHER|Non-interventional|Standard of care intervention
223508360|NCT04139499|PROCEDURE|Drug-induced sleep endoscopy (DISE)|DISE involves administering anesthetic to a patient to simulate a sleep state, and then visualizing the upper airway using transnasal flexible endoscopy. Sites of obstruction at key locations including the adenoids, soft palate, lateral oropharynx, tongue base, and epiglottis can be identified.
223508361|NCT04139499|PROCEDURE|High-resolution manometry (HRM):|After the necessary clinical information has been obtained (if obstruction is occurring at those levels and, if so, to what degree), a flexible high-resolution manometry (HRM) catheter will be passes through the contralateral nostril to record pressure along the length of the pharynx at those same sites.
223508362|NCT00610948|BIOLOGICAL|panitumumab|Given IV
223508363|NCT00610948|DRUG|everolimus|Given orally
223508364|NCT00610948|DRUG|fluorouracil|Given IV
223508365|NCT00610948|DRUG|leucovorin calcium|Given IV
223508366|NCT00610948|DRUG|oxaliplatin|Given IV
223508367|NCT06345118|BEHAVIORAL|Otago exercise program|"The OEP consists of 17 strength and balance exercises and a walking program performed thrice a week by the older adult at home.~Program Prescription The program is designed to be delivered over 6 months and includes a minimum of 5 visits. The first visit is Day 1 of Otago when performance of the functional measures is assessed, and the exercises are prescribed at the Rehabilitation Center of the National Geriatric Hospital. Then, the therapist will see the patient for 4 visits over an 8-week period (typically every other week). This is considered the initial bolus of Otago. Then, the therapist will follow the patient via phone calls every week and make a visit at three months, four months, five months, and six months to reassess the patient's training ability and compliance.~Monitoring:~Calendars can be completed each month to document any falls. A calendar or diary can be used to monitor compliance with the exercise programme"
223508368|NCT01449032|BIOLOGICAL|MSC|No of cells after culture expansion
223508369|NCT01449032|BIOLOGICAL|Saline|3 cc saline
223607943|NCT06022796|OTHER|Healthy Ketogenic Ready-to-Eat Meals|Participants will be provided nutrition education via 5 dietary workshops focusing on a healthy ketogenic diet. In addition, HK-RTE meals will be provided to participants as a form of meal replacement for lunch and dinner over 1 month. Participants will be expected to follow a healthy ketogenic diet thereafter.
223607944|NCT06022796|OTHER|Healthy Ketogenic Diet|Participants will receive nutrition education via 5 dietary workshops focusing on a healthy ketogenic diet, without the provision of HK-RTE meals.
223607945|NCT01787630|DEVICE|Hyaluronic acid|Injection in connection with ultrasound
223607946|NCT02539901|BEHAVIORAL|Evaluation of the detection of non-linguistic sounds|Evaluation of the detection of non-linguistic sounds (sound room)
223607947|NCT02539901|BEHAVIORAL|Free hearing test categorization|Free hearing test categorization evaluation
223607948|NCT02539901|BEHAVIORAL|Early Social Communication Scale (ECSP)|Early Social Communication Scale (ECSP) evaluation
223607949|NCT02539901|BEHAVIORAL|psychomotor infancy development scale|
223607950|NCT02539901|BEHAVIORAL|"NEPSY (two domains: memory and learning and attention and executive functions)."|NEPSY evaluation
223607951|NCT06175481|OTHER|Popliteal Vein Compliance|Compliance of the popliteal vein is calculated as the distensibility, with the ratio of functional caliber/native caliber/cuff pressure value ( mmHg-1 ).
223607952|NCT04579640|DIETARY_SUPPLEMENT|Vitamin D|Capsules containing 800 IU (20 micrograms) or 3,200 IU (80 micrograms) cholecalciferol
223607953|NCT06383806|BEHAVIORAL|Imagery Rehearsal Therapy (IRT)|The intervention will consist of 7 therapy sessions (once per week for 7 weeks) which will be delivered via videoconference. During the sessions, participants will learn techniques for managing and changing nightmares.
223607954|NCT02058446|DRUG|Amlodipine/Valsartan|Amlodipine/Valsartan: 5 mg/80 mg
223607955|NCT02182934|DRUG|Ginsana|
223607956|NCT02182934|DRUG|Placebo|
223607957|NCT01646086|BEHAVIORAL|12 month behavioral weight loss intervention|The intervention for all groups will follow a standard behavioral weight loss protocol. Participants will meet in groups of up to 20 persons; groups will meet weekly for the first six months, then biweekly for two months and monthly for the remaining four months of the 12-month treatment period. Session content will be centered on behavioral goal setting and attention to caloric intake and physical activity. Participants will be asked to keep daily diet and physical activity logs.
223607958|NCT06171685|DRUG|Teclistamab Monotherapy|standard of care
223607959|NCT06171685|DRUG|Teclistamab|investigational doses compared to SOC
223607960|NCT05450094|BEHAVIORAL|Screening Only|The Screening Only intervention integrates enhancements to school-based mental health (SBMH). Each school's typical SBMH service delivery system will be enhanced with biweekly meetings of voluntary school teams (comprised of administrators, school counselors, general and special education teachers, and other school-employed mental health professionals) to 1) follow standardized evidence-based intervention decision making process to identify students with mental health risk, plan and/or refer for an evidence-based intervention, monitor intervention progress, and adjust intervention plans as needed; 2) administer teacher-rated and student self-report universal screening twice annually; 3) review screening and related school records data to identify students with mental health risk; and 4) review screening, referral, and receipt data to monitor progress of entire SBMH service delivery system.
223607961|NCT05450094|BEHAVIORAL|Enhanced Screening|The Enhanced Screening intervention involves the enhancements to school-based mental health (SBMH) of the Screening Only intervention with the addition of 3 empirically-based implementation supports, including training, coaching, and data-based feedback. Enhancement aim to increase school teams' awareness and understanding of students' mental health well-being and need for intervention. enhancements.
223607962|NCT01345188|DRUG|Ranexa|1000 mg Ranexa orally once daily titrated as tolerated after 1 week up to taking 1000 mg twice daily.
223607963|NCT01345188|DRUG|Placebo|1000 mg placebo orally once daily titrated as tolerated after 1 week up to taking 1000 mg twice daily.
223607964|NCT04313075|DRUG|Leronlimab|Leronlimab is a humanized IgG4,κ monoclonal antibody (mAb) to the chemokine receptor CCR5.
223607965|NCT05889676|DIAGNOSTIC_TEST|VEMP by bone conduction|New bone conducted VEMP elicited by transducer B250
223607966|NCT05651932|DRUG|Cohort A1 & A2: KTX-1001|KTX-1001: Orally for 28 days each cycle until progression. Dexamethasone: Orally once weekly
223607967|NCT05651932|DRUG|Cohort B1 & B2: KTX-1001+Mezigdomide|Drug: KTX-1001: Orally for 28 days each cycle until progression Drug: Dexamethasone: Orally once weekly Drug: Mezigdomide Dexamethasone: Orally once weekly
223607968|NCT05651932|DRUG|Cohort C1 & C2: KTX-1001 + Carfilzomib (KYPROLIS®)|Drug: KTX-1001: Orally for 28 days each cycle until progression Drug: Dexamethasone: Orally once weekly Drug: Carfilzomib (KYPROLIS®): IV, once weekly for 3 weeks in each 28-day cycle
223607969|NCT05651932|DRUG|Cohort D: KTX-1001+ pomalidomide (Pomalyst, Imnovid)|Drug: KTX-1001: Orally for 28 days each cycle until progression Drug: Dexamethasone: Orally once a week Drug: Pomalidomide (Pomalyst, Imnovid): Orally, for 21 days in each 28-day cycle
223754680|NCT04109664|PROCEDURE|laparoscopic sleeve gastrectomy|The greater omentum is carefully dissected from the stomach at a distance of 2cm for the patients with AR, and 6cm for patients with AP. The omental dissection was performed using 5mm-abdominal ligature (Ligasure®, Metronic-Covidien, Minneapolis, USA), from the antrum towards the angle of His. Transection from the omentum is continued until the left crus has been identified. All sleeves are transected using 36 French orogastric tubes. Green cartridges (4.8 mm staple height) are used for the first firing and blue cartridges (3.5 mm) for the rest. Neither oversewing sutures to the staple line nor staple line reinforcement products are used. Homeostatic metallic clips are used for bleeding at the staple line. If bleeding persists and cannot be controlled, an interrupted suture is performed at the point of bleeding. A leak test with methylene blue is performed to the gastric remnant to assess the integrity of the suture line.
223607970|NCT05150990|BEHAVIORAL|Virtual Reality|Older adults (residents of senior living communities) engage in four 20-minute virtual reality activities (via the Rendever platform) with their adult child each week for 4 consecutive weeks. The 4 sessions include immersive virtual adventures (e.g., bucket list travel) and reminiscence activities (e.g., virtual life story). Adult children participate remotely from their own homes.
223607971|NCT05150990|BEHAVIORAL|Video Chat|Older adults (residents of senior living communities) engage in four 20-minute video chat sessions (via the Zoom platform) with their adult child each week for 4 consecutive weeks. Adult children participate remotely from their own homes.
223607972|NCT05256966|OTHER|Sauna (steam)|Steam Sauna
223508370|NCT06085209|DEVICE|The truFreeze Spray Cryotherapy|A novel FDA cleared technique that allows for liquid nitrogen (LN2) to be delivered in a metered fashion via a catheter through a flexible bronchoscope.
223607973|NCT01966289|DRUG|CY|CY is administered intravenously at 200 mg/m2
223607974|NCT01966289|BIOLOGICAL|GVAX|GVAX is administered intradermally at 5E8 colon cancer cells + 5E7 GM-CSF secreting cells
223754681|NCT01169506|DEVICE|sublingual silicon capillary|Stable patients with COPD and healthy individuals were asked to open their mouth and a small butterfly silicon capillary was placed sublingually. After 15 minutes, while the mouth was closed completely and nose breathing was performed, the capillary system was connected to a capnometer and sublingual tonometric PCO2 was measured. At the same time, PETCO2 was also measured and arterial blood was drawn for pH, PO2 and PCO2 analysis
223754682|NCT03266120|OTHER|Art|Participants will receive a hands-on art activities intervention consisting of two art activities sessions each week lasting approximately 60 minutes each in duration for four weeks for a total of eight sessions. Art activities will include hand papermaking, image transfer, visual storytelling, linocut printmaking, paper batik, mixed media collage, and sensation drawing based activities. Participants will complete sets of self-report psychometric assessments before, during, and following the art intervention. Heart rate and blood pressure will be monitored before, during, and following completion of the art intervention.
223754683|NCT03266120|OTHER|Gardening|Participants will receive a hands-on gardening intervention consisting of two gardening sessions each week lasting approximately 60 minutes each in duration for four weeks, for a total of eight sessions. Gardening activities will include planting seeds, bulbs and tubers, transplanting seedlings, vegetative propagation and sight, smell, taste and touch sensory based activities. Participants will complete sets of self-report psychometric assessments before, during, and following the gardening intervention. Heart rate and blood pressure will be monitored before, during, and following completion of the gardening intervention.
223754684|NCT01553006|DRUG|cefditoren pivoxil|comparison of different dosages of cefditoren pivoxil
223754685|NCT04714996|DRUG|ES-481|"Treatment Period Week 1 - 25 mg qd, Week 2 - 25 mg bid, Week 3 - 50 mg bid, Week 4 - 75 mg bid.~Step-down and Washout Period Day 1 - 125 mg, Day 2 - 100 mg, Day 3 - 75 mg, Day 4 - 50 mg, Day 5 - 50 mg, Day 6 - 25 mg, Day 7 - 25 mg, Days 8 to 14 - 0 mg"
223754686|NCT04714996|DRUG|Placebo|Placebo on Week 1, Week 2, Week 3 and Week 4
223754687|NCT04714996|DRUG|Open-Label Extension Study|Dosing will be at the discretion of the Investigator with a minimum dose of 25 mg/day (25 mg qd) to a maximum dose of 150 mg/day (75 mg bid).
223754688|NCT02299557|DRUG|Oxymetazoline gel|Oxymetazoline gel applied intra-anally once daily
224311585|NCT06325397|OTHER|High Intraocular Pressure (IOP)|Prospective, single-surgeon, randomized, paired-eye study; patients undergoing sequential, uncomplicated bilateral phacoemulsification using Active Sentry handpiece® with Intraocular Pressure (IOP) ≤ 24 millimeters of mercury (mmHg) (low IOP) in one eye and with IOP ≥ 65 millimeters of mercury (mmHg) (high IOP) in the other eye.
224311586|NCT06325397|OTHER|Low Intraocular Pressure (IOP)|Low Intraocular Pressure (IOP) Prospective, single-surgeon, randomized, paired-eye study; patients undergoing sequential, uncomplicated bilateral phacoemulsification using Active Sentry handpiece® with intraocular IOP ≤ 24 millimeters of mercury (mmHg) (low IOP) in one eye and with IOP ≥ 65 millimeters of mercury (mmHg) (high IOP) in the other eye
223508371|NCT06085209|DEVICE|Ballon dilation|An endoscopic balloon that is inflated with water to pressures between 45 and 131 psi (3-9 atm) using a syringe and pressure manometer.
223754689|NCT02299557|DRUG|Placebo gel|Placebo gel applied intra-anally once daily
223508372|NCT06085209|DEVICE|Radial Incision|Carbon dioxide (CO2) laser or Monopolar electrocautery knife
223508373|NCT02043847|RADIATION|Total Marrow Irradiation|Subjects in this trial will receive total marrow irradiation 3Gy per day for up to four days and as little as one day
223508374|NCT02043847|DRUG|Melphalan|Subjects will receive standard melphalan 200mg/m\^2 (100mg/m\^2 day-2 and day-1) conditioning therapy prior to transplant
223754690|NCT00271349|DRUG|Budesonide|
223754691|NCT00787774|DRUG|resume raltegravir|resume raltegravir after 16 weeks of stopping
223754692|NCT02818777|DRUG|cannabidiol|"Purified CBD, is a strawberry flavored liquid, in sesame oil, provided as 100 mg/ml, extracted from high CBD plant material.~A component of cannabis that has evidence suggesting it is relatively safe and perhaps neuroprotective, reduces tremor, anxiety and psychosis and is well tolerated in PD. Besides limiting the psychoactive effect of THC, studies support that CBD has anti-inflammatory, anticonvulsant, anti-oxidant, anxiolytic and antipsychotic properties."
223508375|NCT02043847|DRUG|Filgrastim (G-CSF)|Subjects to begin GCSF 5 μg/kg/d SC or IV on Day 5 and continue until ANC \> 1000/mm\^3 over period of 3 days.
223508376|NCT02043847|PROCEDURE|Autologous transplant|Subjects will receive standard melphalan 200mg/m\^2 (100mg/m\^2 day-2 and day-1) conditioning with autologous stem cell rescue
223508377|NCT02043847|RADIATION|Total Marrow Irradiation|Subjects in this trial will receive total marrow irradiation 6Gy per day for up to four days and as little as one day
223607975|NCT01966289|DRUG|SGI-110|SGI-110 is administered subcutaneously at 60 mg/m2
223607976|NCT00466921|DRUG|lenalidomide|10 mg daily orally administered on days 1 - 21 followed by 7 days rest of a 28-day cycle, increasing dose by 5 mg every cycle, up to a maximum of 25 mg.
223754693|NCT02820012|OTHER|Scoliosis|Questionnaires, radiography
223754694|NCT00559520|DIETARY_SUPPLEMENT|Impact|"Patient receiving 3 drinks Impact a day during 5 days before surgery"
223754695|NCT00559520|DIETARY_SUPPLEMENT|Oral Impact|"Patient receiving 3 drinks Oral Impact a day during 5 days before surgery"
224311587|NCT00805467|DRUG|Fostamatinib Disodium (R935788)|50 mg PO BID; 100 mg PO BID; 100 mg PO QD; 150 mg tablet PO QD
224311588|NCT05779852|OTHER|self-hypnosis and dressing|self-hypnosis during dressing
224311589|NCT05779852|OTHER|dressing|dressing without self-hypnosis
223508378|NCT02043847|DRUG|Melphalan|Subjects will receive standard melphalan 200mg/m\^2 (100mg/m\^2 day-2 and day-1) conditioning therapy prior to transplant
223508379|NCT02043847|DRUG|Filgrastim (G-CSF)|Subjects to begin GCSF 5 μg/kg/d SC or IV on Day 5 and continue until ANC \> 1000/mm\^3 over period of 3 days
223508380|NCT02043847|PROCEDURE|Autologous transplant|Subjects will receive standard melphalan 200mg/m\^2 (100mg/m\^2 day-2 and day-1) conditioning with autologous stem cell rescue
223508381|NCT02043847|RADIATION|Total Marrow Irradiation|Subjects in this trial will receive total marrow irradiation 9Gy per day for up to four days and as little as one day
223508382|NCT02043847|DRUG|Melphalan|Subjects will receive standard melphalan 200mg/m\^2 (100mg/m\^2 day-2 and day-1) conditioning therapy prior to transplant
223508383|NCT02043847|DRUG|Filgrastim (G-CSF)|Subjects to begin GCSF 5 μg/kg/d SC or IV on Day 5 and continue until ANC \> 1000/mm\^3 over period of 3 days
223508384|NCT02043847|PROCEDURE|Autologous transplant|Subjects will receive standard melphalan 200mg/m\^2 (100mg/m\^2 day-2 and day-1) conditioning with autologous stem cell rescue
223508385|NCT02363491|DRUG|OPN-305|For the dose confirming part of the study, patients will receive a starting dose of 5 mg/kg OPN-305.
223508386|NCT04121013|OTHER|mothership|Randomized controlled study: allocation to active or no intervention arm will be done accordingly to the design temporal sequence
223508387|NCT02203760|DRUG|Pazopanib plus Gemcitabine|Pazopanib 800 mg orally once daily plus Gemcitabine 1000 mg/m2 i.v. over 30 min d 1 and d 8 q3w or
223508388|NCT02203760|DRUG|Pazopanib|Pazopanib 800 mg orally once daily
223508389|NCT01477411|DRUG|PA21|The maximum dose of PA21 will be 15.0 g/day.
223508390|NCT01477411|DRUG|Digoxin|The maximum dosage of Digoxin will be 0.5 mg/day
223508391|NCT03132272|DEVICE|Immunoadsorption with Globaffin|Immunoadsorption for treatment of persons with Alzheimer Dementia
223508392|NCT00003685|PROCEDURE|fatigue assessment and management|
223508393|NCT00003685|PROCEDURE|nausea and vomiting therapy|
223508394|NCT00003685|PROCEDURE|pain therapy|
223508395|NCT00003685|PROCEDURE|quality-of-life assessment|
223508396|NCT00003685|RADIATION|radiation therapy|
223508397|NCT02000037|DEVICE|IR Reflexotherapy|"18 IR reflexotherapy sessions :~* Once a week for 12 weeks at the beginning of the study~* Once a week for 3 weeks, 9 months after the beginning of the study~* Once a week for 3 weeks, 15 months after the beginning of the study"
223508398|NCT02000037|BEHAVIORAL|Dietary care|Dietary consultation 1, 2, 3, 6, 9, 12, 15 and 18 months after the beginning of the study
223508399|NCT02822755|OTHER|Home Exercise Program and Adherence Logs|Both groups will receive physical therapy prescribed home exercises and be asked to record adherence to their program on an exercise log.
223508400|NCT01530997|RADIATION|Intensity Modulated Radiotherapy (IMRT)|All patients will receive IMRT. Dose painting IMRT will be used and all doses will be specified to the planning target volume (PTV). The high risk planning target volume (PTV-HR) and standard risk planning target volume (PTV-SR) will be treated to the following respective total doses: 60 Gy and 54 Gy. The dose per fraction to the PTV-HR and PTV-SR will be 2 Gy per day and 1.8 Gy per day, respectively. The PTV-HR will include the gross tumor and the PTV-SR will include the lymph nodes at risk for harboring micro-metastatic disease (i.e. subclinical disease).
223508401|NCT01530997|DRUG|Cisplatin|Cisplatin, 30mg/m2, will be given intravenously over 60 minutes weekly during IMRT; 6 total doses for a total of 180 mg/m2. It is preferred that the doses be administered on days 1, 8, 15, 22, and 29, and 36 of IMRT; however, this is not mandatory.
223508402|NCT01530997|PROCEDURE|Limited surgical evaluation|4 to 14 weeks after completion of CRT, patients will have at least a biopsy of the primary tumor and limited neck surgery to remove those lymph nodes that were involved with cancer prior to CRT.
223508403|NCT05156242|DEVICE|Active-tDCS priming MCE|tDCS is used to enhance cortical excitability before motor control exercises.
223508404|NCT05156242|DEVICE|Sham-tDCS priming MCE|tDCS will be set at 0 mA for 20 minutes before motor control exercise.
223508405|NCT05156242|DEVICE|NMES priming MCE|NMES is used to enhance lumbar multifidus motor unit recruitment before motor control exercise.
223508406|NCT05156242|OTHER|Conventional physical therapy|Conventional physical therapy includes modality for pain control, general exercise to improve muscle strength, endurance, and flexibility, and functional training (sit to stand, walking, etc.).
223508407|NCT03075631|OTHER|Questionnaire|Questionnaires
223607977|NCT00793507|OTHER|Oral Health Care Early Intervention Project|The intervention group will receive routine preventive dental care, 2 to 4 times per year depending on risk of caries. The intervention group will also receive pre-scheduling, reminders, and care coordination by the dental hygienist. The control group will receive usual care, but will not receive pre-scheduling, reminders, or care coordination by the dental hygienist. In order to determine the incidence of early childhood caries at study enrollment, both intervention and control groups will receive a standardized oral examination with an assessment of caries presence and extent on the day of enrollment, at 12 months and at 24 months after enrollment. Both children in the control group and intervention group will be referred to a dentist if found to need restorative care.
223607978|NCT01957371|BEHAVIORAL|Mindful Yoga Therapy|Veterans will participate in twice weekly Mindful Yoga Therapy, which includes meditation, breathing practices, physical postures/movements, and guided rest (yoga nidra), as well as daily home practice.
223607979|NCT02549001|DRUG|P-3058 10%|
223607980|NCT02549001|DRUG|vehicle of P-3058 10%|
223607981|NCT02549001|DRUG|amorolfine 5%|
223607982|NCT01022138|BIOLOGICAL|HER2Bi-armed activated T cells|Immediately after pheresis, the lymphocytes are activated with soluble monoclonal anti-CD3 antibody, which cross-links the CD3 receptors on T cells and activates them.
223607983|NCT01022138|DRUG|Cyclophosphamide|After recovering from the last cycle of chemotherapy (approx. two-four weeks) patients will be re-staged. If there are no residual chemotherapy related toxicities, they will be given lymphodepleting chemotherapy consisting of one dose of Cyclophosphamide 1.0 gm/m2 on day -7. Appropriate anti-emetics will be given as pre-medications before the dose of Cyclophosphamide
223607984|NCT01022138|OTHER|Laboratory biomarker analysis|The association between the \[18F\]-FDG PET/CT assessments (percent changes from baseline in SUVpeak) and immunologic biomarker changes as well as tumor response will be explored.
223607985|NCT04117529|OTHER|Blood sample|Collection of 2 blood sample : The first one at the inclusion in the study, the second one between 6 months and 9 months after the inclusion. The sample consists of 2 tubes of EthyleneDiamineTetraAcetic (EDTA) of 7 mL.
223508408|NCT04089085|BEHAVIORAL|STRONGer Together|STRONGer (Successes/Strengths, Triggers, Remember your medications, Ongoing communication, Never give up!, Gratitude) Together is an asthma educational and cognitive behavioral skills intervention for children between 8 - 12 years of age. The intervention is implemented in small groups in 30-minute sessions.
223508409|NCT05274035|DRUG|Perampanel|"For children ≥4 years old, the initial dose is 2 mg per day, the titration interval is ≥2 weeks, the daily dose is increased by 2 mg each time (based on clinical response and tolerability), and the maintenance dose is ≥4 mg per day, up to a maximum dose of 12 mg per day.~For children \<4 years old, the initial dose is 0.04 mg/kg per day, the titration interval is ≥ 2 weeks, the daily dose is increased by 0.04 mg/kg each time (based on clinical response and tolerability), and the maintenance dose is ≥ 0.08 mg/day per day kg, the highest dose is 0.24 mg/kg per day.~According to the actual clinical situation, the initial dose and addition plan are judged by the investigator."
223607986|NCT05447663|DRUG|Siremadlin|Siremadlin was administered at a starting dose of 30 mg/day on days 1-5 of a 28-day treatment cycle (Part 1).
223607987|NCT03501225|PROCEDURE|ozone|After local anesthesia, it was performed sulcular incision with scalpel blade number 15 and removal of soft tissues. Osteotomy was performed at low rotation and odontosecion at high speed, under constant irrigation with ozonated water. Tooth removal, careful curettage, bone regularization and surgical shop cleaning were then performed under abundant irrigation with ozonated water according to randomization. The suture was then performed.
223607988|NCT03501225|PROCEDURE|water|After local anesthesia, it was performed sulcular incision with scalpel blade number 15 and removal of soft tissues. Osteotomy was performed at low rotation and odontosecion at high speed, under constant irrigation with redistilled water. Tooth removal, careful curettage, bone regularization and surgical shop cleaning were then performed under abundant irrigation with redistilled water according to randomization. The suture was then performed.
223607989|NCT00506688|DRUG|reduced glutathione sodium salt|646 mg GSH-Na powder per vial to prepare a 4ml solution, twice daily for 24 weeks.
223607990|NCT00506688|DRUG|0.9% normal saline (control)|4 ml of a 0.9% normal saline solution (9mg/ml NaCl), twice daily for 24 weeks.
223607991|NCT01653639|BIOLOGICAL|Recombinant Factor VIII (Kogenate FS, BAY14-2222)|50 IU/kg single dose using the 3000 IU vial size (600 IU/ml)
223607992|NCT01653639|BIOLOGICAL|Recombinant Factor VIII (Kogenate FS, BAY14-2222)|50 IU/kg single dose using the 2000 IU vial size (400 IU/ml)
223607993|NCT00226382|DRUG|Pegylated Interferon-alfa-2a|Pegasys once weekly
223607994|NCT01397461|DRUG|ozenoxacin placebo|cream
223607995|NCT01397461|DRUG|retapamulin 1% ointment|ointment
223607996|NCT01397461|DRUG|ozenoxacin 1% cream|1% cream
223607997|NCT02766868|DRUG|FACE-Flu/Bu/Cy|Chemotherapy with Fludarabine+cytarabine+cyclophosphamide+etoposie followed by conditioning regimen with Fludarabine, busulfan and Cyclophosphamide
223607998|NCT03604029|DEVICE|Near Infrared Spectroscopy|Near Infrared Spectroscopy (NIRS) sensors are applied to injured leg compartments and a control compartment to continuously measure tissue oxygenation.
223607999|NCT00391144|PROCEDURE|intravitreal triamcinolone injection of avastin (1.25 mg)|
223608000|NCT05139927|BEHAVIORAL|Motivational interviewing (MI) counseling|Those assigned to receive Component A will engage in a MI single session lasting approximately 30-45 minutes. The overall goal of the session is to increase participants' motivation and readiness to test for COVID-19 in various circumstances.
223608001|NCT05139927|BEHAVIORAL|Text messages (TMs) and quiz questions (QQs)|"This intervention lasts 6 weeks. This component is grounded in principles of behavioral economics. Its main goal is to add interest and excitement to the goal of COVID-19 testing, serve as a reminder that COVID-19 testing is recommended in a number of scenarios, and nudge participants toward testing and creating a habit of serial screening and COVID-19 testing as needed. Participants first receive a brief orientation to the component (15 min.), and the participant will put the study phone number into his/her phone and a test TM and QQ will be sent. TMs and QQs are programmed into the Telerivet program and sent automatically. Twice a week participants will receive a TM with information about COVID and COVID-19 testing followed by a true/false question about that TM two days later, for which they earn 10 points for a correct answer, and 5 points for an incorrect answer. Participants earn modest prizes based on their points."
223608002|NCT05139927|BEHAVIORAL|Peer education|This component has two aspects: Participants are trained to educate their peers on core messages about the importance of COVID-19 testing that address social norms about COVID-19 testing and highlight COVID-19 testing as an altruistic act (15-20 min. training). Then, participants are given the opportunity to educate three peers who are Black and Latino/Hispanic frontline essential workers on the core messages. These peers contact the study directly and receive a brief assessment and referrals to testing, but are not enrolled in the study.
223608003|NCT05139927|BEHAVIORAL|Access to COVID testing|Component D is an adaptive intervention component that avoids unnecessary costs; it is only provided if needed. Level 1: Over a 2-3 week period, navigation includes a brief needs assessment and guidance to assist participants in prioritizing, accessing, and completing COVID-19 testing sequences in a timely fashion and resolving barriers such as transportation or the possible need to take off work if diagnosed with COVID-19. Level 2: 1 month after enrollment, participants will be contacted by phone. If they have not been tested, we will provide them with a BinaxNOW test kit which can be picked up or mailed to them.
223608004|NCT05729568|DRUG|Teropavimab|Administered intravenously
223608005|NCT05729568|DRUG|Zinlirvimab|Administered intravenously
223608006|NCT05729568|DRUG|Lenacapavir Tablet|Administered orally
223608007|NCT05729568|DRUG|Lenacapavir Injection|Administered subcutaneously
223608008|NCT05729568|DRUG|Antiretroviral Therapy|Antiretroviral therapy, administered orally may include regimens such as: bictegravir/emtricitabine/tenofovir alafenamide, darunavir/cobicistat/emtricitabine/tenofovir alafenamide, dolutegravir/abacavir lamivudine, and rilpivirine/emtricitabine/tenofovir alafenamide.
223608009|NCT05287646|DEVICE|Suction Suspension First|Participants will be fit with a socket capable of being suspended by both traditional suction and elevated vacuum. Participants will be assessed first with the elevated vacuum system inactive (traditional suction). Residual limb kinematics and skin deformation during movement tasks will be evaluated utilizing dynamic stereo x-ray. The evaluation will then be repeated with the elevated vacuum system active.
223508410|NCT01103518|DRUG|Ethinyl Estradiol + Cyproterone acetate|Ethinyl Estradiol (0.035mg) + Cyproterone acetate (2mg), coated tablets. Each treatment cycle consists of one tablet, once per day for 21 days followed by a 7-day rest period. A total of 4 treatment cycles will be completed during the study treatment period.
223508411|NCT04769778|DRUG|Valsartan 80Mg Oral Tablet|treatment with 80mg /day of valsartan
223508412|NCT02470871|BIOLOGICAL|Eptacog alfa (activated) or pdFVII|"Comparator Drug 1: Recombinant activated FVII (rFVIIa). Subjects with eptacog alfa (activated) as their routine FVII replacement therapy will receive a single dose of eptacog alfa (activated) in the study.~Comparator Drug 2: Plasma-derived FVII (pdFVII). Subjects with pdFVII as their routine FVII replacement therapy will receive a single injection of pdFVII in the study."
223508413|NCT02470871|BIOLOGICAL|CSL689|Experimental Drug: Recombinant fusion protein, linking activated FVII with albumin (rVIIa-FP). Subjects will receive a single dose of CSL689 at either a low dose (Arm 1) or a high dose (Arm 2)
223508414|NCT05555693|OTHER|Collecting clinical data, EGG，Brain Metabolomic Characteristics(with Magnetic Resonance Spectroscopy), blood gas data and blood sample|Collecting clinical data(before induction of anesthesia and first day after surgery), EGG（first day after surgery），Magnetic Resonance Spectroscopy data (before induction of anesthesia and first day after surgery)blood gas data(before induction of anesthesia and first day after surgery) and blood sample （before induction of anesthesia and first day, third day and 7th day after surgery）
223508415|NCT06569264|PROCEDURE|Alveolar ridge preservation using autogenous demineralized dentin graft and i-PRF|Flapless atraumatic extraction. After thorough mechanical cleaning, the sockets will be rinsed with 5 ml of an aqueous 0.125% chlorhexidine digluconate solution, followed by a 5 ml sterile saline rinse to remove tissue debris from the socket. Followed by inspection of extraction socket integrity, using a William's graduated periodontal probe. Extracted teeth will be cleaned from periodontal ligaments, cementum, soft tissue attachment, caries or restorations using a high-speed fine finishing stone and saline irrigation. The pulp chamber will be cleaned with sterile endodontic files. Teeth will be ground, using hand bone mill.The (ADDG) particles prepared by demineralization of tooth particles in 0.6N hydrochloric acid for 30 min to achieve demineralized then washed twice in saline and dried with sterile gauze. For i-PRF blood will be withdrawn in plastic tubes. The tube will be centrifuged at around 700 RPM for 3 minutes, and extraction socket will be filled with the graft material.
223608010|NCT05287646|DEVICE|Elevated Vacuum Suspension First|Participants will be fit with a socket capable of being suspended by both traditional suction and elevated vacuum. Participants will be assessed first with the elevated vacuum system active. Residual limb kinematics and skin deformation during movement tasks will be evaluated utilizing dynamic stereo x-ray. The evaluation will then be repeated with the elevated vacuum system inactive.
223608011|NCT04181762|DRUG|secukinumab|STUDY DRUG
223608012|NCT04181762|DRUG|Placebo|Placebo
223608013|NCT06041919|DRUG|RESP301|Nitric Oxide agent
223608014|NCT06041919|DRUG|HRZE|isoniazid 75 mg (H), rifampicin 150 mg (R), pyrazinamide 400 mg (Z), ethambutol 275 mg (E)
223608015|NCT05948631|BEHAVIORAL|MISC intervention|MISC is a semi-structured, participatory caregiver intervention following these steps: (1) Identify the mother's personal and cultural characteristics, which include a respectful discussion around the mother's child-rearing views, objectives, needs and expectations. (2) Create a baseline through videotaped interactions. (3) Create caregivers' personal interaction profile on the basis of videotaped interaction. The caseworker builds on the initial videotaped interaction and uses subsequent bi-weekly videotaped interactions to give feedback to mothers on the frequency of mediational behaviors thereby quantifying the quality of mother-child interactions. Interactional characteristics are jointly identified and conceptualized according to MISC principles. The mother learns to understand both her own and the child's behavior within a meaningful framework, enhancing reflection of caregiving practices. (4) In-service training (once a month). (5) Re-evaluate training efficacy.
223608016|NCT05948631|BEHAVIORAL|Treatment as Usual (TAU)|TAU consists of supportive services including trauma informed, client-centered, and strength-based case management and advocacy. All services are focused on the mother and do not include any child-focused intervention. Instead, staff provide in-home intensive case management services to assess and provide safety planning, assess other social service needs, link abused mothers to community resources, and assist clients in rehousing. TAU direct contact with the mother consists of bi-weekly contact, which matches the contact frequency for the intervention group. However, MISC mothers will be receiving TAU+MISC-IPV (2 hours bi-weekly contact) compared with TAU only (30 minutes biweekly contact).
223608017|NCT02845323|DRUG|Nivolumab in combination with Urelumab|Two cycles of Nivolumab Two cycles of Urelumab
223608018|NCT02845323|DRUG|Nivolumab monotherapy|Two cycles of Nivolumab alone
223608019|NCT05996328|OTHER|Home-delivered meals and short-term dietary counseling|Home-delivered, low-sodium, nutritionally robust meals for 6 weeks plus two additional remotely delivered dietary counseling sessions in addition to the study-defined standard of care.
223608020|NCT05996328|OTHER|Study -defined standard of care|study-defined standard of care consists of standardized dietary education and a single dietary counseling session shortly after discharge
223608021|NCT03028610|DEVICE|radiofrequency generator|
223608022|NCT03750266|OTHER|No intervention data collected through routine scans|No intervention, we wish to use the images a mother would have done as part of her normal medical care and make both 3D animations and 3D models of the baby and it's CDH.
223608023|NCT01884896|DRUG|Metoprolol Succinate ER Tablet 200 mg|1 \* 200 mg tablet per day
223608024|NCT01884896|DRUG|'TOPROL-XL®' ER Tablets 200 mg|1 \* 200 mg tablet per day
223608025|NCT00314964|DRUG|PD-0299685|
223608026|NCT01588444|DEVICE|cortical FDBA|cortical mineralized freeze-dried bone allograft
223608027|NCT01588444|DEVICE|Cancellous FDBA|CANCELLOUS FREEZE-DRIED BONE ALLOGRAFT (from LifeNet Health)
223608028|NCT01712802|OTHER|Denture Adhesives: Cream|Using Polident as denture adhesive to compare its effect on PRO and subjective outcomes.
223608029|NCT01712802|OTHER|Denture Adhesives: Powder|Using Poligrip powder as denture adhesive to compare its effect on PRO and subjective outcomes.
223608030|NCT01712802|OTHER|Saline|work as control for Denture Adhesives: Cream and Powder
224311590|NCT06316583|OTHER|TrP-DN and Acupuncture|Treatment is conducted by pain specialists and acupuncturists, each having over 5 years of relevant work experience. The treatment occurs within the three weeks leading up to menstruation, administered once a week for a total of three sessions. Additionally, participants are to engage in abdominal stretching exercises starting from the treatment day. These exercises are to be done 3-5 times daily, with each session lasting approximately 2 minutes, and this regimen is to continue for one month. If participants experience significant pain during menstruation, they may take NSAIDs orally for symptomatic relief.
223508416|NCT06569264|PROCEDURE|Alveolar ridge preservation using vitamin C with dentin graft and i-PRF|Flapless atraumatic extraction. After thorough mechanical cleaning, the sockets will be rinsed with 5 ml of an aqueous 0.125% chlorhexidine digluconate solution, followed by a 5 ml sterile saline rinse to remove tissue debris from the socket. 25mM of pure vitamin C in Fresh blood, and the tube will be centrifuged at around 700 RPM for 3 minutes. Extraction socket will be filled with the corresponding graft material and the dentin graft.
223508417|NCT04702139|DEVICE|shoulder arthroplastis|\- Group (Treatment): Placement of the Game-Ready splint immediately after surgery for 12 hours. They will then be put on the standard splint which they will keep for 2 weeks as for the other group but without ice packs.
223508418|NCT04702139|DEVICE|shoulder arthroplastis|\- Group (Control): Placement of a standard splint immediately after surgery for 2 weeks with ice packs to be used for an average of 8 days.
223508419|NCT03892915|COMBINATION_PRODUCT|evidence-based depression treatment|We will use a stepped care approach to depression treatment. Participants with clinical depression (defined as PHQ-9\>9) will be offered either Problem Solving Therapy (PST) or Antidepressant Therapy (ADT), but those with moderate to moderately severe depression will be recommended PST, while those with severe depression will be recommended ADT. Participants with subthreshold depressive symptoms (PHQ-9: 5-9) will receive depression psychoeducation and continued depressive monitoring.
223508420|NCT00965991|DRUG|metformin|patients received glyburide initial dose of 500 mg PO BID. Increased as necessary to a maximum dose of 2000 mg QD to control blood glucose
223508421|NCT00965991|DRUG|Glyburide|Initial dose of 2.5mg PO BID increased as necessary to a maximum dose of 20 mg (10mg BID) QD to control blood glucose
223608031|NCT05799768|BEHAVIORAL|Ketogenic diet|Ketogenic diet counseling
223608032|NCT04906304|DRUG|Everolimus Pill|standard dose versus low dose Sandimun
223608033|NCT04906304|DRUG|Sandimmun (Neoral) dose plus cellcept|Sandimmun (Neoral) dose plus cellcept
223608034|NCT04477577|BEHAVIORAL|New Parent Intervention|This arm will receive the Obstetric and Pediatric primary care provided within MGH obstetric and pediatric primary care practices, with additional active and targeted engagement of new parents by a health coach.
223608035|NCT04477577|BEHAVIORAL|Safety Control|This arm will receive the Obstetric and Pediatric primary care provided within MGH obstetric and pediatric primary care practices, with additional infant safety education materials.
223608036|NCT05377619|DRUG|Prucalopride|prucalopride 2 mg 1 hour before the challenge with intake of wine (200 ml) and a dinner
223608037|NCT05377619|DRUG|Buspirone|buspirone 10 mg 1 hour before the challenge with intake of wine (200 ml) and a dinner
223608038|NCT05377619|DRUG|Placebo|placebo 1 hour before the challenge with intake of wine (200 ml) and a dinner
223608039|NCT04975776|BEHAVIORAL|Sleep restriction therapy|The intervention includes psychoeducation and sleep restriction therapy, sleep restriction instructions, problem-solving, and support for participants in adjusting sleep restriction instructions to their individual needs and life circumstances. At the final session, participants create an individual plan for maintaining new sleep habits and coping with insomnia relapse. During the intervention, participants are free to seek and receive standard care for insomnia.
223608040|NCT04975776|BEHAVIORAL|Sleep hygiene|The control condition will include written, general information about sleep and lifestyle and environmental factors that could improve or disturb sleep. The participants will be free to seek and receive standard care for insomnia.
223608041|NCT00637416|DRUG|Lansoprazole|Lansoprazole 30 mg taken by mouth daily for 3 months
223608042|NCT00637416|OTHER|Placebo|placebo taken by mouth daily for 3 months
223608043|NCT05175586|DIAGNOSTIC_TEST|First data analysis|A series of questions were asked to a number of patients with diagnoses related to primary idiopathic stiff shoulder and/or extrinsic stiff shoulder secondary to trauma or surgery. These patients are part of the physiotherapy clinic receiving the research. This questionnaire answers basic questions for the structure of the study such as age and sex, physical behaviour during the week, endurance, athletic disability, reason for attending the clinic, exploratory motor tests, etc. Subsequently, physiotherapeutic tests related to the pathology within the research were performed consisting of joint range, percentage of shoulder disability and pain scale.
223608044|NCT05175586|PROCEDURE|Second data analysis|Three treatment sessions of Percutaneous Neuromodulation (PNM) and Orthopaedic Manual Therapy (OMT) (Maitland and Mulligan) (group 1) and three treatment sessions of Orthopaedic Manual Therapy (OMT) (Maitland and Mulligan) (group 2) were performed at a rate of two sessions per month for three months. These therapies were compared with the clinical examination performed prior to each new session to verify changes in joint range, percentage of shoulder disability, strength and pain scale.
224311591|NCT05915325|PROCEDURE|Physical training|"1. Supervised Physical Training in SeniorGym for 12 weeks: 1) Aerobic exercise: Patient-tailored intensity-modulated ergometer training for the limbs; 2) Resistance exercise: Patient-tailored resistance exercise by Theraband for the limbs~2. Nutrition intervention for 24 weeks: Dietitian consultation, education and intervention for 24 weeks"
224311592|NCT02066103|DRUG|Paclitaxel|
223508422|NCT06327256|DRUG|BI 3000202|BI 3000202
223508423|NCT06327256|DRUG|Placebo|Placebo-matching BI 3000202
223508424|NCT06327256|DRUG|Midazolam|Midazolam
223508425|NCT05573009|BEHAVIORAL|cognitive behavioral approach-based stress reduction program|"Five days lasting stress reduction program based on cognitive behavioral approach(each session will be an average of 60 minutes) will be initiated in the third day of hospitalisation to the intervention group.~Session main topics are:~Session 1 - Introducing the purpose and content of the program - Stress Psychoeducation Session 2 - Cognitive restructuring Session 3 -Behavioral coping Session 4 - Problem solving training Session 5-Upcoming parenthood"
223508426|NCT02181738|DRUG|Nivolumab|Specified dose on specified days
223508427|NCT02181738|DRUG|Doxorubicin|Specified dose on specified days
223508428|NCT02181738|DRUG|Vinblastine|Specified dose on specified days
223608045|NCT05175586|OTHER|database|Age and sex were expressed as mean ± standard deviation (SD). The rest of the variables were expressed as mean, absolute and relative frequency. The chi-square test was used to analyse the differences between the examinations in terms of the time taken and the treatments used in the two groups. A confidence level of 95% was established, considering a value of p\<0.05 as statistically significant.
223608046|NCT01499966|PROCEDURE|Plaster of Paris/ Tubigrip|"After informed consent was obtained the patients were randomized such that each patient was allocated to use either a Tubigrip (Group A) or Plaster of Paris (Group B). The standardized treatment in the form of RICE (Rest, Ice, Compression and Elevation) protocol was given to all patients. The Patients were randomized using the Block randomization. One hundred and twenty six white papers were taken and TG for Tubigrip and POP for Plaster of Paris were written and the patients were allowed to pick the envelope of their choice. The authors were blinded till the opening of the envelope by the patients. Patient's usage of analgesia in form of Paracetamol was specifically noted. The patients in TG group receive the Tubigrip treatment and the patients in POP group were given a below knee plaster cast. Patients were instructed to follow up at 2 weeks and then at 6 weeks"
223608047|NCT01147055|DRUG|crizotinib|Treatment A: a single 250-mg dose of crizotinib will be administered in the fasted state on Day 1 as 1 × 50-mg and 2 × 100-mg Immediate Release Tablets.
223608048|NCT01147055|DRUG|rifampin|Treatment B: 600 mg once a day doses of rifampin will be orally administered after overnight fasting from Day 1 to Day 14.
223754696|NCT01083095|BIOLOGICAL|Sporozoite Challenge Model for Plasmodium vivax in Humans|Eighteen naïve volunteers were exposed to the bite of carrying P. vivax sporozoites. Volunteers were randomly allocated to 1 of 6 groups and exposed to different numbers of mosquito biting, for 10 min. After feeding, dissection of all mosquitoes exposed in the cage was performed, to confirm the presence of a blood meal in their midguts and sporozoites in their salivary glands. If a volunteer did not get the number of infective bites assigned for his/her group, he/she was allowed to be bitten for a new group of mosquitoes until a total of 3±1, 6±1, or 9±1 mosquito bites were achieved.
224311593|NCT00993486|BIOLOGICAL|Donor lymphocyte preparation depleted of functional host alloreactive T-cells (ATIR)|Single intravenous infusion
223508429|NCT02181738|DRUG|Dacarbazine|Specified dose on specified days
223508430|NCT03776786|BIOLOGICAL|TY014|TY014 Injection, (100 mg/5 mL/Vial), Yellow Fever Virus (YFV) Monoclonal Antibody (mAb)
223508431|NCT03776786|OTHER|0.9% Saline|Placebo
223508432|NCT05482243|DIETARY_SUPPLEMENT|Whey protein|Throughout 1 week (either in week 1 or 2), all participants will perform a 1-week resistance type exercise-training program, consisting of two different exercises. Leg press and leg extension exercise will be performed on regular weightlifting machines (Technogym, Rotterdam) at 3 days during the 1-week period (e.g. Monday-Wednesday-Friday). During the resistance exercise training protocol, participants will continue their habitual diet as usual. However, patients with CKD will be provided with a protein supplement following the exercise sessions.
223508433|NCT02689479|PROCEDURE|Positron-Emission Tomography|Dynamic scanning is performed for 60 minutes. Image acquisition is performed in 3D and reconstructed using an iterative OSEM VUEPOINT algorithm
223508434|NCT02689479|BIOLOGICAL|11C-5-HTP|150-400 MBq \[11C\]5-HTP (approximately 2-5 MBq/kg) is administered manually as an intravenous bolus in a intravenous catheter in the arm prior to PET imaging.
223508435|NCT02689479|PROCEDURE|Magnetic Resonance Imaging|Analysis will focus on adipose tissue distribution and composition in the liver.
223508436|NCT02689479|PROCEDURE|Mixed-Meal Tolerance Test (MMTT)|
223508437|NCT02689479|PROCEDURE|Continuous Glucose Monitoring System® (CGMS)|CGMS involves the subcutaneous (SC) placement of a glucose sensor connected by tubing to a pager-sized monitoring device that stores glucose data. Subjects will have the sensor placed in the clinic and wear it continuously for 72 - 84 hours (Gold) or 72-144 hours (iPro2).
223508438|NCT02689479|PROCEDURE|Glomerular Filtration Rate Testing|
223508439|NCT02689479|PROCEDURE|Blood draw|
223508440|NCT00581204|DEVICE|Near-Infrared Diffuse Optical Spectroscopy|Early predictor of hemorrhagic shock
223508441|NCT00855478|DEVICE|Cypher stent ™ or Cypher Select ™|Cypher drug-eluting stent
223508442|NCT06469372|DEVICE|Cardiac amyloidosis deep learning model|This is a deep learning algorithm which intakes a patient's age, sex, clinical factors known to be related to amyloidosis and their ECG and echocardiogram results and determines their estimated risk for having cardiac amyloidosis.
223508443|NCT01053468|BEHAVIORAL|Physical Activity Resource Kit|"The Intervention group (INT) will receive a Physical Activity Resource Kit which includes a step pedometer, a breast cancer-specific Physical Activity Guidebook (Exercise for health), a step pedometer resource (Step into survivorship), and a physical activity and step journal to record their daily step totals and daily physical activities.~Participants will be instructed to wear their pedometer for the entire duration of the study (i.e., chemotherapy duration)."
223508444|NCT01053468|BEHAVIORAL|Standard Materials|Participants in this usual care group will receive a generic physical activity leaflet from the Canadian Public Health Agency
223508445|NCT05995366|DRUG|ABBV-903|Solution; Oral
223508446|NCT04631978|DIAGNOSTIC_TEST|Comprehensive ophthalmologic examination|Measurements of best-corrected visual acuity, refractive error, intraocular pressure, axial length, slit lamp examination of the anterior segment, dilated fundus examination, and optical coherence tomography angiography imaging.
223508447|NCT05420025|OTHER||
223508448|NCT04886037|OTHER|sestrin|Serum sestrin levels involved in inflammation and energy metabolism are compared between endometriosis and healthy control group.
223608049|NCT01147055|DRUG|crizotinib|Treatment B: A single 250-mg dose of crizotinib will be administered in the fasted state on Day 9 as 1 × 50-mg and 2 × 100-mg Immediate Release Tablets.
223608050|NCT06174129|OTHER|Routine examinations|Electrocardiography and clinical parameters examinations, including age, sex, body-mass index, underlying medical conditions, blood pressure, heart rate, type 2 diabetes duration, laboratory values, and medications
223608051|NCT04661046|DRUG|Traditional Chinese Medicine|Chinese medicine prescription
223608052|NCT04721210|OTHER|Transcranial magnetic stimulation|"The investigated method is called transcranial magnetic The impact on the SMA will be made using a special inductor of the double conical coil type. Navigation will be carried out through the use of the international system 10-20%. The threshold of motor response will be determined by stimulating the motor area of the legs with the intensity of stimulation necessary to trigger a motor response with an amplitude of more than 50 mv."
223608053|NCT04806074|BEHAVIORAL|Experimental Group|Evidence-based food-related national and international guidelines were (i) specifically arranged considering the Food Literacy Wheel (Rosas et al., 2021) and personalised materials contained these guidelines were designed, (ii) matched with tailored behaviour change techniques (BCT Taxonomy v1, by Michie et al., XXXX) that indicated how to develop/implement each competence/behaviour, and (iii) digitally delivered weekly. Psychological variables of the Health Action Process Approach model (HAPA; Schwarzer, 2008) were integrated in the intervention, to study potential food literacy's psychological determinants. Weekly introduction videos featuring the lead psychologist were made available. Participants' groups in WhatsApp were built to incentive experience-sharing. Food literacy domains and HAPA determinants were assessed weekly, post-intervention, and in follow-up moments 3-, 6- and 9-months after the intervention.
223608054|NCT04806074|BEHAVIORAL|Comparison Group|Food-related guidelines were delivered in a single moment in the first week of the intervention, on their original format and referring their original source (national's and international's entities websites). There was not a thematic for each specific week. No weekly introduction videos or WhatsApp groups existed in this condition. Food literacy domains and HAPA determinants were assessed weekly, post-intervention, and in follow-up moments 3-, 6- and 9-months after the intervention.
223608055|NCT05275595|OTHER|Medical records review|"Data on clinical and laboratory findings are reviewed from medical records for details of underlying disease, severity of COVID-19 and associated complications, testing methods for SARS-CoV-2 virus and duration of RT-PCR positivity, therapy received, and duration of hospital stay. Underlying CKD was categorized as nephrotic syndrome, other kidney diseases with CKD stage 1-5. In patients with nephrotic syndrome, the presence of nephrotic-range proteinuria at evaluation at onset, relapse or following non-response to immunosuppression, was considered as 'relapse'.~The Patients will be followed up until discharge, death or 4weeks after diagnosis of COVID-19, whichever was earlier, until 20 January."
223608056|NCT05275595|OTHER|Medical records review|Data on clinical and laboratory findings are reviewed from medical records for details of underlying disease, associated complications, therapy received, and duration of hospital stay. Underlying CKD was categorized as nephrotic syndrome, other kidney diseases with CKD stage 1-5.
223608057|NCT04320784|OTHER|Time restricted eating|TRE group consumed 100% of its estimated daily energy needs in an 8-hour time window: from 10:00 AM to 6:00 PM
223608058|NCT04320784|OTHER|Control|CTRL group consumed 100% of its estimated daily energy needs in 3 meals between 7:00 AM and 9:00 PM
223608059|NCT00234923|DRUG|lopinavir/ritonavir|400 mg lopinavir/ 100 mg ritonavir, BID
223608060|NCT00234923|DRUG|lamivudine/zidovudine|300mg lamivudine/150mg zidovudine, BID
223608061|NCT04903535|DEVICE|Alonefire SV003 10W 365nm UV Flashlight|Investigator will use a Nitric Oxide Analyzer while attached to a small suction port on the subject's ear lobe to be tested for Nitric Oxide. After getting the baseline assay, the investigator will shine a low-intensity UV Flashlight (Alonefire SV003 10W 365nm UV Flashlight) at the ear lobe for 10 seconds, repeated three times at 20 second intervals, to determine if there is photobleaching. Then the assay will then be performed on the opposite ear lobe. Fifteen minutes after the third UV flashlight exposure, the investigator will collect air from the subject's ear during photolysis into a 20mL glass syringe (once from each ear). Fifteen minutes after the third UV flashlight exposure, the investigator will collect air from the subject's ear during photolysis into a 20mL glass syringe (once from each ear). The subject and the investigator will wear UV goggles during the experiment.
223608062|NCT01187485|DRUG|Androderm® 2.5mg|Subjects will be asked to replace the study drug patch every 24 hours at night following the written and verbal instructions you will receive. The study drug patch should be placed over a small amount of a steroid cream on the skin to reduce irritation.
223608063|NCT01187485|DRUG|Androderm® 5.0mg|Subjects will be asked to replace the study drug patch every 24 hours at night following the written and verbal instructions you will receive. The study drug patch should be placed over a small amount of a steroid cream on the skin to reduce irritation.
223754697|NCT05683119|OTHER|Exercise and blood draw|This project intends to investigate the effects of circulating fluctuations in oestradiol and progesterone, experienced during the menstrual cycle \[MC\] and oral contraceptive pill \[OCP\] use, on aspects of exercise physiology and athletic performance in female athletes. This research aims to determine if a particular hormonal profile affects physiological functioning (e.g., muscle strength, maximum oxygen uptake) and/or athletic performance in female athletes. The intervention will include a stretching regimen, balance test, push-ups, agility test, handgrip muscle test, vertical jump, flexibility test, cycling protocol, blood sample and height/ weight measurements.
223754698|NCT04595864|OTHER|Transarterial chemoinfusion (TAI) with mFOLFOX6 (oxaliplatin, calcium folinate, and 5-FU)|TAI
223754699|NCT05230212|OTHER|Pecan Breakfast Shake|The pecan breakfast shake contains 68 grams of blended raw pecans. Participants will consume this shake at either visit 1 or visit 2 depending on randomization procedures.
223754700|NCT05230212|OTHER|Cream Breakfast Shake|The cream breakfast shake contains 138 grams of heavy whipping cream. Participants will consume this shake at either visit 1 or visit 2 depending on randomization procedures.
223754701|NCT02191228|DRUG|Linagliptin - single dose|
223754702|NCT02191228|DRUG|Linagliptin - Multiple dose|
224200780|NCT03112707|DRUG|Aspirin|After percutaneous coronary intervention with bioresorbable polymer-coated everolimus-eluting Synergy® stent implantation, dual antiplatelet therapy with aspirin 100 mg od and a P2Y12 inhibitor will be continued for a duration of 1 month, after which single antiplatelet therapy with aspirin will be recommended indefinitely. In case of need for oral anticoagulation, patients will receive an oral anticoagulant in addition to a P2Y12 inhibitor without aspirin for 30 days.
224311594|NCT05353010|DRUG|Tacrolimus|Tacrolimus 5mg (1 mg \* 5 capsules)
223508449|NCT03255954|OTHER|Interpersonal Counseling for University Counseling Centers|Interpersonal Counseling (IPC) is a brief version of Interpersonal Psychotherapy (IPT). IPC synthesizes the fundamental IPT principles into 3-6 sessions. Individuals receiving IPC are initially assessed for symptoms of depression, and then encouraged to identify interpersonal problem areas which may be contributing to their presenting symptoms.
223508450|NCT00002619|BIOLOGICAL|filgrastim|
223508451|NCT00002619|DRUG|carboplatin|
223508452|NCT00002619|DRUG|thiotepa|
223508453|NCT00002619|PROCEDURE|autologous bone marrow transplantation|
223508454|NCT00002619|PROCEDURE|peripheral blood stem cell transplantation|
223608064|NCT01187485|DRUG|Androderm® 7.5mg|Subjects will be asked to replace the study drug patch every 24 hours at night following the written and verbal instructions you will receive. The study drug patch should be placed over a small amount of a steroid cream on the skin to reduce irritation.
223754703|NCT04401696|DEVICE|Bubble CPAP|"The bCPAP will be delivered using an oxygen flow meter as the oxygen source. This inspiratory limb containing oxygen from the flow meter will be connected to humidifier and tubing from humidifier will be connected to short binasal prongs, which would be applied to neonate with the help of adhesive bandage on both cheeks. It will be ensured that binasal prongs make appropriate seal. An orogastric tube will be placed for gastric decompression. A 1000 ml/500ml bottle filled with sterile water be used and marks will be made on it at 1cm distance, with '10' marked at base and '0' mark at the water interface.~The expiratory limb from the nasal prongs was connected to tubing that will be dipped in water up to the desired level to provide positive end expiratory pressure. Pressure is varied by varying the depth of the dipped end of tubing."
223508455|NCT02371252|DRUG|Generic alendronate|The patients will be given the generic alendronate 1 tablet per week for approximately 1 year after enrollment.
223508456|NCT03606070|DIAGNOSTIC_TEST|PET-MRI|"* a PET-MRI examination performed before the chemoradiotherapy treatment (so-called baseline PET-MRI)~* a PET-MRI examination performed midway through treatment (PET-MRI1 under treatment), after receiving 33 ± 4 Gy (approximately 2.5 months after the first PET-MRI)."
223508457|NCT01837888|DEVICE|WheelSee Training Program|WheelSee sessions will be administered by a peer-trainer, who will be trained in a 2-day workshop to use social cognitive approaches (i.e. facilitating successful performance of wheelchair skills, learning through observation of peers, positive verbal reinforcement from peers and family members, and re-interpretation of physiological symptoms) to foster the improvement of self-efficacy for wheelchair use. Each WheelSee session will be tailored to the individual goals of participants, which will be identified during the start of each WheelSee session.
223508458|NCT01867476|OTHER|Automated Adherence Monitoring System|
223508459|NCT02656342|DRUG|D-Cycloserine|Predicted to enhance stabilization of the effects of concentrated exposure treatment
223508460|NCT02656342|DRUG|Placebo|Predicted to have no enhancing effect
223508461|NCT03430570|BEHAVIORAL|Tablet TRAC Emotion Regulation Intervention|The intervention focuses on developmentally appropriate strategies for emotion regulation during difficult situations, particularly those related to risk, using 3 primary groups of strategies identified during qualitative work in Project TRAC (R34 MH078750): 1) getting away (physically or cognitively) from triggers for strong emotions, 2) releasing emotional energy in healthy ways (physically or verbally) or 3) changing cognitions and appraisals about emotional triggers. Using strategies effective in TRAC, teens will engage in games to practice and apply strategies to risk scenarios, as well as personalize content learned.
223508462|NCT02318277|DRUG|MEDI4736|MEDI4736 administered intravenously (IV) every two weeks (q2w)
223508463|NCT02318277|DRUG|INCB024360|INCB024360: Oral daily dosing
223508464|NCT05089175|DRUG|Low-dose aspirin|FIGO adopts and supports that in high-risk women, defined by the first-trimester combined test, aspirin \~150 mg/night should be commenced at 11-14+6 weeks of gestation until either 36 weeks of gestation, when delivery occurs, or when pre-eclampsia is diagnosed.
223508465|NCT01691482|DRUG|Albuterol/salbutamol|Albuterol/salbutamol (daily)
223508466|NCT01691482|DRUG|Ipratropium|Ipratropium (daily)
223608065|NCT06965725|DEVICE|Annuloplasy ring sizing device|A single time use of a novel sizing tool for mitral valve repair surgery (used ONLY in an observational capacity - this device does NOT influence decision-making during the conduct of the operation in any way).
223608066|NCT06975761|DRUG|Resin Based sealer|Post-operative pain after Root Canal Therapy by using resin based sealer
223608067|NCT06975761|DRUG|ZnO eugenol based sealers|Post-operative pain after Root Canal Therapy by using ZnO eugenol based sealer
223608068|NCT06976177|DRUG|MT1013|MT1013 is a novel calcimimetic agent
223608069|NCT06977035|DEVICE|Nerve Conduction Study|Sensory and Motor Nerve Conduction study on upper and lower limbs.
223608070|NCT04596826|DRUG|Dronabinol 5 MG|oral administration
223608071|NCT04596826|DRUG|Dronabinol 10 MG|oral administration
223608072|NCT04596826|DRUG|Placebo|oral administration
223754704|NCT04401696|OTHER|Nasal Oxygen|The oxygen will be delivered from a wall oxygen source, delivered between 1 to 6 L/min and the rate varied via a flow regulator.
223608073|NCT01890837|DRUG|Daikenchuto (TU-100)|Subjects will receive 5g TID (15g/day) of TU-100. Dosage form is granule. Subject will take a daily dose divided 3 times per day for 2 weeks.
223608074|NCT01890837|DRUG|Placebo|Subjects will receive daily dose of TU-100 placebo. Dosage form is granule. Subject will take a daily dose divided 3 times per day for 2 weeks.
223608075|NCT06807580|DRUG|Placebo|The placebo will be nearly identical in size, color, and shape to micronized progesterone
223608076|NCT06807580|DRUG|Progesterone|Oral micronized progesterone 200 mg
223608077|NCT06383598|DRUG|18F-FDG|All study participants will undergo one 18F-FDG PET/CT scan.
223608078|NCT04923126|DRUG|Mirdametinib|By mouth, nasogastric (NG) tube or gastrostomy tube (G-tube) BID, days 1-28
223608079|NCT04007393|BEHAVIORAL|Lifestyle Modification Therapy (LSMT)|LSMT will consist of both in-person and by telephone sessions delivered throughout the entirety of the 48-week intervention phase. Each session will last 30-60 minutes. A trained study coordinator (a registered dietician or someone trained by our registered dietician) will delivery this therapy which consists of counseling using education, goal setting and barrier reduction. Topics covered will include calories, tracking, healthy food choices, reducing high fat, added sugar foods, setting goals and portions, changing the quality of your diet, volumetrics, purposeful activity, quick and easy meals, problem solving, food cues and eating patterns, emotional eating, accurate tracking, eating away from home, unhelpful thoughts, structured menus and the role of protein, social cues, managing stress, slips and relapse prevention, long-term physical activity and overcoming obstacles, high-risk situation and keys to success, motivation and looking to the future (long-term plans).
223608080|NCT04007393|DRUG|Phentermine Pill|Phentermine will be started only if a participant does not lose 5% of BMI after 12 or 24 weeks of LSMT depending on their random assignment. Subjects will take 15 mg of phentermine every morning for 12 weeks at which time there will be an assessment of weight loss. Subjects who achieve 5% or more BMI reduction after 12 weeks of phentermine will continue 15 mg every morning for the remainder of the study (through week 48) along with their LSMT.
223608081|NCT04007393|DRUG|Topiramate Pill|Participants who do no not achieve at least 5% BMI reduction after 12 weeks of phentermine+LSMT will be re-randomized 1:1 to either topiramate+phentermine+LSMT or topiramate+placebo+LSMT. Topiramate dosing will begin at 50 mg every morning for the first 7 days, and then increase to 100 mg every morning through week 48. At the end of week 48 the taper off will be 50 mg every morning for 7 days and then discontinue.
223608082|NCT06593496|BEHAVIORAL|Text Message Reminder|Randomized selection of recruited participants that will receive text messages reminding them to take their blood pressure.
223754705|NCT02234921|DRUG|Cyclophosphamide|A single dose of cyclophosphamide, 300 mg/m2, will be administered intravenously 3 Days prior to the first vaccine.
223754706|NCT02234921|BIOLOGICAL|DRibble Vaccine|DRibble vaccine will be administered at Weeks 1, 4, 7, 10, 13, 16, 19 and 22. Eight vaccinations will be administered. Week 1 and 4 vaccines will be administered by intranodal injections performed using ultrasound guidance.
223754707|NCT02234921|BIOLOGICAL|HPV Vaccinations|Patients will receive a dose of 0.5-mL CERVARIX at week 1 (Day 4) and week 7 by intramuscular injection at a site distant from the DRibble vaccine.
224311595|NCT05353010|DRUG|IN-A001(Tegoprazan)|IN-A001 50mg(Tegoprazan 50mg\* 1 tablet)
223608083|NCT06595914|OTHER|Clinical implementation strategies|Clinical implementation strategies, selected based on ED clinician survey/interview findings from Aim 1 using the Implementing Promoting Action on Research Implementation in Health Services (i-PARIHS) implementation science framework
223608084|NCT03254940|BEHAVIORAL|Charge|Text messaging-based study to determine effect of different components on weight loss.
223608085|NCT03966872|BEHAVIORAL|Integrated Illness Management and Recovery|Education and skills training groups on illness management of chronic medical and psychiatric illness.
223608086|NCT03966872|BEHAVIORAL|Chronic Disease Self-Management Program|Education and skills training groups on illness management of chronic conditions
223608087|NCT06986642|OTHER|core stability exercises|"core stability exercises General Exercises~1. Brisk walking (30 minutes)~2. Squats (3 sets, 10-15 repetitions)~3. Lunges (3 sets, 10-15 repetitions per leg)~4. Push-ups (3 sets, 10-15 repetitions)~5. Seated row (3 sets, 10-15 repetitions)~1\. Brisk walking (30 minutes) 2. Squats (3 sets, 10-15 repetitions) 3. Lunges (3 sets, 10-15 repetitions per leg) 4. Push-ups (3 sets, 10-15 repetitions) 5. Seated row (3 sets, 10-15 repetitions)"
223608088|NCT06986642|OTHER|Genreal Exercises|Genreal Exercises
223608089|NCT02784847|DRUG|Triheptanoin|Triheptanoin oil administered three times per day during meals at a total dose 1mg/kg/day for 3 months
223608090|NCT00921778|DEVICE|Lapcone|Use of Lapcone during LSH
223608091|NCT00921778|PROCEDURE|laparoscopic supracervical hysterectomy|laparoscopic supracervical hysterectomy
223608092|NCT03310528|BEHAVIORAL|Interview questionnaire|Complete interview questionnaire regarding the composition and timing of their most recent food intake.
223608093|NCT03310528|PROCEDURE|Gastric ultrasound exam|Gastric ultrasound exam prior to upper GI endoscopy procedure.
223608094|NCT05236257|DRUG|Larotrectinib (Vitrakvi, BAY2757556)|Pediatric patients with IFS harboring an NTRK gene fusion.
223608095|NCT05236257|DRUG|Standard of Care|Standard of care for the patients from the eligible external cohorts.
223608096|NCT06990737|PROCEDURE|Sentinel lymph node biopsy (SLNB)|Participants will have SLNs excised from the affected area(s) per standard of care
223608097|NCT06990737|PROCEDURE|Lymphadenectomy|Surgeon preference will dictate the order of the surgery for resecting the primary tumor. Elective neck dissection (END) will include nodal basins based on the primary site of disease, at-risk nodal basins, and any additional dissection per the surgeon's discretion. In the event of a positive SLN, the completion neck dissection (CND) should be completed.
223608098|NCT06990737|DRUG|Adjuvant Definitive Therapy|Use of chemotherapy will depend on the specific phase of treatment and high-risk features as per standard of care and NCCN Head and Neck Cancer-Clinical Practice Guidelines in Oncology
223608099|NCT03886168|OTHER|Signal processing intervention of a biomedical device|This is a signal processing intervention of an FDA approved biomedical device for study participants that have received the cochlear implant based on clinical recommendations (i.e. not study related). Based on image processing of pre- and post-implant CT, cochlear segmentation, electrode scalar localization, and definition of the electrode-to-neural interface, the investigators will manipulate the stimulus delivery of the incoming signal within the FDA approved clinical software and thereby is within the electrical and clinical specifications of the FDA approved device and accompanying software.
223608100|NCT04742920|DEVICE|Middle Meningeal Artery Embolization|MMA embolization using the Onyx™ non-adhesive liquid embolic agent within 72 hours after randomization in addition to standard management
223608101|NCT04742920|PROCEDURE|Standard Management|"Procedure : Surgical Management Surgical evacuation of the subdural hematoma~Other: Conservative Management Standard medical management: drug treatment and/or observation"
223608102|NCT03069131|DRUG|Rifaximin|twice daily administration of 1 tablet containing 550 mg of active rifaximin
223608103|NCT03069131|OTHER|Placebo|twice daily administration of 1 rifaximin placebo tablet
223608104|NCT03427749|DIAGNOSTIC_TEST|SPECT Imaging with 99mTc-Tetrofosmin Research Imaging|This is an observational study; patients will be managed according to the standard clinical care of the local site. Study end will be defined as completion of all SPECT imaging at rest and stress. Studies will be acquired at 6 initial sites with mixed prior experience at MBF imaging, to demonstrate feasibility of use in a clinical setting.
223754708|NCT02234921|DRUG|Imiquimod|Imiquimod cream (5%, 250 mg) will be self-applied topically for 5 consecutive days by patients to a 4 x 5-cm outlined area of healthy extremity skin starting on the day of the second vaccine and again during each additional vaccine cycle.
223754709|NCT00000514|DRUG|chlorthalidone|
223754710|NCT00000514|DRUG|atenolol|
223754711|NCT00000514|DRUG|reserpine|
224311596|NCT05353010|DRUG|IN-A001(Tegoprazan) + Tacrolimus|IN-A001 50mg(Tegoprazan 50mg\*1 tablet) and Tacrolimus 5mg(1mg \* 5capsules)
224311597|NCT01761370|PROCEDURE|AHA diet plus exercise with BIB placement|AHA diet plus exercise with BIB placement for 6 months
224311598|NCT01761370|PROCEDURE|AHA diet plus exercise with sham BIB placement|AHA diet plus exercise with sham BIB placement
224200781|NCT03112707|DRUG|P2Y12 inhibitor|After percutaneous coronary intervention with bioresorbable polymer-coated everolimus-eluting Synergy® stent implantation, dual antiplatelet therapy with aspirin 100 mg od and a P2Y12 inhibitor will be continued for a duration of 1 month, after which single antiplatelet therapy with aspirin will be recommended indefinitely. In case of need for oral anticoagulation, patients will receive an oral anticoagulant in addition to a P2Y12 inhibitor without aspirin for 30 days.
223508467|NCT01111487|DEVICE|Expiratory positive airway pressure (EPAP) by face mask.|Implementation of the EPAP as group pressure, 10 or 15 cmH2O, for 20 minutes then evaluated the electromyographic activity of muscles and sternocleidomastoid parasternal the tenth and twentieth minutes of your application.
223508468|NCT00096408|PROCEDURE|Total Abdominal Hysterectomy|For patients with clinical stage I disease, removal of the uterus and both tubes and ovaries are considered current standard treatment in Australia.
223508469|NCT00096408|PROCEDURE|Total Laparoscopic Hysterectomy|The technique of total laparoscopic hysterectomy (TLH), utilising the McCartney tube, has been developed by Anthony J. McCartney over the last 10 years. It allows the completion of the hysterectomy entirely laparoscopically, without the need for additional vaginal surgery.
223508470|NCT05299450|DIETARY_SUPPLEMENT|Beet It shots|In addition to the procedures for the control group, women will be supplied with 84 Beet-It shots which they will be asked to take every morning with breakfast for 12 weeks. Women below 60kg will be advised to take a proportion of the 'shot' in order to comply with European Commission Accepted Daily Intake for nitrate, the active ingredient, of 0-5mg/kg. https://www.beet-it.com/product/beet-it-sport-shot/
223508471|NCT05299450|BEHAVIORAL|Exercise|In addition to the procedures for the control group, women will be supplied with gym membership for 12 weeks, 2 initial personal training sessions to design a personal exercise program followed by monthly personal training sessions.
223508472|NCT05299450|OTHER|Control group|Women will be supplied with a wearable device to measure physical activity, weighing scales and a home blood pressure monitor. They will be asked to record minutes of physical activity, exercise undertaken, resting blood pressure, resting heart rate and weight daily for 12 weeks.
223508473|NCT01987674|DIETARY_SUPPLEMENT|Pre-meal protein drink|
223508474|NCT01987674|OTHER|Water drink|
223508475|NCT03097471|DEVICE|BPK-S Integration (Ceramic)|primary total knee endoprosthesis
223508476|NCT05754112|OTHER|B lymphocyte profiling|All individuals will undergo peripheral venous blood sampling and ultrasound-guided synovial tissue biopsy following a standardized procedure. B-lymphocytes will be sorted from PBMCs isolated by Ficoll gradient method using magnetic CD19-microbeads whereas tissue B-lymphocytes will be isolated from synovial tissue biopsies digested with Liberase. CD19 positive cells from PBMC will be incubated with pro-inflammatory molecules in presence or absence of Ubadacitinib. After stimulation, CD19 positive cells will be collected and processed for single cell RNA sequencing. Moreover, the impact of JAK-1 selective inhibition on B-lymphocyte cultures stimulation will be tested using ELISA method for the assessment of cytokines/chemokines production. Synovial tissue and synovial tissue B-lymphocyte subpopulations will be assessed through FACS analysis using IgD/CD27 classification. Finally, we will compare the transcriptomic profile of synovial tissue B lymphocytes from 5 subject groups.
223508477|NCT06478940|DRUG|3 mixtatin pulpotomy|pulp treatment with applying 3mixture of antibiotic (Metronidazole, cefixime, and Ciprofloxacin) along with simvastatin
223508478|NCT06478940|DRUG|MTA pulpotomy|pulp treatment with applying MTA
223508479|NCT02112175|DRUG|Lenalidomide|
223508480|NCT04728464|PROCEDURE|Periodontally Accelerated Osteogenic Orthodontics (PAOO)|Fixed appliance will be placed for every patient, then surgical procedure will be applied after reflecting a full-thickness labial flap.
223508481|NCT03987607|DEVICE|neuromuscular blockade monitoring|Neuromuscular blockade monitoring via two different types of monitoring devices
223508482|NCT04874441|DIAGNOSTIC_TEST|Diagnosis strategy based on C. glabrata / krusei PCR|For diagnosis, a blood cultures and blood tubes for PCR will be collected and patients will be treated with echinocandins in the first instance with an early switch to fluconazole if the C. glabrata / krusei PCR is negative
223508483|NCT01111188|DRUG|PD 0332991|"PD 0332991 will be given on Days 1-12 followed by 9 days of non-treatment in a 21-day cycle. Dose will depend on dose escalation schedule.~(-3a) 50 mg (-3) 50 mg (-2)75 mg (-1)75 mg (1)100 mg (2)125 mg (3)125 mg (3a)100 mg"
223508484|NCT01111188|DRUG|bortezomib|"Given as intravenous bolus on days 8, 11, 15, and 18 of 21-day cycle. Dose depends on dose-escalation schedule.~(-3a)1.0 mg/m2 (-3) 0.7 mg/m2 (-2) 0.7 mg/m2 (-1) 1.0 mg/m2 ( 1) 1.0 mg/m2 ( 2) 1.0 mg/m2 ( 3) 1.3 mg/m2 (3a)1.3 mg/m2"
223508485|NCT04757844|DEVICE|Functional Near-Infrared Spectroscopy (fNIRS)|The hemodynamic response in prefrontal cortex will be measured using an Octamon+ system (Artinis). Eight emission and two detector probes will be arranged on the participant's forehead.
223608105|NCT07009626|OTHER|Computer-based high-validity birth simulator|Computer-based high-validity birth simulator: All students in the intervention group underwent the same scenario of birth. Initially, the aim was to diagnose shoulder dystocia by ensuring that the shoulders were not delivered after the fetal head was delivered.
223608106|NCT07008105|BEHAVIORAL|Cognitive Behavioral Therapy|CBT endorses a pain management model and teaches people skills to cope with chronic pain through reframing thoughts and encouraging behavioral change.
223608107|NCT07008105|BEHAVIORAL|Pain Reprocessing Therapy|PRT advocates a pain treatment model in which pain can be substantially reduced by helping people learn that their pain is brain-based and can be substantially reduced or eliminated by decreasing fear of pain and bodily injury and providing education on the neuroscience of pain.
224200782|NCT03303807|DEVICE|Extracorporeal CO2 removal (ECCO2-R) (PrismaLung®, Prismaflex ® Baxter)|A low-flow CO2 removal device (Prismalung®, Baxter) will be used with a conventional renal replacement therapy (RRT) platform (Prismaflex®, Baxter). In patients already treated with continuous RRT because of renal failure or metabolic acidosis, the HF 1400® (Baxter) set will be used to combine RRT and decarboxylation. Gas flow through the gas exchanger will be set up to 10 L/min, with an oxygen concentration from 0.21 to 1 and a blood flow of 200-400 mL/min. Patients will be ventilated with a target tidal volume of 6 ml/kg (predicted body weight) and a target plateau pressure below 30 cmH2O.
224200783|NCT03888898|OTHER|Reusable respirator fit test and competency evaluation|Feasibility of rapid conversion to reusable elastomeric respirator use during public health emergency
224200784|NCT03888898|OTHER|Control fit test evaluation|control comparator for fit testing time threshold
223508486|NCT04505280|DRUG|Lidocaine 1% Injectable Solution|Greater occipital nerve and cervical region injections once a week for 4 weeks
223508487|NCT02810132|DRUG|Metformin|See above
223508488|NCT02810132|DRUG|Placebo|See above
223508489|NCT03275272|DIAGNOSTIC_TEST|level of IGF-1 in infants|Measurment of blood level of IGF-1 in infants
223508490|NCT03855839|DEVICE|Posture shirt|Posture shirts are designed, and marketed to the general public and health service providers to improve posture and consequently alter muscle activity, reduce musculoskeletal pain and discomfort.
223508491|NCT03855839|DEVICE|Compression shirt|Compression shirts are designed for recreational sport activities and can be bought in any local sports store
223608108|NCT07008105|BEHAVIORAL|Emotion Awareness and Expression Therapy|EAET advocates a pain treatment model in which pain can be substantially reduced by helping people learn that their pain is brain-based and can be substantially reduced or eliminated by decreasing fear of pain and of various emotional/interpersonal problems.
223608109|NCT06867497|DRUG|BR2021|intravenous administration for 30 minutes
223608110|NCT06867497|DRUG|BR2021-1|intravenous administration for 30 minutes
223608111|NCT07010341|DIAGNOSTIC_TEST|ntra-operative Indocyanine Green (ICG) Fluorescence Quantification|After a single intravenous bolus of indocyanine green (25 µg/kg), a near-infrared sensor records raw fluorescence intensity from the superior parathyroid gland and the ipsilateral common carotid artery at 60-120 seconds. No images are stored; only peak intensity values are logged to calculate the perfusion ratio R = PTG / CCA. The measurement is observational, adds ≤2 minutes to operative time, and involves no therapeutic intent.
223608112|NCT04908735|DRUG|Ruxolitinib|Participants will receive ruxolitinib orally twice daily for 24 weeks.
223508492|NCT06184763|OTHER|6-minute walk test|"6-minute walk test in a 40-metre corridor. Included patients are used to performing this test, which is part of the standard care performed during patient follow-up, at least once a year.~Parameters collected during the test: distance walked, minimum SpO2, average SpO2, maximum heart rate, average heart rate, average heart rate over the last 2 minutes, dyspnea scale."
223508493|NCT02726295|DRUG|E. coli Nissle 1917(Mutaflor®)|
223508494|NCT02726295|DRUG|Placebo|
223508495|NCT00407030|DRUG|incobotulinumtoxinA (Xeomin) (240 Units)|"incobotulinumtoxinA (Xeomin, also known as NT 201 or Botulinum toxin type A (150 kiloDalton), free from complexing proteins) (240 Units)"
223508496|NCT00407030|DRUG|incobotulinumtoxinA (Xeomin) (120 Units)|"incobotulinumtoxinA (Xeomin, also known as NT 201 or Botulinum toxin type A (150 kiloDalton), free from complexing proteins) (120 Units)"
223508497|NCT00407030|DRUG|Placebo|Placebo
223508498|NCT03017287|DEVICE|GlucoMe App|Assessment of the the GlucoMe App
223508499|NCT04489056|GENETIC|Swabs for microbiome analysis|After informed consent, vaginal swabs will be collected during speculum examination from the lateral vaginal wall and posterior fornix vaginae using a sterile cotton swab combined with an epithelial brush. A rectal swab will be collected by insertion of a sterile swab into the anal sphincter. Intraoperative swabs of the placenta and uterine cavity will be collected during caesarean section under sterile conditions. Neonatal swabs (buccal mucosa and skin) will be collected directly after delivery and in the neonatal period. Stool samples will be taken from the meconium, defined as first stool of the infant and the stool of the newborn in the neonatal period.
223508500|NCT05253534|DEVICE|GlaucoT Glaucoma Treatment Device|"In this study, flicker light therapy, the effectiveness of which was investigated in the treatment of glaucoma based on some methods used in different diseases, is described for the first time in glaucoma.~Studies investigating the neurodegenerative properties of glaucoma have found similarities in the pathophysiology of Alzheimer's disease and glaucoma.~40 Hz flicker of light Alzheimer 's the positive effects on the knitted cortex have also been shown in studies. 40 Hz flicker light is aimed to reduce glaucoma and retinal ganglion cell loss due to glaucoma, by reducing neurodegeneration by decreasing amyloid and metabolite accumulation by increasing both microglial phagocytic activation effect and retinal blood flow."
223508501|NCT04613570|DIAGNOSTIC_TEST|Upper gastrointestinal endoscopy|"In all patient's complete gastroscopy first with White light and then with virtual chromoendoscopy will be made;~* Suspicious lesions with dysplasia/cancer will be biopsied 1-2 fragments in a different vial; if an irregular area of mucosa (pattern C) with no clearly defined lesion then 1-2 guided biopsies fragments will be taken and sent in a different vial;~* EGGIM (Endoscopic Grading of Gastric Intestinal Metaplasia) will be calculated according to previous description of this classification:~* If EGGIM 0 (no endoscopically apparent IM) biopsies will be made in antrum, incisura and corpus according to Sydney-Houston protocol;~* If EGGIM 1 or more guided biopsies of suspicious areas of IM should be made replacing the random biopsies in that particular area;~* Antrum, incisura and corpus fragments should be sent in 3 separate vials;"
223508502|NCT01356888|DEVICE|Percutaneous Coronary Intervention (Abbott Laboratories - Xience Prime DES)|Stenting
223608113|NCT07020988|DRUG|Staccato Alprazolam|Study participants will receive single dose of Staccato Alprazolam at pre-specified time points.
223608114|NCT07020988|DRUG|Midazolam|Study participants will receive single dose of IV Midazolam at pre-specified time points.
223608115|NCT07020988|DRUG|Diazepam|Study participants will receive single dose of Nasal Diazepam by inhalation at pre-specified time points.
223508503|NCT01356888|DEVICE|Percutaneous Coronary Intervention (Orsiro DES)|stenting
223508504|NCT06386120|OTHER|PEEP setting strategy|The attending physician selects different PEEP setting strategies
223608116|NCT04205838|BIOLOGICAL|Anakinra|Given SC
223608117|NCT04205838|BIOLOGICAL|Axicabtagene Ciloleucel|Given via infusion
223608118|NCT04205838|DRUG|Cyclophosphamide|Given via infusion
223608119|NCT04205838|DRUG|Fludarabine|Given via infusion
223608120|NCT04205838|DRUG|Fludarabine Phosphate|Given via infusion
223608121|NCT06696027|DIAGNOSTIC_TEST|Single nucleotide polymorphisms (SNP)|Utilizing single nucleotide polymorphisms (SNP) genotyping mosaic loss of y (mLOY) of individual patient will be assessed.
224200785|NCT02099929|OTHER|Coffee with Sugar|300mL of Coffee with 30g of Sugar
224200786|NCT02099929|OTHER|Coffee without Sugar|300mL of Coffee without Sugar
224200787|NCT02099929|OTHER|Decaffeinated Coffee without Sugar|300mL of Decaffeinated Coffee without Sugar
224200788|NCT02099929|OTHER|Water with Sugar|300mL of Water with 30g of Sugar
224200789|NCT02099929|OTHER|Water without Sugar|300mL of Water without Sugar
223608122|NCT06696027|DIAGNOSTIC_TEST|3'mRNA sequencing|3'mRNA sequencing analyzes gene expression profiles related to the immune response in different study cohorts, aiding in understanding the genetic underpinnings of inflammation and its association with mLOY.
223608123|NCT06696027|DIAGNOSTIC_TEST|Enzyme-linked immunosorbent assay (ELISA) and Legendplex Array|Used to measure cytokine levels in the serum of investigated patients, aiding in profiling inflammatory markers that are indicative of disease activity, response to treatment and consequence of mLOY..
223608124|NCT06696027|DIAGNOSTIC_TEST|Flow Cytometry|Employed to analyze immune cell phenotypes in investigated cohorts. This test helps identify various immune cell subsets and their activation states, which are critical for understanding disease mechanisms and its association with mLOY.
223754712|NCT06484608|DRUG|Isotonic Saline with Dextrose|This clinical trial involves two interventions for maintaining fluid therapy in neonates post-surgery. The first intervention, isotonic saline with dextrose, involves administering 0.9% saline solution combined with 5% dextrose. This isotonic solution aims to maintain serum sodium levels within the normal range and minimize the risk of hyponatremia and hypernatremia in postoperative neonates. The second intervention, hypotonic saline with dextrose, involves administering 0.45% saline solution combined with 5% dextrose. This hypotonic solution is being compared to the isotonic solution to evaluate its effectiveness in maintaining electrolyte balance.
223754713|NCT00150046|DRUG|Everolimus|
223754714|NCT04339699|DEVICE|NobleStitch™EL Suture Mediated Closure System|Percutaneous closure of Patent Foramen Ovale (PFO) using NobleStitch™EL suture Medicate Closure System
223754715|NCT04339699|DEVICE|Amplatzer PFO Occluder|Percutaneous closure of Patent Foramen Ovale (PFO) using Amplatzer PFO Occluder
223754716|NCT00656630|DRUG|Acamprosate|Two 333mg capsules, 3 times daily (Total dose, 1998 mg daily), 1 week duration
223754717|NCT00656630|DRUG|Naltrexone|50mg capsule, Once daily, 1 week duration
223754718|NCT00656630|DRUG|Placebo|Matched placebo capsule, 1 week duration
223754719|NCT01340092|OTHER|Family Navigator|"Families in the intervention group will receive approximately six sessions with a Family Navigator. The Family Navigator will:~1. Help family identify key issues they need to address to get their child autism-specific services~2. Help family address barriers to obtaining these services and strategize approaches to overcome them."
223754720|NCT03483675|BIOLOGICAL|Immunosuppressive Therapy|Discontinued IST
223754721|NCT03483675|BIOLOGICAL|Immunosuppressive Therapy|Continued IST
223754722|NCT03483675|OTHER|Survey Administration|Ancillary studies
223754723|NCT02374879|DEVICE|Blood Glucose Monitoring Systems.|In vitro diagnostic medical device.
223754724|NCT00682188|BEHAVIORAL|Counseling Intervention|Six 30-minute individual student-centered counseling sessions based on the 5A approach to assist adolescents in making changes in their diet and level of physical activity delivered by school nurses over 2 months (weekly in month 1, biweekly in month 2)
223754725|NCT00682188|BEHAVIORAL|Information Intervention|Six individual sessions with the school nurse over 2 months to check weight and behavioral changes and provide a series of six pamphlets on weight and weight management
223754726|NCT02621814|DIETARY_SUPPLEMENT|Low glycation formula feeding|Formula feeding on demand for 3 months
223754727|NCT02621814|DIETARY_SUPPLEMENT|Commercially common formula feeding|Formula feeding on demand for 3 months
223754728|NCT02956733|PROCEDURE|dermotaxis|In dermotaxis (Singhs skin traction) method two parallel kirschner wires (1.5mm) will be passed through the dermis on either side of the wound margins and interconnected by compression device consisting of threaded rod having two blocks and compression knob. Gradual compression will be applied daily at the rate of 1 turn/12hours on both sides of the wound.
224200790|NCT03494673|DIAGNOSTIC_TEST|BOLD MRI|"1. Prospective End-tidal targeting RespirAct device(A specially designed gas blender and sequential rebreathing circuit) will be used to implement the gas targeting method which involves precise elevations in End-tidal PCO2 while maintaining a fixed End-tidal PO2~2. BOLD MR images will be obtained by using a T2\*-weighted two-dimensional gradient-echo sequence with echoplanar readout."
224200791|NCT00140101|DEVICE|ZoMaxx™ Drug-Eluting Coronary Stent System|Drug eluting stent implantation stent in the treatment of coronary artery disease.
223508505|NCT03666793|OTHER|global care|Medication Reconciliation at admission, Multidisciplinary medication review, Medication Reconciliation at discharge
223508506|NCT03193307|DRUG|Microgynon® 30|Run in period \& Treatment Period
223508507|NCT03193307|DRUG|BI 409306|Day 18 \& 29 (Treatment Period)
223508508|NCT01984060|OTHER|HOME-EX|"Motivational Counseling: The first session will be an hour face-to-face interview to establish a rapport with subjects, assess motives and competence. The rest will be 30 min. phone calls to assess week's performance and agree on an action plan for next 2 weeks.~Exercise Intervention: Using the average number of steps for each subject from their baseline assessment, the targeted number of steps the subject needs to walk every day will be calculated. The individualized strength training exercise will target the upper and lower body. If possible, they will be encouraged to progressively increase from their individual baseline sets and repetitions to a maximum of 4 sets of 15 repetitions for each exercise"
224200792|NCT00140101|DEVICE|TAXUS™ EXPRESS2™ Paclitaxel Eluting Coronary Stent|Drug eluting stent implantation stent in the treatment of coronary artery disease.
224200793|NCT06563440|OTHER|Digital app and information system|A custom digital app and information system that consists of four modules: (1) ID module - captures child's demographic and biometric data and builds a printable QR-code; (2) Assay module - captures point of care test image, interprets, and transmits results to the central ministry of health data center; (3) Education module - stores and plays back short educational videos for pre- and post-screening counseling; (4) SCD e-Passport module - entry and display of child's salient clinical information.
223508509|NCT03845868|OTHER|Dietary and environmental exposure (Observational study)|
223508510|NCT02829957|DRUG|Apixaban|10mg BID for 7 days, then 5mg BID for three months
223608125|NCT06696027|DIAGNOSTIC_TEST|Laboratory assessment|Serum Chemistry
223608126|NCT06696027|DIAGNOSTIC_TEST|Assessment of Pulmonary Involvement|Results of routine clinical assessment of pulmonary involvement (such as lung ultrasound, computed tomography, chest x-ray, whole-body plethysmography) will be compared to mLOY, ELISA/ Legendplex/ flow cytometry/ transcriptome analysis results.
224200794|NCT06567717|DRUG|Zinc|Zinc has not previously been investigated in the treatment of IPF.
223754729|NCT02956733|PROCEDURE|loop suture technique|The loop suture technique involves using corrugated drains and Ethilon no.1. It is an extension of the purse string suture technique where a surgical suture is passed as a running stitch in and out along the edge of a wound in such a way that when the ends of the suture are drawn tight the wound is closed. Two corrugated drains (1 \& 2) will be anchored to the skin adjacent to the fasciotomy incision using Ethilon no.1. Then the sutures will be passed from one edge of the wound through the skin and corrugated drain to the other in an alternating fashion.
223754730|NCT04785274|DEVICE|non-invasive hemoglobin (SpHb)|hemoglobin measuring device
223754731|NCT01889316|DEVICE|Novii|The Novii is a modified device with similar technology to the AN24 device already being used in the USA.
223754732|NCT01889316|DEVICE|AN24|
223754733|NCT02665416|DRUG|Selicrelumab|Selicrelumab will be provided as concentrate for solution to be administered via SC injection
223754734|NCT02665416|DRUG|Vanucizumab|Vanucizumab will be provided as solution to be administered via IV infusion.
223754735|NCT02665416|DRUG|Bevacizumab|Bevacizumab will be administered via IV infusion.
223754736|NCT05200754|OTHER|Convalescent/Vaccine-boosted Plasma (CP/PVP)|"Plasma from apheresis obtained from donors, who have recovered from SARS-CoV-2 infection or received a successful vaccination against SARS-CoV-2.~CP/PVP infusion is administered on two following days. Each CP/PVP bag contains approx. 238 - 337 ml anti-SARS-Cov-2 CP/PVP for infusion."
223754737|NCT03951922|BEHAVIORAL|Horticultural activity|Therapeutic horticulture activities are plant-related activities that include but not limited to digging, watering, planting, weeding, trimming, fertilizing, mulching, harvesting, learning about organic farming, and exploring options to incorporate horticulture into daily activities
223754738|NCT02071524|DRUG|Group Colloid|Group Colloid: cristalloid 1:2 (gelofusine: ringer lactate)
223754739|NCT02071524|DRUG|Cristalloid administration|Only Ringer Lactate administration
223754740|NCT04860102|PROCEDURE|hands on|Hands-on was defined as involving one hand on the fetal head, applying pressure to control expulsion, with the other hand applying pressure on the maternal perineum
223754741|NCT06176950|OTHER|Oral History Interviews|I will ask interview subjects about their educational and career path, their research interests and clinical work in the field of neonatology. I will also ask them about their personal and professional motivations and thoughts about their work. And we will discuss how their interactions with colleagues and patients/caregivers shaped their work experience and decision making.
223754742|NCT00896558|DRUG|GSK1322322/placebo|GSK1322322/placebo escalating doses from 500mg to 1500mg
223754743|NCT00896558|DRUG|GSK1322322/placebo and midazolam|GSK1322322/placebo and 5mg midazolam
223754744|NCT01162382|DEVICE|Transcranial Magnetic Stimulation|Four 100-second trains and then one 65-second train, with 30-second inter-train intervals, at 1 Hz and 120% of the resting motor threshold will be applied over the right dorsolateral prefrontal cortex. Subsequently, twenty-five 30-second trains, with a 30-second inter-train interval, at 10 Hz and 120% of the resting motor threshold will be applied over the left dorsolateral prefrontal cortex.
223754745|NCT03718442|DEVICE|PhotonBlade vs Bovie for lumpectomy shaved surgical margins|For each enrolled patient, six shaved margins will be obtained (superior, inferior, medial, lateral, anterior, and posterior). For each patient, electrocautery will be used to obtain 3 of the shaved margins, and PhotonBlade to obtain the other 3 shaved margins. Once the lumpectomy site shaved margins have been obtained, the shaved surgical margins will be evaluated by a pathologist whom is blinded in regards to the dissection device that was used for each margin. The pathologist will be evaluating each shaved margin and reporting the outcomes (qualitative severity and depth of thermal artifact)
223754746|NCT01886807|DEVICE|TrueView PCD Video Laryngoscope|
223754747|NCT01623596|DRUG|Fingolimod|
223754748|NCT01623596|DRUG|Disease Modifying therapy|
223754749|NCT02029534|DRUG|Atorvastatin 20 mg|
223754750|NCT02029534|DRUG|Atorvastatin 80 mg|
223508511|NCT02829957|DRUG|Rivaroxaban|15mg BID for 7 days, then 20mg daily for three months
223508512|NCT05469308|OTHER|questionary|When the patients renew their treatment in community pharmacy, they have an adherence record with a pharmacist who calculates the PDC score, and perform questionaries on adherence to the DOACs, and collects data about clinical history and pharmacological information on the prescribed DAOCs, demography.
223754751|NCT01802658|DRUG|Zoledronic acid|Zoledronic acid 5 mg. IV. 3 infusions. Administration 3 times inclusion M12 and M24 over two years.
223508513|NCT01181765|BIOLOGICAL|Infliximab 5 mg/kg body weight infused over 2 hours|Subjects will receive IV Infusion of infliximab 5 mg/kg body weight at Week 0, Week 2, Week 6, Week 14 and Week 22 as per the approved Canadian product monograph of infliximab.
223508514|NCT02576366|DRUG|Voriconazole|
223508515|NCT02576366|DRUG|Rifampin|
223508516|NCT00158431|PROCEDURE|Arthroscopy plus Medical Management|Arthroscopic Surgery
223508517|NCT00158431|OTHER|Medical Management|education, optimized medication, weight loss where needed, HA or cortisone injections if needed, physiotherapy
223608129|NCT06697899|DRUG|TGRX-678|All participants are given TGRX-678 orally at 240 mg
223608130|NCT07029776|DRUG|teclistamab+daratumumab followed by talquetamab+daratumumab followed by duration treatment with daratumumab and lenalidomide extended/maintenance|teclistamab+daratumumab followed by talquetamab+daratumumab each for 4 cycles followed by 2-year fixed duration treatment with daratumumab and lenalidomide extended/maintenance therapy for a maximum of 24 cycles, or until myeloma progression.
223608131|NCT07029776|PROCEDURE|melphalan (MEL)-based hematopietic stem cell transplantation (HSCT) followed by drug therapy|Subjects who are MRD-positive (a threshold of 10\^5) will receive a single melphalan (MEL)-based hematopietic stem cell transplantation (HSCT) followed by teclistamab+daratumumab followed by talquetamab+daratumumab each for 4 cycles followed by a 2-year fixed duration treatment with daratumumab and lenalidomide extended/maintenance therapy for a maximum of 24 cycles, or until myeloma progression.
223608132|NCT04770701|DRUG|Ahah Drug|"\- Composition Ahah containing concentrated extracts of plants: Eclipta prostrata 200mg, dioscorea cirrhosa 200mg, phyllanthus urinaria 150mg, adenosma glutinosum 150mg, impatiens balsamina 75mg and ascorbic acid 250mg~-Take 1tablet x 2 times / 24 hours. Maintained for 9 months."
223754752|NCT01802658|DRUG|NA Cl|NACl 100 ml IV. 3 infusions. Administration 3 times inclusion M12, M24 over two years.
223754753|NCT04988217|DRUG|Interferon-Alpha2B|Nebulized interferon alpha 2B
223754754|NCT04988217|DRUG|Placebo|Nebulized placebo
223754755|NCT04347382|DRUG|Honey|1gm/Kg/Day
223754756|NCT04347382|DRUG|Nigella Sativa / Black Cumin|80mg/Kg/day
223754757|NCT04347382|DRUG|Placebos|Empty capsule with 250ml of distilled water
223754758|NCT01324349|DEVICE|Veriset Hemostatic Patch|Topical hemostat
223754759|NCT01324349|DEVICE|Fibrin Sealant (TachoSil®)|Topical hemostat
223754760|NCT03119415|BEHAVIORAL|Cooperative Learning|CL is an umbrella term that includes peer tutoring, reciprocal teaching, collaborative reading, and other methods in which peers help each other learn in small groups. CL is not prescriptive but rather is a conceptual framework within which teachers design their own small-group activities. Johnson, Johnson, and Holubec's approach to CL combines positive interdependence with individual accountability, a high degree of face-to-face social interaction among youth, and support for the development of cooperative social skills. The Johnsons' approach offers teachers the combination of specific cooperative activities and the conceptual tools to create their own lesson plans using positive interdependence.
223754761|NCT01243359|DRUG|sunitinib malate|Given PO
223754762|NCT01243359|BIOLOGICAL|bevacizumab|Given IV
223754763|NCT01243359|OTHER|pharmacological study|Correlative studies
223608133|NCT04770701|DEVICE|Ahah Placebo|"\- Composition Ahah (not containing concentrated extracts of plants): Eclipta prostrata 200mg, dioscorea cirrhosa 200mg, phyllanthus urinaria 150mg, adenosma glutinosum 150mg, impatiens balsamina 75mg and ascorbic acid 250mg)~-Take 1tablet x 2 times / 24 hours. Maintained for 9 months."
223608134|NCT07036120|DEVICE|orthosis|(1) one pair of two orthoses, regardless of the right and left sides; (2) loosen the two Velcro straps, put the large Velcro strap into the arch of the foot, and put the small Velcro strap on the thumb; (3) place the rigid plastic fixation plate along the medial edge of the foot and align the axis of rotation with the 1st metatarsalphalangeal joint; (4) tighten the Velcro straps as much as possible to prevent dislocation of the orthoses, without interfering with sleep; (5) tighten the Velcro straps to prevent dislocation of the orthoses, and to prevent the orthoses from moving out of position. Tighten the Velcro straps as much as possible without disturbing sleep to prevent the orthosis from shifting and to position the phalanx correctly in the outer table. Contact the laboratory staff for a new pair of orthotics if the adhesive tape is not sufficiently sticky to maintain positional fixation during sleep.
223608135|NCT07036120|BEHAVIORAL|foot exercises|"1. Warm-up: 30 seconds per movement~   1. Joint loosening~  2. Plantar relaxation~2. Toe spreading: 10 reps/set, 3 sets/day~3. Toe grasping towel: 10 times/set, 3 sets/day~4. Standing Heel Raise: 10 times/group, 3 groups/day~5. Short Foot Exercise: 10 times/sets, 3 sets/day~6. Relax the soles of the feet again at the end of all exercises."
223608136|NCT06456580|BIOLOGICAL|Telitacicept|Subcutaneous injection
223608137|NCT06456580|DRUG|Placebo|Subcutaneous injection
223608138|NCT07059663|OTHER|Schroth Method with Core Stabilization Exercises|The Schroth method will focus on postural correction techniques aimed at improving spinal alignment, reducing the curvature of the spine, and enhancing trunk control. Key exercises will include spinal elongation, de-rotation, and specific breathing techniques to help reduce the scoliotic curve. Core stabilization exercises will target the deep trunk muscles, such as the transversus abdominis and multifidus, to improve spinal stability. These exercises will involve bodyweight exercises, resistance bands, and stability balls, aimed at increasing muscle endurance and promoting better posture. The interventions will be performed three times a week for 10 weeks, with each session lasting 60 minutes
223608139|NCT07059663|OTHER|Schroth Method|The control group will receive the Schroth method alone, focusing solely on postural correction exercises. These exercises will aim to improve spinal alignment, reduce curvature, and enhance postural control through spinal elongation, de-rotation, and specific breathing techniques designed to address the scoliosis. The control group will not receive any core stabilization exercises in addition to the Schroth method. This intervention will also be performed three times a week for 10 weeks, with each session lasting 60 minutes
223754764|NCT01243359|OTHER|laboratory biomarker analysis|Correlative studies
223754765|NCT01243359|OTHER|fluorine F 18 fluorothymidine|Undergo FLT PET/CT
223754766|NCT01243359|PROCEDURE|positron emission tomography|Undergo FLT PET/CT
223754767|NCT01243359|PROCEDURE|computed tomography|Undergo FLT PET/CT
223754768|NCT04225169|OTHER|Breathing exercises|The patient was taken to a quiet room and asked to lie on the bed. For the first 5 minutes, the researchers explained how the exercise is done with pictures and demonstrated it to the patient. The patient was asked to perform the exercise for 5 minutes under supervision by the researchers. If the patient performed DBE correctly, practice was discontinued. If not, the patient was asked to practice for another 5 minutes. If the patient still could not perform the exercise correctly at the end of this time, they were excluded from the sample. DBE was performed according to the Cleveland Clinic guideline as follows:
223754769|NCT00543764|OTHER|pathway|Comparison of pre and post pathway
223754770|NCT00748215|DRUG|calcium aluminosilicate anti-diarrheal|Given orally
223754771|NCT00748215|OTHER|placebo|Given orally
223754772|NCT01561352|DRUG|activated recombinant human factor VII|If non-responding haemorrhagic cystitis to 24-hour trial of conventional therapy, 80 mcg/kg is administered i.v. for the first dose. If necessary, two additional doses of 120 mcg/kg can be administered i.v.
223754773|NCT05175066|DRUG|Bisoprolol|For patients who were candidates to start therapy with anthracycline, bisoprolol was administrated as explained before to determine the effect of this drug on the reduction of anthracycline-induced cardiomyopathy.
223754774|NCT05175066|DRUG|Placebo|Tablets with similar shape and size and color to bisoprolol were given to the patients whom undergone chemotherapy with anthracyclines to compare the effects between two groups.
223754775|NCT04944901|DRUG|SB-121|SB-121 is a formulation of L. reuteri
223754776|NCT04944901|DRUG|Placebo|Placebo oral formulation
223754777|NCT02330796|DRUG|Bucillamine|Bucillamine Tablets
223754778|NCT02330796|DRUG|Colchicine|
223754779|NCT05284838|OTHER|Error Management Training (Difficult)|Error Management Training is used to teach head computed tomography interpretation. Participants encounter difficult questions.
223754780|NCT05284838|OTHER|Error Management Training (Easy)|Error Management Training is used to teach head computed tomography interpretation. Participants encounter easy questions.
223754781|NCT05284838|OTHER|Error Avoidance Training|Error Avoidance Training used to teach head computed tomography interpretation.
224200795|NCT06567717|OTHER|Placebos for zinc and nicotinamide riboside|These will be identical in appearance to the active substances
223608140|NCT07066618|BEHAVIORAL|Breakfast-Loaded Hypocaloric Diet|Participants in this group consumed a hypocaloric diet in which 50% of daily energy intake was provided at breakfast, 35% at lunch, and 15% at dinner. Meal times were standardized as follows: breakfast (7:00-9:00), lunch (12:00-14:00), and dinner (18:00-20:00). The diet was individually tailored and provided 20% fewer calories than the participants' total energy expenditure. Macronutrient distribution followed recommended guidelines: 45-60% carbohydrates, 10-20% protein, and 20-35% fat.
223608141|NCT07066618|BEHAVIORAL|Dinner-Loaded Hypocaloric Diet|Participants in this group consumed a hypocaloric diet in which 15% of daily energy intake was provided at breakfast, 35% at lunch, and 50% at dinner. Meal times were standardized as follows: breakfast (7:00-9:00), lunch (12:00-14:00), and dinner (18:00-20:00). The diet was individually tailored and provided 20% fewer calories than the participants' total energy expenditure. Macronutrient distribution followed recommended guidelines: 45-60% carbohydrates, 10-20% protein, and 20-35% fat.
223608142|NCT06937164|BEHAVIORAL|Isometric Exercise Training (IET)|Participants perform four repetitions of 90 degree bilateral isometric leg extensions on a dynamometer at 30% of their maximum voluntary contraction (MVC). Each contraction is held for 2 minutes, with 2-minute rest intervals between bouts. Sessions are performed three times per week for four weeks. This behavioral intervention is designed to investigate the acute and chronic effects of isometric exercise on blood pressure, heart rate variability, and muscle fatigue.
223608143|NCT06937164|BEHAVIORAL|Expectation-Enhancing Informational Framing|Participants receive a brief standardized presentation highlighting isometric exercise as an evidence-based intervention for lowering blood pressure. The presentation includes statements designed to enhance outcome expectations based on prior literature and expert framing.
223608144|NCT06939790|BEHAVIORAL|Digital Cognitive-Behavioral Therapy for Insomnia (dCBT-I)|The digital CBT-I (dCBT-I) is a self-guided online program replicating the structure and content of standard face-to-face CBT-I, aiming to offer a more accessible treatment for chronic insomnia. It includes video lessons, interactive exercises, and relaxation techniques, with core components such as sleep education, sleep restriction, stimulus control and cognitive restructuring. Supervision is provided through periodic check-ins.
223608145|NCT06939790|BEHAVIORAL|standard face-to-face group-based Cognitive-Behavioral Therapy for Insomnia (CBT-I)|The control group will receive standard face-to-face group-based CBT-I, the current gold-standard treatment for chronic insomnia. Delivered by trained professionals, the intervention includes seven structured sessions covering core components such as sleep education, sleep restriction, stimulus control, cognitive restructuring, and relaxation techniques. Sessions last about 90 minutes and aim to improve sleep quality through evidence-based strategies.
223608146|NCT06947824|BEHAVIORAL|Fasted Morning Exercise (12h)|A 30-minute exercise session will take place on a treadmill in the morning (7:00, \~1h after participants' habitual wake-up time), after a 12h overnight fast. The session will consist of 30 minutes of steady state cycling at 65% of VO2max, following a 5 min warm-up.
223754782|NCT03200899|BEHAVIORAL|MAPSS-MS|MAPSS-MS is a computer-assisted cognitive rehabilitation intervention. It is a combination of home computer training and 8-weeks of group sessions on lifestyle change and compensatory cognitive strategies.
223754783|NCT03200899|OTHER|Usual Care plus computer games|"Participants assigned to this arm receive their usual medical care and referral to the My Brain Games website."
223754784|NCT04646499|DEVICE|Transcranial alternating current stimulation|Transcranial alternating current stimulation (tACS) will be applied at 40 Hz (gamma band) during eight sessions over the course of a month.
223754785|NCT06167018|BEHAVIORAL|Gut-directed hypnotherapy|Gut-directed hypnotherapy for patients with irritable bowel syndrome (IBS). Gut-directed hypnotherapy (8-12 sessions), were given either in an individual manner or in a group setting.The hypnosis treatment is administered by two nurses specially trained in Cognitive Behavioral Therapy (CBT) and hypnotherapy. The treatment was based on the North Carolina protocol. Patients assessed gastro-intestinal symptom severity before, during and after treatment, as well as at follow-up.
223754786|NCT00837707|DRUG|aripiprazole|Flexible dose: 5-30 mg/day
223754787|NCT00012558|DRUG|lithium|
223754788|NCT00012558|DRUG|valproate|
223754789|NCT00012558|DRUG|bupropion|
223754790|NCT00012558|DRUG|paroxetine|
223754791|NCT00012558|DRUG|lamotrigine|
223754792|NCT00012558|DRUG|risperidone|
223754793|NCT00012558|DRUG|inositol|
223754794|NCT00012558|DRUG|tranylcypromine|
223754795|NCT00012558|BEHAVIORAL|Cognitive Behavioral Therapy|
223754796|NCT00012558|BEHAVIORAL|Family-focused Therapy|
223754797|NCT00012558|BEHAVIORAL|Interpersonal and Social Rhythms Therapy|
223754798|NCT05165212|DRUG|Amoxicillin|Patients will be given 10% of a standard weight-based dose of amoxicillin and observed for signs/symptoms of allergic reaction for 30 minutes. If no reaction occurs, they will given the remaining 90% of the standard dose and observed for an additional 30 minutes.
223754799|NCT05972538|DEVICE|Osstell ( Osstell AB, Goteborg, Sweden).|Implant stability were assessed on 15, 30,60 and 90 days of prosthesis delivery
223754800|NCT05972538|DEVICE|periodontal probe (Vivacare, TPS, Vivadent, Schaan, Lichtenstein|Clinical evaluation included assessment of pocket depth, plaque index and bleeding on probing) around the implant abutments on 15, 30,60 and 90 days of prosthesis delivery
223754801|NCT05972538|OTHER|questionnaire for patient satisfaction|A questionnaire was used to evaluate patient satisfaction on 90 days at the end of follow up period.
223754802|NCT04151290|DIAGNOSTIC_TEST|Cognoa ASD diagnostic device|Cognoa device is intended to aid healthcare providers in diagnosing Autism Spectrum Disorder (ASD)
223754803|NCT01165866|DRUG|Treatment 1. Metoclopramide|metoclopramide 0.3mg/kg maximum dose 10mg will be added in the burette and mixed with normal saline to make up 50cc of medication for intravenous administration.
224200796|NCT06567717|DRUG|Nicotinamide riboside|Nicotinamide riboside has not previously been investigated in the treatment of IPF.
223754804|NCT01165866|DRUG|Treatment 2 Ondansetron|Single dose of Ondansetron 0.15 mg/kg
223754805|NCT03408015|DRUG|Lifitegrast|Lifitegrast ophthalmic solution, 5.0%. 1 drop instilled into each eye once in the morning and once before bed.
224200797|NCT02830646|OTHER|DFG mesure|Measure the effect of gastric bypass on the report DFG / VEC.
224200798|NCT00002879|DRUG|cladribine|
224200799|NCT04862052|PROCEDURE|Intravascular management of prior implanted coronary drug eluting stent restenosis|Intravascular devices will be assessed for the management of prior implanted drug eluting stent restenosis management.
223608147|NCT06947824|BEHAVIORAL|Fasted Evening Exercise (6h)|A 30-minute exercise session will take place on a treadmill in the evening (19:00, exactly 12 hours after the morning session), after a 6h fasting period. The session will consist of 30 minutes of steady state cycling at 65% of VO2max, following a 5 min warm-up.
223608148|NCT06947824|BEHAVIORAL|Fasted Evening Exercise (12h)|A 30-minute exercise session will take place on a treadmill in the evening (19:00, exactly 12 hours after the morning session), after a 12h fasting period. The session will consist of 30 minutes of steady state cycling at 65% of VO2max, following a 5 min warm-up.
223608149|NCT06947824|BEHAVIORAL|Fed Morning Exercise (12h AMEx-Fed)|A 30-minute exercise session will take place on a treadmill in the morning (7:00, \~1h after participants' habitual wake-up time), after consuming a small pre-exercise snack (30 min before exercise). The session will consist of 30 minutes of steady state cycling at 65% of VO2max, following a 5 min warm-up.
223608150|NCT06750497|BEHAVIORAL|Forearm immobilization|Two days of forearm immobilization
223608151|NCT06949644|COMBINATION_PRODUCT|Light and Citalopram|Participants will receive placebo or citalopram, followed by bright light exposure
223608152|NCT03657849|DEVICE|EBUS TBNA|All patients undergo EBUS TBNA with two needle sizes
223608153|NCT01678612|OTHER|Copper-alloy surfaced objects|Room assigned to the Experimental arm will be furnished with copper-alloy surfaced objects,i.e. bed-rails, bed-rail levers, IV poles, nurse workstation, HCW clipboards, sink handles.
223608154|NCT02621294|OTHER|Measuring protein requirement|a repeated measures design will be used on each athlete receiving eight graded intakes of protein on separate days in the form of AA in random order ranging from 0.2 to 3.5 g/(kg/d). Three baseline samples of breath and urine will be collected at 60, 45 and 30 min before the stable isotope is given orally. During a period of 150 to 270 min. after stable isotope ingestion, 5 breath and urine samples (every 30 min) will be collected to determine an isotopic plateau in breath and urine. The rate of release of 13CO2 from the oxidation of L-\[1-13C\] phenylalanine (F 13CO2) in breath will be measured and a breakpoint analysis will determine total protein requirement
223608155|NCT03944291|PROCEDURE|Pudendal Nerve Block|Pudendal Nerve Block
223608156|NCT02711007|DRUG|apatinib|Apatinib is a small-molecule VEGFR tyrosine kinase inhibitor, similar to vatalanib (PTK787), but with a binding affinity 10 times that of vatalanib or sorafenib.
223608157|NCT04208438|DIAGNOSTIC_TEST|BVI Device|Non-Invasive measurement of jugular blood volume using Mespere BVI device
223754806|NCT05252039|BEHAVIORAL|Goals in Focus|"Goals in Focus (GiF) is a symptom-specific treatment program that targets motivational negative symptoms in patients with schizophrenia-spectrum disorders.~The aim is to improve setting and pursuit of personal relevant goals.~GiF follows a 24-individual-sessions treatment manual. GiF includes five treatment phases: 1) Preparation, 2) Goal-setting, 3) Goal-pursuit, and 4) Reflection and preparation of autonomous goal-pursuit. The interventions include generating positive goals, behavioral activation, training of anticipatory pleasure, challenging demotivating beliefs, training of problem-solving skills and social skills training."
223754807|NCT01302912|PROCEDURE|Lymphoma-Biopsy|Patients after biopsy of orbital lymphoma
223608158|NCT04208438|DIAGNOSTIC_TEST|Point-of-Care Ultrasound|Point-of-Care ultrasound of external and internal jugular veins
223608159|NCT00874848|BIOLOGICAL|Imprime PGG Injection|4 mg/kg i.v. over 2 hrs, weekly, in three week cycles
223608160|NCT00874848|BIOLOGICAL|Cetuximab|initial loading dose of 400 mg/m\^2 over 120 min and subsequent doses at 250 mg/m\^2 over 60 min, weekly on Days 1, 8 and 15 of each 3-week treatment cycle
223608161|NCT00874848|DRUG|Paclitaxel|200 mg/m\^2 i.v. over 3 hr on Day 2 of each 3-week treatment cycle for the first 4 to 6 treatment cycles
223608162|NCT00874848|DRUG|Carboplatin|dose equal to an AUC of 6 mg/mL · min based on the Calvert formula; i.v. over 30 min on Day 2 of each 3-week treatment cycle for the first 4 to 6 treatment cycles
223608163|NCT03559933|DEVICE|PEPNS System|PEPNS System therapy will be delivered periodically up to 48 hours or less if patient is no longer being mechanically ventilated.
223608164|NCT01581060|DRUG|WX-554|Capsules of WX-554
223754808|NCT06404151|DEVICE|monitoring|rc02, ORI , spO2
223608165|NCT01037738|PROCEDURE|ACL reconstructive surgery and ACS/ Orthokin application|ACL reconstructive surgery and ACS/ Orthokin or Placebo intraarticular application on Day 0,1,6 and 10 postoperatively, regarding the Arm
223608166|NCT00716846|DRUG|simvastatin|10mg, 2 weeks
223608167|NCT00716846|DRUG|atorvastatin|10mg
223608168|NCT00716846|DRUG|pitavastatin|2mg
223608169|NCT03625336|DIAGNOSTIC_TEST|MRI|An MRI will be obtained utilizing 3 different MRI sequences
223608170|NCT02034838|DRUG|atazanavir 300mg boosted with ritonavir 50 mg|"atazanavir 300 mg with ritonavir 100 mg once a day at 8:00 am for study day 1 and 9.~atazanavir 300 mg with ritonavir 50 mg once a day at 8:00 am for 7 consecutive days (study days 2-8)"
223608171|NCT03570359|DRUG|Interferon Beta-1A|Interferon Beta-1A via inhalation
223608172|NCT03570359|OTHER|Placebo|Placebo via inhalation
223608173|NCT02057159|BIOLOGICAL|NeuroVax|TCR peptides in IFA
223608174|NCT02057159|BIOLOGICAL|IFA Placebo|IFA Placebo
223608175|NCT01516463|DRUG|Collagenase Santyl|Applied topically (2 mm thickness once daily)
223608176|NCT01516463|BIOLOGICAL|Bacitracin|Applied topically (2 mm thickness) once daily
223608177|NCT01772732|DRUG|Simotinib Hydrochloride|
223608178|NCT02913950|OTHER|validation of pediatric stool scale|validation of pediatric stool scale
223608179|NCT06433089|PROCEDURE|Thoracic paravertebral block|Thoracic paravertebral block was performed before surgery
223608180|NCT02713828|DRUG|Phase I: Glembatumumab Vedotin|"Escalation Phase: Three to 6 patients will be enrolled in each dose cohort based on a standard Phase I dose escalation scheme. For the dose-escalation, the starting dose of glembatumumab vedotin will be 1.9 mg/kg q3w (Cohort 1). In the event of ≥ 2 DLTs, the dose will de-escalate to Cohort -1 (1.3 mg/kg).~Dose escalation from Cohort 1 to Cohort 2 (2.2 mg/kg) may proceed if three patients in Cohort 1 complete the DLT observation period with 0 DLTs, or if six patients in Cohort 1 complete the DLT observation period with 0 or 1 DLTs."
223608181|NCT02713828|DRUG|Phase II: Glembatumumab Vedotin|In Stage 1, approximately 20 eligible, treated patients will be enrolled. If ≥ 2 patients achieve a tumor response (Partial Response \[PR\] or Complete Response \[CR\]), an additional 15 eligible, treated patients will be enrolled in Stage 2, for a maximum total of 35 eligible, treated patients.
223608182|NCT04686383|DRUG|CAL056 mesylate|Dosage form: 20 mg CAL056 mesylate/tablet
223754809|NCT02086669|PROCEDURE|Pneumatic dilatation|
223754810|NCT02086669|PROCEDURE|Laparoscopic myotomy|
223608183|NCT01238302|PROCEDURE|Conventional arthroscopic rotator cuff repair|"* Under general anesthesia, the patient was placed in the lazy lateral decubitus position on the operating table.~* The surgical area was prepared and draped with Betadine.~* Small stab incisions were made in the creation of 4-5 portals as needed.~* A scope was explored via the arthroscopic portal into the GH joint \& subacromial space.~* Repair of full thickness rotator cuff tear was done with suture anchors.~* The skin was closed with Nylon or medical staples.~* Sterile dressing was applied on surgical wound."
223608184|NCT01238302|PROCEDURE|Arthroscopic rotator cuff repair with PRP|"* Under general anesthesia, the patient was placed in the lazy lateral decubitus position on the operating table.~* The surgical area was prepared and draped with Betadine.~* Small stab incisions were made in the creation of 4-5 portals as needed.~* A scope was explored via the arthroscopic portal into the GH joint \& subacromial space.~* Repair of full thickness rotator cuff tear was done with suture anchors.~* After tying sutures of the medial row, PRP gels were applied on the repair site.~* The lateral row was secured using suture anchors.~* The skin was closed with Nylon or medical staples.~* Sterile dressing was applied on surgical wound."
223754811|NCT05834517|DRUG|Hyaluronic acid|Hyaluronic Acid (HA) is an addition to the local chemotherapeutic agents. Hyaluronic acid was discovered by Meyer and Palmer. HA is widely found in the extracellular matrix and it plays an essential role in controlling cell behavior including random motility, metabolic reactions, chemotaxis, proliferation and invasion. HA is released by many cells including fibroblasts
223754812|NCT05834517|PROCEDURE|non surgical periodontal therapy|NSPT, with or without adjunctive therapies, is an effective treatment for periodontitis. It reduces PD and results in formation of some new attachment; however, it also has several limitations, and surgical therapy might be required to control inflammation and optimize outcomes. When used for non-surgical scaling and root planing, periodontal curettes can reach a mean PD of up to approximately 5.5 mm. The mean PD in which a plaque-free and calculus-free surface can be established is \<4 mm
223754813|NCT01530321|OTHER|Spinal Manipulation|5 minutes of high velocity, low amplitude thrust to cervical and upper thoracic spine.
223754814|NCT01530321|OTHER|Light Massage|5 minutes of light pressure massage to the neck and upper back
223754815|NCT03673163|DRUG|Lidocaine|Infusion of 2% lidocaine hydrochloride at 4 mL/h,prior to surgery and discontinued until 24 h after surgery.
223754816|NCT03673163|DRUG|Control|Infusion of normal saline at 4 mL/h, prior to surgery and discontinued until 24 h after surgery.
223754817|NCT02727920|DIETARY_SUPPLEMENT|Energy drink|
223754818|NCT02727920|OTHER|Placebo|placebo drink
223754819|NCT05694728|BIOLOGICAL|Recombinant Nonavalent (Types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (HPV) Vaccine (Escherichia Coli)|"For Mid-dosage group, a 3-dose regimen administered at months 0, 2 and 6.~For High-dosage group, a 3-dose regimen administered at months 0, 2 and 6."
223754820|NCT05694728|BIOLOGICAL|Recombinant Quadrivalent Human Papillomavirus (Types 6,11,16,18) Vaccine (Saccharomyces cerevisiae)|A 3-dose regimen administered at months 0, 2 and 6.
223754821|NCT01024712|DRUG|carboplatin|
223754822|NCT01024712|DRUG|gefitinib|
223754823|NCT01024712|DRUG|paclitaxel|
223754824|NCT01024712|PROCEDURE|quality-of-life assessment|
223508518|NCT05684614|OTHER|Negative mood induction procedure|"The negative mood induction procedure (MIP) used in this study has previously been shown to effectively induce sadness. This MIP takes place in a virtual environment of an urban park and includes the following methods to induce negative mood: 1) Velten's tasks, consisting of interactive phrase formulations with negative thoughts and beliefs about the self (e.g., I don't have any future); 2) visualizing International Affective Pictures; and 3) recalling a negative autobiographical memory related to a significant loss (e.g., a person, a pet)."
223608185|NCT02106520|DRUG|Bevacizumab|
223608186|NCT02106520|DRUG|placebo|
223754825|NCT01575184|OTHER|caudo-ipsilateral traction of shoulder|After the head rotation (0, 40, 80 degrees) to the contralateral side from the ultrasound measuring site, the slight caudo-ipsilateral traction of shoulder will be applied without changing the degree of the head rotation.
223754826|NCT01575184|OTHER|The ultrasonographic measurements without shoulder traction|After the head rotation (0, 40, 80 degrees) to the contralateral side from the ultrasound measuring site, the no traction of shoulder will be applied.
223754827|NCT02886390|DEVICE|ischemic conditioning|In this study, the remote ischemic conditioning treatment was composed of five cycles of bilateral upper limb ischemia intervened by reperfusion, which was induced by two cuff placed around the upper arms respectively and inflated to 200 mm Hg for 5 minutes followed by 5 minutes of reperfusion by cuff deflation.
223754828|NCT05796674|DEVICE|Clareon UVA IOL|Clareon UVA IOL placed in the capsular bag in the posterior chamber of the eye during cataract surgery to replace the natural crystalline lens. Models CC60WF and CCA0T0 are indicated for the visual correction of aphakia. Models CCW0T3, CCW0T4, CCW0T5, and CCW0T6 are indicated for the visual correction of aphakia and preexisting corneal astigmatism.
223754829|NCT05796674|DEVICE|WaveTec Optiwave Refractive Analysis (ORA) System|Intra-operative system used during refractive cataract surgery to capture wavefront images of the patient's eye for the purpose of optimizing IOL implantation
223754830|NCT05796674|PROCEDURE|Cataract surgery|Cataract extraction by phacoemulsification, followed by implantation with a Clareon UVA IOL
223754831|NCT03995212|DRUG|CR845 1.0 mg|Oral CR845 1.0 mg administered twice daily
223754832|NCT03995212|DRUG|Placebo|Oral Placebo administered twice daily
223754833|NCT03863028|OTHER|Simulation training|It is not a randomized trial - all three groups are exposed to simulation training.
223754834|NCT00969553|DRUG|BI 6727|Dose level 1
223754835|NCT01894269|DRUG|Lamivudine 100mg once daily; or Entecavir 0.5mg once daily.|In experimental group, Lamivudine 100mg once daily; or Entecavir 0.5mg once daily will be commenced after TACE.
223754836|NCT03173716|PROCEDURE|Definity|Real-Time Myocardial Perfusion Echocardiography (RTMPE) will be performed as opposed to the standard echocardiogram (TTE) of the control arm
224200800|NCT02561728|DEVICE|Hangar Helmet|Child will be fitted with the Hangar Helmet
224200801|NCT02561728|DEVICE|P-Pod Helmet|Child will be fitted with the P-Pod Helmet
223508519|NCT05684614|OTHER|Spontaneous emotion regulation task|Participants are instructed to use whatever strategy they want by doing, saying, and/or thinking whatever they want to feel better for 2 min
223608187|NCT02864160|BEHAVIORAL|Health Coaching|Life style coaching in 3 in-person meetings and 14 phone calls; written educational materials; self-management tools (stretch band, a glucometer, and a diabetes cookbook in Spanish).
223608188|NCT02864160|BEHAVIORAL|Comparison Group|Written educational materials; self-management tools (stretch band, a glucometer, and a diabetes cookbook in Spanish).
223608189|NCT01288001|DRUG|Ostenil plus|2% Sodium Hyaluronate plus Mannitol injection
223608190|NCT01518842|BIOLOGICAL|Intravitreal Bone Marrow Stem Cells|One intravitreal injection of a 0.1-ml cell suspension containing around 10x106 bone marrow mononuclear stem cells(BMMSC). All treatments were performed by a single retinal specialist using topical proparacaine drops under sterile conditions (eyelid speculum and povidone-iodine). Autologous BMMSC were injected into the vitreous cavity using a 27 gauge needle inserted through the inferotemporal pars plana 3.0 - 3.5 mm posterior to the limbus. After the injection, central retinal artery perfusion was confirmed with indirect ophthalmoscopy. Patients were instructed to instill one drop of 0.3% ciprofloxacin into the injected eye four times daily for 1 week after the procedure.
223608191|NCT05917054|OTHER|use of bipolar vascular sealing method on the renal allograft at the back-table stage|Ligation of small vessels and lymphatics of the renal graft at the back-table stage prior to transplantation to the recipient is a routine practice in kidney transplantation. Bipolar vascular sealing method will be used for this purpose in Group 1, while the conventional silk-tie method will be used in Group 2.
223608192|NCT02384512|DRUG|Azilect®|AZILECT® 1mg Tablets
223608193|NCT01258283|OTHER|Addional imaging|All patients will systematically have an 18F-FDG PET-CT (18F-fluorodeoxyglucose positron emission tomography/computed tomography) and a 123MIBG (Iodine 123 metaiodobenzylguanidine) scintigraphy
223608194|NCT00825903|BEHAVIORAL|Exercise|Exercise 3 times each week for a total of 12 weeks. Each session is 50 min. in length.
223608195|NCT02776059|DRUG|Standard of care + pegfiltrastim|prednisolone or pentoxifyline orally for 28 days + pegfilgrastim (Neulasta®) 6 mg in 0.6 mL SQ
223608196|NCT02776059|DRUG|Standard of care|Oral prednisolone or pentoxifyline for 28 days only
223608197|NCT01239823|OTHER|Whole Body Vibration Training|The subjects will participate in a 12-week exercise program with two sessions (1/2 hour) per week.
223608198|NCT01239823|OTHER|Exercise without vibration|Participants will complete the same exercises without vibration twice a week for 12 weeks (1/2 hour sessions).
223508520|NCT05684614|OTHER|Positive mood induction procedure|"The positive mood induction procedure (MIP) used in this study has previously been shown to effectively induce sadness. This MIP takes place in a virtual environment of an urban park and includes the following methods to induce positive mood: 1) Velten's tasks, consisting of interactive phrase formulations with positive thoughts and beliefs (e.g., Life is wonderful); 2) visualizing International Affective Pictures; and 3) recalling a positive autobiographical memory"
223608199|NCT05158725|DEVICE|Standard Colonoscopy|In this arm, subjects will undergo colonoscopy using a standard colonoscope
223608200|NCT05158725|DEVICE|Discovery aided colonoscopy|the Discovery is a customized detection support software, developed utilizing AI deep learning technology to support endoscopic lesion detection in the colon. In this arm, a standard colonoscope is used with the Discovery.
223608201|NCT05158725|DEVICE|Discovery and G-EYE|The G-EYE® Endoscope is a standard colonoscope which is remanufactured by installing the G-EYE® balloon on the distal bending section of the colonoscope. in this arm, the G-EYE® Endoscope is used with the Discovery
223608202|NCT03156283|BEHAVIORAL|SleepWell24 Application|An evidence-based behavioral change smartphone application designed to promote adherence to positive airway pressure (PAP) therapy
223508521|NCT00754559|DRUG|Tocilizumab|8mg/kg iv every 4 weeks
223508522|NCT01663987|DRUG|tiotropium bromide|18 mcg once a day (QD)
223508523|NCT01663987|DRUG|Placebo|once a day (QD)
223508524|NCT01829503|DRUG|decitabine and cytarabine|
223508525|NCT01829503|OTHER|Supportive Care|blood product transfusions, antiemetic medications, antiviral and antifungal medications, empiric antibiotics
223508526|NCT04305652|OTHER|The Progressively Lowered Stress Threshold Model|PLST is a conceptual model for reducing behavioral symptoms in individuals with dementia. The PLST model provides the foundation for a psychoeducational intervention that assists formal and informal caregivers in understanding behaviors and planning care for individuals with dementia. If the model is to be applied at home, at least three home visits are made in line with the listed principles. While making a diagnosis during the first home visit, a maintenance plan for the problems is created in other home visits and the caregiver is trained to implement the care plan. After the home visits, the process is carried out by providing counseling through telephone calls or face-to-face interviews when necessary.
223608203|NCT03156283|OTHER|Usual Care Plus Activity Monitor|Participants will receive usual care at the Mayo Clinic Center for Sleep Medicine when first diagnosed with sleep apnea and prescribed positive airway pressure therapy. In addition, they will receive a commercial activity monitor with an associated smartphone application to isolate the effect of SleepWell24 on PAP adherence from potential novelty effects due to receiving a generic health behavior change app.
223608204|NCT05141461|PROCEDURE|Group C|"Patients will receive 2 mg midazolam and 50 ug fentanyl for sedation before the block procedure. Each patient will be positioned appropriately, then a high-frequency linear array transducer (13-6 MHz) will be placed in the interscalene region to define the brachial plexus on the short axis. Under sterile conditions, a 50 mm block needle will be advanced into the interscalen area using the in-plane method. After localization and negative aspiration, 15 ML of 5% bupivacaine drug will be injected into the interscalene area. 100 ml of NACI will be given intravenously within 15 minutes.~General anesthesia will be performed using 2 mg/kg of propofol and 1-2 µg/kg of fentanyl. Tracheal intubation will be facilitated with 0.6mg/kg rocuronium. Anesthesia will be maintained using 50% oxygen and 2% sevoflurane. Patients will be extubated into the operating room after reversing residual muscle relaxation. A multimodal analgesia regimen will be applied postoperatively."
224200802|NCT01022177|PROCEDURE|acupuncture|acupuncture of the eye in traditional chinese schematics
223508527|NCT00002238|DRUG|Interferon beta-1b|
223508528|NCT00002238|DRUG|Zidovudine|
223754837|NCT01726738|DRUG|BRAF inhibitor dabrafenib and MEK inhibitor trametinib|Patients will receive the BRAF inhibitor dabrafenib and MEK inhibitor trametinib orally at the RP2D determined in the Phase I/II study (BRF113220): trametinib 2mg QD and dabrafenib 150 mg BID on a continuous basis. A cycle will be defined as 3 weeks in duration. Cycles will be repeated until disease progression (clinical or radiological). Patients may remain on treatment after progression (at the discretion of the investigator) as long as they are still experiencing clinical benefit.
223754838|NCT05588102|DRUG|Selective Serotonin Reuptake Inhibitor（SSRIs，Fluoxetine, paroxetine, fluvoxamine, sertraline, citalopram, escitalopram）|Subjects in the intervention group received SSRIs antidepressants combined with Electronic cognitive training based on mobile phone platform for 52 weeks (once a day, 60min each time)
223754839|NCT05987865|BEHAVIORAL|Neurofeedback training|Features related to PD symptoms will be extracted from the brain recordings in real-time and used to drive a visual cursor on a computer screen placed in front of the participant, while the participant will be asked to try to control the cursor by regulating their brain signals.
223754840|NCT03488979|OTHER|educational interventional group|• Patient Education Tool (Appendix 3) and the patient's own IVC images will be shared with each patient in the intervention group in real time. If feasible, each intervention patient will also receive a printed copy of his or her IVC image.
223754841|NCT01385475|BEHAVIORAL|RT|8 week RT Intervention
223754842|NCT05811611|BEHAVIORAL|WeChat Mini Program plus tailored online health promotion videos|Participants have access to a WeChat Mini Program. Participants will also watch online health promotion videos tailored to their current sexual behaviors.
223754843|NCT05811611|BEHAVIORAL|WeChat Mini Program Only|Participants only have access to a WeChat Mini Program.
223608205|NCT05141461|PROCEDURE|Group Dex|"Patients will receive 2 mg midazolam and 50 ug fentanyl for sedation before the block procedure. Each patient will be positioned appropriately, then a high-frequency linear array transducer (13-6 MHz) will be placed in the interscalene region to define the brachial plexus on the short axis. Under sterile conditions, a 50 mm block needle will be advanced into the interscalene area using the in-plane method. After localization and negative aspiration, 15 ML of 5% bupivacaine drug will be injected into the interscalene area. 5 mg dexamethasone intravenously will be given in 100 ml NACI within 15 minutes.~General anesthesia will be performed using 2 mg/kg of propofol and 1-2 µg/kg of fentanyl. Tracheal intubation will be facilitated with 0.6mg/kg rocuronium. Anesthesia will be maintained using 50% oxygen and 2% sevoflurane. Patients will be extubated into the operating room after reversing residual muscle relaxation. A multimodal analgesia regimen will be applied postoperatively."
223608206|NCT01628055|BIOLOGICAL|Privigen|10% liquid intravenous immunoglobulin at a single dose of 1.0g/kg, run at 0.5ml/kg/hr for the first 30 minutes, then increased to 2.5ml/kg/hr until complete (\~3-4 hours depending on weight).
223608207|NCT01628055|OTHER|Normal Saline|"Normal Saline is a sterile, nonpyrogenic solution for fluid and electrolyte replenishment. It contains no antimicrobial agents. The pH is 5.0 (4.5 to 7.0).~It contains 9 g/L Sodium Chloride with an osmolarity of 308 mOsmol/L and 154 mEq/L Sodium and Chloride.~The infusion will start at 0.5 ml/kg/hr for the first 30 minutes and then increased to 2.5 ml/kg/hr for 3-4 hours."
223608208|NCT04999345|OTHER|Rehabilitation|Progressive resistance exercise and graded aerobic exercise will be provided for those in the experimental group.
223608209|NCT04999345|OTHER|Health education|Health education and gross joint range of motion exercise for bilateral upper and lower extremities will be provided for those in the control group.
223754844|NCT01672476|DRUG|Placebo|Placebo
223754845|NCT01672476|DRUG|Valsartan|Valsartan 80mg
223754846|NCT01672476|DRUG|Fimasartan|Fimasartan 30mg
223754847|NCT01153412|OTHER|Osteopathic Manipulative Treatment|Osteopathic manipulation to determine balance and stability in elderly
223754848|NCT02248090|DRUG|AZD9496|AZD9496
223754849|NCT02248090|DRUG|AZD9496|If initial dosing of AZD9496 is tolerated then subsequent cohorts will test increasing doses until a maximum tolerated dose or maximum feasible dose is defined
223754850|NCT01542216|BEHAVIORAL|Nutrition and Exercise Group|Patients randomized to this arm will receive nutrition and exercise consultations. Exercise consultations will home- and institution-based.
223754851|NCT01542216|BEHAVIORAL|Yoga and Stretching Group|Patients randomized to this arm will receive consultations on yoga and stretching exercises.
223754852|NCT01846975|DRUG|IV Abatacept|Transition from weekly SC- to a single IV-Abatacept but also the return to weekly SC treatments after a 4 week break.
223754853|NCT00885547|DRUG|tripterygium wilfordii (TW)|90 mg/d for 6 months
223754854|NCT02806050|DRUG|Palbociclib|all patients will be treated with palbociclib, on a 3 weeks on, 1 week off cycle until progression
223754855|NCT02806050|DEVICE|FES PET|all patients will have a FES PET at baseline
223754856|NCT02806050|DRUG|Letrozole|all patients will be treated with Letrozole daily until progression
223754857|NCT01385124|DRUG|Oral Cannabidiol|Cannabidiol will be dissolved in oil to a predefined concentration. Patients will be given oral cannabidiol 10 mg twice daily from conditioning starting day and until day +30 after allogeneic transplantation.
223754858|NCT04384302|OTHER|Visual training|Pre-defined visual training protocol including the optometrical unit exercises
223754859|NCT01940926|DRUG|68Ga-BNOTA-PRGD2|Single dose intravenous injection of nearly 111 MBq 68Ga-BNOTA-PRGD2 at 30 minutes before PET/CT scanning
223754860|NCT04563091|DEVICE|Hemodialysis with online HFR|"1. Hemodialytic therapy using 240-minute online HFR on Flexya® hemodialysis machine (Medtronic, Mirandola, Italy). The blood flow from vascular access will be maintained at values \> 250 ml/minute, the flow of dialysis fluid will be 500 ml/minute. Weight loss during dialytic treatment will be prescribed according to the patient's clinical needs.~2. Assess potassium (intra and extra cellular), sodium, bicarbonatemia, calcemia, urea, blood sugar values and ECG every 30 minutes during dialysis and every 60 minutes after dialysis.~3. Body impedance analysis at time 0 at 240 minutes, after 60 minutes after the end of dialysis and after 7 hours after the end of dialysis.~4. Use of the Natrium sensor (Medtronic, Mirandola, Italy) during HFR dialytic treatment."
223754861|NCT04248816|BEHAVIORAL|Usual care|Subjects will receive outreach through their providers as is standard of care.
223754862|NCT04248816|BEHAVIORAL|Opt-out|Research staff will send a letter to patients encouraging them to get a surveillance ultrasound and include an order slip for them to get it done at a health system facility.
223608210|NCT03314272|DEVICE|Space Glucose Control|Development of a closed loop control system via Space Glucose Control that automatically infuses insulin on the basis of an automated algorithm, which integrates a continuous glucose signal, could help overcome these obstacles and permit strict glycemic control without increasing the workload.
223608211|NCT00583037|DEVICE|Neurally Adjusted Ventilatory Assist (NAVA)|Mechanical ventilation controlled by diaphragm electrical activity
223608212|NCT02606799|DEVICE|CytoSorb cytokine elimination|Hemoperfusion using continuous veno-venous hemofiltration (citrate regional anticoagulation) with CytoSorb cytokine elimination over a period of 48h immediately following admission to the intensive care unit
223608213|NCT02709603|DRUG|hyoscine butyl bromide|oral hyoscine butyl bromide; 2 tablets (buscopan 10 mg) 30 minutes before the procedure
223608214|NCT02709603|DRUG|placebo|oral placebo; 2 tablets 30 minutes before the procedure
223608215|NCT05906459|DIAGNOSTIC_TEST|Anti-HCV antibody and HCV core antigen testing|"HCV antibody screening were carried out with rapid diagnostic testings (RDTs) by colloidal gold method, using fingertip blood or residual blood from other testings.~For samples with positive HCV antibody RDTs screening results, HCV core antigen detection will be carried out subsequently as diagnostic test. HCV core antigen detection will be conducted with chemiluminescent particle immunoassay using residual blood from other testings."
223608216|NCT02331667|OTHER|Seafood|The aim is to investigate the effect of meals consisting of mackrel and herring on learning abilities by using a two-armed individually randomized non-blinded intervention trial.
223608217|NCT02331667|OTHER|Non-seafood|The aim is to investigate the effect of meals consisting of meat on learning abilities by using a two-armed individually randomized non-blinded intervention trial.
223608218|NCT00020124|DRUG|doxorubicin hydrochloride|
223754863|NCT04248816|BEHAVIORAL|Opt-out + Incentive|Research staff will send a letter to patients encouraging them to get a surveillance ultrasound and include an order slip plus an unconditional $20 incentive for them to get it done at a health system facility.
223754864|NCT00397800|BIOLOGICAL|rituximab|
223754865|NCT00397800|DRUG|cyclophosphamide|
223754866|NCT00397800|DRUG|fludarabine phosphate|
223754867|NCT00397800|RADIATION|yttrium Y 90 ibritumomab tiuxetan|
223754868|NCT05410470|DRUG|Ruxolitinib|
223754869|NCT02131402|DEVICE|ocufilcon D|Contralateral pair of study lenses. Test lens (enfilcon A) in one eye and a control lens (ocufilcon D) in the contra lateral eye.
223754870|NCT02131402|DEVICE|omafilcon A|Contralateral pair of study lenses. Test lens (enfilcon A) in one eye and a control lens (omafilcon A) in the contra lateral eye.
223508529|NCT05077111|PROCEDURE|Thoracic Epidural Anesthesia|Group A pre-medicated once using Midazolam 3-4mg intravenous (IV) and Fentanyl 50mcg, placed in the setting position. Using a winged 18G (Gadge), 9cm length Tuohy Epidural needle, a 20G springwound closed tip epidural catheter be inserted between T3-T4. A test dose (5ml) 2% Lidocaine given, followed by 5-8 ml Bupivacaine 0.5% and 50mcg Fentanyl as a loading dose. Further top-up dose of 5 ml Bupivicaine 0.5% after 45 minutes.
223508530|NCT05077111|PROCEDURE|General Anesthesia with One Lung Ventilation|Group B premedicated once by 3-4mg Midazolam IV, Ranitidine 50mg, Metoclopramide 10mg and Dexamethasone 4mg. Preoxygenation with 100% O2. Induction of anesthesia with Propofol (2mg/kg) and Fentanyl (1mcg/kg). Tracheal intubation by 37-39 Fr Double Lumen Endotracheal Tube insertion facilitated with Cisatracurium 0.1mg/kg. and confirmation of its position by Fiberoptic Bronchoscopy. Selective Lung Ventilation strategy can be performed through the endobroncheal tube of the non operated lung once needed. Anesthesia maintained with Isoflurane (1-2%) and Cisatracurium (0.05mg/kg per dose). Later, anesthesia discontinued and extubation after full neuromuscular recovery after reversal of muscle relaxant by Neostigmine (0.05mg/kg) and Atropine (0.02mg/kg).
223508531|NCT01016041|DEVICE|everolimus stent|stenting
223508532|NCT01016041|DEVICE|paclitaxel stent|stenting
223508533|NCT05254860|PROCEDURE|LPS Ventral Rectopexy|Continuous Locked Suture vs Traditional 6-points suture for Laparoscopic Ventral Rectopexy to verify if the operative time of a standard laparoscopic ventral rectopexy for the treatment of severe rectal prolapse could be further reduced using continuous locked suture vs traditional 6-points suture for mesh fixation
223508534|NCT00000544|BEHAVIORAL|diet therapy|
223608219|NCT01958359|BEHAVIORAL|Short IVR|IVR-based alcohol diary with feedback
223608220|NCT01958359|BEHAVIORAL|Therapeutic IVR|IVR-based conversation offering a menu of exercises and vignettes.
223608221|NCT03027349|OTHER|No intervention are provided|
223754871|NCT02131402|DEVICE|methafilcon A|Contralateral pair of study lenses. Test lens (enfilcon A) in one eye and a control lens (methafilcon A) in the contra lateral eye.
223754872|NCT05705063|OTHER|LCHF Ketogenic Diet|Low Carbohydrate, Moderate Protein, High Fat Ketogenic Dietary Intervention 6 weeks
223754873|NCT05400174|DIAGNOSTIC_TEST|Tilt table (upright position)|Different versions of cognitive assessments will be administered in the supine and upright positions.
223754874|NCT06249321|DRUG|mFOLFIRINOX plus IMRT|Chemotherapy will be administered according to the newest edition of National Comprehensive Cancer Network (NCCN) guideline and a modified FOLFIRINOX regimen will be the first choice. Patients with advanced pancreatic adenocarcinoma will receive the modified FOLFIRINOX regimen (oxaliplatin \[70 mg per square meter of body surface area\], irinotecan \[130 mg per square meter\], leucovorin \[200 mg per square meter\], and fluorouracil \[2000 mg per square meter\] every 2 weeks). Four-week chemotherapy is considered as a cycle. Patients will be recommended to receive Intensity-Modulated Radiation Therapy (IMRT) after about 2\~6 cycles of chemotherapy. The following treatment after radiotherapy will be applied according to the newest edition of NCCN guideline.
223754875|NCT00654160|DRUG|fluorouracil|
223754876|NCT00654160|DRUG|irinotecan hydrochloride|
223754877|NCT00654160|DRUG|leucovorin calcium|
223754878|NCT00654160|OTHER|pharmacogenomic studies|
223754879|NCT00654160|OTHER|pharmacological study|
223754880|NCT00287664|DRUG|terlipressin|
223754881|NCT04277754|OTHER|Observational|To Observe and describe motor and visual development
223754882|NCT04268420|DRUG|FMP013|Falciparum Malaria Protein-13
223754883|NCT04268420|DRUG|ALFQ|ALF with QS-21, saponin molecule derived from the tree bark of Quillaja species
223754884|NCT05463302|DEVICE|Active sleepgift blanket|Participants for group1 will be provided with real/active sleepgift blanket first for 10 consecutive nights and then cross over.
223608222|NCT05113030|OTHER|PERIODONTAL STATUS OF FEMALE PATIENTS WITH PCOS (NEWLY DIAGNOSED) OF ADOLESCENT AGE GROUP WILL BE ASSESSED|Test group(1st) enrollment criteria in PCOS group will be females of adolescent age newly diagnosed with PCOS, with \>16 natural teeth. The diagnosis of PCOS will be according to Rotterdam criteria, and periodontal parameters will be recorded to evaluate periodontal status
223608223|NCT05113030|OTHER|PERIODONTAL STATUS OF FEMALE PATIENTS WITH PCOS (NEWLY DIAGNOSED) OF ADULT AGE GROUP WILL BE ASSESSED|Test group(2 nd) enrollment criteria in PCOS group will be females of adult age newly diagnosed with PCOS, with \>16 natural teeth. The diagnosis of PCOS will be according to Rotterdam criteria, and periodontal parameters will be recorded to evaluate periodontal status
223608224|NCT05305963|RADIATION|Mammogram|mammogram
223608225|NCT02240511|DIETARY_SUPPLEMENT|RE and BCAA Supplementation|RE: Resistance Exercise BCAA: Branched Chain Aminoacids
223608226|NCT02240511|OTHER|Resistance Exercise|
223608227|NCT06026878|DRUG|gemcitabine,nimotuzumab, toripalimab|same as before
223608228|NCT06026878|DRUG|gemcitabine, cisplatin|same as before
223608229|NCT05397249|BEHAVIORAL|Mindfulness Training|The participants are given strategies of mindfulness, asked to complete worksheets and participate in meditations.
223608230|NCT00003199|DRUG|tamoxifen citrate|Given orally
223608231|NCT00003199|DRUG|busulfan|Given orally
223608232|NCT00003199|DRUG|thiotepa|Given IV
223754885|NCT05463302|DEVICE|Sham Sleepgift Blanket|Participants for group 2 will be provided with sham sleepgift blanket for 10 consecutive nights and then cross over.
223508535|NCT00842036|BEHAVIORAL|Community Reinforcement and Family Training|Community Reinforcement and Family Training (CRAFT) is an intervention designed for the concerned significant other (CSO) of a drug or alcohol using loved one. The CRAFT intervention consists of approximately 12 sessions lasting 45-60 minutes. The goal of the CRAFT intervention is to train the CSO in new ways to interact with the person of concern (PC). There are four components that the CSO is trained on which include awareness training, community reinforcement training, treatment entry training, and CSO mood enhancement.
223508536|NCT00842036|BEHAVIORAL|Treatment Entry Training|Treatment Entry Training (TEnT) is a component of the Community Reinforcement and Family Training intervention and it is currently under investigation to determine if it is sufficient to produce the primary and most consistent outcome of CRAFT- treatment entry of the drug user. The intervention will consist of a minimum of 4 sessions and a maximum of 6 sessions that are each 45-60 minutes long. TEnT will include awareness training, safety training, and the Treatment Entry Training component of CRAFT.
223608233|NCT00003199|DRUG|melphalan|Given IV
223608234|NCT00003199|BIOLOGICAL|aldesleukin|Given SC
223608235|NCT00003199|BIOLOGICAL|sargramostim|Given SC
223608236|NCT00003199|PROCEDURE|peripheral blood stem cell transplantation|Undergo autologous peripheral blood stem cell infusion
223608237|NCT00003199|RADIATION|radiation therapy|May undergo radiotherapy after completion of IL-2/GM-CSF
223608238|NCT02578199|BEHAVIORAL|motivational interviewing and nutrition|Motivational Interviewing and Nutritional Counseling
223608239|NCT03218176|DEVICE|Proximal single upper limb|Measurement of pain, pressure under tourniquet, feeling and abolition of pulse doppler and pulse oximetry
223608240|NCT03218176|DEVICE|Proximal staggered upper limb|Measurement of pain, pressure under tourniquet, feeling and abolition of pulse doppler and pulse oximetry
223608241|NCT03218176|DEVICE|Distal single upper limb|Measurement of pain, pressure under tourniquet, feeling and abolition of pulse doppler and pulse oximetry
223608242|NCT03218176|DEVICE|Distal staggered upper limb|Measurement of pain, pressure under tourniquet, feeling and abolition of pulse doppler and pulse oximetry
223608243|NCT03218176|DEVICE|Proximal single lower limb|Measurement of pain, pressure under tourniquet, feeling and abolition of pulse doppler and pulse oximetry
223608244|NCT03218176|DEVICE|Proximal staggered lower limb|Measurement of pain, pressure under tourniquet, feeling and abolition of pulse doppler and pulse oximetry
223608245|NCT03218176|DEVICE|Distal single lower limb|Measurement of pain, pressure under tourniquet, feeling and abolition of pulse doppler and pulse oximetry
223608246|NCT03218176|DEVICE|Distal staggered lower limb|Measurement of pain, pressure under tourniquet, feeling and abolition of pulse doppler and pulse oximetry
223608247|NCT04305847|OTHER|perioperative satisfaction assessment|Satisfaction assessment at 24 and 48 hours post operatively by self-administered survey questionnaire based on different scales: Evan-LR, Net Promotor Score, Satisfaction score.
223608248|NCT06038422|DRUG|GTP regimen|Refractory/recurrent hemophagocytic lymphohistiocytosis patients will be treated with GTP regimen (Emapalumab+Teniposide+Methylprednisolone)
223608249|NCT01890564|OTHER|Pressure controlled ventilation|For pressure controlled ventilation, the peak inflating pressure (PIP) is set for each tidal breath.
223608250|NCT01890564|OTHER|Volume controlled ventilation|For volume controlled ventilation, the tidal volume is set.
223608251|NCT01890564|OTHER|PRVC ventilation|Pressure-regulated, volume-controlled (PRVC) is an auto-regulated pressure-controlled mode of mechanical ventilation with a user-selected tidal volume target.
223608252|NCT03888729|DRUG|sofosbubir/velpatasvir|SOF/VEL (400 mg/100 mg) FDC once daily
223608253|NCT03888729|DRUG|sofosbubir/velpatasvir/voxilaprevir|SOF/VEL/VOX (400 mg/100 mg/100 mg) FDC once daily
223608254|NCT04600583|DEVICE|Triathlon® Total Knee System (Stryker Orthopaedics, Mahwah, NJ USA)|All patients, regardless of the alignment arm they are randomized to will undergo a primary total knee arthroplasty with the Triathlon® Total Knee System using Mako Robotic-Arm Assisted Technology. The surgical intervention will be administered by a physician wherein the expected duration of surgery is approximately 1.5 hours.
223754886|NCT02437851|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery to remove anal or perianal cancer (SISCCA)
223754887|NCT04231877|DRUG|Polatuzumab Vedotin|Given IV
223754888|NCT04231877|BIOLOGICAL|Rituximab|Given IV
223754889|NCT04231877|DRUG|Prednisone|Given PO
223754890|NCT04231877|DRUG|Etoposide|Given IV
223754891|NCT04231877|DRUG|Doxorubicin|Given IV
223754892|NCT04231877|DRUG|Cyclophosphamide|Given IV
223754893|NCT04231877|BIOLOGICAL|Glofitamab|Given IV
223754894|NCT04231877|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA scan
223754895|NCT04231877|PROCEDURE|Echocardiography|Undergo echocardiography
223754896|NCT04231877|PROCEDURE|FDG-Positron Emission Tomography|Undergo FDG-PET scan
223608255|NCT00535119|DRUG|Carboplatin|Given IV
223608256|NCT00535119|OTHER|Laboratory Biomarker Analysis|Correlative studies
223608257|NCT00535119|DRUG|Paclitaxel|Given IV
223608258|NCT00535119|OTHER|Pharmacological Study|Correlative studies
223608259|NCT00535119|DRUG|Veliparib|Given PO
223608260|NCT00230542|DRUG|Carboplatin|Given intravenously following pemetrexed over 30-45 minutes once every three weeks for 6 cycles (18 weeks)
223608261|NCT00230542|DRUG|Pemetrexed|Given intravenously over 30 minutes once every three weeks for 6 cycles (18 weeks)
223608262|NCT02329899|OTHER|Second step of investigations|"Second step according to results of the first step:~* exploration of coagulation factors;~* factor XIII and fibrinolysis investigations;~* investigation of platelet function;~* investigation of thrombocytopenia."
223608263|NCT00338923|DRUG|HO/03/03|
223754897|NCT04231877|PROCEDURE|Computed Tomography|Undergo CT scan
223754898|NCT04231877|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
223754899|NCT04231877|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223754900|NCT04231877|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
223754901|NCT05622045|BEHAVIORAL|Voice data|Recorded response to a question about their participation in a weight loss study.
223754902|NCT06571110|PROCEDURE|Traditional Acupuncture|Acupuncture is a type of treatment where thin needles are gently inserted into specific parts of your body. It's often used to help with things like pain, headaches, stress, and anxiety.
223754903|NCT06571110|PROCEDURE|Sham Acupuncture|Sham acupuncture in this trial involves the insertion superficially to mimic the procedure of true acupuncture without providing any therapeutic effect. The needles will be similar to those used in the true acupuncture group but will not be stimulated, ensuring blinding and controlling for placebo effects.
223608264|NCT04649814|OTHER|Questionnaire|Questionnaire for all, interview for part of the respondents.
223608265|NCT02820675|OTHER|structured case analysis|implementation of a structured analysis of cases coded as sepsis, severe sepsis, or septic shock after risk adjustment for low-risk-fatalities, high-risk-survivors, and coding errors for preventable deaths, best practice, quality improvement and improvement in coding precision.
223608266|NCT02820675|OTHER|"strucured screening every patient, every shift"|implementation of a strutured screening and rescue algorithm on regular wards, emergency departements, and intermediate and intensive care units by checking every patient in every shifts for clinical signs of deterioration and apllying a rescue algorithm including consiliary help and/or the help of outreach teams
223608267|NCT06302582|BIOLOGICAL|Platelet-rich plasma (PRP) combined with human umbilical cord mesenchymal stem cells (huMSCs)|Inject 3mL PRP+huMSCs (5 × 106) into the edge and bottom of the wound, with 0.5 ml at each point and a distance of approximately 1-3 cm between each point. Then, apply autologous PRP gel (PRP+thrombin mixture, 2ml) evenly on the wound, with a thickness of about 2mm
223608268|NCT06302582|OTHER|Control group|Standard therapy for patients with stage 3 and 4 stress injury
223608269|NCT05733858|DEVICE|tRNS|For tRNS, the electrical current is delivered alternatively (an alternating current). The stimulation intensity will be set as 1.5 to 2 mA (based on the tolerance of participants). The stimulation frequency will be random frequencies ranging from 101 and 640 Hz.The stimulation period of tRNS and tDCS will be 20 minutes.
223754904|NCT06810076|BEHAVIORAL|Machine Learning-Based Clinical Decision Support: Overdose Prevention Alert (OPA) Intervention|In this study, researchers will pilot test an interruptive, ML CDS tool for opioid overdose risk across thirteen primary care clinics at the UF Health in Gainesville, FL. When a patient is identified by the ML algorithm as having an elevated overdose risk and a PCP signs an opioid prescription for the patient, an Opioid Prevention Alert (OPA) will be triggered. The alert will include the rationale for the patient's elevated risk status and provide three risk mitigation recommendations: optimizing pain treatment and mental health support, reviewing and discussing risks with the patient, and offering naloxone annually if no prior naloxone order is found in the patient's record. PCPs can also select an override reason, such as the patient already has naloxone, declined the intervention, is not present/it is not the right time, or the alert is not relevant/other comments, when appropriate.
223754905|NCT05660824|DEVICE|Stromal Vascular Fraction infiltration|Procedure to prepare SVF: In the operations room and after aseptic technic, local anesthesia is applied in the liposuction incision site with lidocaine 1% without epinephrine subcutaneously. 60 ml of tumescent solution are injected. After 15-20 minutes waiting, 15 ml of lipoaspiration per side are recollected into a double syringe. This is centrifuged for 4 minutes at 2.500 rpm and the remaining fat is separated from the other fractions. Two 1.4 mm GEMS syringes are attached together, and fat is transferred at least 30 times from one syringe to the other. Syringe content is again centrifugated for 4 minutes. The oil is discarded and approximately 1.5ml SVF fraction remains.
223608270|NCT05733858|DEVICE|tDCS|For tDCS, the electrical current is delivered in a continuous and consistent manner (direct current). The stimulation intensity will be the same as that of tRNS (1.5 to 2 mA based on the tolerance of participants), which is safe for stroke patients.The stimulation period of tRNS and tDCS will be 20 minutes.
223608271|NCT05733858|DEVICE|sham stimulation|For the sham stimulation condition, the electrode placement will be the same as the other real eletrical stimulation conditions. The current will first turn up for 30 seconds and subsequently turn off in the next 30 seconds to provide sensory feeling without actually stimulating the brain.
223608272|NCT05733858|BEHAVIORAL|digital MT|For the digital MT, the participants will be encouraged to move the affected arm as symmetrically and simultaneously as the unaffected hand while looking at the real-time image on the computer screen. The activities practiced during digital MT will include intransitive movements (e.g., flexion and extension of the wrist) and transitive movements (e.g., picking up a pen). The amount of time exposed to intransitive and transitive movements will be balanced for each participant. The participants will practice 30 intransitive and 30 transitive tasks over the 20 training sessions, and the actual movements will be selected based on each individual's ability and his/her needs.
223754906|NCT05660824|PROCEDURE|Plattelet Rich Plasma infiltration|Procedure to prepare PRP: 15 cm of peripheral blood obtained by venipuncture are centrifugated at 1500 RPM during 5 minutes. Using PRP Arthrex kit platelets poor plasma is discarded and 1-3 mm of PRP are ready to be injected
223754907|NCT06653166|DEVICE|bougie (S Guide)|bougie (S Guide)
223754908|NCT06653166|DEVICE|videolaryngoscopy|videolaryngoscopy hyperangulated or Macintosh
223754909|NCT02818218|PROCEDURE|Liver Transplant|liver transplant recipient surgery
223608273|NCT05456737|OTHER|assessment|Application of various assessment methods to determine the foot characteristics, foot posture, functional activity, balance levels and quality of life of the determined groups.
223608274|NCT01522326|DRUG|Ibuprofen|Ibuprofen 400mg tablet. Take one dose by mouth.
223608275|NCT01522326|DRUG|Metoclopramide|Metoclopramide 10mg tablet. Take one tablet by mouth.
223608276|NCT04130607|OTHER|Conceptual teaching|"The present study is designed to contrast two instructional methods - explicit instruction in likelihood ratios and pretest/posttest probabilities versus implicit instruction based on presentation of multiple cases. These will be compared to a no intervention control group."
223608277|NCT03553758|DRUG|Ketamine|Subjects' brain waves will be monitored by EEG recording under ketamine general anesthesia over the course of approximately 60 minutes. Patients pain and dissociation will be assessed before the induction of ketamine and periodically after. Approximately 1 hour after ketamine induction, Midazolam will be administered to reduce patient dissociation.
223608278|NCT00487357|BEHAVIORAL|Supplemental Survey|Questionnaire give during home visit to collect behavioral, risk factors and other smoking status data on MATCh parents/guardians.
223608279|NCT03210207|PROCEDURE|GASTROPLICATURE|All procedures were performed by a single surgeon. All patients underwent 2-row gastric plication. Dissection was started at the greater curvature of the stomach in contact to the gastric wall from prepyloric area to 2-cm proximal to the Hiss angle preserving the anatomy of Hiss angle. All vessels along the greater curvature were separated using LigaSure (Covidien, Mansfield, MA, USA). The greater curvature (from the perimeter) was invaginated using 2 rows of 00 prolene or 00 nylon sutures. Two layers of plication were performed with continuous sutures with 1 surgical sting in all patients to prevent any displacement of inverted folds such as eversion outside or intussusception into esophagus or pylorus. All sutures were extramucusal to avoid their absorption by gastric acid. Finally, a tube shaped stomach was achieved in which the greater curvature was inverted in to the stomach.
223508537|NCT00842036|BEHAVIORAL|12- step Al/Nar- Anon Facilitation|The underlying philosophy of the 12- step approach for concerned significant others (CSO) is that the CSO is powerless to control the drinker/drug user and must detach, focusing instead on accepting the situation and on strengthening his or her mental health. Eight content areas are discussed with the CSO over the course of the intervention. There will be a minimum of 8 sessions and a maximum of 12 sessions that are each 45-60 minutes long.
223608280|NCT05113511|DRUG|SCT510|Subjects received a single intravenous infusion (3 mg/kg) of SCT510 for 90 minutes , and the volume of administration was calculated based on the subject's weight.
223508538|NCT03219736|PROCEDURE|Standard of Care therapies|If at any point during the treatment it is deemed medically necessary by the treating PED attending that a subject from the control arm (Group 1) requires an escalation of therapy, they may be moved from the group to the NIPPV/BiPAP group (Group 2) or be removed from the study (i.e. if intubated).
223508539|NCT03219736|DEVICE|NiPPV Therapy|If at any point during the treatment it is deemed medically necessary by the treating PED attending that a subject from a NIPPV/BiPAP group (Group 2) is not tolerating NIPPV they may be removed from the study. Patients may not tolerate NIPPV due to agitation, vomiting or need for escalation of care.
223508540|NCT03219736|PROCEDURE|Routine Respiratory Care|It may be up to the treating physicians discretion to treat patient with other medications that are currently used to treat severe asthma exacerbations, such as Epinephrine and Terbutaline
223508541|NCT02086045|DEVICE|DESolve Novolimus Eluting Bioresorbable Coronary Scaffold System|percutaneous coronary
223508542|NCT01370538|DRUG|Esomeprazole|Nexium 20 mg administered as 22.3 mg of esomeprasole magnesium hydrate, capsule, oral dose
223508543|NCT00875901|RADIATION|Peripherally located lung tumor|12 cobalt gray equivalent per fraction for 4 fractions, 2-3 treatments per week (every other day), over 2 weeks for a total of 48 cobalt gray equivalent (Fractions at lest 40 hours apart)
223508544|NCT00875901|RADIATION|Centrally located lung tumor|6 cobalt gray equivalent per fraction for 10 fractions, 5 treatments per week over 2-3 weeks for a total of 60 cobalt gray equivalent (no more than one fraction per calendar day)
223508545|NCT04193527|DRUG|DaTSCAN™ Ioflupane (123I) Injection|All participants (Participants with PS, ET, and HV) received a single dose of DaTSCAN™ ioflupane (123I) injection within the range of 111 to 185 megabecquerel (MBq) (3 to 5 millicurie \[mCi\]) per participant at a maximum volume of 5 milliliter \[mL\]) intravenously on Day 1.
223508546|NCT02662465|PROCEDURE|Laser|Patients who develop oral mucositis even after the prevention, will be divided into three groups for laser sessions with the purpose of treatment of oral mucositis. The group assignment obeyed severity of oral mucositis.
223508547|NCT03135795|DRUG|Sufentanil|Patients received intravenous sufentanil 0.5μg/kg for induction,and received PCA after surgery with sufentanil 1ug/ml using a controlled infusion pump, which was programmed to use a loading dose of 2ml, background infusion at 2m/h, PCA dose of 1ml, lockout time of 10min, and maximal dose of 12ml within 1 hour period.
223508548|NCT03135795|DRUG|dexmedetomidine|Patients received intravenous dexmedetomidine 1μg/Kg for induction.
223508549|NCT03135795|DRUG|propofol|Patients received intravenous propofol 2mg/Kg for induction, and received intavenous pump of propofol (0.3-0.6mg/kg/h) for maintenance.
223508550|NCT03135795|DRUG|Rocuronium|Patients received intravenous rocuronium 0.6mg/Kg for induction.
223508551|NCT03135795|DRUG|sevoflurane|Patients received inhalation of sevoflurane (1-2%) for maintenance.
223508552|NCT03135795|DRUG|remifentanil|Patients received intavenous pump of remifentanil (0.1-0.2ug/kg/min) for maintenance.
223508553|NCT03135795|DRUG|Parecoxib|Parecoxib 40mg was given single intravenously before incision.
223508554|NCT06178913|OTHER|Exercise intervention|The exercise intervention method is a circuit training method that combines strength training and aerobic exercise forms and consists of a total of 12 movements. Performing movements 1 to 12 in order is 1 set. After completing the set, when the heart rate returns to the plateau (less than 59% of maximum heart rate), proceed to the next set, for a total of 3 sets.
223508555|NCT01002391|PROCEDURE|reduction mammaplasty|Dressing following reduction mammaplasty is removed on the first postoperative day
223608281|NCT05113511|DRUG|Bevacizumab|Subjects received a single intravenous infusion (3 mg/kg) of bevacizumab for 90 minutes , and the volume of administration was calculated based on the subject's weight.
223608282|NCT00447226|DRUG|Oral lapatinib tablets or placebo tablets|Subjects administered open label lapatinib, 1500 mg to be taken orally once a day, for 12 weeks. After 12 weeks, subjects with a partial or complete response per Response Evaluation Criteria in Solid Tumors (RECIST) will continue to receive open label lapatinib (1500 mg/day orally) until disease progression. Subjects who maintain stable disease will be randomized in a 1:1 ratio to enter stage 2 of the study and receive double blind therapy of either lapatinib 1500 mg/day orally or placebo. Subjects who progress on placebo will have the option to receive lapatinib 1500 mg/day orally until further progression. Those who progress on lapatinib will be withdrawn from the study.
223608283|NCT02536027|PROCEDURE|continuous venovenous hemofiltration|Continuous renal replacement therapy (CRRT) has become routine for patients with AKI, chronic renal failure, ﬂuid overload as well as oliguria in ICU. In clinical practice, continuous venovenous hemofiltration (CVVH) is actually the method of choice for CRRT in critically ill and hemodynamic instable patients. CVVH has significant beneficial effects on removing inflammatory cytokines, improving oxygen index, decreasing vasopressor requirements, increasing cardiac index, and regulating immune dysfunction, specifically in patients with septic shock.
223608284|NCT00004652|DRUG|pimozide|
223608285|NCT02722954|DRUG|Demcizumab|Drug: Demcizumab at starting dose of 2.5mg/kg administered intravenously (IV).
223608286|NCT02722954|DRUG|Pembrolizumab|Drug: Pembrolizumab administered 2mg/kg IV every 3 weeks
223608287|NCT05666141|DEVICE|Pharyngeal Electrical Stimulation|"A Phagenyx catheter is inserted trans-nasally. The catheter design incorporates a nasogastric feeding tube with built-in stimulation electrodes. The intervention consists of 3 PES sessions. A session is a 10-minute stimulation, once per day. The sessions will be given on three consecutive days at optimal parameters."
223608288|NCT05666141|OTHER|Sham treatment|In the Sham condition, the same method and same device will be used. The time spent interacting with the patient will remain constant, including placement of the PES catheter which will be left in situ in the subject for the duration of intervention (10 minutes). However, the base-station will be set to 0 milliampere (mA), so Sham subjects do not receive any active electrical current.
223608289|NCT03308006|BIOLOGICAL|Stem cells|Participants will be exposed to e abdominal liposuction procedure under local anesthesia for stem cells harvesting. Stem cells will be separated from fat cells in the adipose tissue then activated in Tissue Culture Lab at Research Center- Jeddah. The activated stem cells will be injected into the knee joint via 22G spinal needle. The intra-articular stem cells injections will be performed under Ultrasound guidance at the theater under spinal anesthesia. Each patient will receive 1.0× 108 stem cells in 3 mL of normal saline.
223608290|NCT05561582|OTHER|Seated knee extension exercise|Participants will be seated in a resistance exercise machine. Weight corresponding to the assigned group will be added to the machine. Participants will extend the dominant knee for 3 sets of 10 repetitions.
223508556|NCT01002391|PROCEDURE|reduction mammaplasty|Dressing following reduction mammaplasty is removed on the sixth postoperative day
223508557|NCT00676689|DEVICE|SAPIEN Transcatheter Valve Implantation|Device Implantation
223508558|NCT04573075|PROCEDURE|Ghost ileostomy|a loop of the small bowel is marked with a silicone strap and externalized through the abdominal wall to avoid a loop ileostomy
223508559|NCT04573075|PROCEDURE|loop ileostomy|a protective loop ileostomy is applied after after colorectal resection and forming of a primary anastomosis
223508560|NCT04573075|PROCEDURE|no outlet|no further intervention is used after colorectal resection and forming of a primary anastomosis
223508561|NCT03109392|DRUG|Nebulized Lignocaine|2.5 ml of 4% lignocaine will be administered via nebulization prior to bronchoscopy
223508562|NCT03109392|DRUG|Lignocaine spray|10 puffs of 10% (10mg/puff) lignocaine spray will be sprayed at 10 seconds intervals into the pharynx immediately prior to bronchoscopy
223608291|NCT02277600|DRUG|BMS-663068|BMS-663068
223608292|NCT02277600|DRUG|Darunavir|Darunavir
223608293|NCT02277600|DRUG|Cobicistat|Cobicistat
223608294|NCT01553903|DRUG|Tamoxifen,|Tamoxifen 20 mg/day during 5 years,
223608295|NCT01553903|DRUG|Exemestane|Exemestane 25mg/day during 5 years
223508563|NCT03109392|DRUG|Combined spray and nebulization|Combination of 2.5 ml of 4% lignocaine via nebulization prior to bronchoscopy and 2 puffs of 10% (10mg/puff) lignocaine spray sprayed at 10 seconds intervals into the pharynx immediately prior to bronchoscopy
223508564|NCT04460261|OTHER|Functional Inspiratory Muscle Training|Both groups were trained 3 days a week under the supervision of a physiotherapist and other days of the week without a supervisor. The treatment program consisted of 4 weeks of foundation IMT followed by 4 weeks of functional IMT. Foundation IMT was applied during the first 4 weeks of training. The participants were asked to sit in a comfortable upright position. Following the foundation IMT, all participants underwent four weeks of functional IMT. Initially, all participants were taught diaphragmatic breathing and activating abdominal wall musculature. Each training session started with warm-up exercises and ended with cool-down exercises. During the loading phase, core stability, dynamic trunk activation and postural control exercises were applied together with IMT.
223608296|NCT01553903|DRUG|Anastrozole|Anastrozole 1 mg/day during 5 years,
223608297|NCT01553903|DRUG|Letrozole|Letrozole 2.5 mg/day during 5 years,
223608298|NCT06422195|OTHER|Dynamic Needle Tip Positioning Technique in Short Axis Approach (DNTP - SA)|Ultrasound guided radial artery cannulation by Dynamic Needle Tip Positioning Technique in Short Axis Approach (DNTP - SA) will be performed by an experienced anesthesiologist who has no subsequent role in the study. The ultrasound transducer is oriented transversely to the radial artery at the wrist, and the vessel appears as a circular anechoic structure in the ultrasound screen with gradual advancing of the needle till reaching the radial artery. Meanwhile, the ultrasound probe is being moved proximally in advance of the needle tip until it disappears from the ultrasound image. The cannula then advanced in the direction of the artery.
223508565|NCT02366130|DRUG|Ra-223 dichloride|55 kBq/kg by vein on Day 1 of each 28 day cycle, and then every four weeks thereafter for 6 cycles.
223508566|NCT02366130|DRUG|Denosumab|120 mg by subcutaneous (SC) injections on Day 1 of Cycles 2-5.
223508567|NCT02366130|DRUG|Hormone Therapy|A single hormonal agent administered daily while on study. Physician to decide what type of hormone therapy participant will receive.
223754910|NCT05377905|DRUG|Microneedle Array Doxorubicin (MNA-D)|The Microneedle array patch is loaded/prepared with a total dose of 50 micrograms of Doxorubicin and is applied to a single selected cSCC remnant for a period of 20 minutes for a total of 4 weekly applications
223608299|NCT06422195|OTHER|Long Axis Approach (LA)|Ultrasound guided radial artery cannulation in Long Axis Approach (LA) will be performed by an experienced anesthesiologist who has no subsequent role in the study. In the LA-IP approach, an ultrasound probe is placed parallel to the radial artery and the artery appears as a tubular anechoic structure in ultrasound.
223608300|NCT02999906|DRUG|Oral Treprostinil|Sustained release oral tablets for three times daily administration
223608301|NCT02999906|DRUG|Placebo|Placebo (sugar pill) for three times daily oral administration
223754911|NCT06535802|OTHER|Focus group|Attend a focus group session
223754912|NCT06535802|OTHER|Clinician Interviews|Participate in clinician interviews
223754913|NCT06535802|OTHER|Intervention testing|Test the virtual health intervention
223754914|NCT06535802|OTHER|Survey|Complete a follow-up survey
223754915|NCT06535802|OTHER|Follow-up Interview|Participate in a follow-up interview
223508568|NCT00906750|BIOLOGICAL|FluMist|FluMist is a live attenuated intranasal influenza vaccine
223508569|NCT00906750|BIOLOGICAL|Inactivated influenza vaccine|Inactivated influenza vaccine
223508570|NCT02262273|OTHER|Data Collection|Colleciton of data from medical records only
223608302|NCT06340945|PROCEDURE|ultrasound-guided thermal ablation|microwave ablation, radio frequency ablation, laser ablation
223608303|NCT00330603|PROCEDURE|Serial exhaled breath collections|collect breath for 5 minutes on 8 occasions
223608304|NCT00996463|PROCEDURE|Electro-thermo-coagulation|Electro-thermo-coagulation
223754916|NCT06535802|OTHER|Virtual Health Intervention|Participate in the virtual health intervention
223508571|NCT05520450|BEHAVIORAL|Telematic support group|The participation of each patient in the study has been established for 4 months; the first and last months correspond to the evaluation phase, the remaining two months are for the intervention. A total of 7 group sessions of 90 minutes duration and weekly frequency are scheduled, carried out via telematics and conducted by an emotional well-being professional, a nurse and a social worker. In this context, it is guaranteed that patients will receive the care, visits and treatments usually used for people who have presented their clinical situation. The only difference between participating in the intervention and not participating in the intervention is the participation in a telematic support group and some additional assessments, i.e. not routinely carried out, which are part of this project. The intervention will be carried out in a group format, with a maximum of 12 patients per session.
223508572|NCT01574495|OTHER|Error Augmentation|error augmentation for arm motor recovery in individuals with stroke
223508573|NCT00251966|DRUG|Esomeprazole|
223508574|NCT05128344|DRUG|AMZ002 injectable solution, 0.5mg/mL|Injectable solution
223508575|NCT05128344|DRUG|Vigabatrin, oral|Oral administration
223508576|NCT00000810|DRUG|Delavirdine mesylate|
223508577|NCT00000810|DRUG|Zidovudine|
223508578|NCT00000810|DRUG|Didanosine|
223508579|NCT01415687|DRUG|Polyethylene Glycol-Based Lavage|"Split dose Polyethylene Glycol-Based Lavage (2L + 2L)~If arrival for colonoscopy is prior to 10AM: at 12 noon on the day before your colonoscopy drink 2L of PEG within two hours. At 8PM that day, drink the remaining 2L of PEG within two hours.~If arrival for colonoscopy is at or after 10AM: at 8PM on the day before your colonoscopy, drink 2L of PEG within two hours. Starting five hours before your arrival time at the Centre on the day of your colonoscopy, drink the remaining 2L of PEG within two hours."
223608305|NCT00996463|DRUG|Sodium Stibogluconate|Intralesional injection of sodium stibogluconate
223608306|NCT00996463|DRUG|DAC N-055|Moist wound treatment with DAC N-055 (German officinal drug of the German drug codex)
223608307|NCT01599663|OTHER|Pain management algorithm|The algorithm guide the clinicians to score ICU patients pain systematically with different pain assessment tools. The tools are the Numeric Rating Scale, Behavioral Pain Scale and Behavioral Pain Scale Non Intubated. The algorithm guide the clinicians to choose between the different pain assessment tools depending on the ICU patient's condition and ability to rate his own pain. Thereafter the algorithm guide the clinicians to treat pain depending on the pain intensity score.
223754917|NCT06982885|DIAGNOSTIC_TEST|artificial intelligence|Artificial intelligence assisted diagnostic system was used to diagnose colorectal lesions
223754918|NCT04473053|DRUG|Nafamostat Mesilate|Nafamostat has been shown to have potential antiviral effects against MERS CoV and is thought to possibly inhibit SARS CoV2 infection via inhibition of viral entry due to inhibition of TMPRSS2. In addition, nafamostat has potent anticoagulant properties which may provide benefit in patients with DIC, a common finding in serious cases of COVID-19. Nafamostat has been broadly well tolerated in clinical trials in patients with DIC and acute pancreatitis.
223754919|NCT04473053|DRUG|TD139|TD139 is a specific inhibitor of galectin-3 which has been investigated in healthy volunteers and patients with IPF. No serious drug related serious adverse events have been reported to date. TD139 had no impact on cardiac, haematological or biochemical measures of safety during trials in humans to date. Beneficial effects on biomarker measures of lung inflammation were observed in patients with IPF. It is the purpose of this investigation to examine the potential for delivery of this inhibitor in pre-ventilator patients hospitalised with COVID-19 to examine whether this may lead to detectable changes in blood biomarkers, reduce viral load and also reduce disease severity such as time to ventilation.
223754920|NCT04473053|OTHER|Standard care|Patients will receive standard care.
223754921|NCT04473053|BIOLOGICAL|Allogeneic SARS-CoV-2 VSTs|The allogeneic SARS-CoV-2 VSTs are manufactured in a single stage process directly from the starting material procured from suitable post COVID-19 recovered individuals. This is an early dose escalation safety trial phase Ib/IIa interventional clinical trial with SARS-CoV-2 VSTs.
223754922|NCT06985498|COMBINATION_PRODUCT|Sandwich stratergy|The patients received blinatumoab after standard induction and consolidation chemotherapy. Autologous stem cells mobilization and collection were performed after blinatumomab. Auto-HSCT was proceeded after successful stem cell collection. CD22 and CD19 CAR-T cells were re-infused 2 days after stem cell reinfusion.
223754923|NCT06587451|DRUG|JPB898 (Induction and Maintenance)|Induction and Maintenance: Intravenous (IV)
223754924|NCT06587451|DRUG|Opdivo-EU (Induction)|Induction: Intravenous (IV)
223754925|NCT06587451|DRUG|Opdivo-US (Induction)|Induction: Intravenous (IV)
223754926|NCT06587451|DRUG|Yervoy-EU (Induction)|Induction: Intravenous (IV)
223754927|NCT06587451|DRUG|Opdivo-EU (Maintenance)|Maintenance: Intravenous (IV)
223754928|NCT02620046|DRUG|Vedolizumab SC|Vedolizumab SC 108 mg injection
223754929|NCT06826196|DRUG|ALD-102|Treatment every 4 weeks for total of 8-week treatment period.
224200803|NCT00379925|BEHAVIORAL|Physical Activity and Dietary Health Promotion Program|Churches within the intervention group will receive a committee training and church cook training designed to teach them how to do a self-assessment of current practices and develop a plan for their program. The intervention is based on the structural model of health behavior and targets opportunities, mass media (within the church), guidelines and policies, and church environment. Intervention churches also receive monthly intervention mailings to support intervention implementation.
224200804|NCT04960774|OTHER|Observational study, no intervention|Observational study, no intervention
224200805|NCT02191930|DRUG|B-CAP|
224200806|NCT02191930|DRUG|Brentuximab Vedotin|
223508580|NCT01415687|DRUG|Pico-Salax (Magnesium Citrate) plus Bisacodyl|"If arrival for colonoscopy is prior to 10AM: 2 tablets Dulcolax at 8PM three days before colonoscopy, 2 tablets Dulcolax at 8PM two days before colonoscopy, and on the day before colonoscopy at 12 noon, drink the first packet of Pico-Salax in 8oz water, and the second packet of Pico-Salax in 8oz of water at 8PM. Day of colonoscopy, drink clear fluids.~If arrival for colonoscopy is at or after 10AM: 2 tablets Dulcolax at 8PM three days before colonoscopy, 2 tablets Dulcolax at 8PM two days before colonoscopy, and on the day before colonoscopy at 8PM, drink the first packet of Pico-Salax in 8oz water. Day of colonoscopy, drink the second packet of Pico-Salax in 8oz water five hours before you are to arrive at the Centre."
223508581|NCT03044912|DRUG|mirabegron|To evaluate the efficacy and safety of Mirabegron 50 mg vs 25 mg in Taiwanese patients with overactive bladder syndrome
223508582|NCT06500936|OTHER|SMS|The intervention included two series of SMS messages. First, women of IG received one weekly SMS messages for 2 weeks. Those women that did not register a mammography in SITAM 45 days after the 2nd message, received the second series, consisting of one weekly SMS message over two weeks.
223508583|NCT05406570|PROCEDURE|Standardized ventilation|Patient will be ventilated with tidal volume 6 mL/kg predicted body weight (PBW) and positive end-expiratory pressure (PEEP) according to the PEEP-FiO2 table of the ARMA trial. A CT scan will be performed with this ventilatory setting and the patients will be switched to the other group
223508584|NCT05406570|PROCEDURE|Personalized ventilation|Patient will be ventilated with PEEP according to the PEEP-FiO2 table of the ARMA trial. Tidal volume will be selected as the tidal volume minimizing cardiopulmonary interactions as assessed on arterial pressure tracing, during a VT trial. A CT scan will be performed with this ventilatory setting and the patients will be switched to the other group.
223508585|NCT06796062|DRUG|Psilocybin|One capsule (1 mg, 20 mg, or 30 mg) administered once orally
223508586|NCT03168815|DEVICE|High Flow Nasal Cannula or Low Flow Nasal Cannula|HFNC vs LFNC
223508587|NCT02315326|DRUG|Ibrutinib|"Arm A: Ibrutinib will be given once daily. The starting dose cohort (level 1) will receive 560 mg/day (4 x 140 mg capsules). During the dose escalation period of the study, the 3+3 design will be applied (see Table 3). Participants will be assigned to cohorts of increasing oral daily doses of ibrutinib (560mg, 840mg) until disease progression, intolerable toxicity or death. Three patients with recurrent/refractory PCNSL or recurrent/refractory SCNSL will be treated with daily oral ibrutinib for a 28-day cycle starting at dose level 1 and observed for toxicities during cycle 1. Arm B: Ibrutinib will be given at the MTD defined in Arm A."
223508588|NCT02315326|DRUG|HD- Methotrexate (MTX)|Arm C1: HD-MTX at 3.5g/m2 (standard hydration/leucovorin support) will be given on day 1 and 15 of each 28-day cycle for a total of 4 cycles totaling 8 HD-MTX administrations. Ibrutinib will be given between days 5 and 14 as well as days 19 and 28 of each cycle and continued daily after completion of HD-MTX treatments.The starting dose of ibrutinib is 560 mg/day (4x140mg capsules)
223508589|NCT02315326|DRUG|Rituximab + HD- Methotrexate (MTX)|Arm C2: Intravenous rituximab (500mg/m2) will be given on day 0, 14, and 28 of cycle 1 and day 14 and 28 of all following cycles. HD-MTX at 3.5g/m2 (standard hydration/leucovorin support) will be given on day 1 and 15 of each 28-day cycle for a maximum of 4 cycles totaling 8 HD-MTX administrations. Ibrutinib will be given between days 5 and 14 as well as days 19 and 28 of each cycle and continued daily after completion of HD-MTX treatments. The starting dose of ibrutinib is 560 mg/day (4x140mg capsules; dose level 1) (see Table 4). Filgrastim will be given at days 7-11 and 22-26.
223508590|NCT02315326|DRUG|procarbazine|Arm D: THIS IS THE ONLY ARM RECRUITING: : Oral procarbazine (100mg/m2/day) will be given on Day 1 through 7 during each cycle. Patients will be maintained on a tyramine-free diet during procarbazine administration.
223508591|NCT04684485|DRUG|Placebo|Placebo Tablet of SCD-044 product in subjects with moderate to severe atopic dermatitis.
223508592|NCT04684485|DRUG|SCD-044_Dose 1|SCD-044 tablets of low dose (Dose 1) in subjects with moderate to severe atopic dermatitis.
223754930|NCT06826196|DRUG|Placebo|Treatment every 4 weeks for 8-week treatment period
223754931|NCT03176186|COMBINATION_PRODUCT|Xenon|50% xenon by inhalation, delivered by customized xenon delivery system, that includes a ventilator, for the 24h period of TH/TTM. The inhalation therapy is provided in combination with protocol-directed Post-Cardiac Arrest Care dictated by the 2015 guidelines from the American Heart Association and the European Resuscitation Council.
223754932|NCT06303115|OTHER|Nicotine Pouch P1312914, 4 mg nicotine|P1312914 pouch product
223754933|NCT06303115|OTHER|Nicotine Pouch P1312915, 8 mg nicotine|P1312915 pouch product
223754934|NCT06303115|OTHER|Nicotine Pouch P1013215, 8 mg nicotine|P1013215 pouch product
223754935|NCT06303115|OTHER|Nicotine Pouch P1013218, 10 mg nicotine|P1013218 pouch product
223754936|NCT06303115|OTHER|Nicotine Pouch P1012919, 12 mg nicotine|P1012919 pouch product
223754937|NCT06303115|OTHER|Smoking Abstinence|No tobacco/nicotine
223754938|NCT06303115|OTHER|Continued UB cigarette smoking|Usual Brand Cigarette
223754939|NCT06007547|DRUG|Poractant Alfa|Poractant alfa (Curosurf) 200mg/kg administered under direct laryngoscopy using a surfactant instillation catheter
223754940|NCT05142358|DEVICE|Continuous Positive Airway Pressure|Use of CPAP device at the start of treatment planning.
223754941|NCT05142358|OTHER|Deep inspiratory breath hold|Treatment during breath holds leads to longer treatment times for patients and radiation oncology departments
223754942|NCT05142358|OTHER|Free Breath|Regular breathing
223754943|NCT07064135|BEHAVIORAL|Prompt Medication Adjustment and Intensive Follow-up|Participants receive prompt adjustment of lipid-lowering therapy perioperatively and 6-8 weeks after carotid endarterectomy to achieve guideline-recommended LDL-C targets, combined with intensive follow-up visits and laboratory monitoring. Intensive follow-up visits and laboratory monitoring of lipid parameters are performed at 6-8 weeks and again at 12-16 weeks postoperatively to optimize lipid management.
223754944|NCT07064135|OTHER|Standard Care|Participants receive standard postoperative care according to guidelines, including lipid management and routine follow-up without additional early intervention or intensive monitoring. Lipid parameters are assessed only once at 12-16 weeks postoperatively.
223754945|NCT06910839|DRUG|PF-07976016|PF-07976016 oral tablets
223754946|NCT06910839|DRUG|PF-06882961|PF-06882961 oral tablets
223754947|NCT07095621|PROCEDURE|3 days discharge|"Patients scheduled for elective minimally invasive DP, eligible for the study and willing to participate will be asked to sign the consent form in person during the preoperative counseling session.~Participants will receive comprehensive preoperative education and will be enrolled in an ERAS protocol that includes urinary catheter removal, initiation of a solid food diet, cessation of intravenous infusions, and oral pain management starting on postoperative day (POD 1). Following discharge on POD3, patients will receive a daily telephonic follow-up by a nurse navigator for the first 7 days after surgery (POD 7)."
223754948|NCT06826430|DRUG|Inaticabtagene autoleucel Injection|Inaticabtagene autoleucel Injection, the autologous 2nd generation CD19-directed CAR-T cells, will be administered by vein. Before CAR-T infusion，patients will get a 3-4 days lymphodepletion therapy with fludarabine and cyclophosphamide.
223754949|NCT06586112|DRUG|ESK-001|ESK-001
223754950|NCT06586112|DRUG|Apremilast|Apremilast
223754951|NCT06586112|DRUG|Placebo|Placebo
223754952|NCT07110662|DRUG|DARATUMUMAB (DARZALEX®)|A single injection of DARZALEX 16 mg/kg body weight administered by intravenous infusion (day 1) in addition to standard symptomatic treatment of NET until re-epidermalization.
223754953|NCT07108491|BIOLOGICAL|Balance Training with Stroboscopic Glasses|"The difficulty level of intermittent visual occlusion was structured from Level 1 to Level 8 based on frequency. As the flicker speed of the lenses decreased and the frequency lowered, the difficulty increased. For example, a setting of 6 Hz means the lenses flicker six times per second, whereas 1 Hz indicates one flicker per second.~Levels 1 to 5 are suitable for dynamic movements such as catching or hitting a ball, while Levels 3 to 8 are appropriate for balance and proprioceptive training.~In this study, participants wore stroboscopic glasses (Senaptec Strobe, Senaptec, USA, 2016) and began at Level 1 (6 Hz). The difficulty was gradually increased each week, with the setting adjusted to Level 3 (4 Hz) in Week 2, Level 4 (3 Hz) in Week 3, and Level 5 (2.25 Hz) in Week 4 (see Table 5).~The training was conducted using the standard Mode A, in which both lenses flicker simultaneously."
223754954|NCT07108491|BIOLOGICAL|Balance Training without Glasses|The exercise program consisted of six types of exercises and was conducted in a 30-minute circuit training format repeated twice per session. Participants took part in two sessions per week for four weeks, totaling eight sessions. The six exercises were completed as a circuit, repeated twice per session. A 30-second rest was provided between exercises and a 2-minute rest between circuits. All exercises were conducted by a licensed physical therapist to ensure safety.
223754955|NCT07110194|DRUG|TQB2825 Injection (Subcutaneous Injection)|TQB2825 is a Cluster of Differentiation 3 × Cluster of Differentiation 20 (CD3×CD20) dual antibody, which can simultaneously target the CD20 on tumor cells and the CD3 on T cells. It can induce T cell activation, proliferation and cytokine release, and effectively target and kill tumor cells.
223754956|NCT07109180|PROCEDURE|Robot-assisted lateral pancreaticojejunostomy|Robot-assisted
223754957|NCT07109180|PROCEDURE|Open lateral pancreaticojejunostomy|Open surgery
224200807|NCT04794452|DEVICE|Battery operated toothbrush|Device on plaque removal efficacy
223508593|NCT04684485|DRUG|SCD-044_Dose 2|SCD-044 tablets of intermediate dose (Dose 2) in subjects with moderate to severe atopic dermatitis.
223508594|NCT04684485|DRUG|SCD-044_Dose 3|SCD-044 tablets of high dose (Dose 3) in subjects with moderate to severe atopic dermatitis.
223508595|NCT04535011|BEHAVIORAL|PPKAY (brief intervention)|PPKAY is a nurse-administered, one-on-one, 15-minute brief intervention (BI) for alcohol use using FRAMES motivational interviewing techniques. The BI is a four-step discussion: 1) Raise the Subject of Alcohol, 2) Provide Feedback, 3) Enhance Motivation 4) Negotiate and Advice.
223508596|NCT04535011|BEHAVIORAL|Standard Booster|After discharge from the hospital, a standard motivational text message will be sent to their cell phone twice monthly for the duration of the study. In a rotating fashion, one of four standard motivational texts translated into Swahili will be sent to their cell phones.
223508597|NCT04535011|BEHAVIORAL|Personalized Booster|After discharge from the hospital, a personalized motivational text message will be sent to participant cell phones twice monthly for the duration of the study. In a rotating fashion, one of four personalized motivational texts will be sent to their cell phones. Personalized texts will be created with the content obtained from the motivational interview sessions. At each session, the research nurse conducting the intervention will record four messages based on the content of the session to be sent as the Personalized Booster.
223508598|NCT05769335|OTHER|eCR|Eating time window from 8:00 to 16:00
223508599|NCT05769335|OTHER|dCR|Eating time window from 12:00 to 20:00
223508600|NCT05769335|OTHER|CR|Eating time window from 8:00 to 20:00
224200808|NCT04794452|DEVICE|Manual toothbrush|Device on plaque removal efficacy
224200809|NCT04372888|BEHAVIORAL|choice decision frame|active choice for genetic testing
224200810|NCT04372888|BEHAVIORAL|opt-in decision frame|"gain frame for genetic testing"
224200811|NCT04372888|BEHAVIORAL|opt-out decision frame|"loss frame for genetic testing"
224200812|NCT04372888|BEHAVIORAL|enhanced choice (context) decision frame|consequences of genetic testing
224200813|NCT04372888|BEHAVIORAL|enhanced choice (norms) decision frame|social norms for genetic testing
224200814|NCT04372888|BEHAVIORAL|enhanced choice (affect) decision frame|commitments for genetic testing
224200815|NCT05332080|PROCEDURE|Telerehabilitation via application on cell phone|Realization of rehabilitation through content in an app they received advice on self-care and the type of exercises to do. The program consisted of hydrotherapy, mobility exercises, muscle strengthening, and activities to improve wrist and hand function, with planned goals.
223754958|NCT07108634|OTHER|RenalGuard Therapy|The RenalGuard Therapy® is comprised of a console, a single-use sterile IV infusion set, urine collection set and a cart. The console is a microcontroller device that has a means for measuring urine output and automatically controls the hydration infusion pump based on the measured urine output and clinician settings. The system is designed for infusion of hydration solutions only. The patient is connected to the console by the IV Infusion set connected to the patient's peripheral IV cannula and the urine collection set connected to the patient's indwelling Foley urinary catheter. The console continuously monitors urine production by measuring the weight of urine in the collection set, converts the urine weight to volume and then, automatically infuses the pre-set volume of hydration fluid to compensate for this output.
223754959|NCT07109141|PROCEDURE|PFA ablation procedure of atrial arrythmia|PFA ablation procedure of atrial arrythmia accroding to the particular patients needs
223754960|NCT07108699|DRUG|HSK39004 Dry Powder Inhaler-0.75mg|HSK39004 Dry Powder Inhaler: Inhale through the mouth, 0.75mg each time, twice a day
223754961|NCT07108699|DRUG|HSK39004 Dry Powder Inhaler-1.5mg|HSK39004 Dry Powder Inhaler: Inhale through the mouth, 1.5mg each time, twice a day
223754962|NCT07108699|DRUG|HSK39004 Dry Powder Inhaler Simulant|HSK39004 Dry Powder Inhaler Simulants, administered via oral inhalation, 1 tablet each time, twice daily
223754963|NCT07108842|PROCEDURE|Conventional Needle Irrigation|Patients in this arm will receive traditional syringe and needle irrigation using a 30-gauge side-vented needle. 2.5% sodium hypochlorite will be used as the irrigant, delivered 1-2 mm short of working length intermittently during root canal instrumentation. No activation device will be used.
223754964|NCT07108842|DEVICE|Conventional Needle Irrigation (Control Group)|Patients in this arm will receive traditional syringe and needle irrigation using a 30-gauge side-vented needle. 2.5% sodium hypochlorite will be used as the irrigant, delivered 1-2 mm short of working length intermittently during root canal instrumentation. No activation device will be used.
223754965|NCT07108842|DEVICE|endoactivator|in group 2 irrigation done with endoactivator
223754966|NCT07108842|DEVICE|Irrigation Solution|irrigation protocol done with disposable syringe
223754967|NCT07108842|DEVICE|Irrigation Solution|irrigation protocol done with endoactivator
223754968|NCT07108842|DEVICE|Sonic Irrigation with EndoActivator (Experimental Group)|Patients in this arm will receive sonic activation of the irrigant using the EndoActivator device during root canal treatment. After initial instrumentation and irrigation with 2.5% sodium hypochlorite, the irrigant will be activated using a medium-sized (25/04) EndoActivator tip for 30 seconds per canal at a sonic frequency (\~6000 cycles/min), to enhance cleaning and irrigant penetration.
223754969|NCT07109752|BEHAVIORAL|eHealth cardiac rehabilitation|A face-to-face interview for goal setting and action planning, as well as learning the use of CR website and accelerometer.
223754970|NCT07108959|PROCEDURE|Erector spinae plane block (Group E)|The ultra sound probe will be placed on the paravertebral region in a Sagittal plane about 3 cm lateral to the T5 spinous process on the operating side to locate erector spinae muscle, rhomboid major and trapezius from inward (To reach T5, we used C7 as an anatomical landmark, which is the most prominent vertebrae in the back and count downwards to reach T5. To locate C7, we will use palpation or ultrasound guidance if there is difficulty in palpation). Following visualization of these muscles and the transverse process of T5, the skin will be infiltrated with 5 ml of 2% lidocaine, and then 30 ml bupivacaine 0.25% will be injected in the plane between the erector spinae muscle and transverse process using a 22-G 10-cm nerve block needle.
223754971|NCT07108959|PROCEDURE|Lidocaine (drug)|Patients in group L will receive an initial bolus of lidocaine 1.5mg /kg over 10 minutes immediately before the induction of general anaesthesia then 1.5mg/kg/hr lidocaine infusion in a 50cc syringe pump intra operatively that will be stopped at the end of surgery.
223754972|NCT07108933|BIOLOGICAL|Autologous platelet-rich plasma|Guided injection of PRP in bony cavities of maxilla after surgical excision of non-malignant tumors.
223754973|NCT07110506|OTHER|Arterial pressure monitoring|Arterial pressure is monitored and obtained
223754974|NCT07109583|BEHAVIORAL|Early dinner|Consume dinner between 17:30 and 19:00 for a week
223508601|NCT06964763|PROCEDURE|surgery + laser|laser
223508602|NCT06964763|PROCEDURE|surgery + fibrine glue|fibrine glue
223754975|NCT07109583|BEHAVIORAL|Delayed dinner|Consume dinner between 20:30 and 22:00 for a week
223754976|NCT07109401|DRUG|Tislelizumab (BGB-A317) Plus Chemotherapy (Cisplatin/Carboplatin and Etoposide)|Neoadjuvant therapy: Tislelizumab + Cisplatin or Carboplatin + Etoposide; Adjuvant therapy: Tislelizumab + Cisplatin or Carboplatin + Etoposide (the total cycle of perioperative chemotherapy is four), followed by Tislelizumab monotherapy for one year.
223754977|NCT07110480|DIETARY_SUPPLEMENT|Supplement|The enrolled patient was advised to take 1 to 2 tablets daily at any time, preferably with a sip of water, as directed by the pharmaceutical company. In detail, starting with the distribution of Assonal®️PEA (T0) by the principal investigator, patients took 2 tablets per day (1 in the morning and 1 in the evening) for the first 15 days of treatment (T1). Treatment continued with 1 tablet per day until the end of the clinical study (T3).
223754978|NCT07110467|PROCEDURE|blinking exercises|The study group was instructed to instill artificial tears and perform blinking exercises three- five times a day for 4 weeks.
223754979|NCT07109089|OTHER|Race Pace-based training|Participants complete one week of endurance training based on race pace zones individually determined from a 5-km time trial performance. The program includes both low-intensity continuous runs and high-intensity interval training sessions.
223508603|NCT03070886|DRUG|Bicalutamide|Given orally (PO)
223508604|NCT03070886|DRUG|Degarelix|Given IM
223508605|NCT03070886|DRUG|Docetaxel|Given IV
223508606|NCT03070886|RADIATION|External Beam Radiation Therapy|Undergo external beam radiation therapy
223508607|NCT03070886|DRUG|Flutamide|Given PO
223508608|NCT03070886|DRUG|Goserelin|Given IM
223508609|NCT03070886|DRUG|Goserelin Acetate|Given IM
223508610|NCT03070886|OTHER|Laboratory Biomarker Analysis|Correlative studies
223508611|NCT03070886|DRUG|Leuprolide|Given intramuscularly (IM)
223508612|NCT03070886|DRUG|Leuprolide Acetate|Given IM
223508613|NCT03070886|DRUG|Nilutamide|Drug
223508614|NCT01017315|DRUG|Baby talcum|50 grams apply locally prior cast application
223508615|NCT05352113|DRUG|SSRIs|SSRIs antidepressants will be used and the oral dose will be determined by the clinical specialist. Once-daily for 6 weeks.
223608308|NCT05047861|PROCEDURE|socket shield technique with autogenous dentin graft|"The crown of the hopeless tooth will be decoronated with a chamfer diamond bur and a large-head round diamond bur under copious irrigation, until the bone crest level.~The root will then be sectioned along the long axis into buccal and palatal halves with a long shank fissure bur.~The lingual root fragment will be carefully retrieved using microperiotome. The remaining buccal root fragment will be thinned and concaved slightly with a long shank fissure bur. The thickness of the buccal root fragment should be at least 1.5 mm to ensure resistance to fracture and resorption.~The coronal part of this shield will be beveled to make a lingual slope for a better emergence profile with a large head round diamond bur.~The socket shield will be checked for immobility so the implant could be inserted palatally into the socket shield.~After the final preparation of the socket shield, Graft will be placed using autogenous dentin graft from the discarded palatal part of the tooth"
223754980|NCT07109089|OTHER|Heart Rate-Based Training|Participants complete one week of endurance training based on heart rate zones individually determined from ventilatory threshold assessments. The program includes both low-intensity continuous runs and high-intensity interval training sessions.
223508616|NCT05352113|PROCEDURE|acupuncture|This study will use the intradermal needle as an acupuncture intervention. Acupoints related to MDD will be stimulated. According to the position of the acupoints, choose a needle of φ0.20\*1.5m or φ0.20\*1.2mm. Press the needle to insert the acupoint vertically and retain it in the skin. After the intervention, the needle will be retained for 72 hours with a day of rest after removal. During needle retention, participants will be instructed to press the acupoints 3-4 times a day for about 1 minute each time, with the amount of stimulation as much as the patient can tolerate, at an interval of about 4 hours. A total of 10 treatment sessions will be performed for 6 weeks.
223508617|NCT05352113|PROCEDURE|sham acupuncture|Sham acupuncture will use the same size, color, and material as the verum intradermal needle with a thin silicone pad in the middle instead of the needle body. The sham acupuncture will be needled on the points 1cm lateral to MDD-related acupoints. After the intervention, the needle will be retained for 72 hours with a day of rest after removal. A total of 10 sessions will be performed for 6 weeks.
223508618|NCT05352113|DRUG|placebo|Oral placebo mimicking SSRIs antidepressants. Once-daily for 6 weeks.
223508619|NCT03934879|BEHAVIORAL|FitClub|Participants will rotate through each fitness module, which includes spin class, Pilates, strengthening exercises (weight training), basketball, running and rhythm, and cardio fitness. Students will meet five days per week during their first class of the day for 35 minutes and participate in two randomly assigned modules for two week periods. After 2 weeks, they participate in 2 different modules. Resting and peak heart rate (during exercise), calories burned and steps taken will be collected during each session.
223508620|NCT03934879|OTHER|Regular School Activities|Students will participate in regular school activities.
223508621|NCT01945242|DRUG|Alogliptin|Alogliptin tablets
223508622|NCT03499665|BEHAVIORAL|PNF, Myofascial Releasing Maneuvers, Home Exercise Group|For Group 1 (n:20), the PNF, myofascial releasing and home exercises were used to decrease pain, jaw restriction and improve functional mobility on the masseter, lateral and medial pterygoid, buccinator, temporalis, orbicularis oris, orbicularis oculi, upper side of trapezius muscle, splenius, scalenous, and cervical extensor muscle in 20 patients with bruxism, for 2 and 6 weeks after pre-evaluation. PNF, myofascial releasing and home exercises were administered for 2 weeks, followed by 3 sets of 10 repeat home exercises and 6 weeks under physiotherapist control.
223508623|NCT03499665|BEHAVIORAL|Myofascial Releasing Maneuvers and Home Exercises Group|In Group 2 (n:15), as myofascial releasing and home exercise group,final evaluation was made with 10 sets of myofascial releasing and home exercises for 2 and 6 weeks.
223508624|NCT03499665|BEHAVIORAL|Control Group|In Group 3 (n:17), as the control group, no myofascial releasing or Proprioceptive Neuromuscular Facilitation exercises were applied.
223508625|NCT06466603|DIETARY_SUPPLEMENT|GABA Probiotic Dose 1|Participants will complete up to a seven week study consisting of screening period, baseline period, up to a 6-week product use period with a total of 42 product use sessions. Screening assessments, baseline questions, product use period questionnaires, adverse event reporting, and end of study experience survey data will be collected. After the 6-week study product use period, all participants will be given the option to continue using GABA Probiotic for an additional 4 weeks. This study will be conducted remotely and will use a web-based data collection platform, Consumer Health Learning and Organizing Ecosystem (Chloe), by People Science where participants will complete study assessments using the Chloe app during the course of the study. Participants will receive the study product during the baseline period. Demographic and medical history data will be collected for the study.
223508626|NCT06466603|DIETARY_SUPPLEMENT|GABA Probiotic Dose 2|Participants will complete up to a seven week study consisting of screening period, baseline period, up to a 6-week product use period with a total of 42 product use sessions. Screening assessments, baseline questions, product use period questionnaires, adverse event reporting, and end of study experience survey data will be collected. After the 6-week study product use period, all participants will be given the option to continue using GABA Probiotic for an additional 4 weeks. This study will be conducted remotely and will use a web-based data collection platform, Consumer Health Learning and Organizing Ecosystem (Chloe), by People Science where participants will complete study assessments using the Chloe app during the course of the study. Participants will receive the study product during the baseline period. Demographic and medical history data will be collected for the study.
223508627|NCT06466603|DIETARY_SUPPLEMENT|Placebo Group|Participants will complete up to a seven week study consisting of screening period, baseline period, up to a 6-week product use period with a total of 42 product use sessions. Screening assessments, baseline questions, product use period questionnaires, adverse event reporting, and end of study experience survey data will be collected. After the 6-week study product use period, all participants will be given the option to continue using GABA Probiotic for an additional 4 weeks. This study will be conducted remotely and will use a web-based data collection platform, Consumer Health Learning and Organizing Ecosystem (Chloe), by People Science where participants will complete study assessments using the Chloe app during the course of the study. Participants will receive the study product during the baseline period. Demographic and medical history data will be collected for the study.
223508628|NCT06050512|DRUG|Mezigdomide|Mezigdomide (MEZI), a novel oral CELMoD® agent with enhanced tumoricidal and immune-stimulatory effects compared to immunomodulatory drugs (IMiDs®), induces maximal degradation of Ikaros and Aiolos, leading to increased apoptosis in myeloma cells.
224311599|NCT04308226|BEHAVIORAL|Patient Navigation|The navigator's principal role is to guide participants through the lung cancer screening (LCS) process. The navigator will work within the existing Boston Health Care for the Homeless (BHCHP) clinical structure and collaborate with participants' primary care providers (PCPs) to facilitate LCS low-dose computed tomography (LDCT) referral, completion, and timely follow-up by addressing participants' barriers to LCS completion and enhancing participants' self-efficacy. The navigator's secondary role is to offer brief tobacco counseling for participants who currently smoke.
223754981|NCT07100496|COMBINATION_PRODUCT|MIG-SPRAY|"MIG-SPRAY® is a film-forming liquid dressing designed for the preventive treatment of migraine.~Key Features:~* Administration:~  * Applied as 2 sprays per nostril, 3 times daily.~ * Treatment duration: 3 months.~* Mechanism: Forms a protective film on the nasal mucosa, potentially modulating local triggers of migraine.~* Use Case: Prophylactic (preventive) therapy for migraine, intended to reduce attack frequency and severity.~Additional Notes:~* Non-systemic (local action).~* CE-marked as a Class I medical device (under EU Directive 93/42/EEC)."
223754982|NCT07107152|BEHAVIORAL|single GPT generated message|Participants receive a single \~640-word message generated by GPT-4.1. The message is tailored to participants' self-reported demographics (age, gender, political ideology, education, urbanicity, health status, and last PCP visit). The message provides persuasive content encouraging colorectal cancer screening, emphasizing stool and colonoscopy screening options. Participants are required to read the message for a minimum of 3 minutes.
223754983|NCT07107152|BEHAVIORAL|AI Chatbot|Participants engage in a multi-turn conversation with a GPT-4.1 chatbot trained to emulate motivational interviewing techniques. The chatbot personalizes its conversation based on each participant's demographics (age, gender, political ideology, education, urbanicity, health status, and last PCP visit). Conversations last at least 3 minutes and aim to increase participant motivation to complete colorectal cancer screening.
223754984|NCT07107152|BEHAVIORAL|Expert-Written Patient Materials|Participants read a 642-word expert-written educational summary from the Journal of the American Medical Association's Patient Page on colorectal cancer screening. The material is designed to provide objective information about screening options and guidelines recommended by the US Preventive Services Task Force. Participants are required to read the material for at least 3 minutes.
223754985|NCT05501106|OTHER|Integrated Improvement strategies|"Integrated improvement strategies include postpartum hemorrhage risk screening, hierarchical management and preparedness, postpartum hemorrhage rescue recording, and review of postpartum hemorrhage cases.~1. A checklist (named as Risk Assessment and Preparedness for Postpartum Hemorrhage (Traffic Light in Delivery Room)) will be used in each virginal delivery to help obstetric staff and teams identify risk factors after admission, before and during labor, and improve the adherence to all known best practices.~2. The Postpartum Hemorrhage Rescue Format will be asked to be used in each postpartum hemorrhage rescue to record the rescue process.~3. Each case of postpartum hemorrhage exceeding 1000 ml will be reviewed. We will convene a QI Panel and a Task Force to assist the hospitals in postpartum hemorrhage case review and quality improvement strategy development."
223754986|NCT06958432|COMBINATION_PRODUCT|Node-Sparing Radiotherapy plus Chemotherapy and PD-1 inhibitor|Patients will receive node-sparing modified short-course radiotherapy, followed by six cycles of CAPOX chemotherapy combined with a PD-1 inhibitor. After neoadjuvant treatment, patients will either undergo total mesorectal excision (TME) surgery or enter a watch-and-wait strategy based on clinical assessment.
223754987|NCT06958432|COMBINATION_PRODUCT|Conventional Radiotherapy plus Chemotherapy and PD-1 inhibitor|Patients will receive conventional-target short-course radiotherapy, followed by six cycles of CAPOX chemotherapy. After neoadjuvant treatment, patients will either undergo TME surgery or enter a watch-and-wait strategy based on clinical assessment.
223754988|NCT02888847|DEVICE|Philips Zoom! White Speed whitening lamp|bleaching protocol with descending built in light intensities
223754989|NCT02888847|DEVICE|Philips Zoom! Advanced power whitening lamp|bleaching protocol with high light intensity
223508629|NCT06050512|DRUG|Ixazomib|Ixazomib, a second-generation proteasome inhibitor, is used primarily in the treatment of multiple myeloma. This activity outlines the mechanism of action, indications, and contraindications for ixazomib as a valuable agent for treating multiple myeloma.
223508630|NCT06050512|DRUG|Dexamethasone|Corticosteroids, such as dexamethasone and prednisone, are an important part of the treatment of multiple myeloma. They can be used alone or combined with other drugs as a part of treatment. Corticosteroids are also used to help decrease the nausea and vomiting that chemo might cause.
223508631|NCT02478502|DRUG|cabazitaxel|cabazitaxel is given to patients with progressive testicular cancer after cisplatin-based chemotherapy
223508632|NCT05050214|DRUG|Obinutuzumab|Each patient will be treated for 1 month and received a total of 3 doses. The first dose of Obinutuzumab (1000 mg) will be split in two separate infusions; on the first day each patient will receive 100 mg and the next day 900 mg of Obinutuzumab. Obinutuzumab (1000 mg) will be also administered at two and four weeks after the first infusion. Obinutuzumab will be administered after standard premedication.
223508633|NCT03142958|DEVICE|Integra Cadence Total Ankle System|Primary or revision on total ankle replacement
223508634|NCT01170130|DRUG|Lidocaine 1% (sterile)|during the phacoemulsification surgery patients will be given intracamerally lidocaine 1% (0.2 ml) and the pupil size will be recorded after 90 seconds
223508635|NCT05420454|DRUG|Docetaxel|75 mg/m2, d1, q3w,6 cycles
223508636|NCT05420454|DRUG|Carboplatin|AUC 6, d1, q3w ,6 cycles
223508637|NCT05420454|DRUG|Trastuzumab|starting dose 8 mg/kg, maintenance dose 6 mg/kg, d1, q3w ,6 cycles
223508638|NCT05420454|DRUG|Pertuzumab|starting dose of 840 mg, maintenance dose of 420 mg, d1, q3w,6 cycles
223508639|NCT05420454|DRUG|Nab paclitaxel|220 mg/m2, d1, q3w,6 cycles
223508640|NCT05420454|DRUG|Epirubicin|90 mg/m2,d1, q3w × 4 cycles,followed by docetaxel
223508641|NCT05420454|DRUG|Cyclophosphamide|600 mg/m2, d1, q3w ,4 cycles,followed by docetaxel
223508642|NCT05420454|DRUG|Docetaxel|100 mg/m2, d1, q3w × 4 cycles
223508643|NCT05420454|DRUG|Epirubicin|90 mg/m2,d1, q2w × 4 cycles,followed by nab-paclitaxel
223508644|NCT05420454|DRUG|Cyclophosphamide|600 mg/m2, d1, q2w × 4 cycles followed by nab-paclitaxel
223508645|NCT05420454|DRUG|Nab paclitaxel|125 mg/m2, d1,8,15, q3w× 4 cycles
223508646|NCT02819544|DRUG|Sodium chloride administration|Sodium chloride administration
223508647|NCT02819544|DRUG|Ropivacaine administration|Ropivacaine administration
223608309|NCT05047861|PROCEDURE|socket shield technique with alloplast graft|"The crown of the hopeless tooth will be decoronated with a chamfer diamond bur and a large-head round diamond bur under copious irrigation, until the bone crest level.~The root will then be sectioned along the long axis into buccal and palatal halves with a long shank fissure bur.~The lingual root fragment will be carefully retrieved using microperiotome. The remaining buccal root fragment will be thinned and concaved slightly with a long shank fissure bur. The thickness of the buccal root fragment should be at least 1.5 mm to ensure resistance to fracture and resorption.~The coronal part of this shield will be beveled to make a lingual slope for a better emergence profile with a large head round diamond bur.~The socket shield will be checked for immobility so the implant could be inserted palatally into the socket shield.~After final preparation of socket shield, Graft will be placed Alloplast graft"
223754990|NCT00136084|DRUG|Cladribine, Cyclophosphamide, Cytarabine, Daunorubicin, Dexamethasone|Since limited characters are allowed in this passage, please see detailed Description to know the dosage, dosage form, frequency of administration for the above mentioned drugs
223754991|NCT00136084|DRUG|Etoposide, Cytarabine, Gemtuzumab, L-asparaginase, Mercaptopurine, methotrexate, Mitoxantrone, Prednisone, Vincristine|Since limited characters are allowed in this passage, please see detailed Description to know the dosage, dosage form, frequency of administration for the above mentioned drugs
223754992|NCT04366622|DRUG|Riociguat (Adempas, BAY 63-2521)|0.5 mg riociguat as an immediate-release (IR) tablet
223754993|NCT05676957|DEVICE|Thermogard XP3|Patients received endovascular hypothermia for 12 hours following endovascular treatment and recanalization.
223754994|NCT05385419|DIAGNOSTIC_TEST|Bronchoscopic and thoracoscopic frozen section biopsies|Flexible bronchoscopy for patients with lung endobronchial lesion, the bronchoscopic biopsy will be sent for frozen section and permenant paraffin section Medical thoracoscopy for patients with undiagnosed pleural effusion, the thoracoscopic biopsy will be sent for both frozen section and permenant paraffin section
223754995|NCT02813343|DEVICE|BlueStar app|BlueStar is a smart-phone enabled application that is designed to serve as a virtual coach for patients. The app sends daily evidence-based, real-time messages as well as longitudinal feedback on how to improve diabetes management. The Bluestar app has been shown to be effective at teaching patients about dietary impacts on their blood glucose levels, encouraging patients to generate higher-quality blood glucose data for enhanced self-monitoring, and to improve overall management of diabetes as represented by reductions in levels of HgbA1c. Benefits have been demonstrated in time periods as brief as three months. One US based study showed a decrease in hospitalizations and emergency department visits among participants who use the application.
223754996|NCT04262895|DRUG|TTI-0102|TTI-0102 is a cysteamine precursor.
223754997|NCT04262895|DRUG|Placebo|Placebo
223754998|NCT04055688|DEVICE|Orbeye surgical videomicroscope|The ORBEYE surgical microscope is an FDA-cleared apparatus designed to facilitate operating procedures that involve fine nerves, blood vessels, and other small anatomic features by providing an enlarged stereoscopic visual field of the surgical site. The 4K 3D digital images of the ORBEYE microscope provide high-resolution stereoscopic images of the fine structures of tissue and blood vessels. As the surgical procedures are displayed on a large 55-inch monitor, the device is expected to reduce fatigue of the operator by eliminating the need for extensive viewing via microscope eyepieces for an extended period of time. The technology adopted in the ORBEYE was developed by Sony Olympus Medical Solutions, and its product design was handled by Olympus Medical Systems Corp. The ORBEYE is marketed by the Olympus Corporation.
223754999|NCT04055688|DRUG|5-Aminolevulinic Acid|5- aminolevulinic acid (5-ALA) is a European Medicines Agency- and Food and Drug Administration- (FDA-) approved drug that is administered to patients 2 to 4 hours before surgery and converted preferentially by tumor cells to protoporphyrrin IX (PPIX). PPIX fluoresces red when exposed to blue light. Use of 5-ALA has previously been shown to permit surgeons to obtain a more complete tumor resection, and its use has also been associated with an increased rate of progression-free survival.(3) There are currently 2 surgical microscope systems available on the market that are equipped with a 5-ALA visualization system. These visualization systems are currently classified by the FDA as Class I-exempt accessories to Class I-cleared surgical microscopes.
223755000|NCT03476083|DRUG|Tenofovir Disoproxil Fumarate (TDF) 300 mg oral daily.|All mothers will receive TDF therapy. However, group A will initiate TDF at the gestational week of 14-16, while group B will initiate TDF at the gestational week of 28. All infants will receive a series of three hepatitis B vaccines (at birth, age of weeks 4 and 24). In addition, the infants in the group B will receive HBIg injection at birth.
223755001|NCT04770376|OTHER|Observational study. Blood samples will be collected at scheduled blood draws performed as per clinical practice before each cycle of chemotherapy.|Collection of blood samples during blood draws performed before each cycle of chemotherapy as per clinical practice.
223755002|NCT05905484|DRUG|Bemnifosbuvir (BEM)|A single dose of BEM will be administered.
223755003|NCT05905484|DRUG|Placebo|A single dose of matching placebo will be administered.
223755004|NCT05905484|DRUG|Moxifloxacin|A single dose of Moxifloxacin will be administered.
223755005|NCT05698264|DEVICE|concomitant TTFields treatment device to standard of care EGFR positive NSCLC treatment|Concomitant to drug therapy, patients will receive treatment with Tumor Treating Fields (TTFields), generated by the medical device NovoTTF-200T with a recommended duration of minimum 18 h a day. TTFields administered using insulated transducer arrays applied to the skin surrounding the region of a malignant tumor.
223755006|NCT05698264|DEVICE|concomitant TTFields treatment device to standard of care anti PD-1 NSCLC treatment|Concomitant to drug therapy, patients will receive treatment with Tumor Treating Fields (TTFields), generated by the medical device NovoTTF-200T with a recommended duration of minimum 18 h a day. TTFields administered using insulated transducer arrays applied to the skin surrounding the region of a malignant tumor.
223755007|NCT06310512|BEHAVIORAL|Structured drug therapy management|Interventions mainly included (1) information collection, clinical assessment, and evaluation of medication regimens; (2) identification of and intervention for medication-related problems; (3) pharmacy instruction and education, and development of personal medication lists; and (4) follow-up and reassessment
223755008|NCT01497210|DEVICE|EASH dressing|Apply study dressing for 4 weeks changing at least every 7 days followed by Aquacel for four weeks.
224311600|NCT05994001|DRUG|cardonilizumab|cardonilizumab:PD1 and CTLA-4 bispecific antibody
223608310|NCT03348839|DEVICE|NeLLY service|Telesurveillance and therapeutic support
223608311|NCT00028847|DRUG|cytarabine|
223755009|NCT00997503|DEVICE|TAXUS Liberté Paclitaxel-Eluting Coronary Stent|The TAXUS Liberté Paclitaxel-Eluting Coronary Stent System is a device/drug combination product comprised of two regulated components: a device (Liberté Coronary Stent System) and a drug product (a formulation of paclitaxel contained in a polymer coating).The polymer coating serves as a carrier system to provide uniform and controlled biphasic release of the drug into the vessel wall once the stent is deployed.
223755010|NCT00997503|DRUG|prasugrel|10mg or 5mg, oral, once daily as maintenance dose through 30-months following index procedure
223608312|NCT00028847|DRUG|imatinib mesylate|
223608313|NCT00020917|BIOLOGICAL|cetuximab|
223608314|NCT00020917|DRUG|fluorouracil|
223608315|NCT00020917|DRUG|irinotecan hydrochloride|
223608316|NCT00020917|DRUG|leucovorin calcium|
223755011|NCT00997503|DRUG|placebo|Oral placebo to match both 10mg and 5mg prasugrel tablets.
223755012|NCT00997503|DRUG|aspirin|"Oral, as prescribed by physician through end of study.~."
223755013|NCT00116831|DRUG|Glipizide|oral anti-diabetic medication
223755014|NCT00116831|DRUG|rosiglitazone maleate|oral antidiabetic medication
223755015|NCT01040585|DRUG|Linezolid|Treatment for VAP as indication approved and as physician criterium.
223755016|NCT01790334|OTHER|Ultrasonography|
223755017|NCT00380393|BIOLOGICAL|GSK malaria vaccine 257049 Vaccine|3 dose intramuscular injection
223755018|NCT00380393|BIOLOGICAL|Sanofi-Pasteur's Human Diploid Cell Rabies Vaccine|3 dose intramuscular injection
224200816|NCT05643027|BEHAVIORAL|Acceptance and Commitment Therapy|Six-session, skills-based behavioral intervention targeting risk factors for opioid use disorder in the context of cancer
224200817|NCT05229562|DRUG|BIIB122|Administered as specified in the treatment arm.
224200818|NCT04464382|PROCEDURE|Outpatient (OA)|"Patients who are candidates for OA and therefore pre-selected based on the primary data and characteristics of the clinical signs, will be admitted to the surgical observation in charge of our service. The patient will be informed in detail of the intervention to be performed and discharge on an outpatient basis and will sign the informed consent understanding and thus accepting all the information. The patient will undergo surgery using a laparoscopic or open technique with minimal incision.~Once the appendectomy is performed, all the selection criteria will be reassessed and the definitive inclusion of the patients will be performed. In this case, we will perform the blind randomization of the patients. If all the inclusion requirements for the study are met, and the patient belongs to the OA group (case group), he will be discharged on an outpatient basis from the post-surgical stay unit without requiring hospital admission."
224311601|NCT05994001|DRUG|LM-302|LM-302 :ClAUDIN 18.2-ADC
224311602|NCT01630967|DRUG|Degarelix|Standard dosing and schedule for administration of degarelix will be used. 240mg s.c. loading dose, 80mg s.c. monthly maintenance dose.
224311603|NCT01626443|DIETARY_SUPPLEMENT|Myo-inositol + D-chiro-inositol + Folic acid|Myo-inositol (550 mg) + D-chiro-inositol (13.8 mg) + Folic acid (200 mcg); 2 x die
224311604|NCT01626443|DIETARY_SUPPLEMENT|Folic acid|Folic acid (200 mcg); 2 x die
224311605|NCT06598878|PROCEDURE|AR gait training|Participants will walk on a pathway projected in augmented reality (AR), following the instructions provided on the pathway Each session will last for 60 minutes, conducted three times per week, over a period of six weeks.
224311606|NCT05307510|DEVICE|Prefabricated splint|Subjects will be provided either a prefabricated splint
224311607|NCT05307510|DEVICE|Custom Orthosis|Subjects will be evaluated by an occupational therapist who will fabricate a custom orthosis.
223608317|NCT04593108|DEVICE|Letrozole misoprostol|Letrozole give pretreatment of abortion by misoprostol
223608318|NCT04593108|DRUG|Misoprostol, placebo|Give placebo pretreatment of abortion by misoprostol
223608319|NCT04377217|OTHER|Video recording|The experimenter will make a standardized video of the patient during the inclusion process, and a second one after 18 months, in order to evaluate the evolution of facial damage. Then algorithms will be developped to be able of differentiating FSHMD patients with facial damage from control subjects using video and audio recordings.
223608320|NCT04303481|OTHER|normal diet|Control
223608321|NCT04303481|OTHER|weight loss program kit|Subjects should adhere to the eating plan, which contained the following kit components : four flavors of collagen drinks \[i.e., Caviar Collagen Enzyme Drink, Collagen Enzyme Drinks (Peach Taste), Collagen Enzyme Drinks (Grape Fruit Taste), Saussurea involucrata Enzyme Drink (Litchi Taste)\], six flavors of mike shakes (i.e., Corn Soup Mike Shake, Strawberry Mike Shake, Chocolate Mike Shake, Vanilla Mike Shake, Banana Mike Shakes, Matcha Mike Shakes), Fruit and Vegitable Congee, and Botanical Liquid Sachet.
223608322|NCT04303481|OTHER|weight loss program kit with A. muciniphila prebiotics|Subjects should adhere to the eating plan, which contained the following kit components : four flavors of collagen drinks \[i.e., Caviar Collagen Enzyme Drink, Collagen Enzyme Drinks (Peach Taste), Collagen Enzyme Drinks (Grape Fruit Taste), Saussurea involucrata Enzyme Drink (Litchi Taste)\], six flavors of mike shakes (i.e., Corn Soup Mike Shake, Strawberry Mike Shake, Chocolate Mike Shake, Vanilla Mike Shake, Banana Mike Shakes, Matcha Mike Shakes), Fruit and Vegitable Congee, Botanical Liquid Sachet, and Probiotics Liquid Sachet
223608323|NCT05347836|DIAGNOSTIC_TEST|ELISA|Determination of serum levels of sCD14 and sCD163 using ELISA
223755019|NCT01933048|DRUG|FluMist|FluMist Intranasal Vaccine
223755020|NCT02353767|PROCEDURE|Noninvasive evaluation of liver fibrosis and steatosis|Transient elastography (using the Fibroscan, CAP Fibroscan) and biomarker panels (FibroTest, Fibromètre, Hepascore, Steatotest, Nashtest)
223755021|NCT01039896|DRUG|Period I : SLM0807, Period II : HKB0701 and SLM0807|
223755022|NCT01039896|DRUG|Period I : HKB0710 and SLM0807, Period II : SLM0807|
223755023|NCT02476968|DRUG|Olaparib|"Olaparib Capsule - 50 mg. Olaparib capsules will be packed in high-density polyethylene (HDPE) bottles with child-resistant closures. Each bottle will contain 120 capsules and 4 bottles will be dispensed for a 4 weekly visit, with a 2 day overage.~Patients will be administered olaparib capsules orally at a dose of 400 mg twice daily.~Eight 50 mg olaparib capsules should be taken at the same time each day approximately 12 hours apart with approximately 240 mL of water."
223755024|NCT04914728|PROCEDURE|mini-invasive lumbar arthrodesis|"* The mini-invasive posterior approach is performed using a trans-muscular Wiltse approach. Pedicle screws, neurological decompression and intersomatic cage placement are performed.~* The mini-invasive anterior approach is performed via a left retroperitoneal pararectal approach. After complete discectomy, an intersomatic cage stabilised by a screwed plate will be placed."
223755025|NCT06221228|BEHAVIORAL|Audio-visual assisted Flipped Classroom (FC) CAPD Training Programme|"FC CAPD programme is a one-week individual intervention, which consists of five sessions (8-hours each).~Pre-class audio-visual tutorials will be provided for self-study prior to face-to-face (F2F) sessions. Six instructional videos, each dedicated to a specific procedure, are accessible for preview and repeated viewing as needed. Such flexibility allows the patients to revise at their own preferred time and pace.~Participants will be asked to take note of any issues or difficulties they encounter while watching the video.~A CAPD education booklet will be prepared and distributed to the patients at the beginning of the F2F training session.~Take-home exercises will allow participants to revise the materials covered in the videos and consolidate their learning."
223608324|NCT05927766|DEVICE|esophagogastroduodenoscopy|patients with upper gastrointestinal symptoms will gone to upper endoscopy and biopsy when indicated
223608325|NCT04052308|BEHAVIORAL|ABPM|Ambulatory Blood Pressure Monitoring at Baseline and at the end of the study
223608326|NCT04052308|BEHAVIORAL|The arterial stiffness and endothelial reactivity|The arterial stiffness and endothelial reactivity will be assessed at baseline and at the end of the study
223608327|NCT04052308|BEHAVIORAL|Euroqol EQ-5D-5L|Answer Euroqol EQ-5D-5L at baseline and at the end of the study
223608328|NCT04052308|BEHAVIORAL|Lectures about knee OA|Patients will participate in two days of lectures two-months apart on the subject of knee OA, but will also come to the hospital at months 1, 3 and 5 after the first class to consult about nutritional habits to be improved; at months 4 and 6 to participate in a group therapy session with the psychologists, 7 sessions with the physical therapy team followed by 7 sessions with the physical educators team (once a week/4 weeks and once every two weeks, three times).
223755026|NCT03837548|OTHER|Training with Neurofeedback|Neurofeedback the brain activities by Magnetoencephalography
223608329|NCT04052308|BEHAVIORAL|Continuous intensity exercise|40 min of treadmill physical exercise (40 min on treadmill at 60% of reserve heart rate.)
223608330|NCT04052308|BEHAVIORAL|Exercises with varying intensity and interval|40 min of treadmill physical exercise ( 40 min on treadmill with alternating intensity between 50% (2 min) and 80% (1 min) of HR, resulting in an average load of 60% ((50% 2) + 80% / 3)), 20 min of sub-maximal strength training and 10 min of cooling exercises.
223608331|NCT02300363|DRUG|Treatment A (rosuvastatin)|10 mg rosuvastatin administered on Day 1 and Day 13
223608332|NCT02300363|DRUG|Treatment B (LX4211)|400 mg LX4211 administered on Day 7 through Day 13
223755027|NCT03837548|OTHER|The other Training with Neurofeedback|Neurofeedback the brain activities by Magnetoencephalography
224311608|NCT00935610|DIETARY_SUPPLEMENT|Immunocal|20 grams per day of Immunocal for 135 days.
223508648|NCT05655169|PROCEDURE|Piezosurgery and GaALAs diode laser|"One incision will be made between the roots of the six upper anterior teeth, and two incisions will be made between the upper canines and the second premolars. The incisions will be 5 mm long and start 4 mm apical to the interdental papilla.~After six weeks of piezosurgery, GaALAs diode laser (wavelength: 810 nm and exposure time of 10 seconds\\point) 10 seconds per point will be applied."
223508649|NCT05655169|PROCEDURE|Piezosurgery|One incision will be made between the roots of the six upper anterior teeth, and two incisions will be made between the upper canines and the second premolars. The incisions will be 5 mm long and start 4 mm apical to the interdental papilla.
223508650|NCT05655169|OTHER|Fixed orthodontic appliance|"After the levelling and alignment phase is completed, the rectangular stainless steel archwires (0.019 × 0.025) will be inserted, then after two weeks, the en masse retraction will be started via closed nickel-titanium coil springs applying 250 g of force per side."
223508651|NCT06276348|GENETIC|Whole genome sequencing|Standard diagnostic whole genome sequencing will be performed.
223508652|NCT06276348|GENETIC|BeginNGS test|Genomic sequencing that screens for 434 genetic diseases.
223508653|NCT06276348|GENETIC|WES|Whole exome sequencing will be performed.
223508654|NCT05698628|PROCEDURE|Distal perfusion catheterization|Distal perfusion catheterization will be done within 1 hour after the VA-ECMO application in the preemptive DPC group. The conventional DPC group will undergo distal perfusion catheterization at the time of limb ischemia sign.
223508655|NCT05661734|DRUG|Suzetrigine|Tablets for oral administration.
223508656|NCT04569097|OTHER|standard of care lingual strengthening|standard or care lingual strengthening approaches with outcome measured with novel pressure metrics
223608333|NCT02300363|DRUG|Treatment C (rosuvastatin + 400 mg LX4211 administered concomitantly)|10 mg rosuvastatin + 400 mg LX4211 administered concomitantly on Day 13
223608334|NCT01209351|DRUG|Placebo|placebo
223608335|NCT01209351|DRUG|teduglutide|teduglutide 4 mg
223608336|NCT06185582|OTHER|Cowhage|25 spicules will be inserted in the center of the predefined skin area on the mandibular area. The spicules will be gently rubbed for 15-20 seconds in circular motion to facilitate epidermal penetration.
223608337|NCT04502641|DRUG|Docetaxel|60mg/m2 on day 1, 3 weeks as one cycle, for 3 cycles.
223608338|NCT04502641|DRUG|5-fluorouracil|600 mg/m² per day as a continuous 120 h infusion on days 1-5, 3 weeks as one cycle, for 3 cycles.
223608339|NCT04502641|DRUG|Cisplatin|60mg/m2 on day 1, 3 weeks as one cycle, for 3 cycles.
223608340|NCT04502641|RADIATION|Intensity Modulated Radiation Therapy|The treatment consisted of definitive radiotherapy with conventional fractionation, a total dose of 68-70 Gy to PTVp, 62-68 Gy to PTVn, 60-62 Gy to PTV-HR, and 50-54 Gy to PTV-LR.
223755028|NCT05522465|DRUG|Prednisone|Prednisone 4mg/kg.d, d1-4
223755029|NCT05522465|DRUG|Dexamethasone|Dexamethasone 0.6mg/kg.d, d1-4
223755030|NCT01064895|DEVICE|Benephit catheter for Targeted Renal Therapy|Local physician-specified agent delivery to the kidneys bilaterally via the renal arteries using the Benephit infusion system.
223755031|NCT00820001|BEHAVIORAL|Booster Treatment|Based on this collective evidence, booster treatment was designed to address three general goals: a) clarify key child and parent/family problems and family preferences regarding target problems, b) directly target and resolve these existing problems using the eight domains contained in the existing treatment protocol administered in the initial outcome study, and c) provide the family with clinical recommendations and information to promote the maintenance of skill developments in targeted domains or adaptive routines designed to prevent any further deterioration in clinical functioning. Thus, the clinician may provide a review of prior content or administer new material specifically for older adolescents, as needed, and will attempt to apply these skills to specific problematic situations identified by the family.
223608341|NCT04502641|DRUG|Platinum|100mg/m2 on day 1, 3 weeks as one cycle, during radiotherapy.
223608342|NCT00613496|DRUG|irbesartan|Irbesartan-tablet (150 mg) 1 in the morning for 7 days, 2 tablets (1 in the morning and 1 in the evening) after day 8 if no contraindication for up titration (investigator will decide on the basis of creatinin, urea and potassium after taking a blood sample) for 9 weeks.
223608343|NCT00613496|DRUG|placebo|Placebo-tablet, 1 in the morning for 7 days, 2 tablets (1 in the morning and 1 in the evening) after day 8.
223608344|NCT01771978|DRUG|Placebo|Received 250 ml of a 5% dextrose solution as placebo
223608345|NCT01771978|DRUG|Diltiazem|Received a 100 µg/kg bolus followed by a 0.3 µg/kg infusion diluted in 250 ml of 5% dextrose solution
223608346|NCT01771978|DRUG|Acetylcystein|Received 150 mg/kg acetylcystein diluted in 250 ml of 5% dextrose solution
223608347|NCT01771978|DRUG|diltiazem and acetylcystein|"Received a combination of drug :diltiazem and acetylcystein~* bolus diltiazem 100 µg/kg followed by a 0.3 µg/kg infusion diluted in 125 ml of a 5% dextrose solution~* 150 mg/kg acetylcystein diluted in 125 ml of 5% dextrose solution"
223755032|NCT00820001|BEHAVIORAL|No-Booster|All cases randomized to this condition will simply participate in all of the proposed routine assessments and will receive assessment feedback. Specifically, these families will be provided with a brief summary of the significant clinical findings obtained in their 36-month follow-up assessment (assessment feedback). Such an assessment was provided to clinicians in the original study in order to highlight specific areas in need of clinical attention based on a review of the normative data and clinical cutoffs available for each instrument. Selected information will be conveyed by phone to the participating parent/guardian in a straightforward manner followed by a discussion of some clinical recommendations designed to address these clinical problems. In addition, the parent/guardian will be provided with a listing of professionals who provide services appropriate for this age group and for children with similar problems.
223755033|NCT00820001|OTHER|No intervention|No intervention was administered with this arm. Saliva samples were collected 2 times in the lab and 2 times at home (once at bedtime, once at wake-up time) per initial voluntary saliva protocol at each timepoints to measure endocrine levels.
223755034|NCT00820001|OTHER|Treatment As Usual|All cases assigned to this arm simply participated in all of the proposed routine assessments.
223755035|NCT04133493|DEVICE|Kerecis Omega3 Wound|"The intervention group will receive, in addition, a fish skin graft (KerecisTM Omega3 Wound) secured with Steristrips, sutures or staples, covered with a nonadherent dressing (Adaptic, Systagenix, Yorkshire, UK or equivalent), the product bolstered down to the wound bed with a foam dressing (HydraFoam, DermaRite) and hydrogel as needed to retain adequate moisture balance and padded with stretch gauze and self adherent wrap as needed.~The wound will be dressed by the site investigator 1 day a week."
223755036|NCT04133493|DEVICE|Fibracol|The Standard of Care Group will receive Fibracol covered with DSD. Change three times per week
223755037|NCT05274256|PROCEDURE|implant placement with simultaneous soft tissue augmentation|implant placement with simultaneous soft tissue augmentation using De-epithelialized free gingival graft and immediate temporization in the maxillary aesthetic zone .
223608348|NCT00502671|DRUG|capecitabine [Xeloda]|1250mg/m2 po bid on days 1-14 of each 3 week cycle
223608349|NCT01768507|DIETARY_SUPPLEMENT|Resveratrol|5 g (10 capsules) as single oral dose on day 1
223608350|NCT03633344|DRUG|Carbowhite|
223608351|NCT03633344|DRUG|Carbowhite placebo|
223608352|NCT05191693|PROCEDURE|ERCP|endoscopic papillary balloon dilation (EPBD) with endoscopic sphincterotomy (EST
223608353|NCT01204177|DRUG|BAY86-9766 MEK Inhibitor + Sorafenib|All patients who meet the entry criteria will receive BAY86-9766 50mg (2x20mg + 1x10mg capsules) twice daily in combination with sorafenib 800 mg (2x200 mg tablets bid). During the first 3 weeks they will receive a reduced dose of sorafenib: 600 mg / daily (1x200mg tablet in the morning + 2x200mg tablets in the evening) daily. This dose will be increased to the standard dose of 800 mg (400 mg bid) if no major side effects occur. Treatment until PD or until one of the withdrawal criteria for this study is met as described in the protocol (e.g. radiological progression or clinical progression)
223755038|NCT03379116|OTHER|enteral nutrition and parenteral nutrition|In the treatment of the burned patients injured,data on nutritional support and patient's outcomes were collected and analyzed.
223608354|NCT00412893|DRUG|Isavuconazole|Loading doses were administered as IV infusion and maintenance doses were administered as IV infusion or oral (capsules).
223608355|NCT00412893|DRUG|Voriconazole|Loading doses were administered as IV infusion and maintenance doses were administered as IV infusion or oral (capsules).
224200819|NCT04464382|PROCEDURE|Hospitalization appendectomy (HA)|"Patients who are candidates for HA and therefore pre-selected based on the primary data and characteristics of the clinical signs, will be admitted to the surgical observation in charge of our service. The patient will be informed in detail of the intervention to be performed and discharge on an outpatient basis and will sign the informed consent understanding and thus accepting all the information. The patient will undergo surgery using a laparoscopic or open technique with minimal incision.~Once the appendectomy is performed, all the selection criteria will be reassessed and the definitive inclusion of the patients will be performed. In this case, we will perform the blind randomization of the patients. If all the inclusion requirements for the study are met, and the patient belongs to the case group (HA), he will be admitted in hospital beds."
224200820|NCT05359640|OTHER|quality of pain|We will recorded the pain by using a short pain questionnaire and a McGill pain questionnaire.
224311609|NCT00935610|DIETARY_SUPPLEMENT|Casein|20 grams per day for 135 days
223608356|NCT04344223|DEVICE|Balance Shoe|Use of experimental balance shoes for carrying out the tests along the three sessions and one of the two familiarization phases
223608357|NCT04344223|DEVICE|Personal Shoe|Use of Personal shoes (the same for each session) for carrying out the tests along the three sessions and one of the two familiarization phases
223608358|NCT00005961|DRUG|O6-benzylguanine|
223608359|NCT00005961|DRUG|carmustine|
223608360|NCT03087695|DIAGNOSTIC_TEST|Plasma EBV DNA|Parameters analyzed will include (1) the change pattern of plasma EBV DNA concentrations, (2) various half-life values (t1/2) of plasma EBV DNA clearance rate calculated over different time periods.
223608361|NCT05503849|BEHAVIORAL|Lifestyle modification|This lifestyle modification aiming to provide proactive health management during pregnancy, which contains the following: 1) balanced dietary intake based on the Chinese Dietary Guideline; 2) sufficient physical activity; 3) changes in lifestyles (e.g. sleep, sun exposure etc.)
223755039|NCT00624962|DIETARY_SUPPLEMENT|nutritional intervention|Nutritional status assessment on enrollment in study, beginning of course 1 and end of study period (week 12 or beginning of Course 5 chemotherapy)
223608362|NCT01798966|DEVICE|SENSIMED Triggerfish|
223608363|NCT03524482|BEHAVIORAL|SmokeFreeText|"SmokefreeTXT is a 6-8 week fully automated text-based cessation intervention. The program is free to U.S. subscribers who have a mobile phone, and is available on smokefree.gov or by texting QUIT to short code 47848. Participants are encouraged to set a quit date within the next 14 days, followed by count-down messages leading to the quit date. Starting on the quit date, participants receive 6 weeks of intervention text messages, and assessment questions (mood, cravings, smoking status). The message library contains 166 messages and 41 behavior change techniques,40 which are delivered at the greatest frequency during the first 2 weeks and taper over time. When in need of assistance, participants can text one of 3 keywords (MOOD, CRAVE, or SLIP) to receive a relevant message from the system. Participants can opt-out by texting STOP at any time. With informed consent, we will be able to access the SmokefreeTXT data for these participants."
223608364|NCT03524482|BEHAVIORAL|Path2Quit|Path2Quit will deliver 20-60 second video clips by multimedia messaging service. The message library will include 75-170 messages. Written text messages will be limited to brief phrases to indicate the topic of the video. Messages will be pushed to participants in the morning, in the afternoon, and 2 hours before the reported usual bedtime. The cultural adaptations will be infused throughout the video segments. Topics include deep structure: race and smoking in general, African American smoking statistics; norms for smoking; concerns about nicotine replacement/medication; family/collectivism; unique stressors; racism/discrimination, depression; co-morbid addiction; neighborhood/environmental influences; menthol cigarettes; race-specific weight issues and concerns; and working as a community against the tobacco industry.
223608365|NCT04044469|BEHAVIORAL|Immunization-enhancement|This group receives a standardized information text, suggesting that medical diagnostics is not very accurate. Reasons for why a serious disease is overlooked are mentioned and discussed.
223755040|NCT00624962|DIETARY_SUPPLEMENT|therapeutic nutritional supplementation|enteral feedings via a nasogastric tube for 50% or more of the total nutritional support days.
223755041|NCT05718635|DIAGNOSTIC_TEST|coloured duplex|colored duplex to locate numbers sites and size of perforators.
223755042|NCT05718635|PROCEDURE|supra facial dissection|flap raising in supra facial plane
224311610|NCT05969613|PROCEDURE|Regional block|regional block with 0.25% Bupivacaine at a dose of 2ml/kg with adrenaline
223755043|NCT00358202|DRUG|cefepime|cefepime hydrochloride 1gm IM q24h
223755044|NCT00358202|DRUG|ceftriaxone|ceftriaxone 1 gm IM q24h
223755045|NCT03070353|DRUG|Dextran 40|Dextran-40 infusion with the dose of 1 g/kg/day (10 ml/kg/day) for 2 days.
223755046|NCT01859507|DRUG|Botox|In the first session, proper history taking and proper counseling of the couple including the description of the new modality (BOTOX injection) of treatment and subsequent dilatation sessions. During examination, all our maneuvers are gentle to gain trust of the patient. Following sterilization, we used surface (Xylocaine gel 2% ASTRA ZENECA) anesthesia before the injection. In addition we used finger like ice packs pre-prepared in a surgical latex glove, on the perineum. We made sure to check that the tip of the needle is not in a vessel by aspirating before proceeding with the injection of each bolus of BOTOX.
223755047|NCT00709371|DRUG|Zonisamide SR placebo/ bupropion SR placebo|2 placebo combination tablets twice daily for 16 weeks (maintenance period)
223755048|NCT00709371|DRUG|Zonisamide SR placebo/ bupropion SR 360 mg/day|2 placebo and bupropion SR 90 mg combination tablets, twice daily for 16 weeks (maintenance period)
223755049|NCT00709371|DRUG|Zonisamide SR 120 mg/day/ bupropion SR placebo|2 zonisamide SR 30 mg and placebo combination tablets, twice daily for 16 weeks (maintenance period)
223755050|NCT00709371|DRUG|Zonisamide SR 360 mg/day/ bupropion SR placebo|2 zonisamide SR 90 mg and placebo combination tablets, twice daily for 16 weeks (maintenance period)
223755051|NCT00709371|DRUG|Zonisamide SR 120 mg/day/ bupropion SR 360 mg/day|2 zonisamide SR 30 mg and bupropion SR 90 mg combination tablets, twice daily for 16 weeks (maintenance period)
223755052|NCT00709371|DRUG|Zonisamide SR 360 mg/day/ bupropion SR 360 mg/day|2 zonisamide SR 90 mg and bupropion SR 90 mg combination tablets, twice daily for 16 weeks (maintenance period)
223755053|NCT00275158|DRUG|L-Arginine Supplementation|
223755054|NCT05449925|PROCEDURE|Injectable PRF and Microneedling|i-PRF and Microneedling Procedure in thin gingiva followed by orthodontic treatment
223755055|NCT04777890|OTHER|suboccipital inhibition|The therapist will seat at the patient's head height and place his second, third, fourth and fifth fingertips'over the patient's suboccipital area during a 10-minute period.
223755056|NCT04777890|OTHER|INYBI|The therapist will place the INYBI at the suboccipital area, specifically placing the fingers of the instrument at the lower border of the occipital. If needed, a rolled towel will be placed behind the INYBI, in order to maintain the physiological lordosis, checking out that the patient doesn't make a cervical extension. Then the therapist will press the vibration button and turn it off after 10 minutes. All patients will receive the treatment with the INYBI's hardest head with a 50 HZ frequency.
223755057|NCT04777890|OTHER|INYBI + upper cervical manipulation|The participant will also be treated with the INYBI during a 10-minute period. After that, the therapist will carry out the upper cervical manipulation technique. Keeping the patient's head on an upper cervical flexion position, the therapist will turn his/her head to the maximum possible rotation, always maintaining its longitudinal axis. Once this is done, a high velocity and short articular amplitude manipulation in rotation will be carried out
223755058|NCT01653522|DRUG|Triptan|
223755059|NCT01653522|DRUG|Doxycycline|
224311611|NCT05969613|PROCEDURE|Wound infiltration|Infiltration of surgical site with 0.25% Bupivacaine at 0.5ml/kg dose
223755060|NCT02163291|DRUG|paclitaxel liposome|S-1 40 mg/m2 bid d1-14 po and paclitaxel liposome 175mg/m2 d1 intravenously infusion for 3 hours, every 3 weeks. After 2 cycles' treatment, if clinical response is complete response（CR）,partial regression（PR） or stable disease（SD）, another 2 cycles is administered and operation is performed after the total 4 cycles. If response is progressive disease（PD）, chemotherapy is stopped and operation is performed.
224311612|NCT05969613|PROCEDURE|Caudal block|Infiltration of caudal epidural space with 0.25% Bupivacaine at 1ml/kg dose
224311613|NCT01143766|DRUG|Gabapentin|gabapentin 900mg PO x 1 dose, 1 hour prior to the procedure
223608366|NCT04044469|BEHAVIORAL|Immunization-inhibition|This group receives a standardized information text, suggesting that medical diagnostics is very accurate and that doctors are very often right in their first initial diagnostic assessments.
223608367|NCT04044469|BEHAVIORAL|Control group|This group receives no further information after watching the videotaped doctor's report.
223608368|NCT01776606|DRUG|Botulinum Toxin Type A|Botulinum Toxin Type A, Dose A; dose applied to the lateral canthal lines
223608369|NCT01776606|DRUG|Placebo|Placebo, Dose B; dose applied to the lateral canthal lines
223608370|NCT01199419|PROCEDURE|comparison of PCI vs. CABG in multivessel disease|invasive treatment of coronary artery disease
223608371|NCT01311336|DRUG|Loratadine|loratadine 10 mg capsule orally once daily for 7 days beginning the day of administration of pegfilgrastim
223755061|NCT02404311|BIOLOGICAL|ALVAC-HIV|a lyophilized vaccine for injection at a viral titer ≥ 1 × 10E6 cell culture infectious dose (CCID)50 and \< 1 × 10E8 CCID50 (nominal dose of 10E7 CCID50) and is reconstituted with 1mL of sterile sodium chloride solution (NaCl 0.4%) for intramuscular (IM) injection as a single dose.
223755062|NCT02404311|BIOLOGICAL|Bivalent Subtype C gp120/MF59®|2 recombinant monomeric proteins, each at a dose of 100 mcg, mixed with MF59® adjuvant (an oil-in-water emulsion) delivered as a 0.5 mL IM injection
223755063|NCT02404311|BIOLOGICAL|ALVAC-HIV (vCP2438) Placebo|a sterile, lyophilized product that consists of a mixture of virus stabilizer, and freeze drying medium and is reconstituted with 1mL of sterile sodium chloride solution (NaCl 0.4%) for injection as a single dose IM
223755064|NCT02404311|BIOLOGICAL|Bivalent gp120/MF59® Placebo|Sodium chloride for injection, 0,9% delivered as a 0.5 mL IM injection
223755065|NCT00864162|DRUG|Ramipril10 mg Capsules, single dose|A: Experimental Subjects received Purepac formulated products under fed conditions
223755066|NCT00864162|DRUG|Atlace® 10 mg capsules, single dose|B: Active comparator Subjects received Monarch Pharmaceuticals Inc. formulated products under fed conditions
223755067|NCT03678142|DIAGNOSTIC_TEST|analysis of last resort antibiotic drug (Flucloxacillin, Imipenem, Vancomycin or Cefepim) in sweat and blood|blood draw (4.7 ml EDTA) and sweat sample taken (Macroduct Sweat Collecting System)
223755068|NCT05717595|DIETARY_SUPPLEMENT|fructose|oral ingestion of fructose vs dextrose
223755069|NCT03001570|DRUG|Cetuximab plus Radiotherapy|Standard dose of a curative radiotherapy treatment is 70Gy given with conventional fractionation (2G daily) in an overall length of 7 weeks. In this study, the fractionation has been modified accordingly Cetuximab pharmacokinetics. Cetuximab will be administered with standard schedule: charge dose of 400mg/mq a week before the beginning of concurrent treatment, then weekly doses of 250mg/mq intravenous for 7 administration. This schedule to obtain the same biological efficacy on tumour with lower toxicity on healthy tissues.
223755070|NCT04347265|OTHER|NMP|Participants received the percutaneous electrical stimulation intervention. Specifically, this consisted of the application of a square wave biphasic electrical current, with 3 Hz frequency and a 250µs pulse width, at the maximal tolerable intensity, to cause an tolerable muscle contraction. The application was 10 stimulations of 10 seconds, with 10 seconds at rest between stimulations. A trained physiotherapist performed the PNM intervention.
223755071|NCT01746784|DRUG|N6022|Intravenous solution of N6022 in normal saline administered by infusion pump over 1-8 minutes depending on the dose
223755072|NCT01746784|DRUG|Normal saline|Intravenous solution of 0.9% (weight/volume) NaCl administered by infusion pump over 1-8 minutes depending on dose of active drug used in same cohort
223755073|NCT00526058|DEVICE|Secura then Futura|Randomized to 6 bi-monthly H.E.L.P. therapy treatments with the Plasmat® Secura apheresis system and then cross over to receive 6 bi-monthly treatments with the Plasmat® Futura apheresis system.
223755074|NCT00526058|DEVICE|Futura then Secura|Randomized to 6 bi-monthly H.E L.P. therapy treatments with the Plasmat® Futura apheresis system and then cross over to receive 6 bi-monthly treatments with the Plasmat® Secura apheresis system.
223755075|NCT03086174|BIOLOGICAL|humanized anti-PD-1 monoclonal antibody Toripalimab|humanized anti-PD-1 monoclonal antibody Toripalimab is a programmed death-1 (PD-1) immune checkpoint inhibitor antibody, which selectively interferes with the combination of PD-1 with its ligands, PD-L1 and PD-L2, resulting in the activation of lymphocytes and elimination of malignancy theoretically.
223755076|NCT00218296|DRUG|Usual Care Group|Nicotine replacement therapy
223755077|NCT00218296|OTHER|Reduction Group|Subject selects preferred method for reduction.
223755078|NCT05147896|DRUG|Semaglutide Oral Tablet|Semaglutide Oral Tablets will be introduced to the active arm as per protocol for regular therapy introduction.
223755079|NCT06347523|PROCEDURE|The VR-based preoperative rehabilitation program;|Patients are provided with VR headsets for personalized pre-rehabilitation educational videos prior to surgery. These videos cover psychological counseling, nutritional advice, and exercise instructions. Additionally, patients engage in VR interactive functional training. After surgery, patients continue with VR technology interactive functional training and watch postoperative educational videos. This intervention is initiated upon the patient's admission and continues until their discharge.
223755080|NCT06347523|PROCEDURE|standard nursing care,|Patients in the control group receive traditional preoperative rehabilitation methods, which may include the following interventions: Joint exercises and rehabilitation exercises guided by a physical therapist. Written or verbal rehabilitation educational materials.
224311614|NCT01143766|OTHER|Standard sedation regimen|Combination opiate and benzodiazepine will be administered to achieve moderate sedation. This is the standard of care.
224311615|NCT04321330|DRUG|Atezolizumab|Atezolizumab 1200 mg will be administered by IV on Day 1 of each 21-day cycle until unacceptable toxicity or loss of clinical benefit.
223608372|NCT01311336|DRUG|placebo|placebo capsule orally once daily for 7 days beginning the day of administration of pegfilgrastim
223608373|NCT01304602|DRUG|Irinotecan|IV over 90 minutes on day 1 of each cycle (every 2 weeks) at the cohort assigned dose level
223608374|NCT01304602|DRUG|BKM120|BKM120, oral, daily starting with cycle 1/day 2 at the cohort defined dose level
223608375|NCT00475566|DEVICE|Dynalink®-E everolimus-eluting peripheral stent|Stenting of atherosclerotic de novo or restenotic lesions (\> 50% stenosis) in the native superficial femoral or proximal popliteal artery
223608376|NCT00475566|DEVICE|Dynalink®-E, everolimus-eluting peripheral stent|Stenting of atherosclerotic de novo or restenotic lesions (\> 50% stenosis) in the native superficial femoral or proximal popliteal artery
223608377|NCT04132310|OTHER|N/A This is an observational study.|This is an observational study.
223608378|NCT03235947|DRUG|Fosfomycin disodium|Fosfomycin disodium 4 g intravenously dissolved in 100 mL of normal saline 0.9% three times in the perioperative period of renal transplant surgery.
223608379|NCT03235947|DRUG|Trimethoprim / Sulfamethoxazole|Trimethoprim / Sulfamethoxazole (160/800 mg) orally every 24 hours during the study follow-up (7 weeks)
223608380|NCT03235947|DRUG|Intravenous placebo|Normal saline 0.9% 100 mL intravenous administered three times in the perioperative period of the renal transplant, at the same times corresponding to disodium fosfomycin
223608381|NCT05743088|BEHAVIORAL|questionnaire|The questionnaire consists of the following parts: socio-demographic data of participants, student perception and attitude towards the COVID-19 pandemic and its consequences, as well as practices of preventive measures in the community.
223608382|NCT05295875|DRUG|ALT-801|Injected subcutaneously (SC)
223608383|NCT05295875|OTHER|Placebo|Injected subcutaneously (SC)
223608384|NCT00997919|DRUG|MABT5102A|single SC dose
223608385|NCT00997919|DRUG|MABT5102A|single IV dose
223608386|NCT02967653|DRUG|Atorvastatin|Member of drug class called statins, primarily used as a lipid-lowering agent and the prevention of events associated with cardiovascular disease
223608387|NCT06507306|DRUG|KQB198|Oral KQB198
223608388|NCT06507306|DRUG|osimertinib|Oral osimertinib
223608389|NCT04473963|DEVICE|Electrographic Flow™ guided ablation|"In addition to standard pulmonary vein isolation (PVI) or PVI touch-up, subjects receive targeted radiofrequency source ablation guided by Electrographic Flow™ (EGF) mapping. EGF mapping enables the full spatiotemporal reconstruction of organized atrial electrical wavefront propagation to identify active sources or origins of excitation that may trigger atrial fibrillation (AF).~EGF mapping involves 1 minute recordings of unipolar electrograms from a basket catheter, which are then processed with the EGF software. Several basket catheter positions are acquired in standard positions in both the left and right atria. EGF-identified sources with activity above the threshold (≥ 26.5%) are considered significant and targeted for ablation. The procedure concludes when all EGF-identified sources are eliminated, defined as reducing source activity below the threshold."
223608390|NCT05897034|DRUG|Doxycyclin|Doxycycline is a moderate-spectrum, second-generation tetracycline that is generally well tolerated
223608391|NCT05897034|DRUG|Pentoxifylline|Pentoxifylline is a vasoactive agent that improves the flow of blood by reducing its viscosity
223608392|NCT05897034|DRUG|Nitazoxanide 500Mg Oral Tablet|Nitazoxanide is a broad-spectrum antiparasitic and broad-spectrum antiviral medication that is used in medicine for the treatment of various helminthic, protozoal, and viral infections
223608393|NCT01613677|DRUG|BKM120|
223608394|NCT01404780|DEVICE|GlideScope (GVL)|The Glidescope (GVL) has not been extensively studied for double lumen tube intubation. The GVL may be particularly useful for patients with difficult airways as it has a camera attached to the blade.
223608395|NCT01404780|DEVICE|Macintosh Direct Laryngoscope (MDL)|Current standard of care at UHN for 50 years
223608396|NCT00410878|DRUG|OROS Hydromorphone HCI (slow release)|
223608397|NCT03701672|OTHER|Opioid Analgesic Treatment|Opioid treatment is determined, prescribed, modified and discontinued at the sole discretion of the treating physician at each research site; regardless of generic name, manufacturer, constituent components, route of administration, and dosing schedule (including titration and run-in periods).
223608398|NCT04935073|DRUG|Prescription of traditional Chinese Medicine named Er Zhi Wan combined with Si Wu Tang|The medicines used in this study including Radix et Rhizoma Ligustrum 15 g, Radix Morindae Sinensis 12 g, Fructus Lycii 15 g, Semen Cuscutae 20 g, Radix Rehmanniae 15 g, Radix Angelicae Sinensis 10 g, Radix Paeoniae Alba 10 g, Ligusticum wallichii 6 g, Poria cocos 15g, Polygonatum 15g, eclipta 10g. which will be taken for 10-15days.After the ET, the treatment group will continue to take Chinese herbal medicine, changing to Shou Tai pills ( Morinda officinalis 15 g, Teasel 15g，Cuscutae 20 g, Eucommia ulmoides 15 g, Rehmannia 15 g, Cornus officinalis 15 g, loranthus parasiticus 20 g, Ligustrum lucidum 15g, Salvia miltiorrhiza 10g, Scutellaria baicalensis 10g, Atractylodes macrocephala 15g); which will be taken for 14days. The hospital will be responsible for the decoction of 200 mL per dose, 1 dose per day, divided into 2 doses in the morning and in the evening.
223608399|NCT04935073|DRUG|Recombinant Human Follitropin Alfa for Injection、Fructose Injection、Tetyacycline Hydrochloride Capsules、Cetrorelix Acetate Powder for Injection|The intervention starts from the 5th day of the menstrual cycle and lasts to the day before IVF-ET.
223608400|NCT04168229|DEVICE|Mermaid 9 ITE|A Hearing aid intended to amplify sounds and deliver them to the ear with a microphone and receiver housed in an in-the-ear hardware.
223608401|NCT04168229|DEVICE|Mermaid 9 BTE|A Hearing aid intended to amplify sounds and deliver them to the ear with a microphone and Receiver housed in a behind-the-ear hardware.
223608402|NCT02423655|OTHER|Algorithm for deferred dialysis intervention|Use combined indications to guide researchers to defer dialyzing progressive CKD patients. Asymptomatic patient will not start dialysis treatment until his eGFR becomes less than 5 ml/min/1.73m2. Or until 1. Patient's Kraemer index is \>6 or with overt fluid overload after trying all conservative means（including appropriate medicines） 2. Patient's Subjective Global Assessment method (SGA) assessment is grade C 3. Patients have indications for emergency dialysis 4. Sever symptoms which cannot be relieved by conservative treatment
223608403|NCT02423655|OTHER|Algorithm for routine dialysis intervention|"Use combined indications to guide researchers to initiate dialysis in progressive CKD patients routinely. Researchers will start dialysis treatment for a patient when his eGFR reaches 7 ml/min/1.73m2 in asymptomatic patients.~Or patients have indications below: 1. Patient's Kraemer index is \>6 or with overt fluid overload after trying all conservative means（including appropriate medicines） 2. Patient's SGA assessment is grade C 3. Patients have indications for emergency dialysis 4. Sever symptoms which cannot be relieved by conservative treatment"
223608404|NCT06375174|PROCEDURE|Thrombectomy|All procedures correspond to standard care and clinical routine
223608405|NCT04451941|DEVICE|Experimental: RecoveriX with individual EEG calibration|RecoveriX applied FES according to individual brainwave by individual EEG calibration for 5 times a week for 4 weeks
223608406|NCT04451941|DEVICE|RecoveriX without individual EEG calibration|RecoveriX applied FES according to the brainwave of other subjects regardless of the individual brainwave for 5 times a week for 4 weeks
223608407|NCT01908530|DEVICE|Microprobe glucose sensor|Assessment of safety and accuracy of a novel continuous glucose monitor based on microprobe technology.
223608408|NCT02228317|DEVICE|Telemedicine consultation|Telemedicine consultation done by telephone or video
223608409|NCT01941329|PROCEDURE|Panretinal Photocoagulation (PRP)|
223608410|NCT01941329|DRUG|Intravitreous injection of ranibizumab|
223608411|NCT01582620|PROCEDURE|Telestroke|remote videoconference consultations
223608412|NCT04585204|DIAGNOSTIC_TEST|Oral glucose tolerance test|Oral glucose tolerance test
223608413|NCT04829149|OTHER|Observational|Statin therapy group and Rosuzet tablet group
223608414|NCT00242541|DRUG|Octreotide acetate|
223755081|NCT05530096|DIAGNOSTIC_TEST|Standard of care|Participants will not receive any intervention in this study. Participants will receive standard of care therapy
223755082|NCT04471844|DEVICE|Optune®|"Optune® is a commercial, portable, battery-operated device intended for continuous home use, which delivers TTFields at a frequency of 200kHz to the brain by means of insulated transducer arrays. The Optune® device produces electric forces intended to disrupt cancer cell division.~In treatment arm I, the patient starts Optune® concurrently with RT/TMZ for 6 weeks, followed by Optune® + TMZ until second disease progression.~In treatment arm II, the patient starts RT/TMZ for 6 weeks, followed by Optune® + TMZ until second disease progression."
223755083|NCT06448403|DEVICE|MRI Scanning|MRI scanning with volumetric, resting and activity-based sequences.
223755084|NCT06448403|DEVICE|64-channel EEG|EEG to quantifiy electric activity.
223755085|NCT06448403|DEVICE|Polysomnography|A randomized group will undergo polysomnography.
223608415|NCT00165178|DRUG|prednisone|Induction Phase: Given orally or intravenously Days 0-28 Intensification Phase: Given orally Days 1-5 of each cycle Continuation Phase: Given orally Days 1-5 of each cycle
223755086|NCT06448403|BIOLOGICAL|Blood samples|Analysis of specific blood biomarkers.
223755087|NCT06448403|BIOLOGICAL|Fecal samples|Analysis of bacterial composition.
223755088|NCT06448403|BEHAVIORAL|Cognitive tests|Interview-based cognitive tests for assesment of cognitive levels.
224311616|NCT06370286|BEHAVIORAL|concurrent exercise (CE)|Participants in the concurrent exercise group engaged in 12-minutes of aerobic exercise (40%-59% of heart rate reserve \[HRR\]) coupled with 13-minutes of resistance exercise (1 set, with 75% of 10-repetition maximum, and 12 repetitions of 8 movements). Prior to and following exercise onset, participants completed a 5-minute warm-up and cool-down.
223608416|NCT00165178|DRUG|dexamethasone|Intensification Phase: Given orally days 1-5 of each cycle Continuation Phase: Given orally days 1-5 pf each cycle
223608417|NCT00165178|DRUG|doxorubicin|Induction Phase: Intravenously on Days 0,1 Intensification Phase: Intravenously on Day 1 of each cycle
223608418|NCT00165178|DRUG|E. coli asparaginase|Intensification Phase: In the muscle weekly. Dose will vary
223608419|NCT00165178|DRUG|vincristine|Induction: Intravenously on days 0, 7, 14, 21 MLL Intensification Phase: Intravenously on Days 1, 8, 15, 22 CNS Therapy: Intravenously on Day 1 Intensification Phase: Intravenously on day 1 of each cycle Continuation Phase: Intravenously on Day 1 of each cycle
223608420|NCT00165178|DRUG|methotrexate|Induction: Intravenously on Day 2 MLL Intensification: Intravenously on Days 1, 8 Intensification: (when doxorubicin completed) Intravenously or into the muscle weekly Continuation: Intravenously or into the muscle weekly
223608421|NCT00165178|DRUG|Leucovorin|Induction Phase: Intravenously or orally begins 36 hours after methotrexate MLL Intensification: Intravenously or orally begins 36 hours after methotrexate
223608422|NCT00165178|DRUG|Asparaginase|Induction: Into the muscle on Day 4 MLL Intensification: Into the muscle on Days 16, 23
223755089|NCT01171131|OTHER|Blood/saliva sampling|one-time blood sample (\~ 1 TBS) and saliva sample (\~ 1 tsp)
223755090|NCT04884685|BIOLOGICAL|SARS-CoV-2 Inactivated Vaccine|600SU inactivated virus in 0·5 mL of aluminium hydroxide solution per injection
223755091|NCT04884685|BIOLOGICAL|Placebo|aluminium hydroxide solution only
223755092|NCT02902510|OTHER|Therapeutic yoga for people with Parkinson's Disease|Held for 8 weeks, individuals participated in therapeutic yoga 60 minutes 2x/week.
223608423|NCT00165178|DRUG|cytarabine|Induction: Intrathecal on Days 0, 14, 28 MLL Intensification: Intravenously on Days 15, 16, 22, 23
223608424|NCT00165178|DRUG|Methotrexate/Hydrocortisone|Induction: Intrathecal on Days 14, 28 MLL Intensification: Intrathecal on Days 2,9
223608425|NCT00587158|DRUG|Paricalcitol|Zemplar® - this medicine, which is the medicine being studied, will be given as a capsule containing 1 microgram of Zemplar® once daily beginning the day after the transplant. It will be continued at the same dose for the first two weeks then, depending on the results of blood and urine testing, will be increased to 2 micrograms daily. The dose will remain at 2 micrograms daily until the end of the study unless there is a medical reason to reduce or stop it or unless the study is stopped early.
223608426|NCT00587158|OTHER|Corticosteroid Avoidance Immune Suppression Protocol|Induction with Alemtuzumab and maintenance with Tacrolimus and Mycophenolate Mofetil. With standard antimicrobial prophylaxis and calcium supplementation.
223608427|NCT05590585|DRUG|dupilumab|Administered by subcutaneous (SC) injection once every 2 weeks (Q2W) following a loading dose
223755093|NCT06074380|DRUG|MIST surfactant|Surfactant will be given via MIST while neonate is on CPAP
223755094|NCT06537882|DIETARY_SUPPLEMENT|G-NiiB synbiotics formula (SLP07)|SLP07 consists of a blend of food-grade Bifidobacterium and Lactobacillus as active probiotics, omega 3, and vitamin E.
223755095|NCT06537882|DIETARY_SUPPLEMENT|Active placebo|Active placebo contains 2mg of vitamin C with corn starch filler
223755096|NCT02225522|OTHER|Rapid whole genome sequencing (StatSeq)|Patients in this arm will received standard genetic testing, the Perkins Elmer StepOne expanded newborn screen and the rapid whole genome sequencing (StatSeq). the receipt of the StatSeq testing is the different factor between arms. the standard genetic testing includes any testing that is clinically available to the attending physician that would normally be ordered for the patient if not enrolled in this study.
223608428|NCT05590585|OTHER|Topical emollient (moisturizer)|Moisturizer should be applied twice daily, as per physician's recommendation, as defined in protocol.
223608429|NCT06436118|BEHAVIORAL|RELAX® glasses|Glasses which are a solution of audiovisual sedation by positive distraction for hospital medical use.
223608430|NCT03714724|DIAGNOSTIC_TEST|Intraabdominal Pressure Measurement|In this method, a sterile set system (AbViser- Wolfe Tory Medical, Saik Lake City, Utah, USA) was used in normal conditions. Measurements will be made in 20 ml saline was given, Pressure transducer was used as a reset point pubic symphysis and intra-abdominal pressure was measured.
223608431|NCT02402582|OTHER|Family-centered empowerment model|FCEM and Control groups had similar inpatient care. Patients in the intervention group received care employing the FCEM in four stages. Stage 1: Awareness and cognition. During 3-5 group sessions they were evaluated for their insight into their perceived illness severity and perceived sensitivity, or the degree to which they felt threatened by their illness. Stage 2: Expectations. 3-5 sessions. Stage 3: Acceptance. Assessed using an educational participation method in group discussion. Stage 4: Formative summative evaluations. The formative evaluation encourages patients to internalize their locus of control by seeing his/her self-empowerment (increasing self-responsibility about their health). Summative evaluations were performed to evaluate the influence of the intervention on HRQoL dimensions, perceived stress and anxiety -- assessed at baseline and at 3 months post-intervention. Empowerment was measured at baseline and at 10 days post-intervention by deploying FCEM questionnaires.
223608432|NCT02402582|OTHER|Control|FCEM and Control groups had similar inpatient care. Upon discharge the Control group underwent routine care and follow-up.
223608433|NCT02139072|DEVICE|CoaguChek XS|CoaguChek XS will be used to measure INR in patients with APL
223608434|NCT02139072|PROCEDURE|Standard Lab Draw|Patients on warfarin for any indication other than APL will measure INR by venous lab draw
223608435|NCT04120415|BIOLOGICAL|Vaccine and vedolizumab (Entyvio)|"Vaccine and vedolizumab infusion (Entyvio):~0.5ml of MVA HIV-B (1 x 108 pfu/ml) will be administered intramuscularly in the deltoid muscle of the non-dominant upper arm at weeks 0 and 8. Participants will be observed after the injection.~Vedolizumab (300mg) is administered as an intravenous infusion (255 ml) over 30 mins in the dominant arm at weeks 10,12,16,20,24,28 and 32. After infusion, the line should be flushed with 30ml of normal saline. Participants will be observed throughout and after the infusion."
223755097|NCT05960747|OTHER|Simulation group|Specific training for medical students by using an augmented virtual reality simulator for thoracentesis
223755098|NCT05863676|PROCEDURE|Oophorectomy|Ovary will be removed for fertility preservation.
223755099|NCT05863676|DIAGNOSTIC_TEST|Infectious Disease Testing|Infectious Disease Testing will be done on participants.
223755100|NCT06505525|PROCEDURE|Extra-articular reconstruction with the Anterolateral Ligament|Anatomical ACL reconstruction combined with extra-articular reconstruction with the Anterolateral Ligament
223508657|NCT03037008|DEVICE|Perineal Sonography|In a modified lithotomy position (supine position with elevated legs), probands will get an examination of their pelvic floor by using a common ultrasound probe head on the perineum. During the examination, the bladder should be filled with around 300ml. If patient appear with empty bladder, the examination can be repeated on an other date. During the examination, the pelvic floor will be observed during rest, coughing and valsalva-maneuver. One examination takes around 30minutes. During ultrasound, we want to illustrate the urethral mobility, the bladder neck opening and the urethral angle as well as the distance from the urethra to the symphysis.
223508658|NCT01670149|DRUG|Rifaximin|Tablets
223508659|NCT01670149|DRUG|Placebo|Tablets
223508660|NCT06032715|BEHAVIORAL|BI (Brief Intervention)|Short structured individual behavioral intervention to reduce inappropriate usage of Z-hypnotics
223608436|NCT04120415|BIOLOGICAL|Placebo vaccine and vedolizumab infusion (Entyvio)|"Placebo Vaccine:~The placebo for MVA HIV-B to be used is a solution composed of S08 buffer (as for the MVA vaccine) that will be intramuscularly in the deltoid muscle of the non-dominant upper arm at weeks 0 and 8. Participants will be observed after the injection.~Vedolizumab infusion (Entyvio):~Vedolizumab (300mg) is administered as an intravenous infusion (255 ml) over 30 mins in the dominant arm at weeks 10,12,16,20,24,28 and 32. After infusion, the line should be flushed with 30ml of normal saline. Participants will be observed throughout and after the infusion."
223608437|NCT04120415|BIOLOGICAL|Placebo vaccine and placebo infusion|"Placebo Vaccine:~The placebo for MVA HIV-B to be used is a solution composed of S08 buffer (as for the MVA vaccine) that will be intramuscularly in the deltoid muscle of the non-dominant upper arm at weeks 0 and 8. Participants will be observed after the injection.~Placebo infusion (Entyvio):~255ml Sodium Chloride (NaCl) 0.9% bag administered as an intravenous infusion over 30 mins in the dominant arm at weeks 10,12,16,20,24,28 and 32. Participants will be observed throughout and after the infusion."
223608438|NCT00022802|DEVICE|Image-guided surgical system|
223608439|NCT03570814|DRUG|Administration of Albendazole on Day 1|Participants will receive Albendazole 400mg on study day 1.
223608440|NCT03570814|DRUG|Administration of Ivermectin on Day 1|Participants will receive Ivermectin 150mcg/kg (max 12mg) on study day 1. Doses of Ivermectin will be determined using a standard dosing pole.
223755101|NCT03149692|OTHER|Penile allograft transplantation|Proof of concept of surgical procedure
223755102|NCT01226381|DRUG|Von Frey electronic|This protocol is based on a study of the interaction setron / paracetamol at 4 different levels of plasma concentrations, by repeating the tests at set intervals, while concentrations of setrons down gradually (half-life of 8 to 10 am ) after a single administration. In addition, the interindividual variability of the effects of paracetamol will be studied, and linking with certain genetic polymorphisms reported by the subjects tested
223608441|NCT03570814|DRUG|Administration of Azithromycin on Day 1|Participants will receive Azithromycin 20mg/kg (max 1gm) on study day 1. Doses of Azithromycin will be determined using a standard dosing pole.
223755103|NCT00003679|DRUG|cyclophosphamide|
223755104|NCT00003679|DRUG|docetaxel|
223755105|NCT00003679|DRUG|doxorubicin hydrochloride|
223755106|NCT00003679|DRUG|tamoxifen citrate|
223755107|NCT00003679|PROCEDURE|conventional surgery|
223755108|NCT00003679|RADIATION|radiation therapy|
223755109|NCT05133999|BIOLOGICAL|Plasma determination of iron, transferrin and ferritin|Iron, transferrin and ferritin levels in plasma
223755110|NCT05133999|OTHER|Fundus Examination by wide field digital imaging camera (PanocamTM camera)|ROP screening using wide field digital retinal imaging according to current recommendations.
223608442|NCT03570814|DRUG|Administration of Azithromycin on Day 15|Participants will receive Azithromycin 20mg/kg (max 1gm) on study day 15. Doses of Azithromycin will be determined using a standard dosing pole.
223608443|NCT02114606|DEVICE|Cytosponge™ Cell Collection Device|The Cytosponge™ Cell Collection Device (Cytosponge) is intended to collect surface cells from the esophagus. The device consists of a swallowable capsule, which dissolves in the body cavity, releasing a self-expandable sponge. The sponge is then retrieved from the esophagus using an attached cord. During the retrieval process, the sponge collects cells from the most superficial layer of the esophageal mucosa. Once removed from the body cavity, the sponge and cells are retained for investigation and/or testing. The Cytosponge™ Cell Collection Device (Cytosponge) received 510(k) clearance from the FDA on November 26, 2014 (K142695). The Cytosponge ™ Cell Collection device is a Class II product under 21 CFR 874.4710 esophagoscope (flexible or rigid) and accessories.
223608444|NCT04280055|DRUG|Psilocybin|0.14 mg/kg p.o. in three sessions spaced by one week
223608445|NCT02275663|DRUG|Azacytidine|
223608446|NCT02275663|DRUG|Fludarabine|
223608447|NCT02275663|DRUG|Cytarabine|
223608448|NCT02275663|DRUG|Filgrastim|G-CSF
223608449|NCT04355208|OTHER|(3M™ Filtek™ Universal )|universal nanofillers resin composite (3M™ Filtek™ Universal )
223608450|NCT02382445|DEVICE|Anesthesia depth monitor|
223608451|NCT02382445|DEVICE|Sham control|Standard care as usual. Bis m Standard care as usual. Bispectral index monitor is not visible for anesthesia provider.
223608452|NCT02382445|DRUG|propofol and sevoflurane|
223608453|NCT02109991|DEVICE|CG-100 device|Colorectal surgery performed per standard of care with deployment of the CG-100 device in the anastomosis site
223608454|NCT06334848|PROCEDURE|transobturator tape|Women with stress urinary incontinence are treated by transobturator tape versus mini sling
223608455|NCT02822898|DRUG|NaCl 0.9% in Glucose 5% with 40mEq Potassium|NaCl 0.9% in Glucose 5% with 40mEq Potassium, administered at 25 mL/kg IBW/h for 48h
223608456|NCT02822898|DRUG|Glucion 5%|Glucion 5% (premixed solution containing 54 mmol/L sodium and 26 mmol/L potassium amongst others), administered at 25 mL/kg IBW/h for 48h
223608457|NCT00981461|DEVICE|HairMax LaserComb|Device application 3 times week, for 26 weeks
223608458|NCT00981461|DEVICE|Control Device|Device application 3 times week, for 26 weeks
223608459|NCT03306992|BEHAVIORAL|Personalized Exercise Program|"The PEP intervention involves a combination of home-based exercise as well as in-patient exercise. The exercise modes will include basic transfer and calisthenics mobility, aerobic and resistance exercises and will be performed in various postures (supine, sitting, standing and walking) with variable challenges (level walking, bending, inclines, steps and squatting).~For patients randomized to the Intervention Group (Group 1), the PEP intervention will be personalized, implemented, and modified (based on the patients AM-PAC mobility stage) by a licensed physical therapist in face-to-face, virtual, or phone meetings (\~30-40 minutes). An exercise education manual, specifically developed for this study, will be used by the physical therapist to educate the patients on all aspects of starting and maintaining the exercise intervention."
223755111|NCT01283126|PROCEDURE|euglycemic and hypoglycemic clamp|Subjects will undergo standard euglycemic and hypoglycemic clamps, and will have concurrent assessments of cognitive function and measurement of interstitial glucose concentrations.
223755112|NCT01781442|DRUG|Temsirolimus|"The recommended dose of Torisel is 25 mg infused over a 30-60 minute period once a week.~Treatment will continue until disease progression or unacceptable toxicity.~The use and dosage recommendations for Torisel will take place on the basis of the approved local product document and will be adjusted solely according to medical and therapeutic necessity."
223755113|NCT06089486|DIAGNOSTIC_TEST|ICA|Patients will undergo annual CAV surveillance with ICA
223755114|NCT06089486|DIAGNOSTIC_TEST|PET|Patients will undergo annual CAV surveillance with PET
223755115|NCT00097721|DRUG|E7389|The first cohort of subjects were to receive E7389 1.4 mg/m\^2 as an intravenous (IV) bolus on Days 1, 8, and 15 of a 28-day cycle. A second cohort of subjects was added and were to receive E7389 1.4 mg/m\^2 as an IV bolus on Days 1 and 8 of a 21-day cycle.
223755116|NCT04927936|BIOLOGICAL|Vaccination once with Janssen vaccine (only priming)|Vaccination (priming) with janssen vaccine. There is no boosting.
223755117|NCT04927936|BIOLOGICAL|Vaccination with Janssen vaccine followed with Janssen vaccine (homologous boosting).|Vaccination (priming) with janssen vaccine. There is boosting with Janssen vaccine.
223755118|NCT04927936|BIOLOGICAL|Vaccination with Janssen vaccine followed with Moderna vaccine (heterologous boosting).|Vaccination (priming) with janssen vaccine. There is boosting with Moderna vaccine.
223608460|NCT03187119|BEHAVIORAL|Pictorial Asthma Action Plan|Participants will receive a PAAP plan, personalized to their asthma treatment. Each participant will take part in a brief education session during which their asthma provider will outline the treatment plan summarized in their PAAP.
223608461|NCT03187119|BEHAVIORAL|Written Asthma Action Plan|Participants will receive a WAAP plan, personalized to their asthma treatment. Each participant will take part in a brief education session during which their asthma provider will outline the treatment plan summarized in their WAAP.
223608462|NCT03708718|DRUG|Prednisolone 5 mg|5mg prednisolone, once a day for 6 months
223608463|NCT03708718|DRUG|Placebo oral capsule; From August 2020 'no additional treatment'|Matched placebo capsule, once a day for 6 months; From August 2020 - no additional treatment above standard of care medication
223608464|NCT01999400|DRUG|Pentasa 500 mg capsule x 2 with 240 mL water; single dose|
223608465|NCT01999400|DRUG|Apriso 375 mg capsule x 3 with 240 mL water; single dose|
223608466|NCT01999400|DRUG|Lialda 1200 mg tablet x 1 with 240 mL water; single dose|
223608467|NCT01999400|DRUG|Delzicol 100 mg mesalamine x 1 with 245 mL water; single dose|
223608468|NCT05432752|DEVICE|Concussion Pen|Device will measure the distance from the eye to the Concussion Pen for ocular motor functions.
223608469|NCT03361293|DEVICE|Active tDCS|Active Transcranial Direct Current Stimulation (tDCS) administered with a Neuroelectrics StarStim Enobio cap system (active mode)
223608470|NCT03361293|BEHAVIORAL|Cognitive training|BrainHQ Computerized cognitive training
223608471|NCT03361293|DEVICE|Sham tDCS|Sham Transcranial Direct Current Stimulation (tDCS) administered with a Neuroelectrics StarStim Enobio cap system (sham mode)
223755119|NCT04927936|BIOLOGICAL|Vaccination with Janssen vaccine followed with Pfizer vaccine (heterologous boosting).|Vaccination (priming) with janssen vaccine. There is boosting with Pfizer vaccine.
223755120|NCT03869450|DEVICE|Restylane Volyme|Hyaluronic based filler
223755121|NCT03869450|DEVICE|Restylane Defyne|Hyaluronic based filler
223755122|NCT03869450|DEVICE|Restylane Lyft Lidocaine|Hyaluronic based filler
223755123|NCT00030563|DRUG|irinotecan hydrochloride|
223755124|NCT00030563|PROCEDURE|adjuvant therapy|
223755125|NCT00030563|PROCEDURE|conventional surgery|
223755126|NCT00030563|PROCEDURE|radiofrequency ablation|
223755127|NCT02290288|PROCEDURE|vaginal surgery|
223755128|NCT02290288|PROCEDURE|laparoscopic surgery|
223755129|NCT01752855|BIOLOGICAL|New formulation adalimumab|New formulation adalimumab 40 mg every other week
223755130|NCT01478321|DRUG|Temozolomide|Given PO
223755131|NCT01478321|RADIATION|hypofractionated radiation therapy|Undergo hypofractionated radiation therapy
223755132|NCT01478321|BIOLOGICAL|bevacizumab|Given IV
223755133|NCT01478321|OTHER|questionnaire administration|Ancillary studies
223755134|NCT00014365|DRUG|MKC-1|
223755135|NCT02888548|PROCEDURE|botulinum toxins (Dysport°) alone|botulinum toxins (Dysport°) alone
223755136|NCT02888548|PROCEDURE|orthosis (Saebo Strech°) + botulinum toxins (Dysport°) combined|orthosis (Saebo Strech°) + botulinum toxins (Dysport°) combined
223755137|NCT00181207|DEVICE|pneumatic vest|
223755138|NCT00181207|OTHER|placebo pneumatic vest|
223755139|NCT00983268|DRUG|capecitabine|1000 mg taken by mouth on the days of radiation only.
223755140|NCT00983268|DRUG|vorinostat|"Vorinostat will be given by mouth on the day of radiation and then Monday-Friday for two weeks after radiation in these 4 possible doses:~* Vorinostat,at 100 mg~* Vorinostat,at 200 mg~* Vorinostat, at 300 mg~* Vorinostat, at 400 mg"
223755141|NCT00983268|RADIATION|Radiotherapy|High-dose hypofractionated radiotherapy consisting of 3000 cGy in 10 fractions, Monday-Friday for 2 weeks.
223755142|NCT00983268|PROCEDURE|Surgery to remove tumor|Patients will be assessed for resectability within six weeks of the end of chemoradiation, if resectable, surgery will be performed.
223755143|NCT02203487|DRUG|BIIF 1149 BS - single rising dose|
223755144|NCT02203487|DRUG|Placebo|
223755145|NCT00634088|DRUG|Ixabepilone, 32 mg/m^2 + Lapatinib, 1000 mg|Lapatinib, 1000 mg, administered orally, once a day, every day, for 7 to 14 consecutive days as a lead-in period prior to the first administration of ixabepilone (Day 1). Following the lapatinib lead-in phase of Cycle 1, and on Day 1 of subsequent cycles, ixabepilone, 32 mg/m\^2, administered as a 3-hour IV infusion. Lapatinib, 1000 mg, administered orally, once a day, every day, for a 21-day cycle.
223755146|NCT00634088|DRUG|Ixabepilone, 32 mg/m^2 + Lapatinib, 1250 mg|Initiated a minimum of 14 days following Day 1 of previous cohort (ixabepilone, 32 mg/m\^2 + lapatinib, 1000 mg). Lapatinib, 1250 mg, administered orally once a day, every day, for 7 to 14 consecutive days as a lead-in period prior to the first administration of ixabepilone. Following the lapatinib lead-in phase of Cycle 1, and on Day 1 of subsequent cycles, ixabepilone, 32 mg/m\^2, administered as a 3-hour IV infusion. Lapatinib administered, 1250 mg, orally, once a day, every day, for a 21-day cycle.
224311617|NCT06370286|BEHAVIORAL|aerobic exercise (AE)|Participants in the aerobic exercise (AE) group participated in 25 minutes of AE (40%-59% of heart rate reserve \[HRR\]). Prior to and following exercise onset, participants completed a 5-minute warm-up and cool-down.
224311618|NCT04020289|BEHAVIORAL|"Psychoeducational Program BalancingMySwing"|"Patients in the intervention arm will receive a nurse-lid 8-session psychoeducational 'BalancingMySwing group psychotherapy"
224311619|NCT06404658|PROCEDURE|Genicular nerve block|patients who receive Genicular nerve block with spinal anathesia .
224311620|NCT03610516|DRUG|CFZ533|Multiple doses of 10 mg/kg CFZ533 intravenous (IV) infusion. CFZ533 was administered every 4 weeks (Q4W; from Day 1 to Day 141), plus an additional dose of 10 mg/kg IV at Day 15, resulting in a Q2W loading regimen up to the third dose on Day 29.
223755147|NCT00634088|DRUG|Ixabepilone, 40 mg/m^2 + Lapatinib, 1250 mg|Initiated a minimum of 14 days following Day 1 of previous cohort (ixabepilone, 32 mg/m\^2 + lapatinib, 1250 mg). Lapatinib, 1250 mg, administered orally once a day, every day, for 7 to 14 consecutive days as a lead-in period prior to the first administration of ixabepilone. Following the lapatinib lead-in phase of Cycle 1, and on Day 1 of subsequent cycles, ixabepilone, 40 mg/m\^2, administered as a 3-hour IV infusion. Lapatinib, 1250 mg, administered orally, once a day, every day, for a 21-day cycle.
223755148|NCT00634088|DRUG|Ixabepilone + Lapatinib + Capecitabine|Planned escalating doses of the triplet combination of ixabepilone, lapatinib, and capecitabine. No participants were enrolled in this arm due to premature termination of the study.
223755149|NCT05360563|OTHER|Home-based physical training|Patients allocated to this group will participate in a 16-week home-based physical training program, structured in three weekly sessions of aerobic and muscle strengthening exercises (which also have components that stimulate flexibility and balance). A third of the weekly physical training sessions will be supervised via telemedicine (with video call) by a clinical exercise specialist, but all patients will have illustrated exercise booklets and a full-time remote support service available for the remaining sessions (via text or voice messages).
223755150|NCT01578928|DRUG|SOM230|
223755151|NCT01110421|DRUG|Cefepime placebo|Form=solution for infusion, Route=intravenous use, administered once every 8 hours infused over 30 minutes immediately before each iv infusion of doripenem for up to 14 days
223755152|NCT01110421|DRUG|Cefepime|Type=once every 8 hours, Unit=mg, Number=50 mg/kg up to 2g/dose, Form=solution for infusion, Route=intravenous use. At least 3 days of iv cefepime administered every 8 hours infused over 30 minutes immediately before each iv infusion of doripenem placebo for up to 14 days
223755153|NCT01110421|DRUG|Doripenem|Type=once every 8 hours infused over 60 minutes, Unit=mg, Number=20mg/kg up to 500mg/dose, Form=solution for infusion, Route=intravenous use. At least 3 days of iv doripenem administered every 8 hours immediately after each iv infusion of cefepime placebo for up to 14 days
223755154|NCT01110421|DRUG|Doripenem placebo|Form=solution for infusion, Route=intravenous use, administered once every 8 hours infused over 60 minutes immediately following each iv infusion of cefepime for up to 14 days
224311621|NCT03610516|DRUG|Placebo|multiple doses of placebo intravenous infusion
223608472|NCT01994616|PROCEDURE|Intralesional cryotherapy|Intralesional (IL) cryotherapy is a treatment for keloids and hypertrophic scars, in which the scar is frozen from inside with the use of a cryoneedle
223608473|NCT01657175|OTHER|Supportive care|"The patients will be randomized to control or supportive care groups.~The control group will be given care as usual wich include clinical follow-ups at the surgical department.~The supportive care group get in addition to the clinical follow-ups a supportive care programme including:~* Discharge information about surgery and life after surgery together with their relatives.~* Active telephone contacts 1/week th first month the 2/month up to six month after discharge by a specialized nurs.~* Open telephone line were the patients can call the nursed ruing daytime. Discharge: approximately 2-4 weeks after surgery"
223608474|NCT01910402|DRUG|Dolutegravir/abacavir/lamivudine FDC|Dolutegravir/abacavir/lamivudine FDC tablets, 50 mg/600 mg/300 mg
223608475|NCT01910402|DRUG|Atazanavir|Atazanavir capsule 300 mg
223755155|NCT01110421|DRUG|Amoxicillin/clavulanate potassium|Form=suspension or tablets, Route=oral (by mouth), may be administered at the discretion of the investigator once every 12 hours for up to 14 days following IV therapy with doripenem or cefepime.
223755156|NCT01733914|PROCEDURE|Acupuncture|Acupuncture in the following acupoints on the contralateral side of pain site: Jiantong, Zhongzhu, Houxi, and Quchi. The patient will receive 5 treatments (each lasts 30 min) per week for four weeks.
223755157|NCT01733914|OTHER|Control|Patients in the waiting list group received conventional orthopaedic therapy including physical exercise, heat or cold therapy. 50 mg diclofenac daily could be taken when the patient suffered from the pain. Injections or cortisone applications of any kind were not allowed.
223755158|NCT01203072|DRUG|DU-176b|DU-176b 5mg tablets oral, once daily for 2 weeks
223755159|NCT01203072|DRUG|DU-176b|DU-176b 15mg tablets, oral once daily for 2 weeks
224311622|NCT05169450|DRUG|Diterpene ginkgolides meglumine injection|Patients will receive intravenously administered diterpene ginkgolides meglumine injection, combined with guidelines-based standard care.
223608476|NCT01910402|DRUG|Ritonavir|Ritonavir tablet 100 mg
223608477|NCT01910402|DRUG|Tenofovir/emtricitabine FDC|Tenofovir/emtricitabine FDC tablet 300 mg/200 mg of FTC
223608478|NCT01466127|DRUG|Oxytocin|Liquid metered-dose nasal spray, 30 IUs, administered once.
223608479|NCT01466127|DRUG|Placebo|Matched nasal spray placebo
223608480|NCT03610841|DIAGNOSTIC_TEST|preterm labor|liver function tests, kidney function tests and platelets measures the ratio of protein to creatinine
223608481|NCT03610841|DIAGNOSTIC_TEST|healthy|liver function tests, kidney function tests and platelets measures the ratio of protein to creatinine
223608482|NCT00483405|BIOLOGICAL|cetuximab|250 mg/m2, intravenously, once per week
223608483|NCT00483405|DRUG|capecitabine|850 mg/m2, orally, twice daily (dose rounded to accommodate 150 mg and 500 mg tablet sizes. Capecitabine given on days 1-14 of 21 day cycle.
223608484|NCT00483405|DRUG|oxaliplatin|130 mg/m2, intravenously on Day 1 of each 21 day cycle
223608485|NCT05527444|DRUG|Secukinumab 150 mg/ml|Secukinumab 150 mg will be administered at Baseline, Week 1, 2, 3, 4, 6, 8 followed by dosing every 4 weeks until Week 24
223608486|NCT05527444|DRUG|Adalimumab Ab|adalimumab biosimilar 40 mg will be administered at Baseline followed by dosing every 2 weeks until Week 24
223608487|NCT05527444|DRUG|NSAID|stable dose
223608488|NCT05527444|DRUG|Thalidomide Pill|If patients have inadequate response to bioagents, thalidomide 50 mg will be administered at 12 week followed by dosing everyday until Week 24.
223608489|NCT06198387|RADIATION|hormone and RT|The patients will receive a two-year course of androgen deprivation therapy (ADT) in combination with abiraterone, along with synchronous metastasis-directed radiation and prostate radiotherapy(RT).
223608490|NCT06198387|DRUG|ADT combined with abiraterone|The patients will receive a two-year course of ADT combined with abiraterone.
223755160|NCT01203072|DRUG|DU-176b|DU-176b 30 mg tablets, oral, once daily for 2 weeks
223755161|NCT01203072|DRUG|DU-176b|DU-176b 60 mg tablets, oral, once daily for 2 weeks
223755162|NCT01203072|DRUG|Placebo|Matching placebo oral tablets, once daily for 2 weeks
224311623|NCT05169450|DRUG|Ginaton|Patients will receive intravenously administered Ginaton, combined with guidelines-based standard care.
223608491|NCT00571038|BEHAVIORAL|Peer Led|Post provided with blood pressure cuffs, pedometers and scale. Two post members trained as peer leaders who encourage post members to take positive steps to improve BP. Peer leader training involves 20 hours of training over 12 months, telephone/email access to clinical experts and educational materials to share with post members.
223608492|NCT00571038|BEHAVIORAL|Seminar|Post provided with blood pressure cuffs, pedometers and scale. Post members, including study participants invited to didactic sessions on cardiovascular health.
223608493|NCT01062152|DRUG|Ezatiostat Hydrochloride|Starting dose 2000 mg orally in divided doses twice daily (1000 mg in AM \& 1000 mg in PM) x 21 days with one week off therapy in a 4-week cycle.
223608494|NCT01062152|DRUG|Lenalidomide (Revlimid®)|10 mg orally per day in one AM dose x 21 days with one week off therapy in a 4-week cycle.
223608495|NCT03325842|DIAGNOSTIC_TEST|ASKp|30 items questionnaire
223755163|NCT03951246|OTHER|Cognitive and Motor Training|"In the first phase of the trial, all participants (patients and healthy children) will complete cognitive and motor functions assessment.~Then the sample of patients who have cognitive/motor impairment will be randomized to an either Intervention or Control group.~In the second phase of the trial, survivors in the Intervention Group will receive 6 sessions of cognitive and motor training during two weeks, and survivors in Control Group will undergo …..~After this treatment phase, motor and cognitive functions assessment will be conducted in all patients once again.~In the third phase, the Control Group will be provided the active intervention (i.e. 6 sessions of cognitive and motor training during two weeks), while the Intervention Group engages in passive reading.~After this, motor and cognitive functions assessment will be carried out in all patients once again."
223755164|NCT02153944|DRUG|Propranolol|Propranolol 40 mg was given orally during study visit
224311624|NCT00293943|PROCEDURE|Pulmonary vein ablation|
224311625|NCT04385303|DRUG|Lorecivivint|One intra-articular injection of 0.07 mg lorecivivint in 2 m vehicle
224311626|NCT04385303|DRUG|Placebo|One intra-articular injection of 0 mg lorecivivint in 2 m vehicle
224311627|NCT03038841|DEVICE|Mobile Health|Patients discharged from hospital will be equipped with a tracking bracelet and a smart phone
223608496|NCT02362750|OTHER|Organizational Interview|Survivorship program leaders will participate in a phone-based organizational interview regarding the organization of the clinical survivorship care program.
223608497|NCT02362750|OTHER|Organizational Survey|Survivorship program leaders will participate in a brief web-based organizational survey regarding the organization of the clinical survivorship care program.
223508661|NCT06651190|OTHER|Pain Caregiver Resource (PainCaRe)|The purpose of the PainCaRe mobile health app is to support parents of young children with cancer (between the ages of 2-11 years) to manage their cancer-related pain at home. The app will ask caregivers to completed a brief 6-question pain assessment once daily and complete ad hoc assessments as needed. Based on the results of the pain assessment, real-time, evidence-based pain management suggestions, including will be provided to parents. The purpose of the pilot randomized controlled trial (RCT) is to evaluate the feasibility of implementing PainCaRe in a future RCT. Please find attached the study protocol for reference.
223508662|NCT05720520|OTHER|Technological education method|Students in the experimental group will play the mobile application developed for stoma and peristomal skin care and are expected to learn the skill in this way. The students in the control group, on the other hand, will learn stoma and peristomal skin care on a model in the traditional skill laboratory and are expected to learn the skill in this way. Afterwards, the knowledge and skill scores of the two groups will be compared and the results will be reported.
223508663|NCT03968003|DIETARY_SUPPLEMENT|Inulin|The intervention group (group A) consumed 10 g of inulin extracted from Thai Jerusalem artichoke by our patent technique (Patent no. 15858) administered once daily before dinner. The placebo group (group B) received isocaloric maltodextrin, while the dietary fiber advice group (group C) received guidance based on age-appropriate intake recommendations.
223508664|NCT01775709|DEVICE|PE tube with Duckbill Valve|PE tube with Duckbill Valve
223508665|NCT05694637|BEHAVIORAL|Screening, Brief Intervention and Referral to Treatment (SBIRT) intervention consisting of the 5As, (Ask, Advise, Assess, Assist, Arrange)|"Trained LHWs will oversee the screening and brief intervention procedures (i.e., the 5As). A culturally acceptable standardized form will be integrated into intake procedures within the HIV that will allow for the documentation and results of using the 5As. The first A will be the screening question where the LHW will Ask study participants about smoking. When a participant reports being a smoker, the LHW will proceed to the next 3 As (Advise, Assess, Assist). These 3As will constitute the brief intervention. The LHW will utilize motivational enhancing discussion between the study participant with a focus on increasing insight and awareness regarding smoking and motivation toward behavioral change. For those participants who are motivated for treatment, a referral will be made to a clinic nurse practitioner for evaluation for treatment with varenicline."
223508666|NCT05694637|DRUG|Varenicline|Referral to treatment with varenicline will be provided to those identified as needing more than a brief intervention. Participants will initiate medication treatment with varenicline for smoking cessation with a quit date scheduled for day 8 following first study dose of the medication. Participants will meet with the study clinician at baseline who will provide medical clearance and sign off on prescription orders. All medication will be provided to participants by the study team. Participants will receive a weekly supply of medication for the first four weeks to ensure proper dosing and monitor for adverse events. For the subsequent 8 weeks, participants will return every 4 weeks to receive the next month's supply of medication. Dosage adjustments will be permitted in an effort to control adverse effects throughout the trial. This will allow us to balance internal validity with good clinical practice. Varenicline will be dosed in accordance with package labeling.
223508667|NCT04304703|DEVICE|WHOOP strap 3.0|WHOOP strap 3.0, a photodiode-based device that tracks sleep, resting heart rate, and heart rate variability.
223508668|NCT00536614|GENETIC|cetuximab|Cetuximab is an EGFR antibody inhibitor; it has been shown to increase the activity of gemcitabine (GEM) in advanced pancreatic cancer.
223508669|NCT01765998|DRUG|Probiotic|Clinical evaluation according to the Crohn's activity scale
223508670|NCT01765998|DRUG|Placebo|
223508671|NCT05265676|DRUG|Enoxaparin Sodium (Venus Remedies Limited)|The test drug is enoxaparin sodium pre-filled syringe 40 mg/0.4mL of Venus Remedies Limited, India
223508672|NCT05265676|DRUG|Enoxaparin Sodium (Sanofi)|The reference drug is enoxaparin sodium pre-filled syringe 40 mg/0.4mL of Sanofi, Germany
223508673|NCT03402412|OTHER|narrow-band UVB|Standard established treatment for atopic dermatitis with narrow-band UVB will be used in this study but initially only on a small amount of skin to assess what changes takes place in the skin.
223508674|NCT02978768|OTHER|Exercise|First year, the investigators investigate the effect of 12-week Tai Chi 6-Form accompanied with music rhythm for patients with mild and moderate AD in behavioral and general health, functional and cognitive decline.
223508675|NCT02978768|DEVICE|Computer-based cognitive training|Second year, the investigators investigate the effect of 12-week computer-based cognitive training games for patients with mild and moderate AD in behavioral and general health, functional and cognitive decline.
223508676|NCT02978768|DEVICE|Physico-Mental rehabilitation Wii|Third year, the investigators investigate the effect of 12-week Physico-Mental rehabilitation Wii (PM Wii) for patients with mild and moderate AD in behavioral and general health, functional and cognitive decline.
223508677|NCT02939664|DEVICE|Banded (with polypropylene mesh) gastric bypass|The patient will be submitted to a Laparoscopic Roux-en-Y banded gastric bypass at the time of the operation, with a polypropylene mesh around the gastric pouch.
223508678|NCT02939664|PROCEDURE|Gastric bypass|In this case a simplified conventional gastric bypass will be performed
223608498|NCT02362750|OTHER|Survivor Survey (1): Pre-Visit Baseline|Survivors will participate in a baseline survey regarding their satisfaction, health-related quality of life, ability to manage their cancer post-treatment and appropriate health care utilization.
223608499|NCT02362750|OTHER|Survivor Survey (2): Post-Visit|Survivors will participate in a survey within one week after their survivorship visit regarding their satisfaction, health-related quality of life, ability to manage their cancer post-treatment and appropriate health care utilization.
223608500|NCT02362750|OTHER|Survivor Survey (3): 3 Month Post-Visit|Survivors will participate in a survey three months after their survivorship visit regarding their satisfaction, health-related quality of life, ability to manage their cancer post-treatment and appropriate health care utilization.
223755165|NCT02153944|DRUG|Methylphenidate|Methylphenidate 20mg was given orally during study visit
223755166|NCT02153944|DRUG|Placebo|Placebo was given orally during study visit
223755167|NCT03101475|DRUG|Durvalumab (MEDI4736)|Durvalumab (MEDI4736) 1500mg Q4W in combination with tremelimumab for up to 4 doses/cycles, followed by durvalumab (MEDI4736) 1500mg Q4W for up to a maximum of 8 months with the last administration on week 48 unless there is unacceptable toxicity.
223755168|NCT03101475|DRUG|Tremelimumab|Tremelimumab (75 mg IV Q4W) in combination with durvalumab (MEDI4736) (1500mg Q4W) for up to 4 doses/cycles
223508679|NCT01951027|DRUG|GX-G3 12.5 μg/kg or Placebo|Single SC injection
223508680|NCT01951027|DRUG|GX-G3 25 μg/kg or Placebo|Single SC injection
223508681|NCT01951027|DRUG|GX-G3 50 μg/kg or Placebo|Single SC injection
223508682|NCT01951027|DRUG|GX-G3 100 μg/kg or Placebo|Single SC injection
223508683|NCT00053742|DRUG|Modified Vaccinia Virus Ankara TBC-MVA|
223508684|NCT00062504|DRUG|Talampanel|10mg, 25 mg, 35 mg, 50 mg, 75mg TID for 3 weeks
223508685|NCT02208622|DIETARY_SUPPLEMENT|Study 1: Whey Supplement Day 1|Whey supplement was given on day 1, control diet on day 2
223508686|NCT02208622|DIETARY_SUPPLEMENT|Study 1: Whey Supplement Day 2|Control diet was given day 1, whey supplement was given day 2
223508687|NCT02208622|DIETARY_SUPPLEMENT|Study 2: Whey Supplement|Whey supplement was given as part of diet for both day 1 and 2 of study
223508688|NCT04616352|OTHER|Resistance to cefuroxime|Non susceptibility in vitro testing
223508689|NCT00670384|BIOLOGICAL|Standardized Allergenic Extract, Short Ragweed (Ambrosia artemisiifolia)|Sublingual drops
223508690|NCT00670384|BIOLOGICAL|Placebo|Sublingual drops
223508691|NCT00033345|DRUG|Indole-3-carbinol|400 mg pill taken daily
223508692|NCT00033345|DRUG|Indole-3-carbinol|800 mg pill taken daily
223608501|NCT02362750|OTHER|Survivor Survey (4): 6 Month Post-Visit|Survivors will participate in a survey six months after their survivorship visit regarding their satisfaction, health-related quality of life, ability to manage their cancer post-treatment and appropriate health care utilization.
223608502|NCT02362750|OTHER|Clinician Survey|Survivorship program clinicians will complete a survey for each survivor who enrolls in the study indicating services provided through the survivorship visit.
223608503|NCT02960607|DRUG|Icotinib|Icotinib (250mg tid) until disease progression or unacceptable toxicities occurred.
223608504|NCT01952236|BEHAVIORAL|Web+Mobile|We propose to evaluate the efficacy and acceptability of a Web+Mobile tobacco cessation intervention in a 2-arm Randomized Controlled Trial with 1,271 adult study participants who agree to quit smoking within a pre-specified amount of time. Participants who meet eligibility criteria will be randomly assigned to either (a) an enhanced Web Only intervention or (b) an enhanced Web+Mobile intervention.
223608505|NCT01952236|BEHAVIORAL|Web Only|A Web-based PC-delivered best practices smoking cessation intervention.
223608506|NCT00200720|BEHAVIORAL|Atkins diet (low carbohydrate diet)|
223508693|NCT00033345|OTHER|Placebo|Placebo pill taken daily during run-in period
223508694|NCT01026038|BIOLOGICAL|13-valent pneumococcal conjugate vaccine|All subjects will receive 1 dose (0.5 mL), IM of 13vPnC vaccine. (at least 24 months after toddler dose).
223508695|NCT03360669|OTHER|Sequence: Clinical/Research|Participants will be assigned to a sequence of: research visit first/clinical visit second.
223508696|NCT03360669|OTHER|Sequence: Research/Clinical|Participants will be assigned to a sequence of: clinical visit first/research visit second.
223508697|NCT05587153|OTHER|perfusion index in all parturient recruited for the study|Using perfusion index and positional hemodynamic changes for the prediction of postspinal hypotension in all parturient recruited for the study
223508698|NCT03601052|DRUG|Remlarsen|Intradermal injection at site of one excisional wound
223508699|NCT03601052|DRUG|Placebo|Intradermal injection at site of second excisional wound
223508700|NCT01402466|BEHAVIORAL|Standard Referral|Participants randomized to this arm will be referred to local HIV care resources
223508701|NCT01402466|BEHAVIORAL|Project Bridge|Arm 2
223508702|NCT05122819|PROCEDURE|Mandibular Molar Extraction Under Local Anesthesia|"Local Anaesthetic to be used: 2% Lidocaine in 1.8 ml cartridge (regularly used for dental anaesthesia regardless of the technique).~Pain on injection and local anaesthesia success will be checked by using numeric pain rating scale (NPRS)."
223508703|NCT02509702|BEHAVIORAL|Connected to Care|10 health educative SMSs' sent once a month 5 SMS-reminders for follow-up appointment sent on days -14, -7, -1 pre- follow-up appointment, and +1, +7 post follow-up appointment
223508704|NCT03432689|DEVICE|Transcranial Magnetic Stimulation|Single-pulse transcranial magnetic stimulation and theta-burst stimulation
223508705|NCT03432689|DRUG|Cycloserine|Cycloserine 100mg
223508706|NCT03432689|DRUG|Placebo Oral Tablet|Placebo capsule matched to cycloserine capsule
223508707|NCT01113957|DRUG|ABT-888|Arm-A subjects will be given ABT-888 on Days 1 -7 every 28 days orally
223508708|NCT01113957|DRUG|pegylated liposomal doxorubicin|Arm B subjects randomized to pegylated liposomal doxorubicin on Day 1, every 28 days intravenously.
223608507|NCT00200720|BEHAVIORAL|DASH diet (high carbohydrate diet)|
223755169|NCT03101475|RADIATION|Sterotactic body radiation therapy (SBRT)|delivered in 3 fractions of 10 Gy over 1 week starting 8 to 14 days after first dose of immunotherapy
223755170|NCT03101475|OTHER|Radiofrequency ablation (RFA)|performed percutaneously under CT, MRI or sonographic guidance 8 to 14 days after start of immunotherapy
223755171|NCT05301205|DRUG|oral gabapentin|will be received oral gabapentin capsule 2 HOURS pre-operatively.
223755172|NCT04122482|BEHAVIORAL|Psychoeducation Course|The investigators are assessing the efficacy of the accommodations course. Specifically, the investigators will evaluate the impact on requesting and receiving accommodations for anxiety and/or depression, employee knowledge of accommodations, and employee self-stigmatizing attitudes. The investigators will also assess if the course helps improve comfort level of disclosing a mental health diagnosis and rates of disclosure in the workplace.
223755173|NCT04054687|DRUG|Tranexamic Acid|Enrolled patients will be placed in one of two groups: either the group receiving a cotton pledget soaked in (0.9%) saline or (100mg/1mL) TXA. Patients will initially be asked to gently blow their nose to remove any clots. Group 1 will receive the saline soaked pledget. After fifteen minutes the pledget will be removed. If patient continues to bleed within a reevaluation period of fifteen minutes, this will be deemed a 'failure' and the examiner will pack the nose with the method of his or her choice. Group 2 will receive the TXA soaked pledget and the procedure will continue like Group 1.
223508709|NCT01113957|DRUG|temozolomide|Arm A subjects will be given temozolomide on days 1-5 every 28 days orally with ABT-888
223508710|NCT01249443|DRUG|vorinostat|Given PO
223508711|NCT01249443|OTHER|diagnostic laboratory biomarker analysis|Correlative studies
223508712|NCT01249443|OTHER|pharmacological study|Correlative studies
223508713|NCT01249443|DRUG|carboplatin|Given IV
223508714|NCT01249443|DRUG|paclitaxel|Given IV
223508715|NCT03790969|DEVICE|26 gauge needle|smaller gauge needle
223508716|NCT03790969|DEVICE|23 gauge needle|control group
223508717|NCT03297827|OTHER|Serum and Urine measurement of cytokines.|To evaluate serum cytokine levels and identifying serum inflammatory markers (serum interleukin-33, IL-37, IL-36, IL-4, IL-6, IL-10, IL-17, IL-23, IL-1, TNF, PDGF, VEGFM TNFa, ANNULIN, MMP-9, MMP-12, NFk-B levels plus metabolic products like MPO, etc and glial factors like GMF, SI000B, GM6001) in patients with acute ischemic \& hemorrhagic stroke.
223508718|NCT05873621|PROCEDURE|ICG-guided lymphadenectomy|Excision of ICG-fluorescent lymph nodes in addition to standard laparoscopic total mesorectal excision in rectal cancer patients after neoadjuvant chemoradiation
223508719|NCT04833608|DEVICE|Vktory insoles|Patients were randomized into either the Carbon fiber insole group or Morton's extension group.
223508720|NCT04833608|DEVICE|Morton's extension insoles|Patients were randomized into either the Vktory carbon fiber insole group or Morton's extension insole group.
223508721|NCT03053999|OTHER|Genome Sequencing|Analyses includes genome sequencing based analysis to identify novel germline variations in blood DNAs and somatic changes in tumor DNAs, which may contribute to the development of pancreatic tumors.
223508722|NCT03053999|OTHER|Data Review|Clinical information retrieved from the patients' medical record including: de-identified demographic data (age, gender, race/ethnicity), medical history, family history, disease status, treatment response, survival information, and selected clinical data from medical record (calcium levels, calcitonin levels).
223508723|NCT04947280|RADIATION|Fractionated Stereotatic Radiation Therapy|Participants prescribed to receive 9 Gy x 3 or 10 Gy x3 image-guided fractionated stereotatic radiation therapy.
223508724|NCT06376227|PROCEDURE|with or without Left Colic Artery Preservation|low ligation (LL) which with preservation of LCA and high ligation (HL) which without preservation of LCA
223508725|NCT02470767|DRUG|Direct Oral Anticoagulant (DOAC)|Treatment pattern following the summary of product characteristics
223508726|NCT00408915|DRUG|Continuous Subcutaneous Lisuride Infusion|
223508727|NCT03667729|BEHAVIORAL|progressive muscle relaxation|intervention group: The experimental group received muscle relaxation training once a week for 3 consecutive months. The results were measured and followed up after 3 months.
223508728|NCT00295243|DRUG|Topotecan|
223608508|NCT03636126|DEVICE|VR + TACS|TACS- A regulated class of transcranial alternating current stimulation (tACS), called Cranial Electrotherapy Stimulation (CES) by Fisher Wallace Laboratories (FWL) is FDA-Cleared to treat depression, anxiety, and insomnia (Proof of FDA clearance and 510k provided in the appendix). FWL tACS delivers weak non-invasive electrical stimulation (1-4 milliamps at 15, 500, and 15,000 Hz) to the frontal/temporal brain regions by electrodes placed above the temples. Land's End Virtual Reality Game Meta-analyses show Virtual Reality (VR) is an effective non-pharmacological method that reduces obstacles to human performance such as pain, insomnia, anxiety, sleep deprivation, and a variety of other stress responses.
223608509|NCT01550757|BEHAVIORAL|Embedded Peer Mentor|This intervention/condition consists of a formerly homeless individual embedded in the PACT or H-PACT clinic team. This person is responsible for community-based follow-up for homeless patients randomly assigned to him or her. In addition to structured, scheduled meetings with assigned study subjects, the peer mentor will also participate in PACT/H-PACT team meetings and serve as a liaison between the study subject and his or her primary care team. Peer mentors will be hired as VA term employees in Research.
223608510|NCT02134717|DRUG|all subjects will receive maraviroc 300mg orally twice a day for 6 weeks|
223608511|NCT02134717|PROCEDURE|Bronchoscopy with bronchoalveolar lavage|Bronchoscopy employs a flexible instrument that is inserted into the trachea and proximal airways after topical anesthesia. Bronchoalveolar lavage involves the instillation of saline solution through the bronchoscope into the airways followed by recovery under suction to collects lung fluid containing cells and proteins.
223608512|NCT02134717|PROCEDURE|venipunctures|Venipunctures will be performed at study entry, after two weeks, and at the end of the study to collect blood for research studies and safety laboratories.
223608513|NCT02134717|PROCEDURE|Skin biopsy|For subjects with sarcoidosis skin lesions, an optional skin biopsy specimen may be collected for research studies.
223608514|NCT02665182|BEHAVIORAL|Up-positioning of the testes|Patients in the experimental arm are asked to elevate their testes during the treatment.
223608515|NCT01504022|OTHER|Telecare, selfmonitoring, lifestyl behaviour|Patients measure their own bloodpressure and the results are shown at a secured website after USB connection of the monitor to the computer. Patients receive medication adjustments and lifestyle advices via this secured website.
223608516|NCT05532358|DRUG|anle138b (TEV-56286)|Anle138b (TEV-56286) as perpetrator
223508729|NCT05374993|DEVICE|3TBA|Induce third molar tooth bud agenesis
223508730|NCT06547801|DIETARY_SUPPLEMENT|2'-Fucosyllactose|3 g/day of powder orally once daily
223508731|NCT06547801|DIETARY_SUPPLEMENT|Maltodextrin|3 g/day of powder orally once daily
223508732|NCT06017375|OTHER|Questionnaire based intervention|Three validated questionnaires amended from hepatitis B to D (Chronic liver disease questionnaire, self-stigma scale and HBV virus knowledge scale) will be used.
223508733|NCT00511290|OTHER|no generic names|
223508734|NCT01348490|DRUG|Ruxolitinib|Ruxolitinib (INCB018424), 5 mg bid
223508735|NCT00300495|DRUG|Amiodarone|Perioperative orally administered
223508736|NCT00300495|OTHER|Control arm, standard care|Control
223508737|NCT01529216|DEVICE|DIAMOND System|Electrical stimulation to the fundus
223508738|NCT01184118|DRUG|FP 220 mcg 2 puffs BID|The design is a prospective 16-week open-label study of inhaled FP hydrofluoroalkane-propelled metered dose inhaler (HFA-MDI), 220 mcg, 4 puffs BID in 36 ICS naive asthma subjects. This is followed by a 4-week run-out period, including FP 220 mcg 2 puffs BID for 2 weeks, then either continue FP 220 mcg 2 puffs BID or discontinue FP (as tolerated), for the remaining two weeks, with subsequent transition to clinical care.
223608517|NCT05532358|DRUG|Fluvoxamine 100 mg QD for 5 days|Anle138b (TEV-56286) as victim
224200821|NCT06558630|PROCEDURE|Endotracheal intubation|Over the course of several years as many as possible ED centres in the Netherlands will be included in the collection of all data involving airway management. Airway management is defined as the process of planning, preparation and execution of endotracheal intubation.
223508739|NCT04626531|OTHER|Web-Based Education|Participants in the intervention group had unlimited access to the Web site, free of charge. The Web site was designed to run on personal computers and smartphones.
223508740|NCT04626531|OTHER|Control Group|The control group didn't apply any interference during the study. Participants in the control group continued their routine follow-up.
223508741|NCT02166788|PROCEDURE|Inguinal Lymphadenectomy|
223508742|NCT02166788|PROCEDURE|Ilio-inguinal Lymphadenectomy|
223508743|NCT00073047|DRUG|Daclizumab|
223508744|NCT04364971|PROCEDURE|singleradius and multiradius total knee arthroplasty|singleradius and multiradius total knee arthroplasty
223508745|NCT03833843|DIAGNOSTIC_TEST|imaging|ECG, Echocardiography and cardiac magnetic resonance imaging
223508746|NCT00002836|BIOLOGICAL|Filgrastim (G-CSF)|For group one (Filgrastim + Chemotherapy), given under the skin (SC) on day 4 every 12 hours until completion of apheresis; for group two (Filgrastim alone), beginning on day of reinfusion twice a day (bid) until white blood count (WBC) reaches a safe level.
223508747|NCT00002836|DRUG|Carmustine|Upon recovery of hematopoiesis patients then receive high by vein (IV) doses of CBT chemotherapy with CTX, carmustine, and thiotepa for 3 days
223508748|NCT00002836|DRUG|Cisplatin|As part of CVP chemotherapy treatment by vein (IV) on days 1-3.
223508749|NCT00002836|DRUG|Cyclophosphamide (CTX)|In group one (Filgrastim + Chemotherapy) as part of CVP chemotherapy treatment by vein (IV) on days 1-3; and group two (Filgrastim alone), upon recovery of hematopoiesis receive high IV doses of CBT chemotherapy with CTX, carmustine, and thiotepa for 3 days.
223508750|NCT00002836|DRUG|Etoposide|CVP chemotherapy treatment IV on days 1-3, with cyclophosphamide (CTX), etoposide, and cisplatin.
223508751|NCT00002836|DRUG|Thiotepa|Upon recovery of hematopoiesis receive high IV doses of CBT chemotherapy with CTX, carmustine, and thiotepa for 3 days.
223508752|NCT00002836|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Infusion of stem cells on Day 0.
223508753|NCT03632720|BIOLOGICAL|Meningococcal polysaccharide (serogroups A,C,Y and W) tetanus toxoid Conjugate vaccine|Pharmaceutical form: solution for injection; route of administration: intramuscular, 0.5 mL
223508754|NCT03632720|BIOLOGICAL|Meningococcal group B vaccine|Pharmaceutical form: suspension for injection; route of administration: deep intramuscular, 0.5 mL
223508755|NCT03632720|BIOLOGICAL|Diphtheria, tetanus, pertussis (acellular component), hepatitis B, poliomyelitis (inactivated) vaccine|Pharmaceutical form: powder and suspension for suspension injection; route of administration: deep intramuscular, 0.5 mL
223608518|NCT03009474|DRUG|CJ-30060|Fixed-dose combination drug containing Amlodipine 5 mg and Valsartan 160 mg and Rosuvastatin 10 mg
223608519|NCT03009474|DRUG|Exforge tab 5/160mg, Crestor tab 10mg|Co-administration of Amlodipine 5 mg/ Valsartan 160 mg(combination drug) and Rosuvastatin 10 mg
223608520|NCT05336578|OTHER|Platelet rich fibrin application|PRFs were prepared by obtaining10 ml blood samples from each patinet and inserting them in a centrifuge device (Intra-Lock International Inc., Boca Raton, USA), under 2700 rpm for 12 min using high speed. The platelet-rich fibrin layer remaining between the acellular plasma and red blood cells in the tube was separated with the help of scissors or a scalpel. After the tooth extraction in the experimental group PRF located to the extraction socket.
223608521|NCT02236468|OTHER|Enhanced-Homestead Food Production Program (old)|Participation in an enhanced-homestead food production program including home gardening and nutrition and health behavior change communication since 2010
223608522|NCT02236468|BEHAVIORAL|WASH/malaria behavior change|WASH/malaria behavior change communication
223608523|NCT02236468|DIETARY_SUPPLEMENT|LNS distribution|Distribution of Nutributter (Fanga Degue) for children
223608524|NCT02236468|OTHER|Enhanced-Homestead Food Production Program (new)|Participation in an enhanced-homestead food production program including home gardening, poultry rearing and nutrition and health behavior change communication since 2014
223608525|NCT00021749|DRUG|Oblimerson sodium, G3139|
223608526|NCT02832934|DRUG|Levothyroxine|The intervention will start with Levothyroxine 50 mcg daily (reduced to 25 mcg in subjects \<50 kg of body weight or if known coronary heart disease - previous myocardial infarction or symptoms of angina pectoris) vs. matching placebo; at 3 months, if the serum TSH level is \<0.4 mU/L, dose will be reduced by 25 mcg; TSH \>=0.4 and \<4.6 mU/L, no change to dose; TSH \>=4.6 mU/L, additional 25 mcg. The process will be repeated at 12 months, then annually; mock titration will be performed in the placebo group. The maximum possible dose of Levothyroxine which will be prescribed is 150 mcg (after 4 increments of 25 mcg at 3 months, 1, 2, 3 years; from the starting dose of 50 mcg).
223608527|NCT02832934|DRUG|Placebo|Control patients will obtain a placebo pill of the same characteristics as the intervention drug, and mock titration will be carried out identically to the intervention drug. Pharmaceutical composition of placebo (100 mg): Lactose monohydrate 66 mg, Maize starch 25 mg, Gelatin 5 mg, Croscarmellose sodium 3.5 mg, Magnesium stearate (vegetable source) 0.5 mg.
223608528|NCT06518044|DRUG|N Acetyl L Cysteine|For subjects in the experimental intervention arm (NAC group), if the patients met the inclusion criteria on day 14 before conditioning, they received NAC from day 14 before conditioning until day +60 post-HSCT. The initial dose of NAC was 400mg orally three times daily (TID). In cases of grade 3 or worse AEs (not including hematologic recovery), dose modifications including dose reductions or interruptions were permitted at the physician's discretion. After the resolution of AEs, the dose was re-escalated from to 400mg TID.
223755174|NCT04054687|OTHER|Placebo|This group will receive pledget soaked in saline. Protocol will continue as with TXA group.
224200822|NCT01064830|DRUG|topical cyclosporine ophthalmic suspension 0.05%|apply 2 drops to 2 target fingernails under occlusion daily
224200823|NCT01064830|DRUG|vehicle|apply 2 drops to 2 target fingernails under occlusion daily for 20 weeks
224200824|NCT06125886|DIAGNOSTIC_TEST|transvaginal ultrasound and microscale endometrial sampling biopsy|Transvaginal ultrasound and endometrial micro tissue pathology examination are used concurrently for endometrial cancer screening in high-risk populations. The specificity, sensitivity, and optimal combination of the two screening methods are clarified, and a cost-effectiveness analysis is conducted on different screening strategy.
223508756|NCT03632720|BIOLOGICAL|Human rotavirus RIX4414 strain vaccine|Pharmaceutical form: oral suspension; route of administration: oral, 1.5 mL
223508757|NCT03632720|BIOLOGICAL|Pneumococcal 13-valent polysaccharide conjugate vaccine|Pharmaceutical form: suspension for injection; route of administration: intramuscular, 0.5 mL
223508758|NCT03368560|OTHER|Sudarshan Kriya Yoga|Sudarshan Kriya Yoga (SKY): A 12-week training course conducted by certified instructors from the Art of Living Foundation. SKY training will take place in group-format (group sizes of 8-15 participants) in an appropriately sized and accessible community hall in London, Ontario.SKY training involves attending a week-long (5 days) course that teaches the basic principles of SKY over 2.5-3 hour daily sessions. This will be followed by once weekly follow up sessions (90 min/wk) for 3 weeks and then bimonthly sessions (every 2 weeks) for the next 8 weeks. In addition, participants will be asked to practice SKY at home daily (25 min/day) throughout the duration of the study period and log practice frequency and any other noteworthy observations in a log sheet that will be provided to them . Nutritional snacks will be provided during the 5 day SKY training course.
223508759|NCT00711204|DRUG|Donepezil Hydrochloride (Aricept)|5mg (or 10mg) tablet, once daily, with a full glass of water.
223508760|NCT03816826|OTHER|physical therapy|both are physical therapy intervention technique used to treat the soft tissue acute injuries
223508761|NCT03896932|OTHER|minipooled- Intravenous immunoglobulin(MP-IVIG)|The process of MP-IVIG preparation will involve the use of caprylic acid for purification and virus inactivation of Igs from mini-pools of 20 plasma donations collected in our CBTS in AUH. The equipment used for the process comprised disposable blood bags, hemodialyzers, and purification and microbial filters.
223508762|NCT04806945|DRUG|HLX10|IV infusion.
223508763|NCT04806945|DRUG|Paclitaxel|IV infusion
223508764|NCT04806945|DRUG|Cisplatin|IV infusion
223508765|NCT04806945|DRUG|Carboplatin|IV infusion
223508766|NCT04806945|DRUG|Placebo to HLX10|IV infusion
223508767|NCT00682435|DRUG|Hydromorphone|"1mg IV hydromorphone, followed by an optional dose of 1mg IV hydromorphone 15 minutes later if the patient answers yes to the question, Do you want more pain medication?"
223508768|NCT06397066|PROCEDURE|White light endoscopy group|White light endoscopy observe the characteristics of mucosa under white light
223508769|NCT06397066|PROCEDURE|Magnifying endoscopy group|NBI+ME to observe the non atrophic area of the gastric fundus gland. The results depend on the ratio of gastric fundus gland.
223508770|NCT02739646|DEVICE|Functional MRI scan|7.0 Tesla functional MRI scan
223508771|NCT00686218|DRUG|imatinib mesylate|Given orally
223508772|NCT00686218|DRUG|panobinostat|Given orally
223508773|NCT00686218|GENETIC|polymerase chain reaction|Testing
223508774|NCT00686218|GENETIC|protein expression analysis|Testing
223508775|NCT00686218|GENETIC|western blotting|Testing
223508776|NCT00686218|OTHER|flow cytometry|Testing
223508777|NCT00686218|OTHER|laboratory biomarker analysis|Testing
223508778|NCT00686218|OTHER|pharmacological study|Testing
223508779|NCT06034314|DRUG|Dronabinol Capsules|Two 10 mg Dronabinol capsules will be administered orally, for a total of 20mg, on test day.
223508780|NCT03389750|DRUG|Intravenous Challenge Drug|Intravenous administration of opioid drugs (oxycodone, oxymorphone, hydromorphone), for the purpose of comparison of their abuse potential among each other, and in comparison to placebo (saline).
223508781|NCT00664677|DRUG|Terameprocol (EM-1421)|Terameprocol (EM-1421) as a single agent given intravenously over 6 hours three times a week for two weeks followed by one week rest (two weeks on, one week off.
223608529|NCT03378817|PROCEDURE|HOPE|HOPE for 1 hour via the renal artery in a recirculating and pressure controlled system, Belzer (UW) machine perfusion solution, perfusate temperature 0-4 °C, perfusate oxygenation pO2 of 60-80 kPa Other Name: Hypothermic machine perfusion (HMP)
223508782|NCT01006408|PROCEDURE|Low Level Laser|Low Level Laser twice a week for 8 weeks
223508783|NCT01006408|PROCEDURE|Placebo followed by Low Level Laser|Placebo twice a week for 4 weeks then crossover to Low Level Laser twice a week for 4 weeks
223508784|NCT01049828|OTHER|No intervention|No treatment for tinnitus will occur in this study.
223508785|NCT06165965|DRUG|SGLT2 inhibitor|SGLT2 dual inhibitor
223508786|NCT02958670|OTHER|18F-AV-1451 (Tau-PET tracer)|Single i.v. administration of 18F-AV-1451 (Tau-PET tracer) and consecutive Positron-Emission-Tomography-Scan
223508787|NCT06091605|PROCEDURE|Soft tissue augmentation around dental implants.|Soft tissue augmentation around dental implants using Omega roll envelope flap (OREF) technique.
223508788|NCT00112853|DRUG|tipifarnib|Given orally
223508789|NCT00112853|DRUG|etoposide|Given orally
223508790|NCT02211157|DRUG|BIBR 796 BS|
223508791|NCT02211157|DRUG|Placebo|
223508792|NCT02211157|OTHER|high fat breakfast|
223508793|NCT00902525|DRUG|90Y-Ibritumomab Tiuxetan|All patients receive 2 courses of age-adjusted R-miniDHAP followed by two doses of 90Y-Ibritumomab Tiuxetan
223508794|NCT04636944|OTHER|web-based COMPASS intervention|COMPASS is a web-based intervention (online CBT program) that was developed for managing illness-related anxiety and depression in patients with long-term conditions (LTC) (https://compass-ltc.org/). COMPASS is tailored to gain an understanding of the difficulties that LTC patients experience and provide information and tools on how to manage these. This qualitative study will explore participants' perspectives on using COMPASS for managing depression and anxiety in heart failure.
223508795|NCT06604598|DRUG|IBU-PCT-DEX|Ibuprofen (Peinlos) 2x400 mg iv, Paracetamol (Bernofarm) 2x1 gr iv, dexamethasone (Phapros) 2x5 mg iv will be given with interval 8 hour, within the IBU-PCT-DEX intervention.
223508796|NCT06604598|DRUG|IBU-PCT-placebo|Ibuprofen (Peinlos) 2x400 mg iv, Paracetamol (Bernofarm) 2x1 gr iv, and 2xplacebo (normal saline alike dexamethasone) will be given with interval 8 hour, within the IBU-PCT-placebo intervention
223608530|NCT03378817|OTHER|Conventional cold storage|No intervention
223755175|NCT00151814|DRUG|Olmesartan medoxomil|Children less than 6 years old: oral suspension or tablets equal to 0.3 mg/kg; 20 mg or 40 mg tablets for older children depending on weight.
223755176|NCT06366399|BEHAVIORAL|Resistance Exercise Timing|1 resistance exercise session consisting of 3 sets, 10 repetitions per set, on 12 different exercises
223755177|NCT00579111|DRUG|Campath|10 mg/day IV daily for 3 days on days -6 to D-4. Campath may be omitted from the conditioning regimen for patients with malignant diseases and matched related donor transplants
223508797|NCT06604598|DRUG|PCT-placebo-placebo|Paracetamol (Bernofarm) 2x1 gr iv, 2xplacebo (normal saline alike paracetamol), 2xplacebo (normal saline alike dexamethasone) will be given with interval 8 hour, within the PCT-placebo-placebo intervention.
223508798|NCT05228340|PROCEDURE|Flexor tenotomy|Minimally-invasive percutaneous needle flexor tenotomy of the long digital flexor tendon
223508799|NCT02608606|DRUG|Tacrolimus|compared oral administration versus sublingual administration of tacrolimus.
223508800|NCT00290238|DEVICE|Vertis Percutaneous Neuromodulation Therapy (PNT)|"* Ten PNT sessions in eleven weeks~* On average, one PNT session per week~* Ten lumbar Safeguide electrodes (three centimeters in length) deployed per lumbar montage~* Forty-five minutes of electrical stimulation for each session~* Electrical stimulation parameters:~  * Continuous 50 Hz current~ * Charge-balanced, biphasic (each phase is 200 microsec), rectangular waveform~ * Intensity to subject's tolerance for ten minutes then increased to a mildly uncomfortable level"
223508801|NCT00290238|DEVICE|Transcutaneous Electrical Nerve Stimulation (TENS)|"* Ten TENS sessions in eleven weeks~* On average, one TENS session per week~* Four 2-inch (5.1 centimeters) diameter pads applied per TENS lumbar montage~* Forty-five minutes of electrical stimulation for each session~* Electrical stimulation parameters:~  * Current at 2 Hz-low frequency~ * Pulse trains delivered as asymmetric, biphasic, square waveform current, with pulse width lasting 20 microsec~ * Intensity titrated according to subject's sensory threshold~ * To maintain blinding, the treating physician or clinician will check on the subject after 10 minutes and dial the channels down just prior to the point of turning off the device."
223508802|NCT05028088|DRUG|sugammadex|This study is a prospective, double-blind, low-intervention, non-randomized controlled clinical trial involving 99 patients with American Society of Anesthesiologists Ⅰ-Ⅲ, body mass index 18.5-24.9 kg/m2, who will undergo laparoscopic radical resection of liver cancer under general anesthesia in the Wuhan Union Hospital. Ultrasonography will be applied to monitor the change rate of diaphragm thickness at different time after extubation to evaluate the recovery rate of muscle relaxant, which indirectly reflects the dose-effect relationship of SUG antagonizing against rocuronium in patients with different liver Child-Pugh grades preoperatively.
223508803|NCT02186171|BIOLOGICAL|Romosozumab|Administered by subcutaneous injection once a month.
223508804|NCT02186171|DRUG|Placebo|Administered by subcutaneous injection once a month.
223508805|NCT02452658|OTHER|Changed menu|After making the hypothetical choice, participants will be exposed to a menu with changed calorie and price labels, as well as several other changes.
223508806|NCT05944510|DRUG|Dextromethorphan|Dextromethorphan 30mg will be administered along with Clozapine (standard of care) in treatment resistant schizophrenia.
223508807|NCT05944510|DRUG|Placebo|Matched placebo will be administered along with Clozapine (standard of care) in treatment resistant schizophrenia.
223508808|NCT04922528|PROCEDURE|Laparoscopic Cholecystectomy with Fluorescent Cholangiography|Indocyanine green is a fluorophore molecule which is metabolized by the liver and excreted exclusively through the biliary system. Intra-operatively, near-infared imaging via the laparoscope will be used to visualize the biliary anatomy in the intervention arm, as an adjunct to standard of care white-light imaging.
223508809|NCT04922528|PROCEDURE|Laparoscopic Cholecystectomy with White Light Imaging|As per the current standard of care, patients undergoing laparoscopic cholecystectomies will have it completed using white light imaging through the laparoscope.
223508810|NCT06812013|OTHER|assessment of foot print and balance|"For static and dynamic balance assessment, Biodex Medical Systems Inc., Shirley, New York, USA (serial n.: 13020193) was used. The device consists of a circular foot platform that permits tilting in all directions, height-adjustable support rails, height adjustable display screen, and a printer. Balance assessment by the Biodex system is a valid and reliable objective measurement.~For assessment of foot print symmetry Tekscan HR walkway Mat™ pressure measurement system, Tekscan Inc. USA will be use. It is made up of a digital mat inserted into a wooden walkway, sensors (4 senses/cm2) embedded in the mat, and a computer running the Tekscan Software (version 7) for data extrapolation."
223608531|NCT06433323|OTHER|Anti-aging cosmetic care product|"This is an intra-individual comparison study.~* frequency of application: Once a day (in the evening)~* modalities of application: Apply the cream on the tested area determined by the randomization~* duration of investigational product application: 56 days (a window of + 72 hours is allowed)"
223608532|NCT03934567|DRUG|Abexinostat|Abexinostat tablets
223608533|NCT00651716|OTHER|flow cytometry|Lymphocyte Analysis: Lymphocyte subset studies will be performed on samples obtained from the patient, donor, or graft. Aliquots will be analyzed using standard flow cytometry.
223608534|NCT00651716|OTHER|laboratory biomarker analysis|Identification of gut-homing and skin-homing Treg subsets
223608535|NCT00651716|OTHER|Data Collection|Patient samples will receive an alphanumeric code assigned by the principal investigator so that patient and donor identity will be known only to study investigators and research staff. Clinical records on each patient will be reviewed by participating investigators or research staff on a routine basis so that relevant clinical information including survival, malignancy relapse, and GVHD can be included in the patient database. Flow cytometry results will also be included in this database.
223608536|NCT00697372|DEVICE|Sirolimus eluting stent|Implantation of Sirolimus eluting stent
223608537|NCT00697372|DEVICE|Everolimus eluting stent|Implantation of Everolimus eluting stent
223608538|NCT01699165|DEVICE|Nasal filter|Active nasal filter
223755178|NCT00579111|DRUG|Busulfan|3.2 mg/kg/day IV daily for 2 days, infused over 3 hours, on Day -5 and Day -4
223755179|NCT00579111|DRUG|Fludarabine|30mg/m2/day IV daily for 4 days on Day -5 to D -2
223755180|NCT00579111|PROCEDURE|Hematopoietic stem cell infusion|Peripheral blood stem cells when possible. Bone marrow cells will be used if peripheral blood cells are insufficient or unavailable.
223755181|NCT00579111|DRUG|FK-506|FK-506 at a dose of 0.03 mg/kd/day will be administered via continuous infusion over 24 hours from 4pm on Day -2 until engraftment or when the patient is able to take PO, then 0.03 mg/kg PO every 12 hours.
224311628|NCT01653301|DRUG|XELAC RT|"Xeloda 1650mg/m2 chronomodulated (h 8.00 a.m. 25% of total dose ; h 6.00 p.m. 25% of total dose; h 11.00 p.m. 50% of total dose) during the whole treatment time.~RT: pelvic treatment is the same for both arms: 45 Gy are delivered to the whole pelvis at 1.8 Gy daily, 5 times per week.~In the XEL-ACRT arm a boost of 10 Gy is delivered to the mesorectum corresponding to the GTV, at 1 Gy for fraction to a total dose of 55 Gy, in 10 fractions over 5 weeks, 2 times a week. The daily dose of the boost will be delivered twice a week immediately after the daily dose administered to the pelvis (concomitant boost)."
223508811|NCT06658158|BEHAVIORAL|Cognitive correction and stimulus control|"Cognitive correction:~a) correcting unrealistic sleep expectations; b) maintaining a natural sleep onset; c) avoiding worry about losing control oversleep; d) not associating nocturnal dreaming with adverse daytime consequences; e) avoiding feelings of frustration due to one night of poor sleep; f) developing tolerance to the impact of insomnia and avoiding compensatory behaviors.~Stimulus control:~1. Minimize wakefulness during time in bed and establish a positive association between sleepiness and the bed.~2. Use the bed only for sleep and sexual activities.~3. Go to bed only when feeling sleepy at night or at the designated sleep time.~4. If unable to fall asleep within approximately 20 minutes of being in bed, leave the bedroom, engage in relaxing activities, and return to bed when feeling sleepy. Repeat this process if unable to fall asleep within approximately 20 minutes.~5. Wake up at the same time every morning, including weekends."
223508812|NCT06658158|BEHAVIORAL|Sleep hygiene education|"1. Sleep until feeling refreshed the next day.~2. Maintain regular exercise and eating habits, avoiding going to bed on an empty stomach.~3. Ensure a comfortable bedroom environment with suitable nighttime temperature, free from light and noise disturbances.~4. Avoid excessive consumption of beverages, alcohol, and smoking at night, and reduce caffeine intake.~5. Avoid bringing problems to bed and refrain from attempting to sleep.~6. Place the alarm clock under the bed or move it away from sight.~7. Avoid daytime napping."
223508813|NCT00954135|DRUG|letrozolo+cyclophosphamide|Letrozole 2,5 mg/daily + metronomic cyclophosphamide 50 mg/daily for 6 months
223508814|NCT00954135|DRUG|letrozolo+sorafenib+cyclophosphamide|"Letrozole (2,5 mg/daily) + metronomic cyclophosphamide (50 mg/daily) + Sorafenib (400 mg/bid/daily) for 6 months"
223508815|NCT01433770|DRUG|Amevive|Alefacept 15mg subcutaneous; once a week for 12 weeks
223508816|NCT04039438|OTHER|No intervention|No intervention will be provided during the study nor participants will be receiving any intervention anywhere else.
223508817|NCT06257121|DEVICE|OSMS position management|Patient position management in real time during radiation using an optical Surface Management System (OSMS) (Vision RT)
223508818|NCT05720975|DEVICE|iNstroke|Patients to undergo thromboaspiration with iNstroke.
223508819|NCT06658184|BEHAVIORAL|sleep restriction and stimulus control|"Sleep restriction: a) Reduce bedtime to match actual sleep time, but ≥4.5 hours, and adjust bedtime according to sleep efficiency; b) Avoid daytime naps and maintain a regular wake-up time.~Stimulus control: a) Reduce wakeful time in bed and rebuild a positive association between sleepiness and bed; b) Use the bed solely for sleeping and sexual activities; c) Only go to bed when feeling sleepy at night or at the designated sleep time; d) If unable to fall asleep within about 20 minutes of being in bed, leave the bedroom and engage in relaxation activities until feeling sleepy, then return to bed for sleep; if still unable to fall asleep within about 20 minutes, repeat the process; e) Wake up at the same time every morning, including weekends."
223508820|NCT06658184|BEHAVIORAL|sleep hygiene education|"Sleep hygiene education:~1. Sleep until feeling refreshed the next day.~2. Maintain regular exercise and eating habits, avoiding going to bed on an empty stomach.~3. Ensure a comfortable bedroom environment with suitable nighttime temperature, free from light and noise disturbances.~4. Avoid excessive consumption of beverages, alcohol, and smoking at night, and reduce caffeine intake.~5. Avoid bringing problems to bed and refrain from attempting to sleep.~6. Place the alarm clock under the bed or move it away from sight."
223508821|NCT05730673|DRUG|700mg leronlimab weekly dose|leronlimab is a humanized IgG4,κ monoclonal antibody (mAb) to the chemokine receptor CCR5
223508822|NCT05730673|DRUG|80mg Regorafenib at week 1|Regorafenib is a small-molecule multiple kinase inhibitor
223508823|NCT05730673|DRUG|120mg Regorafenib at week2|Regorafenib is a small-molecule multiple kinase inhibitor
223508824|NCT05730673|DRUG|160 mg Regorafenib at week 3|Regorafenib is a small-molecule multiple kinase inhibitor
223508825|NCT03166254|DRUG|Pembrolizumab|-Pembrolizumab will be given intravenously over the course of 30 minutes
223508826|NCT03166254|BIOLOGICAL|NEO-PV-01 vaccine|-Generation of the vaccine is expected to take approximately 12 weeks
223508827|NCT03166254|PROCEDURE|Biopsy|-Surgical or core needle biopsy of an accessible site for DNA and RNA sequencing, immunological analysis, and generation of NEO-PV-01 vaccine
223508828|NCT03166254|DRUG|Poly ICLC|-NEO-PV-01 is combined with the adjuvant poly-ICLC prior to administration.
223608539|NCT01699165|DEVICE|Placebo nasal filter|Placebo nasal filter
223608540|NCT03165422|OTHER|Non-Interventional|Non-Interventional
223608541|NCT00740584|DRUG|3% SPL7013 Gel (VivaGel)|A single application of VivaGel applied to the vagina on five separate occasions, each occasion separated by a minimum of 5 days.
223608542|NCT00378781|DRUG|Heparin|Heparin flush solution into CVC once daily.
223608543|NCT00378781|DRUG|Minocycline-EDTA|M-EDTA flush solution into CVC once daily.
223608544|NCT03337334|DEVICE|tACS at tremor frequency|tACS applied between the stimulation electrodes at tremor frequency
223608545|NCT04526912|DRUG|VIB7734|Single subcutaneous dose
223608546|NCT04526912|DRUG|Placebo|Intravenous single dose matched to VIB7734.
223608547|NCT02837458|DEVICE|High-Frequency|high-Frequency electrical stimulation over superficial radial nerve through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft, Netherlands)
223608548|NCT02837458|DEVICE|Sham Stimulation|Sham transcutaneous electrical stimulation over superficial radial nerve through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft, Netherlands)
223608549|NCT04992663|DEVICE|PICO glasses and controller with BirthVR|"PICO glasses will be used for VR in the intervention group. BirthVR is a guided meditation VR application designed by qualitative research (VIREL study) performed by this study group.~The BirthVR application contains the following components:~* Information/introduction video (including a virtual reality tour through the labour ward of the Zuyderland MC)~* Fase 1: Beach environment, guided meditation/breathing exercise (1 session: 25 minutes)~* Fase 2: Underwater environment, guided meditation/breathing exercise (1 session: 25minutes)~* Fase 3: Mountain environment, breathing technique exercise on demand by using the controller (1 session: 30 minutes)~* Counseling video (cesarean section, epidural anesthesia)"
223608550|NCT02686918|OTHER|Advanced Practice Nurse consultation|
223608551|NCT00006343|BIOLOGICAL|recombinant interferon alfa|
223608552|NCT00006343|DRUG|cytarabine|
223608553|NCT00006343|DRUG|imatinib mesylate|
223608554|NCT03826069|OTHER|Augmented reality-based curriculum|Participants in the Augmented Reality Group will be taught principles in augmented reality and training sessions will be enhanced by an augmented reality platform. This involves training on virtual reality simulators with superimposed videos and guides demonstrating correct procedure. In this study, the videos and guides will be on identifying and removing polyps.
223608555|NCT03826069|OTHER|Conventional Simulation Curriculum|Participants in this group will will train from low- to high-fidelity colonoscopy simulation. During training, the participants will receive guidance and feedback from expert endoscopists. In addition, there will be didactic sessions covering theory of colonoscopy.
223608556|NCT06845488|BEHAVIORAL|CBT|"Participants will receive will receive 12 weeks of weekly CBT for Social Anxiety, including an intervention to improve conversational skills. The CBT for Social Anxiety will include imaginal exposure, which is a way of using the imagination to work with situations that produce anxiety. Participants will also receive a mindfulness intervention."
223608557|NCT06845488|DEVICE|VR|The VR software, the Virtual Communicator (VC) consists of a highly realistic avatar that interacts with the client in one of several situations. The therapist controls its gestures, facial expressions, body movements, and speech and builds and saves modular combinations of gestures and facial expressions that can be assembled in any order to create a conversational interaction. The software has two adult avatars of ambiguous race/ethnicity, male and female. The VC is delivered without a headset interactively over the internet, on a secure, password-protected connection that increase access by not requiring headsets and not requiring the client to come to the office. The VC can be done in English, or in Spanish where appropriate. Treatment will be done for 12 sessions. The VR software is used to provide CBT exposures to reduce anxiety and also to practice social interactions.
223608558|NCT06256445|DRUG|Polyene Phosphatidylcholine|Formulated as an injectable solution containing Polyene Phosphatidylcholine at concentration of 25 mg/mL
223608559|NCT06256445|DRUG|Matching placebo of AYP-101|Phosphate buffered saline placebo for injection
223608560|NCT04945642|RADIATION|High-Dose Rate Brachytherapy|Undergo HDR-BT
223608561|NCT04945642|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
223608562|NCT06122584|DRUG|[18F]PSMA-1007|Diagnostic radiopharmaceutical for PET scan
223608563|NCT04024696|DRUG|Abexinostat|Abexinostat Tosylate Tablets
223755182|NCT01120613|DRUG|Chronotherapy|"Patients identified with nocturnal hypertension while treated with blood pressure medications will have one medication switched from daytime to night time dosing in the following preference:~1. ACE or ARB~2. Calcium Channel Blockers~3. Alpha Blocker~4. Beta Blocker~If patient is on only one daytime BP medication, it will be switched to night time dosing. No dose adjustments will be made nor any new medications will be added. Only timing of BP medication will be changed."
223755183|NCT05548660|OTHER|Pharmacogenetic testing|Genetic testing of CYP2B6, CYP2C19, CYP2C9, CYP2C cluster CYP2D6, CYP3A5, CYP4F2, DPYD, HLA-A, HLA-B, IFNL4, NUDT15, SLCO1B1, TPMT, UGT1A1, and VKORC1.
223755184|NCT05548660|OTHER|Pharmacist note with genotype-guided analgesic recommendations|"CYP2C9 normal metabolizers will be recommended to receive ibuprofen and intermediate and poor metabolizers will be recommended to receive naproxen.~CYP2D6 normal metabolizers will be recommended to receive tramadol and ultrarapid, intermediate and poor metabolizers will be recommended to receive oxycodone."
223755185|NCT05548660|OTHER|Pharmacist detailed note with genotype-guided recommendations per CPIC guidelines|Genotype-guided recommendations for all actionable phenotypes resulted from the 16-gene PGx panel per CPIC guidelines and FDA labeling
223755186|NCT04958057|BEHAVIORAL|SAIL|6 monthly group sessions with the study nurse with a background in prenatal care and the PI that will include each group will include preeclampsia education, coaching on stress management, resource navigation, and training in problem solving.
223508829|NCT03166254|PROCEDURE|Leukapheresis|-Peripheral blood mononuclear cells (PBMCs) for comprehensive immune system monitoring will be obtained from leukapheresis samples collected up to 7 days prior to initiation of NEO PV-01 vaccination and at 7 days (Week 20) following the first NEO-PV-01 booster vaccination.
223508830|NCT03166254|PROCEDURE|Peripheral blood samples|-Blood samples (80 mL) for immune monitoring will be obtained prior to study treatment and at Weeks 6, 14, 16, 24, 36, 48, 63, 75, 87, and 99.
223508831|NCT05695482|OTHER|Neuromuscular training exercises|The 6-week exercise intervention consists of 25-minute group sessions of Neuromuscular training supervised by a researcher.
223755187|NCT00006181|BEHAVIORAL|Team-based intervention|
223755188|NCT00006181|BEHAVIORAL|One-on-one intervention|
224311629|NCT01653301|DRUG|XELOX RT|"* Xeloda: 1300 mg/m2 chronomodulated (h 8.00 a.m. 25% of total dose ; h 6.00 p.m. 25% of total dose; h 11.00 p.m. 50% of total dose), during the whole treatment time;~* Oxaliplatin: 130mg/m2, days 1, 19, 38~RT: pelvic treatment is the same for both arms: 45 Gy are delivered to the whole pelvis at 1.8 Gy daily, 5 times per week; In the XELOX-RT arm a boost of 5.4 Gy is delivered to the mesorectum corresponding to GTV, at 1.8 Gy daily, in 3 fractions, to a total dose of 50.4 Gy. The boost will be delivered at the end of the irradiation of the pelvis (sequential boost)."
223508832|NCT05695482|OTHER|Hip abductors muscular strength exercises|The 6-week exercise intervention consists of of 20-minute group sessions of progressive resistance training, supervised by a researcher.
223508833|NCT05111119|BEHAVIORAL|Making PrEP Smart|"The Making PrEP Smart intervention is a mobile-based application with the following components:~* Notification-based PrEP Reminders and Adherence Self-Monitoring~* HIV self-testing facilitation, interpretation of results, and testing support~* HIV partner testing facilitation, interpretation of results, and testing support~* Nearby HIV clinic contact information"
224311630|NCT01331629|OTHER|ART-THERAPIE|8 sessions of art therapy during radiotherapy
223508834|NCT06658171|BEHAVIORAL|Relaxation training and stimulus control|"Relaxation training: Progressive muscle relaxation; Breathing relaxation; Imagery training; Mindfulness relaxation.~Stimulus control: a) Reduce wakeful time in bed and rebuild a positive association between sleepiness and bed; b) Use the bed solely for sleeping and sexual activities; c) Only go to bed when feeling sleepy at night or at the designated sleep time; d) If unable to fall asleep within about 20 minutes of being in bed, leave the bedroom and engage in relaxation activities until feeling sleepy, then return to bed for sleep; if still unable to fall asleep within about 20 minutes, repeat the process; e) Wake up at the same time every morning, including weekends."
223508835|NCT06658171|BEHAVIORAL|Sleep hygiene education|"1. Sleep until feeling refreshed the next day.~2. Maintain regular exercise and eating habits, avoiding going to bed on an empty stomach.~3. Ensure a comfortable bedroom environment with suitable nighttime temperature, free from light and noise disturbances.~4. Avoid excessive consumption of beverages, alcohol, and smoking at night, and reduce caffeine intake.~5. Avoid bringing problems to bed and refrain from attempting to sleep.~6. Place the alarm clock under the bed or move it away from sight.~7. Avoid daytime napping."
223608564|NCT04916535|OTHER|diagnostic flow|exams to estimate the risk of adverse events in patients with MAD
223608565|NCT04700098|BEHAVIORAL|Internet-based behavioral treatment for insomnia|Internet version of cognitive-behavioral treatment for insomnia
223608566|NCT04700098|BEHAVIORAL|Online insomnia patient education|Online insomnia patient education
223608567|NCT05774717|DRUG|Tranexamic acid|1 gram IV (intravenous) tranexamic acid administered in the operating room just prior to starting the case (10 minutes), at time that routine preoperative antibiotic is given.
223608568|NCT05297786|DRUG|Lanadelumab Injection [Takhzyro]|Lanadelumab 300 mg subcutaneous injection
223608569|NCT05297786|DRUG|Placebo|Placebo injection
223608570|NCT06434012|OTHER|registry|This is registry for Infective Endocarditis
223608571|NCT05314998|DRUG|Oxaliplatin|85 mg/m2 D1 over 2 hours every; 14 days, 12 cycles, 24 weeks
223608572|NCT05314998|DRUG|Irinotecan|150 mg/m2 D1 over 90 minutes to begin 30 min after the Folinic acid infusion is started; every 14 days, 12 cycles, 24 weeks
223608573|NCT05314998|DRUG|Folinic acid|400 mg/m2 (racemic mixture) (or 200 mg/m2 if L-folinic acid is used), IV infusion over 2 hours; every 14 days, 12 cycles, 24 weeks
223608574|NCT05314998|DRUG|5-fluorouracil|2.4 g/m2 IV continuous infusion over 46 hours (1200 mg/m2/ day); every 14 days, 12 cycles, 24 weeks
223608575|NCT05314998|DRUG|Gemcitabine|1000mg/m2 is given as an IV infusion over 30 minutes; on day 1, 8 and 15 out of 28 days (= 1 cycle); Repeated 6 times (i.e., 6 cycles) for 24 weeks
223608576|NCT05314998|DRUG|Capecitabine|1660mg/m2/day in two divided doses administered orally for 21 days followed by 7 days' rest (one cycle) for six cycles i.e. 24 weeks
223608577|NCT06800274|DRUG|NAAGA (N-acetyl-aspartyl-glutamate) 49 mg/mL|80 patients were randomly assigned to NAAGA in single dose (49 mg/mL), instilled as 1 drop per eye four times daily for four weeks. Specific diagnostic tests and procedures for dry eye disease were performed at week 0 (baseline), week 2 and week 4.
223608578|NCT06800274|DRUG|azelastine hydrochloride 0.05%|54 patients were randomly assigned to azelastine hydrochloride 0.05% instilled as 1 drop per eye 2 times a day in the conjunctival sac for for four weeks. Specific diagnostic tests and procedures for dry eye disease were performed at week 0 (baseline), week 2 and week 4.
223608579|NCT06113211|DRUG|Narcotic pain medication|Primary intervention is pain medication received postoperatively. Control group will receive the standard of care which is opioid medications. Experimental group will receive a nonopioid pain control regimen.
223608580|NCT06113211|DRUG|Nonnarcotic pain medications|Primary intervention is pain medication received postoperatively. Control group will receive the standard of care which is opioid medications. Experimental group will receive a nonopioid pain control regimen.
223608581|NCT05528341|BIOLOGICAL|NKG2D-CAR-NK92 cells|NKG2D-CAR-NK92 cells will be administered intravenously over 1h. The starting dose of NKG2D-CAR-NK92 cells will be 0.5×10\^6-2×10\^6/kg, twice a week. The first evaluation of the efficacy after 3 weeks of treatment.
223608582|NCT06260670|DEVICE|Electrographic Flow™ Mapping using Ablamap® Software and FIRMap™ Catheter|"Subjects will receive ElectroGraphic Flow™ (EGF) mapping with Ablamap® Software and a commercially available 64-pole basket mapping catheter (FIRMap™ Catheter, Abbott Laboratories, Abbott park, IL). The FIRMap™ catheter will be inserted into the right and left atrium to acquire 1 minute recordings of electrical signals in several standardized positions, and turn these into electrographic flow (EGF) maps.~Subjects will receive concomitant high density (HD) electroanatomical mapping of these regions with the commercially available Ensite Precision mapping system and Advisor™ HD Grid mapping catheter (Abbott Laboratories, Abbott Park, IL)."
224311631|NCT05326282|DIAGNOSTIC_TEST|Multi-parametric ultrasound|Diagnostic ultrasound parameters used to evaluate the prostate. Transrectal scans will be performed
223508836|NCT00334399|DRUG|Miglitol|
223508837|NCT02946996|DRUG|Metformin|
223508838|NCT02946996|OTHER|OPC|OPC is a derivative of grape seed extract
223608583|NCT00413218|DRUG|Isavuconazole|Administered by intravenous infusion.
223608584|NCT00413218|DRUG|Caspofungin|Administered by intravenous infusion.
223608585|NCT00413218|DRUG|Voriconazole|Administered by intravenous infusion.
223608586|NCT00206336|DRUG|Topiramate (drug)|Topiramate 25 mg to 200 mg
223608587|NCT03385226|DRUG|Pembrolizumab|Pembrolizumab is a humanised monoclonal antibody which targets the programmed cell death 1 (PD-1) receptor. It blocks a protective mechanism on cancer cells, and allows the immune system to destroy those cancer cells.
223608588|NCT03385226|RADIATION|Radiotherapy|12Gy in 3 fractions
223608589|NCT04639024|DRUG|ADCT-301|Patients will receive ADCT-301 37.5 ug/kg infused day 1,8, and 15 of a q3week cycle. Patients will have up to 2 cycles to assess response and safety to therapy and if they are not progressing may continue for up to 6 cycles.
224311632|NCT04993066|DEVICE|GentleMax Pro Plus|The GentleMax Pro Plus laser system to be used in this study received 510(k) market clearance from the U.S. Food and Drug Administration (FDA) under K201111 on May 26, 2020
223608590|NCT01196026|BIOLOGICAL|Fluarix™|One or two intramuscular injections
223608591|NCT01196026|BIOLOGICAL|Havrix™ Junior|Two intramuscular injections
223608592|NCT01687296|DRUG|fluticasone propionate inhalation solution|2×0.5mg/2ml twice daily nebulized to treat an acute exacerbation of asthma for 7 days
223608593|NCT01687296|DRUG|oral prednisone|once daily (2mg/kg.day, up to 40mg/day for 4 days, then 1mg/kg.day or half of the original dose, up to 20mg/day for 3 days) to treat an acute exacerbation of asthma for 7 days
223608594|NCT01687296|DRUG|placebo inhalation solution|4ml 0.9% saline nebulized twice daily
223608595|NCT01687296|DRUG|placebo tablet|placebo soluble tablet, oral ,once daily
223608596|NCT01687296|DRUG|salbutamol|Salbutamol MDI 2 puffs twice daily or Nebules twice daily, and can be increased up to every 4 hours on an as-needed basis, through the treatment period.
224311633|NCT00506701|DRUG|Tadalafil|40 mg tablet
223608597|NCT06258304|DRUG|GIGA-564|Administered by intravenous infusion
223608598|NCT06258304|DRUG|GIGA-564|Administered by intravenous infusion
223608599|NCT01471834|DEVICE|BAROSTIM NEO System|
223608600|NCT01471834|DRUG|Medical Management|
223608601|NCT05152108|DEVICE|BCI feasibility test|Testing the feasibility of BCI device by determining the accuracy of BCI control
223508839|NCT05968885|PROCEDURE|Intradetrusor Botox® (onabotulinumtoxinA) injection|The toxin produced by Clostridium botulinum binds to the nerves endings and inhibits the muscular contractions, help to treat overactivity of the bladder muscles.
223508840|NCT05968885|DRUG|Combine Mirabegron and Solifenacin.|Combination pharmacotherapy
223608602|NCT05326633|COMBINATION_PRODUCT|MRP and High Protein Supplement (HPRO) and Neuromuscular Electric Stimulation (NMES)|Mobility-based physical rehabilitation sessions performed 5 times/week by a study PT to provide strength and cardiopulmonary endurance training. High whey protein shakes prescribed to a total intake of 1.6-1.8 g/kg/d in 2 divided doses based on caloric needs. 2 x 30-minute lower extremity electric stimulation sessions/day, 5 times/wk performed by study PT.
223608603|NCT05144841|BIOLOGICAL|MK-2140 (zilovertamab vedotin)|IV infusion of 2.5 mg/kg
223608604|NCT05144841|BIOLOGICAL|MK-2140 (zilovertamab vedotin)|IV infusion of 2.25 mg/kg
223608605|NCT04912583|DEVICE|High tidal volume|A high tidal volume (14-16 ml/kg pbw) with positive end-expiratory pressure will be applied during mechanical ventilation.
223608606|NCT04912583|DEVICE|Low tidal volume|A low tidal volume (8-10 ml/kg pbw) with positive end-expiratory pressure will be applied during mechanical ventilation.
223608607|NCT04300101|OTHER|Prospective cohort|"Immunohistochemical determinations: Cell of Origin (COO) (according with Hans algorithm), evaluation of Cluster of Differentiation (CD) (CD20, CD5, CD10), Bcl6, Bcl2 (cut off\>50%), MUM1/IRF4, c-myc (cut off\>40%) and Ki67, FISH for c-myc and if rearranged for Bcl2 e Bcl6.~mRNA expression by Nanostring Single cell analysis Immune checkpoint expression Proteomic analysis Metabolic analysis Radiomic analysis"
223608608|NCT04300101|OTHER|Retrospective cohort|"Immunohistochemical determinations: Cell of Origin (COO) (according with Hans algorithm), evaluation of Cluster of Differentiation (CD) (CD20, CD5, CD10), Bcl6, Bcl2 (cut off\>50%), MUM1/IRF4, c-myc (cut off\>40%) and Ki67, FISH for c-myc and if rearranged for Bcl2 e Bcl6.~mRNA expression by Nanostring Single cell analysis Immune checkpoint expression Proteomic analysis Metabolic analysis Radiomic analysis"
223608609|NCT00752479|BIOLOGICAL|Mesenchymal stem cells infusion, Basiliximab,Methylprednisolone,RATG ,Cyclosporine ,Mycophenolate mofetil|"Cell therapy~Mesenchymal cells infusion.~Induction therapy:~Basiliximab (20 mg i.v.day 0 and day 4 post-tx). Low dose RATG (0.5 mg/kg/day i.v. day 0-6 post-tx). Methylprednisolone (500 mg to 25 mg from day 0 to 6 post-tx. Then stop).~Maintenance therapy:~Cyclosporine (from day 0: dose according to target trough blood level). Mycophenolate mofetil (750 mg b.i.d. from day 1 post-tx)."
223608610|NCT00752479|DRUG|Basiliximab, Methylprednisolone,RATG,Cyclosporine,Mycophenolate mofetil|"Routine immunosuppressive therapy~Induction therapy:~Basiliximab (20 mg i.v.day 0 and day 4 post-tx). Low dose RATG (0.5 mg/kg/day i.v. day 0-6 post-tx). Methylprednisolone (500 mg to 25 mg from day 0 to 6 post-tx. Then stop).~Maintenance therapy:~Cyclosporine (from day 0: dose according to target trough blood level). Mycophenolate mofetil (750 mg b.i.d. from day 1 post-tx)."
223508841|NCT00055965|DRUG|carboplatin|
223508842|NCT00055965|DRUG|cisplatin|
223508843|NCT00055965|DRUG|gemcitabine hydrochloride|
223508844|NCT07004192|DRUG|HCG injection|5000 IU hCG injection
223508845|NCT07004192|OTHER|No intervention|No hCG administered in this group.
223508846|NCT05970796|BEHAVIORAL|Pelvic floor muscle training|"The pelvic floor muscle training program will be provided via an intra-vaginal biofeedback device - Smart Kegel Trainer, which will be connected to the product application installed on the mobile phone or tablet so the participants can monitor their pelvic floor contractions in real time and directly in the application. Participants will be asked to complete three sets of 8 to 12 maximal pelvic floor muscle contractions and three to ten fast contractions per training session. The home program will be tailored to each participant and include pelvic floor safe exercises recommended by the Continence Foundation of Australia."
223508847|NCT03361072|DIETARY_SUPPLEMENT|Oral immunotherapy|Milk, peanut or egg oral immunotherapy
223508848|NCT06868667|DRUG|Belantamab mafodotin|Humanized anti-B-cell maturation antigen (BCMA) antibody/drug conjugate.
223508849|NCT06868667|DRUG|Daratumumab|Anti-cluster of differentiation 38 \[CD-38\] monoclonal antibody.
223508850|NCT06868667|DRUG|Bortezomib|Proteasome Inhibitor.
223508851|NCT06868667|DRUG|Dexamethasone|Synthetic glucocorticoid with anti-tumor activity.
223508852|NCT05052645|PROCEDURE|Auricular acupuncture|Placement of acupuncture needles in specific points on the ear in two consecutive treatments spaced 7 days apart.
223508853|NCT02851524|OTHER|posturography|
223608611|NCT00213265|BIOLOGICAL|7-valent pneumococcal conjugate vaccine|For transplant patients, vaccination will be started at 4 months or greater after transplantation. The second dose will be given 8 weks following the frist, the third dose 8 weeks after the second, and the fourth will be given 8 weeks after the third.
223608612|NCT00213265|BIOLOGICAL|Pneumococcal 7-valent Conjugate Vaccine|"Healthy infants: The Prevnar schedule for healthy infants consists of 3 doses of 0.5 ml each, at approximately 2 month intervals, followed by a fourth dose of 0.5 ml at 12-15 months of age (i.e., 2, 4, 6, and 12-15 months)~Previously unvaccinated older infants and children, who are beyond the age of the routine infant schedule, should receive the follwong schedule:~7-11 months of age: 3 doses (2 doses at least 4 weeks apart with the third dose after the first birthday and separated from the second dose by at least two months)~12-23 months of age: 2 doses (at least 2 months apart)~≥24 months through 9 years of age: 1 dose"
223608613|NCT02072265|DEVICE|Infrared thermal images|
223755189|NCT01764568|BEHAVIORAL|Metacognitive Training (MCT)|The metacognitive group training program that will form the basis of the 16 session MCT intervention has been described in previous research (Moritz \& Woodward 2007a; Moritz \& Woodward 2007b; Moritz 2011) and can be obtained online at no cost (www.uke.de/mkt). This experimental intervention will consist of two 8-module cycles occurring twice a week for 8 weeks, for a total of 16 sessions. Each module will include a 45 to 60 minute instructor-led group session using PowerPoint slides and homework assignments to facilitate learning. Groups will consist of 4-10 subjects. Subjects will be able to attend the alternate (Cognitive Remediation) group after completion of the MCT group if they wish.
223755190|NCT01764568|BEHAVIORAL|Cognitive Remediation (CR)|The CR group will use a computerized cognitive remediation program that has been used with schizophrenia patients, Scientific Brain Training Pro (SBT Pro; Vianin et al, 2010). Modules focus on attention, working memory, verbal memory, and planning and reasoning. Each session will incorporate psycho-educational group discussion of strategies, and individual work through exercises on personal tablet computers and personalized level of difficulty. The CR treatment will take place twice per week for 8 weeks, for a total of 16 sessions. Groups will consist of 4-10 subjects. Subjects will be able to attend MCT after completion of CR if they wish.
223755191|NCT06026865|DIETARY_SUPPLEMENT|S-Adenosyl-L-methionine (SAMe)|S-adenosyl-L-methionine 1200 mg/daily as 2400mg S-Adenosyl-L-methionine disulfate tosylate
223755192|NCT06026865|OTHER|Placebo|Placebo of identical appearance, smell and taste, with the same schedule.
223755193|NCT05346263|DEVICE|Intermittent Abdominal Pressure Ventilation|Patients of experimental group will use IAPV in daytime ventilation. Intermittent abdominal pressure ventilation (IAPV) is a portable ventilator with an internal battery and PneumoBelt corset as an interface.
223755194|NCT05346263|DEVICE|Usual ventilation|NIV
223755195|NCT01108536|DEVICE|adaptive prosthetic socket|trans tibial socket with actuator zones (inflatable fluid bladders)
223755196|NCT02434835|DRUG|[14C]KWA-0711|
223755197|NCT01023646|OTHER|Carbohydrate + Protein|Light Tuna Packed in water.
223755198|NCT01023646|OTHER|Carbohydrate + Fat|Butter
223755199|NCT01023646|OTHER|Fiber|Unrefined Carbohydrate
223755200|NCT01023646|OTHER|Carbohydrate load|Carbohydrate
223755201|NCT05528237|DEVICE|Flocked swab paired with Roche Cobas 4800|Consenting individuals will insert the sterile flocked swab into the vagina, rotate at least once, and store in the provided dry tube. The sample will be stored at ambient temperature and routed to the lab for HPV testing with Roche Cobas 4800.
223755202|NCT00733863|BIOLOGICAL|Placebo|
223755203|NCT00733863|BIOLOGICAL|CAD106|
223755204|NCT06042036|OTHER|Spontaneous mode of mechanical ventilation|any mode of mechanical ventilation classified as spontaneous or proportional, mainly pressure support ventilation, but also CPAP, APRV, NAVA, PAV+
223508854|NCT04967417|DRUG|Pemetrexed, Carboplatin, Pembrolizumab|"* Pemetrexed 500mg/m2~* Carboplatin AUC 5.0~* Pembrolizumab 200mg"
223508855|NCT04967417|DRUG|Paclitaxel, Carboplatin, Pembrolizumab|"* Paclitaxel 200mg/m2~* Caboplatin AUC 6.0~* Pembrolizumab 200mg"
223508856|NCT06690931|DEVICE|Brain-Computer Interface with FES and VR|"The intervention utilizes the recoveriX PRO system. This is a neurofeedback therapy device that combines Brain-Computer Interface based motor imagery, functional electrical stimulation (FES), and virtual reality (VR). This approach enables participants to engage in motor imagery exercises while receiving real-time feedback based on neural signals.~Participants will complete a total of 24 recoveriX sessions, scheduled at 6 sessions per week, with each session lasting 1 hour."
223508857|NCT06690931|DEVICE|Motor imagery with Functional Electrical Stimulation and Virtual Reality feedback|"The participants will train the Motor Imagination (MI) combined with Functional Electrical Stimulation (FES) and Virtual Reality (VR) feedback. Feedback provided to the patients will not be linked to the neural signals.~The amount of stimulation delivered by the feedback devices (FES and VR) will be similar to the experimental group."
223508858|NCT07018258|PROCEDURE|Erector Spinae Plane (ESP) Block|Ultrasound-guided bilateral erector spinae plane (ESP) block performed at the T7 vertebral level. The intervention will be applied in three different patient positions-lateral, prone, or sitting-prior to laparoscopic cholecystectomy.
223508859|NCT00985374|DRUG|RAD001|5mg or 10mg po daily
223508860|NCT00985374|DRUG|RG1507|16mg/kg iv every 3 weeks
223508861|NCT06693492|DEVICE|Ultrasound technique for diagnosis; Focused Ultrasound Stimulation for intervention|Both chronic and post-acute patients are evaluated through the ultrasound technique to further characterize the mechanisms underlying DOC following acquired brain injuries (e.g., stroke, traumatic brain injury, anoxic events). Furthermore, the predictive value of structural and functional markers for DOC chronicization is explored by following up post-acute DOC patients 1 year after the acute event. Finally, to innovate the therapeutic approach to DOC patients, we adopt the low-intensity focused ultrasound (FUS) on a group of selected 10 patients out of the 100 DOC patients enrolled in the study to modulate brain networks' functioning targeting key brain structures for the recovery of consciousness.
223508862|NCT05330429|DRUG|Magrolimab|Administered intravenous infusion
223508863|NCT05330429|DRUG|Bevacizumab|Administered intravenous infusion
223508864|NCT05330429|DRUG|Irinotecan|Administered intravenous infusion
223508865|NCT05330429|DRUG|Fluorouracil|Administered intravenous infusion
223508866|NCT05330429|DRUG|Leucovorin|Administered intravenous infusion
223508867|NCT01294930|OTHER|Urine density|measurement of urine color, density and plethysmographic variability index before and during surgery.
223508868|NCT07028086|DRUG|VAM_GROUP|Mitoxantrone Liposome 24mg/m², IV, administered as a single dose or divided doses at the investigator's discretion based on the patient's condition; Azacitidine 75mg/m², IV drip, Day 1 to Day 7; Venetoclax 100mg on Day 1, 200mg on Day 2, and 400mg on Day 3 to Day 14.
223508869|NCT06687044|BEHAVIORAL|Sleep restriction|Go to bed before 23pm
223508870|NCT06687044|BEHAVIORAL|Stimulation control|Avoid drugs, alcohol, caffeine, and nicotine
223508871|NCT06687044|BEHAVIORAL|Cognitive therapy|Listen to 30 minutes of soothing music every night for 8 weeks
223508872|NCT06687044|BEHAVIORAL|Sleep principles discussion|The principles of sleep hygiene are discussed, but without the application of stimulus control or sleep restriction
223508873|NCT07028424|DRUG|Nal-IRI|NAL-IRI 50 mg/m2, administered over 80-100 minutes, on day 1 of a 14-days cycle
223608614|NCT04979650|DRUG|Methylprednisolone succinate|1 gram of methylprednisolone succinate within 500 ccs of normal saline
223608615|NCT04979650|DRUG|Normal saline|500 g of normal saline without methylprednisolone succinate
223755205|NCT03437785|DRUG|CKD-495 75mg|CKD-495 75mg Tab.
223755206|NCT03437785|DRUG|CKD-495 150mg|CKD-495 150mg Tab.
223755207|NCT03437785|DRUG|Artemisiae argyi folium 95% ethanol ext.(20→1) 60mg|Artemisiae argyi folium 95% ethanol ext.(20→1) 60mg Tab.
223755208|NCT03437785|DRUG|Rebamipide 100mg|Rebamipide 100mg Tab.
223755209|NCT03437785|DRUG|Placebo of the CKD-495 75mg|Placebo of the CKD-495 75mg Tab.
223608616|NCT01568840|OTHER|Global Postural Reeducation Group|Sessions happened once a week for 10 weeks, lasting 60 minutes each and consisted in manual therapy maneuvers and global postural reeducation treatment.
223608617|NCT01568840|OTHER|Segmental Exercises Group|Sessions happened once a week for 10 weeks, lasting 60 minutes each and consisted in segmental exercises (stretching and strengthening) treatment.
223608618|NCT04131946|OTHER|Community-Based (Intervention Arm)|Community dispensed FIT
223608619|NCT05088057|DRUG|Camrelizumab|200mg on Day 1 of each cycle in the neoadjuvant and adjuvant phases of the study for a total of 17 cycles (Q3W), intravenous (IV) infusion.
223608620|NCT05088057|DRUG|Doxorubicin|60mg/m² on Day 1 of Cycles 1-4 (Q3W)of the neoadjuvant phase of the study, IV infusion.
223608621|NCT05088057|DRUG|Cyclophosphamide|600 mg/m² on Day 1 of Cycles 1-4 (Q3W)of the neoadjuvant phase of the study, IV infusion.
223608622|NCT05088057|DRUG|Docetaxel|75mg/m² on Day 1 of Cycles 1-4 (Q3W) or Cycles 5-8 (Q3W) of the neoadjuvant phase of the study, IV infusion;
223608623|NCT02378324|OTHER|Screening without fee|All women in three districts in Gothenburg, Sweden, that were eligible for invitation in the regular screening program were individually randomized by computer program in two parallel arms 1:1.
223608624|NCT01463241|BEHAVIORAL|Behavioral and Affective Skills in Coping (BASIC)|The investigator's seek to develop a treatment protocol that integrates five core intervention principles that are common to evidence-based treatments for youth depression, anxiety, and disruptive behavior problems. The protocol will be designed for implementation in everyday community practice settings by practitioners. The BASIC protocol will include (a) a therapist manual guiding the use of five BASIC skills \[Belief Repair, Action, Solving Problems, Incentives, and Calming\]; (b) child and parent materials to facilitate learning skills, practicing them in-session, and using them outside sessions; and (c) a decision tree to guide judgments about which skills to use and when to switch skills or treatment focus.
223608625|NCT02486016|DRUG|Duragesic reference fentanyl TDS|25 µg/hour
223608626|NCT02486016|DRUG|Apotex generic fentanyl TDS|25 µg/hour
223608627|NCT02486016|DRUG|Mylan generic fentanyl TDS|25 µg/hour
223608628|NCT00056979|DRUG|CAMPATH-1H|
223608629|NCT00056979|DRUG|Anti-CD45|
223608630|NCT00056979|DRUG|FK506|
223608631|NCT00056979|DRUG|Fludarabine|
223755210|NCT03437785|DRUG|Placebo of the CKD-495 150mg|Placebo of the CKD-495 150mg Tab.
223755211|NCT03437785|DRUG|Placebo of Artemisia Herb 95% Ethanol Soft Ext.(20→1) 60mg|Placebo of Artemisia Herb 95% Ethanol Soft Ext.(20→1) 60mg Tab.
223755212|NCT03437785|DRUG|Placebo of the Rebamipide 100mg|Placebo of the Rebamipide 100mg Tab
223755213|NCT03591237|BEHAVIORAL|Mindfulness-Based Cognitive Therapy|The patients participate in eight weekly group sessions of two hours each and will be asked to do an additional 45 minutes of daily training at home. The participants will be asked to record their home training to allow assessment of their adherence to the intervention. Generally, the program corresponds to the manualized MBCT program, but with adaptations that take into account the special needs of cancer patients, including shorter sessions, shorter yoga exercises and the omission of the all-day session. The sessions include psychoeducation and formalized mindfulness exercises with focus on the participants' here-and-now experience of their pain.
223755214|NCT04659278|DIETARY_SUPPLEMENT|Endourage 1200 mg OMD ™ Oral Mucosal Drops|The CBD/THC ratio of OMD 1200 is 14:1 and the CBD/Terpene ratio is 1:1. Each ¼ dropper contains 10.2 mg of CBD and 0.7 mg of THC. The total % THC is 0.28%. These ratios indicate that the product will not cause euphoria.
223755215|NCT04659278|DIETARY_SUPPLEMENT|Isolate|The isolate formulation contains 0% cannabinoids (CBD 0.00%; CBDa 0.00%; detla 9 THC 0.00%; THCa 0.00%).
223755216|NCT04659278|OTHER|Placebo|Total CBD = CBD + (CBD-A \* 0.877). Total THC = THCA-A \* 0.877 + Delta 9 THC, ND = \<LOQ, T-Caryophyllene = Trans-Caryophyllene, \<LOQ = Less Than Limit of Quantitation, QNS = Quantity Not Sufficient. (%) = Percent, (ppm) = Parts per Million, (ppb) = Parts per Billion, (μg/Kg) = Microgram per Kilogram, (mg/g) = Milligram per Gram, ppm = (μg/g), ppb = (μg/kg),
223755217|NCT04659278|DIETARY_SUPPLEMENT|Peppermint Oil, masking flavor|Mentha piperita Leaf /Stem Oil; Physical state: Liquid. Color: Colorless to pale yellow; Characteristic peppermint odor; Not dangerous goods.
223755218|NCT04167007|DRUG|Gemcitabine|Gemcitabine at 1000 mg/m² as intravenous (IV) infusion over 30-40 minutes on days 1, 8, and 15, followed by 1 week of rest, every 28 days
223608632|NCT05747183|PROCEDURE|ProTaper Ultimate|Root canal preparation using ProTaper Ultimate files.
223608633|NCT05747183|PROCEDURE|ProTaper Gold|Root canal preparation using ProTaper Gold files.
223608634|NCT05865522|OTHER|Trapezius Massage|The patients in Trapezius Massage Group will be given classical massage to the trapezius muscle for 6 weeks, 2 sessions per week (12 sessions in total) by the researcher in the physical therapy unit.
223608635|NCT05865522|OTHER|Foot Massage|The patients in Foot Massage Group will be given foot massage for 6 weeks, 2 sessions per week (12 sessions in total) by the researcher in the physical therapy unit.
223755219|NCT04167007|DRUG|FOLFOX|Oxaliplatin at 85 mg/m² given as a 2 hours IV infusion on days 1 and 15; Folinic acid 400 mg/m² (racemic form) or 200 mg/m² (L-form) in 250 ml glucose 5% solution given as a 2 hours IV infusion on days 1 and 15; and 5-FU 2400 mg/m² administered as continuous 46-hour IV infusion on days 1-3 and 15-17, every 28 days.
223608636|NCT01552863|DRUG|Oxycodone|One capsule of 40 mg PF-00345439 Formulation A, single dose
223608637|NCT01552863|DRUG|Oxycodone|One capsule of 40 mg PF-00345439 Formulation E, single dose
223608638|NCT01552863|DRUG|Oxycodone|One capsule of 40 mg PF-00345439 Formulation F, single dose
223608639|NCT01552863|DRUG|Oxycodone|One capsule of 40 mg PF-00345439 Formulation G, single dose
223608640|NCT01552863|DRUG|Oxycodone|One capsule of 5 mg PF-00345439 Formulation TBD, single dose
223608641|NCT01552863|DRUG|Oxycodone|One capsule of 40 mg PF-00345439 Formulation H, single dose
223608642|NCT03672292|DRUG|SCY-078|Oral tablets of SCY-078
223608643|NCT03672292|DRUG|Voriconazole|Voriconazole IV vials or oral tablets
223608644|NCT03672292|OTHER|Oral Placebo Tablets|Oral Placebo Tablets matching SCY-078
223608645|NCT06215261|DRUG|Methylone|Methylone capsules, given orally, once a week for 3 weeks (Part A) or 4 weeks (Part B)
223608646|NCT03940300|DIETARY_SUPPLEMENT|Fresh organic vegetables|"Individual participation in this program will take 12 weeks, from screening and enrollment through evaluation. Once enrolled, visits will occur on a weekly basis to ensure that participants receive each week's dose of fresh organic vegetables. At an optional Visit 13, offered 6 months after Visit 1, an additional health screening will be conducted."
223608647|NCT02773485|RADIATION|High Dose Radiation|The aim will be to deliver 52.5-60 Gy/ 25 fractions to the gross disease and 45 Gy/ 25 fractions to suspected microscopic disease along with weekly gemcitabine (300 mg/ m2) .
223755220|NCT03735667|DEVICE|ACURATE neo2™ Transfemoral TAVR System|ACURATE neo2™ Transfemoral TAVR system: Support frame made of nitinol, supra-annular processed tri-leaflet porcine pericardial valve and an outer skirt to limit paravalvular regurgitation (manufactured by Boston Scientific Corporation, Marlborough, MA, USA).
223608648|NCT02773485|DRUG|Systemic chemotherapy|This arm will receive maximum 8 cycles of gemcitabine 1000 mg/m2 and cisplatin 25 mg/m2 delivered on day 1 and 8 every 3 weekly.
223608649|NCT05782062|DEVICE|Cleaner XT|Wire like device that rotates to allow for wall to wall disruption of thrombus.
223608650|NCT05782062|DEVICE|Balloon|Use of balloon for disrupting thrombus.
223608651|NCT05567250|BEHAVIORAL|Behavioral: Telephone-based ACEs care coordination|The 211LA care coordinator will use the agency's extensive resource directory to identify and provide appropriate referral recommendations to each family. In addition, they will develop a care coordination plan, noting these recommendations and plans for follow-up, to be provided to the family's clinical care provider. The coordinator will routinely follow-up with the family until 1) children begin receiving services, 2) families refuse services, or 3) children are deemed ineligible by service providers.
223608652|NCT02698514|DRUG|Sevoflurane|Anesthesia was maintained with sevoflurane in patients undergoing standardized nociceptive stimulus (long-lasting tetanic stimulus of the ulnar nerve; 30 s, 50 mA, 50 Hz, square-wave).
223608653|NCT02698514|DRUG|Desflurane|Anesthesia was maintained with desflurane in patients undergoing standardized nociceptive stimulus (long-lasting tetanic stimulus of the ulnar nerve; 30 s, 50 mA, 50 Hz, square-wave).
223608654|NCT04007016|PROCEDURE|"a new osteotomy from the inner L shaped iliac osteotomy"|"There were two ostectomies were used in the osteotomy. The first was was a cured and 5mm width and the second one was straight 1.5cm width. All the directions was started from the inner to outer just a bove the triradiate cartilage and its shape likeL"
223608655|NCT01418430|DRUG|CHOP-daclizumab|
223608656|NCT05956899|DRUG|Palonosetron|IV palonosetron 1.5mcg/kg prior to commencement of general anaesthesia
223608657|NCT05956899|DRUG|Ondansetron|IV ondansetron 0.15mg/kg at the start of wound closure
223608658|NCT05993923|OTHER|GPOU|"Intervention upstream of the perioperative management according to the nutritional grade. Grade 4 Nutrition patients will be hospitalized earlier, i.e. 10 to 15 days before surgery for the start of artificial nutrition. A temporary return home can be organized with the supervision of a service provider until a second admission for surgical management. Grade 2 Nutrition patients will be called 24 to 48 hours before the surgical procedure.~Anticipation of discharge at admittance Early mobilization Comorbidity management Prevention of iatrogenia Management of geriatric frailties Daily medical and paramedical assessment Detailed discharge report"
223608659|NCT03797586|OTHER|Electroacupuncture group|Bilateral Tianshu (ST25), Fujie (SP14), Shangjuxu (ST37) will be used in the EA group. With the local skin of the patients was routinely sterilized in a prone position in relaxation, acupuncturists will insert needles into the acupuncture points. For ST25 and SP14, 0.30×50mm or 0.30×75mm needles will be vertically inserted to the muscle layer of the abdominal wall, where participants will feel sharp pain and acupuncturists will feel resistance from the needle tip. For ST37, 0.30×40 mm needles will be vertically inserted approximately 15 mm deep, followed by three-time manipulation of even lifting and twisting method to elicit the sensation of deqi. Then paired alligator clips of the EA apparatus will be attached to the needle holders of the bilateral ST25, SP14, and ST37. EA stimulation will be retained for 30 minutes with a continuous wave of 10 Hz and current intensity of 0.5 to 4 mA.
223608660|NCT03797586|OTHER|Sham electroacupuncture group|Bilateral sham ST25, SP14, and ST37 will be used in the SA group. After sterilizing the skin, 0.30×40mm needles will be straightly inserted at the sham points about 2-3mm until they can be fixed on the skin when attached by the alligator clips. No manipulation will be used, and no deqi sensation are elicited for all sham points. The bilateral sham ST25, SP14, and ST37 points will be attached by the same EA apparatus with a continuous wave of 10 Hz and current intensity of 0.1 to 0.2 mA for 30 minutes with only the initial 30 seconds on.
223755221|NCT03735667|DEVICE|Medtronic CoreValve TAVR System|Medtronic CoreValve Evolut R or Evolut PRO Transcatheter Aortic Valve Replacement (TAVR) System (or any future Corevalve iterations): The support frame is manufactured from nitinol, which has multilevel, self-expanding properties and is radiopaque. The bioprosthesis is manufactured by suturing valve leaflets and a skirt from porcine pericardium into a tri-leaflet configuration (manufactured by Medtronic CoreValve LLC, Santa Ana, USA).
223755222|NCT03735667|DEVICE|Edwards SAPIEN 3 TAVR System|Edwards SAPIEN 3 TAVR system (or any future SAPIEN iterations): balloon-expandable transcatheter aortic bioprosthesis, support frame made of cobalt-chromium, three leaflets constructed of processed bovine pericardial tissue and an outer polyethylene terephthalate (PET) sealing cuff to mitigate paravalvular regurgitation (manufactured by Edwards Lifesciences, Inc., Irvine, California, USA)
223608661|NCT06562127|BEHAVIORAL|TRAIN-Vets|The TRAIN-Vets intervention entails 6 months of thrice-weekly aquatic-based exercise training at Veterans Affairs Palo Alto Health Care System (VAPAHCS). After completion of the 6-months of exercise training, Veterans in this condition will participate in 2 months of weekly structured on-line cognitive training focused on improvement of executive function and attention based out of the San Francisco Veterans Affairs Health Care System (SFVAHCS). Concurrently, Veterans in TRAIN-Vets will also participate virtually in personalized risk factor reduction sessions based at SFVAHCS focused on other risk factors and symptoms.
223608662|NCT06562127|BEHAVIORAL|Health Education Control|The Health Education Control (HEC) receives mailed educational materials about brain health and dementia risk factor reduction over 8 months, as well as regular contact with study staff.
223755223|NCT03735667|DEVICE|ACURATE Prime™ Transfemoral TAVR System XL|ACURATE Prime™ Transfemoral TAVR system: Support frame made of nitinol, supra-annular processed tri-leaflet porcine pericardial valve and an outer skirt to limit paravalvular regurgitation (manufactured by Boston Scientific Corporation, Marlborough, MA, USA).
223755224|NCT06564584|DRUG|TLC-2716 Dose 1|Capsules administered orally
223755225|NCT06564584|DRUG|TLC-2716 Dose 2|Capsules administered orally
223755226|NCT06564584|DRUG|Placebo|Capsules administered orally
223755227|NCT01464658|PROCEDURE|panniculectomy|surgery
223755228|NCT01094548|BIOLOGICAL|Tecemotide (L-BLP25)|After receiving single low dose of cyclophosphamide, subjects will receive 8 consecutive weekly subcutaneous vaccinations with 806 microgram (mcg) of tecemotide (L-BLP25) at Weeks 1, 2, 3, 4, 5, 6, 7 and 8 followed by maintenance vaccinations (806 mcg of tecemotide (L-BLP25) at 6-Week intervals, commencing at Week 14, until disease progression requiring anti-tumor therapy is documented.
223755229|NCT01094548|BIOLOGICAL|Tecemotide (L-BLP25)|After receiving multiple low dose of cyclophosphamide, subjects will receive 8 consecutive weekly subcutaneous vaccinations with 806 mcg of tecemotide (L-BLP25) at Weeks 1, 2, 3, 4, 5, 6, 7 and 8 followed by maintenance vaccinations (806 mcg of tecemotide (L-BLP25) at 6-Week intervals, commencing at Week 14, until disease progression requiring anti-tumor therapy is documented.
223755230|NCT01094548|DRUG|Single low dose cyclophosphamide|An intravenous (IV) infusion of 300 milligram per square meter (mg/m\^2) (to a maximum 600 mg) of cyclophosphamide will be given 3 days before the first vaccine treatment.
223755231|NCT01094548|DRUG|Multiple low dose cyclophosphamide|An IV infusion of 300 mg/m\^2 (to a maximum 600 mg) of cyclophosphamide will be given 3 days before the first vaccine treatment plus an intravenous dose of cyclophosphamide (300 mg/m\^2, to a maximum of 600 mg) 3 days prior to the tecemotide (LBLP25) administration at week 5 of the weekly treatment phase and 3 days prior to every tecemotide (L-BLP25) administration during the treatment phase with 6-Weekly administration of tecemotide (L-BLP25), commencing at Week 14 up to a maximum treatment period of 2 years.
223755232|NCT05278078|OTHER|psychological support|psychological support will be given to the patients in the experimental group.
223755233|NCT05278078|OTHER|nutritional education|nutritional education will be given to the patients in the experimental group.
223755234|NCT05278078|OTHER|psychological support and nutritional education|psychological support and nutritional education will be given to the patients in the experimental group.
223755235|NCT05278078|OTHER|no intervation|No intervention will be applied to the control group
223608665|NCT06493734|RADIATION|Stereotactic body radiation therapy|SBRT will be delivered in 15 fractions of 4 to 4.5Gy (risk-adapted), one fraction each weekday for 3 weeks.
223608666|NCT05708001|DEVICE|transcranial alternating current stimulation (tACS)|tACS will be delivered by a battery-driven current stimulator Starstim SS32 (Neuroelectrics) through surface Ag/AgCl electrodes placed into holes of a neoprene cap corresponding to the international 10/20 EEG system. Gel (Parker Lab, Inc.) will be applied to optimize signal conductivity and lower impedance. Two tACS (active and sham) conditions will be applied in randomized order. 40 Hz tACS will be delivered to different brain areas of the memory network. We will employ a multielectrode montage based on electric field modeling using the individual MRI to optimally reach the target areas. The maximum injected current per electrode is 2mA and the overall maximal current is 4mA to generate an average electric field of 0.25 V/m.
223608667|NCT05708001|DEVICE|high-density electroencephalography (hdEEG)|EEG will be recorded with a 257-channel EEG system. An EEG net is applied at once on the head with evenly spaced sensors that provide full scalp coverage, including the cheek. The net contains Ag/Ag-Cl electrodes that are interconnected by thin rubber bands and contain small sponges soaked with saline water that touch the participant's scalp surface directly. Net application takes about 10 min to derive to impedances of \<30 kOhms. EEG is recorded with 1 kHz and band-pass filtered between DC-200 Hz. Vertex electrode Cz is used as an acquisition reference.
223608668|NCT05708001|DIAGNOSTIC_TEST|Montreal Cognitive Assessment (MoCA)|Clinical Evaluation and Cognitive Assessment - to characterize the level of dementia and changes in cognitive status measured at the baseline and after 4 weeks of gamma/sham tACS intervention, and in a follow-up 3 months after the stimulation using MoCA.
223608669|NCT02864901|DRUG|KSL-W|Antimicrobial KSL-W Plaque reducing chewing gum
223755236|NCT01466946|BEHAVIORAL|semi-structured interviews|Use semi-structured interview methods to gather narrative data from research participants, as more open-ended interviews allow participants to share information that is most relevant to their own experiences (Patton, 2002; Rubin \& Rubin, 2005; Kvale, 1996). Semi-structured interviewing can generate a rich understanding of a participant's life routines, experiences, and attitudes related to a topic of inquiry, and can yield a nuanced and thorough description of a research participant's life story and belief systems.
223755237|NCT05804266|PROCEDURE|Coventional coagulation|In the conventional group, the haemostasis of vessels will be performed with the conventional coagulation technique under CO2 insufflation. First, submucosal fibres surrounding a blood vessel will be dissected and the vessel will be isolated. After, both sides of the isolated vessel will be coagulated using SWIFT COAG E3, 89 W for POEM and SWIFT COAG E4, 124 W for ESD until the blood vessel turns white and can be finally cut.
223755238|NCT05804266|PROCEDURE|Underwater coagulation|In the treatment group, the prophylactic haemostasis of vessels will be accomplished by the underwater coagulation technique. First, physiological solution will be instilled until there is no more air around the blood vessel. Then, the vessel will be coagulated using SWIFT COAG E3, 89 W for POEM and SWIFT COAG E4, 124 W for ESD until it turns white and, after the removal of all the physiological solution, can be finally cut.
223755239|NCT04732975|DEVICE|CardioFlux|Non-invasive screening for ACS
223755240|NCT00212953|PROCEDURE|Advanced Life Support|
223755241|NCT01257958|DRUG|19 nor vitamin d|
223755242|NCT04426617|PROCEDURE|Ultrasound Guided Transversus Abdominis Plane Block|The patient will lie in the supine position. The transducer will be placed in the axial plane on the mid-axillary. transversus abdominis muscle will be visualized. A skin wheel using 3 ml of lidocaine 1 % is made 2 to 3 cm medial to the medial aspect of the transducer and the 22 gauge is inserted in-plane pointing laterally. Then Injection of local anaesthetic mixure in the right plane.
223755243|NCT02501980|BIOLOGICAL|Biomarker testing and Ultrasonography|
223755244|NCT04081948|OTHER|Erector spinae plane block (Group E)|"Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. Postoperative patient evaluation will be performed by an anesthesiologist blinded to the procedure.~Postoperative pain assessment will be performed using the VAS score (0 = no pain, 10 = the most severe pain felt). The VAS scores at rest and during cough will be recorded at postoperative 1, 2, 4, 8, 16, 24 and 48 hours. If the VAS score will be ≥ 4, 0.5 mg/ kg meperidine IV will be administered. Sedation level will be assessed with a 4-point sedation scale (0 = awake, eyes open, 1 = sleepy but responding to verbal stimulus, 2 = sleepy and hard to evoke, 3 = sleepy, not aroused by shaking). The first time of the use of rescue analgesic, intraoperative and postoperative opioid consumption, side effects such as nausea, vomiting, itching and block related complications will be recorded."
223755245|NCT04081948|OTHER|Sham block group (Group S)|"Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. Postoperative patient evaluation will be performed by an anesthesiologist blinded to the procedure.~Postoperative pain assessment will be performed using the VAS score (0 = no pain, 10 = the most severe pain felt). The VAS scores at rest and during cough will be recorded at postoperative 1, 2, 4, 8, 16, 24 and 48 hours. If the VAS score will be ≥ 4, 0.5 mg/ kg meperidine IV will be administered. Sedation level will be assessed with a 4-point sedation scale (0 = awake, eyes open, 1 = sleepy but responding to verbal stimulus, 2 = sleepy and hard to evoke, 3 = sleepy, not aroused by shaking). The first time of the use of rescue analgesic, intraoperative and postoperative opioid consumption, side effects such as nausea, vomiting, itching and block related complications will be recorded."
223755246|NCT02000375|DRUG|DHEA|DHEA: Daily oral administration of DHEA(Dehydroepiandrosterone) at the dosage of 100 mg/die in combination with a daily oral administration of anastrozole at dosage of 1 mg/die or letrozole at the dosage of 2.5 mg/die or exemestane at the dosage of 25 mg/die without interruption.
223755247|NCT02073422|DEVICE|Fractional flow reserve|Guidewire-based index of coronary artery stenosis severity measured when coronary microvascular resistance is minimised by administration of a vasodilator drug.
223755248|NCT02073422|OTHER|Magnetic resonance imaging|Cardiac magnetic resonance imaging at 3.0 Tesla, including perfusion MRI at rest and during pharmacological stress with intravenous adenosine (140-210 ug/kg/min).
223755249|NCT00378066|DRUG|Bevacizumab|Bevacizumab, Capecitabine, Oxaliplatin
223755250|NCT02394080|DEVICE|Photodynamic Bone Stabilization System|Treatment of acute humerus fractures
223608670|NCT04905745|PROCEDURE|Korean integrative medicine|"Any kind of Korean integrative medicine will be applicable and the treatment will be entirely determined by experienced clinicians. On the premise of the above, the following examples are the treatments applicable to the subject of this observational study.~* Chuna: Chuna therapy is performed on the face and cervical spine to induce decompression of the captured facial nerve. In addition, SJS Non-Resistance Technique-Facial palsy (SJS NRT-F), a technique of Chuna, can be performed to stimulate the intrinsic receptive sensation of the facial muscles to promote the neuromuscular response.~* Acupuncture: acupuncture can be applied on paralyzed muscle and others to improve symptoms and paralysis status.~* Pharmacopuncture: pharmacopuncture can be applied on paralyzed muscle and others to improve symptoms and paralysis status.~* Herbal medicine: It is prescribed according to clinical judgment according to the patient's symptoms and disease status."
223608671|NCT05730387|OTHER|Observational only|This is a non-interventional study
223608672|NCT06002763|OTHER|PROMIS-29 v2.1 (Patient-Reported Outcomes Measurement Information System)|PROMIS-29 is a survey designed to screen for pain, impairments in mood, physical function, and activities of daily living.
223755251|NCT04067284|BEHAVIORAL|Nutrition education|"Nutrition Education on~* Continued breastfeeding until two years of age~* Food groups~* Balanced diet~* Introduction to locally available nutritious and low-cost foods~* Amount and frequency of complementary feeding~* Safe water, and~* Handwashing with soap before feeding"
223755252|NCT04067284|DIETARY_SUPPLEMENT|Homemade yogurt supplementation|The homemade yogurt supplementation will start a week after beginning of 6 months of age once the child is introduced to solid foods of the mother's choice. The yogurt will be supplied to the mothers every day at time of feeding.
223755253|NCT04067284|OTHER|Usual care|No intervention/ control group
223755254|NCT01973101|DRUG|Cisplatin|50 mg/m2 - Day 1
223755255|NCT01973101|DRUG|Gemcitabine|Gemcitabine 1000mg/m2 on day 1 and day 8.
223755256|NCT01973101|DRUG|cisplatin|Cisplatin 40 mg/m2 on day 1, day8, day15, day22, day 36 of radiotherapy period.
223755257|NCT01973101|RADIATION|Radiotherapy|45 Gy
223755258|NCT01973101|RADIATION|Brachytherapy|80 Gy
223755259|NCT02271191|DRUG|Nicardipine|nicardipine 1-5 ug/kg/min and remifentanil 0.05 ug/kg/min during deliberate hypotension in spine surgery
223608673|NCT06002763|OTHER|WHOQoLBREF (World Health Organization Quality of Life Brief Version)|The WHOQOL-BREF is a 26-item version of the 100-item WHOQOL-100 quality of life measure that addresses four quality of life domains: physical health, psychological health, social relationships and environment.
223608674|NCT06002763|OTHER|EQ-5D-3L1 (not an acronym)|The EQ-5D-3L1 is a generic measure of health status consisting of two parts. The first part assesses health in five dimensions: MOBILITY, SELFCARE, USUAL ACTIVITIES, PAIN / DISCOMFORT, ANXIETY/DEPRESSION. The second part of the questionnaire consists of a VAS on which the patient rates their perceived health from 0 (the worst imaginable health) to 100 (the best imaginable health).
223755260|NCT03913481|PROCEDURE|Acute normovolemic hemodilution|In the ANH arm, after induction of general anesthesia, a total blood volume of at least 650 ml of blood will be drawn from a central line. The amount of volume drawn can be replaced with Ringer lactate or a similar crystalloid fluid up to a 3:1 ratio.
223755261|NCT03913481|PROCEDURE|Standard care|Best available treatment without ANH
223755262|NCT01378793|BEHAVIORAL|Relaxation Acupressure|Apply pressure (stimulate) to the 9 acupoints for 3 minutes per point giving a total treatment time of 27 minutes done once daily for a period of 6 weeks.
223755263|NCT01378793|BEHAVIORAL|Stimulating Acupressure|Apply pressure (stimulate) to the 10 excitatory acupoints for 3 minutes per point giving a total treatment time of 30 minutes done once daily for a period of 6 weeks.
223755264|NCT01987427|DRUG|lorcaserin + phentermine placebo|lorcaserin 10 mg BID + phentermine placebo BID
223755265|NCT01987427|DRUG|lorcaserin + phentermine-HCl + phentermine placebo|lorcaserin 10 mg BID + phentermine-HCl 15 mg QD + phentermine placebo QD
223755266|NCT01987427|DRUG|lorcaserin + phentermine-HCl|lorcaserin 10 mg BID + phentermine-HCl 15 mg BID
223755267|NCT03215134|OTHER|Self-criticism intervention|Compassion Focused Therapy (Gilbert, 2010) adapted to focus specifically on reducing self-criticism. This intervention was originally developed for a student population (Rose, McIntyre \& Rimes, submitted) and is now being evaluated in a primary mental-health service.
223755268|NCT03548766|BIOLOGICAL|Homologous Blood Transfusion|Homologous, or allogenic, blood transfusions involves someone collecting and infusing the blood of a compatible donor into him/herself.
223755269|NCT03548766|BIOLOGICAL|Autologous Blood Transfusion|Autologous blood transfusion is the collection and re-infusion of the patient's own blood or blood components.
223755270|NCT06163508|DRUG|Q-Cells®|Long term observational study of patients who received 1 of 3 different amounts of Q-Cells®.
223755271|NCT02410720|OTHER|Instruction leaflet|Patients will receive the Picoprep solution with an instruction leaflet of how to use it and the dietary modifications needed
223508874|NCT07028424|DRUG|Ciprofloxacin|6 capsules/cycle : 500 mg twice daily on days 1, 8, 15 (on day of gemcitabine infusion) for a maximum of 6 months
223755272|NCT02410720|OTHER|Mobile App|Patients will receive Picoprep solution with an instruction leaflet + Picoprep Mobile App which will be downloaded to their smartphones that has the same information plus a reminder utility
223755273|NCT02410720|OTHER|Explanation of paper and application instructions|The research fellow will explain instructions to patients
223755274|NCT02410720|OTHER|Picoprep solution|
223508875|NCT07028424|DRUG|Paclitaxel|80 mg/m2 weekly on days 1, 8, 15 of each 28-days cycle (at the discretion of investigator)
223508876|NCT07028424|DRUG|Gemcitabine|1,000 mg/m2 intravenously (IV) over 30 minutes weekly on days 1, 8, 15 of each 28-days cycle
223508877|NCT07028424|DRUG|Oxaliplatin|60 mg/m2 (starting 2 hours later, administered over 110-130 minutes) on day 1
223508878|NCT07028424|DRUG|Leucovorin|"As part of NALIRIFOX -for 8 cycle treatment: (L + D racemic form) 400 mg/m2 on day 1 (equivalent to 200 mg/m2 levoleucovorin) (starting 30 minutes after oxaliplatin, administered over 25-35 minutes)~As part of LV5FU2 maintenance treatment: 400 mg/m2 IV infusion over 30 min on day 1 (equivalent to 200 mg/m2 levoleucovorin). LV could be administered over 2 hours to oxaliplatin according to The National Thesaurus of Digestive Oncology (TNCD) https://www.snfge.org/sites/www.snfge.org/files/tncd/2024-05/tncd\_chap-09-cancer-pancre%CC%81as\_2024-05-17\_1.pdf, at investigator's discretion"
223508879|NCT07028424|DRUG|5-Fluorouracil|"As part of NALIRIFOX -for 8 cycle treatment: 2400 mg/m² IV initiated on day 1, with continuous infusion over 46 hours (no bolus infusion with 5-FU)~As part of LV5FU2 maintenance treatment: 400 mg/m2 bolus over 10 min then 2,400 mg/m2 IV infusion over 46h"
223508880|NCT07028424|OTHER|Placebo|6 capsules/cycle : 500 mg twice daily (morning and evening; 12 hours should elapse between two doses) on days 1, 8, 15 (on day of gemcitabine infusion) for a maximum of 6 months
223508881|NCT06695104|BEHAVIORAL|YMCA Produce Rx (YPRx) Program Only (Control)|Participants in the control group will receive weekly, home-delivered produce bags of fresh vegetables and fruits and sized for each participants' household. Produce deliveries will be administered for 52 weeks.
223508882|NCT06695104|BEHAVIORAL|YMCA Produce Rx (YPRx) Program + the Diabetes Prevention Program (DPP)|Participants will receive weekly, home-delivered produce bags of fresh vegetables and fruits and sized for each participants' household. Produce deliveries will be administered for 52 weeks. Additionally, participants will be registered for a free, year-long YMCA membership and enrolled in the DPP. Through the DPP, participants will receive health education, coaching, and peer support via 26 virtual group sessions over a year.
223508883|NCT06687018|OTHER|Kaltenborn mobilisation|Kaltenborn mobilisation Grade 3 along with common treatment for 3 minutes, repeated 3 sets with rest of 1 minutes, three sessions per week for four weeks. Conventional treatment comprises a hot pack for 10 minutes, SWD for 5 minutes, and nerve and tendon gliding exercises.
223508884|NCT06687018|OTHER|Mulligan mobilisation|Mulligan mobilisation with 10 repetitions with 3 sets and three sessions per week for four weeks. Conventional treatment comprises a hot pack for 10 minutes, SWD for 5 minutes, and nerve and tendon gliding exercises
223508885|NCT06714448|DRUG|Sodium valporate|This study will not administer any treatment, only observe the treatment as prescribed in real-world clinical practices.
223512359|NCT01791296|DRUG|Dexmedetomidine|At 21:30h, all current IV sedatives (whether continuous or intermittent) will be decreased by 50% and study drug started at 0.2 mcg/kg/hour at 21h30 to allow sleep between 22h00 and 6h00. Study infusion will be halved at 6:00am and d/c at 6:15am. The infusion rate will be increased by 0.1mcg/kg/hour every 15 minutes when the Riker-SAS is ≥ 4 up to a maximum rate of 0.7 mcg/kg/hr until the targeted sedation goal of a Riker-SAS of 3 is reached. For agitation (ie., Riker-SAS ≥ 5), 'as needed' IV midazolam (1-5 mg IV q1h prn agitation) may be administered during the upwards titration of the study medication. Administration of any dose of as needed IV midazolam will result in the increase of the study medication by 0.1 mcg/kg/hr when ≥ 15 minutes have elapsed since the last upwards titration.
223755275|NCT04590547|DRUG|GLS-1027|GLS-1027 is an oral medication with high bioavailability that has IL-6 and IL-1β inhibitory activity.
223755276|NCT04590547|DRUG|Placebo|Placebo looks like GLS-1027
223755277|NCT05477563|BIOLOGICAL|CTX001|Administered by intravenous (IV) infusion following myeloablative conditioning with busulfan
223755278|NCT00981006|PROCEDURE|human cardiac stem cells|Single intramyocardial Injection of autologous hCSCs : 20 cites of infarcted myocardium Implantation of gelatin hydrogel sheet incorporating bFGF: 200 microgram. CABG surgery.
223608675|NCT01219985|OTHER|standard and respiratory-gated PET acquisitions|"After fasting for at least 6 hours, normal glucose blood level was checked and each patient received an intravenous injection of 18F-FDG (5MBq/kg). After a 60-minute uptake phase in a quiet environment, patients underwent the PET/CT examination.~* Whole-body PET/CT (Ungated session) The Ungated acquisition consisted in a whole-body, free-breathing CT followed by standard multistep PET, used as routine clinical practice in the department.~* Respiratory-gated PET/CT (CT-based session) The CT-based method consisted in an additional single-step, 10-minute List Mode respiratory gated PET acquisition followed by an end-expiration breath-hold CT added to the end of the clinical protocol, with continuous respiratory signal recording during these examinations."
223755279|NCT02547129|DEVICE|Static Antibiotic Spacer Surgical Implant|Joint spacer for treatment of joint infection
223755280|NCT02547129|DEVICE|Articulating Antibiotic Spacer Surgical Implant|Joint spacer for treatment of joint infection
223755281|NCT00805766|DRUG|TA-650|(1) Screening Period: 5 mg/kg of TA-650 will be intravenously infused over a period of more than 2 hours at week 0. If patients do not meet the Eligibility Criteria at week 8, they will be administered 5 mg/kg of TA-650 at week 8. (2) Increased Dose Period: 10 mg/kg of TA-650 will be intravenously infused over a period of more than 2 hours every 8 weeks for 32 weeks.
223755282|NCT06267235|OTHER|Dietary protein restriction|The consumption of different diets restricted in protein replaced by either carbohydrate or fat and an habitual diet.
223755283|NCT03925324|BIOLOGICAL|Human Allogeneic Mesenchymal Bone Marrow Cells (aMBMC)|Allogeneic Mesenchymal Bone Marrow Cells (aMBMC) 1.5 million cells/kg
223755284|NCT03925324|OTHER|Placebo|1.5 mL/kg Lactated Ringer's Solution
223755285|NCT02944318|BEHAVIORAL|The Movement Program|The program duration will be one academic year (around ten months) in 2017. The intervention strategies will focus on: (1) teachers' training and activities on health in curriculum; (2) active opportunities in the school environment (facilities and materials for PA practice) and (3) health education (posters and folders to students and parents).
223755286|NCT00005770|DEVICE|Acupuncture|
223755287|NCT00138983|DRUG|Alendronate versus alfacalcidol (1-alpha OH vitamin D)|
223755288|NCT01367769|OTHER|No intervention|There will be no intervention in this study.
223755289|NCT03826758|OTHER|E-DYNAMIC Clinical Decision Support|Clinical decision support system
223755290|NCT02170610|DRUG|BIBR 1048 MS|
223755291|NCT02170610|DRUG|Pantoprazole|
223755292|NCT00757835|DRUG|treatment with latanoprost/timolol fixed combination|dosing in the evening with the two fixed combinations
223755293|NCT00757835|DRUG|latanoprost/timolol fixed combination drops|once in the evening
223755294|NCT00094965|DRUG|Oxaliplatin (SR96669)|oxaliplatin in combination with FOLFOX4
223755295|NCT00753116|DEVICE|Renal Denervation with a catheter-based procedure|Disruption of the renal nerves with a catheter-based procedure
223755296|NCT05601206|BEHAVIORAL|Stepped collaborative care intervention|Using website that was specifically designed for advanced cancer patient, collaborative with treatment from health professional
223755297|NCT05601206|BEHAVIORAL|Enhanced Usual Care|Usual care from health providers
223755298|NCT00628433|DRUG|Placebo|Placebo
223755299|NCT00628433|DRUG|HE3286|daily for 28 days
223755300|NCT05106855|RADIATION|Low Laser Radiation|One group will receive laser application to check if there is acceleration of healing.
223755301|NCT05106855|OTHER|Changing the implant surface|Changing the treatment surface of the dental implant to see if osseointegration occurs more quickly.
223755302|NCT05106855|RADIATION|Low Laser Radiation off|This group will receive laser application off.
223755303|NCT05106855|PROCEDURE|Implant placement immediately after tooth extraction|When the last alternative is tooth extraction, this will be done, and in the same surgical intervention the dental implant will be placed.
223755304|NCT05106855|PROCEDURE|Installing the dental crown with early loading|The installation of the dental crowns will be performed in a period of 6 to 8 weeks, after the dental implant has been installed.
223755305|NCT05951530|OTHER|traditional physical therapy|this group received conventional upper extremity active ROMs and stretches for 30 minutes three to five times a week for 6 weeks without using the app-based cognitive training.
223755306|NCT05951530|OTHER|mobile app-based cognitive training|This group received mobile app-based cognitive training of 30minutes session three to five times a week for 6 weeks which includes a few activities such as the memory, coordination and alertness along with conventional UE exercises for 15 minutes three to five times a week for 6 weeks.
223755307|NCT00591942|DEVICE|Full ceramic crowns or 3-unit fixed partial dentures.|Subjects who met the inclusion/excluson criteria received two ceramic crowns or one three-unit dental bridge on posterior teeth. The crowns and dental bridge were cemented using two different dental adhesives. Follow-up to assess sensitivity of the crowns/bridges occur at 24 hrs. and 1 week post seating by telephone. Clinical visits to assess sensitivity and the integrity of the crowns/bridges occur at 6, 12, 18 and 24 months post seating of the restorations.
223755308|NCT06157177|DRUG|Metaxalone 640 mg Oral Tablet|Metaxalone 640 mg used for the treatment of discomforts associated with acute, musculoskeletal pain.
223755309|NCT01883687|PROCEDURE|Septoplasty|
223755310|NCT02063737|BEHAVIORAL|Text-message assessments only|Text message assessments only. No intervention for high level fatigue.
223755311|NCT02063737|BEHAVIORAL|Text-message interventions for high level fatigue|Intervention messages to promote alertness while on duty at work including activities. Additionally at the end of the shift, participants were queried on their adoption of the suggested activities and perception of the activities' effectiveness.
223755312|NCT02293070|OTHER|Delayed Enhanced Cardiac Magnetic Resonance Imaging|Subjects in this study get a Delayed Enhanced Cardiac Magnetic Resonance Imaging 2-6 weeks after they undergo cryoablation for atrial fibrillation. This MRI is compared to the pre-procedure cardiac MRI to determine if it possible to visualize the cryoablation lesions.
223755313|NCT02293070|PROCEDURE|Cryoablation|All subjects in this study undergo a cryoballoon ablation procedure to achieve pulmonary vein isolation for the purposes of treatment of atrial fibrillation
223755314|NCT06522191|OTHER|Physiotherapy Training (PT)|Both groups received the same therapist-led standardized PT for 5 days a week including 2 days of RR plus 3 days of conventional rehabilitation (CR) for 5 weeks. RR training will be given 40 min per session using an intelligent feedback robotic system. The system allows patients to move a cursor to targets on a monitor using a unilateral exoskeleton robotic arm and handle, which supports shoulder, elbow, forearm, and optionally multi-joint movements. The system provides visual and auditory feedback, offering exergame training with 1Dimension (D), 2D, and 3D options adjustable to three levels (low to high). Exergames and their parameters will be customized based on each patient's capacity. The CR protocol consists of joint range-of-motion, correct movement, stretching and balance exercises, gait training (walking on level surfaces, stairs), strengthening of antagonist muscle pattern will be provided. Each CR session will last 45 min of active treatment.
223755315|NCT06522191|DEVICE|Cross-Education Intervention|Participants in the CE group will have the less affected upper extremity undergo game-based, unilateral, repetitive movement training using RR to enhance the effectiveness of the training to be provided to the affected side. Similar therapeutic games (exergames) planned for the more affected upper extremity will be selected through the unilateral exoskeleton RR device. As described in the PT section, upper extremity movements will be performed using the robotic arm and handle during the games. The difficulty level will be adjusted by the supervisor physiotherapist based on the grip threshold on the robotic handle, the game's difficulty level (low to high), workspace arrangement before each session, and suspension level according to the patient's needs. An approximately 20-minute program will be implemented, consisting of 8 games, each lasting about 2.5 minutes, tailored to the patient's capacity.
223755316|NCT06522191|OTHER|Control Intervention|The exercises to be administered in the control intervention will be selected based on the patient's level of impairment but will be planned without progression or intensity increase, and the involvement of the upper extremity will be kept to a minimum. The exercises will include lower limb joint range of motion exercises, weight bearing, weight shifting, and gait training.
223755317|NCT00641095|BIOLOGICAL|rituximab|concentrate for solution for infusion
223755318|NCT00641095|DRUG|Cyclophosphamide|Tablets
223755319|NCT00641095|DRUG|Fludarabine|Film coated tablet
223755320|NCT03957512|PROCEDURE|Heart surgery|All invasive procedures
223755321|NCT06352450|DIAGNOSTIC_TEST|Active isolated stretching (AIS)|Active isolated stretching (AIS) is a technique that involves stretching specific muscles or muscle groups while actively engaging the opposing muscles. It typically involves holding a stretch for 1-2 seconds and then releasing. This method aims to improve flexibility, increase range of motion, and enhance muscle function.
223755322|NCT06352450|DIAGNOSTIC_TEST|Myofascial release (MFR)|Myofascial release (MFR) is a technique used to release tension and tightness in the fascia, which is the connective tissue that surrounds and supports muscles and organs. It involves applying gentle, sustained pressure to specific areas of the body to help relax the fascia and alleviate restrictions. MFR aims to improve mobility, reduce pain, and enhance overall movement and function.
223755323|NCT02159521|DEVICE|EkoSonic® Endovascular System|
223755324|NCT02159521|BIOLOGICAL|Alteplase|Recombinant tissue plasminogen activator
223755325|NCT00210704|DRUG|Dapoxetine|
223755326|NCT05583396|DIAGNOSTIC_TEST|Acute exercise|The measurement will be repeated within one to seven days.
223755327|NCT05251376|DRUG|Levomethadone HCl|One dose given orally on Day 8 of the study.
223755328|NCT05251376|DRUG|Methadone|Daily usual oral dose given on Day 1 and Day 2 of the study.
223755329|NCT05251376|DRUG|Morphine Sulfate|Administered daily and as needed from Day 3 of the study until subject back on usual daily methadone dose.
223755330|NCT05251376|DIAGNOSTIC_TEST|x-ray|Abdominal x-rays done at specific study timepoints to assess the location of the LYN-014.
223755331|NCT05251376|DIAGNOSTIC_TEST|blood tests|Done at specific timepoints throughout the study for PK (pharmacokinetics), genotyping and safety labs.
223755332|NCT04649775|DEVICE|AirFLO2|Mask device
223755333|NCT04262037|DIAGNOSTIC_TEST|lung ultrasound|Lung ultrasound will be performed after induction of anesthesia and at the end of the operation with a 5-MHz curved array probe (MindrayDC-N6; Mindray; Shenzhen, China
223755334|NCT02479737|DEVICE|Blood drainage post cardiac surgery using PleuraFlow System|
223755335|NCT05437978|OTHER|"Cap Sport Santé 83 program"|"In Var department (France), the  Maison Sport-Santé 83  has set up a program called Cap Sport Santé 83 to support patients who received a prescription to practice APA regularly. This program helps long-term illnesses patients to restart physical activity by considering their pathology. The Cap Sport Santé 83 program is composed of 5 stages which aim to encourage adherence to APA practice by relying on the medical prescription system. Throughout the process, the patient is supervised and supported by the program's coordinator."
223508886|NCT07033338|BEHAVIORAL|Occupational Activities and Finger Exercise Program|The intervention group received the program three days a week (Wednesday, Thursday, and Friday), once daily, with sessions held from 10:00 to 12:00 in the morning and from 14:00 to 16:00 in the afternoon. The participants were divided into two subgroups (13 participants in the first group, 12 in the second). The intervention consisted of a combined occupational activities and finger exercise program. Each session began with finger exercises, followed by occupational activities. The finger exercises involved movements requiring the participation of the fingers, hands, and arms, and were performed in 10 progressive steps. These movements were designed to promote engagement without causing fatigue or discomfort in elderly participants. Occupational activities included threading beads, completing line patterns, sewing buttons, assembling wooden blocks, performing cutting exercises, limited painting, dough manipulation, cutting and gluing, wrapping rope, tying rope between two points, stack
223508887|NCT07034131|OTHER|Osteo-Buddy|"Osteo-Buddy is a Virtual Health Assistant (VHA) accessible on mobile phones that helps users with:~1. Evaluating their risk level of osteoporosis~2. Recommending screening and referrals~3. Lifestyle interventions through motivation, education and tailored guidance~As a 24/7 VHA, it offers real-time, personalised advice based on user inputs and health data."
223508888|NCT07034131|OTHER|Usual Care|Access to digitalised educational materials on osteoporosis, titled 'Healthy Bones'
223608676|NCT06314607|GENETIC|Prospective Biological Collection|"All samples that can be collected at each visit :~* Saliva sampling (added by the research)~* Collection of 2 to 4 additional tubes of blood (maximum 56mL) (added by the research if blood sampling in routine care)~* Urine and stool samples (added by the research)~* CSF sample residues (added by the research if lumbar punction in routine care)~* Lesion sample residues and surgical waste fragments (added by the research if surgery in routine care)"
223608677|NCT06314607|GENETIC|Retrospective Biological Collection|Requalification of all biological samples obtained as part of ONCONEUROTEK research, with patient consent (blood, saliva, urine, Stool, CSF, lesion sample and surgical waste fragments)
223608678|NCT05379465|OTHER|No intervention|No intervention was done.
223608679|NCT00209352|DRUG|Acyclovir|
223608680|NCT01317251|OTHER|Dietary intervention (without dairy products)|Control diet without dairy products
223608681|NCT01317251|OTHER|Dietary intervention (high milk content)|Diet with a high content of milk (\~1200 mg Ca/d from milk)
223608682|NCT01317251|OTHER|Dietary intervention (high cheese content)|Diet with a high content of cheese (\~1200 mg Ca/d from cheese)
223608683|NCT02842294|DRUG|Bevacizumab|
223608684|NCT00760955|DRUG|TAK-583|TAK-583 5 mg, tablets, orally, once daily for up to 6 months.
223608685|NCT00760955|DRUG|TAK-583|TAK-583 50 mg, tablets, orally, once daily for up to 6 months.
223608686|NCT00760955|DRUG|TAK-583|TAK-583 100 mg, tablets, orally, once daily for up to 6 months.
223608687|NCT00760955|DRUG|Placebo|TAK-583 placebo-matching tablets, orally, once daily for up to 6 months.
223608688|NCT04797780|DRUG|Tamibarotene|Administered as specified in the treatment arm
223608689|NCT04797780|DRUG|Placebo|Administered as specified in the treatment arm
223608690|NCT04797780|DRUG|Azacitidine|Administered as specified in the treatment arm
223608691|NCT06223685|DRUG|Rifaximin 200 MG|Dosage 3x2 tablets per day 14 days
223755336|NCT01540058|OTHER|Cancer Type ID test|"CancerTYPE ID is a real-time RT-PCR assay that measures and interprets the differential expression of 92 genes as a molecular correlate for tumor classification. The test classifies 28 main tumor types and 50 subtypes using an algorithm incorporating gene expression data from a reference database of 2,094 tumor specimens. CancerTYPE ID is used, in conjunction with other clinical and diagnostic procedures, to help identify tumor type and histological subtype. The performance characteristics and reproducibility of the test have been published previously (Erlander et al., 2011 ; Kerr et al., 2012).~CancerTYPE ID is conducted on formalin-fixed paraffin-embedded (FFPE) tumor specimens at bioTheranostics' high complexity laboratory, which is certified by Clinical Laboratory Improvement Amendments (CLIA), accredited by the College of American Pathologists (CAP), and approved by the State of New York."
223755337|NCT01540058|OTHER|No test Empiric strategy|Empiric strategy
223755338|NCT03616288|DIETARY_SUPPLEMENT|thiamine (as thiamine hydrochloride)|Opaque capsules containing varying amounts of thiamine hydrochloride and cellulose filler. All thiamine is delivered as thiamine hydrochloride, calculated using a 1.271 correction factor (ratio of molecular weights of thiamine hydrochloride and thiamine).
223608692|NCT06223685|DIETARY_SUPPLEMENT|Probiotic|2x1 capsules per day. 12 weeks.
223755339|NCT01050985|DRUG|Temsirolimus and capecitabine|temsirolimus in escalating doses starting at 15-mg IV on days 1 and 8 of a 14 day cycle capecitabine in escalating doses starting at 1000 mg/m2 by mouth twice a day on days 1-7 of a 14-day cycle
223608698|NCT05973006|BIOLOGICAL|NVX-CoV2601 co-formulated Omicron XBB.1.5 SARS-CoV-2 rS vaccine|Coformulated Omicron XBB.1.5 SARS-CoV-2 rS vaccine with Matrix-M adjuvant: supplied as a solution for preparation for injection, at a concentration of 10 µg antigen and 100 µg adjuvant per mL. All injections will be administered in a 0.5 mL injection volume at a dose of 5 µg antigen with 50 µg Matrix-M adjuvant.
223608699|NCT05973006|BIOLOGICAL|Prototype/XBB.1.5 Bivalent Vaccine (5 µg)|A site-mixed bivalent vaccine prepared by combining 0.25 mL of NVX-CoV2373 and 0.25 mL NVX-CoV2601. All injections will be administered in a 0.5 mL injection volume at a dose of 5 µg total antigen (2.5 µg prototype antigen + 2.5 µg Omicron XBB.1.5 antigen) with 50 µg Matrix-M adjuvant.
223608700|NCT03637569|OTHER|Measurement of triceps skinfold thickness|By using skin thickness caliper, measure triceps skinfold thickness on the half of forearm (Rt side). In every 3 weeks, triceps skinfold thickness will be measured.
223608701|NCT05132218|DRUG|Ensatinib|Prospective, exploratory, single-arm, multi-center, real-world research
223608702|NCT02489292|BIOLOGICAL|HepaStem|HepaStem will be administered in maximum 4 infusion days, spread over an 8-week period with an interval of 2 to 3 weeks between infusion days. The target total dose of cells will be 50x10E6 cells/kg body weight
223608703|NCT03318016|DRUG|Cyclophosphamide 500 MG|ATO at a fixed dose of 0.15 mg/kg/d IV followed by Cyclophosphamide 500 mg/m2 on day 4 as a single IV dose along with hydration for a maximum of 6 doses
223608704|NCT03318016|DRUG|Cyclophosphamide 1000 MG|Enrolled subjects will receive 3 consecutive days of ATO at a fixed dose of 0.15 mg/kg/d IV followed by Cyclophosphamide 1000 mg/m2on day 4 as a single IV dose along with Mesna (in subjects receiving ≥1000mg/m2 Cy) and hydration for a maximum of 6 doses
223608705|NCT03318016|DRUG|Cyclophosphamide 2000 MG|Enrolled subjects will receive 3 consecutive days of ATO at a fixed dose of 0.15 mg/kg/d IV followed by Cyclophosphamide 2000 mg/m2on day 4 as a single IV dose along with Mesna (in subjects receiving ≥1000mg/m2 Cy) and hydration for a maximum of 6 doses
223608706|NCT03318016|DRUG|Cyclophosphamide 3000 MG|Enrolled subjects will receive 3 consecutive days of ATO at a fixed dose of 0.15 mg/kg/d IV followed by Cyclophosphamide 3000 mg/m2on day 4 as a single IV dose along with Mesna (in subjects receiving ≥1000mg/m2 Cy) and hydration for a maximum of 6 doses
223608707|NCT03318016|DRUG|Cyclophosphamide 4000 MG|Enrolled subjects will receive 3 consecutive days of ATO at a fixed dose of 0.15 mg/kg/d IV followed by Cyclophosphamide 4000 mg/m2on day 4 as a single IV dose along with Mesna (in subjects receiving ≥1000mg/m2 Cy) and hydration for a maximum of 6 doses
223608708|NCT04355546|OTHER|Non-interventional|As this is a Non-interventional trial, only data obtained within the current routine management of COPD at outpatient respiratory centres or GP centres will be documented.
223608709|NCT06427473|BEHAVIORAL|Dietary program|Participants will attend 8-week online dietary course. In addition to weekly classes, participants are required to photograph each meal.
223755340|NCT00916175|DIETARY_SUPPLEMENT|P1&P2|"* First period (4 weeks) intake food product P1\&P2 (in lemon gelatin 230 ml before breakfast) plus 1500 kilo calories diet~* Second period, cross over from AG\&CC group, 4 weeks intake food product P1\&P2 (in lemon gelatin 230 ml before breakfast and 230 ml after supper) plus 1500 kilo calories diet"
223755341|NCT00916175|DIETARY_SUPPLEMENT|P1&CC|"* First period (4 weeks) intake food product P1\&CC (in lemon gelatin 230 ml before breakfast) plus 1500 kilo calories diet.~* Second period, cross over from AG\&P2 group, 4 weeks intake food product P1\&CC (in lemon gelatin 230 ml before breakfast and 230 ml after supper) plus 1500 kilo calories diet."
223755342|NCT00916175|DIETARY_SUPPLEMENT|AG&P2|"* First period (4 weeks) intake food product AG\&P2 (in lemon gelatin 230 ml before breakfast) plus 1500 kilo calories diet.~* Second period, cross over from P1\&CC group, 4 weeks intake food product AG\&P2 (in lemon gelatin 230 ml before breakfast and 230 ml after supper) plus 1500 kilo calories diet"
223755343|NCT00916175|DIETARY_SUPPLEMENT|AG&CC|"* First period (4 weeks) intake food product AG\&CC (in lemon gelatin 230 ml before breakfast) plus 1500 kilo calories diet~* Second period, cross over from P1\&P2 group, 4 weeks intake food product AG\&CC (in lemon gelatin 230 ml before breakfast and 230 ml after supper) plus 1500 kilo calories diet"
223755344|NCT00916175|DIETARY_SUPPLEMENT|TA (concentrated 5:1 aloe vera gel)|"* First period (4 weeks) intake food product TA (in lemon gelatin 230 ml before breakfast) plus 1500 kilo calories diet.~* Second period, cross over from P3 group, 4 weeks intake food product TA (in lemon gelatin 230 ml before breakfast and 230 ml after supper) plus 1500 kilo calories diet."
223755345|NCT00916175|DIETARY_SUPPLEMENT|P3|"* First period (4 weeks) intake food product P3 (in lemon gelatin 230 ml before breakfast) plus 1500 kilo calories diet.~* Second period, cross over from TA group, 4 weeks intake food product P3 (in lemon gelatin 230 ml before breakfast and 230 ml after supper) plus 1500 kilo calories diet."
223755346|NCT04892238|DIAGNOSTIC_TEST|13-C urea breath test|"Standard urea breath test (UBT) (HELICARB, LLC ISOCARB, reg. cert. #РЗН 2016/3773 issued by Roszdravnadzor on 29.02.2016) with 13C-carbamide of 99% purity used for the study.~Samples of exhaled air obtained before and after 20 minutes after 50 mg 13C-urea intake are analysed for 13C/12C isotope ratio with the use of infrared spectrometer IRIS.Doc (Kibion, Sweden). Delta over baseline (δ) of 13C / 12C is calculated based on the results of the initial and second samples, the results were shown in ppm (‰). The results of the test is negative if δ was \<4.0‰; test results with δ ≥4.0‰ are considered positive."
223755347|NCT03774940|DIAGNOSTIC_TEST|peripheric blood count|preoperative peripheric blood count
223755348|NCT00694369|DRUG|Comparator: etoricoxib|etoricoxib 90 mg; 120 mg (once daily) over three days.
223755349|NCT00694369|DRUG|Comparator: ibuprofen|ibuprofen 2400 mg (600 mg Q6h) over three Days
223755350|NCT00694369|DRUG|Comparator: acetaminophen + codeine|acetaminophen 2400 mg/codeine 240 mg (600/60 mg Q6h) over three Days
223755351|NCT00694369|DRUG|Comparator: placebo|matching placebo over three Days
223755352|NCT01250587|DRUG|PDC31|This study involves the sequential administration of PDC31 to 4 cohorts of patients. The dose will be escalated in the absence of dose-limiting toxicities. PDC31 is to be administered as a 3-hour continuous infusion.
223508889|NCT07031635|OTHER|Hydrotherapy (Warm Shower)|Pregnant women who met the inclusion criteria and agreed to participate in the intervention group received a warm shower once cervical dilation reached 5 cm. Based on their preference, participants either stood or sat during the 30-minute shower.
223508890|NCT07038967|OTHER|Coloured photography|Coloured photography will be performed preoperatively and at 3 and 6 months postoperatively.
223508891|NCT07038967|OTHER|Fluorescein angiography|Fluorescein angiography will be performed preoperatively and at 3 and 6 months postoperatively. The following features will be recorded on each angiography:
223508892|NCT07038967|OTHER|Optical coherence tomography|Optical coherence tomography (OCT) scanning will be performed using the optical coherence tomography scanner OCT (OPTOVUE OCT). OCT will be performed preoperatively and at 3 and 6 months postoperatively.
223508893|NCT07040306|DRUG|Methimazole(MMI)|Determine the enrolled GD patients and adjust the dosage of methimazole according to the 2016 American Thyroid Association guidelines. Conduct thyroid function, liver function, TRAb, and blood routine tests during outpatient follow-up to observe the treatment effect and provide medication guidance.
223508894|NCT07041450|DIAGNOSTIC_TEST|Digital MoCA|A digital version of the Montreal Cognitive Assessment used to evaluate cognitive function. Administered on a tablet at Visit 1 or Visit 2 (randomized).
223508895|NCT07041450|DIAGNOSTIC_TEST|XpressO|A digital cognitive pre-screening tool used to screen for cognitive function. Administered on a tablet at Visit 1.
223508896|NCT07041450|DIAGNOSTIC_TEST|MoCA|The standard paper-baed Montreal Cognitive Assessment used to evaluate cognitive function. Administered at Visit 1 or Visit 2 (randomized), opposite the digital MoCA.
223508897|NCT07041450|DIAGNOSTIC_TEST|Blood-based Biomarkers (BBM)|Participants provide a blood sample that is analyzed for Alzheimer's disease-related biomarkers, including PrecivityAD2 and MTBR. These biomarkers are used to assess the biological stage of disease and support diagnostic triage and eligibility assessment for disease-modifying therapy (DMT)
223508898|NCT07041450|OTHER|Amyloid Treatment Screening Tool (ATST)|A questionnaire administered to assess eligibility for amyloid-targeted therapies. Both clinician and patient-centered versions are used.
223508899|NCT07041450|OTHER|MoCA Brain Health Questionnaire (MBHQ)|A questionnaire designed to capture participants' physical health, emotional well-being, diet, exercise, and social engagement as it relates to cognitive health. Responses are used as part of exploratory analyses to evaluate associations with cognitive status and Alzheimer's disease diagnosis.
223508900|NCT07041450|OTHER|MoCA Medical Questionnaire|A structured questionnaire administered to participants to gather information on their medical history, including prior diagnoses, medications, and other health conditions. This data helps to contextualize cognitive symptoms and support diagnostic decision-making in the study.
223508901|NCT07041450|OTHER|Functional Activities Questionnaire+ (FAQ+)|A questionnaire designed to assess the participant's ability to perform daily activities, providing insights into their functional status and cognitive impairment. It is a longer version of the original FAQ questionnaire. It is used as part of the screening and exploratory analysis to better understand the relationship between functional abilities and Alzheimer's disease progression.
223755353|NCT01308307|DEVICE|photorefraction|photorefraction is a name of device.
223755354|NCT00819988|DRUG|Pregabalin|Pregabalin capsule 75 mg given preoperatively, then eith 50 mg or 25 mg given every 8 hours for 3 days postoperatively based on renal function
223755355|NCT00819988|OTHER|Sugar pill|Single dose given 30-60 minutes preoperatively, then given every 8 hours for 3 days postoperatively
223755356|NCT03152539|RADIATION|MRI|
223755357|NCT03152539|DEVICE|EEG|
223755358|NCT03152539|DEVICE|NIRS|
223755359|NCT00314236|DEVICE|BST-CarGel with Microfracture|Microfracture performed with BST-CarGel added to the treated defect
223755360|NCT00314236|PROCEDURE|Microfracture without BST-CarGel|Microfracture performed without BST-CarGel added to the treated defect.
223755361|NCT00907374|DRUG|benazepril|benazepril 10 mg orally once daily
223755362|NCT00907374|DRUG|benazepril|40-80 mg benazepril plus 25-100 mg losartan orally once or twice daily
223755363|NCT02457403|DEVICE|ROTEM|Assess coagulopathy with ROTEM device compared to conventional laboratory tests. ROTEM will be used on all patients, however, determination of blood products used will be based on patient's randomization group.
223755364|NCT02457403|OTHER|Conventional Therapy|Assess coagulopathy with conventional laboratory tests (PT/INR, Hemoglobin, Platelet count). Conventional laboratory tests will be obtained on all subjects, however, determination of blood products used will be based on patient's randomization group.
223755365|NCT02048020|DRUG|paclitaxel|Given IV
223755366|NCT02048020|DRUG|carboplatin|Given IV
223755367|NCT02048020|RADIATION|intensity-modulated radiation therapy|Undergo IMRT
223755368|NCT02048020|PROCEDURE|quality-of-life assessment|Ancillary studies
223755369|NCT02717481|DEVICE|US-CT Fusion examination|Patients will undergo an US examination using an US device with US-CT Fusion capabilities.
223755370|NCT04360577|PROCEDURE|acupuncture|Acupuncture at back-shu points according to heat-pain threshold measurement at 24 well-points, combing with electro-acupuncture at Baihui(GV20), Yintang(GV29), Neiguan(PC6), Zusanli(ST36), and Gongsun(SP4).
223755371|NCT05723016|OTHER|preimplantation genetic test for aneuploidies (PGT-a)|preimplantation genetic test for embryo aneuploidies after IVF
223755372|NCT04401917|DRUG|[18F]NOS|Participants will undergo approximately 60 minutes of dynamic whole-body scanning, including the brain, starting at approximately the time of injection of \[18F\]NOS. PET/CT imaging sessions will include an injection of ≤ 6.5 mCi (approximate range for most studies is anticipated to be 3.5-6.5 mCi) of \[18F\]NOS.
223755373|NCT03076424|OTHER|no intervention used|Patients will be giving a blood sample after 8 hours of fasting.
223755374|NCT05407246|DRUG|Hemay005|Hemay005 60 mg treatment group (group A): hemay005 tablets 60 mg bid were used during the treatment period; Hemay005 75 mg treatment group (group B): hemay005 75 mg bid was used during the treatment period; Placebo group (Group C): placebo (hemay005 tablet simulant) bid was used during the treatment period;
223755375|NCT06381869|DIETARY_SUPPLEMENT|Pea protein (NUTRALYS ® S85 plus) in water|After selection and randomization, the subjects will consume per os Pea protein (NUTRALYS® S85 plus) in water containing 0,41 g of tested protein/kg of body weight.
223755376|NCT06381869|DIETARY_SUPPLEMENT|Pea protein (NUTRALYS ® S85 plus) within meal|After selection and randomization, the subjects will consume per os Pea protein (NUTRALYS® S85 plus) within a meal containing 0,41 g of tested protein/kg of body weight.
223755377|NCT06381869|DIETARY_SUPPLEMENT|Whey protein in water|After selection and randomization, the subjects will consume per os whey protein in water containing 0,41 g of tested protein/kg of body weight.
223755378|NCT06381869|DIETARY_SUPPLEMENT|Whey protein within meal|After selection and randomization, the subjects will consume per os whey protein within a meal containing 0,41 g of tested protein/kg of body weight.
223755379|NCT00122941|DIETARY_SUPPLEMENT|multiple micronutrients|
223755380|NCT00594464|DRUG|Rotigotine|"2 mg/24 h, 4 mg/24 h, 6 mg/24 h and 8 mg/24 h patch;~Single patches and a combination of 2 of these patches for a dosage of up to 16 mg/24 h;~One (1) regimen on day of surgery, but exceptionally extended for up to 2 (two) weeks if the patient requires unexpected ventilation after surgery."
223755381|NCT03876314|BEHAVIORAL|Physical Activity Condition|Subjects will attend virtual group exercise sessions 3x/week for 1 year. Each subject will be encouraged to walk at a moderate intensity (target heart rate (HR)= 40-59% HR reserve) dependent on resting HR and age. Subjects will perform aerobic exercise on their own and resistance exercises will be completed in virtual exercise sessions with an instructor 1 hour/day for 3 days/week for 1 year. At the exercise sessions, these participants will be asked to record measures of the exercises completed and may be asked to provide measures of heart rate (assessed by palpation for 20-seconds) and rate of perceived exertion (RPE). They will be asked to submit exercise logs providing this information. Data from exercise logs and exercise specialist records will be reviewed for evidence of progression, consistent attainment of moderate intensity, and with respect to the prescribed duration of the aerobic and strength training components.
223755382|NCT06063148|DEVICE|Enrolled Participant|Participant will undergo at most 10 SpO2 measurements paired with at most 10 routine blood gas samples.
223755383|NCT03594162|DRUG|iC9-CAR19 cells|One of two dose levels will be given: 1 x 10\^5 or 5 x 10\^5
223755384|NCT03594162|DRUG|AP1903|Subjects who develop grade 4 CRS or grade 3 CRS that is refractory to standard of care interventions will be given AP1903 at .4 mg/kg.
223755385|NCT03594162|DRUG|Cyclophosphamide|900 mg/m\^2 IV over 1 hour on day 4 of lymphodepleting chemotherapy.
223755386|NCT03594162|DRUG|Fludarabine|25 mg/m\^2/day IV over 30 minutes administered for 3 consecutive days.
223755387|NCT01327352|DRUG|Oshadi D|oral administration
223755388|NCT00775437|DRUG|Adalimumab|Adalimumab solution for injection for subcutaneous use.
223755389|NCT00949624|DRUG|CP-868,596|Oral tablet 60 mg BID continuous
223755390|NCT00949624|DRUG|Docetaxel|Intravenous 75 mg/m2 every three weeks
223508902|NCT02968394|DRUG|omalizumab|
223508903|NCT07045220|BEHAVIORAL|TTMCR|A trans-theoretical model (TTM)- based multidisciplinary CR program (TTMCR) to improve behavior change and cardiac rehabilitation outcomes
223508904|NCT07045857|BEHAVIORAL|follow up of patients that had H. Pylori infection and recieved medical treatment for recurrence|follow up of patients that had H. Pylori infection and recieved medical treatment for recurrence and influential factors for recurrence
223508905|NCT07046130|BEHAVIORAL|Resistance Training|The mininum resistance training volume (12 sets/week) will be applied.
223508906|NCT07046104|OTHER|implant retained overdenture prosthesis|implant retained only prosthesis
224200825|NCT03956901|OTHER|pvi guided fluid management|"GDFM Group: 500 ml bolus crystalloid after~2 ml \\ kg crystalloid infusion to be started~If PVI \<13 MAP is \<65 mmHg, continue infusion of fluid, 1-2 µg NE bolus to be entered after 5 min.~PVI \<13 MAP\> 65 mmHg to continue fluid infusion If PVI\> 13 MAP \<65 mmHg, 250 ml bolus crystalloid \\ colloid will be given and bolus 1-2 µg NE, If it continues after 5 minutes, liquid and NE doses will be repeated. Liquid treatment will be continued until PVI \<13.~PVI\> 13 MAP \<65 mmHg 250 ml bolus fluid to be given, if continued 5 minutes later to be repeated,repetition of fluid will continue until PVl \<13."
223508907|NCT07046104|OTHER|implant canine retained overdenture prosthesis|prosthesis retention from implant and canine
223508908|NCT07044726|DRUG|Povidone-Iodine|Providone-Iodine for periurethral preparation
223508909|NCT07044726|DRUG|Sterile water|Sterile water for periurethral preparation
223508910|NCT07045922|BEHAVIORAL|Motor-Cognitive Training Program|"Participants assigned to the intervention group participated in a structured motor-cognitive training program in addition to their regular physical education (PE) classes. The training was designed to integrate physical movement with cognitive engagement in a game-based format, suitable for the preschool age group.~The program was conducted twice weekly for eight weeks, with each session lasting approximately 25-30 minutes. Activities progressed in complexity over time, incorporating elements of motor planning, executive functioning, and balance control. Sessions consisted of:~Warm-up phase: Light aerobic activities such as jogging, dynamic stretching, and coordination drills (e.g., knee pulls, toe walking).~Main training phase:~Activities targeting core cognitive-motor domains:~Running drills (forward, backward, lateral)~Jumping and landing mechanics~Ball handling and coordination tasks (e.g., passing, tennis ball exercises)~Balance and proprioceptive challenges (e.g., walking"
223508911|NCT07045922|OTHER|Regular Physical education classes|Participants in the control group continued with their regularly scheduled physical education (PE) classes as mandated by the school curriculum. They did not receive any additional motor-cognitive or structured exercise training. Furthermore, they were instructed not to engage in any external physical activity programs outside of the regular PE sessions throughout the study duration. This restriction was monitored to ensure group consistency.
223508912|NCT07045350|PROCEDURE|Platelet-rich fibrin (PRF)|Application of autologous platelet-rich fibrin (PRF) prepared from peripheral blood with or without the addition of 4 mg dexamethasone directly into the blood collection tube prior to centrifugation. PRF was applied into the extraction socket after impacted mandibular third molar surgery. The test group received PRF prepared from blood enriched with dexamethasone, while the control group received standard PRF without dexamethasone, to evaluate postoperative pain, edema, and trismus.
223508913|NCT07046208|OTHER|physiothreapy protocol|Aerobic training (treadmill or exercise bike) for 15 minutes, anaerobic training at the weight training station, performing exercises for the upper limbs (bench press and front pull) and lower limbs (180º leg press and extension chair) with weight determined by the 1 Repetition Maximum (1RM) test, performing 3 sets of 12-15 repetitions (depending on the session) and respiratory muscle training using POWERbreathe (30-40% of the MIP performed in the manovacuometry test).
223608710|NCT06427473|BEHAVIORAL|Exercise program|Everyday walking steps more than 4000 steps. To accurately track participants' daily step counts, the research team provided quailfied pedometers.
223608711|NCT06427473|BEHAVIORAL|Mindfulness program|Participants will attend 8-week online mindfulness course. In addition to weekly classes, participants practiced mindfulness individually for 5 minutes each day and maintained a mindfulness diary.
223608712|NCT04305171|PROCEDURE|non-surgical periodontal treatment|scaling and root planing, home care instruction
223608713|NCT02672462|DEVICE|Radio frequency renal denervation system (Golden Leaf GL-06E15A)|
223608714|NCT00132808|DRUG|Zoledronic Acid|Zoledronic acid 5 mg intravenous
223608715|NCT00132808|DRUG|Placebo|Physiologic 0.9% normal saline
223608716|NCT02848807|DIETARY_SUPPLEMENT|NUTRIDRINK Compact Protein|high-energy, high-protein, oral liquid nutritional supplement; dosage: 2x125 ml per day, 7 days per week for 12 weeks (3 months)
223608717|NCT06369389|OTHER|Patients eligible for CAR-T treatment|Patients eligible for CAR-T treatment for their hemopathy at TOULOUSE University Hospital under early access or marketing authorization or as part of a clinical trial between 01/01/2019 and 31/12/2028
223608718|NCT05237323|DRUG|mycophenolate mofetil 2 g per day|mycophenolate mofetil 2 g per day and methylprednisolone in an average starting dose 24 \[24; 32\] mg per day and standard drug therapy for heart failure.
223608719|NCT05237323|DRUG|azathioprine of 150 [75; 150] mg per day|azathioprine at an average dose of 150 \[75; 150\] mg per day and methylprednisolone in an average starting dose 24 \[24; 32\] mg per day and standard drug therapy for heart failure.
223608720|NCT02225093|DRUG|Caffeine|Oral
223608721|NCT02225093|DRUG|Dextromethorphan|Oral /.L
223608722|NCT02225093|DRUG|Enzalutamide|Oral
223608723|NCT02225093|DRUG|Enzalutamide Placebo to Match (PTM)|Oral
223608724|NCT04215640|DEVICE|Microfidelity (MIFI) catheter|Patients are randomized into the MIFI group and control group. Radiofrequency ablation will target slow pathway for AVNRT or accessory pathway for AVRT. Microfidelity (MIFI) catheter equipped with mini-electrodes will be used for ablation in the MIFI group.
223608725|NCT04215640|DEVICE|Conventional ablation catheter|Patients are randomized into the MIFI group and control group. Radiofrequency ablation will target slow pathway for AVNRT or accessory pathway for AVRT. Blazer II radiofrequency ablation catheter will be used for ablation in the control group.
223608726|NCT05585840|DEVICE|Biofeedback-based virtual reality game|The application will be a biofeedback-based virtual reality game developed by the researchers in collaboration with engineering in line with the literature review.
223608727|NCT03785379|BEHAVIORAL|Caloric restriction|A structured dietary training will be implemented to educate participants about recommended dietary habits.Patients will follow a caloric restriction (CR) diet, with an energy intake equal to the measured Resting Metabolic Rate (RMR) and with 45% carbohydrate, 20%protein, 35%fat, and 30 g/day fibers. At each follow-up, nutritionist will adjust CR to the latest measured RMR and assess the compliance to the diet.
223755391|NCT00949624|DRUG|CP-868,596|Oral tablet 100 mg BID continuous
224200826|NCT05130086|DRUG|Islatravir|60 mg Islatravir taken orally in tablet form once monthly for up to 24 weeks
223508914|NCT07044882|PROCEDURE|conventional osteotome technique|Patients indicated for internal sinus lifting with simultaneous implant placement, where sinus elevation is conducted with regular manual osteotomes.
223608728|NCT03785379|BEHAVIORAL|Exercise training|Trainers will supervise participants during 12-weeks of structured exercise consisting of 150 min/week workouts, divided in three sessions of progressive mixed (aerobic and resistance) exercise. All aerobic exercise will be performed using treadmill and/or cycle ergo-meter.
223608729|NCT01714765|DRUG|Dovitinib|Cohort 0: 200mg, Cohort 1: 300mg, Cohort 2: 300mg, Cohort 3: 400mg, Cohort 4: 500mg. Cohort -1: 100mg
223608730|NCT01714765|DRUG|Everolimus|Cohort 0: 5mg, Cohort 1: 5mg, Cohort 2: 10mg, Cohort 3: 10mg, Cohort 4: 10mg, Cohort -1: 5mg.
223608731|NCT06108128|OTHER|Executive functioning observational tasks|Interventions take place solely at the measurement level, where children will be seen in observational tasks of general executive functioning and executive functioning around eating in which various food and non-food stimuli are presented and children's responses to task instructions are recorded.
223608732|NCT00604630|DRUG|recombinant human erythropoietin alfa|40,000 IU in 50ml 0.9% NaCl iv on 3 consecutive days, starting within 6 hours after onset of symptoms
223608733|NCT00604630|DRUG|0.9% NaCl|50ml 0.9% NaCl iv on 3 consecutive days, starting within 6 hours after onset of symptoms
223608734|NCT02954393|PROCEDURE|Scaling and root planing|SRP will be performed in four to six appointments lasting approximately 1 h each, using manual curettes (Hu-Friedy, Chicago, IL, USA) and ultrasonic device (Cavitron Select SPC, Dentsply professional, York, PA, USA) under local anesthesia. The deep sites will be scaled throughout the first week and treatment of the entire oral cavity will be completed in 14 days.
223608735|NCT02954393|DRUG|Metronidazole active phase|Metronidazole 400 mg thrice a day for 14 days in the active phase of the periodontal treatment (beginning with the first SRP session).
223608736|NCT02954393|DRUG|Metronidazole healing phase|Metronidazole 400 mg thrice a day for 14 days in the healing phase of the periodontal treatment (3 months after active phase).
223608737|NCT02954393|DRUG|Amoxicillin active phase|Amoxicillin 500 mg thrice a day for 14 days in the active phase of the periodontal treatment (beginning with the first SRP session).
223608738|NCT02954393|DRUG|Amoxicillin healing phase|Amoxicillin 500 mg thrice a day for 14 days in the healing phase of the periodontal treatment (3 months after active phase).
223608739|NCT02954393|DRUG|Placebos active phase|Amoxicillin and metronidazole placebos thrice a day for 14 days in the active phase (beginning with the first SRP session).
223608740|NCT02954393|DRUG|Placebos healing phase|Amoxicillin and metronidazole placebos thrice a day for 14 days in the healing phase (3 months after active phase).
223608741|NCT05276817|DEVICE|Epic Diode|HP solution will be inserted to the bottom of the periodontal pocket using a disposable side port needle applicator. The diode tip will be inserted into the pocket, parallel with the root surface and moved in slow side to side motions, painting in the full depth and width of the pocket while activating the diode laser.
223608742|NCT05276817|DRUG|HP|HP solution will be inserted to the bottom of the periodontal pocket using a disposable side port needle applicator. The solution will be in the pocket for 30 seconds, and then removed using sterile gauze and water spray.
223608743|NCT05276817|DEVICE|Sham|The diode tip will be inserted into the pocket, parallel with the root surface and moved in slow side to side motions, painting in the full depth and width of the pocket. The diode laser will not be activated during the sham treatment. Coe-Pak periodontal dressing will be applied to the control quadrant to isolate it.
223608744|NCT05711121|PROCEDURE|Transforaminal epidural steroid injection|Fluoroscopy-guided transforaminal epidural injection for radicular pain resulting from a disc herniation.
223608745|NCT05711121|PROCEDURE|Caudal epidural steroid injection|Fluoroscopy-guided caudal epidural injection for radicular pain resulting from a disc herniation.
223608746|NCT02728453|DRUG|Empagliflozin|Treatment with empagliflozin vs. glimepiride to understand whether empagliflozin may reduce left ventricular mass in patients with type 2 Diabetes mellitus.
223608747|NCT02728453|DRUG|Glimepiride|Treatment with empagliflozin vs. glimepiride to understand whether empagliflozin may reduce left ventricular mass in patients with type 2 Diabetes mellitus.
223608748|NCT02276703|DEVICE|Skin Conductance Monitor|monitors skin conductance values
223608749|NCT03015324|DRUG|Hydroxychloroquine|Hydroxychloroquine
223608750|NCT02898402|PROCEDURE|blood sample and questionnaire|In addition to normal blood sample performed at entry before delivery, an extra 5 ml blood sample will be taken to establish Q fever serodiagnosis and a short questionnaire will be filled in for clinical and epidemiological data.
223608751|NCT02403999|OTHER|Test shampoo|Participants used Oilatum Soothe \& Protect Shampoo at home in place of their usual wash product at least twice weekly for a two week period.
223608752|NCT02403999|OTHER|Test bath foam|Participants used Oilatum Soothe \& Protect Bath Foam at home in place of their usual wash product at least twice weekly for a two week period.
223608753|NCT02403999|OTHER|Test head to toe wash|Participants used Oilatum Soothe \& Protect Head to Toe Wash at home in place of their usual wash product at least twice weekly for a two week period.
223608754|NCT06538922|BEHAVIORAL|Single Session Family Intervention|A health coach will deliver a 2-hour single-session consultation to support parent-teen dyadis in applying evidence-based family skills in daily life. Participants will then practice daily on their own for the next 7 days.
223608755|NCT05943015|PROCEDURE|Quadratus Lumborum Block II|Patients are placed in the lateral decubitus position. The area where the block will be applied is disinfected with povidine iodine. A convex ultrasound probe is placed on the midaxillary line above the iliac crest. By visualizing the psoas major and the transverse process adjacent to the quadratus lumborum muscle, using the in-plane technique, using a 22 gauge 80 mm peripheral block needle negative aspiration into the middle layer of the thoracolumbar fascia posterior to the quadratus lumborum muscle, then 0.5-1 ml of saline 20 ml of 0.25% bupivacaine will be injected after hydrodissection is observed. The same will be done to the other side.
223755392|NCT00949624|DRUG|Docetaxel|Intravenous 75 mg/m2 every three weeks
223508915|NCT07044882|PROCEDURE|Hydrodynamic Piezoelectric technique|Patients indicated for internal sinus lifting with simultaneous implant placement, where sinus elevation is conducted with Hydrodynamic Piezoelectric technique.
223508916|NCT07046273|DRUG|F027|The starting dose is 0.25 mg once weekly. After 4 weeks the dose should be increased to 0.5 mg once weekly. After at least 4 weeks with a dose of 0.5 mg once weekly, the dose can be increased to 1 mg once weekly for 24 weeks.
223608756|NCT05943015|DRUG|Patient controlled intravenous analgesia|Afterward of the operation, patients will be treated with patient-controlled analgesia with intravenous tramadol, with 20 mg bolus 20 minutes lock time, 4-hour limit 100 mg and 24-hour limit 400 mg
223608757|NCT05943015|PROCEDURE|Quadratus Lumborum Block III|Patients are placed in the lateral decubitus position. The area where the block will be applied is disinfected with povidine iodine. A convex ultrasound probe is placed on the midaxillary line above the iliac crest. By visualizing the transverse process adjacent to the psoas major and quadratus lumborum muscles, using the in-plane technique, using a 22 gauge 80 mm peripheral block needle after negative aspiration into the anterior layer of the thoracolumbar fascia anterior to the quadratus lumborum muscle muscle, 0.5-1 ml of serum After observing hydrodissection with physiological, 20 ml of 0.25% bupivacaine is injected. The same is done to the opposite side.
223755393|NCT00949624|DRUG|CP-868,596|Oral tablet 100 mg BID continuous
223755394|NCT00949624|DRUG|Docetaxel|Intravenous 100 mg/m2 every three weeks
223755395|NCT00949624|DRUG|CP-868,596|Oral tablet 60 mg BID continuous
223608758|NCT05943015|DRUG|Patient controlled intravenous analgesia|Afterward of the operation, patients will be treated with patient-controlled analgesia with intravenous tramadol, with 20 mg bolus 20 minutes lock time, 4-hour limit 100 mg and 24-hour limit 400 mg
223608759|NCT05943015|PROCEDURE|Paravertebral Block|Patients are placed in the lateral decubitus position. The area where the block will be applied is disinfected with povidine iodine. The linear ultrasound probe is placed longitudinally at the T6 level, 2-2.5 cm lateral to the spinous processes. Transverse process, superior costotransverse ligament and pleura are visualized, 22 gauge 80 mm peripheral block needle is passed with in-plane technique, superior costotransverse ligament is passed, negative aspiration into the paravertebral space under the ligament, followed by 0.5-1 ml of saline and hydrodissection of the pleura, followed by 20 ml of 0.25% bupivacaine is injected.The same is done to the opposite side.
223608760|NCT05943015|DRUG|Patient controlled intravenous analgesia|Afterward of the operation, patients will be treated with patient-controlled analgesia with intravenous tramadol, with 20 mg bolus 20 minutes lock time, 4-hour limit 100 mg and 24-hour limit 400 mg
223608761|NCT06553495|OTHER|Nerve block|Analgesic effect of different nerve blocks
223608762|NCT04383782|BEHAVIORAL|Expectancy Challenge|Expectancy challenge intervention (see description in study arms).
223608763|NCT04383782|BEHAVIORAL|Expectancy Challenge + Behavioral Activation|Expectancy challenge + behavioral activation interventions (see description in study arms)
223608764|NCT04383782|BEHAVIORAL|Control|Neutral reading condition (see description in study arms).
223608765|NCT03553524|OTHER|morning HIIT --> afternoon HIIT|Arm 1 will start with morning HIIT at visit 2 and afternoon HIIT at visit 3
223608766|NCT03553524|OTHER|afternoon HIIT --> morning HIIT|Arm 2 will start with afternoon HIIT at visit 2 and morning HIIT at visit 3
223608767|NCT01930942|RADIATION|preoperative concurrent chemoradiation|Radiation is given with 5000 cGy in 25 fractions (5 weeks). Concurrent chemotherapy consists of oxaliplatin (50 mg/m2 ) intravenously over 2 h on days 1, 8, 15, 22 and 29, and capecitabine (825 mg/m2 twice day) was given orally on each day of radiation.
223608768|NCT00128310|DRUG|Vinorelbine|
223608769|NCT00128310|DRUG|Gemcitabine|
223608770|NCT05725746|DIAGNOSTIC_TEST|Point of care device to measure HbA1c|After consent the participant will meet with the research team virtually to obtain HbA1c. The HbA1c self check equipment will be sent to the participant. During the video call the research team will talk the participant through obtaining their HbA1c with the point of care device.
223608771|NCT06437964|OTHER|No use of prophylactic antibiotics|In the endoscopic secondary prevention of cirrhotic patients with gastroesophageal variceal bleeding, do not use any antibiotics before the endoscopic operation.
223608772|NCT06437964|DRUG|Prophylactic Antibiotics|Intravenous infusion of 2.0g ceftriaxone before endoscopic therapy
223608773|NCT04030520|BEHAVIORAL|POPPi|behavioral intervention with offer of HIV self test
223608774|NCT04030520|BEHAVIORAL|Comparison|standard of care
223755396|NCT00949624|DRUG|AG-013736|Oral tablet 5 mg BID continuous
223755397|NCT00949624|DRUG|Docetaxel|Intravenous 75 mg/m2 every three weeks
223755398|NCT06442735|OTHER|intrapartum ultrasound|In IPUS group, the patient's labor was observed by intrapartum ultrasound.
223755399|NCT06442735|OTHER|vaginal examination|In VE group, the patient's labor was observed by vaginal examination.
223755400|NCT02733510|DRUG|methylprednisolone|Steroid pulse therapy : Methylprednisolone 0.5 g daily for 3 days, followed by a tapered dose of 60 mg per day for a period of five days.
223755401|NCT02842502|PROCEDURE|Collection of supernumerary biopsies during skin graft pellet procedure|
223755402|NCT01304745|BEHAVIORAL|Physical training in group|Physical training in group, 6-9 participants, two times av week (1.5 hours) over a period of 16 weeks, focusing on strength and endurance training including body awareness and relaxation.
223755403|NCT01304745|BEHAVIORAL|Educational and counseling in group|Educational and counseling groups with 6-9 participants, with seven group meetings 2.5 hours over a period of seven weeks. Each session starts with a (20 minutes) lecture were one out of seven different topics are presented (Fatigue, sexuality, coping and coping strategies, etc).
223755404|NCT03131440|BEHAVIORAL|Core|The core intervention will include educational materials, access to a basic smartphone app and a Fitbit.
223755405|NCT03131440|BEHAVIORAL|Support Calls|Participants will receive 6 bi-weekly phone calls from study staff.
223755406|NCT03131440|BEHAVIORAL|App+|"Participants will receive deluxe version of smartphone app with additional features."
223755407|NCT03131440|BEHAVIORAL|Online gym|Participants will receive access to online exercise videos.
223755408|NCT03131440|BEHAVIORAL|App notifications|Participants will receive motivational app notifications
223755409|NCT03131440|BEHAVIORAL|Buddy|Participants will choose a buddy to receive a Fitbit and support them during the intervention.
223755410|NCT03710421|PROCEDURE|CS1-CAR T Therapy|Undergo CS1-CAR T therapy
223755411|NCT03710421|DRUG|Cyclophosphamide|Given IV
223755412|NCT03710421|DRUG|Fludarabine|Given IV
223755413|NCT03710421|PROCEDURE|Leukapheresis|Undergo leukapheresis
223755414|NCT03892460|DEVICE|neuromuscular electrical stimulation|bilateral quadriceps exercise with neuromuscular electrical stimulation
223755415|NCT01750008|PROCEDURE|Global Fibroid Ablation|
223755416|NCT01750008|PROCEDURE|Myomectomy|
223608775|NCT06039995|PROCEDURE|Comprehensive Oral Care|"The intervention mentioned in this study involves a combination of oral care strategies for patients in the intervention group. These strategies include:~Chlorhexidine Mouthwash: Patients in the intervention group will receive Chlorhexidine mouthwash. Chlorhexidine is known for its effectiveness in maintaining oral hygiene.~Toothbrushing: In addition to Chlorhexidine mouthwash, patients in the intervention group will undergo toothbrushing. This involves cleaning the teeth and surrounding oral tissues to ensure thorough oral hygiene.~Moisturizing Gel Application: The intervention group will also receive the application of moisturizing gel on the interior and exterior surfaces of the oral cavity. This helps in maintaining the moisture content of the oral tissues.~These interventions aim to enhance oral care beyond traditional methods, potentially reducing the risk of Ventilator-Associated Pneumonia (VAP) and improving overall patient outcomes in the intensive care unit (ICU)."
223608776|NCT06039995|PROCEDURE|Traditional Oral Care|"In the control arm, patients receive the intervention known as Traditional Oral Care. This involves the use cotton swab dipped in 0.2% Chlorhexidine mouthwash for oral hygiene."
223608777|NCT06039995|DEVICE|Mechanical Tooth Brushing using 0.2% Chlorhexidine|Toothbrushing: In addition to Chlorhexidine mouthwash, patients in the intervention group will undergo toothbrushing. This involves cleaning the teeth and surrounding oral tissues to ensure thorough oral hygiene.
223755417|NCT06541288|DIAGNOSTIC_TEST|AI Prediction Model|Pelvic MRI was performed after pathologic diagnosis clarified the diagnosis of cervical cancer. Further pelvic lymph node metastasis status was determined by artificial intelligence multimodal fusion prediction modeling
223755418|NCT06541288|DIAGNOSTIC_TEST|Conventional Imageing Assessment|Pelvic MRI was performed after pathologic diagnosis clarified the diagnosis of cervical cancer.Further pelvic MRI images are read by a specialized imaging physician to determine pelvic lymph node status.
223755419|NCT03517527|BEHAVIORAL|Exercise|
223755420|NCT00746941|DRUG|mefloquine|250 mg orally each day for 3 days and then weekly up to 6 months.
223755421|NCT03229824|DEVICE|Antiseptic occlusive dressing group|A chlorhexidine gluconate occlusive adhesive dressing (Tegaderm CHG) will be applied to the intervention drain sites and changed every seven days.
223608778|NCT06039995|DEVICE|Moisturizing Gel|Moisturizing Gel Application: The intervention group will also receive the application of moisturizing gel on the interior and exterior surfaces of the oral cavity. This helps in maintaining the moisture content of the oral tissues.
223608779|NCT06039995|DEVICE|Oral care using Cotton swab dipped in 0.2% Chlorhexidine|This involves the use cotton swab dipped in 0.2% Chlorhexidine mouthwash for oral hygiene
223608780|NCT06290687|DRUG|Neoadjuvant Chemotherapy|"Standard of care neoadjuvant systemic therapy is currently cisplatin-based chemotherapy in cisplatin-eligible participants. Participants will start treatment within 60 days of Transurethral Resection of Bladder Tumor. Regimens may include:~* Cisplatin - Gemcitabine (Gem/Cis)~* Dose Dense Methotrexate - Vinblastine - Adriamycin - Cisplatin (MVAC)"
223608781|NCT06290687|PROCEDURE|Partial cystectomy with Extended pelvic lymph node dissection|Partial cystectomy will then be performed using the surgical technique at the discretion of the treating Urologic Oncologist. Extended pelvic lymphadenectomy will then be performed at the discretion of the treating Urologic Oncologist. Surgery will be performed within 60 days of Transurethral Resection of Bladder Tumor for Cisplatin-ineligible participants. Surgery will be performed within 60 days of completing neoadjuvant chemotherapy for Cisplatin-eligible participants.
223608782|NCT06290687|DRUG|Adjuvant systemic therapy|Standard of care adjuvant systemic therapy in eligible participants. The choice of adjuvant systemic therapy will be left to the discretion of the treating Medical Oncologist but must fall within the SOC as outlined in NCCN guidelines.
223608783|NCT07021274|BEHAVIORAL|DBT skills training adjusted to autistic needs|Adjustments to fit the specific learning style of people with autism. Simplified skills - fewer words, ,more pictures, autism relevant examples. Hands- on training using props and role play. adjustments so sensory sensitivities.
223608784|NCT05976711|DEVICE|Magnetic resonance imaging (with PROUD software)|Philips Ingenia 3.0T MR system with in-house developed PROUD software
223608785|NCT06877897|DIAGNOSTIC_TEST|Submental ultrasound criteria|According to the submental ultrasound criteria, a maximum hyoid bone displacement of ≥1.38 cm is required in the swallowing function assessment to qualify for the oral feeding diet and tube removal training protocol.
223608786|NCT06877897|DIAGNOSTIC_TEST|Routine swallowing function assessment of speech-language pathologist|The speech-language pathologist (SLP) assessment includes the evaluation of sensory and motor functions of the oral and facial muscles, phonation, swallowing motion, and other relevant factors.
223755422|NCT01011842|PROCEDURE|Radiotherapy|Standard of care
223755423|NCT01011842|PROCEDURE|Align RT|Standard of care
223755424|NCT03316885|DEVICE|Clareon® IOL|Foldable, single-piece posterior chamber IOL intended for long-term use over the lifetime of the cataract patient. This device is CE-marked (European Conformity) in the countries with participating Investigators.
223755425|NCT03316885|PROCEDURE|Cataract Surgery|Routine small incision cataract surgery with unilateral IOL implantation
223755426|NCT00230698|DRUG|topiramate|
223755427|NCT03606954|COMBINATION_PRODUCT|Combination topical corticosteroid|Comparison of a vasoconstriction index between the 2 study arms
223755428|NCT05387317|BIOLOGICAL|Pfizer-BioNTech Standard dose|"Standard Dose - (30ug in 0.3ml)~The Pfizer-BioNTech COVID-19 vaccine, BNT162b2, encodes a P2 mutant spike protein and is formulated as an RNA-lipid nanoparticle (LNP) of nucleoside-modified mRNA (modRNA)."
223755429|NCT05387317|BIOLOGICAL|AstraZeneca Standard dose|"Standard Dose (5xE10vp in 0.5ml)~ChAdOx1 nCoV-19 is a recombinant replication-defective chimpanzee adenovirus expressing the SARS-CoV-2 spike (S) surface glycoprotein"
223755430|NCT05387317|BIOLOGICAL|Pfizer-BioNTech Fractional dose|"Fractional Dose - (15ug in 0.15ml)~The Pfizer-BioNTech COVID-19 vaccine, BNT162b2, encodes a P2 mutant spike protein and is formulated as an RNA-lipid nanoparticle (LNP) of nucleoside-modified mRNA (modRNA)."
223755431|NCT05387317|BIOLOGICAL|AstraZeneca Fractional dose|"Fractional Dose (2.5E10vp in 0.25ml)~ChAdOx1 nCoV-19 is a recombinant replication-defective chimpanzee adenovirus expressing the SARS-CoV-2 spike (S) surface glycoprotein"
223755432|NCT05387317|BIOLOGICAL|Moderna Standard dose|Standard dose (50ug in 0.25ml)
223755433|NCT05387317|BIOLOGICAL|Moderna Fractional dose|Fractional dose (20ug in 0.1ml)
223755434|NCT01760083|DEVICE|Biolimus-eluting stent implantation|Recanalization of chronic coronary artery occlusion and subsequent implantation of one or ore Biosensor stents
223608787|NCT06722872|OTHER|Laughter therapy|Laughter therapy, developed by Dr. Madan Kataria in 1995, is a structured exercise program use of laughter and breathing exercises.Laughter therapy sessions begin with warm-up techniques, including clapping, singing, and stretching movements. These are followed by breathing exercises to prepare the lungs for laughter. After the breathing exercises, laughter is simulated using acting techniques. Shortly thereafter, the simulated laughter spreads from person to person through group dynamics, transforming into genuine laughter, which is then followed by a series of laughter exercises. A laughter therapy session may conclude with laughter meditation, during which participants allow natural laughter to flow freely, followed by guided relaxation exercises. To maximize the benefits of laughter's contagious nature, it is recommended that laughter therapy be conducted in groups. Each session varies depending on the target audience, typically lasting around 45 minutes.
223608788|NCT06886412|BEHAVIORAL|Maternal Holding Intervention Group|The infant is required to be held in the mother's arms before, during, and after the procedure. The maternal holding method will be shown or explained to the mother by the researchers.
223608789|NCT06886412|BEHAVIORAL|Breast Feeding Intervention Group|The infant's mother is instructed to begin breastfeeding 2 minutes before the procedure, continuing during and after the procedure. The breastfeeding position for the infant will be shown or explained to the mother by the researchers.
223608790|NCT06726486|DIETARY_SUPPLEMENT|Atémpero|A complete hyperproteic and hypercaloric diet with a mixture of fibres enriched in omega 3, L-arginine and nucleotides (which provides vitamin C and Zinc) was administered.
223608791|NCT06726486|DIETARY_SUPPLEMENT|Control (Standard treatment)|A complete high-protein and high-calorie diet with mixed fibre was administered.
223608792|NCT06725394|OTHER|Filling out the survey|Data were collected using an information form, the Smartphone Addiction Scale-Short Version (SAS-SV), the Perceived Stress Scale (PSS-10), and the Neck Disability Index (NDI).
223608793|NCT06725966|PROCEDURE|Conventional Epley maneuver|Epley maneuver using a mechanized chair
223608794|NCT06725966|PROCEDURE|Personalized Epley maneuver|Personalized Epley maneuver, using a mechanized chair
223755435|NCT04820790|OTHER|Mobile applications|Monitoring of patients with home oxygen through a mobile application
223755436|NCT04371380|DRUG|Cabotegravir Tablets|Cabotegravir tablets will be white to almost white oval shaped film coated tablets with a unit dose of 30 mg and will be administered orally.
223755437|NCT04371380|DRUG|Rilpivirine Tablets|Rilpivirine tablets will be off-white, round, biconvex film coated tablets with a unit dose of 25 mg and will be administered orally.
223755438|NCT04371380|DRUG|Cabotegravir extended release suspension for injection (long-acting)|Cabotegravir long-acting will be a sterile white to slightly pink suspension containing 200 mg per mL of GSK1265744 as free acid for administration by intramuscular injection.
223755439|NCT04371380|DRUG|Rilpivirine extended release suspension for injection (long-acting)|Rilpivirine long-acting will be a sterile white suspension containing 300 mg per mL of rilpivirine as the free base for administration by intramuscular injection.
223755440|NCT00928928|PROCEDURE|Open colectomy|Open colectomy. Epidural anaesthesia used
223755441|NCT00928928|PROCEDURE|laparoscopic colectomy|Laparoscopic colectomy. Epidural anaesthesia used
223755442|NCT03904407|OTHER|Lactobacillus Probiotic Capsule|"One over-the-counter, probiotic capsule taken by mouth once daily for 4 weeks. Each capsule contains 10 billion cells comprised of:~* Lactobacillus crispatus LbV 88~* Lactobacillus jensenii LbV 116~* Lactobacillus gasseri LbV 150N~* Lactobacillus rhamnosus LbV 96"
223755443|NCT03904407|OTHER|Matching Lactobacillus Probiotic Placebo Capsule|Lactobacillus Probiotic placebo capsules identical in appearance taken by mouth once daily for 4 weeks
223755444|NCT00262509|DEVICE|Egress Badge|Egress Badge is worn by subjects who are asked to use the badge to exit the building. The badge indicates the direction of each exit sign on route to an exit.
223755445|NCT03928951|OTHER|General practitioner reassessment of urinary infection antibiotherapy prescribed by emergency departments|Antibiotherapy will be prescribed by emergency physicians and general practitioners will be contacted 4 to 5 days later to know if antibiotherapy was modified
224200827|NCT05368714|BEHAVIORAL|Economic Empowerment (EE)|EE will be provided via a child development account (CDA). CDAs provide children with basic financial education, introduce them to formal financial institutions, and incentivize them to save by matching their deposits. Any of the child's family members, relatives, or friends will be allowed and encouraged to contribute towards the CDA. The account will be matched with money from the program. The maximum family contribution to be matched by the program will be an equivalent of US $10 per month per family or US $120 for the 12-month intervention period.
223608795|NCT06725316|BEHAVIORAL|4-7-8 breathing exercises|Steps of doing 4-7-8 breathing exercise; firstly, the breath taken is exhaled completely through the mouth as if whistling. Then the lips are closed and inhaled quietly through the nose (4 seconds). The breath is held for seven seconds. At the last stage, the lips are tightened and exhaled through the mouth for 8 seconds. Then normal breathing is done for one minute. Breathing is repeated four times every hour.
223755446|NCT05309109|OTHER|Hemodialysis sessions|Patients will receive thrice weekly 4 hours hemodialysis sessions during 12 months.
223755447|NCT04090554|DEVICE|Cytosponge™|The device consists of a spherical mesh enclosed in a gelatine capsule and attached to a string. The capsule is swallowed and allowed to reach the stomach . In the stomach the capsule is left for up to 5 minutes where it dissolves allowing the sponge to expand to its full size. It is then withdrawn using the suture, and as it does so collects cells from the lining of the oesophagus.
223755448|NCT05256667|COMBINATION_PRODUCT|RCT-SV|Group 1- Endodontic treatment in a single visit using chemomechanical preparation and passive ultrasonic irrigation, followed by obturation and final restoration.
223608796|NCT06726512|DEVICE|XEOS AURA 10|Surgery is performed according to standard of care. Directly after surgery, the surgical specimen is taken outside the operation theatre in a dedicated imaging room at the Department of Nuclear Medicine where high-resolution PET-CT imaging of the surgical specimen is performed.
223608797|NCT06725524|BIOLOGICAL|JMT601|intravenous infusion on day 1 once a week
223608798|NCT06726278|DRUG|Misoprostol 400mcg Tab|Misoprostol 400 µg is a synthetic prostaglandin E1 analog used in this clinical trial to evaluate its effects in inducing uterine contractions or labor. This dosage form is typically administered orally, and its primary mechanism involves the softening and dilation of the cervix, making it a common choice in obstetric practices for labor induction. The study will evaluate its efficacy and safety profile when compared to the placebo group. Misoprostol is administered in a single dose of 400 µg, and participants will be monitored for any adverse reactions or labor-related outcomes.
223608799|NCT06726278|DRUG|Placebo|participants will receive a placebo treatment, consisting of an inert substance that has no active pharmacological effect. The placebo is administered in the same manner (vaginally) and at the same time point as Misoprostol, but without any therapeutic action. This group is used to control for potential psychological effects of the intervention, ensuring that any observed
223755449|NCT05256667|OTHER|RCT-TVWD|Group 2- Endodontic treatment in two visits using chemomechanical preparation and passive ultrasonic irrigation, followed by intracanal dressing and temporary restoration for 7 days. After 7 days, an identical chemomechanical preparation on visit 2 will be performed, followed by obturation and final restoration.
223755450|NCT05256667|OTHER|RCT-TVWOD|Group 3- Endodontic treatment in two visits using chemomechanical preparation and passive ultrasonic irrigation, followed by temporary restoration for 2 days, without intracanal dressing. After 2 days, an identical chemomechanical preparation on visit 2 will be performed, followed by obturation and final restoration.
223608800|NCT06725992|DRUG|IY-NS250|Ilaprazole 20mg + Sodium bicarbonate 500mg
223608801|NCT06725992|DRUG|IY-NT-SR|Ilaprazole 10mg
223608802|NCT06725797|PROCEDURE|wound hygiene with hypothermal sulfurous water by packs|GROUP A: After dressing removal, the wound is exposed. Sulphur thermal water at spring temperature (23°C) is applied for 20 minutes on the untreated wound by packs on non woven gauzes entirely covering the area. Eventually, if dried, gauzes are externally watered with additional sulphurous thermal water during the 20 minutes. After water application the wound follows the other 3 steps of the wound hygiene protocol: non viable tissue removal, edges reactivation and dressing. Non interactive dressings, just for wound moisture management, are used on cleaned wound/s. Dressing fixation, elastic bandages or off-load will be provided when required. the intervention will be repeated every 48 hours for both arms.
223608803|NCT06725797|PROCEDURE|wound hygiene with hypothermal sulfurous water by limb full immersion|GROUP B: After dressing removal, the wound is exposed. Sulphur thermal water at spring temperature (23°C) is applied for 20 minutes on the untreated wound by limb full immersion in a limb tub. After the immersion, the wound follows the other 3 steps of the wound hygiene protocol: non viable tissue removal, edges reactivation and dressing. Non interactive dressings, just for wound moisture management, are used on cleaned wound/s. Dressing fixation, elastic bandages or off-load will be provided when required. the intervention will be repeated every 48 hours for both arms.
223608804|NCT06720155|BEHAVIORAL|Sleeper stretch|Participants will complete their regularly scheduled workout activities over 8 weeks, with the addition of the sleeper stretch into the dynamic warm-up. Participants will be instructed to lie side-lying with the dominant arm downward, the trunk rotated posteriorly 20 to 30°, the shoulder raised to 90°, the elbow flexed to 90°, and both knees semi-flexed to ensure stability. Participants will then be asked to use the opposite hand to grasp the dominant hand below the wrist and gradually internally rotate the forearm towards the floor; (i.e., the participant will perform passive internal rotation with the opposite arm). This stretch position will be completed on both sides. Participants will be instructed to complete 2 sets of 10 repetitions for each arm and hold the position for \~2 seconds.
223608805|NCT06720155|BEHAVIORAL|Standard workout|Participants will complete their regularly programmed dynamic warm-ups before scheduled workout for 8 weeks.
223608806|NCT07046689|DIAGNOSTIC_TEST|68Ga-MY6349 PET/CT|Each participant will receive an intravenous injection of 68Ga-MY6349 and undergo PET/CT imaging at baseline and following two cycles of Trop2-ADC therapy.
223608807|NCT06726538|BIOLOGICAL|Intravenous administration of Autologous, adipose-derived mesenchymal stem cells|"Patients in group A will receive two infusions of autologous, adipose-derived mesenchymal stem cells at day 0 and day 90 ± 14 at a dose of 10\^6 cells/kg.~Autologous, adipose-derived mesenchymal stem cells used in this study were harvested from autologous fat tissue through an enzyme method and expanded using our in-house optimized serum-free and xeno-free culture under a physiological oxygen concentration of 5%. For clinical use, cells at passage 3 will be harvested in 100 mL Ringer's lactate. Therapeutic ASC products must pass the following releasing criteria: (1) negative for bacteria, fungi and mycoplasma; (2) more than 90% viability; (3) expression of more than 95% positivity for CD105, CD73, and CD90 and less than 2% positivity for CD45, CD34, CD11b, CD19, and HLA-DR; and (4) endotoxin \<5 EU/kg. The patient will be infused with 1x106 cells/kg body weight within 60 minutes via the intravenous route."
223608808|NCT06919562|PROCEDURE|Percutaneous coronary intervention with protocolized implantation of a second generation thin-strut bioresorbable scaffold guided by intracoronary imaging|Percutaneous coronary intervention (PCI) with implantation of the MeRes100 thin-strut BRS with protocolized PSP (predilatation, sizing, postdilatation) method and intracoronary imaging guidance.
223608809|NCT06744621|OTHER|Fingerstick|fingersticks during their labor process
223608810|NCT07066579|BEHAVIORAL|Valsalva Maneuver|Patients are instructed to perform the Valsalva maneuver by blowing into a 10-cc syringe to generate approximately 20 mmHg pressure for 15-20 seconds before arteriovenous fistula cannulation during each dialysis session.
223608811|NCT07066865|DEVICE|omniLenz|sutureless dehydrated amniotic membrane (omnigen) mounted on contact lens (omnilenz)
223755451|NCT01820455|DRUG|Chlorhexidine, Mupirocin|Chlorhexidine baths and intranasal mupirocin ointment once daily for five days
223755452|NCT01820455|DRUG|Soap baths, Lubricating Jelly|Soap and water baths with lubricating jelly to the nares, once daily for 5 days
223608812|NCT07065695|PROCEDURE|transposition surgery|Reconstructs spermatic vein drainage via end to side/end to end anastomosis with vessels (e.g., inferior epigastric vein) under 8-15× magnification, preserving testicular arteries/lymphatics.
223608813|NCT07065695|PROCEDURE|microscopic simple ligation|Blocks venous reflux via double ligation and division of spermatic veins under microscopy, with identical surgical exposure and vascular protection.
223608814|NCT07066163|DEVICE|Kinesia U|KinesiaU is a commercially available wearable technology, which includes a smart watch and a mobile application which can continuously monitor and quantify motor symptoms such as tremor, bradykinesia, dyskinesia, gait parameters throughout the day. The technology has been validated for motor symptoms and has high agreement with clinician ratings of motor severity. The motion sensor records data using KinesiaU smart watch and is then transmitted to a secure cloud database, where specialized algorithms analyze the information to detect motor symptoms and compute severity scores every 2 minutes. The results are then not only available to clinicians in the form of detailed reports for review but also for PwP in easily understandable format on the phone application . The validity of this device has been studied to assess tremor, bradykinesia and dyskinesia.
223608815|NCT07066163|OTHER|Standard of care treatment|Participants in the control group will receive standard of care, consisting of regular management of their motor symptoms and monitoring using motor dairy, interview by their neurologist, family physician, and other healthcare providers.
223608816|NCT07066605|DRUG|Group A (Dexmedetomidine Group)|patients will receive dexmedetomidine infusion starting at 0.2 mcg/kg/hr.
223608817|NCT07066605|DRUG|Group B (Control Group)|patients will receive standard ICU sedation protocol without dexmedetomidine (e.g., fentanyl)
223608818|NCT06810778|DRUG|Duvelisib|15 and 25 mg BID
223608819|NCT06810778|DRUG|Venetoclax|200, 400, and 800 mg QD
223608820|NCT07065136|BIOLOGICAL|627|subcutaneous injection
223608821|NCT07065136|OTHER|Placebo|Single subcutaneous injection
223608822|NCT07066111|DRUG|Tramadol|The control group routinely injected tramadol 100mg(Tramal) intramuscularly
223608823|NCT07066111|DRUG|bupivacaine liposome (ultrasound-guided high iliofascial space block)|the experimental group was given ultrasound-guided high iliofascial space block: High-frequency linear probe (5-13 MHZ, Sonosite, USA) was used to identify the iliac bone, iliac muscle and deep circumiliac artery. Then a short oblique puncture needle was used, with the intraplanar technique, and the needle was inserted from the outside. When the needle tip reached the surface of the iliac muscle (iliac fascia space), 20ml of bupivacaine liposome was injected. After the operation, electrocardiogram monitoring(Mindray) was performed for 1 hour to observe adverse reactions.
223508917|NCT07046273|DRUG|Ozempic®|The starting dose is 0.25 mg once weekly. After 4 weeks the dose should be increased to 0.5 mg once weekly. After at least 4 weeks with a dose of 0.5 mg once weekly, the dose can be increased to 1 mg once weekly for 24 weeks.
223508918|NCT07045415|BEHAVIORAL|Pelvic Floor Muscle Exercises.|A structured pelvic floor muscle training (PFME) program provided by a nurse, based on EAU and AUA guidelines, consisting of 20-minute sessions delivered 3 times a week
223508919|NCT07044791|BEHAVIORAL|Nutritional counseling. No drug treatment will be administered in this study.|Nutritional counseling. No drug treatment will be administered in this study.
223508920|NCT07045376|OTHER|evidence-based multi-strategy educational training program on surgical smoke|"Based on evidence from the literature, the content of the evidence-based multi-strategy educational training program includes:~Providing a surgical smoke protection handbook and displaying environmental education posters.~Using an official LINE account to disseminate knowledge about surgical smoke, protective techniques, and related information.~Organizing a hands-on workshop on surgical smoke hazard prevention, allowing participants to practice operating smoke evacuation equipment."
223508921|NCT07044960|DRUG|KHN702 tablet or placebo|Subject will receive a single KHN702 tablet or matching placebo orally in fasted state.
223508922|NCT07044960|DRUG|KHN702 tablet or placebo|All participants will receive KHN702 tablet or matching placebo orally once a day for 7 days in fasted state.
223508923|NCT07046650|COMBINATION_PRODUCT|cisplatin-based chemotherapy|Patients were required to have a creatinine clearance of more than 60 and to receive standard doses of cisplatin and gemcitabine (gemcitabine 1000mg /m2 on day 1.8 and cisplatin 70 mg /m2 on day 1, q3w). A total of 4-6 courses of treatment were performed.
223508924|NCT07045714|PROCEDURE|Unilateral Laminotomy with Bilateral Lumbar Decompression (ULBLD)|Unilateral laminotomy with bilateral lumbar decompression (ULBLD) using endoscopic uniportal technique
223508925|NCT07044947|DRUG|Oteseconazole (VT-1161) 150mg capsule|Subjects with SVVC will be treated by Oteseconazole with 600 mg (150 mg per capsule) on D1, 450 mg on D2
223508926|NCT06729073|DRUG|Diclofenac sodium gel|topical administration
223508927|NCT06729073|DRUG|Diclofenac diethylamine 1.16% gel|Topical administration
223508928|NCT05583305|DIAGNOSTIC_TEST|Imaging assessment|Investigators shall perform cranial MRI examinations. The scanning protocol will employ an MRI scan protocol with T1-weighted, T2-weighted, FLAIR, susceptibility weighted imaging, diffusion weighted imaging, and time-of-flight magnetic resonance angiography (MRA) sequences. In addition, high-resolution magnetic resonance vessel wall imaging (HRMRI) allows assessment of the vessel wall using specific the SPACE sequence and the MATCH sequence. Assessors of the HRMRI images shall be blinded to the group allocation and clinical information.
223508929|NCT05583305|DIAGNOSTIC_TEST|Neurosonology assessment|Investigators shall perform carotid duplex ultrasonography (CD) assessment, focusing on the peak systolic (PSV) and end diastolic velocity (EDV) of bilateral extracranial internal carotid arteries (ICA) Brightness mode imaging shall gauge the intimal thickness and plaque characteristics (if any) of bilateral ICAs.
223508930|NCT05583305|DIAGNOSTIC_TEST|Blood Test|Nine milliliters of EDTA blood will be drawn during the research clinic visit for evaluation of the degree of neurovascular inflammation. Serum plasminogen activator inhibitor-1 (PAI-1) and high-sensitive C-reactive protein (hsCRP) are markers of vascular inflammation, atherosclerosis, and thrombotic risk. Serum neurofilament light chain (NfL) is a biomarker for neuroaxonal injury that correlates with small vessel disease.
223755453|NCT02245789|PROCEDURE|Tracheal intubation|Tracheal intubation will be performed using a Macintosh laryngoscope or a McGrath Mac videolaryngoscope
223755454|NCT02245789|DRUG|Propofol and remifentanil anesthesia|The standardized anesthetic procedure used a closed-loop anesthesia system with bispectral index as control variable and with two proportional-differential control algorithms, one for propofol target-controlled infusion system and one for remifentanil target-controlled infusion system.
223755455|NCT04352751|OTHER|convalescent plasma|"* Plasmapheresis, 900 - 1000 mL each time.~* Standard apheresis plasma collection protocol using Haemonetics MCS+ intermittent blood flow system or Terumo Optia, Cobe-Spectra, Trima or Fresenius continuous flow system to be used.~* Isovolumic saline replacement should be done.~* Each donor can donate convalescent plasma again after an interval of every 2 weeks"
223755456|NCT02180412|BIOLOGICAL|Panhematin|Glucose loading
223755457|NCT02180412|OTHER|Glucose|Glucose is administered to both groups as routine care.
223755458|NCT05603416|DIETARY_SUPPLEMENT|Perilla frutescens extract|oral dissolvable powder - dosage 300mg
223755459|NCT05603416|DIETARY_SUPPLEMENT|Placebo|oral dissolvable powder - dosage 300mg no active ingredient
223755460|NCT02679859|OTHER|BNP guided medical therapy optimisation|
223755461|NCT03309683|DEVICE|Olympus Quick Clip Pro - Single Use Repositionable Clips|A hemoclip will be placed after every 0,5-1,0 cm of the resected area to proximate wound edges.
223755462|NCT06482905|BIOLOGICAL|Anti-B7-H3 Chimeric Antigen Receptor T-Cell (CAR-T Cell) Injection/TX103|"Safety Run-In: Dose:6×10\^7 CAR+ T cells~Cohort A Single delivery route(Multi-dose)、Cohort B Dual delivery route(Multi-dose)： 3+3 dose escalation design： Dose Level 1: 6×10\^7 CAR+ T cells Dose Level 2: 1.5×10\^8 CAR+ T cells Dose Level 3: 2.5×10\^8 CAR+ T cells"
223755463|NCT05644704|OTHER|Lower extremity and core muscle training|Lower extremity training: single leg balance training Core muscle training: pelvic control training
223608824|NCT07064811|PROCEDURE|Exercise Intervention Protocol|Subjects participated in the supervised exercise program twice weekly (with a 48-72-hour interval between sessions) for 24 weeks, totaling 48 supervised sessions. The progressive resistance training program used velocity-based training principles \[24-26\], a novel approach in exercise oncology that allows for precise load management and indi-vidualization based on daily performance capacity
223755464|NCT05363735|OTHER|Ultrasound Elastography|Patients will be examined by ultrasound elastography.
223755465|NCT00738972|DRUG|valsartan|80 mg valsartan. Duration: 12 months. Tablets
223755466|NCT00738972|DRUG|pravastatin|40 mg pravastatin. Duration: 12 months. Tablets
223755467|NCT00738972|DRUG|simvastatin|40 mg simvastatin. Duration: 12 months. Tablets
223755468|NCT00738972|DRUG|ezetimibe (+) simvastatin|ezetimibe (+) simvastatin 10/40 mg. Duration: 12 months. Tablets
223755469|NCT01335958|DRUG|DMUC5754A|Escalating intravenous dose
223755470|NCT05049148|OTHER|Platelet count in excised tumors|Tumors excised in patients requirering a brain or medullary surgery will be assess to determine their platelet count.
223608825|NCT07064811|PROCEDURE|SPoRT-Control Intervention|structured written instructions for a personalized home-based resistance training program. The protocol was designed to prioritize safety, progressive adaptation, and individualization based on each participant's functional capacity and available resources at home. The program was intended to be performed two to three times per week on non-consecutive days, focusing exclusively on lower-body training through a single primary movement. Each session consisted of three effective sets of 12 repetitions, which served as the standard training volume for the main exercise.
223608826|NCT07066540|DRUG|Reamberin® solution for infusion, 1.5 %|Reamberin® in daily dose 10 mL/kg
223755471|NCT01914224|BEHAVIORAL|dietary education of low sodium and high potassium consumption|
223755472|NCT01914224|BEHAVIORAL|dietary education of low sodium consumption only|
223755473|NCT06446947|OTHER|blood sampling|Blood sampling (6ml) on admission and a second on discharge from intensive care.
223755474|NCT01897675|PROCEDURE|Incision and Drainage with packing (wick) placement|
223755475|NCT01897675|PROCEDURE|Abscess drainage with loop placement|
223755476|NCT03327610|OTHER|VC-CMV20|Application of a ventilator hyperinflation intervention with Volume Control Continuous Mandatory Ventilation (VC-CMV). The inspiratory flow was set at 20Lpm and the tidal volume was increased in steps of 200mL until the peak airway pressure of 40cmH2O was achieved. After achieving the target pressure, this ventilatory regimen lasted 15 minutes. Positive end expiratory pressure and the inspired oxygen fraction were not modified.
223608827|NCT07066683|OTHER|CLINICAL ASSESSMENT OF BODY FUNCTION (PROM AND PHYSICAL EXAMINATION) and ACTIVITIES AND PARTICIPATION|"Tip: Ensure that this name matches the name used in the associated Arm Description.~CLINICAL ASSESSMENT OF BODY FUNCTION (PROM AND PHYSICAL EXAMINATION):~* Perceived fatigue~* Mental functions~* Sensory functions and pain~* Neuromusculoskeletal and movement-related functions~* Functions of the cardiovascular and respiratory systems~  o Exercise stress test~* Fatigability (neuromuscular fatigue)~  * Lower limbs~ * Maximum voluntary strength and power~ * Study of the central and peripheral components of fatigue~ACTIVITIES AND PARTICIPATION~* Mobility~  * Clinical standard tests for balance and walking~ * Quantified motion analysis~* Activity level Quality of life The same evaluation tests will be performed on patients and healthy volunteer controls"
223755477|NCT03327610|OTHER|VC-CMV50|Application of a ventilator hyperinflation intervention with Volume Control Continuous Mandatory Ventilation (VC-CMV). The inspiratory flow was set at 50Lpm and the tidal volume was increased in steps of 200mL until the peak airway pressure of 40cmH2O was achieved. After achieving the target pressure, this ventilatory regimen lasted 15 minutes. Positive end expiratory pressure and the inspired oxygen fraction were not modified.
223755478|NCT03327610|OTHER|PC-CMV1|Application of a ventilator hyperinflation intervention with Pressure Control Continuous Mandatory Ventilation (PC-CMV1). The inspiratory time was set at 1 second and the pressure control was increased until a peak pressure of 40cmH2O was achieved. After achieving the target pressure, this ventilatory regimen lasted 15 minutes. Positive end expiratory pressure and the inspired oxygen fraction were not modified.
223755479|NCT03327610|OTHER|PC-CMV3|Application of a ventilator hyperinflation intervention with Pressure Control Continuous Mandatory Ventilation (PC-CMV1). The inspiratory time was set at 3 seconds and the pressure control was increased until a peak pressure of 40cmH2O was achieved. After achieving the target pressure, this ventilatory regimen lasted 15 minutes. Positive end expiratory pressure and the inspired oxygen fraction were not modified.
223608828|NCT07065487|DEVICE|Intraoral Scanner - Standard Protocol|A full-arch digital impression is obtained using a high-precision intraoral scanner. Scan bodies are placed on multi-unit abutments and scanned without the use of external reference markers or geometric aids. The scan follows the manufacturer-recommended scanning path to capture the complete arch. This serves as a baseline digital technique for comparison with geometric pattern-assisted scanning.
223608829|NCT07065487|DEVICE|Intraoral Scanner with Geometric Reference Pattern|The same intraoral scanner is used, but with an additional geometric reference pattern introduced in the scanning field to improve stitching accuracy and alignment of the digital scan.
223608830|NCT07065487|PROCEDURE|Conventional Splinted Impression Technique|A physical impression is taken using open-tray impression copings splinted with DuraLay resin and polyvinyl siloxane (PVS) material in a custom tray, according to conventional protocols for full-arch implant prostheses.
223608831|NCT07065019|OTHER|The Internalized Stigma Scale in Mental Illness (ISS)|The ISS consists of 29 items and is a self-report scale assessing internalized stigma. ISS includes 5 subscales: 1. Alienation (6 items), 2. Confirmation of Stereotypes (7 items), 3. Perceived Discrimination (5 items), 4. Social Withdrawal (6 items), 5. Resistance to Stigmatization (5 items). ISS is a Likert-type scale calculated as 'strongly disagree' (1 point), 'disagree' (2 points), 'agree' (3 points), 'strongly agree' (4 points). The items of the 'Resistance to stigmatization' subscale are reverse scored. High scores on this scale indicate how aggressive the person's internalized stigma is negatively. ISS has been adapted for many diseases other than mental illnesses in our country and its validity and reliability have been demonstrated.
223608832|NCT07065110|DIAGNOSTIC_TEST|Blood draw for the laboratory assessment|Blood draw for testing of metabolics.
223608833|NCT07065110|DIETARY_SUPPLEMENT|Skin test panel|Testing of improving the skin hydration and other skin-related parameters.
223608834|NCT07065110|DIETARY_SUPPLEMENT|HA gel|Participants obtained altogether 3 flasks with 500ml of SH60, SH 120 solution. They tooj 15 ml of the SH60 or SH120 aupplements (experimental group) once daily in the morning before breakfast for 3 months.
223608835|NCT07065110|DIETARY_SUPPLEMENT|Xanthan gum|Participants obtained altogether 3 flasks of placebo solution. They took 15 mL of placebo solution (control group) once daily in the morning before breakfast for 3 months.
223755480|NCT03327610|OTHER|PSV10|Application of a ventilator hyperinflation intervention with Pressure Support Ventilation (PSV). The cycling off was set at 10% of peak inspiratory flow and the pressure support was increased until a peak pressure of 40cmH2O was achieved. After achieving the target pressure, this ventilatory regimen lasted 15 minutes. Positive end expiratory pressure and the inspired oxygen fraction were not modified.
223755481|NCT03327610|OTHER|PSV25|Application of a ventilator hyperinflation intervention with Pressure Support Ventilation (PSV). The cycling off was set at 25% of peak inspiratory flow and the pressure support was increased until a peak pressure of 40cmH2O was achieved. After achieving the target pressure, this ventilatory regimen lasted 15 minutes. Positive end expiratory pressure and the inspired oxygen fraction were not modified.
223755482|NCT01814735|OTHER|Brown rice|
223755483|NCT01814735|OTHER|White rice|
223755484|NCT05399524|OTHER|Standard of Care|Neuronavigation and intraoperative 5-ALA
223608836|NCT06308913|DRUG|INCB081776|INCB081776 will be given orally on a daily basis. The highest safe/tolerable dose and schedule will be established by the ongoing phase 1 clinical trial of INCB081776 plus INCBMGA00012 (NCT03522142), which is 120 mg daily.
223608837|NCT06308913|DRUG|Pembrolizumab|Immune checkpoint blockade with anti-PD-1 (Pembrolizumab) will be given as 200 mg IV on cycle 1 day 15 and cycle 1 day 36. Starting from cycle 2, pembrolizumab will be given on day 1 on each subsequent cycle.
223755485|NCT05399524|OTHER|Additional pre- and intra-operative imaging|Additional DTI scan during routine pre-operative tumour MRI scan, additional use of intraoperative ultrasound in addition to normal to standard of care (Neuronavigation and intraoperative 5-ALA)
223755486|NCT00228345|PROCEDURE|Optical coherence tomography,Fluorescein angiography|
223755487|NCT05961215|DEVICE|Penguin Cold Cap|Penguin cold cap: administered 60 minutes prior to melphalan infusion and continue for 5 hours after melphalan infusion start time, for a total of 6 hours, on Days -2 and -1.
223755488|NCT02921048|DIETARY_SUPPLEMENT|omega-3 fatty acids|
223755489|NCT04217473|BIOLOGICAL|TILT-123|TNFalpha and IL-2 coding oncolytic adenovirus TILT-123
223755490|NCT03498378|DRUG|Avelumab|Avelumab (IV on days 1 and 15 of 28 day cycle)
223755491|NCT03498378|DRUG|Palbociclib|"Palbociclib (PO daily, days 1-21 of 28 day cycle)~Palbociclib will be administered in capsules of 125 mg, 100 mg, and 75 mg, depending on dosage. Patients will be instructed to take their assigned dose once daily with food for 21 days followed by 7 days off therapy. Patients will be encouraged to take their dose at approximately the same time each day."
223755492|NCT03498378|DRUG|Cetuximab|"Cetuximab (IV 400 mg/m2 x 1, then weekly)~Cetuximab is administered intravenously once weekly via infusion pump or syringe pump with infusion rate not to exceed 10 mg/min."
223755493|NCT01982851|PROCEDURE|Epidural de novo|Patients will have the epidural space identified with a loss-of-resistance technique utilizing a 17-G Tuohy epidural needle. The epidural catheter will be inserted 5 cm into the epidural space. Epidural analgesia will be initiated with fentanyl 100mcg + bupivacaine 0.125% 10-20 mL (in divided doses). Maintenance epidural analgesia will then be initiated.
223755494|NCT01982851|PROCEDURE|CSE|The epidural space will be located using the loss-of-resistance technique utilizing a 17-G Tuohy epidural needle. Patients will receive the intrathecal study drug via a 27-G pencil-point spinal needle utilizing the standard needle-through-needle technique. A 19-G epidural catheter will be inserted 5 cm in the epidural space. Maintenance epidural analgesia will then be initiated.
223755495|NCT00680901|DRUG|Lapatinib|5 pills at 250mg each once daily
223755496|NCT00680901|DRUG|Placebo|5 pills once daily
223755497|NCT00680901|DRUG|Capecitabine|1700mg/m2/day in two daily doses
223755498|NCT00680901|DRUG|Oxaliplatin|130mg/m2 on day 1
223755499|NCT01420445|DRUG|YHD001 dose level 1|three times daily / 7 days
223755500|NCT01420445|DRUG|YHD001 dose level 2|three times daily / 7 days
223608838|NCT06308913|RADIATION|Palliative RT|Palliative RT will be given as either 24 Gy in 3 fractions (8 Gy per fraction) or 20 Gy in 5 fractions (4 Gy per fraction). The palliative radiation therapy dose will be determined based on the clinical judgment of the treating radiation oncology physician. Palliative RT must be completed between cycle 1 day 29 to cycle 1 day 33. After completion of palliative radiation therapy, patients will continue with additional cycles of INCB081776 and pembrolizumab until disease progression, intolerance to the combination regimen, or patient withdrawal.
223608839|NCT06771544|DRUG|Pembrolizumab|Given IV
223608840|NCT06771544|DRUG|Cyclophosphamide|Given PO
223755501|NCT01420445|DRUG|Pelargonium sidoides extract|6-9mL three times daily / 7 days
223755502|NCT01420445|DRUG|placebo|three times daily / 7 days
223755503|NCT00974012|DRUG|Divalproex Sodium|500 mg ER Tablet
223755504|NCT00974012|DRUG|Depakote®|500 mg ER Tablet
223755505|NCT03551912|PROCEDURE|Surgery|All patients coming for elective surgery
223755506|NCT03559140|PROCEDURE|Applied saline solution at 2.5 oC (Cryotherapy group)|Patients assigned to this group will receive a final irrigation (application of cryotherapy) with 5 mL cold (8oC) 17% EDTA followed with 20 mL cold (8oC) sterile saline solution delivered to the WL using a cold (8oC) sterile microcannula attached to the Endo Vac System (Kerr Endo) for 5 minutes.
223755507|NCT03559140|PROCEDURE|Applied saline solution at 8oC (Cryotherapy )|Patients assigned to this group receive a final irrigation (application of cryotherapy) with 5 mL cold (2.5oC) 17% EDTA followed with 20 mL cold (2.5oC) sterile saline solution delivered to the WL using a cold (2.5oC) sterile microcannula attached to the Endo Vac System (Kerr Endo) for 5 minutes.
223755508|NCT03559140|PROCEDURE|Applied saline solution at room temperature (No cryotherapy)|Patients assigned to this control group were treated identically to the experimental groups, except that they will receive a final irrigation ( application of irrigant at room temperature) with 5 mL (room temperature) 17% EDTA followed with 20 mL (room temperature) sterile saline solution delivered to the WL using a sterile microcannula attached to the Endo Vac System (Kerr Endo) for 5 minutes.
223755509|NCT02112669|DEVICE|VasQ|
223755510|NCT03189615|DRUG|Lu AF35700|Single oral dose of 10 mg Lu AF35700
223755511|NCT03359642|OTHER|blood sample|14 ml whole blood for Peripheral blood mononuclear cell (PBMC) and monocytes isolation
223755512|NCT03359642|OTHER|stool samples|Study of the fecal microbiota
223755513|NCT03359642|OTHER|food questionnaire|food questionnaire on the seven days before the collection
223608841|NCT07065591|DRUG|Metformin|The intervention group will receive metformin (max: 500mgx4=2000mg daily). Both groups will start with an initial dose of 500mg daily and the dose will be gradually titrated to 2000mg daily in 6 weeks to allow patients adopting to the gastrointestinal symptoms. Both groups shall be put on metformin or placebo for 6months and then both groups will stop their respective medications and continue on diet modification and exercise therapy only.
223755514|NCT03359642|OTHER|colonoscopy|Only for patients with ulcerative colitis (in routine care)
223755515|NCT03359642|OTHER|VOCs profile|Volatile Organic Compounds (VOCs) profile obtained by mass spectrometry
223755516|NCT00494832|DRUG|Dexmedetomidine|"10 minutes loading dose of 0.9 mcg/kg~Maintenance dose of 0.6 mcg/kg/hour"
223755517|NCT00494832|DRUG|Normal Saline|"10 minutes loading dose of 0.9 mcg/kg~Maintenance dose of 0.6 mcg/kg/hour"
223755518|NCT03864315|DEVICE|HGM|To Study the Efficacy of Therapeutic Pulsed Ultrasound in the Treatment of Vitiligo: a Randomized, Intra-individual, Left-right Comparison Study
223755519|NCT01625455|DRUG|Aprepitant|Aprepitant will be given orally in a dose of 125mg on day 1 and 80mg daily on each subsequent day for a total of 7 days.
223755520|NCT01625455|DRUG|Placebo|Placebo will be given orally for a total of 7 days.
223755521|NCT02034461|DEVICE|Utah Slanted Electrode Array|Microelectrode slanted arrays with a large number of electrodes will be surgically implanted into peripheral nerves of patients with limb amputations or peripheral nerve trauma.
223755522|NCT04809220|DRUG|Dulaglutide|Administered SC
223755523|NCT04809220|DRUG|Oral antihyperglycemics|Administered orally
223755524|NCT03254186|DRUG|Propranolol Hydrochloride|Propranolol is started 10 mg tablet twice per day per oral, two week up-titration to reach a total dose of 20mg per oral four times per day over the first two weeks, then will remain on a stable dose for six weeks.
223755525|NCT03254186|DRUG|Placebo Oral Tablet|Identical placebo is started one tablet twice per day per oral, increase over the first two weeks to reach one tablet four times per day, then will remain on this dose for six weeks.
223755526|NCT05894876|OTHER|No treatment is given|No treatment is provided to the participants as part of this study.
223755527|NCT01062555|DRUG|Cyclosporine & Cellcept|Dose and frequency determined as usual by transplant physicians. The drugs are not experimental drugs. The study is looking at reducing negative side effects of some of the drugs.
223755528|NCT01062555|DRUG|Prograf & Cellcept|Dose and frequency determined as usual by transplant physicians. The drugs are not experimental drugs. The study is looking at reducing negative side effects of some of the drugs.
223755529|NCT01062555|DRUG|Low Dose CNI (Cyclosporine or FK) and Cellcept|Dose and frequency determined as usual by transplant physicians. The drugs are not experimental drugs. The study is looking at reducing negative side effects of some of the drugs.
223755530|NCT01062555|DRUG|Rapamune and Cellcept|Dose and frequency determined as usual by transplant physicians. The drugs are not experimental drugs. The study is looking at reducing negative side effects of some of the drugs.
223755531|NCT00005955|DRUG|temozolomide|
223755532|NCT02346084|DRUG|Maraviroc 300 mg tablet (PO) and Maraviroc 1% gel (PR and PV)|"Tablets: daily 300 mg oral maraviroc, Selzentry®,(MVC) for 8 consecutive days Gel: daily rectally administered 1% MVC gel for 8 daily consecutive days Female Participants - will receive an additional third regimen of daily vaginally administered MVC 1% gel for 8 consecutive days.~Each treatment regimen will be followed by a washout period of 14 to 21 days.~Participants will also be randomized to a biopsy sampling schedule (i.e., D8, D9, or D10 sampling)."
223755533|NCT03234660|DRUG|Dexmedetomidine Hydrochloride|dexmedetomidine 1mcg/kg loading and 0.5mcg/kg/hr continuous infusion during surgery
223755534|NCT03234660|OTHER|control|0.9% normal saline continuous infusion
223755535|NCT03035955|DRUG|Azelaic acid|15% gel twice daily for four weeks to one side of face
223755536|NCT04404647|PROCEDURE|Irreversible electroporation|The IRE procedure will be carried out as ultrasound guided technique either percutaneously or during laparotomy. Needle spacing and electrical pulse delivery will be performed in a standardized way.
223755537|NCT00937872|DRUG|250 mg SRT2104 Suspension|Single 10 mL oral dose of 250 mg SRT2104 delivered as a suspension formulation.
223755538|NCT00937872|DRUG|Carbon-14 radio-labeled SRT2104|Single 10 mL IV dose containing 100 microgram (not more than 250 nCi, 9.25 kBq) Carbon-14 radio-labeled SRT2104, administered by IV infusion over 15 minutes, starting 2 hours and 45 minutes after the oral dose is administered.
223755539|NCT05732649|BEHAVIORAL|Auditory neurofeedback|Network interaction measured with EEG at visual areas will be coupled with the intensity of a sound.
223755540|NCT05732649|BEHAVIORAL|Tactile neurofeedback|Network interaction measured with EEG at visual areas will be coupled with the intensity of tactile stimulation (i.e., electrical or vibrotactile stimulators applied on both hands and feet).
223755541|NCT05732649|BEHAVIORAL|Auditory and tactile neurofeedback|Network interaction measured with EEG at visual areas will be coupled with the intensity of a sound and tactile stimulation.
223755542|NCT05732649|BEHAVIORAL|Neurofeedback|Participants train to decrease the intensity of a sensory stimulation (defined in Experiment 1) that is coupled with the network interaction at a specific brain region.
223608842|NCT07065591|OTHER|Placebo|The placebo group will receive placebo. The placebos will be manufactured with Good Manufacturing Practice (GMP) standard such that each placebo pill will look like metformin pill (500mg). Both groups will start with an initial dose of 500mg daily and the dose will be gradually titrated to 2000mg daily in 6 weeks to allow patients adopting to the gastrointestinal symptoms. Both groups shall be put on metformin or placebo for 6months and then both groups will stop their respective medications and continue on diet modification and exercise therapy only.
223608843|NCT03071393|DEVICE|Hypoxia via Hypoxico Hyp-123|During acute intermittent hypoxia, subjects will undergo 15 brief exposures (60-120 seconds) of low oxygen air (9-15% inspired oxygen) delivered by an air generator, alternated with 15 brief exposures (60-120 seconds) of ambient room air.
223608844|NCT03071393|DEVICE|Sham via Hypoxico Hyp-123|During sham intermittent hypoxia, subjects will undergo 15 brief exposures (60-120 seconds) of normal oxygen air (21% inspired oxygen) delivered by an air generator, alternated with 15 brief exposures (60-120 seconds) of ambient room air.
223755543|NCT02641379|DRUG|Peginterferon alfa-2a|PEG-IFN is available as 180 microgram (mcg) per 0.5 mL, prefilled syringe and pen for single dose sc. injection\\n
223755544|NCT02641379|DRUG|Ribavirin|Ribavirin is available as 200 mg tablets
223755545|NCT05847075|OTHER|Heat Therapy|Participants in the HT group will undertake whole body heat treatment according to previous methods. Participants will be housed in an environmental chamber initially set at 55.0oC on three non-consecutive days of the week during 12 weeks. Each session will last 60 min.
223755546|NCT05847075|OTHER|StrengthTraining|Participants will perform supervised exercise in a gym on three non-consecutive days of the week. Each session will last \~60 min and will consist of a warm up, the resistance training and a cool down. All sessions will be conducted by qualified sport and exercise scientists for 12 weeks.
223755547|NCT05847075|OTHER|Sedentary Control|Participants will not receive any intervention during 12 weeks.
223755548|NCT03010111|OTHER|QFT-IT Test and other blood sampling|In all enrolled health care workers, QFT-IT Test and other blood sampling were performed.
223755549|NCT02017314|DRUG|Morphine|
223755550|NCT04996459|DRUG|Tislelizumab|Tislelizumab 200mg iv q3w
223755551|NCT02508025|OTHER|Functional Capacity Evaluation|Assessment of work related physical capacity
223755552|NCT04964128|DEVICE|MiniMed™ 780G insulin pump with Klue Health app utilizing meal gesture micro insulin dosing (meal gesture dosing)|The AHCL system with Meal Gesture Dosing evaluated in this study includes a commercial/CE-Marked insulin pump with investigational software, and the Klue Health mobile app with investigational software (installed on Apple Watch) for meal gesture detection and micro dosing.
223755553|NCT01677975|PROCEDURE|FNA (fine needle aspiration)|
223755554|NCT05296785|PROCEDURE|intramedullary nail with Limb Reconstruction System|bone transport by Limb Reconstruction System over intramedullary nail on fracture tibia
223755555|NCT05033639|DRUG|Melatonin 6 MG|Melatonin is an endogenously produced indolamine principally synthesized in the pineal gland from serotonin. It is described as a ubiquitous molecule which plays a vital role in the physiologic function of the body. Melatonin, also known as N-acetyl-5-methoxytryptamine which has a a) immunomodulator; b) free radical scavenger; c) prevention of oxidative stress and d) anti-inflammatory7-10.
223755556|NCT05033639|OTHER|Breast Milk|Naturally occurring milk from the mother of the infant.
223755557|NCT06376240|DIETARY_SUPPLEMENT|Pyridoxamine 300mg per day|oral supplement
223755558|NCT06376240|OTHER|Placebo 300mg placebo per day|oral supplement
223755559|NCT00446147|DRUG|Pyridoxine|100mg BID/daily, Per oral
223755560|NCT00446147|DRUG|Placebo|placebo 100mg BID/daily, Per oral
223755561|NCT04249258|DRUG|Dobutamine|Dobutamine will then be administered at doses of 5mcg/kg/min, 10mcg/kg/min, 15mcg/kg/min and 20mcg/kg/min.
223755562|NCT05021367|DRUG|TQB3823 tablets|TQB3823 is a small molecule Poly ADP-ribose Polymerase (PARP) inhibitor that can inhibit the enzyme activity of PARP1/2, making it difficult to repair the DNA in cancer cells, leading to cell death and delaying or blocking tumor development.
223755563|NCT05016232|BEHAVIORAL|PrEP N' Shine: Strength Based Case Management (Stage 1)|Support, facilitate, and assist in linkage to PrEP clinic and to facilitate initiation of, and obtaining, PrEP medications.
223755564|NCT05016232|BEHAVIORAL|PrEP N' Shine: Stepped Adherence Training and Counseling (Stage 2)|"1. Initially TGW in this arm will receive daily 2-way gender-affirming text message reminders, and~2. Then those continuing to have poor adherence will receive the 4 (once per week for 3 to 4 weeks) more intensive counseling session with a clinical interventionist."
223608845|NCT05253443|BEHAVIORAL|Mentalizing Imagery Therapy and caregiver skills mobile application|8-week long mobile application intervention course including caregiver skills training and Mentalizing Imagery Therapy techniques with optional weekly group meetings.
223608846|NCT05253443|BEHAVIORAL|Caregiver skills mobile application|8-week long mobile application intervention course including caregiver skills training with optional weekly group meetings.
223608847|NCT07064668|DRUG|TUDCA (Tauroursodeoxycholic Acid) Supplementation|TUDCA administered orally according to protocol-defined dosage.
223608848|NCT07064668|DRUG|Immune checkpoint inhibitor (ICI)|Administered intravenously according to standard practice or protocol.
224200828|NCT05368714|BEHAVIORAL|Multiple Family Group based Family Strengthening (MFG-based FS)|MFG-based FS approach is a family-centered, group delivered, evidence-informed, strength-based intervention designed for children and adolescents whose families struggle with poverty and associated stressors. MFG is based on building support for parents and families by providing opportunities for parents and children to communicate in a safe setting with other families who have shared experiences. The core components of MFG are known as 4Rs and 2S's: rules, responsibility, relationships, respectful communication, stress and social support. Participants in this study arm will receive 16 session of MFG-based FS sessions, delivered by delivered by trained Community Health Workers and Parent Peers.
223608849|NCT07065669|DEVICE|Dorsal medial Prefrontal Cortex intermittent theta burst stimulation|iTBS stimulation of the dmPFC is a FDA-approved treatment for adults with OCD
223608850|NCT07065669|DEVICE|cTBS to ROFC|continuous theta burst stimulation (cTBS) 1,800 pulses per session
223608851|NCT04866680|PROCEDURE|Personalized Circulating DNA follow-up|FFPE tissue sample will be collected before and after surgery blood samples will be collected before and after surgery and every 3 to 4 months
223608852|NCT06474845|DEVICE|T-Control® catheter|Patients will be catheterized with T-Control® for 4 weeks
223608853|NCT06474845|DEVICE|Foley-type catheter|Patients will be catheterized with a conventional Foley-type catheter for 4 weeks
223608854|NCT07065799|DEVICE|Group 1: NHF/LTOT|Patients assigned to this group will start NHF (Nasal High Flow) + oxygen therapy at home and undergo a preliminary trial with NHF to set the optimal flow using the MyAIRVO 3 (Fisher \& Paykel Healthcare, Auckland, New Zealand) with Optiflow+Duet interface. Patients assigned to this group will be required to use NHF for a minimum of 6 hours per night during sleep, while no restrictions will be set on the duration of use or the times of day to use the device. Patients will continue this treatment for a period of 3 months. At the end of the 3 months, there will be a one-week wash-out period, after which treatment with the control respiratory strategy (HMV+LTOT) will begin.
223608855|NCT07065799|DEVICE|Group 2: HMV/LTOT|Patients assigned to this group will start home treatment with HMV (Home Mechanical Ventilation) + oxygen therapy and will be treated with HMV using a pressure support (PS) ventilator. HMV will be administered via nasal mask or full face mask according to patients' preference. Patients assigned to this group will be required to use HMV for a minimum of 6 hours per night in addition to daily home oxygen therapy for at least 15 hours. Moreover, no restrictions will be imposed on the duration of use or the times of day to use the device. Patients will continue this treatment for a period of 3 months. At the end of the 3 months, there will be a one-week wash-out period, after which treatment with the studied respiratory strategy (NHF+LTOT) will begin.
223608856|NCT06916494|DRUG|Rutin|Rutin 40 mg tid. Treatment will be given for 2 cycles (21 days per cycle)
223608857|NCT06916494|DRUG|Gemcitabine, Cisplatin|Cisplatin 100 mg/m² D2 q3w, and Gemcitabine 1000 mg/m² D1, D8 q3w. Treatment will be given for 2 cycles (21 days per cycle)
223608858|NCT06916494|DRUG|Tislelizumab|Tislelizumab 200 mg D1 q3w Treatment will be given for 2 cycles (21 days per cycle)
223608859|NCT06915831|DEVICE|Continuous positive airway pressure (CPAP)|All-night CPAP will be applied with bedtimes 23:00h to 7:00h.
223608860|NCT02599779|DRUG|Pembrolizumab|200mg given intravenously over 30 minutes day 1 of every 3 week cycle until progression as per immune related response criteria
223608861|NCT02599779|RADIATION|Stereotactic Body Radiation Therapy|Dose and duration dependent on body site. In Arm A: SBRT given at the time of progression on pembrolizumab. In Arm B: SBRT given before the 2nd course of pembrolizumab.
223608862|NCT06914440|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|The prescribed dose of radiation is 24 Gy delivered in 3 fractions (8 Gy/fraction) using SBRT technique. Subjects received SBRT for the primary breast cancer lesion at 8Gy/Fraction each time for 3 consecutive days, 1 week before the start of systemic therapy. The first day of radiation is C1D1.
223608863|NCT06914440|DRUG|Toripalimab|Toripalimab will be administered at a fixed dose of 240 mg via intravenous infusion every 3 weeks (q3w). The first dose is given on Cycle 2 Day 1 (C2D1), followed by dosing on the first day of each subsequent cycle for a total of 4 cycles. (Toripalimab×4 240mg D1 q3w)
223608864|NCT06914440|DRUG|Neoadjuvant Chemotherapy|Combined with Toripalimab, Nab-paclitaxel will be dosed at 125 mg/m² based on body surface area, administered by intravenous infusion weekly (Days 1, 8, 15 of each 21-day cycle) for 4 cycles.(T×4, Nab-Paclitaxel 125mg/m2，D1、D8、D15 q3w).
223608865|NCT06914440|PROCEDURE|Surgery|Surgery will be performed 2-6 weeks after completion of neoadjuvant therapy. The surgical approach will be determined by the investigator based on disease status and patient preference.
223608866|NCT06914440|DRUG|Adjuvant Chemotherapy|The anthracycline may be either Epirubicin (body surface area-adjusted 50 mg/m²) or Liposomal Doxorubicin (body surface area-adjusted 30 mg/m²) combined with Cyclophosphamide (body surface area-adjusted 600 mg/m²). Both drugs were administered intravenously every 3 weeks, and then the first day of each course was administered for 4 cycles. (EC×4, Epirubicin 50 mg/m² or Liposomal Doxorubicin 30 mg/m², comined with Cyclophosphamide 600 mg/m², D1, q3w)
223755565|NCT00181961|DRUG|Maca Root|
224200829|NCT05368714|BEHAVIORAL|EE plus MFG-based FS|EE plus MFG-based FS directly addresses both the economic needs and mental health functioning. It will consists of an EE intervention that comprises a family monetary savings program using CDAs, and a family-based dialogue and training via MFG focused on strengthening family relationships and mental health challenges.
223608867|NCT06914440|RADIATION|Adjuvant Radiotherapy|Conventional radiotherapy will be delivered to the breast/chest wall and regional lymph nodes (investigator-selected technique), with explicit prohibition of tumor bed boost irradiation.
223608868|NCT06914440|DRUG|Endocrine therapy|Investigator-selected adjuvant endocrine therapy will be deterimend according to applicable guidelines, considering menopausal status, recurrence risk, treatment history, comorbidities as well as patient preference.
223608869|NCT03162471|DIAGNOSTIC_TEST|non-contact measurement of intraocular pressure|Non-contact measurement of corneal biomechanical properties and intraocular pressure with an Ocular Response Analyzer. Parameters measured: corneal hysteresis (CH), corneal resistance factor (CRF), Goldman-correlated IOP (IOPg), corneal compensated IOP (IOPcc) and waveform score (WS).
223608870|NCT06921057|OTHER|exergame|playing exergames
223608871|NCT06921681|DEVICE|Cryobiopsy of lymph nodes group 6 sec|"Included patients receive transbronchial access with EBUS needle (19, 21 or 22 gauge needle) Hereafter, three times EBUS-TBNA followed by four EBUS-guided-CBs with a 1.1mm cryoprobe will be performed. Included patients are 1:1 randomized to receive CB with cryoprobe activated for either 3 sec of freezing time (group 3sec) or 6 sec. of freezing time (group 6sec) before the biopsy together with the whole EBUS bronchoscope is extracted. The EBUS-guided CB will be conducted four times in each group. Aiming access to one lymph node if one lymph node cannot be punctured, another lymph node will be chosen. Even if tissue-extraction out of a lymph node via cryoprobe fails once to several times, overall no more than 4 attempts for cryobiopsy will be done"
223608872|NCT06921681|DEVICE|Cryobiopsy lymphnode group 3 sec|"Included patients receive transbronchial access with EBUS needle (19, 21 or 22 gauge needle) Hereafter, three times EBUS-TBNA followed by four EBUS-guided-CBs with a 1.1mm cryoprobe will be performed. Included patients are 1:1 randomized to receive CB with cryoprobe activated for either 3 sec of freezing time (group 3sec) or 6 sec. of freezing time (group 6sec) before the biopsy together with the whole EBUS bronchoscope is extracted. The EBUS-guided CB will be conducted four times in each group. Aiming access to one lymph node if one lymph node cannot be punctured, another lymph node will be chosen. Even if tissue-extraction out of a lymph node via cryoprobe fails once to several times, overall no more than 4 attempts for cryobiopsy will be done"
223608873|NCT06921018|BEHAVIORAL|change in diet|the participants will either be assigned consumption of a vegan diet or their habitual average danish diet with a high intake of meat for the intervention period which is 4 weeks.
223608874|NCT06920836|DRUG|QR052107B 100 mg|QR052107B 100 mg QD
223608875|NCT06920836|DRUG|QR052107B 400 mg|QR052107B 400 mg QD
223608876|NCT06920836|DRUG|Placebo|placebo QD
223755566|NCT05718232|DRUG|Lenvatinib|Lenvatinib will be taken within 3 days of randomization (dose: 8 mg qd for patients \<60kg, and 12 mg qd for patients ≥ 60kg)
223755567|NCT05718232|PROCEDURE|TACE|TACE will be performed one day after oral administration of lenvatinib. Either cTACE or DEB-TACE can be used, depending on the condition of each center.
223755568|NCT05718232|RADIATION|SBRT|SBRT will be given within 3 weeks after the first TACE with linear accelerator-based photon beams. Gross tumor volume is defined as intrahepatic tumor and vascular invasion including a 1-cm margin into the contiguous HCC. Prescription dose will be 4500-5000 cGy in 5-8 fractions.
223755569|NCT03984786|BEHAVIORAL|Assessment Interview|An interviewer will administer a pre-treatment assessment interview. This 30-45 minute interview will be performed after randomization immediately after the initial telephone screen, where the interviewer will use the AUD section of the SCID-5.
223755570|NCT03984786|BEHAVIORAL|Guidance|Guidance from a health educator through regular weekly online messages. Participants may also be contacted through emails and phone calls. The team of guides consists of registered social workers, psychologists, and graduate students, with experience delivering ICBT.
223755571|NCT03984786|BEHAVIORAL|ICBT for alcohol misuse|The 8-week internet-delivered cognitive behaviour therapy (ICBT) course for alcohol misuse. The course consists of 12 lessons distributed across 8 weeks (1 to 2 lessons a week).
223755572|NCT01452464|BIOLOGICAL|MenACWY-CRM|MenACYW-CRM vaccination received as part of routine clinical care and as registered in the vaccine records.
223755573|NCT01667978|DRUG|Norethindrone acetate|
223755574|NCT00799578|DRUG|Cysteamine|Drug is in enteric-coated capsule form. The dosage will begin at 1g/m-squared body surface area with a maximum dose of 1000mg twice daily. Treatment period is 3-6 months.
223755575|NCT04407130|DRUG|Ivermectin + Doxycycline + Placebo|"Arm I: 200 mcg/kg (12 mg tablet) ivermectin (IVERA) single dose and 200 mg stat doxycycline day-1 followed by 100mg doxycycline 12hrly for 4 day (i.e. day2-day5)~Placebo one tablet D2-5"
223755576|NCT04407130|DRUG|Ivermectin + Placebo|Arm II: Ivermectin - 200 mcg/kg (12 mg tablet) once per day D1-D5 + Placebo two tablets D1 followed by Placebo one tablet D2-5
223755577|NCT04407130|DRUG|Placebo|Arm III: 3 Placebo tablets D1 followed by 2 tablets D2-5
223755578|NCT04353011|OTHER|questionnaire assesment|questionnaire assesment
223755579|NCT01070316|DRUG|Everolimus|Everolimus is available in tablet form. The starting dose will be 5 mg/m2/day, rounded to the nearest 2.5 mg/dose, to be taken daily. After two weeks, serum trough level will be measured and dose adjusted according to the following algorithm If Blood trough level is less than 2.5 ng/ml than increase dose by 5 mg/m2/day; If Blood trough level is 2.5-5.0 ng/ml than increase dose by 2.5 mg/m2/day; If Blood trough level is 5.1-10.0 ng/ml than increase dose by 0 mg/m2/day (no change); If Blood trough level is 10.1-15.0 ng/ml than decrease dose by 2.5 mg/m2/day
223755580|NCT02531321|DRUG|Levonorgestrel and Ethinyl Estradiol|All participants will take a combined oral contraceptive containing 150mcg levonorgestrel and 30mcg ethinyl estradiol for 21 days. Pharmacokinetics and pharmacodynamics will be compared between participants using antiretroviral regimens including ritonavir-boosted protease inhibitors and those using regimens that do not interact with oral contraceptives.
223755581|NCT05393557|OTHER|Upfront preparation of microcirculation to minimize risks of no-reflow and reperfusion injury|Tirofiban (intra-coronary bolus of 25µg/Kg) + Nitroglycerin (intracoronary 100-200 µg) + Verapamil (intracoronary 100-200 µg, yet excluding patients with 2nd or 3rd degree AV block, HR \< 60, or SBP \<100 mmHg) + 2 cycles of intermittent balloon inflation
223755582|NCT01770288|OTHER|Anaerobic wingate test|
223755583|NCT03214809|DIAGNOSTIC_TEST|ultrasound protocol|after first assessment and treatment by the MET team, an Multi-organ ultrasound protocol will be run by the MET doctor
223608877|NCT06919315|BEHAVIORAL|CO-OP intervention|CO-OP intervention: Initial phase: Goalsetting is mandatory and based on the participant's prioritized ADL performance issues identified in their baseline COPM. Education phase: Individual education in the metacognitive Goal-Plan-Do-Check strategy. Training phase: CO-OP training that involves repetitive use of the Goal-Plan-Do-Check for problem solving and skill acquisition. The therapist employs dynamic performance analysis and guided discovery to help participants understand performance issues and formulate plans for achieving their goals. Participants then execute and evaluate these plans, with a focus on developing domain-specific cognitive strategies. The therapist actively encourages generalization and transfer of skills. Homework is mandatory.
223608878|NCT06919315|BEHAVIORAL|Usual practice|Usual practice: Initial phase: Goalsetting is optional and may be based on previous assessment or on a conversation with the participant. Training phase: Different approaches may be taken such as observation and practice of activities or consultation about performance issues and how participants may deal with them. The therapist may guide the participant's performance verbally, physically or trough picture materials. Homework may be included.
223608879|NCT06921824|OTHER|Glucagon|A three-hour intravenous infusion with glucagon with increasing infusion rate (from 0,01 ng/kg/min up to 50 ng/kg/min)
223608880|NCT04148430|DRUG|Anakinra|100mg subcutaneous
223608881|NCT06921174|DEVICE|"Use of the Crescendo 2 Intravaginal Device"|"Self-administered perineal massage at home with Crescendo device.~Three times per week, 10 minutes each session, over a 12-week period."
223608882|NCT06921174|PROCEDURE|Classical Perineal Massage Therapy|"Performed manually by a pelvic floor physiotherapist.~One 30-minute session per week for 12 weeks."
223608883|NCT06919133|DEVICE|The MENTINA app|A smartphone-based app is developed and used in this trial. The smartphone-based MENTINA app allows for daily self-monitoring of depressive symptoms such as mood, sleep, activity etc and rule-based feedback based on self-monitored data as well as collected sensor data. Libary with relevant content will also be available and incoorporated in the rule-based feedback.
223608884|NCT06919133|OTHER|Control|The MENTINA app is installed but no content and self-monitoring is available. No rule-based feedback. Only outcome measures can be done.
223608885|NCT06927115|OTHER|Maitland Mobilization|Provide maitland mobilization technique along with conventional exercises like Monkey bar, towel stretching, and codmen exercise to each subject.
223608886|NCT06927115|OTHER|Mulligan Mobilization|Provide mulligan mobilization technique along with conventional exercises like Monkey bar, towel stretching, and codmen exercise to each subject.
223608887|NCT02583555|BEHAVIORAL|Interview followed by frequent telephone support|Interview followed by telephone support
223608888|NCT06936176|DEVICE|Neurovascular Intravascular Shockwave Catheter|"Device:~Neurovascular Intravascular Shockwave Catheter (single-use, rapid-exchange balloon catheter with integrated shockwave emitters).~Intravascular Shockwave Therapy Device (IVL-HVG-N01, generates localized shockwaves to fracture calcifications).~Procedure:~Patients undergo standard CAS preparation with guidewire placement and cerebral protection.~If conventional balloon angioplasty fails (residual stenosis \>70%), the IVL catheter is advanced to the target lesion.~Shockwave therapy is applied at 6 atm, followed by low-pressure balloon dilation (8 atm) if needed.~Subsequent stent deployment is performed per standard practice."
223608889|NCT00924443|DRUG|clofarabine|
223608890|NCT06951685|DEVICE|Xeltis Peripheral Artery Disease (XPAD) Bypass Conduit|The XPAD bypass conduit is a sterile, restorative biodegradable polymer-based vascular graft, consisting of a tubular structure with a 33cm length and 6mm inner diameter. It is comprised of a highly porous polymer matrix and an embedded electropolished nitinol reinforcement layer (Strain Relief System). The XPAD conduit is in a straight configuration and may be implanted above the knee for elective femoral popliteal bypass surgery.
223608891|NCT06537674|DRUG|Trastuzumab intravenous drip/Trastuzumab Subcutaneous Injection|Group A is Trastuzumab intravenous drip,Group B is Trastuzumab Subcutaneous Injection
223608892|NCT02822261|DRUG|Coppertone (BAY987516)|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation: SR15-66\_R84-088)
223608893|NCT04676035|DRUG|Midazolam, Warfarin, Omeprazole, VitaminK1 and SHR3680|"* Experimental: Midazolam, Warfarin, Omeprazole, VitaminK1 and SHR3680~* Midazolam, Warfarin, Omeprazole and VitaminK1 QD on Day 1 and Day 22, SHR3680 240 mg once daily (QD) from Study Day 6 - 27"
223608894|NCT00364091|DRUG|R89674 0.025% ophthalmic solution|
223608895|NCT01210586|BEHAVIORAL|Part 2|Comparing smoking symptomatology by HRT and nicotine patch status using a 2x2 randomized design.
223755584|NCT02051530|DIETARY_SUPPLEMENT|tryptophan depletion|tryptophan depletion involves the ingestion of an amino acid mixture that is devoid of tryptophan. on the other day participants receive placebo, being the same mixture but including tryptophan
223755585|NCT02196792|DEVICE|E-Poly liner|E-Poly liner with a titanium cup
223755586|NCT02196792|DEVICE|ArComXL liner|ArComXL liner with a titanium cup
223755587|NCT02196792|DEVICE|32 mm femoral head|Stem with a 32 mm CoCr femoral head
223755588|NCT02196792|DEVICE|36 mm femoral head|Stem with a 36 mm CoCr femoral head
223608896|NCT01521663|DRUG|IPX159|
223608897|NCT01521663|DRUG|Placebo|
223608898|NCT01907763|DRUG|SOTB07 200mg|
223608899|NCT01907763|DRUG|SOTB07 400mg|
223608900|NCT01907763|DRUG|SOTB 200mg placebo|Placebo of SOTB07 200mg
223608901|NCT01907763|DRUG|SOTB 400mg placebo|Placebo of SOTB07 400mg
223755589|NCT03978364|DRUG|Azacitidine combined HHT|Azacitidine 75mg/m2，iH，qd×7days，HHT，3mg/m2 ivdrip qd×3 days
223755590|NCT03978364|DRUG|Azacitidine regimen|Azacitidine 75mg/m2，iH，qd×7days，28 days a cycle
223755591|NCT05798416|DRUG|Exercise under inhalation CO2|Participants perform shuttle walk test at high altitude while using the novel portable device for inhalation of CO2
223755592|NCT05798416|OTHER|Exercise under inhalation ambient air|Participants perform shuttle walk test at high altitude while inhaling ambient air
223755593|NCT06287073|DRUG|JARDIANCE®|JARDIANCE®
223755594|NCT03026465|DEVICE|Polymer-free stent|PCI using a polymer-free dual-drug sirolimus- and probucol-eluting stent (Coroflex ISAR)
223755595|NCT03026465|DEVICE|Biodegradable-polymer stent|PCI using a biodegradable-polymer biolimus-eluting stent (Biomatrix)
223755596|NCT04382248|OTHER|Smartphone App|An app for monitoring medications, blood pressure, exercise, healthy eating
223755597|NCT04382248|BEHAVIORAL|Tailored education|in-person coaching
223755598|NCT01885312|BEHAVIORAL|Adaptive Tailored Intervention|Adaptive
223755599|NCT01885312|BEHAVIORAL|Consequence-based Intervention|Loss Framed
223755600|NCT01885312|BEHAVIORAL|Tailored, not adaptive, based Intervention|Baseline tailored not adaptive
223755601|NCT01885312|OTHER|Assessment only|EMA only
223755602|NCT05354128|DRUG|Thrombolytic|Standard intravenous thrombolysis.
223755603|NCT05354128|PROCEDURE|percutaneous coronary stenting|Percutaneous coronary stenting
223755604|NCT01615471|BEHAVIORAL|Group weight loss with companion internet|Monthly in-person group sessions with an companion internet weight loss intervention
223755605|NCT05111691|PROCEDURE|Dry needling|Dry needling
223755606|NCT00454168|BIOLOGICAL|PR1 leukemia peptide vaccine|Given subcutaneously
223755607|NCT00454168|BIOLOGICAL|sargramostim|Given subcutaneously
223755608|NCT00454168|OTHER|placebo|Given subcutaneously
223755609|NCT01719185|DRUG|Phentermine and B12|
223755610|NCT01719185|DRUG|Phentermine|
223608902|NCT01622387|PROCEDURE|Coronary artery bypass (CABG) surgery using a radial arterial conduit|Use of radial artery as a bypass conduit/graft to the left circumflex coronary artery region of the heart in CABG surgery
223608903|NCT01622387|PROCEDURE|Coronary artery bypass surgery using a long saphenous vein conduit|Use of long saphenous vein as a graft/conduit vessel to the left circumflex coronary artery region of the heart in CABG surgery
223755611|NCT00690963|PROCEDURE|Radiotherapy|Dose excalation based on normal tissue toxicity using 5 dose bins ranging from 56.8 Gy/ 27 fractions to 67.3 Gy in 27 fractions.
223755612|NCT00692770|DRUG|Nexavar (Sorafenib, BAY43-9006)|Sorafenib 400 mg twice daily (BID)
224200830|NCT03372018|BEHAVIORAL|Promotora-led Intervention (PLI)|Behavioral life-style program with cognitive-behavioral content lead by a team of trained community health workers (called promotoras) with the following principal goals - encouraging participants to lose 7% of their total weight and complete 150 minutes of moderate physical activity per week.
224200831|NCT03372018|BEHAVIORAL|Usual care (UC)|Participants in this arm will be given educational materials in spanish discussing mental health and diabetes prevention.
224200832|NCT05336318|BEHAVIORAL|Peer support|patients were supported by a mentor
223755613|NCT00692770|DRUG|Placebo|Placebo 2 tablets twice daily (BID)
224200833|NCT05562713|BEHAVIORAL|Present Bias without Loss Aversion|Small prize for each step completed; large prize for independent CIC
224200834|NCT05562713|BEHAVIORAL|Present Bias with Loss Aversion|Prizes only if fully independent CIC demonstrated
224200835|NCT01389700|DRUG|SAR279356|"Pharmaceutical form: solution for infusion~Route of administration: intravenous infusion"
223755614|NCT04413084|OTHER|Gaze stability exercises|Business card will be placed at eye level. Begin with simpler exercises and progress toward harder one.
223755615|NCT04413084|OTHER|Brandt-Daroff Exercises|"Brandt-Daroff Exercises~1. Start sitting upright on the edge of the bed.~2. Turn your head 45 degrees to the left, or as far as is comfortable.~3. Lie down on your right side.~4. Remain in this position for 30 seconds or until any dizziness has subsided.~5. Sit up and turn head back to center.~6. Turn your head 45 degrees to the right, or as far as is comfortable.~7. Lie down on your left side.~8. Remain in this position for 30 seconds or until any dizziness has subsided.~9. Sit up and turn head back to center."
223755616|NCT04327986|DRUG|M7824|Intravenous (IV) on Days 1 and 15 of every cycle
223755617|NCT04327986|DRUG|M9241|Subcutaneous injection on Day 1 of every cycle
223755618|NCT04327986|RADIATION|SBRT|Radiation therapy will be starting on Day 17 (+5 days) of Cycle 1 and continue for 5 consecutive business days.
223755619|NCT01998451|DRUG|Tauroursodeoxycholic acid|patients from double sphincter group and general gallbladder sphincter group all received Tauroursodeoxycholic acid after surgery for 6 months.
223755620|NCT00175890|DRUG|Levetiracetam|Dosing was stratified by age. A dose of 20 mg/kg/day titrating to 40 mg/kg/day for children one month to less than six months old and a dose of 25 mg/kg/day titrating to 50 mg/kg/day for children 6 month to less than 4 years old, was used in this study. The total daily dose was administered b.i.d.
223755621|NCT00175890|OTHER|Placebo|Placebo solution, which is indistinguishable from the Levetiracetam oral solution.
223755622|NCT03325686|DIETARY_SUPPLEMENT|vitamin D supplement|D; received 50,000 IU of vitamin D supplement weekly
224200836|NCT01389700|DRUG|placebo|"Pharmaceutical form: solution for infusion~Route of administration: intravenous infusion"
224200837|NCT03637270|DIETARY_SUPPLEMENT|Dietary supplementation|Before and after each exercise session, the research assistant will give subjects protein supplement or carbohydrate supplement according to the treatment assignment and ask them to drink it down right away.
224200838|NCT03637270|OTHER|Exercise training|Including aerobic cycling training and progressive resisted exercise
224200839|NCT00380575|DRUG|YM087|
223608904|NCT01558050|DIETARY_SUPPLEMENT|red rice supplement|patricipants take a red rice supplement or placebo daily for 8 weeks
223608905|NCT05345301|DIAGNOSTIC_TEST|Event related desynchronization measurement|Individuals will spend one hour and receive cues to open or close their hand while wearing a EEG cap and EMG sensors on their forearm.
223608906|NCT01053039|DRUG|Intrathecal Morphine|Treatment group to receive 0.2mg of intrathecal morphine followed by PCA morphine.
223608907|NCT01053039|DRUG|Intrathecal Saline|The control group will receive intrathecal saline followed by PCA. All patients will receive a standardized postoperative regimen.
223608908|NCT02324816|DEVICE|The Zeltiq CoolSculpting System|The CoolSculpting System delivers non-invasive cooling for the reduction of subcutaneous fat.
223608909|NCT05613829|OTHER|Burn surgery|Patients underwent burn surgery
223755623|NCT03325686|OTHER|Placebo|placebo
223755624|NCT01522066|PROCEDURE|Perineural catheter|Patients in the experimental group will receive a single dose of local anesthetic though an indwelling catheter both before and after surgery.
223608910|NCT01088620|DRUG|Panitumumab|"Panitumumab 9 mg/kg BW will be administered IV every 3 weeks (q3w) for a maximum of four cycles.~In case of CR, PR or SD status at the end of the combination treatment, a panitumumab single drug treatment, consisting of 9 mg/kg BW administered every 3 weeks, will be performed until detection of disease progression."
223608911|NCT01088620|DRUG|Pemetrexed|Pemetrexed 500 mg/m² will be administered IV every 3 weeks (q3w) for a maximum of four cycles.
223608912|NCT01088620|DRUG|Cisplatin|Cisplatin 75 mg/m² will be administered IV every 3 weeks (q3w) for a maximum of four cycles.
223608913|NCT05169424|DEVICE|Trelegy Ellipta|Trelegy Ellipta
223608914|NCT05169424|DEVICE|Stiolto Respimat|Stiolto Respimat
223608915|NCT05169424|DRUG|Tiotropium + Olodaterol (5/5 mcg)|Tiotropium + Olodaterol (5/5 mcg)
223608916|NCT05169424|DRUG|Fluticasone Furoate + Umeclidinium + Vilanterol (100/62.5/25 mcg)|Fluticasone Furoate + Umeclidinium + Vilanterol (100/62.5/25 mcg)
223755625|NCT01522066|PROCEDURE|Single-shot block|Patients in the control group will receive a single shot of local anesthetic, in standard fashion, before surgery.
223608917|NCT04022655|OTHER|ICU Care|No intervention
223608918|NCT00916019|OTHER|exercise training|60 min of low-intensity exercise, 5 days/week, 12 weeks
223608919|NCT05297188|DEVICE|ergonomic sleep mask|Ergonomic sleep mask; It is a material that covers the eye and ear completely and can be adjusted according to the patient, can be washed and reused at 30 degrees after use, 95% cotton, 5% polyester structure and 100% light proof properties.
223608920|NCT00005818|DRUG|irinotecan hydrochloride|Given IV
223608921|NCT00005818|DRUG|semaxanib|Given IV
223608922|NCT00005818|OTHER|laboratory biomarker analysis|Correlative studies
223608923|NCT03748719|DEVICE|Stereotactic Body Radiation Therapy (SBRT)|SBRT treatment
223608924|NCT00130611|OTHER|BNP measurement|
223608925|NCT00130611|OTHER|Clinical examination|
224200840|NCT03558607|DRUG|Ruxolitinib|"Induction chemotherapy include combination of cytarabine (200mg/m2) and idarubicin (12mg/m2). Both 7+3 and 5+2 regimen is allowed according to age and performance status (PS) as follows;~* If Age \< 55 years and ECOG PS \< 2 : 7+3 regimen~* If Age ≥ 55 years or ECOG PS = 2 : 5+2 regimen~Ruxolitinib is administered for 14 days during induction/consolidation phase. After complete remission after induction, ruxolitinib is administered for the first 14 days during consolidation chemotherapy. Maximum 3 cycles of consolidation is recommended. In case of allogeneic stem cell transplantation (alloSCT), ruxolitinib is discontinued at the time of transplantation. After completion of consolidation, 2 years of ruxolitinib maintenance is planned. The follow-up period is from the time of enrollment until 24 months."
224200841|NCT05078632|OTHER|Montreal-Toulouse Test adapted in eye tracking|participant pass an eye tracking test to evaluate comprehension
224200842|NCT05399407|OTHER|Health e-coaching|Management of overweight / obesity
224200843|NCT00768105|DRUG|AZD1656|Dose titration of oral suspension to a tolerable dose in 2-3 dose steps. Investigational product given twice daily for eight days.
224200844|NCT00768105|DRUG|Placebo|Dosing to match AZD1656
224200845|NCT06573697|OTHER|low-frequency continuous wave EA|In each treatment session, the subjects will receive EA treatment. The selected acupoints for needling will be BL2, GB1, GB14, ST2, SI18, ST6, ST4, ST7, SJ17, EX-HN16, EX-HN5, on affected side, and LI4, bilaterally. After the de-qi sensation is achieved, electrical stimulator will be connected to BL2-GB1, and ST4-ST6, and 2Hz continuous wave will be used for 20 min.
224200846|NCT06573697|OTHER|discontinuous wave EA|In each treatment session, the subjects will receive EA treatment. The selected acupoints for needling will be BL2, GB1, GB14, ST2, SI18, ST6, ST4, ST7, SJ17, EX-HN16, EX-HN5, on affected side, and LI4, bilaterally. After the de-qi sensation is achieved, electrical stimulator will be connected to BL2-GB1, and ST4-ST6, and 40Hz discontinuous wave will be used for 20 min.
224200847|NCT06573697|OTHER|dilatational wave EA|In each treatment session, the subjects will receive EA treatment. The selected acupoints for needling will be BL2, GB1, GB14, ST2, SI18, ST6, ST4, ST7, SJ17, EX-HN16, EX-HN5, on affected side, and LI4, bilaterally. After the de-qi sensation is achieved, electrical stimulator will be connected to BL2-GB1, and ST4-ST6, and 2/100Hz dilatational wave will be used for 20 min.
224200848|NCT03072329|PROCEDURE|Pudendal nerve block|
224200849|NCT03072329|DRUG|Bupivacaine|
223608926|NCT01447186|BEHAVIORAL|Post-Test Questionnaire|Questionnaire following Demographic questionnaire, Pre-Test Knowledge Questionnaire and slide set review.
223608927|NCT01447186|BEHAVIORAL|Interviews|Using draft slide set, participants engage in think-aloud exercises, where each slide is reviewed and described.
223608928|NCT01447186|BEHAVIORAL|Focus Groups|Up to 40 subjects will participate in the formative focus groups. Each group will be scheduled with 6 to 10 participants to explore Hispanic men's beliefs and concerns about prostate cancer and early detection.
223608929|NCT01292096|OTHER|Provision of extra (care coordination and management) services|The pilot intervention begins at the patient's bedside in the hospital and continue after his/her discharge into the community, utilizing a flexible and intensive care management model with a multi-disciplinary team approach. Community Based Care Managers (CBCMs) overseen by a social worker, will connect patients to needed community services including housing for homeless patients, accompany patients to appointments and facilitate transportation to medical, benefits enrollment, and perform other services based in the hospital and community.
223608930|NCT03469713|DRUG|Nivolumab|"Hypofractionated radiation will be administered to a metastatic disease site at a dose and schedule of 30 Gy in 3 consecutive fractions. The day of first administration of Nivolumab will be designated as Time 1. Nivolumab will be given as flat dose of 240 mg in intravenous infusion beginning on day 1 every 14 days for 6 months, than switch to 480 mg q4-weekly in responding (CR, PR, SD) patients until PD or unacceptable toxicity .~SRT will be administered between the first and second administration of Nivolumab (7 days after the first infusion of Nivolumab)."
223755626|NCT00655564|DRUG|Alefacept|"Alefacept's FDA indication is for the treatment of adult subjects with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy. The approved dosing regimen is 15mg once weekly as an intramuscular injection or 7.5mg given once weekly as an intravenous bolus. The recommended regimen is a course of 12 weeks.~Alefacept is supplied as a lyophilized powder. Alefacept contains LFA3-IgG1 Fusion Protein and excipient materials (citrate, glycine and sucrose)."
223755627|NCT05504629|BEHAVIORAL|Concurrent training order 1|atag
223755628|NCT05504629|BEHAVIORAL|RT+ET|aetaer
223608931|NCT02402140|OTHER|Pharmaceutical Intervention|Patients allocated to group 1, with pharmaceutical intervention, received instructions on the proper use of immunosuppressants as doses, frequency, importance, schedules on the following days 3, 5, 7, 10, 14, 21, 28, 60 and 90 after kidney transplant. Teaching materials were designed to assist in the pharmaceutical guidelines that understood the importance of immunosuppressive drugs, the risk of rejection, the schedules and the most appropriate way for the administration. In addition to these guidelines, pharmacists helped patients in filling out the patient diary. This diary contains all the medications that the patient administers and encourages them to write down daily doses in order to remind them. This was a standardized pharmacist intervention.
223755629|NCT05365672|BIOLOGICAL|MIC|Single intravenous infusion of 1.5x10exp8 MIC per kg of body weight
223608932|NCT02956317|DRUG|STP705|The Cotsiranib drug substance is composed of two siRNA oligonucleotides, targeting TGF-β1 and Cox-2 mRNA respectively, and formulated in nanoparticles with Histidine-Lysine co-Polymer (HKP) peptide at a ratio of 1:4 in mass weight (siRNA:peptide), which is further formulated into a dry powder drug product. The administration route would be intra-dermal injection.
223608933|NCT02956317|DRUG|Placebo|Normal Saline
223608934|NCT06058325|OTHER|Healthy school lunch|The healthy school lunch will be co-created together with school staff, parents, and children, and should be healthy according guidelines of the Dutch nutrition center.
223608935|NCT00942825|DRUG|CBP501 + Cisplatin + Pemetrexed|"CBP501, pemetrexed and cisplatin will be administered on the same day (Day 1), every 3 weeks for a maximum of six cycles. A cycle is considered to be 3 weeks (21 days).~1. CBP501 25 mg/m² will be administered as an i.v. infusion of 1 hour.~2. Pemetrexed 500 mg/m² will be administered as an i.v. infusion over 10 minutes, immediately after the CBP501 infusion.~3. Cisplatin 75 mg/m² will be administered as a 1-hour i.v. infusion immediately after the pemetrexed infusion."
223755630|NCT05365672|OTHER|Standard of Care|No application of the investigational medicinal product MIC
223755631|NCT06149689|COMBINATION_PRODUCT|mFOLFIRINOX plus radiotherapy|Patients with advanced pancreatic adenocarcinoma will receive a modified FOLFIRINOX regimen (oxaliplatin \[70 mg per square meter of body surface area\], irinotecan \[130 mg per square meter\], leucovorin \[200 mg per square meter\], and fluorouracil \[2000 mg per square meter\] every 2 weeks). Four-week chemotherapy is considered as a cycle. Patients will be recommended to receive Intensity-Modulated Radiation Therapy (IMRT) after about 4\~6 cycles of chemotherapy. The following treatment after radiotherapy will be applied according to the newest edition of National Comprehensive Cancer Network (NCCN) guideline.
223755632|NCT00593671|PROCEDURE|Preimplantation genetic screening after embryo biopsy|Preimplantation genetic screening after embryo biopsy
223755633|NCT01909349|BEHAVIORAL|self-regulation|Web-based support for behavior change regarding physical activity and fruit \& vegetable consumption
223755634|NCT01653496|PROCEDURE|Enhanced recovery after surgery|The main 18 elements of ERAS program included are described in detail in the brief summary of the study
223755635|NCT01184547|BEHAVIORAL|Combex|12 weeks of exercise with a trainer post discharge.
223755636|NCT01184547|BEHAVIORAL|Standard of Care|No exercise training received.
223755637|NCT05659628|COMBINATION_PRODUCT|CD19-7×19 CAR-T combined with Tislelizumab|Participants will receive 2×106/Kg CD19-7×19 CAR-T cells infusion and Tislelizumab 200mg every 21 days for 6 cycle on the 31st day after CAR-T infusion.
223755638|NCT03594097|OTHER|Treatment cookies|Plain flour, Coconut Nourish, Queen Garnet Plum, Unsalted Butter, Artificial Sweetener
223755639|NCT03594097|OTHER|Control cookies|Plain flour, Coconut Powder, Unsalted Butter, Artificial Sweetener, Food Colour
223755640|NCT06987695|DRUG|Maridebart cafraglutide|Maridebart cafraglutide will be administered SC.
223755641|NCT06987695|DRUG|Placebo|Placebo will be administered SC.
223755642|NCT06854653|DRUG|PTX-100|Peptidomimetic inhibitor of GGTase 1
223755643|NCT03244124|OTHER|Self-Etching Application Strategy|In Group SET, the adhesive system Futurabond Universal will be used in 50 teeth, according to the manufacturer's instructions, in the self-etching mode. The adhesive system will be brushed during 20 seconds in the cavity, will be air-dried during 5 seconds, and activated during 10 seconds with LED light; After applying the adhesive, the restorations will be made with composite Admira Fusion (VOCO GmbH, Germany), and evaluated every 6 months for pain assessment, shape, staining or recurrent caries, using scores.
223755644|NCT03244124|OTHER|Enamel Etching Application Strategy|In Group SEE, 37% phosphoric acid will be applied during 30 seconds, only in enamel in 50 teeth. This acid will be removed using water, the cavity will be air-dried, and then, the adhesive system Futurabond Universal will be used in 50 teeth, according to the manufacturer's instructions. The adhesive system will be brushed during 20 seconds in the cavity, will be air-dried during 5 seconds, and activated during 10 seconds with LED light; After applying the adhesive, the restorations will be made with composite Admira Fusion (VOCO GmbH, Germany), and evaluated every 6 months for pain assessment, shape, staining or recurrent caries, using scores.
223755645|NCT03244124|OTHER|Etch&Rinse Dry Application Strategy|In Group ERDry, 37% phosphoric acid will be applied during 30 seconds, only in enamel, and 15 seconds, only in dentin, in 50 teeth. This acid will be removed using water, the cavity will be air-dried, keeping dentin dry (but not overdry) and then, the adhesive system Futurabond Universal will be used in 50 teeth, according to the manufacturer's instructions. The adhesive system will be brushed during 20 seconds in the cavity, will be air-dried during 5 seconds, and activated during 10 seconds with LED light; After applying the adhesive, the restorations will be made with composite Admira Fusion (VOCO GmbH, Germany), and evaluated every 6 months for pain assessment, shape, staining or recurrent caries, using scores.
223755646|NCT03244124|OTHER|Etch&Rinse Wet Application Strategy|In Group ERWet, 37% phosphoric acid will be applied during 30 seconds, only in enamel, and 15 seconds, only in dentin, in 50 teeth. This acid will be removed using water, the cavity will be air-dried, keeping dentin wet and then, the adhesive system Futurabond Universal will be used in 50 teeth, according to the manufacturer's instructions. The adhesive system will be brushed during 20 seconds in the cavity, will be air-dried during 5 seconds, and activated during 10 seconds with LED light; After applying the adhesive, the restorations will be made with composite Admira Fusion (VOCO GmbH, Germany), and evaluated every 6 months for pain assessment, shape, staining or recurrent caries, using scores.
223755647|NCT05608122|OTHER|Obervation|This study is an observational study without any intervention
223755648|NCT05608122|OTHER|Obervation|This study is an observational study without any intervention
223755649|NCT06329453|PROCEDURE|Colon Tissue Biopsy|Colonoscopy and colon tissue biopsy.
223755650|NCT06275165|OTHER|acupressure|In the experimental group, routine nursing care and acupressure (Neiguan and Zusanli points) were performed from the 1st to the 5th day after the postoperative transfer from the ward to the hospital room. Twice a day, 3 minutes each time, 12 minutes in total.
223755651|NCT04006665|DIAGNOSTIC_TEST|Lung Ultrasonography (Baseline)|Lung Ultrasonography will be performed prior to docking Robotic arms in basal three lung zones on both sides.
223755652|NCT04006665|DIAGNOSTIC_TEST|Lung Ultrasonography ( At the end of surgery)|Lung Ultrasonography will be performed after removal of Robotic arms and before extubation in basal three lung zones on both sides to assess degree of atelectasis.
223755653|NCT05863637|OTHER|Intensive Short-Term Dynamic Psychotherapy|A dynamic and intensive psychotherapy with eight therapeutic sessions
223755654|NCT02417051|BEHAVIORAL|Disaster Worker Resiliency Training|The Disaster Worker Resilience Training (DWRT) Program is a 4 hour program which consists of a participant training manual, an instructor-training manual, and a digital presentation. It uses adult training techniques that emphasize active participation in individual and group experiential learning activities. The curriculum is organized into a preface and four chapters, each with action oriented learning objectives. Overall program objectives include a demonstrate an ability to: 1) Recognize signs and symptoms of disaster work-related stress, 2) Obtain support through employer and community resources, and 3) Build resilience by using stress reduction and coping strategies.
223755655|NCT04476537|DEVICE|OncoTreat|OncoTreat is a computational pipeline that begins with a tumor expression profile and ends with a list of several candidate regimens.
223755656|NCT06663605|DRUG|PALI-2108|Oral dose
223755657|NCT06663605|DRUG|PALI-2108 Placebo|Oral dose
223755658|NCT05283538|DIAGNOSTIC_TEST|Coronary Artery Calcification Realization|Coronary Artery Calcification Realization
223755659|NCT04116853|BEHAVIORAL|ADAPTIVE Extended-Care Program|Each extended-care intervention phone call will be initiated by the interventionist, and will begin with a brief check-in followed by a discussion of any barriers experienced by participants in meeting their weight maintenance goals. Each call will end with a formal goal setting session. Calls are expected to last for approximately 10-20 minutes.
223608936|NCT00942825|DRUG|Cisplatin + Pemetrexed|"Pemetrexed and cisplatin will be administered on the same day (Day 1), every 3 weeks for a maximum of six cycles. A cycle is considered to be 3 weeks (21 days).~1. Pemetrexed 500 mg/m² will be administered as an i.v. infusion over 10 minutes.~2. Cisplatin 75 mg/m² will be administered as a 1-hour i.v. infusion immediately after the pemetrexed infusion."
223608937|NCT03933761|DRUG|Pamiparib|60 mg of pamiparib (3 capsules of 20mg) will be administered orally twice a day, once in the morning and once in the evening continuously in 28 day cycles.
223608938|NCT00573014|OTHER|Cervical Spine Clearance|All OBTPs with gross movement of all four extremities admitted to MetroHealth Medical Center who underwent a CT CS at MHMC between October 2006 and September 2008 will be included. Prospective data will be collected on these patients including age, gender, mechanism of injury, Glasgow Coma Scale (GCS) on admission, results of CT CS, GCS at the time of collar clearance, day of collar clearance, collar complications, date of reexamination, and results of reexamination. We will define an obtunded patient as a patient who was unable to reliably describe the presence or absence of CS symptoms in the opinion of the examining physician. Patients needed to have gross movement of all four extremities to be included in the study. We defined cervical collar complications as skin breakdown identified either by the skin care team during weekly rounds in the intensive care unit or by the treating physician at any time.
223608939|NCT02800083|DRUG|Pitolisant (BF2.649)|
223608940|NCT02800083|DRUG|Placebo|
223608941|NCT00595478|BEHAVIORAL|Motivational Enhancement Therapy (MET)/CBT+CM|Behavioral Treatment
223608942|NCT00595478|BEHAVIORAL|Motivational Enhancement Therapy (MET)/CBT|Behavioral Treatment
223608943|NCT02601833|DEVICE|Silver Diamine Fluoride|No caries removal will take place. The tooth will be dried and Silver Diamine Fluoride will be placed on the carious dentin until saturated. Excess will be blotted dry with a cotton pellet.
223608944|NCT02601833|PROCEDURE|Conventional Caries Management|These children will receive restorative dental care in alignment with the American Academy of Pediatric Dentistry guidelines, within the confines of the Mott Children's Health Center clinic. This treatment typically includes administration of local anesthesia, placement of rubber dam, caries removal with rotary and hand instruments, and placement of a final restoration.
223608945|NCT04205734|DIAGNOSTIC_TEST|MTX Assessment|Measurement of Methotrexate Polyglutamate levels.
223608946|NCT03405818|DRUG|Tavaborole 5% Topical Solution|topical solution for application to toenails
223608947|NCT02168218|OTHER|7-day overfeeding|7-day overfeeding with an excess sucrose intake corresponding to 40% total energy requirements
223608948|NCT02237755|DRUG|Clomiphene citrate|clomiphene citrate 100mg/day will be added to the standard gonadotropin regiment
223608949|NCT02237755|DRUG|Gonadotropins|All patients will be stimulated with a fixed GnRH-antagonist protocol. Ovarian stimulation will be initiated with 450 IU of gonadotropins either in the form of a combination of highly purified urinary FSH and LH or with a combination of Rec FSH and Rec LH.
223755660|NCT04116853|BEHAVIORAL|STATIC Extended-Care Program|Each extended-care intervention phone call will be initiated by the interventionist, and will begin with a brief check-in followed by a discussion of any barriers experienced by participants in meeting their weight maintenance goals. Each call will end with a formal goal setting session. Calls are expected to last for approximately 10-20 minutes.
223755661|NCT06863766|DIETARY_SUPPLEMENT|fortified formula milk powder group|Fortified formula milk powder is supplemented with fiber, bitter gourd powder,mulberry leaves extract, whitekidney beans extract, and probiotics, and packaged in 25-gram sachets. The milk powder is consumed orally, two sachets per day for a duration of 8 weeks.
223608950|NCT02401451|DEVICE|RhythmPadGP|ECG acquisition using a novel device RhythmPadGP
223608951|NCT04720677|OTHER|Turkish Version of The Italian Spine Youth Quality of Life (ISYQOL) Questionnaire|Turkish Version of The Italian Spine Youth Quality of Life (ISYQOL) Questionnaire
223608952|NCT00258934|BIOLOGICAL|Inactivated, split-virion influenza vaccine|0.1 mL single annual dose
223608953|NCT00258934|BIOLOGICAL|Inactivated, split-virion, influenza virus|0.5 mL single annual dose
223608954|NCT01622465|BEHAVIORAL|Ergometer cycling|Patients will participate of the exercises program with ergometer cycling and conventional exercises. The program will initiate after two weeks of the postoperative and will continue until three months of the postoperative
223608955|NCT01622465|BEHAVIORAL|Conventional exercises|Patients will participate only of the conventional exercises program. The program will initiate after two weeks of the postoperative and will continue until three months of the postoperative
223755662|NCT06863766|DIETARY_SUPPLEMENT|regular milk powder group|Regular milk powder does not contain and additional supplementation, and the color, flavor, shape, taste, and weight are same with the formula milk powder.
223755663|NCT05778734|BEHAVIORAL|CM-PST|CM-PST is a tailored behavioral intervention that enables young adults with AUD to successfully manage and overcome everyday life challenges influencing their alcohol intake.
223755664|NCT05778734|BEHAVIORAL|CM only|CM is a behavior therapy that rewards individuals for evidence of positive change (alcohol abstinence).
223755665|NCT02734602|DRUG|Ketamine|Ketamine will be administered after the initial PET scan for subjects participating in the ketamine aim.
223608956|NCT05310331|COMBINATION_PRODUCT|Donafenib combined with paclitaxel and platinum ± PD-1 antibody|Patients will receive Donafenib (200mg, bid) combined with paclitaxel (135mg/m2) and cisplatin (creatinine clearance rate \> 60ml/min, 50 mg/m2) or paclitaxel (175 mg/m2) and carboplatin AUC=5 (40ml/min \< creatinine clearance rate \< 60ml/min) ± PD-1 antibody every 3 weeks.
223608957|NCT02415270|OTHER|Reduced Nicotine Cigarettes|Human topography data will show if smokers smoke their cigarettes differently from baseline following randomization. Select biosamples of participants will be used to analyze how biomarkers differ among groups
223608958|NCT02415270|OTHER|Reduced ROS/RNS|Human topography data will show if smokers smoke their cigarettes differently from baseline following randomization. Select biosamples of participants will be used to analyze how biomarkers differ among groups
223608959|NCT02415270|OTHER|Control|Human topography data will show if smokers change the way they smoke due to being in a research study. Select biosamples of participants will be used to analyze how biomarkers differ among groups
223608960|NCT03565614|BEHAVIORAL|Reablement|Intensive home-based rehabilitation is delivered up to 3 months by an interprofessional team (nurse, enrolled nurse, physiotherapist, occupational therapist, social worker). The entire team completed a 5-week college course. The team negotiates goal-directed contents of the rehabilitation initiatives with the user. Each user is handled deliberately based on decisions in the team in cooperation with the care managers overarching goals in admitted services. All participants have personal contact persons, and these contact persons have twice the time per participant as compared to traditional home care. The interprofessional team also has regular meetings to discuss every participant, and all rehabilitation goals activities related to those are documented.
223608961|NCT03565614|BEHAVIORAL|Traditional home care|Traditional home care and required rehabilitation efforts as by the municipality's current practice. Includes the same professions as is included in the reablement intervention, but the team has had no joint college course, does not use the systematic goal-directed and negotiated approach as the reablement intervention, and has about half the time per participant as compared to the reablement intervention.
223608962|NCT01406977|DRUG|BPS804|
223608963|NCT01110031|BIOLOGICAL|Ofatumumab|Anti-CD20 monoclonal antibody
223608964|NCT03848936|OTHER|Survey|Survey includes age, gender, cerebral palsy type, education, mental status, working status, living conditions, comorbidities, pain, spasticity, contractures, deformities, mobility status and gross motor function classification system level
223608965|NCT05179525|DRUG|Risperidone ISM® 100 mg|100 mg of risperidone ISM® administered every 4 weeks
223608966|NCT05179525|DRUG|Risperdal 4mg Tablet|4 mg oral risperidone once daily for 7 days
223608967|NCT03274063|OTHER|Supported self-management|Participants will be supplied with urate self-testing kits. Participants will have a mobile phone application installed which will prompt the participant to perform urate self-testing, enable the clinical research team to advise on escalation of urate lowering therapy, and collect quality of life data .
223608968|NCT03274063|OTHER|Usual care|Participants will have a mobile phone application installed which will allow the research team to collect quality of life data.
223608969|NCT04992845|DEVICE|Anterior Vertebral Body Tethering|The SCOLI-TETHER (MIScoli) System is intended for anterolateral vertebral body fixation and internal fastening of the convex side of the thoracic curvatures thereby reducing the deformity and preventing the progression of idiopathic scoliosis in growing children/adolescents at high risk for curve progression while preserving motion.
223608970|NCT02656953|OTHER|VDU lenses (Zeiss® Officelens Plus)|The treatment group (n=22) was given progressive VDU glasses (Zeiss® Officelens Plus), specially designed for VDU work. The participants were asked to wear their new glasses for six months during computer work.
223608971|NCT02656953|OTHER|Progressive lenses (Zeiss® Multifocal Precision Plus)|The comparison group (n=18) was given progressive glasses (Zeiss® Multifocal Precision Plus). The participants were asked to wear their new glasses for six months during computer work.
223608972|NCT02384018|BIOLOGICAL|autologous mesenchymal stromal cell|Islet transplantation patients will receive autologous MSCs following islets infusion
223608973|NCT02363959|DRUG|Hyperbaric Oxygen Therapy|2 hours of breathing \>99% medical grade oxygen inside an air-pressurized chamber at 2 ATA once a day for 20 sessions. These sessions will be scheduled 3-5 times per week, depending on the availability of the patient and the hyperbaric medicine physician.
223608974|NCT02363959|PROCEDURE|Endobronchial Biopsy of Airway Epithelium|During standard post-transplantation bronchoscopies, participants in this study will undergo an endobronchial biopsy of the airway epithelium for each donor lung.
223755666|NCT00157378|DRUG|Risperidone, Haloperidol|
223755667|NCT06074107|DRUG|BEBT-908 for injection|The initial dose is 22.5mg/m2, intravenous drip, on the 1st, 3rd, 5th, 8th, 10th and 12th day of each cycle，21 days as a cycle, 6 cycles as the total treatment cycle.
223755668|NCT05277311|DRUG|LongShengZhi capsule|LongShengZhi capsules, orally, 5 capsules each time, three times a day.
223755669|NCT05277311|DRUG|LongShengZhi capsule placebo|LongShengZhi capsules placebo, orally, 5 capsules each time, three times a day.
223755670|NCT04141995|DRUG|Digoxin|Tablet, Oral: Generic: 0.125 mg, 0.25 mg
223755671|NCT04141995|DRUG|5Fluorouracil|5-FU will be given as a 46 hour continuous IV infusion
223755672|NCT04141995|DRUG|Calcium Leucovorin|IV injection over 90 minutes
223755673|NCT04141995|DRUG|Irinotecan|IV administration over 90 minutes
223755674|NCT04141995|DRUG|Oxaliplatin|IV administration
223755675|NCT06527144|DRUG|3mg TQC3721 Suspension for Inhalation|TQC3721 suspension for inhalation is target inhibitor.
223608975|NCT04422704|BEHAVIORAL|Technology-based-Intervention|"The intervention is intended to address the concerns and needs that emerge from the participants' interviews. The intervention is based on the principles of the process of adaptation to retirement defined by Atchley and the Prochaska and Diclemente Model on the phases of preparation for retirement. The material to be used will be based on existing resources for retired people, awareness through multimedia material and knowledge of possible contributions of different technological devices to the retirement process.~The sessions consisted of showing different exercises and devices to perform physical activities, cognitive training, relaxation activities, counselling about healthy eating and leisure-time activities."
223608976|NCT00950248|DRUG|Idebenone|idebenone, lactose monohydrate, microcrystalline cellulose, croscarmellose sodium povidone, magnesium stearate, silicon dioxide, film-coat: Opadry II 85F23495 (consisting of: aluminium lake, FD\&C yellow #6, macrogol/PEG 3550, polyvinylalcohol, titanium dioxide, talc)
223608977|NCT00950248|OTHER|placebo|lactose monohydrate, microcrystalline cellulose, magnesium stearate, film-coat: Opadry II 85F23495 (consisting of: aluminium lake, FD\&C yellow #6, macrogol/PEG 3550, polyvinylalcohol, titanium dioxide, talc)
223608978|NCT00373178|DRUG|rosiglitazone|
223608979|NCT00373178|DRUG|metformin|
223608980|NCT00373178|DRUG|Anti-diabetic medications|
223608981|NCT00829114|DRUG|ETHINYL ESTRADIOL AND LEVOGESTREL|30 MCG OF ETHINYL ESTRADIOL AND 150 MCG LEVOGESTREL
223608982|NCT00829114|DRUG|ETHINYL ESTRADIOL AND LEVOGESTREL|30 MCG OF ETHINYL ESTRADIOL AND 150 MCG LEVOGESTREL
223608983|NCT03742453|DIAGNOSTIC_TEST|contrast-enhanced ultrasound|CEUS is performed using SonoVue (Bracco, Milan, Italy) intravenous administration in eligible participants within a month before/after EOB-MRI.
223608984|NCT03742453|DIAGNOSTIC_TEST|EOB-MRI|EOB-MRI is performed using standard dose of hepatocyte specific contrast media (primovist or eovist) according to standard protocol of our institution.
223608985|NCT04667546|OTHER|Survey|Patients or their parents will complete a survey at D2, D5, D10 and D28 to assess the presence or absence of a symptom
223608986|NCT05400772|OTHER|electromyographic device|An 8-channel surface EMG system (Noraxon Telemyo DTS system, Scottsdale, USA) will be used to measure signals from muscles during surface electromyography measurements.
223608987|NCT03151187|OTHER|Teaching intervention|Two two hour teaching modules on the diagnosis and treatment of disruptive behaviour disorders in children and youth
223755676|NCT06527144|DRUG|6mg TQC3721 Suspension for Inhalation|TQC3721 suspension for inhalation is target inhibitor.
223755677|NCT06527144|DRUG|Placebo TQC3721 suspension for inhalation|Placebo without active drug substance.
223755678|NCT06608069|BEHAVIORAL|Educational counselling|Enrolled participants will be counselled and educated by pharmacist on the therapy and benefits of adherence.
223608988|NCT00148876|DRUG|Capecitabine|Capecitabine 2500 mg/m² orally day 1-14 q day 22
223608989|NCT00148876|DRUG|Trastuzumab|Trastuzumab 6 mg/kg body weight every 3 weeks i.v.
223608990|NCT01900652|DRUG|Emibetuzumab|Administered IV
223608991|NCT01900652|DRUG|Erlotinib|Administered Orally
223608992|NCT03767751|BIOLOGICAL|Dual Specificity CD38 and bcma CAR-T Cells|1\) Biological: Dual Specificity CD38 and BCMA CAR-T Cells,2)1-5X10E6/Kg
223608993|NCT04791631|PROCEDURE|Epiretinal membrane surgery|Surgery for epiretinal membrane i.e. standard 3-port pars plana vitrectomy and epiretinal membrane and internal limiting membrane peel. Phakic patients will undergo cataract surgery.
223608994|NCT04629690|OTHER|SOLAR|The participants will obtain a multidisciplinary assessment regarding their medical conditions, medication review, cognitive assessment, functional assessment, gait and balance assessment by senior clinicians and a management plan will be implemented.
223608995|NCT05175742|BIOLOGICAL|PTX-COVID19-B|Sterile solution for injection
223608996|NCT05175742|BIOLOGICAL|Pfizer-BioNTech COVID-19 vaccine|Sterile solution for injection
223608997|NCT05175742|BIOLOGICAL|Placebo|0.9% sodium chloride (normal saline) injection
223608998|NCT00863291|DRUG|buprenorphine|buprenorphine (range = 0.2-1.6 mg/day, starting dose = 0.2 mg/day, N = 20)
223608999|NCT00863291|DRUG|placebo|Placebo in a manner similar to the active comparator
223755679|NCT06917378|PROCEDURE|Percutaneous coronary intervention of coronary chronic total occlusion|Coronary CTO was identified by coronary angiography, and its revascularization was attempted by either antegrade, retrograde or both approach.
223755680|NCT03101137|DRUG|Caudal block with dexmedetomedine|After induction, the electrical cardiometry is applied in supine position and a measurement for the baseline cardiac output, systemic vascular resistance and stroke volume is taken. In left lateral position, the back is sterilized. The block is done by introducing a 23-gauge needle perpendicular to the sacrococcygeal membrane. The needle is inserted until there is release of resistance as it pierces the sacro-coccygeal membrane. Then, it is directed upwards to make an angle of 20-30° with the skin about 2 mm. 1 ml/kg bupivacaine 0.25% along with dexmedetomidine 1 μg/kg (diluted with normal saline to 1ml) is injected over about 60s. Then, another measurement for the hemodynamics is taken at 5, 10, 20 and 30 minutes after caudal block.
223609000|NCT04209933|DRUG|Bismuth potassium citrate containing quadruple therapy|Bismuth potassium citrate:given for 14 days at a dose of bismuth potassium citrate 220 mg 0 BID,rabeprazole 10 mg BID, amoxicillin 1000 mg BID, and clarithromycin 500 mg BID
223609001|NCT04209933|DRUG|Colloidal pectin bismuth capsules containing quadruple therapy|Bismuth potassium citrate:given for 14 days at a dose of Colloidal pectin bismuth capsules 200 mg 0 BID,rabeprazole 10 mg BID, amoxicillin 1000 mg BID, and clarithromycin 500 mg BID
223609002|NCT04209933|DRUG|Colloidal pectin bismuth particles A quadruple therapy|Bismuth potassium citrate:given for 14 days at a dose of Colloidal pectin bismuth particles 150 mg BID,rabeprazole 10 mg BID, amoxicillin 1000 mg BID, and clarithromycin 500 mg BID
223609003|NCT04209933|DRUG|Colloidal pectin bismuth particles B quadruple therapy|Bismuth potassium citrate:given for 14 days at a dose of Colloidal pectin bismuth particles 300 mg BID,rabeprazole 10 mg BID, amoxicillin 1000 mg BID, and clarithromycin 500 mg BID
224200850|NCT06542068|BEHAVIORAL|Line Bot Assistance|"The chatbot is expected to provide self-help solutions and multiple counseling resources for stress and distress, options for face-to-face or online call requests, and a survey on mental health and stress.~In terms of keywords, it will establish counseling response resources and methods for finding resources for special sensitive situations (e.g., feeling moody, suicidal, stressed, not wanting to intern, etc.)."
223755681|NCT03101137|DRUG|Caudal dexamethasone|After induction, the electrical cardiometry is applied in supine position and a measurement for the baseline cardiac output, systemic vascular resistance and stroke volume is taken. In left lateral position, the back is sterilized. The block is done by introducing a 23-gauge needle perpendicular to the sacrococcygeal membrane. The needle is inserted until there is release of resistance as it pierces the sacro-coccygeal membrane. Then, it is directed upwards to make an angle of 20-30° with the skin about 2 mm. 1 ml/kg bupivacaine 0.25% along with dexamethasone 0.1mg/kg (diluted with normal saline to 1ml) is injected over about 60s. Then, another measurement for the hemodynamics is taken at 5, 10, 20 and 30 minutes after caudal block.
223755682|NCT03101137|DRUG|Control (bupivacaine)|After induction, the electrical cardiometry is applied in supine position and a measurement for the baseline cardiac output, systemic vascular resistance and stroke volume is taken. In left lateral position, the back is sterilized. The block is done by introducing a 23-gauge hypodermic needle perpendicular to the sacrococcygeal membrane. The needle is inserted until there is release of resistance as it pierces the sacro-coccygeal membrane. Then, it is directed upwards to make an angle of 20-30° with the skin about 2 mm. 1 ml/kg the control (bupivacaine) 0.25% is injected over about 60s. Then, another measurement for the hemodynamics is taken at 5, 10, 20 and 30 minutes after caudal block.
223755683|NCT07110350|PROCEDURE|Laparotomy refers to a definitive single-stage exploratory abdominal surgery. Damage Control Surgery refers to a staged surgical approach including initial abbreviated laparotomy followed by planned.|This intervention involves exploratory laparotomy performed for abdominal trauma at a single tertiary care trauma center in Taiwan between 2013 and 2024. Patients are stratified based on whether they received a single definitive laparotomy or staged damage control surgery. Staged surgery is defined as an abbreviated initial laparotomy followed by planned reoperation(s), regardless of whether physiological indications were strictly met. This study specifically investigates the discrepancy between guideline-based indications and actual surgical practice.
223755684|NCT07110181|BEHAVIORAL|a blended version of the Unified Protocol for Adolescents (UP-A)|The blended UP-A includes 8 weekly modules, 6 of which (Modules 2 - 7)are online self-guided sessions. The online self-guided sessions will last approximately 45 minutes each. Over the course of these 6 weeks, participants will also have 6 therapist-guided online sessions via videoconference, each lasting 30 minutes. Two face-to-face individual sessions are scheduled, one at the beginning of each (Module 1) and one at the end (Module 8), each with an expected duration of 90 minutes.
223609004|NCT04109326|OTHER|APAD|"8 PA sessions supervised at the hospital centers and 44 unsupervised home sessions, to be performed twice a week.~6 consultations for nutrition education to teach the principles of well balanced diet, to foster weigh control during treatment, and to induce appropriate feeding behaviors after treatment."
223609005|NCT02267538|DRUG|dexmedetomidine hydrochloride for injection|"Before anesthesia, dexmedetomidine hydrochloride for injection (200 ug/2 ml) will be diluted with normal saline to 50 ml (final dexmedetomidine concentration 4 ug/ml).~Before the induction of anesthesia, a loading dose will be administered by intravenous infusion at a rate of \[0.9\*kg\] ml/h for 10 minutes (i.e., dexmedetomidine 0.6 μg/kg in 10 minutes), followed by continuous infusion at a rate of \[0.1\*kg\] ml/h (i.e., dexmedetomidine at a rate of 0.4 μg /kg/h) until the end of surgery.~At the end of surgery, the infusion rate will be decreased to \[0.025\*kg\] ml/h (i.e., dexmedetomidine at a rate of 0.1 ug/kg/h) and continued until the end of mechanical ventilation after surgery."
223609006|NCT02267538|DRUG|0.9% sodium chloride for injection|"Before anesthesia, 0.9% sodium chloride for injection 50 ml will be prepared.~Before the induction of anesthesia, a loading dose will be administered by intravenous infusion at a rate of \[0.9\*kg\] ml/h for 10 minutes, followed by continuous infusion at a rate of \[0.1\*kg\] ml/h until the end of surgery.~At the end of surgery, the infusion rate will be decreased to \[0.025\*kg\] ml/h and continued until the end of mechanical ventilation after surgery."
223609007|NCT00576225|DRUG|CT-2103/carboplatin|CT-2103 (175 mg/m2 10 min IV infusion) and carboplatin (AUC 6, 30 min IV infusion) on day 1 of each 21-day cycle for up to 6 cycles.
223609008|NCT00576225|DRUG|paclitaxel/carboplatin|Paclitaxel (175 mg/m2, 3 hr IV infusion) and carboplatin (AUC 6) (30 minute IV infusion) on day 1 of each 21-day cycle for up to 6 cycles.
223609009|NCT00089466|DRUG|AMD11070|AMD11070 taken daily. Dosage dependent on arm.
223609010|NCT00869518|DRUG|rifabutin plus trimethoprim sulfamethoxazole|rifabutin 300 mg PO daily or equivalent depending on concomitant medications plus trimethoprim-sulfamethoxazole 1 DS tab twice daily both for 7 days
223609011|NCT00869518|DRUG|placebo plus trimethoprim-sulfamethoxazole|placebo plus trimethoprim-sulfamethoxazole 1 DS tab twice daily both for 7 days
223609012|NCT01629277|DEVICE|Closed-loop|Subcutaneous insulin delivery will be adjusted according to the computer-based algorithm advice, based on subcutaneous glucose readings
223609013|NCT01629277|DEVICE|standard insulin pump|Subcutaneous insulin delivery will be administered according the standard insulin pump settings
223755685|NCT07110181|DRUG|Standard psychiatric treatment|Participants in the control group will receive treatment as usual, including pharmacotherapy and routine clinical follow-up, as determined by their treating psychiatrists.
223755686|NCT05717777|OTHER|There is no intervention, only observational study|There is no intervention, only observational study
224200851|NCT06032767|OTHER|observational group|patients initially diagnosed with nasopharyngeal carcinoma treated with IMRT
224200852|NCT06019286|DIAGNOSTIC_TEST|SCINEXA score|\- 18 signs of extrinsic aging of SCINEXA score: sunburn, freckles, actinic lentigo, hyperpigmentation and/or melasma, change in phototype, yellowness, pseudoscars, coarse wrinkles, solar elastosis, cutis rhomboidalis, elastosis, comedones and cysts of Favre-Racouchot, xerosis, teleangectasias, permanent erythema, actinic keratosis, basal cell carcinoma, squamous cell carcinoma and malignant melanoma (extrinsic SCINEXA score). Each item will be scored as 0 (none), 1 (mild), 2 (moderate) or 3 (severe). For some items (uneven pigmentation, cutis rhomboidalis nuchae, elastosis, comedones and cysts of Favre Racouchot, and malignant skin tumors, a binary scale was used: (yes) or (no). Maximun possible score is 54
224200853|NCT00609063|DRUG|Atorvastatin|80-mg atorvastatin capsules taken daily for 6 months
224200854|NCT00609063|DRUG|Placebo|Placebo capsules taken daily for 6 months
224200855|NCT04637217|DIAGNOSTIC_TEST|Optical Coherence Tomography|Spectral Domain Optical Coherence Tomography(SD-OCT) examination will be performed for every patient: posterior pole scan, EDI-OCT(enhanced depth imaging-OCT) and peripapillary RNFL(retinal nerve fiber layer)
223755687|NCT06118346|BEHAVIORAL|Female-Specific Cognitive Behavioral Therapy (FS-CBT)|FS-CBT is a unique 12-session weekly group CBT treatment designed for women Veterans with AUD and/or risky drinking, and provides (1) AUD interventions, (2) general female-specific content, (3) female-Veteran content, (4) wellness and self-care, and (5) a novel 24/7 social support for abstinence discussion mobile app.
223609014|NCT03413306|DRUG|Eltrombopag|Eltrombopag is an oral mimetic thrombopoietin selectively binding transmembrane and juxtamembrane domains of the thrombopoietin receptor different from the binding site of thrombopoietin. Therefore it does not compete for binding with the native molecule. It is promoting thrombopoiesis and release platelets from mature megakaryocytes. Also it promotes more primitive multilineage progenitors and hematopoietic stem cells to proliferate and differentiate into thrombocytes, erythrocytes and leukocytes.
223609015|NCT03413306|DRUG|IST (ATG + CsA)|
223609016|NCT01364025|PROCEDURE|uterosacral ligament suspension colpopexy bilateral|Uterosacral ligament suspension colpopexy bilateral
223609017|NCT03892239|BEHAVIORAL|RunIn3 Prevention Program|"The intervention will be delivered online. Every two weeks we will send a link to participants that will direct them to an online questionnaire. The online questionnaire will collect information on complaints and symptoms related to running, and the volume, intensity and frequency of running practice within the 2-week period. If the participant reports any symptom and if she/he accepts a suggestion regarding running training, an algorithm embedded in the online system will automatically suggest a training volume for the next two weeks based on the distance and/or duration reported by the participant.~Through a website we will make available informative texts, videos and infographics in order to increase the participant's knowledge regarding topics such as: musculoskeletal symptoms; foot strike patterns; training workload; running shoes; warming-up/cooling-down, stretching; and concomitant strength training."
223609018|NCT03892239|BEHAVIORAL|Feedback Based Surveillance|The intervention will be delivered online. Every two weeks we will send a link to participants that will direct them to an online questionnaire. The online questionnaire will collect information on complaints and symptoms related to running, and the volume, intensity and frequency of running practice within the 2-week period. If the participant reports any symptom and if she/he accepts a suggestion regarding running training, an algorithm embedded in the online system will automatically suggest a training volume for the next two weeks based on the distance and/or duration reported by the participant.
223755688|NCT06118346|BEHAVIORAL|Usual Care|Usual care means that participants will receive brief alcohol counseling and have access to available treatments for AUD at the VA.
223755689|NCT06676657|DEVICE|iPancreas automated insulin delivery system|The Model Predictive Control (MPC) insulin infusion algorithm contains a model within the controller that takes as an input the aerobic metabolic expenditure in addition to the CGM and meal in puts. The algorithm uses heart rate and accelerometer data collected on the patient's body to calculate metabolic expenditure (METs). The METs then acts on the model for the insulin dynamics, whereby more energy expenditure and longer duration exercise can lead to a more substantial effect of insulin on the CGM. The MPC also has missed meal insulin bolus detection where the system will calculate the amount of insulin that was missed for a meal. The missed meal boluses can be delivered automatically without any input from the user. This feature can also be disabled. The MPC has a new feature called hyperglycemia pattern detection and dosing algorithm that will analyze problem patterns associated with high blood sugar and automatically calculate and deliver a correction dose.
223755690|NCT05794789|BEHAVIORAL|Social Identity|This group will receive the same content as the education+planning as well as two additional sessions. This includes short overviews of the benefits of PA as a family, brainstorming how a family can each assist each other in PA, and an activity for developing a family PA action plan. Behavior change techniques such as identity salience, identity similarity, and identity fit and contrast are included in the coaching session include. This will be supplemented by an organization of fun family PA roles for all members (e.g., activity planner, goal setter, supporter, etc.) to instill involvement as well as items (creation of a family PA t-shirt, family PA photos and display, etc.) to instill distinctiveness, which is a central feature of a social identity. Worksheets and discussion will be included. The second session will involve only the parent(s) to focus on parental support identity and the content is based on the behavior change principles of self-identity theory.
223755691|NCT06866548|DRUG|anti-IGF-1R mAb (Teprotumumab/IBI311) + anti-PD-1 mAb (Tislelizumab)|"Drug: Teprotumumab/IBI311 Given by IV infusion Initiate dosing with 10 mg/kg for first infusion, followed by 20 mg/kg every 3 weeks.~Drug: Tislelizumab Given by IV infusion 200 mg every 3 weeks"
223755692|NCT06869837|OTHER|Group EOİPB|Bilateral external oblique intercostal plane block under USG guidance will be applied 45 minutes before cholecystectomy surgery.
223609019|NCT06399250|OTHER|meal service|We're not subjecting patients to an intervention, as we will evaluate the current in-hospital meal service. As the three channel food concept is standard of care, we're not subjecting patients to dietary or behavioral changes. We will compare the data to an historic control.
223609020|NCT04556019|PROCEDURE|Hepatobiliopancreatic surgery|Different surgical techniques tailored to each patient´s pathology
223609021|NCT00586885|DRUG|L-alanine|6g of L-alanine (powder)once per day for the first month, twice per day for the second month, then three times per day from the third month for 10 months.
223609022|NCT01587430|DRUG|high dose ARA-C|high dose ARA-C consolidation together with high cumulative dose of anthracyclines daunorubicin, idarubicin, mitoxantrone(720-660 mg/m2)
223609023|NCT01587430|DRUG|standard dose ARA-C|
223609024|NCT00947115|PROCEDURE|Blood sampling|Blood samples were collected at Years 5, 6, 7, 8, 9 and 10.
223609025|NCT00947115|PROCEDURE|Cervico-vaginal secretion (CVS) samples|CVS samples were collected at Years 5, 6, 7, 8, 9 and 10 in subjects who volunteered for this procedure.
223609026|NCT00512785|DRUG|imidafenacin, KRP-197/ONO-8025|0.1 mg BID for 52 weeks
223609027|NCT00512785|DRUG|imidafenacin, KRP-197/ONO-8025|0.1 mg BID for 12 weeks and 0.2 mg BID for 52 weeks
223609028|NCT05768035|BIOLOGICAL|Allogeneic T cell progenitors, cultured ex-vivo|Injection of T cell progenitors 6 days after haplo HSCT and 2 days after the last administration of cyclophosphamide
223609029|NCT01169935|DRUG|Administration of intra-dermal Endorem|single dose, intradermal
223609030|NCT01169935|BIOLOGICAL|Mantoux test|single dose, intradermal
223755693|NCT05165615|DEVICE|Insulin Pump t:slim X2 with Control-IQ technology|Usage of Insulin pump t:slim X2 with Control-IQ technology in previous users of AndroidAPS
223755694|NCT06626061|BEHAVIORAL|Cognitive Behavioral Stress management in in person group Format|The CBSM sessions will be delivered to participants in groups of ten, totaling eight sessions, each focused on a specific theme related to stress management. All participants will attend the complete sessions in person.
223755695|NCT06626061|BEHAVIORAL|Cognitive Behavioral Stress management Hybrid Format|The CBSM (hybrid) sessions will be offered to participants online, including a total of eight video modules, each dedicated to a specific theme related to stress management. Participants will also have access to three interactive virtual sessions, summary sheets in PDF format, and audio recordings for relaxation.
223755696|NCT03027869|DEVICE|transcranial direct current stimulation|15 minute anodal stimulation 1.5mA
223755697|NCT00560950|BIOLOGICAL|pneumococcal 23v polysaccharide vaccine|Duration of Treatment: Single vaccination on Day 1
223755698|NCT06689436|DRUG|5 mg Apixaban Oral Dissolving Film (fasting)|Single dose of 5 mg Apixaban Oral Dissolving Film will be administered orally after at least 10 hours overnight fast
223755699|NCT06689436|DRUG|5 mg Apixaban Oral Dissolving Film (fed)|Single dose of 5 mg Apixaban Oral Dissolving Film will be administered orally at 30 minutes after the start of a standardized high-fat, high-calorie breakfast that is preceded by at least 10 hours overnight fast
223755700|NCT06689436|DRUG|5 mg Apixaban Oral Tablet (US RS/RLD)|Single dose of 5 mg Apixaban Oral Tablet (US RS/RLD) will be administered orally after at least 10 hours overnight fast
223609031|NCT01169935|BIOLOGICAL|Autologous Endorem-labelled mononuclear cells|single dose, intravenous
223609032|NCT01169935|DRUG|Administration of Endorem|single dose, intravenous
223609033|NCT01481454|BIOLOGICAL|Quadrivalent Influenza Vaccine (split virion, inactivated)|0.5 mL, Intramuscular
223609034|NCT01481454|BIOLOGICAL|Quadrivalent Influenza Vaccine (split virion, inactivated)|0.5 mL, Intramuscular
223609035|NCT01481454|BIOLOGICAL|Quadrivalent Influenza Vaccine (split virion, inactivated)|0.5 mL, Intramuscular
223609036|NCT01481454|BIOLOGICAL|2011 to 2012 Trivalent Influenza Vaccine|0.5 mL, Intramuscular
223755701|NCT06689436|DRUG|5 mg Apixaban Oral Tablet (EU product)|Single dose of 5 mg Apixaban Oral Tablet (EU product) will be administered orally after at least 10 hours overnight fast
223755702|NCT06869135|OTHER|Saliva collection, longitudinal|1 ml of saliva will be collected with Salivette swabs. Subjects will undergo assessments and saliva sampling at enrollment time (T0) and one year after (T12).
224200856|NCT05084807|OTHER|Endoscopy|"* A dyspepsia test will be performed to avoid selection bias. In subjects strictly asymptomatic, a blood analysis will be proposed.~* Subjects who present strictly normal laboratory tests (including celiac serology and negative H Pylori tests) and no genetic risk of celiac disease will be invited to perform an upper gastrointestinal endoscopy.~* During gastroscopy, samples of normal mucosa will be taken for histological and lymphocyte subpopulations analysis. The percentage of lymphocyte subpopulations will be assessed by flow cytometry.~* To compare whether there are differences between the lymphocyte subpopulations related to the age and sex of the healthy individuals, a student's t test, ANOVA or the corresponding non-parametric test will be used. The values will be expressed according to: mean +/- 2DS or median and interquartile range."
224200857|NCT01387672|DRUG|Nitrates (NABT Main trial)|nitroglycerin; isosorbide mononitrate
223609037|NCT01709656|BIOLOGICAL|MSC|"human mesenchymal stem cells,1\*10\^4-6 cells /Kg , IV (in the vein) on day 1 of each 14-60 day cycle,1-6 times treatment.~a total of 24 weeks for follow up."
223609038|NCT01709656|DRUG|"celecoxib, Celebrex®"|"non-steroid anti-inflammatory drugs (NSAID):celecoxib, Celebrex® 0.2g Bid(twice a day),PO (Per Os);a total of 24 weeks for follow up"
223609039|NCT04483609|OTHER|Questionnaire administration pre test|After the translation and cultural adaptation of the SF-Qualiveen scale is completed, face-to-face pre-test will be performed on 10 patients with multiple sclerosis.
223609040|NCT04483609|OTHER|Questionnaire administration validation and reliability|After the pre-test is completed, if necessary, arrangements will be made, and then the validity and reliability of SF-Qualiveen will be made in 80 individuals with Multiple Sclerosis.First of all, participants will be asked to complete two questionnaires (SF-Qualiveen and Urinary Distress Inventory). Two weeks after this assessment, they will be asked to respond to SF-Qualiveen again.
223755703|NCT03114462|RADIATION|Stereotactic Hypofractionated Radioablation|Starting dose is 8.0 Gy per fraction for 5 fractions (total dose = 40.0 Gy). Subsequent cohorts of participants receive an additional 0.5 Gy per fraction.
223755704|NCT03114462|BEHAVIORAL|Questionnaires|Quality of life and symptom questionnaires completed at: Baseline, on days receiving HYDRA, 6 weeks after last dose of HYDRA, 3 months after last dose of HYDRA, and 6 months after last dose of HYDRA. Also after the 6 month follow-up visit, every 3 months for the first 2 years, and then every 6 months after that for up to 5 years.
224200858|NCT01387672|OTHER|Placebo|Placebo ointment
223609041|NCT03058900|DRUG|Fecal microbiota transplantation (FMT)|One fecal microbiota transplantation is performed at baseline using gastroscopic guidance. The transplant consists of 50 g feces obtained from a healthy non-related donor. The donor feces is suspended into NaCl (0.9%) and glycerol (10%), and will be stored at minus 80 degrees celsius until use. The total volume of the suspension is 250 mL and its temperature will be 37 degrees celsius when infused into the small intestine of the recipient.
223609042|NCT03058900|OTHER|Drug: Placebo (saline)|One identical appearing sham procedure is performed at baseline using gastroscopic guidance. 250 mL saline (NaCl 0.9%) is infused into the small intestine of the recipient.
223609043|NCT03058900|DRUG|Methotrexate (MTX)|Weekly methotrexate in maximum tolerable dosis
223609044|NCT02229409|BEHAVIORAL|Walkadoo|Walkadoo is a MeYou Health, LLC product.
223609045|NCT02137096|DRUG|Etoposide phosphate|Etoposide is one of three drugs used in the high-dose conditioning phase
223609046|NCT02137096|DRUG|Carboplatin|Carboplatin is one of the drugs used in the high-dose conditioning phase.
223609047|NCT02137096|DRUG|Ifosfamide|Ifosfamide is one of the drugs used in the high-dose conditioning phase
223609048|NCT02137096|PROCEDURE|Autologous Stem Cell Transplantation|Autologous Stem Cell Transplantation follows the high-dose chemotherapy phase of the arm.
223609049|NCT01584362|DRUG|oxfendazole|administration of a single oral 1.0 mg/kg dose of oxfendazole
223609050|NCT01584362|DRUG|placebo|single oral dose of placebo
223755705|NCT06696690|DEVICE|MNS|The MNS treatment group use the NeuroTrac™ Multi-TENS transcutaneous electrical stimulator to provide an asymmetric biphasic pulse train with a frequency of 35 Hz, an amplitude of 20 mA and a pulse width of 300 ms, which is on for 20 seconds and off for 50 seconds. The treatment lasts for 8 hours per day and the treatment course lasts for one week.
223755706|NCT06696690|DEVICE|Sham stimulation|The sham stimulation treatment group utilized the same stimulation device and was subjected to a safe yet ineffective stimulation protocol for sham stimulation. The treatment lasts for 8 hours per day and the treatment course lasts for 14 days.
223755707|NCT04568161|PROCEDURE|Physical Characteristics|Body weight, height and waist circumference
223755708|NCT04568161|PROCEDURE|Muscular Sympathetic Nervous Activity|Microneurography technique.
223755709|NCT04568161|DIAGNOSTIC_TEST|Cardiac Function|Echocardiography.
223755710|NCT04568161|DIAGNOSTIC_TEST|Heart rate|Electrocardiography
223755711|NCT04568161|DIAGNOSTIC_TEST|Blood pressure|Non-invasive photoplethysmography.
223755712|NCT04568161|DIAGNOSTIC_TEST|Blood Assessments|Serum and Plasma will be extracted by centrifugation. Endothelial microparticles by flow cytometry Interleukin-6 and tumor necrosis factor α by ELISA, High-sensitive reactive serum C-reactive protein by immunoturbidimetric assay, NT- ProBNP According to Central Laboratory, Hospital das Clinicas, HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo. Endothelin-1 by immunoenzymatic method Nitric oxide by gas chemiluminescence Lipoperoxidation by fluorimetry Carbonyl by spectrophotometer, and Superoxide Dismutase (SOD) by colorimetry.
223755713|NCT04568161|DIAGNOSTIC_TEST|Muscle blood flow|Venous occlusion plethysmography
223609051|NCT01584362|DRUG|oxfendazole|administration of a single oral 3.0 mg/kg dose of oxfendazole
223609052|NCT01584362|DRUG|oxfendazole|administration of a single oral 0.3 mg/kg dose of oxfendazole
223609053|NCT01584362|DRUG|oxfendazole|administration of a single oral 10 mg/kg dose of oxfendazole
223609054|NCT01584362|DRUG|oxfendazole|administration of a single oral 20 mg/kg dose of oxfendazole
223609055|NCT01584362|DRUG|oxfendazole|administration of a single oral 30 mg/kg dose of oxfendazole
223609056|NCT05977062|OTHER|Self screening|Score ISI (Index de Sévérité de l'Insomnie)
223609057|NCT05977062|OTHER|Phone call|Phone call at the beginning of the program and at the middle and at the end.
223609058|NCT05977062|OTHER|Online questionnaires|To be completed at week 1, 6, 12 and 24.
223609059|NCT01223183|DRUG|hypertonic saline (7%)|single treatment by inhalation
223609060|NCT01223183|DRUG|isotonic saline|single treatment by inhalation
223609061|NCT06069635|OTHER|Fatigue protocol (repeated sprint ability)|The test performed on an outdoor field (artificial grass carpet) in the form of 6 repetitions of maximal 2× 15 m shuttle sprints interspersed with 20 seconds of passive recovery , Before the RSA protocol, all players perform a brief standardized warm-up (approximately 20 minutes long), in 1at submaximal speed (followed by 40 seconds of passive recovery The fatigue index (FI) used to characterize the RSA performance was calculated in terms of percentage decrement score At the end of the RSA protocol , usually the time elapsed between the end of the last sprint and the beginning of the measurements was no more than 20 seconds, to avoid masking effects related to progressive recovery from fatigue.
223755714|NCT04568161|DIAGNOSTIC_TEST|Endothelium-dependent vascular function|Brachial ultrasound
223755715|NCT04568161|DIAGNOSTIC_TEST|Vascular intima-media thickness|Carotid ultrasound
223609062|NCT06069635|OTHER|Sham Comparator: Control group|approximately 20 minutes long), which consisted of : 6 minutes of incremental running from 60% to 80% of maximal aerobic speed; 6 minutes of dynamic flexibility exercises; 2 minutes of forward, backward, and lateral jogging and high-knee and ''butt-kick'' runs; 2 minutes of shuttle sprints (5 m in 1 direction and 5 m in the opposite direction, repeated for 2 minutes) at submaximal speed (followed by 40 seconds of passive recovery); and 2 minutes of RSA protocol simulation at submaximal speed (2 repetitions), again followed by 40 seconds of passive recovery. take apenalty of water and rest
223609063|NCT00924339|DIETARY_SUPPLEMENT|soy protein diet|Intervention-Group (n = 15): Fat- modified dietary regime and a minimum amount of soy protein: 0,25 g/ kg BW/d
223609064|NCT00924339|DIETARY_SUPPLEMENT|rapeseed oil|Control-Group (n = 15): Diet reduced in SFA, modified in fatty acid pattern. Only rapeseed oil should to be used for preparation of the meals (baking, frying, in salad, and as spread.
223609065|NCT00682526|DEVICE|SmartLink Wireless Monitoring System (K033642)|All EMS transported patients age 18 or over who have their ECG attempted to be wirelessly transmitted and with the intention to treat with coronary reperfusion therapy (PCI or thrombolytics)based on their initial presentation.
223609066|NCT02087969|PROCEDURE|Dry Needling|
223609067|NCT02087969|PROCEDURE|Stretching|
223609068|NCT03063905|DRUG|Buprenorphine|Patients taking buprenorphine to wean off an opiate addiction
223609069|NCT00509626|BEHAVIORAL|exercise intervention|
223609070|NCT00509626|OTHER|questionnaire administration|
223609071|NCT00509626|PROCEDURE|CAM exercise therapy|
223609072|NCT00509626|PROCEDURE|management of therapy complications|
223609073|NCT00509626|PROCEDURE|psychosocial assessment and care|
223609074|NCT00509626|PROCEDURE|quality-of-life assessment|
223609075|NCT03893500|DEVICE|Home-based 6 minute walk test|Participants will receive a loaner Apple Watch with the Walk.Talk.Track. (WTT, produced by PHaware) app downloaded. Participants will perform a daily 6MWT at home using the Apple Watch and WTT app. They will undergo a history and physical, blood draw, echocardiogram and in-clinic 6MWT at the baseline and 12-week follow up visit.
223609076|NCT01228526|DEVICE|PriMatrix|
223609077|NCT03133351|DEVICE|PCM|A fresh whole blood sample will be tested by PCM to determine the reference range.
223609078|NCT01707901|DRUG|ONO-8539|Treatment
223609079|NCT01707901|OTHER|Placebo|Placebo
223609080|NCT00662545|DRUG|Entecavir with continued standard of care antiretroviral therapy|1 mg by mouth daily
223609081|NCT00662545|DRUG|continued standard of care with tenofovir in addition to emtricitabine or lamivudine|continued standard of care with tenofovir in addition to emtricitabine or lamivudine
223609082|NCT00653380|DRUG|Doxycycline Monohydrate|Capsules, 100 mg, single-dose
223755716|NCT04568161|DIAGNOSTIC_TEST|Physical Capacity|Cardiopulmonary exercise test
223755717|NCT04568161|DRUG|Anthracycline & Cyclophosphamide treatment scheme|Four session of intravenous (in bolus) infusion of doxorubicin 60mg/m2 and cyclophosphamide 600mg/m2 with an interval of 21 days between sessions.
223609083|NCT00653380|DRUG|Monodox|Capsules, 100 mg, single-dose
223609084|NCT01571011|BEHAVIORAL|CURB|The intervention is made up of 14 internet modules based on behavioral activation, cognitive behavioral therapy, and interpersonal psychotherapy as well as motivational interviews in the primary care setting (to enhance behavior change). It is suggested that an adolescent navigates through 2 modules a week. The motivational interviews with the physicians occur directly before and after the adolescent is exposed to the website (at baseline and 3 months) in the providers office. The parents of the enrolled adolescents are also invited to navigate through their own, 3 module, parent internet program.
223609085|NCT02745028|DIETARY_SUPPLEMENT|Monosodium glutamate|A single dose of weight adjusted monosodium glutamate will be added at the time of a repeat radionuclide gastric emptying study
223609086|NCT03180125|DRUG|Sodium Hyaluronate|median nerve in CTS hydro-dissection using 1% lidocain followed by injection of Sodium hyaluronate guided by ultrasound
223609087|NCT03180125|DEVICE|ultrasound|ultrasound guided injection
223609088|NCT03180125|DRUG|Sodium Hyaluronate and 1% lidocain|injection in the carpal tunnel
223609089|NCT03180125|DRUG|Corticosteroid and 1%lidocain|injection in the carpal tunnel
223609090|NCT02112292|DRUG|tetrahydrocannabinol|
223609091|NCT02112292|DRUG|cannabidiol|
223609092|NCT02112292|DRUG|Placebo|
223609093|NCT03047421|DIAGNOSTIC_TEST|Comparison of accuracy of DES-OSA and P-SAP scores|Comparison of accuracy of DES-OSA and P-SAP scores with the result of the PSG (polysomnography)
223609094|NCT04479202|DRUG|Berberine|Patients in the intervention group received berberine daily, regardless of gastrointestinal symptoms.If the patient has a serious drug-related adverse event, the drug will be discontinued and the patient will be excluded from the study.
223609095|NCT04479202|DRUG|Montmorrillonite|Patients in the control group were routinely not given special treatment.However, if the patient has diarrhea symptoms, montmorillonite powder should be given orally.
224200859|NCT01093040|DRUG|CAT-354|150 mg CAT-354 or placebo given SC on Day 1
223609096|NCT02941224|DEVICE|SELUTION DCB (sirolimus coated balloon)|
224200860|NCT01093040|DRUG|CAT-354|300 mg CAT-354 or placebo given SC on Day 1
223609097|NCT01112878|DRUG|Sugar pill|"Dosage form: capsule, by mouth~Dosage: not applicable~Frequency and Dosage:~* once in the preoperative holding area and once before discharge from PACU~* continuation of 1 capsule twice daily with meals, 1 to 4 days after surgery."
223609098|NCT01112878|DRUG|Gabapentin|"Dosage form: capsule, by mouth~Dosage: 600 mg~Frequency and duration:~* once in the preoperative holding area and once before discharge from PACU~* continuation of 1 capsule twice daily with meals, 1 to 4 days after surgery."
223609099|NCT01112878|DRUG|Clonidine|"Dosage form: capsule, by mouth~Dosage: 0.2 mg~Frequency and duration:~* once in the preoperative holding area and once before discharge from PACU~* continuation of 1 capsule twice daily with meals, 1 to 4 days after surgery."
223609100|NCT00900029|BIOLOGICAL|No HP802 Treatment|
223609101|NCT00900029|OTHER|No HP802 Vehicle Treatment|
223609102|NCT05325021|DIAGNOSTIC_TEST|Axial length measurement in millimeter (mm) by optical biometry device|Axial length measurement of the anisometropic eye and the fellow one in millimeter (mm) by optical biometry device.
223609103|NCT05325021|DIAGNOSTIC_TEST|Autorefractometer to measure the refractive error in both eyes.|Measurement of the refractive state of both eyes for each subject to asses the refractive error in diopter (D).
223609104|NCT00822536|DRUG|Aspirin and Clopidogrel|Aspirin \<= 325 mg/j Clopidogrel = 75 mg /j
223609105|NCT00822536|DRUG|Aspirin|Aspirin : \<= 325 mg/j
223609106|NCT03152591|DRUG|LIK066|LIK066 tablets for oral administration
223609107|NCT03152591|DRUG|Placebo|Placebo tablets matching LIK066 tablets, for oral administration
223609108|NCT00511238|DRUG|carfilzomib|Subjects will receive carfilzomib 20 mg/m2 as an intravenous bolus over 2 minutes on Days 1, 2, 8, 9, 15, and 16 of 28 day cycles. A maximum of 12 cycles will be administered.
223609109|NCT00511238|DRUG|carfilzomib|Subjects will receive carfilzomib intravenously over up to 10 minutes on Days 1, 2, 8, 9, 15, and 16 of 28 day cycles. In cycle 1, the dose is 20 mg/m2. If all doses are administered and well-tolerated over Cycle 1, beginning with Cycle 2 the dose will escalate to 27 mg/m2 cycle. A maximum of 12 cycles will be administered.
223609110|NCT01487850|BIOLOGICAL|blood sample|blood sample in each musician to search for specific antibodies against molds isolated from instruments
223609111|NCT03772665|DRUG|Emixustat|Once daily oral tablet taken for 24 months
223609112|NCT03772665|DRUG|Placebo|Once daily oral tablet taken for 24 months
223609113|NCT06423131|PROCEDURE|TCRαβ Depleted haploidentical HCT|Use the CliniMACS TCRα/β deplete from the mobilized peripheral blood stem cells of haploidentical donor in children
223609114|NCT00163020|DRUG|17-alpha-hydroxyprogesterone caproate injectable|250mg of 17-alpha-hydroxyprogesterone caproate (+ preservatives) injectable weekly starting as early as 19wks gestation until 34.0wks gestation of delivery which ever comes first.
223609115|NCT00163020|DRUG|Placebo|Weekly doses of placebo (NS + preservatives) via injection as early as 19weeks until 34.0weeks gestation or delivery which ever comes first.
223609116|NCT00187473|PROCEDURE|liver biopsy|Liver biopsy every 5 years
223609117|NCT01311882|DRUG|MK-4305 40 mg|4 x 10 mg MK-4305 tablets
223609118|NCT01311882|DRUG|MK-4305 20 mg|2 x 10 mg MK-4305 tablets
223609119|NCT01311882|DRUG|Zopiclone|1 x 7.5 mg Zopiclone tablet
223609120|NCT01311882|DRUG|Grossly Matching Placebo for Zopiclone|Grossly Matching Placebo for Zopiclone
223609121|NCT01311882|DRUG|Matching Placebo for MK-4305|Matching Placebo for MK-4305
223609122|NCT03027622|BEHAVIORAL|quality of life in the patients with mild pericoronitis|active surviallence by OHIP-14 TR after treatment
223609123|NCT03947710|OTHER|High-protein meals|Patients on maintenance hemodialysis will consume high protein meals during dialysis for one week (3 dialysis sessions)
223609124|NCT03947710|OTHER|Low- protein meals|Patients on maintenance hemodialysis will consume low protein meals during dialysis for one week (3 dialysis sessions)
223609125|NCT03947710|OTHER|No meals|Patients on maintenance hemodialysis will not consume meals during dialysis for one week (3 dialysis sessions)
223609126|NCT03686735|OTHER|5 anchors and numbers|"How helpful was this visit? 0 This visit was not helpful at all~1 2-3 There were many ways it could have been better 4 5 Neither useless nor helpful visit 6 7-8 Exceptionally helpful visit 9 10 One of the most helpful doctor visits I have ever had"
223609127|NCT03686735|OTHER|5 anchors and no numbers|How helpful was this visit? This visit was not helpful at all There were many ways it could have been better Neither useless nor helpful visit Exceptionally helpful visit One of the most helpful doctor visits I have ever had
223609128|NCT03686735|OTHER|Visual analog scale with 3 anchors and numbers|How helpful was this visit? 0 neutral/50 100 Least helpful visit Most helpful visit
223609129|NCT03686735|OTHER|Visual analog scale with 3 anchors and no numbers|"How helpful was this visit?~This visit was not Neither useless nor One of the most helpful doctor helpful at all helpful visit visits I have ever had"
223609130|NCT02205671|BEHAVIORAL|Building Better Caregivers Small-group Workshop|
223609131|NCT04388761|DRUG|Allogeneic adipose derived mesenchymal stem cells|Injection of Allogeneic adipose derived mesenchymal stem cells into the Kidney allograft
223609132|NCT00670904|OTHER|Pharmacist-delivered group program for smoking cessation|Participants assigned to the treatment group participated in a pharmacist-delivered program at the clinic. The six-hour program consisted of three in-person sessions delivered at 2-week intervals over 5 weeks to a small group of smokers. Participants were offered their choice of one medication either bupropion IR or nicotine patch using doses and durations based on current medical practices. Participants receiving bupropion received a quantity sufficient to complete 12 weeks of therapy. Participants receiving nicotine patches received a quantity sufficient to complete 8 weeks of step-down therapy.
223609133|NCT00670904|OTHER|Brief standard care session for smoking cessation delivered over the telephone|Those assigned to the control group received one 5 to 10 minute session delivered by the clinical pharmacist over the telephone that included all the components of standard care recommended by the Clinical Practice Guidelines for brief interventions delivered by health care providers. Participants were offered their choice of one medication either bupropion IR or nicotine patch using doses and durations based on current medical practices. Participants receiving bupropion received a quantity sufficient to complete 12 weeks of therapy. Participants receiving nicotine patches received a quantity sufficient to complete 8 weeks of step-down therapy.
223609134|NCT02892526|OTHER|Abdominoplasty with exeresis of cutaneous tissue|
223609135|NCT02892526|OTHER|Collection of cutaneous tissue|
223609136|NCT06106126|DRUG|GST-HG171 Tablets|150mg GST-HG171 100mg Tablets and ritonavir
223609137|NCT06125366|DRUG|BAY1747846|Single dose; IV injection.
223609138|NCT06125366|DRUG|Matching placebo|Single dose; IV injection.
223609139|NCT05754853|DRUG|MRG002|Administrated intravenously
223609140|NCT05754853|DRUG|Docetaxel Injection|Administrated intravenously
223609141|NCT05754853|DRUG|Paclitaxel Injection|Administrated intravenously
223609142|NCT05754853|DRUG|Gemcitabine Hydrochloride for Injection|Administrated intravenously
223609143|NCT05754853|DRUG|Pemetrexed Disodium Injection|Administrated intravenously
223609144|NCT02986711|BEHAVIORAL|Motivational Text Messages|Motivational text messages in addition to survey questions about smoking status
223609145|NCT02986711|BEHAVIORAL|Control|Only survey questions about smoking status
223609146|NCT03059316|COMBINATION_PRODUCT|Massimo device|Massimo is a newly introduced device which can measure the peripheral organ perfusion and expressed it as perfusion index(PI).
223609147|NCT03059316|DRUG|Nitroglycerin drug|Nitroglycerin is a drug used as an hypotensive agent through its vasodilation effect on veins
223609148|NCT03059316|DRUG|Labetalol|Labetalol is an antagonist of adrenergic receptors (a1, b1, b2) which is used as an hypotensive inducer. This drug targets the beta receptors 5 to 10 times more specific than alpha receptors so that minor tachycardia happens
223609149|NCT03868254|DEVICE|XEN Group|Chart review was conducted in participants with open angle glaucoma who underwent placement of the implant XEN 45 Gel Stent as a standalone procedure from 1 January 2014 to 1 October 2015.
223609150|NCT03868254|PROCEDURE|Phacoemulsification|Chart review was conducted in participants with open angle glaucoma who underwent placement of the implant XEN 45 Gel Stent in combination with phacoemulsification (Phaco) from 1 January 2014 to 1 October 2015.
223609151|NCT04145882|PROCEDURE|additional osteotomies|varisation osteotomy, supination osteotomy or both
223609152|NCT04515212|OTHER|Optic Nerve Ultrasounds|Patients will have up to four ultrasounds of the optic nerve.
223609153|NCT04977401|PROCEDURE|Endoscopic submucosal dissection|Dissecting superficial gastric or rectal lesion/polyp after injection of the submucosa for lifting, using a electrosurgical knife through the endoscope
223609154|NCT04977401|DEVICE|use of Orise Gel as lifting agent for endoscopic submucosal dissection|Injection of some colloidal solution (ORISE gel) in the submucosal layer in order to obtain long lifting effect and thus allowing the endoscopist to dissect under the lesion.
223609155|NCT04977401|DEVICE|use of glycerol as lifting agent for endoscopic submucosal dissection|Injection of some colloidal solution (glycerol) in the submucosal layer in order to obtain long lifting effect and thus allowing the endoscopist to dissect under the lesion.
223609156|NCT03211494|DEVICE|INTELLiVENT-ASV|INTELLiVENT-ASV, with software 2.60
223609157|NCT03211494|OTHER|Conventional lung protective ventilation|Lung protective ventilation according to the ARDSnet guidelines
223609158|NCT03194126|PROCEDURE|Mifepristone + Misoprostol OR oxytocine + laminaria|Three laminaria placed 12 hours prior to administration of misoprostol
223609159|NCT03194126|PROCEDURE|Mifepristone + Misoprostol OR oxytocine|standart support
223609160|NCT03264365|BEHAVIORAL|Intervention|"Intervention (plus standard care)~* Patients photographs during the ICU-stay,~* Written information about life after ICU~* First consultation face-to-face in hospital setting at three months after ICU~* Visit ICU and photographs given~* Consultations as needed"
223609161|NCT00988013|RADIATION|IM-TMI (3Gy)|Patients will receive 3Gy per day for 1 day.
223609162|NCT00988013|RADIATION|IM-TMI (6Gy)|Patients will receive 3Gy per day for 2 days.
223609163|NCT00988013|RADIATION|IM-TMI (9Gy)|Patients will receive 3Gy per day for 3 days.
223609164|NCT00988013|RADIATION|IM-TMI (12Gy)|Patients will receive 3Gy per day for 4 days.
223609165|NCT04410718|OTHER|Glycaemic levels|Glycaemic levels during admission for COVID-19
223755718|NCT05695495|DRUG|N,N-Dimethyltryptamine (5mg)|Intravenous bolus application over 45 seconds
223755719|NCT05695495|DRUG|N,N-Dimethyltryptamine (10mg)|Intravenous bolus application over 45 seconds
223755720|NCT05695495|DRUG|N,N-Dimethyltryptamine (15mg)|Intravenous bolus application over 45 seconds
223609166|NCT05217160|DRUG|KeraStat® Gel with Morphine application|"Administration and application of KeraStat® Gel with Morphine (Bi-Weekly):~KeraStat® Gel with Morphine will be formulated by mixing liquid Morphine 25mg/mL into 5mg of KeraStat, this will be individually packaged in 5mL tubes at a concentration of 5mg/mL. Each 5mL tube will cover and area of 300cm2 which is approximately 1.5% TBSA of an average, 60kg subject.~Home Administration and application of KeraStat® Gel with Morphine (Every 1-3days):~Dressing is to be changed every 1-3 days, no more than once a day. Subjects will be provided the appropriate amount of pre-compounded KeraStat® Gel with Morphine in 5mL tubes."
223609167|NCT05217160|DRUG|KeraStat® Gel application|"Administration and application of KeraStat® Gel (Bi-Weekly):~Each 5mL tube will cover and area of 300cm2 which is approximately 1.5% TBSA of an average, 60kg subject.~Home Administration and application of KeraStat® Gel (Every 1-3days):~Dressing is to be changed every 1-3 days, no more than once a day. Subjects will be provided the appropriate amount of pre-compounded KeraStat® Gel in 5mL tubes."
223609168|NCT00922623|DEVICE|Belotero®|Hyaluronic acid dermal filler, Belotero®, single use syringe, injected into mid to deep dermal layer
223609169|NCT00723307|DRUG|Metformin|White film-coated tablets, 850mg tablet twice daily, 1.5 years duration
223609170|NCT00723307|DRUG|Placebo|White coated tablet; one tablet twice daily; 1.5 years duration
223609171|NCT00228358|DRUG|ex vivo-expanded HER2-specific T cells|Laboratory-expanded T cells, given IV
223609172|NCT00228358|DRUG|cyclophosphamide|Given IV
223609173|NCT00228358|BIOLOGICAL|denileukin diftitox|Given IV
223609174|NCT00228358|OTHER|flow cytometry|Intracellular cytokine staining (correlative study)
223609175|NCT00228358|OTHER|immunoenzyme technique|ELIspot assay (correlative study)
223609176|NCT02348125|DRUG|Mitochondrial Cocktail|
223755721|NCT05695495|DRUG|N,N-Dimethyltryptamine (20mg)|Intravenous bolus application over 45 seconds
223755722|NCT05695495|DRUG|N,N-Dimethyltryptamine (25mg)|Intravenous bolus application over 45 seconds
223755723|NCT05695495|DRUG|Placebo (saline)|Intravenous bolus application over 45 seconds
223755724|NCT06875024|BEHAVIORAL|Intelligent intervention programs|The intervention involves a structured exercise program, with participants in the experimental group engaging in cycling exercises three times per week, each session lasting 30 minutes during hospitalization. After discharge, they will follow a walking program, increasing their daily step count by 1,000 steps above the average recorded during hospitalization, for a total of 12 weeks. Structured questionnaires and medical records will be used for data collection at four time points: the first week of enrollment (T0), hospital discharge (T1), the eighth week post-enrollment (T2), and the twelfth week post-enrollment (T3). Additionally, a tri-axial accelerometer-equipped smart wristband will be used to monitor and record participants' heart rate, respiration, blood pressure, daily step count, and sleep quality.
223755725|NCT07027631|DEVICE|Magnesium Sulfate Iontophoresis|Magnesium Sulfate iontophoresis utilizing an iontophoretic drug delivery system
223755726|NCT07027631|DEVICE|Shock Wave Therapy|using Shock Wave Therapy Device
223755727|NCT07027631|OTHER|stretching and strengthening|stretching and strengthening exercises
223755728|NCT04846673|DRUG|Pregabalin 150mg + Alpha-lipoic acid 480mg|Pregabalin qd + alpha-lipoic acid qd
223755729|NCT04846673|DRUG|Pregabalin 150mg|pregabalin qd
223755730|NCT04846673|DRUG|Alpha-Lipoic Acid 480mg|alpha-lipoic acid qd
223755731|NCT06286735|DIETARY_SUPPLEMENT|cinnamomum|60 capsules of 500 mg of powdered cinnamomum bark (Cinnamomum verum; 40% polyphenols). Participants in this group will be instructed to consume two capsules per day, one after lunch and one after dinner for 3 months.
223755732|NCT06286735|OTHER|Placebo|60 capsules with 500 mg of corn starch per month, until the end of the three months of intervention. Participants in this group will be instructed to consume two capsules per day, one after lunch and the other after dinner for 3 months.
223755733|NCT06880861|OTHER|Non-Interventional Study|Non-Interventional Study
223755734|NCT06884267|OTHER|standard hyperkalemia management implementation|The interventions include HK disease management and quality audits for health care professionals (HCPs) and patients (Figure 1). The main contents of HK disease management in CKD include a standardized clinical pathway based on guideline adoption and medical trainings to educate HCPs and patients.
223755735|NCT06722521|DRUG|Pitavastatin 4mg and ezetimibe 10mg, taken once daily|Intensive lipid-lowering therapy without aspirin
223755736|NCT06722521|DRUG|Pitavastatin 2 mg with aspirin 100 mg, taken once daily.|Moderate-intensity lipid-lowering therapy with aspirin
224200861|NCT01093040|DRUG|CAT 354|600 mg CAT-354 or placebo given SC on Day 1
224200862|NCT01211496|BEHAVIORAL|High-speed power training|High speed resistance training, 3 sessions per week for 12 weeks
224200863|NCT01211496|BEHAVIORAL|Slow-speed strength training|Slow speed resistance training, 3 sessions per week for 12 weeks
223609177|NCT02871635|DRUG|BI 695501|
223609178|NCT02871635|DRUG|HUMIRA|
223609179|NCT00233766|DEVICE|Bx VELOCITY Stent containing 45% and 70% of Sirolimus dose|
223609180|NCT03530826|OTHER|No intervention|No Intervention
223609181|NCT04811066|DEVICE|Transcranial direct current stimulation|"Transcranial electrical stimulation device. A weak direct electrical current, up to 2 mA, is passed between two electrodes placed on the scalp. Electrodes are housed in 35 cm2 sponges saturated with 4 ml of saline solution (0.9 % NaCl) per side, per pad.~Stimulation is phased in with a 30-second ramp up of the electrical current to the specified stimulation parameters. Following the specified stimulation period, the current is phased-out with a ramp down of the current. For sham stimulation, the ramp-up and ramp-down periods are retained, but stimulation is switched off during the specified stimulation period."
223609182|NCT02420379|DRUG|eteplirsen|Eteplirsen 30 mg/kg will be administered as an IV infusion once a week for 96 weeks.
223609183|NCT06106048|OTHER|Closed kinetic chain exercises|"Group A was treated with closed kinetic chain exercises. Group A: Group A was treated with closed kinetic chain exercises. Closed kinetic chain exercises enhance the proprioception by coordinating the mechanical receptors as well as the strength of the external shoulder rotator muscles, reduce the pain and improve the shoulder.~Closed kinetic chain exercises include:~* Push up~* Scapular push up~* Scapular dip~* Crab walk~Common Treatment:~Cryotherapy 10 minutes 2 times per day. Ultrasonography 1Mhz frequency, 0.4 watt/cm for 10 minutes. Transcutaneous electrical stimulation (TENS) 10 minutes, modulation mode, frequency 280, wavelength 80.~Cross arm stretching 5 times 30 sec hold. Shoulder isometric exercises 10 repetitions 3 sets for 3 times per week."
223609184|NCT06106048|OTHER|Abdominal contraction exercises|"Group B was treated with abdominal contraction exercises for periscapular activation that includes: Wall slide, knee pushup, external rotation kneeling, Full can and External rotation with elevation and isometric low row.~Common Treatment:~Cryotherapy 10 minutes 2 times per day. Ultrasonography 1Mhz frequency, 0.4 watt/cm for 10 minutes. Transcutaneous electrical stimulation (TENS) 10 minutes, modulation mode, frequency 280,wavelength 80.~Cross arm stretching 5 times 30 sec hold. Shoulder isometric exercises 10 repetitions 3 sets for 3 times per week."
223609185|NCT01402817|DRUG|Sutent®/Sunitinib|Upon enrollment, subjects will receive Sutent® orally. Adults (Age \>18) will receive 25mg. Children will receive 10mg/m2/day. All subjects will take the daily dose for 28 days followed by a 14 day rest period. If subjects tolerate the initial dose, adults will be increased to 37.5mg and children will be increased to 15mg/m2/day. Again, subjects will take that dose for 28 days followed by a rest period of 14 days. Adults who tolerate the increase will go up to the maximum dose of 50mg. The maximum dose for children is 15mg/m2/day.
223609186|NCT00314639|DRUG|modafinil|Modafinil OR Placebo 100mg orally (on the morning) from day 0 to day 14 and 200mg orally (on the morning) from day 15 to day 28. AND REVERSE : Modafinil OR Placebo 100mg orally (on the morning) from day 42 to day 56 and 200mg orally (on the morning) from day 57 to day 70.
223609187|NCT02447016|DRUG|Tenofovir disoproxil/emtricitabine/rilpivirine|
223609188|NCT02447016|DRUG|Tenofovir disoproxil/emtricitabine/efavirenz|
223609189|NCT02620592|DRUG|ZYDPLA1 tablet|The oral dose of ZYDPLA1 tablet administered with 240 ± 10 mL of water at ambient temperature.
223609190|NCT02620592|DRUG|Placebo tablet|The oral dose of placebo tablet administered with 240 ± 10 mL of water at ambient temperature.
223609191|NCT00977171|DRUG|Droxidopa|Oral, 100, 200, 300, 400, 500, or 600 mg TID, duration includes up to a 2 week titration period followed by a 12 week treatment period
223609192|NCT01051687|DRUG|Botulinum toxin A|"Dilution of 1 ml of unpreserved saline per 100 U vial of BOTOX (Allergen pharmaceuticals, Irvine, CA). 2 units were injected intradermally every 1 cm2 with a 1ml syringe and 30 gauge needle.~For each patient with focal vitiligo, one vitiliginous patch - or two patches from different sites- will be treated. The other patches from the contra lateral site will be left untreated and used as control at the follow-up visit. For each patient with segmental vitiligo, half of the lesion will treated. The other half will be left untreated and used as a control at the follow-up visit."
223609193|NCT01934491|BEHAVIORAL|Cognitive Training A|
223609194|NCT01934491|BEHAVIORAL|Cognitive Training B|
223755737|NCT06886295|DEVICE|Prosthetic controller|The intervention includes an upper limb prosthesis composed at the minimum by skin-surface electrodes for myoelectric signals, a vibrotactile actuator, a multi-articulated and instrumented hand prosthesis and a centralized control system. The centralized prosthetic controller processes the myoelectric signals acquired at the residual limb to enable the movements on the multi-articulated prosthesis.
223755738|NCT05177198|PROCEDURE|M-MIST + Clindamycin augmented PRF|modified minimally invasive surgical technique with Clindamycin (at concentration of 150 mg/ml) augmented platelet-rich fibrin.
223755739|NCT05177198|PROCEDURE|M-MIST + PRF|modified minimally invasive surgical technique with platelet-rich fibrin alone.
223755740|NCT06728072|DRUG|Standard of Care Chemotherapy + Metronidazole, ciprofloxacin, aspirin|Metronidazole, ciprofloxacin, aspirin is initiated Cycle 1 Day 1 of chemotherapy. May be initiated any time from 7 days before Cycle 1 Day 1 up to and including Cycle 1 Day 3
223755741|NCT06716138|DRUG|ANS03|ANS03 is a rationally next generation TKI targeting both ROS1 and NTRK developed by Shenzhen Avistone Biotechnology (the sponsor).
223755742|NCT07044180|DRUG|pipecuronium bromide|Investigation of muscle relaxation with pipecuronium bromide
223755743|NCT07044180|DRUG|Rocuronium bromide|Muscle relaxation with rocuronium as a control
224200864|NCT01863095|BEHAVIORAL|Personalized Feedback and Exercise|
224200865|NCT04934891|DRUG|ION547|ION547 will be administered by SC injection.
223609195|NCT01473732|DRUG|Everolimus|Starting dose 1.5 mg bid, target trough level 6-10 ng/ml.
223609196|NCT01473732|DRUG|Tacrolimus|Target trough level of Tacrolimus 3-5 ng/ml.
223609197|NCT01473732|DRUG|Mycophenolic acid|Myfortic Min. dose 360 mg bid and Max dose 720 mg bid. Used in both arms. Used for one year.
223609198|NCT01165983|DRUG|Placebo|0mg tablet, taken orally for 12 weeks daily
223609199|NCT01165983|DRUG|Aliskiren|150mg tablet, taken orally for 12 weeks daily
223609200|NCT03558542|OTHER|cardiopulmonary rehabilitation plus neurorehabilitation|Patients with stroke will undergo an accompanying structured cardiopulmonary rehabilitation program along with a neurorehabilitation program
223609201|NCT01217944|DRUG|Ranibizumab|0.5 mg ranibizumab intravitreal injection
223609202|NCT01217944|DRUG|Verteporfin PDT|Verteporfin (6 mg/m2) intravenous infusion
223609203|NCT01217944|DRUG|Sham Ranibizumab|Empty vial to mimic the intravitreal injection
223609204|NCT01217944|DRUG|Sham verteporfin PDT|Sham vPDT intravenous infusion of dextrose 5% solution followed by light application (PDT).
223609205|NCT03261388|BEHAVIORAL|Activity-Based Locomotor Exercise Program (ABLE)|The ABLE program is an intensive locomotor based intervention that is offered at the Golden Valley Courage Kenny Rehabilitation Institute.
223609206|NCT01441804|DRUG|Peginterferon alfa2a|patients receive a dose of 180 µg of PEGASYS once a week for 24 weeks
223609207|NCT01441804|DRUG|Ribavirin|patients receive a dose 800 to 1200 mg of ribavirin once a day(according to weight) for 24 weeks
223609208|NCT01441804|DRUG|Peginterferon alfa2a|patients receive a dose of 180 µg of PEGASYS once a week for 48 weeks
224200866|NCT04934891|DRUG|Placebo|ION547-matching placebo will be administered by SC injection.
223609209|NCT01441804|DRUG|Ribavirin|patients receive a dose 800 to 1200 mg of ribavirin once a day(according to weight) for 48 weeks
224200867|NCT05010915|DEVICE|Transcranial magnetic stimulation|Transcranial magnetic stimulation
223609210|NCT06319703|BEHAVIORAL|Diabetes Self-Management Education and Support (DSMES) Videos|Text message-delivered video-based DSMES intervention.
223609211|NCT06319703|BEHAVIORAL|Community Health Worker Support (CHW)|Assess participants' SDOH barriers to Type 2 diabetes care and link them to available resources in the community.
223609212|NCT02814942|DEVICE|Cardiac Resynchronization Therapy|Cardiac resynchronization therapy with or without ICD
223755744|NCT04754347|DEVICE|Computer Aided Detection device|The Computer Aided Detection device, Skout, is designed to help endoscopists detect potential colorectal polyps during colonoscopies. The system performs automated real-time analysis on endoscopic video data to identify potential polyps and produces an informational visual aid around the appropriate sections of the video frames on a display monitor.
223609213|NCT04182841|DEVICE|RheOx|RheOX is a CE-marked device-based, energy delivery system that delivers energy to ablate soft tissue such as the airway epithelium and sub-mucosal tissue layers. The energy is delivered via a proprietary catheter through the bronchoscope.
223609214|NCT05072938|DRUG|Mucotra SR Tablet 150mg|Rebamipide/Nizatidine Combination Therapy
223609215|NCT05072938|DRUG|Axid Capsule 150mg|Nizatidine Monotherapy
223609216|NCT04840082|DIAGNOSTIC_TEST|Nasopharyngeal swab for COVID-19 testing|A nasopharyngeal swab was performed endoscopically video guided to measure the actual length from to the mid turbinate and the posterior nasopharyngeal wall
223609217|NCT04098809|DEVICE|16 French urinary catheter|16 French urinary catheter
223609218|NCT04098809|DEVICE|20 French urinary catheter|20 French urinary catheter
223609219|NCT00193206|DRUG|Gemcitabine|Gemcitabine 2000 mg/m2 IV D1 q 14 days x 6 cycles
223609220|NCT00193206|DRUG|Epirubicin|Epirubicin 50 mg/m2 D1 q 14 days x 6 cycles
223609221|NCT00193206|DRUG|Albumin-bound Paclitaxel|ABI-007 175 mg/m2 D1 q 14 days x 6 cycles
223609222|NCT00203164|DRUG|rasagiline mesylate|rasagiline mesylate 1 mg oral once daily
223755745|NCT06740344|PROCEDURE|Two-handed facemask hold|Two-handed mask hold technique while giving facemask ventilation, with another operator designated to deliver PIP via the T-piece.
223755746|NCT06740344|PROCEDURE|Control: One-handed facemask hold|One-handed mask hold technique while giving facemask ventilation, with the same operator holding the mask and delivering PPV via the T-piece.
223755747|NCT06736808|OTHER|Handout Written at Below a Sixth Grade Reading Level|Participants randomized to this experimental arm will read a simplified handout on pelvic organ prolapse written at below a sixth grade reading level.
223755748|NCT06736808|OTHER|Handout Written at Above a Sixth Grade Reading Level|Participants randomized to this control arm will read a standard handout on pelvic organ prolapse written at above a sixth grade reading level.
224200868|NCT03246321|COMBINATION_PRODUCT|repetitive ePIPAC-OX|Instead of standard palliative treatment, enrolled patients receive laparoscopy-controlled electrostatic pressurised intraperitoneal aerosol chemotherapy with oxaliplatin (ePIPAC-OX) (92 mg/m2 body-surface area \[BSA\]) with intravenous leucovorin (20 mg/m2 BSA) and bolus 5-fluorouracil (400 mg/m2 BSA) every six weeks. Four weeks after each procedure, patients undergo clinical, radiological, and biochemical evaluation. ePIPAC-OX is repeated until clinical, radiological, or macroscopic disease progression, after which standard palliative treatment is (re)considered.
223609223|NCT02195570|OTHER|Quit Smoking Now (QSN)|"The Quit Smoking Now (QSN) program, offered by the Florida Area Health Education Center, was developed based on principles of the Centers for Disease Control and Prevention's Best Practices for Comprehensive Tobacco Control, and the U.S. Department of Health and Human Services' Treating Tobacco Use and Dependence Clinical Guidelines with an emphasis on reaching medically-underserved populations. The QSN curriculum will be delivered in 6 one-hour sessions . Pregnancy-specific session goals and content cover the effects of smoking on the developing fetus, secondhand smoke exposure, the importance of social support, and postpartum relapse."
223609224|NCT02195570|BEHAVIORAL|Prize-based Contingency Management (CM)|Women will earn chances to win prizes for biochemically verified abstinence from tobacco.
223609225|NCT01426958|DRUG|afatinib|standard therapeutic dose
223609226|NCT01426958|DRUG|ritonavir + afatinib|simultaneous intake of ritonavir and afatinib on second treatment day
223609227|NCT01426958|DRUG|ritonavir + afatinib|on the second treatment day the first ritonavir tablet will be taken 6 hours after the afatinib tablet
223609228|NCT04713280|PROCEDURE|Maxillary posterior dento-alveolar intrusion|Mini-screw supported maxillary or bi-maxillary posterior dento-alveolar intrusion
223609229|NCT05855772|DEVICE|Extracorporeal shock waves|Extracorporeal shock waves are non-invasive and simple treatments that are easy to apply to a wide surface and have fewer side effects with low intensity. In addition, there is an advantage of improving blood circulation through an increase in reactive blood flow and creation of new blood vessels.
223609230|NCT05855772|BEHAVIORAL|Posture Correction Exercise Program|The exercise program mainly consists of stretching and muscle strengthening exercises, which have shown improvement effects in terms of head vertebrae and pain. In order to optimize the muscle activity between pairs due to FHP, the selected exercise should focus on providing an appropriate proportion of muscle activity for each other as well as muscle strength.
223609231|NCT04550637|DRUG|Oral apixaban|apixaban (5 mg bid) is given until 12 weeks after surgery
223609232|NCT02968368|DRUG|Ferric maltol|
223609233|NCT02968368|OTHER|Placebo|
223609234|NCT00940940|BIOLOGICAL|Zostavax (Live attenuated herpes zoster vaccine)|0.6 mL subcutaneous
223609235|NCT00940940|BIOLOGICAL|Placebo vaccine|0.65 mL subcutaneous
223609236|NCT05406336|OTHER|Predicted uncontrolled BP status (yes/no) at follow up visit, derived using a machine learning algorithm|The investigators have created a machine learning algorithm to predict uncontrolled blood pressure (BP) status (yes/no) at a follow up visit among adults with uncontrolled BP at their current visit. The investigators will determine whether adding this information to a vignette describing a patient will increase the likelihood that a clinician will intensify antihypertensive medication treatment.
223755749|NCT07047612|DRUG|ICP-332 Tablets|ICP-332 will be administered as tablet
223755750|NCT07047612|DRUG|ICP-332 Placebo Tablets|ICP-332 Placebo will be administered as tablet
223755751|NCT06891300|DRUG|ketamine hydrochloride|Participants will undergo intravenous (IV) ketamine infusions (0.5 mg/kg infused over 40 minutes) under medical supervision. Treatments will be administered twice weekly for two weeks, for a total of four infusions.
223755752|NCT00366990|BEHAVIORAL|Low Sodium Diet|Group sessions once a week for 16 weeks, bi-weekly for 16 weeks, and monthly for 16 weeks on behavioral \& weight loss topics with a focus on lowering sodium intake.
223609237|NCT05361824|DRUG|Ketorolac Injection|dosage form: intravenous dosage: 30mg frequency: 8 hours apart (TDS) duration: for 48 hours post operatively
223609238|NCT05361824|DRUG|Paracetamol|dosage form: intravenous dosage: 1gm frequency: 6 hours apart (QID) duration: for 48 hours post operatively
223609239|NCT04234867|DRUG|Dapagliflozin|once daily for 5 days
223609240|NCT04234867|DRUG|Placebo oral tablet|once daily for 5 days
223609241|NCT04234867|OTHER|Stress|single dose after last administration of experimental drug
223609242|NCT04234867|OTHER|Placebo Stress|single dose after last administration of experimental drug
223609243|NCT04917484|DRUG|Lu-177-DOTA-Octreotide|Lu-177-DOTATOC in standard doses or individualized doses.
223609244|NCT05733156|RADIATION|SBRT + LDRT|Stereotactic body radiotherapy (SBRT) and low-dose radiotherapy (LDRT) are administered concurrently. SBRT is administered three times, at intervals of 1-2 days, and patients are treated with LDRT along with SBRT. LDRT is planned to irradiate EQD2 6 Gy considering the scattered dose caused by SBRT.
223609245|NCT00991939|DRUG|Dexamethasone USP Micronized|The dose for dexamethasone is 30 mg/day for patients \< 60 kg and 40 mg/day for patients \> 60 kg. The patient will be dosed on days 1-4, 15-18 and 29-32. On the remaining days during the treatment phase of the study, the patient will receive placebo capsules.
223609246|NCT00991939|DRUG|Prednisone|Prednisone will be administered to study patients at a dose of 60 mg/day for patients less than 60 kg and 80 mg/day for patients \> 60 kg for 21 days. The following schedule for tapering of prednisone will be used: after three weeks of treatment at either 60 mg/day (for patients \< 60 kg) or 80 mg/day (for patients ≥ 60 kg), the dose will be reduced to 40 mg/day for 1 week, then 20 mg/day for 1 week, then 10 mg/day for 1 week, then 5 mg/day for 1 week and then stopped. Placebo capsules will be added as necessary during the treatment phase of the study, to maintain blinding.
223609247|NCT02278861|DRUG|Oral isotretinoin|Oral isotretinoin - 10mg/day (one pill) after lunch for six months
223609248|NCT02278861|DRUG|Tretinoin 0,05% cream|Topical tretinoin 0,05% cream - applied every other night in the face and forearms for six months
223609249|NCT02278861|DRUG|Sunscreen FPS 60|Sunscreen FPS 60 applied on sun exposed areas every 3 hours daily
223609250|NCT00123318|DRUG|epirubicin|50mg/m2 IV day 1
223755753|NCT00366990|BEHAVIORAL|Regular Sodium Intake|Group sessions once a week for 16 weeks, bi-weekly for 16 weeks, and monthly for 16 weeks on behavioral \& weight loss topics.
223755754|NCT07108543|PROCEDURE|Antegrade versus retrograde cross k-wire|\> Closed reduction of distal radius fracture followed by percutaneous insertion of two or more K-wires in an antegrade direction (from proximal to distal), crossing the fracture site under fluoroscopic guidance. The wires are introduced from the radial metaphysis and directed distally to stabilize the fracture.
223755755|NCT07109661|BEHAVIORAL|Rational Positive Parenting Program (rPPP)|The Rational Positive Parenting Program (rPPP) is a structured cognitive-behavioral group intervention based on Rational Emotive Behavior Therapy (REBT). It comprises 8-10 weekly sessions focused on addressing irrational parenting beliefs, improving emotion regulation, and teaching positive behavior management strategies for children with disruptive behaviors. Participants in the control group will not receive the intervention during the active phase, but will be offered the rPPP after final assessment to ensure ethical treatment.
223755756|NCT07109336|DEVICE|Heterogeneous Treatment Effect-Based Decision Model|Heterogeneous Treatment Effect-Based Decision Model
223755757|NCT06895811|BIOLOGICAL|PSMA-UCAR T (BRL-302)|"Three patients will be firstly enrolled at a dose level (DL) of 5.0 × 10\^6cells/kg in the DL1 group, following lymphodepleting chemotherapy which will be given under instruction of protocol and investigators' assessment;~Based on preliminary safety data, efficacy information, and PK/PD parameters obtained at DL1 cohort, the investigator may enroll another three patients in a decreased dose level group of DL-2: 3 × 10\^6 cells/kg or DL-1:1 × 10\^6 cells/ kg, after thorough discussions between the investigators."
223755758|NCT06776965|OTHER|Dietary Questionnaire|Self administered dietary questionnaire at baseline, 6 and 12 months.
224200869|NCT00629382|DEVICE|Polymyxin B immobilized fiber column|Hemoperfusion with PMX will be performed in ICU. The 1st PMX treatment (day 0) will be carried out for 2 hours and ideally within 24 hours but not later than 48 hours after diagnosis of severe sepsis. The second PMX treatment has to be performed 24 to 48 hours after the end of the first PMX treatment, ideally after 24 hours. Hemoperfusion therapy will be performed in addition to conventional medical therapy in the ICU.
223609251|NCT00123318|DRUG|cisplatin|60mg/m2 IV day 1
223609252|NCT00123318|DRUG|5-fluorouracil|5-FU 200mg/m2/d IV 21 day continuous infusion Cont. infusional 5-FU 225mg/m2/day, 7 days/wk throughout entire period RT via CADD pump through PICC line
223609253|NCT00123318|RADIATION|Radiotherapy|45Gy 25 Fractions, 5 days/week for 5 weeks
223609254|NCT00307905|DRUG|Traumeel S|homeopathic remedy
224200870|NCT00629382|OTHER|Conventional medical therapy in the ICU|Including, but not limited to: antibiotic therapy, nutrition, administration of gamma-globulins, vasopressors, hemodynamic monitoring, organ support in the ICU including mechanical ventilation, corrective measures for metabolic abnormalities, renal replacement therapy when appropriate.
224200871|NCT00944528|RADIATION|Radiosurgery|Single dose or radiation in 15Gy, 18Gy or 21Gy
224200872|NCT04013373|DEVICE|SOZO Bioimpedance Spectroscopy Device|Bioimpedance spectroscopy measurements for assessment of fluid status
224200873|NCT02037594|BEHAVIORAL|Sexual Health Counseling|This brief intervention presents PrEP within the context of a patient's comprehensive sexual health plan and is designed to enhance decision-making around PrEP use and decrease sexual risk taking.
223609255|NCT00307905|DRUG|Placebo remedy|identical size, shape and taste of treatment medication
223609256|NCT02766634|BIOLOGICAL|Filgrastim Hospira (US)|5 micrograms/kilogram (ug/kg) subcutaneous (SC) injection once a day for 5 days
223609257|NCT02766634|BIOLOGICAL|U.S.-approved Neupogen®|5 micrograms/kilogram (ug/kg) subcutaneous (SC) injection once a day for 5 days
223609258|NCT00366691|DRUG|Acular LS|
223609259|NCT00366691|DRUG|Lotemax|
223609260|NCT06143267|OTHER|Infusion of either NST or placebo at different blood glucose levels|In a randomized, double-blind crossover design, participants will undergo six experimental days with controlled plasma glucose levels, consisting of two euglycemic, two hyperglycemic (around 8mmol/l), and two hypoglycemic (around 2.5mmol/l) days, with each pair of similar days involving the administration of either saline (placebo) or NST.
223609261|NCT02258646|BEHAVIORAL|Exercise training at home|
223609262|NCT02258646|BEHAVIORAL|Telemonitoring and education/self-management|
223609263|NCT05659368|DRUG|Tirzepatide|tirzepatide once weekly
223609264|NCT04851054|PROCEDURE|Surgery for colon cancer with intention to cure|Surgery by open or laparoscopic approach
223755759|NCT06776965|OTHER|Evaluation of disease activity (DAS-28, ASDAS, EVA, number of swollen joints, number of painful joint, nocturnal pain, morning stiffness)|Self administered questionnaire of disease activity at baseline, 6 and 12 months.
223755760|NCT06844331|DEVICE|Thoracic ultrasound|The investigators want to investigate that TUS/US can use to identify and to monitir the disease progression in the patients with F-ILD
223755761|NCT06898658|BEHAVIORAL|Mindfulness Intervention|"Hybrid MAPs course will be delivered by a Spanish-speaking Latina certified mindfulness instructor, with a blend of in-person instruction, online instruction and asynchronous (audio-recorded) content instruction over 6-wks. There will be three live-2hr classes (2 in-person, 1 online) and three 3 weeks of 1-hr self-guided audio/week asynchronous content (1hr/wk). Additionally, the instructor will invite the intervention group to join optional weekly via Zoom 1x/wk for 30-min sessions for time to encourage questions, dialogue, and brief group mindfulness practice opportunities.~Class attendance and engagement with audio-recorded materials will be tracked. The study team will call or text participants weekly to maintain engagement, remind about any upcoming scheduled classes, and answer any questions. Participant attendance in classes (in-person and zoom) will be monitored."
223755762|NCT06760039|DRUG|R-CMOP Regimen|Rituximab intravenous drip, Cyclophosphamide intravenous drip, Liposomal Mitoxantrone intravenous drip, Vincristine intravenous drip, Prednisone orally
223755763|NCT06760039|DRUG|R-CHOP Regimen|Rituximab intravenous drip, Cyclophosphamide intravenous drip, Doxorubicinin intravenous drip, Vincristine intravenous drip, Prednisone orally
223755764|NCT07064577|DRUG|ROS-scavenging Nanoenzymes|ROS-scavenging nanoenzymes are applied to the treatment area, once daily during radiotherapy.
223755765|NCT07064577|BEHAVIORAL|Standard of care|Standard of care
223755766|NCT06127511|OTHER|Food (peanut)|After the recruitment, the participants will follow a peanut-free diet for two weeks.
223755767|NCT05716139|PROCEDURE|Natural Cycle|The participant will be administered a S/C injection of 250mcg r-hCG to assist ovulation and timing of the embryo transfer, when the dominant follicle reaches ≥ 18mm and serum LH \< 20 IU/L, the administration of r-hCG will be in the evening, and the embryo transfer will be scheduled seven days later (window of ± two days). The participant will begin transvaginal progesterone gel (8 %) twice daily starting 36 hrs after the trigger until ten weeks of gestation.
223755768|NCT05716139|PROCEDURE|Artificial Cycle|Estrogen priming with oral estradiol valerate 6mg/day (2mg every 8 hours) starting from cycle D1-D5 after a first TVU. TVU will be performed 10-15 days after beginning estradiol until ET ≥ 7mm, maximum until 21 days. Patients will begin progesterone injection 100mg/day until blastocyst transfer. Frozen embryo transfer will be performed on day 6 +/- 2 days of progesterone administration. After embryo transfer, a supplementation with transvaginal progesterone gel (8 %) twice daily starting from the day of embryo transfer until ten weeks of gestation. Patients will continue Estradiol 2 mg thrice daily until 6 weeks of gestation; then dose tapering will be done to 2 mg twice daily until 9 wks of gestation. From 9th wk the estrogen dose will be tapered further to 2 mg once daily for 10 days before stopping.
223755769|NCT06874452|DRUG|Xanax|The patients will each receive a single tablet of 0.5mg XANAX 30 minutes before surgery. Patients older than 65 years or with liver disease will receive a reduced dose of 0.25 mg rather than 0.5 mg of oral XANAX 30 minutes before surgery.
223755770|NCT06874452|OTHER|Placebo Tablets|The patients will each receive a single tablet of placebo 30 minutes before surgery.
223755771|NCT05535777|BEHAVIORAL|Enhanced texts with Callback by a Person|"Enhanced texts - Callback by a person: Patient randomized to this study arm will receive a phone call back by a call center agent if they press 1 in response to a question on the original text message. The call center agent's job is to schedule patients for clinical visits. These call center agents will be trained by our faculty and staff and will have the usual HIPAA and other patient confidentiality training."
223755772|NCT05535777|BEHAVIORAL|Enhanced Bidirectional Texts|"Patients randomized to this study arm will receive a text message from a call center agent if they press 1 in response to a question on the original text message. The bidirectional texts will have an agent who can answer questions and schedule an appointment through text message back-and-forth conversations with the patient."
223755773|NCT06841692|DIAGNOSTIC_TEST|Diuretic Testing|The administration of hydrochlorothiazide and bumetanide is used to stimulate and assess tubular function.
223755774|NCT06770322|PROCEDURE|Conventional|According to the clinician's own practice, the cuff of the endotracheal intubation tube will be manually inflated with the help of a syringe and the pressure will be measured with manometry and a note will be taken.
223755775|NCT06770322|PROCEDURE|manometer|The cuff pressure will be measured by manometry and the cuff of the endotracheal intubation tube will be inflated with 25-30 cmH2O.
224200874|NCT02037594|BEHAVIORAL|Enhanced Adherence Intervention|This brief intervention is provides standard of care PrEP adherence information plus specific counseling, troubleshooting, and support.
224200875|NCT02037594|BEHAVIORAL|PrEP Information (Active Control)|Standard of Care Information about PrEP
223609265|NCT03236077|BEHAVIORAL|Fit and Fab|participate in a targeted exercise program at the YMCA. Will include: Targeted exercise classes, Strength-training, Group support sessions
223609266|NCT03187444|PROCEDURE|Examinations|Several examinations are realized on each patients, in addition to the usual visit and after verification of the criteria of inclusion and signature of consent.
223609267|NCT04397744|BEHAVIORAL|Unidas por Vida y Salud prevention program|The Unidas por Vida y Salud (United for Life and Health) prevention program is led by the El Paso Cancer and Chronic Disease Consortium (CCDC), the only Breast and Cervical Cancer Services (BCCS) provider in El Paso. This prevention program will use a well-integrated network of community organizations and health service providers to connect medically underserved women to services. To reach the most underserved women and increase preventive cancer screening and timely follow-up, diagnosis, and treatment, the multi-method approach uses evidence-based strategies, including face-to-face educational sessions led by promotoras (community health workers), client reminders, and provision of community-based navigation services to affordable and free screening services. The program also includes clinic-based navigation for those requiring diagnostics or treatment delivered by trained nurses and case workers.
223609268|NCT05434390|BEHAVIORAL|Estoy PrEParado/ I am PrEPared intervention|Participants will receive an Information, Motivation, and Behavioral skills model PrEP intervention tailored for mixed immigrant status Latino men who have sex with men
223609269|NCT05434390|BEHAVIORAL|Usual Care|Participants will be offered PrEP navigation services as part of usual care at the study site.
223609270|NCT03786536|DEVICE|MediSieve Magnetic Haemofiltration System|The MediSieve Magnetic Haemofiltration System is a medical device intended for use in extracorporeal clinical procedures to remove magnetic targets (e.g. malaria infected red blood cells) from a patient's bloodstream.
223609271|NCT04249817|OTHER|Video Conferencing with Exteneded Role Practitioner (VC-ERP)|Participant goes to Ontario Telemedicine site for follow-up. At site, participant will get a physical assessment by an extended role practitioner and then will connect to their rheumatologist by videoconferencing for completion of follow-up.
223609272|NCT00060632|DRUG|ridaforolimus|"Administered intravenously once weekly for 4 weeks (1 cycle).~In the absence of disease progression or unacceptable toxicity, patients could continue to receive additional cycles."
223609273|NCT06440941|OTHER|chatbot-based mindfulness-based stress reduction|During the intervention, participants will be involved in a developed chatbot and undergo a single-item assessment to verify the stability of their mental states for subsequent mindfulness-based stress reduction (MBSR) sessions, deemed stable if rated as excellent, very good, or good; They will then engage in conversations with the chatbot, responding to prompts like What is the most recent thing that made you happy? to foster interactive communication and relaxation. Subsequently, participants need to follow guided MBSR sessions and are encouraged to interact with the chatbot for at least one hour daily; all interactions will be monitored and recorded. After eight weeks, a post-intervention assessment will be conducted, followed by pre-post statistical analyses. A total of ten participants with the most and least significant changes in depression levels will be selected for an open-ended questionnaire.
223609274|NCT04402879|PROCEDURE|Prone Positioning (PP)|"The intervention for this study is PP. Patients at participating sites allocated to the intervention arm of the study will be prompted by ward nurses and respiratory therapists to assume and maintain a prone position for varying durations, four times per day until the occurrence of a primary outcome event or hospital discharge.~The target duration (dose) of PP is \> 8 hours per day for up to 60 days, or until oxygen requirements are \< 2 L per minute or \< 2 L per minute above baseline home oxygen requirements."
223609275|NCT03101501|DRUG|Mitomycin c|Low dose mitomycin C at a concentration of 0.02% will be applied a duration of 10 to 30 seconds at the time of the surgical procedure.
223609276|NCT03101501|DEVICE|Raindrop Near Vision Inlay|Implanted to improve near vision in Presbyopic or Pseudophakic subjects.
223609277|NCT02794766|DRUG|Inulin+SS|Experimental treatment: A gum of inulin 1g plus Streptococcus salivarius 1 billion CFU per oral each 12 hours for 10 days
223609278|NCT02794766|DRUG|S salivarius|Active comparator: A gum of Streptococcus salivarius 1 billion CFU per oral each 12 hours for 10 days
223609279|NCT02794766|DRUG|Placebo|Placebo 1 gum each 12 hours for 10 days
223609280|NCT03038295|DRUG|Propranolol|Oral propranolol:0.25mg/kg daily(every 24 hours)；Eye drop propranolol(0.2%):3 microdrops,in each eye, four times daily (every 6 hours) .Both administration routes will be discontinued until retinal vascularization will be completed, but no more than 90 days.The study will be discontinued immediately in the presence of serious adverse effects attributable to the pharmacological actions of propranolol (severe hypotension, bradycardia or bronchospasm).In case of surgery or induction of anesthesia during the administration of propranolol, the drug should be discontinued at least 24 hours before surgery.In cases of severe hypotension or bradycardia may be administered one or more of the following drugs:Atropine.Isoproterenol hydrochloride (isoprenaline).Terlipressin.Glucagon In case of severe bronchospasm may be used salbutamol aerosol or salbutamol + ipratropium bromide. Betamethasone could be used for aerosol or systemic (intravenous or intramuscular).
223609281|NCT03038295|DRUG|placebo|Oral/eye drop placebo will be taken in enrolled newborns. Other treatment will follow the standard treatment schedule of Early Treatment For Retinopathy Of Prematurity Cooperative Group.
223609282|NCT00829842|OTHER|oral hygiene|oral hygiene with 0.12% chlorexidine
223609283|NCT00829842|OTHER|placebo|oral hygiene placebo
223609284|NCT03071887|BEHAVIORAL|Relaxation Response Resiliency Program (3RP)|The 3RP blends stress management principles, cognitive behavioral therapy, and positive psychology. The 3RP focuses on 3 major areas: (1) eliciting the relaxation response; (2) increasing stress awareness; and (3) promoting adaptive strategies. The 3RP intervention currently consists of eight, 90-minute weekly group sessions. The investigators plan to adapt the intervention to address common concerns for older, HIV-infected women, including: stress of managing a chronic long-term, life threatening illness; additional medical comorbidities; pain and fatigue; stigma and social isolation; depression and anxiety; and sexuality concerns.
223609285|NCT02073682|DRUG|Edoxaban|After the 5 day treatment with LMWH, patients receive edoxaban 60 mg once daily (QD) as 2 × 30 mg tablets (or 1 x 30 mg tablet QD for patients requiring dose adjustment) for the remainder of the treatment period.
223609286|NCT02073682|DRUG|Dalteparin|Dalteparin was administered via subcutaneous injection at a dose of 200 IU/kg (maximum daily dose 18,000 IU) for 30 days, and at a dose of 150 IU/kg from Day 31 to the end of treatment.
223755776|NCT06832137|OTHER|CMTS4520 (dietary fiber probiotics)|CMTS4520 is a synbiotic formulation containing a standardized ratio of plant-derived prebiotics and clinically validated probiotic strains. Participants will receive 2 weeks of CMTS4520 daily for chronic constipation.
223755777|NCT06832137|OTHER|Placebo|Capsules with matching volume and consistent appearance to CMTS4520.
223755778|NCT06904599|DRUG|Human chorionic gonadotropin (hCG)|2500 IU intramuscular on days 1, 3, and 5 of the protocol. Patients who have at least a partial response by day 7 will receive 3 weekly doses for an additional 4 weeks.
223755779|NCT06904599|DRUG|Prednisone|Oral prednisone 1 mg/kg/day for 14 days
223755780|NCT06904599|DRUG|Dexamethasone|IV dexamethasone 0.15 mg/kg/day for 14 days
223755781|NCT04009655|OTHER|music|music selected by musician
224200876|NCT02037594|BEHAVIORAL|Standard of Care Adherence Support (Active Control)|Standard of care information and instruction about PrEP adherence.
223755782|NCT02917031|DRUG|Saxagliptin|5 mg or 2.5 mg, plain, yellow, biconvex, round, film-coated tablet
224200877|NCT00554268|DRUG|PBI-05204|Starting dose = 0.0083 mg/kg/day by mouth (PO) x 3 weeks per cycle
224200878|NCT01067729|DEVICE|AWBAT Wound Dressing|
223755783|NCT02917031|DRUG|Sitagliptin|50 mg or 100 mg, gray capsule
223609287|NCT02073682|DRUG|Low molecular weight heparin|Therapeutic doses of subcutaneous LMWH were administered for at least 5 days (to patients in the edoxaban group); this 5-day period may have included the pre-randomization LMWH (if applicable). The choice of parenteral LMWH was up to the treating physician.
223609288|NCT04841616|PROCEDURE|Endoscopic Ultrasound -Guided Fine Needle Biopsy|Patients will undergo EUS FNB with the 22-gauge FNB needle (Acquire®, Boston Scientific Natick, MA). After each pass, the needle is removed and the stylet will be introduced into the needle to extrude any aspirated material on a glass slide for inspection of the presence of a macroscopic visible core (MVC). The total length of the MVC will be measured before placement into a formalin bottle. EUS-FNB is completed if the obtained MVC is longer than 4mm and deemed adequate by endoscopist. If the obtained MVC is \< 4mm, the procedure is repeated until a MVC of ≥ 4mm is obtained and deemed adequate by endoscopist. A maximum of 7 passes is allowed.
223609289|NCT04841616|PROCEDURE|Contrast-Enhanced Harmonic Endoscopic Ultrasound|After initial evaluation, 2.5ml of second-generation contrast media, SonoVueTM (Bracco, Ceriano Laghetto, Italy), will be injected. After infusion, the point of puncture will be determined when the parenchyma of the pancreas was enhanced. The contrast-enhanced area was identified and then the biopsy was directed toward that area, while avoiding unenhanced (i.e. necrotic) areas and not changing the target lesion. Rest of the procedure is identical with that in conventional EUS arm.
223609290|NCT06144879|PROCEDURE|double rods without dual-headed screw|adult patients with severe spinal deformity who underwent PSO osteotomy and posterior spinal corrective surgery with traditional double rods (No dual-headed screw used)
223609291|NCT06144879|PROCEDURE|three rods with one dual-headed screw|adult patients with severe spinal deformity who underwent PSO osteotomy and posterior spinal corrective surgery with three rods (one dual-headed screw used in unilateral side)
223609292|NCT06144879|PROCEDURE|four rods with two dual-headed screw|adult patients with severe spinal deformity who underwent PSO osteotomy and posterior spinal corrective surgery with four rods (two dual-headed screw used in bilateral side)
223755784|NCT02917031|DRUG|Placebo to match saxagliptin|2.5 mg or 5 mg, plain, yellow, biconvex, round, film-coated tablet
223755785|NCT02917031|DRUG|Placebo to match sitagliptin|50 mg or 100 mg, gray capsule
223755786|NCT07099170|BEHAVIORAL|Brochure-Based Pelvic Floor Muscle Training|Brochure-based pelvic floor muscle training will be conducted by providing participants with a brochure containing information about the anatomy, functions, and importance of the pelvic floor, as well as instructions on how to contract the pelvic floor muscles. All educational content will be delivered solely through the brochure, and no additional verbal or written information will be provided to the participants. The brochure will include detailed explanations of pelvic floor muscle contractions and imagery techniques. Participants will be given 30 minutes to review the brochure and apply the training independently.
224200879|NCT01067729|DEVICE|AWBAT™, Biobrane®|Comparison of burn dressings on randomized body sites using patient as own control
224200880|NCT03856502|DRUG|8 mg of dexamethasone|Effect of intrathecally administered dexamethasone in spinal anaesthesia for surgical correction of the hip fracture.
224200881|NCT03856502|DRUG|12,5 mg of 0,5 % of levobupivacaine|Local anaesthetic standardly used in spinal anaesthesia for surgical correction of the hip fracture by the particular hospital's protocol.
224200882|NCT04139642|DEVICE|SimpleSway|"During the 9-month period each practitioner who receives the balance + weight device is asked to provide anonymous feedback via a kiosk regarding if the balance data influenced clinical decision making after every patient. The kiosk has four marked buttons indicating a 4-point Likert Scale, so the practitioner just presses one of the four buttons to indicate their agreement with the statement, The balance measurement influenced my clinical decision making with this patient. After 9 months, the devices are switched so that every practitioner who had a weight only device receives balance + weight device and vice versa. After the second 9-month period concludes all devices will be retrieved by study personnel, and participants will be asked to complete surveys regarding their experience and attend group feedback sessions regarding their experiences."
224200883|NCT00957840|PROCEDURE|NIRS, aEEG, and CSF concentration of biomarkers|NIRS and aEEg will be done twice weekly, and CSF will be analyzed with each reservoir tap
224200884|NCT05319652|BEHAVIORAL|Pain self-management program|Each week for eight weeks, participants are invited to complete self-directed lessons on particular themes. The program covers goal setting, stress management through relaxation, breathing and mindfulness, pacing, physical activity, thoughts and emotions, sleep, nutrition, flare-up management, and planning. Through pain education, positive testimonials from individuals with CNCP applying the suggested strategies, reflective activities, goal setting and monitoring, and the gradual development of a personal plan, the program supports self-efficacy building to manage CNCP.
224200885|NCT01708252|DEVICE|Ulthera System Treatment|Focused ultrasound energy delivered below the surface of the skin
224200886|NCT05580432|BEHAVIORAL|Parenting with Positive Behavior Interventions|"Parenting with Positive Behavior Interventions is a 5 month packaged intervention. The curriculum and each element of the training and coaching program is described in detail below.~Each month, participants will participate in the following five activities:~1. Didactic Training: Participants will view a presentation~2. Workbook/Homework: Participants will complete a guided worksheet~3. Coaching Meeting - Planning: Participants will meet with a coach who is an expert in autism and behavior~4. Coaching - Observation/ Feedback: The coach will observe parent implementing the strategy, then provide feedback and direction regarding use of technique~5. Virtual Parent Community of Support Meeting: Attend parent led community support meeting to network, share experiences and information, and exchange ideas"
224200887|NCT02912507|DEVICE|Cutera enlighten laser|high-powered, Q-switched 670nm Picosecond laser system indicated for tattoo removal
224200888|NCT02912507|DEVICE|CynoSure PicoSure 755nm laser|high-powered, Q-switched Alexandrite system that delivers laser energy in the 755 nm wavelength and has received FDA clearance (K133364) for tattoo and benign pigmented lesion removal.
224200889|NCT01177865|OTHER|informational intervention|
224200890|NCT01177865|OTHER|questionnaire administration|
224200891|NCT03250611|PROCEDURE|Occipital Condyle Screw|Occipito-Cervical Screw-Rod Fixation Technique
224200892|NCT03414099|DRUG|Ketum|Ketum (Mitragyna speciosa) is an indigenous plant of Southeast Asia reported to have medicinal value in traditional culture
224200893|NCT03414099|DRUG|Placebo|Placebo drink matched for taste and appereance
223609293|NCT05193162|OTHER|No any intervention|have no any intervention
223609294|NCT00181766|DRUG|Strattera (atomoxetine)|Up to maximum of 1.2mg atomoxetine/kg PO QD, or 120 mg atomoxetine PO QD (whichever is less).
223609295|NCT01086774|OTHER|Systane Ultra Lubricant Eye Drops|Single drop in both eyes
223609296|NCT00270309|BEHAVIORAL|Self-management|
223609297|NCT00987311|DIETARY_SUPPLEMENT|1- Dairy drink containing probiotics A|1- Dairy drink containing probiotics A
223609298|NCT00987311|DIETARY_SUPPLEMENT|2- Dairy drink containing probiotics B|2- Dairy drink containing probiotics B
223609299|NCT00987311|DIETARY_SUPPLEMENT|3- Dairy drink without probiotics (control)|3- Dairy drink without probiotics (control)
223609300|NCT03353480|DRUG|Azithromycin Tablet manufactured in China|250 mg Azithromycin Tablet manufactured in China
223609301|NCT03353480|DRUG|Azithromycin Tablet manufactured in US|250 mg Azithromycin Tablet manufactured in US
223609302|NCT02742220|OTHER|Isometric Handgrip Training Group|Intervention period will last eight weeks. Experimental group will perform three sessions per week of home-based handgrip exercise. The exercise protocol will consist of four unilateral sets (dominant arm) with two minutes of isometric contraction, with 30% of maximum voluntary contraction, and four minutes of interval between sets. Patients will receive a diary to record the sessions and report difficulties during the training. Visits will be scheduled at weeks 1 and 5 to provide feedback to individuals, discuss possible problems during the training and adjust the intensity of the exercise. In addition the patients be recommended to increase daily physical activity levels, and weekly, there will be phone contacts with the patients to reinforce the exercise recommendations.
223609303|NCT02742220|OTHER|Control Group|Intervention period will last eight weeks. Patients will be recommended to increase daily physical activity levels, and weekly, there will be phone contacts to reinforce the recommendations.
223609304|NCT00402870|DEVICE|ProSeal LMA|ProSeal LMA vs Tracheal Tube
223609305|NCT00402870|DEVICE|ProSeal LMA, Tracheal Tube|ProSeal LMA vs Tracheal Tube
223609306|NCT01968330|BEHAVIORAL|Go!®to sleep|
223609307|NCT05498168|GENETIC|ratio of predicted neoantigens|10 ml of whole blood is collected from each patient prior surgery Fresh tumor tissue samples (\~ 1cm3 ) are collected during surgery
223609308|NCT00855816|BEHAVIORAL|Breathing training|relaxation training
223609309|NCT03393494|DRUG|Adapalene and Benzoyl Peroxide Topical Gel|Test product
223609310|NCT03393494|DRUG|Epiduo Topical Product|RLD product
223609311|NCT03393494|DRUG|Placebo|Placebo gel
223609312|NCT04496856|DIETARY_SUPPLEMENT|Whey protein and Collagen supplementation|Participants of each arm will consume 30 g daily of the assigned protein supplementation for 30 days. The protein supplementation will be given as protein powder which the participants will have to dissolve in cold drinks. During the intervention fat free mass, muscle strength, functional ability, wound healing and life quality of the participants will be monitored.
223609313|NCT00536237|DRUG|Comparator: niacin / Duration of Treatment: 17 Weeks|
223609314|NCT00536237|DRUG|MK0524A, niacin (+) laropiprant / Duration of Treatment: 17 Weeks|
223609315|NCT00536237|DRUG|Comparator: placebo (unspecified) / Duration of Treatment: 17 Weeks|
223609316|NCT03530943|BEHAVIORAL|Animal Assisted Activities|Students interact with canines in small group settings under the supervision of their handlers during structured and semi-structured activities designed to strengthen physiological, emotion and behavioral regulation
223609317|NCT03530943|BEHAVIORAL|Academic Stress Management tools|Evidence-based workshops focus on evidence-based content and activities designed to enhance academic stress management knowledge and skills, motivation and learning, adaptive sleep, and study and test-taking behavior through strengthening physiological, emotion and behavioral regulation
223609318|NCT03222687|DRUG|tacrolimus|Immunosuppressive therapy included tacrolimus and prednisone. Tacrolimus treatment was initiated at a dosage of 0.05-0.1 mg/kg/day twice daily and used for at least 6 month. Prednisone was started at 2 mg/kg/day and tapered off gradually after initiation of treatment.
223609319|NCT03222687|DRUG|prednisone|Immunosuppressive therapy included tacrolimus and prednisone. Tacrolimus treatment was initiated at a dosage of 0.05-0.1 mg/kg/day twice daily and used for at least 6 month. Prednisone was started at 2 mg/kg/day and tapered off gradually after initiation of treatment.
223609320|NCT00002404|DRUG|Valacyclovir hydrochloride|
223609321|NCT02096016|PROCEDURE|Human Papilloma Virus test from the vaginal vault|Surveillance after surgical treatment of early stage cervical cancer
223609322|NCT01965704|DRUG|Ondansetron|Pregnant women may receive a second dose of IV ondansetron if they have not delivered within 4 hours of receiving the IV study medication. 50% of the 90 mother/baby pairs will receive ondansetron; the baby will always get the same study medication as the mother.
223609323|NCT01965704|DRUG|Placebo|All doses of placebo, whether IV or oral, will mimic the same volume as the ondansetron group to maintain the blind. Pregnant women may receive a second dose of IV placebo if they have not delivered within 4 hours of being given the IV study medication. 50% of the 90 mother/baby pairs will receive placebo; the baby will always receive the same study medication as the mother.
223609324|NCT01526213|DRUG|Fexofenadine|This randomized, open-label, single-dose, 3-way crossover study in healthy volunteers will be conducted in the CTRC. Once subjects are identified as eligible to participate, based on their screening evaluation and according to inclusion/exclusion criteria, they will undergo 3 phases. By randomized crossover design, the subject will receive fexofenadine with water, grapefruit juice, or furanocoumarin-free grapefruit juice.
223609325|NCT00061893|DRUG|celecoxib|Given orally, Celecoxib 250 mg/m2 PO BID (500mg/m2/day) from Day 1 of Cycle 1 through Day 21 of Cycle 14. The dose should be rounded off to the nearest 100 mg. If PK studies are being done, Celecoxib should be given 24 hours prior to the other drugs for Cycle 1 only. \[Celecoxib may be interrupted for up to 7 days around the time of surgical procedures.\] .
223609326|NCT00061893|DRUG|cyclophosphamide|Given IV, 1200 mg/m2 IV infusion over 1 hour with MESNA uroprotection, on Day 1. For children \< 1 year treat with 50% doses calculated on a m2 basis. If tolerated (no delay in administration of the next cycle due to delayed count recovery or delayed resolution of other toxicities and no serious toxicities), consider increasing to 75% and then to 100% of the calculated full dose.
223609327|NCT00061893|DRUG|doxorubicin hydrochloride|Given IV, Doxorubicin 75 mg/ m2 /course continuous IV infusion over 48 hours, beginning Day 1. Note: The total doxorubicin dose per cycle is 75 mg/ m2, which will be given as 37.5 mg/m2/day x 2 days. Doxorubicin may be given as a continuous infusion or brief infusion.
223755787|NCT07099170|BEHAVIORAL|Verbal Instruction-Based Pelvic Floor Muscle Training|Verbal instruction-based pelvic floor muscle training involves providing participants with information about the anatomy, functions, and importance of the pelvic floor, as well as instruction on how to correctly contract the pelvic floor muscles. All explanations will be delivered verbally, and no additional equipment or visual aids will be used. During the training, imagery techniques based on verbal cues will be employed. Commonly used metaphors such as a hammock, a faucet, an elevator, or a ship will be utilized to facilitate imagery. Participants will be asked to focus on their pelvic floor and imagine the contractions, and they will be informed about the potential effects of these contractions during the session.
223755788|NCT07099170|BEHAVIORAL|Visual-Aided Pelvic Floor Muscle Training|Visual-aided pelvic floor muscle training includes providing participants with information about the anatomy, functions, and importance of the pelvic floor, as well as training on how to properly contract the pelvic floor muscles. The training will be conducted using anatomical models, visual materials, and videos. Following the explanation of pelvic floor anatomy with models and visual aids, the function and importance of the pelvic floor will be presented through video demonstrations. During the session, the pelvic floor will be visually represented using common metaphors such as a hammock, a faucet, an elevator, or a ship, and these visuals will support the use of imagery techniques. Participants will be asked to focus on their pelvic floor and imagine the contractions, and they will be provided with information about the expected effects of the contractions.
223609328|NCT00061893|DRUG|etoposide|Given IV, Vincristine 2 mg/m2 IV push, on Day 1. Maximum dose 2 mg. For children \< 1 year treat with 50% doses calculated on a m2 basis. If tolerated (no delay in administration of the next cycle due to delayed count recovery or delayed resolution of other toxicities and no serious toxicities), consider increasing to 75% and then to 100% of the calculated full dose.
223609329|NCT00061893|DRUG|ifosfamide|Given IV,Ifosfamide 1800 mg/m2 /day IV infusion over 1 hour, Days 1-5 of each cycle. (9,000 mg/m2 max total dose per cycle). Prehydrate for 6 hours, 1,000 ml/m2 total volume (165 ml/m2/hour for 6 hours). For children \< 1 year treat with 50% doses calculated on a m2 basis. If tolerated (no delay in administration of the next cycle due to delayed count recovery or delayed resolution of other toxicities and no serious toxicities), consider increasing to 75% and then to 100% of the calculated full dose.
223609330|NCT00061893|DRUG|vinblastine sulfate|Given IV, Vinblastine 1 mg/m2/d IV push three times per week beginning Day 1 of Cycle 1 and continuing through Day 21 of Cycle 14. In weeks during which vincristine is given, hold one dose of vinblastine and administer only 2 doses of vinblastine during that week. If vinblastine is due the same day as vincristine, hold that dose of vinblastine. \[Vinblastine may be interrupted for up to 7 days around the time of surgical procedures.\]
223609331|NCT00061893|DRUG|vincristine sulfate|Given IV, Vincristine 2 mg/m2 IV push, on Day 1. Maximum dose 2 mg. For children \< 1 year treat with 50% doses calculated on a m2 basis. If tolerated (no delay in administration of the next cycle due to delayed count recovery or delayed resolution of other toxicities and no serious toxicities), consider increasing to 75% and then to 100% of the calculated full dose.
223609332|NCT00061893|PROCEDURE|conventional surgery|Patients who respond to induction chemotherapy undergo surgery on week 13. Patients who have inadequate margins after surgery undergo radiotherapy beginning on week 15. (see Detailed Description for frequency of administration and groups evaluated)
223609333|NCT00061893|RADIATION|radiation therapy|Patients with unresectable lesions undergo radiotherapy 5 days a week for approximately 6 weeks beginning on week 13. (see Detailed Description for frequency of administration and groups evaluated)
223609334|NCT00061893|DRUG|MESNA|The total daily MESNA dose is equal to at least 60% of the daily cyclophosphamide or ifosfamide dose, or by continuous infusion of the 60% dose. MESNA continuous infusion should be started at the same time as the cyclophosphamide/ifosfamide and be completed no sooner than 8 hours after the end of the cyclophosphamide or ifosfamide infusion. The oral dose of MESNA is 2x the IV dose. Patients able to tolerate oral MESNA may receive the final dose by mouth at 40% of the oxazaphosphorine (cyclophosphamide or ifosfamide) dose. The dose should be given two hours earlier than the IV dose would be given. Additionally, if the patient vomits within two hours after the oral dose, the dose should be repeated or IV MESNA given.
223609335|NCT00061893|DRUG|Filgrastim|G-CSF (Filgrastim) 5 micrograms/kg/day subcutaneously beginning 24 to 48 hours after the last dose of chemotherapy, and continuing until the absolute neutrophil count is 2,000/µL or greater after nadir.
223609336|NCT00687804|DRUG|Ranibizumab|0.5 mg ranibizumab administered by intravitreal injection.
223609337|NCT00687804|PROCEDURE|Laser|Laser photocoagulation treatment
223609338|NCT00687804|PROCEDURE|Sham laser|Sham to laser procedure.
223609339|NCT00687804|DRUG|Sham to ranibizumab|Sham to ranibizumab administered as an intravitreal injection.
223755789|NCT07099170|BEHAVIORAL|External Palpation-Aided Pelvic Floor Muscle Training|External Palpation-Aided Pelvic Floor Muscle Training This training involves educating participants on the pelvic floor's anatomy, function, and importance, along with instructions on proper muscle contraction. After an educational session using anatomical models, visuals, and videos, external palpation is used to guide correct muscle activation. In a hook-lying position and fully clothed, participants receive light, transverse pressure from a physiotherapist on key pelvic floor muscles (ischiocavernosus, bulbospongiosus/bulbocavernosus, or perineum). The therapist observes real-time muscle response, provides feedback, and offers verbal cues. Imagery techniques (e.g., hammock, faucet, elevator, ship) may be used to support motor learning and awareness.
223755790|NCT07091279|DRUG|Propranolol|Propranolol, oral, titrated in weekly increments from 10 mg TID to a maximum of 200 mg TID (total daily dose: 30 mg to 600 mg at 8 weeks), based on tolerability. Participants will continue at the highest tolerated dose for additional 4 weeks. Target doses: 10 mg, 40 mg, 80 mg, 120 mg, 160 mg, 200 mg TID.
223755791|NCT07091279|DRUG|Placebo|Placebo for Propranolol
223755792|NCT07099911|BEHAVIORAL|NMES|Acute bout of neuromuscular electrical stimulation during a 3-h OGTT.
223755793|NCT07099911|BEHAVIORAL|Sham (No Treatment)|Sham stimulation during a 3-h OGTT.
223755794|NCT06025513|DEVICE|Embrace Patch|Tension offloading skin patch
223755795|NCT07104825|PROCEDURE|Intraoperative autonomic neural blockade (ANB)|Local anesthetic block of the neurovascular tissue along the lesser curve of the stomach and celiac trunk during sleeve gastrectomy or gastric bypass surgery.
223755796|NCT07104825|PROCEDURE|Laparoscopic Standard of Care Abdominal Wall Block|Administration of local anesthetic to abdominal incisions (standard of care)
223755797|NCT07109830|DIAGNOSTIC_TEST|Cognitive assessment|Cognitive assessment using BCI-game
223755798|NCT07109830|DIAGNOSTIC_TEST|NEPSY-II|Standardized cognitive assessment
223755799|NCT07109284|BIOLOGICAL|Sacituzumab tirumotecan|Sacituzumab tirumotecan 5 mg/kg, intravenously (iv), Q2W
223755800|NCT07109284|BIOLOGICAL|Tagitanlimab|Tagitanlimab 900mg, intravenously (iv), Q2W
223755801|NCT07101471|DRUG|Tofacitinib|Tofacitinib with a suggested dose of 5 mg twice daily with or without adjuvant prednisolone.
223755802|NCT07108738|PROCEDURE|Pulpotomy|Teeth will be anesthetized then Rubber dam and high suction will be used in pulpotomy procedure. Cavity outline will be performed by sterile #330 high speed bur using water spray. Caries will be removed by large spoon excavator. When pulpal exposure occurred, the roof of pulp chamber will be removed by low speed round bur. Haemostasis will be obtained by applying pressure with a moist cotton pellet with saline. Then the test materials will be applied. after that, pulp stumps of all molars in each group will be dressed using Intermediate restorative material, then the tooth will be restored with a preformed stainless steel crown
223755803|NCT07108738|PROCEDURE|Radiation|Radiographic evaluation will be performed immediately after teeth restoration (baseline radiograph), then after three, six, and twelve months for the furcation radiolucency area and bone radiodensity. A photo-simulated phosphorus plate sensor was used to take direct standardized digital radiographs. The parallel periapical technique was obtained by Rinn, which is attached to the X-ray tube with its arm fastened to the film holder that contained a coated PSP (photo-stimulated phosphorus plate). To ensure standardization during radiographic film retakes, condensation rubber base impression material will be positioned on the outside of the film holder, and the child is told to bite on it while the material is set. The sensor wil exposed to an X-ray machine (Planmeca ProX, Helsinki, Finland) with a central ray perpendicular to the sensor at 70 kVp, 6 mA, and 0.8 s. Radio-densitometric and radiometric analysis of the radiographs will be performed by RadiAnt software.
223755804|NCT07108881|DRUG|C|isotonic saline solution infusion (fluid preloading) to achieve correction of hypovolemia before spinal anesthesia using cardiac ultrasoud guidance by measurment of VTI variation after a 250ml saline solution loading, with a maximum of 4 challenges, until hypovolemia complete correction
223755805|NCT07108881|DRUG|T|"isotonic saline solution coloading after spinal anesthesia associated with recsue boluses of Ephedrine would be the standard of care in this arm. No correction of hypovolemia is done before spinal anesthesia. parturients receive a cristalloid coloading with saline isotonic solution with rescue boluses of ephedrine if hypotesion happens after spinal anesthesia"
223755806|NCT07109674|DEVICE|adjustable compression device (type circaid® reduction kit, Medi-Bayreuth)|inelastic compression during intensive phase of physical therapy
223755807|NCT07109674|DEVICE|Comparison of inelastic compression efficiency|The effect of compression on volume reduction, physical functioning, disease-related symptoms and comfort
223755808|NCT07108647|OTHER|Progressive Hip Strengthening Program|"This 12-week, in-season exercise intervention is designed for athletes with FAI syndrome and consists of three progressive phases.~Phase 1 (Weeks 1-4): Focus on neuromuscular re-education and motor control using low-load exercises to improve hip and core activation, alignment, and stability.~Phase 2 (Weeks 5-8): Targeted strengthening with increased load and movement complexity, emphasizing single-leg control, endurance, and pelvic stability.~Phase 3 (Weeks 9-12): Integration of dynamic control, proprioception, and sport-specific movement patterns to support return to performance.~Exercises target gluteus medius, gluteus maximus, core musculature, and functional movement systems. Participants complete the program \>=3 times per week. Weekly questionnaires will monitor symptoms, adherence, and other management (e.g., physiotherapy)."
223609340|NCT02870153|DRUG|SOX|Oxaliplatin 130mg/m2 IV on D1 every 21 days and S-1 80mg/m2/day PO \[BSA \<1.25 40mg bid (total 80mg/day); BSA ≥1.25 - \<1.5 50mg bid (total 100mg/day); BSA ≥1.5 60mg bid (total 120mg/day)\], divided by two on D1-14 every 21 days
223609341|NCT02870153|DRUG|XELOX|Oxaliplatin 130mg/m2 IV on D1 every 21 days and Capecitabine 2000mg/m2/day PO, divided by two on D1-14 every 21 days
223609342|NCT05377424|DRUG|Consume 20mg of istradefylline|Consume a single 20 mg istradefylline tablet
223609343|NCT05377424|OTHER|Low Oxygen therapy|Breathing short periods of low oxygen, consisting of 15 episodes of 1 minute of breathing 10% oxygen, with 2 minutes of breathing 21% oxygen. 45 minutes total.
223609344|NCT05377424|DRUG|Placebo counterpart to the istradefylline drug|Consume a single microcrystalline cellulose
223609345|NCT05377424|OTHER|SHAM counterpart to low oxygen therapy.|Breathing short periods of sham low oxygen, consisting of 15 episodes of 1 minute of breathing 21% oxygen, separated by 2 minutes of breathing 21% oxygen. 45 minutes total.
223609346|NCT04390243|DRUG|Binimetinib|Given PO
223609347|NCT04390243|DRUG|Encorafenib|Given PO
223609348|NCT01769963|OTHER|Research diet|Participants will be provided specially prepared meals to eat at home for three weeks. During the first week, participants will eat foods that have standard amounts of AGEs in them (this is called the control diet). During the second and third weeks, participants will eat the same foods, only they will be prepared in our kitchen in a way that limits the amount of AGEs in them (called the intervention diet).
223609349|NCT01255891|RADIATION|Androgen suppression plus radiation therapy|Adjuvant androgen suppression plus radiation therapy
223609350|NCT04142801|DEVICE|MeMo web application|The patient betwenn 2 consultation could use the application MeMo. MeMo is a web application that can thus be used on any web browser (computer or tablet). On tablet, the application can be installed on home screen to look like a native app, and used offline.
223609351|NCT04142801|OTHER|Control group|the patient have the classical follow up at the memory center (consultation)
223609352|NCT04851912|OTHER|Winterlight Apps|Longitudinal speech recordings
223609353|NCT00004936|DRUG|iodinated contrast dye|
223609354|NCT00004936|PROCEDURE|computed tomography|
223609355|NCT00004936|PROCEDURE|magnetic resonance imaging|
223609356|NCT00004936|RADIATION|gadopentetate dimeglumine|
223609357|NCT05682339|OTHER|Quinine|Quinine, which is a bitter compound, extracted from the bark of the cinchona tree and has been shown in our previous studies to lower blood glucose in doses of 300-600 mg, will be 'active' in this condition.
223609358|NCT05682339|OTHER|L-isoleucine|L-isoleucine, which is a branched-chain amino acid, and one of the building blocks of protein, therefore is part of our daily diet, will be 'active' in this condition.
223609359|NCT05682339|OTHER|Combination of quinine and L-isoleucine|In this condition, both quinine and L-isoleucine will be administered as 'active'.
223755809|NCT07108647|OTHER|Progressive Muscle Relaxation|Participants in the time and attention control group will complete a 12-week, three-phase progressive muscle relaxation (PMR) program based on the Jacobson method. Phase 1 introduces isolated muscle tensing and relaxing to build awareness of muscle tension and promote body-mind connection. Phase 2 focuses on sequential relaxation of muscle groups, enhancing control and reducing stress. Phase 3 transitions to full-body relaxation through guided breathing and visualization techniques. Sessions are practiced 2-3 times per week using audio guides, with weekly check-ins from study staff. Symptom response, adherence, and participant experience are tracked throughout the season.
223609360|NCT05682339|OTHER|Control|"In the condition, where quinine is 'active', control for L-isoleucine (5 ml oraplus and 95 ml saline) will be administered. In the condition, where L-isoleucine will be 'active', control for quinine (10 ml distilled water) will be administered.~Whereas, in a control condition, both for quinine and L-isoleucine, a control solution will be administered."
223609361|NCT04104607|DRUG|CC-1, PSMAxCD3|Infusion of CC-1 over 24 hours for 7 days with possible intra-patient dose-escalation
223609362|NCT04800250|PROCEDURE|Treatment of gingival recessions|Patients will have a surgery for their gingival recessions. They will be enrolled in the split mouth-study. They will have on one side mucogain matrix transplant, an on another side they will have the gold standard procedure
223609363|NCT04572763|DRUG|Copanlisib|Intravenous infusion
223609364|NCT04572763|DRUG|Venetoclax|Tablet taken orally
223609365|NCT06091735|DRUG|OSS|experimental
223609366|NCT06091735|DRUG|OSS+Linzess|experimental
223609367|NCT06091735|DRUG|PEG-Interferon Alfa|Placebo Comparator
223609368|NCT04200092|COMBINATION_PRODUCT|0.5mg AZ-010; placebo|Subject will receive a single inhaled dose (0.5mg) of AZ-010 or matching Staccato Placebo
223609369|NCT04200092|COMBINATION_PRODUCT|1mg AZ-010|Subject will receive a single inhaled dose (1.0 mg) of AZ-010 or matching Staccato Placebo
223609370|NCT04200092|COMBINATION_PRODUCT|3mg AZ-010|Subject will receive a single inhaled dose (3.0 mg) of AZ-010 or matching Staccato Placebo
223609371|NCT04200092|COMBINATION_PRODUCT|AZ-010 1mg|2-period, 2-treatment open-label crossover design
223609372|NCT04200092|DRUG|IV Granisetron 1mg|2-period, 2-treatment open-label crossover design
223609373|NCT04200092|OTHER|Placebo|Participants in Part A, Cohorts 1, 2, and 3, double-blind, randomized, and placebo-controlled study who received placebo.
223609374|NCT03754517|DIAGNOSTIC_TEST|RPR Titer|RPR titer; TPPA/FTA-ABS; Next-Generation Sequencing
223609375|NCT06463262|DIAGNOSTIC_TEST|ctDNA|the effects of neoadjuvant RT, in the form of either proton therapy or SBRT, on the ctDNA
223755810|NCT07108413|BEHAVIORAL|Activ4Brain Program|The Activ4Brain Program consists of 24 sessions, twice a week for 3 months. Participants engage in 50 min exercise sessions of moderate intensity (60-80% of maximal heart rate) including 5 min warm-up, 40 min aerobic exercises, and 5 min cool-down. The warm-up period includes similar body movements as the main part of the exercise and dynamic stretching while the cool down period consists of static stretching. The main part of the exercise session is divided in four blocks. Each block consists of 5 min aerobic exercises and 5 min of cognitive training. Participants are instructed to keep moving, marching in place, while performing the cognitive training tasks to maintain the increased heart rate. Each group class is composed of four participants with as must as possible a narrow age range given the participants' schedule convenience.
223755811|NCT07108413|BEHAVIORAL|Aerobic Exercise Program|The Aerobic Exercise Program consists of 24 sessions, twice a week for 3 months. Participants engage in 50 min exercise sessions of moderate intensity (60-80% of maximal heart rate) including 5 min warm-up, 40 min aerobic exercises, and 5 min cool-down. The warm-up period includes similar body movements as the main part of the exercise and dynamic stretching while the cool down period consists of static stretching. The main part of the exercise session consists of a sequence of four different 5 min blocks of aerobic exercise repeated twice. Each block consists of a combination of three different rhythmic movements. Each group class is composed of four participants.
223755812|NCT07110233|DEVICE|TheraSphere® Yttrium-90 microspheres|Administered intra-arterially
223755813|NCT07110233|OTHER|Health Related Quality of Life Questionnaires (HRQOL)|Surveys administered
223755814|NCT07109986|DRUG|UB-VV410|Treatment with single dose of UB-VV410, intravenous injection at Day 1. Note: Subjects may receive retreatment with UB-VV410 if there are preliminary findings suggesting incomplete improvement and acceptable safety.
223609376|NCT05986214|OTHER|VC-OPTIONS|Participants will be enrolled in the Annie texting VC-OPTIONS protocol
223609377|NCT06848699|DRUG|HLX43 dose 1|HLX43 is an anti-PD-L1 monoclonal antibody conjugated with a novel high potency DNA topoisomerase I (topo I) inhibitor, with a drug-antibody-ratio (DAR) of 8.
223609378|NCT06848699|DRUG|HLX43 dose 2|HLX43 is an anti-PD-L1 monoclonal antibody conjugated with a novel high potency DNA topoisomerase I (topo I) inhibitor, with a drug-antibody-ratio (DAR) of 8.
223609379|NCT06848699|DRUG|HLX43 dose 3|HLX43 is an anti-PD-L1 monoclonal antibody conjugated with a novel high potency DNA topoisomerase I (topo I) inhibitor, with a drug-antibody-ratio (DAR) of 8.
223609380|NCT06848699|DRUG|HLX43 dose 4|HLX43 is an anti-PD-L1 monoclonal antibody conjugated with a novel high potency DNA topoisomerase I (topo I) inhibitor, with a drug-antibody-ratio (DAR) of 8.
223609381|NCT06848699|DRUG|HLX43 dose 5|HLX43 is an anti-PD-L1 monoclonal antibody conjugated with a novel high potency DNA topoisomerase I (topo I) inhibitor, with a drug-antibody-ratio (DAR) of 8.
223609382|NCT06848699|DRUG|Serplulimab|anti-PD-1 humanized monoclonal antibody injection
223609383|NCT00196664|DRUG|Paroxetine|
223609384|NCT06419036|DEVICE|Pneumowave DC|Pneumowave biosensor(s) will be used to collect data from chest +/- movement.
223609385|NCT05671380|BEHAVIORAL|Longitudinal Proactive Outreach (LPO).|All participants will receive personalized invitation materials (in their preferred language) with messages culturally and linguistically tailored to BIPOC communities, guided by the literature on culturally adapting evidence-based interventions. The study team will tailor these resources in collaboration with the CE core. The tailored mailed packet will include an invitation letter and a brochure describing the types of tobacco treatment services available from their health system and from Quit Partner. One week after the written materials are sent, participants assigned to this condition will receive LPO by a MI-trained coach. The MI outreach call protocol will consist of 6 contact attempts over two weeks.The MI outreach call protocol will be repeated at 3, 6, and 9 months for a total of four outreach cycles because participants may not have quit or may have relapsed.
223755815|NCT06008288|DRUG|JAB-21822|800mg, orally QD with 21 days each cycle, treatment till disease progression or intolerable toxicity or withdraw for other reasons
223755816|NCT07109531|DRUG|ASKC202+ Limertinib|ASKC202 orally once per day (QD) combined with Limertinib orally BID for every cycle of 21 days until disease progression or other criteria for treatment discontinuation will be met.
223609386|NCT05671380|BEHAVIORAL|Ask-Advice-Connect (AAC)|Licensed Practical Nurses will be trained to ask all patients if they smoke, document smoking status in the EHR, advise patients to stop smoking, and complete an electronic referral to Quit Partner or the smoking cessation clinic. AAC will be designed to connect participants to Quit Partner Minnesota to receive tobacco cessation counseling. Quit Partner™ is a family of programs available to help Minnesota residents quit commercial tobacco, administered by the Minnesota Department of Health (MDH). Quit Partner programs are provided by National Jewish Health (NJH). Any Minnesota resident can access a free 2-week supply of Nicotine Replacement Therapy (NRT). Uninsured and underinsured residents can access the full Quit Partner programs, including free one-on- one coaching, more NRT, and additional supports. Quit Partner also offers four population- specific programs and calls are available in several languages.
223609387|NCT05262270|DRUG|Extended-Release Naltrexone|XR-NTX (Extended-Release Naltrexone) doses of 380mg (Weeks 0, 3 and 6) via intramuscular (IM) injections in the gluteus.
223755817|NCT07109531|DRUG|Pemetrexed + Cisplatin /Carboplatin|The standard chemotherapy treatment of cisplatin/carboplatin combined with pemetrexed on Day 1of 21 day cycles for 4\~6 cycles (every 3 weeks).
223755818|NCT03087201|DRUG|nabiximols|"starting dose (1 puff): 2.7 mg delta-9-tetrahydrocannabinol (THC) and 2.5 mg cannabidiol (CBD), maximum dose (12 puffs): 32.4 mg THC/30 mg CBD, no target dose is defined~Duration of treatment: 13 weeks"
223609388|NCT05262270|DRUG|Extended Release Buprenorphine|Extended-Release buprenorphine (XR-BUP) two doses of 300mg XR-BUP (Weeks 0, 4) via subcutaneous injections in the abdomen. Option for 100mg at Weeks 3 and 6 (if needed to alleviate side effects).
223609389|NCT05262270|DRUG|Placebo (PLB) Injectable matched to XR-NTX|3 doses of intramuscular injections (Week 0, 3, 6)
223609390|NCT05262270|DRUG|Placebo (PLB) Injectable matched to XR-BUP|2 doses of subcutaneous injections (Week 0, 4)
223609391|NCT03869008|DEVICE|gammaCore Sapphire|"gammaCore SapphireTM (non-invasive vagus nerve stimulator) is intended to provide non-invasive vagus nerve stimulation (nVNS) on the side of the neck. gammaCore provides a mild electrical stimulation to the vagus nerve, which runs through the neck and carries information to the central nervous system.~Subjects will be instructed to use the gammaCore Sapphire to stimulate 2 minutes on each side of the neck, twice a day, every day. The subject controls the intensity level of the electrical stimulation."
223755819|NCT03087201|DRUG|placebo|analogous to experimental intervention
223755820|NCT02283814|DRUG|BIA 2-093|
223755821|NCT02283814|DRUG|Topamax|
223755822|NCT04633408|BEHAVIORAL|STAR-C Virtual Training and Follow-up (STAR-VTF)|STAR-C Virtual Training and Follow-up (STAR-VTF) is adapted from an evidence-based, in-person program that trains family caregivers to manage BPSD (behavioral and psychological symptoms of dementia)
223755823|NCT03722017|OTHER|Deprescribing intervention|"In addition to a medication history, a study Pharmacist or Nurse Practitioner will review the reconciled total enrollment medication list. The following information will be ascertained for each medication: (1) Medication Indication; and, (2) Deprescribing rationale: Rationales for deprescribing (i.e., stopping or reducing dose) will be assessed for each medication.~Deprescribing Recommendations: For each medication recommended for deprescribing, the deprescribing action will be specified as: (1) Stop prior to hospital discharge without need for monitoring; (2) Stop prior to hospital discharge with symptoms/physiologic monitoring; (3) Stop at specified time point following hospital discharge; (4) Reduce over time with monitoring until medication is stopped; (5) Reduce to lower dose without need for monitoring; (6) Reduce to lower dose with symptoms/physiologic monitoring."
223755824|NCT06442137|DRUG|Chazhu Xiaozhi decoction|Below is the composition of Chazhu Xiaozhi decoction: Camellia Sinensis Radix 15g, Atractylodis Rhizoma 15g, Herba Gynostemmatis Pentaphylli 15g, Ilicis Cornutae Folium 15g, Alismatis Rhizoma 9g, Nelumbinis Folium 6g, Crataegi Fructus 6g, Polygoni Orientalis Fructus 3g.
223755825|NCT06442137|DRUG|Control placebo|The control placebo is a ten-fold dilution of the Chazhu Xiaozhi decoction, supplemented with colorants and bittering agents to mimic the appearance and color of the treatment drug.
223508931|NCT06734026|BEHAVIORAL|Cafe Therapy|Participants will be volunteer workers for two hours per day, three days per week for 6-8 weeks, alongside a trained researcher. Participants will complete at least 18 sessions of training within the time frame. Participants will run the Café with supervision from a researcher, serving customers prepackaged food and drinks per our protocol, along with guidance and direction from a therapist, once a week. Participants will be responsible for interacting with customers and arranging supplies. On a weekly basis, participants will be asked how they feel (for example tired, stressed, overwhelmed, etc) before and after their session and to rate how well they performed in the café.
223755826|NCT05169658|BIOLOGICAL|Mosunetuzumab|Given SC
223755827|NCT05169658|BIOLOGICAL|Obinutuzumab|Given IV
223755828|NCT05169658|DRUG|Polatuzumab Vedotin|Given IV
223755829|NCT05169658|PROCEDURE|FDG-Positron Emission Tomography|Undergo FDG-PET and FDG-PET/CT
223755830|NCT05169658|PROCEDURE|Computed Tomography|Undergo CT and FDG-PET/CT
223755831|NCT05169658|PROCEDURE|Positron Emission Tomography|Undergo PET/CT and FDG-PET/CT
223755832|NCT05169658|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
223755833|NCT05169658|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
223755834|NCT05169658|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223755835|NCT06338345|DIAGNOSTIC_TEST|Therapeutic drug monitoring of beta-lactam|During the 24 first hours after inclusion, 5 blood samples will be collected to mesure plasmatic concentrations of the studied beta-lactam, of creatinin and of albumin
224200894|NCT06212609|OTHER|transcranial electrical stimulation therapy|new procedure of non-invasive, individualized and optimized transcranial electrical stimulation therapy in the management of pharmaco-resistant focal epilepsies
223609392|NCT03869008|DEVICE|Sham Device|The Sham device delivers no electrical stimulations but subjects randomized to the Sham device will received the same instructions to use the Sham device to stimulate 2 minutes on each side of the neck, twice a day, every day for the first 4 weeks after randomization.
223609393|NCT05630001|DRUG|Iptacopan|Treatment with iptacopan at a dose of 200 mg b.i.d. will start on the first day (Day 1) and continue for 24 weeks.
223609394|NCT05683184|DRUG|[11C]OMAR|For each \[11C\]OMAR PET scan, up to 20 mCi of \[11C\]OMAR will be administered.
223609395|NCT05564754|DEVICE|Feedback-controlled temperature device|If core body temperature exceeds 37.7°C a feedback controlled-device will be used and set at 37.5°C.
223609396|NCT05564754|OTHER|High MAP|A MAP target of \>85mmHg will be used. Vasopressors will be titrated to this target during 36h.
223609397|NCT05564754|OTHER|Deep sedation|Deep sedation for at least 36h
223609398|NCT05564754|OTHER|Fever control without a device|Management of fever in the ICU without a device
223755836|NCT05253482|PROCEDURE|wet cupping therapy|Vacuum cups will used on different acupuncture points to perform WCT: The one on the posterior median line, in the depression below the processus spinosus of the 7th cervical vertebra was DU 14 (Dazhui) point; the ones on the back, 3.0 cm lateral to the lower border of the spinous process of the 3rd thoracic vertebra interscapulum region were UB 42 (Pohu) bilateral points; and the ones on the back, 3.0 cm lateral to the lower border of the spinous process of the 7th thoracic vertebra were UB 46 (Geguan) bilateral points and additionally the patient's trigger points which we detect during the examination. There will be 5-7 points in total. The technique used will be triple S (Sucking, Scarification, Sucking) in all sessions.
223755837|NCT03592615|PROCEDURE|cataract surgery|Cataract surgery in this study is only for the purpose of vision correction, not for the treatment of ocular pathology other than cataract, e.g., treatment for lens dislocation. The surgery used in this study should not be combined with other procedures, such as limbal relaxing incision for treating astigmatism.
224200895|NCT01935492|DRUG|Paclitaxel, Bevacizumab, liposomal doxorubicin, Capecitabine|"1. st line:~   * Paclitaxel and bevacizumab: 8 cycles, unless PD or unacceptable toxicity occurs earlier.~  * Bevacizumab until PD or unacceptable toxicity~  * At PD patients will go to the 2nd treatment line.~2. nd line:~   * Non-pegylated liposomal doxorubicin (Myocet®) (or capecitabine): 8 cycles, unless PD or unacceptable toxicity occurs earlier.~  * At PD patients will go to the 3rd treatment line. If possible, it is advised to cross-over from 2nd line non-pegylated liposomal doxorubicin to 3rd line capecitabine."
223609399|NCT05564754|OTHER|Low MAP|A MAP target of \>65mmHg will be used. Vasopressors will be titrated to this target during 36h.
223609400|NCT05564754|OTHER|Minimal sedation|A strategy of minimal sedation in the ICU, used only as needed to facilitate transport, imaging and invasive procedures.
223609401|NCT05592639|PROCEDURE|Videoendoscopic radical inguinal lymphadenectomy or open radical inguinal lymphadenectomy|Intervention is a Videoendoscopic radical inguinal lymphadenectomy (VEIL) which is a surgical technique utilised in removing inguinal lymph nodes.
223609402|NCT04559893|BEHAVIORAL|Collaborative Care|Collaborative care consists of a team of providers that includes a care coordinator, a primary care provider (PCP) and a behavioral health consultant (BHC), who provide evidence- and measurement-based care to a panel of patients using a clinical registry. In our model, the CC team also includes a behavioral health psychotherapist (BHP) who consults on a regular basis but does not deliver direct care.
223609403|NCT06275412|BEHAVIORAL|The 3Ms 2.0 Intervention|The 3Ms is a culturally tailored, mHealth intervention for primary caregivers of Black adolescents with T1D focused on promoting daily parental monitoring of adolescent diabetes care and delivered via an Internet platform, Computer Intervention Authoring System (CIAS). The intervention content is based on the Information-Motivation-Behavioral Skills (IMB) model. Caregivers randomized to The 3Ms receive 3 sessions. The caregiver is guided through each session by an interactive and emotive three-dimensional narrator that reads and speaks aloud. Additional intervention content includes brief videoclips to provide skills demonstrations of supportive parenting practices related to diabetes care and text message reminders. Each session is no more than 20 minutes in length. The intervention is delivered over a three-month window, with the two follow-up sessions available to be accessed by the caregiver at one-month intervals after completion of the initial session.
223609404|NCT06275412|BEHAVIORAL|Educational Attention Control (EAC)|The EAC intervention consists of three sessions delivered in an mHealth format via the CIAS internet platform over three months, with access for a maximum of six months. EAC provides structured information on topics of interest to caregivers of adolescents with T1D such as travelling with diabetes, or emergency preparedness for persons with diabetes. All participants receive their standard medical care.
223609405|NCT04185402|DRUG|Azithromycin|In study communities randomized to the Azithromycin Continuation arm, all individuals aged 1 month and older will receive a single mass distribution of azithromycin several weeks after the baseline and 36-month monitoring visits. In study communities randomized to Azithromycin Discontinuation, participants will receive no treatment.
223609406|NCT06556615|BEHAVIORAL|Interview|Interviews, presentation of questionnaires
223609407|NCT05939999|OTHER|Experimental: Elastic tape (ET)|The elastic tape will be allocated in the chest wall and abdomen of individuals and will be used during the 8 weeks of rehabilitation protocol.
223609408|NCT05939999|OTHER|Sham Comparator: Sham (SH)|The micropore tape will be allocated in the chest wall and abdomen of individuals and will be used during the 8 weeks of rehabilitation protocol.
223755838|NCT03592615|PROCEDURE|Corneal refractive surgery|Corneal refractive surgery in this study is only for the purpose of vision correction, not for the treatment of ocular pathology other than refractive error, e.g., treatment for corneal scar. The surgery used in this study should not be combined with other procedures, such as limbal relaxing incision for treating severe astigmatism.
223755839|NCT01398566|BEHAVIORAL|SuperBetter play|average 10 min of game play per day for 6 week period
223609409|NCT01004926|DEVICE|Echelon foot|One Echelon foot for each subject, for a period of a month.
223609410|NCT06226038|OTHER|Magnet disc|Magnetic field promote proliferation and stimulate osteoblast differentiation
223609411|NCT06226038|OTHER|Stainless steel|For control
223609412|NCT00825201|DRUG|paclitaxel albumin-stabilized nanoparticle formulation|Given IP
223609413|NCT00825201|OTHER|liquid chromatography|Plasma and peritoneal fluid samples will be collected prior to nab-paclitaxel, at completion of nab-paclitaxel infusion and at hours 1, 2, 4, 6, 8, 12, 24 and 48 following completion of infusion.
223609414|NCT00825201|OTHER|mass spectrometry|Plasma and peritoneal fluid samples will be collected prior to nab-paclitaxel, at completion of nab-paclitaxel infusion and at hours 1, 2, 4, 6, 8, 12, 24 and 48 following completion of infusion.
223609415|NCT00825201|OTHER|pharmacological study|Plasma and peritoneal fluid samples will be collected prior to nab-paclitaxel, at completion of nab-paclitaxel infusion and at hours 1, 2, 4, 6, 8, 12, 24 and 48 following completion of infusion.
223609416|NCT00825201|OTHER|laboratory biomarker analysis|Correlative studies
223609417|NCT05730309|BEHAVIORAL|Customized discharge and expedited referral instructions|The intervention for subjects with LVH on research POCUS will consist of three elements: 1) disclosure of presence of LVH to subject, ED team and primary care physician (PCP) (if applicable); 2) educational discharge instructions describing high BP, HTN, LVH, implications for development of cardiovascular disease (such as development of heart failure, stroke), options for treatment (lifestyle, medications) and importance of follow-up; A preliminary version will be refined prior to the start of the trial by feedback from ED physicians and patients. Refinement will target content, phrasing, and literacy level. 3) referral to outpatient care, consisting of one of two options, based on whether the subject has an established PCP. For subjects with existing PCP, the study team will call the office, inform about study participation, LVH findings, and secure a follow-up appointment. For those with no PCP, study team will arrange for follow-up to special clinic.
223755840|NCT05692661|RADIATION|proton plus carbon ion radiotherapy|CTV1: whole breast, 40.05Gy(RBE) in 15 fractions with proton ion therapy; CTVboost: Tumor bed, carbon ion dose escalation study with four dose levels \[10.2Gy(RBE)/3Fx,10.8Gy(RBE) /3Fx,11.4Gy(RBE)/3Fx and 12Gy(RBE)/3Fx \].
223755841|NCT01799356|DRUG|Moxifloxacin|daily 400 mg moksifloksasin
223609418|NCT01035671|DRUG|alpha-tocopherolquinone (A0001)|28 days of low dose (1.0 g total daily dose) oral A0001 capsules. Treatment taken twice daily with meals.
223609419|NCT01035671|DRUG|alpha-tocopherolquinone (A0001)|28 days of high dose (1.5 g total daily dose) oral A0001 capsules. Treatment taken twice daily with meals.
223609420|NCT01035671|DRUG|placebo|28 days of placebo oral capsules. Treatment taken twice daily with meals.
223609421|NCT00799903|DRUG|Darapladib|Lp-PLA2 inhibitor administered in addition to standard therapy
223609422|NCT00799903|DRUG|Placebo|Placebo administered in addition to standard therapy
223609423|NCT06102876|OTHER|Physical activity (PA) program|The PA program is specific for each patient according to their mobility profile assessed using a decision tree comprising 3 tests: 1) the number of repetitions in the 30-second sit-to-stand test, 2) the score in the Short Physical Performance Battery (SPPB) test and 3) grip strength. The PA program has to be performed once daily.
223755842|NCT01799356|DRUG|Ofloxacin|daily 800 mg oflaksasin plus 1000 mg metronidazol treatment
223609424|NCT01216813|OTHER|informational intervention|
223755843|NCT01799356|DRUG|Metronidazole|daily 1000 mg metronidazol plus 800 mg oflaksasin treatment for uPID
223609425|NCT01216813|PROCEDURE|assessment of therapy complications|
223755844|NCT02787252|DEVICE|Implant procedure, Freedom Spinal Cord Stimulation System|A needle is carefully inserted near the spinal cord. The stimulator is then slide through the needle to lay close to the spinal cord. The end of the stimulator is then sutured underneath the skin of the back.
223755845|NCT04112433|DEVICE|PURE EP 2|Enrolled patients receiving cardiac ablation treatment using the current standard of care with additional monitoring and intracardiac electrogram signal collection via the PURE EP 2 system.
223755846|NCT02550327|DRUG|Nab-paclitaxel|125 mg/m2
223755847|NCT02550327|DRUG|Gemcitabine|1000 mg/m2
223755848|NCT02550327|DRUG|Cisplatin|25 mg/m2
223755849|NCT02550327|DRUG|Anakinra|100 mg
223755850|NCT05144152|DIAGNOSTIC_TEST|M3|A panel of four bacterial gene markers (Fn, m3, Ch and Bc)
223609426|NCT01216813|PROCEDURE|psychosocial assessment and care|
223609427|NCT01185015|DRUG|Sigmart (nicorandil)|Sigmart will be administered for 2 weeks when the subject enters the secondary treatment period (Day 15 to approximately Day 28), at the dosage of 5 mg per oral tid in addition to the previous anti-anginal regimen.
223609428|NCT01440088|DRUG|TH-302 in Combination with Doxorubicin|"300 mg/m2 of TH-302 will be administered by IV infusion over 30-60 minutes on Days 1 and 8 of a 21-day cycle.~Doxorubicin may be delivered as a bolus administration or as a continuous infusion administration; administration schedule must be specified prior to enrollment.~Doxorubicin bolus administration: 75 mg/m2 administered by bolus injection starting on Day 1 of a 21-day cycle.~Doxorubicin continuous administration: 75 mg/m2 administered by continuous IV infusion over 48-96 hours starting on Day 1 of a 21-day cycle.~Doxorubicin administration will start between 2 to 4 hours after completion of the TH-302 infusion when used in combination with TH-302."
223755851|NCT05144152|DIAGNOSTIC_TEST|FIT|faecal immunochemical test
223755852|NCT00363974|DRUG|XIAP antisense|2 days loading dose followed by weekly 2hr infusion
223755853|NCT00427635|DRUG|Esomeprazole|
223755854|NCT01598116|PROCEDURE|Urine collection and ultrasonography|Bagged urine collection and ultrasound at each visit
223755855|NCT01598116|PROCEDURE|Urine collection|Bagged urine collection
223755856|NCT02412969|PROCEDURE|Lumbar Epidural|control group will receive lumbar puncture epidural
223755857|NCT02412969|PROCEDURE|Dural Puncture Epidural|intervention group will receive a dural puncture epidural
223755858|NCT04334642|OTHER|A mindfulness based intervention|It is a pilot study of feasibility and preliminary effectiveness composed of a longitudinal intervention that uses as a baseline measure a Mindfulness Training of 2 cycles (each cycle is formed by 4 days of intervention); two follow-up measures (1 and 6 months after the 2nd cycle); and a final measurement (12 months after the start of the study).
223755859|NCT00659867|DEVICE|PENTAX EC-3870CIFK / EC-3870CILK confocal colonoscopes|chromoscopy-guided endomicroscopy with targeted biopsies
223755860|NCT00659867|DEVICE|PENTAX EC-3870CIFK / EC-3870CILK confocal colonoscopes|Standard endoscopy with random and targeted biopsies
223755861|NCT02335138|BEHAVIORAL|Couples HIV Testing and Counseling (CHTC, CVCT)|Male couples randomized to the experimental group (Couples HIV Testing and Counseling, CHTC/CVCT) will receive HIV counseling and testing as a couple via an online, HIPPA-compliant videoconferencing service. The dyad-centered session will last less than one hour and focus on couples agreement, prevention strategies, and/or linkage to HIV care, depending on each couple's test results. Participants will complete follow-up surveys at 3 and 6 months post-testing.
223755862|NCT02335138|BEHAVIORAL|at-home test kit|Male couples in the control group will receive test kits, but will not receive any testing intervention. Once individual results are reported,participants will be contacted via phone by study staff with options for referrals to services for the reactive partner(s). Participants will complete follow-up surveys at 3 and 6 months post-testing.
223755863|NCT02159547|DRUG|Dexketoprofen|50 mg intravenous arveles in 50 ml saline in 5 minutes
223755864|NCT02159547|OTHER|Normal Saline|50 ml normal saline
223755865|NCT04445545|DEVICE|High intensity laser therapy (HILT)|Laser application with powers greater than 500 milliwatts (mW) in the myofascial trigger point and muscle belly of the upper trapezius. Laser therapy will be applied to the upper trapezius muscle with a total energy delivery of 1,060J divided into 3 phases will be achieved (phase 1, 500J; phase 2, 60J; phase 3, 500J). It will work with an average power of 3W and an energy density of 50J/cm2. For the application of laser therapy, the 12W BTL-6000 equipment that emits infrared wavelengths of 1064nm will be used.
223755866|NCT04445545|DEVICE|Therapeutic Ultrasound (US)|Application of ultrasound therapy in the myofascial trigger point of the upper trapezius muscle. The ultrasound application will be performed with the person in a seated position. The ultrasound parameters will consist of a frequency of 1MHz, the intensity of 1.5 W/cm2, a Duty cycle of 100%, an ERA of 5cm2, and a treatment time of 6 minutes.
223755867|NCT04445545|PROCEDURE|Stretching exercise|t the end of the assigned treatment will be added a treatment protocol of upper trapezius stretching exercises for the evaluated limb with shortening. The stretches will consist of 4 series of 30 seconds with an interval of 30 seconds between series
223755868|NCT06958419|COMBINATION_PRODUCT|Node-Sparing Radiotherapy plus first-line therapy|Patients will receive node-sparing modified short-course radiotherapy, followed by 8 cycles of FOLFOX chemotherapy combined with bevacizumab and a PD-1 inhibitor. After induction therapy, patients will continue with maintenance therapy using bevacizumab, PD-1 inhibitor, and 5-fluorouracil (5-FU), administered every 2 weeks (Q2W).
223609429|NCT01440088|DRUG|Doxorubicin|"Doxorubicin may be delivered as a bolus administration or as a continuous infusion administration; administration schedule must be specified prior to enrollment.~Doxorubicin bolus administration: 75 mg/m2 administered by bolus injection starting on Day 1 of a 21-day cycle.~Doxorubicin continuous administration: 75 mg/m2 administered by continuous IV infusion over 48-96 hours starting on Day 1 of a 21-day cycle."
223609430|NCT02470520|PROCEDURE|CRRT|continuous renal replacement therapy
224200896|NCT01935492|DRUG|Paclitaxel, Bevacizumab, liposomal doxorubicin, Capecitabine|"Arm B~1. st line~   * Paclitaxel and bevacizumab: 4 cycles, unless PD or unacceptable toxicity~  * Bevacizumab until PD or unacceptable toxicity~  * At PD \< 3 months after last paclitaxel start 2nd treatment line.~  * At PD ≥ 3 months after last paclitaxel, start another 4 cycles~  * Bevacizumab until the next PD or unacceptable toxicity~  * At the next PD start the 2nd treatment line.~2. nd line:~   * Myocet® or capecitabine: 4 cycles, unless PD or unacceptable toxicity~  * At PD \< 3 months start the 3rd treatment line. If possible, advised to cross-over from 2nd line Myocet® to 3rd line capecitabine.~  * At PD ≥ 3 months after last administration of Myocet® or capecitabine, start another 4 cycles of Myocet® or capecitabine~  * At the next PD start 3rd treatment line."
223609431|NCT05437523|OTHER|Constipation Action Plan|The author team previously developed and assessed this constipation action plan using the universal precautions approach to produce a tool which could optimize knowledge transfer from clinicians to patients, and support stepwise home self-management of functional constipation. The Uniformed Services Constipation Action Plan can be freely downloaded at the following web link: https://wrnmmc.libguides.com/pediatrics/USAP
223609432|NCT05437523|OTHER|Standard of care without constipation action plan|Standard of care without constipation action plan
223609433|NCT06369974|DRUG|Antisense oligonucleotide treatment (ASO)|Drug: nL-TUBB4-001; Personalized antisense oligonucleotide
223508932|NCT07046286|PROCEDURE|Compare the two brands of radiofrequency ablation catheters for the treatment of lower limb varicose veins.|"1. Surgical Procedures: Standardized radiofrequency ablation (GSV/SSV closure) was carried out in both groups by the same team. Catheter parameters were set as 120°C and 1 cm/min withdrawal speed. The treatment segment of the great saphenous vein was required to be \>1 cm from the skin before anesthesia. For calf varicose veins, treatment was done after great saphenous vein ablation.~   * Experimental Group: Utilized Xianruida's catheter with advanced features. Surgical and device - related information was recorded.~  * Control Group: Used Medtronic's catheter. Similar data were recorded as in the experimental group.~2. Postoperative Management: Consistent for both groups.~   * Compression: Applied elastic bandage + Class II compression stockings.~  * Medication: Patients took oral anticoagulants and painkillers as needed, with usage details recorded during follow - up."
223609434|NCT01366326|DRUG|Methylnaltrexone bromide|Subcutaneous MNTX
223609435|NCT03793361|DRUG|Regorafenib|"Oral Drug in the form of 40 mg tablets - Regorafenib (120 mg/d) once daily for 3 weeks on / 1 week off plus Best Supportive Care (BSC) until progression (according to RECIST 1.1), intolerance or consent withdrawal.~Provided by BAYER"
223609436|NCT03793361|DRUG|Placebo|"Oral tablets - Placebo plus BSC until progression (according to RECIST 1.1) or unacceptable toxicity. Patients who have received placebo may be offered open-label regorafenib (cross-over option) after objective tumor progression~Provided by BAYER"
223609437|NCT00195949|PROCEDURE|Laparoscopic pyloromyotomy|
223609438|NCT02332174|DRUG|rufinamide|comparison of different doses, sex and medication conditions
224200897|NCT06234969|DEVICE|Continuous Theta Burst Stimulation to the Intraparietal Sulcus|Continuous Theta Burst Stimulation delivered to the Intraparietal Sulcus
223508933|NCT07045688|DRUG|Efficacy of Vonoprazan based dual therapy for naive patient with Helicobacter Pylori infection|we assess the efficacy of Vonoprazan based dual therapy for eradication of Helicobacter Pylori infection in naive patient.
223508934|NCT07045688|DRUG|Efficacy of Vonoprazan based triple therapy for naive patient with Helicobacter Pylori infection|we assess the efficacy of Vonoprazan based triple therapy for eradication of Helicobacter Pylori infection in naive patient.
223508935|NCT07045688|DRUG|Efficacy of PPI based triple therapy for naive patient with Helicobacter Pylori infection|we assess the efficacy of PPI based triple therapy for eradication of Helicobacter Pylori infection in naive patient.
223508936|NCT07057180|OTHER|Observation by the Researcher and Self-evaluations by nurses|Observation by the Researcher
223508937|NCT07057180|BEHAVIORAL|This involves nurses' self-assessment of their caregiving behaviors and perceptions|This refers to the clinical observation performed by the nurse researcher
223508938|NCT07056907|PROCEDURE|Lumbar drain placement|This intervention involves temporary cerebrospinal fluid (CSF) drainage via lumbar drain in acute ischemic stroke patients with MRI-confirmed hemodynamic failure. The lumbar drain is inserted at the bedside or in a procedural suite under sterile conditions and connected to a pressure-regulated, closed drainage system. Drainage is continuous for 48-72 hours, with volume and pressure carefully monitored. This intervention is distinct in targeting stroke patients without hydrocephalus, using CSF drainage as a novel method to improve cerebral perfusion and vascular reserve. The effect is evaluated with serial BOLD-CVR MRI performed before and after the drainage period, making this one of the first interventional stroke studies to use functional MRI as a physiological endpoint.
223508939|NCT07056595|DRUG|Finerenone|Finerenone is a new nonsteroidal mineralocorticoid receptor antagonist. Planned dose - 10 mg/day
223508940|NCT05771493|OTHER|Measurement of baseline characteristics|Calculation of the correlation between BMI, WC and PI
223508941|NCT07056530|BEHAVIORAL|Telenursing Counseling|Structured weekly phone-based counseling sessions delivered by a trained nurse for 8 weeks, focusing on medication adherence, healthy lifestyle behaviors, stress management, and self-monitoring of blood pressure.
223508942|NCT05963230|OTHER|Ultrasound scans|Ultrasound scans collected by experts in ultrasound-guided regional anaesthesia.
223508943|NCT04462172|DEVICE|FNS|perform preoperative preparation, intraoperative operation and internal fixation implantation according to the instructions provided in the product packaging.
223508944|NCT04462172|DEVICE|MCS|three cancellous screws with an inverted triangle pattern are used to fix the fracture of femoral neck.
223508945|NCT00394667|DRUG|Tesofensine|
223508946|NCT00123877|DRUG|GPX-100 (13-deoxydoxorubicin)|
223508947|NCT00306722|DRUG|AQUAVAN® (fospropofol disodium) Injection|
223508948|NCT03572218|BEHAVIORAL|BWL|The BWL sessions will be based on the Diabetes Prevention Program (DPP) manual. A diet of 1200-1499 calories per day will be prescribed for participants \< 250 lb, and 1500-1800 for those ≥ 250 lb. Participants will be instructed to eat a balanced deficit diet. Session topics during the first 12 weeks will include self-monitoring, stimulus control, slowing eating, social support, cognitive restructuring, portion sizes, and goal-setting. Those during weeks 13-26 will focus on continued self-monitoring and skills required for weight loss maintenance and relapse prevention. Physical activity will be prescribed at a level consistent with data showing that \>250 min/wk is associated with improved long-term weight loss. BWL sessions will last 60 minutes.
223508949|NCT03572218|BEHAVIORAL|BIAS|Following 60 minutes of BWL treatment, the BIAS intervention will devote 30 minutes to stigma-related content. Session topics will include: psychoeducation about weight and weight stigma; challenging myths and cognitive distortions related to weight; strategies for coping with instances of stigma; and increasing empowerment and body esteem. The effects of weight stigma on health behaviors will be discussed, and sessions will focus specifically on helping participants overcome stigma-related barriers to weight management. In the every-other-week and monthly weight loss maintenance sessions from weeks 13-26, strategies for coping with weight stigma and challenging internalized beliefs will be reviewed, and participants will be encouraged to use these strategies in the context of weight management.
223508950|NCT02937922|OTHER|AEROBIC|The aerobic exercise session (AE) will consist of 40 minutes on an exercise bike in heart rate (HR) corresponding to 60% of heart rate reserve (moderate intensity) acquired by the formula of Karvonen: \[(HR max - HR rest) x desired intensity\] + HR rest; monitored through heart monitor brand Polar and perceived exertion rating (Borg scale of 6-20). It will be added to the exercise time 5-7 minutes to proper heating.
223508951|NCT02937922|OTHER|RESISTANCE|The resistance exercise session (RE) will last 40 minutes and will consist in carrying out 4 sets of 12 repetitions with interval of 90 seconds between sets and exercises. The weight will be adjusted to 60 % of a maximum repetition (1-RM) (moderate intensity) in four exercise for the lower limbs: leg press, knee extension, bend knees and plantar flexion (calf). The cadence of each series will be controlled by electronic metronome and performed with 2 seconds in the concentric phase and 2 seconds in the eccentric phase. It will be added to the exercise time 5-7 minutes for the warming to be held in the leg press exercise (one set of 15 to 20 repetitions with 1/3 load set for the session).
223508952|NCT02937922|OTHER|COMBINED|The combined exercise session (resistance and aerobic) will last 40 minutes. The exercise resistance phase of the combined session will consist of 20 minutes, according to the resistance exercise described above. Immediately after resistance exercise, patients will perform aerobic exercise (AE) for 20 minutes. In order to keep the equivalent time among the three interventions (aerobic exercise, resistance and combined) will be performed two series (2 x 12 repetitions) in each resistance exercise.
223508953|NCT03110835|RADIATION|Radioiodine|Administration of radioiodine
223508954|NCT02037074|DRUG|Drug: EVP-6308|Arms 1, 2, 3
223508955|NCT02037074|DRUG|Placebo|Arm 4
224200898|NCT06234969|DEVICE|Sham Continuous Theta Burst Stimulation|Sham Continuous Theta Burst Stimulation
224200899|NCT06385821|BIOLOGICAL|Grippol Quadrivalent|Solution for intramuscular and subcutaneous administration, 0.5 ml/dose. Children from 36 months to 5 years - in the upper third of the outer surface of the shoulder intramuscularly (in the deltoid muscle) at a dose of 0.5 ml once (Day 1). Children from 6 to 35 months - in the anterolateral surface of the thigh intramuscularly 0.25 ml twice with an interval of 3-4 weeks (Day 1, Day 25±3).
223755869|NCT06958419|COMBINATION_PRODUCT|First-line treatment|Patients will receive 8 cycles of FOLFOX chemotherapy combined with bevacizumab, followed by maintenance therapy with bevacizumab and 5-fluorouracil (5-FU), administered every 2 weeks (Q2W).
223755870|NCT05151744|DRUG|Vamikibart|Vamikibart will be administered by IVT injection in the study eye.
223755871|NCT05151744|DRUG|Ranibizumab|Ranibizumab will be administered by IVT injection in the study eye.
223755872|NCT05151744|OTHER|Sham Procedure|Sham is a procedure that mimics an IVT injection and involves the blunt end of an empty syringe (without a needle) being pressed against the anesthetized eye.
223755873|NCT04403139|DRUG|Shingrix|All participants will receive the FDA-approved recombinant zoster (RZV) vaccine (Shingrix) given at the approved dose and schedule.
223755874|NCT06135155|DRUG|PEG-rhGH with new preparation|A single subcutaneous injection of PEG-rhGH with new preparation
223755875|NCT06135155|DRUG|PEG-rhGH with present preparation|A single subcutaneous injection of PEG-rhGH with present preparation
223755876|NCT03711162|DRUG|GLPG1690|GLPG1690, film-coated tablets for oral use.
223755877|NCT03711162|DRUG|Placebo|Matching placebo, film-coated tablets for oral use.
224200900|NCT06385821|BIOLOGICAL|Grippol Plus|Suspension for intramuscular and subcutaneous administration, 0.5 ml/dose. Children from 36 months to 5 years - in the upper third of the outer surface of the shoulder intramuscularly (in the deltoid muscle) at a dose of 0.5 ml once (Day 1). Children from 6 to 35 months - in the anterolateral surface of the thigh intramuscularly, 0.25 ml twice with an interval of 3-4 weeks (Day 1, Day 25±3).
223508956|NCT00286455|DRUG|Alogliptin|Alogliptin 12.5 mg, tablets, orally, once daily for up to 26 weeks.
223508957|NCT00286455|DRUG|Alogliptin|Alogliptin 25 mg, tablets, orally, once daily for up to 26 weeks.
223508958|NCT00286455|DRUG|Placebo|Alogliptin placebo-matching tablets, orally, once daily for up to 26 weeks.
223508959|NCT02249780|PROCEDURE|Postoperative parathyroid function test|Calcium and parathormone dosage at 24 hours and ten day after surgery
223508960|NCT02249780|PROCEDURE|No postoperative parathyroid dosage and supplementation|The patients will be clinically followed for 24 hours after surgery and caclium and parathormone dosage will be done at ten days after surgery. No supplementation will be given.
223508961|NCT02249780|PROCEDURE|ICG parathyroid angiography|Injection of 3,5 mL of indocyanine green intravenously and perform angiography of parathyroid glands after thyroid removal.
223508962|NCT02249780|DRUG|Parathyroid supplementation|Supplementration with Calcimagon D3 Forte (1gr Calcium and 800 IU of 25-OH-vitamin D) from surgery day to up to 10 days afeter surgery.
223508963|NCT03939832|OTHER|Fraction of inspired oxygen level|A fraction of inspired oxygen level during cardiac surgery using cardiopulmonary bypass will be set differently: 0.5 versus 1.0.
223508964|NCT06215937|OTHER|No Intervention|No intervention
223508965|NCT06117137|DRUG|SGLT2 inhibitor|"Group empagliflozin: stander treatment of type two diabetes mellitus plus empagliflozin~Group dapa:standard treatment of type 2 Diabetes mellitus and dapagliflozin"
223508966|NCT00448032|DRUG|PPM-204|
223508967|NCT02054949|DRUG|N-Acetyl Cysteine (NAC)|NAC will be started at 500 mg by mouth twice daily for the first 2 weeks, then increased to 500 mg in the am and 1000 mg in the pm for week 3, and then increased to 1000 mg am and pm for weeks 4 through 8. Subjects will be maintained at the highest tolerated dose.
223508968|NCT04652843|PROCEDURE|Rectosignoidoscopy|Rectosignoidoscopy for colonic biospsies collection
223508969|NCT04652843|PROCEDURE|Coloscopy|Coloscopy for colonic biospsies collection
223508970|NCT04394832|BEHAVIORAL|Brief cognitive intervention|See the information provided in the experimental arm description.
223508971|NCT04601909|DRUG|FX-322|active comparator
223508972|NCT04601909|OTHER|placebo|placebo
223508973|NCT02594878|DRUG|Pamidronatdinatrium|
223508974|NCT02594878|OTHER|Natrium chloride 9mg/ml|
223508975|NCT05892718|DRUG|HCB101|HCB101 administered via. intravenous (IV) infusion.
223508976|NCT06511674|OTHER|Cognitive-emotional and pain assessments|Data collection on cognitive-emotional and pain parameters using questionnaires.
223508977|NCT03234556|PROCEDURE|Biopsy of Prostate|Undergo SR-Bx
223508978|NCT03234556|OTHER|Laboratory Biomarker Analysis|Correlative studies
223508979|NCT03234556|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|Undergo MRI
223508980|NCT03234556|DIAGNOSTIC_TEST|MRI Ultrasound Fusion Guided Biopsy|Undergo MRUS-Bx
223508981|NCT06232460|DIETARY_SUPPLEMENT|H80|5g, 10g \& 20g
223508982|NCT06908889|OTHER|Skin's lesion patients|Skin swabs will be obtained from the patient's facial lesional (FLS) and perilesional sites (FPS) using a sterile cotton swab. The microbiota of the same anatomical face regions will be collected on volunteers, once the 10 SMH patients have been enrolled. The swab is premoistened in a specific cocktail solution and rubbed onto the skin surface for 45sec. The pressure during the sampling involves rubbing the area of interest with a smear over the entire zone. The skin reddens slightly under the exerted pressure.
223508983|NCT06908889|OTHER|Skin's lesion vulunteers|Skin swabs will be obtained from the patient's facial lesional (FLS) and perilesional sites (FPS) using a sterile cotton swab. The microbiota of the same anatomical face regions will be collected on volunteers, once the 10 SMH patients have been enrolled. The swab is premoistened in a specific cocktail solution and rubbed onto the skin surface for 45sec. The pressure during the sampling involves rubbing the area of interest with a smear over the entire zone. The skin reddens slightly under the exerted pressure.
223508984|NCT06097273|BIOLOGICAL|mRNA-1083|Suspension for injection
223508985|NCT06097273|BIOLOGICAL|Placebo|0.9% sodium chloride suspension for injection
223508986|NCT06097273|BIOLOGICAL|Influenza Vaccine|Commercially available formulation (Suspension for injection \[pre-filled syringe\])
223508987|NCT06097273|BIOLOGICAL|COVID-19 Vaccine|Commercially available formulation (Suspension for injection)
223508988|NCT06470828|DRUG|TAK-861|Oral tablet.
223755878|NCT05161130|PROCEDURE|Lumbar Spinal Fusion|Lumbar Spinal Fusion with or without posterior stabilization
223755879|NCT05609955|DRUG|MgSO4|The treatment group who received intravenous magnesium sulfate therapy with 20% magnesium sulfate regimen, 30mg/kg body weight dissolved in 100ml NaCl in 1 hour intravenously
223755880|NCT04727658|RADIATION|Radiosurgical thalamotomy on GammaKnife|fractional radiosurgical thalamotomy on an accelerator (3 sessions of 50 Gy at the isocenter )
223755881|NCT03729336|DEVICE|Midstream urine collection device|Non-invasive midstream urine collection device
223508989|NCT06470828|DRUG|Placebo|TAK-861-matching placebo tablet.
223508990|NCT04330781|DEVICE|Intraoral stent|Radiotherapy with intraoral stent
223508991|NCT04330781|OTHER|No intraoral stent|Radiotherapy without intraoral stent
223508992|NCT04740424|DRUG|FS222|Dosing of participants will occur intravenously (IV), at a fixed dose in treatment cycles once every 4 weeks (Q4W) until disease progression or unacceptable toxicity.
223508993|NCT00551356|DRUG|Insulin lispro mix 25|Insulin lispro mix 25 given SC twice-daily in conjunction with oral antidiabetic medications.
223508994|NCT00551356|DRUG|Glargine|Insulin glargine given SC once-daily in conjunction with oral antidiabetic medications.
223508995|NCT06885268|DRUG|noradrenaline infusion for management blood pressure|A single concentration of noradrenaline (10 μg/ml) will be initiated 15-60 seconds prior to the induction of anaesthesia, then titrated and maintained until 4 hours after surgery to meet pre-specified mean arterial pressure (MAP) targets. The drug infusion will be started at a dose of 0.01 μg/kg/min and will be titrated to a maximum of 0.1 μg/kg/min. Anaesthesiologists will be advised to use the lowest possible dose of noradrenaline. Avoidance of MAP decreases of \>20% from baseline values or \<60-70 mm Hg will be required in both groups. Individual baseline MAP value will be defined as resting blood pressure obtained in at least two measurements at the surgery ward on the day before surgery. Noradrenaline will be administered peripherally in all patients who do not have a central venous catheter in place.
223609439|NCT03133507|BEHAVIORAL|Reapprasial Condition|Children in this condition will be instructed to think about how the procedure will help them become adjusted to cold weather.
223609440|NCT03133507|BEHAVIORAL|Reassurance Condition|Children will be reassured by the experimenter .
223609441|NCT03133507|BEHAVIORAL|Distraction Condition|Children in this condition will be instructed to focus their attention on a picture on a computer screen rather than on the pain.
223609442|NCT04252131|DRUG|cassia seed tablet|traditional Chinese herbs
223609443|NCT03645733|PROCEDURE|Lower Temperature Group|Dialysate temperature of 35 degree centigrade. The intervention group will start off using a dialysate temperature that is 36 °C. Thereafter the dialysate temperature will be reduced every two week by 0.5 °C until 35 °C or the lowest tolerated temperature reached.
223609444|NCT01207258|BEHAVIORAL|Motivational Enhancement Therapy|20 minute manual-driven, optionally audio-recorded Motivational Enhancement Training intervention by a MI-trained therapist during their ED visit and a 10-15 minute phone booster at 7 to 10 days.
223609445|NCT06443710|DRUG|Technetium [99mTc]-H7ND injection|Technetium \[99mTc\]-H7ND injection is a radiolabeled fibroblast activation protein inhibitor
223609446|NCT03862183|OTHER|continuing medical education program|educating all the involved doctor the same medical knowledge on hypertension control
223609447|NCT02114463|PROCEDURE|Local analgesic|Patient will be performed under combined lumbar plexus and sciatic nerve block with 0.33% ropivacaine.At the end of surgery,two catheters are left in the wound.One is intraarticular and the other is on the surface of articular cavity.And then a pump elastomeric infusion pump will be connected with the catheters, which runs 5mL every hours.
223609448|NCT02114463|PROCEDURE|Intravenous analgesic|People in this group will also receive an anesthesia of combined lumbar plexus and sciatic nerve block with 0.33% ropivacaine.An intravenous electronic analgesia pump infusion of flurbiprofen axetil 250mg,palonosetron 0.5mg,pentazocine 240mg.dezocine 30mg will will provide postoperative pain management.The patients will received a 2 mL/h continuous basal infusion and 1 mL boluses with a lockout time of 30 min after a 5 mL Loading dose at the end of the surgery.
223609449|NCT02114463|DRUG|ropivacaine|0.2% ropivacaine
223609450|NCT02114463|DRUG|flurbiprofen|flurbiprofen axetil 250mg,palonosetron 0.5mg,pentazocine 240mg.dezocine 30mg
223609451|NCT02625792|DRUG|Endo-Clot(TM)|After patients treated with ESD, Hemostatic power was applied on the post-resection surface by Endo-Clot™ system. And treated with proton pump inhibitor as usual.
223609452|NCT04626375|DRUG|Bioarginine|In the Bioarginine group the partecipants take bioarginine (2 vials per os of 1.66 g every 12 hours) for 4 week
223609453|NCT04626375|DRUG|Placebo oral tablet|In the Placebo group the participants take bio-arginine (2 vials per os of 1.66 g every 12 hours) for 4 week
223609454|NCT05520632|DIAGNOSTIC_TEST|Brainstem Auditory Evoked Potentials|Performing Brainstem Auditory Evoked Potentials under sedation
223609455|NCT04830930|DRUG|CKD-381|single-dose, oral administration of CKD-381 1 tablet
223609456|NCT01562080|DIETARY_SUPPLEMENT|Armolipid Plus|one tablet per day during 12 weeks
223609457|NCT01562080|DIETARY_SUPPLEMENT|placebo|one tablet per day during 12 weeks
223609458|NCT05865626|OTHER|VOT with and without cash incentive|Here we are interested in the remote monitoring of TB treatment, and the impact that financial motivation can have on compliance with this monitoring. the cross-over here means that participants in each intervention group will at some point receive VOT without motivation and then VOT with motivation, depending on whether they start with one or the other combination
223609459|NCT03351517|DRUG|Tapentadol 100 MG|100 mg of oral extended release tapentadol will be given to the patients undergoing total knee replacement surgery on spinal anesthesia to evaluate its efficacy in the management of post-operative pain.
223609460|NCT03351517|DRUG|Placebo Oral Tablet|A matching placebo will be given to the patients undergoing total knee replacement surgery on spinal anesthesia to evaluate its efficacy in the management of post-operative pain.
223609461|NCT05695807|DEVICE|Carboxytherapy|Device generating CO2 gas
223609462|NCT03391661|BEHAVIORAL|Pain neuroscience education patient exercise|Patients complete a 15 to 20-minute on-line exercise that inquires about 5 domains: the degree of central sensitization symptoms, catastrophizing and kinesiophobia, personality factors, stressors that triggered or exacerbated the pain, and adverse childhood experiences.
223609463|NCT03391661|BEHAVIORAL|Health behavior control intervention|Patients engage in a 15 to 20-minute on-line exercise examining their health behaviors in five domains: exercise, sleep, diet, hygiene, and social connections.
223609464|NCT00740207|DRUG|VISIPAQUE 270|VISIPAQUE 270 (Iodixanol Injection) is provided in bottles/flexible containers, ready to use sterile, pyrogen-free colorless to pale yellow solution
223609465|NCT00740207|DRUG|Isovue 250|ISOVUE-250 (Iopamidol Injection) is provided in single dose bottles/vials, ready to use, aqueous, nonpyrogenic, colorless to pale yellow sterile solution
223609466|NCT02507388|DRUG|Brolucizumab 3 mg/50 μL|Administered as an intravitreal injection
223609467|NCT02507388|DRUG|Brolucizumab 6 mg/50 μL|Administered as an intravitreal injection
223609468|NCT02980471|DEVICE|Pulse Oximeter|Blood removal and reintroduction as measured by the plethysmograph of a pulse oximeter
223609469|NCT00855244|OTHER|Diagnostic exams|Growth hormone stimulation testing, oral glucose tolerance test, hyperinsulinemic euglycemic clamp
223609470|NCT04982939|DRUG|Sintilimab|Sintilimab, 200mg IV d1 Q3W
223609471|NCT04982939|DRUG|S-1|S-1, 40-60mg BID d1-14 Q3W
223609472|NCT04982939|DRUG|Oxaliplatin|Oxaliplatin，130mg/m2 d1 Q3W
223609473|NCT00102128|DRUG|Cellular Therapy (Cultured Autologous Skeletal Myoblast Transplantation)|
223609474|NCT04410094|DRUG|Lazertinib|Lazertinib tablets will be administered orally.
223609475|NCT04410094|DRUG|Itraconazole|Itraconazole capsules will be administered orally.
223609476|NCT04410094|DRUG|Rifampin|Rifampin capsules will be administered orally.
223609477|NCT03274908|OTHER|regular medical treatment|regular medical treatment
223755882|NCT03729336|DEVICE|Catheter for urine collection|In-and-out catheter obtains urine through the urethra.
223755883|NCT06343844|DIAGNOSTIC_TEST|cardiac imaging to assess left ventricular volumes and function|non-invasive cardiac imaging (echocardiography and MRI)
223755884|NCT02340299|DEVICE|nHFOV|Extubation to ventilator-derived nHFOV using binasal prongs
223609478|NCT01380795|BIOLOGICAL|CTC|every two cures of a standard chemotherapy patients will be taken sample of blood to monitor CTC presence and EGFR/ K-ras status of that CTC
223609479|NCT06579963|OTHER|Cool roof|Cool roofs are a sunlight reflecting roof coating that can reduce indoor temperature. Cool roofs have high solar reflectance (reflecting the ultraviolet and visible wavelengths of sunlight, reducing heat transfer to the surface of a roof) and high thermal emittance (radiating absorbed solar energy).
223609480|NCT01257516|DRUG|Pregabalin immediate release, 300 mg|300 mg immediate release capsule administered twice daily for four days
223755885|NCT02340299|DEVICE|nCPAP|Extubation to ventilator-derived nCPAP using binasal prongs
223755886|NCT02283112|OTHER|antivirals, antimicrobials, oral contraceptive, erectile dysfunction agents|
223755887|NCT05235191|DRUG|methadone tablets|The intervention with the active drug (methadone) will start with the dose of 1 tablet (5 mg) twice a day (every 12 hours) and titrated on subsequent visits up to the maximum dose of 6 tablets a day (totaling 30 mg divided into 2 daily doses to facilitate therapeutic adherence).
223755888|NCT05235191|DRUG|Placebo|In this arm patients will take placebo tablets (the same number, color and physical aspects as the methadone tablets).
223609481|NCT01257516|DRUG|Pregabalin controlled release, 330 mg|Two tablets of 330 mg (total dose of 660 mg) given concurrently once daily for four days
223609482|NCT04995575|PROCEDURE|collection of the biopsy, blood samples|"for the patients recruited retrospectively collection of biopsy is not considered intervention, as the relapse samples were collected according to standard of care in the participating hospitals.~For the prospective collection of samples, the relapsed patients will be asked to donate tissue and blood samples"
223609483|NCT02929030|DEVICE|Nano|The stent system comprises of 2 components: stent steel platform, antiproliferative drug sirolimus, and stent balloon
223609484|NCT01522716|BIOLOGICAL|Mesenchymal stromal cells|Allogenous mesenchymal stromal cells, to be injected intravenously at a dose of 1-2 million/kg at a frequency of once a month (frequency may be changed during the study if deemed appropriate by investigators) for 6-9 months.
223609485|NCT03349658|OTHER|general anesthesia|effect of general anesthesia on transcranial regional cerebral oxygen saturation
223609486|NCT03349658|OTHER|spinal anesthesia|effect of spinal anesthesia on transcranial regional cerebral oxygen saturation
223609487|NCT03232996|OTHER|Computer game based balance and walking rehabilitation for individuals with Parkinson's Disease|All the participants will take part in an 8 week (twice per week) computer game based exercise program for dual task balance and dual task walk training. Participants will be standing in front of LED monitor. They will be asked to wear a head band which will be instrumented with motion sense mouse. Thus, hands-free head rotations will be used to interact with the computer games selected for the DT rehabilitation program. Participants will play few interactive computer games during - Normal standing (fixed surface), Standing on a compliant sponge pad and then while walking on a treadmill.
223609488|NCT03062514|DEVICE|PINS Vagus Nerve Stimualtor|PINS Vagus Nerve Stimualtor
223755889|NCT05595993|DRUG|Cilostazol|Study participants will be allocated to receive oral administration of 200 mg cilostazol.
223755890|NCT05595993|DRUG|Placebo|Study participants will be allocated to receive oral administration of placebo.
223755891|NCT05489315|DEVICE|Positioning with peanut ball|If participants are randomly selected to receive a peanut ball, the intent is for the patient to remain on the peanut ball during their labor progression.
223755892|NCT05489315|OTHER|Traditional positioning|If participants are randomly selected to NOT receive a peanut ball, the intent is for the patient to undergo traditional positioning/use wedge pillows during their labor progression.
223755893|NCT02235779|OTHER|Transbronchial lung cryobiopsy|
223755894|NCT00394212|DEVICE|Transoral Suturing|suturing of anastomosis
223755895|NCT00394212|OTHER|Sham Endoscopy|suturing not performed
223755896|NCT01902446|DRUG|Chlorhexidine gluconate|Study solution will be applied to the oropharynx and will be distributed for 15 seconds with a swab stick. No suction will be applied for at least 30 seconds.
223755897|NCT01139281|DRUG|Ginkgo Biloba Extract (GBE761)|The subjects were randomized and allocated in two groups: Control Group(CG) and Study Group(SG). the study group received GBE761(120mg twice a day) plus cisplatin and was guided to ingest GBE761 just before initial cisplatin dosage. The maximum cumulative cisplatin dosage was 300mg/m². They were followed up for ninety days. Comparisons were made between baseline distortion-product otoacoustic emissions measurements and those DPOAE records after maximum cumulative cisplatin dosage.
223755898|NCT01139281|DRUG|Placebo|The subjects were randomized and allocated in two groups: control group and study group. The control group received placebo plus cisplatin and was guided to ingest Placebo just before initial cisplatin dosage. The maximum cumulative cisplatin dosage was 300mg/m². They were followed up for ninety days. Comparisons were made between baseline distortion-product otoacoustic emissions measurements and those DPOAE records after maximum cumulative cisplatin dosage.
223755899|NCT00117858|PROCEDURE|Anodal DC polarization of left prefrontal cortex|
223755900|NCT03323528|DRUG|Benzalkonium Chloride-Benzocaine Topical|Dorithricin = tyrothricin, benzalkonium chloride, benzocaine
223755901|NCT03323528|DRUG|Placebo Oral Tablet|"Placebo Oral Tablet = a lozenge with matched appearance and the same excipients as Active Comparator Dorithricin lozenge.~Intervention: Patients are instructed to administer at home 1 lozenge at intervals of 2 hours (±15 minutes) up to a maximum of 8 lozenges per day."
223609489|NCT05144100|PROCEDURE|Surgery with or without Neck Dissection|An appropriate surgery as open, endoscopic, TLM, TORS or a combination with or without neck dissection e.g. levels dissected, sparing or sacrifice of the SCM, accessory nerve, etc as per patient disease and status will be performed
223609490|NCT05144100|RADIATION|Radiation|Patients will receive IMRT with normal tissue sparing techniques (70Gy/35# or 66Gy/ 30#) along with concurrent weekly cisplatin. Weekly cisplatin will be administered during IMRT at a dose of 40 mg/m2 IV on days 1, 8, 15, 22, 29, 36, and 43 for a total of upto 7 weekly doses, administered during the course of IMRT.
223609491|NCT05144100|DRUG|Cisplatin based chemotherpay|Cisplatin (dose-40 mg/m2weekly,upto6-7cycles) cycle 1 will be administered within first 2 # of radiation. The rest of the cycles will be given weekly.
223609492|NCT05212558|OTHER|Placebo respiratory muscle training|Unloaded respiratory muscle training plus conventional respiratory exercises
223609493|NCT05212558|OTHER|Inspiratory muscle training|Inspiratory muscle training plus conventional respiratory exercises
223609494|NCT05212558|OTHER|Combined inspiratory and expiratory muscle training|Combined inspiratory and expiratory muscle training in the same respiratory cycle plus conventional respiratory exercises.
223609495|NCT00556998|DRUG|Voriconazole|Voriconazole will be used for prophylaxis purpose. 6 mg/kg IV q12h on the first day (Day 1) and 4 mg/kg IV q12h for at least 5.5 days. The IV treatment is no more than 20 days. Then switch to 300 mg oral tablets q12h for at least 6.5 days. The total treatment duration is no more than 30 days.
223609496|NCT04976686|OTHER|Diet modification|Participants will reduce their carbohydrate consumption to 80g daily
223609497|NCT04314986|DRUG|Cohort 1: AR882 or placebo|AR882 or matching placebo administered once daily for 10 days
223609498|NCT04314986|DRUG|Cohort 2: AR882 or placebo|AR882 or matching placebo administered once daily for 10 days.
223609499|NCT04314986|DRUG|Cohort 3: AR882 or placebo|AR882 or matching placebo administered once daily for 10 days
223609500|NCT04314986|DRUG|Cohort 4: AR882 or placebo|AR882 or matching placebo administered once daily for 10 days
223609501|NCT00947271|BEHAVIORAL|DVD 1|The first version of a 20-minute educational DVD aimed to help adult patients reduce sexual risk behaviors (i.e., number of partners, unprotected sex, incident sexually transmitted diseases \[STDs\]) and improve health
223755902|NCT00588445|DRUG|Gefitinib|"Patients will receive gefitinib 250 mg po daily for at least 21 days preoperatively (depending on the timing of the surgery). Treatment with gefitinib will be stopped 2 days before the date of surgery.~Patients who have had at least a minor response to gefitinib therapy preoperatively (\> 25% reduction in tumor measured bidimensionally) and / or have mutations in the protein-tyrosine kinase domain of the EGF receptor gene identified will continue on the study and will resume gefitinib treatment after at least 7 days from surgery providing adequate wound healing has occurred.~Patients who are determined to be candidates for adjuvant chemotherapy and/or radiation therapy by their treating physician may receive treatment with adjuvant chemotherapy and/or radiation therapy. The post-operative gefitinib will be started after completion of the chemotherapy and/or radiation therapy."
223755903|NCT05795894|BEHAVIORAL|STAI-Y|Situational Anxiety and Trait Anxiety Inventory
223755904|NCT05795894|BEHAVIORAL|BDI scale|• Beck Depression Inventory scale
223755905|NCT05795894|BEHAVIORAL|M.I.N.I.Kid|"Suicidal risk module of the Mini-International Neuropsychiatric Interview child/adolescent version"
223755906|NCT05795894|BEHAVIORAL|PCL-5|Post-traumatic Check List Scale
223755907|NCT03240133|DRUG|BCX7353|oral liquid formulation
223755908|NCT03240133|DRUG|Placebo|oral liquid formulation to match BCX7353
223755909|NCT05771259|OTHER|Assessment of knowledge and behaviour|Assessment of knowledge and behaviour
223755910|NCT03146234|GENETIC|CAR-GPC3 T cells|"Self-controlled dose escalation will be applied to the first 3 - 6 subjects enrolled.~Classical 3+3 dose escalation will be applied to subsequent subjects based on the self-controlled dose escalation study."
223755911|NCT00197327|DRUG|Epidural bupivacaine (0.25% versus 0.0625%)|
223755912|NCT03278990|BEHAVIORAL|Value Affirmation and Future Selves Combination|Following the questionnaire, participants will complete a 10- to 15-minute writing exercise. In the control condition, they will be given a list of values, select two that are least important to them, then write about why those values might be important to others. Next, they will write a short letter to themselves in 2 weeks. In the treatment condition, they will be given a list of values, select two that are important to them, then write for about why those values are important to them and how they have played a role in their life. They will then write a short letter to themselves twenty years in the future.
223755913|NCT03278990|BEHAVIORAL|Control writing exercise|In this sham comparator, participants will also write, however, the content of the writing exercise is different. Participants write for five minutes about what they did that day. Next, for five minutes, they write a letter to themselves next week.
223609502|NCT00947271|BEHAVIORAL|DVD 2|The second version of a 20-minute educational DVD aimed to help adult patients reduce sexual risk behaviors (i.e., number of partners, unprotected sex, incident STDs) and improve health
223609503|NCT03314701|DEVICE|Biphasic Intermittent Positive Airway Pressure (BIPAP)|"Following endotracheal intubation BIPAP mode will be started with:~* Inspiratory positive airway pressure \[IPAP\] at 20 cmH2O~* Expiratory positive airway pressure \[EPAP\] at 5 cmH2O~* PRESSURE SUPPORT is difference between these two pressures \[IPAP\]- \[EPAP\]~* Mandatory pressure will be delivered at rate of 10-12/min. To produce an end tidal carbon dioxide partial pressure in the range of 35-40 mmHg hypercapnia will not be allowed"
223609504|NCT03314701|DEVICE|Airway Pressure Release Ventilation (APRV)|"* high airway pressure (Phigh) will be set at 20 cmH2O~* low airway pressure ( Plow) will be set at 5 cmH2O~* the release phase setting will be adjusted to terminate the peak expiratory flow rate to ≥ 50%; release frequency of 10-12 cycles/min~* T high at 4.5-6 seconds~* T low at 0.5 to 0.8 second"
223609505|NCT02838758|DEVICE|Cryoablation|A minimally invasive cryoablation device. It delivers focused nitrous oxide to the target tissue via a 22-gauge needle to create an approximately 9.4mm by 5.4mm spherical freezing zone of temperature between -20 to -100° C.
223609506|NCT02838758|DRUG|Lidocaine|Roughly 3cc of lidocaine will be injected near the intermetatarsal neuroma under ultrasound visualization.
223609507|NCT02838758|DRUG|Saline|Roughly 3cc of saline will be injected near the intermetatarsal neuroma under ultrasound visualization.
223609508|NCT05887557|OTHER|Active Referral|As an implementation science study, all clinical intervention components will be delivered as part of routine clinical care at participating clinical sites. Clinicians and staff at referral sites throughout San Francisco and Alameda counties (emergency departments, psychiatric emergency services, community clinics, care navigation and case management programs, and community-based services) will refer eligible patients who are out of care and are interested in linking to drop-in and/or mobile care services at one of the study sites. Clinical referrals will include basic patient information and contact/locator information to facilitate linkage to care. Referrals will be site-specific based on the site where the patient is interested in accessing care.
223609509|NCT05887557|OTHER|Drop-In Multidisciplinary HIV Care|Each site will independently implement a drop-in multidisciplinary site-based HIV care model. Core intervention features include drop-in care (no appointments), panel management to review clinical progress for all referred patients, and case management. Each site may include adaptations to the care model determined during Aim 1 formative work.
223609510|NCT05887557|OTHER|Mobile HIV Care|Each site will independently implement a mobile care model using site-specific resources. At a minimum, the mobile care team will include a clinical nurse with telemedicine (video visit) consultation with a clinician (MD/NP/PA). Mobile teams will also administer medications (including long-acting ART when available) and collect laboratory specimens (e.g. HIV viral loads)
223609511|NCT05887557|OTHER|Staged Care|Clinical decision rules to escalate/de-escalate care intensity will be finalized developed during Aim 1 formative work, though will be based on a combination of clinical assessment and patient preference.
223609512|NCT05887557|OTHER|Identify and prepare champions at referral sites|Identify implementation champions at each referral site. Champions will receive marketing materials to promote uptake of clinical referrals to a drop-in/mobile care site by referral site providers/staff. This strategy is aimed at improving referring provider confidence in the value of referral to the care model, reduce perceived referral complexity/improve provider capability to refer, and provide positive peer pressure to promote referrals.
223609513|NCT05887557|OTHER|Audit and feedback at referral sites|Investigators will provide monthly reports to implementation champions at each referral site on aggregate number of referrals and the success of referrals (proportion linking to care). This strategy is aimed at improving perceived value of the intervention and increasing provider motivation to refer.
223609514|NCT05887557|OTHER|Build a coalition among referral and clinical sites|Investigators will facilitate formation of a coalition of referral and clinic sites to improve cross-site collaboration and promote positive peer pressure to improve intra-site communication and increase referrals.
223609515|NCT05887557|OTHER|Assess for readiness and identify barriers|Investigators will conduct patient in-depth interviews and clinical team focus group discussions to assess barriers to implementation of the clinical intervention. Findings from interviews and focus group discussions will inform site-specific implementation plans and adaptation of the intervention.
223755914|NCT04055597|OTHER|Robot and tDCS on-line|Combined transcranial direct current stimulation(tDCS) on-line and upper extremity rehabilitation robot for 5 times a week for 4 weeks
223755915|NCT04055597|OTHER|Robot and sham tDCS|Combined sham tDCS and upper extremity rehabilitation robot for 5 times a week for 4 weeks
223755916|NCT01598792|BIOLOGICAL|ADXS11-001|Escalating doses will be administered: 3.3 x 10e8,1 x 10e9 and 3.3 x 10e9 cfu to patient in 3 different groups. Dose-escalation will only occur if fewer than two patients in each group of six experience Dose Limiting Toxicity (DLT).
223755917|NCT02511470|OTHER|Metronome on|Metronome on during participants performance of CPR on a pediatric manikin
223755918|NCT02511470|OTHER|Metronome off|Metronome off during participants performance of CPR on a pediatric manikin
223609516|NCT05887557|OTHER|Promote adaptability|During a co-design workshop among drop-in/mobile care site teams and site-specific meetings, the study team will collectively finalize core clinical intervention components and outline site-specific adaptations (i.e. adaptable periphery of clinical intervention).
223609517|NCT05887557|OTHER|Develop a formal implementation blueprint|With each drop-in/mobile care team, develop site-specific implementation plan that includes defining care team and leadership structure, clinic workflow, implementation timeline, and progress measures. This process, and the resulting blueprint, will incorporate site-specific barriers and facilitators to implementation.
223609518|NCT05887557|OTHER|Develop educational materials; conduct ongoing training|Compile a manual that includes detailed description of core intervention features, planned local adaptations, and implementation guidance. We will conduct site-specific meetings to provide training on this manual. We will also conduct regular (at least monthly) meetings between the study team and the clinic site to provide technical assistance and coaching.
223609519|NCT05887557|OTHER|Create a learning collaborative|Create a cross-site learning collaborative with periodic meetings and workshops throughout the study period to facilitate cross-site communication, sharing of best practices and encourage positive peer pressure to support implementation.
223609520|NCT00490269|DRUG|Placebo|
223609521|NCT00490269|DRUG|Dronabinol|
223609522|NCT03707301|OTHER|Questionnaires|Questionnaires of satisfaction and the Hospital Anxiety and Depression scale.
223609523|NCT02864121|OTHER|all patients included in IDAHO study|
223609524|NCT02320916|PROCEDURE|23Gauge|Arterial puncture will be made using a 23Gauge needle
223609525|NCT02320916|PROCEDURE|25Gauge|Arterial puncture will be made using a 25Gauge needle
223755919|NCT00462319|BEHAVIORAL|Education, weight reduction and physical exercise|
223755920|NCT02259933|DRUG|KUC 7483 CL|
223755921|NCT02259933|DRUG|Placebo|
223755922|NCT05729334|DEVICE|Clinicgram Euclides|"Clinicgram Euclides is a software that allows automated calculation of the area of skin lesions using a mobile device. Three different photographs will be taken of the subject's skin lesion. The area of the skin lesion will be calculated using the photograph of the skin lesion, and:~* for EUCLIDES 2D, an external marker. The investigator will outline the skin lesion and the external marker in the photograph prior to the calculation of the skin lesion area.~* for EUCLIDES 3D, a two reference points selected by the investigator."
223755923|NCT03033017|OTHER|Blood Testing|
223755924|NCT04871295|BEHAVIORAL|Noom Healthy Weight|Behavioral: Noom Healthy Weight; mobile behavior change program for weight loss with 1:1 coaching The intervention consists of a curriculum, provided through daily articles that users are encouraged to read; logging features for weight, meals, and physical activity; in-app groups; and a virtual coach, who will communicate with participants via in-app messaging. During the first week of the study, participants will be introduced to the program, the Noom app, and their coach. Coaches will use a secure dashboard to monitor patient progress, which is used to increase engagement and motivation. Participants are encouraged to log their weight and physical activity on a weekly basis, and meals daily.
223755925|NCT05935579|DRUG|Durvalumab|Durvalumab 1500 mg will be administered intravenously once every three weeks, with intravenous infusion on Day 1 of each cycle.
224200901|NCT03957343|DEVICE|Pacing and Planning App|Participants will download and use the Pacing and Planning app through mybrainpacer.ca. The app will be used to track and monitor their daily tasks and symptoms at any time, for as long as they would like to use the app. While using the app, participants will also fill out short assessments, including the Rivermead Post-Concussion Questionnaire once a month (to monitor symptoms) and an overall symptom question once a week (to rate how they feeling in general from a lot better to a lot worse).
223609526|NCT04694690|OTHER|Self adhesive resin cement|Self adhesive resin cement
223609527|NCT04694690|OTHER|Resin cement|Resin Cement system used after surface treatment
223609528|NCT04400058|BIOLOGICAL|Octagam 10%|Octagam 10%, 2 g/kg divided by 4 days (0.5 g/kg/day), administered by intravenous infusion over approximately 2 hours per day over 4 consecutive days
223609529|NCT04400058|OTHER|Saline Solution|Placebo
223609530|NCT04941495|OTHER|conventional physiotherapy|"1. TENS for 15 minutes on Constant Mode according to patient comfort.~2. Infrared for 15 minutes.~3. Isometric exercises: Isometric neck flexion, extension, side bending exercises were given. 3 sets of 10 repetitions each were given. And resistance was given for 6-8 seconds for each movement.~4. Stretching exercises: Passive stretching for Sternocleidomastoid, short sub occipital muscles, Trapezius \& Scalene, Pectoralis Major was given. 3 sets of 10 reps were given and each stretch was maintained for 10 seconds.~5. Home Plan: self stretches and isometrics.~6. Postural Education: posture correction in daily life activities in sitting, walking, lying."
223609531|NCT04941495|OTHER|Cervical proprioceptive training|"1. TENS for 15 minutes on Constant Mode according to patient comfort.~2. Infrared for 15 minutes.~3. Isometric exercises: Isometric neck flexion, extension, side bending exercises were given. 3 sets of 10 repetitions each were given. And resistance was given for 6-8 seconds for each movement.~4. Stretching exercises: Passive stretching for Sternocleidomastoid, short sub occipital muscles, Trapezius \& Scalene, Pectoralis Major was given. 3 sets of 10 reps were given and each stretch was maintained for 10 seconds.~5. Home Plan: self stretches and isometrics.~6. Postural Education: posture correction in daily life activities in sitting, walking, lying.~7. The patients wearing a cap with a laser pointer attached to it were seated three feet away from the target A, B and C. Start Chart A with a 3 cm, chart B 2cm and chart C 1cm narrow pathway were presented to the patients. The time taken by the patient to complete the pathway without any error was noted."
223609532|NCT04064749|BEHAVIORAL|Text messages|The brief intervention includes providing feedback on the individual's gambling score; providing an educational fact about the relationship between problem gambling and financial well-being; talking with the individual about the 'pros' and 'cons' of gambling with suggested strategies that could potentially reduce their gambling behaviors; and concluding with an action oriented closing question. Participants in the intervention group will also receive up to five text messages a week for one month.
223609533|NCT00216671|DRUG|early initiation of treatment with Risperdal Consta|25 mg to 50 mg Risperdal Consta intrmuscular injection every 14 days starting at baseline. Treatment with oral antipsychotics or risperidone will continue 21 days after the first injection of Risperdal Consta. This treatment will then be tapered off within the next 7 days.
223755926|NCT05935579|DRUG|Lenvatinib Oral Product|The dose of lenvatinib is 12mg/day for patients with a body weight of ≥60 kg, and 8mg/day for patients with a body weight of \<60 kg, taken once daily.
223755927|NCT05935579|DRUG|Chemotherapy|GEMOX regimen: Gemcitabine 1000mg/m2 will be administered intravenously over 30 minutes on Day 1 and Day 8; Oxaliplatin 100mg/m2 will be administered intravenously over 2 hours on Day 1, and the cycle will be repeated every 3 weeks.
223755928|NCT06228430|DRUG|Acyclovir 800 mg Tablet|Acyclovir 800 mg Tablet (Test Drug)
223755929|NCT06228430|DRUG|Zovirax™ 800 mg Tablet|Zovirax™ 800 mg Tablet (Reference Drug)
223755930|NCT01879566|OTHER|No intervention will be done. The study is observational|
223755931|NCT03856437|BEHAVIORAL|HPV vaccination messages|Digital multimedia messages consisting of text and imagery conveying the benefits of being vaccinated against HPV, the costs of not being vaccinated against HPV, or neither benefits or costs but simply a call for action.
223755932|NCT01176292|DEVICE|Rotating Platform High-Flex Cruciate Substituting TKA|
223755933|NCT01176292|DEVICE|Rotating Platform Cruciate Substituting TKA|
223755934|NCT00110812|DRUG|IL-2|7.5 MIU injected intramuscularly; one arm uses Proleukin together with HAART of choice (protease inhibitor and at least 2 nucleoside/nucleotide reverse transcriptase inhibitors)
223508996|NCT06885268|COMBINATION_PRODUCT|standard blood pressure management|Patients in the control group will receive standard blood pressure management reactive to blood pressure values. In the light of the current ESA/ESC 2022 guidelines, all patients in the control group will be treated to avoid MAP \<60-70 mm Hg. Ephedrine boluses (5 mg each, up to 25 mg total intravenous dose) will be recommended as a first-line hypotension treatment. Subsequent treatment will involve administering peripheral noradrenaline. Notwithstanding, there is a variation in clinical practice regarding the choice and timing of vasopressors and fluids to be administered during and after surgery, therefore, hypotension treatment will not be further protocolized to increase the feasibility and generalizability of the trial.
223755935|NCT04941508|BEHAVIORAL|the mother's recorded voice|Children will be assigned to listen to the mother's recorded voice at 2 times (in the holding area 3 minutes before induction of anesthesia till induction of anesthesia is ended) and (during emergence from anesthesia till complete recovery).
223755936|NCT04941508|DRUG|Dexmedetomidine|Children will be given a single bolus of dexmedetomidine 0.2 µ/kg IV at 2 times (in the holding area 3 minutes before induction of anesthesia) and (at the end of surgery).
223609534|NCT00216671|DRUG|routine initiation of treatment with Risperdal Consta|25 mg to 50 mg Risperdal Consta intrmuscular injection every 14 days starting at week 12. Treatment with oral antipsychotics or risperidone will continue 21 days after the first injection of Risperdal Consta. This treatment will then be tapered off within the next 7 days.
223609535|NCT03214354|DRUG|Alemtuzumab|Alemtuzumab, Day -7 to -3. Dose: 0.2mg/kg/dose SC once daily x 5 days
223609536|NCT03214354|RADIATION|Total Body Irradiation|TBI 300 cGy on Day -2
223609537|NCT03214354|DRUG|Sirolimus|Sirolimus is used for GVHD prophylaxis
223609538|NCT05938075|BIOLOGICAL|VXCO-100|Sterile suspension for injection
223609539|NCT05938075|BIOLOGICAL|COVID-19 mRNA vaccine|Sterile suspension for injection
223609540|NCT03605108|DIETARY_SUPPLEMENT|Probiotic|"• Probiotic fomula per capsule:~* 2 Billion CFUs~* HU36 - 30 mg~* HU58 - 20 mg~* Bacillus clausii -25 mg~* Bacillus coagulans 10B - 35 mg~* Prepro - 22 mg. The prebiotic that is to be used in the proprietary blend is a vegetable grade cellulose."
223609541|NCT03605108|OTHER|Placebo|Rice flour only
223755937|NCT04941508|OTHER|saline 0.9% placebo|Children will be given the same volume of saline at 2 times (in the holding area 3 minutes before induction of anesthesia) and (at the end of surgery).
223755938|NCT02478138|PROCEDURE|Sentinel lymph node mapping|Thirty (30) patients will be enrolled under informed consent based upon their medical diagnosis, planned surgical procedures, and suitability for the procedure. During the study, patients will receive injections of ICG and will be imaged using a commercial NIR imaging system (Pinpoint, Novadaq, Waterloo ON). After the study, patients will continue with their planned management.
223755939|NCT02478138|DRUG|Indocyanine Green (ICG)|
223755940|NCT02478138|DEVICE|near-infrared fluorescence (NIR) imaging (Pinpoint, Novadaq, Waterloo)|
223755941|NCT04761068|DEVICE|VEST|Venous External Support for vein grafts in CABG
223755942|NCT05909371|OTHER|exercise|Application of two different exercises to liver transplant individuals.
223755943|NCT02243150|DRUG|G1T28-1 (CDK 4/6 Inhibitor)|
223755944|NCT02243150|DRUG|Placebo|
223755945|NCT05802693|DRUG|Targeted Epidermal Growth Factor Receptor Variant III(EGFRvIII) autochimeric antigen receptor T cell injection|Infusion of Epidermal Growth Factor Receptor Variant III Chimeric antigen receptor T(EGFRvIII CAR-T) with Omaya capsule
223755946|NCT04933591|DRUG|Diosmin / Hesperidin|Venoactive drugs are used for patients with varicose veins as a tool for alleviating symptoms
223755947|NCT04552938|OTHER|pre-LVA|Venous serum samples were collected from patients before LVA.
223609542|NCT04683003|BIOLOGICAL|TAK-755|TAK-755 IV infusion
223609543|NCT04961541|BIOLOGICAL|ICC Vaccine|Intramuscular (deltoid) injections of in-clinic mix of various doses of quadrivalent hemagglutinin nanoparticle influenza vaccine(qNIV2), SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56.
223609544|NCT04961541|BIOLOGICAL|qNIV Nanoparticle Vaccine2 in-clinic mixed with Matrix-M1 Adjuvant|Intramuscular (deltoid) injections of 60 μg qNIV Nanoparticle Vaccine2 in-clinic mixed with 75 μg Matrix-M1 Adjuvant on Days 0, Day 56, and an additional dose on Day 70.
223609545|NCT04961541|BIOLOGICAL|SARS-CoV-2 rS Nanoparticle Vaccine in-clinic mixed with Matrix-M1 Adjuvant|Intramuscular (deltoid) injections of 5 μg SARS-CoV-2 rS Nanoparticle Vaccine in-clinic mixed with 50 μg Matrix-M1 Adjuvant on Days 0 and Day 56.
223609546|NCT00664885|OTHER|Culturally Sensitive Collaborative Treatment|a collaborative care model, for treating depressed patients in general medical care
223609547|NCT00851279|DEVICE|Magnetic irrigated ablation catheter|Magnetic irrigated catheter to be used with the magnetic navigation system
223755948|NCT04552938|OTHER|post-LVA|Venous serum samples were collected from patients one-month after LVA.
223755949|NCT03865329|BEHAVIORAL|Intervention- Home-based Pulmonary Rehabilitation|Home-based Pulmonary Rehabilitation (PR) with health coaching using a remote system that will allow patients to complete PR at home. The program involves upper and lower extremity exercises, self-report of symptoms (fatigue, breathlessness, physical activity and overall well-being).
223755950|NCT02930850|DEVICE|Rad-67 Pulse oximeter|Noninvasive pulse oximeter that measures hemoglobin
223755951|NCT04736459|PROCEDURE|Pre-washed catheter vs. Unwashed catheter in the intrauterine insemination|The pre-washed catheter will be washed with culture medium before intrauterine insemination The unwashed catheter will not be washed with culture medium as a standard intrauterine insemination procedure
223755952|NCT06087172|DIAGNOSTIC_TEST|Six Minutes Stepper Test (6MST)|Patients were applied two 6MST and 6MWT. 6MWT was conducted to test convergent validity of 6MST.
223755953|NCT05780671|OTHER|oxygen|inhaled oxygen 10L/min with face mask for 1 hour
223755954|NCT06833229|PROCEDURE|FDG-PET|PET scan are performed within 28 days before the start of immunotherapy, then at week 6 and week 12 of follow-up. Various metabolic parameters extracted from the standard PET image (ΔSUVmax, ΔTLG, appearance of new visceral lesion(s)), parametric (metabolic glucose rate (Ki), volume of distribution (VD)) and tumor response based on PERCIST criteria (adapted to immunotherapy) are assessed.
223755955|NCT04335721|DRUG|Voxelotor|Voxelotor 1500mg once a day
224200902|NCT04909879|BIOLOGICAL|COVI-MSC|COVI-MSC are allogeneic culture-expanded adipose-derived mesenchymal stem cells
224200903|NCT04909879|DRUG|Placebo|Excipient solution
224200904|NCT00026156|DRUG|docetaxel|
224200905|NCT00026156|DRUG|vinorelbine tartrate|
223609548|NCT05381363|DRUG|Inhaled Interferon α2b|Drug: Inhaled Interferon α2b; 1-2 years old: 1 dose, three times per day; 3-7 years old: 1 dose, four times per day; 7-18 years old: 2 doses, four times per day
223609549|NCT05381363|OTHER|Standard of Care|Standard of care treatment will be provided based on the New Coronavirus Pneumonia Prevention and Control guideline (9th edition), published by National Health Commission of China
223609550|NCT03539601|DRUG|Crisaborole ointment, 2%|Applied twice a day (BID)
223609551|NCT03539601|DRUG|Hydrocortisone butyrate cream, 0.1%|Applied BID
223609552|NCT03539601|DRUG|Pimecrolimus cream, 1%|Applied BID
223755956|NCT05915767|DIETARY_SUPPLEMENT|Olive leaf tea|Fresh olive leaves will be procured from Chakwal, Pakistan. The leaves will be rinsed to remove dust and debris and dried at 40℃ in the oven. The leaves will be ground into powder form and then incorporated in tea bags containing 1.8 g leave powder/tea bag. Participants in treatment group will be instructed to dip the tea bag in 200-250 ml boiling water for 3-5 minutes.
223755957|NCT05351424|OTHER|Audiovisual Intervention- Radiation Therapy Education|A video with educational information will be shown regarding radiation therapy.
224200906|NCT04261153|OTHER|Cognitive stimulation|3 cognitive stimulation sessions in total from the HAPPYNeuron® software, approximately 20 minutes each and spread over several days
224200907|NCT05345418|BIOLOGICAL|Umbilical Cord-Derived Mesenchymal Stem Cell for Male Patients with Sexual Deficiency|Patients will receive two administrations at a dose of 1.5 million cells/kg patient bodyweight via the IV route with a 3-month intervening interval. A validated umbilical cord blood mesenchymal stem cells (UC-MSC) line was selected from the Vinmec Tissue Bank and cultured under xeno-free, serum-free and antibiotic-free conditions as previously described. To prepare UC-MSCs for therapy, aliquots of Passage 3 (P3) UC-MSCs will be thawed and cultured to P5 to get approximately 500 million cells and dispensed to 10 million UC-MSCs/ml/vial for cryopreservation. Upon request from the clinical team, aliquots of P5 UC-MSCs will be thawed in a temperature control water bath or incubator on the infusion day. The UC-MSCs will be washed and suspended in Ringer Lactate.
224200908|NCT02874820|RADIATION|[11C]BU99008|Baseline and blocked scans
224200909|NCT02874820|DRUG|Idazoxan|Idazoxan dose up to 80mg
224200910|NCT04040738|PROCEDURE|Upper extremity surgery under general anaesthesia|Forearm, wrist and hand surgery after fentanyl and propofol induction of anaesthesia, with sevoflurane maintenance
224200911|NCT04040738|PROCEDURE|Upper extremity surgery under regional anaesthesia|Forearm, wrist and hand surgery under brachial plexus block with 0.4 ml/kg of 0.33% bupivacaine solution Other Names: Marcaine 5 mg/ml Astra Zeneca OGYI-T 6496/14
223609553|NCT03539601|DRUG|Crisaborole Vehicle|Applied BID
223609554|NCT06062329|DEVICE|Symphony Thrombectomy System|The Symphony Thrombectomy System will be used to restore blood flow to the pulmonary arteries by removing thrombus/embolus/clot using aspiration and mechanical clot engagement.
223609555|NCT04875091|BEHAVIORAL|Ready SET Health|"This behavioral weight loss intervention will span 16 weeks. The first session (Week 1) will be a virtual Weight Loss 101 group kick-off followed by 15 weeks of a technology-mediated program consisting of the following: weekly emailed content (videos and readings explaining key skills and strategies to produce weight loss) and weekly emailed tailored feedback (based on self-monitoring data from participants). A trained interventionist (coach) will lead the group session, provide weekly tailored feedback, and monitor participant progress."
223609556|NCT01970306|DEVICE|MatriStem PSM|All esophageal anastomoses will be reinforced circumferentially with ACell MatriStem PSM.
223609557|NCT01444885|DRUG|Placebo|2 weeks treatment of Cilostazol 100mg, or placebo oral tablets bid after 2 weeks treatment of Cilostazol 50mg, or placebo oral tablets bid (Total 4 weeks)
223609558|NCT01005498|DIETARY_SUPPLEMENT|Low carbohydrate - high fat diet|The diet has an energy content of 1600 kcal or 1800, with 50% from fat, 20% from carbohydrates and 30% from proteins.
223609559|NCT01005498|DIETARY_SUPPLEMENT|High carbohydrate - low fat diet|The diet has an energy content of 1600 or 1800 kcal, with 30% from fat, 55-60% from carbohydrates and 10-15% from proteins.
223609560|NCT00226811|DRUG|Sunitinib|50mg daily, taken by mouth for 28 days followed by 2 weeks of drug free period was one cycle. Cycles were repeated until progression of disease or unacceptable toxicity was observed
223609561|NCT03136289|BEHAVIORAL|Family Consumer Behaviors|The relationship between family consumer behaviours (healthy food availability and supermarket spending) and adolescent prediabetes and diabetes.
223609562|NCT06465004|DIETARY_SUPPLEMENT|Consumption of protein - rich drink|The participants will drink on of three protein - rich drinks
223609563|NCT06498206|OTHER|AR training|Dichoptic augmented reality training with dual-pathway (parvocellular pathway and magnocellular pathway) and interocular push-pull paradigms developed based on neural deficits in unilateral amblyopia.
223609564|NCT06498206|OTHER|Patching|Conventional patching therapy.
223609565|NCT00982826|DRUG|ABT-072|See Arms information for a detailed description.
223609566|NCT00982826|DRUG|Placebo|See Arms information for a detailed description.
223609567|NCT05026359|DEVICE|Bilateral ankle coordination training|Developed a novel bilateral ankle coordination training program with visual feedback and bilateral ankle control, based on the concept of bilateral movement therapy. The bilateral ankle coordination training includes 3 days a week, 30 minutes each time, lasting 4 weeks, and a total of 12 training sessions.
223609568|NCT00644020|DRUG|mitomycin, Fluorouracil|All participants will receive 10mg mitomycin and 1g Fluorouracil through the chemoradiative pump which was transplanted during the operation, and this procedure would be executed a day before each research treatment period.
223609569|NCT04728386|OTHER|curcumin solution|2 % curcumin solution as root canal irrigant
223609570|NCT04728386|OTHER|sodium hypochlorite|2.5% sodium hypochlorite solution as root canal irrigant
223609571|NCT00550017|DRUG|Epofolate|Intravenous solution, intravenous, initially 3 patients will be treated and if there is a DLT then additional 3 patients will be treated in that dose level. 3-5 minute IV bolus on Days 1 through 4 of a 21-day cycle, until the disease progresses
223609572|NCT04811846|DEVICE|Bipolar transurethral resection of bladder tumor (TURBT)|Standard resection in piecemeal technique with standard bipolar cutting loop. (Storz medical, 27040 GP1)
223609573|NCT04811846|DEVICE|Bipolar transurethral plasma kinetic vaporization of bladder tumor (PKVBT)|Vaporization of bladder tumor with standard bipolar vaporization electrode. (Storz medical, 27040 NB)
223609574|NCT00745537|OTHER|repeated mood measures and phone depression care management|The adolescent mothers will be assigned a depression care management who will support the mother in making choices about depression treatment, educate about treatment options, discuss barriers and solutions, counsel to comply with treatment recommendations, and assisted to problem-solve if failure to respond occurs.
223609575|NCT06056661|BEHAVIORAL|WMR|Participants will complete up to five sessions that will take 2 hours each. Sessions will take place in person. Participants will learn skills related to getting into and out of romantic relationships and identifying and pursuing goals for romantic relationships.
223755958|NCT05351424|OTHER|ASTRO Radiation Therapy for Breast or Prostate Cancer Brochure|Brochure with written information will be given to the subject regarding radiation therapy.
223755959|NCT05351424|OTHER|Audiovisual Intervention- Cancer Clinical Trials Education|A video with educational information will be shown regarding cancer clinical trials.
223755960|NCT05351424|OTHER|NCI Taking Part in Cancer Research Studies Brochure|Brochure with written information will be given to the subject regarding cancer clinical trials.
223755961|NCT06092515|DIETARY_SUPPLEMENT|Fermented High Zinc Wheat Flour Flatbread|"* Participants in this group will receive flatbreads made from fermented high zinc wheat flour.~* The flatbreads will be prepared using traditional fermentation methods.~* These flatbreads will be provided to participants to consume daily, along with vegetables or pulses (daal), for six days a week over the course of six months."
223755962|NCT06092515|DIETARY_SUPPLEMENT|Unfermented High Zinc Wheat Flour Flatbread|"* Participants in this group will receive flatbreads made from unfermented high zinc wheat flour,~* The flatbreads will not undergo a fermentation process.~* These flatbreads will be provided to participants to consume daily, along with vegetables or pulses (daal), for six days a week over the course of six months."
223609576|NCT04783909|PROCEDURE|Phacoemulsification cataract surgery|All surgeries were performed using Infinity (Alcon Laboratories, Inc.) under topical anaesthesia by one surgeon through 2.2 mm incision in the upper corneal limbus. The hydroimplantation of IOL to the capsular bag was performed in all cases.
223609577|NCT00652795|DRUG|Doxycycline Monohydrate|Tablets, 150 mg, single-dose
223609578|NCT00652795|DRUG|Monodox|Capsules 50 mg (3 x 50 mg dose), single-dose
223609579|NCT00421057|BEHAVIORAL|Combined Strength Training and Functional Endurance Exercise|Participants will be taught to stretch a Theraband as far as your arms or legs can stretch and the proper posture for walking for exercise. The Estimated Timed-Get-Up and Go test (ETGUPGo) and a 6-minute walk test will be performed to check your level of fatigue and physical ability.
223609580|NCT00421057|BEHAVIORAL|Questionnaire|Questionnaires taking approximately 30 minutes total to complete.
223609581|NCT02733523|BEHAVIORAL|"Program Sentirnos bien (Feeling well)"|"Group-based intervention delivered face-to face and held once a week during 3 months. It comprises:~1. Promoting the uptake of self-care healthy habits: providing information, setting personal goals and sharing experiences to facilitate behavioural change, specially on physical activity and healthy dietary habits.~2. Promoting social capital at individual level: facilitating mutual knowledge and mutual support among participants and fostering participation in sociocultural and community activities in the neighbourhood through visits to the community assets accompanied by volunteers.~3. Promoting health literacy: improving navigation through the health care system, communication with health professionals, as well as the understanding and decision making when buying food."
223609582|NCT02003092|DRUG|RX-5902|escalating doses (mg)
223609583|NCT01523418|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|The treatment with Xarelto 10mg tablets should comply with the recommendations. Rivaroxaban 10mg OD, 6-10 hours post-op, provided hemostasis has been achieved, for a period of 2 weeks (TKR) \& 5 weeks (THR)
223755963|NCT06092515|DIETARY_SUPPLEMENT|Post-Harvest Fortified Whole Wheat Flour Flatbread|"* Participants in this group will receive flatbreads made from whole wheat flour fortified post-harvest~* These fortified flatbreads will be provided to participants for daily consumption, along with vegetables or pulses (daal), for six days a week over the course of six months."
223755964|NCT06092515|DIETARY_SUPPLEMENT|Low Zinc Whole Wheat Flour Flatbread (Control Group)|"* Participants in this group will serve as the control group.~* They will receive flatbreads made from whole wheat flour with a low zinc content~* These low zinc flatbreads will be provided to participants for daily consumption, along with vegetables or pulses (daal), for six days a week over the course of six months. six days a week over the course of six months."
223755965|NCT04682821|OTHER|Artificial intelligence assistant system|The intervention is the use of the artificial intelligence assistant system in addition to the common training. The system is an non-invasive AI system which could help the endoscopists to diagnosis and monitor the blind spot during the gastroscope.
223755966|NCT00096512|DRUG|sorafenib tosylate|Given orally
223755967|NCT00096512|OTHER|laboratory biomarker analysis|Correlative studies
223755968|NCT04013620|DRUG|Belatacept 250 Milligram Intravenous Powder for Solution|"Phase 1 (from 3 to 12 months post transplantation): conversion to belatacept (IV, 5mg/Kg days 1, 15 and 30 then every months) and CNI withdrawal.~Phase 2 (from 12 to 18 months post transplantation) : belatacept arrest and CNI resumption (tacrolimus target 6 ng/ml)"
223755969|NCT05428475|DIAGNOSTIC_TEST|[18F]FDG-PET Scan|185 MBq of \[18F\]FDG will be administered IV 30 minutes prior to PET scan. Images will be acquired for 30 minutes. Resulting images will be evaluated for patterns of FDG-uptake to support the diagnosis of the participant symptoms of cognitive impairment.
223755970|NCT03384251|BEHAVIORAL|comprehensive sex education|A comprehensive sex education program to be delivered in approximately six (6) sessions comprising of an introductory lesson on susceptibility and severity of teenage pregnancy, personal and community values, female reproductive system, contraception and decision-making skills.
223755971|NCT06240156|OTHER|3D arch pad design Insole group|3D three-dimensional design that is already available on the market (patent number I315187). Its arch support principle is designed using 3DBS (Three-Dimensional Biomechanics System - 3DBS), which can conform to the user's feet.
224200912|NCT02871921|BEHAVIORAL|Conversational Engagement|Examine whether increasing social interaction through face-to-face (video chat) conversations could improve cognitive function and whether the efficacy is mediated by improved psychological well-being, targeting older adults aged 75 and older who are socially isolated
223609584|NCT03670563|OTHER|Short foot exercise protocol|Exercises that target intrinsic foot muscles
223609585|NCT03670563|OTHER|Short foot exercise plus NMES|Exercises that target intrinsic foot muscles supplemented by NMES for muscle re-education
223755972|NCT06240156|OTHER|flat Insole group|General Insole without any special features
224200913|NCT05937230|DEVICE|Drug-coated balloon|Paclitaxel is a pharmacologically active substance for anti-neointima.
224200914|NCT05937230|DEVICE|Drug-eluting stents|Drug-eluting stent is composed of a metal stent, primer, and drug coating.
224200915|NCT00394121|DRUG|Fluticasone propionate/formoterol fumarate|
224200916|NCT02162381|DRUG|methylphenidate|a single dose of methylphenidate 10 mg to be taken orally in the morning
224200917|NCT02162381|OTHER|guidance|subjects will be given an explanation and advice about how to perform well in visual field testing
223609586|NCT03081884|DRUG|FACBC PET-CT Imaging|"Participants will fast for 4 hours to normalize their neutral amino acid levels. One hour prior to the scan, participants will drink up to 450ml of standard oral contrast. Participants will lie on the scanning bed while the bed moves through the PET/CT scanner for the CT portion of the exam. After completion of the CT scan, approximately 10 units of FACBC will be injected for the PET scan portion of the exam. The bed will move through the scanner again and the PET portion of the exam will take 30 minutes. The entire visit will take about two hours.~Standard of care procedures include conventional imaging (CT and/or MRI; bone scan and/or NaF PET per institutional standards) and radical prostatectomy with extended pelvic lymph node dissection."
223609587|NCT03676972|DEVICE|LithoVue Ureteroscope System|The LithoVue System is intended to be used to visualize organs, cavities and canals in the urinary tract (urethra, bladder, ureter, calyces and renal papillae) via transurethral or percutaneous access routes.
223609588|NCT02552134|OTHER|exercise training|
223609589|NCT02552134|OTHER|recommendation to be active|
223609590|NCT03948334|DRUG|ZPL389 30mg|30mg of ZPL389; once daily
223609591|NCT03948334|DRUG|ZPL389 50mg|50mg of ZPL389; once daily
223609592|NCT03948334|DRUG|TCS and/or TCI|Topical corticosteroids (TCS) and /or topical calcineurin inhibitors (TCI) were used concomitantly or intermittently based on disease severity.
223609593|NCT04339829|DRUG|Dacomitinib|Dacomitinib orally on a continuous daily basis at a starting dose of 45 mg QD
223609594|NCT02169986|BEHAVIORAL|electronic reminders|
223609595|NCT00598936|DEVICE|CDI 1000 COM and INVOS 5100|CDI 1000 and INVOS 5100 sensors were attached to subject's forehead for a 12 hour period, digital photographs were taken before and after sensor placement.
223609596|NCT00497757|BIOLOGICAL|enriched hematopoetic stem cell infusion|Enriched Hematopoetic Stem Cell Infusion
223609597|NCT05897229|OTHER|Analysis of costs with patient care during hospitalization|Analysis of direct costs with supplies, medications, diets, laboratory tests and imaging exams, and invasive procedures such as mechanical ventilation, dialysis, and the use of vasoactive drugs.-analysis of costs referring to working hours of physicians, nurses and physical therapists in each unit normalized for the same number of beds.- cost minimization and consequential cost analysis.
223609598|NCT01128426|OTHER|No Intervention|No Intervention
223755973|NCT01397175|DEVICE|Biolimus-eluting stent|Biolimus-eluting stent (BES, BioMatrix or BioMatrix Flex, Biosensors, USA) has bio-degradable polymer which is consisted with poly-lactic acid (PLA) and degraded into H2O and CO2 while releasing the biolimus. BES would be expected to reduce the stent thrombosis comparing with the DES with durable polymer.
223755974|NCT01397175|DEVICE|Everolimus-eluting stent|Everolimus-eluting stent (EES, Xience V or Xience Prime, Abbott, USA) use the MULTILINK VISION stent platform and durable polymer containing everolimus. It has the thinnest strut thickness among the available DES in Korea.
223755975|NCT01397175|DEVICE|Zotarolimus-eluting stent|Zotarolimus-eluting stent with biolinx polymer (ZES, Endeavor Resolute or Endeavor Resolute Intergrity, Medtronic, USA) has DRIVER stent platform. The durable polymer in this DES has changed from phosphorylcholine (PC) polymer which was used in Endeavor to Biolinx polymer which has more biocompatible features.
224200918|NCT00709904|DRUG|Open-label Semuloparin sodium|"0.4 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml pre-filled syringe~Subcutaneous injection once daily with an initial dose given 8 hours after surgery"
223609599|NCT03087136|DIAGNOSTIC_TEST|anti-aquaporin-4 antibody|Serum anti-aquaporin-4 antibody
223609600|NCT03087136|DIAGNOSTIC_TEST|anti-myelin oligodendrocyte glycoprotein|Serum anti-myelin oligodendrocyte glycoprotein
223609601|NCT03796065|BEHAVIORAL|FSI-R Treatment|The FSI-R involves a series of separate and joint meetings with parents and children to discuss challenges the family has faced and the strengths that helped them make it through past challenging times. Additional psychoeducation on mental health and promoting resilience along with coaching to enhance parenting skills is provided throughout and may be tailored to family needs. The FSI-R provides a shared space for refugee families both to recognize their strengths and to problem-solve in a more collective way on family challenges and shared hopes for the future. The FSI-R is delivered in the home, by a trained interventionist, over the course of 10-modules.
223609602|NCT02442024|BEHAVIORAL|Modified Diet|Two months of a diet in which the ingestion of protein and lipid precedes that of carbohydrates.
223609603|NCT02442024|BEHAVIORAL|Standard Diet|Two months of a diet in which the ingestion of protein and lipid follows that of carbohydrates.
223609604|NCT04483726|PROCEDURE|minimally invasive distal pancreatectomy|Minimally invasive distal pancreatectomy (either laparoscopic or robot-assisted)
223609605|NCT04483726|PROCEDURE|open distal pancreatectomy|open distal pancreatectomy
223609606|NCT04807933|BEHAVIORAL|Heart rate variability Biofeedback [HRV-BFB]|BFB consists of a physiological recording used as a visual physiological feedback that can teach us how to control our physiology, which is naturally unconscious and uncontrollable. The BFB focused on the heart rate variability (HRV-BFB) could regulate the autonomic nervous system (vagal tone and sympathetic-parasympathetic balance) and the emotional state. The HRV BFB has received several clinical and experimental confirmations as a physiological remediation method. It is an innovative and non-pharmacological therapy frequently used to relieve stress.
223755976|NCT00093457|DRUG|sorafenib tosylate|BAY 43-9006 given orally at 400 mg BID in a 28 day cycle
224200919|NCT00709904|DRUG|Placebo (for Semuloparin sodium)|"0.4 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml prefilled syringe strictly identical in appearance containing the same volume but without active component~Subcutaneous injection once daily"
224200920|NCT00709904|DRUG|Semuloparin sodium|"0.4 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml pre-filled syringe~Subcutaneous injection once daily"
224200921|NCT06379139|OTHER|•Dynamic Full-Field Optical Coherence Tomography analysis of endotracheal tube|Dynamic full-field optical coherence tomography analysis of endotracheal tube sections to better apprehend strucural characterization of endotracheal tube-deposited biofilm
224200922|NCT02263222|DRUG|MDT-10013|
224200923|NCT04094402|OTHER|None. It is an observational study|None. It is an observational study
224200924|NCT02353572|DRUG|Melphalan|Given IV
224200925|NCT02353572|DRUG|Bortezomib|Given IV
224200926|NCT02353572|DRUG|Dexamethasone|Given IV
224200927|NCT02353572|PROCEDURE|Autologous Transplant|Undergo autologous hematopoietic stem cell transplant
224200928|NCT03004430|BEHAVIORAL|Mantra Meditation|Silent mantra meditation with spiritual mantra
223755977|NCT01389180|BEHAVIORAL|Behavioral Drug and HIV Risk Reduction Counseling|BDRC is a highly individualized, structured, and prescriptive behavioral treatment designed to be provided by nursing or other available personnel in China who generally do not have advanced training or experience in psychotherapy or counseling techniques. BDRC provides education about HIV, Hepatitis C, and other bloodborne or infectious diseases, heroin addiction and MMT, incorporates coping skills training components of CBT, and makes use of explicit and detailed short-term behavioral contracts (either verbal or written), aimed at small, easily achievable, and measurable objectives linked to reduction of HIV risk behaviors and heroin use and improvements in daily functioning supporting sustained recovery
223609607|NCT02472574|DEVICE|YL-1 type of intracranial hematoma puncture needle|YL-1 type of intracranial hematoma puncture needle(Pat. NO.is ZL：93244252•8) was originated by Beijing WanTeFu Medical Apparatus Co.Ltd in 1997. With integration of needle and bur drill it is designed as hard tunnel.By the technique of skull self-holding, the puncture needle can being fixed in the target of haematoma for several days.This technique is convenient, simple and safe. To position haematoma's location, drills 3 millimeter holes in the localization point of puncture, then insert the drainage tube to inhale hematoma, gives the filament resolver interrupted for liquefication drainage afterward.
223609608|NCT02472574|DRUG|rt-PA|Up to 4 doses of 0.3\~1.0 mg of rt-PA will be administered through the catheter that was placed directly into the intracerebral hemorrhage using minimally invasive surgery.
223609609|NCT00775996|DRUG|Clorazepate Dipotassium 15mg Tablets|
223609610|NCT04448977|DRUG|Ocrevus|"Participants with MS will be divided into two treatment groups: those who will begin to take Ocrevus (the early Ocrevus group (EO), and those who plan to be begin treatment with Glatimer acetate SC (Copaxone) (EC). Both groups will be matched to the EO group for age, gender and education. The HC group will be free of neurological disease or injury and will be matched to the EO group for age, gender, and education."
223609611|NCT01592071|OTHER|Replace reactive foods with non-reactive foods|Subjects were provided with the test results and an individualized dietary plan based on replacing reactive foods with non-reactive foods as replacements per the Immuno Bloodprint results.
223609612|NCT00818792|DEVICE|Coronary stent|Comparison of bare-metal stent (Vision) and drug-eluting stent (Xience V)
223609613|NCT01100320|DRUG|Reformulated OXY (oxycodone HCl)|Reformulated OXY 40-mg tablet x 1 dose taken with food
223609614|NCT01100320|DRUG|Original OxyContin® (OXY) (oxycodone HCl)|Original OxyContin® (OXY) 40-mg tablet x 1 dose taken with food
223609615|NCT04036981|DRUG|Botulinum toxin type A|Injection of botulinum toxin A into the spastic elbow flexor muscle or muscles
223609616|NCT00550953|DRUG|telmisartan+amlodipine|
223609617|NCT00550953|DRUG|telmisartan|
223755978|NCT01389180|BEHAVIORAL|Educational Counseling|EC uses a didactic lecture-discussion format, incorporating charts, slides, and audiovisual materials and handouts, to educate the patient about core recovery topics, including HIV and other infectious diseases transmission and effective protection strategies, heroin addiction and treatment with methadone maintenance, the importance of taking the methadone regularly, staying away from drugs, and improving social, family and vocational functioning.
223755979|NCT01389180|BEHAVIORAL|Treatment as Usual|TAU group will receive manual-guided minimal counseling approximating the current standard of care provided in MMTs in China, consisting of an initial introductory session (introduction to MMT and basic education about HIV risks) and subsequent, brief (up to 20 minutes) support and advice sessions once per month
223755980|NCT00994331|PROCEDURE|Percutaneous coronary intervention|non surgical procedure to open blocked coronary arteries
223755981|NCT04055857|OTHER||There is no Intervention.
224200929|NCT03004430|BEHAVIORAL|Progressive Muscle Relaxation|Progressive Muscle Relaxation
223755982|NCT01446965|DEVICE|wearable defibrillator|LifeVest wearable defibrillator
223755983|NCT02852265|DRUG|Etonogestrel contraceptive implant|Place nexplanon
223755984|NCT04050111|BIOLOGICAL|Stromal-vascular fraction|Concentrate of stromal-vascular fraction of cells derived from autologous adipose tissue
224200930|NCT00658086|DRUG|ALN-RSV01|administered by nebulization once daily for 3 days
224200931|NCT00658086|DRUG|normal saline|administered by nebulization once daily for 3 days
224200932|NCT00258310|DRUG|capecitabine|Capecitabine 1000mg/day for one year
224200933|NCT00258310|PROCEDURE|Surgery, chemotherapy and/or radiotherapy|Surgery, chemotherapy and/or radiotherapy
224200934|NCT03099655|DEVICE|Attain Stability Quad Left Ventricular Pacing Lead|cardiac stimulation
224200935|NCT00024557|DRUG|IL13-PE38QQR|
224200936|NCT00024557|PROCEDURE|targeted fusion protein therapy|
224200937|NCT00024557|PROCEDURE|surgery|
224200938|NCT04962958|PROCEDURE|Hepatic arterial infusion chemotherapy|administration of Oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries
224200939|NCT04962958|DRUG|Folfox Protocol|Oxaliplatin , fluorouracil, and leucovorin
223609618|NCT06262100|DEVICE|Carragelose|Application of Carragelose containing eye drops
223609619|NCT04005261|DIAGNOSTIC_TEST|C-peptide concentrations|The patients will be grouped by their C-peptide concentrations
223609620|NCT05398094|DRUG|Sotorasib|AMG510 (Sotorasib) is small molecule that specifically and irreversibly inhibits the KRAS-G12C mutant protein. AMG510 (Sotorasib) finished product is presented as tablets containing 120mg and will be packaged in bottles of 120 tablets.
223609621|NCT03534193|OTHER|Molly Center Diabetes Care Guide (Paper-based)|Diabetes education with Registered Nurse in addition to Paper based education modules
223609622|NCT03534193|OTHER|Tablet based interactive diabetes education modules|Molly Center Standard Diabetes Education plus access to interactive diabetes education modules through bedside tablet.
223609623|NCT05395325|OTHER|Kinesiotaping|Kinesio tape would be applied (1)over the extensor muscles of the affected hand for facilitating the extension of hand. We will apply the tape from the upper 1/3 length of dorsal side of the forearm and split the tape into five equal bars to the distal interphalangeal joint of each finger along the finger bones. (2) from above the scapula spine to the medial deltoid. (3) from medial border of scapula to anterior deltoid.This intervention would be executed for five days per week for three weeks.
224200940|NCT04962958|DRUG|Donafenib|administration of Donafenib
224200941|NCT03741816|DRUG|Indirect pulp capping|Indirect pulp capping is a procedure in which a material is placed on a thin partition of remaining carious dentin that, if removed might expose the pulp.
223609624|NCT05395325|OTHER|Hand rehabilitation program|In the thirty-minute hand rehabilitation program, a motor-relearning theory would be implemented into the intervention by teaching the participants how to use their upper limb properly without any compensatory motions. Therefore, for establishing a correct movement pattern, an occupational therapist would provide a hand-guided activity, in which the participants could practice reaching movement as well as hand grasp and release in a more natural way. Besides, the therapist would also help the patients release their muscle tone by stretching the spastic muscles for five minutes before and after this hand rehabilitation period
223609625|NCT05395325|OTHER|Steroid injection|all the steroid injection would be executed by physicians. The 23G needles would be used for the injections. The examiners would be clear and familiar with the protocol, and the injections would be executed for only one time during the study period in experimental group.
223609626|NCT04777331|DRUG|Prasinezumab|Prasinezumab will be administered as an IV infusion to participants Q4W.
223609627|NCT04777331|DRUG|Placebo|Prasinezumab placebo will be administered to participants.
223609628|NCT04823442|DRUG|Mirabegron|Mirabegron: a single dose of 200 mg mirabegron (4 tablets of 50 mg)
223609629|NCT04823442|DRUG|Bisoprolol Fumarate|a single dose of 10 mg (2 tablets of 5 mg)
223609630|NCT04015206|OTHER|Group Interpersonal Psychotherapy|Group Interpersonal Psychotherapy added to usual treatment (Pharmacotherapy + clinical management)
223609631|NCT01079416|DEVICE|Capsule endoscopy, Esophagogastroduodenoscopy|
223609632|NCT05157126|DRUG|Gentamicin|Liquid gentamicin administered at the open fracture site
223609633|NCT05157126|DRUG|normal Saline|Normal saline administered at the open fracture site
223755985|NCT03764722|DRUG|Levosimendan|"The patient will initially receive a standard dose of 0.1 mcg/kgmc/min. In case of good tolerance of the drug - the dose will be increased to 0.2 mcg/kgmc/min. If hypotension SBP \<90 mmHg occurs, the dose will be reduced to 0.05 mcg / kgm / min. If the hypotension persists despite the reduction of the drug - the infusion will be terminated and the patient will be excluded from the study. The infusion will be terminated within 24 hours, the patient will be examined again 4 hours after the end of the infusion, by the attending physician and unless there are contraindications - discharged home.~Patients will be hospitalized every 4 weeks for the next 6 months."
223755986|NCT06452524|DEVICE|axial length (AU) and anterior chamber depth (ACD), optical coherence tomography (OCT)|Non-cycloplegic and cycloplegic refraction, best corrected visual acuity (BCVA), axial length (AU) and anterior chamber depth (ACD), optical coherence tomography (OCT) macular and OCT subfoveal choroidal measurements were performed in all cases.
223755987|NCT02432716|DRUG|Insulin glulisine|Insulin (glulisine) Glulisine 20 IU/IN (.1ml/10 units intranasal in each nostril), once per study
223755988|NCT02432716|DRUG|Saline|Placebo Comparator: Placebo Sterile Normal Saline 20 IU/IN (.1ml intransal in each nostril), once per study
223755989|NCT06469255|OTHER|Diet Treatment|4 weeks low calorie diet treatment
223755990|NCT01389297|BEHAVIORAL|SMART Recovery face-to-face meetings|Attending these meetings at least weekly in frequency
223755991|NCT01389297|BEHAVIORAL|Overcoming Addictions web application|Logging into and using the web application at least weekly during the course of the study
223755992|NCT04212585|DIAGNOSTIC_TEST|Serology test|"Serology for Helicobacter pylori (immunoglobulin G for all sites, immunoglobulin M optional, immunoglobulin A optional) will be collected from all participants. 90 samples (immunoglobulin G, immunoglobulin M and immunoglobulin A) at least needed from each site.~Stool antigen for Helicobacter pylori"
223755993|NCT01828034|DRUG|Gemcitabine|
223755994|NCT01828034|DRUG|Cisplatin|
223755995|NCT01828034|DRUG|MEK162|
223755996|NCT00253565|DRUG|capecitabine|
223755997|NCT00253565|DRUG|imatinib mesylate|
223755998|NCT06103006|OTHER|Telerehabilitation|The structured telerehabilitation program focused on 4 specific objectives: breathing, stretching, posture, and stability. The duration was between 20-30 minutes. Exercises involving the major muscle groups (upper, lower extremity, and trunk muscle groups) were applied by the physiotherapists. Strengthening and stretching sets and repetitions were started with 1 set of 8-15 reps (progress to \>1 set).
223755999|NCT02871375|DEVICE|Delefilcon A multifocal contact lenses|Multifocal contact lenses worn in a daily wear, daily disposable modality (new pair of lenses each morning)
223756000|NCT02871375|DEVICE|Habitual multifocal contact lenses|Multifocal contact lenses worn per subject's habitual prescription and habitual daily wear modality
223609634|NCT05556759|PROCEDURE|control|patient will be operated under general anesthesia
223609635|NCT05556759|PROCEDURE|IPS|patients will receive ultrasound-guided anterior IPS block with 30 ml of bupivacaine 0.25% followed by general anesthesia.
223609636|NCT05556759|PROCEDURE|Supra-iliac QL|patients will receive ultrasound-guided supra-iliac anterior QL block with 30 ml of bupivacaine 0.25% followed by general anesthesia.
223609637|NCT00442728|DEVICE|ELECTRICAL STIMULATION|
223609638|NCT00812773|DRUG|GSK2190915|Investigational Product
223609639|NCT00264199|DRUG|GLP-1|iv. by weight (1.0 pmol/kg/min )
223609640|NCT00264199|DRUG|placebo|same rate of infusion as GLP-1
223609641|NCT00596752|DRUG|Alprostadil|"* Active Substance: Prostaglandin E1~* Pharmaceutical Form: solution for infusion~* Concentration: 40 μg b.d.~* Route of Administration: intravenous infusion"
223609642|NCT00596752|OTHER|Placebo|"* Active Substance: Lactose~* Pharmaceutical Form: solution for infusion~* Concentration: 40 μg b.d.~* Route of Administration: intravenous infusion"
223609643|NCT00006474|DRUG|O6-benzylguanine|
223609644|NCT00006474|DRUG|temozolomide|
223609645|NCT00006474|PROCEDURE|conventional surgery|
223756001|NCT03592121|DRUG|AB-101|Apply approximately 1 hour prior to sexual activity
223756002|NCT03592121|DRUG|Placebo|Apply approximately 1 hour prior to sexual activity
223756003|NCT02850874|PROCEDURE|Hyperthermic intraperitoneal chemotherapy|HIPEC in this study involves the washing of the peritoneal cavity with a heated (40-48°C), (1000 mg/m sq) solution of gemcitabine in 1.5% dextrose for 90 min. Compared with systemic delivery of chemotherapy, intraperitoneal delivery can increase site-specific concentration of chemotherapeutic agents and decrease duration of perfusion, vascular complications, and systemic toxicity. The use of heated chemotherapeutic agents, compared to conventional protocols, has been shown to increase direct cytotoxicity to malignant cells and augment penetration into tumors.
224200942|NCT01004575|DEVICE|implantation of Kaname Cobalt-Chromium coronary stent|implantation of Kaname Cobalt-Chromium coronary stent
223756004|NCT02850874|PROCEDURE|Open pancreaticoduodenectomy|"Tumors of the pancreatic head will be surgically removed by open PD (standard and pylorus-preserving approaches) with the aim of achieving en bloc R0 tumor resection (no macroscopic residual cancer remaining). In all patients, a lymphadenectomy will be performed along the hepatoduodenal ligament, common hepatic artery, vena cava, and the interaortocaval and right side of the superior mesenteric artery. In cases with portal vein involvement, a venous resection will be performed to achieve R0 resection. Patients with arterial infiltration by the tumor will be deemed locally nonresectable and will be excluded from analysis.~Established, routine surgical and ERAS protocols will be followed for pre-, intra-, and postoperative care of patients. Patients will be discharged after postoperative day 5 if tolerating oral intake and showing no signs or symptoms of complications."
223756005|NCT02850874|DRUG|Gemcitabine|Neoadjuvant and adjuvant systemic chemotherapy will be administered to all PDAC patients with the aim of diminishing the tumor burden and maximizing the chance of complete surgical resection. Gemcitabine (GEMZAR®) will be administered for 6 months (including period of neoadjuvant therapy) according to established institutional guidelines for dosing, frequency, duration, administration route, and setting.
223609646|NCT04716946|DRUG|Durvalumab|Patients will receive durvalumab 1500mg durvalumab via IV infusion over 1 hour, once every 4 weeks (Q4W) for up to a maximum of 6 months (up to 6 doses/cycles) unless there is unacceptable toxicity, withdrawal of consent, or another discontinuation criterion is met.
223609647|NCT04716946|RADIATION|Stereotactic Body Radiation Therapy|Radiation therapy will be performed with external beam ionizing radiation in accordance with institutional standard practice. 3D conformal radiation therapy (3D-CRT), intensity-modulated radiation therapy (IMRT) or volumetric arc therapy (VMAT) will be used at the discretion of the treating radiation oncologist.
223609648|NCT04770220|DRUG|Experimental: ALZ-801|ALZ-801 tablet 265 mg once daily in the evening for the first 2 weeks, then ALZ-801 tablet 265 mg BID
223609649|NCT04770220|DRUG|Placebo Comparator: Placebo|Placebo tablet BID
223609650|NCT05690984|DRUG|Dexamethasone|Dexamethasone will be used for the double purpose of premedication and therapeutic effect. On Day 1 of Cycle 1, subjects will be administered 40 mg dexamethasone as an IV infusion. On Days 8, 15, 22 of Cycle 1 and Days 1 and 15 of Cycles 2-4, dexamethasone will be given as a single oral dose of 40 mg. For Cycles 5-12, dexamethasone will be given as a single oral dose of 4 mg on Days 1 and 15.
223609651|NCT05690984|DRUG|Isatuximab|Following premedication (if applicable), subjects will be given isatuximab 10 mg/kg body weight as an intravenous (IV) infusion on Days 1, 8, 15, and 22 (i.e., weekly) during Cycle 1 and on Days 1 and 15 (i.e., Q2W) during Cycles 2-12.
223609652|NCT05690984|DRUG|Lenalidomide|On Days 1-21 for all 12 cycles, lenalidomide will be given to subjects as a single daily oral dose.
223609653|NCT04669301|BEHAVIORAL|MAAT-G|Memory and Attention Adaptation Training (MAAT) is a cognitive-behavioral therapy (CBT)-based intervention for CRCD. As a CBT-based intervention, MAAT focuses on an individual's psychological response to injury as compared to the biological events triggering CRCD. MAAT is a series of manualized workshops delivered by a psychologist via video-conferencing, supplemented by a participant workbook, which provide instruction and practice with adaptive behavioral coping skills, stress management techniques, and compensation strategies.
223609654|NCT04669301|BEHAVIORAL|Supportive therapy (time and attention control)|"Supportive Therapy (ST) is a behavioral placebo and controls for non-specific psychotherapeutic factors of the clinician-subject relationship, such as empathy and support, but does not provide active cognitive training. ST utilizes reflective listening to help deepen awareness of participants' emotional experience. Timing and duration of ST sessions will mirror the intervention, and will consist of 10 weekly sessions, 30 to 45 minutes each, delivered by trained psychologists via video-conferencing."
223609655|NCT06514885|OTHER|SDF solution application|silver diamine fluoride (SDF) solution is highly effective in stopping and arresting the progress of decay in dental roots of older adults. The American Dental Association (ADA) has published a guideline based on the up-to-date evidence to support the use of SDF for managing tooth decay. As a non-invasive procedure, application of SDF is simple, quick, painless and non-aerosol generated.
223609656|NCT06514885|OTHER|Tonic water|Tonic water will be used as a placebo to mimic the SDF solution.
223609657|NCT02940496|DRUG|Elbasvir/Grazoprevir|Given PO
223609658|NCT02940496|OTHER|Laboratory Biomarker Analysis|Correlative studies
223609659|NCT02940496|BIOLOGICAL|Pembrolizumab|Given IV
223609660|NCT02940496|DRUG|Ribavirin|Given PO
223609661|NCT01970267|PROCEDURE|Laser Ablation of Floaters|
223609662|NCT01970267|PROCEDURE|Sham Laser Treatment|Laser will be set at 0.3 millijoules (mJ). There will be a 100% absorptive filter (black spot) of about 1cm placed centrally on the lens. All laser aiming beams will be placed within the 1cm filter. Laser will be applied at 0.3 mJ at the absorptive black spot (100% density filter) in order to create a realistic treatment therapy procedure.
223609663|NCT02652351|BIOLOGICAL|Human umbilical cord mesenchymal stem cells|A single dose of 2×107 hUC-MSC will be implanted to patients by intravenous infusion or Hepatic artery intervention, and repeated every week for four times.
223609664|NCT00820469|DRUG|Rituximab 375|rituximab 375 mg/m2 IV weekly, during 4 weeks
223609665|NCT00820469|DRUG|rituximab 1000|rituximab 1000 mg IV, two infusions on day 1 and day 15
223609666|NCT04118387|DRUG|Acetazolamide + supplemental oxygen + PAP therapy|Every participant will undergo measurement of the apneic threshold. The apneic threshold (AT) can be determined by inducing central apnea using non-invasive ventilation (NIV) or eliminating central apnea using supplemental CO2. The requisite change to induce central apnea is referred to as the CO2 reserve, which can be positive or negative. The central apnea index and the apneic threshold will be measured while participants receiving medication or oxygen (or both). In addition, participants will get PAP therapy during all the conditions.
223609667|NCT04118387|DRUG|Zolpidem + PAP therapy|The central apnea index and the apneic threshold will be compared under two conditions: zolpidem or placebo. In addition, participants will get PAP therapy during both the conditions.
223609668|NCT04118387|DRUG|Buspirone + PAP therapy|The central apnea index and the apneic threshold will be compared under two conditions: buspirone or placebo. In addition, participants will get PAP therapy during both the conditions.
223609669|NCT06907693|DIAGNOSTIC_TEST|CT Pulmonary Angiography Scan|Computed tomography (CT) pulmonary angiography scan of the chest with IV contrast
223756006|NCT01988571|DRUG|Atorvastatin|40 mg tablet taken by mouth each morning for 24 months.
223756007|NCT01988571|DRUG|Placebo|One placebo tablet taken each morning orally for 24 months.
223756008|NCT01150214|PROCEDURE|DE-MRI|Using Delayed-Enhancement Magnetic Resonance Imaging (DE-MRI) to identify fibrotic and scarred cardiac tissue. DE-MRI is a non-invasive method of identifying the extent and the distribution of structural remodeling or fibrosis and scarring associated with atrial fibrillation both pre- and post-ablation.
223609670|NCT06710860|BEHAVIORAL|The intelligent voice-interactive tailored communication system-based intervention|Participants in intervention group will receive the ScreenTalk intervention consisting of 3 modules:(1) a measurement module, (2) an algorithmic tailoring module, and (3) an open di-alogue module. All participants will be required to complete 3 modules within 1 month. If the intervention group does not undergo CRC screening at the follow-up time point, the system will repeatedly provide tailored communication intervention to further enhance the CRC risk perception of FDRs based on the current evaluation results. The primary outcome (uptake of CRC screening) will be measured at 3 months post-intervention (T1), 6 months post-intervention (T2), 9 months post-intervention (T3) and 12 months post-intervention (T4).
223756009|NCT01296516|BEHAVIORAL|Non-intervention group|A pedometer and written material on a healthy lifestyle.
223609671|NCT06911840|OTHER|No Intervention: Observational Cohort|No intervention
223609672|NCT06763991|PROCEDURE|Two-stage connection|Two-stage connection refers to a procedure that connecting and incorporating the cartilage framework with the residual ear during the second stage surgery of ear reconstruction. An intact cartilage framework is embedded in skin pocket in the first stage, hence, in the second stage of surgery, parts of the cartilage framework that has already survived will be shaved off to ensure the firm combination between the residual era cartilage and grafted costal cartilage.
223609673|NCT06763991|PROCEDURE|One-stage connection|One-stage connection refers to a procedure that connecting and incorporating the cartilage framework with the residual ear in the first stage surgery of ear reconstruction. In one-stage surgery, the cartilage framework is connected with the residual ear (non-deformed, unexcluded part) to form a smooth and complete ear subunit structure. In this way, it is necessary to trim the excess postauricular skin, which may pose a greater risk of blood supply. After the first stage of surgery, the overall appearance of surgical ear is already roughly similar to that of a normal ear.
223609674|NCT06927167|OTHER|Chin Tuck Exercise|Chin Tuck Exercises and Cervical Extension Exercises on Forward Head Posture
223609675|NCT06927167|OTHER|Seated cervical extension exercises|Perform seated cervical extension exercises focusing on activating posterior neck muscles
223609676|NCT06892483|OTHER|Pre-Pregnancy BMI|Pre-pregnancy BMI between 18.5-24.99
223609677|NCT06892483|OTHER|Pre-Pregnancy BMI|Pre-pregnancy BMI between 25-39.99
223609678|NCT06434766|DEVICE|sham stimulation|sham theta-burst transcranial magnetic stimulation
223609679|NCT06434766|DEVICE|intermittent theta-burst stimulation (iTBS)|intermittent theta-burst transcranial magnetic stimulation
223609680|NCT06920706|DEVICE|RIC|The ischemic preconditioning training device is applied to the subjects' upper arms to administer pressure (200 mmHg). The pressure is maintained for 5 minutes, followed by 5 minutes of release, completing one ischemia-reperfusion cycle. Each training session consists of 5 consecutive cycles, performed twice daily for 14 days.
223756010|NCT01296516|BEHAVIORAL|Face to face|Motivational meetings held once per week; Behavioral sessions weill be led by a trained interventionist.
223756011|NCT01296516|BEHAVIORAL|Telehelath Group|Participants will speak to Trestletree personnel once a week via phone.
223756012|NCT02233010|OTHER|The level of NGAL after pre op,post op 4hr, post op 12hr|
223756013|NCT00004412|DRUG|Arginine Butyrate|To determine if Arginine Butyrate accelerates healing of refractory leg ulcers over Standard Local Care alone.
223609681|NCT06920706|DEVICE|Sham-RIC|The ischemic preconditioning training device is applied to the subjects' upper arms to administer pressure (60 mmHg). The pressure is maintained for 5 minutes, followed by 5 minutes of release, completing one ischemia-reperfusion cycle. Each training session consists of 5 consecutive cycles, performed twice daily for 14 days.
223756014|NCT00004412|OTHER|Standard local care dressing|To heal leg ulcers.
223756015|NCT05190042|DEVICE|Cotinuous suture|Cotinuous suture using surgery thread
223756016|NCT05190042|DEVICE|Clips|Hemostatic clips
223756017|NCT05660694|DRUG|Triamcinolone|Comparison of Triamcinolone with Pentoxifylline and Vitamin- E Efficacy
223756018|NCT05660694|DRUG|Pentoxifylline with Vitamin E|Comparison of Triamcinolone with Pentoxifylline and Vitamin- E Efficacy
223756019|NCT00422331|DRUG|Lithium Carbonate Capsule|
223756020|NCT06291142|DEVICE|Observation - Nailfold capillaroscopy|Nailfold capillaroscopy examination
223756021|NCT00649896|DRUG|Mylan Estradiol Transdermal System 0.025 mg/day|
223756022|NCT00649896|DRUG|Climara® Transdermal System 0.025 mg/day|
223756023|NCT01071928|DRUG|Docetaxel|Docetaxel IV 75 mg/m2 over approximately 60 minutes on Day 1
223756024|NCT01071928|DRUG|ASA404|ASA404 (given after Docetaxel)IV 1800 mg/m2 over approximately 20 minutes on Day 1
223756025|NCT03891654|DIAGNOSTIC_TEST|Dynamic Contrast Enhanced Computed Tomography|Patients will receive DCE-CT prior to the start of standard of care, Stereotactic Body Radiation Therapy (SBRT), as well as 6 hours post administration of SBRT and 6 weeks post administration of SBRT.
223756026|NCT00422032|DRUG|Clofarabine|"Group A: 15 mg/m\^2 IV over 1 hour daily for 5 days~Group B: 30 mg/m\^2 IV over 1 hour daily for 5 days"
223756027|NCT03594383|DEVICE|ULTRASOUND|Lung ultrasound done through POCUS to diagnose pneumonia
223756028|NCT03283020|DRUG|RemifentanilMNTX|Remifentanil infusion TCI 3 ng/ml, Methylnaltrexone injection 0.3 mg/kg
223756029|NCT03283020|DRUG|PlaceboMNTX|Placebo (NaCl 0.9%) TCI infusion, Methylnaltrexone injection 0.3 mg/kg
223756030|NCT06646029|DEVICE|RMO flexion orthosis (splint)|RMO flexion is an orthosis fabricated by hand therapists made of thermoplastic material design to position the involved finger in relative flexion at the metacarpal joint compared to adjacent fingers to facilitate PIP extension during daily activity use.
223756031|NCT06646029|OTHER|Standard of care|Treatment includes finger stretches, active range of motion (AROM), passive range of motion (PROM), thermal modalities, LMB finger extension orthosis.
223756032|NCT06571981|DEVICE|TUP ultraportable US with teleradiology capacities|Comparison of abdominal ultrasound examinations in an at-risk population diagnosed with viral hepatitis: Ultraportable ultrasound with teleradiology capacities (TUP) versus conventional ultrasound (CUS).
223609682|NCT06921395|DRUG|Fang Le Shu (Follitrope)|rFSH 150 IU, 225 IU, 300 IU per syringe
223756033|NCT06571981|DEVICE|CUS conventional ultrasound|Comparison of abdominal ultrasound examinations in an at-risk population diagnosed with viral hepatitis: Ultraportable ultrasound with teleradiology capacities (TUP) versus conventional ultrasound (CUS).
223756034|NCT02346136|BEHAVIORAL|Tai Chi training|
223609683|NCT06921395|DRUG|Guo Na Fen (Gonal-F)|rFSH 450 IU per pen
223609684|NCT01895946|DRUG|AZD5363|Oral AZD5363 twice daily, 4 days on 3 days off: tablet formulation for one week, followed by two weeks with capsule formulation.
223609685|NCT01895946|DRUG|AZD5363|Oral AZD5363 twice daily, 4 days on 3 days off, tablet formulation. On day 4 AZD5363 tablet without food. On day 11 AZD5363 tablet with food.
223609686|NCT06935058|OTHER|Chocolade milk|Participants will drink 400 ml of chocolate milk after exercise.
223609687|NCT06935058|OTHER|Water (Placebo)|Participants will drink 400 ml of water after exercise.
223609688|NCT00979927|DRUG|SPC3649|5 weekly doses
223609689|NCT00979927|DRUG|saline|5 weekly doses
223609690|NCT06940609|DEVICE|accelerated intermittent theta burst stimulation|Intermittent theta burst stimulation (iTBS), a FDA-approved form of noninvasive neuromodulation, can reduce neuropsychiatric symptoms and modulate inflammation in the thalamus as detected using dMRS, suggesting a potentially effective and efficient treatment approach with a pathophysiological component that is readily quantifiable.
223609691|NCT04654260|BEHAVIORAL|Behavioral Therapy for Irritability in Autism|The child-focused components of BTIA are organized in modules dedicated to emotion regulation, problem solving and practice of planned steps to prevent or resolve conflicts. Each session contains a set of six to seven goals, and each goal contains a menu of techniques and activities that can be used to attain this goal. In order to administer the treatment in a flexible yet reliable manner, the therapist works collaboratively with the child and his or her parents to select activities that are perceived as relevant for attaining the session's goal. The parent-focused components of BTIA include include education about the effects of antecedents and consequences on disruptive behavior, developing strategies for reducing or altering antecedent events that may lead to disruptive reactions and helping parents to use reinforcement of competent and calm responses in potentially frustrating situations.
223756035|NCT02346136|BEHAVIORAL|Educational Control|
223756036|NCT03539835|OTHER|Resistance training (RT)|Resistance training (RT) will include 15 repetitions for two sets and to exhaustion on the third set for seven major muscle groups: the leg and chest press, knee extension, leg curl, row, abdominal crunch, and bicep curl. Resistance is gradually increased to account for strength gains when subjects are able to complete 20 repetitions on the third set.
223756037|NCT03539835|BEHAVIORAL|Cognitively-based compassion training control (CBCT)|Cognitively-based compassion training control (CBCT) classes will be performed in a group setting for 1.5-2 hours per week, and consist of didactics, class discussion, and guided meditation practice. Each class will begin with a period of meditation to calm and focus the mind, followed by analytical practices designed to challenge unexamined assumptions regarding feelings, and actions toward others with a focus on generating spontaneous empathy and compassion for themselves and others.
223756038|NCT06482008|DRUG|Hepatic arterial infusion chemotherapy(HAIC) combined with adebrelimab plus apatinib|HAIC every 3 weeks until 6 treatments have been completed, or HAIC therapy is terminated if patients have not reached 6 treatments and experience intolerable adverse effects; adebrelimab, fixed dose 1200 mg, IV, D1, every 21 days (Q3W), in combination with apatinib, 250 mg (0.25 g), orally, once daily (QD), consecutively dosing in 3-week (21-day) treatment cycles. Study treatment will continue until the subject develops an intolerable toxic reaction, withdraws informed consent, and progresses according to RECIST v1.1 as confirmed by the investigator (after the subject develops disease progression as defined by RECIST v1.1, if the investigator assesses that the subject is still clinically beneficial and can tolerate the study treatment, the subject may continue to receive the study drug; if it is considered that the subject no longer has clinical benefit, then treatment may be terminated), or other termination criteria specified in the protocol, whichever occurs first.
223756039|NCT05203263|DEVICE|(810A-v1) device prototype|Sequence with Serial Number from (810-v1 101) to (810-v1 140). Application on brown spots located on the face (6 treatments during the study).
223756040|NCT05203263|DEVICE|(810B-v1) device prototype|Sequence with Serial Number (810-v1 141) to (810-v1 160). Application on brown spots located on the face (6 treatments during the study).
223756041|NCT05203263|DEVICE|(810C-v1) device prototype|Sequence with Serial Number (810-v1 161) to (810-v1 200). Application on brown spots located on the face (6 treatments during the study).
223756042|NCT00129363|DRUG|Carvedilol|
223609692|NCT04654260|BEHAVIORAL|Psychoeducation and Supportive Therapy (PST)|Each PST session will start with a review of events of the past week and include queries of topics such as school, interests, hobbies, and family with an overarching goal of enhancing subjective well-being. A major objective is to enables the participant to discuss his or her concerns with a therapist toward a goal of enhancing overall psychological wellbeing. Education about autism diagnosis and services is also provided to families as part of PST.
223609693|NCT02640495|DRUG|Intravenous Artesunate as part of standard medical practice|Intravenous Artesunate 2.4 mg/kg
223609694|NCT05275036|DEVICE|early detection test|Blood collection and early detection testing
223609695|NCT06348667|OTHER|Specific ankle stability exercises|Exercise program specifically designed to address ankle dorsiflexion and mediolateral displacement of the center of pressure, using the described device (BB). Done twice a week for 5 weeks.
223609696|NCT06348667|OTHER|Conventional physiotherapy exercises program|Conventional exercise program performed in the center twice a week, of which all participants are part.
223609697|NCT03834831|DIETARY_SUPPLEMENT|Coenzyme Q10|Coenzyme Q10
223609698|NCT03834831|DIETARY_SUPPLEMENT|Selenium|Selenium
223609699|NCT03057275|DEVICE|Abdominal fetal/maternal monitoring|A single patch placed on the abdomen that incorporates 5 electrodes and a monitoring device
223609700|NCT05020210|DRUG|Sivelestat sodium|Patients were treated with Sivelestat Sodium within 72 hours of the diagnosis of ARDS.
223609701|NCT02671097|DRUG|Rosuvastatin|5 mg tablet single dose on Day 01 in Period 1 and on Day 08 in Period 2.
223609702|NCT02671097|DRUG|BAY1841788 (ODM-201)|600 mg single dose, administered as 2 x 300 mg tablets on Day 01 in Period 2; 600 mg BID multiple dose, administered as 2 x 300 mg tablets on Day 04 to Day 08 in Period 2.
224311634|NCT06551714|PROCEDURE|Phase 1 cardiac rehabilitation|"Day 1:Patients were informed about the surgery, positioning and mobilization.Range of motion (ROM), respiratory control, diaphragmatic breathing, pursed lip breathing, thoracal expansion exercises, assisted coughing,forced expiration techniques, which are the components of active breathing techniques cycle (ABTC), were taught.The use of incentive spirometry (IS) was demonstrated.Patients were performed 10 repetitions of IS exercises, and 5 repetitions ABTC and were asked to repeat them every hour.The patient was made to sit for 10 minutes and was walked 60 meters twice a day.~2:ROM, IS and diaphragmatic breathing exercises were applied 10 times each.ABTC was repeated in 5 sets. 120 meters was walked 5 times during the day.~3:Sitting time was increased to 30 minutes and walking distance was increased to 240 meters.5 steps were climbed.~4:Walking distance was increased to 360 meters.One flight of stairs was climbed.Discharge training was given."
224311635|NCT06551714|PROCEDURE|Neurophysiological facilitation techniques|"In addition to the phase 1 cardiac rehabilitation program for the group receiving neurophysiological facilitation (NPF) techniques:~NPF techniques such as perioral stimulation, intercostal tension, anterior basal lift, vertebral pressure, moderate manual pressure and abdominal co-contraction were applied for ten times for ten seconds.~Diaphragm facilitation exercise was performed by inhaling against resistance and holding the breath against resistance for 5 seconds.~Unilateral and bilateral upper extremity proprioceptive neuromuscular facilitation (PNF) movements combined with breathing were performed.~NPF techniques were performed 10 times each day throughout the treatment, while other applications (diaphragm facilitation, combined breathing exercise with upper extremity PNF technique and respiratory facilitation) were performed 5 times on the first day and 10 times on the other three days."
223756043|NCT06351683|DRUG|MitoQ (mitoquinol mesylate)|MitoQ is an antioxidant molecule designed to target cell stress
223609703|NCT02471222|DRUG|ADS-5102|Oral capsules to be administered once daily at bedtime for 4 weeks
223609704|NCT02471222|OTHER|Placebo|Oral capsules to be administered once daily at bedtime for 4 weeks
223609705|NCT01242605|DRUG|selumetinib|The starting dose of selumetinib will depend on the cohort. The first dose of selumetinib to be studied will be 75 mg twice daily (bd). Selumetinib will be taken every day (continuously) either once or twice a day, depending on the dose. Treatment with selumetinib may continue until disease progression.
223609706|NCT01242605|DRUG|gemcitabine|gemcitabine: taken in combination with cisplatin will be given at 1000 mg/m\*2 in 250 - 500 ml 0.9% saline over 30 minutes by intravenous infusion on days 1, and 8 of each 21-day cycle for eight cycles in total
223609707|NCT01242605|DRUG|cisplatin|cisplatin: 25 mg/m\*2 in 1000 ml 0.9% saline given over 1 hour followed by 500mls 0.9% saline over 30 minutes followed by gemcitabine on days 1, and 8 of each 21-day cycle for eight cycles in total
223609708|NCT00308854|PROCEDURE|Photodynamic Therapy|
223609709|NCT02736344|DEVICE|BioNIR Ridaforolimus Eluting Coronary Stent|
223609710|NCT00003763|PROCEDURE|radionuclide imaging|
223609711|NCT00003763|RADIATION|indium In 111 folic acid|
223609712|NCT05879497|DIAGNOSTIC_TEST|68Ga-NY104 PET/CT|Participants will be administered a single, intravenous bolus of 68Ga-NY104 The recommended administered activity of 68Ga-NY104 is 1.8-2.2 MBq per kilogram bodyweight, subject to variation that may be required owing to variable elution efficiencies obtained during the lifetime of the 68Ga / 68Ga generator The CT and PET imaging session will begin approximately 45 to 75 minutes after 68Ga-NY104 administration.
223756044|NCT06351683|OTHER|Placebo|Control capsules that contain all inactive ingredients found in the study drug capsules (i.e., placebo capsules do not contain mitoquinol mesylate)
223756045|NCT04770584|BEHAVIORAL|Fear Conditioning|Participants will be administered increasing intensities of mild electric shock via electrodes connected to the foot. New Biopac stimulators that can deliver higher shock intensity, provided participants agreement will be used to assure adequate conditioning levels. Stimulation is measures in milliamps (mA), and each delivered stimulation will be 0.5 seconds long (500 milliseconds). To colored (blue, red, \& yellow) light stimuli (CS). The light stimulus is followed by a shock or no shock depending on color.
223756046|NCT04770584|OTHER|Avoidance conditioning|Via button pressing. Only one stimulus-CS will enable control over experiencing the shock: the participant can press the button during the first 2 seconds of the light presentation to avoid the shock.
223609713|NCT03511157|OTHER|Ischemic Preconditioning|See Ischemic Preconditioning Experimental group description
223609714|NCT03511157|OTHER|Control Group|See Control group description
223609715|NCT00548145|DRUG|Pitavastatin|2 mg by orally/day Duration: 12 months
223756047|NCT04770584|OTHER|Pavlovian fear extinction learning|After avoidance conditioning, the CS+ associated with avoidance responding appears with no button to press and no shock is administered.
223609716|NCT00548145|DRUG|cholesterol-lowering medicine other than statin(e.g.,Ezetimibe,Colestimide)|duration: 12 months
223609717|NCT03223376|COMBINATION_PRODUCT|fruquintinib +paclitaxel|treatment arm(fruquintinib +paclitaxel)- subjects will receive Fruquintinib orally, once daily for 3 wks on/ 1 wk off combined with paclitaxel 80mg/㎡ at day 1,8,15 of 4-week cycle. Patients will receive a cycles of 4 weeks of study treatment or until the occurrence of progressive disease (PD), death, unacceptable toxicity, withdrawal of consent or other conditions that meet the end of treatment cretieria
223609718|NCT03223376|COMBINATION_PRODUCT|fruquintinib placebo + paclitaxel|control arm(fruquintinib placebo + paclitaxel)- subjects will receive Fruquintinib placebo orally, once daily for 3 wks on/ 1 wk off combined with paclitaxel 80mg/㎡ at day 1,8,15 of 4-week cycle. Patients will receive a cycles of 4 weeks of study treatment or until the occurrence of progressive disease (PD), death, unacceptable toxicity, withdrawal of consent or other conditions that meet the end of treatment cretieria
223756048|NCT04770584|OTHER|Willingness to pay to avoid shock|On the next day, participants receive a monetary stipend to use to pay to guarantee that they are not to receive any shocks if they press a button from the CS+. This and all previously described experimental phases noted above will occur inside of the fMRI scanner.
223756049|NCT00980395|DRUG|rituximab|375 mg/m2 IV Day 1. Repeat every 28 days for a maximum of 6 cycles.
223756050|NCT00980395|DRUG|bortezomib|1.3 mg/m2 IV Days 1 and 4. Repeat every 28 days for a maximum of 6 cycles.
223756051|NCT00980395|DRUG|cladribine|4 mg/m2 IV over 2 hours Days 1-5. Repeat every 28 days for a maximum of 6 cycles.
223756052|NCT01052545|BEHAVIORAL|Audit-Feedback|Applied as a post-prescription antimicrobial review based on established guidelines.
223756053|NCT00382538|DRUG|Addition of mifepristone 200 mg 24 hours before induction|
223756054|NCT05137873|OTHER|Dunn-2 infant Sensory Profile (PS2-N)|The Dunn-2 infant Sensory Profile evaluates the child's sensory integration process
223756055|NCT01666756|DIETARY_SUPPLEMENT|Chinese herbal formulation PHY906|Given PO
223756056|NCT01666756|DRUG|sorafenib tosylate|Given PO
223609719|NCT03325595|DRUG|AEF0117|0.2, 0.6, 2, or 6mg of AEF0117
223609720|NCT03325595|DRUG|Placebo|Matching capsule placebo
223609721|NCT02033746|DEVICE|Han's Acupoint Nerve Stimulator|frequency delivery(3 seconds of 2 Hz followed by 3 seconds of 100 Hz(dense disperse method).
223609722|NCT02377648|DEVICE|Everolimus-Eluting Bioresorbable Vascular Scaffold (ABSORB)|Placement of bioresorbable vascular scaffold in presence of at least one critical angiographic de novo lesion (DS ≥70%) or a non-critical angiographic de novo lesion (50% ≤ DS \<70%) associated with concomitant signs or symptoms of myocardial ischemia.
223609723|NCT01918280|PROCEDURE|Seminal analyses and testicular biopsy|Two seminal analyses spaced out 3 months followed by a testicular biopsy if the azoospermia is confirmed on semen analyses.
223756057|NCT01666756|OTHER|laboratory biomarker analysis|Correlative studies
223756058|NCT01666756|OTHER|pharmacological study|Correlative studies
223756059|NCT00453999|DRUG|Peramivir 200 mg|Peramivir (200 mg in 100 mL of solution) intravenous infusion (over 15 minutes) and an orally administered oseltamivir placebo suspension (6.25 mL) treatment
223756060|NCT00453999|DRUG|Peramivir 400 mg|Peramivir (400 mg in 100 mL of solution ) intravenous infusion (over 15 minutes) and an orally administered oseltamivir placebo suspension (6.25 ml)
223756061|NCT00453999|DRUG|Oseltamivir|Placebo peramivir infusion (over 15 minutes) and a 75-mg dose of oseltamivir suspension (6.25 mL)
223756062|NCT05515848|OTHER|No intervention|There is no intervention in this retrospective study.
223756063|NCT04226482|DEVICE|New Device|Laparoscopic appendectomy using new ultrasonic shears.
223756064|NCT04226482|DEVICE|Used Device|Laparoscopic appendectomy using reprocessed ultrasonic shears.
223609724|NCT02800980|PROCEDURE|Drainage and sclerotherapy.|Lymphocele percutaneous / transvaginal drainage with a use of a vascular catheter followed by sclerotherapy.
223609725|NCT02800980|PROCEDURE|Drainage alone.|Lymphocele percutaneous / transvaginal drainage with a vascular catheter alone (without sclerotherapy).
223756065|NCT00802412|DRUG|Topiramate|Topiramate will be titrated over 5 weeks to a maximum dosage of 200 mg according to the following schedule: 25mg daily for days 1-7, 50mg daily for days 8-14, 75mg daily for days 15-21, 100mg daily for days 22-28, 150mg daily for days 29-35, 200mg daily for days 36-42. Maximum dosage will be maintained for 6 weeks, followed by a one-week taper-off period (100mg daily for 4 days and 50mg daily for 3 days).
223756066|NCT00802412|DRUG|Placebo|Placebo/study medication will be administered in opaque capsules in an identical fashion to maintain the double-blind study design.
223756067|NCT02812758|DEVICE|transthoracic echocardiography|recording of data on cardiac output measured non-invasively by transthoracic echocardiography, including the SVV
223756068|NCT05360836|OTHER|Conservative treatment via telerehabilitation|"Patients will do their exercises in the form of a WhatsApp video call or a Zoom video call.~Contrast bath, massage application for 5 minutes, passive, active assistive normal range of motion. Ice application. After 4 weeks strenghtening exercise. The treatment time 8 weeks."
223756069|NCT05360836|OTHER|Conservative treatmen + motor imagery|"Patients will do their exercises in the form of a WhatsApp video call or a Zoom video call.~Contrast bath, 5-minute massage, passive, active auxiliary normal range of motion. Ice application. Strengthening exercise after 4 weeks. The duration of treatment is 8 weeks. This group applies motor images for a maximum of 5 minutes. They will implement functionality-based motor images."
223756070|NCT05514158|DRUG|RC48-ADC|RC48 for injection is a novel antibody-drug conjugate, with a her-2-targeting antibody and a microtube inhibitor
223756071|NCT05514158|DRUG|RC98|RC98 is a recombinant humanized IgG1 monoclonal antibody targeting programmed cell death-Ligand 1 (PD-L1)
223756072|NCT01140763|DEVICE|Sysmex's 5-blade lymph node cutter|"A maximum of 3 dissected sentinel lymph nodes (SLN) per subject will be included in this study. Lymph nodes will be sliced at 1 mm intervals with Sysmex's 5-blade lymph node cutter. Alternate slices will be allocated to either reference histopathology or test histopathology. Three serial sections will be cut every 200 µm (level): the 1st section per level for hematoxylin \& eosin (H\&E), the middle section of the 3rd level for Immunohistochemistry (IHC)(pan- cytokeratin antibody clone AE1/AE3). All other sections will be blanks in case further analysis is needed."
223609726|NCT03089541|BEHAVIORAL|Survey Arm|Contingency Management for completion of surveys and evidence of tobacco use status
223609727|NCT03348176|OTHER|Vegetable exposure|Repeated exposure to variety of vegetables
223609728|NCT03348176|BEHAVIORAL|VIPP-Feeding Infants|Promoting responsive feeding practices
223609729|NCT03348176|OTHER|Control|Phone calls with mother about development of child, no advice on complementary feeding
224200943|NCT05722275|DIAGNOSTIC_TEST|Peritoneal metastasis status ascertainment|Each participant with gastric cancer will undergo enhanced CT examination for detection of peritoneal metastasis. Within two weeks of CT examination, the participant will undergo diagnostic laparoscopy to confirm the status of peritoneal metastasis.
224200944|NCT02792400|DRUG|LY2403021|Glucagon receptor antagonist
224200945|NCT02792400|DRUG|LY2403021 placebo|
223609730|NCT02022163|BIOLOGICAL|Low dose of H7 VLP vaccine + Alhydrogel|Low dose of H7 VLP vaccine mixed with Alhydrogel, 2 doses given 21 days apart
223609731|NCT02022163|BIOLOGICAL|Med dose of H7 VLP vaccine + Alhydrogel|Med dose of H7 VLP vaccine mixed with Alhydrogel, 2 doses given 21 days apart
224200946|NCT02792400|PROCEDURE|Standardised liquid meal|
224200947|NCT02792400|DRUG|Linagliptin|DPP-4-inhibitor
224200948|NCT02792400|DRUG|Linagliptin placebo|
224200949|NCT02792400|DRUG|Empagliflozin|SGLT2-inhibitor
224200950|NCT02792400|DRUG|Empagliflozin placebo|
224200951|NCT02226575|BEHAVIORAL|A cognitive behavior therapy distress management program targeting wellbeing in patients with atrial fibrillation and their relatives|Controls only delivery standard care. Experimental group deliver standard care plus a distress management program (cognitive behavioral therapy) performed in groups by a nurse, a pedagogue and a cardiologist (all trained in the distress management program).
224200952|NCT02188927|OTHER|Implementation of ANL|Advance Notification Letter will be send two weeks before Standard Invitation for screening colonoscopy
223609732|NCT02022163|BIOLOGICAL|High dose of H7 VLP vaccine + Alhydrogel|High dose of H7 VLP vaccine mixed with Alhydrogel, 2 doses given 21 days apart
223756073|NCT01391728|BEHAVIORAL|Active Lifestyle all your Life|"Intervention After the first data collection the participants are randomised in an intervention and control group. The control group receives the normal treatment that may be given after a radius fracture and may vary from one care unit to another (but there is no preventive programme within the normal activity as far as we know). In groups of 6-8 participants the intervention group starts the programme Active lifestyle all your life with group meetings around every other week (10-12 times) and with 2 individual meetings directed at discussing fall risks in the participant's own home environment. After a summer break, Christmas and New Year three follow-up meetings take place, one of which is an individual meeting. The intervention is then terminated, but the participants are encouraged to continue the activity themselves."
223756074|NCT05289596|BEHAVIORAL|Sleep Healthy Using the Internet (SHUT-i)|SHUTi is a six session, 6-8 week cognitive behavioral therapy for insomnia program over the internet. The online, self-paced program offers illustrations, graphics, videos and built-in algorithms offering brief sleep diaries, personalized sleep window recommendations, education from sleep experts, peer stories about insomnia, and skills to help participants relearn proper sleep dynamics and increase sleep efficiency.
223756075|NCT01039181|DRUG|Calcitriol|12 mcg Calcitriol will be given orally three times per week for 6 months. In this portion of the study, all patients will get the same dose of calcitriol along with the standard chemotherapy (5-fluorouracil-mitomycin C-leucovorin).
223756076|NCT06105385|OTHER|Suboccipital Myofascial Release Technique|With the patient in a supine position, the therapist sits behind the patient with his or her forearms on the treatment table. The therapist places his fingers between the occiput and axis, with his fingers in semi-flexion (2nd, 3rd and 4th fingers), and continues to hold his hands on the occiput until relaxation is achieved in the suboccipital muscles. A light traction is applied at the end of the technique. Average application time is 4-5 minutes.
223609733|NCT02022163|BIOLOGICAL|High dose of H7 VLP vaccine|High dose of H7 VLP vaccine, 2 doses given 21 days apart
223609734|NCT02022163|BIOLOGICAL|Placebo|Placebo, 2 doses given 21 days apart
223609735|NCT02037217|DEVICE|ExAblate Transcranial MRgFUS System|
223609736|NCT02119663|DRUG|Ruxolitinib|5 mg tablets to be administered by mouth twice daily (BID)
223609737|NCT02119663|DRUG|Placebo|5 mg matching placebo tablets to be administered by mouth twice daily (BID)
223609738|NCT02119663|DRUG|Capecitabine|150 mg or 500 mg tablets to be administered by mouth twice daily (BID)
223609739|NCT01227863|DRUG|MAXINOM®|Dexamethasone...............................................0,1% Neomicyn......................................0,35% polimixyn B...................................0,1%
223609740|NCT01227863|DRUG|Maxitrol®|Dexamethasone...............................................0,1% Neomicyn......................................0,35% Polimixyn B...................................0,1%
223756077|NCT05930665|DRUG|Cadonilimab+Bevacizumab+Pemetrexed+Carboplatin|Cadonilimab 10mg/kg intravenous (IV) every 3 weeks + Bevacizumab 7.5mg/kg IV every 3 weeks + Pemetrexed 500 mg/m² IV every 3 weeks + Carboplatin AUC 5 IV every 3 weeks for 4 to 6 cycles, followed by maintenance with Cadonilimab 10mg/kg IV every 3 weeks + Bevacizumab 7.5mg/kg IV every 3 weeks
223756078|NCT03007394|DRUG|Lorcaserin|Lorcaserin Capsule
223756079|NCT03007394|DRUG|Placebo Oral Capsule|sugar pill to mimic lorcaserin 10mg capsule
224200953|NCT02188927|BEHAVIORAL|No included ANL|Sending Standard Invitation only six weeks before planned screening colonoscopy
223609741|NCT04093440|OTHER|lifestyle modification|nutrition counselling, diet and physical exercise monitoring, smoking cessation, and medication optimization
223609742|NCT05854979|DIAGNOSTIC_TEST|Gastric Ultrasound|A gastric ultrasound will be completed on every patient and administered the same way in each arm. The patient will be placed in supine position. A curvilinear ultrasound probe will be placed on the sagittal plane below the xiphoid process. The probe will then slide along the costal margin to the right until the gastric antrum is identified. At this point, the ultrasound image will be obtained, and appropriate measurements will be taken. The patient will be placed in the right lateral decubitus position and the above procedure will be repeated.
223609743|NCT04355793|DRUG|Ruxolitinib|Ruxolitinib starting dose level 5 mg orally, twice daily (BID).
223609744|NCT02863328|DRUG|semaglutide|Oral administration once-daily.
223609745|NCT02863328|DRUG|empagliflozin|Oral administration once-daily.
223609746|NCT00242996|BIOLOGICAL|filgrastim|
223609747|NCT00242996|BIOLOGICAL|rituximab|
223609748|NCT00242996|BIOLOGICAL|sargramostim|
223609749|NCT00242996|DRUG|carmustine|
223609750|NCT00242996|DRUG|cyclophosphamide|
223609751|NCT00242996|DRUG|etoposide|
223609752|NCT00242996|PROCEDURE|adjuvant therapy|
223609753|NCT00242996|PROCEDURE|bone marrow ablation with stem cell support|
223609754|NCT00242996|PROCEDURE|peripheral blood stem cell transplantation|
223609755|NCT00892775|BIOLOGICAL|Priorix-Tetra (combined measles-mumps-rubella-varicella vaccine)|Vaccine will be administered subcutaneously in the left upper arm (deltoid region)
223609756|NCT00892775|BIOLOGICAL|GSK Biologicals' 208136, new formulation|Vaccine will be administered subcutaneously in the left upper arm (deltoid region)
224200954|NCT01830257|OTHER|sending message|Sending the suggestive short message
224200955|NCT01139801|DRUG|Oxytocin|Foley balloon placement with intravenous low dose oxytocin administration starting 2 milliunits per minute.
224200956|NCT01139801|DRUG|Misoprostol|Misoprostol, 25 mcg, is placed intravaginally into the posterior fornix of the vagina in conjunction with Foley balloon placement
223609757|NCT01252030|DEVICE|physical activity monitors|physical activity monitors
223609758|NCT01252030|OTHER|No physical activity monitors|No physical activity monitors
223609759|NCT00699660|BEHAVIORAL|CAPS/WHODAS|CAPS/WHODAS structured clinical PTSD interview
223609760|NCT00699660|BEHAVIORAL|Nonstructured Interview|Usual PTSD clinical PTSD interview, not CAPS or SCID
223609761|NCT02682082|PROCEDURE|Endoscopic ultrasound-guided celiax plexus neurolysis|Endoscopic ultrasound-guided celiax plexus neurolysis
223609762|NCT02682082|DRUG|Bupivacaine|Endoscopic ultrasound-guided celiax plexus neurolysis w/wo Bupivacaine
223609763|NCT00398320|DRUG|Capecitabine|850 mg/m2 by mouth twice a day for days 1-14 oa a 21 day cycle
223756080|NCT03662438|OTHER|Home-based physiotherapy program|The home-based physiotherapy program will consist of a total of 2 home visits by a physiotherapist which will be scheduled at the start and midpoint of the 10-week program. The visit will include activity education, goal setting and establishment of a home exercise regimen in patient's own home and community environment). Participants will be contacted weekly via telephone to provide encouragement for patient on the program, enquire about compliance to the exercise program and safety (e.g. falls and healthcare utilisation).
223756081|NCT03662438|DEVICE|Prescription of a Portable Oxygen Concentrator (POC) device|Participants will be prescribed a lightweight Portable Oxygen Concentrator (POC) device \[Philips SimplyGo Mini\] to be used during exercise and when going into the community setting. Familiarisation and training on the usage of the device will also be provided in conjunction with the home-based physiotherapy program.
223756082|NCT00899691|GENETIC|protein expression analysis|
223756083|NCT05358275|DEVICE|surgical cutting guide with piezo|3D planned lid surgery
223756084|NCT05358275|OTHER|control|ordinary cyst enucleation
223756085|NCT05874180|DRUG|DW6013|"Drug: DW6013 Single oral administration of DW6013 in fed condition~Drug: Linagliptin and Metformin Single oral administration of Linagliptin and Metformin in fed condition"
223756086|NCT02550457|OTHER|Functional elastic tape tensioned|Application of Kinesio Taping with tension in the erector spine muscles.
223756087|NCT02550457|OTHER|Functional elastic tape non-tensioned|Application of Kinesio Taping without tension in the erector spine muscles.
223756088|NCT02550457|OTHER|Rigid Tape|Application of Micropore tape in the erector spine muscles.
223756089|NCT04943965|DIAGNOSTIC_TEST|Ultrasound imaging|"The intervention is non-invasive, chest wall, echocardiographic image acquisition in the cardiac operating room prior to a scheduled cardiac surgery. Echocardiographic images will be taken at three, key, timepoints in the operating room prior to cardiac surgery:~1. Pre-induction.~2. Post-induction / Pre-PAC~3. Post-induction / Post-PAC"
223756090|NCT06466174|DIETARY_SUPPLEMENT|Placebo 1 to Probiotic A|42 day Crossover study design between Placebo 1 and Probiotic A (n = 25)
223609764|NCT00398320|DRUG|Oxaliplatin|130 mg/m2 intravenously on day 1 of a 21 day cycle
223609765|NCT00398320|DRUG|Bevacizumab|7.5mg/kg Intravenous on day 1 of a 21 day cycle
223756091|NCT06466174|DIETARY_SUPPLEMENT|Probiotic A to Placebo 1|42 day Crossover study design between Probiotic A and Placebo 1 (n = 25)
223756092|NCT06466174|DIETARY_SUPPLEMENT|Placebo 2 to Probiotic B|42 day Crossover study design between Placebo 2 and Probiotic B (n = 25)
223756093|NCT06466174|DIETARY_SUPPLEMENT|Probiotic B to Placebo 2|42 day Crossover study design between Probiotic B and Placebo 2 (n = 25)
223756094|NCT06159972|DEVICE|EndoFLIP|EndoFLIP is a small balloon catheter that is inserted through the endoscope at the time of endoscopy.
223756095|NCT03688672|DEVICE|Apioc Contact Lens Design|Novel soft contact lens design.
223756096|NCT03522181|OTHER|saline|saline
223756097|NCT03522181|OTHER|Insulin|
223756098|NCT04964453|DRUG|Placebo|Healthy subjects were given a single dose of placebo tablet(s) matched to the active treatment, subjects receiving placebo were equally distributed across dose groups. Tablet(s) were taken orally with 240 milliliter of water after an overnight fast of at least 10 hours.
223756099|NCT04964453|DRUG|BI 474121|Healthy subjects were given a single dose of BI 474121 as a uncoated tablet(s) taken orally with 240 milliliter of water after an overnight fast of at least 10 hours.
223756100|NCT00987116|DRUG|Prednisone - Azathioprine|"Rapid strategy consists of decreasing the prednisone dose if at each monthly consultation the patient fulfils the criteria for improvement or minimal manifestation state, in order to discontinue it before twelve months. The starting dose is 0.75 mg/kg/day.~Classical strategy consists of decreasing the prednisone dose if at each monthly consultation the patient fulfils the criteria for minimal manifestation state, in order to discontinue it before twelve months. The starting dose is 1.5 mg/kg/2days."
223756101|NCT05540366|OTHER|Physical therapy combined with aerobic exercise|30 minutes of physical therapy with education, manual therapy and therapeutic exercise at both temporomandibular and cervical regions, combined with a 30 minutes aerobic exercise programme on a bike.
223756102|NCT05540366|OTHER|Physical Therapy|30 minutes of physical therapy with education, manual therapy and therapeutic exercise at both temporomandibular and cervical regions (same programme than the intervention group)
223756103|NCT01133691|DIETARY_SUPPLEMENT|clear fluid, light breakfast|clear fluid 7 ml/kg, breakfast consisting of yoghurt, muesli, mild
223756104|NCT02254707|DRUG|BILB 1941 ZW|
223756105|NCT02254707|DRUG|Placebo|
223756106|NCT04631939|DEVICE|Metacognitive training game|"In the fantasy world Macu'ta, players explore the world by walking around with an avatar in order to find the puzzles and proceed in the game. The intervention consists of 4 different puzzles. Unbeknownst to the player, the first pieces of evidence of each puzzle are often misleading, i.e. indicate the wrong solution, such that hasty decisions are punished. Players receive immediate feedback and are shown the correct response after submitting their solution, as well as explicit cues that educate them on the value of making adequately informed decisions. The order of the puzzles is fixed for each player, but different per session."
224200957|NCT06542172|DIETARY_SUPPLEMENT|500 mL/day of full-fat milk from corn-fed cows (fat >3.8%) for 12 weeks|All milk is provided by the Inner Mongolia Yili Industrial Group Limited by Share Ltd (Inner Mongolia, China).
223609766|NCT01586221|OTHER|Music & Physical Therapy|Participants will receive combined Music Therapy and Physical Therapy for 6 Weeks. Two times per week for 1 hour.
223609767|NCT00064792|DRUG|Simvastatin Susp.|During the simvastatin phase of the trial, therapy will be initiated at 0.5 mg/kg/day for six weeks and then increased to 1.0 mg/kg/day if adverse side effects are minimal or absent.
223609768|NCT00064792|DRUG|OraPlus|During this trial and for two months prior, patients will be maintained on 150 mg/kg/day of dietary cholesterol (150 mg/ml in OraPlus) for the duration of the trial
223609769|NCT00002458|BIOLOGICAL|monoclonal antibody 3F8|
223609770|NCT01870726|DRUG|INC280|"Phase Ib: INC280 was given at the starting dose of 200mg capsules twice daily with escalation to higher strengths.~Phase II: INC280 was given at the dose of 400mg (tablets) twice daily."
223609771|NCT01870726|DRUG|Buparlisib|Buparlisib was given at the starting dose of 50mg once daily with escalation to higher strengths.
223609772|NCT04218539|DRUG|Psilocybin|10mg Psilocybin
223609773|NCT04218539|DRUG|Placebo|25mg Diphenhydramine
223609774|NCT01836926|PROCEDURE|Open intersphincteric resection|"laparotomy arm: surgical Instruments for open approach operation: Abdominal anterior resection combined with peranal intersphincteric resection of the rectum~Abdominal step a high ligation of the inferior mesenteric artery is performed together with a full mobilization of the left colon. A circular incision of the anal canal is performed 1 cm below the tumour. Both the mucosa and the muscular layer are incised to transect the internal anal sphincter. A coloanal anastomosis, transverse coloplasty or colonic J-pouch and a diverting loop ileostomy are associated with the hand-sewn coloanal anastomosis.~laparoscopic approach group: instruments used: laparoscopic instruments mentioned at the arm description~intervention: laparoscopic mobilization of the rectum and colon combined with the peranal intersphincteric resection as in the laparotomy approach"
223609775|NCT01836926|DEVICE|transanal minimally invasive intersphincteric resection|minimally invasive approach group: instruments used: laparoscopic instruments mentioned at the arm description instruments: laparoscopic instruments mentioned in the laparoscopic rectal resection arm intervention: laparoscopic mobilization of the rectum and colon combined with the peranal intersphincteric resection as in the laparotomy approach
223609776|NCT03507010|RADIATION|Radiotherapy|Patients randomized to the Radiotherapy arm will be treated with electrons and receive a total dose of 30 Gy (two separate courses of five daily fractions of 3.0 Gy each).
223609777|NCT03507010|OTHER|Sham Radiotherapy|Patients randomized to the sham-radiotherapy will not be treated and the radiotherapy treatment will only be simulated.
223609778|NCT03478735|PROCEDURE|Ultrasound Guided Greater Occipital Nerve Block at C2|Ultrasound guided injection
223609779|NCT03478735|PROCEDURE|Landmark-Based Greater Occipital Nerve Block|Traditional landmark-guided technique at the superior nuchal line. This approach relies solely on superficial bone-based anatomic landmarks to infiltrate local anesthetic and corticosteroid around the nerve at the level of the superior nuchal line.
223609780|NCT03301350|DRUG|Carboplatin|Carboplatin is a platinum compound alkylating agent which covalently binds to DNA; interferes with the function of DNA by producing interstrand DNA cross-links.
223609781|NCT03301350|DRUG|Paclitaxel|Paclitaxel promotes microtubule assembly by enhancing the action of tubulin dimers, stabilizing existing microtubules, and inhibiting their disassembly, interfering with the late G2 mitotic phase, and inhibiting cell replication. In addition, the drug can distort mitotic spindles, resulting in the breakage of chromosomes. Paclitaxel may also suppress cell proliferation and modulate immune response.
223609782|NCT03301350|DRUG|Doxorubicin|Inhibition of DNA and RNA synthesis by intercalation between DNA base pairs by inhibition of topoisomerase II and by steric obstruction. Doxorubicin intercalates at points of local uncoiling of the double helix. Although the exact mechanism is unclear, it appears that direct binding to DNA (intercalation) and inhibition of DNA repair (topoisomerase II inhibition) result in blockade of DNA and RNA synthesis and fragmentation of DNA. Doxorubicin is also a powerful iron chelator; the iron-doxorubicin complex can bind DNA and cell membranes and produce free radicals that immediately cleave the DNA and cell membranes.
223609783|NCT03301350|DRUG|Cyclophosphamide|Cyclophosphamide is an alkylating agent that prevents cell division by cross-linking DNA strands and decreasing DNA synthesis. It is a cell cycle phase nonspecific agent. Cyclophosphamide also possesses potent immunosuppressive activity. Cyclophosphamide is a prodrug that must be metabolized to active metabolites in the liver.
223609784|NCT03301350|DRUG|Pegfilgrastim|Pegfilgrastim provides growth factor support in a single dose. It stimulates bone marrow to create neutrophils for patients undergoing chemotherapy.
223609785|NCT03301350|DRUG|Filgrastim|Filgrastim provides growth factor support in multiple doses. It stimulates bone marrow to create neutrophils for patients undergoing chemotherapy.
223609786|NCT03137225|DEVICE|Neurally Adjusted Ventilatory Assist|Neurally Adjusted Ventilatory Assist delivered via RAM cannula .
223609787|NCT03137225|DEVICE|Nasal Intermittent Positive Pressure Ventilation|Nasal Intermittent Positive Pressure Ventilation delivered via RAM cannula
223609788|NCT01487889|OTHER|Fatty acid composition of complementary food|Groups receive commercial vegetable-potato-meat-meals as part of complementary food which differs in the fatty acid composition
223756107|NCT04631939|DEVICE|Control games|"In the fantasy world Macu'ta, players explore the world by walking around with an avatar in order to find the puzzles and proceed in the game. The control intervention consists of 4 different puzzle games requiring exclusively dexterity and accuracy (i.e., not including any metacognitive elements). The order of the puzzles is fixed for each player, but different per session."
223756108|NCT00615563|BEHAVIORAL|NO BI Drug administered|
223756109|NCT04138875|DRUG|Rituximab|Rituximab is dosed at 375mg/m2 as an intravenous infusion. No adjustments are necessary for hepatic or renal impairment. Dosing will be done on baseline weight and height, however in patients who experience a \>10% change in weight dosing will be readjusted.
224311636|NCT01119781|DRUG|BIIB017(peginterferon beta-1a)|peginterferon beta-1a administered by a single subcutaneous (SC) injection using a pre-filled syringe on Day 1 at a dose of either 63 or 125 mcg depending on subpopulation assignment reflecting whether a healthy volunteer or level of renal impairment.
223609789|NCT00390650|DRUG|Saredutant|
223756110|NCT04138875|DRUG|Brentuximab Vedotin|Brentuximab vedotin is to be given as intravenous infusion at a dose of 1.2mg/kg during induction and 1.8mg/kg with each cycle. Dose reductions to 1.2mg/kg are allowed at investigator discretion.
223756111|NCT04138875|DRUG|Bendamustine|Bendamustine is to be given intravenously at a dose of 90mg/m2 on day 1 and day 2 of each high risk cycle. Dose reductions to 60mg/m2 are allowed at investigator discretion.
223756112|NCT04845607|DRUG|Amiodarone Injection|Amiodarone continuous infusion during 24 hours from return of spontaneous circulation.
224200958|NCT06542172|DIETARY_SUPPLEMENT|500 mL/day of full-fat milk from grass-fed cows (fat >3.8%) for 12 weeks|All milk is provided by the Inner Mongolia Yili Industrial Group Limited by Share Ltd (Inner Mongolia, China).
224200959|NCT06542172|DIETARY_SUPPLEMENT|500 mL/day of low-fat milk (fat <1.5%) for 12 weeks|All milk is provided by the Inner Mongolia Yili Industrial Group Limited by Share Ltd (Inner Mongolia, China).
224200960|NCT06622824|DRUG|KX-826 0.5% BID|0.5% of the investigational drug KX-826 to be applied topically to scalp twice daily for 24 weeks
224200961|NCT06622824|DRUG|KX-826 1.0% BID|1.0% of the investigational drug KX-826 to be applied topically to scalp twice daily for 24 weeks
224200962|NCT06622824|DRUG|Vehicle (Placebo) applied BID|Matching placebo applied topically to scalp twice daily for 24 weeks
223609790|NCT01248949|DRUG|MEDI3617|Participants will receive MEDI3617 via IV infusion in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons.
223609791|NCT01248949|DRUG|Bevacizumab|Participants will receive bevacizumab via IV infusion in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons.
223609792|NCT01248949|DRUG|Paclitaxel|Participants will receive paclitaxel via IV infusion in each cycle until unacceptable toxicity, documented disease progression, or other reasons.
223609793|NCT01248949|DRUG|Carboplatin|Participants will receive carboplatin via IV infusion in each cycle until unacceptable toxicity, documentation of disease progression, or other reasons.
223756113|NCT01772641|OTHER|Scheduled Gradual Reduction + Varenicline|Participants will receive a four-week Scheduled Gradual Reduction (SGR) intervention in which participants cut down on the number of cigarettes smoked. This is done through a smoking schedule in which participants smoke a cigarette at given fixed and equal intervals throughout their waking day. Additionally, they will take 0.5 mg of Varenicline (VN) once a day for the first three days, then 0.5 mg twice a day for the next four days, and they will continue for 13 weeks at 1.0 mg twice per day.
223756114|NCT01772641|OTHER|Scheduled Gradual Reduction + Placebo Drug|Participants will receive a four-week Scheduled Gradual Reduction (SGR) intervention in which participants cut down on the number of cigarettes smoked. This is done through a smoking schedule in which participants smoke a cigarette at given fixed and equal intervals throughout their waking day. Additionally, they will take placebo pills matching the schedule of the VN group.
223756115|NCT01772641|OTHER|Basic Advice + Varenicline|Participants will receive informational pamphlets with advice about quitting smoking. Additionally, they will take 0.5 mg of Varenicline (VN) once a day for the first three days, then 0.5 mg twice a day for the next four days, and they will continue for 13 weeks at 1.0 mg twice per day.
223756116|NCT01772641|OTHER|Basic Advice + Placebo Drug|Participants will receive informational pamphlets with advice about quitting smoking. Additionally, they will take placebo pills matching the schedule of the VN group.
223609794|NCT00286429|DRUG|Alogliptin and insulin|Alogliptin 12.5 mg, tablets, orally, once daily and insulin for up to 26 weeks.
223609795|NCT00286429|DRUG|Alogliptin and insulin|Alogliptin 25 mg, tablets, orally, once daily and insulin for up to 26 weeks.
223609796|NCT00286429|DRUG|Insulin|Alogliptin placebo-matching tablets, orally, once daily and insulin for up to 26 weeks.
223609797|NCT00502008|DRUG|Coccinia Cordifolia (herbal extract)|
223609798|NCT01973413|DEVICE|Diabetes Assistant (DiAs)|The Control-to-Range (CTR) algorithm that will be used in DiAs will automatically adjusts insulin delivery in response to CGM values that have exceeded or are predicted to exceed the bounds of a pre-specified blood glucose range.
223609799|NCT01973413|DEVICE|Tandem t:slim Insulin Pump|FDA, market-approved insulin pump.
223609800|NCT01973413|DEVICE|Dexcom G4 Platinum sensor|FDA, market-approved continuous glucose monitor (CGM)
223609801|NCT00816192|PROCEDURE|Long-term electrical isolation of pulmonary veins|All AAD except amiodarone will be stopped five half-lives before the procedure. Our ablation protocol will require 3 catheters. A quadripolar stearable mapping catheter was inserted into the coronary sinus, a decapolar circular mapping catheter was placed at the antrum of the PV after transeptal puncture to help for electrical disconnection of all four PV with the randomized ablation catheter. After transseptal access, an intravenous bolus of heparin was administered and repeated 3 to 4 hours later. Atrial burst will then be used to induce AF. With the ablation catheter positioned proximal to Lasso catheter on the atrial aspect of PV ostium, isolation will be performed.
223609802|NCT03851198|PROCEDURE|Standard Care or Usual Clinical Practice|The guidelines for the management according to the mild cognitive impairment in primary care will be the treatment guidelines for the Standard Care.
223609803|NCT01746225|DRUG|nab-Paclitaxel|Induction phase: 3 cycles of nab-Paclitaxel days 1, 8, 15. Maintenance phase with three maintenance schedules of nab-Paclitaxel (same total dose per cycle, different number of administrations)
223609804|NCT03941626|BIOLOGICAL|CAR-T/TCR-T cells immunotherapy|According to tumor burden and other conditions, patients will be treated with cyclophosphamide or fludarabine,then,CAR-T cells will be infused 48-72 hours later.
223609805|NCT03915470|DRUG|XF-73|XF-73 is a dicationic porphyrin derivative having potent bactericidal properties with a novel mode of action.
223756117|NCT01122667|DRUG|anacetrapib|single dose administration of anacetrapib (MK0859) 100 mg oral tablet
223756118|NCT05410626|DRUG|prolong-release methylphenidate|This randomization, cross-over design study will enroll subjects who receive a stable dose of immediate-release methylphenidate (IR-MPH) for at least 4 weeks. Eligible subjects will be switching from IR-MPH to the first brand prolong-release methylphenidate (PR-MPH) for 4 weeks and switching to another brand for 4 weeks. The study consists of 3 parts: screening, study period, and post-treatment follow-up. The duration of this study will be 8 weeks with 2 visits during the study period. The primary outcome is the efficacy of treatment will be evaluated by SNAP-IV.
223756119|NCT01853033|BIOLOGICAL|ABT-122|Injection
223756120|NCT01853033|BIOLOGICAL|Placebo|Placebo Injection
223756121|NCT05824806|BIOLOGICAL|PRP Protocol A|Platelet rich plasma protocol A
223756122|NCT05824806|BIOLOGICAL|PRP Protocol B|Platelet rich plasma protocol B
223609806|NCT03915470|DRUG|Placebo|Placebo to match XF-73 nasal gel for colour and viscosity.
223609807|NCT01882530|DRUG|Paracetamol|
223609808|NCT01882530|DRUG|Nefopam|
223609809|NCT01882530|DRUG|Ketoprofen|
223609810|NCT01882530|DRUG|Morphine|
223609811|NCT02150915|OTHER|Acupuncture therapy (leopard spot needling technique)|Comparison of the effects of a new or extraordinary acupoint versus a classical acupoint
223609812|NCT03160898|DRUG|Reldesemtiv|Oral tablet
223609813|NCT03160898|DRUG|Placebo|Oral tablet
223609814|NCT00078247|DRUG|Abacavir|300 mg tablet taken orally twice daily
223609815|NCT00078247|DRUG|Lamivudine|300 mg tablet taken orally daily
223609816|NCT00078247|DRUG|Zidovudine|300 mg tablet taken orally twice daily
223609817|NCT00078247|DRUG|Tuberculosis treatment|Tuberculosis treatment
223756123|NCT05824806|DEVICE|Hyaluronic acid|Hyaluronic acid
223609818|NCT03704909|DRUG|Adrenaline|i.v bolus of adrenaline 0.15µg/Kg rescue boluses of adrenaline 0.15µg/Kg
223609819|NCT03704909|DRUG|Ephedrine|i.v bolus of Ephedrine 0.1mg/Kg rescue boluses of Ephedrine 0.1mg/Kg
223609820|NCT00862056|PROCEDURE|Cardiac CT|All participants will undergo a coronary artery CT angiogram with contrast.
223609821|NCT00249678|BEHAVIORAL|Behavior Therapy|
223609822|NCT02508909|PROCEDURE|Videoscopic ilioinguinal dissection|Inguinal dissection is performed after subcutaneous inflation via three ports. Iliac dissection is obtained through a pro-peritoneal access.
223609823|NCT06021509|DEVICE|NovoClasp® transcatheter mitral valve clip and steerable guide catheter|The experimental device is a class III implanted valve device, which will be used to treat the mitral valve regurgitation via transcatheter edge-to-edge repair.
223609824|NCT03580226|OTHER|No intervention|No intervention
223609825|NCT03245775|BEHAVIORAL|iChoose|12 bi-weekly sessions \& 24 IVR calls/12 months, 24 physical activity sessions over 6 months; delivers intervention to parents and children only
223609826|NCT03245775|BEHAVIORAL|Family Connections|2 in-person sessions spaced one week apart \& 10 IVR calls/6 months, promotes physical activity but does not include structured exercise sessions; delivers intervention to parents only
223609827|NCT03162419|DRUG|Standard Medical Therapy|The patients in group A will be given standard medical therapy only as per requirement. Lactulose, bowel wash, albumin, terlipressin, antibiotics and anti-virals in hepatitis B reactivation will be continued and recorded.
223609828|NCT03162419|BIOLOGICAL|Plasma Exchange|High volume plasma exchange sessions till a maximum of ten sessions.
223609829|NCT03162419|BIOLOGICAL|GCSF|The GCSF in a dose of 5 ug/kg/day on day 1,2,3,4,5 followed by every 3rd day till day 28
223609830|NCT01834352|DRUG|Walnut Protein Flour|Daily ingestion of gradually increasing amounts of walnut protein flour in order to induce desensitization to walnut and an unrelated tree nut.
223609831|NCT01834352|DRUG|Oat flour|Oat flour that is administered as a placebo in identical increasing doses as the active walnut flour treatment.
223756124|NCT03444974|OTHER|adapted treatment according to the MATRIX-A therapy|cognitive and behavioral treatment of drug abuse/dependency issues, as well as connected parameters
223756125|NCT01364428|DRUG|insulin degludec|"Injected subcutaneously (under the skin) once daily, in combination with unchanged pre-trial oral anti-diabetic drug (OAD) treatment.~Dose was individually adjusted."
223756126|NCT01364428|DRUG|insulin degludec|"Injected subcutaneously (under the skin) once daily, in combination with unchanged pre-trial oral anti-diabetic drug (OAD) treatment.~Dose was individually adjusted."
223756127|NCT05799001|BEHAVIORAL|Dance therapy|"Patients will be randomized in 2 groups, experimental or control.~The experimental group will have 4 months of dance therapy with a professional dancer and will then resume there usual activities.~The control group will start with their usual activities in the nursing home for the first 4 months and then, they will have dance sessions with a nurse previously trained by the dancer."
224311637|NCT06501716|PROCEDURE|Indocyanine Green|"Tumor resection, direct visualization of the chiasm and both optic nerves and ICG administration will be provided as it is recommended by the standard of care. ICG will be administered by an injection of 5 mg of ICG diluted in a 10 mL syringe performed in the line closest to the heart followed by a 10-mL saline bolus. Using near-infrared lighting, the investigators will determine the time between anterior cerebral arteries (ACA) peak luminescence to the peak luminescence of the superior hypophyseal arteries enveloping the optic chiasm (ACA to chiasm time). Because luminescence of large vessels precedes small arterial penetration, signal from the ACAs was considered as time 0 to account for possible differences in the arm-brain time between patients. In addition, the investigators will analyze the proportion of superior hypophyseal branches on the chiasm that luminesced from ICG."
223609832|NCT02451514|BIOLOGICAL|MenABCWY+OMV vaccine|Intramuscular injection of a single dose at Day 1 to subjects in the MenABCWY+OMV Group or as a 2 doses at Day 1 and Day 31, one month apart, to subjects in the MenACWY and Naive Groups.
223609833|NCT05487911|DEVICE|Repetitive Transcranial Magnetic Stimulation|4 weeks of active rTMS (total of up to 20 sessions)
223609834|NCT06508671|DRUG|DL-3-n-butylphthalide|Take butylphthalide soft capsules orally
223609835|NCT06508671|DRUG|Empty Medication Capsules|Take empty medication capsules orally
223609836|NCT00769912|DRUG|50% N2O- 50%O2 mixture|50% N2O- 50%O2 mixture administration
223609837|NCT00769912|DRUG|Placebo (air)|Placebo administration during the intervention
223609838|NCT02240355|DRUG|RO6885247|oral solution
223609839|NCT02240355|DRUG|placebo|oral solution
224311638|NCT00661895|DRUG|Hydrochlorothiazide|Hydrochlorothiazide 25 mg tablets
223609840|NCT04601805|DEVICE|Observation|We will record the vascular changes that follow the inflammatory bowel diseases
223609841|NCT01092910|DEVICE|Esteem Totally Implantable Hearing System|The Esteem System is a totally implantable hearing system designed to improve hearing in adult subjects suffering from mild to severe hearing loss that is sensorineural in origin.
223756128|NCT02351869|DRUG|Nitrous Oxide|
223756129|NCT02351869|DRUG|Midazolam|
224311639|NCT00661895|DRUG|Lisinopril|Lisinopril 5mg Tablet, 10 mg tablet, 20 mg tablet
223609842|NCT06294340|OTHER|Exposure to loud pre-recorded road traffic noise|Participants of both arms will be exposed to the same loud pre-recorded road traffic noise in a laboratory setting.
223609843|NCT01578122|DEVICE|25mmHg ECS|"Thigh-length graduated elastic compression stockings applying 25 mmhg of targeted pressure at the ankle worn daily (from morning to night) for two years.~Before receiving the randomly allocated treatment, each patient will wear cotton, class III Varisma Comfort® stay-up stockings (20-36 mm Hg)."
223609844|NCT01578122|DEVICE|35 mmHg ECS|Thigh-length graduated elastic compression stockings applying 35mmhg of pressure at the ankle worn daily (from morning to night) for two years Before receiving the randomly allocated treatment, each patient will wear cotton, class III Varisma Comfort® stay-up stockings (20-36 mm Hg).
223609845|NCT00145132|PROCEDURE|β-CIT-SPECT, Neurophysiology|β-CIT-SPECT scans and EEG recordings, two assessments each
223609846|NCT00685113|DRUG|DR-3001|4mg/day vaginal ring inserted vaginally and replaced every 4 weeks
223756130|NCT05054530|DRUG|GMA106 Injection|GMA106 solution for injection. Subjects in each cohort will receive a single injection of GMA106 or matching placebo under fasting conditions and at the following target dose levels.
223756131|NCT05054530|DRUG|GMA106 Matching Placebo|Matching Placebo for GMA106
223756132|NCT05581316|DIAGNOSTIC_TEST|Patients' procalcitonin, thrombocyte, and leukocyte levels were assessed every other day for 4 weeks, beginning on the first day they were admitted to the burn center.|This patients who were included in this study were assessed for four weeks from the first day of hospitalization and taken to the treatment program. All patients who use peripheral venous catheters in this group.
223756133|NCT04201561|DRUG|sodium selenite pentahydrate|High-dose inorganic selenium (2000 μg/40 ml) will be administered before chemotherapy in patients assigned to the experimental group.
223756134|NCT04201561|DRUG|Normal saline|Normal saline (40 ml) will be administered before chemotherapy in patients assigned to the control group.
223756135|NCT04201561|DRUG|Chemotherapy|Paclitaxel (175mg/m2), carboplatin (AUC 5.0 or 6.0) IV, and bevacizumab IV (15mg/kg) D1, every three weeks.
223756136|NCT00914030|OTHER|Neuropsychological evaluation|Study one: global/local processing, with a neutral prime (stimulus influencing the processing of the subsequent stimulus)Study two: global/ local processing with a prime whose elements are collinear.Study three: global/local processing with a prime whose elements are not collinear
223609847|NCT00685113|DRUG|DR-3001|6mg/day vaginal ring inserted vaginally and replaced every 4 weeks
223756137|NCT06466096|OTHER|no intervention|this is an observation study, no intervention
223756138|NCT01469468|DRUG|Simvastatin|Day 1: Single dose of simvastatin 20 mg Day 8: single dose of simvastatin 20 mg (with PF-05175157)
223756139|NCT01469468|DRUG|PF-05175157|Days 2-9 inclusive: daily dosing of PF-05175157 200 mg
223609848|NCT00685113|DRUG|Placebo|Placebo vaginal ring inserted vaginally and replaced every 4 weeks
223609849|NCT00908804|PROCEDURE|open appendectomy|
223609850|NCT00908804|PROCEDURE|laparoscopic appendectomy|
223609851|NCT02420236|BEHAVIORAL|High-intensity resistance training|
223609852|NCT02420236|BEHAVIORAL|General physical activity|
223609853|NCT02420236|BEHAVIORAL|Multidisciplinary rehabilitation program|
223609854|NCT04374240|GENETIC|AdNRGM|"AdNRGM is an E1-E3 deleted, replication deficient type 5 adenovirus which contains the E. coli NTR gene regulated by the CMV promoter, an internal ribosomal entry site (IRES) and the human GMCSF gene.~CB1954 \[5-(aziridin-1-yl)-2,4-dinitrobenzamide\]"
223609855|NCT05486611|DEVICE|W-GenZD Mobile Application|"W-GenZD is a mobile application program that delivers evidence-based therapy for the symptoms of mild-moderate depression and anxiety in adolescents in brief conversations with a fully automated relational agent called Woebot. It is a brief, self-guided 4 week-intervention that draws from cognitive behavioral therapy (CBT), interpersonal psychotherapy for adolescents (IPT-A), and elements of dialectical behavior therapy (DBT), depending on the presenting situation, to help the adolescent develop emotion regulation skills in the context of their everyday life. In this way, the mobile application is designed to be targeted, relevant, and integrated into the lived experience of adolescents, capable of delivering the appropriate technique for the problem at hand, at the time of need."
223756140|NCT01504724|DRUG|bevacizumab|intravitreal bevacizumab injection (1.25 mg/0.05 mL) was done 4.0 mm posterior to the corneal limbus using a 30-gauge needle after topical anesthesia
223756141|NCT00743652|BIOLOGICAL|13-valent Pneumococcal Conjugate Vaccine|4 doses of 13vPnC (0.5ml, IM) will be administered. (3 doses infant series, and 1 toddler dose)
223756142|NCT00743652|BIOLOGICAL|13-valent Pneumococcal Conjugate Vaccine|3 doses of 13vPnC (0.5ml, IM) will be administered. (2 doses for infant series catch-up, and 1 toddler dose)
223756143|NCT00743652|BIOLOGICAL|13-valent Pneumococcal Conjugate Vaccine|2 doses of 13vPnC (0.5ml, IM) will be administered. (1 dose infant series catch-up, and 1 toddler dose)
223756144|NCT00743652|BIOLOGICAL|13-valent Pneumococcal Conjugate Vaccine|2 doses of 13vPnC (0.5ml, IM) will be administered. (2 catch-up dose(s) greater than 60 days apart )
223756145|NCT00743652|BIOLOGICAL|13-valent Pneumococcal Conjugate Vaccine|1 dose of 13vPnC (0.5ml, IM) will be administered. (1 catch-up dose)
223756146|NCT01838005|BEHAVIORAL|Conditional cash transfer|Eligible women randomized to the intervention group will receive the standard of care plus small and increasing cash payments, on the condition that they attend scheduled clinic visits on time (+/-5days), accept HIV services, deliver in a health facility, and at six weeks postpartum adhere to prescribed infant prophylactic drugs (cotrimoxazole, extended NVP) and provide blood sample for DNA PCR infant early HIV diagnosis.
224311640|NCT00661895|DRUG|Lisinopril and Hydrochlorothiazide|L 10 mg and H 12.5 mg tablets, L 20 mg and H 12.5 mg tablets, L 20 mg and H 25 mg tablets
223609856|NCT05486611|DEVICE|Digital Education Application (W-EdZD)|"Digital Education will be available to the participant via the 'Quest GenZ' smartphone application but will be devoid of active elements included in WB002. We will source this material from kidshealth.org, which is supported by Nemours Children's Health. We have received permission to use their content.~The materials are written at an 8th grade reading level and will include general health (e.g., food plate guide, caffeine, online safety, study skills) articles. A new article will be provided to the participant at a rate of once per week across the 4 weeks (4 articles total) and they will receive a weekly notification when a new article is available. Each article will be available for one week from release date."
223609857|NCT01773187|DRUG|Pacritinib|
223756147|NCT00367068|DRUG|baclofen, intrathecal|
223756148|NCT00367068|DEVICE|infusion pump for intrathecal baclofen, Synchromed, Medtronic|
223756149|NCT01163994|DRUG|ceftriaxone|intravenously, 2 g, qd, 15 days
223756150|NCT01163994|DRUG|doxycycline|orally, 100 mg, bid, 15 days
223756151|NCT01163994|OTHER|erythema migrans patients treated with doxycycline|orally, 100 mg, bid, 15 days
223756152|NCT05935241|BEHAVIORAL|mPATH|The active mPATH intervention takes 6 months including (1) The physical activity education session , (2)mHealth learning and practice; (3)Personalized physical activity training, plan, and biweekly phone calls over 24 weeks (4) mHealth strategies to encourage physical activity and facilitate intervention adherence (5) (5) mPATH during 6-12 months: mPATH will be delivered mainly in 24 weeks before the 6-month data collection. During 6-12 months, the participants will have access to study mHealth strategies, and exercise videos. No additional physical activity training by staff will be supported.
224311641|NCT00661895|DRUG|Nifedipine XL|30 mg extended release tablets, 60 mg extended release tablets
223609858|NCT01773187|DRUG|Best Available Therapy|
223609859|NCT06060587|DRUG|Docetaxel|75 mg/m2 via IV
223609860|NCT06060587|DRUG|ADT|Prior to randomization as part of standard of care.
223609861|NCT06060587|DRUG|Abiraterone|1000 mg by mouth
223609862|NCT00704860|OTHER|Open label pharmacotherapy|"Dosage and drug types change based on patients need and response.~doxepin, clomipramine, amoxapine, amitriptyline, maprotiline, desipramine, nortriptyline, trimipramine, imipramine, protriptyline, isocarboxazid, phenelzine, tranylcypromine, moclobemide, fluvoxamine, paroxetine, fluoxetine, sertraline, citalopram, escitalopram, venlafaxine, atomoxetine, pramipexole, bromocriptine, quetiapine, clozapine, olanzapine, ziprasidone, aripiprazole, paliperidone, Risperidone, bupropion, mirtazapine, pindolol, topiramate, trazodone, Lithium,"
223609863|NCT02978833|BIOLOGICAL|PRP|
223609864|NCT02978833|BIOLOGICAL|Whole Blood|
223609865|NCT02978833|DEVICE|Ultrasound|
223609866|NCT00015795|DEVICE|airway interruption test|
223756153|NCT05935241|OTHER|Attention Control|A registered nurse from the study team will provide 6 monthly home visit (approximately 55-60 minutes each) to provide physical activity education, physical activity safety at home evaluation, feedback, and social activity (meaningful or enjoyable activities as identified by the participants, such as playing cards, doing arts and crafts, listening to music, talking about life history, etc.).
224200963|NCT01984931|DRUG|Trimebutine Maleate (NEWBUTIN SR 300 mg Tab)|Trimebutine Maleate (NEWBUTIN SR 300 mg Tab)is a noncompetitive spasmolytic agent. It possesses moderate opiate receptor affinity and has marked anti-serotonin activity especially on'M' receptors. A single dose of NEWBUTIN SR 300 mg Tab orally will be given one hour prior to the said operation time and another 300 mg orally as soon as the patient wakes post operatively.
224200964|NCT01984931|DRUG|Metoclopramide hydrochloride monohydrate|
224200965|NCT03159611|DRUG|Tenoten for children|Oral. 10 drops daily, at the same time in the morning, 15 minutes before feeding.
224200966|NCT03159611|DRUG|Placebo|Oral. 10 drops daily, at the same time in the morning, 15 minutes before feeding.
224200967|NCT06697483|DRUG|Daratumumab|Patients who are R2-ISS 3 or 4 OR MRD (Minimal Residual Disease) positivity will receive daratumumab plus lenalidomide maintenance.
224200968|NCT06697483|DRUG|Lenalidomide|"Patients are R2-ISS 1,2 and MRD (Minimal Residual Disease) negative after autologous stem cell transplantation.~Patients will receive the single drug lenalidomide maintenance."
224200969|NCT04016909|PROCEDURE|aerobic exercise plus calorie restriction|both a 6-month aerobic exercise program (moderate intensity) and caloric restriction (12.5% energy deficit)
224200970|NCT02431507|DEVICE|Magnap|This is a non-randomized clinical trial.Patients 21-70 years diagnosed with moderate to severe obstructive sleep apnea will have the Magnap Magnetic Apnea Device surgically implanted on the subject's hyoid bone and used in conjunction with an external neck brace and magnet to open airway during sleep in treatment of Obstructive Sleep Apnea. We will monitor for safety, brace compliance and improvement of symptoms of sleep apnea for a total of 13 months.
224200971|NCT04272411|DEVICE|Sham SCS stimulation|Sham SCS stimulation via implanted neuromodulation device for 45 min during the steady state of a hyperinsulinemic euglycemic clamp.
224200972|NCT04272411|DEVICE|Tonic SCS stimulation|Tonic SCS stimulation via implanted neuromodulation device for 45 min during the steady state of a hyperinsulinemic euglycemic clamp.
224200973|NCT04272411|DEVICE|Burst SCS Stimulation|Burst SCS stimulation via implanted neuromodulation device for 45 min during the steady state of a hyperinsulinemic euglycemic clamp.
224200974|NCT05303844|DRUG|H101|H101 intratumorally injection starts at day 0.
224200975|NCT05303844|DRUG|Tislelizumab|Tislelizumab will be initiated on day 1. Tislelizumab will be administered at 200 mg i.v. every 3 weeks until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
224200976|NCT06108973|DEVICE|Capnography|To know the Co2 graph in COPD and Normal patients under General Anesthesia
224311642|NCT00661895|DRUG|Metoprolol tartrate|50 mg tablets \& 100 mg tablets
224311643|NCT00661895|DRUG|Atenolol|50 mg tablet
224311644|NCT00661895|DRUG|Valsartan|80 mg tablets \& 160 mg tablet
224311645|NCT00661895|DRUG|Doxazosin|4 mg tablets
223756154|NCT03452592|DRUG|Alflutinib|Patients take Alflutinib orally once per day at dose of 80 mg or 160 mg
223756155|NCT06262841|DEVICE|Piezosurgery|Piezosurgery used as an osteotomy device
223756156|NCT06262841|DEVICE|Conventional burs|Conventional burs used as an osteotomy device
224200977|NCT04921319|DIAGNOSTIC_TEST|VExUS score|"The care team will be informed of the VExUS immediately after the ultrasound is performed and given a suggested target for the following 24 hours as follows:~* VExUS 0: The patient will likely tolerate more fluid if clinically needed.~* VExUS 1: The patient has evidence of mild venous congestion. The investigators recommend targeting a net neutral or negative fluid balance with diuresis.~* VExUS 2-3: The patient has evidence of moderate to severe venous congestion. The investigators recommend targeting a fluid balance of negative 1-2L with diuresis. If the investigator cannot obtain ultrasound images of sufficient quality to calculate VExUS, the care team will be informed that there is no recommendation for that subject on that day."
224200978|NCT00518011|DRUG|Erlotinib|150 mg po daily
224200979|NCT00518011|DRUG|Gemcitabine|As prescribed
224200980|NCT00648583|DRUG|Ondansetron Tablets 24 mg|24mg, single dose fed
224200981|NCT00648583|DRUG|Zofran® Tablets 24 mg|24mg, single dose fed
224200982|NCT02596009|DEVICE|Breezhaler®|No active drug or placebo were administered to patients during this study. Each patient were required to inhale via all three (03) study devices (Breezhaler®, Ellipta® and Handihaler®). Each patient was required to produce at least three (03) inhalational profiles via each inhalational device, following the training and demonstration for correct inhalational procedure, for each device.
224200983|NCT02596009|DEVICE|Ellipta®|No active drug or placebo were administered to patients during this study. Each patient were required to inhale via all three (03) study devices (Breezhaler®, Ellipta® and Handihaler®). Each patient was required to produce at least three (03) inhalational profiles via each inhalational device, following the training and demonstration for correct inhalational procedure, for each device.
224311646|NCT00661895|DRUG|Clonidine|0.2 mg tablets
224311647|NCT00661895|DRUG|Hydralazine|50 mg tablets
224311648|NCT00661895|DRUG|Metoprolol succinate|50 mg tablet \& 100 mg tablet
224311649|NCT00661895|DRUG|Amlodipine|5 mg tablets \& 10 mg tablets
223756157|NCT01007695|DRUG|Valproic Acid|Valproic Acid is FDA approved and indicated as monotherapy and adjunctive therapy in the treatment of patients with complex partial seizures that occur either in isolation or in association with other types of seizures. Valproic Acid is indicated for use as sole and adjunctive therapy in the treatment of simple and complex absence seizures, and adjunctively in patients with multiple seizure types which include absence seizures.
223756158|NCT05432310|COMBINATION_PRODUCT|A cryopreserved formulation of autologous mPB CD34+ hematopoietic stem and progenitor cells transduced ex vivo with the EFS-ADA lentiviral vector encoding the human ADA enzyme|Autologous transplantation of EFS-ADA lentiviral vector transduced, mPB CD34+ cells by central venous infusion, following reduced intensity conditioning with busulfan
223756159|NCT01667666|DRUG|Nebulized hypertonic saline|The first 5 patients will receive 3% hypertonic saline in a nebulizer, the second 5 patients will receive 4.5% nebulized hypertonic saline, the third group 6% nebulized hypertonic saline, and the fourth group of 5 patients will receive 7% nebulized hypertonic saline. The nebulizer is dosed 2-3 times a day for 36 hours.
223756160|NCT01411878|BEHAVIORAL|Reducing the Risk|Reducing the Risk: Building Skills to Prevent Pregnancy, STD and HIV (RtR) was developed by Richard Barth, MSW, Ph.D. in California. The training manual is in its 5th Edition and was last published in 2011. This curriculum is one of the first that was evaluated using an experimental design, with a longitudinal follow up (6 months and 18 months) and tested on a large group of high school students (N = 758). It is also one of the first programs to show an impact on beliefs of adolescent sexual behavior prevalence and actual behavior as well as increasing parent-child communication about abstinence and contraception (Kirby, Barth, Leland, and Fetro, 1991).
223756161|NCT01411878|BEHAVIORAL|Love Notes|The second healthy relationships program for high-risk youth, Love Notes, was developed to educate participants about healthy relationships, including issues of decision-making, communication and conflict resolution, and overall safety, including the prevention of pregnancy and sexually transmitted disease (Pearson, 2009). Love Notes is a derivative of the Prevention and Relationship Enhancement Program (PREP; Stanley, Markman, \& Jenkins, 2009), which is relationship marriage education program listed as an evidence-based practice (EBP) by SAMSHA (www.samhsa.gov). This curriculum builds on social exchange theory and meets the needs of youth who are alienated and in need of loving personal relationships.
223756162|NCT00310908|DRUG|Tramadol Hcl|Active Comparator
223756163|NCT03706807|OTHER|Mindfulness-Based Intervention|This intervention is a meditative practice which the individuals will practive in their daily life following the MBHP protocol
223756164|NCT03706807|OTHER|Cognitive Stimulation|A basic computer workshop in order to develop the psychomotricity involving the use of mouse, keyboard, MS paint, photo gallery and PowerPoint presentations to surf on the internet, learn how to play online games and use social networks
223609867|NCT03481699|BEHAVIORAL|Incremental theory of personality|"The experimental intervention (originally developed by David S. Yeager and colleagues) teaches that individuals have the potential to change. It has three main parts. First, participants are asked to read scientific studies that provide evidence that behaviors are controlled by thoughts and feelings in brains, and that pathways in the brain have the potential to be changed under the right circumstances. Second, participants read several testimonials purportedly written by upperclassmen to bring credibility to the ITP. Finally, participants are asked to write their own version of such a narrative. This self-persuasive writing exercise has been shown to facilitate the internalization of the intervention message, building on a long line of research on cognitive dissonance."
223609868|NCT03481699|OTHER|Educational Intervention|The educational intervention involved scientific information about the human brain. It was designed to be parallel to the experimental intervention and, hence, it has also three main parts. First, participants are asked to read scientific information about the different areas of the brain and their specialties. Second, participants read several testimonials written by upperclassmen about their transition to high school and how their brains help them to adapt to the new space and all the physical differences of the building and the classes. Finally, participants are asked to write a letter to another student explaining the main things he or she has learned about the brain and thinks are important for adapting to the new physical environment in high school.
223609869|NCT03644667|BIOLOGICAL|tocilizumab|6 doses: 8mg/kg (maximum of 800 mg) given once every four weeks by intravenous infusion over a 20-week period, with a minimum of 21 days between each infusion.
223609870|NCT03644667|BIOLOGICAL|Placebo|The placebo is 0.9% sterile normal saline. 6 doses: 8mg/kg (maximum of 800 mg) given once every four weeks by intravenous infusion over a 20-week period, with a minimum of 21 days between each infusion.
223609871|NCT03644667|DRUG|Standard of Care Triple IS|"Standard of care triple maintenance IS includes:~1. A calcineurin inhibitor-tacrolimus (Prograf ®) per site standards by sublingual, oral or intravenous route to attain target trough levels.~   Exception: Should a participant be unable to tolerate tacrolimus, the site physician investigator may choose cyclosporine treatment.~2. An anti-proliferative treatment-mycophenolate mofetil or Myfortic® (enteric-coated mycophenolate sodium) will be administered, per protocol.~   Exception: Should a participant be unable to tolerate mycophenolate mofetil, the site physician investigator may choose an alternative treatment.~3. Steroids-methylprednisolone/prednisone dosing will be given according to the local center standard of practice early post transplantation. After 6 months, prednisone may be withdrawn at the discretion of the site physician investigator, per protocol."
223609872|NCT02436538|OTHER|Anti Mullerian hormone level; Mullerian duct anomaly type|Diagnosis of Mullerian duct anomaly type Clinically or by Imaging Anti-Müllerian Hormone levels
223609873|NCT05476016|DEVICE|Near-infrared (NIR)|NIR spectral assessment of glycated nail keratin vs HbA1c
223756165|NCT06203457|BIOLOGICAL|Efgartigimod|Patients receiving efgartigimod infusions
223756166|NCT04046185|DRUG|PD-1 inhibitor combined progesterone|Toripalimab combine with progesterone
223756167|NCT04046185|DRUG|progesterone|progesterone
223756168|NCT04120610|DIAGNOSTIC_TEST|FlowMet-R|FlowMet-R is a noninvasive blood flow measurement.
223756169|NCT04120610|DIAGNOSTIC_TEST|ABI|Ankle Brachial Index is a ratio-metric blood pressure measurement in the ankle and arm.
223756170|NCT04120610|DIAGNOSTIC_TEST|TBI|Ankle Brachial Index is a ratio-metric blood pressure measurement in the toe and arm.
223756171|NCT05575141|PROCEDURE|incisional hernia repair|Incisional hernia repair for the treatment of wide ventral incisional hernias.
223756172|NCT02771496|OTHER|Other: observational only- no intervention|Other: observational only- no intervention
223756173|NCT06145971|BEHAVIORAL|brief Cognitive Behavioural Therapy for Insomnia (bCBTi)|Two sessions of Cognitive Behavioural Therapy for Insomnia, encompassing a cognitive therapy technique and a behavioural technique as a minimum.
223609874|NCT04688229|DEVICE|Hummingbird hand training device plus standard of care rehabilitation|The Hummingbird is a comprehensive hardware and software platform that isolates the hand, wrist, and forearm in a neutral and comfortable position, allowing linear force and angular torque to be measured at the finger-tips between 0-10 Newtons at milli-newton resolution at 100 Hz per digit, in 5 degrees of freedom simultaneously, in real-time, for all 5 digits. The platform allows isolating and characterizing fine resolution forces with sufficient sensitivity and resolution to record data in severe paralysis. The platform also comprises therapeutic software to train exploratory, individuated, and inter-digit complex finger movements by coupling force and torque output to NeuroAnimation physics-based virtual interface in engaging therapeutic experiences.
223609875|NCT04688229|OTHER|Comparison (sham) intervention|During each hour of sham therapy the therapist will select cognitive tasks (e.g. puzzles and games) targeted to a level of difficulty based on the subjects ability. No grasping or object manipulation using the target upper limb will be included in this intervention. Rather, the participant will use either the unaffected limb (or non-targeted limb for SCI subjects) as needed for any particular puzzle or game.
223609876|NCT06428370|PROCEDURE|Damage Control Surgery|Simple resection, drop, and open abdomen in case of Hinchey III-IV
223609877|NCT00103740|DRUG|zoledronic acid|5 mg zoledronic acid in 5 mL of sterile water for infusion
223609878|NCT00103740|DRUG|placebo to zoledronic acid|5 mL of sterile water for infusion
223609879|NCT00103740|DRUG|Risedronate|30mg oral tablets overencapsulated to match the placebo capsules
223609880|NCT00103740|DRUG|Placebo to risedronate|oral capsules
223609881|NCT00103740|DRUG|Calcium and vitamin D supplements|Calcium and vitamin D supplements were supplied
223609882|NCT03410303|DIAGNOSTIC_TEST|Intraoperative ultrasound and 2 months post-operative ultrasound ( ± 1 month)|An ultrasound of the position of the prosthesis during surgery, under general anesthesia, is performed. A follow-up visit will be carried out 2 months (± 1 month) after the surgery as part of the usual care. An ultrasound of the position of the prosthesis is performed without anesthesia, either as part of the treatment or as part of the research. This measurement is performed without the intraoperative measurement by an independent sonographer.
223609883|NCT01863329|PROCEDURE|retrobulbar ultrasound|both optic nerve sheath diameter (the posterior 3mm of the papilla), 5 individual measurement
223609884|NCT02503150|BIOLOGICAL|APDC + Chemotherapy|Patients in Arm APDC+Chemotherapy receive maximum 12 cycles (14days/cycle) mFOLFOX6 chemotherapy. Each cycle chemotherapy consist of Oxaliplatin at 85mg/ m2 infused for 2 hours only on day 1,and Leucovorin at 400 mg/m2 was administered intravenously for 2 hours, followed by continuous intravenous administration of 5-Fluorouracil at 400 mg/m2 (2.4g/m2 for 46 hours).On day 8 of cycle1-3 and 7-9, patients also receive APDC vaccine infusion in 100ml saline. After 12 cycles, patients in Arm APDC+chemotherapy will receive 5-Fluorouracil /Leucovorin (Leucovorin at 400 mg/m2/day administered intravenously for 2 hours, intravenous bolus of 5-Fluorouracil at 400 mg/m2 , followed by continuous intravenous administration of 5-Fluorouracil at 1200 mg/m2/d for 2 days, repeated every 2 weeks) plus APDC therapy (once every 3 months). Treatments will continue unless disease progression, intolerable toxicity or patients withdrawal).
223756174|NCT04240145|DEVICE|MSCT Abdomen|Visceral fat volumetry using MSCT and it's relation to NASH
223756175|NCT02129803|DEVICE|High-Flow, 20 LPM (via Optiflow cannula)|Nasal high flow humidification (20LPM) therapy will be administered using Optiflow with Airvo 2.
223756176|NCT02129803|DEVICE|Low FLow, 5 LPM (via Optiflow cannula)|standard humidified wall medical air.
223756177|NCT05378139|DEVICE|Vital signs measurements with new app|Patients vital signs are monitored through an app for the nurses to use
223756178|NCT04923971|OTHER|Purdue Pegboard|Participants will assemble the pegboard with their left, right, and both hands in each environmental condition.
223756179|NCT02979145|OTHER|No intervention involved|
223756180|NCT03873389|DRUG|Ocrelizumab|Patients who are beginning this medication based on patient's treating physician's recommendation will be enrolled in the study.
223756181|NCT03830554|OTHER|Organic Atlas cedar wood essential oil (Cedrus Atantica)|At first day of admission, Intervention group received an intervention kit consist of 5 small glass essential oil bottles. Each essential oil bottle contains a small cotton ball saturated with two drops of Organic Atlas cedar wood essential oil (Cedrus Atantica). Participants were asked to open the bottle, inhale the smell directly and put it opened at 20 cm beside bed during night.
223756182|NCT00459836|DRUG|PR-104|
223756183|NCT00459836|DRUG|docetaxel|
223756184|NCT00459836|DRUG|gemcitabine hydrochloride|
223756185|NCT00459836|OTHER|laboratory biomarker analysis|
223756186|NCT00459836|OTHER|pharmacological study|
224200984|NCT02596009|DEVICE|Handihaler®|No active drug or placebo were administered to patients during this study. Each patient were required to inhale via all three (03) study devices (Breezhaler®, Ellipta® and Handihaler®). Each patient was required to produce at least three (03) inhalational profiles via each inhalational device, following the training and demonstration for correct inhalational procedure, for each device.
224200985|NCT00802152|OTHER|Home monitoring|The subject will take their blood pressure or glucose measurements 1-4 times per day, depending on patient condition. They will upload these measurements using the device to a secure website at least every other day. Data will be reviewed at least 2 times per week Monday through Friday by the clinic nursing staff. Data indicating problems, e.g., critical out of range values, will be communicated to the patient's primary care physician after review by the nurse. The physician will then determine what is needed for follow up action based on the patient's condition and data (e.g., telephone call to patient home, scheduling a clinic appointment, etc).
223756187|NCT06304090|BEHAVIORAL|routine rehabilitation treatment|"All participants were given routine rehabilitation treatment by professional rehabilitation therapists, including exercise therapy, guided education, psychological therapy, acupuncture and massage therapy, to promote the development of motor and cognitive function, as well as to improve intellectual development\[. Besides, swallowing function training was also provided, including direct training, indirect training, and compensatory training, as follows The mendelson maneuver: performed 5 days per week, twice per day, 5-10 minutes each time.~Cold stimulation of the pharynx: performed every day, twice per day, 3-5 minutes each time.~Passive head extension: to stretch the submental muscle for 2-3 seconds, with upward resistance applied to the lower cheek for no less than 5 times a day and no less than 5 minutes each time.~Direct feeding training: with powdered milk, once a day, 5 days a week."
223756188|NCT06304090|PROCEDURE|Stellate ganglion block|The percutaneous approach via the paratracheal route was used for Stellate ganglion block . The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
223756189|NCT06304090|DRUG|Lidocaine Hydrochloride|The patients were provided with Stellate ganglion block , using 0.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate ganglion block . The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
223756190|NCT04515342|DIAGNOSTIC_TEST|DXA|Each participant will undergo one DXA scan
223609885|NCT02503150|DRUG|Chemotherapy|Patients in Arm Chemotherapy receive maximum 12cycles (14days/cycle) mFOLFOX6 chemotherapy. Each cycle chemotherapy consist of Oxaliplatin at 85mg/ m2 infused for 2 hours only on day 1, and Leucovorin at 400 mg/m2 was administered intravenously for 2 hours, followed by continuous intravenous administration of 5-Fluorouracil at 400 mg/m2 (2.4g/m2 for 46 hours). After 12 cycles, patients in Arm chemotherapy will receive only 5-Fluorouracil /Leucovorin (Leucovorin at 400 mg/m2/day administered intravenously for 2 hours, intravenous bolus of 5-Fluorouracil at 400 mg/m2 , followed by continuous intravenous administration of 5-Fluorouracil at 1200 mg/m2/d for 2 days, repeated every 2 weeks). Treatments will continue unless disease progression, intolerable toxicity or patients withdrawal).
223609886|NCT04224961|DEVICE|Respiratory Muscle Training|Two commercially available pressure-threshold RMT devices that utilize a spring-loaded flange to provide resistance against inspiration and expiration independent of respiratory flow rate will be used to provide the necessary range of resistance. Each participant will use two RMT devices, one for IMT and one for EMT.
223609887|NCT02434042|DIETARY_SUPPLEMENT|BB536|Intervention consists of daily administration of 1g probiotic Bifidobacterium longum BB536, administer daily for five days a week at a fixed dosage of 9 log CFU/day for BB536 and continue for 10 months.
223609888|NCT02434042|OTHER|Placebo|Intervention consists of daily administration of 1g of 100% dextrin, administer daily for five days a week and continue for 10 months.
223609889|NCT03945149|DIETARY_SUPPLEMENT|Turmipure Gold™|30 subjects will take 1000mg in 4 capsules (with 250ml water before breakfast , each day, during 5 weeks
223609890|NCT03945149|DIETARY_SUPPLEMENT|Placebo|30 subjects will take 4 capsules with 250ml water before breakfast , each day, during 5 weeks
223609891|NCT02909374|OTHER|Balance training|The balance-training program was developed based on well-established principles of exercise and on the knowledge that balance control relies on the interaction of several physiological systems, as well as interaction with environmental factors and the performed task. It includes exercise with dual- and multi task performance. It is progressive as the exercises can be performed at different levels (basic, moderate, and advanced), making it progressively challenging for each individual throughout the whole program. The training is conducted as an individually tailored group program.
223609892|NCT02321345|OTHER|Palliative Care Support|Palliative care meetings Quality of Life Assessments
223609893|NCT02982057|DEVICE|the ABSORB:bioresorbable vascular scaffold|
223609894|NCT02982057|DRUG|O.M.T|
223609895|NCT00815893|DRUG|dexmedetomidine|dexmedetomidine 1.0 mcg/kg infusion for 10minutes
223609896|NCT00815893|DRUG|Normal Saline 0.9%|0.9% Normal Saline 0.25ml/kg infusion for 10minues
223609897|NCT00815893|DRUG|propofol 1%|"Propofol: The initial target = 3 μg/ml. The TCI is adjusted by 0.5μg/ml according to patient comfort during the procedure.~The Orchestra® Base Primea(Fresenius, Brezins, France) offers a Target Controlled Infusion (TCI) target controlled infusion."
223609898|NCT01643824|RADIATION|Proton Beam Therapy|"\- Prescription dose to PTV as according to the following dose escalation schema: Arml 1: 60 GyE /10 fx, 6GyE fraction dose, 5 days/week, for HCC free from the alimentary tract (i.e., stomach, duodenum, esophagus, small and large bowel) (more than 2cm from clinical target volume), TLV30 \<40%, and/or RLV30 \<30%) Arm 2: 50 GyE /10 fx, 5GyE fraction dose, 5 days/week, for HCC close to the alimentary tract (less than 2cm from clinical target volume) but not contact with the alimentary tract, TLV30\<50% and RLV30\<40% Arm 3: 35 GyE /10 fx, 4GyE fraction dose, 5 days/week, for HCC contact to the alimentary tract (contact with clinical target volume), TLV30\<60%, and/or RLV30\<50%~\- Dose prescription : 95% isodose volume of prescribed dose encompassed PTV"
223609899|NCT04611828|DEVICE|Philips SmartSleep|closed-loop auditory stimulation
223609900|NCT01336153|DRUG|MLC601|group A (100 patients; NeuroAid 400mg, 4 capsules 3 times daily) or for 3 month
223609901|NCT01336153|DRUG|Placebo|group B (50 patients; placebo, 4 capsules 3 times daily) for 3 months
223609902|NCT03910088|DRUG|Pregabalin 100Mg Oral Cap|giving a drug to relieve post-dural puncture headache
223609903|NCT03910088|DRUG|Hydrocortisone|Giving drug to relieve post-dural puncture headache
223609904|NCT03910088|DRUG|Acetaminophen|giving a drug to relieve post-dural puncture headache
223609905|NCT03910088|OTHER|oral fluids|giving oral fluids to maintain good hydration
223609906|NCT03910088|DRUG|Caffeine|giving a drug to relieve post-dural puncture headache
223609907|NCT03910088|DRUG|Diclofenac|giving a drug to relieve post-dural puncture headache
223609908|NCT01992263|DIETARY_SUPPLEMENT|Vitamin D (600 IU)|Daily oral dose for 12 months
223609909|NCT01992263|DIETARY_SUPPLEMENT|Vitamin D (2000 IU)|Daily oral dose for 12 months
223609910|NCT01992263|DIETARY_SUPPLEMENT|Vitamin D (4000 IU)|Daily oral dose for 12 months
223609911|NCT01992263|OTHER|Placebo|Daily oral dose for 12 months
223609912|NCT01996085|DRUG|lisinopril|"Angiotensin converting enzyme inhibitor recommended in case of:~1. hyperconstrictive profile (SVRI \> 2500-2800 dyn•s•cm-5•m2)~2. hyperdynamic profile (CI \> 4.2 l/min/m2 and/or HR \> 80/min) and office SBP ≥ 160 mm Hg and/or DBP ≥ 100 mmHg and/or 24-h mean SBP ≥ 140 mm Hg and/or 24-h mean DBP ≥ 90 mm Hg (in combination with nebivolol)~3. hypervolemic profile (man - TFC \> 34 1/kOhm; women - TFC \> 24 1/kOhm) and office SBP ≥ 160 mm Hg and/or DBP ≥ 100 mmHg and/or 24-h mean SBP ≥ 140 mm Hg and/or 24-h mean DBP ≥ 90 mm Hg (in combination with diuretic)~4. balanced profile"
223609913|NCT01996085|DRUG|Telmisartan|Angiotensin receptor blocker recommended in terms as for lisinopril in case of its intolerance (e.i. cough)
223609914|NCT01996085|DRUG|Nebivolol|"Beta-blocker recommended in case of:~1.hyperdynamic profile (CI \> 4.2 l/min/m2 and/or HR \> 80/min)"
223609915|NCT01996085|DRUG|Indapamide/hydrochlorothiazide|"1. hypervolemic profile (man - TFC \> 34 1/kOhm; women - TFC \> 24 1/kOhm)~2. hyperconstrictive profile (SVRI \> 2500-2800 dyn•s•cm-5•m2) and office SBP ≥ 160 mm Hg and/or DBP ≥ 100 mmHg and or 24-h mean SBP ≥ 140 mm Hg and/or 24-h mean DBP ≥ 90 mm Hg (in combination with lisinopril/telmisartan)"
223609916|NCT01996085|DRUG|Amlodipine|1/ SVRI \> 2800 dyn•s•cm-5•m2 (in combination with lisinopril/telmisartan)
223609917|NCT01996085|DRUG|lisinopril|Drug choice at the discretion of physician (blinded to ICG)
223609918|NCT01996085|DRUG|Telmisartan|Angiotensin receptor blocker recommended as for lisinopril in case of its intolerance (e.i. cough)
223609919|NCT01996085|DRUG|Nebivolol|Drug choice at the discretion of physician (blinded to ICG)
223609920|NCT01996085|DRUG|Indapamide/hydrochlorothiazide|Drug choice at the discretion of physician (blinded to ICG)
223609921|NCT01996085|DRUG|Amlodipine|Drug choice at the discretion of physician (blinded to ICG)
223609922|NCT02197091|OTHER|questionnaire administration|Ancillary studies
223609923|NCT02197091|OTHER|medical chart review|Ancillary studies
223609924|NCT00525005|DRUG|DOS (Docetaxel, Oxaliplatin and S-1)|Docetaxel 52.5mg/m2 IV on D1 (diluted in 250 ml of normal saline over a 1 hour of each cycle before oxaliplatin) Oxaliplatin 105mg/m2 IV on D1 (diluted in 250 ml of 5% DW for 2 hours) S-1 80mg/m2/day on D1-14 (2 weeks of treatment followed by a 1-week rest period)
223609925|NCT02921490|DEVICE|FDG PET/MR examination.|All recruited patients will undergo an FDG PET examination focused on the lumbar spine.
223609926|NCT01002183|DRUG|Fosmidomycin|450 mg capsules, every 12 hrs for 3 days
223609927|NCT04314583|BEHAVIORAL|Attention Control|Participants in this group will be asked to recall 3 to 5 events from the prior day of the intervention and write, or if unable to write, speak about these events.
223609928|NCT04314583|BEHAVIORAL|Gratitude Journaling|The gratitude journaling intervention involves participants writing or speaking 3-5 things for which they are grateful and focusing on these attributes. Participants will do this weekly for 12 weeks.
223756191|NCT04515342|OTHER|Muscle strength and function assessment|Each patient will have their muscle strength and function assessed with the measurements of handgrip strength, 10 m gait speed and a 30 s sit-to-stand test. They will also fill out a questionnaire assessing Strength, Assistance in walking, Rise from a chair, Climb stairs, and Falls (SARC-F questionnaire).
223756192|NCT04515342|OTHER|Blood samples|Each patient will undergo a physical examination and also deliver blood samples.
223609929|NCT04511858|OTHER|maximum effort test on a cycloergometer|5 h test on cycloergometer
223609930|NCT04511858|OTHER|maximum effort test on a treadmill|5 h test on treadmill
223609931|NCT00546949|PROCEDURE|Minimal invasive decompression|foraminotomy, laminotomy, microscopic decompression
223609932|NCT00546949|PROCEDURE|Interspinous Process Decompression (IPD)|Interspinous device
223609933|NCT01920308|DEVICE|5 mm Bard LifeStent Vascular Stent|The LifeStent® Vascular Stent is a peripheral stent intended to improve luminal diameter in the treatment of symptomatic de-novo or restenotic lesions up to 240 mm in length in the native superficial femoral artery (SFA) and popliteal artery with reference vessel diameters ranging from 4.0 - 6.5 mm.
223609934|NCT01023724|DRUG|Ketorolac Tromethamine 0.45%|Acuvail to be given 1 drop BID for one day prior to surgery and then 1 drop BID post operatively for 14 days.
223609935|NCT01023724|DRUG|Bromfenac 0.09%|Drug given one drop BID for one day pre operatively and then BID for 14 days post operatively
223609936|NCT03314311|BEHAVIORAL|Rehabilitation programme|The RESTORE trial is a 12 week multi-disciplinary intervention involving exercise, nutrition advice and education sessions
223609937|NCT02424175|BIOLOGICAL|Fecal Microbiota Transplantation|
223609938|NCT02774148|DRUG|IV Acetaminophen|The patient will receive 1,00mg IV Acetaminophen every 8 hours until 3 doses have been received post-operatively.
223609939|NCT02774148|DRUG|PO Acetaminophen|The patient will receive 1,000mg po Acetaminophen every 8 hours.
223609940|NCT02151890|BIOLOGICAL|Stem Cell|Out of 112 high risk patients for POF diagnosis was established in 10 cases. Endometrial fractional biopsy was taken, stained with H\&E stain and by Immunohistochemical (IH) staining by stem cell marker OCT4. IH expression of stem cell was evaluated before and after transplantation according to Edessy Stem Cell Scoring (ESS). After laparoscopic injection of stem cell sample in the ovaries, participants were followed up monthly for a period of one year by hormonal (FSH, LH and E2), clinical (resuming menstruation and pregnancy), US (folliculometry), histopathological (HP), and IH expression of stem cell (stem cell positivity and scoring according to ESS).
223609941|NCT02663622|DRUG|Efprezimod alfa|Acute GVHD prophylaxis
223609942|NCT02663622|DRUG|Methotrexate|Acute GVHD prophylaxis
223756193|NCT03504696|OTHER|Non-interventional|Non-interventional
223609943|NCT02663622|DRUG|Tacrolimus|Acute GVHD prophylaxis
223756194|NCT00816725|BEHAVIORAL|Mothers and babies Internet course and PPD informational brochure|An eight-lesson, self-help, Web-based program for the prevention of postpartum depression based on cognitive behavioral therapy, social-learning, and attachment theory. The PPD informational brochure is a four-page pamphlet that contains information about postpartum depression.
223756195|NCT01144507|PROCEDURE|Abdominal Ultrasound|To establish eligibility and/or markers regarding echo pattern types.
223756196|NCT01144507|OTHER|Sample collection procedures|Samples of urine, serum, plasma, and blood for DNA from children and blood for DNA from parents will be requested from participating subjects
223756197|NCT01194947|DEVICE|RCM imaging|RCM imaging will be performed using a commercially-available RCM (Vivascope 1500, Lucid Inc, Rochester, NY, USA) with 830-nm diode laser with emitting power less than 35 milliwatts
223756198|NCT00217360|BEHAVIORAL|a customised multifactorial falls prevention program|
223756199|NCT02689258|DRUG|HTX-011B|HTX- 011B (bupivacaine/meloxicam) via injection
223756200|NCT02689258|DRUG|Placebo|Saline placebo via injection
223756201|NCT02689258|DRUG|HTX-011A|HTX- 011A (bupivacaine/meloxicam) via injection
223756202|NCT02689258|DRUG|HTX-002|HTX-002 via combination
223756203|NCT02689258|DRUG|Bupivicaine HCl|Bupivacaine HCl via injection
223756204|NCT00897065|GENETIC|microarray analysis|
223756205|NCT00897065|GENETIC|polymerase chain reaction|
224311650|NCT02333656|OTHER|New OA model|"The general practitioners and the physiotherapists will attend an inter-active workshop and deliver osteoarthritis care in line with international recommendations for osteoarthritis treatment. The general practitioner will refer eligible patients to treatment by physiotherapists at Healthy Living Center or by physiotherapists in private practice. This treatment will include a standardized patient education program followed by structured exercise program with individual adjustments. The general practitioner will schedule a follow-up after the 12-week treatment and will receive a treatment report from the physiotherapist."
223609944|NCT02663622|DRUG|Placebo|100 ml saline IV infusion.
223609945|NCT05356585|GENETIC|SignateraTM assay|A customized tumor-informed ctDNA test that, after receiving the tumor tissue, examines whole exome sequencing of a biopsied tumor to find the somatic tumor-derived mutations. From those mutations, the 16 most clonal mutations are used to create a personal assay
223609946|NCT01588600|OTHER|Dietary Fiber|Fiber added to breakfast
223609947|NCT03469687|DEVICE|Symax uncemented hip stem|
223609948|NCT04813887|OTHER|questionnaire|Self-questionnaire on skin diseases reported during pregnancy
223609949|NCT01659684|BIOLOGICAL|standard intravenous immunoglobulin|Human standard intravenous immunoglobulin (IVIG), 0.5 g/Kg of body weight, monthly after confirmation of primary gestational CMV infection
223756206|NCT00897065|GENETIC|protein expression analysis|
223756207|NCT00897065|OTHER|diagnostic laboratory biomarker analysis|
223756208|NCT00897065|OTHER|fluorescent antibody technique|
223756209|NCT00897065|OTHER|immunohistochemistry staining method|
223756210|NCT00897065|OTHER|immunologic technique|
223756211|NCT02261376|DRUG|DS-1971a|DS-1971a is supplied as a powder or crystals and will be given as an oral suspension with Bitrex® (taste masking agent). Each subject will receive a single oral dose of 200 mg DS 1971a .
223756212|NCT05401955|OTHER|Physical exercise|An adapted physical exercise protocol
223756213|NCT02221310|DRUG|Gemtuzumab Ozogamicin|Gemtuzumab Ozogamicin 7.5 mg/m\^2/dose given IV over 2 hours once during conditioning
223756214|NCT04504383|DRUG|PN-943|Administered by the oral route BID for the duration of the study.
223756215|NCT04504383|DRUG|Placebo|Administered by the oral route BID for 12 weeks.
223756216|NCT01520129|OTHER|Interpersonal and social rhythm therapy|IPSRT Subjects will receive weekly 45 minute sessions of IPSRT for 20 weeks. IPSRT sessions focus on reducing symptoms by teaching patients to: a) increase regularity of social rhythms and regulate sleep-wake cycles; b) resolve interpersonal problems that contribute to mood symptoms (role dispute, role transition, grief, or interpersonal deficits); and c) recognize and accept the symptoms of subthreshold BP disorder (psychoeducation). Although we train therapists in techniques that are specific to each component, in practice, these strategies are administered flexibly and fluidly, without distinct boundaries between modalities. During the course of a session, therapists move seamlessly among the techniques, according to patients' needs.
223756217|NCT03184181|OTHER|EPTE® group|Therapeutic Percutaneous Electrolysis once week for four weeks associated with eccentric exercises devices at home.
223756218|NCT03184181|OTHER|Dry needling group|The intervention for this group consisted of dry needling in trigger points associated with eccentric exercises devices at home.
223756219|NCT04602858|DEVICE|Reactive Balance Training|Reactive balance training involves the use of the Trip and Slip walkway that is able to expose participants to unpredictable trips and slips. Trips and slips will occur at random location on the walkway and times within the gait cycle, with the participants receiving 3-monthly retraining sessions along with an educational booklet.
223756220|NCT04602858|OTHER|Control|The control intervention will be receiving an educational booklet as part of standard care. The education component will target a variety of fall risk factors and provide strategies to mitigate these risk factors.
223756221|NCT03823248|DRUG|MoLuoDan|oral administration of Moluodan concentrated pills with warm water before meal for 8 pills each time for three times a day
223756222|NCT03823248|DRUG|Sanchi powder|oral administration of Sanchi powder mixing with warm water before meal for 3g each time for twice a day
223756223|NCT03823248|DRUG|Folic Acid Tablet|oral administration of folic acid tablets half an hour after meal for 5 mg each time for 3 times a day.
223756224|NCT03823248|DRUG|MoLuoDan simulation|oral administration of Moluodan simulation medicine with warm water before meal for 8 pills each time for three times a day
223756225|NCT03823248|DRUG|Sanchi powder simulation|oral administration of Sanchi powder simulation medicine mixing with warm water before meal for 3g each time for twice a day
223756226|NCT03823248|DRUG|Folic Acid Tablet simulation|oral administration of folic acid simulation tablets half a hour after meal for 5 mg each time for 3 times a day.
223756227|NCT03712410|BEHAVIORAL|PISCES|The intervention is based on Problem Solving Therapy and is a coping skills intervention designed for family caregivers of hospice patients.
224200986|NCT05676164|DEVICE|KANG XIAN|This product is a liquid composed of silica, stabilizer, xylitol, flavoring agent and water. The pH value of the product is 5.0 \~ 8.0, and the total heavy metal content (measured by Pb2+) is less than 10µg/ml.
223609950|NCT06457711|DIETARY_SUPPLEMENT|Free diet Group (FDG)|Participants were offered nutritional guidance and were encouraged to adhere to the principles of the Mediterranean diet and follow the dietary recommendations outlined in Harvard's Healthy Eating Plate.
223609951|NCT06457711|DIETARY_SUPPLEMENT|Very low Calorie Ketogenic Diet Group (VLCKDG)|Participants were offered nutritional guidance and were encouraged to adhere to the principles of the very low-calorie ketogenic diet (VLCKD) protocol
223609952|NCT06457711|DIETARY_SUPPLEMENT|Intermittent Fasting Group (IFG)|Participants were offered nutritional guidance and were encouraged to adhere to the principles of the intermittent fasting schedule
223609953|NCT02430857|OTHER|OMT|Manuel osteopathic treatment of the spine
223609954|NCT02865902|DEVICE|Low-Level Laser Therapy by Ezlase; Biolase®|comparision of the effects of low-level-laser therapy on wound healing of palatal donor site
223609955|NCT04869969|PROCEDURE|percutaneous nephrolithotomy (supine position)|percutaneous nephrolithotomy to be done in the supine position
223609956|NCT04869969|PROCEDURE|percutaneous nephrolithotomy ( prone position)|percutaneous nephrolithotomy in the prone position
223609957|NCT04308629|OTHER|Transcranial direct current stimulation|
223609958|NCT04266054|BEHAVIORAL|Digital Storytelling Intervention|12-minute digital storytelling intervention in Spanish, with four individuals explaining their personal Type 2 Diabetes stories.
223609959|NCT04933487|DEVICE|IOL implantation experimental|Monolateral implantation of toric intraocular lenses Ankoris. (Manufactured by PhysIOL sa/nv, Liège, Belgium).
223609960|NCT02744638|OTHER|probiotic yoghurt|verum is a liquid probiotic yoghurt containing all four probiotics as described in the arm description. Study participants consume daily two bottles (125g) during an intervention period of four weeks.
223609961|NCT02744638|OTHER|chemically acidified milk|Placebo is chemically acidified milk without bacterial strains. Study participants consume daily two bottles (125g) during an intervention period of four weeks (randomly assigned).
223609962|NCT02744638|DRUG|Arilin|2 tablets Arilin 500mg for 7 days
223609963|NCT00050947|DRUG|oxcarbazepine|
223609964|NCT02177682|DRUG|Afuresertib|Size 4 and Size 1 opaque white capsules containing 25 mg and 100 mg of afuresertib, respectively, to be administered orally.
223609965|NCT04375345|DEVICE|hip arthroplasty|complex primary total hip arthroplasty or revision total hip arthroplasty performed through anterolateral or posterolateral approach
223609966|NCT02587819|DRUG|Treatment with BSCT|"The study product BSCT (anti-nf-P2X7) 10% Ointment was anti-nf-P2X7 (highly purified sheep IgG) in an ointment formulation for topical administration. The formulation contained 10% weight by weight of the active pharmaceutical ingredient in an anhydrous ointment base.~Fifty (50) to 100 mg of product (an amount the size of a small pea) was applied topically twice a day for 28 days to a 25 cm2 area of skin containing a single BCC lesion. The product was to be applied in the morning and in the evening after washing."
223609967|NCT01594931|DRUG|pyronaridine/artesunate|Tablets of fixed dose combination of pyronaridine and artesunate at a ratio of 3:1. The tablets were taken daily for 3 days.
223609968|NCT02135055|OTHER|blood sample collection|Patients were included 1 hrs later(before the study drug is administrated), 3 d and 7 d after sedation with midazolam, blood sample is collected. Flow cytometry is performed to test the mHLA-DR and according the value of mHLA-DR, assign the participant to the 4 groups as described in the arm.
223609969|NCT02135055|DRUG|Midazolam|The loading dose of midazolam is 0.03-0.3 mg/kg, intravenous injected slowly for 10 minutes, then 0.04-0.2 mg/kg/h for maintenance of sedation.
223609970|NCT02135055|DRUG|Morphine|Morphine is the only analgesic drug that permitted to use. 2 mg morphine is given a bolus when the participant feel pain. If the pain is not alleviated, 0.4-1 mg/h morphine is maintained.
223609971|NCT02135055|PROCEDURE|Sedation interruption|Sedation interruption is performed at 8 am every morning.
223609972|NCT00741975|BEHAVIORAL|Affect Management|12-session group intervention including affect management training as well as sexual health skills training
223609973|NCT00741975|BEHAVIORAL|General Health Promotion|12-session group intervention including health information on a variety of developmentally relevant health topics
223609974|NCT05802589|PROCEDURE|Lumbar Erector Spinae Plane Block|Erector spinae plane block was applied with a 22G/80 mm block needle (Stimuplex A, Braun, Melsungen, Germany) using in-plane technique using a convex USG transducer from the 4th lumbar vertebral level.
223609975|NCT05802589|PROCEDURE|Pericapsular Nerve Group Block|Pericapsular nerve group block was performed using a 22G/80 mm block needle (Stimuplex A, Braun, Melsungen, Germany) and a convex USG transducer using an in-plane technique under the iliopsoas muscle in the plane between the iliopsoas tendon and the periosteum and between the anterior inferior iliac spine and the iliopubic eminence.
223609976|NCT05802589|PROCEDURE|no peripheral block|No peripheral block was applied. Standard multimodal analgesia method was applied.
223609977|NCT04206735|OTHER|Interprofessional Education (IPE)|We will use the training stated in the arm description above. In addition, prerecorded webinars that include evidence-based practice management of COPD will be released every month for the champions and clinicians to watch at their leisure.
223609978|NCT04206735|OTHER|Usual care|Usual care of patients hospitalized with severe COPD exacerbation
223609979|NCT00497445|PROCEDURE|angioplasty / surgery|Percutaneous vascular intervention or surgery for peripheral arterial disease
223609980|NCT00497445|PROCEDURE|Angioplasty / surgery and exercise therapy|Percutaneous vascular intervention or surgery for peripheral arterial disease followed by supervised exercise therapy
223609981|NCT00597402|DRUG|Avastin|Avastin will be administered 10 mg/kg every other week beginning a minimum of 28 days after last major surgical procedure, open biopsy, or significant traumatic injury. Following completion of XRT, patients will receive treatment that includes 6 cycles of Avastin, beginning a minimum of 14 days after last XRT.
223609982|NCT00597402|DRUG|Temozolomide|Daily temozolomide 75 mg/m2/day for 6.5 weeks of radiation treatment. Following completion of XRT, patients will receive treatment including temozolomide 200 mg/m2/day on the 1st 5 days of each 28-day cycle.
223609983|NCT00597402|RADIATION|Radiation Therapy (XRT)|Treatment with standard XRT (radiation) for 6.5 weeks.
223609984|NCT00597402|DRUG|Irinotecan|Following completion of XRT, patients will receive 6 cycles of treatment that includes irinotecan. Beginning a minimum of 14 days after last XRT, the irinotecan dose will depend on whether the patient is on enzyme-inducing antiepileptic drugs (EIAED). (EIAED:340 mg/m2 every other week, non-EIAED: 125 mg/m2.)
223609985|NCT04265014|OTHER|Goal-directed fluid treatment|Goal-directed fluid treatment for major abdominal surgery
223609986|NCT04265014|OTHER|Liberal Fluid Therapy|Liberal Fluid Therapy for major abdominal surgery
223609987|NCT03667755|PROCEDURE|fast track recovery surgery with whey protein infused carbohydrate loading and early oral feeding|participants will be carbohydrate loaded with whey protein infused carbohydrate drink and started on early oral feeding post-operation
223609988|NCT01467505|DRUG|Telaprevir|Tablet
223609989|NCT01467505|DRUG|Ribavirin|Tablet
223609990|NCT01467505|DRUG|Pegylated Interferon Alfa-2a|Subcutaneous Injection
223609991|NCT01467505|DRUG|Immunosuppressant Regimen|Cyclosporine (CsA) based immunosuppressant regimen or Tacrolimus (TAC) based immunosuppressant regimen, as per standard practice. Immunosuppressant regimen were not considered study drugs.
223609992|NCT00687180|DRUG|Treatment with mycophenolat mofetil|
223609993|NCT00687180|DRUG|Treatment with azathioprin|
223609994|NCT01229189|DIETARY_SUPPLEMENT|Vitamin D|Maternal dose of 4000 IU daily for 20 weeks Neonatal dose of 400 IU daily for 24 weeks
223609995|NCT01229189|DIETARY_SUPPLEMENT|Placebo|Placebo will be supplemented to pregnant women and their neonates in the same pattern as in intervention group.
223609996|NCT03870295|DIAGNOSTIC_TEST|Sympathetic skin response (SSR) measure|Ankle - ground distance measurement, hand and foot cutaneous temperature reading, low intensity electrical stimulations on hand and on foot to determine SSR at these two points and DN4 questionnaire to assess the possible presence of neuropathic pain
223609997|NCT06027203|PROCEDURE|prostate biopsy|Prostate biopsy by either transrectal or transperineal technique
223609998|NCT00792012|RADIATION|Hypofractionated Intensity-Modulated Radiation Therapy|All patients will receive one fraction of radiation therapy a day, 5 days a week, Monday through Friday. Radiation fraction size and number of fractions depend on dose fraction level the patient is assigned to.
223609999|NCT00792012|DRUG|Temozolomide|Temozolomide will be administered orally, once a day starting on the first day of radiation, for 28 consecutive days during radiation, and after radiation for those patients completing radiation in less than 28 days.
223610000|NCT02433886|PROCEDURE|Gamma Ventral Capsulotomy|
223610001|NCT02620969|OTHER|Blood and dialysate sampling|Blood and dialysate sampling
223610002|NCT06040411|OTHER|Acupressure|Acupressure was applied to each point for 2 minutes and the total application time was 15 minutes on average (for 5 points). During the application, the most appropriate position in which the individual would be comfortable was preferred, taking into account the privacy of the individual. First of all, the supine position was preferred, and alternatively, the sitting position was preferred. At the end of the application, it was ensured that the person was in a position that he/she was comfortable.
223610003|NCT04891016|DRUG|FLOT combined with toripalimab|Patients received FLOT combined with toripalimab on Day 3 every 3 weeks, for a total of 3 cycles, followed by surgical treatment. Postoperative adjuvant therapy was determined based on pathological results: if a pathological complete response (pCR) was achieved, patients received 2 additional cycles of the neoadjuvant regimen; if pCR was not achieved, patients were given 4 cycles of SOX combined with toripalimab postoperatively.
223610004|NCT02585362|BEHAVIORAL|physical exercise|The standardized Training program will be performed twice a week in the Kantonsspital Winterthur and once a week in a home based setting
223756228|NCT06821854|DEVICE|PN20 (Plinest)|"PN20 (Plinest) is a single-use viscoelastic, and sterile gel for intradermal use. PN20 contains polynucleotides (20 mg/ml- 2%), water, sodium chloride, sodium phosphate and disodium phosphate.~PN20 is administered using a fine needle (usually 30 G) by injecting the solution into the dermis. Depending on the medical assessment, different injection techniques, such as linear threading, serial punctures, crosslinked, radial fanning or mixed, can be used. The injection site must consist of healthy skin. PN20 can also be administered by means of modern non-invasive techniques (electroporation, hydroelectrophoresis, etc.). In all these cases, thoroughly cleanse and disinfect the area to be treated before application.~PN20, thanks to its versatility and manageability, can be used in any skin area; in the current clinical investigation the face, neck or décolleté will be treated."
223756229|NCT05336058|OTHER|No intervention|In this non-intervention study, 10ml of whole blood of enrolled subjects was collected for multi-target PCR detection of cfDNA methylation.
223756230|NCT02452151|DRUG|Infliximab-Biosimilar|
223610005|NCT02585362|BEHAVIORAL|nutrition counseling|At least 3 times, participants will receive nutrition counseling to improve energy- and protein intake
223610006|NCT02585362|DIETARY_SUPPLEMENT|whey protein supplement|On workout days study participants will consume twice a day 15 g of the supplement powder with approximately 150 ml water. On the remaining days participants consume the supplement once a day.
223610007|NCT05042700|DRUG|Melatonin|Enema with 25 mg melatonin
223610008|NCT05042700|DRUG|Placebo|Enema without melatonin
223610009|NCT06435377|PROCEDURE|Procedure: Cold EMR + APC|"* Initial submucosal injection of saline solution and methylene blue, followed by 'piece-meal' resection using a dedicated cold snare~* Biopsy of the resection bed~* Ablation of the defect using argon plasma coagulation (APC)."
223610010|NCT00258492|BEHAVIORAL|Aerobic exercise|
223756231|NCT02452151|DRUG|Infliximab-Innovator|
223756232|NCT05157932|BEHAVIORAL|Talk test prescription|Participants will be enrolled in the virtual cardiac rehab program and receive an exercise prescription based on the Talk test method.
223610011|NCT02320006|OTHER|acupuncture|For RN4、CV6 CV3 and EX-CA1, needles will be inserted vertically to the abdominal muscles. The acupuncturist can feel resistance from the tip of the needle when touching the muscles and continues to insert it to a depth of 2-3 mm and stops. For ST36 and SP6, needles will be inserted vertically to a depth of 25 mm. The needles will be manipulated with an even lifting and twisting method three times to achieve the sensation of deqi.
223610012|NCT03086096|DEVICE|LifePearl Microspheres loaded with Irinotecan|LifePearl Microspheres are embolisation microspheres for transcatheter chemoembolisation (TACE), that can be loaded with chemotherapeutic agents. In this registry, LifePearl Microspheres will be loaded with Irinotecan.
223756233|NCT05157932|BEHAVIORAL|CPET prescription|Participants will be enrolled in the virtual cardiac rehab program and receive an exercise prescription based on their CPET results completed at baseline
223610013|NCT03449758|DRUG|SARILUMAB|Pharmaceutical form:Solution for injection in pre-filled syringe Route of administration: Subcutaneous
223610014|NCT03449758|DRUG|Azathioprine|Pharmaceutical form:Tablet Route of administration: Oral
223610015|NCT03449758|DRUG|Chloroquine|Pharmaceutical form:Tablet Route of administration: Oral
223610016|NCT03449758|DRUG|Hydroxychloroquine|Pharmaceutical form:Tablet Route of administration: Oral
223610017|NCT03449758|DRUG|Leflunomide|Pharmaceutical form:Tablet Route of administration: Oral
223610018|NCT03449758|DRUG|Methotrexate|Pharmaceutical form:Solution for injection Route of administration: Subcutaneous / Intramuscular
223610019|NCT03449758|DRUG|Sulfasalazine|Pharmaceutical form:Tablet Route of administration: Oral
223610020|NCT01860287|DRUG|Buprenorphine 0.2 MG Sublingual Tablet|This is a within-subjects, double-blind, placebo-controlled experiment during which each participant will receive sublingual buprenorphine (0.2)
223610021|NCT01860287|DRUG|Placebo|This is a within-subjects, double-blind, placebo-controlled experiment during which each participant will receive a placebo
223610022|NCT01860287|DRUG|Buprenorphine 0.4 MG Sublingual Tablet|This is a within-subjects, double-blind, placebo-controlled experiment during which each participant will receive sublingual buprenorphine (0.4)
223610023|NCT05413408|OTHER|Education and contact|"The intervention consists of three phases, including investigative learning activity (this section will last about one week), higher-order thinking activity (this section will last about two hours), collaborative activity (this section will last about two hours). Both the intervention group and the control group will be interns in the hospital simultaneously. The study outcomes include nursing students' knowledge, attitude, and behavioral intentions regarding stigma towards schizophrenia. The intervention effect will be evaluated by the researcher, comparing results between and within the two groups from baseline (T0) to immediately after first and second session intervention (T1), immediately after third session intervention (T2), and three months follow-up (T3).~The control group only has one session and will be given a book of schizophrenia knowledge, and they will be asked to finish reading it in four weeks."
223610024|NCT02848222|DEVICE|Bruder Moist Heat Compress|
223610025|NCT02848222|OTHER|Washcloth|
223610026|NCT03601260|DRUG|Allopurinol|Treatment of gout patients by oral dosage of 100 mg-300mg/ day of Allopurinol
223610027|NCT06096649|OTHER|Topical Vehicle + Zinc Di-(dibutyryl lisinate)|Instructions: Apply to the entire face twice daily - morning and evening
223610028|NCT06096649|OTHER|Topical Vehicle|Instructions: Apply to the entire face twice daily - morning and evening
223610029|NCT03864939|DRUG|dHAM|A dehydrated human amnion membrane (dHAM, 1x3cm) is placed around the neurovascular bundle (NVB) on the left and right side and vesicourethral anastomosis (VUA) during radical retropubic prostatectomy (RRP).
223610030|NCT03864939|DRUG|No dHAM|A standard radical retropubic prostatectomy (RRP) without dHAM is performed (Walsh, 2005).
223610031|NCT05653414|OTHER|short early psychological care associated with encouragement of early support consultation with generalist practitioner or midwife|4 consultations with a psychologist over 2 months maximum
223610032|NCT05653414|OTHER|encouragement of early support consultation with generalist practitioner or midwife|encouragement of early support consultation with generalist practitioner or midwife
223610033|NCT02219646|DRUG|Vardenafil|Vardenafil 10 mg twice daily for six months
223756234|NCT01667640|RADIATION|sector irradiation|"Gross Tumor Volume (GTV) is defined as the visible margin of the resection on post- operative MRI and planning- CT-scan. The Clinical Treatment Volume (CTV) is the same as the GTV plus a 5 mm margin The Planning Treatment Volume (PTV) includes the CTV plus a 1mm margin.~A non-invasive immobilization is used for the planning CT and treatment delivery with an accuracy of ≤ 1mm.~Treatment planning will conform to ICRU 50/62 rules for coverage of GTV, CTV and PTV. Additionally, organs at risk are delineated according to the ICRU 62 rules.~Treatment with radiotherapy will start 2 to 3 weeks after surgery. The prescribed dose for the PTV is 30 Gy in 5 fractions.~Isodose distributions will be calculated through the target in three planes. Dose volume histograms will be reported."
224200987|NCT05676164|DEVICE|TIAN XIA|The products are dark yellow granules made from rice, soybean, lotus root powder, orange peel, coix seed and yam.
224200988|NCT04891445|BEHAVIORAL|Nursing monitoring program|A clinical pathway will be activate that allows all the necessary interventions, once the person is diagnosed, to be carried out on the same day, and a mental health nursing team will monitor the entire process.
224311651|NCT04371107|OTHER|consultation|Patients are followed up by teleconsultation or remote follow-up until the end of symptoms and for a maximum of 2 months
223610034|NCT02219646|DRUG|Placebo|Placebo two tablets daily for 6 months
223610035|NCT02147886|DRUG|Cabaletta for IV infusion once weekly during 24 weeks|Cabaletta for IV infusion once weekly
223610036|NCT02147886|DRUG|Cabaletta for IV infusion once weekly during 24 weeks|
223610037|NCT04537975|DEVICE|C2Rx|Hemofiltration
223610038|NCT04537975|OTHER|Standard of Care (SOC)|Standard of care that excludes any protocol restrictions.
224311652|NCT04371107|DRUG|Azithromycin|azithromycin treatment 500 mg on day 1 then 250 mg the following 4 days from day 2 to day 5, per os.
223610039|NCT03814707|DRUG|Topical application of 0.2% hyaluronic acid gel|Topical application of 0.2% hyaluronic acid gel will be placed immediately in palatal donor site after free gingival graft harvesting
223610040|NCT03814707|BIOLOGICAL|Platelet rich fibrin|Placement of Platelet rich fibrin in the palatal donor sie after free gingival graft harvesting and suturing by criss cross sutured then covered by periodontal pack.
223610041|NCT01145534|DRUG|glibenclamide|5 mg as pills, taken daily during the morning for 60 days
223610042|NCT01145534|OTHER|medicinal plant infusion|INfusion fo Cissus verticillata L., 1 g in 150 mL water, ingested daily for 60 days.
223610043|NCT02372526|OTHER|Mealtest: High protein 200 kcal 200 ml liquid meal consumed during 10 minutes|
223610044|NCT02372526|OTHER|Mealtest: High fat 200 kcal 200 ml liquid meal consumed during 10 minutes|
223610045|NCT02372526|OTHER|Mealtest: High carbohydrate 200 kcal 200 ml liquid meal consumed during 10 minutes|
223610046|NCT02372526|OTHER|Mealtest: High fat 200 kcal 200 ml liquid meal with pancreatic lipase inhibitor consumed during 10 minutes|
223610047|NCT05229393|OTHER|Cervical plus Diaphragmatic Manual Therapy plus Breathing Reeducation Exercises|"Diaphragmatic Manual Therapy consists of techniques intended to indirectly stretch and mobilize the diaphragmatic muscle fibers. This will help to improve muscle contraction and decrease tension. The experimental maneuvers include the Doming Diaphragmatic Technique as described by Leon Chaitow, Lewit, and the Manual Diaphragmatic Release Technique as described by Leon Chaitow. Both maneuvers are performed in two sets of 10 repetitions, within a 1-minute interval.~Cervical Manual Therapy consists of vertebral mobilization techniques according to the Mulligan technique.~Breathing Reeducation Exercises consist of i) recognition of the abnormal breathing pattern, ii) relaxation techniques for all the primary and accessory respiratory muscles, iii) diaphragm breathing reeducation iv) pursed lips exercise v) reeducation of the normal breathing rate"
223610048|NCT05229393|OTHER|Cervical Manual Therapy plus sham Diaphragmatic Manual Therapy|"Ultrasound sham as Diaphragmatic Manual techniques. Disconnected ultrasound will be applied in the same position as for the experimental group for 15 min as a placebo treatment.~Cervical Manual Therapy: will consist of vertebral mobilization techniques according to Mulligan -"
223610049|NCT05229393|OTHER|Conventional Physiotherapy Program|Conventional Physiotherapy Program consists of TENS for 15min, Microwave pulsed Diathermy for 10min, soft tissue techniques for 15min
223610050|NCT05036174|DRUG|Diphenhydramine 5%|Diphenhydramine 5% ointment
223610051|NCT05036174|DRUG|Placebo|Placebo matched to diphenhydramine 5% ointment
223610052|NCT01803425|OTHER|Synflorix™ data collection|Safety monitoring and evaluation: recording of all AEs during the study period using diary cards, follow-up visit or telephone contact. Recording of SAEs throughout the study period for each subject.
223610053|NCT01916382|DRUG|Nitisinone|drug
223610054|NCT05941416|DIAGNOSTIC_TEST|Nordic Orofacial test- screening arabic modified version|Nordic Orofacial Test- screening is an instrument that can be used for the identification of orofacial myofunctional disorders in children aged three years or older, in youths and in adults. It is divided into two sections, interview and examination. The screening can be directed by dental or health care professional personnel.
223610055|NCT06344728|DRUG|Brensocatib Oral Solution|Brensocatib solution
223610056|NCT06344728|DRUG|Brensocatib Oral Tablet|Brensocatib tablet
223610057|NCT05062005|DRUG|Induction Chemotherapy|Induction regimens: TP (docetaxel 75 mg/m²; cisplatin 75 mg/m²) Q3w, TPF (docetaxel 60 mg/m²; cisplatin 60 mg/m²; 5-fluorouracil 600-750 mg/m² per day, continuous intravenous infusion d1-5) Q3w, or GP (gemcitabine: 1000 mg/m2 d1, d8; cisplatin 80 mg/m2) Q3w.
223610058|NCT05062005|DRUG|Concurrent Chemotherapy|Cisplatin 100 mg/m², Q3w.
223610059|NCT05062005|RADIATION|Definitive Radiotherapy|For all patients, the prescribed dose is 66-70 Gy (once a day, 5 times a week).
223610060|NCT06056492|BEHAVIORAL|Experience of nitrous oxide sedation at assessment|Apart from the Lead researcher, a dental nurse assisted with the dental treatment on every appointment. A specially trained sedation nurse was responsible for the monitoring during sedation. The Porter Brown inhalation sedation machine (RA Services, Keighly, W. Yorkshire, UK) was used. Once the appropriate nasal hood was selected, 100% O2 was introduced for 1-2 minutes. Following that, the level of N2O was increased in 10% increments until signs of sedation were observed. The endpoint was between 30-40% nitrous oxide.
223610061|NCT01436578|DRUG|Posaconazole oral suspension 40 mg/mL|Posaconazole oral suspension prescribed according to the current local label
223610062|NCT06138769|DRUG|Lenvatinib|Lenvatinib 12 mg (body weight 60 kg or greater) or 8 mg (body weight \< 60 kg) once orally every day
223610063|NCT01606709|DRUG|GnRH agonist|GnRH agonist 1mg one dose
223610064|NCT01606709|DRUG|hCG|5,000 IU one dose
223610065|NCT00001499|DRUG|paclitaxel|
223610066|NCT00001499|DRUG|cisplatin|
223610067|NCT00001499|PROCEDURE|chest radiotherapy|
223610068|NCT02857673|BEHAVIORAL|Child Abuse Prevention Problem Solving|The CAPPS intervention includes problem solving, motivational interviewing, and referral to existing services. Intervention providers will conduct three core problem solving sessions and three sessions tailored to the common problems experienced by parents of CSHCN: caregiver burden, difficulties navigating complex medical services, and social isolation. Intervention providers will use their motivational interviewing skills during regular, ongoing interactions with their clients to enhance willingness to participate meaningfully in CAPPS sessions. Referral to existing services in the medical home and in the community will occur as needs arise during CAPPS sessions.
223610069|NCT02857673|BEHAVIORAL|Active Control Group|Parents in both study groups will receive the standard medical and social work services offered in the patient-centered medical homes where their children receive care. In addition, to account for potential surveillance bias, families in the control group will be contacted by a member of the study team six times over 12 weeks, approximating the frequency of contact that the intervention group receives from the CAPPS providers.
223610070|NCT06172686|DRUG|Piperaquine tablets , which will be administered orally as a single dose of 480mg (320mg+160mg).|The first arm will receive Piperaquine tablets, that will be administered orally. Sub-curative regimen will be given as two tablets of 320mg and 160mg (total of 480mg).
223610071|NCT06172686|DRUG|Doxycycline (100mg tablets strength as Doxycycline Hyclate) will also be administered orally and will be given as 1 tablet (100mg) Once daily for 7 days.|The second arm will receive Doxycycline (100mg tablets strength as Doxycycline hyclate) that will also be administered orally. Sub-curative regimen will be given as 1 tablet (100mg) once daily for 7 days.
223610072|NCT00397384|DRUG|cetuximab|Given IV
223610073|NCT00397384|DRUG|erlotinib hydrochloride|Given PO
223610074|NCT00397384|OTHER|laboratory biomarker analysis|Correlative studies
223610075|NCT04360746|OTHER|Pharmaceutical intervention|Pharmaceutical intervention will include a complete medication review by a clinical pharmacist with the following process: medication reconciliation, medication indication and dosage check, medication effectiveness and appropriateness assessment, drug-drug or drug-disease interactions check, medication duplications check, length and cost of treatment evaluation. The pharmacist will use the following tools: Medication appropriateness index (MAI), ACB (Anticholinergic cognitive burden) score and the using the assessment of underutilization (AOU) index.
223610076|NCT04360746|OTHER|Rehabilitation|A multidisciplinary team provided medical, nursing, physical, occupational, and social work interventions. Rehabilitation care include: (a) individual physical therapy (PT), 2 to 3 times a week; (b) 30 to 40 min of PT in an adapted fitness room, aerobic training on a treadmill with and without partial weight support and stationary bicycles, 2 to 3 times a week ; (c) 30 to 40 min of virtual reality training by performing challenging functional tasks, 2 times a week and (d) 30 to 45 min of individual occupational therapy (OT), cognitive evaluation and stimulation, safety education, and learning to use assistive devices, 3 times a week.
223610077|NCT04084717|DRUG|Crizotinib|"Crizotinib is an orally administered, chemotherapy drug that works by blocking ALK, MET and ROS1 receptor tyrosine kinases from working.~Participants will receive crizotinib, orally (by mouth), at a dose of 250 mg, twice per day, every day of each 28 day cycle."
223610078|NCT04295525|DIETARY_SUPPLEMENT|400 mg mucoadhesive oral tablet|AqualiefTM (Metis Healthcare s.r.l., Milano, Italy)
223610079|NCT04295525|DIETARY_SUPPLEMENT|placebo mucoadhesive oral tablet|placebo
223610080|NCT02734745|DEVICE|flash glucose monitoring|Patients will use Freestyle Libre for 14 days at home, during this period they will have to perform at least 7 measurements of capillary blood glucose per day . Patients also will go to our clinical center on two separate occasions , to run a test breakfast. In one of the two occasions it will be specifically induced a moderate initial hyperglycemia and subsequent hypoglycemia . During the test meal and in the subsequent hours for a total of 6 hours , will be carried out frequent blood sampling for measurement of blood glucose using the Yellow Springs glucose analyzer ( YSI system ) , simultaneous measurements with Freestyle Libre and with glucometer.
223610081|NCT04391114|PROCEDURE|Traditional HoLEP|Holmium laser enucleation of the prostate (HoLEP), first reported by Fraundorfer et al in 1998, is a more recent step in the evolution of holmium laser prostatectomy. HoLEP is a safe and effective procedure which has demonstrated comparable results to TURP and open prostatectomy for patients with symptomatic enlarged prostate, with low morbidity and short hospital stay \[4\]. The improvement in outcome parameters is durable, and the late complications and reoperation rates reported are very low \[5\]. HoLEP is equally suitable for small, medium and larger prostate glands, with clinical outcomes that are independent of prostate size, unlike TURP. HOLEP offers patients the alterative of being treated endoscopically with minimal blood loss, short catheterization time, and decreased hospital stay \[6\].
223610082|NCT04391114|PROCEDURE|Top-Down HoLEP|The main difference between the Top-Down and Traditional approach is that the direction of lateral dissection begins from upwards to downwards. This could help in avoiding the overtraction of the mucosal strip overlying the posterior urethral sphincter, which theoretically leads to a decrease in the incidence of postoperative stress incontinence. Moreover, using the Top-Down approach should lead to a decrease in the incidence of lost enucleation planes, which results in decreasing the intraoperative time and decreasing the number of cases required to master the HoLEP technique.
223610083|NCT02196935|OTHER|clinical course|Detailed presentation including labs, demographics, imaging of those who undergo ERCP/EUS with be prospectively recorded. Details of procedure including sedation strategy and success will be collected. Results of procedure including final pathology results with be recorded.
223610084|NCT04915443|DEVICE|Periotome|"Dental instrument used to perform atraumatic dental extraction.~After the initial de attachment, the periotome was inserted between the root and the bone parallel to the long axis of the root and pushed apically to the maximum depth that the tissue allowes severing the PDL and leaving it for 10-15 seconds allowing the biomechanical creep to occur.~This proses is repeated at different points of entries at all the different surfaces of the tooth."
223610085|NCT04915443|DEVICE|Piezotome|"Dental device used for many purposes one of which is performing atraumatic dental extraction.~An LC2 tip was used for all the procedures and it was inserted between the tooth root and the bone parallel to the long axis of the root and moved in a sweeping motion 3-4mm toward the apex severing the PDL."
223610086|NCT01387841|BEHAVIORAL|yoga|Postures,relaxation techniques
223610087|NCT01387841|BEHAVIORAL|Jacobsons PMRT group|jacobsons Progressive muscle relaxation training involving 16 muscle groups
223610088|NCT02619474|OTHER|Whiteboard|"1. On morning rounds, the child's management will be discussed with the family and the day's plan for treatment and investigations will be written on the whiteboard.~2. The second step will be to review and update the whiteboard at the end of the day. Anything that has been left out or uncompleted will be highlighted and brought up on the following morning's rounds. Next, the nurse will ask the family to write down any questions.~3. Lastly, on the afternoon before a child's discharge, the nurse will take particular care to make sure the parents write down all of their concerns prior to going home. These specific questions concerning discharge planning will be addressed in detail at rounds the following morning."
223610089|NCT00254319|DRUG|Avastin, Alimta|
223610090|NCT04510649|DRUG|Part A|in Part A, all subjects will receive Surufatinib 300 mg in a single dose on study days 1 and 11 and receive Rabeprazole 30 mg single dose on study days 5 through 11
223610091|NCT04510649|DRUG|Part B|in Part B, all subjects will receive Surufatinib 300 mg in a single dose on study days 1 and 12 and receive Rifampin 600 mg single dose on study days 5 through 16
223610092|NCT04722874|DEVICE|Ortho-k lenses|Ortho-k lenses will be administered nightly.
223610093|NCT04722874|DEVICE|RLRL|RLRL will be performed twice a day with an interval of at least 4 hours, each treatment last 3 minutes. Nightly treatment should be performed at least 30 minutes before ortho-k lens insertion.
223610094|NCT00524277|BIOLOGICAL|GP2 peptide + GM-CSF vaccine|Given intradermally every 3-4 weeks for a total of up to 6 inoculations
223610095|NCT00524277|BIOLOGICAL|GM-CSF (sargramostim)|GM-CSF given intradermally very 3-4 weeks for a total of up to 6 inoculations
223610096|NCT00524277|BIOLOGICAL|AE37 + GM-CSF vaccine|Given intradermally every 3-4 weeks for a total of up to 6 inoculations
223610097|NCT00524277|BIOLOGICAL|GM-CSF (sargramostim)|Given intradermally every 3-4 weeks for a total of up to 6 inoculations
223610098|NCT02788344|OTHER|Daily practice care for patients with suspected of STEMI|N/A: Practice care evaluation in real-life setting
223610099|NCT03973216|BEHAVIORAL|A primary care group-based therapeutic yoga program|The intervention includes therapeutic yoga training and education sessions on benefits of yoga and effects of stress on the body.
223756235|NCT01667640|RADIATION|whole brain irradiation|"For whole brain radiation the entire brain, the base of the skull and the meninges are included.~Radiation is performed fractionated with 40 Gy. The caudal boundary of the radiation-target volume is between the 2. and the 3. cervical vertebra. The radiation is performed via two lateral, opposing and isocentric contra fields. The face/ventral skull is shielded with individual blocs or MLC.~The used energy for the radiation fields should be between 6 and 16 MV. The specification point of the dose or the standardization point has to be chosen in that way that the point is in the middle of the target volume. The target volume is radiated within the tolerance range of 95% - 107 %. The maximum/minimum doses in the target volume and possible doses peaks are documented."
223756236|NCT02205593|BEHAVIORAL|Control|Regular follow-up and treatment WITHOUT behavioural intervention
223610100|NCT01322100|DEVICE|The Electroporation System|The Electroporation System comprises of 3 parts: 1.Switch Box, 2. Driver, 3. Brain Probe
223610101|NCT01322100|DRUG|Bleomycin|Bleomycin dosage for i.v. use is 15.000 IU/m2, and is administered 10-30 minutes before the electric pulses. Bleomycin dosage for intratumoral use is either 2.000 IU, 4.000 IU, or 6.000 IU per 3 ml, and 20 % of the calculated tumor volume is injected.
223610102|NCT04844736|PROCEDURE|CT Simulation|"Patient will undergo routine CT simulation to initiate radiation treatment planning process. For the purposes of this study, the day of CT simulation mapping scan will be counted as day 0. After the patient completes the CT simulation scan, the CT images and plan/structure files will be sent to the treatment planning system. The treating physician will contour the gross tumor volume (GTV) including the involved primary lung tumor and/or the involved lymph nodes."
223756237|NCT06495918|DRUG|OTX-TKI|Intravitreal Injection of OTX-TKI
223756238|NCT06495918|DRUG|Aflibercept|Intravitreal Injection of 2mg of aflibercept
223756239|NCT06495918|DRUG|Aflibercept|Intravitreal Injection of 8mg of aflibercept
223756240|NCT05625035|DRUG|Lianhua Qingwen capsules|Lianhua Qingwen capsules: 4 capsules once, three times daily
223756241|NCT04307485|DRUG|Ticagrelor|90mg ticargrelor based DAPT vs 60mg ticargrelor based DAPT
223756242|NCT01728025|DRUG|Ranolazine|
223756243|NCT04264468|COMBINATION_PRODUCT|neoadjuvant chemotherapy|This study prospectively included 150 breast cancer patients (30 patients in the first stage and 120 patients in the second stage) who were treated with the commonly used neoadjuvant chemotherapy recommended by NCCN, received surgical treatment after neoadjuvant chemotherapy, and evaluated the efficacy according to the surgical pathological response.Based on the Mammaprint technology analysis of patients with pathologic complete response (pCR), partial response and no response, we analyzed the characteristic genes related to breast cancer in the tumor tissues and evaluated the accuracy and sensitivity of the Mammaprint test for the efficacy of neoadjuvant chemotherapy
223756244|NCT00575744|PROCEDURE|Sentinel Node Biopsy|Once the patient is asleep under anesthetic, they receive an intraoperative injection of 1.0 mCi of Technetium-99 sulfur colloid into normal breast tissue surrounding the primary cancer or biopsy cavity directed subareolar or around the tumor. This is followed by blue dye injected in the subareolar complex approximately 5 minutes prior to incision. The sentinel node biopsy is performed, followed by lumpectomy/mastectomy, and a completion axillary node dissection if the sentinel node(s) were positive.
223756245|NCT04231786|PROCEDURE|Breast ultrasonography findings|Breast ultrasonography findings in patients over 30 years of age diagnosed with polycystic ovary syndrome.
223756246|NCT02474095|OTHER|Quality-of-Life Assessment|Ancillary studies
223756247|NCT02474095|PROCEDURE|Transcutaneous Acupoint Electrical Stimulation|Undergo ALTENS
223756248|NCT06528392|BIOLOGICAL|Efgartigimod|Efgartigiomd-hyaluroidase (EFG) is a neonatal Fc receptor (FcRn) inhibitor, which blocks the recycling of Immunoglobulin G (IgG), including pathogenic IgG
224311653|NCT05108402|DIAGNOSTIC_TEST|Phenotyping|"After inclusion in the study, between V1 and V4, patients will be phenotyped among: NaCl sensitive patients and non-NaCl sensitive patients. they will have a low sodium diet for 2 weeks. The first week without salt supplementation and the second with salt supplementation. At the end of V4, if patient is NaCl sensitive he will continue into treatment period and go through randomization, and for patient non-NaCl sensitive they will drop out of study."
224311654|NCT05108402|DIETARY_SUPPLEMENT|Drug intake|"After being phenotyped, NaCl sensitive patients will continue the study in one of the 2 treatments arms : royal water (bottle) or salt sachet."
223610103|NCT00610402|OTHER|blood sample tear drop sample|blood sample tear drop sample
223610104|NCT05539885|PROCEDURE|Pre-incisional Ultrasound guided (PIFP) block|Patients in group P will be injected with 0.4 mL/kg of 0.25 bupivacaine in the fascial plane between the internal intercostal and pectoralis major muscles on each side of the sternum after induction of anesthesia and before skin incision under ultrasound guidance.
223610105|NCT05539885|PROCEDURE|Post-incisional Surgeon delivered parasternal block group|"After sternal closure, the surgeon will inject bupivacaine (0.5- to 2-mL aliquots depending on the weight) in the fascial plane under direct vision between the 5 anterior (2nd-6th) intercostal spaces on each side 1 to 1.5 cm lateral to the sternal edge using 25-gauge, 50 mm needle. The surgeon will inject the same dose and concentration of bupivacaine used in the ultrasound technique. This technique was prescribed before by Chaudhary et al (23).~In both techniques, the maximum dose of bupivacaine will never be exceeded (2 mg/kg). In addition, all patients were administered 2 mL of 0.25% bupivacaine at the site of the mediastinal drain location."
223610106|NCT00003575|BIOLOGICAL|filgrastim|
223610107|NCT00003575|BIOLOGICAL|recombinant interleukin-12|
223610108|NCT00003575|DRUG|etoposide|
223610109|NCT00003575|DRUG|ifosfamide|
223756249|NCT00195247|DRUG|TTI-237|
223756250|NCT06300333|DRUG|Methotrexate|use low dose of Methotrexate in treatment of un distectopic tubal pregnancy
223756251|NCT01820754|DRUG|Ipilimumab|"Neoadjuvant (Pre-Surgery): Cycles 2 and 3: Ipilimumab 10 mg/kg IV over 90 minutes~Adjuvant (Post-Surgery): Ipilimumab 10 mg/kg IV every 3 weeks times 2 doses beginning 4 weeks postoperative ( up to 10 weeks if needed for recovery)~Maintenance: Ipilimumab 10 mg/kg/IV every 12 weeks times 2 doses"
223756252|NCT01820754|DRUG|Paclitaxel, Cisplatin, Carboplatin|"Neoadjuvant (Pre-Surgery) Cycle 1: Paclitaxel 175 mg/m2 IV over 3 hours , followed by Cisplatin 75 mg/m2 IV over 60 minutes or carboplatin AUC 6 IV over 30-60 minutes on day 1(Every 21 days x 1 cycle)~Cycles 2 and 3: Ipilimumab 10 mg/kg IV over 90 minutes, Paclitaxel 175 mg/m2 IV over 3 hours , followed by Cisplatin 75 mg/m2 IV over 60 minutes or carboplatin AUC 6 IV over 30-60 minutes on day 1(Every 21 days x 2 cycles)"
223610110|NCT05120427|DIETARY_SUPPLEMENT|Lipid based nutrient Supplements (LNS):|LNS are 20 g/\~110 calorie nutrient supplements that provide energy, protein, essential fatty acids and a wide range of micronutrients critical for children ages 6 to 24 months of age. They are designed to complement diets without displacing breastmilk and local dietary preferences and can be mixed into the child's meal or eaten directly from the sachet.
224200989|NCT04891445|BEHAVIORAL|As usual|Referral to the family doctor for a request for follow-up by the gastroenterologist. The specialist prescribes the tests for the definitive diagnosis that will take place in other units (with their corresponding appointments). After this, the patient will return to the specialist to establish the treatment to follow. Pharmacological treatment will be dispensed at the hospital pharmacy (collected once a month until completion of treatment and confirmation of cure). This last step of the treatment will be done in a new consultation at the gastroenterology service after blood tests to verify the disappearance of the viral load.
224200990|NCT05270512|DEVICE|Dermal Cooling System|Controlled localized cooling may be applied to lesions using the Dermal Cooling System.
224200991|NCT03930615|DRUG|Letermovir|LET tablet or intravenous infusion at a total daily dose of 240 mg (when given with cyclosporin A) or 480 mg (when given alone).
224200992|NCT03930615|DRUG|Placebo|Placebo was administered as tablets matched to LET or as inactive (saline or dextrose) intravenous infusion.
224311655|NCT06231095|DEVICE|continuous theta burst stimulation - cTBS|Continuous theta burst stimulation (cTBS) is a quicker and potentially more effective technique to reduce cortical hyperactivity than repetitive transcranial magnetic stimulation (rTMS). The study involves a cycle of 35 cTBS stimulations in the supplementary motor area (SMA) over 5 working days, with 7 stimulation sessions each day lasting 40 seconds. A 1-hour break between sessions will be observed, and each session will comprise 600 pulses at 90% of the motor threshold intensity.
223610111|NCT05120427|DEVICE|Growth Charts|Growth charts have been locally developed to allow parents an easy assessment of their children's height at their home. Charts will be placed on walls inside homes and will provide parents the opportunity to measure their child whenever they want, and will also contain information on the most suitable local foods as well as the importance of diverse diets and frequent feeding.
223610112|NCT04773119|PROCEDURE|PVI only|Patients in this group receive PVI only
223610113|NCT04773119|PROCEDURE|PVI with substrate ablation|Patients in this group receive PVI as well as substrate ablation
223610114|NCT00948753|DRUG|Maraviroc 150 MG|Maraviroc b.i.d. (in addition to the standard prophylaxis therapy of tacrolimus and methotrexate) beginning after last dose of chemotherapy conditioning regimen until day 30 after stem-cell infusion.
223610115|NCT00948753|DRUG|Maraviroc 300 mg|Maraviroc b.i.d. (in addition to the standard prophylaxis therapy of tacrolimus and methotrexate) beginning after last dose of chemotherapy conditioning regimen until day 30 after stem-cell infusion.
223610116|NCT00948753|DRUG|Maraviroc 300 mg Phase II|Maraviroc b.i.d. (in addition to the standard prophylaxis therapy of tacrolimus and methotrexate) beginning after last dose of chemotherapy conditioning regimen until day 30 after stem-cell infusion.
223610117|NCT00799682|DRUG|Xalatan|0.005% 1 drop in each eye daily between 7:00 p.m. and 9:00 p.m.
223610118|NCT00799682|DRUG|Travatan Z|0.004%, 1 drop in each eye daily between 7:00 p.m. and 9:00 p.m.
223610119|NCT02727218|PROCEDURE|Chest tube removal|chest tube removal post thoracoscopic surgery
223610120|NCT00731419|DEVICE|SEMS|Comparing plastic and metal stents
223610121|NCT00269971|DRUG|epoetin alfa|
223610122|NCT04473209|PROCEDURE|non-surgical periodontal therapy|supra and subgingival debridement
223610123|NCT06035705|OTHER|Patient acuity tool|A tool for measuring patient acuity as a part of daily management will be implemented in four somatic in-patient care units.
223610124|NCT03217955|BEHAVIORAL|CBT-SA|Info has been included in arm description
223610125|NCT03217955|BEHAVIORAL|Standard Treatment|Info has been included in arm description
223610126|NCT00893958|DRUG|Mycophenolate Mofetil|Prophylaxis of Organ Rejection
223610127|NCT01867749|BEHAVIORAL|Group Interpersonal Psychotherapy (IPT-G)|
223610128|NCT01867749|BEHAVIORAL|Coping with Depression (CWD)|
223610129|NCT04208308|DIETARY_SUPPLEMENT|Chia seeds supplementation (25 g)|Dosage: 1 daily dose energy 498,75 kJ / 118,75 kcal, protein 3,25 g, carbohydrates 9 g, fiber 6 g, fats 6,5 g, Calcium 160 mg Phosphorus 247,5 mg Kalium 37,5 mg Natrium 5,25 mg Zincum 0,975 mg Manganum 0,625 mg Omega-3 fatty acids 4,475 g Omega-6 fatty acids 1,475 g Vitamin B1 0,1 mg Vitamin B2 0,0075 mg Vitamin B3 0,75 mg Vitamin C 0,2 mg
223610130|NCT04208308|DIETARY_SUPPLEMENT|Chia seeds supplementation (15 g)|Dosage: 1 daily dose energy 299 kJ / 71,2 kcal, protein 1,95 g, carbohydrates 5,4 g, fiber 3,6 g, fats 3,9 g, Calcium 96 mg Phosphorus 148,5 mg Kalium 22,5 mg Natrium 3,15 mg Zincum 0,59 mg Manganum 0,375 mg Omega-3 fatty acids 2,684 g Omega-6 fatty acids 0,885 g Vitamin B1 0,06 mg Vitamin B2 0,0045 mg Vitamin B3 0,45 mg Vitamin C 0,12 mg
223610131|NCT04208308|DIETARY_SUPPLEMENT|Combine supplementation: chia seeds (15g) and fish oil Maxi Cor 70+20|"Chia seeds - 1 daily dose Fish oil TID~Chia seeds supplementation (15 g) and fish oil supplementation (pharmacological supplement) - Maxi Cor 70+20 (EPA 675 mg +DHA 510 mg)~On dose (15g) of chia seeds contains:~energy 299 kJ / 71,2 kcal, protein 1,95 g, carbohydrates 5,4 g, fiber 3,6 g, fats 3,9 g, Calcium 96 mg Phosphorus 148,5 mg Kalium 22,5 mg Natrium 3,15 mg Zincum 0,59 mg Manganum 0,375 mg Omega-3 fatty acids 2,684 g Omega-6 fatty acids 0,885 g Vitamin B1 0,06 mg Vitamin B2 0,0045 mg Vitamin B3 0,45 mg Vitamin C 0,12 mg"
223610132|NCT04208308|DIETARY_SUPPLEMENT|Fish oil supplementation|"TID~Daily dose:~Fish oil supplementation (pharmacological supplemment) - Maxi Cor 70+20 (EPA 825 mg +DHA 525 mg)"
223610133|NCT03464747|DEVICE|EIRUS system (Maquet Critical Care AB, 17154, Solna, Sweden)|continuous measurement of venous lactate through a central venous catheter by microdialysis
223610134|NCT04201665|DRUG|Carbetocin|Patients will receive a single dose of carbetocin 100 mcg (Pabal ®) at admission to high dependency obstetric unit after cesarean section.
223610135|NCT04201665|DRUG|Oxytocin|Patients will receive 5 units of oxytocin ( Syntocinon ®) as a 250 ml 0.9% NaCl infusion at admission to high dependency obstetric unit after cesarean section.
223610136|NCT05851833|BEHAVIORAL|Early Mobilization|The time the patient began to sit, stand, and walk after surgery is earlier than traditional model.
223610137|NCT03279029|BIOLOGICAL|blood samples|blood samples
223610138|NCT03279029|BIOLOGICAL|biopsy|biopsy of aortic valve
223610139|NCT04183374|OTHER|Life style|Lifestyle intervention i.e. diet, exercise, smoking cessation, alcohol limitations, dietary supplementation
223610140|NCT00313417|DIETARY_SUPPLEMENT|Creatine monohydrate|Up to 10 grams
223610141|NCT00313417|OTHER|Placebo|Placebo will be given in the same way and appearance as the active treatment
223756253|NCT01589081|DRUG|Intravenous Nicotine|Subjects will be given an IV challenge dose of nicotine or placebo in a constant volume of 2 mL on any study session day. The nicotine solutions (1.0 mg/70kg or 1.5 mg/70kg or 2.0 mg/70kg) will be administered over 1 min. This rate of drug delivery (2 mL over one minute) has been safe in our IRB-approved studies of nicotine. Most investigators have administered nicotine over 10 seconds without any adverse reactions. We concur with the IRB recommendation that the lower doses (1.0 mg/70kg; and 1.5 mg/70kg) will be administered first and the higher dose (2.0 mg/70kg) will be administered last.
223756254|NCT01589081|DRUG|Progesterone|To stimulate the luteal phase of the menstrual cycle, Prometrium capsules containing 200 mg of micronized progesterone or placebo (lactose containing) capsules will be administered orally at 120 minutes before the injection of IV nicotine.
223756255|NCT01262482|DRUG|Oxaliplatin|130 mg/m2, IV during 2 hours on day 1 of each 21 day cycle. Number of cycles: until progression, intolerance or unacceptable toxicity develops, or until patient or investigator decide to stop the treatment.
223756256|NCT01262482|DRUG|Sorafenib|400mg, orally, 2 times per day. Until progression, intolerance or unacceptable toxicity develops, or until patient or investigator decide to stop the treatment.
223756257|NCT01391065|RADIATION|MR PET Guided Brachytherapy|
223756258|NCT06582485|DRUG|iCM012 solution 2 mg/mL|200 mL IMP solution is administered ex vivo by gravity as single infusion through the renal artery/-ies over a period of 5-10 minutes.
223756259|NCT06582485|DRUG|Placebo|200 mL IMP solution is administered ex vivo by gravity as single infusion through the renal artery/-ies over a period of 5-10 minutes.
223756260|NCT05630352|BIOLOGICAL|Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 3 microgram dose|Injection in the muscle
223756261|NCT05630352|BIOLOGICAL|Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 6 microgram dose|Injection in the muscle
223756262|NCT05630352|BIOLOGICAL|Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 10 microgram dose|Injection in the muscle
223756263|NCT05630352|BIOLOGICAL|Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 1 microgram dose|Injection in the muscle
224200993|NCT04596618|DEVICE|Forearm cooling|forearm cooling will be performed for active cooling assessment.
224200994|NCT02309541|DEVICE|feedback canceller algorithm (Firmware)|The study consists of two phases. Phase 1: optimization of parameters of new feedback canceller algorithm. Phase 2: comparison of new and reference feedback canceller algorithms.
224200995|NCT03506724|DRUG|Nifedipine|Nifedipine 10mg oral will be given and the MAP will then be calculated 20 minutes after medication is given. If SBP is ≥160mmHg or DBP is ≥110mmHg, nifedipine 20mg oral will be given and the MAP will then be calculated 20 minutes after medication is given. If SBP is ≥160mmHg or DBP is ≥110mmHg, nifedipine 20mg oral will be given and the MAP will then be calculated 20 minutes after medication is given and institution specific protocol will be performed.
224200996|NCT03506724|DRUG|Labetalol|Labetalol 20mg IV will be given over 2 minutes and the MAP will then be calculated 10 minutes after medication is given. If SBP is ≥160mmHg or DBP is ≥110mmHg, labetalol 40mg IV will be given over 2 minutes and the MAP will then be calculated 10 minutes after medication is given. If SBP is ≥160mmHg or DBP is ≥110mmHg, labetalol 80mg IV will be given over 2 minutes and the MAP will then be calculated 10 minutes after medication is given. If SBP is ≥160mmHg or DBP is ≥110mmHg, then another medication will be chosen based on institution specific protocol.
224200997|NCT06207656|DRUG|EBC|"Patients will receive the following per 28-day cycle:~* Encorafenib: 300 mg (4 × 75 mg oral capsule) daily (QD)~* Binimetinib: 45 mg (3 × 15 mg oral tablet) twice daily (BID)~* Cetuximab: 500 mg/m2 every 2 weeks as per standard institutional practice."
224200998|NCT00803582|PROCEDURE|Traditional Chinese acupuncture|Acupuncture at two Hegu (LI4) and two Lieque (Lu7) points on the wrist, one Lianquan (CV23) and two Renying (St9) points on the neck and two Zhaohai (Ki6) for 12 30-minute sessions
224200999|NCT00803582|PROCEDURE|Placebo acupuncture|Placebo acupuncture at two Hegu (LI4) and two Lieque (Lu7) points on the wrist, one Lianquan (CV23) and two Renying (St9) points on the neck and two Zhaohai (Ki6) for 12 30-minute sessions.
223756264|NCT03742141|DEVICE|Intraoperative Video Laryngoscopy|The IOVL is a disposable, otherwise standard fiberoptic laryngoscope that is inserted alongside the endotracheal tube following intubation for surgical procedures.
223756265|NCT03742141|DRUG|Glycopyrrolate|0.004mg/kg as per routine prior to intubation
224201000|NCT00006092|DRUG|Arsenic Trioxide|
224201001|NCT05117307|DRUG|Bupivacaine 0.25% Injectable Solution|Ultrasound-guided block with 20 ml %0.25 bupivacaine, per side
224311656|NCT05065710|DRUG|ZL-1211|Phase 1 dose escalation part will enroll about 12-42 patients, Phase 2 dose expansion part will enroll about 15-40 patients in each cohort
223610142|NCT05189912|DEVICE|Specimen retrieving bag|Specimen retrieving bag was used to retrieve resected polyps.
223610143|NCT05189912|BEHAVIORAL|Sucking polyps to the instrument channel port|Remove the colonoscope suction valve and connect a polyp trap to suction onto the instrument channel port.
223610144|NCT05751746|DRUG|Magnesium sulfate|Magnesium sulfate will be administered following a protocol that obstetricians already use in our hospital.
223756266|NCT03023085|DRUG|BLI4700|BLI4700 bowel preparation
223756267|NCT00884299|DIETARY_SUPPLEMENT|Diet rich in antioxidants|Dietary intervention based on diet with increased consumption of foods containing antioxidants such as fresh fruits, fruit juices and vegetables. Patients are advised by a physician and a specialist nurse during regular scheduled outpatient clinic visits to increase fresh fruit /fruit juices/vegetable consumption of at least one portion per day compared to baseline and to maintain this regime throughout the study period.
223756268|NCT05828251|PROCEDURE|Vitrectomy (Sequential phakoemulsification and vitrectomy)|Standard treatment for FTMH at our department with phakoemulsification followed by pars plana vitrectomy and gas 4 weeks later.
223756269|NCT05828251|PROCEDURE|Combined phako-vitrectomy|Phakoemulsication and pars plana vitrectomy are performed in the same setting. This procedure is normally only offeres to selected cases at our department.
223756270|NCT05828251|PROCEDURE|Phako (Sequential phakoemulsification and vitrectomy)|Standard treatment for FTMH at our department with phakoemulsification followed by pars plana vitrectomy and gas 4 weeks later.
224311657|NCT00609180|BEHAVIORAL|Minimal (Trophic) Feeding|Enteral feeds will be started at 10 cc per hour and continued at this rate for 144 hours. After 144 hours of trophic enteral feeds, the feeding rate will be advanced to full-calorie rates, which will continue for the duration of mechanical ventilation up to Day 28.
223610145|NCT04327102|BEHAVIORAL|Health education tools combined with health literacy intervention|On the basis of the control group, the intervention measures to improve the health literacy of patients were implemented and self-made health education tools were used. During hospitalization, health knowledge lectures shall be organized for patients. Before the activity, the theme of the activity shall be clarified. Each participant shall be organized by the educator to sit on the tool chart in a U-shape. According to the theme of the tool map, patients interact with educators. And learn the knowledge content related to hypertension health literacy. Before the end of the activity, the educator will review all the contents discussed in the activity quickly, answer the questions in the activity, and help the participants to sort out and consolidate the knowledge acquired in the education. Follow up intervention for patients after leave hospital.
223610146|NCT02328248|PROCEDURE|Biological patch|Use biological patch as opposed to plastic patch to repair hiatal hernia laparoscopically
223610147|NCT04424667|OTHER|donor milk|pasteurized donor milk
223610148|NCT04709042|PROCEDURE|Chordal tension measurement|"The chordal tension measurement will be performed during surgery. The neochordae are connected to the measuring device through crocodile clips (e.g. machine-patient interface).We start to apply traction on the chordae that is in the center of the flailing area thanks to a millimeter screw and under TEE control. After obtaining a stable tension (plateau value), the other chordae are then tracked, one at a time, with an individual screw. When we achieve an equivalent tension on all chordae, a traction on all chordae is applied thanks to the principal screw under TEE control until obtaining a perfect coaptation. When the correction is optimal (good echocardiographic result, chordal tension low and equally spread on each chordae), the measurements are then stopped, and the chordae are fixed at the apex of the left ventricle at the optimal length."
223610149|NCT04709042|OTHER|Cardiac Magnetic Resonance Imaging (MRI)|Patients will undergo 2 MRI exams: 1 MRI before surgical intervention (maximum 21 days before) and 1 MRI three months after surgery (+/- 14 days), with intravenous administration of gadolinium.
223610150|NCT01088334|OTHER|screening|CT-Chest/abdomen and mammography in women
223756271|NCT05111977|DEVICE|Vibrant capsule|A capsule delivering mechanical vibrations
224201002|NCT04372810|PROCEDURE|High Velocity Low Amplitude manipulation (HVLA)|The thrust manipulation technique was used, which consists of high speed and small amplitude manipulation. The therapeutic intervention was performed through decompressive maneuvers for the tibiotarsal joints. The choice of the place of application of the manipulation technique was delimited by the identification of the area or areas with compressive compartmental impairment and joint restriction. The use of the method depended directly on the identification of one or more regions of joint restraint.
224201003|NCT04372810|PROCEDURE|Care assessment and guidance|Evaluation and care guidelines on glycemic control and diabetic foot care.
224201004|NCT06566222|PROCEDURE|chemoradiotherapy after surgery|chemoradiotherapy after surgery vs preoperative chemoradiotherapy
224201005|NCT06566222|OTHER|High-risk Factors|High-risk Factors vs low-risk Factors
224201006|NCT01281475|DRUG|Levodopa|"Levodopa/Carbidopa (4:1)~Dosages are based on levodopa.~Subjects randomized to the levodopa arm will receive a levodopa dose of 5 mg/kg/day in the first 2 weeks of the study, a levodopa dose of 10 mg/kg/day in the second 2 weeks of the study, and a levodopa dose of 15 mg/kg/day (up to a maximum of 800 mg per day) for the remaining duration of the study.~Levodopa/Carbidopa is a combined formulation that will be dispensed as capsules. It should be taken 3 times a day."
224201007|NCT01281475|DRUG|Placebo Oral Capsule|The placebo contains excipients similar to those in the active drug, but it does not contain levodopa or carbidopa.
224201008|NCT04931875|DEVICE|Total body PET/CT (uExplorer)|A total-body PET/CT scanner (uEXPLORER) with a 194-cm scan range will be applied in patients affected with lymphoma.
224201009|NCT00029159|DRUG|estrogen|Participants were started on ethinyl estradiol at a daily dose of 50ng/kg at the beginning of the 3rd year of the study. The estrogen was continued until study end.
224201010|NCT00029159|DRUG|androgen|Oxandrolone or placebo capsule, .06mg/kg/day, orally, for 2 years
224201011|NCT00029159|OTHER|placebo|an inactive substance
224201012|NCT04917406|DRUG|Application of lidocaine together with dexamethasone|Lidocaine 2% is applied on the positive pole while dexamethasone 4 mg/ml is applied on the negative pole. Through the use of current the drugs penetrate the fascia.
224201013|NCT04917406|DEVICE|Application of ultrasound as physical therapy|The application dose will be 0.65 Watt for 7 minutes in the area of most painful affectation by means of a circular movement and a 1MZ head.
224201014|NCT03978806|BEHAVIORAL|Active Comparator: peer navigator|The intervention is aimed to provide support with social challenges and adherence. The peer navigator will meet with patients to provide support with social challenges and use motivational interviewing to provide support with adherence.
224201015|NCT03978806|OTHER|Placebo Comparator: Control Arm (standard of care)|Control patients will have met the same inclusion and exclusion criteria as intervention patients.
224201016|NCT02263677|DRUG|Sitagliptin|60 day supply of 100mg Sitagliptin. The investigators will use an MRS (a non invasive method using magnets) to evaluate liver fat before and after subjects take a diabetes medication. The investigators will also collect a small amount of blood to measure liver, kidney and hormone functions. This will be done 4 times. Also, at the time of the subject gets their first dose of medication they will have a DEXA (low exposure x-ray often used in clinical practice to measure bone density and body composition).
224201017|NCT05343247|DIAGNOSTIC_TEST|Cameriere method|Cameriere et al. designed a quantitative approach through a formula based on sex and the ratio between length and apex opening measurements of each lower left tooth.
224311658|NCT00609180|BEHAVIORAL|Full Feeding|Upon admission to the ICU, a full-calorie feeding rate will be determined, which will be calculated to deliver 25 to 35 kcal/kg predicted body weight (PBW) each day. Enteral feeds will be initiated at 25 cc per hour. The feeding rate will be increased by 25 cc per hour every 6 hours until goal rate is achieved, which will be administered for the duration of mechanical ventilation up to Day 28.
224311659|NCT00609180|DIETARY_SUPPLEMENT|Omega-3 Fatty Acids and Antioxidant Supplements|Omega-3 fatty acids, GLA, and antioxidants will be administered through a feeding tube every 12 hours as a 120-cc bolus. Dosing will continue for 21 days or until discontinuation of mechanical ventilation.
223610151|NCT01179581|DRUG|GLPG0634|single ascending doses, oral solution (1 to 10 mg/dose) and capsules (10 to 200 mg/dose)
223610152|NCT01179581|DRUG|placebo|single dose, oral solution or capsule (matching corresponding study medication)
223610153|NCT01179581|DRUG|GLPG0634|multiple dose, capsule, 10 days
223610154|NCT01179581|DRUG|placebo|multiple dose, capsule, 10 days
223610155|NCT03708107|DEVICE|MEP|MEP® will be applied with an acupuncture needle (0,30 x 25 mm). The needle will be introduced perpendicularly to the MTrP with 100 uA and then increased up to 600 uA. The current will be paused if the patient feels a burning sensation, pain or oppression, waiting up to the patient feels no discomfort. The procedure will be repeated as many times is necessary until the patient do not feel any discomfort for more than 1 minute.
223610156|NCT03708107|OTHER|Ischemic compression|Ischemic compression will be applied perpendicularly to the MTrP, increasing gradually the pression until the patient refers the maximum tolerable pain. This pressure will be applied for 1 minute.
223610157|NCT00235586|PROCEDURE|10 vit. D deficient subjects take vit. D for 3 months.|
223610158|NCT03056417|BEHAVIORAL|The Complete Health Improvement Program|The Complete Health Improvement Program is a nationally recognized program that encourages a diet of whole plant based foods, moderate exercise, stress reduction, and social support.
223610159|NCT02041507|OTHER|Air insufflation method.|Air insufflation colonoscopy.
223610160|NCT02041507|OTHER|Water Immersion method.|Water Immersion during insertion, air insufflation during withdrawal.
223756272|NCT03766178|DRUG|Nimotuzumab + SHR-1210|"SHR-1210: 200 mg/time, intravenous injection, q2W continuous medication, a course of treatment needs 28 days. The cumulative longest medication period is 2 years.~Nimotuzumab: 200 mg/time, intravenous injection, administered on the 1st and 8th days of each cycle, every 2 weeks is one cycle."
223756273|NCT02403908|DEVICE|nMARQ Circular and Crescent catheters|Radiofrequency denervation of right and left pulmonary arteries ostia and of main pulmonary artery \<2 mm proximal from both ostia of right and left pulmonary arteries.
223756274|NCT01871363|RADIATION|chemoradiation|"* radiotherapy: 50 Gy to the pelvis (25x 2 Gy on days 1-35, excluding weekends) .IMRT planing and technique with high energy photons will be used. All fields will be treated daily. Multileaf collimators will be used to shape individual radiation fields. Patients will be irradiated in a prone position with a full bladder and by using belly board to minimize exposure of the small bowel.~* capecitabine 825 mg/m² p.o. twice daily on days 1-35 (including weekends),~* bevacizumab: at dose 5 mg/kg on days -1, 15, 31.~* Radical surgery (TME): to be undertaken ideally 6-8 weeks following completion of chemoradiation."
223756275|NCT06016452|DRUG|Chlorophyllin|Chlorophyllin is a water-soluble compound obtained from the green plant pigment called chlorophyll. It has been shown to have anti-cancer, anti-bacterial, anti-viral, anti-inflammatory, and antioxidant properties. It is also used as an oral formulation and is an over-the-counter drug in various countries, and also as a food coloring agent.
223756276|NCT02189057|OTHER|AssureRx GeneSight genotyping results|
223756277|NCT02189057|OTHER|Treatment as usual|
223756278|NCT04915391|DIAGNOSTIC_TEST|Skin biopsy and blood sample for inflammation markers, RNA and proteins|A skin biopsy will be performed at the baseline visit from which primary cell cultures of fibroblasts and keratinocytes will be obtained. Four to six weeks later a second biopsy on the scar will be performed and analyzed anatomically and pathologically. In addition, at the initial visit, blood samples will be drawn for analysis of inflammation markers, RNA and proteins.
223756279|NCT05270434|PROCEDURE|time interval between ESWL and ERCP is 12h|The patients received intravenous analgesia before the ESWL. After the last ESWL session, the patients are treated with following ERCP within 12h.
223756280|NCT05270434|PROCEDURE|time interval between ESWL and ERCP is greater than 12h|The patients received intravenous analgesia before the ESWL. After the last ESWL session, the patients are treated with following ERCP ≥12 h.
223756281|NCT05270434|DRUG|morphine, buprenorphine, pethidine, tramaldol, metamizole and acetylsalicylacid (Analgesics)|Analgesics administrated include morphine, buprenorphine, pethidine, tramaldol, metamizole and acetylsalicylacid. They will only be administrated as needed.
223756282|NCT02444247|OTHER|High Dose Exercise (300 kcal)|Subjects will participate in 3 physical activity sessions per week expending 300 kcal per session and rate their liking of exercise.
223756283|NCT02444247|OTHER|Low Dose Exercise (150 kcal)|Subjects will participate in 3 physical activity sessions per week expending 150 kcal per session and rate their liking of exercise.
223756284|NCT02444247|OTHER|No Exercise (0 kcal)|Subjects will participate in 3 sessions per week expending 0 kcal per session and rate their liking of exercise.
223756285|NCT02444247|OTHER|Sedentary Option|Subjects will rate their liking of sedentary activities (reading magazines, playing word games, puzzles) as an alternative to exercise.
223756286|NCT04344873|OTHER|Placebo|Placebo injection at day one and day fourteen.
223610161|NCT02041507|OTHER|Water Exchange method.|Water Exchange during insertion, air insufflation during withdrawal.
223610162|NCT03540108|DIETARY_SUPPLEMENT|Lactobacillus plantarum ECGC 13110402|The study will consist of two phases: a treatment period (12 weeks) with either the active or placebo and a wash-out period (4 weeks). Following a screening visit to ensure adherence to the inclusion criteria, the study will consist of a baseline, midpoint, endpoint (week 6 and 12, respectively) and washout visit (week 16).
223610163|NCT03540108|DIETARY_SUPPLEMENT|Placebo Comparator: Maltodextrin|Please see intervention description above.
223610164|NCT04365712|DEVICE|Piezoelectric tool|
223610165|NCT04365712|DEVICE|Oscillating Saw|
223610166|NCT01907464|OTHER|clinical parameters description|description of weight, height, Bone Mass Index, dietary questionnary, amenorrhea time, pathology time for the two arms
223610167|NCT01907464|OTHER|para clinical parameters description|description of DMO, mass, basal metabolism, IGF-1/IGFBP-3 for the two arms
223610168|NCT01907464|OTHER|hormonal parameters dosing|dosing of leptine, leptine receptor, adiponectine, ghreline for the two arms
223756287|NCT04344873|DRUG|Abatacept 10 mg/kg|Abatacept injection at day twenty eight and day forty two.
223756288|NCT05711732|DIAGNOSTIC_TEST|MyCare Oncology Busulfan Assay Kit|This is a sample collection study only. Patient treatment will not be determined by the outcome of the analytical test results.
223756289|NCT06049043|OTHER|Intervention to Help Orient Men to Excel (IN-HOME)|A multi module online training
223756290|NCT06049043|OTHER|"AARP's English Care at Home resource webpage"|Caregiver information from the American Association of Retired Persons
223756291|NCT06475768|DIAGNOSTIC_TEST|Stress Echocardiogram|Exercise testing via treadmill with simultaneous gas exchange analysis and pre- and post-exercise transthoracic echocardiography.
223756292|NCT06475768|DIAGNOSTIC_TEST|Cardiovascular Magnetic Imaging (cMRI)|Non-invasive imaging scan used to examine function and structure of the heart
223756293|NCT06475768|DIAGNOSTIC_TEST|Cardiac Magnetic Resonance Elastography (cMRE)|Non-invasive imaging scan used to measure myocardial stiffness
223756294|NCT06247514|BEHAVIORAL|The BEET Diabetes Program|The BEET Diabetes program is an adapted CBT program specifically designed to treat disordered eating and improve diabetes self-management. Participants receive support from BHPs to guide them through the program, maintain motivation, and facilitate appropriate goal setting.
223756295|NCT06247514|BEHAVIORAL|Cognitive Behavioral Therapy Guided Self-Help|"6-session cognitive behavioral therapy delivered through the self-help book Overcoming Binge Eating Self-help by Christopher G. Fairburn.~The manual focuses on reducing binge-eating episodes. Guided support sessions can be provided by personnel with no background training or knowledge of CBT or disordered eating behaviors, as the book acts as the expert."
223756296|NCT06029699|DEVICE|high flow nasal cannula|device are used for weaning patients after mechanical ventilation extubation
223756297|NCT06029699|DEVICE|non invasive positive pressure ventilation|device are used for weaning patients after mechanical ventilation extubation
224311660|NCT00609180|DIETARY_SUPPLEMENT|Placebo|The study placebo will be administered through a feeding tube every 12 hours as a 120 cc bolus. Dosing will continue for 21 days or until discontinuation of mechanical ventilation.
224311661|NCT06273501|DRUG|Magtrace|Patients will receive superficial and interstitial injection with a 23 G needle with of a total volume of 0.1 - 1 ml Magtrace at four sites in or near the tumor in vulva, the same localization as the injections of Technetium99m and Patent blue for tracing SLNs performed at the surgery. The injection is performed by one of the gynecologic cancer surgeons participating in this study.The time of migration of SPIO to the groin nodes is not known for vulvar cancer. Transportation by dynamic MRI, with selective sequences repeated during a time span of 1- 60 minutes after the injection.
224311662|NCT03082144|DRUG|MTX|MTX 15 mg,via lumbar puncture,once per week, 4 weeks in total
224311663|NCT03082144|DRUG|Ara-C|Ara-C 50mg,via lumbar puncture,once per week, 4 weeks in total
224311664|NCT03082144|RADIATION|Radiotherapy|The sites of symptomatic disease, bulky disease observed on MRI, including the whole brain and basis cranii, 40 Gy in 20 fractions;and/or segment of spinal canal received 40-50 Gy in 20-25 fractions.
223756298|NCT00328913|DRUG|5-hydroxytryptophan (food supplement)|
223756299|NCT01102413|DRUG|Monofer|Infusion or injections
224311665|NCT00315289|PROCEDURE|Nasolacrimal balloon catheter duct dilation|
224311666|NCT00315289|PROCEDURE|Nasolacrimal intubation|
224311667|NCT00315289|PROCEDURE|Simple Nasolacrimal duct probing|
224311668|NCT01056289|DRUG|Desvenlafaxine Succinate Sustained-Release Formulation 50 mg|DVS SR 50 mg Reference Group/Arm, oral tablet, 2 tablets/day during the first week and 1 tablet/day during weeks 2 through 4 of the double-blind treatment phase.
223610169|NCT01907464|OTHER|bone modeling markers dosing|dosing of osteocalcine, bone alkalin phosphatase, C-telopeptide of type-I collagene, osteoprotegerine/ RANKL for the two arms
223610170|NCT00086047|BEHAVIORAL|Coping Skills Training|8 weekly sessions of behavioral treatment
223610171|NCT00086047|BEHAVIORAL|Education|8 weekly sessions of fibromyalgia education
223610172|NCT02563314|DEVICE|Non-invasive mechanical ventilation - Normoxia|Maintenance of an oxygen setting allowing normal oxygen saturation during non-invasive mechanical ventilation (SpO2 targeted 96-98%)
223610173|NCT02563314|DEVICE|Non-invasive mechanical ventilation - Controlled hypoxemia|Maintenance of an oxygen setting allowing mild hypoxemia during non-invasive mechanical ventilation (SpO2 targeted 88-92%)
223610174|NCT00096421|BEHAVIORAL|Tight control of blood glucose levels|
223610175|NCT00096421|BEHAVIORAL|Conventional control of glucose levels|
223610176|NCT04766463|DRUG|SHR8554 Injection|SHR8554 Injection; high dose
223756300|NCT01102413|DRUG|Iron Sulphate|Oral intake
223756301|NCT04685564|DRUG|RBD1016|"Sentinel cohort design is used in each cohort: each cohort will be administered in two batches, the first 2 subjects will receive RBD1016 or placebo respectively, and safety assessment will be done on D8±1. After safety is confirmed through SRC assessment, the remaining 6 subjects will be randomly assigned to receive RBD1016 or placebo in a ratio of 5:1. SRC will assess the safety after all the subjects in each cohort complete the 28-day safety observation and the subjects may proceed to the next dose cohort with permission.~Only after all the subjects in the previous dose cohort have completed the safety assessment by SRC (observed for 28 days) may the next dose cohort be initiated with permission."
223756302|NCT04685564|DRUG|Placebo|the same as RBD1016
224311669|NCT01056289|DRUG|Desvenlafaxine Succinate Sustained-Release Formulation 25 mg|DVS SR 25 mg Taper Group/Arm, oral tablet, 2 tablets/day during the first week and 1 tablet/day during weeks 2 through 4 of the double-blind treatment phase.
224311670|NCT01056289|DRUG|Placebo|DVS SR Placebo Abrupt Discontinuation Group/Arm, oral tablet, 2 tablets/day during the first week and 1 tablet/day during weeks 2 through 4 of the double-blind treatment phase.
224311671|NCT05990985|DRUG|Mitoxantrone hydrochloride liposome injection|Mitoxantrone hydrochloride liposome injection (18 mg/m\^2) will be administered by intravenous infusion on day 1 in a 3-week treatment cycle.
224311672|NCT05990985|DRUG|RiTUXimab Injection|RiTUXimab Injection (375 mg/m\^2) will be administered by intravenous infusion on day 0 in a 3-week treatment cycle.
224311673|NCT05990985|DRUG|Cyclophosphamid|Cyclophosphamid (750 mg/m\^2) will be administered by intravenous infusion on day 1 in a 3-week treatment cycle.
224311674|NCT05990985|DRUG|Vincristine|Vincristine (1.4 mg/m\^2，maximum dose 2mg ) will be administered by intravenous infusion on day 1 in a 3-week treatment cycle.
224311675|NCT05990985|DRUG|Prednisolone|Prednisolone (100mg/d) will be administered by intravenous infusion on day 1-5 in a 3-week treatment cycle.
223610177|NCT04766463|DRUG|SHR8554 Injection|SHR8554 Injection; low dose
223610178|NCT04766463|DRUG|Placebo|Saline Solution
223610179|NCT04766463|DRUG|Morphine|Morphine
223610180|NCT04811742|OTHER|bathing|immerson bathing and showering
223610181|NCT03579940|DRUG|Lasmiditan|Administered orally.
223610182|NCT03579940|DRUG|Placebo|Administered orally.
223610183|NCT02246595|BIOLOGICAL|CaCP29|
224311676|NCT04247100|DEVICE|Transcutaneous Electrical Nerve Stimulation (TENS)|Active Transcutaneous Auricular Microstimulation delivered by TENS device
224311677|NCT04247100|DEVICE|Sham Transcutaneous Electrical Nerve Stimulation|Sham therapy will be delivered by applying the TENS device with non-conductive electrodes so that no microstimulation is delivered
224311678|NCT06298019|BIOLOGICAL|KYV-101|The investigational product, KYV-101, is an autologous CD19-targeted CAR T-cell immunotherapy.
224311679|NCT04575064|OTHER|Standard of Care (SoC)|Standard supportive care is expected to vary regionally and may change throughout the trial based on new and emerging data on best care guidelines for patients.
224311680|NCT04575064|DRUG|Remdesivir|Remdesivir 200mg IV on day 1, followed by 100 mg IV daily infusion for 9 days or until discharge from hospital, whichever occurs first
224311681|NCT03202979|DRUG|Trazodone 20 mg|"Oral administration of trazodone 20 mg (corresponding to 10 drops of trazodone hydrochloride 6% oral solution), three times a day, for 8 weeks. Trazodone total daily dose: 60 mg.~After the 8-week treatment period, patients will receive trazodone 10 mg (corresponding to 5 drops of trazodone hydrochloride 6% oral solution) three times a day for 1-week tapering period in double blind conditions."
224311682|NCT03202979|DRUG|Trazodone 10 mg|"Oral administration of trazodone 10 mg (corresponding to 5 drops of trazodone hydrochloride 6% oral solution), three times a day, for 8 weeks. Trazodone total daily dose: 30 mg.~In order to maintain the study double-blind conditions,patients randomized in this group will be co-administered with placebo oral solution (5 drops).~After the 8-week treatment period, patients will receive placebo oral solution three times a day for 1-week tapering period in double blind conditions."
224311683|NCT03202979|DRUG|Placebo|"Oral administration of placebo oral solution (10 drops) three times a day, for 8-week treatment.~After the 8-week treatment period, patients will receive placebo oral solution three times a day for 1-week tapering period in double blind conditions."
223756303|NCT06088433|DRUG|Ticagrelor|Comparison of 12 month of ticagrelor SAPT（90mgBID\*1 month, followed by 60mgBID) versus 12 months of dual anti-platelet therapy (Aspirin 100mgQD+clopidogrel 75mgQD \* 1 month, followed by clopidogrel 75mgQD)
223756304|NCT06088433|DRUG|Clopidogrel|Comparison of 12 month of ticagrelor SAPT（90mgBID\*1 month, followed by 60mgBID) versus 12 months of dual anti-platelet therapy (Aspirin 100mgQD+clopidogrel 75mgQD \* 1 month, followed by clopidogrel 75mgQD)
224311684|NCT05595148|PROCEDURE|Immediate WBAT|Men or women over 18 years who present with a fracture of the acetabulum, pelvis, distal femur, proximal tibia, distal tibia, who will undergo fracture fixation within 7 days of their injury and consent to the research study.
224311685|NCT05595148|OTHER|No Intervention: Delayed WBAT|Patients with ankle fractures will be instructed to touch-down (toe touch or foot flat) weight bear (approximately 10% of body weight) while in the boot for. Patients will be instructed to keep foot off of floor or set ball of foot or heal on ground for balance using walker or crutches at all times. After the 6 week post op visit, patients may begin weight bearing as tolerated. Patients with tibial plateau fractures will be instructed to touch down (toe touch or foot flat) weight bear (approximately 10% of body weight) for at least 6 weeks. After the 6 week post op visit, patients may begin weight bearing as tolerated until full weight bearing is achieved.
224311686|NCT01877746|DRUG|Combination of prednisone and azathioprine|"* Prednisone for a total of 90 days, with initial dose 1mg/kg/day p.o., given for 12 days and then tapered every 5 days for 5mg/day to the maintenance dose of 0.2mg/kg/day. The daily dose of Prednisone will be rounded to the nearest value divisible by 5.~* Azathioprine for 100 days in total, with dose 1 mg/kg/day. The daily dose of Azathioprine will be rounded to the nearest value divisible by 25."
223610184|NCT02246595|BIOLOGICAL|Placebo|
223610185|NCT01202266|DRUG|PF-05161704 or Placebo|PF-05161704 and Placebo (3:1) oral dosing Suspensions administered twice daily for 14 days immediately after breakfast and dinner
223610186|NCT01202266|DRUG|PF-05161704 or Placebo|PF-05161704 and Placebo (3:1) oral dosing Suspensions administered twice daily for 14 days immediately after breakfast and dinner
223610187|NCT01202266|DRUG|PF-05161704 or Placebo|PF-05161704 and Placebo (3:1) oral dosing Suspensions administered twice daily for 14 days immediately after breakfast and dinner
223610188|NCT01202266|DRUG|PF-05161704 or Placebo|PF-05161704 and Placebo (3:1) oral dosing Suspensions administered twice daily for 14 days immediately after breakfast and dinner
223610189|NCT01202266|DRUG|PF-05161704 or Placebo|PF-05161704 and Placebo (3:1) oral dosing Suspensions administered twice daily for 14 days immediately after breakfast and dinner or once daily for 14 days immediately after breakfast
223610190|NCT01202266|DRUG|PF-05161704 or Placebo|PF-05161704 and Placebo (3:1) oral dosing Suspensions administered once daily for 14 days immediately after breakfast
223610191|NCT01202266|DRUG|PF-05161704 or Placebo|PF-05161704 and Placebo (3:1) oral dosing Suspensions administered once daily for 14 days immediately after breakfast
223610192|NCT01202266|DRUG|PF-05161704 or Placebo|PF-05161704 and Placebo (3:1) oral dosing Suspensions administered once daily for 14 days immediately after breakfast
223610193|NCT00257426|DRUG|octreotide acetate|200mcg,3 times per day, 7 days per week, up to 36 weeks
223610194|NCT00671034|DRUG|Calaspargase Pegol-mknl|Given IV
223610195|NCT00671034|DRUG|Cyclophosphamide|Given IV
223756305|NCT06088433|DRUG|Aspirin|Comparison of 12 month of ticagrelor SAPT（90mgBID\*1 month, followed by 60mgBID) versus 12 months of dual anti-platelet therapy (Aspirin 100mgQD+clopidogrel 75mgQD \* 1 month, followed by clopidogrel 75mgQD)
223756306|NCT05898295|OTHER|no intervention|No intervention: only observation of the child behavior
223610196|NCT00671034|DRUG|Cytarabine|Given IV, IT, PO, or SC
223610197|NCT00671034|DRUG|Daunorubicin Hydrochloride|Given IV
223610198|NCT00671034|DRUG|Dexamethasone|Given PO or IV
223610199|NCT00671034|DRUG|Doxorubicin Hydrochloride|Given IV
223610200|NCT00671034|OTHER|Laboratory Biomarker Analysis|Correlative studies
223610201|NCT00671034|DRUG|Mercaptopurine|Given PO
223610202|NCT00671034|DRUG|Methotrexate|Given IV, IT, or PO
223610203|NCT00671034|DRUG|Pegaspargase|Given IV
223610204|NCT00671034|OTHER|Pharmacological Study|Correlative studies
223610205|NCT00671034|DRUG|Prednisone|Given IV or PO
223610206|NCT00671034|RADIATION|Radiation Therapy|Some patients undergo RT
223756307|NCT02574871|OTHER|Psychological and biological data collection|Psychological and biological data collection for identification of the chronic stress presence
223756308|NCT04209309|DEVICE|repetitive transcranial magnetic stimulation|
223756309|NCT02859649|BEHAVIORAL|neuropsychological test|neuropsychological test
223756310|NCT04079478|OTHER|AI|Artificial intellignece colonoscopy
223756311|NCT00233051|DRUG|Salmeterol or Salmeterol/Fluticasone|
223756312|NCT02262351|OTHER|30 Second Pulse Check|To detect atrial fibrillation
223756313|NCT02262351|DEVICE|Watch BP Home A|Blood pressure device that detects atrial fibrillation
223756314|NCT02262351|DEVICE|HeartCheck Hand-held ECG device|To detect atrial fibrillation
223756315|NCT05923892|DRUG|OPS-2071|There are 3 dose groups of OPS-2071，OPS-2071 tablets, 50 mg、100mg、200mg. Take 4 tablets/bid, after meals in the morning and evening, with an interval of at least 8 hours for 2 weeks(The dosing interval will be 12 hours from Day 5 to Day 7).
223756316|NCT05923892|DRUG|placebo|Take 4 tablets/bid, after meals in the morning and evening, with an interval of at least 8 hours for 2 weeks(The dosing interval will be 12 hours from Day 5 to Day 7).
223756317|NCT05257538|OTHER|FMT|Fecal microbiota transfer from a healthy and tested volunteer
223756318|NCT05257538|OTHER|placebo enema|colored water enema
223756319|NCT05239273|OTHER|Complex Decongestive Therapy|Phase 1 of CDT will be applied. This application consists of manual lymph drainage, skin care, compression bandage and exercises.
223756320|NCT05239273|OTHER|Control|No intervention
223756321|NCT05907850|DRUG|Riboflavin|Commercially available source of riboflavin capsules
223756322|NCT05907850|DRUG|Placebo|Placebo capsule compounded to be similar in appearance to the active intervention
223756323|NCT01425879|DRUG|Akt Inhibitor MK2206|Given PO
223756324|NCT01425879|OTHER|Diagnostic Laboratory Biomarker Analysis|Correlative studies
223756325|NCT01425879|OTHER|Pharmacological Study|Correlative studies
223756326|NCT06086080|OTHER|Standard care|Bracing and physical therapy
223756327|NCT06086080|OTHER|Taping|The patient is treated with tape in special configuration (McConell modified) for the patella + standard care
223756328|NCT06086080|DEVICE|Sham taping|Taping with no treatment disposition
223756329|NCT02361255|OTHER|no intervention|
223756330|NCT03447665|BEHAVIORAL|Bedtime routine|Tailored bedtime routine
223756331|NCT03447665|BEHAVIORAL|Sleep schedule|Tailored sleep schedule, including morning rise time, cut-off for last nap of the day, and bedtime.
223756332|NCT03447665|BEHAVIORAL|Intervention (bedtime)|Parents implement behavioral sleep intervention at bedtime.
223756333|NCT03447665|BEHAVIORAL|Intervention (after night wakings)|Parents implement behavioral sleep intervention following each night waking.
223756334|NCT04360564|OTHER|Recurrent pregnancy loss|As described before.
223756335|NCT01354496|DRUG|LY2409021 Reference Form|Administered orally
223756336|NCT01354496|DRUG|LY2409021 Test-Med Formulation (medium particle size)|Administered orally
223756337|NCT01354496|DRUG|LY2409021 Test-High Formulation (high particle size)|Administered orally
223756338|NCT01354496|DRUG|LY2409021 Test-Low Formulation (low particle size)|Administered orally
223756339|NCT03216850|DEVICE|Sublingual microcirculation assessment|Non-invasive investigation of the endothelial glycocalyx in the sublingual microcirculation.
223756340|NCT02347748|BEHAVIORAL|Reading pre-procedure script|Patients will be read a pre-procedure comfort talk script in the pre-procedure work-up area
223756341|NCT02347748|BEHAVIORAL|Reading pre-extubation script|Patients will be read a comfort talk script before extubation
223756342|NCT02347748|BEHAVIORAL|Reading 2 scripts|"Patients will be read a pre-procedure comfort talk script in the pre-procedure work-up area.~Patients will be read a comfort talk script before extubation"
223756343|NCT02386696|OTHER|Ultrasound|Lung ultrasound examination on healthy volunteers
223756344|NCT06165835|DEVICE|breathing training|Breathing training for six weeks.
223756345|NCT06122636|DIETARY_SUPPLEMENT|The probiotic to be used in the intervention corresponds to PRODEFEN Plus manufactured by ITALFARMACO S.A. laboratory|Each patient should take 1 sachet per day, dissolve it in a glass of water, hold in the mouth for 2-3 minutes and then swallow, for a period of 30 days.
223756346|NCT06122636|OTHER|Placebo|The placebo will be administered in an envelope with the same packaging, size, shape and color of contents as the intervention of interest, except that the placebo will not contain the active ingredient of the intervention.
223756347|NCT03042858|OTHER|Infants with PPV|Data will be collected for up to 18 years to monitor for inguinal hernia.
223756348|NCT03042858|OTHER|Infants without PPV|Basic data will be collected regarding the surgery and the subject's study participation will be complete.
223756349|NCT05568472|OTHER|Best Practice|Standard of care hormone therapy and standard visit with clinician
223756350|NCT05568472|PROCEDURE|Biospecimen Collection|Undergo correlative studies
223756351|NCT05568472|PROCEDURE|Endocrine Drug Therapy|Undergo endocrine therapy
223756352|NCT05568472|BEHAVIORAL|Health Education|Receive list of websites
223756353|NCT05568472|OTHER|Questionnaire Administration|Ancillary studies
223756354|NCT05568472|OTHER|Symptom Specific Assessment Tool|Receive a weblink via email or text message and asked 6 brief questions about symptoms
223756355|NCT04307212|OTHER|50% heart rate reserve (HRR) low intensity exercise|Trained and untrained participants will exercise at a constant load intensity of 50% HRR (low intensity)
223756356|NCT04307212|OTHER|75% HRR moderate intensity exercise|Trained and untrained participants will exercise at a constant load intensity of 75% HRR (moderate intensity)
223756357|NCT04307212|OTHER|Control no exercise|Trained and untrained participants will have a no exercise control day
223756358|NCT03190889|OTHER|HOME|At home rehabilitation following ACL reconstructive surgery as described in the HOME arm.
223756359|NCT03190889|OTHER|TNMT|Standard of care, clinical rehabilitation following ACL reconstructive surgery with the addition of specified targeted neuromuscular training as described in the TNMT arm.
223756360|NCT04477811|DRUG|Vitamin K1|vitamin k1 tablets
223756361|NCT04477811|DRUG|Vitamin k2|vitamin k2 45 ug tablets twice daily
223756362|NCT04477811|OTHER|placebo|placebo tablets
223610207|NCT00671034|DRUG|Thioguanine|Given PO
223610208|NCT00671034|DRUG|Vincristine Sulfate|Given IV
223610209|NCT03609086|OTHER|Melatonin analysis|Measurement of 6-hydroxymelatonin
223610210|NCT01301313|DRUG|Levosimendan|Levosimendan 2.5 mg / ml ampoules. The drug will be administrated in continuous intravenous perfusion in a single dose of 0.1 - 0.2 micrograms/ kg / min for 24 hours.
223610211|NCT01301313|DRUG|Conventional intensified inotropic treatment|Increasing the dose and / or the number of inotropes (dopamine and / or dobutamine and / or milrinone and / or adrenaline)
223610212|NCT00853151|DRUG|LY2428757|14 mg subcutaneous injection 1 time a week for 5 weeks
223610213|NCT00853151|DRUG|TT223|subcutaneous injection once a day for 4 weeks
223756363|NCT05079204|OTHER|Intra oral scan|Cover key details of the intervention. Must be sufficiently detailed to distinguish between arms of a study and/or among similar interventions Intervention consists in an 3D intra oral representation of the oral cavity.
223756364|NCT05079204|OTHER|No intervention|No intervention
223756365|NCT02306135|OTHER|n/a- this is an observational study|
223756366|NCT01256112|BEHAVIORAL|Parent Supported Behavioral Intervention|Parents of participants receive training in behavioral support at home in order to facilitate lifestyle change associated with dietary choices and physical activity designed to produce gradual weight loss.
223756367|NCT01256112|BEHAVIORAL|Nutrition/Activity Education (NAE)|
223756368|NCT04946292|BEHAVIORAL|Theory-derived intervention|The intervention will be delivered through multimedia materials and group activities, as appropriate. Participants will spend approximately 30-45 minutes for the intervention. Intervention materials and activities will be carefully designed to address all the constructs/ domains of the selected theoretical model(s). The effectiveness of the interventions will be evaluated using behavioural outcomes (diet, brushing, flossing) and clinical outcomes (oral hygiene, caries and periodontal conditions).
224201018|NCT05343247|DIAGNOSTIC_TEST|London Atlas method|The London Atlas requires the user to assess the tooth development and eruption and then match it to one of the 31 pictures of age categories.
224201019|NCT04045405|DRUG|CDR132L|i.v. administration
224201020|NCT03258515|DRUG|AZD6094 200 mg|A potent and selective small molecule mesenchymal epithelial transition (MET) kinase inhibitor with significant antitumor activity.
224201021|NCT03258515|OTHER|Placebo|AZD6094 matching placebo without any pharmacological activity.
224201022|NCT03258515|DRUG|Moxifloxacin|A fluoroquinolone broad-spectrum antibiotic, produces a mild, but reproducible increase in QT interval corrected (QTc) in healthy normal participants at time to reach maximum concentration (tmax - approximately 2 hours (0.5 to 4 hours)). This effect is close to the ECG interval measured from the onset of the QRS complex (onset of the QRS complex to the J point) to the offset of the T wave (QT)/QTc effect that represents the threshold of regulatory concern, around 5 ms mean QTc interval prolongation.
224201023|NCT00580931|DRUG|Nicotinamide|1500 mg twice a day for 6 months
224201024|NCT00580931|DRUG|Enduramide placebo|1 tab twice a day
223610214|NCT00853151|DRUG|Placebo for LY2428757|subcutaneous injection 1 time a week for 5 weeks
223610215|NCT00853151|DRUG|Placebo for TT223|subcutaneous injection once a day for 4 weeks
223610216|NCT02376868|DEVICE|3D OCT-1 Maestro|OCT machines used for diagnostic purposes
223610217|NCT02376868|DEVICE|iVue|OCT machines used for diagnostic purposes
223610218|NCT04053166|DEVICE|individualized home-based physical activity|Subjects will have to reach a daily goal in number of steps, based on the initial evaluation, during 6 months . They will wear connected wrists, and will be contacted twice a month by phone call by an adapted physical activity to revaluate these goals.
223610219|NCT04053166|OTHER|MRI|An MRI will be performed for each patient at the end of the study to identify IPH and other features of histological vulnerability (lipid core, fibrous cap integrity and calcifications).
223610220|NCT04053166|BIOLOGICAL|blood sampling|Blood will be collected, to analyse monocyte phenotype by flow cytometry, blood rheology by ektacytometry, coagulation by rotational thromboelastometry (ROTEM). Plasma will be extracted from blood to assess inflammation, oxidative stress and antioxidant markers.
223610221|NCT04053166|OTHER|Questionnaires|sedentary, physical activity, nutrition and quality of life questionnaire will be performed fo each patient.
223610222|NCT04053166|OTHER|6-minute walk test|The 6-minute walk test is a simple, individualized test that measures how fast a patient walks on a flat, hard surface for 6 minutes.
223610223|NCT04830579|DRUG|Etoricoxib film-coated tablet 120 mg|Etoricoxib is manufactured by Pharmtechnology LLC, Republic of Belarus. Each tablet contains 120 mg of etoricoxib.
223610224|NCT04830579|DRUG|Arcoxia® film-coated tablet 120 mg|Arcoxia® is manufactured by Frosst Iberica SA, Spain. Each tablet contains 120 mg of etoricoxib.
223610225|NCT01789684|OTHER|Active Provider Intervention|Participating Sites assigned to the active intervention cluster will receive a multi-faceted provider education and decision support intervention to improve appropriate referral of breast cancer patients at risk for HBOC to genetic counseling and pre-surgical referral among newly diagnosed patients.
223610226|NCT00200603|DEVICE|calcium phosphate macroporous bioceramics|
223610227|NCT00269919|DRUG|Risperidone Long-Acting Injectable (RLAI)|The RLAI 25 mg or 37.5 mg or 50 mg will be administered intramuscularly depending on Investigator's discretion every 2 weeks for 2 years.
223610228|NCT02656355|OTHER|Weight shift training and APA feedback|Use COP trajectory to train weight shift on force plate. To give APA visual feedback for subjects after weight shift training.
223610229|NCT02656355|OTHER|Weight shift training without APA feedback|Use COP trajectory to train weight shift on force plate.
223610230|NCT04616859|DIETARY_SUPPLEMENT|Alcohol and Energy Drink (AmED)|Multiple oral dose of alcohol mixed with ED
223610231|NCT04616859|DIETARY_SUPPLEMENT|Alcohol and Energy drink Placebo|Multiple oral dose of alcohol mixed with ED placebo (soft drink)
223610232|NCT04616859|DIETARY_SUPPLEMENT|Alcohol placebo and Energy drink|Multiple oral dose of alcohol placebo (water) mixed with ED
223610233|NCT04616859|DIETARY_SUPPLEMENT|Alcohol placebo and energy drink placebo|Multiple oral dose of alcohol placebo (water) mixed with ED placebo (soft drink)
223610234|NCT00797277|DRUG|IM olanzapine|10mg olanzapine IM
223610235|NCT00797277|DRUG|IM haloperidol plus lorazepam|IM 5 mg haloperidol plus IM 2 mg lorazepam
223756369|NCT04946292|BEHAVIORAL|Conventional health education|The conventional health education will be delivered through an oral health talk and oral health booklet. Topics covered are: (i) common oral diseases and its consequences; (ii) common dental problems among older adults; (iii) importance of oral health measures (healthy diet, toothbrushing and dental flossing); and (iv) proper techniques for toothbrushing and dental flossing.
223756370|NCT03518385|DIAGNOSTIC_TEST|ultrasound,transvaginal scan|The presence of fluid in the uterine cavity during hormonal stimulation.
223756371|NCT00947479|OTHER|continuous positive airway pressure (CPAP)|After being qualified into the study according to the aforementioned inclusion criteria and after giving an informed consent the polysomnography will be performed in all patients during night rest.In all patients eligible to sleep apnea treatment according to apnea/hypopnea index (AHI, number of apneic/hypopneic episodes per 1 h of effective sleep) from diagnostic polysomnography, CPAP treatment will be introduced under polysomnographic surveillance and the same panel of clinical and biochemical parameters will be evaluated.
223756372|NCT01228747|DRUG|Levetiracetam|Oral dose at flexible increase doses: 1000 mg/day or 2000 mg/day or 3000 mg/day, twice daily, 28 weeks
223756373|NCT01228747|DRUG|Placebo|Matching oral placebo tablets twice daily for 28 weeks
223610236|NCT02471014|DRUG|Pneumovax 23|All participants will receive a single 0.5 mL Pneumovax 23 intramuscular vaccine at baseline.
223756374|NCT03625245|OTHER|Control Yogurt|125 g/day
223610237|NCT02471014|OTHER|Blood tests|All participants will have two 50 milliliter blood draws: at baseline and up to 6 weeks later.
223610238|NCT02471014|OTHER|Questionnaires|"All participants will answer the following questionnaires:~UCLA Loneliness Scale Questionnaire will be used to measure a difference between the groups.~Perceived Stress Scale-10 Questionnaire will be used to measure a difference between the groups.~Interpersonal Support Evaluation List-12 will be used to measure a difference between the groups Life Orientation Test-Revised will be used to measure a difference between the groups."
223610239|NCT06095219|OTHER|Non- contrast Magnetic Resonance Imaging (MRI) of the hip|Asymptomatic volunteers will undergo a non-contrast MRI of the hip at 3 Tesla. Following this, MRI images will be automatically segmented utilizing a validated artificial intelligence based algorithm to calculate 3D outcome parameters.
223610240|NCT06095219|OTHER|Magnetic Resonance Imaging (MRI) of the hip with intra-articular contrast agent|The data was derived from a retrospective study involving patients at Inselspital's outpatient clinic who underwent 3 Tesla hip MRI scans with intra-articular contrast agent. A validated artificial intelligence based algorithm was utilized for automated segmentation and the calculation of 3D outcome parameters.
223756375|NCT03625245|OTHER|Yogurt Variety 1|125 g/day
223756376|NCT03625245|OTHER|Yogurt Variety 2|125 g/day
223756377|NCT00732147|DRUG|Pramlintide acetate|120 micrograms given subcutaneously before each meal X 3.
223610241|NCT04551118|DEVICE|Transcranial alternating current stimulation (tACS) -active|Transcranial alternating current stimulation (tACS) is a non-invasive neuromodulation technique of the brain with an AC micro-electrical stimulator, two rubber electrodes in saline-soaked sponges, and a control software to set the output of the stimulation type. Participants receive 20 min sessions of 1.5 mA alternating current delivered over the dorsolateral prefrontal cortex, for 7 consecutive days.
223610242|NCT04551118|DEVICE|Transcranial direct current stimulation (tDCS)-active|Transcranial direct current stimulation (tDCS) is a non- invasive neuromodulation technique of the brain with a DC micro-electrical stimulator, two rubber electrodes in saline-soaked sponges, and a control software to set the output of the stimulation type. Participants receive 20 min sessions of 1.5 mA direct current delivered over the dorsolateral prefrontal cortex, for 7 consecutive days.
223610243|NCT04551118|DEVICE|Transcranial electrical stimulation (TES)-sham|Transcranial electrical stimulation (TES) is a non-invasive neuromodulation technique of the brain with micro-electrical stimulator, two rubber electrodes in saline-soaked sponges, and a control software to set the output of the stimulation type. Participants receive sham stimulation over the dorsolateral prefrontal cortex, with current turned off after 30 second. The session last 20 min for 7 consecutive days.
223610244|NCT00659113|DRUG|cisplatin|
223610245|NCT00659113|DRUG|tegafur-gimeracil-oteracil potassium|
223610246|NCT00659113|OTHER|cytology specimen collection procedure|
223756378|NCT00732147|DRUG|Placebo|120 micrograms given subcutaneously before each meal x 3.
223756379|NCT01394679|DRUG|(99m Tc) ECDG (Ethylenedicysteine-Deoxyglucose)|One injection of Technetium-99m Ethylenedicysteine-Deoxyglucose to yield a target dose of 25 mCi (range of 20-30 mCi)by IV push and less than 1 mg of EC-DG
223756380|NCT01394679|DRUG|18 F FDG followed by PET/CT imaging|Single injection of 18 F FDG range of 10-20 mCi
223756381|NCT06056050|BIOLOGICAL|Tetanus, Reduced Diphtheria and Acellular Pertussis (Five Components) Combined Vaccine, Adsorbed (Aged 6 Years and Older) (Tdcp)|1 dose of Tdcp vaccine (0.5ml) on Day 0
223756382|NCT06056050|BIOLOGICAL|23-Valent Pneumococcal Polysaccharide Vaccine（PPV23）|1 dose of PPV23 vaccine (0.5ml) on Day 0
223756383|NCT06056050|BIOLOGICAL|Diphtheria and Tetanus Combined Vaccine, Adsorbed (DT)|1 dose of DT vaccine (0.5ml) on Day 0
223756384|NCT01228357|DRUG|SSRI treated group|Antidepressant administration of SSRI class for 12 weeks under therapeutic dose
223756385|NCT01228357|DRUG|non-SSRI treated group|Antidepressant administration of non-SSRI class for 12 weeks under therapeutic dose
223756386|NCT00546611|DRUG|PEP005|
223756387|NCT04416087|OTHER|Exercise|Positron emission tomography (PET) imaging at rest and during supine bicycle exercise Tumor blood flow and its heterogeneity will be measured with PET at rest and during supine bicycle exercise.
223756388|NCT02074995|BIOLOGICAL|BVS857|Group 1A\&1B receive first dose as IV then remaining doses as SC. Groups 2, 3 and 4 receive only SC doses.
223756389|NCT02074995|OTHER|placebo|Group 1B receive first dose as IV then remaining doses as SC. Groups 2, 3 and 4 receive only SC doses.
223756390|NCT03318354|DRUG|Torrent's Olmesartan Medoxomil Tablets 40 mg|
223756391|NCT03318354|DRUG|Daiichi Sankyo Inc's Benicar Tablets 40 mg|
223756392|NCT00844363|PROCEDURE|NB-UVB|UVB light will be administered to the entire body except for the genitals in men and eyelids, which will be shielded.NB-UVB dosing is increased by 5-20% increments in exposure time, depending on response of the patient.
224201025|NCT05069129|BIOLOGICAL|Recombinant COVID-19 Vaccine (CHO cell，NVSI-06-08)|Intramuscular injection of Recombinant COVID-19 Vaccine (CHO cell，NVSI-06-08) in the deltoid muscle of the upper arm
223610247|NCT00659113|PROCEDURE|endoscopic biopsy|
224201026|NCT05069129|BIOLOGICAL|Inactivated COVID-19 vaccine (Vero cells)|Intramuscular injection of Inactivated COVID-19 vaccine (Vero cells) in the deltoid muscle of the upper arm
224311687|NCT01877746|DRUG|Combination of prednisone and azathioprine|"* Prednisone for a total of 6 months, with initial dose 1mg/kg/day p.o. given for 4 weeks with a subsequent maintenance dose of 0,33 mg/kg/den. The daily dose of Prednisone will be rounded to the nearest value divisible by 5.~* Azathioprine for 6 months in total, with dose 2mg/kg/day. The daily dose of Azathioprine will be rounded to the nearest value divisible by 25."
224311688|NCT01877746|OTHER|No intervention|No intervention, only standard medical therapy
224201027|NCT05069129|BIOLOGICAL|3 doses Recombinant COVID-19 Vaccine (CHO cell，NVSI-06-08)|Intramuscular injection of Recombinant COVID-19 Vaccine (CHO cell，NVSI-06-08) in the deltoid muscle of the upper arm on 0，30，60 days
224311689|NCT02014207|OTHER|dietary treatment|
223610248|NCT01751984|DRUG|ETC-1002|Weeks 1-2, 60 milligrams per day (mg/day); Weeks 3-4, 120 mg/day; Weeks 5-6, 180 mg/day; Weeks 7-8, 240 mg/day
223610249|NCT01751984|DRUG|Placebo|Placebo once daily for 8 weeks
223610250|NCT01119469|BEHAVIORAL|Psychotherapy (CT or ET)|weekly 50-minute sessions for 12 weeks
223610251|NCT01689142|DRUG|Insulin glargine new formulation (HOE901)|Pharmaceutical form: solution Route of administration: subcutaneous
223610252|NCT01689142|DRUG|Insulin glargine (HOE901)|Pharmaceutical form: solution Route of administration: subcutaneous
223610253|NCT02911870|DRUG|SNAC|Oral administration
223610254|NCT02911870|DRUG|Placebo|Oral administration
223610255|NCT02911870|DRUG|Moxifloxacin|Oral administration
223610256|NCT05221502|DRUG|Delamanid + Bedaquiline + OPC-167832 10 mg|Delamanid (300 mg QD) + Bedaquiline (400 mg QD x 2 weeks, then 200 mg TIW) + OPC-167832 (10 mg QD) for 17 weeks
223610257|NCT05221502|DRUG|Delamanid + Bedaquiline + OPC-167832 30 mg|Delamanid (300 mg QD\] + Bedaquiline (400 mg QD x 2 weeks, then 200 mg TIW) + OPC-167832 (30 mg QD) for 17 weeks
223610258|NCT05221502|DRUG|Delamanid + Bedaquiline + OPC-167832 90 mg|Delamanid (300 mg QD) + Bedaquiline (400 mg QD x 2 weeks, then 200 mg TIW) + OPC-167832 (90 mg QD) for 17 weeks
224201028|NCT03644927|BEHAVIORAL|Progressive exercise training|The 12 week progressive exercise program gradually increases the walking/running intensity and length of exercise every 2 weeks for the first 6 weeks and then maintains the higher intensity level for weeks 7-12,. The exercise intensity is based on percentile targets defined by the baseline cardiopulmonary test (CPX test). Participants will be called at weeks 4 and 10 to assess and foster exercise motivation, using basic principles of motivational interviewing..
223610259|NCT05221502|DRUG|RHEZ|RHEZ for 8 weeks followed by 18 weeks of rifampin and isoniazid (for a total of 26 weeks)
223610260|NCT03923634|DEVICE|Princess® RICH|Princess® RICH is injected into lateral canthal lines and/or perioral rhytids
223610261|NCT03047577|BEHAVIORAL|Brief intervention|A 15-20minute discussion about the patients alcohol use and its association with current health conditions, option for a discussion with social worker and written material (information about how alcohol affects health and contact details for seeking more support)
223610262|NCT01157247|PROCEDURE|Comparison of intravenous fentanyl and local anesthetic infiltration in pain reducing during spinal needle puncture|
223610263|NCT01699230|DIETARY_SUPPLEMENT|Omega 3|To show the existence of a atrial cardiomyocytes membranes modification in omega-3 supplemented patients with coronary atherosclerosis
223610264|NCT03697642|PROCEDURE|With nasopharyngeal airway|Nasopharyngeal airway is previously inserted into selected nostril. NG tube is properly lubricated and placed through Nasopharyngeal airway.
223610265|NCT03697642|PROCEDURE|Without nasopharyngeal airway|NG tube is properly lubricated and placed into selected nostril
223610266|NCT04494906|OTHER|Interactive stepping exercise|An exercise intervention based on the principle of square stepping exercise
223610267|NCT04494906|OTHER|Square stepping exercise|Square stepping exercise
223610268|NCT04486651|DRUG|Irinotecan Hydrochloride Injection|160 mg/m² administered as IV infusion on Day 1 of each 14-day cycle.
224201029|NCT03644927|BEHAVIORAL|Waitlist Control|Participants will be screened for eligibility and if randomized into the waitlist control group. Wait list participants will wait for 12-weeks before they can participate in the progressive exercise training program. The 12 week progressive exercise program is identical to the one used in the intervention group. Specifically, the 12 week progressive exercise program gradually increases the walking/running intensity and length of exercise every 2 weeks for the first 6 weeks and then maintains the higher intensity level for weeks 7-12. The exercise intensity is based on percentile targets defined by the baseline cardiopulmonary test (CPX test). Participants will be called at weeks 4 and 10 to assess and foster exercise motivation, using basic principles of motivational interviewing.
223610269|NCT04486651|DRUG|HX008|200 mg administered as IV infusion on Day 1 of each 21-day cycle.
223610270|NCT04486651|DRUG|Placebo|Administered as IV infusion on Day 1 of each 21-day cycle.
223610271|NCT04914065|OTHER|Regular care in the surgery intensive care unit|"Part 1: Two arms(muscle thickness observation):~1. Inspiratory muscles: diaphragm~2. Anti-gravity muscles: rectus femoris and the vastus intermedius~Part 2: Predictors of short-term and long-term goals in the ICU~1. Short-term goal: successful ventilator weaning in the ICU- pass weaning profile without re-intubation in the hospital~2. Long-term goal- Quality of life after hospital discharge: SF-36 (Taiwan version)"
223610272|NCT00545090|DRUG|ibandronate [Bonviva/Boniva]|150mg po monthly for 6 months
223610273|NCT04110782|OTHER|Radium223|55 kBq/ Kg
223610274|NCT01388907|OTHER|Ringer lactate solution|Ringer lactate solution was applied directly onto the uterine surgical sites at the end of the myomectomy surgery, to prevent post-surgical adhesion formation.
224201030|NCT01077791|BEHAVIORAL|original cognitive therapy|12 weekly sequences of an original cognitive therapy based on videos involving the learning of a better use of contextual information to infer others' intention. Group of 5 patients trained by 2 therapeutics. Comparison with a non-cognitive psychoeducational training (same organisational design).
224201031|NCT02080273|DRUG|Colgate Cavity Protection toothpaste|0.76% monofluorophosphate (1000 ppm MFP), Colgate Cavity Protection toothpaste is a control treatment.
224201032|NCT02080273|DRUG|Colgate Total toothpaste|0.32% sodium fluoride (1450 ppm NaF) and 0.3% triclosan. Colgate Total toothpaste is the active comparator toothpaste
224201033|NCT02080273|DRUG|Parodontax toothpaste|1400 ppm sodium fluoride (NaF), Parodontax toothpaste is the active comparator toothpaste
223610275|NCT01388907|DEVICE|Prevadh film|Prevadh film was applied directly onto the uterine surgical sites at the end of the myomectomy surgery to prevent post-surgical adhesion formation.
223756393|NCT04377477|RADIATION|Single fraction whole lung radiotherapy|Participants will undergo irradiation of the lungs, administered in a single fraction at the average prescription dose of 0.7 Gy
223610276|NCT05092945|OTHER|Cold exposure|The liquid-conditioned tube suit will be perfused with 18°C water using a temperature- and flow-controlled circulation bath from time 0 to 180 min.
223610277|NCT05092945|DRUG|Oral Nicotinic acid|A total of 500 mg of nicotinic acid will be given orally, at a rate of 2 doses of 150 mg and 2 doses of 100 mg: one dose of 150 mg at time 0 and 60 minutes, one dose of 100 mg at time 120 minutes and 180 minutes.
223610278|NCT05460988|PROCEDURE|Flap surgery|All the sites showing a residual pocket in a sextant allocated to surgery group will receive flap surgery. After the administration of oral local anaesthesia (Articaine 1:100000) an intrasulcular flap will be raised. In order to preserve interdental tissue the flaps will be designed accordingly the principles of papillary preservation flap. Toot root will be carefully debrided using both ultrasonic instruments and Grecey's curettes. Bone recontouring and ostectomy/osteoplasty will be avoided. Single simple sutures will be used to close the flap (Vicryl 5-0).
223756394|NCT00500292|DRUG|Vandetanib|once daily oral tablet two dose strengths
223610279|NCT05460988|PROCEDURE|Non surgical re-instrumentation|The sites showing remaining pockets (PD\>4mm), in the sextants allocated to re-instrumentation group, will be treated with subgingival debridement. The subgingival debridement will be performed after the administration of local oral anaesthesia (Articaine 1:100000) using a periodontal tip on ultrasonic instrument (EMS) and Gracey's curettes.
223756395|NCT00500292|DRUG|FOLFOX regimen=oxaliplatin, fluorouracil, & folinic acid|intravenous infusion
223756396|NCT05020392|DRUG|BTK inhibitor+ Fludarabine-based chemotherapy + CAR-T-CD19 Cells|BTK inhibitor from enrollment to more than 90 days after CAR-T-CD19 infusion. Fludarabine-based lymphodepletion chemotherapy was followed by CART19 infusion at a dose of 1x10\^6/kg on day 0 and day 1 respectively.
223756397|NCT05020392|DRUG|Fludarabine-based chemotherapy + CAR-T-CD19 Cells|Fludarabine-based lymphodepletion chemotherapy was followed by CART19 infusion at a dose of 1x10\^6/kg on day 0 and day 1 respectively.
223756398|NCT06095323|DEVICE|compression sleeves for upper limbs with a pressure level of 1 (15-20mmHg)|The intervention group will wear compression sleeves for upper limbs with a pressure level of 1 (15-20mmHg) during the day for 12 months.
223756399|NCT04244188|OTHER|Collection of datas|Collection of datas: pre- and postoperative scanner and endoprosthesis characteristics
223756400|NCT04926532|DRUG|Toripalimab|Toripalimab is a humanized anti-PD-1 monoclonal antibody
223756401|NCT04926532|DRUG|Sorafenib|Sorafenib is a multi-kinase inhibitor
223756402|NCT01653080|PROCEDURE|dynamic contrast-enhanced MRI|Studies will be performed on standard clinical MR Systems which are available on Campus. With the proposed imaging technique, we are able to acquire a 3D volume covering the orbit with a temporal resolution of approximately 15s. The affected eye will be immobilized to reduce motion artifacts. A routinely used MR contrast agent will be administered in a dose of 0.1mmol/kg bodyweight.
223756403|NCT04935411|OTHER|nAMD|patients diagnosed with Neovascular Age-Related Macular Degeneration
223756404|NCT03836196|RADIATION|LDR Brachytherapy and External Beam Radiation Therapy|Low Dose Rate Brachytherapy (LDR-PB) and External Beam Radiation Therapy (EBRT)
223756405|NCT03733821|DEVICE|Repetitive Transcranial Magnetic Stimulation|Non-invasive brain stimulation tool
223756406|NCT05465382|DEVICE|Saline Lavage|Three rounds of 10cc of sterile 0.9% normal saline will be injected into the injured ankle joint and withdrawn from the joint using an anteromedial 16-gauge needle attached to a 10cc syringe.
223756407|NCT05465382|OTHER|No intra-articular saline lavage|Subjects in group 2 will not undergo normal saline lavage.
223756408|NCT05465382|DRUG|Lidocaine - intra-articular injection|Intra-articular injection of 10cc of 1% lidocaine without epinephrine via the existing anteromedial 16-gauge needle.
223756409|NCT05465382|OTHER|Synovial Fluid Aspiration|Aspiration of ankle joint via standard anteromedial approach. Performed using sterile technique using 16-guage needle attached to 10cc syringe.
223610280|NCT05650021|DEVICE|SpaceOAR Vue|CBCT images acquired during the first five fractions of radiotherapy
223756410|NCT02482025|OTHER|SMMRT|Includes My HealtheVet registration and enrollment
223756411|NCT02860715|DRUG|GX-I7|Interleukin-7 (IL-7) is T cell growth factor that can be used for treating lymphopenia patients. GX-I7 is a protein drug recombining human IL-7 and hybrid Fc (hyFc). HyFc made by Genexine is composed of hinge-CH2 region of Immunoglobulin D (IgD) and CH2-CH3 region of Immunoglobulin G4 (IgG4). The recombined region is not exposed and each region's characteristics can reduce immunogenicity and improve the efficacy of drug. Consequently, it will be able to treat the patients with lymphopenia in effective ways.
223756412|NCT02860715|DRUG|Placebo|This is the placebo of GX-I7 described above.
223756413|NCT04982250|BEHAVIORAL|Enhanced peer PrEP referral + HIVST delivery|After a brief training, young female PrEP users will be encouraged to refer up to 4 peers to PrEP using strategies gained from the training, PrEP educational materials (i.e., brochures), HIVST kits (2 kits/peer = 8 kits total), and Kenya MOH-style referral cards.
223756414|NCT02283710|DRUG|Pentoxifylline|Pentoxifylline 600 mg BD
223756415|NCT02283710|BEHAVIORAL|Lifestyle modification|obtaining ideal body weight by calorie restriction diet and programmed physical activity.
223756416|NCT01048723|DRUG|RAD001|Patients were instructed to take RAD001 in the morning, at the same time each day.
223756417|NCT00176553|DRUG|Dextromethorphan|Patients will receive an inert carrier with or without dextromethorphan. The study drug will be administered at 1.5 mg/kg/dose on a BID schedule. The first dose to be given prior to each scheduled intravenous and/or intrathecal administration of methotrexate and continued for a total of seven days.
223756418|NCT05518968|BEHAVIORAL|Acceptance and commitment therapy|8 weekly coach-guided videoconferencing sessions and the use of a web app based on acceptance and commitment therapy
224311690|NCT00995280|DEVICE|single lumen needle oocyte retrieval|single lumen needle use during oocyte retrieval
224311691|NCT00995280|DEVICE|double lumen needle oocyte retrieval|double lumen needle with 1 time follicle flushing with at least 2 ml during oocyte retrieval
224311692|NCT01421173|DRUG|Vorinostat|Starting dose: 200 mg by mouth on Days -8 to -2.
223610281|NCT04994756|PROCEDURE|Stroke/Thrombectomy/Aneurysm-specific surgical procedures|Participants are retrospectively and/or prospectively entered into registry based on disease indication and respective surgical procedure.
223610282|NCT05904795|OTHER|PNF strengthening exercises|PNF strengthening exercises 10 repetitions, 1set , 4 days/week along with range of motion exercises total of 4 sessions were given consisting 40 minutes
223610283|NCT05904795|OTHER|de-lorme and watkins exercises|"The group was given de-lorme and watkins progressive resistance exercises along with range of motion exercises .10 repetitions, 1set, 4 days /week along with range of motion exercises.~total of 4 sessions per week each consisting of 40 minutes."
223610284|NCT03187132|DEVICE|Digital Pain Reduction Kit|A two-component intervention consisting of (1) virtual reality, experiences lasting 3-30 minutes used to distract individuals from pain and to teach skills related to chronic pain; (2) TENS unit, used to reduce acute localized pain.
223610285|NCT03187132|DEVICE|Active Control|An active control TENS unit used to reduce acute localized pain.
223756419|NCT01148511|DRUG|Ranibizumab 0.5 mg|Ranibizumab was supplied as a sterile solution in sealed glass vials.
223756420|NCT01080898|OTHER|tests|color photographs, FLUORESCEIN angiography and OCT
223756421|NCT03365700|PROCEDURE|Radiofrequency Ablation|Left atrial catheter ablation with pulmonary vein antrum isolation documented by a circular mapping catheter.
223756422|NCT03365700|PROCEDURE|Cryoballoon ablation|Cryoballoon pulmonary vein isolation with the Arctic Front Advance® System or any future development generations of this product line. Additional substrate modification is allowed with the catheter type assigned at the index procedure.
223756423|NCT02885961|DRUG|Dabigatran|Anti-coagulant
223756424|NCT02885961|RADIATION|FDG PET scan|Scan using PET combined with a high resolution CT scan (HRCT)
223610286|NCT02045095|DRUG|MLN7243|"Dose escalation stage Schedule A: Intravenous infusion on Days 1, 4, 8, 11 for a 21-day treatment cycle.~Schedule B: Intravenous infusion on Days 1, 8, 15 for a 28-day treatment cycle.~Dose expansion stage: MLN7243 will be administered following schedule A (twice-weekly, 21-day dosing) and/or B (once-weekly, 28-day dosing)."
223610287|NCT03594773|BEHAVIORAL|Cognitive Behavioral Therapy|Participants will receive 8 one-on-one sessions over 8 to 12 weeks.
223610288|NCT03594773|BEHAVIORAL|Interpersonal Psychotherapy|Participants will receive 8 one-on-one sessions over 8 to 12 weeks.
223610289|NCT05234047|PROCEDURE|MDCT (multidetector computed tomography)|MDCT will be performed at inclusion and after 2 years
223610290|NCT05234047|PROCEDURE|Dual-energy X-ray absorptiometry|DXA will be performed at inclusion, 1 and 2 years after inclusion
223610291|NCT06394986|PROCEDURE|Hemodialysis session|Change of arteriovenous fistula volume blood flow / cardiac output ratio in patients with chronic heart failure (NYHA I-II classes) and with preserved ejection fraction as a result of a hemodialysis session will be explored.
223610292|NCT03618420|DRUG|Aminohippurate Sodium Inj 20%|Diagnostic aid/agent used to measure effective renal plasma flow (ERPF)
223756425|NCT02283515|DRUG|Rosuvastatin|Rosuvastatin (RSV) is one of new synthetic, second-generation, sulfur-containing, hydrophilic statin, a highly efficient competitive inhibitors of HMG CoA Reductase having important role in reducing serum cholesterol concentrations and lowers the risk of cardiovascular disease.
223610293|NCT03618420|DRUG|Iohexol Inj 300 mg/mL|Diagnostic aid/agent used to measure glomerular filtration rate (GFR)
223610294|NCT01243723|DRUG|Eductyl suppository|One suppository every morning during 21 days
223610295|NCT01243723|DRUG|Placebo suppository|One suppository every morning during 21 days
223610296|NCT04879693|DEVICE|Continuous Glucose Monitoring System|Continuous Glucose Monitoring System
223610297|NCT04640649|OTHER|Algorithm prediction|Patients with early and intermediate AMD in at least one eye who are at risk of converting to wet AMD or GA expansion will be randomly assigned to a test group or control group. The test group will have their baseline data analyzed by an algorithm to predict the probability of conversion to wet AMD. If the probability is high for conversion at or before 3 months, patients will have earlier follow-up care than the control group (standard follow-up care every 6 months).
223610298|NCT06368791|BEHAVIORAL|Box Breathing|Participants are guided to find a quite and comfortable spot to sit and unwind. They are then directed to inhale deeply for four seconds, hold that breath for another four seconds, and then exhale slowly over four seconds. Following a brief four-second pause, they begin the next cycle of breathing. To assist with this exercise, participants will have access to a video featuring a red dot tracing a square pattern, moving at the pace needed for the breathing technique.
223756426|NCT00002627|BIOLOGICAL|filgrastim|
223756427|NCT00002627|DRUG|carboplatin|
223756428|NCT00002627|DRUG|cyclophosphamide|
223756429|NCT00002627|DRUG|mesna|
223756430|NCT00002627|DRUG|paclitaxel|
223756431|NCT00002627|PROCEDURE|peripheral blood stem cell transplantation|
223756432|NCT06190431|OTHER|Learning the use of an in-exsufflation device with the guidance of a physiotherapist|Learning to use an in-exsufflation device with the guidance of a physiotherapist
223756433|NCT06190431|OTHER|Using the coaching mode|Learning the use of an in-exsufflation device using a coaching mode (playful visual stimulation) in addition to guidance of a physiotherapist
223756434|NCT04121260|DRUG|Daratumumab|Participants will receive dose 1 daratumumab with 30,000 U (2000 U/mL) with rHuPH20 SC injection.
223756435|NCT02963337|DRUG|remifentanil|Remifentanil PCA will be used to deliver intravenous drug boluses from 20 to 40 micrograms per 2 min lockout interval.
223756436|NCT02963337|DRUG|combined spinal-epidural analgesia|Patient controlled epidural analgesia will be used to deliver epidural boluses of 6-10 ml of 0,1% bupivacaine with 2 micrograms of fentanyl per ml per 15 min lockout interval.
223756437|NCT00772499|DRUG|olmesartan medoxomil + hydrochlorothiazide + amlodipine + hydralazine if necessary to control blood pressure|Tablets and capsules for oral administration once or twice daily for up to 52 weeks
223756438|NCT00772499|DRUG|atenolol+ hydrochlorothiazide + amlodipine + hydralazine if necessary to control blood pressure|Tablets and capsules for oral administration once or twice daily for up to 52 weeks
223756439|NCT05282719|DRUG|venetoclax combined with azacitidine|On day 1 of each cycle, decitabine 75 mg/m2 will be given subcutaneously, and will continue for 5 days. Simultaneously the patient will start out with Venetoclax 100mg and progress to 400mg until the 14 day cycle is finished.
224311693|NCT01421173|DRUG|Gemcitabine|Starting dose: 2175 mg/m2 by vein on Days -8 and -3. This includes the gemcitabine 75 mg/m2 loading dose.
224311694|NCT01421173|DRUG|Busulfan|"AUC: 4,000 micrometer (microM).min/day, or 105 mg/m2/day) on Days -8 to -5.~Pharmacokinetics will be performed with the first dose of 32 mg/m2 by vein on Day -8. The doses on Days -6 and -5 will be subsequently adjusted to target an AUC of 4,000 microMol.min-1. In the event that PK adjusting not possible, a dose of busulfan of 105 mg/m2 will be administered on days -6 and -5."
224311695|NCT01421173|DRUG|Melphalan|60 mg/m2 by vein on Days -3 and -2.
224311696|NCT01421173|PROCEDURE|Stem Cell Infusion|Infusion of stem cells by vein on Day 0.
224311697|NCT01421173|DRUG|Rituximab|375 mg/m2 on days +1 and +8 for patients with CD20+ tumors.
224311698|NCT01421173|DRUG|G-CSF|5 mcg/kg/day (rounded up the nearest vial) subcutaneously beginning on Day +5 and continuing until neutrophil recovery is documented.
224311699|NCT01421173|DRUG|Palifermin|60 mcg/kg by vein daily for 6 doses. Three doses administrated prior to start chemo (24 hours must elapse between the last dose and first therapeutic dose of chemo) and three doses after the last chemo starting on day 0.
224311700|NCT01421173|DRUG|Dexamethasone acetate|8 mg by vein twice a day from day -8 AM to day -2 PM.
223610299|NCT06368791|BEHAVIORAL|Breathing and Mindfulness Exercise|The second intervention involves a 10-minute session of guided breathing exercises that blend elements of mindfulness meditation with gentle body movements and controlled breathing. Participants are advised to find a quiet space, sit comfortably, and adopt an upright posture. They are then led through a series of brief exercises, incorporating mild stretches for the upper body and focused, mindful breathing.
223610300|NCT06368791|BEHAVIORAL|Everyday life control|Participants are instructed to not perform the anti-stress intervention and to proceed with their daily activities as usual.
223756440|NCT00527930|DRUG|TS-1 and Eloxatin|"S-1 80 mg/m2/day on day 1-14 Oxaliplatin 130 mg/m2 IV for 2 hour on day 1 Every 3 week~Number of Cycles: until progression or unacceptable toxicity"
223756441|NCT06083350|DIETARY_SUPPLEMENT|Yeast beta-glucan|Produced by Angel Yeast Co., LTD
223756442|NCT06083350|DIETARY_SUPPLEMENT|Starch|Produced by Angel Yeast Co., LTD
223756443|NCT03170973|OTHER|Exercise|After a 12-hour fast, volunteers will collect blood in the antecubital vein to measure basal serum values. 12 after the first blood collection they will perform a physical exercise session on a treadmill. The same will be divided in 3 times: heating, conditioning and cooling. The heating will be of 7 minutes, the cooling of 5 minutes and the time of conditioning will correspond to the energy expenditure of 250Kcal with light intensity based on Borg's perception of effort, that is, in the original scale a value between 9 and 11. After 24 hours after the first blood collection the volunteers will return to the laboratory after a 12-hour fast and blood samples will be collected again.
224311701|NCT02188914|RADIATION|Positron emission tomography scan|
224311702|NCT02188914|OTHER|Magnetic resonance imaging|
224311703|NCT02619435|DRUG|regorafenib|Patients will receive regorafenib orally 160 mg once daily for the first 3 weeks of each 4-week cycle.
224311704|NCT03937336|BEHAVIORAL|Bike Intervention Group|A 1-month biking-based program. The biking program consists of 4 sessions/month of 120 min at physical education lessons in school, and will focus on promote biking through theory and practice lessons about cycle training skills including on-road training
223756444|NCT05211128|PROCEDURE|Robotic Surgery|Surgical procedure using robotic technologies.
223756445|NCT05211128|PROCEDURE|Open Surgery|Surgical procedure using a large, open cut in the skin.
223756446|NCT05211128|PROCEDURE|Laparoscopic Surgery|Surgical procedure using small incisions and trochars.
223756447|NCT04695132|BEHAVIORAL|Illness Management and Recovery treatment programme|The Illness Management and Recovery treatment programme is a psychosocial treatment aimed at attaining illness management skills and promoting a sense of personal recovery amongst patients with serious mental illness. The original treatment protocol has been translated to Swedish and adapted to a forensic mental health setting. The treatment consists of ten chapters containing information and practical exercises relating to topics relevant for mental health and mental health recovery. These topics include medication use, stress reduction, problem solving, recovery goals and navigating the forensic mental health system. Participants are assigned practical homework and tasks to be completed outside of treatment sessions. Group sessions are conducted to present and discuss treatment material. Individual sessions are used to rehearse treatment content, personalize the treatment and review progress in achieving tasks agreed upon in the group setting.
223756448|NCT01315704|DRUG|Drug intervention|before-after interventional (anti-dementia drugs and/or vitamin D) study
224311705|NCT06355999|BEHAVIORAL|Color Feedback|Feedback is given about the correctness of the response on the color dimension
224311706|NCT06355999|BEHAVIORAL|Shape Feedback|Feedback is given about the correctness of the response on the shape dimension
223610301|NCT03468244|BIOLOGICAL|Personalized mRNA Tumor Vaccine|subcutaneous injection with personalized mRNA tumor vaccine at least four times
223610302|NCT03430778|OTHER|High end-tidal CO2|maintaining of end-tidal CO2 with the range of 40-45 mmHg
223610303|NCT03430778|OTHER|Low CO2 group|maintaining of end-tidal CO2 with the range of 30-35 mmHg
224311707|NCT04864470|BEHAVIORAL|Stroke Odysseys|"The participants will take part in a twelve-week performance programme that takes place online/in a community halls/arts centre. Sessions run for three hours and during these sessions, participants devise a dance and music performance work from their own stories. The culmination of the programme will be a public facing performance to an audience of carers, health care practitioners, friends, family and the wider community, done online through Zoom.~After the performance is completed, participants will be invited to a training programme where they learn to act as advocates for life after stroke - termed 'stroke ambassadors'. The training will be a four-day programme. The programme will take place once weekly and is led by a team of artists supported by a leadership coach, on Zoom.~Following training, ambassadors will support artists in recruitment, befriend the newly discharged stroke survivors and take part in small scale performance tours to challenge the perception of disability."
224311708|NCT02281292|BIOLOGICAL|LKA651 ophthalmic solution|
224311709|NCT02281292|BIOLOGICAL|Ranibizumab ophthalmic solution|
224311710|NCT02281292|BIOLOGICAL|Sham injection|Mock injection administered as an empty hub without needle
223610304|NCT01966523|BEHAVIORAL|Intervention|Provider Training: i. on-line education course and ii. algorithms and checklists. The course consists of 4 cases: 2 for urinary tract infection and 2 for lower respiratory tract infections with multiple choice questions and evidence-based feedback. To reinforce provider learning, posters displaying algorithms guiding appropriate antimicrobial initiation for infections will be placed in all nursing home units. Laminated pocket cards with the algorithms will be given to providers. Providers will complete simple checklists for each suspected infection throughout the study. B. Proxy Information: The printed material explains, in a lay fashion: i. the nature of infection in advanced dementia, ii. treatment options, iii. concerns about antimicrobial overuse, and iv. features of appropriate antimicrobial use.
223610305|NCT01966523|OTHER|Control|
223610306|NCT02246959|BEHAVIORAL|Process Incentive|Daily sweepstake conditional on daily medication adherence
223756449|NCT01025427|DRUG|Raltegravir, tenofovir/emtricitabine|16 controllers will be treated with open-label raltegravir/tenofovir/emtricitabine for 24 weeks.
223756450|NCT05860283|DEVICE|Core stabilization exercise using pressure biofeedback unit|"From crook lying:~* 1st and 2nd weeks LEVEL 1: ADIM and hold for 10 seconds LEVEL 2 : Hold for 5 sec. Repeat 10 times. Opposite lower extremity on plinth; bent leg fall out.~* 3rd and 4th week LEVEL 3 : Opposite lower extremity on plinth a)Lift bend leg to 90˚ hip flexion b)Slide heel to extend knee c)Lift straight leg to 45˚.~* 5th and 6th weeks LEVEL 4 : Hold opposite lower extremity at 90˚ of hip flexion a)Lift bend leg to 90˚ hip flexion b)Slide heel to extend knee c)Lift straight leg to 45˚.~From prone lying:~Extension of each lower extremity. The exercise progression each week will be evaluated.Each exercise session lasted 20 min. The patients had to hold each exercise for 10 seconds, three sets per session and each set 10 repetitions."
223756451|NCT05860283|PROCEDURE|Diaphragmatic release technique|This technique will be given 3 days per week for 6 weeks with total technique duration of 45 minutes. The maneuver will be repeated in 4 sets per session, each set will consist of 5 deep breaths with 2-min intervals in between sets.
223756452|NCT04258605|DEVICE|ASHCOM Shoulder System|Reverse Shoulder Arthroplasty
223756453|NCT04694677|DRUG|women receiving tranexamic acid|women receiving tranexamic acid during myomectomy
223756454|NCT04694677|DRUG|women receiving misoprostol|women receiving misoprostol in myomectomy
223756455|NCT04328831|BIOLOGICAL|IBI322|Recombinant anti-human CD47/PD-L1 bispecific antibody injection
223756456|NCT00208936|DRUG|Taxol, Cisplatin, 5-Fluorouracil, G-CSF|
223756457|NCT03821493|DRUG|PF-06651600 10 mg tablets|"On Day 1 in Period 1, a single oral dose of 30 mg (3 x 10 mg tablets) will be administered.~On Day 4 of Period 2, a single oral dose of 30 mg (3 x 10 mg tablets) will be administered after itraconazole."
223756458|NCT03821493|DRUG|Itraconazole Solution 200 mg|"Itraconazole 200 mg will be administered as 20 mL (10 mg/mL) oral solution once daily on Days 1-5 in Period 2.~On Day 4 of Period 2, co-administration of itraconazole 200 mg and PF-06651600 30 mg will occur. Itraconazole will be administered first followed by PF-06651600 tablets."
223756459|NCT01017237|DRUG|Dexmedetomidine|Dexmedetomidine will be infused at a rate of 6 mcg/kg/hr for four minutes; resulting in a loading dose of 0.4 mcg/kg, Followed by an infusion of 0.5 mcg/kg/hr will be initiated and continued until the completion of surgery.
223756460|NCT01017237|DRUG|Midazolam|Midazolam 0.04 mg/kg i.v. administered after dexmedetomidine loading dose.
223756461|NCT01017237|DRUG|Ketamine|Ketamine 0.25 mg/ml administered i.v. following the dexmedetomidine loading dose and the midazolam.
223756462|NCT01548612|DRUG|Sodium nitroprusside|Intravenous infusion of 0,5 mcg/kg/min for 240 minutes
223756463|NCT01548612|DRUG|Glucose solution|Intravenous infusion of glucose solution 5% for 240 minutes
223756464|NCT05071885|OTHER|games based exercise|Range of motion and strengthening exercises
223756465|NCT00483964|DRUG|Bacopa monnieri|
223756466|NCT00483964|DRUG|Nardostachys jatamansi|
223756467|NCT00483964|DRUG|Olanzapine|
223756468|NCT05392361|DRUG|gabapentin (neurontin® capsule 300mg) treatment|Taking gabapentin (neurontin® capsule 300mg, Pfizer) medication at night as a conservative treatment
223756469|NCT05392361|DRUG|baclofen (baclofen Tab. 10mg) treatment|Taking baclofen (baclofen Tab. 10mg, Handok co, Seoul, Korea) medication at night.
223756470|NCT04716127|BEHAVIORAL|Proximity-incentive strategy based on vaginal self-sampling for women 50 to 65 years who do not participate to cervical cancer screening|"* Direct offer of a vaginal self-sampling kit with information to perform at home and send back to the laboratory for HR-HPV testing~* The psychosocial determinants involved in decision-making process and compliance to cervical cancer screening will be collected from open questionnaires and by semi-directive phone interviews~* Control ; Receive reminder to send the self-sample to the laboratory : After 3 and 6 months without return, women receive a remind letter to send the vaginal self-sample to the laboratory. We call return the receipt of the vaginal self-sample at the laboratory.~* Control ; Receive reminder to perform cervical smear in case of positive HR-HPV test : In case of a positive HR-HPV test, women are asked to perform a control cervical smear. After 3, 6 months and 12 months without return, women and their health-care professional will receive a remind letter or a call to perform a cervical smear for control. We call return the performance of a pap smear."
223756471|NCT03532620|DRUG|Pitavastatin Calcium|"In Pitavastatin treatment group, Pitavastatin calcium tablet 2mg/day was given for 12 months in combination with lifestyle modification. But month 3 is the check point. If LDL-C target was achieved at Month 3, doses remained the same. If LDL-C target was not achieved at Month 3, doses were doubled."
223756472|NCT03532620|DRUG|Atorvastatin Calcium|"In Atorvastatin treatment group, Atorvastatin calcium tablet 20mg/day was given for 12 months in combination with lifestyle modification. But month 3 is the check point. If LDL-C target was achieved at Month 3, doses remained the same. If LDL-C target was not achieved at Month 3, doses were doubled."
223756473|NCT03462238|PROCEDURE|Blood collection for Ppi assay|A 4.5 ml blood sample will be taken with a citrate vacuum tube.
223756474|NCT03462238|RADIATION|CT Scan|A scanner will be performed
223610307|NCT02246959|BEHAVIORAL|Outcome Incentive|Incentives conditional on LDL cholesterol reduction
223756475|NCT00828191|DRUG|Progesterone|25 mg, once a day, SC
223756476|NCT00828191|DRUG|Progesterone|100 mg, twice a day, vaginally
223756477|NCT02402985|OTHER|High animal protein diet group|25-30% protein, 40 % carbohydrates, 30-35 % fat over 6 weeks
223756478|NCT02402985|OTHER|High plant protein diet group|25-30% protein, 40 % carbohydrates, 30-35 % fat over 6 weeks
223756479|NCT06538272|DRUG|ONO-2910|ONO-2910 Tablet will be orally administered once daily.
223756480|NCT06538272|DRUG|Placebo|Placebo Tablet will be orally administered once daily.
223756481|NCT04227106|BIOLOGICAL|EB-101|autologous RDEB keratinocytes isolated from skin biopsies and transduced with a recombinant retrovirus containing a full-length COL7A1 expression cassette for C7
223610308|NCT01802008|PROCEDURE|3-minute withdrawal time|"For subjects randomized to the 3-minute withdrawal time, advancement to the cecum will be followed by segmental withdrawal in each of 3 segments of the examined colon. Each segment will be examined over 1 minute, followed by a second look over each segment over 2 minutes by the same endoscopist."
223610309|NCT01802008|PROCEDURE|6-minute withdrawal time|"For subjects randomized to the 6-minute withdrawal, advancement to the cecum will be followed by segmental withdrawal in each of 3 segments of the examined colon. Each segment will be examined over 2 minutes, followed by a second look over each segment over 2 minutes by the same endoscopist."
223756482|NCT03627819|DIETARY_SUPPLEMENT|Plant sterol-enriched margarine|Margarine enriched with plant sterol esters
223756483|NCT03627819|DIETARY_SUPPLEMENT|Plant stanol-enriched margarine|Margarine enriched with plant stanol esters
223756484|NCT03627819|DIETARY_SUPPLEMENT|Control margarine|Margarine without any addition
224311711|NCT05824416|DEVICE|Experimental: ALBA|"Device: Improve Upper Limb Mobility~The patients will undergo treatment with the conventional therapy, consisting of four types of exercises, including supine and seated exercises, bimanual seated activity, and bipedal exercise. In addition to training with the ALBA® device, Shoulder flexion, abduction, and external rotation, elbow flexion and extension."
223756485|NCT02459028|BEHAVIORAL|Positive Psychology intervention|"Intervention group: Participants are instructed to practice 4 out of 10 differentPositive Psychology Exercises (Gratitude, Optimism, Act of Kindness, Social Relations, Forgiveness, Flow, Savoring, Goals, Spirituality, Taking Care of the Body) for at least 15 minutes, at least one day every week including on bad days (defined as days with higher than average levels of pain intensity or feeling down in the dumps) for 8 weeks."
223756486|NCT02459028|BEHAVIORAL|Positive Psychology intervention (Control exercise)|Control group: Control Exercise (Attention Training): Participants assigned to the control group are instructed to be more attentive to their surroundings and write about three specific events or activities from the past 7 days for at least 15 minutes once a week for 8 weeks. This condition is designed to control for the effects of time and participation in an intervention activity.
223610310|NCT04157777|OTHER|Perineum massage with olive oil|"Descriptive form used for data collection included questions about women's sociodemographic features, medical and obstetric history and previous and present birthsof women participated in the study.~The Reeda Scale The scale is consisted of five parameters of healing: Redness, Edema, Ecchymosis, Discharge Approximation.~Pregnant women who came to the delivery room and met the criteria were randomly selected and assigned to experimental and control group according to age and educational status.~There was not any change in the birth process of the delivery room during data collection and the pregnant women received routine care and treatments.~REEDA scale was administered by other midwives who worked at the puerperal room where pregnant women stayed after birth and did not know their groups because those who gave vaginal birth were early discharged from the hospital as they could answer only the first three parameters of REEDA scale."
223610311|NCT01900158|DRUG|Amphinex, Gemcitabine and Cisplatin|Amphinex administration on day 0, followed by gemcitabine administration (1000 mg/m2) and laser light application (652 nm) on day 4 followed by systemic gemcitabine (1000 mg/m2) and cisplatin (25 mg/m2) given on Day 1 and Day 8 of each 21-day cycle, for up to a total of eight cycles. Either one or two PCI treatments (Amphinex, Gemcitabine and intraluminal laser light of 652nm) during the 8 cycles of chemotherapy
223610312|NCT04164134|OTHER|blood draw|"Control samples for the Rb survivor group (adult) are already available at the VUMC for the platelet study; unselected volunteers from an anti-cancer campaign. Control samples (adult) for the EV study will be collected in a blooddrive at the Essen site.~Pediatric patients. For the pediatric Rb patients, blood draw is part of standard care (3mth-4y). The control blood samples of healthy children (12) will be drawn from healthy children, where the blood draw is already part of otherwise planned care (e.g. patients which are completely healthy besides having an unrelated problem for which surgery is required). Controls will be age-matched as much as possible."
223756487|NCT01511575|GENETIC|RNA analysis|
223756488|NCT01511575|GENETIC|reverse transcriptase-polymerase chain reaction|
224311712|NCT05824416|BEHAVIORAL|Conventional Therapy|The conventionl therapy will receive conventional treatment, consisting of four types of exercises, including supine and seated exercises, bimanual seated activity, and bipedal exercise
224311713|NCT03842813|DEVICE|DES-CRE8|Polymer-free Amphilimus™ (Sirolimus + Fatty Acid) eluting coronary stent. The absence of the polymer minimizes the risk of inflammation/thrombosis, while the propriety formulation enhances drug absorption.
223610313|NCT04585425|BEHAVIORAL|Sleep hygiene advice|Participants receive standard sleep hygiene advice.
223610314|NCT04585425|BEHAVIORAL|Bedtime music listening|Participants in the intervention group listen to their preferred sleep playlist daily at bedtime for minimum 30 minutes.
223610315|NCT01811888|BEHAVIORAL|Quantitative sensory testing (QST)|
223610316|NCT03658005|OTHER|Blood sample|3 blood samples, for a maximum of 60mL, will be taken at 0-3h, 3-6h and \>6h, between two doses of ticagrelor (taken at 0 and 12 hours).
223756489|NCT01511575|OTHER|laboratory biomarker analysis|
223756490|NCT03920631|DRUG|Nivolumab|Nivolumab (1 mg/Kg or 3 mg/kg) every 2 weeks per cohort dose level and schedule
223756491|NCT03920631|BIOLOGICAL|Microtransplantation|HLA-mismatched peripheral blood stem cells
223756492|NCT02246803|PROCEDURE|CABG+Pulmonary vein isolation procedure|Coronary artery bypass (CABG) using cardio-pulmonary bypass (CBP) and occlusion. Concomitant pulmonary vein isolation in CBP prior to occlusion and CABG
223756493|NCT02246803|PROCEDURE|Isolated CABG|Coronary artery bypass (CABG) using cardio-pulmonary bypass (CBP) and occlusion.
223756494|NCT00752882|DRUG|ceftazidime|
223756495|NCT06221033|DEVICE|manual hyperinflation|Each participant will assume a relaxed comfortable in supine position. Bag valve resuscitation circuit locked at pressure 35 cm H20 will be used. Six sets of six MHI breaths will be applied. MHI breaths had a slow inspiration for three seconds duration, a three second end inspiratory pause (hold) then an uninterrupted expiration as a quick release
224311714|NCT04181749|DRUG|aspirin and atorvastatin|Patients will be randomized and prescribed either no treatment or aspirin 75mg and Atorvastatin 40mg
223756496|NCT06221033|OTHER|Diaphragmatic proprioceptive neuromuscular facilitation technique|"Rhythmic initiation technique that is derived from the PNF concept will be initiated by four 20-second manual diaphragm stimulations. After every stimulation the patient rested for one minute. Therapist's hands will be placed below the rib cage, just below the costal arches and will support patient's exhalation phase by slight lengthening his diaphragm simultaneously in posterior-superior direction using a verbal cue exhale. At the same time, the patient will verbally be encouraged to take a deep breath"
223756497|NCT06221033|OTHER|traditional physiotherapy|This group will receive the traditional medical treatment and chest physiotherapy only.
223756498|NCT04045678|DRUG|LY03003 ( Rotigotine, extended-release microspheres)|"Patients to be enrolled to 70 mg dose group will receive 14 mg in the first week, 28 mg in the second week, 42 mg in the third week,56 mg in the fourth week and then 70 mg in the next 5 weeks.~Patients to be enrolled to 84 mg dose group will receive 14 mg in the first week, 28 mg in the second week, 42 mg in the third week,56 mg in the fourth week, 70mg in the fifth week and then 84 mg in the next 5 weeks."
224311715|NCT02509299|OTHER|Physiotherapy program 1|The standard medical treatment and additionally they will receive physiotherapy. The program will be performed every day during the hospital stay and it will include global active range of motion (ROM) exercises and muscle strengthening like upper and lower limbs flexion-extension do single-leg stance, and sit to stand exercises.
223610317|NCT04212598|DRUG|Sintilimab|Patients who completed concurrent chemoradiotherapy standard dose would received the Sintilimab as a consolidate therapy for one year.
223610318|NCT01701206|BEHAVIORAL|HIV knowledge Intervention|
223610319|NCT05005481|OTHER|NIL intervention|NIL intervention will be performed on patients.
223610320|NCT05962866|OTHER|I and II. Performing Leopold Maneuvers by the pregnant|24-32 and 32-38 days of pregnancy by the pregnant woman. 1st and 2nd leoppold maneuvers are performed by the pregnant woman, 2 times between weeks.
223610321|NCT01574235|BIOLOGICAL|Nivestim®|
223610322|NCT02481739|OTHER|retrospective study|
223610323|NCT02234804|DEVICE|Xience Prime Stent|
223610324|NCT02234804|DEVICE|Medtronic Resolute Integrity stent|
223610325|NCT02234804|PROCEDURE|Angiography|
223610326|NCT02234804|PROCEDURE|OCT|
223610327|NCT03211975|OTHER|To study the evolution of the prognosis of infectious endocarditis on native valves and on prostheses|To study the evolution of the prognosis of infectious endocarditis on native valves and on prostheses
223756499|NCT04045678|DRUG|Placebo, extended-release microspheres|"Patients to be enrolled to 70 mg dose group will receive 14 mg in the first week, 28 mg in the second week, 42 mg in the third week,56 mg in the fourth week and then 70 mg in the next 5 weeks.~Patients to be enrolled to 84 mg dose group will receive 14 mg in the first week, 28 mg in the second week, 42 mg in the third week,56 mg in the fourth week, 70mg in the fifth week and then 84 mg in the next 5 weeks."
223756500|NCT04052542|BEHAVIORAL|Traditional online continuing education|30-minute, online, interactive, educational video describing the benefits of preventive post-extubation NIV, the indications and contraindications for preventive post-extubation NIV, and the value of working together as an interprofessional ICU team when implementing preventive post-extubation NIV
223756501|NCT04052542|BEHAVIORAL|Interprofessional education|One-time, 90-120-minute, in-person, interprofessional educational workshop consisting of a 30-minute didactic session and a 60-90-minute small group session
223756502|NCT04052542|BEHAVIORAL|Just-in-time education|"Just-in-time, point-of-care education provided by trained advanced practice providers who will be on-hand in the study ICU, where they will deliver the education at the bedside during rounds when a patient meets criteria for preventive post-extubation NIV"
223756503|NCT01770561|DEVICE|Integrated sensor and infusion set.|Change patients from current devices to the Integrated sensor and infusion set.
223756504|NCT00856908|DRUG|AZD1656|Tolerable dose given twice daily
223756505|NCT00856908|DRUG|Placebo|Tolerable dose given twice daily
223756506|NCT06021951|DRUG|Bempedoic Acid 180 MG Oral Tablet|Bempedoic Acid 180 MG Oral Tablet \[Nexletol\]
223756507|NCT06021951|DRUG|Bempedoic Acid/Ezetimibe 180 MG-10 MG Oral Tablet|Bempedoic Acid/Ezetimibe 180 MG-10 MG Oral Tablet \[NEXLIZET\]
223756508|NCT01712256|BIOLOGICAL|Vacc-4x|Vacc-4x is a peptide-based HIV immunotherapy administered intradermally. Vacc-4x peptides are reconstituted in sterile water.
224311716|NCT02509299|OTHER|Physiotherapy program 2|COPD patients included in this group will receive the standard medical treatment and additionally, they will receive a physiotherapy program. The program will be performed every day during the hospital stay and included neuromuscular stimulation therapy on quadriceps accompanied by lower limbs exercises
223610328|NCT04666896|OTHER|Tailored home-based exercise therapy|exercises were divided into four types: 1) shrug exercises; 2) external rotation exercises; 3) bench slides; and 4) wall slides.
223610329|NCT04666896|OTHER|Standard home-based exercise therapy|The exercise program consisted of 4 types of exercises for training 1) balance and proprioception; 2) isometric strength; 3) rotator cuff muscles; and 4) open chain elevation
223610330|NCT04185675|DEVICE|The laryngoscope used for tracheal intubation under general anesthesia for patients with expected non-difficult airway conditions.|All the patients will receive the same anesthesia induction, and are randomized to three groups to receive different types of laryngoscope for intubation. These are the direct Macintosh laryngoscope, adjustable videolaryngoscope and nonadjustable videolaryngoscope.
223610331|NCT00714415|DRUG|BeneFIX|Patients will be treated in accordance with the requirements of the labeling of BeneFIX in Germany. The dosage and duration of therapy is to be determined by the physician to meet the patients' individual needs for treatment.
223610332|NCT05465343|DRUG|Furmonertinib|Furmonertinib 160mg orally QD
223610333|NCT04270708|DRUG|Dexmedetomidine|Patients with Autism will be treated with intranasal Dexmedetomidine as a sedative for EEG
223610334|NCT04270708|DRUG|Triclofos 100 MG/ML|Patients with Autism will be treated with oral Triclofos as a sedative for EEG
223610335|NCT06236685|DEVICE|Electric impedance tomography|EIT is rarely used during general anesthesia for standard procedures. In the anesthesia arm, all patients will be monitored by EIT.
223610336|NCT03315039|DRUG|Liposomal Annamycin|2-hour intravenous infusion liposomal annamycin daily for 3 consecutive days followed by 18 days off study drug (i.e., one treatment cycle = 21 days).
223756509|NCT05832957|BEHAVIORAL|Drive fun|"The Drive Fun intervention program aims to promote the development of adaptive self-awareness and facilitate the acquisition of management strategies that foster safe and confident driving among participants. The program utilizes a driving simulator to provide a guided learning experience, which incorporates various sources of information, as well as games and thinking tasks. Additionally, participants will engage in reflective exercises that draw upon their occupational experiences and their driving performance within the simulator. Parental involvement is also incorporated to ensure ongoing support for the continued practice of learned skills."
223756510|NCT05832957|BEHAVIORAL|educational intervention|7 individual sessions of one hour at the driving lab at Tel Aviv university and 4 group sessions- 90 minutes by Zoom of group sessions of an educational intervention of safe driving according to Ministry of Education. The intervention focuses only on the cognitive aspects since it is based on imparting educational knowledge regarding safe driving with opportunities for gamified, non-driving-related activities such as board games (e.g., rush hour) and social games
223756511|NCT05832957|OTHER|No intervention|one-time short guidance on safe driving at the end of the study.
223756512|NCT01069133|DRUG|Rifaximin|550mg BID open-label
223756513|NCT01069133|DRUG|rifaximin|550mg PO BID
223756514|NCT03200925|OTHER|"Jumping into Kangaroo Care - a video created by the Ohio Department of Health"|The video is 8 minutes and 52 seconds in length. The video discusses the benefits and logistics of Kangaroo Care from professional's perspectives and from new mother's perspectives.
223756515|NCT01536431|DRUG|Pro insulin peptide|Patients will receive 10 micro gr of the peptide every 2 weeks (12 doses).
223756516|NCT01536431|DRUG|Pro insulin peptide|Patients will receive 10 micro gr of the peptide monthly (ever 4 weeks, 6 doses) and saline injections monthly alternating with the peptide (2 weeks interval between the drug and saline).
223756517|NCT01536431|DRUG|Saline|Patients will receive 0 micro gr of peptide, but have saline injections every 2 weeks (controls).
223756518|NCT03467087|DEVICE|Myopuls 2000D|Device: Myopuls 2000D (Curatec Services GmBH, 47443 Moers, Germany)
223756519|NCT02196324|DRUG|serlopitant|NK1 receptor antagonist
223756520|NCT02196324|DRUG|Placebo|Placebo
223756521|NCT00134212|DRUG|Dopexamine and norepinephrine|
223756522|NCT00134212|DRUG|Epinephrine|
223756523|NCT02964858|RADIATION|Standard Arm|Radiation will be started within 3-4 weeks of completion of chemotherapy. Computed Tomography (CT)scan will be acquired for treatment planning, which will be done using External Beam Planning System. The target volumes will be defined by clinical examination, staging Positron Emission Tomography with CT (PET-CT) and response PET-CT. The staging PET-CT will be fused and co-registered with the planning CT scans for target volume delineation. For Involved Field Radiotherapy,Clinical target volume (CTV) will include the entire nodal region depending on the site involved. For Involved Site RT , CTV will include the involved nodal volume in the staging PET-CT. For extranodal sites, the CTV will include the involved extranodal region as per the staging PET-CT. The total dose will be prescribed to the Planning Target Volume based on dose uniformity guidelines. All patients will be treated with 3 Dimensional Conformal Radiotherapy or Intensity Modulated Radiotherapy where indicated.
223756524|NCT02964858|RADIATION|Experimental Arm|Radiation will be started within 3-4 weeks of completion of chemotherapy. Computed Tomography (CT)scan will be acquired for treatment planning, which will be done using External Beam Planning System. The target volumes will be defined by clinical examination, staging Positron Emission Tomography with CT (PET-CT) and response PET-CT. The staging PET-CT will be fused and co-registered with the planning CT scans for target volume delineation. For Involved Field Radiotherapy,Clinical target volume (CTV) will include the entire nodal region depending on the site involved. For Involved Site RT,CTV will include the involved nodal volume in the staging PET-CT. For extranodal sites, the CTV will include the involved extranodal region as per the staging PET-CT. The total dose will be prescribed to the Planning Target Volume based on dose uniformity guidelines. All patients will be treated with 3 Dimensional Conformal Radiotherapy or Intensity Modulated Radiotherapy where indicated.
223756525|NCT05444361|DEVICE|Cryoneurolysis|Cryoneurolysis of the 2nd-6th thoracic intercostal nerves will be treated on the ipsilateral surgical side (bilaterally for bilateral surgical procedures): for each nerve the cryoneurolysis device will be triggered using 2 cycles of 2-minute gas activation separated by 1-minute defrost periods (Epimed) or 1 cycle of 5.5 minutes \[all but 4 participants: 064-067\] or 3 minutes \[only 4 participants 064-067; change based on new laboratory data, then changed back based on inadequate freeze\] of argon and 30 seconds of helium (Varian). For active probes, the gas will be deployed to the tip where a drop in temperature to approximately -70°C will result in cryoneurolysis.
224201034|NCT04824573|DEVICE|Inspiratory Muscle Training|Inspiratory Muscle Training (IMT) was performed with Powerbreathe Classic-Light Resistance device. To determine the intensity of the training, MIP values were measured with the help of the respiratory pressure meter-RP Check (MD Diagnostics Ltd. RP Check MIP \& MEP) device before each training. The pressure corresponding to 50 percent of the MIP value in the Powerbreathe device was determined as training workload. It was applied two days a week for four weeks, with five-set and five repetitions, for 20 minutes with 30 seconds rest in between. This inspiratory muscle training program has previously been used by several studies to improve respiratory muscle strength.
224201035|NCT04824573|OTHER|Manual Therapy|"In the manual diaphragm release technique; While the participant was breathing in, the physiotherapist raised his hand slowly to accompany the rising movement of the ribs and deepened the contact during exhalation. The maneuver was performed in two sets of 10 deep breaths.~In thoracic mobilization application; The physiotherapist, standing behind the participant, wrapped the crossed arms from his right upper arm with his left hand and performed stretching, extension, lateral flexion, and thoracic rotation with his right hand.~In HVLA thoracic manipulation; the physiotherapist, with the support hand on the participant's elbows, applied HVLA thrust in the posterior-anterior and inferior-superior directions with the help of his body while the manipulating hand was on the transverse processes.~For cervical joint mobilization; the physiotherapist was applied using the right hand in flexion, extension, right-left rotation, and lateral flexion directions."
224201036|NCT01053169|BIOLOGICAL|Beriplex® P/N|Intravenous infusion, the dosage and the frequency of administration is calculated on an individual patient basis.
223610337|NCT01576432|BEHAVIORAL|Assess pain with the NIPS score|In group 1 (BF+SSC), neonates dressed with a diaper were held in prone, in SSC with the mother; BF was started at least 5 minutes before heel lance and maintained during sampling. In group 2 (sucrose + SSC), neonates were held in prone between the mothers' breast at least 5 minutes before sampling and 2 ml 24% sucrose was given with a sterile syringe in the mouth 2 minutes before heel lance. In group 3 (SSC), neonates were held between the mother's breast as in group 2, but no sucrose was given. In group 4 (Sucrose), 2 ml 24% sucrose was administered through a sterile syringe in the mouth 2 minutes before heel lance to neonates laid on supine on a cot; the procedure was done in the presence of the mother. Mothers were allowed to speak or touch their babies in all the groups.
223610338|NCT01460758|DEVICE|Medial Frontal rTMS Double-Cone-Coil|High frequency rTMS ( Alpine Biomed Mag Pro Option) applied over medial superior frontal cortex (supplementary motor cortex) (Brodmann area 6/8),Double-Cone-water-cooled-Coil (2000 Stimuli of 10 Hz each session), 110% motor threshold.
223610339|NCT01460758|DEVICE|Left DLPFC Butterfly Coil|High frequency rTMS ( Alpine Biomed Mag Pro Option): 2000 stimuli of 10 Hz over the left DLPFC (each session), Butterfly-water-cooled-Coil, 110% motor threshold.
223610340|NCT01460758|DEVICE|Placebo Stimulation|Sham Stimulation (conventional butterfly-coil, angled 45°): left DLPFC continuous rTMS, 10 Hz, 2000 Stimuli each session, 110% motor threshold
223610341|NCT01103427|DEVICE|Internet-based behavioral coaching|"Those in the active comparator arm will benefit from automated coaching by e-mails with advice, information and support for smoking cessation. These e-mails will be adapted to their personal profile."
223756526|NCT05444361|DEVICE|Sham Comparator|Sham cryoneurolysis of the 2nd-6th thoracic intercostal nerves will be applied on the ipsilateral surgical side (bilaterally for bilateral surgical procedures): for each nerve the cryoneurolysis device will be triggered using 2 cycles of 2-minute gas activation separated by 1-minute defrost periods (Epimed) or 1 cycle of 5.5 minutes \[all but 4 participants: 064-067\] or 3 minutes \[only 4 participants 064-067; change based on new laboratory data, then changed back based on inadequate freeze\] of argon and 30 seconds of helium (Varian). However, for sham probes, the gas is not deployed to the tip and therefore there is no drop in temperature resulting in cryoneurolysis.
223610342|NCT01103427|DEVICE|SMS based coaching|Those in the experimental SMS based coaching arm will benefit from automated coaching by SMS with advice, information and support for smoking cessation. These SMS's will be adapted to their personal profile.
223610343|NCT01103427|DEVICE|SMS coaching - UNN recruited|Those in the experimental SMS based coaching arm- UNN recruited - will benefit from automated coaching by SMS with advice, information and support for smoking cessation. These SMS's will be adapted to their personal profile.
223610344|NCT01103427|DEVICE|SMS craving function - UNN recruited|Those in the experimental SMS based craving/panic function arm - will in addition to the automated coaching by SMS have a panic/craving SMS function. Thus by sending a SMS they will receive instant advise and support for smoking cessation by SMS.
223610345|NCT03029910|OTHER|Cryotherapy and eccentric exercise|12 weeks, 5 days/week, once a day, 2 exercises, 3 sets/exercise, 15 repetition/set. Of excentric exercise of foot plantar flexors. First exercise with knee in extension. Second exercise with knee in flexion. Previously subjects should cool their leg in ice water during sixteen minutes at a temperature of 8ºC (+/-2ºC)
223610346|NCT03029910|OTHER|Vibration and eccentric exercise|12 weeks, 5 days/week, once a day, 2 exercises, 3 sets/exercise, 15 repetition/set. Of excentric exercise of foot plantar flexors. First exercise with knee in extension. Second exercise with knee in flexion. During the exercise subjects will be subjected to vibration. Vibration parameters: Frequency: 35Hz, Amplitude: 4 millimeters, Force: 3,9G
223610347|NCT00612755|DRUG|Peginterferon alfa-2a + ribavirin|Peginterferon alfa-2a 180 mcg/week ribavirin 1000-1200 mg/day during 24 weeks
223610348|NCT05467384|DRUG|Amlodipine|5mg/day in two divided doses
223756527|NCT06093100|DEVICE|wearable technology|Three wearable devices
223756528|NCT04965636|DRUG|Mepolizumab|Mepolizumab will be provided in pre-filled safety syringe
224201037|NCT01053169|BIOLOGICAL|Fresh Frozen Plasma (FFP) and Beriplex® P/N|FFP is administered before Beriplex® P/N. Each treatment is given as an intravenous infusion, with the dosage of each calculated on an individual patient basis.
224201038|NCT01053169|OTHER|Fresh Frozen Plasma|Intravenous infusion, the dosage and the frequency of administration is calculated on an individual patient basis.
223610349|NCT01210898|BIOLOGICAL|Adjuvanted seasonal influenza vaccine|Full or half dose of adjuvanted seasonal influenza vaccine; Full or half dose of unadjuvanted seasonal influenza vaccine
223610350|NCT04233203|DRUG|Insulin Faster Aspart|Currently receiving Faster Aspart during 3 or more months.
223610351|NCT04233203|DEVICE|Insulin pump|Currently receiving CSII therapy during 6 or more months.
223610352|NCT02754531|DEVICE|USG|USG used was SonoSite® M-Turbo Bothell, WA, USA, probe linear (Array HFL 38 frekuensi 6-13 MHz). Internal subglottic diameter equals external diameter of the uncuffed endotracheal tube or trachea diameter, result rounded to the smallest uncuffed endotracheal tube size.
223610353|NCT02754531|OTHER|Cole Formula|Internal diameter of the uncuffed endotracheal tube equals (age in years/4) + 4mm.
223610354|NCT01764555|DRUG|acetaminophen 2 g|
223610355|NCT04516109|DEVICE|Modified hip capsule side fixed slotted cannula|Modified hip capsule side fixed slotted cannula used during surgery to allow for continued access to the hip joint.
223610356|NCT04516109|DEVICE|Modified bone graft delivery tool set|Modified bone graft delivery tool set for grafting subchrondral cysts arthroscopically during hip arthroscopy procedure.
223610357|NCT04789876|OTHER|Phosphate mobile app|The phosphate mobile app has the features of i) matching phosphate binder with dietary phosphate intake, ii) educational videos of phosphate management, iii) food database with local food items, iv) record-keeping and goal setting.
224201039|NCT03188250|BEHAVIORAL|Chama cha Mamtoto|Chama cha Mamatoto is a community-based model of peer support group in pregnancy and infancy that combines health education, relationship building and a savings and loans program, led by community health workers
224201040|NCT00956813|DIETARY_SUPPLEMENT|flaxseed|Given orally
224201041|NCT00956813|OTHER|placebo|Given orally
223610358|NCT04789876|BEHAVIORAL|One-off dietary counselling with a phosphate booklet|One-off 45-minute dietary counselling delivered by a dietitian at the baseline of the study. Patients received a complimentary phosphate booklet after the counselling session. The phosphate booklet contains similar educational information as per the phosphate mobile app excluding the matching of phosphate binder with dietary phosphate information.
223610359|NCT02951494|OTHER|AlterG Anti-gravity treadmill|Participants in this group will complete a 12 week aerobic exercise training protocol with 40% lower body weight support on an AlterG Anti-gravity treadmill
223610360|NCT00277550|DRUG|Tegaserod and Placebo|
223610361|NCT00075621|DRUG|filgrastim|16 mg/kg/day for 3 days prior to stem cell collection, through day before last collection
223610362|NCT00075621|DRUG|melphalan|200 mg/kg over 2 days
223756529|NCT06311461|PROCEDURE|Acupuncture|The acupuncturist will swab each point with alcohol. Needles will be inserted and retained for 30 minutes. Each needle will be rotated 3 times to stimulate the qi in the meridian; 10 minutes after insertion, 20 minutes after insertion, and just prior to removal at 30 minutes. Needles will be inserted using the standards of clean needle technique established by the Council of Colleges of Acupuncture and Oriental Medicine. One size acupuncture needle, 0.25 diameter × 40 mm length, will be used. All acupuncture needles are sterile, disposable, and made of surgical stainless steel with stainless steel wound heads. Sessions will be repeated twice weekly (with at least 2 off days in between) for 5 weeks (10 sessions).
223756530|NCT06311461|OTHER|Attention control|Viewing non-pain related TED talk videos over 5 weeks approximately equal to 10 hours of treatment for the acupuncture group.
223756531|NCT06501235|BEHAVIORAL|Cognitive-Behavioral Therapy (CBT)|An adaptation of the Robles and Peralta's (2010) stress management program will be followed. This program includes key techniques from the CBT approach, such as deactivation techniques, cognitive restructuring, and assertiveness training.
223756532|NCT06501235|BEHAVIORAL|Virtue-Based Intervention (VBI)|A Well-being Training based on Contemplative Practices (WTCP) (Cebolla \& Alvear, 2019; Alvear \& Cebolla, 2023) will be followed. WTCP combines mindfulness practices with various activities based on virtues such as gratitude, altruism, or compassion. This program focuses on generative or constructive meditations, and puts special emphasis on virtuous actions, emotion regulation (both positive and negative emotions) and compassion, and includes strategies from positive psychology, such as strengths-based interventions, savoring, kindness, or the three good things.
223756533|NCT04429217|OTHER|immediate post-operative complete weight-bearing after surgery|"Patients randomized to the experimental post-operative rehabilitation intervention will undergo to immediate complete weight-bearing starting immediately after surgery. Immediate complete weight-bearing consists in the possibility to undergo all the everyday activities without limiting weight-bearing and without the use of walking aids.~During the rehabilitation period, patients will wear an ankle brace (VACOankle® OPED); this will ensure the safety of the early recovery phases, protecting from dangerous movements while allowing the mobilization in the healthy range of movement."
223756534|NCT04429217|OTHER|delayed weight-bearing for 6 weeks after surgery|"Patients randomized to the control post-operative rehabilitation intervention will undergo to delayed weight-bearing starting at 6-weeks post-operatively. Delayed weight-bearing consists in the limitation of the weight-bearing to 20-30% of patient's total weight using crutches for the first 6 weeks after surgery.~During the rehabilitation period, patients will wear an ankle brace (VACOankle® OPED)."
223756535|NCT01220258|DRUG|Azithromycin ophthalmic solution, 1%|1 drop twice daily (BID) for the first 2 days and then 1 drop once daily (QD) for the remainder of treatment period (approximately 28 days total)
223756536|NCT04829487|DRUG|Ergocalciferol Capsules|Given to subjects 50,000 IU per week for 8 weeks
223756537|NCT04829487|DRUG|Placebo|Placebo capsules
223756538|NCT02925546|DRUG|GSK2798745 Micronized API without SLS and hypermellose (Tablet A)|This is an immediate release tablet containing 2.4 mg of micronized GSK2798745 API; to be administered orally with 240 mL of water under fasted/fed conditions
223756539|NCT02925546|DRUG|GSK2798745 Micronized API with SLS and hypermellose (Tablet B)|This is an immediate release tablet containing 2.4 mg of micronized GSK2798745 API with SLS and hypermellose; to be administered orally in fasted/fed conditions with 240 mL of water
223756540|NCT02925546|DRUG|GSK2798745 milled API without SLS and hypermellose (Tablet C)|This is an immediate release tablet containing 2.4 mg of milled GSK2798745 API with SLS and hypermellose; to be administered orally in fasted/fed conditions, with 240 mL of water
223756541|NCT01179971|DIETARY_SUPPLEMENT|Fish oil, gamma-linolenic acid|3 g/d DHA + EPA
223756542|NCT02207049|BEHAVIORAL|Snacking|Snacks will be provided to preschoolers, either as part of total caloric needs or above total caloric needs
223756543|NCT02207049|BEHAVIORAL|No Snacking|Caloric needs will be provided to preschoolers within three meals
223756544|NCT05294848|BEHAVIORAL|Gaze-Contingent Feedback Training|Feedback according to participants' viewing patterns, in order to modify their attention toward threat stimuli.
224311717|NCT02509299|DRUG|Standard medical treatment|"The standard medical treatment consists on:~* Inhaled bronchodilators: Short acting inhaled β2 agonists ( salbutamol and terbutaline) and anticholinergic agents (ipratropium and oxitropium bromide).~* Glucocorticoids:~Inhaled glucocorticoids including beclomethasone dipropionate, budesonide, flunisolide, fluticasone propionate and triamcinolone acetonide, depending on the expert criteria.~\- Antibiotics: The antibiotics were administered according to the GOLD criteria including the β-lactamase inhibitor and fluoroquinolones."
224311718|NCT05149677|BEHAVIORAL|Music therapy|Music therapy intervention + Standard of Care for labor pain
224311719|NCT04673682|DRUG|D309|D309(Testosterone) 1 vial, Once, IM injection
224311720|NCT04673682|DRUG|CKD-845|CKD-845(Testosterone) 1 vial, Once, IM injection
223610363|NCT00075621|PROCEDURE|autologous peripheral blood stem cell transplantation|autologous peripheral blood stem cell transplantation
223610364|NCT01461707|BEHAVIORAL|Mobile phone-based physical activity|Participants will receive the mobile phone-based physical activity program using the trial app.
224311721|NCT00019864|BIOLOGICAL|filgrastim|
224311722|NCT00019864|DRUG|cisplatin|
224311723|NCT00019864|DRUG|dexrazoxane hydrochloride|
224311724|NCT00019864|DRUG|doxorubicin hydrochloride|
224311725|NCT00019864|DRUG|leucovorin calcium|
224311726|NCT00019864|DRUG|methotrexate|
224311727|NCT00019864|PROCEDURE|adjuvant therapy|
223610365|NCT01461707|BEHAVIORAL|Activity monitor|Participants will receive an activity monitor
223756545|NCT05294848|BEHAVIORAL|Attention Bias Modification|Attention training via repeated trials of a dot-probe task intended to direct attention toward threat stimuli using threat and neutral face stimuli.
223756546|NCT05294848|BEHAVIORAL|Neutral Control|Dot-probe task using only neutral stimuli with no training toward threat
223756547|NCT05804175|DEVICE|Linshom Continuous Predictive Respiratory Monitoring|Observational study. Monitoring of Linshom, pulse oximetry and capnography data with comparison to current standard of care.
223610366|NCT03513276|DRUG|100cc of 2% ropivacaine|Multimodal analgesia + Local infiltration anesthesia
223610367|NCT03513276|DRUG|Saline Solution|Multimodal analgesia + Saline solution
223610368|NCT03513276|DRUG|Adrenaline 10mcg/ml|
223610369|NCT06324292|PROCEDURE|complete denture, CG|fabrication of conventional complete denture followed by a digital denture
223610370|NCT06324292|PROCEDURE|complete denture, DG|fabrication of digital complete denture followed by a conventional one
223610371|NCT00950313|OTHER|Self Assessment|Self assessment used to determine current risk of diabetes and likelihood of requiring further testing
223610372|NCT00950313|OTHER|Electronic risk score|Patients current risk of diabetes is determined by a electronic risk algorithm. They are then invited to attend fof further testing.
223610373|NCT03000855|PROCEDURE|EUS-guided choledocho-duodenostomy|"The CBD would be identified by a linear echoendoscope and a suitable puncture site in the bulb of the duodenum would be located. The common bile duct would be punctured with a 19-gauge needle and the position would be confirmed by aspiration of bile and contrast injection. A 0.025 or 0.035 guide wire would be passed through the needle in to the CBD. A fully covered metal stent would then be inserted after track dilation."
223610374|NCT03000855|PROCEDURE|Endoscopic retrograde cholangiopancreatography with covered metallic stent|After cannulation of the CBD, a cholangiography would be performed to assess the diameter of the CBD, the length and position of the biliary stricture. The endoscopist would decide on the appropriate size of SEMS to be placed. The stents should be visible from the duodenal lumen after deployment.
223610375|NCT05674019|OTHER|MRI exam|Brain MRI Morphometric exam
223610376|NCT01582139|DEVICE|Heart rate informed SSM+HMM|The Safety Supervision Module + Hyperglycemic Mitigation Module (SSM+HMM) of the Closed Loop is informed about heart rate during exercise. The goal is to demonstrate the feasibility of a modular insulin management system based on continuous glucose monitoring that additionally employs heart rate information to reduce exercise-related hypoglycemic episodes.
223610377|NCT00970112|PROCEDURE|Open Flap Debridement|Open flap debridement - access flap + scaling and root planning
223610378|NCT01693536|BEHAVIORAL|Lifestyle counselling|as in Arm Description
223610379|NCT00123123|DRUG|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine gluconate oral rinse
223610380|NCT00123123|DRUG|placebo|
223610381|NCT03741504|PROCEDURE|micro-osteoperforations (MOPs)|three (3) micro-osteoperforations (MOPs) in the cortical and medullar bone, distal to the upper canine. These MOPs will be at the apical, medial and gingival zone of the bone located at the distal surface of the canine in the buccal and in the palatal side. The deep of the MOPs will be at 6 mm. It is going to be done with a PROPEL
223610382|NCT03461146|DRUG|MT-6548|Oral tablet
223610383|NCT04392843|OTHER|Fasting|Subjects remain fasted prior to insulin-induced hypoglycemia.
223610384|NCT04392843|OTHER|Feeding|Subjects eat a normal breakfast and lunch prior to insulin-induced hypoglycemia.
223756548|NCT05512507|BEHAVIORAL|Physical Therapy Program|Physical Therapy Program
223756549|NCT03480672|DRUG|Pembrolizumab 25 MG/1 ML Intravenous Solution [KEYTRUDA]|intravenous application, 12 months, in 3-week cycle (q3w) 200 mg
223756550|NCT03480672|OTHER|adjuvant radiochemotherapy|adjuvant radiochemotherapy with cisplatin
223756551|NCT06670053|DRUG|Testosterone|"Clinical testosterone therapy~No research interventions will be used as a part of the study since the research is observational. Testosterone treatment will be prescribed and followed by participant's clinical physician."
223756552|NCT01719887|DEVICE|Conservative treatment|Conservative treatment with functional brace.
223756553|NCT01719887|PROCEDURE|Operative treatment|Operative treatment with open reduction and internal fixation using 4,5mm locking compression plate.
223756554|NCT01719887|OTHER|Physiotherapy|Physiotherapy is arranged to both groups at 3 and 9 wks.
223756555|NCT06653894|PROCEDURE|PENG block with 0.25% bupivacaine.|In the PENG group, patients were placed in the supine position. A convex ultrasound probe was positioned under sterile conditions on the operated side, aligned with the iliac bone below the anterior superior iliac spine (ASIS). The anterior inferior iliac spine (AIIS), iliopubic eminence (IPE), iliopsoas muscle, and its tendon were identified. Using an in-plane technique, a 22G 100-mm peripheral block needle was advanced toward the IPE, targeting the space between the iliopsoas muscle tendon and the IPE. Proper placement was confirmed via hydrodissection. Subsequently, 20 mL of 0.25% bupivacaine was administered slowly, with aspiration performed every 5 mL to avoid intravascular injection. The correct spread of the local anesthetic was verified via ultrasound, confirming elevation of the iliopsoas tendon.
224311728|NCT00019864|PROCEDURE|conventional surgery|
223610385|NCT05336747|BEHAVIORAL|Voice lessons|12 x 60 minute one-on-one vocal training lessons, once weekly in person or over videoconferencing, and additional 60 min per week home training of vocal pitch control using an internet based vocal pitch app.
223610386|NCT05586984|PROCEDURE|Laparoscopic uterine lateral suspension|Laparoscopic uterine lateral suspension done with four trocar sites. Fix a 1.5cm\*32cm mesh to uterus at anterior lower segment and bilateral round ligaments by non-absorbable sutures (Surgilon 2-0, Ethicon, Norderstedt, Germany), and to lateral abdominal fascia by non-absorbable sutures (Prolene 1-0, Ethicon, Norderstedt, Germany). Reperitonization done to avoid mesh exposure in peritoneal cavity. Concomitant anterior and posterior colporrhaphy may be performed.
223610387|NCT05586984|PROCEDURE|Transvaginal sacrospinous fixation|Transvaginal sacrospinous fixation done by hand suturing uterus to right sacrospinous ligament with non-absorbable suture (Prolene 1-0, Ethicon, Norderstedt, Germany). Concomitant anterior and posterior colporrhaphy may be performed.
223610388|NCT02636205|DEVICE|Armeo therapy|Participants will receive 18 sessionsx30 mins of ArmeoSpring therapy over 6weeks.
223610389|NCT00096434|DRUG|sorafenib tosylate|Given orally
223610390|NCT00096434|OTHER|laboratory biomarker analysis|Correlative studies
224311729|NCT00019864|PROCEDURE|neoadjuvant therapy|
224311730|NCT01902368|OTHER|gluten free diet|
223610391|NCT02753426|DRUG|Doxycycline|Doxycycline 20mg capsule by mouth, twice a day for 30 days.
223756556|NCT06653894|PROCEDURE|anterior quadratus lumborum block|"The quadratus lumborum and psoas major muscles, along with the transverse process of the L4 vertebra, were visualized in the midaxillary line using an in-plane technique. A 22G, 100-mm peripheral block needle (Stimuplex® Ultra; B. Braun Melsungen AG, Melsungen, Germany) was advanced into the subfascial plane between the quadratus lumborum and psoas major muscles, and 1-2 mL of 0.9% saline was injected to confirm correct placement via hydrodissection.~Following this, 20 mL of 0.25% bupivacaine (Buvasin® 0.5%, VEM, Tekirdağ, Turkey) was injected incrementally, with aspiration performed every 5 mL. Proper spread of the local anesthetic was confirmed by ultrasound visualization of a hypoechoic distribution between the fascial planes."
223756557|NCT05462340|DRUG|[18F]ASEM|\[18F\]ASEM demonstrated excellent imaging properties, as was recently confirmed by others. \[18F\]ASEM is the 1st validated α7 human PET radiotracer to examine α7-nAChR characteristics in the living brain of SCZ patients. Previous α7 studies in the SCZ literature were done using brains harvested post-mortem, and under variable storage conditions. The proposed studies will also determine α4β2-nAChR \[18F\]AZAN binding characteristics in the same subjects who complete α7-nAChR PET studies with \[18F\]ASEM, which will be highly significant for understanding these receptors in SCZ.
223756558|NCT05462340|DRUG|[18F]AZAN|The most widely used PET radioligand for human imaging of α4β2-nAChR is 2-\[18F\]FA. Because 2-\[18F\]FA exhibits very slow brain kinetics, the investigators developed \[18F\]AZAN, a highly α4β2 specific tracer with optimal brain kinetics. Therefore, the proposed studies will utilize \[18F\]AZAN to determine α4β2-nAChR \[18F\]AZAN binding characteristics in the same subjects who complete α7-nAChR PET studies with \[18F\]ASEM, which will be highly significant for understanding these receptors in SCZ.
223756559|NCT06666491|DRUG|Tafenoquine|A single dose of TQ will be administered orally on Day 1 or Day 2.
223756560|NCT06666491|DRUG|Primaquine|A single dose of PQ will be administered orally, daily, on Day 1 or 2 to Day 14 (or Day 15 if PQ started on Day 2).
223756561|NCT06666491|DRUG|Chloroquine|A single dose of CQ will be administered orally, daily, on Days 1 to 3.
223756562|NCT02814786|RADIATION|MRI scanner|"This examination is divided in 2 parts:~* Passive movement: after placing the ankle joint in the fixture, each child will be asked to relax the lower limb musculature and then the fixture will be cyclically moved by a technician at a speed which does not trigger spasticity.~* Active movement: no technician will be present and children will be asked to perform voluntary plantar-dorsiflexion between the extreme positions on the beat of the metronome."
224311731|NCT06007911|DRUG|Navitoclax Dose Level -1|25 mg by mouth on days 1-7.
223610392|NCT02753426|DRUG|Placebo (for Doxycycline)|Inactive pill manufactured to mimic Doxycycline 20mg. Capsule by mouth, twice a for 30 days.
223610393|NCT03573323|DRUG|Ixekizumab|Administered SC
223610394|NCT03573323|DRUG|Guselkumab|Administered SC
223610395|NCT03573323|DRUG|Placebo|Administered SC
223610396|NCT04354662|DRUG|Toripalimab|240mg d1
223610397|NCT04354662|DRUG|Docetaxel|50mg/m2, d1;
223610398|NCT04354662|DRUG|Fluorouracil|2600 mg/m², d1
223610399|NCT04354662|DRUG|Leucovorin|200 mg/m², d1
224311732|NCT06007911|DRUG|Navitoclax Dose Level 0|50 mg by mouth on days 1-10.
223610400|NCT04354662|DRUG|Oxaliplatin|85 mg/m², d1
223610401|NCT06555809|DRUG|Artesunate Injection|Additional blood sample will be collected when other standard of care blood specimens are collected during the 2-day period after the start of intravenous artesunate treatment.
223610402|NCT05921760|DRUG|Ivosidenib|ivosidenib taken once daily
223610403|NCT05921760|DRUG|Recommended Combination Dose (RCD) of ivosidenib|The RCD of ivosidenib taken once daily
223610404|NCT05921760|DRUG|Nivolumab|Nivolumab taken by intravenous infusion
223610405|NCT05921760|DRUG|Ipilimumab|Ipilimumab taken by intravenous infusion
223610406|NCT03209531|BEHAVIORAL|Operant Conditioning|Active encouragement and feedback to increase motor evoked response when stimulated.
223610407|NCT03209531|BEHAVIORAL|Control|Absence of active encouragement and feedback to increase motor evoked response when stimulated.
223610408|NCT03209531|DEVICE|Single Pulse Transcranial Magnetic Stimulation|Transcranial magnetic stimulation to elicit a motor evoked response from the quadriceps muscles.
223756563|NCT02814786|OTHER|Gait analysis|For gait evaluation, each child will undergo a lower limb gait analysis in a motion analysis laboratory equipped with Camera system and 4 AMTI force plates Sixteen reflective markers will be placed on the lower limbs. Each child will walk bare foot and gait will be recorded during each of five 10-meter trials. A velocity of 1 m/s (+/- 10%) will be imposed using a stop watch in order to eliminate the influence of velocity on gait kinematics and kinematics while comparing across subjects. Each child will be allowed to walk for 5 minutes after attaching the reflective markers and before recording the gait data. In addition to the joint kinematics, joint powers and moments will be computed using an inverse dynamics method.
223756564|NCT05969314|DRUG|Cannabis capsules|Cannabis capsules containing 5 mg of THC and CBD each or 2.5 mg of THC and CBD each.
223756565|NCT03974750|DEVICE|Bimanual motor skill learning with the REAplan(R) rehabilitation robot|REAplan(R) rehabilitation robot : training to perform complex, coordinated, bimanual movements
223756566|NCT06607718|OTHER|Resistance Training|Resistance training for elderly patients in the acute care unit.
224311733|NCT06007911|DRUG|Navitoclax Dose Level 1|75 mg by mouth on days 1-10.
224311734|NCT06007911|DRUG|Navitoclax Dose Level 2|100 mg by mouth on days 1-10.
224311735|NCT06007911|DRUG|Venetoclax Dose Level -1|400 mg by mouth on days 1-7.
223610409|NCT05981547|DEVICE|Libre 3 continuous glucose monitoring sensor|Libre 3 CGM sensor applied to women prior to their Oral Glucose Tolerance test.
223610410|NCT02303249|OTHER|Review of discharges and cross-sectoral video conferencing immediately after discharge|The intervention is video conference which is randomized and is an intervention that is assigned by the investigator.
223610411|NCT00835250|PROCEDURE|Transvaginal hybrid NOTES cholecystectomy|Cholecystectomy performed by using a combination of working tools inserted through the entry port for the minilaparoscopy and the videogastroscope, inserted into peritoneal cavity by transvaginal approach. The gallbladder is removed transvaginally through the videogastroscope.
223610412|NCT00835250|PROCEDURE|Cholecystectomy|Extirpation of the gallbladder by a surgical procedure
223610413|NCT01865227|BEHAVIORAL|Group Counseling|
223610414|NCT03202563|DRUG|Gemigliptin 50mg|For patients who have been randomized to Gemigliptin(Experimental arm), the patients continue to take a gemigliptin 50mg 1 tablet by once daily during study treatment period(Visit 3(day 1)\~Visit 6(day 91))
223610415|NCT03202563|DRUG|Dapagliflozin 10mg|For patients who have been randomized to Dapagliflozin(Active Comparator arm), the patients continue to take a dapagliflozin 10mg 1 tablet by once daily during study treatment period(Visit 3(day 1)\~Visit 6(day 91))
223610416|NCT03202563|PROCEDURE|Diet/exercise questionnaire|"doing exercise with about intermediate intensity(50\~70%) for ≥150minutes in total over at least 3 times(every other day) weekly should be recommended and regular diet without greater changes in life style as much as possible during the whole study period.~the questionnaire regarding diet/exercise will be collected at -day 6, day 1, day29, day85, day 91"
223610417|NCT03202563|DEVICE|Continuous Glucose Monitoring System(CGMS)|For patients who have been screening completely, the subjects will be attached CGMS(ipro-2) twice from Visit 2(-day 6) to Visit 3(day 1) and Visit 5(day 85) to Visit 6(day 91)
223610418|NCT03202563|DRUG|Metformin|For patients who have been taking metformin, the patients who had taken at least 1000 mg of metformin daily and continue the same dosage and administration as before participant in the study
223610419|NCT06363734|DRUG|Osimertinib plus Dalpiciclib|osimertinib 80mg daily plus dalpiciclib 125mg daily for 21 days followed by 7 days off in each 28-day treatment cycle
223610420|NCT05543902|BEHAVIORAL|Breastfeeding Problems Management Model (BPMM)|The BPMM was composed of interventions with the leadership of a nurse and included topics of the early postpartum period; postpartum 1st, 2nd, 6th, and 8th weeks; increasing breastfeeding motivation and breastfeeding success; and preventing and eliminating breastfeeding problems. The components of the model included meeting women face-to-face, giving education using a booklet, providing breastfeeding consultancy on the phone, and home visits.
223610421|NCT02432417|DRUG|Chloroquine|CQ will start with one week before the start of radiotherapy and end on the last day of radiotherapy.
223610422|NCT06345547|OTHER|ultrasound|"Ultrasound of m. quadriceps and m. thenar All ultrasound measurements will be performed in triplicate, with the average of the scores used in final analyses. Four parameters will be evaluated: muscle thickness, muscle cross sectional area, pennation angle and echo intensity (gain, depth and frequency will be kept constant).~Hand grip strength measurement: measurement by an electronic hand dynamometer DynEx1TM (MD Systems, Inc. Ohio, USA). The recommendations for the handgrip strength test of the American Society of Hand Therapists will be followed: The maximum of the three values will be considered for analysis."
223610423|NCT03508934|DEVICE|GTS (Continuous Glucose Monitoring)|Hospitalized patients with DM2 will be monitored with Glucose Telemetry System (GTS)
223610424|NCT03508934|OTHER|POC (Point of Care)|Hospitalized patients with DM2 will be monitored with POC (Point of Care) blood glucose levels.
223610425|NCT02545608|DEVICE|Restylane Vital|
223610426|NCT03311165|OTHER|no intervention|no intervention was given
223610427|NCT00934765|BEHAVIORAL|weight loss|self-directed weight loss, guided weight loss, weight loss by gastric by-pass surgery
223610428|NCT05947864|BIOLOGICAL|Biological samples (blood and oral fluid)|"For the study population (allo-HSCT recipients): 4 visits with biological sampling (blood and oral fluid) at each visit:~* Visit V1 (inclusion visit = D1): immediately before the first dose of MMR (dose-1),~* Visit V2 (D1 + 35 (+/-7) days): immediately before the second dose of MMR (dose-2)~* Visit V3 (D1 + 70 (+/-14) days)~* Visit V4 (D1 + 365 (+/-90) days) For healthy volunteers: a single visit (V1) with biological sampling (blood and oral fluid)"
223610429|NCT01034930|PROCEDURE|Insertion of dental implants|Each patient will receive 2 screw-type Straumann (Institut Straumann AG, Basel, Switzerland) standard implants Ø4.1 mm, with SLA surface in the canine region of the mandible with an interconnecting line approaching parallelism with the terminal mandibular hinge axis, according to a standard surgical protocol.
223610430|NCT04161937|BEHAVIORAL|Behavioural Intervention|Behavior intervention will comprise of combination of intensive education session, group counseling, goal setting and monitoring based on the Diabetes Prevention Program (DPP).The curriculum includes 24 sessions: 16 core sessions weekly during the first four months of the program followed by a monthly maintenance sessions.
223610431|NCT05594407|DRUG|dexmedetomidine-ketamine-lidocaine|In the DKL group, patients will be administered in a total volume of 20 mL,1mL/10 kg of the solution containing ketamine, lidocaine and dexmedetomidine at predefined concentrations. As maintenance, they will be receiving 1mL/10kg/h of the aforementioned solution
223610432|NCT05594407|DRUG|Remifentanil|In the Remifentanil group, patients will be administered in a total volume of 20 mL, 2 mcg/kg of fentanyl. As maintenance, they will be receiving 1 mL/10kg/h of a remifentanil solution
223610433|NCT02949999|DRUG|Voclosporin|
223610434|NCT00137514|DRUG|chloroquine|
223610435|NCT00137514|DRUG|amodiaquine|
223610436|NCT03610191|DIAGNOSTIC_TEST|Serum biomarker tests|Blood was collected at preoperatively, immediately after operation and 24 h after operation in patients from the surgical group but not volunteers. Serum MD2, CysC, DNA methylation marker and SNP mutation sites on CTNNA2 gene were test.
223756567|NCT06607718|DIETARY_SUPPLEMENT|Oral Nutritional Supplementation|To receive two daily packs of a hypercaloric and hyperproteic oral nutritional supplement for 3 months.
223756568|NCT06607718|OTHER|Control Group|No intervention
223756569|NCT06586281|DRUG|Guselkumab|This is a longitudinal study consisting of a two-time visit by psoriatic arthritis patients. The aim of the study is to determine the effect of biological therapies in liver disorders in patients with psoriatic arthritis.
223756570|NCT06598124|OTHER|Investigational Product (IP)|1 single dose of IP consisting in 400 mL of milk with low lactose content and GOS.
223756571|NCT06598124|OTHER|Comparator Product (CP)|1 single dose of CP consisting in 400 mL of milk with lactose
223756572|NCT04287738|BEHAVIORAL|Navigated Care|Telephone-based collaborative dementia care was delivered by a trained care team navigator, who provided education, support and care coordination with a team of dementia specialists (advanced practice nurse, social worker, and pharmacist). For more details, please see references below.
223756573|NCT03521986|PROCEDURE|Subxiphoid uniportal VATS|Patients were placed in a supine position, and the operating table was manipulated as needed to elevate the appropriate side of the body for surgery. The surgical procedures followed principles of pulmonary resections
223756574|NCT03521986|PROCEDURE|Intercostal uniportal VATS|The surgical procedures followed principles of pulmonary resections
223610437|NCT03610191|BEHAVIORAL|Neuropsychological battery tests|both surgical patients and volunteers will accept three times of NPB tests. For surgical patients the tested time point are preoperative, one day before discharge and 3 months after surgery. For volunteers the tested time interval would be similar to that of surgical patients.
223610438|NCT03610191|PROCEDURE|Cardiac surgery|patients scheduled for cardiac surgery will accept the surgical procedure.
223610439|NCT05375227|OTHER|Teeth brushing|The participants will be invites to brush their teeth twice a day for 3 months using either an electric toothbrush or a mannual toothbrush and low abrasivity toothpaste
223610440|NCT04764513|BIOLOGICAL|Ex-vivo expanded γδ T cell infusion|"Phase 1: Patients receive ex-vivo expanded γδ T cell (Dose escalation, 3 cohorts, x5 dose increments between cohorts, 2×10\^6、 1×10\^7 and 5×10\^7 of cells per kg of body weight).~Phase 2: Patients receive ex-vivo expanded γδ T cell at the maximum tolerated dose determined in Phase 1."
223610441|NCT00238979|DRUG|Enteric-Coated Mycophenolate Sodium (EC-MPS)|
223610442|NCT01964417|DRUG|Colonoscopy after bowel cleansing|
223610443|NCT04818970|DEVICE|Narrow Band ultraviolet B-Band Light|Daily doses of NB-UVB for 8 consecutive days.
223610444|NCT04818970|DEVICE|non Narrow Band ultraviolet B-Band Light|Daily doses of non-NB-UVB for 8 consecutive days.
223610445|NCT05988879|DRUG|Peginterferon alfa-2b Injection|The pegylated interferon α-2b injection is administered subcutaneously at a dose of 180ug once a week.
223610446|NCT02577692|OTHER|Oxygen|breathing oxygen
223610447|NCT02577692|OTHER|Ambient|breathing ambient air
223610448|NCT02203695|DRUG|Enzalutamide|Enzalutamide (MDV3100) 160 mg PO once daily for 6 months (2 months prior to SRT, 2 months during SRT and 2 months following SRT)
223610449|NCT02203695|RADIATION|SRT|Salvage radiation therapy (3D-CRT (Three dimensional conformal radiation therapy)/IMRT) 66.6-70.2 Gy given 1.8 Gy M-F for 37 -39 fx
223610450|NCT02641431|PROCEDURE|mapping/ablation|Mapping/ablation procedures will be performed under general anesthesia. After femoral venous access and percutaneous epicardial access, a multipolar catheter will be positioned at the right ventricle apex. High-density endocardial and epicardial electroanatomical maps will be performed using the CARTO3 system to define areas of delayed fragmented prolonged potentials during stable sinus rhythm and during spontaneous or ajmaline-induced type 1 BrS ECG pattern. Ajmaline (1mg/Kg in 5 minutes) will be used for the provocative test. Complete endo and epicardial maps will be obtained to ensure reconstruction of a 3-dimensional geometry of the cardiac chambers and to identify areas of abnormal electrograms as characterized by prolonged fragmented ventricular signals
223610451|NCT02641431|DRUG|Ajmaline|Epicardial mapping will be performed before and after ajmaline (1mg/Kg in 5 minutes).
223610452|NCT02641431|PROCEDURE|ablation|Radiofrequency will be delivered on areas of the abnormal electrograms using an externally irrigated 3.5-mm tip ablation catheter.
223610453|NCT02641431|PROCEDURE|mapping|A re-map focusing on the targeted area will be obtained after ablation. Re-mapping and ajmaline reinfusion will be used to confirm the elimination of all the abnormal electrogram and BrS-ECG pattern disappearance.
223610454|NCT01732276|DRUG|gefitinib|
223610455|NCT00904735|DRUG|hydroxyurea|Given orally
223610456|NCT00904735|DRUG|imatinib mesylate|Given orally
223610457|NCT04869540|OTHER|Usual care|Evidence based care for transition-aged youth (TAY) with ASD.
223756575|NCT07099300|DIAGNOSTIC_TEST|Abdominal Radiography|Obtain plain film radiographs 3 times after adminstration of WSC
224201042|NCT04797637|DEVICE|ABBy® Adjustable Panniculus Retractor for Wound Care|The ABBy (G-Squared Medical, Brentwood, TN) is an extended-wear panniculus retractor/tissue stabilizer that is intended for use postoperatively after abdominal procedure. It is placed directly onto patient skin, superior to a transverse incision, and is then used to elevate redundant tissues away from an incision or wound (https://www.gsquaredmedical.com/How-it-Works.html). The ABBy can be removed and replaced by patients and can be used for up to 10 days. This study aims to assess the effect of ABBy use on postoperative pain, pain medication requirement, and patient satisfaction, when used as a patient-positioning device in women following cesarean delivery.
224201043|NCT02010346|PROCEDURE|Early headgear treatment|The treatment with headgear is done as early treatment, beginning at ages 7-8 (Arm 1), or later, durning the maximal growth (arm 2)
224201044|NCT00120380|DRUG|Aerosolized iloprost|
224201045|NCT00120380|DRUG|Placebo|
224201046|NCT00170898|DRUG|Lumiracoxib|
224201047|NCT05173922|BEHAVIORAL|Safety in Dementia|Safety in Dementia is an online tool that, in a stepwise fashion, guides a caregiver individual through decisions related to firearm access for a person with dementia. It includes information and a comparison of the options and their risks and benefits. It guides the caregiver through clarification of personal feelings and values and identifying their decision/plan. The control group will view national Institute on Aging Home Safety Checklist.
224201048|NCT01321970|PROCEDURE|Stress ultrasound|Qualitative interpretation of the left ventricular wall motion abnormalities is performed in real time in the resting phase and during pharmacological stress. The translation of quantitative data is then performed for each of the 17 segments on a bulls-eye pattern identical to that of scintigraphy.
224311736|NCT06007911|DRUG|Venetoclax Dose Levels 0 to 2|400 mg by mouth on days 1-14.
224311737|NCT06007911|DRUG|Cladribine|5 mg/m\^2 intravenously days 1-5.
223610458|NCT04869540|OTHER|'Got Transition' toolkit and resources|Providers will be trained in the 'Got Transition' toolkit (the systems level component of the intervention) and have access to web-based transition resources.
223610459|NCT04869540|BEHAVIORAL|PSE intervention|A family-based problem solving education (PSE) intervention.
223610460|NCT03655041|DIETARY_SUPPLEMENT|Beta-alanine|Beta-alanine in sustained-release tablets to increase muscle carnosine content
223610461|NCT03655041|DIETARY_SUPPLEMENT|Placebo|Maltodextrin is used as a placebo as it does not lead to any increases in muscle carnosine
224201049|NCT01321970|PROCEDURE|Scintigraphy|Image acquisition is synchronized to the electrocardiogram. The tomographic sections are represented in the 3 directions of space, the analysis is also done on the classical representation in 17 segments. (Typically used in ultrasound perfusion scintigraphy or PET).
224311738|NCT06007911|DRUG|Cytarabine (Cladribine Low Dose Cytarabine Backbone)|20 mg/m\^2 subcutaneous days 1-10.
224311739|NCT06007911|DRUG|Cytarabine (CLAG-M Backbone)|1.5 g/m\^2 intravenously days 1-5.
224311740|NCT06007911|DRUG|Mitoxantrone|10 mg/m\^2 intravenously days 1-3.
224311741|NCT06007911|DRUG|Granulocyte Colony-Stimulating Factor|300 mcg subcutaneously days 1-5.
224311742|NCT03634475|DRUG|PP-001|Drug - no placebo
224311743|NCT04293796|PROCEDURE|Vacuum-assisted biopsy|The vacuum-assisted (7-10G), minimal invasive biopsy (VAB), either guided by ultrasound, after neoadjuvant systemic treatment on patients with clinical complete response on primary breast cancer management we recommend to take at least 12 biopsies with 7-10G needle sizes with sentinel lymph node biopsy.
223610462|NCT01669486|OTHER|CPOT, BPS|Scoring pain of the patients during nurses activity in ICU, in particular before and after nurses manoeuvers.
223610463|NCT02691559|DEVICE|Amniotic fluid analysis by blood gas device|Amniotic fluid analysis by blood gas device in maternal inflammation group vs normal pregnancy group
223756576|NCT05550623|DEVICE|Tourniquet|Tourniquet use in transfemoral amputation.
223610464|NCT01450865|DRUG|flupirtine|Potassium channel opener (SNEPCO)
223610465|NCT00166829|DRUG|sirolimus, tacrolimus, mycophenolate mofetil|
223756577|NCT07101406|OTHER|Türkiye Nutrition Guideline Diet|A diet structured according to the Türkiye Nutrition Guideline (TÜBER) for pregnant women, consisting of 45-60% carbohydrates, 12-20% protein (minimum 70 g), and 20-35% fat. Diets were tailored weekly based on blood glucose levels and individual dietary intake records.
223756578|NCT07101406|OTHER|DASH Diet|A dietary plan based on DASH guidelines: 45-60% carbohydrates (≥175 g), 12-20% protein (≥70 g), 20-35% fat (≤6% saturated), ≤2300 mg sodium, ≥4700 mg potassium, ≥1250 mg calcium, ≥500 mg magnesium. Includes low-fat dairy, lean meats, fruits/vegetables, and nuts/seeds.
223756579|NCT07101289|BEHAVIORAL|Personal health planning and nutritional coaching|Behavioral support will be offed by ZealCare, an evidence-based, virtual coaching behavioral support program for patients with chronic conditions.
223610466|NCT02738749|DEVICE|Implantable cardioverter-defibrillator (ICD)|Patients with newly implanted implantable cardioverter-defibrillators (ICDs) for primary prevention will be enrolled.
223610467|NCT01204749|DRUG|AMG 386|Weekly Intravenous (IV) AMG 386 15 mg/kg
223610468|NCT01204749|DRUG|AMG 386 Placebo|Weekly Intravenous (IV) placebo 15 mg/kg
223610469|NCT01204749|DRUG|Paclitaxel|Paclitaxel 80 mg/m2 intravenous (IV) weekly (3 on/1 off)
223610470|NCT01204749|DRUG|Paclitaxel|Paclitaxel 80 mg/m2 intravenous (IV) weekly (3 on/1 off)
223610471|NCT02650765|OTHER|Indications for head CT imaging after acute head injury|Indications for head CT imaging after acute head injury as per the Scandinavian guidelines for initial management of minimal, mild and moderate head injuries in adults.
223610472|NCT02996149|PROCEDURE|Endoscopic lung volume reduction coil treatment|
223610473|NCT04775563|OTHER|COVID-19 vaccine hesitancy scale in rheumatic diseases|The instrument was developed by Freeman et al, prior to its application, translation, cultural adaptation, and validation were performed.
223610474|NCT04775563|OTHER|COVID-19 vaccine hesitancy associated factors|The instrument includes questions about the doctor-patient relationship, perception of the COVID-19 vaccine, perception of risk of COVID-19 infection, perception of the severity of the pandemic in Mexico, perception of the severity of their rheumatic disease, perception of the control of comorbidities, perception of the intensity of the immunosuppressive treatment, positioning of the patient towards vaccines for COVID-19
223610475|NCT06264739|DRUG|esp Dexmedetomidine (dekstomid)|After anesthesia and surgical procedures, bilateral ESP block will be applied under ultrasonography guidance from the midline 3 cm lateral from the T10 level. After cleaning the area with povidone-iodine before the block, the T10 transverse protrusion will be determined using a linear ultrasound probe. Local anesthetic will be applied between the transverse process and the erector spinae muscle with the help of an insulated needle designed for peripheral block procedures. The location of the needle will be confirmed by hydrodissection with physiological saline without local anesthesia. After the location of the needle is confirmed, 20 ml of LA and saline mixture will be applied and the same process will be repeated in the contralateral side. Of the total 40 ml LA, 20 ml will consist of bupivacaine 0.5% (marcaine), 10 ml will consist of lidocaine 2% (aritmal), and 10 ml will consist of physiological saline.
223610476|NCT06264739|DRUG|esp remifentanyl (ultiva)|After anesthesia and surgical procedures, bilateral ESP block will be applied under ultrasonography guidance from the midline 3 cm lateral from the T10 level. After cleaning the area with povidone-iodine before the block, the T10 transverse protrusion will be determined using a linear ultrasound probe. Local anesthetic will be applied between the transverse process and the erector spinae muscle with the help of an insulated needle designed for peripheral block procedures. The location of the needle will be confirmed by hydrodissection with physiological saline without local anesthesia. After the location of the needle is confirmed, 20 ml of LA and saline mixture will be applied and the same process will be repeated in the contralateral side. Of the total 40 ml LA, 20 ml will consist of bupivacaine 0.5% (marcaine), 10 ml will consist of lidocaine 2% (aritmal), and 10 ml will consist of physiological saline.
223756580|NCT07101289|OTHER|Prescription Produce|Eat Well is a prescription produce program that provides a reloadable, restricted use debit card to participants to purchase fresh, frozen, or canned fruits, vegetables, and legumes at grocery stores.
224311744|NCT04416165|DIAGNOSTIC_TEST|18F-FDG and 68Ga-DOTA-FAPI -04 PET/CT|Each subject receive a single intravenous injection of 18F-FDG and 68Ga-DOTA-FAPI-04, and undergo PET/CT imaging within the specified time.
224311745|NCT02276950|PROCEDURE|Coronary artery bypass surgery|Primary isolated coronary artery bypass surgery with or without use of cardio-pulmonary bypass
224311746|NCT02276950|PROCEDURE|Heart valve surgery|Heart valve surgery, aortic valve replacement or other heart valve procedures
224311747|NCT00294775|DRUG|Candesartan|
224311748|NCT06389695|DRUG|68Ga-NYM032 injection|The radiation dose is about 3-6 mCi for a single patient.Using a syringe to withdraw 68Ga-NYM032 injection, the dose will be administered via an intravenous injection and the injection time will be about 45-60 seconds.
224311749|NCT05377892|OTHER|Dietary protein|High protein followed by reduced protein diet
224311750|NCT05991648|PROCEDURE|Kangaroo Care (skin-to-skin contact)|Skin-to-skin contact between the mother and the child. The naked newborn, wearing only a diaper and a hat, is placed in a vertical position in direct contact between the mother's breasts. An elastic fabric support (made of cotton or synthetic elastic fiber) will be used to facilitate the position.
224311751|NCT02727881|DRUG|Squalamine lactate ophthalmic solution, 0.2%|Squalamine lactate ophthalmic solution, 0.2%
224311752|NCT02727881|DRUG|Placebo Ophthalmic solution|Placebo Ophthalmic solution
224311753|NCT02727881|DRUG|ranibizumab|ranibizumab
223756581|NCT07109960|OTHER|Isometric exercise and hand reflexology|"Each participant in the isometric exercise group receives included ankle exercises, knee workouts, head exercises, static abdominis exercises, and sustained hand grip exercises. Every contraction lasted for 10 seconds, 10 repetitions, two IE sessions over a period of three days. Each IE session lasted between 25 and 35 minutes.~Each participant in the hand reflexology group underwent two the sessions of hand reflexology. Each session had a duration of 15 minutes, which was then followed by a five-minute period of rest.~While isometric exercise- hand reflexology experimental group was given for the participant, the same intervention of isometric exercise and hand reflexology groups Furthermore, no interventions were done for the control group (received routine care only)."
223756582|NCT07109544|OTHER|Breathing Therapy|The patients in the control group will be receiving breathing therapy by a certificated clinical nurse
223756583|NCT07110415|DRUG|Yangxinshi tablet|"Basic treatment: All patients received a conventional treatment regimen, including outcome-improving drugs (aspirin, β-blockers, statins, and angiotensin-converting enzyme inhibitors (ACEIs)) and symptom-relieving drugs (nitrates, calcium antagonists, and diuretics).~Trial drug: Yangxinshi tablet, 3 tablets/3 times a day, taken orally"
223756584|NCT07110415|DRUG|Blank control|"Basic treatment: All patients received a conventional treatment regimen, including prognosis-improving drugs (aspirin, β-blockers, statins, and ACEIs) and symptom-relieving drugs (nitrates, calcium antagonists, and diuretics).~Trial drug: Blank control"
223756585|NCT07108998|DRUG|Epcoritamab|Epcoritamab is the investigational product under study in combination with SOC drugs in this protocol. During C1, epcoritamab will be initiated using step-up dosing (SUD) C1D1 .16mg, C1D8 .8mg, C1D15 3 mg, C1D22 24 mg vs 48 mg (full dose) during safety lead in to determine the RP2D. On Cycles 2-3 the RP2D (24mg vs 48 mg) will be administered on Days 1, 8, 15, 22. Then Cycles 4-9 RP2D will be administered on Days 1 \& 15. Then Cycle 10-12 RP2D on Day 1 of each cycle. Epcoritamab is administered subcutaneously. The SOC BTKi are oral medications administered daily during the trial period.
223756586|NCT07109466|OTHER|Mulit-modality Balance Intervention|Participants will attend a virtual group balance class that focuses on movement and obstacle negotiation 3 times per week for 3-months
223756587|NCT07109466|OTHER|Gerofit|Participation in a virtual wellness program that consists of a warm up, aerobic training, and general strength training 3-times per week for up to 12 months
223756588|NCT07108985|DRUG|Sitagliptin 100 mg|Sitagliptin 100 mg, taken once daily for 24 weeks.
223756589|NCT07108985|DRUG|Sitagliptin 100 mg + Dapagliflozin 10 mg|Sitagliptin 100 mg + Dapagliflozin 10 mg, taken once daily for 24 weeks.
223756590|NCT07108985|DRUG|Sitagliptin 100 mg + Dapagliflozin 10 mg|Sitagliptin 100 mg + Dapagliflozin 10 mg, taken once daily for 24 weeks.
223756591|NCT07108985|DRUG|Sitagliptin 100 mg + Dapagliflozin 10 mg + Lobeglitazone 0.5 mg|Sitagliptin 100 mg + Dapagliflozin 10 mg + Lobeglitazone 0.5 mg, taken once daily for 24 weeks.
223756592|NCT07108309|BIOLOGICAL|BCD-236|as an intravenous infusion
223756593|NCT07108309|DRUG|Chemotherapy|CHT (at the investigator's discretion):
223756594|NCT07108504|DRUG|Gemcitabine|Gemcitabine, 1000 mg/m², d1, 8, 15, q4 week
223756595|NCT07108504|DRUG|LM-302|LM-302, 1.8 mg/kg, d1, q2 week
223756596|NCT07109804|DEVICE|Deep Brain Stimulation (DBS)|The DBS system delivers electrical current into deep areas of the brain. In this study, the electrical current will be delivered continuously during the study duration to an area of the brain called the cuneiform nucleus (CnF). Stimulation frequencies are anticipated to be between 20 and 50 Hertz. Participants may choose to continue stimulation following study termination. This area of the brain is associated with the body's ability to start a movement.
223756597|NCT07109804|PROCEDURE|Deep Brain Stimulation (DBS) Device Implant Procedure|Participants will undergo a one-time implantation of Cartesia DBS electrodes (bilateral) including the Vercise pulse generator in a single surgery (up to approximately 6 hours) to implant bilateral directional DBS leads in the cuneiform nucleus.
223756598|NCT07109804|OTHER|Training Sessions|Training sessions occurs 3 times/week at the study center to condition the subjects before DBS implantation and after DBS implantation. Each session may last up to 60 minutes. Training sessions include joint mobility (passive stretching), volitional neuromuscular activation (active hip mobility), task isolation (weight shifting), task integration (stepping), and activity rehearsal (walking).
223756599|NCT07109648|BEHAVIORAL|Access to app|"The intervention is offering a free subscription to a mental health app that combines self-guided digital tools with AI-powered support. The app features functions such as an emotional diary and structured courses on topics including managing anxiety and stress regulation. A personalized chatbot, powered by large language models (LLMs) and trained on content grounded in cognitive behavioral therapy, delivers evidence-based strategies such as cognitive restructuring, behavioral activation, and emotion regulation. The chatbot also guides users through these resources using natural, supportive conversations.~Participants were randomly assigned to one of two groups:~A treatment group offered free access to the app for three months, or A control group, which will receive free access to the app for one month at the end of the study"
223756600|NCT07108348|GENETIC|Adenosine deaminase acting on RNA1|Previous studies have demonstrated that increased ADAR1 expression is associated with poor survival in gastric and metastatic colon cancer. In rectal cancer, however, the relationship between ADAR1 levels and TNT response in locally advanced disease has not been investigated. Another point is that ADAR1 can also be studied using immunohistochemistry; however, its sensitivity and specificity are low, so in our study, RNA will be isolated and analyzed using real-time PCR.
223756601|NCT07108790|OTHER|Concentrated growth factors, collagen membrane and xenograft bone graft|Ten sites were treated by concentrated growth factors (CGF), collagen membrane, and xenograft bone graft.
223756602|NCT07108790|OTHER|Collagen membrane and xenograft bone graft|Ten sites were treated with a collagen membrane and a xenograft bone graft.
223756603|NCT07110402|PROCEDURE|Autogenous transplant of fragmented adipose tissue taken from abdominal integuments|Treatment of chondromalacia of the cartilage in the knee joint by arthroscopic technique with the use of autogenous graft of fragmented adipose tissue taken from the abdominal wall.
223756604|NCT07110402|PROCEDURE|PRP GF (platelet-rich plasma with growth factors)|Treatment of chondromalacia of the cartilage in the knee joint by arthroscopic technique with the use of PRP GF (platelet-rich plasma with growth factors)
224311754|NCT03837002|OTHER|foot care protocol|foot assesment, foot care, foot care education
224311755|NCT01386983|DRUG|5ARI|Dutasteride or Finasteride
223610477|NCT05505344|DEVICE|VentriJect Seismofit validation|All participants will have a resting and exercising electrocardiogram (ECG) trace and a lung function test, called spirometry, will be performed. They will take part in a maximal CPET to determine V̇O2 peak. Participants will also have their V̇O2 peak estimated twice, twenty minutes apart, using the VentriJect Seismofit device. A short questionnaire will be administered to explore the acceptability of completing a maximal CPET and having V̇O2 peak estimated using VentriJect Seismofit.
223756605|NCT07110402|PROCEDURE|Mesenchymal cells centrifuged from bone marrow cells taken from the iliac crest|Treatment of cartilage chondromalacia in the knee joint by arthroscopic technique using mesenchymal cells centrifuged from bone marrow cells taken from the iliac crest
223756606|NCT07110402|PROCEDURE|Hyaluronic acid - low molecular weight|Treatment of chondromalacia of the cartilage in the knee joint with the use of Hyaluronic Acid - low molecular weight
223756607|NCT07110402|PROCEDURE|Hyaluronic acid - cross-linked|Treatment of chondromalacia of the cartilage in the knee joint by arthroscopic technique with the use of cross-linked Hyaluronic Acid Arti Aid Plus, Synovial, Durolain, StavOn, Collagenu
223610478|NCT02316418|DEVICE|Hairstetics™ anchoring system|"Overall, up to 360 prosthetic hair implants will be set in the scalp. The procedure will be performed in accordance with the instructions in the device Instructions for Use. Training and certification of operators by the Sponsor is a prerequisite for use of the study device by the former.~Hair extensions will be attached to the fibers four weeks after the implantation."
223610479|NCT04308941|DIAGNOSTIC_TEST|Intraocular pressure|The intraocular pressure will be measured using one of three devices
223610480|NCT05282771|DRUG|Halobetasol Propionate and Tazarotene Lotion 0.01%/0.045%|The study drug is to be self-administered by applying as a thin layer once daily to cover only affected areas and rubbed in gently for approximately 8 weeks.
223610481|NCT05282771|DRUG|Duobrii® Lotion (Halobetasol propionate and tazarotene lotion), 0.01%/0.045%|The study drug is to be self-administered by applying as a thin layer once daily to cover only affected areas and rubbed in gently for approximately 8 weeks.
223610482|NCT05282771|DRUG|Placebo|The study drug is to be self-administered by applying as a thin layer once daily to cover only affected areas and rubbed in gently for approximately 8 weeks.
223610483|NCT04438395|DEVICE|Cardiac ablation via catheter|Cardiac ablation with a catheter to treat atrial flutter and/or atrial fibrillation
223610484|NCT00366951|PROCEDURE|Foley catheter only|
223610485|NCT00366951|PROCEDURE|Extraamniotic saline infusion|
223610486|NCT01721863|OTHER|Exercise training|Exercise group will undergo progressively aerobic exercise training with 40-85% maximal oxygen consumption for 40 minutes, 3 sessions per week for 12 weeks.
223756608|NCT07108764|DRUG|Lidocaine|Patients will receive an IV bolus (50 ml) of lidocaine (1mg/kg) diluted with saline over 10 min before induction of anesthesia. This will be followed by intraoperative lidocaine infusion in a dose of 1.5mg /kg/hr till the end of surgery.
223756609|NCT07108764|DRUG|Dexmedetomidine|Patients will receive an IV bolus (50 ml) of dexmedetomidine in dose 0.5 μg/kg over 10 min before induction of anesthesia. This will be followed by intraoperative dexmedetomidine infusion in a dose of 0.3 μg/kg/hr till the end of surgery.
223756610|NCT07100678|PROCEDURE|Porcelain-Fused-to-Metal Fixed Dental Prosthesis|This prosthesis consists of a metal substructure for strength and a porcelain coating for improved aesthetics. The treatment will be planned and delivered by prosthodontic specialist. The intervention is non-surgical
223756611|NCT03928288|DRUG|Cabergoline 0.5 MG|Medication
223756612|NCT03928288|DRUG|Placebo - Cap|Placebo capsule
223756613|NCT07109245|DRUG|Haloperidol|The oral investigational agent haloperidol (Generic Brand: TEVA-HALOPERIDOL) will be self-administered, at night, over 7 days. Haloperidol will be titrated up to 2 mg.
223756614|NCT07109245|DRUG|Placebo|Oral placebo, encapsulated and to be taken at an equivalent titration schedule to Haloperidol.
223756615|NCT07109245|DRUG|Insulin Lispro|A total of 160 IU of intransal insulin (=1.6 mL) will be administered on MRI scanning visits (80 IU = 0.8 mL delivered per nostril). Humalog; Eli Lilly Canada
223756616|NCT07109245|OTHER|Saline|A total of 1.6 mL of intranasal saline will be administered on each MRI scanning visit (0.8 mL delivered per nostril).
223610487|NCT01338818|DRUG|Ritalin LA (methylphenidate hydrochloride extended release)|Ritalin LA 20 mg or 30 mg (a racemic mixture of d- and l-thre-Methylphenidate Hydrocloride (MPH), Extended release hard capsules) taken orally once daily in doses of 40, 60, or 80 mg. For 40mg dose patients took (2) Ritalin LA 20mg daily, for 60mg patients took (2) Ritalin LA 30mg daily and for 80mg patients took (2) Ritalin LA 30mg daily + (1) Ritalin LA 20mg daily for their optimal dose.
224311756|NCT01386983|DRUG|5ARI + AB|5ARI: Dutasteride or Finasteride AB: Doxazosin, Tamsulosin, Terazosin, or Alfuzosin
224311757|NCT04691726|DRUG|lidocaine 10mg/ml|bolus i.v. + continuous i.v. infusion
223610488|NCT04508426|DRUG|[14C]AR882|Single dose of \[14C\]AR882
223610489|NCT03943641|OTHER|This is not an intervention study|This study is based on retrospective analysis of linked routinely-collected healthcare data
223610490|NCT05423314|PROCEDURE|knee brace cold therapy|"receiving a knee brace cold therapy to use it in the post op recovery rehabilitation, sent to patient's home directly during pre-op phase."
223756617|NCT07109882|DRUG|Chlorzoxazone|This group will receive Chlorzoxazone twice daily for two weeks
223756618|NCT07109882|DRUG|Orphenadrine Citrate|This group will receive Orphenadrine Citrate twice daily for two weeks.
223756619|NCT06924320|DRUG|MET233 and MET097|For subcutaneous administration
223756620|NCT06924320|DRUG|Placebo|Sterile 0.9% (w/v) saline for subcutaneous administration.
223756621|NCT06924320|DRUG|MET233|For subcutaneous administration
223756622|NCT06924489|PROCEDURE|Colonoscopy after bowel cleansing with 2D imaging device|participants will undergo colonoscopy examination using 2D imaging colonoscope to detect potential adenomas or polyps. The classification of the detected lession will be determined by the edoscopic diagnosis based on the JNET classification system or by the pathological diagnosis with tissues from biopsy or polypectomy.
224311758|NCT04691726|DRUG|Placebo|bolus i.v. + continuous i.v. infusion
224311759|NCT04691726|DRUG|Metamizole|2,5 g i.v. BD
224311760|NCT04691726|DRUG|Morphine|continuous i.v. infusion adjusted to VAS scale score
224311761|NCT00465465|BIOLOGICAL|MVA 85A|i.d. injection
223610491|NCT04499495|OTHER|PENTASA (mesalamine/ 5-Aminosalicylic acid (5-ASA)|"The 5-ASAs of interest in the study are mesalazine (5-ASA); sulfasalazine (5-ASA+sulfapyridine); and balsalazide (5-ASA) and will be grouped together as 5-ASA. For sulfasalazine and balsalazide, the equivalent dose to 5-ASA will be calculated as: balsalazide 6.75g is equivalent to 2.4g of mesalamine; and Sulfasalazine 4g is equivalent to 1.6g of mesalamine.~The dose will be stratified by oral monotherapy, rectal monotherapy, oral and rectal combination therapy."
223610492|NCT05254106|DEVICE|Lower limb artery revascularization with paclitaxel-eluting device|Lower limb artery revascularization with paclitaxel-eluting stent and/or paclitaxel-coated balloon
223610493|NCT03015168|RADIATION|capecitabine and concurrent intensity modulated radiotherapy|patients with rectal cancer undergoing capecitabine and concurrent intensity modulated radiotherapy
223610494|NCT03843892|DRUG|OFEV|twice daily
223610495|NCT01423968|BIOLOGICAL|Lipopolysaccharide infusion|Lipopolysaccharide 4 nanogram/kg body weight
223610496|NCT01423968|OTHER|saline|
223756623|NCT06924489|PROCEDURE|Colonoscopy after bowel cleansing with 3D imaging device|participants will undergo colonoscopy examination using 3D imaging colonoscope to detect potential adenomas or polyps. The classification of the detected lession will be determined by the edoscopic diagnosis based on the JNET classification system or by the pathological diagnosis with tissues from biopsy or polypectomy.
223756624|NCT07108855|DRUG|Indocyanine Green (IC-Green)|Systemic administration of indocyanine green during the endoscopic procedure.
223756625|NCT07108855|DIAGNOSTIC_TEST|Fluorescence guided identification using indocyanine green|Near-infrared quantified fluorescence molecular endoscopy (qFME) will be used during the endoscopic procedure.
223756626|NCT07108595|DRUG|T- Dxd|T-DXd based therapy
223610497|NCT06227897|DRUG|Aumolertinib|Aumolertinib 110 mg per day orally for 3 years.
223610498|NCT02239159|OTHER|TES(transcutaneous electric stimulation)|Stimulation will be given through electrodes attached to the skin
223756627|NCT07110246|DRUG|Dabrafenib|Given orally (PO)
223756628|NCT07110246|DRUG|Trametinib|Given PO
223756629|NCT07110246|PROCEDURE|Magnetic Resonance Imaging (MRI)|Undergo imaging by MRI
223756630|NCT07110246|PROCEDURE|Specimen Collection|Under collection of blood and optional CSF samples
223756631|NCT07110246|PROCEDURE|Optional Lumbar puncture|Undergo optional lumbar puncture
223756632|NCT06923228|DRUG|CGB-500 Ointment with 1% tofacitinib|experimental drug
223610499|NCT06290596|DRUG|Vasopressin|Hemostatic drug.
223610500|NCT06290596|DRUG|Tranexamic acid|Hemostatic drug.
223610501|NCT06290596|OTHER|Saline|Placebo
223610502|NCT04787107|DEVICE|Mechanical Chair Massage|Healthcare staff will be placed into either massage or break intervention
223610503|NCT04376307|PROCEDURE|minimal flow anesthesia|Investigators will use minimal flow anesthesia (0,5 lt/min) during surgery with one lung ventilation
223610504|NCT03090477|BEHAVIORAL|Pharmaceutical care and adherence aids|Medication review including drug-interaction check, individual patient counseling to improve understanding of treatment rationale and to elicit and address treatment-related concerns, provision of information booklets and adherence aids (calender blister packaging and smartphone medication reminder application), phone calls and face-to-face visits to follow-up on medication-related issues scheduled over a period of 6 months.
223610505|NCT03402334|BEHAVIORAL|Patient counseling for HCV associated CVD risk factors|Patients will be counseled for cardiovascular disease risk factors associated with Hepatitis C infection. Such risk factors include atherosclerosis, heart attack, and stroke. Cardiovascular risk factors can be managed through connection with primary care and reduced through curative HCV treatment.
223756633|NCT06923228|DRUG|Ruxolitinib 1.5% Cream QD|topical cream
223756634|NCT02090127|DRUG|ficlatuzumab|humanized anti-hepatocyte growth factor (HGF) monoclonal antibody IV administration at 16.5mg/kg every 2 weeks with a ±2 day window around dosing dates, as long as subject is deriving clinical benefit as determined by the Investigator
223756635|NCT01090726|DEVICE|Storz videolaryngoscope|Storz videolaryngoscope being used for the actual intubation
223756636|NCT01090726|DEVICE|Airtraq|Airtraq being used for the actual intubation
223756637|NCT01119911|OTHER|Blood sampling from peripheral venous catheter.|Venipuncture is performed on the opposite limb of the peripheral venous catheter. Within 3 minutes, a second sample is taken from existing peripheral venous catheter used for fluid administration. Intravenous fluids are then stopped for 30 seconds and a tourniquet applied proximal to the device for another 30 seconds. A 2-mL syringe is attached and 0.5 mL of blood aspirated and discarded. Thereafter, 2 mL blood is slowly drawn during about 15 seconds, into a different 2-mL syringe, to allow a gentle pumping action that may reduce vacuum in the syringe and thus hemolysis rates. Afterwards, the intravenous device is flushed with 2 mL normal saline and infusion restarted.
223756638|NCT03921710|DRUG|CAPA-IVM|Immature oocytes were plated into a 4-well dish (Nunc, Denmark) at 10 COCs/well using CAPA medium (Medicult IVM medium; Origio, Denmark supplemented with 1 mIU/mL rFSH, 5 ng/mL insulin, 10 nM estradiol, 10 mg/mL human serum albumin \[SAGE, Denmark\] and 25 nM CNP under oil for 24 h at 37°C, 6% carbon dioxide in air). After 24 hours, COCs were washed and transferred into IVM medium (Origio, Denmark) containing 5 ng/mL insulin, 10 nM estradiol, 100 ng/mL human recombinant amphiregulin and 100 mIU/mL rFSH, and incubated under oil for 30 h at 37°C, 6% carbon dioxide in air.
223610506|NCT05917613|BEHAVIORAL|Enhanced Skills Training in Affective and Interpersonal Regulation combined with Modified Prolonged Exposure (ESTAIR/MPE)|Psychotherapeutic manual for the treatment of Complex Post-Traumatic Stress Disorder (CPTSD)
223610507|NCT01068522|DEVICE|Parenchymal Intracranial pressure monitor|Treatment based on readings from Parenchymal intracranial pressure monitor.
223610508|NCT01068522|OTHER|Treatment based on clinical and imaging observations|Treatment based on clinical and imaging observations.
223610509|NCT02868554|DEVICE|AcceleDent Aura|Patients receiving vibration therapy will be instructed to bite down on the AcceleDent mouthpiece, which vibrates at a .25 Newtons (25 grams) force level with a 30 Hertz frequency for 20 minutes per day.
223610510|NCT02868554|DEVICE|Accelerated Invisalign therapy|Patients receiving accelerated Invisalign therapy will be instructed to wear each aligner 24 hours day. Patients will be permitted to progress to the subsequent aligner after 4 days of compliant aligner wear.
223610511|NCT06434896|OTHER|ctDNA analysis after surgery|ctDNA analysis of post-surgery blood samples will be performed directly after informed consent for MEDOCC-CrEATE.
223610512|NCT02553057|DEVICE|mechanical ventilation|
223610513|NCT02714569|DRUG|LY3202328|Administered orally
223610514|NCT02714569|DRUG|Placebo|Administered orally
223610515|NCT02714569|DRUG|Atorvastatin|Administered orally
223610516|NCT02714569|DRUG|Simvastatin|Administered orally
223610517|NCT01142882|BEHAVIORAL|Traditional Prevention|Participants in the traditional prevention intervention condition will complete two sessions (of approx. one hour in duration) across the course of a week, conducted by a trained HIV (and infectious disease) prevention educator; these sessions will typically be conducted in small groups of 2-4 participants but may be offered individually.
223610518|NCT01142882|BEHAVIORAL|Web-based Prevention|Participants in the web-based intervention condition will complete an interactive, web-based HIV, hepatitis and STI prevention program. Youth will be asked to complete a customized plan of approximately 2-4 hours in length using the web-based tool; participants will complete two 60-minute sessions per week until they complete their customized plan. Participants can choose to access this intervention using dedicated computer stations set up at their substance abuse treatment setting or can complete these sessions at their own home via the web.
223610519|NCT05566028|DRUG|D745 formulation I|QD for 24 weeks or 52 weeks(if extension study) with D150 and D759
223610520|NCT05566028|DRUG|D745 formulation II|QD for 24 weeks or 52 weeks(if extension study) with D150 and D759
223610521|NCT05566028|DRUG|D745 Placebo|QD for 24 weeks or 52 weeks(if extension study) with D150 and D759
223610522|NCT05919823|DRUG|Xanomeline and Trospium Chloride Capsules|Oral xanomeline 50 mg/trospium 20 mg BID on days 1-2 followed by xanomeline 100 mg/trospium 20 mg BID on days 3-7. The dose is increased to xanomeline 125 mg/trospium 30 mg BID on days 8-35 unless the subject is experiencing adverse events from the xanomeline 100 mg/ trospium 20 mg dose. Subjects who were increased to xanomeline 125 mg/trospium 30 mg will have the option to return to xanomeline 100 mg/ trospium 20 mg depending on clinical response and tolerability.
223610523|NCT05919823|DRUG|Placebo|Placebo Capsules
223610524|NCT00191308|DRUG|pemetrexed|500 mg/m\^2 IV q 21 days for 3 cycles unless disease progression occurs
224201050|NCT01321970|PROCEDURE|Coronary angiography|"Performed in interventional cardiology setting using a guide introduced through the radial or femoral artery. The injection of iodine allows opacification of coronary arteries and their visualization by fluoroscopy. The qualitative interpretation of the data is translated in terms of percentage of stenosis of the coronary artery. It is thus considered that the stenosis is significant at over 70% obstruction of the lumenal diameter. This interpretation is made for each of the three main coronary arteries and their tributaries:~* Right coronary (proximal, middle and distal) and collateral (inter ventricular posterior ventricular posterior retro)~* Inter ventricular anterior (proximal, middle and distal) and its tributaries (diagonal and septal)~* Circumflex (proximal, middle and distal) and collateral (first and second marginal)"
223610525|NCT00191308|DRUG|cisplatin|75 mg/m\^2 IV q 21 days for 3 cycles unless disease progression occurs
223610526|NCT00191308|PROCEDURE|Radical Non-Small Cell Lung Cancer (NSCLC) surgery|All participants proceeded to surgery within 4-8 weeks from the last dose of pemetrexed.
223610527|NCT04192266|DRUG|Estradiol|2.0 mg of estradiol will be taken by mouth by the study participant 5-6 hours before each of 5 PE treatment sessions (Session 2- 6)
223610528|NCT04192266|DRUG|Placebo oral tablet|2.0 mg placebo pills will be taken by mouth by the study participant 5-6 hours before each of 5 PE treatment sessions ( Sessions 2-6)
224201051|NCT00117013|DRUG|Fluorine-19-Fluoroded Xyglucose|
224201052|NCT00117013|DRUG|Topotecan|
224201053|NCT05043220|DEVICE|PPG and PROM|description will follow
224201054|NCT06701162|PROCEDURE|Ultrasoud-guided TAP block|the ultrasound probe was placed at the mid-axillary line, and the needle was inserted into the space between the internal oblique and transverse muscles, splitting the inter-muscular fascia after injection of local anesthetic.
224201055|NCT06701162|PROCEDURE|Ultrasound-guided Ilio-inguinal Ilio-Hypogatric block|the ultrasound probe was positioned transversely on the abdominal wall at the contact point of the anterosuperior iliac spine. The needle was inserted into the space between the internal oblique and transverse muscles, causing separation of the intermuscular fascia layers upon injection of the anesthetic mixture
224201056|NCT00636922|DRUG|RAD001(Everolimus)|In this study, 5-azacitidine will be administered sc for 7 doses over 9 days in a 28 day cycle. Everolimus will be administered orally with the first dose starting on day 5 (first Friday) of each cycle and continued until day 21 of each cycle. Patients will be treated with combined azacitidine + Everolimus for a minimum of 6 cycles and until at least 2 cycles after documentation of CR. Upon cessation of azacitidine, the patient will be permitted to take Everolimus maintenance therapy until progression at the investigator's discretion.
224201057|NCT00590785|DRUG|Doxorubicin|High-dose doxorubicin + cyclophosphamide (AC) x 6 cycles with G-CSF on Days 3 - 12 and followed in postmenopausal patients and hormone receptor-positive premenopausal patients by tamoxifen 20 mg daily for 5 years.
224201058|NCT00590785|DRUG|Cyclophosphamide|High-dose doxorubicin + cyclophosphamide (AC) x 6 cycles with G-CSF on Days 3 - 12 and followed in postmenopausal patients and hormone receptor-positive premenopausal patients by tamoxifen 20 mg daily for 5 years.
224201059|NCT00590785|DRUG|G-CSF|High-dose doxorubicin + cyclophosphamide (AC) x 6 cycles with G-CSF on Days 3 - 12 and followed in postmenopausal patients and hormone receptor-positive premenopausal patients by tamoxifen 20 mg daily for 5 years.
224201060|NCT00590785|DRUG|tamoxifen|High-dose doxorubicin + cyclophosphamide (AC) x 6 cycles with G-CSF on Days 3 - 12 and followed in postmenopausal patients and hormone receptor-positive premenopausal patients by tamoxifen 20 mg daily for 5 years.
224201061|NCT00590785|DRUG|ciprofloxacin|High-dose sequential doxorubicin x 4 given with G-CSF on Days 3 - 12+ and followed by high-dose cyclophosphamide x 3 (A+C) given with G-CSF and ciprofloxacin on Days 3-12, followed in postmenopausal patients and hormone receptor-positive premenopausal patients by tamxifen 20 mg daily for 5 years.
224201062|NCT06277466|DRUG|Fresh normal pancreatic tissues or adjacent tissues of pancreatic cancer were collected from controls and T2DM patients without hypoglycemic drugs|Compared with newly diagnosed T2DM patients, healthy subjects in the control group had normal levels of blood glucose, lipids, glycated hemoglobin levels, etc. Fresh normal pancreatic tissues or adjacent tissues of pancreatic cancer were collected before taking antidiabetic drugs in both groups.
223756639|NCT03921710|DRUG|Standard-IVM|Immature oocytes are plated into a 4-well dish at 10 COCs/well using IVM medium supplemented with 75 mIU/mL recombinant FSH (Merck, Switzerland), 100 mIU/mL hCG (MSD, USA), 0.01 mg/mL growth hormone (Merck, Switzerland) and 10 mg/mL human serum albumin (SAGE, Denmark). COCs were incubated for 30 hours at 37°C, 6% carbon dioxide in air.
223756640|NCT03561857|DEVICE|Confocal Laser Endomicroscopy|"The study is divided in 2 parts.~1. Ex vivo study~   * Prostate specimens will be stained using Fluorescein~  * Images/sequences of normal and abnormal prostatic tissues, and peri-prostatic tissues will be acquired.~2. In vivo study~   * Intravenous injection of contrast agent~  * pCLE imaging every 5mm of the NVB dissection zone."
223756641|NCT00820742|DRUG|Macugen|Intravitreous injection of Pegaptanib Sodium 3.47 mg/mL solution every 6 weeks
223610529|NCT04192266|BEHAVIORAL|Prolonged Exposure (PE) therapy|There will be an introductory Prolonged Exposure (PE) therapy session, followed by 5 imaginal exposure sessions, such that there will be 2 sessions per week conducted for a total of 6 sessions over 3 weeks. The PE sessions are 60 minutes long and consist of imaginal exposure. Specifically, the patient is instructed to imagine the trauma and recount it aloud for about 25-30 minutes. In the following 15 minutes, the patient processes her reactions to revisiting the traumatic event by discussing related thoughts and feelings. The session ends with in vivo exposure homework to be completed that same day as the session. In the last session, imaginal exposure is conducted one last time for the same duration as previous sessions. The therapist and patient review treatment progress and discuss applications of treatment principles to daily life.
223610530|NCT06583629|BEHAVIORAL|Emotional Freedom Technique|EFT is a self-help technique that incorporates conscious awareness of thoughts and feelings with a gentle touch involving tapping with fingertips on acupuncture/acupressure points on the face, hands, and body. EFT also helps relieve primary physical and emotional symptoms. Gary Craig created EFT, which involved lightly tapping on the body on 12 acupressure sites (also known as acupoints). This acupoints are situated along the body's meridians, or virtual energy channels
223610531|NCT01843023|DRUG|Extended Release Naltrexone|naltrexone for extended release injectable suspension
223610532|NCT01843023|BEHAVIORAL|Psychosocial Treatment|Psychosocial treatment will consist of group and individual drug abuse counseling at MMTC and in the community.
223610533|NCT01843023|DRUG|Buprenorphine|Participants assigned to TAU will receive buprenorphine for opioid withdrawal and will either be tapered off the medication or will remain on it for individualized lengths of time during the six month study.
223610534|NCT00779025|DEVICE|PD-F-5254|Female Personal Lubricant (MINE)
223610535|NCT00779025|DEVICE|10855-096|Male Personal Lubricant (YOURS)
223610536|NCT02376972|DRUG|RIFAXIMIN VAGINAL TABLET 25 MG|RIFAXIMIN VAGINAL TABLET 25 MG O.D./5 DAYS INTRAVAGINALLY
223610537|NCT02376972|DRUG|RIFAXIMIN VAGINAL TABLET 100 MG|RIFAXIMIN VAGINAL TABLET 100 MG O.D./5 DAYS INTRAVAGINALLY
223610538|NCT02376972|DRUG|PLACEBO VAGINAL TABLET|PLACEBO VAGINAL TABLET O.D./5 DAYS INTRAVAGINALLY
223756642|NCT00752583|PROCEDURE|Peritoneal dialysis|Blood, urine and dialysate sampling
223756643|NCT00752583|PROCEDURE|Haemodialysis|Blood, urine and dialysate sampling
223756644|NCT05742880|DIAGNOSTIC_TEST|6 Minute Walking Test|6 Minute walking test
223756645|NCT05742880|DIAGNOSTIC_TEST|Blood gas analysis|Blood gas analyisis
223610539|NCT02376972|DRUG|METROGEL VAGINAL|METROGEL VAGINAL O.D./5 DAYS INTRAVAGINALLY
223610540|NCT03008694|DEVICE|PET/CT|pet/ct is used as radiotherapy simulation
223610541|NCT00003967|DRUG|etoposide|
223610542|NCT00003967|DRUG|topotecan hydrochloride|
223610543|NCT04146350|PROCEDURE|PPV+/-Cat|pars plana vitrectomy+/-cataract
223756646|NCT05742880|PROCEDURE|Wearing a Surgical Facemask|Wearing a Surgical Facemask
223756647|NCT05742880|PROCEDURE|Wearing a FFP2- Facemask|Wearing a FFP2- Facemask
223756648|NCT05742880|PROCEDURE|Wearing no Mask|Wearing no Mask
223756649|NCT02181556|DRUG|FOLFIRI Protocol|injection of FOLFIRI and Aflibercept every 14 days until progression of disease
223610544|NCT04146350|PROCEDURE|PPV+/-Cat+Gas|pars plana vitrectomy+/-cataract+gas tamponade
223610545|NCT04146350|PROCEDURE|PPV+ILM+/-Cat+/-Gas|pars plana vitrectomy+internal limiting membrane peeling+/-cataract+/-gas tamponade
223610546|NCT04146350|PROCEDURE|PPV+ILM+/-Cat+/-Oil|pars plana vitrectomy+internal limiting membrane peeling+/-cataract+/-silicone oil tamponade
223610547|NCT04146350|PROCEDURE|PSR|posterior scleral reinforcement
223610548|NCT04146350|PROCEDURE|PSR+ PPV+ILM+/-Cat+/-Oil （or Gas）|posterior scleral reinforcement+pars plana vitrectomy+internal limiting membrane peeling+/-cataract+/-silicone oil tamponade (or gas)
223610549|NCT04146350|PROCEDURE|Gas|gas tamponade alone
223756650|NCT02181556|DRUG|Aflibercept Injection|injection of FOLFIRI and Aflibercept every 14 days until progression of disease
223610550|NCT05368194|DIETARY_SUPPLEMENT|Isocaloric Unprocessed Diet|Intervention consists of an unprocessed diet meeting the Nordic and Australian Dietary Guidelines for food groups and micronutrients, wherein participants will be supplied with food providing kilocalories (kcal) in accordance with their nutritional needs as calculated based on theSchofield equation based on their weight, activity multiplier, and age at baseline. Almost all food and beverage products provided during this treatment to fall into the category of unprocessed/minimally processed foods and processed culinary ingredients in accordance with the NOVA classification system.
223610551|NCT05368194|DIETARY_SUPPLEMENT|Isocaloric Processed Diet|Intervention consists of a processed diet based on the dietary intake pattern resembling a processed western dietary intake pattern representative of the typical intake pattern of American men aged 19- 50, wherein participants will be supplied with food providing kcals in accordance with their nutritional needs as calculated based on the Schofield equation based on their height, weight, activity multiplier, and age at baseline. Almost all food and beverage products provided during this treatment to fall into the category of processed foods and ultra-processed foods in accordance with the NOVA classification system.
223756651|NCT00779454|DRUG|Gemcitabine, Oxaliplatin, Capecitabine,|Gemcitabin: 1,000 mg/m2 day 1 Oxaliplatin: 60 mg/m2 day 1 Capecitabine: 1,000 mg/m2 x 2 daily days 1-7
223756652|NCT00779454|DRUG|Panitumumab, Gemcitabine, Oxaliplatin, Capecitabine|Gemcitabine: 1,000 mg/m2 day 1 Oxaliplatin: 60 mg/m2 day 1 Capecitabine: 1,000 mg/m2 x 2 daily days 1-7 Panitumumab: 6 mg/kg day 1
223610552|NCT05368194|DIETARY_SUPPLEMENT|Excess Calorie Unprocessed Diet|Intervention consists of an unprocessed diet meeting the Nordic and Australian Dietary Guidelines for food groups and micronutrients, wherein participants will be supplied with food providing kilocalories (kcal) in accordance with their nutritional needs as calculated based on theSchofield equation based on their weight, activity multiplier, and age at baseline, plus an excess of 500 kcal per day. Almost all food and beverage products provided during this treatment to fall into the category of unprocessed/minimally processed foods and processed culinary ingredients in accordance with the NOVA classification system.
223610553|NCT05368194|DIETARY_SUPPLEMENT|Excess Calorie Processed Diet|Intervention consists of a processed diet based on the dietary intake pattern resembling a processed western dietary intake pattern representative of the typical intake pattern of American men aged 19- 50, wherein participants will be supplied with food providing kcals in accordance with their nutritional needs as calculated based on the Schofield equation based on their height, weight, activity multiplier, and age at baseline, plus an excess of 500 kcal per day. Almost all food and beverage products provided during this treatment to fall into the category of processed foods and ultra-processed foods in accordance with the NOVA classification system.
223610554|NCT02067936|DRUG|Group A propofol + remifentanil|Predicted TOL90% according to Bouillon model
223610555|NCT02067936|DRUG|Group B propofol + remifentanil|TOL 90% according to the Bouillon interaction model
223610556|NCT02067936|DRUG|Group C propofol + remifentanil|TOL 90% according to the Bouillon interaction model
223610557|NCT02067936|DRUG|group D propofol + remifentanil|TOL 90% according to the Bouillon interaction model
223610558|NCT00748371|DRUG|aspirin|40mg aspirin: one 40-mg aspirin capsule by mouth each morning + one Avicel capsule by mouth each evening
223610559|NCT00748371|DRUG|aspirin|1300mg aspirin: one 650-mg capsule by mouth twice daily
223610560|NCT00748371|DRUG|placebo|Placebo: one Avicel (cellulose) capsule by mouth twice daily
223610561|NCT03305770|DEVICE|verofilcon A contact lenses|Daily disposable soft contact lenses
223756653|NCT03919175|DRUG|Umbralisib|Umbralisib is an investigational drug which blocks a protein called PI3K. PI3K is a protein that plays a role in the way cells grow. In this type of cancer, PI3K is increased and more active than usual. This helps the cancer cells to grow and survive.
223756654|NCT03919175|DRUG|Rituximab|Rituximab works by targeting the CD20 antigen on normal and malignant B-cells. Then the body's natural immune defenses are recruited to attack and kill the marked B-cells
224201063|NCT06277466|DRUG|Fresh blood samples were collected from healthy subjects and T2DM patients without hypoglycemic drugs|"The newly diagnosed T2DM group should not have taken antidiabetic drugs and meet the diagnosis of T2DM. Fresh blood samples were collected before medication for detection.~In the control group (healthy subjects), the indicators of physical examination were within the normal range and no hypoglycemic drugs were taken. Similarly, fresh blood samples should be taken for testing."
224201064|NCT04897334|DEVICE|tDCS|tDCS is a type of non-invasive brain stimulation in which small electrical currents are applied to the scalp via 2 electrodes. During sham stimulation, the current, 2 mA, will be delivered for a short amount of time and then turn-off. To deliver the current, electrodes that are placed in saline soaked sponges. They will be attached to the left side of your head; they will be held in place with an elastic cap. For both real and sham stimulation the electrodes will be placed on the scalp. Most people cannot tell the difference between real and sham stimulation.
223610562|NCT03305770|DEVICE|delefilcon A contact lenses|Daily disposable soft contact lenses
223610563|NCT05433025|DEVICE|Cervigard Neck Collar|A device used to treat neck pain caused by forward head posture
223610564|NCT01819155|BIOLOGICAL|Adjuvanted seasonal trivalent inactivated influenza vaccine|
223610565|NCT01819155|BIOLOGICAL|Seasonal trivalent inactivated influenza vaccine|
223610566|NCT01819155|BIOLOGICAL|Saline (bacteriostatic 0.9% sodium chloride for injection)|
223610567|NCT01470456|DRUG|SAR3419|Pharmaceutical form:solution for infusion Route of administration: Intravenous
223610568|NCT01470456|DRUG|rituximab|Pharmaceutical form:solution for infusion Route of administration: intravenous
223610569|NCT04633928|BIOLOGICAL|N-TEC: Autologous nasal chondrocytes and ECM proteins|Cells expanded in vitro and cultured in a collagen type I//III scaffold
223610570|NCT01643382|DRUG|Insulin|Insulin will be given in a continuous low dose infusion. The infusion will be adjusted based on the patient's blood sugar with the goal of keeping the level between 100-140 mg/dL
223756655|NCT02317302|DEVICE|FDG-PET/MR|
223756656|NCT02317302|DEVICE|FDG-PET/CT|
223756657|NCT01940120|DEVICE|Percutaneous mitral valve repair using MitraClip implant|Procedure/Surgery: Mitral valve repair or replacement surgery Repair or replacement of mitral valve
223756658|NCT05371314|DIAGNOSTIC_TEST|P/FP ratio|PaO2/FiO2 X PEEP, SpO2/FiO2 X PEEP
223756659|NCT01088646|DEVICE|PillCam® Express Capsule Endoscopy Delivery System|"The PillCam® Express Capsule Endoscopy Delivery System is comprised of three parts: a catheter, a syringe and the capsule holder. The catheter is passed through the accessory channel of a standard endoscope and the capsule holder is snapped on to the distal end of the device. The endoscope is used to guide the Capsule Endoscopy Delivery System to the proximal duodenum. The capsule is then released pneumatically, using an air-filled syringe attached to the proximal end of the catheter.~Once the capsule is deployed, the endoscope is withdrawn and the capsule holder is cut off at the distal part of the device with scissors. The catheter is then retracted and discarded.~The PillCam® Express Capsule Endoscopy Delivery System is single-use, disposable and latex-free."
223756660|NCT01572038|DRUG|Docetaxel|Participants may receive 'docetaxel' taxane chemotherapy as per investigator's choice, administered in line with the respective product information and/or recognized clinical practice guidelines.
223610571|NCT01643382|DRUG|Insulin, Asp(B28)-|Insulin will be given through subcutaneous injection every few hours based on the patient's blood sugar level.
223610572|NCT00491127|DRUG|gemcitabine|
223610573|NCT00491127|DRUG|cisplatin|
223610574|NCT00491127|DRUG|dexamethasone|
223610575|NCT03472326|DRUG|GS-9131|Tablet(s) administered orally once daily
223610576|NCT03472326|DRUG|BIC|Tablet(s) administered orally once daily
223610577|NCT03472326|DRUG|TAF|Tablet(s) administered orally once daily
223610578|NCT03472326|DRUG|ARV regimen|ARV regimen may consist of the ARV agents containing nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) and non-nucleoside reverse transcriptase inhibitor (NNRTI)
223610579|NCT03472326|DRUG|DRV|Tablet(s) administered orally once daily
223610580|NCT03472326|DRUG|RTV|Tablet(s) administered orally once daily
223610581|NCT06453967|DIAGNOSTIC_TEST|blood glucose levels|measurement of blood glucose level at admission ,during ICU admission and at discharge for patients with acute decompensated heart failure
223610582|NCT06140706|BEHAVIORAL|transcutaneous Spinal Cord Stimulation (tSCS)|Neurostimulation for upper extremity training, delivered through video telehealth, 8 weeks of home use for (i) feasibility and (ii) potential functional improvement.
223610583|NCT02951078|PROCEDURE|Thulium Laser en Bloc Resection of bladder tumor|
223756661|NCT01572038|DRUG|Nab-paclitaxel|Participants may receive 'nab-paclitaxel' taxane chemotherapy as per investigator's choice, administered in line with the respective product information and/or recognized clinical practice guidelines.
223756662|NCT01572038|DRUG|Paclitaxel|Participants may receive 'paclitaxel' taxane chemotherapy as per investigator's choice, administered in line with the respective product information and/or recognized clinical practice guidelines.
223756663|NCT01572038|DRUG|Pertuzumab|Participants will receive pertuzumab 840 milligrams (mg) IV on Day 1 or Day 2 of Cycle 1, followed by 420 mg IV on Day 1 or Day 2 of each subsequent 3-week cycle.
223756664|NCT01572038|DRUG|Trastuzumab|Participants will receive trastuzumab (Herceptin) 8 milligrams per kilogram (mg/kg) IV on Day 1 or Day 2 of Cycle 1, followed by 6 mg/kg IV on Day 1 or Day 2 of each subsequent 3-week cycle, administered in line with the respective product Information and/or recognized clinical practice guidelines.
223756665|NCT05448690|PROCEDURE|Two different approaches|Please refer to Groups
223756666|NCT05448690|PROCEDURE|Non-combined approach|Either transnasal, transcranial or a staged approach
223756667|NCT04490993|DRUG|APL-1202 in combination with Epirubicin|"* Induction period: APL-1202 is administered for 12 consecutive weeks~* Maintenance period: after 12-week drug free period, APL-1202 is administered for another12 consecutive weeks as maintenance treatment~* Follow up period: APL-1202 is administered at every 3-month interval if no events occurred in the treatment period and until the occurrence of events or the end of the entire clinical trial Intravesical Epirubicin hydrochloride will be administered once weekly for consecutive 6-8 weeks in the induction period, followed by once monthly in the maintenance period until end of 12 months"
223756668|NCT04490993|DRUG|Placebo in combination with Epirubicin|"* Induction period: placebo is administered for 12 consecutive weeks~* Maintenance period: after 12-week drug free period, placebo is administered for another12 consecutive weeks as maintenance treatment~* Follow up period: APL-1202 is administered at every 3-month interval if no events occurred in the treatment period and until the occurrence of events or the end of the entire clinical trial Intravesical Epirubicin hydrochloride will be administered once weekly for consecutive 6-8 weeks in the induction period, followed by once monthly in the maintenance period until end of 12 months"
223756669|NCT01888497|DRUG|Gabapentin|250 mg, oral, prior to bedtime on the night before performance testing
223756670|NCT01888497|DRUG|Diphenhydramine citrate|76 mg, oral, prior to bedtime on the night before performance testing
223756671|NCT01888497|DRUG|Triazolam|0.5 mg, oral, prior to bedtime on the night before performance testing
223610584|NCT02951078|PROCEDURE|Electrical transurethral resection of bladder tumor|
223756672|NCT01888497|DRUG|Placebo|Oral, prior to bedtime on the night before performance testing
223756673|NCT04152447|DEVICE|VR device|Patients use a VR device
223756674|NCT06080152|DEVICE|Mobility Tool|An A-Linker device will be given to 12 patients 3 months before their total knee arthroplasty
223756675|NCT03837262|COMBINATION_PRODUCT|Flash Glucose Monitoring and structured education|A feasibility study assessing the use of flash glucose sensing technology with structured education to improve glycemic outcomes in T2D adults and children
223756676|NCT00065533|DRUG|pemetrexed|
223756677|NCT00001720|DRUG|Alendronate|
223756678|NCT03034954|DEVICE|Active HD-tDCS|Participants will receive active HD-tDCS at 3mA for 20 minutes
223756679|NCT03034954|DEVICE|Sham HD-tDCS|Participants will receive sham HD-tDCS
223610585|NCT02426736|DRUG|Dexamethasone|
223610586|NCT02426736|DRUG|Bupivacaine|
223610587|NCT02426736|PROCEDURE|Interscalene brachial plexus block|Performed with real time ultrasound guidance.
223610588|NCT02770989|PROCEDURE|Vimecon Laser CAI percutaneous cardiac ablation|The Vimecon Laser CAI catheter is entered through the femoral vein to access the pulmonary vein (PV) area in the heart in order to ablate the cardiac wall near the PV to create scar tissue and to isolate the PV in order to treat atrial fibrillation.
223610589|NCT04988529|BEHAVIORAL|Smartphone-based serious game intervention|Smartphone-based serious game intervention consists in the use of a serious game designed specifically to improve depressive symptoms. The psychological content consists of CBT intervention with the following psychotherapeutic components: Motivation for change, Psychoeducation, Cognitive Flexibility, Behavioural Activation, and positive psychotherapeutic strategies. To encourage physical activity, the serious game incorporates a mixed reality through physical activities such as taking a walk in real life affects aspects inside the game.
223610590|NCT05990634|DEVICE|LifeChamps Platform|Participants will be provided with the study equipment, i.e., a mobile app, smartwatch, smart t-shirt, smart scale, location home sensor, and a micro-computer, with which they will need to interact with the devices for three months in the respective study phase (pre-pilot/feasibility trial). Specifically, participants should wear the activity tracker wristband (Fitbit Charge 4) as much as possible. The smart t-shirt should as well be worn daily as much as possible. Additionally, participants should use the smart scale to weigh themselves and the mobile app to fill in selected PROMs monthly, while the ambient home sensors (location home sensor (LOCS) and smart plug) will be passively collecting information about their everyday living during these three months. Lastly, participants' clinical and demographic data from the local EHRs will be collected.
223610591|NCT04708093|DEVICE|whole body vibration training|Oscillating platform
223610592|NCT01696370|DRUG|Trimetazidine|Trimetazidine 20mg three times per day for 3 months
223610593|NCT01696370|OTHER|Placebo capsule|one capsule three times per day for 3 months
223610594|NCT04223713|PROCEDURE|TriRec|Trileaflet Reconstruction of the Aortic Valve
223610595|NCT04223713|PROCEDURE|Aortic valve replacement|Biological Prosthesis, Device: Edwards Perimount
223610596|NCT06006195|OTHER|patients with dysphagia symptoms|patients with dysphagia symptoms examined by high resolution impedance manometry
223756680|NCT02684643|OTHER|enhanced individualised therapy|additional dialysis dosage, modification of medication and prescribed dietary plan
223756681|NCT02684643|OTHER|non-enhanced individualised therapy|modified medication, prescribed dietary plan and regular three times/week dialysis dosage
223756682|NCT02684643|OTHER|regular intervention|Phosphate binders and calcitriol would be prescribed according to the guidelines. Phosphate binders included in the study are calcium acetate, calcium carbonate or sevelamer. Dosage is based on patients serum phosphate and calcium level. Calcitriol prescribed in the study is Rocaltrol and the dosage is based on PTH, serum phosphate and calcium level. Patients' diet habit will not be altered.
223756683|NCT05602415|DRUG|Anlotinib|Anlotinib of 12mg will be administered orally, once daily, 2-days on/1-day off, until disease progression according to RECIST 1.1, death, unacceptable toxicity, or withdrawal of consent for any reasons. A cycle was considered to be 3 weeks. Anlotinib should be started 3-4 weeks after surgery, and continued for 3 months (4 cycles). The dose could be reduced to 8-10 mg once daily for patients who had grade 3 or 4 treatment-related toxicities, or for patients with intolerable grade 2 toxicity, despite maximum supportive care measures. If dose reduction was necessary, then the dose of anlotinib was reduced to 10 mg once daily. If further dose reduction was necessary, the dosage was reduced to 8 mg once daily. If the dosage of 8 mg once daily was not tolerable, then the patient stopped receiving anlotinib.
223610597|NCT06006195|OTHER|patients without dysphagia symptoms|patients without dysphagia symptoms examined by high resolution impedance manometry
223610598|NCT06312202|OTHER|Drowning|Drowning is defined as the process of experiencing respiratory impairment from submersion or immersion in liquid.
223610599|NCT05717816|DEVICE|intramedullary nail and plate|fusing Charcot ankle using retrograde intrameudllary femoral nail and plate
223610600|NCT03843086|DEVICE|Low Intensity Linear Shockwave Device for the treatment of Erectile Dysfunction|"This is a prospective, randomized, clinical study aimed to evaluate the safety and efficacy of the two treatment schedules on symptomatic erectile dysfunction patients using low intensity shockwave therapy. The patients are randomized in a 1:1 ratio into two active treatment groups.~Group A: 5 daily sessions within a week (Monday, Tuesday, Wednesday, Thursday, Friday), in which 720 shocks of treatment energy will be applied in every session to each treated region (left and right corpora cavernosa and crura).~Group B: Three sessions per week (Monday, Wednesday, Friday) for 2 consecutive weeks, in which 600 shocks of treatment energy will be applied in every session to each treated region (left and right corpora cavernosa and crura)"
223610601|NCT00700713|BIOLOGICAL|Meningococcal polysaccharide diphtheria toxoid conjugate|0.5 mL, IM
223610602|NCT00700713|BIOLOGICAL|Meningococcal polysaccharide diphtheria toxoid conjugate|0.5 mL, IM
223610603|NCT00700713|BIOLOGICAL|Meningococcal polysaccharide diphtheria toxoid conjugate|0.5 mL, IM
223610604|NCT04104737|DEVICE|Spire Medical Health Tag|"Collect data to validate the respiratory rate performance of the Medical Health Tag developed by Spire Health. The Medical Health Tag respiratory rate will be evaluated during non-motion conditions over the range a range of 5-50 breaths per minute via Reference EtCO2.~A FDA cleared, GE Healthcare S5 Multi-parameter monitoring system with End Tidal Carbon Dioxide (EtCO2) and 3- lead ECG will be used for the Respiratory and Pulse Rate References."
223610605|NCT02120066|PROCEDURE|Vitrectomy for submacular hemorrhage|
223610606|NCT02120066|DRUG|subretinal injection of tissue-plasminogen activator|
223756684|NCT05602415|RADIATION|Radiotherapy|Postoperative radiotherapy would be performed. Postoperative intensity-modu¬lated RT (IMRT) will be performed (50 Gy in 2.0 Gy per fraction). No boost dose would be added if the margin was negative, a boost dose of 10-16 Gy would be added if the margin was microscopically positive, and a boost dose of 16-18 would be added if the margin was gross positive.
223756685|NCT05602415|PROCEDURE|Surgery|Surgery
223756686|NCT02431754|DRUG|Tadalafil|Administered orally
223756687|NCT02431754|DRUG|Placebo|Administered orally
223756688|NCT02431754|DRUG|Alpha1 Blocker|Administered orally
223756689|NCT03924258|DIAGNOSTIC_TEST|Iron status testing|Blood sample for iron status testing
223610607|NCT00869752|BIOLOGICAL|anti-IGF-1R recombinant monoclonal antibody MK-0646|MK-0646 should be given 1st followed within 30-60 minutes by cisplatin and then etoposide for cycles which include both MK-0646 and chemotherapy. Cycles are 21 days
223610608|NCT00869752|DRUG|cisplatin|MK-0646 should be given 1st followed within 30-60 minutes by cisplatin and then etoposide for cycles which include both MK-0646 and chemotherapy. Cycles are 21 days
223610609|NCT00869752|DRUG|etoposide|MK-0646 should be given 1st followed within 30-60 minutes by cisplatin and then etoposide for cycles which include both MK-0646 and chemotherapy. Cycles are 21 days
223610610|NCT03976388|DEVICE|Clinical Virtual Simulator|Interactive medical case delivered using touch-sensitive screens in small group sessions.
223610611|NCT03976388|OTHER|Small-Group Discussion|Small group discussion led by a physician.
223610612|NCT01104896|DRUG|Nicotine patch|One or two 15 mg nicotine patch(es) applied from 6am to 10 pm during 21 days
223610613|NCT01104896|DRUG|Placebo|One or two placebo patch(es) applied from 6am to 10 pm each day for 21 days
223610614|NCT02214641|BEHAVIORAL|Resilient, Empowered, Active Living with Diabetes|Individualized lifestyle intervention incorporating the following topics: Diabetes knowledge; access to healthcare; communication with healthcare providers; incorporation of diabetes self-care tasks within daily habits and routines; social support; and emotional well-being. Participants receive a total of 10-16 hours of intervention by a licensed occupational therapist with training in diabetes education, motivational interviewing and the REAL Diabetes intervention protocol.
223610615|NCT02214641|BEHAVIORAL|Information Control|Participants will receive a packet of informational materials about diabetes, and receive periodic follow-up phone calls to match for attention dose. The packet of materials will be delivered in an initial home visit. Follow-up phone calls will occur at approximately two week intervals to inquire whether participants have reviewed specific sections of the intervention materials, and clarify information included in the packet.
223610616|NCT01027715|OTHER|EEG monitoring and treatment of EEG seizures|Seizures will prompt treatment with loading doses of phenobarbital (20mg/kg), fosphenytoin (20mg/kg),and midazolam (0.05mg/kg bolus and .15mg/kg/hr infusion tapered over 48 hours)in that order for persisting seizures.
223610617|NCT01698385|OTHER|Diet and exercise counseling|diet and exercise counseling, setting of specific goals, follow-up of achievements, laboratory tests and measurements
223610618|NCT01936714|PROCEDURE|cataract surgery|
223756690|NCT02579746|BEHAVIORAL|DASHNa-CC|The 8-week DASHNa-CC intervention incorporated Dietary Approach to Stop Hypertension (DASH) diet, sodium reduction with the food therapy of Traditional Chinese Medicine, and included an intervention manual, two sessions of classroom instruction delivered in Mandarin, and a 20-minute telephone follow-up.
223756691|NCT02579746|BEHAVIORAL|usual care|education booklet, encouragement of physician visit, use of public health resources if needed
223756692|NCT00554671|OTHER|Algorithm driven medication titration|Clinical pharmacists will change medications to achieve goals in hypertension, dyslipidemia and diabetes
223756693|NCT00554671|BEHAVIORAL|Monitoring|Clinical pharmacists will monitor the progress of patients in lifestyle modification and cardiac risk factor control goals
223756694|NCT00554671|BEHAVIORAL|Group support|Peer support are provided in the group setting
223756695|NCT00554671|BEHAVIORAL|Self efficacy|Patients are taught with self-monitoring skills for diabetes and blood pressure, as well as healthy cooking and practiced under supervision
223756696|NCT04200248|DRUG|RBM-007 Injectable Solution|RBM-007 Injectable Solution
223756697|NCT04200248|DRUG|Aflibercept|EYLEA® (aflibercept) Injection, for Intravitreal Use
223756698|NCT04200248|DRUG|Sham|Sham intravitreal injection
223756699|NCT02155335|DRUG|Prefilled Syringe delivery of Golimumab|Golimumab 50 mg solution for subcutaneous injection using prefilled syringe
223756700|NCT02155335|DRUG|Smartject Device delivery of Golimumab|Golimumab 50 mg solution for subcutaneous injection using Smartject Device.
223756701|NCT06432530|OTHER|C-Reactive Protein (CRP), Erythrocyte Sedimentation Rate (ESR), Complete Blood Count (CBC) values, and indexes derived from the CBC.|Patients' hematological parameters were recorded, and hematological inflammatory indexes (NLR: neutrophil/lymphocyte; MLR: monocyte/lymphocyte; PLR: platelet/lymphocyte; NLPR: neutrophil/(lymphocyte\*platelet); SII (neutrophil\*platelet/lymphocyte): systemic inflammatory index; SIRI (neutrophil\*monocyte/lymphocyte): systemic inflammatory response index; AISI (neutrophil\*platelet\*monocyte/lymphocyte): aggregate index of systemic inflammation. ) were derived from baseline CBC tests.
223756702|NCT02781636|DEVICE|Device: StimGuard Protect System|Lead implanted adjacent to tibial nerve. Wireless rechargeable system.
223756703|NCT00482495|BIOLOGICAL|bevacizumab|
223756704|NCT00482495|GENETIC|gene expression analysis|
223756705|NCT00482495|GENETIC|protein expression analysis|
223756706|NCT00482495|OTHER|laboratory biomarker analysis|
223756707|NCT01218516|BIOLOGICAL|Farletuzumab|"Combination Therapy: Farletuzumab 7.5 mg/kg will be administered intravenously on Cycle 1, Week 1 and Cycle 1, Week 2 (loading dose). Beginning on Cycle 2, Week 1, farletuzumab (7.5 mg/kg) will be administered intravenously on Week 1 of all additional cycles.~Monotherapy: Farletuzumab 7.5 mg/kg will be administered intravenously on Week 1 of every 3-week cycle until disease progression."
223756708|NCT01218516|OTHER|Placebo|"Combination Therapy: Placebo will be administered intravenously on Cycle 1, Week 1 and Cycle 1, Week 2 (loading dose). Beginning on Cycle 2, Week 1, placebo will be administered IV on Week 1 of all additional cycles.~Monotherapy: Placebo will be administered intravenously on Week 1 of every 3-week cycle until disease progression."
223756709|NCT01218516|DRUG|Carboplatin|Carboplatin will be administered intravenously to achieve area under the serum concentration-time curve of 5 to 6 mg/mL\^min \[AUC5-6\].
223756710|NCT01218516|DRUG|Paclitaxel|Paclitaxel 200 mg/m\^2 will be administered intravenously.
223756711|NCT01218516|DRUG|Pemetrexed|Pemetrexed 500 mg/m\^2 will be administered intravenously.
223756712|NCT01218516|DRUG|Cisplatin|Cisplatin 75 mg/m\^2 will be administered intravenously.
223756713|NCT02761811|DEVICE|SyMapCath I™ catheter and SYMPIONEER S1™ Stimulator/Generator|Radiofrequency ablation of renal arterial sympathetic nerves
223756714|NCT05419102|PROCEDURE|peri-implantitis surgery with enamel matrix derivative|surgical procedures around dental implants with peri-implantits to remove infectious material and apply enamel matrix derivative to the implant.
223756715|NCT03561974|DEVICE|Humidification|Patients will benefit of humidification and warming of delivered gaz by non-invasive ventilation thanks humidification system.
223610619|NCT03890237|BEHAVIORAL|Her Spaces|Her Spaces will comprise a set of activities leveraging the Her Spaces curriculum and program model which includes curriculum-based sessions for 11-13 year old girls, with 40 sessions delivered weekly over the course of 10 months
223756716|NCT01023165|PROCEDURE|Humulin, Humalog, Novolog|Supervising Physician reviews patient activation after intravenous bolus insulin treatment each week and adjusts the amounts of insulin and carbohydrates to be given in the next treatment session based on patient treatment outcomes.
223756717|NCT03038464|DIAGNOSTIC_TEST|Synovial biopsy|Biopsy of jint prior reimplantation of new joint prosthesis
223756718|NCT03702478|OTHER|Questionnaire|No intervention only observational
223756719|NCT06192225|BEHAVIORAL|pre-trained guided slow paced breathing (~6 breaths per minute)|Slow PACE breathing
223756720|NCT05957133|PROCEDURE|Multicomponent exercise without action observation.|Different exercise modalities are integrated: Aerobic, mobility, strength, balance and coordination exercises.
223756721|NCT05957133|PROCEDURE|Multicomponent exercise associated with action observation|Different exercise modalities are integrated: aerobic, mobility, strength, balance and coordination exercises carried out at all times by the physiotherapist and observed by the participants.
223508997|NCT06939439|DRUG|Tislelizumab + SOX Chemotherapy|The intervention in this study involves the use of tislelizumab, a humanized IgG4 anti-PD-1 monoclonal antibody, in combination with the standard SOX chemotherapy regimen for postoperative adjuvant therapy in patients with stage III gastric or gastroesophageal junction adenocarcinoma who are ctDNA-MRD positive. Tislelizumab is administered at a dose of 200 mg intravenously every 3 weeks for a total duration of 1 year, alongside 6-8 cycles of SOX chemotherapy. The SOX regimen includes oxaliplatin (130 mg/m² intravenously every 3 weeks) and tegafur, with the dose of tegafur determined based on body surface area and administered orally twice daily for 14 days every 3 weeks.
223610620|NCT03890237|BEHAVIORAL|Act With Her|Act With Her was designed to facilitate adolescent transitions to adulthood via improvements across the six GAGE domains (education, bodily integrity, health, psychosocial well-being, voice and agency, and economic empowerment). Project activities fall into three main categories: curriculum-based programming with adolescent girls and boys, community transformation, and systems strengthening. Act With Her will work with 10-13 year old girls and boys for 10 months and implement community-level and high-level system strengthening work up to 24 months (in rural and pastoralist areas).
223610621|NCT03890237|BEHAVIORAL|Act With Her + Asset Transfer|This arm will implement the Act With Her program described above, using program curricula with 10-13-year-old girls and boys over 10 months and conducting community-level systems strengthening up to 24 months. Additionally, the girls participating in this arm will receive one of three asset transfer options. The packages will be of equal value (115 USD) - one will include school supplies, one will include hygiene supplies, and will be a combination of both. Each adolescent girl will choose which package she would like to receive and will receive components of the package at 3 timepoints over the course of the first 10 months of the project.
223610622|NCT03890237|BEHAVIORAL|Act With Her (simple)|This arm will implement the Act With Her curricula described above with 10-13 year old girls and boys over 10 months. The adolescent groups will follow the same model (near-peer, same-sex mentors, 40 weekly meetings for girls, 18 meetings for boys, 4 of which are joint sessions for boys and girls, 6 sessions for parents), but will not include community-level systems strengthening activities
223610623|NCT06137586|OTHER|Infusion of GIP[1-42], GIP[1-30] or placebo|This is a single arm study. All participants will go through all five experimental days in a randomized order. The interventions are A) 4pmol/kg/min GIP\[1-42\] B) 8pmol/kg/min GIP\[1-42\] C) 4pmol/kg/min GIP\[1-30\] D) 8pmol/kg/min GIP\[1-30\] E) Saline (placebo)
223610624|NCT04980612|BEHAVIORAL|Mindfulness Based Pain Reduction|40 participants will participate in a MBPR program. It will be an optimized mindfulness program specifically designed for treating cLBP that we will develop and test in this project. The format is the same as MBSR: 8 weeks of weekly 2½-hour group sessions and a daylong retreat.
223756722|NCT01026870|DRUG|SCH 32088 mometasone furoate (MF) metered-dose inhaler|2 inhalations from a MF 50 mcg inhaler each morning and evening, approximately 12 hours apart, for 12 weeks.
223756723|NCT01026870|DRUG|Placebo metered-dose inhaler BID|2 inhalations from a placebo metered-dose inhaler each morning and evening, approximately 12 hours apart, for 12 weeks.
223756724|NCT00515307|PROCEDURE|Cellular transplantation|600 million to 1 billion cells will be infused through the portal vein over 30 minutes. Infusion will be done one time.
223756725|NCT03377946|BIOLOGICAL|probiotics|the probiotics group was taking probiotics 4 packets a day
223756726|NCT03377946|BIOLOGICAL|placebo|the placebo group was taking placebo 4 packets a day
223756727|NCT00383838|BEHAVIORAL|brief, voluntary substance use intervention|
223756728|NCT01435291|DRUG|Advagraf Capsule|"Other Names:~* FK506E~* MR4~* tacrolimus modified/prolonged release Drug: MPA Solution for infusion and per os Other Name: Mycophenolate Mofetil or Mycophenolic Acid Drug: Basiliximab IV infusion Other Name: Simulect Drug: Corticosteroids per os Other Name: Methylprednisolone or equivalent"
223756729|NCT01435291|DRUG|Prograf Capsule|"Other Names:~* FK506E~* MR4~* tacrolimus Drug: MPA Solution for infusion and per os Other Name: Mycophenolate Mofetil or Mycophenolic Acid Drug: Basiliximab IV infusion Other Name: Simulect Drug: Corticosteroids per os Other Name: Methylprednisolone or equivalent"
223756730|NCT04171414|BIOLOGICAL|CT-P17 SC AI (adalimumab)|Subcutaneous Injection of Adalimumab 40mg once every two weeks
223756731|NCT03516669|DRUG|Clarithromycin|Twenty patients receive intraluminal clarithromycin eradication of H. pylor.
223756732|NCT03516669|DRUG|Amoxicillin, Clarithromycin|Patients fail to achieve intraluminal eradication of H. pylori will be assigned to the oral antibiotic rescue therapies with triple therapy which contains a proton pump inhibitor, amoxicillin and clarithromycin for 14 days.
223756733|NCT00675857|DRUG|NC-503 (eprodisate disodium)|capsules of 400 mg Dosage: 4 capsules (1600 mg) BID for 26 weeks
223756734|NCT00675857|OTHER|placebo|Dosage: 4 capsules BID for 26 weeks
223756735|NCT01714310|DRUG|lisdexamfetamine|Titration and open label treatment from baseline visit for 12 week study.
223756736|NCT01714310|DRUG|Placebo|Initiated at end of study week 4 and continued to study week 12.
223756737|NCT01714310|DRUG|fluoxetine|Initiated at end of study week 4 and continued to study week 12.
223756738|NCT05869929|DIETARY_SUPPLEMENT|Vegetables|4-5 servings of vegetables daily, per USDA guidelines.
223756739|NCT02822508|DRUG|BLI801 Laxative|BLI801 oral laxative
223756740|NCT02822508|DRUG|BLI801 Placebo|BLI801 oral laxative placebo
223756741|NCT03217929|DEVICE|Active-taVNS|Stimulation will be performed using the Neurodyn II (Ibramed) equipment approved by the national regulatory agency (ANVISA). The following parameters will be used: 120 Hz (hertz) of frequency, 250 μs of pulse duration and 12 milliamperes of intensity for a continuous stimulation for 30 minutes. This intensity corresponds to a non-painful mild paresthesia without muscle contraction previously described and evaluated. The 25 cm² (centimeters) electrodes will be positioned over the retroauricular area. A total of 10 sessions (one session per day during 10 week-days) will be performed. Every session will be followed by an interview with a trained psychiatrist to evaluate possible adverse effects and guarantee safety issues regarding the study itself.
223756742|NCT03217929|DEVICE|Sham-taVNS|Regarding sham protocol, the device will be turned off after 60 seconds of stimulation without the knowledge of the patient. After this initial period, the referred paresthesia seems to diminish due to nerve accommodation.
224201065|NCT04897334|DEVICE|sham tDCS|tDCS is a type of non-invasive brain stimulation in which small electrical currents are applied to the scalp via 2 electrodes. During sham stimulation, the current, 2 mA, will be delivered for a short amount of time and then turn-off. To deliver the current, electrodes that are placed in saline soaked sponges. They will be attached to the left side of your head; they will be held in place with an elastic cap. For both real and sham stimulation the electrodes will be placed on the scalp. Most people cannot tell the difference between real and sham stimulation.
223610625|NCT04980612|BEHAVIORAL|Mindfulness Based Stress Reduction|10 participants will participate in MBSR program. MBSR is a standardized and manualized 8-week program, delivered once a week in 2½-hour group sessions and a daylong retreat. It trains individuals in several mindfulness practices, e.g. focus on breath, varying degrees and directions of object orientation, open monitoring of awareness of intero- and exteroceptive stimuli and thoughts, de-reification (i.e. the notion that thoughts and perceptions are not always true to reality), and meta-awareness (i.e., awareness of thinking) in addition to focused attention.The program typically includes audio-recordings and a workbook for home practice and has shown benefits in patients with cLBP.
223610626|NCT06154707|DRUG|Denosumab Injection|Denosumab injection 60mg (1.0ml/ branch, Jiangsu Taikang Biological Medicine Co., LTD., s20233111), once every 6 months, 60mg, subcutaneous injection, at the same time to supplement calcium and vitamin D.
223610627|NCT06154707|OTHER|Normal saline injection (1.0ml/ branch)|Placebo drug, the main component of normal saline injection (1.0ml/ dose). In addition to the different production batch number, its appearance, character, specification, administration mode and frequency are exactly the same as the experimental group of drugs (different production batch number is convenient for later unblinding reference). Take calcium and vitamin D supplements.
223610628|NCT05939362|OTHER|MRI follow-up|MRI follow-up for patient with early onset Alzheimer's disease
223610629|NCT06182969|DRUG|APG-2575|Take orally once daily (QD) for 12 weeks.
223610630|NCT06182969|OTHER|Placebo|Take orally once daily (QD) for 12 weeks.
223610631|NCT01922141|DRUG|Aliskiren|Aliskiren 150 mg and aliskiren 300 mg tablets will be supplied centrally. These will be blinded with matching placebos for the 2 dose strengths.
223610632|NCT01922141|DRUG|Amlodipine|Amlodipine 5 mg/10 mg will also be blinded and supplied centrally. For Aliskiren dual therapy arm , Amlodipine is in the regimen; where as for monotherapy arms, Amlodipine is an optional add-on therapy.
223610633|NCT01922141|DRUG|Ramipril|Ramipril 5 mg and ramipril 10 mg capsules will be supplied centrally. These will be blinded with matching placebos for the 2 dose strengths.
223610634|NCT01922141|DRUG|Hydrochlorothiazide|Hydrochlorothiazide 12.5 mg/25 mg will be open label and supplied locally. It is an optional add-on to each arm.
223610635|NCT04528719|BIOLOGICAL|mRNA-1345|Formulation for injection
223610636|NCT04528719|DRUG|Placebo|0.9% sodium chloride (normal saline) injection
223610637|NCT03314064|DRUG|Dolutegravir 50 mg|DTG is an integrase inhibitor that has been developed for ART of HIV-infection in combination with other antiretrovirals. DTG will be available as 50 mg tablets to be administered once daily.
223610638|NCT02446717|DRUG|ABT-493, ABT-530|ABT-493 (tablet) dosed with ABT-530 (tablet)
223610639|NCT02446717|DRUG|ribavirin (RBV)|Tablet
223610640|NCT02446717|DRUG|ABT-493/ABT-530|Tablet; ABT-493 coformulated with ABT-530
223610641|NCT04589442|BIOLOGICAL|Split thickness skin graft|standard of care graft
223610642|NCT04589442|BIOLOGICAL|microsurfaced split thickness skin graft|standard of care graft that has been microsurfaced
223610643|NCT02527590|OTHER|pneumatic stimulations(allodynic area)|2 series of 20 pneumatic stimulations (air jet) on a allodynic area for recording evoked potentials
223610644|NCT02527590|OTHER|pneumatic stimulations (healthy area)|2 series of 20 pneumatic stimulation on a healthy area (either contralateral or above or below allodynic area) will no pain triggering for recording evoked potentials
223610645|NCT02527590|OTHER|pneumatic stimulations no auditory masking|2 series of pneumatic stimulations (air jet) on the hand (without feeling pain) for recording evoked potentials
223610646|NCT02527590|OTHER|no stimulation (control)|no stimulation (control condition): air jet directed beside the hand
223610647|NCT02527590|OTHER|pneumatic stimulations with audidory masking|2 series of 20 pneumatic stimulations (air jet) on the hand (without feeling pain) with auditory helmet that totally masked the air jet noise.
223610648|NCT05357716|DEVICE|HeartWatch|The HeartWatch arm band provides continuous, high-quality single lead electrocardiograph (ECG) data in a variety of environments. The ECG data is transmitted via Bluetooth and stored on the user's smartphone. It is then uploaded to the cloud for subsequent analysis using either a commercial ECG software package or a customized software package from HelpWear.
223610649|NCT05357716|DEVICE|Event Recorder|A standard 1 or 2-lead Sirona Event Recorder will be used to collect high-resolution data. Subjects will be asked to wear the clinical monitor for at least 48 hours and no longer than 84 hours. ECG signals will be continuously collected as long as the skin patches are attached to the skin and the recorder is properly connected to the wires.
224201066|NCT04897334|BEHAVIORAL|Cognitive Therapy|During both the treatment and the sham intervention, participants will undero cognitive therapy training by performing the NBack task. In this sequential letter memory exercise participants are presented with sequential stimuli in the form of a series of letters. For each new stimulus they are asked to indicate if the current stimulus matches the stimulus from 2 trials prior. This exercise stimulates cognitive demand in working memory, executive function and attention and is correlated with dorsolateral prefrontal cortex activity.
224201067|NCT00181974|DRUG|Tisseel Fibrin Sealant|
224201068|NCT00394992|DRUG|oxaliplatin+capecitabine|postoperatively oxaliplatin 130 mg/m2 i.v. day 1 plus capecitabine 1000 mg/m2 b.i.d. on day 1-14, q3w
223610650|NCT05357716|DEVICE|Holter Monitor|A standard 5-lead SEER Holter will be used to collect 3-channels of high-resolution data. Subjects will be asked to wear the clinical, conventional monitor for at least 36 hours and no longer than 60 hours. During this time ECG signals will be continuously collected.
223610651|NCT05820659|BEHAVIORAL|peer rejection task and impossible puzzle task|"Peer rejection task: Adolescents will be informed that two peers will take turns to choose who they will chat with for different topics. Participants will not be chosen by virtual White peers 75% of the time. In reality, White peers are computerized avatars and whether or not adolescents are chosen by those peers is programmed with PsychoPy software.~Impossible puzzle task: Adolescents will be asked to fit all puzzle pieces into a wooden frame with a wrong piece provided."
223610652|NCT01629173|PROCEDURE|Dynamic impression insole|We sequentially padded (1)a 6.5-mm thick P-cell (21 Shore A hardness, Acor orthopedic Inc. Cleveland, Ohio, USA), and (2)a piece of metatarsal pad and arch support made of Ethylene Vinyl Acetate (EVA) (40 Shore A hardness, Schein orthopadie service KG. Remscheid, Germany) to the bottom of the impressed 9-mm thick plastazote (15 Shore A hardness, Schein orthopadie service KG. Remscheid, Germany) with double-sided adhesive tape in the forefoot region and just proximal to the first, second, and third metatarsal head region. We additionally padded a 2-mm thick Multiform (30 Shore A hardness, Schein orthopadie service KG. Remscheid, Germany) on the top of the impressed insole with double-sided adhesive tape.
223756743|NCT03328689|OTHER|Physical activity program|This arm will begin with PT assessment. Following this, participants will meet with a specialist who will design an individualized physical activity program. Classes will include warm up, 40 minutes of individualized exercises and a cool down that will include back pain specific exercises including core strengthening. The first 4 weeks of exercise will include a 30-minute education program. Education comprise information on back pain, efficient use of the back during daily activities, self-management, self-efficacy and pain neurophysiology. Classes will run for a 12-week period. Participants will be encouraged to attend the exercise facility at least 3 times a week. An activity monitor will be provided to all participants. We will use group classes to facilitate the development of social support.
223756744|NCT03328689|OTHER|Control group standard care|"Participants from the control group will receive usual care which will often include recommendation to keep activity, home exercise programs and advice to engage in physical activity.~Participants in the control group will also receive and activity monitor for collection of physical activity data. This activity monitor may also be used for positive feedback and activity reinforcement"
223756745|NCT01919658|PROCEDURE|nerve block|A nerve block performed as per standard of care: femoral nerve blocks, and saphenous nerve blocks performed more distally (within 10cm superior to the adductor tubercle).
223756746|NCT02586493|DRUG|Placebo|Subjects will receive 1 inhalation once-daily until visit 2.
224201069|NCT00394992|DRUG|Oxaliplatin+capecitabine+bevacizumab|postoperatively oxaliplatin 130 mg/m2 i.v. day 1 plus bevacizumab 7.5 mg/kg on day 1 plus capecitabine 1000 mg/m2 b.i.d. on day 1-14, q3w
223508998|NCT06939439|DRUG|SOX Chemotherapy|The control group will receive standard SOX chemotherapy alone, serving as an active comparator to evaluate the incremental benefit of adding tislelizumab. This design ensures a rigorous comparison while maintaining alignment with current standard-of-care practices.
223508999|NCT06942611|DEVICE|transcranial electrical stimulation treatment.|Stimulation targeting the primary motor cortex, current intensity is 1-2mA, duration is 30 minutes, once daily for 5 consecutive days
223509000|NCT06938971|OTHER|Exercise training|Participants allocated to the exercise intervention group will receive standard care plus an exercise intervention. The exercise intervention will consist moderate-to-high intensity supervised and unsupervised home-based exercise training (bicyling, walking, or running) 5 times/week for 18 weeks.
223509001|NCT02428647|DIETARY_SUPPLEMENT|MNP|MNP containing containing 10 mg zinc and 14 other nutrients, including 6 mg iron, 0.56 mg copper, 17 μg selenium, 90 μg iodine, 400 μg RE vitamin A, 5 μg vitamin D, 5 mg vitamin E, 30 mg ascorbic acid, 0.5 mg vitamin B1, 0.5 mg vitamin B2, 6 mg niacin, 0.5 mg vitamin B6, 0.9 μg vitamin B12, and 150 μg folate
223509002|NCT02428647|DIETARY_SUPPLEMENT|preventive zinc supplement|7 mg zinc daily as dispersible tablet
223509003|NCT02428647|DIETARY_SUPPLEMENT|therapeutic zinc supplement|20 mg zinc per day for 10 days during diarrhea episodes, as dispersible tablet
223509004|NCT02428647|DIETARY_SUPPLEMENT|preventive placebo supplement|dispersible daily placebo tablet
223509005|NCT02428647|DIETARY_SUPPLEMENT|therapeutic placebo supplement|dispersible placebo tablet for 10 days during diarrhea episodes
223509006|NCT02428647|DIETARY_SUPPLEMENT|placebo powder|placebo powder
223509007|NCT04484701|DRUG|68Ga-PSMA-11|PET/CT scan with radiotracer 68Ga-PSMA-11
223509008|NCT03724227|DRUG|ACE-011|ACE-011 will be administered subcutaneous injection
223509009|NCT01091883|DEVICE|Exablate treatment|MR Guided Focused Ultrasound
223509010|NCT01091883|RADIATION|Radiation|External Beam Radiation
223509011|NCT00138242|DRUG|carboplatin|
223509012|NCT00138242|DRUG|docetaxel|
223509013|NCT00138242|PROCEDURE|adjuvant therapy|
223509014|NCT04594603|OTHER|Phacoemulsification for cataract|Phacoemulsification for removal of cataract
223509015|NCT05212935|BIOLOGICAL|Rotavirus Vaccine|administration of the 3 doses of Rotavirus human bovine pentavalent reassortant vaccine
223509016|NCT01872208|BIOLOGICAL|HAV implantation|Patients will be implanted with a Human Acellular Vessel (HAV) as an above-knee femoro-popliteal bypass graft using standard vascular surgical techniques.
223509017|NCT06582641|BEHAVIORAL|Peer Group Connection - Middle School (PGC-MS)|Peer Group Connection - Middle School (PGC-MS) is the treatment condition. PGC-MS is a school-based positive youth development program for students entering the transition year into middle school (6th or 7th grade). PGC-MS aims to improve school engagement and social-emotional learning skills that support adolescent health and educational outcomes for program participants. Participants receive 45-minute outreach sessions held 3 to 4 times per month for the full school year. Schools are expected to implement a minimum of 18 outreach sessions over the school year. PGC-MS outreach sessions are delivered by older peer leaders (8th, 9th, or 10th graders) who are carefully selected by faculty advisors and trained on how to deliver program content.
223509018|NCT06064526|OTHER|No intervention|Non-interventional study based on secondary use of hospital medical records
223509019|NCT06454487|OTHER|Isometric Hand Grip Training|IHG training will be performed with an inflatable ball three days per week for 12 weeks (with at least a day of rest between each session) with intensity set based on RPE (Borg CR-10 scale).
223509020|NCT06454487|OTHER|CR|Standard of Care
223509021|NCT05165966|BIOLOGICAL|High-dosage of COVID-19 vaccine (Vero cell), Inactivated|High-dose COVID-19 Vaccine(Vero Cell),Inactivated:1200SU inactivated SARS-CoV-2 virus in 0.5 mL of aluminium hydroxide solution per injection
223509022|NCT05165966|BIOLOGICAL|Medium-dose COVID-19 Vaccine(Vero Cell),Inactivated|Medium-dose COVID-19 Vaccine(Vero Cell),Inactivated: 600SU inactivated SARS-CoV-2 virus in 0.5 mL of aluminium hydroxide solution per injection
223509023|NCT02912611|PROCEDURE|Education and Protocol based management|
223509024|NCT03076164|DRUG|Trametinib|Trametinib 1.5mg once daily by mouth
224201070|NCT01059552|DRUG|vorinostat|vorinostat once daily for 12 weeks of therapy
224201071|NCT06542887|DRUG|Atomoxetine|Participants will continue receiving their treatment with atomoxetine at a dose of 0.5-1.4 mg/kg/day
224201072|NCT06542887|DRUG|Black Seed Oil Cap/Tab|Participants will receive black seed oil in the form of soft gelatin capsule 450 mg at a dose of 40-80 mg/kg/day given in one to two divided doses after meals for 12 weeks.
224201073|NCT00301639|DRUG|OROS methylphenidate hydrochloride|
224201074|NCT00301639|DRUG|methylphenidate hydrochloride|
224201075|NCT06330545|RADIATION|Radiation therapy|Patients with Dupuytren's Contacture will undergo Collagenase Clostridium Histolyticum injection and release followed by two 5-day courses of radiation therapy separated by 6-8 weeks. They will then be followed for 3 years for recurrence.
224201076|NCT05964400|BEHAVIORAL|duoABLE|Stroke participant-caregiver duos (dyads) will meet with an occupational therapist 12 times (2x/week for 6 weeks, approximately 30 minutes/session) to apply activity monitoring, activity scheduling, collaborative problem solving, self-assessment, and social interdependence to self-selected activities that aim to increase both dyad members' physical activity levels
224201077|NCT04440761|OTHER|Observation only|Observation only
224201078|NCT06621173|DRUG|HNF4α srRNA|"HNF4α srRNA will be administered intravenously for the treatment of metastatic colorectal cancer. The dosing regimen is planned for a second dose 14 ± 3 days post-initial treatment, followed by subsequent treatments every 28 ± 7 days, with adjustments made based on patient tolerance and therapeutic response.~According to Amendment 1, after enrollment, the investigator will determine the HNF4α srRNA dose, whether to combine it with immunotherapy, and the dose and schedule of the combination, based on the patient's treatment history and the safety/efficacy data of HNF4α srRNA administered via peripheral vein for hepatocellular carcinoma, intrahepatic cholangiocarcinoma, or colorectal cancer. Participants initially on HNF4α srRNA monotherapy who are considered for combination with immunotherapy must complete at least two treatment cycles and the post - treatment safety assessment."
224201079|NCT05117294|DRUG|Bocidelpar|Oral
224201080|NCT03752866|DEVICE|Portico™ Valve, Portico Delivery System(s) and Loading System(s)|Subjects will undergo implantation of a commercially available Portico transcatheter aortic heart valve using the Portico TAVI system.
224201081|NCT03752866|DEVICE|Portico™ Valve, FlexNav Delivery System(s) and Loading System(s)|Subjects will undergo implantation of a commercially available Portico transcatheter aortic heart valve using the FlexNav Delivery and Loading Systems.
224201082|NCT06571955|DEVICE|Implantation of LARS artificial grafted ligament to treat ACL injury|Implantation procedure will be realized by a well-trained orthopaedic surgeon and will consist of ACL repair using LARS artificial grafted ligament.
224201083|NCT06571955|DEVICE|Implantation of LARS artificial non-grafted ligament to treat ACL injury|Implantation procedure will be realized by a well-trained orthopaedic surgeon and will consist of ACL repair using LARS artificial non-grafted ligaments.
223509025|NCT03076164|DRUG|Erlotinib|Erlotinib 75mg once daily by mouth
223509026|NCT00226044|DRUG|Omeprazole rectally 1mg/kg|A single dose of 1 mg/kg rectally administered omeprazole.
223509027|NCT06222047|OTHER|breast milk|give breast milk before the OG catheter insertion
223509028|NCT06222047|OTHER|dextrose|give %20 dextrose before the OG catheter insertion
223509029|NCT00615316|DRUG|Guaraná|Guaraná extract 75mg/day
223509030|NCT00615316|DRUG|Placebo|Placebo 1tab/d
223509031|NCT02676622|DRUG|mobilization of stem cells to prepare for Leukapheresis|"Cyclophosphomide 2 g/m2 x 2 consecutive days.~Filgrastim (G-csf) 10 mcg/kg SC will start 5 days after the last dose of CY and will end the day before the last leukapharesis."
223509032|NCT02676622|OTHER|Leukapheresis- Collection of stem cells|"Placement of an Apheresis Catheter on the day of collection of stem cells.~Leukapheresis will be performed on a continuous flow separator machine to target 3-8 x 106 CD34+ cells/kg body weight."
223509033|NCT02676622|DRUG|Preparative regimen 4-6 weeks after Leukapheresis|"Prior to starting medicines, a central venous line will be placed (arm or chest)~Cyclophosphamide iv: 50 mg/kg iv over 2 hours~Mesna iv (uro-protectant): 36 mg/kg iv over 12 hours~r-ATG (Thymoglobulin, Genzyme): 2.5 mg/kg/dose iv over 6 hours on days -3,-2,-1"
223509034|NCT02676622|OTHER|Stem Cell Transplant|"Infusion of the(cryopreserved and thawed)peripheral blood stem cells (PBSC)occurs on Day 0.~Day +5: start Filgrastim (G-csf) subcutaneous injections~Hospitalization in isolation room for 4-5 weeks"
223509035|NCT02676622|DRUG|Low-dose IL-2 administration|"IL-2 Subcutaneous injections will start once ANC is \> 500/µL and patient is afebrile (start IL-2 will be approximately day +20)for 6 weeks of treatment.~Once patient or parent has learnt the administration and patient is tolerating it well, then the rest of the treatment can be administered at home after discharge with weekly follow up visits."
223509036|NCT01622335|DRUG|Nitrous oxide|General anesthesia with Nitrous Oxide, 70%, O2 30%) 1-5 L, Sevoflurane 1-2%, ETCO2: 32-35 mmHg.
223509037|NCT01622335|OTHER|General anesthesia with oxygen|General anesthesia with(Air, 70%, O2 30%) 1-5 L, Sevoflurane 1-2%, ETCO2: 32-35 mmHg.
223509038|NCT02015936|BEHAVIORAL|Six Week Physical Activity Intervention|Tailored Wii Fit prescription based on physical fitness assessments and a schedule of six home visits by an oncology RN.
223509039|NCT02015936|OTHER|Progress Reporting|Participants will keep a log to record the physical activities they have done with the Wii Fit during the 6-week period. Audio-recording may be included for quality control. Self-report data will be collected by Internet surveys through the University of South Florida (USF) Health Qualtrics application at baseline (T1) and at 6 weeks post-intervention (T2). The nurse will take small amount of the participant's hair (20 strands) for a hormone test during the first visit and last visit.
223509040|NCT02137356|RADIATION|standard dose pelvic radiation therapy|"radiation therapy to pelvis delivered using standard conformal or IMRT techniques.~50.4-55 Gy"
223509041|NCT02137356|DRUG|standard dose capecitabine|825 mg/m2 twice daily, 5 days a week (max dose 2000mg twice daily), only on days when radiation is delivered
223509042|NCT02137356|DRUG|dose-escalated selinexor treatment|Selinexor oral drug will be given twice weekly according to the dose escalation schedule described in the protocol. Selinexor will be started on the day radiation begins, until the end of week 6.
223509043|NCT06445595|OTHER|patients with traumatic brain injury|Patients will be contacted by phone
223509044|NCT04662632|COMBINATION_PRODUCT|VT-X7 Treatment System with Tobramycin Sulfate|Seven-day local antibiotic irrigation with tobramycin sulfate via the VT-X7 Knee or Hip Spacer.
223610653|NCT01629173|PROCEDURE|Custom molded insole|The custom molded insole was made by sequentially padded Multiform (30 Shore A hardness, Schein orthopadie service KG. Remscheid, Germany), P-cell (21 Shore A hardness, Acor orthopedic Inc. Cleveland, Ohio, USA), Ethylene Vinyl Acetate (EVA)(40 Shore A hardness, Schein orthopadie service KG. Remscheid, Germany), and cork (50 Shore A hardness, Schein orthopadie service KG. Remscheid, Germany) on the positive plaster cast impressed by an impression box while holding the subtalar joint at a neutral position.
224201084|NCT01539707|DRUG|Solifenacin succinate suspension 5 mg|Adolescents and children are given a single dose of solifenacin succinate liquid suspension orally via syringe in the morning of day 1 followed by a glass of water. Doses are calculated per weight of the participant, targeting to have equivalent dose of 5 mg dose of solifenacin once daily in adults (referred to as PED of 5 mg).
223756747|NCT02586493|OTHER|Questionnaire|ELLIPTA Inhaler Ease of Use Questionnaire is a four-point Likert scale. This questionnaire will be filled by investigator (designee) based on responses received from subject. Responses for the questionnaire are Very difficult, Difficult, Easy, Very easy. Subjects will be give either version A or B at Visit 2.
223756748|NCT03002051|DEVICE|EUS-guided drainage|"* Ultrasonographic evaluation of the lesion by linear echoendoscope and positioning for transenteric puncture in shortest distance between enteric wall and the target lumen for drainage.~* EUS-guided transenteric puncture by using a 19-gauge needle followed by placement of a 0.035 or 0.025-inch guidewire into the target lumen.~* After the needle is removed in remaining the guidewire, the tract is dilated over the guidewire by using bougie dilator or needle type cystotome (Endoflex, Voerde, Germany). And then, the tract may be more dilated by using balloon catheter (4-mm).~* After dilation of the tract, stent delivery system is inserted over the guidewire into the target lumen.~* After complete deployment of the distal flange under EUS and fluoroscopic guidance into the target lumen, proximal retraction of the delivery system until the blue mark on the handle of the introducer is seen. And then, the proximal flange is deployed slowly under endoscopic guidance."
223610654|NCT01629173|PROCEDURE|9-mm uncompressed Plastazote|We used 9-mm flat Plastazote(15 Shore A hardness, Schein orthopadie service KG. Remscheid, Germany) as an insole
223610655|NCT01629173|PROCEDURE|7-mm Ethylene Vinyl Acetate (EVA)|We used 7-mm flat Ethylene Vinyl Acetate (EVA) (40 Shore A hardness, Schein orthopadie service KG. Remscheid, Germany) as an insole
223756749|NCT01467232|BIOLOGICAL|Injection of autologous CD133+ stem cells at the time of coronary artery bypass grafting|Following completion of the distal coronary artery bypasses, autologous CD133+ stem cells, or placebo (saline solution containing autologous plasma without CD133+) will be injected into the myocardium.
223756750|NCT01467232|BIOLOGICAL|Injection of autologous CD133+ stem cells at the time of coronary artery bypass grafting|Following completion of the distal coronary artery bypasses, autologous CD133+ stem cells, or placebo (saline solution containing autologous plasma without CD133+) will be injected into the myocardium
223610656|NCT01327599|DRUG|Travoprost 0.004%+Timolol 0.5% ophthalmic solution|Fixed dose combination topical ocular agent preserved with polyquaternium-1 (POLYQUAD)
223610657|NCT01678378|BEHAVIORAL|SHARP Intervention|Providers and staff located in high school school health centers (i.e., nurse practitioners, nurses,physicians, health educators, medical assistants) will be trained to address adolescent relationship abuse with school health center clients using knowledge, skills, and resources gained through the SHARP Intervention training. The training includes strategies to help youth recognize adolescent relationship abuse among themselves and their peers, to learn strategies to increase safety (harm reduction), and to utilize adolescent relationship abuse-related resources.
223610658|NCT03830359|OTHER|T2769|At least 55 enrolled patients for at least 50 evaluable patients treated by T2769 for 42 days
223610659|NCT02715609|DRUG|Disulfiram|
223756751|NCT00420524|DRUG|Patupilone/EPO906|
223756752|NCT00542750|DRUG|N-Acetylcysteine|N-Acetylcysteine 1200 mg twice daily for four weeks
223756753|NCT01188408|DRUG|Liposome Entrapped Docetaxel (LE-DT)|110 mg/m2 IV (in vein) on day 1 of each 21 day cycle, 6 cycles or until disease progression or unacceptable toxicity
224201085|NCT03917654|BIOLOGICAL|Pfs230D1M-EPA/AS01|The Pfs230D1M-EPA was formulated as conjugated Pfs230D1M in 4 mM phosphate-buffered saline (PBS) to a 2X dilution of the high dose (160 (Micro)g/mL in 0.5 mL volume) in cGMP compliance at Walter Reed Bioproduction facility in April 2016 and will be provided as a single use vial. AS01B adjuvant was manufactured for use in the SHINGRIX vaccine by GSK
223610660|NCT02715609|DRUG|Copper Gluconate|
223610661|NCT02715609|PROCEDURE|Surgery|
223610662|NCT02715609|RADIATION|Radiation|
223610663|NCT02715609|DRUG|Temozolomide|
223610664|NCT06966440|DIAGNOSTIC_TEST|circulating tumor DNA (ctDNA)-based MRD|MRD testing will be performed before the start of the first treatment cycle, and at weeks 8 and 11 of each subsequent cycle. MinerVa Prime is a tumor-informed MRD assay based on a fixed panel spanning 769 cancer-related genes.
224201086|NCT03917654|BIOLOGICAL|HAVRIX|HAVRIX (Hepatitis A Vaccine; HAV) is produced by GSK and is a sterile suspension of inactivated virus for IM administration. The virus (strain HM175) is propagated in MRC-5 human diploid cells. HAVRIX is FDA approved for active immunization against disease caused by HAV for persons 12 months of age and older.
223610665|NCT06966440|DRUG|adjuvant chemotherapy regimens|Patients will be administered with appropriate adjuvant chemotherapy regimens including but are not limited to: GEM monotherapy/adjustable GEM monotherapy, S-1 monotherapy/adjustable S-1 monotherapy, fluorouracil monotherapy/adjustable fluorouracil monotherapy, GEM plus CAP regimen/adjustable GEM plus CAP regimen, mFOLFIRINOX regimen, GEM plus nab-paclitaxel regimen/adjustable GEM plus nab-paclitaxel regimen.
223610666|NCT05816083|BEHAVIORAL|Virtual Reality Tool|Virtual Reality Tool for At-Risk Trauma-Exposed Young People
224201087|NCT03917654|BIOLOGICAL|TYPHIM Vi (Salmonella typhi vaccine)|TYPHIM Vi (Typhoid Vi Polysaccharide Vaccine), produced by Sanofi Pasteur SA, for IM use, is a sterile solution containing the cell surface Vi polysaccharide extracted from Salmonella enterica serovar Typhi, S typhi Ty2 strain (inactivated, subunit vaccine). TYPHIM Vi vaccine is indicated for active immunization for the prevention of typhoid fever caused by S typhi and is FDA approved for use in persons 2 years of age or older
223756754|NCT03668652|DEVICE|Focal HIFU treatment using Focal One (EDAP TMS) or TULSA-PRO (Profound Medical)|"HIFU arm:~Focal ablation of prostate cancer using HIFU Focal One or TULSA -PRO"
223756755|NCT03668652|PROCEDURE|Radical prostatectomy|"Prostatectomy arm:~Robot assisted or open retropubic prostatectomy"
223610667|NCT02612922|DRUG|Nitazoxanide|Nitazoxanide 600 mg administered orally twice daily for five days
223610668|NCT02612922|DRUG|Placebo|Placebo administered orally twice daily for five days
223610669|NCT00310596|DRUG|Gadopentetate dimeglumine (Magnevist, BAY86-4882)|0,1mmol/kg at 10 mL/15 sec
223610670|NCT00310596|DRUG|Gadopentetate dimeglumine (Magnevist, BAY86-4882)|same dose as arm 1 at bolus rate (2mL/sec)
223756756|NCT02492139|DEVICE|Pumping CE-marked Symphony Pumpset|Pumping with the CE-marked Symphony Pumpset
223756757|NCT02492139|DEVICE|Pumping BrownieForSymphony Pumpset|Pumping with the the BrownieForSymphony Pumpset
223756758|NCT03995381|OTHER|Decision aids|Shared decision making with decision aids
223756759|NCT01797328|PROCEDURE|cold arm|1 hour/day of cold provocation of such an extent that it is unpleasant but does not cause shivering
223756760|NCT01797328|PROCEDURE|warm arm|To the best of ability avoid feeling cold during 6 weeks
223756761|NCT01604343|DRUG|Placebo|Form=solution for injection, route=subcutaneous use; every 2 weeks from Week 0 through Week 50.
223756762|NCT01604343|DRUG|Placebo|Form=solution for injection, route=subcutaneous use; Weeks 2, 6, and every 4 weeks through Week 104.
223756763|NCT01604343|DRUG|Sirukumab|Type=exact, unit=mg, number=50 or 100, form=solution for injection, route=subcutaneous use; every 2 weeks for 100 mg and every 4 weeks for 50 mg, Week 52 through Week 104.
223610671|NCT00310596|DRUG|Gadopentetate dimeglumine (Magnevist, BAY86-4882)|0,3mmol/kg at 10 mL/15 sec
223610672|NCT00310596|DRUG|Gadopentetate dimeglumine (Magnevist, BAY86-4882)|same dose as arm 3 at bolus rate (2mL/sec)
223756764|NCT01604343|DRUG|Sirukumab|Type=exact, unit=mg, number=100, form=solution for injection, route=subcutaneous use; Weeks 0, 2, and every 2 weeks through Week 104.
223756765|NCT01604343|DRUG|Sirukumab|Type=exact, unit=mg, number=50, form=solution for injection, route=subcutaneous use; Weeks 0, 4, and every 4 weeks through Week 104.
223756766|NCT00749983|DIETARY_SUPPLEMENT|Creatine supplementation|
223756767|NCT00749983|DIETARY_SUPPLEMENT|Dextrose supplementation|
223756768|NCT01811095|OTHER|Training|"Training with the da Vinci® Skills Simulator to complete a proficiency-based curriculum in 6 simulator exercises relevant to robotic suturing over a 5-week period. We will ask participants in the training group to aim to complete the exercises Camera targeting 1, Camera targeting 2, Suture sponge 1, Suture sponge 2,and Suture sponge 3 to the target score (overall score green checkmark and all component scores to the level of yellow triangle or green checkmark, equivalent to a completed score) on two non-consecutive attempts. For the Suturing skills (SymbionixTM): Horizontal suturing defect task, the scoring is different. For this task, we have elected to ask participants to aim to complete the task ten times,rather than to achieve a certain target score."
223756769|NCT04888546|DRUG|Anlotinib hydrochloride capsules＋ TQB2450 injection|"Anlotinib hydrochloride capsules is a new type of small molecule multi-target tyrosine kinase inhibitor against angiogenesis.~TQB2450 is a humanized monoclonal antibody targeting PD-L1, which prevents PD-L1 from binding to the PD-1 and B7.1 receptors on the surface of T cells, so as to restore the activity of T cells and thereby enhance the immune response, and has the potential to treat various types of tumors."
223756770|NCT01715103|PROCEDURE|vaginal swabs by washing and cytobrush|vaginal swabs by washing and cytobrush
223756771|NCT01471548|DRUG|TKI258|
223756772|NCT03949829|DIAGNOSTIC_TEST|Cardiovascular CT|Cardiac and cardiovascular non-contrast and contrast CT
223756773|NCT01117727|DEVICE|Brain Computer Interface Switch|Subjects will wear an EEG cap for 1-2 hours typical per session and use the brain computer interface to operate assistive technology. Subjects will be asked to participate in 14-20 sessions.
223756774|NCT00554827|DIETARY_SUPPLEMENT|Vitamin B12|"1 mg intramuscular injection~Administered at least 10 days prior to start of pralatrexate if patient has elevated methylmalonic acid (MMA) and/or homocysteine(Hcy) levels.~Administered every 8-10 weeks throughout the study and for at least 30 days after last dose of pralatrexate."
223756775|NCT00554827|DIETARY_SUPPLEMENT|Folic Acid|"1 mg orally~Administered at least 10 days prior to start of pralatrexate if patient has elevated methylmalonic acid (MMA) and/or homocysteine(Hcy) levels.~Administered daily throughout the study and for at least 30 days after last dose of pralatrexate."
223756776|NCT00554827|DRUG|Pralatrexate|Intravenous (IV) push over 3-5 minutes into a patent IV line containing normal saline (0.9% sodium chloride). Pralatrexate will be administered via intravenous (IV) push over 3-5 minutes. The frequency of pralatrexate will be administered weekly for 3 or
223756777|NCT02244333|DRUG|ALNA®|
223756778|NCT06679634|DRUG|Chemoplaque also referred to as Episcleral Topotecan|Sustained Release Episcleral Topotecan
223610673|NCT00310596|DRUG|Moxifloxacin (BAY12-8039)|400 mg at 0,07 mL/sec over 60 min
223610674|NCT00310596|DRUG|Placebo|0,9% saline at 0,6mL/kg at bolus rate
223610675|NCT02657304|BEHAVIORAL|Coaching group|patients will have a medical consultation at 2 weeks post-diagnostic and one phone call/month for duration of 5 months. The consultations will use visual support, CPAP device and its accessories.
223610676|NCT02657304|OTHER|Control group|patients receive only usual care (standard), it's mean: diagnosis with explanation of the disease and benefit of CPAP, entrusts a medical device provider, then an appointment proposed by the doctor or taken by the patient (5 months).
223610677|NCT06458452|OTHER|Using Virtual Reality based serious gaming module for Advanced Cardiac Life Support|Group VG will use Artificial Intelligence driven Voice Recognition as an interface for game control whereas Group CG will only use hand held Virtual Reality controllers as an interface for game control
223610678|NCT02240641|DRUG|Lacidipine|
223610679|NCT02240641|DRUG|Diuretics|
223610680|NCT02240641|DRUG|antihypertensive drugs|
223610681|NCT02240641|DRUG|alpha blockers|
223610682|NCT02240641|DRUG|Angiotensin-Converting Enzyme Inhibitors|
223610683|NCT02240641|DRUG|beta blockers|
223610684|NCT03728010|DIAGNOSTIC_TEST|Electrical impedance tomography. Pulmonary mechanics measurement.Arterial gas measurement. Esophageal pressure measurement|After general anesthesia, patients will be ventilated with three tidal volume level (4, 6 and 8 cc / Kg / IBW), in two levels of PEEP, 6 cm2 H20, and best PEEP, the latter obtained after a recruitment maneuver and decremental titration.
223610685|NCT04260646|DEVICE|Enuresis Alarm Rodger and Timer watch (Rodger)|Nocturnal enuresis fluid sensitive alarm and Timer watch (Rodger) vibrating or sounding alarm for remembering timed voiding intervals
223610686|NCT04260646|DEVICE|Timer watch (Rodger)|Timer watch (Rodger) vibrating or sounding alarm for remembering timed voiding intervals
223610687|NCT01123616|PROCEDURE|abdominal wall closure|triclosan-coated (PDS-Plus) and non-coated (PDS) suture to close the abd. wall
223756779|NCT05793944|BEHAVIORAL|SmartMom text messaging|SmartMom is a mobile health program delivered via text messaging that guides participants through each week of pregnancy. Participants receive three messages per week with links to content focused on improving knowledge, providing information about prenatal assessments and screening, and encouraging the adoption of behaviours to support healthy pregnancy and physiologic birth. Messages are consistent with current professional guidelines and peer reviewed prenatal education curricula. SmartMom provides optional supplemental streams for individuals who wish to have additional messages addressing topics such as reducing use of tobacco, alcohol or illicit drugs, depression, obesity, and maternal age over 35.
223756780|NCT05793944|BEHAVIORAL|Control text messaging|Control arm participants will receive weekly text messages with accurate, general-interest information about pregnancy and about progress of the trial. Content is not geared to decision-making during pregnancy that may affect health outcomes.
223756781|NCT04342104|OTHER|Monitoring for aggravation|"Monitor patients on CPAP or NIV and analyzing possible variables that may predict failure, namely:~* lymphopenia~* thrombocytopenia~* CRP~* ferritin~* LDH~* troponin I~* NT-ProBNP~* Liver enzymes~* D-dimers~* radiologic aggravation  1 day and 1 week after starting NIV or CPAP"
223756782|NCT04342104|OTHER|Evaluate HACOR score effectivity in this patients|Apply the HACOR score after starting NIV and CPAP and later verify if it was effective in predicting NIV/CPAP failure
223610688|NCT05280353|OTHER|Glubran 2|Application of Glubran 2 sealant (liquid) in axillary hollow
223610689|NCT06110806|BEHAVIORAL|MBIE|MBIE administered over 20 sessions, targets increasing psychological flexibility and acceptance by decreasing avoidance and attempts to control distressing or undesired internal experiences, and includes psychoeducation, targeted mindfulness practice, in vivo exposures, and counter-conditioning.
223610690|NCT05724953|BEHAVIORAL|Affective Awareness|Intervention involving psychoeducation and daily emotion awareness practices
223756783|NCT02981381|DEVICE|NEST-1|The NeoSync EEG Synchronized TMS (NEST) is an electromechanical medical device that produces and delivers a sinusoidal magnetic field to areas of the brain in the treatment of PTSD. The device includes an EEG recording module that is used to record individualized alpha frequency (IAF) on randomized personal passport modules (PPM) pre-assigned to be NEST-1 compatible.
223756784|NCT02981381|DEVICE|SHAM|The SHAM NeoSync EEG Synchronized TMS (NEST) is a device, identical to the active NEST-1 device, that is configured to simulate the delivery of active treatment without actively delivering sTMS therapy. The device includes an EEG recording module that is used to record individualized alpha frequency (IAF) on randomized personal passport modules (PPM) pre-assigned to be SHAM compatible.
224201088|NCT03917654|BIOLOGICAL|Menactra|Menactra (Sanofi Pasteur) is a sterile, intramuscularly administered vaccine that contains Neisseria meningitidis serogroup A, C, Y, and W-135 capsular polysaccharide antigens individually conjugated to diphtheria toxoid protein. No preservative or adjuvant is added during the manufacturing process. Menactra is FDA approved for active immunization to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135 (but does not protect against serotype B) for use in individuals 9 months through 55 years of age.
223610691|NCT06047145|DIETARY_SUPPLEMENT|soy isoflavones|1 capsule daily for 84 days
223610692|NCT06047145|DIETARY_SUPPLEMENT|Placebo|1 capsule daily for 84 days
223610693|NCT06261905|DRUG|[11C]-PHNO|PHNO is used as a tracer for in-vivo imaging.
223610694|NCT06261905|DIETARY_SUPPLEMENT|Calcitriol|Calcitriol is an active form of Vitamin D and is given in 3 0.5mcg capsules per dose.
223610695|NCT06261905|OTHER|Placebo Control|A placebo is an inert capsule, which contains no active ingredients. The placebo will be given in 3 0.5mcg capsules per dose.
223610696|NCT06261905|PROCEDURE|PET Scan|A high resolution PET Scan performed using a NeurExplorer CT scanner.
223610697|NCT04903028|DEVICE|Sham rTMS|Two electrodes on the scalp will be connected to transcutaneous electrical nerve stimulation.
223610698|NCT04903028|DEVICE|Active rTMS 10 Hz DLPFC|10 Hz repetitive transcranial magnetic stimulation (rTMS) will be delivered over left dorsolateral prefrontal cortex (DLPFC).
223610699|NCT06059989|DRUG|Infliximab subcutaneous|Mono and combination therapy group
223610700|NCT06059989|DRUG|Immunosuppressive Agents|Combination group only
223610701|NCT02989753|DIETARY_SUPPLEMENT|VAL070-A|After randomization (V1 visit), 8 capsules per day of VAL070-A during 12 weeks (from visit V1 to visit V2). They will consume 3 capsules at the beginning of their breakfast, 2 capsules at the beginning of their lunch and 3 capsules at the beginning of their dinner.
223610702|NCT02989753|DIETARY_SUPPLEMENT|VAL070-B|After randomization (V1 visit), 8 capsules per day of VAL070-B during 12 weeks (from visit V1 to visit V2). They will consume 3 capsules at the beginning of their breakfast, 2 capsules at the beginning of their lunch and 3 capsules at the beginning of their dinner.
223610703|NCT02989753|DIETARY_SUPPLEMENT|Placebo|After randomization (V1 visit), 8 capsules per day of placebo during 12 weeks (from visit V1 to visit V2). They will consume 3 capsules at the beginning of their breakfast, 2 capsules at the beginning of their lunch and 3 capsules at the beginning of their dinner.
223610704|NCT06263829|OTHER|Use of Tappt App|Use of Tappt, a novel digital medication companion solution
223756785|NCT02981381|DEVICE|NEST-2|The open-label NeoSync EEG Synchronized TMS (NEST) that produces and delivers a sinusoidal magnetic field to areas of the brain in the treatment of PTSD. The device is distinct in both color and sound both SHAM and NEST-1 devices. PPMs corresponding with both SHAM and NEST-1 devices are compatible with the NEST-2 device.
223756786|NCT04998136|DRUG|Semaglutide 2.4 mg|Administered subcutaneously (s.c., under the skin) as well as reduced-calorie diet and increased physical activity for 44 weeks. Doses gradually increased to 2.4 mg
223756787|NCT04998136|DRUG|Placebo (semaglutide 2.4 mg)|Administered s.c. as well as reduced-calorie diet and increased physical activity for 44 weeks
223756788|NCT05083988|DEVICE|virtual reality glasses|a system composed of a head-mounted wide view display placed in front of the eyes and headphones placed in ears, it has the ability to block the real-world stimuli. This could distract the patient from the dental environment, which helps reduce anxiety
223756789|NCT05083988|DEVICE|music|Music can be used to distract patients from the anxiety provoking stimulus. It helps the patient to escape from the stressful reality as it activates imaginary. Psychosocially music can offer peace and comfort to patients during dental treatment as it helps in making the environment less threatening.
223756790|NCT00843921|DRUG|N-carbamylglutamate|100 mg/kg/day or 2.2 g/M2/day in 3-4 divided doses for 3 days
223756791|NCT04308317|DRUG|Tetrandrine|Tetrandrine 60mg QD for 1week
223756792|NCT04176094|OTHER|16h overnight duty|schedule observed by participating ICUs.
223756793|NCT04176094|OTHER|24h overnight duty|schedule observed by participating ICUs.
223756794|NCT04176094|OTHER|Handover training|Formal handover training for residents in both interventions. ICUs with a pre-existing standardized handover training and process will be asked to continue handover practices throughout the study. In ICUs without a pre-existing standardized handover training and process, ICU education directors will be provided with materials to include in orientation of residents to the ICU and local training to ICU staff physicians at least once per year.
223756795|NCT05457569|OTHER|Focus group (FC) - WP1|"3 group meetings for each group of parents:~1. Parents only~2. Parents and representatives of patient support groups~3. Parents and health professionals specialized in the care of these children at risk"
223756796|NCT05457569|OTHER|Child Neurodevelopment Questionnaires - WP2|during the 4th month of corrected infant age
223756797|NCT05457569|OTHER|Evaluation of compliance for the acquired skills in terms of development support - WP2|during the 4th month of corrected infant age
223756798|NCT05457569|OTHER|Evaluation of physiotherapist satisfaction with the follow-up and the time spent at the consultation - WP2|at the end of the study
223610705|NCT05073471|BEHAVIORAL|Patterned Sensory Enhancement (PSE)|"Patterned Sensory Enhancement (PSE) is one of Neurologic Music Therapy (NMT) techniques. NMT is a research-guided clinical model that is driven by advances in neuroscience and the understanding of the perception, production, and performance of music and how music can influence and change non-musical brain and behavior function.~PSE is a technique that uses the rhythmic, melodic, harmonic, and dynamic-acoustical elements of music to provide temporal, spatial, and. force cues for movements which reflect functional movements of activities of daily."
223610706|NCT05073471|DEVICE|Transcranial Direct Current Stimulation (tDCS)|"We will apply five small electrodes to participant's head. Once the electrodes are in place, a small electrical current will be passed between the electrodes. Participants will also get sham tDCS, which means they will not receive any real stimulation from the electrodes. Most individuals do not find the procedure uncomfortable, and there are no known long-term risks of tDCS. When the current goes through the electrodes, you may feel an itching or tingling sensation under the electrodes or see brief flashes of light, or you may not feel anything at all. If the sensation is unpleasant, participant can report to co-investigator immediately. If participant finds the procedures too uncomfortable, they may stop it at any time. A trained staff member will be present throughout the procedure."
223610707|NCT02193295|BEHAVIORAL|Caloric Restriction|Dietary intervention to reduce lipid content in liver and muscle with minimal overall weight loss. Weekly visits for measurements of body weight, body composition, blood glucose and MRS measurements of liver and muscle lipid.
223610708|NCT06324630|OTHER|Produce Prescription Delivery|Fruit and vegetable box delivery
223610709|NCT06324630|OTHER|Healthy Meal Kit Delivery|Ingredients to cook healthy meals delivered to home
223610710|NCT06324630|OTHER|Produce Prescription Mobile Market|Voucher to purchase fruits and vegetables at a mobile market
223610711|NCT06184594|OTHER|eNav|The eNav toolkit is a digital navigation toolkit that includes a website and text messaging support. The website includes information, motivational support, decisional support and cues to action (e.g., ability to request a CRC screening test). The eNav tool also includes text-messaging based navigation (e.g., reminders, instructions to complete the screening test).
223756799|NCT05457569|OTHER|4 Focus Group (FC) - WP2|"* Parents who accepted the follow-up~* Parents who have partially completed the programme~* Maternal and Child Protection \& CAMSP professionals~* Physiotherapists in a private practice"
223756800|NCT01213979|DRUG|500 mg iron isomaltoside 1000|500 mg iron isomaltoside 1000 given as a bolus injection over 2 minutes
223756801|NCT01213979|DRUG|1000 mg iron isomaltoside 1000|1000 mg iron isomaltoside 1000 given as a infusion over 15 minutes
223756802|NCT04938232|DRUG|Nivolumab|Intravenous infusion
223756803|NCT04938232|DRUG|Ipilimumab|Intravenous infusion
223756804|NCT06247046|DRUG|Live SK08 powder|Oral Powder
223756805|NCT06247046|DRUG|Placebo|Oral Powder
223756806|NCT03754959|DRUG|BI 1358894|Film-coated tablet
223756807|NCT03754959|DRUG|Placebo|Film-coated tablet
223756808|NCT03754959|DRUG|Midazolam|Solution for injection
223756809|NCT04390581|DEVICE|Juvéderm® VOLIFT with Lidocaine|Consists of one injection of Juvéderm® VOLIFT with Lidocaine to both hands no more than 6ml for both hands total on Day 1. Optional on Day 30.
223756810|NCT00915369|DRUG|Nanoxel (Paclitaxel Nanoparticle formulation )|Nanoxel (Nanoparticle Paclitaxel) at 4 different dose levels of 220, 260, 310 and 375 mg/m2. Each patient will recieve upto 6 cycles.
223756811|NCT04329312|RADIATION|Thoracic computed tomography|Patients undergo contrast-enhanced thoracic computed tomography as part of their routine clinical work up.
223756812|NCT01115595|BIOLOGICAL|Intervention|Dermatophagoides pteronyssinus from ALK company
223756813|NCT01115595|OTHER|Control|Injection by buffer solution WITH standard allergic medication (oral antihistamine and/or topical nasal steroid)
223756814|NCT04196478|DEVICE|doppler ultrasound|a 7.5 MHz ultrasound (US) linear probe is needed, grey-scale ultrasound and Color Doppler and a minimum display facility of the Doppler velocity spectrum for blood flow calculation are mandatory tools.
223756815|NCT06423547|OTHER|no intervention|this is an observation study,no intervention
223756816|NCT00203528|DRUG|divalproex sodium ER|
223610712|NCT06184594|OTHER|Standard of Care|Standard of care procedures for selecting their CRC screening test.
223610713|NCT03838978|DEVICE|Calypso Knee System (Implantable Shock Absorber)|The Calypso Knee System is an extra-capsular knee implant designed to fill the therapeutic gap between conservative care and more invasive surgical interventions for knee osteoarthritis.
223610714|NCT06813417|BIOLOGICAL|GCAR1|GCAR1 is a patient-specific cell therapy product containing a mixture of autologous lymphocytes transduced with a lentiviral vector encoding a chimeric antigen receptor (CAR) targeting GPNMB. The CAR comprises a single-chain variable fragment (scFv) binding domain derived from a fully human GPNMB-specific monoclonal antibody (CDX-011), a CD8 hinge and transmembrane domain, and the CD137 (4-1BB) and CD3 zeta chain intracellular signaling domains. Following infusion, the autologous GPNMB CAR T-cells expressing the genetically engineered anti-GPNMB CAR enable the specific targeting of GPNMB-expressing cells. Upon binding to GPNMB-expressing cells, the CAR transmits T cell activation signals that promote the elimination of target cells through CAR T cell degranulation and the release of cytotoxic molecules. The cellular signal also facilitates CAR T cell proliferation and persistence that may enable prolonged disease control through immunosurveillance3.
223610715|NCT05697341|PROCEDURE|Ultra-Mini-PCNL|treatment to extract or disintegrate renal stones
223610716|NCT05697341|PROCEDURE|Stented SWL|treatment to disintegrate renal stones in the presence of a JJ
223756817|NCT00203528|DRUG|risperidone|
223610719|NCT06859476|DRUG|Manzanilla Sophia®|"Ophthalmic solution. Laboratorios Sophia, S.A. de C.V., Zapopan, Jalisco, Mexico.~Route of Administration: Ophthalmic."
223756818|NCT00006890|DRUG|prednisone|Prednisone 50mg on alternate days
223756819|NCT00006890|DRUG|thalidomide|THALIDOMIDE 200 mg qhs
223756820|NCT01849211|DRUG|rocuronium|
223756821|NCT02009033|DRUG|Lactated Ringer|When normovolæmic status of the patient is secured, 35 ml/kg of the allocated fluid is infused during the operation (estimated time for this type of operation is 180 minutes), however max. 3500 ml.Lactated Ringer is the interventional medication.
223756822|NCT02009033|DRUG|Hydroxyethylstarch|
223756823|NCT02174835|DRUG|AVP-786|
223756824|NCT02174835|DRUG|AVP-923|
223756825|NCT01110746|DRUG|Viaject 7|100IU/mL administered subcutaneously
223756826|NCT01110746|DRUG|LISPRO|100IU/mL administered subcutaneously
223756827|NCT03249285|DRUG|Peri|Perindopril 4 mg /day, orally with titration to 8 mg/day after 1 month if BP (Blood pressure) is not controlled
223756828|NCT03249285|DRUG|HCTZ|Hydrochlorothiazide 12, 5 mg day, orally with titration to 25 mg/day after 1 month if BP is not controlled
223756829|NCT02790346|PROCEDURE|arthrodesis talonavicular|
223610720|NCT06859476|DRUG|Meticel Ofteno® 0.5%|"Ophthalmic solution. Laboratorios Sophia, S.A. de C.V., Zapopan, Jalisco, Mexico.~Route of Administration: Ophthalmic."
223756830|NCT02790346|PROCEDURE|tendon gestures|
223756831|NCT01895673|OTHER|Gadolinium|All patients will undergo PET-MRI additional to the PET-CT they routinely undergo. All patients will be administered Gadolinium for the PET-MRI scan. This is an extra intervention than they would normally undergo.
223756832|NCT02963493|DRUG|Melphalan flufenamide (Melflufen)|
223756833|NCT02963493|DRUG|Dexamethasone|IV dexamethasone may be substituted for oral dexamethasone in the US. Oral only in Europe.
223756834|NCT00620594|DRUG|BEZ235|
223756835|NCT00797082|DEVICE|MRI|MRI = Myocardial Perfusion Stress
223756836|NCT00797082|DEVICE|MPS|MPS = Myocardial Perfusion Scintigraphy
223756837|NCT03588637|OTHER|No intervention|No intervention
223756838|NCT03144180|DEVICE|Q-cup|This technology is a different way of collecting umbilical cord blood.
223756839|NCT00005861|DRUG|pegylated liposomal doxorubicin hydrochloride|
223756840|NCT00884234|OTHER|Vehicle Control|Two sequential doses of Vehicle Control at Baseline (Day 0) and Week 2
223756841|NCT00884234|DRUG|RT001 (Botulinum Toxin Type A Topical Gel)|Two sequential doses of RT001 at Baseline (Day 0) and Week 2
223756842|NCT03849820|DEVICE|Robotic-assisted partial nephrectomy|Application of the da Vinci surgical robot to assist the partial nephrectomy
223756843|NCT03849820|OTHER|Open partial nephrectomy|Open surgery to conduct the partial nephrectomy
223756844|NCT00001442|DRUG|paclitaxel concurrent with radiation therapy|
223756845|NCT02530112|OTHER|Survey|
223756846|NCT04930887|DRUG|Exparel (Bupivacaine Liposome)|Non-opioid postsurgical analgesic used in the management of postsurgical pain; 133 mg/10 mL (13.3 mg/mL) single-dose vial (per Pacira), study administers 3cc bilaterally
223756847|NCT04930887|DRUG|Saline|Prescription medicine used for fluid and electrolyte replenishment for intravenous administration; Exparel-matched Placebo treatment
223756848|NCT02712944|DRUG|Testosterone|Testosterone
223756849|NCT02712944|DRUG|Saline|Placebo
223756850|NCT06225726|PROCEDURE|urethral bladder resection|urethral bladder resection. Per-operative bladder ultrasound elastography and simultaneous cystometry
223756851|NCT04976036|DRUG|Nintedanib|150 mg oral nintedanib soft caps, once a day for 2 weeks and twice a day for 10 weeks (12 hours interval)
223756852|NCT04976036|DRUG|Placebo|150 mg oral placebo soft caps, once a day for 2 weeks and twice a day for 10 weeks (12 hours interval)
223756853|NCT04076774|DEVICE|Wondaleaf Female Condom|Wondaleaf: Wondaleaf is an ultra thin (of 0.02 mm) polyurethane female/male condom (16x8cm) that has folded extended adhesive shields (front 18x18cm, back 18x10cm), which at unfolding covers the entire external genitalia to prevent direct skin contact and exchange of body fluid between sexual partners during intercourse. Insertion of the condom body into the vagina is through use of a small medical grade cotton tissue packed inside the foil package. This is inserted into the end of the condom body and used to push the condom into the vagina. Each condom is individually packaged without prior lubrication. However, lubricant is expected to be used at donning the condom and during sexual intercourse. The lubricant will be supplied in separate packets together with the condom. Unlike latex, polyurethane condoms are unlikely to cause any allergic reaction and are much stronger than conventional latex condoms
223756854|NCT04076774|DEVICE|FC2 Female Condom|FC2: The FC2 is a second-generation female condom manufactured by the Female Health Company (Chicago, IL). The FC2 has US FDA approval and has been granted the CE Mark (Conformité Européenne) of the European Union. The FC2 is the only female condom that has been pre-qualified by the World Health Organisation. The device is similar in design to the FC1, but is made from a synthetic polymer (nitrile) film that is softer and more elastic than the polyurethane of the earlier device. The condom is designed as a loose-fitting pouch that lines the vagina. It has two flexible rings. The outer ring at the open end is rolled from the nitrile material. The outer ring remains outside the vagina and covers the external genitalia during intercourse. An internal polyurethane ring is removable and serves as the insertion mechanism and anchors the device within the vagina. FC2 measures 180mm in length and 80mm in lay-flat width. The device is pre-lubricated with dimethicone.
223756855|NCT03663283|DRUG|Liposomal Bupivacaine|Interscalene Nerve Blocks
223756856|NCT03663283|DRUG|Bupivacaine Hydrochloride|Interscalene Nerve Blocks
223756857|NCT04259957|DEVICE|Immersive Virtual Reality|Immersive virtual reality games and mindfulness in Oculus Quest Virtual Reality headset
223756858|NCT02667483|DRUG|DS-5141b|DS-5141b, Subcutaneous injection
223756859|NCT03121326|DIAGNOSTIC_TEST|blood and urine sampling|Ten mL blood and 15mL urine are collected.
223756860|NCT05863897|BEHAVIORAL|e-COGRAT (a blended eHealth intervention)|The blended eHealth intervention for fatigue complaints after ABI, e-COGRAT, is a cognitive behaviorial intervention. It consists of 12 weekly sessions, including 6 individual online sessions, 2 face-to-face group sessions and 4 online group sessions, in 4 groups of 4 patients.
223756861|NCT04079985|OTHER|Animal-assisted therapy|The sessions were held in the primary care centre, and had specific objectives agreed in advance by the research team. The sessions had the following schedule: Session 1, lower extremities in sitting position; Session 2, upper extremities in sitting position; Session 3, cervical spine in sitting position; Session 4, dorsal spine in sitting position; Session 5, lumbar spine in sitting position; Session 6, Static Standing and Upper Extremities; Session 7, Static Standing; Sessions 8, 9, 10 and 11, Dynamic Standing; and Session 12, Safety Reinforcement.
223756862|NCT03829371|DRUG|Velcade|Subcutaneous use
223756863|NCT03829371|DRUG|Melphalan|Oral use
223756864|NCT03829371|DRUG|Prednisone|Oral use
223756865|NCT03829371|DRUG|Lenalidomide|Oral use
223756866|NCT03829371|DRUG|Dexamethasone|Oral use
223756867|NCT03829371|DRUG|Daratumumab|Subcutaneous Injection
223756868|NCT06647030|DEVICE|CURATE.DTx sessions|"Participants will interact with CURATE.DTx twelve minutes per day, three days a week, for ten weeks.~CURATE.DTx is a cognitive training DTx developed by our research team in The N.1 Institute for Health (N.1) and The Institute for Digital Medicine (WisDM). CURATE.DTx is comprised of CURATE.AI and a modified version of the Multi-Attribute Task Battery (MATB), Online MATB.~CURATE.AI is a small data AI-derived platform that can dynamically personalize treatment by modulating drug dose or therapy intensity. We previously implemented CURATE.AI into Online MATB - the modernized, online version of MATB, a flight deck simulator program developed by NASA and the United States Air Force."
223756869|NCT06647030|BEHAVIORAL|Interview|After the last DTx session (regardless of study completion by the participant), a 60-minute interview session will be conducted by a team member, either at the Institute for Digital Medicine (WisDM) in person or via Zoom. All responses will be audio-recorded and transcribed verbatim. We will use thematic analysis of anonymized transcripts to identify emerging or recurring themes. Data will be analyzed using NVivo. The analysis will begin with open/primary coding, where we will descriptively label data. Subsequently, we will group the labels into categories based on literature (i.e., secondary coding). These categories will then help create broader themes/assertions.
223756870|NCT06213402|OTHER|Data collection from EHR.|Collection of clinical and laboratory data. Reviwe of the electronic health record
223756871|NCT05114421|DRUG|Lenvatinib|Given PO
223756872|NCT05114421|BIOLOGICAL|Pembrolizumab|Given IV
223756873|NCT05539482|BEHAVIORAL|Community-based Health Education based on core intervention package|"Community-based Health Education will potentially include the following three components:~1. A manual of emergency preparedness and self-protection against COVID-19 infection. The main content will include hand washing, mask wearing and social distancing guidelines.~2. Early testing. Participants will be trained on how to recognize the early symptoms of COVID-19 and appropriate practice to take in a response, and they will be provided with testing resources.~3. Knowledge of vaccines and their benefits and resources for vaccination.~Collaborators should design and implement health programs based on the core intervention package."
223756874|NCT05539482|BEHAVIORAL|Health Information Sharing Group|Collaborators are encouraged to collect and share health information to the participants. Shared information should be previewed by researchers.
223756875|NCT05296603|DRUG|IBI-322 Plus Lenvatinib|"IBI322 is based on the 3+3 model, with a dose ascent starting from 10mg"
223756876|NCT02308735|OTHER|N/A - No intervention|
223756877|NCT05243095|OTHER|Computer assited, game-based cognitive training|"After recording the demographic information of the participants, the Stroop Test was applied to evaluate attention. After the stages of the test were explained to the participants in detail, they were shown once in practice.~The training group received 20 minutes of cognitive training every day for 8 weeks. No training was applied to the control group. Groups were evaluated at baseline and after 8 weeks."
223756878|NCT04619706|DRUG|FSD201|Tablets for oral administration.
223756879|NCT04619706|DRUG|Placebo|Placebo tablets matched to FSD201 for oral administration.
223756880|NCT04619706|OTHER|Standard of Care for Covid-19|Standard of care for Covid-19 as determined by site PI
223756881|NCT01358227|DRUG|PR104|Dose escalation of PR104 to determine maximum tolerated dose for weekly administration
223756882|NCT05008991|DEVICE|Spirometry|Spirometry assesses the integrated mechanical function of the lung, chest wall, respiratory muscles, and airways by measuring the total volume of air exhaled from a full lung (total lung capacity \[TLC\]) to maximal expiration (residual volume \[RV\]). This volume, the forced vital capacity (FVC) and the forced expiratory volume in the first second of the forceful exhalation (FEV1), should be repeatable to within 0.15 L upon repeat efforts in the same measurement unless the largest value for either parameter is less than 1 L. In this case, the expected repeatability is to within 0.1 L of the largest value.
223756883|NCT00606892|DRUG|Varenicline|Varenicline (1 mg per day) given for 4 days prior to laboratory session
223756884|NCT00606892|DRUG|Placebo|Sugar Pill
223610721|NCT06672042|DEVICE|CHAMP App|"CHAMP® App is a proprietary, downloadable, mobile Software Application and software platform designed and developed by the Children's Mercy Hospital of Kansas City (CMH), that permits parents and caregivers to transmit to the care team data to permit remote monitoring of the patient's condition. The parent or caregiver enters into the CHAMP App data including vital signs, intake and output, video, and images of patients (collectively, CHAMP® Data), which operates on computers, mobile devices, and handheld computers. The CHAMP® App is intended to be used in the clinical care of pediatric patients in the home setting that are followed by specialty health care teams to improve patient self-management through the use of asynchronous data. Videos and data related to the patient are entered by the parent and sent electronically to the Clinical Care Team as recommended by the clinical team."
223610722|NCT05508087|DIAGNOSTIC_TEST|electrocardiography, echocardiography with the determination of global longitudinal strain, cardiopulmonary exercise test, and diagnostic of endothelial function by Angioscan|We use electrocardiography, echocardiography with the determination of global longitudinal strain, cardiopulmonary exercise test, and diagnostic of endothelial function by Angioscan for the prediction of cardiovascular complications after high dose chemotherapy and hematopoietic cell transplantation in patients with haemoblasts.
223610723|NCT03265236|DIAGNOSTIC_TEST|Anti - modified citrullinate vimentin|patients with early and late RA
223610724|NCT03384641|DRUG|Bedaquiline 200 mg|Participants will receive bedaquiline 200 mg (2\*100 mg tablets) once daily for 2 weeks followed by 100 mg tablet tiw for 6 weeks with at least 48 hours between doses.
223756885|NCT00606892|DRUG|IV Nic|IV Nicotine given during the laboratory session following 4 days of exposure to the study medication (varenicline or placebo). This nicotine was given during each laboratory session which followed the 4 days of exposure to either placebo then varenicline or varenicline then placebo.
224201089|NCT03917654|BIOLOGICAL|AVAXIM|AVAXIM - Pediatric \[Hepatitis A Vaccine Inactivated\] is a sterile, whitish, cloudy suspension. The active ingredient is a purified and formaldehyde-inactivated hepatitis A virus (HAV) obtained from the GBM strain, cultured on MRC-5 human diploid cells. HAV is adsorbed onto aluminum.
224201090|NCT04065386|DEVICE|Active taVNS|Patients will receive transcutaneous auricular vagal nerve stimulation (taVNS) for 5 consecutive days, at the cymba conchae, bilaterally, during 45 minutes (alternating 30 s on and 30 s off periods). Current intensity: 3 mA or less according to the participant's pain threshold, width: 200-300 μsec.
224201091|NCT04065386|DEVICE|sham taVNS|Patients will receive transcutaneous auricular vagal nerve stimulation (taVNS) for 5 consecutive days, at the ear lobe, bilaterally, during 45 minutes (alternating 30 s on and 30 s off periods). Current intensity: 3 mA or less according to the participant's pain threshold, width: 200-300 μsec.
224201092|NCT01919853|BEHAVIORAL|Mindfulness-Based Stress Reduction|
224201093|NCT01919853|BEHAVIORAL|Attention Control|
224201094|NCT04686500|DEVICE|Tidal volume measured by spirometer and DIBH surface from CT image|The SOC DIBH CT scan will be transferred to Eclipse treatment planning system for treatment planning. Tidal volume measured by spirometer and DIBH surface from CT image will be used as a reference surface for patient treatment initial setup. CBCT will be acquired before each fractional treatment for the patient alignment before beam delivery.
224201095|NCT05316376|DRUG|albumin-bound paclitaxel|albumin-bound paclitaxel (100 mg/m2, days 1, 8, and 15, every 4 weeks) combined with carboplatin (AUC = 5 day 1, every 4 weeks)
224201096|NCT05316376|DRUG|paclitaxel|paclitaxel (175 mg/m2, day 1, every 3 weeks) combined with carboplatin (AUC=6, day1, every 3 weeks)
224201097|NCT06475105|DRUG|Oral Acetazolamide|Participants will be randomized into group receiving either oral acetazolamide or placebo for up to 3 days
224201098|NCT06475105|DRUG|Placebo|Participants will be randomized into group receiving either oral acetazolamide or placebo for up to 3 days
224201099|NCT04045054|BEHAVIORAL|Link Team|A VA home care Link Team (clinical pharmacist, social worker, physical activity trainer) provides the intervention based on a conceptual model of home care as a bridge between hospital and home, in which three interconnected domains determine short-term and long-term outcomes: medical complexity (e.g., medication management), social complexity (e.g., caregiving, environment), and functional impairment (e.g., mobility, physical activity). The Link Team provides support and assessment for each domain, and will use tablet technology and wearable sensors in the home to gather patient data and facilitate communication. At the end of formal home care services, the Link Team provides patient-centered care in: 1) support for the the Veteran and caregiver in the event of changes in medical condition or medications and social or caregiver stressors; and 2) coaching to the Veteran and the caregiver during this transition period to optimize functional mobility and physical activity.
224201100|NCT02614352|DRUG|Atorvastatin + Candesartan|
224201101|NCT02614352|DRUG|AG1502|
224201102|NCT05359146|DRUG|161Tb-DOTA-LM3|"161Tb-DOTA-LM3 is a therapeutic medicinal product with three main components, namely (a) Terbium-161 (161Tb), a beta minus-, gamma- and Auger-/conversion electron-emitting radionuclide with a half-life of 6.96 days; (b) DOTA, a chelator that allows stable complexation of 161Tb; and (c) LM3, an antagonistic SST analogue which binds to SST2 receptors (SST2 receptor antagonist).~All doses are presented as a sterile aqueous solution for i. v. infusion with renal protection."
224201103|NCT05359146|DRUG|177Lu-DOTATOC|"177Lu-DOTATOC = 177Lu-edotreotide is a therapeutic medicinal product with three main components (a) Lutetium-177 (177Lu), a beta minus and gamma--emitting radionuclide with a half-life of 6.65 days; (b) DOTA, a chemical chelator that allows stable complexation of 177Lu; and (c) TOC (= \[Tyr\]3-octreotide) an agonistic somatostatin analogue which binds to SST2 and much less to SST5 receptors (SST2 receptor agonist).~All doses are presented as a sterile aqueous solution for i. v. infusion with renal protection."
224201104|NCT00088400|DRUG|TransMID|
224201105|NCT02919033|OTHER|Usual care|The hypertension care of this arm complies with the national guideline and includes designated follow-ups by PCPs once every 1-3 months for stage-1 (≥ 140/90 mm Hg) hypertension patients, once every 1 month for stage-2 (≥ 160/100 mm Hg) and once every 2 weeks for stage-3 (≥ 180/110 mm Hg) patients.
223756886|NCT06456281|DIAGNOSTIC_TEST|A noninvasive cfDNA multi-omics assay|Peripheral venous blood samples will be collected from pancreatic cancer patients, individuals with precancerous lesions, and healthy controls. Subsequently, cfDNA will be extracted and subjected to low-pass whole genome sequencing (LP-WGS) and hybrid capture-based targeted methylation sequencing (TMS).
223756887|NCT04307628|OTHER|Walnut|Study participants will eat 2 ounces of walnuts each day.
223756888|NCT04307628|OTHER|Nut-Free|Study participants will not eat nuts.
223756889|NCT03522766|OTHER|urine sample|The subjects are asked to give a maximum of 15 urine samples during the study
223756890|NCT02791620|DEVICE|a nanofractional radiofrequency device|A nanofractional radiofrequency device. noninvasive fractional radiofrequency device that provides ability to control and adjust the ratio of ablation and coagulation effect. Venus Viva, licensed by Health Canada, is cleared by the FDA for ablation and resurfacing dermatological procedures.
223756891|NCT00633191|DRUG|Anti-pseudomonas IgY gargle|Gargle (solution), \> 5FKU, every night after toothbrushing, life-long
223756892|NCT02101502|OTHER|Questioner|Obstetrics and gynecology health problems questionnaire for patients Educational effectiveness special questionnaire for medical staffs Institutional capacity special questionnaire for institution employees
223756893|NCT04185233|OTHER|Games on an iPad|Many games will be programmed on the iPad and organized by age. The child will choose one game and play it during all the procedure time.
223756894|NCT04185233|DRUG|Nitrous Oxide|Nitrous oxide will be provided to the child by a mask 3 minutes before the intervention and during all this one.
223756895|NCT03766100|BEHAVIORAL|Cognitive behavioural therapy (CBT-i)|CBT-i aims to alter behaviours that sustain or add to insomnia and correct cognitions that drive these behaviours. The behavioural components of CBT-i are stimulus control (SC) and Sleep Restriction Therapy (SRT). SC works through the extinction of a conditioned arousal that emerges when bed and bedroom have become associated with wakefulness. With SRT time in bed is reduced to build up sleep pressure. When wakefulness is decreased, time in bed is gradually increased until optimal sleep is attained. With the cognitive component, insomnia is treated by identifying and changing unhelpful or inaccurate thinking regarding sleep and distressing emotional responses to insomnia. The last component of CBT-i aims to reduce hyperarousal with relaxation techniques, scheduled worry time, creating a time to unwind, and employing cognitive therapy strategies.
223756896|NCT02202447|DRUG|EC1169|"PART A: EC1169 - Dose dependent on cohort, IV (in the vein) on days 1 and 8 of each 21 day cycle for the QW schedule.~PART B: EC1169 cohort 1 - taxane naive - Recommended Phase 2 dose, IV (in the vein) on days 1 and 8 of each 21 day cycle for the QW schedule.~PART B: EC1169 cohort 2 - taxane exposed - Recommended Phase 2 dose, IV (in the vein) on days 1 and 8 of each 21 day cycle for the QW schedule."
223756897|NCT02202447|OTHER|EC0652|PART A AND B: EC0652 is in development as a radioimaging agent for PSMA-expressing tumors. All patients receive a baseline 99mTc-EC0652 SPECT/CT scan for PSMA expression prior to Cycle 1 Day 1.
223756898|NCT00983216|DRUG|Colchicine|A single dose of colchicine 0.6 mg administered alone at 7:30 a.m. on Day 1.
224201106|NCT02919033|DEVICE|Self-management|"* Usual care~* Patients receive a BP telemedicine system developed by CareLinker Inc. (Shanghai, China) to facilitate BP self-management in addition to all the usual care components. The system consists of: 1) a BP tele-monitor with embedded GSM module that can upload BP readings; 2) a mobile App that allows patients to manually input healthcare data, display history BP measurements and lab test results, receive personalized lifestyle coaching contents and medication reminders, and communicate with PCPs through text-messaging.~* All patients receive proficiency training in using the BP tele-monitor, and mobile App."
223610725|NCT06998563|OTHER|Rotational Profile- Hip Internal and External Rotation Measurement|Hip internal and external rotation angles measurement, hip range of motion evaluations will be performed. Measurements will be performed using a universal goniometer. The children will be positioned in the prone position with their knees flexed 90° and placed on the edge of the bed. The tuberositas tibia will be chosen as the pivot point of the goniometer, and the movable arm will be aligned with the tibial crista. The fixed arm will be placed perpendicular to the floor and the movable arm will be guided by the tibial crista. During hip rotation, it will be ensured that the hip remains stable and the movement occurs only in the hip joint.
223610726|NCT06998563|OTHER|Rotational Profile- Craig's Test Measurement|The Craig's (Ryder) test, also known as the 'Trochanteric Prominence Angle Test', will be performed on the children included in the study according to the following protocol. The children will be placed in a prone position. The physiotherapist stood on the opposite side of the hip to be tested. The hips of the children will be placed in the extension position and the knee on the side to be tested will be held in the 90° flexion position. The physiotherapist palpated the trochanter major with the left hand and internal rotated the hip with the right hand. At the point where the trochanteric process will be most prominent, the angle between the tibia and the vertical plane will be measured using a goniometer and the femoral anteversion angle will be recorded.
223610727|NCT06998563|OTHER|Rotational Profile- Foot/Thigh Angle Measurement|Foot/thigh angle assessment will be performed by measuring the angle between the long axis of the femur bone and the foot with a goniometer in the prone position. One arm of the goniometer will be placed parallel to the long axis of the femur, while the other arm will be placed so that it passes through the 2nd and 3rd metatarsals. Normally, the thigh-foot angle should be in external rotation between 10-15°. In young children, this angle can be considered normal up to 30°. A decrease in the thigh-foot angle will indicate internal tibial torsion (expressed as a negative value), which is the internal rotation of the tibia. In this case, there is an abnormal internal rotation of the tibia. If the measured foot-thigh angle exceeds 30°, it is considered to be external tibial torsion (external rotation of the tibia).
223610728|NCT06998563|OTHER|Rotational Profile- Heel Bisector Line Measurement|The heel bisector line test is an evaluation method that helps diagnose metatarsus adductus. During the test, the child will be placed in the prone position with the heel between the physiotherapist's fingers. Then, the midpoint of the lines drawn from the malleoli will be determined. From this point, a perpendicular line will be drawn from the heel to the toes along the foot axis with the help of a goniometer. Normally, this line should end between the 1st and 2nd toes. If the line ends at the 3rd, 4th or 5th toes, this may indicate the presence of metatarsus adductus.
223610729|NCT06998563|OTHER|Rotational Profile- Q Angle Measurement|The Q-angle is defined as the angle formed between an imaginary line connecting the anterior superior iliac spine of the pelvis to the midpoint of the patella and the proximal projection of the line from the tibial tubercle to the center of the patella. The child will first be placed in a supine position with legs extended and muscles relaxed, and the midpoint of the patella will be marked with a colored pencil. Then, the goniometer will be placed at the midpoint of the patella and care will be taken to fix the movable arm so that it points to the anterior superior iliac spine and the fixed arm so that it follows the tibia and the angle between the two will be recorded. The measurement will be recorded in two different positions, lying and standing. Q angle between 10-15° in boys and 15-20° in girls will be considered normal.
223610730|NCT06998563|OTHER|Rotational Profile- Navicular Drop Test Measurement|The navicular drop test is commonly used in clinics to assess pes planus. It will begin with the child sitting, feet flat on the floor, and no weight bearing. The navicular tubercle will be palpated and marked first, then the distance from the tubercle to the floor will be measured. The child will then stand with equal weight on both feet and the distance will be measured again. Measurements will be taken bilaterally and recorded in millimeters. The difference between the weighted and unweighted measurements will indicate foot posture: 5-9 millimeters is normal (neutral), 10 millimeters or more will indicate pronation (inward rotation), and 4 millimeters or less will indicate supination (outward rotation). This test is important for assessing the degree of pes planus.
223756899|NCT00983216|DRUG|Ketoconazole|one 200 mg Ketoconazole tablet administered twice daily at 7:15 a.m. and 7:15 p.m. on Days 15-18 without regard to meals, then along with colchicine at 7:15 a.m. on Day 19 after an overnight fast of at least 10 hours; final dose of 200 mg administered at 7:15 p.m. on Day 19
223756900|NCT00983216|DRUG|Colchicine|A single dose of colchicine 0.6 mg administered along with ketoconazole at 7:15 a.m. on Day 19 after an overnight fast of at least 10 hours
223756901|NCT03618264|DRUG|Miscible liquid of dexamethasone and ropivacaine|Intervention in this study will be peri-incisional scalp infiltration with dexamethasone, ropivacaine and normal saline miscible liquids for participants who will undergo elective craniotomy. The local infiltration solution containing 0.33mg dexamethasone and 5mg ropivacaine per milliliter will be infiltrated along the incision and throughout the entire thickness of the scalp before skin incision. The volume of local infiltration solution will be decided by surgeons according to the cut length, and the capacity of the solution will be recorded by investigator.
223756902|NCT03618264|DRUG|Ropivacaine|Intervention in this study will be peri-incisional scalp infiltration with ropivacaine for participants who will undergo elective craniotomy. The local infiltration solution containing 5mg ropivacaine per milliliter will be infiltrated along the incision and throughout the entire thickness of the scalp before skin incision. The volume of local infiltration solution will be decided by surgeons according to the cut length, and the capacity of the solution will be recorded by investigator.
223756903|NCT04736238|PROCEDURE|Arthroscopy surgery|The patient receives intraspinal anesthesia or general anesthesia under supine position. Establish an anteromedial channel at the inner side of the tibial anterior tibial tendon at the level of the tibiotalar joint, and establish an anterolateral channel at the lateral angle of the talus. Exploring and clearing the ankle joint and dealing with possible combined injuries, such as talar cartilage injury, ankle impingement, and loose ankle joints. Then observe the lateral sulcus through the anterior medial channel, clean the synovium in the lateral sulcus, and explore the anterior talofibular ligament. A double-line anchor was inserted into the fibula side stop of the anterior talofibular ligament through the anterolateral channel. The anterior talofibular ligament was sutured using an outside-in technique in the anterior inferior safety zone of the distal end of the fibula. Fix the ankle joint with the suture after the dorsiflexion, neutral valgus position.
223756904|NCT04736238|PROCEDURE|BrostrÖm surgery|The patient receives intraspinal anesthesia or general anesthesia under supine position. The first ankle arthroscopy is performed to deal with possible combined injuries, such as talar cartilage injury, ankle impingement, and loose ankle joints. Then, open surgery was performed, and an arc incision was made at the anterior edge of the lateral malleolus to the tip of the fibula. After separating the subcutaneous tissue, the anterolateral joint capsule and talofibular ligament are exposed. A double-line anchor was placed at the fibular side stop of the anterior talofibular ligament. Tighten and suture the anterior talofibular ligament, anterolateral joint capsule, and extensor support belt with an anchor band. Fix the ankle joint with the suture after the dorsiflexion, neutral valgus position.
223756905|NCT05372692|DRUG|mesothelin-specific chimeric antigen receptor T cell injection|Autologous T cell injection
223756906|NCT00594061|DEVICE|Iowa/Nucleus 10/10 mm and Freedom Cochlear Implantation|Participants will receive one standard Nucleus Freedom electrode array and an Iowa/Nucleus 10/10 mm electrode array on the contralateral side.
223756907|NCT01971853|DRUG|oral placebo|Ibuprofen placebo and Acetaminophen placebo will be added to a Demerol-Vistaril regimen
223756908|NCT01971853|DRUG|Oral Analgesics|Ibuprofen at 5.0 mg/kg and Acetaminophen at 15.0 mg/kg will be added to a Demerol-Vistaril regimen
224201107|NCT02919033|OTHER|PCTM intervention|"* Usual care~* Self-management~* PCPs and cardiologists use the secure CareLinker website to review patient data including BP measurements, lab test results and medications in use and comorbidities. The auto analytics tools of the website reveal BP average, BP trend, and risk score of each patient. Text alerts of abnormal BP variability will be pushed to PCPs' App when they occur and proactive interventions including phone consultation and medication dosage adjustment will be offered. A case review session will be set once every 1-2 months for PCPs and cardiologists to exam patients' disease progresses. The proprietary web-based analytic module also produces automated individualized medication recommendations to PCPs.~* PCPs and cardiologists receive training of the CareLinker website."
224201108|NCT04176354|DRUG|Palbociclib + an aromatase inhibitor|Palbociclib + an aromatase inhibitor therapy
224201109|NCT04176354|DRUG|Palbociclib + Letrozole|Palbociclib + Letrozole therapy
224201110|NCT04176354|DRUG|Letrozole|Letrozole monotherapy
224311762|NCT02105558|DRUG|Epidural anesthesia|"￼An epidural involves injecting pain-blocking medication into a space between the vertebrae and the spinal fluid; it usually takes about 15 minutes to work.~Epidurals will be placed in a sterile fashion using a 17g Tuohy needle to locate the epidural space via loss-of-resistance to saline at the lumbar vertebral level. 3 ml of 1.5% lidocaine with 5ug/ml of epinephrine will then be used for test dose to exclude intrathecal or intravenous placement of the catheter. Epidural solution composed of 5ml of 0.2% ropivacaine and another 5 ml of 0.2% ropivacaine will then be administered."
223610731|NCT06998563|OTHER|Rotational Profile- Foot Progression Angle Measurement|The foot progression angle will be used as an important parameter in determining potential disorders and alignment errors in the child's walking pattern by reflecting the rotational relationships between the femur, tibia and foot. For this measurement, two chairs will first be placed opposite each other with a distance of 2 m between them. Then, the child will be asked to sit on the chair. In the sitting position, the middle of the heel and the second toe will be marked with colored paint. After the marking, the child will be asked to walk naturally on a flat surface to the chair opposite. The child will stand up from the sitting position and walk approximately 5-6 steps on a flat surface to the chair opposite. Then, the child will be asked to sit on the chair opposite and clean the paint off his foot. This colored marking will be made in a way that will create the child's walking traces. When the child finishes walking, these traces will be measured in degrees using a goniometer.
223610732|NCT06998563|OTHER|Muscle Shortness/Flexibility- Thomas Test Measurement|The Thomas test will be performed to evaluate shortness/tightness in the hip flexor muscle group, especially in the iliopsoas muscle. The child will be placed in the supine position, the lumbar spine will be fixed and the assessment will begin. During the test, while the assessed hip is in knee extension, the opposite hip and knee will be passively flexed by the physiotherapist, and the hip movement of the assessed side will be observed during this time. The Thomas test will be recorded as negative if no flexion movement is observed in the assessed hip. In the presence of shortness/tightness, the assessed hip is seen to be flexed, and in this case, the Thomas test will be recorded as positive.
223756909|NCT04869072|DRUG|Convalescent plasma|"Convalescent plasma will be delivered as FFP. Three units of 200ml CP/FFP harvested from one donor will be transfused to one recipient, i.e. there will be a match between donor and recipient and each recipient will receive CP/FFP only from one donor.~CP/FFP will be administered intravenously at the infusion rate of 100ml/hour, starting from day 0, with a new transfusion every 24 hours, for a total of 3 transfusions (see scheme)."
223756910|NCT05128175|DRUG|WD-1603 Carbidopa-Levodopa Extended-Release Tablets|For fasting conditions in the morning, a single oral dose will be administered to each subject under fasting conditions before 5 minutes of serving a standardized vegetarian breakfast as per the randomization schedule; for fasting conditions in the afternoon and evening, a single oral dose will be administered to each subject under fasting condition before 5 minutes of serving standardized vegetarian lunch and dinner as per randomization schedule. For fed condition, single oral dose will be administered to each subject after 30 minutes of serving standardized vegetarian breakfast, lunch and dinner as per randomization schedule. Dosing interval between two subsequent dosing should be 5 hours in each period. There will be one tablet for A, B, C, D and E.
223756911|NCT04960228|BEHAVIORAL|Altruism Video|The video provides three vignettes about a diverse set of people who may be more vulnerable to serious health consequences from COVID-19. In each of the stories, high vaccine uptake of those around these vulnerable individuals serves to protect them. This communicates that getting the COVID-19 vaccine can be done for prosocial reasons and to foster a sense of community, as it provides protection not only to oneself, but also to others.
223756912|NCT04960228|BEHAVIORAL|COVID-19 Informational Text|The topics included in the text are how COVID-19 spreads, hygiene, physical distancing, and travel restrictions. Participants will complete three comprehension questions, one after each of the following sections: hygiene, physical distancing, and travel restrictions.
223756913|NCT03561181|BIOLOGICAL|S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine|Group 1:3/2/1 dose(s) according to age of subjects. Single intramuscular dose contains 10 µg S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine.
223756914|NCT03561181|BIOLOGICAL|S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine|Group 2:3/2/1 dose(s) according to age of subjects. Single intramuscular dose contains 5 µg S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine.
223756915|NCT03356249|DIAGNOSTIC_TEST|Next-Generation Sequencing|In 500 patients with suspected or proven sepsis or septic shock (according to the Sepsis-3 definitions), patients´ characteristics and routine blood parameters will be determined at sepsis onset as well as 72 hours afterwards. At the same time points, 2 sets of blood cultures and one blood tube for Next-Generation Sequencing (NGS)-diagnostics will be collected. An evaluation of outcome will be performed at 28 days after sepsis onset.
223756916|NCT03671902|DEVICE|Fluid shift|We are using lower body negative and positive pressure to create a fluid shift in the body. This study is investigating if there are changes in phonocardiographic parameters related to changes in blood volume caused by this fluid shift
223756917|NCT03799484|DRUG|Botulinum toxin type A|Botulinum toxin type A will be administered to both sides
223756918|NCT03799484|DRUG|2.5% lidocaine/2.5% prilocaine|2.5% lidocaine/2.5% prilocaine will be applied to one side of the forehead
223756919|NCT03799484|DEVICE|petrolatum ointment|petrolatum ointment will be applied to one side of the forehead
223756920|NCT00794196|BEHAVIORAL|Pharmaceutical care program for antidepressant treatment|The pharmaceutical care program is a support program for patients starting and maintaining antidepressant treatment.
223756921|NCT04564625|OTHER|Vitamin D Assessment|index admission vitamin D assessment
223756922|NCT04564625|OTHER|Fracture|rate of nonunion (i.e., failure of a fractured bone to heal)
223756923|NCT05817396|BEHAVIORAL|Promotion of Physical Activity-related Health Competence (PAHCO)|"Intervention for the curriculum content PAHCO at nursing schools in Bavaria"
223756924|NCT02254538|DRUG|BILR 355 BS|
223756925|NCT02254538|DRUG|PEG 400|
223756926|NCT04120532|BEHAVIORAL|Perioperative Rehabilitation|Physical therapist will be consulted one day before and after the operation (OP) day. On the day before the OP day, they focus on education, including how to get up from bed and stand up from a chair. Five rehabilitation exercises are also demonstrated: 1) ankle flexion and extension, 2) knee flexion and extension, 3) hip joint abduction and adduction, 4) hip joint flexion and extension, and 5) drawing-in maneuver. The participants will be required to repeat each component to confirm that they can do it correctly. Each exercise is suggested to be done 10 times per day following MI-TLIF, and the number will be recorded 3 days (pre-OP day, post-OP day, and post-OP day 2).
223756927|NCT06142721|OTHER|3D Gait Analysis|3D gait analysis was applied to children. Static, kinematic and kinetic walking parameters were evaluated
223756928|NCT00149747|BEHAVIORAL|Moderate-Intensity Aerobic Physical Activity|Moderate-Intensity Aerobic Physical Activity. 4+ days per week, 60+ minutes per day, moderate or greater intensity physical activity
223756929|NCT00149747|BEHAVIORAL|Health Education Class|2 classes a week, 90+minutes per class, general health education, excluding information on physical activity
223610733|NCT06998563|OTHER|Muscle Shortness/Flexibility- Popliteal Angle Measurement|The popliteal angle test will be used to evaluate shortness or tightness of the hamstring muscles. The hip and knee will be placed in a 90° flexion position while the child is in the supine position. While the physiotherapist passively moves the knee joint towards extension, the popliteal angle will be measured using a goniometer. While one arm of the goniometer is placed parallel to the lateral surface of the femur, the other arm is held parallel to the fibula head and the angle will be measured. The knee joint will be extended until it encounters resistance and the angle between the tibia and the vertical plane will be recorded as the popliteal angle.
223610734|NCT06998563|OTHER|Muscle Shortness/Flexibility- Silfverskiöld Test Measurement|Gastrocnemius assessment will be evaluated with the Silfverskiold test for all children participating in the study. The assessment will be performed bilaterally in supine positions where the child does not bear weight on their feet. The knee joint will be in full extension and 90° flexion, the subtalar joint will be in a neutral position, and the ankle dorsiflexion will be measured with the fixed arm of the universal goniometer on the fibula shaft and the mobile arm following the fifth metatarsal shaft. The measured angles will be recorded in degrees (°). Passive ankle dorsiflexion of ≤ 10° with the knee extended and a minimum of 10° increase in dorsiflexion with the knee flexed will be considered as isolated gastrocnemius muscle shortness.
223610735|NCT06998563|OTHER|Muscle Shortness/flexibility- Ober Test Measurement|The Ober test will be performed to measure the length of the iliotibial band. Both the Ober test and the modified Ober test are widely used and accepted tests to assess iliotibial band length. During the test, the child will be placed in a supine position with the lower leg slightly bent at the hip and knee. The upper leg will be in 90° flexion of the knee. Once positioning is complete, the physiotherapist will hold the ankle of the upper leg with one hand and stabilize the hip with the other hand. The leg will then be abducted and the knee extended and the leg moved until the femur is in line with the body. Finally, the thigh will be allowed to fall towards the surface in this plane and the result of the test will be judged by the amount of adduction of the hip. If the knee hangs in the air, the test is positive. If the knee falls, the test is negative
223756930|NCT05077943|BEHAVIORAL|Breathing and chest mobilization exercises|Patients walk regularly 5 times per week and increase the distance day by day according to their improved ability. Patients also do breathing and chest mobilization exercise 3 times per week. It is a recorded moderated exercise for 30 minutes duration. Patients can access the video as a home-based activity through an online videos platform and will be supervised.
223756931|NCT05077943|BEHAVIORAL|Second phase cardiac rehabilitation|Independently, patients walk regularly 5 times per week and increase the distance day by day according to their improved ability without breathing and chest mobilization exercise.
223756932|NCT00669812|DRUG|carmustine|
223756933|NCT00669812|DRUG|cyclophosphamide|
223756934|NCT00669812|DRUG|cytarabine|
223756935|NCT00669812|DRUG|doxorubicin hydrochloride|
223756936|NCT00669812|DRUG|epirubicin hydrochloride|
223756937|NCT00669812|DRUG|etoposide|
223756938|NCT00669812|DRUG|ifosfamide|
223756939|NCT00669812|DRUG|melphalan|
223756940|NCT00669812|DRUG|methotrexate|
223756941|NCT00669812|DRUG|prednisolone|
223756942|NCT00669812|DRUG|vincristine sulfate|
223756943|NCT00669812|PROCEDURE|autologous hematopoietic stem cell transplantation|
223509045|NCT04662632|DRUG|Standard of Care|Forty-two days (minimum) systemic antibiotic administration adjuvant to two-stage exchange arthroplasty with temporary antibiotic-impregnated cement spacer per standard of care. Antibiotics will be selected by treatment provider and administered in accordance with national and local treatment guidelines.
223756944|NCT00669812|PROCEDURE|biopsy|
223756945|NCT00669812|PROCEDURE|peripheral blood stem cell transplantation|
223756946|NCT04152889|DRUG|Camrelizumab|Camrelizumab, 200 mg solution intravenously for 30 min in first day every 3 weeks. Repeated every 21 days. 21 days for a cycle.
223756947|NCT04152889|DRUG|S-1|Tegafur-gimeracil-oteracil potassium: 80 - 120 mg bid orally in 14 days, followed by 7 days off. Rrepeated every 21 days. 21 days for a cycle.
223756948|NCT04152889|DRUG|Docetaxel|Docetaxel: 40 mg/m\^2 solution intravenously for 1 hour in first day every 3 weeks. Repeated every 21 days, 21 days for a cycle, from second cycle to seventh cycle.
223756949|NCT00500422|DRUG|Doxil|Starting dose of 20 mg/m\^2 IV over 2 hours on Day 1, 21 day cycle
223756950|NCT00500422|DRUG|Gemcitabine|500 mg/m\^2 IV over 30 minutes on Days 1 and 8, 21 day cycle
223756951|NCT00500422|DRUG|Velcade|Starting dose of 0.7 mg/m\^2 IV on Days 1 and 8 of first 21 day cycle; increased dose of 1.0 to 1.3 on Days 1, 4, 8, and 11 of subsequent 21 day cycles
223756952|NCT04753164|DRUG|ACT-539313|ACT-539313 as capsules at a strength of 100 mg, taken orally, b.i.d. in the morning at breakfast and in the evening at dinner, with a glass of water during the treatment period.
223756953|NCT04753164|DRUG|Placebo|Matching placebo as identical capsules indistinguishable from ACT-539313, taken orally, b.i.d. in the morning at breakfast and in the evening at dinner, with a glass of water during the treatment period.
223756954|NCT06031974|BEHAVIORAL|DISCO Intervention|optimal medical management in accordance with European Society of Cardiology recommendations + dietary intervention based on Dietary Approaches to Stop Hypertension (DASH diet) + strict monitoring of eating and lifestyle behaviors
223509046|NCT04662632|PROCEDURE|Two-stage exchange arthroplasty|Stage 1 consists of surgical removal of the infected prosthesis, debridement, and implantation of a temporary spacer. Stage 2 surgery consists of explantation of the temporary spacer, debridement, and implantation of a permanent prosthesis, followed by systemic administration of postoperative antibiotics for 42 days (inclusive) to 90 days (inclusive).
223509047|NCT04662632|COMBINATION_PRODUCT|VT-X7 Treatment System with Vancomycin Hydrochloride|Seven-day local antibiotic irrigation with vancomycin hydrochloride via the VT-X7 Knee or Hip Spacer.
223509048|NCT05804292|OTHER|Questionnaire administration|Questionnaire administration
223509049|NCT03884036|BIOLOGICAL|Vitamin D|Vitamine D
223509050|NCT01794169|DRUG|Azacitidine|
223509051|NCT01794169|DRUG|DA|
223509052|NCT04634903|BEHAVIORAL|Supportive Therapy SSI|Online, 30-minute self-administered program for youth
223756955|NCT05019924|DIETARY_SUPPLEMENT|Semaine|The dietary supplement is designed, and marketed commercially to be taken in servings of two capsules per day, up to four times per day (a total of 8 capsules daily). Most consumers, however, will only take a serving three times per day, or one with each major meal (breakfast, lunch and dinner).
223756956|NCT01015586|DRUG|Lamotrigine|Six week titration from 25 mg/day to 200 mg/day, then 200 mg/day maintenance for additional six weeks
223756957|NCT01015586|DRUG|Placebo|Placebo once daily for 12 weeks
223756958|NCT01573780|DRUG|Smac mimetic TL32711|Given IV
223756959|NCT01573780|DRUG|gemcitabine hydrochloride|Given IV
223756960|NCT01573780|OTHER|laboratory biomarker analysis|Correlative studies
223756961|NCT01573780|OTHER|pharmacological study|Correlative studies
223756962|NCT01573780|PROCEDURE|biopsy|Optional correlative studies
223756963|NCT05920434|OTHER|randomized controlled study|randomized controlled study,no drugs or devices were administered to the participants.
223756964|NCT04130243|OTHER|Blood test|Withdrawal of (extra) blood to measure serum biomarkers with a blood test
223756965|NCT00736801|DRUG|Salmeterol and Salmeterol / Fluticasone|Patients inhale salmeterol for 2 weeks, followed by an inhalation of both salmeterol and fluticasone for 2 weeks.
223509053|NCT04634903|BEHAVIORAL|Behavioral Activation SSI|Online, 30-minute self-administered program for youth
223756966|NCT02595853|OTHER|Non interventional study|All upper gastro-intestinal bleeding need endoscopic hemostasis. Endoscopic hemostasis conventional methods are injection of saline with epinephrine, placement of hemoclips and thermic or plasma coagulation. Hemospray™ will be sprayed onto bleeding lesions seen in endoscopy after failure of conventional methods or in salvage therapy at the discretion of endoscopists. Retrospective analysis of prospectively cellected data.
223756967|NCT00111969|DEVICE|Celacade™ system|
223756968|NCT04603729|DRUG|Dexamethasone 2 MG/ML|Dexamethasone 8mg/day will be given intravenous for 5 days to group 1 participants
223756969|NCT04603729|DRUG|Methylprednisolone Injection|methylprednisolone 1mg/kg/day will be given intravenous for 5 days to group 2 participants
223756970|NCT03458130|DRUG|AG10|TTR stabilizer
223756971|NCT03458130|DRUG|Placebo Oral Tablet|Nonactive control
223756972|NCT03999307|RADIATION|Low-Level Laser Therapy (LLLT)|LLLT will be applied in this group
223756973|NCT03999307|PROCEDURE|Flapless Corticopunture|Small holes in the cortical bone will be achieved using 1-mm diameter round surgical Tungsten bur
223756974|NCT03999307|OTHER|Control|Typical orthodontic treatment with no LLLT or flapless corticopuncture
223756975|NCT00122343|DRUG|ridaforolimus|AP23573 will be administered intravenously (IV) at a fixed dose of 12.5 mg over 30 minutes once daily for 5 days (QDx5) every 2 weeks. A 4-week period comprised of 2 courses of AP23573 is defined as a cycle of treatment.
223509054|NCT04634903|BEHAVIORAL|Growth Mindset SSI|Online, 30-minute self-administered program for youth
223509055|NCT05639205|DIAGNOSTIC_TEST|Lateral Flow Device|Regular asymptomatic staff testing with a Lateral Flow Device including support payments if unwell.
223509056|NCT00875407|OTHER|Scintigraphy in 123I-IBZM|
223509057|NCT03416933|OTHER|Blood sampling|2x10 ml of patient peripherical blood will be collected at D0, D15, D30, D90, D180, D270 and with progression or at the end of the follow-up at the 12th month.
223509058|NCT05376553|DRUG|Cemiplimab|350mg intravenous infusion over 30 minutes
223509059|NCT05376553|DRUG|Cisplatin|"100mg/m² intravenous infusion over 60 minutes to 3 hours, mixed in 1000 ml of normal saline~Schedule: Day 1, every 21 days (+ 2 days)"
223509060|NCT05376553|DRUG|Docetaxel|"75 mg/2 intravenous infusion over 60 minutes, mixed as described in~Schedule: Day 1, every 21days (+ 2 days)"
223509061|NCT03279419|DIAGNOSTIC_TEST|Thermal imaging|Use of thermal imaging camera to capture images of peripheral vasculature (hands).
223509062|NCT02347956|PROCEDURE|Reduced port robotic distal gastrectomy|
223509063|NCT00394472|DRUG|AZD3355|
223509064|NCT01925820|DRUG|Pegasys&Entecavir|180 mcg Peg-IFN alfa-2a (Pegasys) once a week for 48 weeks. Entecavir daily will also be administered concurrently for 48 weeks and then given as monotherapy for an additional 96 weeks.
223509065|NCT03112369|BEHAVIORAL|Narrative Exposure Therapy (NET)|An international evidence-based program (EBP) for PTSD based on exposure therapy, an oral tradition of story-telling, and use of tactile medium of natural elements.
223509066|NCT03112369|BEHAVIORAL|Motivational Interviewing w/Skills Training (MIST)|Motivational interviewing (MI) coupled with skills training is based on enhancing motivation to change and building skills to address substance use behaviors.
223509067|NCT05359757|OTHER|Effect of Naturalistic Teaching Strategies in Children with autism spectrum disorder|"In this group, the patients will be provided with both the naturalistic therapeutic techniques the PECS Therapy.~A baseline of the kids in this group will be made using the portage guide and PECS~* Incidental teaching trial, natural language paradigm, and time delay concepts will be incorporated in the therapy sessions and communication using picture cards will be made.~* 40 minutes session will be conducted in which 20 minutes session will be for naturalistic teaching techniques and 20 minutes will be for PECS.~* This will be followed for 30 sessions"
223509068|NCT05359757|OTHER|PECS Therapy only|"A baseline will be developed using the portage guide and PECS.~* Communication strategies using the PECS picture cards will be made~* 30 minutes session will be conducted~* This will be followed for 30 sessions"
223756976|NCT05193474|BEHAVIORAL|integrated palliative care|shared decision making with patient, and timely integrated palliative care according to patient's preference
223756977|NCT00706836|DRUG|Pregabalin 50mg|One dose of oral pregabalin (50 mg) to be administered one hour prior to fMRI scan
223756978|NCT00706836|DRUG|Pregabalin 200 MG|One dose of oral pregabalin (200 mg) to be administered one hour prior to fMRI scan
223756979|NCT00706836|DRUG|placebo|One dose of matched oral placebo to be administered one hour prior to fMRI scan
223756980|NCT06378086|DEVICE|RHA® Redensity with new anesthetic agent|A sterile, biodegradable, biocompatible, viscoelastic, clear, colorless, homogenized gel implant. It consists of cross-linked hyaluronic acid produced by fermentation of Streptococcus zooepidemicus, formulated to a concentration of 15 mg/g and 0.3% w/w of new anesthetic agent in a physiologic buffer.
224311763|NCT02105558|DRUG|Combined spinal and epidural anesthesia|"A spinal is an injection directly into the spinal fluid; it is given in addition to the epidural technique and takes effect in five minutes.~The epidural space will be located with a 17g Tuohy needle and dural puncture performed with 25g Pencan needle via needle-through-needle technique. Spinal injection of 2ml 0.2% ropivacaine will then be performed and spinal needle removed. An epidural catheter will then be placed and test dose performed with 3 ml of 1.5% lidocaine with 5ug/ml of epinephrine. Maintenance dose will be via an epidural pump using 0.2% ropivacaine at a rate of 12 ml/hr."
224311764|NCT04707781|DIAGNOSTIC_TEST|chest CT|assessment of interstitial lung disease using chest CT
224311765|NCT03167463|PROCEDURE|flap|Repair choanal atresia with using flap during surgery
223756981|NCT06378086|DEVICE|RHA® Redensity with lidocaine|A sterile, biodegradable, biocompatible, viscoelastic, clear, colorless, homogenized gel implant. It consists of cross-linked hyaluronic acid produced by fermentation of Streptococcus zooepidemicus, formulated to a concentration of 15 mg/g and 0.3% w/w lidocaine in a physiologic buffer.
223756982|NCT04974671|RADIATION|Stereotactic Body Radiation Therapy|1-5 fraction Stereotactic Body Radiation Therapy to all sites of progression
223756983|NCT01094691|PROCEDURE|Renal Allograft Biopsy|A renal allograft biopsy will be performed when the urine is determined to be Haufen negative.
223756984|NCT03432806|OTHER|blood draws|Patients will have 10 mL of peripheral venous blood drawn immediately prior to surgery, in the post anesthesia care unit (PACU), and at the first postoperative clinic visit for a total of 30 mL.
224311766|NCT00226174|DRUG|Curcuminoids|
224311767|NCT04122144|BEHAVIORAL|ENHANCED -SPS intervention|a) Enhanced VL counseling: Explanation of VL \& Importance of VL suppression,assessment of adherence, counseling based on VL result and schedule for next VL testing and the role of VL and the MTCT risk; b).Standardized peer mother support: includes training of peer mothers on mandatory enhanced VL counseling during the routine peer counseling and education, follow up of mothers and continued adherence counseling and disclosure support and bi-weekly phone calls to mothers to provide VL counseling and follow up
224311768|NCT03972735|OTHER|Psychiatric interview|PANSS, MADRS, PSP, YMRS
224311769|NCT03972735|OTHER|Clinical, diagnostic and functional evaluation|ISMI, STORI, SERS, S-QOL, WEWMBS, BIRCHWOOD, MARS
224311770|NCT03972735|OTHER|neuropsychological assessment|WAIS IV, BEM 144, TMT A, TMT B, D2-R, V-LIS
224311771|NCT03972735|OTHER|NECT PROGRAM|Narrative Development and Cognitive Therapy (NECT) is a 12 session group-based manualized intervention combining psychoeducation, cognitive restructuring and narrative enhancement. The 2h sessions are conducted by two trained facilitators.
223509069|NCT04570280|OTHER|Aerobic Exercises|Aerobic exercises with treadmill will be applied 3 times a week for 12 weeks.
223509070|NCT04570280|OTHER|Resistive Exercises|Resistive exercises with sandbag will be applied 3 times a week for 12 weeks.
223509071|NCT04570280|OTHER|Range of Motion Exercises|Range of Motion Exercises will be applied 3 times a week for 12 weeks.
223509072|NCT03701178|OTHER|BioHPP PEEK|milled BioHPP PEEK in a new material can be used as a dental restoration
223509073|NCT06124677|DRUG|Faricimab|The Injections were performed according to local standard protocol, that included the use of 2-3 drops of topical tetracaine anesthesia, use of eye speculum, topical 5% povidone-iodine disinfection, a 30G-needle, injection site 3.5 mm posterior from the limbus marked by calipers in supertemporal or inferotemporal quadrants, a sterile cotton tip tamponade at the site of injection after removal of the needle, and no post-procedure antibiotics.
223509074|NCT00832962|GENETIC|Genotyping|Whole blood sample
223509075|NCT00832962|OTHER|Usual prophylaxis|Prophylactic anti-RhD
223509076|NCT04143438|PROCEDURE|EOS 3D imaging protocol pre- and post-surgery|Patients will undergo a EOS 3D Imaging protocol before and 6 months after undergoing patello-femoral surgery. This protocol is already used routinely in the hospital before every patello-femoral surgery.
223509077|NCT02319083|PROCEDURE|Coronary artery bypass surgery|Patients will undergo coronary artery bypass grafting
223509078|NCT04430621|DRUG|Follicle Stimulating Hormone|FSH will be administered s.c. in the morning to male healthy subjects
223509079|NCT00002316|DRUG|Lobradimil|
223509080|NCT00002316|DRUG|Amphotericin B|
223509081|NCT04129970|DEVICE|Intermittent Theta Burst Stimulation|iTBS will be delivered to the left dorsolateral prefrontal cortex (DLPFC) at 80% of resting motor threshold using standard stimulation parameters; triplet-bursts will be delivered at high frequency (50 Hz) with an inter-burst interval of 200 ms. Each TBS train will last 2 seconds and consists of 10 triplet-bursts (30 pulses). Each iTBS session will involve 10 TBS trains repeated every 10 seconds for 190 seconds, with a total number of 600 pulses delivered during each session.
223509082|NCT02716142|DRUG|rectal misoprostol|patients will take 2 tablets of rectally misoprostol 400 microgram 60 minutes before the procedure
223509083|NCT02716142|DRUG|sublingual misoprostol|patients will take 2 tablets of sublingual misoprostol 400 microgram 60 minutes before the procedure
223509084|NCT00360100|DRUG|Zmax|
223509085|NCT01812018|DRUG|Endostar|Endostar administered at 7.5 mg/m2, intravenously (IV), on Day 1-14 every 21 days for up to 4-6 consecutive cycles
223509086|NCT01812018|DRUG|Gemcitabine|Gemcitabine administered at 1000 mg/m2, intravenously (IV), on Day 1 and Day 8, every 21 days for up to 4-6 consecutive cycles
223509087|NCT01812018|DRUG|Docetaxel|Docetaxel administered at 75 mg/m2, intravenously (IV), on Day 2, every 21 days for up to 4-6 consecutive cycles
223509088|NCT03931785|DRUG|MD-7246|Oral tablet
223509089|NCT03931785|DRUG|Placebo|Matching oral tablet
223509090|NCT00831896|BIOLOGICAL|TAK-701|"Either 2, 5, 10, or 20 mg/kg IV. Cycle 1: single dose at 2x the dose assignment; Cycle 2 and beyond: dose once every two weeks~Dosing continues until disease progression, unacceptable toxicity related to TAK-701, or maximum of 12 cycles, unless determined that patient would benefit from continued therapy."
223509091|NCT03254147|DRUG|warfarin|warfarin
223509092|NCT03254147|DRUG|dabigatran|Non-vitamin K dependent oral anti-coagulants (NOACs)
223509093|NCT03254147|DRUG|Apixaban|Non-vitamin K dependent oral anti-coagulants (NOACs)
223756985|NCT03432806|PROCEDURE|colectomy or hepatectomy|"Three small pieces of otherwise normal-appearing liver of 0.5-1 cm3 collected intraoperatively from patients in all four groups (including Group D). Because liver biopsy is less frequently performed during operations for benign colon lesions or Stage I-III colon cancers, this single aspect of the protocol can be made optional at the discretion of the surgical attending or the patient, however bloods and tissue from pathology will still be collected."
223756986|NCT03432806|DIAGNOSTIC_TEST|Fibroscan test|This may be done either at a preoperative clinic setting or immediately prior to surgery.
223756987|NCT00281203|PROCEDURE|blood drawing|blood will be drawn on the entry visit and will starting the intravenous (IV) line on the day of bronchoscopy
223756988|NCT00281203|PROCEDURE|fiberoptic bronchoscopy|A flexible instrument will be passed through the mouth and into the lungs. Portions of the lungs will be washed, by injecting and immediately suctioning out a small amount of fluid. The entire return will be used for research purposes, and no results will be reported to the participant. Bronchoscopy is performed once.
223756989|NCT02669368|DRUG|Magnesium Sulfate|Patients in each group receive Magnesium sulfate 30 mg/kg in 0.9% normal saline (total volume 100 ml) intravenously for 5 min before induction of anesthesia
223756990|NCT02669368|DRUG|Saline|Patients in each group receive 0.9% normal saline (total volume 100 ml) alone intravenously for 5 min before induction of anesthesia
223756991|NCT02669368|DRUG|Standard dose Rocuronium|0.6 mg/kg of Rocuronium given with induction of anesthesia
223756992|NCT02669368|DRUG|Low dose Rocuronium|0.45 mg/kg of Rocuronium given with induction of anesthesia
223756993|NCT04209179|DRUG|PCO371|PCO371 capsule
223756994|NCT04209179|DRUG|Placebo|Placebo capsule
223756995|NCT02508571|OTHER|Direct swallowing training (DST)|The DST consists of placing a bolus of 0.05-0.2 mL of formula milk (if the parents refuse, distilled water) via a 1-mL syringe directly on the medial-posterior part of the tongue approximately at the level of the hard and soft palate junction. The volume is started with 0.05 mL, and increased in increments of 0.05 mL to a maximum of 0.2 mL until the swallowing reflex is observed. Once the minimal volume necessary to initiate the swallow reflex is identified, it is used for the duration of the training. The bolus is provided every 30 sec over the 15-minute program or as tolerated. It is continued until infants are able to complete independent oral feeding, 2 days in a row with no adverse events that do not self-resolve.
223756996|NCT02508571|OTHER|Oral sensorimotor stimulation (OSMS)|The OSMS consists of a 15-minute stimulation program, whereby the first 12 minutes involve stroking the cheeks, lips, gums, and tongue, and the final 3 minutes consist of sucking on a pacifier. It is continued until infants are able to complete independent oral feeding, 2 days in a row with no adverse events that do not self-resolve.
223756997|NCT02508571|OTHER|Sham intervention|The sham intervention consisted of the therapists placing his/her hands into the incubator or bassinet for 15 minutes without touching the infants. It is continued until infants are able to complete independent oral feeding, 2 days in a row with no adverse events that do not self-resolve.
223756998|NCT03758196|DEVICE|Radiofrequency ablation instruments|Renal Sympathetic Denervation from the adventitia of renal artery
223509094|NCT03254147|DRUG|Edoxaban|Non-vitamin K dependent oral anti-coagulants (NOACs)
223509095|NCT03254147|DRUG|Rivaroxaban|Non-vitamin K dependent oral anti-coagulants (NOACs)
223509096|NCT03521609|BEHAVIORAL|Emotional intelligence intervention|Brief group intervention based on emotional intelligence
223509097|NCT02262221|OTHER|Scheduled radiologic evaluations|Scheduled radiologic evaluations (CT or MRI scan) and PET scan in the case that patiets are ≥ 50 years old and with a smokink history ≥ 20 pack year
223509098|NCT04125758|BEHAVIORAL|Mindfulness training|Brief audio recordings discussing mindfulness or guided mindfulness practices.
223509099|NCT04125758|BEHAVIORAL|Tracking time spent on mobile device|Participants will record each day how much time they estimate they spent on their smart phone in the past 24 hours.
223509100|NCT02504775|DRUG|Mejoral® 500 Tablets|500 mg tablet of paracetamol
223509101|NCT02504775|DRUG|Tylenol® Caplets|500 mg tablet of paracetamol
223509102|NCT04210076|BEHAVIORAL|MBAT-T|The MBAT-Team program builds on the basic 4-week, 8-hour MBAT-Soldier program. In addition to the basic program, MBAT-Team includes exercises promoting the cultivation of attention and emotion regulation in the service of effective team interactions (e.g., mindful communication and listening; monitoring and attention to the activities and emotional states of others, and additional practices to promote collective mindfulness).
223509103|NCT04210076|BEHAVIORAL|MBAT-I|The MBAT-Individual program is based on the basic 4-week, 8-hour MBAT-Soldier curriculum.
223509104|NCT02534623|PROCEDURE|Spinal anesthesia|
223509105|NCT02534623|PROCEDURE|General anesthesia|
223509106|NCT02534623|DRUG|bupivacaine|
223509107|NCT02534623|DRUG|fentanyl|
223509108|NCT02534623|DRUG|propofol|
223509109|NCT02534623|DRUG|sevoflurane|
223509110|NCT03142204|DRUG|[18F]F-AraG|Single dose IV injection of \[18F\]F-AraG for each imaging day.
223509111|NCT05171335|DRUG|Lenvatinib|"Participants will receive approximately six, 28-day cycles of lenvatinib (LENVIMA®, Eisai Inc., Woodcliff Lake, NJ). Lenvatinib will be administered at 12 mg orally once daily for patients with a body weight ≥60 kg and at 8 mg orally once daily for patients with a body weight of \<60 kg.~Administration of lenvatinib will occur at least 2 weeks before the first standard of care TACE procedure and study drug treatment will continue for 6 months. Lenvatinib will be held for 7 days before and 7 days after each TACE. Participants can receive up to 3 TACE procedures per protocol depending on their response and transplantation time."
223509112|NCT05171335|PROCEDURE|Transcatheter Arterial Chemoembolization|Traditional standard of care: Transcatheter Arterial Chemoembolization (TACE) treatment for hepatocellular carcinoma. Chemotherapeutic drug-coated particles are inserted via a catheter into an artery that supplies blood to a tumor where the drug works to cut off blood supply to the tumor.
223509113|NCT04605588|DRUG|Nitazoxanide|Nitazoxanide (500 mg po BID for day 1and then 500 mg BID for 4 days)
223509114|NCT04605588|DRUG|Placebo Nitazoxanide|Placebo Nitazoxanide (500 mg po BID for day 1and then 500 mg BID for 4 days)
223509115|NCT04605588|DRUG|Ribavirin|Ribavirin (600 mg po BID for day 1and then 400 mg BID for 4 days)
223509116|NCT04605588|DRUG|Placebo Ribavirin|Placebo Ribavirin (600 mg po BID for day 1and then 400 mg BID for 4 days)
223756999|NCT05534477|DEVICE|Verily Clinical Study Watch|The Study Watch is an investigational wrist worn wearable device made with biocompatible contact materials containing various sensors capable of continuous recording of physiological, activity, and environmental data.
223757000|NCT05534477|DEVICE|Vivalink ECG Patch|The Vivalink ECG Patch is a continuously recording ECG monitor and will be used as a reference device for measuring participants' pulse rate, pulse rate variability, and pulse rate coverage. The Vivalink ECG Patch is a medical device manufactured by VivaLNK Inc. and has been cleared by the FDA.
223757001|NCT05534477|DEVICE|Modus StepWatch 4|Modus StepWatch 4 is an ankle-worn wearable medical device, and will be used as a reference device for measuring participants' ambulatory time and daily step count. The Modus StepWatch 4 is FDA listed.
223757002|NCT01845792|DRUG|Cabazitaxel with Abiraterone Acetate|Cabazitaxel intravenously every 3 weeks, in combination with abiraterone acetate and prednisone orally daily.
223757003|NCT01845792|DRUG|Cabazitaxel|Cabazitaxel intravenously every 3 weeks
223757004|NCT00045747|DRUG|7-hydroxystaurosporine|
223757005|NCT00045747|DRUG|fluorouracil|
223610736|NCT06998563|OTHER|Muscle Shortnes/flexibility- Duncan-Ely Test Measurement|The Duncan-Ely test will be used to evaluate the shortness and tightness of the rectus femoris muscle. While the child is lying in the prone position, the hip will be fixed with one hand by the physiotherapist and the hip and knee will be kept in extension. In this position, the knee joint will be passively flexed in order to stretch the rectus femoris muscle on the tested side. If no shortness or tightness is observed in the rectus femoris muscle on the same side during the test and hip extension is maintained, the Duncan-Ely test will be recorded as negative. However, when the knee is flexed and a flexion movement is observed in the hip, the test will be recorded as positive.
223610737|NCT06998563|OTHER|Muscle Shortness/Flexibility- Sit-Reach Test Measurement|The Sit-Reach test will be used to evaluate the flexibility of the hamstring and lower back muscle groups. The S\&R Sit and Reach® table will be used for this test. The child will sit in front of the table with dimensions of 55 centimeters long, 35 centimeters wide, and 30 centimeters high, and his/her feet will be positioned on the foot surface of the table. The child will be asked to place his/her hands on top of each other and stretch forward in a slow and controlled manner, bringing the ruler on the table forward. He/she will be asked to wait 1-2 seconds at the farthest point without stretching forward or backward. Scoring will be done according to the ruler on the table. (On this table, the child's ability to bring the ruler to the tips of his/her toes corresponds to 23 centimeters). The test will be repeated three times for each child to ensure reliability, and the highest value will be recorded in centimeters.
223610738|NCT06998563|OTHER|Postural Control Assessment with Biodex Balance System (BBS)|Postural stability, limits of stability, and sensory integration of balance will be assessed using the Biodex Balance System®. Biodex Balance System is a validated and reliable device used to evaluate postural stability, limits of stability, and fall risk. It consists of a balance platform, arm supports, a screen, and a printer. The platform can be set to static or dynamic mode (12 levels; level 12 = most stable, level 1 = least stable with up to 20° movement in all directions). Prior to testing, children will be informed about the procedures. The heel and toe positions will be recorded based on medial-lateral (B-J), anterior, and posterior (1-21) axes. Arm support and screen height will be individually adjusted. Child-specific posture and identification data will be entered into the system. Three tests will be performed: postural stability, limits of stability, and sensory integration of balance.
223757006|NCT01087086|BEHAVIORAL|Crononutrition|"After the recruitment and selection of the study participants, the study will consists of a 2-month nutritional intervention (Crononutrition versus AHA) followed by second 6-month period (autonomy phase) in which the subjects of the study will continue with their ruled dietary patterns, but without any dietary or psychological support."
223757007|NCT01087086|BEHAVIORAL|American Heart Association|"After the recruitment and selection of the study participants, the study will consists of a 2-month nutritional intervention (Crononutrition versus AHA) followed by second 6-month period (autonomy phase) in which the subjects of the study will continue with their ruled dietary patterns, but without any dietary or psychological support."
223757008|NCT00190801|DRUG|pemetrexed|
223757009|NCT00190801|DRUG|cisplatin|
223757010|NCT04283643|OTHER|Transcranial Focused Ultrasound|Non-invasive brain stimulation technique
223757011|NCT04283643|OTHER|Transcranial Magnetic Stimulation|Non-invasive brain stimulation technique
223757012|NCT00003294|BIOLOGICAL|filgrastim|
223757013|NCT00003294|DRUG|amifostine trihydrate|
223757014|NCT00003294|DRUG|carboplatin|
223757015|NCT00003294|DRUG|paclitaxel|
223757016|NCT00850395|DRUG|maraviroc|No intervention; any procedure at the discretion of the treating physician, in line with the SmPC
223757017|NCT03676530|DEVICE|Pro-Tec Shin Splint Compression Wrap|EVA Foam pad compression device with Velcro straps that is placed over tibial site of pain.
223757018|NCT04365868|DRUG|belapectin|intravenous
223757019|NCT04365868|DRUG|Placebo|intravenous
223757020|NCT01779193|DIETARY_SUPPLEMENT|lactic acid bacteria|oral lactobacillus capsule (dose of 2 \* 10\^9 cfu per capsule), one pill daily
223757021|NCT01779193|DIETARY_SUPPLEMENT|cranberry|oral cranberry capsule, one pill daily
223757022|NCT01779193|DIETARY_SUPPLEMENT|placebo|placebo capsule without lactic acid bacteria and cranberry, one pill daily
223757023|NCT06407466|OTHER|taping|"Kinesiology taping; In order to facilitate the muscle, while the subject is standing and his body is flexed to ensure hip flexion, both I bands will be applied from the origin to the insertion, with 30% stretching from the medial and lateral, starting from the Ischial Tuberositas to the border of the Popliteal Fossa."
223757024|NCT06407466|OTHER|Control|The routine training program will continue without intervention.
223757025|NCT06407466|OTHER|mobilization|Instrument-assisted soft tissue mobilization; The subject is in a prone position on a bed, with the lower extremity in a neutral position, and a hazelnut-sized amount of lubricant will be applied to the working surface, and will be applied to the skin on the back of the upper leg for 5 minutes, targeting the tissue structures. (Hamstring and deep fascia covering this muscle) Pressure and speed will be adjusted according to the subject's tolerance so as not to cause pain.
223757026|NCT05883137|DEVICE|Optiflow Switch|High flow nasal oxygen with the Optiflow Switch device
223757027|NCT04060056|OTHER|Standardized breakfast|Participants will be provided with a standardized breakfast on a morning of the days they wear a continuous glucose monitoring (CGM) device.
223757028|NCT04060056|OTHER|Standardized snack|Participants will be provided with a standardized snack 2 hour after they have the standardized breakfast.
223757029|NCT04060056|OTHER|Standardized lunch|Participants will be provided with a standardized lunch 2 h after they have the standardized snack.
223757030|NCT00765310|DIETARY_SUPPLEMENT|R-alpha lipoic acid|600 mg in morning on empty stomach (two 300 mg capsules)
223757031|NCT00765310|DIETARY_SUPPLEMENT|Placebo|two capsules once daily in morning on empty stomach
223757032|NCT02979340|PROCEDURE|MRI|non-invasive assessment of hepatic fibrosis and steatosis
223757033|NCT02992782|BEHAVIORAL|Standard Care|Home program of decongestive exercise and daily use of a compression sleeve
223757034|NCT02992782|BEHAVIORAL|Exercise and Compression Garment|Decongestive progressive resistance exercise using flat-knit garment and daily use of a compression sleeve
223509117|NCT04605588|DRUG|Hydroxychloroquine|Hydroxychloroquine sulfate (400 mg po BID for day 1 and then 200 mg BID for 4 days)
223509118|NCT04605588|DRUG|Placebo Hydroxychloroquine|Placebo Hydroxychloroquine sulfate (400 mg po BID for day 1 and then 200 mg BID for 4 days)
223509119|NCT01230814|DRUG|Neo-Penotran® Forte (active ingredient Metronidazole & Miconazole Nitrate)|Neo-Penotran® Forte (active ingredient Metronidazole \& Miconazole Nitrate), co-formulated vaginal suppositories containing metronidazole 750 mg with miconazole 200 mg and excipients (Witepsol S 55). Witepsol S 55 is a hard fat suppository base. Such bases consist mainly of triglyceride esters of the higher saturated fatty acids along with varying proportions of mono- and diglycerides. 117 subjects receive nightly for 5 consecutive night each month.
223509120|NCT01230814|DRUG|Placebo|Placebo vaginal suppositories, identical in appearance to the active product; contains Witepsol S 55, Titanium Dioxide and D+C yellow #10 with no metronidazole or miconazole.117 subjects receive nightly for 5 consecutive nights each month.
223509121|NCT02527265|BIOLOGICAL|Afrezza|"Pharmaceutical form: powder~Route of administration: inhalation"
223509122|NCT02330263|DIETARY_SUPPLEMENT|carbohydrate beverage|400ml of 12.8 g/100 ml carbohydrate beverage
223509123|NCT01573728|BEHAVIORAL|Low dose exercise|Exercise totaling 50 minutes per week and low intensity
223509124|NCT01573728|BEHAVIORAL|Public Health Exercise|At least 150 minutes at moderate intensity
223509125|NCT02182453|DRUG|BI 10773 - single rising dose|
223509126|NCT02182453|DRUG|Placebo|
223509127|NCT03816137|BIOLOGICAL|ConM SOSIP|Recombinant HIV-1 trimeric gp140 Env protein: ConM SOSIP gp140. Model immunogens will be used at the dosage of 20 mcg or 50 mcg or 100 mcg and will be admixed with 500 mcg MPLA formulated in liposomes and administered by intramuscular injection into the left or right deltoid muscle.
223509128|NCT03816137|BIOLOGICAL|EDC ConM SOSIP|Chemically fixed version of recombinant HIV-1 trimeric gp140 Env: EDC ConM SOSIP. Model immunogens will be used at the dosage of 100 mcg and will be admixed with 500 mcg MPLA formulated in liposomes and administered by intramuscular injection into the left or right deltoid muscle.
223509129|NCT03816137|BIOLOGICAL|ConS UFO|Recombinant HIV-1 trimeric gp140 Env protein: ConS UFO gp140. Model immunogens will be used at the dosage of 50 mcg or 100 mcg and will be admixed with 500 mcg MPLA formulated in liposomes and administered by intramuscular injection into the left or right deltoid muscle
223509130|NCT03816137|BIOLOGICAL|EDC ConS UFO|Chemically fixed version of recombinant HIV-1 trimeric gp140 Env : EDC-ConS UFO. Model immunogens will be used at the dosage of 100 mcg and will be admixed with 500 mcg MPLA formulated in liposomes and administered by intramuscular injection into the left or right deltoid muscle.
223509131|NCT03816137|BIOLOGICAL|Mosaic SOSIPs|Mosaic gp140 Env trimers (Mos3.1, Mos3.2, Mos3.3) designed to overcome the immunodominance of hypervariable regions of Env. The immunogen will be used at the dosage of 100 mcg (100mcg or 2 x 50 mcg or 3 x 33 mcg) or at 40 mcg (2 x 20mcg) and will be admixed with 500 mcg MPLA formulated in liposomes and administered by intramuscular injection into the left or right deltoid muscle.
223509132|NCT03816137|BIOLOGICAL|763 SOSIP|HIV-1 envelope sequence, identified from two HIV infected individuals that displayed HIV neutralisation breadth early in infection (less than 12 months). The immunogen will be used at the dosage of 20 mcg or 50mcg or 100mcg and will be admixed with 500 mcg MPLA formulated in liposomes and administered by intramuscular injection into the left or right deltoid muscle.
223509133|NCT03816137|BIOLOGICAL|AMC011 SOSIP|HIV-1 envelope sequence, identified from two HIV infected individuals that displayed HIV neutralisation breadth early in infection (less than 12 months). The immunogen will be used at the dosage of 20 mcg or 50mcg or 100mcg and will be admixed with 500 mcg MPLA formulated in liposomes and administered by intramuscular injection into the left or right deltoid muscle.
223509134|NCT02835521|PROCEDURE|Reception|
223509135|NCT02835521|DRUG|Joint injection with triamcinolone hexacetonide|joint injection with corticosteroids
223757035|NCT02992782|BEHAVIORAL|Exercise and Adjustable Compression Wrap|Decongestive progressive resistance exercise using adjustable compression wrap and daily use of a compression sleeve
223757036|NCT02376166|DRUG|Metformin|850 mg PO twice daily for the remainder of the study period (the dose of metformin will be increased to the 850 mg PO twice daily dose in the absence of grade \> 1 toxicities)
223757037|NCT04180020|OTHER|ID/LAB|ID/LAB is the new model in which OUD is managed by Infectious Disease (ID) specialists and/or Hospitalists concurrent with management of the infectious diseases, using long-acting injectable buprenorphine (LAB).
223757038|NCT04180020|OTHER|TAU|TAU is designed to systematize what is the current practice at the participating hospitals and in most U.S. hospitals while offering a minimum standard of care. TAU will constitute recommendation for MOUD initiation and consultation for addiction medicine when available; in practice, it is typically detoxification from opioids and referral to community-based addiction treatment after hospital discharge.
223757039|NCT05450471|DRUG|Corticosteroid Topical|The L-lactide and trimethynele carbonate (TCM) Terpolymers polymer implant will be placed in the ethmoidal region, at the same time that the nasal endoscopic examination will be performed.
223757040|NCT05450471|OTHER|Placebo|Placebo
223757041|NCT04291339|PROCEDURE|High-flow nasal oxygen technique|High-flow nasal oxygen will be applied to the patients through nasal openings using Optiflow system during anesthetic induction. Pulse oximetry and oxygen reserve index will be monitored continuously.
223757042|NCT04291339|PROCEDURE|Mask ventilation technique|Oxygen will be supplied through the mouth and nose to the patients using facial mask during anesthetic induction. Pulse oximetry and oxygen reserve index will be monitored continuously.
223757043|NCT00037921|PROCEDURE|Bacterial colonization|
223757044|NCT06300164|DIETARY_SUPPLEMENT|Unripre Carob|The standard cookies and test cookies (with carob addition) to be used in the study will be produced by Dr. Lecturer Özlem ÖZPAK AKKUŞ at Toros University Nutrition Principles Laboratory. Prof. Dr. Özlem ÖZPAK AKKUŞ will produce the cookies. For standard cookies, 1 egg, 325 g gluten-free flour (Söke flour), 75 grams butter, 50 grams sugar, 10 grams baking powder, 10 grams vanilla will be added and the prepared bread mixture will be divided into 50 equal parts. To make cookies with the addition of unripe carob, the same recipe as the standard cookie will be used to make the test cookie with the addition of unripe carob fruit flour, divided into 50 equal parts, and the amount of unripe carob fruit flour will be added by calculating the daily fiber consumption amount of the patients participating in the study to be 25 g.
223757045|NCT01100411|DEVICE|Air Optix Aqua|Contact lens material: Lotrafilcon A
223757046|NCT01100411|DEVICE|Biofinity|Contact lens material: Comfilcon A
223757047|NCT01100411|DEVICE|Proclear|Contact lens material: Omafilcon A
223757048|NCT01100411|DEVICE|Acuvue Oasys|Contact lens material: Senofilcon A
223757049|NCT01100411|DEVICE|Acuvue 2|Contact lens material: Etafilcon A
223757050|NCT01100411|DEVICE|Purevision|Contact lens material: Balafilcon A
223757051|NCT02948491|OTHER|Music therapy|Song that the mother sings to the child before birth, recording of the mother's voice.
223757052|NCT04832373|DEVICE|Interaction with humanoid robot|A humanoid robot will be installed for 30 days in children. It has a touchscreen tablet, allowing manual interaction complementing the voice interaction. The robot speaks, hears, and has facial and voice identification.
224201111|NCT06436469|BEHAVIORAL|Mindfulness-Based Stress Reduction (MBSR) Program|The intervention involves participation in a structured Mindfulness-Based Stress Reduction (MBSR) program. Participants engage in a series of sessions over a four week period. During these sessions, participants learn and practice mindfulness techniques such as deep breathing and body scans. The program is designed to enhance participants' awareness of their thoughts, emotions, and bodily sensations in the present moment, promoting a nonjudgmental acceptance of their experiences. By cultivating mindfulness skills, participants aim to reduce stress, enhance emotional regulation, and develop resilience in coping with the challenges of their work environment.
224314249|NCT02546466|BEHAVIORAL|Minimal Intervention Strategy (MIS)|The MIS group will receive an educational and counseling booklet (The Back Book) as recommend by Dupeyron et al. (2011) containing information about the low back pain clinical features, risk factors and prognosis, fear avoidance beliefs, how to deal with an acute pain crisis, the early resumption of normal or vocational activities, even when still experiencing pain, and the importance of improvement in functional activity levels and posture, not just pain relief (Delitto et al. 2012). Participants from this group will not receive FT intervention and the investigator will encourage participants to not receive any kind of treatment during the one month epoch after the initial assessment. They will be followed by one of the investigators that will make phone calls to clarify doubts and reinforce the counseling.
223757053|NCT03628612|BIOLOGICAL|AUTO CAR T cell therapy|No study drug is administered in this study. Patients previously treated with AUTO CAR T cell therapy will be monitored for safety following the first infusion.
223757054|NCT01486654|DEVICE|Transcranial Direct Current Stimulation - Cathodal stimulation|Cathodal transcranial direct stimulation (tDCS) to the left hemisphere, 1.0 mA for 13 minutes, is received five days a week, for six weeks, during the initial 13 minutes of 90 minutes of speech-language treatment.
223757055|NCT01486654|DEVICE|Transcranial Direct Current Stimulation - Anodal stimulation|Anodal transcranial direct stimulation (tDCS) to the left hemisphere, 1.0 mA for 13 minutes, is received five days a week, for six weeks, during the initial 13 minutes of 90 minutes of speech-language treatment.
223757056|NCT01486654|DEVICE|Transcranial Direct Current Stimulation - Sham stimulation|Sham stimulation provided together with 90 minutes of speech language therapy, 5 days a week, for 6 weeks.
223757057|NCT00405548|DRUG|BNP (nesiritide)|
223757058|NCT00405548|DRUG|Placebo|
223757059|NCT03554291|DRUG|Famotidine 20 MG|Famotidine 20 mg capsule taken daily for 24 weeks.
223757060|NCT03554291|OTHER|Placebo|Placebo capsule taken daily for 24 weeks.
223757061|NCT03465618|DRUG|89Zr-DFO-cRGDY-PEG-Cy5-C' dots PET Imaging|A low dose spiral CT is performed first per the standard procedure. These images will be used for both attenuation correction and registration of the serial image set. The initial PET brain scan will be acquired up to about 24 hours post injection. Based upon the discretion of the physician, non-surgical patients have the possibility of a second scan and third up to about 48 hours post injection. The times per bed position may be adjusted after the first patient is imaged, and his/her scans evaluated. Additional low dose CT scans will be performed at the image session for attenuation correction and image registration. PET study may be done on a PET-MR scanner for ease.
223757062|NCT03465618|OTHER|Blood and Urine samples|Venous blood and urine samples will be obtained at approximately 0.5 hours post injection at the end of each scan
223757063|NCT05567289|PROCEDURE|Blood sample collection|"Enrolled patients will undergo sequential blood collection beginning prior to conditioning, then on the day of transplant (day 0), followed by days 7, 14, 21, 28, 56 (2 months) and 90 (3 months) post-transplant.~Bone marrow aspirates taken within this period as part of routine care will also be collected, these are typically performed around day 100 and whenever there is suspicion of disease recurrence.~The study will also collect an additional blood sample at the onset of treatment for aGvHD for those who receive systemic corticosteroids (PO or IV steroid equivalent to ≥0.5mg/kg prednisolone)."
223757064|NCT05567289|PROCEDURE|Bone marrow aspirate|Bone marrow aspirates taken within this period as part of routine care will also be collected, these are typically performed around day 100 and whenever there is suspicion of disease recurrence.
223757065|NCT02036502|BIOLOGICAL|Pembrolizumab|Intravenous (IV) infusion
223757066|NCT02036502|DRUG|Lenalidomide|Oral capsule
223757067|NCT02036502|DRUG|Dexamethasone|Oral tablet IV infusion
223757068|NCT02036502|DRUG|Carfilzomib|IV infusion
223757069|NCT01452607|DRUG|SPI-1005|200 mg Ebselen oral capsules (SPI-1005), single dose
223757070|NCT01452607|DRUG|Placebo|0 mg Ebselen oral capsules (SPI-1000), single dose
223757071|NCT02473354|DRUG|Remifentanil|The opioid used for this study is Remifentanil and is commonly used in the operating room. Remifentanil will be given under normoxic (breathing room air \[21% Oxygen\]) and hyperoxic (breathing 50% oxygen) conditions to determine if the measurement of the specific respiratory parameters will predict the OIRD response.
223757072|NCT02473354|DRUG|Oxygen|Remifentanil will be administered under normal oxygen (normoxia) and increased oxygen (hyperemic) conditions.
223610739|NCT06998563|OTHER|Muscle Strength Assessment with Micro-FET2|Muscle tests will be performed using the MicroFET 2 digital hand dynamometer according to the device manual. The measurement will be performed in supine, prone, side-lying and sitting positions by preventing compensatory movements. During the test, the arms will be positioned so that they will not receive power from anywhere on/to the side of the body. Measurements will be performed bilaterally. While the child to whom the test is applied is expected to perform the requested movement with all his/her strength, the evaluating physiotherapist will apply resistance in the opposite direction in proportion to the strength. During the evaluation of the same muscle, a 30-second break will be given between repetitions, and a five-minute rest will be given before moving on to the test for a different muscle. Isometric muscle strength of the Iliopsoas, Gluteus Maximus, Gluteus Medius, Quadriceps, Hamstring, Tibialis Anterior, and Gastrosoleus muscles will be evaluated.
223610740|NCT06998563|OTHER|Functional Capacity Assessmnet with 6 Minute Walk Test Measurement|"The 6MWT will be done on a flat 30-meter track marked every 3 meters, with clear start and finish lines. Before the test, the child rests 15 minutes while contraindications will be checked. If none, blood pressure, oxygen saturation, pulse, and Borg scale scores for dyspnea and fatigue will be recorded. Medications taken will be noted. The child will be instructed to walk at their own pace for 6 minutes, allowed to stop or rest, and continue until test is over is announced. The test will start with test is started and end with test is over. The timer will run continuously even if paused. The test ends if chest pain, severe breathlessness, cramps, unsteadiness, sweating, pallor, or oxygen saturation \<85% occurs. Afterward, the child will be sits and post-test vitals and Borg scores will be recorded. Distance walked and any complaints during the test will be noted."
223610741|NCT06998563|OTHER|Lower Extremity Functional Scale|The Lower Extremity Functional Scale will be used to evaluate the functional ability of the entire lower extremity in individuals with musculoskeletal disorders. This scale will question the difficulty experienced in various daily activities due to the problem in the lower extremity with 20 items. Each item will be scored between 0-4 on a Likert scale (0=extremely difficult/too difficult to do the activity; 4=not difficult at all). The total score varies between 0-80 and the higher the score, the higher the functional level. A validity and reliability study has been conducted for the Turkish version of the scale to be used in evaluating lower extremity functions.
223610742|NCT06998563|OTHER|Pain Assessment with Viusal Analog Scale|"The Visual Analog Scale is a simple and reliable tool that is widely used to assess subjective experiences such as pain. It consists of a 10 cm horizontal line with one end indicating no pain and the other end indicating worst pain imaginable. Individuals will mark the point that reflects their perception of intensity, which will then be measured in millimeters or centimeters to obtain a numerical score. Higher values will indicate greater severity. The Visual Analog scale is valid and reliable in a variety of populations and conditions, including musculoskeletal pain."
223610743|NCT06998563|OTHER|Demographic Information Form|All children's gender, age, body weight, height and dominant side information will be recorded before clinical evaluations. The body mass index (kilogram/meter2) of the child will be calculated and recorded with the recorded body weight (kilogram) and height (meter) values.
223610744|NCT06998563|OTHER|Ankle Joint Dorsiflexion Range of Motion Measurement|Dorsiflexion range of motion with the knee joint in full extension and 90° flexion, the subtalar joint in a neutral position, the ankle dorsiflexion will be measured with the fixed arm of the universal goniometer on the fibula shaft and the mobile arm following the fifth metatarsal shaft. The measured angles were recorded in degrees (°). Measurements will be made bilaterally.
223610745|NCT06998563|OTHER|Leg Length Measurement|Leg Length Measurement, the child will be placed in a supine position. The legs will be positioned in extension and the muscles will be relaxed. The physiotherapist will measure and record the child's right leg length from the SIAS bone to the medial malleola with a flexible metal tape measure. Measurements will be made bilaterally.
223610746|NCT05907395|DRUG|PF-07293893|PF-07293893 will be prepared as an oral suspension given in escalating single doses to be determined.
223610747|NCT05907395|DRUG|Placebo|Matching placebo will be prepared as an oral suspension given in each cohort.
223610748|NCT04544956|DRUG|GSK3228836|GSK3228836 will be available as a clear colorless to slightly yellow solution for injection in 150 mg/milliliters (mL) vial to be administered SC once weekly.
223610749|NCT04544956|DRUG|Nucleos(t)ide therapy|Participants receiving nucleos(t)ide therapy upon entry in the study will continue to receive nucleos(t)ide therapy for the duration of the study.
223757073|NCT02473354|DRUG|Carbon dioxide|Carbon dioxide is used as part of the hypercapnia ventilatory response measurement (HCVR)
223757074|NCT02741700|BEHAVIORAL|Gout Storytelling Video Intervention|The investigators developed a storytelling intervention for African-Americans with gout, to address barriers to optimal gout management and provide cues for better disease management, which were narrated by several Veterans with gout. One of the veterans also presented a PowerPoint on gout and its management. The intervention was shown to the participants on a touchscreen computer or the desktop screen at the baseline study visit. Subsequently, they were provided with DVD with similar intervention to watch at home.
223757075|NCT00811577|DRUG|Placebo|Patients in the Placebo-only arm were dosed intradermally with placebo (saline) in three trocar sites on Day 9 (plus/minus 2 days) and Day 21 (plus/minus 2 days) after arthroscopic shoulder surgery. In the AZX100-placebo arm, 3 or 10 mg or placebo (saline) was administered intradermally at each of three trocar sites on each patient 9 ± 2 days and 21 ± 2 days after arthroscopic surgery. The three trocar sites (anterior, lateral, and posterior sides of the shoulder) were randomized to receive the same dose of study agent for both dose administrations.
223757076|NCT00811577|DRUG|AZX100|AZX100 Drug Product 3 or 10 mg or placebo (saline) was administered intradermally at each of three trocar sites on each patient 9 ± 2 days and 21 ± 2 days after arthroscopic surgery. The three trocar sites (anterior, lateral, and posterior sides of the shoulder) were randomized to receive the same dose of study agent for both dose administrations.
224201112|NCT05950204|DIETARY_SUPPLEMENT|ω-3 polyunsaturated fatty acids (DHA and EPA), Vitamin D (cholecalciferol), Calcium (calcium carbonate)|Intervention with 100 mg/kg/d of LCPUFA-ω3 with a ceiling dose of 3 g/d, + 1,000 mg of calcium/day and 4,000 IU (100 µg)/d of VD in those children \> 9 years and 20,000 UI/week = 2,857 UI/d in those \< 8 years for 6 weeks. The other group of patients will receive only the same dose of VD and calcium.
224201113|NCT02599298|DEVICE|Continuous Positive Airway Therapy|
223610750|NCT06613802|OTHER|Time|This is a cross sectional study, and the exposure where the outcome is expected to change by is time. Years included in the study are 2013-2014, 2018-2019 and 2023
223610751|NCT00108771|DRUG|ZR-02-01 Fentanyl Transdermal Matrix Patch|Study patches were replaced every 72 hours and were to be applied on the upper chest or lateral aspect of the upper arms. The patch application sites were to be rotated so the patch was not applied to the same skin site for successive applications. Patients were supplied with Tegaderm if needed to keep the patches adhered during the 72 hour wear period.
223610752|NCT00108771|DRUG|Placebo Patch|Study patches were replaced every 72 hours and were to be applied on the upper chest or lateral aspect of the upper arms. The patch application sites were to be rotated so the patch was not applied to the same skin site for successive applications. Patients were supplied with Tegaderm if needed to keep the patches adhered during the 72 hour wear period
223610753|NCT03275805|OTHER|Duration of Pavlik Harness treatment|The only intervention that varies from standard of care (12 weeks of treatment) will be the duration of bracing (for the treatment to normalization arm). Patients in both arms will have identical follow up protocols and imaging to closely monitor hip morphology.
223610754|NCT03275805|OTHER|12 week standard of care|The intervention for this arm will be standard treatment for this pathology.
223610755|NCT06700525|BEHAVIORAL|Non-Sedentary Behavior Habit Formation|"Action Plans Addition to the StandUPTV platform:~The StandUPTV mHealth platform will be used to assess SST and deliver behavior change components. Participants will receive a technology kit including a Fitbit Charge 4+ and Wi-Fi-enabled smart plugs. The Fitbit and smart plugs will need to be used for the entire duration of the study participation. Participants will also be assisted with establishing an action plan for a non-sedentary break from evening sedentary screen time, which will be trigger by a StandUPTV alert delivered after performing 30 minutes of evening sedentary screen time."
223610756|NCT06700525|BEHAVIORAL|Sedentary Screen Time Reduction Smartphone App|The StandUPTV application is used to monitor and reduce sedentary screen time (SST). The StandUPTV app has three components: LOCKOUT: Electronic lockout turns off screens when a predetermined limit is reached (50% of baseline value of weekly sedentary screen time). The app also includes planning tools and personalized strategies to limit SST. TEXT: Push notification prompts provide reminders, coaching, and personalized feedback (up to 2 per day). EARN: Opportunities to earn SST by engaging in MVPA, measured in 10-minute bouts.
223610757|NCT06702553|DRUG|Nitric Oxide Gas|Patients will receive 80 parts per million (ppm) NO during CPB through the oxygenator. After weaning of CPB, test gases will be delivered via inspiration limb of ventilator at a dose range of 40-80 ppm until 6 hours after ICU admission or until extubation after surgery, whichever comes first.
223610758|NCT06702553|DRUG|Standard Care Arm|Patients in this group will receive standard care and 80 ppm nitrogen (N2, control group) are added to the gas mixture as control. In the circumstances when the N2 is not applicable, such as when the plasma-chemical NO synthesis device is employed for NO generatiaon and delivery, the device will be connected to the CPB and ventilator circuits, but the synthesis will remain inactive in the control group. Consequently, the circuit will be supplied with air devoid of NO.
223610759|NCT06725056|OTHER|DS-MCE and EGD examinations|sequentially performing DS-MCE and EGD examinations on AUGIB patients with stable hemodynamics
223610760|NCT06725940|DEVICE|68Ga-GZMB PET/CT|68Ga-GZMB PET/CT
223610761|NCT07053956|OTHER|Chewing Gum|Patients admitted to our outpatient clinic for bronchial asthma undergo regular FeNO measurements. If the value is ≥ 25 ppb (elevated), the patients are randomized into two groups after obtaining their consent. In the control group, a FeNO measurement is performed again after 15 minutes. In the second group, the FeNO measurement is measured again after 15 minutes of consuming sugar-free, antioxidant-containing chewing gum. The following data are then collected and documented from the patients: age, gender, height, weight, smoking status, current medication, other illnesses, whole body lung function test, and laboratory tests (eosinophils, IgE). Participation in the study will not change the course of the patient's stay in our clinic.
223610762|NCT07060859|DRUG|Topical Application of Dexamethasone, Ascorbic Acid, and β-Sodium Glycerophosphate|A topical combination of dexamethasone (anti-inflammatory), ascorbic acid (antioxidant), and β-sodium glycerophosphate (mineralization support) was applied directly to the implant site during surgery. The intervention aimed to enhance early osseointegration by modulating local biological responses.
223610763|NCT07066995|BIOLOGICAL|Mesothelin and Claudin 18.2 CAR-T cells|"The intervention in this clinical trial involves a novel approach using Mesothelin and Claudin 18.2 Chimeric Antigen Receptor T (CAR T) cells combined with chemotherapy. The goal is to assess safety and efficacy in patients with specific hematologic malignancies.~Treatment Regimen:~Fludarabine Phosphate (Days -4 to -2): IV administration of fludarabine phosphate over 30 minutes on days -4 to -2. It's part of the preparatory regimen to enhance the body's response to CAR T-cell therapy.~Cyclophosphamide (Day -2): IV cyclophosphamide over 60 minutes on day -2.~Mesothelin and Claudin 18.2 Chimeric Antigen Receptor T Cells (Day 0): IV administration of investigational therapy, Mesothelin and Claudin 18.2 CAR T cells, over 10-20 minutes on day 0.~Additional Doses: Eligible patients responding well to the initial Mesothelin and Claudin 18.2 CAR-T cell infusion without unacceptable side effects and sufficient CAR-T cell availability may receive 2 or 3 additional doses."
223610764|NCT06753448|DRUG|Diosmin and Hesperidin Combination|Participants will take diosmin and hesperidin combination for 14 days after total knee replacement surgery.
223610765|NCT06523868|OTHER|GRAIL Galleri|A multi-cancer early detection (MCED) blood test.
223610766|NCT06241170|PROCEDURE|mesentery-guided resection margin|Mesentery-guided resection margin where the mesentery adjacent to the intestine completely transitions from abnormal to normal upon palpation and transillumination, compared to the proximal normal mesentery. Open, laparoscopic, hand-assisted, or robotic mobilization are all acceptable, but extracorporeal resection and anastomosis are required. After intestinal mobilization , the diseased intestinal segment is exteriorized from the abdominal cavity.
224201114|NCT02599298|BEHAVIORAL|Sleep-Study Guided Multidisciplinary Therapy|
224201115|NCT00991211|DRUG|Bendamustine|Comparison of Bendamustine + Rituximab with CHOP + Rituximab
224201116|NCT00991211|DRUG|Standard chemotherapy CHOP + Ritiximab|Cyclophosphamid 750 mg/m² d 1 + Doxorubicin 50 mg/m² d 1 + Vincristin 1,4 mg/m² max. 2 mg d 1 + Prednison 100 mg absolute p.o. d 1-5 + Rituximab 375 mg/m² d 1 q3w as standard Chemotherapy
224201117|NCT03950817|DRUG|Nebulized Sub-dissociative Dose Ketamine at either 0.75 mg/kg|Nebulized Sub-dissociative Dose Ketamine at 0.75 mg/kg
223610767|NCT06241170|PROCEDURE|traditional resection margin|"2 cm proximal to the site where gross lesions disappear. After transecting the bowel, re-examine the mucosal condition; if mucosal ulcers or obvious scars are present, extend the incision until reaching the site with normal mucosa. Definition of gross lesions: Evaluation from the outer intestinal wall: The site where the tough texture, thickening, or contracture at the mesenteric edge of the intestinal wall disappears; evaluation from the intestinal lumen: The site where mucosal ulcers, fissures, or obvious scars disappear. Mucosa appearing seemingly abnormal is considered normal."
224201118|NCT03950817|DRUG|Nebulized Sub-dissociative Dose Ketamine at 1 mg/kg|Nebulized Sub-dissociative Dose Ketamine at either 0.75 mg/kg, 1 mg/kg, and 1.5 mg/kg.
223610768|NCT06926855|OTHER|CHC-level cluster randomized control trial|"CHW (with clinic champion support) outreach to eligible patients, verbally consent patients, confirm eligibility, conduct social needs screening, make service or resource referrals, plan and support referral completion as needed, follow-up with patients to assess referral completion and outcomes~Implementation supports: financial support for CHW, clinic champion, and CHC administration of trial activities; 12 weeks of preparatory CHW training and coaching; practice coaching and technical support for data collection at all sites; additional support for sites without existing research data infrastructure; CHW Learning Collaborative through intervention and follow-up period for implementation support and cross-training control sites."
223610769|NCT06902181|BEHAVIORAL|Experimental Group - 100% CXMCI-01 Essential Oil|Participants in the experimental group will inhale 100% CXMCI-01 essential oil twice(CXMCI-01-M in morning, CXMCI-01-N in night) daily for 28 days using an aroma necklace. Each session involves placing 2 drops of the essential oil on a cotton pad inside the necklace. Inhale near the nose for 5 minutes, then wear the aroma necklace and continue inhalation for 60 minutes.
223610770|NCT06902181|BEHAVIORAL|Control Group - 0.1% CXMCI-01 Essential Oil (placebo)|Participants in the placebo group will inhale a 0.1% CXMCI-01 essential oil dilution twice (CXMCI-01-M in morning, CXMCI-01-N in night) ) daily for 28 days. The protocol mirrors the experimental group: inhalation near the nose for 5 minutes, followed by wearing an aroma necklace infused with the diluted essential oil for 60 minutes. This group serves as a placebo comparator to evaluate the effectiveness of the experimental intervention.
223610771|NCT02762214|DEVICE|Clermont-Ferrand Uterine Manipulator|"Pelvic cytology is obtained before starting surgical procedures (washing number 1).~After tubal coagulation, Clermont-Ferrand Uterine Manipulator is installed inside the uterus. At the end of the hysterectomy, after colporrhaphy, a second cytology is obtained (washing number 2)"
223610772|NCT02762214|OTHER|No uterine Manipulator|"Pelvic cytology is obtained before starting surgical procedures (washing number 1). None uterine manipulator is used and the cervix is closed with a cross stitch.~Tubal coagulation, At the end of the hysterectomy, after colporrhaphy, a second cytology is obtained (washing number 2)"
223610773|NCT03363620|DEVICE|Orthodontic Brackets|arch form development in the orthodontic treatment with 2 different kind of ligation brackets with the same arches protocol in the leveling and alignment phase
223610774|NCT03363620|DEVICE|Orthodontic Brackets|arch form development in the orthodontic treatment with 2 different kind of ligation brackets with the same arches protocol in the leveling and alignment phase
223610775|NCT01589393|DRUG|Enoxaparin|Enoxaparin 30 mg subcutaneously twice daily for six doses starting 36-48 hours post traumatic injury.
223610776|NCT01589393|OTHER|Placebo|0.9% normal saline in equal volume to active comparator given subcutaneously twice daily starting 36-48 hours post traumatic injury for six doses.
223610777|NCT00434109|DRUG|Sunitinib malate|Sunitinib malate (Sutent) at a dose of 37.5mg will be administered orally once daily on days 1-28 in a 42-day cycle. Treatment with Sutent will begin no sooner than seven days after the first hepatic artery embolization. Subsequent embolizations (if necessary) will be scheduled during scheduled Sutent treatment breaks. No fewer than seven days shall separate treatment with Sutent and scheduling of hepatic artery embolizations.
224201119|NCT03950817|DRUG|Nebulized Sub-dissociative Dose Ketamine at 1.5 mg/kg.|Nebulized Sub-dissociative Dose Ketamine at 1.5 mg/kg.
224201120|NCT00905437|DRUG|Placebo|Placebo as an adjunct to standard of care
223610778|NCT00434109|PROCEDURE|Hepatic Artery Embolizations|1-3 selective hepatic artery embolizations will be performed at approximately 5-week intervals, based on the extent of hepatic involvement with tumor.
223610779|NCT02406105|RADIATION|Radiosurgical thalamotomy|Cybernetic microradiosurgery based thalamotomy
223610780|NCT02406105|DRUG|CyberKnife|
223610781|NCT02321553|OTHER|Brown rice|brown rice cake
223610782|NCT02321553|OTHER|White rice|white rice cake
223610783|NCT06241053|OTHER|Multimodal therapy with McConnell taping|"Multimodal therapy includes core exercises, hip exercises and vastus medialis training.~Core exercises include curls ups, toa taps, side planks, supine straight leg raising, side lying straight leg raising, prone knee flexion, draw foot circles in supine and side lying, prone cobra, hip and knee extension, weight bearing, hip flexion sitting on ball, wight bearing forward and backward on the ball, stairs up on Swiss ball. Hip training includes Hip abduction, Hip external rotation in standing and sitting. VMO muscle strengthening will includes squats with a ball."
223610784|NCT06241053|OTHER|Multimodal therapy without McConnell taping|Multimodal therapy without McConnell taping
223610785|NCT05590507|BEHAVIORAL|Mindfulness Audio Recordings|A 5-minute audio file aimed to increase likelihood of experiencing positive affect associated with physical activity. Participants will listen to a mindfulness audio file at the beginning of each physical activity session they choose to engage in during weeks 2-4
223610786|NCT05460143|OTHER|Near-infrared Spectroscopy scan|Near-infrared spectroscopy is a non-invasive neuroimaging technique which uses light in the near-infrared spectrum to measure changes in brain oxygenation and metabolism.
224201121|NCT00905437|DRUG|Pregabalin|75 mg BD for 14 days
224201122|NCT06184646|DIETARY_SUPPLEMENT|Prune|30 g of prune/day
224201123|NCT03561272|OTHER|Smart Phone Application|Oral medication adherence phone application.
224201124|NCT03561272|OTHER|POD|Pill dispensing system that dispenses the medication, controls dispensed dosage, and confirms dispensing to patient through wireless communication back to the control center.
223610787|NCT05460143|OTHER|Magnetic Resonance Imaging scan|Magnetic Resonance Imaging is a non-invasive neuroimaging technique which provides detailed structural images of the brain.
223610788|NCT00461084|DRUG|BIAXIN (CLARITHROMYCIN)|Biaxin (clarithromycin) 500 mg will be administered by mouth twice daily for 12 weeks in all patients. In H. pylori positive patients, Prevpak standard therapy (lansoprazole, amoxicillin, clarithromycin) will be administered for the first 2 weeks.Following Biaxin (clarithromycin) antibiotic therapy, the patient will be reassessed for eradication of H. pylori if previously present.
223757077|NCT04530006|DIAGNOSTIC_TEST|Amantadine Hydrochloride|"Patients who are eligible for the study will be administered a regular 200 mg dose of FDA approved drug amantadine. This will be done at the following timepoints:~1. Within 4 weeks of the start of treatment; but as close to commencement of treatment (Day 1 of radiotherapy) as possible for newly diagnosed patients.~2. Cycle 1, Day 1 of chemotherapy (temozolomide or lomustine) +/- 7 days~3. Day 1 +/- 7 days for each visit where MRI is obtained (typically every 8-12 weeks - pre-cycles 4, 7, 10, for temozolomide or pre-cycles 3, 5, and 7 for lomustine)"
223757078|NCT06496009|DRUG|PD-1 Inhibitors|advanced or metastatic non-small cell lung cancer who are PD-L1 negative and receiving first-line immunotherapy in routine clinical practice
223757079|NCT06539117|OTHER|Early feeding post caesarean section|In this group, participants were encouraged to commence oral sips of 150 millilitres of water from 6 hours post-caesarean delivery by the staff nurse. Thereafter, they were given semi-solid diet (250 milliliter of pap) from the 12th hour, and subsequently solid diet (a plate of well- cooked rice) by the trained nursing staff.
223757080|NCT02120976|DRUG|JTT-252 or Placebo|Subjects will receive JTT-252 or Placebo
223757081|NCT02120976|DRUG|JTT-252|Subjects will receive JTT-252
223757082|NCT01068509|BIOLOGICAL|Cvac|Cvac consists of autologous dendritic cells (DCs) incubated with the antigen, mannosylated fusion protein (M-FP), to target the DCs to the specific mucin 1 antigen.
223757083|NCT00363779|DRUG|Cyclosporine|An oral preparation given every 12 hours, 5-10 mg/kg/day in divided doses. Doses are adjusted to maintain a therapeutic level between 200-400 ng/ml. Levels will be checked twice weekly and once the patient has achieved steady state levels they shall be monitored once every 2 weeks. These therapeutic levels shall be maintained for 3 months.
223757084|NCT00363779|GENETIC|Gene expression analysis|A permutation test will be performed to examine whether the overall expression profile changes due to treatment. This will be done by comparing the number of significant genes to the distribution of this number if in fact there is no difference between pre-treatment and post-treatment gene expression.
223757085|NCT00363779|GENETIC|Microarray analysis|Gene expression profiling will be carried out on Affymetrix microarrays to compare pretreatment and posttreatment samples.
224201125|NCT06211075|BEHAVIORAL|Cognitive Behavioural Therapy for Insomnia with Motivational Interviewing|This intervention implements elements of Cognitive Behavioural Therapy for Insomnia with motivational interview techniques incorporated into the intervention, aiming to build long-lasting motivation, better rapport with the patients and self-efficacy to increase engagement rate despite its remotely delivered format. The whole intervention is delivered online.
223610789|NCT00461084|DRUG|Biaxin (clarithromycin)|Biaxin (clarithromycin) 500 mg will be administered by mouth twice daily for 12 weeks in all patients. In H. pylori positive patients, Prevpak standard therapy (lansoprazole, amoxicillin, clarithromycin) will be administered for the first 2 weeks.Following Biaxin (clarithromycin) antibiotic therapy, the patient will be reassessed for eradication of H. pylori if previously present.
223610790|NCT03722394|BEHAVIORAL|Pain Neuroscience Education|15 minute verbal one-on-one education session
223610791|NCT00258167|BEHAVIORAL|"filling the Experience of Caregiving Inventory"|8 weeks of group therapy for family members
223610792|NCT02021630|OTHER|Outcomes|No intervention will occur during this study. Evaluation of changes in patients' family after having patient has bariatric surgery.
223757086|NCT00363779|OTHER|Laboratory biomarker analysis|Analysis of differential gene expression profiles in patients with LGL leukemia treated with cyclosporine.
223757087|NCT01822080|DRUG|Dienogest (Visanne, BAY86-5258)|2 mg dienogest (DNG) once daily by mouth
223757088|NCT01822080|DRUG|Placebo|Matching placebo once daily by mouth
223757089|NCT00921180|DRUG|Entecavir and peginterferon alfa-2a|Entecavir (Baraclude) 0.5 mg/day po at week 1-4 Peginterferon alfa-2a (Pegasys) 180 ug/week sc at week 5-52
223757090|NCT00921180|DRUG|Placebo and peginterferon|Placebo 0.5 mg/day po at week 1-4 Peginterferon alfa-2a (Pegasys) 180 ug/week sc at week 5-52
223757091|NCT02442778|DRUG|AVP-786-18|18 mg of Deudextromethorphan hydrobromide (d6-DM) and 4.9 mg of Quinidine sulfate (Q)
223757092|NCT02442778|DRUG|Placebo|Administered as capsules.
223757093|NCT02442778|DRUG|AVP-786-28|28 mg of d6-DM and 4.9 mg of Q
223757094|NCT02442778|DRUG|AVP-786-42.63|42.63 mg of d6-DM and 4.9 mg of Q
223757095|NCT01165138|DRUG|Fluticasone furoate/Vilanterol Inhalation Powder|Fluticasone furoate/Vilanterol Inhalation Powder inhaled orally once daily for 12 weeks
223757096|NCT01165138|DRUG|Fluticasone Furoate Inhalation Powder|Fluticasone Furoate Inhalation Powder inhaled orally once daily for 12 weeks
223757097|NCT01165138|DRUG|Placebo Inhaltion Powder|Placebo Inhaltion Powder inhaled orally once daily for 12 weeks
223757098|NCT03498742|OTHER|NO Intervention|Routine clinical data; asthma control test and spirometry
223757099|NCT00384800|DRUG|Thalidomide(THADO), Tegafur/Uracil(UFUR)|
223757100|NCT00256152|DEVICE|AF Suppression Pacing Algorithm|
223757101|NCT05046041|DRUG|Mifepristone + Misoprostol|A single 200 mg mifepristone (one tablet) to be taken orally either at home or at the hospital, followed approximately 24 - 48 hours later with administration of 400 mcg misoprostol. Repeat doses of 400 mcg (two tablets) of misoprostol will be administered buccally (buccal) every three hours until the abortion is achieved.
223757102|NCT02858245|OTHER|No intervention - registry|
223757103|NCT03684018|BIOLOGICAL|IgPro10|Normal human immunoglobulin G administered intravenously
223757104|NCT01002833|BIOLOGICAL|Exposure to Plasmodium falciparum infected mosquitoes|Healthy volunteers are exposed to the bites of 5 Plasmodium falciparum infected mosquitoes
223757105|NCT06973993|OTHER|live music|live music will be played during waiting time in ER room
223757106|NCT06973993|OTHER|recorded music|recorded music will be transmitted during waiting time in ER room
223757107|NCT06973993|OTHER|no music|no music will be played or transmitted during waiting time in ER room
223757108|NCT02338765|BEHAVIORAL|mHealth Physical Activity|
223757109|NCT02338765|BEHAVIORAL|Buddy-partnered exercise|
223757110|NCT04128163|DRUG|QL1206|"subcutaneous injection of 60 mg（60mg:1ml）, Q6M, twice for one year.~Dietary Supplement: Elemental Calcium Oral, at least 500 mg Dietary Supplement: Vitamin D Oral, 1000 IU"
223757111|NCT04128163|DRUG|Placebos|"subcutaneous injection of（1ml）, Q6M, twice for one year.~Dietary Supplement: Elemental Calcium Oral, at least 500 mg Dietary Supplement: Vitamin D Oral, 1000 IU"
223757112|NCT01314209|DRUG|Dexmedetomidine|Dexmedetomidine 0.7 microg/kg/h 12-hour intravenous infusion
223757113|NCT00004065|DRUG|tanespimycin|
223757114|NCT05415696|PROCEDURE|Prostatic artery embolization|Patients will undergo PAE with 100-300 µm or 300-500 µm Embospheres following standard PAE technique performed by Interventional Radiology at Stanford University
223757115|NCT00005828|DIETARY_SUPPLEMENT|green tea extract|
223757116|NCT01386736|DRUG|Vitamin D drops|Subjects will be randomly assigned to Vitamin D 3,000 Units per day or Placebo drops.
223757117|NCT01386736|DRUG|Placebo drops|Subjects will be randomly assigned to Vitamin D 3,000 Units per day or Placebo drops.
223757118|NCT01418937|BIOLOGICAL|CervarixTM (GSK580299)|Three intramuscular injections
223757119|NCT03030079|DEVICE|Experimental Electrical Stimulation Regimen|The electrodes will pass an electrical current through the skin and into the muscle first at a low intensity for 5 minutes to allow the subject to adjust to the sensation. The current will then be gradually increased to a level sufficient to elicit a non-painful motor contraction. The subject will sit in a relaxed position as the electrical stimulator contracts the muscles for a duration of 15 minutes.
223757120|NCT01976832|BEHAVIORAL|Music with movement|Participants in the intervention group will receive the intervention delivered by their family member according to the validated 8-week music with movement (MWM) intervention protocol.
223757121|NCT01976832|BEHAVIORAL|Social interaction|"The control group will receive a protocol for social interaction as the control condition, where caregivers were asked to discuss up to date news with PWeD.~The design of the control condition will be highly similar to the MWM protocol in terms of the frequency and duration of the sessions, the number of people involved, and the total intervention period."
224201126|NCT06441266|DRUG|KeraStat cream|KeraStat Cream is a non-sterile, non-implantable, emollient-based wound dressing intended to act as a protective covering in the management of a variety of skin conditions. The intervention is a topical cream applied at least twice daily starting at start of radiation therapy until 1-month from the end of radiation therapy completion
224201127|NCT06441266|DEVICE|M-PART Assessments via MyCap|The M-PART approach harnesses the remote data collection capabilities of MyCap to facilitate remote collection or data including but not limited to toxicity assessments, quality of life surveys, and patient-provided photographs of the skin in the treated area
223757122|NCT01500707|DRUG|SCH 900800|SCH 900800, one 20 mg tablet, orally
223757123|NCT02506504|DEVICE|Inspiratory help then sham ventilation|The Inspiratory Pressure Support is used to increase the intensity and the duration of training session. For the sham ventilation, the device deliver a non effective quantity of oxygen.
223757124|NCT02506504|DEVICE|Sham ventilation then Inspiratory help|The Inspiratory Pressure Support is used to increase the intensity and the duration of training session. For the sham ventilation, the device deliver a non effective quantity of oxygen.
223757125|NCT02692677|DRUG|JNJ-42756493|Participants will receive a single oral solution at a dose of 12 milligram (mg) of unlabeled JNJ--42756493 admixed with 14C- labeled JNJ--42756493.
223757126|NCT02194868|BIOLOGICAL|Recipients|"1. Adult recipient:~   * collected 20 ml pre-transplant~  * collected 30 ml for adults on day 20 post-transplant at engraftment for cell phenotype,~  * collected 30 ml on days 30, 60, 90, 180, 360 days post-HSCT for cell phenotyping at all time points, functional INKT at day 60 or 90 depending on the number of cells collected and anti-viral ELISPOT studies on days 180 and 360~2. Children recipients~   * collected residual blood pre-transplant~  * collected residual blood on day 20 post-transplant at engraftment for cell phenotype,~  * collected residual blood on days 20, 30, 90, 180 and 360 post-HSCT"
223757127|NCT02194868|BIOLOGICAL|Donors|"1. Adult donors :~   * collected 20 ml of blood, (if possible before granulocyte colony-stimulating factor (GCSF) administration)~  * collected 1 ml of the stem cell graft for adult recipient or 2 ml of bone marrow for children recipients These samples will be collected at the same time of those needed for transplant.~2. Children donors samples~   * collected residual blood~  * 2ml of bone marrow (bottom of tube)"
223757128|NCT01485211|DRUG|cross-linking with hypo-osmolar riboflavin|Hipo-osmolar riboflavin was applied every 20 seconds until the TCT reached 400µm. UVA irradiation was performed for 30 min. Pachymetry was recorded at the thinnest point of the cornea preoperatively, after epithelial removal, after iso-osmolar riboflavin, after hypo-osmolar riboflavin, after UVA irradiation, and at 1, 6 and 12 months.
223757129|NCT00962104|DRUG|Atomoxetine|40-120 milligrams (mg) taken by mouth, once daily for 10 weeks.
223757130|NCT00962104|DRUG|Placebo|Taken by mouth, once daily for 10 weeks.
223757131|NCT01933867|PROCEDURE|Water immersion|Water immersion means infusion of room temperature water during colonoscope insertion without air insufflation.
223757132|NCT01933867|PROCEDURE|Air insufflation insertion|
223757133|NCT02013167|DRUG|Blinatumomab|Blinatumomab is administered as a continuous intravenous infusion (CIV).
223757134|NCT02013167|DRUG|Standard of Care Chemotherapy|"* FLAG (fludarabine, cytarabine arabinoside, and granulocyte colony-stimulating factor) ± anthracycline-based regimen (e.g. idarubicin 10 mg/m² days 1 \& 3; fludarabine 30 mg/m² days 1-5; cytarabine arabinoside 2 g/m² days 1-5). Patients \> 60 years: Idarubicin 5 mg/m² day 1 \& 3; fludarabine 20 mg/m² day 1-5; cytarabine arabinoside 1 g/m² day 1-5~* HiDAC (high-dose cytarabine arabinoside) - based regimen ≥1 g/m²/day ± anthracycline and/or in combination with other drugs such as native Escherichia coli asparaginase, polyethylene glycol linked to asparaginase (PEG-asparaginase), vinca alkaloids, steroids, etoposide or alkylating agents~* High-dose methotrexate-based regimen (HDMTX; 500 mg/m² to 3 g/m² infused up to 24 hours) in combination with native E. coli asparaginase, PEG-asparaginase, vinca alkaloids, steroids, etoposide or alkylating agents.~* Clofarabine as a single agent as recommended in the prescribing information or clofarabine-based regimens with 20 mg/m²/day for up to 5 days."
223610793|NCT04787978|OTHER|Physical Activity and Education Intervention|"The intervention involves peer teams, health coaches and community health workers \[CHW\]. Each participant will be assigned to a CHW and grouped into a team of 10-20 participants based on participant proximity to a Columbus Recreation and Parks Center. Each team will be assigned 4 health coaches, 2 medical students, 1 undergraduate student and 1 nursing student from OSU Health Sciences Colleges.~The lifestyle intervention is 24 weeks consisting of 1 hour and 15 minutes of in person training time per week. The training time consists of 45 minutes of physical activity and 30 minutes of educational content was informed by evidence-based strategies and stakeholder feedback.~Health coaches will implement the curriculum based on the Diabetes Prevention Program and the American Heart Association Check, Change, Control Program and develop team-based SMART (specific, measurable, achievable, relevant, and time-bound) wellness goals."
223757135|NCT06044376|COMBINATION_PRODUCT|Formula milk with triple Bifidobacterium probiotic strain|Formula milk with triple Bifidobacterium strain containing Bifidobacterium longum BB536 (6.9 x 10\^7 CFU/serving), Bifidobacterium breve M16-V (6.9 x 10\^7 CFU/serving), Bifidobacterium longum subsp. infantis M-63 (6.9 x 10\^7 CFU/serving).
223610794|NCT06414447|DIAGNOSTIC_TEST|Huxley Medical|diagnostic
223610795|NCT01583842|DRUG|124I-Metaiodobenzylguanidine (MIBG) (no-carrier added)|"124I-MIBG (no-carrier added) Administration (infusion, 1-2 minutes) followed by sequential PET/CT dosimetry scans on Days 0, 1, 2 and 5.~Optional 124I-MIBG (no-carrier added) Administration \& PET/CT scan 6 weeks later."
223610796|NCT01583842|DRUG|124I-MIBG (carrier added)|"124I-MIBG (carrier added) Administration (infusion, 60 minutes) followed by sequential PET/CT dosimetry scans on Days 0, 1, 2 and 5.~Optional 124I-MIBG (carrier added) Administration \& PET/CT scan 6 weeks later."
223610797|NCT01583842|PROCEDURE|Positron Emission Tomography (PET) /Computerized tomography (CT)|A PET scan measures important body functions, such as metabolism. CT imaging uses special x-ray equipment, and in some cases a contrast material, to produce multiple images of the inside of the body. Combined PET/CT scans combine the processes of both a PET and CT at the same time.
223610798|NCT04309708|DEVICE|Nimodipine pump infusion|Patients with nimodipine pump infusion with pump infusion line and other infusion equipments
223610799|NCT03795116|DEVICE|LED-RL phototherapy|The LED-RL treatment device has a 4.7 cm x 6.1 cm rectangular array of LEDs and emits visible red light (633 nm) at a power density of 360.2 W/m2 at room temperature and a distance of 10 mm from the target surface.
223610800|NCT03795116|DEVICE|Mock irradiation|The mock therapy device is designed to sound, look, and feel identical to the LED-RL treatment device (i.e., has the same physical components and thermal output), except it does not emit visible red light.
223610801|NCT05640440|DIAGNOSTIC_TEST|Executive function testing|Assessment of executive function subdivision
223610802|NCT03271424|DIAGNOSTIC_TEST|Oraquick HIV Self Test - Choice|This is an oral swab in home HIV test.
223610803|NCT03271424|DIAGNOSTIC_TEST|Atomo HIV Self Test - Choice|This is a blood finger prick in home HIV test.
223610804|NCT03271424|DIAGNOSTIC_TEST|Oraquick HIV Self Test and Atomo HIV Self Test - Both|This is an oral swab in home HIV test and this is a blood finger prick in home HIV test.
223610805|NCT04869839|OTHER|oral examination|examination done by dentist
223610806|NCT03984214|DRUG|Dronabinol in Oral Dosage Form|Titration period for 4 weeks: titration according to tolerability from 2.5 mg (3 x 1 droplet) up to 30 mg (3 x 12 droplets) per day; dose increased by 2.5 mg (3 x 1 droplet) every other day Maintenance period for 12 weeks: individually tolerated maximum dose (up to 30 mg ≙ 3 x 12 droplets) at end of titration period will be continued for maintenance treatment Tapering period for 2 weeks: dose is decreased every other day by 5 mg (3 x 2 droplets) Safety follow-up: 4 weeks after end of treatment
223610807|NCT03984214|DRUG|Placebo in Oral Dosage Form|Titration period for 4 weeks: titration according to tolerability from 3 x 1 droplet up to 3 x 12 droplets per day; dose increased by 3 x 1 droplet every other day Maintenance period for 12 weeks: individually tolerated maximum dose (up to 3 x 12 droplets) at end of titration period will be continued for maintenance treatment Tapering period for 2 weeks: dose is decreased every other day by 3 x 2 droplets Safety follow-up: 4 weeks after end of treatment
223610808|NCT04575571|OTHER|No intervention, this is an observational study that uses validated questionnaires and qualitative interviews..|No intervention, this is an observational study that uses validated questionnaires and qualitative interviews.
223610809|NCT02502045|DEVICE|Morning Simulated Sunlight|Timed morning simulated sunlight (Philips Wake Up Light, Model HF3520) peaking at 300 lux delivered over a 40 minute ramp between 5-9 a.m. for 14 consecutive days
223610810|NCT02502045|DEVICE|Non-therapeutic Red Light|Non-therapeutic red light control at 5 lux will be used as the control condition
223610811|NCT03263624|DEVICE|fractional carbon dioxide laser|One hand of each patient will receive three sessions of fractional carbon dioxide laser at four- week interval.
223610812|NCT03263624|DRUG|Tazarotene Cream 0.1%|tazarotene cream 0.1% once daily
223610813|NCT01797263|OTHER|Yoga|A 12-week yoga intervention modified for Veterans with fibromyalgia. Each weekly session will last approximately 75 minutes. The standardized sequence of yoga poses will be introduced to participants and the instructor will tailor them to the participant's needs and abilities. Deep breathing exercises will be taught and emphasized throughout every session. Participants will be encouraged to exercise according to their limits, rather than rigid adherence to posture techniques. The yoga intervention will be tailored to the individual. It will include low intensity, low impact modified poses adapted with pathophysiologic changes of fibromyalgia in mind. Participants will also be given a Playaway(c) device with guided relaxation exercise recorded on it and asked to listen to it three times a week to reinforce the in person yoga session content.
223610814|NCT01797263|OTHER|Structured Exercise|A 12-week group exercise session consisting of a graded aerobic exercise program. The program will start at low intensity with gradual increases in exercise intensity and duration. Each weekly session will last 75 minutes. The fitness instructor will teach participants to use a table-top ergometer at a sub-maximal level, determine baseline fitness, and develop an individualized exercise prescription. The fitness instructor will provide educational tips on exercise and selection of physical activities. Participants will be given a pedometer and heart rate monitor to track their exercise at home. They will also be given an exercise DVD to use at home.
223610815|NCT00918177|DRUG|AP09004|
223610816|NCT00918177|DRUG|Carbidopa/Levodopa, immediate release|
223757136|NCT06044376|OTHER|Formula milk|Formula milk without any addition of probiotic strain
223757137|NCT02220244|DRUG|MD1003 100mg capsule|
223610817|NCT03321084|OTHER|MatPliates|The MatPilates program was specialized developed for this trial, in which all exercises belong to contemporaneous Pilates style. Each session has 60 minutes of duration, divided in three blocs (stretching, exercise and relaxation), with mean of 10, 40 and 10 minutes respectively (VIEIRA et al., 2016). Each exercise will be performed in one series of 10 to 15 repetitions and will be modified accordingly the patient need.
223757138|NCT02146638|DRUG|Morphine|
223757139|NCT02146638|DRUG|Fentanyl|
223757140|NCT01869283|OTHER|Kinesiotherapy|
223757141|NCT01869283|OTHER|Ultrasound|
223757142|NCT01869283|OTHER|Diadynamic currents|
223757143|NCT02098577|OTHER|Crossover|Crossover cycle
223757144|NCT02098577|OTHER|Stabilometric Platform|This Stabilometric plate allows to assess the balance with an objective and reliable measurement, in both standard static or dynamic unstable condition
223757145|NCT03397082|DRUG|Lidocaine gel|5mL of lidocaine gel applied topically to cervix previous to clamping and paracervical blockade.
223757146|NCT03397082|DRUG|Placebo|5mL of sterile gel applied topically to cervix previous to clamping and paracervical blockade.
223757147|NCT00261742|DRUG|Penicillin versus cefuroxim per os|
223757148|NCT03221803|OTHER|OT Vertical attachment|new extra coronal castable attachment
223757149|NCT03221803|OTHER|OT cap attachment|standard extra coronal attachment
223757150|NCT01616485|DRUG|TA-1790|2 TA-1790 100 mg capsules
223757151|NCT01616485|DRUG|Sildenafil citrate|2 sildenafil citrate 50 mg capsules
223757152|NCT01616485|DRUG|Placebo|2 placebo capsules for TA-1790 100 mg capsules
223757153|NCT01616485|DRUG|Nitrostat|glyceryl trinitrate tablet, USP 0.4 mg
223757154|NCT00603746|DRUG|GW685698X|GW685698X
223757155|NCT00714064|BIOLOGICAL|23vPPV, dTpa (Pneumovax, Boostrix)|Group A will receive 23vPPV during 3rd trimester and dTpa at delivery
223757156|NCT00714064|BIOLOGICAL|23vPPV, dTpa (Pneumovax, Boostrix)|Group B will receive 23vPPV at delivery and dTpa 7 months following delivery
223757157|NCT00714064|BIOLOGICAL|23vPPV, dTpa (Pneumovax, Boostrix)|Group C will receive dTpa at delivery and 23vPPV 7 months following delivery
223610818|NCT03321084|OTHER|Control|Will not be submitted to any physical intervention. It continues in your daily life with only phone monitoring.
223610819|NCT02098798|PROCEDURE|HD Colonoscopy|High definition colonoscopy procedure in surveillance colonoscopy
223610820|NCT02098798|PROCEDURE|HD Colonoscopy + iSCAN|
223610821|NCT02098798|PROCEDURE|HD Colonoscopy + dye spray|
223757158|NCT01318096|DRUG|raltegravir and tenofovir and lamivudine|raltegravir 400mg BID and tenofovir 300mg qd and lamivudine 300mg gd for 48 weeks
223757159|NCT01318096|DRUG|efavirenz+tenofovir+lamivudine|efavirenz 600mg QN +tenofovir 300mg qd +lamivudine 300mg qd for 48 weeks
223757160|NCT05233566|DRUG|Ketamine|NMDA antagonist
223757161|NCT05233566|DRUG|Normal saline|IV fluid acting as a placebo
223757162|NCT00965822|OTHER|North American ginseng|3 day, once daily, dosing
223757163|NCT00965822|OTHER|Placebo|3 day, once daily dosing
223757164|NCT04484324|OTHER|Stretching exercises|Post-facilitation stretch is a technique involves a maximal contraction of the muscle at mid-range with a rapid movement to maximal length followed by a static stretch.
223757165|NCT04974970|DRUG|Peanut Immunotherapy|Treatment will be injected peanut extract every 2 weeks for a period of 3 months.
223757166|NCT01810029|BEHAVIORAL|Cardiac Rehabilitation plus Transcendental Meditation|The stress reduction intervention, Transcendental Meditation program is added on to the standard cardiac rehabilitation programs for patients with documented coronary artery disease
223757167|NCT04152512|BEHAVIORAL|Questionnaire administration|Questionnaire administration (4 different forms: pre-treatment, 3-4 months after treatment, 1 year after treatment, 2-5 years (yearly) after treatment
223610822|NCT02568761|PROCEDURE|Injection Snoreplasty|Nonsurgical treatment involving the injection of 1.5 ml of 50% ethanol (1 ml of 99.5% ethanol diluted in 1ml of 2% xylocaine) into the upper palate.
223610823|NCT02568761|OTHER|Oropharyngeal Exercises|Myofunctional isometric and isotonic exercises of the soft palate, pharyngeal side walls, face and tongue.
223610824|NCT01914263|BIOLOGICAL|cytokine induced killer cell|The eligible patients are infused with a single dose of 8x10\^9 cord blood-derived cytokine indued killer cells.
223757168|NCT03349216|PROCEDURE|Intravenous Regional Anesthesia|in this research patients will receive intravenous regional anesthesia as infusion of mini dose (that is 1.5 mg/kg ) lidocaine 0.5% and immediately after procedure their torniquettes (A.T.S. 2000, Zimmer, Inc., Bloomfield, CN) will be deflated (hence named Rapid MiniBier's block). the pain score will be assessed by NRS system before during and after the procedure.
223757169|NCT03349216|DRUG|Systemic Analgesia|in this group the patients will receive ketamine 1-2 mg/kg IV slow ( Bioniche,Ireland Ketamine Hydrochloride 500mg/10cc)and titrated to effect. again here the pain score will be assessed before procedure and after the procedure every 5 minutes until 30 minutes by NRS ( Numerical Rating Score)
223757170|NCT00764270|DIETARY_SUPPLEMENT|R-alpha lipoic acid|300 mg R-alpha lipoic acid or placebo twice daily for 12 weeks, followed by a washout period of 12 weeks, followed by another treatment phase of the other treatment placebo or 300 mg R-alpha-lipoic acid for 12 weeks
223757171|NCT03468881|OTHER|Communication Skills Training Package (KEW)|A training package (called KEW: Know, Encourage and Warm-up) for therapeutic radiographers to manage emotional talk with breast cancer patients in treatment.
223757172|NCT02098590|BIOLOGICAL|CPS-immunization|Subjects will be exposed 3 times to bites from 15 NF54 Plasmodium infected mosquitoes during each immunization, while taking chloroquin prophylaxis.
223757173|NCT02098590|BIOLOGICAL|malaria challenge infection, P. falciparum NF135.C10|Subjects will receive bites from 5 Anopheles mosquitoes infected with Plasmodium falciparum NF135.C10 sporozoites.
223757174|NCT02098590|BIOLOGICAL|malaria challenge infection, P. falciparum NF166.C8|Subjects will receive bites from 5 Anopheles mosquitoes infected with Plasmodium falciparum NF166.C8 sporozoites.
223757175|NCT02098590|BIOLOGICAL|malaria challenge infection, P. falciparum NF54|Subjects will receive bites from 5 Anopheles mosquitoes infected with Plasmodium falciparum NF54 sporozoites.
223757176|NCT02098590|DRUG|atovaquone/proguanil|All participants will be treated with atovaquone/proguanil when they develop a malaria infection or on day 28 after malaria challenge infection.
224201128|NCT06441266|OTHER|Clinical Assessments|Participants will undergo assessments at baseline (prior to radiation therapy start), weekly during and after radiation therapy until 1-month post-radiation therapy. Medical history will be collected at baseline including primary cancer site, HPV status (if oropharyngeal cancer primary), laterality, TNM classification, stage, surgical resection prior to radiation therapy, weight, body mass index and patient self-reported Fitzpatrick skin phototype.
224201129|NCT06441266|OTHER|Feedback phone interview|Participant satisfaction, perceptions and preferences with using M-PART will be discussed.
224201130|NCT01187511|DRUG|GSK561679|Verucerfont is a corticotropin releasing hormone receptor 1 (CRF1) antagonist.
224201131|NCT01187511|DRUG|Placebo|Placebo is an inactive tablet design to look exactly like GSK561679
224201132|NCT01306968|DRUG|hyperbaric oxygen|"The chamber will be compressed with air to 1.5 atm abs. Once the chamber is compressed to 1.5 atm abs, the subjects will don a hood and breathe 100% oxygen. Hoods will be supplied with oxygen with flows of at least 30 liters per minute and overboard dumping of excess gas. Each subject will complete 40 sessions.~The duration of the hyperbaric oxygen exposures will be 60 minutes (±2 minutes), timed from when the chamber hatch or door closes, and ending when the chamber hatch or door opens (door-to-door time equals 60 minutes). The total intervention exposure time is 50 minutes (±2 minutes). The interval to compress to the intervention pressure (1.5 atm abs) and will be 5 minutes (±1 minute). The interval to decompress from the study pressure will be 5 minutes (±1 minute)."
223509136|NCT04491708|OTHER|Pilates exercises|The participants attended two half-hour Pilates exercise classes twice a week, for one month, to familiarize themselves with the exercises and to learn the 5 Pilates' principles. After the learning period, two experimental sessions were performed: a Mat Pilates session and a Reformer apparatus Pilates session. The order of each session was randomized and drawn beforehand. Each experimental session lasted about one and a half hours and the interval between the sessions was 48 hours. Participants were asked to not perform any exercise and to refrain from food or fluids except water eight hours prior to each experimental session. Prior to the start of the experimental sessions, participants received a standard breakfast of 321 kcal that was 76% (61 g) carbohydrate, 8% (6,7 g) protein, 16% (5,9) fat, provided by the study researchers. All sessions were conducted at the same time in the morning, and the room temperature (22°C) and humidity (40-50%) were controlled during the whole session.
223509137|NCT04802915|PROCEDURE|Intraoperative ERM and ILM staining with their assessment and removal|ERM and ILM staining is performed after vitrectomy. After that we evaluate the condition of macular zone and make a decision to remove the ERM and the need to remove the ILM
223509138|NCT04512625|BIOLOGICAL|Desensitizers|The main aims and objectives of the present study were to evaluate and compare the effectiveness of three commercially available desensitizing agents: Gluma (Hareus Kulzer), Sheildforce Plus (Tokuyama), and Telio CS (Ivoclar Vivadent) desensitizer in reducing the pre- and post-cementation sensitivity for full coverage restorations.
223509139|NCT00170755|DRUG|Darifenacin|Darifenacin 7,5 mg tablets, Darifenacin 15 mg tablets administered once daily
223509140|NCT03428269|OTHER|simulation by gaming (LabForGames Warning)|comparison of the efficacy of two educational methods to improve the clinical reasoning skills of nursing students facing patient deterioration
223509141|NCT03428269|OTHER|traditional education|comparison of the efficacy of two educational methods to improve the clinical reasoning skills of nursing students facing patient deterioration
223509142|NCT01748552|DRUG|Placebo|Administered orally as capsules
223509143|NCT01748552|DRUG|LY2922083|Administered orally as capsules
223509144|NCT04630626|DEVICE|Simplify Disc|The Simplify Disc is a cervical artificial disc manufactured from polyether ether ketone (PEEK) endplates and a mobile, zirconia-toughened alumina ceramic core.
223509145|NCT04630626|OTHER|ACDF|Historical ACDF control data
223509146|NCT01330524|DRUG|Avastin and Triamcinolone|1.25 mg Avastin and 2mg Triamcinolone will be injected trough vitreal
223509147|NCT01330524|OTHER|placebo|2mg placebo
223509148|NCT02738398|RADIATION|FDG PET/CT|
223509149|NCT05169957|DRUG|Ipilimumab|Ipilimumab administered IV over 85-100 minutes at 3 mg/kg (combined with nivolumab administered IV over 30-60 minutes at 1 mg/kg) every 3 weeks for a total of 4 doses or until progression or unacceptable toxicity.
223509150|NCT05169957|DRUG|Nivolumab|Nivolumab administered IV over 30-60 minutes at 1 mg/kg (combined with ipilimumab administered IV over 85-100 minutes at 3 mg/kg) every 3 weeks for a total of 4 doses of the combination therapy or until progression or unacceptable toxicity. Subjects may receive maintenance dosing of nivolumab alone administered IV over 30-60 minutes at 240 mg every 2 weeks or 480 mg every 4 weeks for a maximum of 52 weeks or until progression or unacceptable toxicity.
223509151|NCT05169957|PROCEDURE|Stereotactic Body Radiation Therapy|24-45 Gy delivered in three fractions to up to 4 liver metastases
223509152|NCT03882359|DIAGNOSTIC_TEST|Echocardiogram|"Images will be recorded in parasternal long, short axis, apical four, two, and three chamber views according to the American Society of Echocardiography (ASE) 17 segment model. Each assessment will include one round of low MI imaging (\<0.3) and one round of very low MI imaging (\<0.2) in each of the pre-specified windows according to the 2014 ASE Sonographer Guidelines.~A baseline echocardiogram will be performed prior to the administration of DEFINITY® or MVT-100. Assessments will be made three times, once from 0 - 1 ½ minutes following injection, once between 1 ½ minutes to 3 minutes following IV injection and once from 3 - 4 ½ minutes following IV injection. Assessments at each time point will include one round of low MI imaging (\<0.3) and one round of very low MI imaging (\<0.2). Each round will include the views in the following order: parasternal long, parasternal short, apical 4, apical 2 and apical 3."
224201133|NCT01306968|OTHER|sham hyperbaric air|A pressure of 1.2 atm abs will provide an equivalent inhaled oxygen concentration of 25%. The duration of the sham exposures will be 60 minutes (±2 minutes). Each subject will complete 40 sessions.
224201134|NCT03590158|BEHAVIORAL|TRF|Participants will be instructed to consume their habitual diet within a self-selected 10 hour period every day.
223757177|NCT05712408|BEHAVIORAL|800g Challenge|The intervention will involve 8 weeks of an online diet program. Outcomes testing will occur at baseline and post-intervention (following 8 week diet program). During the first 4 weeks, participants will receive educaitonal material and log their daily points in an online application and attend a weekly check-in call with members of the research team. During weeks 5-8, participants will log their daily points in the online application.
223757178|NCT05820971|OTHER|C-short plus usual practice|"Peer reviewer will be reminded of the following 10 CONSORT items (including a short description):~* Outcomes (6a)~* Sample size (7a)~* Sequence generation (8a)~* Allocation concealment (9)~* Blinding (11a)~* Outcomes and estimation (17a/b)~* Harms (19)~* Registration (23)~* Protocol (24)~* Funding (25)"
223757179|NCT01113879|BEHAVIORAL|Aerobic exercise|An aerobic exercise intervention will target cardiorespiratory fitness by progressing from 50-70% of the participants' maximum heart rate.
223757180|NCT01113879|BEHAVIORAL|Stretching|Stretching will occur for 50 minutes a day, three days/week for 12 weeks.
223757181|NCT03080558|DRUG|Indocyanine green|Use of Indocyanine Green during Rectal shaving by laparoscopy.
223757182|NCT04210752|DRUG|Treatment 1 (EG-HZ-001)|"Subjects will receive two single IM vaccinations, 2 months apart, the first on Day 1 and the second on Day 60 (±5 days). Subjects will be randomised to treatment at a ratio of 1:1:1:1:1 (n=8 per treatment)~Route of Administration: IM injection"
223757183|NCT04210752|DRUG|Treatment 2 (EG-HZ-002)|"Subjects will receive two single IM vaccinations, 2 months apart, the first on Day 1 and the second on Day 60 (±5 days). Subjects will be randomised to treatment at a ratio of 1:1:1:1:1 (n=8 per treatment)~Route of Administration: IM injection"
223757184|NCT04210752|DRUG|Treatment 3 (EG-HZ-003)|"Subjects will receive two single IM vaccinations, 2 months apart, the first on Day 1 and the second on Day 60 (±5 days). Subjects will be randomised to treatment at a ratio of 1:1:1:1:1 (n=8 per treatment)~Route of Administration: IM injection"
223757185|NCT04210752|DRUG|Treatment 4 (EG-HZ-004)|"Subjects will receive two single IM vaccinations, 2 months apart, the first on Day 1 and the second on Day 60 (±5 days). Subjects will be randomised to treatment at a ratio of 1:1:1:1:1 (n=8 per treatment)~Route of Administration: IM injection"
223757186|NCT04210752|DRUG|Treatment 5|"Shingrix~Suspension for injection supplied as a single dose vial of lyophilised VZVgE antigen component to be reconstituted with the accompanying vial of AS01B adjuvant suspension component. After reconstitution, a single dose of ShingrixTM is 0.5 mL.~Route of Administration: IM injection"
223757187|NCT00258076|DRUG|EVRA transdermal contraceptive patch 6 mg NGMN and 0.75 mg EE|
223757188|NCT02603835|DEVICE|SSO2 Therapy|Delivery of SSO2 Therapy for 60 minutes selectively into the left main coronary artery (LMCA) using the TherOx DownStream System along with a single use disposable device called the TherOx DownStream Cartridge and a commercially available, qualified SSO2 delivery catheter
223757189|NCT00357188|DRUG|Atazanavir Sulphate + Ritonavir|Capsules, Oral, ATV 300 mg + RTV 100 mg, once daily, 10 days.
224201135|NCT05923320|BEHAVIORAL|training|The experimental group was given training on infancy vaccines and breastfeeding. The times of the trainings are determined based on the Postpartum Care Management Guide of the Ministry of Health. In the hospital on the first day after birth, 2-7. days and 30-42. Three days in total, trainings were given on breastfeeding and childhood vaccinations by making home visits. The training content has been prepared by taking into account the Ministry of Health Breastfeeding Guide (5) and the Ministry of Health's vaccination calendar and the Primary Care Vaccine Guide. The trainings will be given to the puerperant women individually. About 30 minutes of training will be given and their questions, if any, will be answered.
224201136|NCT02780206|OTHER|Stable isotope amino acid infusion|such as glycerol, D2O, tyrosine, phenylalanine, glucose, arginine, and citrulline
224201137|NCT03596476|PROCEDURE|Upper gastrointestinal (GI) endoscopy|An upper gastrointestinal (GI) endoscopy will be performed at V1. Four esophageal biopsies will be taken in both the proximal and the distal esophagus.
224201138|NCT03596476|PROCEDURE|Wireless pH monitoring|Wireless pH monitoring will be performed at V1. The pH capsule will be clipped into the esophagus during the upper GI endoscopy. The esophageal pH will be recorded for 96 hours (ambulatory recording).
224201139|NCT03596476|PROCEDURE|Post prandial esophageal High Resolution Impedance Manometry|Post prandial esophageal HRIM will be performed at V2. The recording will be started after transnasal insertion of the HRIM probe. A standardized meal will be given to the patient (Big Mac, medium portion of French fries, orange juice). The recording will be realized for one hour after the end of the meal.
224201140|NCT03596476|PROCEDURE|pH-impedance monitoring|24-h pH-impedance monitoring on PPI will be performed at V3. A transnasal catheter will be inserted into the esophagus and the recording will be performed for 24 hours (ambulatory recording).
223509153|NCT03882359|DRUG|MVT-100|After randomization, MVT-100, the experimental drug, is administered via IV infusion or bolus administration and echocardiograms are subsequently obtained.
224201141|NCT01314508|DRUG|Increlex|Increlex therapy will begin at 40 micrograms/kg/day twice a day. The dose will be escalated by 20 mcg twice a day every other week up to 100mcg/kg/week.
223509154|NCT03882359|DRUG|Definity|After randomization, Definity, the active comparator, is administered via IV infusion or bolus administration and echocardiograms are subsequently obtained.
223509155|NCT03723525|COMBINATION_PRODUCT|Package of HIV care|"A. Screening and management (Preventive / Pre-emptive therapies dosages) of different opportunistic infections (OI). Detail information mentioned in the manual (refer to uploaded protocol).~B. Rapid ART Initiation~1. PLHIV without suspicion or active OI: Initiate ART within seven days or same day after HIV serology disclosure~2. PLHIV with suspicion or active OI: Defer initiation if clinical symptoms suggest tuberculosis or cryptococcal meningitis. Detail information mentioned in the manual (refer to uploaded protocol).~C. Enhanced Adherence/Retention Support: mHealth: Receive text messages in mobile regarding appointment reminder (pill pick up, CD4 test, viral load test, early infant diagnosis (EID) test etc.) and general awareness messages (positive prevention, the importance of regular health check-up etc.). PLHIV with advanced HIV disease will also receive weekly/biweekly home-based adherence/ retention support linked to community care centre and community home-based care."
224314250|NCT05187130|OTHER|Mindfulness|60 patients in the mindfulness-based breathing and music therapy group were divided into subgroups of 5 participants each. Each 6-person group started by having participants complete the pretest State Anxiety Inventory, Beck Depression Inventory, and Psychological Well-Being Scale via Survey Monkey. Mindfulness-based breathing and music therapy was applied to each patient group in approximately 45-minute sessions per day. At the end of the session, participants re-filled the posttest State Anxiety Inventory, Work-Related Tension Scale, and Psychological Well-Being Scale. A total of 3 sessions were completed with an interval of two days.
223610825|NCT04320017|DIAGNOSTIC_TEST|Electrocardiogram, transthoracic echocardiography and clinico-biological parameters in routine care|"* 12 derivations electrocardiogram done at baseline and repeated every 3 days~* transthoracic echocardiography at baseline~* clinical features at baseline: WHO performans status comorbidities and treatments~* biological results in routine care, such as baseline full blood count, inflammation markers: C-reactive protein, procalcitonin, interleukin-6 and ferritin, coagulation and troponin and brain natriuretic peptide"
223757190|NCT00357188|DRUG|Atazanavir Sulphate + Ritonavir + Efavirenz|Capsules/Tablets, oral, ATV 400 mg + RTV 100 mg + EFV 600 mg, once daily, 14 days.
223757191|NCT00891137|BIOLOGICAL|human myeloid progenitor cells|Single intravenous injection/infusion
223610826|NCT00202761|BEHAVIORAL|PIH|Intensified training
223610827|NCT02318966|DIETARY_SUPPLEMENT|Medical Food - Glycosade|double blind randomised crossover of 2 starches - glycosade and UCCS
223757192|NCT01499888|PROCEDURE|Allogeneic Non-Myeloablative Stem Cell Transplantation|"Alemtuzumab-based non-myeloablative allogeneic hematopoietic stem cell transplantation using immune-suppressive agents and low-dose total body irradiation (TBI) without standard chemotherapy.~Transplant regimen Day -7 to -3: Alemtuzumab (1mg/kg, total dose) divided over the 5 days, IVPB over 2 hours daily Day -3 until 100% chimerism obtained: Sirolimus dosed for target trough level of 10-15 ng/mL Day -2: Total body irradiation with 300cGy Day 0: Stem cell infusion"
224201142|NCT01148628|DRUG|RAD 001 in combination with Caelyx|RAD001 (tablets; 2.5mg) is administered daily at 5, 7.5, 10 mg. CAELYXTM (vials; 50 mg/25mL)is administered i.v.every 4 weeks at 40mg/m2. One treatment cycle is 4 weeks.
224201143|NCT03252015|DRUG|Probe Drug Cocktail|Administered orally
224201144|NCT03252015|DRUG|Lasmiditan|Administered orally
223610828|NCT01544725|DRUG|Procedural sedation with ketamine-propofol combination|"K= Kétamine P= Propofol RSS= Ramsay Sedation Score~At t0: 0.5 mg/kg of K (0.1 ml/kg of 5 mg/ml K) followed by 0.5 mg/k of P (0.1 ml/kg of 5 mg/ml P).~At t0 + 4 min, if needed to obtain an optimal sedation (RSS of 4 or 5): 0.25 mg/kg of K (0.05 ml/kg of 5 mg/ml K) followed by 0.25 mg/kg of P (0.05 ml/kg of 5 mg/ml P).~At t0 + 8 min, if needed to obtain an optimal sedation (RSS of 4 or 5): 0.25 mg/kg of K (0.05 ml/kg of 5 mg/ml K) followed by 0.25 mg/kg of P (0.05 ml/kg of 5 mg/ml P).~At t0 + 12 min, if maximal doses have been reached (1 mg/kg of K + 1 mg/kg of P) but the optimal sedation has not been obtained, the procedural sedation will be recorded as a failure in the analysis, and the patient will receive another procedural sedation product (at the discretion of the caregiver)."
223610829|NCT01544725|DRUG|Procedural sedation with ketamine alone|"K= Ketamine I= Intralipid placebo~At t0: 1 mg/kg of K (0.1 ml/kg of 10 mg/ml K), followed by 0.1 ml/kg of I (physical placebo of propofol in the other arm).~At t0 + 4 min, if needed to obtain an optimal sedation (Ramsay Sedation Score of 4 or 5): 0.5 mg/kg of K (0.05 ml/kg of 10 mg/ml K), followed by 0.05 ml/kg of I.~At t0 + 8 min, if needed to obtain an optimal sedation (Ramsay Sedation Score of 4 or 5): 0.5 mg/kg of K (0.05 ml/kg of 10 mg/ml K), followed by 0.05 ml/kg of I.~At t0 + 12 min, if maximal doses have been used (2 mg/kg of K) but the optimal sedation has not been obtained, the procedural sedation will be recorded as a failure in the analysis, and the patient will receive another procedural sedation product (at the discretion of the caregiver)."
223610830|NCT04809571|OTHER|Photoacoustic imaging and Confocal Raman spectroscopy measurement|All subjects will first have their basic history and clinical measurements taken, followed by skin physiology measurements and photoacoustic mesoscopic imaging as well as confocal Raman spectroscopy measurements.
223610831|NCT03368365|DEVICE|Ventilotel ®|Using of the spirometer of Aqsitania company, Ventilotel ®, to analyse the respiratory function at rest and to predict unplanned hospitalizations.
223610832|NCT03767946|DIAGNOSTIC_TEST|Quantiferon Gold Plus Test|Small volume of whole blood incubated with specific TB antigen and then dosage of Interferon gamma production.
223610833|NCT01172535|DRUG|Lopinavir/ritonavir|Heat-stable tablets of 100 mg lopinavir, 25 mg ritonavir, or liquid formulation of 80 mg lopinavir, 20 mg ritonavir, dosed according to World Health Organization (WHO) pediatric weight band dosing guidelines
223610834|NCT05487222|DEVICE|ICON|hemodynamics variability in response to different fluid regiemens
223610835|NCT04371575|DRUG|Carbamazepine|There is no actual intervention as the study is observational. First choice tratment is Carbamzepine and Oxcarbazepine. In medically refractory patients, first choice surgery is microvascular decompression
223610836|NCT01593631|DIETARY_SUPPLEMENT|Acid lactase|capsules cotaining 3300 FCC units of acid lactase
223610837|NCT01593631|DIETARY_SUPPLEMENT|Acid lactase|capsules containing 9000 FCC of acid lactase
223610838|NCT01593631|DIETARY_SUPPLEMENT|Lyoph. yoghurt bacteria|capsules containing 2 billion lyoph. yoghurt bacteria
223610839|NCT01593631|DIETARY_SUPPLEMENT|Acid lactase plus yoghurt bacteria|Capsules containing 3300 FCC of acid lactase and 2 billion lyoph. yoghurt bacteria
223610840|NCT01593631|DIETARY_SUPPLEMENT|Placebo|Capsules containing di-calcium-phosphate
223610841|NCT03008161|DRUG|NPT088|IgG1 Fc-GAIM fusion protein, a recombinant fusion protein
223757193|NCT01499888|DRUG|Alemtuzumab|In this protocol, patients will be given alemtuzumab 1mg/kg divided equally over five days with the maximum dose of 20mg per day.
224201145|NCT03252015|DRUG|Placebo|Administered orally
224201146|NCT05322200|RADIATION|A computerized tomography (CT) coronary angiogram|Participants in both arms will undergo CT coronary angiogram with Plaque Map analysis at baseline prior to therapy initiation and following 12 months of treatment.
224201147|NCT05322200|PROCEDURE|Vicorder (Skidmore medical, UK)|Participants in both arms will undergo aortic carotid-femoral pulse wave velocity (cfPWV)through the Vicorder (Skidmore medical, UK), which uses oscillometric cuff-based measurements to establish the index of arterial stiffness. The procedure will be done at baseline and 12 months after therapy initiation.
224314251|NCT03426163|DEVICE|Virtual reality|Application of knee MRI transformed virtual reality system
223509156|NCT03723525|COMBINATION_PRODUCT|Standard HIV care|Standard of HIV care includes screening and management of OI (OI- tuberculosis (TB), bacterial pneumonia, herpes, and candidiasis), baseline assessment (CD4 and other blood tests- complete blood count, hemoglobin, platelets, liver function test, renal function test, urine for albumin, chest x-ray), at 6 months CD4 test, viral load (twice a year) and then on a yearly basis, additional lab test at 3 months, 6 months, antiretroviral (ARV) toxicity monitoring like hemoglobin (Zidovudine), Serum Glutamic-Pyruvic Transaminase (Nevirapine/Efavirenz), Creatinine (Tenofovir), prophylaxis (Co-trimoxazole preventive therapy CD4\<350 and WHO stage III and IV and Isoniazid preventive therapy if eligible) and ART / follow up (generally monthly/ bimonthly).
223509157|NCT01526369|DRUG|Trastuzumab|
223509158|NCT01526369|DRUG|Paclitaxel|
223610842|NCT03008161|DRUG|Placebo|Placebo
223610843|NCT05800223|DRUG|Almonertinib|The dosage is 110 mg/day (2 tablets/day) orally once a day
223610844|NCT05800223|RADIATION|SBRT|SRT, 27Gy-40Gy/3-5f
223610845|NCT06006650|DRUG|Pembrolizumab, Albumin Paclitaxel, 5-fluorouracil, Cisplatin|Pembrolizumab, Albumin Paclitaxel, 5-fluorouracil, Cisplatin
223610846|NCT04977440|DIETARY_SUPPLEMENT|Whey protein|"Patients were randomly divided into two groups: Group (A): Enteral feeding with normal protein intake ( 1.0 gm pin /kg/day ) Group (B): Enteral feeding with high protein intake ( 1.5- gm open /kg/day ) -Patient's- nonprotein- caloric intake was calculated according to REE :(25xactual body weight in kg ) and received it as follow : 1/2 the calculated amount of caloric intake in DAY 1 3/4 of the calculated amount of caloric intake in DAY 2~-Full calculated caloric amount in DAY 3~This regimen was followed long as the patient was tolerating the amount of feeding, and in case of intolerance:~The volume of feeding boluses was decreased or Increase the time interval between boluses or IV metoclopramide or erythromycin was given"
223610847|NCT01302717|DEVICE|LV pacing|The left ventricular lead are positioned preferentially at the posterolateral or lateral venous branches of the coronary sinus.
223610848|NCT01302717|DEVICE|RV pacing|The right ventricular lead are positioned at the right ventricular apex.
223509159|NCT01526369|DRUG|Lapatinib|
223509160|NCT06256874|BEHAVIORAL|Myofascial Release Training|Myofascial release, also known as fascial release or fascial manipulation, is a physical therapy used to treat muscle and fascial tissue tension or pain. It involves applying appropriate pressure and stretching to release tight fascia and soft tissues, improving blood circulation, alleviating pain, and promoting rehabilitation. Myofascial release therapy is commonly used to treat muscle spasms, chronic pain, skeletal and joint issues, among others.
223509161|NCT05463471|DRUG|Compound sodium acetate ringer injection|Quickly infuse 500ml of compound sodium acetate ringer injection for volume expansion within 20-30 minutes
223509162|NCT05463471|DRUG|Albumin|Quickly infuse 500ml of albumin for volume expansion within 20-30 minutes
223509163|NCT03149380|BEHAVIORAL|Web-based education|The investigators will utilize interactive lessons and activities to educate about Alzheimer's disease prevention, treatment and caregiving, with focus on evidence-based lifestyle and nutritional recommendations that have been associated with delaying cognitive decline.
223610849|NCT05754723|BEHAVIORAL|e-Psychotherapy/Psychoeducation|Participants will receive six weekly self-guided psychoeducation sessions. Then, after 6 weeks participants will complete monthly clinical questionnaires for 6 months. Also, participants will begin bi-weekly journaling exercises for 6 months. Based on the journaling entries, if the AI algorithm detects MDD, GAD, SAD or ADHD that requires treatment will make a referral to the diagnosis-specific e-CBT (MDD, GAD, SAD or ADHD). If after 6 months, no referral decision is made by the AI algorithm no extra follow-up will be provided. Once the AI makes a referral recommendation, participants will be placed in a diagnosis-specific e-CBT program specific to the diagnosis determined by the AI algorithm (MDD, GAD, SAD, or ADHD). The asynchronous e-CBT programs will consist of 12 weekly modules and homework. Weekly homework is reviewed by a therapist, who will provide personalized feedback based on the participant's preferred method (i.e., text, video, or audio).
223610850|NCT01683799|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|6-week behavioral treatment for insomnia
223610851|NCT04256824|DRUG|coated vicryl plus|Coated Polyglactin 910 with Triclosan (coated vicryl plus)
223509164|NCT01260324|OTHER|No intervention given in this observational study|No intervention given in this observational study
223509165|NCT01260324|OTHER|No intervention given in this observational study|No intervention given in this observational study
223509166|NCT02596893|DRUG|GED-0301|
223509167|NCT02596893|DRUG|Placebo|
223509168|NCT01259882|DRUG|PF-05089771|Subjects will receive single ascending doses of PF-05089771 or placebo to investigate the safety/tolerability and PK of PF-05089771. The PK of alternative formulations of PF-05089771 and the effect of food on PK may also be investigated.
223509169|NCT01259882|DRUG|PF-05089771|Subjects will receive single ascending doses of PF-05089771 or placebo to investigate the safety/tolerability and PK of PF-05089771. The PK of alternative formulations of PF-05089771 and the effect of food on PK may also be investigated.
223509170|NCT01259882|DRUG|PF-05089771|Subjects will receive single doses of PF-05089771 or placebo in a fully randomized crossover design. The investigation of the safety/tolerability and PK of PF-05089771 will occur. In addition the exploratory pharmacodynamics of PF-05089771 will be investigated using novel biomarkers.
223509171|NCT01259882|DRUG|PF-05089771|Subjects will receive single doses of PF-05089771 or placebo in a fully randomized crossover design. The investigation of the safety/tolerability and PK of PF-05089771 will occur.
223509172|NCT01259882|DRUG|PF-05089771|Subjects will receive single doses of PF-05089771 or placebo in a fully randomized crossover design. The investigation of the safety/tolerability and PK of PF-05089771 will occur.
223509173|NCT01259882|DRUG|PF-05089771|Subjects will receive single doses of PF-05089771 or placebo in a fully randomized crossover design. The investigation of the safety/tolerability and PK of PF-05089771 will occur.
223509174|NCT06092957|DRUG|Cisplatin-based induction chemotherapy|Cisplatin-based induction chemotherapy will be given every 3 weeks for 3 cycles before radiotherapy including GP, TP, and TPF regimen.
223509175|NCT06092957|DRUG|Full course of PD-1/PD-L1 blockades|a) Camrelizumab 200mg, b) Toripalimab 240mg, or c) Adebrelimab 1200mg will be started on day 1 of induction chemotherapy and given every 3 weeks for up to 12 cycles, or until intolerable toxicity, or disease progression or withdrawal from the treatment.
223509176|NCT06092957|RADIATION|Reduced-dose IMRT|GTVnx:60Gy/30F/2.0Gy，CTV1:54Gy/30F/1.8Gy，CTV2:48Gy/30F/1.6Gy
223757194|NCT01499888|DRUG|Sirolimus|On day -1, patients will receive a loading dose of 12 mg followed by 4 mg per day. Subsequent dosing will be based on clinical toxicity, GVHD concurrent medications, medical conditions, prior drug levels, drug-drug interactions, and blood levels with target of 3 to 12 ng/mL.
223757195|NCT00456716|DRUG|sorafenib|400mg po bid
223757196|NCT01787578|DRUG|Sobetirome|50 mcg or 100 mcg once-daily oral
223757197|NCT05813158|DRUG|Group 1(low concentration-high volume bupivacaine US guided Erector Spinae Plane block)|Patients will preoperatively receive low concentration-high volume ultasound guided Erector Spinae Plane block, and then the patient will be transferred to the operating room ) one syringe of 30ml bupivacaine 0.25% {15 ml bupivacaine 0.5% and 15ml normal saline} for each patient
223757198|NCT05813158|DRUG|Group 2(high concentration-low volumecbupivacaine US guided Erector Spinae Plane block)|Patients will preoperatively receive high concentration-low volume ultasound guided Erector Spinae Plane block, and then the patient will be transferred to the operating room (one syringe of 15 ml bupivacaine 0.5% {15 ml bupivacaine 0.5% } for each patien).
223757199|NCT05172661|BEHAVIORAL|Integrated physical-cognitive training|Perform a postural task and a cognitive task at the same time (dual-task model) 70 minutes/session\*2 sessions/week\*6 weeks
223757200|NCT05172661|BEHAVIORAL|Consecutive physical-cognitive training|Perform a postural task and a cognitive task separately for identical durations 70 minutes/session\*2 sessions/week\*6 weeks
223757201|NCT02572466|OTHER|Hemodialysis|ESRD group received long-term hemodialysis
223757202|NCT00133874|DRUG|SB-275833 ointment, 1%|
223757203|NCT03323658|DRUG|Bexarotene|Given topically
223757204|NCT03323658|OTHER|Questionnaire Administration|Ancillary studies
223757205|NCT03864874|DIAGNOSTIC_TEST|Intraoperative intracavitary lung ultrasonography|Ultrasonography on the deflated lung for detection of lung nodules
224201148|NCT05322200|OTHER|Blood tests for inflammation and oxidative stress markers|All the participants will have (non-fasting) blood samples performed to assess serum glucose, lipid profile and serum biomarkers for plaque initiation (Lipid profile, LpPLA2), endothelial activation (MCP-1), plaque inflammation (hsCRP, IL6, IL18, TNF, advanced glycation end-products), vulnerable transformation (vEGF, PAI-1, BMP-6) and measures of oxidative stress (Ox-LDL, TAOS, TBARs) at baseline, and at 12 months after therapy initiation
223757206|NCT03080259|BEHAVIORAL|Stimulant Diversion Prevention (SDP)|provider training, patient/parent education and counseling, strategies for use by patients and parents, and treatment adjustments
223757207|NCT04248595|DRUG|Homoharringtonine|De novo AML or relapsed AML patients recieve chemotherapy regimen contained homoharringtonie and azacitidine.
223757208|NCT04248595|DRUG|Azacitidine|De novo AML or relapsed AML patients recieve chemotherapy regimen contained homoharringtonie and azacitidine.
223757209|NCT03098342|PROCEDURE|Methylene blue-mediated photodynamic therapy|Using the 2% MB aqueous solution as a photosensitiser. After the rest period, the lesion was immediately illuminated with incoherent red light (peak emission spectrum at 630-640 nm)
223757210|NCT03098342|DRUG|Amorolfine 5% Nail Lacquer|Patients will be detailed instruction regarding the use of 5% Amorofine Nail Lacquer (Loceryl®) as its recommended protocol.
223757211|NCT05817019|DRUG|Sugammadex Sodium|Sugammadex Sodium 2mg/kg when TOF \>= 2, postoperative period
223757212|NCT05817019|DRUG|neostigmine 50µg/kg + glycopyrollate 0.01mg/kg|neostigmine 50µg/kg + glycopyrollate 0.01mg/kg when TOF \>= 2, postoperative period
223757213|NCT00062465|DRUG|TwHF|
224201149|NCT02305069|DRUG|Pioglitazone|Described elsewhere
224201150|NCT02305069|DRUG|Insulin|Administered to simulate the feeding response in study visits. Description of amount administered provided elsewhere.
224201151|NCT02305069|DRUG|Octreotide|Administered to simulate the feeding response in study visits. Description of amount administered provided elsewhere.
224201152|NCT02305069|DRUG|Glucose|Administered to simulate the feeding response in study visits. Description of amount administered provided elsewhere.
224201153|NCT02305069|DRUG|Mixed Amino Acids|Administered to simulate the feeding response in study visits. Description of amount administered provided elsewhere.
223509177|NCT06092957|RADIATION|Standard-dose IMRT|GTVnx：69.96Gy/33Fr/2.12Gy；CTV1：60.60Gy/33Fr/1.82y；CTV2：54.12Gy/33Fr/1.64Gy
223509178|NCT06092957|DRUG|Concurrent Chemotherapy|Cisplatin 100mg/m2 every 3 weeks for 2 cycles
223509179|NCT05541471|DRUG|VX-548|Tablets for oral administration.
223509180|NCT05541471|DRUG|Midazolam|Syrup for oral administration.
223509181|NCT05541471|DRUG|Digoxin|Tablets for oral administration.
223509182|NCT01679665|BIOLOGICAL|320U /0.5ml|inactivated vaccine(vero cell) against EV71 of 320U /0.5ml, two doses, 4 weeks interval
223509183|NCT01679665|BIOLOGICAL|0/0.5ml placebo|0/0.5ml placebo, two doses, 4 weeks interval
223509184|NCT05861401|GENETIC|Janus Kinase 1 and 2|Under complete sterile precautions, 3mL of blood will be withdrawn by venipuncture and put in EDTA tube; DNA extraction will be done after centrifugation and used for genotyping assay of (JAK 1 and JAK2) gene with the polymerase chain reaction(PCR).
223509185|NCT01727427|DRUG|Heparin, fondaparinux, vitamin-K antagonists, aspirin|Parenteral or oral anticoagulant Antiplatelet agent
223509186|NCT05647382|DIAGNOSTIC_TEST|blood cell analysis, blood gas surveillance, chest radiograph and echocardiography|Laboratory parameters of all postoperative patients including blood cell analysis, blood gas surveillance, liver, and kidney function alone with chest radiograph and echocardiography were dynamically monitored.
223509187|NCT03112187|DRUG|Iron Supplement|Ferfer® is a multi-ingredient supplement containing micro-encapsulated iron pyrophosphate (to form liposomes), vitamin C and vitamin B12 which are valuable for the control of nutritional deficiencies or increased organic needs of iron.
223509188|NCT01103115|DIETARY_SUPPLEMENT|Calcium 600mg plus Vit D 400 IU|Daily supplementation with 600mg Calcium plus 400IU Vitamin D3
223509189|NCT01103115|DIETARY_SUPPLEMENT|Calcium 600mg plus Vit D 800 IU|Daily supplementation with 600mg Calcium plus 800IU Vitamin D3
223509190|NCT01103115|DIETARY_SUPPLEMENT|Placebo|placebo tablets
223509191|NCT02913859|RADIATION|Radiotherapy to the pelvis|Radiotherapy to the pelvis and prostate
223509192|NCT02913859|DRUG|Hormonal therapy (LHRH agonist and/or antiandrogens)|life-long hormonal therapy (LHRH agonist and/or antiandrogens)
223509193|NCT01324466|DRUG|NB-001|Topical, 5 times daily until investigator assessment of healing or a maximum of 4 days
223757214|NCT03073590|COMBINATION_PRODUCT|Intervention factory with hot lunch|A nutritionally enhanced lunch meal program (increased dietary diversity plus inclusion of multi-nutrient fortified rice), provision of once weekly iron/folate supplement to female workers, and a BCC program conducted in the factory setting focused on improving health and nutrition for women and children, with a focus on anemia prevention.The BCC program will be enhanced to include modules on nutrition (balanced diets/dietary diversity, iron/folate rich foods), infant and young child nutrition (IYCN), and an overview module on anemia prevention, hand-washing with soap and dietary diversity at the very beginning of the intervention.
223757215|NCT03073590|COMBINATION_PRODUCT|Intervention factory without lunch program|In a selected garment factory that does not have a lunch program, the intervention will consist of the twice weekly provision of iron/folate supplements to female workers, and the enhanced BCC program, as described above.
223757216|NCT03073590|COMBINATION_PRODUCT|Control factory with lunch program|One control factory who provides regular lunch meal and a nutrition and health behavior change communications (BCC) program.
223757217|NCT03073590|BEHAVIORAL|Control factory without lunch program|One control factory was selected where only the standard Behavior change communication (BCC) was implemented.
223757218|NCT02472938|DRUG|dimethyl fumarate|dimethyl fumarate 120 mg capsules
223757219|NCT02472938|OTHER|Placebo|Placebo for BG00012
223757220|NCT00615056|DRUG|Bevacizumab (avastin)|Bevacizumab intravenous \[IV\] infusion 5 mg/kg every two weeks until disease progression, intolerance or withdrawal of consent.
223757221|NCT00615056|DRUG|FOLFIRI (Irinotecan, leucovorin, 5-fluorouracil [5FU])|Irinotecan (180 mg/m²) intravenous infusion \[IV\] over 90 minutes, concurrently with leucovorin (400 mg/m²) intravenous infusion \[IV\] over 2 hours followed immediately by 5-FU bolus (400 mg/m²) intravenous \[IV\] and a subsequent 5-FU infusion (2400 mg/m² over 46-48 hours), repeated every 2 weeks until disease progression, intolerance or withdrawal of consent.
223757222|NCT00615056|DRUG|AG-013736 (axitinib)|Axitinib is given at a starting dose of 5 mg twice daily \[BID\] continuous dosing until disease progression, intolerance or withdrawal of consent.
224201154|NCT02305069|OTHER|[2H5]phenylalanine|Administered to allow the determination of leg protein breakdown rates in study visits. Description of amount administered provided elsewhere.
224201155|NCT02305069|OTHER|[1-13C]leucine|Administered to allow the determination of muscle protein synthesis rates in study visits. Description of amount administered provided elsewhere.
224314252|NCT05346926|DEVICE|3D-printed cast|The 3D-printed casts are produced using 3D print technology based on software by Belgian software company: The patient's forearm is scanned with a tablet (duration: approx. 5 min), whereupon the cast is printed overnight according to the scan (duration: approx. 4h) and adjusted to the patient during the next appointment.
224314253|NCT05346926|DEVICE|Conventional cast|A conventional plaster cast is applied for treatment of the distal radius fracture.
224314254|NCT00753857|OTHER|Drug Facts Box|Educational intervention of 1 page summary of drug efficacy and side effects
224314255|NCT00753857|OTHER|Standard Brief Summary|Ads consisted of the standard second page called the brief summary
223509194|NCT01324466|DRUG|Vehicle|Topical, 5 times daily until investigator assessment of healing or a maximum of 4 days
223509195|NCT02759263|BEHAVIORAL|Cogmed Working Memory Training|Cogmed Working Memory Program will be used as a computerized home-based intervention. Families will receive a link for downloading a web-based software program. The program will be installed on a computer at a family's home by a research assistant. Parents and adolescents will be actively involved, and during the installation session, adolescents will complete several practice trials. The 25 sessions will be completed individually by the adolescent with parental supervision. For the first 5 sessions, the participant trains on the same set of games; on the 6th session and every 5th session thereafter, a new task is introduced and replaces one of the initial tasks. At the end of each session, the adolescent can play an age-appropriate computerized game as a reward. After each session, results are uploaded by parents to a secure website, to keep track of the participant's progress. Families will be contacted weekly to check program function and discuss concerns.
223509196|NCT03052257|BEHAVIORAL|Educational - glaucoma|Discussion of glaucoma and the potential for blindness, facilitated by the glaucoma educator using a 3-dimensional model eye and photographic representation of glaucomatous vision loss; One-one-one demonstration of eye drop instillation techniques, Provision of a mnemonic aid which alerts the participant to missed doses; Review of the participant manual: An illustrated brochure on glaucoma and eye drop instillation. An individualized schedule for dosing of glaucoma medications. Individualized suggestions for improving adherence based on the subject's responses to the (SASES).
223509197|NCT03052257|BEHAVIORAL|Dose monitoring and reminder|"Participants will be provided with a smart bottle to house one of their glaucoma medications. The smart bottle records the date and time that the bottle is opened. For participants in the intervention arm only, a reminder through AdhereTech will be activated."
223509198|NCT03052257|BEHAVIORAL|Educational - general|The control information session will include review of a Powerpoint presentation on general eye health, including but not specific to glaucoma.
223509199|NCT03052257|BEHAVIORAL|Dose monitoring|"Participants will be provided with a smart bottle to house one of their glaucoma medications. The smart bottle records the date and time that the bottle is opened."
223509200|NCT00038246|DRUG|Estramustine|140 mg by mouth (po) three times a day on Days 1-5, 8-12
223509201|NCT00038246|DRUG|Thalidomide|200 mg by mouth every day once a week with dose escalation every week if no dose limiting toxicity.
223509202|NCT00038246|DRUG|Paclitaxel (Taxol)|100 mg/m\^2 by vein (IV) over 3 hours Day 3 and Day 10
223509203|NCT04667728|DEVICE|Professional continuous glucose monitoring (CGM) sensor (iPro™2)|Professional continuous glucose monitoring (CGM) sensor (iPro™2) following treatment adjustments and personalized diet plan
223509204|NCT00004228|DRUG|asparaginase|Given IV
223509205|NCT00004228|DRUG|cyclophosphamide|Given IV
223509206|NCT00004228|DRUG|cytarabine|Given IV
223509207|NCT00004228|DRUG|daunorubicin hydrochloride|Given IV
223509208|NCT00004228|DRUG|dexamethasone|Given IV
223509209|NCT00004228|DRUG|doxorubicin hydrochloride|Given IV
223509210|NCT00004228|DRUG|leucovorin calcium|Given IV
223509211|NCT00004228|DRUG|mercaptopurine|Given IV
223509212|NCT00004228|DRUG|methotrexate|Given IV
223509213|NCT00004228|DRUG|prednisone|Given IV
223610852|NCT04256824|DRUG|Vicryl|Coated Polyglactin 910 without Triclosan (vicryl)
223610853|NCT00988598|DRUG|PF-04447943|25 mg of PF-04447943 orally every 12 hours for 7 days
223610854|NCT00988598|DRUG|Placebo|25 mg matching placebo to PF-04447943 orally every 12 hours for 7 days
223757223|NCT00615056|DRUG|FOLFOX (oxaliplatin, leucovorin, 5-fluorouracil [5FU])|Oxaliplatin (85 mg/m²) intravenous infusion \[IV\] over 120 minutes, concurrently with leucovorin (400 mg/m²) intravenous infusion \[IV\] over 2 hours followed by 5-FU IV bolus (400 mg/m²) and a subsequent 5-FU IV infusion (2400 mg/m² over 46-48 hours), repeated every 2 weeks until disease progression, intolerance or withdrawal of consent.
223610855|NCT01057849|DRUG|risperidone|3-6 mg per day
223610856|NCT01057849|DRUG|olanzapine|5-20 mg per day
223610857|NCT01057849|DRUG|Aripiprazole|10-30 mg per day
223610858|NCT03498950|OTHER|laser therapy|laser irradiation on the taste papillae
223610859|NCT04591938|DEVICE|Fantom Encore Bioresorbable scaffold implantation|Fantom Encore Bioresorbable scaffold implantation
223610860|NCT02347397|DEVICE|SS Bipolar Head + SL-TWIN Stem|Subject will undergo hemiarthroplasty surgery with SS Bipolar Head \& SL-TWIN Stem
223610861|NCT02347397|DEVICE|Bipolar Head + SL-PLUS Stem|Subject will undergo hemiarthroplasty surgery with Bipolar Head \& SL-PLUS Stem
223610862|NCT06335784|BEHAVIORAL|Imagery Rescripting (IR)|Imagery rescripting (IR) is a technique where the individual is instructed to imagine a negative memory or image as vividly as possible, and to change it in a direction that he/she desires. IR seems particularly efficient because it is based on the experienced emotions during perceptual information processing, thereby eliciting stronger emotional responses than verbal processing.
223610863|NCT06335784|BEHAVIORAL|Imagery Rescripting (IR) and Targeted Memory Reactivation (TMR) during sleep|Targeted Memory Reactivation (TMR) is a technique used to strengthen a memory trace during sleep. TMR is used to modify memory formation through the application of cues during sleep. In this TMR protocol, an olfactory cue is associated with the imagery rescripting (IR) during the day, and then administered during sleep. In that way, the replay of the associated memory and its corresponding neural representation in memory networks are artificially promoted, a procedure which usually strengthens memory consolidation. Previous studies have shown that TMR in sleep reduces emotional arousal, making it a promising technique for insomnia.
223610864|NCT06335784|BEHAVIORAL|Sleep Hygiene|Sleep hygiene education includes modifications in the behavior (e.g., exercise, coffee, alcohol intake) and environment (e.g., light, noise, temperature conditions) that offer to the individual the foundation for healthy sleep. Sleep hygiene is an important component in treating ID, but insufficient and less effective than CBT-I when offered alone.
223610865|NCT06335784|BEHAVIORAL|Sleep Hygiene + Odor|Sleep hygiene instructions will be applied in the presence of an odor, which will be also used during the night.
223610866|NCT06335784|OTHER|"Rocking bed if patients still have insomnia complaints (ISI >10) after the 4 weeks of the intervention"|Rocking stimulation boosts brain oscillations in deep sleep (i.e., sleep spindles and slow oscillations) into a rhythmic appearance supporting a neurophysiological mechanism whereby continuous rocking entrains endogenous thalamo-cortical sleep oscillations. The beneficial effects of rocking strengthening the continuity of sleep might have clinical applications and it will be of interest to evaluate if such non-pharmacological could improve sleep and reduce such features of hyperarousal in ID patients.
223610867|NCT03974386|DEVICE|oXiris blood purification set|Continuous venovenous hemofiltration and adsorption (CVVHA) with oXiris filter for up to 72 hours if required. The filter will be replaced every 24 hours. The setting of CVVHA is as follows: blood flow rate 200 mL/min, replacement fluid rate 2000 mL/hr, pre-dilution 50% and post-dilution 50%. If continuous renal replacement therapy is indicated after 72 hours, conventional hemofiltration filters will be used.
223610868|NCT03315572|OTHER|Interviewer administered version of ease of use items|The adult ease of use items will be modified to incorporate language appropriate for pediatric subjects. The interview will be administered by trained clinic-staff for subjects aged 5 to 7 years and those aged 8 to 11 years having difficulty in reading.
223610869|NCT03315572|OTHER|Self-administered version of ease of use items|The interview will be self-administered by subjects aged 8 to 11 years.
223610870|NCT03315572|OTHER|Caregiver version of ease of use items|Caregivers will be asked questions regarding their observations and experiences while their child was using ELLIPTA inhaler.
223610871|NCT05195658|DEVICE|Thrombectomy and Stenting under neuroprotection|"Endovascular management of the stroke culprit lesion using the Micronet-covered CGuard stent under neuroprotection.~Transient flow achieved using a balloon guide catheter (e.g. MoMa or FlowGate) with additional active aspiration/s at key procedural steps. If indicated, targeted (extra- and/or intracranial) thrombus retrieval using either a thrombus aspiration device and/or a stentriever.~Use of pharmaco-sedation versus general anesthesia is as indicated clinically and is according to the anesthesiologist and operator decision - according to routine practice in the center.~Patient pre-procedural (including imaging and other diagnostic work-up), procedural, and post-procedural (including blood pressure tight control) management, including pharmacotherapy, are according to the AHA/ASA stroke management guidelines and the devices IFUs. Overall study patient management and intervention is according to routine clinical practice in the study center."
223757224|NCT00615056|DRUG|AG-013736 (axitinib)|Axitinib is given at a starting dose of 5 mg twice daily \[BID\] continuous dosing until disease progression, intolerance or withdrawal of consent.
224201156|NCT05163925|DEVICE|Eurosets ECMO Life System|"ECMOLIFE System in combination with ECMOLIFE Centrifugal Pump and ECC (extra-corporeal-circulation) Tubing Set is intended to pump blood through the extracorporeal circuit to provide extracorporeal circulation.~ECMOLIFE System must be used only in combination with ECMOLIFE Centrifugal Pump.~ECMOLIFE System is intended to operate in the following hospital environments: Operating Room, Catheter Laboratory, Emergency Room, Intensive Care Unit and during intra-hospital patient transportation from one to another Unit.~ECMOLIFE System is intended to be used by qualified healthcare professionals specifically trained in the field of extracorporeal circulation: Perfusionists (Thoracic Cardiovascular Surgery - OR), Intensivists, ICU Nurses (ICU), Emergency physicians / Intensivists (ER), Cardiologist (CathLab)."
224201157|NCT03886402|DEVICE|GID SVF-2|Treatment of erectile dysfunction with the subjects own cells
224201158|NCT02463604|PROCEDURE|Coronary Angiography|Coronary angiography is performed following usual site standards
224201159|NCT00002738|DRUG|leucovorin calcium|
224201160|NCT00002738|DRUG|trimetrexate glucuronate|
223757225|NCT00615056|DRUG|FOLFIRI (irinotecan, leucovorin, 5-fluorouracil [5FU])|Irinotecan (180 mg/m²) intravenous infusion \[IV\] over 90 minutes, concurrently with leucovorin (400 mg/m²) intravenous infusion \[IV\] over 2 hours followed immediately by 5-FU bolus (400 mg/m²) IV and a subsequent 5-FU IV infusion (2400 mg/m² over 46-48 hours), repeated every 2 weeks until disease progression, intolerance or withdrawal of consent.
224311772|NCT06460207|OTHER|fMRI neurofeedback|fMRI neurofeedback is a technique that allows individuals to observe real-time feedback of their brain activity as measured by fMRI scans. During a session, the participant lies inside an MRI scanner while their whole brain is scanned. This data is processed in real-time by a computer and then presented to the participant in the form of visual feedback. This feedback might be presented as a graph, a color-coded representation, or some other easily interpretable format. The participant is instructed to modulate their brain activity based on the feedback they receive. This can involve various mental strategies, such as focusing attention on specific thoughts, images, or sensations. Over repeated sessions, participants learn to consciously influence their brain activity based on the feedback they receive. Through trial and error, they discover which mental strategies are most effective for achieving their desired changes in brain activity.
223757226|NCT00615056|DRUG|Bevacizumab (avastin)|Bevacizumab intravenous infusion \[IV\] 5 mg/kg every two weeks until disease progression, intolerance or withdrawal of consent.
223757227|NCT00615056|DRUG|FOLFOX (oxaliplatin, leucovorin, 5-fluorouracil [5FU])|Oxaliplatin (85 mg/m²) IV infusion over 120 minutes, concurrently with leucovorin (400 mg/m²) intravenous infusion \[IV\] over 2 hours followed by 5-FU IV bolus (400 mg/m²) and a subsequent 5-FU IV infusion (2400 mg/m² over 46-48 hours), repeated every 2 weeks until disease progression, intolerance or withdrawal of consent.
224311773|NCT01631071|BIOLOGICAL|Virosomal influenza vaccine|Intramuscular administration (M. deltoideus) of a single dose of 0.5 mL virosomal influenza vaccine
224311774|NCT05631197|OTHER|Biorepair Total Protection Plus + desensitizing enamel-repair shock treatment|Domiciliary use twice a day
223509214|NCT00004228|DRUG|thioguanine|Given PO
223610872|NCT03349788|PROCEDURE|LCA-nP|The group underwent lapaoroscopic radical rectectomy without preserving left colic artery.
223509215|NCT00004228|DRUG|vincristine sulfate|Given IV
223509216|NCT00004228|RADIATION|radiation therapy|
223509217|NCT02369679|DEVICE|Precast Adjustable Compression Wrap (Circaid)|"A physiotherapist well trained in lymphedema treatment will apply a lymphatic drainage to the affected upper limb. Then the physiotherapist will apply the precast adjustable compression wrap to the patient. The patient would maintain the precast adjustable compression wrap until the next session of treatment. The first 10 sessions will be daily from Monday to Friday.~After the 10 first sessions, the treatment will be applied on alternate days (3 per week) until the patient receive a tailored compression garment (7-14 days)."
223610873|NCT03349788|PROCEDURE|LCA-P|The group underwent lapaoroscopic radical rectectomy with preserving left colic artery.
223610874|NCT03423316|BEHAVIORAL|Supervised exercise therapy|The therapy will be conducted three times each week for 12 weeks. Each session takes 1 hour, consisting of 5 minutes of warmup activities, 50 minutes of intermittent exercise, and 5 minutes of cool-down activities. Exercise consists of walking on a treadmill initiated at 2 mph and 0% grade, until claudication pain becomes moderately severe. After claudication pain subsides, the subject will restart the walk. At the end of the session, the total exercise duration will be recorded. After a patient is able to walk 8-10 minutes at the initial workload, the grade is increased by 1-2%, or the speed is increased by 0.5 mph as tolerated.
223610875|NCT04389723|DIETARY_SUPPLEMENT|Qualia Mind|Multi-ingredient Dietary supplement
223610876|NCT04389723|DIETARY_SUPPLEMENT|Placebo|Multi-ingredient Placebo
223610877|NCT02167516|DRUG|glucosamine sulfate|glucosamine sulfate capsule: One each time, 3 times a day, Oral,for 4 weeks placebo(for Xinfeng capsule): Three each time, 3 times a day, Oral,for 4 weeks
223610878|NCT02167516|DRUG|Xinfeng capsule|Xinfeng capsule:Three each time, 3 times a day, Oral,for 4 weeks placebo(for glucosamine sulfate capsule): One each time, 3 times a day, Oral,for 4 weeks
223610879|NCT04585282|BEHAVIORAL|Plus Cognitive behavioral therapy of insomnia（CBT-I plus）|Cbt-i plus program is an enhanced version of cbt-i program, which increases the response to depression and anxiety symptoms.
223610880|NCT04585282|BEHAVIORAL|Cognitive behavioral therapy of insomnia（CBT-I）|Cognitive behavioral therapy of insomnia is mainly aimed at correcting the bad behaviors and beliefs among the maintenance factors of insomnia, which is considered as the first-line treatment program of insomnia disorder. Cognitive behavioral therapy of insomnia mainly includes five important components: sleep restriction, secondary control, cognitive therapy, relaxation therapy and sleep hygiene.
223610881|NCT01598467|PROCEDURE|Robotic assisted sacrocolpopexy (RASC)|Robotic assisted sacrocolpopexy (RASC) will be performed with the Da Vinci Surgical robot (Intuitive Surgical). THe mesh used will be a Type I (Amid classification), polypropylene mesh
223610882|NCT01631994|DRUG|metoclopramide|1 tablet of 10mg of oral dissolving metoclopramide will be taken by patient 45 minutes prior to ingestion of the capsule.
223610883|NCT00724672|DRUG|etanercept|etanercept 50 mg subcutaneously once weekly
223610884|NCT00724672|DRUG|infliximab|infliximab 3 mg/kg IV at Weeks 0, 2, and 6
223610885|NCT00724672|DRUG|adalimumab|adalimumab 40 mg subcutaneously biweekly
223610886|NCT06153368|DRUG|Cadonilimab+mFOLFIRINOX|"Cadonilimab 6 mg/kg，IVD，D1，Q2W~+mFOLFIRINOX（Oxaliplatin 85 mg/m2 IV over 4 hours ; Irinotecan 150 mg/m2 IV over 90 minutes ; Leucovorin(l-LV) 400 mg/m2 IV over 2 hours 5-fluorouracil 2.4 g/m2 for 46 hours continuous infusion.） on days 2 of a 14-day cycle."
223610887|NCT03769038|DEVICE|chronic total occlusion|chronic total occlusion of coronary atery was opened and then stents were placed
223610888|NCT00558116|DEVICE|Dynamic splinting|The Dynasplint carpal tunnel device will be worn for 30 minutes, twice daily, for 60 consecutive days.
223610889|NCT02233972|DRUG|Midazolam|
223610890|NCT02233972|DRUG|Ginkgolides Meglumine Injection|
223610891|NCT02233972|DRUG|placebo|
223610892|NCT02694302|DEVICE|Walkbot|Walkbot(robot assisted gait training) 30 minutes and conventional physical therapy 30 minutes each per day to be administered 5 times a week for 3 weeks.
223610893|NCT02694302|DEVICE|Conventional physical therapy|Conventional physical therapy 30 minutes to be administered twice a day, 5 times a week for 3 weeks.
223610894|NCT04316559|OTHER|Placebo|Placebo capsule
223610895|NCT04316559|DRUG|TRV734|biased agonist at mu opioid receptors
223610896|NCT06504316|DEVICE|CRRT filter|The subjects will be accepted CRRT using a filter for 72 hours. The subjects will be continued to CRRT or not after 72 hours (the first session of treatment) according to clinical situation by clinician decision. CRRT prescription: 1 Blood purification access: Central vein indwelling double lumen catheter (diameter 11F-13.5F) can be placed in femoral vein, internal jugular vein and subclavian vein; 2.Anti-coagulation prescription: Anticoagulant is used according clinical situation by clinician decision (such as heparin, sodium citrate, and so on); 3. Modality of CRRT: CVVH: blood flow 150-200ml/min; replacement fluid flow 30-35ml/kg/h (100% post-dilution).
223610897|NCT03070535|OTHER|HIGH and LOW meal ingestion|The study will examine CSF biomarker responses to HIGH and LOW meals in 80 men and women with and without the E4 allele in a cross-over design. After an overnight fast, participants will ingest either a HIGH or LOW meal on separate days 3-5 weeks apart in random order. Three hours after meal ingestion, participants will undergo a cognitive battery, followed by spinal fluid collection. Blood samples will also be taken at 7 time points before and after meal ingestion.
223610898|NCT05766176|DIAGNOSTIC_TEST|COVID-19 Antibody|This descriptive study examines the levels of neutralizing antibodies against COVID-19 in health workers before and after the Quantitative Anti-SARS-CoV-2 Test is an examination to measure in vitro quantitative antibodies (including IgG) against the receptor binding domain (RBD) of the SARS-CoV Spike (S) protein. -2, which aims to assess the adaptive humoral immune response to the SARS-CoV-2 Spike protein. Measurement with the ECLIA method. Ratio Scale after the 2nd booster COVID-19 vaccine in Surakarta, Indonesia.
223610899|NCT02938208|DEVICE|Jupiter Full Face Mask|Full Face Mask for the treatment of obstructive sleep apnea (OSA) using CPAP therapy.
223610900|NCT02150447|DRUG|Proton pump inhibitor|Lansoprazole 30 mg, daily
223610901|NCT02150447|DRUG|Placebo|Placebo, daily
223610902|NCT02393937|DRUG|Reference: Metronidazole Gel 1%|Participants are assigned to one of three groups in parallel for the duration of the study
223610903|NCT02393937|DRUG|Test: Metronidazole Gel 1%|Participants are assigned to one of three groups in parallel for the duration of the study
223610904|NCT02393937|DRUG|Placebo Gel|Participants are assigned to one of three groups in parallel for the duration of the study
223610905|NCT01594229|DRUG|ABT-199|ABT-199 is taken orally once daily for 3 days out of each 28 day cycle. This is a dose escalation study, therefore the dose of ABT-199 will change throughout the study.
223610906|NCT01594229|DRUG|Rituximab|Rituximab will be given by intravenous infusion for 1 day out of each 28 day cycle.
223610907|NCT01594229|DRUG|Bendamustine|Bendamustine will be given by intravenous infusion for 2 days out of each 28 day cycle.
223610908|NCT05060770|GENETIC|transcriptomic analysis|transcriptomic analysis on preserved tumor tissue
223610909|NCT02068625|DRUG|Rasagiline|Rasagiline 1mg daily orally for 7 days
223610910|NCT02068625|DRUG|Placebo|Oral treatment with placebo for 7 days
223610911|NCT03093337|OTHER|Early post hospital discharge psychomotor therapy|The intervention consisted on 20 psychomotor therapy sessions between 2 and 9 months, in order to support infants' development, and parent-infant interactions and adjustment. The therapy was based on body and emotional positive feelings and experiences, leading to improve sensory motor and perceptive integration, interactive and exploratory behaviors, physiological and tonic-emotional self-regulation, motor organization and early coordination. The intervention was a partnership with the parents, leading to decode the baby needs and expectations, for the parents to experiment more positive feelings, to become more confident in their own skills and more sensitive, and in synchrony with their baby. Intervention was supported by a detailed assessment scale implemented in the regional network related to the follow-up for vulnerable babies.
223610912|NCT05740943|DRUG|Lorlatinib|Patients were assigned to receive oral lorlatinib at a dose of 100 mg daily in a course of treatment that was measured in cycles of 28 days. 3 cycles of induction treatment will be required for the study.
224311775|NCT05631197|OTHER|Sensodyne Repair & Protect|Domiciliary use twice a day
224311776|NCT01885026|BEHAVIORAL|eScreen|Access to the eScreen platform offering assessment of alcohol and drug use, with automated feedback on problematic or non-problematic use. Follow-up over time based on user needs.
224311777|NCT01885026|BEHAVIORAL|Assessment only of alcohol and drug use.|Assessment of alcohol and drug use at baseline and follow-up.
223610913|NCT04472234|OTHER|BPA levels|BPA (Bisfenol A) in urine, blood and follicle fluid samples
223610914|NCT05936398|BEHAVIORAL|Respiratory Muscle Training - VIH|The VIH group will train every second day with gradual progression based on session length and breathing frequency. Participants will begin with 3 minutes of exercise with a frequency of 20 breaths·min-1 during the first session and add no more than 1 minute or 2 breaths·min-1 with each consecutive session.
223610915|NCT05936398|BEHAVIORAL|Respiratory Muscle Training - ITPL|The IPTL group will train 5 days a week, twice a day, with at least 6 hours break between sessions. The session will consist of 30 dynamic inspiratory maneuvers with progressive overload based on gradually increased resistance. The VIH group will train every second day with gradual progression based on session length and breathing frequency. Participants will begin with 3 minutes of exercise with a frequency of 20 breaths·min-1 during the first session and add no more than 1 minute or 2 breaths·min-1 with each consecutive session.
223610916|NCT02682368|DIAGNOSTIC_TEST|Point of Care Ultrasound by Surgeons (POCUSS)|"POCUSS-1. To identify the gallbladder and it's contents, complications and perform measurements, elicit sonographic Murphy.~POCUSS-2: To perform focused left lower quadrant sonography and identify bowel wall thickness, diverticulae, measure the colonic wall thickness, assess pericolic fat and detect possible complications; evaluate sensibility on graded compression."
223610917|NCT02682368|DIAGNOSTIC_TEST|Radiology report|Radiologist report compared to the point of care ultrasound impression.
223610918|NCT02682368|PROCEDURE|Surgery-Intra-operative findings|Intra-operative findings compared to the previously performed point of care ultrasound.
223610919|NCT03158194|BEHAVIORAL|CBT for anxiety-related asthma|The specific assignments in the intervention will be based on individual behavior analysis for each participant.
223610920|NCT01450761|BIOLOGICAL|Ipilimumab|
223610921|NCT01450761|BIOLOGICAL|Placebo matching Ipilimumab|
224311778|NCT01885026|BEHAVIORAL|Internet-based treatment for depression or anxiety|Internet-based treatment for primary diagnoses of depression, panic anxiety or social phobia.
224311779|NCT06633848|PROCEDURE|spinal surgery|spinal surgery
224311780|NCT01687426|DRUG|Brimonidine Tartrate 0.025%|1 drop in each eye daily four times a day for 14 days
223610922|NCT01450761|DRUG|Etoposide|
223610923|NCT01450761|DRUG|Cisplatin|
223610924|NCT01450761|DRUG|Carboplatin|
223610925|NCT06493058|OTHER|Prone positioning|The babies in the study group were given the supine, right lateral and left lateral positions (12×1), which are used in nursing care practices in the clinic after extubation, in addition to the supine, right lateral and left lateral positions (12×1), the prone position was given twice a day for 2×2 hours twice a day within 48 hours after extubation, with the head on the midline of the neck and the head facing to the right or left side.
223610926|NCT00672919|DRUG|Pioglitazone|Pioglitazone 30 mg to 45 mg, tablets, orally, once daily in combination with stable statin therapy for up to 17 weeks.
223610927|NCT00535002|DRUG|Yohimbine|Participants were pre-treated with either yohimbine or placebo.
223610928|NCT00535002|DRUG|Placebo|
223610929|NCT05318404|DIETARY_SUPPLEMENT|Jejunostomy feeding|Maintain jejunostomy feeding till postoperative 1st visit after esophagectomy in delayed feeding group
223610930|NCT01327677|DRUG|Fentanyl|25-50 mcg every 20 minutes
223610931|NCT01327677|DRUG|Fentanyl|20mcg/demand dose with an 8 minute lock out
223610932|NCT01634776|DIETARY_SUPPLEMENT|Flaxseed oil|Families will be asked to mix the contents of one capsule (1200 mg flaxseed oil or 1288 mg corn oil) into a cup of participants' food, twice a day.
223610933|NCT01634776|DIETARY_SUPPLEMENT|corn oil|
223610934|NCT04668768|DRUG|Glucarpidase|Glucarpidase injection to prevent toxicities due to high dose methotrexate treatment
223610935|NCT01818596|DRUG|E/C/F/TAF|E/C/F/TAF (150/150/200/10 mg) FDC tablet administered orally once daily with food
223610936|NCT01220739|DEVICE|Transcranial Laser Therapy|Transcranial laser therapy is administered with the NeuroThera® Laser System (NTS) in subjects diagnosed with acute ischemic stroke. A laser system is a medical instrument that concentrates energy light on an area. Laser treatment has been used to deliver intense light energy to aid in the healing of tissues and wounds. The transcranial laser treatment procedure consists of applying the NTS laser to twenty different sites on the skull for two minutes at each site.
223610937|NCT04197349|BIOLOGICAL|ALD1910|Single Dose IV infusion
223610938|NCT04197349|BIOLOGICAL|Sumatriptan|Single dose subcutaneous injection
223610939|NCT04197349|BIOLOGICAL|ALD1910|Single dose subcutaneous injection
223610940|NCT01076530|DRUG|vorinostat|
223610941|NCT01076530|DRUG|temozolomide|
223610942|NCT01076530|OTHER|diagnostic laboratory biomarker analysis|
223610943|NCT01076530|OTHER|pharmacological study|
223610944|NCT03018899|PROCEDURE|paravertebral block|Ultrasound guided two-segment paravertebral block
223610945|NCT03018899|PROCEDURE|epidural anesthesia|thoracic epidural anesthesia
223610946|NCT04393402|PROCEDURE|lung ultrasound (LUS)|Patients with Covid-19 Disease and admitted in critical care unit will be performed a LUS
223610947|NCT01366482|DEVICE|Cotavance Drug-Eluting Balloon|Treatment with a paclitaxel-coated angioplasty balloon (without preceding plaque excision)
223610948|NCT01366482|DEVICE|TurboHawk/SilverHawk + Cotavance Drug-Eluting Balloon|Plaque excision with a SilverHawk or TurboHawk plaque excision device followed by treatment with a paclitaxel-coated angioplasty balloon
223610949|NCT01366482|DEVICE|TurboHawk/SilverHawk + Cotavance Drug-Eluting Balloon|Plaque excision followed by treatment with a paclitaxel-coated angioplasty balloon
223610950|NCT05732675|BEHAVIORAL|"Vina-STEAM (Skills to Empower Affirmative Men)"|The investigators propose and pilot test a community-based, peer-driven minority stress as well as HIV-stigma reduction program in small group of GBM in Ho Chi Minh City, Viet Nam.
223610951|NCT02050009|DRUG|metformin hydrochloride|Given PO
223610952|NCT02050009|DRUG|carboplatin|Given IV
223610953|NCT02050009|DRUG|paclitaxel|Given IV
223610954|NCT02050009|OTHER|laboratory biomarker analysis|Correlative studies
223610955|NCT03859271|BEHAVIORAL|Brief motivational interviewing|Children and parents will receive BMI and instant messaging delivered by a trained research nurse. At the time of recruitment, both children and parents will receive an education talk on the significance of and misconceptions about regular physical activity for cancer survivors and strategies for overcoming barriers to engaging in physical activity. Parents will then receive a face-to-face BMI to motivate their children to engage in regular physical activity. Parents will also be encouraged to motivate their children to intensify their physical activity levels progressively, with the ultimate goal of achieving the Global Recommendations on Physical Activity on Health suggested by the World Health Organization. Additionally, they will be invited to download a mobile health application from the Centre for Health Protection, Department of Health, HKSAR website that contains information on physical activity.
223610956|NCT03859271|BEHAVIORAL|Placebo control|Children and parents will receive the education talk on physical activity and ask to download the mobile health application that contains information on physical activity at the time of recruitment similar to the intervention group. However, parents will not receive BMI and instant messaging throughout the study period.
223610957|NCT03257124|DRUG|AZD9291|AZD9291 160mg per oral daily (1 cycle of 28 days)
223610958|NCT00813189|DEVICE|GH treatment|GH treatment will be administered at a weekly dose of 0.46 mg/kg/ week, divided into seven daily subcutaneous injections. Subcutaneous injections should be given slowly, in the thigh. In order to prevent lipoatrophy, the injection site should be varied. The injection should be given at bedtime.
223610959|NCT03801174|BEHAVIORAL|Partner-assisted intervention|All patients will receive group-based weight loss program for 6 months featuring a calorie-restricted diet and physical activity. Then, all patients will receive a weight loss maintenance intervention for 12 months that involves maintenance-specific content, transitions to individual telephone calls, and decreases frequency of contact. Partners will attend some patient group sessions and be informed of patients' goals and relapse plans. Intervention will be withdrawn for the last 6 months to examine sustainability of effects.
223610960|NCT03801174|BEHAVIORAL|Patient-only intervention|All patients will receive group-based weight loss program for 6 months featuring a calorie-restricted diet and physical activity. Then, all patients will receive a weight loss maintenance intervention for 12 months that involves maintenance-specific content, transitions to individual telephone calls, and decreases frequency of contact. Intervention will be withdrawn for the last 6 months to examine sustainability of effects.
224311781|NCT01687426|DRUG|Vehicle|1 drop in each eye daily four times a day for 14 days
224314256|NCT04855149|OTHER|Patient satisfaction|Patient satisfaction evaluated with EVAN LR questionnaire
223610961|NCT00038064|DRUG|Darbepoetin alfa|Darbepoetin alfa will be administered 4.5 mcg/kg QW until hemoglobin correction is achieved. Subjects meeting hemoglobin criteria for correction will receive a maintenance dose of darbepoetin alfa of 4.5 mcg/kg Q3W.
223610962|NCT00038064|DRUG|rHuEPO|150 IU/kg TIW
223757228|NCT05040633|DEVICE|BTL 4110 Smart Laser Therapy Equipment (BTL Industries Ltd, United Kingdom (UK))|Participants will receive 12 LLLT sessions during the course of the trial, thrice weekly for 4 consecutive weeks. Doses will be as per the recommendations of the Wold Association of Laser Therapy.
223610963|NCT00268840|DRUG|Docetaxel|Docetaxel 50 mg/m2 ou 35 mg/m² (suivant le bilan hépatique) à J1 et J15 toutes les 4 semaines
223610964|NCT00268840|DRUG|Gemcitabine|Gemcitabine 1200 mg/m2 à J1 et J15 toutes les 4 semaines
223610965|NCT00659074|DRUG|Ondansetron|ODT, single-dose, fasting
223610966|NCT00659074|DRUG|Zofran|ODT, single-dose, fasting
223610967|NCT01740414|DRUG|MN-166 (50 mg) First|In this arm of the study participants were first maintained on 50 mg MN-166 BID for approximately 14 days, and were then switched onto placebo maintenance. The subjective and analgesic effects of Oxycodone (0 mg, 15 mg and 30 mg) were tested under each of the two maintenance conditions (Placebo \& MN-166).
223610968|NCT01740414|DRUG|Placebo First|This arm of the study participants were first maintained on placebo for approximately 14 days, and were then switched onto 50mg MN-166 BID maintenance. . The subjective and analgesic effects of Oxycodone (0 mg, 15 mg and 30 mg) were tested under each of the two maintenance conditions (Placebo \& MN-166).
223610969|NCT06434181|DIETARY_SUPPLEMENT|Beetroot Juice|Beet-It Sports Shot, 70mL, containing 6.5 mmol nitric oxide (taking two shots per day in active group)
223610970|NCT06434181|DIETARY_SUPPLEMENT|Placebo Control|Beet-It Placebo Shot, 70mL (taking two shots per day in placebo group)
223610971|NCT04792021|DRUG|N-acetylcysteine|Oral formulation: 600 mg sachets of N-acetylcysteine
223610972|NCT00171171|DRUG|deferasirox|
223610973|NCT01329237|OTHER|dynamic physical exercise and OCT imaging|supine dynamic physical exercise during coronary angiography and optical coherence tomography OCT imaging of the coronary stent
223610974|NCT02256566|BEHAVIORAL|emotional memory training exercise|
223610975|NCT02256566|BEHAVIORAL|memory training exercise|
223610976|NCT05236608|DRUG|Nivolumab|Administered together with ADG106 via intravenous infusion.
223757229|NCT05040633|OTHER|Standard Exercise Therapy|Exercise therapy will consist of strengthening and stretching exercises. At each visit, participants will perform each of the exercises under the supervision of a licensed physiotherapist.
224201161|NCT03799237|OTHER|GOS trap and dengue NS1 antigen kit|The GOS trap lure and sticky surfaces to trap gravid Aedes mosquitoes. Three GOS traps will be placed on every 3 floors of the residential blocks. The traps will be changed weekly. Trapped Aedes mosquitoes will be identified to species. The mosquitoes will then be dissected, to remove the abdomen from the thorax. Five to seven abdomens of the same mosquito species will be pooled and tested for dengue NS1 antigen using the SD Biosensor Standard Q dengue NS1 antigen test kit. If the pool is tested positive for dengue NS1, the head and thorax of the respective abdomens will be subjected to the same procedure for dengue NS1 antigen test, individually. This may allow us to identify a focus where there could be dengue-infected individuals. Flyers/Posters will be disseminated besides, house-to-house approach to inform the residents of the findings and apartment blocks where these mosquitoes were found. The apartment management will also make use of social media disseminate this information.
223610977|NCT05236608|DRUG|ADG106|Administered as an intravenous infusion over 90 minutes.
223610978|NCT05272475|DIETARY_SUPPLEMENT|Chamomile Tea|Chamomile tea bags consumed by subjects as described in study arms section.
223610979|NCT05272475|DIETARY_SUPPLEMENT|Chamomile Extract Capsule|"Chamomile extract capsules consumed by subjects as described in Experimental: Chamomile Extract Capsule study arms section."
223610980|NCT04934501|DIAGNOSTIC_TEST|High-frame-rate contrast-enhanced ultrasound measurements (echoPIV)|Patients will undergo high-frame-rate contrast-enhanced ultrasound measurements, within 6 to 8 weeks after the endovascular procedure, at the vascular center of Rijnstate hospital. Prior to these measurements a venous cannula will be placed to ensure venous access for the contrast administration.
224314257|NCT02065856|BIOLOGICAL|AVANZ Salsola|AVANZ Salsola
223610981|NCT04934501|DIAGNOSTIC_TEST|Computed tomography angiography (CTA) scan|Patients will undergo a CTA scan of the lower extremities at the Radiology dept. of Rijnstate hospital the same day as the echoPIV measurements. This CTA scan serves as a reference for the vessel geometry and stent location.
223610982|NCT03531086|DRUG|Ioflupane I 123|Ioflupane I 123 will be administered IV push prior to SPECT imaging
223610983|NCT04880096|OTHER|eDOL|e-health tool (mobile app for patients and web platform for caregivers in pain clinics)
223610984|NCT02442440|DRUG|anisodamine|Anisodamine will be given first as bolus of 10 mg, followed by 0.1-0.5mg/kg/hr. The adjustment of pump infusion rate is largely at the discretion of treating physician, with the aim of improving microcirculation and limit the side effect to a minimum. For example, if serum lactate continues to elevate, the infusion rate can be increased. Discontinuation on severe side effect or recovery of shock (normalized lactate, weaned from vasopressor) or death.
223610985|NCT06139744|DRUG|DAO supplement|One tablet of the supplementary study product is taken orally before morning, lunch and dinner every day, and each tablet contains 4.2mg of dehydrated pea seedling powder.
223610986|NCT06139744|DRUG|Placebo|Placebo is orally supplemented with one tablet each day before morning, lunch and dinner, and placebo does not contain dehydrated pea seedling powder 4.2mg.
223610987|NCT04800601|OTHER|Rehabilitation program 1|"Both groups will benefit from a conventional rehabilitation treatment including a repetitive walking.~In addition to this conventional rehabilitation, the experimental group will receive an ankle isokinetic program, 5 times a week, for 6 weeks (with a minimum of 25 sessions)"
223610988|NCT04800601|OTHER|Rehabilitation program 2|"Both groups will benefit from a conventional rehabilitation treatment including a repetitive walking.~The control group will have a supplement in conventional rehabilitation equal to the additional time of the experimental group."
223610989|NCT00688584|BEHAVIORAL|Pamphlet-based personalized alcohol feedback (PAF)|participants in this condition will be mailed their respective pamphlets
223610990|NCT00688584|BEHAVIORAL|control pamphlet condition|The goal is to test if it is the specific content of the pamphlet that leads to the change or just the receipt of any pamphlet.
223610991|NCT00337207|BIOLOGICAL|bevacizumab|Bevacizumab 15 mg/kg every 3 weeks over 30 to 90 minutes. One cycle = 3 weeks. Treatment continues until progressive disease or unacceptable toxicity.
223610992|NCT05755139|DEVICE|IPL with smart diagnostic handpiece|treatment with IPL following diagnostic with SMART system
223610993|NCT05669547|DEVICE|dual hormone fully closed loop (DHFCL)|dual hormone fully closed loop consisting of an algorithm, sensors and both insulin and glucagon infusion.
223610994|NCT05350163|BIOLOGICAL|T-cell Receptor α/β Depleted Donor Lymphocyte Infusions|T-cell Receptor α/β Depleted Donor Lymphocyte Infusions following CD34+-selected Allogeneic Stem Cell Transplantation from Related and Unrelated Donors for Patients
223610995|NCT05627232|DRUG|Tazemetostat|Given PO
223610996|NCT05627232|DRUG|Liposome-encapsulated Daunorubicin-Cytarabine|Given IV
223610997|NCT05627232|PROCEDURE|Bone Marrow Aspiration and Biopsy|Undergo bone marrow aspiration and biopsy
223610998|NCT05627232|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223610999|NCT05627232|DRUG|Palbociclib|Given PO
223611000|NCT05565196|BEHAVIORAL|Birth companions|The intervention will have the following components: 1) Orient facilities and providers to benefits of BC; 2) Develop/update formal standard operating procedures (SOP) for implementing BC and develop plans to implement SOP; 3) Assess data required for implementation and an audit and feedback cycle for tracking coverage; 4) Assess and carry out modest structural changes in facilities to facilitate BC; 5) Use human centered design to develop materials/resources and a means to distinguish/recognize the BC, taking into account common barriers and misconceptions; 6) Prepare providers to integrate BC into care team; 7) Orient ANC clients to BC rationale and selection; 8) Prepare BCs to support women; 9) Iterate model and track intervention/policies.
223611001|NCT04498143|OTHER|"Project SAVE (Stop Adolescent Violence Everywhere) SSI"|Internet-based, 30-minute single session intervention targeting NSSI via decreasing urge to act on self-punishment/self-harm thoughts/urges.
223611002|NCT04498143|OTHER|"Active Comparator: Supportive Therapy (Share Your Feelings) SSI"|Internet-based, 30-minute single session intervention to increase feelings disclosure.
223611003|NCT05714150|BEHAVIORAL|Complex Balance Tasks|The intervention will consist of a single session of practicing complex (cognitively engaging) balance tasks using an exergaming balance platform.
223611004|NCT05585710|OTHER|Pulsed Lavage Washout|Use of pressurized, pulsed triple antibiotic solution to irrigate mastectomy pocket
223611005|NCT05585710|PROCEDURE|Implant-based breast reconstruction|Standard of care; use of triple antibiotic solution delivered via bulb syringes to irrigate mastectomy pocket
223611006|NCT05585710|PROCEDURE|Bilateral or unilateral mastectomy|Standard of care
223611007|NCT05585710|DEVICE|Tissue expander|Standard of care
223611008|NCT05585710|OTHER|Acellular dermal matrix|Standard of care
223611009|NCT04502290|DEVICE|Combined Non-invasive brain stimulation and functional electrical hand stimulation|Participants will receive synchronously combined non-invasive brain stimulation (delivered via electrical/magnetic stimulation) with functional electrical stimulation (delivered via DS7A or Neuromove) of the weak hand
223611010|NCT01138488|DRUG|insulin degludec/insulin aspart|Insulin degludec/insulin aspart administered as a single subcutaneous injection (under the skin).
223611011|NCT00837213|DRUG|Benzoyl peroxide with clindamycin|Benzoyl peroxide wash - Clindamycin foam
223611012|NCT00837213|DRUG|Benzoyl peroxide with clindamycin and doxycycline|Benzoyl peroxide wash - Clindamycin foam - Doxycycline capsules
223611013|NCT02293798|DEVICE|silk surgical scaffold|surgical implant
223611014|NCT02545218|PROCEDURE|Perineorraphy|Surgery for improperly healed perineal tear
223611015|NCT02545218|OTHER|Pelvic floor exercise|Pelvic floor exercise tutored by physio therapist.
223757230|NCT05096936|OTHER|Pilates|"The solo Pilates method will be applied twice a week for 12 weeks using the following exercises:~20 Breaths, Double leg stretch, Single leg stretch, Leg circles, Hip lift on ball, Abdominal tightening on ball, Alternating two supports, Side bend, Side kick - side kick, Side kicks, Shell and Swan and Neck pull stretches; in the tenth session, we evolved some exercises: The saw, Swan dive, Book close series, Hip lift on the ball and Front pulls; in the eighteenth session we changed again some exercises for: Leg pull back, Rolling like a Ball, Swimming, Roll over and Leg pull front."
224201162|NCT02923557|DRUG|Pirarubicin|single immediate intravesical dose of pirarubicin (THP) intravesical therapy (THP 40 mg for 30 min) within 24 hours of nephroureterectomy.
223611016|NCT01944124|BEHAVIORAL|Mobile Health|Participants monitored their blood pressure 3x per week, blood glucose 1x per week, pedometer steps daily and body weight monthly. Measures from devices were transferred or inputted to a smartphone data portal. Planned exercise was logged electronically on the smartphone.
223611017|NCT01944124|BEHAVIORAL|Exercise Prescription|An exercise program was prescribed tailored to participant fitness level (using the Step Test Exercise Prescription (STEP-TM) protocol). Briefly, STEP-TM required participants to step up and down a set of 2 steps 20 times at a comfortable pace. A predictive equation including post-test heart rate, time to complete test, age, body weight and sex was used to calculate fitness. An exercise program was prescribed including aerobic exercise most days of the week for 30-60 minutes in duration at a target heart rate tailored to fitness level. Light resistance training was also prescribed 2-4 times per week.
223611018|NCT01558947|DRUG|Peri-operative chemotherapy of ECX|Preoperative chemotherapy of ECX for 3 cycles(Epirubicin 50mg/m2 on day 1; capecitabine 1000mg/m2, 2 times / day, 1 to 14 days; cisplatin 60mg/m2 on day 1, need hydration, 21 day/cycle), operation after 2\~4 weeks, and postoperative chemotherapy of ECX for 3 cycles 4\~6 weeks after surgery.
223611019|NCT01558947|DRUG|Peri-operative chemotherapy of XP|Preoperative chemotherapy of XP for 3 cycles(capecitabine 1000mg/m2, 2 times / day, 1 to 14 days; cisplatin 60mg/m2 on day 1, need hydration, 21 day/cycle), operation after 2\~4 weeks, and postoperative chemotherapy of XP for 3 cycles 4\~6 weeks after surgery.
223611020|NCT02396706|DRUG|Ivy Leaves Cough Liquid|
223611021|NCT02396706|DRUG|Placebo|
223611022|NCT01931306|DRUG|Afatinib|BIBW2992 low to medium dose once daily
223611023|NCT05817565|DEVICE|Ultrasound (Phyaction 190 I); with a frequency of 3 MHz was used|Intermittent cervical traction (traction force equal 8% of body weight) was applied with the patient lying supine and the head in neutral position.
223611024|NCT06117241|BEHAVIORAL|IMAGINE HEALTHY|An anti-inflammatory nutrition program including cooking classes, physical activity, and stress reduction.
224201163|NCT01159652|DRUG|zaleplon|10 mg
223611025|NCT05646537|BEHAVIORAL|Neuro-Linguistic Programming Techniques|"The new behavior creation technique of NLP is based on the argument that the imagination process and reality are recorded in the same way in the brain.~Using the Participant's eye movements and imagination . He will be asked to imagine himself while caring for the stoma. participient will then be asked to re-enact the process with the correct stages of stoma care and the jurals that must be adhered to in order to successfully care for it.~Questions will be asked about where he can find the support he needs to carry out this process successfully. At the end of this whole process, he will be expected to construct what life is like with a stoma.The technique will be applied to the patient once and will be instructed to remember this successful process every time he or she feels distressed about the stoma.~At the end of 6 months, the quality of life and compliance will be evaluated by asking the scale questions again."
223611026|NCT05802446|OTHER|Real-time fMRI Neurofeedback|Neurofeedback with real-time fMRI is a recent technique that allows to record the BOLD signal from a particular brain region and to display it back in real-time to the participant. With this feedback on brain activity, subjects can learn to control the activity of selected brain areas. Trial after trial, participants develop their individual strategies to voluntarily regulate the signal. The main objective of the neurofeedback training is that the participant develops an enhanced ability to exert control over activity in the target area(s) even without feedback. By manipulating targeted brain circuits, this training can induce modifications in particular behaviors and promote selective plasticity within the corresponding brain networks.
223611027|NCT05566769|DEVICE|NMOSDCopilot smartphone application|NMOSDCopilot includes active tests for walking, cognition, dexterity and vision, and e-questionnaires related to pain, fatigue, quality of life, bladder and bowel dysfunction, depression
223611028|NCT00133042|DRUG|omalizumab|
223611029|NCT05303623|OTHER|Conventional Physiotherapy|Conventional Physiotherapy to contain breathing and thoracal expansion exercises, bronchial hygiene techniques and gradual mobilization in 1 time a day.
223611030|NCT05303623|OTHER|Conventional Physiotherapy+ inspiratory muscle training|Conventional Physiotherapy to contain breathing and thoracal expansion exercises, bronchial hygiene techniques and gradual mobilization in 1 time a day. In this group addition to conventional physiotherapy inspiratory muscle training will be performed with the threshold-loaded inspiratory muscle training device, starting at 30% of the maximum inspiratory mouth pressure value, during 5 days, in 2 sessions, 4 sets per day, 6-8 breaths in each set and 2 minutes of rest between sets.
223611031|NCT05303623|OTHER|inspiratory muscle training|In this group inspiratory muscle training will be performed with the threshold-loaded inspiratory muscle training device, starting at 30% of the maximum inspiratory mouth pressure value, during 5 days, in 2 sessions, 4 sets per day, 6-8 breaths in each set and 2 minutes of rest between sets.
223611032|NCT04555460|PROCEDURE|Hemicraniectomy|Large hemicraniectomy and duraplasty
223757231|NCT05096936|OTHER|Photobiomodulation|Applications of FBM or placebo (MR4 ACTIVet PRO Laser Shower Portable, MRM, USA) will last for 115s and will deliver 60 J at each point. The mode of application, with the patient supine on a stretcher, with the grouping probe held stationary in contact with the skin, at a 90-degree angle, in the pubic mound and in the perineum region.
223757232|NCT02231346|DRUG|Berodual® Respimat® - inhaler|
223757233|NCT06208436|OTHER|Adjuvant chemotherapy|Patients received adjuvant chemotherapy (5-FU-based or gemcitabine-based regimens) or underwent surgery alone
223757234|NCT02876965|PROCEDURE|Muscle Stretching|Subjects completed one stretching session on the main muscle groups of the body weekly.
223757235|NCT02876965|PROCEDURE|Physical Exercise|Subjects completed 3 moderate intensity aerobic physical exercise sessions weekly.
223757236|NCT00717769|DRUG|SUN13834|Low dose, orally 3 times a day (tid) for 28 days of SUN13834
223757237|NCT00717769|DRUG|Placebo|Placebo, orally (tid) for 28 days of SUN13834
223757238|NCT01137942|DRUG|clarithromycin, metronidazole, proton pump inhibitor|appropriate dose of antibiotics and proton pump inhibitor
223757239|NCT05677542|DRUG|secukinumab|all patients who received secukinumab
224201164|NCT01159652|DRUG|zolpidem extended release|12.5 mg
224201165|NCT01159652|DRUG|bedtime placebo|placebo
224201166|NCT01159652|DRUG|middle of the night placebo|placebo
223611033|NCT04555460|OTHER|Conservative medical therapy|Conservative medical therapy was based on published guidelines for the early management of patients with ischemic stroke
224201167|NCT00987506|DEVICE|XIENCE V®|Participants with placement of a XIENCE V® EESS
224201168|NCT03810027|DIAGNOSTIC_TEST|Bladder diary|3-day bladder diary
224311782|NCT03511326|DRUG|Methyl Aminolaevulinate 16% Cream|Subject will received one session of methyl aminolevulinate Daylight Photodynamic therapy
224311783|NCT04226950|DRUG|Recombinant Interferon Alpha|Recombinant Interferon Alpha, with an initial dose of 300 wu twice a week. Other interferons that have been listed can be used if Recombinant Interferon Alpha (300 wu) is not available, and the specific dose will be determined by the researchers;
224311784|NCT04226950|DRUG|Pegylated interferon alfa-2b|Pegylated Interferon Alfa-2b, with an initial dose of 135 ug once a week (body surface area \< 1.73 m2) or 180 ug once a week ( body surface area≥1.73 m2).
223611034|NCT01910415|DRUG|Lumacaftor|
223757240|NCT05040581|BEHAVIORAL|1-Day CBT-Based Workshop for Preventing PPD|The intervention is a 6-hour long CBT-based workshop. The intervention will be delivered in in modules and contain content on PPD etiology (with a focus on modifiable risk factors), the development of cognitive skills including cognitive restructuring, behavioural skills such as problem solving, sleep strategies, behavioural activation, assertiveness, and self-care, and the final module will involve goal setting and action planning.
223757241|NCT03439969|DEVICE|Mobile Text Messages|Dental inter-proximal control with floss holder and receiving 16 SMS during 4 months.
223757242|NCT03439969|DEVICE|Intra Oral Camera|"SPT - Appointment with Intra-Oral Camera~* Examination and diagnosis (15 min) using Intra-oral camera.~* Motivation, discussion about desired outcomes and treatment needs (using Intra-oral camera) followed by instrumentation (scaling, polishing) (30 min)."
223757243|NCT02529384|OTHER|Breast magnetic resonance scanning|Just a muti-b value series in breast MRI
223757244|NCT00831532|DRUG|Dimebon|Dimebon 5mg in healthy controls
223757245|NCT00831532|DRUG|Dimebon|Dimebon 5mg in mild hepatic impairment patients
223757246|NCT00831532|DRUG|Dimebon|Dimebon 5mg in moderate hepatic impairment patients
223757247|NCT00831532|DRUG|Dimebon|Dimebon 5mg in Severe Hepatic Impairment
224311785|NCT02750748|DRUG|Naltrexone|
223611035|NCT01910415|DRUG|Lumacaftor Placebo|
223611036|NCT01910415|DRUG|Ivacaftor|
223611037|NCT01910415|DRUG|Ivacaftor Placebo|
223611038|NCT01910415|DRUG|moxifloxacin hydrochloride|
223611039|NCT02698826|OTHER|Protocol for rapid FiO2 optimization|"We plan to test a protocol for FiO2 optimization for mechanically ventilated post-cardiac arrest subjects, with a therapeutic goal of partial pressure of arterial oxygen (PaO2) of 60-99 mmHg, based on the PaO2 range that was associated with the lowest risk of poor outcome in our previously published work. We also use PaO2 (measured by arterial blood gas \[ABG\] analysis) as the ultimate goal rather than arterial oxygen saturation (SaO2) measured by pulse oximetry because an SaO2 value \<100% on pulse oximetry monitoring does not always exclude supranormal PaO2. The protocol in this application begins with very rapid reduction of FiO2 as much as possible according to SaO2 values, and when FiO2 is maximally reduced by SaO2 an ABG is measured, followed by finer adjustment of FiO2 to achieve a PaO2 60-99 mmHg. The protocol not only prescribes each downward titration of FiO2 but it also includes detailed limbs for upward titration of FiO2 to account for potential overshoot in FiO2 reduction."
223611040|NCT02526602|PROCEDURE|Preservation (endopelvic fascia)|Robotic assisted radical prostatectomy with preserving of endopelvic fascia
223611041|NCT02526602|PROCEDURE|Opening (endopelvic fascia)|Robotic assisted radical prostatectomy with opening of endopelvic fascia
223611042|NCT00490958|DRUG|telmisartan|
223611043|NCT01540357|BEHAVIORAL|Mindfulness-based therapy|Treatment was performed as group therapy at two training weekends which were separated by an interval of 7 weeks (eleven hours/weekend) and in four further two-hour sessions (week 2, 9, 18 and 22).
223611044|NCT01540357|BEHAVIORAL|Treatment after waiting time|Treatment was performed after completion of the active arm.
223611045|NCT02915263|DRUG|IGIV-C|Gamunex-C \[immune globulin injection (human) 10% caprylate/chromatography purified\] is a sterile solution of human immune globulin protein.
223611046|NCT02915263|DRUG|0.9% Sodium Chloride|Sodium Chloride (also known as saline) is a solution of sodium chloride, or salt, and sterile water.
223611047|NCT01939847|OTHER|Treatment suggestion|Based on any actionable findings of the molecular profiling results, the investigators will come up with a suggestion for approved treatment or for clinical trial by referencing institutional clinical trials or potentially nationwide possibilities (www.clinicaltrials.gov).
223611048|NCT02289313|BEHAVIORAL|Healthy Youth Living Program|Physical activity and healthy eating program at the Alternative Learning Center co-developed by students, school staff and academic partners.
223611049|NCT01310764|PROCEDURE|Trabeculectomy|Both groups underwent trabeculectomy ,but in active group bevacizumab was used and in sham group mitomycin c was used during the surgery.
223611050|NCT04774263|OTHER|Individual interviews|Discussion between the searcher and the participant about representations and acceptability about a potential real time localization system
223611051|NCT02916901|DRUG|CKD-519 200mg|
223611052|NCT02916901|DRUG|Placebo|
223611053|NCT01436786|OTHER|Guided Imagery|The 12 week intervention consists of a set of 4 GI compact discs (CDs), each 20 minutes in length. Participants will be instructed to listen to the CD once a day in a recommended order for weeks 1-4 and used in any order for weeks 5-12.
223757248|NCT06058195|PROCEDURE|Quadratus lumborum plane block|QLB (quadratus lumborum plane block): 20 ml of 0.25% bupivacaine will be used each time for plane block on both sides. Patients will be sedated with 1 mg midazolam and 50 mcg fentanyl intravenously in the preoperative preparation room in the operating room and 20 ml of 0.25% bupivacaine was administered bilaterally on each side under ultrasound guidance. After the block application, the patient was taken to the operating room and standard general anaesthesia was applied.
224201169|NCT03190707|BEHAVIORAL|Intervention|"1. Detection of ill-being: An extended consultation with the midwife. The midwife will screen the women for symptoms of anxiety, depression and personality disorders.~2. Knowledge sharing: An additional midwife consultation accompanied by the health visitor. The aim of is sharing knowledge and transmission of information between the two sectors responsible for making a shared plan for the course of the process for the pregnant woman.~3. Strengthen parenting skills through:~   * Two visits by the health visitor before birth and eight after. The visits are based on the parent training program The Circle of Security, aiming at promoting a secure attachment between child and carer.~  * Teaching the woman/couple on the importance of breast-feeding and how to succeed."
224201170|NCT06439511|DEVICE|Darwin smartphone app|The participant must look into the smartphone camera with the Darwin app for about 30 seconds.
224201171|NCT06439511|DEVICE|Pulse oxymetry|Heart rate will be measured with pulsoe oximetry (gold standard)
224201172|NCT04301024|OTHER|assessing the nitrous oxide misuse|assessing the nitrous oxide misuse among teenagers consulting in an addioctology center dedicated to young drug users in montpellier
224201173|NCT06651216|OTHER|Stool analysis|Analysis of infant fecal microbiota
223611054|NCT05783336|BEHAVIORAL|Stepping Stones and Creating Futures Plus (SSCF+)|Group-based intervention delivered to small friendship networks, by a facilitator.
223611055|NCT05028335|OTHER|Carbamide Peroxide (PC) 22%) + placebo gel|Application of one drop of Polanight bleaching agent (SDI, SP, Brazil) on each corresponding tooth in a tray that was used for 45 minutes a day, for a period of twenty-one days. After the bleaching treatment, the participants were instructed to wash the trays under running water and dry them. The volunteers were instructed to apply a small amount of placebo gel, without active ingredient, with color, texture and odor similar to 1.5% oxalate gel (Painless, BM4, SC, Brazil) in the spaces related to the vestibular portions of the teeth trays, which were used for 10 minutes.
223757249|NCT06058195|PROCEDURE|Transverse abdominis plane block|TAPB (transverse abdominis plane block): 20 ml of 0.25% bupivacaine will be used each time for plane block on both sides. Patients will be sedated with 1 mg midazolam and 50 mcg fentanyl intravenously in the preoperative preparation room in the operating room and 20 ml of 0.25% bupivacaine was administered bilaterally on each side under ultrasound guidance. After the block application, the patient was taken to the operating room and standard general anaesthesia was applied.
224201174|NCT06651216|OTHER|breast milk analysis|Analysis of the effect of breast milk miRNAs on infant fecal microbiota
224201175|NCT05764733|DRUG|Bisphosphonate|Medicine used to treat bone problems, called osteopenia or osteoporosis.
224311786|NCT02750748|OTHER|Intravail|
224311787|NCT04532801|DRUG|Kisspeptin-10|kisspeptin-10 IV infusion
224311788|NCT04532801|OTHER|mixed meal tolerance test|mixed meal tolerance test
223611056|NCT05028335|OTHER|Carbamide Peroxide (PC) 22%) + Potassium Oxalate gel 1.5%|Application of one drop of Polanight bleaching agent (SDI, SP, Brazil) on each corresponding tooth in a tray that was used for 45 minutes a day, for a period of twenty-one days. After the bleaching treatment, the participants were instructed to wash the trays under running water and dry them with absorbent paper. The volunteers applied a small amount of 1.5% potassium oxalate gel (Painless, BM4, SC, Brazil) in the spaces relative to the vestibular portions of the tray's teeth, which were used for 10 minutes.
223611057|NCT05565703|OTHER|PARO Robotic Seal Intervention|PARO is a therapeutic robot used to comfort PWD exhibiting agitation and restlessness (www.parorobots.com). Participants are brought out to the activity are on the ACE Unit and provided with an isolation gown to wear during their interaction with the seal. The robot is then placed on their laps for them to hold on their laps, pet, rock and pick up. The participants can also brush the robot and/or give it a bath with baby wipes. The researcher encourages participant engagement with the robot. If the participant does not want the robot on their lap it is placed on a bedside table for them to interact with.
223611058|NCT05565703|OTHER|Attention Control|The participants are randomly assigned and receive a one hour visit by the researcher or research assistant
223611059|NCT00452868|DRUG|Donepezil|Donepezil 5 milligrams a day for 6 weeks
223611060|NCT06219096|PROCEDURE|NIF image-guided laparoscopic anatomical liver resection with the novel ICG@HSA administration|After ligation of the target hepatic segmental portal vein, the novel ICG regimen (0.5 mg ICG powder and 500 mg human serum albumin added to 20 ml saline, shaken and allowed to stand for more than 5 minutes, ICG: 0.025 mg/ml, human serum albumin: 25 mg/ml) was intravenously infused continuously at a rate of 1 ml/min until significant fluorescence imaging appeared in the demarcated area, upon which the infusion was terminated.
223611061|NCT06219096|PROCEDURE|NIF image-guided laparoscopic anatomical liver resection with the guideline-recommended ICG administration|After ligation of the target hepatic segmental portal vein, 2.5 mg of ICG (2.5 mg/ml) was intravenously injected.
223611062|NCT01567111|PROCEDURE|11C-Metomidate Positron Emission Tomography|Dose of intravenous 11C-Metomidate injection is 440MBq and emission scanning of upper abdomen. PET/CT imaging will be done using the Discovery PET/CT VCT or 690 scanner (General Electric Medical Systems, Milwaukee, WI, USA)
223757250|NCT06058195|PROCEDURE|Intravenous analgesia|IVA (Intravenous analgesia): These patients will be administered 1000 mg paracetamol intravenously in the preoperative waiting room in the operating room approximately 20-30 minutes before induction of anaesthesia. No block procedure will be performed. Patients will not be given any analgesic medication before awakening from anaesthesia.
223757251|NCT05071703|DRUG|Trilaciclib|"* Carboplatin combined with Etoposide (ES-SCLC patients)~* plus Topotecan (second/third line ES-SCLC patients)"
224201176|NCT05764733|BEHAVIORAL|Resistance Training/Bone-Loading Exercise|Exercise in small groups three days per week under the supervision of exercise physiologists. Heart rate and blood pressure will be measured before and after each session and participants will warm-up by walking or cycling for five minutes at a slow pace. All RT exercises will be conducted on machines which accommodate different body sizes and allow small increments in resistance, both important considerations for low functioning older adults with obesity.
224201177|NCT05764733|OTHER|Placebo|Capsules identical to the active alendronate capsules without any active ingredients with the same dosing and follow up as BIS treatment group.
223611063|NCT03641040|DIAGNOSTIC_TEST|Video-oculography|measure and analyze angles of ocular deviations between dominant and non-dominant eye using VOG with alternate cover.
223611064|NCT03641040|DIAGNOSTIC_TEST|Alternative prism cover test|measure and analyze angles of ocular deviations between dominant and non-dominant eye using APCT
223611065|NCT01474941|DRUG|PF-04620110 or Placebo|Multiple oral doses of 5 mg PF-04620110 as a modified-release formulation or placebo once daily for 2 weeks
223611066|NCT01474941|DRUG|PF-04620110 or Placebo|Multiple oral doses of 5 mg PF-04620110 as a modified-release formulation or placebo twice daily for 2 weeks
223611067|NCT01474941|DRUG|PF-04620110 or Placebo|Repeat Arm 1 or Arm 2
223611068|NCT01879683|DRUG|LiRIS® 400 mg|LiRIS® 400 mg is a drug-device combination product which is placed in the bladder during cystoscopy, remains in the bladder for up to 14 days gradually releasing lidocaine, and removed from the bladder via cystoscopy.
223611069|NCT05711134|BEHAVIORAL|Audit and Feedback on Individual Practice Patterns|Providers are given feedback on their practice patterns of ordering computed tomography of the cervical spine.
223611070|NCT04317040|DRUG|Efprezimod alfa|Efprezimod alfa is given on Day 1.
223611071|NCT04317040|DRUG|Placebo|Placebo is given on Day 1.
223611072|NCT03896321|DRUG|Antiplatelet Agents|effect of dual antiplatelet in management of coronary artery ectasia
223757252|NCT02276612|DRUG|E/C/F/TAF|150/150/200/10 mg fixed-dose combination (FDC) tablet administered orally once daily with food
224201178|NCT04616768|OTHER|PRO questionnaire|These text message surveys will inquire about seven symptoms, requesting a response rating the patient's response. The seven symptoms have been selected by lung and GI oncology clinicians at PCAM from a list of twelve validated symptoms from the National Cancer Institute's Common Terminology Criteria for Adverse Events and will be scored on a five point scale from 0 (no present) to 4 (disabling). The patients will also receive a question asking about their activity level over the prior month
224201179|NCT04616768|OTHER|Step monitoring|A CRC will provide patients with a Fitbit at enrollment and instruct them on how to wear the Fitbit device and periodically sync the device with their phone which will send updated step data to the research team.
223611073|NCT03896321|DRUG|Anticoagulants|effect of oral anticoagulants in management of coronary artery ectasia
223611074|NCT02241148|DRUG|Acetaminophen 500mg|500 mg, tablets every 8 hours
223611075|NCT02241148|DEVICE|Kinesio taping|Taping will be changed every week.
223757253|NCT02023450|DRUG|saquinavir and ritonavir|micro and low dose
223757254|NCT02023450|DRUG|saquinavir and ritonavir|standard dose
223757255|NCT04124107|DEVICE|multiparametric MRI and 68Ga-PSMA PET/MRI|All participants will undergo multiparametric MRI examination. If mpMRI is unfavorable for prostate cancer, participants will undergo 68Ga-PSMA PET/MRI examination
223757256|NCT04124107|PROCEDURE|Prostate biopsy|Participants with unfavorable mpMRI but favorable 68Ga-PSMA PET/MRI will undergo both 68Ga-PSMA PET/MRI-ultrasound-fusion targeted biopsy and transperineal ultrasound guided 12-core systematic biopsy
223757257|NCT05041790|DRUG|Choline Alfoscerate|Choline Alfoscerate 400mg per oral 3 times a day during the entire treatment period.
223611076|NCT06531486|OTHER|XS-02 capsules|Upon completion of all screening visits, eligible patients will be treated with XS-02 capsules at the appropriate dose.
223611077|NCT00004092|BIOLOGICAL|filgrastim|Given IV or subcutaneously
223611078|NCT00004092|DRUG|carboplatin|Given IV
223611079|NCT00004092|DRUG|cyclophosphamide|Given IV
223757258|NCT05041790|DRUG|Placebo|Placebo of Choline Alfoscerate 400mg per oral 3 times a day during the entire treatment period.
223757259|NCT00316979|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|
223757260|NCT00571506|DRUG|Rosiglitazone|Rosiglitazone 4 mg tablets by mouth daily for 3 months
223757261|NCT00571506|DRUG|Pioglitazone|Pioglitazone 30 mg tablet by mouth once daily
223757262|NCT02382081|PROCEDURE|Patient-initiated shared care|
223757263|NCT01303575|BEHAVIORAL|HIV, STI and Pregnancy Prevention Curriculum|"A complete internet-based, It's Your Game...Keep It Real Intervention Program"
223757264|NCT01303575|BEHAVIORAL|Control Curricula|A computer-based, science education program that does not contain elements of sexual health education
223611080|NCT00004092|DRUG|doxorubicin hydrochloride|Given IV
223611081|NCT00004092|DRUG|paclitaxel|Given IV
223611082|NCT00004092|DRUG|thiotepa|Given IV
223757265|NCT00832403|OTHER|implants of polytetrafluoroethylene in tha nasal fossa|surgical implants of polytetrafluoroethylene in the nasal fossa
223757266|NCT01306370|DRUG|Tranexamic Acid|"Two dosage during the surgical intervention: the first dosage 15-30' before the leg ischemia and the second dosage at 60 -90' after the first dosage.~Each dosage: 2 ampoules of 500mg/5 mL/ampoule"
223757267|NCT01306370|DRUG|Fibrin glue|Topical administration, before to close the surgical wound. Dosage: 2 mL.
223757268|NCT01306370|BIOLOGICAL|Fibrin glue|Topical administration, before to close the surgical wound.
223757269|NCT01306370|OTHER|Habitual haemostasis|The surgical habitual haemostasis.
223757270|NCT03250468|BEHAVIORAL|CBT-I|Each weekly session will focus on several psychological and behavioural techniques that include sleep restriction, relaxation strategies, cognitive therapy, stimulus control therapy, and education about proper sleep hygiene.
223757271|NCT03034785|DEVICE|FlexiMitt|The proposed research designs and fabricates a new technological innovation in wearable soft-sensors, called flexi-mitts, for measuring force modulation and joint angles of the hand (wrist and fingers) of toddlers.
223757272|NCT00262067|DRUG|Bevacizumab|Patients received bevacizumab until disease progression, treatment limiting toxicity, or death due to any cause up to a maximum treatment duration of 48 months. The dose of bevacizumab was based on the patient's weight at either screening or baseline and remained the same throughout the blinded treatment phase of the study. The initial dose was delivered over 90±10 minutes. If there were no infusion related adverse events (fever and/or chills), the second infusion was delivered over 60±10 minutes. If the 60 minute infusion was well tolerated, all subsequent infusions were delivered over 30±10 minutes.
223757273|NCT00262067|DRUG|Placebo|Placebo consisted of the vehicle for bevacizumab without the antibody.
223757274|NCT00262067|DRUG|Chemotherapy|"The chemotherapy was selected by the investigator prior to randomization. Chemotherapy treatment continued until disease progression, unacceptable toxicity, investigator/patient decision, or death, whichever occurred first, except for the anthracycline-based regimens, which had a maximum treatment duration of 8 cycles.~Taxanes - 1 of the following 2 taxanes on Day 1 of every 21-day cycle~1. Docetaxel 75-100 mg/m\^2 IV~2. Paclitaxel protein-bound particles (Abraxane®) 260 mg/m\^2 IV~Anthracyclines - 1 of the following 4 anthracycline-based regimens on Day 1 of every 21-day cycle~1. 5-fluorouracil 500 mg/m\^2 IV + epirubicin 90-100 mg/m\^2 IV + cyclophosphamide 500 mg/m\^2 IV~2. 5-fluorouracil 500 mg/m\^2 IV + doxorubicin 50 mg/m\^2 IV + cyclophosphamide 500 mg/m\^2 IV~3. Doxorubicin 50-60 mg/m\^2 IV + cyclophosphamide 500-600 mg/m\^2 IV~4. Epirubicin 90-100 mg/m\^2 IV + cyclophosphamide 500-600 mg/m\^2 IV~Capecitabine: 1000 mg/m\^2 orally twice daily on Days 1-14 of each 21-day cycle"
223757275|NCT01889680|DRUG|5-FU|400 mg/m2 IV bolus day 1 followed by 2400 mg/m2 continuous IV infusion over 46 hours (days 1 and 2) every 14 days until disease progression
223757276|NCT01889680|DRUG|LV|400 mg/m2 IV day 1 every 14 days until disease progression
223757277|NCT01889680|DRUG|ziv-aflibercept|4 mg/kg IV day 1 every 14 days for 6 cycles (induction regimen); 4 mg/kg IV day 1 every 14 days until disease progression (continuation regimen)
223611083|NCT00004092|PROCEDURE|peripheral blood stem cell transplantation|Patients receive autologous peripheral blood stem cells
223611084|NCT02509923|DRUG|Z-215 10mg|Z-215 10mg, capsules
223611085|NCT02509923|DRUG|Z-215 20mg|Z-215 20mg, capsules
223611086|NCT02509923|DRUG|Rabeprazole Sodium 10mg|Rabeprazole Sodium 10mg tablets
223611087|NCT02509923|DRUG|Rabeprazole Sodium 20mg|Rabeprazole Sodium 20mg tablets
223611088|NCT01177007|DEVICE|TheraSphere, Yttrium-90 glass Microspheres|Patients with unilobar disease will receive 120 ± 10% Gy (dose may be lower if clinically indicated) of TheraSphere to the affected lobe. Patients presenting with bilobar disease will have their liver assessed and the lobe presenting the highest treatment priority will receive the first treatment of TheraSphere. Assigning priority of lobes to receive treatment is based on tumor bulk, associated clinical symptoms attributed to the tumor and technical/angiographic considerations. In patients with bilobar disease where the second lobe does not require immediate treatment, or in unilobar disease where tumors develop in the untreated lobe, additional TheraSphere treatment may be administered at any subsequent time. A treatment may consist of a single 120 ± 10% Gy infusion to a lobe, or, if angiography indicates the need, the 120 ± 10% Gy dose may be split into multiple infusions per lobe to ensure delivery of a total of 120 ± 10% Gy to each treated lobe.
223757278|NCT01889680|DRUG|mFOLFOX6|5-FU 400 mg/m2 IV bolus plus leucovorin 400 mg/m2 IV plus oxaliplatin 85 mg/m2 IV on day 1 followed by 5-FU 2400 mg/m2 continuous IV infusion over 46 hours (days 1 and 2) every 14 days
223757279|NCT02258204|DRUG|Ketamine|Co-administration of subanesthetic dose of ketamine with tPA for thrombolysis in acute ischemic stroke.
223757280|NCT02258204|DRUG|Placebo|
223757281|NCT05625763|DIAGNOSTIC_TEST|sonoclot signature analysis|Investigate the value of global hemostasis studies (Sonoclot signature analysis) in cases of pre-eclampsia and if there a correlation between it and the specific traditional assays of hemostasis.
224311789|NCT00071292|BEHAVIORAL|stress reduction program|
224311790|NCT00071292|BEHAVIORAL|meditation|
224311791|NCT06241469|DRUG|Sintilimab,nab-paclitaxel and tegio|Immunotherapy combined with chemotherapy
223611089|NCT05083533|BEHAVIORAL|tele-rehabilitation exercise|"Telerehabilitation allows patients to interact with providers remotely and can be used both to assess patients and to deliver therapy. Treatment program planned to stretch the muscles of individuals with short hamstring muscle group.~Stretching exercises for hamstring muscle group shortening were applied 4 days a week, which lasted for 8 weeks in total. For the first four weeks, 3 different stretching exercises per day were planned and performed as 10 seconds of stretching and 5 repetitions. For the last four weeks, 4 different stretching exercises were planned per day and performed with 20 seconds of stretching and 10 repetitions."
223757282|NCT02933177|BEHAVIORAL|2 months control condition - 4 months chariot-flash|"The control condition is to propose the usual procedures for the management of productive symptoms during the emergence or increase of these symptoms.~The chariot-flash condition is a chariot with eleven drawers. Each drawer contains an activity (lasting about 15 minutes):~* Boards of known photographs to recall autobiographical memories~* Newspapers to read, talk, associate memories around an article~* Massage Oil, refreshing wipes, cream to reconnect with the body~* Clay, cookie pieces, washable felt and paper to create shapes, draw.~* Walk with a person of the healthcare team the case of behavioral disorders in type of ambulation and untimely exit .~* Listening to music~* Relaxation-Breathing~* Cushion, foam balls to vent his energy on secure hardware.~* Plush doll or to invest a vector object of affection and empathy~* Sensory flash balls that the patient can squeeze, throw, roll.~* Games with which the patient can play according to its possibilities."
223757283|NCT02933177|BEHAVIORAL|4 months control condition-2 months chariot flash|"The control condition is to propose the usual procedures for the management of productive symptoms during the emergence or increase of these symptoms.~The chariot-flash condition is a chariot with eleven drawers. Each drawer contains an activity (lasting about 15 minutes):~* Boards of known photographs to recall autobiographical memories~* Newspapers to read, talk, associate memories around an article~* Massage Oil, refreshing wipes, cream to reconnect with the body~* Clay, cookie pieces, washable felt and paper to create shapes, draw.~* Walk with a person of the healthcare team the case of behavioral disorders in type of ambulation and untimely exit .~* Listening to music~* Relaxation-Breathing~* Cushion, foam balls to vent his energy on secure hardware.~* Plush doll or to invest a vector object of affection and empathy~* Sensory flash balls that the patient can squeeze, throw, roll.~* Games with which the patient can play according to its possibilities."
223757284|NCT01461772|RADIATION|Radiation therapy|pelvic radiation therapy (Extended filed radiation therapy and addition of brachytherapy is allowed)
223757285|NCT01461772|DRUG|Carboplatin|carboplatin 130mg/m2BSA on day 1,8,15,22,29,and 36
223757286|NCT01461772|DRUG|Cisplatin|Cisplatin 40mg/m2BSA on day 1,8,15,22,29,and 36
223757287|NCT05540964|OTHER|Antiretroviral Therapy Interruption(ATI)|Study participant that were previously infused with autologous genetically modified cell product will be taken off ART and followed closely by monitoring HIV rebound.
223757288|NCT04160793|DEVICE|Genital Nerve Stimulation|Implantation the vaginal way a stimulation's electrode to the dorsal nerve of the clintoris in local anesthesia
223757289|NCT01116258|DRUG|AZD5847|oral suspension, 15 days
223757290|NCT01116258|DRUG|Placebo|oral suspension, 15 days
223757291|NCT00885599|DRUG|Herbal API|mouthwash;rinse full strength for 30 seconds with 20 ml (2/3 fl. Ounce or 4 teaspoonfuls) morning and night.
223757292|NCT00885599|DRUG|Cepacol|mouthwash;rinse full strength for 30 seconds with 20 ml (2/3 fl. Ounce or 4 teaspoonfuls) morning and night.
223757293|NCT00885599|DRUG|Listerine Antiseptic Mouth Rinse|mouthwash;rinse full strength for 30 seconds with 20 ml (2/3 fl. Ounce or 4 teaspoonfuls) morning and night.
224201180|NCT04616768|OTHER|Active nudge text feedback|"Intervention patients in arm c will receive text feedback describing worsening or severe symptoms collected from their remote PRO questionnaires (i.e. Your following symptoms are severe or have gotten worse:) and their step count (Your Fitbit step count compared to last week is worse.). They will also receive an active nudge question on their upcoming visit (i.e. Do you plan on discussing these symptoms with your oncologist at your upcoming visit? Type 1 if you plan to discuss them; Type 2 if you do not plan to discuss them.)."
224201181|NCT04616768|OTHER|PROStep Dashboard (clinicians)|"The study team will provide an updated PROStep Dashboard to lung or GI oncology clinicians for each patient enrolled in the intervention arms prior to their appointments. W2H will generate the dashboards and the study team will physically deliver it to their office or touchdown space or send electronically. The Dashboard will include:~1. Home-based PRO report, including the weekly survey results for each question in tabular and graphical form~2. Step data report, including a summary of number of daily steps in graphical form (with rolling weekly averages) and weekly averages in tabular form~3. A list of all acute care utilization in the UPHS system in the prior 6 months including Oncology Evaluation Unit visits, Emergency department visits, Inpatient admissions~4. Whether the patient has had an outpatient palliative care visit~5. Whether the patient has had a documented Serious Illness Conversation"
224201182|NCT06228456|DRUG|Ticagrelor 60mg|Patients in the ticagrelor arm will receive a 180 mg loading dose of ticagrelor followed by ticagrelor 60 mg bid maintenance dose for 30±5 days. Patients will maintain aspirin 81 mg once daily for the duration of the study.
224201183|NCT06228456|DRUG|Clopidogrel|Patients in the clopidogrel arm will continue to receive clopidogrel 75 mg/daily for 30±5 days. Patients will maintain aspirin 81 mg once daily for the duration of the study.
224201184|NCT05952154|PROCEDURE|Transapical beating-heart septal myectomy|We have invented a beating-heart myectomy device.Through a minimally invasive intercostal incision, septal myectomy could be accomplished via a transapical access in the beating heart using the device. The whole process of resection is monitored, navigated, and evaluated by real-time transesophageal and transthoracic echocardiography. Left ventricular end-diastolic volume and the grade of mitral regurgitation are evaluated each time after resection. Multiple resections are performed to tailor the muscular resection for sufficient enlargement of left ventricular end-diastolic volume and improvement of mitral regurgitation, while preventing iatrogenic injuries.
224201185|NCT06652945|OTHER|Uterine artery embolization|Uterine artery embolization under fluoroscopy
224201186|NCT00031902|BIOLOGICAL|bleomycin sulfate|
224201187|NCT00031902|BIOLOGICAL|rituximab|
223757294|NCT00885599|DRUG|placebo mouthwash|colored water mouthwash;rinse full strength for 30 seconds with 20 ml (2/3 fl. Ounce or 4 teaspoonfuls) morning and night.
224201188|NCT00031902|DRUG|prednisolone|
224201189|NCT00031902|DRUG|vincristine sulfate|
223757295|NCT03272919|OTHER|Arm 1: Investigational INF|INF utilizes three holds or positions, which widens tiny openings in arteries surrounding nerves and improves blood flow to targeted nerves. The improved blood flow in these nerves stimulates healing and reduces or even stops nerve pain.
223757296|NCT03272919|OTHER|Arm 2: standardized muscle stretching and strength|subjects will receive a standardized program of muscle stretching and strengthening exercise under the supervision of treating physical therapist.
223757297|NCT03127969|OTHER|Fluidotherapy treatment|fluidotherapy and joint protection and exercise
223757298|NCT03127969|OTHER|Joint protection and exercise|joint protection and exercise
223757299|NCT02299531|OTHER|Varying meal energy density and portion size|
224201190|NCT03699722|BEHAVIORAL|Education + Activities|Format:Video; discussion; information handouts; facilitated referral
224201191|NCT03699722|BEHAVIORAL|Information|Format: Information handouts
224201192|NCT01603927|DEVICE|Narrow band imaging for 'optical diagnosis' of colonic polyps (Olympus).|Colonoscopists will narrow band imaging to provide an 'optical diagnosis' for colonic polyps found during routine colonoscopies performed for the diagnosis of symptoms or asymptomatic screening.
224201193|NCT06662422|DEVICE|Spark Biomedical Sparrow Ascent Transcutaneous Auricular Neurostimulation (tAN) System|The Spark Biomedical Sparrow Ascent Transcutaneous Auricular Neurostimulation (tAN) System is a single-use electrode placed on and around the ear which provides transcutaneous auricular neurostimulation (tAN), which targets the auricular branch of the vagus nerve (ABVN) and the auriculotemporal nerve (ATN).
224201194|NCT01852669|PROCEDURE|Inversion|Patients inverted 30 degree head down in Trendelenburg position
224201195|NCT01852669|PROCEDURE|Shock Wave Lithotripsy|Shock wave lithotripsy
224201196|NCT01852669|DRUG|Hydration|Hydration of patient with 0.5L NaCl and 20mg frusemide IV
224201197|NCT00743873|BIOLOGICAL|Plasma Rich in Growth Factors (PRGF)|US guided IM injection 3-6mg
224201198|NCT00743873|DRUG|placebo|injection of 6 cc of saline into injured area
224201199|NCT05376293|BEHAVIORAL|Behavioral Internet program|The 12-week behavioral Internet program is designed to increase physical activity to recommended levels. Participants will be asked to plan and report aerobic exercise weekly, watch weekly video lessons, and complete brief weekly homework assignments.
224201200|NCT05376293|BEHAVIORAL|Informational newsletter condition|Newsletters will focus on the health benefits of regular physical activity, exercise safety, and will provide information on national exercise guidelines.
224201201|NCT06609811|BIOLOGICAL|Intranasal Influenza Live Attenuated Vaccine|This vaccine is produced by Changchun BCHT Biotechnology Co.
223757300|NCT00343733|DRUG|OraVescent Fentanyl|
223757301|NCT05242081|DRUG|S-ketamine|S-ketamine 0.5mg/kg for induction and 0.2mg/kg/h for maintenance
224201202|NCT06609811|BIOLOGICAL|Intranasal Influenza Live Attenuated Vaccine|This vaccine is produced by Changchun BCHT Biotechnology Co.
223509218|NCT02369679|DEVICE|Multilayer Compression Bandages|"A physiotherapist well trained in lymphedema treatment will apply a lymphatic drainage to the affected upper limb. Then the physiotherapist will apply the multilayer bandage to the patient. The patient would maintain the multilayer compression bandage until the next session of treatment. The first 10 sessions will be daily from Monday to Friday.~After the 10 first sessions, the treatment will be applied on alternate days (3 per week) until the patient receive a tailored compression garment (7-14 days)."
223757302|NCT05242081|DRUG|Sufentanil|Sufentanil 0.2-0.3μg/kg for induction and remifentanil 0.05-0.15μg/kg/min for maintenance
223757303|NCT02696369|DRUG|2% lidocaine HCl with epinephrine 1:200,000|
223757304|NCT02696369|DRUG|2% lidocaine HCl with epinephrine 1:80,000|
223757305|NCT03811795|OTHER|ECG monitoring with a Kardia Mobile monitor|The participants in the study will undergo a total of two follow-up visits after ablation (approximately 3 and 6 months) with a 12-lead electrocardiogram at each visit. An assessment of rhythm will be performed with daily transmissions as well as subject-activated event recordings for symptoms with the Kardia Mobile smartphone based monitor. The Kardia Mobile System is an FDA-cleared, clinical grade mobile ECG monitor coupled with a smartphone app that is able to record a single-lead ECG and securely transmit the tracings to the study investigators via the Kardia Pro commercial (HIPPA compliant) remote monitoring service for clinicians.
223757306|NCT02849548|DRUG|suvorexant|First in class orexin antagonist approved by the FDA for the treatment of insomnia
223757307|NCT02849548|OTHER|placebo|Pill with inactive ingredients
223757308|NCT01317238|DRUG|smallpox vaccine CJ-50300|Conventional CJ-50300 2.5 x 100000 pfu/dose vaccination
223757309|NCT03195959|OTHER|Hypoxia and Hyperoxia|10 minutes of breathing a gas mixture with FiO2 0.16 via a tight fitting mask. After 10 minutes of breathing ambient air (normoxia), patients were exposed to hyperoxia (FiO2 1.0) for 10 minutes.
223757310|NCT06052774|PROCEDURE|Non-Surgical periodontal therapy|Supra and Subgingival debridement for all patients except periodontally healthy individuals
223757311|NCT03126097|DRUG|JNJ-64155806 150 mg|JNJ-64155806 150 mg (3\*50 mg tablet) twice daily will be administered under fed conditions on Days 1 to 7 \[JNJ-64155806 Alone Phase\] and on Days 60 to 66 \[JNJ-64155806 + COCP Coadministration Phase\].
223757312|NCT03126097|DRUG|Ethinylestradiol/drospirenone 0.02 mg/3 mg|Each tablet contains 3 mg drospirenone and 0.02 mg ethinylestradiol administered as combined oral contraceptive pill (COCP) given on Days 18 to 41 (lead-in phase), Days 46 to 69 (coadministration phase - Days 59 to 66 under fed conditions).
224201203|NCT04025697|OTHER|Complete Denture|A conventional CD will be constructed
224201204|NCT04025697|OTHER|Rapid prototyped denture|A 3d printed complete denture will be constructed
224201205|NCT06859359|OTHER|Hypertension Disorders of Pregnancy (HDP) Implementation Bundle|The HDP Implementation Bundle will consist of 4 main blocks namely; patient education, home BP monitoring, a contextualized follow-up protocol and provision of free anti-hypertensives if need. Collectively, these will lead to design and development of a contextualized home BP monitoring program.
224201206|NCT05150925|OTHER|Cast treatment|Dorsal cast placed in OR
224201207|NCT05150925|OTHER|Immediate mobilization|Immediate mobilization postoperatively without casting
224201208|NCT05150925|PROCEDURE|Volar plating|Volar plating of distal radius fracture
224201209|NCT00998231|BIOLOGICAL|blood sample|Blood collections and peripheral blood mononuclear cells extraction will be operated after each evaluation and followed by RNA extraction, reverse transcription and gene expression quantification by real-time PCR.
224311792|NCT01058772|OTHER|INDUCTION of LABOUR|Induction of labour will be performed by using dinoprostone 2 mg vaginally or dinoprostone 0.5 mg intracervically at 6-8h interval (up to 5 doses) or dinoprostone 10 mg vaginal device. Patients, in which cervical ripening does not occur (Bishop score \< 7) after 5 attempts with PGE2, will be offered either oxytocin or Foley catheter induction or C-section, according to local protocols.
224311793|NCT05987319|DEVICE|RadioFrequency Microneedling Device|RadioFrequency device will be used for the treatment of dermatologic conditions.
224311794|NCT03302026|BEHAVIORAL|Realtime biofeedback using fMRI|Real-time fMRI (rt-fMRI) allows for rapid analysis of brain activation while an individual is actively performing a task, and can be used to provide real-time neurofeedback to individuals during fMRI scanning. Using neurofeedback, individuals can learn to modulate activity in specific regions of the brain. We propose to use rt-fMRI neurofeedback training to help smokers consciously modulate activation in areas related to cravings and self-control in order to improve control smoking urges. Participants will complete four sessions: an intake session and 3 scanning visits. The primary outcome is the ability to resist smoking during a validated smoking lapse paradigm.
224311795|NCT05287256|DRUG|Oral Delta-8-THC Cannabis|Delta-8-THC cannabis will be orally self-administered by study participants
224311796|NCT05287256|DRUG|Oral Delta-9-THC Cannabis|Delta-9-THC cannabis will be orally self-administered by study participants
224311797|NCT05287256|DRUG|Oral Placebo|Placebo will be orally self-administered by study participants
224311798|NCT05287256|DRUG|Vaporized Delta-8-THC Cannabis|Delta-8-THC cannabis will be self-administered by study participants using a vaporizer
224311799|NCT05287256|DRUG|Vaporized Delta-9-THC Cannabis|Delta-9-THC cannabis will be self-administered by study participants using a vaporizer
224311800|NCT05287256|DRUG|Vaporized Placebo|Placebo will be self-administered by study participants using a vaporizer
223611090|NCT05083533|BEHAVIORAL|Home exercise|All participants received home exercise for 8 weeks. The exercise program includes stretching exercises Stretching exercises for hamstring muscle group shortening were applied 4 days a week, which lasted for 8 weeks in total. For the first four weeks, 3 different stretching exercises per day were planned and performed as 10 seconds of stretching and 5 repetitions. For the last four weeks, 4 different stretching exercises were planned per day and performed with 20 seconds of stretching and 10 repetitions.
223611091|NCT05802043|BEHAVIORAL|Cognitive Stimulating Interventions|a quasi-experimental research design.The study subjects of group 1, the study group, will receive the proposed interventions, the cognitive stimulation interventions through small groups of study subjects receiving 12 sessions of group activities (2 sessions/week, approximately 45- 60 minutes/session). A group size of 6 to 8 will be conducted. The interventions group will be conducted in activity rooms within the elderly club.
223611092|NCT04226508|OTHER|Physical exercise|"The patients can choose between three modality of EX:~1. Autonomous supervised training : a personalized activity is proposed. People choosing this modality have a written material, in which all the exercise, the activity, the frequency, the duration, the intensity are specifically described and reported, to perform the training at home. A training diary and 7 meetings (face to face, or skype or other modality) are proposed for monitoring the intervention.~2. Personal training program: a personalized activity is proposed. Patients are followed individually in a gym contest by a qualified kinesiologist.~3. Group training program: the training is performed in a small group, supervised and monitored by a qualified kinesiologist. The instructor-user ratio is 1:4 - 1:8, depending on the functional conditions and the heterogeneity of the participants."
223611093|NCT01961271|DRUG|Buprenorphine transdermal patch|Please see Arm Description.
223611094|NCT05376631|PROCEDURE|Fresh gas flow of 5 L/min|A fresh gas flow of 5 L/min is used during emergence from general anesthesia.
223611095|NCT05376631|PROCEDURE|Fresh gas flow of 10 L/min|A fresh gas flow of 10 L/min is used during emergence from general anesthesia.
223611096|NCT02518386|OTHER|No intervention|No intervention is planned
223611097|NCT04603261|DIAGNOSTIC_TEST|Contrast concentration in urine|"Iodinated contrast content of urine samples, collected post-contrast over a period of 5 days at all times of natural excretion within that period, will be assayed.~Serum creatinine will be measured daily before (day 0) and during 5 days post-contrast, and again at 1 month post-contrast."
223611098|NCT00226486|OTHER|multifactorial intervention|Identification of medical, cardiovascular, physical risk factors for falls; e.g. vision, drug-use, depression, carotid sinus syndrome, orthostatic hypotension, etc. Individual intervention; treatment of disease, drug review, pacemaker, exercises, new glasses, all if indicated.
223611099|NCT00226486|OTHER|Usual care|No intervention, but ususal care after an accidental fall.
224201210|NCT02346071|BEHAVIORAL|Acceptance and Commitment Therapy|"All patients will have a thorough clinical psychiatric and somatic assessment in order to determine eligibility and a psychiatric consultation (SPC) of 1-1½ hrs. duration approx. 2 weeks after randomization.~The ACT treatment is manualized and given in groups of 7-8 patients with 9 3-hour sessions (i.e. 27 hours in total) over a period of 3 months and one follow up meeting (3 hours) three months after end of treatment. The parents and other relevant close relatives (e.g. siblings, boy/girlfriends) to the patient participate in a workshop where ACT principles are applied. One individual consultation with the adolescent and parents will be offered at the end of 8 sessions of group therapy."
224201211|NCT02346071|OTHER|Enhanced Usual Care (EUC)|"All patients will have a thorough clinical psychiatric and somatic assessment in order to determine eligibility and a psychiatric consultation (SPC) of 1-1½ hrs. duration approx. 2 weeks after randomization.~The consultation is according to a manual and includes psycho-education related to the diagnosis of multiorgan BDS, health promoting recommendations and counselling regarding existing medicine or other treatment. An individualized treatment plan will be sent to the patient's general practitioner, to optimize management in primary care and support by social services."
223611100|NCT04914026|OTHER|Biomarker analysis|Blood collection. Blood samples will be collected at diagnosis, during surveillance, during treatment and every 3-6 months
224201212|NCT02908191|DRUG|ABI-H0731|
224201213|NCT02908191|DRUG|Placebo for ABI-H0731|
224311801|NCT04319016|OTHER|pregnant women with laboratory-confirmed 2019-n-CoV|Clinical records and compiled data of all consecutive hospitalized and outpatient pregnant women with laboratory-confirmed 2019-n-CoV were included in a merged database
224314258|NCT03301571|OTHER|Change in preload and afterload|Afterload: Three levels of positive end-expiratory pressure (PEEP) will be examined post-operatively: 0 cm H20, 5 cm H2O, 10 cm H2O Preload: Trendelenburg position for 5 minutes will be investigated
223757313|NCT03126097|DRUG|COCP Placebo|Participant will receive COCP placebo tablets once daily on Days 42 to 45 (lead-in phase) and Days 70 to 73 (JNJ-64155806 + COCP coadministration phase).
224311802|NCT01090752|DRUG|Pioglitazone|placebo-controlled, randomized, cross-over study was to explore the effects of pioglitazone (45 mg q.d. for 6 weeks) on the renal, hormonal and blood pressure responses to changes in sodium intake in a population prone to insulin resistance
223611101|NCT00755495|DRUG|Ramelteon and doxepin|Ramelteon 8 mg, tablets, orally, once daily and doxepin 3 mg, liquid, orally, once daily for up to five weeks.
223757314|NCT01194206|RADIATION|stereotactic body radiation therapy|At least 3 gold standard Cyberknife fiducials will be placed in the liver w/in 6 cm of the tumor for image guidance during radiation therapy. At least 1 wk will elapse between fiducial placement and tx planning simulation to allow for fiducial settling and any migration.The full radiation tx will be given ideally in 3 consecutive days. In any case there must be a minimum of 24 hrs between fractions and all 3 fractions will be delivered w/in 14 days. The dose to at least 95% of the tumor will be 37.5 Gy total in 12.5 Gy fractions.
223757315|NCT06848686|BEHAVIORAL|Prevention Ambassadors|Delivery of prevention supplies and information on local services plus training to build the capacity of PWUD to distribute HIV self-testing (HIVST) kits with information and referrals to other PWUD in their social networks to promote HIV testing and HIV service engagement among PWUD.
223757316|NCT06848686|BEHAVIORAL|SSP Standard of Care|Delivery of prevention supplies and information on local services.
223757317|NCT05196906|PROCEDURE|Modified Broström operation and anatomic reconstruction operation|Patients with CLAI and GJL will accept the Modified Broström operation or anatomic reconstruction operation.
223757318|NCT05537623|BEHAVIORAL|Safe Alternatives for Teens and Youths (SAFETY)|Please see description of experimental arm (arm one)
223757319|NCT05537623|BEHAVIORAL|Supportive Therapy|Please see description of active comparator arm (arm two)
223757320|NCT06272877|OTHER|Fluidotherapy|Fluidotherapy is a dry environment created by mobilizing solid particles using heated air flow. Fluidotherapy will be applied 20 minutes a day, 5 days a week for 4 weeks.
223757321|NCT06272877|OTHER|conventional rehabilitation program|The conventional rehabilitation program determined before the study will be implemented by a physiotherapist in the hospital for 6 weeks.
223757322|NCT05855330|DRUG|Arginine Hydrochloride|Arginine will be infused based on the manufacturer's instructions (R-Gene 10, Pfizer), over 30 minutes. However, rates may be slowed to over 60 minutes for patients experiencing symptoms of flushing, nausea, vomiting, or headache at the research team's discretion. Pediatric doses will be drawn up by the pharmacy.
223757323|NCT06055023|DRUG|ZL-82 12.5mg|1 case,The starting dose,Take the medicine once on D1,D1-7.
223757324|NCT06055023|DRUG|ZL-82 25mg|1 case,The starting dose,Take the medicine once on D1,D1-7.
223757325|NCT06055023|DRUG|ZL-82 50mg|1 case,The starting dose,Take the medicine once on D1,D1-7.
223757326|NCT06055023|DRUG|ZL-82 100mg|1 case,The starting dose,Take the medicine once on D1,D1-7.
223757327|NCT06055023|DRUG|ZL-82 200mg|1 case,The starting dose,Take the medicine once on D1,D1-7.
223757328|NCT06055023|DRUG|ZL-82 300mg|1 case,The starting dose,Take the medicine once on D1,D1-7.
223611102|NCT00755495|DRUG|Ramelteon|Ramelteon 8 mg, tablets, orally, once daily and doxepin placebo-matching liquid, orally, once daily for up to five weeks.
223611103|NCT00755495|DRUG|Doxepin|Ramelteon placebo-matching tablets, orally, once daily and doxepin 3 mg, liquid, orally, once daily for up to five weeks.
223611104|NCT00755495|DRUG|Placebo|Ramelteon placebo-matching tablets, orally, once daily and doxepin placebo-matching liquid, orally, once daily for up to five weeks.
223611105|NCT00311935|PROCEDURE|method of hernia repair|
223611106|NCT05066386|OTHER|Modified RCRI risk stratification|"The objective of the study is to compare the predictive value of RCRI and substitution of the DM on insulin component with HH ratio for 30- and 90-day mortality, and postoperative acute myocardial injury(AMI) and acute kidney injury(AKI)."
223611107|NCT04333368|BIOLOGICAL|Umbilical cord Wharton's jelly-derived human|Umbilical cord Wharton's jelly-derived human MSC (at the dose of 1 Million / kg) will be administered via a peripheral or central venous line over 60 minutes, using tubing with a 200-μm filter. Cells, in a 150 mL volume, will be delivered at D1 - D3 - D5.
223611108|NCT04333368|OTHER|NaCl 0.9%|NaCl 0.9% (150 mL) given via an intravenous route at D1 - D3 - D5
223757329|NCT06055023|DRUG|ZL-82 450mg|1 case,The starting dose,Take the medicine once on D1,D1-7.
223757330|NCT06055023|DRUG|ZL-82 600mg|1 case,The starting dose,Take the medicine once on D1,D1-7.
223757331|NCT06055023|DRUG|zL-82 placebo 12.5mg|1 case,The starting dose,Take the medicine once on D1,D1-7.
223757332|NCT06055023|DRUG|ZL-82 placebo 25mg|1 case,The starting dose,Take the medicine once on D1,D1-7.
223757333|NCT06055023|DRUG|ZL-82 placebo 50mg|1 case,The starting dose,Take the medicine once on D1,D1-7.
223757334|NCT06055023|DRUG|ZL-82 placebo 100mg|1 case,The starting dose,Take the medicine once on D1,D1-7.
223757335|NCT06055023|DRUG|ZL-82 placebo 200mg|1 case,The starting dose,Take the medicine once on D1,D1-7.
224311803|NCT01090752|DRUG|Metformin|placebo-controlled, randomized, cross-over study was to explore the effects of pioglitazone (45 mg q.d. for 6 weeks) on the renal, hormonal and blood pressure responses to changes in sodium intake in a population prone to insulin resistance
224311804|NCT03263975|OTHER|Gatorade or Enterade|Commercially available oral rehydration therapies
224311805|NCT02572245|DEVICE|PF-06410293 PFS|PF-06410293 40 mg administered subcutaneously by Prefilled syringe
224311806|NCT02572245|DEVICE|PF-06410293 PFP|PF-06410293 40 mg administered subcutaneously by prefilled pen
224311807|NCT04868994|DIAGNOSTIC_TEST|Whole Body MRI and ENMG|Whole body muscle MRI lasting 30 to 45 min without injection of contrast medium an ENMG
224311808|NCT04746794|BEHAVIORAL|Population-level screening|"The study intervention involves having patients complete a familial cancer risk assessment survey. Those who are found to be at high risk will be offered genetic testing for a panel of hereditary cancers. A previvor plan will be created to assist patients and their providers in completing the appropriate follow-up for those with a mutation identified."
223757336|NCT06055023|DRUG|ZL-82 placebo 300mg|1 case,The starting dose,Take the medicine once on D1,D1-7. Edit
223757337|NCT06055023|DRUG|ZL-82 placebo 450mg|1 case,The starting dose,Take the medicine once on D1,D1-7.
223757338|NCT06055023|DRUG|ZL-82 placebo 600mg|1 case,The starting dose,Take the medicine once on D1,D1-7.
223757339|NCT05460494|BEHAVIORAL|RELOAD-C|RELOAD-C is a web-based platform that centralizes 6 brief videos of our MCP expert (Dr. Applebaum) discussing sources of meaning, links to virtual group meetings facilitated by a social worker trained in MCP to promote discussion of MCP concepts, and written content providing guidance on homework and exercises referenced in the MCP videos
223757340|NCT04171856|DEVICE|REAplan(R)|motor skill learning with the REAplan(R) rehabilitation robot, to be perfomed with the affected arm
223611109|NCT04043559|OTHER|MRI scanner|MRI was performed with a 1.5T magnet (Ingenia, Philips, The Netherlands; diffusion-weighted imaging b-values = 0 and 1,000 s/mm2, TR 4,280 ms, and TE 97 ms). In case of technical problems with the 1.5T MRI scanner, a 3T magnet (Skyra, Siemens, Erlangen, Germany) was used. MRI was analyzed by an experienced rater (DR), blinded to clinical data and MRI sequences other than diffusion-weighted imaging.
223611110|NCT04043559|OTHER|Contrast transoesophageal echocardiography|Contrast transoesophageal echocardiography (including Valsalva manoeuvre)
223611111|NCT01978496|DRUG|Placebo|matching placebo
223611112|NCT01978496|DRUG|Eletriptan 20 mg|20mg oral
223611113|NCT01978496|DRUG|Eletriptan 40 mg|40mg oral
223757341|NCT06346782|BEHAVIORAL|Internet-Based Parent-Child Interaction Therapy|I-PCIT consists of two phases. The first phase is designed to enhance positive parent-child interactions. The second phase is designed to enhance parents' behavior management parenting behaviors.
223757342|NCT05673408|DEVICE|Philips IntelliVue X3 Patient Monitor|All subjects enrolled in this study will receive one Philips non-invasive blood pressure cuff. This cuff will be connected via compatible hose to the Philips IntelliVue X3 monitor hosting the released or investigational NIBP algorithm. The invasive blood pressure from the radial arterial line will also be connected to the Philips IntelliVue X3 monitor. The Philips IntelliVue X3 monitor will in turn be connected to a laptop for data collection.
223757343|NCT06446713|RADIATION|Image guided hybrid hyper-fractioned dose escalation with proton therapy|"Radiation: Image-guided hybrid hyper-fractioned dose escalation with proton therapy~The investigational radiation regime will be administered in a two-part schedule:~* The first 4 weeks (i.e. first 20 fractions) of the radiation treatment of the pathological tumor will be according to the conventional clinical standard with proton therapy: 20x 2 Gy to the CTV70 and 20 x 1.55 Gy to the CTV54.~* In week 4 (\~ fraction 16) GTV80 will be determined on conventional weekly CT and additional MR imaging (conventional clinical protocol). Only this adapted tumor volume, the so-called GTV80, will receive the dose escalation (i.e., 80.5 Gy).~* In the last 3 weeks (last 15 fractions) patients will be radiated twice per day (i.e. hyperfractionation). The GTV80, CTV70 and CTV54 will receive 1.55 Gy in the morning, and the GTV80 and CTV70 will receive additional dose in the afternoon."
223757344|NCT06550700|PROCEDURE|laparoscopic hybrid surgery (LHS)|First performed the laparoscopic exploration of the entire abdominal-pelvic cavity to determine the resectability of the primary and metastatic lesions. After the blood vessel detachment and bowel detachment, the distal bowel of the tumor was severed and the pneumoperitoneum was closed. The liver metastases were then removed in both cohorts by open resection through the right subcostal incision.
223757345|NCT06326424|DEVICE|Empatica EmbracePlus|wear a biosensor watch to passively collect biosensor data over 48 hours. The EmbracePlus will collect heart rate variability, accelerometry, and electrodermal activity.
223757346|NCT06239844|OTHER|Experimental: Nav-Team|Participants in this arm will receive additional assistance related to asthma, log encounters, complete surveys.
223757347|NCT05370287|OTHER|oxygen inhalation|Subjects will breath 100% oxygen through a mask.
223757348|NCT05370287|DEVICE|Adaptive optics imaging|Adaptive optics scanning laser ophthalmoscopy (AOSLO) and adaptive optics - optical coherence tomography (AO-OCT) retinal imaging
223757349|NCT05527080|OTHER|physiotherapy|Some infants will receive physiotherapy as a part of their clinically indicated care.
223757350|NCT05527080|DEVICE|brace|Some infants in the hip dysplasia group will receive brace and/or cast as a part of their clinically indicated care
224201214|NCT02908191|DRUG|Entecavir|Used to treat adults with chronic hepatitis B virus
224201215|NCT02908191|DRUG|Tenofovir disoproxil fumarate|Used to treat adults with chronic hepatitis B virus
224201216|NCT02908191|DRUG|Pegasys|Used to treat adults with chronic hepatitis B virus who show signs of liver damage
224201217|NCT02908191|DRUG|Nucleos(t)ide|Used to treat adults with chronic hepatitis B virus
224201218|NCT04507282|DRUG|LMWH|COVID 19 positive patients anticogulation level, subprophylactic level and prophylactic level
224201219|NCT04288960|DEVICE|Gwalk accelerometer walking trials|No intervention. Participants will wear a belt mounted accelerometer and complete walking trials to assess validity of the device
224201220|NCT01826929|OTHER|Therapeutic education|
224201221|NCT03090945|OTHER|This is an obsevational cohort study|no intervention
224201222|NCT00197704|DIETARY_SUPPLEMENT|Multivitamins|5000 IU of retinol, 20 mg of B1, 20 mg of B2, 25 mg of B6, 100 mg of niacin, 50 mcg of B12, 500 of C, 200 mg of E, 0.8 mg of folic acid, and 100 mcg of selenium taken orally on a daily basis from the start of TB therapy through 8 months of anti-TB therapy
224201223|NCT00197704|OTHER|Placebo|Placebo pill taken orally on a daily basis from the start of TB therapy through 8 months of anti-TB therapy
224201224|NCT02183168|DRUG|Meloxicam suppository|
224201225|NCT02183168|DRUG|Meloxicam tablet|
223611114|NCT01978496|DRUG|Eletriptan 80 mg|80mg oral
223611115|NCT00006252|DRUG|fludarabine phosphate|30 mg/sq m/day IV infusion for 5 days (Days -7 thru -3)
224201226|NCT02183168|DRUG|Indomethacin|
223611116|NCT00006252|DRUG|Cyclophosphamide|1 g/sq m/day IV infusion x 3 days (Days -5 thru -3)
223611117|NCT00006252|BIOLOGICAL|PBSC|2-8,000,000/kg CD34+ cells via infusion on Day 0
223611118|NCT00006252|DRUG|G-CSF|5 ug/kg/day subQ injection until ANC \> 1000/uL for 3 days beginning Day 5
223611119|NCT00006252|BIOLOGICAL|Donor lymphocytes|10,000,000 CD3+ cells/kg via infusion
223611120|NCT01231919|DRUG|Akt inhibitor MK2206|Given PO
224201227|NCT00379821|DRUG|Atovaquone-proguanil|Atovaquone-proguanil: once a day for 3 days, Pediatric tablet: 62.5 mg/25 mg, Full strength tablet: 250 mg/100 mg
224201228|NCT00379821|DRUG|Artesunate|Artesunate: 4mg/kg once a day for 3 days, 50 mg tablet
224201229|NCT00379821|DRUG|Azithromycin|Azithromycin 30 mg/kg once a day for 3 days, 200 mg/5cc suspension
224201230|NCT00379821|DRUG|Chloroquine|Chloroquine: 10 mg/kg on days 0 and 1, 5 mg/kg/day on day 2, 100 mg tablet.
223611121|NCT01231919|OTHER|diagnostic laboratory biomarker analysis|Correlative studies
223611122|NCT01231919|OTHER|pharmacological study|Correlative studies
223611123|NCT03263273|DRUG|1% Topical Minocycline Gel|Treating Papulopustular Rosacea while monitoring for safety and efficacy of the active intervention
223611124|NCT03263273|DRUG|3% Topical Minocycline Gel|Treating Papulopustular Rosacea while monitoring for safety and efficacy of the active intervention
223757351|NCT01732523|DIAGNOSTIC_TEST|Contrast enhanced carotid ultrasound|
223757352|NCT06466083|OTHER|no intervention|this is an observation study,no intervention
223757353|NCT04731987|BEHAVIORAL|Beverage consumption|"Volunteers will consume, in random order, daily 330 ml of 1 experimental beverage per period (Orange Juice, Control Beverage, Control Beverage supplemented with hesperidin) for 6 weeks in each period.~At the beginning and the end of each period, exploration will be conducted at fasted state and at post-prandial state after the administration of a high-fat high-sugar meal."
223757354|NCT04478357|DRUG|4 mg Fesoterodine ER tablet from Zwickau|Manufactured at Zwickau
223757355|NCT04478357|DRUG|4 mg fesoterodine ER tablet from Freiburg|Manufactured at Freiburg
223757356|NCT04478357|DRUG|8 mg fesoterodine ER tablet from Zwickau|Manufactured at Zwickau
223757357|NCT04478357|DRUG|8 mg fesoterodine ER tablet from Freiburg|Manufactured at Freiburg
223757358|NCT01785979|DRUG|prednisone induction - chloroquine|At study entry, the patients will undergo physical examination and laboratory tests, including blood cell count, malaria microscopy, immune-chromatographic test for malaria antigen, malaria serology titers, and serum protein studies with immunoglobulin M quantification, immune-fixation and immunoglobulin free light chains measurement. We will assess all participants at 1, 3, 6 and 12 months after enrollment. Clinical examination and routine laboratory tests are done every 3 months during the follow-up period. Immunoglobulin M quantification and malaria serology are done at baseline, and at month 12 visit.
223757359|NCT01785979|DRUG|Chloroquine|At study entry, the patients will undergo physical examination and laboratory tests, including blood cell count, malaria microscopy, immune-chromatographic test for malaria antigen, malaria serology titers, and serum protein studies with immunoglobulin M quantification, immune-fixation and immunoglobulin free light chains measurement. We will assess all participants at 1, 3, 6 and 12 months after enrollment. Clinical examination and routine laboratory tests are done every 3 months during the follow-up period. Immunoglobulin M quantification and malaria serology are done at baseline, and at month 12 visit.
223757360|NCT01271088|DRUG|N-acetylcysteine|N-acetylcysteine 600 mg twice a day,one week after administration of antibiotics
223757361|NCT00196560|DEVICE|Immobilization in External Rotation|
223757362|NCT02357147|DRUG|Placebo|"Combination Phase - Placebo will be administered IV (intravenous infusion) once weekly for six 21-day cycles.~Maintenance Phase - Placebo will be administered IV (intravenous infusion) once weekly until disease progression."
223757363|NCT02357147|DRUG|Amatuximab|"Combination Phase - Amatuximab 5mg/kg will be administered IV (intravenous infusion) once weekly for six 21-day cycles.~Maintenance Phase - Amatuximab 5mg/kg will be administered IV (intravenous infusion) once weekly until disease progression."
223757364|NCT02357147|DRUG|Pemetrexed|Combination Phase - Pemetrexed 500 mg/m\^2 will be administered IV on Day 1 of each 21-day cycle for 6 cycles.
223757365|NCT02357147|DRUG|Cisplatin|Combination Phase - Cisplatin 75 mg/m\^2 will be administered IV on Day 1 of each 21-day cycle for 6 cycles.
223757366|NCT04656067|DRUG|Oxytocin ,Tranexamic acid and Ethamsylate|Is to compare blood loss during elective cesarean section intraoperative and postoperative in cases receiving Oxytocin versus Tranexamic acid and Ethamsylate
223757367|NCT04760275|DRUG|Fluoxetine|"This will be a single-blind SMART design of 24 weeks duration that will employ two sequential levels of randomization, one in each of two 12-week stages of the study.~In Stage 1, participants will be randomized 1:1 to receive 12 weeks of the medication fluoxetine in upward-titrated dosages. In Stage 2, also 12 weeks in duration, participants who remit during the first 12 weeks of treatment will continue maintenance-level therapy with fluoxetine. All participants who do not remit will be randomized (1:1) to either (1) optimization of fluoxetine (increasing the dose of fluoxetine as tolerated), or (2) optimization of fluoxetine and addition of Cognitive Behavioral Therapy (CBT)."
224201231|NCT00690573|BIOLOGICAL|Adalimumab|Adalimumab administered subcutaneously every other week, with dosage determined by body weight at study entry (20 mg for children weighing less than 30 kg, 40 mg for children weighing 30 kg or more).
223611125|NCT03263273|OTHER|Topical Vehicle Gel|Treating Papulopustular Rosacea while monitoring for safety and efficacy of the vehicle intervention
223611126|NCT05277376|DRUG|Bemotrizinol (6%)|Active sunscreen ingredient (Broad spectrum UV-Filter)
223611127|NCT01854970|DRUG|esomeprazole|Patients with pharyngolaryngeal symptoms will have a clinical evaluation, laryngoscopy, and pharyngoesophageal pH-impedance. Then a treatment by esomeprazole during 8 weeks in the term of which the second clinical evaluation and pH-impedance will be made.
224201232|NCT05838755|DRUG|GSK3858279|GSK3858279 will be administered
224201233|NCT05838755|DRUG|Placebo|Placebo will be administered
224311809|NCT01261091|PROCEDURE|Early Tracheostomy|Tracheostomy is performed as percutaneous dilatative tracheostomy by neurointensivists whenever possible. If anatomically or otherwise indicated, surgical tracheostomy is applied.
223611128|NCT03703544|OTHER|High glycemic index|Wheat yellow noodle, glutinous rice, tea with sucrose, biscuits, jelly made with sucrose and teriyaki chicken rice.The foods provided have been tested as high glycemic index. Participants' blood glucose will be monitored using the Continuous Glucose Monitor.
223611129|NCT03703544|OTHER|Low glycemic index|Beta-glucan yellow noodle, basmati rice, tea with isomaltulose, biscuits, jelly made with isomaltulose and mung bean noodles.The foods provided have been tested as low glycemic index.Participants' blood glucose will be monitored using the Continuous Glucose Monitor.
223611130|NCT00207311|DRUG|Xenical, Pegasys, Copegus|Xenical 120mg three times daily for 36 weeks or xenical placebo (Arm 1). Pegasys 180 mcg weekly for 48 weeks. Ribavirin daily for 48 weeks.
223611131|NCT00207311|BEHAVIORAL|Xenicare Program|Xenicare program for 36 weeks.
223611132|NCT02134860|OTHER|Bed rest|8 days of full bed rest
223611133|NCT02134860|OTHER|OGTT|Oral glucose tolerance test with 75 g of glucose before and after bed rest
223611134|NCT02134860|OTHER|IVGTT|Intravenous glucose tolerance test mimicking the glucose profile from the corresponding OGTT
223611135|NCT02134860|OTHER|Cognitive testing|Daily testing of memory and concentration using standardized tests
223611136|NCT02134860|OTHER|Muscle and fat biopsies|Biopsies will be obtained before and after bed rest
223611137|NCT02134860|OTHER|Dual-energy X-ray Absorptiometry (DXA) scan|DXA scan to evaluate fat and muscle distribution before and after bed rest
223611138|NCT02134860|OTHER|MRI|Functional MRI to evaluate cognitive function and abdominal MRI to evaluate visceral fat before and after bed rest
223611139|NCT06021639|DIETARY_SUPPLEMENT|The last 24 hours will consume low fiber food.|White bread, white rice, plain pasta or noodles, cereals not containing more than 1 gram of fiber per serving., canned or cooked skinless and seedless fruit, skinless and seedless raw fruit, pulp-free or low-fiber fruit or vegetable broth, seedless, seedless, skinless, such as canned or well-cooked carrots, string beans or peppers vegetables, tender red meat, poultry and fish, eggs, no more than two tablespoons per day, soft (creamy) peanut butter, milk, yogurt or plain cheese, salad dressings without oils or nuts, desserts without nuts.
223611140|NCT02059226|BEHAVIORAL|cognitive behavioural therapy|Internet-based CBT
223611141|NCT02059226|OTHER|Internet-based resource page|Static webpage
223611142|NCT03740659|DRUG|Levofloxacin + Dexamethasone|Levofloxacin + Dexamethasone ophthalmic solution + dexamethasone 21-phosphate administered twice: 90(±15) min. and 60(±15) min. before limbal paracentesis.
223611143|NCT03740659|DRUG|Levofloxacin|Levofloxacin ophthalmic solution (Oftaquix®) administered twice: 90 (±15) min. and 60 (±15) min. before limbal paracentesis).
223611144|NCT03740659|DRUG|Dexamethasone|Dexamethasone ophthalmic solution (Tamesad®) administered twice: 90 (±15) min. and 60 (±15) min. before Limbal paracentesis.
223611145|NCT04579341|DIETARY_SUPPLEMENT|probiotics|probiotics administration
223611146|NCT00931931|BIOLOGICAL|HSV1716|
223611147|NCT03869554|DIAGNOSTIC_TEST|Detection of Fabry disease|Systematic detection of Fabry disease
223611148|NCT05458206|OTHER|mulligan snag mobilization and diaphragmatic release|"The patients will be in the supine position. The therapist makes manual contact bilaterally under the costal cartilages of the lower ribs (7th to 10th ). During the patient's inspiration, the therapist will gently pull the points of hand contacts toward the head and slightly laterally. During exhalation, the therapist will deepen hand contact toward the inner coastal margins.~mulligan snag, Apply a passive intervertebral movement in a superior anterior direction along the facet plane. While maintaining this glide as the patient actively moves in any range of physiological movement"
223611149|NCT01599000|DRUG|Artemether-lumefantrine combination|fixed-dose tablet, six doses over three days, according to weight group
223611150|NCT02988778|DRUG|Budesonid 50mcg (Noex)|Suspention to nasal use, 2 atomization in each nostril during the morning and at night.
223611151|NCT02988778|DRUG|Budesonid 50mcg (Busonid)|Suspention to nasal use, 2 atomization in each nostril during the morning and at night.
223611152|NCT02921659|DIETARY_SUPPLEMENT|Niagen™|nicotinamide riboside chloride, 250mg capsules
223611153|NCT02921659|DIETARY_SUPPLEMENT|Placebo|silicified microcrystalline cellulose, vegetarian capsule
223611154|NCT03485066|BEHAVIORAL|Tetris|The video game Tetris is a cognitively challenging task, which requires mental rotation, problem solving and fast visuo-spatial and motor coordination.
223757368|NCT04760275|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|"This will be a single-blind SMART design of 24 weeks duration that will employ two sequential levels of randomization, one in each of two 12-week stages of the study.~In Stage 1, participants will be randomized 1:1 to receive 12 weeks of weekly CBT implemented with Coping Cat (CC). In Stage 2, also 12 weeks in duration, participants who remit during the first 12 weeks of treatment will continue maintenance-level therapy with CBT. All participants who do not remit will be randomized (1:1) to either (1) optimization of CBT (intensifying exposure practice and skills review), or (2) optimization of CBT and addition of the medication fluoxetine."
223757369|NCT06200532|OTHER|FOOTSAK (FOOTwear self-assessment kit)|FOOTSAK is a Footwear Self-Assessment Kit intended to empower people with diabetes by providing the necessary tools and instructional materials to enable self-assessment to determine whether footwear has adequate length and width. It includes measuring tools (an internal footwear length gauge, scale dividers for measuring internal footwear width, a slide rule for measuring foot length and width, a ruler and magnifying glass for reading off measurements) and instructional materials (booklet instructions and video materials)
224201234|NCT07005778|OTHER|Traditional pain education|Participants in the control group received a 70-minute lecture based on the biomedical model of pain. Educational content included anatomical pathways for pain process (receptors, Aδ and C fibers, spinal cord, and ascending tracts), mechanisms of action potential generation, and the Gate Control Theory. The role of the brain was briefly addressed in the context of descending inhibition. While the Neuromatrix Theory was mentioned, the presentation lacked metaphorical or narrative-based content. Case examples centered on inflammation and tissue injury.
224311810|NCT01261091|PROCEDURE|Late Tracheostomy|Tracheostomy is performed as percutaneous dilatative tracheostomy by neurointensivists whenever possible. If anatomically or otherwise indicated, surgical tracheostomy is applied.
224311811|NCT04040192|DRUG|Crisaborole 2%|Crisaborole ointment 2%
224311812|NCT04040192|DRUG|Vehicle|Vehicle ointment
224314259|NCT03301571|OTHER|Inspired oxygen|Following fractions of inspired O2 will be investigated: 0.5 and 1.0 for 10 minutes respectively
223611155|NCT00202007|DRUG|Aripiprazole tablet, 5-30mg/day, oral, 6 weeks|
223611156|NCT00202007|DRUG|Risperidone tablet, 1-6mg/day, oral, 6 weeks|
223611157|NCT00329888|PROCEDURE|Endoscopic papillary balloon dilatation|
223611158|NCT00329888|PROCEDURE|Endoscopic sphincterotomy|
223611159|NCT03692039|PROCEDURE|M-pro files in rotating motion|An endodontic file that has controlled memory properties
223611160|NCT03692039|PROCEDURE|ProTaper Next files in rotating motion|An endodontic file that has an off center mass of rotation
223611161|NCT04726683|PROCEDURE|Dry needling and placebo injection|Dry Needling is applied with a filiform needle to penetrate the skin and stimulate the underlying myofascial trigger point of the masseter muscle. Dry needling is combined with placebo injection, in which the tip of a beveled needle is cut and the process of injection is simulated without penetrating the skin.
223611162|NCT04726683|PROCEDURE|Injection and placebo dry needling|Lidocaine injection applied in the myofascial trigger point of the masseter muscle. Lidocaine injection is combined with placebo dry needling, in which the tip of a filiform needle is cut and the dry needling technique simulated without penetrating the skin
223611163|NCT04726683|PROCEDURE|Dry needling and injection|Dry Needling is applied with a filiform needle to penetrate the skin and stimulate the underlying myofascial trigger point of the masseter muscle. Dry needling is combined with lidocaine injection applied in the myofascial trigger point of the masseter muscle.
223611164|NCT04726683|PROCEDURE|Placebo dry needling and placebo injection|Placebo dry needling, in which the tip of a filiform needle is cut and the dry needling technique simulated without penetrating the skin. Placebo dry needling is combined with placebo injection, in which the tip of a beveled needle is cut and the process of injection is simulated without penetrating the skin
223611165|NCT01527968|DRUG|Tranexamic Acid|TXA as 10mg/kg x 1 dose in 100mL normal saline over 15 minutes prior to the procedure then an infusion of 1mg/kg/hr during the procedure + placebo (normal saline as the dummy for eACA.)
223611166|NCT01527968|DRUG|Epsilon Aminocaproic Acid|eACA as 150mg/kg in 250mL of IV normal saline over 15 minutes prior to the procedure then an infusion of 15mg/kg/hr during the procedure + placebo (normal saline as the dummy for TXA).
223611167|NCT01527968|DRUG|Normal Saline|Control Normal Saline x 2 infusions as the double dummy for TXA and eACA.
223611168|NCT02591940|PROCEDURE|Surgery or Treatment by Heart Catheter|
223611169|NCT05973734|BIOLOGICAL|Infusion of recipient T regulatory cell|Patients will undergo a single apheresis collection with a target total blood volume of 20-30 L and the collected cells used as the source of purified Tregs to be infused following the islet transplantation. In the event a patient is unable to meet the collection target, a second collection may be performed.
223611170|NCT05973734|BIOLOGICAL|Infusion of concomitant Donor Derived Vertebral Bone Marrow|The cells from the donor VB and spleen are processed under cGMP conditions and released for infusion after the respective recipient has undergone transplant and conditioning. Under this protocol, the donor's VB will be obtained at the same time as the pancreatic islets and will be the source of HSC for infusion with the intent to establish immune tolerance to the donor's pancreatic islet cells. Subjects will receive one infusion of allogeneic cadaveric islets. Subjects will receive induction therapy with ATG and Belatacept and maintenance immunosuppression with Tacrolimus Extended-release tablets (Envarsus XR) and Mycophenolate Mofetil (MMF). After islet transplantation, the VBM cells will be infused in one time window: on day 0-1. Subjects will undergo closed-loop insulin pump glucose control peri-transplant.
223611171|NCT03116711|OTHER|Positive CIQ plus High Carbohydrate Diet|Positive Carbohydrate Intolerance Questionnaire plus High Carbohydrate Diet
223611172|NCT03116711|OTHER|Positive CIQ plus High Protein Diet|Positive Carbohydrate Intolerance Questionnaire plus High Protein Diet
223611173|NCT03116711|OTHER|Negative CIQ plus High Carbohydrate Diet|Negative Carbohydrate Intolerance Questionnaire plus High Carbohydrate Diet
223611174|NCT03116711|OTHER|Negative CIQ plus High Protein Diet|Negative Carbohydrate Intolerance Questionnaire plus High Protein Diet
223611175|NCT04663503|OTHER|Exercise program|Depending on the age, there will be two components of the exercise program completed by the patients. The first component will be strengthening exercises. The second component will be endurance activities. This will be administered by the physical therapist
223611176|NCT01388569|OTHER|flow cytometry|
223611177|NCT01388569|OTHER|immunologic technique|
223611178|NCT01388569|OTHER|laboratory biomarker analysis|
223611179|NCT00952458|DEVICE|BIS monitoring|Neuromonitoring of depth of sedation with Bispectral Index
223611180|NCT01695135|DRUG|Abiraterone acetate|Abiraterone 1000 mg (4 x 250 mg tablets) taken orally once daily
223611181|NCT01695135|DRUG|Placebo|Placebo (4 tablets) taken orally once daily
223611182|NCT01695135|DRUG|Prednisone|Prednisone 5 mg tablet taken orally twice daily
223611183|NCT02107066|BEHAVIORAL|Exercise|Weekly telephone counseling to increase aerobic exercise to 150 min/wk for 6 months.
223611184|NCT04664374|OTHER|MyMood|Users will use the MyMood tool. Each MyMood session consists of a brief survey, followed by a few psycho-educational 'tips'(targeted psycho-educational interventions received from time to time based on symptom severity reports as determined by the software algorithm).
223611185|NCT01488526|DRUG|TDF treatment|About 100 mothers treated with tenofovir from 30-32 weeks of pregnancy to the week 4 of postpartum, then observed to the end of the study at post-partum week 28, paired infants received standard HBV prophylaxis.
223611186|NCT04445142|PROCEDURE|fovea-sparing internal limiting membrane peeling|fovea-sparing internal limiting membrane peeling surgery
223611187|NCT04946890|DRUG|MRX2843|MRX2843 is treated at 80mg/d, 120mg/d and 180mg/d respectively
223757370|NCT05832645|OTHER|Meditation with guided tea consumption|Mindful consumption of tea along with an approximately 10-min guide
223757371|NCT05832645|OTHER|Breathing meditation|10-min breathing meditation
223757372|NCT04917744|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
224201235|NCT07005778|OTHER|PNE-based education|"Students in the intervention group received a 70-minute lecture grounded in the biopsychosocial model of pain. The session emphasized that pain is not a direct result of tissue damage, but rather a complex and context-dependent output of the brain. The lecture explored how pain emerges from the brain's interpretation of various inputs, including sensory signals, prior experiences, beliefs, emotions, and environmental factors.~Instructional strategies included the use of clinically relevant metaphors and storytelling to promote reconceptualization of pain. Examples such as the alarm system were used to illustrate peripheral and central sensitization, while real-life anecdotes (a player unaware of injury during a game or a nail-in-foot case with no significant damage) highlighted the dissociation between nociception and pain experience."
224201236|NCT07006753|PROCEDURE|Transvaginal Diverticulum Wall Filling and Coverage Technique|This surgical intervention is a modified transvaginal technique for the treatment of circumferential female urethral diverticulum (UD). Instead of performing a complete diverticulectomy, the procedure utilizes the patient's own demucosalized diverticular wall to fill the diverticular cavity and reinforce closure of the ostium. The technique aims to preserve the integrity of the dorsal urethra, reduce the risk of fistula, minimize dead space, and improve functional outcomes such as continence and sexual function. This approach is specifically designed for circumferential UD, which poses unique anatomical and surgical challenges.
224201237|NCT02051673|BIOLOGICAL|Biological/Vaccine: Enriched Hematopoetic Stem Cell Infusion|Enriched Hematopoetic Stem Cell Infusion
224201238|NCT07029490|OTHER|Chatbot|The Chatbot used in this study will be used after mammography to facilitate follow-up, answer patient questions, and provide information.
223611188|NCT01434173|DRUG|Moxifloxacin (Avelox, BAY12-8039)|Eligible patients who are new users of moxifloxacin during the study period. A new user is defined as a person who has a first recorded dispensing of moxifloxacin during the study period and who has not had a previous recorded dispensing for any of the study antimicrobials during the previous 180 days
223611189|NCT01434173|DRUG|Amoxicillin, Amoxicillin plus clavulanic acid, Cefuroxime, Clarithromycin, Doxycycline, Levofloxacin, Telithromycin|Eligible patients who are new users of one of the other study antimicrobials (amoxicillin, amoxicillin plus clavulanic acid, cefuroxime, clarithromycin, doxycycline, levofloxacin, or telithromycin) during the study period. A new user is defined as a person who has a first recorded dispensing of a study a study antimicrobial during the study period and who has not had a previous recorded dispensing for any of the study antimicrobials during the previous 180 days.
223611190|NCT00158717|DRUG|Hepsera|
223611191|NCT00684996|DRUG|etaracizumab|Given IV
223757373|NCT04917744|OTHER|Laboratory Biomarker Analysis|Ancillary studies
223757374|NCT04917744|OTHER|Medical Chart Review|Review of medical charts
223757375|NCT04828889|DEVICE|Anal dilators|Anal sphincter training for relaxation
223757376|NCT04828889|PROCEDURE|lateral internal sphincterotomy|lateral internal sphincterotomy is a firmly established method for treating anal fissures.
223757377|NCT00256698|DRUG|Fulvestrant|intramuscular injection 250 mg loading dose (LD) regimen
223757378|NCT00256698|DRUG|Anastrozole|1 mg oral tablet
223757379|NCT06856720|DEVICE|Neuromuscular Electrical Stimulation (NMES)|Participants will receive NMES application for 30 minutes, three times a week, over a period of 12 weeks. The sessions will be supervised by a physiotherapist. Large muscle groups (quadriceps) will be used, with the following current parameters: frequency of 5 Hz, pulse width of 400 μs, 4 seconds of stimulation (on) for 12 seconds of rest (off), and intensity adjusted to the maximum tolerable level for the patient. These parameters are based on studies that have shown significant improvements in glycemic control and insulin sensitivity, especially in older adults with type 2 diabetes.
223757380|NCT06856720|BEHAVIORAL|Aerobic and resistance exercise|This group will participate in an exercise program combining aerobic and resistance activities, performed three times per week for 12 weeks. The activities will be adapted to the participants' physical capabilities and supervised by a physiotherapist. The program follows the international recommendations and it includes a 5-minute warm-up with flexibility exercises, 20 minutes of aerobic exercise at 60-75% of maximum heart rate or moderate perceived exertion, 20 minutes of resistance exercise at 50-70% of one-repetition maximum (1RM) focusing on large muscle groups (10-15 repetitions per exercise, 1-3 sets), and a 5-minute cool-down with static stretching and breathing exercises for relaxation.
223757381|NCT06856720|BEHAVIORAL|Health literacy education|Participants will receive educational sessions on diabetes management, the role of exercise in glycemic control, and strategies to enhance adherence to physical activity.
223757382|NCT03962543|DRUG|Mirdametinib (PD-0325901) oral capsule or dispersible tablet|Mirdametinib (PD-0325901) capsule or dispersible tablet
223757383|NCT05627492|BEHAVIORAL|Dialectical behavioral therapy|DBT will be conducted over 2 years. Participants and their treatment providers will decide on the frequency of sessions collaboratively. This may include individual and/or skills sessions in addition to phone coaching for those who attend individual sessions at least once per month. DBT consultation will also remain a component of the treatment. Participants may choose skills training, conducted in approximately 60 minute meetings, and individual therapy conducted in approximately 60 minute sessions. Family participation in skills training is highly encouraged. Skills training may include: psychoeducation, mindfulness skills, emotion regulation skills, distress tolerance skills, interpersonal skills, and walking the middle path skills. Individual therapy sessions aim to aid the youth in applying skills in their daily lives. We adopt the standard DBT hierarchy of treatment targets.
224201239|NCT06722950|DRUG|CAPEOX|CAPEOX: 130mg/m2 of oxaliplatin (D1, central intravenous drip for 2h (time window + 20min)), 1000mg/m2 of capecitabine tablets each time, orally, twice a day (D1-D14, morning and evening); repeat the CAPEOX chemotherapy regimen every 3 weeks.
223611192|NCT00684996|BIOLOGICAL|bevacizumab|Given IV
223757384|NCT06165861|OTHER|Experimental (with VR-G)|Watching video with using VR-G before undergoing open heart surgery
223757385|NCT04927390|DRUG|Mycophenolate Mofetil 500mg|Mycophenolate Mofetil oral tablet twice daily for up to 96 weeks
223757386|NCT06022185|DIAGNOSTIC_TEST|Web Based Training on E-health Literacy, Digital Literacy and Healthy Lifestyle Behaviors.|"In the trainings planned for elderly individuals, digital literacy and e-health literacy levels will be improved, knowledge and awareness levels of elderly individuals will be increased and they will be provided with information in this direction. healthy lifestyle behaviors.~Personal information form, E-Health Literacy Scale, Acquisition and Confirmation of Health Information in Digital Environment Scale, Healthy Lifestyle Behaviors Scale-II will be used in the research."
223757387|NCT00003055|DRUG|cisplatin|
224201240|NCT06722950|DRUG|Placebo|Placebo：3 times a day (daily), taken with boiled water.
224201241|NCT06722950|DRUG|AC591|AC591 : 3 times a day (daily), taken with boiled water.
224201242|NCT06722911|DRUG|Nimotuzumab|Nimotuzumab 400 mg on Day 1 and 15 of a 28-day cycle (6 cycles) ; Patients will receive Nimotuzumab 600 mg on days 1 and 8 of every 21-day cycle. Patients will receive six treatment cycles unless there is radiologic evidence of disease recurrence and unacceptable toxicity.
224201243|NCT06722911|DRUG|AG|Patients will receive nab-paclitaxel 125 mg/m\^2 followed by gemcitabine 1,000 mg/m\^2 as one intravenous infusion over 30-40 minutes on days 1 and 8 of every 21-day cycle. Patients will receive six treatment cycles unless there is radiologic evidence of disease recurrence and unacceptable toxicity.
223611193|NCT06217848|DRUG|Saxenda|Patients will receive subcutaneous injections of Saxenda 18 mg/3 mL Pen (liraglutide\_obesity) starting at 0.6 mg qd. Increase by 0.6 mg qd at weekly intervals to 1.2 mg qd in week 2, 1.8 mg qd in week 3, 2.4 mg qd in week 4, 3.0 mg qd in week 5, and maintain for 8 weeks at a maximally tolerated dose within 3.0 mg starting in week 5. If the subject's response to treatment does not allow for escalation to the planned dose, subjects will inject an adaptive maximally tolerated dose within the planned dose at each cycle. Total duration of Saxenda treatment is 12 weeks.
223611194|NCT01775371|DEVICE|Patient controlled analgesia (PCA)|Loading dose 0.1 mg/kg morphine and demand dose of 1 mg morphine available every 6 minutes
223611195|NCT01775371|OTHER|Usual Care|Usual opioid analgesia determined by the provider
223611196|NCT00651339|DRUG|botox|botox injection
223757388|NCT00003055|DRUG|irinotecan hydrochloride|
223757389|NCT06629311|DEVICE|Autotransfusion device|Standard cardiac surgery using I-SEP and SAME™ autotransfusion device
223757390|NCT06701513|DRUG|Deucravacitinib|As prescribed by treating clinician
223757391|NCT03004833|DRUG|Nivolumab|Infusion of Nivolumab
223757392|NCT03004833|DRUG|Adriamycin|Infusion of Adriamycin
223757393|NCT03004833|DRUG|Vinblastine|Infusion of Vinblastine
223757394|NCT03004833|DRUG|Dacarbazine|Infusion of Dacarbazine
223757395|NCT06688175|DRUG|IMRT combined with lobaplatin-based concurrent chemotherapy|IMRT combined with two cycles of lobaplatin-based concurrent chemotherapy
223757396|NCT06702449|COMBINATION_PRODUCT|Candidate UTI vaccine low dose formulation 1|Candidate UTI vaccine low dose formulation 1 administered intramuscularly according to a 0, 2 months administration schedule.
223757397|NCT06702449|COMBINATION_PRODUCT|Candidate UTI vaccine low dose formulation 2|Candidate UTI vaccine low dose formulation 2 administered intramuscularly according to a 0, 2 months administration schedule.
223757398|NCT06702449|COMBINATION_PRODUCT|Candidate UTI vaccine medium dose formulation 1|Candidate UTI vaccine medium dose formulation 1 administered intramuscularly according to a 0, 2 months administration schedule.
223757399|NCT06702449|COMBINATION_PRODUCT|Candidate UTI vaccine medium dose formulation 2|Candidate UTI vaccine medium dose formulation 2 administered intramuscularly according to a 0, 2 months administration schedule.
223757400|NCT06702449|COMBINATION_PRODUCT|Candidate UTI vaccine high dose formulation 1|Candidate UTI vaccine high dose formulation 1 administered intramuscularly according to a 0, 2 months administration schedule.
223757401|NCT06702449|COMBINATION_PRODUCT|Candidate UTI vaccine high dose formulation 2|Candidate UTI vaccine high dose formulation 2 administered intramuscularly according to a 0, 2 months administration schedule.
223757402|NCT06702449|COMBINATION_PRODUCT|Candidate UTI vaccine HTD formulation 2|Candidate UTI vaccine HTD formulation 2 administered intramuscularly according to a 0, 2 months administration schedule.
223611197|NCT01145846|DRUG|Cytarabine plus Daunorubicin [Arm II (AD regimen)]|Cytarabine 200 mg/m2/day by continuous iv infusion over 24 hours daily for 7 days (D 1-7) plus Daunorubicin 90 mg/m2/day iv daily for 3 days (D 1-3)
223611198|NCT05416216|BEHAVIORAL|WELL|The WELL intervention is a multi-level, three-strategy program to promote the wellbeing of the ECE workforce.
223757403|NCT06702449|COMBINATION_PRODUCT|Placebo|Placebo administered intramuscularly according to a 0, 2 months administration schedule.
223757404|NCT06703125|DIAGNOSTIC_TEST|Eyelink Portable Duo|Eye-tracking data will be collected using a commercially-available remote eye-tracking system (Eyelink Portable Duo). Eye movements and pupil diameter will be collected while participants view a series of developmentally appropriate pictures and movies. The eye-tracker consists of two cameras; one that monitors eye movements and a second scene camera that monitors head movements, which permits eye tracking to take place without any equipment touching the child. Children will be asked to sit in highchair or on their the lap of the caregiver and will face a computer monitor. After a sticker is applied to the forehead of the child and brief eye-movement calibration completed, next visual stimuli (i.e., pictures and videos) will be presented on a laptop computer monitor that is placed at approximately 60-80cm from the child. The eye tracking portion of the visit will last approximately 15 minutes or until the child is no longer able to attend to pictures/videos.
223757405|NCT04629417|DEVICE|Smart Physiotherapy Activity Recognition System (SPARS)|Wearable smart watch that records inertial data such as (accelerometer, gyroscope magnetometer) while patients are performing physiotherapy exercises.
223757406|NCT06899516|OTHER|The Lexington Attachment to Pets Scale (LAPS; Johnson, Garrity, & Stallones, 1992)|The LAPS is a established tool for measuring the emotional bond between humans and their animal companions. Animal attachment is assessed according to three factors: the bond between owners and their dogs or cats, the closeness of the human-animal relationship, and the importance of the animal in the owner's life (Johnson et al., 1992). Higher scores indicate greater attachment.
223757407|NCT06900621|OTHER|ice water|Patients who apply SPTM are given a semifowler position with the head of the bed at least 45°, if there is no contraindication. The water temperature (5-9 °C) will be measured with a calibrated digital thermometer. After VAS scoring, patients are sprayed with 5 ml of ice water placed in spray cans every 30 minutes until all the water is used up in the mouth, tongue, palate, floor of the mouth, inside the right and left cheeks, depending on the group. A total of 5 rounds are made with 5 ml of water in one round (0.2 ml is sprayed on the tongue, palate, floor of the mouth, inside the right and left cheeks) and each round is planned to be completed in 1 minute and last at most 5 minutes. This application is applied to the intervention groups 5 times in total (30th min- 60th min- 90th min- 120th min- 150th min). The first oral intake of the patients is routinely started at the 180th minute.
223757408|NCT06900621|OTHER|room temperature water|Patients who apply SPTM are given a semifowler position with the head of the bed at least 45°, if there is no contraindication. The water temperature (15-24 °C) will be measured with a calibrated digital thermometer. After VAS scoring, patients are sprayed with 5 ml of room temperature water placed in spray cans every 30 minutes until all the water is used up in the mouth, tongue, palate, floor of the mouth, inside the right and left cheeks, depending on the group. A total of 5 rounds are made with 5 ml of water in one round (0.2 ml is sprayed on the tongue, palate, floor of the mouth, inside the right and left cheeks) and each round is planned to be completed in 1 minute and last at most 5 minutes. This application is applied to the intervention groups 5 times in total (30th min- 60th min- 90th min- 120th min- 150th min). The first oral intake of the patients is routinely started at the 180th minute.
223757409|NCT06885645|DRUG|KH815 for injection|KH815 for injection is a dual-payload Antibody Drug Conjugate (ADC) targeting TROP2 antigens.
223757410|NCT06803797|BEHAVIORAL|Behavior Change Technique Package|"Behavior Change Technique 1: Goal setting (Behavior) (BCT 1.1). Goal setting for behavior is defined as setting a goal for the behavior to be achieved.~Behavior Change Technique 2: Action planning (BCT 1.4). Action planning is defined as detailing the plan of where, for how long, and at what time taking medication is going to be performed.~Behavior Change Technique 3: Self-monitoring of behavior (BCT 2.3). Self-monitoring of behavior is defined as monitoring and recording behavior.~Behavior Change Technique 4: Prompts/Cues (BCT 7.1) This BCT is defined as prompt rehearsal and repetition of the behavior in the same context repeatedly, so that the context elicits the behavior."
223611199|NCT04468581|BEHAVIORAL|Use of mobile application|Use of the TraceTogether mobile application during the COVID-19 period
223611200|NCT03030417|DRUG|LMP744|Indenoisoquinolines, such as LMP744, are potent inhibitors of the enzyme topoisomerase I (Top1). Top1 is necessary for transcription, replication, recombination, and the repair of double-strand deoxyribonucleic acid (DNA) breaks. It relaxes the supercoiled DNA by introducing a single-strand break, generating a free strand that rotates around the Top1-bound DNA complex. In the absence of external triggers, Top1-DNA cleavage complexes are generally short lived. Top1 inhibitors are potent anticancer agents because they stabilize the formation of the Top1-DNA cleavage complex in tumor cells, which induces DNA damage, delays DNA repair, and results in cell cycle arrest and apoptosis. LMP744 exhibited antitumor activity with lower toxicity than other agents in preclinical studies. Treatment of patients with LMP744 is expected to reduce tumor burden at doses that are well-tolerated.
223611201|NCT03030417|OTHER|Ondansetron|Anti-emetic for nausea or vomiting.
223611202|NCT03030417|OTHER|Olanzapine|Persistent nausea or vomiting.
223611203|NCT03030417|OTHER|Lorazepam|Persistent nausea or vomiting.
223611204|NCT03030417|OTHER|Diphenoxylate hydrocholoride (HCL) + Atropine Sulfate|Diphenoxylate hydrocholoride (HCL) 2.5 mg + Atropine Sulfate 0.025 mg/tablet for diarrhea.
223611205|NCT03030417|OTHER|Loperamide|Antidiarrheal. 4mg by mouth (PO) after first unformed stool and 2mg PO every 2 hours as long as unformed stools continue. No more than 16mg during a 24-hour period.
223611206|NCT03030417|OTHER|Diphenhydramine|Diphenhydramine 50 mg intravenous (IV) for allergic reaction.
223611207|NCT03030417|OTHER|Steroid|For allergic reaction at discretion of principal investigator.
223611208|NCT03030417|OTHER|Epinephrine|For allergic reaction at discretion of principal investigator.
223611209|NCT01166841|PROCEDURE|PSVC line clamped|A line clamp will be placed on the PSVC line while on cardiopulmonary bypass.
223611210|NCT04247230|DRUG|Tetracaine|Von Frey hair (monofilaments) was used to assess the changes in touch sensitivity on the glans penis after the application of IMP.
223611211|NCT04247230|OTHER|Matching placebo (PET500)|Von Frey hair (monofilaments) was used to assess the changes in touch sensitivity on the glans penis after the application of IMP.
223611212|NCT04247230|DRUG|STUD100|Von Frey hair (monofilaments) was used to assess the changes in touch sensitivity on the glans penis after the application of IMP.
223611213|NCT02385851|DRUG|CHS-1701|
223611214|NCT02385851|DRUG|Pegfilgrastim|
223611215|NCT02729220|OTHER|Bronchoscopy|Sampling of airways
223611216|NCT03790722|OTHER|Ergometry H|"After a pre-rest period of 12 minutes, the subjects are physically strained on the ergometer for 48 minutes (6 minutes loading phase followed by a 2-minute rest phase; 30 watts increase every 8 minutes up to a maximum load of 180 watts), followed by a 12-minute rest periodmaximum load of 180 watts), followed by a 15-minute post-rest period.~Mobil-O-Graph PWA blood pressure cuff is applied to the upper arm with the previously determined higher systolic blood pressure (reference parameter).~SOMNOtouchTM RESP and GeTeMed Vitaguard 3100 are accordingly applied to the arm with the previously determined lower systolic blood pressure."
223611217|NCT03790722|OTHER|Ergometry L|"After a pre-rest period of 12 minutes, the subjects are physically strained on the ergometer for 48 minutes (6 minutes loading phase followed by a 2-minute rest phase; 30 watts increase every 8 minutes up to a maximum load of 180 watts), followed by a 12-minute rest periodmaximum load of 180 watts), followed by a 15-minute post-rest period.~Mobil-O-Graph PWA blood pressure cuff is applied to the upper arm with the previously determined lower systolic blood pressure (reference parameter).~SOMNOtouchTM RESP and GeTeMed Vitaguard 3100 are accordingly applied to the arm with the previously determined higher systolic blood pressure."
223611218|NCT01078441|DRUG|liposomal doxorubicin|Given IV
223611219|NCT01078441|DRUG|bortezomib|Given subcutaneously.
223611220|NCT01078441|DRUG|dexamethasone|Given orally
223611221|NCT01078441|DRUG|cyclophosphamide|Given IV
223611222|NCT02175017|DRUG|ONO-4538|ONO-4538 Study in Patients With Squamous NSCLC
223757411|NCT03642691|BIOLOGICAL|Ryplazim|Plasminogen IV replacement therapy
223757412|NCT06499350|DRUG|FC084CSA+Tislelizumab combination (dose escalation)|Increasing dose levels of FC084CSA+fixed dose Tislelizumab combination therapy
223757413|NCT06499350|DRUG|RP2D of FC084CSA+Tislelizumab combination (dose expansion)|RP2D of FC084CSA+fixed dose Tislelizumab combination therapy
223611223|NCT02175017|DRUG|ONO-4538|ONO-4538 Study in Patients With Non-Squamous NSCLC
223611224|NCT02864693|DEVICE|Kinnex|The Kinnex is a microprocessor controlled hydraulic ankle foot device (Freedom Innovations, Irvine, CA).
223611225|NCT02864693|DEVICE|Pacifica LP|The Pacifica LP is a carbon-fiber ankle foot device (Freedom Innovations, Irvine, CA)
223611226|NCT01031719|BIOLOGICAL|adjuvanted A(H1N1) influenza vaccine|7.5 ug of HA antigen; adjuvanted; monovalent
223611227|NCT01031719|BIOLOGICAL|non-adjuvanted A(H1N1) influenza vaccine|15ug of HA antigen, non-adjuvanted; trivalent
224201244|NCT06723964|DRUG|AP505|AP505 is a Anti-PD-L1 and Anti-VEGF Antibody Fusion Protein.
224311813|NCT06158555|DRUG|250 ML NaCl 4.5 MG/ML Injection|Bolus 250 ml crystalloid. Usually 0.9% saline or compound sodium lactate solution at discretion of attending clinician
223611228|NCT01031719|BIOLOGICAL|non-adjuvanted A(H1N1) influenza vaccine|15 mcg of antigen; non-adjuvanted; trivalent
223611229|NCT02491983|DRUG|Palbociclib|
223611230|NCT02491983|DRUG|Fulvestrant|
223611231|NCT02491983|DRUG|Letrozole|
223611232|NCT03546946|BEHAVIORAL|Gaze-Contingent Music Reward Training|Participants will hear their selected music track playing, dependent on their gaze location, when viewing a grid on neutral and negative faces.
223611233|NCT03546946|BEHAVIORAL|Control Training|Participants will hear their selected music track playing, regardless of their gaze location, when viewing a grid on neutral and negative faces.
223611234|NCT04520971|DEVICE|780G|780G closed-loop insulin delivery system (Medtronic)
223757414|NCT07096544|DEVICE|CardioMEMS Device|The CardioMEMS device will be implanted during a right heart catheterization procedure. The device will be positioned in the pulmonary artery and calibrated using a Swan-Ganz catheter. After implantation, PAP measurements will be taken daily using the home monitoring system provided to the patient. These readings will be transmitted wirelessly to the clinical team, who will review the data at least once per week. Adjustments to the patient's medical therapy and LVAD speed settings will be made based on the hemodynamic data provided by the CardioMEMS device.
223757415|NCT07100119|DRUG|LY4256984|Administered IT
223757416|NCT07100119|DRUG|Placebo|Administered IT
223757417|NCT07108816|DRUG|Neoadjuvant Sacituzumab tirumotecan + tagitanlimab Followed by adjuvant tagitanlimab|"Patients will receive 4 cycles of neoadjuvant treatment with preoperative Sacituzumab tirumotecan in combination with tagitanlimab, followed by surgery.~After surgery, patients will receive up to 13 cycles of adjuvant tagitanlimab."
223611235|NCT04520971|DEVICE|standard of care|continue with standard of care treatment (pump without closed-loop or MDI)
223611236|NCT05225129|OTHER|blood flow restriction exercise|blood flow restricted exercise, resistance training will be applied, corresponding to 30% of 1 maximum repetition for 8 weeks, 2 days in a week
223611237|NCT05546034|DIAGNOSTIC_TEST|Standard nutrition screening tools to be compared with routine blood tests|None other than completion of questionnaires one of which would be done in routine practice
223611238|NCT00001944|DRUG|Vinorelbine|
223757418|NCT07108751|DEVICE|Endoscopy|Endoscopy will be performed to all patient
223757419|NCT07110077|OTHER|Young First Aiders Traing of Early Secondry School children|Training Young First Aiders in Early Secondary School Children with a pre-, immediate post- and final post-tests to determine knowledge change.
223757420|NCT06924567|DIAGNOSTIC_TEST|Implant motion provocation CT|Implant Movement Analysis. A low dose CT scan is performed with the hip fixed in external rotation. Then another low dose CT scan is performed with the hip fixed in internal rotation.The CT scans are then overimposed to each other and implant motion in relation to host bone is visualized,
223757421|NCT06924515|PROCEDURE|Intercostal suture|止血完成后使用结扎缝合引线器夹持1-0规格的PDS可吸收缝线在主操作口的头侧上一肋间穿入，于副操作空使用双关节分离钳在胸腔内抓持缝线后将缝线从结扎缝合引线器脱离，此时在主操作口足侧下一肋间穿入结扎缝合引线器，在胸腔内由分离钳夹持缝线经结扎缝合引线器钩爪夹持后将缝线牵拉出胸腔外，以此依次行连续缝合共5次缝合引线操作后拉拢缝线将主操作口闭合，打结结束缝合完成肋间肌及壁层胸膜的缝合。
223757422|NCT06923020|OTHER|Exposure: Nutritional Status|The assessment of nutritional risk screening (NRS) and nutritional assessments were conducted using NRS 2002 and Patient-Generated Subjective Global Assessment (PG-SGA).
223757423|NCT06923020|OTHER|Exposure: Nutritional Status|The assessment of nutritional risk screening (NRS) and nutritional assessments were conducted using NRS 2002 and Patient-Generated Subjective Global Assessment (PG-SGA).
223757424|NCT06924554|BEHAVIORAL|Motivational Training Program|This study presents the protocol for a non-randomized controlled trial evaluating a motivational-based training program for pre-service Physical Education teachers, grounded in Self-Determination Theory and the circumplex model. The program, embedded in a Master's in Physical Education Teacher Education, consists of theoretical and practical training to foster motivating teaching styles and minimize demotivating ones. The study will involve at least 38 pre-service teachers, divided into an experimental group (n = 19) and a control group (n = 19). The experimental group will participate in a 14-hour training program combining theoretical and practical components. The control group will follow the standard Physical Education Teacher Education curriculum.
223757425|NCT06923371|BEHAVIORAL|Direct Cash Support for Maternal and Infant Health (High fee)|The high fee group will receive direct cash assistance to pregnant women and mothers of infants to improve access to healthcare, alleviate financial strain, and facilitate healthier lifestyle choices. This group will receive a higher level of financial support compared to the low fee group, with the aim of examining how larger amounts of financial assistance affect maternal and infant health, healthcare access, and well-being.
223757426|NCT06923371|BEHAVIORAL|Behavioral: Direct Cash Support for Maternal and Infant Health (Low fee)|The low fee group will receive direct cash assistance to pregnant women and mothers of infants to improve access to healthcare, reduce financial strain, and support healthier lifestyle choices. This group will receive a lower level of financial support compared to the high fee group, allowing us to compare the effects of varying levels of financial assistance on maternal and infant health outcomes.
223757427|NCT06924203|PROCEDURE|AmaIgam|(AmaIgam group): 30 carious moIars, wiII be restored with (amaIgam).
223757428|NCT06924203|PROCEDURE|Stainless steel|A pre-formed stainless steel crown will be cemented over the carious molar without extensive tooth preparation or caries removal.
223757429|NCT06918353|DIAGNOSTIC_TEST|Diagnosis and Severity Grading of AECOPD Disease|Diagnosis and severity grading of AECOPD disease, as well as assessment of traditional Chinese medicine syndromes
223757430|NCT06924216|PROCEDURE|alveolar bone grafting|"cancellous iliac crest bone will be harvested following the usual surgical procedure. For patients of group a-PRF, it was mixed with 1 cc of the supernatant previously collected, in order to obtain a cohesive bone graft, easier to manipulate.~The oral mucosal lining will be closed, and a membrane of PRF (PRF group) will be put over the suture line. The alveolar cleft will be then filled with cancellous iliac crest bone along its entire height. A new membrane of PRF will be placed over the bone graft, in order to enclose and protect it. Finally, muco-periosteal flaps will be advanced and sutured without tension over the alveolar crest"
223757431|NCT06924216|PROCEDURE|alveolar bone grafting Plus Platelet rich fibrin|"the PRF group: centrifugation at 1300 rpm during 5 minutes, collection of 1 cc of the supernatant, and centrifugation at 1300 rpm during 3 minutes. Careful removal of the clot and separation from the red blood cell fraction with scissors.~the Platelet-rich fibrin will be added to the surgical site mixed with the iliac crest bone graft and it will also be used as a membrane before closure of the mucoperiosteal flap"
224311814|NCT04937114|PROCEDURE|Barbed suture|Experimental: Wound will be closed using unidirectional barbed sutures in muco-gingival surgeries Active Comparator: Wound will be closed using conventional sutures in muco-gingival surgeries
224311815|NCT02907255|DEVICE|Oximetry monitor|Wireless respiratory monitoring system
223611239|NCT00001944|DRUG|XR9576|
223611240|NCT05001035|OTHER|Time of assessment|Immediate and after one month and after two months
223611241|NCT02950909|PROCEDURE|Static exercise for emphasized neck extensors|Emphasized activation of the deep neck extensors was searched for applying a localized resistance with the thumb and index finger at the level of the vertebral arch of C4 while pushing into flexion in a ventral-cranial direction, approximately parallel to the surface of the zygapophyseal joint, asking the patient to resist maximally during 6 seconds in sitting position
223611242|NCT02950909|PROCEDURE|Dynamic exercise for emphasized neck extensors|The patient was asked to fix his gaze at an object lying between both elbows hoping to in order to emphasize extension in the lower cervical spine and consequently activation of the extensors in this region.
223611243|NCT02950909|PROCEDURE|Static exercise for general neck extensors|Emphasized activation of all neck extensors was searched for applying the resistance with the therapist's hand or a wall respectively a towel at the occiput in sitting position
223611244|NCT02950909|PROCEDURE|Dynamic exercise for general neck extensors|. The patient was asked to fix his gaze at an object lying between both hands. Extension consequently occurred in the entire cervical spine.
223611245|NCT06322888|BEHAVIORAL|Exercise Training Program|A 12-week aerobic and resistance-training exercise intervention with a certified exercise trainer in person or virtually. FitBit activity tracker, resistance bands, hand weights, and stationary bike will be provided to participants. Hand weights will be returned at end of study.
223611246|NCT04724915|PROCEDURE|Conventional Total Knee Arthroplasty|People will undergo surgery to replace the knee joint with a prosthesis in case of osteoarthritis. This will be performed with manual instrumentarium (jig-based).
223611247|NCT04724915|PROCEDURE|Robot-Assisted Total Knee Arthroplasty|People will undergo surgery to replace the knee joint with a prosthesis in case of osteoarthritis. This will be performed with the help of a surgical robot.
223611248|NCT04915729|DRUG|tenecteplase|tenecteplase
223611249|NCT04915729|DRUG|alteplase|alteplase
223611250|NCT03301493|OTHER|Genomic testing|Genomic profiling, indicated as assessed by the medical need and as deemed appropriate by the physician according to routine practice
223611251|NCT05335876|BIOLOGICAL|onasemnogene abeparvovec|Onasemnogene abeparvovec is a non-replicating recombinant adeno-associated virus serotype 9 containing the human survival motor neuron gene under the control of the ytomegalovirus enhancer/chicken β-actin-hybrid promoter. Onasemnogene abeparvovec is administered as a one-time intravenous (IV) infusion or intrathecal (IT) injection. Dosage determined by participant weight.
223611252|NCT05934435|OTHER|Empowered Relief|psycho-educational pain skills training
223611253|NCT06138626|BEHAVIORAL|Alert|An alert that appears when anesthetic fresh gas flow is excessive
223611254|NCT01684202|DRUG|OPC-41061|orally administered at 3.75, 7.5, 15, or 30 mg once daily after breakfast for up to 11 days.
223611255|NCT05651906|PROCEDURE|Kidney Transplantation|Kidney transplantation as the best option for patients with end-stage kidney disease.
223611256|NCT01522300|OTHER|Evaluation of the Tomosynthesis|An exam by tomosynthesis will be realised at the inclusion of the patient in the study.
223611257|NCT01522300|OTHER|Avaluation of a medical device: the tomosynthesis|An exam by tomosynthesis will be realised at the inclusion of the patient in the study
223611258|NCT05932472|DRUG|Aspirin|Aspirin at currently prescribed dose
223611259|NCT04332718|DEVICE|Smartphone ECG|Patients who are randomised to the 30-day smartphone ECG monitoring will be contacted within one month from randomisation. Patients will be taught on how to use the smartphone ECG monitoring. Patients are required to monitor their ECG 3 times a day for 30 days. Patients will be contacted during the monitoring period to assess for compliance and to ensure that the recording is done correctly.
223611260|NCT00587678|DRUG|Simvastatin|40mg each night
223757432|NCT05238883|DRUG|HFB200301|Participants will be administered HFB200301 as described in the experimental arm.
223757433|NCT05238883|DRUG|Tislelizumab|Participants will be administered tislelizumab as described in the experimental arm.
224311816|NCT03196219|DRUG|C16G2|C16G2
224311817|NCT03196219|DRUG|Placebo|Varnish Placebo
223611261|NCT00587678|DRUG|Ezetimibe|10mg daily
223611262|NCT00587678|DRUG|Simvastatin/Ezetimibe|40mg/10mg each night
223611263|NCT03710642|DRUG|Prazosin|Oral prazosin HCl capsules (or placebo) will be administered twice daily, with individualized doses up to a maximum of 4 mg QAM mid-morning and 6 mg at bedtime (QHS), or matching placebo capsules
223611264|NCT03710642|DRUG|Placebo oral capsule|Placebo capsule matched to appearance of active drug.
223611265|NCT02240771|PROCEDURE|Transarterial chemotherapy|"Femoral artery would be punctured at the upper thigh using 18 gauge needle under local anesthesia. Catheterization of the hepatic artery feeding the tumor would be done and placing the catheter tip beyond the gastroduodenal artery, the chemotherapeutic drugs would be administered.~Mixture would be prepared by using Doxorubicin 50mg and Cisplatin 100mg. Hydrocortisone 100mg and augmenting dose of analgesic and sedative would be injected prior to the administration of the drug.~The drug mixture would then be injected through the indwelling arterial catheter by continuously flushing alternately, repeatedly and rapidly between two-leur lock syringes."
223611266|NCT02240771|DRUG|Oral chemotherapy|"Drugs used would be Thalidomide and Capecitabine in the following dosage schedule- Thalidomide---50mg once a day (OD) for 7 days, increased to 100mg OD for 7 days, 200mgOD for 7 days further increased to 300 mg OD.~Capecitabine---- 500mg OD for 7 days, then 1000mg OD for next 7 days, increased to a maximum dose of 1500mg OD~Maintenance dose - Capecitabine 1500 mg - every alternate week Thalidomide - 300 mg OD. Total leucocyte count \& Platelet count would be monitored every 15 days"
223611267|NCT02348996|OTHER|Bioimpedance|status of overhydration determine by BCM once a week to determine dry weight
223611268|NCT02348996|OTHER|Clinical evaluation|Doctors or nurses will evaluate patients on a daily basis and determine dry weight
223611269|NCT05747742|DEVICE|RLRL device|Crossover device (RLRL of 50% or 100% intensity - alternate to first group). Cross over arms after one month of use and one month of washout period.
223611270|NCT05282927|OTHER|Implementation Strategy: Foundational REP|The goal is to test implementation intensification approaches for group PT sites that have not met implementation adoption benchmarks, specifically Foundational REP vs. Enhanced REP. The investigators propose that low intensity implementation support that promotes adapting Group PT for context and provides tools for ongoing evaluation (defined as foundational REP), will be sufficient for some but not all sites to successfully implement group PT as a clinical service.
223611271|NCT05282927|OTHER|Implementation Strategy: Enhanced REP (enREP)|The goal is to test implementation intensification approaches for sites that have not met implementation adoption benchmarks, specifically Foundational REP vs. EnREP. The investigators posit that monitoring sites' progress and adding, for sites with low adoption, higher intensity strategies (defined as EnREP) that directly influence teams' capacity and skills to effectively self-organize and problem-solve will lead to higher implementation adoption, penetration, fidelity, and value.
224314260|NCT03301571|OTHER|Pacemaker mode|Following pacemaker settings will be investigated: Atrioventricular pacing 10 bpm over the patients' intrinsic rhythm, atrial pacing 10 bpm over the patients' intrinsic rhythm, ventricular pacing 10 bpm over the patients' intrinsic rhythm
223611272|NCT02741635|DEVICE|New Nasal Pillows Mask|Nasal Pillows mask for the treatment of obstructive sleep apnea (OSA)
223611273|NCT02727907|DRUG|BCD-033 (interferon beta 1a)|Subcutaneous injection of BCD-033, 44 µg (0,5 ml) 3 times per week, every other day, for 92 weeks
223757434|NCT01076712|OTHER|Physiotherapy Interventions|Physiotherapy interventions including strengthening exercise, balance training, gait training with visual cus and gait training with treadmill
223757435|NCT01076712|OTHER|Education Classes|Education Classes
223757436|NCT05774847|OTHER|No intervention|No intervention
223757437|NCT04620681|BIOLOGICAL|CD8 Depleted, Non-engrafting,HLA mismatched unrelated donor lymphocytes|Infusion of mononuclear cells, apheresis products depleted of CD8+ T cells using the CliniMACS® system with CliniMACS® CD8 reagent
223757438|NCT04620681|DRUG|Standard of Care Chemotherapy|Standard of care cytarabine-based chemotherapy
223757439|NCT04634084|PROCEDURE|Experimental group(Bursa Implantation)|Prior to all rotator cuff repairs, a subacromial bursectomy is performed with an oscillating shaver so that the rotator cuff can be visualized and repaired.In the experimental group, instead of being discarded, this minced bursal tissue will be collected via a sterile filtration device attached to the oscillating shaver. The bursal tissue is then placed into a sterile syringe, and reimplanted back onto the bursal surface of the rotator cuff repair at the completion of the case. The arthroscopic fluid is turned off, and fluid is evacuated from the shoulder prior to reimplantation of the bursa.. Nothing is added to the bursa prior to reimplantation. There are no reagents. The bursa tissue is purely the minced bursa tissue removed from the patient, and never leaves the sterile field.
223757440|NCT04634084|PROCEDURE|Control Group(Standard of Care)|Prior to all rotator cuff repairs, a subacromial bursectomy is performed with an oscillating shaver so that the rotator cuff can be visualized and repaired.The current standard of care procedure is to discard this tissue, and then proceed with the rotator cuff repair
223757441|NCT00224211|BEHAVIORAL|Music|
223757442|NCT06316414|BIOLOGICAL|Omalizumab|Administration of Omalizumab at the doses indicated for asthma in the EMA information leaflet.
223757443|NCT03265093|OTHER|Platelet Rich Fibrin Injection|Venous blood will be taken from the patient every session and I-PRF will be created in the centrifuge. I- prf will be injected on one side and corticosteroid will be injected on the other side in patients with bilateral oral lichen planus. Once a week in the first month after treatment and one time at the end of the second month, the patient will be called to the control.
223757444|NCT03265093|DRUG|Corticosteroid|Corticosteroid injection
223757445|NCT00301405|DRUG|Thalidomide|Open label drug
223757446|NCT03833076|DEVICE|Medical device Procto|Medical device Procto presents itself as a translucent green gel with a typical smell.
223757447|NCT03833076|DEVICE|Matching placebo|IP placebo presents itself as a translucent green gel with a typical smell.
223757448|NCT04623164|DRUG|Cocktail from complex phytoadaptogens (CFA)|Cocktail from complex phytoadaptogens (CFA) is composed from 70% alcohol extracts of Glycyrrhiza glabra, Rhodiola rosea, Acantopanax senticosus in the ratio 2:1:1. Application of CFA in 3 group was carried out after non-surgical periodontal therapy (NSPT). After NSPT the patient filled out an Estberg questionnaire to determine the chronotype. After processing the questionnaire, a chronotype was identified and the patient was prescribed CFA dosage. Application of CFA was carried out in the periods of exacerbation of chronic periodontitis within 28 days with a dosage of CFA depending on the chronotype of the person - morning chronotype at 45 drops in the morning before 10.00 o'clock; independent chronotype 20 drops 3 times a day; evening chronotype 30 drops at 14.00 o'clock and 20 drops at 19.00 o'clock.
223757449|NCT04623164|PROCEDURE|Standard non-surgical periodontal treatment (NSPT)|Oral hygiene instructions (including brushing technique, the use of interdentally flosses, and/or brushes), NSPT (mouth scaling and root planing using an ultrasonic scaler UDS-L LED (Woodpecker, China) and Graceys curettes (Hu Friedy, Chicago, USA)). The treated periodontal pockets were irrigated with 0.12% chlorhexidine gluconate. Patients were given recommendation to rinse their mouth three times daily for 14 days using 0.12% chlorhexidine gluconate
223757450|NCT04311034|DRUG|RC48|Participants will be treated with RC48-ADC at a dose of 2.0 mg/kg, every 2 weeks. They will continue the medication until one of the following conditions occurred: disease progression, intolerance of toxicity, investigators believed that the subject could no longer benefit from treatment, or this study ended.
223757451|NCT04302571|BEHAVIORAL|combined aerobic and resistance physical activity|Five training sessions weekly for 12 weeks are scheduled. Each session lasts 60 minutes divided into 45 minutes of aerobic workout and 15 minutes of circuit training. The aerobic workout consists of walking on a flat floor or on a slight uphill (maximum slope 3%): patients should walk until submaximal walking capacity (80% of their MWT) and rest as they would experience pain at the lower limbs; afterwards, they should start to walk again, once the pain was improved. Resistance training consists of calisthenics exercises focused on trunk and lower limbs muscles (bicycle, flutter kicks, squats, lunges, calf raises, wall sits and power press) with at least 3 repetitions for each exercise, interspersed by 30 seconds recovery. Duration of repetitions increases every 3 weeks.
223757452|NCT04302571|BEHAVIORAL|sham exercise|general recommendation to perform regular aerobic physical activity
223611274|NCT02727907|DRUG|Rebif (interferon beta 1a)|Subcutaneous injection of Rebif, 44 µg (0,5 ml) 3 times per week, every other day, for 48 weeks
223611275|NCT02727907|DRUG|Placebo|Subcutaneous injection of placebo, 0,5 ml 3 times per week, every other day, for12 weeks
223611276|NCT01427933|BIOLOGICAL|Ramucirumab (IMC-1121B)|Administered intravenously
223611277|NCT01427933|DRUG|Eribulin|Administered intravenously
223611278|NCT01633541|DRUG|AT-101|Patients will receive AT-101 40 mg orally two times a day.
223611279|NCT01633541|DRUG|Docetaxel|Docetaxel (Taxotere) 75 mg/m2
223611280|NCT01633541|DRUG|Cisplatin|Cisplatin 100 mg/m2
223611281|NCT01633541|DRUG|Carboplatin|Carboplatin AUC (area under the curve) 6. Maximum dose of 700 mg
223611282|NCT00806039|OTHER|Early Renal Involvement|Renal Consultation
223611283|NCT01010971|DRUG|Ciclesonide HFA 160 μg|Ciclesonide HFA Nasal Aerosol 160 μg once daily
223611284|NCT01010971|DRUG|Ciclesonide HFA 80 μg|Ciclesonide HFA Nasal Aerosol 80 μg once daily
223611285|NCT01010971|DRUG|Placebo|Placebo HFA Nasal Aerosol once daily
223611286|NCT03507205|DEVICE|Biomatrix; Biomatrix Flex; Nobori|Biodegradable polymer-coated biolimus-eluting stents
223611287|NCT03507205|DEVICE|Xience Prime|Durable polymer-coated everolimus-eluting stents
223757453|NCT02586701|OTHER|Prehabilitation Plus|Supervised exercise program and home-based exercise program.
223757454|NCT00794872|OTHER|blood sampling|
223757455|NCT02020668|OTHER|Physiotherapy|
223757456|NCT02020668|OTHER|Wait list control|
223757457|NCT03264404|DRUG|Pembrolizumab|Pembrolizumab 200 mg IV every 3 weeks until progression
223757458|NCT03264404|DRUG|Azacitidine|50 mg/m2 subcutaneous daily for 5 days every 28 days
223611288|NCT03507205|DEVICE|Xience V/Promus; Cypher|Durable polymer-coated everolimus-eluting stents; Sirolimus-eluting stents
223611289|NCT03507205|DEVICE|DP-ZES-RI|Durable polymer-coated zotarolimus-eluting stents
223611290|NCT03507205|DEVICE|Endeavor; Resolute|Durable polymer-coated zotarolimus-eluting stents
223757459|NCT03100786|DRUG|Dexamethasone|Active treatment with dexamethasone from randomisation (IV followed by oral according to disease severity at the start of treatment): Dexamethasone for intravenous injection and dexamethasone for oral ingestion
223757460|NCT03100786|OTHER|Placebo|Treatment with matched placebo: Standard saline for intravenous injection and placebo oral tablets containing cellulose
223757461|NCT03369717|DRUG|Amoxi Clavulanate|Postoperative antibiotics
223757462|NCT05929235|DRUG|FX-909|FX-909 is an orally available new molecular entity that inhibits basal- and ligand-activated transcription by PPARG.
223757463|NCT06237140|OTHER|PNF+ biofeedback exercise group|Neurorehabilitation will be applied to this group, 5 sessions a week for 4 weeks, to increase balance and walking skills and reduce the risk of falling.
223757464|NCT03036566|DEVICE|Lithium disilicate ceramic (Ivoclar)|Three unit high strength ceramic bridges replacing a single tooth.
223757465|NCT05512221|OTHER|GBAT+I, GBAT+E - Phase I|Phase I is the development phase, which is informed by the study team's previous pilot study and autistic advisors. It will include the development of engagement booster materials. Booster materials will be tested in 2 groups (GBAT+I and GBAT+E) of six participants each. Groups include GBAT+Individual (GBAT+I; individual sessions to supplement the 10 group sessions) and GBAT+Engagement Booster (GBAT+E; supplemental materials). The first 4-6 eligible adults recruited will participate in GBAT+I and the second 6 eligible adults recruited will participate in GBAT+E. Both groups will consist of 10 weekly 60-90-minute GBAT group sessions. Participants in the GBAT+I group will also attend 30-minute individual booster sessions, approximately between Weeks 4-5, 5-6, 6-7, and 7-8. Participants in the GBAT+E group will be asked to use booster materials in between group sessions (e.g., worksheets, goal trackers, interactive learning activities).
223757466|NCT05512221|OTHER|Watchful Waiting and Groups - Phase 2|"Phase 2a will include a watchful waiting (WW) condition and assignment to 1 of 2 treatment conditions: GBAT+I or GBAT+E.~Participants will be assigned to WW for 10 wks. They will not receive specific therapeutic services during WW, but a member of the study team will contact them at weeks 1, 2, 4, 6, and 8 to maintain engagement and monitor for clinical deterioration.~After WW, participants will be randomly assigned to one of the treatment conditions (GBAT+I or GBAT+E). All groups will consist of 10 weekly 60-90-minute GBAT group sessions. GBAT+I participants will attend four 30-minute individual booster sessions. GBAT+E participants will be asked to use booster materials between group sessions (e.g., worksheets, goal trackers, interactive learning activities)~WW group size is based on study feasibility and availability of resources. Additional participants will also be recruited at the end of the WW period to supplement group sizes."
223757467|NCT05512221|OTHER|GBAT+IE|"Phase 2b will include assignment to GBAT+IE, which includes components of both GBAT+I (individual sessions) and GBAT+E (supplemental materials)~All groups will consist of 10 weekly 60-90-minute GBAT group sessions. Participants in the GBAT+I group will also attend 30-minute individual booster sessions, approximately between Weeks 4-5, 5-6, 6-7, and 7-8. Participants in the GBAT+E group will be asked to use booster materials in between group sessions (e.g., worksheets, goal trackers, interactive learning activities). Participants in GBAT+IE will participate in both the individual sessions and use of booster materials."
223757468|NCT05939739|BIOLOGICAL|Blood samples|Samples collected during blood sampling for array CGH (1 EDTA tube for index case and 2 biological relatives)
223757469|NCT05939739|OTHER|Consultation for results delivery|at 4 months
223757470|NCT05939739|OTHER|Study Humanities and Social Sciences|Interview offered to 20 families with positive results and 10 families with negative results
223757471|NCT05898646|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
223611291|NCT03994666|BIOLOGICAL|allogeneic umbilical cord-derived mesenchymal stem cells|Injection of mesenchymal stem cells
223611292|NCT03994666|BIOLOGICAL|Placebo (NaCl)|Placebo injection
223611293|NCT00530738|DRUG|Lipoplus|i.v. fat emulsion for parenteral nutrition
223611294|NCT00530738|DRUG|Lipofundin MCT|i.V. fat emulsion for parenteral nutrition
223757472|NCT05898646|BIOLOGICAL|Daratumumab|Given SC
223757473|NCT05898646|PROCEDURE|Echocardiography Test|Undergo echocardiography
223757474|NCT05898646|OTHER|Questionnaire Administration|Ancillary studies
223757475|NCT05898646|PROCEDURE|X-Ray Imaging|Undergo x-ray imaging
224314261|NCT01707771|PROCEDURE|Roux-en-Y gastric bypass|Active Comparator: Roux-en-Y gastric bypass
224314262|NCT01707771|BEHAVIORAL|diet and lifestyle modifications|Active Comparator: diet and lifestyle modifications
224314263|NCT02549027|DRUG|MK-1064|Oral MK-1064 tablets (10 and 50 mg strengths)
224314264|NCT02549027|DRUG|MK-6096|Oral MK-6096 tablets (5 mg strength)
223611295|NCT03826238|DIAGNOSTIC_TEST|Validation Gate task|"The task is to observe several moving unfilled white circles on a dark background. The circles move in straight paths. Every so often, a randomly selected circle will displace to a point inconsistent with its trajectory, which will look like a jump. The subjects' task is to press the space bar every time they detect a displacement (e.g. jump). A session consists of 30 minutes, it starts with 2 training blocks which are followed by 2 no-cognitive load blocks and 6 blocks with increasing cognitive load conditions. During the assessment the eye movement as well as the key presses are registered in order to calculate early and late saccades as well as conscious reporting. Resting-state EEG will also be recorded and compared to the ones of age-matched healthy controls. Task-dependent EEG data will be recorded during the Validation Gate task."
224314265|NCT02549027|DRUG|Placebo|Oral placebo tablets (matching active MK-1064 tablets, matching active MK-6096 tablets)
223757476|NCT05898646|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223509219|NCT03816917|OTHER|cutaneous parameters of psoriasis (exposure)|characteristic of the cutaneous domains of the psoriasis: age at start, disease duration, current and previous treatment PASI, BSA, nail involvement
223757477|NCT06416748|PROCEDURE|Minimally invasive simple hysterectomy|Patients with SHAPE inclusion criteria (FIGO 2018 stage IA2 and IB1 up to 2 cm, with limited stromal invasion: \&amp;amp;lt; 10 mm on LEEP/cone and \&amp;amp;lt; 50% depth on imaging) should undergo conization with surgical margins free from invasive disease or conization with involved surgical margins followed by MRI scan or expert ultrasound scan showing no residual disease. In case of residual disease at post conization imaging still fitting inclusion criteria, another conization is recommended. After these steps minimally invasive (laparoscopy or robotic) simple hysterectomy is performed with sentinel lymph node biopsy algorithm. Adjuvant therapy is given only in case of positive surgical margins, metastatic lymph nodes, and extensive LVSI with depth of stromal infiltration over 2/3.
224314266|NCT02400853|DEVICE|Standard cranial echography|Standard cranial echography will be done at day 5 day 7 post-birth looking for radiological finding of intraventricular hemorrhage
224314267|NCT02400853|PROCEDURE|Cord blood analysis|Cord blood will be collected during deliverance and analysed
224314268|NCT03450044|BIOLOGICAL|Dendritic cells|Adoptive transfer of autologous DCs
223509220|NCT03816917|OTHER|comorbidity (exposure)|medical and medication history, current and previous comorbidity
223509221|NCT03816917|OTHER|family history (exposure)|Family history of PsC, PsA, IBD, AS, and uveitis
223509222|NCT03816917|OTHER|lifestyle (exposure)|"* Intoxications~* Lifestyle: occupation and injuries, sport and physical hobbies"
223509223|NCT03816917|OTHER|patient reported outcomes (exposure)|VAS-score on fatigue, PsC severity, joint pain and general well-being
223509224|NCT03816917|OTHER|inflammatory markers (exposure)|Measurements of inflammatory and bone remodeling markers in serum and plasma
223509225|NCT03816917|OTHER|genetic (exposure)|Assessment of known HLA- and SNP-associations with PsA or PsA
223509226|NCT02255279|BIOLOGICAL|Adjuvanted Trivalent Influenza Vaccine, 1 dose for non-naive subjects (day 1), two doses for naive subjects (day 1 and day 29)|A 0.25 mL (for children 6 to \<36 months old) and 0.5 mL (for children ≥36 months to \< 72 months old) dose of aTIV, a trivalent (surface antigen, formaldehyde-inactivated) influenza virus vaccine, adjuvanted with MF59C.1, administered at day 1 (for all subjects) and day 29 (for naïve subjects).
223509227|NCT02255279|BIOLOGICAL|Non-adjuvanted Trivalent Influenza Vaccine, 1 dose for non-naive subjects (day 1), two doses for naive subjects (day 1 and day 29).|A 0.25 mL (for children 6 to \<36 months old) and 0.5 mL (for children ≥36 months to \< 72 months old) dose of TIV , an egg-derived trivalent split influenza vaccine licensed in Mexico, administered at day 1 (for all subjects) and day 29 (for naïve subjects)
223509228|NCT03718403|DRUG|Theophylline|Theophylline will be given to maintain a peak level between 10-15 mcg/mL
223509229|NCT01120444|DEVICE|BD Research Catheter with 34G x 1.5 mm needle|bolus injection of insulin given intradermal prior to standardized meal
223509230|NCT01120444|DEVICE|Subcutaneous delivery of insulin using Disetronic Accu-Chek Rapid D infusion set|bolus delivery of insulin given subcutaneously prior to standardized meal
223509231|NCT06501183|BIOLOGICAL|Anti-CDH17 CAR-T cells|Anti-CDH17 CAR-T cell injection will be administered intravenously after lymphodepleting.
223509232|NCT04627753|DRUG|Rituximab, lenalidomide|Maintenance for 2 years
223509233|NCT03268161|DIAGNOSTIC_TEST|Mutational analysis of clonal B cells|"Mutational analysis based on medullary or blood samples stored in a bio-bank during routine lymphocyte phenotyping.~Mutations affecting MYD88 (MYD88 L265P mutation), CXCR4 (Whim-like CXCR4 mutation) loci are sought."
223509234|NCT00118859|BEHAVIORAL|Integrative care for low back pain|
223509235|NCT00118859|BEHAVIORAL|Conventional treatment for low back pain|
223509236|NCT02555358|DRUG|docetaxel,0xaliplatin,capecitabine|docetaxel 60mg/m2， ivgtt，2h，d1;capecitabine 1000mg/m2 po bid d1-14; oxaliplatin 130mg/m2， ivgtt，2h，d1;q21d
223509237|NCT02555358|DRUG|oxaliplatin,capecitabine|oxaliplatin 130mg/m2， ivgtt，2h，d1;capecitabine 1000mg/m2 po bid d1-14;q21d
223509238|NCT04612231|BEHAVIORAL|TEACCH School Transition to Employment and Postsecondary Education (T-STEP)|The T-STEP Program is a 12-week transition intervention targeting specific challenges that young adults with ASD experience in executive function, social communication, and emotion regulation including group intervention, internship, and counseling services
223509239|NCT04612231|BEHAVIORAL|Counseling Services Alone|The Counseling Services Alone Intervention will receive 12 hours of individual counseling focused on job exploration/career counseling, academic counseling, and self-advocacy counseling.
223509240|NCT03167424|DEVICE|Treatment of restenosis|Treatment of in-stent restenosis
223509241|NCT04960943|DRUG|Pyrotinib with or without trastuzumab|After enrollment, patients of all the three cohorts were given 400 mg/d oral pyrotinib continuously, every 21 days as a cycle; Cohort 1 and 2 : Patients with gastric cancer or esophageal adenocarcinoma were combined with paclitaxel 80 mg/m2, intravenously, once on the first and eighth day. Cohort 3: Patients with colorectal cancer were given trastuzumab at an initial load dose of 8 mg/kg followed by 6 mg/kg every 3 weeks.
223509242|NCT02756091|OTHER|No study-specific intervention|
223509243|NCT06353932|OTHER|keeping the endotracheal tube cuff pressure within a certain range|The endotracheal tube cuff pressures of the study group patients were kept within the range of 20-25 cm H2O.
223509244|NCT01890538|DRUG|Administration of 100 mg dimenhydrinate intravenous|
223509245|NCT01890538|DRUG|2 g piracetam intravenous|
223509246|NCT01137565|DRUG|AMG 853|Single dose administration of AMG 853 or placebo in tablet form to adolescent and adult subjects with asthma
223509247|NCT01137565|DRUG|Placebo|Placebo to AMG 853
223509248|NCT05706285|PROCEDURE|Regional Block Comparison|Comparing postoperative pain and opioid consumption in groups
223509249|NCT00363467|DRUG|G-CSF|"Mobilization Option 1:Twenty-four to 48 hours following completion of consolidation chemotherapy, patients will begin to receive G-CSF at 10 mcg/kg twice daily subcutaneously.~Mobilization Option 2: If patients have recovered hematologically from consolidation chemotherapy, they may receive G-CSF at 10 mcg/kg twice daily subcutaneously."
223509250|NCT00363467|DRUG|Leukapheresis|leukapheresis
223757478|NCT04625803|DRUG|Camrelizumab , apatinib and chemotherapy|"Camrelizumab 200 mg, IV infusion on Days 1 each 14-day cycle~Apatinib 250mg oral administration once a day, for two months~mFOLFOX6 oxaliplatin 85 mg/m\^2 IV infusion on Day 1 of each14-day cycle. Fluorouracil: 400 mg/m2 as a bolus injection given after a two-hour leucovorin infusion at a dose of 400 mg/m2. The loading dose is then followed by a 46-hour 5-fluorouracil infusion of 2,400 mg/m2 via a pump programmed to provide a constant drug infusion rate."
223757479|NCT03783507|BEHAVIORAL|Order 1|"Meal Order 1:~Meal Session 1 participant receives meal 1 (3 low-ED, 0 medium-ED, 2 high-ED) Meal Session 2 participant receives meal 2 (3 low-ED, 1 medium-ED,1 high-ED) Meal Session 3 participant receives meal 3 (1 low-ED, 2-medium ED, 2 high-ED) Meal Session 4 participant receives meal 4 (1 low-ED, 3 medium-ED, 1 high-ED)"
223757480|NCT03783507|BEHAVIORAL|Order 2|"Meal Order 2:~Meal Session 1 participant receives meal 2 (3 low-ED, 1 medium-ED,1 high-ED) Meal Session 2 participant receives meal 3 (1 low-ED, 2-medium ED, 2 high-ED) Meal Session 3 participant receives meal 4 (1 low-ED, 3 medium-ED, 1 high-ED) Meal Session 4 participant receives meal 1 (3 low-ED, 0 medium-ED, 2 high-ED)"
223757481|NCT03783507|BEHAVIORAL|Order 3|"Meal Order 3:~Meal Session 1 participant receives meal 3 (1 low-ED, 2-medium ED, 2 high-ED) Meal Session 2 participant receives meal 4 (1 low-ED, 3 medium-ED, 1 high-ED) Meal Session 3 participant receives meal 1 (3 low-ED, 0 medium-ED, 2 high-ED) Meal Session 4 participant receives meal 2 (3 low-ED, 1 medium-ED,1 high-ED)"
223757482|NCT03783507|BEHAVIORAL|Order 4|"Meal Order 4:~Meal Session 1 participant receives meal 4 (1 low-ED, 3 medium-ED, 1 high-ED) Meal Session 2 participant receives meal 1 (3 low-ED, 0 medium-ED, 2 high-ED) Meal Session 3 participant receives meal 2 (3 low-ED, 1 medium-ED,1 high-ED) Meal Session 4 participant receives meal 3 (1 low-ED, 2-medium ED, 2 high-ED)"
223757483|NCT06365827|OTHER|observational study|no intervention of interest
223757484|NCT05087875|BEHAVIORAL|TRAC: Tracking and Reducing Alcohol Consumption|The TRAC intervention focuses on increasing motivation and building skills for avoiding triggers and managing situations that encourage alcohol consumption. Participants set goals for reducing their drinking and learn strategies to help them achieve those goals. It requires four 30-minute sessions with a counselor using mobile phones.
223757485|NCT05087875|OTHER|No intervention|The comparison group will be evaluated based on daily self-monitoring data.
223757486|NCT04844554|OTHER|Active HD-tDCS 3mA|This group will receive HD-tDCS 3mA intensitie. 0 sessions at ICU simultaneously to physical rehabilitation. The HD- tDCS will be started with a 30 s ramp-up to the desired intensity, which was maintained for 20 min.
223757487|NCT04844554|OTHER|Sham HD-tDCS|This group will receive sham HD-tDCS. The intervention will be applied in 10 sessions at ICU simultaneously to physical rehabilitation. The HD- tDCS will be started with a 30 s ramp-up them turn off.
223757488|NCT01345279|DRUG|cisplatin|50 mg/m2 IV cisplatin on day 1 and then every 3 weeks for 6 courses
223757489|NCT01345279|DRUG|topotecan|topotecan 0.75 mg/m2 on days 1, 2, and 3. The regimen was repeated every 3 weeks for 6 courses
223757490|NCT01345279|DRUG|paclitaxel|135 mg/m2 paclitaxel on day 1 and then every 3 weeks for 6 courses
223757491|NCT04249128|DIETARY_SUPPLEMENT|Vegetarian Collagen|Collagen is a protein made up of amino-acids, which are in turn built of carbon, oxygen and hydrogen.
223757492|NCT04249128|DIETARY_SUPPLEMENT|Keratin|Keratin (/ˈkɛrətɪn/) is one of a family of fibrous structural proteins known as scleroproteins. α-Keratin is a type of keratin found in vertebrates. It is the key structural material making up hair, nails, feathers, horns, claws, hooves, calluses, and the outer layer of skin among vertebrates.
223757493|NCT04249128|DIETARY_SUPPLEMENT|Ceramides|Ceramides are a family of waxy lipid molecules. A ceramide is composed of sphingosine and a fatty acid. Ceramides are found in high concentrations within the cell membrane of eukaryotic cells, since they are component lipids that make up sphingomyelin, one of the major lipids in the lipid bilayer.
223757494|NCT04249128|DIETARY_SUPPLEMENT|Astaxanthin|is a naturally-occurring carotenoid found in algae, shrimp, lobster, crab and salmon.
223757495|NCT04902495|OTHER|MTA Pro Root|pulp therapy
223757496|NCT04902495|OTHER|MTA HP Repair|pulp therapy
223509251|NCT00363467|DRUG|Busulfan|Busulfan IV daily x 4 days (transplantation days -5,-4,-3,-2). The day -5 and -4 dose will be 130mg/m2
223509252|NCT00363467|PROCEDURE|Stem cell reinfusion|autologous stem cell transplant
223509253|NCT01899287|BEHAVIORAL|group education|"The experimental intervention consists of:~A. Group education on general skin-protective behaviour. B. Group education and counselling on work-related skin-protective behaviour, which might extend to a work-place visit.~C. Social guidance related to OHE. D. Telephone hot-line for work and case-related problems, maintained by nurse."
223509254|NCT06386549|BEHAVIORAL|tele-rehabilitation|Using the social networking tool WeChat, families of children with burns are educated and trained through texts, photos, voice messages, and live videos, twice a week for a total of 12 weeks
223509255|NCT00903344|DRUG|Vitamin D3|4000IU vitamin D3 tablet taken daily
223509256|NCT00903344|DIETARY_SUPPLEMENT|Multivitamin|Multivitamin containing 400IU vitamin D in tablet taken daily
223509257|NCT01272778|DRUG|Lorazepam|Oral capsule, 0.2 mg, single acute dose
223509258|NCT01272778|DRUG|Lorazepam|oral capsule, 0.5 mg, single acute dose
223509259|NCT01272778|DRUG|Lorazepam|oral capsule, 1.0 mg, single acute dose
223509260|NCT01272778|DRUG|Lorazepam|oral capsule, 2.0 mg, single acute dose
223509261|NCT01272778|DRUG|Placebo|oral capsule, single acute dose
223509262|NCT04456283|BEHAVIORAL|Survival|5 year survival after Chemoradiation theraphy for Rectal Cancer
223509263|NCT00874809|DEVICE|CGMS with an insulin pump using rapid acting insulin|To determine basal changes subject will wear a CGMS with an insulin pump infusing rapid acting insulin
223509264|NCT01524705|DRUG|Insulin Glargine|Glargine-injectable, variable, once daily (QD), 6 months
223509265|NCT01524705|DRUG|Metformin|Metformin-oral, up to 1000mg, twice daily (BID), 6 months
223509266|NCT01524705|DRUG|Prandial insulin|Aspart or glulisine or lispro
223509267|NCT01524705|DRUG|Exenatide|Injectable, 5mcg, twice daily (BID), 6 months
223509268|NCT00008333|DRUG|vinorelbine tartrate|
223509269|NCT01755156|DRUG|Omarigliptin|Omarigliptin 25 mg capsule administered orally once weekly (preferably on the same day of each week)
223509270|NCT01755156|DRUG|Matching placebo to omarigliptin|Matching placebo to omarigliptin capsule administered orally once weekly (preferably on the same day of each week)
224311818|NCT02620436|OTHER|Core Mother Shelter Model|"1. Infrastructure, Supplies, Equipment: All MHs will have: latrines, lockable cupboards, doors, windows, lighting, mattresses, mosquito nets, cooking space and utensils, and a bathing site.~2. Policies, Management, Finances:. The policies, management, and financial structures will follow the same general principles, but will be site-specific to account for cultural variation.~3. Linkages with Health Facilities: Each MH will be operationally linked to the health facility and 1) ensure daily check-ins by a health facility staff; 2) ensure every pregnant woman has someone able to contact a staff if she is incapacitated; and 3) will orient women to procedures upon arrival. Clinical services will be conducted at the health facility."
224311819|NCT03183596|DRUG|Bupivacaine|20-60cc of 0.25% Bupivacaine
224311820|NCT03183596|DRUG|Dexamethasone|2-4mg of Dexamethasone
224311821|NCT02079779|OTHER|Robotic-assisted therapy|The robotic device is designed to intensively rehabilitate the upper limb. Indeed, this robot allows the patient to perform a lot of active, passive, or assisted exercises. The level of assistance is determined and provided by the robot in function of the patient performance (i.e. quality of movements).
224311822|NCT02079779|OTHER|Classical therapy|Conventional therapy will be performed by therapists specialized in neuro-rehabilitation
224311823|NCT02055664|DRUG|Ropivacaine 0.2%|
224311824|NCT02055664|DRUG|Chlorure de sodium 0.9%|
224311825|NCT01422187|DRUG|Taliglucerase alfa|Taliglucerase infusion every two weeks for 21 months
224311826|NCT06187090|DIETARY_SUPPLEMENT|Oral Ultramicronized-Palmitoylethanolamide (um-PEA; 600 mg per day) in tablet form|Um-PEA is to be taken orally once a day (600 mg per day) around mealtime during the 12-week initial phase of the study. During the 24-week extension phase of the study, the trial medication is to be taken from once a day up to twice a day (600-1200 mg per day), based on clinical judgment of the improvement obtained so far, around mealtime.
224311827|NCT03777618|PROCEDURE|gluteal augmentation with flap in circumferential body lift|classic circumferential bodylift surgery, using two differents well-known flaps for gluteal augmentation
224311828|NCT03551288|DRUG|SUVN-911|Tablet
223611296|NCT05034419|DEVICE|Parasym|Stimulation will be done under anesthesia for 30 minutes. Stimulation parameters include a pulse width of 200 μs, amplitude of 20 mA and a pulse frequency of 20 Hz. The Parasym devise (Parasym Health, London, UK) will be used for stimulation. The device will be connected to a clip electrode that will be attached to the external ear. In the active group, the ear clip electrode will be attached to tragus in the active stimulation group. This device has been deemed non-significant risk by the FDA. In the control group, no stimulation will be done.
223611297|NCT05034419|DEVICE|Sham stimulation|Sham stimulation
223611298|NCT03360643|DIAGNOSTIC_TEST|Point-of-care ultrasound prior to radiology ultrasound|Point-of-care ultrasound performed by pediatric emergency medicine physicians prior to radiology-performed ultrasound
223611299|NCT03360643|DIAGNOSTIC_TEST|Radiology-performed ultrasound|Ultrasound performed an ultrasound technician and/or radiologist, and interpreted by a radiologist
223611300|NCT01011543|PROCEDURE|Diagnostic techniques in pulmonary tuberculosis|Two different methods to obtain a diagnosis of pulmonary tuberculosis in patients with negative classic sputum samples are compared.
223611301|NCT03386721|DRUG|simlukafusp alfa|simlukafusp alfa will be administered as per the dosage regimen mentioned in arm descriptions.
223757497|NCT04902495|OTHER|Biodentine|pulp therapy
224311829|NCT05801952|DEVICE|Aerobika* OPEP, PARI O-PEP (Flutter), PARI PEP® S System|The 4-day physiotherapy program consists of performing bronchial drainage using one of the three devices: Aerobika\* OPEP Device (Trudell Medical International), Flutter - PARI O-PEP Device (PARI Respiratory Equipment, Inc.) and PEP - PARI PEP® S System (PARI Respiratory Equipment, Inc.).
223611302|NCT03386721|DRUG|Atezolizumab (MPDL3280A), an Engineered Anti-PD-L1 Antibody|Atezolizumab will be administered as per the dosage regimen mentioned in arm descriptions.
223611303|NCT03386721|DRUG|Gemcitabine|Single-agent treatment administered as per approved protocol.
223757498|NCT00470288|PROCEDURE|bladder flap during cesarean section|
223757499|NCT06141629|DEVICE|accu chek Aviva Expert|This bolus calculator estimates the dose of insulin to be administrated on the basis of the following parameters: current blood glucose, grams of carbohydrate, carbohydrate to insulin ratio, insulin sensitivity, target blood glucose and quantity of insulin previously administered.
223757500|NCT06141629|DEVICE|Accu Chek Aviva Nano|This meter is a normal glucometer without bolus calculator.
223757501|NCT03960502|DRUG|AG-881|Single oral dose of approximately 50 mg AG-881 (free form) containing approximately 100 microcuries (μCi) of \[14C\]AG-881.
223611304|NCT03386721|DRUG|Vinorelbine|Single-agent treatment administered as per approved protocol.
223611305|NCT05114473|OTHER|Workshops|Several face-to-face workshops given by a researcher
223611306|NCT05114473|OTHER|Online-accessed material|Access to a website containing the educational program
223611307|NCT01509235|PROCEDURE|Chest physiotherapy|The whole exercise session consisted of three short period of exercise of 5 minutes each entirely done under the physiotherapists' supervision (FA).
223611308|NCT02330055|PROCEDURE|Forty-five degrees elevated upper body position|
223611309|NCT02330055|PROCEDURE|non-elevated upper body position|
223611310|NCT02330055|DEVICE|Noninvasive wrist pulse oximeter (WristOx Model 3150)|The noninvasive wrist pulse oximeter (WristOx Model 3150) is used to measure the SpO2 and the pulse rate of the patient in the first night after delivery.
223757502|NCT03960502|DRUG|[13C315N3]AG-881|Single IV microdose of approximately 100 μg.
223757503|NCT05036993|BEHAVIORAL|Coaching|Faculty will be paired with a certified coach who is also a faculty member and receive 6 sessions of coaching over 3 months
224311830|NCT02227446|DRUG|Vancomycin antibiotic powder|At the time of fracture fixation 1000 mg of Vancomycin powder placed into the wound during wound closure.
224311831|NCT01635816|BIOLOGICAL|JE Vaccine existing facility|Will receive JE live attenuated SA 14-14-2 vaccine manufactured in the existing facility (250 infants).
224311832|NCT01635816|BIOLOGICAL|JE vaccine new plant lot 1|Will receive Lot 1 JE live attenuated SA 14-14-2 vaccine manufactured in the new GMP facility (250 infants).
224311833|NCT01635816|BIOLOGICAL|JE vaccine new plant lot 2|Will receive Lot 2 JE live attenuated SA 14-14-2 vaccine manufactured in the new GMP facility (250 infants).
224311834|NCT01635816|BIOLOGICAL|JE vaccine new plant lot 3|Will receive will receive Lot 3 JE live attenuated SA 14-14-2 vaccine manufactured in the new GMP facility (250 infants).
223757504|NCT03031912|BIOLOGICAL|V920 (rVSVΔG-ZEBOV-GP) Ebola Virus Vaccine|The rVSVΔG-ZEBOV-GP vaccine is a live attenuated recombinant virus consisting of a single recombinant VSV isolate (11481 nt, strain Indiana) with the gene for the Zaire ebolavirus GP (ZEBOV GP), Kikwit strain replacing the gene for the VSV GP, which has been deleted. This results in a VSV backbone with the ZEBOV GP constituting the envelope of the virus.
223757505|NCT03031912|OTHER|Saline|Normal saline (0.9%) has been chosen as an inert substance to serve as placebo control.
223757506|NCT02248129|DRUG|Telmisartan and hydrochlorothiazide|
223757507|NCT02085564|PROCEDURE|Peritoneal washing cytology|The methode is describes in the detailed study description
223757508|NCT05024565|BEHAVIORAL|prolonged intravenous infusion of β-lactams Antibiotics|(1) Carbapenems: Calculate the daily dose according to the creatinine clearance rate and divide it into 3 times. Each time, the dose is injected intravenously at 1/2 dose for 15 minutes, and the remaining 1/2 dose is injected at a constant rate for 3 hours. (2) Cephalosporins: calculate the allowable daily dose according to the creatinine clearance rate, inject at a uniform rate within 24 hours. (3) β-lactams and β-lactamase inhibitor compound: the daily dose is calculated according to the creatinine clearance rate and injected at a uniform rate within 24 hours.
223757509|NCT02584751|DRUG|Omeprazole|Omeprazole is a commonly prescribed anti-reflux medication. If a SCI patient has GERD, they will be prescribed with 40mg omeprazole twice daily for two months
223757510|NCT02584751|DEVICE|24 Hour pH Monitor|Monitors the acidity and levels of pH in the esophagus for 24hours and helps diagnose people with GERD
223757511|NCT02584751|PROCEDURE|Pulmonary Function Examination|Assess pulmonary function such as lung volumes, spirometry, and max inspiration/expiration pressures.
223757512|NCT02584751|PROCEDURE|Exhaled Nitric Oxide|Used to measure inflammation markers for airway resistance.
223757513|NCT02584751|PROCEDURE|Exhaled Breath Concentrate (EBC)|EBC will be used to measure airway inflammation via specific markers, such as 8-isoprostane. This marker, if elevated, has been identified as an indicator for asthma inflammation.
223757514|NCT02584751|PROCEDURE|Bernstein's Acid Clearance Test|Bernstein test is a clinical test for the diagnosis of chest pain in association with gastric acid exposure
223757515|NCT02584751|PROCEDURE|Esophageal Motility|Esophageal Motility will be used to measure a subject's ability to swallow a bolus (i.e. saline solution) and record pressure changes throughout the esophagus during the swallow. This will also be used to identify anatomical landmarks, such as lower esophageal sphincter, which are necessary for proper placement of 24hr pH catheter.
223757516|NCT05531162|OTHER|Cognition and emotional neuropsychologicl evaluations|Cognitive ans sensory performances during repetitive micro and partial gravity exposure
223757517|NCT02534792|OTHER|Revalvulation|
224311835|NCT03531138|OTHER|Pulmonary Rehabilitation|All patients will undergo supervised pulmonary rehabilitation program on 2 days per week for 3 months. Apart from that, they will ask to perform the home exercise program which is scheduled as 3 days per week and fill out the exercise follow-up form. Supervised exercise sessions consist of aerobic(treadmill walking, bicycle training, arm ergometer training) and strengthening training(free weights). A 6-min walk test, a 10-meter walking speed test and a 5 times sit to stand test will be performed to determine the exercise capacity of the patient. The tests will be carried out at the beginning and end of rehabilitation. At each testing session, the tests will be performed sequentially by the same physiotherapist, giving 20 minute rest periods within the same day.
223611311|NCT02330055|OTHER|Stop-Bang questionnaire|"The Stop-Bang questionnaire is a well-established clinical tool to quantify the risk factors of Obstructive Sleep Apnea, which can lead to desaturation in the patient. The STOP Bang questionnaire includes snoring, tiredness, observed apneas, blood pressure, Body Mass Index, age, neck circumference and gender.~The investigators will ask the patient to answer the questionnaire and measure the neck circumference."
223611312|NCT02330055|OTHER|Epworth Sleepiness Scale|"The Epworth Sleepiness Scale is a well-established clinical tool to quantify daytime sleepiness. It is clinically used for the diagnosis of sleep disorders.~The investigators will ask the patient to complete the questionnaire and will specify that the questionnaire pertains to the patient's pre-admission condition."
223611313|NCT02330055|OTHER|P-SAP Score|"The P-SAP Score is a well-established clinical tool to quantify the risk factors of Obstructive Sleep Apnea, which can lead to desaturation in the patient.~The investigators will ask the patient to answer the questionnaire and will assess the Mallampati Score. The investigators will also measure the neck circumference and the Thyromental distance."
223611314|NCT02330055|OTHER|self-reported pain|A verbal numerical rating scale is used to asses the pain during the study-night.
223611315|NCT02976935|OTHER|hyperpolarised 129 Xenon|Hyperpolarised 129 Xe to assess lung function
223757518|NCT01852292|DRUG|Buparlisib|Buparlisib comes in gelatin capsules and is taken orally at a dose of 100 mg/day.
223757519|NCT01852292|DRUG|Buparlisib matching Placebo|Buparlisib matching placebo comes in gelatin capsules and is taken orally at a dose of 100 mg/day.
223757520|NCT01852292|DRUG|Paclitaxel|Paclitaxel is an intravenous infusion that is given once every week in 80 mg/m\^2.
223757521|NCT04320940|DRUG|Phenobarbital Sodium Injection|The initial dose will be administered intravenously over a 30-minute period. The time period between the first and second dose of phenobarbital cannot occur within 30 minutes of the end of the first dose.
224311836|NCT05555823|DRUG|ATR-002|300 mg tablets for oral intake
224311837|NCT05555823|DRUG|Placebo|matching tablets for oral intake
224311838|NCT05555823|DRUG|Repaglinide|0,5 mg tablets for oral intake
223611316|NCT02151188|DIETARY_SUPPLEMENT|Bread, Soy milk and cow milk|The study will examine the metabolic effects of two liquid proteins (soy milk and cow milk) with carbohydrate (bread) meals.
223611317|NCT02151188|DEVICE|real-time ultrasonography (GE LOGIQ P5 ultrasound in CNRC)|
223757522|NCT03935035|BEHAVIORAL|internet-delivered Cognitive Therapy for PTSD (iCT)|Participants will receive 10 hours of Cognitive Therapy for PTSD over 12 weeks, with a baseline assessment at the beginning and follow up interview at the end of treatment. The treatment consists of online modules (9 core modules, 11 optional modules and parent/carer modules) and a weekly phone call with a qualified and trained therapist.
223757523|NCT00849368|DRUG|Azathioprine / Allopurinol|"Both drugs are applied orally. A pre-specified dose escalation regimen will be chosen.~Azathioprine: Imurek (R) 50 mg and 25 mg tablets~Allopurinol: Mephanol (R) 100 mg tablets"
224311839|NCT05555823|DRUG|Celecoxib|100 mg capsules for oral intake
224311840|NCT05171608|PROCEDURE|Ultrasound-based protocol based fluid therapy|"Protocol of the interventional group according to the ultrasonographic findings:~Ultrasound scan 2 hours before surgery:~IVCCI\>40 percent and absence of symmetric anterior 'B-profile' on the lung ultrasound indicate intravenous (IV) fluid therapy: 8 ml/kg of isotonic, balanced crystalloid infusion.~IVCCI≤40 percent AND/OR symmetric anterior 'B-profile' contraindicates further IV fluid therapy.~A 2nd ultrasound scan at 30 minutes before surgery:~IVCCI\>40 percent and absence of symmetric anterior 'B-profile' on the lung ultrasound indicate further IV fluid therapy: 5 ml/kg of isotonic, balanced crystalloid infusion.~IVCCI≤40 percent AND/OR symmetric anterior 'B-profile' contraindicates further IV fluid therapy."
224311841|NCT01820975|DIETARY_SUPPLEMENT|High protein intake|
223757524|NCT04655716|DRUG|Sodium Bicarbonate 150Meq/L/D5W Inj|Urine alkalinisation will be performed to achieve urine pH 7.5-8.5. Urine alkalinisation will be continued for up to 10 days or until patient is discharged or until primary endpoint is reached. Urine pH will be measured at point of care by dipstick.
224311842|NCT01820975|OTHER|Placebo comparator|No protein intake
224311843|NCT00875797|DIETARY_SUPPLEMENT|parenteral glutamine|Dipeptiven, Fresenius Kabi, Graz, Austria was given intravenously through central venous line in a dose up to 30 g per day
223757525|NCT04452266|OTHER|questionnaire assesment|Each patient will to answer questions about their medical history.
223757526|NCT01914666|DRUG|Duloxetine|Administered orally
223757527|NCT04491162|OTHER|Body weight support treadmill training + conventional therapy|"Conventional gait therapy was done based on the principles of the proprioceptive neuromuscular facilitation (PNF) and Motor Relearning program (MRP) concepts.~Patients in intervention arm were additionally trained with a 40% body weight support and a comfortable walking speed on treadmill for twenty minutes. The training, which was conducted three times a week, for period of two weeks."
224201245|NCT06723548|DRUG|Telitacicept|Patients with MG who fulfill the inclusion criteria will receive Telitacicept 240mg weekly as an adjunct to their medication. Upon reaching MMS, significant symptom improvement, or a QMG score reduction of at least 6 points, Telitacicept is reduced to biweekly doses. Pyridostigmine and NSISTs are tapered based on patient response. Following this, Prednisone is tapered, starting with rapid reduction early and slowing later. If a patient on 60mg Prednisone daily achieves treatment goals within 6-8 weeks of Telitacicept initiation, the tapering sequence is 60mg every other day for 4 weeks, then 30mg daily for 2-4 weeks, and so on, until reaching 5mg daily or 10mg every other day. At this point, Telitacicept may be reduced to 160mg biweekly.
224201246|NCT06925646|PROCEDURE|Finger hyperperfusion via adenosine|"Subjects will be fitted with a mouthpiece and/or facemask to systematically reduce the fraction of inspired oxygen (FiO2) they breathe, starting with room air (21% O2), and then progressive hypoxic mixtures of 18%, 15%, 12%, and 10% FiO2 in sequence for five minutes each.~Blood flow to the hand downstream from the brachial catheter will be increased by brachial artery infusions of adenosine administered at 6.25 mcg/100ml tissue per minute for 30 minutes into the brachial artery to increase blood flow by 5 to 10-fold."
224201247|NCT06925646|PROCEDURE|Finger hypoperfusion via by norepinephrine|"Subjects will be fitted with a mouthpiece and/or facemask to systematically reduce the fraction of inspired oxygen (FiO2) they breathe, starting with room air (21% O2), and then progressive hypoxic mixtures of 18%, 15%, 12%, and 10% FiO2 in sequence for five minutes each.~Blood flow to the hand downstream from the brachial catheter will be decreased to \~25% of baseline, by infusing norepinephrine at 4 ng/100ml of tissue per minute for 30 minutes."
224201248|NCT06925646|PROCEDURE|Baseline hypoxic test|Subjects will be fitted with a mouthpiece and/or facemask to systematically reduce the fraction of inspired oxygen (FiO2) they breathe, starting with room air (21% O2), and then progressive hypoxic mixtures of 18%, 15%, 12%, and 10% FiO2 in sequence for five minutes each.
224201249|NCT07047443|DRUG|SHR- A1811|HER2 ADC
224311844|NCT00875797|DIETARY_SUPPLEMENT|enteral glutamine|Alitraq, Abbott Laboratories, B.W. Zwolle, the Netherlands was given via nasogastric tube as continuous infusion of enteral diet, dose up to 30 g per day
224311845|NCT03846583|DRUG|Tucatinib|Tucatinib is a drug that inhibits human epidermal growth factor receptor 2 (HER-2) protein, which is a protein expressed in the cancer cells. By inhibiting this protein, tucatinib may help stop or reduce the growth of the tumor
224311846|NCT03846583|DRUG|Abemaciclib|Abemaciclib is a cyclin-dependent kinase (CDK) inhibitor. CDK inhibitors work to stop cell growth.
224314269|NCT03589040|DRUG|Etonogestrel 68Mg Implant|Etonogestrel single-rod subdermal implant (68mg/rod) will be administered to all study participants
224314270|NCT03589040|DRUG|rilpivirine|Oral rilpvirine 25mg
224314271|NCT03589040|DRUG|darunavir|Oral darunavir+ritonavir 600/100mg
223509271|NCT01755156|DRUG|Glimepiride|Glimepiride 1 or 2 mg tablet/capsule administered orally once daily and up-titrated to a maximum dose of 6 mg daily. Participants rescued with open-label glimepiride during Phase A will not receive glimepiride or matching placebo to glimepiride during Phase B.
223509272|NCT01755156|DRUG|Matching placebo to glimepiride|Matching placebo to glimepiride tablet/capsule administered orally once daily and up-titrated to a mock maximum dose of 6 mg daily. Participants rescued with open-label glimepiride during Phase A will not receive glimepiride or matching placebo to glimepiride during Phase B.
223509273|NCT01755156|DRUG|Insulin glargine|During Phase B of the study, participants who received a maximum up-titration of open-label glimepiride or blinded glimepiride/matching placebo to glimepiride, may be rescued with open-label insulin glargine.
223509274|NCT01755156|DRUG|Metformin|Participants continue stable pre-study dose of metformin tablet(s) administered orally (\>= 1500 mg daily) throughout the study.
223509275|NCT05666856|BEHAVIORAL|Community Reinforcement And Family Training|"Community Reinforcement Approach and Family Training (CRAFT) is a scientifically based intervention designed to help concerned significant others (CSOs) to engage treatment-refusing substance abusers into treatment. This new intervention method was developed with the belief that the CSO can play a powerful role in helping to engage the substance user in treatment. It is often the substance user who reports that family pressure or influence is the reason sought treatment. CSOs benefit by becoming more independent and reducing their depression, anxiety and anger symptoms even if their loved one does not enter treatment.~CRAFT uses a positive approach versus confrontation, emphasizing learning new skills to cope with old problems. Some components include: how to stay safe, outlining the context in which substance abusing behavior occurs, teaching CSOs how to use positive reinforcers (rewards) and how to let the substance user suffer the natural consequences for their using behavior."
223611318|NCT00963391|OTHER|ABHS use|"Centers assigned to the intervention group were provided with ABHS dispensers with a gel solution with ethyl alcohol at 62% as active ingredient (Purell®, GOJO Industries, Dayton, Ohio). A total of 85 dispensers were installed, one dispenser was installed in each center of size less than 14 children, and one per classroom plus an additional one for common areas in centers with more than 28 children. Proper safety measures were followed.~Standardized ABHS training workshops for staff and children in centers allocated to the intervention were carried out simultaneously with dispenser installation. Thirty minute refresher sessions about ABHS technique were provided to staff and children on a monthly basis, for a total of 8 sessions per center."
223611319|NCT00540072|DRUG|daptomycin|
223611320|NCT02992574|RADIATION|Post Mastectomy Radiation therapy|Post mastectomy radiotherapy to the chest wall and ipsilateral supra-clavicular fossa to a dose of 40 Gy in 15 fractions over 3 weeks
223611321|NCT03903419|DIAGNOSTIC_TEST|Feasibility study for the realization of 68Ga-PSMA PET-CT and 18F-FDOPA PET-CT for identification of early recurrence in patients treated with radiotherapy for glioblastoma.|"This study is a non-randomized, prospective, feasibility study assessing 68Ga-PSMA PET-CT and 18F-FDOPA PET-CT to differentiate early recurrence from post-radiation modifications in patients treated with radiotherapy for glioblastoma.~Patients with a MRI performed since the end of the radiotherapy until 12 months of follow up after the end of radiotherapy, will be referred for both 68Ga-PSMA and 18F-FDOPA PET-CT, whatever the conclusion of the MRI (post radiation modifications, relapse or doubtful MRI)."
223757528|NCT04491162|OTHER|Conventional therapy|Conventional gait therapy was done based on the principles of the proprioceptive neuromuscular facilitation (PNF) and Motor Relearning program (MRP) concepts.
223611322|NCT03407755|PROCEDURE|Intraocular gas|Participants randomized to either air or SF6 gas in the anterior chamber.
223757529|NCT05953077|BEHAVIORAL|Conversational recasting|The treatment procedure uses 24 treatment doses embedded into child-friendly activities (crafts, book reading, play). Each each consists of a clinician eliciting use of a targeted grammatical form, a child's attempt (correct or incorrect) to use that form, and an immediate clinician repetition of the child's attempt (a recast), correcting any ungrammatical elements as needed. Clinicians must also attempt to gain the child's attention before providing the recast. Treatment sessions are approximately 30 minutes in duration.
223757530|NCT06090110|DEVICE|Vagal Nerve Stimulation|Transcutaneous Auricular Vagal Nerve Stimulation
223757531|NCT06090110|DEVICE|Sham stimulation|Sham stimulation with a non-conduction electrode
223757532|NCT05849402|DEVICE|Active Comparator: Active aiTBS|Participants will be randomized to active or sham aiTBS condition, and receive 10 aiTBS to left DLPFC (LDLPFC) sessions a day for 5 days of course.
223757533|NCT05849402|DEVICE|Sham Comparator: Sham aiTBS|Participants will be randomized to active or sham aiTBS condition, and receive 10 aiTBS to left DLPFC (LDLPFC) sessions a day for 5 days of course.
223757534|NCT04700514|DRUG|Dexmedetomidine|Dexmedetomidine (1 mcg/kg loading for 10 min, then 1 mcg/kg/min continuous infusion) is used with sevoflurane in every time of general anesthesia
223757535|NCT04520425|PROCEDURE|Osteopathic manipulative therapy|"1. Mandibular: the clinician applies gentle pressure bilaterally to the subject's mandible, in the direction of the patient's clavicles.~2. Frontal: the clinician applies gentle pressure bilaterally to the subject's forehead, in a direction halfway between the parietals and ears.~3. Temporal: the clinician applies gentle pressure bilaterally to the subject's temples, in the direction of the patient's occiput.~4. Parietal: the clinician applies gentle pressure bilaterally to the subject's parietal bones, in the direction of the patient's occipital atlanto joint.~5. Occipital: the clinician applies gentle pressure to the subject's occipital bone, in the direction of the patient's neck."
223757536|NCT01670357|DRUG|DA-6034 3%|Eye drop, 1 drop/each eye, 4 times/day, for 4 weeks
223757537|NCT01670357|DRUG|DA-6034 5%|Eye drop, 1 drop/each eye, 4 times/day, for 4 weeks
223757538|NCT01670357|DRUG|DA-6034 Placebo|Eye drop, 1 drop/each eye, 4 times/day, for 4 weeks
223757539|NCT01296724|OTHER|Measure of intravesical pressure|For the installation of the urinary catheter, a valve connected to a pressure head is intercalated between the probe and the collecting bag. Various Intravesical pressure measurements will be conducted after injection of 0 ml/kg, 0.5 ml/kg, 1 ml/kg, 1.5 ml/kg, 2 ml/kg, 2.5 ml/kg 3 ml/kg, 3.5 ml/kg and 4 ml/kg of physiological saline.
223757540|NCT01296724|OTHER|Measure of intravesical pressure|For the installation of the urinary catheter, a valve connected to a pressure head is intercalated between the probe and the collecting bag. Various IVP measurements will be conducted after injection of 0 ml/kg, 0.5 ml/kg, 1 ml/kg, 1.5 ml/kg, 2 ml/kg, 2.5 ml/kg 3 ml/kg, 3.5 ml/kg and 4 ml/kg of physiological saline.
223757541|NCT02586012|DRUG|rFVIII|Recombinant FVIII concentrate is an FDA approved, and both efficacious and safe, therapy for the treatment and prevention of bleeding in hemophilia A. The rFVIII infusion dose will be calculated as follows: \[(weight in kg x desired FVIII increase of 100 IU/dL)/(2)\].
224201250|NCT07047924|DEVICE|MCOK-01|The investigational device is a Rigid Gas Permeable contact lenses for orthokeratology. MCOK-01 applied the reverse geometry design and adopted the lens material which possesses the highest oxygen permeability among all the materials for orthokeratology lens.
224201251|NCT07047742|DIETARY_SUPPLEMENT|lemon juice|in this study for the first arm fresh lemon juice two times daily is advised
224201252|NCT07047742|DIETARY_SUPPLEMENT|Roselle|for the second arm Roselle tea is advised tow times per day
224201253|NCT07047742|OTHER|Education on urolithiasis management|all the arms except control group receive education about urolithiasis management
224201254|NCT07047625|BEHAVIORAL|control group (Routine nursing)|the implementation of routine treatment and nursing measures, including (1) Monitoring vital signs: according to the condition of vital signs change detection, found abnormal, timely notify the doctor, comply with medical treatment, observe the curative effect. (2) Relieve pain: tell patients the method of distraction, follow the doctor's advice, and observe the curative effect. (3) Improve disease awareness: Inform patients or family members of disease-related knowledge, examination, diagnosis and treatment, surgery and other purposes, significance and precautions. (4) Ensure patient safety: strengthen safety education, strict three check seven pairs, bed placed a variety of safety warning signs. (5) Avoid the occurrence of unexpected risks: guide patients and their families to prevent burns, trauma, etc. (6) Prevention of infection: strict implementation of disinfection and isolation system, the implementation of hand hygiene norms, reduce visits. (7) Raise the affected limb, early f
223757542|NCT05686681|BEHAVIORAL|Brief Behavioral Activation for Improving Social Connectedness|"Brief Behavioral Activation for Improving Social Connectedness (BBAISC): BBAISC was developed to address social connectedness. Grounded in Behavioral Activation (Lejuez et al., 2011), BBAISC is a structured, 6-session skill-building intervention that has 4 key elements (Pepin et al., 2020):~1. Psychoeducation: Psychoeducation focused on homebound status, social connectedness, and associated changes in behavior.~2. Behavioral Activation intervention rationale: Framing how changing behavior can positively impact social connectedness (i.e., improve social connectedness and reduce loneliness).~3. Exploration of life areas, values, and activities: Focused on identifying life areas and values most relevant to the participant. Then, these values are used to generate activities that are aligned with those values.~4. Activity monitoring and planning: Participants are encouraged to schedule and organize their day based on what is important rather than their current mood or feeling state."
223757543|NCT01462903|BIOLOGICAL|tumor infiltrating lymphocytes, IL-2|Biological: Infusion of Tumor Infiltrating Lymphocytes (10e9-10e10 cells) by iv in 30 Minutes. Followed by daily sc injections of 2 MIE Interleukin-2 for two weeks.
223757544|NCT05581212|OTHER|Tuberculosis Case-Finding, Treatment and Prevention Public Health Pack|Combined active case-finding, treatment and prevention of TB amongst HH contacts of TB cases, associated with initiation of standard of care (SOC) treatment in active TB cases and initiation of TB preventive therapy in those contacts without active TB, based on free screening. This intervention will be compared to the standard of care available in the country.
223757545|NCT00896545|BEHAVIORAL|5-keys counseling|5-session small group intervention
223757546|NCT00896545|BEHAVIORAL|Lifestyle counseling|5-session small group behavioral intervention
223757547|NCT02886377|BIOLOGICAL|blood test of anti-AQP4 antibody|Patients were sub-divided into an AQP4 seropositive group and an AQP4 seronegative group, according to blood test of the AQP4-Ab.
223757548|NCT03407326|DIETARY_SUPPLEMENT|Alternative RUTF|The alternative RUTF contains oat, peanuts, sugar, milk powder, vegetable oil as well as premix containing concentrated minerals and vitamins and emulsifier.
223757549|NCT03407326|DIETARY_SUPPLEMENT|Standard RUTF|Standard RUTF contains peanut paste, sugar, non-fat dried milk (NFDM), vegetable oil, a premix containing concentrated minerals and vitamins, and emulsifier.
223757550|NCT02492906|OTHER|Osteoarthrosis|Primary severe knee osteoarthrosis and chronic knee pain.
223611323|NCT02946034|DRUG|Viekira Pak ± ribavirin|12 weeks treatment with AbbVie Viekira Pak ± ribavirin
223611324|NCT02946034|DRUG|Mavyret|8 or 12 weeks treatment with AbbVie Mavyret
223611325|NCT04515758|OTHER|Exercise and Cognitive Training|Exercise: 12-week, twice-weekly 60-minute program. Each session includes a brief 5 minute educational lesson on a health-related topic (i.e. healthy eating, good posture, etc.). Each participant receives individualized and progressive exercise program from qualified exercise providers (YMCA instructors). The programs include whole body exercises including squats, rows, chest press, bicep/tricep exercises, shoulder exercises, and core exercises. A 5 warm-up is done (individually or in a group) and a 5 minute group cool-down (stretching) is done each class. Cognitive training: focuses on dual-task training (provided by an Android tablet). Each cognitive task requires the participant to choose and execute the response appropriate for the stimuli presented. Participants must prioritize their response and perform tasks as fast as possible while maintaining accuracy. The difficulty of the training is individualized and progressive based on their ongoing performance.
224205917|NCT04271241|OTHER|Passive stretching (PS) training|PSBil and PSMono underwent 12 weeks of PS training, 3 sessions per week (36 sessions in total). In PSBil, each session lasted 40 min and included two maneuvers for both the knee extensor and plantar flexor muscles with the following protocol: 45 s elongation and 15 s recovery in the resting position, all the cycle repeated for five times 7. In PSMono, exercises were performed only on the right limb and each session had a duration of 20 min. Ctrl did not underwent any PS exercise throughout the study. To promote participants' compliance, daily classes were held at different day time (morning and afternoon) at the University Sports Centre gym. Each class was supervised by an expert operator, which monitored the attendance, the correct exercise execution and the intensity exerted during the exercise (80% of the point of discomfort). The participants not attending at least the 80% of classes were excluded from the study, and a new participant was recruited to substitute the drop out.
223611326|NCT04515758|OTHER|Exercise Training Only|Exercise: 12-week, twice-weekly 60-minute program. Each session includes a brief 5 minute educational lesson on a health-related topic (i.e. healthy eating, good posture, etc.). Each participant receives individualized and progressive exercise program from qualified exercise providers (YMCA instructors). The programs include whole body exercises including squats, rows, chest press, bicep/tricep exercises, shoulder exercises, and core exercises. A 5 warm-up is done (individually or in a group) and a 5 minute group cool-down (stretching) is done each class.
223611327|NCT04649515|BIOLOGICAL|TY027|TY027 Injection, (100 mg/5 mL/Vial), SARS-CoV-2 Monoclonal Antibody (mAb) - 1,500 mg of TY027
223611328|NCT04649515|BIOLOGICAL|TY027|TY027 Injection, (100 mg/5 mL/Vial), SARS-CoV-2 Monoclonal Antibody (mAb) - 2,000 mg of TY027
223611329|NCT04649515|OTHER|0.9% saline|Placebo
223611330|NCT04311255|PROCEDURE|regional anesthesia for the upper limb|pecs-II block and intercostal nerve block
223757551|NCT02492906|OTHER|Healthy|Healthy and non-symptomatic volunteers.
223757552|NCT06183684|DEVICE|Laplace TTVR System|Transcatheter Tricuspid Valve Replacement (TTVR) System for the treatment of severe, symptomatic tricuspid regurgitation
223757553|NCT04167774|DRUG|Camrelizumab|Camrelizumab will be administered as a 30-minute IV infusion Q3W at a dose of 200mg (3mg/kg for underweight patients).
223757554|NCT04167774|DRUG|nb-Paclitaxel|nb-Paclitaxel will be administered as a 30-minute IV infusion Q3W at a dose of 260mg/m2 for 4-6 cycles.
223611331|NCT03948841|OTHER|magnetic resonance imaging|
223611332|NCT01951651|DRUG|Exenatide|Type 2 diabetic subjects will be randomized to receive either Exenatide 10 micrograms twice daily injected subcutaneously or glipizide 5 mg twice daily orally for 6 months. All subjects will receive baseline measurements of fasting plasma glucose, free fatty acids, plasma adipocytokines, plasma lipids, and glycosylated hemoglobin (HbA1c) as well as measurement of liver and myocardial fat content and left ventricular function with magnetic resonance imaging/spectroscopy. All subjects will also undergo measurements of monocyte inflammatory proteins at baseline. All subjects will undergo repeat measurements of fasting plasma glucose, Free Fatty Acids, adipocytokines, HbA1c, monocyte inflammation, as well as hepatic/myocardial fat content determination and left ventricular function at the end of the 6 months.
223611333|NCT01951651|DRUG|Glipizide|Type 2 diabetic subjects will be randomized to receive either Exenatide 10 micrograms twice daily injected subcutaneously or glipizide 5 mg twice daily orally for 6 months. All subjects will receive baseline measurements of fasting plasma glucose, free fatty acids, plasma adipocytokines, plasma lipids, and glycosylated hemoglobin (HbA1c) as well as measurement of liver and myocardial fat content and left ventricular function with magnetic resonance imaging/spectroscopy. All subjects will also undergo measurements of monocyte inflammatory proteins at baseline. All subjects will undergo repeat measurements of fasting plasma glucose, Free Fatty Acids, adipocytokines, HbA1c, monocyte inflammation, as well as hepatic/myocardial fat content determination and left ventricular function at the end of the 6 months.
223611334|NCT06164834|DRUG|Clopidogrel 75 mg|Clopidogrel 75 mg tablet
223611335|NCT06164834|DRUG|Tegoprazan 25 mg|Tegoprazan 25 mg tablet
223611336|NCT06164834|DRUG|Esomeprazole 20mg|Esomeprazole 20 mg tablet
223611337|NCT01383226|PROCEDURE|Thoracic endosonography|Thoracic endosonography is a minimal invasive diagnostic intervention
224201255|NCT07047625|BEHAVIORAL|Experimental group （Health education path）|On the basis of the control group, the health education path nursing program was adopted. The specific intervention measures were as follows: ① A program implementation team was set up, including 2 urologists, 2 nurses and 1 psychological counselor. All members have received relevant professional training; ②Two nurses were the main liaisons for the intervention and were responsible for monitoring the treatment and nursing of patients throughout the course. The workflow was as follows: starting from the patient's discomfort experience, the patient was managed according to the nursing procedure steps. By assessing the patient's existing discomfort symptoms, interventional cognitive intervention and psychological intervention, and based on the intervention plan proposed in this study, a health education path nursing plan was developed for patients from the aspects of diet, liquid intake, position adjustment, and symptomatic intervention (see Table 1). In the process of intervention, feedb
224201256|NCT07046988|DRUG|Terbinafine Tablets|"Oral administration once daily:~For patients weighing \<20 kg: 62.5 mg qd; For patients weighing 20-40 kg: 125 mg qd; For patients weighing \>40 kg: 250 mg qd; Total 8 weeks."
224201257|NCT07048626|COMBINATION_PRODUCT|PRP treatment|PRP treatment involves drawing a blood sample, processing it to concentrate platelets, and then injecting that concentrated plasma back into the body, typically at the site of an injury or area needing regeneration. The procedure aims to utilize the growth factors within the platelets to accelerate healing and tissue repair.
224201258|NCT07048626|COMBINATION_PRODUCT|low level laser therapy post prp treatment|will receive low-level laser therapy post prp treatment upto 12 weeks .Low-level laser therapy (LLLT) is a non-invasive treatment for hair loss that uses low-intensity laser light to stimulate hair follicles and improve blood circulation. It's often used on its own or combined with other therapies like PRP.
224201259|NCT07048561|OTHER|observation alone|No interventions will be conducted during the one-year observation period, maintaining participants' normal daily living conditions.
224201260|NCT07047807|BEHAVIORAL|PDAC-PATHWAYS|A digital app for patients initiating neoadjuvant therapy for PDAC
224201261|NCT07047807|OTHER|Usual Care|Routine treatment
224201262|NCT07046897|DIETARY_SUPPLEMENT|Consumption of probiotics strain 5|Consumption of probiotic capsules containing the probiotic bacteria Bacillus coagulans strain 5.
224201263|NCT07046897|DIETARY_SUPPLEMENT|Consumption of probiotics strain 6|Consumption of probiotic capsules containing the probiotic bacteria Bacillus coagulans strain 6.
224201264|NCT07047105|DIETARY_SUPPLEMENT|Nepalese Pepper (Zanthoxylum Armatum) extract 150mg|The intervention is a powdered form of Zanthoxylum Armatum (ZA) extract delivered in capsule form. The dosage is 150mg.
224201265|NCT07047105|DIETARY_SUPPLEMENT|Nepalese Pepper (Zanthoxylum Armatum) extract 300mg|The intervention is a powdered form of Zanthoxylum Armatum (ZA) extract delivered in capsule form. The dosage is 300mg.
224201266|NCT07047105|DIETARY_SUPPLEMENT|Placebo|Microcristalline Cellulose MCC
224201267|NCT07047105|DIETARY_SUPPLEMENT|Caffeine 75mg|Caffeine anhydrous Pulver, 75mg
224201268|NCT07046871|BEHAVIORAL|1. Intervention Name (Arm 1) Name: Adapted Basketball Program with Video Support Type: Behavioral Description: A 7-week basketball intervention for adolescents with obesity, combining pedagogically a|A 7-week basketball intervention for adolescents with obesity, combining pedagogically adapted activities with pre-session video instruction delivered via a private Facebook group.
223611338|NCT00782717|DRUG|Nepafenac ophthalmic suspension, 0.1% (NEVANAC)|1 drop TID beginning the day before surgery, continuing on the day of surgery and through the first 90 days following surgery.
223611339|NCT00782717|OTHER|Nepafenac ophthalmic suspension vehicle|1 drop TID beginning the day before surgery, continuing on the day of surgery and through the first 90 days following surgery
223611340|NCT00782717|DRUG|Prednisolone acetate ophthalmic suspension (OMNIPRED)|One drop in the study eye 4 times daily (morning, late morning, late afternoon, and bedtime)for two weeks postsurgery.
223611341|NCT03088488|DIAGNOSTIC_TEST|fasting venous blood samples|
224201269|NCT07046871|BEHAVIORAL|ADAPT Adapted Basketball Program|A 7-week adapted basketball intervention including non-competitive, inclusive drills tailored to adolescents with obesity, without any video supplementation.
224201270|NCT07047911|OTHER|Observational only - surgical management not assigned by study|Observational only - surgical management not assigned by study
224205918|NCT03549143|OTHER|IBS|No intervention, description of routine practice only
224205919|NCT04429633|DRUG|Candesartan|If GLS decreased less than 18% or LVEF decreased to 45-50% during the treatment of adjuvant trastuzumab, start candesartan medication.
224205920|NCT05496634|BEHAVIORAL|Sedantary|An informative presentation
224205921|NCT05496634|BEHAVIORAL|Exercise therapy|Pilates exercise therapy
224205922|NCT04062643|DIAGNOSTIC_TEST|Obesity assessment|Body mass index (BMI (kg/m2) was calculated from measurements of weight to the nearest kg and height
224205923|NCT05353816|DEVICE|Corheart 6 Left Ventricular Assist System|Implantation of the Corheart 6 Left Ventricular Assist Device for mechanical circulatory support.
224205924|NCT00000705|DRUG|Zidovudine|
224205925|NCT04466436|OTHER|tryptophan|measurement of tryptophan in serum
224205926|NCT02508649|DRUG|selepressin|
224205927|NCT02508649|DRUG|placebo|
224205928|NCT05217537|DRUG|Omadacycline Injection [Nuzyra]|Single dose of 100 mg omadacycline IV in 100 mL of normal saline
224205929|NCT05217537|DRUG|Omadacycline Oral Tablet|Single dose of 300 mg omadacycline PO (2 x 150 mg tablets)
223757555|NCT03277846|DEVICE|Nexalin Based Trans-Cranial Electrical Stimulation|The Nexalin device, FDA clearance (501K=K024377, Classification: Stimulator, Cranial Electrotherapy: CFR 882. 5800: U.S. Patent #6904322B2), produces a square waveform that provides trans-cranial electrical stimulation to the brain delivered at a frequency of 77.5 Hz at 0 to 4 mA peak current.
223757556|NCT00827411|DRUG|Aspirin and clopidogrel / Prasugrel|modification of aspirin and clopidogrel/Prasugrel maintenance doses based on a biological assay
223757557|NCT00827411|DEVICE|VerifyNow|point of care assay VerifyNow (ACCUMETRICS San Diego USA)
223757558|NCT00827411|DRUG|Aspirin and clopidogrel / Prasugrel|aspirin and clopidogrel/ Prasugrel maintenance doses (according to international guidelines)
223757559|NCT00827411|DRUG|Aspirin and clopidogrel / Prasugrel|maintenance dose of clopidogrel / Prasugrel and aspirin
223757560|NCT00827411|DRUG|Aspirin|Interruption of clopidogrel / Prasugrel after one year of follow-up
223757561|NCT01720459|DIETARY_SUPPLEMENT|Micronized trans-resveratrol|
223611342|NCT03016065|DIETARY_SUPPLEMENT|Pea Fiber|Baked goods (2 snacks) with fiber-fortified with 5 g/snack of ground pea hulls
223611343|NCT03016065|DIETARY_SUPPLEMENT|Control|Baked goods (2 snacks) without added fiber
223757562|NCT01720459|DIETARY_SUPPLEMENT|Placebo|
223757563|NCT04047082|DIAGNOSTIC_TEST|Quantitative aortogram (videodensitometry)|Patients that performed TAVR will have their aortogram analysed in the cath-lab by videodensitometry (quantitative aortogram)
223757564|NCT03998124|BEHAVIORAL|Peer facilitator training|Peer facilitation of a project-based activity without staff present
223757565|NCT03998124|OTHER|Usual care|Staff-led social activity
223757566|NCT04013191|DRUG|Padsevonil|Padsevonil will be administered in predefined dosages.
223757567|NCT01396863|PROCEDURE|HDF during the first examination|"The patient will receive treatment with pre-dilution hemodiafiltration during the first examination.~During the second examination the patient will receive treatment with low flux hemodialysis.~MRI of the brain will be performed before and after the treatment. The MRI-data will later be processed to determine the degree of brain volume change due to the treatment."
223757568|NCT01396863|PROCEDURE|HD during the first examination|"The patient will receive treatment with low flux hemodialysis during the first examination.~During the second examination the patient will receive treatment with pre-dilution hemodiafiltration.~MRI of the brain will be performed before and after the treatment. The MRI-data will later be processed to determine the degree of brain volume change due to the treatment."
223611344|NCT05463081|DEVICE|Laser treatment|"Laser radiation is emitted by a series of pulses following each other through a pause. The duration of one pulse is 20-200 ns, the pause between pulses is 30 us. The energy of one pulse is about 1 mJ.~General laser radiation parameters for 1st and 2nd stages are: beam with diameter of 4 millimeters (mm) scans treatment area by 4 circles with step of 2 mm (50 percentage (%) overlap), average power of 10-25 Watt (W), treatment time in one point of 1-10 seconds (s), treatment step of 5 mm, from 1 to 5 repetitions of total vagina treatment. General laser radiation parameters for 3d stage are: beam diameter of 6 mm, average power of 15-30 W, duration of ns-pulses packet of 50-100 milliseconds (ms), pause between packets of 50-100 ms, treatment duration up to 65 s, treatment in permanent motion with speed of 10-50 mm/s.~The procedure is performed without anesthesia. The doctor always focuses on the participant's feeling of warmth."
223757569|NCT03523559|GENETIC|bladder tissue of Interstitial Cystitis and normal bladder tissue|Obtain the bladder tissue of Interstitial Cystitis and normal during the operation
223757570|NCT04250064|DRUG|Bevacizumab Injection|Additional concurrent low-dose Bevacizumab with standard EBRT
223757571|NCT04250064|RADIATION|Ultra-low-dose RT|Ultra-low-dose EBRT instead of standard dose RT
223757572|NCT03662100|BIOLOGICAL|LY3074828|Administered SC
223757573|NCT03662100|DRUG|LY3074828|Administered SC
223757574|NCT03662100|DEVICE|Auto-injector (AI)|AI to administer LY3074828
223757575|NCT03662100|DEVICE|Prefilled syringe (PFS)|PFS to administer LY3074828
223757576|NCT00200226|DRUG|misoprostol|misoprostol 400mcg 12 hrs prior to procedure
223757577|NCT00200226|DRUG|vitamin B6|Vitamin B6 50 mg orally 12 hrs prior to procedure
223757578|NCT02009410|DRUG|Creon|Creon 25000 (2 capsules per meal 3 times per day and 1 capsule/snack 2 times per day) during 12 weeks
223757579|NCT02009410|DRUG|Creon 25000 matching Placebo|Creon 25000 placebo matching capsules (2 capsules per meal 3 times per day and 1 capsule/snack 2 times per day) during 12 weeks
224311847|NCT03846583|DRUG|Trastuzumab|"• Trastuzumab is called a targeted therapy because it works by attaching itself to specific receptors on the surface of breast cancer cells, known as HER2 receptors. When Trastuzumab attaches to HER2 receptors, the signals that tell the cells to grow are blocked and the cancer cell may be marked for destruction by the immune system."
223757580|NCT06132607|DEVICE|Preoperative 3D lung reconstruction created with open-source software|Preoperative 3D lung reconstruction created with open-source software 3D Slicer
223757581|NCT02904057|DEVICE|Radiesse (+) Injectable Implant|Treated subjects will receive a maximum volume of 3.0 cc of Radiesse (+) per jawline.
223757582|NCT01275066|DRUG|BMN 110 Weekly|BMN 110 Weekly: Intravenous infusion of BMN 110 at a dose of 2.0 mg/kg administered over a period of approximately 4 hours once a week.
223757583|NCT01275066|DRUG|Placebo|Intravenous infusion of placebo solution at a volume equivalent to that needed for 2.0 mg/kg dose of BMN 110 administered over a period of approximately 4 hours once a week.
223757584|NCT01275066|DRUG|BMN 110 Every Other Week|BMN 110 Every Other Week: Intravenous infusion of BMN 110 at a dose of 2.0 mg/kg administered over a period of approximately 4 hours every other week and infusions of placebo on alternating weeks.
223757585|NCT04175093|DIAGNOSTIC_TEST|asymmetric dimethylarginine|measurement by ELISA of asymmetric dimethylarginine
223757586|NCT01581463|DRUG|Liothyronine, Sodium|Single 100-microgram (2 X 50 microgram) dose.
223757587|NCT06438042|DEVICE|Use of a powered low air pressure motorised therapeutic mattress that combines the motorised and static technologies|Patients with a high risk of pressure injury, without pressure injury, lying more than 20 hours a day, will ly a on a XTECH®25 mattress
223757588|NCT02310178|PROCEDURE|Bariatric surgery|all of the current bariatric surgeries are allowed in this prospective cohort study
223757589|NCT01404091|DRUG|LY2940094|Administered orally
223757590|NCT05092555|DIAGNOSTIC_TEST|Nasopharyngeal swap for Reverse transcription polymerase chain reaction|Nasopharyngeal swap and Blood sample is taken for doing previous tests and CT chest is done for all patients
223757591|NCT00816699|OTHER|preprint preoperative anesthetic risk information|preprint preoperative anesthetic risk information
223611345|NCT05463081|DIAGNOSTIC_TEST|Blood test|Taking blood from a vein for Wassermann reaction (WR), human immunodeficiency viruses (HIV), hepatitis B infection (HBsAg), hepatitis C infection (HCVAg) determination, glucose test (to include the participant in the study) and clinical blood analysis (to include the participant in the study and evaluate procedure efficiency)
224201271|NCT06724354|OTHER|The Surgical Site Infections Precaution Package Form includes the parameters that should be applied to patients before, during and after surgery.|Surgical site infections are a preventable cause of morbidity following surgical procedures. Strategies to reduce SSI rates should address preoperative, perioperative and postoperative factors, and multiple interventions can be combined into 'bundles'. Adoption of these measures may reduce SSIs, but this is dependent on a high level of package compliance. The aim of this study was to evaluate the change in SSI rates after the implementation of the SSI prevention package after neurosurgical operations. It is thought that if the results of our study are positive, the package form created will be pioneered for use in other patient groups. In addition, reducing SSI rates will shorten the postoperative recovery time of patients and reduce hospital costs.
224311848|NCT03846583|DRUG|Aromatase Inhibitor|These drugs act by lowering the amount of estrogen produced by the body by blocking an enzyme called aromatase
223611346|NCT05463081|DIAGNOSTIC_TEST|Clinical urine test|Urine sampling for Clinical urine test (to include the participant in the study).
223611347|NCT05463081|DIAGNOSTIC_TEST|Vaginal smear|Vaginal smear for flora investigation (to include the participant in the study and evaluate procedure efficiency)
223611348|NCT05463081|DIAGNOSTIC_TEST|Pelvic ultrasound|Pelvic ultrasound investigation to determine pathologies of the pelvic through a gynecological probe (to include the participant in the study).
223611349|NCT05463081|OTHER|Female Sexual Function Index|Female Sexual Function Index will be used to collect feedback on changes in the participants life quality (to evaluate procedure efficiency).
223611350|NCT05463081|OTHER|International Consultation on Incontinence Questionnaire - Short Form|International Consultation on Incontinence Questionnaire will be used to collect feedback on changes in the participants' life quality (to evaluate procedure efficiency).
223611351|NCT05463081|OTHER|The Short Form Health Survey|The Short Form Health Survey will be used to collect feedback on changes in the participants' life quality (to evaluate procedure efficiency).
223611352|NCT05463081|DIAGNOSTIC_TEST|Vaginal Health Index|Vaginal Health Index will be investigated by clinical examination for vaginal elasticity, vaginal secretions, epithelial mucous membrane, vaginal hydration. Potential of hydrogen (pH) will be investigated by test-lines paper (to evaluate procedure efficiency).
223611353|NCT05463081|DIAGNOSTIC_TEST|Vital signs determination|Vital signs determination (respiration rate, blood pressure, pulse rate, body temperature).
223611354|NCT05463081|DIAGNOSTIC_TEST|pH of vagina determination|Potential of hydrogen (pH) of vagina will be investigated by test-lines paper (to evaluate procedure efficiency).
223611355|NCT05463081|DIAGNOSTIC_TEST|Physical parameters determination|Physical parameters determination (body weight, age, height, body mass index).
223611356|NCT02905266|BIOLOGICAL|Nivolumab|-Specified dose on specified days
223611357|NCT02905266|BIOLOGICAL|Ipilimumab|-Specified dose on specified days
223611358|NCT01669317|OTHER|8-ounce glass of cherry juice|You will be given an 8-ounce glass of cherry juice or artificial cherry juice to drink when you arrive at the Sleep Laboratory.
223611359|NCT01669317|OTHER|Artificial Cherry Juice|You will be given an 8-ounce glass of artificial cherry juice
223611360|NCT00241722|DRUG|Alvimopan|
223611361|NCT00241722|DRUG|Placebo|
223611362|NCT06312657|BEHAVIORAL|Drug Cue|Individualized drug cues paired with choice options reinforced by $0.25
223611363|NCT06312657|BEHAVIORAL|Money|Two money values will be tested ($0.25 and $4.00)
223611364|NCT06312657|DRUG|Withdrawal|Participants will be maintained on an opioid agonist. Placebo will be substituted to produce mild-to-moderate withdrawal.
223611365|NCT04871425|DRUG|Ketamine|IV ketamine
223611366|NCT04871425|DRUG|Fentanyl|IV fentanyl
223611367|NCT03149172|DEVICE|Equimatrix®|Ridge preservation bone grafting after tooth extraction
223611368|NCT03149172|DEVICE|Bio-Oss®|Ridge preservation bone grafting after tooth extraction
223611369|NCT03149172|DEVICE|Endobon®|Ridge preservation bone grafting after tooth extraction
223611370|NCT03291483|OTHER|whole body vibration|whole body vibration is a mechanical stimulus characterized by oscillatory movements.Whole body vibration's potential beneficial effects occurs by transmission of mechanical and sinusoidal vibrations to the whole body through the feet.
223611371|NCT03291483|OTHER|plyometric training|Plyometric exercises refers to performance of stretch-shortening cycle (SSC) movements that involve a high-intensity eccentric contraction immediately after a rapid and powerful concentric contraction.
223611372|NCT03796117|DEVICE|Pulsed current|"For stage 1 of the study, which corresponds to analysis of the evoked torque, evaluation of the discomfort level, current intensity, analysis of neuromuscular efficiency and clinical efficiency, 2 configurations (PC1 and PC2) will be used.~PC1, will be set at a frequency of 100 Hz, phase duration of 1000 microseconds, ON-OFF time of 5s:10s.~PC2, will be set at a frequency of 100 Hz, phase duration of 200 microseconds ON-OFF time of 5s:10s.~For stage 2 of the study, which corresponds to the analysis of the fatigability level, only the PC1 configuration will be used."
223611373|NCT03796117|DEVICE|Russian Current|"For stage 1 of the study, which corresponds to analysis of the evoked torque, discomfort level, current intensity, neuromuscular efficiency and clinical efficiency, 2 configurations (RC1 and RC2) will be used.~RC1, will be set to a frequency of 100 Hz, burst duty cycle of 20%, ON-OFF time of 5s:10s.~RC2, will be set at a frequency of 100 Hz, burst duty cycle of 50%, ON-OFF time of 5s:10s.~For stage 2 of the study, which corresponds to the analysis of the fatigability level, only the RC2 configuration will be used."
223611374|NCT02292719|DRUG|OBV/PTV/r|Tablet
223611375|NCT02292719|DRUG|Sofosbuvir|Tablet
223611376|NCT02292719|DRUG|Ribavirin (RBV)|Tablet
223757592|NCT01147991|BIOLOGICAL|EBNA1 C-terminal/LMP2 chimeric protein-expressing recombinant modified vaccinia Ankara vaccine|
223757593|NCT01147991|OTHER|laboratory biomarker analysis|
223757594|NCT01147991|OTHER|pharmacological study|
223757595|NCT01290848|BEHAVIORAL|Take TIME Health Campaign|"1. Provision of free, family-based events, at least twice per month, that offer opportunities for physical activity and/or healthy eating in a safe, tobacco-free environment.~2. Information dissemination, via project web site, media and other formats, on how to achieve a healthier lifestyle with the already hectic family schedules.~3. Adoption of guidelines by community organizations and the Township of Uxbridge that will reduce tobacco exposure, increase safety and promote physical activity and healthy eating for young children."
223757596|NCT05572619|DEVICE|1st Reading|The medical team visually checks the non-contrast CT without cELVO and diagnose the large vessel occlusion.
223757597|NCT05572619|DEVICE|2nd Reading|The medical team visually checks the non-contrast CT with assistance from the cELVO and diagnose the large vessel occlusion.
223757598|NCT01308190|DRUG|Capecitabine (Xeloda)|Capecitabine 825 mg/m2 every 12 hours orally on days of radiotherapy
223757599|NCT01308190|RADIATION|50.4 Gy|Radiotherapy was administered in daily fractions of 1.8 Gy 5 days a week according to standard schema. The total dose is 45 Gy plus a boost of 5.4 Gy to the tumor area
223757600|NCT01308190|PROCEDURE|Transanal Endoscopic Microsurgery|6-8 weeks after Chemoradiotherapy
223757601|NCT01308190|PROCEDURE|Total Mesorectal Excision|Standard surgical treatment of T2 , T3s, N0, M0 rectal cancer. Early after diagnosis
223611377|NCT02538042|DRUG|Nicotine Patch|Both groups will receive nicotine patches (21 mg/d if smoking ≥10 cigs/d or 14 mg/d if smoking \<10 cigs/d) to wear for 3 weeks prior to the quit date. After the quit date, both groups will wear the nicotine patch for 10 weeks. Participants that smoked ≥10 cigs/d will wear a 21 mg/d patch for 6 weeks, a 14 mg/d patch for 2 weeks, and a 7 mg/d patch for 2 weeks. Participants that smoked \<10 cigs/d will wear a 14 mg/d patch for 6 weeks, then step down to a 7 mg/d patch for 4 weeks.
223611378|NCT02538042|DRUG|SPECTRUM Nicotine Research Cigarettes (0.07 mg)|For 3 weeks prior to their quit day, participants will switch to smoking SPECTRUM Nicotine Research Cigarettes instead of their usual brand.
223611379|NCT02538042|BEHAVIORAL|MCE+|During the 3-week, pre-quit period, participants will undergo six, 60 minute sessions during which they will view smoking-related environments and smoke their assigned cigarettes.
223611380|NCT02538042|BEHAVIORAL|MCE-|During the 3-week, pre-quit period, participants will undergo six, 60 minute sessions during which they will view nature environments and smoke their assigned cigarettes.
223611381|NCT04936061|DEVICE|CoolStat active device|The CoolStat active device will administer a therapeutic flow of dry air into the nostril.
223611382|NCT04936061|DEVICE|CoolStat sham device|The CoolStat sham device will administer a sham flow of ambient air into the nostril.
223757602|NCT01427088|DEVICE|CR Technology, TAMAS for repetitive TMS|repetitive TMS, lef DLPFC, 20Hz, 100% of MEP, 2weeks
223757603|NCT03093675|DEVICE|TELELAP ALF-X Robotic Surgical System|The surgical procedures will be performed using the innovative TELELAP ALF-X robotic system, equipped with multiple independent arms. Initial entry will be through a classic open in which the arm with the video camera will be inserted. The device has four independent arms (one for the video camera and three for surgical instruments). Patients will be in the lithotomy position, supported by Allen stirrups and under general anesthesia. The uterus will be manipulated with a multi-use uterine manipulator. After having induced a pneumoperitoneum, high-definition 3D-technology optics will be inserted. Three laparoscopic instruments will be used to complete the procedure. Standard techniques will be used.
223757604|NCT01041716|OTHER|None - Observational study|None - Observational study
223757605|NCT02142166|PROCEDURE|Biomarker in serum, liquor, micro-dialysate|Daily (21 days) analysis of biomarker in serum, in liquor and in micro-dialysate
223757606|NCT02142166|PROCEDURE|Biomarker in serum and in liquor|Single analysis of biomarker in serum and liquor
223611383|NCT05801666|OTHER|Acupuncture|Acupuncture 5 points
223611384|NCT03026881|DRUG|Fluzoparib|Fluzoparib either at 20,30,40mg twice daily,capsule oral.
223611385|NCT03026881|DRUG|Apatinib|Oral
223611386|NCT03026881|DRUG|Paclitaxel|Intravenous injection
223757607|NCT00963573|DRUG|Loratadine|loratadine/betamethasone oral solution (1 mg/0.05 mg/1 mL), at a dose of 10 mg/0.5 mg
223757608|NCT00963573|DRUG|Betamethasone|loratadine/betamethasone oral solution (1 mg/0.05 mg/1 mL), at a dose of 10 mg/0.5 mg
223757609|NCT00838266|DRUG|mouthrinse (Grape Seed Extract + nicomethanol fluorhydrate)|Antiplaque mouthrinse containing active component three times a day, during 1 minute, for 4 days
223757610|NCT00838266|OTHER|mouthrinse containing non-active component|Antiplaque mouthrinse containing non-active component three times a day, during 1 minute, for 4 days
223757611|NCT00072150|DRUG|bortezomib|Given IV
223611387|NCT05989880|DEVICE|SafeLM as a supraglottic airway device with video capability|The device will be inserted using the video capability and used as a primary airway device for the duration of the surgical procedure. Once the device is in place, the cuff will be inflated with the recommended volume of air to ensure an adequate seal around the laryngeal opening. The position of the device will be confirmed by observing the video image of the glottis on the monitor. The adequacy of ventilation and oxygenation will be assessed by monitoring the patient's end-tidal CO2, pulse oximetry, and clinical signs of effective ventilation. Leak and cuff pressure will be assessed. The device will be removed at the end of the surgical procedure or if there are any signs of device malfunction, airway obstruction, or inadequate ventilation.
223757612|NCT00222456|BEHAVIORAL|Sensitizing parents|
223757613|NCT04441333|DEVICE|AspivixTM cervical vacuum tenaculum|Traction of the cervix for IUD insertion using the AspivixTM cervical vacuum tenaculum
223757614|NCT03227887|OTHER|Two samples of saliva|"1. Without stimulation : the 1st will be used to measure the flow of naturally secreted saliva~2. With stimulation: The 2nd will be used to measure the flow and viscosity of the saliva secreted after stimulation"
223757615|NCT03227887|OTHER|Chewing behaviour|Measure the time taken by the subjects to chew the food and the number of bites they use before swallowing The test will be done twice.
223757616|NCT03227887|OTHER|Study of the food bolus|"2 tests:~1. Evaluate using a compression test the structure of each bolus to determine their degree of destructuration over time Measure the quantity of the saliva incorporated~2. The bolus will be analysed visually"
223757617|NCT03227887|OTHER|Mouthfeel|Describe the mouthfeel by answering a paper questionnaire after consumption of the cereal products
224314272|NCT05651789|DRUG|Carvedilol|Carvedilol is started at a dose of 6.25mg/d, and titrated to a maximum dose of 12.5mg/d. Doses are increased 3 days later. Avoid systolic blood pressure \<90 mmHg.
223757618|NCT01746758|BEHAVIORAL|SMS text messaging referral|The text messaging system has been designed to use codes of reproductive health conditions and their treatments. Text messages are sent by drug stores and received at the dispensaries, forwarded by a bespoke software called Snapshot, which captures data online from any computer anywhere by use of a login for confidentiality.
223611388|NCT05989880|DEVICE|SafeLM as a supraglottic airway device without video capability|The device will be blindly inserted without using the video capability and used as a primary airway device for the duration of the surgical procedure. Once the device is in place, the cuff will be inflated with the recommended volume of air to ensure an adequate seal around the laryngeal opening. The position of the device will be confirmed by observing the video image of the glottis on the monitor. The adequacy of ventilation and oxygenation will be assessed by monitoring the patient's end-tidal CO2, pulse oximetry, and clinical signs of effective ventilation. Leak and cuff pressure will be assessed. The video capability of the device will be used to assess the accuracy of placement after the fact. The device will be removed at the end of the surgical procedure or if there are any signs of device malfunction, airway obstruction, or inadequate ventilation.
223611389|NCT05989880|DEVICE|SafeLM as a conduit for intubation using an endotracheal tube with video capability|The device will be inserted, and an endotracheal tube will be advanced through the device under direct visualization using the video capability of the device. Once the device is in place, the cuff will be inflated with the recommended volume of air to ensure an adequate seal around the laryngeal opening. The endotracheal tube will be introduced through the working channel of the SafeLM under direct visualization using the video capability of the device. The endotracheal tube will be advanced into the trachea, and the position will be confirmed by end-tidal carbon dioxide (EtCO2) detection and chest auscultation. The cuff of the endotracheal tube will be inflated, and mechanical ventilation will be resumed. The SafeLM device will be removed, and the position of the endotracheal tube will be confirmed once again.
223611390|NCT05989880|DEVICE|SafeLM as a conduit for intubation using a bougie with video capability|The device will be inserted. Once the device is in place, the cuff will be inflated with the recommended volume of air to ensure an adequate seal around the laryngeal opening.The position of the device will be confirmed by observing the video image of the glottis on the monitor. The video camera on the SafeLM will be turned on to visualize the vocal cords.A standard airway bougie will be introduced through the working channel of the SafeLM under direct visualization using the video capability of the device.The SafeLM device will be removed, and an appropriately sized endotracheal tube will be advanced into the trachea. If a bougie is not able to be inserted into the tracheal under direct visualization, direct insertion of an endotracheal tube into the trachea will be attempted, followed by flexible scope intubation.
223611391|NCT00034294|DRUG|GT160-246|
223611392|NCT04676620|PROCEDURE|CK surgery|CK and LASIK are both effective methods for the correction of hypeopia. They have been proved to offer many advantages in terms of visual acuity, corneal sensitivity, and corneal biomechanics compared with traditional refractive surgeries.
223611393|NCT01187628|DRUG|Fosrenol (Lanthanum Carbonate, BAY77-1931)|Daily dose: 750-2250mg/day,(270-750mg each 3 times a day) for 52 weeks.
223611394|NCT01059734|GENETIC|DNA analysis|
223611395|NCT01059734|GENETIC|RNA analysis|
223611396|NCT01059734|GENETIC|mutation analysis|
223611397|NCT01059734|GENETIC|polymerase chain reaction|
223611398|NCT01059734|GENETIC|polymorphism analysis|
223611399|NCT01059734|OTHER|laboratory biomarker analysis|
223611400|NCT04327570|OTHER|Patient sampling|Blood draw, NP/rectal swab, bronchoscopy if clinically indicated, lung tissue if applicable
223611401|NCT03136016|BEHAVIORAL|educational activities|Group 2 will receive classroom-based educational activities based on an earlier study, called PAPPAS, which was developed in the same city and constituted a school-based intervention with the objective of reducing the consumption of sweetened beverages and biscuits and increase the consumption of fruits, vegetables and beans
223611402|NCT03136016|BEHAVIORAL|nudging|In group 3, changes in the environment will be included that will facilitate both physical activity and healthy food choices
223611403|NCT03136016|BEHAVIORAL|nudging + educational activities|Group 4 will receive both interventions
224201272|NCT06723119|OTHER|Resveratrol (VRES) 500 mg oral once daily.|Resveratrol supplement will be provided in capsule form within a distinctly labeled bottle. Participants will be instructed to consume 2 capsules (500mg) of their assigned supplement with at least 8oz of water immediately upon waking for 17 days.
223611404|NCT04931069|OTHER|Microbiota analysis|Microbiota analysis will be carried out on different samples: blood, stool and saliva samples will be collected during the surgery, between 5 and 10 days after surgery and at 3 and 6 months after the surgery. Bile, pancreatic and intestinal mucosa samples will only be collected during the surgery.
223611405|NCT02220829|DRUG|Preventive administration of Rapaflo|Rapaflo treatment: 8 mg daily during 4 months and 8 mg every other day for 2 months.
223611406|NCT02220829|DRUG|Standard Care|Administration of alpha-blocker Rapaflo only at onset of symptoms.
223611407|NCT06251310|DRUG|SW-682|SW-682 tablet administered orally
224201273|NCT06723119|OTHER|Placebo 500 mg oral once daily.|Placebo will be supplement will be provided in capsule form within a distinctly labeled bottle. Participants will be instructed to consume 2 capsules (500mg) of their assigned supplement with at least 8oz of water immediately upon waking for 17 days.
224201274|NCT07048327|OTHER|No intervention (observational study)|No intervention (observational study)
223611408|NCT06251310|DRUG|Combination Therapy|Appropriate combination therapy
224201275|NCT07047248|DEVICE|PBM|A whole body red light therapy (NovoTHOR®) will be carried out during 20 minutes
224201276|NCT07047248|OTHER|Placebo PBM|A placebo whole body red light will be carried out during 20 minutes
224205930|NCT03107715|BEHAVIORAL|Breastfeeding Champion|iPad-based behavioral intervention facilitated by researcher
224205931|NCT03107715|BEHAVIORAL|Positive Messaging|iPad based behavioral intervention facilitated by researcher
223611409|NCT03575728|OTHER|MyChart-MHT|All participants in this study will receive targeted psycho-educational interventions from time to time based on symptom severity reports as determined by the software algorithm
223611410|NCT05317663|BEHAVIORAL|Test Health Warning Label (HWL)|Effect of Health Warning Label (HWL)
223611411|NCT05317663|BEHAVIORAL|Test without Health Warning Label (no-HWL)|Effect of no Health Warning Label (no-HWL)
223757619|NCT05262634|OTHER|Data collection (laboratory and obstetric results)|"Maternal data: age, pregnancy, parity, singleton or multiple pregnancy, BMI, obstetric history data, and ethnicity.~Laboratory chemical results: hemoglobin (Hb), number of erythrocytes, mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), number of hypochromic erythrocytes (HRC), erythrocyte distribution width (EBW), ferritin, C reactive protein (CRP).~Maternal pregnancy outcomes and complications: Hb before and after delivery, mode of delivery, placenta abruption, preeclampsia/eclampsia, gestational diabetes, gestational cholestasis, pregnancy-induced hypertension, bacteriuria or urinary tract infections, peripartum and postpartum hemorrhage, puerperal infections, uterine subinvolution.~Perinatal outcomes: gestational age, birth weight, intrauterine growth retardation, preterm birth, macrosomia, premature rupture of membranes, Apgar score, intrauterine fetal death, pH values, admission to neonatology"
223611412|NCT05842070|PROCEDURE|Low-Intensity Egg Freezing Protocol|The low-intensity egg freezing protocol involves fewer ultrasounds, bloodwork and injections, contributing to a lower cost. Otherwise, this protocol does not differ significantly from the other routine high-intensity clinic protocols.
223611413|NCT05842070|PROCEDURE|High-Intensity Egg Freezing Protocol|The high-intensity egg freezing protocol is a routinely used clinic protocol where patients are coming for frequent ultrasounds and bloodwork, as well as more injections, contributing to a higher overall cost for egg-freezing.
223611414|NCT02586727|DRUG|aflibercept|This study will consist of 2 simultaneous treatment arms of aflibercept: A six week dosing regimen arm and a treat and extend (TAE) dosing regimen arm, total duration 54 weeks. In the TAE arm the patients will receive an intravitreal aflibercept injection first visit, again at the second visit at 6 weeks, and then begin treat and extend from second injection forward.
223757620|NCT05022758|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|One of NOAC (Non-vitamin K antagonist oral anticoagulants)
223757621|NCT05022758|DRUG|Warfarin|One of OAC (Oral anticoagulation therapy)
223757622|NCT01661712|DEVICE|Transcutaneous electrical stimulation|Transcutaneous electrical stimulation (one night of electrical current titrated according to skin sensation)
223757623|NCT01661712|DEVICE|Sham stimulation|Sham stimulation for one night (no electrical stimulation)
223757624|NCT00743912|DRUG|rifaximin|550 mg TID
223757625|NCT01200875|PROCEDURE|Ultrasound-guided platelet-rich-plasma (PRP) injection|One ultrasound-guided intratendinous or intramuscular PRP injection
223757626|NCT01200875|PROCEDURE|Platelet-Rich Plasma (PRP)|One ultrasound-guided PRP injection
223757627|NCT00934544|DRUG|Ruxolitinib|5 mg tablets packaged as 60-count in high-density polyethylene bottles
223757628|NCT00934544|DRUG|Best Available Therapy (BAT)|Prescribing and usage per respective package inserts
223757629|NCT04033003|BEHAVIORAL|Group ANC|Intervention groups of up to 14 women of similar gestation age (10 to 20 weeks) for nine meetings. The first meeting is an individual meeting with the midwife and the standard history and physical exam as well as lab tests are completed. Group meetings are held once a month until 28 weeks of pregnancy, then every 2 weeks until 34 weeks of pregnancy, and the remaining group meetings are once a week. Prior to the start of each group, blood pressure, weight, and a urinalysis are measured for each woman.
223757630|NCT01191710|OTHER|In vitro fertilization|In vitro fertilization procedure with gonadotropin induced follicular ovarian stimulation
223757631|NCT02611258|DRUG|Tadalafil|Tadalafil 20 mg to be taken orally once daily, for 3 months
223611415|NCT04382885|DRUG|Cariprazine|Oral Solution
223611416|NCT03784677|DRUG|TRPV6 Calcium Channel Inhibitor SOR-C13|Given IV
223757632|NCT02312232|DRUG|levodopa, carbidopa, ODM-104|
224314273|NCT05651789|DRUG|Propranolol|Propranolol is started at a dose of 20 mg/d and the dose will be increased by 10 mg twice a day steps every 2-3 days until the target (heart rate: 55\~60 bpm) or to a maximum dose of 160 mg/d. Systolic arterial pressure is not less than 90 mm Hg and heart rate is not less than 50 bpm.
223611417|NCT00096980|DRUG|Raptiva (efalizumab)|
223611418|NCT01648972|DRUG|Gastrografin|
223611419|NCT01648972|DRUG|Placebo|
223611420|NCT04311762|DRUG|cisplatin|Intratumoral delivery of cisplatin via bronchoscopy (endobronchial ultrasound)
223611421|NCT03554928|DIAGNOSTIC_TEST|magnetic resonance imaging|Participants will receive a 60 minute magnetic resonance imaging assessment
223611422|NCT03822767|BIOLOGICAL|sIPV-sIPV-bOPV vaccination schedule|Two intramuscular injections of the investigational vaccine (0.5 ml) on Day 0 and Day 30 respectively; Single dose of bOPV (0.1 ml) on Day 60. The investigational Sabin strain inactivated poliovirus vaccine (Vero cell)(sIPV) was manufactured by Sinovac Biotech Co., Ltd . The poliovirus (Live) vaccine type I \& type III (Human Diploid cell) ( bOPV) was manufactured by Beijing Bio-institute Biological Products Co., Ltd.
223611423|NCT03822767|BIOLOGICAL|wIPV-wIPV-bOPV vaccination schedule|Two intramuscular injections of the control vaccine(0.5 ml) on Day 0 and Day 30 respectively; Single dose of bOPV (0.1 ml) on Day 60. The investigational Sabin strain inactivated poliovirus vaccine (Vero cell)(sIPV) was manufactured by SANOFI PASTEUR S.A. The poliovirus (Live) vaccine type I \& type III (Human Diploid cell) ( bOPV) was manufactured by Beijing Bio-institute Biological Products Co., Ltd.
223757633|NCT03465293|OTHER|Bacterial composition and activity after bowel preparation|Bacterial composition and activity and patient's symptoms will be assessed pre and post bowel preparation taken as part of the preparation to have a pre-planned colonoscopy
223757634|NCT04322396|DRUG|Azithromycin|Azithromycin
223757635|NCT04322396|DRUG|Hydroxychloroquine|Hydroxychloroquine
223757636|NCT04322396|DRUG|Placebo oral tablet|Placebo Azithromycin
223757637|NCT04322396|DRUG|Placebo oral tablet|Placebo Hydroxychloroquine
223757638|NCT04061694|PROCEDURE|Immediate loading, fully guided surgery and 3D printed restoration|Fully guided surgery installation of single dental implants. 3D printed restorations that were immediate loaded.
223757639|NCT04061694|PROCEDURE|Immediate loading|Only subjected to immediate loading. Conventional procedure.
223757640|NCT00392613|PROCEDURE|Strict versus lenient rate control|
223757641|NCT02487394|PROCEDURE|Exhaled Breath Condensate (EBC)|Collection of EBC condensate
223757642|NCT01406821|PROCEDURE|Ultrasound-guided platelet-rich-plasma (PRP) injection|Blood will be drawn, and platelet-rich plasma will be injected into the tendon under ultrasound guidance.
223757643|NCT01406821|PROCEDURE|Ultrasound-guided dry needling|Blood will be drawn, and tendon will be penetrated with dry needle under ultrasound guidance. Nothing will be injected into the tendon.
223611424|NCT04514822|DIAGNOSTIC_TEST|Dynamic PET|After transmission CT scan for subsequent PET data attenuation correction, continual dynamic clinical PET scans were performed in a single bed position immediately after 18F-FDG intravenously injection (210 ± 30 MBq) in list mode for 60 minutes in supine position, dynamic 48 time frames PET/CT imaging was obtained.And then underwent whole body static PET scan.
223757644|NCT02575781|DRUG|SAR428926|Pharmaceutical form:concentrate for solution for infusion Route of administration: intravenous
223757645|NCT00280254|PROCEDURE|Hemodynamically Oriented Echocardiography-based Strategy|
223757646|NCT03722329|DRUG|Eculizumab|Eculizumab Injection. 300 mg, single dose
223611425|NCT03203083|OTHER|performance of the single leg squat task|The single-leg squat (SLS) is a clinical functional test commonly used to evaluate clinical abnormal movement patterns of the lower limbs in terms of kinetic chain or co-ordinating muscle activity. This scale accounts for the assessment of five dimensions: overall impression, trunk posture, pelvis in space, hip joint motion and knee join motion. The SLS is potentially promising as a functional test since it involves both daily activity and athletic task.
223611426|NCT04090411|DRUG|Induction- PF-06480605 50 mg SC Q4W|PF-06480605
223611427|NCT04090411|DRUG|Induction- PF-06480605 150 mg SC Q4W|PF-06480605
223611428|NCT04090411|DRUG|Induction- PF-06480605 450 mg SC Q4W|PF-06480605
223611429|NCT04090411|OTHER|Induction- Placebo SC Q4W|0 mg Placebo
223611430|NCT04090411|DRUG|Chronic- PF-06480605 50 mg SC Q4W|PF-06480605
223611431|NCT04090411|DRUG|Chronic- PF-06480605 150 mg SC Q4W|PF-06480605
223611432|NCT04090411|DRUG|Chronic- PF-06480605 450 mg SC Q4W|PF-06480605
223611433|NCT01849406|DRUG|nasal spray Budesonide|one week therapy of nasal budesonide twice per day
223757647|NCT04313920|OTHER|Nutritional Supplement|50 g Carbohydrate
223757648|NCT04135716|DIAGNOSTIC_TEST|Colonoscopy with assistance of Endo.Angel|Patients in exposed group will receive colonoscopy with assistance of Endo.Angel,a real-time quality monitoring system based on computer vision,which is used to monitor the velocity of insertion of the endoscope, record the time of insertion and withdrawal of the endoscope, and remind endoscopists of the blind areas caused by intestinal segment slipping.
223757649|NCT04135716|DIAGNOSTIC_TEST|Colonoscopy without assistance of Endo.Angel|Patients in non-exposed group will receive colonoscopy without assistance of Endo.Angel.
223757650|NCT00052845|DRUG|docetaxel|70 mg/sq m IV infusion over 1 hour Day 2 of ea cycle
224201277|NCT07047560|DRUG|fractionated liposomal irinotecan (II)-based combination chemotherapy (FOLFIRInali-3) plus bevacizumab (Bev)|"Liposomal irinotecan (II): 30 mg/m² IV on D1 and D3, Q2W; Fluorouracil (5-FU): Q2W;~* 400 mg/m² IV bolus on D1~* Followed by 2400 mg/m² continuous IV infusion over 46-48 hours Leucovorin (LV): 400 mg/m² IV infusion on D1 Bevacizumab: 5 mg/kg IV infusion on D1, Q2W."
223611434|NCT01849406|DRUG|Nasal spray Normal Saline|one week therapy of nasal normal saline twice per day
223611435|NCT00756418|DRUG|montelukast|montelukast 5 mg QD 4-weeks.
223611436|NCT00756418|DRUG|Theophylline|Theophylline 100 to 200 mg BID 4-weeks.
223611437|NCT04370613|BEHAVIORAL|Prospective Imagery visualization task|Participant visualizes brief mental imagery of prospective situations of different valence (neutral, positive, negative).
223611438|NCT02699320|OTHER|Complications|Not involved
223611439|NCT03612336|OTHER|ENDS (vaporizer/e-cig) and smoking cessation counseling|Participants in the intervention group will receive an ENDS and nicotine-containing e-liquids, which they will be allowed to use ad libitum. Additionally, they will receive smoking cessation counseling. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 24-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6, 12 and 24 months, participants will be asked to come to a clinical visit.
223757651|NCT00052845|DRUG|estramustine phosphate sodium|280 mg PO tid Days 1-5 of ea cycle
223757652|NCT00052845|DRUG|exisulind|Two 125 mg capsules PO bid Days 1-21 of ea cycle
223757653|NCT06278675|DEVICE|Acupuncture needles|"1. Experimental group: Sterile stainless steel needle electroacupuncture treatment was applied, and the acupuncture points were as follows: bilateral Zusanli (ST36), Neiguan (PC6), Hegu (LI4), Shaoshang (LU11), and Feng Long (ST40). 1 time a day, 30 minutes each time, for 7 days.~2. Control group: Placebo needles were applied, and the acupuncture points were as follows: bilateral Zusanli (ST36), Neiguan (PC6), Hegu (LI4), Shaoshang (LU11), and Feng Long (ST40). 1 time a day, 30 minutes each time, for 7 days."
223757654|NCT05928650|OTHER|Evaluation of menstrual function|Evaluation of serum estradiol levels and menstrual history characteristics between sprinters, long marathon runners and non-athletes.
223757655|NCT05329597|GENETIC|Genotyping|Genotyping is performed using the subjects' blood cells
223757656|NCT05227924|DEVICE|Total hip arthroplasty (primary or revision)|Total hip arthroplasty with at least one medical device from the SYMBOL range
224201278|NCT07047755|DRUG|Trastuzumab Rezetecan|Trastuzumab Rezetecan
223757657|NCT02897596|DRUG|Grazoprevir 100 mg/d 8 weeks|Patients with 1b HCV genotype will be received treatment with Grazoprevir (100 mg) during 8 weeks.
223757658|NCT02897596|DRUG|Elbasvir 50 mg/d 8 weeks|Patients with 1b HCV genotype will be received treatment with Elbasvir (50mg) during 8 weeks.
223757659|NCT02897596|DRUG|Grazoprevir 100 mg/d 12 weeks|Patients with 1a or 4 HCV genotype will be received treatment with Grazoprevir (100 mg) during 12 weeks.
223757660|NCT02897596|DRUG|Elbasvir 50 mg/d 12 weeks|Patients with 1a or 4 HCV genotype will be received treatment with Elbasvir (50mg) during 12 weeks.
223757661|NCT02567396|OTHER|Laboratory Biomarker Analysis|Correlative studies
223757662|NCT02567396|OTHER|Pharmacological Study|Correlative studies
223757663|NCT02567396|DRUG|Talazoparib|Given PO
223757664|NCT03076138|DEVICE|Gene-activated matrix (OCP + plasmid DNA with VEGF gene)|Bone grafting procedure with investigated medical device
223757665|NCT01529359|DIETARY_SUPPLEMENT|Lactibiane Tolerance|Probiotics combination 2 gelules per days during 6 weeks
223757666|NCT01529359|DIETARY_SUPPLEMENT|Placebo|Placebo 2 gelules per days for 6 weeks
224201279|NCT07047755|DRUG|Pertuzumab|Pertuzumab
224314274|NCT05026996|DRUG|Pelacarsen|Single subcutaneous injection of pelacarsen
224314275|NCT06246214|DEVICE|Blue Light Therapy|The BlueLT device is equipped with a narrow band short wavelength Light Emitting Diode (LED) - wavelength peak(λp) of \~470 nm (blue).
223757667|NCT01691027|BEHAVIORAL|Visuo-motor training|Participants will undergo training on three developed software modules on Samsung Galaxy Note Pro tablets to see their effect on low vision rehabilitation
223757668|NCT01010282|DRUG|Glycerin and Polysorbate 80 based artificial tear|1-2 drops in each eye, as needed, but at least twice daily
223757669|NCT01010282|DRUG|Formulation 1: Carboxymethylcellulose sodium, glycerin and Polysorbate 80, based artificial tear|1-2 drops in each eye, as needed, but at least twice daily
223757670|NCT01010282|DRUG|Formulation 2: Carboxymethylcellulose sodium, glycerin, and Polysorbate 80 based artificial tear|1-2 drops in each eye, as needed, but at least twice daily
223757671|NCT03848546|BEHAVIORAL|PDA|"Subjects receive personal dietary fiber advice to increase their fiber intake. This advice will be provided using an online web-portal, where subjects can choose high-fiber alternatives that closely match their own intake. The aim is to swap product for low in fiber for a high fiber alternative (such as white bread, whole wheat bread)."
223757672|NCT03848546|OTHER|Control (no intervention)|No intervention
223757673|NCT00782210|DRUG|Olodaterol (BI1744)|Comparison of low and high doses on efficacy and safety in COPD patients
223611440|NCT03612336|OTHER|Smoking cessation counseling|Participants in the control group will receive smoking cessation counseling only. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 24-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6, 12 and 24 months, participants will be asked to come to a clinical visit.
223611441|NCT00798525|DRUG|Argatroban|Argatra (Argatroban) will be diluted to 0.6 mg/ml and 0.5 µg/kg/min will be administered continuously in patients without liver disfunction. In patients with liver disfunction, defined by a bilirubin of \> 4mg/dl, argatroban will be administered as a continuous infusion of 0,25 µg/kg/min with a final concentration of 0,3 mg/ml.
223611442|NCT00798525|DRUG|Lepirudin|Refludan (Lepirudin) will be diluted to a final concentration of 0.1mg/ml and initiated as a continuous infusion of 5µg/kg/h in patients with continuous renal replacement therapy. In patients with moderate renal impairment (Creatinine ≥1,3 mg/dl) a final concentration 0,2 mg/ml of will be used to provide continuous infusion of 10 µg/kg/h. Patients without renal impairment (Creatinine \< 1,3 mg/dl) will receive a continuous infusion of 50 µg/kg/h by a final concentration of 1 mg/ml of Lepirudin.
223611443|NCT00365924|DRUG|Forteo|Open label single arm study with Forteo as an intervention
223757674|NCT00782210|DRUG|Olodaterol (BI1744)|Comparison of low and high doses on efficacy and safety in COPD patients
223757675|NCT00782210|DRUG|placebo|Olodaterol (BI1744) placebo inhaled orally once daily from the Respimat inhaler
224201280|NCT07048457|PROCEDURE|Radical cystectomy|The intervention in this clinical trial consists of definitive surgical management through radical cystectomy with bilateral pelvic lymph node dissection (PLND), urinary diversion, and metastasectomy of surgically resectable or previously radiated metastatic disease. Surgical approach may be either open or robotic, based on surgeon discretion and patient-specific factors. The PLND will be performed in a standard oncologic fashion, including dissection of the common iliac, external iliac, internal iliac, and obturator nodal basins bilaterally. In cases where metastatic lymph nodes are identified beyond these regions, the lymph node dissection may be extended to achieve gross resection of involved nodal disease within the abdomen or retroperitoneum.
223757676|NCT06466954|OTHER|Evaluating spinopelvic alignment parameters|Evaluation of thoracic kyphosis, lumbar lordosis, pelvic tilt, and pelvic torsion
224201281|NCT07048431|DIAGNOSTIC_TEST|Shear Wave Elastography Measurement|It is a non-invasive imaging technique used to evaluate tissue stiffness. This method involves the use of ultrasound-based shear wave elastography to assess bilateral tibial nerve, by measuring the speed of shear wave propagation through the tissue. Stiffness values are expressed in kilopascals (kPa).
223757677|NCT06466954|OTHER|Measuring uterine dimensions|Measurement of corpus length, corpus width, cervix length, and cervix width
223757678|NCT04400097|PROCEDURE|suture|suture methods of autograft conjunctival transplantation
223757679|NCT02627859|DEVICE|Durolane SJ|1ml single intra-articular injection in ankle
223757680|NCT05851352|DIAGNOSTIC_TEST|serum anti-endometrial antibodies|\- Take blood samples from patients to measure anti-endometrial antibody concentrations in the serum of women with endometriosis using human Endometrium Antibody, EMAb ELISA Kit .This assay employs the qualitative enzyme immunoassay technique
223757681|NCT04895384|DEVICE|Edwards ClearSight and Masimo SET|Placement of Edwards ClearSight and Masimo SET on the patient intraoperatively.
223757682|NCT00003589|DRUG|cisplatin|
223757683|NCT00003589|DRUG|gemcitabine hydrochloride|
223757684|NCT00003589|DRUG|paclitaxel|
223757685|NCT00964808|DRUG|Buprenorphine|Start: Day 0 (T=0), 10 micrograms/t until the day of discharge from the Hospital. New plaster at T= 7 days.
223757686|NCT00964808|DRUG|Oxycodone|Start: 10 hours (+/- 2 hours) after the operation. Dosage: 10 mg \* 2 pr. day until time to discharge from the Hospital or latest at day 12.
223757687|NCT00265616|DRUG|propofol|liquid, mg/kg.h, titrated after EEG
223757688|NCT00265616|DRUG|thiopental/pentobarbital|liquid, mg/kg.h, titrated after EEG
223757689|NCT00654381|DRUG|BI 1356|5 mg/daily
223757690|NCT00654381|DRUG|BI 1356|10 mg/daily
223757691|NCT00654381|DRUG|voglibose placebo|three times daily
223757692|NCT00654381|DRUG|BI 1356 placebo|once daily
224201282|NCT07047079|OTHER|Preoperative rehabilitation exercises + Usual care|"1. Preoperative rehabilitation exercises~   1. Intervention methods: At the time of admission, the investigator demonstrated the content of preoperative rehabilitation exercises and provided a guidebook. Participants exercise on their own for approximately 3-7 days from the day of admission to the day of surgery as directed by the investigator and the manual.~  2. Exercise content:~      * Pulmonary function exercises: including abdominal breathing exercises and effective cough learning.~     * Muscle strength exercises: including straight leg raises and lateral leg raises.~     * Knee range of motion exercises: including knee flexion exercises and knee extension exercises.~     * ankle pump exercise~2. Usual care: Provided by a ward nurse."
224314276|NCT06246214|DEVICE|ControlLT|The ControlLT (placebo) device is equipped with a dim long-wavelength enriched LED.
224314277|NCT02186834|DRUG|Selinexor|Selinexor orally as outlined in the study treatment arm.
223757693|NCT00654381|DRUG|voglibose|0.6 mg/daily
223757694|NCT05015491|BEHAVIORAL|Noom Healthy Weight Program|"The Healthy Weight program follows guidelines from the Obesity Society's 2013 Guidelines for the Management of Overweight and Obesity in Adults NIH Practical Guide on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults. Users are encouraged to log their weight (Weight Logging) at least 1x/week and log their food and beverages (Food Logging) daily. Exercise logging (steps via automatic collection or manually added) is done daily. The Noom Food color grading system is founded on calorie-density (Volumetrics diet, Barbara Rolls) and is a simple and effective method for creating long lasting changes in diet and food choice. Coaches are contacted via In-app messaging or phone communication."
223757695|NCT06457022|OTHER|Modified Constraint Induced Movement therapy|patient wears a restraint instrument in his unaffected hand, then applying massed practice to his affected upper extremity. The patient wears padded glove in his unaffected upper extremity for restraining the patient from using his unaffected upper extremity for about 3 hours per day including the treatment session and the home program. So, by this way the patient is reinforced to use his affected upper extremity during this period of time to achieve his activities of daily living. Finally, the total time, the patient spends it during the day wearing the glove should be recorded each day.
223757696|NCT06457022|OTHER|Dual task training in the form of cognitive - motor task|Verbal fluency: Ask the hemiparetic patient to title many words of specific type as fruits, vegetable or animals. Mental tracking: as the hemiparetic patient to subtract serial 3 between number 90 and 100.
223757697|NCT06457022|OTHER|Conventional physiotherapy rehabilitation program|Ultrasound on shoulder. Graduated active exercises for shoulder. Prolonged stretching for spastic muscles
223757698|NCT01782781|DRUG|ropivacaine, ketorelac and epinephrine|Active group
223757699|NCT01782781|DRUG|Placebo|Placebo group
223757700|NCT01894828|DIETARY_SUPPLEMENT|Nutritional supplements|Patients are asked to drink two 200ml bottles of nutritional supplement daily for 14 days before surgery
223757701|NCT02607514|BEHAVIORAL|hyperthermic yoga|heated yoga, 90-minutes
223757702|NCT00141063|DRUG|Focalin XR|
223757703|NCT04210154|DEVICE|Haemodiafiltration|pre-dilution and post-dilution Haemodiafiltration
223757704|NCT06032624|PROCEDURE|combined ultra-sound guided femoral and sciatic nerve block.|Femoral nerve block, The femoral area will be scanned behind the midpoint of the inguinal ligament and the depth of the image will be set at 3-5 cm, and a linear high frequency 8-12MHz) probe will be placed perpendicular to the course of the femoral nerve., the volume of 15 ml of bupivacaine will be injected to perform the block. Sciatic nerve block, A curvilinear low-frequency (3-9 MHz) probe will be used to do a scan of the sub-gluteal region below a line from the ischial tuberosity and greater trochanter which are seen as two hyperechoic bony prominences,A volume of 25 ml of bupivacaine will be injected to perform the block.
223757705|NCT03683134|BEHAVIORAL|Mediterranean diet|Participants will receive nutrition education and educational materials from a registered dietitian on patients on the patterns of a Mediterranean style diet. Seven education sessions will be delivered through an online platform. Participants will be asked to complete one education session per week for the first six weeks and the final session at week 9.
223757706|NCT03683134|DIETARY_SUPPLEMENT|Olive oil and mixed nuts|Participants in the Mediterranean diet group will receive 3 liters of extra-virgin olive oil and 3 pounds of mixed nuts (1.5 pounds raw almonds and 1.5 pounds raw walnuts) at baseline and at 6 weeks. Participants will be educated by oral and written means, on consumption goals of the nuts and olive oil.
223757707|NCT03683134|BEHAVIORAL|American Heart Association|Participants will receive nutrition education and educational materials from a registered dietitian on patients on the dietary recommendations from the American Heart Association for heart health. Seven education sessions will be delivered through an online platform. Participants will be asked to complete one education session per week for the first six weeks and the final session at week 9.
223757708|NCT06445335|DIAGNOSTIC_TEST|FibroScan|Performance of a FibroScan measurement.
223757709|NCT01437553|DEVICE|iMAP|IVUS and iMAP analysis for acute coronary syndromes
223757710|NCT06574230|OTHER|TRAINING PROGRAM|Each training session included a structured set of exercises aimed at enhancing these skills. For example, participants practiced precision drills to target specific areas of the dartboard, endurance drills to build stamina for longer games, and competitive exercises to simulate real-game conditions. This combination of theoretical knowledge, practical skill development, and strategic gameplay was designed to comprehensively improve the participants\&#39; dart-throwing abilities over the course of the program. A 12-week dart training program, with sessions conducted three times per week, each lasting 90 minutes. In the first week, participants received comprehensive theoretical and practical instruction covering the rules of the game, proper breathing techniques, and throwing mechanics. This initial phase was designed to ensure a solid understanding of the fundamentals before progressing to more advanced training.
223757711|NCT00826267|DRUG|lapatinib|lapatinib tablets 1500 mg daily
223757712|NCT00826267|DRUG|BIBW 2992|BIBW 2992 high dose once daily (allowed dose reduction to medium or low once daily in case of AE)
223757713|NCT00826267|DRUG|trastuzumab|trastuzumab 4mg/kg i.v. week 1, followed by 2mg/kg i.v. weekly
223757714|NCT04019912|OTHER|Gait Training plus music|GaitTrainer3 is a platform that integrates gait training via a treadmill and RAS. The device is indeed equipped with an instrumented deck that issues acoustic cues to determine the exact tempo and rhythm during gait training and visual real-time biofeedback to prompt patients to follow their gait pattern. In fact, the device provides online feedback, including step length, speed, and symmetry, to encourage patient progress and monitor patient performance. Patient footfalls were compared in real-time to the desired footfalls step by step and documented in a histogram.
223757715|NCT04019912|OTHER|Traditional Gait Training|The traditional training will be provided by a conventional treadmill.
223757716|NCT03624868|BEHAVIORAL|Tai Chi|See above description
223757717|NCT03624868|BEHAVIORAL|Wellness Education|See above description
223757718|NCT04809688|DIETARY_SUPPLEMENT|Saskatoon berry|Freeze dried Saskatoon berry (30 g) will be orally administrated daily for 10 weeks.
223757719|NCT04809688|DIETARY_SUPPLEMENT|Dried Saskatoon berry|Prediabetic patients (fasting glucose 5.6-6.9 mM/L, HbA1c 5.7-6.9%, or OGTT 2 h glucose 7.8-11 mM/L) will be randomized in two groups. One group participants will take 40g of dried Saskatoon berry/day for 12 weeks. Another group will take 40g of dried Saskatoon berry/day for 12 weeks,
224314278|NCT02186834|DRUG|Liposomal doxorubicin|Pegylated liposomal doxorubicin at a starting dose of 20 mb/m² as outlined in the treatment arm.
223757720|NCT02514356|BEHAVIORAL|Own adherence|In this intervention group, participants receive weekly SMS messages informing them of their adherence that week as measured by the wise pill device used by the participant.
223757721|NCT02514356|BEHAVIORAL|Own and group level adherence|In this intervention group, participants receive weekly SMS messages informing them of their adherence that week as measured by the wise pill device used by the participant. In addition, in the same message they are informed of the adherence demonstrated by the other participants
223757722|NCT05148481|DRUG|BIIB104|Administered as specified in the treatment arm
223757723|NCT05148481|DRUG|Placebo|Administered as specified in the treatment arm
223757724|NCT05010889|PROCEDURE|Peroral endoscopic myotomy (POEM)|POEM is performed as previously described by Inoue et al (Endoscopy 2010), including four main steps mucosal incision, submucosal tunneling, myotomy and mucosal entry closure.
223757725|NCT00044954|BIOLOGICAL|therapeutic allogeneic lymphocytes|
223757726|NCT00044954|DRUG|cyclosporine|
223757727|NCT00044954|DRUG|fludarabine phosphate|
223757728|NCT00044954|DRUG|mycophenolate mofetil|
223757729|NCT00044954|PROCEDURE|allogeneic bone marrow transplantation|
223757730|NCT00044954|PROCEDURE|peripheral blood stem cell transplantation|
223611444|NCT03741582|OTHER|TransMiCable|"TransMiCable will have one service line 3.43 km-long with four stations (El Tunal , Juan Pablo II , Manitas , and Paraiso, see highlighted stops in Figure 2). El Tunal is the station that connects to the city's bus rapid transit system. The planned capacity of TransMiCable is 3,600 persons per hour in 163 cabins or gondolas. Each cabin fits ten passengers, with space for wheelchairs and bicycles and will be equipped with free Wi-Fi. The expected travel time reductions from each station to portal El Tunal, through the shortest pathway, are: 26 minutes saved from Juan Pablo II station-from 32 to 6 minutes; 31 minutes saved from Manitas station-from 38 to 7 minutes and 49 minutes saved from Paraiso station-from 62 to 13 minutes 22. In conjunction with TransMiCable, urban projects will be implemented including the construction of parks, outdoor gyms, sport courts, community centers for children and older adults, a market, an administrative, and a tourism offices."
223611445|NCT03884790|DEVICE|surgical repair of long bone defects|"Current treatment of bone defects usually implies the use of bone grafts and/or biocompatible materials, to create a scaffold that bridges the defect, favoring the migration of cells from the neighboring tissues to fill the gap. Autograft and Allograft are the treatments most currently used for large bone loss, but both treatments have significant disadvantages. Different types of synthetic materials have been tested for repair of long bone gaps.~However, at the moment, there is not any bone substitute with the ideal/desirable osteoinductive, osteoconductive and mechanical properties. GreenBone Implant is a synthetic, acellular, reabsorbable, new generation bone graft, being suitable for surgical reconstruction of bone defects."
223611446|NCT03382990|DEVICE|DES or BMS|DES or BMS placement during the procedure of PCI in patients with AMI is depend on the operator's decision.
223611447|NCT04378270|DEVICE|PopSole™ Offloading Device|Specifically, the PopSole™ Offloading Device allows the provider to pop bubbles in the device (like popping paper or plastic bubble sheeting), thereby offloading the surgical area or area of pain. This customizable approach to offloading may increase compliance as it can easily fit in a normal walking shoe and is personalized for each patient. It can also be attached to a slide for use in the shower. Currently no post-operative devices for offloading the foot can be used in the shower.
223611448|NCT02726724|OTHER|5 observers|
223611449|NCT02726724|OTHER|1 observer|
223611450|NCT04944849|DIAGNOSTIC_TEST|Reaction Time Tests|While doing our research, the reaction time test in the Human Benchmark application, where the reaction time to many different stimuli on the computer can be evaluated, the Aim Trainer test and the auditory reaction time tests at https://playback.fm/audio-reaction-time will be applied.
223757731|NCT00044954|RADIATION|radiation therapy|
223757732|NCT03758638|BEHAVIORAL|Healthy Eating & Active Living Taught at Home|PAT National Center will train educators affiliated with PAT sites in HEALTH; among these, using the HEALTH training curriculum, which includes training materials, an \~8 hour training delivered through a synchronous web-based experience, and ongoing consultation. Participants at HEALTH sites receive usual care PAT+evidence-based life-style change strategies to prevent weight gain and promote weight loss embedded within and delivered as part of home visits. In addition to the usual care PAT curriculum content, goal setting related to healthy weight, and the importance of parental modeling of healthy eating and physical activity are incorporated throughout the discussion and visit. HEALTH will be delivered over 24 months via a (1) core and (2) maintenance phase. The visits begin with greater frequency, and taper. Consistent with PAT practice, the frequency and number of visits are determined by the family's needs and preferences.
223757733|NCT03758638|BEHAVIORAL|Usual Care|The Foundational (usual care) curriculum uses a strength-based, solution-focused model to provide parents with child development knowledge and parenting support, empowering parents as their child's first and most influential teacher.
223757734|NCT02623803|DRUG|Lidocaine|
223757735|NCT02623803|DRUG|Placebo D5W|
223757736|NCT02413827|DRUG|Combination of varlilumab and ipilimumab|"Eligible patients will receive assigned treatments once every 3 weeks for a total of 4 treatments.~Phase l dose: The planned dose of varlilumab will be dependent on the cohort assigned at enrollment. Varlilumab doses are 0.3 mg/kg or 3 mg/kg. Ipilimumab dose is 3 mg/kg."
223757737|NCT02413827|DRUG|Cohort A: varlilumab & ipilimumab; Cohort B: varlilumab, ipilimumab, CDX-1401 & poly-ICLC|"Eligible patients will receive assigned treatments once every 3 weeks for a total of 4 treatments.~Phase ll dose: The planned dose of varlilumab will be established from Phase I. Ipilimumab dose is 3 mg/kg. Patients assigned to receive CDX-1401 will receive a dose of 1 mg along with 2 mg poly-ICLC."
223757738|NCT01091792|DRUG|Bevacizumab|Bevacizumab every 2 weeks 10mg/kg beginning 2 weeks after start of Radiation Therapy
223757739|NCT01515683|BEHAVIORAL|Only support from an anaesthetic nurse on the surgery ward|Additional staff are only present if required by law.
223757740|NCT01515683|BEHAVIORAL|Support: a theatre nurse + an anaesthetic nurse|Theatre nurse stay with the patient, follow her to the operating table and stays with her until she is anaesthetized
223757741|NCT01515683|BEHAVIORAL|Support: a nurse from the ward + an anaesthetic nurse|A nurse from the ward follows the patient to the operating table and stays with her until she is anaesthetized.
223757742|NCT01515683|BEHAVIORAL|Optional relative supports|Optional relative follows the patient to the operating table and stays with her until she is anaesthetized
223757743|NCT06287346|DEVICE|dental implant|ceramic dental implant
223611451|NCT03399630|OTHER|Injection of Autologous Adipose Tissue|Injection of Autologous Adipose Tissue to study the safety and efficacy of treating osteoarthritis
223611452|NCT03399630|OTHER|Injection of lactated ringers|Injection of placebo lactated ringers to compare against the injection of autologous adipose tissue.
223611453|NCT04584437|OTHER|Infrared Energy and Dietary Supplement|Infrared Energy with a wavelength of 5 - 20 microns. Multivitamins and minerals including Vitamin C Supplements.
223611454|NCT06359613|DIETARY_SUPPLEMENT|nutrient rich food product|Cupcakes from flour blends of Sorghum, chickpea, Flaxseed and Almond will be prepared and flour concentration will be so adjusted to provide \>20% daily value of nutrients for children of 3-8 years of age. 2 cupcakes/ day, 35g each will be provided to participants for 12 weeks.
223611455|NCT06359613|DIETARY_SUPPLEMENT|food product|Cupcakes from usually used gluten free rice flour will be prepared. 2 cupcakes/ day, 35g each will be provided to participants for 12 weeks.
223611456|NCT00747084|PROCEDURE|Colonoscopy|The purpose of the study is to conduct an RCT study to determine the effectiveness of loading the sigmoid colon with warm water and warm water irrigation for dealing with colonic spasms in enhancing patient abdominal comfort during unsedated colonoscopy.
223611457|NCT01132313|DRUG|BI 207127|28 weeks, high dose, TID
223611458|NCT01132313|DRUG|BI 201335|40 weeks, QD
223611459|NCT01132313|DRUG|BI 207127|4 weeks, low dose TID
223611460|NCT01132313|DRUG|BI 201335|24 weeks, QD
223611461|NCT01132313|DRUG|Ribavirin|16 weeks, according to label
223611462|NCT01132313|DRUG|Ribavirin|28 weeks, according to label
223757744|NCT00134381|DRUG|Green Tea|Green tea product (EGCG or caffeine) in vehicle will be applied immediately after and at sequential time points after exposure of a 5x5-cm area of skin to a dose of UVB that is 0.5-2 times the subject's minimal erythema dose (MED)
223611463|NCT01132313|DRUG|Ribavirin|28 weeks, according to label
223757745|NCT00134381|DRUG|Placebo|Placebo (vehicle alone) will be applied immediately after and at sequential time points after exposure of a 5x5-cm area of skin to a dose of UVB that is 0.5-2 times the subject's minimal erythema dose (MED)
223757746|NCT04632251|DEVICE|SENSEI®|SENSEI® laparoscopic tethered gamma probe is an intra-operative laparoscopic gamma probe system
223611464|NCT01132313|DRUG|BI 207127|40 weeks, high dose, TID
223611465|NCT01132313|DRUG|BI 207127|24 weeks, very high dose, BID
223757747|NCT02750891|DRUG|DSP-7888|Phase1 portion: 1.75 or 3.5 mg/body, Id every 1-4 weeks Phase 2 portion: recommended phase 2 dose, Id every 1-4 weeks
223757748|NCT04066426|DRUG|naproxen sodium+codeine phosphate, naproxen sodium+dexamethasone, naproxen sodium, paracetamol|NSAID, steroid, opioid, paracetamol and combinations of this drugs can be used in temporomandibular disorders.
223757749|NCT01909661|OTHER|Damira/Celia peptide hydrolyzed casein|
223757750|NCT01909661|OTHER|Picot riz/Celia rice/Sanutri arroz|
223757751|NCT02852096|OTHER|Dual or Multiple Paraffin Blocks|Assessing Her2/Neu Expression in Gastric Cancer With Dual or Multiple Tumor Tissue Paraffin Blocks
224205932|NCT02392975|PROCEDURE|Fast MR|Enrolled subjects will undergo fast MR within 24 hours of CT completion. Subjects will be scanned using one of 2 Philips Ingenia MR 3T scanners. The estimated duration of the fast MR is less than 5 minutes, even if up to 2 sequences are repeated for motion.
223611466|NCT01132313|DRUG|BI 207127|16 weeks, standard dose, BID
223611467|NCT01132313|DRUG|BI 201335|24 weeks, QD
223757752|NCT02852096|OTHER|One Paraffin Blocks|Assessing Her2/Neu Expression in Gastric Cancer With One Tumor Tissue Paraffin Blocks
223757753|NCT01675882|BIOLOGICAL|Viaskin Peanut 50 mcg|Subjects epicutaneously administered for 24 hours every 24 hours with a patch containing 50 mcg peanut proteins as whole peanut extract
223757754|NCT01675882|BIOLOGICAL|Viaskin Peanut 100 mcg|Subjects epicutaneously administered for 24 hours every 24 hours with a patch containing 100 mcg peanut proteins as whole peanut extract
223757755|NCT01675882|BIOLOGICAL|Viaskin Peanut 250 mcg|Subjects epicutaneously administered for 24 hours every 24 hours with a patch containing 250 mcg peanut proteins as whole peanut extract
223757756|NCT01675882|BIOLOGICAL|Viaskin Placebo|Subjects epicutaneously administered for 24 hours every 24 hours with a patch containing a matching placebo formulation
223757757|NCT05080452|DIAGNOSTIC_TEST|Dynamic infrared thermography (DIRT)|Visualizing hot spots
223757758|NCT02795559|OTHER|Glucose|75g glucose dissolved in 300ml water
223611468|NCT01132313|DRUG|Ribavirin|48 weeks, according to label
223757759|NCT02795559|OTHER|Inulin|75g glucose plus 24g inulin dissolved in 300ml water
223757760|NCT02795559|OTHER|Resistant starch|75g glucose plus 28g resistant starch in 300ml water
223757761|NCT03741764|DEVICE|Vivosorb|Resorbable implant device
223611469|NCT01132313|DRUG|Ribavirin|40 weeks, according to label
223611470|NCT01132313|DRUG|BI 207127|16 weeks, high dose, TID
223611471|NCT01132313|DRUG|BI 207127|28 weeks, high dose, TID
223611472|NCT01132313|DRUG|BI 201335|28 weeks, QD
223611473|NCT01132313|DRUG|BI 201335|16 weeks, QD
223611474|NCT01132313|DRUG|Ribavirin|24 weeks, according to label
223611475|NCT01132313|DRUG|BI 201335|24 weeks, QD
223611476|NCT01132313|DRUG|BI 201335|28 weeks, QD
223611477|NCT01132313|DRUG|BI 207127|24 weeks, standard dose, BID
223611478|NCT01132313|DRUG|BI 201335|24 weeks, QD
223611479|NCT01132313|DRUG|BI 201335|16 weeks, QD
223611480|NCT01132313|DRUG|BI 207127|16 weeks, high dose, BID
223611481|NCT01132313|DRUG|BI 201335|24 weeks, QD
223611482|NCT01132313|DRUG|Ribavirin|16 weeks, according to label
223611483|NCT01132313|DRUG|Ribavirin|16 weeks, according to label
223611484|NCT01132313|DRUG|BI 207217|28 weeks, high dose BID
223611485|NCT01132313|DRUG|BI 201335|16 weeks, QD
223611486|NCT01132313|DRUG|BI 207127|24 weeks, high dose, TID
223611487|NCT01132313|DRUG|Ribavirin|48 weeks, according to label
223611488|NCT01132313|DRUG|BI 207127|4 weeks, high dose, TID
223611489|NCT01132313|DRUG|BI 201335|28 weeks, QD
223611490|NCT01132313|DRUG|Ribavirin|24 weeks, according to label
223611491|NCT01132313|DRUG|Ribavirin|24 weeks, according to label
223611492|NCT04041934|DIETARY_SUPPLEMENT|tryptophan|Each experimental session will be carried out over a week. Adolescents will take part randomly in three sessions. In order to limit inter-individual differences, the diet of the first 3 days will be fixed to the RDA followed by 3 days where dietary intake will be supplemented with different protein (PROT REF : ratio = 0,04 PROT1 : ratio = 0,07, session PROT2 : ratio = 0,11). Tryptophan (Trp) / Large neutral amino acids (Lnaa) ratio of proteins taken varies-double-blind between sessions. All proteins had the same dose and packages. Neither the researcher nor the participants were aware of the quality of the protein.
223611493|NCT04078347|PROCEDURE|Paravertebral block at T4 and T5 level|Paravertebral block is performed at T4 and T5 level under realtime ultrasound guidenance with 10ml of 0.5% ropivacaine for each block, respectively.
223611494|NCT04452019|DEVICE|Use of standard standing frame|Two training sessions in a standard standing frame, max 30 min. pr. session
223611495|NCT04452019|DEVICE|Use of a new device; Innowalk Pro|Two training sessions in Innowalk Pro, max 30 min pr. session
223611496|NCT05113446|DIAGNOSTIC_TEST|Delirium assessment using S-CAM|Twice a day, the rounds of nurses in shifts, 8:00 am - 10:00 am, 4:00 pm - 6:00 pm Trained research assistants assessed delirium using S-CAM
223611497|NCT04457232|PROCEDURE|Computed Tomography|Undergo PET/CT imaging
223611498|NCT04457232|OTHER|Gallium Ga 68 FAPi-46|Given IV
223611499|NCT04457232|PROCEDURE|Positron Emission Tomography|Undergo PET/CT imaging
223611500|NCT06066606|DRUG|Vilanterol and Fluticasone Furoate (low dose)|Participants are administered 25 µg of vilanterol + fluticasone furoate
223611501|NCT06066606|DRUG|Vilanterol and Fluticasone Furoate (high dose)|Participants are administered 100 µg of vilanterol + fluticasone furoate
223611502|NCT06066606|DRUG|Placebo|Participants are administered placebo
223611503|NCT00310089|BIOLOGICAL|filgrastim|
223611504|NCT00310089|BIOLOGICAL|pegfilgrastim|
223611505|NCT00310089|DRUG|cediranib maleate|
223611506|NCT00310089|DRUG|cyclophosphamide|
223611507|NCT00310089|DRUG|docetaxel|
223611508|NCT00310089|DRUG|doxorubicin hydrochloride|
223611509|NCT00310089|OTHER|laboratory biomarker analysis|
223611510|NCT00310089|PROCEDURE|conventional surgery|
223611511|NCT00310089|PROCEDURE|neoadjuvant therapy|
223611512|NCT03201419|DRUG|FE 201836|Oral solution for daily intake
223611513|NCT03201419|DRUG|Desmopressin|Desmopressin Orally Disintegrating Tablet (ODT)
223611514|NCT03201419|DRUG|Placebo oral solution|Manufactured to mimic experimental drug
223611515|NCT03201419|DRUG|Placebo ODT|Manufactured to mimic experimental drug
223611516|NCT01307436|BIOLOGICAL|Epaxal|0.25ml Epaxal: at least 12 IU hepatitis A antigen coupled to immunopotentiating reconstituted influenza virosomes (IRIV)
223611517|NCT01307436|BIOLOGICAL|Havrix 720|0.5ml Havrix 720: at least 720 EU hepatitis A antigen adsorbed onto aluminium hydroxide
223611518|NCT04342429|RADIATION|Proton-beam Therapy for Small Cell Lung Cancer|The goal of intensity-modulated proton therapy (IMPT) is to deliver radiation to the tumor while minimizing exposure to surrounding normal tissues.
223611519|NCT06683599|PROCEDURE|Apneic oxygenation|1 L/kg/min FiO2 1.0 low-flow nasal supplemental oxygen with conventional nasal cannula during tracheal intubation performed with a video laryngoscope with Miller-blade or Macintosh-blade size No. 0 or No. 1.
223611520|NCT07013136|DRUG|Folic Acid 5 MG|In this study, oral folic acid at 5 mg/d (\~83.3 μg/kg) is chosen. In a rat model of AKI with ischaemia-reperfusion, intraperitoneal injection of 5-methyltetrahydrofolate (5-MTHF) at 3 μg/kg body weight twice (30 min before ischaemia and 3 h after reperfusion) improved kidney function and alleviated oxidative stress within 24 hours. The average body weight is around 60 kg for Chinese. Considering the oral route often requires larger doses than injection to produce the same effect, oral folic acid at 5 mg/d (\~83.3 μg/kg) is chosen to test its effect on AKI. Depending on the clinical condition, the therapeutic dose of folic acid varies. For foetal support during pregnancy, daily doses of 1 mg of folic acid are recommended; for lowering homocysteine, up to 5 mg daily are generally used.
223611521|NCT05393661|OTHER|inpatient physical therapy poststroke|routine care
224201283|NCT07047079|OTHER|The navigator guides the whole process of preoperative rehabilitation exercise + Usual care|"1. The navigator guides the whole process of preoperative rehabilitation exercise~   1. On the day of admission, the same intervention as in the preoperative rehabilitation autonomous exercise group was added:~      * Exercise Verification: Subjects demonstrate prescribed exercises to ensure correct execution.~     * Education \& Rapport:The navigator establishes therapeutic rapport and provides essential disease education.~  2. During the preoperative period (admission to surgery), the navigator implements:~      * Daily Supervised Exercise: Two 20-minute face-to-face rehabilitation sessions in the patient's room daily.~     * Standardized Reminders:Daily exercise adherence reminders via We Chat at 19:00-20:00.~     * Comprehensive Support: assessing needs and connecting to resources,,offering psychosocial/emotional support ,verbal interpretation, addressing exercise barriers and developing self-management skills~2. Usual care: Provided by a ward nurse."
223611522|NCT07029724|DEVICE|TrueCPR Multisensory Feedback Device|TrueCPR (Physio-Control, Inc., Redmond, WA, USA) is a real-time CPR feedback device that provides both visual and auditory cues to support the delivery of high-quality chest compressions. The system consists of two pads (chest and back) that measure compression depth using electromagnetic signal transmission. The device offers auditory rate guidance via a metronome and visual feedback through a color display indicating the adequacy of compression depth and recoil. Performance data-including compression depth, rate, ratio, and the percentage of compressions that are too shallow or too deep-are recorded and analyzed using dedicated software. TrueCPR delivers multisensory feedback (auditory and visual) for both professional rescuers and trainees.
223611523|NCT07029724|DEVICE|Ambu Smartman ALS Pro+ (AW301) Simulation Manikin|The Ambu SmartMan ALS Pro+ (AW301) is an advanced simulation manikin designed to support training in both Basic and Advanced Life Support (BLS and ACLS). It features multiple operational modes, including feedback, skills, code, and application modules, with or without manikin dependency. The manikin provides real-time auditory feedback through an integrated metronome and allows online monitoring by instructors. It records performance metrics such as compression depth and rate, compression-to-decompression ratio, hand position accuracy, and number of compressions with leaning.
223611524|NCT07029724|DEVICE|Metronome|The Ambu SmartMan ALS Pro+ (AW301), which is an advanced simulation manikin, offers real-time auditory feedback via an integrated metronome function. Devices that provide only a fixed auditory tempo-such as a metronome-are generally classified as coaching devices, because they do not measure or analyze the user's actions during CPR.
223611525|NCT02728154|OTHER|Blood Sample|One tablespoon of blood will be drawn once during the study.
223611526|NCT02728154|OTHER|Stool Sample|One stool sample will be collected.
223757762|NCT02561975|OTHER|Double pulmonary diffusing|"Measure of double pulmonary diffusing will be done as the single-breath test: the patient will be seated and connected to device by an oral tip. Measure begins by a maximal inhalation of a gas mixture (0.28% of CO, 14% of He, 21% of O2,450 ppm of NO/N2 and 40ppm of NO).After, the patient will maintain an apnea of 4 secondes and will breathe out in oral tip until his residual capacity.~With the expired air, some parameters will be assessed:~* Alveolar volume (VA)~* Membrane ductance (Dm) and pulmonar capillary volume (values adjusted by Haemoglobin)~* Values of TLCO, TLCO/VA, TLNO, TLNO/VA Vc, Dm, Vc/VA, Dm/VA, TLNO/TLCO et Dm/Vc"
223611527|NCT06725251|BEHAVIORAL|Art Therapy|Dyads will take part in a portrait-making project utilizing a collage approach. Each participant (i.e. dementia diagnosed individuals and care partners) will be instructed to create a portrait of him/herself. Participants will be provided with a sample portrait as well as bins of materials. \]The intervention will be administered for 1 ½ hours weekly, at the same day/time, for 4 consecutive weeks.
223757763|NCT05017194|DRUG|Emodepside|Treatment with ascending doses of emodepside (from 5 mg to 30 mg) or albendazole (400 mg) or placebo.
223757764|NCT04508270|BEHAVIORAL|Early mobilization|Mobilization as soon as patients can, which is not limited on walking
223611528|NCT06725563|PROCEDURE|Endoscopically placed lumen-apposing metal stents for the treatment of IBD-strictures|We will apply standard procedures for endoluminal stenting. A therapeutic colonoscope will be advanced through the bowel up until the stricture. A guidewire will be passed through the lumen at the stricture site. LAMS will be used for strictures \&lt;6cm, with stents ranging in size from 10-16mm in diameter and up to 60mm in length. The stent will be deployed across the stricture with the assistance of endoscopic and fluoroscopic imaging. Individuals will undergo a repeat colonoscopy in 1-3 months to remove the stent.
223757765|NCT00810953|DRUG|Pentamidine|two dose of 6 mg/kg with or without standard chemotherapy.
223611529|NCT06727149|OTHER|Control Group|No intervention was performed to reduce pain, fear and anxiety in the control group
223611530|NCT06727149|OTHER|Virtual Reality Group|The children in the VR group were informed about the virtual reality glasses and told that they could remove the glasses at any time if they felt uncomfortable during the procedure
223611531|NCT06726252|DEVICE|FFR measurement and intravascular imaging|Participants undoing anticipated percutaneous coronary intervention will be performed wire-based FFR measurement, and intravascular imaging, including IVUS and integrated OCT-IVUS using a single cathete to assess the accurary of OUFR, using wire-based FFR measurement as the gold standard.
223757766|NCT05983718|DEVICE|Surgical Guide|For this case, after the patient is given anesthesia, the guide will be placed on the teeth. All the drillings will be performed through the guided path. There will be no need for raising flap according to flapless surgery. At the end of the operation, the operation site will be checked and hemostasis will be provided. The operator will record the operation in the source documentation. 2 ± 1 days later, a postoperative CT scan will be taken. A follow-up visit will be due 14 ± 2 weeks later, after the osseointegration period.
223757767|NCT05983718|PROCEDURE|Guide-pin-assisted Freehand surgery|The regular protocol of the implant surgery will be followed. Before the surgery begins, the patient will be given anesthesia to ensure they are comfortable and pain-free during the procedure. Doctors will go through the digital planning to understand the desired angulation. Then the bony bed will be prepared raising flap from targeted area. Then a guide-pin will be inserted by drilling and through radiographic image the direction will be confirmed. Following the hole of the guide-pin, the implant will be inserted. At the end of the operation, the raised flap will be sewn and hemostasis will be provided. The operator records the operation in the source documentation. 2 ± 1 days later, a postoperative CT scan will be taken. A follow-up visit will be due 14 ± 2 weeks later, after the osseointegration period.
223757768|NCT02984384|DRUG|Acetylsalicylic acid|The Aspirin intervention will be 81 mg enteral (by mouth, feeding tube or rectal) twice a day with no variation in dosing allowed.
223757769|NCT02984384|DRUG|Low Molecular Weight Heparin (LMWH)|The LMWH intervention will be 30 mg enoxaparin subcutaneous (under the skin) twice a day with variations in dosing allowed, per the standard of care at sites, as needed for patients who are very obese or exhibit renal dysfunction.
223757770|NCT00688480|DRUG|Placebo|1 capsule, orally for 9 months
223757771|NCT00688480|DRUG|Allopurinol|Allopurinol 300 mg once/day orally, 9 months
223757772|NCT00735371|DRUG|LDX 30 mg|Eligible subjects will be randomized in a 1:1:1:1 ratio to a daily morning dose of LDX (30, 50, or 70mg/day) or placebo for a double-blind stepwise forced dose titration (3 weeks) followed by a 1-week Dose Maintenance Period. The test product is LDX, available in 30, 50, and 70mg capsules. All test products will appear identical to placebo to protect the study blind.
223611532|NCT05283564|OTHER|Percussive Ventilation Breathhold SABR (PVB-SABR)|Number of lung cancer patients with successful administration of PVB technique in PVB-SABR treatment
223611533|NCT07064941|BEHAVIORAL|Exercise|Exercise for 30 min a day 5x a week with a choice between Aerobic or strength training. Subjects will choose an aerobic activity to perform 3x/week (e.g. brisk walking, hiking, jogging). They will start at 15-20 min/day depending on fitness level and build up by 5 min intervals/week as tolerated to 50 min/day or 150 min/week by 12 weeks. Subjects will choose strength exercises to perform 2x/week, on days separate from aerobic activity. They will start with 1-2 exercises (e.g. squats, lunges, planks with and without resistance) and gradually add exercises to include all muscle groups (arms, legs, chest, back, abdomen). Start with 2 sets of 10 reps, and work up to 3 sets of 15 reps of given exercises.
223757773|NCT00735371|DRUG|LDX 50 mg|Eligible subjects will be randomized in a 1:1:1:1 ratio to a daily morning dose of LDX (30, 50, or 70mg/day) or placebo for a double-blind stepwise forced dose titration (3 weeks) followed by a 1-week Dose Maintenance Period. The test product is LDX, available in 30, 50, and 70mg capsules. All test products will appear identical to placebo to protect the study blind.
224201284|NCT07048314|DRUG|Allogeneic adipose-derived mesenchymal stem cells (HB-adMSCs) at the doctor's office|2.00x10⁸ HB-adMSCs IV at the doctor's office.
223611534|NCT07066956|DEVICE|ATLAS 2030 Exoskeleton|They underwent intensive training with 4 weekly sessions during 6 weeks with the ATLAS 2030 exoskeleton, a wearable device that provides gait assistance through eight degrees of freedom, four for each leg, including hip, knee, and ankle rotations. During training sessions, participants were fitted with the exoskeleton and performed 25 minutes of automatic forward walking, 15 minutes of active forward walking, 15 minutes of automatic forward walking, 5 minutes of automatic backward walking, 5 minutes of active backward walking, and exoskeleton removal. During the walk, therapeutic activities based on therapeutic objectives were carried out according to the participants' abilities.
223611535|NCT07065708|DIAGNOSTIC_TEST|Visual biofeedback using transperineal ultrasound|Transperineal ultrasound with visual biofeedback
223611536|NCT07065708|DIAGNOSTIC_TEST|Transperineal ultrasound without visual biofeedback|Transperineal ultrasound without visual biofeedback
223611537|NCT07065123|OTHER|The population undergoing TAVR for aortic valve stenosis with outcomes of permanent pacemaker implantation and complete left bundle branch block after surgery|The population undergoing TAVR for aortic valve stenosis with outcomes of permanent pacemaker implantation and complete left bundle branch block after surgery
223611538|NCT06941415|DRUG|Bumetanide|Standard of care treatment with bumetanide (intravenous or oral administration) per treating clinician's orders
223611539|NCT06941415|DRUG|Furosemide|Standard of care treatment with furosemide (intravenous or oral administration) per treating clinician's orders
223611540|NCT06169111|BIOLOGICAL|REGulatory T cells in Autism induced by maternal Immune activation|REGulatory T cells in Autism induced by maternal Immune activation
223611541|NCT04880369|DIETARY_SUPPLEMENT|Soy isoflavones|Commercially available dietary supplement (capsule) containing 60 mg isoflavones (genistein, daidzein and glycitein).
223611542|NCT04880369|DIETARY_SUPPLEMENT|Lignans|Commercially available dietary supplement (capsule) containing 63 mg lignans (secoisolaricirecinol)
223611543|NCT04880369|DIETARY_SUPPLEMENT|Placebo|The placebo capsules are supplied and packaged by Region Hovedstadens Apotek (Denmark) and will contain lactose monohydrate, potato starch, gelatin, magnesium stearate and talc.
223611544|NCT06064383|DEVICE|suicide attacks|select the most common causes, risk factors, methods and circumstances surrounding suicidal attempts in children and adolescents at aaiut university children hospital
223611545|NCT04486872|BIOLOGICAL|Autologous humanized anti-CD19 and anti-CD20 dual specific CAR-T Cells|Autologous Humanized Anti-CD19 and Anti-CD20 Dual Specific CAR-T Cells injection. Within 3 to 5 days after the pretreatment, the subjects received a single A-02 reinfusion, the infusion dose of each group of subjects 1.00 × 10\^6/kg, 3.00 × 10\^6/kg or 5.00 × 10\^6/kg (if applicable), it is recommended to complete the infusion within 30 min after cell recovery.
223757774|NCT00735371|DRUG|LDX 70 mg|Eligible subjects will be randomized in a 1:1:1:1 ratio to a daily morning dose of LDX (30, 50, or 70mg/day) or placebo for a double-blind stepwise forced dose titration (3 weeks) followed by a 1-week Dose Maintenance Period. The test product is LDX, available in 30, 50, and 70mg capsules. All test products will appear identical to placebo to protect the study blind.
223757775|NCT00735371|DRUG|Placebo|Placebo will be identical to test product.
224201285|NCT07048314|DRUG|Allogeneic adipose-derived mesenchymal stem cells (HB-adMSCs) in the OR|100 million stem cells (1.00x10⁸ HB-adMSCs) in the corpora cavernosa of the penis suspended in a 4 cc of sterile saline. 50 million stem cells (5.0x 10⁷ HB-adMSCs) along the right neurovascular bundle and 50 million cell (5.0x 10⁷ HB-adMSCs) along the left neurovascular bundle of the penis suspended in a 4 cc of sterile saline during the surgery
224201286|NCT07048314|DRUG|Placebo in the OR|4 cc of saline solution in the corpora cavernosa of the penis and 4 cc of saline solution along the right and left neurovascular bundles of the penis during the surgery .
223611546|NCT01640444|DRUG|FOLFIRI + bevacizumab|"* Bevacizumab 5 mg/kg iv, followed by~* Irinotecan 180 mg/m2 iv administered over a period of 30-90 minutes, followed by~* Leucovorin (LV) 400 mg/m2 iv administered over a period of 2 hours, followed by~* 5-FU 400 mg/m2 iv bolus, followed by~* 5-FU 2,400 mg/m2 for 46 h continuous infusion. This treatment will start on day 1 and will be repeated every 2 weeks (1 cycle)."
223611547|NCT01640444|DRUG|FOLFIRI + cetuximab|"* Cetuximab in an initial 120-minute infusion on day 1 of 400 mg/m2, followed by 60-minute infusions of cetuximab at a dose of 250 mg/m2, once weekly~* FOLFIRI:~  * Irinotecan 180 mg/m2 iv administered over a period of 30-90 minutes, followed by~ * Leucovorin (LV) 400 mg/m2 iv administered over a period of 2 hours, followed by~ * 5-FU 400 mg/m2 iv bolus, followed by~ * 5-FU 2,400 mg/m2 for 46 h continuous infusion FOLFIRI will be given after the cetuximab infusion on day 1 of each period (every 2 weeks: 1 cycle)."
223611548|NCT00185575|DRUG|duloxetine|
223611549|NCT03108417|DEVICE|continuous negative external pressure|continuous negative external pressure will be applied to the anterior neck at night
223611550|NCT05268172|DRUG|IFN-γ and CIK cells, Tcm cells or CAR T cells|A 50ng/ mL IFN-γ solution was prepared, and the required volume of IFN-γ solution was calculated according to the final concentration of 5ng/ mL according to the volume of pleural fluid or ascites of the patient. CIK cells were injected 1.0-2.0×109 on the second day and review three days later.T cells and CAR T cells were selected sequentially according to the re-examination of pleural fluid or ascites.
223611551|NCT03360799|OTHER|Questionnaire Administration|Complete questionnaires
223611552|NCT00915707|OTHER|Baseline|Subjects are allowed time in bed for sleep as their usual time at home.
223757776|NCT00323973|DRUG|Bisoprolol|10 mg qd
223757777|NCT05763888|OTHER|No drug will given|No intervention will be given to the subject
223757778|NCT01554566|DIETARY_SUPPLEMENT|honey|The subjects in the I/C group consumed 0.5 ml honey/kg/day in the first 12-week period (period 1) while the subjects in the C/I group did not receive honey as a control in period 1. After period 1 the subjects of each group exchanged their protocol for the following 12-week period (period 2).
224201287|NCT07048314|DRUG|Placebo in clinic|30 mL syringe of the product should be mixed into a 250cc bag of sodium chloride solution 0.9% for infusion. should be administered intravenously, with a dosing rate of 4-5mL/min.
224314279|NCT02186834|DRUG|Dexamethasone|Participants will be instructed to take Dexamethasone 40 mg (10 tablets) orally once weekly with meals (ideally with breakfast to minimize insomnia). Participants older than 75 years and patients previously intolerant to 40 mg dosage will be allowed to receive 20 mg (5 tablets) once a week.
224314280|NCT06633341|BIOLOGICAL|CD5 CAR T-cells|Each subject receive CD5+ T-lymphoma Targeted CAR T-cells by intravenous infusion
223757779|NCT03941522|OTHER|Early discharge from hospital|Patients randomized to the group 23-hour stay will be discharged on the day after their surgery if they meet the discharge criteria.
223757780|NCT00994448|DRUG|Bupropion SR 150mg tabs|Bupropion SR 150mg tabs (Zyban) twice daily
223757781|NCT00994448|DRUG|Placebo tablets|One placebo tablet twice daily
223611553|NCT00915707|OTHER|Sleep restriction|Subjects sleep is reduced to 4.5 hours in bed for 4 nights.
223611554|NCT00915707|OTHER|Reduced Sleep Quality|Subjects sleep quality is reduced for 4 nights.
223611555|NCT00289926|DRUG|dehydroepiandrosterone|dehydroepiandrosterone capsules 50.0 mg /capsule DHEA 248.5 mg /capsule Microcrystalline Cellulose, NF 1.5 mg /capsule Magnesium Stearate, NF in a 60 mg Capsule
223611556|NCT00289926|DRUG|placebo|Placebo capsules of 298.5 mg /capsule Microcrystalline Cellulose, NF 1.5 mg /capsule Magnesium Stearate, NF in a 60 mg Capsule manufactured to mimic the active DHEA capsule
223611557|NCT02696759|OTHER|Blood & Fecal Collection|Prior to first dose of chemotherapy: (a) Blood sample for research; (b) Fecal sample for research using a kit provided by the research staff for home collection of the fecal sample. The kit may be brought back to the clinic or mailed in a discreet package; (c) Questionnaire on health related quality of life. During chemotherapy: Questionnaires on health related quality of life and regarding any treatment side effects. Questionnaires will be completed every 2 weeks during standard office visits. After chemotherapy, prior to surgery: (a) Blood sample for research; (b) Fecal sample for research using a kit provided by the research staff for home collection of the fecal sample. The kit may be brought back to the clinic or mailed in a discreet package.
223611558|NCT02632357|OTHER|Spinal Manipulation|
223611559|NCT03064971|BEHAVIORAL|Standard Care|Standard of care provided by QuitlineNC includes Quit Coaches, counseling calls, nicotine replacement therapy, and written materials
223757782|NCT02182375|DRUG|BI 201335 NA|
223757783|NCT02182375|DRUG|Raltegravir|
223757784|NCT03405142|DRUG|Panitumumab-IRDye800|Intravenous (IV) panitumumab-IRDye800 (50 mg) 1 to 5 days prior to surgery (lymphadenectomy). Panitumumab dose is \< 1/12 of the therapeutic dose.
223757785|NCT03405142|DRUG|Lymphoseek|Local, peri-tomoral injection with 2 mCi Lymphoseek (99mTc Tilmanocept) (as 4 x 0.1 mL injections of Lymphoseek solution
223757786|NCT04891848|OTHER|inflammation|inflammatory values in complete blood count (CBC)
223757787|NCT03962335|BEHAVIORAL|Vegetarian diet|7-days dietary profile with a Vegetarian diet (VD), containing inulin and resistant starch-rich foods and including no meat and fish, but containing eggs and dairy, for 3 months
223757788|NCT03962335|BEHAVIORAL|Mediterranean diet with butyrate|7-days dietary profile with Mediterranean diet with oral supplementation with butyrate (MD+Bt), 2 g/day, for 3 months
223611560|NCT03064971|BEHAVIORAL|smoking cessation DVD|"The evidence-based How to Quit DVD contains 60 minutes of smoking cessation information and strategies"
223611561|NCT03064971|BEHAVIORAL|PTF DVD|Culturally specific smoking cessation DVD. This DVD contains 60 minutes of material.
223611562|NCT00930878|DEVICE|Cardiac Stenting|Drug Eluting stent
223611563|NCT04842383|DRUG|Hemp Oil|Hemp oil extract rich in varins (THCV and CBDV) as well as cannabidiol (CBD) in combination with 3% peppermint oil extract
223611564|NCT02499705|DIETARY_SUPPLEMENT|Sucralose|2 packets
223757789|NCT03962335|BEHAVIORAL|Mediterranean diet|7-days dietary profile with Mediterranean diet (MD), including 2 portions per week of fish and 3 portions per week of fresh and processed meat (2 of which fresh or processed red meat), for 3 months
223757790|NCT00820612|DRUG|Indomethacin|100 mg PR once at the time of ERCP
223757791|NCT00820612|OTHER|Placebo suppositories|2 placebo suppositories at the time of ERCP
223757792|NCT01323075|PROCEDURE|Truncal block|Patients will have a truncal block during hand or wrist surgery.
223757793|NCT00436748|DRUG|Darbepoetin Alfa|Administered by subcutaneous or intravenous injection
223757794|NCT00436748|DRUG|Placebo|Matching placebo solution for subcutaneous or intravenous injection to maintain the blind in the Q2W arm.
223757795|NCT05188352|OTHER|Chest physiotherapy|The program included diaphragmatic breathing exercises, thoracic expansion exercises, incentive spirometer exercises, and coughing techniques.
224201288|NCT06742788|DEVICE|Transcutaneous Auricular Vagus Nerve Stimulation (taVNS)|"Transcutaneous Auricular Vagus Nerve Stimulation (taVNS) is an emerging, non-invasive adjunctive therapy.~The taVNS protocol is configured with a pulse width of 500 µs, a frequency of 25 Hz, and a current intensity titrated to each patient's pain tolerance threshold (range: 0.5-2.0 mA). The stimulation is to be carried out for a total of 1.5 hours daily, with the sessions divided into three parts, each lasting 30 minutes. At least one of these periods occur within 2 hours before bedtime.~The study will use the Chinese National Institutes for Food and Drug Control certificated taVNS device TVNS-100 (Xinzhile Medical Technology Co., Jiangxi, China). The study includes an intervening period of 4 weeks."
224314281|NCT04228835|DIAGNOSTIC_TEST|Fluorescence Cholangiography|Administration of ICG for fluorescence cholangiography
223611565|NCT02499705|DIETARY_SUPPLEMENT|Sucrose|equisweet to sucralose
223611566|NCT02499705|DIETARY_SUPPLEMENT|Sucralose + maltodextrin|sucralose plus equicaloric (to sucrose) maltodextrin
223611567|NCT03658447|DRUG|Pembrolizumab|200mg Pembrolizumab given 3 weekly for upto 35 cycles
223757796|NCT05188352|OTHER|Aerobic exercise training|"A treadmill was used for aerobic exercise. Training intensity was used at 60-75% of maximal VO2.~Each session had a five-minute warm-up and cool-down period. Blood pressure and ECG were recorded during training sessions before exercise, at the third minute of each workload, after exercise, and during each minute of the recovery period."
223757797|NCT02033733|DRUG|Cisatracurium infusion|"This group will include postcardiac arrest patients that have received a cisatracurium infusion as part of their therapeutic hypothermia protocol. It will only include patients that had their infusion started within 2 hours from protocol initiation. Patients that received an infusion as a rescue measure (beyond the first 2 hours) or did not receive and infusion at all will not be included in this group.~Most patients admitted to our ICU postcardiac arrest prior to October 2011, will likely belong to this group (the cisatracurium infusion group)."
223757798|NCT02033733|DRUG|Cisatracurium prn bolus|Patients that have not received a cisatracurium infusion within the first 2 hours from protocol initiation will be in this group. These are likely to be patients admitted to our ICU after October 2011 (when the protocol change happened).
223757799|NCT01610791|DRUG|tocilizumab [RoActemra/Actemra]|8 mg/kg iv every 4 weeks, total of 6 infusions
223757805|NCT04155515|DRUG|TG-2349|TG-2349 400mg
223757806|NCT04155515|DRUG|DAG181|DAG181 200mg
223757807|NCT04155515|DRUG|Ribavirin|Ribavirin 1000mg/1200mg
223757808|NCT00003082|BIOLOGICAL|monoclonal antibody A27.15|
223757809|NCT00003082|BIOLOGICAL|monoclonal antibody E2.3|
223757810|NCT04560634|DRUG|Norepinephrine|Norepinephrine is administered as a continuous infusion at 0.05 mcg/kg/min and is kept to maintain systolic blood pressure within 90-120% of baseline during spinal anaesthesia. The infusion is started at the same time cerebrospinal fluid is obtained, immediately before injection of spinal medications, through a small-bore tubing connected directly to the peripheral intravenous catheter. It is stopped 5 minutes
223757811|NCT04560634|DEVICE|ClearSight®, Edwards Lifescience, Irvine, CA|"All patients are connected to a ClearSight® monitor (ClearSight®, Edwards Lifescience, Irvine, CA) by an inflatable finger cuff placed on the midphalanx of hand middle or ring finger with no radial artery catheter and its heart reference system (HRS) is zeroed at the level of the patient's midaxillary line.~The ClearSight® monitoring is started in the pre-anaesthesia room and calibrated for 5 minutes before recording. The monitoring continues throughout the procedure until patient transfer in the recovery room. All data are anonymously collected on a USB pen for statistical analysis."
223757812|NCT00004903|BIOLOGICAL|filgrastim|
223757813|NCT00004903|BIOLOGICAL|recombinant interferon alfa|
223757814|NCT00004903|DRUG|cisplatin|
223757815|NCT00004903|DRUG|cyclophosphamide|
223757816|NCT00004903|DRUG|cytarabine|
223757817|NCT00004903|DRUG|etoposide|
223757818|NCT00004903|DRUG|melphalan|
223757819|NCT00004903|PROCEDURE|peripheral blood stem cell transplantation|
223757820|NCT06051058|BEHAVIORAL|Care Transitions App|Patients in the intervention arm will be randomized to receive the Care Transitions App and utilize it to support their care transition care plan for multiple chronic conditions.
223757821|NCT05892627|DIETARY_SUPPLEMENT|PoZibio|PoZibio (50 x 10\^9 CFUs/ CAPSULE)
223757822|NCT05892627|DIETARY_SUPPLEMENT|Placebo|Placebo
223757823|NCT01885481|DRUG|Dexamethasone|epidural steroid injection using dexamethasone
223757824|NCT01885481|DRUG|Betamethasone|epidural steroid injection using betamethasone
223757825|NCT02837536|OTHER|Horizontal iCare|IOP of the right eye will be measured using the iCare tonometer held in the horizontal position first and then in the vertical position.
223757826|NCT02837536|OTHER|Vertical iCare|IOP of the right eye will be measured using the iCare tonometer held in the vertical position first and then in the horizontal position.
223757827|NCT04883632|COMBINATION_PRODUCT|Saypha Volume Lidocaine|"correction of Nasolabial Folds using injection of Saypha Volume Lidocaine manufactured in 2 different plants at Croma Pharma.~The amount injected depended on the size of the area to be corrected and the desired level of soft tissue augmentation. It was estimated that a maximum volume of 4 mL per treatment was needed but should not have exceeded 10 mL in total per treatment or 20 mL per year. and use in respective indications. The investigational device was administered to eligible subjects on investigation Day 0. A touchup treatment at Week 2 was optional at the investigator's discretion if full correction was"
223757828|NCT02148328|BIOLOGICAL|Trivalent virosomal influenza vaccine|Trivalent virosomal influenza vaccine will be administered intramuscularly on Day 1 in healthy participants.
223757829|NCT02148328|BIOLOGICAL|Commercial vaccine 1|Trivalent commercial virosomal influenza vaccine will be administered intramuscularly on Day 1 in healthy participants.
223757830|NCT02148328|BIOLOGICAL|Quadrivalent virosomal influenza vaccine|Quadrivalent virosomal influenza vaccine will be administered intramuscularly on Day 1 in healthy participants.
223757831|NCT02148328|BIOLOGICAL|Commercial vaccine 2|Quadrivalent commercial influenza vaccine will be administered intramuscularly on Day 1 in healthy participants.
223757832|NCT05263999|BIOLOGICAL|Itolizumab|Itolizumab \[Bmab600\]
223757833|NCT05263999|DRUG|EQ001 Placebo|EQ001 Placebo
223757834|NCT00850200|RADIATION|Proton Radiation Plan|Between 21-39.6 Gy/CGE to the PTV
223757835|NCT00850200|RADIATION|Conventional Photon Radiation Plan|Between 21-39.6 Gy/CGE to the PTV
223757836|NCT00850200|RADIATION|Intensity Modulated Radiation Plan|Between 21-39.6 Gy/CGE to the PTV
223757837|NCT05459064|DEVICE|Motiva Flora TE|This is a retrospective, observational study - collecting data on patients who have gone through the staged procedure with the Motiva Flora Tissue Expander / Long-term breast implant.
223757838|NCT02711800|DRUG|Lactobacillus rhamnosus|The investigators will use Culturelle®, a probiotic composed of the micro-organisms Lactobacillus GG. This formulation has been used for the treatment of gastrointestinal inflammation in numerous clinical trials. Dosing will follow the manufacturer's recommendation for children (1 capsule/packet per day), and will be monitored by the study Co-PI, Dr. Seed. Weekly side effects and clinical changes will be monitored by both study therapist and caregiver using the Children's Global Assessment Scale and the Clinical Global Impression Scale (Severity, Improvement, and Efficacy). The treatment duration is 30 days.
223757839|NCT02956213|OTHER|HEPA portable air filter|A high efficiency (MERV17) portable air filter (HEPA portable air filter) will be placed in the subject's bedroom and will run 24/7 for the duration of the study.
223757840|NCT02956213|OTHER|Sham Control/Active Comparator|A portable air filtering device will be placed with no high-efficiency air filter, but only the basic carbon filter in place. Then at cross over, there will be an active HEPA portable air filter used
224205933|NCT02392975|PROCEDURE|Computed Tomography|The Investigator will recruit children in whom a head CT is ordered as standard of care for TBI. Consenting subjects will undergo fast MR shortly after CT and results will be compared.
224205934|NCT04205292|PROCEDURE|hysteroscopic|Women in the intervention group will receive an inpatient treatment with two-dose of Methotrexate followed by hysteroscopic resection under ultrasound guidance
223611568|NCT03658447|DRUG|177Lu-PSMA|6-weekly 177Lu-PSMA treatments for upto 6 cycles starting at 8.5GBq with administered radioactivity reduced by 0.5GBq for each cycle.
223611569|NCT01939184|DRUG|WC3055|12.5, 25, 50 or 75 mg dose
223611570|NCT01939184|OTHER|Placebo|Placebo
223611571|NCT05658705|PROCEDURE|15-min supine time|The length of preoperative supine time before AVS was 15 minutes.
223611572|NCT05658705|PROCEDURE|2-hour supine time|The length of preoperative supine time before AVS was 2 hours.
223757841|NCT00839839|PROCEDURE|Oocyte Vitrification|All oocytes retrieved will be vitrified (rapidly frozen) after egg retrieval. The oocytes will then be warmed on the same day and fertilized per standard IVF-ICSI. Resulting embryos will be transferred back to the patient as per protocol.
223757842|NCT00664716|BIOLOGICAL|Baminercept alfa 1|experimental - one dose level
223757843|NCT00664716|BIOLOGICAL|Placebo|Placebo comparator
223757844|NCT00664716|BIOLOGICAL|Baminercept alfa 2|experimental - second dose level
223757845|NCT00664716|BIOLOGICAL|Baminercept alfa 3|experimental - third dose level
223757846|NCT00664716|BIOLOGICAL|Baminercept alfa 4|experimental - fourth dose level
223757847|NCT00664716|BIOLOGICAL|Baminercept alfa 5|experimental - fifth dose level
223757848|NCT00003255|DRUG|carboplatin|
223757849|NCT00003255|DRUG|topotecan hydrochloride|
223757850|NCT01105247|DRUG|PCI-32765|420 mg daily or 840 mg daily
223757851|NCT06498284|DRUG|HM-002-1005|HM-002-1005 extended release tablets for oral administration compared with matching placebo tablets
223757852|NCT00651482|DRUG|Everolimus|
223757853|NCT00651482|DRUG|Bevacizumab|
223757854|NCT02104089|DEVICE|Zenith® t-Branch™ Thoracoabdominal Endovascular Graft|Instead of making a large incision in the chest, the physician makes a small incision near each hip to insert, and guide the study device(s) into place in the aorta.
223757855|NCT04758767|DRUG|CID-103|anti-CD38 antibody
223757856|NCT04905316|DRUG|Canakinumab|Canakinumab (ACZ885) will be dosed at 200mg via subcutaneous injection every 3 weeks x 3 injections that will start with concurrent chemoradiation, followed by 200mg via intravenous infusion every 4 weeks x 12 infusions that will start with the initiation of durvalumab. Intravenous Canakinumab (ACZ885) should start no sooner than 3 weeks after the last subcutaneous Canakinumab (ACZ885) injection. Canakinumab (ACZ885) will be concurrent with thoracic chemoradiation and durvalumab therapy for up to 15 cycles, or until disease progression or unacceptable toxicity, whichever occurs first.
223757857|NCT04905316|DRUG|Durvalumab|Patients will be treated with durvalumab either at a dose of 10mg per kilogram of body weight intravenously every 2 weeks or at a 1500 mg fixed dose administered every 4 weeks as consolidation therapy after completion of concurrent chemoradiation therapy, as per standard of care.
223757858|NCT04905316|RADIATION|Radiation therapy|Radiation therapy will be performed with external beam ionizing radiation as per standard of care in accordance with institutional practice. Intensity-modulated radiation therapy (IMRT) or volumetric arc therapy (VMAT) will be used at the discretion of the treating radiation oncologist. Patients will be simulated in the treatment position with standard immobilization techniques for thoracic radiotherapy. The prescription dose will be 60 Gy (±10%) in 2Gy fractions to fields encompassing gross tumor and lymph nodes, as per institutional guidelines. The dose must satisfy institutional guidelines and minimize risk to adjacent organs at risk.
223611573|NCT02519205|OTHER|Survey|
223611574|NCT00839644|DEVICE|High frequency chest wall oscillation|Therapy prescribed twce daily for twenty minute sessions. High frequency chest wall oscillation (HFCWO) applies sharp compression pulses via an air-pulse generator and inflatable vest. HFCWO generates transient increases in airflow at low lung volumes, cough-like shear forces, and alterations in the consistency of secretions.
223611575|NCT00839644|DEVICE|Oscillatory Positive Expiratory Pressure|Therapy was prescribed twice daily for 20 minute sessions and included airway vibration, oscillating PEP, and forced expiratory technique (FET) with coughing.
223611576|NCT00839644|OTHER|PD&P: Postural drainage and percussion|Each of the six positions are to be clapped or vibrated for 4 minutes. After each position the patient is to do three forced expiratory techniques (FET) and cough, continue with FET and coughing until all mobilized mucus has been cleared.
223611577|NCT01657292|DRUG|Oleogel-S10 ointment|Intraindividual comparison: One randomly assigned wound half is treated with Oleogel-S10 ointment and fatty gauze wound dressing
223611578|NCT01657292|DEVICE|Octenilin® wound gel|Intraindividual comparison: The other wound half is treated with Octenilin® wound gel and fatty gauze wound dressing
223611579|NCT01996280|BEHAVIORAL|Motivational Interviewing|The MI is a single brief motivational intervention lasting 1.5 hrs. The MI includes MI structured strategies tailored to the patient's readiness to change such as: the Typical Day exercise, the use of personal feedback reports (e.g., normative feedback about their drinking), discussions about the pros and cons of use, and completion of a change plan; It is designed to follow MI principles of invoking autonomy and emphasizing collaboration with the interventionist.
223757859|NCT04905316|DRUG|Chemotherapy|Chemotherapy will be as per standard of care in accordance with institutional practice. Patients will be treated with carboplatin or cisplatin with etoposide, paclitaxel, albumin-bound paclitaxel or pemetrexed at the discretion of the treating thoracic medical oncologist. Chemotherapy will be concurrent with radiation therapy as per standard practice, with cycle 1 day 1 of chemotherapy starting on fraction 1 of radiation ± 5 days.
223757860|NCT05232851|BIOLOGICAL|Liposomal HPV-16 E6/E7 Multipeptide Vaccine PDS0101|Given SC
223757861|NCT05232851|BIOLOGICAL|Pembrolizumab|Given IV
223757862|NCT05232851|PROCEDURE|Computed Tomography|Undergo CT, FDG-PET/CT
223757863|NCT05232851|PROCEDURE|FDG-Positron Emission Tomography|Undergo FDG-PET/CT
223757864|NCT05232851|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223757865|NCT05232851|PROCEDURE|Biopsy|Undergo biopsy
223757866|NCT04164901|DRUG|Vorasidenib|Vorasidenib oral film-coated tablets
223757867|NCT04164901|DRUG|Matching Placebo|Matching Placebo oral tablets
223757868|NCT05097833|BEHAVIORAL|Enhanced Saint Francis Fatherhood FIRE Program|Fathers receive an enhanced series of pro-parenting, relationship, and economic stability workshops over 16 weeks. Workshop series are based on a diverse curricula including a combination of either 24/7 Dad or Parent Project and Connections to Success and the Nurturing Fathers enhancement program.
224205935|NCT02360124|DRUG|silver diammine fluoride|topical application of the SDF solution onto tooth root surfaces
223757869|NCT05097833|BEHAVIORAL|Services as Usual Saint Francis Fatherhood FIRE Program|Fathers receive the services as usual approach which includes a series of pro-parenting, relationship, and economic stability workshops over 13 weeks. Workshop series are based on a diverse curricula including a combination of either 24/7 Dad or Parent Project and Connections to Success.
223757870|NCT06641856|OTHER|Sample Collection|All participants will provide nasal and pharyngeal swabs for virome analysis. A subset of 30 elderly volunteers will also provide peripheral blood samples and undergo bronchoscopy under general anesthesia to collect upper and lower respiratory tract samples.
223757871|NCT06639698|DIETARY_SUPPLEMENT|Diosgenin|Patients will take a tablet containing diosgenin (120 mg), alpha-lactalbumin (100 mg) and vitamin D (50 mcg) - two times per day for six months
223757872|NCT03900533|BEHAVIORAL|Adjunctive group emotion regulation skills training|The adjunctive emotion regulation skills training is delivered in a group format once a week during 7 weeks to adolescents and parents jointly together with treatment as usual
223757873|NCT03900533|BEHAVIORAL|Treatment as usual|Treatment as usual at the child- and adolescent psychiatric clinic is delivered during 7 weeks
223757874|NCT06059404|BEHAVIORAL|Meals + RD services only|Registered dietitians (RD) will provide tailored dietitian counseling and nutrition education
223757875|NCT06059404|BEHAVIORAL|Meals + OT services only|Occupational therapists (OT) will provide tailored home safety recommendations and fall prevention education/strategies
223757876|NCT06059404|BEHAVIORAL|Meals + RD + OT services|A combination of tailored registered dietitian and occupational therapy services will be provided
223757877|NCT05816525|PROCEDURE|Partial removal of carious tissue|Nonselective carious tissue excavation will be performed in the periphery of the cavity to achieve a good marginal seal. In the pulpal wall selective, partial carious tissue excavation is performed to the soft dentin, removing tissue only the amount that is necessary for placing the restoration. The tooth is restored with high-viscosity glass-ionomer cement.
223757878|NCT05816525|PROCEDURE|Final restoration|The teeth will be restored with composite resin after 12 months follow up, if the tooth is asymptomatic, responds to sensibility tests and there are no periapical changes radiographically. Glass ionomer cement will be only partially removed to create space for the final restoration.
223757879|NCT06414174|DEVICE|Split septum needleless connector|Participants in this study are limited to very preterm neonates or neonates with birth weight under 1500 grams. Split septum mechanism is still widely use in Indonesia, therefore the use of mechanical valve mechanism as needleless connector for central line access in very preterm neonates have never been tested.
223757880|NCT06414174|DEVICE|Mechanical valve needleless connector|Participants in this study are limited to very preterm neonates or neonates with birth weight under 1500 grams. Split septum mechanism is still widely use in Indonesia, therefore the use of mechanical valve mechanism as needleless connector for central line access in very preterm neonates have never been tested.
223757881|NCT04070300|BEHAVIORAL|Interval exercise|Aerobic interval training during 12 weeks 3 times a week: 4 x 4 minutes intervals at an intensity of 90-95% of VO2 peak and active breaks of 3 minutes between intervals.
223757882|NCT02279186|DRUG|Tranexamic Acid|Intravenous Injection
223757883|NCT00025285|DRUG|carboplatin|
223757884|NCT00025285|DRUG|irinotecan hydrochloride|
223757885|NCT00025285|DRUG|thalidomide|
223757886|NCT01069055|OTHER|Sterile Saline|Group I: 100 ml intravenous saline infusion as placebo 30 minitues before the surgery.
223757887|NCT01069055|DRUG|Intravenous lornoxicam|Group II: 8 mg intravenous lornoxicam infusion in 100 ml saline 30 minitues before the surgery.
223757888|NCT01069055|DRUG|Intravenous paracetamol|Group III: 1 g intravenous paracetamol infusion in 100 ml saline 30 minitues before the surgery.
223757889|NCT01768390|OTHER|toothpaste containing 5,000 ppm fluoride|1 cm tootpaste twice daily during 2 minutes
223757890|NCT01768390|OTHER|1450 GCP|Twice gaily toothbrushing with normal adult toothpaste containing 1450 ppm F representing good clinical practice
223757891|NCT04900077|DEVICE|Carriere® Motion™ Appliance|class II malocclusion corrector
223757892|NCT02638298|DEVICE|Prevana Dressing|negative pressure wound therapy (NPWT) dressing
223757893|NCT02638298|OTHER|Standard Dry Gauze Dressing|Standard Dry Gauze Dressing
223757894|NCT06398990|OTHER|Cognitive Exercise Therapy Approach|It will continue twice a week for 12 weeks. After the initial evaluation of the cases, one-on-one, face-to-face training will be provided with the patient in the first week (2 sessions) in order to ensure their compliance with the treatment and to fully understand the treatment method. Then, treatments will be carried out synchronously with the patients twice a week via the online platform (Zoom).
223757895|NCT06398990|OTHER|Yoga|It will continue twice a week for 12 weeks. After the initial evaluation of the cases, one-on-one, face-to-face training will be provided with the patient in the first week (2 sessions) in order to ensure their compliance with the treatment and to fully understand the treatment method. Then, treatments will be carried out synchronously with the patients twice a week via the online platform (Zoom).
223757896|NCT06398990|OTHER|Routine Medical Treatment|Assessments of individuals in this group will be made face-to-face in the relevant clinic.
224205936|NCT02360124|OTHER|Water as placebo|topical application of water as a placebo in the control arm
223509276|NCT05666856|BEHAVIORAL|We The Village Peer Community Forum|An online peer support forum with other CSOs. Members of the forum post questions or comments to weekly peer-led discussions and receive responses and feedback from other CSO forum members. Members typically express concerns regarding their IP's wellbeing and ask other members to share any strategies they have employed when dealing with their IPs. Interactions typically, are based either in 12-Step strategies members have learned (usually through Al-Anon or Nar-Anon Family Groups or Family Training Workshops provided by treatment programs) or in CRAFT skills learned (usually from treatment programs or other We The Village members). A staff member from We The Village monitors forum interactions to ensure members are interacting respectfully.
223509277|NCT03049397|OTHER|Communication Intervention|Complete Enhancing Connections program
223509278|NCT03049397|OTHER|Questionnaire Administration|Ancillary studies
223509279|NCT00001311|DEVICE|heparin-surface modified intraocular lens|
223509280|NCT02144246|OTHER|Non-hormonal period|
224205937|NCT02360124|OTHER|saturated potassium iodide solution|topical application of SDF solution followed by KI solution onto tooth root surfaces
224201289|NCT06742788|DEVICE|sham transcutaneous auricular vagus nerve stimulation (staVNS)|The sham transcutaneous auricular vagus nerve stimulation (staVNS) serves as a sub-threshold therapeutic stimulus functions as a sham stimulus. The staVNS protocol is set at a pulse width of 500 µs and a frequency of 25 Hz, with an intensity value of 0.1 mA. The stimulation is to be carried out for a total of 1.5 hours daily, with the sessions divided into three parts, each lasting 30 minutes. At least one of these periods occur within 2 hours before bedtime. The study will use the Chinese National Institutes for Food and Drug Control certificated taVNS device TVNS-100 (Xinzhile Medical Technology Co., Jiangxi, China). The study includes an intervening period of 4 weeks.
224201290|NCT01209000|PROCEDURE|Kidney Biopsy|Patients scheduled to undergo a clinically indicated kidney biopsy will be requested to consent to an additional renal core, to be set aside until all clinical care is complete.
223509281|NCT02144246|DRUG|Ortho-cyclen, Ethinyl estradiol/norgestimate, 0.035 mg/0.250 mg|
223509282|NCT00152854|DRUG|Acetaminophen|acetaminophen 1g po qid
223509283|NCT00152854|DRUG|acetaminophen|acetaminophen 1g po qid for 7 days
223509284|NCT00152854|DRUG|placebo, sugar pill|
223509285|NCT04772924|BEHAVIORAL|fasting|more than 12 hour of fasting as ceremony of Ramadan
223509286|NCT04772924|BEHAVIORAL|not fasting|preferred not to take long term fasting
223509287|NCT04250675|DEVICE|Intermittent pneumatic leg compressions|Patients will be asked to use the ArtAssist® device to compress the foot and ankle (120 mmHg) of both legs for 2 hours daily for 3 months.
223509288|NCT04250675|DEVICE|Sham|Patients will be asked to use the ArtAssist® device to compress the foot and ankle (30 mmHg) of both legs for 2 hours daily for 3 months.
223509289|NCT03750084|OTHER|questionary|The intervention consists of a digitally distributed questionary.
223509290|NCT01791400|DRUG|metoclopramide, injection,20mg, one time|metoclopramide, intravenous injection,20mg, one time
223509291|NCT01791400|DRUG|Sumatriptan, injection, 6 mg, one time|Sumatriptan, subcutaneous injection, 6 mg, one time
223509292|NCT00527748|DEVICE|Non-Measuring Ankle Exerciser|Stretching exercise performed 10 times per day, for six (6) weeks.
223509293|NCT05032599|BIOLOGICAL|CD5 CART|Subjects will be pretreated with chemotherapy prior to infusion of CAR T cells: After the collection of PBMC and about 5 days before infusion, lymphodepletion (fludarabine at 30 mg/m\^2/day and cyclophosphamide at 250 mg/m\^2/day; for prior-SCT donor-derived CAR T-cell infusion) or intensified lymphodepletion (fludarabine at 30 mg/m\^2/day and cyclophosphamide at 30 mg/kg/day; for new donor-derived CAR T-cell infusion) will be administrated for 3 days.
223611580|NCT01996280|BEHAVIORAL|Culturally Tailored MI|CTMI is a single brief motivational intervention lasting 1.5hrs. The CTMI follows the same sequence of structured strategies as the MI arm, and while the components in CTMI and MI are parallel, the focus within them is different. CTMI components culturally relevant material, such as acculturation stress. The CTMI components, which are MI structured strategies, are culturally tailored to address relevant concerns and issues. There are also culturally tailored feedback element, such as ethnic normative feedback related to drinking.
223611581|NCT00931775|DRUG|Pindolol|Pill orally administered. 15 mg/day t.i.d.
223611582|NCT01559051|PROCEDURE|Lipoaspiration with Local anesthesia|Patients undergo a liposuction under local Anethesia. The AD-SVF are then isolated and infused IV and by inhalation delivery.
223611583|NCT04269876|DIETARY_SUPPLEMENT|Marine Lipid Oil Concentrate|Marine Lipid Oil Concentrate softgels
223611584|NCT04269876|DIETARY_SUPPLEMENT|Dietary Supplement|Dietary Supplement capsules
223611585|NCT04269876|DIETARY_SUPPLEMENT|Placebo|Placebo softgels
223611586|NCT04269876|DIETARY_SUPPLEMENT|Placebo|Placebo capsules
223611587|NCT00650845|DRUG|Dotarem®-enhanced MRI|Single IV administration before MRI exam
223611588|NCT00650845|OTHER|non-enhanced MRI|non injected MRI
223611589|NCT00917839|DRUG|lamotrigine|100 mg, once daily, 12 months
223611590|NCT04371601|DRUG|Oseltamivir|Oseltamivir capsules
223611591|NCT04371601|DRUG|hormones|a moderate amount of hormone
223611592|NCT04371601|DEVICE|oxygen therapy|oxygen therapy,mechanical ventilation and other supportive therapies
223611593|NCT04371601|PROCEDURE|mesenchymal stem cells|mesenchymal stem cells
223611594|NCT01003652|PROCEDURE|thyroidectomy|Comparison between two groups of patients. One group is operated on using harmonic Focus for haemostasis compared to a second group of patients operated on with the conventional haemostasis using tie-and-clamp technique
223611595|NCT06130592|DIAGNOSTIC_TEST|ultrasound muscle imaging technique|ultrasound muscle imaging technique in antenatal ultrasound screening of congenital multiple arthrogryposis
223611596|NCT04424342|OTHER|Pre-test procedure|The Turkish version of CPQ8-10 was subjected to a preliminary test on a group of 20 children, who were not included in the final study, in order to discuss the intelligibility of the items and to determine comprehension problems for children of this age group
223611597|NCT04424342|OTHER|Test re-test|The Turkish version of CPQ8-10 was administered to 50 children who were asked to complete the questionnaire on their own without any assistance. These 50 children were interviewed for a second time within two weeks to measure the reliability of the test-retest
223611598|NCT04638426|DRUG|HL237 tablet|Treatment A : HL237 100mg, twice a day, Treatment B : HL237 200mg, twice a day, Treatment C : HL237 400mg, twice a day
223611599|NCT04638426|DRUG|Placebo of HL237 tablet|Placebo of HL237, twice a day
223611600|NCT05482841|DIAGNOSTIC_TEST|Lung ultrasound score|To evaluate the incidence of pulmonary atelectasis in the post-anesthesia care unit (PACU) using lung ultrasound.
223611601|NCT01698723|DRUG|Ribavirin|
223611602|NCT01698723|DRUG|Placebo|
223611603|NCT04178720|DEVICE|Lehfilcon A contact lenses|Investigational silicone hydrogel contact lenses
223611604|NCT04178720|DEVICE|Comfilcon A contact lenses|Commercially available silicone hydrogel contact lenses
223611605|NCT04178720|DEVICE|CLEAR CARE|Hydrogen peroxide-based system for cleaning and disinfecting silicone hydrogel contact lenses
223611606|NCT01301833|DRUG|teneligliptin|
223611607|NCT01301833|DRUG|glinide|
223611608|NCT01301833|DRUG|biguanide|
223611609|NCT01301833|DRUG|alpha-glucosidase inhibitor|
223611610|NCT03922620|DRUG|Liposomal bupivacaine|Local infiltration of 20cc of Liposomal Bupivacaine infiltrated to the surgical area
223611611|NCT03922620|DRUG|Peripheral Nerve Block|Peripheral Nerve Block performed by anesthesia team (blocks will be given by same anesthesia provider utilizing same technique every time in order to reduce variations in delivery of peripheral nerve block).
223509294|NCT02612467|OTHER|Stratified care|"Patients are stratified according to the SBT subgroups (low, medium and high risk) and the appropriate matched intervention will be delivered accordingly.~Low risk: Reassuring information. Onwards referral, investigation or further treatment is not recommended Medium risk: In addition to reassuring information patients receive evidence based individualised treatment focusing on restoring function (targeting back pain, leg pain, co-morbid pain and disability) High risk : In addition to medium risk treatment patients will receive individualised psychologically informed physiotherapy aiming to reduce pain and disability."
223509295|NCT02612467|OTHER|Current care|Treatment based on clinical judgement, clinical need and patient preferences. No access to guidance tools.
223509296|NCT03410537|DRUG|Taurine|
223509297|NCT03410537|DRUG|Placebo|
223611612|NCT01813448|DRUG|Fidaxomicin|oral
223611613|NCT01813448|DRUG|Placebo|oral
223509298|NCT02324907|DEVICE|Procedure/Surgery|Tibiotalocalcaneal (TTC) arthrodesis with a novel dynamic compression intramedullary nail. The assignment of the device is at the discretion of the standard of care provider, not the study investigator.
223509299|NCT01598220|BEHAVIORAL|Computer-assisted cognitive remediation therapy|"Comparison of two groups:~The experimental group performs 48 sessions of computer exercices designed to remedy cognitive domains(attention, speed of processing, working memory,reasoning and problem solving) frequently affected in schizophrenia.~The intervention has a period 6 months , two sessions a week. All exercises provided a visual or verbal feedback to immediately terminate the execution.In addition to, the therapist after the sessions interactively explain the results and the strategies employed by the patient."
223509300|NCT01598220|OTHER|attentional task|The Control group performs 48 sessions of watching videos and answer questions about these videos, in a period of 6 months , two sessions a week.
223509301|NCT05316051|DEVICE|Inverted foot orthoses|Inverted functional orthoses will be used in this study based on Blake (1986) inverted orthotic technique. Two groups of foot orthosis will be fabricated with two different inverted angles: 25° inverted angle and 15° inverted angle.
223509302|NCT02376335|BIOLOGICAL|Rituximab|The Rituximab dosing regimen identified is that used in the proof of concept study, which is also the established treatment regimen for Rituximab use in rheumatoid arthritis. All interventions will be administered with a clinician present throughout the infusion in participants who have been encouraged to have adequate oral hydration in the 24 hours prior to attendance. Resuscitation equipment will be immediately available during the infusion period. Blood pressure, heart rate and temperature will be monitored during the infusion. Participants will continue to be observed in the Clinical Research Facility for at least 1 hour after the infusion.
223509303|NCT02376335|OTHER|Placebo|Participants will be randomised to Rituximab therapy (1000 mg IV on day 1 and 15) or placebo (0.9% Sodium Chloride 250 mls) control
223509304|NCT06368362|BEHAVIORAL|Benign cognitive bias modification for interpretation|Benign cognitive Bias Modification for Interpretation (CBM-I) trains participants to interpret ambiguous information as neutral or benign rather than pain-related.
223509305|NCT06368362|BEHAVIORAL|Pain-related cognitive bias modification for interpretation|Pain-related cognitive Bias Modification for Interpretation (CBM-I) trains participants to interpret ambiguous information as pain-related.
223509306|NCT03914014|OTHER|connective tissue manipulation|From the estimated date of ovulation to the onset of menstrual bleeding, connective tissue massage will be applied to the sacral, lumbar, lower thoracic and anterior pelvic regions for 5 days per week. The application will take 10 min. During the massage treatment, the physiotherapist will touch the end of the middle finger with the skin of the patient and apply the skin to the pull. The patient will be in the supine position during the treatment of the anterior pelvic region while the patient is in the sitting position during the treatment of the back area.
223509307|NCT03914014|OTHER|placebo ultrasound|From the estimated date of ovulation to the beginning of the next menstrual bleeding, placebo ultrasound will be applied a total of 10 minutes (5 minutes for sacral and lumbar, and lower thoracic regions and 5 min for the anterior pelvic region). Placebo ultrasound application will be performed with superficial circular movements without applying excessive pressure. During the application, the device will only be switched on, the dose will not be adjusted and the patient will be given an image of ultrasound dose.
223509308|NCT02719860|DIETARY_SUPPLEMENT|Green tea|4 cups/day of green tea for 6 months; each cup is prepared by brewing 2 tea bags in 12 oz of water
223509309|NCT02719860|DIETARY_SUPPLEMENT|Black tea|4 cups/day of black tea for 6 months; each cup is prepared by brewing 2 tea bags in 12 oz of water
223509310|NCT02719860|DIETARY_SUPPLEMENT|Placebo tea|4 cups/day of placebo tea for 6 months; each cup is prepared by brewing 2 tea bags in 12 oz of water
223509311|NCT02164721|DEVICE|Three-lead CRT-D (Defibrillator)|The three-lead CRT-D (Defibrillator) will consist of a pulse generator, a right atrial lead, a right ventricular lead and a left ventricular lead.
223509312|NCT03043937|OTHER|registry|
223509313|NCT03479346|DRUG|GGT|Usage: 3g, three times a day, each taken before or between meals for 12 weeks Manufacturing company: HANPOONG PHARM \& FOODS Co. Ltd.
223509314|NCT03479346|DRUG|Placebo|Usage: 3g, three times a day, each taken before or between meals for 12 weeks Manufacturing company: HANPOONG PHARM \& FOODS Co. Ltd.
223509315|NCT01467284|BEHAVIORAL|Step Ahead|Promotion of weight gain prevention among teachers and staff in public high schools through Step Ahead, a comprehensive intervention targeting three levels suggested by the ecological framework health behavior change: organizational school level, interpersonal level, and individual level.
223611614|NCT00724204|DIETARY_SUPPLEMENT|follow on formula without probiotics|A follow on formula without probiotics
223611615|NCT00724204|DIETARY_SUPPLEMENT|follow on formula with Lactobacillus salivarius CECT5713|follow on formula with Lactobacillus salivarius CECT5713 in a dose of 2x10E8 cfu/day
223509316|NCT01467284|BEHAVIORAL|Basic Intervention|Promotion of weight gain prevention among teachers and staff in public high schools through receipt of the workbook print materials and access to website similar to the enhanced intervention.
223509317|NCT00276393|DRUG|Basal insulin|
223611616|NCT03209856|DRUG|Vitamin D|Vitamin D supplement will be given. Then, it will be maintained if pregnancy occurred
223757897|NCT06649890|DEVICE|Xperience™ Advanced Surgical Irrigation|Xperience™ solution will be applied twice during reconstruction procedures: first after achieving hemostasis and second just before implant introduction. The solution will be warmed to body temperature before use. Both tissue expanders/implants and mastectomy pockets will be soaked with Xperience™, using sterile syringes. A 1-minute dwell time with a total volume of 500 mL per mastectomy pocket will be employed, twice. Additionally, 500 mL of Xperience™ will be applied to implants before insertion, with a 5-minute dwell time. Excess solution will be suctioned throughout, and no rinsing will occur post-irrigation. Surgical site closure will follow standard procedures.
223757898|NCT06649890|DEVICE|Dilute Povidone-Iodine|5% dilute povidone-iodine solution will be prepared by mixing povidone-iodine solution and normal saline at the appropriate ratio. Both tissue expanders/implants and mastectomy pockets will be soaked with dilute povidone-iodine, using sterile syringes. A 1-minute dwell time with a total volume of 500 mL per mastectomy pocket will be employed, twice. Additionally, 500 mL of dilute povidone-iodine will be applied to implants before insertion, with a 5-minute dwell time. Excess solution will be suctioned throughout. Surgeon discretion will determine rinsing after irrigation. Surgical site closure will follow standard procedures.
223757899|NCT01241903|DRUG|rosuvastatin|Patients (n = 54) presenting acute coronary syndrome/non-ST elevation myocardial infarction who present within 8 hours of symptom-onset will be randomized to two groups to receive rosuvastatin (40 mg oral dose) or placebo at the time of presentation, in addition to standard of care (aspirin, clopidogrel, low molecular weight heparin). Blood will be collected at baseline (time of enrollment, immediately prior to drug or placebo), at 6 - 8 hours, at 18 - 24 hours, and at 30 days for analysis of platelet - leukocyte co-aggregate formation, biomarkers of platelet - leukocyte interactions, and biomarkers of myocardial necrosis. Additional samples may be collected just after revascularization, in patients undergoing PCI. The group of patients treated with rosuvastatin will be maintained on rosuvastatin 20 mg daily and the group randomized to placebo will be given rosuvastatin (20 mg oral once daily) within 48 hoursof enrollment and after planned PCI, but before hospital discharge.
223757900|NCT01241903|DRUG|placebo|frequency and duration
223757901|NCT05942248|OTHER|No Intervention|No Intervention
223757902|NCT05837130|OTHER|Blood sample collection and an optional cerebrospinal fluid (CSF) collection|No study drug will be administered to study participants.
223757903|NCT05837130|OTHER|Blood sample collection|No study drug will be administered to study participants.
223757904|NCT06548061|DEVICE|Visualase Thermal Therapy System|Spine laser interstitial therapy used instead of open decompression followed by spine stereotactic radiosurgery (SSRS).
223757905|NCT06957808|DRUG|Diroximel fumarate (DRF)|Diroximel fumarate is an immunomodulating drug licensed for use in multiple sclerosis. It has been found to cross the blood brain barrier and increase brain glutathione levels.
223757906|NCT06957808|DRUG|Placebo|A placebo pill given to participants.
223757907|NCT05040152|BEHAVIORAL|Dietary Counseling and Surveillance|Receive dietary recommendations
223757908|NCT05040152|OTHER|Exercise Intervention|Complete home exercises
223757909|NCT05040152|OTHER|Informational Intervention|Receive education brochures
223757910|NCT05040152|OTHER|Questionnaire Administration|Ancillary studies
223757911|NCT05040152|BEHAVIORAL|Telephone-Based Intervention|Receive telephone-based weight loss intervention
223757912|NCT01539187|DEVICE|VizAblate System|VizAblate enables a minimally invasive procedure to visualize, target, and ablate uterine fibroids using intrauterine ultrasound and radiofrequency (RF) energy
223757913|NCT00485316|PROCEDURE|Laparoscopic assisted resection of colorectal carcinoma|
223757914|NCT01978314|DEVICE|75 mg / 6 mL VFI™|Visible fluorescent injectate, a mixture of two different molecular weight carboxymethyl dextran molecules (5 kD and 150 kD) with different fluorescent dye molecules attached.
224201291|NCT03220282|OTHER|Donor milk|For late preterm newborns who are breastfeeding and whose mothers are not making enough breast milk yet to meet their nutritional needs, the study will compare the intervention of banked donor breast milk with the control of preterm infant formula.
224201292|NCT03220282|OTHER|Preterm infant formula|Preterm formula determined by clinical practice
223509318|NCT02832947|DRUG|Rivaroxaban 10 mg|At study month 7 (+/-1 month), patients receive at 8 a.m. a single dose of 10 mg rivaroxaban. Study specific blood tubes are sampled the same day at the indicated time points from T -1h to T 12h.
223509319|NCT01975584|BEHAVIORAL|Trier Social Stress Test|Participants will participate in a standardized role play (Trier Social Stress Test ). A role play is pretending to be in a certain situation. A research staff member will describe the role play, during which teh participant will act out a scene. Participants will be asked to imagine that they are in a certain role with several other research team members who will also participate in the role play. Participants will also be asked to do some math problems without using paper or pencil.
223509320|NCT05364489|DRUG|Bevacizumab combined with Oxaliplatin and TAS-102|"Bevacizumab (Anda, Qilu Pharmaceutical): 5 mg/kg, repeated every 2 weeks, administered by intravenous drip (ivgtt).~Oxaliplatin: 85 mg/m2, repeated every 2 weeks, by intravenous infusion (ivgtt). TAS-102: 35 mg/m2 (maximum single dose 80 mg), orally, twice a day, on days 1 to 5, repeated every 2 weeks.~Continuous administration until disease progression, death, toxicity intolerance, withdrawal of informed consent, or other reasons specified in the protocol; for patients who still benefit after comprehensive evaluation after initial disease progression, the investigator may decide whether to continue the treatment with the experimental drug ."
223509321|NCT02329275|PROCEDURE|Testicular biopsy|
223509322|NCT03283995|OTHER|Cardiac Volume Monitoring VolumeView|hemodynamic measure
223509323|NCT03283995|DEVICE|echocardiography|hemodynamic measure
223509324|NCT00463775|DRUG|Topiramate|SSRI plus topiramate SSRI plus placebo
223509325|NCT01091415|PROCEDURE|calcium phosphate bone cement injection|volar locking plate alone versus calcium phosphate bone cement as well as volar locking plate
223509326|NCT01093885|DRUG|Ambrisentan|"Drug is dispensed in tablet form. Ambrisentan with anti-fibrotic to assess benefit on skin~Dosing of ambrisentan will begin at 5mg daily for the first month. Half the patients will remain at 5mg daily, while the remaining patients will be increased to a maintenance dose of 10mg daily on the fourth week."
223509327|NCT04429971|OTHER|PrEP screening program|ICAP Pre-Exposure Prophylaxis (PrEP) Screening for Substantial Risk and Eligibility tool
223509328|NCT04429971|OTHER|PrEP starter pack|emtricitabine/tenofovir alafenamide or emtricitabine/tenofovir disoproxil
223757915|NCT00726570|DEVICE|Sequential compression device therapy|"Pneumatic stockings will be applied to patients.~Pressures ranging from 12 to 40 mmHg will be applied at different levels of the lower limb for 40-second cycles at 2-minute intervals. Therapy will continue until the morning after surgery."
223757916|NCT00726570|DRUG|Dalteparin|"* 2500 UI qd if ≤ 50 kg body weight~* 5000 UI qd if \> 50 kg"
223757917|NCT00726570|PROCEDURE|TEG|"A 2-ml blood sample will be used for each exam. A full analysis will be run both with and without heparinase at each time point.~TEG analyses will be run at:~* Patient admission (before SCD start)~* 40-60 min after admission~* Morning after surgery"
223757918|NCT03905785|BEHAVIORAL|Samarthan|Samarthan intervention was designed as group program, training parents in cognitive-behavioural techniques for managing child's difficult behaviour and issues. Program was focused on parent-child problem solving method and positive interaction.
223757919|NCT02266056|DRUG|Deep neuromuscular block using rocuronium and reversal with suggamadex|Deep neuromuscular block and moderate neuromuscular block with Esmerone and reversal with bridion
224201293|NCT06928610|BEHAVIORAL|HeartMath Resilience Program|Resiliency-based intervention designed to reduce stress, build resilience, and maintain energy levels.
223611617|NCT04689789|DIAGNOSTIC_TEST|optical coherence tomography angiography|optical coherence tomography aniography is a non-invasive, fast, diagnostic imaging technique that evaluates the retinal vascular network
223611618|NCT01005095|DIETARY_SUPPLEMENT|Vitamin D3|Patients will be treated daily with 800 IU of Vitamin D3 by tablets plus a bottle of 75,000 IU vitamin D3 solution every 3 weeks
223611619|NCT01005095|DIETARY_SUPPLEMENT|Vitamin D3|Patients will receive 800 IU of vitamin D3 by tablets plus a 3 weekly placebo solution
223611620|NCT00781833|DEVICE|Radio Frequency Microstimulator|Implantable peripheral muscle microstimulator, delivering controlled pulsatile stimulation to femoral nerves for knee extension and peroneal nerves for dorsiflexion.
223757920|NCT02266056|DRUG|Moderate neuromuscular block using rocuronium and reversal with suggamadex|Moderate neuromuscular block and moderate neuromuscular block with Esmerone and reversal with bridion
223757921|NCT06292715|PROCEDURE|microwave ablation of the spleen|Ultrasound-guided percutaneous puncture for splenic ablation treatment
223757922|NCT06292715|OTHER|Splenic artery balloon implantation|Splenic artery balloon implantation
223757923|NCT01917071|OTHER|thoracic spine manipulation|a manual technique applied to the mid back to promote motion
223757924|NCT02098161|OTHER|Laboratory Biomarker Analysis|Correlative studies
223757925|NCT02098161|OTHER|Questionnaire Administration|Ancillary studies
223757926|NCT02098161|DRUG|Smac Mimetic LCL161|Given PO
223757927|NCT04140461|DRUG|Amphotericin B|The trial group and the control group received AmB 0.5mg/kg for 4 weeks and 0.7mg/kg for 2 weeks respectively.
223757928|NCT04140461|DRUG|Flucytosine|The trial group and the control group received 100mg/kg for 4 weeks and for 2 weeks respectively.
223757929|NCT03948685|DRUG|Carvedilol SR|blood pressure, heart rate based titrated carvedilol SR for 24 weeks
223757930|NCT03948685|DRUG|Placebo|Placebo
223757931|NCT05398640|BIOLOGICAL|OOS AMTAGVI|Patients will undergo preparative lymphodepleting chemotherapy. Infusion of lifileucel is then given and is followed by administration of IL-2.
223757932|NCT00748267|OTHER|questionnaire administration|
223757933|NCT00748267|PROCEDURE|hypnotherapy|
224201294|NCT04502862|DRUG|SAR231893|Pharmaceutical form: Solution for injection; Route of administration: Subcutaneous
224201295|NCT04502862|DRUG|Placebo|Pharmaceutical form: Solution for injection; Route of administration: Subcutaneous
224201296|NCT05227053|DEVICE|Arctic Front™ Cardiac Cryoablation Catheter|Pulmonary vein isolation will be performed with the Arctic Front™ cardiac cryoablation catheter system
224201297|NCT06903975|DRUG|prabotulinumtoxinA-xvfs|Each participant will receive 60 units (U) of prabotulinumtoxinA-xvfs into each SCM for a total of 120 U. Participants will return in 2 weeks to determine if any touch-up injection is needed.
224201298|NCT06910267|BEHAVIORAL|APS Treatment as Usual|APS agencies conduct in-home investigations of alleged abuse and neglect against disabled and older adults. Investigations result in short-term stop-gap measures, primarily brief case-management centering on referral linkage to community-based services and provision of resource allocation. No direct psychological services or treatments are provided by APS, however referral to other services is also standard.
224201299|NCT06910267|BEHAVIORAL|Intervention-Behavioral Activation (BA)|Participants will be will be guided through 8 one-hour sessions via home telehealth by the study community health worker. Each weekly \< 60 minute BA session will include modules focusing on 1) Psychoeducation for depression and techniques for self-management, including pharmacologic and psychosocial treatment options; 2) Introduction of BA and guided problem-solving techniques to enhance self efficacy for managing depression and other chronic illnesses; 3) BA and problem-solving techniques to support medication management and adherence strategies; 4) BA to develop strategies and techniques for communicating with health providers and/or support resources to foster positive mood and self management; and 5) Developing a relapse prevention plan, which includes identifying triggers for lower functioning, support resources, and practice of BA techniques.
224201300|NCT04281147|DRUG|Radium-223 dichloride (Xofigo, BAY88-8223)|Follow clinical administration
224201301|NCT06936306|PROCEDURE|GBT|GBT Protocol
224201302|NCT06936306|DEVICE|Master|Use master piezon
223757934|NCT00748267|PROCEDURE|therapeutic conventional surgery|
223757935|NCT01295515|DRUG|Pegylated Interferon Alpha 2b (PEGINTRON)|pegylated preparation of interferon alpha 2b
223757936|NCT03740438|DIAGNOSTIC_TEST|Hemoglobin concentration|Perioperative hemogloin concentration
223757937|NCT03855995|PROCEDURE|Whole blood sample|Whole blood samples will be collected from all enrolled children hospitalised and suspected of having an AESI or meningitis.
224201303|NCT06936306|PROCEDURE|scalling|scalling
224201304|NCT06942546|DEVICE|Wrist orthosis|The wrist orthosis referred in this study is two different prefabricated (of the shelf) types; a semi-rigid orthosis in elastic fabric with a volar splint or a short elastic wrist orthosis without a splint. Both ment to be worn when the person use the hand in everyday occupation.
224314282|NCT01504958|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|"Each subject will receive up to 1800 pulses of up to 20Hz per day to all simulated brain regions together. Treated brain areas will be alternated each day (only 3 a day).~Sham participants will receive the same study procedures as patients receiving active rTMS."
223757938|NCT04570085|DRUG|Caffeine|100mg caffeine capsule treatment, beginning after caffeine diet during 6 weeks, titrate in 3 weeks (by 100mg stages) until 400mg aim dose per day in 2 doses during 27 weeks, and finally interrupt according to the same negative titration.
223611621|NCT02966561|BEHAVIORAL|Pedometer-based activity promotion|"The central components of the 2 x 45 minutes lasting pedometer-based physical activity behaviour change intervention BCI are the following behaviour change techniques (BCTs):~* Instruction on how, where and when to perform the behaviour~* Prompt goal setting for physical activity~* Prompt self-monitoring of behaviour~* Feedback on behaviour. Participants receive a pedometer and a booklet with a physical activity diary and associated information on the importance of goal setting and keeping a physical activity diary, exercise recommendations, possibilities to stay active after rehabilitation and appropriate physical activities."
223611622|NCT02966561|BEHAVIORAL|Short patient education and exercise|"The central components of the 2 x 45 minutes lasting intervention are revisions of knowledge of the pulmonary rehabilitation (standard care) in combination with related exercises:~* Revision of knowledge on exercise recommendations~* Revision of knowledge on possibilities of self-regulation of endurance training exercise intensity with the rate of perceived exertion (BORG-Scale)~* Revision of self-regulation of endurance exercise intensity~* Revision of strengthening activities consistent with the exercise recommendations.~Participants receive a booklet with information on the rate of perceived exertion, exercise recommendations, possibilities to stay active after rehabilitation and appropriate physical activities."
223611623|NCT02966561|OTHER|Pulmonary rehabilitation (Standard care)|Standard care is an in-patient pulmonary rehabilitation (PR) in a specialized German Rehabilitation Clinic. PR is a comprehensive, multidisciplinary intervention based on a patient assessment followed by a combination of patient-tailored therapies. PR lasts on average 25 days. PR includes the following obligatory main components: Checking and, if required, adjusting the current COPD medication according to current COPD-guidelines; physical training (4-5 units/week endurance training \[45 min\] and 3 units/week of strength training \[45 min\] per week, 7 units/week whole body vibration muscle training/week); structured COPD-patient education (6 hours patient education COPD + 1 hour device training); respiratory physiotherapy in groups \[2-4 units/week with 45 min\]. PR is implemented by an interdisciplinary rehabilitation team.
223611624|NCT04270539|BEHAVIORAL|Nap|Participants will be given 20-min nap opportunity in the classroom on a daily basis during school-days.
223611625|NCT04301544|BEHAVIORAL|INDAK (Improving Neurocognition through Dance and Kinesthetics)|INDAK (Improving Neurocognition through DAnce and Kinesthetics) is a structured modular dance consisting of 8 types of ballroom dances (Reggae, Cha-cha, Samba, Merengue, Bachata, Swing, Tango and Salsa) with increasing complexity. The intervention group will receive dance intervention from a dance teacher two times a week, one hour each time, for 12 months. Each 60-minute session has 3 parts: 10 minutes warm-up/ stretching, 40 minutes dance proper and 10 minutes cool down. This dance intervention will last for 12 months.
223611626|NCT04301544|BEHAVIORAL|Nutrition Counseling|The dietary advice will follow Filipino Nutrition Research Institute (FNRI) recommendation called Pinggang Pinoy or Filipino Plate, which is a picture of a nine-inch plate with foods proportionally distributed among the food groups to provide approximately 1,200 to 1,500 calories per day. It is advised that half of the plate is composed of green leafy vegetables and one serving of fruit per meal. For fruits, 4 to 6 servings are encouraged per day. In general, affordable nutritious food is recommended: high consumption of local fruits and vegetables, brown/purple rice instead of white rice, coconut oil and other vegetable oils, and fish. Participants will be asked to use structured 3-day meal diary for diet monitoring. Individual counseling sessions depending on identified vascular risks based on FNRI recommendations will also be conducted. This is followed-up by study nutritionists every 3-month of intervention period.
223757939|NCT04570085|DRUG|Placebo|Placebo capsule treatment, beginning after caffeine diet during 6 weeks, titrate in 3 weeks until 2 doses aim dose per day during 27 weeks, and finally interrupt according to the same negative titration.
223757940|NCT02046148|BIOLOGICAL|GBS trivalent vaccine|Intramuscular injection - Liquid formulation of a vaccine containing polysaccharide capsules from serotypes Ia, Ib, and III of the Group B Streptococcus and conjugated to the Corynebacterium diphtheriae CRM197 carrier protein
223757941|NCT02046148|BIOLOGICAL|Placebo|Intramuscular injection - Normal saline
223757942|NCT05850169|OTHER|Creative Dance Therapy|"After completion of the initial assessments, the intervention group received 3 sessions per week of creative dance training for 4 weeks (12 sessions), with each session lasting approximately 40 minutes. The creative dance training took place in a 40-square-metre mirrored hall with a tatami mat on the floor. The training was conducted individually for each child in the IG. Different children's songs were selected for each session in harmony with the rhythm of the dance movements. In each session, 10 minutes of warm-up movements and 20 minutes of creative dance training were conducted, accompanied by songs. Meanwhile, materials such as spiky and heavy balls, ribbons, rhythm sticks and holihop were included in the application.~The creative dance training was planned by diversifying the 8 movement models (breath, tactile, core-distal, head-tail, upper-lower, body side, cross lateral and vestibular) of Brain Dance, which is a part of creative dance (Gilbert, 2002,2015)."
223757943|NCT01434524|DRUG|LIVACT|LIVACT contains 13.0 g of free amino acids
223757944|NCT06007183|BIOLOGICAL|CHIKV VLP vaccine booster|CHIKV VLP vaccine is comprised of chikungunya virus virus-like particles (CHIKV VLP) 40mg, aluminum hydroxide 2% adjuvant, and formulation buffer supplied as a single dose of 0.8 mL in a pre-filled syringe, to be administered via intramuscular (IM) injection in the deltoid muscle.
223757945|NCT06007183|BIOLOGICAL|Placebo booster|Placebo is comprised of formulation buffer supplied as a single dose of 0.8 mL in a pre-filled syringe administered via IM injection in the deltoid muscle.
223757946|NCT01012011|DRUG|Sorafenib (Nexavar, BAY43-9006)|Daily dose, dosage frequency and duration will be decided by physicians.
223757947|NCT05932095|BEHAVIORAL|TCM Daoyin|The TCM Daoyin training program consisted of two 90-min training classes and at least five 30-min at-home practice sessions per week for 12-weeks. All sessions included 10 min of warmup and 10 min of cooldown.
223757948|NCT05932095|BEHAVIORAL|Health education|Health education is provided by psychologist and TCM doctor, including work, rest, diet and other basic programs.
223757949|NCT06425055|DRUG|Vonafexor|"* One tablet of a low dose of vonafexor QD from Day 1 to Week 4~* One tablet of a medium dose of vonafexor QD from Week 5 to Week 8~* One tablet of a high dose of vonafexor QD from Week 9 to Week 24"
224201305|NCT06942403|OTHER|Associated product 1 : RV2666C|Applied twice a day minimum during 7 days (from Day 1 to Day 7)
223611627|NCT04301544|BEHAVIORAL|Standardized Vascular Care|The management advice for hypertension, diabetes, and dyslipidemia will be based on Filipino standard clinical practice guidelines. This is followed-up by study physicians every 3-month of intervention period
223611628|NCT00278746|DRUG|Zinc and ORS|Government and private providers and village health workers were trained to prescribe zinc and ORS for use in diarrheal episodes in 1 month to 5 years old children in intervention communities
223611629|NCT00278746|DRUG|ORS only|Promoted routine management of diarrhea in underfive with ORS
223611630|NCT04177212|DEVICE|MRZF111|MRZF111 kit consisting of one syringe of RADIESSE® Volume injectable implant, injection needles and additional components. Physiological saline solution (0.9% NaCl) is used to dilute Radiesse Volume by 1:2. Radiesse consists of calcium hydroxylapatite particles suspended in an aqueous-based gel carrier.
223611631|NCT00648557|DRUG|Levothyroxine Sodium Tablets 200 mg|3x200mcg, single dose fasting
223611632|NCT00648557|DRUG|Synthroid Tablets 200 mg|3x200mcg, single dose fasting
223611633|NCT05686291|BEHAVIORAL|Hybrid volunteer training programme|The volunteer training will consist of a 6-module online course, followed by 5 face-to-face courses, incorporating the key volunteer training components, including Keyes theory, bio-psycho-social model, stress bucket model, recovery model and CHIME model.
223611634|NCT00946543|RADIATION|hypofractionated radiation therapy|
223611635|NCT00946543|RADIATION|intensity-modulated radiation therapy|
223611636|NCT04979611|DRUG|68Ga-NOTA-exendin-4|A single dose of 37-111 Mega-Becquerel (MBq) 68Ga-NOTA-exendin-4 will be injected intravenously
223611637|NCT00718692|DRUG|Sym001|Each cohort will receive one single dose of Sym001 according the assigned dose level.
223611638|NCT04725500|DEVICE|Auto-Titrating EPAP|In the Auto-titrating EPAP mode, the device automatically adjusted EPAP to the minimum level able to abolish tidal expiratory flow limitation.
223611639|NCT00554047|OTHER|Multidisciplinary Memory Clinic|Post-diagnosis treatment and coordination of care for patients with dementia and their informal caregivers delivered by Multidisciplinary Memory Clinics (MMCs)
223611640|NCT00554047|OTHER|General Practitioners|Post-diagnosis treatment and coordination of care for patients with dementia and their informal caregivers delivered by general practitioners
223611641|NCT01412788|PROCEDURE|peri-areolar incision|peri-areolar incision was used to carry out lumpectomy in breast-conserving surgery.
223611642|NCT01412788|PROCEDURE|traditional incision|Traditional incision above tumor was used to carry out breast-conserving surgery.
223611643|NCT01792115|DRUG|Vitamin E 200 IU/d|Supplement-low dose
223611644|NCT01792115|DRUG|Vitamin E 400 IU/d|Supplement-intermediate dose
223611645|NCT01792115|DRUG|Vitamin E 800 IU/d|Supplement High Dose
223611646|NCT01792115|BEHAVIORAL|Diet and Exercise|Diet and Exercise for all Arms of the study at baseline
223611647|NCT00857857|DRUG|GW870086X|Investigational product
224201306|NCT06942403|OTHER|Associated product 2 MORNING : RV5000A|"Applied in the mornings from Day 8 to Day 95 or Day 176\*~\* for subjects post injections"
224201307|NCT06942403|OTHER|Test product : RV4983A|"Applied once a day, at the evening. Avoid contact with eyes. If sensations of discomfort appear, allow more time between applications.~* From Day 8 to Day 95 (87 days) for post LASER and post peeling subjects~* From Day 8 to Day 176 (169 days) for post-injections subjects"
223611648|NCT00857857|DRUG|FP|Positive control
223611649|NCT00857857|DRUG|Placebo|Placebo control
223611650|NCT05675501|DRUG|Encapsulated Benzoyl Peroxide Cream|"Subjects will use a pea-size amount for each area of the face"
223611651|NCT02333786|OTHER|Long-axis/in-plane US-guided arterial catheterization|Cannulate the radial artery or posterior tibial artery of an infant of a preschool child putting the 24 gauge needle parallel to the ultrasound transducer.
223611652|NCT02333786|OTHER|Short-axis/out-of-plane US-guided arterial catheterization|Cannulate the radial artery or posterior tibial artery of an infant or a preschool child putting the 24 gauge needle perpendicular to the ultrasound transducer.
223611653|NCT03163901|OTHER|Osteopathic Manipulative Treatment|OMT techniques applied in the thoracic spine soft tissue, cervical spine soft tissue, suboccipital release, occipital condyle condylar decompression, and cranial venous sinus release.
223611654|NCT02023684|DRUG|control saline|Surgical bed irrigation with saline 40ml
223611655|NCT02023684|DRUG|Lidocaine|surgical bed Irrigation Lidocaine 0.5%, 40ml
223611656|NCT02023684|DRUG|Ropivacaine|surgical bed Irrigation Ropivacaine 0.2%, 40ml
223611657|NCT00277784|PROCEDURE|Ultrasound examination|one ultrasound examination
223611658|NCT05311930|DRUG|2.5mg/d Hetrombopag|After the subjects signed the informed consent and passed the screening, they entered the treatment period and received a starting dose of 2.5 mg/d of Hytrombopag. During the treatment process, the clinician adjusted the drug dose according to the patient's own conditions. The maximum drug dose was 7.5 mg qd, 28 d Evaluate efficacy and safety after completion;
223611659|NCT04618744|DRUG|ORMD-0801 (Insulin) capsule 8 mg BD|8 mg ORMD-0801, 1 capsule, twice a day, once in the morning and once in the evening.
223611660|NCT04618744|OTHER|Placebo|Matching Placebo
223611661|NCT02797392|BEHAVIORAL|Lifestyle intervention|1\) Systematic collection of information on lifestyle risk factors using questionnaire 2) Risk estimation and stratification into risk groups based on questionnaire data and information from the electronic patient record (EPR) using validated risk estimation models, 3) An individual electronic health profile with personalized advise on lifestyle change and 4) targeted preventive services incl. lifestyle counseling at the GP or the municipality for citizens at increased risk of lifestyle disease and citizens with risk behavior, respectively.
223611662|NCT01505816|DEVICE|Multifocal Intraocular Lens (RAYNER M-FLEX T TORIC IOL)|Multifocal IOL implantation
223611663|NCT04988750|DEVICE|NaviFUS System|Using the neuronavigator to precisely guide the ultrasound energy to brain tissues in real-time and intraoperatively.
223611664|NCT00930930|DRUG|cisplatin|Given IV
223611665|NCT00930930|DRUG|everolimus|Given orally
223611666|NCT00930930|DRUG|paclitaxel|Given IV
223611667|NCT00930930|OTHER|placebo|Given orally
223611668|NCT00930930|PROCEDURE|Venous blood draw|Venous blood (2-3 tablespoons) will be taken for germline DNA analysis to complement the correlative studies in the tumor tissue. Blood can be drawn at any time prior, during, or after completion of study treatment
223757950|NCT03616353|PROCEDURE|Perineural Hydrodissection|The subcutaneous tissues of the ulnar aspect of the wrist at the level of the carpal tunnel will be infiltrated with 2 ml of lidocaine 1% for local anesthetic. Using ultrasound guidance and aseptic technique, the needle will then be angled deep to the median nerve within the carpal tunnel, and 5 ml of a 50%/50% mixture of lidocaine 1% and sensorcaine 0.5% will be injected under pressure. While continuing to use ultrasound guidance and aseptic technique, the needle will then be angled superficial to the median nerve within the carpal tunnel, and 5 ml of a 50%/50% mixture of lidocaine 1% and sensorcaine 0.5% will be injected under pressure. The needle will be returned to its original angle deep to the median nerve, and the syringe will be changed to inject 40 mg Depo-Medrol in 1ml of saline.
223757951|NCT03616353|PROCEDURE|Corticosteroid Injection|The subcutaneous soft tissues of the ulnar aspect of the wrist at the level of the carpal tunnel will be infiltrated with 2 ml of lidocaine 1% for local anesthetic. Using ultrasound guidance and aseptic technique, the needle will then be angled deep to the median nerve within the carpal tunnel, and 40 mg Depo-Medrol in 1ml of saline will be injected into the area deep to the median nerve.
223757952|NCT01524861|DRUG|Placebo|a placebo tablet bis in die for 12 months
223757953|NCT01524861|DRUG|alpha-lipoic acid|alpha-lipoic, tablets of acid 400 mg bis in die (800 mg/day), for 12 months
223757954|NCT01524861|DRUG|L-acetyl carnitine|L-acetyl carnitine tablets, 500 mg bis in die (1000 mg/day), for 12 months
223757955|NCT04963582|PROCEDURE|Acupuncture|LI4 is located on the dorsum of the hand, midway between the 1st and 2nd metacarpal bones, approximately in the middle of the 2nd metacarpal bone on the radial side. Acupuncture is practiced by using 0,25x25mm sized needles. LI4 point is punctured perpendicularly 2cm in the direction of the palm center.
224311849|NCT01291771|PROCEDURE|Invasive FFR + CFR measurements are performed during coronary angiography using a pressure guide wire|The guide is placed in the distal segment of the coronary artery to measure instantaneously distal pressure and temperature with a tip sensor. Proximal pressure and temperature are being measured from the probe used to catheterize the coronary vessel and from the shaft of the guide. After basal measurement, intracoronary injection of 150µg of adenosine is performed to induce peripheral vasodilatation leading to hyperaemia in the vessel. Additional injection of 3mL 0.9% saline bolus at room temperature at the time of hyperaemia is performed to calculate CFR from transit mean time. FFR and CFR are being recorded at the time of hyperaemia. Subsequently IMR is being calculated from distal pressure and transit mean time. The measurements will be performed in the LAD, circumflex and right coronary arteries.
224311850|NCT04836897|DEVICE|PrizValve® valve and transapical delivery system|Transcatheter aortic valve replacement system
224311851|NCT04362553|DEVICE|wearable vital signs sensor|vital signs monitoring during standard of care procedures; TTE, swan-ganz catheterization
224311852|NCT02583958|DEVICE|Urgo 3103166|URGO 310 3166 dressing should be changed as often as required (let to the Investigator's convenience). The dressing change frequency is based on the exudate level and the clinical progress of the wound (up to 7 days).
224311853|NCT02583958|DEVICE|Aquacel Extra|Aquacel Extra hydrofibre dressing can be left in place up to 7 days, where clinically indicated.
224311854|NCT00715624|DRUG|Lixisenatide (AVE0010)|Self administered by subcutaneous injections once daily within the hour preceding breakfast.
224311855|NCT00715624|DRUG|Placebo|Self administered by subcutaneous injections once daily within the hour preceding breakfast.
224311856|NCT00715624|DRUG|Basal Insulin|Dose to be kept stable.
223509329|NCT01603511|DEVICE|Rewarming modality|A commercial charcoal heater will be applied to the torso or the head in two of the trials. The control trial involves shivering only.
223509330|NCT03307096|PROCEDURE|Microperc surgery|Parents are treated by Microperc Percutaneous Nephrolithotomy
223509331|NCT03307096|PROCEDURE|FURS|Parents are treated by FURS
223509332|NCT01052142|BIOLOGICAL|Lipovaxin-MM|Patients will receive three doses of Lipovaxin-MM by intravenous infusion at intervals of four weeks OR patients will receive 4 doses of Lipovaxin-MM by intravenous infusion at weekly intervals
223757956|NCT04653779|DRUG|Evogliptin 5mg/Metformin 1000mg|Size reduction of a tablet formulation
223757957|NCT00063869|DRUG|Etanercept|
223757958|NCT04263974|OTHER|Smartphone Application|Exercises and recommendations, based on current scientific evidence, and delivered through the app for Smartphone called CareHand. The intervention protocol is based on strengthening and stretching recommendations for rheumatoid arthritis and osteoarthritis in hands, transferred to an application format through explanatory videos together with tools to improve the autonomy, motivation and adherence of the patient
223757959|NCT04263974|OTHER|Conventional treatment|Conventional approach provided by the Andalusian Public Health System in Primary Care settings. This approach consists of routine visits to the general practitioner specialist, and the delivery of an exercise sheet and recommendations. This general mobility and stretching worksheet contains detailed images, as well as a description of how to perform the exercises and the dose to be taken. While most exercises are intended for the wrist and hands, this sheet also includes basic exercises for the elbow joint.
223757960|NCT01289769|DRUG|Dexmedetomidine|dexmedetomidine 0.7 microgram per kilogram in saline 20 ml given within 10 minutes before intubation
224311857|NCT00715624|DRUG|Metformin|Metformin if given to be continued at stable dose (1.5 gram per day) up to the end of treatment.
224311858|NCT00715624|DEVICE|Pen auto-injector|
224311859|NCT00807716|OTHER|walking skill group|12 Individualized group training sessions with focus on functional exercises like walking and stair climbing including balance training under physiotherapy guidance, 12 times 70 minutes.
224311860|NCT00807716|OTHER|usual physiotherapy care|physiotherapy, mostly in non-weight bearing, 12 times 40 minutes
224311861|NCT03510390|DRUG|Metformin|850 mg, oral, twice daily, 9-14 days
224311862|NCT03316274|DRUG|Nivolumab|Given via intralesional injection
223509333|NCT05750004|PROCEDURE|computer guided immediate implant placement|Atraumatic extraction followed by immediate implant placement using safe angle position computer guided surgical stents, followed by customized healing abutments. after 3 months, Impressions for final prosthesis will be done
223509334|NCT06433544|OTHER|6-week online mindfulness course|The experimental group received a 6-week online mindfulness course, once a week for 90 minutes each session.
223611669|NCT03658824|OTHER|Behavioural Activation (BA)|"BA is based on the assumption that depression may be precipitated and is maintained by a reduction in healthy, adaptive behaviours and positive reinforcement of these, and an increase in avoidance behaviours. Together, these changes reduce the person's immediate distress, often at the expense of their medium and longer term goals. The therapy involves helping the individual to re-establish healthy patterns of activity, and replace avoidance behaviours with more adaptive behaviours that are constructive in the longer term.~The intervention consists of up to 20 individual therapy sessions of Behavioural Activation, with one booster session three months after the end of therapy. Each session lasts approximately 50 minutes and this is supplemented by home practice between sessions."
223611670|NCT02647424|DRUG|Letrozole|Letrozole 2.5 mg daily from Day 2 to 6
223611671|NCT02647424|DRUG|Clomiphene|After one month of washout period, clomiphene 50 mg daily from day 2 to day 6 given
223611672|NCT00008229|BIOLOGICAL|filgrastim|
223611673|NCT00008229|DRUG|melphalan|
223611674|NCT00008229|PROCEDURE|peripheral blood stem cell transplantation|
223611675|NCT00008229|RADIATION|holmium Ho 166 DOTMP|
223611676|NCT02709330|DRUG|Lunasin Regimen|LunaRich X Capsules, Reliv Now, ProVantage
223611677|NCT02709330|OTHER|Historical control|Matched historical controls will be identified from the PatientsLikeMe database.
223611678|NCT01411956|OTHER|"24-minute video episode of patient education TV sitcom White Coats"|The series features a fictional married couple of Family Medicine physicians who work in the same practice, located in our community. In both their professional and private lives and, in moments both humorous and serious, these doctors teach patients about a wide variety of health topics. The intervention episode addressing hypertension will focus on three different patient-physician plot lines, which were developed to specifically address each of the beliefs about hypertension highlighted in the theoretical model (susceptibility, seriousness, barriers, self-efficacy and outcome efficacy.).
223757961|NCT01289769|DRUG|Placebo|normal saline 20 ml( the same volume as dexmedetomidine) giving within 10 minutes.
224201308|NCT06942403|OTHER|Associated product 2 EVENING: RV5000A|"Applied in the evenings from Day 8 to Day 95 or Day 176\*~\* for subjects post injections"
224201309|NCT06941623|DIAGNOSTIC_TEST|Ultrasonography of gastric residual volume|Gastric ultrasound will be performed by the radiologist on each participant before the study and at 0, 10, 20, 30, 60, 90, 120 minutes after drinking in the position of head upright 45 degree with left lateral decubitus to evaluate the gastric residual volume and time to empty gastric antrum. If time to empty gastric antrum is extended, ultrasound will be serial performed at 150 and 180 minutes.
224201310|NCT06941623|DIAGNOSTIC_TEST|Point-of-care testing of glucose|We will perform the point-of-care test of glucose before the study and at 60, and 120 minutes after drinking.
224201311|NCT06941623|OTHER|Hunger numeric rating scale|Hunger will be measured by a numeric rating scale(NRS) before drinking, 60 and 120 minutes after drinking. The Numeric Rating Scale(NRS) is used for the self-report measurement of hunger levels, defined by numbers from 0 to 10, where 0 represents the lowest level of hunger and 10 represents the highest.
224201312|NCT06941623|OTHER|Thirst numeric rating scale|Thirst will be measured by a numeric rating scale(NRS) before drinking, 60, and 120 minutes after drinking. The Numeric Rating Scale(NRS) is used for the self-report measurement of thirst levels, defined by numbers from 0 to 10, where 0 represents the lowest level of thirst and 10 represents the highest.
223611679|NCT01411956|OTHER|Placebo video|The control group watched a 25-minute patient education video on depression.
223611680|NCT01356446|PROCEDURE|implementation surgical checklist|a checklist according to the suggestions raised by the WHO is implemented
223611681|NCT01279681|BIOLOGICAL|bevacizumab|Given IV
223611682|NCT01279681|DRUG|capecitabine|Given PO
223611683|NCT01279681|DRUG|fluorouracil|Given IV
223611684|NCT01279681|DRUG|leucovorin calcium|Given IV
223611685|NCT01279681|DRUG|oxaliplatin|Given IV
223611686|NCT06527326|DIETARY_SUPPLEMENT|Live Combined Bifidobacterium|the Bifidobacterium genus supplement
223611687|NCT06527326|DIETARY_SUPPLEMENT|Placebo|Placebo
223611688|NCT04071197|DEVICE|Gastostomy-biliary tube|gastrostomy followed by ERCP with nasobiliary stent placement in the CBD with its distal end been exit from the previously performed gastrostomy instead of the nostril
223611689|NCT04071197|DEVICE|External biliary diversion, internal biliary diversion and nasobiliary tube|All biliary diversion modalities other than gastrobiliary tube
223611690|NCT01310465|DRUG|zoledronic acid|zoledronic acid, 5mg(100ml), intravenous, one time at three days postoperatively
223611691|NCT01310465|DRUG|sodium chloride|sodium chloride, 100ml, intravenous, one time at three days postoperatively
223611692|NCT01555372|DEVICE|Hook Plate|All participants will have an open reduction internal fixation. The affected upper limb will be temporarily fixed by a sling after admission. Under necessary test, general anaesthetic and antibiotic prophylaxis, the patients will be placed in a beach-chair position in an orthopaedic theatre. The operated side will be prepped and draped and a transverse incision will be made over the fracture site. The fracture ends will be identified, reduced and fixed with HP. X-ray was applied to check the grade of reduction before the operation is completed. Post-operative care will include early active mobilization managed by a standard physiotherapy rehabilitation regime.
223611693|NCT01555372|DEVICE|Locking Plate|All participants will have an open reduction internal fixation. The affected upper limb will be temporarily fixed by a sling after admission. Under necessary test, general anaesthetic and antibiotic prophylaxis, the patients will be placed in a beach-chair position in an orthopaedic theatre. The operated side will be prepped and draped and a transverse incision will be made over the fracture site. The fracture ends will be identified, reduced and fixed with locking plate. X-ray was applied to check the grade of reduction before the operation is completed. Post-operative care will include early active mobilization managed by a standard physiotherapy rehabilitation regime.
223611694|NCT00430105|DRUG|cyclophosphamide|
223611695|NCT05090735|PROCEDURE|SPIP and TAP Block|Injection of Bupivacaine 0.25% for SPIP Block and TAP Block.
223611696|NCT05090735|PROCEDURE|SPIP Block|Injection of Bupivacaine 0.25% for SPIP Block
223611697|NCT03678311|DEVICE|Continuous Positive Airway Pressure (CPAP)|If diagnosed with Long QT Syndrome and have Sleep Apnea index \>5 pauses per hour then given CPAP to wear for approximately 3 months.
223757962|NCT00314574|DRUG|omalizumab (Xolair)|Omalizumab (Xolair) was administered by subcutaneous (SC) injection every 2 or 4 weeks. Xolair was supplied as a sterile, white, preservative-free, lyophilized powder in single-use vials that were reconstituted with Sterile Water for Injection (SWFI), USP.
223757963|NCT00314574|DRUG|placebo|Placebo was administered by subcutaneous (SC) injection every 2 or 4 weeks. Placebo contained the same ingredients as the lyophilized formulation of Xolair,excluding omalizumab.
223757964|NCT00314574|DRUG|corticosteroids|Minimum dose of 500 µg of fluticasone dry-powder inhaler or its equivalent ex-valve dose twice a day.
223757965|NCT00314574|DRUG|long-acting beta-agonists|50 µg salmeterol twice daily or 12 µg formoterol twice daily.
223757966|NCT04972019|DEVICE|Telerehabilitation Experimental Group|"Experimental training will occur in the home. The experimental training will last 8 weeks, each week having up to 4 sessions of therapeutic game play (based on tolerance). Each session will start with vitals and subjective pain level being measured and logged.~They will wear a computer system modified with biosensors, then do motor and cognitive baselines. Subsequently, participants will play an increasing number of games, targeted at cognitive domains of executive function (primary), memory and attention. At the end of every session vitals and subjective pain will be measured and logged.~Clinical Coordinator will call homes weekly to ascertain general health and issues with participation.~At the end of week 4 and 8 participants and their caregivers in the experimental group will fill a subjective evaluation questionnaire to gauge perceived benefits and technical difficulties when using the experimental system. Questions will be scored on a 5-point Likert scale."
224201313|NCT06941623|OTHER|Nausea numeric rating scale|Nausea will be measured by a numeric rating scale(NRS) before drinking, 60, and 120 minutes after drinking. The Numeric Rating Scale(NRS) is used for the self-report measurement of nausea levels, defined by numbers from 0 to 10, where 0 represents the lowest level of nausea and 10 represents the highest.
224201314|NCT06941779|DEVICE|Cueing|Inertial sensors (via a smartphone worn on the lower back) will capture and analyze validated gait-related characteristics (via a gold-standard inertial system worn on both feet). Personalised auditory cues (via smartphone) will be examined for their ability to correct variable gait. To reduce burden on participants (i.e., minimal number of wearable sensors) and to streamline data capture and deliver auditory cues, a single smartphone and a gold standard reference (2 inertial wearables on each foot) will only be used. All devices attached over clothes via belt attachments.
223611698|NCT01372059|OTHER|RGRM|RGRM is multi-sensory method. The group including 6-8 participants is headed by a certified therapist of the method using a unique note system. The Note system is the combined body of body symbols in red and blue, with the audio codes and movements and be assembled in countless combinations to stimulate different parts of the brain. The movements are exercised by the hands tapping on the knees and feet stamping on the floor without the need for tools other than the body. The RGRM is developed to stimulate mobility, reading and speech, rhythm-esteem, body image, balance, memory, coordination, motor skills, concentration, perseverance and social skills. The group will have two sessions per week during 12 weeks.
223611699|NCT01372059|OTHER|Therapeutic riding|The horses walk provides sensory input through movement, which is variable, rhythmic, and repetitive. The many textures, sounds, sights, movement experiences of working around a horse provide an enriched sensory environment. The participants gain from the physical benefits of being on a moving horse and are socially and emotionally stimulated by interacting with a horse and the rest of the group. The intervention is headed by educated therapists (occupational therapist and physical therapist), in conjunction with experienced horse handler and specially trained therapy horses. The treatment is held in group format (4-6 participants) twice per week in 12 weeks which runs in sessions where two participants ride at the same time.
223611700|NCT01372059|OTHER|Receives no intervention|Receives no intervention and acts as a control group in the analyses but will receive rhythm and music therapy after one year, when the long-term follow-up is completed.
223611701|NCT06543901|PROCEDURE|Submuscular plating|the patient was fixed with a submuscular plate
223611702|NCT06543901|PROCEDURE|Traction and casting|the patient was placed on a traction with a thomas splint and then was casted with a hip spica
223611703|NCT01064115|DRUG|Cetirizine Hydrochloride|Cetirizine Hydrochloride Tablets 10 mg
223611704|NCT01260714|DRUG|Azacitidine|Given SC
223611705|NCT01260714|DRUG|Etoposide|Given IV
223611706|NCT01260714|OTHER|Laboratory Biomarker Analysis|Correlative studies
223611707|NCT01260714|DRUG|Mitoxantrone Hydrochloride|Given IV
223611708|NCT04085549|DEVICE|Berry Oil Cream|Cream containing berry and plant oils and humectants; a medical device product in development
223611709|NCT04085549|OTHER|Reference Cream|Commercial refence cream not containing berry and plant oils.
223611710|NCT02744092|DRUG|Rivaroxaban|Anticoagulation therapy.
223611711|NCT02744092|DRUG|Apixaban|Anticoagulation therapy.
223611712|NCT02744092|DRUG|Edoxaban|Anticoagulation therapy.
223611713|NCT02744092|DRUG|Dabigatran|Anticoagulation therapy.
223611714|NCT02744092|DRUG|Warfarin|Anticoagulation therapy.
224201315|NCT06942195|OTHER|Ca-1000|Calcium, an essential mineral and a key component of dairy, is a regular part of our daily diet. Recent studies have shown that calcium, at doses of 1000 mg, stimulates gut hormones and motility, will be 'higher dose' in this condition.
224201316|NCT06942195|OTHER|Ca-500|Calcium, an essential mineral and a key component of dairy, is a regular part of our daily diet. Recent studies have shown that calcium, at doses of 500 mg, stimulates gut function. In this condition, it will be considered 'lower dose.'
224201317|NCT06942195|OTHER|Control|Saline (an isotonic solution containing 2.8 g of sodium chloride (NaCl), dissolved in 225 mL of distilled water).
223611715|NCT02744092|DRUG|Dalteparin|Anticoagulation therapy.
223611716|NCT02744092|DRUG|Enoxaparin|Anticoagulation therapy.
223611717|NCT02744092|DRUG|Fondaparinux|Anticoagulation therapy.
223611718|NCT01885221|BEHAVIORAL|Multimedia Support Intervention|
223611719|NCT01365286|DRUG|Ivabradine (Procoralan)|Ivabradine 7,5 mg b.i.d. for 5 days and Placebo b.i.d. for 5 days (Ivabradine-Placebo)
223611720|NCT01365286|DRUG|Placebo|Placebo b.i.d. for 5 days and Ivabradine 7,5 mg b.i.d. for 5 days (Placebo-Ivabradine)
223611721|NCT01633788|DRUG|AGN-195263 0.1%|1 drop of AGN-195263 0.1% instilled in each eye twice daily.
223509335|NCT05682469|BEHAVIORAL|VR cognitive training|"All participants will receive trainings for 60 minutes per day, two days per week for 16 sessions.~All participants will receive one immersive leisure-based VR cognitive training for 40 minutes. VR cognitive training receives four gardening activities.~The cognitive elements including attention, working memory, processing speed, and executive function incorporated training."
223611722|NCT01633788|DRUG|AGN-195263 0.03%|1 drop of AGN-195263 0.03% instilled in each eye twice daily.
223611723|NCT01633788|DRUG|AGN-195263 0.01%|1 drop of AGN-195263 0.01% instilled in each eye twice daily.
223611724|NCT01633788|DRUG|AGN-195263 Vehicle|1 drop of AGN-195263 vehicle (placebo) instilled in each eye twice daily.
223757967|NCT04972019|OTHER|Telerehabilitation Sham Control Group|"Sham control group will train playing web games while wearing a biosensor connected to a laptop provided, showing the web games. However biosensor data will not be used to control game difficulty.~Sham group controls will start every session with vitals and subjective pain levels being measured and logged. Then participants will play the same frequency and duration of sessions, however those will consist of web games training the same domains (memory, focusing, executive function). Interaction will be through a mouse, and data will be downloaded to a server maintained by the company doing the web games. Data will then be transferred to the research team.~At the end of every session vitals and subjective pain levels will again be measured and logged.~Once a week the Clinical Coordinator will call the home to ascertain general health and determine is there were issues with that week participation."
223757968|NCT04183556|DRUG|Naproxen|use of naproxen twice a day orally in mens time
223757969|NCT04183556|DIETARY_SUPPLEMENT|Turmeric|Use of turmeric orally (1 gram powder formula) in mens time
223757970|NCT02581696|DRUG|Lafutidine|Lafutidine 10mg, 1 tablet, bid
223757971|NCT02581696|DRUG|Irsogladine maleate|Irsogladine maleate 2mg, 2 tablet, qd
223757972|NCT03194451|OTHER|non-interventional study|teeth collection
223757973|NCT02815748|DRUG|SP2086|SP2086 was taken only one time at 100mg dose in health volunteers
223757974|NCT06049056|OTHER|Invitation|During Recruitment Method 3, x4 practices will send letters with a URL link providing the potential participant with access to the online questionnaire, x4 practices will send letters with a QR code providing the potential participant with access to the online questionnaire, and x2 practices will send letters with a URL link and a QR code providing the potential participant with access to the online questionnaire,
223757975|NCT03266328|PROCEDURE|Primary Percutaneous Coronary Intervention (PPCI)|Percutaneous Coronary Intervention in patients of acute myocardial infarction diagnosed using ECG findings
223757976|NCT00449956|DRUG|dorzolamide hydrochloride (+) timolol maleate|Dorzolamide hydrochloride 1% + timolol 0.5%, 8-week
223757977|NCT00449956|DRUG|Comparator: timolol maleate|timolol maleate 0.5%, 8-week
223757978|NCT00449956|DRUG|Comparator: dorzolamide hydrochloride|dorzolamide hydrochloride 1%, 8-week
223757979|NCT01334658|PROCEDURE|Phacoemulsification cataract surgery|"A group received BSS ® (ALCON LABORATORIES, INC.) and another group received glucose-bicarbonate-Ringer Lactate (GBRL) \[500 cc. Ringer Lactate (GLICOLABOR, Pharmaceutical LTD.) enriched with 1.5 ml of glucose in water (25%) and 08 ml of sodium bicarbonate (8.4%)\] as a solution for irrigation during surgery.~All surgeries were performed by single surgeon (HON), using the standard surgical technique quick-chop. Immediately before surgery, solutions for irrigation \[BSS ® (ALCON LABORATORIES, INC..) and glucose-bicarbonate-Ringer Lactate (GBRL)\] were brought to the operating table in a temperature of 22 degrees Celsius. The microcoaxial Phacoemulsification was performed under a phaco Legacy Series 20000 (ALCON LABORATORIES, INC..)."
223757980|NCT01334658|DRUG|Glucose-bicarbonate-Ringer Lactate (GBRL)|"A group received BSS ® (ALCON LABORATORIES, INC.) and another group received glucose-bicarbonate-Ringer Lactate (GBRL) \[500 cc. Ringer Lactate (GLICOLABOR, Pharmaceutical LTD.) enriched with 1.5 ml of glucose in water (25%) and 08 ml of sodium bicarbonate (8.4%)\] as a solution for irrigation during surgery.~All surgeries were performed by single surgeon (HON), using the standard surgical technique quick-chop. Immediately before surgery, solutions for irrigation \[BSS ® (ALCON LABORATORIES, INC..) and glucose-bicarbonate-Ringer Lactate (GBRL)\] were brought to the operating table in a temperature of 22 degrees Celsius. The microcoaxial Phacoemulsification was performed under a phaco Legacy Series 20000 (ALCON LABORATORIES, INC..)."
224201318|NCT06942364|OTHER|Action Observation Therapy|"The AOT video comprised four specific tasks designed to improve lower extremity function, balance, and gait (Figure 1):~1. Sitting Balance: Movements to enhance balance while seated (Figure 2).~2. Sit-to-Stand Transition: Exercises to facilitate the transition from sitting to standing.~3. Walking and Balance: Gait and balance training on a parallel bar or flat surface.~4. Single-Leg Balance: Activities focused on improving balance on one leg. For each task, children observed the movement for 1 minute, then practiced the action for 5 minutes. A 1-minute rest period was allowed between tasks, with a total AOT session lasting 30 minutes. All sessions were conducted by the same physiotherapist."
223509336|NCT05682469|BEHAVIORAL|Traditional cognitive training|"All participants will receive trainings for 60 minutes per day, two days per week for 16 sessions.~The control group is performing traditional cognitive training program."
223611725|NCT03536585|DEVICE|Vulvovaginal treatment|"* Radiofrequency and pulsed electro-magnetic fields treatment of the vaginal canal to maintain an internal temperature of approximately 42 C for the proximal thermometer and 45 C for the mid and distal thermometers for 15 minutes.~* Radiofrequency and pulsed electro-magnetic fields treatment of the labia to maintain an external temperature of approximately 40 C - 45 C for 15 minutes.~* Radiofrequency and pulsed electro-magnetic fields treatment of the mons pubis to maintain an external temperature of approximately 40 C - 47 C for 15 minutes."
223509337|NCT00292370|DRUG|Open Label (OL) Paroxetine|Open-label Paroxetine
223611726|NCT03536585|DEVICE|Baseline|Subject is acting as their own control. The baseline general appearance photograph will act as the comparator.
223611727|NCT00310011|DRUG|cisplatin|
223611728|NCT00310011|DRUG|gemcitabine hydrochloride|
223611729|NCT00310011|DRUG|paclitaxel|
223611730|NCT00310011|PROCEDURE|conventional surgery|
223611731|NCT00215111|BEHAVIORAL|Low carbohydrate, reduced glycemic load, and a control diet|
223611732|NCT04948853|BEHAVIORAL|Individual Placement Support - Supported Employment|Individual, person-centered intervention designed to help individuals living with mental illnesses obtain and sustain meaningful employment. This is an evidence-based practice for individuals with severe mental illnesses.
223611733|NCT01929226|BIOLOGICAL|ETI-204|Monoclonal Antibody
223757981|NCT01334658|DRUG|Balanced Salt Solution (BSS®)|"A group received BSS ® (ALCON LABORATORIES, INC.) and another group received glucose-bicarbonate-Ringer Lactate (GBRL) \[500 cc. Ringer Lactate (GLICOLABOR, Pharmaceutical LTD.) enriched with 1.5 ml of glucose in water (25%) and 08 ml of sodium bicarbonate (8.4%)\] as a solution for irrigation during surgery.~All surgeries were performed by single surgeon (HON), using the standard surgical technique quick-chop. Immediately before surgery, solutions for irrigation \[BSS ® (ALCON LABORATORIES, INC..) and glucose-bicarbonate-Ringer Lactate (GBRL)\] were brought to the operating table in a temperature of 22 degrees Celsius. The microcoaxial Phacoemulsification was performed under a phaco Legacy Series 20000 (ALCON LABORATORIES, INC..)."
223611734|NCT01929226|OTHER|Placebo|Placebo for ETI-204
223611735|NCT04734886|DIETARY_SUPPLEMENT|L. reuteri DSM 17938 + vitamin D|1 \* 10\^8 CFU of L. reuteri DSM 17938 + 10 ug vitamin D3, two capsules per day for 6 months
223611736|NCT04734886|DIETARY_SUPPLEMENT|Placebo + vitamin D|Placebo tablet + 10 ug vitamin D3, Similar in shape and taste to intervention capsules but without the probiotic components, two capsules per day over six weeks
223611737|NCT03164811|PROCEDURE|goal directed fluid therapy|pulse pressure variation will be used to as a goal to guide fluid administration in this group
223611738|NCT03164811|OTHER|Controlled|standard fluid treatment by an anesthesiologist
223611739|NCT02492178|DRUG|Intrarectal artesunate|
223611740|NCT02492178|DRUG|Intravenous artesunate|
223611741|NCT02492178|DRUG|Intravenous quinine|
223611742|NCT04248699|DIETARY_SUPPLEMENT|Lumenato|tomato oleoresin obtained from yellow dry tomato pulp
223611743|NCT01552070|BEHAVIORAL|Recruitment maneuver|Recruitment maneuver will be performed immediately (within 2 minutes) after intubation, consisting of a continuous positive airway pressure of 40 cmH2O over 30 seconds.
223611744|NCT01552070|OTHER|without recruit maneuver|After oral intubation, each patient will be mechanically ventilated, with a tidal volume of 6mL/kg, a respiratory rate of 20 to 25 breaths/minute, a positive end-expiratory pressure (PEEP) of 5 cmH2O, and an FiO2 of 100%. PEEP titration according to FiO2 and ARDSnet.
223611745|NCT00881738|DRUG|Clarithromycin 250 mg Tablets (Geneva, USA)|
223611746|NCT00881738|DRUG|Biaxin 250 mg Tablets (Abbott Laboratories, Inc, USA)|
223611747|NCT03793348|DEVICE|MCD|Micro coring skin removal with automated coring device
223611748|NCT00195936|DRUG|Cinacalcet|Single oral dose of Cinacalcet for children with Hypophosphatemic Rickets
223611749|NCT04802811|DRUG|SHR2150；Placebo|Single dose；SHR2150-dose 1 or Placebo-dose 1
223611750|NCT04802811|DRUG|SHR2150；Placebo|Single dose；SHR2150-dose 2 or Placebo-dose 2
223611751|NCT04802811|DRUG|SHR2150；Placebo|Single dose；SHR2150-dose 3 or Placebo-dose 3
223611752|NCT04802811|DRUG|SHR2150；Placebo|Single dose；SHR2150-dose 4 or Placebo-dose 4
223611753|NCT04802811|DRUG|SHR2150；Placebo|Single dose；SHR2150-dose 5 or Placebo-dose 5
223757982|NCT05888129|PROCEDURE|surgery after neoadjuvant chemotherapy|surgery after neoadjuvant chemotherapy
223611754|NCT01454791|DRUG|diclofenac sodium topical gel|diclofenac sodium topical gel 1% applied 1-4 times per day for two weeks either preceded by or followed by two weeks of placebo
223611755|NCT01454791|OTHER|Placebo|a placebo gel is applied 1-4 times per day for two weeks.
223611756|NCT04934371|DEVICE|Transcranial Direct Current Stimulation (tDCS)|TDCS is a procedure that sends weak electrical currents between points on the scalp. Some of this current flows through the brain, and may induce temporary changes in brain activity lasting 30-60 minutes beyond the time of stimulation. TDCS is believed to be very low risk. TDCS has been applied in more than 4900 studies and hundreds of people to treat various neurological and psychiatric conditions, including depression, epilepsy, chronic pain and Parkinson's. In this study we will use tDCS to suppress symptom of tinnitus and hyperacusis.
223611757|NCT04934371|DEVICE|Sham TDCS|Sham control will be administered to the same area as active TDCS
223611758|NCT06371105|OTHER|10-week water-based aerobic training|The water-based aerobic program was adopted from the protocol previously used by Costa et al. (2018, 2020). This training program was carried out thrice a week over 2 non-consecutive days 48 hours apart for 10 weeks according to ACSM guidelines
223611759|NCT02807623|DRUG|Ibuprofen|The participants will take their first dose of the study drug immediately after influenza vaccine receipt. The medication will be blinded and dispensed by a research pharmacist. The participants will receive instructions on the dosing, frequency and a recommendation to take with food or milk and will be provided a snack with their first dose.
223611760|NCT02807623|BEHAVIORAL|Compound Exercise of Push-ups|The participants will perform an exercise intervention of push-ups as immediately as possible but no more than 15 minutes after influenza vaccine receipt. The number of pushups performed will be at least 80% of the participants last Army Physical Fitness Test (APFT) score in one session. The number of pushups will be recorded. A baseline lactate fingerstick blood specimen will be collected with either the serology sample (if possible) or from the hand opposite the vaccine receipt arm prior to performing pushups and a second finger stick sample within 3-8 minutes, but no more than 15 minutes after vaccine receipt.
223611761|NCT02807623|DRUG|oral placebo|The participants will take their first dose of the study drug immediately after influenza vaccine receipt. The medication will be blinded and dispensed by a research pharmacist. The participants will receive instructions on the dosing, frequency and a recommendation to take with food or milk and will be provided a snack with their first dose.
223611762|NCT00425724|DRUG|Methylprednisolone pulses plus prednisone versus Cyclosporine A|The patients will be randomised to receive either MP pulses i.v. or cyclosporine A p.o. The MP pulses will consist of three doses of methylprednisolone 30 mg/kg i.v. given over a period of one week in hospital. On the intermediate days and for a month after the MP pulses, the patients will be given prednisone 30 mg/m2/day p.o., after which the prednisone medication will be gradually run down over 3 months. The patients randomised into the cyclosporine A group will receive an initial dose of 5 mg/kg/day, after which the dosage will be titrated to an optimal therapeutic level by monitoring the B-Cya concentration. The cyclosporine A treatment will be continued for 12 months.
223611763|NCT00239239|DRUG|Darbepoetin alfa|darbepoetin alfa SC dosing 0.45 mcg/kg 3 times per week through study day 40. Optional extended treatment period: 200 mcg Q2W through study day 110
223757983|NCT00892567|BIOLOGICAL|9 Peptides from Her-2/neu, CEA, & CTA|Each vaccination will be administered on days 1, 8, 15, 36, 43, and 50. All participants will receive 9 class I MHC-restricted synthetic peptides and a class II MHC-restricted tetanus helper peptide administered in Montanide ISA-51. The vaccine will be administered subcutaneously (1 ml) and intradermally (1ml) at a single vaccination site.
223757984|NCT01253252|RADIATION|[18F] Fluorodeoxyglucose PET Scan Imaging|"Positron Emission Tomography (PET) is a nuclear medicine imaging technique which produces a 3-dimensional image of functional processes in the body. The system detects pairs of gamma rays emitted indirectly by a positron-emitting radionuclide, which is introduced into the body on a biologically active molecule. Images of tracer concentration in 3-dimensional space are then reconstructed by computer analysis.~The biologically active molecule chosen for PET is 18-fluorodeoxyglucose. The concentrations of tracer imaged then give tissue metabolic activity, in terms of regional glucose uptake.~The dose of 18FDG that is recommended for adults in a standard exploration varies from 200 to 500 MBq according to the weight of the patient and the camera used. No allergic or other incident has been observed after several thousands of examinations."
223757985|NCT01253252|RADIATION|CT scan|Computed tomography (CT) is a medical imaging method employing tomography created by computer processing. Digital geometry processing is used to generate the PET's three-dimensional space image.
223757986|NCT01253252|BIOLOGICAL|Blood sampling for biological investigations|A venous blood sample of a total of 30 ml for measurement of enzymes associated with the development of aneurysms (= biomarkers).
223757987|NCT01250470|OTHER|Laboratory Biomarker Analysis|Correlative studies
223757988|NCT01250470|DRUG|Montanide ISA-51/Survivin Peptide Vaccine|Given SC
223757989|NCT01250470|BIOLOGICAL|Sargramostim|Given SC
223757990|NCT04637958|DEVICE|THA|Total hip arthroplasty
223757991|NCT02086110|DIETARY_SUPPLEMENT|Synbiotic|
223757992|NCT02086110|DIETARY_SUPPLEMENT|Prebiotic|
223611764|NCT02102295|DRUG|Experimental toothpaste|Experimental toothpaste was containing 0.3% L-ascorbic acid 2-phosphate magnesium salt and 950 ppm fluoride. The registered participants were instructed to brush their teeth twice a day in their customary manner.
223611765|NCT02102295|DRUG|Control toothpaste|Control toothpaste was containing 950 ppm fluoride. The registered participants were instructed to brush their teeth twice a day in their customary manner.
223611766|NCT02213835|OTHER|Specific Carbohydrate diet (SCD)|
223611767|NCT04092686|DRUG|SEP-363856 75mg|SEP-363856 75mg tablet dosed once daily
223611768|NCT04092686|DRUG|SEP-363856 100mg|SEP-363856 100mg tablet dosed once daily
223611769|NCT04092686|DRUG|Placebo|Placebo tablet dosed once daily
223611770|NCT03826121|DIETARY_SUPPLEMENT|Sesame Oil Cake Extract|Sesame Oil Cake Extract 1.5 g/day for 12 weeks.
223611771|NCT03826121|DIETARY_SUPPLEMENT|placebo|placebo for 12 weeks.
223611772|NCT06261177|DEVICE|Functional Electrical Stimulation (FES)|45 mins per day for the duration of 4 weeks (20 sessions).
223757993|NCT05087654|OTHER|Combination of 3D VR and Hands-on Horticultural Activities|The intervention program consisted of 8 two-hour sessions that were conducted once a week for 8 consecutive weeks.
223757994|NCT01627938|DRUG|Dexrazoxane (DRZ) plus Mitoxantrone (MX)|Dosage: DRZ (600 mg/m2) : MX (12 mg/m2) ratio 50:1 DRZ infusion / MX infusion once every three months over a period of 12 months, i.e. 5 infusions
223757995|NCT01627938|DRUG|Placebo plus Mitoxantrone (MX)|MX Dosage: 12mg/m2 Placebo infusion / MX infusion once every three months over a period of 12 months, i.e. 5 infusions
223757996|NCT02882321|DRUG|Oxidative Phosphorylation Inhibitor IACS-010759|Given PO
223757997|NCT02882321|OTHER|Pharmacological Study|Correlative studies
223757998|NCT05999006|DEVICE|ELIOS Procedure|Treatment with the ELIOS System
223757999|NCT02997033|OTHER|No intervention|No intervention
223758000|NCT05358496|DIAGNOSTIC_TEST|Data collection|Clinical data collection
223758001|NCT03376178|COMBINATION_PRODUCT|lidocaine and ropivacaine injection through catheters|injection of local anesthetic through an endhole or a sixhole femoral nerve catheter in the context of total knee replacement. Analgesic properties at 24 and 48h of both groups registered.
223611773|NCT06261177|DEVICE|Sham FES|Sham FES
223611774|NCT02953522|OTHER|191 mcg/day of Folate|Diet containing 191 mcg / day of Folate
223611775|NCT02953522|OTHER|90 mcg / day of Folate|Diet containing 90 mcg / day of Folate
223611776|NCT00972192|BEHAVIORAL|Inpatient HIV testing|Participants who were randomized to the intervention group received free HIV testing and their results before they were discharged from the hospital.
223611777|NCT00972192|BEHAVIORAL|Outpatient HIV testing|Participants randomised to the control arm received referral for testing post-discharge
223611778|NCT01835821|DEVICE|prosthetic crowns|prosthetic crowns
223611779|NCT04639544|DIETARY_SUPPLEMENT|Placebo|Each participant will consume 1 capsule per day in one of the main meals without any restriction in the diet or in their life habits
224205938|NCT03026868|PROCEDURE|quadrilateral surface plate|Both anterior and posterior approaches were always conducted to manage the fragments of quadrilateral surface. Novel quadrilateral surface plate was used in this study to examine whether the fragments could be fixed through single Stoppa approach.
223611780|NCT04639544|DIETARY_SUPPLEMENT|Lactobacillus strain|Each participant will consume 1 capsule per day in one of the main meals without any restriction in the diet or in their life habits
223611781|NCT02326285|DRUG|Gefitinib|Patients will be treated for 12 days with gefitinib 250 mg/day p.o. (d -12 to -1) and induced with chemotherapy docetaxel 75 mg/m2 and cisplatin 50 mg/m2 d1+2 and intercalated gefitinib 250 mg/day d4-20 (cycle 1 and 2) and d4-17 (for cycle3). Surgery is planned in the 4th week after d1 of the last cycle.
223611782|NCT02326285|DRUG|docetaxel|chemotherapy docetaxel 75 mg/m2 and cisplatin 50 mg/m2 d1+2 and intercalated gefitinib 250 mg/day d4-20 (cycle 1 and 2) and d4-17 (for cycle3).
223611783|NCT02326285|DRUG|cisplatin|chemotherapy docetaxel 75 mg/m2 and cisplatin 50 mg/m2 d1+2 and intercalated gefitinib 250 mg/day d4-20 (cycle 1 and 2) and d4-17 (for cycle3).
223611784|NCT02326285|PROCEDURE|Surgery|Surgery should be performed in the 4th or at the latest 5th week after d1 of the last cycle of chemotherapy (d64 to 78).
223611785|NCT06233188|PROCEDURE|orthogantic surgery|surgery that correcting the maxilla and mandible related with each other
223611786|NCT02942758|DRUG|low-dose Azacitidine|Azacitidine 75 mg/d s.c. for 7 days, repeated 28-day treatment cycle
223611787|NCT02942758|DRUG|Pioglitazone|Pioglitazone 45 mg p.o. continuously from day 1
223611788|NCT02942758|DRUG|ATRA|ATRA \*45 mg/m² p.o. from day 1 to 28, 15 mg/m² from day 29 continuously; \*this regimen will be chosen for the first dose to be evaluated.
223611789|NCT02942758|DRUG|standard-dose AZA|Azacitidine 75 mg/m²/d s.c. for 7 days, repeated 28-day treatment cycle
223611790|NCT00215358|DRUG|Formoterol Fumarate|
223611791|NCT00028483|DRUG|cBR96-doxorubicin immunoconjugate|
223611792|NCT00028483|DRUG|docetaxel|
223611793|NCT05599308|DEVICE|OMRON blood pressure monitor with AFib screening feature|Blood pressure measurement by an oscillometric blood pressure monitor
223758002|NCT04242056|DRUG|18F-PM-PBB3|"18F-PM-PBB3 brain PET studies will be conducted for 38 subjects. Dynamic PET/MRI studies will be collected by PET/MRI scanner for 100 minutes (4×15 s, 8×30 s, 960 s, 2×180 s, 8300 s, 3×600 s). Volumes of interest (VOIs) will be delineated from corresponding MR images by manual including bilateral frontal, parietal, mesial temporal, lateral temporal, hippocampal, occipital, anterior cingulate, posterior cingulate, cerebellum areas, and genu region of white matter. The DVRs will be computed from Logan graphic analysis by using cerebellum as reference input.~SUVR of every cortical VOI to the gray matter of cerebellum will be calculated from nine 10-min dynamic image sets."
223758003|NCT05992506|DIAGNOSTIC_TEST|POD risk estimation using PEUMA|A software will analyze intraoperative EEG recording for the estimation of a POD Risk Index
223758004|NCT02844296|BEHAVIORAL|Video about exercise|Video about short-bout exercise will be played for the participants.
223758005|NCT02844296|BEHAVIORAL|App about exercise|A smartphone App about exercise will be installed in participants' mobile phone.
223758006|NCT02844296|BEHAVIORAL|Leaflet about exercise|A leaflet about exercise will be provided for the participants.
223758007|NCT02844296|BEHAVIORAL|Video about diet|Video about healthy diet will be played for the participants.
223758008|NCT02844296|BEHAVIORAL|App about diet|A smartphone App about healthy diet will be installed in participants' mobile phone.
223758009|NCT02844296|BEHAVIORAL|Leaflet about diet|A leaflet about healthy diet will be provided for the participants.
223758010|NCT03640026|DRUG|Tacrolimus|Tacrolimus will be initiated at 0.1 mg/kg/day in two separate 12-hour oral doses (capsules) for 14 days.
223758011|NCT06353490|DEVICE|Infrared Forehead Thermometer (GE-TF03)|Infrared Forehead Thermometer (GE-TF03) is an investigational device intended to measure body temperature on the forehead. GE-TF03 took three measurements for each subject.
223758012|NCT06353490|DEVICE|Infrared Ear Thermometer (GE-TE06)|Infrared Ear Thermometer (GE-TE06) is an investigational device intended to measure body temperature in the ear canal. GE-TF06 took three measurements for each subject.
223758013|NCT06353490|DEVICE|Electronic Thermometer (MT-B321FB)|Electronic Thermometer (MT-B321FB) is an investigational device intended to measure body temperature on the temporal artery. MT-B321FB took three measurements for each subject.
223611794|NCT05599308|DEVICE|Microlife WatchBP Home A|Blood pressure measurement by an oscillometric blood pressure monitor
223611795|NCT04820244|OTHER|No intervention|No intervention
223611796|NCT00859547|BIOLOGICAL|rThrombin, 1000 IU/mL|rThrombin,1000 IU/mL, 1000 IU/mL, applied topically to the bleeding site during a single surgery procedure on Day 1.
223611797|NCT05272371|COMBINATION_PRODUCT|Chemoimmunotherapy (Dinutuximab beta in combination with chemotherapy)|Dinutuximab beta in combination with chemotherapy.
223611798|NCT00003425|BIOLOGICAL|filgrastim|
223611799|NCT00003425|DRUG|amifostine trihydrate|
223611800|NCT00003425|DRUG|cyclophosphamide|
223611801|NCT00003425|DRUG|melphalan|
223611802|NCT00003425|PROCEDURE|peripheral blood stem cell transplantation|
223611803|NCT03310723|DEVICE|Face Mask preoxygenation|Standard face mask preoxygenation.
223611804|NCT03310723|DEVICE|OptiFlow preoxygenation|Preoxygenation using transnasal humidified rapid insufflation ventilatory exchange (THRIVE).
223611805|NCT00181363|DEVICE|Mamma board|use of mamma board during radiotherapy
223611806|NCT01480960|OTHER|Pulmonary rehabilitation + whole body vibration training|standard inpatient rehabilitation program including endurance and strength plus squats on a vibration plate for 4x2 minutes, 3 times per week
223611807|NCT06071949|DRUG|Adezunap|Sublingual spray with maximum application of 16 actuations per day or a maximum daily dose of 17,6mg THC distributed over 4 daily intakes.
223758014|NCT06353490|DEVICE|Electronic Thermometer (MT-B231)|Electronic Thermometer (MT-B231) is a reference device that measured axillary temperature one time for each subject.
223758015|NCT01564303|DRUG|Acetylcysteine, Phosphodiesterase type 5 inhibitor ,Carnitine|to evaluate the effect of the above agents on Kidney functioning parameters
224205939|NCT00888472|PROCEDURE|Leukocytapheresis|5000 ml, the blood volume per body, treated once. Twice at an interval of 6 days.
224205940|NCT04461626|DEVICE|Persona fixed bearing knee system (All patients will receive Persona fixed bearing knee system)|
223611808|NCT06071949|DRUG|Placebo|Sublingual spray with maximum application of 16 actuations per day distributed over 4 daily intakes.
223611809|NCT01599975|DRUG|Long acting methylphenidate|Treatment with long-acting methylphenidate, 36 mg a day as 2 tablets of 18 mg each.
223611810|NCT01599975|DRUG|Long acting methylphenidate|18 mg tablets, 2 tablets daily by mouth x 2 weeks, then washout x 2 weeks, then crossover to 2 tablets of matched placebo x 2 weeks.
223611811|NCT01599975|DRUG|Matched placebo|2 tablets of matched placebo daily by mouth
223611812|NCT06115616|BEHAVIORAL|Morning exercise|Exercise before noon in the morning
223611813|NCT06115616|BEHAVIORAL|Afternoon exercise|Exercise in the late after noon
223611814|NCT02098746|DRUG|Pioglitazone/glimepiride|Pioglitazone/glimepiride combination tablets
223611815|NCT05087771|DRUG|injectable naltrexone|360 mg dose to be given prior to hospital discharge
223611816|NCT05087771|DRUG|oral naltrexone|50 mg tab dispense 30 day supply to be given at hospital discharge
223611817|NCT02944214|DRUG|Febuxostat|It acts as an inhibitor of xanthine oxidase, thus lowering urate concentrations in the body
223611818|NCT02944214|DRUG|Benzbromarone|It is structurally related to the antiarrhythmic amiodarone, and it is a uricosuric agent and non-competitive inhibitor of xanthine oxidase
223611819|NCT01919944|DRUG|VLY-686|capsules containing either 10 mg or 50 mg VLY-686
223611820|NCT01919944|DRUG|Placebo|Sugar capsule to mimic either VLY-686 10 mg capsule or 50 mg capsule
223611821|NCT03816735|DEVICE|Cikatridina|Women are asked to insert the suppositories according to the manufacturer's protocol.
223611822|NCT03816735|DEVICE|Juliet Feminine Laser|Women will receive the laser treatment twice during the study period.
223758016|NCT06448936|OTHER|Patient-reported outcome measures (PROMs)|Administration of questionnaires investigating the impact of facial difficult-to-treat basal cell carcinoma treated by surgery on patient's quality of life over the course of one year. The questionnaires will be submitted at baseline (i.e., before surgery) and at 3-months follow up.
223758017|NCT03129672|PROCEDURE|allograft arthrodesis of ankle|patients that underwent trought a block resection of a malignant tumor of the distal tibia and reconstruction with allograft arthrodesis
223758018|NCT00235872|BIOLOGICAL|adalimumab|40 mg eow, sc
223611823|NCT05777044|BEHAVIORAL|Yoga|Participation in Hatha Yoga twice a week for 45 minutes for 10 weeks. The total potential dose is 900 minutes over the course of the intervention.
223758019|NCT00004066|BIOLOGICAL|filgrastim|
223758020|NCT00004066|DRUG|docetaxel|
223758021|NCT00004066|DRUG|gemcitabine hydrochloride|
223758022|NCT05103124|DEVICE|Hydral|The investigational product GUM Hydral will be administered for a 30-days treatment period
223611824|NCT04062110|DEVICE|plaster cast|Closed Reduction of Fracture and Application of Plaster Cast
223758023|NCT05103124|OTHER|Placebo|The placebo product will be administered for a 30-days treatment period
223758024|NCT02272413|DRUG|BI 695502|
223758025|NCT02272413|DRUG|Avastin|
223758026|NCT04780425|BEHAVIORAL|DESMOND|as previously described
223758027|NCT04780425|OTHER|usual care|usual care as per standard treatment guidelines of Ghana unstructured/adhoc diabetes education during clinic visits
223758028|NCT01164449|DEVICE|Space TGC|Space TGC with incorporated eMPC algorithm to establish glycaemic control with a blood glucose target range of 80-150 mg/dL (4.4-8.3 mM)
224201319|NCT06942364|OTHER|conventional physiotherapy|Conventional physiotherapy is a widely used therapeutic approach that focuses on improving physical function, mobility, and overall quality of life through evidence-based techniques. It typically includes exercises for strength, flexibility, balance, and coordination, along with manual therapy, postural training, and education about movement and body mechanics. This traditional method is commonly applied in the rehabilitation of patients with neurological, orthopedic, and musculoskeletal conditions. In pediatric populations, such as children with cerebral palsy, conventional physiotherapy plays a vital role in promoting motor development, enhancing functional independence, and preventing secondary complications.
223611825|NCT01410890|BIOLOGICAL|alglucosidase alfa|Intravenous (IV) infusion of 20mg/kg body weight every other week (qow)
223611826|NCT01467141|DRUG|insulin aspart|Injected s.c. (under the skin) three times a day
223611827|NCT01467141|DRUG|human insulin|Injected s.c. (under the skin) 30 minutes before the meals
223611828|NCT01467141|DRUG|isophane human insulin|May be administered s.c. (under the skin) in both treatment groups thrice daily
223758029|NCT04729166|BEHAVIORAL|Structured education and follow-up|This structured educational material was developed by the authors on the basis of the literature. Interventions of the study were carried out in the 32nd-42nd week of pregnancy, 3rd-7th day postpartum, and at the 1st month. At first stage, a 15-20-minute education was given to the pregnant women in the study group in the breastfeeding room of the facility, educational booklets were distributed. The main emphasis parts of the education were repeated with a standard summary information form at each follow-up.
223758030|NCT03800719|BEHAVIORAL|AWARD advice|"At baseline, brief smoking cessation advice following AWARD model will be delivered to subjects within about 2 to 5 minutes:~* Ask about smoking history and habit~* Warn about the risks of smoking using a leaflet~* Advise to quit smoking as soon as possible and use nicotine replacement therapy (NRT) or SC services~* Refer subjects to free smoking cessation services in Hong Kong if they agree~* Do it again: smokers who have tried to quit but relapsed will be encouraged to quit again and those who have reduced smoking will be advised to further reduce or quit smoking"
223758031|NCT03800719|BEHAVIORAL|Health warning leaflet|At baseline, an A5-sized leaflet will be given to subjects, which includes information about risks of smoking, pictures of smoking-related diseases, and smoking cessation services provided in Hong Kong.
223758032|NCT03800719|BEHAVIORAL|Active referral to smoking cessation (SC) services|At baseline, subjects will be encouraged to seek smoking cessation services in Hong Kong. If subjects agree, their contact information will be sent to the preferred service providers for a quick appointment and follow-up.
223758033|NCT03800719|BEHAVIORAL|Regular messages through Instant Messaging (IM)|A total of pre-set 26 messages will be sent to subjects through WhatsApp 12 weeks after baseline to remind the quit date and to encourage abstinence. Messages are tailored based on subjects' sociodemographic characteristics and smoking habit following Social Cognitive Theory and Transtheoretical Model. Messages will be sent with the schedule of once daily for 1 week (the week across the quit date), 3 times a week for 4 weeks (2 weeks each before and after the week with quit date) and once a week for remaining 7 weeks. The schedule will be adjusted according to the quit date and also smokers' requests. The format of regular messages will mainly be text-based but also include pictures, animations and videos.
223758034|NCT03800719|BEHAVIORAL|Psychosocial support and referral to SC services through IM|Personalized interactive text or voice conversation will be provided by trained smoking cessation advisors through WhatsApp for 3 months after baseline. Advisors will periodically proactively send messages to subjects to initiate the conversation (e.g. asking recent progress of smoking cessation) and deliver evidence-based advice. Advisors will also actively refer subjects, if they have expressed the need, to smoking cessation services providers. A standard operation algorithm for advisors used in the pilot feasibility trial will be modified for the use.
224205941|NCT01607866|PROCEDURE|Quadrant parotidectomy|Excision of one quadrant of the parotid gland which is comparable to half of the superficial lobe of the gland
224205942|NCT01607866|PROCEDURE|Superficial parotidectomy|Excision of the whole superficial lobe of the parotid gland
223611829|NCT05001334|BEHAVIORAL|Kangaroo care training|During perinatal period, mothers are given extra training (other than routine newborn care) about kangaroo care. Baby-mother diad is called for weight check-ups.
223611830|NCT00247403|DRUG|2-deoxyglucose (2DG)|Addition of 2DG to stereotactic radiosurgery. Dose escalation study.
223611831|NCT00938184|DRUG|Paroxetine 12.5 milligrams tablet|Single dose of paroxetine 12.5 milligrams controlled release tablet will be administered orally.
223611832|NCT00938184|DRUG|Paroxetine 25 milligrams tablet|Single dose of paroxetine 25 milligrams controlled release tablet will be administered orally.
223611833|NCT00938184|DRUG|Paroxetine 50 milligrams tablet|Single dose of paroxetine 50 milligrams controlled release tablet (as two tablets of 25 milligrams) will be administered orally.
223611834|NCT03689023|OTHER|A controlled multimodal intervention|The intervention is interdisciplinary, multimodal and patient activating and uses the existing setting and work flows at the Clinic as well as new interventions, ensuring that the patients receive education about cardiovascular risk factors, physical activity and healthy diet through a systematic approach including targeted patient education
223611835|NCT00669214|DRUG|efalizumab|All patients received a conditioning dose of efalizumab 0.7 mg/kg subcutaneously (SC) on Day 0, followed by 11 weekly doses of 1.0 mg/kg SC beginning on Day 7. After 12 weeks of blinded treatment, all patients continued into the open-label treatment period from Day 84 (Week 12) through Day 168 (Week 24).
223611836|NCT00669214|DRUG|placebo|All patients received a conditioning dose of placebo equivalent SC on Day 0, followed by 11 weekly doses of placebo SC beginning on Day 7. After 12 weeks of blinded treatment, all patients continued into the open-label efalizumab treatment period from Day 84 (Week 12) through Day 168 (Week 24).
223758035|NCT03800719|BEHAVIORAL|Message on general health delivered by short message service (SMS)|After baseline, regular messages using SMS will be sent to subjects with similar frequency to Intervention group. The messages include information on general health and reminders on follow-up surveys and biochemical validation for quitting.
223758036|NCT04886011|COMBINATION_PRODUCT|placebo gel|just methyl cellulose gel was applied to the ulcer
223758037|NCT04886011|COMBINATION_PRODUCT|camel whey protein gel|camel whey protein gel was prepared and dissolved in methyl cellulose gel base and applied to the ulcer
223758038|NCT03031288|DEVICE|A|standard bottle
223758039|NCT03031288|DEVICE|B|vented base bottle
223758040|NCT05678335|DRUG|Hydroxychloroquine|Oral hydroxychloroquine 200mg twice daily for 12weeks.
223758041|NCT05678335|DRUG|Tacrolimus|Oral Tacrolimus 1-2mg twice daily for 12 weeks.
223758042|NCT03348696|DRUG|Dexamethasone tapering dose|dexamethasone standard of care pre-medication + dexamethasone tapering dose
223758043|NCT03348696|DRUG|Dexamethasone physician choice|Dexamethasone standard of care pre-medication + dexamethasone physician choice
223758044|NCT01100008|PROCEDURE|Magnetic resonance imaging (MRI)|MRI cardiac and pulmonary with gadolinium
223758045|NCT02103829|BEHAVIORAL|Brief Intervention #1|Brief online suggestion intended to increase the likelihood of quitting smoking that takes less than 1 minute to complete.
223611837|NCT04699565|DIAGNOSTIC_TEST|Cardiac magnetic resonance|Evaluate the predictive value of myocardial viability measured with cardiac magnetic resonance for the identification of LV REM 6 months after STEMI
223611838|NCT01033539|OTHER|Probiotic strain ATCC PTA 4659|Placebo control containing no probiotic strain of ATCC PTA 4659 High dose of ATCC PTA 4659 1\*10 10 CFU/bag Low dose of ATCC PTA 4659 1\*10 8 CFU/bag
223611839|NCT01889823|OTHER|Hypoxia|Subjects will be breathing an individualized mix of nitrogen and room air titrated to an oxygen saturation of 80-85%.
223758046|NCT02103829|BEHAVIORAL|Brief Intervention #2|Brief online suggestion intended to increase the likelihood of quitting smoking that takes less than 1 minute to complete.
223758047|NCT02103829|BEHAVIORAL|Brief Intervention #3|Brief online suggestion intended to increase the likelihood of quitting smoking that takes less than 7 minutes to complete.
223758048|NCT05357872|DEVICE|deep anesthesia depth|The anesthesiologist adjusted the intravenous speed of remifentanil and propofol to maintain the bispectral index (BIS, BIS monitor; Aspect Medical System, Newton, MA) between 40-50 and 50-60 during the operation.
223758049|NCT05357872|DEVICE|light anesthesia depth|The anesthesiologist adjusted the intravenous speed of remifentanil and propofol to maintain the bispectral index (BIS, BIS monitor; Aspect Medical System, Newton, MA) between 40-50 and 50-60 during the operation.
223611840|NCT01889823|OTHER|Hyperoxia|Subjects will be breathing 100% oxygen
223611841|NCT01230463|DRUG|Ketorolac Tromethamine|15 mg ketorolac IV as a bolus 30 minutes before closure of surgery.
223758050|NCT00643370|OTHER|CT scan of the chest under deep inspiration breath hold|computed tomography scan of the chest under dep inspiration breath hold conditions
223758051|NCT02128295|DEVICE|Electric breast pump - A|
223758052|NCT02128295|DEVICE|Electric breast pump - B|
223758053|NCT02108821|BIOLOGICAL|Fecal Microbiota Transplantation (FMT)|The process of fecal microbiota transplantation (FMT), where fecal bacteria from a healthy individual is transferred into a recipient as an alternative therapy for individuals affected with these life-altering diseases: Crohn's Disease (CD), and/or Ulcerative Colitis (UC).
223758054|NCT03086785|DRUG|Apatinib|apatinib 500mg qd po or combined capecitabine 1000mg/m2 bid d1-14 q3w
223758055|NCT06067594|DIAGNOSTIC_TEST|Fine Needle Aspiration Cytology (FNAC) procedure+calcitonin measurement|Fine needle aspiration (FNA) nodule biopsy: FNA is performed on each patient as long as ATA guideline criteria is met. In case of suspicion of medullary carcinoma, in search of a nodule or medullary focus, FNA will be performed on all non-cystic or spongiform nodules larger than 0.8 cm.
223758056|NCT05005858|PROCEDURE|Alveolar ridge splitting|Patients with Kennedy Class I. and II. mandibles with insufficient bone width were included in this study. Ridge splitting was carried out with the use of a piezoelectric surgery device by preparing osteotomies and after mobilization of the buccal cortical by placing an autologous bone block harvested from the retromolar region as a spacer between the buccal and lingual cortical plates. Block-grafts were stabilized by osteosynthesis screws. Implant placement was carried out after a 3-month healing period.
223758057|NCT05005858|DEVICE|Creating osteotomies with piezoelectric device|Osteotomies were carried out with piezoelectric surgery device (NSK Variosurg3 Ultrasonic Bone Surgery System, NSK Europe GmbH, Eschborn, Germany)
223758058|NCT02340234|DRUG|Lebrikizumab|Lebrikizumab will be administered SC as per the schedule specified in the respective arms.
223758059|NCT02340234|DRUG|Placebo|Placebo matching to lebrikizumab will be administered as per the schedule specified in the respective arms.
223758060|NCT02340234|DRUG|TCS Cream|TCS cream (triamcenolone acetonide 0.1% or hydrocortisone 2.5% cream) twice daily
223611842|NCT01230463|DRUG|Ketorolac Tromethamine|30 mg ketorolac IV as a bolus 30 minutes before closure of surgery.
223611843|NCT03749759|PROCEDURE|Cataract surgery|A biofeedback measurement will be carried out during cataract surgery of both eyes
223611844|NCT06601062|DEVICE|Tele-BE|Clinicians and their patients use the newly developed telehealth tool to support their use of CBT during session
223611845|NCT03453905|DIAGNOSTIC_TEST|CTFEA|CT scans are used to generate a finite element model of patient-specific long bones. The bone model is loaded in stance position. Load based on patient's weight and the mechanical response, including the risk of fracture, is computed.
223611846|NCT03453905|OTHER|Conventional decision algorithm|Decision on surgery vs follow-up will be based on expert opinion and Mirels' score
223611847|NCT00837915|DRUG|Loratadine 10mg /Pseudoephedrine Sulfate 240 mg Extended-Release Tablets|
223758061|NCT00534235|PROCEDURE|Decompression|Either microsurgical decompression or laminotomy to remove bone impinging on nerves causes the patient pain
223758062|NCT00534235|DEVICE|Posterolateral Fusion and Implantation of Pedicle Screws|
223758063|NCT00534235|DEVICE|Implantation of coflex Interlaminar Technology|
223758064|NCT02151708|DRUG|Placebo|Eligible subjects were randomly allocated in a 1:1:1 ratio to receive either 90mg motilitone or 180mg motilitone or placebo motilitone three times daily for 2weeks.
223758065|NCT02151708|DRUG|motilitone|Eligible subjects were randomly allocated in a 1:1:1 ratio to receive either 90mg motilitone or 180mg motilitone or placebo motilitone three times daily for 2weeks.
223758066|NCT04619056|DRUG|CEB-01 membrane loaded with SN-38|CEB-01 is a polymeric drug with a delivery system loaded with SN-38, and will be placed in the surgical bed at the time of tumor resection.
223758067|NCT05001243|DRUG|Compound Pilocarpine, Brimonidine, Oxymetazoline, Hyaluronic acid, Bromfenac|PBOHB to improve uncorrected near vision in healthy presbyopic patients
223758068|NCT05001243|DRUG|Pilocarpine Hydrochloride|Apply in the fellow eye
223758069|NCT05001243|DRUG|Brimonidine Tartrate|Apply in the fellow eye
223758070|NCT02187302|DRUG|CRLX101|
223758071|NCT02187302|DRUG|Bevacizumab|
223758072|NCT02187302|DRUG|Standard of Care (Investigator Choice)|
223611848|NCT04053257|OTHER|Hand hygiene compliance observation with video camera surveillance system and performance feedback of the HH rates to HCWs|"Intervention:~We will report baseline HH compliance rates and HAI rates to HCWs during a meeting where all HCWs are present. During this meeting we will remind major infection control measures, give examples of common mistakes they made without violating personal privacy rights of HCWs and patients."
223611849|NCT04126694|BEHAVIORAL|CBT with smartphone application SenseSupport|SenseSupport intervention system used as an augment to a 12 week in-person CBT treatment for transdiagnostic binge eating pathology
223758073|NCT02479854|DRUG|Asmakast|1 chewable tablet contains 5 mg montelukast
223758074|NCT02479854|DRUG|Singulair|1 chewable tablet contains 5 mg montelukast
224201320|NCT06943742|DIAGNOSTIC_TEST|Magnetoencephalography plus Computed Tomography/Magnetic Resonance Imaging|Use Magnetoencephalography and Computed Tomography/Magnetic Resonance Imaging in the preoperative assessment of pediatric brain tumors.
224201321|NCT06942715|OTHER|Electric Induction Cookstoves|The intervention consists of high-quality, locally available electric induction cookstoves with one or two burners, each equipped with cloud-connected data loggers, and includes compatible cookware.
223611850|NCT00217425|BIOLOGICAL|bevacizumab|"A - CHOP: 15 mg/kg IV infusion once every 21 days for 6-8 cycles. Bevacizumab is to be administered prior to CHOP therapy. Continuous bevacizumab: 15 mg/kg IV infusion once every 21 days.~Initial dose should be infused over 90 minutes. If no adverse reactions occur, the second dose should be administered over 60 minutes. Again, if no adverse reactions occur, the third and subsequent doses should be administered over 30 minutes. If infusion-related adverse reactions occur, subsequent infusions should be administered over the shortest period that is well-tolerated. Infusions should be run in via a volumetric infusion device. Do NOT administer as an IV push or bolus."
223611851|NCT00217425|DRUG|cyclophosphamide|IV infusion per institutional guidelines.
223758075|NCT06493630|BEHAVIORAL|Hypnobreastfeeding Education|Hypnobreastfeeding Education: Monitoring breastfeeding myths, breastfeeding expectations and breastfeeding self-efficacy with hypnobreastfeeding education
223758076|NCT05072353|DEVICE|SEFFICARE|"The SEFFI is a 5-step technique:~1. Preparation: the lower/lateral abdomen is chosen as the donor site.~2. Anesthesia: the donor site is injected with a local anesthetic.~3. Harvesting: a 0.8 mm or 0.5 mm cannula connected to a 10-ml VacLok® syringe is used to harvest the adipose tissue. The total amount of the harvested tissue could vary from 10 to 30 mL.~4. Washing: The syringe containing the lipoaspirate tissue is immediately filled with sterile physiological solution. After some minutes the syringes in the decanting stand will show a separation by the gravity of the tissue (top) from the physiological solution (bottom).~5. Fluidification: the syringe containing the adipose tissue should be connected to an empty 10 ml syringe. After pushing the tissue about 3 times from one syringe to the other, a good fluidification of the tissue is obtained.~The resulting tissue (2.5 mL per syringe) is ready for grafting the amputation wound."
223758077|NCT00805116|DIETARY_SUPPLEMENT|Whale blubber oil|15 ml/day for 4 months, divided on dosage morning and evening, orally.
223758078|NCT00805116|DIETARY_SUPPLEMENT|Cod liver oil|15 ml/day for 4 months, divided on dosage morning and evening, taken orally
223758079|NCT06132022|OTHER|Mandala|Mandala work is one of the non-pharmacological approaches and is used to support patients and caregivers in various diseases. Mandala is a method that anyone can apply based on coloring a circular shape.
223758080|NCT06132022|OTHER|Routine care|The clinic's routine information will be given to the caregivers of the control group.
223758081|NCT00638703|BIOLOGICAL|Oxalobacter formigenes|NLT (not less than) 10\^7 CFU Oxalobacter formigenes twice daily for 24 weeks
223758082|NCT00638703|DRUG|Placebo|placebo
223758083|NCT02719158|DRUG|6 mg ciprofloxacin|Single administration of OTO-201
223758084|NCT02719158|DRUG|12 mg ciprofloxacin|Single administration of OTO-201
223758085|NCT02719158|OTHER|Sham|
223758086|NCT01061554|DIETARY_SUPPLEMENT|Omega-3 oils from tri-glycerides|Single-dose administration of approximately 5 grams of omega-3 oils from triglycerides
223758087|NCT01061554|DIETARY_SUPPLEMENT|Omega-3 oils from marine phospholipids|Single-dose administration of approximately 5 grams of omega-3 oils from marine phospholipids
223758088|NCT00202618|DRUG|Valsartan|
223758089|NCT00202618|DRUG|Amlodipine|
223758090|NCT03137693|OTHER|Standard of Care Schedule Variation: SABR|SABR will be delivered over 3 days, prior to surgery.
224205943|NCT06505213|OTHER|no intervention|no intervention
223611852|NCT00217425|DRUG|doxorubicin|Intravenously, either as a bolus injection or as a continuous infusion through a central venous line.
223611853|NCT00217425|DRUG|prednisone|Prednisone is taken orally.
223611854|NCT00217425|DRUG|vincristine|IV push using extravasation precautions.
223611855|NCT04608721|OTHER|Postpartum Anxiety|Postpartum anxiety will be assessed at 1-3 days (T1), 1(T2), 3 (T3), 6 (T4) and 12 months (T5) postpartum by using the State-Trait Anxiety Inventory (STAI) with a score ≥40 serving as a positive screen.
223611856|NCT01121146|DEVICE|Total Hip Replacement|Comparison of Marathon and Enduron polyethylene
223611857|NCT02589054|OTHER|Monitoring|
223611858|NCT04058444|COMBINATION_PRODUCT|ERAS protocol|No routine bowel preparation Antibiotics prophylaxis PONV (Postoperative Nausea and Vomiting) prophylaxis Spinal anesthesia Post- Cesarean analgesia (Acetaminophen 1g IV q6h, Tramadol 50mg IV q6h, Quadratus lumborum Block Oral pain relief medication Pain scores every day (VAS) Hospital length of stay Patient satisfaction
223611859|NCT03273673|OTHER|Biofeedback Intervention|Visual and Tactile Biofeedback
223611860|NCT00997035|DRUG|Voriconazole|"1% voriconazole (topical) plus 0.01% preservative, 1 drop applied to the affected eye every one hour while awake for 1 week, then every 2 hours while awake until three weeks after enrollment.~5% natamycin (topical), 1 drop applied to the affected eye every one hour while awake for 1 week, then every 2 hours while awake until three weeks after enrollment.~400 mg BID PO on study day one (loading dose), then 200 mg BID PO until 3 weeks from enrollment for patients weighing greater than 50 kg. For patients 40-50 kg, the loading dose is 300 mg BID PO on study day 1, then 150 mg BID PO until 3 weeks from enrollment. For patients weighing \<40 kg, the loading dose is 200 mg BID PO, then 100 mg BID PO until 3 weeks after enrollment."
223611861|NCT00997035|DRUG|Placebo|"1% voriconazole (topical) plus 0.01% preservative, 1 drop applied to the affected eye every one hour while awake for 1 week, then every 2 hours while awake until three weeks after enrollment.~5% natamycin (topical), 1 drop applied to the affected eye every one hour while awake for 1 week, then every 2 hours while awake until three weeks after enrollment.~Two tablets BID PO on study day one, then one tablet BID PO until 3 weeks from enrollment."
223611862|NCT02375035|DEVICE|CAMPROBE|To assess patient's experience and complications of the CAMPROBE biopsy needle and compare the results with known published outcomes from standard transrectal biopsies
223611863|NCT04045379|PROCEDURE|LASER|Use of the SmartXide Touch V²LR, Co2 Laser System to perform ambulatory intravaginal and vulvar application of LASER, to postmenopausal genitourinary syndrome. The patient will be in gynecological position, after remove of vaginal secretion, with gauze and under topic anesthesia, the LASER will be applied, according to the protocol of the manufactured.
223611864|NCT04045379|PROCEDURE|Microablative Radiofrequency|Use of Linly™ equipment to perform ambulatory intravaginal and vulvar application of fractionated microablative radiofrequency, to postmenopausal genitourinary syndrome. The patient will be in gynecological position, after remove of vaginal secretion, with gauze and under topic anesthesia, the radiofrequency will be applied, according to the protocol of the manufactured.
223611865|NCT04045379|DRUG|Estriol|The patient will perform self application of this vaginal estriol daily for 2 weeks and after that the applications will occur twice a week.
223611866|NCT00089596|PROCEDURE|Expansion of umbilical cord stem cells|
223611867|NCT03285269|DIAGNOSTIC_TEST|Ultrasound Protocol|Ultrasound of the inferior vena cava, heart and lungs.
223611868|NCT03285269|DEVICE|Bioreactance|Bioreactance assessment using Cheetah Bioreactance Device (FDA Approved). Bioreactance is a non-invasive measure of cardiac output.
223611869|NCT03285269|PROCEDURE|Passive Leg Raise|A passive leg raise involves placing the patient supine and raising the legs to simulate an intravenous fluid bolus.
223611870|NCT00249509|DRUG|Nefazodone|
223611871|NCT00249509|DRUG|Bupropion|
223611872|NCT04526626|DEVICE|Radiofrequency ablation for treatment of lower limb varicose veins (ClosureFast, Medtronic)|Thermal injury to long saphenous vein
223611873|NCT01391624|DRUG|Flaxseed oil|3 g (3 capsules/day) of flax oil for a period of 8 weeks
223611874|NCT01391624|DRUG|Paraffin + # 2 dye|3 capsules of mineral oil (ineffective) for 8 weeks.
224201322|NCT06942884|DRUG|Dexmedetomidine and dexamethasone in addition to bupivacaine in rectus sheath block|addition of dexmedetomidine to dexamethasone in rectus sheath block
223611875|NCT03852017|BEHAVIORAL|Audio Program|
223611876|NCT02544503|DEVICE|Single-pulse Transcranial Magnetic Stimulation (TMS)|Single-pulse Transcranial Magnetic Stimulation (TMS) is a brief magnetic pulse that is applied through a coil to the section of the head that overlays the motor cortex of the brain. Subjects will be comfortably seated in a dental chair surrounded by a frame that carries a coil holder to assist with the application of TMS to the brain. Single-pulse transcranial magnetic stimulation (TMS) will be administered at study visits.
223611877|NCT02544503|DEVICE|Paired-pulse Transcranial Magnetic Stimulation (ppTMS)|Paired-pulse Transcranial Magnetic Stimulation (ppTMS) is two brief sequential magnetic pulses that are applied through a coil to the section of the head that overlays the motor cortex of the brain. Subjects will be comfortably seated in a dental chair surrounded by a frame that carries a coil holder to assist with the application of TMS to the brain. Paired-pulse transcranial magnetic stimulation (ppTMS) will be administered at study visits.
223611878|NCT02544503|DEVICE|Low-frequency Repetitive Transcranial Magnetic Stimulation (rTMS)|Low-frequency Repetitive Transcranial Magnetic Stimulation (rTMS) is a sequence of brief magnetic pulses that are applied at 0.1 Hz frequency at low intensity through an air-cooled coil to the section of the head that overlays the motor cortex of the brain. Subjects will be comfortably seated in a dental chair surrounded by a frame that carries a coil holder to assist with the application of TMS to the brain. Low-frequency repetitive transcranial magnetic stimulation (rTMS) will be administered at study visits.
223611879|NCT02544503|DEVICE|Sham Motor Cortex Stimulation|Sham motor cortex stimulation will be applied at study visits.
223611880|NCT04041271|OTHER|Cervical range of motion (CROM)|Subjects will perform full-range cervical flexion, extension, side-bending and rotation actively in sitting position. In supine position, cervical flexion-rotation will be performed passively by the assessor.
223611881|NCT04041271|OTHER|Pressure pain threshold (PPT)|A digital algometer with rubber head will be used to apply pressure on the muscles of subjects. When the subjects start to feel pain, the algometer will be removed immediately.
224201323|NCT06942884|DRUG|dexamethsone in addition to bupivacaine in rectus sheath block|addition of dexamethasone in rectus sheath block
223758091|NCT03137693|PROCEDURE|Breast-conserving Surgery|Breast-conserving surgery will be scheduled for 6-8 weeks after SABR and will be conducted by a Moffitt breast surgeon.
223758092|NCT03914560|OTHER|Burn injury|minor burn injury
223758093|NCT01389440|DRUG|Gemcitabine and Erlotinib|Administration of gemcitabine (300mg/m2/weekly)with Erlotinib (100 mg/daily) and radiotherapy (45 Gy/daily) after a period of infusion with a full dose of Gemcitabine (1.000mg/m2/weekly) and Erlotinib (100 mg/daily)
223758094|NCT00591448|OTHER|Virtual Reality (VR)|See above
223758095|NCT03365674|DEVICE|Vibration|Vibration applied with vibrator switch-on state (100Hz)
223758096|NCT03365674|DEVICE|Placebo vibration|Vibrator applied with switch-off state
223758097|NCT06207539|DRUG|hyoscine N-butyl bromide under the generic name of buscopan ampoule produced by Sanofi company|compare between the effects of misoprostol with hyoscine N-butyl bromide and misoprostol alone on shortening the time of abortion induction in the second trimester.
223758098|NCT06207539|DRUG|misoprostol under the generic name of misotac tablets|compare between the effects of misoprostol with hyoscine N-butyl bromide and misoprostol alone on shortening the time of abortion induction in the second trimester.
223758099|NCT03341988|DRUG|Ombitasvir-Paritaprevir-Ritonavir Tab 12.5-75-50 milligram|To asses curability of( Ombitasvir ,Paritaprevir,Ritonavir) in ch HCV infected patients in those with CKD vs ESRD 2- Also assess duration of sustained viral response,treatment, relapse or failure of therapy in CKD vs ESRD
223758100|NCT03088176|DRUG|Talimogene Laherparepvec 1 Million Pfu/Ml Inj,Susp,1Ml,Vil|Up to 4mL administered on C1D1 intratumorally
223758101|NCT03088176|DRUG|Talimogene Laherparep 100 Mil Pfu/Ml 1Ml|Up to 4 ML administered on Week 4 Day 1 and every 2 weeks thereafter
223758102|NCT03088176|DRUG|Dabrafenib|150mg PO qday
223758103|NCT03088176|DRUG|Trametinib|2mg PO qday
223758104|NCT02838264|DRUG|PF-06463922|Single oral dose of PF-06463922 50 mg on Day 1 of Period 1 and Day 5 of Period 2
223758105|NCT02838264|DRUG|PF-06463922|Single oral dose of PF-06463922 75 mg on Day 1 of Period 1 and Day 5 of Period 2
223758106|NCT02838264|DRUG|PF-06463922|Single oral dose of PF-06463922 100 mg on Day 1 of Period 1 and Day 5 of Period 2
223758107|NCT02838264|DRUG|PF-06463922|Highest safe single oral dose (mg) of PF-06463922 identified in the previous cohorts will be administered on Day 1 of Period 1 and Day 5 of Period 2
223758108|NCT02838264|DRUG|Itraconazole|200 mg oral dose of itraconazole on Days 1 to 11 during Period 2
223758109|NCT02250196|DRUG|PEG-Asc|received 1 L solution of PEG-Asc at 7 p.m the evening before colonoscopy and another 1 L solution of PEG-Asc at 5 hours before procedure
223758110|NCT02250196|DRUG|SPMC 2|received one sachet of SPMC at 7 p.m the evening before colonoscopy and another sachet of SPMC at 5 hours before procedure
223758111|NCT03087656|DRUG|Ceftriaxone|Intravenous Ceftriaxone will be given during the procedure.
223758112|NCT03087656|DRUG|Levofloxacin|Oral Levofloxacin will be given for 3 days after the procedure.
223758113|NCT00112242|BIOLOGICAL|Melan-A ELA + Montanide|"A maximum of 3 vaccination cycles (cycles 1-3) has been given, each cycle consisting of 4 vaccines in 4 week intervals. The intervals between cycles were 8 weeks. After 3 cycles, patients without major tumor progression requiring other treatment who showed an immunological response received booster vaccinations every 3 months."
224205944|NCT03739684|DRUG|18F-DCFPyL|A single dose of 9 mCi (333 MBq) IV injection of 18F-DCFPyL
224205945|NCT03739684|DIAGNOSTIC_TEST|PET/CT Imaging|PET/CT imaging will be acquired 1-2 hours post-PyL injection
224205946|NCT01888159|PROCEDURE|Bilateral Salpingectomy|
224205947|NCT01888159|PROCEDURE|Tubal sterilization with bipolar energy|
224205948|NCT00417859|DEVICE|Total knee arthroplasty: mobile bearing|Total knee arthroplasty: mobile bearing
224205949|NCT01305135|DRUG|azacitidine and idarubicin|azacitidine:100mg, 75mg/m²/d, during 7days every 28 days (D1-D7). Idarubicin: 5mg/ml, 5mg/m²/d (palier1) or 10mg/m²/d (palier2), D8
224205950|NCT04556500|OTHER|investigating the psychometric properties of Turkish Affordance in the Home Environment for Motor Development-Toddler (AHEMD-T)|AHEMD-T will apply to parents who have 18-42 months child/children
223509338|NCT00292370|DRUG|Placebo|Double-blind placebo taken with OL paroxetine
223509339|NCT00292370|DRUG|Quetiapine|Double-blind quetiapine taken with OL paroxetine
223509340|NCT00025311|DRUG|topotecan hydrochloride|
223509341|NCT06024265|DRUG|ER2001 injection|The minimum initial dose is 0.04mg/kg, then escalate to 0.08mg/kg, 0.16mg/kg and 0.32mg/kg. The planned duration of the treatment is 14 weeks, and ER2001 will be administrated intravenously at the first day of weeks 1, 3, 4, 5, 6, 7, 8, and 14.
223509342|NCT03255499|BEHAVIORAL|Exercise|Exercise
223509343|NCT03255499|BEHAVIORAL|Cognitive|Cognitive
223509344|NCT03255499|BEHAVIORAL|Active control|Active control, including a blend of computer games, board games, quizzes, trivia
223509345|NCT02868710|OTHER|Exercise|Continuous aerobic exercise prescribed according to two exercise intensity methods: individualized (i.e. ventilatory threshold) and standardized (i.e. heart rate reserve)
223509346|NCT03443544|PROCEDURE|Aggressive debridement|Aggressive debridement of the tissues undergoing fascitis
223509347|NCT01935505|BEHAVIORAL|Consulting|The physicians adopted a non-directive approach, included the five 'A' (ask, advice, assess, assist and arrange), assessing the stage of readiness in quitting smoking, strengthening clients' motivation to quit smoking using the five 'R' (relevance, risks, rewards, roadblocks and repetition) approach, and providing advice to overcome psychological craving, psychological dependence and social-cultural factors associated with tobacco dependency. Each smoker takes more than 30 min to complete the intervention.
223509348|NCT01935505|DRUG|Nicotine patch|According to the smokers' level of nicotine dependency, disease history, cigarette consumption, prescription of drugs were provided, Nicotine Replacement Therapy, bupropion and varenicline.
223509349|NCT01935505|BEHAVIORAL|Telephone intervention|Smokers received follow-up by a counselor at 1 week, 1, 3, 6 months and 1, 2 years using a detailed questionnaire by telephone interview. At each follow-up, we collected data, asked whether the smokers have any problem with drug use or other problems, provided problem-oriented suggestions or advice as appropriate, encouraged them to insist.
223509350|NCT01935505|BEHAVIORAL|Consulting+Telephone+Drug intervention|Include all the above interventions
223509351|NCT02520440|BIOLOGICAL|Monitoring of plasmatic levels of Citrulline|Measured plasma amino-acids levels
223611882|NCT04041271|OTHER|Cranial-cervical angle (CCA)|Subjects will stand in a relaxed position with colour markers on the earlobe and C7 spinous process. A photo of the head posture will be taken to calculate the included angle between the markers and the horizontal line.
223611883|NCT04041271|OTHER|Jaw kinematics|Jaw kinematics is measured by Ultrasonic Jaw Motion Analyzer (Zebris). The subjects will perform jaw opening, closing, lateral left, lateral right and protrusion for three times.
223611884|NCT04041271|OTHER|Muscle activation|Surface electromyography is used to assess the activities of bilateral masseter, anterior temporalis, sternocleidomastoid muscle and upper trapezius. Subjects will perform jaw resting and clenching.
223611885|NCT00068341|BIOLOGICAL|trastuzumab|Cycle 5-7 post-op only Day 1 4mg/kg IV Day 8, 15 2mg/kg IV Cycle 8 Cycle 8 Day 1, 8, 15 2mg/kg IV Day 22 6mg/kg IV
223611886|NCT00068341|DRUG|carboplatin|Cycle 1-8 Day 1 or 2 AUC = 6 IV
223611887|NCT00068341|DRUG|docetaxel|Cycle 1-8 Day 1 or 2: 75 mg/m2 IV
223611888|NCT00068341|BIOLOGICAL|trastuzumab|"Cycle 1-4 pre-op Day 1 4mg/kg IV Day 8, 15 2mg/kg IV~Cycle 5-7 post-op Day 1 4mg/kg IV Day 8, 15 2mg/kg IV~Cycle 8 Day 1, 8, 15 2mg/kg IV Day 22 6mg/kg IV"
223611889|NCT06528236|DIAGNOSTIC_TEST|Artificial intelligence model|Using the artificial intelligence model to diagnosis benign, borderline, and malignant ovarian masses.
223611890|NCT01080807|DRUG|Armodafinil|At the baseline visit, patients who continued to meet eligibility criteria were randomly assigned (1:1) to receive either 150 mg of armodafinil or matching placebo treatment only on nights worked for 6 weeks. Study drug was taken once nightly, 30 to 60 minutes prior to the start of the night shift, on nights worked. Armodafinil treatment was titrated as follows (only on nights worked): the first dose was 50 mg (1 tablet), the second and third doses were 100 mg (2 tablets), and the fourth and subsequent doses were 150 mg (3 tablets). Placebo tablets matching armodafinil tablets were administered on the same schedule.
223758114|NCT00112242|BIOLOGICAL|Melan-A ELA + NY-ESO-1b + MAGE-A10 + Montanide|"A maximum of 3 vaccination cycles (cycles 1-3) has been given, each cycle consisting of 4 vaccines in 4 week intervals. The intervals between cycles were 8 weeks. After 3 cycles, patients without major tumor progression requiring other treatment who showed an immunological response received booster vaccinations every 3 months."
223758115|NCT00112242|BIOLOGICAL|Melan-A -ELA + NY-ESO-1b + MAGE-A10 peptide + Montanide + CpG|"A maximum of 3 vaccination cycles (cycles 1-3) has been given, each cycle consisting of 4 vaccines in 4 week intervals. The intervals between cycles were 8 weeks. After 3 cycles, patients without major tumor progression requiring other treatment who showed an immunological response received booster vaccinations every 3 months."
223758116|NCT00112242|BIOLOGICAL|Melan-A-EAA/ELA + NY-ESO-1 lp + MAGE-A10 + Montanide + CpG|"A maximum of 3 vaccination cycles (cycles 1-3) has been given, each cycle consisting of 4 vaccines in 4 week intervals. The intervals between cycles were 8 weeks. After 3 cycles, patients without major tumor progression requiring other treatment who showed an immunological response received booster vaccinations every 3 months."
223758117|NCT00112242|BIOLOGICAL|Melan-A-EAA/ELA + NY-ESO-1 lp + MAGE-A10 + Montanide + CpG+ IL-2|"A maximum of 3 vaccination cycles (cycles 1-3) has been given, each cycle consisting of 4 vaccines in 4 week intervals. The intervals between cycles were 8 weeks. After 3 cycles, patients without major tumor progression requiring other treatment who showed an immunological response received booster vaccinations every 3 months."
223758118|NCT04213456|DIETARY_SUPPLEMENT|Nutritional Sport Formula|Powder added to water,high protein and multi vitamins and minerals
224201324|NCT06939309|PROCEDURE|Acupuncture|In this study, both the acupuncture SC group and the acupuncture CS group will receive two acupuncture treatments in one session. The SC group will first receive acupuncture at the standardized acupoint followed by the controlled acupoint, while the CS group will first receive acupuncture at the controlled acupoint followed by the standardized acupoint.
223509352|NCT02520440|DEVICE|Intra-abdominal pressure monitoring|Intra-abdominal Hypertension is defined as an average pressure of the day ≥ 12 mmHg; abdominal compartment syndrome is defined as a sustained (minimally two standardized measurements, performed 1-6 h apart) increase in Intra-abdominal pressure above 20 mmHg with new onset organ failure.
223509353|NCT02520440|BIOLOGICAL|Monitoring of plasmatic levels of Arginine and Glutamine|Measured plasma amino-acids levels
223509354|NCT06569277|OTHER|A mobile application|Those who agreed to download a mobile app for colonoscopic bowel preparation on their smartphones.
223509355|NCT02635789|DRUG|NPC-12G gel|NPC-12G gel is administered topically twice a day for 12 weeks
223509356|NCT02635789|DRUG|Placebo gel|NPC-12G gel placebo is administered topically twice a day for 12 weeks
223509357|NCT01520662|OTHER|Implementation of a secure web-based patient Wellness Portal|Patients in intervention practices will review and update their wellness records, risk factor information, allergy and contraindication profile, and personal preferences through the Wellness Portal before they visit their primary care provider.
223509358|NCT06569784|DRUG|[14C]HSK31858|A single oral dose of 40 mg/120 μCi \[14C\]HSK31858 after fasting for at least 10 hours.
223509359|NCT02533674|DRUG|Gemcitabine plus PM060184|
223509360|NCT04787120|DEVICE|SQUIDperi|Liquid embolic delivery syringes and micro-catheter
223509361|NCT06570408|BEHAVIORAL|Western Ontario and McMaster University Osteoarthritis Index (WOMAC)|1\. WOMAC is widely used in the evaluation of Hip and Knee Osteoarthritis. It is a self-administered questionnaire consisting of 24 items divided into 3 subscales
223509362|NCT06570408|BEHAVIORAL|Visual Analogue Scale (VAS)|2\. VAS is one of the pain rating scales used in epidemiologic and clinical research to measure the intensity or frequency of various symptoms.
223509363|NCT06570408|DIAGNOSTIC_TEST|Kellgren Lawrence Grading Scale (KL score)|3\. KL score is the most widely used clinical tool for the radiographic diagnosis of OA.Each radiograph was assigned a grade from 0 to 4,
223509364|NCT06570408|BEHAVIORAL|Quality of Life Questionnaires and Assessments:|4\. Quality of Life Questionnaires and Assessments: include quality of life, intestinal tract, conscious assessment of pain relief.etc.
223509365|NCT00002226|DRUG|SU5416|
223509366|NCT04266314|DEVICE|Maternal-fetal monitoring|Maternal-fetal monitoring evaluates fetal and maternal heart rate, maternal respirations, fetal movement, and maternal skin conductance (a way to monitor emotional response)
223509367|NCT04266314|OTHER|NICU Network Neurobehavioral Scale|Evaluates neurobehavioral organization, neurological reflexes, motor development, and signs of stress and withdrawal of substance-exposed infants.
223758119|NCT04213456|DIETARY_SUPPLEMENT|Placebo|Low caloric formula (Powder added to water), without added vitamins and minerals.
223758120|NCT06470659|BEHAVIORAL|WW Clinic|Telehealth platform that specializes in medical weight management and integrates the behavioral and lifestyle support from WW
223611891|NCT01080807|DRUG|Matching Placebo|At the baseline visit, patients who continued to meet eligibility criteria were randomly assigned (1:1) to receive either 150 mg of armodafinil or matching placebo treatment only on nights worked for 6 weeks. Study drug was taken once nightly, 30 to 60 minutes prior to the start of the night shift, on nights worked. Armodafinil treatment was titrated as follows (only on nights worked): the first dose was 50 mg (1 tablet), the second and third doses were 100 mg (2 tablets), and the fourth and subsequent doses were 150 mg (3 tablets). Placebo tablets matching armodafinil tablets were administered on the same schedule.
223611892|NCT05237349|DRUG|Envafolimab|300mg,sc,d1,Q3W
223611893|NCT05237349|DRUG|Oxaliplatin|130mg/m2, iv,d1,Q3W
223611894|NCT05237349|DRUG|S1|40mg/m2, op,bid,d1-14,Q3W
223611895|NCT01513408|OTHER|immunohistochemical detection of lymphocytes T CD8+/Foxp3 ratio|For each patients included the study, a tumour block from the initial biopsy, as well as a representative block of residual tumour (area of complete tumoral regression, area of partial tumoral regression or area of unmodified residual tumour) will be chosen by the initial pathologist in each investigating centre. Once the pathologist has verified the concordance between the images observed on the blocks sent from the investigating centres, and the associated pathology reports, immunohistochemical analysis will be performed on the slides prepared from each block.
223611896|NCT00458380|PROCEDURE|Controlled ovarian stimulation, perifollicular vascularity assessment, IVF, embryo transfer.|
223611897|NCT01425502|BEHAVIORAL|DQIP Intervention|"The DQIP intervention comprises of:~* Educational outreach~* Information technology application~* Financial incentives"
223611898|NCT03512171|DRUG|Dextroamphetamine|One oral dose of dextroamphetamine (0.43mg/kg). The amphetamine is given in order to induce the release of their own dopamine for study with positron emission tomography (PET).
223611899|NCT03512171|DRUG|Placebo|One oral dose of placebo to estimate D2 receptor levels at baseline with PET imaging (necessary to calculate dopamine release in the amphetamine condition).
223611900|NCT03512171|DIAGNOSTIC_TEST|[18F]Fallypride|Radioligand for measuring dopamine D2 receptors with positron emission tomography (PET)
223611901|NCT03512171|DIAGNOSTIC_TEST|[18F]-FE-PE2I|Radioligand for measuring dopamine transporters with positron emission tomography (PET)
223611902|NCT00202514|DRUG|divalproex sodium extended release|
223611903|NCT04645446|DRUG|Pro-ocular gel|Topical gel in multidose formulation to be applied laterally to the forehead twice a day, morning and night for 3 months
223611904|NCT04645446|DRUG|Placebo gel|Topical gel in multidose formulation to be applied laterally to the forehead twice a day, morning and night for 3 months
223611905|NCT05923879|DRUG|Selinexor combined with lenalidomide and rituximab|Selinexor combined with lenalidomide and rituximab
223611906|NCT01072188|DEVICE|Arginine/Calcium Carbonate|One time treatment
223611907|NCT01072188|DEVICE|Nupro - Fluoride Free|Brush twice daily
223758121|NCT02381912|OTHER|EORTC QLQ-C30 and EORTC BLS-24 questionnaire|Questionnaires answered at baseline and 4 months follow up.
223758122|NCT01632202|DEVICE|Seprafilm|Seprafilm Adhesion Barrier (membrane) is a sterile, bioresorbable, translucent adhesion barrier composed of two anionic polysaccharides, sodium hyaluronate (HA) and carboxymethylcellulose (CMC). Together, these biopolymers have been chemically modified with the activating agent 1-(3-dimethylaminopropyl) -3- ethylcarbodiimide hydrochloride (EDC).
223758123|NCT01632202|DEVICE|Sterile Saline Solution|For those randomized not to receive Seprafilm slurry, a syringe will be filled with 25ml of sterile saline.
223758124|NCT02144740|DIETARY_SUPPLEMENT|NWT-03, an egg-white protein hydrolysate|For placebo comparator, a combination of sweetener + aroma, which was equal to the combination used in the intervention period, was given
223758125|NCT02144740|DIETARY_SUPPLEMENT|Placebo|A combination of sweetener + aroma , which was equal to the combination used in the intervention period, was given.
223758126|NCT04277091|OTHER|High-intensity interval training|Arm-cranking exercise
223758127|NCT04277091|OTHER|Moderate-intensity continuos training|Arm-cranking exercise
223758128|NCT01072851|BEHAVIORAL|Multimedia Education|A four minute exposure to an educational video with controlled content on the importance of colorectal cancer screening and explaining the processes and procedures.
223758129|NCT01072851|BEHAVIORAL|Print Media|Exposure to a printed brochure with controlled content on the importance of colorectal cancer screening and explaining the processes and procedures.
223611908|NCT04908085|BEHAVIORAL|Occupational Performance Coaching|Six sessions of OPC delivered by telephone over 10 weeks.
223611909|NCT00725777|DRUG|artemether-lumefantrine|Standard artemether-lumefantrine treatment
223611910|NCT03922581|BEHAVIORAL|Mindfulness-Based Cognitive Therapy|The intervention consists of MBCT for the prevention of depression relapse with adaptations for discussing trauma and PTSD. Participants attend eight, weekly 90-minute group sessions involving skills training and in-class practice. Participants will return one month after the intervention has ended for a follow-up assessment.
223611911|NCT05404243|DRUG|phenolization|In case of phenolization group, an Abbocath catheter 18 G is introduced into the cystic cavity. Undiluted 88% phenol is instilled into the cavity, ensuring that the cystic cavity is filled. It is maintained for 5 min until complete coagulation of the cyst is achieved.
223611912|NCT05404243|PROCEDURE|Conventional surgery|In case of conventional surgery, entire exeresis is performed by means of an electric scalpel
223758130|NCT01072851|BEHAVIORAL|Usual and customary waiting room process|No specialized educational intervention to promote colorectal cancer screening or to explain the process
223611913|NCT00168441|DRUG|Botulinum Toxin Type A|
223611914|NCT04472611|DRUG|Standard of Care (SOC) and Colchicine+Rosuvastatin|Patients will take Rosuvastatin 40mg daily and Colchicine 0.6mg twice for 3 days and then 0.6mg daily during hospitalization
223758131|NCT01874834|OTHER|ozone|Exposure to 300 ppb ozone with intermittent exercise about 20 hr after exposure to each arm (ie, either air, ozone, diesel exhaust, or ozone combined with diesel exhaust)
223758132|NCT00099463|PROCEDURE|Blood Test|
223758133|NCT00099463|PROCEDURE|Urine Test|
223758134|NCT00099463|PROCEDURE|Physical Exam|
223758135|NCT00099463|DRUG|Vaccine|
223758136|NCT00099463|DRUG|VRC-SRSDNA015-00-VP|
223758137|NCT03862664|PROCEDURE|Collection of data|The investigators will retrieve retrospectively the medical record of donors who underwent hepatic lobectomy for liver transplantation
223758138|NCT06121271|DRUG|Lu-177 DOTATATE (Lutathera®)|Treatment with Lutathera will consist of a total cumulative intravenous (IV) administered radioactivity dose of 29.6 GBq (800 mCi) or 14.8 GBq (400 mCi) for 4 cycles or 2 cycles of Lutathera, respectively.
223758139|NCT04116710|BIOLOGICAL|HS-110 (viagenpumatucel-L)|Vaccine derived from irradiated human lung cancer cells genetically engineered to continually secrete gp96-Ig
223758140|NCT04116710|BIOLOGICAL|HS-130|Vaccine derived from irradiated human lung cancer cells expressing the co-stimulatory fusion protein OX40L-Ig
223758141|NCT00544596|DRUG|R-(-)-gossypol acetic acid|Given orally
223611915|NCT04419831|DIAGNOSTIC_TEST|Yale Stress Pain Test (YSPT)|Yale Stress Pain Test involves 10 minutes exposure to 3 cycles of ice cold bucket hand immersion (stress) or 3 cycles of warm water immersion
223758142|NCT00544596|DRUG|cisplatin|Given IV
223758143|NCT00544596|DRUG|etoposide|Given IV
224201325|NCT06939309|PROCEDURE|Rehabilitation|Participants will complete a 30-minute rehabilitation session, which includes electrotherapy and thermotherapy applied to the shoulder.
224201326|NCT06942026|DRUG|Control 1|Researchers will perform oral care with ozonated water and hypochlorous acid solution to restore oral mucous membrane integrity.
224311863|NCT05800067|DRUG|axi-cel|Axicabtagene ciloleucel (Axi-cel) is an autologous anti-CD-19 chimeric antigen receptor(CAR) T-cell therapy approved by FDA in 2017 for the treatment of patients with relapsed/refractory large B-cell lymphoma (R/R LBCL). Now, it is the standard treatment for these patients recommended by NCCN and other guidelines. Axi-cel was approved for R/R LBCL patients who had received 2 or more prior lines of therapy on 2021 June in China.
223611916|NCT00566423|OTHER|Blood draw|Venous and Arterial Blood draw samples; 6 Minute Walk test
223611917|NCT05757752|BEHAVIORAL|Problem Solving Therapy and Integrated Care|The intervention, will consist of problem solving therapy techniques to promote PAD self-management behaviors and depression/distress management.
223611918|NCT03732274|DRUG|TEW-7197|TEW-7197 will be administered orally for 5 days per week (5D/W) at the same time in the morning and evening (BID) approximately 12 hours apart. Durvalumab will be administered as a dose of 1500 mg every 4weeks.
223611919|NCT04685798|DEVICE|Diffusion-weighted imaging magnetic resonance imaging|The research MRI study of the head and neck will be performed on a Siemens 3T MRI Scanner system
223611920|NCT04685798|DEVICE|FDG PET/CT|Standard of care
223611921|NCT05480683|DIAGNOSTIC_TEST|CT exam|Noncontrast CT of the pelvis with specific penile anatomical positioning for coverage and with the protocol optimized for application of Agatston calcium scoring post processing.
223611922|NCT00028704|PROCEDURE|conventional surgery|
223611923|NCT00028704|RADIATION|radiation therapy|
223611924|NCT06427031|DRUG|TJO-083|Diquafosol ophthalmic sodium solution, 1 drop 3 times a day
223611925|NCT06427031|DRUG|Diquafosol ophthalmic sodium solution 3%|Diquafosol ophthalmic sodium solution, 1 drop 6 times a day
223611926|NCT06065618|OTHER|Without intervention|Without intervention
223611927|NCT03205124|PROCEDURE|Electrical Stimulation|"The experimental treatment involves implantation of 2 sterilized fine-gauge Teflon coated wires percutaneously. The ends of the wire are stripped for conductivity. Electrical stimulation is given at a fixed continuous frequency of 20Hz. The stimulus intensity is the maximum tolerable limit. The wires are then taped to the skin with surgical wound tape at a location away from the wound for strain relief. To ensure sterility, care is taken to dress the sutured wound and hand, as well apply the splint.~The wires are removed either immediately at the conclusion of the pre-operative appointment and immediately after surgery or at the first surgical follow-up with dressing change, within one week of surgery."
223758144|NCT00582933|DRUG|BUSULFAN, MELPHALAN, FLUDARABINE, G-CSF|"All research participants will be conditioned for transplantation with intravenous busulfan (busulfex®) (0.8- 1.0 mg/Kg/dose Q6H x 10 doses), melphalan (70 mg/m2/dose x 2 doses) and fludarabine (25 mg/m2/day x 5 doses). Doses of busulfan will be adjusted according to plasma levels. All research participants will also receive ATG (thymoglobulin®) prior to transplant to promote engraftment.All research participants will also receive G-CSF posttransplant to foster engraftment.~The preferred source of stem cells will be peripheral blood stem cells (PBSC) induced and mobilized by treatment of the donor with G-CSF for 5-6 days. PBSC obtained through 2-3 leukaphereses will be Isolex® 300i separated CD34+ stem cell column selected and E-rosette depleted (E-). The CD34+Eperipheral blood progenitors will be administered to the research participants after they have completed cytoreduction."
223758145|NCT00582933|DRUG|BUSULFAN, MELPHALAN, FLUDARABINE, G-CSF|"All research participants will be conditioned for transplantation with intravenous busulfan (busulfex®) (0.8- 1.0 mg/Kg/dose Q6H x 10 doses), melphalan (70 mg/m2/dose x 2 doses) and fludarabine (25mg/m2/day x 5 doses). Doses of busulfan will be adjusted according to plasma levels. All research participants will also receive ATG (Thymoglobulin®) prior to transplant to promote engraftment. No drug prophylaxis against GvHD will be administered post transplant. All research participants will also receive G-CSF posttransplant to foster engraftment.~The preferred source of stem cells will be peripheral blood stem cells (PBSC) induced and mobilized by treatment of the donor with G-CSF for 5-6 days. PBSC obtained through 2-3 leukaphereses will be Isolex® 300i separated CD34+ stem cell column selected and E-rosette depleted (E-). The CD34+Eperipheral blood progenitors will be administered to the research participants after they have completed cytoreduction."
224201327|NCT06941584|DIAGNOSTIC_TEST|Test for AQP4, AChR, LGI1, and CASPR2 autoantibodies using cell-based assay|To evaluate the prevalence of specific autoantibodies (AQP4, AChR, LGI1, and CASPR2) in the population of patients carrying AIRE mutations (second cohort)
224201328|NCT06941584|GENETIC|AIRE single gene sequencing|To assess the prevalence of AIRE gene mutations in patients with NMOSD associated with AQP4 autoantibodies, myasthenia gravis (MG) associated with AChR autoantibodies, acquired neuromyotonia, and autoimmune encephalitis associated with CASPR2 and LGI1 autoantibodies (first cohort)
224201329|NCT06941584|GENETIC|Molecular typing of HLA class I and II alleles|To assess the HLA haplotypes of class I and II by comparing patients with and without AIRE mutations, as well as those with and without autoimmune neurological diseases
224311864|NCT01380548|DIETARY_SUPPLEMENT|Placebo|Placebo; once/day; for 12 weeks
224311865|NCT01380548|DIETARY_SUPPLEMENT|Iron alone|Iron (3 mg); once/day; for 12 weeks
224311866|NCT01380548|DIETARY_SUPPLEMENT|Low-dose 5-aminolevulinic acid with iron|5-Aminolevulinic acid (12.5 mg) and iron (3 mg); once/day; for 12 weeks
224311867|NCT01380548|DIETARY_SUPPLEMENT|Medium-dose 5-aminolevulinic acid with iron|5-Aminolevulinic acid (25 mg) and iron (3 mg); once/day; for 12 weeks
224311868|NCT01380548|DIETARY_SUPPLEMENT|High-dose 5-aminolevulinic acid with iron|5-Aminolevulinic acid (50 mg) and iron (3 mg); once/day; for 12 weeks
224311869|NCT00229723|DRUG|gefitinib (Iressa)|250 mg oral tablet
224311870|NCT00229723|DRUG|cisplatin|intravenous infusion
223611928|NCT03205124|PROCEDURE|Sham Stimulation|"The experimental treatment involves implantation of 2 sterilized fine-gauge Teflon coated wires percutaneously. The ends of the wire are stripped for conductivity. Electrical stimulation is begun until the patient senses the stimulation, then the stimulation is discontinued.The wires are then taped to the skin with surgical wound tape at a location away from the wound for strain relief. To ensure sterility, care is taken to dress the sutured wound and hand, as well apply the splint.~The wires are removed either immediately at the conclusion of the pre-operative appointment and immediately after surgery or at the first surgical follow-up with dressing change, within one week of surgery."
223611929|NCT06521710|PROCEDURE|Intraoperative Somatic-Autonomic Nerve Grafting|A one-sided graft using a genitofemoral (GFN) nerve graft between one obturator nerve and the corpora cavernosa
223611930|NCT05778981|DIAGNOSTIC_TEST|FMD - Troponin measurement|Echographic FMD evaluation. Pre and post-operative troponin measurements.
223758146|NCT00582933|DRUG|BUSULFAN, MELPHALAN, FLUDARABINE, G-CSF|"All research participants will be conditioned for transplantation with intravenous busulfan (busulfex®) (0.8- 1.0 mg/Kg/dose Q6H x 10 doses), melphalan (70 mg/m2/dose x 2 doses) and fludarabine (25mg/m2/day x 5 doses). Doses of busulfan will be adjusted according to plasma levels. All research participants will also receive ATG (Thymoglobulin®) prior to transplant to promote engraftment. No drug prophylaxis against GvHD will be administered post transplant. All research participants will also receive G-CSF posttransplant to foster engraftment.~The preferred source of stem cells will be peripheral blood stem cells (PBSC) induced and mobilized by treatment of the donor with G-CSF for 5-6 days. PBSC obtained through 2-3 leukaphereses will be Isolex® 300i separated CD34+ stem cell column selected and E-rosette depleted (E-). The CD34+Eperipheral blood progenitors will be administered to the research participants after they have completed cytoreduction."
223758147|NCT01655017|PROCEDURE|biopsy|adipose tissue biopsy (to evaluate inflammation and fibrosis)
223758148|NCT05585970|DIAGNOSTIC_TEST|procalcitonin|The PCT level in healthy individual without infection is below the limit of detection (0.01 ng/mL), and it is significantly elevated under the stimulation of pathogens
223758149|NCT01440738|BEHAVIORAL|health workshops|health workshops in relation to: Increase knowledge of healthy habits (physical activity, diet), incorporate and maintain a balanced diet. Incorporate and maintain regular physical activity
223758150|NCT00696137|DRUG|BEMA Fentanyl|buccal soluble film; 200, 400, 600, 800, and 1200 mcg fentanyl; up to 4 times daily
223758151|NCT01874262|DEVICE|Mobile-phone based patient support|The mobile-phone based patient support (investigational medical device) is a stand-alone software product used on the patients' own smart phone and used in addition to medical treatment.
223758152|NCT01874262|DEVICE|e-diary|All patients (active and control group) participating in the study will report their daily use of ticagrelor in an e-diary which will be initiated on all study patients' smart phones.
223758153|NCT00853554|DRUG|Hydromorphone Hydrochloride tablet 8 mg|Hydromorphone Hydrochloride tablet 8 mg, single dose fasting
223758154|NCT00853554|DRUG|Dilaudid® tablet 8 mg|Dilaudid® tablet 8 mg, single dose fasting
223758155|NCT00565279|DRUG|ASF1057|Twice daily, topical
223611931|NCT04640311|DRUG|Daprodustat|Daprodustat will be available as oral tablets.
223758156|NCT00565279|DRUG|ASF1057|Twice daily, Topical
223611932|NCT01409876|RADIATION|brachytherapy|interstitial image- guided PDR/HDR brachytherapy
223758157|NCT00409383|DRUG|Genasense® (oblimersen)|Cohorts 1 and 2: Genasense 7 mg/kg/day by continuous intravenous infusion beginning on Day 1 and continuing for 7 days (Week 1) and beginning again on Day 22 and continuing for 7 days (Week 4); Cohort 3: Genasense 900 mg as a 1-hour intravenous infusion on Day 1, 4, 8, and 11 (Weeks 1 and 2) and Day 22, 25, 29, and 32 (Weeks 4 and 5).
223758158|NCT00409383|DRUG|Abraxane® (paclitaxel protein-bound particles for injectable suspension)|Cohorts 1 and 2: Abraxane 175 mg/m2 or 260 mg/m2 as a 30-minute intravenous infusion on Day 8 and Day 29 following end of Genasense continuous infusion; Cohort 3: Abraxane 175 mg/m2 as a 30-minute intravenous infusion on Day 4 and Day 25 following end of Genasense 1-hour infusion
223758159|NCT00409383|DRUG|Temodar® (temozolomide)|Cohorts 1-3: Temodar 75 mg/m2/day orally on Days 1 through 42 (Week 1 through Week 6)
223758160|NCT03480334|OTHER|Nivolumab plus radiotherapy|Nivolumab 240 mg i.v. at 2-weekly intervals combined with 20Gy radiotherapy (RT) to a preferably progressive and not pre-irradiated single lesion. Nivolumab will be continued for a maximum of 18 months or until disease progression or unacceptable toxicity.
224311871|NCT00229723|RADIATION|radiotherapy|radiation therapy
224311872|NCT00229723|DRUG|Gefitinib (Iressa)|500 mg oral tablet
224311873|NCT03931525|DEVICE|Fractitional Radiofrecuency with Drug Delivery|Electromagnetic energy within the spectrum of radio frequencies applied to the skin whose purpose is to generate thermal effects and which will be complemented with a skin drug
223611933|NCT00002306|DRUG|Fluconazole|
224311874|NCT03931525|DEVICE|Fractitional Radiofrecuency|Electromagnetic energy within the spectrum of radio frequencies applied to the skin whose purpose is to generate thermal effects
224311875|NCT04408235|DRUG|Enoxaparin|Low-Dose LMWH: enoxaparin 4000 IU daily; High dose LMWH: 70 IU/kg twice daily
224314283|NCT01504958|BEHAVIORAL|NICE Cognitive Training|"12 levels of difficulty in tasks designed to relate to the region of the brain being stimulated (left and right parietal cortex, left and right DLPFC, left superior temporal gyrus, left inferior frontal gyrus).~A particular cognitive exercise will start 200msec after the termination of each TMS train.~Sham participants receive sham cognitive training that follows the same procedures as the active group."
224314284|NCT01000558|OTHER|biologic sample preservation procedure|
224314285|NCT03115216|PROCEDURE|FLA-CEIOL|Femtosecond laser-assisted cataract extraction and intraocular lens placement
224314286|NCT03115216|PROCEDURE|CEIOL|Manual cataract extraction and intraocular lens placement
223758161|NCT02661360|BEHAVIORAL|Swaddling Intervention for Preterm Infants|Procedure for swaddling includes folding one corner of the blanket down two thirds of the way down the blanket in order to make the blanket into a triangular shape. The infant will be positioned with shoulders at the fold of the blanket. The infant will be positioned with the blanket so that elbows, hips, and knees flexed with hands near the face by wrapping one side of the blanket across the chest holding the hands in place, pulling the bottom corner up toward the infant's face, and securing the blanket with the last corner pulled across the infant's chest again and around their back. The blanket will be tight enough to keep extremities in place but one finger will be able to be placed between the infant and the blanket.
223758162|NCT02661360|BEHAVIORAL|Unswaddled Control|Procedure for control is blanket loosely draped across the infant without providing containment and without touching the anterior surface of the infant.
223758163|NCT03404479|DRUG|Diacerein|For 12 weeks, administered twice a day by oral.
224201330|NCT06949748|DRUG|Flecainide (monotherapy)|"• Medication: Flecainide acetate, administered orally.~* Initial Dosing and Titration:~* Patients were started on an appropriate dose based on body weight and renal function.~* The typical starting dose was 100-150 mg per day, split into two doses.~* Dosing was titrated as needed, depending on patient response and tolerability, under close ECG and clinical monitoring.~* Monitoring Protocol:~* Continuous ECG monitoring during drug initiation (especially in-hospital or via Holter).~* Regular outpatient follow-up visits, including:~* 12-lead ECGs~* Holter monitoring~* Echocardiography (to monitor LVEF and assess for reverse remodeling)~* ECG parameters (QRS width, QTc interval) were closely monitored for proarrhythmic changes."
224201331|NCT06531512|DRUG|Xianglei Tangzu Gao|Active ingredients: Extracts of Plectranthus amboinicus and Centella Asiatica
224201332|NCT06531512|OTHER|Vehicle Cream|Cream base of Xianglei Tangzu Gao
223611934|NCT03030469|OTHER|Change in electronic health record default for new opioid analgesic prescriptions|
223611935|NCT04867746|OTHER|data collection by health questionnaires|Health questionnaires to assess scores concerning pain and function of the treated leg and overall health
223611936|NCT04867746|OTHER|assessment of muscle strength|Muscle strength will be measured bilaterally using a dynamometer (Biodex System 4 Pro: Biodex Medical Systems, Shirley, NY, USA). For the knee, maximum isokinetic flexion and extension torques will be collected between full extension and full flexion at a movement speed of 60°/s (5 repetitions) and 240°/s (15 repetitions). Maximum joint torques in each movement direction will be recorded for each joint and normalized to body weight.
223611937|NCT04867746|OTHER|assessment of gait|Instrumented gait analysis on a treadmill with an embedded plantar pressure plate (h/p/cosmos, Zebris FDM-T, Isny, Germany; 7168 sensors; area, 1.5 \* 0.5 m; range, 1-120 N/cm2; precision, 1-120 N/cm2 ± 5%; sampling rate, 120 Hz) and on an overground walkway with two embedded force plates (Kistler force plate 9260AA6, Kistler AG, Winterthur, Switzerland; sampling rate 2400 Hz). Simultaneously with the plantar pressure or force data, kinematic and electromyographic (EMG) data will be collected. Participants will then walk for 1 minute at their preferred walking speed (0% slope and at 15% slope) and at 1.2 m/s (0% slope). For all conditions, kinematic, EMG and pressure data will be recorded for 1 minute. Subsequently, the treadmill speed will be increased to preferred running speed and 2.3 m/s (0% slope), and data for 1 minute running will be recorded. Subjects will then complete overground walking and running trials on the walkway with embedded force plates.
223611938|NCT04867746|OTHER|assessment of squatting and single leg hops|Participants perform three jumps on a force plate. Maximum jump length, Maximum flexion and extension angles and joint moments will be identified. Subsequently, participants perform three squats onto two force plates (one per foot). On- and off times will be computed for each muscle and condition.
223611939|NCT04867746|OTHER|assessment of postural stability|The length of the centre of pressure path will be measured during two 30-second unipedal stance trials using a force plate.
223611940|NCT03316144|BIOLOGICAL|Toripalimab|Dose escalation study evaluating three dose levels (1, 3 and 10 mg/kg) of JS001. Subjects will be assigned to a dose schedule in the order of study entry.
223611941|NCT03956550|DRUG|REGN5069|Intravenous (IV) Dose every 4 weeks (Q4W)
223611942|NCT03956550|DRUG|Matching Placebo|Intravenous (IV) Dose every 4 weeks (QW4)
223611943|NCT04198480|DRUG|JMT103|2 mg/kg subcutaneously (SC) every 4 weeks with a loading dose of 2 mg/kg SC on study days 8 and 15.
223611944|NCT00150267|DRUG|Xalacom|
223611945|NCT00006591|DRUG|Ritonavir|
223611946|NCT00006591|DRUG|Amprenavir|
223611947|NCT02776111|OTHER|Blood Sample|A one time blood sample will be provided.
223611948|NCT01574508|DRUG|Transient Continuous Subcutaneous Insulin Infusion|Patients will be given Continuous Subcutaneous Insulin Infusion during two weeks confinement in the hospital. The initial dosage will be body weight (kg)\*0.5, and will be adjusted according to the 7 points glucose monitoring records in the hospital.
223611949|NCT01574508|DRUG|Transient Multiple Daily Insulin Injections|Patients will be given Transient multiple daily insulin injections during two weeks confinement in the hospital. The initial dosage will be body weight (kg)\*0.5, and will be adjusted according to the 7 points glucose monitoring records in the hospital
223611950|NCT01372969|DRUG|Cx601|Suspension of adult expanded allogenic adipose-derived stem cells (eASCs) at a doses of 20 million cells and 40 million cells.
223611951|NCT05768412|PROCEDURE|Radial Artery Access|The radial artery is stabilized between the thumb and forefinger of the left hand and 1 to 2 mL of subcutaneous lidocaine is used to create a wheal over the zone of planned entry.
223611952|NCT00984308|PROCEDURE|CPAP Therapy for Newly Diagnosed Obstructive Sleep Apnea (OSA)|Continuous Positive Airway Pressure (CPAP) is provided for those patients who are diagnosed with OSA.
223611953|NCT00172263|PROCEDURE|blood sampling|
223611954|NCT03965494|DRUG|BGB 324 (before surgery)|Given by mouth either BEFORE therapeutic conventional surgery
223611955|NCT03965494|DRUG|BGB 324 (after surgery)|Given by mouth either AFTER therapeutic conventional surgery
223611956|NCT02405156|DRUG|Letrozole|
223611957|NCT02405156|DRUG|Placebo|
223611958|NCT02405156|DRUG|Misoprostol|
223611959|NCT03056677|DIETARY_SUPPLEMENT|Control|200mls water will be given prior to a mixed carbohydrate meal
223611960|NCT03056677|DIETARY_SUPPLEMENT|Normal Whey protein|Whey protein (50grams) drink will be given prior to a mixed carbohydrate meal
223611961|NCT03056677|DIETARY_SUPPLEMENT|Modified whey protein|Modified whey protein (50grams) drink will be given prior to a mixed carbohydrate meal
223611962|NCT01620229|DRUG|brentuximab vedotin|Given IV
223611963|NCT01620229|OTHER|laboratory biomarker analysis|Correlative studies
223758164|NCT03404479|DRUG|Celecoxib|For 12 weeks, administered twice a day by oral.
223611964|NCT01620229|OTHER|pharmacological study|Correlative studies
223611965|NCT04331717|DEVICE|Bead Block 300-500 um|These patients will undergo embolization with 300-500µm Bead Block particles.
223611966|NCT04331717|BEHAVIORAL|Weight Management|All participants will be enrolled in weight management through the Johns Hopkins Weight Management Center. During weeks -4 through 0, participants will be required to go to weekly visits. Weight management will include counseling on diet, exercise and behavior change. Food programs, pharmacotherapy and other procedures will not be utilized.
223611967|NCT04331717|DRUG|Lupron|22.5 mg will be given as a single intramuscular or subcutaneous injection once every 12 weeks according to the standard of care for prostate cancer. If leuprolide acetate, 22.5 mg for 3-month administration is not available, a suitable substitute may be allowed upon approval by the principle investigator
223758165|NCT02485106|DRUG|Rifaximin|400mg three times per day for 28 days
223758166|NCT02485106|DRUG|Corticosteroid or pentoxifylline|Corticosteroid 40mg/day or pentoxifylline 400mg three times per day for 28 days
223758167|NCT04246606|DIAGNOSTIC_TEST|IHC4 score|"The IHC4 score is a prognostic tool that incorporates immunohistochemical parameters of ER (H-score), PR (% of positive cells), HER2 (positive or negative status), and Ki67 (% of positive cells).~IHC4 score, combined with nodal status and tumor grade, age, and the type of endocrine therapy (tamoxifen or aromatase inhibitors) provides a clinical score IHC4+C.~IHC4+C provides a prognostic risk of distant recurrence at 10 years for patients who underwent endocrine therapy for 5 years. IHC4+C defined three distinct risk categories:~* \<10%: low risk~* \[10-20%\]: intermediate risk~* \>20%: high risk"
223758168|NCT05669456|DEVICE|Halo Alert System|The Halo Alert System consists of an EEG sensor headband and is paired with a data transfer device.
223758169|NCT04306809|BEHAVIORAL|Internet-delivered ACT for PTSD and chronic pain|The participants will go through an active internet-based ACT treatment focused on education about PTSD, value-based exposure for the traumatic memory and avoided situations, and behavior change through exercises targeting the processes mindfulness, cognitive defusion and acceptance. The treatment is delivered on a safe internet platform. Participants have planned telephone contact with their assigned psychologist 3 times during the program and can also contact their psychologist via a message system in the platform and expect answer within 48 hours.
223758170|NCT00842348|DRUG|lanreotide (Autogel formulation)|Autogel 120 mg
223758171|NCT05014022|DIAGNOSTIC_TEST|Multiparametric renal MRI|10 patients in the cohort will undergo MRI scanning at day 30 and 90
223758172|NCT05066971|COMBINATION_PRODUCT|Self-adjustment of medication|Each week, based on the information provided by HM (heart rate and hours of activity each day), the rate control medication is adjusted to increase the total of activity time.
223758173|NCT05320991|DRUG|Ketamine|Ketamine is applied with a Graseby 3500 intravenous infusion pump controlled by the STANPUMP software (Steven Shafer, M.D., Anesthesiology Service, PAVAMC 3801 Miranda Ave., Palo Alto, USA). Target plasma levels are 100 ng/ml with an initial bolus administered as a 2 mg/ml solution.
223758174|NCT05320991|DRUG|Nacl 0.9%|Saline solution will also be applied with the Graseby 3500 intravenous infusion pump controlled by the STANPUMP software (Steven Shafer, M.D., Anesthesiology Service, PAVAMC 3801 Miranda Ave., Palo Alto, USA).
223758175|NCT06072937|DEVICE|IntelliStent|Staged implantation of IntelliStent. The system comprises a nitinol self-expanding stent with a hollow element delivered over-the-wire into the main pulmonary artery or its left and right branches, using an 18 Fr transfemoral introducer sheath. The stent consists of two sections, one with a larger diameter and one with a smaller diameter, available in 6 sizes suitable for vessel sizes ranging from 20mm to 30 mm. Additional smaller sizes are currently under development.
223758176|NCT04558931|DRUG|CellProtect|In vitro expanded and activated autologous NK cells
223758177|NCT04558931|DRUG|Isatuximab|Naked immunoglobulin (Ig) G1 monoclonal antibody (mAb) that selectively binds to the human cell surface antigen molecule classified as cluster of differentiation (CD) 38
223758178|NCT04977258|OTHER|Treadmill aerobic exercise without water intake|The volunteers will be submitted to a cardiovascular rehabilitation session with 40 minutes of treadmill aerobic exercise followed by 60 minutes of recovery at the supine position.
223758179|NCT04977258|OTHER|Treadmill aerobic exercise with water intake of a predetermined amount.|The volunteers will be submitted to a cardiovascular rehabilitation session with 40 minutes of treadmill aerobic exercise and water intake followed by 60 minutes of recovery at the supine position.
224201333|NCT01258452|DRUG|CHF 5074|Drug is administered to subject in a fasting state
224201334|NCT01258452|DRUG|CHF 5974|Drug is administered to subject after consumption of a high fat, high calorie meal
223611968|NCT03648294|OTHER|adrenalectomy for primary addosteronism|All of the clinical and biological data were retrospectively compiled from the patient computerized record. The variables analyzed were: age, sex, body mass index (BMI), PAH discovery circumstances, pre- and postoperative systolic and diastolic blood pressure assessments, number of pre-hypertensive antihypertensive drug - and postoperatively, the laterality, the size and nature of the lesions, the operating time, the surgical technique used. The biological data evaluated were pre- and postoperative plasma and plasma creatinine, preoperative serum aldosterone concentrations, plasma renin activity, and preoperative aldosterone / renin ratio. Hypokalemia was defined as serum concentration below 3.5 mmol / L.
223611969|NCT02919774|DRUG|POMA|"Pomaglumetad (POMA) is a mGluR 2/3 partial agonist"
223611970|NCT02919774|DRUG|placebo|matching placebo tablets
223611971|NCT00592904|DRUG|E2007|Perampanel doses will be up-titrated in 2 mg steps at minimum weekly intervals starting at 2 mg daily and up-titrated to 12 mg daily (taken orally).
224201335|NCT06103656|DRUG|Drug: Chinese Herbal Medication|Capsules, 26 month course, starting 2 months pre-OIT.
224201336|NCT06103656|DRUG|Drug: Placebo|Placebo capsules that look identical to E-B-FAHF-2 containing corn starch, 26 month course, starting 2 months pre-OIT
224201337|NCT06103656|DRUG|Drug: Omalizumab|4 months course, starting 2 months pre-OIT through the 2 month build-up phase
224201338|NCT01995409|BEHAVIORAL|No smoking material provided in households with newborn infants|
223611972|NCT04881617|BEHAVIORAL|Lexical Retrieval Training (LRT)|In person or via teletherapy: Participants work on producing spoken and written names of personally relevant target items using a self-cueing hierarchy. Treatment focuses on the use of strategies that capitalize on spared cognitive-linguistic abilities to support word retrieval. The participant completes two (one hour each) sessions per week with a clinician plus daily home practice exercises.
223611973|NCT04881617|BEHAVIORAL|Video-Implemented Script Training for Aphasia (VISTA)|In person or via teletherapy: Participants work on producing personally relevant scripts of 4-6 sentences in length. Length and complexity of scripts are individually tailored. The participant completes 30 minutes per day of home practice, during which they speak in unison with a video/audio model of a healthy speaker clearly articulating the scripts. Biweekly (one hour each) sessions with a clinician target clear and accurate script production, script memorization, and conversational usage of scripts.
223611974|NCT02089594|DRUG|Hyperbaric Oxygen|HBOT Group: Pressurization will proceed with 100% oxygen at 1.0 pounds per square inch (psi) per minute, the minimal pressurization rate, to 1.5 ATA (atmospheres absolute) or 7.35 psi and will take approximately 7 minutes. Pressurization will then resume until the final depth of 1.5 ATA is achieved. The patient will remain at depth for approximately 45 minutes and the subject will be informed of the onset of depressurization, which will occur at the same rate as pressurization. Total dive time will be 60 minutes.
223611975|NCT02089594|DRUG|No Hyperbaric Oxygen|Subjects will receive their usual care during the equivalent eight-week HBOT treatment period. There will be no hyperbaric chamber experience. At the conclusion of the eight-week control period both control and experimental subjects will be retested and the control group will be crossed over to receive the identical 40 HBOTs of the HBOT group.
223611976|NCT01359904|OTHER|High Dialysate bath|The dialysate bath assigned is 10mmol/L glucose, while the control group is assigned to 5.5 mmol/l glucose solution.
223611977|NCT04372420|DRUG|RhBMP-2 absorbable sponge in grade II furcation|The collagen sponge is impregnated with rhBMP-2 at a concentration of 0.5 μg/ml/1cm3 and were stored at 4°C. This rhBMP-2 impregnated collagen sponge was then dispensed at grade II furcation site
223611978|NCT04372420|PROCEDURE|PLATELET RICH FIBRIN in grade II furcation|For preparation of PRF, patient's venous blood is collected into 10ml glass tube or glass-coated plastic tube and centrifuged at 2700 rpm for 12min which leads to two different layers in the test tube, the upper platelet rich fibrin and the lower RBC portion. The formed PRF clot could then be removed from the glass tube and used in grade II furcation
223611979|NCT01944540|PROCEDURE|Optimized ESD with snaring|
223611980|NCT01944540|PROCEDURE|Conventional ESD|
223611981|NCT02660853|DIAGNOSTIC_TEST|FEV1|Participants have FEV1 test
223611982|NCT02686385|DRUG|Prednisolone|
223611983|NCT02686385|DRUG|N-Acetylcysteine|NAC (N-Acetylcysteine) dosing-Loading dose: 150 mg/kg IV; mix in 200 mL of 5% dextrose in water (D5W) and infuse over 1 h Dose 2: 50 mg/kg IV in 500 mL D5W over 4 h Dose 3: 100 mg/kg IV in 1000 mL D5W over 16 h
223758180|NCT04977258|OTHER|Treadmill aerobic exercise with water intake according to the desire to drink|The volunteers will be submitted to a cardiovascular rehabilitation session with 40 minutes of treadmill aerobic exercise and water intake followed by 60 minutes of recovery at the supine position.
223758181|NCT03700697|BEHAVIORAL|Family Stress Module Intervention|as above
223758182|NCT01622855|BEHAVIORAL|PPRS|Video including psycho-education and modeling of adaptive behavioral coping strategies for use post-assault.
223758183|NCT06095791|DRUG|Immunomodulators with FDA approval on the 1st January 2023.|Disproportionnality analysis studying the association between immunomodulators with FDA approval on the 1st January 2023 and atrial fibrillation in the World Health Organization pharmacovigilance database.
223758184|NCT01299922|DRUG|cyclosporine +mycophenolic acid+prednison|Cyclosporine for 26 weeks Prednisone+mycophenolic acid 106 weeks
223611984|NCT04012580|BEHAVIORAL|Therapist-assisted ICBT|An 8-week transdiagnostic internet-delivered cognitive behavioural therapy (ICBT) will be delivered to participants. In addition to the online program, therapists, registered social workers, psychologists or supervised graduate students will provide support by email once a week.
223611985|NCT06149455|OTHER|Duration of antibiotics|Patients will be randomized to a short (2 days) or long (7 days) of pre-operative antibiotics, the choice of agent will be dependent upon bacterial sensitivities if available which is standard of care.
223611986|NCT03706443|OTHER|Systane Complete|Lubricant eye drop which is based on propylene glycol 0.6%. Used for temporary relief of burning and irritation due to dryness of the eye.
223611987|NCT03706443|OTHER|Systane Ultra|Lubricant eye drop which is based on polyethylene glycol 400 0.4% and propylene glycol 0.3%. Used for temporary relief of burning and irritation due to dryness of the eye.
223758185|NCT01299922|DRUG|Mycophenolic Acid + prednison|Mycophenolic Acid + prednison for 106 weeks
223758186|NCT05516082|DEVICE|Lens A|DDH contact lens for 15 minutes
223758187|NCT05516082|DEVICE|Lens B|DDSH contact lens for 15 minutes
223758188|NCT00451867|DRUG|Mycophenolate Mofetil|
223758189|NCT00451867|DRUG|Mycofenolate Mofetil (MMF)|2000 mg per day divided into 2 equal doses.
223758190|NCT00451867|DRUG|Placebo|Placebo
223758191|NCT06133309|BEHAVIORAL|Experiential Phenomenological Interview|"Consciousness fluidity of patients suffering from depressive disorder and treated with Esketamine will be evaluated thanks to Experiential Phenomenological Interview and EQFC Trait questionnaire"
223758192|NCT02165319|DEVICE|Barrel|Barrel-shaped endotracheal tube will be used during general anesthesia.
223758193|NCT02165319|DEVICE|Tapered|Tapered-shaped tube will be used during general anesthesia.
223758194|NCT01524627|DRUG|Varenicline|Varenicline will be prescribed to non-abstinent smokers at the same doses as have been demonstrated to be clinically effective: 0.5 mg twice a day for 3 days and then 1mg twice daily for the remainder of the treatment course of 8 weeks.
223758195|NCT01524627|DRUG|Placebo|Placebo will be prescribed to non-abstinent smokers at the same doses as have been demonstrated to be clinically effective for Varenicline: 0.5 mg twice a day for 3 days and then 1mg twice daily for the remainder of the treatment course of 8 weeks.
223758196|NCT06108505|OTHER|Lacticaseibacillus with oats|Subjects will receive 7.5 gr of oats containing Lacticaseibacillus
223758197|NCT06108505|OTHER|Plain oats|Subjects will receive 7.5 gr of plain oats
223758198|NCT00022321|DRUG|gemtuzumab ozogamicin|
223611988|NCT02056795|DEVICE|Asia-Med Special No 16 (0.30x30mm) needles|Subjects will do balance assessment in lab. In treatment room, practitioner will clean insertion area with alcohol swab, allow adequate time to dry, and insert 2 Asia-Med Special No 16 (0.30x30mm) needles: one at proximal insertion of fibularis longus anterior to fibular neck, in proximity to common fibular nerve (GB-34); one over sinus tarsi and lateral ligaments of ankle mortise (GB-40). Needles will be inserted approximately 1-2cm, connected for 10 min at 2Hz to electrical stimulation (ITO ES-130, 500 ohm test load, 1 to 500Hz). Needles will disposed of in sharps container. Area will be wiped with long handled cotton swab, pressure will be applied for 2 seconds. Subjects will be asked to slowly get up from table and return to lab for second balance assessment.
223611989|NCT02056795|DEVICE|Streitberger placebo needles (Asia-Med, 0.03 x 30 mm)|As with experimental group, controls will do balance assessment pre- and post-intervention. Streitberger placebo needles (Asia-Med, 0.03 x 30 mm), blunted with a telescoping mechanism, will be used. Subjects will feel slight prick, and shaft will telescope into handle, creating illusion of skin penetration. Needles will be held in place by plastic ring covered by a bandage. They are validated for blinding. They will be placed over non-traditional acupuncture points on medial aspect of leg, in direct opposition to treatment group needles. Needle placement is not intended to produce therapeutic outcome. The needles will be connected to a wire, which will be turned on for 10 minutes but no stimulation will be felt.
223611990|NCT01860833|DRUG|Ibuprofen|time of treatment 14 days
223611991|NCT01860833|DRUG|Celecoxib|time of treatment 14 days
223611992|NCT01860833|DRUG|Diclofenac|time of treatment 14 days
223611993|NCT02939586|PROCEDURE|Haemodiafiltration post-dilution model|Participants will be randomly assigned into either HD or HDF group. The participants will received the assigned treatment for 2 months, 1 month wash-out (HD) and cross-over to the other dialysis model- eg. HDF (2months) and switch to HD for 2 months, with 1 month washout period (using standard HD). Haemodialysis post-dilution model will be delivered using fresenius 5008 machine. Prescription for HDF post-dilution will be comparable to HD.
223611994|NCT02939586|PROCEDURE|Haemodialysis|Participants will be randomly assigned into either HD or HDF group. The participants will received the assigned treatment for 2 months and cross-over to the other dialysis model- eg. HD (2months) and switch to HDF for 2 months, with 1 month washout period (using standard HD). Haemodialysis treatment will be delivered using fresenius 5008 machine. treatment time/parameters may vary depends on individual prescription.
223611995|NCT06106802|DRUG|Lazertinib|Lazertinib 240mg/day
223611996|NCT06106802|DRUG|Tepotinib|Tepotinib 500mg/day
223611997|NCT00302341|DRUG|Pafuramidine maleate (DB289)|Oral tablet, 100 mg bid, 14 days
223611998|NCT00302341|DRUG|Trimethoprim-Sulfamethoxazole (TMP-SMX)|15 mg/kg, oral tablet split tid X 21 days
223611999|NCT04688749|DIAGNOSTIC_TEST|Electrical Impedence Spectroscopy DermaSense|Two sets of measurements will be performed to each subject, either at a nevus in contrast with a nearby clear patch of skin. The duration of each measurement will last for approximately 1.5 minutes and the excel file will be directly available to researcher, allowing him/her for data storage and data visualization.
223612000|NCT05912764|OTHER|Patient support|Patients will be supported by nurses before and after intervention and hospital leave
223612001|NCT01225094|DRUG|curcumin|Patients will take the study medication (500 mg x 4 capsules, twice daily \[BID\]) for two days leading up to repair, totaling 4000 mg per day. They will take a dose (2000 mg) the morning of repair, at the same time as regular medications not held for surgery. While they are on call to the operating room, they will take another dose of 2000 mg and then another 2000 mg dose 6 hours after the repair. Final dose is administered the morning after repair.
223612002|NCT01225094|OTHER|placebo|The placebo will look, smell, taste, and in every way be identical to the active drug. Patients will take the study medication in the exact same manner as the curcumin regimen.
223612003|NCT04883866|BEHAVIORAL|Telephone Breastfeeding Support Program|On the 3rd day after discharge, a reminder messages will be sent to the mothers in the inter vention group. Throughout the program, 21 reminder messages will be sent to mothers in the first month after discharge to support the mother and encourage breast milk via a messaging application (whatsapp, bip, telegram, etc.). In addition, a total of seven phone calls, once a week in the first month after discharge and once a month in the eighth, twelfth and sixteenth weeks, will be made to check personalized information about individual breastfeeding questions of mothers.
223612004|NCT04883866|BEHAVIORAL|Sending a breastfeeding guide for premature babies to the phone of mothers in addition to the routine discharge procedure|In addition to the routine discharge procedure, a breastfeeding guide for premature babies will be sent to the mothers' phone.
223612005|NCT01770574|DEVICE|ReproBone|Artificial bone graft is inserted as a wedge in the calcaneal lengthening osteotomy
223612006|NCT01770574|PROCEDURE|calcaneal lengthening|Autologous bone graft is harvested from the iliac crest and inserted as a wedge in the calcaneal lengthening osteotomy
223612007|NCT03191630|BEHAVIORAL|Fitbit (Control)|Study procedures include group sessions at the OSU Transplant Clinic with 10-12 participants for 6 months and a 6-month maintenance phase without contact from study personnel until month 12. Session 1 for the control group will be identical to the Intervention with the only exception being that participants in the control group will not be asked to increase their step goal. Throughout their participation, subjects will be asked questions only about their use of the Fitbit activity tracker. The research team will not be in contact with them for 6 months, after which time there will be a final group session.
223612008|NCT03191630|BEHAVIORAL|SystemCHANGE and Fitbit (Intervention)|Study procedures include group sessions with 10-12 participants for 6 months and a 6-month maintenance phase without contact from study personnel until month 12. Study personnel will demonstrate proper Fitbit activity tracker use, and teach participants to sync to their smartphone and retrieve data from their Fitbit. Subjects will be called to encourage them to increase their step goal 5% each month. Fitbit activity tracker reports will be reviewed and participants will be asked to identify what people or things influence their physical activity. Subjects will be asked what they are learning about physical activity, their contentment level with current physical activity, and if they want to make changes. Participants will continue for months, after which time there will be a final group session.
224201339|NCT02879552|PROCEDURE|Traditional upper blepharoplasty|The skin incisions were marked using a skin marking pen. Preseptal orbicularis skin and muscle were removed using a size-15 scalpel blade and scissors. Hemostasis was achieved with conservative electrocuatery. The skin was closed with a running 6-0 nylon suture.
223612009|NCT02707146|BEHAVIORAL|Visit Planner|The Visit Planner is an application hosted on an iPad that guides the patient in preparing for the primary care visit
223758199|NCT04049656|DEVICE|HFVI|Subjects in the HFVI intervention group will be monitored in the same manner as the control group, but the HFVI monitor display will also be available to the anesthesia provider in real time. Bolus doses of 25ug or 50 ug of fentanyl will be recommended to be administered when the HFVI values begin to decrease below 50, and as needed based on the judgment of the clinician responsible for the case. All anesthetic medications that are given, patient events, and vital sign recordings will be included in the anesthetic record and data collection forms.
223758200|NCT04908670|BEHAVIORAL|Understanding Pain in less than 5 minutes, and what to do about it! https://www.youtube.com/watch?v=C_3phB93rvI|Watching pain neuroscience education video
223758201|NCT04908670|PROCEDURE|PA manipulation|Low grade PA manipulation on the cervical, thoracic and lumbar spine
223758202|NCT03476304|DEVICE|Endocrown restoration|The endodontically treated tooth will be impressed, and an endocrown restoration will be manufactured with resin composite in a cast and cemented with self adhesive cement
223758203|NCT03476304|DEVICE|Post retained composite restoration|The endodontically treated tooth will receive a fiber post cemented with self adhesive cement and after this, the tooth will be impressed and a semi direct composite restoration will be cemented with self adhesive cement.
223758204|NCT03476304|DEVICE|Post retained ceramic restoration|The endodontically treated tooth will receive a fiber post cemented with self adhesive cement and after this, the tooth will be impressed and a ceramic restoration will be cemented with self adhesive cement.
223758205|NCT01251588|BIOLOGICAL|autologous cultured chondrocytes on porcine collagen membrane|Implantation received in the previous MACI00206 study
223758206|NCT01251588|PROCEDURE|Microfracture|Arthroscopic Microfracture treatment received in the previous MACI00206 study
223612010|NCT02707146|OTHER|Attention Control Pamphlet|Patients in the attention control arm will receive an approved educational handout on health lifestyle
223612011|NCT02707146|DEVICE|iPad|
223612012|NCT05829954|OTHER|questionnaire|All questionnaire were obtained via online survey system.
223612013|NCT06129279|OTHER|EFT group|"Preliminary tests will be carried out and then the 1st EFT session will be held.~After 30 days, the first final tests will be performed and then the second EFT session will be held.~After 30 days, only the 2nd final tests will be performed."
223612014|NCT00724178|DIETARY_SUPPLEMENT|cholecalciferol plus calcium carbonate|oral calciferol 100,000 IU by mouth bimonthly and calcium carbonate (1 gr) by mouth daily
223612015|NCT02884388|PROCEDURE|combined nerve block|Patients in this group were assigned to receive lower lumbar plexus block, sciatic nerve block, and paraspinal nerve L1-2 block.
223612016|NCT02884388|PROCEDURE|general anesthesia|Patients in this group were assigned to receive general anesthesia.
223612017|NCT04168658|COMBINATION_PRODUCT|Physical activity and education intervention|"At least six staff from each nursing home that assigned to the intervention group will be invited to attend two educational workshops. Participants in the intervention group will receive the following interventions.~1. Face-to-face workshops: Five 1-hour educational workshops on physical activity will be delivered in months 1, 3, 5, 7 and 9 of the program held at each nursing home.~2. Booklet: At the first educational workshop, each participant will be provided with a pictorial booklet.~3. Exercise: The physical activity training consists of 50-60 min exercise sessions three times a week on non-consecutive days for 12 months.~4. Others (newsletters, phone calls, and reminders): The intervention group will also receive newsletters containing myth dispelling information on osteoporosis and physical activity, motivational phone calls and a total of 52 SMS via mobile phones (reminders to attend workshop sessions and physical activity motivating messages) over 12 months."
223612018|NCT04168658|BEHAVIORAL|Education intervention|Participants in the control group will only receive educational materials (i.e. face-to-face workshops and booklet) and will be wait listed to receive no other interventions of this study until after the post-intervention.
223612019|NCT03573141|OTHER|Physical Therapy|Subjects received a comprehensive physical therapy evaluation after baseline data collection and received a normal course pf physical therapy treatment based on impairments identified.
223612020|NCT01361646|DRUG|LC350189|Single Ascending Dose: 10, 25, 50, 100, 200, 400, 600mg Multifle Ascending Dose: 100, 200, 400, 600, 800mg
223612021|NCT05291793|DRUG|Tenoxicam 20 Mg Powder for Solution for Injection Vial|Tenoxicam 20 Mg Powder is mixed with dissolving solvent then administered intraarticularly
223612022|NCT05291793|DRUG|Methylprednisolone|Methylprednisolone 40 Mg (suspension) administered intraarticularly
223758207|NCT01581632|DEVICE|LipiScan/LipiScan IVUS|Evaluation of the coronary artery using near infrared spectroscopy using either a LipiScan catheter or a LipiScan/IVUS catheter following a clinically indicated coronary angiogram and endothelial function testing with a positive diagnosis of endothelial dysfunction. The procedure is repeated following 6 months of Lp-PLA2 inhibition.
223758208|NCT01209910|OTHER|Water|Subjects in this arm will be able to drink water with some conditions.
223758209|NCT04010266|DEVICE|RelieVRx headset|RelieVRx is a virtual reality therapy intended as adjunctive treatment for acute surgical pain
223758210|NCT04010266|DRUG|multi-modality pain management|combination of medications may be used such as a local anesthesia, ibuprofen, acetaminophen, gabapentin, ketamine, lidocaine, and opioids
223758211|NCT05240846|PROCEDURE|Paramedian conventional palpation group|Patients in this group underwent conventional landmark guided paramedian spinal anesthetic. The spinal anesthesia will be administered based on conventional landmark-based paramedian approach.
223758212|NCT05240846|PROCEDURE|Ultrasound assistance paramedian spinal group|This group will have their spinal anesthetic done based on ultrasound assistance paramedian spinal. Spinal anesthesia with a paramedian approach was performed based on the optimum puncture point, suggested puncture angles, and puncture depth. The suggested puncture angles included the cephalad angle measured by the built-in angle program of the ultrasound and the medial angle measured by a 180° protractor (Deli). The puncture depth, the distance from the skin to the posterior complex, was measured utilizing the ultrasound clipper tool.
223758213|NCT04492891|DRUG|Cyclosporine|2.5 mg/kg PO BID 7 days
223612023|NCT05291793|DRUG|Saline|2ml sterile saline administered intraarticularly
223758214|NCT04492891|OTHER|Standard of Care Treatment|Standard of Care Treatment, N= 25 Patients, 7 days
223612024|NCT01468740|DRUG|Doxorubicin|"The four-drug ABVD chemotherapy regimen and the seven-drug BEACOPP-baseline chemotherapy regimen contain doxorubicin.~* Early stage favorable Hodgkin Lymphoma: 2 cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) + 30 Gy involved field (IF) radiation~* Early stage unfavorable Hodgkin Lymphoma: 4 cycles of ABVD + 30 Gy involved field (IF) radiation or 4 cycles of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP)-baseline + 30 Gy IF radiation~* Advanced Hodgkin Lymphoma: 8 cycles of BEACOPP-baseline. After the completion of chemotherapy sites of initial bulky disease (those at least 5 cm in diameter) and residual tumor larger than 2.5 cm in diameter receive 30 Gy of irradiation."
223612025|NCT01468740|DRUG|Bleomycin|"The four-drug ABVD chemotherapy regimen and the seven-drug BEACOPP-baseline chemotherapy regimen contain bleomycin.~* Early stage favorable Hodgkin Lymphoma: 2 cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) + 30 Gy involved field (IF) radiation~* Early stage unfavorable Hodgkin Lymphoma: 4 cycles of ABVD + 30 Gy involved field (IF) radiation or 4 cycles of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP)-baseline + 30 Gy IF radiation~* Advanced Hodgkin Lymphoma: 8 cycles of BEACOPP-baseline. After the completion of chemotherapy sites of initial bulky disease (those at least 5 cm in diameter) and residual tumor larger than 2.5 cm in diameter receive 30 Gy of irradiation."
223612026|NCT01468740|DRUG|Vinblastine|"The four-drug ABVD chemotherapy regimen contains vinblastine~* Early stage favorable Hodgkin Lymphoma: 2 cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) + 30 Gy involved field (IF) radiation~* Early stage unfavorable Hodgkin Lymphoma: 4 cycles of ABVD + 30 Gy involved field (IF) radiation"
223612027|NCT01468740|DRUG|Dacarbazine|"The four-drug ABVD chemotherapy regimen contains dacarbazine~* Early stage favorable Hodgkin Lymphoma: 2 cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) + 30 Gy involved field (IF) radiation~* Early stage unfavorable Hodgkin Lymphoma: 4 cycles of ABVD + 30 Gy involved field (IF) radiation"
223612028|NCT01468740|DRUG|Etoposide|"The seven-drug BEACOPP-baseline chemotherapy regimen contains etoposide.~* Early stage unfavorable Hodgkin Lymphoma: 4 cycles of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP)-baseline + 30 Gy IF radiation~* Advanced Hodgkin Lymphoma: 8 cycles of BEACOPP-baseline. After the completion of chemotherapy sites of initial bulky disease (those at least 5 cm in diameter) and residual tumor larger than 2.5 cm in diameter receive 30 Gy of irradiation."
223612029|NCT01468740|DRUG|Cyclophosphamide|"The seven-drug BEACOPP-baseline chemotherapy regimen contains cyclophosphamide.~* Early stage unfavorable Hodgkin Lymphoma: 4 cycles of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP)-baseline + 30 Gy IF radiation~* Advanced Hodgkin Lymphoma: 8 cycles of BEACOPP-baseline. After the completion of chemotherapy sites of initial bulky disease (those at least 5 cm in diameter) and residual tumor larger than 2.5 cm in diameter receive 30 Gy of irradiation."
223612030|NCT01468740|DRUG|Vincristine|"The seven-drug BEACOPP-baseline chemotherapy regimen contains vincristine.~* Early stage unfavorable Hodgkin Lymphoma: 4 cycles of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP)-baseline + 30 Gy IF radiation~* Advanced Hodgkin Lymphoma: 8 cycles of BEACOPP-baseline. After the completion of chemotherapy sites of initial bulky disease (those at least 5 cm in diameter) and residual tumor larger than 2.5 cm in diameter receive 30 Gy of irradiation."
223612031|NCT01468740|DRUG|Procarbazine|"The seven-drug BEACOPP-baseline chemotherapy regimen contains procarbazine.~* Early stage unfavorable Hodgkin Lymphoma: 4 cycles of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP)-baseline + 30 Gy IF radiation~* Advanced Hodgkin Lymphoma: 8 cycles of BEACOPP-baseline. After the completion of chemotherapy sites of initial bulky disease (those at least 5 cm in diameter) and residual tumor larger than 2.5 cm in diameter receive 30 Gy of irradiation."
223612032|NCT01468740|DRUG|Prednisone|"The seven-drug BEACOPP-baseline chemotherapy regimen contains prednisone.~* Early stage unfavorable Hodgkin Lymphoma: 4 cycles of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP)-baseline + 30 Gy IF radiation~* Advanced Hodgkin Lymphoma: 8 cycles of BEACOPP-baseline. After the completion of chemotherapy sites of initial bulky disease (those at least 5 cm in diameter) and residual tumor larger than 2.5 cm in diameter receive 30 Gy of irradiation."
223612033|NCT05206812|DRUG|durvalumab|"* durvalumab 1500 mg QD\*~* Surgery within 1 to 8 weeks - 4 cycles of durvalumab 1500 mg/m2 (Day 1, Day 8)+cisplatin 80 mg/m2 (Day 1) q3wks -durvalumab 1500 mg q4wks (Maximum of 10 cycles)"
223758215|NCT05687435|DRUG|Changyanning tablet|"Changyanning Tablet is produced by Jiangxi Kang'enbei Traditional Chinese Medicine Co., Ltd，composed of Euphorbia humifusa, golden ear grass, camphor tree root, Elsholtzia splendens and maple leaves. It is mainly used for the treatment of acute and chronic intestinal diseases caused by various reasons.~If the symptoms of the subject become worse and unbearable during the study period, it is allowed to add Pinaverium Bromide to the patient according to the specific situation."
223758216|NCT05687435|OTHER|Changyanning tablet placebo|"Changyanning Tablet placebo is produced by Jiangxi Kang'enbei Traditional Chinese Medicine Co., Ltd. Changyanning Tablet placebo has the same appearance, smell, taste, specifications and packaging with Changyanning Tablet, but does not contain active pharmaceutical ingredients.~If the symptoms of the subject become worse and unbearable during the study period, it is allowed to add Pinaverium Bromide to the patient according to the specific situation."
223758217|NCT02679911|DRUG|Loceryl NL|Topical over the entire toenail plate of all affected toenails, once weekly in the evening (at bed time) after filing down the affected toenails.
223758218|NCT02679911|DRUG|Ciclopirox NL|Topical over the entire toenail plate of all affected toenails and surrounding skin, once daily in the evening (at bed time) after removing the free toenail edge and diseased toenails if needed
223612034|NCT01156220|DRUG|Furosemide|Injection, 40 mg, single dose over 5 min
224201340|NCT02879552|PROCEDURE|Brassiere suture with blepharoplasty|"Prior to skin closure as above, three 6-0 polyglactin sutures are passed along the lateral fourth of the orbital rim. The sutures attach the inferior orbicularis oculi edge to the arcus marginalis of lateral ROOF. Sutures are placed until there is a visible plumping of the sub-brow tissues."
224201341|NCT01462188|PROCEDURE|Immediate stenting|Primary coronary stenting
224201342|NCT01462188|PROCEDURE|Delayed stenting|Coronary stenting 3 to 7 days after having reopened the vessel in the acute phase
224201343|NCT00448929|DEVICE|OculusGen Biodegradable Collagen Matrix Implant|Trabeculectomy with OculusGen Biodegradable Collagen Matrix Implant
223612035|NCT01156220|DRUG|aminohippurate sodium|Injection, 500 mg, single dose over 5 min
223612036|NCT02525588|DEVICE|Triathlon CS fixed bearing total knee prosthesis|The patient will receive either the N2Vac polyethylene inlay or the X3 polyethylene inlay for their CS total knee.
223612037|NCT02459119|DRUG|Regorafenib|Regorafenib will be packaged as 40 mg tablets in a bottle. Patients will be instructed to maintain a daily medication calendar.
223612038|NCT02408133|OTHER|Home exercise|Will be offered to the group, instructional material (manual exercises) and point you to an exercise routine to be performed independently for range of motion and muscular fitness, using the environmental resources of the same household. A daily frequency in performing this exercise routine is suggested. Also, be given incentives and guidelines for the practice of active commuting (walking) to be accumulated at least 10 to 20 minutes of this activity daily. All control guidelines and training for the use of the exercise manual will be offered through an introductory lecture and subsequent weekly telephone contacts (2 times a week). The participants in this group should fulfill their respective program for a total period of 12 weeks.
223612039|NCT02339753|DRUG|Carboplatin|Blood sampling will be done at the time before administration (0hr pre-dose), 1hr, 2hr, 5hr for pharmacokinetic study.
223612040|NCT03992079|PROCEDURE|ReCOVER Enhanced Recovery Protocol|The experimental group will receive preemptive pain management before surgery, an opioid-free strategy during surgery, and an opioid-sparing multimodal pain management protocol after surgery.
223612041|NCT01433016|DRUG|13C Sodium Octanoate|13C labeled Sodium Octanoate Substrate is provided in powder form in doses of 100mg for single breath test, and is dissolved in 150cc of tap water before ingestion. Duration of the observation after the drug ingestion is one hour.
223612042|NCT02649140|DIETARY_SUPPLEMENT|Vinegar group|Each participant in vinegar group drink 15ml vinegar(Ninghuafu,Sanxi,China)after dinner at noon and evening respectively for a period of four weeks.
223612043|NCT03369418|DEVICE|Alpha-Stim Active|The study device is a safe, commercially available take-home cranial electrotherapy stimulation device that applies an electrical current to a subject's head to treat anxiety, depression or insomnia
223612044|NCT03369418|DEVICE|Alpha-Stim Inactive|The study device given to the inactive group will be identical to the active except the electrodes attached to the device will be inactive. The device will not transmit anything when turned on because the electrodes are inactive.
223612045|NCT04353245|OTHER|BIOMARKERS IN THE LONG TERM IMPACT OF CORONAVIRUS INFECTION IN THE CARDIORRESPIRATORY SYSTEM|Organize care follow-up for patients who have had COVID-19 coronavirus infection for scientific purposes. Thus, it is expected to obtain relevant data on cardiac sequelae and pulmonary. These data are important for understanding the long-term prognosis of patients surviving this infection.
223612046|NCT01485094|DRUG|GRT6010|Oral solution given once daily.
223612047|NCT01485094|DRUG|Pregabalin|Over-encapsulated pregabalin capsules 75mg twice daily on Days 1 to 3, and 150mg twice daily on Days 4 to 7.
223612048|NCT01485094|DRUG|Matching Placebo|"Matching Placebo capsules to the over-encapsulated Pregabalin capsules and Matching Placebo oral solution to the GRT6010 solution.~Capsules twice daily on Days 1 to 7. Solution once daily."
223612049|NCT02702466|OTHER|SPA Therapy|Immersion bath and shower ( 1 treatment ) Underwater shower with localized massage on the painful area ( 1 treatment ) or equivalent underwater massage Illutations ( 1 treatment ) or equivalent ( poultice ) Mobilization Pool ( 1 care) Education to exercise
223612050|NCT01094678|DEVICE|Zilver® PTX™ Stent|Stenting of the superfemoropopliteal artery.
223612051|NCT00763646|DRUG|Taxotere, Cisplatin, and 5-FU|Taxotere/Cisplatin/5-FU x 3 cycles (3 weeks per cycle or 9 weeks total), 1 - 2 weeks, Taxotere/Cisplatin/5-FU x 3 cycles (3 weeks per cycle or 9 weeks total)
223612052|NCT04955457|OTHER|Healthy women active teachers|The neuropsychological testing data, psychometric measure, demographic, clinical and lifestyle information and blood samples were collected at similar time points. This group not received any intervention.
223612053|NCT02564133|DEVICE|Transthoracic echocardiography|A transthoracic echocardiography is performed to discover a patent foramen ovale
223612054|NCT05048173|PROCEDURE|Sentinel lymph node mapping and biopsy|Sentinel lymph node mapping with indocyanine green dye followed by biopsy if positive
223612055|NCT05048173|PROCEDURE|Lymphadenectomy|Conventional lymphadenectomy
223612056|NCT03064646|OTHER|Organ Preservation|Patients with a complete response or a almost complete response after neoadjuvant treatment will be offered an organ preservation strategy
223612057|NCT05665010|OTHER|Genetic susceptibility|Genetic susceptibility increases the risk of ovarian injury
223612058|NCT01064934|PROCEDURE|Lipid apheresis|Weekly lipid apheresis procedure for lipoprotein(a) lowering
223612059|NCT01064934|OTHER|Standard care|Standard care for maximum cardiovascular risk reduction (behavioural, exercise, nutrition, drugs, etc.)
223612060|NCT05572866|OTHER|COVID-19 pandemic|To retrospectively review the surgical volume across 2019-2022 to see the impact of the COVID-19 pandemic.
223612061|NCT05491408|DEVICE|Cough assist device|A device that facilitates airway secretion clearance in COPD patients, thus avoiding hospitalisations and preventing pneumonias and episodes of respiratory failure \[4,5\].
223612062|NCT05282069|DRUG|DA-8010 Placebo|Participants receive placebo to match DA-8010 orally once a day.
223612063|NCT05282069|DRUG|DA-8010 2.5mg|Participants receive DA-8010 2.5mg orally once a day.
223612064|NCT05282069|DRUG|DA-8010 5mg|Participants receive DA-8010 5mg orally once a day.
223612065|NCT05282069|DRUG|Solifenacin 5mg|Participants receive solifenacin 5 mg orally once a day.
223612066|NCT05282069|DRUG|Solifenacin succinate placebo|Participants receive placebo to match solifenacin 5 mg orally once a day.
223612067|NCT02148523|BEHAVIORAL|Comparison to peers|
223612068|NCT02148523|BEHAVIORAL|Adherence feedback|
223612069|NCT02148523|DEVICE|Electronic pill bottle|This device can remotely track medication taking and will be used by subjects to store once-a-day statin medication already prescribed pre-trial.
223612070|NCT05103826|DRUG|SHR6390、Famitinib|SHR6390, oral;Famitinib, oral.
223612071|NCT03170700|BEHAVIORAL|Nutrition program with in-person parental feeding content|Participants will attend the nutrition program (Eating Smart • Being Active) and be provided with in-person parental feeding content.
223612072|NCT03170700|BEHAVIORAL|Nutrition program with online parental feeding content|Participants will attend the nutrition program (Eating Smart • Being Active). They will access parental feeding content online.
223758219|NCT01939587|DRUG|PBF-680 5 mg|
223758220|NCT01939587|DRUG|PBF-680 20 mg|
223758221|NCT01939587|DRUG|Placebo|
223758222|NCT01109082|PROCEDURE|posterior spine fusion|vertebrae are fused to straighten a spinal curve
223758223|NCT00684853|DRUG|bevacizumab|1.25 mg of bevacizumab intravitreal
223612073|NCT02054585|OTHER|NaCl 0.9%|"Children will be included in each group in a randomized way using SAS (Statistical Analysis System) program.~Intervention: In this arm children will receive 20 ml/kg bolus of IV NaCl 0.9% The bags will be identical and the content will be 1 liter. This way if a second bolus is administrated before hospitalization or discharge is decided, the child will still receive the same fluid."
223612074|NCT02054585|OTHER|NaCl 0.9 +5% dextrose|"Children will be included in each group in a randomized way using SAS (Statistical Analysis System) program.~Intervention: In this arm children will receive 20 ml/kg bolus of IV NaCl 0.9% + 5% dextrose. The bags will be identical and the content will be 1 liter. This way if a second bolus is administrated before hospitalization or discharge is decided, the child will still receive the same fluid."
223758224|NCT00684853|DRUG|vetaporfin|full fluence of vetaporfin
223758225|NCT06125821|OTHER|questionnaire|questionnaire
223758226|NCT05942326|BEHAVIORAL|Sleep GOALS|Web-based interventions
223758227|NCT05942326|BEHAVIORAL|Education|Brochures from the American Academy of Sleep Medicine (e.g., sleep hygiene, sleep in women) and SNAP education connection (e.g., family-friendly activities, meal planning)
223758228|NCT05756972|DRUG|PM8002|IV infusion
223758229|NCT05756972|DRUG|Carboplatin|IV infusion
223758230|NCT05756972|DRUG|Pemetrexed|IV infusion
223758231|NCT05007561|DRUG|Naltrexone Hydrochloride|oral naltrexone
223758232|NCT05007561|DRUG|Placebo|oral sugar pill
223758233|NCT05028205|BEHAVIORAL|Prevention Plus|Families will receive a behavioral intervention for childhood obesity provided by a BHC. This will consist of three, in-person meetings (months 1, 3, and 5), and three, 20-minute phone calls (months 2,4, and 6). During in-person visits, child height and weight will be taken, and BMI will be plotted on the BMI-for-age growth chart. During these sessions, families will receive feedback on child growth and weight status. Prevention Plus materials and child and caregiver energy balance behavior goals will be reviewed. The phone calls will be with the caregiver, where caregivers will be asked to measure the height and weight of their child, calculate BMI, and plot on the BMI-for-age growth chart. The BHC will discuss the family's progress on achieving child and caregiver goals and implementation of behavioral parenting strategies. Families will receive a fruit and vegetable prescription (FVx) in addition to the standard Prevention Plus family-based behavioral weight loss treatment.
223758234|NCT03133650|DRUG|WST 11-mediated VTP therapy|Administration of WST11 in conjunction with endoscopic illumination at 753 nm emitted by a diode laser and administered to the participant by optical fibre catheters (cylindrical light diffusers) and a standard upper GI endoscope.
223758235|NCT01232101|DEVICE|covered or uncovered stents|Patients are randomized to covered or uncovered stent. Stent patency is monitored and compared as well as complications, efficacy and technical success.
223758236|NCT05669508|DEVICE|RISES-T System|Non-invasive closed-loop electrical stimulation of the spinal cord through the skin
223758237|NCT05669508|OTHER|Occupational/Physical Therapy|Exercise therapy to improve function of upper and/or lower limbs
224201344|NCT01717729|PROCEDURE|Radiofrequency Ablation|For RFA, we used a commercially available system (RF 2000; Radio Therapeutics, Mountain View, Calif) and a needle electrode with a 15-gauge insulated cannula that had 10 hook-shaped expandable electrode tines with a diameter of 3.5 cm at expansion (LeVeen; Radio Therapeutics).The radioactivity per seed ranged from 0.5 to 0.6 millicuries (mCi)
223758238|NCT02105610|DRUG|desflurane, isoflurane, sevoflurane|
223758239|NCT02105610|DRUG|total intravenous anesthetics|
223758240|NCT06589440|DRUG|SR-8541A|SR-8541A administered orally in combination with intravenous botensilimab and balstilimab
223758241|NCT00938145|PROCEDURE|Specimen Ultra-High field MRI|Immediately following removal of the bladder and lymph nodes, the specimens will be transported to the ultra-high-field MRI scanner for high resolution imaging.
223758242|NCT00938145|DRUG|chemotherapy|The majority of patients will be candidates to receive neoadjuvant chemotherapy prior to radical cystectomy as part of standard clinical care. Patients will most often receive cisplatin based therapy for a period of three months (four 21 day cycles).
223758243|NCT00938145|PROCEDURE|Cystectomy and Lymphadenectomy|The patient will undergo radical cystectomy and pelvic lymph node dissection with no deviation from standard surgical care. A urinary tract reconstruction will follow as either a continent or incontinent form of diversion.
223758244|NCT04399928|DEVICE|Total Hip Arthroplasty|Total hip arthroplasty with the R3 Acetabular Hip system.
223758245|NCT05965349|BEHAVIORAL|Healthy Mind, Healthy Living|A telephone, 8-week MBCT workshop series including: (1) learning mindfulness skills; (2) practicing mindfulness skills in class and at home; and (3) dialogue and inquiry.
223758246|NCT04814225|OTHER|Test Product 1|Pea Protein powder
223758247|NCT04814225|OTHER|Test Product 2|Pea \& Oat Protein Powder
223758248|NCT04814225|OTHER|Test Product 3|Oat Protein Powder
223758249|NCT04814225|OTHER|Comparator|Whey Protein Isolate
224201345|NCT01717729|RADIATION|iodine|The 125I seeds (0.8 mm in diameter and 4.5mm in length) were enclosed in a NiTinol capsule (China Institute of Atomic Energy, Beijing). These seeds could produce 27.4-31.5 keV X-ray and 35.5 Kev γ ray, with a half-life of 59.6 days. The radioactivity per seed ranged from 0.5 to 0.6 millicuries (mCi).
224201346|NCT02626273|RADIATION|weight loss|
224201347|NCT00993525|DRUG|Intravitreal injection of ranibizumab|0.5 mg at week 0 0.5mg at weeks 12,24,36,48 if fluorescein leakage from active vessels on angiography
223758250|NCT00368264|DRUG|infliximab|azathioprine (2 mg/lkg) plus four infusions of infliximab (5mg/kg)
223758251|NCT00368264|DRUG|placebo|azathioprine (2 mg/kg) plus four placebo infusions
223758252|NCT06045091|DRUG|Human BCMA targeted CAR-NK cells injection|Allogenic genetically modified anti-BCMA CAR transduced NK cells
223758253|NCT06666387|DIAGNOSTIC_TEST|PET-MR examination|PET-MR examination
224201348|NCT00465322|DRUG|fluvastatin|
224201349|NCT01040468|PROCEDURE|Roux-en-Y Gastric Bypass surgery|Surgical intervention for weight loss. This is a one-year study and participants will attend five study visits.
224201350|NCT01040468|PROCEDURE|Laparoscopic Adjustable Gastric Banding surgery|Surgical intervention for weight loss. This is a one-year study and participants will attend five study visits.
223758254|NCT06872697|OTHER|whole body vibration|In the group receiving whole-body vibration in addition to conventional treatment, the whole-body vibration will be performed with the patient's hips and knees in approximately 20° flexion, and the bed inclined to 25-30°. The vibration platform will be fixed at the end of the bed, and the patients will apply pressure with their feet on the platform. The whole-body vibration will be administered for 3 minutes, 1-4 sets, at a frequency of 20-25 Hz, 5 days a week, for 4 weeks, depending on the protocol, in addition to conventional physiotherapy.
224311876|NCT05885984|BEHAVIORAL|Acceptance and Commitment Therapy (ACT) plus health education|Session 1: Reviewing experiences on struggles with CRF, realising consequence of controlling, introducing acceptance as an alternative, adopting virtual mindfulness. Education (patient): epidemiologic features of advanced lung cancer. Session 2: Separate thoughts/feelings related to CRF. Education (patient): treatments and symptoms of advanced lung cancer. Session 3: Reviewing caregiver's experiences of struggling with caregiving burden,introducing acceptance as an alternative. Education (caregiver): epidemiologic features of advanced lung cancer. Session 4: Separate caregivers' thoughts/feelings related to caregiving burden. Education (caregiver): treatments and symptoms of advanced lung cancer. Session 5:Understand the importance of values and clarifying personal values for dyads. Education (dyads): eating suggestions. Session 6: Emphasise ongoing value-based goals and commitment to actions for a meaningful cancer life for dyads. Education (dyads): exercising suggestions.
223612075|NCT04589871|OTHER|Taping technique|Fixmull stretch and Leukotape (rigid tape) were used in taping to guide the patellar trajectory orientation while performing the movement. Individuals were asked to lay down in supine position with knee in a slightly bent position. Fixomull stretch was used as an adhesive pre-wrap to protect the skin and provide some of the checking force. The main check strap was provided by stripes of rigid tape (Leukotape). The knee cap was taped, started on the outer aspect of the knee cap and pulled inwards. Finished at the back of the inside of the knee. Two further pieces of tape (Fixomull Stretch and Leukotape) applied distal to the patella unloaded the infrapatellar fat pad.
223758255|NCT06872697|DEVICE|Neuromuscular Electrical Stimulation|In this group, neuromuscular electrical stimulation (NMES) will be applied to the targeted muscle groups. The application will be carried out with the patient in a comfortable seated or lying position. Stimulation parameters will be set as follows: a frequency of 35-50 Hz, a pulse duration of 200-400 microseconds, and an intensity adjusted to elicit visible muscle contractions without causing discomfort. NMES will be applied for 20-30 minutes per session, 3-5 times a week, for 4-6 weeks, depending on the protocol, in addition to conventional physiotherapy.
223758256|NCT06872697|OTHER|Conventional Physiotherapy|The conventional treatment program will include normal range of motion, airway clearance techniques, breathing exercises, and mobilization.
223758257|NCT04813159|DEVICE|Remote Ischaemic Conditioning (RIC)|The RIC protocol will comprise inflation of the automated RIC device to 20 mmHg above systolic blood pressure for 5 minutes and deflation for a further 5 minutes, a cycle which will be completed four times in total. The RIC protocol will be repeated daily for the next 2 days.
223758258|NCT04813159|DEVICE|Sham-control|The sham protocol will comprise low-pressure inflation to 20 mmHg for 5 minutes and deflation for a further 5 minutes, a cycle which will be completed four times in total by a visually identical pneumatic cuff used in the active arm. The sham control protocol will be repeated daily for the next 2 days.
223758259|NCT04305951|PROCEDURE|Comprehensive acupuncture therapy (CAT)|"CAT will be conducted for 2 sessions per week for 12 consecutive weeks.~The following 14 body acupoints with only manual stimulation will be used: HT7 (Shenmen), LI4 (Hegu), TH5 (Waiguan), ST36 (Zusanli), ST40 (Fenglong) and SP6 (Sanyinjiao) in two sides, and CV12 (Zhongwan) and CV4 (Guanyuan) in midline. Electrical stimulation will be conducted on the following frontal acupoints: GV20 (Baihui), EX-HN3 (Yintang), GB15 (Toulinqi), GB8 (Shuaigu), EX-HN5 (Taiyang), and ST8 (Touwei) on two sides, and left and right EX-HN1 (Sishencong).~Disposable acupuncture needles (0.25 mm in diameter and 25-40 mm in length) will be inserted at a depth of 10-30 mm perpendicularly or obliquely into acupoints. Manual manipulation will be carried out for all acupoints to evoke needling sensation. Electrical stimulation is additionally delivered on the 6 pairs of the frontal acupoints. Each session of treatment will last 30 minutes."
223758260|NCT04305951|PROCEDURE|Comfy Acupressure for the Elderly (CAE)|"CAE intervention will be conducted for 3 times per week for 12 consecutive weeks.~CAE consists of 12 steps which need about 15 minutes to complete and mainly concentrates on the acupoints on face, head, neck, and shoulder. The detailed CAE Operation Guide will be provided for the provider and the video demonstration is accessible at https://www.youtube.com/watch?v=pAqNIZPKmnM."
223758261|NCT06816940|OTHER|CONTROL GROUP:|will be provided exclusively therapeutic exercises protocol to develop in the home setting that you must perform following a daily activity for three weeks. They will be evaluated before any intervention is carried out
223758262|NCT06816940|OTHER|EXPERIMENTAL GROUP|will be provided therapeutic exercises protocol to develop in the home setting that you must perform following a daily activity for three weeks, and rurgery was also performed using the dry needlig
223758263|NCT05724134|DRUG|Insulin human|Insulin infusion rate (IIR) will be determined empirically first to maintain mean basal fasting plasma glucose, and then either maintained at the basal rate (MH protocol) or be reduced stepwise toward euinsulinemia (RE protocol).
223758264|NCT05724134|DRUG|Octreotide Acetate|Octreotide will be infused at 30 ng/kg/min to suppress endogenous insulin, glucagon, and growth hormone secretion. Co-administered with glucagon and rhGH.
223758265|NCT05724134|DRUG|Glucagon|Glucagon will be replaced at a constant rate of up to 0.65 ng/kg/min to maintain baseline counterregulatory response. Co-administered with octreotide and rhGH.
223758266|NCT05724134|DRUG|Growth Hormone, Human|Recombinant human growth hormone (rhGH) will be replaced at a constant rate of up to 3 ng/kg/min to maintain baseline counterregulatory response. Co-administered with octreotide and glucagon.
223758267|NCT05724134|OTHER|[6,6-2H2] D-glucose|Stable isotope tracer administered to calculate glucose kinetics during pancreatic clamp.
223612076|NCT04589871|OTHER|A supervised exercise protocol|Quadriceps Strengthening; Terminal knee extension; Ball kicking; Strengthening of Vastus Medialis;
223612077|NCT06383832|DRUG|Dapagliflozin|Dapagliflozin tablets oral 10mg/d qd, intervention for 12 weeks.
224311877|NCT05885984|OTHER|Health education|Session 1: health education on the epidemiologic features of advanced lung cancer will be taught to patients. Session 2: health education on treatments and related symptoms of advanced lung cancer will be taught to patients. Session 3: health education on the epidemiologic features of advanced lung cancer will be taught to caregivers. Session 4: health education on treatments and related symptoms of advanced lung cancer will be taught to caregivers. Session 5: health education on eating suggestions for advanced lung cancer patients and caregivers will be taught. Session 6: health education on exercising suggestions for advanced lung cancer patients and caregivers will be taught.
224311878|NCT03904264|DEVICE|Receiver in the canal (RIC) hearing aids|The RIC hearing aids fitted to subjects in arm 1 of the study will be manufactured by Widex.
224311879|NCT03526159|DRUG|Gentamicin Sulfate|Gentamicin (formulated as gentamicin sulfate) is a well-known, well-characterized antibiotic that has been used for four decades as a treatment against gram negative bacteria. It, like other aminoglycoside antibiotics, has the well documented added potential to facilitate readthrough of premature termination codons in eukaryotic cells and organisms.
224311880|NCT03207737|BEHAVIORAL|MENTOR + Telehealth|Participants will live on campus for one week and complete the MENTOR program, which is a course about resilience and how nutrition, exercise and mindfulness help with resilience for individuals with a spinal cord injury. Different experts will cover the three main topics with lectures and application of knowledge through related activities. Participants will then begin a one-year telehealth program at home. The telehealth program will consist of readily available information focusing on nutrition, exercise and mindfulness for individuals with a spinal cord injury and a telehealth coach who will interact on the phone with the participants once every two weeks. This will continue for a total of 26 phone calls until the participant returns for 1-year follow-up testing.
223612078|NCT01367834|DRUG|somatotropin|Subjects will receive 5 mg somatotropin (growth hormone) pens with cartridges. Subcutaneous injections are to be given every evening around bedtime. Dosing regimen: 50 mcg/kg/day to be adjusted at 4 month intervals to the closest 0.1 mg. Subjects will be given 12 months of treatment (from 12 to 24 months of life). Subjects will visit their pediatrician or pediatric endocrinologist at 4 and 8 months of life.
223612079|NCT02917135|DEVICE|Angel® Catheter|"The Angel® Catheter is a retrievable inferior vena cava (IVC) filter attached to a multi-lumen central venous access (CVC) catheter. The device is designed to be placed at the bedside in the inferior vena cava, via the femoral vein, for the prevention of pulmonary embolism (PE) and for access to the central venous system.~The Angel® Catheter is intended for short-term (less than 30 days) vascular access via the femoral vein."
223612080|NCT00240461|DIETARY_SUPPLEMENT|COLD-fX natural health product|200 mg/COLD-fX natural health product - 2 capsules twice daily for 6 months
223612081|NCT00240461|DIETARY_SUPPLEMENT|COLD-fX|400 mg COLD-fX natural health product 2 times daily for 6 months
223612082|NCT00240461|OTHER|Placebo|crystalline substance 200 mg twice daily for 6 months
223612083|NCT02939365|DRUG|Belatacept|The transition to belatacept monotherapy and possibly to q 8 weeks administration can be safely done by applying personalized (i.e. precision) medicine. This includes phenotypic analysis of lymphocyte subsets, a quiescent molecular profiling of blood and urine prior to drug withdrawal and immune monitoring with KSORT after stepwise withdrawal of steroids and antiproliferatives. Furthermore, trough PK of belatacept will be measured for conversion to q 8 week therapy for discovering research purposes.
223758268|NCT05724134|DRUG|20% D-glucose (aq)|20% D-glucose (aq) (D20W) will be administered to counteract hypoglycemia or strongly downward blood glucose trends, as needed.
223758269|NCT05724134|DIETARY_SUPPLEMENT|BOOST Plus|"Nutritional supplement will be administered to provide three standardized mixed meals on the day before the pancreatic clamp."
223758270|NCT05724134|DIETARY_SUPPLEMENT|CORE Bar|Energy bar used as a standardized snack on the day before the pancreatic clamp.
223758271|NCT05724134|DEVICE|Harvard Apparatus PHD ULTRA CP syringe pump|Syringe pump used for highly precise administration of insulin, octreotide/glucagon/rhGH, and D20W (as needed) even at low infusion rates.
223758272|NCT05724134|DEVICE|Yellow Springs Instruments (YSI) 2500 Biochemistry Glucose/Lactate Analyzer|Glucose oxidase analyzer used to detect plasma glucose levels at the point of care. YSI have been the gold standard in clamp studies for many years. Two machines will run in parallel to ensure accuracy of results.
223758273|NCT06122246|BEHAVIORAL|Community Health Worker (CHW)|Participants will receive the additional support of a Community Health Worker (CHW).
223758274|NCT06122246|OTHER|Remote Blood Pressure (BP) Management Program (RBPM)|Participants will receive a medical model of remote BP management (RBPM).
223758275|NCT05608824|DEVICE|Shear wave elastography and microvascular flow imaging.|Subjects will undergo serial SWE and MFI imaging throughout their rehabilitation episode of care to assess changes over time, status in rehabilitation and comparison to the contralateral extremity.
223758276|NCT06697496|DEVICE|QuitBot Smoking Cessation Chatbot Program|Participate in Quitbot chatbot program
223758277|NCT06697496|DEVICE|QuitBot Smoking Cessation Text Messaging Program|Participate in Quitbot texting program
223758278|NCT06697496|OTHER|Survey Administration|Ancillary studies
223758279|NCT06697496|OTHER|Interview|Ancillary studies
223758280|NCT06697496|PROCEDURE|Carbon Monoxide Measurement|Ancillary studies
223758281|NCT06877520|DEVICE|Pivot Extend Tricuspid Regurgitation Spacer Device|The Pivot Extend Tricuspid Regurgitation Spacer Device is an investigational implant designed to reduce tricuspid regurgitation (TR) by occupying the regurgitant orifice and improving leaflet coaptation. The device is implanted via a transcatheter procedure under imaging guidance. Following implantation, participants will undergo post-procedural monitoring for at least 24 hours to ensure safety and device stability. The device is intended for long-term placement, with scheduled follow-up assessments at designated intervals over a 12-month period to evaluate its safety and efficacy. Device removal may be performed if adverse events occur or if deemed necessary by the investigator.
223758282|NCT06878872|BEHAVIORAL|T1DAL Program|T1DAL is a 16-week behavioral program. Teens meet in virtual groups and individually with a health coach throughout the program. Teens learn healthy lifestyle behaviors specific to living with type 1 diabetes and get opportunities to connect with other teens who are living with type 1 diabetes.
223612084|NCT04021095|DEVICE|Head protection prototype device|The proposed experimental HPPD uses biocompatible material using FDMÔNylon which has high fatigue resistance, chemical resistance with impact resistance and toughness which is free of powders. It is HSA unclassified as yet and the FDMONylon is not FDA approved yet.
223612085|NCT05851196|OTHER|Proprioceptive training|A physiotherapist tailors the exercises to the patient's functional demands and pain- or fear-inducing activities. Guided by the therapist, patients look for ways to integrate the exercises into their daily life activities. Each week, patients receive feedback from the physiotherapist, and the training program is gradually progressed. The patients are instructed to perform the exercises daily, integrated into their daily activities, hobbies, and work. The program contains: (1) exercises to improve the sense of posture and movement, (2) exercises to correct the reference frame from which patients control posture and movement, (3) muscle control exercises, (4) exercises to increase variability in postures and movement patterns, (5) functionality: patients search for ways to correct and integrate alternative postures and movement patterns into their daily life, (6) high training frequency and high load, (7) focus on sensing, localizing and differentiating, rather than movement control.
223612086|NCT05413668|DRUG|RVP-001|Intravenous administration of RVP-001
223612087|NCT05413668|DRUG|Placebo|Intravenous administration of saline placebo
223612088|NCT04706949|DRUG|Pyrotinib combined with pemetrexed plus carboplatin|"1. Pyrotinib: oral administration within 30 minutes after breakfast, 400mg / day, continuous administration for 21 days as a cycle; each continuous pause time and the cumulative pause time of each cycle should not exceed 14 days. It is allowed to suspend the drug for many times due to adverse events.~2. Pemetrexed: the recommended dosage is 500mg / m2, once every three weeks. 3) Carboplatin: the dosage was determined according to Calvert formula, in which AUC was 5mg / ml / min."
223758283|NCT06880601|DRUG|Teclistamab|"Participants are planned to receive Te monotherapy during the first 5 cycles of treatment (1 cycle= 28 days) Participants will receive Te sc monotherapy consisting of 2 step-up doses (0.06 and 0.3 mg/kg) followed by a weekly treatment dose of 1.5 mg/kg for the first 2 cycles From cycle 3 Day 1, participants will receive Te sc Q2W at the dose of 3 mg/kg- From cycle 7 Day 1, participants will receive Te sc Q4W at the dose of 3 mg/kg.~After cycle 5, participants in PR or better will continue treatment with Te in combination with 4 Ali infusions (cycles +6, +9, +12, +15). The four doses of ALI will be administered with increasing dosage during Te treatment as follows:~* before Te Cycle 6: ALI 10 x 10\^6/kg~* before Te Cycle 9: ALI 20 x 10\^6/kg~* before Te Cycle 12: ALI 30 x 10\^6/kg~* before Te Cycle 15: ALI 40 x 10\^6/kg~Teclistamab single agent will be continued until progression, unacceptable toxicity or patients refusal."
223758284|NCT06714292|PROCEDURE|Endoscopic Clipping|localization of colon lesion with fluorescent clip
223758285|NCT06714292|PROCEDURE|ICG injection|localization of colon lesion with ICG(indocyanine green) through endoscopic tattooing
223758286|NCT03216447|DRUG|Advagraf|Tacrolimus prolonged-release hard capsules (QD)
223758287|NCT03216447|DRUG|Prograf|Tacolimus capsules (q12h)
223758288|NCT06888804|PROCEDURE|ultrasound-guided posterior tibial nerve pulsed radiofrequency|The posterior tibial nerve (PTN) was identified with a 5-12 MHz linear ultrasonography (US) probe at the level of the medial malleolus, where it runs posterior to the posterior tibial artery. Using the in-plane technique, a 22-gauge, 10-cm radiofrequency cannula was inserted under US guidance and advanced until the tip was adjacent to the nerve. Pulse radiofrequency was applied at 42°C for 240 s with a pulse width of 20 ms.
223758289|NCT06888804|OTHER|Control Group|No intervention
223758290|NCT05732506|DRUG|Edoxaban|There are not intervention.
223758291|NCT06750783|DRUG|Xuezhikang|The Xuezhikang group takes Xuezhikang at a dose of 600 milligrams twice a day, orally after meals;
223758292|NCT06750783|DRUG|Atorvastatin|The atorvastatin group takes atorvastatin 20mg once a day, orally after meals.
223612089|NCT02152176|DEVICE|Titration of morphine by Patient Controlled Analgesy|PCA is never used for titration but only for relay of titration. Self-controlled analgesia by PCA is our intervention.
223612090|NCT06091150|PROCEDURE|Endovascular management of direct carotid-cavernous fistula|Coiling and embolization of direct carotid-cavernous fistula
223612091|NCT01588561|DRUG|Intravenous Nicotine|Subjects received a single infusion of nicotine, 1.5 mg/70kg (New England Compounding Center, Framingham, MA), administered over 1 minute into the antecubital vein 10 minutes into their MRI scans.
223758293|NCT02344368|OTHER|0.2 ml sucrose 25%|Administered on the tongue by a syringe, a half dose two minutes before blood sampling and the other half dose immediately before sampling
223612092|NCT01588561|OTHER|Saline - placebo|Subjects received a single infusion of saline, administered over 1 minute into the antecubital vein 10 minutes into their MRI scans.
223612093|NCT04837573|BEHAVIORAL|Sister Circle protocol|The intervention is an 8-week, therapeutically-informed protocol.
223612094|NCT01337336|DRUG|fluticasone propionate/salmeterol xinafoate|combination fluticasone priopionate and salmeterol xinafoate 250/50mcg
223758294|NCT02344368|OTHER|0.5 ml sucrose 25%|Administered on the tongue by a syringe, a half dose two minutes before blood sampling and the other half dose immediately before sampling
223758295|NCT06276634|OTHER|Acute Intermittent Hypoxia|During each AIH session, the participant will be equipped with a non-rebreathing face mask, and provided with the AIH intervention. The AIH intervention involves alternating breathing cycles: one with lower oxygen concentration (9-10% Oxygen) than that at sea level (\~21% Oxygen) lasting between 30 and 60 seconds, followed by a similar duration of normal room air (21% Oxygen). This cycle will be repeated 15 times in one session, continuous blood oxygen levels and heart rate will be monitored.
223758296|NCT06276634|OTHER|Sham-Acute Intermittent Hypoxia|During each Sham-AIH session, the participant will be equipped with a non-rebreathing face mask, and provided with the Sham-AIH intervention. The Sham-AIH intervention involves alternating breathing cycles: both with oxygen concentrations of \~21% Oxygen lasting between 30 and 60 seconds, followed by another similar duration of normal room air (21% Oxygen). This cycle will be repeated 15 times in one session, continuous blood oxygen levels and heart rate will be monitored.
223758297|NCT02594722|DEVICE|FES-cycling|Patients performed an endurance tests with functional electrical stimulation during 30 minutes with an oxygen uptake measure.
223612095|NCT01337336|DRUG|Anticholinergics|tiotropium; ipratropium alone; or ipratropium + albuterol
223612096|NCT03954067|BIOLOGICAL|ASP9801|Administered by intratumoral injection
223758298|NCT02594722|DEVICE|Classic cycloergometer|Patients performed an endurance tests on classic ergometer during 30 minutes with a sham electrical stimulation with an oxygen uptake measure.
223758299|NCT04376645|PROCEDURE|Mandibular Setback with maxillary impaction|Occlusal bite force will be measured after surgery to correct vertical disproportions
223758300|NCT04376645|PROCEDURE|Mandibular setback only|Occlusal bite force will be measured after surgery without changing vertical disproportions.
223612097|NCT03954067|COMBINATION_PRODUCT|Pembrolizumab|Administered by Intravenous Infusion
223612098|NCT00673582|DRUG|Rosuvastatin|10 mg/day rosuvastatin
223612099|NCT00673582|DRUG|Placebo|Placebo, 10 mg a day for 96 weeks
223758301|NCT02359266|DIETARY_SUPPLEMENT|Vitamin D|Given to patients with existing vitamin D deficiency
223612100|NCT01828229|BEHAVIORAL|female inactivity and hypercaloric diet|female inactivity and hypercaloric diet for 2 weeks
223612101|NCT01828229|BEHAVIORAL|inactivity|inactivity for 2 weeks
223612102|NCT01828229|BEHAVIORAL|inactivity and hypercaloric diet|inactivity and hypercaloric diet for 2 weeks
223758302|NCT02460640|PROCEDURE|Tap block|intravenous patient-controlled analgesia with morphine and tap block with subcostal and posterior approach with ropivacaine 0,5% 15ml+15ml
223758303|NCT02460640|PROCEDURE|intravenous Patient controlled analgesia|intravenous patient-controlled analgesia with morphine
223758304|NCT02460640|DRUG|Morphine|
223758305|NCT02460640|DRUG|Ropivacaine|
223758306|NCT01457872|BEHAVIORAL|Strength-based case management|Strength-based case management
223758307|NCT01457872|BEHAVIORAL|Control condition - referral only|Referral only
223758308|NCT05112393|OTHER|Development of new estimating Glomerular Filtration Rate (eGFR) equation|"Development Cohort:~A new estimating Glomerular Filtration Rate(eGFR) equation will be developed by using a nonlinear regression model utilizing a generalized least squares algorithm."
223758309|NCT05112393|OTHER|Validation of new estimating Glomerular Filtration Rate (eGFR) equation|"Validation Cohort:~Internal validation will be performed by comparing bias, precision and accuracy of the new equations and the other established equations to the measured GFR."
223758310|NCT00214994|DRUG|Gabitril|
223758311|NCT04962568|DIAGNOSTIC_TEST|DTEE|endexpiratory diaphragm thickness in mm
223758312|NCT04962568|DIAGNOSTIC_TEST|DTEI|endinspiratory diaphragm thickness in mm
223758313|NCT04962568|DIAGNOSTIC_TEST|DEx|diaphragm excursion during rest and diaphragmatic excursion during maximal inspiration in mm
224311881|NCT03207737|BEHAVIORAL|Telehealth Only|Participants will complete a one-year telehealth program at home. The telehealth program will consist of readily available information focusing on nutrition, exercise and mindfulness for individuals with a spinal cord injury and a telehealth coach who will interact on the phone with the participants once every two weeks. This will continue for a total of 26 phone calls until the participant returns for 1-year follow-up testing.
224311882|NCT00735397|DRUG|perampanel|Perampanel 2 mg to 12 mg, once daily in the Open-Label Extension (OLE) study up to approximately 5 years
224311883|NCT04767191|DRUG|artemether lumefantrine|The drugs are approved and in use by the Kenya Ministry of Health as the 1st and 2nd line treatment for malaria. The study is to assess the continued efficacy of the two drugs in the treatment of uncomplicated malaria.
223612103|NCT01828229|BEHAVIORAL|normal activity and hypercaloric diet|normal activity and hypercaloric diet for 2 weeks
223612104|NCT01828229|BEHAVIORAL|inactivity and iso-caloric diet|inactivity and iso-caloric diet for 2 weeks
223612105|NCT01618669|DRUG|Regadenoson|Administered as an intravenous (IV) bolus
223612106|NCT01618669|PROCEDURE|Single photon emission computed tomography (SPECT) myocardial perfusion imaging (MPI)|
223612107|NCT03918421|OTHER|Clinical examination and patients' questionnaires regarding activity and participation (preliminary Immunogloblin M (IgM)-Rasch-built overall Disability Scale (RODS), and finalized IgM-RODS)|Rasch-built overall Disability Scale (RODS) is a disease-specific, patient-based, linearly weighted scale that captures activity and social participation limitations to detect activity limitations in patients with Immunogloblin M (IgM) anti-myelin-associated-glycoprotein peripheral neuropathy. For this study, the preliminary RODS is a 146 item patient-reported outcome instrument that assesses activity and social participation limitation. Rasch Measurement Methods examine the extent observed data (patients' actual responses to scale items) accord with predictions of those responses from a mathematical model.
223612108|NCT05617144|OTHER|Aromatherapy treatment|60 minutes after pain medication administration primary investigator will turn on the diffuser (manufacture ScentSationals)and administer aromatherapy with a mixture of four drops of lavender and four drops of peppermint for 60 minutes.
223612109|NCT00059345|PROCEDURE|Acupuncture|Electroacupuncture treatments provided two times per week for 6 weeks
223612110|NCT00059345|PROCEDURE|Placebo acupuncture|Placebo acupuncture treatments provided 2 times per week for 6 weeks
223758314|NCT05628740|DRUG|3 mg NOC-100 (via nebulizer)|Participants determined to be eligible for Part 1 of the study will be enrolled and will be assigned to receive a single dose of the reference nebulizer treatment of NOC 100 at 3 mg (Treatment A) in Period 1
223758315|NCT05628740|DRUG|1 mg NOC-110 (via DPI) [1x 1 mg capsule]|Participants will be randomized to receive single doses of 1 mg NOC-110 (via DPI) in a crossover fashion according to a prespecified randomization schedule
223758316|NCT05628740|DRUG|3 mg NOC-110 (via DPI)|Participants will be randomized to receive single doses of 3 mg NOC-110 (via DPI) in a crossover fashion according to a prespecified randomization schedule
223758317|NCT05628740|DRUG|Placebo (via DPI)|Participants will be randomized to receive single doses of placebo via capsule in a crossover fashion according to a prespecified randomization schedule
223758318|NCT05628740|DRUG|6 mg NOC-110 (via DPI)|Participants will be randomized to receive single doses of 6 mg NOC-110 via DPI in a parallel fashion according to a prespecified randomization schedule
223758319|NCT05628740|DRUG|Placebo (via DPI) [2x Placebo capsules]|Participants will be randomized to receive single doses of Placebo (via DPI) \[2x Placebo capsules\] in a parallel fashion according to a prespecified randomization schedule
223758320|NCT00000826|DRUG|Clarithromycin|
223758321|NCT00000826|DRUG|Rifabutin|
223758322|NCT00000826|DRUG|Sulfamethoxazole-Trimethoprim|
223758323|NCT00000826|DRUG|Dapsone|
223612111|NCT00059345|OTHER|Usual Care|Usual care for knee osteoarthritis
223612112|NCT01951560|DRUG|Valproic Acid|By infusion over 1 hour
223612113|NCT01951560|DRUG|Isotonic saline solution|By infusion over 1 hour
223612114|NCT05010980|OTHER|CMR|clinical indication
223612115|NCT05010980|OTHER|scintigraphy|clinical indication
223612116|NCT00002043|DRUG|Dapsone|
223758324|NCT00000826|DRUG|Fluconazole|
223758325|NCT05545852|PROCEDURE|GTPET(Gasless Transaxillary Posterial Endoscopic Thyroidectomy)|Gasless Transaxillary Posterial Endoscopic Thyroidectomy and Ipsilateral Central Lymph Node Dissection
223758326|NCT05545852|PROCEDURE|COT(Conventional Open Thyroidectomy)|Conventional Open Thyroidectomy and Ipsilateral Central Lymph Node Dissection
223758327|NCT06358391|DEVICE|TS-RF Transseptal Needle|Apply radiofrequency energy to the electrode tip via the TS-RF Generator and puncture the atrial septum
223758328|NCT06358391|DEVICE|BRK Transseptal Needle|Cross and puncture the atrial septum with the BRK Transseptal Needle
223612117|NCT02186574|DRUG|Tenofovir disoproxil|
223612118|NCT02186574|DRUG|Placebo Oral Tablet|
223612119|NCT01702558|DRUG|Capecitabine|Capecitabine will be administered at de-escalating doses (starting from 750 mg/m\^2) to determine the MTD.
223612120|NCT01702558|DRUG|Trastuzumab emtansine (T-DM1)|Trastuzumab emtansine will be administered at a dose of 3.6 mg/kg via IV infusion every 3 weeks.
223758329|NCT04160273|DIAGNOSTIC_TEST|patient questionnaire and telephone follow-up|PDI scale is filled in before returning home and follow-up at one month and one year thanks to a telephone call during which the patient answers the PCL-S questionnaire
223758330|NCT01696435|DIETARY_SUPPLEMENT|vitamin D3|Vitamin D3 (cholecalciferol), 2000 IU per day
223758331|NCT01696435|DRUG|omega-3 fatty acids (fish oil)|Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid \[EPA\] and 375 mg of docosahexaenoic acid \[DHA\]).
223758332|NCT01696435|DIETARY_SUPPLEMENT|Fish oil placebo|Fish oil placebo
223612121|NCT01702558|DRUG|Trastuzumab emtansine (T-DM1)|Trastuzumab emtansine will be administered at a dose of 2.4 mg/kg via IV infusion every week.
223758333|NCT01696435|DIETARY_SUPPLEMENT|Vitamin D placebo|Vitamin D placebo
223612122|NCT01702558|DRUG|Capecitabine|Capecitabine will be administered at the MTD determined in Cohort 1.
223612123|NCT04800458|BIOLOGICAL|Blood samples|"* Thrombopoietin : 7 ml whole blood.~* Anti-platelet antibodies free : 14 ml whole blood.~* Anti-platelet antibodies bound :~If the platelet count is ≥ 50 G / L : 14 ml whole blood for Peripheral blood mononuclear cell (PBMC) and monocytes isolation ; If the platelet count is \< 50 G / L and ≥ 20 G / L : 28 ml whole blood for Peripheral blood mononuclear cell (PBMC) and monocytes isolation ; If the platelet count is \< 20 G / L and ≥ 10 G / L: 42 ml whole blood for Peripheral blood mononuclear cell (PBMC) and monocytes isolation ; If the platelet count is \< 10 G / L : 49 ml whole blood for Peripheral blood mononuclear cell (PBMC) and monocytes isolation."
223612124|NCT01300312|DRUG|Eperisone hydrochloride and Diclofenac sodium|Fixed dose capsule formulation of eperisone hydrochloride 50 mg plus diclofenac sodium 50 mg to be given 3 times a day after meals for 7 to 10 days
223612125|NCT01300312|DRUG|Eperisone hydrochloride|eperisone hydrochloride 50 mg as tablet formulation to be given 3 times daily after meals for 7 to 10 days
223612126|NCT02962167|BIOLOGICAL|Modified Measles Virus|Administration of MV-NIS either into the tumor bed, if surgery to remove local tumor
223758334|NCT05653960|OTHER|EMR or ESD|Endoscopic mucosal resection (EMR) and endoscopic submucosal dissection (ESD) are two main endoscopic treatment options for colorectal neoplasms
223758335|NCT02914496|BEHAVIORAL|Acceptance and Commitment Therapy (ACT)|ACT is a specific form of Cognitive behavior therapy (CBT) which will be given as a course consisting of seven sessions where each session is two hours long.
223758336|NCT04784585|BEHAVIORAL|Enhanced Education|"The Enhanced Education intervention option seeks to: 1) enhance understanding of personal health-behavior links, 2) improve health literacy by checking the adequacy of participant understanding, and 3) remind participant of important elements of Behavioral Obesity Treatment (BOT) dietary goals."
224205951|NCT01115699|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|Active 10 Hz rTMS will be applied to the left dorsolateral prefrontal cortex (L-DLPFC) with an intensity of 120% motor threshold. The L-DLPFC location is defined as that area 5 cm anterior to the motor cortex for activation of abductor pollicis brevis. Subjects will receive a total of 3000 stimuli per session. The TMS trains are 4 seconds on and 26 seconds off for a total of 37 1/2 minutes. Treatment will occur 5 days per week for up to six weeks. Subjects will be monitored during rTMS for any side effects or adverse events.
223612127|NCT02962167|BIOLOGICAL|Modified Measles Virus Lumbar Puncture|Administration of MV-NIS into the cerebrospinal fluid via lumbar puncture
223612128|NCT02186613|BEHAVIORAL|Telephone support|Telephone support intervention to improve breastfeeding rates. The intervention will consist in weekly calls during the first two months and every two weeks between the second and the sixth month. The intervention will be done by pediatric nurses and we have developed a protocol of important issues to deal depending on the age of the baby.
223612129|NCT05826067|OTHER|collection of bacterial strains|Urine (and blood) samples will be collected following SOC procedures for diagnostic purposes, at each visit of the patient (initial visit, follow up study or visit for new episode. For patients needing a catheter, urine sample will be collected before the insertion of the catheter, and before renewal of the catheter. Catheter tips will also be collected and sonicated to isolate bacteria. E. coli will be stored for analysis.
223612130|NCT06340308|DIETARY_SUPPLEMENT|Berberine-based Food Supplement, Artichoke Extract, Phytosterols, Fenugreek and SelectSIEVE® OptiChol|Patients will take 1 tablet of Berberine-based Food Supplement, Artichoke Extract, Phytosterols, Fenugreek and SelectSIEVE® OptiChol for 12 weeks
223612131|NCT06340308|DIETARY_SUPPLEMENT|Berberine-based Food Supplement, Artichoke Extract, Phytosterols, Fenugreek and SelectSIEVE® OptiChol|Patients will take 2 tablets of Berberine-based Food Supplement, Artichoke Extract, Phytosterols, Fenugreek and SelectSIEVE® OptiChol for 12 weeks
223612132|NCT03782233|DRUG|A continuous intravenous infusion of 0.5-0.6 mg/kg/h Rocuronium Bromide Intravenous Solution (50 Mg/5 mL) to keep the target neuromuscular blockade (PTC = 1-2).|50 patients undergoing laparoscopic gastrectomy surgery will be allocated to group D. A continuous intravenous infusion of 0.5-0.6 mg/kg/h rocuronium to keep the target neuromuscular blockade (PTC = 1-2).
223612133|NCT03782233|DRUG|A continuous intravenous infusion of 0.2-0.3 mg/kg/h Rocuronium Bromide Intravenous Solution (50 Mg/5 mL) to keep the target neuromuscular blockade (TOF = 1-2).|33 patients undergoing laparoscopic gastrectomy surgery will be allocated to group M. A continuous intravenous infusion of 0.2-0.3 mg/kg/h rocuronium to keep the target neuromuscular blockade (TOF = 1-2).
223612134|NCT01680666|PROCEDURE|central line placement|central line placement
223612135|NCT01680666|DEVICE|Ultrasound|Ultrasound guided central venous access
223612136|NCT04917965|OTHER|Laboratory clotting studies|Cord blood will be utilized to perform lab test including PT, aPTT, fibrinogen, platelet count, platelet mapping, and TEG6s
223612137|NCT01954641|OTHER|ACCURE Navigator|"The ACCURE Real-Time Registry will automatically alert the ACCURE Navigator to follow a schedule of patient-interactions. The Navigator has been trained to employ the teachback method of patient education as appropriate per encounter. For instance: (1) initial face-to-face interaction, after the patient's first visit with the oncologist; (2) telephone call 3 business days after the initial visit; (3) contact the patient 10-21 days after the initial visit; and (4) after treatment has begun, contacting the patient every 8 weeks.It is projected that 50% of the staff will attend the Healthcare Equity Training (HET) and Booster Sessions."
223612138|NCT01954641|OTHER|Usual Care by Cancer Center Care Team|The Usual Care group will receive the support and care that is usually given to patients at their designated cancer center.
223612139|NCT02179411|OTHER|tilt test|
223612140|NCT00003619|BIOLOGICAL|filgrastim|
223612141|NCT00003619|DIETARY_SUPPLEMENT|vitamin E|
223612142|NCT00003619|DRUG|busulfan|
223612143|NCT00003619|DRUG|cytarabine|
223612144|NCT00003619|DRUG|etoposide|
223612145|NCT00003619|DRUG|fludarabine phosphate|
223612146|NCT00003619|DRUG|isotretinoin|
223612147|NCT00003619|DRUG|topotecan hydrochloride|
223612148|NCT00003619|PROCEDURE|bone marrow ablation with stem cell support|
223612149|NCT00003619|PROCEDURE|peripheral blood stem cell transplantation|
223612150|NCT04351217|BEHAVIORAL|Music|Raga Ahir Bhairav and Bhairavi were used, played primarily on flute, without lyrics.
223612151|NCT04351217|BEHAVIORAL|Progressive Muscle Relaxation|The instructions were recorded in both English and the local language, Kannada
223612152|NCT03259087|DRUG|MK-3866|Single IV infusion of 200 mg administered over 30 minutes (±5 minutes) on Day 1 of each treatment period.
223612153|NCT00335400|DRUG|Anesthetic Dilating Gel|
223612154|NCT00356044|PROCEDURE|Coronary angioplasty|
223612155|NCT03097965|DIETARY_SUPPLEMENT|PROGRAM|
223612156|NCT03097965|OTHER|DIET|
223612157|NCT04950465|OTHER|Sensodyne Sensitivity & Gum|Sensodyne Sensitivity \& Gum toothpaste containing 0.454% SnF2.
223612158|NCT04950465|OTHER|Crest Cavity Protection Fresh Lime|Crest Cavity Protection Fresh Lime is containing 1150 parts per million fluoride as Sodium fluoride.
223612159|NCT04950465|OTHER|Sensodyne Repair and Protect|Sensodyne Repair and Protect dentifrice containing 5.0% weight/weight calcium sodium phosphosilicate.
223612160|NCT03356275|BEHAVIORAL|Mindfulness for Resilience in Illness: Support for Parents|Mobile application focusing on emotional coping skills for parents of children and adolescents with chronic pain. Components of the module include: library of mindfulness meditations/relaxations; peer support videos; and psychoeducational information related to pain, stress, and mindfulness.
223612161|NCT03820882|DEVICE|Catfish|Patients will be treated for mechanical recanalization with Catfish within 8 hours after stroke onset plus standard medical management.
223612162|NCT03820882|DEVICE|Solitaire FR|Patients will be treated for mechanical recanalization with Solitaire FR within 8 hours after stroke onset plus standard medical management.
223612163|NCT02883803|BIOLOGICAL|Injection of mesenchymal stem cells|Injection of mesenchymal stem cells
223612164|NCT02883803|BIOLOGICAL|Injection of albumin alone|Injection of albumin alone
223612165|NCT00483691|BEHAVIORAL|Home Visit|Homw visits scheduled weekly for one year.
223612166|NCT02133898|OTHER|L-methylfolate|L-methylfolate, an FDA approved medical food will be administered in 15 mg capsule form once daily for 90 days
223612167|NCT05416866|PROCEDURE|Retrolaminar block on the operative side|After the skin near the puncture site was disinfected, 2ml of 1% lidocaine was injected into the puncture site for local infiltration. The needle was inserted beneath the ultrasound probe using an in-plane orientation to contact the lamina of the T8-T11 vertebra. Then we retracted the tip of needle to the lamina about 1 mm and withdrew to make sure that there was no blood or cerebrospinal fluid. Then, 30-40 mL mixture was injected posterior to the lamina of T8-T11.
223612168|NCT05416866|PROCEDURE|Quadratus lumborum block on the operative side|In our study, we applied a transmuscular approach to the QLB. After the patients were placed in the lateral position, the skin near the puncture site was disinfected, a low-frequency (3-5 MHz), curvilinear probe is used and is located vertical to the iliac crest at the posterior axillary line to find the Shamrock sign. After the local infiltration for puncture site, the 22-G needle is then inserted in plane and directed to the QL muscle. After the proper position of the needle tip between the psoas major muscle and the QL muscle is confirmed, 30 ml mixture is injected into the interfascial plane.
224205952|NCT06375954|PROCEDURE|Endoscopic biliary drainage|Decompression of the bile duct by endoscopic aproach.
223612169|NCT05416866|PROCEDURE|Transversus abdominis plane block on the nonoperative side|After placing the patients in the supine position, the skin was disinfected. A linear probe was placed in the transverse plane at the midaxillary line between the lower costal margin and iliac crest. When the external oblique, internal oblique, and transversus abdominis muscles were observed, 2ml of 1% lidocaine was injected into the puncture site for local infiltration.Then, a 22-gauge, 80-mm needle was advanced using an in-plane technique in an anteromedial to posterolateral direction toward the TAP (the fascial plane between the internal oblique and transversus abdominis muscles). After the correct position of the needle tip was verified, 20 ml mixture was injected into the TAP. The ultrasound showed that the local anesthetic separated the internal oblique and transversus abdominis muscles, confirming the success of the block.
223612170|NCT02072863|DRUG|Oprozomib|Study subjects will receive oprozomib administered orally.
223612171|NCT02072863|DRUG|Melphalan|Study subjects will receive melphalan 9 mg/m2.
223612172|NCT02072863|DRUG|Prednisone|Study subjects will receive prednisone 60 mg/m2.
224311884|NCT04767191|DRUG|dihydroartemisinin piperaquine|Antimalarial Combinations
223758337|NCT04784585|BEHAVIORAL|Self-Efficacy|"This intervention option is based on a previously established self-efficacy intervention for weight loss, which is a multi-component intervention for increasing self-efficacy. To provide variety in this intervention option and limit time spent in a single intervention, components are split into independent modules that either prompt: 1) attainable intention setting related to dietary adherence (e.g., I will focus on eating mostly fruits/vegetables in my next meal/snack in order to take back control of my eating); 2) barrier identification for adhering to dietary goals along with a brief problem-solving exercise; 3) devising a small self-reward; OR 4) self-assessment of thoughts/behaviors that could interfere with dietary adherence in the next several hours with coping strategies (e.g., stimulus control, social support)."
223758338|NCT04784585|BEHAVIORAL|Motivation|"To provide variety in this intervention option and limit time spent in a single intervention, components are split into independent modules that either: 1) guide participants in identifying values related to weight control (e.g., longevity, quality of life, being a role model) and connect those values to their behavior in the current moment.; 2) use a collaborative non-judgmental approach to explore the consequences of letting barriers drive behavior (e.g., Take a moment to consider the effect on your longevity if you let your preference for sweets determine your behavior.); 3) prompt participants to identify reasons for change, thereby eliciting change talk; OR 4) engage participants in a brief self-assessment of motivation for dietary adherence (i.e., On a scale of 1-10, how important to you is it to stick to your dietary goals today)."
223758339|NCT04784585|BEHAVIORAL|Self-Regulation|"There are 4 independent modules that prompt self-monitoring and self-awareness efforts: 1) advise participants to record everything that they eat before they eat it, with attention to eating in the subsequent few hours; 2) use the traffic light model to enhance awareness of dietary intake. This module provides the traffic light categories of foods (i.e., green=healthiest choices, yellow=sometimes choices, and red=rare choices), and asks participants to check-off foods that they intend to eat vs. stay away from in the next few hours; 3) advise participants to track portion sizes carefully and provide a portion size guide that is available to them until the following EMA survey; OR 4) provide a tutorial on noticing hunger/satiety cues and slowing down rate of eating, with an experiential exercise for use during their next eating episode."
223758340|NCT04784585|BEHAVIORAL|Generic Risk Alert (Active Comparator)|"Participants will be notified that the JITAI algorithm has determined heightened lapse risk in the following 2-3 hours (i.e., We have detected that your risk of lapsing from your weight loss diet is higher than usual and may require attention.)."
223758341|NCT04784585|BEHAVIORAL|Online Behavioral Obesity Treatment|The online BOT consists of: (a) 12 weekly multimedia lessons for training in behavioral weight loss skills; (b) online tools for self-monitoring weight, diet, and physical activity; and (c) weekly automated text-based feedback on progress to date. Participants are given a goal of losing 1-2lbs per week to achieve a total weight loss of ≥10% of initial body weight. Participants are prescribed a calorie goal of 1200-1800 kcal/day tailored on initial weight. Participants are given guidelines to follow a lowfat or Mediterranean diet to meet the prescribed calorie goal. Participants are given a physical activity goal tailored on initial activity level that gradually increases to 200 min/wk of activity, emphasizing brisk walking as the primary form of activity. They also receive a primer in self-monitoring weight, diet, and physical activity. Participants are instructed to self-monitor and follow the prescribed diet for the 6-month study period.
223758342|NCT04926961|DEVICE|Sham transcranial magnetic stimulation (TMS)|Sham TMS will be applied using the MagVenture MagPro X100 stimulator with the placebo side of the Cool-B65 A/P coil.
223758343|NCT04926961|DEVICE|Real transcranial magnetic stimulation (TMS)|Real TMS will be applied using the MagVenture MagPro X100 stimulator with the active side of the Cool-B65 A/P coil.
223758344|NCT03564340|DRUG|Ubamatamab|Administered per the protocol
223758345|NCT03564340|DRUG|Cemiplimab|Administered per the protocol
223758346|NCT03564340|DRUG|Sarilumab|Administered per the protocol
223509368|NCT02961582|DEVICE|Sacral Neuromodulation|"SNM starts with a screening phase. In this phase a tined lead is inserted into the third sacral foramen and attached to an external stimulator, after which the patient enters a four-week stimulation test period. If the screening phase is successful (defecation frequency (DF) ≥3 a week), the external stimulator is changed for a pacemaker that is implanted in the buttocks. If the screening phase is unsuccessful (DF \<3 a week), the lead is explanted.~Patients in the intervention group are asked to limit the use of additional conservative treatments for constipation (such as laxatives and colonic irrigation) to what is necessary to relieve (the most severe) complaints. What is necessary to relieve complaints is determined by the patient."
223509369|NCT02961582|OTHER|Personalized Conservative Treatment|The control group will receive the best and least invasive alternative treatment, which is personalized conservative treatment (PCT). PCT includes, a combination of laxative/medication use and/or colonic irrigation, depending on the preferences of the patient. Use of PCT will be documented.
223509370|NCT01560988|DRUG|Borage and Echium Seed Oils|4.0 g/day borage seed oil and 7.0 g/day echium seed oil. Pills will be taken three times per day for six weeks.
223509371|NCT01560988|DIETARY_SUPPLEMENT|Corn oil pills|Corn oils pills will be taken three times per day for six weeks.
223509372|NCT03225222|DIAGNOSTIC_TEST|biopsy|prostate biopsy
223509373|NCT04093700|DEVICE|SureLock All-Suture Anchor|Subjects that have been implanted with the SureLock All-Suture Anchor to repair the glenoid labrum
223509374|NCT02455856|DRUG|JNJ-42847922|Participants will receive single dose of 5 milligram (mg) JNJ-42847922 as 5 mg/milliliter \[mL\] oral solution on Day 1 and Day 6.
223509375|NCT02455856|DRUG|Itraconazole|Participants will receive single dose of itraconazole as 200 mg (2\*100 mg capsule) from Day 2 to Day 6.
223509376|NCT02799290|BIOLOGICAL|ADIPOSE TISSUE EXTRACT|Adipose tissue extract is obtained on site with lipoaspirate adipose tissue prepared though incubation and filtration
223509377|NCT02799290|BIOLOGICAL|PLATELET-RICH PLASMA GEL|Autologous platelet rich plasma is obtained onsite and activated following commercial kit instructions
223509378|NCT04315207|BEHAVIORAL|Telephone call|"All patients are informed that they will receive a telephone call between 08 AM and 5 PM on workdays, as soon as the results of invasive workup are available. This is expectedly 3 to 5 days after invasive workup. At the telephone call, patients are free to ask for a later call, to summon relatives, to turn on the loud speaker, and/or ask the physician to call one relative of choice to share the information.~Regardless of group, all patients are informed on the possibility of malignancy at every patient-physician encounter."
223758347|NCT03564340|DRUG|Tocilizumab|Administered per the protocol
223758348|NCT02388737|DRUG|Vonoprazan|Vonoprazan tablets
224201351|NCT01040468|BEHAVIORAL|Intensive Lifestyle Modification|Intensive lifestyle modification program for weight loss. Participants randomized to this condition will receive an weekly individual treatment of 30 minutes for the first 6 months and every-other-week sessions from months 7 to 12. Treatment will be provided by a behavioral psychologist or registered dietitian following a structured curriculum used in our prior studies. During the first 4 months, participants will be prescribed a 1000-1200 kcal/d diet that provides four daily servings of meal replacement products (liquid shakes, cereals, meal bars, etc), combined with an evening dinner entree. Each serving of the meal replacement (HMR 170; Boston, MA) will provide 170 calories, with 16 g of protein, 22 g of carbohydrate, and 2 g of fat. Dinner entrees (containing at least 20 g of protein and approximately 220-260 kcal) will be consumed with a garden salad and a serving of fruit (and other vegetables allowed ad libitum throughout the day).
224201352|NCT03363724|OTHER|HaGuide version 1.0 software module|
223758349|NCT02388737|DRUG|Lansoprazole|Lansoprazole capsules or tablets
223758350|NCT02388737|DRUG|Vonoprazan Placebo|Vonoprazan placebo-matching tablets
223758351|NCT02388737|DRUG|Lansoprazole Placebo|Lansoprazole placebo-matching capsules
223758352|NCT00324779|BIOLOGICAL|rituximab|
224201353|NCT02163746|PROCEDURE|CO2 (carbon dioxide) laser|
224201354|NCT02163746|PROCEDURE|Surgical Deroofing|
224311885|NCT02404766|OTHER|C0-C1 dorsal glide manual mobilization|
224311886|NCT02404766|OTHER|C7-T1 ventral cranial glide manual mobilization|
224311887|NCT05998148|OTHER|virtual phone appointment visits|Patient will have post-operative appointments that place with telemedicine. The visits will will be virtual phone appointments scheduled at approximately 6 weeks, 12 weeks, and 6 months after surgery.
223509379|NCT04315207|BEHAVIORAL|In-person meeting|"All patients are provided a written and verbal appointment date 5 workdays after invasive workup, and that they will receive a telephone call if 1) results are not available at the time of the meeting, and/or 2) if results need urgent action (such as small-cell lung cancer).~At the in-person meeting, patients are free to invite family and relatives (up to 4 persons, restriction due to space available).~Regardless of group, all patients are informed on the possibility of malignancy at every patient-physician encounter."
223509380|NCT01210209|OTHER|genome-wide association study|
223509381|NCT01407978|BIOLOGICAL|Vaccination with Fluval P monovalent influenza vaccine|"* Vaccination with Fluval P monovalent influenza vaccine with 6 μg HA/0.5 ml active ingredient content and aluminium phosphate gel adjuvant.~* Dose: 0.25 ml /total 3 μg HA/ in age group 3-12 years, and 0.5 ml /total 6 μg HA/ in age group 12-18 years, single dose."
223509382|NCT01407978|BIOLOGICAL|Vaccination with Fluval AB|"* Vaccination with Fluval AB trivalent influenza vaccine with 15 μg HA/0.5ml/strain active ingredient content and aluminium phosphate gel adjuvant.~* Dose: 0.25 ml /total 3x7.5 μg HA/ in age group 3-12 years, 0.5 ml /total 3x15 μg HA/ in age group 12-18 years, single dose."
223509383|NCT01407978|BIOLOGICAL|Vaccination with Fluval AB Novo|"* Vaccination with Fluval AB Novo trivalent influenza vaccine with 6 μg HA/0.5ml/strain active ingredient content and aluminium phosphate gel adjuvant.~* Dose: 0.25 ml /total 3x3 μg HA/ in age group 3-12 years, 0.5 ml /total 3x6 μg HA/ in age group 12-18 years, single dose."
223509384|NCT00676754|PROCEDURE|Statens Serum Institut RT23 2TU tuberculin|
223509385|NCT01428973|DRUG|Mycophenolate mofetil|Tablets. For HLA-identical sibling donors:15 mg/kg t.i.d from day 0 to day 28. For alternative donor: 15 mg/kg, from day 0 to day 42.
223612173|NCT06271434|DIETARY_SUPPLEMENT|THYROX (Atlantic krill oil|The daily content of krill oil is 2000 mg, including omega-3 fatty acids 350 mg, EPA - 240 mg, DHA- 110 mg, phospholipids - 800 mg, astaxanthin 200 mg.
223612174|NCT06271434|DIETARY_SUPPLEMENT|Placebo|The control capsules will be made of olive oil of equal size and color.
223612175|NCT02172638|PROCEDURE|Fast-Track Protocol|
223612176|NCT02172638|PROCEDURE|Usual management|
223612177|NCT00548600|PROCEDURE|Iridium Implant|Temporary iridium implant of the prostate will be done and a dose of 3000 cGy will be delivered in the next 48-72 hours. Two weeks later 20 fractions of external beam radiation at a dose of 4000 cGy will be administered over a period of 4 weeks.
223612178|NCT00548600|RADIATION|Standard external beam irradiation|Standard external beam irradiation at a dose of 6400 cGy in 32 fractions over 6 and a half weeks will be administered.
223612179|NCT06502548|PROCEDURE|Endometriosis|"Anatomopathology waste will be recovered, i.e. the remainder of the endometriosis lesions and the remainder of the endometrial biopsy.~A blood sample will be taken the day before surgery, as part of the treatment, for a hormonal check-up."
223612180|NCT06502548|PROCEDURE|Tubal ligation or Hysterectomy|During surgery, an endometrial biopsy will be taken for research purposes. A blood sample will be taken the day before surgery, as part of the treatment, for a hormonal check-up.
223612181|NCT00671424|DRUG|Hydrochlorothiazide (HCTZ)|
223612182|NCT00671424|DRUG|Remogliflozin etabonate (GSK189075)|
223612183|NCT00671424|DRUG|Furosemide|
223612184|NCT05649007|DEVICE|hip arthroplasty with prosthesis|Use of femoral stem and acetabular cup for hip arthroplasty
223612185|NCT05497089|DRUG|Temelimab 54mg/kg|Temelimab 54mg/kg will be given as monthly (every 4 weeks) intravenous (IV) infusion over 24 weeks (6 infusions in total)
223612186|NCT05497089|DRUG|Placebo|Placebo will be given as monthly (every 4 weeks) intravenous (IV) infusion over 24 weeks (6 infusions in total)
223612187|NCT02366195|DRUG|Talimogene Laherparepvec|The initial dose of talimogene laherparepvec is up to 4.0 mL of 10\^6 PFU/mL. Subsequent doses of talimogene laherparepvec are up to 4.0 mL of 10\^8 PFU/mL.
223612188|NCT01153126|BEHAVIORAL|Comprehensive Health Enhancement Support System (CHESS.)|Half of the participating women will be randomly assigned to usual care and half will be offered a fully CHESS.
223612189|NCT05084586|DRUG|Intravesical Solution|After the Transurethral Resection of Bladder Tumor(TURBT) surgery, 50 mg Epirubicin solution in 150 ml saline was continuously instiled into the bladder for 2 hours. A drainage catheter was closed in order to fill the bladder with epirubicin solution.
223612190|NCT05084586|DRUG|Intravesical Solution|After the Transurethral Resection of Bladder Tumor(TURBT) surgery, 50 mg Epirubicin solution in 50 ml saline was instiled into the bladder for 2 hours. A drainage catheter was closed in order to fill the bladder with epirubicin solution.
223612191|NCT01544426|PROCEDURE|Office hysteroscopy and endometrial snip|Office hysteroscopy with endometrial snip
223758353|NCT05705908|OTHER|Hot Foot Bath 1|"* Hot foot bath device has a built-in heater (max. 44°C),~* Hot foot bath device has anti-slip base, vibration and 2 rotating massage rollers, digital display/control panel and timer (20-60 minutes).~* It is filled with water at 40 degrees so that it passes the ankle of the patient by 20 cm (4 liters of water)."
223612192|NCT01544426|PROCEDURE|Office hysteroscopy|Office hysteroscopy
223612193|NCT01788566|DRUG|Necitumumab|Administered IV
223612194|NCT01788566|DRUG|Gemcitabine|Administered IV
223612195|NCT01788566|DRUG|Cisplatin|Administered IV
223612196|NCT01379183|DRUG|Erythromycin|200 mg suspension
223612197|NCT01379183|DRUG|Placebo|200 mg suspension
223612198|NCT01379183|PROCEDURE|Magnetic Resonance Imaging|An MR enterography procedure uses magnetic resonance imaging (MRI) technology to obtain detailed images of the small bowel.
223612199|NCT01379183|OTHER|Barium Sulfate Solution|Participants will be given a low concentration of barium sulfate solution (1350 mL) prior to the MRI procedure. Barium sulfate is a radiopaque agent. Radiopaque agents are used to help diagnose certain medical problems. Since radiopaque agents are opaque to (block) x-rays, the areas of the body in which they are localized will appear white on the x-ray film. This creates the needed distinction, or contrast, between one organ and other tissues. The contrast will help the doctor see any special conditions that may exist in that organ or part of the body.
223612200|NCT06332066|DRUG|Oxytocin nasal spray|Intranasal OT will be performed using a spray containing 24IU (12IU administered to each nostril), sorbitol, benzyl, alcohol glycerol, distilled water. Dosage and administration method was determined by standard OT studies instructions and guidelines. The substance will be prepared immediately after randomization by an external preparation and delivered and stored until administration under required conditions. The nasal spray will be self administered, with nursing staff supervising for proper administration of substance, and for supervision of side effects.
223758354|NCT05705908|OTHER|Hot Foot Bath 2|"* Hot foot bath device has a built-in heater (max. 44°C),~* Hot foot bath device has anti-slip base, vibration and 2 rotating massage rollers, digital display/control panel and timer (20-60 minutes).~* It is filled with water at 40 degrees so that it passes the ankle of the patient by 20 cm (4 liters of water).~* 3 drops of lavender essential oil were dripped in the water"
224311888|NCT02338804|BIOLOGICAL|MV|MV is an intravenous intralipid suspension with 5 various vaccines, including DPT (diphtheria, pertussis, and tetanus ), typhoid, Staphylococcus aureus, paratyphoid A and B. Accessories include microbial A, lecithin, Twain-80, span 20 and soy-bean oil for injection. Inject 0.5 ml of the mixture subcutaneously every week. Best reaction after injection was defined as showing regional red and swollen at the injection point and mild fever and to achieve this, dose increasing or reduction is acceptable.
223612201|NCT05142605|BEHAVIORAL|Meaning-Centered Grief Therapy|Meaning-Centered Grief Therapy is a therapy that focuses on helping participants find a sense of meaning or purpose in participants' life after participants' loss. Parents will be provided (via mail or email) a workbook. This support program will involve 16 sessions that will take place about once a week. Each session will last 60 to 90 minutes and will be delivered through videoconferencing.
223612202|NCT05142605|BEHAVIORAL|Supportive Psychotherapy|Supportive Psychotherapy will help participants cope with participants' loss by giving them a place to express participants' feelings and providing participants with support during the sessions. Supportive counseling will involve 16 sessions that will take place about once a week. Each session will last 60 to 90 minutes and will be delivered through videoconferencing.
223612203|NCT05142605|BEHAVIORAL|Enhanced Usual Care|Enhanced usual care includes any support or resources participants may receive as part of participants' standard care (for example, therapy sessions with a local therapist), enhanced with additional resources.
223612204|NCT06281535|DEVICE|Implant loading|Placement of abutments and final restorations either 2 months following implant placement in early loading group or 3 months in conventional loading group
223612205|NCT00259714|DRUG|dialysate sodium individualization|"Dialysate sodium level prescribed matches the subject's average pre-dialysis serum sodium (individualized)."
223612206|NCT00259714|DRUG|standard dialysate sodium|The prescribed dialysate sodium is 140 mEq/L
223612207|NCT04416048|DRUG|Rivaroxaban|Treatment with Rivaroxaban 20 mg (15 mg for subjects with an eGFR ≥30 mL/min/1.73m2 and \<50 mL/min/1.73m2) once daily (OD) for at least 7 days. In case of hospitalization for more than 7 days, the therapeutic treatment with rivaroxaban will be continued for the duration of the hospital stay until discharge. After at least 7 days of therapeutic treatment with rivaroxaban or after hospital discharge, the study dose of rivaroxaban will be adjusted as follows. Patients randomized to the rivaroxaban study arm will reduce daily dosage to 10 mg OD, provided that they were not diagnosed with a condition requiring continued therapeutic anticoagulation. Thromboprophylaxis therapy will be given for 28 days up to day 35 post randomization or even longer. If the patient cannot be discharged from the hospital prior to day 35 post randomization, the thromboprophylaxis phase will also start upon hospital discharge, but is then shorter than 28 days, because the study ends at day 60 post randomization.
223612208|NCT04416048|OTHER|Standard Of Care (SOC)|Standard of care treatment
223612209|NCT01620086|DEVICE|Active Repetitive Transcranial Magnetic Stimulation 1 Hz|active rTMS delivered at 1Hz frequency over temporal cortex
223612210|NCT01620086|DEVICE|Active Repetitive Transcranial Magnetic Stimulation 10 Hz|active rTMS delivered at 10 Hz frequency over temporal cortex
223758355|NCT03252522|COMBINATION_PRODUCT|Broad Spectrum Micronutrients; a 36-ingredient blend of vitamins, minerals, amino acids, and antioxidants|60% of participants will take 3-4 capsules of broad spectrum micronutrients three times per day for eight weeks. Following the initial 8 weeks (of the RCT), all participants will have the option to participate in an open label extension, during which time the child would take the active micronutrient treatment for 8 weeks
223758356|NCT03252522|DIETARY_SUPPLEMENT|Placebo|40% of participants will take 3-4 capsules of inactive placebo three times per day for eight weeks.
223758357|NCT05862025|DIAGNOSTIC_TEST|Echocardiography evaluation|"Patients will undergo mandatory transthoracic echocardiography during assessment of Staphylococcus aureus bacteremia.~Later, they will also undergo mandatory transesophageal echocardiography.~Both test will be performed during the first 14 days from bacteremia onset."
223758358|NCT05510323|DRUG|Prednisolone|RAS blockade as much as tolerated or allowed
223758359|NCT05510323|DRUG|Prednisolone plus Cyclophosphamide|RAS blockade as much as tolerated or allowed
223758360|NCT00431171|DRUG|Lithium carbonate|
223758361|NCT00276718|BIOLOGICAL|bleomycin sulfate|
223758362|NCT00276718|DRUG|carboplatin|
223758363|NCT00276718|DRUG|etoposide|
223758364|NCT00276718|PROCEDURE|conventional surgery|
223758365|NCT03059381|DRUG|Fycompa|The usual oral dosage for adults and children 12 years of age or older is initially 2 milligrams (mg) once daily as perampanel at bedtime, and the daily dose may then be increased by 2 mg at intervals of 1 week or longer. The maintenance dose is 8 mg once daily in the absence of concomitant antiepileptic drugs that accelerate the metabolism of this product, or 8 to 12 mg once daily in the presence of such concomitant drugs. The dosage may be increased or decreased as necessary by 2 mg at intervals of 1 week or longer depending on symptoms, but the maximum daily dose should not be over 12 mg.
223758366|NCT05498194|DIAGNOSTIC_TEST|ratio of predicted neoantigens|10 ml of whole blood is collected from each patient prior surgery Fresh tumor tissue samples (\~ 1cm3 ) are collected during surgery
223758367|NCT04734340|PROCEDURE|EIT-guided PEEP setting|Ventilator parameter setting by EIT
223758368|NCT04734340|PROCEDURE|ARDS-net PEEP setting|Ventilator parameter setting according to ARDS-net table
223758369|NCT01627613|DRUG|AP301|"AP301 25 mg powder for reconstitution for solution for inhalation~Orally delivered doses of 87.6 mg AP301 are inhaled every 12 hours (± 30 min), for a total of 7 days."
223758370|NCT01627613|DRUG|Saline solution|Placebo solution (0.9% physiologic NaCl) is inhaled every 12 hours (± 30 min), for a total of 7 days.
223758371|NCT04270500|BEHAVIORAL|Prehabilitation program|The preoperative period (prehabilitation) represents a more appropriate time than the postoperative period to implement an intervention. Prehabilitation is a process of enhancing an individual's functional capacity before the scheduled surgery, aimed at improving the patient's tolerance to upcoming physiologic stress, by three principal elements: exercise training, nutritional intervention, and psychological support.
223758372|NCT00002510|BIOLOGICAL|filgrastim|
223758373|NCT00002510|DRUG|cyclophosphamide|
223758374|NCT00002510|DRUG|etoposide|
223758375|NCT00002510|DRUG|mesna|
223758376|NCT00002510|PROCEDURE|peripheral blood stem cell transplantation|
223758377|NCT00002510|RADIATION|radiation therapy|
223758378|NCT03732911|BEHAVIORAL|Intervention|Participants will receive the following intervention bundle (1) educational materials about child development and developmental monitoring checklists; (2) age and language appropriate picture books; and (3) two tailored text messages per week for a 6-month period.
223758379|NCT03262948|DRUG|nab-paclitaxel|albumin-bound paclitaxel is 260 mg/m2 intravenously over 30 minutes on Days 1 of each 21-day cycle cycle immediately after albumin-bound paclitaxel
223758380|NCT03262948|DRUG|Paclitaxel|paclitaxel is 175 mg/m2 intravenously over 3 hours on Days 1 of each 21-day cycle cycle immediately after paclitaxel
223509386|NCT01428973|DRUG|Sirolimus|Tablets. 6 mg loading dose on day -3, followed by (1)-2 mg daily to a target trough level of 5 to 10 ng/mL. Full doses will be given until day 100 (sibling recipients) or 180 (alternative donor recipients). Doses will then be progressively tapered to be definitely discontinued by day 180 (sibling donors) or 365 (alternative donor recipients) in the absence of GVHD.
223512360|NCT01791296|OTHER|Placebo|At 21:30h, all current IV sedatives (whether continuous or intermittent) will be decreased by 50% and study drug started at 0.2 mcg/kg/hour at 21h30 to allow sleep between 22h00 and 6h00. Study infusion will be halved at 6:00am and d/c at 6:15am. The infusion rate will be increased by 0.1mcg/kg/hour every 15 minutes when the Riker-SAS is ≥ 4 up to a maximum rate of 0.7 mcg/kg/hr until the targeted sedation goal of a Riker-SAS of 3 is reached. For agitation (ie., Riker-SAS ≥ 5), 'as needed' IV midazolam (1-5 mg IV q1h prn agitation) may be administered during the upwards titration of the study medication. Administration of any dose of as needed IV midazolam will result in the increase of the study medication by 0.1 mcg/kg/hr when ≥ 15 minutes have elapsed since the last upwards titration.
223758381|NCT03262948|DRUG|Carboplatin|carboplatin is administered on Day 1 of each 21-day，followed by paclitaxel or nab-paclitaxel
223758382|NCT03018392|DEVICE|Stryker Tritanium Spinal System|open transforaminal lumbar interbody fusion (TLIF) utilizing the Stryker Tritanium cages with pedicle screw fixation according to instructions for use and package labeling for on-label indications
223758383|NCT03824197|OTHER|EVOO|Extra-virgin olive oil that is rich with oleocanthal and other phenols.
223758384|NCT03824197|OTHER|OO|Olive oil low in oleocanthal and other phenols.
223758385|NCT04661345|OTHER|Proteomic analysis of synovial fluids|Characterization of the proteome of infected/aseptic synovial fluid for the identification of molecular hallmarks strictly related to the presence of a bacterial infection mediated by coagulase-negative Staphylococci
223758386|NCT04661345|OTHER|Proteomic analysis of the isolated coagulase-negative Staphylococci|Characterization of the secretome of coagulase-negative Staphylococci isolated from infected prosthetic implants
223758387|NCT00422565|DEVICE|Endeavor, Medtronic|Zotarolimus-eluting stent
223758388|NCT00422565|DEVICE|Cypher, Cordis|Sirolimus-eluting stent
223758389|NCT00422565|DEVICE|Taxus Liberte, Boston Scientific|Paclitaxel-eluting stent
223758390|NCT06284096|BEHAVIORAL|Psychoeducation|The study is planned to consist of 7 sessions, occurring once a week, with approximately 60-70 minutes allocated for each session. Considering the attention span of the participants, the sessions will be divided into two parts, with a session lasting 30-40 minutes followed by a 15-minute break.
223758391|NCT06719973|DRUG|M9466|Participants will receive an escalating doses of M9466 orally in 21-day cycles until disease progression, intolerable toxicity, death, withdrawal of study or study consent, lost to follow-up, or end of study.
223758392|NCT06719973|DRUG|Carboplatin|Carboplatin will be administered intravenously on Day 1 of each 21-day cycle.
223758393|NCT06719973|DRUG|Etoposide|Etoposide will be administered intravenously as per standard of care.
223758394|NCT06719973|DRUG|Atezolizumab|Atezolizumab will be administered intravenously as per standard of care.
223758395|NCT06719973|DRUG|M9446|M9446 dose will be further investigated in Module 2 Part A of the study.
223758396|NCT06719973|DRUG|M9446|M9446 recommended Dose for Expansion (RDE) will be further investigated in Module 2 Part B of the study.
223758397|NCT06719973|DRUG|Carboplatin|Carboplatin will be administered intravenously as per standard of care.
223758398|NCT04406064|BIOLOGICAL|Viral Specific T-cells (VSTs)|VSTs will be infused into study participants who have evidence of SARS-CoV-2 infection.
223758399|NCT03299842|DRUG|ZX008 (Fenfluramine Hydrochloride)|ZX008 is supplied as an oral solution in a concentration of 2.5 mg/mL. Subjects will be titrated to an effective dose beginning with 0.2 mg/kg/day (maximum: 30 mg/day).
223612211|NCT01620086|DEVICE|Active control site Repetitive Transcranial Magnetic Stimulation at 1Hz|active rTMS delivered at either 1 Hz frequency over the vertex
223612212|NCT01620086|DEVICE|Sham control site Repetitive Transcranial Magnetic Stimulation|sham rTMS delivered at 1Hz frequency over the vertex
223612213|NCT01620086|DEVICE|Active control site Repetitive Transcranial Magnetic Stimulation at 10 Hz|Active 10 Hz rTMS delivered over the vertex
223612214|NCT00738335|DRUG|erlotinib hydrochloride|
223612215|NCT00738335|OTHER|immunoenzyme technique|
223612216|NCT00738335|OTHER|laboratory biomarker analysis|
223612217|NCT00738335|OTHER|liquid chromatography|
223612218|NCT00738335|OTHER|mass spectrometry|
223612219|NCT00738335|OTHER|pharmacological study|
223612220|NCT00738335|RADIATION|stereotactic radiosurgery|
223612221|NCT02633670|DEVICE|Hemopatch|
223612222|NCT02633670|DEVICE|No Hemopatch|
223612223|NCT02576223|DRUG|Ropivacaine hydrochloride|Ropivacaine injected perineural at the suprascapular nerve.
223758400|NCT05960591|DEVICE|ADEPTH|ADEPTH sensor will be used for bore depth measurements during plate osteosynthesis procedures.
223758401|NCT00960518|DRUG|adefovir|adefovir at 10 mg daily for 48 weeks
223758402|NCT00960518|PROCEDURE|TACE|An emulsion that consisted of 50 mg of cisplatin and 10 mL of lipiodol at a volume ratio of 1:1 was injected into the blood supply artery of the tumor under fluoroscopic guidance. The injection could be slowed or discontinued if retrograde flow occurred. Embolization was subsequently performed with granules of gelatin sponge particles.
223758403|NCT02659215|DEVICE|Hyalofast|Implantation of Hyalofast scaffold with autologous bone marrow aspirate concentrate via arthroscopy/mini-arthrotomy.
223758404|NCT02659215|PROCEDURE|Microfracture|Microfracture is a well-established arthroscopic surgical technique for cartilage repair which involves several systematic steps, including debridement to a stable cartilage margin, careful removal of the calcified cartilage layer, and homogeneous placement of microfracture penetrations within the cartilage defect, with resultant complete defect fill by a well-anchored clot
223758405|NCT02208791|DRUG|Sirolimus|Sirolimus, 2mg once daily, will be added to the maintenance immunosuppression composed of tacrolimus, prednisone and mycophenolate. The prescription of tacrolimus will be tapered down to achieve a peripheral blood trough level between 3 e 5 ng/mL and micophenolate will be reduced to 540mg bid.
223758406|NCT02208791|DRUG|No intervention|
224201355|NCT02418338|OTHER|speckle tracking (2D strain) echocardiography|2D echocardiography videos of both ventricles to perform 2D strain post-examination evaluation
224201356|NCT06001736|PROCEDURE|Contralateral C7 root transfer for the treatment of spastic hemiparesis.|Performing surgery to transfer the C7 nerve to treat stroke patients experiencing spastic hemiparesis.
223612224|NCT02576223|DRUG|Isotonic Saline|Saline injected perineural at the suprascapular nerve.
223612225|NCT02576223|DRUG|PCA-pump|"PCA (Patient controlled analgesia) pump with the following settings:~Age \> 70 years or weight \< 60 kg: bolus dose 2,5 mg i.v. morphine, 15 minutes lockout Age \< 70 years and weight \> 60 kg: bolus dose 5 mg i.v. morphine, 15 minutes lockout Lockout time 15 minutes."
223758407|NCT02595736|DRUG|Placebo (SC)|Administered SC
223758408|NCT02595736|DRUG|LY3200327 (SC)|Administered SC
223758409|NCT02595736|DRUG|LY3200327 (IV)|Administered IV
224201357|NCT01808508|DEVICE|Continuous positive airway pressure|Continuous positive airway pressure is a machine used with sleep which compresses air delivered via a nasal mask and thus helps stent the airway open.
224201358|NCT01808508|DEVICE|Sham or placebo continuous positive airway pressure|Sham or placebo CPAP is a machine used instead of therapeutic CPAP. This machine is similar to a therapeutic CPAP machine but has built in leaks and does not deliver pressure. It is not effective in treating OSAS.
224201359|NCT03752424|DRUG|Silver nanoparticles|The active group will receive silver nanoparticles in different dosage forms as an anti-microbial drug.
224201360|NCT03752424|DRUG|Topical approved anti-microbial gel|The placebo group will receive topical FDA approved anti-microbial jel in different dosage forms as control drug.
224201361|NCT01431807|DRUG|SYR-472|oral, for up to 52 weeks.
224201362|NCT05853237|DEVICE|laser therapy for wound management|comparison between laser effect on post median sternotomy incision compared to traditional wound care
224201363|NCT05335759|OTHER|Coaching programme for improvement and development of teaching skills in preceptorship|Training program An intervention based on coaching. The strategies of this program consisted of three 6-hour sessions using case studies and role-playing for motivation towards the development of the teaching role in the preceptorship of undergraduate nursing students and debriefing and a 4-hour booster session seven months later.
224201364|NCT01017731|BIOLOGICAL|IMC-1121B|IMC-1121B (Ramucirumab) 10 mg/kg intravenously (IV) over 60 minutes, once every 3 weeks for minimum of 9 weeks.
224201365|NCT01017731|DRUG|Moxifloxacin|Administered orally
223758410|NCT02595736|DRUG|Placebo (IV)|Administered IV
223758411|NCT00764621|PROCEDURE|Primovist MRI|Contrast-enhanced MRI with an i.v. application of Primovist in the approved dosage
224201366|NCT01017731|DRUG|Diphenhydramine|Administered IV
224201367|NCT00833391|DRUG|open label|This is an open-label, randomized, single-dose, five-period, crossover study. All subjects will receive GSK1838262.
224201368|NCT05378269|DRUG|Tamoxifen|Tamoxifen vaginal insert
224201369|NCT05378269|OTHER|Placebo|Placebo vaginal insert
223612226|NCT03067428|DIETARY_SUPPLEMENT|Glucose|Participants will adhere to a fructose restricted diet for a period of six weeks (\<7.5 grams/meal and/or \<10 grams/day; ad-libitum intake). In addition, the amount of fructose that will be restricted - which is based on the average individual fructose intake assessed prior to randomization - will be supplemented as glucose powder three times daily during the meal.
223758412|NCT00764621|PROCEDURE|Extracellular contrast media (ECCM) MRI|Contrast-enhanced MRI with an i.v. application of an approved extracellular contrast medium in the approved dosage
223758413|NCT00764621|PROCEDURE|Contrast-enhanced CT|Contrast-enhanced 3 phase multidetector CT with an i.v. application of an approved iodinated contrast medium in the approved dosage
223758414|NCT04780386|DRUG|NVP-1805|orally, once daily on Period 1 and Period 3 (or Period 2 and Period 4)
223758415|NCT04780386|DRUG|NVP-1805-R1and NVP-1805-R2|orally, once daily on Period 1 or Period 3 (or Period 2 and Period 4)
223758416|NCT00721695|DRUG|OMS302|OMS302 Irrigation Solution
223758417|NCT00721695|DRUG|OMS302-PE|OMS302-PE HCI Irrigation Solution
223758418|NCT00721695|DRUG|Vehicle|Standard topical mydriatics and Balanced Salt Solution Irrigation Solution
223758419|NCT04607993|BEHAVIORAL|Prone position ventilation technique|"1. Inform the children's family members of the purpose and method of prone position ventilation~2. Assess the fixation of various catheters~3. Suspend feeding before placing prone position~4. Confirm the time to start prone position ventilation under the joint assessment of medical staff~5. Place the child in a prone position with the participation of researchers, doctors and nursing staff, with the child's head tilted to one side to avoid damage to the eyes and nose due to compression, and the arms are bent upward to form a W . Bend both lower limbs downward to form an M shape, and use a soft pillow cushion to measure the knee joints to avoid compression~6. The whole process ensures the smooth fixation of tracheal intubation and various catheters~7. Proper sedation during prone position ventilation to achieve good human-machine synchronization~8. At least 6-8 hours in prone position every day"
223758420|NCT00347295|DRUG|Brotizolam|
223758421|NCT00347295|DRUG|Estazolam|
223758422|NCT01170728|DEVICE|Coloplast Virtue® Male Sling|The Virtue Male sling is a class II single use implantable sub-urethral, permanent, non-absorbable, support sling indicated for the surgical treatment of male stress urinary incontinence (SUI) resulting from intrinsic sphincter deficiency (ISD). The device consists of a knitted monofilament polypropylene mesh which provides surface area for supporting the bulbous urethra. The four arms are covered with polyethylene sleeves with braided polyester sutures attached at the end of the mesh arms providing proper attachment to the introducer for positioning of the sling. The single use introducer allows for implanting both the trans-obturator arms and pre-pubic arms of the mesh sling.
223758423|NCT04585516|PROCEDURE|endoscopy|Colonoscopy or gastroscopy
223758424|NCT05794256|OTHER|No interventions are planned|No interventions are planned
223758425|NCT02030171|OTHER|functionnal reeducation|Specific functionnal reeducation for chronic low back pain
223758426|NCT01095588|DRUG|200 mg Avanafil|2 X 100mg tablets avanafil
223758427|NCT01095588|DRUG|Placebo|2 tablets
223758428|NCT02061969|DRUG|linagliptin|5mg linagliptin tablets
223758429|NCT02061969|DRUG|insulin glargine|
223758430|NCT02244203|DRUG|BI 60732|
223758431|NCT02244203|DRUG|Placebo|
223758432|NCT01344369|DRUG|Norethindrone/Ethinyl Estradiol|0.4 mg/0.035 mg Chewable Tablets
223758433|NCT01344369|DRUG|FEMCON® Fe|0.4 mg/0.035 mg Chewable Tablets
223758434|NCT01364090|DRUG|Pegylated interferon alfa 2b|Pegylated interferon alfa 2b 1.5 mcg/kg/week to a maximum of 150 mcg/week administered subcutaneously once weekly directly observed.
223758435|NCT01364090|DRUG|Ribavirin|Ribavirin - 800-1400 mg daily according to weight taken orally with food, self administered in split doses.
223758436|NCT06336369|DIAGNOSTIC_TEST|analyzing brown adipose tissue, body composition and metabolic health|cooling procedure, PET-CT imaging, MR imaging, blood sampling, indirect calorimetry, thermograpy, impedance analysis
223758437|NCT05737472|DIETARY_SUPPLEMENT|High-protein RUTF|The high-protein RUTF is isocaloric to the standard RUTF. To have a higher protein quantity and quality, the recipe has greater proportions of milk powder plus whey protein and vegetable oil. A total of 15% of energy is from protein. The protein quality score, digestible indispensable amino acid score (DIAAS )of the high protein, RUTF is 1.18 which is equivalent to a Protein Digestibility Corrected Amino Acid Score (PDCAAS) of 1.19
224201370|NCT04968873|PROCEDURE|Cholecystectomy and common bile duct exploration|During elective open cholecystectomy, a basal commcn dile duct (CBD) manometry was obtained immediately after cholecystectomy, with a 10 Fr. silicone T tube introduced into the cystic duct and connected to a glass manometer.
223612227|NCT03067428|DIETARY_SUPPLEMENT|Fructose|Participants will adhere to a fructose restricted diet for a period of six weeks (\<7.5 grams/meal and/or \<10 grams/day; ad-libitum intake). In addition, the amount of fructose that will be restricted - which is based on the average individual fructose intake assessed prior to randomization - will be supplemented as fructose powder three times daily during the meal.
223758438|NCT05737472|DIETARY_SUPPLEMENT|Standard RUTF|The standard RUTF was manufactured according to WHO recommendations, with at least 50% of protein-sourced dairy, mainly skim milk. A total of 10% of energy is from protein. The protein quality score, digestible indispensable amino acid score (DIAAS) of the standard RUTF is 0.76, which is equivalent to a Protein Digestibility Corrected Amino Acid Score (PDCAAS) of 0.86.
223758439|NCT02204254|DEVICE|Radiofrequence|Associated to arm radiofrequence
223758440|NCT02204254|DRUG|Doxycycline|doxycycline 100 mg / day for 3 months with clinical evaluation, photos, and confocal SSSB V1 and V4 (M6). Tour V2 M1 for clinical evaluation of safety review, collection of adverse events and issuing end of treatment. Visit V3 M3 on adverse effects.
223758441|NCT03316833|DEVICE|Resolute Onyx|Percutaneous coronary revascularization of patients with unprotected left main coronary artery disease up to intermediate anatomical complexity (defined by a SYNTAX score \<33), must be performed with the exclusive use of drug-eluting stents of the Resolute Onyx TM family
223758442|NCT04287907|DEVICE|Monitor Group|Use of colorimetric end tidal CO2 to guide provider during provision of mask ventilation, where colour change indicates effective breaths
223758443|NCT01454726|OTHER|Diaoshi Jifa therapy plus the Western medical treatment.|Diaoshi Jifa treatment
223758444|NCT01454726|OTHER|drug|the Western medical treatment alone.
223758445|NCT03848845|DRUG|belantamab mafodotin|belantamab mafodotin will be available as 20 milligrams per millilitre (mg/mL) solution for IV infusion, supplied as frozen liquid. belantamab mafodotin solution will be diluted in normal 0.9% saline to the appropriate concentration for the dose.
223758446|NCT03848845|DRUG|Pembrolizumab|Pembrolizumab will be available as 100 mg/4 mL solution that should be stored under refrigeration at 2-8 degree Celsius. Pembrolizumab injection (solution) will be diluted prior to IV administration in 0.9% sodium chloride injection or 5% dextrose injection.
223758447|NCT01606046|DEVICE|vapocoolant spray|spray for 5 seconds from a distance of 30 cm just before the needle EMG
223758448|NCT01606046|DRUG|topical anesthetic cream|application of EMLA cream on the needle electrode insertion site 60 minutes before the needle EMG
223758449|NCT01127503|DRUG|Metyrosine|Metyrosine (250 mg capsules) were to be used at all dose levels (administered as multiples of that dosing unit). The starting dose was 250 mg/day of metyrosine. Dose escalation was to be carried out weekly for 8 weeks (up to a maximum of 8 capsules/day \[2000 mg/day if metyrosine\]) with dosage increments of 1 capsule/day per week. Weekly dose escalation was to stop based upon the investigator's assessment of safety, but not efficacy (i.e., dose escalation was to be forced to the maximum of 8 capsules/day assuming acceptable safety and tolerability).
223758450|NCT01127503|DRUG|Placebo|Placebo capsules were identically matched to Metyrosine.
223758451|NCT06277804|DRUG|LTC004 in Combination With Cyclophosphamide and Fludarabine|LTC004 was given on day 1 and cyclophosphamide (250 mg/m2) in combination with fludarabine (25 mg/m2) was given on days 3 and 4 of each cycle, Q3W, until disease progression, withdrawn informed or intolerable
223758452|NCT04168177|PROCEDURE|PCA|Patient controlled analgesia
223758453|NCT04168177|PROCEDURE|ESP|erector spinae plane block
223758454|NCT00219674|BEHAVIORAL|Group I: Video training|"Participants will receive the AED with a video that provides instructional training."
223758455|NCT00219674|BEHAVIORAL|Group II: Video training + enhanced self-efficacy (SE)|Partcipants will receive the AED with instructional video, a manikin, and additional training materials by mail.
223758456|NCT00219674|BEHAVIORAL|Group III: In-person training + enhanced SE|Participants will receive a face-to-face training session in their home as well as the AED with instructional video, manikin and training materials.
223758457|NCT00219674|BEHAVIORAL|Group IV: In-person training + enhanced SE + support|Participants will receive a face-to-face training session in their home as well as the AED, instructional video, manikin, and a resource manual with information to enhance the family member's confidence in their role as care provider.
223758458|NCT04169867|BIOLOGICAL|Collection of stool samples|Patients receiving routine treatment (immunotherapy using anti-PD1 / anti-PDL1 and / or anti CTLA4 antibodies), financed by the Polish National Health Fund (NFZ).
223758459|NCT02481895|BEHAVIORAL|E-neurocognitive module|The experimental group will take part of a 12-week extension with a total of 36 hours training with the e-neurocognitive module tailored for bipolar patients
223612228|NCT02696265|PROCEDURE|CFAE guided ablation|CFAE/spatiotemporal dispersions mapping and ablation during AF aimed at restoring sinus rhythm during ablation. Pulmonal vein isolation will be checked before and after ablation using a mapping catheter.
223612229|NCT02696265|PROCEDURE|PVI guided ablation|Wide antral pulmonary vein isolation during mapping catheter control of pulmonary vein signals
223612230|NCT03775798|DRUG|Direct antiviral agents for hepatitis C|Direct-acting antivirals for hepatitis C
223612231|NCT02166892|OTHER|Specially designed plates|
223612232|NCT01844453|PROCEDURE|Endometrial Biopsy|The Local Endometrial Injury will be performed using the standard technique using a Pipelle sampling catheter in the outpatient department. After a speculum examination is performed and the cervix is well visualized, the Pipelle will be inserted gently through the cervical canal into the uterine cavity and advanced slowly until resistance is noted. At this point the internal piston is withdrawn to create negative suction and the Pipelle is gently maneuvered up and down alongside the uterine cavity wall. The Pipelle catheter is then withdrawn gently and any obtained specimen (uterine lining) will be sent for histopathological examination.
223612233|NCT02562716|DRUG|Fluorouracil|Given IV
223612234|NCT02562716|DRUG|Gemcitabine Hydrochloride|Given IV
223612235|NCT02562716|DRUG|Irinotecan Hydrochloride|Given IV
223612236|NCT02562716|DRUG|Oxaliplatin|Given IV
223612237|NCT02562716|DRUG|Paclitaxel Albumin-Stabilized Nanoparticle Formulation|Given IV
223612238|NCT02562716|PROCEDURE|Pancreatectomy|Undergo pancreatectomy
223612239|NCT04064658|PROCEDURE|Remote ischemic preconditioning|Remote ischemic preconditioning consisted of five 5-min cycles of bilateral arm ischemia/reperfusion, which is induced by a sphygmomanometer placed on bilateral arm and inflated to 200 mmHg for 5-min followed by deflating the cuff for 5-min.
223612240|NCT04064658|PROCEDURE|Sham remote ischemic preconditioning|Sham remote ischemic preconditioning consisted of five 5-min cycles of bilateral arm ischemia/reperfusion, which is induced by a sphygmomanometer placed on bilateral arm and inflated to 60 mmHg for 5-min followed by deflating the cuff for 5-min.
223612241|NCT04064658|PROCEDURE|Encephaloduroarteriosynangiosis|Encephaloduroarteriosynangiosis is an indirect revascularization surgery of moyamoya disease
223758460|NCT02829749|DEVICE|NeoChord beating heart mitral valve implantation|The NeoChord DS1000 procedure is performed in five steps: (1) Device Preparation; (2) Left Ventricular Access; (3) Leaflet Capture and Verification; (4) Suture Deployment and (5) Suture Closure. The sutures are placed via a ventriculotomy 2-4 cm postero-lateral from the apex of the left ventricle via thoracotomy. The procedure is performed on a beating heart through a 2 to 3 inch right antero-lateral thoracotomy, then one to five Goretex neochordae are introduced with a transcatheter delivery system through the apex of the heart, into the left ventricle, and fixed on the free edge of the prolapsed leaflet. This is performed with transesophageal echocardiographic guidance.
223758461|NCT02829749|PROCEDURE|Control|traditional mitral valve repair performed under cardiac arrest
223758462|NCT04026906|DEVICE|Cyanoacrylate glue|One drop of cyanoacrylate glue will be applied to the intravenous (IV) insertion site and another drop under the hub of the IV catheter
223758463|NCT04026906|OTHER|Transparent polyurethane dressing|The IV will be secured in the usual manner with tape and a transparent dressing.
223758464|NCT02332551|DEVICE|NanoKnife|Irreversible electroporation (IRE) is a new, minima-invasive image-guided treatment method for tumors not amenable for surgical resection or thermal ablation, due to vicinity near vital structures such as vessels,bile ducts and the gallbladder .
223612242|NCT05318261|PROCEDURE|Spontaneous breathing trial|A spontaneous breathing trial (SBT) is used to identify patients who are likely to fail liberation from mechanical ventilation. The test can be done according to the usual modalities of the participating centre, following the international recommendations, meaning either by disconnecting the endotracheal tube from the ventilator and connecting it to a source of oxygen through the T-tube or by setting pressure support with low positive end-expiratory pressure (PEEP). The choice of the method will not be determined according to the participation in this study but will be done according to the habits of the participating centre.
223758465|NCT00847496|DEVICE|AWBAT|One-time application of dressing over partial-thickness burns
223509387|NCT00743080|PROCEDURE|Laparoscopic myomectomy and supracervical hysterectomy with GYNECARE MORCELLEX|"Laparoscopic myomectomy with GYNECARE MORCELLEX: Laparoscopic approach. Longitudinal incision close to the midline of myoma. Identification of cleavage plane. Enucleation of myoma. Suturing myometrial. Removal of myoma with a automatic morcellator (GYNECARE MORCELLEX).~Laparoscopic supracervical hysterectomy using GYNECARE MORCELLEX: Laparoscopic approach. Use of bipolar diathermy and scissor starting with the round ligament and then the utero-ovarian ligament, otherwise the infundibulopelvic ligament in case of removal of adnexa. Identification, desiccation with polar diathermy, and transection of the uterine vessels. Repetition of the procedure on the contra-lateral side. Opening of vagina just below uterine vessels using an unipolar needle. Removal of uterus by means of GYNECARE MORCELLEX. Abdominal cavity irrigation."
223509388|NCT00743080|PROCEDURE|Laparoscopic myomectomy and supracervical hysterectomy with ROTOCUT G1|"Laparoscopic myomectomy with ROTOCUT G1: Laparoscopic approach. Longitudinal incision close to the midline of myoma. Identification of cleavage plane. Enucleation of myoma. Suturing myometrial. Removal of myoma with a automatic morcellator (ROTOCUT G1).~Laparoscopic supracervical hysterectomy using ROTOCUT G1: Laparoscopic approach. Use of bipolar diathermy and scissor starting with the round ligament and then the utero-ovarian ligament, otherwise the infundibulopelvic ligament in case of removal of adnexa. Identification, desiccation with polar diathermy, and transection of the uterine vessels. Repetition of the procedure on the contra-lateral side. Opening of vagina just below uterine vessels using an unipolar needle. Removal of uterus by means of ROTOCUT G1. Abdominal cavity irrigation."
223612243|NCT01539759|DEVICE|Immediate Postplacental Placement of an IUD during cesarean delivery|Women randomized to this arm will have an IUD placed during their cesarean delivery, immediately after delivery of the placenta
223758466|NCT00847496|DEVICE|Biobrane|One-time application over partial-thickness burns
223758467|NCT01784783|BEHAVIORAL|HOPE Intervention|"If the male partner chooses not to complete the study questionnaire, he may decline and participate only in the HOPE intervention component of the study. (This does not preclude the possibility of the female partner continuing to participate in the study.) Investigators anticipate that this will occur and also expect that some women and male partners randomized to the intervention arm will refuse the HOPE intervention when offered. Study staff will attempt to collect data on reasons for refusal to participate and will continue to follow these couples through 6 months postpartum to collect maternal and infant outcome data, provided the female partner does not withdraw from the study.~Key educational messages will be presented using an electronic tablet highlighting key messages and will include with relevant images as visual aids. This will help to facilitate comprehension and ensure that all relevant materials are covered during each intervention session."
223758468|NCT01784783|BEHAVIORAL|INVITE Intervention|Women will receive a clinic invitation to give to their male partners to attend the next antenatal visit for couple HIV counseling and testing.
223758469|NCT04679077|OTHER|Cytocam-IDF imaging device|Observation of the microcirculation
223758470|NCT04210635|OTHER|ZEN cart|essential oils + relaxing music + dim light
224201371|NCT06110767|DEVICE|non-immersive virtual reality|Non-Immersive Virtual Reality Based Physical Activity Application: Application will be carried out 3 days a week, 30 minutes a day, for 4 weeks. Kinect Adventures and Kinect Sports game packages will be used using the Microsoft Kinect Xbox 360 game console. It is planned that the participants will engage in physical activity with these game packages.
224201372|NCT06110767|BEHAVIORAL|Healty Diet Programme|Healthy nutrition program: It will be implemented for 4 weeks.Healthy Nutrition Program: Türkiye Ministry of Health nutrition program will be prepared based on the recommendations of the Turkey Nutrition Guide published by the Ministry of Health in 2016 (TÜBER-2016). A personalized healthy nutrition program will be created in line with this guide, taking into account the age, gender and physical activity status of healthy individuals.
224201373|NCT03933046|DIAGNOSTIC_TEST|PSG|polysomnography and urine analaysis for protein levels
224201374|NCT06137339|OTHER|Avocado Group|Participants will consume provided avocados daily and track consumption for the duration of the study. Participants will be adding avocados to their diet and will receive education on maintaining usual diet.
224201375|NCT00337155|DRUG|Radium-223 dichloride (BAY88-8223)|3 doses of radium-223 at different dose levels, 25, 50 or 80 kBq/kg b.w.given as injection.
224201376|NCT04285736|DRUG|Ivabradine|Ivabradine (5mg twice daily)
224201377|NCT04285736|DRUG|Conventional Treatment|
224205953|NCT06375954|DEVICE|Self-expandable metallic stent (SEMS)|"Self-expandable metallic stent (SEMS) deployment:~* Covering: Uncovered or Partially Covered. Non covered if gallbladder is present.~* Size: 10x40mm or 10x60mm or 10x80mm."
223509389|NCT01292473|DRUG|Placebo|Placebo was supplied lyophilized in vials.
223509390|NCT01292473|DRUG|Omalizumab|Omalizumab was supplied lyophilized in vials.
223509391|NCT01216280|DRUG|placebo capsule|2 x 10 mg placebo capsules administered orally with water, b.i.d.
223509392|NCT01216280|DRUG|10 mg Natura-alpha capsule and 10 mg placebo capsule|10 mg Natura-alpha capsule and 10 mg placebo capsule administered orally with water, b.i.d.
223509393|NCT01216280|DRUG|2 x 10 mg Natura-alpha capsules|2 x 10mg Natura-alpha capsules administered orally with water, b.i.d.
223509394|NCT06174532|PROCEDURE|Traditional Medthod|Before surgery, the patient's lower jawbone tumor is replicated using a 3D-printed original model without adjustments. Then, the model undergoes manual modification by drilling and adjusting the jawbone model at the tumor site using drills and manual instruments. Subsequently, the reconstructed model is formed preoperatively based on this modified model. During surgery, the patient isn't guided by surgical guides, and the incision lines are relatively dependent on the surgeon. Additionally, while fixing the remaining bone after the sectioning, the surgeon uses pre-bent fixation plates made earlier to assist in stabilizing the bone.
223758471|NCT03298828|BIOLOGICAL|CD19 CAR and PD-1 knock out engineered T-cells|A single dose of 1 x 10\^6/kg CD19 CAR transduced and PD-1 knock out engineered T-cells will be given as an intravenous injection through a Hickman line or PICC line(peripherally inserted central catheter) on day 0.
223758472|NCT03298828|BIOLOGICAL|CD19 CAR T-cells|A single dose of 1 x 10\^6/kg CD19 CAR transduced T-cells will be given as an intravenous injection through a Hickman line or PICC line(peripherally inserted central catheter) on day 0.
223758473|NCT00254995|BIOLOGICAL|None administered in this study|N/A in this study
223758474|NCT01470846|PROCEDURE|epidural analgesia|thoracic position (T8-T9 or T11-T12) depending on the site of surgery
223612244|NCT02446184|PROCEDURE|Fetal Cystoscopy|Fetal cystoscopy will be performed under maternal local anesthesia and fetal anesthesia. The dilated posterior urethra will be directly evaluated. Laser fulguration will be performed in case of posterior urethral valves. However, if a non membrane-like structure is found, even with the fluid injection or the guide-wire, urethral atresia (UA, US or Prune Belly syndrome) will be diagnosed and we will not attempt to perforate this structure. A vesicoamniotic shunting placement will be performed in this situation depending on the patient's consent prior to the surgery.
223612245|NCT02446184|PROCEDURE|Fetal vesicoamniotic shunt|Fetal vesicoamniotic shunt will be performed under ultrasound guidance
223612246|NCT01425801|DRUG|LAS100977 0.313 μg|Dry powder inhalation, once-daily, single-dose
223758475|NCT01470846|PROCEDURE|PCA|Morphine 2 mg / 10 min (no max dose) + droperidol 2.5 mg / 50 mL.
223758476|NCT01489969|DRUG|Neu-P11|1 tablet daily 1-2 before bed time for 28 days of double blind treatment
223758477|NCT06255652|DRUG|Cephradin|Velosef
223758478|NCT01911507|DRUG|INC280|Given PO
223758479|NCT01911507|DRUG|erlotinib hydrochloride|Given PO
223758480|NCT04763499|OTHER|freeze dried strawberry powder|approximately 24 strawberries that have been freeze dried into a powder
223758481|NCT02223767|DEVICE|Experimental: Verum TMS|Intensity of 100 % of the resting motor threshold with 10 Hz and intertrial interval (ITI) of 26 s. 1560 pulse in 40 trains at all . One train lasts 4 s.
223758482|NCT02223767|DEVICE|Experimental: Sham TMS|Sham stimulation with 10 Hz and ITI of 26 s. 1560 pulse in 40 trains at all . One train lasts 4 s.
223758483|NCT00853177|PROCEDURE|MEOPA inhalation|N2O of 50% and 50% O2
223758484|NCT00853177|PROCEDURE|xylocaine|Ampoule-bottle of 20 ml
223612247|NCT01425801|DRUG|LAS100977 0.625 μg|Dry powder inhalation, once-daily, single-dose
223758485|NCT04702373|OTHER|passive range of motion exercise therapy|Systematic flexion-extension with gentle compression at the end of the movement is performed 10 times at the wrist, elbow, shoulder, ankle, knee, and hip joints. Ten repetitions of adduction-abduction are performed at the shoulder and hip joints.
223758486|NCT06305533|DEVICE|LASER disinfection|In test group 1, the diode Laser will be used to disinfect the inner layer of the pockets and thus reducing the microbial load. Diode laser (Biolase, EpicX, BIOLASE, Inc, USA) settings will be as follows: wavelength: 940nm; power: 1W; 300μm uninitiated fibers; continuous radiation mode; and energy level: 80 J/s. The laser fibers then will be inserted into the pockets in such a way that they will be in contact with the soft tissue wall of the pockets and parallel to the root surface and then will be moved to the apical surface through a horizontal sweeping motion (1mm/s) while remaining in contact with the soft tissue wall of the pockets.
223758487|NCT06305533|DEVICE|Photodynamic therapy|the second test group will receive additional adjunctive aPDT using a ICG photosensitizer activated with diode laser. In details, pockets will be irrigated by a syringe loaded with an ICG photosensitizer solution (Verdye, Diagnostic green, Germany) at a concentration of 5mg/ml. The ICG solution will be allowed to stay in the pockets for 2min, and washing out excess solution from the pockets before laser irradiation. Afterwards, a 300μm bulb optical fibre of the 810nm diode laser unit (QuickLase, United Kingdom) set at 300mw in pulsed mode (100ms ON/100ms OFF) will be inserted along the pocket and activated for 30s with continuous vertical movements from the bottom of the pocket to the gingival margin
224311889|NCT02338804|OTHER|standard treatment|Patient will receive a comprehensive histological and imaging check up to evaluate the histological type, stage of the disease and performance status. Then the patient will receive standard treatment, in brief, surgical resection for early stage patients and systemic treatment including chemotherapy for advanced stage patients, according to NCCN guide line.
223612248|NCT01425801|DRUG|LAS100977 1.25 μg|Dry powder inhalation, once-daily, single-dose
223612249|NCT01425801|DRUG|LAS100977 2.5 μg|Dry powder inhalation, once-daily, single-dose
223612250|NCT01425801|DRUG|Salbutamol 400 μg|Pressurized inhalation suspension, once-daily, single-dose
223612251|NCT01425801|DRUG|Salbutamol placebo|Pressurized inhalation, once-daily
223612252|NCT01425801|DRUG|LAS100977 placebo|Dry powder inhalation, once-daily
223612253|NCT01960582|BEHAVIORAL|New Practice Strategy|Application of a structured case management strategy on housing adaptation cases
223612254|NCT02289638|DEVICE|Intubrite|Video-Laryngoscopy
223612255|NCT02289638|DEVICE|MIL|Direct-Laryngoscopy
223612256|NCT00721240|DRUG|montelukast|5mg montelukast once daily for 12 weeks
223758488|NCT06305533|PROCEDURE|Root surface debridement|For all groups, sites with initial PPD 4-6 mm will be treated with RSD using area specific (Graecy) curettes.
223758489|NCT00614796|BEHAVIORAL|Coach, using a stepcounter with exercise counseling|5 counseling meetings of 30 min in the first 3 months. In counseling, patients will be stimulated individually to enhance a physically active lifestyle.
223758490|NCT05932446|DRUG|LY3819469|Administered SC.
223758491|NCT04782778|DRUG|Bupivacaine 0.25% Injectable Solution|1 mg/kg Bupivacaine (0.25%)
223758492|NCT02403505|BIOLOGICAL|CEA protein antigen plus BCG Vaccine Mix for percutaneous use|"* By the percutaneous route with the multiple puncture device~* CEA protein antigen 0.05 mg plus BCG Organism 50 MG Mix"
223758493|NCT01654965|OTHER|Laboratory Biomarker Analysis|Correlative studies
223758494|NCT01654965|BIOLOGICAL|Pegfilgrastim|Given SC
223758495|NCT01654965|OTHER|Pharmacological Study|Correlative studies
223758496|NCT01654965|DRUG|Tivantinib|Given PO
223758497|NCT01654965|DRUG|Topotecan Hydrochloride|Given IV
223758498|NCT01674686|DRUG|Sarpogrelate|Sarpogrelate 100mg twice a day
223758499|NCT01674686|DRUG|Atorvastatin|Atorvastatin 80mg daily
223758500|NCT01410734|DRUG|Indocyanine green (ICG)|2.5mg indocyanine green (ICG) will be administerly (IV injection) 30 minutes before surgery
223758501|NCT06291558|OTHER|Exercise|The first 5 minutes of heating in the exercise program are planned to be implemented for 8 weeks, and the last 5 minutes are a cooling period. In the exercise program, which is planned to last 40 minutes in total, respiratory exercises will be applied to heating and cooling peryotes. As respiratory exercise, diaphragmatic respiratory exercise will be applied to heating and cooling peryots with 5 repetitions. Elastic resistant bands (Therand) will be used in resistant exercise training that will last for 30 minutes. The participants will be started to work with the resistance that they can do 10 again but cannot reach 14 repetitions. Elastic resistant bands are shoulder flexion, shoulder extension, shoulder ablution, shoulder horizontal abduction, elbow extension, hip ablution, hip flexion, and hip exercise. These exercises will be held once a week, 10 repetitions, 2 sets, for 8 weeks.
223758502|NCT02342704|DRUG|natalizumab|Administered as specified in the treatment arm
223758503|NCT02342704|DRUG|fingolimod|Administered as specified in the treatment arm
223758504|NCT05886569|DEVICE|DIGIPREDICT Physiopatech|Application of the DIGIPREDICT Physiopatch investigational device
223758505|NCT00614913|RADIATION|Proton radiation therapy|A total dose of 63 Gy will be delivered in 15 equally divided daily fractions over a 3 week coarse as an out-patient.
223758506|NCT02347527|BEHAVIORAL|Active Implicit Priming|A 10-minute implicit priming intervention, associating food images with images of positive or negative valence.
223758507|NCT02347527|BEHAVIORAL|Control Implicit Priming|A 10-minute implicit priming intervention, associating food images with images of neutral valence.
223758508|NCT05225896|GENETIC|Description of clinical characteristic and genetic tumors|"This is a non-interventional study involving clinical data and biological samples (DNA). Clinical data are collected for the center and samples are already stored in biobank repositories and collected as part of good clinical practice in the diagnostic process of patients with suspected autoimmune encephalitis, meaning that the standard diagnostic and therapeutic approaches will not be altered in the selected study population. Patients have already gave explicit written consent for biological specimens sampling and storage at the Centre de Ressources Biologiques des Hospices Civils de Lyon (CRB-HCL) (including tissue, cells or biological fluids) and genetic analysis for research purposes. Additionally, patients will be informed about the present study."
223758509|NCT03106207|PROCEDURE|Upper gastric endoscopy (UGE)|UGE will be performed before the gastric bypass surgery and post-surgery at two, six and 12 months of clinical visit.
223758510|NCT02515266|OTHER|nutrition: protein intake|additional protein fortification of human milk
223758511|NCT03843684|DEVICE|3D-printed foot orthoses|3D printed foot orthoses with arch support
223758512|NCT03843684|DEVICE|5 degrees lateral wedge insoles|Insoles with a lateral inclination set at 5 degrees
223758513|NCT01358318|OTHER|Satiety|Single consumption of snack bars to determine satiety and food intake at next meal.
223758514|NCT01878539|DEVICE|coagulometer|
223758515|NCT01878539|BEHAVIORAL|training programme|
223758516|NCT01456325|DRUG|Erlotinib|Participants will receive erlotinib 150 mg tablet orally once daily from Day 1, Cycle 1.
223758517|NCT01456325|DRUG|Onartuzumab (MetMab)|Participants will receive onartuzumab 15 mg/kg IV infusion on Day 1 of every 3-week cycle.
223758518|NCT01456325|DRUG|Placebo|Participants will receive onartuzumab matching placebo on Day 1 of every 3-week cycle.
223758519|NCT01819805|DRUG|No intervention|This is an observational study. Patients taking extended release tramadol hydrochloride 75 mg and acetaminophen 650 mg orally twice daily will be observed.
223758520|NCT00189046|BEHAVIORAL|driving and laboratory tests|
223758521|NCT03793907|DEVICE|FitBit|Wear Fitbit
223758522|NCT03793907|OTHER|Quality-of-Life Assessment|Ancillary studies
223758523|NCT03793907|OTHER|Questionnaire Administration|Ancillary studies
223758524|NCT03793907|OTHER|Resistance Training|Complete strength training
223758525|NCT03793907|BEHAVIORAL|STEPS to Enhance Physical Activity|Complete a walking program
223758526|NCT00302003|RADIATION|radiation therapy|Undergo radiation therapy
223758527|NCT00302003|DRUG|doxorubicin hydrochloride|Given IV
223758528|NCT00302003|DRUG|vincristine sulfate|Given IV
223758529|NCT00302003|DRUG|prednisone|Given orally
223758530|NCT00302003|DRUG|cyclophosphamide|Given IV
223758531|NCT00302003|DRUG|ifosfamide|Given IV
223758532|NCT00302003|DRUG|vinorelbine tartrate|Given IV
223758533|NCT00302003|DRUG|dexamethasone|Given IV
223758534|NCT00302003|DRUG|etoposide phosphate|Given IV
223758535|NCT00302003|DRUG|cisplatin|Given IV
223758536|NCT00302003|DRUG|cytarabine|Given IV
223758537|NCT00302003|BIOLOGICAL|filgrastim|Given IV or subcutaneously
223758538|NCT00514410|DRUG|Folic Acid|Folic acid 5 mg once a day for three months as a supplement to their antidepressant treatment
223758539|NCT00514410|DRUG|Placebo|Matching placebo taken once a day for three months
223758540|NCT05365438|DRUG|Omega 3-Atorvastatin|Atmeg 2 capsules with 1 pack of Omethyl cutielet
223758541|NCT05365438|DRUG|Omega 3-Atorvastatin|Atmeg 2 capsules
223758542|NCT05365438|DRUG|Atorvastatin-Ezetimibe|ezetimibe/atorvastatin 10/20 mg
223758543|NCT06441734|DIAGNOSTIC_TEST|cbc serum ferritin serum iron|by using sample of blood to do cbc and serum ferritin and serum iron during 1year
223758544|NCT00283439|BIOLOGICAL|AMG 531|"Planned Cohorts:~1. 100 mcg,~2. 300 mcg,~3. 700 mcg,~4. 1000 mcg;~   Optional Cohorts:~5. cohort expansion,~6. schedule change,~7. new dose"
223758545|NCT02042924|RADIATION|FLT PET/CT|Functional marrow imaging using the FLT PET/CT will be performed prior to preparative for HSCT and approximately 3 months post-transplant (Day 100 +/- 5 days).
223758546|NCT02042924|DEVICE|MRI|MRI imaging will be performed prior to preparative for HSCT and approximately 3 months post-transplant (Day 100 +/- 5 days).
223758547|NCT06391866|OTHER|extracorporeal circulation|extracorporeal circulation during cardiosurgical operation
223758548|NCT03111420|DRUG|P2Y12 inhibitor|Administration of P2Y12 inhibitor antiplatelet therapy
223758549|NCT03111420|DEVICE|Platelet function test|Blood is drawn for testing of platelet aggregation activity
223758550|NCT03310424|OTHER|No active intervention.|No active intervention is undertaken. Collection of samples for bio-informatic analysis only
223758551|NCT06096415|DRUG|ABX-101 1mg|ABX-101 1mg will be provided to patients stratified 1:1 by GCS scoring (GCS 4-8; GCS 9-12)
223758552|NCT06096415|DRUG|ABX-101 2mg|ABX-101 2mg will be provided to patients stratified 1:1 by GCS scoring (GCS 4-8; GCS 9-12)
223758553|NCT01632891|DRUG|Lopinavir/ritonavir|Participants received two 200 mg/50 mg tablets of lopinavir/ritonavir orally twice daily.
223509395|NCT06174532|PROCEDURE|Virtual surgical planning|Before surgery, the patient's lower jawbone is 3D-printed, designed to remove the tumor mass, and create a suitable margin for reconstructive plate bending. Subsequently, the reconstruction plate is pre-bent preoperatively based on this model. During surgery, the patient is guided by specific surgical guiding tools: cutting guides. Additionally, while fixing the remaining bone after sectioning, the surgeon is assisted by bone fixation instruments to stabilize the alignment of the two bone fragments according to anatomical structure and then proceeds to use pre-bent reconstruction plates to secure the bone.
223509396|NCT05033535|DRUG|Sacubatril Allisartan medoxomil|Sacubatril Allisartan medoxomil ：A randomized, double-blind, placebo and positive drug parallel controlled, multi-center phase II clinical study on the effectiveness and safety of treating mild and moderate essential hypertension
223509397|NCT05033535|DRUG|Olmesartan Medoxomil|Efficacy for lowering blood pressure of Olmesartan medoxomil
223509398|NCT02238327|PROCEDURE|blood draw|Blood will be drawn for plasma, serum, and PBMCs. Clinical labs drawn will be for hepatitis, CMV, hemoglobin and carboxyhemoglobin.
223509399|NCT02238327|PROCEDURE|questionnaires|The following questionnaires are administered to participants by study personnel at each visit: LEAP questionnaire, St. George's, and MMRC.
223509400|NCT02238327|PROCEDURE|Lung function testing|The routine lung function endpoints of FVC, FEV1, FEV1/FVC, and FEF25-75% will be measured before and after bronchodilator administration (4 puffs of albuterol). The best of three reproducible forced expiratory attempts is used in analysis. Percent- predicted spirometric values are based on age, height, gender, and ethnicity. DLco will be measured using the automated single-breath procedure of the integrated testing system, which conforms to ATS standards. DLco will be adjusted for hemoglobin and carboxyhemoglobin.
223509401|NCT02238327|PROCEDURE|Six-Minute walk test|Six-minute walk tests are performed in a 100 foot (30.48 m) segment of straight hallway marked at 10 foot (3 m) intervals. In addition to the usual ATS protocol, the patient is monitored, when available, with Bluetooth wireless pulse oximetry and the time and distance recorded after six minutes and if they desaturate to \<88%. Dyspnea (Borg 0-10) and perceived exertion (Borg 6-20) scales are completed at the beginning and the end of test.
223509402|NCT02238327|RADIATION|Quantitative CT scans|Subjects will undergo a standard chest CT. The CT scans will use a phantom shipped between sites to standardize results and capture contiguous volume scans acquired at slice thicknesses of 5.0 mm in the axial plane and reconstructed with 512 x 512 pixel matrices. CT examinations will encompass the entire thorax and be performed during a breath-hold at end-inspiration. We will measure % of lung tissue below a threshold for emphysema (i.e. -950 Hounsfield units). Measurements have been histologically-verified and give reproducible measurements. The data set is assembled and analyzed with the image data anonymized.
223509403|NCT02238327|PROCEDURE|Nasal secretion and cell collection|Participants will be instructed to blow their nose to remove accumulated mucus. Two sprays of commercially available nasal saline will be instilled in each nostril. The participant will then be ask to exhale through the rinsed nostril into a specimen cup. We will repeat this up to 5 times on each side depending on the participants' tolerance to the procedure. Using an otoscope, a small curette will then be used to collect 3 to 5 samples of nasal cells from each nostril. These samples will be used immediately for analysis or banked for future study.
223509404|NCT02238327|PROCEDURE|Echocardiogram|The cardiac ultrasound will use standard ultrasound techniques to image two-dimensional slices of the heart using 3D real-time imaging.
223509405|NCT01933516|DRUG|GP2013|GP2013
223509406|NCT01128920|BEHAVIORAL|Skin and Needle Hygiene Intervention|Intervention incorporates psychoeducation, correction of false beliefs, counseling to counteract barriers to hygienic practices, motivational enhancement, and behavioral skills training in hygiene practices
223509407|NCT01128920|OTHER|No intervention - assessment-only condition|No intervention is assigned in this condition
223509408|NCT00548691|DRUG|Ferric Carboxymaltose|
223509409|NCT00548691|DRUG|Standard Medical Care (SMC)|
223509410|NCT05055427|DRUG|Shen Cao Gan Jiang Tang (Gan Cao Gan Jiang Tang with Ginseng)|"Patients take Shen Cao Gan Jiang Tang (Gan Cao Gan Jiang Tang with Ginseng), one bag of decoction (90ml) two times a day for 10 days. In additional, patients also receive the Standard of Care (SOC) for the treatment of COVID-19 based on the Vietnam Ministry of Health guideline.~Ingredients per formula (tang): 12 grams of honey-fried Radix Glycyrrhizae, 6 grams of Rhizoma Zingiberis (stir-baked), 6 grams of Panax Ginseng. The decoction of concentrated extract is packed into aluminum foil vacuum bag, 90ml per bag, 1 formula (tang) is equivalent to 2 bags. Patients use the decoction directly from the bag.~Daily dose: 1 bag per time, 2 times per day"
223509411|NCT03702595|OTHER|Hip flexors stretching protocol|Stretching protocol of rectus femoris, vastus lateralis and iliopsoas according to Kaltenborn- Evjenth Orthopaedic Manual Therapy Concept (OMT)
223509412|NCT04334681|PROCEDURE|Un-roofing curettage method|In this method, the roof of the pilonidal cyst is opened, and the inside is cleaned, and curettage is performed. The wound is closed with a dressing after hemostasis.
223509413|NCT04334681|PROCEDURE|Modified Limberg Flap Group|In this method, the pilonidal cyst is excised with a rhomboid incision and closed with the modified Limberg flap method.
223509414|NCT01818310|BIOLOGICAL|Group A: Intramuscular|"Intramuscular BMAC application The study subjects in the Group A will receive a treatment of 35ml BMAC administered intramuscularly into the affected limb, in individual punctures of 1 ml.~The punctures will be applied into the crural muscle around the defect, the procedure takes approx. 60 minutes."
223758554|NCT01632891|DRUG|Emtricitabine/tenofovir disoproxil fumarate|Participants received one 200 mg/300 mg tablet of Emtricitabine/tenofovir disoproxil fumarate orally once daily.
223758555|NCT01632891|DRUG|Efavirenz|Participants received one 600 mg tablet of efavirenz orally once daily.
223758556|NCT01632891|DRUG|Nevirapine|If unable to take efavirenz, participants received on 200 mg tablet of nevirapine orally once daily.
223758557|NCT01632891|DRUG|Trimethoprim/sulfamethoxazole|Participants received one 160 mg/800 mg tablet of trimethoprim/sulfamethoxazole orally once daily.
223758558|NCT04188262|COMBINATION_PRODUCT|NVS Therapy|Combination Product: NVS Therapy which includes NVS Injection (investigational product) and the following investigational devices: NVS Delivery Catheter, NVS light Fiber, and NVS light source.
223758559|NCT04915781|OTHER|Not applicable, this is an observational study|Not applicable, this is an observational study
223509415|NCT01818310|BIOLOGICAL|Group B: Intraarterial|Intraarterial BMAC application The study subjects in the Group B will receive a treatment of 35ml BMAC administered intraarterially into the affected limb.
223509416|NCT01818310|BIOLOGICAL|Group C: Intravenous|Group C: Intravenous The study subjects in the Group C will receive a treatment of 35ml BMAC administered intravenously into the affected limb.
223509417|NCT01818310|PROCEDURE|Group D: Surgical endovascular treatment with maximum medicamentous treatment|Group D: Control Group Control Group - no experimental intervention, standard endovascular treatment or bypass surgery or maximum medicamentous treatment
223509418|NCT01744626|DRUG|CC-292|Cohort 1: 375 mg CC-292 will be administered twice a day on Days 1-28 Cohort 2: 500 mg CC-292 will be administered twice a day on Days 1-28
223509419|NCT01744626|DRUG|Rituximab|Cohort 1: Rituximab once per cycle Cohort 2: Rituximab once per cycle
223509420|NCT02123511|DRUG|acetylcysteine|Oral rinse
223509421|NCT02123511|OTHER|placebo|Oral rinse
223509422|NCT02123511|OTHER|quality-of-life assessment|Ancillary studies
223509423|NCT02123511|OTHER|questionnaire administration|Ancillary studies
223509424|NCT06164600|DIETARY_SUPPLEMENT|Bovine colostrum|A powdered form of the first 6 hours bovine colostrum \[65 mg lactoferrin, lactoperoxidase: 2.8 unit and immunoglobulins in the form of 350 mg IgG, 35.3 mg of Ig A and 25.3 mg Ig M\]
223509425|NCT06164600|DRUG|Placebo|Oral placebo sachets will be provided by ImmuGuard® manufacturing company.
223509426|NCT00049309|DIETARY_SUPPLEMENT|dietary intervention|
223509427|NCT00049309|DIETARY_SUPPLEMENT|flaxseed|
223509428|NCT00265005|DRUG|alteplase|Iv administration of 1 mg/ml up to two times and 2 mg/ml if needed.
223509429|NCT03903770|DEVICE|Upper extremity rehabilitation|Participants receive the SUPER intervention 3 times per week for 1 hr, during 4 weeks. For participants with a low recovery potential for hand function, the SUPER interventions consists in robot-assisted reaching movements and unilateral and bilateral VR activities. The robot-assisted activity consists of a reaching task to six targets placed at maximal reach distance. For the VR activity, we use a reach and grasp VR activity based on a shopping task. Participants with good potential for hand recovery also receive 30 min of electromyography-triggered muscle stimulation, combined with the VR activity. The muscle stimulation is triggered when the participant attempts to grasp a virtual object and helps with hand opening movements.
223509430|NCT05038514|OTHER|musıc therapy|After the prone position was given to the patients, according to the randomization table, the intervention group was given 30 minutes by the nurse. nature-based music therapy will be applied.
223509431|NCT06344169|DRUG|Sebacoyl Dinalbuphine Ester|SDE will be dissolved in benzyl benzoate and sesame oil (a total volume of 2ml) will be prepared in a 5-ml syringe 30 min before administration. Intramuscular injection into the gluteal muscles will be performed by an anesthesiologist under sonography-guidance
223509432|NCT06344169|DRUG|Morphine|A single dose of morphine (0.15mg) will be administered along with bupivacaine during spinal anesthesia.
223509433|NCT04695782|RADIATION|Pencil beam proton radiotherapy|Doseescalated pencil beam proton Therapy
223509434|NCT02284854|DRUG|BIA 2-093|
223509435|NCT02284854|DRUG|Carbamazepine|
223509436|NCT02551809|BIOLOGICAL|UB-311|Intramuscular injection
223509437|NCT02551809|DRUG|Placebo|Intramuscular injection
223509438|NCT03777176|DRUG|Dasiglucagon|Glucagon analog
223509439|NCT03777176|OTHER|Standard of Care|Standard of care according to site and/or country
223509440|NCT00322426|DEVICE|Sensory Cueing Device|
223509441|NCT05230654|DRUG|Fosaprepitant|Fosaprepitant: 4 mg/kg IV Granisetron+dexamethasone: granisetron:40mcg/kg, IV ; dexamethasone : S\<0.6m2, 2 mg/dose, q12h IV/PO; S\>0.6m2, 4 mg/dose, q12h , IV/PO. When used with fosaprepitant, dexamethasone dose was halved.
223509442|NCT05230654|DRUG|Placebo(normal saline)|Placebo(normal saline): 4 ml/kg IV Granisetron+dexamethasone: granisetron:40mcg/kg, IV ; dexamethasone : S\<0.6m2, 2 mg/dose, q12h IV/PO; S\>0.6m2, 4 mg/dose, q12h , IV/PO.
223509443|NCT02688335|DEVICE|Cloud9|Low-pressure Continuous Positive Airway Pressure (CPAP = 2 - 4 cm H2O).
223509444|NCT03385642|DEVICE|ChondroMimetic|ChondroMimetic is a single-use, biphasic implant that serves as an osteochondral scaffold for the repair of cartilage defects in the knee
223509445|NCT01546779|DEVICE|Tri-Gym|40 CF patients performed airway clearance using the VISex, by exhaling against chosen resistance being motivated by visual feedback of raising colored balls. The level of resistance was set to cause longest expiration/volume, until mucus was transported from the peripheral to the central airways, to be expectorated by the subsequent cough.
223509446|NCT02531711|OTHER|Diet A|Experimental analgesic dietary intervention
223758560|NCT05498558|OTHER|No intervention.|No intervention.
223758561|NCT00481728|DRUG|Tolterodine|Single dose per patient as determined by protocol.
223758562|NCT00481728|PROCEDURE|Filling cystometry|This is a procedure.
223758563|NCT00481728|PROCEDURE|Intravesical neurostimulation|This is a procedure.
223758564|NCT01907633|DRUG|No intervention|This is an observational and a retrospective study of existing data, so there will be no interventions. The exposure groups will be domperidone, proton pump inhibitors (omeprazole, lansoprazole, esomeprazole, rabeprazole, and pantoprazole), and metoclopramide.
223758565|NCT02919670|DIETARY_SUPPLEMENT|Enterade|
223758566|NCT02919670|DIETARY_SUPPLEMENT|Placebo|
223758567|NCT02919670|OTHER|Standard Supportive Care|
223758568|NCT02304042|DRUG|Carbetocin|Carbetocin will be given slowly iv after delivery of the anterior shoulder.
223758569|NCT02304042|DRUG|Oxytocin|Oxytocin will be given slowly iv after delivery of the anterior shoulder.
224311890|NCT02737904|OTHER|APT|APT for 30 minutes per day on 5 days per week for 4 weeks: 2 minute warm up consisting of passive cycling, where the legs of the participant are moved passively by the APT at 10 revolutions per min (rpm). Next, the participant will cycle for up to 26 minutes, at 60rpm. In this phase, the participant is required to actively cycle and to maintain a symmetrical pattern of movement using the feedback on the display. If the participant is unable to actively cycle at any point during the 26 minute exercise period, or if they have a spasm, the MOTOmed APT will revert to the passive mode. The final phase is a cool down where participants again will have 2 minutes of passive cycling at 10rpm.
224311891|NCT02737904|OTHER|Usual care|Personalised in-patient rehabilitation programme
224311892|NCT01054404|DRUG|Furosemide|Furosemide 0.3 mg/kg
223758570|NCT00240071|DRUG|Avastin|All patients will received Avastin 15 mg/kg IV every three weeks. The first evaluation will be done at Week 6. Patients with objective response or stable disease will continue therapy with restaging every 6 weeks until evidence of disease progression. Patients with progression of disease will be taken off study.
224311893|NCT01054404|DRUG|Placebo|Placebo (up to 5mL)
223758571|NCT00240071|DRUG|Hormonal therapy|aromatase inhibitor (letrozole 2.5mg/d PO, anastrazole 1mg/d PO, or exemestane 25mg/d PO)or Selective Estrogen Receptor Modulator (SERM) (tamoxifen 20mg/d PO)
223758572|NCT04858958|DRUG|Furmonertinib 160mg|randomized to 160mg QD
223509447|NCT02531711|OTHER|Diet B|Healthy comparator diet
223509448|NCT01749293|PROCEDURE|Haploidentical Transplant|Subjects will be dosed with pre-transplant Fludarabine (180mg/m2)and Busulfan total AUC 2400 μmol\*min/L or 6.4mg/kg. Subjects will then undergo total body irradiation 2Gy. Subjects will undergo haploidentical allogeneic bone marrow transplant, followed by Cyclophosphamide, Tacrolimus and MMF based GVHD prophylaxis.
223509449|NCT01749293|DRUG|Fludarabine|Subjects in this trial will receive Fludarabine 30 mg/m2 IV QD, adjusted for CrCl from Days -8 through -3.
223509450|NCT01749293|DRUG|Busulfan|Subjects in this trial will receive Busulfan total AUC 2400 μmol\*min/L or 6.4mg/kg in 4 doses with seizure prophylaxis from Days -6 through -3.
223509451|NCT01749293|RADIATION|Total Body Irradiation|Subjects in this trial will receive total body irradiation (2Gy fractionated) from Day -2 or -1.
223509452|NCT01749293|DRUG|Cyclophosphamide|Subjects in this trial will receive Cyclophosphamide 50 mg/kg IV QD on Days 3 and 4 post-transplant.
223509453|NCT06135012|DEVICE|Cavitron ultrasonic surgical aspirator (CUSA)|Transection of pancreatic tissue with cavitron ultrasonic surgical aspirator (CUSA).
223509454|NCT06135012|OTHER|Scalpel|Transection of pancreatic tissue with scalpel.
224311894|NCT00880789|BIOLOGICAL|CMV/AdV specific T cells|CTL Dose Given from Day +30 post SCT (stem cell transplant). For the trial, two patients are allocated in each cohort and are followed for 30 days post IV injection of transduced T-cells for evaluation of DLTs. A maximum 18 patients will be accrued into each group. The final MTD will be the dose with probability closest to the target toxicity rate at these termination points. The trial continues until a minimum of 12 patients have been treated. The trial will stop when the maximum 18 patients have been treated, or when six patients have been treated at the current MTD. We therefore expect to enroll between 12-18 patients into this trial.
224311895|NCT02518672|DIETARY_SUPPLEMENT|MAG-DHA|MAG-DHA 8 x 625 mg softgels by mouth, every day at bedtime for 90 days.
224311896|NCT02518672|DIETARY_SUPPLEMENT|Placebo|Placebo (sunflower oil) 8 x 625 mg softgels by mouth, every day at bedtime for 90 days.
224311897|NCT02876757|DRUG|5ARI|Exposure to finasteride/dutasteride
224311898|NCT02630979|BEHAVIORAL|Measuring satisfaction, knowledge and bias|Questionnaire based assessment.
224311899|NCT03016975|DEVICE|Edwards Cardioband System|Transcatheter mitral valve repair with the Edwards Cardioband System
224311900|NCT03016975|DRUG|Guideline Directed Medical Therapy|GDMT Only
223509455|NCT06034431|OTHER|Ride Share|"The Investigators' proposed study addresses the Prostate Cancer Research Program overarching challenge of Advancing Health Equity and Reducing Disparities in PCa by examining and addressing travel burden to PCa treatment centers. Investigators will focus on Black men (including those of Caribbean descent), a high-risk population experiencing poorer health outcomes for unjust and preventable reasons.~This research will inform efforts to reduce travel burden in the healthcare acquisition process and improve the timeliness of treatment in Black men with PCa in Massachusetts and other states. This project will improve the quality of life and enhance outcomes and overall health and wellness for this group. Investigators will use findings from this pilot study to obtain future funding for a multicenter randomized clinical trial that will estimate the effect of equity - oriented programs that remove transportation barriers to treatment and reduce Black-White disparities in PCa outcomes"
223509456|NCT05604157|OTHER|Use of Tourniquet|Application of tourniquet or not in adults undergoing a primary total knee replacement.
223509457|NCT03418363|DIETARY_SUPPLEMENT|DHEA Oral Capsule|Daily 100mg DHEA supplement
223509458|NCT03418363|OTHER|Placebo Oral Capsule|Daily oral capsule
223509459|NCT02898831|OTHER|Cold Compress|Cold Compress placed on lower abdomen prior to and during IUD insertion.
223509460|NCT01975285|DRUG|Dexamethasone|0.5% Bupivacaine with 1:200,000 epinephrine + Dexamethasone 4mg per 20cc
223509461|NCT01975285|DRUG|Saline|0.5% Bupivacaine with 1:200,000epinephrine + Saline 1 ml per 20cc
223509462|NCT05388175|DEVICE|Rigid catheter|Participants will be invited to positioning a rigid catheter in the manikin's trachea for surfactant aministration
223509463|NCT05388175|DEVICE|Soft catheter|Participants will be invited to positioning a rigid catheter in the manikin's trachea for surfactant aministration
223509464|NCT02441699|BEHAVIORAL|Improved water supply and sanitation|Village-level reticulated water supply with distribution to household taps; pour-flush pit latrines.
223509465|NCT03615534|OTHER|Therapeutic Lifestyle Changes|Four-week therapeutic lifestyle changes run-in period, comprising individualized moderate physical activity and total calories reduction.
223509466|NCT03615534|OTHER|Placebo|
223509467|NCT03615534|DRUG|Fenofibrate|
223509468|NCT03615534|DIETARY_SUPPLEMENT|Wax Matrix Extended Release Niacin (WMER Niacin)|
223509469|NCT03581747|DEVICE|Nevisense|Measurement of electrical impedance
223758573|NCT04858958|DRUG|Furmonertinib 240mg|randomized to 240mg QD
223758574|NCT00941083|DRUG|Raltegravir (Use RAL as a simplification strategy)|RAL QD: RAL 800 mg/24 hs
223758575|NCT00941083|DRUG|Raltegravir (Use RAL as a simplification strategy)|RAL BID 400 mg/12 hs
223758576|NCT00941083|DRUG|Raltegravir (Use RAL as a simplification strategy)|RAL BID to QD
223758577|NCT01563575|OTHER|fast-track implementation process|Undergo fast-track implementation process (WHO-HPH recognition Process), including: baseline data collection, quality plan, implementation for one year, follow-up data collection, revision of quality plan, external site visit and data validation
224311901|NCT00002737|BIOLOGICAL|recombinant interferon alfa|
224311902|NCT00002737|DRUG|chemotherapy|
224311903|NCT00002737|DRUG|isotretinoin|
224311904|NCT01590797|DRUG|Sitagliptin|Sitagliptin 100 mg once daily for 24 weeks
224311905|NCT01590797|DRUG|Placebo|Matching placebo once daily for 24 weeks
223758578|NCT04657536|DEVICE|high frequency fulguration equipment|All subjects will be carried out with 3 standard protocol TRF treatments to the vulvovaginal tissue using the high frequency fulguration equipment (Shenzhen Peninsula Medical co., Ltd) at 10-day to 15-day intervals. Radiofrequency energy was applied to the vaginal canal through a specialized probe combining monopolar and bipolar treatment modes. Monopolar treatment mode is for 15 minutes. Aim the three indication points A, B and C on the probe to the direction of 12 o'clock in turn. Each area should be treated for about 5 minutes. Rotate the probe clockwise when changing the area for treatment.Bipolar treatment mode is for 10 minutes. Firstly, indication point A is aimed to 12 o'clock for 5-minutes treatment and then the probe is rotated 90°clockwise for another 5-minutes treatment. The power setting will be 35-40w, and the target temperature setting will be 40 to 45℃, titrated to subject tolerance.
223758579|NCT04657536|DRUG|promestriene vaginal soft capsules|Promestriene vaginal soft capsules（Zhejiang Anbao Pharmaceutical Co. LTD）will be used 10mg once a day for continuous 20 days.
223758580|NCT01457495|BIOLOGICAL|DTPa-HBV-IPV/Hib (Infanrix-hexa™)|3 doses administered intramuscularly into the right thigh at study month 0, 2 and 8
223758581|NCT01457495|BIOLOGICAL|DTPa-IPV/Hib (Infanrix-IPV/Hib™)|3 doses administered intramuscularly into the right thigh at study month 0, 2 and 8
223758582|NCT01457495|BIOLOGICAL|HBV (Engerix™-B)|3 doses administered intramuscularly into the left thigh at study month 0, 2 and 8
224311906|NCT01590797|BIOLOGICAL|Insulin|Participants can be on on pre-mixed (mixture of rapid- and long-acting insulin) or intermediate- or long-acting insulin at a dose of at least 12 U/day.
224311907|NCT01590797|DRUG|Metformin|At randomization, participants will be stratified according to their use of metformin (on or not on). All participants receiving metformin will be required to be on a daily dose of metformin at least 1500 mg per day.
224311908|NCT01900561|BEHAVIORAL|Interactive Voice Response Symptom Management|The Interactive Voice Response (IVR) system will provide automated telephone monitoring of PC survivor symptoms and goals for symptom reduction, based on a patient empowerment approach.
224311909|NCT01900561|BEHAVIORAL|Tailored Newsletters|Personally tailored newsletters will incorporate elements of CBT to improve survivors' identification with the material, confidence/self-efficacy in symptom management, and to reduce common cognitive distortions related to successful implementation of behavior change. Information collected during automated phone assessments will be used to construct tailored newsletters, which will be sent following each automated call.
224311910|NCT01596309|DIETARY_SUPPLEMENT|Cocoa extract|Participants will follow a hypocaloric diet during two periods of 4 weeks, each. Within these diets, participants will consume daily 2 ready prepared frozen meals containing cocoa extract (0.7 g per meal; 1.4g per day) or nothing (placebo).
224311911|NCT01006018|DRUG|Sitagliptin + Pioglitazone PLACEBO|Sitagliptin 100 mg tablet daily + Pioglitazone PLACEBO 15 mg capsule daily
223509470|NCT03640182|OTHER|Health management model of TCM preventive medicine|The Health management model include: (1) Body constitution measurement (2) Health promotion literacy education lectures (3) Medical Ba-Duan-Jin duo-in qigong practice.
223509471|NCT01383824|DEVICE|Silent™ Hip|A short cementless, femoral component for use in total hip arthroplasty
223509472|NCT05375266|OTHER|Sampling|This is an observational study. Consequently, study participation does not alter the therapy of the treated disease. Blood will be drawn from patients at several time points during and after radiotherapy (RT) and therapy with immune checkpoint inhibitor (ICI) for detailed immunomonitoring of the patients. In addition, faeces and sputum of the patients for microbiomic and metabolomic measures will be collected. Whenever possible, adequate tissue samples are taken from the center of the tumor and a biopsy is taken from the edge of the tumor including the adjacent mucosa in the nearby area without affecting the pathological assessment (study group). Blood, faeces and sputum will be taken from patients of the control group prior to surgery. After surgery, only blood will be taken.
223509473|NCT06092983|DRUG|HS-10383|HS-10383 administered as one 50 mg, 150 mg, 300 mg and 450 mg capsule once daily, depending upon randomization.
223509474|NCT06092983|DRUG|HS-10383 Placebo|HS-10383 Placebo administered as one 50 mg, 150 mg, 300 mg and 450 mg capsule once daily, depending upon randomization.
223509475|NCT06221254|BEHAVIORAL|COBMINDEX digital application|COBMINDEX is a Cognitive, behavioral and mindfulness-based stress reduction with daily self-exercise. The intervention comprises of 7 sessions in which stress reduction techniques are learned. In this arm the Patient learns techniques and practices using digital application.
223509476|NCT06221254|BEHAVIORAL|Human therapist (Control)|COBMINDEX is a Cognitive, behavioral and mindfulness-based stress reduction with daily self-exercise. The intervention comprises of 7 sessions in which stress reduction techniques are learned. In this arm the Patient learns techniques from a human therapist (the comperator for learning from the application) and practices using digital application.
223509477|NCT00004856|BIOLOGICAL|trastuzumab|Given IV
223509478|NCT00026403|DRUG|cisplatin|
223509479|NCT00026403|DRUG|gemcitabine hydrochloride|
223509480|NCT00026403|RADIATION|radiation therapy|
223509481|NCT04032262|DIAGNOSTIC_TEST|Gastrointestinal and Parkinson's Disease|Subjects with Parkinson's disease will come for visits that will contain questionnaires about their PD, their bowel movements, and do further tests using anal rectal probes to understand further their constipation, and other tests to gather data on their digestion.
223509482|NCT04032431|BEHAVIORAL|Telerehab VR intervention|Training with VR system using software specifically designed to reproduce activities of daily living
223509483|NCT04604366|DRUG|misoprostol|it stimulates uterine contractions
223509484|NCT02618395|DRUG|SPARC001A|
223509485|NCT02618395|DRUG|SPARC001B|
223509486|NCT02618395|DRUG|Reference001 - Hydrocodone|Hydrocodone-acetaminophen
224311912|NCT01006018|DRUG|Sitagliptin + Pioglitazone|Sitagliptin 100 mg tablet daily + Pioglitazone 15 mg capsule daily
224311913|NCT01006018|DRUG|PLACEBO|Sitagliptin placebo 100 mg tablet daily + Pioglitazone placebo 15 mg capsule daily
224311914|NCT01791270|DEVICE|Continuous positive airway pressure (CPAP) therapy|"Device: CPAP accordingly to the normal therapy in daily practice. In the group of 61 patients with OSA: we compared the results before and after three months of correct treatment with CPAP.~First, an automatic continuous positive airway pressure device (autoCPAP REMstar) was used to evaluate the pressure titration by night registration at patient home. AutoCPAP gets complete information about the optimum level to be set as therapeutic (CPAP pressure).~The patient has been reevaluated periodically in the outpatient Sleep Unit to verify proper adaptation and compliance of CPAP.~We considered a proper compliance when patients used CPAP ≥ 4 hours/day. This data has been extracted from the counter included in the CPAP compressor.~Procedures:~1. \- Respiratory Polygraphy~2. \- Ambulatory Blood Pressure Monitoring~3. \- Endothelial dysfunction, by determining the hyperaemic response to ischemia using a Laser-Doppler flowmeter.~4. \- ß1en subunit expression in peripheral blood leukocytes."
224311915|NCT04590352|PROCEDURE|nasopharyngeal and throat swab|diagnostic specimens via nasopharyngeal swab and throat swab were collected following the current standard operating procedures.
224311916|NCT04590352|PROCEDURE|collection of mucosal lining fluid|MLF will be collected via nasal absorption at the inclusion visit by study staff and four more time points by the parents or by the children themselves. Nasal absorption is performed by maneuvering a strip of synthetic absorptive matrices (SAM) into the lumen of the nostril, avoiding rubbing against the nasal mucosa. The outside of the nose is then pressed with a finger to cause apposition of the SAM against the mucosa.
223758583|NCT01466270|DRUG|donepezil hydrochloride|Given PO
223758584|NCT01466270|DRUG|Placebo|Given PO
223758585|NCT02457533|BEHAVIORAL|Lifestyle behavioral. Health plan, telephone support|'Lifestyle behavioral. Health plan, telephone support'
223758586|NCT00028756|DRUG|doxorubicin hydrochloride|Given IV
223758587|NCT00028756|DRUG|gemcitabine hydrochloride|Given IV
223758588|NCT00028756|DRUG|vinblastine sulfate|Given IV
223758589|NCT00028756|DRUG|methotrexate|Given IV
223758590|NCT00028756|DRUG|cisplatin|Given IV
223758591|NCT00028756|BIOLOGICAL|filgrastim|Given SC
224201378|NCT02238639|PROCEDURE|Diagnostic and therapeutic strategy: Highly sensitive D-dimer testing and, if positive, multidetector computed tomographic pulmonary angiography (MDCT).|"If MDCT is positive for pulmonary embolism, patients will receive anticoagulant treatment according to updated guidelines.~If MDCT is negative for pulmonary embolism, patients will receive standard management for their exacerbation."
224201379|NCT02585193|BEHAVIORAL|Weight Watchers Intervention|All participants are enrolled in this single arm of the study. All participants receive the Weight Watchers intervention which consists of weekly group intervention/support meetings in which weight loss behaviors (diet, physical activity) are discussed.
224201380|NCT03381807|BIOLOGICAL|hAESCs|5\*10\^7 hAESCs is infused into uterine cavity with TCRA on Day0, Day7 and after the first menstruation
224311917|NCT04590352|PROCEDURE|blood collection via fingerprick|Participants will be asked to wash their hands with soap and warm water. The procedure involves cleaning the ball of the fingertip with an alcohol swab, then using a sterile disposable lancet to pierce the skin (BD Microtainer Lancet or similar). The lancet is placed in a spring-loaded device, which propels the lancet a fixed distance (a few mm) into the skin when the trigger is pressed. Approximately 10-20 drops of blood (0.3 ml) will then be collected with a sterile capillary tube. The participant is given a cotton wool pad to mop up any extra blood, and an elastoplast-type bandage is placed over the finger if necessary. Fingerprick blood samples will only be collected from participants older than 6 months at 28-32 days after the first home visit (d0). Lancet length will be adjusted for age (2.0 mm for participants 8 years and older, 1.5 mm for participants older than 6 months and younger than 8 years).
224311918|NCT01014377|DEVICE|VascuActive|
223512361|NCT03164707|DIAGNOSTIC_TEST|Blood Glucose Level|ON Admission Blood Glucose Level Fasting Blood Glucose Level
223512362|NCT03042637|DRUG|Acthar Gel and Tacrolimus|Combination therapy with Acthar Gel and Tacrolimus (0.5-3.0 mg BID) following 6 months of ACTH therapy only
223512363|NCT05229354|BIOLOGICAL|TV005|The TV005 admixture is comprised of four monovalent dengue vaccine candidates representing each of the four DENV serotypes: rDEN1Δ30, rDEN2/4Δ30(ME), rDEN3Δ30/31, and rDEN4Δ30.
223512364|NCT05229354|BIOLOGICAL|rDEN2Δ30-7169 attenuated virus strain|based on a cDNA derived DENV-2 virus (strain Tonga/74) in which the 3´ UTR of DENV-2 contains a 30 (nt) deletion (nt 173 - 143) homologous to the ∆30 deletion in the 3´ UTR of rDEN4Δ30 (named Δ30 for consistency). A plasmid was constructed to encode the entire genome of DENV-2 Tonga/74. The cDNA of the 3´ UTR of DENV-2 Tonga/74 was then modified to introduce a 31-nucleotide deletion homologous to the DEN4Δ30 deletion (∆30). Genome-length, capped, RNA transcripts were synthesized from the plasmid p2Δ30-7169 and purified
223512365|NCT05137626|DRUG|AT-527 + digoxin|"* Day 1: A single dose of digoxin will be administered.~* Day 15: A single dose of AT-527 and digoxin will be co-administered."
223512366|NCT05137626|DRUG|AT-527 + digoxin|"* Day 1: A single dose of digoxin will be administered.~* Day 15: A single staggered dose of AT-527 and digoxin will be administered (2 hours later)."
223512367|NCT04835597|BEHAVIORAL|Behavioral Assessment|Complete movement assessment
223512368|NCT04835597|OTHER|Electronic Health Record Review|SAE data is collected
223512369|NCT06501209|BEHAVIORAL|5A-5R-based counselling session|"The 5As (Ask, Advise, Assess, Assist, Arrange) summarize all the activities that a healthcare provider can do to help a tobacco user (both smoking within 3-5 minutes in a primary care setting. This model can guide you through the right process to talk to respondents who are ready to quit tobacco use and deliver advice.~The 5 R's - relevance, risks, rewards, roadblocks, and repetition - are the content areas that should be addressed in a motivational counseling intervention to help those who are not ready to quit."
223512370|NCT06501209|BEHAVIORAL|Counseling through mobile phone call and text message|Participants will get weekly a phone call and a text message
223512371|NCT02602145|OTHER|follow-up CTA|All patients will receive PAD stents as their normal standard of care determined by their treating physician. If the patient would decide to enroll in the study, we will perform a post-operative contrast-enhanced CTA of the lower extremities at 6-12 months after stenting.
223612257|NCT01094535|DRUG|Synthetic Human Secretin|S-MRCP has recently emerged as a widely-accepted noninvasive technique to assess morphological changes in the pancreatic ducts, as well as functional secretory capacity of the gland. Twelve patients will each undergo four Secretin-enhanced magnetic resonance cholangiopancreatography (S-MRCP) evaluations, at a dose of 0.2 ucg/kg per exam, each S-MRCP will require 16-32 ucg of secretin (12 vials). Secretin, provided by the Repligen Corporation, will be administered by IV bolus injection over 30 seconds followed by a 30 second saline flush. The maximum dose of secretin will be 18.5 ucg.
223612258|NCT05607524|DIETARY_SUPPLEMENT|probiotics|Eat a capsule for once, and twice a day
224201381|NCT01495104|DRUG|RO4917838|Multiple doses
223758592|NCT02240381|PROCEDURE|assessment of therapy complications|During OGTT 75gm of glucose will be given followed by phlebotomy
223758593|NCT02240381|PROCEDURE|assessment of therapy complications|During clamp procedure tritiated glucose, D20, regular insulin will be given, followed by phlebotomy.
223612259|NCT05607524|DIETARY_SUPPLEMENT|placebo|Eat a capsule for once, and twice a day
223612260|NCT00746616|DEVICE|Durom Hip Resurfacing System|Hip resurfacing devices in the young, active patient with advanced hip disease instead of traditional total hip arthroplasty.
223612261|NCT03763019|PROCEDURE|Conventional rehabilitation|Static and dynamic control of position, balance skills, weight shift, and activities of daily living.
223612262|NCT03763019|PROCEDURE|Respiratory rehabilitation|Forced expiration, forced inspiration (thoracal expansion exercise), coughing exercise, incentive spirometric trainer, diaphragmatic respiration exercise, autogenic drainage, percussion.
223612263|NCT00500188|DRUG|Imatinib Mesylate (Gleevec)|300 mg orally twice daily
223612264|NCT02728089|DRUG|MK-7625A 1.5 g (ceftolozane 1 g/tazobactam 0.5 g)|MK-7625A 1.5 g (ceftolozane 1 g/tazobactam 0.5 g) administered as an intravenous (IV) infusion
223612265|NCT03233113|BEHAVIORAL|Exposure therapy|"Exposure therapy (i.e., exposure-based cognitive behavioral therapy) for spider phobia according to condition-specific, scripted treatment manuals inspired by evidence-based exposure programs for anxiety/phobias (for both arms: Abramowitz, Deacon, \& Whiteside, 20011; Antony, Craske, \& Barlow, 1995) as well as the seminal account of the judicious use of safety behaviors thesis (for the experimental arm only: Rachman, Radomsky, \& Shafran, 2008). Exposure and response prevention involves confronting a live spider while resisting safety-seeking behaviors; exposure with judicious safety behaviors involves strategically using safety behaviors while confronting a live spider."
223612266|NCT06301451|DEVICE|General dietary guidance and hydrogen water prepared by portable hydrogen rich water machine|The trial group drink the hydrogen water prepared by the experimental equipment on the basis of receiving general dietary guidance.
223612267|NCT00420862|PROCEDURE|Spiral Computed Tomography|
223612268|NCT03678701|DIETARY_SUPPLEMENT|Pre-meal 100% whey protein intake|Participants in the protein group will be provided 100% whey protein powder and will be advised to drink 30g of protein dissolved in 237ml (8oz) of water, one hour before lunch and dinner.
223612269|NCT00424944|BIOLOGICAL|GMZ2 (malaria vaccine)|100 micrograms of GMZ2 in each vaccination
223758594|NCT02240381|OTHER|laboratory biomarker analysis|Correlative studies
223758595|NCT04550624|DRUG|Pembrolizumab Injection [Keytruda]|200mg IV on day 1 of each cycle
223758596|NCT04550624|DRUG|Lenvatinib Mesylate|20mg PO daily days 1-21 of each cycle
223612270|NCT00424944|BIOLOGICAL|GMZ2 malaria vaccine|100 micrograms of GMZ2
223612271|NCT00424944|BIOLOGICAL|Verorab vaccine|Anti-rabies vaccine
223758597|NCT06026904|DEVICE|transcutaneous auricular vagus nerve stimulation|taVNS was developed as a non-invasive variant of VNS where the vagus nerve is stimulated through the skin of the auricle, which has become a promising avenue for research and, potentially, treatment of various disorders. Commonly, taVNS is applied via the ear targeting the auricular branch of the vagus nerve, where the stimulation elicits far-field potentials. In line with preclinical studies, acute taVNS enhances invigoration of effort and response inhibition capability.
223758598|NCT00004923|DRUG|docetaxel|
223758599|NCT00004923|DRUG|irinotecan hydrochloride|
223758600|NCT01459172|OTHER|limonene containing massage oil|daily massage application to the breast for 4 weeks
223758601|NCT04514575|BIOLOGICAL|Plasma transfusion|Transfusion of allogeneic fresh frozen plasma or cryoprecipitate
223758602|NCT00917332|BEHAVIORAL|"relaxation (breathing and muscles) and guided imagery (safe place)"|intervention group: daily practice of relaxation and guided imagery CD, for a rew weeks, until childbirth.
223612272|NCT06821607|BEHAVIORAL|In-Clinic Physical Therapy|Patients in this group will receive all PT sessions in-clinic with a trained physical therapist. Treatment provided for this group will be consistent with evidence-based guidelines that recommend patient education, exercise instruction, manual therapy interventions, and psychosocial interventions. Specific interventions to be provided within each of these categories: Education, Exercise, Manual Therapy, and Psychosocial interventions. Components of the intervention will be determined by the treating therapist based on patients' symptoms, examination findings, and patients' preferences and goals.
223758603|NCT01556672|DRUG|Adalimumab|Adalimumab will be administered sub-cutaneously to all patients entering the study with a loading dose of 80 mg followed by 40 mg at week 1 and 40 mg every other week. Patients who did not have small bowel lesions detected will be in the study and receive adalimumab until week 12. Patients who had small bowel lesions detected will be in the study and receive adalimumab until week 24.
223758604|NCT01556672|DEVICE|Capsule endoscopy|All patients will undergo capsule endoscopy (EndoCapsule EC type 1; Olympus) to treatment initiation (adalimumab) in order to detect the presence of small bowel lesions suggestive of Crohn's disease. Twenty-four (24) weeks after treatment with adalimumab was initiated, patients for whom small bowel lesions were detected will undergo a second capsule endoscopy to evaluate changes in bowel inflammation.
223758605|NCT01034410|DRUG|AS1411|AS1411 40mg/kg/day or AS1411 80mg/kg/day
223758606|NCT01034410|DRUG|Cytarabine|Cytarabine 2g/m2 bid Days 4-7
224201382|NCT01495104|DRUG|valproate|Multiple doses
224201383|NCT03918980|DRUG|LOU064|LOU064 will be administered as oral capsules in parts 1 to 6.
224201384|NCT03918980|DRUG|Placebo|Matching placebo capsules will be administered in parts 1,2, 4 and 6.
224201385|NCT03902249|DRUG|Dexamethasone|
224201386|NCT01906931|DEVICE|Portable oxygen concentrator|Respironics EverGo portable oxygen concentrator on setting 6
224201387|NCT01906931|DEVICE|Portable oxygen cylinder|Portable oxygen cylinder at flow rate 5 Litres/min
223612273|NCT06821607|BEHAVIORAL|Telehealth Physical Therapy (Telerehabilitation)|Those randomized to telerehabilitation will receive all PT care, including the initial evaluation and 7 follow-up sessions, via real-time video conferencing technology. Like the interventions provided to those receiving in-clinic PT, treatments provided in the telerehabilitation group will be consistent with evidence-based guidelines, adapted for delivery via real-time video visits. Consistent with the in-clinic group, specific interventions will be selected by the treating physical therapist based on patients' symptoms, examination findings, and preferences and goals. There will be an emphasis: Open-ended questions to allow patients to describe the participant's impairments and limitations; Review patient-reported measures of disability and pain intensity to help identify functional impairments; and Clinical examination of spinal movements and impairments in strength, flexibility, and joint mobility.
223612274|NCT06367257|PROCEDURE|App Usage|Conducting patient surveys with app
223612275|NCT06367257|OTHER|Standard of Care|supportive care during and after radio(chemo)therapy according to hospial standards
223612276|NCT06470997|BIOLOGICAL|Blood sample collection|6 collections of 5mL blood samples as part of usual care (pre-inclusion visit at Day-7, inclusion visit at Day 0, visit1 at Day 14, visit2 at Day 28, visit3 at Day 90, visit4 at 6 months) and 5 blood sample collections of 5 mL for proteomic analysis in the context of research (inclusion visit at Day 0, visit1 at Day 14, visit2 at Day 28, visit3 at Day 90, visit4 at 6 months)
223758607|NCT01932216|PROCEDURE|Cholecystectomy|Gallbladder removal
223758608|NCT04070833|DIETARY_SUPPLEMENT|Vitamin D|Dietary Supplement: Vitamin D-3 (cholecalciferol), 2000 IU Other Name: cholecalciferol
223612277|NCT06470997|PROCEDURE|Liver biopsy|1 liver biopsy performed as part of routine care and 1 additional sample for research: transparietal needle biopsy under ultrasound identification under local anesthesia by a radiologist, 1 to 2 cm per core taken, 2 cores are taken.
223758609|NCT04070833|DRUG|Fish oil|Drug: Omega-3 fatty acids (fish oil) Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid \[EPA\] and 375 mg of docosahexaenoic acid \[DHA\])
223612278|NCT04171297|PROCEDURE|Ultrasound evaluation of DE|To evaluate diagnostic accuracy of ultrasound for the presence of deep endometriosis.
223758610|NCT04070833|DIETARY_SUPPLEMENT|Vitamin D placebo|Vitamin D placebo
223758611|NCT04070833|DRUG|Fish oil placebo|Fish oil placebo
223758612|NCT02825069|OTHER|Early introduction of solid foods|Early introduction of solid foods
223612279|NCT04428229|OTHER|Optic nerve sheath diameter|Pre and post-trendelenburg optic nerve sheath diameter will be measured
223612280|NCT03055520|OTHER|cognitive training|The Kumon method (www.kumon.com) of arithmetic calculation employs the errorless-learning (EL) strategy and consists of a structured, hierarchical series of exercises, beginning with simple ones (e.g. addition and subtraction) and then proceeding to more complex exercises (e.g. advanced algebra, calculus).
223612281|NCT03055520|OTHER|placebo|nonspecific recreation including befriending and free simple activities.
223612282|NCT04417608|PROCEDURE|Infraclavicular brachial plexus block|Ultrasound-guided infraclavicular brachial plexus block
223612283|NCT03915314|DIAGNOSTIC_TEST|Neuropsychological tests|The investigators do the neuropsychological tests, Mini-Mental score examination (MMSE),Charlson Comorbidity Index(CCI)，Quality of Recovery Score - 40 (QoR-40),CAGE Alcoholism Questionnaire,blood albumin、hemoglobin content、ALT、AST、BUN、Cr、1 day before the surgery（baseline);serum biomarkers of endothelial dysfunction，blood brain barrier disruption and neuronal injury to be measured at 2 time points,1 day before the surgery（baseline）and postoperative day 1； Confusion Assessment Method（CAM)，Numerical Rating Scale（NRS）once before discharge from PACU and 1、2、3 days after surgery twice a day； QoR-40 1 day after surgery.
223612284|NCT03117855|DRUG|Capecitabine|Given PO
223758613|NCT06034054|OTHER|nursing counceling|"* Providing an educational booklet containing information about pastry, verbally explaining the content of the prepared educational booklet.~* Answering the information and questions that the patient needs in addition, and receiving contact information in October.~* Monthly calls will be made to patients 6. providing information that the same tests will be performed again per month, if necessary, this monthly call counseling by reaching out without waiting indicating what they can receive."
223758614|NCT01304485|DRUG|Sodium Acetate C11|PET Imaging with Sodium Acetate C11
223758615|NCT00024362|DRUG|BBR 3464|
223758616|NCT03106727|BEHAVIORAL|Household model|The proposed intervention is a 'Household Model' where, instead of being assigned to HIV or TB patients, CHWs will rather be assigned to households and will be trained to provide support for a wider range of conditions including HIV, hypertension, diabetes and pediatric malnutrition. The new model is designed to improve retention in care for clients with chronic, non-communicable diseases, along with increased uptake of women's health services and treatment for pediatric malnutrition, while sustaining the high retention rates for clients in the HIV program.
223612285|NCT03117855|OTHER|Laboratory Biomarker Analysis|Correlative studies
223612286|NCT03117855|RADIATION|Radioembolization|Undergo yttrium Y-90 radioembolization
223612287|NCT04791618|BEHAVIORAL|Health360x plus health coach|Access to health360x which provides monitoring, in the moment color coded feedback and goal setting for self management skills
223612288|NCT04791618|BEHAVIORAL|Health360x only (High tech)|All participants will have access to Helath360x with reminders generated for goal setting.
223758617|NCT03193606|OTHER|nano silver fluoride solution|prepared Nano-silver fluoride could have the capability to arrest caries. As its Nano silver particles have an antimicrobial activity against Mutans Streptococci and Lactobacilli; the main pathogens involved in the development of carious lesions. In addition, its fluoride component is well known to enhance remineralization and inhibit bacterial activity. So, Nano silver fluoride could be a promising solution to combat residual bacteria in tooth cavity with effective remineralization potential on remaining carious dentin
223758618|NCT01870128|DRUG|Combination Steroid|Methylprednisolone 1000 mg intravenous for 3 days Methotrexate 15 to 25 mg PO per week Hydroxychloroquine 200 mg twice daily Sulfasalazine 2000 to 3000 mg per day
223758619|NCT01870128|DRUG|Methotrexate|Methotrexate 15 to 25 mg PO per week
223758620|NCT01870128|DRUG|Combination|Methotrexate 15 to 25 mg PO per week Hydroxychloroquine 200 mg Twice daily Sulfasalazine 2000 to 3000 mg per day
223758621|NCT01489046|DRUG|BMS-986001|Capsules, Oral, 100 mg, Once daily, At least 48 weeks
223758622|NCT01489046|DRUG|BMS-986001|Capsules, Oral, 200 mg, Once daily, At least 48 weeks
223612289|NCT00217217|DEVICE|Echo-Planar Magnetic Resonance Imaging (EP-MRSI)|variable-setting low-frequency MRI
223612290|NCT00731679|DRUG|Rifaximin|
223612291|NCT00731679|DRUG|Placebo|
223612292|NCT00292019|PROCEDURE|Laparoscopic|Patients with prostate cancer who are eligible for a radical prostatectomy will have their surgery conducted with the aid of surgical robots.
223612293|NCT01940835|PROCEDURE|Upper endoscopy with small bowel biopsies and brushings.|
223612294|NCT01940835|OTHER|Blood draw|Blood will be collected for serum, DNA, and peripheral blood mononuclear cells (PBMC).
223758623|NCT01489046|DRUG|BMS-986001|Capsules, Oral, 400 mg, Once daily, At least 48 weeks
223758624|NCT01489046|DRUG|Placebo matching with BMS-986001|Capsules, Oral, 0 mg, Once daily, At least 48 weeks
223758625|NCT01489046|DRUG|Efavirenz|Tablets, Oral, 600 mg, Once daily, Entire Treatment Phase
223758626|NCT01489046|DRUG|Lamivudine|Tablets, Oral, 300 mg, Once daily, Entire Treatment Phase
223758627|NCT01489046|DRUG|Tenofovir|Tablets, Oral, 300 mg, Once daily, Entire Treatment Phase
224201388|NCT00182273|PROCEDURE|Canalith repositioning maneuver (CRM)|
223612295|NCT01940835|OTHER|Stool sample|Stool samples will be collected at baseline for future microbiome and virome studies.
223612296|NCT01598922|BEHAVIORAL|Internet Cognitive Behavioral Therapy|8 weeks of online treatment program
223612297|NCT01374633|DRUG|1: Sevoflurane|"Mean sevoflurane infusion rate will be around 6 ml/h or 72 ml for 12 hours. Maximal infusion rate will be around 12 ml/h, or 144 ml for 12 hours. Packaging: bottle containing 250 ml of liquid sevoflurane for evaporation. Administration mode: anaesthetic conserving device for volatile anaesthetics."
223612298|NCT05799131|DEVICE|QBX (5F/6F) Peripheral Balloon Expandable Stent System|"The QBX Stent System is a flexible, balloon expandable stent, made of a cobalt chromium alloy manufactured by QualiMed Innovative Medizinprodukte GmbH. The design is suitable for peripheral vessel diameters from 5 to 10 mm.~The QBX Stent System is available as 6F and 5F variations where the 6F system is mounted on an 0.035 over-the-wire delivery system, and the 5F is mounted on an 0.018 over-the-wire delivery system. Both are available in a full range of diameters and lengths."
223612299|NCT00330122|PROCEDURE|fore locked plate|
223612300|NCT00330122|PROCEDURE|external radiocarpal fixer|
223612301|NCT04671264|DEVICE|Sallowing VC during six weeks|"follow-up was required for at least 6 times, once every two weeks through the whole study.~For patients who had no colonoscopy examination within a year, colonoscopy was a must to exclude organic diseases.~These included blood routine, blood biochemistry, urine routine, fecal routine, fecal occult blood, thyroid stimulating hormone (TSH), blood pregnancy test and ECG examination. Patients should finish all the examination in the run-in period and at the end of treatment period.~Dairy cards were designed mainly for the record of the daily defecation of patients and filled out by the enrolled patients, and the content included date, whether the patients swallow capsules (time), whether the patients discharge capsules (time), defecation, defecation time, degree of defecation exertion(0\~4), BSF scale, complete or incomplete defecation, whether the patient had the sense of anal obstruction, whether manual assistance was applied, and whether first-aid medicine was used (bisacodyl)."
223612302|NCT03724929|PROCEDURE|Blood sample|Blood samples will be systematically collected at W0, W2, W6, W14 and W52 for vedolizumab pharmacokinetic parameters, including the vedolizumab trough levels and the specific anti-vedolizumab antibody. A supplementary blood sample will be collected at W10 which is the point where a significant greater number of patients were in remission.
223612303|NCT03724929|DEVICE|Rectosigmoidoscopy|Rectosigmoidoscopy will be performed in each center at time points W0, W10 and W52.
223612304|NCT02488005|DEVICE|Ultrasound|An ultrasound of the small bowel will be done by a radiologist or ultrasound technician. Subject should not eat or drink anything (i.e. no food and no water/beverages) for 8 hours prior to their ultrasound appointment
223612305|NCT02964000|DEVICE|Low level 1 Watt|The Phoenix Thera-Lase System will be on 1 watt
223758628|NCT03125369|PROCEDURE|Sleeve gastrectomy + duodeno-jejunal bypass|
223758629|NCT03125369|PROCEDURE|Roux-Y gastric bypass|
223612306|NCT02964000|DEVICE|Phoenix Thera-Lase System 42|The Phoenix Thera-Lase System will be on 42 watts
223612307|NCT02964000|DEVICE|Phoenix Thera-Lase System 74|The Phoenix Thera-Lase System will be on 74 watts
223612308|NCT03286452|DEVICE|PuraPly™ Antimicrobial Wound Matrix|PuraPly™ Antimicrobial Wound Matrix consists of a collagen sheet coated with 0.1% polyhexamethylenebiguanide hydrochloride (PHMB) intended for the management of wounds.
223758630|NCT05525819|DRUG|Control group|The cases will be subjected to spinal anesthesia with a 3 ml volume (2.5 ml of hyperbaric bupivacaine 10 mg in addition to 0.5 normal saline). 50 ml of normal saline was infused over a ten-minute period, followed by 200 ml infusion till the end of operation.
223758631|NCT05525819|DRUG|Intrathecal group|The cases will be subjected to the same anesthetic mixture as controls with adding dexmedetomidine 5 μg in the saline component. 50 ml of normal saline was infused over a ten-minute period, followed by 200 ml infusion till the end of operation.
223758632|NCT05525819|DRUG|Intravenous group|The intravenous group will receive 2.5 ml of hyperbaric bupivacaine (10 mg), in addition to intravenous dexmedetomidine, which will be started at 1 μg/kg loading dose diluted in 50 ml saline administered within 10 min, followed by maintenance at a 0.4 μg/kg/h dose diluted in 200 ml saline till the end of the procedure.
223758633|NCT04206293|DEVICE|Juvederm® VOLITE|1 mL of Juvéderm® VOLITE contains hyaluronic acid gel 12.0 milligram (mg), lidocaine hydrochloride 3.0 mg in a phosphate buffer pH 7.2 q.s. 1 mL (or gram).
223758634|NCT01586468|DRUG|WF10|0.5 mg/kg B.W.
223758635|NCT01586468|DRUG|NaCl Solution|NaCl Solution
224201389|NCT06557473|DRUG|Lidocaine IV|1.5mg/kg IV for induction of GA
224201390|NCT06557473|DRUG|Fentanyl|Fentanyl IV 2 µg/kg for GA induction
224201391|NCT06694974|BEHAVIORAL|APP calculation for FIB-4|the investigators plan to use the smartphone App for FIB-4 calculation and notify the patients.
224201392|NCT06694974|BEHAVIORAL|Standard Care (in control arm)|The standard group proceeds as regular practice
224201393|NCT05276869|OTHER|WeeFIM instrument|In a formative setting, the WeeFIM tool examines functional independence in kids aged 6 months to 7 years old. It can also be used with children over the age of 7 who show functional ability. The instrument may be controlled by observational data or a meeting, and it takes 15 to 20 minutes to create \[10\].
223612309|NCT00079560|DRUG|dronabinol|dronabinol to prevent development of marijuana withdrawal
223758636|NCT06288516|DRUG|Benralizumab 30 mg/ml|Benralizumab administered subcutaneously every 4 weeks for the first 3 dose and then every 8 weeks
223758637|NCT04127760|RADIATION|radiotherapy|Radiotherapy would start within 2 months after the operation, and 5 days of radiotherapy is performed every week. The dose of each radiotherapy is 1.8 Gy for 6 weeks, and the total dose is 54 Gy.
223758638|NCT00599937|DRUG|ATRA|early introduction of ATRA
223758639|NCT00599937|DRUG|ATRA and or Chemo as maintenance|patients were randomized both to receive or not receive intermittent ATRA (45 mg/m2/d, 15 days every 3 months) and to receive or not receive continuous CT with 6 mercaptopurine (90 mg/m2/d, orally) and methotrexate (15 mg/m2/wk, orally), according to a 2-by-2 factorial design stratified on the initial induction treatment group
223758640|NCT04587934|DEVICE|iRes Warmer with ResusView|Rapid heart rate display utilizing optimized ECG algorithm in iRes Warmer in babies delivered between 23+0 and 32+6 weeks estimated gestational age
223612310|NCT02478099|DRUG|MPDL3280A|Anti-PD-L1 antibody
223612311|NCT01377662|DRUG|OND-PR002 and MPh-IR|"Drug: OND-PR002~Single daily oral doses of 8 mg Ond-PR002~Drug: MPh-IR~Single daily oral doses of 20 mg MPh-IR"
223612312|NCT01377662|OTHER|Placebo: Two dextrose capsules for Ond-PR002 and MPh-IR|Single daily oral doses
223612313|NCT02481297|DRUG|Lirilumab|3 mg/kg by vein given on Day 1 of each 28 day cycle.
223612314|NCT02481297|DRUG|Rituximab|375 mg/m2 by vein weekly for the first 4 weeks on Days 1,8, 15, and 22 of Cycle 1. After Cycle 1, given on Day 1 of Cycles 2 - 12.
223612315|NCT00180388|PROCEDURE|endoscopic vein harvesting|
223612316|NCT00180388|PROCEDURE|open vein harvesting|
223612317|NCT05977842|DEVICE|CTO PCI using DCB-only strategy|Successful CTO recanalization treated with DCB at the occlusion site
223612318|NCT01593553|OTHER|ECG screening for atrial fibrillation using intermittent ECG recorder|ECG screening for atrial fibrillation with intermittent ECG recording (Zenicor device) for 14 days. Introduction of anticoagulants in the case of atrial fibrillation.
223612319|NCT00834262|DRUG|biphasic insulin aspart 30|Dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
223612320|NCT00834262|DRUG|biphasic insulin aspart 50|Dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
223612321|NCT00834262|DRUG|biphasic insulin aspart 70|Dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
223612322|NCT03967054|DRUG|Ivermectin|Ivermectin (6 mg tablet) given monthly from July-October each rainy season as a 3-day course of approximately 300 mcg/kg/day as estimated by height bands.
223612323|NCT03967054|DRUG|Placebo oral tablet|placebo in the same size, color and shape at the ivermectin tablet
223612324|NCT05980585|DEVICE|CPM Device|Daily use of the CPM wearable device
223612325|NCT05431478|DEVICE|Serafilcon A contact lenses|Reusable silicone hydrogel contact lenses worn during the day and removed at night for daily cleaning and disinfection
223612326|NCT05431478|DEVICE|Senofilcon A contact lenses|Reusable silicone hydrogel contact lenses worn during the day and removed at night for daily cleaning and disinfection
223758641|NCT04587934|OTHER|iRes Warmer without ResusView|Electrocardiogram monitoring using external ECG monitor in babies delivered between 23+0 and 32+6 weeks estimated gestational age
223758642|NCT00774033|DEVICE|autologous epidermal cells harvesting kits|autologous epidermal cells harvesting kits used for the treatment of acute burn
223758643|NCT00774033|PROCEDURE|classic skin grafts|classic skin grafts used for the treatment of acute burn
223758644|NCT00962130|DEVICE|Continuous glucose monitoring system|one or two monitors will be placed in the tissue to be transferred
223758645|NCT02227485|DRUG|Punica granatum Pleniflora (Golnaar) mouth rinse|"All the patient in intervention group use 10 ml of Golnaar mouth rinse for 2 minutes every night for 2 weeks."
223758646|NCT02227485|DRUG|Chlorhexidine (0.2%)|All the patient in control group use 10 ml of chlorhexidine (0.2%) for 2 minutes every night for 2 weeks.
223758647|NCT02227485|PROCEDURE|Tooth bleaching|Tooth bleaching for both groups one time after using mouth rinses.
223758648|NCT01454934|DRUG|Eribulin|Administration of eribulin mesylate at a dose of 1.4 mg/m2 i.v. over 2 to 5 minutes on Days 1 and Day 8 of every cycle, where the duration of each cycle is 21 days.
223758649|NCT01454934|DRUG|TPC -Vinorelbine,Gemcitabine,Docetaxel, and Pemetrexed|"* Vinorelbine 30 mg/m2 i.v. on Day 1, every 7 days~* Gemcitabine 1250 mg/m2 i.v. on Days 1 and 8, every 21 days~* Docetaxel 75 mg/m2 i.v. on Day 1 every 21 days~* Pemetrexed 500 mg/m2 i.v. on Day 1 every 21 days (nonsquamous histology only)."
223758650|NCT02773043|DEVICE|CZT SPECT camera|
223758651|NCT04966338|BIOLOGICAL|Ocrelizumab (CinnaGen, Iran)|Ocrelizumab (CinnaGen, Iran) will be administered via intravenous (IV) infusion.
223758652|NCT04966338|BIOLOGICAL|Ocrelizumab (Roche, Switzerland)|Ocrelizumab (Roche, Switzerland) will be administered via intravenous (IV) infusion.
224311919|NCT01179711|DEVICE|Glasses prescription|At initial visit(of study), the physician will reduce the diopter of hyperopic glasses as much as the patient can maintain their eye alignment (maximum amount 1.5D).
223612327|NCT05431478|DEVICE|CLEAR CARE|Hydrogen peroxide based contact lens cleaning and disinfecting solution
223612328|NCT03127293|DIAGNOSTIC_TEST|DEXA|Blood samples (10 mL) were drawn at the time of DEXA scans in postpartum period
223612329|NCT02326597|OTHER|Decision Aid Tool|The tool is a web based decision aid that provides information about the risks and benefits associated with sickle cell disease therapies. Participants will be provided a unique access ID and password to access the information.
223612330|NCT02326597|OTHER|Standard Practice|Standard of care teaching and discussion regarding treatment options given by patient's healthcare provider.
223612331|NCT02369913|OTHER|Blood Drawn|Both groups will have 1 teaspoon of blood drawn for analysis.
223758653|NCT00430092|DRUG|Difluprednate|
223758654|NCT00430092|DRUG|Difluprednate|
224311920|NCT03769961|OTHER|No intervention|No interventions - Observational study
224311921|NCT02369302|DRUG|DWC20141|Tablet
224311922|NCT02369302|DRUG|DWC20142|Tablet
224311923|NCT02369302|DRUG|DWC20141, DWC20142|Tablet
224311924|NCT06021691|BEHAVIORAL|Acquired nurturing environment|Superimposed effects of intrauterine high-sugar environment exposure and postnatal nurturing environment exposure
224311925|NCT05173857|DEVICE|Advance PTX|PTA in Dysfunctional Haemodialysis Access
223612332|NCT02286921|DRUG|Testosterone cypionate|Depo-Testosterone Injection, for intramuscular injection, contains testosterone cypionate which is the oil-soluble of the androgenic hormone testosterone. Testosterone cypionate is a white or creamy white crystalline powder, odorless or nearly so and stable in air. Depo-Testosterone Injection is available in two strengths, 100 mg/mL and 200 mg/mL testosterone cypionate.
223758655|NCT00430092|DRUG|Placebo|
223758656|NCT01079871|OTHER|FID 114657 (ORB Preserved Ocular Emulsion)|Patients will dose as needed throughout the day (PRN) for 4 weeks.
223758657|NCT02021591|BEHAVIORAL|Mobile Diabetes Detective (MoDD)|MoDD is a web-based application that is designed to help individuals with diabetes identify specific problems related to glycemic control, and engage in problem-solving process. MoDD includes a number of messages that explain its users the nature of various problems related to glycemic control, aspects of individuals' behaviors that might have contributed to these problems, and alternative behaviors that could help to improve glycemic control. In addition to these messages displayed on the MoDD website, study participants may receive SMS messages with reminders to test blood glucose, or to follow the selected new behavior.
223758658|NCT04877262|OTHER|weight maintenance diet (WMD)|A diet meeting the participant's weight maintenance energy needs will be provided.
224311926|NCT05173857|DEVICE|Advance LP (Low Profile)|Plain Old Balloon Angioplasty (POBA)
224311927|NCT05173857|DRUG|Paclitaxel (PTX)|Paclitaxel (PTX)
224311928|NCT06452901|OTHER|Progression and structured surgical training.|Participants will be exposed to different amounts of open vascular surgical training, but only group I will receive the complete structured and progressive training program. This ensures that all participants have access to the potential benefits derived from the intervention. Current evidence supports this approach, which supports the benefits of medical simulation in the training process of surgical residents.
224311929|NCT02849938|DEVICE|TytoCare Device|Tyto is a handheld, mobile device designed for capture and transmission of ear/throat/skin images and lung/heart auscultations. It may be used to perform non-invasive, medical examinations, either on a patient (by another person, most commonly a family member, or by a medical professional) or self-performed by the patient, for remote review by a medical practitioner. It is suitable for use on patients in both clinical and home environment.
224311930|NCT05055583|DRUG|Toripalimab in Combination With Platinum-based Chemotherapy|Toripalimab will be administered at a fixed dose of 80 mg (2ml)/vial, IV, D1, with a full dose of 240 mg at one time, every 3 weeks for 3-4 cycles. Squamous cell carcinoma will be combined with cisplatin/carboplatin and Nab-paclitaxel: carboplatin, AUC=5, D1, IV, q3w, or cisplatin, 75 mg/m2, IV, q3w, and Nab-paclitaxel, 130 mg/m2, D1, IV, q3w, for 3-4 cycles. Non-squamous cell carcinoma will be combined with cisplatin/carboplatin and Pemetrexed, cisplatin/carboplatin is the same as above, Pemetrexed will be given at 500 mg/m2, D1, IV, q3w, for 3-4 cycles.
224311931|NCT05055583|PROCEDURE|Surgical treatment stage|After the last treatment (Day 21 of Cycle 4), surgery was performed within 4-6 weeks.
223612333|NCT02286921|DRUG|Enzalutamide|Enzalutamide is a white crystalline non-hygroscopic solid. It is practically insoluble in water. Enzalutamide is provided as liquid-filled soft gelatin capsules for oral administration. Each capsule contains 40 mg of enzalutamide as a solution in caprylocaproyl polyoxylglycerides. The inactive ingredients are caprylocaproyl polyoxylglycerides, butylated hydroxyanisole, butylated hydroxytoluene, gelatin, sorbitol sorbitan solution, glycerin, purified water, titanium dioxide, and black iron oxide.
223612334|NCT02286921|DRUG|Testosterone Enanthate|Testosterone Enanthate Injection, for intramuscular injection, contains testosterone enanthate which is the oil-soluble ester of the androgenic hormone testosterone. Enanthate Injection is available as a colorless to pale yellow solution. Each mL contains 200 mg testosterone enanthate in sesame oil with 5 mg chlorobutanol as a preservative.
223612335|NCT01158781|BEHAVIORAL|Experimental: gait, balance, arm function, cognition|12 weeks of training for balance, gait, upper limb function, and cognition, including functional electrical stimulation with surface electrodes, robotics, and motor learning
223612336|NCT05192993|OTHER|visual motor integration group|Oculomotor exercises as follow:(1) Eye follow with a stationary head 2)Saccadic eye movements 3) Gaze stability 4)Eye/head co-ordination 5)Balancing exercises
223612337|NCT05192993|OTHER|Handwriting intervention programs|(1)Eye motor coordination (2)position in space(3)coping-figure ground(4)spatial relationship(5)visual closure(6)constancy of shapes(7)far and near coping
223612338|NCT05192993|OTHER|visual motor integration program and Handwriting intervention programs|"Oculomotor exercises as follow:(1) Eye follow with a stationary head 2)Saccadic eye movements 3) Gaze stability 4)Eye/head co-ordination 5)Balancing exercises 6)Eye motor coordination (7)position in space(8)coping-figure ground(9)spatial relationship(10)visual closure(11)constancy of shapes(12)far and near coping~Hand writing intervention as follow (1)Eye motor coordination (2)position in space(3)coping-figure ground(4)spatial relationship(5)visual closure(6)constancy of shapes(7)far and near coping"
223612339|NCT01815827|DRUG|inclacumab|single intravenous doses
223612340|NCT04345562|PROCEDURE|Skin preparation patterns with ChloraPrep 2 x 26 mL single|2 different patterns of skin preparation
223612341|NCT05661279|PROCEDURE|general anesthesia|general anesthesia
223758659|NCT01352390|BEHAVIORAL|Planning Prompt|A prompt to have their child their health test reminder mailing to color
223758660|NCT01352390|BEHAVIORAL|Control Condition|A basic reminder mailing will prompt each subject to get a health test as specified on the mailing
223758661|NCT01529424|DRUG|ISIS apoC-III Rx|Dose 1
223758662|NCT01529424|DRUG|ISIS apoC-III Rx|Dose 2
223758663|NCT01529424|DRUG|ISIS apoC-III Rx|Dose 3
223758664|NCT01529424|DRUG|Placebo|Dose 1
223758665|NCT01529424|DRUG|Placebo|Dose 2
223758666|NCT01529424|DRUG|Placebo|Dose 3
223758667|NCT00846118|DRUG|Pitavastatin|1-4mg/day
223758668|NCT02118428|DEVICE|Mirasol-treated Whole Blood|Transfusion with fresh Whole Blood treated with the Mirasol Pathogen Reduction Technology System for Whole Blood
223758669|NCT02118428|BIOLOGICAL|Untreated Whole Blood|Transfusion with untreated fresh Whole Blood
223758670|NCT04019691|DEVICE|Mix-and-Match|Phacoemulsification and implantation of Tecnis ZKB00 multifocal IOL with +2.75 D add power (Abbott Medical Optic Inc., Santa Ana, CA) in the dominant eye, and a Tecnis ZLB00 multifocal IOL with +3.25 D add power (Abbott Medical Optics Inc.) in the non-dominant eye.
224311932|NCT05055583|DRUG|Adjuvant treatment stage|Postoperatively, a comprehensive evaluation will be conducted by the investigator, and the intention will receive maintenance therapy within 6-12 weeks of the MDT assessment. Toripalimab: a fixed dose of 80 mg (2ml)/vial, IV, D1, a full dose of 240 mg at one time, every 3 weeks administered until PD or intolerable toxicity, for a maximum duration of 1 year.
224311933|NCT04588493|DIAGNOSTIC_TEST|Lower extremity Lymphoscintigraphy|Study of lymphoscintigraphy (LCG) abnormalities in a group of patients with history of infiltration of modeling substances in buttocks and hips and complain about lower extremities edema. LCG was performed and evaluated by a single nuclear medicine specialist through injection of the sulfur nanocolloid Technetium 99m, injected intradermal and interdigital in bilateral toes. Dynamic studies were requested for all patients. Standardized acquisition times at 15, 30, 60 and 120 minutes after injection were taken. The following parameters were considered to obtain the transport index in each pelvic limb: transport kinematics, distribution pattern, index time for the appearance of regional lymph nodes, number and collection of colloids in lymph nodes and presence and quality of the colloid uptake by the lymphatic vessels. Summation of these five components resulted in the transport index, which could range from 0 to 45 points
223612342|NCT05661279|PROCEDURE|general anesthesia plus Rhomboid intercostal block|the patients will be positioned in lateral decubitus with moving the scapula laterally by abducting the ipsilateral arm across the chest. under complete aseptic situations A high-frequency (6-12 MHz) linear US probe will be put medial to the medial border of the scapula in an oblique sagittal plane with the orientation marker directed cranially.at the T6-7 level, the tissue plain between the rhomboid major and intercostal muscles is identified, and a single injection of 25mL of bupivacaine (0.25%) will be administered via 18-gauge Tuohy advanced in plane from a superomedial to an inferolateral direction, followed by general anesthesia
223612343|NCT05661279|PROCEDURE|Serratus anterior plane block|The patient will be positioned supine with his arm abducts at 90°. the US high frequency (6-12 MHz) linear probe of sonosite M turbo ultrasonography (FUJIFIM sonosite, Inc., Bothell, WA, USA) will be put in sagittal plane at the midaxillary line. identification of the fascial plane between the serratus anterior muscle and external intercostal muscles will be performed between the fourth and fifth ribs in the midaxillary area . At this point the18-gauge Tuohy needle will be advanced in plane with injection of 25mL of 0.25 %, bupivacaine. followed by general anesthesia
223612344|NCT03642652|BEHAVIORAL|SMS|Text reminders to mobile telephone
223612345|NCT02739399|DRUG|Phenylephrine|Intravenous administration
223612346|NCT00203489|DEVICE|KERLIX A.M.D. Gauze|
223758671|NCT04019691|DEVICE|EDOF|Phacoemulsification and implantation of Tecnis Symfony ZXR00 trifocal IOLs (Abbot Medical Optics Inc.) in both eyes.
223758672|NCT04019691|DEVICE|Trifocal|Phacoemulsification and implantation of FineVision PodFT IOLs (PhysIOL SA) in both eyes.
223758673|NCT00882531|DRUG|isotretinoin|0.25 mg/kg, 1 per day, 4 month of treatment
223758674|NCT00882531|DRUG|placebo|
223758675|NCT02191189|DRUG|Nevirapine suspension, into Enterion™ capsule|
224201394|NCT03296267|PROCEDURE|Gastroduodenoscopy|Gastroduodenoscopy with duodenal biospies: A tube is placed via the mouth into the second part of the duodenum. Biopsy forceps is used to take duodenal biopsies.
223758676|NCT02191189|DRUG|Nevirapine suspension|
223758677|NCT03057691|OTHER|antidepressive and anti-anxiety therapy|These therapies include antidepressants, antianxiety drugs and psychotherapy. Subjects choose the therapy follow their own will. All of the above-mentioned therapies are identified by experienced psychiatrists in the same center. The treatment information will be recorded in each visit. The study is considered non-interventional, and no antidepressive or anti-anxiety therapies are mandated.
223758678|NCT02848976|OTHER|Re-training to effort (RE)|The RE program includes three weekly sessions, supervised individually by a teacher in adapted physical activity, during 1:30, for four weeks, for a total of 12 sessions
224201395|NCT00242567|DRUG|Zoledronic Acid|"Zoledronic acid was provided by Novartis in vials containing 4 mg/5 mL liquid concentrate. Prior to administration, the liquid concentrate from one vial was to be further diluted with 100 mL of calcium-free infusion solution (0.9 % weight by volume sodium chloride solution or 5 % weight by volume glucose solution). If refrigerated, the solution had to be allowed to reach room temperature before administration.~After addition of the liquid concentrate to the infusion media, the infusion solution was to be used as soon as practicable to reduce the risk of microbiological hazard. If storage of the solution was necessary, it had to be refrigerated at temperatures between 2-8 degrees C and was to be used within 24 hours.~The infusion solution containing 4 mg zoledronic acid was to be administered every 4 weeks as an i.v. infusion over no less than 15 minutes."
224201396|NCT00242567|DRUG|Androgen Deprivation Therapy (ADT)|Androgen deprivation therapy (ADT) was to be administered according to institutional protocols, in accordance with relevant prescribing information. The type and duration of androgen deprivation was at the discretion of the treating specialist, and could include orchiectomy where this would normally have been performed. Androgen deprivation therapy was provided by the investigational center, or obtained by the patient from usual sources. Anti-androgen monotherapy and intermittent ADT were excluded in the first 12 months of the study.
224201397|NCT06653686|OTHER|Hyperthermia combined with oral febuxostat.|Extracorporeal high-frequency hyperthermia combined with oral febuxostat
224201398|NCT06653686|DRUG|Febuxostat|The control group subjects were administered oral febuxostat.
224201399|NCT06702163|DEVICE|EXOPULSE MOLLII SUIT (active)|"Exopulse Mollii suit is a new assistive device that has been developed by Exoneural Network (initially Inerventions AB), a Swedish med-tech company.~Exopulse Mollii suit is a full-body garment with integrated 58 electrodes that can transcutaneously stimulate several groups of muscles. This stimulation is not intended to obtain a motor effect (contraction of the muscles in question), but rather to decrease the spasticity in spastic muscles by activating the antagonistic muscles via the physiological mechanism of reciprocal inhibition. The device is CE labelled and is intended to use for reducing spasticity and improving blood circulation. The outfit is very easy to put on, it can be used for one hour every day and the analgesic effects last 24 hours or more."
224201400|NCT06702163|DEVICE|EXOPULSE MOLLII SUIT (sham)|In the sham condition, the control unit will be programmed to start stimulating for 1 minute then it will shut off.
224201401|NCT04338646|OTHER|Clinical tests|Questionnaire about urinary symptoms, gait difficulties, fear of falling. Clinical test: Time to be Ready to Void
224201402|NCT06693336|DRUG|SMS001|One time administration
224311934|NCT00073697|DRUG|Escitalopram|Participants will receive escitalopram for a minimum of 32 weeks or approximately 8 months. Participants whose symptoms become stabilized will continue the initial treatment for another 6 months.
223612347|NCT05937061|BIOLOGICAL|Blood sample analysis|Analysis of complete blood count, hemogram, serum proteins, serum iron status (iron, transferin, ferritin). Group comparison - intervention vs. control.
223758679|NCT02378844|DEVICE|gammaCore®-R|Subjects will be instructed to treat three times per day, 2 consecutive bilateral stimulations, upon waking, six to eight hours following the first daily treatment, and six to eight hours following the second daily treatment (one stimulation on the right side immediately followed by a second stimulation on the left side).
223758680|NCT02378844|DEVICE|gammaCore®-R Sham|Subjects will be instructed to treat three times per day, 2 consecutive bilateral stimulations, upon waking, six to eight hours following the first daily treatment, and six to eight hours following the second daily treatment (one stimulation on the right side immediately followed by a second stimulation on the left side).
223612348|NCT05937061|OTHER|Anthropometrics measurement - at inclusion to the study (all groups).|Measurement of body height (cm), weight (kg) and calculating BMI (kg/m2). Group comparison - intervention vs. control.
223758681|NCT02580370|BIOLOGICAL|Botulinum toxin type A|Topical botulinum toxin type A
223758682|NCT02580370|BIOLOGICAL|Placebo comparator|Topical placebo comparator
223612349|NCT05937061|RADIATION|Bone mineral density measurement (DXA)|Analysis of bone mineral density with DXA in patients with milk allegy. Analysis ordered by medical doctor.
223612350|NCT05937061|OTHER|Influence of food allergy on growth (intervention groups)|Gathering the data about of body height (cm), weight (kg) BMI (kg/m2) at the diagnosis of food allergy and comparison versus data at the enrollment in the study to asses growth.
223612351|NCT04089761|DEVICE|Nerivio|Nerivio™ is an FDA-authorized remote electrical neuromodulation (REN) device for the acute treatment of migraine with or without aura in patients 18 years old or above who do not have chronic migraine. The device delivers transcutaneous electrical stimulation to the upper arm to induce conditioned pain modulation (CPM) that activates a descending endogenous analgesic mechanism. The treatment is self-administered and controlled by a smartphone application.
223612352|NCT06245733|OTHER|Compassion-Based Education Program Adapted for Adults|Training will be given once a week. This training will last 10 weeks in total.
223612353|NCT01553019|RADIATION|Proton radiation|Proton Radiation Therapy: R(0) negative ... 50.40 cobalt gray equivalent (CGE) at 1.8 CGE per fraction ; R(1) micro-positive ...54.00 CGE at 1.8 CGE per fraction; R(2) gross positive...59.40 CGE at 1.8 CGE per fraction
223758683|NCT01776983|DEVICE|Photosensitivity under the influence of immunocomp|Siascopy measurement of reflected light
223758684|NCT06317493|OTHER|Stimuli|"Auditory Stimuli: Pure tone bursts with main frequencies of 500, 1000, 2000, and 4000 Hz. Each tone will be presented at 10dB above the estimated individual threshold per frequency and compared to the responses to trials without auditory stimuli. Auditory stimulus duration: 25ms, there is 200ms baseline period before each trial, and 2000 ms interstimulus interval.~Visual stimuli: an animated movie adapted for the age and controlled for luminosity levels.~Pupil data will be collected through a Tobii PRO screen-based eye-tracker that measures eye-movements and pupil dilation using the infrared light cameras."
223758685|NCT05697900|DIETARY_SUPPLEMENT|Creatine Monohydrate|The CrM group supplemented the diet with five grams of micronized creatine monohydrate per day for eight weeks. The CrM supplement was fully dissolved in ≈500 mL of water and drank immediately after each training session (in the morning on non-training days).
223758686|NCT05697900|DIETARY_SUPPLEMENT|Placebo|A placebo group intakes five grams of maltodextrin daily throughout the study. The placebo supplement was fully dissolved in ≈500 mL of water and drank immediately after each training session (in the morning on non-training days).
223758687|NCT05697900|DIETARY_SUPPLEMENT|Creatine Hydrochloride|The Cr-HCl group supplemented the diet with five grams of micronized creatine monohydrate per day for eight weeks. The Cr-HCl supplement was fully dissolved in ≈500 mL of water and drank immediately after each training session (in the morning on non-training days).
223758688|NCT03930316|DEVICE|NOX T3|portable sleep study device
223758689|NCT05905588|DIETARY_SUPPLEMENT|Hydrogen-rich water|Patients drink 600mL hydrogen-rich water per day by applying hydrogen-rich water cup (Qingdao Haizhisheng Corp.,LTD, Qingdao, China) for 12 weeks. The dissolved hydrogen concentration is 5 ppm.
224201403|NCT05958979|OTHER|Control Marketing Strategies|Participants will self-administer experimenter-provided e-cigarettes
223612354|NCT01553019|DRUG|Gemcitabine|Gemcitabine 300 mg/m2 infused over 30 minutes, weekly during proton therapy.
223612355|NCT04747899|OTHER|Positional release technique|"Experimental group is given Positional Release Technique along with the hot pack, muscle stretching and posture correction.~Positional release technique position will maintained for almost 90 seconds. This technique will be repeated for three times each session, with 10 sec relaxation, 3 days/week.~Upper trapezius stretching 5 repetitions×1 set, 3 days/ week. Total of 3 sessions were given each consisting of 30 min.~Posture correction in ADLs as well as in working place by advising correct sitting posture, the participants will advised to relieve muscle tension after every 20-30 minutes of work by getting up; stretching the arm, shoulder, neck, and back muscles."
223612356|NCT04747899|OTHER|Traditional physical therapy|"Hot pack for 15-mins. Upper trapezius stretching 5 repetitions×1 set, 3 days/ week. Total of 3 sessions are given each consisting of 30 min.~Posture correction in ADLs as well as in working place by advising correct sitting posture, the participants will advised to relieve muscle tension after every 20-30 minutes of work by getting up; stretching the arm, shoulder, neck, and back muscles."
223612357|NCT02316496|DRUG|cetuximab|cetuximab 500mg/m²/ IV infusion, (q2w)
224201404|NCT05958979|OTHER|Experimental Marketing Strategies|Participants will self-administer experimenter-provided e-cigarettes
224201405|NCT01721200|OTHER|Decision Support Tool|Educational decision support tool for patients with rheumatoid arthritis
224201406|NCT01721200|OTHER|Usual Care|Subjects randomized to the Usual Care Group will receive their biologic drug teaching from the rheumatologist as part of their routine care.
224201407|NCT05500456|DEVICE|Clear aligners|Each aligner will be worn for about two weeks, and then replaced by the next in the series until the final position is achieved.
224201408|NCT05500456|DEVICE|Fixed appliances|Conventional wires and brackets will be used.
223612358|NCT02316496|DRUG|Irinotecan|Irinotecan 180mg/m², in 500ml NaCl 0.9% solution, 90 min IV infusion (q2w)
223612359|NCT00899756|GENETIC|molecular diagnostic method|
223612360|NCT00899756|GENETIC|mutation analysis|
223612361|NCT05747703|COMBINATION_PRODUCT|Ria Treatment Platform|combined medication, coaching, education, and monitoring
223612362|NCT02094651|DRUG|divalproex sodium|The drug is an FDA approved medication for seizures but has not been approved for the treatment of epileptiform EEG abnormalities in the absence of clinical seizures.
223612363|NCT02094651|OTHER|Placebo|The placebo is an inactive substance that looks like the active drug.
223612364|NCT05293067|DIAGNOSTIC_TEST|high-sensitive troponin|Values of high-sensitive troponin would be measured as follows: 1) preoperatively - one day before the planned intervention and 2) postoperatively - 8 hours after the operation and the first day after the operation.
223758690|NCT05905588|DIETARY_SUPPLEMENT|placebo|Patients drink 600mL tap water per day by applying analogue cup for 12 weeks. This cup has the same appearance as the hydrogen-rich water cup, and the hydrogen-rich water and placebo water were indistinguishable. The dissolved hydrogen concentration is 0 ppm in placebo water.
223758691|NCT04900896|DEVICE|Myoelectric Elbow-Wrist-Hand Orthosis|An arm orthosis that uses myoelectric signals to control the level of mechanical assistance provided to a user's elbow and hand in order to overcome upper limb weakness or paralysis and achieve functional tasks.
223758692|NCT02299050|DRUG|Cycloset|Bromocriptine QR 0.8 mg tablet 0.8 mg/day with dose increased to a maximum of 3.2 mg/day or as tolerated to a minimum of 2.4 mg/day Other names: Cycloset, B-QR
223758693|NCT00909636|DRUG|ABT-333|See arm description for more information
223758694|NCT00909636|DRUG|Placebo|See arm description for more information
223758695|NCT02619409|DRUG|Bupivacaine Only|The bupivacaine only group will receive bupivacaine 0.5% 3cc plus sterile saline 0.1cc.
223758696|NCT02619409|DRUG|EPI25|The EPI25 group will receive bupivacaine 0.5% 3cc, epinephrine 1:1000 0.025cc, and sterile saline 0.075cc.
223758697|NCT02619409|DRUG|EPI50 group|The EPI50 group will receive bupivacaine 0.5% 3cc, epinephrine 1:1000 0.05cc, and sterile saline 0.05cc
223758698|NCT02619409|DRUG|EPI75 group|The EPI75 group will receive bupivacaine 0.5% 3cc, epinephrine 1:1000 0.075cc, and sterile saline 0.025%.
223758699|NCT02619409|DRUG|EPI100 group|The EPI100 group will receive bupivacaine 0.5% 3cc, and epinephrine 1:1000 0.1cc.
223758700|NCT00706966|DRUG|dutasteride|6 months of dutasteride 3.5 mg daily
223612365|NCT05129540|DEVICE|Custom-made foot orthosis|The foot orthoses for group A will be custom made using phenolic foam molds of the feet. They consist of a polypropylene layer of 3 mm from heel to just proximal to the metatarsal heads, and an upper sheet of 30 Shore A polyethylene foam.
223612366|NCT05129540|DEVICE|Placebo orthosis|"A flat insole made of the same material as the upper layer of the custom-made foot orthoses used for group custom-made foot orthosis."
223612367|NCT01112397|DRUG|AZD1480|continuous daily oral capsule
223612368|NCT03863665|DEVICE|A&D BP Digital Blood Pressure Monitor (UA-767PBT-Ci) CE Declaration UA-767PBT-Ci|Telemetric home monitoring is a promising strategy to facilitate home BP monitoring after stroke, which should improve adherence and optimize medication to better control BP. Telemetry allows patients with hypertension to monitor their own BP and automatically send the information to a secure website, available to their clinicians to monitor and adjust their treatment.
223612369|NCT04739436|DEVICE|Hearing amplification|Bilateral vs. unilateral hearing aids for hearing loss
223758701|NCT06262360|PROCEDURE|General anesthesia with mask ventilation|Randomization to General anesthesia with mask ventilation
223758702|NCT06262360|PROCEDURE|General anesthesia and spontaneous laryngeal mask ventilation|Randomization to General anesthesia and spontaneous laryngeal mask ventilation
223758703|NCT06262360|PROCEDURE|General anesthesia with spontaneous laryngeal mask ventilation with pressure support|Randomization to General anesthesia with spontaneous laryngeal mask ventilation with pressure support
223758704|NCT02995915|OTHER|Nicotine Replacement Therapy|Participants will be prescribed NRT patch and one nicotine rescue method (e.g., nicotine gum, lozenge, inhaler) for use during the post-quit phase of the study. Participants will be given the choice between nicotine gum or nicotine lozenge, and will be instructed to use the rescue method as needed to reduce cigarette cravings
223758705|NCT02995915|DRUG|Bupropion|All participants who are medically eligible will be prescribed bupropion, which they will start two weeks prior to their quit day. Dosage will be 150 mg/daily for days 1-7 and 300 mg/daily (administered in two daily doses) until the 6-month follow-up.
224201409|NCT03926728|BIOLOGICAL|CTH522-CAF01 IM|On-site reconstitution of IMPs is performed by mixing 85 mcg CTH522 with CAF01. The preferred for IM is in the non-dominant deltoid muscle. IM injection will be performed with a 1-2 mL polypropylene Luer-Lok™ syringe via 23-25 gauge needle. The identity of the injected trial vaccine will be known to the clinical site staff dispensing and/or injecting the trial vaccine to the subject and by the unblinded trial monitor. The identity of the trial vaccine administered will remain unknown to the subject during the trial.
224205954|NCT06375954|DEVICE|Lumen-apposing metal stent (LAMS) and double-pigtail plastic stent (DPPS)|"Lumen-apposing metal stent (LAMS) with coaxial double-pigtail plastic stent (DPPS) deployment:~* LAMS size: 6x8mm or 8x8mm. Consider 10x10mm if bile duct \> 18mm.~* DPPS size: 7Fr x 3-7cm."
224205955|NCT03563235|DRUG|Xulin Jiangu granules|Xulin Jiangu granules tablets
223612370|NCT06308419|DRUG|Gemcitabine|Given by IV
223758706|NCT02995915|BEHAVIORAL|Cognitive Behavioral Treatment|Participants will receive 4 60-minute sessions of CBT telephone counseling for alcohol and smoking cessation.
223758707|NCT02995915|BEHAVIORAL|Mobile Contingency Management|Participants will be asked to provide video recordings of themselves taking carbon monoxide readings in order to confirm smoking abstinence, and breathalyzer to confirm abstinence from alcohol. Participants are asked to upload these videos to the study's secured server, and are provided monetary reward for videos that suggest smoking abstinence and alcohol abstinence.
223758708|NCT02995915|BEHAVIORAL|Mobile Monitoring|Participants will be asked to provide video recordings of themselves taking carbon monoxide readings and breathalyzer. Participants are asked to upload these videos to the study's secured server, and are provided monetary reward for providing the video recordings, regardless of abstinence.
223758709|NCT02884089|DRUG|Abemaciclib|Administered orally
223758710|NCT02884089|DRUG|Metformin|Administered orally
223758711|NCT02884089|DRUG|Iohexol|Administered intravenously (IV)
224311935|NCT00073697|BEHAVIORAL|Interpersonal Psychotherapy|Participants will receive interpersonal psychotherapy (IPT) for 8 months and possibly an additional 6 months.
224311936|NCT00073697|OTHER|Escitalopram plus IPT|Participants whose symptoms become stabilized will continue the initial treatment for another 6 months. Those who do not will have the second treatment added to their regimen until remission occurs.
223612371|NCT06308419|DRUG|Nab-Sirolimus|Given by IV
223612372|NCT04346329|DRUG|Hydroxychloroquine|Treated group
223612373|NCT04346329|DRUG|Placebo oral tablet|Placebo Group
223612374|NCT04628780|BIOLOGICAL|PF-07209960|PD-1 targeted IL-15 mutein
223612375|NCT03410524|DRUG|Simethicone Solution|200 mg of Simethicone in 3 mL of Simethicone Solution Formulation
223612376|NCT03410524|DRUG|Water|3 mL of water as placebo added to the bowel preparation
223612377|NCT02732964|OTHER|Pandora Music|Patients enrolled will be exposed to Pandora music for 30 minutes prior to their spinal anesthesia and cesarean delivery, and throughout their surgery.
223758712|NCT02884089|DRUG|Placebo|Administered orally
223758713|NCT03123159|DIAGNOSTIC_TEST|DxN HBV Assay|Molecular diagnostic test to detect Hepatitis B
223758714|NCT01631474|DRUG|CB-03-01|Topical cream, applied once a day
223758715|NCT01631474|DRUG|Vehicle|Topical cream, applied once or twice a day
223758716|NCT01631474|DRUG|CB-03-01|Topical cream, applied twice a day
223758717|NCT00789282|OTHER|multidisciplinary approach|Provides an integrated, proactive approach to the management of patients with chronic diseases (ie: diabetes and sequelae) Wagner Model- care encompassed in 3 overlapping galaxies: wider community; the health care system; and the provider organization. There are 6 essential elements: community resources and policies; health care organization; patient self-management support; delivery system design; decision support; and clinical information systems.
223758718|NCT00789282|OTHER|multifactorial approach - for enhanced care group|optimized medical management support for development of enhanced patient self management skills organized proactive follow-up chronic disease management teams
223758719|NCT00789282|OTHER|reflects current patterns of care|"Continue under the care of their family physician and specialists with referral to diabetic assessment and treatment centers at the discretion of the patient and physician.~Normal manner of care: could attend diabetic self education classes and consultations regarding management of diabetes. Or, participate in other patient self management program of their choice."
223758720|NCT00004881|BIOLOGICAL|MVA-MUC1-IL2 vaccine|
223758721|NCT04254614|DEVICE|Personalised mobile application for IBD patients|"Patients will use a mobile application for ±6months (exact period depends on interval of biologic treatment) with the following functionalities:~* Personal interactive timeline to prepare for biologic treatment with reminders for blood tests, a questionnaire to exclude contra-indications for biologic treatment (e.g. current infection) and a message from the gastroenterology nurse when blood tests results and the questionnaire have been checked. Only in case of abnormal results or answers patients will be contacted by telephone by their gastroenterology nurse, which is currently standard care.~* Information about the patients' diagnosis and biologic treatment.~* General information on e.g. IBD treatment, vaccinations, frequently used medical terms, preparing for outpatient visits, what to do in case of disease symptoms.~Patients will fill in a questionnaire to measure study outcomes at baseline and at the end of the study period."
224311937|NCT01772797|DRUG|LDK378|LDK378 is a capsule to be taken daily by mouth.
224311938|NCT01772797|DRUG|AUY922|AUY922 is an intravenous infusion that will be administered by the investigative site to the patient on a weekly basis.
224311939|NCT00901576|DRUG|SPD503|SPD503 (guanfacine hydrochloride) extended-release 4 mg orally administered tablets
223612378|NCT02732964|OTHER|Mozart Music|Patients enrolled will be exposed to Mozart music for 30 minutes prior to their spinal anesthesia and cesarean delivery, and throughout their surgery.
223612379|NCT05315479|DRUG|N1539|Once daily
223612380|NCT05373849|DIETARY_SUPPLEMENT|essentiel oil mixtures in inhaler sticks (step 1) - no intervention (step 2)|The participant will receive the study treatment (essential oils mixture in inhaler sticks for 2 months) and the control (no intervention for 2 months). At inclusion and at the end of each period, questionnaires of well-being, anxiety and stress will be completed
223612381|NCT05373849|DIETARY_SUPPLEMENT|no intervention (step 1) - essential oils mixture in inhaler sticks (step 2)|The participant will receive the control (no intervention for 2 months) and the study treatment (essential oils mixture in inhaler sticks for 2 months). At inclusion and at the end of each period, questionnaires of well-being, anxiety and stress will be completed.
223612382|NCT00773162|DRUG|Seroquel|seroquel XR- oral extended release tablets, 50mg - 300mg, 16 weeks
223612383|NCT00773162|DRUG|Sugar Pill|Sugar pill to match seroquel
223612384|NCT06056583|DRUG|Cimetidine 200 MG|Cimetidine will serve as the probe drug
223612385|NCT01926834|DRUG|Erigeron Injection|Erigeron Injection, 30ml, iv, qd, for 7days
223612386|NCT01926834|DRUG|placebo|normal saline, 500ml,i.v.,qd, for 7 days
223612387|NCT03387865|PROCEDURE|tissue biopsies|additional biopsies will be performed during a diagnostic or therapeutic procedure, in order to sample tumor tissue and healthy tissue.
223612388|NCT03387865|PROCEDURE|blood sampling|additional blood samples will be collected during a SOC sampling procedure (2 EDTA 7.5 ml tubes, 2 SST 7.5 ml tubes and 2 citrate 5 ml tubes)
223612389|NCT03387865|GENETIC|DNA banking|constitutional and somatic genetic alterations will be analysed for subjects who consent, from either tumor or healthy tissue, or whole blood buffy coat after centrifugation
223612390|NCT00273273|PROCEDURE|blood draw|
223758722|NCT00854503|DRUG|Simvastatin|20 mg/day in one oral administration
223758723|NCT00854503|DRUG|Rosuvastatin|20 mg/day in one oral administration.
224205956|NCT03563235|DRUG|Calcitriol capsules|Calcitriol capsules tablets
224205957|NCT05431348|DEVICE|Smartwatch|Patients will wear the smartwatch during treatment which measures, activity, steps, sleep and heartrate
224205958|NCT05431348|DIAGNOSTIC_TEST|Serum Cortisol|Level of cortisol in serum will be determined
224205959|NCT05431348|OTHER|Questionnaires|Patients are asked to fill in patient reported outcomes (PROMS) and specific questions on stress, exercise and fatigue (QSC-R23, IPAQ-SF, MVI-20)
224205960|NCT02863588|BIOLOGICAL|seropositive for Toxoplasma gondii|blood sample
224205961|NCT03755856|OTHER|Questionnaire|Health-related quality of life
223758724|NCT04571112|DEVICE|NBM stimulation using the Vercise device (Boston Scientific, Marlborough, Massachusetts, US)|This will either be turned on or off depending on the arm which the patient is randomized to. After 8-weeks, the subject will switch arms for another 8-weeks.
223758725|NCT01196767|DRUG|Ropivacaine (in one arm); catheterization (in both).|"Parallel study with two groups:~1. ropivacaine (2 mg.mL-1), at the rate of 4 mL.hr-1 through two subcutaneous catheters lateral to the sternum, both alimented by an elastomeric pump.~2. same protocol, with normal saline instead of ropivacaine."
223758726|NCT02624284|DEVICE|transcranial direct current stimulation (tDCS)|"Active tDCS: A neuroConn DC-Stimulator Plus will apply a constant direct current (1.0 mA to 2.0 mA via 5x7 electrode) to the left dorsal lateral prefrontal cortex. Each participant will receive anodal stimulation for a period of 20 minutes. For anodal stimulation over the left DLPFC, the anodal electrode will be placed over the left F3 and the cathodal electrode over the right supraorbital area (international EEG 10/20 system).~Sham tDCS: During sham tDCS, a 1.0 mA to 2.0 mA current will be delivered for approximately 30 seconds before being extinguished over a course of seconds. Again, the anodal electrode will be placed over the left F3 and the cathodal electrode over the right supraorbital area. Most participants cannot distinguish between real and sham tDCS."
223758727|NCT01339975|BIOLOGICAL|Biological sample|"2 blood samples of 10mL + one urine sample~* on pre-operative d-1/d, post-operative d1 and d5(+/-2),~* one month post-operative,~* at the end of the study in the absence of disease progression or at the date of recurrence or progression if the case arises."
224311940|NCT00901576|DRUG|Concerta|CONCERTA (methylphenidate HCl) extended-release 36 mg orally administered tablets.
224311941|NCT00901576|DRUG|SPD503 + Concerta|SPD503 4 mg + CONCERTA 36 mg orally administered tablets (taken together).
223612391|NCT05874024|PROCEDURE|induction of labour with double balloon catheter placement for 6 hours|catheter placement for 6 hours beginning in the morning at around 8 a.m.
223612392|NCT05874024|PROCEDURE|induction of labour with double balloon catheter placement for 12 hours|catheter placement for 12 hours in the evening at around 8 p.m.
223612393|NCT00858624|DRUG|ketamine|Administration of low dose intravenous ketamine. Dose: 0.075mg/kg over 10 minutes followed by 0.005mg/kg/min over 20 minutes. Given as single infusion.
223612394|NCT02977858|OTHER|Educational practice for HCPs,Dissemination only|Study participants are health care professionals (HCPs) who will be provided educational material and complete knowledge assessments
223612395|NCT02977858|OTHER|Educational practice for HCPs,Spaced Education|Study participants are health care professionals (HCPs) who will be provided educational material via a Spaced Education program; participants will subsequently complete knowledge assessments
223758728|NCT01339975|BIOLOGICAL|Biological sample|"2 blood samples of 10mL + one urine sample~* before starting the therapy~* at first therapeutic evaluation (2 or 3 months depending on the treatment chosen)~* at the end of the study or at the date of disease progression."
223758729|NCT00556855|OTHER|E-DO|topical lotion, once daily (evening), total duration: 4 weeks
223612396|NCT04323059|DIETARY_SUPPLEMENT|Standardized milk-based formulation|Nutritional formulations prepared from locally available food stuffs for reversing childhood malnutrition
223758730|NCT00556855|OTHER|Placebo|topical lotion, once daily (evening), total duration: 4 weeks
223758731|NCT06187545|DEVICE|Minimum viable prototype|Deep sedation in critical ill patients using minimum viable prototype
223758732|NCT06187545|DEVICE|Usual care|Deep sedation without minimum viable prototype
223758733|NCT01225445|DRUG|Ramipril|2.5 mg daily
223758734|NCT04038489|DRUG|Aspirin|325 mg aspirin daily during AC-T chemotherapy
223758735|NCT04038489|DRUG|Tamoxifen Pill|Tamoxifen (either 20 mg daily or 10 mg twice a day) during AC-T chemotherapy
223758736|NCT04038489|DRUG|Doxorubicin|Doxorubicin (60 mg/m2) Given by IV with cyclophosphamide
223612397|NCT02934165|BEHAVIORAL|Family Safety 123|Theoretically-based injury prevention videos for families
223612398|NCT02934165|BEHAVIORAL|AAP TIPP sheets|American Academy of Pediatrics The Injury Prevent Program materials converted to web-based materials.
223612399|NCT04415814|PROCEDURE|Unilateral Pedicle Screw Fixation|Pedicle screws are installed unilaterally on the one side of the vertebrae and fixed with rod
223612400|NCT04415814|PROCEDURE|Bilateral Pedicle Screw Fixation|Pedicle screws are installed bilaterally on the both sides of the vertebrae and fixed with rods
223612401|NCT03622814|BEHAVIORAL|Partners at Meals|The focus of the intervention was to facilitate meals using knowledge of the person with dementia's past history and lifelong preferences as well as their stage of disease, altering the behavior of the caregiver at meals to ameliorate dysfunctional behaviors, and altering the environment to make it more focused on the process of meals. Families recorded three meals including behavior at home each month.
223612402|NCT03622814|BEHAVIORAL|Enhanced Usual Condition|Enhanced Usual Condition (EUC) Staff and volunteers at the EUC sites received training in communication between family and friends of the person with dementia. Following the general model of the Savvy Caregiver (Hepburn), communication training will occur every six months in these two sites. Families will be trained by project staff to record three meals including behavior at home each month.
223758737|NCT04038489|DRUG|Cyclophosphamide|Cyclophosphamide (600 mg/m2) Given by IV with doxorubicin
223758738|NCT04038489|DRUG|Paclitaxel|Paclitaxel 80 mg/m2 or 175 mg/m2 based on provider preference. Given by IV after completion of doxorubicin/cyclophosphamide therapy
223758739|NCT05627895|OTHER|Neurofeedback|Participants will be shown their brain activity measured in real-time using an MRI scanner. They can then use mental strategies, such as imagination to influence and regulate this activity.
223758740|NCT00748644|DRUG|Rituximab|"rituximab infusion will be performed at J1, J15, M6, M12 and M18(i.e. a total of 5 infusions), at the dose of 500 mg at a fixed dosage.~All patients received corticosteroids, starting from induction with prednisone (or equivalent) at a dose of 1 mg/kg/day with gradual tapering according to a regimen adjusted to body weight over a mean of 18 months since diagnosis."
224311942|NCT01559389|DRUG|Solifenacin|Women presenting with UUI symptoms receive 5 to 10 milligrams (mg) of daily solifenacin for up to 16 weeks
224311943|NCT05404334|DIAGNOSTIC_TEST|Androgen receptor status and BRCA mutation|Androgen receptor status by IHC and germ line BRCA mutation
223758741|NCT00748644|DRUG|Azathioprine|"azathioprine (2 mg/kg/d) for 12 months, then progressively tapered until its discontinuation at month 22.~All patients received corticosteroids, starting from induction with prednisone (or equivalent) at a dose of 1 mg/kg/day with gradual tapering according to a regimen adjusted to body weight over a mean of 18 months since diagnosis."
223612403|NCT06242301|OTHER|The collective person-centered dialogue intervention|"* Educate and train the interdisciplinary team and staff.~* Upon hospitalisation, the interdisciplinary team introduces an interactive dialogue tool to patients and their relatives. The tool is designed to facilitate a person-centered dialogue and assess the patients' needs, motivations, and challenges regarding eating and physical activity during hospitalization and in everyday settings.~* Following the needs assessment, the interdisciplinary team will introduce and initiate a personalised action plan based on a predefined template that includes suggestions for actions related to the needs assessment.~* Collaboratively, the interdisciplinary team, patients, and relatives evaluate and adjust the action plan, discussing relevant actions and potential community support for maintaining daily activities.~* Before discharge, discussions are guided by predefined questions. Patients receive a contact number for follow-up and information on oral nutritional supplementation prescriptions."
223758742|NCT01123538|DRUG|Progesterone|200 mg/day oral micronized natural progesterone (e.g. Utrogestan® 100mg) + 0.05 mg/day transdermal (i.e. plaster) 17β-estradiol (e.g. Estraderm® 50µg) during a year
223612404|NCT02907151|OTHER|Survey|Complete a survey prior to the consultation and a questionnaire after
223612405|NCT05306587|DRUG|Darzalex|Investigate the home administration of Darzalex SC reported by both patients and healthcare professionals compared to the hospital administration setting.
223612406|NCT01867762|DRUG|JNJ 49095397|JNJ 49095397 400 microgram will be inhaled by participants once daily by using a dry powder inhaler for 12 weeks.
223612407|NCT01867762|DRUG|Placebo|Placebo will be inhaled by participants once daily by using a dry powder inhaler for 12 weeks.
223612408|NCT01862536|DRUG|Tadalafil|Daily use of study drug to treat pulmonary hypertension.
223612409|NCT01862536|DRUG|placebo|Daily use in double blind study.
223612410|NCT00503269|PROCEDURE|Hemorrhoidectomy|Hemorrhoidectomy under local anaesthesia
223612411|NCT00503269|PROCEDURE|Hemorrhoidectomy|General anaesthetic haemorrhoidectomy
223612412|NCT00921349|PROCEDURE|Ligation of varices|all varices are ligated until obliteration
223612413|NCT00921349|DRUG|Nadolol|Nadolol (beta-blocker)
223612414|NCT01156714|BEHAVIORAL|Treadmill training with aerobic exercise|walk on treadmill for aerobic exercise
223612415|NCT01156714|BEHAVIORAL|Memory training with computerized memory program|memory testing and training on computer program
223612416|NCT01156714|BEHAVIORAL|Combination of treadmill training and computerized memory|both exercise and cognitive computer training
223612417|NCT05932797|OTHER|Multimodal intervention in Long Covid19|The intervention will consist of physical, psychological, cognitive and nutritional training and treatment to be carried out at the Teaching and Research Assistance Center of the University of Magellanus (CADI UMAG), program includes 12 sessions of cognitive behavioral therapy sessions, 12 kinesic rehabilitation sessions, 12 treatment sessions per nutrition professional, 12 rehabilitation sessions with occupational therapy professional and 12 rehabilitation sessions with a speech therapist.
223612418|NCT02052752|DRUG|3% Benzoyl Peroxide|Test product contained 3% benzoyl peroxide in the form of a gel. It was applied on participant's face once-daily at approximately the same time on Days 0, 1, 2 and 3.
223612419|NCT02052752|DRUG|3% Benzoyl Peroxide Placebo|The vehicle gel was similar to the test product except that it did not contain 3% benzoyl peroxide. The vehicle gel served as the negative control and was applied on participant's face once-daily at approximately the same time on Days 0, 1, 2 and 3.
223758743|NCT01123538|DRUG|Chlormadinone acetate|5 mg/day oral chlormadinone acetate (e.g. Luteran® 5mg)+ 0.05 mg/day transdermal (i.e. plaster) 17β-estradiol (e.g. Estraderm® 50µg)
223758744|NCT00846924|DEVICE|a 30-day ambulatory cardiac event monitor|Patients will be fitted with dry electrode belt (including cardiac event monitor)and instructed to wear the device for as many hours(waking and sleeping) each day as possible, for a total of 30 days.
223758745|NCT00846924|DEVICE|24-hour Holter|Repeat standard 24-hour Holter Monitor
223758746|NCT04433897|OTHER|Questionnaire|"All women fulfilled 3 questionairres~* TANGO~* ICIQ -N~* Perceived Stress Scale"
223758747|NCT03897972|BEHAVIORAL|Non-personalised diet advice delivered via the eNutri app (control)|Non-personalised dietary advice to improve food choices based on standard population guidelines delivered by the eNutri app and irrespective of the dietary intakes from the food frequency questionnaire (control group).
223758748|NCT03897972|BEHAVIORAL|Personalised diet advice delivered via the eNutri app (intervention)|Personalised dietary advice to improve food choices based on adherence to an 11-item diet quality score, which is determined by the eNutri app in response to the dietary intakes from the food frequency questionnaire (intervention group).
223758749|NCT04766749|OTHER|RIPC|RIPC is delivered with a standard blood pressure cuff placed on the upper thigh. The cuffs are inflated to 200 mm Hg and keep inflated for 5 minutes,Then deflated to 0 mmHg and keep uninflated for 5 minutes, This cycle is repeated four times
223612420|NCT02052752|DRUG|Neutrogena Rapid Clear®|A commercial product containing 2% salicylic acid that reportedly improves acne lesions was applied on participant's face once-daily at approximately the same time on Days 0, 1, 2 and 3.
223612421|NCT03609996|DEVICE|Panretinal Photocoagulation|Laser treatment for PDR
223612422|NCT03609996|DRUG|Lucentis|Intraviteral injection
223758750|NCT03341052|OTHER|Normal Diet|The normal diet will consist of the participants' normal eating habits, and will be tracked by a food log. The participants will be on their normal diet during week 1 and week 3.
223758751|NCT03341052|OTHER|High Fat Diet|The high fat diet will consist of 2700 kcal, 100g total fat (33%), 300mg cholesterol, 350g carbohydrates (52%), and 100g protein (15%). The participants will be on this diet during week 2.
223758752|NCT03341052|OTHER|Low Fat Diet|The low fat diet will consist of 1200 kcal, 26g fat (20%), 78mg cholesterol, 150g carbohydrates (50%), and 100g protein (30%). The participants will be on this diet during week 4.
223758753|NCT02385812|PROCEDURE|Low-dose computed tomography Annual scan x3|Annual scan x3
223758754|NCT02385812|PROCEDURE|Low-dose computed tomography Baseline scan only|Baseline scan only
223758755|NCT01209897|BEHAVIORAL|Smoking cessation booklet|
223612423|NCT02114229|DRUG|alisertib|Alisertib will be administered orally at 80 mg/m\^2 per day for enteric coated tablet formulation and 60 mg/m\^2 per day for oral solution formulation.
223612424|NCT02114229|DRUG|methotrexate|Methotrexate will be given at a dose of 5 g/m\^2/dose as an intravenous infusion over 24 hours on day 1 of each induction cycle except in patients ≤ 31 days of age at enrollment. These young infants will receive methotrexate at a reduced dose of 2.5g/m\^2/dose.
223612425|NCT02114229|DRUG|cisplatin|Cisplatin will be given intravenously (IV): 75 mg/m\^2 IV infusion.
223612426|NCT02114229|DRUG|carboplatin|Carboplatin may be substituted for cisplatin during induction for patients having Grade 4 ototoxicity or bi-lateral hearing loss after having prior cisplatin dose reduction. Route of administration is IV.
223612427|NCT02114229|DRUG|cyclophosphamide|Cyclophosphamide will be given 1.5 g/m\^2 IV infusion during induction and consolidation.
223758756|NCT01641367|DRUG|Darunavir|Participants were administered darunavir orally as one 600 mg tablet twice a day (1200 mg per day) with food (taken with Ritonavir 100 mg twice a day \[200 mg per day\])
223758757|NCT01641367|DRUG|Etravirine|Patients were administered Etravirine orally as two 100 mg tablets or one 200 mg tablet twice a day (400 mg per day) following a meal.
223758758|NCT01641367|DRUG|Emtricitabine/tenofovir disoproxil fumarate|Patients were administered FTC/TDF orally as one fixed dose combination tablet (FTC 200 mg/TDF 300 mg) once daily, with or without food.
223758759|NCT01641367|DRUG|Raltegravir|Participants were administered Raltegravir orally as one 400 mg tablet twice daily (800 mg per day), with or without food
223758760|NCT01641367|DRUG|Second line ART regimens - based on a boosted protease inhibitor (bPI) plus two nucleoside analogues (NRTIs)|LPV/r and ATV/r were the preferred bPIs for second-line ART. TDF + (3TC or FTC) or AZT + 3TC were the most frequent NRTI backbones. Cohort A did not include any of the new drugs; therefore, it is distinct from Cohorts B, C, and D.
223758761|NCT01641367|DRUG|Study provided drugs according to patient resistance profile (DRV, ETR, RTV, FTC/TDF) + any in country available drug as applicable & available|For Cohort D, in many situations a participant received the same regimen that patients are getting in Cohorts B and C if that was the best combination that can be obtained according to his/her resistance profile and drug availability (as for many countries there were no further drug options beyond the available study drugs).
223758762|NCT01641367|OTHER|SOC adherence versus SOC+CPI adherence|"* not participating in the adherence randomization; OR~* randomized to SOC adherence; OR~* randomized to SOC+CPI adherence."
223758763|NCT04634292|BEHAVIORAL|EEG|EEG + walking task + auditory task
223612428|NCT02114229|DRUG|etoposide|"Etoposide will be given 100 mg/m\^2 IV infusion.~In case of etoposide reactions, etoposide phosphate will be given 40 mg/kg/day."
223612429|NCT02114229|DRUG|topotecan|Topotecan will be administered by intravenous infusion over 4 hours on days 1-5 of each consolidation cycle for Stratum B2 and B3 patients not receiving craniospinal irradiation. The initial dose of Topotecan will be based on patient's age with subsequent doses adjusted, if necessary, to achieve a topotecan lactone area under the curve (AUC) of 140 ± 20 ng/mL\*hr.
223612430|NCT02114229|DRUG|vincristine|Vincristine will be given 1 mg/m\^2 IV via 25 mL normal saline (NS) mini-bag (maximum 2 mg for all patients) or administration per local institutional standards for participating sites.
223758764|NCT01018420|DRUG|Colchicine|two 0.6 mg capsules (1.2 mg dose) followed by an additional 0.6mg capsule every hour for 6 additional doses
224201410|NCT03926728|BIOLOGICAL|CTH522-CAF09b IM|On-site reconstitution of IMPs is performed by mixing 85 mcg CTH522 with CAF09b. The preferred for IM is in the non-dominant deltoid muscle. IM injection will be performed with a 1-2 mL polypropylene Luer-Lok™ syringe via 23-25 gauge needle. The identity of the injected trial vaccine will be known to the clinical site staff dispensing and/or injecting the trial vaccine to the subject and by the unblinded trial monitor. The identity of the trial vaccine administered will remain unknown to the subject during the trial.
224201411|NCT03926728|BIOLOGICAL|CTH522 ID|24 mcg CTH522 given ID is in the non-dominant deltoid muscle. ID with a 1 mL syringe via a 26-28 gauge needle using a NanoPass device or similar. The identity of the injected trial vaccine will be known to the clinical site staff dispensing and/or injecting the trial vaccine to the subject and by the unblinded trial monitor. The identity of the trial vaccine administered will remain unknown to the subject during the trial.
224201412|NCT03926728|BIOLOGICAL|CTH522 TO|24 mcg CTH522 (12 mcg in each eye) TO administrations will be performed using a Gilson positive displacement pipette. The identity of vaccine will be known to the clinical site staff dispensing/administrating the trial vaccine to the subject and by the unblinded trial monitor. The identity of the trial vaccine administered will remain unknown to the subject during the trial.
224201413|NCT03926728|BIOLOGICAL|Placebo (Saline)|Placebo only given as IM, ID and TO.
224201414|NCT01900353|OTHER|brushing methods|
224201415|NCT02243059|DRUG|Gadofosveset trisodium (Ablavar™ )|
223758765|NCT01018420|DRUG|Moxifloxacin|400 mg capsule at the 6 hour point
223758766|NCT01715506|BEHAVIORAL|Educational intervention|The educational intervention (EI), Relation Related Care (RRC), consists of a two-day seminar and one hour monthly guidance for six months. Course material, a book particularly designed for this intervention and dealing with person centered care and use of restraint, is distributed ahead of the course part of the intervention to all participants.
223758767|NCT01297673|PROCEDURE|video-urodynamic examination|Assessment of bladder function during video urodynamic determine of incidence degree and localization of vesico ureteral reflux based on the result of video urodynamics
223758768|NCT02090452|DEVICE|Real time transmission of patient related data. Device used: MobiMed 3.1, manufactured by Ortivus AB Sweden|
224201416|NCT02243059|DEVICE|MRI|
224201417|NCT05486663|OTHER|Tactile/kinesthetic Group|Tactile/kinesthetic stimulation is performed in three stages. In the first stage; for tactile stimulation; The baby is placed in the prone (prone) position in the incubator. Light massage was applied in the head, shoulder, back, legs and arms of the infants. Each massage is applied 12 times for 1 minute. Massage was performed for 5 seconds. In the second stage Kinesthetic stimulation, including elbow flexion-extension movement, palm massages, flexion-extension of the knees and legs and plantar massages, was applied while the neonate was in supine position. Each kinesthetic stimulation was performed for 5 seconds. Each movement was repeated six times, with a total duration of 5 minutes. Tactile stimulation was repeated once after kinesthetic stimulation. The total duration of TKS was 15 minutes which was performed three times daily preferably between breastfeeding or bottle feeding for 14 consecutive days.
224311944|NCT04302636|DIETARY_SUPPLEMENT|Low glycemic index diet|The LGIT diet of the experimental group consisted of 55% fat, 30% protein and 15% carbohydrate, and the glycemic index of the food was limited to less than 50. The meal was prepared by a public nutritionist who evaluated the nutritional composition of the inpatients provided by the canteen and then added or subsumed the compound nutrition powder.
224311945|NCT05242718|DIETARY_SUPPLEMENT|N-Acetyl-L-cysteine (NAC)|Health Canada Natural Product Number (NPN) 80056946
224311946|NCT05242718|DIETARY_SUPPLEMENT|Echinacea purpurea|Health Canada Natural Product Number (NPN) 80093896
224311947|NCT05242718|DIETARY_SUPPLEMENT|Curcumin|Health Canada Natural Product Number (NPN) 80043455
224311948|NCT05242718|DIETARY_SUPPLEMENT|Palmitoylethanolamide|Health Canada Natural Product Number (NPN) 80097472
224311949|NCT06292117|OTHER|CYP2C19 Genotype|qPCR-based genotyping assay interrogating all Association for Molecular Pathology (AMP) recommended Tier 1 and Tier 2 single nucleotide polymorphisms (SNPs) for CYP2C19 (\*2, \*3, \*4, \*5, \*6, \*7, \*8, \*9, \*10, \*17, \*35)
223612431|NCT02114229|PROCEDURE|Surgical resection|"For patients with localized AT/RT, gross total resection results in a significant survival benefit. Maximal resection that can be achieved without undue risk to the patient should be attempted prior to trial enrollment. Decisions about initial resectability will be at the discretion of the local neurosurgeon. In rare instances, the feasibility of completely resecting residual tumor may change as a result of induction chemotherapy; in these cases a second-look operation is encouraged if and may be performed prior to consolidation therapy."
223612432|NCT02114229|RADIATION|Radiation therapy|The guidelines for this protocol were developed to maximize the curative potential of radiation therapy and minimize the risk of treatment complications for children with newly diagnosed CNS AT/RT. Focal irradiation is indicated for children \< 36 months with no evidence of metastatic disease. Craniospinal irradiation is indicated for children age \> 36 months.
223612433|NCT04854694|DEVICE|FaceView Mask™|transparent surgical N95 respirator designed to improve communication
223612434|NCT04854694|DEVICE|conventional surgical N95 respirator|standard N95 respirator
223758769|NCT02053727|DRUG|Abatacept|Abatacept Injection, 125 mg/Syringe (125 mg/mL), is a sterile solution for SC administration, which contains approximately 126 mg abatacept.
223758770|NCT02053727|DRUG|Placebo|
223758771|NCT04462042|RADIATION|Proton radiotherapy|Proton radiotherapy
223758772|NCT04462042|RADIATION|Photon radiotherapy|Conventional photon radiotherapy
223758773|NCT05668767|DRUG|Surufatinib Durvalizumab EP/EC|Etoposide: total 100 mg/m2, once a day, continuous intravenous drip for more than 3 hours, days 1 to 3, q3w Cisplatin: total 75 mg/m2, once a day, continuous intravenous drip for more than 3 hours, days 1 to 3, q3w; or Carboplatin: AUC 5-6, intravenous infusion, administered on day 1 of each treatment cycle, q3w
224314287|NCT05744141|PROCEDURE|Relaxation Exercises|"Relaxation exercises consist of voluntary, rhythmic and regular stretching and relaxation of large and small muscle groups until the whole body relaxes. For this exercise application, the Relaxation Exercises CD prepared by the Turkish Psychological Association will be used. The CD consists of 30 minutes and relaxation exercises are explained with the sound of a stream accompanied by verbal instructions. This exercise includes rhythmic breathing, muscle relaxation exercises and music (stream sound)."
223612435|NCT04157062|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|During the rTMS session, an electromagnetic coil is placed against the subjects scalp. The electromagnet painlessly delivers a magnetic pulse that stimulates nerve cells in the region of the brain involved in memory and thinking.
223612436|NCT05199545|DIETARY_SUPPLEMENT|Dietary supplement|Dietary supplement under study is based on Rhodiola rosea L. and Crocus sativus L. extracts
223612437|NCT05199545|OTHER|Placebo|Placebo of the dietary supplement
223612438|NCT06999330|DEVICE|Theta burst stimulation active coil|MagVenture TMS Therapy active coil with theta burst stimulation. Resting motor threshold: 90%; Number of pulses per session: 1200 pulses; Inter-train interval: 8 seconds; Pulse frequency in burst: 50 Hertz; Session length: 10 min; Time between sessions: 50 minutes.
223612439|NCT06999330|DEVICE|Sham coil|MagVenture TMS Therapy sham coil
223612440|NCT06726031|DEVICE|wearing VR glass|The intervention is the application of VR headsets during the procedure for patients who were previously indicated for transradial coronary angiography and were randomized to the VR headset group.
223612441|NCT06725485|DRUG|Low-Dose Lidocaine|Low-dose lidocaine infusion 10-30 mcg/kg/min administered within 1 hour of ICU admission.
223612442|NCT07049432|DRUG|N803|N-803 subcutaneously (SubQ) administered on day 1 of each 21-day cycle for up to 6 cycles.
223758774|NCT05298852|DIAGNOSTIC_TEST|High resolution computed tomography of the chest|All participants were subjected to High resolution computed tomography of the chest.
223758775|NCT03100825|DRUG|QVM149|QVM149 (indacaterol acetate/glycopyrronium bromide/mometasone furoate)
223758776|NCT02421458|RADIATION|6 x 6 Gy|radiation in 6 fraction of 6 Gy, twice a week during 3 weeks
223758777|NCT02421458|RADIATION|16 x 3.125 Gy|radiation in 16 fraction of 3.125 Gy, 4 times a week during 4 weeks
223758778|NCT04987073|PROCEDURE|skin biopsy|A skin biopsy to cultivate fibroblasts.
223758779|NCT03237728|DRUG|0.06mg/kg,KB|0.06mg/kg,Q8h,Day1-Day7
223512372|NCT05770973|OTHER|Compression dressing (build by Kompressen, gauze swabs, Nobamed Paul Danz AG, Wetter, Germany and NOBALUMENAL® - steril, eye pad, Nobamed Paul Danz AG, Wetter, Germany|Compression dressing after ptosis surgery
223512373|NCT05845255|DEVICE|mjn-SERAS|Using of wearable, non-invasive device for EEG recording and forecasting of epileptic seizures
223512374|NCT03948789|PROCEDURE|Magnetic Resonance Imaging-controlled high-focussed ultrasound therapy|Magnetic Resonance Imaging-controlled high-focussed ultrasound
223512375|NCT03948789|PROCEDURE|Myomectomy (laparoscopic or open surgical)|Myomectomy (laparoscopic or open surgical)
223512376|NCT01965483|RADIATION|once-weekly breast irradiation|
223758780|NCT03237728|DRUG|0.12mg/kg,KB|0.12mg/kg,Q8h,Day1-Day7
223758781|NCT03237728|DRUG|0.24mg/,KB|0.24mg/kg,Q8h,Day1-Day7
223758782|NCT03237728|DRUG|Placebos|Placebos,Q8h,Day1-Day7
223758783|NCT04509843|BEHAVIORAL|socioeconomic status|it is a cross-sectional study for assessment the impact of socioeconomic status on periodontal health through using a definite scale mentioned in the protocol related to the middle east people.
224311950|NCT01708018|PROCEDURE|WATSU|"WATSU (WaterShiatsu) is a gentle form of hydrotherapy that was established in the 1980s. The standardized 60min-intervention applied in this trial is called WATSU-Transition-Flow (Dull, 1997) and is adapted for the third trimester. The mother's abdomen is not being touched during the treatment.~The treatment takes place in a one-to-one hands-on-setting in the warm- water-therapy-pool (35°C, 95°F) of the University Hospital in Bern and consists of acupressure massage according to the Japanese massage-technique Shiatsu, in an attempt to harmonize the mother's energy-flow in the so called meridians (energy-channels) of Traditional Chinese Medicine. These meridians are also sought to be influenced by slow passive stretches of the mother's extremities. In addition, mobilization of her spine is being enhanced by gravity-free movements.~During the study, each participant in the intervention group will be treated twice with WATSU (60min treatment at day 1 and 4)."
224311951|NCT00576108|DRUG|KD7040 Topical Gel|KD7040 topical gel
224311952|NCT00576108|DRUG|Placebo gel|Placebo gel
223758784|NCT04422145|BEHAVIORAL|Structured nurse led intervention programme|A diabetes research nurse, over a period of 12 months, provided a structured education programme to participants focussing on the avoidance of hypoglycaemia and the treatment of this if/when it occurred.
223758785|NCT04422145|OTHER|Standard care|Participants continue on their current diabetes care plan and are looked after by their usual diabetes care provider
223758786|NCT04693585|BEHAVIORAL|MESSSSAGE - live|mHealth education and social support intervention, synchronous via call
223758787|NCT04693585|BEHAVIORAL|MESSSSAGE - asynchronous|mHealth education and social support intervention, asynchronous via text
223758788|NCT03221595|DEVICE|Operative|This operation involves reducing and providing rigid fixation of displaced rib fractures with permanent plates or splints
223758789|NCT05372796|OTHER|IASTM|instrument-assisted soft tissue mobilization
223758790|NCT05372796|OTHER|home exercise|home exercise
224311953|NCT05775133|DEVICE|ICG|"Patient will receive a standard dose of indocyanine green (ICG) 45 minutes prior to surgery. ActivSight will be used during laparoscopic cholecystectomy - the surgeon will perform the procedure in their standard fashion.~Video data will be analyzed in real-time by Activ Surgical's ActivInsight surgical artificial intelligence platform to identify anatomic structures and surgical phase. The surgeon will be blinded to this information, and will see the standard screens and information they do when performing the procedure in a non-study setting."
223758791|NCT05372796|DEVICE|Chattanooga direct Tens device (DJO UK Ltd, Guildford Surrey, United Kingdom)|OTES (Occipital Transcutenous Electric Stimulation)
223758792|NCT02146482|OTHER|Sit-stand computer workstation|A sit-stand computer workstation allows one to sit or stand throughout the day while maintaining continued use of one's computer.
223512377|NCT01994005|BEHAVIORAL|Facebook|Facebook page with contraception information used for counseling
223512378|NCT01994005|BEHAVIORAL|Pamphlet|Contraceptive knowledge pamphlets
223512379|NCT03169374|DEVICE|Virtual Reality Technology|Patients in this arm will participate in virtual reality sessions planned for 5 minutes at a time, during which they are shown relaxing virtual environments.
223512380|NCT01793129|DEVICE|Hypothermia|Induced Whole-body hypothermia (with a target esophageal temperature of 33.5°C) for 72 hours
223512381|NCT01793129|PROCEDURE|Normothermic Control|Normothermic Control group (with esophageal temperature at or near 37.0°C) for 96 hours
223512382|NCT04128215|BEHAVIORAL|Control Period|Participants completed an 8-week control period of normal lifestyle.
223512383|NCT04128215|BEHAVIORAL|Exercise Period|Participants completed an 8-week exercise intervention period of remotely supervised home-based non-weight-bearing all-extremity high intensity interval training (NWA-HIIT). NWA-HIIT consisted of 4x4-min bouts at 90% of maximal heart rate (HRmax) interspersed by 3x3-min bouts at 70% of HRmax. A 10-min warm-up and 5-minute cool-down at 70% of HRmax were included.
223512384|NCT03487458|PROCEDURE|Rib Fixation Surgery|Rib Fixation Surgery
223512385|NCT06211868|BEHAVIORAL|Digital wearable and AI-human symbiotic lifestyle intervention|Digital wearable and AI-human symbiotic lifestyle intervention
223512386|NCT00670514|BEHAVIORAL|Nix Individual|Eight 40-minutes sessions at the local dental clinic during 4 months. Written material and counseling by a dental hygienist with special training in smoking cessation, according to a fixed program. A traditional smoking cessation program with a mixture of behavior therapy, coaching and pharmacological advises. Two questionnaires.
223512387|NCT00670514|BEHAVIORAL|Fimpa dig fri|"One 30-minute counseling session at the local dental clinic, focusing on explaining the content of a traditional self-help program (Fimpa dig fri). The leaflet contains an 8-week program with instructions and tasks to perform. Two questionnaires."
223512388|NCT03027050|PROCEDURE|T-PRF|Applied for treatment of periodontal bone loss.
223512389|NCT03027050|PROCEDURE|Open Flap Debridement alone|
223512390|NCT01837953|BEHAVIORAL|Group Psychodynamic Interpersonal Psychotherapy|For those participants randomized to the USH + Group Psychodynamic Interpersonal Psychotherapy (GPIP) condition, this intervention will consist of 16 weekly 90 minute sessions of GPIP. GPIP was developed and empirically tested in a randomized controlled trial (RCT) at our Centre. GPIP will be preceded by an individual pre-group preparation session conducted by a psychologist trained in GPIP to orient the patient to the therapy. Patients are given a rationale for the treatment. Examples of the patient's cyclical relational patterns (CRPs) that may underlie their symptoms are discussed and the patient will be encouraged to work on these in the groups. Therapists will be given a written summary of each patient's CRP.
223512391|NCT01837953|BEHAVIORAL|Unguided Self-Help|All participants will first receive 10 weeks of Unguided Self-help. The USH will be based on Dr. Christopher Fairburn's CBT-oriented and evidence based self-help treatment plan for binge eating explained in his book, Overcoming Binge Eating. The USH program follows six steps: (1) Getting Started: Self-monitoring, weekly weighing; (2) Regular Eating: Establishing a pattern of regular eating; (3) Alternatives to Binge Eating: Substituting alternative activities; (4) Problem Solving and Taking Stock: Practicing problem solving and reviewing progress; (5) Dieting and Related Forms of Avoidance: Tackling the three forms of dieting and other forms of avoidance eating; and (6) What Next? Preventing relapse and dealing with other problems.
223512392|NCT01428713|DRUG|Oral tranexamic acid|Group A received oral tranexamic acid at 1300 mg (two 650mg tablets), three times each day on days 1 to 5 of menstrual cycle for 3 cycles.
223758793|NCT02079688|DRUG|SB011, 2 % (Water/Oil/Water) emulsion of hgd40|"Treatment will be performed BID on 14 consecutive days and one single last application at the site on Day 15 (29 applications in total).~Two preferably disseminated and contralateral, comparable lesional treatment areas of approximately 50 cm2 each and located on arms, legs, chest, stomach or neck will be chosen. All patients will perform treatment with both formulation SB011 containing 2% hgd40 and the active ingredient-free vehicle. Comparison of the IMPs will be performed intraindividually.~Approximately 5 mg/cm2 (250 μl) of SB011 (2% hgd40) and the vehicle will be applied to the respective treatment areas. The time between the two applications should include min. 8 hours and max. 16 hours. Patients compliance will be controlled by weighing of the IMPs at each visit. On day 1 the application of the IMPs will be demonstrated to the patients at the clinical site. The first treatment as well as the morning treatment on Days 3, 5, 8, 12, and 15 will be carried out at the clinical site"
223758794|NCT02079688|DRUG|Multiple W/O/W formulation, active ingredient-free vehicle|"Treatment will be performed BID on 14 consecutive days and one single last application at the site on Day 15 (29 applications in total).~Two preferably disseminated and contralateral, comparable lesional treatment areas of approximately 50 cm2 each and located on arms, legs, chest, stomach or neck will be chosen. All patients will perform treatment with both formulation SB011 containing 2% hgd40 and the active ingredient-free vehicle. Comparison of the IMPs will be performed intraindividually.~Approximately 5 mg/cm2 (250 μl) of SB011 (2% hgd40) and the vehicle will be applied to the respective treatment areas. The time between the two applications should include min. 8 hours and max. 16 hours. Patients compliance will be controlled by weighing of the IMPs at each visit. On day 1 the application of the IMPs will be demonstrated to the patients at the clinical site. The first treatment as well as the morning treatment on Days 3, 5, 8, 12, and 15 will be carried out at the clinical site"
223612443|NCT07048483|BEHAVIORAL|Nutrition Education|This intervention uses curated audio-visual messages through videos and films to engage participants in learning about healthy eating behaviors, followed by structured, brief discussions designed to reflect on the content and relate it to personal dietary habits. The intervention leverages narrative-based media to increase self-efficacy for healthy eating.
223612444|NCT07048483|OTHER|control group|Educational materials about food and healthy in the form of handouts will be provided to participants to review.
223612445|NCT07056946|OTHER|Fascia Iliaca Nerve Block|With the patient in the proper position, the skin is disinfected and the transducer positioned to identify the femoral artery and the iliopsoas muscle and fascia iliaca. The transducer is moved laterally until the sartorius muscle is identified. After a skin wheal is made, the needle is inserted in-plane
223612446|NCT07056946|OTHER|Caudal Block Anesthesia|The caudal block will be performed by visualizing the sacral hiatus at the level of the sacral cornu after placing the probe transversely obtaining a short axis view, two hyperechoic lines will appear between the sacral cornu the superficial line is the sacrococcygeal ligament
223612447|NCT07065955|OTHER|Longevity diet alone or in combination with fasting mimicking diet|The longevity diet generally consists of three isocaloric meals and one snack (for normal-weight individuals) or slightly hypocaloric meals (in the case of overweight or obesity). The diet consists of 50-60% of calories from complex carbohydrates, 30-35% of calories from mostly unsaturated fats, and 10-11% of calories from proteins, primarily from plant sources and fish, and occasionally from eggs, dairy, and meat, especially for those over 65. The diet is formulated to provide all necessary nutrients, including vitamins and minerals. The fasting-mimicking diet is a dietary intervention in which normal food is replaced with a standardized, highly hypocaloric vegan diet for a limited period of 5 consecutive days. This diet is designed to stimulate the same processes normally activated during fasting while minimizing the side effects of total food deprivation.
223612448|NCT04896593|BEHAVIORAL|Smartphone App|Smartphone app teaching suicide prevention skills.
223612449|NCT03718897|DIAGNOSTIC_TEST|Endoscopic retrograde cholangiopancreatogram|Biopsy specimens are attained via endoscopic retrograde cholangiopancreatogram in patients with suspicious biliary tract cancer.
223612450|NCT01376414|OTHER|Urea Breath Test (UBT) for H. pylori infection|13C UBT to detect H. pylori infection. Single bedside test that determines infection in about ten minutes. Test machine is a product of Exalenz bioscience.
223612451|NCT02777827|DRUG|Abediterol 0.156 μg|Dry powder for inhalation
223612452|NCT02777827|DRUG|Abediterol 2.5 μg|Dry powder for inhalation
223612453|NCT02777827|DRUG|Abediterol 0.05 μg|Pressurised metered-dose inhaler
223612454|NCT02777827|DRUG|Abediterol 0.156 μg|Pressurised metered-dose inhaler
223612455|NCT02777827|DRUG|Abediterol 2.5 μg|Pressurised metered-dose inhaler
223612456|NCT02777827|OTHER|Placebo|Pressurised metered-dose inhaler and dry powder for inhalation.
223612457|NCT00745043|DRUG|bronchodilator response|
223612458|NCT02755220|DEVICE|Cingularbio® Aortic valve replacement|the patients will be replaced by Cingularbio heart valve
223612459|NCT05846373|DRUG|Nicotinic Acid 500 MG Extended Release Oral Tablet|Nicotinic acid 500 mg for 12 weeks
223612460|NCT05846373|DRUG|Nicotinic Acid 1000 MG Extended Release Oral Tablet|Nicotinic acid 1000 mg per day for 11 weeks, titrated from 500 mg/day for 1 week
223612461|NCT05846373|OTHER|Placebo|Placebo 1000 mg per day for 11 weeks, titrated from 500 mg/day for 1 week
223612462|NCT00761826|DEVICE|MEL 80 Mixed Astigmatism Treatment|Treatment of Naturally Occuring Mixed Astigmatic corrections up to 6.0 D.
223612463|NCT01270815|DRUG|Pregabalin controlled release, 330 mg, 400 to 500 calories|A single oral dose of 330 mg controlled release tablet administered following a 400 to 500 calorie medium-fat lunch
223612464|NCT01270815|DRUG|Pregabalin controlled release, 330 mg, 600 to 750 calories|A single oral dose of 330 mg controlled release tablet administered following a 600 to 750 calorie medium-fat lunch
223612465|NCT01270815|DRUG|Pregabalin controlled release, 330 mg, 800 to 1000 calories|A single oral dose of 330 mg controlled release tablet administered following an 800 to 1000 calorie medium-fat lunch
223612466|NCT01270815|DRUG|Pregabalin immediate release, 300 mg|A single oral dose of 300 mg immediate release capsule administered fasted
223612467|NCT03858374|DEVICE|transferred by air-suspending mattress|Put mattress in advance on the bed. When patients need to be transferred from bed to bed, fill the mattress with gas and keep it inflated, then pull the mattress .
223612468|NCT03858374|DEVICE|transferred by slide board|When patients need to be transferred from bed to bed, insert slide board under patient, then pull the slide board.
223612469|NCT03858374|DEVICE|transferred by bedsheet|When patients need to be transferred from bed to bed, just lift the bedsheet.
223612470|NCT00176462|DRUG|aminopterin|Therapy will be divided into five phases: Induction, Consolidation, Delayed Intensification (only for those patients meeting clinical criteria defining a high risk of relapse), Intensive Continuation, and Continuation
223612471|NCT00176462|DRUG|L-asparaginase|Therapy will be divided into five phases: Induction, Consolidation, Delayed Intensification (only for those patients meeting clinical criteria defining a high risk of relapse), Intensive Continuation, and Continuation
223612472|NCT00176462|DRUG|cyclophosphamide|Therapy will be divided into five phases: Induction, Consolidation, Delayed Intensification (only for those patients meeting clinical criteria defining a high risk of relapse), Intensive Continuation, and Continuation
223612473|NCT00176462|DRUG|cytarabine|Therapy will be divided into five phases: Induction, Consolidation, Delayed Intensification (only for those patients meeting clinical criteria defining a high risk of relapse), Intensive Continuation, and Continuation
223612474|NCT00176462|DRUG|daunomycin|Therapy will be divided into five phases: Induction, Consolidation, Delayed Intensification (only for those patients meeting clinical criteria defining a high risk of relapse), Intensive Continuation, and Continuation
223612475|NCT00176462|DRUG|dexamethasone|Therapy will be divided into five phases: Induction, Consolidation, Delayed Intensification (only for those patients meeting clinical criteria defining a high risk of relapse), Intensive Continuation, and Continuation
223612476|NCT00176462|DRUG|6-mercaptopurine|Therapy will be divided into five phases: Induction, Consolidation, Delayed Intensification (only for those patients meeting clinical criteria defining a high risk of relapse), Intensive Continuation, and Continuation
223612477|NCT00176462|DRUG|methotrexate|Therapy will be divided into five phases: Induction, Consolidation, Delayed Intensification (only for those patients meeting clinical criteria defining a high risk of relapse), Intensive Continuation, and Continuation
223612478|NCT00176462|DRUG|6-thioguanine|Therapy will be divided into five phases: Induction, Consolidation, Delayed Intensification (only for those patients meeting clinical criteria defining a high risk of relapse), Intensive Continuation, and Continuation
223612479|NCT00176462|DRUG|vincristine|Therapy will be divided into five phases: Induction, Consolidation, Delayed Intensification (only for those patients meeting clinical criteria defining a high risk of relapse), Intensive Continuation, and Continuation
223612480|NCT00176462|DRUG|Triple Intrathecal Therapy (MTX, Cytarabine, Hydrocortisone)|
223612481|NCT00176462|DRUG|Leucovorin|
223612482|NCT01600079|BIOLOGICAL|ZOSTAVAX™|ZOSTAVAX™ (Zoster Vaccine Live) administered in routine clinical conditions of use
223612483|NCT05168228|PROCEDURE|Oil- versus waterbased contrast in hysterosalpingography (HSG)|The Neuro-H2Oil study looks at the offspring of the H2Oil study, a randomized controlled trial (RCT) comparing hysterosalpingography (HSG) with oil- versus water-based contrast during fertility work-up. For more information please see NTR 3270 (original H2Oil study), www.trialregister.nl. The control group is the Database for Controls in Neuroscience Studies (D-CNS), registered as NL9574 (https://www.trialregister.nl/trial/9574).
223612484|NCT01797913|DRUG|gemcitabine|gemcitabine，1000mg/m2，ivgtt，DAY1\&DAY8
223612485|NCT00002913|DRUG|paclitaxel|Given IV
223612486|NCT00002913|DRUG|cisplatin|Given IV
223612487|NCT00002913|DRUG|topotecan hydrochloride|Given IV
223612488|NCT00002913|BIOLOGICAL|filgrastim|Given SC
223612489|NCT01725594|DRUG|CAT 2003|
223612490|NCT01725594|DRUG|Placebo|
223612491|NCT04010591|DEVICE|impedance measurement during urodynamic study|Impedance information is measured through the belt in the abdomen of the subject. The urodynamic test is performed from the state in which the urine of the bladder is completely emptied to the state of the bladder until the state becomes full, so the impedance measurement is measured from the state where the urine of the bladder is completely emptied to the state of the bladder until the state becomes full.
223612492|NCT05581069|BEHAVIORAL|STEPS|STEPS is a psychosocial intervention that targets self-determination, self-regulation, and self-knowledge to improve functional independence and quality of life in adults.
223612493|NCT00003917|DRUG|topotecan hydrochloride|
223612494|NCT05745519|OTHER|Pittsburgh sleep quality index (PSQI)|The scale is suitable for the evaluation of sleep quality in patients with sleep disorders and mental disorders, as well as for the evaluation of sleep quality in general people.
223612495|NCT05745519|DEVICE|ANSWatch|Measure eight physiological parameters including heartbeat, systolic blood pressure, diastolic blood pressure, heart rhythm variability HRV, low frequency component LF, high frequency component HF, LF/HF low frequency high frequency component ratio, and irregular heartbeat within five minutes
223612496|NCT04284475|DIAGNOSTIC_TEST|Quadriceps strength|Using a handheld dynamometer, in supine position in a standardized position of the dominant leg Measurement of the maximal isometric voluntary quadriceps contraction Measure expressed as Newton and Newton/kg
223612497|NCT04284475|DIAGNOSTIC_TEST|Grip strength|Testing of dominant hand using a handgrip Measurement of the maximal isometric voluntary grip contraction Measure is expressed as kg
223612498|NCT04284475|DIAGNOSTIC_TEST|ICU mobility scale|Scoring the physical capacity of the patient on a 10-points validated scale: the ICU mobility scale
223612499|NCT03452709|BEHAVIORAL|therapeutic exercise|The duration of the groups is planned to be from 12 weeks with 3 programmed sessions per week. physical activity programmed by an instructor in patient with high risk of cardiovascular.
223758795|NCT04400396|DIETARY_SUPPLEMENT|standard HM fortification|Based on the assumed energy and macronutrient composition of HM, the commercial multi-component HM fortifier was added, in order to compensate identified nutritional deficits.
223758796|NCT04400396|DIETARY_SUPPLEMENT|target HM fortification|Based on the measured energy and macronutrient composition of HM, modular protein and fat supplements are added, in addition to the commercial multi-component HM fortifier, in order to correct identified specific nutritional deficits. For this purpose, an Excel program to calculate modular protein and fat supplements to be added to fortified HM was developed and registered (Nona R, Cardoso M, Portuguese Directorate of Intellectual Property Services, IGAC-DSPI, nº 480/2020, 26 February 2020)
223758797|NCT02212587|DRUG|TOBI|New inhalation devices such as the podhaler can administer tobramycin inhalation powder TIP/TOBI and achieve very high sputum drug levels. TOBI will be administered using the Podhaler
223758798|NCT04264286|DRUG|Prophylactic esmolol|Patients will receive prophylactic esmolol after the end of the surgery
223758799|NCT04264286|DRUG|Placebo|Patients will prophylactic placebo after the end of the surgery
223758800|NCT04655911|BIOLOGICAL|ABO-101|Gene therapy rAAV9.CMV.hNAGLU
223758801|NCT04037202|OTHER|Foot massage|Foot massage includes classical massage techniques such as effleurage, petrissage and friction techniques. Effleurage is the movement of stroking and lubricating superficial tissues. Therefore, it is performed at the beginning and ending of the massage. Petrissage is the slow and rhythmic movement to apply direct pressure to the soft tissue underlying the skin with the balls of the fingers and thumbs. Friction is the application of pressure through small circular movements only in small areas, using hand or fingers. While muscle tissue is compressed and relaxed, blood and lymph circulation increases. Thus, lactic acid in the muscle fibers is diminished and fatigue and stress are decreased.
223758802|NCT00219128|DRUG|aliskiren|
223758803|NCT02820194|RADIATION|Stereotactic Body Radiation Therapy|Stereotactic body radiation is a therapy for delivering a conformal high dose of radiation to the tumor and a minimal dose to surrounding critical tissues, with a hypofractionation schedule
223758804|NCT02820194|PROCEDURE|Microwave Ablation|Microwave ablation (MWA) is a newer technology that utilizes high-frequency electromagnetic radiation to create thermal damage and coagulation necrosis
223758805|NCT03261349|DRUG|Ledipasvir and sofosbuvir|To assess whether Harvoni® (ledipasvir and sofosbuvir) could eradicate HCV and lead to durable complete remission of these lymphomas.
223758806|NCT05572983|DRUG|Chidamide combined with CHOP|A)Chidamide: 20mg, D1, 4,8,11, po; B) Cyclophosphamide: 750 mg/ m2, D1, iv.drip; C) Doxorubicin: 50 mg/ m2, D1, iv.drip (or epirubicin 70 mg/ m2, D1, iv.drip); D) Vincristine: 1.4 mg/ m2, D1 (maximum dose 2mg, maximum dose 1.5mg for age over 70 years), iv; E) Prednisone: 40mg/m2, D1-5,po
223758807|NCT05572983|DRUG|Chidamide|Chidamide: 20mg，qw（d1,d4）,po
223758808|NCT02386111|DRUG|Combination of varlilumab and sunitinib|"During the treatment phase of the study, eligible patients will receive varlilumab for up to 8 cycles. Treatment cycles are 6 weeks each with varlilumab administered once every 3 weeks and sunitinib administered daily for 4 weeks followed by a 2 week rest. There is no limit on the number of cycles of sunitinib. Patients may be discontinued from receiving study treatment (sunitinib or varlilumab) based on the results of disease assessments or if experiencing side effects that make study therapy intolerable.~Phase l Dose: The planned dose of varlilumab will be dependent on the cohort assigned at enrollment. Varlilumab doses are 0.3 mg/kg, 1 mg/kg or 3 mg/kg.~The Study was terminated prior to initiation of Phase II.~All patients will receive sunitinib at a dose of 50 mg."
223758809|NCT03319927|BEHAVIORAL|IPM educational workshop and consultation|The interventions include a baseline assessment conducted by a research assistant and objective measures of pesticide exposure (center dust samples, children's silicone wristbands), review of assessment by the nurse child care health consultant, goal setting with the director, educational workshop, 7 monthly consultation visits, and post-intervention review of goals and post-assessment findings (conducted by research assistant and objective measures of pesticide exposure).
223758810|NCT00154453|PROCEDURE|obtain surgical specimen for analysis|
223758811|NCT00048542|BIOLOGICAL|Double-Blind Adalimumab/Placebo + MTX|Subcutaneous injection of 24 mg adalimumab or placebo per square meter of body surface area (BSA) every other week (eow) concomitantly with MTX treatment for 32 weeks during the Double-Blind phase. Total body dose of adalimumab was not to exceed 40 mg.
223758812|NCT00048542|BIOLOGICAL|Double-Blind Adalimumab/Placebo|Subcutaneous injection of 24 mg adalimumab or placebo per square meter of body surface area (BSA) every other week (eow) without MTX treatment for 32 weeks during the Double-Blind Phase. Total body dose of adalimumab was not to exceed 40 mg.
223512393|NCT01428713|DRUG|Oral Contraceptive Pills|Group B received combined oral contraceptive pills with 3 weeks of hormonal pills and 1 week of placebo for 3 cycles.
223512394|NCT02039206|DEVICE|Deep TMS|1Hz Stimulation
223512395|NCT05181696|DIAGNOSTIC_TEST|Chest X-ray|Retrospective analysis of chest x-rays of patients with COVID-19
223512396|NCT02062346|DRUG|BQ123|Intravenous infusion of BQ123 ( selective ETA antagonist )
223512397|NCT02062346|DRUG|BQ123/788|or BQ123/788 (mixed ETA/B antagonists)
223512398|NCT02062346|DRUG|Placebo|Intravenous infusion of saline
223512399|NCT04922879|BEHAVIORAL|Individualized lung rehabilitation|Early respiratory function training, reasonable oxygen therapy to prevent hypoxemia, Positive pressure vibration training to promote coughing ability recovery, early exercise, Health education and psychological support.
223512400|NCT00862277|BIOLOGICAL|Menactra®|0.5 mL, Intramuscular (from a previous study)
223512401|NCT00862277|BIOLOGICAL|Menomune®|0.5 mL, Intramuscular (from a previous study)
223512402|NCT04802785|DRUG|Citicoline|Citicoline 500 mg (Vitaae®) per os
223512403|NCT04802785|DRUG|Cytochrome C6|Cytochrome10 mg per os
223512404|NCT04802785|DRUG|Sodium Chloride Oral Product|Sodium Chloride (NaCl) 2.6 g. per os
223512405|NCT04802785|DRUG|Potassium Chloride Oral Product|Potassium Chloride 1.5 g per os
223512406|NCT04802785|DRUG|Sodium Citrate Oral Product|Sodium Citrate 2.90 g per os
223512407|NCT04802785|DRUG|Dextrose Oral Tablet, Chewable|Dextrose 13.5 g per os
223512408|NCT04802785|DRUG|Domperidone Oral Product|Domperidone 1 tablet per os
223512409|NCT04802785|DRUG|Simethicone|3-4 capsules per os
223512410|NCT04802785|DRUG|Acetylsalicylic acid|Acetylsalicylic acid 150 mg per os
223512411|NCT04802785|DRUG|Magnesium hydroxide|magnesium hydroxide 30 mg per os
223512412|NCT04802785|DRUG|Probiotic Formula|1 capsule per os.
223512413|NCT04802785|DRUG|Melatonin 5 mg|Melatonin 5 mg per os.
223512414|NCT06006221|BEHAVIORAL|Qi-gong relaxation exercise|Qi-gong relaxation exercise is a mindfulness-based exercise and is a type of exercise that consists of breathing-compatible body movements and relaxation used to relax the body and mind, reduce stress, distract attention from negative thoughts, accelerate blood flow, and improve emotions.
223512415|NCT02312128|OTHER|Questionnaire|DASH Score, PRWE Score, Mayo Wrist Score
223512416|NCT02312128|RADIATION|X- Ray|X-ray exposures in two planes 6., 9., 12. postoperative week, half and one year after surgery
223512417|NCT02312128|OTHER|Grip Strength|Grip strength measurement
223512418|NCT02312128|OTHER|VAS Score|Measurement pain according to the visual analogue scale (VAS)
223758813|NCT00048542|DRUG|OLE BSA Adalimumab +/- MTX|Comparison of subcutaneous injection of 24 mg adalimumab per square meter of body surface area (BSA) every other week (eow) either with or without concomitant MTX treatment for a minimum of 44 weeks (up to a maximum of 136 weeks) during the Open-Label Extension BSA Phase.
223612500|NCT03452709|DEVICE|ABPM ambulatory blood pressure monitoring|Arterial pressure is a biological variable which fluctuates over a 24 hour period depending on the period of activity/rest, which is known as circadian the BP rhythm. Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) vary, on average, more than 50 mm Hg throughout the day in a normotensive adult.
223612501|NCT05465291|PROCEDURE|Exercise group|This group will receive passive/active range of motion (ROM) exercises. ROM exercises will include major muscle groups (i.e. biceps, triceps, and lower limbs) and will be applied from second day till seventh day of admission .
223612502|NCT05465291|PROCEDURE|Neuromuscular Electrical Muscle Stimulation group|"* Patients in NEMS group will receive neuromuscular electrical stimulation from second day till seventh day of admission.~* Neuromuscular electrical stimulation will be implemented simultaneously on the rectus femoris, vastus lateralis, and vastus medialis muscles of both lower limbs, with two stimulators, in two 30-min sessions per day starting from the second day till seventh day of admission ."
223612503|NCT05465291|PROCEDURE|Neuromuscular Electrical Muscle Stimulation and Exercise group|Patients in this group will be subjected to Neuromuscular Electrical Muscle Stimulation and Exercise.
223612504|NCT03840954|OTHER|Neuromuscular Electrical Stimulation|"The application of NMES will be performed with the patient positioned in the supine position in the bed. Self-adhesive electrodes will be positioned at the motor points of the quadriceps and anterior tibial muscles respectively. A symmetrical biphasic pulsed current with a frequency of 80 Hz, a pulse width of 500 μs and an intensity at the motor threshold will be applied up to the maximum tolerated by the patient. ON and OFF time and total session time will be used according to protocol with progressive increase of the total intervention time and reduction of OFF time of the NMES. The device used will be the Neurodyn II model, manufactured by IBRAMED.~Patients will receive NMES for as long as they remain hospitalized or for up to 3 weeks."
223612505|NCT01250041|PROCEDURE|continuous femoral nerve block|ultrasound guided femoral nerve catheter insertion.
223612506|NCT01250041|PROCEDURE|continuous saphenous nerve block|ultrasound guided saphenous nerve catheter insertion
223612507|NCT01408459|DIETARY_SUPPLEMENT|Tomato Product|Motivational Telephone Counseling weekly
223612508|NCT01408459|DIETARY_SUPPLEMENT|Control|No Motivational telephone Counseling
223612509|NCT03801226|DRUG|Two-hour dwell with 10% dextrose in sterile water|Patients will be randomized to undergo a two-hour dwell with 10% dextrose in sterile water at their first or second study visit and will receive the alternate intervention at the other study visit.
223612510|NCT03801226|DRUG|Two-hour dwell with Dianeal Low-Calcium with 4.25% Dextrose|Patients will be randomized to undergo a two-hour dwell with Dianeal Low-Calcium with 4.25% Dextrose at their first or second study visit and will receive the alternate intervention at the other study visit.
223612511|NCT01994044|PROCEDURE|Cervical fusion|
223612512|NCT04166097|OTHER|Heart Smart Interventional Program|6-week program consisting of weekly didactic sessions that follow the steps outlined in the book.
223612513|NCT02870608|OTHER|lung and liver elastography measurement of fetus|
223612514|NCT04119232|BEHAVIORAL|Social incentives-based program|Individual participants will use a wearable device to monitor daily step counts, set a step goal, and receive automated daily feedback on step goal attainment. Participants will be placed on a team of 3 randomly assigned participants and receive the social incentives intervention.
223612515|NCT01696890|DEVICE|integrated follow-up|close interaction between HF clinic and general practitioner in response to telemonitoring alerts. All subjects will be monitored daily for heart rate, blood pressure, and body weight, after which these data are transferred automatically to the general practitioner. This device is custom-made.
223612516|NCT01696890|DEVICE|standard care|no interaction between HF clinic and general practitioner in response to telemonitoring alerts. General practitioner is responsible for adaptations to therapy according to clinical presentation of the patient.
223612517|NCT04797351|BEHAVIORAL|Dialectical Behavior Therapy - Skills|Pre-treatment session + 12 sessions DBT Skills Group (only) intervention
223612518|NCT03690895|OTHER|Retrospective survival analysis|Kaplan-Meier model
223612519|NCT03145259|DRUG|Diclofenac Epolamine Patch|patch
223612520|NCT03145259|DRUG|diclofenac sodium solution|solution
223612521|NCT02361008|DEVICE|TEE-guided perventricular device closure without CBP|Perventricular device closure through minithoracotomy under the TEE-guidance without CBP.The device is an eccentric occluder made by Shanghai Shape Memory Alloy Co.,Ltd in Shanghai,China
223612522|NCT02361008|PROCEDURE|Surgery repair with CBP|Traditional surgery repair under the CBP.
224311954|NCT02953977|BEHAVIORAL|Diabetes Prevention Program|An adapted version of the Diabetes Prevention Program will be delivered to intervention participants.
223612523|NCT01918956|BIOLOGICAL|PURETHAL Birch, 20.000 AUM/ml|comparison of different up-dosing regimes
223612524|NCT05269108|PROCEDURE|Fluoroscopy-free RIRS|RIRS for renal stone under direct visualization, without fluoroscopy
223612525|NCT05269108|PROCEDURE|Standard RIRS|RIRS for renal stone under fluoroscopy-guidance
223612526|NCT00125320|DRUG|RSD1235|
223612530|NCT04257201|OTHER|Yellow Oyster -- 84 g|Participants will consume the standardized test day salad plus 84 g (raw weight) mushrooms. Mushrooms will be cooked prior to being served
223612531|NCT04257201|OTHER|Yellow Oyster -- 168 g|Participants will consume the standardized test day salad plus 168 g (raw weight) mushrooms. Mushrooms will be cooked prior to being served
223612532|NCT04257201|OTHER|White button -- 84 g|Participants will consume the standardized test day salad plus 84 g (raw weight) mushrooms. Mushrooms will be cooked prior to being served
223612533|NCT04257201|OTHER|White button -- 168 g|Participants will consume the standardized test day salad plus 168 g (raw weight) mushrooms. Mushrooms will be cooked prior to being served
223612534|NCT04257201|OTHER|Control|Participants will consume the standardized test day salad only
223612535|NCT02075112|DRUG|Soy isoflavone|Patients will receive genistein 150 mg daily for the duration of radiation treatment. If a patient is experiencing significant side effects attributable to genistein, the treating physician has the option to reduce genistein to 150 mg every other day.
223758814|NCT00048542|DRUG|OLE FD Adalimumab +/- MTX|Comparison of adalimumab administered subcutaneously every other week (eow) either with or without concomitant MTX treatment for up to 224 weeks during the Open-Label Extension Fixed Dose (FD) Phase.
223758815|NCT03914196|DIAGNOSTIC_TEST|Liver Stiffness Ultrasound|Research imaging will include liver assessments of stiffness (ultrasound shear wave elastography), tissue attenuation (if available), and blood flow (gray-scale and Doppler imaging).
223758816|NCT02902198|DIETARY_SUPPLEMENT|Placebo|Tap water 200ml
223758817|NCT02902198|DIETARY_SUPPLEMENT|Glucose|25g Glucose in 200ml tap water
223758818|NCT02902198|DIETARY_SUPPLEMENT|Monosodium glutamate|1g monosodium glutamate in 200ml tap water
223758819|NCT02902198|DIETARY_SUPPLEMENT|Quinine|17mg quinine in 200ml tap water
223758820|NCT06800170|DIETARY_SUPPLEMENT|myo-Inositol plus DIoscorea Villosa|myo-Inositol + alpha-lactalbumin + folic acid once daily, Dioscorea Villosa + alpha-lactalbumin + Vitamin D twice daily
223758821|NCT01892631|OTHER|Text message influenza vaccination reminder|Practices in the text messaging intervention arm will be asked to send a text message to patients under 65 at risk of influenza.
223758822|NCT01892631|OTHER|Standard care|Practices in the standard care arm will be asked to proceed with their seasonal influenza campaign as planned.
223758823|NCT00046735|DRUG|Lenalidomide|The planned doses for investigation are as follows: 5, 10, and 25 mg/day. Lenalidomide will be administered as a single daily dose for 4 weeks followed by a 2-week rest period. Dosing will be in the morning at approximately the same time each day, at least 1 hour before the morning meal. Patients will be assigned to dose level in the order of study entry. No dose adjustments or suspensions are allowed during the first cycle, except discontinuation for DLT
223758824|NCT01373749|DRUG|NO inhalation|NO inhalation was performed as the only treatment for PPHN during the whole course.
223758825|NCT01373749|DRUG|NO inhalation continued with sildenafil|NO inhalation was performed as the primary treatment for PPHN in the first 48 hours, NO inhalation will be replaced by sildenafil after 48 hours of therapy.
223758826|NCT00712465|DRUG|AZD1305|Extended Release tablet, repeated administration
223758827|NCT00712465|DRUG|Digoxin|Tablet, repeated administration
223758828|NCT02363465|OTHER|Echographic measurement of skin thickness|"(Epi)Dermal thickness at the proximal forearm and the deltoid region will be measured using imaging technology, more specifically high-frequency ultrasound (20-40 MHz) in B-mode (VEVO 2100®, Visual Sonics). This non-invasive measuring technique has already been proven to be accurate.~The echographic measurement will be performed on the left and right deltoid region and on two sides of the proximal forearm. Both the dorsal part and the volar/palmar part of the proximal forearm will be investigated. Ultrasound will be executed using gel (Aquasonic®) to optimize imaging."
223758829|NCT05747144|DIAGNOSTIC_TEST|Biometry|Biometric measurements performed with IOL Master, if executable Contact or immersion echobiometry if IOL Master cannot be performed
223512419|NCT02312128|OTHER|Range of Motion measurement|Angle measurement of the active range of motion in the wrist
223512420|NCT01052428|DRUG|metoprolol succinate (Toprol XL)|Toprol XL 100 mg once a day for 2 years
223512421|NCT01052428|DRUG|Placebo|Placebo 100 mg once a day for 2 years
223512422|NCT00871000|BIOLOGICAL|Boostrix Polio™ 711866|Single dose, intramuscular administration.
223512423|NCT00871000|BIOLOGICAL|Priorix Tetra TM 208136|Single dose, subcutaneously.
223512424|NCT00871000|BIOLOGICAL|Tetravac TM|Single dose, intramuscular administration.
223512425|NCT00707369|DRUG|Amoxicillin and Metronidazole|tablets: Amoxicillin 3H2O 574 mg and 400 mg metronidazole three times daily for 7 days
223512426|NCT00707369|DRUG|Placebo|Placebo tablets (cellulose powder, lactose monohydrate, magnesium stearate, microcrystalline cellulose): three times daily for 7 days
223512427|NCT01745302|DRUG|TCM|TCM: In China,TCM herbs are given on the basis of the TCM syndrome differentiation as diagnosed by the TCM herbal specialist. Prescriptions formulated into granules origin from Professor Liu Jia-xiang in Longhua hospital. Package of granules is made into three types with functions such as benefiting Qi recipe, benefiting Yin recipe and detoxication and resolving masses recipe.The herbal treatment is adapted to the syndromes.
223512428|NCT01745302|DRUG|EGFR-TKI|Erlotinib 150 mg oral once a day or Gefitinib 250 mg oral once a day or Icotinib 125 mg oral three times a day
223512429|NCT06569979|OTHER|Survey|"The survey was developed using the Google Forms platform. The first part of the questionnaire consisted of descriptive information such as age, gender, duration of academic experience. In addition to this informations, the questionnaire also included information related the status of use ICF in any fields.~In the other part of the questionnaire, a total of 59 questions (16 related to body functions, 3 related to body structures, 30 related to activity and participation, 10 related to environmental factors) were asked to the academicians whether these categories are present in the amputee rehabilitation course content. Academicians were asked to answer yes or no to each question."
223512430|NCT06570083|BEHAVIORAL|Mobile Exercise Support|Participants receive three months of personalized support via WeChat, including tailored exercise recommendations, motivational messages, and educational content.
223512431|NCT06570083|BEHAVIORAL|Self-help physical activity booklet|Participants receive a self-help booklet to promote physical activity among the elderly. The booklet will include guidelines for safe and effective exercises, tips for staying motivated, and information on the health benefits of regular physical activity.
223512432|NCT02685436|DRUG|Omeprazole and domperidone|wheezy infants with abnormal MII-pH or reflux esophagitis will be given omeprazol(10mg/once/day) and domperidone (0.2mg/kg/day t.d.s)
223512433|NCT06281002|DEVICE|conventional impression stone casts digitization|"Nine conventional physical open tray impressions will be poured into a hard dental stone to obtain nine definitive implant casts with conventional implant analogs to act as a reference comparator.~Impressions will be digitized to reference STL files."
223512434|NCT06281002|DEVICE|digital scanning with coupled scanning aiding device|Nine optical impressions will be obtained while additional geometric scanning aids are coupled with the scan bodies to get nine CAD/CAM 3D-printed polymer casts with digital implant analogs.
223512435|NCT06281002|DEVICE|Digital Implant Model assessment of accuracy|The nine STL files of optical scanning will serve as reference data for comparison with the digitized DIMs to evaluate the accuracy of representation of the actual position of implants in the software.
223758830|NCT05747144|DIAGNOSTIC_TEST|Retinography (Color) + Autofluorescence (AF)|Colour + AF: EIDON, if available (60° not modulable) Colour: COBRA (60° non-modifiable) AF: Spectralis-Heidelberg (choose 55°) Other if available (choose posterior pole examination between 50-60°)
224311955|NCT04521387|PROCEDURE|injection therapy|The injection will be carried out with aseptic precautions, under regional anesthesia with 1ml of 1% Lignocaine through one puncture of the skin and frequent changes in the inside needle position.
224311956|NCT04521387|DRUG|Platelet Rich Plasma|Platelet rich plasma injection in the painful area of humeral epicondyle.
224311957|NCT04521387|DRUG|Corticosteroid Injection|Corticosteroid injection in the painful area of humeral epicondyle.
224311958|NCT04521387|DRUG|Hyaluronic Acid Injection|Hyaluronic acid injection in the painful area of humeral epicondyle.
224311959|NCT04521387|OTHER|Placebo Injection|Saline injection in the painful area of humeral epicondyle.
224311960|NCT02210845|BEHAVIORAL|Supervised exercise|Supervised exercise intervention is training with professional trainers once a week. It will include aerobic exercise tailored to the individual participant.
224311961|NCT02210845|BEHAVIORAL|Financially incentivized weight Loss|Financially incentivized weight loss encourages participants to achieve a monthly goal weight reduction for a 50 dollars prize.
223612536|NCT02075112|RADIATION|Radiation|All patients will undergo computed tomography (CT) simulation with intravenous (IV) contrast unless medical contraindications to IV contrast exist. Gross disease will be treated to 70 Gy in 2 Gy/day.
223612537|NCT02075112|DRUG|Cisplatin|Cisplatin chemotherapy 100 mg/m² on days 1, 22, and 43 of radiation treatment.
223612538|NCT04026321|DRUG|SQ001 125mL/day|SQ001 125mL/day will be administered by intravenous route at a rate of 3 mL/minute
223612539|NCT04026321|DRUG|SQ001 250mL/day|SQ001 250mL/day will be administered by intravenous route at a rate of 3 mL/minute
223612540|NCT04026321|DRUG|SQ001 500mL/day|SQ001 500mL/day will be administered by intravenous route at a rate of 3 mL/minute
223612541|NCT04026321|DRUG|SQ001 625mL/day|SQ001 625mL/day will be administered by intravenous route at a rate of 3 mL/minute
223758831|NCT05747144|DIAGNOSTIC_TEST|OCT B-scan and OCT angiography (OCTA)|"OCT B-scan:~2 scans (6 mm)~1 cross line~OCTA:~3x3 mm + 6x6 mm centred on the fovea 4.5 mm centred on the optic nerve"
223758832|NCT05747144|DIAGNOSTIC_TEST|Microperimetry|1\) fixation pattern 2) retinal sensitivity map
223758833|NCT05747144|DIAGNOSTIC_TEST|Electrophysiological exams|Layer-by-layer assessment of the retina using focal ERG and pattern ERG according to standardised and published methods , For patients with visus \< 3/10 and unstable fixation a protocol based on component analysis of the photopic ERG from diffuse flash will be used.
223758834|NCT05126927|BIOLOGICAL|68Ga-NODAGA-SNA006|A PET contrast agent to assess the level of tumor tissue-infiltrating CD8 + T cells in patients with solid tumors
223758835|NCT00578175|BIOLOGICAL|Priorix-Tetra™ (MMRV vaccine 208136)|One subcutaneous injection.
223758836|NCT00578175|BIOLOGICAL|ProQuad®|One subcutaneous injection.
223758837|NCT00578175|BIOLOGICAL|Havrix®|Two intramuscular injections.
223758838|NCT00578175|BIOLOGICAL|Prevnar®|One intramuscular injection.
223758839|NCT00191503|DRUG|Pemetrexed|
223758840|NCT00191503|DRUG|Gemcitabine|
223612542|NCT04026321|DRUG|Saline 0.9%|Saline 0.9% will be administered by intravenous route at a rate of 3 mL/minute
223612543|NCT01499615|DEVICE|cardiac monitor|All children receive the same intervention which is the application of the 4 ekg electrodes
223612544|NCT00003279|BIOLOGICAL|BCG vaccine|
223612545|NCT00003279|BIOLOGICAL|monoclonal antibody BEC2|
223758841|NCT01649258|DRUG|granisetron transdermal system|Given granisetron transdermal system patch
224311962|NCT02210845|OTHER|Standard Care at BCDiabetes|usual care dictated by GCP at BCDiabetes.ca
223612546|NCT05887921|PROCEDURE|Inguinal Lymphadenectomy|arm A: open lymphadenectomy performed by a surgical team with extensive experience in traditional surgery arm B: laparoscopic lymphadenectomy performed by a surgical team with extensive experience in minimally invasive surgery
223612547|NCT02724098|DRUG|Dexmedetomidine|
223612548|NCT00330759|BIOLOGICAL|Denosumab|120 milligrams by subcutaneous injection every 4 weeks
223612549|NCT00330759|DRUG|Zoledronic Acid|4 milligrams intravenous Zoledronic Acid over minimum 15 minutes every 4 weeks
223612550|NCT03976258|DRUG|buprenorphine/naloxone|This is an observational study. Buprenorphine/naloxone for opioid use disorder will be provided in a standardized way by experienced providers through already established funded treatment programs.
223612551|NCT03976258|DRUG|Methadone|This is an observational study. Methadone for opioid use disorder will be provided in a standardized way by experienced providers through already established funded treatment programs.
223758842|NCT01649258|DRUG|fosaprepitant dimeglumine|Given IV
223758843|NCT01649258|OTHER|laboratory biomarker analysis|Correlative studies
223758844|NCT03751085|DEVICE|AW frame|AW stereotactic frame for intracranial lesion biopsy
223758845|NCT03445624|DRUG|Infliximab|follow up the patients who received this drugs for 1 year by abdominal ultrasound,peripheral hemogram and colonoscopy
223758846|NCT04849156|OTHER|Sperm selection by thermotaxis|Selection of healthy sperm by thermotaxis procedure
224311963|NCT04308057|PROCEDURE|Aquatic exercise|Participants belonging to Group D (sedentary group) will be randomised 1-to-1 between remaining sedentary (n=20) and following a self-managed, 8-week, aquatic-based exercise programme (n=20). The latter group will be offered an 8-week access to pool facilities. For Group D participants, all baseline assessments will be repeated at 8 weeks.
224311964|NCT06350916|BEHAVIORAL|SeamlessMD® Mobile Application|Mobile cloud-based applications (apps), such as SeamlessMD®, are readily accessible on smart phones and offer an innovative strategy to encourage and track patient adherence to recommended ERAS components pre- and postoperatively.
224311965|NCT05378555|DRUG|Ketamine Hydrochloride|All patients in this study will receive oral ketamine for the treatment of pain from vaso-occlusive crisis. Patients will receive 0.5 mg/kg ketamine Q8hrs for 48 hours.
224311966|NCT01153295|PROCEDURE|Clinical diagnosis based on symptom criteria|The diagnosis is based on ROME III criteria, abscence of danger signals and FBC, CRP
224311967|NCT01153295|PROCEDURE|Diagnosis of exclusion|The diagnosis is based on normal investigations involving endoscopy with biopsy, stool for ova and parasites, FBC, CRP, TSH, Ca, ALT, alanine aminotransferase; alkaline phosphatase, serum bilirubin, Screening for lactose and celiac sprue
223758847|NCT02252627|DRUG|Administration of phenylephrine|Intravenous phenylephrine will be administered in 50-100 microgram increments until the mean arterial blood pressure has increased by 25% compared to baseline, or until a maximum dose of 1mg has been administered.
223758848|NCT02252627|OTHER|Measurement of stroke volume|The measurement of stroke volume will be performed using an Oesophageal Doppler Monitor
223612552|NCT03976258|DRUG|Naltrexone Injection|This is an observational study. Naltrexone injection for opioid use disorder will be provided in a standardized way by experienced providers through already established funded treatment programs.
223612553|NCT03976258|DRUG|Heroin|This is an observational study. Participants using heroin will be enrolled into this group.
223612554|NCT03780335|DIAGNOSTIC_TEST|Computation of quantitative flow ratio|Computation of QFR was performed offline, using AngioPlus system(Pluse medical imaging technology, Shanghai, China). In the first step, 2 diagnostic angiographic projections before PCI, at least 25° apart, were selected and 3D reconstruction of the interrogated vessel without its side branches was performed. Then, the software computed the QFR.
223612555|NCT03110471|BEHAVIORAL|West Wales Adverse Drug Reaction (WWADR) Profile|Nurse-led medicines' monitoring in care homes: a process evaluation of the impact and sustainability of the West Wales Adverse Drug Reaction (WWADR) Profile and pharmacist involvement
223612556|NCT03110471|BEHAVIORAL|usual care|usual care
223612557|NCT04049708|OTHER|Reliability of physical function|Test-retest reliability of physical function in hemodialysis patients
223612558|NCT00989001|DRUG|Vernakalant|Maximum volume of 100 mL as per the dosing schedule, administered intravenously (IV) over 10 minutes
223612559|NCT00989001|DRUG|Placebo|Injection
223612560|NCT03726489|DEVICE|Daavlin 7 series 3 panel narrow band phototherapy home units|"Daavlin 7 series 3 panel narrow band phototherapy home units (with 8-12 bulbs and a smaller, flat surface with door, measuring 21 wide, 74.5 tall, and 23.5). This unit is a class II device with a FDA 510K indication for psoriasis, vitiligo and atopic dermatitis/eczema. The unit will have a dosimetry controller, a UV sensor built in that measures the intensity of the light. This sensor will adjust the treatment time to compensate for any variation in output due to aging of the lamps or other factors"
223612561|NCT03726489|DEVICE|narrow band phototherapy clinic units|Office based narrow band phototherapy unit (units typically have at least 24 bulbs in a surround structure
223612562|NCT02655029|DRUG|Perindopril/Indapamide/Amlodipine fixed dose combination|Dose selection is based on investigators management.
223612563|NCT03744949|DRUG|Remifentanil dose 0.5 ug/kg|Remifentanil will be given (dosage of 0.5 µg/kg of adjusted body weight bolus) from an infusion pump over 30 seconds
223612564|NCT03744949|DRUG|Remifentanil dose 1 ug/kg|Remifentanil will be given (dosage of 1 µg/kg of adjusted body weight bolus) from an infusion pump over 30 seconds
223612565|NCT03744949|DRUG|Remifentanil dose 1.5 ug/kg|Remifentanil will be given (dosage of 1.5 µg/kg of adjusted body weight bolus) from an infusion pump over 30 seconds
223612566|NCT03744949|DRUG|Remifentanil dose 2 ug/kg|Remifentanil will be given (dosage of 2 µg/kg of adjusted body weight bolus) from an infusion pump over 30 seconds
223612567|NCT00468026|DEVICE|ProstaPlant Stent|
223612568|NCT01067378|OTHER|Peer-led debriefing|
223612569|NCT01067378|OTHER|Expert instructor debriefing|
223612570|NCT00242671|PROCEDURE|Isocapnic Hyperponea|
223758849|NCT02252627|OTHER|Contrast enhanced ultrasound scan|Microvascular blood flow will be measured using a contrast enhanced ultrasound scan
223758850|NCT02252627|DRUG|Administration of ephedrine|Intravenous ephedrine will be administered in 3-6mg increments until the mean arterial blood pressure has increased by 25% compared to baseline, or until a maximum dose of 30mg has been administered.
223612571|NCT01380769|DRUG|CRLX101|CRLX101 is administered at 15mg/m2 IV every other week
223612572|NCT01380769|OTHER|Best Supportive Care|best supportive care
223612573|NCT03654690|DIAGNOSTIC_TEST|HIV self-test|Home delivery of HIV self-test kits (OraSure OraQuick Rapid HIV test)
223612574|NCT03654690|BEHAVIORAL|Counseling|Post-Test HIV Risk ReductionCounseling
223612575|NCT00203229|DRUG|lamotrigine|The intervention type is 'drug' and this arm is a placebo pill created and supplied by the manufacturers of lamotrigine (Lamictal). This drug is an anti-seizure medication.
223612576|NCT00203229|DRUG|Placebo|The intervention type is 'drug' and this arm is a placebo pill created and supplied by the manufacturers of lamotrigine (Lamictal) to be exact replicas of the actual drug being studied. The placebo arm is titrated in the exact same manor as the active drug arm.
223612577|NCT04229628|OTHER|No special intervention|No special intervention
223612578|NCT06295861|OTHER|no different intervention between the two cohort.|no different intervention between the two cohort.
223612579|NCT03754348|RADIATION|PET scan with tracer injection [18F] DPA-714|the subject will receive a dose of 3.5MBq / kg intravenous (in bolus) more or less 20%, knowing that the minimum dose injected is unchanged at 150MBq and the maximum dose at 370 MBq. Irradiation will remain below 10 mSv
223612580|NCT06284850|DRUG|Empagliflozin10Mg Tab|TB JARDIANCE 10MG
223612581|NCT06105840|PROCEDURE|Acupressure and Standardized Curcuminoid from Turmeric Extract|capsules containing curcuminoid from Tumeric Extract three times a day for 3 weeks and acupressure massage at points provide comfort for knee pain twice a week for 3 weeks
223612582|NCT06105840|PROCEDURE|Sham Acupressure and Placebo|capsules containing starch three times a day for 3 weeks and acupressure massage at points that are not to provide comfort for knee pain twice a week for 3 weeks
223612583|NCT05876507|BEHAVIORAL|Progressive relaxation exercise|Progressive relaxation exercises will take 25-30 minutes of patients daily.
223612584|NCT00390767|BIOLOGICAL|MultiGeneAngio|Escalating doses of MultiGeneAngio, one dose per patient administered as one treatment, infused intra-arterially
223612585|NCT04039958|DRUG|Soviredia|Test drug (Soviredia)1 tablet contains 400 mg Sofosbuvir and 90 mg Ledipasvir
223612586|NCT04039958|DRUG|Harvoni (first dose)|Reference drug (Harvoni) 1 tablet contains 400 mg Sofosbuvir and 90 mg Ledipasvir
223612587|NCT04039958|DRUG|Harvoni (Second dose)|Reference drug (Harvoni) 1 tablet contains 400 mg Sofosbuvir and 90 mg Ledipasvir
223612588|NCT03647657|DRUG|177Lu-PP-F11N|Intravenous application of 2 x 1 gigabequerel (GBq) 177Lu-PP-F11N with and without co-medication with Sacuitril (100 mg Entresto) in each patient
223612589|NCT03647657|DRUG|Sacuitril|Medication with Sacuitril (100 mg Entresto) additional to the injection of 177Lu-PP-F11N
223758851|NCT02877628|OTHER|Pharmacokinetic-pharmacodynamic model in liver transplantation|Biological: tacrolimus and calcineurin dosage, donor and recipient CYP3A5 and ABCB1 genotypes determination
223758852|NCT00402675|PROCEDURE|Timing of percutaneous coronary intervention|Immediate, early or selective invasive angiography
223612590|NCT00091091|OTHER|medical chart review|
223758853|NCT02619695|DRUG|Fastjel|2.5% ketoprofen gel (Fastjel) has been administer as 2 gr in 5 cm area.
223612591|NCT00091091|OTHER|questionnaire administration|
223612592|NCT00091091|PROCEDURE|management of therapy complications|
223612593|NCT02335307|GENETIC|CYP2D6 genotyping|CYP2D6 genotype results and an interpretive report will be placed in the electronic medical record to assist the physician with prescribing medication for pain management.
223612594|NCT02335307|OTHER|Pain assessment questionnaire|A pain assessment questionnaire will be administered at baseline and 3 months.
223612595|NCT02335307|OTHER|Physician assessment|20-item survey administered to physicians treating patients enrolled in the study
223612596|NCT00117299|DRUG|PTK787/ZK222584|PTK787/ZK222584 is administered at the dosage of 1250 mg o.d. orally
223758854|NCT01229475|PROCEDURE|Ablation with stepwise approach|Stepwise approach for repeat AF ablation
223758855|NCT01229475|PROCEDURE|Linear ablation|Linear ablation for AF ablation
223758856|NCT03365206|OTHER|Questionnaire on practices and knowledge in terms of oral hygiene|Questionnaire on practices and knowledge in terms of oral hygiene during a dental consultation
223758857|NCT01869192|DRUG|Epirubicin|Epirubicin 90 mg/m2 d1 q3w
223758858|NCT01869192|DRUG|Cyclophosphamide|Cyclophosphamide 600 mg/m2 d1 q3w
223758859|NCT01869192|DRUG|Docetaxel|Docetaxel 75 mg/m2 d1 q3w
223758860|NCT01869192|DRUG|Capecitabine|Capecitabine 1000 mg/m2/dose bid x 14d q3w
223758861|NCT01869192|RADIATION|Radiation Therapy|Standard dosing, fields depending on clinical findings
223758862|NCT04134000|DRUG|Atezolizumab|1200 mg IV q3w until recurrence of disease, disease progression (e.g., muscle-invasive or metastatic UBC), symptomatic deterioration (i.e., uncontrollable pain secondary to disease or unmanageable ascites, etc.) attributed to disease progression as determined by the investigator, Intolerable toxicity related to atezolizumab, including development of an immune-mediated adverse event determined by the investigator to be unacceptable given the individual patient's potential response to therapy and severity of the event, any medical condition that may jeopardize the patient's safety if he or she continues on study treatment, use of another non-protocol anti-cancer therapy or pregnancy.
223758863|NCT04134000|DRUG|BCG|1 or 1/2 instillation per week until recurrence of disease, disease progression (e.g., muscle-invasive or metastatic UBC), symptomatic deterioration (i.e., uncontrollable pain secondary to disease or unmanageable ascites, etc.) attributed to disease progression as determined by the investigator, Intolerable toxicity related to atezolizumab, including development of an immune-mediated adverse event determined by the investigator to be unacceptable given the individual patient's potential response to therapy and severity of the event, any medical condition that may jeopardize the patient's safety if he or she continues on study treatment, use of another non-protocol anti-cancer therapy or pregnancy.
223758864|NCT04582851|OTHER|some risk factors correlated with TMD|exposure factors causing TMD
223758865|NCT05243212|BIOLOGICAL|CAR-BCMA|CAR-BCMA T-cells are genetically modified autologous T-cells directed to the B-cell maturation antigen (BCMA). CAR-BCMA T-cells identify and eliminate BCMA-expressing malignant plasma cells. Upon binding to BCMA-expressing cells, the CAR transmits a signal to promote T cell expansion, activation, persistence and elimination of malignant plasma cells.
223758866|NCT05180136|DIETARY_SUPPLEMENT|Rice bran extract group|Rice bran extract 1,000 mg/day for 8 weeks
223758867|NCT05180136|DIETARY_SUPPLEMENT|Control group|Placebo 1,000 mg/day for 8 weeks
223758868|NCT04943731|DEVICE|Provox Life|Phase 1: Like for like transition, Phase 2: Provox Life day/night regimen
223758869|NCT02462967|DRUG|GR-MD-02|GR MD 02 (galactoarabino rhamnogalacturonate), a complex carbohydrate drug that binds to galectin 3
223758870|NCT02462967|DRUG|Placebo|Placebo for GR-MD-02
223758871|NCT05155384|OTHER|Pain Neuroscience Education|main topics of pain neuroscience education; neurophysiology of the nervous system, protective mechanism of pain, acute pain formation and chronic pain, factors that increase/reduce pain, central sensitization mechanism, neuroplasticity and treatment strategies in chronic pain.
223612597|NCT00742183|DEVICE|Mepilex|Mepilex Ag - dressing changes every 5-7 days, more frequently if needed
223612598|NCT00742183|DEVICE|Silvadene|Silvadene - dressing changes every day, more frequently if needed
223612599|NCT04057807|DRUG|LPS|LPS (0.4 ng/kg)
223612600|NCT00665535|PROCEDURE|Turning or repositioning schedule|Turning schedule randomly assigned at 2, 3, or 4 hours
223758872|NCT05155384|OTHER|Relaxation exercises|Relaxation exercises are a training based on deep relaxation techniques and visual imagery. Relaxation exercises will be applied at the end of the training sessions.
223758873|NCT05155384|OTHER|Cognition target exercise|Cognition target exercises are a time-based approach that is not symptom-conditioned (not based on fatigue or pain). It includes functional and dynamic exercises.
223758874|NCT05155384|OTHER|Pelvic floor stretching exercises|Pelvic floor stretching exercises; consists of stretching exercises involving the pelvic floor muscles and surrounding group muscles (such as piriformis, hamstring, adductor group muscles and lumbar extensors).
223758875|NCT05155384|DEVICE|Transcutaneous electrical nerve stimulation|It will be used with superficial electrodes attached to the suprapubic region of the patients for 20 minutes in each session.
223612601|NCT00665535|PROCEDURE|Turning or repositioning schedule|Turning schedule randomly assigned at 2, 3 or 4 hours
223612602|NCT03953833|BIOLOGICAL|Recombinant anti-HER2 humanized monoclonal antibody conjugate for injection.R&D code: B003.|"Usage: Intravenous infusion; Dose escalation stage: doses 0.6, 1.2, 2.4, 3.6, 4.8 mg / kg, 1-6subjects each. Dose expansion stage: 20 subjects are enrolled and take the recommended dose based on the result of dose escalation stage.~Infusion time：90 minutes(90min-106min suggested) for the first time; if no infusion reaction happens, the follow-up time is adjusted to at least30 minutes(30min-40min suggested).Dose escalation stage: treatment cycle is administered every 21days,the infusion is taken at the first day of each treatment cycle.Observation period of DLT is the 21st day of the first treatment cycle."
223758876|NCT02393963|DRUG|Tranexamic Acid|0.5g Tranexamic Acid in 0.9% Sodium Chloride (study group) will be injected into the joint after final closure through a temporary catheter that is brought out through the incision.
223758877|NCT02393963|OTHER|Placebo|0.9% Sodium Chloride (placebo group) will be injected into the joint after final closure through a temporary catheter that is brought out through the incision.
223758878|NCT00577512|DRUG|DTPACE|"* Dexamethasone 200 mg Intravenous Infusion Piggy-Back (IVPB) Days 1-7~* Thalidomide 200 mg by mouth (PO) Days 1-7~* Cisplatin 15mg/m2 Days 1-4 (modify for renal insufficiency)~* Adriamycin 15 mg/m2 Days 1-4~* Cyclophosphamide 600 mg/m2 Days 1-4~* Etoposide 60 mg/m2 Days 1-4"
223758879|NCT04419688|DRUG|STT-5058|Monoclonal Antibody STT-5058
223758880|NCT04419688|DRUG|Placebo|Matching placebo to STT-5058
223758881|NCT04061603|DEVICE|Adagio AF Cryoablation System (iCLAS™)|Endovascular ablation of the left and right atrium
223758882|NCT00963339|DEVICE|Foresee Home|Home Monitoring
223758883|NCT02126969|RADIATION|Low dose fractionated radiation - 80cGy with chemotherapy|Chemotherapy + 80 cGy of RT
223758884|NCT02126969|DRUG|Docetaxel and Carboplatin AUC 6|Docetaxel 75 mg/m2 and Carboplatin AUC 6 without Radiation
223758885|NCT01450410|DRUG|Nicotinic acid|Nicotinic acid / laropiprant (Tredaptive 1000 mg/20 mg modified-release tablets). Patients treated with nicotinic acid 1g/day receive one dose of one month and 2 g / day thereafter. Nicotinic acid treatment will last for 12 weeks.
223758886|NCT01450410|DRUG|Placebo|Placebo treatment will last for 12 weeks.
223758887|NCT02018289|PROCEDURE|Triclosan coated suture|Suture of the abdominal wall with triclosan coated suture
223758888|NCT02018289|PROCEDURE|No triclosan|Suture of the abdominal wall with suture without triclosan coat
223758889|NCT04949269|DRUG|Deucravacitinib|Specified dose on specified days
223758890|NCT04949269|DRUG|Famotidine|Specified dose on specified days
223758891|NCT00011089|DRUG|Tenofovir disoproxil fumarate|
223758892|NCT05645822|OTHER|Screen&treat|Study participants will be tested with an RDT to prove the presence of antibodies against Trypanosoma brucei gambiense. Should the RDT be positive, they will be offered the 10-day treatment with fexinidazole, and an additional blood sample will be taken for the post hoc confirmation of the disease.
223612603|NCT06100679|BEHAVIORAL|Responsible Engaged and Loving (REAL) Fathers Initiative|REAL Fathers is a multilevel norms-shifting intervention among: young fathers (ages 16-25 whose oldest child is under the age of 3); couple dyads (fathers and wives); mentoring dyads and groups; and communities. Respected men in the community are identified by participating young fathers, their partners and community members to become mentors. Mentors participate in a training and mentor young fathers through home and group sessions on conflict resolution, non-violent discipline, family planning, and couple communication. Mentoring is supplemented with a monthly poster campaign designed to reinforce messages from the home and group mentoring sessions and a community celebration. REAL Fathers aims to build positive partnerships and parenting practices among young fathers to: 1) reduce incidence of intimate partner violence; 2) reduce harsh physical punishment of children; 3) improve early childhood development; 4) decrease unmet need for family planning.
223612604|NCT04095182|DRUG|Zebinix 400mg|Zebinix 400mg group is administered with two Zebinix 200mg tablets per day. (Single dose: Day 1, Multiple dose: Day5\~11)
223612605|NCT04095182|DRUG|Placebo for Zebinix 400mg|"Placebo for Zebinix 400mg group is administered with two placebo for Zebinix 200mg tablets per day.~(Single dose: Day 1, Multiple dose: Day5\~11)"
223612606|NCT04095182|DRUG|Zebinix 800mg|Zebinix 800mg group is administered with a Zebinix 800mg tablet per day. (Single dose: Day 1, Multiple dose: Day5\~11)
223612607|NCT04095182|DRUG|Placebo for Zebinix 800mg|"Placebo for Zebinix 800mg group is administered with a placebo for Zebinix 800mg tablets per day.~(Single dose: Day 1, Multiple dose: Day5\~11)"
223612608|NCT04095182|DRUG|Zebinix 1600mg|Zebinix 1600mg group is administered with two Zebinix 800mg tablets per day. (Single dose: Day 1, Multiple dose: Day5\~11)
223758893|NCT00555984|DRUG|Propofol + Remifentanil|Administered intravenously during surgery for maintenance of General Anesthesia
223612609|NCT04095182|DRUG|Placebo for Zebinix 1600mg|"Placebo for Zebinix 1600mg group is administered with two placebo for Zebinix 800mg tablets per day.~(Single dose: Day 1, Multiple dose: Day5\~11)"
223612610|NCT05569447|PROCEDURE|Balloon Tamponade|A tamponade device that was fashioned using an 18F red rubber catheter and Penrose drain that was cut to the approximate length of the tract and ligated proximally and distally with #0 silk.
223612611|NCT00972335|DRUG|Everolimus|This drug will be dosed at 10 mg orally DAILY for the duration of the study.
223612612|NCT00972335|DRUG|Bevacizumab|This drug will be given IV at 10 mg/kg on Days 1 and 15 of each 28-day treatment cycle for the duration of the study.
223758894|NCT00555984|DRUG|Sevoflurane + Remifentanil|the (Sevoflurane + Remifentanil) arm: Sevoflurane as inhalational agent and Remifentanil as intravenous agent for maintenance of General Anesthesia
223758895|NCT05614245|BIOLOGICAL|VBI-2901e|Intramuscular injection of VBI-2901e, an investigational trivalent coronavirus vaccine that contains three coronavirus spike proteins with aluminum phosphate and E6020 adjuvants
223612613|NCT05575362|OTHER|Group A|Group A will receive Epleys maneuver and Cawthorne Cooksey exercise for two weeks.
223612614|NCT05575362|OTHER|Group B|Group B will receive Half Somersault maneuver along with Cawthorne Cooksey exercise for two weeks.
223612615|NCT03477396|DRUG|Aromatase Inhibitor|Aromatase inhibitor per treating investigator's discretion
223612616|NCT03477396|OTHER|Laboratory Biomarker Analysis|Correlative studies
223612617|NCT03477396|OTHER|Pharmacokinetic Study|Correlative studies
223612618|NCT03477396|OTHER|Questionnaire Administration|Ancillary studies
223612619|NCT03477396|DRUG|Ribociclib|Given PO
223758896|NCT00423891|DRUG|Entecavir|Tablets / Oral Solution, Oral, Naïve: 0.015 mg/kg up to 0.5 mg; Experienced: 0.030 mg/kg up to 1 mg, once daily, 48 - 120 weeks depending on response
223758897|NCT02508636|DRUG|Enzalutamide|Given orally
223758898|NCT02508636|DRUG|Leuprolide|Given via intramuscular injection
223758899|NCT02508636|RADIATION|Intensity-Modulated Radiation Therapy|A total dose of 45 Gy in 25 fractions of 1.8 Gy each.
224311968|NCT02781038|BEHAVIORAL|Teaching intervention|Subjects will receive a pamphlet which describes the relationship between smoking and negative outcomes in fracture healing.
224311969|NCT02781038|BEHAVIORAL|Control|Subjects in this group will not receive the pamphlet
223758900|NCT03588364|OTHER|Osteopathic Manipulation|Osteopathic manipulation involves a number of different manual techniques. These include muscle inhibition; myofascial release; muscle energy stretch; counterstrain; facilitated positional release ; osteopathy in the cranial field ; balanced ligamentous tension/ligamentous articular strain; one or all of these techniques may be used. Participants will be positioned on an exam table supine, seated, lateral decubitus, prone, or in their position of greatest comfort for the procedure.
223612620|NCT00786799|DIETARY_SUPPLEMENT|Omega-3 Fatty Acids|"Omega-3's are administered in the form of an orange pudding made by Coromega~1 mg of omega-3 fatty acid 2 times per day"
223758901|NCT03423732|DRUG|CardioCell|"Patients in the N-O CLI trial will receive a full dose of IMP three times during the trial: at baseline, after 45 days post index administration and after 3 months post index administration.~IMP will be administered into femoral artery and intramuscularly with 50:50 proportion. The intramuscularly dose will be administered into muscles above and below the knee in 50:50 proportion."
223758902|NCT03423732|DRUG|Placebos|"Patients randomized to the control group will receive 0.9% NaCl and 5% albumin injections (in the same volume as CardioCell) in the same manner.~Control group will receive the same amount of fluid used for WJMSCs preparation, without cells."
223758903|NCT01325779|DRUG|heparin|subcutaneous heparin 5000 units every 8 hours
223758904|NCT01325779|DRUG|enoxaparin|subcutaneous enoxaparin 40 milligrams every 24 hours
224311970|NCT00238758|DRUG|Omega-3 Polyunsaturated Fatty Acids|
224311971|NCT00695058|DEVICE|Transcutaneous mechanical nerve stimulation by A medical vibrator (FERTI CARE personel, Multicept A/S, Albertslund, Danmark)|"A medical vibrator (FERTI CARE personel, Multicept A/S, Albertslund, Denmark) will be used. The stimulation works through a vibrating disc of hard plastic with a diameter of 3.5 cm. The stimulation point will be the perineum in women and the perineum or the frenulum in men.~In the women the stimulation will be performed with a vibration amplitude of 2 mm and a frequency of 100 Hz. In the men the vibration parameter/location will be determined by the results of the new pressure profile studies (aim 3).~A daily stimulation sequence consisting of 10 seconds of stimulation followed by a 10 second pause repeated 10 times will be used through 6 weeks in both the women with stress incontinence and overactive bladder syndrome.~In the 3 groups of patients the subjects will be randomized to either active treatment or placebo treatment. The placebo treatment will be done with a vibration device with an amplitude of 0 mm. Subjects will be randomized by a draw."
224311972|NCT00003302|PROCEDURE|biopsy|
223612621|NCT00786799|DIETARY_SUPPLEMENT|Omega-3 Fatty Acids|"Omega-3 Fatty Acids in orange pudding form~1 packet two times per day"
223612622|NCT01988675|RADIATION|Whole Brain Irradiation|
223612623|NCT01988675|RADIATION|Partial Brain Irradiation|
223612624|NCT01988675|BEHAVIORAL|Neuropsychological Testing|
223612625|NCT01988675|BEHAVIORAL|Quality of Life Questionnaire|
223612626|NCT01988675|DEVICE|Magnetic Resonance Imaging (MRI) Assessments|MRI Assessments include Diffusion Tensor Imaging (DTI)and Gd-DTPA (Diethylenetriamine Pentaacetic Acid - a radioactive tracer injected into the patient and viewed on images).
223612627|NCT05960981|BEHAVIORAL|Online-delivered Group-based Parent Mediated Intervention for Young Children with ASD|The program consists of eight weekly 2-hour group sessions, with each group consisting of 8 to 10 families. During the sessions, supervisors present the strategies to the parents and explain how to integrate them into their interactions with their children. Sample videos are shown to illustrate the strategies, and group discussions allow parents to discuss their application. In the second half of each session, the parents' recorded videos are watched, and supervisors provide feedback on whether the strategies were accurately implemented. At the end of each session, supervisors address any questions the parents may have.
223612628|NCT00726648|DRUG|CDP323|50mg capsules, 100mg bid for 4 weeks
223612629|NCT00726648|DRUG|CDP323|250mg capsules, 500mg bid for 4 weeks
223612630|NCT00726648|DRUG|CDP323|250mg capsules, 1000mg bid for 4 weeks
223612631|NCT00726648|DRUG|CDP323|250mg capsules, 1000mg daily for 4 weeks
223612632|NCT00726648|DRUG|Placebo|placebo capsules for 4 weeks
223612633|NCT01219309|DIETARY_SUPPLEMENT|Omega 3/6 fatty acids|3 capsules bid orally
223612634|NCT01219309|DIETARY_SUPPLEMENT|Placebo (olive oil)|3 capsules bid orally
223612635|NCT03637777|DIAGNOSTIC_TEST|16S rRNA gene sequencing|Specimens collected from patients will be used for next generation sequencing of the bacteria-specific 16S rRNA gene
223612636|NCT02430090|DRUG|Levobupivacaine|this used in intratechal area and for spinal anesthesia in ceserean section
223612637|NCT02430090|DRUG|Fentanyl|this used in intratechal area and for spinal anesthesia in ceserean section
223612638|NCT02430090|DRUG|Sufentanil|this used in intratechal area and for spinal anesthesia in ceserean section
223612639|NCT02430090|DRUG|Levobupivacaine|this used in intratechal area and for spinal anesthesia in ceserean section
223612640|NCT02430090|DRUG|Levobupivacaine|this used in intratechal area and for spinal anesthesia in ceserean section
223612641|NCT03253042|OTHER|WBV exercise program|The intervention will consist of a 8-week whole-body vibration exercise program with the platform configured at a frequency of 40 Hz and peak-to-peak amplitude of 4 mm. The sessions will be held 2 times a week, consisting of 4 sets of 1 and a half minutes of exercise on the platform. Rest intervals of 1 minute between sets will be respected.
223612642|NCT03253042|OTHER|Sham WBV exercise program|The intervention will consist of a 8-week exercise program, but the platform will remain off at all sessions. A device will be attached to the side of the platform in order to produce a sound, similar to the sound produced by the vibrating platform when it is in operation.
223612643|NCT00254137|DRUG|capecitabine|
223612644|NCT00254137|DRUG|irinotecan|
223612645|NCT00254137|DRUG|oxaliplatin|
223612646|NCT00254137|DRUG|cetuximab|
223612647|NCT04955171|DRUG|BEOVU intravitreal injection|BEOVU intravitreal injection
223612648|NCT03917849|BEHAVIORAL|Exercises program for patellar tendinopathy|To compare the effectiveness of the inertial flywheel resistance program versus slow heavy resistance in patients with chronic patellar tendinopathy
223612649|NCT04093713|PROCEDURE|A novel technique to block the inferior alveolar nerve block using Mepivecaine with Levonordefrin|blocking the inferior alveolar nerve using extroral landmarks
223612650|NCT05706922|OTHER|Venous blood sample, vaginal swab|Venous blood samples and vaginal swab will be obtained on the same day.
223612651|NCT02223715|OTHER|CDI Pts|
223758905|NCT04412330|OTHER|ICU Recovery + Physical Therapy|Physical therapy interventions will be supervised by a physical therapist (\>20 years of experience in ICU and pulmonary rehabilitation). Potential interventions include endurance/aerobic training (treadmill training, upper and lower extremity ergometer, and recumbent step machine), upper and lower extremity resistance strength training, balance training, functional movement training, and education. If the interventions are providing in the home environment the exercises will be completed through Zoom, video communications app. Home-based interventions will include seated and standing exercise including resistance exercises (such as lifting small weights) and endurance (e.g. marching or stepping in place, repetitive sit-to-stand training). Physical therapist will provide verbal instructions for motivation and adherence to exercise interventions.
223758906|NCT05483946|DEVICE|Measurement of compartment compressibility|Application of the CPM#1 device for compartment compressibility ratio measurement - for each participant, a pre-defined number of measurements will be conducted per leg and forearm
223758907|NCT04384965|DEVICE|MagPro X100 Stimulator, B70 Fluid-Cooled Coil|Treatment will occur 8 times per treatment day (50 min pause between treatments). Each treatment session will consist of a single iTBS treatment, delivering 600 pulses of iTBS (bursts of 3 pulses at 50 Hz, bursts repeated at 5 Hz, with a duty cycle of 2 seconds on, 8 seconds off, over 60 cycles / \~3 minutes) at a target of 110% of the subject's resting MT.
223758908|NCT04514601|OTHER|Standard Operating Protocol|This was a written protocol on how the handover process should be conducted.
223758909|NCT05991102|DEVICE|Radiofrequency electromagnetic field treatment|Radiofrequency electromagnetic field treatment using a carrier frequency of 13.56 MHz
223758910|NCT05037838|PROCEDURE|Longitudinal strain obtained thanks to transesophageal ultrasound data recorded during liver transplantation|Longitudinal strain of Left Ventricule and longitudinal strain of Right Ventricule free wall obtained thanks to TransEosophagal Ultrasound performed during the Liver Transplant
223758911|NCT03812965|DRUG|Botulinum toxin type A|2 units/point of botulinum toxin type A
223758912|NCT04733963|DRUG|Fruquintinib Plus Capecitabine|Maintenance therapy with fruquintinib at the dose determined in phase safety lead-in, orally once daily, on d1-21, given every 4 weeks (Q4W); plus capecitabine at the dose 850mg/m2, orally twice daily, d1-7, given every 2 weeks (Q2W); until progressive disease, death from any cause, unacceptable toxicity or informed consent withdrawal
223758913|NCT04733963|DRUG|Bevacizumab Plus Capecitabine|Maintenance therapy with bevacizumab at the dose 5mg/kg q2w (Q2W); plus capecitabine at the dose 850mg/m2, orally twice daily, d1-7, given every 2 weeks (Q2W); until progressive disease, death from any cause, unacceptable toxicity or informed consent withdrawal
223758914|NCT03621878|OTHER|Neural mobilization exercises -Tensioner technique|Exercise aiming to lengthen the neural structure using more than one joint.
223612652|NCT03901131|DRUG|Norethisterone enantate/estradiol valerate (Mesigyna, BAY98-7040)|Follow clinical administration
223612653|NCT01011374|DRUG|ranibizumab (Lucentis)|0.5 mg, administered intravitreally every 4 weeks
223612654|NCT00605124|OTHER|Knee muscle exercises|Home exercises three times a week, control every three months
223612655|NCT06166966|OTHER|Flipped Education Model|The effect of the Inside Out Education Model on the course success of nursing students.
223612656|NCT05005663|OTHER|surgical management of incisional hernia|surgical repair of the incisional hernia
223612657|NCT02635607|DRUG|Follitropin Beta|Patients will start stimulation with a daily s.c. injection of 150IU follitropin beta on menstrual cycle day 3. A modification of the rFSH dose will be allowed from stimulation day 6 onward in case that a high ovarian response occurs at the discretion of the investigator.
223612658|NCT02635607|DRUG|Ganirelix|Ganirelix 0.25mg daily s.c. will start after 4 days of rFSH stimulation
223612659|NCT02635607|DRUG|Ganirelix|Ganirelix 0.25mg daily s.c. will start when at least one of the following criteria are fulfilled: (i) the presence of at least one follicle measuring≥12 mm; (ii) serum E2 levels\>600 pg/ml; and (iii) serum LH levels\>10 IU/l.
223758915|NCT03621878|OTHER|Neural mobilization exercises -Slider technique|Exercise aiming to slide/glide the neural structure using more than one joint.
223758916|NCT03621878|OTHER|Transcutaneous Electrical Nerve Stimulation (TENS)|Electrotherapy device aiming to decrease patient's symptoms.
223758917|NCT03007511|DEVICE|Fidmi enhanced enteral feeding device|Fidmi enhanced enteral feeding device is intended to provide nutrition to a patient directly into the stomach through a stoma. The Fidmi PEG device would be investigated in this study on patients suffering from dysphagia, who are scheduled for PEG procedure in order to improve surgical initial insertion, device replacement and removal.
223612660|NCT02635607|DRUG|rhCG|An amount of 250ug rhCG will be administered to induce final oocyte maturation as soon as at least three follicles of ≥17 mm were observed
223612661|NCT02635607|DRUG|triptorelin|0.2mg triptorelin will replace rHCG to trigger in case of high risk of overstimulation
223612662|NCT03520985|DRUG|Pomalidomide|"Pomalidomide (4 mg p.o.) will be administered on every other day of each 28-day treatment cycle.~Treatment duration:~Treatment cycles are repeated until confirmed disease progression."
223612663|NCT03520985|DRUG|Dexamethasone|"For patients ≤ 75 years of age:~Low-Dose Dexamethasone (40 mg p.o.) will be administered once per day on days 1, 7, 15, and 21 of a 28-day cycle.~For patients \> 75 years of age:~Low-Dose Dexamethasone (20 mg p.o.) will be administered once per day on days 1, 7, 15, and 21 of a 28-day cycle.~Treatment duration:~Treatment cycles are repeated until confirmed disease progression."
223612664|NCT01745367|DRUG|Tivozanib Hydrochloride|
223758918|NCT02739191|DEVICE|PICO, Smith & Nephew|Direct application of negative pressure wound therapy following Foot and Ankle surgery
223758919|NCT05749081|DRUG|Lacidophilin tablets in combination with vonorazan dual therapy|2400mg lacidophilin tablets three times daily,1000mg amoxicillin capsules three times daily and 20mg vonoprazan Fumarate Tablets twice daily for 10 days
224311973|NCT00003302|DIAGNOSTIC_TEST|magnetic resonance imaging|
223612665|NCT01745367|DRUG|paclitaxel|
223612666|NCT01745367|DRUG|Placebo|
223612667|NCT00287222|DRUG|Bevacizumab|15 mg/KG I.V. every 21 days
223612668|NCT00287222|DRUG|Erlotinib|150 mg orally every day
223612669|NCT05220085|DRUG|Brolucizumab Ophthalmic Dbll 6 Mg/0.05 mL Intravitreal Solution|Intravitreal injection
223612670|NCT05514600|PROCEDURE|closure of parastomal hernia fascial defect|For subjects randomized to the fascial closure arm, the parastomal defect will be closed using barbed, running suture prior to placement of the mesh.
223758920|NCT05749081|DRUG|Placebo in combination with vonorazan dual therapy|2400mg placebo three times daily,1000mg amoxicillin capsules three times daily and 20mg vonoprazan Fumarate Tablets twice daily for 10 days
223758921|NCT00651027|DRUG|PF-868554|200 mg, Child-Pugh Class A
223758922|NCT00651027|DRUG|PF-868554|200 mg, Child-Pugh Class B
223612671|NCT06344299|OTHER|potential predictors|Researchers want to investigate some important factors that influence elderly patients not to undergo radical surgery.
223612672|NCT01392131|DIETARY_SUPPLEMENT|Oncoxin|20 patients with hepatocellular carcinoma will receive syrup Oncoxin 25 ml bd and capsule Oncoxin 1 cap bd for 24 weeks
223758923|NCT00651027|DRUG|PF-868554|200 mg, healthy volunteers
223758924|NCT05551143|OTHER|LiftKit|"The LiftKit contains 7 tools that could assist EMS providers when lifting/moving patients. These tools are:~1. Simple Strap - A sling to lift a seated patient~2. Strap and slide stick - A strap system for raising a supine patient to a sitting posture.~3. Slip Preventer- An envelope that goes over the patients feet with high friction straps for the EMS providers to stand on that prevent the patient from sliding forward when lifted.~4. Drag Straps - straps with handles that can be clipped on tarps used to drag patients~5. The Binder Lift - a vest with handles that allow EMS providers to easily get hold of patient they need to lift.~6. Patient Turning Straps - a way to log-roll a patient that in on the floor while in a standing posture.~7. The ELK - an inflatable seat cushion that can raise a patient who in the floor to chair level"
223758925|NCT01262014|DRUG|Pazopanib|800 mg (2x400mg) pazopanib per day should be taken orally without food at least one hour before or two hours after a meal until disease progression, the development of unacceptable toxicity, noncompliance, withdrawal of consent by the patient, or investigator decision.
223758926|NCT06357637|DIAGNOSTIC_TEST|Measure of abdominal circumference|Measure of abdominal circumference preoperatively in both sitting and lying position
223612673|NCT01392131|OTHER|Supportive treatment|patients will receive only supportive treatment. No chemotherapy, radiotherapy, tumor ablation or surgery will be performed
223612674|NCT05576922|OTHER|Prosthetic-surgical approach + autogenous graft|Coronally advanced flap with an autogenous graft (CTG)
223612675|NCT05576922|OTHER|Prosthetic-surgical approach + graft substitute|Coronally advanced flap with a graft substitute (collagen matrix and rhPDGF-BB)
223612676|NCT04299685|OTHER|Interview|Qualitative family interviews of 20 family units, or more until data saturation, of at least one parent and one adolescent (aged 10-19 year old) will be conducted based on deductive thematic approach. Each interview will last for about an hour, be conducted in Cantonese, and audio-taped for transcription in verbatim in Chinese.
223612677|NCT06462183|DRUG|RGT-61159|Oral MYB inhibitor
223612678|NCT05534399|PROCEDURE|Intra-vesical BoNTA injections|"Intra-vesical BoNTA injections will be performed according to the protocol currently applied by the department.~They will be performed in the operating room or in the outpatient clinic under strict asepsis, including the wearing of sterile gloves by the surgeon associated with an antiseptic brushing of the patient and the establishment of sterile fields.~A rigid or a flexible cystoscope will be used.~After the introduction of the cystoscope under visual control, complete bladder emptying will be performed. The bladder will be filled again, slowly and at low pressure to allow the bladder mucosa to expand.~BoNTA (BOTOX® 200 U) will be diluted as follows: BOTOX® 200 U: in 30 mL of saline solution~The solution obtained will be injected all along the bladder wall, sparing the trigone in 20 (BOTOX® 200 U) points using a Bonee®-type needle.~A complete bladder emptying will be performed at the end of the procedure."
223612679|NCT01934257|OTHER|Marketed milk-based lactose-containing infant formula|
223612680|NCT01934257|OTHER|Marketed milk-based lactose-free infant formula|
223612681|NCT01934257|OTHER|Marketed soy-based lactose-free infant formula|
223612682|NCT03539718|DRUG|Taurolidine heparin|Taurolock-hep 500 at end of session
223612683|NCT03539718|DRUG|Heparin Sodium|Heparin sodium 5000 at end of session
223612684|NCT01396213|DRUG|Larazotide Acetate|gelatin capsule
223612685|NCT01396213|DRUG|placebo|gelatin capsule
223758927|NCT06073925|DRUG|VIT D|50000 IU per week of VIT D
223758928|NCT04871243|OTHER|Qualitative Interview|Individual semi-structured interviews
223758929|NCT04734496|OTHER|National Healthcare System Standard of care for each disease type (National Institute for Health and Care Excellence guidelines)|National Healthcare System Standard of care for each disease type (National Institute for Health and Care Excellence guidelines)
223758930|NCT02505633|DEVICE|Stimuplex insulated needle|"2P2I group: nerve stimulating needle is advanced twice and LA is injected 15 mL at a time.~1P1I group: nerve stimulating needle is advanced once and LA is injected 30 mL."
223758931|NCT02505633|DRUG|lidocaine mixed with epinephrine|2P2I group and 1P1I group use the same LA (1.5% lidocaine mixed with 1:200,000 epinephrine). But 2P2I group is injected LA at equally divided doses (15 mL at a time). 1P1I group is injected LA 30 mL at once.
223758932|NCT04231500|DIAGNOSTIC_TEST|Skin swabs|Pre-moistened skin swabs will be collected before the patient starts the conditioning regimens (before conditioning; start of HSCT = day 0, on the day of the transplantation an the repeated in week 4, 12, 24, 36 and 52 after allo-HSCT. The first swab serves as baseline reference (ideally taken at the earliest one week after a systemic antibiotic treatment). Swabs will be taken from the neck, back, right hip, buccal oral cavity and the genital mucosae. In patients who develop acute or chronic skin-GVHD additional swabs will be taken from affected skin at the time of diagnosis and then again according to the schedule of the non-lesioned skin swabs.
224311974|NCT00003302|DIAGNOSTIC_TEST|mammography|
224311975|NCT04582084|DRUG|Etanercept|Patients received biosimilar etanercept 25 mg twice weekly or 50 mg once weekly.
223612686|NCT04601012|DIAGNOSTIC_TEST|Optical coherence tomography angiography|Each subject underwent optical coherence tomography angiography to evaluate the retinal vessel density.
223612687|NCT04268108|BIOLOGICAL|liquid tumor infiltrating lymphocytes|Isolatation and amplification PD-1+ cells from peripheral blood lymphocytes under GMP conditions for clinical use.
223612688|NCT01576289|OTHER|Histological analysis|Systematic histological analysis of biopsy specimens obtained during routine endoscopic examination
223612689|NCT01837277|DRUG|Dolutegravir 50 mg|Use of Dolutegravir -based regimens: patients will receive a Dolutegravir -based ART regimen (RAL 400 mg BID + TDF 300 mg QD + 3TC 150 mg BID)
223612690|NCT01837277|DRUG|Efavirenz-based regimens|Efavirenz-based regimens: patients will receive an EFV-based regimen (EFV 600 mg QD + TDGF 300 mg QD + 3TC 300 mg QD)
223758933|NCT04231500|DIAGNOSTIC_TEST|Skin punch biopsies|During the first visit, a single skin punch biopsy will be taken to state the skin condition and microbiome before allo-HSCT. Further biopsies will only be taken in case of acute or chronic cutaneous GVHD. A 4-6 mm punch biopsy will be taken from the affected skin area and a second one from a nearby unaffected part of the skin. Before the biopsy, skin disinfection will be performed to avoid contamination with surface bacteria.
223758934|NCT04231500|DIAGNOSTIC_TEST|additional blood sampling|an additional tube of blood (2.7ml) and an additional tube of serum (6ml) will be taken and frozen during visits 1, 2, 3 and 7 in the course of blood collection, in order to be able to carry out any later laboratory tests that may prove to be useful depending on the course of the study.
223758935|NCT00785486|DRUG|Midazolam Alone|Midazolam 2 mg syrup was given orally after a fast of at least 10 hours.
223758936|NCT00785486|DRUG|Qualaquin (quinine) alone steady state|Qualaquin (quinine) 324 mg capsules were given orally every 8 hours for 7 days ( 21 doses total). On day 9 after taking Qualaquin (quinine) for 5 days according to the stated regimen and fasting for at least 10 hours, all participants took their usual dose of Qualaquin (quinine). Blood was drawn at times sufficient to characterize the pharmacokinetics of quinine at steady state
223758937|NCT00785486|DRUG|Midazolam and Qualaquin at steady state|On the morning of day 10 after taking Qualaquin (quinine) for 6 days according to the stated regimen (324 mg every 8 hours), all participants took their usual dose of Qualaquin (quinine) with an oral dose of midazolam 2 mg after a fast of at least 10 hours
223758938|NCT00169650|OTHER|Registry and database|Subjects undergoing laparoscopic pyeloplasty for ureteropelvic junction obstruction at Methodist Urology in Indiana will be asked to participate in a registry and database to review outcomes of the surgery.
223758939|NCT02513524|PROCEDURE|Direct Observed Therapy test|There is one group only, all of whom will undergo direct observed therapy testing
223758940|NCT06391463|OTHER|Carriage of MRB ou BC|Study of the epidemiology of the carriage of BMR and BC germs in patients in the neonatology department
224311976|NCT03201445|DRUG|Filgotinib|200 mg tablet administered orally once daily
223612691|NCT03018691|DRUG|OPA-15406|
223612692|NCT03018691|DRUG|Placebos|
223612693|NCT02218645|DRUG|WE 941 OD tablets|
223612694|NCT02218645|DRUG|Brotizolam|
223758941|NCT00544076|DRUG|sildenafil citrate|Given orally
223758942|NCT00544076|DRUG|alprostadil|Given intraurethrally
223612695|NCT04899622|BEHAVIORAL|MBSR|Participants will attend weekly online classes (two hours duration) of MBSR for eight weeks. The classes will be delivered live online to groups of up to fifteen participants and will be led by Mindfulness instructors with MSc degrees in Mindfulness Based Interventions. The programme content will be based on the standard MBSR programme and is tailored towards key concerns and difficulties experienced by individuals with chronic pain.
223758943|NCT00544076|PROCEDURE|robotic-assisted laparoscopic surgery|Undergo prostatectomy
223758944|NCT00544076|PROCEDURE|quality-of-life assessment|Ancillary studies
223758945|NCT00544076|OTHER|questionnaire administration|Ancillary studies
224311977|NCT03201445|DRUG|Placebo|Placebo to match filgotinib tablet administered orally once daily
223612696|NCT04899622|BEHAVIORAL|Exercise|"Participants will attend weekly classes of supervised classes (1 hour) for eight weeks, following the MBSR class. The exercise class will be delivered live online to the group by an experienced Physiotherapist and will consist of a range of flexibility and strengthening exercises which will be advanced every two weeks for the duration of the eight week programme. The exercises will also be available in video format on the mobile application Physitrack which each participant will be invited to download. This will allow the participants to review the exercises between sessions, record online if they have completed each exercise and in addition rate their pain experience while completing the exercises."
223612697|NCT04899622|BEHAVIORAL|Online Self-Management Guide|Participants will receive standard evidence based self-guided information which they will access independently via the members area of the study website. This 'Online Self-Management Guide' will consist of eight categories of self-management; (1) What is chronic pain? (2) Chronic pain and nutrition (3) Sleep issues with chronic pain (4) Activity and exercise (5) Pacing (6) Using a pain diary (7) Relaxation and mindfulness and (8) Course summary. The information will be presented in the form of general text, links to online resources and videos. The information in this area will be updated biweekly during the eight week programme with the participants receiving bi-weekly email reminders.
223612698|NCT05045261|DRUG|administration of SLGN in arm C|administration of 3mg SLGN weekly for 24 weeks in arm C
223612699|NCT05045261|DRUG|Discontinuation of NUC treatment in arms B and C|NUC treatment will be stopped after 28 weeks in arms B and C
223612700|NCT03445884|DRUG|68Ga-NODAGA-E[c(RGDyK)]2|200 MBq 68Ga-NODAGA-E\[c(RGDyK)\]2 administered IV.
223612701|NCT05104307|DEVICE|Cardiac Performance System (CPS) Device|CPS is a passive measurement system that acquires signals from multiple sensor sources that monitor cardiac heart sounds. The passive sensor systems measure sound only and do not produce energy. The CPS system also includes a Patient Monitor device that acquires data from the sensors as well as from three standard ECG electrodes. The CPS system does not acquire or store any protected health information or any subject characteristics. The CPS system has received FDA clearance K173156. Note that the CPS system was previously named Integrated CardioRespiratory (ICR) system. The CPS is FDA cleared for the ejection fraction (EF) assessment which will be its intended use for this study.
223612702|NCT03984539|BEHAVIORAL|Cognitive Behavioural Therapy-Enhanced|CBT-E is a 20-session transdiagnostic eating disorders treatment based on the principles of cognitive behavioural therapy which has been developed over the past 40 years. The treatment focusses on tracking and modifying eating behaviours, providing psychoeducation, addressing overvaluation of weight and shape, body image, food restriction and restraint, emotion regulation, and relapse prevention.
224311978|NCT03201445|DRUG|Standard of Care|Locally approved treatment, accepted by medical experts as a proper treatment for IBD conditions, prescribed according to best clinical practice, with no known testicular toxicity.
224311979|NCT01228019|DRUG|Niacin (+) laropiprant|Niacin (+) laropiprant (TREDAPTIVE) prescribed according to the current local label
224311980|NCT05179330|DEVICE|OMEGO®|Lower limb rehabilitation with and without visual feedback
224311981|NCT03892499|DRUG|Olinciguat|Oral Tablet
224311982|NCT03892499|DRUG|Itraconazole|Oral Capsule
223758946|NCT04612634|BIOLOGICAL|Hepatitis A (Live) Vaccine, Freeze-dried produced by Changchun|Administration of one dose of Hepatitis A (Live) Vaccine, Freeze-dried produced by Changchun. 0.5ml per dose
223758947|NCT04612634|BIOLOGICAL|Hepatitis A (Live) Vaccine, Freeze-dried produced by Zhejiang|Administration of one dose of Hepatitis A (Live) Vaccine, Freeze-dried produced by Zhejiang. 0.5ml per dose.
223612703|NCT03984539|BEHAVIORAL|Cognitive Behavioural Therapy-Ten|CBT-T is a 10-session treatment based on cognitive behavioural therapy. It was developed based on clinical experience as well as core components of evidence-based versions of CBT for eating disorders, including CBT-E. The aim of the intervention is to provide only the hypothesized critical elements of CBT for eating disorders so that the interventions can be provided quicker.
223758948|NCT04612634|BIOLOGICAL|Hepatitis A (Live) Vaccine, Freeze-dried produced by the Institute of Medical Biology, CAMS|Administration of one dose of Hepatitis A (Live) Vaccine, Freeze-dried produced by the Institute of Medical Biology, Chinese Academy of Medical Sciences. 1.0ml per dose.
223758949|NCT05640570|DRUG|The individualized Jade Wind-Barrier Herbal Tea Bag|The individualized Jade Wind Barrier Herbal Tea Bag is composed of Astragali Radix (Zhi Huangqi) 4g, Saposhnikoviae Radix (Fangfeng) 2g, Atractylodes macrocephala Koidz (Baizhu) 2g, Nelumbinis Folium (Heye) 1g, Chrysanthemum morifolium Ramat (Juhua) 1g.
223758950|NCT02052921|PROCEDURE|Rectal resection|Surgical rectal resection
223758951|NCT02052921|OTHER|Observation|
223758952|NCT03637465|BEHAVIORAL|Hydrate Philly|"Hydrate Philly is a multi-component intervention that includes water safety testing, provision of 1-2 hydration stations per recreation center, distribution of reusable water bottles for youth, a campaign to promote the acceptability of tap water, and the reduction of access to competing unhealthy beverages through vending machine standards and discouraging black bags (characteristic small, black, plastic bags provided to customers with their corner store purchases, typically including a sugar sweetened beverage and/or unhealthy snack foods)."
223758953|NCT03863613|DEVICE|Pessary|A soft, flexible, silicone pessary (Arabin®, Dr Arabin GmbH \& Co KG, Germany) will be inserted through the vagina, upward around the cervix.
223758954|NCT03863613|PROCEDURE|Cervical cerclage|Cervical cerclage using Mc Donald technique, under anaesthesia
223758955|NCT03863613|DRUG|Vaginal progesterone|Cyclogest® 400mg, Actavis, United Kingdom, applied once daily at bedtime
223758956|NCT04332289|OTHER|Heavy water experiment|3 times daily heavy water (deuterated-water) and mixed meal administration for one week
223758957|NCT04594850|BIOLOGICAL|Cellgram-ED|Patients will receive single injection of Cellgram-ED(mesenchymal stem cell) intracavernously.
223758958|NCT03240627|DRUG|LH-8|LH-8 cutaneous solution
223758959|NCT03240627|DRUG|Placebo|Placebo cutaneous solution
223758960|NCT01049724|OTHER|Tear collection|Tear collection
223758961|NCT00892164|DEVICE|harmonic scalpel device (FOCUS)|hemostatic device utilized intraoperatively
223758962|NCT00892164|DEVICE|electrothermal bipolar vessel sealing system (LIGASURE PRECISE)|hemostatic device utilized intraoperatively
223758963|NCT06492161|DEVICE|Physical activity measure|After surgery, patients patients will be fitted with GT3X ActiGraph's activity monitor to capture and record continuous physical activity.
223758964|NCT00000796|DRUG|Cycloserine|
223758965|NCT00000796|DRUG|Ethionamide|
223758966|NCT00000796|DRUG|Capreomycin sulfate|
223758967|NCT00000796|DRUG|Aminosalicylic acid|
223758968|NCT00000796|DRUG|Streptomycin sulfate|
223758969|NCT00000796|DRUG|Ethambutol hydrochloride|
223758970|NCT00000796|DRUG|Amikacin sulfate|
223612704|NCT00556907|RADIATION|Intraoperative radiotherapy|20Gy to surface of tumor bed and 5Gy at depth of 1cm from surface of tumor bed
223612705|NCT00556907|DEVICE|Intraoperative radiotherapy|20gy to tumor bed, 5gy at depth of 1cm from surface of tumor bed
223612706|NCT01284517|DRUG|Lurasidone|Tablets 20-120 mg, PM dosing,daily for 6 weeks
223612707|NCT01284517|DRUG|Placebo|Equivalent to Lurasidone dosing
223758971|NCT00000796|DRUG|Isoniazid|
223758972|NCT00000796|DRUG|Pyrazinamide|
223612708|NCT03626792|OTHER|Hypertensive group|Pilates 12-week training on the ground, often 3 times a week for 50 minutes of prescribed method exercises.
223758973|NCT00000796|DRUG|Pyridoxine hydrochloride|
223758974|NCT00000796|DRUG|Levofloxacin|
223758975|NCT00000796|DRUG|Rifampin|
223758976|NCT00000796|DRUG|Clofazimine|
223758977|NCT04683185|DRUG|E6742|E6742 tablets.
223758978|NCT04683185|DRUG|Placebo|E6742-matched placebo tablets.
223758979|NCT03151759|RADIATION|Neoadjuvant radiotherapy|Neoadjuvant radiotherapy prior to rectal cancer surgery
223758980|NCT01020071|PROCEDURE|pattern scanning laser iridotomy and iridoplasty|peripheral laser iridotomy and iridoplasty using pattern scanning laser technique
223758981|NCT02109328|DRUG|Alisertib|"SINGLE-ARM, SINGLE-DRUG PHASE: Alisertib will be given PO in a dosage of 50 mg BID for 7 Days (Days 1-7) of each 21 day treatment cycle.~In the randomized phase, Experimental arm will consist of the following drugs:~Alisertib will be given PO in a dosage of 40 mg twice daily on days 1-3, 8-10 and 15-17 of a 28 day cycle.~Paclitaxel: 60 mg/m2 over 60 minutes on Days 1, 8, and 15 in a 28-day cycle."
223758982|NCT02109328|DRUG|Paclitaxel|Placebo will be given PO. Paclitaxel will be infused at the dose of 80 mg/m2 IV over a period of 60 minutes on Days 1, 8, and 15 in a 28-day cycle.
223758983|NCT02109328|DRUG|Placebo|Placebo oral tablets
223758984|NCT06240897|DEVICE|CURATE.Dtx|CURATE.Dtx is a self-guided digital multitasking game that involves a combination of four subtasks played simultaneously, targeting different cognitive domains.
223758985|NCT06240897|DEVICE|Optional games|The patient will first be asked how he/she feels and what they have done that day. The patient then selects a digital local pet (dog, cat, bird) and can customize its appearance, name and background location. The player can interact with their pet via several actions such as feed, bathe, train and accessorize. Playing with digital pets can help reduce stress and anxiety in the elderly. It can be a positive distraction in alleviating the elderly's worries and discomforts. In order to purchase accessories for their digital pet, they are encouraged to play short games that include Grocery Snap, Down Memory Lane and Pet Escape. These games are aimed at improving memory and reduce cognitive decline.
223758986|NCT05180084|BEHAVIORAL|Cognitive behavior therapy|Internet-based CBT intervention based on CBT theory, self-determination theory and self-compassion therapy for low self-esteem among young adults.
223758987|NCT03768115|DRUG|Autologous Plasma Eye Drop|Autologous plasma crimped segments
224311983|NCT06339697|DRUG|different types of laxatives (compounded polyethylene glycol electrolyte dispersions and compounded sodium pico-sulfate)|Bowel preparation with different types of laxatives (compounded polyethylene glycol electrolytes and compounded sodium picosulfate)
224311984|NCT03191591|BEHAVIORAL|First 1,000 Days Program Site|Program components will include 1) Enhancements to and improved use of electronic health records to improve the quality of preventive services and screening for social determinants of health; 2) Staff and provider training; 3) Consistent behavior change messaging; 4) Patient education via print materials, text messaging and short videos; and 5) Strengthening the integration of clinical and public health services to support behavior change and address social determinants of health.
224311985|NCT01577550|DRUG|BI 655066 (very high i.v. dose)|Single very high i.v. dose BI 655066
223612709|NCT03626792|OTHER|Normotensive group|Pilates 12-week training on the ground, often 3 times a week for 50 minutes of prescribed method exercises.
223612710|NCT01677325|DRUG|Chinese herb (YiQiSanJu)|Chinese herb formula:Huangqi,huanglian,yinchen,ect
223612711|NCT04504981|BEHAVIORAL|Y2Prevent|Y2Prevent (Y2P) is a groupl level intervention that consists of 7 weekly group sessions focused on helping young African American men who have sex with men (AAYMSM) identify life goals and safeguard their health to achieve those goals
223612712|NCT03686904|DRUG|Benzalkonium Gel|antibiofilm solution (BlastX) topical wound gel
223612713|NCT03686904|OTHER|standard of care topical gel|standard of care topical gel (hydrocolloid topical gel)
223612714|NCT03686904|PROCEDURE|Debridement|Removing dead tissue from infected wound (in clinic)
223612715|NCT03686904|DRUG|benzalkonium irrigation|washing and lavaging in clinic with benzalkonium irrigation
223612716|NCT03686904|OTHER|Saline Irrigation (SOC Irrigation)|Normal Saline Irrigation (SOC Irrigation)
223612717|NCT04457765|DRUG|Povidone-Iodine (PVP-I)|1.25% Povidone-Iodine (PVP-I) (also known as betadine) to be used pre-procedure in the operating room via irrigation into the nasal cavity to act as viricidal preparation for the procedure. 240mL of 1.25% PVP-I will be distributed evenly among the right and left nasal cavities using a a 70mL syringe.
223612718|NCT00040443|DRUG|CX516|
223612719|NCT00040443|DRUG|Placebo|
223612720|NCT01759043|PROCEDURE|guiding catheter|using a single transradial guiding catheter for coronary angiography and intervention
223612721|NCT01759043|PROCEDURE|diagnostic catheter|diagnostic for coronary angiography and guiding catheter selection for intervention
223612722|NCT03129867|DRUG|Ticagrelor|Ticagrelor 60mg or 90 mg as routine use of each Center
223612723|NCT00170872|DRUG|Lumiracoxib|
223612724|NCT01020786|DRUG|Pemetrexed|"Induction Therapy: 500 milligrams per square meter (mg/m\^2) given intravenously (IV) on Day 1 of every 21-day cycle for 4 cycles.~Maintenance Therapy: 500 mg/m\^2 given IV on Day 1 of every 21-day cycle until disease progression or unacceptable toxicity."
223612725|NCT01020786|DRUG|Carboplatin|Dosage equal to area under the curve (AUC)6 milligrams per milliliter per minute (mg/mL/min) for participant, given IV on Day 1 of every 21-day cycle for 4 cycles.
223612726|NCT00269672|BIOLOGICAL|13-valent Pneumococcal Conjugate Vaccine|
223612727|NCT02366351|DRUG|SHR3824|Once daily, 12 weeks
223612728|NCT02366351|DRUG|Placebo|Once daily, 12 weeks
223612729|NCT06185517|DIAGNOSTIC_TEST|Questionnaire translation and validation|Michigan Retinal Degeneration Questionnaire (MRDQ) and the Michigan Vision-Related Anxiety Questionnaire (MVAQ). Validation of a French translation
223612730|NCT02058953|PROCEDURE|Craniotomy scheduled|Resection of affected brain tissue
223612731|NCT02058953|PROCEDURE|Collection for non-craniotomy|CSF, Blood, biopsy
223612732|NCT05189548|BIOLOGICAL|A single-center and single-arm design was used to evaluate the safety and preliminary immunogenicity of the adsorbed cell-free leukiche (three-component) combination vaccine|A single-center and single-arm design was used to evaluate the safety and preliminary immunogenicity of the adsorbed cell-free leukiche (three-component) combination vaccine
223612733|NCT02959593|DEVICE|VISIOR video goggles|View commercially available content through the VISIOR video goggles continuously for thirty minutes.
223612734|NCT05792813|DRUG|LGYY|LGYY = Linggui Yangyuan paste
223612735|NCT05792813|DRUG|LGYY mimetic|LGYY = Linggui Yangyuan paste
223612736|NCT05792813|DRUG|WZYZ|WZYZ= Wuzi Yanzong oral solution
223612737|NCT05792813|DRUG|WZYZ mimetic|WZYZ= Wuzi Yanzong oral solution
223612738|NCT00115440|RADIATION|Bononophenylalanine (BPA)-based BNCT|Boronophenylalanine is infused into a peripheral vein prior to neutron irradiation.
223612739|NCT05470335|PROCEDURE|nurse-led sheath insertion|radial sheaths for coronary examination and intervention are performed by experienced nurses
223612740|NCT00000526|DRUG|encainide|
223612741|NCT00000526|DRUG|flecainide|
223612742|NCT00000526|DRUG|moricizine|
223612743|NCT02537249|DRUG|Dexmedetomidine|Formula for administrated were randomized by computer-generated randomization. The patients and anesthesiologist, who administered and conducted all this trial, were blinded to the medication allocation. An anesthesiologist, who responsible for preparation of medication was the only person, recognized of the randomization code during trial. After one-lung ventilation, dexmedetomidine group would start the loading of dexmedetomidine (1μg/kg) during 20 minutes.
223612744|NCT02537249|DRUG|Normal saline|Saline placebo infusion will be adjusted the same fashion as the active comparator drug.
223612745|NCT05616923|DRUG|Trametinib|Topical cream containing 0.1 mg/g trametinib
223612746|NCT01165541|DRUG|Mirtazapine|mirtazapine (7.5-45mg)
223612747|NCT01165541|DRUG|Quetiapine fumarate extended release (Quetiapine XR)|Quetiapine fumarate extended release 50-400mg/d
223612748|NCT06217107|BEHAVIORAL|Micro-learning content|This is a series of modules designed to provide disease education, additional communication through 'push notifications,' promote self-management, and medication adherence in women of color with lupus and lupus nephritis. Leveraging technology, this program is asynchronous, promotes engagement and retention of information through micro-learning, and allows the investigators to better understand patient experiences beyond structured surveys by capturing what is happening in the patient-coach relationship.
223758988|NCT01640366|DEVICE|PICO|Single-use Negative Pressure Wound Therapy System
223758989|NCT02045511|BEHAVIORAL|Baltimore HEARS|Tailored aural rehabilitation for participant and communication partner
223612749|NCT06217107|BEHAVIORAL|Health360x app|The coach and participant will use problem-solving tools embedded in Health360x to map out potential barriers to goal attainment and create goal action plans. This application has the potential to help improve health-related quality of life, and reduce morbidity and mortality associated with Lupus. The intervention also tests the role of health coaches in the lupus ecosystem. The potential economic gain and impact on more extant social determinants of health can create long ranging benefits on the health and wellbeing of the community.
223612750|NCT06217107|BEHAVIORAL|Culturally congruent coaching|The coaching process includes specified visits over the course of our proposed 6-month intervention. These visits will occur remotely using HIPAA compliant video conferencing tools or in person when it is safe and convenient to meet in person. Overall, the coaches will work with Lupus patients to facilitate experiential learning, improve functioning and performance in the context of working towards specific goals.
223612751|NCT02289664|DEVICE|MAC|Direct-Laryngoscopy
223612752|NCT02289664|DEVICE|Coopdech|Video-Laryngoscopy -1
223612753|NCT02289664|DEVICE|CoPilot|Video-Laryngoscopy -2
223612754|NCT02289664|DEVICE|Intubrite|Video-Laryngoscopy -3
223612755|NCT05404087|DEVICE|Dedicated breast CT|Administration of contrast agent and scanning of the breast in order to evaluate the enhancement of the tumor
223612756|NCT04072913|OTHER|Vaginal samples (biopsies + vaginal smear)|Two types of samples are envisaged: tissue (large biopsies, coin of conization or hysterectomy) to affirm the diagnosis and detect the matrix metalloproteinases and their tissue inhibitors by immunohistochemistry; cell sample (monolayer smear type) to evaluate the expression of oncogenic Human papillomavirus.
223612757|NCT00138593|DRUG|vildagliptin|
223612758|NCT00130858|DRUG|Topotecan|
223612759|NCT00130858|DRUG|Carboplatin|
223612760|NCT03705052|OTHER|Questionnaire|Patients and caregivers were asked to complete a questionnaire
223612761|NCT03512834|DRUG|Avelumab|Avelumab 10mg/kg, administered via I.V infusion over 1hour, every 2weeks until disease progression or unacceptable toxicity
223612762|NCT03512834|DRUG|Paclitaxel|Paclitaxel 80mg/m2 D1,8 and 15 , administered via I.V infusion, every 4 weeks.
223612763|NCT02745171|OTHER|physical therapy|Will be held 15 sessions, 2 times a week, lasting 50 minutes, a physical therapy protocol developed by the Pro-Parkinson Physiotherapy based on the Guide of the Dutch Society of Physiotherapy (Keus, 2004).
223612764|NCT03912012|DRUG|Iohexol renal clearance measurement|intravenous injection of Iohexol (Omnipaque 300mg) with blood sampling at 0, 120, 180 and 240 minutes (during Day 1.
223612765|NCT03912012|DEVICE|microcirculation assessment through Laser Doppler associated to iontophoresis.|endothelial function evaluated following a protocol of iontophoresis of acetylcholine (during Day 1).
223612766|NCT03912012|DEVICE|Cardiovascular assessment though Intima-media Thickness and Extra-media Thickness measurement|carotid ultrasound (during Day 1)
223612767|NCT03912012|BIOLOGICAL|Blood sampling|37 mL of blood sample will be performed at Day 1
223612768|NCT03912012|BIOLOGICAL|Urine sampling|The urinary collection will be done during the Day 1, on the first morning urination
223612769|NCT03912012|DEVICE|High-resolution peripheral quantitative computed tomography (HR-pQCT)|assessment of the Body Mass Index by HR-pQCT (during the Day 1)
223612770|NCT03912012|RADIATION|Dual-energy X-ray (DXA)|assessment of bone parameters by DXA (during the Day 1)
223612771|NCT02095470|DEVICE|video laryngoscope|newly developed innovatory device
223612772|NCT02095470|DEVICE|traditional laryngoscope|traditional way for intubation
223612773|NCT06421584|DEVICE|Surgical telementoring|The intervention group receives intraoperative guidance by telementoring. The telementor is remotely located but able to see the real-time footage of the ongoing procedure and simultaneously verbally communicate with the operating resident wearing a headset during surgery. Additionally, feedback by telestration may be given to the operating resident if required. This involves graphic annotations on a still picture of the ongoing surgery which the telementor may design if required.
223612774|NCT03787550|DRUG|The Sedatives, analgesics and antibiotics|The sedatives (dexmedetomidine, midazolam, propofol), analgesics (butorphanol, remifentanil, sufentanil), and six antibiotics (linezolid, voriconazole, tigecycline, teicoplanin, caspofungin and meropenem) will be used according to the clinical need.
224311986|NCT01577550|DRUG|Placebo, i.v.|Single i.v. administration of placebo
224311987|NCT01577550|DRUG|BI 655066 (high s.c. dose)|Single high s.c. dose BI 655066
224311988|NCT01577550|DRUG|BI 655066 (low i.v. dose)|Single low i.v. dose BI 655066
223612775|NCT05356832|DIAGNOSTIC_TEST|Pelvic Floor Health Knowledge Quiz|It is a questionnaire to measure the knowledge level of the participants about pelvic floor health.
223612776|NCT05292716|DEVICE|MitraClip|MitraClip
223612777|NCT04637737|DEVICE|anterioposterior Weight Shifting Training with Visual Biofeedback|"The training group received an additional anterioposterior weight shifting training with visual Biofeedback 5 times per week for 4weeks. AP training is made to instantly know your training status during training by measuring and processing the foot pressure in real time using the F-Scan (Tekscan) hardware system and Software Development Kit (SDK).~Before training, all patients are instructed to place both feet at shoulder width, place the inverted foot approximately 30 cm in front of the unaffected side foot, move the body forward with the chest straight in an upright position, and be instructed to put the weight on the affected side.~On the screen shown, measure the maximum weight distribution during the first 10 times and set the value added by 5% as the target value.~It is designed to induce the maximum weight shift through the archery game."
223612778|NCT04637737|BEHAVIORAL|Conventional therapy|The control group received the usual gait training.
224311989|NCT01577550|DRUG|BI 655066 (high medium i.v. dose)|Single high medium i.v. dose BI 655066
224311990|NCT01577550|DRUG|BI 655066 (very low i.v. dose)|Single very low i.v. dose BI 655066
224311991|NCT01577550|DRUG|BI 655066 (low s.c. dose)|Single low s.c. dose BI 655066
224311992|NCT01577550|DRUG|BI 655066 (high i.v. dose)|Single high i.v. dose BI 655066
224311993|NCT01577550|DRUG|Placebo, s.c.|Single s.c. administration of placebo
224311994|NCT01577550|DRUG|BI 655066 (low medium i.v. dose)|Single low medium i.v. dose BI 655066
224311995|NCT02132806|PROCEDURE|Piezosurgery with biomaterial mp3 + bracket|
224311996|NCT02132806|PROCEDURE|Piezosurgery with biomaterial mp3|
224311997|NCT02132806|PROCEDURE|Piezosurgery|
224311998|NCT06297915|DRUG|Ketamine|Ketamine infusion was administered at 1 mg/kg (in 1 hour)
223612779|NCT06263894|OTHER|Experimental group|Alexander technique will be applied to the experimental group.
223612780|NCT02598440|DRUG|Alendronate|Participants wil receive once-weekly oral alendronate (70 mg tablet)
223612781|NCT02598440|DRUG|Ibandronate|Participants wil receive once-monthly oral ibandronate (150 mg tablet)
223612782|NCT01880658|DRUG|Capecitabine|Capecitabine 1000mg/m2,po(orally) on day 1-14 of 21 day cycle. Number of cycles: 16 cycles (1 year)
223612783|NCT01314001|DRUG|Varenicline|Day 1-3: 0.5mg once daily orally Day 4-7: 0.5mg twice daily orally Day 8-84: 1.0mg twice daily orally
223612784|NCT01314001|DRUG|Placebo|"Day 1-3: 0.5mg once daily orally Day 4-7: 0.5mg twice daily orally Day 8-84: 1.0mg twice daily orally~Week 1 - 6: 21mg placebo patch Week 7 - 8: 14mg placebo patch Week 9 - 11: 7mg placebo patch"
223612785|NCT01314001|DRUG|Transdermal Nicotine|Week 1-6: 21mg nicotine patch Week 7-8: 14mg nicotine patch Week 9-11: 7mg nicotine patch
223612786|NCT01226225|BEHAVIORAL|Aerobic interval training|Patients will enter a training program during which aerobic interval training is implemented. Three sessions per week, each lasting for 60 minutes. Total duration of the program: 3 months.
223612787|NCT01226225|BEHAVIORAL|Moderate endurance training|Patients will enter a training program during which moderate endurance training is implemented. Three sessions per week, each lasting for 60 minutes. Total duration of the program: 3 months.
223612788|NCT02485561|BEHAVIORAL|Health communication intervention|This study will compare the effects of adding narratives that describe personal experiences with colon cancer screening to educational information alone to explore potential differences in reactions to different role models on individuals' screening intentions and behaviors.
223612789|NCT02485561|BEHAVIORAL|Education information|Educational materials such as those from the Centers for Disease Control and Prevention are used to present educational information to participants about colon cancer and screening tests.
223758990|NCT02045511|DEVICE|Baltimore HEARS|Tailored fitting and programming of a personal sound amplifier. This will be accompanied by a component of aural rehabilitation.
223758991|NCT03729531|PROCEDURE|Conventional vein harvesting technique|Long incision will be used to expose the vein, the perivascular tissue will be dissected carefully by scissors, to check for leakage, the vein will be distended by injecting saline.
224201418|NCT04832984|BEHAVIORAL|Mobile health|Participants will be issued a fitness tracker, Bluetooth enabled glucometer, and a custom developed app which they can communicate digitally to the study investigators either as a group or individually. In the beginning of the study, participants will be taught on how to use the program, how to interact with their coach, and the importance of maintaining motivation throughout the program. Participants will have access to a pharmacist-participant messaging, group messaging, daily challenges for behavior change, education articles (biweekly bite-sized content over 24 weeks), food logging, steps and exercise logging, and feedback. They will be asked to log their weight, meals, and physical activity within the program on a weekly basis. Pharmacist will monitor participant progress through a web-based dashboard. Community pharmacist will be assisting users in setting specific, measurable, attainable, realistic, and time-based goals on a weekly basis.
224201419|NCT04832984|BEHAVIORAL|Usual care|Participants will be issued a fitness tracker and Bluetooth enabled glucometer but these functions will not be enabled or linked to any app. All participants will be given physical tracking sheets to log in their food intake, blood glucose levels and food diary but will not have access to a personal coaching. Participants are free to seek any assistance for their medical care during the study period.
224201420|NCT00534521|DEVICE|Posterior Tibial Nerve Device|The PTNS device (Urgent® PC) is a minimally invasive neuromodulation system designed to deliver retrograde access to the sacral nerve through percutaneous electrical stimulation of the tibial nerve (PTNS). It is a combination of a stimulator and a lead set. The stimulator is a battery powered, external pulse generator and is designed, constructed, and manufactured for multiple use in conjunction with the lead set. The lead set (comprised of the lead wires, needle electrode, and alcohol pad) transfers the electrical current from the stimulator to the tibial nerve via the needle electrode. The tibial nerve travels up the leg to the sacral nerve plexus which regulates the bladder and pelvic floor function.
224201421|NCT00534521|DEVICE|Sham|This 2- piece needle, comprised of a needle handle and blunt-tip shaft feels like a slight prick when touched to the skin. However the shaft retracts as it appears to enter the skin but the skin is not punctured. The Streitberger needle specifically activates the dorsolateral prefrontal cortex, which is associated with the placebo effect.
224201422|NCT02267759|DEVICE|McGrath videolaryngoscopy|After the softened nasotracheal tube was inserted into the nares until its tip passed through the posterior nares, McGrath videolaryngoscope was introduced into the mouth and the nasotracheal tube was advanced.
224201423|NCT02267759|DEVICE|Macintosh laryngoscopy|After the softened nasotracheal tube was inserted into the nares until its tip passed through the posterior nares, Macintosh laryngoscope was introduced into the mouth and the nasotracheal tube was advanced.
224201424|NCT04449640|PROCEDURE|Hysteroscopic septum resection.|Resection of a uterine septum by hysteroscopic surgery.
224201425|NCT00207974|DRUG|Marine active|
224311999|NCT06297915|DRUG|Lidocain|Lidocaine infusion was administered at 3 mg/kg (in 1 hour)
224312000|NCT06421298|DRUG|Tafolecimab|450mg Q4W ≤6cycle
224312001|NCT06421298|DRUG|Sintilimab|200mg Q3W ≤2years
223612790|NCT04347863|OTHER|Group swallowing disorder diet preparation program|This program included food properties, select food, type of cooking, using thickener and tasting
223612791|NCT00082498|DRUG|SCH-D (vicriviroc)|Group 2 will receive 5 mg vicriviroc daily; Group 3 will receive 10 mg vicriviroc daily; and Group 4 will receive 15 mg vicriviroc daily. If at or after Week 16 a participant's viral load has not met certain criteria, a dose increase of vicriviroc may occur and the participant will enter Step 2. As of 10/12/05, patients in Group 2 and any patients who entered Step 2 following virologic failure in Step 1 will be unblinded and offered either 15 mg vicriviroc daily through this study or the option of seeking alternative treatment.
223612792|NCT00082498|DRUG|Placebo|Patients in Group 1 will receive placebo.
223612793|NCT01521507|DEVICE|LipiFlow System|In-office device treatment for meibomian gland dysfunction by a physician
223612794|NCT01521507|DEVICE|Warm Compress Therapy + Lid Scrub|At-home daily warm compress therapy and lid hygiene
223612795|NCT05424016|DRUG|Propranolol|120 mg/d propranolol started in a progressive way (with control of Blood Pressure and heart rate during the consultations) neurosurgical consultation and an MRI every six months
223758992|NCT03729531|PROCEDURE|no-touch vein harvesting technique|The vein will be harvested by low-frequency electrotome, about 5mm surrounding tissue will be preserved with the vein, distention should be avoided, the vein will not be cut off until being anastomosed.
224312002|NCT06421298|DRUG|Nab paclitaxel|130mg/m² Q3W 4-6cycles
224312003|NCT06421298|DRUG|Docetaxel|75mg/m² Q3W 4-6cycles
223612796|NCT05424016|OTHER|follow-up|routine follow-up (neurosurgical consultation and an MRI every six months)
223612797|NCT05206175|OTHER|Affect Treatment Program for Methamphetamine Use Disorder|Telemedicine based group and individual therapy, drug screens, contingency management, therapeutic app engagement, psychiatric interventions for adjuvant medications.
223612798|NCT03073239|GENETIC|ALS patients genetic characterization|Genetic findings in ALS patients
223612799|NCT03073239|OTHER|ALS patients epidemiological caracterization|Epidemiological characterization in ALS patients
223612800|NCT00184795|DRUG|0.5 mg estradiol / 0.1 mg norethisterone acetate (NETA)|One tablet per day for 24 weeks
223612801|NCT00184795|DRUG|0.5 mg estradiol / 0.25 mg norethisterone acetate (NETA)|One tablet per day for 24 weeks
223612802|NCT00184795|DRUG|placebo|Placebo tablets for 24 weeks
223612803|NCT05694039|DEVICE|Hearing Aids|The intervention group uses hearing aids, and the intervention group receives hearing aid intervention for 5 years.
223612804|NCT04048486|OTHER|Developmental score according to The Ages & Stages Questionnaires®, Third Edition - ASQ®-3|Ages \& Stages Questionnaires®, Third Edition (ASQ®-3) is a developmental screening tool designed for use by early educators and health care professionals. It relies on parents as experts, is easy-to-use, family-friendly and creates the snapshot needed to catch delays and celebrate milestones.
223612805|NCT04048486|OTHER|Physical development and General Health|Physical development and General health examination
223612806|NCT04048486|OTHER|Developmental Red flags|Developmental Red flags Questionnaires
223758993|NCT01051128|DEVICE|Prometra Programmable Implantable Pump System|The Prometra Programmable Pump is a battery-operated, implantable, programmable infusion pump that dispenses drug solution into the intrathecal space through an implanted infusion catheter. All functions of the system (e.g., dosing) are controlled externally using a hand-held, battery-operated programmer.
223758994|NCT04686864|BEHAVIORAL|Support Group for Caregivers|"Engage parents in the community via this support group, so they can be supported by other parents who know the system, can advise them on how to proceed, and empower them to help their children. Parents will learn psychoeducation about eating disorders and how to support their children."
224312004|NCT06421298|DRUG|Gemcitabine|1250mg/m² Q3W 4-6cycles
224312005|NCT02914210|DEVICE|Virtual physical therapy rehabilitation program|Virtual Exercise Rehabilitation Assistant (VERA), a virtual physical therapy delivery system installed in patient's home
224312006|NCT02914210|OTHER|No intervention|Traditional physical therapy delivered in clinic or via home-health visits
223612807|NCT01969006|DRUG|Marcaine ½%|
223612808|NCT01969006|PROCEDURE|Needle prick|
223612809|NCT05712070|BEHAVIORAL|App-guided lifestyle modification|Smart watch and smartphone application-based life style modification for 12 weeks
223612810|NCT05712070|BEHAVIORAL|A book-based self-education of lifestyle modification|A take-home book-based self-education for lifestyle modification
223612811|NCT01403493|BEHAVIORAL|Patient education|
223612812|NCT02731495|DIETARY_SUPPLEMENT|EGCG|EGCG (Epigallocatechin -3-gallate)
223612813|NCT02731495|DIETARY_SUPPLEMENT|Placebo (deionized water)|
223612814|NCT06279455|OTHER|Pelvic Floor Muscle Exercise|A 12-week pelvic floor muscle exercise program was applied to pregnant women.
223612815|NCT01290614|OTHER|Pharmacist based QI program|Per a study protocol, the pharmacist will call each subject (who has not opted out) and discuss their CKD. In brief, the pharmacist will introduce themselves, ask the subject if they have time to discuss their medical care, inform the subject that they have CKD, briefly discuss CKD, ask the subject if they can come for labs, discuss hypertension management as appropriate, and answer any questions. In addition, for subjects with poorly controlled hypertension, the study pharmacist will arrange for a nutrition consult for a low sodium diet, a mainstay of hypertension management in patients with CKD. Finally, for patients with advanced CKD (GFR \<30 mL/min per 1.73 m2) who are not seeing a nephrologist, the study pharmacist will arrange for a nephrology outpatient appointment to assess the need for placement of access for renal replacement therapy.
223612816|NCT01290614|OTHER|Usual Care|"Patients in the control arm will continue to receive usual care from their VA providers."
223612817|NCT01358825|PROCEDURE|Blood Sampling|A blood sample will be taken at 5 years of age, after vaccination in the primary study.
223612818|NCT00671489|DIETARY_SUPPLEMENT|Omega-3 Polyunsaturated Fatty Acid|A capsule of omega-3 Polyunsaturated Fatty Acid, 300mg (including 70% docosahexaenoic acid, 7% eicosapentaenoic acid and other), 7 capsules per day in 12 week.
224312007|NCT00144157|DRUG|Nevirapine|
224312008|NCT00144157|DRUG|Zidovudine|
224312009|NCT00144157|DRUG|3TC|
224312010|NCT01346293|BIOLOGICAL|Diphtheria and Tetanus Toxoids and Acellular Pertussis + Measles, Mumps, Rubella + Varicella Virus|0.5 mL, Intramuscular (DTap-IPV); Subcutaneous (M-M-R®II and VARIVAX®)
224312011|NCT01346293|BIOLOGICAL|Diphtheria and Tetanus Toxoids and Acellular Pertussis + Poliovirus + MMR + Varicella Virus|0.5 mL, Intramuscular (IM) DAPTACEL®; Subcutaneous (SC) MMR®II and VARIVAX®; IM or SC IPOL®
224312012|NCT01346293|BIOLOGICAL|Diphtheria and Tetanus Toxoids and Acellular Pertussis + Measles, Mumps, Rubella + Varicella Virus|0.5 mL, Intramuscular (DTap-IPV); Subcutaneous (M-M-R®II and VARIVAX®)
224312013|NCT01346293|BIOLOGICAL|Diphtheria and Tetanus Toxoids and Acellular Pertussis + Poliovirus + MMR + Varicella Virus|0.5 mL, Intramuscular (IM) DAPTACEL®; Subcutaneous (SC) MMR®II and VARIVAX®; IM or SC IPOL®
223612819|NCT05184517|DRUG|Oph1|0.5% CsA ophthalmic formulation, twice daily for 4 days and once on the fifth day, one eye (right).
223612820|NCT05184517|DRUG|Restasis|0.05% CsA ophthalmic formulation twice daily for 4 days and once on the fifth day, one eye (right).
223612821|NCT03986203|DEVICE|Spry Belt|The Spry Belt delivers energy to the user that may help prevent bone loss. Participants will wear the device for 30 minutes a day, 5 days a week for one year. The active and sham devices are identical except for the specific energy that is delivered to the user.
223612822|NCT01295593|DRUG|valproic acid and 2-chlorodeoxyadenosine|VPA : daily, oral, starting dose 10mg/kg/day total dose, taken in 2 separate administrations of around 5 mg/kg/day each, for a maximum of 6 months CdA : 5.6 mg/m²/day IV during 3 days, every 28 days, for a maximum of 4 cycles
223612823|NCT03962179|DEVICE|VACStent|Evaluation of the suitability of the medical device for sealing leaks in the gastrointestinal tract
223612824|NCT02309008|DRUG|PAC-14028|Participants will receive PAC-14028 cream applied topically once a day for 9 days
223612825|NCT02309008|OTHER|Vehicle|Participants will receive vehicle cream applied topically once a day for 9 days
223612826|NCT02602522|DRUG|Shandong Danshen-Jiang-Fu Granule|Danshen-Jiang-Fu Granule is prepared from 4 kinds of Chinese herbs including Danshen (Salvia Miltiorrhiza), Paojiang (Roasted Ginger), Xiangfu(Rhizoma Cyperi), Wuyao(Lindera Aggregata). The producing area of Danshen in Shandong Danshen-Jiang-Fu Granule is Laiwu District in Shandong province.
223612827|NCT02602522|DRUG|Sichuan Danshen-Jiang-Fu Granule|Danshen-Jiang-Fu Granule is prepared from 4 kinds of Chinese herbs including Danshen (Salvia Miltiorrhiza), Paojiang (Roasted Ginger), Xiangfu(Rhizoma Cyperi), Wuyao(Lindera Aggregata). The producing area of Danshen in Sichuan Danshen-Jiang-Fu Granule is Zhongjiang District in Sichuan province.
223612828|NCT06097663|DRUG|MAS825|Active MAS825 single dose
223612829|NCT06097663|DRUG|MAS825 Placebo|MAS825 placebo single dose
223612830|NCT06097663|DRUG|DFV890|Oral tablet of DFV890 active once daily
223612831|NCT06097663|DRUG|DFV890 placebo|Oral tablet of DFV890 placebo once daily
223612832|NCT04079595|DEVICE|Head immobilization mask|Immobilization
223612833|NCT01479868|DRUG|TMC435|TMC435 150 mg will be administered once daily for 12 weeks along with peginterferon alpha-2a and ribavirin.
223612834|NCT01479868|DRUG|Pegylated interferon alpha-2a|Pegylated interferon alpha-2a 180 microgram will be administered as subcutaneous injection of 0.5 mL until 24 to 48 weeks.
223612835|NCT01479868|DRUG|Ribavirin|Ribavirin 1000 or 1200 mg twice daily will be administered each day until 24 to 48 weeks.
223612836|NCT00354146|DRUG|tipifarnib (R115777)|
223612837|NCT02081157|DEVICE|GalaFlex Mesh|
223612838|NCT01508169|DEVICE|Foot orthosis (Orthotics Unit of the Clinical Hospital of UNICAMP)|Custom foot orthoses made of ethylene-vinyl acetate (EVA) with medial arch supports and metatarsal pads (supporting the diaphysis of the second to fourth metatarsals) that were manufactured by the Orthotics and Prostheses Unit of the Clinical Hospital of UNICAMP.
223612839|NCT01825187|DEVICE|ULTRAPRO Mesh|Patients who are randomized to this group will received ULTRAPRO Mesh for their hernia repair
223612840|NCT01825187|DEVICE|3DMAX|Patients who are randomized to this group will receive 3DMAX mesh for their hernia repair
223612841|NCT01825187|OTHER|Evaluation|To evaluate the ease of use and time it takes residents to place and perform the surgery using these two different meshes.
223612842|NCT02364141|OTHER|Trunk restraint therapy|"Reaching training with trunk restraint by a harness that limited the trunk movements.~Forty-five training minutes, twice a week, totaling twenty sessions, were performed. The training was based in the motor learning concepts including repetitive and task-specific practice. The training task consisted of grasping a cone (3.5 cm diameter base, 13 cm high) and fitting random targets as requested by the therapist in a training platform (54 cm length, 64 cm extent, 1.5 cm high) with 9 targets (6.5 cm diameter) placed 10-13 cm apart, along 3 lines. The targets that were ordered in a way that stimulated the complete range of motion of shoulder and elbow, had pictures, colors, letters and numbers on them yielding variability and feedback to the performing tasks."
223612843|NCT02364141|OTHER|Trunk unrestraint therapy|"Unrestraint reaching training, only with verbal feedback to maintain the trunk right position.~Forty-five training minutes, twice a week, totaling twenty sessions, were performed. The training was based in the motor learning concepts including repetitive and task-specific practice. The training task consisted of grasping a cone (3.5 cm diameter base, 13 cm high) and fitting random targets as requested by the therapist in a training platform (54 cm length, 64 cm extent, 1.5 cm high) with 9 targets (6.5 cm diameter) placed 10-13 cm apart, along 3 lines. The targets that were ordered in a way that stimulated the complete range of motion of shoulder and elbow, had pictures, colors, letters and numbers on them yielding variability and feedback to the performing tasks"
224201426|NCT01520766|DEVICE|prefabricated titanium post|posts: diameter of 1.4 mm; length of 13 mm adhesively luted within the root canal using self-adhesive resin cement and direct composite cores using an etch-and-rinse adhesive were built up crown preparation was performed, while the finishing line for the final restoration was set at least 2 mm apical the composite build-up in dentin to ensure a proper dentin ferrule design
224201427|NCT01520766|DEVICE|prefabricated glass fiber reinforced composite post|posts: diameter of 1.4 mm; length of 13 mm adhesively luted within the root canal using self-adhesive resin cement and direct composite cores using an etch-and-rinse adhesive were built up crown preparation was performed, while the finishing line for the final restoration was set at least 2 mm apical the composite build-up in dentin to ensure a proper dentin ferrule design
224201428|NCT01150409|DRUG|hydrocortisone|1\) Hydrocortisone 50 mg IV every 12 hours x 4 doses (2 days), followed by Hydrocortisone 50 mg IV every 24 hours x 2 doses (2 days)
224201429|NCT01150409|DRUG|Normal Saline|0.9% sodium chloride (equal volume to hydrocortisone) IV every 12 hours x 4 doses (2-days), followed by 0.9% sodium chloride (equal volume to hydrocortisone) IV every 24 hours x 2 doses (2-days)
224201430|NCT00441207|DRUG|Ascorbic Acid|Delivered via IV Infusion.
224201431|NCT06567080|BIOLOGICAL|JWCAR201|JWCAR201 is a autologous CAR-T targeting CD19/CD20
224201432|NCT06004401|DRUG|Vonopazan +Amoxicillin|Vonopazan 20mg 2//day+Amoxicillin
224201433|NCT06004401|DRUG|Rabeprazole +colloidal pectin bismuth +Amoxicillin +Clarithromycin|Rabeprazole tablets 10mg 2/day+colloidal pectin bismuth 200mg 2/day+Amoxicillin 1g 2/day+Clarithromycin 500mg 2/day
224201434|NCT06004401|DRUG|Vonopazan +Minocycline|Vonopazan 20mg 2/day+Minocycline 100mg 2/day
224201435|NCT06004401|DRUG|Rabeprazole +colloidal pectin bismuth +Metronidazole +Clarithromycin|Rabeprazole tablets 10mg 2/day+colloidal pectin bismuth 200mg 2/day+Metronidazole 0.4g 3/day+Clarithromycin 500mg 2/day
224201436|NCT06113263|PROCEDURE|Anterior cervical decompression surgery|The aim of the surgery is to reduce the compression of the affected nerve. With anterior cervical decompression surgery this is achieved by removing the disc and osteophytes.
223612844|NCT06155461|PROCEDURE|Preoperative Ultrasonographic Evaluation of Caval Aorta Diameter Index|to evaluate the ability of preoperative ultrasound measurements of IVC to aorta diameter index and the inferior vena cava collapsibility index (IVCCI) for predicting post induction hypotension after general anesthesia in geriatric patients.
223612845|NCT04035252|DIAGNOSTIC_TEST|Carotid artery reactivity test (CAR-test)|The CAR test will be applied to stimulate the sympathetic nervous system. This thermal stimulus is known to elevate blood pressure via sympathetic pathways, so it can be used to study the vascular response to sympathetic activation. The participant will submerge their left hand in a bucket of ice water (approximately 4 degrees celcius) for 3 minutes, which is reported to be sufficient to induce a maximal dilation in the common carotid artery. At baseline and every minute after the hand is submerged in ice water, the blood pressure will be measured to check whether a sympathetic stimulation is achieved. During this test as well the carotid artery as the abdominal aorta will be visualized using ultrasound.
223612846|NCT03742973|DRUG|Baricitinib|Administered orally.
223612847|NCT03742973|DRUG|Placebo|Administered orally.
223612848|NCT01363700|DRUG|DE-114 ophthalmic solution|
223612849|NCT01363700|DRUG|Placebo ophthalmic solution|
223758995|NCT03175094|BEHAVIORAL|Holistic Health Recovery Program for HIV+|Holistic Health Recovery Program for HIV+ (HHRP+) is a CDC-recommended, evidence based behavioral (psychoeducational) group intervention focused on harm reduction principles. The investigators systematically adapted HHRP+ using findings from qualitative interviews with the target population of adult women living with and at-risk for HIV who are justice-involved (on probation, parole, or recently released from prison or jail).
223758996|NCT03767218|COMBINATION_PRODUCT|Late follicular phase stimulation with recombinant-human FSH|Start of ovarian stimulation with recombinant-human FSH (Bemfola 225 IU daily) from the late follicular phase of the menstrual cycle onwards. Start of GnRH antagonist (ganirelix 0.25mg/day) when serum LH \> 10 IU/L, till day of trigger.
223758997|NCT03767218|COMBINATION_PRODUCT|Early follicular phase stimulation with recombinant-human FSH|Start of ovarian stimulation with recombinant-human FSH (Bemfola 225 IU daily) from day 2 of follicular phase onwards. Initiation of GnRH antagonist (ganirelix, 0.25mg/day) on stimulation day 6 till day of trigger.
223758998|NCT05210127|PROCEDURE|Scarf osteotomy for Hallux Valgus deformity|An experiment of foot muscle strength and activation, during gate phases after hallux valgus correction with the use of core foot system protocol
223758999|NCT04725435|BEHAVIORAL|Kangaroo care|Experimental: Kangaroo care The mother kangaroo will care for at least 60 minutes.
223759000|NCT04725435|BEHAVIORAL|Facilitated Tucking Position|"Experimental 1: Manual Facilitated Tucking Position, infants will be given a manual facilitated tucking position during the heel stick procedure.~Experimental 2: Facilitated Tucking Position with the Nesting Bed (Tortoise Neo Bed), the facilitated tucking position will be given by the clinic nurse with the nesting bed during the heel stick collection procedure."
223759001|NCT03862391|DRUG|Analgesics|while patients are in the PACU after general anesthesia, if patients' VAS scores are higher than 3, we will give them 50 mg of deksketoprofen as analgesic.
223759002|NCT03862391|DRUG|Antiemetics|while patients are in the PACU after general anesthesia, if patient' Nausea and vomiting scores are higher than 1, we will give them 4 mg of ondansetron
223759003|NCT03661437|DEVICE|Actigraph|Wear Actiwatch
223759004|NCT03661437|OTHER|Questionnaire Administration|Ancillary studies
223759005|NCT03661437|PROCEDURE|Systematic Light Exposure|Undergo BWL treatment
223759006|NCT03661437|PROCEDURE|Systematic Light Exposure|Receive DWL treatment
223759007|NCT01116232|BIOLOGICAL|anti-thymocyte globulin|Infuse the first dose over a minimum of 6 hours, and subsequent doses over a minimum of 4 hours via a 0.22 micron in-line filter.
223612850|NCT01363700|DRUG|Olopatadine Hydrochloride 0.1% Ophthalmic Solution|
223612851|NCT02230566|DRUG|UX003|UX003 is a sterile concentrate formulation of rhGUS for intravenous infusion
223612852|NCT02230566|OTHER|Placebo|Placebo consisting of the UX003 formulation buffer (without rhGUS)
223612853|NCT00804700|BEHAVIORAL|Active teaching in synchronous listening to music while exercising|Subjects will be instructed to exercise while listening to four audio tutorials that are stored on their MP-3 player. These tutorials guide the subject on how to synchronize his or her body movements to the beat of the music.
223612854|NCT00531258|DEVICE|rTMS|Bilateral rTMS
224201437|NCT06113263|PROCEDURE|Posterior cervical foraminotomy with or without laminectomy|The aim of the surgery is to reduce the compression of the affected nerve. With posterior cervical decompression surgery more space is created for the nerve by widening the foramina where the nerve exits
223612855|NCT00531258|DEVICE|Sham rTMS|sham rTMS
223612856|NCT01274026|DRUG|sapropterin dihydrochloride|"In 30 PKU patients found previously to exhibit no decrease in blood PHE levels behavioral and cognitive function, neurotransmitter levels, and gene expression of enzyme activity will be measured at baseline and after 4 weeks of Kuvan administration. Rating inventories of executive function performance and behavior will be administered to patients and parents.~Urine neurotransmitters, blood microarray expression, and plasma amino acids will be measured (plasma PHE and TYR levels will also be measured at weeks 1 and 2). Nutrient analysis of 3 day food diaries will be conducted."
223612857|NCT00113841|DRUG|Curcumin|2 grams (Capsules) orally in 2 divided doses (a.m., p.m.)
223612858|NCT00113841|DRUG|Bioperine|5 mg (Tablets) orally twice daily
223612859|NCT02526277|DEVICE|MMF07 Foot Massager|
223612860|NCT02526277|DEVICE|Heat Therapy|
223612861|NCT03788174|DRUG|Apatinib|Apatinib (500 mg qd p.o.) until disease progression or intolerable toxicity or refused by the patients.
224201438|NCT04108884|DEVICE|App measurement|App measurement twice a day in the first two weeks after enrollment and twice a week (on different days) from the third week onward and whenever patients feel palpitations
224201439|NCT04108884|DEVICE|14 day Holter ECG|14 day moblie patch Holter ECG for AF confirmation
224201440|NCT03079869|DRUG|Ferric Citrate|One to two tablets of Ferric Citrate phosphorus binder administered by mouth before every meal to prevent dietary phosphorus absorption.
224201441|NCT00387231|PROCEDURE|Percutaneous coronary angioplasty/intervention (PCI)|
224201442|NCT00387231|DRUG|Anti-ischemic drug therapy|
224201443|NCT02411110|COMBINATION_PRODUCT|LiRIS®|LiRIS® is a drug-device combination product which is placed in the bladder during cystoscopy and remains in the bladder, gradually releasing lidocaine until removed from the bladder via cystoscopy.
223759008|NCT01116232|BIOLOGICAL|rituximab|"The total dose chosen for this protocol is 28 mg/kg divided in two doses (14 mg/kg on days -7 and +3). Initial infusion: Start rate of 50 mg/hour; if there is no reaction, increase the rate by 50 mg/hour increments every 30 minutes, to a maximum rate of 400 mg/hour. Subsequent infusions: If patient did not tolerate initial infusion follow initial infusion guidelines. If patient tolerated initial infusion, start at 100 mg/hour; if there is no reaction, increase the rate by 100 mg/hour increments every 30 minutes, to a maximum rate of 400 mg/hour. Note: If a reaction occurs, slow or stop the infusion. If the reaction abates, restart infusion at 50% of the previous rate.~In patients who tolerated the Rituximab well in the past, a rapid infusion rate can be used over 90 minutes with 20% of the dose administered in the first 30 minutes and the remaining 80% is given over 60 minutes."
223759009|NCT01116232|DRUG|sirolimus|For adults, Sirolimus will be administered at 12 mg orally loading dose on day -3, followed by 4 mg orally single morning daily dose (target serum level 3-12 ng/ml by HPLC).
223759010|NCT01116232|DRUG|tacrolimus|Tacrolimus will be administered intravenously at a dose of 0.03 mg/kg (ideal body weight) q 24h by continuous infusion starting on Day -3. Intravenous Tacrolimus will be discontinued once the patient starts eating and the drug will then be given orally at a dose of approximately 4 times the intravenous dose.
223759011|NCT01116232|OTHER|laboratory biomarker analysis|laboratory biomarker analysis
223759012|NCT01116232|PROCEDURE|allogeneic hematopoietic stem cell transplantation|allogeneic hematopoietic stem cell transplantation
223759013|NCT01116232|PROCEDURE|management of therapy complications|management of therapy complications
223759014|NCT01116232|PROCEDURE|peripheral blood stem cell transplantation|peripheral blood stem cell transplantation
223759015|NCT03247166|DEVICE|TOPS™ System|The TOPS™ System is an alternative to spinal fusion that is designed to stabilize but not fuse the effected vertebrai level to alleviate pain stemming from degenerative joints
223759016|NCT01289808|DRUG|Glucose 25%|1ml of glucose 25% once
223759017|NCT01289808|DRUG|Glucose 25%|1ml glucose once per os
223612862|NCT03788174|DRUG|POF|The POF regimen consisted of a 3-hour infusion of paclitaxel (135 mg/m2) followed by oxaliplatin (85 mg/m2) and Calcium Levofolinate (200 mg/m2).Subsequently, a 46-hour infusion of fluorouracil (2400 mg/m2) was administered using an ambulatory pump, repeating the cycle every 14 days.
223612863|NCT05003037|DRUG|Surufatinib,Toripalimab,Pemetrexed,Carboplatin/Cisplatin|Surufatinib at the dose determined in phase safety lead-in，250 mg，qd，po，every 3 weeks(q3w) ; Toripalimab at the dose 240mg，iv, d1, given every 3 weeks (q3w); Pemetrexed at the dose 500 mg/m2，iv，d1，given every 3 weeks (q3w); Carboplatin at the dose AUC=5\~6，iv，d1，given every 3 weeks (q3w) or Cisplatin at the dose 75 mg/m2，iv ,d1，q3w; Maintenance treatment：After the end of the first-line treatment, patients with CR, PR, and SD can continue to maintenance treatment with Surufatinib RP2D，d1-21，q3w＋Toripalimab 240mg，d1，q3w+Pemetrexed 500mg/m2，d1，q3w was taken until the disease progressed.
223612864|NCT00230646|BEHAVIORAL|Exercise counseling|
223612865|NCT00580723|OTHER|PRK 124|Topical PRK 124 (0.125%) moisturizing lotion applied twice daily to the face for 48 weeks
223612866|NCT03223402|OTHER|Nevirapine plus lamivudine|In this Pilot study, the efficacy of a bi-therapy consisting of NVP+3TC instead of NVP+2NRTI should be evaluated before a large multicenter study evaluating this combination is started.
223612867|NCT06350188|OTHER|experimental|15 patients ˃receive kinisio-tape ,2 session / week for 2 weeks. Followed by stretching exercises, they will be assessed pre and immediately post application, after two weeks and follow up after one month
223612868|NCT06350188|OTHER|traditional|15 patients ˃ will receive ischemic pressure release followed by stretching exercises 2 session / week for 2 weeks, will be assessed pre and immediately post application, after two weeks and follow up after one month.
223612869|NCT03258307|OTHER|Preoperative level|Blood sample
223612870|NCT05202418|BEHAVIORAL|Biofeedback Enhanced Treatment|The intervention involves biofeedback enhanced cognitive behaviorally based coping skills treatment. Treatment will consist of a 6-visit group intervention conducted online, via Emory zoom. Groups will include 5-8 patients each. Sessions will include brief, daily homework to facilitate mastery that is developmentally tailored to youth (e.g., practice skills with support from phone or tablet apps). Groups will meet approximately every week for 6 weeks. Advanced Ph.D. students in clinical psychology and Principal Investigator will deliver the treatment protocol. Participants will complete questionnaires before and after each session to measure autonomic reactivity, lifetime stress, depression, anxiety in response to stress induction, and coping strategies.
223612871|NCT02753946|DRUG|ZTI-01|6g ZTI-01 intravenous infusion TID q8 hours
223759018|NCT02482103|PROCEDURE|Renal denervation|Catheter based renal nerve ablation
223759019|NCT00847288|OTHER|Monthly Review Arm|Monthly review of Cardiac Compass Trends with OptiVol. This intervention is related to disease management.
223759020|NCT00847288|OTHER|Quarterly Review Arm|Quarterly review of Cardiac Compass Trends with OptiVol. This intervention is related to disease management.
223759021|NCT02953379|DRUG|EMS Mometasone gel|The patient should administer 2 spray in each nostril, once daily.
223759022|NCT02953379|DRUG|Mometasone spray nasal|The patient should administer 2 spray in each nostril, once daily.
223759023|NCT00913809|DRUG|Desipramine HCL 100 mg Tablets Cord Laboratories|
223612872|NCT02753946|DRUG|Piperacillin-tazobactam|4.5g piperacillin-tazobactam intravenous infusion TID q8 hours
223612873|NCT00016497|PROCEDURE|bilateral myringotomy|
223759024|NCT00913809|DRUG|Norpramin 100 mg Tablets Merrell Dow Pharmaceuticals, Inc|
224201444|NCT02411110|COMBINATION_PRODUCT|LiRIS Placebo|LiRIS placebo is a drug-device combination product, matching the LiRIS® which is placed in the bladder during cystoscopy, remains in the bladder until removed from the bladder via cystoscopy.
223612874|NCT00016497|PROCEDURE|bilateral myringotomy and tubes|
223612875|NCT00016497|PROCEDURE|adenoidectomy|
223759025|NCT06139159|OTHER|Outreach/navigator|"* Conduct outreach activities with people in the community who are hard to reach and with limited access to health care, conduct informal screening for symptoms of mental illnesses, encourage and refer individuals at-risk, suspected of having, or affected by mental health issues to clinics for triage.~* Document outreach, screening, and referral activities in LHW database"
224201445|NCT03806478|DRUG|APH-1105|The investigational drug product, APH-1105 is a sterile, pyrogen-free lyophilized powder intended for intranasal administration.
223759026|NCT06139159|OTHER|Auxiliary to care|"* Arrange consultation for those at-risk, suspected, or affected individuals at clinics for triage.~* Introduce the patient to the clinical team via a warm hand-off and assist in scheduling a follow -up visit.~* Support patients in attending their clinic visits; help patients address barriers through education, referral, and navigation to ancillary community services (SAVAME, legal, housing, economic, etc);~* Engage, activate, and empower patients to participate in the care process~* Frequent contact with patients: +1 every two weeks during the first 3 months, +1 every month for months 4-6.~* Assist with group sessions: affinity groups~* Identify community-based resources.~* Document outreach, screening, referral, and auxiliary care activities in LHW database"
223759027|NCT06139159|OTHER|Stepped care and task shifting|"* Support counselling initiated by the psychologist~* Reinforce patient education about depression, anxiety, trauma, and other syndemic conditions.~* Work with patients' families and peers to reduce stigma, address syndemic factors and social conditions.~* Contact frequency with patients: +1 every two weeks during the first 3 months, +1 every month for months 4-6.~* Co-lead group sessions: affinity groups~* Provide Mental Health First Aid to members of the community.~* Document outreach, screening, referral, auxiliary and stepped care activities in LHW database"
223759028|NCT03828812|BEHAVIORAL|Breakfast promotion|Recommendation of having breakfast daily
223759029|NCT03828812|BEHAVIORAL|Nighttime snack reduction|Recommendation of reducing frequency of nighttime snacking
223759030|NCT02357940|DRUG|Experimental Product|1% Colloidal Oatmeal Balm
223759031|NCT03304847|OTHER|ablation|radio-frequency applications on arrhythmogenic substrate
223759032|NCT05091008|DRUG|Ledipasvir-Sofosbuvir 90 Mg-400 Mg Oral Tablet|proper history was taken. HCV genotyping was done revealed GT 4 in all included patients. Basic ECG and abdominal US were performed prior to treatment. Concomitant HBV infection was excluded by HBs Ag and anti-HBc antibody HIV screening was done prior to treatment. Basic investigations were done prior to therapy. All included patients received Ledipasvir-Sofosbuvir fixed-dose combination one tablet (90 mg Ledipasvir, 400 mg Sofosbuvir), orally once daily at a fixed time with or without food for 12 weeks. Regular visits were arranged at 4, 8, and 12 weeks with easy access to the pediatric hepatology unit and the treating physician if any urgent problem in between the visits. Every visit, laboratory investigations were checked. Adverse events (after excluding other possible causes) were reported for the safety profile of the drug. The efficacy of the drug, HCV-RNA was assessed by quantitative real-time PCR at 4 weeks and after the end of the treatment course (12 weeks)
223759033|NCT06410144|BEHAVIORAL|Program A|Subjects in the Control group will receive 1) National Kidney Foundation information, and 2) support from a kidney therapy educator.
223759034|NCT06410144|BEHAVIORAL|Program B|Subjects in the intervention group will receive 1) a video and paper decision aid, and 2) coaching from a decision support specialist. The visits will be aimed at supporting patients with kidney therapy decision-making.
223759035|NCT02242851|DRUG|Telmisartan|
223759036|NCT02275481|DRUG|Arformoterol tartrate inhalation solution|Arformoterol tartrate inhalation solution 15 mcg (BROVANA) will be administered BID (morning and evening, approximately 12 hours between doses) using a standard jet nebulizer with a face mask or mouthpiece connected to an air compressor
223759037|NCT02275481|DRUG|Tiotropium|Tiotropium 18 mcg (SPIRIVA) will be administered QD (morning) via the HandiHaler®.
223759038|NCT06363565|DIETARY_SUPPLEMENT|supplementation of compound nutrients|Folic acid, vitamin B6, vitamin B12, and betaine per day orally for 12 weeks.
223759039|NCT06363565|DIETARY_SUPPLEMENT|placebo control|The placebo is an excipient and the color, flavor, shape, taste, and weight are same with the tablet of supplement.
223612876|NCT06039709|COMBINATION_PRODUCT|5-ALA and Low-Intensity Focused Ultrasound (SDT)|5-ALA (20mg/kg orally) given \~6 hours prior to LIFU. Focused ultrasound will target a maximum of 50% of the tumor.
223612877|NCT03074565|DEVICE|Ultrasonic alone|Sanative therapy using ultrasonic instrumentation alone
223612878|NCT03074565|DEVICE|Ultrasonic+|Sanative therapy using ultrasonic plus hand instrumentation
223612879|NCT02519439|DRUG|ganaxolone|225 mg capsules 450 mg to 900 mg 2x/day
223612880|NCT05054998|RADIATION|Fludeoxyglucose F-18|Given IV
223612881|NCT05054998|PROCEDURE|Magnetic Resonance Imaging|Undergo PET/MRI
223612882|NCT05054998|PROCEDURE|Positron Emission Tomography|Undergo PET/MRI
223759040|NCT03553732|OTHER|Registry|Patients who are diagnosed with prostate cancer and elect to be monitored by an Active Surveillance protocol by the Urology Clinic at Zuckerberg San Francisco General Hospital and Trauma Center will be included in this group. The intervention is the implementation of a registry, designed to replace existing but suboptimal systems for tracking patients. All Active Surveillance patients monitored by the clinic will be included.
223759041|NCT04100707|PROCEDURE|Genicular block was applied|This procedure is performed with ultrasound and / or fluoroscopy, sterile staining and covering of painful knee to the middle of thigh and leg, localization of superomedial, superolateral, inferomedial genicular nerves are tested and then conventional radiofrequency is applied to all 3 nerve regions
223612883|NCT01126723|OTHER|Tai Chi|The Tai Chi intervention will consist of a 12 week, instructor-led, group-based Tai Chi training program (two, one-hour sessions per week).
223612884|NCT01126723|OTHER|Education-Control|The Education-Control intervention consists of a 12 week, instructor-led attention control program consisting of health education and mind-body breathing exercises (two, one-hour sessions per week)
223612885|NCT02483806|PROCEDURE|PEEP|After induction of anesthesia, including insertion of TEE probe, change position from supine to lateral position. Measure ABGA and cardiac indices for the baseline value. Apply each PEEP (0, 5, 10 cmH2O) serially at the random order. 6 sequences (0-\>5-\>10, 0-\>10-\>5, 5-\>10-\>0, 5-\>0-\>10, 10-\>5-\>0, 10-\>0-\>5) are equally applied to 6 patients (total 6x6=36 patients) who agreed to this study. Measure ABGA and cardiac indices after 20 min at each step of peep apply(3 times).
223612886|NCT04369313|PROCEDURE|delayed cord clamping|umbilical cord clamping more than 30 seconds after birth
223612887|NCT04369313|PROCEDURE|early cord clamping|umbilical cord clamping within 15 seconds after birth
223612888|NCT00837200|DRUG|Oncaspar, Doxil, Decadron|Once enrolled, patients will receive a cycle (28 days) of Oncaspar (2500 IU/m2 IV on days 1, 15; Doxil 20 mg/m2 IV days 1,15; and Decadron 20 mg PO days 1, 8, 15, 22. Continue until disease progression or unacceptable side effects.
223612889|NCT05897008|BIOLOGICAL|CMAB007|for subcutaneous injection only
223612890|NCT05897008|BIOLOGICAL|Xolair|for subcutaneous injection only
223612891|NCT05402514|BEHAVIORAL|Digitally delivered exercise and education treatment Joint Academy|The Joint Academy® (www.jointacademy.com) program for people with subacromial shoulder pain consist of two daily distributed and progressively adaptable exercises there are delivered through the app as videos with subtitles. Patient education is provided 2-3 times per week as short lessons in the app with a quiz following the text to ensure that the information is properly understood by the patients. An individual physical therapist is assigned to each patient with compulsory telephone or video consultations at the start of the treatment, at 6 weeks and at 3 months. An asynchronous chat function with the physical therapist is available during the treatment period as well as a peer support chat.
223612892|NCT03107260|OTHER|To evaluate the relationship between oxygen saturation and the incidence of postoperative cognitive dysfunction in emergency surgery in elderly patients|Evaluate the relationship between oxygen saturation and the incidence of postoperative cognitive dysfunction in non-cardiac, thoracic and vascular emergency surgery in patients 65 years of age and older. The occurrence of POCD will be defined by the MMSE decrease of at least 4 points at 24, 48 or 72 hours
223612893|NCT01541046|BIOLOGICAL|Biogaia L. reuteri DSM 17938|Freeze-dried Lactobacillus reuteri DSM 17938 suspended in oil. Brand Name Active Agent: BioGaia™
223612894|NCT01541046|BIOLOGICAL|Probiotic Placebo|Description of Placebo: contains same excipients as Active Agent, without the active ingredient
223612895|NCT03805802|OTHER|active product|Once daily consumption over the period of the study
223612896|NCT03805802|OTHER|reference product|Once daily consumption over the period of the study
223612897|NCT04894032|PROCEDURE|Combination of Laparoscopic Uterosacral Ligament and Round Ligament Plication.|Laparoscopic Uterosacral Ligament Plication, Fixation of PVC fascia and the combination with round ligament plication
223612898|NCT03901144|DRUG|2% urea/20% glycerol cream|Moisturizing cream for topical application
223612899|NCT03901144|DRUG|Miniderm® 20% cream|Moisturizing cream for topical application
223612900|NCT03901144|DRUG|Diprobase® cream|Emollient cream for topical application
223612901|NCT05163262|OTHER|sexuality questionnaire|Questionnaire evaluating the sexuality of head trauma victims by comparing their sexual focus, the quality of their relationship, their self-esteem, their mood before the trauma to their current situation
223612902|NCT05724407|OTHER|Diagnostic assistance tool|"Diagnostic assistance tool for analysis of 5 prognostic and predictive markers of breast cancer (HER2, Ki67 Index, Mitoses, Estrogen Hormone Receptor, Hormone Progesteron receptors hormone of Progesteronereceptor).~Each anatomo-histopathological slide will be re-read 3 times:~* Reading 1: first reading by a pathologist in the care setting~  * Reading via the standard care procedure (microscope and physical slides)~* Reading 2: Second reading by another pathologist from the same center, as part of the research.~  * Reading via the standard procedure of care (microscope and physical slides)~* Reading 3: Third reading by the initial physician, with the algorithmic tool MoSi4BCa after digitization of the slides by a laboratory technician and after a wash-out period of 2 months."
223612903|NCT01864343|DEVICE|EMCOOLS flex pad; Philips Innercool RTx|Surface cooling with EMCOOLS flex pads (out-of-hospital); Infusion of 1000ml to 2000ml of cold saline (out-of-hospital); central-venous cooling (Philips Innercool RTx)
223612904|NCT03858985|DEVICE|Cervical Transcutaneous Vagus Nerve Stimulation (Active Comparator)|Both sham and active nVNS treatment produce low-voltage electrical signal that induce reliable sensation on subject skin on upper anterior cervical area (overlying carotid artery).
223612905|NCT03858985|DEVICE|Cervical Transcutaneous Vagus Nerve Stimulation (Sham Comparator)|Both sham and active nVNS treatment produce low-voltage electrical signal that induce reliable sensation on subject skin on upper anterior cervical area (overlying carotid artery).
223612906|NCT03532126|DEVICE|Dermal filler for midface deficit|During this procedure the device (a dermal filler) will be deep intradermal, subcutaneous or supraperiosteal injected according to its CE mark.
223612907|NCT05275374|DRUG|XP-102|XP-102 will be administered orally once or twice daily in a continuous regimen.
223612908|NCT05275374|DRUG|Trametinib|Trametinib will be administered 2mg orally once a day.
223612909|NCT04383457|DEVICE|RIA-device (Remote Investigation and Assessment)|The investigated new system consists of a high-speed digital video camera, a digital radiometric infrared camera, LED lights and a computer for data recording. This system faces the subject at a distance of approximately one meter, capturing a 30 second recording of the subject's face.
223612910|NCT04690530|PROCEDURE|mechanical ventilation|mechanical vantilation will be performed
223612911|NCT04690530|DRUG|Sedation|sedation wil be performed
223612912|NCT03292068|COMBINATION_PRODUCT|Acupuncture, acupressure|"Intervention group will receive usual care in combination with Pyonex-needles and Kulplåster. The control group will only receive usual care."
223612913|NCT03292068|DIETARY_SUPPLEMENT|Timbal diet|Intervention group will receive usual care in combination Timbal diet including Protein-enriched ice cream, made with egg yolks and Cream. The control group will only receive usual care.
223612914|NCT03292068|OTHER|Extended telephone counseling|Intervention group will receive usual care in combination with Extended telephone counseling. The control group will only receive usual care.
223612915|NCT02451995|DEVICE|Ripple Mapping guided AT ablation|Diagnosing the mechanism and delivering ablation within the atria in patients with atrial tachycardia on the basis of Ripple Mapping
223612916|NCT02451995|DEVICE|Local activation Time Mapping AT Ablation|Diagnosing the mechanism and delivering ablation within the atria in patients with atrial tachycardia on the basis of local activation time mapping
223612917|NCT01361893|OTHER|Lifestyle Counseling|We will utilize a combination of quantitative and qualitative techniques to ascertain factors, attitudes, and beliefs of African American parents of infants less than 6 months old.
223612918|NCT01915043|OTHER|health education for lymphedema prevention|All subjects received a multimodal intervention consist in a multimodal program with an educational approach
223612919|NCT04736381|DRUG|Belatacept Injection [Nulojix]|Drugs administrated are part of the usual care
223612920|NCT06333379|OTHER|Compare the levels of Galactomannan (GM) levels in exhaled breath condensate (EBC) and BALF|Investigators tested EBC-GM levels and BALF-GM levels in patients with confirmed IPA to compare the diagnostic value of EBC-GM versus BALF-GM.
223759042|NCT05812014|BIOLOGICAL|SARS-CoV-2 Bivalent mRNA vaccine (LVRNA021)|One dose was administered by intramuscular injection, 100μg，1.0ml/dose
223759043|NCT05812014|DRUG|0.9% sodium chloride solution|One dose was administered by intramuscular injection, 1.0ml/dose
223759044|NCT05223855|OTHER|Physiotherapeutic hydrotherapy treatment|"Physiotherapeutic hydrotherapy treatment The intervention consists of physiotherapeutic one-on-one treatment in a 34-36 degrees centigrade hot water, where the participants are placed supine in the water supported by the physiotherapist as well as buoyant aqua noodles. The physiotherapist supports and moves the participants in the water and adapts to the participant's reaction.~The combination of heat, water, movement and touch affects the musculoskeletal and neuromuscular systems and thus has a depth-relaxing effect (Schoedinger, 2010)."
223759045|NCT05931328|DRUG|thiotepa combined with pomalidomide|thiotepa combined with pomalidomide: thiotepa 30mg/m2,intravenously guttae, on day 1; pomalidomide 12mg orally daily for 2 weeks. A chemotherapy cycle lasts for 3 weeks.
223759046|NCT03530579|BEHAVIORAL|Educational group trainings|"Participants will receive 6 two and a half hour educational group training's over the course of 6 months. These sessions will be led by a trained CHW in your language and will be held on a monthly basis in a community based location.~Session 1: What is Diabetes~* Why is Prevention Important~Session 2: Nutrition Session 3: Physical Activity Session 4: Cardiovascular Disease \& Diabetes Complication Session 5: Stress Management Session 6: Access to Service"
223759047|NCT03530579|BEHAVIORAL|Community Health Care Worker|A community health care worker answer your questions about diabetes and refer participant to a physician. Survey will be completed at the start of the study and during the 3rd, 6th and 12th months
223612921|NCT03468361|OTHER|Natural Product Petroselinum crispum (Parsley)|Parsley herb, in fresh form will be obtained from the local market available. The herb will be properly washed with distilled water and dried properly for 10 to 15 days under shade in the lab. Soft gelatin capsules will be filled with parsley powder (dried herb) in amount normally recommended in daily routine (1g) will be administered to patients once daily.
223612922|NCT03468361|OTHER|Placebo|Soft gelatin capsules will be filled with 1 gram of lactose (inert pharmaceutical ingredient) and will be administered to patients once daily.
223612923|NCT03552497|DIAGNOSTIC_TEST|Radiomics|The high-throughput extraction of large amounts of quantitative image features from radiographic medical images
223612924|NCT02085018|DRUG|Omeprazole|Drug
223759048|NCT02829593|OTHER|hypoglycemia (low blood sugar) and MRI|hypoglycemia (low blood sugar) and MRI
223759049|NCT01747083|DRUG|FDC(gemigliptin/metformin HCl sustained release 50/1000mg(25/500mg x 2tablets))|
223759050|NCT03274986|DEVICE|ACRYSOF® IQ Extended Depth of Focus IOL|Implantable IOL intending to extend the depth of focus and provide continuous functional vision from distance to near while maintaining distance vision and a visual disturbance profile comparable to a monofocal IOL.
223759051|NCT03274986|DEVICE|ACRYSOF® IQ Monofocal IOL|Monofocal IOL implanted for long-term use over the lifetime of the pseudophakic subject
223759052|NCT03274986|PROCEDURE|Cataract surgery|IOL bilateral implantation
223612925|NCT02085018|DRUG|Matched placebo|Matched placebo
223612926|NCT00135317|DRUG|darbepoetin alfa|
223612927|NCT05820854|OTHER|Self-assess and reporting self-care self-efficacy levels|Patients will have to self-report the self-care self-efficacy levels they experienced in managing the OAC therapy.
223759053|NCT04842539|OTHER|Fecal Microbiota Transplantation|In the Fecal Microbiota Transplantation procedure 100 ml volume of strained and filtered stool will be delivered through a nasojejunal tube.The recipient patient will be kept nil per oral for at least 4 hours prior to the stool instillation. 100 mL of freshly prepared stool suspension will be given.
223759054|NCT04842539|OTHER|Standard of care|Nutritional supplementation and other supportive measures as per standard guidelines
224201446|NCT03806478|OTHER|Placebo|The placebo is a sterile, pyrogen free lyophilized powder identical in appearance to the experimental drug
224201447|NCT03596060|DRUG|Fentanyl|Fentanyl will be used for introduction in both regional and general anesthesia. It will also be used for general anesthesia maintenance.
224201448|NCT03596060|DRUG|Propofol|Propofol will be used for introduction in general anesthesia.
224201449|NCT03596060|DRUG|Rocuronium|Rocuronium will be used for introduction in general anesthesia.
224201450|NCT03596060|DRUG|Chirochaine|Chirochaine 0.5% will be used in regional anesthesia.
224201451|NCT03596060|DRUG|Morphine|Morphine will be administered bolus iv in General anesthesia group postoperatively before patients leave OR.
224201452|NCT01731574|DRUG|dapivirine|
224201453|NCT01731574|DRUG|miconazole|
224201454|NCT04259801|DRUG|NNC0480-0389|Part 1: A single dose of NNC0480-0389, dose increased in each cohort. Part 2: Weekly doses (for 4 weeks) of NNC0480-0389, dose increased in each cohort.
223612928|NCT00990743|DRUG|SYL040012|Administration of single and multiple doses of SYL040012 in ophthalmic drops solution
223612929|NCT00351754|DRUG|Isovue|
223612930|NCT03353805|BEHAVIORAL|questionnaire|questionnaire
223612931|NCT03413124|DRUG|MGL-3196 Tablet|MGL-3196 in Tablet form
223612932|NCT03413124|DRUG|MGL-3196 Capsule|MGL-3196 in Capsule form
223612933|NCT01214005|BEHAVIORAL|smoking abstinence|3 days of biologically-confirmed smoking abstinence
223612934|NCT04958889|OTHER|No intervention|(observational study)
223612935|NCT01431781|DRUG|Stilamin+common daily treatment|"dose:250 micrograms bolus intravenous in 3 minutes when ERCP starts and continuous infusion for 11 hours after ERCP.~Common daily treatment: fasted for 6h after ERCP, Fluid replacement, Gastric acid inhibition, Antiinflammatory."
223612936|NCT01431781|OTHER|Common daily practice|Fasted for 6h after ERCP, Fluid replacement, Gastric acid inhibition, Antiinflammatory
223612937|NCT00458120|BIOLOGICAL|rDEN1delta30|Live attenuated 10\^3 dose of rDEN1delta30 vaccine. Participants must have been previously vaccinated with rDEN4delta30 or rDEN2/4delta30(ME) vaccines.
223612938|NCT00458120|BIOLOGICAL|rDEN2/4delta30(ME)|Live attenuated 10\^3 dose of rDEN2/4delta30(ME) vaccine. Participants must have been previously vaccinated with rDEN4delta30 or rDEN1delta30 vaccines.
223612939|NCT00458120|BIOLOGICAL|Placebo to rDEN1delta30 or rDEN2/4delta30(ME)|Placebo vaccines for rDEN1delta30 and rDEN2/4delta30(ME)
223612940|NCT02294058|DRUG|Ozanimod|Capsules for oral administration once a day
224201455|NCT04259801|DRUG|Semaglutide|Part 1: Single dose of semaglutide (0.5 mg). Part 2: Weekly doses of semaglutide alone for 8 weeks (2 x 0.25 mg, 2 x 0.5 mg and 4 x 1 mg) followed by weekly fixed doses of 1 mg semaglutide for 4 weeks.
223612941|NCT02294058|DRUG|Interferon beta-1a|Administered by intramuscular injection once a week
223612942|NCT02294058|DRUG|Placebo to ozanimod|Matching placebo capsules administered orally once a day
223612943|NCT02294058|DRUG|Placebo to interferon beta-1a|Placebo intramuscular injection once a week
223612944|NCT03923894|DIETARY_SUPPLEMENT|Blueberry Yeast Fermentation Freeze Dying Powder Extract|Blueberry Yeast Fermentation Freeze Dying Powder Extract 2.07 g/day for 8 weeks.
223612945|NCT03923894|DIETARY_SUPPLEMENT|Placebo|Placebo 2.07 g/day for 8 weeks.
223612946|NCT02111330|DRUG|PBF-509|
223612947|NCT02111330|DRUG|Placebo|
223612948|NCT04891380|DEVICE|LUCAS 2 Active Decompression 2|Chest compression with active decompression of the chest. Measurement of physiological parameters.
223612949|NCT04891380|OTHER|Hypotension|measurement of physiological parameters
224201456|NCT04259801|DRUG|Placebo (NNC0480-0389)|Placebo for NNC0480-0389. Part 1: A single dose of placebo (NNC0480-0389), dose increased in each cohort. Part 2: Weekly doses (for 4 weeks) of placebo A, dose increased in each cohort.
223612950|NCT04891380|OTHER|Intensive care transport|Measurement of physiological parameters
223612951|NCT04311684|DEVICE|hybrid Brillouin-Raman spectroscopy|Combination of Brillouin and surface-enhanced Raman (SERS) spectroscopy for assessment of both visco-elastic (i.e. mechanical) and chemical characterization of urinary proteins at the same time from the same excitation laser source
223612952|NCT04827888|PROCEDURE|Orthopaedic surgery|One of the 25 most common orthopedic surgeries reported in the database which are the following as per surgical types: spine surgery (CPT codes 63030, 63047, 22612, 22551 or 22558), trauma (CPT codes 27236, 27125, 27244, 27814, or 27792), sports medicine injuries (CPT codes 29881, 29827, 29880, 29888, 29826, 29877, 29807, or 23412), or joint arthroplasty (CPT codes 27447, 27130, 23472, 27487, 27134, 27446, or 27486).
223612953|NCT04470635|DIAGNOSTIC_TEST|ELISA|Saliva sample collection
223612954|NCT03564613|DRUG|DTG|Subjects with DTG exposure during any trimester will be included
223612955|NCT05210491|OTHER|Review of eyelid positioning in increasing brightness levels|Up to 30 seconds, three times, looking into a video camera as glare is incrementally increased.
223612956|NCT00250341|DRUG|QVAR|480 mcg
223612957|NCT00250341|DRUG|Advair|250/50 mcg
223612958|NCT00250341|DRUG|Servent Diskus|50 mcg
223612959|NCT05771766|OTHER|Postural Drainge and aerobic training|This will be a randomized controlled trial Patients will be divided into two groups randomly. Both groups will receive postural drainage as baseline treatment thrice a week for two weeks. The intervention group will undergo additional Aerobic Training thrice a week for two weeks as well along with postural drainage. Aerobic training will include 5-step stair-climbing and 10 step walk during each session.
223612960|NCT05771766|OTHER|Postural Drainage|Postural Drainage
223612961|NCT00298974|DRUG|hydrocodone / acetaminophen extended release|2 tablets twice daily
223612962|NCT00298974|DRUG|Placebo|2 tablets twice daily
223612963|NCT02904733|OTHER|mHealth platform|Use of a mHealth platform to inform and empower patient of hies/her own health
223612964|NCT01950403|DRUG|linaclotide acetate|Given PO
223612965|NCT01950403|OTHER|placebo|Given PO
223612966|NCT01950403|OTHER|pharmacological study|Correlative studies
223612967|NCT01950403|OTHER|laboratory biomarker analysis|Correlative studies
223612968|NCT03575403|DRUG|Alcohol|In each arm and during sessions, subjects will receive doses of alcohol designed to raise breath alcohol levels (BAL) to 0.03 g/dl.
223612969|NCT03575403|DRUG|Placebos|Subjects will receive oral placebo capsules.
223612970|NCT03575403|DRUG|Duloxetine (60 MG)|Subjects will receive 60-mg of oral duloxetine capsules.
223612971|NCT03575403|DRUG|Methylphenidate|Subjects will receive methylphenidate capsules.
223612972|NCT03575403|DRUG|Duloxetine (30 MG)|Subjects will receive 30-mg of oral duloxetine capsules.
223612973|NCT00189839|DRUG|tacrolimus|Immunosuppression
223612974|NCT05326711|BEHAVIORAL|Telerehabilitation-based motor imagery training|"Telerehabilitation has been defined as the delivery of rehabilitation services through information and communication technologies."
223612975|NCT02864563|PROCEDURE|Blood sampling|"* Blood sample at diagnosis to evaluate MYCN amplification in plasma.~* In case of NB with a MYCN amplification, blood samples are also collected during treatment and follow-up."
223612976|NCT00657644|DRUG|Levitra (Vardenafil, BAY38-9456)|4 weeks treatment with 10 mg vardenafil followed by a flexible titration phase for 8 weeks
223612977|NCT01223729|DRUG|Acetyl-L-Carnitine|2 g acetyl-L carnitine twice a day
223612978|NCT01223729|OTHER|placebo|placebo twice per day
223612979|NCT06276426|OTHER|Soy foods|Soy milk, soy yogurt, tofu, tempeh, soy nuts, edamame, soy protein bar, and soy-based frozen meat substitutes.
224201457|NCT04259801|DRUG|Placebo (semaglutide)|Part 1: Single dose of placebo (semaglutide) (0.5 mg). Part 2: Weekly doses of placebo (semaglutide) alone for 8 weeks (2 x 0.25 mg, 2 x 0.5 mg and 4 x 1 mg) followed by weekly fixed doses of 1 mg semaglutide for 4 weeks.
224201458|NCT04580511|DEVICE|CELLIS (Porcine Acellular Dermal Matrix, PADM)|Biological membrane used in abdominal reconstruction
223612980|NCT06276426|OTHER|Non-Soy Plant-Based Foods|Pea milk, almond milk yogurt, chickpeas, chickpea chips, lentil chips, non-soy protein bar, and non-soy based frozen meat substitutes.
223612981|NCT01683539|BEHAVIORAL|The Thinking Skills for Work Program|The Thinking Skills for Work includes assessment of cognitive strengths and weaknesses and their relationship with work history, computerized cognitive practice, compensatory strategy training, and integration of cognitive and work services.
223612982|NCT01683539|BEHAVIORAL|The Cognitive Skills for Work Program|The Cognitive Skills for Work includes assessment of cognitive strengths and weaknesses and their relationship with work history, compensatory strategy training, and integration of cognitive and work services.
223612983|NCT02722226|OTHER|Simulation|High fidelity simulation based sedation learning program
223612984|NCT02722226|DEVICE|Airway management|Workshop on using airway management and oxygenation devices.
223612985|NCT02722226|BEHAVIORAL|Crisis resource management|Learning crisis resource management principles
223612986|NCT05079828|DIAGNOSTIC_TEST|18F-PSMA-1007|PET/CT scan using 18F-PSMA-1007
223612987|NCT05079828|DIAGNOSTIC_TEST|68Ga-PSMA-11|PET/CT scan using 68Ga-PSMA-11
223612988|NCT04661436|DIAGNOSTIC_TEST|Contrast-Enhanced Ultrasound|"The research will study the qualitative analysis indicators of contrast-enhanced ultrasound, including: enhancement uniformity, enhanced range, presence or absence of enhancement defect area, presence or absence of nourishing blood vessels, etc.; and quantitative analysis indicators, including: peak time, peak intensity, rising slope, Area under the curve, etc., analyze the correlation between the changes of various parameters before and after neoadjuvant treatment（NAT） and the pathological response of patients, and try to find indicators and cut-off values that can predict and early evaluate the efficacy.~This study will study the qualitative and quantitative parameters of MRI-enhanced scanning and the changes of DWI parameters, analyze the correlation between the parameters of patients before and after NAT and pathological response, and try to find indicators and cut-off values that can predict and early evaluate the efficacy."
223612989|NCT04544358|BEHAVIORAL|BAILAMOS©|BAILAMOS© includes a 4-month, twice-weekly dance program. The PI and a professional dance instructor co-developed an extensive BAILAMOS© Dance Manual and class-by-class schedule.
223612990|NCT05432713|DRUG|LP-168 tablet|Lp-168 is a small molecule kinase inhibitor that is administered once daily via oral administration
223612991|NCT05432713|DRUG|LP-168 Placebo tablet|LP-168 placebo tablets contain excipients for LP-168 tablets, but do not contain the active ingredients of the drug, and are used for comparison in clinical trials with the same usage and dosage as LP-168 tablets
223612992|NCT02521922|DEVICE|VSP System - NEHB Configuration|VSP System - NEHB Configuration will take and record participant vital signs. NEHB is the last name of the physician who developed the configuration. It is not an acronym.
223612993|NCT02521922|DEVICE|VSP System - PAL Configuration|VSP System - PAL Configuration will take and record patient vital signs. PAL is the name created by the engineering team of this device. It is not an acronym.
223759055|NCT04104009|OTHER|Education|"Following the randomization process, group education of pregnant women will be conducted through four one-hour meetings.~Education program: teaching about the basics of childbirth physiology, visit to the maternity ward with the aim of reducing the fear of childbirth, applying the deep inhale and exhale exercise in the first birth stage, applying the classical music listening technique that will continue until the end of pregnancy daily (in the evenings before bedtime) (for 15 minutes), teaching and applying techniques for successful breastfeeding, maternal and infant health care after delivery. The training program will be implemented so that after 4 workshops a 5-week break will be taken. At the end of the program, the educator arranges with the respondents a weekly telephone check (for the sake of communication quality) to inform them of adherence to the agreed classical music listening.Pregnant women who do not meet expectations will be excluded from the study."
223759056|NCT04104009|OTHER|No education|In the control group there will be no education, no breathing exercises and no listening to classical music.
223759057|NCT02360163|PROCEDURE|Traditional Landmark Technique (TLT)|
223759058|NCT02360163|DEVICE|ultrasound guided peripheral intravenous access (USGPIVA)|
223759059|NCT03139890|OTHER|High-fat (HF-LC-LP) milkshake|During this experimental day, men will receive a high-fat milkshake
223759060|NCT03139890|OTHER|High-carbohydrate (LF-HC-LP) milkshake|During this experimental day, men will receive a high-carbohydrate milkshake
223759061|NCT03139890|OTHER|High-protein (LF-LC-HP) milkshake|During this experimental day, men will receive a high-protein milkshake
223759062|NCT02273219|DRUG|AEB071|Oral, 100-400 mg twice daily A potent, oral, selective inhibitor of the classical Protein Kinase C (PKC)
223759063|NCT02273219|DRUG|BYL719|Oral, 200-350 mg daily An oral class I α-specific PI3K inhibitor belonging to the 2-aminothiazole class of compounds
223759064|NCT03044405|DIAGNOSTIC_TEST|Fluid challenge|Fluid bolus of 500 ml of crystalloids is given over 15 minutes. Positive fluid responsiveness is defined by an increase in SV of at least 15%.
224201459|NCT03911817|DRUG|Midodrine|The oral vasoactive drug (Midodrine) at a dose of 10-20 mg every 8 hours will be used in one arm .After the blood pressure goal is met for more than 24 hours without IV vasopressor ,midodrine will be discontinued prior to discharge
224201460|NCT03508076|DEVICE|Vibrating Capsule|Patients in this group would be treated with Vibrating Capsule
224201461|NCT03508076|DEVICE|Sham Capsule|Capsules can't vibrate but look the same as Vibrating Capsule
224201462|NCT06288490|DIETARY_SUPPLEMENT|amorphous calcium carbonate|
224201463|NCT02224794|DEVICE|Ovation® Abdominal Stent Graft Platform|
224201464|NCT02861404|GENETIC|skin flakes collection|viral status assessment of skin flakes
224201465|NCT00186875|DRUG|Etoposide, cytarabine, vincristine, dexamethasone|See Detailed Description section for details of treatment interventions.
224201466|NCT00186875|DRUG|methotrexate, teniposide, PEG-asparaginase|See Detailed Description section for details of treatment interventions.
224201467|NCT00186875|DRUG|mitoxantrone, cyclophosphamide, mercaptopurine, vinblastine|See Detailed Description section for details of treatment interventions.
224201468|NCT00186875|DRUG|L-asparaginase, erwinia asparaginase|See Detailed Description section for details of treatment interventions.
224201469|NCT00186875|PROCEDURE|chemotherapy, intrathecal chemotherapy, steroid therapy|See Detailed Description section for details of treatment interventions.
224201470|NCT00186875|PROCEDURE|Hematopoietic Stem Cell Transplant|See Detailed Description section for details of treatment interventions.
224201471|NCT00186875|PROCEDURE|Natural Killer (NK) Cell Transplant|See Detailed Description section for details of treatment interventions.
224201472|NCT06541509|DRUG|Semaglutide|"10 overweight patients with heart failure will be enrolled, including 5 patients with heart failure with preserved ejection fraction (HFpEF) and 5 patients with heart failure with reduced ejection fraction (HFrEF). The diagnosis of HFpEF and HFrEF will be based on the most recent European Society of Cardiology guidelines for the diagnosis and treatment of heart failure.~After their baseline blood sample collections, all participants will receive once-weekly subcutaneous semaglutide (Ozempyc, Novo Nordisk A/S Bagsvaerd, Denmark) at a dose of 0.25 mg for 2 weeks, 0.5 mg for 2 weeks, and then 1.0 mg for a period of 12 weeks. At the end of the 3-month and 4-month period, blood sample collections will be repeated. All blood samples will be sent to Stanford Cardiovascular Institute for further analyses. At baseline, and again at 4 months transthoracic echocardiography, 6-minute walk test, and body composition assessment will be performed."
224201473|NCT03910439|BIOLOGICAL|Avelumab|Avelumab 800 mg intravenous (IV) over 60 minutes (+/- 20 minutes) on days 1 and 15 of each 28-day cycle
223759065|NCT03044405|DIAGNOSTIC_TEST|Focused transthoracic echocardiography|Focused transthoracic echocardiography is performed to assess expansion of stroke volume after fluid challenge. Also mitral E and A waves, left ventricle outflow tract velocity time integral (LVOT VTI) and its variability, inferior vena cava diameters during breathing cycles are measured.
223759066|NCT02265822|DRUG|melatonin in children premedication|
223612994|NCT01035489|DEVICE|CRT in heart failure; Right ventricular apex v.s. high posterior septum|RV lead is randomized to either apex or high posterior septum
223612995|NCT01035489|DEVICE|CRT in heart failure; Right ventricular apex v.s. high posterior septum|RV lead is randomized to either apex or high posterior septum
223612996|NCT03359174|DRUG|All-trans retinoic acid|Fixed low dose of ATRA 10 mg twice daily for 24 weeks.
223612997|NCT01180686|DEVICE|Activator IV single impulse instrument|This is a manually operated device that delivers a single thrust into the joint involved.
223612998|NCT01180686|DEVICE|Multiple thrust Impulse adjusting instrument|A device used for delivering 12 thrusts to the involved joint of the lumbar spine.
223612999|NCT04889183|DRUG|Semaglutide|Patients will be treated for 24 weeks with semaglutide 3.0 mlg/ml s.c. once weekly. The starting dose of semaglutide will be 0.24 mg per week subcutaneous injection with increasing doses at 4, 8, 12, and 16 weeks to 0.5, 1,0, 1.7 and 2.4 mg.
223613000|NCT04889183|DRUG|Placebo|Patients will receive a matching placebo sc. once weekly during the treatment period of 24 weeks.
223759067|NCT02265822|DRUG|midazolam in children premedication|
223759068|NCT04425746|DRUG|Afamelanotide|
223759069|NCT04425746|DRUG|Placebo|
223759070|NCT00089570|DRUG|terlipressin|
223759071|NCT00089570|DRUG|Placebo|
223759072|NCT04932785|OTHER|Regular diet|Regular diet
223759073|NCT04932785|OTHER|Clear Liquid Diet|Clear Liquid Diet
223759074|NCT01166828|BEHAVIORAL|TELLEPUPPS|The TELEPUPPS participants will learn self care management of PUP through a program based on a social cognitive behavioral model to reinforce problem solving and self-efficacy in preventing pressure ulcers.
223759075|NCT00816101|OTHER|Procellera™ Antimicrobial Dressing|Dressing indicated for partial and full-thickness wounds.
223759076|NCT00816101|OTHER|Mepilex® Border Lite|Self-adherent foam dressing
223759077|NCT00816101|DEVICE|Adhesive Bandage|Adhesive bandage
223613001|NCT02591108|DEVICE|Neuromuscular Block Aid|Neuromuscular Block Aid, is a quantitative mechansim for collecting the the train-of-four and can be kept in an electronic medical record, also known as a train-of-four monitor, is used to assess neuromuscular transmission when neuromuscular blocking agents (NMBAs) are given to block musculoskeletal activity. By assessing the depth of neuromuscular blockade, peripheral nerve stimulation/monitoring can ensure proper medication dosing and thus decrease the incidence of side effects. Peripheral nerve stimulation is most commonly used for ongoing monitoring in the intensive care unit (ICU).
223613002|NCT02591108|DEVICE|Standard of Care: Microstim Plus|A peripheral nerve stimulator, also known as a train-of-four monitor, is used to assess neuromuscular transmission when neuromuscular blocking agents (NMBAs) are given to block musculoskeletal activity. By assessing the depth of neuromuscular blockade, peripheral nerve stimulation/monitoring can ensure proper medication dosing and thus decrease the incidence of side effects. Peripheral nerve stimulation is most commonly used for ongoing monitoring in the intensive care unit (ICU).
223613003|NCT00239733|DRUG|Anti-D|30-minute infusion administered in an outpatient setting
223613004|NCT03715803|DEVICE|Calistar A mesh to treat anterior and apical POP|Single incision surgery using Calistar A mesh to treat anterior and apical pelvic prolapses
223613005|NCT03715803|DEVICE|Calistar S mesh to treat anterior and apical POP|Single incision surgery using Calistar S to treat anterior and apical pelvic prolapses
223613006|NCT04714164|BEHAVIORAL|Group Cognitive Behavioral Therapy|Therapy will be delivered weekly for 8 weeks by Zoom.
223613007|NCT03055117|BEHAVIORAL|Group-based exercise rehabilitation|Group- based physiotherapy-led exercise rehabilitation
223613008|NCT03055117|BEHAVIORAL|Individual exercise rehabilitation|Individual physiotherapy-led exercise rehabilitation
223759078|NCT06071455|OTHER|Platelet-rich fibrin|injected distal to the canine on the experimental side.
223759079|NCT06071455|OTHER|Vitamin D3|injected distal to the canine on the experimental side.
223759080|NCT05861791|DRUG|Fentanyl|opioid group receives only fentanyl citrate 1200mcg for continuous infusion drug
223759081|NCT05861791|DRUG|ketorolac tromethamine with nefopam hydrochloride|non-opioid group receives ketorolac tromethamine 150mg with nefopam hydrochloride 100mg for continuous infusion drug
223613009|NCT03055117|BEHAVIORAL|Home exercise|Supervised home exercise
223613010|NCT06024486|DIAGNOSTIC_TEST|fibrinogen to albumin ratio (AFR) and C-reactive protein to albumin ratio (CAR)|measurement of serum albumin, fibrinogen and CRP
223613011|NCT06527118|OTHER|ACTIVITIES TO LEARN SELF CARE SKILLS|This activity program, which was prepared to develop self-care skills, aims to teach self-care skills of children with intellectual disabilities by having fun. The program was prepared by the educator and finalized after the approval of expert opinions.
223759082|NCT04640948|DEVICE|High flow nasal therapy|Controlled oxygen administration using at least 20 L/min of flow rate and titrated up as tolerated. Titration of supplemental oxygen to an arterial saturation between 88 - 92%.
223759083|NCT04640948|DEVICE|Low flow oxygen|Controlled oxygen administration using (venturi mask or nasal cannulae) titrated to an arterial saturation between 88 - 92% as the initial oxygen administration method with a flow rate of \<20 L/min.
223759084|NCT01693328|DRUG|PecFent® (fentanyl) nasal spray|
223759085|NCT02986620|GENETIC|IDH mutation test performed at diagnosis or relapse until January 31st, 2019.|Observation of the test result.
223759086|NCT01886248|DRUG|Freeze-dried Concentrated Human Antithrombin Ⅲ 500 IU|
223759087|NCT05702593|PROCEDURE|Static stretching|The participant was positioned supine for static stretching to be applied to the hamstring muscles. The physiotherapist flexed the participant's hip to the point where resistance to the movement was first observed, with the knee extended.At this point, after waiting for 40 seconds, it was returned to the previous position. This application was made on both sides \[Bretischwerdt\]. The technique was repeated three times, with a 15-second rest interval between each repetition.
224201474|NCT03910439|RADIATION|External beam radiotherapy|5 gray (Gy) per fraction will be delivered on 5 consecutive treatment days for a total dose 25 Gy
224201475|NCT00029107|DRUG|Rituximab|anti-CD20 monoclonal antibody
223759088|NCT05702593|PROCEDURE|Myofascial Release|For hamstring muscles, the participants were asked to assume a long sitting position on a firm, flat surface with their arms behind their backs and their body weight on their palms. A foam roller was placed under the hamstring muscles and slowly moved the tuberositas ischii popliteus back and forth with pressure for 4 minutes.
223613012|NCT05570266|DIAGNOSTIC_TEST|Breast Cancer Risk Prediction Software|Genotyping of known breast cancer-related markers (313 variants) will be conducted using a microarray genotyping chip (Genetic Risk). Survey answers will determine Gail Model scores and thus Clinical Risk Score.
223759089|NCT01371097|OTHER|Progressive Resistance strength training|Resistance strength training is given as circle training. The resistance is increased with regularly intervals.
223759090|NCT00454090|DRUG|AZD8330|oral tablet
223613013|NCT02416739|DRUG|Nicotinamide|Nicotinamide (1g/day) or placebo treatment is added to the standard drug treatment (gefitinib or erlotinib) to EGFR mutated NSCLC patients
223613014|NCT06212557|DEVICE|KIOS App|KIOS provides patients on demand individualized advice and reinforcement of lifestyle interventions to improve self-management during Medication-Assisted Treatment (MAT)
223613015|NCT06212557|BEHAVIORAL|KIOS App education|Educational tools provided to participants with opioid use disorder
223759091|NCT01867593|DEVICE|C-11 methionine PET|
223759092|NCT05595317|DEVICE|Non-immersive Virtual Reality|The traditional physiotherapy program will consist of hot pack (15 minutes), TENS (20 minutes), and 1 set of /10 repetitions of knee flexion/extension exercise for the right and left in a sitting position with hands clasped on opposite shoulders. In the non-immersive virtual reality application, Microsoft Kinect Xbox 360 Adventures games will be applied at the light level exercise level under the supervision of a physiotherapist. The participant will play a game in which he stands in a standing boat in a boat going on a flowing river and has to overcome obstacles by jumping, crouching and stepping left and right (River rush game).
223759093|NCT05595317|DEVICE|Sham Non-immersive Virtual Reality|The traditional physiotherapy program will consist of hot pack (15 minutes), TENS (20 minutes), and 1 set of /10 repetitions of knee flexion/extension exercise for the right and left in a sitting position with hands clasped on opposite shoulders. As a sham application, the participants will sit in a chair in front of the screen and try to prevent the balls sent from the opposite direction by using their upper extremities while their bodies are fixed with the help of a belt, under the supervision of a physiotherapist (Rally ball game).
223759094|NCT02214277|DEVICE|Cerebral Protection System-The SENTINEL System with TAVR|Claret Medical Sentinel Cerebral Protection System is intended for use as an embolic protection system to contain and remove embolic material (thrombus/debris) that may enter the carotid arteries.
223759095|NCT02214277|DEVICE|TAVR|
223759096|NCT03420703|OTHER|erector spinae plane block|ultrasound guided erector spinae plane block will be administered to this group.
223759097|NCT03420703|DEVICE|Intravenous morphine patient controlled analgesia device|Intravenous morphine patient controlled analgesia device will be given to the patients postoperatively and 24 hour morphine consumption will be recorded
223759098|NCT00587379|DRUG|Atorvastatin|40 mg atorvastatin pill daily
223759099|NCT00587379|DRUG|placebo|40 mg pill per day
223759100|NCT02188615|PROCEDURE|Neo-adjuvant Chemoradiotherapy followed by Mckeown MIE|Neo-adjuvant Chemoradiotherapy followed by Mckeown MIE
224201476|NCT06132711|OTHER|APRIL-BAFF-Bicephali CAR-T cells|Peripheral blood mononuclear cells were collected and subjected to CD3+T cells were enriched, transfected with APRIL-BAFF-Bicephali lentiviral vector, expanded by in vitro culture, and pretreated with clear lymphocytes using the FC protocol before infusion of APRIL-BAFF-Bicephali CAR-T cells.
224201477|NCT00226447|DRUG|Pegylated Interferon|
224201478|NCT00226447|DRUG|Lamivudine|
224201479|NCT03952377|DRUG|SX600|Transforaminal Epidural Injection
224201480|NCT03952377|DRUG|Placebo|Transforaminal Epidural Injection
224201481|NCT04551027|BEHAVIORAL|compensatory cognitive treatment|a brief group compensatory cognitive intervention including 12 meetings of 1 hour in a group of five and focuses on these cognitive domains: prospective memory, vigilance and attention, memory and learning and executive functions
223613016|NCT06212557|BEHAVIORAL|Treatment as usual|Behavioral counseling in clinic
224201482|NCT03277859|BEHAVIORAL|SAA-TBI|Yoga twice a week for 75 minutes for 8 weeks
224201483|NCT04509440|DRUG|isotonic dextrose 5% in water (D5W) solution|Neurol prolotherapy (NP) is the subcutaneous perineural injection of isotonic dextrose 5% in water (D5W) solution.
223613017|NCT04154046|PROCEDURE|Tenotomy(cutting) of flexor tendons is performed with needle|"Patient is placed in seated posture with feet elevated. The toe(s) with hammer, mallet or claw toe deformity is anesthetized by a digital toe block with 1-5 ml of 1% lidocaine administered for each toe. The toe digital block is administered through a plantar approach, at the web level of the deformed toe(s), with a 0,6 mm diameter and 30mm long needle.~After anesthetizing the toe(s) the plantar aspect of the toe at web level is disinfected with an alcohol based disinfectant twice.~Both the long and short flexors are then severed with a 1.2mm diameter and 40mm long needle through a plantar approach, immediately proximal to the web level of the toe.~After the procedure a dry gauze bandage is applied and the patients treated foot/feet is/are elevated for 20 minutes to achieve haemostasis, and the bandage is checked for bleeding before discharge."
223613018|NCT05986786|DEVICE|Patients will receive 1 IVT injection of AVT06 PFS depending on their chorioretinal vascular disease schedule|Patient will receive AVT06 (proposed aflibercept biosimilar) PFS injection
223613019|NCT02677935|OTHER|Community education programs|
223613020|NCT04868955|OTHER|Oral screen training|Oral screen training (IQoro®) during 13 weeks.
223613021|NCT06368258|DIETARY_SUPPLEMENT|Red yeast rice|Red yeast rice 160 mg (total monacolins 2.8 mg)
223613022|NCT06368258|OTHER|Placebo|Placebo
223759101|NCT02188615|DRUG|Cisplatin|only Radical Chemoradiotherapy
223759102|NCT02188615|DEVICE|Mckeown MIE|only Mckeown MIE using thoracoscopy and laparoscopy
223759103|NCT03689556|DIAGNOSTIC_TEST|FLT PET/CT|Patients will receive 3'-deoxy-3'-\[18F\]fluorothymidine (FLT) PET/CT scans before CIRT and after completion of CIRT.
223759104|NCT05111366|DRUG|TQB2450 injection|TQB2450 is an injection in the form of 1200mg, ivgtt, q3W.
223613023|NCT02434822|BIOLOGICAL|Shanchol™: Oral Cholera Vaccine Killed Bivalent (O1 and O139) Whole Cell|1.5 mL, Oral administration
223613024|NCT02434822|BIOLOGICAL|Shanchol™: Oral Cholera Vaccine Killed Bivalent (O1 and O139) Whole Cell|1.5 mL, Oral administration
223613025|NCT02434822|BIOLOGICAL|Shanchol™: Oral Cholera Vaccine Killed Bivalent (O1 and O139) Whole Cell|1.5 mL, Oral administration
223759105|NCT05111366|DRUG|Anlotinib hydrochloride capsules|Anlotinib Hydrochloride is a capsule in the form of 8 mg,10 mg, and 12 mg, orally, once daily, 2 weeks on/1 week off.
223759106|NCT04915404|DRUG|Berubicin Hydrochloride|Berubicin intravenously infused will be administered at a dose of 7.1 mg/m2 as free base (equivalent to 7.5 mg/m2 Berubicin HCl) as a 2-hour intravenous (IV) infusion once daily for 3 consecutive days followed by 18 days off study drug (each cycle = 21 days).
223759107|NCT02366078|BEHAVIORAL|SMART|Paced breathing meditation with cognitive training
223759108|NCT00344773|DRUG|Gefitinib|250mg tablet oral tablet once daily
223759109|NCT02152410|DEVICE|acupuncture|Acupuncture will be applied according to the standards for reporting interventions in clinical trials of acupuncture (STRICTA)
223759110|NCT02152410|DRUG|Morphine|bolus of 5 mg of morphine (5 cc) and 2 mg (2cc) every 10 minutes if no improvement of VAS (VAS\> 30).
223759111|NCT05967962|BEHAVIORAL|The Trauma Film Paradigm|"Trauma film paradigm is a well-known, validated and established procedure that produces reactions similar to those generated by trauma, and that is often used in research to predict susceptibility for peritraumatic and posttraumatic reactions. In this study the trauma film paradigm will be utilized to simulate combat exposure. The two groups of participants will undergo the trauma film paradigm by watching 16 min traumatic combat scenes vs. non-traumatic movie scenes, respectively. Participants will be given standardized instructions (i.e., ''Imagine you are present at the scene; Do not close your eyes)."
223759112|NCT05967962|BEHAVIORAL|non-traumatic (neutral) film|non-traumatic (neutral) film
223759113|NCT02766244|DEVICE|ICG/SPY|indocyanine green fluorescence imaging
223759114|NCT02766244|DRUG|Antibiotic Ointment|Antibiotic ointment
223759115|NCT00714259|DRUG|Fludarabine|Fludarabine 30 mg/m2/day x 3 days
223759116|NCT00714259|RADIATION|Total Body Irradiation|TBI 200cGy x1 dose on transplant day
223759117|NCT00714259|OTHER|Infusion of Stem Cells|On Day 0 pts will received an infusion of HLA matched sibling donor stem cells. Dose is determined by the volume of cells obtained from donor. Minimum dose is 2x10\*6 CD34+ cells per kilogram of recipient weight.
223759118|NCT02510911|DRUG|Caffeine (100 mg)|"Patients after laparoscopic colectomy will receive 3 times daily capsules with 100 mg caffeine together with the meals.~First capsule will be taken on the evening of surgery if surgery was completed before 1 pm, otherwise the first capsule will be taken on the morning of the next day.~Treatment consists of 10 capsules and will be stopped after the first solid bowel movement."
223759119|NCT02510911|DRUG|Caffeine (200 mg)|"Patients after laparoscopic colectomy will receive 3 times daily capsules with 200 mg caffeine together with the meals.~First capsule will be taken on the evening of surgery if surgery was completed before 1 pm, otherwise the first capsule will be taken on the morning of the next day.~Treatment consists of 10 capsules and will be stopped after the first solid bowel movement."
223759120|NCT02510911|DRUG|corn starch (250 mg approx.)|"Patients after laparoscopic colectomy will receive 3 times daily capsules with 250 mg corn starch together with the meals.~First capsule will be taken on the evening of surgery if surgery was completed before 1 pm, otherwise the first capsule will be taken on the morning of the next day.~Treatment consists of 10 capsules and will be stopped after the first solid bowel movement."
223759121|NCT02510911|OTHER|Radiopaque marker|"On the morning of the first, second and third day after surgery patients will take 1 capsule each day with radiopaque markers .~On day 4 after surgery an abdominal X-ray will be performed to localize the markers.~Each gelatin capsule contains 10 markers consisting of polyurethane encapsulated barium sulfate (40%)."
223759122|NCT02729649|DEVICE|ArmAssist robotic training|
223759123|NCT02729649|OTHER|Conventional therapy|
223759124|NCT02729649|OTHER|Extended conventional therapy|
223759125|NCT02141074|DRUG|nonacog beta pegol|For intravenous (i.v.) injection. A single dose of 40 U/kg, unless the bleeding episode is severe in which case it should be treated with 80 U/kg.
223759126|NCT01902485|OTHER|Timing of Contraceptive Initiation in Medical Abortion|
223613026|NCT01611038|DIETARY_SUPPLEMENT|Methylselenocysteine|Methylselenocysteine capsule given daily
223613027|NCT01611038|DIETARY_SUPPLEMENT|Placebo|Placebo capsule given daily
223759127|NCT04209088|OTHER|Pulmonary ultrasounds|"Two ultrasounds will be performed by the same pediatrician for each child included: the first at nine days of life +/- two days, the second at fifteen days of life +/- two days.~A blind replay of ultrasound images to calculate the score will be performed by a another investigator."
223759128|NCT00874068|OTHER|InFat™ based infant formula|high sn-2 palmitic acid oil based infant formula
223759129|NCT00874068|OTHER|Standard vegetable oil based infant formula|standard vegetable oil based infant formula
223759130|NCT05709184|COMBINATION_PRODUCT|Lyophilized fecal microbiome transfer|Five days of vancomycin followed by five days of lyophilized fecal microbiome transfer, administered in a loading dose of 15 capsules, and a daily maintenance dose of 10 capsules.
223759131|NCT05709184|DRUG|Vancomycin|Ten days of oral vancomycin 125 mg four times daily
223613028|NCT02677168|DEVICE|cNEP|continuous negative external pressure
223759132|NCT02459392|OTHER|Epiduroscopy|"Epiduroscopy has two main uses in the pain clinic:~Releasing epidural adhesions for the relief of chronic sciatica. Adhesions can form around the lower lumbar nerve roots after decompressive surgery for disc disease or after a bad bout of inflammatory sciatica in the absence of surgery. Epidural adhesions can usually be identified on an enhanced magnetic resonance scan using intravenous gadolinium. They also cause uneven spread of X-ray contrast when performing an epidurogram.~Injecting mixtures of local anesthetic and depot steroid around inflamed nerve roots when epidural injections / nerve root blocks have been unsuccessful. The presence of adhesions can prevent epidurally injected drugs from reaching the inflamed nerve roots."
223759133|NCT02459392|DRUG|Hyaluronic Acid|Drug administration
223759134|NCT02459392|DRUG|DepoMedrol|Drug administration
223759135|NCT02753894|DRUG|ASP1585|Oral
223613029|NCT03568240|DIAGNOSTIC_TEST|Patients suffering from Sleep apnea|PSG test
223613030|NCT00354380|DRUG|Methylene blue|
223613031|NCT00354380|DRUG|Artesunate|
223613032|NCT00354380|DRUG|Amodiaquine|
224312014|NCT03333135|PROCEDURE|Pulsed Electromagnetic Field therapy (PEMF)|PEMF Therapy based on Biological Electromagnetic (BEM) microbial wave technology provides micro-magnetic emissions to the center of the palm (Laogong acupoint). While participating in the study, the subjects will undertake 2 sessions of therapy every day (1 session in the morning and evening). Each session will last for 16-min (8-min for left and 8-min for right hand).
223613033|NCT01332994|DRUG|rituximab [MabThera/Rituxan]|1 g intravenously at Week 16 and 18
224312015|NCT03333135|PROCEDURE|Pulsed Electromagnetic Field Sham therapy|PEMF therapy will be administered however it will not produce micro-magnetic emissions. The therapy will be used on the center of the palm (Laogong acupoint) of each hand. While participating in the study, the subjects will undertake 2 sessions of therapy every day (1 session in the morning and evening). Each session will last for 16-min (8-min for left and 8-min for right hand).
224312016|NCT04366323|DRUG|ALLOGENEIC AND EXPANDED ADIPOSE TISSUE-DERIVED MESENCHYMAL STEM CELLS|Two doses of 80 million adipose-tissue derived mesenchymal stem cells
224312017|NCT01461915|DRUG|Nab paclitaxel|Nab-paclitaxel 125 mg/m2 will be administered IV over 30 minutes. Nab-paclitaxel will be administered weekly for 3 weeks followed by 1 week of rest (28-day cycle).
224312018|NCT01461915|DRUG|Gemcitabine|Following the completion of nab-paclitaxel administration, gemcitabine IV infusion at 1000 mg/m2 will be administered over 30 minutes. Gemcitabine will be administered weekly for 3 weeks followed by 1 week of rest (28-cycle).
224312019|NCT01461915|DRUG|Dociparstat|Following the completion of gemcitabine administration, dociparstat IV bolus at 4 mg/kg will be administered in 5 minutes immediately after completion of gemcitabine administration. Immediately following the dociparstat IV bolus administration, dociparstat 48-hour IV continuous infusion at 0.375 mg/kg/hr will be administered.
224312020|NCT03354260|OTHER|Personalized adapted oral diet and nutritional education|Optimized personalized oral nutrition in ICU and nutritional follow up with therapeutic educational after exit of ICU
224312021|NCT05724563|DRUG|Zimberelimab|Zimberelimab 360 mg IV every 3 weeks until disease progression, unacceptable toxicity, death, or discontinuation from the study treatment for any other reason.
223613034|NCT01332994|DRUG|tocilizumab [RoActemra/Actemra]|8 mg/kg intravenously every 4 weeks for 12 weeks.
223613035|NCT01332994|DRUG|tocilizumab [RoActemra/Actemra]|8 mg/kg intravenously every 4 weeks from Week 16 to Week 28
223613036|NCT02800863|DEVICE|Dorsal Root Ganglion (DRG) Stimulation (Axium™ Neurostimulator System)|Electrical stimulation of the DRG using the Axium™ Neurostimulator System
223613037|NCT02800863|DEVICE|Dorsal Root Ganglion (DRG) Stimulation (Proclaim™ Neurostimulator System)|Electrical Stimulation of the DRG using the Proclaim™ Neurostimulator System.
223613038|NCT03360123|DRUG|Midazolam Hydrochloride 2Mg/mL Syrup|Midazolam HCl Syrup 0.5mg/kg (Max: 15mg) taken 10-15 minutes prior to dental treatment.
224312022|NCT05724563|DRUG|Domvanalimab|Domvanalimab 1200 mg IV every 3 weeks until disease progression, unacceptable toxicity, death, or discontinuation from the study treatment for any other reason.
224312023|NCT04331119|DRUG|Duvelisib|SecuraBio will supply duvelisib
224312024|NCT04331119|PROCEDURE|Peripheral blood draw|-Prior to transplant, cycle 1 day 1 of duvelisib, and at the time of all imaging studies
224312025|NCT03239743|DEVICE|Virtual Reality|Child will wear and interact with virtual reality headset while waiting for surgery.
224312026|NCT03239743|DRUG|Midazolam|Child will receive Midazolam to help with pre-operative anxiety prior to surgery
223613039|NCT03360123|DRUG|Triazolam 0.125 MG|Triazolam: 0.125mg tablet taken 30 minutes prior to dental treatment.
223613040|NCT04651868|OTHER|GLP-2|A 210 mins intravenous infusion with GLP-2 (10 pmol × kg\^-1 × min\^-1)
223613041|NCT04651868|OTHER|Placebo|A 210 mins intravenous infusion with isotonic NaCl
223613042|NCT04651868|OTHER|CCK|A 180 mins intravenous infusion with cholecystokinin (0.4 pmol × kg\^-1 × min\^-1)
223613043|NCT04651868|OTHER|Placebo|A 180 mins intravenous infusion with isotonic NaCl
223613044|NCT06061081|DRUG|VH3739937|VH3739937 will be administered.
223613045|NCT06061081|DRUG|Placebo|Placebo will be administered.
223613046|NCT05496296|DEVICE|Altrazeal® Transforming Powder Dressing|Pressure injury wounds will be evaluated at each study visit (cleaned, photographed, measured) and a dressing will be applied according to the study arm
223613047|NCT04255589|DRUG|CKD-495 75mg|CKD-495 75mg Tab.
223613048|NCT04255589|DRUG|Artemisia Herb 95% Ethanol Soft Ext.(20→1) 60mg|Artemisiae argyi folium 95% ethanol ext.(20→1) 60mg Tab.
223613049|NCT04255589|DRUG|Placebo of the CKD-495 75mg|Placebo of the CKD-495 75mg Tab.
223613050|NCT04255589|DRUG|Placebo of Artemisia Herb 95% Ethanol Soft Ext.(20→1) 60mg|Placebo of Artemisia Herb 95% Ethanol Soft Ext.(20→1) 60mg Tab.
223613051|NCT05528393|DIAGNOSTIC_TEST|Blood sampling|blood sampling
223613052|NCT05733052|OTHER|Polyester suture|A No2 polyester suture will be used for tying special anatomical structures fr telieving the symptom. of stress urinary incontinence
223613053|NCT02309801|DIETARY_SUPPLEMENT|Daidzin|Super-Absorbable Soy Isoflavones, LifeExtension, USA. Single oral dose of 4 capsules (containing 80 mg of daidzin-daidzein).
223613054|NCT02309801|DIETARY_SUPPLEMENT|Alcohol|Alcohol single oral dose
223613055|NCT00279916|DRUG|Triamcinolone acetonide nasal spray|"Subjects aged 12 years or older received 2 metered sprays in each nostril once daily (55 micrograms/spray) (total daily dose 220 micrograms).~Subjects younger than 12 years old received received 1 metered spray in each nostril once daily (55 micrograms/spray) (total daily dose 110 micrograms)."
223613056|NCT00279916|DRUG|Placebo nasal spray|"Subjects aged 12 years or older received an aqueous solution lacking triamcinolone, 2 metered sprays in each nostril once daily.~Subjects younger than 12 years old received received 1 metered spray of placebo solution in each nostril once daily."
224312027|NCT02586246|DRUG|CDP870|Self-injection
223759136|NCT05039970|OTHER|WellQuest™|WellQuest™ is a mobile device-based serious health game.
223759137|NCT01589432|DRUG|ABT-639|two 50 mg oral capsules
223759138|NCT01589432|DRUG|Placebo|2 placebo capsules
223613057|NCT01068574|OTHER|BASIC Score (Observational)|The BASIC Score will be assessed by a study staff, but there are no interventions.
223613058|NCT01451385|DRUG|COV795|COV795 is a multilayer extended-release tablet for oral administration of oxycodone hydrochloride (15 mg) and acetaminophen (650 mg)
223613059|NCT01833559|DIETARY_SUPPLEMENT|Dietary control|
223759139|NCT01589432|DRUG|Lidocaine|3mg/kg infusion over 30 minutes
223759140|NCT05891938|OTHER|H2 gas inhalation|H2 gas inhalation treatment for 4 weeks in on community dwelling adults of various ages
223759141|NCT05844163|OTHER|observation|observation
223759142|NCT06354907|BEHAVIORAL|The Kids' Empowerment Program|The 12-session KEP provides support and information while teaching children self-management skills based on techniques derived from a combination of best, evidence-based practices (e.g., using elements of cognitive behavioral therapy, behavioral activation, brief behavioral activation, and interpersonal therapy. Adjustment is enhanced with a comprehensive approach that strengthens cognition (how to think about things), changes behavior (problem solving or planning actions), and focuses on emotions (identifying and expressing feelings), social relationships (peers, parents, siblings), and physical health (de-stressing, exercise). Group leaders follow a training manual with developmentally appropriate scripts, instructions for behavioral applications in (e.g., craft or game activities) and practice plans.
223759143|NCT06239779|OTHER|Education|The education intervention will involve a PowerPoint presentation delivered individually by a physician to each participant in intervention group, covering an overview of fibromyalgia, coping strategies, and the potential impact of smart phone addiction on fibromyalgia.
223759144|NCT04793360|DEVICE|LiverCare|The LiverCare kits contains Streck tubes and PAX gene tubes, which will be collected at the surveillance schedule outlined above, but also prior to any liver biopsy or DSA measurement. For patients who have a histological diagnosis of allograft rejection who are undergoing treatment, serial monitoring of LiverCare will be performed following the schedule above. All research blood tests will be timed with standard clinical testing to avoid any additional needle sticks.
223759145|NCT06879106|OTHER|Intervention group|"The Mindfulness-Based Cognitive Therapy (MBCT) intervention is an educational program consisting of the themes Mindfulness and Autopilot, Living in Our Mind, Focusing the Distracted Mind, Recognizing Hate, Allowing, Thoughts Are Not Real, How Can I Best Take Care of Myself, and Sustaining and Expanding New Learning."
223759146|NCT07030322|DEVICE|Overground Robotic Exoskeleton|Participants will have received training on their personal exoskeleton device prior to data collection. There is no required use dosage of the Ekso Indego Personal for this observational study.
223759147|NCT06685887|DRUG|HIPEC|HIPEC treatment (Oxaliplatin, physiological saline at 43°C for 60 min) was performed after the Laparoscopic exploratory surgery.
223759148|NCT06685887|DRUG|SOX|Oxaliplatin, 130 mg, i.v. + S-1 (40 mg per dose for BSA \<1.25; 60 mg per dose for BSA 1.25 to 1.5; 60 mg per dose for BSA ≥1.5, twice daily for each treatment cycle d1-14, q3w
223613060|NCT01833559|DRUG|Insulin|If feast blood glucose is over 7.0 mmol/L, the patient will be hospitalized and insulin will be used. The kind of insulin used depends on the need of patients.
223613061|NCT02717494|BIOLOGICAL|PPV-23|PPV-23 was a polysaccharide PNC vaccine, licensed in Brazil, directed against 23 serotypes.
223613062|NCT02717494|BIOLOGICAL|PCV-10|PCV-10 was a conjugate PNC vaccine, licensed in Brazil, directed against 10 serotypes.
223613063|NCT02717494|OTHER|NaCl|NaCl was the placebo for the study against which the two vaccines were compared during pregnancy.
223613064|NCT00214981|DRUG|Modafinil|
223613065|NCT02053636|DRUG|lucitanib|
223613066|NCT01242592|DRUG|Anti-Tuberculosis Treatment|
223613067|NCT06281093|OTHER|questionary|Parental questionnaire on pregnancy history and environmental exposure
223613068|NCT06281093|OTHER|Daily continuous recording of radiofrequency exposure levels|Daily continuous recording of radiofrequency exposure levels (1 week) by positioning a dosimeter close to the incubator
223613069|NCT06281093|OTHER|Follow-up of daily infants clinical parameters|Follow-up of daily infants clinical parameters
223613070|NCT06281093|OTHER|recording of cerebral (EEG)|recording of cerebral (EEG)
223613071|NCT06281093|OTHER|autonomic nervous (ECG) activity|autonomic nervous (ECG) activity
223759149|NCT06685887|DRUG|Immune Checkpoint Inhibitors|Tislelizumab, 200 mg, q3w
223759150|NCT06709456|PROCEDURE|Ultrasonography-guided pleural drainage|Ultrasonography-guided pleural drainage with insertion of a small-bore intrapleural catheter. Contralateral and repeated drainage conducted as specified during ICU stay until day 90.
223759151|NCT06589505|DEVICE|Software as a Medical Device|The subject will undergo treatment using the Software as a Medical Device
223759152|NCT04413162|OTHER|Kinect motion tracking system|Kinect motion tracking system is used to measure shoulder range of motion compared to goniometric measurement.
223759153|NCT02940431|OTHER|High Autonomy|Children will be given two active video games (AVGs) of their choice. After two weeks, a researcher will monitor progress and exchange the AVGs and sedentary games. At each exchange, children will be allowed to select their next game.
223613072|NCT05244746|PROCEDURE|rectus sheath block|blocking the nerve underneath the rectus muscle by bupivicaine
223613073|NCT03764644|BEHAVIORAL|Combined ABMT and CBT|ABMT: A trial begins with a fixation cross (+) for 500 ms, immediately followed by a stimuli pair consisting of a neutral and threatening stimulus that is centred horizontally. Stimuli pairs consist of two faces, pictures or words. After presentation of the stimuli pair, a probe (: or ..) always appears on the location of the neutral stimulus. The probe remains on the screen until the participant presses the corresponding key (: or ..), after which the next trial begins. Each session, participants see 160 trials of which 128 trials include one neutral and one threatening stimulus. The remaining 32 trials include a neutral-neutral stimuli pair. CBT: FRIENDS program individual
223613074|NCT03764644|BEHAVIORAL|Combined Sham ABMT and CBT|ABMT: A trial begins with a fixation cross (+) for 500 ms, immediately followed by a stimuli pair consisting of a neutral and threatening stimulus that is centred horizontally. Stimuli pairs consist of two faces, pictures or words. After presentation of the stimuli pair, a probe (: or ..) always appears on the location of the neutral stimulus. The probe remains on the screen until the participant presses the corresponding key (: or ..), after which the next trial begins. Of the 160 trials, the probe appears with equal frequency on the location of the neutral and threatening stimulus (128 trials). The remaining 32 trials include a neutral-neutral stimuli pair. CBT: FRIENDS program individual
223613075|NCT05529693|DIETARY_SUPPLEMENT|Experimental: Bif-038 arm, high dose|Active trial product with minimum 10 billion CFU daily dose
223613076|NCT05529693|DIETARY_SUPPLEMENT|Experimental: Bif-038 arm, low dose|Active trial product with minimum 1 billion CFU daily dose
223613077|NCT05529693|DIETARY_SUPPLEMENT|Placebo Comparator: Placebo arm|Similar product to trial product but without Bif-038
223759154|NCT02940431|OTHER|Low Autonomy|Children will be given their most-liked active video game (AVG) from the baseline relative reinforcing value assessment. After two weeks, a researcher will monitor progress and exchange the AVGs and sedentary games. At each exchange, children will receive a pre-determined game.
223759155|NCT05427695|DRUG|Lactobacillus sakei proBio65|Lanto Sinus probiotic Lactobacillus sakei is a currently available over the counter supplement from the common source kimchi and produced in South Korea. Patients will be instructed to mix 1 packet with lukewarm distilled or boiled water in 240mL NeilMed® sinus rinse bottle.
223759156|NCT05427695|OTHER|Isotonic Saline Solution|Saline sinus irrigations (SAL group): NeilMed® Isotonic Sinus Rinse™ is marketed as a saline sinus irrigation formula. Subjects will be given instructions to mix one unlabeled packet (containing NeilMed® premixed buffered salt powder) with lukewarm distilled or boiled water in 240mL NeilMed® sinus rinse bottle.
223759157|NCT06767228|BEHAVIORAL|Reformer Pilates|This intervention involves a structured reformer pilates program designed to enhance core endurance, posture, and body awareness. The program includes exercises such as Footwork Series, Pelvic Lift, Arm Circles, Leg Circles, Frog Series, Long Box Series, Short Box Series, Elephant, Knee Stretch Series, Stomach Massage, and Side Stretch. The program emphasizes progressive resistance, controlled movements, and professional supervision to ensure safety and effectiveness. Sessions are conducted twice weekly for six weeks.
223759158|NCT05491551|BEHAVIORAL|Mindfulness-Based Treatment-Regulation of Craving|"Participants will be trained in using the MBT-based mindfulness strategy as described above (notice craving and accept the feeling without judgment or reaction). Participants will then be instructed to think of accepting and non-reactive responses when they see the instruction ACCEPT during ROC-T. On each trial, participants will receive an instruction and then be exposed to a novel alcohol image for 6 seconds. On 25% of the trials, they will see the LOOK instruction, and be allowed to experience craving (as baseline). On 75% of the trials, participants will see ACCEPT and then practice thinking about the negative consequences of drinking. After the picture disappears, they will rate their craving on every trial using a 1-5 Likert scale."
223759159|NCT05491551|BEHAVIORAL|Cognitive-Based Therapy-Regulation of Craving|"Participants will be trained in using the CBT strategy by first considering and reading about the negative consequences of drinking. Participants will then be instructed to think of those negative consequences (Focus on the negative consequences associated with drinking) when they see the instruction REFRAME during ROC-T.On each trial, participants will receive an instruction and then be exposed to a novel alcohol image for 6 seconds. On 25% of the trials, they will see the LOOK instruction, and be allowed to experience craving (as baseline). On 75% of the trials, participants will see REFRAME and then practice thinking about the negative consequences of drinking. After the picture disappears, they will rate their craving on every trial using a 1-5 Likert scale"
223759160|NCT06877364|BIOLOGICAL|GcMAF|GcMAF is an immunomodulatory protein derived from vitamin D-binding protein via enzymatic deglycosylation. In this study, GcMAF will be administered (e.g., subcutaneously) once or twice-weekly for 12-16 weeks, followed by a 4-8-week observation period. The primary objectives include assessing clinical efficacy in chronic inflammatory conditions and confirming safety. GcMAF activates macrophages and dendritic cells, modulates M1/M2 profiles, and may reduce inflammatory markers such as CRP and ESR.
224201484|NCT04509440|DRUG|corticosteroid with local anaesthetics (40 mg of triamcinolone acetonide (40 mg/ml) with 1.5 ml mepivacaine HCl 3% )|Corticosteroid with local anaesthetics (40 mg of triamcinolone acetonide (40 mg/ml) with 1.5 ml mepivacaine HCl 3% ) (local anesthetic). They were given as a single local soft tissue injection at the point of maximal tenderness on the lower medial aspect of the knee region.
223613078|NCT01462240|DEVICE|LPS Flex Porous Femoral Components|Porous femoral components in total knee arthroplasty
223613079|NCT05721521|OTHER|Spin Bike Exercise|30 minute spin bike class led by a qualified instructor.
223613080|NCT05721521|OTHER|Control|30 minute completing seated activities (e.g., wordsearches)
223613081|NCT03467711|OTHER|tidal volume challenge|transiently increasing tidal volume from 6 to 8 mL/kg predicted body weight (tidal volume challenge)
223613082|NCT03467711|OTHER|volume expansion|give 6ml/kg (predicted body weight) volulyte for 10min
223613083|NCT06169553|OTHER|Holistic injection-related injection treatment|Participants in the intervention group will be provided additional supports to address their social and medical needs, including infectious disease management, addictions medicine, peer support, and systems navigation. Each participant will receive individualized care depending on their unique needs.
223613084|NCT00770601|DRUG|Canakinumab|
223613085|NCT03779698|OTHER|BiodentineTM|In the experimental group, BiodentineTM was used following the manufacturer's recommendations. The whole pulp chamber was entirely filled with BiodentineTM until the occlusal surface. Follow-up was done for all children clinically at 3, 6 and 12 months and radiographically at 6 and 12 months.
223613086|NCT03779698|DRUG|Formocresol|In control group, a sterile cotton pellet moistened with 1:5 concentration formocresol then blotted to remove excess was placed for 5 minutes on the pulp stumps and then the pulps were covered with zinc oxide-eugenol (IRM; Dentsply, Milford, DE) dressing. Follow-up was done for all children clinically at 3, 6 and 12 months and radiographically at 6 and 12 months.
223613087|NCT04366661|DIAGNOSTIC_TEST|low dose CT|Invited participants from institutes exposed to a high level of smoke pollution such as employees of Transport and Oil Ministries are inquired for their personal history of cigarette smoking then subjected to low dose CT
223613088|NCT06303596|OTHER|Hippotherapy|Hippotherapy: Hippotherapy in psychiatry is not concerned only about the patient sitting on a horse and the horseback movement influencing the physical condition of the patient and his functional and postural disorders. This therapy is concerned with positive effects on a patient's mental state and use mainly contact with the horse, work with the horse from the ground and riding on horseback. It aims for enjoyment, social communication, and the development of cognitive and executive functions.
223613089|NCT06303596|OTHER|Standard psychiatric treatment|Standard psychiatric treatment: Standard psychiatric treatment includes medication and routine activities provided by the Community Mental Health Center.
223613090|NCT04485546|DRUG|cenegermin-bkbj|Cenegermin-bkbj ophthalmic solution administered as one drop in affected eye(s) every 2 hours 6 times daily for 8 weeks
223613091|NCT00099138|BEHAVIORAL|Caloric Restriction (CR)|
223613092|NCT00099138|BEHAVIORAL|Exercise|
223613093|NCT01817439|DRUG|Amiodarone|patients will be randomly assigned to oral OR IV Amiodarone
223613094|NCT04693559|PROCEDURE|secondary alveolar bone graft|Under general anaesthesia, the soft tissue in the gingiva surrounding the alveolar cleft will injected with 0.5% lidocaine with 1:100,000 parts of epinephrine. At the alveolar cleft site, gingival sulcus incisions will made on both the sides of the cleft. The tissue will then elevated beneath the periosteum. The mucosa of the nasal floor and the oral mucosa will dissected. Next, the bone particles will implanted into the bone defect. The cleft site will closed without tension by advancement of the gingival flaps
223759161|NCT06877364|OTHER|Placebo Injection (Saline)|Participants in the placebo arm will receive a visually matching injection of normal saline (placebo) on the same schedule as the GcMAF arm (e.g., once or twice-weekly for 12-16 weeks). This allows for double-blind comparison of safety and efficacy endpoints. The placebo is designed to be identical in appearance and administration route to maintain blinding for investigators and participants.
223759162|NCT03037398|DEVICE|Vercise Deep Brain Stimulation System|
223759163|NCT06909643|DIAGNOSTIC_TEST|Artificial intelligence (AI)-based diagnostic model|Collect magnetic resonance imaging and pathological slides of resected tumor of the enrolled patients. Analyze the data using the AI model to generate diagnostic results (sensitive or insensitive to the neoadjavant therapy). No intervention to patients would be performed in this diagnostic test study.
223759164|NCT07096518|OTHER|ChatGPT-Integrated Lecture|This group received a structured and interactive educational lecture integrated with ChatGPT, an AI language model, enabling students to learn collaboratively through guided activities related to endotracheal suctioning. Students compared the information obtained from ChatGPT with evidence-based, up-to-date clinical guidelines and discussed the comparison results together in the classroom. The instructor provided guidance throughout the process.
223759165|NCT03271736|BEHAVIORAL|Stepping-in-place exercise with external auditory cues|The stepping-in-place exercise includes 10-session training. In each session, subjects are asked for stepping for 50 steps. In auditory cued condition, the cued frequency is set at 110% of the usual walking cadence. While in non-cued condition, we ask the subjects to step according to their own internal rhythm.
223759166|NCT03271736|DEVICE|Transcranial magnetic stimulation (TMS)|TMS is used to assess the cortical excitability of the motor cortex. The stimulation intensity is set at 130% of the motor threshold in single-pulse condition. In paired-pulse condition, the first stimulus is set at 80% of the motor threshold and the second stimulus is set at 130% of the motor threshold.
223759167|NCT06399146|DEVICE|Picterus App|Take a photo off the patient's skin (sternum).
223759168|NCT02411331|DRUG|Ethanol 40% + Enoxaparine 400UI/ml|
223759169|NCT02411331|DRUG|Vancomycine 5 mg/ml + Héparine 2500UI/ml|
223759170|NCT05758740|BEHAVIORAL|E-health enhanced behavioural change intervention|Participants will first receive a face-to-face brisk-walking training programme with lectures and demonstrations following a standardized brisk training content. The training will be provided face-to-face at the elderly community centres and parks. Each training session lasts for one hour and is two times per week for two weeks. After that, a conventional behavioural change intervention will begin following a standardized intervention implementation manual and the physical activity amount will be logged by the participants using a logbook. Physical activity counselling will be conducted by a trained research assistant face-to-face at the elderly community centre. Each counselling session lasts for one hour and is once per week for 12 weeks.
224201485|NCT02164084|DRUG|SB204|SB204 Gel with hydrogel
224201486|NCT02164084|DRUG|Vehicle Gel|Vehicle Gel with hydrogel
224201487|NCT02930538|OTHER|Survey|Completing a survey on RedCap
224201488|NCT00539006|DRUG|FPNS|fluticasone propionate nasal spray
223613095|NCT04693559|PROCEDURE|harvesting of the autogenous bone graft|osteotome and then cut into small bone granules. The bone granules will then carefully placed into a syringe and pressed to its densest state by pushing the plunger
223613096|NCT04693559|PROCEDURE|Nanocrystalline Hydroxyapatite|Nanocrystalline Hydroxyapatite will be used to fill the alveolar defect
223613097|NCT00181662|DRUG|Curcumin|
223613098|NCT00895115|DIETARY_SUPPLEMENT|vitamin E|Given once daily
223613099|NCT00895115|PROCEDURE|sham intervention|No supplementation
223613100|NCT06141863|OTHER|questionnaire|Neck Disability Index, The Fonseca Anamnestic Index (FAI) and Visual Analogue Scale (VAS)
223613101|NCT02569684|DIETARY_SUPPLEMENT|Prebiotic fibers: oligofructose and inulin|
224201489|NCT00539006|DRUG|FFNS|fluticasone furoate nasal spray
224201490|NCT00539006|DRUG|placebo FPNS|placebo nasal spray matching fluticasone propionate nasal spray
223613102|NCT02569684|DIETARY_SUPPLEMENT|Maltodextrin|
223613103|NCT03441087|DEVICE|Transvaginal ultrasound|
223613104|NCT03441087|DEVICE|Hysteroscopy|
223613105|NCT03036020|RADIATION|CereTom Neurologica Samsung|Diagnosis of acute stroke patients by cerebral CT diagnostics prehospital
223613106|NCT02160652|PROCEDURE|Laparoscopic ureteral re-implantation.|Laparoscopic ureteral re-implantation for the treatment of malignant ureteral obstruction.
223613107|NCT06162026|BEHAVIORAL|RACS app|risk assessment questions, symbol matching task, voice tasks
223613108|NCT00676013|PROCEDURE|Integra|Grafting using the Commercial product Integra as a skin substitute over full thickness burn following excision.
223613109|NCT00676013|PROCEDURE|AlloDerm|Grafting using the commercial product AlloDerm as a skin substitute
223613110|NCT00676013|PROCEDURE|Homograft|Grafting using homograft as a skin substitute
223613111|NCT00676013|PROCEDURE|Autograft|grafting using patients own skin from a separate donor site
223613112|NCT00428948|DRUG|Tolvaptan|Tolvaptan was supplied as tablets.
223613113|NCT00428948|DRUG|Placebo|Placebo was supplied as tablets.
223613114|NCT03761186|BEHAVIORAL|traditional diabetes diet|Diet with carbohydrate content 50-60% of total energy intake
223613115|NCT03761186|BEHAVIORAL|moderately low carbohydrate diet|Diet with carbohydrate content 30-40% of total energy intake
224201491|NCT00539006|DRUG|placebo FFNS|placebo nasal spray matching fluticasone furoate nasal spray
223613116|NCT03761186|BEHAVIORAL|strictly low carbohydrate diet|Diet with carbohydrate content 15-20% of total energy intake
223613117|NCT02862873|PROCEDURE|Spinal anaesthesia|
223613118|NCT02862873|DRUG|Ondansetron|
223613119|NCT02862873|OTHER|saline solution|
223613120|NCT05659771|BEHAVIORAL|Food properties manipulation to alter eating behavior and food and energy intake|Food properties of commercially available food products
223613121|NCT02506634|DRUG|Esomeprazole MUPS, 20 mg|According to the guidelines, the PPI treatment duration would be 8 weeks(Esomeprazole MUPS, 20 mg bid) for patients with reflux esophagitis and 4 weeks (Esomeprazole MUPS, 20 mg bid) for patients with normal findings on endoscopy.
223759171|NCT05758740|BEHAVIORAL|Conventional behavioural change intervention|Participants will first receive a face-to-face brisk-walking training programme with lectures and demonstrations following a standardized brisk training content. The training will be provided face-to-face at the elderly community centres and parks. Each training session lasts for one hour and is two times per week for two weeks. After that, e-health enhanced behavioural change intervention will begin following a standardized intervention implementation manual and using participants' own smartphones installed with two Apps (i.e., Samsung Health and WhatsApp). The physical activity amount will be logged by the smartphone using Samsung Health. Physical activity counselling will be conducted by a trained research assistant remotely using a smartphone. The remote counselling sessions totally last for accumulatively 1 hour per week for 12 weeks.
223759172|NCT00403273|DRUG|Botulinum toxin A|100 units of Botulinum toxin A in 5 cc of normal saline in the Painful TKA at screening visit
223759173|NCT00403273|DRUG|Normal Saline|Single Intra-articular Injection of 5 cc of normal saline in the Painful TKA at screening visit
223759174|NCT03120065|OTHER|Electronic Dose Monitoring (MEMS)|The MEMS cap is an electronic bottle cap that records the time and date of a bottle being opened. The research personnel will extract the timing of the MEMS bottle opening events for adherence analysis.
223759175|NCT05597007|BEHAVIORAL|VPICS Clinic|Participants will complete a mix of mandatory synchronous and asynchronous sessions with their Health Group to address PICS. Participants will spend 15 minutes daily on physiotherapy, and 15 minutes on cognitive therapy. There are also 2h time slots everyday for participants to join for an optional check-in with their health coach, who can support them in their individual activities. Participants will spend 15 minutes weekly responding to journal prompts about nutrition and general challenges.
223759176|NCT00213174|BEHAVIORAL|school playgrounds|
223759177|NCT04467827|DIAGNOSTIC_TEST|examining group|Posture assessment in young healthy people depending on their level of physical activity
223759178|NCT05091567|DRUG|Atezolizumab|Atezolizumab will be administered intravenously at a fixed dose of 1200 mg on Day 1 of each 21-day cycle for 4 cycles in the induction phase. Atezolizumab will be administered intravenously at a fixed dose of 1200 mg on Day 1 of each 21-day cycle in the maintenance phase.
224312028|NCT05046964|DEVICE|Masimo Radical-7 Pulse CO-Oximeter|The Radical-7 Pulse CO-Oximeter uses photospectroscopy to non-invasively measure the total hemoglobin (SpHb) in a patient's blood throughout their C-section.
223613122|NCT00854880|DRUG|PDC339|
223613123|NCT00854880|DRUG|Placebo|
223613124|NCT00943930|DRUG|THC (delta-9 tetrahydrocannabinol), d-amphetamine, oral THC|During each study session participants will be asked to smoke a cigarette. The cigarette may contain marijuana or it may contain placebo (a blank). Participants will also be asked to swallow a capsule 2-hours prior to smoking the cigarette. The capsule could contain placebo (a blank), THC (delta-9 tetrahydrocannabinol, or d-amphetamine.
223613125|NCT03899298|BIOLOGICAL|Amniotic and Umbilical Cord Tissue Procedure|Amniotic and Umbilical Cord Cell Therapy with protocols dependent on the patient condition. Protocols include options for IV, Injection, Intranasal and/or Nebulizer.
223613126|NCT04417361|DRUG|Galcanezumab Prefilled Syringe|Galcanezumab will be supplied in preloaded syringes, each with a dose of 120 mg. Participants will first receive the first month's supply (240 mg) at study visit 2, and then will receive a two month supply at study visit 3. So, at study visit 2 and 3, each participant will get two pre-filled syringes.
223613127|NCT04417361|DRUG|Placebo|Placebo will be supplied in preloaded syringes, each with a dose of 120 mg. Participants will first receive the first month's supply (240 mg) at study visit 2, and then will receive a two month supply at study visit 3. So, at study visit 2 and 3, each participant will get two pre-filled syringes.
223613128|NCT04892082|BEHAVIORAL|Mindful Moment|The Mindful Moment program is a web-based self-guided cognitive-behavioral intervention to reduce parenting stress, targeting postpartum mothers. It consists of 6 weekly modules, each module targeting a specific thematic content, and providing mothers with both information and specific therapeutic strategies (with a strong focus on the third wave of cognitive-behavioral techniques) to address each thematic content. Modules are sequential.
223613129|NCT04892082|OTHER|Waiting-List Control (WLC)|The control group only receive the intervention at the end of the intervention group.
223613130|NCT00776971|OTHER|Sugar-sweetened soft drink|500mL as a preload drink
223613131|NCT00776971|OTHER|Aspartame-sweetened soft drink|500mL as a preload drink
223613132|NCT00776971|OTHER|Semi-skimmed milk|500mL as a preload drink
223613133|NCT00776971|OTHER|Water|500mL as a preload drink
223759179|NCT05091567|DRUG|Lurbinectedin|Lurbinectedin 3.2 mg/m² will be administered intravenously on Day 1 of each 21-day cycle in the maintenance phase.
223759180|NCT05091567|DRUG|Carboplatin|Carboplatin will be administered according to the standard of care treatment for 4 cycles in the induction phase.
223759181|NCT05091567|DRUG|Etoposide|Etoposide will be administered according to the standard of care treatment for 4 cycles in the induction phase.
223759182|NCT02041598|OTHER|CHW Intervention|5 group educational sessions, 2 1v1 Visits with a CHW, Phone Calls as needed during 6-month study period
223759183|NCT05368207|DRUG|Pembrolizumab|Pembrolizumab is an antineoplastic agent, monoclonal antibody against PD-L1.
223759184|NCT05049161|DRUG|Temelimab 18 mg/kg|temelimab 18 mg/kg will be given as monthly (4-weekly) intravenous (IV) infusions over 48 weeks (12 administrations in total)
223613134|NCT00063778|BIOLOGICAL|AVX101|Alphavirus replicon particle vaccine expressing HIV Gag antigen
223613135|NCT00063778|OTHER|placebo|phosphate buffered saline, pH 7.2, HSA, sodium gluconate, and sucrose
224312029|NCT01832779|OTHER|Achalasia subjects|Information about the subject's medical history, leading up to the need for an Achalasia treatment, the procedure itself and how the subject does after the procedure, including after the subject's gets home, will be collected. This will be done by gathering relevant information from the subject's medical chart and/or by talking with the subject prior to and after your medical procedures. There are no specific study procedures or tests. All information collected is part of the subject's medical care and will be collected even if the subject is not in the study.
224312030|NCT02176785|DEVICE|transcranial Direct Current Stimulation (tDCS)|tDCS will be delivered using a Chattanooga Ionto™ Iontophoresis System - Phoresor.
223759185|NCT05049161|DRUG|Temelimab 36mg/kg|temelimab 36 mg/kg will be given as monthly (4-weekly) intravenous (IV) infusions over 48 weeks (12 administrations in total)
223759186|NCT05049161|DRUG|Temelimab 54 mg/kg|temelimab 54 mg/kg will be given as monthly (4-weekly) intravenous (IV) infusions over 48 weeks (12 administrations in total)
224312031|NCT01269541|DRUG|Mupirocin|Topical in the nose 3 times daily for 5 days
223613136|NCT02132819|OTHER|Withholding feeds|At least 2 feeds before the transfusion, 2 feeds after the transfusion and feeds during the transfusion are withholded
223613137|NCT02132819|OTHER|feeding during transfusion|The feeding process will be continued during the transfusion
223613138|NCT01288989|BIOLOGICAL|IMC-3C5|Escalating doses of IMC-3C5 administered intravenously (i.v.), weekly or every other week
223613139|NCT05940701|COMBINATION_PRODUCT|Curasept Biosmalto Mousse and toothpaste|at each visit a Curasept Biosmalto Mousse will be applied on the facial surface of the maxillary and mandibular anterior teeth using a tray.
223613140|NCT05940701|OTHER|Colgate toothpaste|The control group will receive a fluoridated toothpaste (Colgate toothpaste)
223613141|NCT06087484|BEHAVIORAL|Mindfulness Intervention for Emotional Distress and Insomnia (MIED-I)|The MIED-I program integrates the rationales and practices from the Unified Protocol for Treatment of Emotional Disorders (UP) and Mindfulness based Interventions. Formal mindfulness exercises (e.g., body scan, mindful breathing, and mindful stretching) and informal mindfulness practices (e.g., mindful tooth brushing) were adapted from Mindfulness based intervention (MBIs).Also, a portion of the CBT-I will be added to the course to provide psychoeducation for insomnia. Variables that have been shown to be effective in interventions for insomnia in past studies, such as awareness, non-responsiveness, and self-compassion, will also be added to better alleviate insomnia symptoms
223613142|NCT00762047|DEVICE|Durasphere FI|Durasphere Injection
223613143|NCT00762047|DEVICE|Sham|Sham injection with anesthesia
223613144|NCT04321070|DRUG|Clindamycin Phosphate|A thin film of investigation product will be applied to the affected areas of the face once daily
223613145|NCT04321070|DRUG|Clindamycin Phosphate RLD|A thin film of investigation product will be applied to the affected areas of the face once daily
223613146|NCT04321070|DRUG|Placebos|A thin film of investigation product will be applied to the affected areas of the face once daily
223613147|NCT05065788|OTHER|data collection|data collection
224312032|NCT01269541|DRUG|Rifampin+Clindamycine or Trimehoprimsulfa|Rifampicin 10 mg/kgx1xVII Clindamycine 300 mgx3 Trimethoprimsulfa 400mg/80mg 2x2
223613148|NCT06189924|DIAGNOSTIC_TEST|Proteomic analysis of exhaled breath condensate|Mechanically ventilated intensive care patients will be sampled for exhaled breath condensate from the ventilator circuit.
223613149|NCT04712370|PROCEDURE|Conventional caudal block|Patients of this group will receive (0.5ml/kg) (plain bupivacaine 0.25% injected in the caudal epidural space) by the conventional method (blind technique without ultrasound).
223613150|NCT04712370|PROCEDURE|Ultrasound-guided caudal block|Using ultrasound, patients of this group will receive (0.5ml/kg) (plain bupivacaine 0.25% injected in the caudal epidural space).
223613151|NCT04712370|PROCEDURE|Ultrasound guided erector spinae plane Block|Under ultrasound guidance, patients of this group will receive (0.5ml/kg) (plain bupivacaine 0.25% injected beneath the erector spinae muscle sheath) at the level of the transverse process of the second lumbar vertebrae(L2).
223613152|NCT03602365|DEVICE|Gentle Jogger (GJ)|Gentle jogger is a passive jogging device which passively moves the feet up and down simulating jogging
223613153|NCT04924595|BEHAVIORAL|Personalised exercise|Personalised exercise intervention including aerobic and resistance training
223613154|NCT06357039|DEVICE|Sleep tracking device|In addition to polysomnography, a device containing EEG+PPG sensors for sleep classification was placed on the forehead, and another device containing PPG and accelerometer sensors was placed on the wrist. The wrist to which the device is attached is randomly assigned.
223759187|NCT05626036|DEVICE|Arthrex Tightrope|High-tensile strength suture syndesmosis repair
223759188|NCT05626036|DEVICE|Synthes Fibulink|High-tensile strength suture syndesmosis repair
223759189|NCT00283660|DIETARY_SUPPLEMENT|10 mg zinc oxide|10 mg zinc oxide
223759190|NCT00283660|OTHER|Placebo|Placebo pill taken five days a week for six months.
223759191|NCT00001368|PROCEDURE|cytokine and leukocyte activation profile|
223759192|NCT06000878|OTHER|first aid e-book|interactive first aid e-book interventions
223759193|NCT04884516|DIETARY_SUPPLEMENT|Retinol gummy|Participants take one retinol gummy per day
224075440|NCT06221020|BEHAVIORAL|Short Form-36|The Short Form-36 (SF-36) is a widely used health assessment tool, extensively applied in both research and clinical practice. It is a concise yet comprehensive questionnaire designed to evaluate individuals' health status and quality of life. The SF-36 covers eight different dimensions of health, including physical functioning, bodily pain, general health, vitality, social functioning, emotional health, mental health, and health change. Each dimension is assessed through a series of questions that address aspects such as an individual's capabilities in daily life, symptoms, and emotional states. The SF-36 allows healthcare professionals and researchers to gain insights into a person's health and quality of life across these varied aspects. Additionally, SF-36 has undergone extensive testing and validation, proving to have good reliability and validity.
224312033|NCT02687217|DRUG|oxygen|"Hyperoxygenation ≥50% of oxygen by mask(non-rebreathing) was given through out the surgery.~Received 6L/min of oxygen through venturimask upto 2 hours in post operative period.~Hyperoxygenation refers to provision of ≥50% of oxygen by mask(non-rebreathing) through out the surgery."
223613155|NCT00679835|DRUG|daptomycin|i.v. daptomycin given at 8 mg/kg or 10 mg/kg by a one or two hour infusion.
223613156|NCT00991653|PROCEDURE|Fasting blood sample.|Fasting blood sample taken following informed consent for genotyping, glucose and insulin levels.
223613157|NCT03104179|DEVICE|Cytosorb Adsorber|Cytokine adsorption during CPB
223613158|NCT04203836|DRUG|LEO 152020 Tablet|film-coated tablet
223613159|NCT03946748|DRUG|REGN3918|Single intravenous (IV) dose, then a subcutaneous (SC) dose once weekly (QW).
224312034|NCT00074828|DRUG|LY517717|
224312035|NCT00074828|DRUG|enoxaparin|
224314288|NCT00127218|DRUG|any statin|Participants will be provided a prescription for fluvastatin 80 mg to be taken on a daily basis, or they may continue their ongoing or any other cholesterol-lowering drugs such as pravastatin 80 mg daily, simvastatin 20 mg daily, atorvastatin up to 20 mg daily or rosuvastatin up to 20 mg daily for 18 months
223613160|NCT00178568|BEHAVIORAL|Stress Management and Healthy Sleep Practices|Eight weekly sessions of 1 hour each reviewing stress management techniques and tips for improving sleep.
223613161|NCT00165672|DRUG|RABEPRAZOLE SODIUM|rabeprazole sodium 5 mg: once daily orally for 4 weeks
223613162|NCT00165672|DRUG|RABEPRAZOLE SODIUM|rabeprazole sodium 10 mg: once daily orally for 4 weeks
223613163|NCT06310616|DRUG|VH4524184|VH4524184 will be administered.
223759194|NCT03460184|DIAGNOSTIC_TEST|G.A Group A:|"G.A will be conducted After pre-oxygenation for 3-5 minutes. thiopental (5 mg/kg) will be administered I.V, followed by succinylcholine 1.5 mg/kg. After tracheal intubation, the patients will be ventilated with 100% oxygen. isoflurane 0.8% will be added, to maintain the anesthesia. Further neuromuscular block will be maintained by using atracurium . After delivery of the fetus, fentanyl IV will be given 1ug/kg as analgesia and 20 IU oxytocin will be given by I.V infusion .Reverse neuromuscular blockade as necessary at completion of surgery. Extubate when the patient is awake~In the sitting position and after complete asepsis , 2-3 ml of Lidocaine will be injected subcutaneously, spinal anesthesia will be performed at interspace L3-4 or L4-5, midline approaches using 22 guage Quinke needle . 2.5 ml of hyperbaric bupivacaine 0.5% in addition to 25 μg fentanyl will be injected into the subarachnoid space after successful dural puncture and confirmation by barbotage."
223759195|NCT03675958|OTHER|Johnstone's Pressure Splint|the intervention consists in the application of two tools used for the treatment of spasticity post - CVD. Johnstone's Pressure Splint added Stretching
223759196|NCT03675958|OTHER|Stretching|the intervention consists in the application of one tool used for the treatment of spasticity post - CVD. Just Stretching
223613164|NCT06310616|DRUG|Loestrin|Loestrin will be administered.
223613165|NCT05950698|DEVICE|Holter Faros 360° EKG (Bittium Corporation)|Patients will lie down on the examination table, a five-lead ECG will be attached to their chest, and they should rest for 5 minutes before starting the ECG recording. ECG data will be collected for a 15-minute period Heart Rate Variability (HRV) recording will be performed between 09:00 and 12:00 in a fixed examination room to minimize environmental factors and diurnal fluctuations in autonomic nervous system functioning.
223759197|NCT02177240|DEVICE|GlideScope® intubation with Flex-it® stylet|GlideScope® intubation with Flex-it® stylet of a simulated difficult airway
223759198|NCT02177240|DEVICE|GlideScope® intubation with GRS® stylet|GlideScope® intubation with GRS® stylet of a simulated difficult airway
224201492|NCT02294565|DRUG|VST-1001|Single-dose injection (peritumoral, periareolar, and/or intradermal) of VST-1001 administered pre-SLNB procedure; VST-1001 is used with medical devices (blue-light LED illuminator and blue-light filtering eyewear) for lymphatic mapping and localization of lymph nodes during a SLNB procedure.
224314289|NCT00127218|DRUG|niacin|long-acting niacin daily for 18 months
224314290|NCT00127218|DRUG|Placebo|matching placebo pill daily for 18 months
223613166|NCT05950698|DIAGNOSTIC_TEST|Beck Depression Inventory (BDI)|The BDI assesses the depression severity. It will be administered before bariatric surgery at time T0 and 3-6-12-24 months after bariatric surgery (T1-T2-T3-T4).
223613167|NCT05950698|DIAGNOSTIC_TEST|Hospital Anxiety and Depression Scales - HADS|The HADS assesses the anxiety and depression symptoms. It will be administered before bariatric surgery at time T0 and 3-6-12-24 months after bariatric surgery (T1-T2-T3-T4).
223613168|NCT05950698|DIAGNOSTIC_TEST|Three Factor Eating Questionnaire-R21 - TFEQ-R21|The TFEQ-R21assesses the quality of eating behavior. It will be administered before bariatric surgery at time T0 and 3-6-12-24 months after bariatric surgery (T1-T2-T3-T4).
223613169|NCT05950698|DIAGNOSTIC_TEST|hort-Form Health Survey-36 itens - SF-36|he TFEQ-R21assesses the quality of life Divided into different areas (functional capacity, general health status, pain, vitality, social aspects, emotional aspects, and mental health). It will be administered before bariatric surgery at time T0 and 3-6-12-24 months after bariatric surgery (T1-T2-T3-T4).
223613170|NCT03449719|RADIATION|SBRT - Ablative radiation Therapy|"The current phase II randomized trial,Ablative Radiation Therapy in patients with Oligometastatic castration resistant prostate cancer (ARTO trial) aims to evaluate the difference in PSA response rate between the experimental arm (AA+SBRT) and control arm (AA) in metastatic castration-resistant prostate cancer patients."
223613171|NCT03449719|DRUG|Abiraterone Acetate|systemic treatment with abiraterone acetate 1000 mg daily and prednisone 10 mg daily, plus GnRH agonist or antagonist
223613172|NCT00213499|PROCEDURE|non invasive ventilation|
223613173|NCT05112562|BEHAVIORAL|Computerized attentional bias modification training|In intervention is designed to train participants to disengage attention from potent e-cigarette cues and is based on the well-established attention retraining paradigm for other psychopathologies.
223613174|NCT05112562|BEHAVIORAL|Placebo attention control training|This control training is very similar to the intervention's overall task structure and stimuli. The only difference is that the this control program is designed to exert no systematic manipulation on the attention deployment pattern between the two stimulus categories, thereby yielding no significant impact on the level of attentional bas toward ENDS-related cues
223613175|NCT00306085|GENETIC|Autologous bone marrow cells|
223613176|NCT00306553|BIOLOGICAL|CYT004-MelQbG10|
223759199|NCT01305031|OTHER|Resuscitation|Use of inspiratory fraction of oxygen needed to achieve oxygen saturation in the preset limits 85-92%
224201493|NCT02294565|DRUG|99mTc-labeled sulfur colloid|Single-dose injection (peritumoral, periareolar, intradermal, and/or subdermal) of 99mTc-labeled sulfur colloid administered per standard of care; the radioactivity of the radioactive colloid is detected with a gamma probe per standard of care.
224201494|NCT05647395|BEHAVIORAL|Tracheal tube cuffs differ in deflation|When removing the endotracheal tube, the gas in the cuff is drawn at a uniform and slow pace
224201495|NCT00795379|BEHAVIORAL|Interoceptive Exposure|Exposure to internal stimuli.
224201496|NCT01783860|DRUG|Azithromycin|
224201497|NCT01783860|DRUG|Doxycycline|
224201498|NCT01742390|DRUG|Aripiprazole|Plateau switch to aripiprazole (ARI) from risperidone (RIS) or paliperidone (PALI)
223613177|NCT04219241|BIOLOGICAL|Cellavita-HD|The participants will receive a total of 12 intravenous administrations of 2x10\^6 cells/weight range divided into three administrations per cycle. Each administration will occur every 30 days and cycles every 180 days (total of 4 cycles).
223613178|NCT06500117|OTHER|eMind application|learning phase accompanied by application for 8 weeks, then independent practical application phases
223613179|NCT06500117|OTHER|questionnaires|"Visual Analogue Scale VAS (craving) and Mobile Application Rating Scale MARS-F"
223613180|NCT06500117|OTHER|focus groupe|Patients who so wish will be able to give us more detailed feedback on the application. The focus groups will be carried out between visit 3 and visit 4.
223613181|NCT06454383|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223613182|NCT06454383|DRUG|Cholestyramine|Given PO
223613183|NCT06454383|PROCEDURE|Computed Tomography|Undergo CT
223613184|NCT06454383|PROCEDURE|Diagnostic Imaging|Undergo imaging scans
223613185|NCT06454383|DRUG|Gemcitabine|Given IV
223613186|NCT06454383|DRUG|Leflunomide|Given PO
224201499|NCT01742390|DRUG|risperidone or paliperidone|
224201500|NCT05153655|PROCEDURE|Local ischemic post-conditioning|"Direct local ischemic post-conditioning will be applied after successful recanalization of the culprit middle cerebral artery. Local ischemic post-conditioning consists of briefly repeated 4 cycles of occlusion and reperfusion (equal duration) of the initially occluded culprit middle cerebral artery using a balloon. The schedule of advancing duration is 0  1  2  3  4  5 min."
224201501|NCT00256217|DRUG|Anastrozole|1 mg. oral every day for 2 - 4 weeks
224201502|NCT01832896|DRUG|Ecallantide subcutaneous dosing|For acute attacks of Hereditary Angioedema in children and adolescents, Ecallantide will be administered.
224201503|NCT03184402|DRUG|DWJ1252|tablet
224201504|NCT03184402|DRUG|Gasmotin|tablet
224201505|NCT03184402|DRUG|Placebo of Gasmotin|tablet
224201506|NCT03184402|DRUG|Placebo of DWJ1252|tablet
224201507|NCT03474952|PROCEDURE|remote ischemic preconditioning (RIPC)|remote ischemic preconditioning consists of 4 cycles of 5-min ischemia and subsequent 5-min reperfusion using pneumatic cuff applied to upper arm
224201508|NCT03474952|PROCEDURE|sham-RIPC|ischemia pressure less than 10 mmHg (sham-RIPC)
224201509|NCT04852185|BIOLOGICAL|Vi-TT|Single-dose V-TT administered to children and adolescents between the ages of 9 months to 15 years.
224201510|NCT04852185|BIOLOGICAL|MCV-A vaccine|Single-dose of MCV-A vaccine (a meningococcal vaccine)
224201511|NCT01179256|DIETARY_SUPPLEMENT|CURCUMIN|oral supplementation of curcumin 2000mg
224201512|NCT01179256|OTHER|no intervention other than stopping study|no intervention other than stopping study
224201513|NCT04700592|OTHER|Gabapentin versus Ketamine|A Comparison of Gabapentin and Ketamine in Acute and Chronic Pain
224201514|NCT04907916|OTHER|SIRTUIN1|The NAD dependent deacetylase activity of Sirtuin1
224201515|NCT00858611|DRUG|VRC-FLUDNA047-00-VP|
224201516|NCT00858611|DRUG|Flulaval (Registered) Seasonal Influenza Vaccine|
223613187|NCT06454383|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223613188|NCT02053090|BEHAVIORAL|Group Education and Stretching|
223613189|NCT02053090|PROCEDURE|Group Acupuncture|
223613190|NCT06823908|OTHER|Reuse of surgical waste|Heathly donnors will be received in the plastic surgery department as part of routine care. They will be informed of the study and their surgical waste (adipose tissue) will be recovered specifically for this research.
223613191|NCT06823908|OTHER|Reuse of biological samples|Patients included in the cellcordes 2 trial who have given their consent for the re-use of their biological samples (Stromal Vascular Fraction) in other clinical research projects, and who have been informed of the cellcordes bio study.
223613192|NCT06281925|DEVICE|Cryotherapy Gloves|All patients in the intervention group will receive cryotherapy with cold packs enclosed in a fabric envelope (gloves). The fabric envelope (gloves) will be patient specific.
223613193|NCT02784171|DRUG|Cisplatin|
223613194|NCT02784171|DRUG|Pemetrexed|
223613195|NCT02784171|DRUG|Pembrolizumab|
223613196|NCT05416879|DEVICE|Actigraph GT3X+BT|7 day monitoring of physical activity, sedentary behaviour and sleep using the Actigraph GT3X+BT
223613197|NCT03842033|BEHAVIORAL|PEAKmAAP|"The PEAKmAAP group will use a mobile app that will help manage asthma."
223613198|NCT03842033|BEHAVIORAL|PEAKmAAP-DS|This group will use the mobile app to help manage asthma. the primary care provider will receive monthly reports to help him/her know how the participants asthma symptoms are over time.
223613199|NCT03842033|BEHAVIORAL|NutriMap Usual Care|This group will use a non-asthma related app daily to record their daily intake of fruits and vegetables.
223613200|NCT04290897|DRUG|Anhydrous Enol-oxaloacetate|Given PO
223613201|NCT04290897|OTHER|Questionnaire Administration|Ancillary studies
223759200|NCT01305031|OTHER|100% oxygen|Use of 100% oxygen needed to achieve oxygen saturation in the preset limits 85-92%
223759201|NCT00574405|DRUG|MDI (split-mix NPH insulin + regular insulin or Lantus + Novolog® [or Humalog®])|MDI = 3-4+ insulin injections/day, using NPH + regular insulin or Lantus + insulin lispro; 12 month treatment duration.
223759202|NCT00574405|DEVICE|CSII (Animas Corporation insulin pump, model IR 1200)|CSII (insulin pump), using Animas Corporation insulin pump, model IR 1200.
223759203|NCT02049489|BIOLOGICAL|ICT-121 DC vaccine|autologous dendritic cells pulsed with peptide antigens
224201517|NCT00417820|DRUG|BCT194|
224201518|NCT00244881|DRUG|cediranib maleate|Given orally
224201519|NCT00244881|OTHER|laboratory biomarker analysis|Correlative studies
224201520|NCT04819932|DRUG|DWJ1451|DWC202008 DWC202009
224201521|NCT05474794|DIAGNOSTIC_TEST|DFI-EUS|"All patients enrolled having a confirmed histologic diagnosis of GIST or leiomyoma will undergo endoscopic ultrasound evaluation.~First, the expert endoscopist will perform EUS-DFI examination for the detection of slow flow vascularization in SELS. Microvascularization EUS-Doppler evaluation will last between three and five minutes."
224201522|NCT05474794|DIAGNOSTIC_TEST|CE-EUS|"Immediately, after the first approach, CE-EUS (using Sulphur hexafluoride ultrasound contrast agent) will be performed for diagnosis confirmation. Sonovue will be administered intravenously in one (2.4 mL) or two administrations (4.8 ml), according to physician´s criteria, followed by an injected flush of 5 mL of sodium chloride solution (9 mg/mL).~CE-EUS it will take around 5 minutes, with a total diagnostic approach around one hour."
224201523|NCT02467972|DIETARY_SUPPLEMENT|Ready-to-eat frozen soups added unripe banana flour|Ready-to-eat frozen soups added unripe banana flour (18 portions; 3 times/week)
223613202|NCT06431633|DRUG|Zimberelimab|"Zimberelimab is a fully human IgG4 monoclonal antibody targeting human PD-1. PD-1 is a type I transmembrane protein that is part of the immunoglobulin gene superfamily and the CD28 family of cell surface receptors. PD-1 is an inhibitory immune checkpoint protein that is expressed on activated B cells, T cells, and myeloid cells, and it plays a key role in limiting the activity of effector T cells.~Zimberelimab is formulated at 30 mg/mL in a buffer solution containing histidine/histidine-HCl buffer solution, sucrose, sodium chloride, and polysorbate 80, at pH 5.5. The investigational product is supplied as a vial contains 120 mg of active Zimberelimab at a concentration of 30mg/mL.~No premedication nor profilaxis is needed before Zimberelimab administration. Zimberelimab doses are administered by IV infusion over 60 minutes, followed by a 30- to 60-minute observation period, on D1 of each 21-day cycle."
223613203|NCT06431633|DRUG|Sacituzumab govitecan|"Sacituzumab govitecan (SG) is an ADC composed of the following 3 components:~o The humanized monoclonal antibody hRS7 IgG1κ, which binds to Trop-2, a transmembrane calcium signal transducer that is overexpressed in many epithelial cancers.~o The camptothecin-derived agent SN-38, a topoisomerase I inhibitor. o A hydrolyzable linker, with the company designation as CL2A that links the humanized monoclonal antibody to SN-38.~Sacituzumab govitecan is approved globally for the treatment of unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) and HR+ breast cancer."
223613204|NCT06431633|DRUG|Cisplatin|"Cisplatin-based adjuvant chemotherapy~Cisplatin - CAS 15663-27-1, is a platinum coordination complex with potent anti-neoplastic activity. Induces apoptosis in cancer cells, possibly via caspase-3 activation."
223613205|NCT06431633|DRUG|Carboplatin|Cisplatin-based adjuvant chemotherapy Structure: The cis-diamino (cyclobutane-1, 1 dicarboxylate) plating. Stability: 24 hours at ambient temperature in 5% glucose, glucosamine or physiologic saline. It is recommended not to dilute with chlorinated solutions for this could affect the carboplatin. Route of administration: Intravenous infusion. Guidelines of Carboplatin administration: According to the standard of each center. Other Name: ATC code: L01XA02
223759204|NCT03734120|OTHER|cryopreservation|Samples were frozen with a programmable freezing unit. Each semen sample was divided into two aliquots. One aliquot was plunged into liquid nitrogen and the other was stored in dry-phase nitrogen for 3 or 6 month. Thawing was performed at room temperature
223613207|NCT06308666|DEVICE|Delefilcon A contact lenses|Daily disposable silicone hydrogel contact lenses indicated for the optical correction of myopia and hyperopia
223613208|NCT01748097|DRUG|sodium bicarbonate 4.2%|
223613209|NCT06624163|BEHAVIORAL|OHWL Clinic Activities (Standard of Care)|Following a directed history and physical at the initial visit, the OHWL Care provider (OCP) develops a medical and weight management plan, which includes laboratory testing (such as for Hemoglobin A1C (HbA1c), consultant referrals (e.g. sleep, heart failure clinics) and referral to nutritionists and physical therapy (PT). The OCP begins the process of establishing patient goals, which will be followed up by the coach. The OCP reviews patient progress with the goals during face-to-face visits (some by telehealth) at two, four and six months. As part of the standard initial clinic evaluation, a medical assistant evaluates grip strength (using a hand dynamometer) the timed up and go mobility test; these are repeated at the 6-month visit.
223613210|NCT06624163|BEHAVIORAL|Coach Activities|A patient coach follows patients outside of clinic to ensure adherence with referral appointments and use of recommended community services. The coach assesses the participant at baseline, 3 months, and 6 months using the Patient-Specific Functional Scale and follows up with patients via phone over 6 months. The coach utilizes S.M.A.R.T. (Specific, Measurable, Achievable, Relevant, Time-bound) goals to facilitate, for example, transportation, barriers to scheduling, etc. The coach follows up on specialist referral recommendations, physical therapy, and nutrition program, as well as social work recommendations. Barriers and facilitators to program adherence are identified and addressed.
224201524|NCT02467972|DIETARY_SUPPLEMENT|Ready-to-eat frozen soups added maltodextrin|Ready-to-eat frozen soups added maltodextrin (18 portions; 3 times/week)
224201525|NCT02467972|DIETARY_SUPPLEMENT|Ready-to-eat frozen soups added inulin|Ready-to-eat frozen soups added inulin (18 portions; 3 times/week)
223613214|NCT04965688|DRUG|Biopsy-Guided Therapy Selection|"All enrolled participants will undergo a tumor biopsy, which will be analyzed for genomic and transcriptomic alterations using FoundationOne (DNA) and Fulgent (RNA). Based on the genomic findings, participants will receive one of the following therapy standard-of-care treatment options:~PI3K inhibitor + anti-estrogen therapy ( alpelisib + fulvestrant)~MTOR inhibitor + anti-estrogen therapy (everolimus + exemestane)~Anti-estrogen therapy alone (fulvestrant monotherapy)~Cytotoxic chemotherapy (capecitabine)"
223613215|NCT05864586|BEHAVIORAL|Vaping study EC A|Vaping two puffs using the study EC device
223613216|NCT05864586|BEHAVIORAL|Vaping study EC B|Vaping two puffs using the study EC device
223613217|NCT05864586|BEHAVIORAL|Vaping study EC C|Vaping two puffs using the study EC device
223613218|NCT05864586|BEHAVIORAL|Vaping study EC D|Vaping two puffs using the study EC device
223613219|NCT05864586|BEHAVIORAL|Vaping study EC E|Vaping two puffs using the study EC device
223613220|NCT05864586|BEHAVIORAL|Vaping study EC F|Vaping two puffs using the study EC device
223613221|NCT05864586|BEHAVIORAL|Vaping study EC G|Vaping two puffs using the study EC device
223613222|NCT05864586|BEHAVIORAL|Vaping study EC H|Vaping two puffs using the study EC device
223613223|NCT05864586|BEHAVIORAL|Vaping study EC I|Vaping two puffs using the study EC device
223613224|NCT05864586|BEHAVIORAL|Vaping study EC J|Vaping two puffs using the study EC device
223613225|NCT04215809|DRUG|Lisaftoclax|Lisaftoclax investigation drug in ramp up dosing
223613226|NCT06848348|DRUG|Halneuron|Halneuron for Subcutaneous Injection
223613227|NCT06848348|DRUG|Placebo|Placebo for Subcutaneous Injection
223613228|NCT05044962|DRUG|Cabotegravir/ Rilpivirine|"For initial injection participants will be given CABENUVA 600-mg/900-mg Kit: (single-dose vial of 600 mg/3 mL (200 mg/mL) cabotegravir , single-dose vial of 900 mg/3 mL (300 mg/mL) rilpivirin).~For subsequent injections participants will be given CABENUVA 400-mg/600-mg Kit: (single-dose vial of 400 mg/2 mL (200 mg/mL) cabotegravir, single-dose vial of 600 mg/2 mL (300 mg/mL) rilpivirine)~CABENUVA® is owned by or licensed to the ViiV Healthcare group of companies, GlaxoSmithKline Research Triangle Park, NC 27709"
223613229|NCT05044962|DRUG|Etonogestrel (ETG) implant|Contraceptive progestin implants are thin rods inserted under the skin of a woman's arm
223613230|NCT05044962|DRUG|Intramuscular depo-medroxyprogesterone acetate (IM DMPA)|DMPA (150 mg of depo-medroxyprogesterone acetate (MPA)/ml IMI) is the most commonly used injectable contraceptive worldwide
223613231|NCT05044962|DRUG|Levonorgestrel|Contraceptive estrogen implants are thin rods inserted under the skin of a woman's arm
223759205|NCT06107491|OTHER|Preoperative educational videos plus routine education|Mothers receiving routine education plus digital video disk before their children receiving congenital heart disease surgery. The content was the same as the routine education but was presented audio-visually, and the video was easy to understand by the general public.
223759206|NCT06107491|OTHER|Preoperative routine education|Mothers receiving routine education before their children receiving congenital heart disease surgery
223759207|NCT00802217|DRUG|Civamide|5 mg liquid filled softgel capsules
223759208|NCT00802217|DRUG|Civamide|5 mg x 2 liquid softgel capsules
223759209|NCT05402527|DIETARY_SUPPLEMENT|Fish nutrients|Intake of fish protein, omega-3 fatty acids, and vitamin D
223759210|NCT05402527|DIETARY_SUPPLEMENT|Whey protein|Intake of whey protein
223759211|NCT05402527|DIETARY_SUPPLEMENT|Maltodextrin|Intake of maltodextrin
223759212|NCT00405574|DRUG|ATN-224|ATN-224 high dose: 300mg ATN-224 low dose: 30mg
223759213|NCT02828839|PROCEDURE|Access needle|The primary purpose of the single-use disposable access needle is to guide the use of a biopsy gun to obtain a tissue sample from the patient's prostate gland through a percutaneous puncture of the perineum. The primary purpose of the disposable needle guide is to stabilize the needle biopsy and better approximate the most direct path to the prostate.
223759214|NCT05361044|BIOLOGICAL|Blood samples Donnor|Additional samples will be preleved in the Normothermic Regional Reperfusion at 30 min, and blood sample will be collected at the end of the Normothermic Regional Reperfusion (4 samples of 5ml).
223759215|NCT01336738|DRUG|Placebo|Tablets (n=6), 0 mg, once daily for 84 days
223759216|NCT01336738|DRUG|150 mg PF-04991532|Tablets (n=1), 150 mg + tablets (n=5), 0 mg, all once daily for 84 days
223759217|NCT01336738|DRUG|450 mg PF-04991532|Tablets (n=3), 150 mg + tablets (n=3), 0 mg, all once daily for 84 days
223759218|NCT01336738|DRUG|750 mg PF-04991532|Tablets (n=5), 150 mg + tablets (n=1), 0 mg, all once daily for 84 days
223759219|NCT01336738|DRUG|Sitagliptin 100 mg|Tablets (n=1), 100 mg strength + tablets (n=5), 0 mg, all once daily for 84 days
223759220|NCT06476223|DRUG|Artificial saliva containing cumin and ginger extract|The sample will be sprayed 2 puff/time, 3 times/day, for 14 days.
223759221|NCT06476223|DRUG|Placebo|The sample will be sprayed 2 puff/time, 3 times/day, for 14 days.
224201526|NCT02467972|DIETARY_SUPPLEMENT|Ready-to-eat frozen soups added nisin|Ready-to-eat frozen soups added nisin (18 portions; 3 times/week)
223613232|NCT05044962|DRUG|NNRTI, PI, or INSTI-containing 1st or 2nd line ART regimens|ART that concurrently contains combinations of non-nucleoside reverse transcriptase inhibitors (NNRTIs), such as efavirenz, and protease-inhibitors (PIs), such as atazanavir/ritonavir or lopinavir/ritonavir, or integrase inhibitors (INSTIs), such as raltegravir or dolutegravir
223613233|NCT03151733|PROCEDURE|single incision laparoscopic surgery|Patients undergo single incision laparoscopic surgery
223613234|NCT03151733|PROCEDURE|conventional laparoscopic surgery|Patients undergo conventional laparoscopic surgery
223613235|NCT05628103|DRUG|SEP-363856|SEP-363856 will be flexibly dosed for 8 weeks.
223613236|NCT05003674|DEVICE|Focused stimulation strategy|Investigational focused stimulation strategy
223613237|NCT05003674|DEVICE|ACE stimulation strategy|Standard of care stimulation strategy
223613238|NCT02313584|DRUG|dabigatran|
223613239|NCT02313584|DRUG|placebo|
223613240|NCT01458483|DEVICE|Baroreceptor Stimulation|The stimulation catheter may be placed in different locations within the IJV at the level of the cervical spine vertebrae. Stimulation amplitudes will be varied from 0.1 mA to 20 mA.
223613241|NCT01564563|DRUG|standard therapy|Standard treatment of bleeding
223613242|NCT01564563|DRUG|placebo|Placebo
223613243|NCT01564563|DRUG|activated recombinant human factor VII|Two days repeated treatment regimen - low dose administered i.v. (into the vein)
223613244|NCT01564563|DRUG|activated recombinant human factor VII|Two days repeated treatment regimen - high dose administered i.v. (into the vein)
223759222|NCT06285539|DRUG|Filgotinib|Filgotinib
223759223|NCT05492084|OTHER|without Intervention|without Intervention
223759224|NCT05567991|BEHAVIORAL|Comprehensive Mindulness-Based Intervention (C-MBI)|C-MBI, was administer online via Zoom and included: 10 Integral Meditation classes lasting approximately 35 minutes each, given twice a week (Monday and Wednesday); 10 minutes of yoga exercises focused on breathing and posture before each IM class; and dietary advice. Regarding this latter, the participants received via email a document which entailed non-mandatory dietary suggestions to promote healthy nutrition, sleep and stress-relief. An online lecture held by the nutritionist with a question-and-answer format was also organized. The degree to which to follow this advice was left to the discretion of each participant. The core of our intervention was represented by the IM training, that is a MBI intervention, that simultaneously uses breathing, focusing attention, releasing of physical tensions, thoughts and feeling sensations through internal senses and imagery, allowing a quick relaxation and more deeply a physical, energetic, and spiritual well-being.
223759225|NCT03003520|DRUG|Durvalumab|"Durvalumab was supplied in single use vials as a liquid solution containing 500 mg (nominal) of durvalumab at a concentration of 50 mg/mL to be infused by intravenous (IV) injection.~Day 1 of each treatment cycle (Induction Period and Consolidation Period) started with the administration of IV durvalumab followed by a 2-hour observation period post infusion."
223759226|NCT03003520|DRUG|Rituximab|Subsequent to durvalumab infusion, rituximab was administered by IV. Rituximab administration could be split over 2 consecutive days according to local clinical practice. Rapid infusion of rituximab was not allowed in this clinical study.
224201527|NCT01102972|DRUG|Reyataz + Norvir + Truvada|atazanavir 300mg + ritonavir 100mg + tenofovir 300mg/emtricitabine 200mg
224201528|NCT01102972|DRUG|Reyataz + Epzicom|atazanavir 400mg + abacavir 600mg/lamivudine 300mg
223613245|NCT04366440|BEHAVIORAL|Order set review and modification with facilitation|The antimicrobial stewardship program will receive facilitation training to aid in reviewing and changing order sets of clean or clean-contaminated procedures to eliminate unnecessary post-operative antibiotics.
223613246|NCT04366440|OTHER|Order set review and modification|The antimicrobial stewardship program will work to eliminate unnecessary post-operative antibiotics by reviewing and changing order sets of clean or clean-contaminated procedures.
223613247|NCT04000061|OTHER|medical chart review|data generated by medical review include Medical history, Medications at presentation, during hospitalization and at discharge, New York Heart Association (NYHA) class, Killip class, Electrocardiographic (ECG) data, echocardiographic data, Interventions (Percutaneous Coronary Intervention (PCI), Coronary Artery Bypass Graft (CABG), Implantable Cardioverter Defibrillator (ICD) implantation, Cardiac Resynchronization Therapy (CRT) Implantation), Outcome Information: all-cause death, HF hospitalizations
223613248|NCT04000061|OTHER|data generated by direct IT export|data generated by direct IT export include Anthropometric data (age, sex, height, weight), Vital signs, Laboratory data
223613249|NCT05421013|DRUG|STP705|STP705 targets TGFB-1 and COX-2 mRNA respectively.
223613250|NCT04485416|DRUG|Eltrombopag|Eltrombopag is an orally administered small-molecule nonpeptide TPO-R agonist.
223613251|NCT07009509|BEHAVIORAL|YES-CAN! program|Youth Engaged Strategies to Change Adolescent Norms
223613252|NCT03471143|DRUG|adrabetadex (2-Hydroxypropyl-Beta-Cyclodextrin)|"VTS-270 (2-Hydroxypropyl-Beta-Cyclodextrin) will be administered intravenously to specifically target liver disease. In the first phase of the study, dosing frequency will be twice a week with IV adrabetadex (VTS-270) for six weeks for a total of 12 administrations. Subjects will be evaluated at each study visit for evidence of adverse effects.~Doses to be studied are 500, and 1000 mg/kg. Six subjects will be studied at each dose level. Cohort 1: Subjects 1-6, 500 mg/kg Cohort 2: Subjects 7-12, 1000 mg/kg"
223613253|NCT04664634|DEVICE|Aria Sensor|The Aria sensor is a wearable patch that continuously monitors physiological signals and provides vibratory haptic cues to increase swallow frequency. The intervention consists of using the sensor over a 3-week period, with active haptic cueing during Week 2 only.
223613254|NCT06726421|RADIATION|Stereotactic body radiotherapy (SBRT)|The preferred treatment plan is SBRT with a fraction dose ≥7 Gy. The prescription dose should ensure a BED of no less than 115. Radiotherapy is usually delivered daily, every other day, or other interval decided by treating radiation oncologist.
223613255|NCT06726421|DRUG|axitinib ± immune checkpoint inhibitors (ICIs), lenvatinib ± ICIs, cabozantinib ± ICIs, sunitinib and pazopanib|Standard systemic therapy are targeted agents or their combination with immunotherapy recommended by guidelines. This may include axitinib ± immune checkpoint inhibitors (ICIs), lenvatinib ± ICIs, cabozantinib ± ICIs, sunitinib and pazopanib, etc.
223613256|NCT06477419|DRUG|Sacituzumab govitecan-hziy|After enrollment, participants will receive SG until disease progression or intolerable toxicity.
223613257|NCT00293618|DEVICE|Automatic Risk Presentation in the operating room|Automatic calculation and presentation of a patient's individual predicted PONV risk by the anesthesia information management system during the entire procedure
223759227|NCT03003520|DRUG|Doxorubicin|A component of the CHOP therapy administered by IV. CHOP therapy was administered following rituximab.
223759228|NCT03003520|DRUG|Vincristine|A component of the CHOP therapy administered by IV. CHOP therapy was administered following rituximab.
223759229|NCT03003520|DRUG|Cyclophosphamide|A component of the CHOP therapy administered by IV. CHOP therapy was administered following rituximab.
223759230|NCT03003520|DRUG|Prednisone|"Prednisone was administered as an IV infusion or by mouth (PO) on Day 1, followed by PO administration on Days 2-5 of each cycle.~Prednisone could be given prior to other drugs of the CHOP therapy. It was administered after lenalidomide dosing in the R2-CHOP treatment arm."
223759231|NCT03003520|DRUG|Lenalidomide|Lenalidomide was administered orally in capsule form on Days 1-14 of the DUR+R2-CHOP treatment arm only.
223759232|NCT01332149|DRUG|Pregabalin|"Subjects in the pregabalin group will start treatment with pregabalin capsule 150 mg/day for 1 week, then their dose will be increased to 300mg/day. After 1-week titration period, dose must be stable during study, no dose adjustment is permitted, and subject who cannot tolerate 300 mg/day pregabalin will be withdrawn.~At the completion of the dose maintenance phase subjects will taper off study medication over a 1-week period. 300 mg/ day subjects will taper to 150 mg/ day."
223613258|NCT00293618|OTHER|Education|Specific information is provided to the intervention group: about PONV, about the prediction model. While the Usual Care group only receives information about the study purposes
223613259|NCT00293618|OTHER|Feedback|Feedback about the physician's personal performance on prevention of PONV
223613260|NCT00369577|DRUG|Inhaled Placebo|Inhaled Placebo, single dose
223613261|NCT00369577|DRUG|Inhaled Loxapine 5 mg|Inhaled Staccato Loxapine 5 mg, single dose
223613262|NCT00369577|DRUG|Inhaled Loxapine 10 mg|Inhaled Staccato Loxapine 10 mg, single dose
223613263|NCT03471780|DIAGNOSTIC_TEST|ultrasound|Transperineal us are made to pregnant ladies in labour
223613264|NCT02850380|OTHER|"FLIP SWITCHES DOWN IN WEIGHTLESSNESS"|"The circular instrument panel that subjects will see into the cylindrical mask consists of one switch surrounded by a luminous ring (left part of the figure below). The switch can be flipped into any direction within the full 360° range. The switch provides no visual cues about down, but the experimenter can add such cues by means of visually polarized labelling displayed on a circular black screen at the center of the panel (right part the figure below)."
223613265|NCT05761002|BIOLOGICAL|the Quadrivalent Vaccine (Gardasil)|• Intralesional injection of the quadrivalent HPV vaccine (Gardasil) at a dose of 0.5ml, into the largest wart at 4-week intervals until complete clearance is achieved or for a maximum of three sessions.
223759233|NCT01332149|DRUG|Placebo matched with pregabalin|Subject will take placebo matched with pregabalin twice a day.
223759234|NCT06207682|DRUG|Avacopan|Orally via capsules
223759235|NCT06207682|DRUG|Simvastatin|Orally via tablets
223759236|NCT05565287|COMBINATION_PRODUCT|ultra early physiotherapy intervention|"* NBAS / NBO and GMs based guidelines in explaining neonatal signs into the NICU (lasting 15-30 minutes)~* NBAS / NBO and GMs based guidelines in explaining neonatal signs to parents, 1st neonatal assessment and intervention upon hospital discharge (lasting one hour)~* NBAS / NBO and GMs based guidelines in explaining neonatal signs to parents, 1st neonatal assessment and intervention every 15 to 20 days until the 3rd month of life (corrected age)."
223759237|NCT01516190|BEHAVIORAL|Exercise|Supervised exercise sessions and independent exercise
223759238|NCT01516190|BEHAVIORAL|Surgical preparation program|Book, tapes, CD
223759239|NCT04615949|DRUG|Cannabidiol, pharmaceutically produced with < 5 ppm THC|CardiolRx 2.5 mg/kg to 7.5 mg/kg of body weight b.i.d taken orally with food
223759240|NCT04615949|DRUG|Placebo|Placebo 2.5 mg/kg to 7.5 mg/kg of body weight b.i.d taken orally with food
223613266|NCT00352430|DRUG|Nitric Oxide/INP Pulse Delivery|
223613267|NCT00352430|DRUG|Nitric Oxide/INO Pulse Delivery|
223613268|NCT02231684|DRUG|semaglutide|Semaglutide administered subcutaneously (s.c. under the skin) in two out of three different strengths (1mg/mL, 3mg/mL and 10 mg/mL).
224312036|NCT06816758|OTHER|Routine Care for Corrosive Esophagitis|This is an observational study, so participants are not assigned interventions. However, the study investigates the outcomes of patients diagnosed with corrosive esophagitis who received routine clinical care. The exposure of interest includes diagnostic and treatment procedures such as endoscopic evaluation (Zargar classification), proton pump inhibitors, corticosteroid therapy, and surgical interventions for complications like strictures. The outcomes and clinical data collected reflect routine care practices over 26 years.
224312037|NCT03503864|DRUG|Arsenic Trioxide|Arsenic trioxide（ATO） is administered 0.16mg/kg per day over eight hours IV daily for ten days. Patients will receive ATO alone on days 1-2 and combined with conventional induction chemotherapy on days 3-10. Nine cycles at most of ATO-combined chemotherapy were applied in the whole scheme.
224312038|NCT06965738|PROCEDURE|Buccal fat reconstruction|Ipsilateral buccal fat rotation flap for reconstruction of lateral oropharyngectomy defect
224312039|NCT06965738|PROCEDURE|No buccal fat reconstruction|No reconstruction of lateral oropharyngectomy defect
224312040|NCT04521413|DRUG|CFI-402411|CFI-402411 is administered orally once daily. The starting dose is 80 mg/day for escalation arms and the recommended dose for the expansion arms.
223613269|NCT02231684|DRUG|semaglutide|Semaglutide administered subcutaneously (s.c. under the skin) in two out of three different strengths (1mg/mL, 3mg/mL and 10 mg/mL) or intravenously (i.v.) (1mg/mL).
223613270|NCT05551611|OTHER|Playgroup|The mobile game will be sent to the students via a link and the students are allowed to install it on their mobile phones with android and ios operating systems. The internet required for the download was provided by the researcher. For the students who did not have a smart phone in the playgroup, the game would be started from the researcher's phone and the game was played sequentially. All students were allowed to use headphones while playing the game. In order to log in to the game, an account was created on behalf of each student, and the game user name and password were sent to the students by e-mail. It was ensured that they did not communicate with anyone and did not receive help during the game with the supervision of the researcher. Waited until each participant completed the game. Then, the mobile game was deleted from the smartphones of all participants, and the download link was inactive until the research process was completed.
224201529|NCT01218386|DRUG|Estradiol valerate|"Experimental group: estradiol valerate (Progynova, 2x2mg per day, 2mg in the morning, 2mg in the evening), orally, during 6-10 consecutive days from day 25 of the cycle onwards.~Both groups:start rFSH (Puregon®) at a dose of 150 IU GnRH antagonist (Orgalutran®) initiation on D6 of the stimulation."
223613271|NCT05551611|OTHER|Control group|The researcher gave a theoretical lesson through the presentation prepared in the powerpoint program about the birth management of a breech-presented fetus in the classroom as in the traditional education method.
223759241|NCT02722694|DRUG|Subcutaneous(SC) Abatacept|Subjects received 125mg weekly SC abatacept injections for 24 weeks. All subjects who complete 24 weeks double-blind treatment are eligible to enter open label period. During this period, subjects in placebo group will be switched to receive abatacept 125mg administered SC weekly till week 52. Subjects in abatacept group will continue to receive abatacept 125mg weekly.
223759242|NCT02722694|OTHER|Placebo|Subjects received weekly SC placebo injections for 24 weeks
223759243|NCT02722694|DRUG|Methotrexate|All Subjects received backup Methotrexate treatment.
223613272|NCT03250208|DIETARY_SUPPLEMENT|Probiotic|Participants randomized to the intervention group will receive Women's Fem Dophilus ® by Jarrow Formulas.
223613273|NCT03250208|OTHER|Placebo|Participants randomized to the control group will receive a placebo containing no active ingredients
224201530|NCT02024386|DRUG|Riociguat|After completion of first V02 max test at altitude, subjects will have a 3-hour rest period. Riociguat will be administered at the 90-minute mark of this rest period.
224201531|NCT01856257|BIOLOGICAL|Anti-thymocyte Globulin (Rabbit)|The target dosage is 6mg/kg total over 3 to 4 days. The recommended route of administration is intravenous infusion using a high-flow vein.
224201532|NCT01856257|BIOLOGICAL|belatacept|Participants will receive belatacept at a dose of 10mg/kg up on day 1, 5, 14, 28, 56 and 84. After 84 days, subjects will receive a maintenance dose of 5 mg/kg every 4 weeks until completion of the trial.
224312041|NCT04521413|DRUG|Pembrolizumab|Pembrolizumab will be given at its labeled dose and schedule, 200 mg administered as an intravenous infusion over 30 minutes every 3 weeks.
224312042|NCT06416787|DRUG|placebo|IBI355 7.5mg/kg Q4W
224312043|NCT06416787|DRUG|IBI355|IBI355 1mg/kg Q4W
224312044|NCT03504163|DRUG|Pembrolizumab (MK-3475)|Pembrolizumab (MK-3475) will be administered as a 400 mg intravenous (IV) infusion at 6- week intervals for 9 doses over a 48-week.
224312045|NCT03504163|DRUG|Bacillus Calmette-Guérin (BCG)|Intravesical BCG will be administrated once per week over a 6-week period as induction therapy, followed by maintenance BCG consistent with standard clinical practice
224312046|NCT05550532|DRUG|Aticaprant|Aticaprant tablet will be administered orally.
224312047|NCT05550532|OTHER|Placebo|Placebo tablet will be administered orally.
224312048|NCT06243601|BIOLOGICAL|Aloe vera Gel|A fresh aloe vera (Aloe Barbadensis) leaf will be plucked from the plant. The leaf will be washed with normal saline, peeled with scalpel and the inner gel will be blended in a blender to convert it into a watery consistency. The solution will be stored in an autoclaved flask.
224312049|NCT03898908|DRUG|encorafenib|"Encorafenib 75mg and 50mg (capsules) for a 450mg daily for oral administration during 56 days and after local radiation treatment.~If no progression of disease progression (PD) is reported, treatment will continue until PD, unacceptable toxicity or death."
224312050|NCT03898908|DRUG|binimetinib|Binimetinib 15mg (tablets) for a 45mg/12 hours for oral administration during 56 days and after local radiation treatment.
224312051|NCT03898908|RADIATION|Whole brain radiation therapy|"The whole brain planning target volume (PTV) will receive 30 Gy in 10 fractions.~Treatment will be delivered once daily, 5 fractions per week, over 2 to 2.5 weeks."
224314291|NCT03897803|DIAGNOSTIC_TEST|strain elastography|strain elastography as apart of muscle ultrasound examination of the biceps brachii and rectus femoris muscles will be performed to the patients and control groups at baseline evaluation and after 4 months follow up in the patients groups only.
223613274|NCT03192761|PROCEDURE|ACL reconstruction hamstrings|"HG reconstruction is performed according to the standard procedure of the department:~A double semi-Tendinosus and gracillis graft is used. Placement of the bony tunnels is anatomical, and the femoral tunnel is positioned through the antero-medial portal. Fixation proximally is by CL-endobutton and at the tibia by Intrafix sheet and screw"
223759244|NCT05996081|BEHAVIORAL|Adherence toolkit|The adherence toolkit consists of a flowchart of adherence intervention, a self-reported adherence questionnaire, and an intervention wheel as a decision support tool for a healthcare provider. The toolkit can guide HIV care providers to identify problems causing nonadherence and to tailor the effective interventions based on the individual problems. It is available in a Bahasa Indonesia version, accompanied by a user guide on the practical application of the intervention, and can be used digitally or printed on paper. The intervention wheel is an integrated HIV medication adherence influencing factors and effective adherence-promoting interventions derived from systematic reviews and meta analyses, including previous studies conducted in Indonesia.
223759245|NCT01195467|DRUG|Truvada/Raltegravir|All subjects currently on Atripla® will switch to Truvada/Raltegravir
223759246|NCT05448664|BEHAVIORAL|Family HBM- mobile messaging|The intervention will consist of two blocks of text messaging based on HBM model, the messages will be sent to the students and their parents in the following 24 weeks.
223759247|NCT05448664|BEHAVIORAL|Adolescent HBM- mobile messaging|The intervention will consist of two blocks of text messaging based on HBM model, the messages will be sent to the students in the following 24 weeks.
223759248|NCT05448664|BEHAVIORAL|Adolescent e-pamphlets|The contents of e-version of three pamphlets, published by Department of Health (http://www.toothclub.gov.hk/en/en\_index.html) will be distributed in an electronic form and sent via a mobile message.
224312052|NCT03898908|RADIATION|Radiosurgery/stereotactic radiosurgery|"Dose selection must be based on previously published Radiation Therapy Oncology Group (RTOG) data, with dose modification left up to the treating physician. The total dose will depend on the size of the metastatic lesion(s) and proximity to critical structures.~Suggested doses are as follow: 1 fraction x 15-25 Gy; 3 fractions x 9-11 Gy; 5 fractions x 6-7 Gy; or 6 fractions x 5-6 Gy.~For GTV \> 20 mm hypofractionated stereotactic radiotherapy could be preferred. Treatment will be delivered once daily, alternate-day, 3 fractions per week."
223613275|NCT03192761|PROCEDURE|ACL reconstruction patella tendon|"PTBG reconstruction is performed according to the standard procedure of the department:~A bone patella tendon bone graft of 1 cm width from the midportion of the tendon is used. Placement of the bony tunnels is anatomical, the femoral being positioned through the antero-medial portal. Fixation proximally and distally is by interference screws."
223613276|NCT03192761|PROCEDURE|ACL reconstruction iliotibial tract|"TIFLG reconstruction is performed as follows:~The TIFL graft is harvested using two lateral incisions. The graft is left attached to the distal iliotibial tract. Placement of the bony tunnels is anatomical, the femoral being drilled outside-in. The tibial drill tunnel is made by retrograde drilling 20 mm, leaving cortical bone at the distal end of the tunnel. Fixation distally is by CL-endobutton or interference screw and on femur by an interference screw outside-in."
223613277|NCT04441255|DRUG|TAK-788|TAK-788 Capsule.
223613278|NCT01839812|DRUG|Cosyntropin|A cosyntropin stimulation test is administered to each patient at 3 time points during the study to evaluate adrenal response.
223613279|NCT02210260|PROCEDURE|Spinal and infusion of local anaesthetic|"Spinal anaesthetic will be performed in the lateral position using a midline approach. L3/4 interspace will be identified using Tuffier's as the anatomical landmark. After confirmation of correct placement using a 25G Whitacre needle, 12.5 mg of hyperbaric Bupivacaine in a mixture with 500mcg Diamorphine will be injected intrathecally.~PLUS~Painbuster® catheters will be placed by the surgeon at the end of the procedure in a location determined by the surgical approach. A bolus dose of 20ml 0.25% L-Bupivacaine will be injected down the catheters prior to the connection of the elastomeric pump which will also contain 270ml 0.25% L-Bupivacaine."
223759249|NCT06784882|DEVICE|continuous peripheral nerve block with OnQ pump|For continuous nerve blocks, the infusion pump that will be used are OnQ pumps (Avanos, Alpharetta, GA) and pre-filled with ropivacaine 0.2% and provided by UCSD's Investigational Drug Services.
223759250|NCT06784882|DRUG|single injection nerve block|An adductor canal single injection nerve block will be performed per standard of care. The adductor canal will be identified by ultrasound in the short-axis view. The distal aspect of the femoral triangle (and beginning of the adductor canal) will be identified distal to the mid-thigh in the ipsilateral limb. Using ultrasound guidance, a standard Tuohy block needle will be advanced through a skin wheal of lidocaine until its tip is in the hypoechoic area immediately distal saphenous nerve adjacent to the femoral artery. Twenty milliliters of ropivacaine 0.5% will be injected in divided doses with repeated negative aspiration.
223759251|NCT01920932|DRUG|brentuximab vedotin|Given intravenously (IV).
223613280|NCT02210260|PROCEDURE|Continuous infusion of local anaesthetic|A Painbuster® catheter will be placed by the surgeon at the end of the procedure in a location determined by the surgical approach. A bolus dose of 20ml 0.25% L-Bupivacaine will be injected down the catheters prior to the connection of the elastomeric pump which will also contain 270ml 0.25% L-Bupivacaine.
223759252|NCT01920932|DRUG|etoposide|Given IV.
223759253|NCT01920932|DRUG|prednisone|Given orally (PO).
223759254|NCT01920932|DRUG|doxorubicin|Given IV.
224312053|NCT06975085|BEHAVIORAL|Presentation of a personal breast cancer risk estimate|Participants answer questions that are used to calculate their personal breast cancer risk using the Gail Model. This risk estimate is presented to participants using written text and an icon array.
223613281|NCT02210260|DRUG|Bupivacaine|
223759255|NCT01920932|DRUG|cyclophosphamide|Given IV.
223759256|NCT01920932|DRUG|Dacarbazine(R)|Given IV.
223759257|NCT01920932|DRUG|filgrastim|Given subcutaneously (SQ) as clinically indicated.
223759258|NCT01920932|OTHER|quality of life assessment|Quality of life assessment will be done at initial clinical visit, and during chemotherapy, completion of therapy, then at 1 year, 2 years and 5 years. It should take no more than 15-20 minutes to complete. Participation is voluntary by participating institution and by participant.
223759259|NCT01920932|RADIATION|radiation therapy|At the end of chemotherapy and recovery of blood counts, radiotherapy will be given to any involved nodes (if any) that are not in complete remission.
223759260|NCT03127397|BEHAVIORAL|Praise message phone call|Praise message phone calls after each completed ART appointment, up to two calls per month.
223759261|NCT05605262|DRUG|Manukamed - Manukapli 100% sterile honey wound dressing - Premium medical grade 16+ Leptospermum Scoparium New Zealand honey|After surgical reconstruction of the tympanic membrane by grafting, Manukamed - Manukapli 100% Sterile honey wound dressing is applied onto the gelfoam to close the area, followed by an antibiotic tampon.
223759262|NCT01816139|DRUG|Vehicle|Vehicle Cream applied to the vagina daily for 2 weeks followed by dosing 2 times a week for 10 weeks
223759263|NCT01816139|DRUG|WC3011 Estradiol Vaginal Cream|WC3011 estradiol vaginal cream applied daily for 2 weeks followed by dosing 2 times a week for 10 weeks
224312054|NCT06971783|OTHER|CT- control group|will receive the application of a placebo gel (without active ingredient), under the same conditions described for the experimental gel.
223613282|NCT02210260|DRUG|Diamorphine|500mcg
223613283|NCT02210260|DEVICE|A Painbuster® catheter|
223613284|NCT02210260|DEVICE|25G Whitacre needle|
223613285|NCT00543777|DIAGNOSTIC_TEST|Magnetic Resonance Elastogram|Pneumatic driver will be placed over the upper abdomen. Patient will feel a vibration (like a cell phone or beeper vibrating). This vibration will create very small waves in the body. The scanner will then receive the vibrations from the liver and use them to create images of the liver tissue.
223613286|NCT00543777|DIAGNOSTIC_TEST|2-Point Dixon Magnetic Resonance Imaging|Imaging performed after the MRE procedure and lasting 20-60 seconds. This procedure is useful in identifying fat tissue.
223613287|NCT04239651|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|rTMS uses powerful (1.0-2.5 Tesla), focused magnetic field pulses to induce electrical currents in neural tissue noninvasively, via an inductor coil placed against the scalp.
223613288|NCT04239651|OTHER|Internet-Delivered Cognitive Behavior Therapy (iCBT)|Cognitive behavioral therapy (CBT) is an evidence-based, structured, intensive, time-limited, symptom-focused form of psychotherapy recommended for the treatment of major depression and anxiety disorders. Internet-delivered CBT (iCBT) is structured CBT delivered via the internet.
223613289|NCT00848783|DRUG|Irinotecan|
223613290|NCT00848783|DRUG|Cisplatin|
223613291|NCT00848783|PROCEDURE|Surgery|
223613292|NCT00848783|DRUG|Floxuridine|
223613293|NCT00848783|DRUG|Capecitabine|
223613294|NCT01205971|BEHAVIORAL|Motivational Interviewing|Motivational interviewing is delivered by trained public housing residents, every 3 months for a total of 8 sessions over 24 months.
223613295|NCT01205971|BEHAVIORAL|Dental Preventive Services|Written oral health educational materials
223613296|NCT03388047|DEVICE|Endoscopy with Polyscope (Polydiagnost TM) coupled with Multi-Spectral Imaging light-source|During surveillance endoscopy procedure, the endoscopist will insert the multispectral endoscopy probe through the working channel and use this to inspect the Barrett's oesophagus segment and any visible lesions
223613297|NCT04239690|OTHER|Micromethods for blood sample analysis|Micromethods in the intervention arm are applied aiming to achieve a mean reduction of 50 % of sampled blood volume during the first two postnatal weeks as compared to standard clinical blood sampling analyses
223613298|NCT04840212|OTHER|Lavender-Sandalwood scented aromatherapy sticker|The Lavender-Sandalwood scented aromatherapy sticker will be placed on the patient gown.
223613299|NCT02937558|DRUG|Glucagon|Room-temperature-stable, non-aqueous injectable liquid formulation of synthetic glucagon peptide
223613300|NCT02937558|OTHER|Placebo|Isotonic saline
223613301|NCT04160663|DIAGNOSTIC_TEST|Carotid Ultrasound|Uses sound waves to examine the blood flow through the carotid arteries and to determine the elastic properties or stiffness of the artery.
223613302|NCT01668225|PROCEDURE|Blood test|"Taking blood sample of the patient during the day 3, triggering day, oocyte collection day and pregnancy test day.~Taking the follicular fluid during the oocyte collection day"
223613303|NCT06444815|DRUG|VET3-TGI|Oncolytic vaccinia virus engineered with immunomodulatory transgenes
223613304|NCT06444815|DRUG|Pembrolizumab|anti-pd1 antibody
223613305|NCT04280731|DIETARY_SUPPLEMENT|fermented quinoa|Quinoa drink fermented with lactic acid bacteria isolated from food
223613306|NCT01429181|DRUG|Non-racemic mixture of methadone HCl|Non-racemic mixture of methadone HCl capsules, 5 mg
223613307|NCT02769221|DEVICE|Rigid video stylet|
223613308|NCT02769221|DEVICE|Video laryngoscope|
223613309|NCT00516256|BEHAVIORAL|CHESS System|Internet-based computer program for 6 months.
223613310|NCT00516256|BEHAVIORAL|Cancer Information Mentor|Phone calls to the patient for 6 months.
223613311|NCT01188304|DRUG|aleglitazar|repeated daily doses
223613312|NCT01188304|DRUG|aspirin|repeated daily doses
223613313|NCT01188304|DRUG|placebo|repeated daily doses
223613314|NCT03316703|PROCEDURE|Conventional open surgery|"Surgical treatment will be performed by stabilizing the fractured vertebral segment (proximal vertebra and vertebra distal to fractured vertebra and fractured vertebra) by means of a 6.5 mm or 6.5 mm diameter polyaxial pedicle screw system. In the fractured proximal and distal vertebrae to the vertebrae, screws will be used up to the vertebral body and fractured vertebra will use shorter screws that do not penetrate the vertebral body. In the fractured vertebra, single or bilateral pedicle screw will be used according to the degree of involvement of the pedicle of the fractured vertebra.~The vertebral fixation system will be applied through the conventional open approach (group A)."
223613315|NCT03316703|PROCEDURE|Minimally invasive percutaneous surgery|"Surgical treatment will be performed by stabilizing the fractured vertebral segment (proximal vertebra and vertebra distal to fractured vertebra and fractured vertebra) by means of a 6.5 mm or 6.5 mm diameter polyaxial pedicle screw system. In the fractured proximal and distal vertebrae to the vertebrae, screws will be used up to the vertebral body and fractured vertebra will use shorter screws that do not penetrate the vertebral body. In the fractured vertebra, single or bilateral pedicle screw will be used according to the degree of involvement of the pedicle of the fractured vertebra.~The vertebral fixation system will be applied through the minimally invasive percutaneous approach (group B) according to allocation after randomization."
223613316|NCT04527367|PROCEDURE|Innovative medical technologies in invasive cardiology and cardiac surgery|A follow-up study included the analysis of medical documentation of the Cardiosurgery and the Invasive Cardiology Departments to provided information on the duration and type of procedure performed.
223613317|NCT03539575|OTHER|[11-C]OMAR|The radiotracer, \[11-C\]OMAR will be administered at no more than 10 micrograms at the beginning of each PET scan.
223613318|NCT05019534|DRUG|Vemurafenib Oral Tablet [Zelboraf]|Vemurafenib 960mg qd or 960mg bid (2 cohorts)
223759264|NCT03661814|DEVICE|Prevena|The NPWT device is a wound dressing with a vacuum system that can be placed over abdominal wounds, placed in the immediate postoperative period over abdominal wounds after clean/contaminated colorectal surgical procedures.
223759265|NCT01231763|OTHER|No intervention (not applicable)|No intervention (not applicable)
223613319|NCT05019534|DRUG|Cetuximab Injection [Erbitux]|Cetuximab 500mg/m2 Q2W
223759266|NCT04916184|OTHER|aerobic exercise|exercise training rehabilitation (aerobic exercise with/without strength training)
223759267|NCT04916184|OTHER|combined exercise|exercise training rehabilitation (aerobic exercise with/without strength training)
223759268|NCT02649881|PROCEDURE|The heart subject will undergo OCT|
224201533|NCT01856257|DRUG|methylprednisolone|Methylprednisolone will be administered at a target dose of 500 mg beginning on the day of transplant, and tapered to 250 mg day 1 post-transplant, 125 mg day 2 post-transplant, 60 mg day 3 post-transplant, 30 mg day 4 post-transplant and day 5 post-transplant 0 mg if therapeutic tacrolimus level achieved for groups 1 and 3.
224201534|NCT01856257|BIOLOGICAL|basiliximab|Basiliximab will be administered in two doses of 20 mg each.
224201535|NCT01856257|DRUG|mycophenolate mofetil|Mycophenolate Mofetil will be administered at a target dose of 1000 mg orally twice a day. Myfortic® (mycophenolate sodium) may be used as a replacement for MMF. Mycophenolate sodium will be dosed at 720 mg PO BID. Mycophenolate sodium will be adjusted based on clinical complications.
224201536|NCT01856257|DRUG|tacrolimus|The site investigator will identify a starting tacrolimus dose at their discretion, in order to achieve the target trough levels, no later than 5 days post-transplantation. The dose will be adjusted to 5-8ng/ml for the active comparator arm (thymoglobulin + tacrolimus + MMF arm) or tapered off in the experimental arm (basiliximab + 20 weeks of tacrolimus + MMF + belatacept).
224201537|NCT03487614|BEHAVIORAL|Behavior-based parental intervention|Behavioral intervention designed to promote healthy feeding behaviors in parents of 2-5 year olds, and to modify parenting practices in a way that encourages adequate physical activity, sufficient sleep, and healthy nutrition, while limiting sedentary behaviors.
224201538|NCT02355366|BEHAVIORAL|Family-Focused Therapy|Family Focused Therapy is a manual-based, psycho-educational intervention which is designed to reduce intra-familial stress, conflict, and affective arousal by enhancing communication and problem solving skills among families who are affected by bipolar disorder (Miklowitz et al., 2013). It concentrates on skills relevant to managing the prodromal stages of bipolar disorder, such as mood monitoring, reducing family conflict, improving problem solving, stabilizing daily routines and regulating sleep/wake cycles (Miklowitz, 2012).
224201539|NCT02355366|BEHAVIORAL|Brief Educational Treatment|Brief Educational Treatment will consist of 1 - 2 sessions involving both parents and adolescents; it will consist of diagnostic feedback following the adolescent's baseline assessment. It will provide families with information and strategies on tracking and managing adolescent mood disorders. Additionally, ongoing medication management and crisis family sessions will be available if required.
224201540|NCT01591902|DRUG|Tesamorelin|Daily 2 mg subcutaneous injections of tesamorelin
224201541|NCT01591902|DRUG|Placebo-Control|3.0 mL vials
224201542|NCT04995302|PROCEDURE|Microoneedling and Amnion Bilayer|Microneedling is conducted following a three-week application of tretinoin cream. Then, scar tissue that has been treated with microneedling is covered with amnion bilayer for 72 hours.
224201543|NCT04995302|PROCEDURE|Microoneedling|Microneedling is conducted following a three-week application of tretinoin cream. Then, scar tissue that has been treated with microneedling is covered with an antibacterial gauze dressing.
224201544|NCT04022759|BEHAVIORAL|Treatment as Usual with Security Prime|"In addition to their treatment as usual (low-intensity guided self-help behavioural activation for depression), participants will complete an initial attachment security priming task during the first session with their allocated clinician. Participants will be prompted in their intervention workbook with a caption regarding what a secure attachment relationship represents. They will be asked to think of a person/ people with whom they feel they have this relationship, and list them. Following this, they are asked to plot these individuals on a diagram of concentric circles in relation to how close they feel this person is to them. The closer to the middle of the diagram the individual places each person, the closer they feel their relationship to that person is.~Prior to each session with their clinician, they will be prompted to complete a repeated security priming task in order to increase feelings of security prior to therapy sessions."
224201545|NCT04022759|BEHAVIORAL|Treatment as Usual (Behavioural Activation)|Clients will engage in treatment as usual. This involves low-intensity guided self-help behavioural activation for depression.
223613320|NCT05019534|DRUG|Camrelizumab|Camrelizumab 200mg Q2W
223613321|NCT01059318|DRUG|Everolimus|Everolimus was formulated as tablets in strengths of 2.5mg, 5mg and 10mg.
223613322|NCT02700828|DRUG|Hydrocortisone|4 \* 0,5 mg/kg /24 hours (in every 6 hours) iv., during hypothermia treatment (max. 72 hours)
223613323|NCT02700828|DRUG|Placebo|4 \* 2 ml isotonic sodium chloride solution /24 hours (in every 6 hours) iv., during hypothermia treatment (max. 72 hours)
223613324|NCT01557907|DEVICE|Subcutaneous delivery via Medtronic Quick-Set|Infusion rates and pre-meal bolus doses will be based on subjects known daily infusion rate and subject's reported insulin to carbohydrate ratio.
223613325|NCT01557907|DEVICE|Intradermal delivery via the BD Research Catheter Set|Infusion rates and pre-meal bolus doses will be based on subjects known daily infusion rate and subject's reported insulin to carbohydrate ratio.
223613326|NCT03419988|BEHAVIORAL|Exercise Intervention|24 sessions of aerobic exercise
223613327|NCT04352023|PROCEDURE|Patient-controlled analgesia|Intravenous patient-controlled analgesia Patient-controlled epidural analgesia
223613328|NCT04131075|PROCEDURE|Coronary Angiography and Multimodal Coronary Physiology Study (FFR, CFR, HMR)|Coronary Angiography according to clinical indication and Multimodal Coronary Physiology Study (FFR, CFR, HMR) for functional assessment of intermediate coronary lesions
223759269|NCT04782908|DEVICE|Transcatheter tricuspid valve edge-to-edge repair|Transcatheter tricuspid valve edge-to-edge repair is an interventional approach to treat severe tricuspid regurgitation. Under general anesthesia a clip delivery system is forwarded through the vena femoralis and right atrium in the right ventricle. A clip is deployed to clamp the tricuspid valve and reduce tricuspid valve regurgitation.
223613329|NCT05254483|BEHAVIORAL|UNICEF kid power program immediately|"The intervention will be delivered via the UNICEF Kid Power website (https://www.unicefkidpower.org/) and any screened device such as a computer, smartphone, smart TV or an electronic tablet can be used to watch the videos and perform the assigned physical activity.~Participants will self-select activities 5 days a week. The participants will have the choice to undertake the physical activity in bouts and accumulate it over the course of the day.~To promote adherence to intervention, a weekly email with reminder to perform the physical activity will be sent to parents. In addition, research-based articles on the importance of physical activity and behavior change in children will also be emailed."
223613330|NCT05254483|BEHAVIORAL|UNICEF kid power program for waitlist control|The wait-list control group will perform physical activity as usual and will only receive a weekly email on the importance of healthy dietary habits in children. The intervention will last 12 weeks. At the end of the study, the wait-list control group will be offered the UNICEF Kid Power intervention for a duration of 12-weeks
223613331|NCT05254483|DEVICE|ActiGraph Accelerometer|The participants will be mailed accelerometers and instructed to wear for 7 consecutive days during their waking hours, prior to the start of intervention. The mail containing the accelerometer will accompany pictorial instructions, explaining in detail the correct way of wearing it.
223759270|NCT04667403|OTHER|Telemedicine|"In addition to his standard follow-up, the patient benefits from a home follow-up of his pain for 6 months from his inclusion in the study.~The patient has to log on via the application, every week. to fill in the questionnaire to evaluate the pain over the past week.~The questionnaire consists of 4 questions to which the patient answers using a numerical scale from 0 to 10.~If the patient's pain is not controlled, the patient can log on in emergency mode as many times as he or she deems necessary.~A nurse path coordinator will be informed of each connection. Depending on the type of alert received, she may initiate a telephone consultation with the oncologist or pain specialist:~* If necessary within 24 hours of the connection if it is a weekly connection,~* Systematic within 3 hours if it is an emergency connection or if the data entered at the time of the weekly connection requires medical intervention."
223759271|NCT02311465|OTHER|Palliative Care|"Components of the palliative care service intervention are expected to include:~* Establishment of a palliative care plan~* Care coordination by palliative care team~* Informational, patient friendly materials supporting Palliative Care~* Communication by palliative care team to all providers and teams involved in patient's care~* Systematic collection of information, including identification of surrogate or health care proxy and advance care planning~* Questionnaires capturing health related quality of life at regular intervals throughout the intervention period"
223759272|NCT02285231|DIETARY_SUPPLEMENT|Arginyl-fructose|
223759273|NCT02285231|DIETARY_SUPPLEMENT|Placebo|
223759274|NCT00000735|DRUG|Ampligen|
223759275|NCT05226286|DEVICE|Medtronic Implantable Tibial Neuromodulation (TNM) System|Stimulation of the tibial nerve using Medtronic's tibial neuromodulation device.
223759276|NCT03356210|BEHAVIORAL|Neurofeedback|The intervention will consist of 20 sessions of symptom-based NF tailored to the individual patient. Training will be conducted using the Othmer method of NF from EEGinfo, comprising bipolar, infra-low frequency training, with the inclusion of synchrony and alfa-/theta training as needed.
223759277|NCT03344185|DIETARY_SUPPLEMENT|Low Glycaemic Diet|This intervention consisted of three low GI meals.
223759278|NCT03344185|DIETARY_SUPPLEMENT|High Glycaemic Diet|This intervention consisted of three meals, all with a high GI value.
223759279|NCT03240575|DRUG|Tiotropium|Fixed Dose Combination
223759280|NCT03240575|DRUG|Olodaterol|Fixed Dose Combination
223759281|NCT03240575|DRUG|Fluticasone propionate|Fixed Dose Combination
223759282|NCT03240575|DRUG|Salmeterol|Fixed Dose Combination
223759283|NCT04561076|DRUG|HLX70|Single-dose, intravenous infusion
223759284|NCT04561076|OTHER|Placebo|Single-dose, intravenous infusion
223759285|NCT04522297|DRUG|Midodrine/Octreotide|oral midodrine plus octreotide as subcutaneous injection
223759286|NCT04522297|DRUG|Nor-epinephrine|Intravenous infusion norepinephrine
223759287|NCT00728377|BEHAVIORAL|Physical activity|Individually Tailored (IT) Exercise Intervention This intervention is designed to increase the amount of physical activity incorporated into the daily lifestyle of pregnant women, primarily through increased walking, with the ultimate goal of achieving the American College of Obstetricians and Gynecologists (ACOG) exercise goals for pregnant women. These goals are the same as the Surgeon General's Guidelines for physical activity for nonpregnant individuals (30 minutes or more or moderate activity on most days of the week).The intervention includes: 1) individually tailored print-based materials (i.e., individually-tailored reports and stage-matched manuals), 2) self-monitoring materials, and 3) goal setting.
223759288|NCT00728377|BEHAVIORAL|Heath & Wellness|The comparison intervention consists of a series of informational booklets published by the American College of Obstetricians and Gynecologists on general issues related to health and wellness during pregnancy. These include alcohol and drug use during pregnancy, easing back pain, as well as the Pregnancy Fitness brochure on the safety of exercise during pregnancy. These booklets are selected to represent high-quality, standard, low-cost, self-help material currently available to the public.
223759289|NCT00784511|DIETARY_SUPPLEMENT|cholecalciferol|4000 IU/d
223759290|NCT00784511|OTHER|microcrystalline cellulose|1/d
223759291|NCT00506090|PROCEDURE|pulsed dye laser therapy|Treatment will begin on the day of suture removal. Each scar will be divided into 3 equal parts. One part will be randomly allocated to be treated with pulsed dye laser and dynamic cooling device at 3 weeks intervals for 6 sessions. Another part will be treated with pulsed dye laser and dynamic cooling device at 6 weeks intervals for 6 sessions. Only dynamic cooling device will be used for remaining part serving as control.
223759292|NCT00829322|DRUG|Modafinil|Modafinil 100mg once daily for 14 days, increasing to 200mg once daily for a further 14 days
223759293|NCT00829322|DRUG|Placebo|One capsule daily for 14 days, increasing to two capsules daily for 14 days
223759294|NCT00004258|DRUG|cilengitide|dose escalation of cilengitide
223759295|NCT06323252|DIETARY_SUPPLEMENT|MastihaOil|1 soft gel capsule of Mastiha oil every day for 3 months
223759296|NCT06323252|BEHAVIORAL|nutritional counsel|nutritional counsel
223759297|NCT05669079|DRUG|decitabine|15 mg/m2 daily intravenously for consecutive 3 days
223759298|NCT05669079|BIOLOGICAL|umbilical cord blood|MNC ≥ 3\*108 cells; HLA compatibility ≥ 5/6
223613332|NCT01149915|DRUG|TH-302|TH-302 will be administered as a 30-minute intravenous infusion daily for 5 days every 21 days. Patients who successfully complete a 3-week treatment cycle without evidence of significant treatment-related toxicity or clinically significant progressive disease will continue to receive treatment for up to six cycles.
223613333|NCT02989883|OTHER|peroral endoscopic myotomy|The procedure consists of four steps: 1) mucosal incision 10-15 cm above the esophagogastric junction to allow entry into the submucosa, 2) creation of a submucosal tunnel until the lower esophageal sphincter is reached, 3) myotomy of the circular muscle layer, and 4) closure of the mucosal entry with endoclips.
223613334|NCT05994027|BEHAVIORAL|ATTACH™ Online Platform Parenting Program|ATTACH Online Platform: Preserving and promoting optimal RF in parents who are experiencing adversities, enables parents to appropriately attribute affective states to their children and respond accurately to meet their children's needs, thus promoting sensitive/ responsive parent-child relationships.
223613335|NCT06029569|PROCEDURE|Rapamycin drug balloon angioplasty|Rapamycin drug balloon treatment for stenosis or blockage of the dialysis pathway in autologous arteriovenous fistula.
223613336|NCT06029569|PROCEDURE|Paclitaxel drug balloon angioplasty|Paclitaxel drug balloon therapy for stenosis or blockage of the dialysis pathway of autologous arteriovenous fistula.
223613337|NCT00474214|BEHAVIORAL|Early hospital discharge facilitated by close nurse practitioner follow-up|
223613338|NCT00970229|DRUG|[123I]MNI-420|Subjects will be injected with 8mCi, not to exceed 8.8 mCi (not \> 10% of 8 mCi limit)of \[123I\]MNI-420, followed by SPECT imaging.
223759299|NCT05669079|DRUG|Granulocyte-colony stimulating factor|Granulocyte-colony stimulating factor will be used when absolute neutrophil count ≤ 1.5 × 109/L
223759300|NCT05669079|DRUG|Recombinant human thrombopoietin / thrombopoietin receptor agonist|Recombinant human thrombopoietin or thrombopoietin receptor agonist will be used when platelet count ≤ 30 × 109/L
223759301|NCT05669079|DRUG|Recombinant human erythropoietin|Recombinant human erythropoietin will be used when hemoglobin ≤ 85 g/L
223759302|NCT01331616|DRUG|Bevacizumab (Avastin)|Dosage is: 10 mg/kg every 2 weeks as monotherapy or in combination (unlabeled) with irinotecan. Patients will also receive Radiotherapy prior to beginning chemotherapy.
223759303|NCT00938483|OTHER|Nutramigen Lipil (Infant formula)|
223759304|NCT05785364|DEVICE|Mpact 3D metal MONOCER cup|adult patients requiring a total hip arthroplasty under 75 years old, will receive the Mpact 3D metal cup, as acetabular sheel device implanted
223759305|NCT04217486|OTHER|Patient will be shown a photograph of their knee at 2 weeks postop|Patients who undergo primary TKA surgery will then be shown a photograph of their knee at 2 weeks postoperative.
223759306|NCT04217486|OTHER|Patient will not be shown a photograph of their knee at 2 weeks postop|Patients who undergo primary TKA surgery will not be shown a photograph of their knee at 2 weeks postoperative.
223759307|NCT03641378|OTHER|Palliative Care Intervention|team of clinicians that specialize in the lessening (palliation) of many distressing symptoms
223759308|NCT03641378|OTHER|Standard Transplant Care|Standard care per hospital guidelines
223759309|NCT02889094|OTHER|Routine care|Routine care recommended for patients co-infected with HIV and hepatitis B virus (per European Association for the Study of the Liver and European AIDS Clinical Society guidelines).
223759310|NCT00697346|DRUG|Alisertib|Alisertib (MLN8237) PIC or ECT
223759311|NCT02880982|DIETARY_SUPPLEMENT|Cholecalciferol|Weekly oral softgel capsule containing 10,000 IU (250 micrograms) cholecalciferol (vitamin D3)
223759312|NCT02880982|OTHER|Placebo|Weekly oral placebo softgel capsule
223759313|NCT01381861|BIOLOGICAL|Carotuximab (TRC105)|Carotuximab (TRC105) 10 mg/kg weekly by intravenous administration on Days 1, 8, 15 and 22 of each 28-day cycle
223759314|NCT04297930|DEVICE|Paul Glaucoma Implant Surgery|This group of patients had glaucoma surgery with the Paul Glaucoma Implant
224201546|NCT05171920|DRUG|Auxora|All patients will receive 2.0 mg/kg (1.25 mL/kg) of Auxora at 0 hour and 1.6 mg/kg (1 mL/kg) at both 24 hours and 48 hours from the Start of the First Infusion of Auxora (SFIA) at 0 hour over 4 hours. Patients with severe hypoxemic respiratory failure at 48 hours will be randomized 1:1 to receive extended treatment with Auxora 1.6 mg/kg (1 mL/kg) at 72, 96, and 120 hours from the SFIA
224201547|NCT05171920|DRUG|Placebo|Patients with severe hypoxemic respiratory failure at 48 hours will be randomized 1:1 to receive 1 mL/kg of Placebo at 72, 96, and 120 hours from the SFIA.
224201548|NCT02097966|DRUG|Daclatasvir|
223613339|NCT04705506|DRUG|Gemigliptin|We collected baseline data from all participants for demographic characteristics,comorbid conditions and biochemistry indexes.The biomarkers for vascular calcification and renal injury were collected.Baseline CAC score and CAVI were done.The patients then were randomized into 2 groups: Group 1 received gemigliptin 50 mg /day for 6 months in addition to standard treatment ,Group 2 will have standard treatment for diabetes mellitus (DM) and chronic kidney disease (CKD).The patients will be followed up every eight weeks.Fasting plasma glucose ,BUN creatinine and 24 hour urine protein were measured at each study visit.Patients were scheduled for follow-up visits at months 2,4,and 6.After 6 months ,all the blood tests,CAC score and CAVI will be done again.
223759315|NCT03221933|BIOLOGICAL|Somatropin Injection low dose group|0.23mg/kg /wk，inject for seven divided doses
223759316|NCT03221933|BIOLOGICAL|Somatropin Injection high dose group|0.46mg/kg /wk，inject for seven divided dose
223759317|NCT05690737|BEHAVIORAL|Tai Chi training|The 24-week Tai Chi training will be prescribed with three 1-hour instructor-led sessions and two 1-hour self-practice sessions per week. A modified 33-short form Yang-style Tai Chi Chuan will be adopted. The Tai Chi sessions will be operated by qualified/certified instructors. Each 1-hour training session will consist of 10 minutes brief warm-up stretching session followed by 45 minutes standard Tai Chi routine activities, and 5 minutes of cool-down stretching. The Tai Chi instructors will have to attend a training session that ensure all of them will deliver the same intervention protocol throughout the study. The research assistant will monitor the fidelity of intervention by visiting the Tai Chi sessions frequently. The training activity will be delivered in group. The group size is 25-30 persons. During the 24 weeks follow-up period, the participants are required to practice Tai Chi with the same frequency by themselves.
224201549|NCT02097966|DRUG|Sofosbuvir|
224201550|NCT02097966|DRUG|Ribavirin|
224201551|NCT04527549|DRUG|Dabrafenib mesylate|Given PO
224201552|NCT04527549|DRUG|Hydroxychloroquine|Given PO
224201553|NCT04527549|DRUG|Placebo Administration|Given PO
224201554|NCT04527549|DRUG|Trametinib dimethyl sulfoxide|Given PO
223613340|NCT03024125|OTHER|High protein|To observe the effect of a high protein (HP) diet over muscle mass, fat mass, and strength changes, focusing in differences between the NP and HP groups.
224201555|NCT05346939|DEVICE|dynamic taping|The athletic trainer will intervene with spiral dynamic technique by using a dynamic tape for the first test and a sham dynamic tape for the second test, or reverse the order.
224201556|NCT03394794|DEVICE|Pelvic floor rehabilitation|The aim is to compare how each treatment improves symptoms and quality of life and which physiologic mechanisms affects. The basal treatment which other therapies are compared to is Kegel.
223613341|NCT03024125|OTHER|Normal protein|To observe the effect of a normal protein (NP) diet over muscle mass, fat mass, and strength changes
223613342|NCT03024125|OTHER|Training|The physical strength training will be performed equally by both groups, containing exercises for upper and lower limbs and aiming for hypertrophy.
224201557|NCT02238886|DIETARY_SUPPLEMENT|Parenteral nutrition. SMOFKABIVEN infusion in central vene. Fresenius Kabi|
224201558|NCT01424657|PROCEDURE|ERCP|Endoscopic retrograde cholangiopancreatography
223613343|NCT02800525|DEVICE|Picosecond laser|Picosecond 532 and 1064 nm laser Treatment of facial pigmented lesions. The energy using depends on the endpoint of immediate whitening of the lesions. The wavelength using depends on the depth of lesions.
223613344|NCT02800525|DEVICE|Q-switched Nd:YAG laser|Q-switched Nd-YAG 532 and 1064 nm laser. Treatment of facial pigmented lesions. The energy using depends on the endpoint of immediate whitening of the lesions. The wavelength using depends on the depth of lesion.
223613345|NCT03141632|DRUG|Dulaglutide|Evaluation visit with assessment of fluid intake
223613346|NCT03141632|OTHER|Placebo|Evaluation visit with assessment of fluid intake
223613347|NCT05112003|DEVICE|Translingual neurostimulation|The device will be placed into and held in the participant's mouth for 20 minutes while the participant undergoes breathing and awareness training
223613348|NCT00983385|DRUG|Tapentadol PR|Tapentadol Prolonged Release (PR) Titration and Optimal Dose Period: Starting at 50 mg Tapentadol PR twice daily, adjusted with 50 mg PR steps (upwards or downwards) as necessary to achieve a balance between pain relief and a satisfactory level of tolerability. Participants were not permitted to exceed a dose of 500 mg of Tapentadol per day.
223613349|NCT00983385|OTHER|Observation period|Eligibility assessment period to characterize the baseline over a one week period (week -1). Participants continued their previous treatment prior to allocation to tapentadol, if eligible.
223613350|NCT00983385|DRUG|Tapentadol PR|Maintenance Period: In this period participants continued Tapentadol Prolonged Release (PR) on the dose established in the Titration and Optimal Dose Period. Tapentadol IR participants were not permitted to exceed a total daily tapentadol dose of 500 mg.
223613351|NCT00897455|GENETIC|DNA analysis|
223613352|NCT00897455|GENETIC|mutation analysis|
223613353|NCT00897455|GENETIC|polymorphism analysis|
223613354|NCT00897455|OTHER|laboratory biomarker analysis|
223613355|NCT00897455|PROCEDURE|evaluation of cancer risk factors|
223613356|NCT04862325|OTHER|Multimodal Prehabilitation|"1. High-intensity endurance exercise training program and physical activity promotion remotely controlled with ICT (information and communications technologies).~2. Nutritional counselling to achieve protein intake of 1.5-1.8 g/kg and whey protein supplements.~3. Psychological intervention including motivational interview, mindfulness meditation and cognitive behavioral therapy"
223613357|NCT03840863|DIETARY_SUPPLEMENT|Commercially-Available Energy Drink|Participant will consume 2 cans of an energy drink (16 oz./can) per day. One in the morning and one in the afternoon.
223613358|NCT01412164|DEVICE|FIREHAWK biodegradable polymer rapamycin-eluting stent|DES PCI for CAD
223613359|NCT03685955|BIOLOGICAL|Amniotic membranes|Amniotic membranes will be employed during participant's genitourinary reconstruction
223613360|NCT03306940|DRUG|Botulinum Toxin Type A|patients were injected to the normal side with dose of 1.25 units/per site
223613361|NCT02343393|DRUG|Hydralazine|
224201559|NCT01424657|PROCEDURE|MRCP|magnetic resonance cholangiopancreatography
223613362|NCT02343393|DRUG|Isosorbide Dinitrate|
223613363|NCT06514872|OTHER|prevalance and determinants of home accidents|home accidents among Turkish older
223613364|NCT02329470|PROCEDURE|Withdrawal of continuous positive airway pressure treatment|Withdrawal of continuous positive airway pressure treatment
223613365|NCT00746070|OTHER|with the clinical treatment ( ex adrenalectomy or spironolactone|with the clinical observational study
223613366|NCT00956917|DEVICE|Akern USA EFG|Impedance measurement device
223613367|NCT00956917|DEVICE|RJL Impedance analyzer|Impedance analyzer
223613368|NCT01364584|DRUG|Exenatide|Subcutaneous injection 2.5 micrograms (mcg) to 10 mcg twice per day (BID)
223613369|NCT01364584|DRUG|Placebo|Subcutaneous injection 2.5 mcg-10 mcg BID
223613370|NCT05162183|DRUG|Glimepiride|Glimepiride dispensing claim is used as the reference group.
223613371|NCT05162183|DRUG|Liraglutide|Liraglutide dispensing claim is used as the exposure group.
223613372|NCT00491465|BEHAVIORAL|Intensive Physical activity|
223613373|NCT00491465|BEHAVIORAL|Control- regular physical activity|
223613374|NCT03636217|OTHER|LGI-Milk Breakfast|This test meal with low glycemic index and milk were served as a breakfast after 12-hours fasting and participants were asked to consume the meal in full, within 15 min.
223613375|NCT03636217|OTHER|LGI-Kefir Breakfast|In crossover design, this test meal with low glycemic index and kefir was served as a breakfast to compare the LGI-Milk Breakfast.
223613376|NCT03636217|OTHER|HGI-Kefir Breakfast|In crossover design, this test meal with high glycemic index and kefir was served as a breakfast to compare the LGI-Milk Breakfast and the LGI-Kefir Breakfast.
223613377|NCT03818750|DEVICE|MRI|"Subjects review alcohol ads in different contexts (neutral context vs positive context such as parties and sport) and answer with buttons lever while being in the MRI to express their desire to consume alcohol or not.~Subjects will be exposed to 288 ads set up."
223613378|NCT03818750|BEHAVIORAL|Alcohol Use Disorders Identification Test|Questionnaire
223613379|NCT00974753|DRUG|Ketorolac 0.5%|Four-times a day starting one week before surgery and continued for 4 weeks post surgery.
224312055|NCT06971783|OTHER|NP- Potassium nitrate gel|The gels will be applied to the sensitive lesions according to the experimental group and will be rubbed for 20 seconds using a microbrush, remaining on the lesions for 10 minutes.
223613380|NCT00974753|OTHER|Saline drops|Four-times a day starting one week before surgery and continued for 4 weeks post surgery.
223759318|NCT05690737|DRUG|Standard prophylactic medication|Participants assigned to the control group will follow the collaborated neurologist's recommendation, to take the prophylactic medication. The Multidisciplinary Panel on Neuropathic Pain (MPNP) of Hong Kong has published the treatment algorithm for migraine, which is in line with the guideline of the Scottish Intercollegiate Guidelines Network (SIGN) on the pharmacological management of migraine (SIGN 155). Beta-blockers, specifically metoprolol and propranolol, are one of the first-line treatments for migraine prophylaxis. The dosage will start on 10mg and slowly increase by 10mg every week until the dosage reached the highest dose of 150mg/day. The whole course will last for 48 weeks. The second line drug such as amitriptyline and the third line drug such as gabapentin will be adopted according to doctor's judgement if necessary. RA will help the participants to make appointment with the neurological doctor, to obtain the prescription. The adverse events will be recorded accordingly.
223759319|NCT02934230|BEHAVIORAL|Prehabilitation Program|"Strength training: This component consists of 1 set of 10 repetitions of each exercise: a. push-ups (modified to the individual's level of function as either wall push-ups, knee push-ups, or full push-ups); b. seated row (performed with an elastic resistance band); c. chest fly (performed with an elastic resistance band); d. deltoid lift (performed with an elastic resistance band); e. biceps curls (performed with an elastic resistance band); f. triceps extensions (performed with an elastic resistance band); g. chair squats; h. hamstring curls; i. standing calf raises; j. abdominal crunches (modified to be performed seated in a chair)~Aerobics: Walking for 20 minutes at moderate intensity.~Flexibility: Chest, arm, leg and truck stretches, with each stretch to be held for 20 seconds, done for 2 repetitions."
223759320|NCT06402188|DEVICE|ColoSeal ICD Device|The subject will undergo scheduled resection per the surgeon's preferred technique. Following completion of the anastomosis, the Intraluminal Colonic Diversion (ICD) Device will be inserted, advanced and positioned with the ICD Delivery System transanally. The ICD Device will remain in place for 10± 2 days. Anastomotic leak testing will be performed prior to scheduled removal.
223759321|NCT01417403|DRUG|hydroxychloroquine|Given PO
223759322|NCT01417403|RADIATION|radiation therapy|Undergo radiotherapy
223759323|NCT06441383|OTHER|Pittsburgh Sleep Quality Index|"The the Pittsburg Sleep Quality Index (PSQI) questionnaire is a standardized tool for the subjective assessment of sleep. Sleep is described according to 7 components: subjective sleep quality, sleep onset latency, sleep duration, sleep efficiency, sleep disorders, medication use and daytime dysfunction. The sum of the scores for these 7 components gives an overall score of 21 points maximum.~The presence of sleep disorders will be defined according to the results of the PSQI, with a value above 5 defining the presence of sleep disorders."
223759324|NCT03643562|DRUG|Adrabetadex|Administered via lumbar puncture (LP) and IT infusion
223759325|NCT01791738|PROCEDURE|Acetabular positioning system|Pre-operative planning through 3D software with design and fabrication of patient specific instruments for placement of a guide pin to be used to aid in bone preparation for insertion of an acetabular cup in total hip arthroplasty
223759326|NCT01433107|DRUG|Terbinafine|1% single application
223759327|NCT01433107|DRUG|Terbinafine Placebo|single application
223759328|NCT02588924|OTHER|Second University of Naples|enrollment of patients with Parkinson's disease; collection of blood samples; measuring out the concentrations of copper, iron and manganese in biological fluids (blood, serum) of patients with Parkinson's disease and of subjects of the control group and assess possible correlations between changes in the content of metals and the pathology.
223759329|NCT02588924|OTHER|Neuromed IRCCS|enrollment of patients with Parkinson's disease; collection of blood samples;
223759330|NCT01749722|DEVICE|NaviAid™ G-Eye procedure|NaviAid™ G-Eye procedure
223759331|NCT01982253|DRUG|Fasiglifam|Fasiglifam tablets
223759332|NCT01982253|DRUG|Placebo to fasiglifam|Fasiglifam placebo-matching tablets
223759333|NCT00017706|BEHAVIORAL|physician-delivered weight control|
223759334|NCT04025528|PROCEDURE|Bariatric Surgery|Weight loss surgery with either gastric sleeve or gastric bypass surgery
223759335|NCT00291122|DRUG|celecoxib 400 mg BID|
223759336|NCT02809430|DEVICE|Continuous Positive Airway Pressure|Auto-titrating Continuous Positive Airway Pressure (APAP) among patients admitted to a rehabilitation unit after ischemic or hemorrhagic stroke for 3 month treatment period.
223759337|NCT06290310|DEVICE|EIT|continuous electric impedance tomography measurement
223759338|NCT06290310|DEVICE|patient-ventilator asynchrony assessment|patient-ventilator asynchrony assessment by flow/time curve and machine learning
223759339|NCT01080313|OTHER|Therapy for head and neck cancer|radiotherapy and/or drug therapy including chemotherapy, biologic therapy and targeted therapy
223759340|NCT04501731|OTHER|Transcranial Magnetic Stimulation (TMS)|With the TMS session we gather information about nerve fibres from the brain to the hand. It will last around 2 hours and 30 minutes.
223759341|NCT04501731|OTHER|Magnetic Resonance Imaging (MRI)|With the MRI scan we will gather information about the brain structure and function. This will last around 30 minutes.
223759342|NCT04501731|OTHER|Motor assessment|"The motor assessment includes a pegboard game, a grab the alien nose game and measure of your maximum grip force. In total it will last around 30 minutes."
223613381|NCT00809900|DIETARY_SUPPLEMENT|Experimental|Administration of of 480 mL cranberry juice
224312056|NCT06971783|OTHER|AO - Acmella Oleracea Extract Gel|The Acmella oleracea gel will be applied to sensitive lesions and rubbed for 20 seconds with the aid of a microbrush, remaining on the lesions for 10 minutes.
224314292|NCT03636997|PROCEDURE|Draining seton|Number 1 silk suture was passed through the fistula track and tied as loose seton
223613382|NCT00155493|PROCEDURE|obtain surgical specimen for analysis|
223613383|NCT01742195|PROCEDURE|Oral EBUS insertion|
223613384|NCT01742195|PROCEDURE|Nasal EBUS insertion|
223613385|NCT05338034|DRUG|HPG1860|The dosage form for clinical research is a dry-filled capsule for oral administration manufactured as strengths of 3 mg, 5 mg, and 8 mg.
223613386|NCT05338034|DRUG|Placebo|Capsule
223613387|NCT01487135|DRUG|EVP-6124|A single oral low dose of EVP-6124 in cranberry juice (180 mL) administered on Day 1 and a high dose of EVP-6124 in cranberry juice (180 mL) administered on Day 2.
223613388|NCT01487135|DRUG|Placebo|Cranberry juice only (180 mL) administered orally on both Day 1 and Day 2.
223759343|NCT04501731|OTHER|Questionnaires|Feasibility, tolerability of such intervention as well as quality of life of PFT survivors will be assessed thanks to questionnaires.
223759344|NCT05160428|BIOLOGICAL|COVID-19 vaccination|different types of covid-19 vaccinations.
223759345|NCT00913744|DRUG|Ocriplasmin|ocriplasmin intravitreal injection (125 µg)
223759346|NCT00913744|DRUG|Sham injection|Sham injection
223759347|NCT05940935|PROCEDURE|Arterial Blood Gas Base Deficit|The base deficit values in the preoperative, intraoperative and postoperative blood gases taken from the patients and the presence and severity of metabolic acidosis were evaluated. Metabolic acidosis severity was defined by base deficit levels: mild from -3 to -5, moderate from -5 to -10, and severe metabolic acidosis below -10.
223759348|NCT04683991|PROCEDURE|Subepithelial connective tissue graft|A de-epithelialized connective tissue graft is harvested from the homolateral palate and transplanted around the implant.
223759349|NCT02945410|OTHER|Caloric Restriction|Participants will consume 30 kcal/kg FFM/day.
223759350|NCT02945410|OTHER|Protein|Participants will consume 1.7 g protein/kg BW/day.
223759351|NCT02945410|OTHER|Exercise|Participants will conduct aerobic exercise designed to expend 15 kcal/kg FFM/day
223759352|NCT02945410|DIETARY_SUPPLEMENT|Calcium and Vitamin D|Participants will be provided calcium and vitamin D supplement in order to maintain calcium and Vitamin D intake constant across all study arms
223759353|NCT02945410|OTHER|Maltodextrin|Participants will be provided with maltodextrin to supplement the liquid diet in order to meet caloric needs within each study arm
223759354|NCT01262885|DRUG|GSK2251052|500 mg tablet, dose levels detailed in Arm description
223759355|NCT01262885|DRUG|Placebo|matching placebo tablet
223759356|NCT03672435|DRUG|Topical Solution|proparacaine 0.5% eye drop
224201560|NCT05157529|DEVICE|AQUABEAM Robotic System|"The AQUABEAM Robotic System is developed and manufactured by PROCEPT BioRobotics, Corp. It is intended for use in patients suffering from lower urinary tract (LUTS) resulting from benign prostatic hyperplasia (BPH). The AQUABEAM Robotic System is designed for cutting of prostate tissue during minimally invasive surgical procedure and shall be inserted via transurethral approach and is advanced through the urethra and into the prostatic urethra.~The system is designed to utilize a high-velocity sterile saline stream as the cutting medium which is projected through a nozzle positioned within the prostatic urethra. The nozzle assembly motion is driven by a motor system, controlled by the user. The pressure is generated by a high-velocity pump system controlled by the AQUABEAM Console. The user is allowed to adjust the desired flow rates manually. All functions are displayed on a medical panel computer. Pre-condition parameters are set on the console before operation."
224201561|NCT05157529|DEVICE|Apogee 2300 digital color doppler ultrasound imaging system|"The SIUI Apogee 2300 is a digital ultrasound imaging system capable of the following operating modes: B-Mode (B, 2B, 4B), M-Mode, CFM, CPA, PWD, CWD, Combined (B, M, CFM, CPA, PWD, CWD, XBeam, Panoscope), others (3D, 4D, Trapezoidal /Extended Sector Imaging, Elastography, Anatomical M-mode, TDI, MFI, ECG, VS Flow, Color M, DICOM).~The system is designed for use in linear, convex, phased array and 3D scanning modes and supports linear, convex, phased array, 3D and endocavity (trans-vaginal and trans-rectal) transducers. The system has cine review, image zoom, measurements and calculations, image storage and review, printing and recording capabilities."
224201562|NCT05188274|DIETARY_SUPPLEMENT|T92|T92 granules (5g/sachet) will be taken BID for 8 weeks, the dosage will be calculated by individual's body weight.
224201563|NCT05188274|DIETARY_SUPPLEMENT|Placebo|The placebo matched to T92 granules will be taken BID for 8 weeks.
224201564|NCT02325739|DRUG|FGF401|FGF401 is a FGFR4 inhibitor.
224201565|NCT02325739|BIOLOGICAL|PDR001|PDR001 is a humanized anti-PD1 IgG4 antibody that blocks the binding of PD-L1 and PD-L2
224201566|NCT04992897|DEVICE|Remote Electrical Neuromodulation (REN)|Acute migraine treament
224201567|NCT04637373|DIAGNOSTIC_TEST|Hysteroscopy|adding Hysteroscopy before and after suction curettage for early missed abortion to define the wall of implantation and look for retained products of conception
224201568|NCT03192631|OTHER|Financial incentive|Incentive of $15 Canadian
224201569|NCT03226366|OTHER|Immediate evaluation by multidisciplinary team|Simultaneous initial evaluation by the ED physician, nurse, and patient care associate
224201570|NCT02182726|DRUG|MOBEC|
224312057|NCT06971783|OTHER|AF - Gel of Acmella Oleracea extract associated with Fluoride.|The Acmella oleracea gel associated with fluoride will be applied to sensitive lesions and rubbed for 20 seconds with the aid of a microbrush, remaining on the lesions for 10 minutes.
223759357|NCT01041625|DRUG|Apremilast (CC-10004)|Apremilast 20 mg tablet PO administered BID over 12 weeks
223759358|NCT02040662|PROCEDURE|Continuous Thoracic Epidural Block|Before anesthesia, continuous thoracic epidural block of T5/T6 is performed (Portex Epidural Minipack set). Identification of paravertebral space by loss of resistance technique (air). A catheter is advanced ca. 3-5 cm, and test dose with 2 ml of lidocaine 2% i injected. At the end of surgery syringe with 0,25% bupivacaine with epinephrine 1:200.000 is connected to catheter and 6 ml bolus is injected, followed by an infusion of the same mixture at 0,06 ml/kg/h for postoperative pain management.
223759359|NCT02040662|PROCEDURE|Continuous Thoracic Paravertebral Block|Before anesthesia, continuous thoracic paravertebral block of T5/T6 is performed (Portex Epidural Minipack set). Identification of paravertebral space by loss of resistance technique (normal saline). After injection of 5-10 ml of normal saline a catheter is advanced medially ca. 5 cm. At the end of surgery syringe with 0,25% bupivacaine with epinephrine 1:200.000 is connected to catheter and 20 ml bolus is injected, followed by an infusion of the same mixture at 0,08 ml/kg/h for postoperative pain management
223759360|NCT02040662|PROCEDURE|Patient-Controlled Analgesia with Morphine|"Once arrived at the PACU all patients are placed on a postoperative analgesia regimen, that include:~* patient-controlled analgesia with morphine (bolus dose 2 mg, lockout time 10 min)~* paracetamol 1000 mg iv every 8 hrs~* ketoprofen 100 mg iv every 12 hrs"
223759361|NCT04488029|OTHER|PCT|PCT is designed to deliver similar therapy as is conventionally provided in-clinic by a Speech Language Pathologist (SLP), which the patient can access from any location using the application installed on a supported tablet. The device functions by allowing clinicians to create a personalized therapy program for each patient from 75 categories of clinical therapies, which patients may access from their tablet device remotely. The PCT software is comprised primarily of authentication and an algorithm that suggests advancement of the therapy program based on observed patient deficits and progress.
223613389|NCT01487135|DRUG|Moxifloxacin|A moxifloxacin 400 mg tablet administered orally on Day 1
223613390|NCT03868033|DRUG|Zoledronic Acid|Use Zoledronic acid as a sequential therapy after denosumab treatment for more than 2 years
223613391|NCT03868033|DRUG|Denosumab|Continuous Denosumab treatment in arm 1 for two years or as a 2nd year treatment in arm 2 for one year
223613392|NCT02863614|DRUG|Ibuprofen 600 mg|
223613393|NCT02863614|DRUG|Lorazepam 1 mg|
223613394|NCT02863614|DRUG|Placebo|
223613395|NCT06014346|OTHER|Psychological strategy|"* flyer given at the interview presenting the 4 most frequent fears as well as a description of the recommended muscular and breathing exercises,~* then realization accompanied by a training of these exercises"
223613396|NCT06014346|OTHER|Physiological strategy|\- ingesting a salty snack
223613397|NCT04493996|BEHAVIORAL|Cognitive training|The cognitive training involves a standardized, paper-and-pencil-based cognitive training that will be performed by the patients at home for approximately 40 minutes per day over a preoperative period of 2-3 weeks
223613398|NCT05555303|DRUG|Amikacin|"In addition to the all-oral RR-TB treatment, add two intramuscular doses each consisting of 30 mg amikacin/kg, a first dose on day 1 and a second dose on day 4, all in the first week of treatment.~The amikacin solution will be admixed with a lidocaine solution in the syringe before administration."
223613399|NCT02919644|BIOLOGICAL|autologous dendritic cells loaded with autologous tumour homogenate|Each vaccine dose consists of 10\_7 autologous dendritic cells loaded with autologous tumor homogenate
223613400|NCT02919644|DRUG|IL2|Each vaccine dose is followed, after two days, by IL-2 as adjuvant, at a dose of 3 MU daily for five consecutive days
223613401|NCT04546035|DEVICE|radial Extracorporeal Shockwave Therapy|rESWT was given on hamstring muscles, with the subject lying on prone position. No anesthesia was required.
223613402|NCT01751100|BEHAVIORAL|HIV Test Offer|HIV education and counseling from a trained Research Assistant and offering of a free rapid, oral HIV test
223613403|NCT01751100|BEHAVIORAL|General Health Screen Offer|A Research Assistant (RA) will provide health education on diabetes, hypertension, and HIV. The RA will then offer free blood pressure check, blood glucose measuring, rapid Hepatitis C (HCV) test, and a free, rapid oral HIV test.
223613404|NCT05561023|DRUG|Hawthorn red pigment|"For patients with refractory cancer pain who meet the enrollment conditions, on the basis of the clinician's normal adjustment of the analgesic regimen (the initial adjustment is the first day), the dose ramp up study of Hawthorn red pigment was started on the third day. The Hawthorn red dose group includes 10 tablets → 15 tablets → 20 tablets / time, orally, twice a day.~3 + 3 dose escalation scheme"
223613405|NCT02464436|DRUG|hRPC|Participants will undergo vitrectomy surgery and subretinal implantation of hRPC in the study eye.
223613406|NCT04001348|DEVICE|Acti-Lance Lite|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler. Perceived pain was assessed on the visual analog scale (VAS, numeric scale). VAS scale was assessed 5 minutes after the lancing procedure."
223613407|NCT04001348|DEVICE|Acti-Lance Universal|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler. Perceived pain was assessed on the visual analog scale (VAS, numeric scale). VAS scale was assessed 5 minutes after the lancing procedure."
223613408|NCT04001348|DEVICE|Acti-Lance Special|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler. Perceived pain was assessed on the visual analog scale (VAS, numeric scale). VAS scale was assessed 5 minutes after the lancing procedure."
223613409|NCT04001348|DEVICE|Medlance Plus Super Lite|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler. Perceived pain was assessed on the visual analog scale (VAS, numeric scale). VAS scale was assessed 5 minutes after the lancing procedure."
223613410|NCT04001348|DEVICE|Medlance Plus Lite|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler. Perceived pain was assessed on the visual analog scale (VAS, numeric scale). VAS scale was assessed 5 minutes after the lancing procedure."
223613411|NCT04001348|DEVICE|Medlance Plus Universal|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler. Perceived pain was assessed on the visual analog scale (VAS, numeric scale). VAS scale was assessed 5 minutes after the lancing procedure."
223613412|NCT04001348|DEVICE|Medlance Plus Extra|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler. Perceived pain was assessed on the visual analog scale (VAS, numeric scale). VAS scale was assessed 5 minutes after the lancing procedure."
223613413|NCT04001348|DEVICE|Medlance Plus Special|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler. Perceived pain was assessed on the visual analog scale (VAS, numeric scale). VAS scale was assessed 5 minutes after the lancing procedure."
223613414|NCT04001348|DEVICE|Prolance Micro Flow|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler. Perceived pain was assessed on the visual analog scale (VAS, numeric scale). VAS scale was assessed 5 minutes after the lancing procedure."
223613415|NCT04001348|DEVICE|Prolance Low Flow|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler. Perceived pain was assessed on the visual analog scale (VAS, numeric scale). VAS scale was assessed 5 minutes after the lancing procedure."
223759362|NCT04488029|OTHER|Workbooks|Subjects in this group will be provided with a standard regime of paper workbooks (e.g. Workbook for Aphasia: Exercises for Expressive and Receptive Language Functioning; Brubaker, 2006) that are typically used by clinicians to practice therapy tasks with individuals. Notably, the control procedure employed here is similar to that employed on a large-scale study examining technology as a treatment option and involved usual care control group by Palmer and colleagues (2015).
223759363|NCT04908254|DEVICE|Crossover Device (PCD or Dayspring - alternate to first group)|Cross over arms after a month of use and a month of washout period
223759364|NCT03779412|BEHAVIORAL|The Happiness Trap|Participants assigned to this condition will be asked to read this self-help book over an 8-week period.
223759365|NCT03779412|BEHAVIORAL|A Mindfulness-Based Stress Reduction Workbook|Participants assigned to this condition will be asked to read this self-help book over an 8-week period.
223759366|NCT00895739|BIOLOGICAL|alemtuzumab|
223759367|NCT00895739|DRUG|cyclosporine|
223759368|NCT04976491|DIETARY_SUPPLEMENT|CD-C-Food|CD patients combined with the characteristics of Chinese diet, remove the refined food, and combined with food intolerance detection method to check the corresponding food
223759369|NCT04976491|DIETARY_SUPPLEMENT|EEN|EEN goup received EEN continuously for 6 moths
223759370|NCT01167062|DRUG|Tamsulosin Hydrochloride OCAS 0.4 mg|One tablet OD for a maximum of 28 days
223759371|NCT01167062|OTHER|Placebo|One tablet OD for a maximum of 28 days
223759372|NCT03904459|OTHER|no intervention|
223613416|NCT04001348|DEVICE|Prolance Normal Flow|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler. Perceived pain was assessed on the visual analog scale (VAS, numeric scale). VAS scale was assessed 5 minutes after the lancing procedure."
223613417|NCT04001348|DEVICE|Prolance High Flow|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler. Perceived pain was assessed on the visual analog scale (VAS, numeric scale). VAS scale was assessed 5 minutes after the lancing procedure."
223613418|NCT04001348|DEVICE|Prolance Max Flow|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler. Perceived pain was assessed on the visual analog scale (VAS, numeric scale). VAS scale was assessed 5 minutes after the lancing procedure."
223613419|NCT04001348|DEVICE|Prolance Pediatric|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler. Perceived pain was assessed on the visual analog scale (VAS, numeric scale). VAS scale was assessed 5 minutes after the lancing procedure."
223759373|NCT01539226|COMBINATION_PRODUCT|Placebo Vaginal Ring|Dapivirine Vaginal Ring containing 0.0 mg of dapivirine
223759374|NCT01539226|COMBINATION_PRODUCT|Dapivirine Vaginal Ring, 25 mg|Dapivirine Vaginal Ring containing 25 mg of dapivirine
224201571|NCT01247649|DEVICE|Physical Logic Continuous Glucose Monitoring System|Patients will be monitored to assess continuous blood glucose levels using the study device (Physical Logic) and reference methods, during 2-3 clinic visits, lasting 6-8 hours each
224201572|NCT04281121|DIETARY_SUPPLEMENT|omega 3 fatty acids|: Life style modification, diet regimen and Omega-3 fatty acids supplementation: The dose of omega-3 fatty acids depended on the weight of patients according to World Health Organization recommendations 400 milligrams per 10 kilograms of body weight and had been given into two doses per day, before morning and evening meals
224201573|NCT04038411|DRUG|PD-1 Antibody, chidamide, lenalidomide and etoposide|PD-1 blocking antibody inhibits PD-1. Chidamide is an histone deacetylase inhibitor. Lenalidomide is a potent inhibitor of TNF-α. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA.
223759375|NCT05291299|BEHAVIORAL|Anti-inflammatory diet|Patients randomized to the intervention group will work with a registered dietitian to create an individualized diet program to help reduce inflammation and Rheumatoid arthritis related symptoms.
223759376|NCT05291299|OTHER|Control/Standard of Care|Patients randomized to the control group will be following standard of care where their doctor will instruct them to follow a Mediterranean diet and provides them with an instructional sheet.
223759377|NCT04633096|BEHAVIORAL|tailored feedback of depression screening results|The feedback for the participant contains the screening result, information about depression in general, guideline based treatment recommendations for patients and contact-information for treatment. The information is tailored to the participant's individual symptom profile, illness perceptions and preferences.
223759378|NCT04633096|BEHAVIORAL|standardized feedback of depression screening results|The feedback for the participant contains the screening result, information about depression in general, guideline based treatment recommendations for patients and contact-information for treatment.
223759379|NCT01099085|DRUG|Simvastatin|simvastatin 40 mg qd daily
223759380|NCT01099085|DRUG|Placebo|Placebo
223759381|NCT02183441|DRUG|BI 1356|
223759382|NCT02183441|DRUG|Ritonavir|
223759383|NCT01506531|PROCEDURE|silo for gastroschisis|silo placed around abdominal contents in gastroschisis patients
223759384|NCT01506531|PROCEDURE|Primary closure of gastroschisis|Primary closure of gastroschisis, if possible
223759385|NCT04118010|DRUG|Vitamin D3|High-dose vitamin D3 50,000 IU /week for 12 weeks
223759386|NCT04118010|DRUG|Placebo vitamin D3|Matching to Vitamin D3 placebo capsules for 12 weeks
223759387|NCT04118010|DRUG|Inulin|Chicory-derived prebiotic inulin 12 g/day for 12 weeks
223759388|NCT04118010|DRUG|Placebo Inulin|Corn-derived maltodextrin 12g/day as the prebiotic placebo for 12 weeks
223613420|NCT04001348|DEVICE|MediSafe Solo 29 Gauge|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler. Perceived pain was assessed on the visual analog scale (VAS, numeric scale). VAS scale was assessed 5 minutes after the lancing procedure."
223613421|NCT04001348|DEVICE|MediSafe Solo 23 Gauge|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler. Perceived pain was assessed on the visual analog scale (VAS, numeric scale). VAS scale was assessed 5 minutes after the lancing procedure."
223613422|NCT06238440|OTHER|Splint and taping methods|"In the control group (CG), a conventional physiotherapy program will be implemented for 2 weeks. A 10-session treatment will be completed using thermal and electrical agents specified in the program prescribed by the physiotherapist.~Splint group: CG + Splint Rigid taping group: CG+ Rigid taping Kinesiotape: CG+ kinesiotape"
223613423|NCT00824473|DRUG|Placebo|Placebo
223613424|NCT00824473|DRUG|0.15% azelastine hydrochloride|0.15% azelastine hydrochloride 822 mcg
223613425|NCT05528055|DRUG|SCR-6920 capsule|SCR-6920 capsule will be oral administered once daily at escalating doses on a continuous basis
223613426|NCT05528055|DRUG|SCR-6920 capsule|SCR-6920 capsule will be oral administered once daily at the recommended phase 2 dose on a continuous basis
223613427|NCT05528055|DRUG|SCR-6920 capsule|SCR-6920 capsule will be oral administered once daily at the recommended phase 2 dose on a continuous basis
223613428|NCT05528055|DRUG|SCR-6920 capsule|SCR-6920 capsule will be oral administered once daily at the recommended phase 2 dose on a continuous basis
223613429|NCT00358397|DRUG|Clostridium novyi-NT spores|
223613430|NCT03487991|BEHAVIORAL|Personalized sleep intervention|Personalized feedback and recommendations based on study observations of sleep behavior and how participants cope with potentially sleep disruptive cognitions on their frequency and impact and on sleep efficiency. A written report is provided to participants and their initial modifications are monitored.
223613431|NCT02125084|DRUG|Everolimus|
223613432|NCT02125084|DRUG|Enzalutamide|
223613433|NCT03959059|DEVICE|Mixed Reality technology|combine image with real body
223613434|NCT03871426|PROCEDURE|manual therapy|Manual Cervical Traction, Trunk Stabilization Maneuver
223613435|NCT02478463|DRUG|Cabotegravir tablet 30 mg once daily for 28 days.|GSK1265744B, lactose monohydrate, microcrystalline cellulose, hypromellose, sodium starch glycolate, magnesium stearate, Aquarius film-coating, white BP18237
223613436|NCT02478463|DRUG|Cabotegravir injection 3 mL (200 mg/mL) IM given once on Day 1.|Cabotegravir will be supplied as sterile suspension for injection 200 mg/mL vial. Each vial appears as sterile white to slightly colored suspension containing 200 mg/mL of CAB for administration by intramuscular (intragluteal) injection and will be administered as 1 × 3 mL Injections (3 mL \[600 mg\] total) IM given once on Day 1 of injection phase
223613437|NCT02036047|DEVICE|exclusive cold polypectomy snare (Exacto cold snare, product number 00711115)|
223613438|NCT02036047|DEVICE|Regular polypectomy snare (Snare Master, SD-210U-10)|
224312058|NCT06396858|DRUG|Rivaroxaban 2.5 Mg Oral Tablet|Patients will receive one tablet, per oral or orogastric route, twice a day, for a maximum of 12 months.
223613439|NCT02558855|OTHER|Thrust Joint Manipulation of the Lumbar Spine|
223613440|NCT02558855|OTHER|Non-thrust Joint Manipulation of the Lumbar Spine|
223613441|NCT03501472|BEHAVIORAL|text-only PWL|
223613442|NCT03501472|BEHAVIORAL|low-emot PWL|
223613443|NCT03501472|BEHAVIORAL|high-emot PWL|
223613444|NCT03501472|BEHAVIORAL|immed posttest|
223759389|NCT06196567|DEVICE|PEMF|Subjects will receive PEMF treatment with the duration of 8 weeks, twice a week with total 16 treatment sessions
223759390|NCT06196567|OTHER|exercise|do the exercise aimed at improving knee muscle strength,twice a week for 8 weeks before surgery
223759391|NCT00401011|DRUG|Perifosine|"Phase I: Patients will receive daily perifosine (doses 50 mg/m2 or 100 mg/m2) at bedtime.~Phase II: All patients will receive daily perifosine at bedtime. Patients will be evaluated every 3 weeks."
224312059|NCT06396858|DRUG|Colchicine 0.5 MG|Patients will receive one tablet, per oral or orogastric route, once a day, for a maximum of 12 months.
224312060|NCT06396858|DRUG|Placebo Rivaroxaban|Patients will receive one tablet, per oral or orogastric route, twice a day, for a maximum of 12 months.
223613445|NCT03501472|BEHAVIORAL|delay posttest|
223613446|NCT03266133|BEHAVIORAL|Sleep Education for Pregnancy|Sleep education specific to pregnancy
223613447|NCT03865082|DRUG|Tilsotolimod|9 doses of Tilsotolimod Intratumoral injection administered as a dose of 8mg at Week 0 Day 1 (7 days prior to the start of Cycle 1), Day 1 and Day 8 of Cycle 1, and on Day 1 of Cycles 2 through 7.
223613448|NCT03865082|DRUG|Nivolumab|Specified dose on specified days.
223613449|NCT03865082|DRUG|Ipilimumab|Specified dose on specified days.
223613450|NCT00962637|DRUG|Androxal|12.5 mg once daily
223613451|NCT00962637|DRUG|Androxal|25 mg once daily
223613452|NCT00962637|DRUG|AndroGel|5 g applied topically daily. The subject was to return to the clinic every 2 weeks for the first 2 months to monitor serum testosterone levels. If testosterone concentration remained below the normal level, the dose of AndroGel® could have been increased to 10 g and then to 15 g according to the guidance provided in the product package insert.
223613453|NCT00962637|DRUG|Placebo|1 capsule daily
223613454|NCT01749969|DRUG|isatuximab SAR650984|Pharmaceutical form:solution Route of administration: intravenous
223613455|NCT01749969|DRUG|lenalidomide|Pharmaceutical form:capsules Route of administration: oral
223613456|NCT01749969|DRUG|dexamethasone|Pharmaceutical form:solution or tablet Route of administration: intravenous or oral
223613457|NCT05233592|DEVICE|CGM|Patients wear a CGM to measure the effects of the COVID-19 booster vaccine on blood sugar levels.
223759392|NCT00401011|DRUG|Bortezomib|Phase I: Patients will receive 1 mg/m2 or 1.3 mg/m2 on days 1, 4, 8, and 11 every 3 weeks. Phase II: Patients will receive bortezomib on days 1,4,8 and 11 every 3 weeks.
224201574|NCT04846010|COMBINATION_PRODUCT|PurWet|(1) cang zhu (Atractylodis Rhizoma), bai (zhu Atractylodis macrocephalae Rhizoma), dang shen (Codonopsis Radix), huang qi (Astragali Radix), Fu ling (Poria), Zhu ling (polyporus), Ze xie (Alismatis Rhizoma), Yi yi ren (Coicis Semen), gan cao (Glycyrrhizae Radix),
223509487|NCT00576407|BIOLOGICAL|Cultured Thymus Tissue for Implantation (CTTI)|Cultured thymus tissue for implantation (CTTI) (previously described as transplantation) is done using allogeneic cultured postnatal tissue from unrelated thymus donors. Thymus tissue, the thymus donor, \& thymus donor's birth mother were screened for safety. Approximately 2-3 weeks post-harvest thymus slices were implanted into the recipient's quadriceps. Dose was number of grams of cultured thymus tissue divided by the recipient's weight in kilograms. Minimum dose was 4 g/m2. Maximum dose 18g/m2. At time of CTTI, a skin biopsy was obtained to look for preexisting T cells. 2-3 months post-CTTI allograft biopsy to evaluate for thymopoiesis \& graft rejection. At time of biopsy, skin biopsy done to look for T cell clonal populations. Post-CTTI, subjects followed by routine research immune evaluations, using blood samples for approximately 2 years.
223509488|NCT06207851|DEVICE|Transcatheter Arterial Micro-Embolization|Participants will undergo TAME with Nexsphere-F.
223613458|NCT01749306|BIOLOGICAL|ABH001|ABH001 applications topically every 4 weeks (±1 week) with protocol-specified dressings until wound healed or up to 44 weeks
223613459|NCT01749306|OTHER|Control wound treatment|Control wound care with protocol-specified dressings every 4 weeks (±1 week) up to 20 weeks with optional cross-over to ABH001 for additional 20 weeks
223613460|NCT00814450|DEVICE|Biopsy needle guidance system (ActiSight™)|The ActiSight system assists in guiding an aspiration or biopsy needle, to a designated point within the body by means of CT visualization.
223613461|NCT03653858|DEVICE|Vercise GEVIA deep brain stimulation (DBS) system|DBS to the superolateral branch of the Medial Forebrain Bundle (slMFB)
224201575|NCT04846010|COMBINATION_PRODUCT|FurFat|(2).shan zha (Crataegi Fructus), Jue Ming Zi (Cassiae Semen), He ye (Nelumbinis Folium), Da huang (Rhei Radix et Rhizoma), Ze xie (Alismatis Rhizoma), dan shen ( Salviae miltiorrhizae Radix).
224201576|NCT04846010|COMBINATION_PRODUCT|PurApo|(3)Sheng Di Huang (Rehmanniae Radix), Xuan Shen (Scrophulariae Radix), mai men dong (Ophiopogonis Radix), shan zhu yu (Corni Fructus), shan yao (Dioscoreae Rhizoma), sha yuan zi (Astragali complanati Semen), ci ji li (Tribuli Fructus), nu zhen zi (Ligustri lucidi Fructus)
224201577|NCT04846010|COMBINATION_PRODUCT|PurPhl|(4) chen pi (Citri reticulatae Pericarpium), hua ju hong (Citri grandis Exocartium rubrum), zhi shi (Aurantii Fructus immaturu), zhi ban xia (Pinelliae Rhizoma preparatum), zhi tian nan xing (Arisaematis Rhizoma preparatum),sha ren (Amoni Fructus), Gua lou (Trichosanthis Fructus), Chuan bei mu ( Fritillatiae cirrhosae Bulbu), Fu ling ( Poria), Da huang ( Rhei Radix et Rhizoma).
224201578|NCT04846010|COMBINATION_PRODUCT|PurClo|(2) Dan shen (Salviae miltiorrhizae Radix), Yu jin (Curcumae Radix), chi shao (Paeoniae Radix rubra), tao ren (Persicae Semen), hong hua (Carthami Flos)
224201579|NCT04846010|COMBINATION_PRODUCT|PurInf|(1) lei gong teng (Tripterygii wilfordii Radix), Huang Qin (Scutellariae Radix), Huang Lian (Coptidis Rhizoma), Huang Bai (Phellodendri Cortex), Zhi Zi (Gardeniae Fructus).
224201580|NCT04846010|COMBINATION_PRODUCT|Smoliv|(2). Vagus never communicates with LES: yu jin (Curcumae Radix), Chai Hu (Bupleuri Radix), chi shao (Paeoniae Radix rubra), Mu Dan Pi (Moutan Cortex), chuan lian zi (Toosendan Fructus), long gu (Fossilia Ossis Mastodi), mu li (Ostreae Concha)
223613462|NCT04161742|DEVICE|Nevisense|Nevisense measures electrical impedance of skin lesions and provides an output called the electrical impedance spectroscopy (EIS) score
223613463|NCT00195039|DRUG|177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu -J591)|"Eligible patients will receive a single dose of 177Lu-J591 (65 or 70 mCi/m2) consisting of J591 chelated at a specific activity of 12-15 mCi of 177Lu per mg of antibody plus sufficient non-radiolabeled, non-DOTA-conjugated (naked) J591 to achieve a total antibody dose of 20 mg. Each dose will be administered by an IV infusion at a rate not to exceed 5 mg/min."
223613464|NCT01814527|DIETARY_SUPPLEMENT|Docosahexaenoic acid|5 capsules containing 440mg of Docosahexaenoic acid (DHA)for total daily dosing of 2200mg of DHA daily
223613465|NCT01814527|DRUG|Placebo|5 capsules that are identical to the treatment.
223613466|NCT04524858|DRUG|ATI-450|Oral, small molecule MK2 inhibitor
223613467|NCT03479086|DRUG|Topiramate|200mg/day 100mg b.i.d
223613468|NCT03479086|DRUG|Naltrexone|50mg/day
224201581|NCT04803032|PROCEDURE|Superficial parotidectomy|The parotid gland was exposed with its capsule by subplatysmal and SMAS flaps. Dissection was performed from the tragal cartilage until the bony anterior wall of the external auditory canal; from there, the dissection was done using a blunt instrument. The styloid process's base is the upper point of the trident landmark; it is the superior portion of the trident landmark. Identification of the posterior belly of the digastric muscle till its origin was performed deep to the sternocleidomastoid muscle. ); it is the lower point of the landmark. The FNT is located in the region between these two structures. The dissection after identification of the main trunk of the facial nerve was similar to the routine parotidectomy. The surgical defect was closed over a removac suction drain using Vicryl materials; the skin was closed by 6-0 absorbable sutures. A dressing was applied to the surgical site. Then, a gauze was wrapped over the parotid area and secured around the forehead and neck.
224312061|NCT06396858|DRUG|Placebo Colchicine|Patients will receive one tablet, per oral or orogastric route, once a day, for a maximum of 12 months.
224314293|NCT03636997|PROCEDURE|Rerouting of track|The seton and fistula track were rerouted to involve the internal anal sphicnter only and spare the external sphincter
223613469|NCT06423469|DEVICE|Noninvasive ICP monitoring|The brain4care system is a FDA approved noninvasive device for surrogate intracranial pressure monitoring. Serial monitoring sessions were performed in included patients. Information recorded was for study purposes only and did not affect any therapy planned for the attending teams.
223613470|NCT02109640|DRUG|Targinact|Post-operative analgesia
223613471|NCT02109640|DRUG|Oxycodone|Postoperative analgesia
223613472|NCT02109640|PROCEDURE|Laparoscopic segmental colectomy|
223613473|NCT03155126|OTHER|Fluid resuscitation|Patients in the saline group were resuscitated with saline, patients in the other group were resuscitated with acetated Ringer's sodium
223759393|NCT00401011|DRUG|Dexamethasone|Phase II: If the patient shows progressive disease after 3 weeks, dexamethasone 20 mg will be added to perifosine and bortezomib on days 1, 2, 4, 5, 8, 9, 11, 12, 15, 16, 18, and 19 to perifosine at bedtime and bortezomib IV on days 1, 4, 8, and 11 q 21 days.
224201582|NCT02676271|PROCEDURE|Proximal varus derotational osteotomy|The purpose of surgery was to relocate the protruded, deformed femoral head from its lateral position back to the acetabulum to achieve containment. Surgery was preceded by a hip arthrography with dynamic examination to find the suitable containment position and plan the correct osteotomy angles accordingly. A sub trochanteric osteotomy was performed then after in an open or closed wedge form, with fixation in an angle that gave best coverage.
223509489|NCT05265364|RADIATION|IMRT with SIB|moderate hypofractioation using 2.5gy/fr in prostate cancer patients usig IMRT SIB technique
223509490|NCT02980900|DIETARY_SUPPLEMENT|Post exercise protein-polyphenol supplement|Participants will ingest a post exercise protein-polyphenol supplement. This will begin 6 days before eccentric exercise and will end 6 days after eccentric exercise.
223509491|NCT02980900|DIETARY_SUPPLEMENT|Post exercise placebo supplement|Participants will ingest an isocaloric placebo supplement after exercise. This will begin 6 days before eccentric exercise and will end 6 days after eccentric exercise.
223509492|NCT02980900|DIETARY_SUPPLEMENT|Pre bed protein-polyphenol supplement|Participants will ingest a protein-polyphenol supplement before bed. This will begin 6 days before eccentric exercise and will end 6 days after eccentric exercise.
223509493|NCT02980900|DIETARY_SUPPLEMENT|Pre bed placebo supplement|Participants will ingest an isocaloric placebo supplement before bed. This will begin 6 days before eccentric exercise and will end 6 days after eccentric exercise.
223509494|NCT06372483|DRUG|VMX-C001|VMX-C001 is human factor X engineered to be insensitive to factor Xa DOACs
223509495|NCT06372483|DRUG|Placebo|VMX-C001 matched placebo
223509496|NCT06372483|DRUG|Rivaroxaban 20 mg Oral Tablet|Fxa DOAC
223509497|NCT06372483|DRUG|Apixaban 5 mg Oral Tablet|Fxa DOAC
223509498|NCT06372483|DRUG|Edoxaban 60 mg Oral Tablet|Fxa DOAC
223509499|NCT00756444|DRUG|Panitumumab|This is a PK study comparing Panitumumab plus Chemotherapy to Chemotherapy alone
223509500|NCT00756444|DRUG|Cisplatin|This is a PK study comparing Panitumumab plus Chemotherapy to Chemotherapy alone
223509501|NCT00756444|DRUG|5FU|This is a PK study comparing Panitumumab plus Chemotherapy to Chemotherapy alone
223509502|NCT04579419|DRUG|Sodium Bicarbonate|Botulinum Toxin diluted in Sodium Bicarbonate
223509503|NCT04579419|DRUG|Normal Saline|0.9 NaCl
223509504|NCT02380157|DRUG|Kaleorid, 750mg (trade name), Potassium chloride (active substance)|4 weeks treatment with Kaleorid, 750mg, 3 tablets 3 times daily.
223613474|NCT02461654|OTHER|Disc FX|Disc FX is an innovative system allowing for a safe and effective approach to a damaged disc without injury to the surrounding structures. The procedure consists of three phases: during the first phase, the disc is punctured with a special needle that functions as a working channel. This needle is used to remove part of the degenerate inner tissue. Then, using a radio-frequency probe, the disc is sealed to minimize the risk of repeated herniation. In the final step, the pathological nerves in the back part of the disc are destroyed with the use of radio-frequency.
223613475|NCT03904212|PROCEDURE|Adipose tissue injection|Injection with freshly harvested autologous adipose tissue
223613476|NCT03904212|PROCEDURE|saline|injection with saline
223613477|NCT03563820|BEHAVIORAL|Resilience and Well-Being Program|"The Resilience and Well-Being Program is offered through VA Puget Sound Rehabilitation Care Services as part of standard clinical care offerings. The program includes five (5) positive psychology group sessions once a week for five weeks. Participants will use strengths-based strategies, narrative strategies, and prospective strategies to learn ways to deal with stressful life challenges and improve their mental health and well-being.~Each participant will be given a brief rating sheet at the end of each session to fill out. The rating sheet will ask participants to rate different aspects of the session (e.g., how helpful or interesting the session was to the participant), if home practice activities were assigned, whether the participant completed the home practice assignment, as well as feedback to improve that session."
223613478|NCT06020157|OTHER|Simple Suture Technique|The half of the full arch flap will be closed by the simple suture technique.
223613479|NCT06020157|OTHER|Continuous Suture Technique|The half of the full arch flap will be closed by the continuous suture technique.
223613480|NCT00669890|DRUG|Gemtuzumab Ozogamicin|Dose Escalation
223613481|NCT00669890|DRUG|Busulfan|Conditioning Regimen
223613482|NCT00669890|DRUG|Cyclophosphamide|Conditioning Regimen
223613483|NCT00669890|DRUG|Thymoglobulin|(Unrelated Donors only)
223613484|NCT00669890|DRUG|Tacrolimus|GVHD Prophylaxis
223613485|NCT00669890|DRUG|Mycophenolate Mofetil|GVHD Prophylaxis
223613486|NCT00669890|DRUG|Methotrexate|GVHD Prophylaxis
223613487|NCT03507036|DEVICE|Profound system|Profound system is a bipolar fractional radiofrequency device which uses microneedles and thermal heat to stimulate neocollagenesis. Based on the its effect on facial skin, it can be hypothesized that bipolar fractional radiofrequency will stimulate similar effect on suprapatellar skin, lifting and reducing laxity of the skin in that region. Bilateral suprapatellar regions will be identified and marked for treatment.
223613488|NCT02296567|DRUG|Ranibizumab|Drug: Ranibizumab Subjects will receive intravitreal Ranibizumab as part of their routine medical care.
223613489|NCT02296567|DRUG|Bevacizumab|Drug: Bevacizumab Subjects will receive intravitreal Bevacizumab as part of their routine medical care.
223613490|NCT02296567|DRUG|Aflibercept|Drug: Aflibercept Subjects will receive intravitreal Aflibercept as part of their routine medical care.
223613491|NCT02296567|DRUG|Ranibizumab|Drug: Ranibizumab Subjects will receive intravitreal Ranibizumab as part of their routine medical care.
223613492|NCT02296567|DRUG|Bevacizumab|Drug: Bevacizumab Subjects will receive intravitreal Bevacizumab as part of their routine medical care
223509505|NCT02380157|DRUG|Placebo|4 weeks treatment with Placebo tablets, 3 tablets 3 times daily.
223509506|NCT00122863|DRUG|Duloxetine Hydrochloride|
223509507|NCT00122863|DRUG|placebo|
223509508|NCT00083447|DRUG|TransMID™|
223509509|NCT04269785|DEVICE|Cryoballoon ablation|Ablation aimed at performing pulmonary vein isolation for atrial fibrillation using cryoballoon catheter (cold therapy)
224201583|NCT06378112|DRUG|GTO®|After teeth extraction, a guided bone regeneration procedure will be performed using a bone graft and a soft collagenated cortical membrane as graft stabilizer. Implant placement surgery will also be performed.
223759394|NCT03696524|DEVICE|tunneled pleural catheter|Placement of a tunneled pleural catheter through the chest wall into the pleural space to drain the patient's chronic pleural effusion. The catheter is an indwelling device that will be drained from home three times per week by nursing care, the patient, or patient's family.
223759395|NCT04447092|DRUG|Gemcitabine|Gemcitabine 1000 mg/m2 iv D1, 8, 15 (every 4 weeks)
223759396|NCT04447092|DRUG|Nab-paclitaxel|Nab-paclitaxel 125 mg/m2 iv D1, 8, 15 (every 4 weeks)
223759397|NCT04447092|DRUG|Pembrolizumab|Pembrolizumab ( 200 ) mg iv D1 (every 3 weeks)
223759398|NCT04447092|DRUG|Oxaliplatin|Oxaliplatin 65 mg/m2 iv over 2 hours D1 (every 2 weeks)
223759399|NCT04447092|DRUG|Leucovorin|Leucovorin 400 mg/m2 iv D1 (every 2 weeks)
223759400|NCT04447092|DRUG|Irinotecan|Irinotecan 140 mg/m2 iv over 1.5 hours D1 (every 2 weeks)
223759401|NCT04447092|DRUG|5FU|5-FU 2400 mg/m2 iv over 46 hours D1 (every 2 weeks)
223759402|NCT00613600|DIETARY_SUPPLEMENT|Glucomannan|Two 665 mg capsules of glucomannan three times a day for 8 weeks
223759403|NCT00613600|DIETARY_SUPPLEMENT|Inert microcrystalline cellulose|Two capsules of inert microcrystalline cellulose three times a day for eight weeks
223613493|NCT02296567|DRUG|Aflibercept|Drug: Aflibercept Subjects will receive intravitreal Aflibercept as part of their routine medical care
223613494|NCT02296567|DRUG|Ranibizumab|Drug: Ranibizumab Subjects will receive intravitreal Ranibizumab as part of their routine medical care
223613495|NCT02296567|DRUG|Bevacizumab|Drug: Bevacizumab Subjects will receive intravitreal bevacizumab as part of their routine medical care
223613496|NCT02296567|DRUG|Aflibercept|Drug: Aflibercept Subjects will receive intravitreal Aflibercept as part of their routine medical care
223613497|NCT02296567|OTHER|Control Group|Control group Subjects will no previous anti-VEGF treatment
223613498|NCT00348985|DRUG|belinostat|
223613499|NCT00348985|DRUG|bortezomib|
223613500|NCT00348985|OTHER|pharmacological study|
223613501|NCT04283305|OTHER|Virtual reality approach avoidance training|In the VR-based AAT, patients are situated in a bar environment where drinks appear on a bar table in front of them. Patients are instructed to react to 100% of the alcoholic beverages with a push response with a controller, and to non-alcoholic drinks in 100% of the trials with a pull response. The stimuli set consists of 50 different beverages, which are displayed three times in total.
223613502|NCT04283305|OTHER|Computer-based approach avoidance training|In the computer-based AAT, patients are situated in front of a computer where drinks appear on the screen in front of them. Patients are instructed to react to 100% of the alcoholic beverages with a push response with a joystick, and to non-alcoholic drinks in 100% of the trials with a pull response. The stimuli set consists of 50 different beverages, which are displayed three times in total.
223613503|NCT03790566|DRUG|Bupivacaine|0.5 ml/kg 0.25% bupivacaine
223613504|NCT03214107|OTHER|Exercise|Participants will be admitted at IRCM at 14:00. At 15:30, participants will performed a 60-minute exercise on the ergocycle at 60% of VO2 peak (moderate intensity). During exercise, capillary glucose levels will be measured every 10 minutes. At 16:30, the exercise will be completed and capillary glucose levels will be monitored every 20 minutes for 1 hour. At 17:30, the participant will be discharged.
223759404|NCT04117126|BEHAVIORAL|Prompted voiding|"Monitoring: This involves asking the incontinent individual, at regular intervals, if he or she needs to use the toilet. The care provider may look for behaviours that the client needs to be toileted (e.g., restlessness, agitation, disrobing), and take the client to the toilet at regular intervals specific to their schedule, rather than routinely every two hours.~Prompting: This process includes prompting the person to use the toilet at regular intervals, and encourages the maintenance of bladder control between prompted voiding sessions.~Praising: This important step is the positive reinforcement of dryness and appropriate toileting, and is the response from the care provider to the individual's success with maintaining bladder control."
224314294|NCT05850585|DRUG|Fecal microbiota transplantation(FMT)|Subjects will receive FMT capsules (10\^12 Colony-Forming Units(CFU)/capsule) in addition to their usual antipsychotics treatment. Subjects will continue to receive FMT capsules for 8 weeks. During this period, both groups could receive first-line atypical antipsychotics recommended by current treatment guidelines.
223613505|NCT03214107|OTHER|Snack|Full snack or Distributed snack
223613506|NCT00764439|DRUG|Nicotine replacement therapy|Nicotine replacement therapy with Standard NRT user direction
223613507|NCT00764439|DRUG|Nicotine replacement therapy|Nicotine replacement therapy with a Novel NRT user direction
223759405|NCT05229224|OTHER|Osteo fluidic Sensitive méthod|Manual therapy, without manipulative treatment, based on rebalancing of the body with manual pressures on specific body areas.
223759406|NCT05229224|OTHER|Placebo method|Soft Manual pressures at specific points that are defined as non-effective and non-deleterious for patients.
223759407|NCT01664143|DRUG|Placebo|Multiple doses of placebo
223759408|NCT01664143|DRUG|RO5508887|Multiple doses of RO5508887
223759409|NCT06471647|DRUG|delta-9-tetrahydrocannabinol (THC) (5)|5 mg of THC
223759410|NCT06471647|DRUG|Placebo|Placebo - dextrose
223759411|NCT06471647|DRUG|delta-9-tetrahydrocannabinol (THC) (10)|10 mg of THC
223613508|NCT05362123|OTHER|non interventional|Online google form questioner
223613509|NCT03746626|BEHAVIORAL|Chaplain visit|The patients will all see a chaplain routinely during 8-week stay according to their personal preference. The chaplain records the 'depth' and frequency of these encounters.
223613510|NCT04494035|DEVICE|CAPERE Thrombectomy System|Arteriovenous graft thrombectomy
223613511|NCT01809821|BEHAVIORAL|Online Sleep Education|
223759412|NCT02455310|BEHAVIORAL|Educational activities to improve dementia care|The multicomponent intervention included active dissemination of educational resources and optional participation in specialist consultation sessions for up to 6 months. The standard intervention included education through a website or conferences, including clinical tools to support implementation of best practices.
223759413|NCT03844126|OTHER|Transition classes|90 minutes spent with patients and their families (separately) to review the changes and challenges associated with healthcare transition and help alleviate some of the barriers traditionally associated with this process.
223759414|NCT02150668|BEHAVIORAL|Homework, Organization, and Planning Skills (HOPS) Intervention|
223759415|NCT02150668|BEHAVIORAL|Homework Support Intervention (HSI)|
223613512|NCT03167333|DRUG|platelet rich plasma|The amount of PPR was about 4-5 cc
223613513|NCT03167333|DRUG|Hyaluronic acid|HA was 2.5cc
223613514|NCT03178383|BEHAVIORAL|Project HEAL|Standard group churches will not be asked to, or provided special encouragement to technical assistance with, institutionalizing health promotion activities in their churches.
223613515|NCT03178383|BEHAVIORAL|Project HEAL 2.0|In this approach, rather than developing a separate health ministry, cancer activities could be integrated throughout existing church ministries (e.g. men's, women's, seniors).
223613516|NCT02749539|DEVICE|Kinesio tape|Standard 2 -inches ( 5-m) Kinesio TexR tape was used for application in the experimental group
223613517|NCT02749539|PROCEDURE|physiotherapy program|active-assistive range of motion exercises (AAROME), active stretching exercises and strengthening exercises for the shoulder joint. Likewise, patients also received postural correction exercises
223613518|NCT02867735|DRUG|LKA651|Interventional
223613519|NCT02867735|OTHER|Sham Comparator|
223613520|NCT04731389|BEHAVIORAL|internet-based cognitive-behavioral therapy|Composed of 4 modules: the first module will address psychoeducation on dermatillomania, self-monitoring of symptoms and habit reversal techniques; the second module works with anxiety coping techniques (diaphragmatic breathing and muscle relaxation); module 3 addresses cognitive correction techniques, such as stopping thinking, analyzing evidence, reassigning severity and responsibilities; the last module reviews the techniques learned and addresses techniques for preventing symptom relapse. The modules will be applied by the patient in an online format, each module lasts an average of 30 minutes. The platform will send notice by email through automation tools, SMS or message by application to patients to remind them to complete 1 module per week.
223613521|NCT04731389|BEHAVIORAL|Quality of life improving intervention|consisting of videos with guidance on quality of life, with a total of 4 videos of 2 minutes, each being made available in 1 week, consisting of: guidance on sleep hygiene; guidance on healthy eating; guidelines on the practice of physical activity and guidelines on the excessive use of social networks.
223613522|NCT05505448|DRUG|REGN14284|Single ascending intravenous (IV) or subcutaneous (SC) administration per the protocol
223509510|NCT04269785|DEVICE|Radiofrequency ablation|Ablation aimed at performing pulmonary vein isolation for atrial fibrillation using radiofrequency catheter (heat therapy)
223509511|NCT04879732|DEVICE|ACTIS|ACTIS Hip stem
223509512|NCT06640582|BIOLOGICAL|Tumor Infiltrating Lymphocytes (TIL)|Tumor Infiltrating Lymphocytes (TIL) IV
223509513|NCT06640582|DRUG|Cyclophosphamide|Cyclophosphamide will be administered as an intravenous (IV) infusion for two days.
223509514|NCT06640582|DRUG|Fludarabine|Fludarabine will be administered as an intravenous (IV) infusion for five days.
223509515|NCT06640582|DRUG|Interleukin-2|After TIL infusion, IL-2 will be started as a bolus administration every eight hours, for a maximum of eight doses.
223509516|NCT06640582|DRUG|Pembrolizumab|Intravenous (IV) infusion
223509517|NCT06638164|OTHER|Control|No attempt was made to increase knowledge, skills and satisfaction. Standard procedure (oral explanation) was applied.
223509518|NCT06638164|OTHER|Virtual reality glasses|In order to increase knowledge, skills and satisfaction, isolation training was given with virtual reality glasses.
223509519|NCT03852693|OTHER|Histopathological review|Histopathological review
223509520|NCT03982693|DRUG|Edetate Disodium|The solution contains up to 3 g of edetate disodium adjusted based on creatinine clearance, 2 g of magnesium chloride, 100 mg of procaine hydrochloride, 2500 U of heparin, 7 g of ascorbate, 2 milliequivalent (mEq) potassium chloride (KCl), 840 mg sodium bicarbonate, 250 mg pantothenic acid, 100 mg of thiamine, 100 mg of pyridoxine, and sterile water to complete 500 mL.
223509521|NCT03982693|OTHER|Placebo|Placebo infusions consist of 500 ml normal saline.
223509522|NCT06641752|DIAGNOSTIC_TEST|Blood drop sampling|The process: blood drop sampling Technique: capillary sampling Frequency: Once Time: 5 minutes Sample collection volume: 1mL Total collection volume: 1 mL
223509523|NCT06642532|DEVICE|TCD group|Transcranial Doppler ultrasound to examine bilateral hemodynamic parameters of middle cerebral artery(MCA), terminal internal carotid artery(TICA), (anterior communicating artery)ACA, and posterior cerebral artery(PCA) (Vs, Vd, Vm, PI index, RI index) from temporal window
223509524|NCT03603184|DRUG|Atezolizumab|Atezolizumab will be administered as I.V. infusion at a fixed dose of 1200 mg, every 21 days until objective radiological disease progression as assessed by the investigator if they do not meet any other discontinuation criteria (patient refusal, toxicity).
223613523|NCT05505448|DRUG|Matching Placebo|Single ascending IV or SC administration per the protocol
223613524|NCT05065905|DRUG|Interferon-Gamma|received by microbiological synthesis; specific antiviral activity on cells is 2x10\*7 Units per mg of protein
223613525|NCT02414308|DRUG|Adipose tissue stem cell injection|Stem cell will be harvested through adipose tissue by liposuction and isolation occurred Injection will distribute through corpora cavernosa and dorsal penile artery
223613526|NCT01933308|OTHER|Continuous high intensity training-CT80|Continuous exercise training at 80% of peak work rate Heart rate (HR) response observed at their target training intensity will be identified from an incremental exercise test completed at baseline. Subjects will be asked to train within ±5beats/min of this HR. Subjects will also perform upper-extremity strength training, stretching and relaxation exercises. Overall, sessions will last approximately 2hrs, including cycling (45-60min), strength training (30min), stretching (10min) and relaxation exercises (20min). Sessions will be held on Mondays, Wednesdays and Fridays. Supervision will be provided by clinical exercise physiologists trained by Dr. Pepin. Self-management training (Living Well with COPD®) will be provided by a healthcare practitioner trained by Dr. Lavoie.
223613527|NCT01933308|OTHER|Training at ventilatory threshold-CTVT|Continuous exercise training at the ventilatory threshold Heart rate (HR) response observed at their target training intensity will be identified from an incremental exercise test completed at baseline. Subjects will be asked to train within ±5beats/min of this HR. Subjects will also perform upper-extremity strength training, stretching and relaxation exercises. Overall, sessions will last approximately 2hrs, including cycling (45-60min), strength training (30min), stretching (10min) and relaxation exercises (20min). Sessions will be held on Mondays, Wednesdays and Fridays. Supervision will be provided by clinical exercise physiologists trained by Dr. Pepin. Self-management training (Living Well with COPD®) will be provided by a healthcare practitioner trained by Dr. Lavoie.
223613528|NCT01933308|OTHER|Interval training-IT|High intensity interval training Heart rate (HR) response observed at their target training intensity will be identified from an incremental exercise test completed at baseline. Subjects will be asked to train within ±5beats/min of this HR. Subjects will also perform upper-extremity strength training, stretching and relaxation exercises. Overall, sessions will last approximately 2hrs, including cycling (45-60min), strength training (30min), stretching (10min) and relaxation exercises (20min). Sessions will be held on Mondays, Wednesdays and Fridays. Supervision will be provided by clinical exercise physiologists trained by Dr. Pepin. Self-management training (Living Well with COPD®) will be provided by a healthcare practitioner trained by Dr. Lavoie.
223613529|NCT02789059|OTHER|muscle oxygenation|Subjects will be invited to perform an isokinetic effort of the knee extensors against an isokinetic dynamometer. During this effort, muscle oxygenation and oxygen consumption will be assessed with a near infrared spectroscopy device and a gas exchange measurement device. Patients affected by Becker muscular dystrophy and healthy controls will be invited to have a muscle biopsy of the vastus lateralis.
223613530|NCT00148759|DRUG|LPV/r|LPV/r 800/200 mg once daily
223613531|NCT03408197|DEVICE|EasyWarm|Perioperative warming with EasyWarm to prevent inadvertent hypothermia during anaesthesia
223613532|NCT03408197|DEVICE|BairHugger|Perioperative warming with BairHugger to prevent inadvertent hypothermia during anaesthesia
223613533|NCT04230317|DIAGNOSTIC_TEST|Chest CT|Low dose CT taken with three different protocols
223613534|NCT01557426|OTHER|Ultrasound|A linear ultrasound transducer will be used with ultrasound gel to obtain an image of subcutaneous structures and tissues over the involved body site. Ultrasound video will be recorded whenever possible, however studies that are not recorded will still be included. Video recording will be initiated once the desired image is obtained. Appropriate measurements will be made and views identified using the features of the ultrasound machine. Scanning of the contralateral body segment will then be performed. The ultrasound probe will be thoroughly cleaned and disinfected between ultrasound scans.
223613535|NCT06342908|PROCEDURE|Biospecimen Collection|Undergo blood and stool sample collection
223613536|NCT06342908|BIOLOGICAL|Dendritic Cell Therapy|Given PpDC vaccine ID
223613537|NCT06342908|PROCEDURE|Leukapheresis|Undergo leukapheresis
223613538|NCT06342908|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223613539|NCT06342908|DRUG|Poly ICLC|Given IM
223613540|NCT02703298|DRUG|TRX-818 capsules|
223613541|NCT05183945|DEVICE|Localization needle|A localization needle which is used for preoperative localization of lung nodules.
223613542|NCT05183945|DEVICE|Coil|A coil which is used for preoperative localization of lung nodules.
223613546|NCT04112966|PROCEDURE|14 sessions of manual lymphatic drainage technique|Early manual lymph drainage including 14 sessions of manual lymphatic drainage technique in the three months following surgery and health education for lymphedema prevention including verbal instructions and written materials.
223613547|NCT04112966|OTHER|the health education|The health education for lymphedema prevention.
223613548|NCT06023940|DIETARY_SUPPLEMENT|High fiber|A pea fiber supplement is added to a diet of regular foods. Participants receive 25g fiber daily.
223613549|NCT01365728|PROCEDURE|LASIK with the iFS femtosecond laser|Patients will undergo bilateral simultaneous LASIK surgery for myopia. One eye will have a LASIK flap created with the Intralase FS60 and the fellow eye will have a LASIK flap created with the Intralase iFS. Both eyes will undergo wavefront-guided LASIK surgery with the Visx CustomVue excimer laser.
223613550|NCT05568628|DEVICE|ultrasound|screening of breast lesions by ultrasonography
223613551|NCT04735874|OTHER|Evaluate vascular disease risk factors in children with Down Syndrome|We will determine CV disease risk profiles in children with DS at our centers. We will compare these data to published national norms of children without DS. Risk factor data will include: anthropometric measures; blood pressure; history of congenital heart disease and associated surgery, sleep apnea, hypothyroidism, and cancer; fasting blood draw \[lipid panel with subfractions (NMR), insulin, glucose, and CRP\].
223613552|NCT04735874|OTHER|Determine the associations between cardiovascular disease risk factors and markers of early atherosclerosis in children with Down Syndrome|We will perform PWV, CIMT, and CD studies in children with DS and compare these data to available data in children without DS. We will also perform multivariable analysis of the influence of combinations of CV disease risk factors on markers of early atherosclerosis in children with DS. Hypothesis: CV disease risk factors will correlate with markers of early atherosclerosis in children with DS but the associations between risk factors and markers of early atherosclerosis will differ between children with DS vs. the general population of children.
223613553|NCT04143685|DRUG|Misoprostol|Oral administration of cytotec every 4 hours until a maximum of 6 doses
224201584|NCT03373825|BEHAVIORAL|Take home rapid drug test|The Rapid Response fentanyl test strips will be offered as take-home rapid drug tests to all participants to assess the willingness to use take-home rapid drug tests and the feasibility of using such an intervention at home. Arm 1 will be offered one method of using the take-home rapid drug test (urine testing). Arm 2 will be offered a second method of using the take-home rapid drug test (testing drug residue).
223613554|NCT04143685|DRUG|Oxytocin|Intravenous infusion of Pitocin through an IVAC until delivery
223759416|NCT06113952|DEVICE|Sharps bin to collect used needles/injections|Enrolled participants will be provided with a Smart Sharps Bin. The bin will collect used needles over a period of 12 months starting from enrollment.
223759417|NCT01965808|DRUG|LY2157299|Administered orally
224201585|NCT01441622|DEVICE|AL539 (SRETT)|recording data with AL539 (SRETT)
224201586|NCT01872832|DRUG|RDEA3170 and Placebo|
224314295|NCT05850585|OTHER|Placebo|Participants will receive a placebo capsule with the same color, appearance, and smell as the FMT capsule, in addition to their usual antipsychotics treatment. Placebo capsules contained the food probiotic Lactobacillus (10\^12 CFU per capsule). Subjects will continue to receive placebo capsules for 8 weeks. During this period, both groups could receive first-line atypical antipsychotics recommended by current treatment guidelines.
223509525|NCT03603184|DRUG|Placebos|Placebo will be administered as I.V. infusion every 21 days until objective radiological disease progression as assessed by the investigator if they do not meet any other discontinuation criteria (patient refusal, toxicity).
223759418|NCT04088682|BEHAVIORAL|Quality improvement strategies and tools|Quality improvement strategies and tools
224201587|NCT02736006|OTHER|20 meters air dive|"A dive in the depth of 20 m during 40 minutes. The divers will be evaluated before and 30, 60, 180 minutes after a 20 meters air dive. Venous bubbles will be detected by precordial Doppler 30 minutes after the dive.~In association with this Doppler, Flow Mediated Dilation, blood samples analysing inflammatory and thrombotic factors and other biomarkers will be explored before and after the dive in order to know how vascular and respiratory tracts in this environment react."
224201588|NCT00623688|DEVICE|Metered Dose Inhaler & Optichamber Advantage Valve Holding Chamber (VHC)|Albuterol is delivered by metered dose inhaler with valved holding chamber. For children less than 6 years of age, a mask is also used.
224201589|NCT00623688|DEVICE|Airlife Sidestream High Efficiency Nebulizer|Albuterol is delivered as a mist mixed with normal saline using a nebulizer machine and face mask or mouth piece.
224201590|NCT05195385|PROCEDURE|Low-dose computed tomography of the chest|Baseline low dose Ct acquisition, then at 1 year and 2 years to depict suspicious lung nodules
224201591|NCT04791410|PROCEDURE|microvascular decompression|Microvascular decompression of rostral ventrolateral medulla
224201592|NCT01267227|DRUG|Pterostilbene 50 mg twice daily|Pterostilbene 50 mg twice by mouth daily for 6 to 8 weeks
224201593|NCT01267227|DRUG|Placebo|Matching placebo by mouth twice daily for 6 to 8 weeks
224201594|NCT01267227|DRUG|Grape Extract|Grape extract 100 mg twice daily for 6-8 weeks
224201595|NCT01267227|DRUG|Pterostilbene 125 mg twice daily|Pterostilbene 125 mg twice daily for 6-8 weeks
224201596|NCT05770778|OTHER|Inclined Backwalk|They will receive inclined backward treadmill gait training exercise for thirty minutes with 2 interval break for 5min every 10 minutes for three times per week over three successive months with a specifically designed physical therapy program according to child need for one hour for each child, three times weekly, over three months.
223509526|NCT03603184|DRUG|Paclitaxel|Paclitaxel 175 mg/m2 will be administered every 21 days for 6-8 cycles or until progression of disease.
223509527|NCT03603184|DRUG|Carboplatin|Carboplatin AUC 5 or AUC 6 will be administered every 21 days for 6-8 cycles or until progression of disease.
223509528|NCT03071965|BIOLOGICAL|Ciliary neurotrophic factor (CNTF)|The investigational product is the NT-501 encapsulated cell system, which consists of cells encapsulated within a semi-permeable polymer membrane and supportive matrices. NT-501 contains NTC-201 cells that secrete recombinant human CNTF, which were derived from genetically modified NTC-200 cells.
223509529|NCT03071965|PROCEDURE|Surgery|Surgery to implant device for NT-501
223509530|NCT03071965|PROCEDURE|Surgery|Sham surgery
223509531|NCT02065804|DRUG|Bupivacaine|injection, once, 5 min
223509532|NCT04103970|BEHAVIORAL|Graded Activity and Pain Education (GAPE)|"GAPE is based on a cognitive behavioral perspective that human behavior is affected by behavioral, cognitive and affective factors, this include the patient's perception of and response to pain. The perspective is a psycho-social perspective which amplify and interact with the individual patient's pathology.~The overall theoretical perspective in GAPE is that fear of movement and/or lack of self-efficacy for exercise can potentially lead to disuse and sedentary behavior, a perspective modified from the fear-avoidance model. In this modified version the patients´ and the physiotherapists´ former experiences, knowledge, and beliefs are factors influencing on the patients´ experience of pain and thereby their self-efficacy for exercise and fear of movement."
223509533|NCT05738291|DRUG|BI 1839100|BI 1839100
223509534|NCT05738291|DRUG|Placebo matching BI 1839100|Placebo matching BI 1839100
223509535|NCT05738291|DRUG|midazolam|midazolam
223509536|NCT05738291|DRUG|digoxin|digoxin
223509537|NCT05738291|DRUG|rosuvastatin|rosuvastatin
223509538|NCT05860296|DRUG|SLC-391|SLC-391 is an AXL inhibitor
223509539|NCT05860296|BIOLOGICAL|pembrolizumab|Immunotherapy
223509540|NCT05618613|DRUG|Elacestrant|Elacestrant 200mg, 300mg, or 400mg once daily oral dosing in cycles of 28 days.
223509541|NCT05618613|DRUG|Onapristone|Onapristone 40mg or 50mg twice daily oral dosing in cycles of 28 days.
223509542|NCT05587998|DRUG|Morphine|Participants will receive IV dose of Morphine as stated in arm description.
223509543|NCT05587998|DRUG|AZD4041|Participants will receive oral doses of AZD4041 as stated in arm description.
223509544|NCT05587998|OTHER|Placebo|Participants will receive oral doses of placebo as stated in arm description.
223509545|NCT05087680|BEHAVIORAL|ACTPrEP|ACTPrEP will include a 60-minute initial session and a series of 30-minute follow-up sessions. Sessions will focus on the Thoughts, Emotions, Associations, Memories, and Sensations (TEAMS) relevant to PrEP uptake and adherence.
223509546|NCT05087680|BEHAVIORAL|Enhanced Standard of Care|Enhanced Standard of Care (ESOC) will include one 30-minute PrEP education session.
223509547|NCT06707038|BEHAVIORAL|AATAP intervention|AATAP is a program created to address the barriers that Black patients face when accessing transplantation. AATAP providers resources in cultural congruency, trust, psychosocial support, and health literacy to provide patients with the individualized support needed to access the kidney transplant waitlist
223509548|NCT04149457|OTHER|Computerized Plasticity-Based Adaptive Cognitive Training|Thirty minutes of training on computerized exercises that targets visual processing speed, memory, attention and alertness.
223509549|NCT04149457|OTHER|Commercially available computerized training|Thirty minutes of training on computerized, casual video games.
223759419|NCT00198016|DEVICE|Coil|
223759420|NCT01996969|DRUG|Regorafenib|Regorafenib will be given 160mg once daily for 3 weeks, followed by a 1 week rest. Treatment will be continued until disease progression or unacceptable toxicity occurs. Response evaluation (CT scans) will be performed every 2 cycles.
223759421|NCT03597581|DRUG|ompenaclid|RGX-202-01 (ompenaclid) is a small molecule inhibitor of the creatine transporter, SLC6a8.
223759422|NCT03597581|DRUG|FOLFIRI|FOLFIRI is a chemotherapy regimen consisting of irinotecan, leucovorin, and 5-fluorouracil. Irinotecan is a topoisomerase inhibitor, which prevents DNA from uncoiling and duplicating.
223759423|NCT03597581|DRUG|Bevacizumab|Bevacizumab is a vascular endothelial growth factor inhibitor.
223759424|NCT03597581|DRUG|FOLFOX regimen|The FOLFOX regimen used for this protocol consists of oxaliplatin given at 85 mg/m2 IV together with leucovorin at 400 mg/m2 IV (substitution with levo-leucovorin 200 mg/m2 IV is allowed) (duration per institutional policy), followed by a 5-FU bolus of 400 mg/m2 (over 2-5 minutes), and then continuous infusional 5-FU given at a dose of 2400 mg/m2 over 46-48 hours (1200 mg/m2/day), given on Days 1 and 15 of each 28-day cycle. A minimum of 8 FOLFOX cycles should be received if tolerated per standard of care guidelines
223759425|NCT04720365|DEVICE|play-based rehabilitaion|usual re-education treatment by their physiotherapist
223759426|NCT00414661|DRUG|CP-690,550|Subjects had to have received CP-690,550 or other blinded study drug in index study. No intervention in this long-term follow-up trial.
223759427|NCT01531946|PROCEDURE|MRI Scan|"Patients will have to spend additional 10min in the scanner.~Additional scan modalities used:~1. Perfusion without contrast: Arterial spin labeling (ASL) with the ability of showing signs of ischemia.~2. Diffusion tensor imaging (DTI): Has a higher sensitivity than DWI in displaying local ischemic lesions.~An overall 20min scan period."
223759428|NCT00250211|PROCEDURE|Functional MRI imaging and tomotherapy|
223759429|NCT00413725|BIOLOGICAL|MRKAd5 HIV-1 gag/pol/nef|Experimental Clade-B based Adenovirus serotype 5 HIV-1 gag/pol/nef vaccine
223759430|NCT00413725|OTHER|Placebo|Placebo
223759431|NCT00357370|DRUG|Dapagliflozin|Tablets, Oral, once daily, up to 12 weeks
223759432|NCT00357370|DRUG|Placebo|Tablets, Oral, 0 mg, once daily, up to 12 weeks
223759433|NCT05787951|DIAGNOSTIC_TEST|Bone marrow aspirite for diagnosis|Routine investigation of acute myeloid leukemia such as bone marrow aspirite for diagnosis ,cbc
223759434|NCT04999631|DRUG|Squaric Acid Dibutyl Ester|Topical squaric acid dibutyl ester (SADBE) dissolved in ethanol at 0.2% concentration.
223759435|NCT04999631|DRUG|Ethanol Solution|Control
223759436|NCT04570293|DRUG|5% lidocaine medicated plaster|The 5% lidocaine medicated plaster is measuring 10 cm x 14 cm contains 700 mg lidocaine (5% w/w) For each patient, the painful area and the trigger point will be chosen for treatment. The investigator will instruct the patient to replace the patch every 12 hours. The patches could be applied during the night (application in the evening and removal in the morning), or during the day. Patients will be told to apply up to three patches at one time.
223509550|NCT05013229|DRUG|IcoSema|Participants will receive a once weekly subcutanous (s.c.) injection of IcoSema, on the same day every week for 52 weeks.
223509551|NCT05013229|DRUG|Insulin glargine|Participants will receive a once daily subcutaneous (s.c.) injection of insulin glargine combined with Insulin aspart 2-4 times a day during mealtimes for 52 weeks.
223509552|NCT05013229|DRUG|insulin aspart|Participants will receive a once daily subcutaneous (s.c.) injection of insulin glargine combined with Insulin aspart 2-4 times a day during mealtimes for 52 weeks.
223509553|NCT05763862|GENETIC|Genetic testing|Same information as details in the experimental arm.
223509554|NCT03964909|PROCEDURE|Functional Magnetic Resonance Imaging|Undergo fMRI
223509555|NCT03964909|PROCEDURE|Magnetic Resonance Imaging|Undergo CVR MRI
223509556|NCT03964909|PROCEDURE|Resting State Functional Connectivity Magnetic Resonance Imaging|Undergo rs-fMRI
223759437|NCT04570293|DRUG|vehicle plaster|Vehicle patches are identical to the active patch, except for the absence of lidocaine, without any optical differences.For each patient, the painful area and the trigger point will be chosen for treatment. The investigator will instruct the patient to replace the patch every 12 hours. The patches could be applied during the night (application in the evening and removal in the morning), or during the day. Patients will be told to apply up to three patches at one time.
223759438|NCT03775668|DRUG|1 µCi of 14C-AAI101 + 500 mg AAI101|Single dose open label
223759439|NCT04931901|DEVICE|EMG TOF device|Use of Stimpod NMX450X as an electromyographic neuromuscular monitor
223759440|NCT01143090|DRUG|Lurasidone HCl|40 mg Lurasidone tablets, 40 - 120 mg per day for up to 6 months
223759441|NCT03145441|DEVICE|CytoSorb®|CytoSorb® is a biocompatible, high adsorptive polymer indicated in conditions where cytokine levels are extremely elevated.
223759442|NCT06174324|DEVICE|PreserFlo Microshunt|The PreserFlo MicroShunt was invented to create a minimally invasive glaucoma drainage device, that comes close to the eye pressure reduction and safety profile of the current gold standard, the trabeculectomy. Reference: Pinchuk L, Riss I, Batlle JF, Kato YP, Martin JB, Arrieta E, Palmberg P, Parrish RK 2nd, Weber BA, Kwon Y, Parel JM. The development of a micro-shunt made from poly(styrene-block-isobutylene-block-styrene) to treat glaucoma. J Biomed Mater Res B Appl Biomater. 2017 Jan;105(1):211-221. doi: 10.1002/jbm.b.33525. Epub 2015 Sep 18. PMID: 26380916; PMCID: PMC5215625.
223759443|NCT06298175|BEHAVIORAL|Self management training|The self-management training programme for the study group consisted of eight sessions. Each session lasted between 40 and 50 minutes and followed a structured format: a 5-minute introduction, a 5-minute summary of the previous session, and a 30-40 minute presentation on the session's topic. Training plan on cognition, emotion regulation and self-management was implemented
223759444|NCT02304224|OTHER|eye masks|eye masks from 21:00 to 6:00 each night during admission
223759445|NCT01211028|BIOLOGICAL|Expanded autologous ASCs|Drug: Expanded autologous adipose-derived adult stroma/stem cells
223759446|NCT06218147|BEHAVIORAL|Nutrition-behavior lifestyle program|The 15 participants randomized to the intervention group will complete the activities described in the arm/group description.
223759447|NCT01245855|DRUG|lipo-PGE1|those in the PGE1 group received additional 20 micrograms/day of lipo-PGE1 intravenously, starting at least 24 hours before PCI and continuing for 5 days
223759448|NCT03073278|RADIATION|Stereotactic Body Radiotherapy|Each group will have different dose of stereotactic body radiotherapy (SBRT). Depending on which group patients are in.
223759449|NCT04019158|DEVICE|Virtual reality headset|All participants will walk in the three conditions described earlier in this form
223759450|NCT03288597|RADIATION|68Ga-DOTANOC PET/CT and 18F-FDG PET/CT in NET|At the beginning of the treatment with SSA, after 6 months, 12 months, or chemotherapy, after 3 months or progression receive 68Ga-DOTANOC PET/CT and 18F-FDG PET/CT
223759451|NCT03288597|RADIATION|68Ga-DOTANOC PET/CT and 18F-FDG PET/CT in NEC|At the beginning of the treatment with chemotherapy 4-6 cycles or progression receive 68Ga-DOTANOC PET/CT and 18F-FDG PET/CT
223759452|NCT03926234|OTHER|Four-level Chinese Emergency triage scale|a four-level category system, i.e. life-threatening (Level I), emergent (Level II), urgent (Level III) and semi-urgent (Level IV) . This system contains critical indicators (cardiac arrest, shock, and apnea), high risk indicators (ACS and DKA), single objective indicators (SBP, RR, HR, and SpO2) and MEWS (synthesis indicator). According to patients' health care problems, patients are rated by nurses into one of the four mentioned levels.
223759453|NCT01790464|DRUG|2% Lidocaine|2% lidocaine and peritonsillar instillation of gauze soaked with 2% lidocaine (Glossopharyngeal Group).
223759454|NCT01790464|DRUG|placebo|
223759455|NCT00197379|DRUG|roxithromycin|
223759456|NCT03096522|DRUG|Phenytoin 2% spray|Patients will undergo anal fistulotomy then they will use phenytoin 2% spray topically on the anal wound resulting from fistulotomy with each sitz bath (twice per day) untill the anal wound heals completely
223759457|NCT03096522|PROCEDURE|Anal fistulotomy|Probing of the fistula tract followed by lay open of the tract and curettage of granulation tissue in its base
223759458|NCT05379296|BEHAVIORAL|Diabetes Prevention Program Plus (DPP+)|The DPP+ includes the CDC-approved DPP lifestyle program expanded to include a CDC-approved module on hypertension prevention and treatment
223509557|NCT06633666|DEVICE|Acupuncture|"1. Fatigue Principal points: Pishu (BL 20), Ganshu (BL 18), Shenshu (BL 23), Baihui (GV 20), Guanyuan (RN 4), Zusanli (ST 36), Sanyinjiao (SP 6)~2. Anxiety/ depression Principal points: Yintang (EX-HN3), Baihui (GV 20), Taichong (LR 3), Neiguan (PC 6), Danzhong (RN 7)~3. Cognitive impairment/ memory loss Principal points: Baihui (GV 20), Sishencong (EX-HN1), Fengfu (GV 16), Taixi (K 13), Xuanzhong (GB 39), Zusanli (ST 36)~4. Insomnia Principal points: Zhaohai (K 16), Shenmai (BL 62), Shenmen (HT 7), Sanyinjiao (SP 6), Anmian (EX-HN22), Sishencong (EX-HN1)"
223509558|NCT05828901|OTHER|S1PR analysis on immune cells|S1P receptor 1 and 5 expression will be measured on immune cells
223509559|NCT06512727|BEHAVIORAL|PROACTIVE Intervention|Duration: Once-weekly face-to-face sessions Session Time: 1.5-2 hours Intervention: (1) culturally congruent self-management (SM) education and + SM resource toolkit, (3) active prayer support, and (3) financial counseling/insurance navigation Reinforcement: daily ecological momentary intervention support using Apple smartwatches
223509560|NCT05290818|DEVICE|MAKO™ Partial Knee Arthroplasty|The robotic-arm will be used to position a partial knee arthroplasty.
223509561|NCT05290818|DEVICE|Triathlon (Stryker) Total Knee Arthroplasty|Triathlon (Stryker) TKA with a cruciate retaining polyethylene insert.
223509562|NCT03445845|DRUG|Secukinumab|Secukinumab : 150 mg per week for 5 weeks, and then every month by subcutaneous injection
223509563|NCT03445845|DRUG|TNF blocker|"TNF blocker (originator or biosimilar) :~* infliximab: 5mg/kg per IV infusion at weeks 0, 2, 6, and then every 6 weeks,~* etanercept: 50mg per week in subcutaneous injection,~* adalimumab: 40mg every other week in subcutaneous injection,~* certolizumab: 400mg every other week 3 times, and then 200mg every other week or 400mg per month in subcutaneous injections,~* golimumab: 50mg every month in subcutaneous injection, in case of overweight (\>100kg) an inadequate response, 100mg every month is allow."
223509564|NCT03445845|BIOLOGICAL|blood specimen|Blood specimen at each visits for measurement of bDMARS blockers concentration and anti-drug antibody concentration
223509565|NCT06126653|DRUG|Low Dose ARD-501|Titratable, liquid formulation, taken orally. The intervention is given relative to the body weight of the individual. 0.2 mg/kg dosing.
223759459|NCT05379296|BEHAVIORAL|Diabetes Prevention Program (DPP)|CDC-approved DPP lifestyle program
223759460|NCT01800916|DEVICE|Coloplast Adhesive baseplate A|Coloplast Adhesive baseplate A is a newly developed 1-piece ostomy appliance.
223759461|NCT01800916|DEVICE|Coloplast Adhesive baseplate B|Coloplast Adhesive baseplate B is a newly developed 1-piece ostomy appliance
223759462|NCT01800916|DEVICE|Coloplast Adhesive baseplate C|Coloplast Adhesive baseplate C is a newly developed 1-piece ostomy appliance
223759463|NCT01800916|DEVICE|SenSura 1-Piece|SenSura 1-piece is the commercial CE-marked Coloplast 1-piece SenSura .
223759464|NCT03444142|DRUG|Exenatide LAR|2 mg, once weekly subcutaneously before breakfast during 4 weeks.
223759465|NCT03444142|DRUG|Dulaglutide|.75 mg once weekly subcutaneously before breakfast during 4 weeks.
223759466|NCT03957538|BEHAVIORAL|Virtual reality angiogram experience video|The VR video is watched via the VR headset, and describes the pre- procedural and procedural experience. Concurrent audio will be provided through earplugs to compete the patients' immersive experience. The video was written and directed by the team, and care has been taken to ensure that the same procedural information is contained within both the British Heart Foundation cardiac catheterisation video and of VR immersive video. Filming was performed within the cardiac catheterisation labs at our tertiary centre using the professional services of Orchard Media (Cardiff, UK). The investigators utilized real physicians and nurses to re-enact a typical day for a mock patient undergoing an uncomplicated procedure. There is also a short explanation of the procedure and animations explaining technical aspects of the procedure contained within the VR video.
223759467|NCT01567488|DRUG|Everolimus|Everolimus 10mg/day
223759468|NCT01567488|DRUG|octreotide LAR|30 mg each 28 days
223759469|NCT04099862|PROCEDURE|ERCP|Endoscopic retrograde cholangiopancreatography (ERCP)
223759470|NCT04099862|PROCEDURE|EUS-BD|Endoscopic UltraSound Biliary Drainage
223759471|NCT05313165|DEVICE|LimFlow Stent Graft System|Creation of an arteriovenous fistula in the desired limb location
223759472|NCT01232296|DRUG|dovitinib|500 mg p.o. o.d. 5 days on/2 days off
223759473|NCT01232296|DRUG|sorafenib|400 mg p.o. b.i.d.
223759474|NCT02431858|DEVICE|E-Catheter (Pajunk)|
223759475|NCT02431858|DEVICE|Sonolong Catheter (Pajunk)|
223759476|NCT01127750|DRUG|FTY720|
223759477|NCT03633981|OTHER|clinical examinations|"Collection of data from the following tests at H0 (as soon as the ECLS is put in place), H12 (within 12 hours following stabilisation of the dynamic state), H24 and every day until complete neurological recovery:~* right and left pupillometry (3 times)~* BIS values~* right and left NIRS values~* right and left transcranial Doppler~* neurological clinical examination"
223613555|NCT04358302|BEHAVIORAL|Pillsy|"The electronic pill bottle cap, Pillsy, and its accompanying software application provides reminders to take a scheduled dosage of medication via bottle cap alerts and smartphone push notifications, text messages, and/or automated phone calls. The Pillsy application records dosing dispense date and time when the user opens the bottle. During the first 2 weeks of the trial, the electronic notifications will be disabled to determine a baseline measure of adherence. Within 1 day after Visit 2, the electronic notifications will be turned on for all participants, resulting in a series of alerts (via electronic pill bottle cap alerts and smartphone push notifications, text message, and/or automated phone calls).~The electronic pill bottle cap, Pillsy, is a commercially available device marketed to consumers. The electronic pill bottle cap does not capture or store PHI. Quick tips on how to use Pillsy can be found at https://www.pillsy.com/instructions"
223613556|NCT05032482|DEVICE|Non-invasive brainstem stimulation|Study participants will self-administer \~19-minute treatments twice daily in the home setting over 24 weeks using a non-invasive brainstem modulation device. All participants will use the same treatment mode during the open label extension.
223759478|NCT03633981|OTHER|neurological assessment when a neurological event occurs|"next neurological event:~* seizures~* pupillary asymmetry~* myoclonias~* brain stem reflex abnormalities~* osteotendinous reflex abnormalities"
223613557|NCT02721875|DRUG|Volasertib|
223613558|NCT02721875|DRUG|Volasertib|
223613559|NCT02721875|DRUG|Azacitidine|
223613560|NCT01739036|BIOLOGICAL|ChAd63 CS/ME-TRAP|Mixture of ChAd63 CS 5 x 1010 vp and ChAd63 ME-TRAP 5 x 1010 vp. Intramuscular needle injection.
223613561|NCT01739036|BIOLOGICAL|MVA CS/ME-TRAP|Mixture of MVA CS 2 x 108 pfu and MVA ME-TRAP 2 x 108 pfu. Intramuscular needle injection.
223613562|NCT01739036|BIOLOGICAL|ChAd63 CS/ME-TRAP/AMA1|Mixture of ChAd63 CS 5 x 1010 vp, ChAd63 ME-TRAP 5 x 1010 vp, and ChAd63 AMA1 5 x 1010 vp. Intramuscular needle injection.
223613563|NCT01739036|BIOLOGICAL|MVA CS/ME-TRAP/AMA1|Mixture of MVA CS 1.33 x 108 pfu, MVA ME-TRAP 1.33 x 108 pfu, and MVA AMA1 1.33 x 108 pfu. Intramuscular needle injection.
223613564|NCT01739036|OTHER|Controlled Human Malaria Infection Administered by Mosquito Bite|Approximately three weeks post MVA dosing.
223613565|NCT02426515|DEVICE|Hilotherm® cooling device and face mask|Hilotherm® is an external cooling device and facial mask through which water circulates at a controlled temperature This allows continuous cooling of the face, and is thought to reduce post-operative swelling and pain.
223613566|NCT00240058|DRUG|Regional phenylephrine arterial infusion, Nitric Oxide Clamp|
223613567|NCT03668002|PROCEDURE|Arteriovenous Fistula (AVF)|If the participant is randomized to the AVF arm of the trial, the surgeon will connect an artery to a vein in the upper extremity, without using artificial material as conduit.
223613568|NCT03668002|PROCEDURE|Arteriovenous Graft (AVG)|If the participant is randomized to the AVG arm of the trial, the surgeon will place a synthetic graft connecting an artery and vein under the skin in an upper extremity.
223759479|NCT03633981|OTHER|mortality assessment|to 28 days
223759480|NCT03460522|DRUG|Inotuzumab ozogamicin|Patients will receive standard of care chemotherapy (only maintenance) after Inotuzumab Ozogamicin.
223759481|NCT03077503|DRUG|Dexmedetomidine|Dexmedetomidine 1 µg/kg diluted to 20 ml with 0.9% normal saline was administration. If adverse events were occurred, the patient will receive rescue drugs.
223759482|NCT03077503|DRUG|Fentanyl|Fentanyl 1 µg/kg diluted to 2 ml with 0.9% normal saline was administration. If adverse events were occurred, the patient will receive rescue drugs.
223759483|NCT03077503|DRUG|0.9% normal saline|0.9% normal saline was use to dilute the study drugs
223613569|NCT00895284|PROCEDURE|Robotic hysterectomy|Robotic hysterectomy.
223613570|NCT00895284|PROCEDURE|Standard Hysterectomy|Standard hysterectomy.
223613571|NCT00006000|DRUG|cisplatin|
223759484|NCT03077503|DEVICE|Skull pins|Skull pins were use to stabilized the patent' s head during surgery
223759485|NCT01854021|PROCEDURE|intravenous anesthesia|intravenous anesthesia
223759486|NCT01854021|PROCEDURE|combined intravenous-inhalational anesthesia|combined intravenous-inhalational anesthesia
223613572|NCT00006000|DRUG|irinotecan hydrochloride|
223613573|NCT00006000|DRUG|semaxanib|
223613574|NCT06108154|BEHAVIORAL|Educational breastfeeding traning session|Educational breastfeeding training session base on dialogical, visual attractive and training session on Proper LATCH techniques and breastfeeding positions to prevent from nipplesoreness.
223613575|NCT02949609|OTHER|Mirror Therapy|Mirror therapy will consist in placing a large mirror in the sagittal plane of the subject so as to reflect his healthy arm while hiding the paretic one, and then asking him to perform movements of his healthy arm while looking at its reflection in the mirror.
223613576|NCT02949609|OTHER|Control Therapy|Performance of the same movements as the experimental group without the mirror or instructions as to where to look, 5 days/week, for 4 weeks.
223613577|NCT05309902|DRUG|Soticlestat|Soticlestat tablet.
223613578|NCT05309902|DRUG|Placebo|Soticlestat placebo-matching tablet.
223759487|NCT01854021|PROCEDURE|inhalational anesthesia|inhalational anesthesia
224201597|NCT05770778|OTHER|Knee Walk|They will receive kneel walk exercise programme for thirty minutes with 2 interval break for 5min every 10 minutes for three times per week over three successive months with a specifically designed physical therapy program according to child need for one hour for each child , three times weekly, over three months.
224201598|NCT04383652|OTHER|Biological sample and clinical data collection|Plasma and serum will be collected at day 0, day 7, day 14, 1 month and 4 months post diagnosis. Clinical data related to COVID-19 diagnosis, symptoms, and outcomes will be collected.
224201599|NCT05724615|BEHAVIORAL|Outreach + Bulk ordering|Participants will be sent an order for their lab screening and the recourse of the labs where they can schedule the screening.
223613579|NCT05309902|DRUG|Moxifloxacin|Moxifloxacin over-encapsulated tablet.
224312062|NCT05436028|DEVICE|Transcatheter Tricuspid Valve Intervention|"Due to unsustainable effect of medical therapy and high risks of surgical treatment, transcatheter tricuspid valve intervention (TTVI) has been a major field of study in the world in the last 10 years. TTVI could potentially reduce TR with lower periprocedural risk and improve the patient's clinical status and prognosis. Per the ESC guidelines for surgical and interventional treatment of tricuspid regurgitation (2021 ESC/EACTS Guidelines for the Management of Valvular Heart Disease), Transcatheter intervention for symptomatic secondary severe TR may be considered in inoperable patients at a Heart Valve Centre with expertise in the treatment of tricuspid valve disease (Class IIb).~Transcatheter tricuspid treatment options can be divided into categories based on their mechanism of action: coaptation enhancement (edge-to-edge repair and spacer device), annuloplasty devices, caval valve implantation and valve replacement."
224312063|NCT04808479|BEHAVIORAL|imFREE mCBT|The imFREE condition is a 32-week tailored, interactive text messaging intervention targeting buprenorphine treatment retention and adherence as well as opioid use and associated health consequences. Following a face-to-face CBT session with a clinician, participants receive CBT skills training via daily text messaging, with content themes around relapse prevention, adherence behaviors, and personalized plans to overcome risk factors for treatment discontinuation.
223613580|NCT05309902|DRUG|Placebo|Moxifloxacin placebo-matching capsule.
223759488|NCT02117063|BEHAVIORAL|Go Girls! Fitness Support Group|Go Girls! is a dance-based patient fitness support group offered by the University of Virginia Pediatric Endocrinology division in conjunction with the Center for Research in Reproduction and the Children's Fitness Clinic at the University of Virginia for girls. The goals of the program are to introduce girls to exercise in a fun, non-threatening environment, meet other girls, enable girls to discover and develop a personal enjoyment of exercise, and enable low-pressure interactions with medical care providers.
223759489|NCT00610493|DRUG|Bevacizumab|5 mg/kg By Vein Over 90 Minutes on Day 1 of Each 21 Day Cycle
223759490|NCT00610493|DRUG|Temsirolimus|5 mg By Vein Over 30-60 Minutes on Days 1, 8, 15 of Each 21 Day Cycle
223759491|NCT00610493|PROCEDURE|Additional Blood Drawn|2 teaspoons each time: 4xDay Cycle 1 after start of first infusion; at Day 8 of Cycle 1; at Day 15 of Cycle 1; and at end of Cycle 1.
223759492|NCT00610493|PROCEDURE|Biopsy|First tumor biopsy during screening visit and Second at the end of Cycle 1
223759493|NCT00610493|PROCEDURE|DCE-MRI Scan|DCE-MRI (dynamic contrast-enhanced magnetic resonance imaging) scan during screening visit, at 24-48 hours after the start of Cycle 1, and at the end of Cycle 1
223759494|NCT00548860|DRUG|Ferric Carboxymaltose|
223759495|NCT00548860|DRUG|Standard Medical Care (SMC)|
223759496|NCT00556595|PROCEDURE|primary electrophysiological approach|primary ablation of atrio-venous breakthrough sites followed by circumferential ablation around pulmonary vein orifice
223613581|NCT03855696|BIOLOGICAL|MG1113|MG1113
223613582|NCT03855696|OTHER|Placebo of MG1113|Placebo of MG1113
223613583|NCT00190723|DRUG|Enzastaurin|
223613584|NCT05370131|OTHER|Avatar-Based Education Program in Hydrocephalus (ABEP-H)|The avatar-based education program in hydrocephalus (ABEP-H) aimed to help parents acquire the knowledge and develop the skills necessary for the care of hydrocephalus children with VP shunts and prevent shunt infection and dysfunction.
223613585|NCT00104650|GENETIC|AMG 162 180 mg (SC) q 12 weeks|A 180 mg AMG 162 (SC) administered every 12 weeks for 2 doses (Day 1 and wk 13) in the treatment phase. If subjected are enrolled in the extension phase, they will continue to receive a 180 mg AMG 162 (SC) administered every 12 weeks for 9 doses.
223613586|NCT00104650|DRUG|IV Bisphosphonate q 4 weeks|IV Bisphosphonate (eg pamidronate or zoledronic acid) every 4 weeks for 6 doses as described by package insert during the treatment phase. If enrolled to the extension phase, subject will be assigned to the AMG 162 180mg (SC) every 4 weeks for 26 doses.
223613587|NCT00104650|GENETIC|AMG 162- 180 mg q 4 weeks|A 180 mg AMG 162 (SC) administered every 4 weeks for 6 doses in the treatment phase. If subjected are enrolled in the extension phase, they will continue to receive a 180 mg AMG 162 (SC) administered every 4 weeks for 26 doses.
223613588|NCT03390465|DRUG|Fimasartan/Amlodipine combination drug, Hydrochlorothiazide|Fimasartan/Amlodipine combination drug, Hydrochlorothiazide
223613589|NCT06393075|BEHAVIORAL|combined care guidance|Pain care guidance animation Rehabilitation exercise guidance animation Demonstrate how to perform rehabilitation exercises Demonstrate how to use a walker
223613590|NCT06393075|BEHAVIORAL|general care guidance|general care guidance
223613591|NCT04800146|PROCEDURE|Blood sample|Patients will be asked to provide blood samples at specified time points: before and after the SARS-CoV-2 vaccination
223613592|NCT06500637|DRUG|TB006|TB006 is a humanized immunoglobulin G4 (IgG4) (S228P) type monoclonal antibody that is highly specific and has a high affinity to human Galectin-3 (hGal-3).
223613593|NCT04932239|OTHER|first aid education|To teach commercial motorcyclists first aid for post-crash while waiting for medical team to reach the scene
223613594|NCT04617067|DRUG|Paricalcitol|Paricalcitol 12mcg, administered orally on every day of each 28-day cycle.
223613595|NCT04617067|DRUG|Gemcitabine (GEM) and Nab-paclitaxel|GEM (at 1,000 mg/m2) and Nab-paclitaxel (at 125 mg/m2 of bodysurface area), administered weekly for 3 of every 4 weeks (on days 1, 8 and 15 only).
223613596|NCT05357027|BIOLOGICAL|TC-E202 cells|T cells genetically engineered with a TCR targeting HPV16 E6 (E6 TCR) that display specific reactivity against HLA-A2+, HPV-16+ target cells
223613597|NCT05357027|DRUG|IL-2|Following cell infusion, the patient receives high-dose bolus IL-2, which is dosed to individual patient tolerance. IL-2 improves the survival of TC-E202 cells after infusion.
223759497|NCT00556595|PROCEDURE|primary anatomical approach|primary circumferential ablation around the pulmonary vein orifice followed by ablation of possible conduction gaps
223759498|NCT00325234|DRUG|Pemetrexed|600 mg/m\^2, administered intravenously (IV) every 21 days until disease progression or unacceptable toxicity.
223759499|NCT00325234|DRUG|Carboplatin|AUC 5 mg\*min/mL, administered IV every 21 days until disease progression or unacceptable toxicity.
223759500|NCT00325234|DRUG|Gemcitabine|1200 mg/m\^2 gemcitabine, administered IV on day 1 and day 8 every 21 days until disease progression or unacceptable toxicity.
223759501|NCT00325234|DRUG|Vinorelbine|30 mg/m\^2 vinorelbine administered IV on day 1 and day 8 every 21 days until disease progression or unacceptable toxicity.
223613598|NCT05357027|DRUG|Fludarabine|Part of the non-myeloablative lymphocyte-depleting preparative regimen.
223613599|NCT05357027|DRUG|Cyclophosphamide Capsules|Part of the non-myeloablative lymphocyte-depleting preparative regimen.
223613600|NCT03934606|BEHAVIORAL|Genetic testing for hereditary predisposition|Change in distress levels (HADS-Anxiety) from Baseline to Assessments #2 and #3, measured as an effect size among participants who receive a pathogenic variant(s), no pathogenic variant(s), and variant(s) of uncertain significance
223613601|NCT05006261|DEVICE|Tele-Tai Chi|12-week simplified TC program using the Tele-TC platform at home, with recommended training sessions at least three times a week, and two or more supplementary live sessions.
223613602|NCT00773513|DRUG|Darbepoetin Alfa|Darbepoetin alfa will be administered as per approved label.
223613603|NCT00773513|DRUG|Epoetin Alfa|Epoetin alfa will be administered as per approved label.
223613604|NCT00773513|DRUG|Epoetin Beta|Epoetin beta will be administered as per approved label.
223613605|NCT00773513|DRUG|methoxy polyethylene glycol-epoetin beta|Participants who are currently not being treated with an ESA will receive methoxy polyethylene glycol-epoetin beta administered at a starting dose of 0.6 mcg/kg body weight once every 2 weeks. Participants who are currently being treated with an ESA will receive methoxy polyethylene glycol-epoetin beta at a dose of 120, 200 or 360 mcg once monthly (based on ESA dose administered in Week -1)
223613606|NCT00991991|GENETIC|gene expression analysis|Laser capture microdissection is performed on the archived tissue samples to isolate melanoma cells. DNA is then purified from the samples and amplified using PCR. Matrix-assisted laser desorption/ionization (MALDI)-time of flight mass spectrometry technology is used to detect mutations of B-Raf and N-Ras. Single nucleotide polymorphism arrays are also performed.
223613607|NCT00991991|GENETIC|polymerase chain reaction|Laser capture microdissection is performed on the archived tissue samples to isolate melanoma cells. DNA is then purified from the samples and amplified using PCR. Matrix-assisted laser desorption/ionization (MALDI)-time of flight mass spectrometry technology is used to detect mutations of B-Raf and N-Ras. Single nucleotide polymorphism arrays are also performed.
223613608|NCT00991991|GENETIC|polymorphism analysis|Laser capture microdissection is performed on the archived tissue samples to isolate melanoma cells. DNA is then purified from the samples and amplified using PCR. Matrix-assisted laser desorption/ionization (MALDI)-time of flight mass spectrometry technology is used to detect mutations of B-Raf and N-Ras. Single nucleotide polymorphism arrays are also performed.
223613609|NCT00991991|OTHER|matrix-assisted laser desorption/ionization time of flight mass spectrometry|Laser capture microdissection is performed on the archived tissue samples to isolate melanoma cells. DNA is then purified from the samples and amplified using PCR. Matrix-assisted laser desorption/ionization (MALDI)-time of flight mass spectrometry technology is used to detect mutations of B-Raf and N-Ras. Single nucleotide polymorphism arrays are also performed.
223613610|NCT00991991|OTHER|medical chart review|Information about the patient's demographics (e.g., TNM staging, sex, age, and tissue collection dates) will be gathered by chart review or from the Multidisciplinary Melanoma Conference at University Hospitals tumor conference report in order to match cases.
223613611|NCT04642391|DRUG|Cosyntropin|Administer 0.25mg Cosyntropin to determine adrenal sufficiency vs. insufficiency in patients with decompensated cirrhosis
223613612|NCT02436616|DEVICE|microEEG|"microEEG is a miniature, wireless, and battery-powered EEG device used to obtain EEG recording in challenging environment. All infants have an initial EEG at study enrollment. Follow up microEEGs will be performed at approximately 2-4 week intervals, depending on the Corrected Gestational Age (CGA).~If ABD events have not resolved at 34 weeks, an 8 hour recording will be performed prior to discharge or at 42 weeks CGA, whichever comes first. EEG will be assessed in 3 hour epochs. The EEG will be reviewed off line by two blinded neurologists and classified as normal or abnormal based on CGA and other findings. Follow up EEGs will be scored similarly, with emphasis on maturation."
223613613|NCT00804466|DEVICE|OncoE6|HPV oncoprotein assay
223613614|NCT00804466|DEVICE|EVA System|low-cost colposcope
223613615|NCT01154868|PROCEDURE|Alveolar ridge augmentation|Under local anesthesia, full-thickness mucoperiosteal flaps will be elevated, followed by degranulation, and collection of all clinical measurements. Crestal and vertical releasing cuts will be performed using diamond-coated discs on the edentulous ridge in need of augmentation. A sequence of bone chisels and osteotomes will be used to split the alveolar ridge in half until a desirable width for implant placement is achieved. Healos® will then be inserted between both osseous plates. Fixation screws will be used as needed to stabilize the expanded alveolar ridge. Collagen barrier membranes (Ossix Plus) will be used to cover the osseous wound. Flaps will be approximated to achieve primary wound closure.
223613616|NCT03863756|RADIATION|EOS|The new EOS-technology (EOS imaging, Paris, France) based on a low-dose X-ray system allows 3D modeling of the spine based on 2-dimensional
223613617|NCT00994526|OTHER|Ham|Ham : 180 g per day during 4 days
223613618|NCT00994526|OTHER|Ham + calcium|Ham : 160g/d during 4 days calcium : 1000mg/d during 4 days
223759502|NCT01234467|DRUG|Bendamustine|Dosage Form: Intravenous (60 minute infusion) Dosage: 120mg/m2 (ECOG = 0-2) or 90mg/m2 (ECOG = 3) Frequency: Day 1 and Day 2; Every 3 weeks of a 21 day cycle. Duration: 3-6 Cycles
223759503|NCT01234467|DRUG|Rituximab|Dosage form: Intravenous Dosage: 375 mg/m2 Frequency: Day 1 of every 3 weeks of a 21 day Cycle Duration: 3-6 Cycles
223759504|NCT02361567|DRUG|Tramacet|Pain medication commonly used post-operatively
223759505|NCT02361567|DRUG|Percocet|Pain medication commonly used post-operatively
223759506|NCT02889354|BEHAVIORAL|Cognitive-behavioral therapy|
223759507|NCT03068299|OTHER|Dance|Sessions of sixty minutes each, which will take place weekly, totaling 24 weeks (6 months). Ten minutes from the start of each session will be reserved for initial exercises, with movements of the upper limbs, lower, accompanied by a motivational music. The process of identifying and memorizing the movements will be carried out as many times as the group deems necessary. The rhythms include combinations of circular and ballroom dances, including waltz, cha-cha-cha, cancan, among others. In all the sessions, the last fifteen minutes are reserved for a conversation about the dance learned/practiced in the day. It is expected to have reached the proposal of a practice of 15 different choreographies and that this was a pleasant moment for all the participants.
223613619|NCT00994526|OTHER|Ham + vitamin E|Ham : 160g/d during 4 days Vitamin E : 80 mg/d during 4 days
223613620|NCT02531724|DRUG|Levosimendan|
223613621|NCT02531724|DRUG|Placebo|Sodium chloride
223613622|NCT03565536|DRUG|Nexavar|for Unresectable tumors ,After the patient had diagnosed as anaplastic thyroid cancer, Nexavar 400mg Bid was used for neoadjuvant treatment. At 1 month and 2 months after treatment, it was assessed whether surgery could be performed.
223759508|NCT03068299|OTHER|Health care guidance|Control group will receive attention, through guidelines for care and health practices for the caregiver and the elderly care recipient. This attention should occur in the same number of sessions of the dance and group intervention group. The control group should follow the same subdivision of the intervention group, in terms of the number of participants per subgroup. The subjects of the guidelines will be raised by the demand of the participants themselves and then worked in an interdisciplinary way.
223759509|NCT02612532|DEVICE|ReCIVA breath sampler|Device developed for standardised collection of breath samples http://www.owlstonenanotech.com/medical/products/reciva
223759510|NCT03023865|PROCEDURE|Staged stress function|A preoperative staged stress function procedure for elongation of the proximal and distal segments to achieve utilizing the native esophagus to establish esophageal continuity
223759511|NCT04951934|DEVICE|EmoLED|This treatment consists of irradiation with the blue light emitted by the device for one minute on the injured area. If the wound has a greater extension than the irradiated area, multiple repeated applications will be performed on adjacent areas, until the entire wound is covered.
223759512|NCT04951934|PROCEDURE|Standard treatment|"The standard treatment consists of: cleansing and possible debridement of the wound, application of the topical treatment indicated for that phase of the wound, intended as the standard of care of the structure, and subsequent bandaging."
223759513|NCT00617682|BIOLOGICAL|PNCRM9|0.5 mL IM at 30-35 wks gestation
223759514|NCT00617682|BIOLOGICAL|Placebo comparator|Sucrose cake (NaCl and sucrose) in aluminum phosphate adjuvant diluent at 0.5 mg per 0.5 mL dose IM at 30-35 wks gestation
223759515|NCT02078804|PROCEDURE|Colonoscopy|20 000 individuals will be randomised to a primary screening colonoscopy and 60 000 to take a feces test for occult blood (FIT) and if positive (10% of individuals) they will be offered a follow-up colonoscopy.
223759516|NCT01414335|DIETARY_SUPPLEMENT|amino acid composition|one single pouch (13g) of amino acid mixture and vitamins diluted into 200 ml of still water. This solution was daily oral taken after a meal.
223759517|NCT01414335|OTHER|Placebo|placebo contained no amino acids and vitamins and was identical in appearance and solution properties.
223759518|NCT02679586|DEVICE|Diffusion weighted MRI|
223759519|NCT04089540|PROCEDURE|New intubation method|
223759520|NCT04089540|PROCEDURE|Conventional intubation method|
223759521|NCT03348358|BEHAVIORAL|quiet music|playing quiet music during labor
223759522|NCT03348358|BEHAVIORAL|Rhythmic music|playing rhythmic music during labor
223759523|NCT03348358|BEHAVIORAL|control|No music during labor
223759524|NCT05039346|OTHER|Phone interviews|Phone interviews will be used to determine the patient's quality of life, symptoms and performance status
223759525|NCT00404352|DRUG|RNF|Single dose of RNF administered subcutaneously three times weekly at least 48 hours apart at a starting dose of 8.8 microgram (mcg) for first 2 weeks followed by 22 mcg for next 2 weeks and finally 44 mcg until 24 months, or 36 months for patients enrolled in the OL extension.
223759526|NCT00404352|DRUG|RNF|Single dose of RNF administered subcutaneously once weekly at a starting dose of 8.8 mcg for first 2 weeks followed by 22 mcg for next 2 weeks and finally 44 mcg until 24 months.
223759527|NCT00404352|DRUG|Placebo|Placebo was supplied as a transparent, sterile solution for injection in pre-filled syringes matching the RNF pre-filled syringes, each containing 0.5 mL.
223759528|NCT05310266|PROCEDURE|Transversus abdominis plane block|The investigators performed transversus abdominis plane block to that patient group for postoperative analgesia
223759529|NCT05310266|PROCEDURE|Quadratus Lumborum Block|The investigators performed quadratus lumborum block to that patient group for postoperative analgesia
223759530|NCT05130567|DRUG|LP-128 capsules|Oral dosing with LP-128 capsules
223759531|NCT05130567|OTHER|Matching Placebo|Oral dosing with placebo capsules to match LP-128 capsules.
223759532|NCT04370691|DEVICE|JETi lower extremity arterial thrombosis|The JETi System is is a hydro-mechanical aspiration system, intended for the removal of intravascular thrombus. The system comprises of the JETi Catheter (6F or 8F), JETi Pump Set, JETi Saline Drive Unit (SDU), JETi Accessory Cart, JETi Suction tubing and JETi Non-Sterile Canister Set. The JETi System is designed to continuously aspirate thrombotic material into the catheter, where a high-pressure stream of saline within the catheter tip macerates the thrombus as it is aspirated.
223613623|NCT03565536|PROCEDURE|operation|If computed tomography (CT) evaluates for possible surgical treatment, complete thyroidectomy and cervical lymph node dissection are performed to completely resect thyroid tissue and metastatic lymphatic tissue.
223613624|NCT03565536|RADIATION|External radiation therapy|As the successful surgery, then continue on the basis of taking on Nexavar plus external beam radiation therapy
223613625|NCT01807598|DRUG|Brentuximab vedotin|
223613626|NCT02021669|DRUG|Omega-3 supplement|Two grams of the EPA form of omega-3 daily and 50 mgs of sertraline daily for 10 weeks
223613627|NCT02021669|DRUG|Placebo|Two grams of corn oil plus 50 mg of sertraline daily for 10 weeks.
223613628|NCT01895595|BEHAVIORAL|Guided Imagery|
223613629|NCT01895595|BEHAVIORAL|Digital Storytelling|
223759533|NCT05949996|OTHER|A nurse-led symptom distress screening program|Five implementation strategies will be conducted individually for each of the study unit at the timepoint when the study unit is being randomly allocated to the implementation condition. For each study unit, all nurses will first receive a half-day training. Each study unit under the implementation condition will receive weekly audit and feedback reports to summarize the proportion of eligible patients, proportion of eligible patients being screened, proportion of patients appropriately referred to JCICC. The senior research assistant with a nursing background will receive training and mentoring from the PI and will be the guided facilitator. The guided facilitator will conduct weekly site visits to address operational issues arise during the implementation. Lastly, while the choice of symptom assessment tool and referral criteria are standardized and cannot be modified, the routine workflow for each study unit can be adjusted according to its context and resources.
223759534|NCT03616990|BEHAVIORAL|TASC Service Linkages - Discharge Area Only|Individuals will meet with TASC Care Coordinators in the discharge area of the Cook County Jail. Individuals will be screened for housing, health and behavioral health needs and then linked to appropriate community-based services.
223759535|NCT03616990|BEHAVIORAL|SRC Overnight Stay|Individuals receiving SRC services will have the option to stay at the SRC overnight. At the SRC, individuals will be able to rest, have a meal, receive a change of clothes, and take a shower in a therapeutic, non-coercive environment.
223759536|NCT03616990|BEHAVIORAL|TASC Services Linkages - SRC Onsite|While at the SRC, individuals will meet with TASC Care Coordinators. Individuals will be screened for housing, health and behavioral health needs and then linked to appropriate community-based services.
223759537|NCT03616990|BEHAVIORAL|APN Appointment|Individuals at the SRC will be able to meet with an Advanced Practice Nurse. As part of that visit, the APN will be able to prescribe medications or reroute prescriptions previously administered by the Cook County Jail's hospital, Cermak, to a participant's desired location as needed.
223759538|NCT03067805|BEHAVIORAL|Sexual Infidelity Condition|
223759539|NCT03067805|BEHAVIORAL|Emotional Infidelity Condition|
223759540|NCT03067805|BEHAVIORAL|Neutral Condition|
223759541|NCT03067805|BEHAVIORAL|Player in Jealousy Condition|
223759542|NCT03067805|BEHAVIORAL|Player in Non-Jealousy Condition|
223759543|NCT06159764|PROCEDURE|Cardioneuroablation|radiofrequency ablation to destroy cardiac ganglionated plexi located in epicardial fat pads around the atrias
223613630|NCT05300776|DIAGNOSTIC_TEST|M-ROSE analysis|"The M-ROSE analysis process consists of 3 procudures.~1. Specimen quality assessment. The BALF undergoes the process of smear, diff-quik stain, gram stain and are analyzed by experts to report the cytoloy and pathogen patterns to determine whether the sample is qualified according to the cell proportions. The qualified BALF samples are: squamous epithelial cell proportion\<1%, columnar epithelial cell proportion \<5% .~2. Distinguish infection and colonization. According to the cytoloy pattern, the proportion of neutrophils \> 50% often strongly suggests pulmonary bacterial infection; Neutrophil phagocytosis proportion\> 5% indicates infection, and phagocytosis of bacteria is the pathogen. Besides, fungal and hyphae can be found under the microscope.~3. Preliminary identification of infectious pathogens. Identify the infected bacteria and fungi, and the results are gram-positive cocci, gram-positive bacilli, gram-negative cocci, gram-negative bacilli, yeasts and molds."
223613631|NCT05581459|OTHER|63 Hz Vibration|Vibrations of 63 Hz were applied with handheld vibration device.
223613632|NCT05581459|OTHER|42 Hz Vibration|Vibrations of 42 Hz were applied with handheld vibration device.
223613633|NCT05581459|OTHER|Sham vibration|Handheld device was applied to the participants without any vibrations.
223613634|NCT04298437|BEHAVIORAL|Addressing Depression and Positive Parenting Techniques (ADAPT) Program|The intervention is a targeted parenting intervention that has modules that help parents build emotion regulation skills, distress tolerance skills and alternative and more helpful ways of thinking about the causes of their child's EBD. The program also includes behavioral parent training skills building modules.
223759544|NCT05714917|OTHER|Observational study with no interventions|This is an observational study and there will be no clinical interventions.
223613635|NCT01887184|DRUG|Dexmedetomidine|Dexmedetomidine 1.5mcg/kg was given intranasally
223613636|NCT01887184|DRUG|Placebo|Intranasal saline was given
223613637|NCT03960112|DEVICE|mpMRI|mpMRI in the detection of prostate cancer in a per patient analysis using cystoprostatectomy specimen
223613638|NCT00056004|DRUG|zileuton|
223759545|NCT00486265|DRUG|AZD4877|intravenous infusion administered on days 1, 2 and 3
223759546|NCT02596646|PROCEDURE|Early Precut|Early precut was performed during ERCP with difficult biliary cannulation
224201600|NCT05724615|BEHAVIORAL|Outreach + Bulk ordering + Text Based Reminders and Scheduling assistance|Participants will be sent an order for their lab screening and the recourse of the labs where they can schedule the screening. They will also receive text messages to remind them to have their lab completed as well as a link to schedule the lab and inform them of walk-in hours.
224201601|NCT03615742|OTHER|Placebo|Inhalation of air through a Turbuhaler that contains no medication, as a control.
223613639|NCT05348200|DRUG|Monad 1|Single therapy cream containing Lidocaine. Lidocaine is a topical anesthetic.
223759547|NCT02596646|PROCEDURE|Prolonged cannulation attempts|Prolonged cannulation attempts was performed during ERCP with difficult biliary cannulation
223759548|NCT04838314|PROCEDURE|regional analgesia|Peri operative regional analgesia by bilateral ESP catheter for 72h
223759549|NCT00852709|DRUG|Clofarabine|On Days 1, 2, and 3 and Days 8, 9, and 10 clofarabine will be administered by IVI 2 hours before each dose of cyclophosphamide
223759550|NCT00852709|DRUG|Cyclophosphamide|Single-agent cyclophosphamide will be administered by 2-hour IVI on Day 0 of cycle 1. On Days 1, 2, and 3 and Days 8, 9, and 10 clofarabine will be administered by IVI 2 hours before each dose of cyclophosphamide
223759551|NCT00217542|BIOLOGICAL|recombinant interferon alfa-2b|Given SC
223759552|NCT00217542|DRUG|amifostine/azacitidine|Given SC
223759553|NCT05026684|OTHER|Personalized cost handout|Patients will be given a personalized cost handout to make transparent the full costs to Veterans of different types of ambulatory visits in order to optimize the value of their health care investments.
223759554|NCT01044082|PROCEDURE|controlled cord traction|In the intervention group, controlled cord traction will be applied as soon as a firm uterine contraction is obtained, and until placental delivery occurs
224201602|NCT03615742|DRUG|Budesonide|1.6mg of budesonide from a Turbuhaler.
224201603|NCT03615742|OTHER|Filtered Air|Exposure to HEPA filtered air, as a control.
223613640|NCT05348200|DRUG|Monad 2|Single therapy cream containing Halobetasol Propionate (low-strength). HPB is a topical corticosteroid.
223613641|NCT05348200|DRUG|Monad 3|Single therapy cream containing Halobetasol Propionate (high strength).
223613642|NCT05348200|DRUG|Combination - CITI-002 (low dose)|Combination cream containing Lidocaine and HBP (low)
223613643|NCT05348200|DRUG|Combination - CITI-002 (high dose)|Combination cream containing Lidocaine and HBP (high)
223613644|NCT00209859|DRUG|Methotrexate|
224201604|NCT03615742|OTHER|Diesel Exhaust|Diesel exhaust standardized to 300µg/m³ of particulate matter with a diameter of 2.5 micrometers or less (PM2.5).
223613645|NCT00209859|DRUG|Intraarticular betamethasone|
223613646|NCT00209859|DRUG|Cyclosporine/placebo-cyclosporine|
223759555|NCT01044082|PROCEDURE|Clinical signs of placental separation|Clinical signs of placental separation will be awaited for, and then placental expulsion may be helped through maternal pushing and/or hypogastric pressure
223759556|NCT00389116|DRUG|gastrograffin|ingestion
223759557|NCT00389116|DRUG|water|oral water ingestion
223759558|NCT01112293|DRUG|GC1008|GC1008 is a human IgG4 kappa monoclonal antibody capable of neutralizing all mammalian isoforms of TGFbeta (i.e., beta1, beta 2 and beta 3). GC1008 is a high affinity antibody with dissociation constants (Kds) of 1.8 nM, 2.8 nM and 1.4 nM for TGF1,2,and 3, respectively.
223613647|NCT00531635|DRUG|Mycophenolate Mofetil|Induction of Mixed Hemopoietic Chimerism in Patients Using Mycophenolate Mofetil
223759559|NCT03504358|PROCEDURE|Liver resection|Partial hepatectomy comprised single or multiple hepatic resections aiming at excising all visible malignant tissue.
223759560|NCT02838212|DRUG|adverse drug reaction|drug-related death
223759561|NCT06210087|OTHER|Spontaneous pushing technique|Pregnant women selected for the experimental group were trained on spontaneous pushing technique in the first stage of labor. During the second stage of labor, the women were encouraged and supported in this direction.
223759562|NCT01734551|DRUG|Morphine|"Start at 0.4mg/kg/day (divided every 3-4 hours, given with feeds. Dose may be increased 25% of initial dose until symptoms are stable, up to 1 mg/kg/day.~Once stable for 72 hrs, weaning may begin (decrease 10% of max dose, every other day). When total dose is \<0.1mg/kg/day, may discontinue."
223759563|NCT01734551|DRUG|Clonidine|Initial dose is 5 mcg/kg/day (divided every 3-4 hrs, given with feeds). Will increase 25% of initial dose every 12-24 hrs until stable, up to 12 mcg/kg/day. Dose is unchanged for 72 hours once stable, then may decrease by 10% every other day. If re-escalation is required, the previous dose may be used with 72 hours for stabilizing.
223759564|NCT00006484|DRUG|carboplatin|
223759565|NCT00006484|DRUG|paclitaxel|
223759566|NCT00006484|DRUG|tirapazamine|
223759567|NCT00782262|DIETARY_SUPPLEMENT|KicStart™|KicStart™ is a nutritionally complete, but lower energy formulated liquid meal. Two sachets of KicStart™ (one for breakfast and one for lunch) provides 450 cal of energy per day, 0.8 grams per kilogram ideal body weight of high quality protein, and the recommended daily allowances (RDI) of minerals, vitamins, trace elements, omega 3 and 6 essential fatty acids. The Kicstart is supplemented with some salads, carbohydrate free vegetables and a small piece of meat fish or chicken each day in order to achieve a total energy intake of approximately 850 kcals/day.
223759568|NCT05181111|DEVICE|Wearable Sensor|The sensor measures vital signs including heart rate and respiratory rate, posture and level of physical activity.
223759569|NCT05181111|OTHER|Usual Care|Usual Care Monitoring
223613648|NCT01550809|OTHER|iBolus|Insulin bolus calculated from data obtained through CGM
223613649|NCT01550809|OTHER|tBolus (traditional bolus)|Insulin bolus dose calculated using the standard procedure based on the insulin-to-carbohydrate ratio
223613650|NCT02386449|DRUG|sodium picosulfate, magnesium oxide and citric acid (Picoprep®)|
223613651|NCT02386449|DRUG|mannitol|
223613652|NCT02386449|DRUG|Bisacodyl|
223613653|NCT01736371|DRUG|1% Sevoflurane|In this group of patients, the maintenance of anesthesia is done by 1% sevoflurane + propofol infusion. Propofol infusion is adjusted according to the Bispectral Index.
223613654|NCT01736371|DRUG|Propofol|In this group the maintenance of anesthesia is maintained by only propofol infusion.
223759570|NCT05179733|DRUG|six courses of zanubrutinib, rituximab and lenalidomide|Patients in ZR2 group will receive 6 cycles of zanubrutinib 160mg bid, day 1-21, orally, lenalidomide 25mg qd, day 2-11, orally, rituximab 375mg/m², day 1, intravenously, every 21 days.
223759571|NCT05179733|DRUG|six courses of rituximab combined with low-dose CHOP|Patients in R-miniCHOP group will receive rituximab 375 mg/m² on day 1, cyclophosphamide 400 mg/m², doxorubicin 25 mg/m², and vincristine 1 mg on day 2, and prednisone 40 mg/m² on days 2-6, every 21 days.
223759572|NCT01556529|PROCEDURE|risk profile information|(1) patient on a regular basis receives individualized reports on his/her quantitative risk for 6 typical diabetes complications over the next 10 years, (2) standard T2DMP care, as outlined by AWMF diabetes guidelines
223759573|NCT01556529|PROCEDURE|standard DMP care|standard disease management of T2DM care
223759574|NCT01556529|PROCEDURE|standard DMP care|standard disease management of T2DM care
223759575|NCT03296306|DRUG|Treatment duration of cisplatin based chemotherapy|"* GP regimen: Gemcitabine (1000 mg/m2 D1, D8), Cisplatin (60 mg/m2 D1), every 3 weeks~* GP-S regimen: Gemcitabine (1000 mg/m2 D1, D8), Cisplatin (35 mg/m2 D1,D 2 or D8), every 3 weeks~* MVAC regimen: Methotrexate (30 mg/m2 IV bolus, D1, 15, 22), Vinblastine (3 mg/m2 IV bolus, D2, 15, 22), Doxorubicin (30 mg/m2 IV bolus D2), Cisplatin (70 mg/m2 D2), every 4 weeks~* HD-MVAC with GCSF regimen: Methotrexate (30 mg/m2 IV bolus, D1), Vinblastine (3 mg/m2 IV bolus, D2), Doxorubicin (30 mg/m2 IV bolus D2), Cisplatin (70 mg/m2 D2), G-CSF (240 ug/m2 SC, D4-10), every 2 weeks"
223759576|NCT02731872|DEVICE|Airvo humidifier|"The Airvo humidifier has adjustable flow settings for delivery of fully saturated breathing gases at 37 °C, 100% humidity.~Flow rates are adjustable between 15 and 45 l/min. Ambient air is drawn in by a low-capacity motor. When coupled to a medical oxygen supply, the regulation of delivered oxygen concentration is ensured."
223759577|NCT05286190|DRUG|Bupivacaine 0.25% Injectable Solution|Bupivacaine 0.25% Injectable Solution
223759578|NCT01753635|DEVICE|supraglottic airway placement and use|
223759579|NCT00353678|DRUG|YM150|
223759580|NCT06143566|DRUG|Polypill|A combination of finerenone 10 mg, empagliflozin 12.5 mg, and losartan 50 mg or 100 mg within a polycapsule.
223759581|NCT06143566|DRUG|Combined prescription of the individual medications|We will initiate participants on an ARB, SGLT2i, and Finerenone if they are not in the polypill arm.
223759582|NCT04225923|DRUG|NPC-21 Low dose|NPC-21 will be administered via an approximately 60-minute intravenous infusion on Day 1 and at Week 4, 8, 12
223759583|NCT04225923|DRUG|NPC-21 High dose|NPC-21 will be administered via an approximately 60-minute intravenous infusion on Day 1 and at Week 4, 8, 12
223759584|NCT04225923|DRUG|NPC-21 Placebo|Placebo will be administered via an approximately 60-minute intravenous infusion on Day 1 and at Week 4, 8, 12
223759585|NCT04576533|BEHAVIORAL|walk out from operating room|After the surgery of laparoscopic colectomy or laparoscopic rectectomy surgery (Dixon technique), patients will be encouraged to walk out from the operating room and return to the ward by walking under the condition of stable physiological parameters, painlessness, clear consciousness and normal muscle strength of lower limb
223613655|NCT01736371|DRUG|Sevoflurane|In this group only sevoflurane was used for maintenance of anesthesia. the dose of sevoflurane is adjusted to maintain Bispectral Index within 45 and 55.
223759586|NCT00855309|DRUG|acyclovir sodium|Given IV
223613656|NCT04740697|OTHER|Treatment requiring adjuvant Hormonal Therapy (HT) with tamoxifen.|"Each included patient will be referred to the health care staff for a blood sample:~* for the determination of the residual plasma concentration of tamoxifen and its active metabolites,~* for the constitution of a biobank.~Patients will then complete a questionnaire to collect information on tamoxifen intake and adherence (via the GIRERD questionnaire), as well as possible Alternative and Complementary Therapeutics (ACT) intake (reason for use, type of ACT, ...)."
223613657|NCT06315946|DEVICE|Pixie® skin tag|The skin tag is treated by treatment with the cryogenic device. To protect the surrounding skin, a protective foam plaster is applied before the device is used on the skin tag. The skin tag is treated for 20 seconds after loading the device for 2 seconds.
223613658|NCT06315946|DEVICE|Wortie® Skin Tag Remover|The skin tag is treated by treatment with the cryogenic device. The frozen metal nib is applied on the skin tag for 40 seconds.
223613659|NCT00003811|BIOLOGICAL|bleomycin sulfate|
223613660|NCT00003811|DRUG|amifostine trihydrate|
223613661|NCT00003811|DRUG|cisplatin|
223613662|NCT00003811|DRUG|etoposide|
223613663|NCT00003811|PROCEDURE|conventional surgery|
223613664|NCT00018967|DRUG|glucarpidase|
223613665|NCT01440855|OTHER|CIS (Cancer Information Service) Information Sheet|CIS Fact Sheet, available on the Cancer Information Service website. Used to control for attention. 5-page document provides information about the CIS:What is it, How can CIS information specialists help me, How can I use CIS's services. Also includes definitions of glossary terms and a table of email and website addresses.
223613666|NCT01440855|OTHER|Facing Forward booklet|NCI's (NCI: National Cancer Institute) Facing Forward 61-page booklet, which describes common feelings and reactions that cancer survivors experience during the re-entry phase and offers behavioral recommendations to help them through this period, i.e., ways of dealing with common problems and guidelines for managing physical, social, and emotional health. Booklet sections: Congratulations on Finishing Your Cancer Treatment, Getting Follow-up Medical Care, Ways to Manage Physical Changes, Body Changes and Intimacy, Your Feelings, Social and Work Relationships, Reflection, 6-page Appendix, which provides information on Financial and Legal Matters, and Resource Organizations.
223613667|NCT02209701|DRUG|Porfiromycin|
223613668|NCT01428908|BIOLOGICAL|A+C+hib Conjugate Vaccine|The group A, C polysaccharide meningococcal and type b haemophilus influenzal conjugate vaccine (Wuxi Royal Biological Co., LTD, 20110101) will be administered intramuscularly on one arm, per 0.5ml dose
223613669|NCT01428908|BIOLOGICAL|Placebo|Placebo will be administered intramuscularly on the other arm, per 0.5ml dose
223613670|NCT01428908|BIOLOGICAL|A+C Vaccine|The group A, C polysaccharide meningococcal vaccine (Wuxi Royal Biological Co., LTD, 20101202) will be administered intramuscularly on one arm, per 0.5ml dose
223613671|NCT01428908|BIOLOGICAL|Hib vaccine|The type b haemophilus influenzal vaccine (Sanofi Pasteur Limited) will be administered intramuscularly on the other arm, per 0.5ml dose
223613672|NCT04334993|DRUG|Blinatumomab|Patients with high risk disease features after 2 induction blocks as defined per protocol will be treated with CNS directed block followed by up to 2 cycles of blinatumomab (for B-cell ALL) followed by allogeneic stem cell transplantation.
223613673|NCT03893032|DRUG|Modafinil 200mg|single 200 mg dose
223613674|NCT03893032|DRUG|mixed amphetamine salts|single 10 mg dose
223613675|NCT03893032|DRUG|Placebo|single oral-administration placebo tablet
223613676|NCT04702841|DRUG|Chimeric antigen receptor modified γδ T cells|Dosage: the total dosage of reinfusion is 0.2-5 × 10\^6 / kg, which is determined according to the body weight of the subject and the effective content of cell preparation.
223613677|NCT04603118|PROCEDURE|Optic ultrasonography|
223613678|NCT04603118|PROCEDURE|Lumbar puncture|
223613679|NCT03607942|DIETARY_SUPPLEMENT|HMO supplement|HMO supplement will be given three times a day, not mixed with any feeding.
223613680|NCT03607942|DIETARY_SUPPLEMENT|Placebo comparator|Control product without any HMOs. The Placebo Comparator will be matched to the experimental product in energy content.
223613681|NCT03117985|OTHER|no drug|Stopping antiretroviral therapy
223613682|NCT02690350|DRUG|U3-1784|Solution for solution in 5% dextrose for infusion, intravenously administered every 2 weeks (q2w) as a 250 mL IV, along with colestyramine or equivalent if clinically indicated
223613683|NCT00917761|DRUG|Entecavir and peginterferon (Pegasys) (52 weeks)|Entecavir 0.5 mg/day po at week 1-4 Peginterferon alfa-2a 180 ug/week sc at week 5-52
223613684|NCT00917761|DRUG|Peginterferon (Pegasys) (96 weeks)|Peginterferon alfa-2a 180 ug/week sc at week 1-96
223613685|NCT00917761|DRUG|Peginterferon (Pegasys) (48 weeks)|Peginterferon alfa-2a 180 ug/week sc at week 1-48
223613686|NCT06149208|BEHAVIORAL|Interview|Families will complete interviews about their experiences with the new treatment standard and managing pain at home
223759587|NCT01113125|DRUG|Betamethason-17-valerate and fusidic acid|0.4 cm creme is applied and covered with a plaster (treatment under occlusion). Dosage every second or third day Treatment is started one week before removal of the central venous catheter and continued for four weeks
223613687|NCT01758913|DRUG|Ibuprofen|To compare the efficacy, the side effects and the renal prostaglandin (PG) excretion between indomethacin and ibuprofen in extremely low birth weight (ELBW) infants.
223613688|NCT03374540|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|15/20 mg
223613689|NCT03374540|DRUG|Vitamin K antagonist (VKA)|Individually adjusted dose
223613690|NCT05922371|DIAGNOSTIC_TEST|NuQ H3.1 Nucleosome Assay|Serial analysis on whole blood of nucleosome levels until resolution of sepsis or discharge.
223613691|NCT03384940|DRUG|DS-8201a|DS-8201a is comprised of an antibody component conjoined to a drug component in a lyophilized powder, which is made into solution for intravenous administration
223613692|NCT01668849|DIETARY_SUPPLEMENT|Grape extract|Grape extract self-administered by mouth daily for 35 days
223613693|NCT01668849|DRUG|Lortab, Fentanyl patch, mouthwash|Lortab 5-10 mg Fentanyl patch 25 mcgs Mary's Magic Mouthwash
223613694|NCT05206149|DRUG|Intranasal glugagon|Intranasal glucagon is administered at the dose of 3 mg. This corresponds to the administration of a single dose of Baqsimi®.
223613695|NCT05206149|DRUG|Intranasal placebo|Intranasal placebo (represented by isotonic saline solution) is administered.
223759588|NCT01113125|DRUG|Fusidic Acid|0.4 cm creme is applied and covered with a plaster (treatment under occlusion). Dosage every second or third day Treatment is started one week before removal of the central venous catheter and continued for four weeks
223759589|NCT01417481|DIETARY_SUPPLEMENT|Glycine|Daily oral supplement of glycine at a dose of 0.5 g/kg divided in three doses during 8 weeks
223759590|NCT01417481|DIETARY_SUPPLEMENT|Placebo|Daily oral administration of placebo (sugar glass) at a dose of 0.5 g/kg divided in three doses during 8 weeks
223759591|NCT00829296|DRUG|nebivolol|Starting at dose of 5 mg daily titrated up to max of 40 mg until target BP of 130/80 is reached
223759592|NCT00829296|DRUG|Metoprolol|Starting at 50 mg daily dose is titrated to max 200 mg until target BP of 130/80 is reached
223613696|NCT02497183|DEVICE|ultrasound|A repeat ultrasound exam following oral contrast material consumption
223759593|NCT06095466|DEVICE|Echocardiographic assessment|M mode, cross sectional and pulsed wave Doppler Echocardiographic examinations will be performed using a with a 2.5 MHz wide angle phased array transducer. Patients will be laid in left lateral position and examined in standard parasternal long and short axis and apical views. Short axis recordings will be performed at the level of the papillary muscles. M mode tracings will be recorded at the level of the papillary muscles and the aortic valves, with 2 -D guidance. LV wall thickness and cavity diameters will be measured by M mode, through the largest diameter of the ventricle, if possible, both in diastole and systole. Using the cross-sectional images as a guide, the M mode tracing of the left ventricle will obtained to calculate measurements according to the recommendations of American Society of Echocardiography.
223759594|NCT06095466|DIAGNOSTIC_TEST|Histopathology and Immunohistochemistry|"In patients who do not survive, we will take a trucut core biopsy from the ventricular myocardium, using ultrasound guidance. Cardiac tissue slices preserve the heterogeneous structure and multicellularity of the myocardium and allow its functional characterization. However, in this protocol, only those patients who consent to autopsy or those who consent to most mortem biopsy will be sampled for cardiac histology in CCM. Thus samples for histology and immunohistopathology will be available in only a few patients.~For the immunohistochemistry study, the sections will be collected on the poly-L-lysine covered slides and dried in a thermostat, at 37°C, for 24 hours, for increasing the adherence of the biological material to the histological slide."
223759595|NCT00327704|DRUG|albumin|albumin 20% 100 ml/8 hours for 3 days
223759596|NCT00327704|DRUG|saline|saline 100 ml/8hours for 3 days
223759597|NCT00004028|DRUG|carmustine|
223759598|NCT00004028|PROCEDURE|conventional surgery|
223759599|NCT01794104|DRUG|LMP400|Top1 inhibitors such as LMP400 are potent anticancer agents because stabilizing cleavage complex formation induces replication-and transcription-mediated DNA damage and delays DNA repair, leading to apoptosis. Preclinical and clinical data indicate that baseline tumor levels of Top1 correlate strongly with ability to respond to Top1 inhibitor therapy.
223613697|NCT02497183|OTHER|iodine based solution of oral contrast material|A solution of oral contrast material that is routinely used in our institution prior to performing a computed tomographic (CT) examinations of the gastrointestinal tract will be given prior to performing the repeat ultrasound/
223759600|NCT02583581|DEVICE|EEG monitoring (MindWave by NeuroSky)|EEG evaluation will be conducted for duration of 10 minutes. 5 minutes without auditory stimulation and 5 minutes with auditory stimulation performed using standard headphone or earphones to reduce external noises.
223613698|NCT05682742|DEVICE|Robotic-assisted Surgery|Subjects scheduled to undergo robotic-assisted surgery
223613699|NCT03308708|DRUG|Norepinephrine infusion|Norepinephrine infusion (5miclml) is immediately started after spinal anesthesia. Rate starts at 30 ml/h and modified according to hemodynamic state
223613700|NCT05211427|PROCEDURE|Biopsy|Biopsy of an oropharynx tumor or of a healthy oropharynx mucosa
223613701|NCT04981379|DRUG|Hydroxychloroquine|Hydroxychloroquine (200 mg), as two tablets per day for 5-day interval + Placebo \[Favipiravir (1600 mg)\], as two tablet per day at the first day and then Favipiravir (600 mg) as two tablet per day for the remaining 4-day interval.
223613702|NCT04981379|DRUG|Favipiravir|Favipiravir (1600 mg), as two tablet per day at the first day and then Favipiravir (600 mg) as two tablet per day for the remaining 4-day interval + Placebo \[Hydroxychloroquine (200 mg)\], as two tablets per day for 5-day interval.
223613703|NCT04981379|DRUG|Favipiravir + Hydroxychloroquine|Favipiravir (1600 mg), as two tablet per day at the first day and then Favipiravir (600 mg) as two tablet per day for the remaining 4-day interval + Hydroxychloroquine (200 mg), as two tablets per day for 5-day interval.
223613704|NCT04981379|DRUG|Placebo|Placebo \[Favipiravir (1600 mg)\], as two tablet per day at the first day and then Placebo Favipiravir (600 mg) as two tablet per day for the remaining 4-day interval + Hydroxychloroquine (200 mg), as two tablets per day for 5-day interval.
223613705|NCT02743013|DRUG|CHF 5993 100/6/12,5 pMDI|
223613706|NCT02743013|DRUG|CHF 5993 100/6/12,5 DPI Test 1|
223759601|NCT02583581|DEVICE|EEG monitoring (EPOC by Emotiv)|EEG evaluation will be conducted for duration of 10 minutes. 5 minutes without auditory stimulation and 5 minutes with auditory stimulation performed using standard headphone or earphones to reduce external noises.
223759602|NCT03624621|BEHAVIORAL|Functional Remediation|Functional remediation includes directed group sessions tapping into the main cognitive domains affected in depression (executive functioning, attention and memory) as well as their implication in daily living.
223759603|NCT03624621|DEVICE|Computerized Cognitive Training (CCT)|12 add-on sessions (20-minute long) after each group session to train cognitive domains.
223759604|NCT03624621|BEHAVIORAL|Psychoeducation|12 sessions of psychoeducation on depression, providing information about the disease, causes, consequences and other useful data for the management of depression.
223759605|NCT03624621|DEVICE|Online games|Participants play non-directed online games during 20 minutes after each psychoeducation grup session to make the two active intervention more similar.
223759606|NCT03029624|DEVICE|eCoin|Patients are implanted with active implantable device called eCoin. eCoin is turned ON in order to deliver neuromodulation therapy.
224201605|NCT01456351|DRUG|Bendamustine plus Rituximab|Bendamustine 90 mg/m² d 1+2 + Rituximab 375 mg/m² d 1 q4w for maximum 6 cycles
224201606|NCT01456351|DRUG|Fludarabine 25 mg/m² d 1-3 + Rituximab 375 mg/m² d 1 q4w|Fludarabine 25 mg/m² d 1-3 + Rituximab 375 mg/m² d 1 q4w for maximum 6 cycles
223613707|NCT02743013|DRUG|CHF 5993 100/6/12,5 DPI Test 2|
223613708|NCT02743013|DRUG|CHF 5993 100/6/12,5 pMDI replicate|
223759607|NCT02703571|DRUG|ribociclib|Combination treatment with LEE and TMT
223759608|NCT02703571|DRUG|Trametinib|Combination treatment with LEE and TMT
223759609|NCT00062569|BEHAVIORAL|Bathing Support Intervention (BSI)|Bathing Support Intervention - Review of caregiver current practices and perceptions and care recipient behavioral symptoms associated with bathing with pattern analysis based on observation; skill building for bathing and communication techniques; coaching for implementation
223759610|NCT00062569|BEHAVIORAL|Caregiver reminiscence with coaching|"BSI plus Reminiscence - BSI as above plus caregiver interview to ascertain pleasant long-term memories (e.g. stories, pictures, music) developed into a crib sheet for caregiver use conversationally prior to and during the bath"
223759611|NCT04347304|DIETARY_SUPPLEMENT|Dark chocolate (20 grams) per day providing 508 mg of polyphenols|subjects will be given 21 grams of dark chocolate providing 289 mg of polyphenols per day for 12 weeks.
223759612|NCT04347304|DIETARY_SUPPLEMENT|white chocolate (20 grams) with no polyphenols|subjects will be given 21 grams of white chocolate (0 mg polyohenols) per day for 12 weeks
223759613|NCT06423235|DRUG|regular dose of JiRui® Prunella oral liquid|Take 10ml twice a day
223759614|NCT06423235|DRUG|2x regular dose of JiRui® Prunella oral liquid|Take 20ml twice a day
223759615|NCT06423235|DRUG|regular dose of placebo|Take 10ml twice a day
223613709|NCT02743013|DRUG|CHF 5993 100/6/12,5 pMDI with Valved Holding Chamber|
223759616|NCT06423235|DRUG|2x regular dose of placebo|Take 20ml twice a day
223759617|NCT05272930|DRUG|Dienogest|Assessment of fibromyalgia effects after the use of dienogest
223759618|NCT03610243|BEHAVIORAL|Self-administered acupressure|Two 2-hour one-on-one training sessions in patient-centered self-administered acupressure will be provided by trainers in the first week (4 hours) in the patient's home or at the university, depending on his/her preference. From the second to fourth weeks of the intervention, participants will engage in 15 minutes of self-administered acupressure twice a day (for a total of 10.5 hours over the 3 weeks). They will log the frequency of self-practice in a diary and be encouraged to undertake self-practice beyond the 4-week intervention. At weeks 2, 3, and 4, a 1-hour follow-up visit will be conducted by the same team of trainers to reinforce learning and self-practice (for a total of 3 hours over the 3 weeks).
223759619|NCT04630093|DIAGNOSTIC_TEST|Panel-based pharmacogenetic genotyping|A DNA sample by saliva (via mouthwash swish and expectorate collection) or buccal cell (via buccal brush) will be obtained for pharmacogenetic testing and questionnaires will be administered at baseline and then again at 3 months and 6 months after receiving PGx results.
223759620|NCT05349162|DEVICE|Implantable cardioverter defibrillator use|Implantation of an implantable cardioverter defibrillator (epicardial or transvenous)
223759621|NCT05411510|PROCEDURE|Densah bur|Surgical treatment
223759622|NCT04102475|OTHER|Eatline|"After discharge from a first hospitalization:~Phone calls at 15 days, 1, 2, 4 and 9 months by a trained psychologist. The phone interview will be guided by the same standardized frame, which was developed by a group of experts and tested with a group of patients. The purpose of this intervention is to provide a therapeutic and motivational approach, with positive reinforcement and reassurance.~* Added to treatment as usual (TAU): outpatient visits (at least monthly consultations) or scheduled hospitalizations~* 6- and 12-month assessments as an outpatient interview with an assessor who is blind to condition"
223759623|NCT04102475|OTHER|Control|"After discharge from the first hospitalization:~* No specific phone calls~* TAU: outpatient visits (at least monthly consultations) or scheduled hospitalizations~* 6- and 12-month assessments as an outpatient interview with an assessor who is blind to condition"
223759624|NCT02808845|OTHER|microalbuminuria|
223759625|NCT01194024|OTHER|Standard of Care|bronchoscopy with collection of bronchioalveolar lavage specimen, blood samples, High-Resolution spiral computed tomography(CT)
224201607|NCT02060227|PROCEDURE|Open Latarjet procedure|
224201608|NCT02060227|PROCEDURE|Arthroscopic Bankart repair|
223613710|NCT00786318|DRUG|ziprasidone|ziprasidone 20mg IM
223613711|NCT00786318|DRUG|Standard therapy|Haldol 5mg/ Ativan 2mg IM
223613712|NCT04184297|DRUG|Tiotropium and Olodaterol (Tio+Olo)|drug
223613713|NCT04184297|DRUG|Long-acting beta2-agonist and Inhaled corticosteroids (LABA and ICS)|drug
223613714|NCT03078894|DIAGNOSTIC_TEST|Zika|Zika Diagnostic test
223613715|NCT03078894|DIAGNOSTIC_TEST|Chikagunya|Chikagunya Diagnostic test
223613716|NCT03078894|DIAGNOSTIC_TEST|Dengue|Dengue Diagnostic test
223613717|NCT02732548|OTHER|Negative Pressure Wound Therapy (NPWT)|
223613718|NCT02732548|OTHER|MIRODERM Application(s)|
223613719|NCT02732548|OTHER|Standard Care|wound measurement, debridement, photography of wound, moist wound environment, infection management, nutritional support
223759626|NCT05017610|DRUG|Liothyronine|Given PO
223759627|NCT05017610|DRUG|Lomustine|Given PO
223759628|NCT05017610|DRUG|Methimazole|Given PO
223759629|NCT06373679|BEHAVIORAL|Switching to E-Cigarette|Participants will receive eleven weeks of e-cigarette products with instructions to switch completely at switch date
223759630|NCT06373679|BEHAVIORAL|Switching using Medication|Participants will receive eleven weeks of FDA approved medication, either varenicline or combination NRT, with instructions to quit smoking cigarettes at quit date
223759631|NCT03002168|DIETARY_SUPPLEMENT|Alpha-cyclodextrin|Alpha-cyclodextrin is approved by the Food and Drug Administration as a dietary ingredient.
223759632|NCT03002168|DIETARY_SUPPLEMENT|Placebo|Placebo tablets identical in appearance to the active comparator
223759633|NCT03002168|RADIATION|Triolein radiolabeled with 100 microcuries of 3^Hydrogen|A MicroCurie (µCi) is a measure of radioactivity.
223759634|NCT03002168|RADIATION|Tripalmitin radiolabeled with 20 microcuries of 14^Carbon|A MicroCurie (µCi) is a measure of radioactivity.
223759635|NCT04296396|DRUG|0 to 20 tablets of oxycodone 5mg|Individualized opioid prescription protocol (IOPP) that includes shared decision making
223759636|NCT04296396|DRUG|Fixed opioid prescription|20 tablets of oxycodone 5mg
223613720|NCT02412098|DRUG|Eleclazine|Eleclazine tablets administered orally
223613721|NCT03089580|DEVICE|Intense Pulsed Light Therapy|Intense pulsed light therapy is a non-invasive and non-laser light treatment that was approved in 1995 by the FDA for dermatology. Participants will receive a total of 4 treatments over the course of the study.
223613722|NCT03089580|PROCEDURE|Sham Treatment|The sham treatment will mimic the IPL treatment but no light will be delivered. Sham treatment will be administered 4 times throughout the study.
223613723|NCT03871699|DRUG|Ferric carboxymaltose|Administration of Ferric Carboxymaltose intravenously, one dose only.
223613724|NCT00977626|DRUG|Part 1 - AZD2423 or Placebo|AZD2423 Oral Solution, multiple dosing during 10-14 days or Placebo Oral Solution, multiple dosing during 10-14 days
223613725|NCT00977626|DRUG|Part 2 - AZD2423|AZD2423 Oral solution, multiple dosing
223613726|NCT00977626|DRUG|Part 3 - AZD2423|AZD2423 Oral solution, single dosing or AZD2423 Oral solution, single dosing - With Food or AZD2423 Oral solution, single dosing - Fasting Condition.
223613727|NCT03087513|DRUG|Sugammadex Injection [Bridion]|The study participants will receive 10 ml syringe containing Sugammadex (2mg/kg) in the first phase followed by Placebo 10 ml syringe containing of 0.9% of normal saline in the second phase.
223613728|NCT03087513|DRUG|Placebo|The study participants will receive Placebo 10 ml syringe containing of 0.9% of normal saline in the first phase followed by 10 ml syringe containing Sugammadex (2mg/kg) in the second phase.
223613729|NCT04593524|DIETARY_SUPPLEMENT|vitamin D 1000 IU and A 6000 IU supplementation and nutritional counseling|24 participants, which are treatment group (I) which receives nutritional counseling, vitamin D 1000 IU, vitamin A 6000 IU
223759637|NCT01077960|BIOLOGICAL|Serostim|Serostim® 4 mg daily given for 12 weeks (following a prior 36-week treatment \[Serono Study 24380\] with Serostim® 4 mg daily given for 12 weeks, followed by 24-weeks of either Serostim® 2 mg every other day or Placebo every other day)
223759638|NCT02757079|DRUG|NPC-15|NPC-15, Melatonin granule 1 mg, 2 mg or 4 mg, once a day, is administered orally before going to bed for 26 weeks after a screening phase of 2 weeks with placebo administration.
223759639|NCT03857633|DIAGNOSTIC_TEST|Cardiac MRI 1 - With Gadolinium Contrast|"Cines for cardiac function and volumes, T2 myomaps, Resting perfusion and strain analysis, Tagging (strain), T1 myomaps, Late gadolinium enhancement~During the MRI scan participants would be required perform a short period of low intensity exercise involving peddling on an adapted cycle for 10-15 minutes to provide additional data on cardiac function under exertion."
223759640|NCT03857633|DIAGNOSTIC_TEST|Cardiac MRI 2 - With Gadolinium Contrast|"Cines for cardiac function and volumes, T2 myomaps, Resting perfusion and strain analysis, Tagging (strain), T1 myomaps, Late gadolinium enhancement~During the MRI scan participants would be required perform a short period of low intensity exercise involving peddling on an adapted cycle for 10-15 minutes to provide additional data on cardiac function under exertion."
223759641|NCT03857633|DIAGNOSTIC_TEST|Cardiac MRI 3 - Without Gadolinium Contrast|"Cines for cardiac function and volumes, T2 myomaps, Resting perfusion and strain analysis, Tagging (strain), T1 myomaps.~During the MRI scan participants would be required perform a short period of low intensity exercise involving peddling on an adapted cycle for 10-15 minutes to provide additional data on cardiac function under exertion."
223759642|NCT03857633|DIAGNOSTIC_TEST|Cardiac MRI 3 - With Gadolinium Contrast|"Cines for cardiac function and volumes, T2 myomaps, Resting perfusion and strain analysis, Tagging (strain), T1 myomaps, Late gadolinium enhancement~During the MRI scan participants would be required perform a short period of low intensity exercise involving peddling on an adapted cycle for 10-15 minutes to provide additional data on cardiac function under exertion."
223759643|NCT03857633|DIAGNOSTIC_TEST|Peripheral Whole Blood Samples|20ml EDTA whole blood samples - collected sequentially during study - max 8 time points
223759644|NCT05105308|BEHAVIORAL|Family Assisted Diet (FAD)|A behavioral intervention consisting of helping parents renourish their child and conduct food exposures with new foods.
223759645|NCT05105308|BEHAVIORAL|Feeling and Body Investigator_ARFID Division (FBI-ARFID)|A sensory and somatic focused intervention that educates children about feelings and bodily sensations, in-session exposures to body and food sensations, different strategies to improve generalization while at home, and strategies to help them understand and track experiences exploring food.
223613730|NCT04593524|OTHER|nutritional Counseling|control group (C) which only receives nutritional counseling for 28 days
223613731|NCT06346015|PROCEDURE|Gamma Entrainment Stimulation|"Audio-assisted therapy: receive audio therapy with a specific device for 30 minutes, once in the morning and evening for 3 months.~(Binaural beat treatment group: receive binaural beat treatment with a specific device for 30 minutes, once in the morning and evening, for 3 months.）"
223613732|NCT05590975|BEHAVIORAL|PACT Intervention|PACT Intervention is a group based session delivered by Peer supporters and adult coaches on PACT module. There will be 10 sessions, one per week for 90 to 120 minutes each.
223613733|NCT00083525|DRUG|WX-UK1 in combination with Capecitabine|
223613734|NCT04170543|DRUG|MEDI3506|Dose 1, Dose 2, Dose 3, Dose 4
223613735|NCT04170543|DRUG|Placebo|Placebo
223613736|NCT04170543|DRUG|Dapagliflozin|Dapagliflozin 10 mg
223613737|NCT00878748|DRUG|Effexor XR|
223613738|NCT00878748|OTHER|Effexor XR discontinue|
223613739|NCT04119674|DRUG|Drug is Anlotinib.|Anlotinib 8 mg/day (Chia-tai Tianqing Pharmaceutical Co., Ltd.) was given orally on days 1 to 14 per 3-week cycle for 2 cycles during concomitant therapy and maximally 8 cycles during adjuvant chemotherapy. One week after discontinuation of adjuvant chemotherapy, anlotinib 8 mg/day was given for maintenance .
223613740|NCT04119674|DRUG|Drug is Temozolomide Capsule.|Temozolomide 75 mg/m2/day was taken for maximally 49 days during concurrent chemoradiotherapy. Beginning 4 weeks after completion of concurrent chemoradiotherapy, patients received adjuvant temozolomide for 5 days every 28 days, first cycle 150 mg/m2/day and subsequent cycles 200 mg/m2/day for maximally 6 cycles .
223613741|NCT04119674|RADIATION|Radiotherapy was initiated 4 to 6 weeks postoperatively.|Radiotherapy was initiated 4 to 6 weeks postoperatively at a dose of 1.8-2.0 Grays (Gy) per fraction for 5 days per week for 6 weeks with a total dose of 54-60 Gy.
223759646|NCT03837899|DRUG|Durvalumab / Tremelimumab Combination Therapy|"Starting dose:~durvalumab: 20mg/kg tremelimumab: 1mg/kg at cycles 2 to 5 only co-administered with durvalumab. The Recommended Phase 2 dose will be used for the dose expansion phase."
223759647|NCT04990960|OTHER|Physiotherapy|During each session (45 minutes)the patient was assessed and trained in self-treatment exercises assigned to treat their cords. This later method was chosen to ensure regular participation in their exercises and early correction of any inaccuracies in the implementation of the exercises regarding AWS treatment . Or the Physiotherapist worked actively on cords with soft or vigorous stretching.
223613742|NCT05668910|GENETIC|whole genomic methylation and fragmentation profile analysis of cfDNA|The assay for gastric cancer early detection will be built based on low-depth methylone sequencing followed with a multi-dimensional model construction with analysing several features such as methylation, fragmentation, and chromosomal copy number alternation.
223613743|NCT03593057|OTHER|Manual therapy|Manual therapy protocol and self-care advice and body awareness.
223613744|NCT03593057|OTHER|Control group|Advice on self-care and body awareness.
223613745|NCT04385186|DRUG|Inactivated convalescent plasma|"Day 0: Transfusion of 200mL of ABO -Rh compatible inactivated convalescent plasma, Start of support treatment selected by medical staff according to each institutional protocol~Day 1: Transfusion of 200mL of ABO -Rh compatible inactivated convalescent plasma"
223613746|NCT04385186|DRUG|Support treatment|Day 0: Start of support treatment selected by medical staff according to each each institutional protocol
223613747|NCT06156735|OTHER|Passive Music Therapy (P)|Music Therapy Intervention
223613748|NCT06156735|OTHER|Active Music Therapy (A)|Music Therapy Intervention
223613749|NCT06156735|OTHER|Standard Care Control Condition (C)|Without any intervention
223613750|NCT05721170|DRUG|Beta blocker|Investigation on beta-blockers in TAVI and brief post-TAVI period.
223613751|NCT04166071|DRUG|Naltrexone|Half of the participants will be randomly assigned to take one dose of naltrexone (50mg, capsule form) during the experimental session
223613752|NCT04166071|DRUG|Placebo|Half of the participants will be randomly assigned to take a placebo capsule during the experimental session
223613753|NCT00801216|DRUG|High-dose sequential chemotherapy and autologous transplant|Two courses of methotrexate 3.5 g/mq day 1 and cytarabine 2 g/mq twice a day, for two days, Rituximab 375 mg/mq days 3 \& 11 and Intrathecal liposomal cytarabine 50 mg day 6(Phase I) followed in case of response by cyclophosphamide 7 g/mq plus Rituximab 375 mg/mq and Intrathecal liposomal cytarabine 50 mg Leukapheresis A and cryopreservation (Phase II), Cytarabine 2 g/mq twice a day for 4 days, Rituximab 375 mg/m2 and Reinfusion of stem cells (Phase III), etoposide 2 g/mq, Intrathecal liposomal cytarabine 50 mg (Phase IV) and high-dose Thiotepa-BCNU supported by autologous stem cell transplant (Phase V), and whole-brain radiotherapy in patients who do not achieve a complete remission after chemotherapy (Phase VI)
223613754|NCT04927650|DIAGNOSTIC_TEST|HPV testing|Undergo collection of cervical samples for HPV testing
223613755|NCT04927650|OTHER|Questionnaire Administration|Complete questionnaires
223759648|NCT06447090|DRUG|Mitoxantrone hydrochloride liposome|Veneclatra (VEN) 400 mg/d (reduced to 100 mg when combined with an azole), d1-7; Mitoxantrone Liposomal 30 mg/m2, d1; Cytosine arabinoside(Ara-C) 100 mg/m2/d, d1-7; Cyclophosphamide (CTX) 400 mg/m2/d, d2, 5); After 1 day of rest, cryopreserved donor stem cells MNC1-2X10\^8 /kg infusion, add low-dose (25 mg Bid) and short-course treatment (stop 2-3 weeks after DLI) oral cyclosporine (CSA) to prevent graft-versus-host disease (GVHD) 3 days before cryopreserved stem cell infusion.
223759649|NCT01353378|DRUG|dexmedetomidine|Intravenously injecting 0.125microgram/kg for 10ml IV(in the vein)in group 1, 0.25microgram/kg for 10ml in group 2 within 10 minutes as soon as the operation begin. The control group receives 10mlsaline in 10 minutes.
223759650|NCT03364296|OTHER|Blood Samples|Blood sample retrieved for biological assessment and biobanking
223759651|NCT01371656|DRUG|levofloxacin|Given PO or IV
223759652|NCT05961566|DEVICE|Use of collagen matrix after subepithelial connective tissue graft harvest|A collagen matrix is placed under the overlying flap after the subepithelial connective tissue graft harvesting.
223759653|NCT01465464|DRUG|Orantinib (TSU-68)|200 mg (1 tablet) of Orantinib was administered orally twice per day after meals, morning and evening.
223759654|NCT01465464|DRUG|Placebo|1 tablet was administered orally twice per day after meals, morning and evening.
223759655|NCT03525197|DIETARY_SUPPLEMENT|Whey protein-based supplement|High quality protein supplement to be consumed twice daily
223759656|NCT03525197|DIETARY_SUPPLEMENT|Collagen protein-based supplement|Lower quality protein supplement to be consumed daily
224312064|NCT04808479|BEHAVIORAL|mHealth ED|The mHealth condition will provide participants with a manualized health psychoeducation session of equivalent duration to the face-to-face CBT session delivered to imFREE participants. Content focuses on various dimensions of health and well-being. Subsequent to this session participants will receive an informational pamphlet regarding BUP and the importance of adherence. the mHealth component of the intervention comprises text reminders for scheduled MM appointments.
223613756|NCT06611527|DEVICE|PS+PEEP group|Application of 4 sets of 20 repetitions with PS to provide a tidal volume equal to 10ml/kg of predicted body weight, PEEP equal to 10 cmH2O, and inspired oxygen fraction (FiO2) to achieve peripheral oxygen saturation (SpO2) between 92-94%
223613757|NCT06611527|DEVICE|CPAP group|Application of CPAP of 10 cmH2O with FiO2 to achieve SpO2 between 92-94% for 30 minutes.
223613759|NCT06610214|OTHER|IMPACT-care intervention|1, Training of Healthcare Staff; 2, Development of Medication Summary; 3, Information Package for Patient and/or Caregiver; 4, Discharge Coaching; 5, Post-Discharge follow-Up call
223613760|NCT03191266|DEVICE|Active rTMS|Active rTMS will receive an intermittent rTMS stimulation protocol.
223613761|NCT03191266|DEVICE|Sham rTMS|Sham rTMS will receive all conditions except the actual intermittent theta burst rTMS stimulation.
223759657|NCT02388984|DRUG|Compound danshen dripping pills|Dosage form:pill. Dosage:20pills. Frequency:three times per day. Duration:24 weeks.
223759658|NCT02388984|DRUG|Placebo|Dosage form:pill. Dosage:20pills. Frequency:three times per day. Duration:24 weeks.
223759659|NCT01465646|DRUG|levothyroxine|
223759660|NCT01465646|DRUG|levothyroxine|
223759661|NCT05871073|DRUG|Ropivacaine 0.75% Injectable Solution|WOUND INFILTRATION AFTER SPINAL SURGERY
224312065|NCT06574347|DRUG|Vebreltinib|Subjects will receive Vebreltinib orally twice per day (BID).
223613763|NCT06922071|OTHER|REMINDER4Care|"REMINDER4Care was an adapted version of the original REMINDER program, tailored to the characteristics, needs, and interests of older adults in RDF.~The REMINDER4Care intervention includes 20 face-to-face group sessions, each approximately 60 to 75 minutes, held twice a week over ten weeks. This program aims to optimize memory, attention, executive function, and emotional regulation while promoting lifestyle habits that protect the aging brain. The sessions include brain health education, cognitive exercises, compensatory memory strategies, training for managing personally relevant goals (with goal setting), and stress management techniques (compassion-based therapies, relaxation methods, and mindfulness). Social support and emotion regulation strategies (like attention management, positive cognitive reappraisal, and reframing speech) were included to address psychosocial risk factors like stress, social isolation, and depression."
223613764|NCT06920771|BIOLOGICAL|PURETHAL Mites 50,000 AUeq/ml|"Biological/Vaccine: Placebo~Increasing volumes of placebo, will be administered by subcutaneous injection (starting with 0.05 ml) at weekly intervals till the maintenance dose (0.5 ml) is reached. Subsequently, maintenance dosages, corresponding to 0.5 ml of placebo, are given at 4-weekly intervals"
223613765|NCT06920771|BIOLOGICAL|Biological/Vaccine: Placebo|Increasing dosages, corresponding to increasing volumes of drug solution (starting with 0.05 ml), will be administered by subcutaneous injection at weekly intervals till the maintenance dose (0.5 ml) is reached. Subsequently, maintenance dosages, corresponding to 0.5 ml of drug solution, are given at 4-weekly intervals.
223613766|NCT05591404|BEHAVIORAL|Trier Social Stress Test (TSST)|Participants randomized to the TSST arm will experience the Trier Social Stress Test.
223759662|NCT05871073|DRUG|dexamethasone 8mg|WOUND INFILTRATION AFTER SPINAL SURGERY
223613767|NCT05481359|DEVICE|Electrographic Flow™ (EGF) mapping and ablation|"Electrographic Flow™ (EGF) mapping enables the full spatiotemporal reconstruction of organized atrial electrical wavefront propagation to identify active sources or origins of excitation that may trigger atrial fibrillation (AF).~EGF mapping involves 1 minute recordings of unipolar electrograms from a basket catheter, which are then processed with the EGF algorithm (Ablamap® Software). Several basket catheter positions are acquired in standard positions in both the left and right atria. EGF-identified sources with activity levels exceeding the recommended threshold are deemed significant and are targeted for ablation. The success of the ablation is confirmed through an EGF remap, where elimination of the source is defined as reduction of EGF source activity below the threshold."
223613768|NCT07015125|DEVICE|Transcutaneous Electrical Nerve Stimulation (TENS)|Use of TENS device for 1 hour during each migraine episode.
223613769|NCT06689878|BEHAVIORAL|Mobile Cognitive Behavioral App|"A mobile cognitive behavioral therapy (CBT) app called Maya that includes modules with educational content and teaching and practice of strategies that address depression and anxiety after stroke."
223613770|NCT06623890|DRUG|Omaveloxolone|Administered as specified in the treatment arm.
223759663|NCT03979443|PROCEDURE|Discharge on the day of surgery|Patient discharge on the day of the surgery, usually within 6-8 hours after procedure
223759664|NCT05162872|DRUG|Niraparib，Sintilimab|Niraparib 200 mg QD D1-21 Sintilimab 200 mg IV q3W
223759665|NCT02699294|OTHER|Manual pressure release|Subjects will be positioned supine on a treatment plinth and will be encouraged to relax as much as possible before pressure is applied. A slow pressure to myofascial latent trigger point will be applied directly over the marked pectoralis minor muscle myofascial latent trigger point site until a moderate but tolerable pain value of 7 out of 10 (0= no pain, 10= severe pain) is reported. Constant pressure will be sustained for 90 seconds if the subjects report that the pain is decreased to a value of 3, the pressure will be increased to restore perceived pain to the value of 7. Then, tissue resistance (barrier) in pectoralis minor muscle will be controlled.
223759666|NCT02699294|OTHER|Contract-relax PNF stretch|Subjects will be in a sitting position with hands being clasped behind the head. The pectoralis minor muscle will be passively and slowly stretched until a strong but tolerable stretch discomfort intensity level of 4 out of 10 (0= no pain, 10= severe pain) is reported. Passive stretch will be sustained for 10 seconds followed by 6 seconds of maximal voluntary isometric contraction of the pectoralis minor muscle. Then, subjects will be instructed to relax for further 4 seconds. Subjects will maintain newly active stretched position of pectoralis minor muscle for 10 seconds with a strong but tolerable stretch discomfort intensity level of 4 out of 10. The procedure will be repeated four times with 30 seconds of rest between two successive trials.
224201609|NCT06101719|DIAGNOSTIC_TEST|Enteral contrast challenge|Contrast agent, volume of contrast, and contrast dilution were not standardized across sites due to the differences in hospital specific formularies; otherwise, the protocol was standardized across sites. Diatrizoate meglumine (osmolality of 1940 mOsm/kg) was used preferentially at eight sites and Ioversol (702 mOms/kg) at one site. Patients received 30-200ml (based on age or weight depending on site) of enteral contrast followed by X-rays at 8-12 hours and 24 hours after contrast administration.
224201610|NCT06416930|DRUG|Cadonilimab Combined with chemotherapy|Cadonilimab (15mg/kg, intravenous drip, D1) + gemcitabine (1250mg/m2, intravenous drip, D1/D8) or vinorelbine (30mg, oral, tiw, D1/D3/D5) or pemetrexed (500mg/m2, intravenous drip, D1), every 3 weeks.
224201611|NCT03026842|DRUG|Decitabine|20 mg/m2/day for 5 days
224201612|NCT03026842|DRUG|Daunorubicin, Cytarabine|Daunorubicin: 45 mg/m2/day for 3 days; Cytarabine: 100 mg/m2/day for 5 days
224201613|NCT03026842|DRUG|Mitoxantrone, Cytarabine|Mitoxantrone: 8 mg/m2/day for 3 days; Cytarabine: 100 mg/m2/day for 5 days
224201614|NCT03026842|DRUG|Aclacinomycin, Cytarabine|Aclacinomycin: 20 mg/day for 5 days; Cytarabine: 100 mg/m2/day for 5 days
224312066|NCT06574347|DRUG|Osimertinib|Subjects will receive Osimertinib 80mg orally once per day (QD).
224312067|NCT06574347|DRUG|PLB1004|Subjects will receive PLB1004 80mg orally once per day (QD).
224312068|NCT04512365|DRUG|Placebo oral capsule|A capsule that contains only dextrose filler administered during the first or second laboratory visit.
224312069|NCT04512365|DRUG|THC|A capsule that contains 7.5 mg of THC as well as dextrose filler administered during the first or second laboratory visit.
224312070|NCT03221348|BIOLOGICAL|CHO-H01|Glyco-engineered anti-CD20 antibody
224312071|NCT00399256|DRUG|Acetylcysteine|
224312072|NCT00399256|DRUG|Zinc|
224312073|NCT05107141|PROCEDURE|Ridge preservation|Ridge preservation in molar areas using a xenograft or an allograft in combination with a barrier collagen membrane
223613771|NCT04904536|DRUG|Atorvastatin|40mg atorvastatin + standard care daily for 12 months.Atorvastatin 40mg has TGA approval for general marketing for the treatment of hypercholesterolaemia and cardiovascular prevention under a number of manufacturer names.The study medication selected will be the atorvastatin 40mg (Apotex) which is scored, and allows down-titration to 20mg should a participant develop symptoms.The study medication will be packaged, labelled and dispensed directly to particpants by the Syntro Health pharmacy in Australia. A comparable atorvastatin 40mg is being sourced in Chile, and will be dispensed from the pharmacy of the Clínica Alemana de Santiago. Similarly, a comparable atorvastatin 40mg is being sourced in Hong Kong, and will be dispensed from the site's pharmacy.
223613772|NCT04904536|OTHER|Standard Care|Standard care for neurological symptoms as a result of COVID-19 infection.
223613773|NCT07022262|BEHAVIORAL|Progressive resistance training plus impact loading|The structure of the exercise sessions will be: 1) warm up; 2) progressive resistance training plus impact loading; 3) cool down. Briefly, the warm-ups will be based on RAMP methodology (i.e., raise, activate, mobilise and potentiate) in order to maximize middle-term performance of the main exercises. Exercises focused on the brace, squat, lunge or jump patterns will be included in the first part of the session. The main part of the session will consist of 9 sets of 10-12 jumps, 9 sets of 10-12 repetitions of lower body resistance exercise and 3 sets of 10-12 repetitions of upper resistance exercise. Each set will be performed with approximately 15-30 seconds of rest for jumps and 2-3 minutes of rest for resistance exercises. Finally, participants will perform a cool down including guided static stretching and relaxing exercises.
223613774|NCT06633913|DEVICE|spTMS-TBS-spTMS|This study uses fMRI in combination with single-pulse TMS (spTMS) and theta-burst stimulation (TBS) to determine if the two effects coming from each are related to one another, and if there will be changes in brain activity when undergoing spTMS that are induced by TBS. Additionally, by stimulating the dlPFC in both patients and healthy controls with this paradigm, researchers are able to specifically compare the after-TBS single-pulse TMS-evoked brain responses with before-TBS responses to observe if TBS will change neural pathways disrupted in those who display high negative affect (e.g. depression, anxiety).
223613775|NCT06693089|OTHER|MIT-ED|The aim is to develop healthier strategies for managing negative thoughts and feelings linked to Eating Disorder (ED) and engage patients in social interactions that fulfill their relational needs. Participants will learn that perfectionism and the need for control in ED are coping strategies shaped by interpersonal patterns with significant others, where low self-esteem and emotional dysregulation play key roles. Metacognitive Intepersonal Therapy (MIT) aims to improve individuals' ability to understand their own emotions and thoughts, recognizing maladaptive, rigid, and biased schemas about self and others. This awareness helps them form a richer understanding of others' minds and use this knowledge to respond more adaptively to social challenges. MIT also helps individuals reflect on how these schemas trigger ED behaviors and develop better coping strategies for interpersonal stressors.
223613776|NCT06719804|DRUG|Propranolol|Oral administration is given solely for the epilepsy seizure event. Dosage: 20mg per dose; The patient's blood pressure and heart rate are monitored after the seizure; if the SBP is above 90 mmHg and the heart rate is above 60 beats per minute, then patients are instructed to take propranolol within 1 hour of a seizure . If the seizure frequency is excessively high, the interval between doses should be no less than 6 hours and the medication should not be administered more than 3 times a day.
223613777|NCT06720857|DIAGNOSTIC_TEST|Identification of a risk stratification model and its predictive value for cardiovascular disorders in the puerperium|Identification of a risk stratification model for cardiovascular/hypertensive disorders in the puerperium using a panel of placental biochemical markers (sFlt-1 and PlGF: already used in pregnancy for prediction of preeclampsia), demographic, clinical and laboratory data.
223613778|NCT06722677|DEVICE|VNS|An neuromodulation treatment that delivers electrical impulses to the brain via the vagus nerve.
223613779|NCT06722677|DEVICE|Sham VNS|An neuromodulation treatment that delivers electrical impulses to the brain via the vagus nerve, the actual intensity is 0 mA.
223613780|NCT06722677|OTHER|Rehabilitation|Rehabilitation movements to improve upper limb function after stroke.
223613781|NCT06725355|DRUG|IN-R00002|Single administration of IN-R00002 60mg
223613782|NCT06725355|DRUG|IN-G00002|Single administration of IN-G00002 60mg
223613783|NCT06725043|DEVICE|Therapeutic ultrasound|Pulsed therapeutic ultrasound (1 MHz , 50% duty cycle and intensity gradually increased till the patient felt a deqi sensation).Each point was stimulated by ultrasound for 5 minutes at bilateral acupuncture points of PC6, PC7, BL60 and KI1(3 times / week for 4 weeks).
223613784|NCT06725043|DEVICE|Placebo therapeutic ultrasound|patients were received placebo therapeutic ultrasound at bilateral acupuncture points of PC6, PC7, BL60, and KI.
223613785|NCT06725043|OTHER|Traditional physical therapy program|Strengthing exercise, balance training, stretching exercises and home exercise program and education
223759667|NCT02699294|OTHER|Z-stretch|Subjects will be positioned supine with knee bent on a treatment plinth, and the legs will be rotated to the opposite direction of the arm to be stretched placing a stabilizing distal tension on the ribs. Then, the subjects will be slowly brought the arm in a circular motion overhead pausing at the points of tightness, maintaining close contact to the treatment table until a strong but tolerable stretch discomfort intensity level of 4 out of 10 (0= no pain, 10= severe pain) is reported. Self-stretch of pectoralis minor muscle, including myofascial latent trigger points will be sustained for 30 seconds. The procedure will be repeated four times with 30 seconds of rest between two successive trials.
223759668|NCT00497536|DRUG|Insulin Aspart (IAsp)|"IAsp 100 U.~≈ bolus protocol: From 6 pm until 6 am~• 50 % of habitual 24 hour insulin need/24 hours = basal rate (per hour)~From 8 am until 6 pm~1 dose/h + 50 % s.c. (≈ bolus)."
223759669|NCT00497536|DRUG|Insulin Aspart (IAsp).|"IAsp 100 U From 6 pm until 8 am~• 50 % of habitual 24 hour insulin need/24 hours = basal rate (per hour)~From 8 am until 6 pm 50 % increase of basal rate"
223759670|NCT00497536|DRUG|Insulin Aspart (IAsp)|"IAsp 100 U From 6 pm until 8 am~• 50 % of habitual 24 hour insulin need/24 hours = basal rate (per hour)~From 8 am until 6 pm 50 % increase of basal rate"
223759671|NCT02235376|OTHER|weaning trial of mechanical ventilation|
223759672|NCT05518149|DRUG|Aticaprant|Aticaprant 10 mg tablet will be administered orally.
223759673|NCT01443247|DRUG|anti-d|intervention group received injection anti-d in dose of 50 µg/kg (250IU/kg) along with platelet concentrate while control ( non intervention ) group received platelet support only
223759674|NCT05180461|DRUG|emodepside|emodepside tablet
223613786|NCT06726798|PROCEDURE|Endoscopic submucosal dissection with EndoRobotics traction device|All patients received robotic ESD under general anesthesia or monitored anaesthetic care at the endoscopy center of Prince of Wales Hospital. The targeted lesion would first be localized and pre-injected using a mixture of normal saline, indigocarmine, epinephrine and sodium hyaluronate. The robotic endoscopic traction device was then inserted to reach the target. Mucosal incision first started from the anal side followed by lifting with the grasper\[Figure 1; Video 1\]. Vio 3 diathermy system (ERBE, Germany) was used with endocut Q effect 3 and forced coagulation effect 3. Further submucosal dissection would be performed by electrocautery knife with traction achieved via EndoRobotics traction. Upon completion, the specimen would be retrieved upon withdrawal of the whole system.
223613787|NCT06460142|DIAGNOSTIC_TEST|Aortic/ cardiac magnetic resonance imaging|MRI scans will be performed to detect systemic vascular involvement in GCA patients, aiming to provide detailed images of affected tissues.
223759675|NCT05180461|DRUG|matching placebo of emodepside|emodepside matching placebo tablet
223759676|NCT05180461|DRUG|ivermectin|ivermectin tablet (overencapsulated for blinding)
223759677|NCT05180461|DRUG|matching placebo of ivermectin|matching placebo of overencapsulated ivermectin tablet
223759678|NCT06115538|OTHER|Levodopa|Levodopa benserazide (100+25 mg) will be given to one group of study patients, and levodopa carbidopa entacapone (100+25+200 mg) will be given to the other group of study patients. Just before the drugs are given (0th minute), at 90 and 180 minutes after the drugs are given, a total of 3 doses will be given.
223759679|NCT00624533|BEHAVIORAL|GDS Method (muscular chains physical therapy method)|Experimental group received 15 GDS method sessions based on the equilibration of articular and muscular tensions that reduced trunk and lumbopelvic stability. GDS method combine specific technics of manual therapy, spinal stabilisation and stretching exercises (4 sessions),supervised group exercise therapy (10 sessions) and home exercise programme with individualised exercises (1 session) Experimental group received 2 sessions of 50 minutes per week during 8 weeks.
223759680|NCT00624533|BEHAVIORAL|Conventional Physical Therapy in Primary Health Care|"Conventional Physical Therapy in Spanish Primary Care Units are based on Electrotherapy (TENS and microwave thermotherapy) and a standard written advices. Patients received 14 sessions of 40 minutes of conventional TENS, 10 minutes of microwave thermotherapy and 1 last session of standard written advices.~Conventional Physical Therapy group received 2 sessions of 50 minutes per week during 8 weeks."
223613788|NCT06460142|DIAGNOSTIC_TEST|Vascular ultrasound|Vascular ultrasound will be employed to examine the temporal and axillary arteries in GCA patients, searching for signs indicative of active inflammation.
223613789|NCT06460142|DIAGNOSTIC_TEST|Transorbital Ultrasound|Transorbital ultrasound will be employed to assess the ophthalmic artery and its branches in GCA patients to detect intracranial inflammatory processes that could lead to severe neuro-ophthalmological complications.
223759681|NCT01603446|DRUG|L-Arginine|NOW® L-Arginine powder
223759682|NCT02797847|DRUG|ALN-TTRSC02|Ascending doses of ALN-TTRSC02 by subcutaneous (SC) injection
223759683|NCT02797847|DRUG|Sterile Normal Saline (0.9% NaCl)|Calculated volume to match active comparator
223759684|NCT02889640|OTHER|SAGA Innovations|An intensive math tutoring program
223759685|NCT02889640|OTHER|Scale-up tutors|Tutors who have been selected for hire via the one in three-and-a-half randomization process
223759686|NCT02889640|OTHER|Standard Tutors|Tutors who have been selected for hire via SAGA's standard hiring process, which does not entail randomization
223759687|NCT03561415|OTHER|Universal Posaconazole Prophylaxis|All patients assigned to this arm will start posaconazole between Day 4 and Day 14 post lung or heart-lung transplant for a minimum of 3 months.
223759688|NCT03561415|OTHER|Pre-emptive Posaconazole Therapy|Posaconazole will be started if a fungal pathogen is identified or there is serological evidence of a fungal pathogen in the absence of any evidence of invasive fungal disease for 3 months.
223759689|NCT00605774|DRUG|epinephrine|Epinephrine 0.06 µg/kg/min infused over two hours during experimental period on Day 2
223759690|NCT00605774|DRUG|epinephrine|Epinephrine 0.06 µg/kg/min infusion during hyperinsulinemic euglycemic clamp on day 2
223613790|NCT06460142|DIAGNOSTIC_TEST|Contrast-Enhanced Ultrasound|Contrast-Enhanced Ultrasound (CEUS) is utilized to evaluate aortic involvement in GCA patients as an alternative, bed-side, realtime, radiation-free diagnostic tool.
223759691|NCT02180334|DRUG|Mosapride citrate|On the day of MMTT, 1 tablet (5 mg) of mosapride will be administered orally to participants of 'mosapride' arm. After 1 hour, MMTT will be performed.
223759692|NCT02180334|DRUG|Linagliptin|During run-in period, 1 tablet (5mg) per day will provided for 7 days. On the day of MMTT, 1 tablet (5 mg) of linagliptin will be administered orally to participants of both arms. After 1 hour, MMTT will be performed.
223759693|NCT02180334|DRUG|Acetaminophen (paracetamol)|On the day of MMTT, 3 tablets (1500 mg) of acetaminophen (paracetamol) will be administered orally to participants of both arms at the start of MMTT with manufactured mixed meal (0 min).
223759694|NCT01590407|DRUG|ALS-002200|ALS-002200
223759695|NCT01590407|DRUG|Placebo|Placebo
223759696|NCT04328974|PROCEDURE|lumbar CSF drainage|We have performed the lumbar CSF drainage on the level of the lumbar spine between L3 and L4 with the patient lying in the lateral decubitus position with hips and knees flexed. A lumbar drainage catheter was inserted using a HermeticTM lumbar accessory kit (Integra Neurosciences, Plainsboro, NJ, USA) in the patients. ICP monitoring via lumbar drainage catheter was practiced using the LiquoGuard® (Möller Medical GmbH \& Co KG, Fulda, Germany). ICP control strategies was initiated when ICP exceeded 15 mmHg in the absence of noxious stimuli at the rate of 10\~20 ml/h via a lumbar drainage catheter until ICP was less than 15 mmHg \[14, 15\].
224075441|NCT06221020|BEHAVIORAL|World Health Organization Quality of Life questionnaire (WHOQOL-BREF)|The World Health Organization Quality of Life questionnaire (WHOQOL-BREF) is a health-related quality of life assessment tool developed by the World Health Organization (WHO). It is designed to evaluate an individual's satisfaction with their life and overall health status. The WHOQOL-BREF is a condensed version of the original WHOQOL-100 questionnaire, intended to reduce the time required to complete it and enhance its applicability.
224201615|NCT05562232|DIETARY_SUPPLEMENT|Creatine Monohydrate|Follows
224201616|NCT00274807|BIOLOGICAL|filgrastim|
224201617|NCT00274807|DRUG|cytarabine|
224312074|NCT05107141|DEVICE|bone graft plus a collagen membrane|
224201618|NCT00274807|DRUG|etoposide|
224201619|NCT00274807|DRUG|mitoxantrone hydrochloride|
223759697|NCT02421133|OTHER|Transitional care program.|"During the patient's stay in hospital, the transition nurse creates a transitional care file including information about the patient (inpatient medical and nurse care plan, medications), the discharge plan, and the contact information of the relevant primary care providers. She notifies the patient's primary care physician of the date of the discharge to home, of the potential medical problems and of the discharge care plan; a primary care physician visit is planned the month following the discharge.~The day of the hospital discharge: meeting with the patient to review the follow-up recommendations. The transition nurse verifies that the medications are prescribed accordingly with the discharge plan, that the patient and his caregiver understand the prescription and are informed with the planned appointments and the biological monitoring.~During 4 weeks after the hospital discharge: follow-up by the transition nurse once a week, alternately by telephone and home visit."
223759698|NCT02421133|OTHER|standard care program|The patients will be discharged according to the usual care plan of each participating hospital. The medical team does a medical and geriatric assessment of the patients according to the recommendations. The communication of information to the primary care providers (nurse, primary care physician…) is left to the discretion of the medical teams of the discharging hospitals, according to their habits of work.
223759699|NCT01554618|DRUG|Exenatide Once Weekly|2 mg exenatide once weekly
223759700|NCT01554618|DRUG|Placebo|Placebo
223759701|NCT04027166|DRUG|Methadone|Methadone will be administered before study procedures
223759702|NCT04027166|DRUG|Methadone|Methadone will be delayed (4 hours) until the end of the procedures
223759703|NCT01566448|DRUG|Ketamine|20mg/5ml swish and spit four times daily
223759704|NCT02131480|DRUG|Doxorubicin|60 mg/m²
223759705|NCT02131480|DRUG|Trabectedin|1,1 mg/m²
224201620|NCT05882656|OTHER|Questionnaire administration|All study participants will be surveyed with the EQ-5D-5L questionnaire to measure their quality of life indicators before the primary total hip arthroplasty and after the surgery (on 4 dates over a 1-year period); the WOMAC questionnaire to measure their functional outcomes before the primary total hip arthroplasty and after the surgery (on 4 dates over a 1-year period); the costs questionnaire to measure direct and indirect costs borne by patients because of their condition before the primary total hip arthroplasty and after the surgery (on 4 dates over a 1-year period).
223759706|NCT05908279|OTHER|Walking test|Walk with and without a metronome
223613791|NCT06460142|DIAGNOSTIC_TEST|Optical coherence tomography angiography|OCTA will be used to assess vascular changes in the retina of GCA patients, providing detailed imaging that can help detect early signs of ocular involvement and identify risk factors of anterior ischemic optic neuropathy.
223613792|NCT06460142|DIAGNOSTIC_TEST|Fluorescein angiography|Fluorescein angiography will be performed to evaluate blood circulation and highlight any blockages in the blood vessels of the retina in patients with GCA to detect vascular abnormalities that may lead to severe vision complications.
223613793|NCT06460142|DIAGNOSTIC_TEST|Fundus autofluorescence|This imaging technique will be used to observe the health of the retina and detect any changes in GCA patients that could suggest disease activity, particularly useful for assessing the integrity of the retinal pigment epithelium.
223759707|NCT05908279|OTHER|Disease assessement|Disease stage assessed by a doctor
223759708|NCT02897128|OTHER|Observational Only - Transcutaneous Oxygen Measurement|The transcutaneous oxygen at your surgical site will be measured at three time points prior to your surgery.
223759709|NCT03397290|DEVICE|Ultrasound (US) Imaging|Ultrasound (US) Imaging will be compared to the chest X-ray for diagnostic accuracy (sensitivity and specificity) in diagnoses of pneumothorax post transthoracic lung biopsy
223759710|NCT06190730|OTHER|Voice-Assisted Remote Symptom Monitoring System (VARSMS)|Utilizing an Alexa Skill activated via an Amazon Echo Dot device, this system will administer two patient-reported outcomes measures to subjects. This will not be used as basis for diagnosis, nor for any clinical intervention.
223759711|NCT04759625|OTHER|Novel biscuit enriched with mushroom powder containing 3g of β-glucans|Daily consumption of a novel biscuit enriched with mushroom powder containing 3g of β-glucans
223759712|NCT04759625|OTHER|Placebo biscuit|Daily consumption of placebo biscuit
223759713|NCT05148312|DRUG|Budesonide Inhalant Product|Single-dose of budesonide solution administered by nebulization.
223759714|NCT00632554|DRUG|prednisolone 0.5 mg/kg/day for three months|period of treatment
223759715|NCT00632554|DRUG|prednisolone 0.5 mg/kg/day for six months|period of therapy
223759716|NCT05986890|PROCEDURE|Roux-en-Y Bypass|laparoscopic Roux-en-Y
223759717|NCT05986890|PROCEDURE|gastrojejunostomy|surgical gastrojejunostomy
223759718|NCT06261268|PROCEDURE|Strip graft with Mucograft|"An apically repositioned flap is made in the vestibular region. The flap is then elevated with a split-thickness preparation, and the mucogingival junction will be repositioned apically and fixed with periosteal-anchored sutures. Then, a free epithelialized gingival strip graft will be harvested from the molar area of the palate. The Strip graft is sutured to the apical end of the recipient bed. The remaining uncovered part of the periosteal bed will be covered with a xenogeneic collagen matrix (Mucograft®. Geistlich Pharma AG, Wolhusen, Switzerland) fixed with simple interrupted and crossed sutures. The edges of the palatal wound (donor area) will be approximated with crossed sutures."
224201621|NCT01285388|DRUG|MB12066|MB12066 10mg, 100mg/tab. once oral dose MB12066 10, 30, 100, 150, 200mg
224312075|NCT02676362|OTHER|Gingival crevicular fluid collection with filter paper|Gingival Crevicular Fluid Dynamics
224312076|NCT03379389|DRUG|Methenamine + Methylthioninium|Methenamine + Methylthioninium
223759719|NCT06261268|PROCEDURE|Free gingival graft|The preparation of the apically repositioned flap and the recipient bed with its apico-coronal design and dimension is performed as in the test group. Subsequently, an epithelialized free gingival graft with the size of the entire recipient area with a thickness of 2 mm will be harvested from the molar area of the palate. The graft is sutured to the recipient periosteal bed using simple interrupted and crossed sutures. In the donor area, a collagen sponge is sutured to the wound by means of crossed sutures.
223759720|NCT02157987|DRUG|bevacuzimab spray|
223759721|NCT02067377|DIETARY_SUPPLEMENT|Serum bovine immunoglobulin (SBI) medical food|Serum bovine immunoglobulin (SBI) is an FDA regulated, orally administered prescription medical food intended for the nutritional management of patients who are unable to absorb necessary nutrients as a result of therapeutic or chronic medical problems.
223759722|NCT02067377|DIETARY_SUPPLEMENT|Placebo (for serum bovine immunoglobulin)|
223613794|NCT06460142|DIAGNOSTIC_TEST|Color Fundus Photography|Color fundus photography will be used to document the appearance of the optic disc and retinal vasculature in GCA patients, aiding in the long-term monitoring of ocular changes and the effects of therapeutic interventions.
223613795|NCT06460142|DIAGNOSTIC_TEST|Cell-based ex-vivo assay with high-content analysis|This assay predicts individual patient responses to different DMARDs by analyzing patient-derived PBMCs for specific immune responses to therapeutic agents.
223613796|NCT06460142|DIAGNOSTIC_TEST|3'mRNA sequencing|3'mRNA sequencing analyzes gene expression profiles related to the immune response in PMR/GCA patients, aiding in understanding the genetic underpinnings of inflammation and vascular remodeling.
223613797|NCT06460142|DIAGNOSTIC_TEST|Enzyme-linked immunosorbent assay|Used to measure cytokine levels in the serum and plasma of PMR/GCA patients, ELISA aids in profiling inflammatory markers that are indicative of disease activity and response to treatment.
223613798|NCT06460142|DIAGNOSTIC_TEST|Flow cytometry|Employed to analyze immune cell phenotypes in patients with PMR and/or GCA, this test helps identify various immune cell subsets and their activation states, which are critical for understanding disease mechanisms and guiding therapy.
223613799|NCT06460142|DIAGNOSTIC_TEST|Laboratory assessment:|Serum Chemistry (nt-proBNP, troponin T, CRP, ESR, blood count)
223759723|NCT01297868|OTHER|exercise|
223759724|NCT02244580|DEVICE|MammaTyper™|MammaTyper™ kit is a molecular in vitro diagnostic test for the quantitative detection of the ribonuclease acid (RNA) expression status of the genes for estrogen receptor (ESR1), progesterone receptor (PGR), human epidermal growth factor receptor 2 (HER2) and proliferation antigen KI 67.
223759725|NCT03377777|OTHER|No intervention|
223759726|NCT03283423|DEVICE|Image-guided Lymphadanectomy in AMIGO|Image guided laparoscopic lymph node biopsy
223759727|NCT04011410|DRUG|Hydroxychloroquine Sulfate 200Mg Tab|Twice daily for 90-days, administered two weeks prior to radiation/surgery of oligometastatic lesions
223759728|NCT06520709|OTHER|No intervention|No intervention
223759729|NCT03387163|DRUG|Sacubitril/Valsartan|commercially available Sacubitril/Valsartan: 24/26; 49/51 ; 97/103
223759730|NCT06032312|OTHER|description|no intervention, just description of the groups
223759731|NCT01495585|DRUG|Lonafarnib|Commercially approved products used to test the research hypothesis
223759732|NCT01495585|OTHER|Placebo|Placebo control
223759733|NCT05769959|DRUG|RO7515629|RO7515629 will be administered intravenously at a dose and schedule as specified for the respective study part and cohort.
223759734|NCT05769959|DRUG|tocilizumab|Tocilizumab will be used as rescue medication only. Tocilizumab will be administered as required for the management of cytokine release syndrome (CRS).
223759735|NCT03811756|DIETARY_SUPPLEMENT|Test syrup containing CoQ10 and collagen|Test group will receive investigational product - test syrup (daily dose 10 mL: fish collagen: 4000 mg, water soluble CoQ10 (Q10Vital®): 50 mg, vitamin C: 80 mg, vitamin A: 920 μg, biotin: 150 μg); continuous administration of investigational product for 12 weeks.
223759736|NCT03811756|DIETARY_SUPPLEMENT|Placebo syrup|Placebo group will receive placebo syrup without active ingredients. (daily dose 10 mL: fish collagen: 0 mg, water soluble CoQ10 (Q10Vital®): 0 mg, vitamin C: 0 mg, vitamin A: 0 μg, biotin: 0 μg); continous administration of placebo product for 12 weeks.
223759737|NCT04448210|BEHAVIORAL|DigiKnowIt News: Teen|Teens will interact with a multimedia educational website that will teach them about pediatric clinical trials including topics such as participant rights and safety, benefits and costs to participating in a study, and different types of procedures used in trials.
223759738|NCT01991002|BEHAVIORAL|14/21 diet|"Diet program is divided into 3 periods: 1. Low carb diet for 14 days; 2. Low carb and regular diet in alternating days for 21 days; 3. Individual carbohydrate-rich diet for 21 days.~The diet consists of a free choice of food ingredients from a detailed list of foods in each category (proteins, carbohydrates, vegetables, fat etc.). The participants are free to choose the types of food as long as they are within the specified allowance (quantity) for each food group."
223759739|NCT03861260|PROCEDURE|Rigid cystoscopy with urethral dilatation|Patients will have a general anaesthetic and a rigid cytoscopic examination of the bladder dilated with sterile water. The urethra will be dilated from FR20 in incremental diameter increases of 2 to French 32 if possible.
224312077|NCT03379389|DRUG|Methenamine + Methylthioninium + Acriflavine + Atropa belladona|Methenamine + Methylthioninium + Acriflavine + Atropa belladona
223759740|NCT03861260|PROCEDURE|Flexible cystoscopy and installation of Glycosaminoglycan layer replacement (laluril)|Patients will undergo flexible cystoscopy and intravesical installations of Hyaluronic acid (HA) + Chondroitin Sulphate (CS) (GAGs) weekly for 4 weeks and then at 8 weeks and 12 weeks.
224312078|NCT03379389|DRUG|Antibiotics|Antibiotics based on individual subjects urine culture / antibiogram
224312079|NCT02834650|OTHER|Cardiac MRI with contrast|Cardiac MRI
224312080|NCT02834650|OTHER|Cardiac MRI without contrast|Cardiac MRI
224312081|NCT02834650|OTHER|Blood Test|Hematocrit, Creatinine, Troponin, BNP
224312082|NCT02834650|OTHER|Heart Rate|Holter Monitor
224312083|NCT02834650|OTHER|Pulmonary Function Test|Pulmonary Function Test
224312084|NCT02834650|OTHER|Genetic Testing|Genetic Testing
224312085|NCT02834650|OTHER|Repeat MRI scan|Repeat MRI scan
223613800|NCT06460142|DIAGNOSTIC_TEST|Immunohistochemistry of Temporal Artery Biopsies|Immunohistochemistry staining of TAB to assess local expression of endothelial adhesion molecules in acute inflammation.
223613801|NCT06460142|DIAGNOSTIC_TEST|Functional assessment questionnaires|The following questionnaires will be applied: FACIT-Fatigue, SF-36, BAS, Birmingham Vasculitis Activity Score, Montreal Cognitive Assessment, Mini-Mental Status Examination. These questionnaires collectively provide a comprehensive evaluation of the functional status, quality of life, and mental health of patients with GCA and PMR.
223759741|NCT00694967|PROCEDURE|McDonald cerclage placement|Transcervical McDonald cerclage placement
223759742|NCT00694967|DRUG|17 hydroxyprogesterone caproate|Weekly 250mg intramuscular injections
223759743|NCT04617691|DRUG|Guselkumab|Guselkumab will be administered as IV solution derived from FVP or PFS-U.
223759744|NCT05715372|BEHAVIORAL|Mediterranean diet|12-week structured program for Mediterranean diet.
223759745|NCT05715372|BEHAVIORAL|AHA walking program|12-week structured AHA walking program.
223759746|NCT05715372|BEHAVIORAL|Mindfulness-based stress reduction|8-week structured mindfulness-based stress reduction (Cabot).
223759747|NCT05715372|BEHAVIORAL|Unstructured Mediterranean diet|Unstructured 12-week program with basic outline for Mediterranean diet.
223509566|NCT06126653|DRUG|High Dose ARD-501|Titratable, liquid formulation, taken orally. The intervention is given relative to the body weight of the individual. 0.5 mg/kg dosing.
223759748|NCT05715372|BEHAVIORAL|Unstructured walking program|Unstructured 12-week walking program.
223759749|NCT05715372|BEHAVIORAL|Unstructured stress reduction|Unstructured program using mobile application for stress reduction.
223509567|NCT06126653|DRUG|Placebo|Titratable, liquid formulation, taken orally.
223759750|NCT03975907|BIOLOGICAL|CAR-BCMA T Cells|The CAR-BCMA T cells (study drug) used in this study are chimeric antigen receptor specifically expressing T cells targeting BCMA.
223759751|NCT05507983|DRUG|Tranexamic acid|Tranexamic acid 1500 mg
223759752|NCT05507983|DRUG|Placebo|Placebo, sodium chloride 0.9%
223759753|NCT00291668|BIOLOGICAL|Certolizumab Pegol|"* Active Substance: Certolizumab Pegol~* Pharmaceutical Form: Solution for injection in pre-filled syringe~* Concentration: 200 mg/mL~* Route of Administration: Subcutaneous use"
223759754|NCT00291668|OTHER|Placebo|"* Active Substance: isotonic sodium chloride solution~* Pharmaceutical Form: Solution for injection~* Concentration: 1 mL~* Route of Administration: Subcutaneous use"
223759755|NCT05768477|OTHER|Consultation|Consultation with the pain specialist, which might entail prescription of medication of vitamins.
223759756|NCT05768477|PROCEDURE|Interventions|Facet injections, nerve denervations, infiltrations, Qutenza, Spinal Cord Stimulation, Transcutaneous Electrical Nerve Stimulation
223759757|NCT05768477|DRUG|Baxter therapy|Ketamine or Linisol baxter therapy
223759758|NCT05768477|BEHAVIORAL|Interdisciplinary therapy|Interdisciplinary therapy provided by the physiotherapist, psychologist and occupational therapist.
223759759|NCT04162028|DRUG|Nebutlized Ketamine|The PK-BAN package will be opened and weight -based dose of ketamine will be administered to the patient via BAN. The medication will be delivered with a minimum time of 5 min and maximum time of 15 min.
223509568|NCT04705337|DRUG|Levosimendan|administration of levosimendan as a continuous iv. infusion, every 4 weeks for 48 weeks (12 infusions in total)
223509569|NCT04705337|OTHER|Placebo|administration of glucose as a continuous iv. infusion, every 4 weeks for 48 weeks (12 infusions in total)
223509570|NCT06962085|PROCEDURE|sacral erector spinae plane block group|In the block group, bilateral sacral erector spinae plane block (10 mL 0.25% bupivacaine (Marcaine %0,5. AstraZeneca Ltd, İstanbul, Türkiye) + 5 mL 1% lidocaine (Lidon 100 mg/ 5mL. ONFARMA İlaç San. Ve Tic. A.Ş, Ankara, Türkiye) will be performed in the lateral position with the help of ultrasound before surgery.
223509571|NCT06962085|DRUG|Opioid Analgesics|Sacral arrector spine block will not be performed in this group. After general anesthesia, hemodynamic values (noninvasive blood pressure, heart rate, peripheral oxygen saturation) and total remifentanil (Rentanil 2 mg. VEM İlaç San. Ve Tic. A.Ş, İstanbul, Türkiye) use will be recorded during the operation. Additionally, numerical pain scores and total meperidine (Aldine 100mg/2mL. VEM İlaç San. Ve Tic. A.Ş, İstanbul, Türkiye) use at 0, 2, 4, 6, 12 and 24 hours after the operation will be recorded. At the 24th hour, the Turkish version of the Quality of Recovery-15 (QoR-15T) Questionnaire will be filled out and recorded.
223509572|NCT06961513|OTHER|Women's health physiotherapy|Women's health physiotherapy for pelvic-floor dysfunction
223509573|NCT06431646|BEHAVIORAL|A web-based education intervention developed for university students with PMS|The web-based education program includes the definition, prevalence, importance, causes, symptoms, diagnosis, risk factors, management strategies and treatment options of PMS. The education emphasizes non-pharmacological strategies for managing PMS, including diet, exercise and body mass index (BMI), sleep hygiene, smoking cessation, stress management, as well as vitamin and mineral supplements, herbal therapy, acupuncture, acupressure and reflexology.
223509574|NCT04344860|DRUG|Recombinant Von Willebrand factor|Recombinant Von Willebrand factor(Vonvendi) is an intravenous therapy that replaces missing VWF to restore hemostasis and reduce bleeding with surgery or delivery.
223509575|NCT04344860|DRUG|Tranexamic Acid Injection [Cyklokapron]|Tranexamic acid (Cyclokapron) is an intravenous anti-fibrinolytic therapy that prevents clot breakdown and reduces bleeding with surgery or delivery.
223509576|NCT04650841|DRUG|Placebo Cream with Naloxone|Participants will be informed that the spray is an effective pain and negative emotion reducing agent.
223509577|NCT04650841|DRUG|Control Cream with Naloxone|Participants will be informed that the spray is saline.
223509578|NCT04650841|DRUG|Placebo Cream with Saline|Participants will be informed that the spray is an effective pain and negative emotion reducing agent.
223509579|NCT04650841|DRUG|Control Cream with Saline|Participants will be informed that the spray is saline.
223509580|NCT06077747|PROCEDURE|Coil Embolization of the Lumbar Vein|Catheter based venography will first confirm Nutcracker physiology with retrograde lumbar vein flow and epidural venous plexus congestion. The lumbar vein will then be coil embolized.
223509581|NCT06009978|DEVICE|Neuromuscular electrical stimulation (NMES)|Neuromuscular electrical stimulation (NMES) 2 times a day á 15 minutes from the third to the eight week after injury. The additional treatment will be perform in the patients home by themselves
223509582|NCT04598919|DRUG|Saracatinab|125 mg once daily by mouth for 24 weeks
223509583|NCT04598919|DRUG|Placebo|once daily by mouth for 24 weeks
223509584|NCT06641401|PROCEDURE|Endoscopic Flexor Hallucis Longus transfer for Acute Achilles tendon rupture|All patients have already undergone the same operation for the same disease. All data are to be collected retrospectively
223509585|NCT06641440|DRUG|Prednisone|patients will be treated for three months in the two groups with the two different protocols for three months both
223509586|NCT06637475|DEVICE|Electric stimulation|"Patients with baseline assessments will be followed up for 8 weeks within a planned treatment program. Treatment protocol for the ES group:~external ES wearable apparatus will be applied three days a week for 30 minutes with symmetrical biphasic current at a frequency of 50 Hertz (Hz), with stimulation and rest periods of 5 s contraction and 5 s rest, with a current intensity ranging from 0-100 mA while the patients are in the supine position. The device will be attached to the patients in such a way that it wraps around the upper thigh, the electrodes will be attached to the anterior and posterior of the right and left thigh, the right-left pelvic side and the right-left gluteal region. The current intensity in each session will be determined as the maximum current intensity that will not cause pain and discomfort in individuals."
223509587|NCT06640452|OTHER|RecoveryFun system|The system components were: VR headset; wereable biosensors, clinical platform, caregiver app and smart services.
223509588|NCT06644976|PROCEDURE|femoral neck CRIF|femoral neck fracture CRiF while under noac. no special intervention beside taking blood test for drug levels
223613802|NCT06726330|PROCEDURE|Fimbriectomy Followed by Delayed Oophorectomy (F-DO)|"This intervention involves two stages:~1. Fimbriectomy: A preventive surgical procedure that removes the fimbrial end of the fallopian tubes, including adjacent ovarian tissue, while preserving ovarian function to avoid premature menopause.~2. Delayed Oophorectomy: The removal of ovaries, performed at menopause or later, depending on patient preference and clinical guidelines.~   * The F-DO strategy aims to reduce the risk of tubo-ovarian or primary peritoneal carcinoma, which often originates in the fallopian tubes, while minimizing the adverse effects of premature menopause such as cardiovascular disease and osteoporosis"
223613803|NCT06726330|PROCEDURE|Bilateral Salpingo-Oophorectomy|This standard surgical intervention involves the removal of both fallopian tubes and ovaries (BSO) to eliminate the risk of tubo-ovarian or primary peritoneal carcinoma. It is typically recommended for women with a genetic predisposition (e.g., BRCA1/2 mutations) around the age of 40-45. While highly effective in preventing cancer, BSO induces premature menopause, which may result in long-term side effects such as increased cardiovascular risk, osteoporosis, and cognitive decline.
223613804|NCT06726083|BEHAVIORAL|Nutrition Intervention|Weekly virtual live group sessions led by a trained study team member will be held twice weekly for 1 hour/week over 12 weeks using a HIPAA compliant online platform. The first class of each week will include the teaching kitchen cooking demonstration (\~30 min) and the remainder of the class will focus on dietary education. The second class each week will provide an opportunity for group discussion to have Veterans share to their peers about how they used the weekly produce
223759760|NCT00704028|DRUG|Ferric Carboxymaltose|15 mg/kg up to a maximum of 750 mg at 100 mg per minute weekly to a maximum cumulative dose of 2,250 mg.
223759761|NCT00704028|DRUG|Iron Dextran|As determined by the investigator to a maximum cumulative dose of 2,250 mg.
223759762|NCT02883296|OTHER|Pelvis Magnetic resonance imaging|
223509589|NCT02213536|RADIATION|VMAT (Volumetric Modulated Arc Therapy)|Delivering a prescribed radiation dose to the whole brain using VMAT to reduce dose to hair follicles on scalp.
223509590|NCT01536509|BEHAVIORAL|Telehealth Behavioral Treatment (TBT)|Families in the TBT condition will receive three individually-tailored behavioral intervention sessions in addition to the online education intervention with 1) guided problem-solving and behavior management training tailored to the unique needs and/or barriers of the family, and 2) discussion of the patient's adherence since the previous session. In addition, patients in the TBT condition will be signed up for text message reminder service offered free of charge via www.mymedschedule.com. These are generic reminder text messages are used to assist with adherence in adolescents. Intervention sessions will be conducted via telehealth delivery with trained postdoctoral psychology fellows or masters-level graduates using webcams, supplied by the study, and SkypeTM free software.
223509591|NCT01536509|BEHAVIORAL|Education Only (EO)|Families in the EO condition will receive three individual sessions in addition to the online education intervention to review 1) online educational intervention material to answer questions participants have, 2) educational brochures from the Crohn's and Colitis Foundation of America (CCFA), which contain additional information (e.g., Guide for Parents, Living with IBD, Guide for Kids and Teenagers), and 3) general healthy lifestyle recommendations (e.g., sleep, exercise, etc.). Sessions will be conducted via telehealth delivery with trained postdoctoral clinical psychology fellows or masters-level graduates using webcams, supplied by the study, and SkypeTM free software.
223509592|NCT02657941|BEHAVIORAL|Motivational group|"Three weekly sessions of one hour, co-managed by two nurses specialized in psycho-education~Session 1: General information on the risk of weight gain and the means of prevention, motivational balance on the practice of physical activity, developing a personal goal, information about the sports center Session 2: brainstorming and card game on Food Hygiene Session 3: Find situations at risk of snacking and consider alternative lines"
223509593|NCT02657941|BEHAVIORAL|educational group|"Three weekly sessions of one hour, co-managed by two nurses specialized in psycho-education~Session 1: General information on the risk of weight gain and means of prevention, video on physical activity, discussions with therapists, information about the sports center Session 2: Video on Food Hygiene, discussions with therapists Session 3: Return on basic concepts covered in the first 2 sessions"
223509594|NCT03390673|DRUG|HD204|Single-Dose 1mg/kg body weight by 90 minute intravenous infusion
223509595|NCT03390673|DRUG|Avastin|Single-Dose 1mg/kg body weight by 90 minute intravenous infusion
223509596|NCT03225989|DRUG|LOAd703|Oncolytic adenovirus serotype 5/35 encoding TMZ-CD40L and 4-1BBL
223509597|NCT04082676|DRUG|Hyperbaric bupivacaine spinal|In this group patient will receive intrathecal hyperbaric bupivacaine based on patients height and weight according to Harten chart with 10 μg of fentanyl (0.1 ml)
223509598|NCT04082676|DRUG|Hyperbaric bupivacaine spinal|In this group will receive intrathecal hyperbaric bupivacaine based on patients height (0.06mg/cm) with 10 μg of fentanyl (0.1 ml)
223509599|NCT06289881|DRUG|Sildenafill-Test product|Test-Product: Sildenafil 100 mg tablets Manufactured by: Actigen Co., Ltd., Thailand
223509600|NCT06289881|DRUG|Sildenafill-Reference product|Reference-product: Viagra 100 mg tablets Manufactured by: FAREVA AMBOISE, France
223509601|NCT00601107|DRUG|Doxercalciferol|
223509602|NCT00601107|DRUG|Placebo|
223509603|NCT00384150|DRUG|galiximab in combination with rituximab|galiximab (500 mg/m2 IV) in combination with rituximab (375 mg/m2 IV)once weekly for 4 weeks.
223759763|NCT06244264|PROCEDURE|Autoblood transfusion|Through a negative pressure suction device, the patient's blood that flows out during surgery is collected into a blood storage filter. During the suction process, it is mixed with an appropriate anticoagulant and passed through multiple layers of filters. When the volume of recovered blood reaches a certain level, it is continuously (or intermittently) centrifuged. Using a high-speed centrifugal blood recovery tank, the red blood cells are separated, and the plasma, waste, cell fragments, anticoagulants, and harmful components are diverted into a waste bag. A large amount of saline is used to repeatedly wash, purify, and concentrate the red blood cells. Finally, the concentrated red blood cells are prepared into a 70% red blood cell suspension with saline and stored in a collection bag for transfusion back to the patients. Open surgery is considered as the standard procedure for metastatic spinal cord compression
223759764|NCT05129878|PROCEDURE|scaling and OHI|patients with PCOS on combined oral contraceptives (COCs) having gingivitis will receive scaling and oral hygiene instructions
223759765|NCT05129878|PROCEDURE|oral Hygiene instructions|patients with PCOS on combined oral contraceptives (COCs) having gingivitis will receive oral hygiene instructions only
224312086|NCT05569551|DEVICE|Adhesive pouch|Is a barrier dressing categorized under class C medical device. It is used to seal up the umbilical stump to prevent contamination until its cord detachment. It has an adhesive film that sticks to skin with a centrally located non-adhesive pouch ensuring that zero pressure is applied on the umbilicus. It is made of polyurethane, the same material as transparent intravenous cannula dressings making it hypoallergenic waterproof and breathable.
224312087|NCT04851535|DRUG|Jaktinib Hydrochloride Tablets|Jaktinib 100mg Bid
224312088|NCT04972110|DRUG|RP-3500 (camonsertib)|RP-3500 (camonsertib, ATR inhibitor) in combination with niraparib or olaparib (PARP inhibitors)
224312089|NCT00403637|DRUG|indacaterol maleate|
224312090|NCT03885752|DRUG|chewed mint gum|In the preoperative waiting area before transferring to the operating room, patients in group G chewed mint gum for 2 minutes and then spit it out.
224312091|NCT03885752|OTHER|swallow twice|asked to swallow twice without any additional treatment.
223613805|NCT06726083|BEHAVIORAL|Contact Control|Weekly virtual live group health education sessions led by staff will be held for two hours/week over 12 weeks. We will enroll up to 15 participants into each virtual class cohort and run multiple different group sessions for a total sample size of 90 participants. The content follows the LIFE study structured successful aging health education curriculum80,81 which was designed to increase self-efficacy and empower older Veterans to take control of their own healthcare. Topics focus on a broad range of healthy aging, such as importance of sleep, safe travel, goal setting, self-care, and common comorbidities
223613806|NCT06725368|DRUG|PCC|"PCC protocol (Paclitaxel - Carboplatin - Cetuximab) by intravenous injection for 16 cycles. 1 cycle lasts 1 week. The Carboplatin + Paclitaxel administration schedule 3 weeks out of 4, with weekly Cetuximab is authorized.~After 16 cycles: maintenance with Cetuximab 500 mg/m2 every 14 days until unacceptable toxicity or progression or death."
223613807|NCT06726629|OTHER|Version Of The New Knee Society Knee Scoring System|All patients will be subjected to the same clinical and radiographic checks, the data of which will be collected in the different centres
224312092|NCT01865942|PROCEDURE|open surgery|The to surgical procedures are individually well know, but the outcome of the procedures in respect to perioperative bleeding and change in quality of life has to our knowledge not been compared.
223613808|NCT05648188|BIOLOGICAL|Sample|Sample of whole blood and tissue for ex vivo expression of A2R, CD39, CD73 and P2RX7
223613809|NCT06506942|DEVICE|Transcatheter Tricuspid Valve Replacement|Replacement of the tricuspid valve through a transcatheter approach
223613810|NCT05503862|DEVICE|YoSperm|The purpose of the app is for at-home semen analysis including sperm motility concentration and sperm quality (YO Score) and compares the results to laboratory standards. We will be utilizing the YoSperm® technology in order for patients to send their semen analysis results directly from their device to their provider via secure email.
223613811|NCT06725641|DRUG|Test preparation：Methylcholine chloroacetate for inhalation|Cholinergic agonists
223613812|NCT06725641|DRUG|Reference preparation：Methylcholine chloroacetate for inhalation（Provocholine）|Cholinergic agonists
223613813|NCT06431243|DRUG|A0/B0 group Purinostat Mesylate 11.2mg/m2|Purinostat Mesylate 11.2mg/m2
223613814|NCT06431243|DRUG|A0/B0 group Purinostat Mesylate 15mg/m2|Purinostat Mesylate 15mg/m2
223613815|NCT06431243|DRUG|A group Purinostat Mesylate 6mg/m2|Purinostat Mesylate 6mg/m2 + FS 500mg
223613816|NCT06431243|DRUG|A group Purinostat Mesylate 8.4mg/m2|Purinostat Mesylate 8.4mg/m2 + FS 500mg
223759766|NCT05129878|PROCEDURE|Scaling and oral hygiene instruction|Systemically Healthy (age and BMI matched) females with gingivitis will receive with OHI and Scaling
223759767|NCT04508842|BIOLOGICAL|CD19/CD22-Dual-STAR-T|Patients with B cell acute leukemia will be enrolled, and Subjects will receive cytoreductive chemotherapy with cyclophosphamide and fludarabine on days -5, -4 and -3 followed by infusion of CD19/CD22-Dual-STAR-T cells.Dual-STAR-T cells will be intravenously infused with a escalated dose of 6E5、1E6、2E6、3E6 cells/kg.
224312093|NCT01865942|PROCEDURE|Minimal access surgery|The to surgical procedures are individually well know, but the outcome of the procedures in respect to perioperative bleeding and change in quality of life has to our knowledge not been compared.
224312094|NCT00865371|DRUG|Abrika Bupropion 150 mg Extended-Released Tablet|A: Experimental Subjects received Abrika formulated products under fed conditions
224312095|NCT00865371|DRUG|Wellbutrin SR® 150 mg Extended-Release Tablet, single dose|B: Active comparator Subjects received GlaxoSmithKline formulated products under fed conditions
224312096|NCT01871571|BIOLOGICAL|bevacizumab|Given IV
224312097|NCT01871571|DRUG|oxaliplatin|Given IV
224312098|NCT01871571|DRUG|leucovorin calcium|Given IV
224312099|NCT01871571|DRUG|fluorouracil|Given IV
224312100|NCT01871571|OTHER|laboratory biomarker analysis|Correlative studies
223613817|NCT06431243|DRUG|A group Purinostat Mesylate 11.2mg/m2|Purinostat Mesylate 11.2mg/m2 + FS 500mg
224312101|NCT00160069|DRUG|Sagopilone (BAY86-5302, ZK 219477)|16 mg/m2, 3-hour infusion, every 3 weeks
224312102|NCT00160069|DRUG|Sagopilone (BAY86-5302, ZK 219477)|22 mg/m2, 30-min infusion, every 3 weeks
224312103|NCT00160069|DRUG|Sagopilone (BAY86-5302, ZK 219477)|22 mg/m2, 3-hour infusion, every 3 weeks
224312104|NCT02910063|DRUG|Blinatumomab|Blinatumomab monotherapy
223613818|NCT06431243|DRUG|A group Purinostat Mesylate 15 mg/m2|Purinostat Mesylate 15 mg/m2 + FS 500mg
223613819|NCT06431243|DRUG|B group Purinostat Mesylate 6 mg/m2|Purinostat Mesylate 6mg/m2 + Tislelizumab 200mg
223613820|NCT06431243|DRUG|B group Purinostat Mesylate 8.4 mg/m2|Purinostat Mesylate 8.4mg/m2 + Tislelizumab 200mg
223613821|NCT06431243|DRUG|B group Purinostat Mesylate 11.2mg/m2|Purinostat Mesylate 11.2mg/m2 + Tislelizumab 200mg
223613822|NCT06431243|DRUG|B group Purinostat Mesylate 15mg/m2|Purinostat Mesylate 15mg/m2 + Tislelizumab 200mg
223613823|NCT07065513|DIAGNOSTIC_TEST|Normal diet|Normal diet (control group, 20 participants: 10 boys and 10 girls).
223613824|NCT07065513|COMBINATION_PRODUCT|Normal diet plus nutritional protein-based bar|: Normal diet plus nutritional protein-based bar (intervention group, 20 participants: 10 boys and 10 girls). The participants will consume 3 servings of 14g each per day, providing 6.8g protein and 283 kcal
223613825|NCT06748001|DRUG|Avapritinib|Avapritinib will be administered in accordance with the parent study protocol.
223613826|NCT07066150|OTHER|Apply a cream containing 0.05% marula oil-derived ceramide NPs|The participants were requested to apply a cream containing 0.05% marula oil-derived ceramide NPs on their faces twice daily for 28 consecutive days.
223613827|NCT06921265|BEHAVIORAL|Training with Speech Language Therapy|"The SLT will consist of an online intervention performed through a web-based platform.~The SLT training of the SLT group will consist of 2 cycles of training lasting 1 (rest) + 5 (training) weeks, 3 times per week, 1 hour each session, separated by a 12-week washout period."
223613828|NCT06921265|DEVICE|Standard rTMS|Stimulation of DLPFC; rTMS will be administered as high-frequency (20Hz) in 2 second trains (40 pulses per train) with an inter-train interval of 22 seconds for a total of 50 trains (2000 pulses per session) at 120% of the patient's resting motor threshold. Patients will undergo an induction with 20-minutes rTMS protocol for 5 consecutive days, then they will start a maintenance phase where rTMS will be performed 3 days a week per 20 minutes preceding the SLT session, for a total of 20 sessions (of whom 15 combined with SLT).
223613829|NCT06921265|DEVICE|Targeted rTMS|The protocol will be the same as standard STIM. The site of stimulation will be defined using EEG/fMRI recordings of language tasks (syntax production for nfvPPA; silent naming for svPPA and lvPPA) to evidence the areas of higher activation/connectivity of the language network. We will define the area of higher fMRI activation; then, we will use fMRI-EEG connectivity and spectral activity to select the site of stimulation, among the areas with the highest fMRI activation and the highest Beta/Gamma frequencies.
223613830|NCT06921265|DEVICE|Standard rTMS (first cycle)|Patients of the SLT + STIM (standard rTMS + targeted rTMS) will firstly undergo the standard rTMS in the first 6 week of training after the baseline visit
223613831|NCT06921265|DEVICE|Standard rTMS (second cycle)|Patients of the SLT + STIM (targeted rTMS + standard rTMS) will secondly undergo the standard rTMS after 12 week washout period
223613832|NCT06921265|DEVICE|Targeted rTMS (first cycle)|Patients of the SLT + STIM (targeted rTMS + standardTMS) will firstly undergo the targeted rTMS in the first 6 weeks of training after the baseline visit
223613833|NCT06921265|DEVICE|Targeted rTMS (second cycle)|Patients of the SLT + STIM (standard rTMS + targeted rTMS) will secondly undergo the targeted rTMS after 12 week washout period
224312105|NCT01789723|DRUG|Fusilev|Fusilev will be administered by IV push (3-5 minutes) at a dose of 5 mg/m2. Fusilev administration, QID or BID will start 24 ± 3 hours after Folotyn administration depending on the dose cohort.
223613834|NCT06920875|BEHAVIORAL|Imagery and Breathing Exercises|Participants performed daily imagery and breathing exercises before bedtime for 10 weeks. The protocol involved a 4-second inhale through the nose and a 4-second exhale through the mouth while visualizing a 200-meter freestyle swim with detailed attention to technique and performance. A 6-day training period was provided to teach the techniques, and participants received daily reminders and feedback via a WhatsApp group.
223613835|NCT06920823|PROCEDURE|antegrade (proximal entry) fixation|In the antegrade headless cannulated screw fixation technique, a small incision was made on the extensor aspect of the fractured metacarpal at the level of the carpometacarpal joint.
223613836|NCT06920823|PROCEDURE|retrograde (distal entry) fixation|In the fixation technique with retrograde headless cannulated screw, a small incision was made on the extensor side of the fractured metacarpal at the level of the metacarpophalangeal joint.
223613837|NCT06921564|OTHER|Combined training|During the 6-week intervention period, the combined training group performed 2 sessions per week of lower-body strength training and 2 sessions per week of small-sided games training in different formats. The strength training was performed on Tuesdays and Thursdays. This training was finished at least one hour before the team's technical and tactical soccer training. The strength training program is designed to include movements for bilateral hip dominant, bilateral knee dominant, unilateral hip dominant, unilateral knee dominant and calf muscles. The exercises were selected to allow players to perform them on the field with minimal equipment, without the need for machines. In addition, small field games training was practiced two days a week. Repetitions in reserve and resistance training-specific ratings of the perceived exertion scale were used to determine training intensity and load.
223613838|NCT06921564|OTHER|Small-sided games alone|The small-sided games group performed 2 sessions per week of small-sided games training program in different formats, without participating in any strength training. The small-sided games training was conducted twice a week on Wednesdays and Fridays (8:00-10:00 p.m.) for 6 weeks. These training sessions started before the team's technical and tactical training. Extra balls are placed at the goals and along the field boundary lines, allowing play to restart immediately after the ball leaves the field. During the games, the offside rule was not applied. The game started with the foot when the ball left edge of the field. Other rules in the games were kept similar to those of official soccer. During the games, the coaches encouraged the players to exert maximum effort. The number of defenders, midfielders, and attackers in the teams was kept as equal as possible.
223759768|NCT05913895|OTHER|hydrogen water|To investigate whether the intervention of hydrogen water adjuvant therapy can improve oral mucositis, oral frailty, pain and Quality of Life with head and neck cancer who have received radiation therapy or combined chemotherapy.
223759769|NCT00313612|DRUG|oxaliplatin|Given IV
223759770|NCT00313612|DRUG|topotecan|Given IV
223759771|NCT01139333|GENETIC|gene expression analysis|
224312106|NCT01789723|DRUG|Folotyn|A cycle of Folotyn treatment is 7 weeks, 6 weeks of treatment followed by 1 week of rest.
224312107|NCT05540028|BIOLOGICAL|IVT PCV-25|25 valent pneumococcal conjugate vaccine
223613839|NCT06921226|OTHER|Psychological Processes|"* The sense of thwarted belonging and perceived burden will be measured using the Interpersonal Needs Questionnaire (INQ; Van Orden et al., 2012). The back-translated French version by Landrault et al. (2019) will be used. This scale is based on a seven-point Likert scale, ranging from 1 (not at all true for me) to 7 (very true for me).~* To assess impulsivity, we will use the short version of the UPPS validated in French by Billieux and colleagues (2012). It comprises 20 items divided into 5 dimensions (negative urgency, positive urgency, lack of premeditation, lack of perseverance and sensation seeking). Participants were asked to respond on a Likert scale from 1 (I strongly agree) to 4 (I strongly disagree).~* We will use the French version of the SRS (Suicidal Rumination Scale, Rogers et al., 2022), back-translated for this study. This eight-item scale assesses suicidal ruminations."
223613840|NCT06921226|OTHER|Risk-taking variables|"* One of the behavioral tasks based on a real-life model of risky decision-making is BART (Lejuez et al., 2002, 2007). It is based on a conceptual framework of balance between reward and loss potential (Leigh, 1999; Lejuez et al., 2002).~* We will measure one of the cognitive aspects of risk-taking behavior, especially the general cognitive decision-making styles (GDMS, from Scott and Bruce, 1995; Gerard et al., 2016).~* We will measure negative (NRTB , Duell et al., 2020) and positive (PRTB, Fryts et al., 2024) self-reported risk-taking behaviour."
224312108|NCT05540028|BIOLOGICAL|PCV 20|20 valent pneumococcal conjugate vaccine
224312109|NCT05949411|OTHER|Screening visit|Subjects will be invited to perform the screening visit to sign the informed consent and then to ensure that they are able to participate in this study.
224312110|NCT05949411|OTHER|Lactulose test|Fasted subjects (at least 10 hours) will receive on oral load of 10 g of lactulose. Then, exhaled H2 will be measured every 30 minutes during 4 hours.
224312111|NCT05949411|OTHER|Administration of standardized meals with characterized dietary fiber content|Subjects will receive standardized breakfasts and lunches characterized in terms of dietary fiber content. Urine, saliva, feces samples will be collected. Breath test and gastrointestinal symptoms will be followed during maximum 8h. Subjects will also complete SF36 questionnaire, food diary and stool/transit questionnaire.
224312112|NCT01269931|PROCEDURE|EBUS-TBNA|Endobronchial ultrasound with transbronchial needle aspiration (EBUS-TBNA) is a revolutionary diagnostic pulmonary procedure that allows visualization and safe, accurate biopsies of intra-thoracic structures during bronchoscopy. Patients enrolled in this study at the University of Calgary would have undergone this procedure regardless of being enrolled in this study. The purpose of the study was to prospectively compare the EBUS-TBNA performance of 2 groups of learners, performing EBUS-TBNA on patients, who had received to different methods of EBUS-TBNA training. Patients were randomly assigned to undergo bronchoscopy with a trainee from Group 1 or Group 2.
224312113|NCT05976126|OTHER|Determination of dioxins (PCDD/Fs), polychlorinated biphenyls (PCBs) and trace elements|Peripheral blood (about 100 mL in several aliquots) was collected from the volunteers, in the early morning, in blood collection tubes (SST II Advance Tubes, BD Vacutainer). The samples were left for approximately 50 min, then the serum was separated from whole blood by centrifugation at 2,000 rcf for 10 min at 4 °C and then aliquots were stored at -80°C until analysis.
223613841|NCT06921226|OTHER|Suicidal ideation and behavior|"Suicidal ideation and behavior were measured using the screening grid, the Columbia Suicide Severity Rating Scale (C-SSRS screen version, Posner, Brown, Stanley et al., 2011). It is composed of 6 questions, which take into account the potential method of suicide, the presence of suicidal intent and/or ideation with a plan or intention. This scale has high reliability and validity in general paediatric emergencies (Scudder et al., 2023) and psychiatric samples (Campos et al., 2023).~It classifies people as being at low or high risk of suicide, based on the presence or absence of significant active suicidal ideation in the last three months."
223613842|NCT06921694|BEHAVIORAL|Runner group|The intervention groups undertake 8 weeks of a combined exercise programme including aerobic elements (running), a schedule of gradually intensifying strengthening exercises and flexibility exercises
223613843|NCT06921694|BEHAVIORAL|Swim/Cycle Group|The intervention groups undertake 8 weeks of a combined exercise programme including aerobic elements (swim/cycle), a schedule of gradually intensitfing strengthening exercises and flexibility exercises
223613844|NCT06921798|OTHER|mHealth|This mHealth intervention is designed to provide health education, and to notify study participants when their result is ready and it is time for them to return to the healthcare clinic for follow up.
223613845|NCT06921642|DEVICE|Echocardiography images|Addition of a recording loop during routine ultrasound, during which the patient is in simplified standardized ventilation
223613846|NCT06920810|DRUG|viscum album|"Active Ingredient: Viscum album Excipients: Ascorbic acid, disodium phosphate dihydrate, monosodium phosphate monohydrate Formulation: Injectable solution contained in a colorless ampoule; the solution is colorless to pale yellow and clear.~Manufacturer: LB Abnoba Co., Ltd. Dosage and Administration: Administered subcutaneously three times per week, with dose escalation according to the following protocol."
223613847|NCT00564213|DRUG|PRK and a single intraoperative topical application of mitomycin C 0.02% for 15 seconds|Mitomycin 0.02%
223613848|NCT06937437|OTHER|Teletherapy|A teletherapy patient presenting with stammering (stuttering) is a person receiving speech therapy remotely, using technology like video conferencing, to address speech fluency difficulties, often including repetitions, prolongations, or blocks in speech.
223759772|NCT01139333|GENETIC|western blotting|
223759773|NCT01139333|OTHER|flow cytometry|
223759774|NCT01139333|OTHER|laboratory biomarker analysis|
223759775|NCT00451035|DRUG|LBH589|
223759776|NCT06040021|OTHER|standardized treatment|Patients enrolled in these 2 cohorts all received standardized treatment of colorectal cancer.
223759777|NCT02445495|DEVICE|GenesisPlus 1064 nm Nd:YAG laser|Genesis Plus 1064 nm Nd: YAG laser to treat onychomycosis
223759778|NCT05904457|DRUG|bevacizumab|Patients will receive bevacizumab 10 mg/kg IV over 30-90 minutes every 2 weeks until disease progression or unacceptable toxicity.
223759779|NCT05904457|DRUG|erlotinib|Patients will receive elrotinib 150 mg orally once a day continuously until disease progression or unacceptable toxicity.
223759780|NCT01625143|OTHER|laboratory biomarker analysis|Correlative studies
223759781|NCT01965288|DEVICE|comfilcon A|test lens Pair(comfilcon A) or the control lens Pair(lotrafilcon B)
223759782|NCT01965288|DEVICE|lotrafilcon B|test lens Pair(comfilcon A) or the control lens Pair(lotrafilcon B)
223759783|NCT03738943|DRUG|Adenosine Triphosphate|See arm/group descriptions
223759784|NCT03738943|DRUG|Acetylcholine|See arm/group descriptions
223759785|NCT03738943|DRUG|Sodium Nitroprusside|See arm/group descriptions
223759786|NCT03738943|DRUG|Adenosine Diphosphate|See arm/group descriptions
224312114|NCT01233895|DRUG|AVE1642|For Part 1, AVE1642 was administered on Day 1 and then every three weeks intra-venously with the dose escalation step starting at 3 mg/kg/infusion with a classical dose escalation schema of 3+3. For Part 2, AVE1642 was administered at doses ranging from 0.5 mg/kg to 12 mg/kg
224312115|NCT01233895|DRUG|Velcade|For Part 2 ONLY, fixed dose of 1.3 mg/m² administered on Days 1, 4, 8, and 11.
224312116|NCT05070026|OTHER|uni-portal VATS group|patients received pulmonary lobectomy under general anesthesia by using uni-portal VATS method
224312117|NCT05070026|OTHER|three port VATS group|patients received pulmonary lobectomy under under general anesthesia by using three port VATS method
224312118|NCT05018546|PROCEDURE|Irrigation force|RIRS with different irrigation force
223759787|NCT03738943|DRUG|Adenosine Monophosphate|See arm/group descriptions
223759788|NCT03738943|DRUG|Uridine Triphosphate|See arm/group descriptions
223759789|NCT03738943|DRUG|Adenosine|See arm/group descriptions
223759790|NCT03738943|DRUG|Vitamin B 6|See arm/group descriptions
223759791|NCT03738943|DRUG|Pyridoxal 5'-Phosphate|See arm/group descriptions
223759792|NCT06148922|OTHER|Brief Mental Health First Aid Workshop|a 2-hour workshop delivered by a registered nurse with a MHFA training certificate
223759793|NCT06148922|OTHER|Semi-structured interviews|One-to-one, face-to-face semi-structured interviews will be conducted by a research assistant. The duration would be around 30 minutes.
223759794|NCT04675216|PROCEDURE|Posterior fossa intracranial pressure measurement|Measurement of posterior fossa pressure in an invasive way
223759795|NCT02752009|PROCEDURE|Axillary Lymph Node Sampling Clip|
223759796|NCT06104501|DEVICE|RadiHeart|The participants' blood pressure will be measured multiple times by both the mercury sphygmomanometer and RadiHeart, by using the same arm sequential method.
223759797|NCT02510378|RADIATION|Short course radiotherapy|"Patients with rectal cancer and resectable liver metastases receive 25 Gy in 5 fractions of 5 Gy over 5 days to the pelvis and XELOX consolidating chemotherapy (with or without target therapy) al least 4 cycles after 2 weeks.~After evaluation, patients with resectable rectal cancer and liver metastasis will undergo surgery. Those patients with unresectable lesions will receive chemotherapy."
223759798|NCT03887364|OTHER|Group A-Diaphragmatic breathing|Patient was in casual and agreeable position in which gravity helped the stomach, for example, a semi fowler's position. Hand was put on the rectus abdominis just beneath the foremost costal edge and requested that the patient take in gradually and profoundly through the nose. Persistent was told to keep the shoulder casual and upper chest very, enabling the belly to rise marginally. At that point persistent was guided to remain loose and breathed out gradually through the mouth. The patient rehearsed this 3 to 4 times and the rest time frame was given so patient couldn't hyperventilate.This group was given 10 reps of 3 sets with 4 weeks of follow up
223759799|NCT03887364|OTHER|Group B-Icing and Airflow Stimulation|"Patient was lying comfortable in semi fowler position. Facial muscle icing was given using ice pack wrapped in cloth over cheeks and nose in butterfly pattern and over forehead for 5 minutes. Ice pack was applied on the patients face (around the cheek \& nose) and accessory muscles (sternocleidomastoid muscles, upper trapezius) for single session of 5 to 10 minutes.~After that airflow stimulation was given with the help of table fan. Table fan was placed on the central area of face. Duration of the fan for the patient was at least 5 minutes to relive dyspnea and distance kept approximate of 60 centimeter (2 rulers)."
223759800|NCT04925011|DRUG|Roxadustat|Starting doses of 20, 50, 70 or 100 mg/30,70,90,or 120mg based on weight and dialysis or not.
223759801|NCT05420558|DIAGNOSTIC_TEST|Fibroblast activation protein inhibitor PET/CT imaging|All participants will receive a 68Ga-labelled fibroblast activation protein inhibitor PET/CT imaging
224312119|NCT03510026|DEVICE|Low thermal device preparation|One participant acts simultaneously as a control and active comparator. One internal thoracic artery is prepared with the normal electrocautery device. The other internal thoracic artery is prepared with the new low thermal device. The participant does not know, which internal thoracic artery is defined to be prepared with the low thermal device.
224312120|NCT04693416|OTHER|Intrapersonal Stigma Reduction|Brief intervention for stigma reduction
224312121|NCT04693416|OTHER|Interpersonal Stigma Reduction|Brief intervention for support persons of intrapersonal intervention participants.
223613849|NCT06937437|OTHER|Traditionally speech therapy|This type of intervention is traditional speech therapy that will be given to stammering adults, to address speech fluency difficulties, often including repetitions, prolongations, or blocks in speech.
223613850|NCT02617654|DRUG|Liraglutide|Treatment with liraglutide for 52 weeks
223613851|NCT02617654|DRUG|Placebo for liraglutide|Placebo for liraglutide. Treatment once daily for 52 weeks
223613852|NCT01857297|BIOLOGICAL|Enzira® vaccine|
223613853|NCT03739346|BEHAVIORAL|Hypnosis|Therapeutic technique in which clinicians make suggestions to individuals who have undergone a procedure designed to relax them and focus their minds.
223613854|NCT03739346|BEHAVIORAL|Tell, show, do technique|The technique involves verbal explanations of procedures in phrases appropriate to the developmental level of the patient (tell); demonstrations for the patient of the visual, auditory, olfactory, and tactile aspects of the procedure in a carefully defined, nonthreatening setting (show); and then, without deviating from the explanation and demonstration, completion of the procedure (do). Tell-show-do technique is used with communication skills (verbal and nonverbal) and positive reinforcement.
223613855|NCT06103994|DIETARY_SUPPLEMENT|Multistrain probiotic|Multistrain Probiotic
224312122|NCT03813953|PROCEDURE|Liver resection|Resection of diseased liver
224312123|NCT00006348|DRUG|ondansetron|
224312124|NCT00006348|OTHER|placebo|
224312125|NCT00474266|BIOLOGICAL|Meningococcal vaccine GSK134612 (Nimenrix)|Single dose intramuscular injection
224312126|NCT00474266|BIOLOGICAL|Priorix-Tetra|2-dose subcutaneous injection
224312127|NCT00474266|BIOLOGICAL|Meningitec|Single dose intramuscular injection
223613856|NCT06103994|OTHER|Placebo|Placebo
223613857|NCT04323072|PROCEDURE|Wide antrectomy|The starting point of resection of the stomach from the pylorus to begin the gastrectomy is 2 cm.
223613858|NCT04323072|PROCEDURE|Smal antrectomy|The starting point of resection of the stomach from the pylorus to begin the gastrectomy is 6 cm.
224201622|NCT05867511|BEHAVIORAL|iPAL App|"The intervention will have a duration of eight weeks. It is theory-based, will be delivered to participants' smartphones via the study app (except components 5 and 6), and comprises the following components:~1. Theory-based individualized feedback.~2. Self-generated motivational messages.~3. Motivation for habit formation through push messages.~4. Motivational images and videos that participants handed in or selected will be sent to them through the app.~5. Study-specific social media groups. Participants will be offered the option to participate in study-specific social media groups.~6. Posting motivational stories. A story of a person, who successfully changed his or her lifestyle to be more physically active and/or less sedentary, will be posted once a week in the study-specific social media groups."
224201623|NCT04327869|DEVICE|Magnetically controlled capsule endoscopy|The subjects swallowed the capsule with water in the left lateral position. When capsule enter stomach cavity, subject was asked to sit up and ingested 4 g aerogenic powder with 5 ml water to distend the stomach, and performed gastric baseline examinations to identify the lesions. After baseline examination, subjects ingested dyed sucralfate gel and performed the first-time examination. The examination was repeated at 30 min intervals, until dyed sucralfate gel disappeared completely.
224312128|NCT00625053|PROCEDURE|Laparoscopic repair|Complete adhesiolysis between viscera and abdominal wall, complete dissection of round ligament and subumbilical fatty tissue to expose the posterior fascia at least 5 cm further than the cranial and caudal limits of the fascial defect or the original incision. Overlap of minimum 5 cm is calculated and mesh inserted in the abdominal cavity through 12mm optical trocar. Fixation of a antiadhesive composite mesh with helicoidal pins with maximum 15mm interval, double crown technique. No pressure decrease maneuver is done during mesh fixation or at another time during the operation. No transparietal suture fixation. No fascial closure.
224312129|NCT00625053|PROCEDURE|Open midline incisional hernia repair|"* Underlay retromuscular repair: Medial border of the anterior fascia opened, posterior aspect of rectus muscle dissected to reach lateral border of rectus sheet, bilaterally. Peritoneum and posterior rectus fascia closed with absorbable running suture. Polyester or light-weight polypropylene mesh is cut to fit the reconstructed area, to have 3cm overlap on caudal and cranial defect limits. Mesh is fixed by absorbable sutures. Anterior fascia is closed with absorbable running suture. Components separation upon need.~* Intraperitoneal onlay repair: Mesh is inserted intraperitoneally and fixed by a complete running suture (optional fixation with helicoidal pins or stapler). Fascial defect is closed with interrupted or running absorbable suture. Components separation upon need."
224312130|NCT04880603|DEVICE|Restrata Graft|Restrata will be meshed in a 1:2 fashion to allow for egress of serous fluid and minimize risk of fluid collection. Restrata will be applied to the entire wound bed not amenable to primary closure and will be underlaid beneath the surrounding skin edges. A split-thickness skin graft is harvested from patient's thigh at 15:1000 inches and placed on top of the Restrata to cover the entire wound bed. The graft is sutured in place using suture choice of surgeon's preference.
224312131|NCT04880603|PROCEDURE|Standard of Care Skin Graft|Standard of Care Skin Graft
224312132|NCT04110379|BEHAVIORAL|Virtual Reality (VR)|All the dental procedures that will be done will be explained to the child using tell-show-do technique. VR glasses will be introduced to the child using tell-show-do technique and he will be given a choice of cartoon episodes to select from according to his own interest and age appropriate to view during the dental treatment. The child will be given five minutes to get familiar with the VR glasses before starting the dental treatment.
223613859|NCT03731091|DRUG|Calcipotriene/ betamethasone dipropionate topical foam, 0.005%/0.064%|Once daily for 4 weeks (28 days)
224312133|NCT04110379|BEHAVIORAL|Conventional Behavior Management Techniques|Conventional behavior management techniques will be done to relieve the child's dental anxiety during the dental treatment such as : tell-show-do technique, distraction, and positive reinforcement, according to the child's behavior.
223613860|NCT03731091|DRUG|Enstilar® foam (LEO Pharma Inc.)|Once daily for 4 weeks (28 days)
223613861|NCT03731091|OTHER|Placebo of Calcipotriene/ betamethasone dipropionate topical foam|Once daily for 4 weeks (28 days)
223613862|NCT00452790|BIOLOGICAL|13-valent Pneumococcal Conjugate Vaccine|1 dose at 6, 10, 14 weeks and 12 months of age
223613863|NCT00452790|BIOLOGICAL|7 valent pneumococcal conjugate vaccine|1 dose at 6, 10, 14 weeks and 12 months of age
223613864|NCT01365364|BEHAVIORAL|Aerobic Physical Exercise|All individuals were submitted to physical exercise reaching maximum effort
223613865|NCT01365364|BEHAVIORAL|Aerobic Physical Exercise|All individuals were submitted to physical exercise reaching maximum effort
223613866|NCT04845763|OTHER|FQoR-15 questionnaire|The FQoR-15 questionnaire (French version) consists of 15 questions concerning five domains (the patient's feelings, comfort, pain, dependence on the health care team and psychological well-being). Two to three minutes are required to complete all the questions. If the patient is not able to read the questionnaire himself, a third person can ask the patient the questions orally. In the case of ambulatory surgery, the patient is contacted by telephone to answer the questionnaire. Each item is scored from 0 to 10 and the total score is the sum of the score obtained for each item, i.e. a score from 0 to 150.
223613867|NCT02517697|DRUG|14 Nitrogen (N) Sodium Nitrite|oral formulation of sodium nitrite 40 mg three times daily for 12 weeks
223613868|NCT02517697|DRUG|Placebo|oral formulation of matching placebo three times daily for 12 weeks
223613869|NCT00882960|DRUG|intravenous fentanyl|An IV will be established and used to deliver Fentanyl at 50 micrograms to patients who meet pre-hospital protocol for pain management. Examples of this may be burn patients, fractures, trauma.
224201624|NCT05517746|DRUG|BAY2395840 tablet|tablets, oral administration
224201625|NCT05517746|DRUG|BAY2395840 oral solution|solution, oral administration
224201626|NCT05517746|DRUG|Placebo oral solution|Placebo matching BAY2395840, oral administration
224201627|NCT05517746|DRUG|Placebo tablet|Placebo matching BAY2395840, oral administration
224312134|NCT00045864|DRUG|Recombinant Human Interleukin-2 and Rituximab|
224312135|NCT03886415|DRUG|Jaktinib hydrochloride tablets|Jaktinib hydrochloride tablets 100mg bid dose group and Jaktinib hydrochloride tablets 200mg qd dose group
223759802|NCT05830474|PROCEDURE|Continuous intra-airway monitoring and intervention during surgey|Continuous monitoring was performed by visual double lumen bronchial catheter. Once sputum or blood gushing into the tracheal carina was found in the distal bronchus on the surgical side, the above secretions were sucked out with a sputum suction tube under video monitoring until the removal was complete
223613870|NCT00882960|DRUG|intra-nasal fentanyl|a mucosal atomization device will be used to deliver 50 mcg of Fentanyl to patients who have been identified at requiring pre-hospital pain management
223613871|NCT04254601|DEVICE|Narrow band ultraviolet B.|NBUB: DIXWELL EMLY 98 -ABRP 64 ,made in France. Red LLL, InGaAs (630 nm, 10 mW, continuous) (RIKTA, Russia)
223613872|NCT04254601|DRUG|topical erythromycin cream 2% (Akne-Mycin- Egypt)|"two times per day on the entire face from the beginning to the end of the treatment period .~The face is washed thoroughly with warm water and gentle soap, rinse well, and pat dry, patients were advised to wait 30 minutes before applying the aknemycin. To help keep new pimples from breaking out, the aknemycin was applied to the whole area usually affected by acne, not just to the pimples themselves"
223613873|NCT03492125|DRUG|MS-553|Oral, multiple dose levels
223613874|NCT03492125|DRUG|MS-553|Oral recommended phase 2 dose of MS-553
223613875|NCT03492125|DRUG|acalabrutinib|Oral
223613876|NCT03492125|DRUG|venetoclax|Oral
223613877|NCT03492125|DRUG|Rituximab|IV
223613878|NCT03492125|DRUG|obinutuzumab|IV
223613879|NCT02918357|DRUG|Ga-68 labeled PSMA-11 PET|Patients will be imaged using Ga-68 labeled PSMA-11 PET to determine if the presence of metastatic disease. Prostate Specific Membrane Antigen (PSMA) is a protein expressed on prostate cancer cells that can be imaged using small molecules that target this protocol.
223613880|NCT03213834|PROCEDURE|Chest thoracoscopy|Thoracoscopy will be performed as per standard protocols, with patient lateral decubitus position. Ten mLs of fluid will be collected to check for biomarkers. Adhesiolysis will be attempted and pleural irrigation will be done. At the end of the procedure, a drain will be inserted and connected to an underwater seal with a negative pressure suction
223613881|NCT03213834|PROCEDURE|Chest fibrinolytic therapy|A chest tube will be inserted under ultrasonography into the most dependent area of the pleural effusion or into the largest loculation in patients with multi-loculated effusions. A of DNase and tPA will be given. Concurrent tPA and DNase will be administered intrapleurally through the chest tube followed by saline flush. The tube will then be clamped for 120 minutes and after which it will be connected back to wall suction. The intrapleural therapy will be given twice daily for a maximum of 6 doses.
223613882|NCT03213834|DRUG|tPA|tPA administered intrapleurally through the chest tube followed by saline flush. The intrapleural therapy will be given twice daily for a maximum of 6 doses.
223613883|NCT03213834|DRUG|DNase|DNase administered intrapleurally through the chest tube followed by saline flush. The intrapleural therapy will be given twice daily for a maximum of 6 doses.
223613884|NCT05075590|DIAGNOSTIC_TEST|Coronary Angiography|Following TAVR, the operators will attempt to selectively engage both the right and left coronary arteries. Catheter choice and engagement technique will be at the discretion of the operator.
223613885|NCT05080530|DRUG|Cholecalciferol|Effect of Vitamin D on diabetic neuropathy symptoms
223759803|NCT04605328|OTHER|Two dimension and three dimension ultrasound|Patient will undergo 2D and 3D ultrasound evaluation after CS for detection of CSD
223759804|NCT01010048|DRUG|progesterone,tamsulosin,propantheline Bromide and nifedipine|clearance rate of stone
224201628|NCT06196970|OTHER|Pilate exercises|After 10 minutes of warmup excercises, participatants perform pilates exercises, Pelvic curl : 45 seconds hold The Hundred : 45 seconds hold Bird Dog : 45 seconds hold Side plank : 45 seconds hold Frequency 3 days a week intensity 45 minutes hold a pose. Time will be 10 to 15 minutes.
223613886|NCT03046030|OTHER|Real acupuncture|Verum acupuncture will be applied on the right SP6 and SP9. For each subject, leg position, acupoint location, and needling parameters (1-2 cm depth, 120 rotations / minute, 90˚ insertion angle, moderate deqi sensations on a 0-10 scale) will be kept constant. For the low dose acupuncture group, needles will be rotated at one point and then the other in 15-second rotations with 20-30 second breaks. The specific starting acupoint will be randomized across subjects but kept consistent for each subject across sessions.
223613887|NCT03046030|OTHER|Sham acupuncture|Placebo acupuncture will be applied at two sham points using specially designed sham acupuncture needles \[20, 35, 104-106\]. The sham needles differ from regular needles by possessing blunt and retractable tips. Instead of penetrating the skin, the point of the Streitberger needle retracts up the handle shaft when the acupuncturist presses it against the skin. This sham device has been validated by studies showing that subjects cannot distinguish between genuine and sham needling \[20, 35, 104\]. Two sham points will be used during placebo acupuncture: sham point 1 is located 1 cun posterior to the superior 1/3 of K9 and K10. Sham 2 is located 1 cun posterior to K8. Both points are located on the leg where there is no meridian passing through. Sham acupuncture treatment will be the same as verum acupuncture.
223613888|NCT03046030|OTHER|VGAIT|In Session 1, all patients will first be introduced to acupuncture treatment, particularly the sensation evoked by acupuncture needles. This will be followed by a five-minute acupuncture exposure applied by a licensed acupuncturist. The exposure will include multiple acupuncture needle manipulations across the two acupoints (SP 6 and SP 9) used in this study. The paradigm applied will be identical to real acupuncture treatment, and the procedure will also be video recorded for the following session. At the beginning of the VGAIT session, patients will be trained for imagery acupuncture outside the fMRI scan. Subjects will first read a script introducing the imagery acupuncture treatment. Then, VGAIT will be applied during scanning. Identical to the acupuncture treatment, there are two fMRI scans during VGAIT, each lasting about 10 minutes. We will ask the patient to measure the sensations they feel during treatment using the MGH Acupuncture Sensation Scale (MASS) after treatment.
223613889|NCT03046030|OTHER|VGAIT control|The control condition will be the same as VGAIT, except we will use cotton swabs repeatedly touching at non-acupoints with a frequency of about 1 Hz using the same paradigm of verum / sham acupuncture. They will also read a script describing what they are about to see. Then, VGAIT control will be applied during scanning. We will ask the patient to measure the sensations they feel during treatment using the MASS after treatment.
223759805|NCT04338464|BEHAVIORAL|Psychosocial therapy for South Asian women experiencing mood disorders|"The 12 week intervention has four major components:~* Relational theory (Belgrave, 2002) \& South Asian identity development (Inman et al., 2001). These foundational components focus on strengthening cultural identity through the exploration of values, navigation and reconciliation of two cultures.~* Transdiagnostic treatment of mood disorders (Ehrenreich-May et al., 2017). This component will focus on skill building in the areas of emotion awareness, resilience, adaptability, self-compassion and healthy coping strategies (Farchione et al., 2012; Bilek \& Ehrenriech-May, 2012; Ritschel, Noriel \& Lindsay, 2015).~* Psychoeducation on mental health, sexual health, and substance use.~* Peer support is a critical component of the intervention and will be provided by the peer researcher on the team. Participants will have access to optional individual peer support for 30 minutes to one hour per week for the duration of the intervention, this can be in person or telephone support."
223759806|NCT00370474|DEVICE|Bi-ventricular lead placement|
223613890|NCT01679873|OTHER|Assess one type of abstract in the randomized arm|Participants will be asked to assess only one abstract in his arm of randomization. Three reminders will be made
223613891|NCT06040944|DRUG|antipsychotic drugs inducing hyperprolactinemia|not exposed
223613892|NCT05525650|DRUG|House Dust Mite Extract, Dermatophagoides Farinae|"\[Group 1\] Group A receives 100 PAU at week 1 and 200 PAU at week 2 as the induction phase.~200 PAU is administered for 3 to 16 weeks as a maintenance phase.~Group B (placebo group) is the placebo arm of group A.~\[Group 2\] As the induction phase, group C received 100 PAU at week 1, 200 PAU at week 2, 300 PAU at week 3, and 400 PAU at week 4.~As the maintenance phase, 400 PAU is administered for 5 to 16 weeks.~Group D (placebo) is the placebo group in Group C.~\[Group 3\] As the induction phase, group E received 100 PAU at week 1, 200 PAU at week 2, 300 PAU at week 3, 400 PAU at week 4, 600 PAU at week 5, and 800 PAU at week 6.~As the maintenance phase, 800 PAU is administered from 7 to 16 weeks.~Group F (placebo) is the placebo arm of group E."
223759807|NCT01393405|DRUG|Methotrexate|"Induction period (week 1-16) (Open label):~25 mg MTX sq once weekly + Steroid taper + 1 mg folic acid daily~Maintenance period (week 17-48) (Randomization):~25 mg MTX sq once weekly + 1 mg folic acid daily + 2.4 g mesalamine or Placebo sq once weekly + 1 mg folic acid daily + 2.4 g mesalamine"
223759808|NCT03942978|OTHER|Longitudinal Equity Action Plan|Patients admitted to general medicine pod randomized to intervention will receive a Longitudinal Equity Action Plan (LEAP), which will include a program manager to ensure they are on appropriate medical therapy, that cardiology is consulted when appropriate, that patient is set up with appropriate follow-up appointment with cardiology, that transportation is set up for follow-up visits, and a post-discharge follow up call to remind patients of the appointment and identify any post-discharge issues. This is in addition to standard of care, and there will not be any drug or device interventions.
223759809|NCT04832464|OTHER|RACE Protocol: Balance training along with resistance, aerobic and cognitive exercises.|therapy for the preservation, enhancement, or restoration of movement and physical function impaired or threatened by disease, injury, or disability that utilizes therapeutic exercise, physical modalities (such as massage and electrotherapy), assistive devices, and patient education and training.
223759810|NCT02094001|RADIATION|Cardiac PET imaging using F-18-FDG, N-13 ammonia( NH3)|After an overnight fast, patients will undergo a 20 minute dynamic PET scan with injection of 3 MBq/kg of N-13 ammonia (NH3) to measure myocardial perfusion. Followed by a 60 min dynamic PET scan with injection of 3MBq/kg of F-18-FDG to measure glucose uptake.
223759811|NCT03664752|DRUG|IDP-120 Gel|IDP-120 Gel, once-daily application
223759812|NCT03664752|DRUG|IDP-120 Vehicle Gel|IDP-120 Vehicle Gel, once-daily application
223759813|NCT03493334|OTHER|Visual feedback|Visual feedback of the neck will be given to participants using two mirrors while performing neck movements.
223759814|NCT03493334|OTHER|No visual feedback|Participants will be asked to perform active movements of their neck with the mirrors covered.
223759815|NCT03402438|DRUG|Fulacimstat (BAY1142524)|single oral dose of 25 mg immediate-release tablet BAY1142524
223759816|NCT03946397|OTHER|Mulstisensory massage|7 minutes of hand massage followed by multisensory immersion (lights and music) for 23 minutes
223759817|NCT00607763|DRUG|Micafungin (Mycamine)|IV
223759818|NCT01224249|DIETARY_SUPPLEMENT|Fish and shellfish|Intake of 1000 grams of fish and shellfish per week for six months.
223759819|NCT03226340|DRUG|S-amlodipine 2.5mg + Chlorthalidone 25mg|patients will receive S-amlodipine 2.5mg + Chlorthalidone 25mg p.o. once a day for 12 weeks.
223759820|NCT03226340|DRUG|S-amlodipine 2.5mg + Telmisartan 40mg|patients will receive S-amlodipine 2.5mg + Telmisartan 40mg p.o. once a day for 12 weeks.
223759821|NCT01274403|DRUG|Melphalan, Prednisone and Thalidomide|
223759822|NCT02769702|DRUG|Acthar|Acthar 80 IU SC twice a week
223759823|NCT03350503|DEVICE|AcrySof IQ Toric A-code IOL|Intended to provide visual acuity, including astigmatism correction, over the lifetime of the cataract patient
223759824|NCT03350503|PROCEDURE|Cataract surgery|Removal of cataractous lens and implantation of IOL
223759825|NCT00098111|DRUG|azathioprine|
223759826|NCT04536727|BEHAVIORAL|Fit & Strong!|The 8-week intervention will consist of the Fit \& Strong! program adapted to address the impact of exercise on enhancing positive affect and reducing negative affect and depressive symptoms. Exercise classes will meet three times per week for 90 minutes per session for eight weeks. Each class is divided into 60 minutes of strength training, flexibility, and cardiovascular exercise and 30 minutes of group education/discussion, which has been adapted to include affect-oriented content
224201629|NCT06196970|OTHER|Burpees exercises|"After 10 minutes of warmup excercises, participatants perform burppes excercises.~1. Stand straight with your feet shoulder-width apart.~2. Squat and place your hands in front of your feet.~3. Jump back until your legs are fully extended and your body is in plank position.~4. Do a push up, jump forward, and then push through the heels to return to the starting position.~5. Repeat until the set is complete. Frequency 3 days a week .Time 10 to 15 minutes with 10 reputation , 3 sets. Rest internal will be 10 seconds after each set."
224201630|NCT00530621|DRUG|enzastaurin|1125 milligrams (mg) loading dose then 500 mg, oral, daily Cycle 1 (28 days), subsequent cycles 21 days, until disease progression
224201631|NCT00530621|DRUG|placebo|oral, daily
223613893|NCT05639257|DRUG|Lamotrigine|Lamotrigine tablets increasing dosis to maximal 300 mg daily
223613894|NCT05639257|DRUG|Namuscla|Namuscla tablets increasing dosis to maximal 501 mg daily
223613895|NCT04231604|BEHAVIORAL|A Lust for Life|A Lust for Life is a universal school-based multi-component programme whose target is to build well-being and emotional resilience in adolescents. The programme was informed by evidence-based psychological approaches including mindfulness, cognitive behaviour therapy and positive psychology. It is delivered in six weekly lessons by the adolescents' school teacher and involves classroom discussions, videos, classroom activities and homework assignments.
223613896|NCT04231604|BEHAVIORAL|Waiting list control|Control group placed on a twelve-week waiting list.
223759827|NCT04536727|BEHAVIORAL|Wait list|Participants randomized to the wait list group receive the 8-week Fit \& Strong! intervention after the intervention group has competed it and after the wait list group has provided their post-outcomes.
223759828|NCT01399593|DRUG|Eculizumab|
223759829|NCT00895791|DEVICE|AXXESS Biolimus A9-eluting bifurcation stent|implantation of stent
224201632|NCT00530621|DRUG|pemetrexed|500 milligrams per square meter (mg/m\^2), intravenous (IV), day 8 Cycle 1 (28 days), day 1 subsequent cycles (21 days), until disease progression
223613897|NCT04887753|OTHER|Synchronisation abilities|The study contains 1 descriptive and 3 experimental sessions. In the descriptive session, participant's clinical motor and cognitive functions are collected. In the first experimental session, participant's beat perception and synchronisation abilities is examined within a finger tapping paradigm. In the following experimental sessions participants synchronsiation abilities is examined during walking paradigms, to music and metronomes, with period and phase auditory manipulations.
223613898|NCT05371912|DEVICE|Trans Cranial Magnetic Stimulation|Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive neurostimulation technique that alters cortical excitability by repeated induction of electromagnetic activity. FDA approved for depression, rTMS is a promising tool in the field of neuropsychiatry with an excellent safety profile.
223613899|NCT01756404|DRUG|Canagliflozin (JNJ-28431754)|A 30mg/day, 100 mg/day, 300 mg/day, or 600 mg/day liquid dose administered once daily; a 300mg/day liquid dose administered in 2 divided doses (2x150 mg); or a 600 mg/day liquid dose administered in 2 divided doses (2x300 mg) using an oral (by mouth) liquid dispenser on Days 1 through 14.
223613900|NCT01756404|DRUG|Placebo|Matching placebo (inactive medication) liquid dose(s) administered using an oral liquid dispenser once or twice daily on Days 1 through 14.
223613901|NCT05533424|OTHER|quadratus lumborum|the patient will be positioned supine with lateral tilt , and the transducer was placed at the level of the anterior superior iliac spine and moved cranially until the three abdominal wall muscles were clearly identified. The external oblique muscle was followed posterolaterally until its posterior border was visualized . The probe was tilted down to identify a bright hyperechoic line that represented the middle layer of the thoracolumbar fascia. The needle will be inserted in plane from anterolateral to posteromedial. The needle tip was placed between the thoracolumbar fascia and the QL muscle, and after negative aspiration, the correct position of the needle was proved by injection of 5 mL of normal saline to confirm the space with a hypoechoic image and hydrodissection. An injection of 20 mL of 0.25% bupivacaine was applied
223613902|NCT05533424|OTHER|transversus abdominis plane|the probe will located between the iliac crest and the lower costal margin in the anterior axillary line at the level of umbilicus, and the layers of abdominal wall were identified (external oblique, internal oblique, and transverse abdominis muscles). In-plane technique was used and the tip of the needle was inserted between the internal oblique and transverse abdominis muscles. After negative aspiration (to exclude intravascular injection), 20 mL of 0.25% bupivacaine was injected. The same technique will be performed on the other side
223613903|NCT01060852|BEHAVIORAL|Media Detective|10-lesson elementary school, media literacy education, substance use prevention program. Each lesson takes approximately 45 minutes to teach and was taught every school day for 2 weeks.
223613904|NCT01405612|DRUG|Midazolam|Single oral administration on Day 1 or Day 5
223613905|NCT01405612|DRUG|Ulimorelin|Intravenous infusion of 480 micrograms/kg on Days 1 to 5
223613906|NCT00791908|PROCEDURE|Electrodessication|Treatment applied to a third of the torso at each study visit.
223759830|NCT00895791|DEVICE|culotte stenting (Xience V)|implantation of stent
223759831|NCT00563238|DRUG|Metoprolol|Metoprolol administered intravenously in 2.5mg boluses until the resting heart rate falls by 10% from baseline to a maximum dose of 10mg, or until there is any apparent adverse reaction.
223759832|NCT01228630|DRUG|Cloratadd-D|The patients receive one pill of treatment every 12 hours ( to get up and going to bed), of a glass of water.
223759833|NCT01228630|DRUG|Allegra-D|The patients receive one pill of treatment every 12 hours ( to get up and going to bed), of a glass of water.
224201633|NCT01330407|PROCEDURE|cryopreserved skin allografts.|
223759834|NCT04859868|DEVICE|Galvanic Vestibular Stimulation|Low electrical currents to the vestibular system, to induce the realistic sensation of motion (i.e., the g-forces that occur during flight) as well as null out motion perception.
224201634|NCT01330407|PROCEDURE|Cultured Epidermal Autografts|
224201635|NCT03409328|BEHAVIORAL|HIV and substance use prevention|The intervention content will be developed through formative research during the initial phase of the study. However, the intervention will address: bisexual-inclusive sexual health education, unique influences of risk behavior among bisexual adolescents, and skills to cope with bisexual stigma and to increase acceptance of one's bisexual identity.
224201636|NCT03544697|PROCEDURE|Skin expansion and repair with flaps|
224201637|NCT02959398|DEVICE|Standard mammography|Standard mammography
224201638|NCT02959398|DEVICE|Standard mammography and tomosynthesis|Standard mammography and tomosynthesis
224201639|NCT02998645|DRUG|eltrombopag|Film-coated tablets (12.5 mg, 25 mg, 50 mg and 75 mg) administered orally, once daily for up to 6 months. East and Southeast Asian participants were treated with 100 mg once daily, to adjust for the lower apparent clearance of eltrombopag. All other participants were treated with 150 mg once daily.
224201640|NCT02998645|DRUG|Cyclosporine|"Supplied as oral soft gel capsules. The starting dose was based on body weight at 10.0 mg/kg/day (acceptable rounding range was from 9.5 to 10.5 mg/kg/day) in divided doses every 12 hours. After Day 1, dosing was titrated individually according to therapeutic trough level between 200 and 400 μg/L for 6 months. After 6 months (only for responders at Month 6), tapering of cyclosporine was done as follows:~* 6-9 months: at the 6 months visit, the dose was reduced by 25% for 3 months~* 9-12 months: at the 9 months visit, the dose was further reduced by 25% for another 3 months~* 12-24 months: dose was maintained"
223613907|NCT00791908|PROCEDURE|Pulsed dye laser (PDL)|Laser treatment applied to a third of the torso at each study visit.
223613908|NCT00791908|PROCEDURE|potassium titanyl phosphate (KTP)|Laser treatment applied to a third of the torso at each study visit.
223613909|NCT05396144|DRUG|Nitrous oxide|Nitrous oxide will be administered by face or nasal mask to be inhaled by the patient
223613910|NCT00120965|DEVICE|AutoPulse|Standard device settings
223613911|NCT00120965|OTHER|Manual CPR|Manual CPR
223613912|NCT04393168|COMBINATION_PRODUCT|Lymphatic clearance measurement|The indocyanine green in 5% human albumin solution (tracer) (50 μL) will be injected intradermally in both forearms or both lower legs using MicronJet600 microneedles paying attention to the contralateral symmetry of the injections. The signal at the injection sites will be measured over time using a hand-held portable device LymphMeter 1.0 for the total duration of 3 h. In the first hour, the signal will be measured every 15 minutes followed by measurements every half an hour. Immediately after injection (t=0 h), 1.5 h and 3 h after injection the skin area occupied by the tracer will be measured using a standard near-infrared camera, Fluobeam. The dermal reaction at the injection site will be assessed by observations for presence of redness/erythema and measuring its extent according to the needs. The patient will be constantly observed for the signs of allergic reactions, skin irritations or intolerances.
223613913|NCT04505332|PROCEDURE|arthroplasty|back pain in orthopedists due to working actively and performing arthroplasty every day
223613914|NCT06330259|DIAGNOSTIC_TEST|menstrual cycle monitoring|frequent serum sampling and 3D ultrasound
223613915|NCT04623840|OTHER|Tadalafil 5Mg Tab + continuous and interval exercise|(n=30) will be sedentary obese men with ED. All participants will receive five milligrams of tadalafil, one time per day, in addition to 3 sessions, per week, of combined continuous and interval aerobic exercise for eight weeks
223613916|NCT04623840|DRUG|Tadalafil 5Mg Tab|(n=30) will be sedentary obese men with ED. All participants will receive five milligrams of tadalafil, one time per day, for eight weeks
223613917|NCT03577678|PROCEDURE|Surgery to fix lateral half prosthesis for clavicle|Surgery to fix lateral half prosthesis for clavicle
223613918|NCT01902121|DRUG|Technosphere® Insulin 10U + 20U|Inhaled Insulin
223613919|NCT01902121|DRUG|Technosphere® Insulin 30U|Inhaled Insulin
223613920|NCT04742114|DEVICE|use the face mask with Expiratory Positive Airway Pressure(EPAP).|The subjects were divided into two groups. The first group use the face mask without EPAP, and the other group use the face mask with EPAP.
223613921|NCT04742114|DEVICE|use the face mask without Expiratory Positive Airway Pressure(EPAP).|The subjects were divided into two groups. The first group use the face mask without EPAP, and the other group use the face mask with EPAP.
223613922|NCT05901402|BEHAVIORAL|aerobic and resistance exercise|The experimental group performed aerobic resistance exercise during pregnancy every day.
223613923|NCT03062293|DEVICE|Functional Re-adaptive Exercise Device|Exercise intervention 3 times per week for up to 30min. Difficulty and time will be progressed as indicated by clinical presentation, assessed by the Physiotherapist team.
223613924|NCT02669992|PROCEDURE|Stapled or Hand-sewn anastomosis|Randomization between stapled or hand-sewn anastomosis
223613925|NCT02669992|PROCEDURE|Mesh or suture stoma site closure|Randomization between suture or Mesh closure of the stoma site
223613926|NCT00685789|DEVICE|acupuncture, deqi|Immediately after insertion of a needle, it is manually rotated backwards and forwards to induce the deqi sensation.
223613927|NCT00685789|DEVICE|acupuncture Non-manipulation|After insertion of a needle, no manipulation is applied, and the needle is retained for 30 minutes.
223759835|NCT00249470|BEHAVIORAL|Abstinence & Work|Participants in the Abstinence \& Work group were invited to attend the workplace throughout a 26-week intervention period, but were required to provide urine samples that indicated recent cocaine abstinence to gain access to the workplace and to maintain the maximum base pay of $8.00 per hour.
223613928|NCT01284023|OTHER|Shaving|Male patients will have the leg hair under each sensor site shaved, using an electric razor, and near infrared spectroscopy monitored for an additional 15 minutes
223613929|NCT02812927|DEVICE|Edelvaiss Multiline-8|Optimised infusion line
223613930|NCT02812927|DEVICE|Standard infusion line|
223613931|NCT06525142|BEHAVIORAL|Audiovisual Intervention|"【Group 1】During the first three days, the researchers will provide a storybook to the father of the premature infant, and the researchers assist in recording the father's voice of the storybook in the form of MP4 recording. At the fourth day, one hour after the baby feeding, the father's voice will be played by the player to the baby, for 2 consecutive days, 2 times/day, 10 minutes/time. The baby's heartbeat, breathing and blood oxygen changes will be recorded and monitored with a physiological monitor. The recording files will be kept by the researcher.~【Group 2】 The intervention will be the same with Group 1 except the following intervention: on the 4th-6th day of the baby's birth, sleeping in the incubator, the baby's reaction behavior will be taken with a mobile phone, 1 time/day, 5 minutes/time, for 3 consecutive days, the image feedback is delivered to the father in person."
223613932|NCT03205176|DRUG|AZD5153|AZD5153 is to be taken as oral capsules once or twice per day each day in 21 day cycles. Dosing will continue until disease progression or other study discontinuation criteria are met.
223613933|NCT03205176|DRUG|Olaparib|Olaparib, 300 mg, will be taken BID as oral capsules.
223613934|NCT02410239|BIOLOGICAL|Mesenchymal Stem Cells|
223759836|NCT00249470|BEHAVIORAL|Work Only|Work Only participants were invited to attend the workplace throughout a 26-week intervention period. Participants in this group continued to provide mandatory urine samples and could earn base and performance pay. Work Only participants could work and earn base and performance pay independent of urinalysis results.
224201641|NCT02139969|DEVICE|GreenLight XPS Laser System|
224201642|NCT01153685|BIOLOGICAL|Fluviral®|Intramuscular injection, one dose
224201643|NCT04672369|BIOLOGICAL|IBI939|IBI939 injection
224201644|NCT04672369|BIOLOGICAL|Sintilimab|Sintilimab injection
224201645|NCT06249035|DIAGNOSTIC_TEST|Transoesophageal echocardiography (TEE)|TEE is a diagnostic modality in which an ultrasound probe is inserted via the oesophagus in order to visualize the heart.
224201646|NCT02098434|BEHAVIORAL|Montreal Imaging Stress Task|Math task developed to induce a stress response in a laboratory setting
224201647|NCT06443216|DEVICE|Auditory closed-loop stimulation|Auditory closed-loop suppression of slow wave sleep
224201648|NCT06443216|DEVICE|Sham stimulation|No auditory stimulation
223613935|NCT00319254|DRUG|SKI-606 (Bosutinib)|SKI-606 (Bosutinib) 400mg once daily, for as long as tolerated or until disease progression.
223613936|NCT03075358|DRUG|Lidocaine spray|Patients are locally anesthetized with 8 puffs (80 mg, 10mg/puff, 0.8 ml) of 10% lidocaine spray applied thoroughly to the cervix, 3 minutes before starting the procedure.
223613937|NCT03075358|OTHER|Normal saline spray|0.8 ml of normal saline spray is applied to the cervix, 3 minutes before starting the procedure
223613938|NCT01505374|PROCEDURE|Study Technique|One leg will receive the saphenous nerve block, at the level of the adductor canal (study technique). The block will be under ultrasound guidance. The local anesthetic will be 15 ml of 0.5% bupivacaine. All study patients, regardless of study arm will receive combined spinal epidural, with 3 ml of 0.5% bupivacaine as the spinal agent. Epidural local anesthetic, if needed, will consist of 2% lidocaine.
223613939|NCT01505374|PROCEDURE|Control Technique|The other leg will receive the femoral nerve block (control technique). The block will be under ultrasound guidance. The local anesthetic will be 30 ml of 0.25% bupivacaine. All study patients, regardless of study arm will receive combined spinal epidural, with 3 ml of 0.5% bupivacaine as the spinal agent. Epidural local anesthetic, if needed, will consist of 2% lidocaine.
223613940|NCT01712204|DRUG|Placebo|Placebo Capsule BID for 16 Weeks
223613941|NCT01712204|DRUG|AC-201|AC-201 50mg Capsule BID for 16 Weeks
223613942|NCT01712204|DRUG|Febuxostat|Febuxostat 80 mg QD for 16 Weeks
223613943|NCT02360228|DEVICE|tACS (alpha)|
223613944|NCT02360228|DEVICE|tDCS|
223613945|NCT03809494|DEVICE|HemaTrate™ Blood Filtration system|Anticoagulated whole blood is loaded into the filtration system. During gravity filtration, the majority of platelets, plasma, and red blood cells pass through the filter into a filtrate bag. The TNCs are captured in the filter material and recovered via a back-flush with 0.9 % saline into a syringe.
223613946|NCT03809494|OTHER|Saline|Normal (0.9%) saline
223759837|NCT00244712|DRUG|emtricitabine/tenofovir|The intervention is an active comparator regimen containing tenofovir/emtricitabine + abacavir/lamivudine placebo + lopinavir/ritonavir.
223759838|NCT00244712|DRUG|abacavir/lamivudine|The experimental intervention is a regimen containing abacavir/lamivudine + tenofovir/emtricitabine placebo + lopinavir/ritonavir.
223613947|NCT04177979|BEHAVIORAL|Near-assisted learning through trained peers|Students randomly allocated to this group were overseen during sessions by trained peer instructors.
223613948|NCT04374045|OTHER|ECG-Holter|Patient will have a ECG-Holter recording during all their hospitalization.
223759839|NCT00624806|BEHAVIORAL|Daily telephone calls|Patients randomized to this group receive daily phone calls to remind them what they should do to prevent ulcers.
223759840|NCT00624806|BEHAVIORAL|Weekly telephone calls|Patients randomized to this group receive weekly phone calls to remind them what they should do to prevent ulcers.
223759841|NCT00500370|DRUG|exenatide|subcutaneous injection (5mcg or 10mcg), twice a day
223613949|NCT02095080|DIETARY_SUPPLEMENT|Leucine intake|Oral consumption of eight hourly experimental meals- Includes 4 tracer-free experimental meals containing a mixture of free amino acids, calories from a flavored liquid and protein free cookies and 4- labeled amino acid experimental meals.
223613950|NCT01192308|DRUG|Tamoxifen 40mg QD|Tamoxifen 40mg QD during 4 weeks
223613951|NCT03308994|OTHER|Delay between MS onset and introduction of first line DMT|Delay between MS onset and introduction of first line DMT : time between date of MS onset ( the first demyelinating neurological events clinically defined) and date of the introduction of the first-line oral DMT (Interferons, Glatiramer Acetate, Dimethyl Fumarate and Teriflunomide)
223613952|NCT03308994|OTHER|EDI|For all cases of multiple sclerosis residence's places of each patient were geolocalized with a Geographic Information System (ARCGIS 10.2) and assigned to an IRIS, IRIS (Ilots Regroupés pour l'Information Statistique) is the smallest French geographic unit for which census data are available and EDI score was calculated for each IRIS. In order to attribute a social deprivation score to the IRIS, we used the French EDI (European Deprivation Index). EDI stands as a continuous variable but EDI will be used as a categorical variable in order to increase the comparability with others studies, so EDI is distributed into quintiles calculated at the French level.
223613953|NCT01079494|OTHER|pharmaceutical care services|Patients treatment related problems and therapeutic needs or complains identified by clinical pharmacist and managed collaboratively by both pharmacist and the physician.
223613954|NCT02315534|DRUG|BBI608|"In arm A, BBI608 will be administered at the recommended Phase 2 dose (RP2D) twice daily for 7(±2) days prior to planned surgical resection or biopsy of recurrent GBM. Upon the clinical recovery of the patient and at a time between 15-28 days after surgery, BBI608 will be administered orally, daily, each day of a 28 day cycle in combination with temozolomide.~In arm B, patients who are not candidates for surgical resection will receive BBI608 administered orally, daily, each day of a 28 day cycle at the RP2D in combination with temozolomide."
223613955|NCT02315534|DRUG|Temozolomide|Temozolomide (TMZ) will be administered orally, once daily, at a dose of 150 mg/m\^2 daily on days 1 through 5 of each 28-day study cycle. The dose of temozolomide can be increased to 200 mg/m\^2 as per standard TMZ dosing guidelines for patients who complete at least one cycle at 150 mg/m\^2.
223613956|NCT06267222|DEVICE|TRANSCRANIAL DIRECT CURRENT STIMULATION + exercises|Participants with SCA will receive trans-spinal tDCS and exercises. There will be no control group or sham stimulation. All participants will receive real tDCS stimulation
223759842|NCT00500370|DRUG|placebo|subcutaneous injection (equivalent volume to active dose), twice a day
224201649|NCT00616889|DRUG|Seroquel|The dosage is flexible from 50-600 mg based on the investigator's clinical judgement and patient tolerance. It may be raised or lowered at will.
224201650|NCT05167994|DRUG|Anlotinib hydrochloride|Anlotinib 12mgQD, from D1 of pre-operative IMRT to 1 month after end of IMRT
224201651|NCT01248000|PROCEDURE|FDG-PET|PET interpretation is based on a site-to-site comparison of FDG uptake both before and after chemotherapy (qualitative approach), according to the criteria defined by Cheson (2008)
224201652|NCT04611152|DRUG|KSI-301|Intravitreal Injection
224201653|NCT04611152|DRUG|Aflibercept|Intravitreal Injection
224201654|NCT04611152|OTHER|Sham Procedure|The sham is a procedure that mimics an intravitreal injection. It involves pressing the blunt end of an empty syringe (without a needle) against the anesthetized eye. It will be administered to participants in both treatments arms at applicable visits to maintain masking.
223759843|NCT05345210|DRUG|Vonoprazan Fumarate+Amoxycillin+Clarithromycin 14days (VAC14)|VAC-14d:Vonoprazan Fumarate 20mg bid po, Amoxycillin 1000mg bid po, Clarithromycin 500mg bid po for 14 days VA-14d:Vonoprazan Fumarate 20mg bid po, Amoxycillin 1000mg bid po for 14 days VA-7d:Vonoprazan Fumarate 20mg bid po, Amoxycillin 1000mg bid po for 7 days VTF-14d:Vonoprazan Fumarate 20mg bid po, Tetracycline 500mg tid po, Furazolidone 100 bid po for 14 days VTF-7d:Vonoprazan Fumarate 20mg bid po, Tetracycline 500mg tid po, Furazolidone 100 bid po for 7 days
223759844|NCT05345210|DRUG|Vonoprazan Fumarate+Amoxycillin 14days (VA14)|VAC-14d:Vonoprazan Fumarate 20mg bid po, Amoxycillin 1000mg bid po, Clarithromycin 500mg bid po for 14 days VA-14d:Vonoprazan Fumarate 20mg bid po, Amoxycillin 1000mg bid po for 14 days VA-7d:Vonoprazan Fumarate 20mg bid po, Amoxycillin 1000mg bid po for 7 days VTF-14d:Vonoprazan Fumarate 20mg bid po, Tetracycline 500mg tid po, Furazolidone 100 bid po for 14 days VTF-7d:Vonoprazan Fumarate 20mg bid po, Tetracycline 500mg tid po, Furazolidone 100 bid po for 7 days
223759845|NCT05345210|DRUG|Vonoprazan Fumarate+Amoxycillin 7days (VA7)|VAC-14d:Vonoprazan Fumarate 20mg bid po, Amoxycillin 1000mg bid po, Clarithromycin 500mg bid po for 14 days VA-14d:Vonoprazan Fumarate 20mg bid po, Amoxycillin 1000mg bid po for 14 days VA-7d:Vonoprazan Fumarate 20mg bid po, Amoxycillin 1000mg bid po for 7 days VTF-14d:Vonoprazan Fumarate 20mg bid po, Tetracycline 500mg tid po, Furazolidone 100 bid po for 14 days VTF-7d:Vonoprazan Fumarate 20mg bid po, Tetracycline 500mg tid po, Furazolidone 100 bid po for 7 days
223759846|NCT05345210|DRUG|Vonoprazan Fumarate+Tetracycline+Furazolidone 14days (VTF14)|VAC-14d:Vonoprazan Fumarate 20mg bid po, Amoxycillin 1000mg bid po, Clarithromycin 500mg bid po for 14 days VA-14d:Vonoprazan Fumarate 20mg bid po, Amoxycillin 1000mg bid po for 14 days VA-7d:Vonoprazan Fumarate 20mg bid po, Amoxycillin 1000mg bid po for 7 days VTF-14d:Vonoprazan Fumarate 20mg bid po, Tetracycline 500mg tid po, Furazolidone 100 bid po for 14 days VTF-7d:Vonoprazan Fumarate 20mg bid po, Tetracycline 500mg tid po, Furazolidone 100 bid po for 7 days
223759847|NCT05345210|DRUG|Vonoprazan Fumarate+Tetracycline+Furazolidone 7days (VTF7)|VAC-14d:Vonoprazan Fumarate 20mg bid po, Amoxycillin 1000mg bid po, Clarithromycin 500mg bid po for 14 days
223759848|NCT04804813|DRUG|Cabozantinib|Cabozantinib tablets
223759849|NCT05627518|DRUG|Linaprazan glurate|100 mg
223759850|NCT05747066|OTHER|No intervention|No intervention
223759851|NCT06183320|PROCEDURE|Restoration with Incremental Composite in Proximal Wall|Proximo-occlusal lesions will receive the self-etch adhesive system Ambar Universal APS with selective acid etching, according to the manufacturers instrucions. Then, proximal wall will be completely restored with Vittra APS composite resin, using the triangular incremental traditional technique described for classe II restorations. Then, Opus Bulk Fill Flow APS will be used in the bulk technique with up to 5mm depth increments, leaving 1 mm in the occlusal for incremental Vittra APS composite resin, that will be used with the traditional incremental technique. Both composites will be light-cured with VALO light-cure unit (Ultradent, USA) for 40 seconds.
223759852|NCT06183320|PROCEDURE|Restoration with Bulk Fill Composite in Proximal Wall|Proximo-occlusal lesions will receive the self-etch adhesive system Ambar Universal APS with selective acid etching, according to the manufacturers instrucions. Then, Opus Bulk Fill Flow APS resin will be used in the bulk technique with up to 5mm depth increments, leaving 1 mm in the occlusal for incremental Vittra APS composite resin, that will be used with the traditional incremental technique. Both composites will be light-cured with VALO light-cure unit (Ultradent, USA) for 40 seconds.
223759853|NCT04561986|DRUG|Tocilizumab|Tocilizumab is a recombinant humanized monoclonal antibody directed against the human interleukin-6 (IL-6) receptor
223613957|NCT02452424|DRUG|PLX3397|PLX3397 capsules, 200 mg
223613958|NCT02452424|BIOLOGICAL|Pembrolizumab|Pembrolizumab, 200 mg, IV
223613959|NCT00946790|DRUG|Hydroxychloroquine Sulfate Tablets, 200 mg (Geneva Pharmaceutical, Inc.)|
223613960|NCT00946790|DRUG|Hydroxychloroquine Sulfate Tablets, 200 mg, Plaquenil (Sanofi Winthrop)|
223613961|NCT03977766|PROCEDURE|Chemotherapy prevalidation|"Outpatient Chemotherapy prevalidation will done~* with the help of a nurse, using the digital application, for cycle 2 and 3.~* by the patient alone, using the digital application, for cycle 4 and 5."
223613962|NCT01647776|OTHER|Stool DNA Test|Stool DNA test is done prior to the colonoscopy.
223613963|NCT01647776|PROCEDURE|biopsies of rectal and colon mucosa|During the standard of care colonoscopy biopsies of rectal and colon mucosa will be taken for analysis of 15-PGDH pathway factors \[levels of prostaglandin E2 (PG E2), and mRNA for 15-PGDH, COX-1 and COX-2 expression\] as markers of risk of developing adenoma.
223613964|NCT01647776|OTHER|Questionnaires|A Food Frequency Questionnaire (FFQ), a Meat Preparation Questionnaire (MPQ), and a Physical Activity Questionnaire (PAQ), all developed at the University of Arizona Cancer Center will be used to collect dietary and physical activity data. Risk Factor Questionnaire (RFQ) developed by the University of Southern California will be used to collect general risk information. Stool (sDNA) test patient satisfaction survey.
223613965|NCT01463306|DRUG|Pregabalin|Pregabalin administered as either capsule or liquid oral formulations. Subjects \<4 years of age at Visit 1 will receive study medication 3 times daily (TID) in equally divided doses. Subjects who are ≥4 years of age at Visit 1 will receive study medication twice daily (BID) in equally divided doses. Children less than 17 years of age will receive from 2.5 mg/kg/day to 10.0 mg/kg/day (maximum 600 mg/day. Adults 17 and older will receive from 150 mg/day to 600 mg/day.
223613966|NCT05650281|OTHER|NO INTERVENTION|NO INTERVENTION
223613967|NCT02082600|OTHER|Sleep deprivation|This group will perform 24 sets of 10 maximum repetitions of eccentric contractions for quadriceps and than will keep awake for 60 hours (2 nights), followed by 1 night of sleep, all inside the lab. During whole protocol, it will be collected several blood samples for evaluation of hormones, cytokines and muscle damage parameters. It will be also evaluated isometric strength and pain.
223613968|NCT02082600|OTHER|Normal sleep|This group will perform 24 sets of 10 maximum repetitions of eccentric contractions for quadriceps and and will be able to sleep the 3 nights. During whole protocol, it will be collected several blood samples for evaluation of hormones, cytokines and muscle damage parameters. It will be also evaluated isometric strength and pain.
223613969|NCT04266925|BEHAVIORAL|3 referees present|We compared player behavior with one versus three referees present on youth soccer fields during match play. The time between these two matches ranged from a few hours to several weeks.
223613970|NCT04266925|OTHER|1 referee present|We compared player behavior with one versus three referees present on youth soccer fields during match play. The time between these two matches ranged from a few hours to several weeks.
223613971|NCT00048698|PROCEDURE|TMS|
223613972|NCT00048698|PROCEDURE|EEG|
223613973|NCT06327828|DEVICE|Semi-automated computer-aided treatment (Digital Thyroid, DigiThy)|Semi-automated computer-aided treatment based on a mathematical model
223613974|NCT06327828|PROCEDURE|Usual care|Guiding methimazole therapy based on the treating physician's decision
223613975|NCT05594628|OTHER|Neuromuscular training|"Neuromuscular training is designed as 8 weeks and 2 times a week, and approximately 20 minutes per session for Neuromuscular training+usual basketball training group. Other group is only going to keep attending usual basketball training.~Neuromuscular training consisted 3 exercises:~First exercise is passing the ball to side to side on bosu with standing on one leg. 60-90 seconds on time, 30-60 seconds off time. 2 sets for both passing sides and bilaterally.~Second exercise is standing on bosu unilaterally and while standing stabilized, switching basketball hand to hand as dribbling on the floor. Exercise will be on for 60-90 seconds and off for 30-60 seconds, 2 sets for each side Third exercise is jumping with one stance/leg, and landing with double stance while a therabant is attached to the belly and pulling with a minimum/medium force from one side. Changing legs after one jump, 6 times for both side is equal to 1 set of the exercise. It will be done 2 sets for both sides."
223613976|NCT00559221|DRUG|FLAG+IDA|Fludarabine, cytarabine, G-CSF
223613977|NCT04205721|BEHAVIORAL|School-based sexuality and HIV prevention scripted lesson plans|The revised life orientation content and implementation approach were designed to address gaps in prior implementation of the sexuality and HIV education content. By using scripted lesson plans and training teachers to use these, it was thought that students would get better information and lessons on the material important for HIV prevention.
223613978|NCT04186871|DRUG|branebrutinib|Specified dose on specified days
223613979|NCT04186871|DRUG|abatacept|Specified dose on specified days
223613980|NCT04186871|DRUG|branebrutinib placebo|Specified dose on specified days
223613981|NCT06061835|OTHER|Non-contrast MRA in preoperative perforator vessels mapping for deep inferior epigastric perforator (DIEP) flap breast reconstruction planning.|"Device: MRA scan Philips Ingenia 1.5 T (Royal Philips, Netherlands)~Preprocedural patient's preparation: the study was performed on an empty stomach (at least 8 hours of fasting).~Type of patient positioning. MRA scanning was performed in the prone position.~Additional devices. The investigators placed the patient on her abdomen on a special coordinate system mesh, for the most precise and convenient way of marking.~Scanning protocol. The investigators added T2 pulse sequence to increase the accuracy of muscle localization assessment and the point of vessel immersion into the muscle at TR and TE using a fat suppression program, wich allows receiving information from moving objects (including blood within the vascular lumen).~Scan viewer program. OsiriX 10.0 Release"
223613982|NCT06061835|OTHER|CTA with iodine contrast in preoperative perforator vessels mapping for deep inferior epigastric perforator (DIEP) flap breast reconstruction planning.|"Device: Device: Toshiba Aquilion 64 CTA scan machine (Toshiba Medical Systems, Tokyo, Japan).~Preprocedural patient's preparation: A catheter was placed in the antecubital vein of one arm, and a bolus injection of 80 ml contrast medium (Omnipaque 300 mg/ml, GE Healthcare, Oslo, Norway, registration number P N015799/01 from July 31, 2003, international nonproprietary name is a Iohexol) was administered through a power injector (M. Schilling GmbH Medical Products, Germany) at 4 ml/s.~Type of patient positioning. CTA scanning was performed in the supine position.~Scan viewer program. OsiriX 10.0 Release"
223613983|NCT01013857|BEHAVIORAL|Health coaching|Calling patients every week to discuss medication adherence
223613984|NCT01013857|BEHAVIORAL|Health coaching plus home titration|Calling patients every week and intensifying medications if appropriate based on physician-created algorithm
223613985|NCT02444325|BEHAVIORAL|Group prenatal care|Women will receive their prenatal care in a group rather than in the 1:1 traditional manner.
223613986|NCT02464410|BEHAVIORAL|Motivational intervention|The intervention session combines elements of motivational enhancement (ME) and cognitive behavioral therapy (CBT). Similar to other ME brief interventions, the intervention content will be covered in a single session. Participants are presented with a variety of risk reduction strategies and strategies for coping with pain that may reduce reliance on opioids for managing pain.
223613987|NCT02464410|BEHAVIORAL|Psycho-educational control|The educational control condition provides educational content related to the biology of pain response and an overview of pain conditions. The overall style is didactic.
223759854|NCT05545735|DRUG|Standard of Care Antibiotic Therapy|Antibiotics will be administered as per the standard of care orally via tablet
224312136|NCT02633748|BEHAVIORAL|Mindfulness-Based Cancer Survivorship|Mindfulness-Based Cancer Survivorship (MBCS) is a four-week standardized mindfulness program, adapted for cancer survivors from Mindfulness-Based Stress Reduction (MBSR). MBCS teaches formal mindfulness practice (meditation) and informal mindfulness during daily activities. Mindfulness has been shown to help stress, fatigue, sleep complaints, and other symptoms but has not been extensively studied in cancer survivors.
224312137|NCT06173856|OTHER|LED phototherapy|LED phototherapy (430-470nm) alone will be applied.
224312138|NCT02774642|BEHAVIORAL|CBTI-PE|Integrates CBT-I and PE with the goal of enhancing both insomnia and PTSD outcomes. Integrated treatment will be delivered in 14 90-minute weekly sessions. CBTI-PE starts with VA rollout CBT-I for the first 3 weeks with a focus on the effects of PTSD on insomnia. PE protocol (psychoeducation) begins on week 4 of treatment and both treatments overlap till week 6 when CBT-I ends and the active treatment of PE begins (i.e., imaginal and in-vivo exposures). However, CBT-I sleep diary review and sleep time adjustment will continue till the end of treatment to increase adherence
223759855|NCT05462600|OTHER|Position change|Distribution of ventilation, respiratory drive, pulmonary mechanics and gas exchange will be measured in 3 unique positions: prone, head of bed (HOB) flat (i.e. 0 degrees) and HOB elevated (i.e. 30 degrees).
224201655|NCT04067505|DRUG|Rivaroxaban|Dose: 15mg twice daily for three weeks, then 20mg once daily until six months after the operation. Application: oral
224201656|NCT04067505|DRUG|Warfarin|Dose: 3mg for 5 days after the operation, later 0.75mg to 18mg depending on INR (2.0-3.0) until 6 months Duration: 6 months Frequency: once daily Application: oral
224201657|NCT04067505|DRUG|Nadroparin|Dose: 1mg/kg Duration: 5 days after the operation Frequency: twice daily Application: subcutaneous
224201658|NCT06327204|DEVICE|940-nm diode laser / one session|laser therapy using a 940-nm diode laser / one session per week
224201659|NCT06327204|DEVICE|940-nm diode laser / two session|laser therapy using a 940-nm diode laser / two session per week
223613988|NCT02464410|OTHER|Long-term opioid therapy informed consent|The Veterans Health Administration instituted a requirement that all patients receiving long-term opioid therapy receive an informed consent process that reviews the risks of opioid therapy. All individuals eligible for this study will meet this definition of long-term opioid therapy. The study therapists for both study arms will deliver the informed consent process during the sessions as part of treatment as usual.
223613989|NCT01903629|DEVICE|MCE|MCE first, followed by standard gastroscopy
223613990|NCT01903629|DEVICE|Standard gastroscopy|
223613991|NCT04386642|DRUG|Tranexamic acid|Tranexamic acid 2000 mg dilute in normal saline solution 50 ml.
223613992|NCT04386642|DRUG|Placebo|normal saline solution in a clear 50-ml syringe
223613993|NCT04891354|DRUG|PDNO|PDNO consists of propylene glycol (1,2-propanediol, PD) chemically combined with NO (to be donated). The drug substance is formulated as an inherent mixture of 4 structure analogues. The mixture consists of an equilibrium of the 2 regioisomers 1-(nitrosooxy) propan-2-ol and 2-(nitrosooxy) propan-1-ol. In addition, each regioisomer is a racemic mixture.
223613994|NCT04891354|DRUG|Sodium chloride (placebo)|Placebo (NaCl, commercially available dilution solution for parenteral use, 9 mg/mL)
223613995|NCT01971385|DRUG|Squaric Acid solution|
223613996|NCT01971385|DRUG|Placebo solution|
223613997|NCT01810718|DRUG|nilotinib|Maximum tolerated dosage (MTD) will be defined in Phase I. First 3 patients (pts) will receive Nilotinib 200mg daily dose. If no dose limiting toxicities after at least 1month the next 3 pts will be treated with 300mg. If are\>=2 dose limiting toxicities the Phase I will end and MTD will be defined as the next lower dosage. If they will observe 1dose limiting toxicities, they will treat other 3 pts (same dosage); if there isn't dose limiting toxicity, they will increase the dosage in the next cohort; but if they will observe another dose limiting toxicity (tot limiting toxicities 2/6 pts), the study will continue using the previous dose. MTD will be considered the maximum dosage used to treat 6 pts achieving at most 1 dose limiting toxicities, or the previous dosage if with this dosage they we will achieve 2 dose limiting toxicities. Doses will not be escalated beyond \>600 or \<200mg/die The MTD will be used for phase II
223613998|NCT04342117|DRUG|duvelisib|25 mg BID, 15 mg BID
223613999|NCT04342117|DRUG|PI3K inhibitor|FDA approved PI3K inhibitors
223614000|NCT00345618|DRUG|Idrabiotaparinux sodium|"0.5 mL pre-filled syringe for 3.0 mg~Subcutaneous injection"
223614001|NCT00345618|DRUG|Warfarin|"Capsules with 1 or 5 mg for INR-adjusted dose (INR checked at least once a month)~Oral administration"
223614002|NCT00345618|DRUG|Placebo (for idrabiotaparinux sodium)|"0.5 mL pre-filled syringe~Subcutaneous injection"
223614003|NCT00345618|DRUG|Avidin|"100 mg in 10 mg/mL solution~Intravenous infusion for 30 minutes"
223614004|NCT00345618|DRUG|Placebo (for warfarin)|"Warfarin matching capsules~Oral administration"
223614005|NCT00345618|DRUG|Enoxaparin|"Prefilled syringes as locally registered~Subcutaneous injection"
223614006|NCT05209373|BEHAVIORAL|Intervention Condition|4-week intervention combining behaviour change and self-compassion education to promote coping with CVD risk and increased engagement in physical activity.
223614007|NCT05209373|BEHAVIORAL|Positive Control Condition|4-week intervention combining behaviour change and self-compassion education to promote coping with CVD risk and increased engagement in physical activity.
223614008|NCT03209466|DRUG|Chlorhexidine gluconate at 0.125%|Application every 24 hours, six weeks Intervention: Procedure: chlorhexidine gluconate
223614009|NCT03209466|DRUG|Placebo Comparator with physiological saline sterile solution|Standard management and physiological saline sterile solution with application every 24 hours, six weeks Intervention.
223614010|NCT01100359|DRUG|carboplatin|
223614011|NCT01100359|DRUG|liposome-encapsulated doxorubicin citrate|
223614012|NCT01100359|OTHER|laboratory biomarker analysis|
223614013|NCT01100359|PROCEDURE|quality-of-life assessment|
223614014|NCT04679974|BEHAVIORAL|Melodic-based Communication Therapy|"General procedures involved in (M.B.C.T.) are as follows: 25 common first words are selected as the targets (e.g., apple, ball, car, dog, cat, eat, go, etc.). Pictures and objects will be used as stimulus items. The top 3-5 incentives as identified by parent survey will be given according to the therapies specific reinforcement schedule. All treatment and evaluation sessions will be videotaped for future/further analysis and verification purposes. For the purposes of the study design, the same 25 words will be used for all participants.~Participants will first listen to the target word set to a melodic tone and rhythm on a compact disc (CD). Clinicians will present the stimulus item (e.g., apple) prior to beginning the steps. Therapy will then progress from clapping and singing the melody to answering sung questions and finally to answering spoken questions with the target word"
223614015|NCT04921228|BEHAVIORAL|Heart rate variability biofeedback|"* 5 days of 3-min HRV readings to establish baseline HRV~* After meeting with study personnel to review HRV biofeedback (BF) practice with the app, participants will be asked to begin HRV BF training for 5 min a day~* Participants will increase the length of HRV BF training by 5 min every few days until they reach 20 min a day of HRV BF training~* Participants will aim for 20 min of daily HRV BF training for 6 consecutive wks out of the 8-wk total BF training protocol~* Study personnel will follow the participants' progress with training via the online portal provided through the Optimal HRV app and have brief (15-min) check-in appts. with participants to discuss how they are experiencing HRV BF, what they find helpful, and barriers to their practice if they are having difficulties~* After completing the 8-wks of BF training (including 2 wks of 5-min titrations to the full 20-min protocol), participants will be asked to take 3-min HRV readings for 5 days to assess post-intervention HRV"
224201660|NCT06327204|DEVICE|940-nm diode laser/ three session|laser therapy using a 940-nm diode laser / three session per week
224201661|NCT01613066|PROCEDURE|Intrabone Allogeneic Transplant|Unrelated single unit intrabone cord blood transplantation
224201662|NCT03166969|PROCEDURE|Holter 21 days|
224201663|NCT05251779|DRUG|Volatile Oil of Cang-Ai|The test group will be given Volatile oil of Cang-Ai (hereafter referred to as CAVO) for inhalation
224201664|NCT05251779|DRUG|Bergamot essential oils|The control group will be given Bergamot essential oils for inhalation.
224201665|NCT00134472|PROCEDURE|Therapeutic mild hypothermia|Keeping 32 - 34 degree celsius of core temperature at least for 72 hours.
223614016|NCT05042583|PROCEDURE|Stellate ganglion block|The probe direction was 30-45 degrees from the sagittal plane of the neck. The anterior nodules of the transverse process of the sixth cervical vertebra were displayed. The important anatomical structures were distinguished, and the internal carotid artery and longus cervical muscle were observed. A 25G, 6cm puncture needle was used with the tip beveled downward, and the needle path and tip were shown under ultrasound. The tip reached the high-echo sieve structure between the carotid artery and longus cervical muscle, and the drug solution was injected after withdrawal without blood and gas . The experimental group was injected with 6ml 0.5% ropivacaine.
223614017|NCT02110095|DEVICE|Picosure Laser System|Picosure Laser System for the Treatment of Unwanted Tattoos
223614018|NCT03580681|OTHER|Plant-based diet|Weekly instructions will be given to the participants in the intervention group about following vegan diet.
223614019|NCT03580681|DIETARY_SUPPLEMENT|Supplement|Unrestricted diet with clinically insignificant amount of omega- 3 oils and vitamin E
223614020|NCT04713956|DRUG|Granulocyte Colony-Stimulating Factor(G-CSF)|G-CSF was administered at 5 ug/kg/day on days-17 to -10. When white blood cell is more than 20G/L, stop using G-CSF.
223614021|NCT04713956|DRUG|Decitabine (DAC)|Decitabine was administered at 20mg/m2/day on days -14 to -10.
223614022|NCT04713956|DRUG|Busulfan (BU)|Busulfan was administered at 3.2 mg/kg/day on days -7 to -4 in G-CSF+DAC+BUCY group, and it was administered at 3.2 mg/kg/day on days -6 to -3 in G-CSF+DAC +BF group .
223614023|NCT04713956|DRUG|Cyclophosphamide (CY)|Cyclophosphamide was administered at 60 mg/kg/day on days -3 to -2.
223614024|NCT04713956|DRUG|Fludarabine (FLU)|Fludarabine was administered at 30 mg/m2/day on days -7 to -3.
223614025|NCT00386243|BEHAVIORAL|Cognitive behavioral therapy|Cognitive behavioral therapy is delivered by phone by a nurse care-manager 6 times over a 12-week period. Sessions last approximately 45 minutes and occur at weeks 14, 16, 18, 20, 22, and 24 of the study.
223614026|NCT00386243|BEHAVIORAL|Pain self-management program|The pain self-management program is delivered by a nurse care-manager during a 12-week period. Sessions are each 45 minutes long and phone-based. They occur at baseline, week 1, week 3, week 6, week 9, and week 12.
223614027|NCT00386243|DRUG|Co-Analgesic Therapy|"Amitriptyline, start at 10-25, titrate to 100 mg Nortriptyline, start at 10-25, titrate to 100 mg~Gabapentin, titrate up to 900-1200 tid venlafaxine, carbemazepine, duloxetine, and/or pregabalin~Cyclobenzaprine, titrate to 10 mg TID fluoxetine, sertraline, citalopram"
223614028|NCT00386243|DRUG|Opioid Analgesics|Tramadol 50 mg BID or TID and titrate to 100 mg QID Acetaminophen/codeine (300mg/30mg). Take 1 or 2 tablets qid prn pain Acetaminophen/hydrocodone (500mg/5mg). Take 1 or 2 tablets qid prn pain Acetaminophen/oxycodone (500mg/5mg). Take 1 or 2 tablets qid prn pain Morphine SR (30mg). Start at 30 mg twice a day (titrate up to 240mg/day if needed) Methadone (5-10mg). Start at 5mg bid; titrate 10mg tid (max 20mg tid)
223614029|NCT04360837|PROCEDURE|alveolar recruitment|incremental and decremental positive end-expiratory pressure alveolar recruitment
223614030|NCT03143504|DIAGNOSTIC_TEST|Skin Testing for Atopic eczema|"FTIR Spectroscopy. This will involve placing the assessment tool briefly in contact with the baby's skin on the arm and thigh.~Transepidermal Water Loss. This will involve placing a probe on the baby's skin for approximately 60 seconds on the arm and thigh. The probe measures the rate of water loss from the baby's skin, which indicates how well it acts as a barrier.~Collection of skin samples. This will involve collecting surface skin samples using small sticky-tape discs to collect only the very top skin cells that are already dead and about to be shed naturally by the body.~Microbial swab. The researchers will rub the baby's skin gently with a wet sterile swab to collect a sample of the microbes on the baby's skin surface.~Buccal swab / saliva sample. The researchers will collect a sample of the baby's saliva using a buccal swab. This sample will be used to analyse the baby's genes (DNA) to assess their inherited risk of eczema."
223614031|NCT02781610|DRUG|Standard of care IV antibiotic(s)|IV antibiotics will be selected by the treating physician following standard of care. Duration of treatment is the assigned intervention.
223614032|NCT01142622|DRUG|Ropivacaine nebulization|Preoperative nebulization of 150 mg of Ropivacaine in the peritoneal cavity.
223614033|NCT01142622|DRUG|Ropivacaine instillation|Preoperative instillation of 150 mg of Ropivacaine in the peritoneal cavity.
223614034|NCT03878680|OTHER|Study questionnaires|"Completion of the International study of Asthma and Allergies in Children(ISAAC)core questionnaires:~1. Core questionnaire on wheezing.~2. Core questionnaire on rhinitis.~3. Core questionnaire on atopic dermatitis."
223614035|NCT03478033|DRUG|Rifampicin|Rifampicin capsules, 150mg
223614036|NCT03478033|DRUG|Rifabutin|Rifabutin capsules, 150mg
223614037|NCT03094533|DRUG|TIVA|total intravenous anesthesia with propofol
224201666|NCT02944682|OTHER|Liquefied petroleum gas (LPG) cookstove|The intervention consists of a high-quality locally-available liquefied petroleum gas (LPG) stove having at least two burners, a continuous supply of LPG fuel for 18 months, and the promotion of stove use on an exclusive basis for cooking. The intervention will be provided free of charge to all intervention households upon enrollment. On a weekly basis, study staff will examine stove condition, perform any repairs necessary, and measure and record weight of LPG tanks in order to anticipate need for refills.
223614038|NCT03094533|DRUG|VIMA|volatile induction and maintenance anesthesia with sevoflurane
223614039|NCT03658733|DRUG|esomeprazole, amoxicillin, tetracycline, furazolidone (only for the first 7 days), colloidal bismuth pectin (for the second 7 days)|Patients will go through a gastroscopy and antimicrobial susceptibility test. Liver and kidney function will be monitored by blood test before and after the treatment. Then, patients will receive a 14-day modified sequential therapy containing esomeprazole for the Helicobacter pylori eradication. The regimen contains a double dose esomeprazole, amoxicillin, tetracycline and furazolidone for the first 7 days, followed by esomeprazole, amoxicillin , tetracycline and colloidal bismuth pectin for the second 7 days.
224201667|NCT05444114|BEHAVIORAL|Mental Exercise|Participants perform a 10 minute mental exercise that is either mindful breathing or listening to a story
224201668|NCT00000667|BIOLOGICAL|gp160 Vaccine (MicroGeneSys)|
224201669|NCT05409157|DRUG|BMS-986166|Specified dose on specified days
224201670|NCT05409157|DRUG|Bisacodyl|Specified dose on specified days
224201671|NCT04736316|BEHAVIORAL|Early CCLAD|Community-based client led antiretroviral therapy delivery groups.
223759856|NCT02983383|PROCEDURE|TAP block group (Group T)|At the end of the operation, patients in Group T in the supine position will have a USI probe placed at the middle point between the costal edge and iliac crest (within the Petit triangle) after necessary antiseptic conditions are ensured. Then after the abdominal muscle layers are observed, the needle (Stimuplex Ultra 22G, 100mm, B.Braun, Germany) tip will be advanced through the muscle layers and pass the fascia, feeling the fascial click, monitored by USI in controlled fashion. After feeling the second click (passing the internal oblique muscle fascia), a test dose of 0.5-1 ml saline will be administered to determine the localization of the needle tip. Then noting the location, with frequent aspiration local anesthetic agent will be administered to the neurofascial plane for TAP block.
223759857|NCT02983383|PROCEDURE|spinal anesthesia|Patients in Group P will have adjuvant added to spinal anesthesia (25 G, Quincke spinal anesthesia needle, Egemen,Turkey).
223759858|NCT06068582|BEHAVIORAL|Strenghtening the brain|Lifestyle intervention containing physical exercise, lifestyle coaching, and cognitive training. The programme contains weekly 30 minutes 1-on-1 fitness and lifestyle coaching with two moments of exercise at home for 20 minutes. Online computerized cognitive training will be done for 60 minutes per week.
223759859|NCT06068582|BEHAVIORAL|Strengthening the mind|Work-focused intervention combining the capability approach and the participatory approach. Together with a work-coach who has been diagnosed with MS themselves, participants will assess important work values, discover challenges participants are facing, think of solutions for these challenges, develop a plan of action and implement these solutions.
223759860|NCT05798390|DRUG|Bempedoic acid and/or its fixed dose combination with ezetimibe|This is a non-interventional study. No study medication will be provided as part of this protocol to the patients. Medications will be as prescribed by the treating physician in line with clinical practice.
223759861|NCT00931749|DEVICE|Low intensity pulsed ultrasound therapy|1 MHz, Spatial Average Intensity of 0.2 W /cm2, pulsed duty cycle 20%, 9.5 minutes, Therapeutic dose= 112.5 J/cm2. Fixed application on the medial side of the knee joint. Three sessions per week, during 2 months ( 24 sessions)
223759862|NCT00931749|DEVICE|Sham Low intensity pulsed ultrasound therapy|The Ultrasound device will not have the transducer´s crystal, so no ultrasonic energy will be provided.
223759863|NCT06591429|RADIATION|Radiotracer [11C]-CS1P1|Radiotracer used in PET/CT scans of the head and neck Dose range: 12-17 mCi
223759864|NCT06591429|RADIATION|Radiotracer [11C]-DPA-713|Radiotracer used in PET/CT scans of the head and neck Dose range:15-20 mCi
223759865|NCT06591429|DRUG|anti-CD20 MS treatment|MS treatment taken indepenently after initial testing
223759866|NCT06591429|RADIATION|Radiotracer [12F]-FDG|used in PET/CT scans of the head and neck Dose: 5-7 mCi
223759867|NCT06809049|BEHAVIORAL|Dalcroze music education|Dalcroze is a type of music education which focuses on free and improvised movement, as well as structure and choreographed sequences. It has been successfully applied to similar populations as an effective, accessible, and sustainable intervention. We hope to use Dalcroze music education to employ a holistic approach to improve the brain-heart symptoms of children with congenital DM1.
223759868|NCT05938790|OTHER|Continuous Fetal Monitoring|Fetal doppler used to monitor fetal heart rate in triage
223759869|NCT05938790|OTHER|Point of Care Handheld Ultrasound|Point of Care Handheld Ultrasound
223759870|NCT06820203|DRUG|Fentanyl and Bupivacaine|Patients will receive premixed intrathecal fentanyl and bupivacaine in the same syringe.
223759871|NCT06820203|DRUG|Fentanyl and Bupivacaine|Patients will receive intrathecal fentanyl and bupivacaine in separate syringes.
223759872|NCT06820203|DRUG|Fentanyl and Bupivacaine|Patients will receive manually mixed intrathecal fentanyl and bupivacaine in the same syringe.
223759873|NCT06335407|DRUG|Dexmedetomidine (DEX) for sublingual (SL) administration (BXCL501) - 40µg|BXCL 501 40µg will be administered orally, as individual films in the Sub Lingual (SL) space.
223759874|NCT06335407|DRUG|Dexmedetomidine (DEX) for sublingual (SL) administration (BXCL501) - 80µg|BXCL 501 80µg will be administered orally, as individual films in the SL space
223759875|NCT00705107|BIOLOGICAL|PegIntron pen (peginterferon alfa-2b; SCH 54031)|PegIntron administered in accordance with approved labeling.
223759876|NCT00705107|DRUG|Rebetol (ribavirin; SCH 18908)|Rebetol administered in accordance with approved labeling
223759877|NCT00417443|DRUG|Clonidine|
223759878|NCT00975533|DEVICE|Tantalus|The TANTALUS System is implanted using minimally invasive procedure (laparoscopy). It uses leads with stitch electrodes to deliver electrical signals to the gastric wall for the treatment of obese subjects with T2DM.
223509604|NCT05349773|PROCEDURE|Pneumatic tourniquet, endoscopic left radial artery harvesting|"Endoscopic radial artery harvesting technique is performed after applying a tourniquet over the distal arm proximally to the elbow. The tourniquet pressure is increased 90 mmHg over the systolic pressure and the tourniquet time will be monitored.~he changes in Heart rate (HR), systolic blood pressure (SBP) and diastolic blood pressure (DBP) will be assessed before and after deflating the tourniquet every 5 minutes for 30 minutes."
223509605|NCT03791697|OTHER|Telehealth 2 week postoperative visit|"The patient randomized into the telephone follow up group, will be contacted, at the pre-scheduled date and time, by the urogynecology clinic nurse. The nurse will utilize a scripted series of postoperative questions, which are consistent with questions asked during our standard postoperative clinic visits.~Vital signs and physical examination will be deferred for the patients in the telephone follow up group.~Any patient responses that are not consistent with a usual postoperative course will be escalated to an in person visit. However, these patients will remain in the group, to which they were originally randomized, for research analysis purposes. (Intent to treat)"
223509606|NCT03004495|DRUG|CHF5259 and CHF6001|b.i.d. for 14 days
223509607|NCT03004495|DRUG|CHF5259 + placebo|b.i.d. for 14 days
223509608|NCT03004495|DRUG|CHF6001 + placebo|b.i.d. for 14 days
223509609|NCT03004495|OTHER|Placebo|b.i.d. for 14 days
223509610|NCT00874016|DEVICE|Airtraq|Intubation using Airtraq
223509611|NCT00874016|DEVICE|Direct Laryngoscopy|Intubation using direct laryngoscopy
223509612|NCT00285714|PROCEDURE|3D stereophotogrammetric imaging|
223509613|NCT00285714|PROCEDURE|3D CT-imaging with cone-beam CT|
223509614|NCT00285714|PROCEDURE|Case report form|
223509615|NCT03902210|BEHAVIORAL|Online Yoga|60 minutes per week of online yoga through Udaya.com
223509616|NCT03902210|BEHAVIORAL|Podcast|60 minutes per week of podcasts
223614040|NCT03658733|DRUG|rabeprazole, amoxicillin, tetracycline, furazolidone (only for the first 7 days), colloidal bismuth pectin (for the second 7 days)|Patients will go through a gastroscopy and antimicrobial susceptibility test. Liver and kidney function will be monitored by blood test before and after the treatment. Then, patients will receive a 14-day modified sequential therapy containing rabeprazole for the Helicobacter pylori eradication. The regimen contains a double-dose rabeprazole, amoxicillin, tetracycline and furazolidone for the first 7 days, followed by rabeprazole, amoxicillin , tetracycline and colloidal bismuth pectin for the second 7 days.
223614041|NCT01568294|DRUG|pomalidomide|2 mg or 4mg oral pomalidomide once per day on Days 1-21 of a 28-day cycle
223614042|NCT05313087|BIOLOGICAL|COVID-19 vaccine|assess response to vaccine
223614043|NCT02956187|BEHAVIORAL|Biofeedback|Functional outlet obstruction will be treated by biofeedback: sessions of biofeedback guided by anorectal manometry combined with instructions for daily exercizing for 4 weeks.
223614044|NCT02956187|DIETARY_SUPPLEMENT|Fiber supplement|3.5 g plantago ovata per day will be administered for 4 weeks.
223759879|NCT00975533|DRUG|Insulin|Insulin treatment will be prescribed, in accordance with the common medical practice at the institute. Dosages will be recorded on a daily basis.
223759880|NCT06858696|DRUG|Mavorixafor|Mavorixafor will be administered per schedule specified in the arm description.
223759881|NCT06660238|OTHER|No interventions|No interventions
223614045|NCT02679287|DEVICE|CLC|The CLC will be deployed with different functionalities at different stages of the trial, resulting in variation in what the subject will be responsible for and what the system will drive.
223614046|NCT03963648|DIAGNOSTIC_TEST|Fractioned Exhaled Nitrogen Oxide measurements|Measurements of Fractioned Exhaled Nitrogen Oxide obtained by blowing into a mouthpiece. The NIOX VERO machine will be used for these measures.
223614047|NCT01840345|DRUG|N-acetyl-l-cysteine|1200 mg BID x 4 weeks
223759882|NCT02132585|PROCEDURE|Speckle tracking echocardiography|
223759883|NCT06923319|DEVICE|Odòn, Kiwi, Simpson skills|time 0, time 1 month and 2 months
223759884|NCT06923956|DRUG|Bempedoic Acid Film Coated Tablet|1 tablet of 180 mg Bempedoic Acid
223759885|NCT06923956|DRUG|Nilemdo® (Bempedoic Acid) Film-coated tablets|1 tablet of 180 mg Bempedoic Acid
223759886|NCT06915493|OTHER|General Anesthesia|Blood glucose measurements during general anesthesia
223759887|NCT05255588|DEVICE|EarlyTect® CRC test|A highly accurate and sensitive real time PCR employing Linear Target Enrichment and Quantitative Methylation-Specific PCR (LTE/qMSP) for measuring SDC2 methylation in stool DNA to detect CRC.
223759888|NCT06108349|DRUG|Cannabidiol|Cannabidiol (CBD) is a non-psychoactive minor cannabinoid component of Cannabis sativa that is emerging as a treatment to mitigate pain, numbness, and tingling associated with peripheral neuropathy. CBD acts through multiple receptors to modulate central and peripheral neuropathic signaling pathways to alleviate pain.
223759889|NCT04909632|DIAGNOSTIC_TEST|Liquid chromatography-mass spectrometry (LC-MS) analysis|The data were acquired by UNIFI software (Waters) and processed by UNIFI and Progenesis QI software. Omics analysis methods, such as principal component analysis (PCA), partial least squares-discriminate analysis (PLS-DA), and orthogonal partial least squares-discriminate analysis (OPLS-DA), were employed to identify the biochemical patterns in tongue coating samples and suggest variables that can be used as biomarkers for diabetes and pre-diabetes.
223614048|NCT06407245|OTHER|Exercise Snacks|"The movement breaks will be individualized to exercise preferences and physical abilities (e.g., fitness, musculoskeletal issues) and adaptable to multiple environments (e.g., home, work) delivered via mobile phone application."
223614049|NCT06407245|OTHER|Placebo Exercise|"The movement breaks will be individualized to exercise preferences and physical abilities (e.g., fitness, musculoskeletal issues) and adaptable to multiple environments (e.g., home, work) delivered via mobile phone application."
223614050|NCT01045694|DRUG|Botulinum Toxin Type A|One-time injection of 50 units of Botulinum Toxin A suspended in 2 mL of normal saline, with approximately 1 mL injected or sufficient quantity to fill joint capsule
223614051|NCT01045694|DRUG|Steroid - Triamcinolone Acetonide|Single injection of 1 - 3 mL of 40mg/mL Triamcinolone acetonide solution
223614052|NCT01045694|DRUG|Lidocaine|Single injection of 1 - 3 mL of 2% Lidocaine
223614053|NCT02226887|PROCEDURE|MESH|"1. Pre-operative :~   It was made by barium enema protocol and transanal endoscopy to rule out anastomotic leaks or strictures contraindicating stoma closure .~2. Surgical technique:~   * Peristomal incision with electrocautery~  * Release the handle of ileum~  * Anastomosis made the with the segment everted sutured by simple manual end to end 3/0 or mechanical side to side (surgeon's election).~  * Return the ileum into the abdominal cavity and the fascial defect is repaired with continuous polydioxanone 1/0 suture respecting 4:1 measurement rule.~  * We add the mesh between the edges of the defect during fascia closure.~  * The skin is sutured purse string style.~3. Post-Op~   * Hospital discharge after verification of normal digestive transit."
223759890|NCT06412978|PROCEDURE|absorbable subcuticular polyglycolic acid staples (INSORB)|Insorb absorbable staples are used for skin closure
223759891|NCT06412978|PROCEDURE|subcuticular, polyglecaprone suture (Monocryl)|Monocryl absorbable staples are used for skin closure
223759892|NCT06867913|DIETARY_SUPPLEMENT|Supplement groupx|"Selenomethionine (e.g., 100 µg/day)~* Myo-inositol (e.g., 600 mg/day or higher)~* Patients on levothyroxine will maintain their current dose (if clinically indicated)."
223759893|NCT06867913|DIETARY_SUPPLEMENT|Supplement groupx|"Selenomethionine (e.g., 100 µg/day)~* Myo-inositol (e.g., 600 mg/day or higher)~* Patients on levothyroxine will maintain their current dose (if clinically indicated)."
223759894|NCT06865885|DRUG|Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL|The intervention arm will receive subcutaneous injection of inclisiran 284mg at the baseline visit, 3 months and 9 month visit.
224312139|NCT02774642|BEHAVIORAL|Hygiene-PE|The investigators have included a non-active sleep control arm (3 Sessions)to allow for the dose response of 14 90 minute sessions. The non-active sleep control condition used in this study is a manualized protocol developed to exclude the active components of standard CBT-I treatment. Hygiene includes presentation of sleep hygiene education and reviewing daily stressors that may impact sleep before starting PE on week 4.
223614054|NCT02226887|PROCEDURE|NO MESH|"1. Pre-operative :~   It was made by barium enema protocol and transanal endoscopy to rule out anastomotic leaks or strictures contraindicating stoma closure .~2. Surgical technique:~   * Peristomal incision with electrocautery~  * Release the handle of ileum~  * Anastomosis made the with the segment everted sutured by simple manual end to end 3/0 or mechanical side to side (surgeon's election).~  * Return the ileum into the abdominal cavity and the fascial defect is repaired with continuous polydioxanone 1/0 suture respecting 4:1 measurement rule.~  * The skin is sutured purse string style.~Post-Op~\- Hospital discharge after verification of normal digestive transit"
223614055|NCT02226887|RADIATION|Post-operative Imaging|Abdominal Tomography 1 year after ileostomy closure
223614056|NCT02226887|RADIATION|Pre-operative Imaging|Contrast study is used to ensure the integrity of the distal anastomosis
223614057|NCT02226887|OTHER|Blood Test and C-reactive protein at 4th day|All patients undergo a Blood Test study of C-reactive protein on day 4 by protocol within the unit before discharge.
223614058|NCT03051308|COMBINATION_PRODUCT|NPT and UW Solution|Tissue preservation solutions for transplantation
223614059|NCT04793113|OTHER|FreshlyFit Meals|FreshlyFit meals are low carbohydrate, high protein meals
223614060|NCT02699710|DRUG|Folic Acid|Folic acid will be administered orally as tablet at a single dose of 5 mg.
223614061|NCT02699710|DRUG|GDC-0853|GDC-0853 will be administered orally as tablet or capsule at a dose of 200 mg.
223614062|NCT02699710|DRUG|Methotrexate|Methotrexate will be administered orally as tablet at a single dose of 7.5 mg.
223614063|NCT02699710|DRUG|Rabeprazole|Rabeprazole will be administered orally as tablet at a dose of 20 mg.
223614064|NCT00374933|DRUG|Non-myeloablative allogeneic stem cell transplant with prophylactic activated DLI|"Prophylactic delayed activated donor lymphocyte infusion (ADLI) after non-myeloablative conditioning and allogeneic peripheral blood cell stem cell transplantation"
223614065|NCT00374933|DRUG|"Prophylactic delayed ADLI"|"Prophylactic ADLI after non-myeloablative conditioning and allogeneic peripheral blood cell stem cell transplantation"
223614066|NCT00374933|DRUG|"Prophylactic delayed activated donor lymphocyte infusion"|"Prophylactic delayed activated donor lymphocyte infusion (ADLI) after non-myeloablative conditioning and allogeneic peripheral blood cell stem cell transplantation"
223614067|NCT04718493|PROCEDURE|Self-expandable metal stent|Endoscopic stenting of intestinal stricture related to Crohn´s disease
223614068|NCT04718493|PROCEDURE|Balloon dilatation|Endoscopic balloon dilatation of intestinal stricture related to Crohn´s disease
223614069|NCT00284219|DEVICE|Transcranial Magnetic Stimulation 10Hz|3\. rTMS subjects will receive 20 trains of rTMS at a rate of 10 Hz for 6 seconds (1200 pulses/session). Pulses will be administered over the left dorsolateral prefrontal cortex, defined as 5 cm anterior and in a parasagital plane to the point of maximum stimulation of the abductor pollicis muscle. Pulse intensity will be set at 100% motor threshold.
223614070|NCT00284219|DEVICE|Magnetic stimulation using a special sham coil|Sham stimulation will be given at the same location as the active, with special sham coil.
223614071|NCT04408040|BIOLOGICAL|Convalescent Plasma|200-425mL convalescent plasma donated by patients previously positive for COVID-19
223614072|NCT02628353|DIETARY_SUPPLEMENT|placebo|1 capsule of placebo product (100 mg carboxymetylcellulose) in one visit
223614073|NCT02628353|DIETARY_SUPPLEMENT|phenolic compound|1 capsule of phenolic compound product (100mg phenolic compound + 100 mg carboxymetylcellulose) in one visit
223614074|NCT06356051|DEVICE|Echocardiography|cardiovascular evaluation
223614075|NCT04740216|BEHAVIORAL|exercise therapy plus jaw device|The mouth-opening rehabilitation exercise lasts for twelve weeks, five days a week, three times a day. Subjects can arrange to perform before or after meals according to personal eating time and preferences. The experimental group performs 30 minutes each time, including 20 minutes of stretching exercises. Ten-minute mouth expander assisted passive exercise.
223614076|NCT04740216|BEHAVIORAL|exercise therapy|the control group performed 20-minute stretching exercises each time.
223614077|NCT05481489|DRUG|Atropine Sulfate|Atropine Sulfate 0.05% Ophthalmic Solution
223614078|NCT02679170|DRUG|Crizotinib|Treatment with crizotinib following routine clinical practice
223614079|NCT01150097|DRUG|Tacrolimus (reduced tacrolimus)|After everolimus whole blood trough levels were confirmed to be in the target range of 3-8 ng/mL, tacrolimus tapering began, achieving a target tacrolimus whole blood trough level of 3-5 ng/mL by 3 weeks after randomization, a level which was maintained for the duration of the study.
223614080|NCT01150097|DRUG|Everolimus (reduced tacrolimus)|Everolimus was started within 24 hours of randomization at a dose of 1.0 mg twice a day (bid, 2 mg daily dose). The dose was adjusted to maintain everolimus trough blood levels between 3-8 ng/mL for the duration of the study.
223614081|NCT01150097|DRUG|Tacrolimus (tacrolimus elimination)|After everolimus whole blood trough levels were confirmed to be in the target range of 3-8 ng/mL, tacrolimus tapering began, achieving a target tacrolimus whole blood trough level of 3-5 ng/mL by 3 weeks after randomization. Tacrolimus elimination was started beginning at Month 4. Tacrolimus was tapered after everolimus whole blood trough levels were within the target range of 6-10 ng/mL. Tacrolimus was completely eliminated by the end of Month 4.
223614082|NCT01150097|DRUG|Everolimus (tacrolimus elimination)|Everolimus was started within 24 hours of randomization at a dose of 1.0 mg twice a day (bid, 2 mg daily dose). The dose was adjusted to maintain everolimus trough blood levels between 3-8 ng/mL until Month 4; beginning with Month 4, the dose was adjusted to maintain everolimus trough blood levels between 6-10 ng/mL.
223614083|NCT01150097|DRUG|Tacrolimus (tacrolimus control)|Tacrolimus trough levels were targeted to be maintained at 8-12 ng/mL until Month 4. At Month 4, tacrolimus whole blood trough levels were decreased to a target trough level of 6-10 ng/mL for the remainder of the study.
223614084|NCT01150097|DRUG|Corticosteroids|For patients in all groups, corticosteroids were initiated at or prior to the time of transplantation according to local practice. Corticosteroids could be used for the duration of the study but could not be eliminated before Month 6. The corticosteroids were not specified in the protocol because they were adminsitered to the participants according to local practice as part of standard of care.
223614085|NCT05276921|OTHER|ultrasound|Quadriceps and abdominal muscle ultrasonography
223614086|NCT02815423|BIOLOGICAL|UCMSCs|Transplatation of umbilical cord mesenchymal stem cells
223614087|NCT02815423|BIOLOGICAL|Percutaneous|Percutaneous injection
223614088|NCT05331586|BEHAVIORAL|Remote Exercise|The pregnant women will perform a home-based structured exercise programme. The exercise will be remotely monitored since the first gestational trimester until delivery
223614089|NCT03383510|OTHER|Climate friendly diet|Participants in the 'Climate friendly' group will be assigned a diet generating low emissions of greenhouse gases. The target is to reduce the participants' diet-related carbon dioxide equivalents (CO2e) to 2.5 kg per person and day, which is approximately a reduction by 50% compared the average CO2e, according to a previous study on diet-related CO2e in Sweden. The participants will be instructed to reduce their consumption of beef and dairy products and increase their consumption of plant-foods i.e. fruits, vegetables, legumes and whole-grain cereals.
223614090|NCT03383510|OTHER|Organic diet|Participants in the 'Organic group' will be assigned an organic diet with very low, or no, content of pesticides. The participants will be instructed to replace at least 50% of their food intake with organic foods.
223614091|NCT03383510|OTHER|Climate friendly and organic diet|The participants in the 'Climate friendly and organic diet group' will be assigned a combination of a climate friendly and organic diet generating low emissions of greenhouse gas and having very low levels of pesticides. The target is to reduce the participants' diet-related CO2e to 2.5 kg per person and day. The participants will be instructed to replace at least 50% of their food intake with organic products.
223614092|NCT03383510|OTHER|Control group (Control diet)|"A conventional diet according to the Nordic Nutrition Recommendations (NNR). The participants will get information about the present dietary guidelines and how they can adhere to the guidelines, for example, by implementing the plate model for meals and learning about recommended levels of intake of macronutrients, micronutrients, fiber and energy."
223614093|NCT04872699|DIAGNOSTIC_TEST|Serology testing, RT PCR|Periodic testings and testings with characteristic symptoms occur
223614094|NCT03483493|BEHAVIORAL|Exposure Response Prevention for tics|The intervention consists of evidence-based interventions adapted from previously published treatment manuals on Exposure and Response Prevention (ERP) and established behavioural intervention for tics protocols. Each of the 10 modules includes age-appropriate texts, animations and exercises. Prticipants are instructed to practice suppressing their tics, this is known as 'response prevention'. Then, with the help of their parent/carer, the participant is instructed to provoke premonitory urges (the urge to tic often felt before the tic is expressed) and try to supress the need to express/demonstrate the tic, this known as 'exposure'.
223614095|NCT03483493|OTHER|Psychoeducation for tics|The comparator intervention reviews the definition of tics, natural history, common presentations, prevalence, aetiology, risks and protective factors and strategies for describing tics to other people etc. Problem-solving and development of expertise in tic disorders is emphasised. The intervention includes strategies for promoting positive behaviours which will be rewarded by a parent as a parallel element to the tic control practice in the behavioural therapy arm. There is no information on tic control within the management package.
223614096|NCT04966949|PROCEDURE|lateral prostate capsule sparing or neurovascular bundles sparing|When resect the bladder and prostate, the lateral prostate capsule or neurovascular bundles will be preserved.
223614097|NCT00992459|DRUG|HPN-100|HPN-100 is a triglyceride that has a similar mechanism of action as NaPBA. It is a liquid with minimal taste and odor. Three teaspoons of HPN-100 (\~17.4mL) delivers equivalent amount of PBA in 40 tablets of NaPBA.
223614098|NCT00992459|DRUG|Buphenyl (NaPBA)|Buphenyl (NaPBA) will be the comparator drug to HPN-100 in this study.
223614099|NCT02154841|BEHAVIORAL|Questionnaire, taste test, visual food test|
223614100|NCT01166204|RADIATION|Radiotherapy|Radiotherapy
223614101|NCT04219904|OTHER|Fludeoxyglucose F-18|Given IV
223614102|NCT04219904|DRUG|Gadobutrol|Given IV
223614103|NCT04219904|PROCEDURE|Magnetic Resonance Imaging|Undergo PET/MRI
223614104|NCT04219904|PROCEDURE|Positron Emission Tomography|Undergo PET/MRI
223614105|NCT01966913|DRUG|Bevacizumab|
223614106|NCT01966913|DRUG|ICE chemotherapy regimen|Etoposide, 300 mg/m²/d in two daily injections at 12-h intervals, Carboplatin, AUC 4/d by injections adjusted daily to the creatinine clearance, Ifosfamide, 2400 mg/m²/d, For 5 consecutive days followed by HSC reinjection and G-CSF (filgrastim- Neupogen) on D11 of each intensive cycle
223614107|NCT05238545|OTHER|gluten-free diet|Diet excluding foods containing gluten.
223614108|NCT02919072|DRUG|Chloroprocaine|The 20 mL epidural anaesthetic solution will be administered as follows: 5 mL of the study anaesthetic solution will be given epidurally and the block will be assessed after 2 minutes from the first injection using cold, pinprick and touch. Then intrathecal placement will be excluded and a further 15 mL of the study anaesthetic solution will be administered epidurally. Two minutes after the start of the second injection, the sensory block will be re-assessed using cold, pinprick and touch. In case of pain or discomfort a 6 mL epidural top-up of the same anaesthetic will be administered.
223614109|NCT02919072|DRUG|Ropivacaine|The 20 mL epidural anaesthetic solution will be administered as follows: 5 mL of the study anaesthetic solution will be given epidurally and the block will be assessed after 2 minutes from the first injection using cold, pinprick and touch. Then intrathecal placement will be excluded and a further 15 mL of the study anaesthetic solution will be administered epidurally. Two minutes after the start of the second injection, the sensory block will be re-assessed using cold, pinprick and touch. In case of pain or discomfort a 6 mL epidural top-up of the same anaesthetic will be administered.
223614110|NCT05286502|DEVICE|fundus photography|color fundus photography
223614111|NCT00543387|DRUG|MK-5108|MK-5108 will be administered orally, every 12 hours (Q12H) during the first 2 days of each cycle. Cycle length will be 14-21 days in Panel 1 and 21 days in Panel 2.
223614112|NCT00543387|DRUG|docetaxel|Docetaxel will be administered intravenously (I.V.) at a dose of 60 mg/m\^2 Q12H during the first 2 days of each 21-day cycle.
223614113|NCT04627207|DRUG|CKD-330 1 Tab. and D085 1 Tab.|Other names: Reference
223614114|NCT04627207|DRUG|CKD-333 1 Tab|Other names: Test
223614115|NCT03611673|OTHER|Smell Test|Oils are used for each of the different scents. Each scent will be put on an aromatherapy inhaling stick.
223614116|NCT04532775|DRUG|magnesium|Preservative free magnesium which was used in the study was prepared in McGuff Pharmaceuticals, Inc. Laboratories and supplied in 50 ml vials containing magnesium (200 mg/ml).
223614117|NCT04532775|DRUG|Methylprednisolone|Methylprednisolone which was used in this study was supplied from E.I.P.I.C.O pharmaceuticals -Egypt under license of UPJOHN s.a Puurs-Belgium (Depo-Medrol).
223614118|NCT04532775|DRUG|Bupivacaine Hydrochloride|local anesthetic drug
223614119|NCT04532775|DRUG|saline 0.9%|solution for intravenous and epidural injection
223614120|NCT00083005|DRUG|docetaxel|
223614121|NCT00083005|DRUG|estramustine phosphate sodium|
223614122|NCT00083005|DRUG|thalidomide|
223614123|NCT04532905|OTHER|Strength Training Exercises Therapy|Five type of exercises: dumbbell bent row over, deadlift, lunge, shoulder press, and squat with each three sets and 10 repetitions. Between each set there will be 2-3 minute rest period and 8-10 minute rest period among each exercise type.
223614124|NCT05109923|DIETARY_SUPPLEMENT|Multi-Ingredient Herbal Supplement|Weeks 0-2 all participants consumed a placebo lead-in period and weeks 2-6 were intervention weeks. Throughout the 8 weeks (2 weeks placebo lead-in and 6 weeks intervention) participants were asked to consume 2 capsules (multi-ingredient supplement) upon waking in the morning and 2 capsules (multi-ingredient supplement) before bed.
223614125|NCT05109923|DIETARY_SUPPLEMENT|Placebo Supplement|Weeks 0-8 all participants consumed a placebo. Throughout the 8 weeks participants were asked to consume 2 capsules (placebo) upon waking in the morning and 2 capsules (placebo) before bed.
223614126|NCT04201613|DEVICE|Robotic exoskeleton|The Kinesiological Instrument for Normal and Altered Reaching Movements (KINARM) robotic exoskeleton used to provide therapy and assessment. The device has framework that supports the arms and the supports are adjustable to ensure a comfortable fit. Motors attached to the framework record shoulder and elbow movements and also move the arms.
223614127|NCT04201613|BEHAVIORAL|Usual Care|This group will receive standard care with no additional therapy.
223614128|NCT01114828|DRUG|OPC-41061|Once-daily oral administration of OPC-41061 at 3.75 mg after breakfast for 7 days
223614129|NCT01114828|DRUG|OPC-41061|Once-daily oral administration of OPC-41061 at 7.5 mg after breakfast for 7 days
223614130|NCT02742545|BEHAVIORAL|MayoExpertAdvisor|Access to MayoExpertAdvisor (MEA) in the electronic medical record (EMR). MEA will provide patient-specific knowledge and treatment suggestions for patients with hyperlipidemia, atrial fibrillation, and/or heart failure via a clickable tab in the Mayo Clinic EMR.
223614131|NCT04520399|OTHER|none intervention|there is no intervention in this study
223614132|NCT00169156|DRUG|Rituximab|375 mg/m2 D1
223614133|NCT00169156|DRUG|Prednisone|40 mg/m2 D1 to D5
223759895|NCT05886296|BEHAVIORAL|Evaluation of the impact of a pre-surgical information session for people who must undergo shoulder rotator cuff surgery on empowerment for their functional rehabilitation process.|To evaluate the effect of the implementation of an information session for people who have to undergo rotator cuff surgery of the shoulder on the post-operative evolution of functionality, quality of life, empowerment and self-efficacy in the three months of the surgical intervention.
223759896|NCT01168024|DEVICE|CINCOR™ System and contrast conservation unit (CCS-1)|Catheter based system to reduce and remove contrast media and contrast modulator to reduce contrast media
223759897|NCT01168024|OTHER|Standard of Care plus peri-procedural hydration|The control group will receive a peri and post-procedural hydration rate.
223759898|NCT06625047|BEHAVIORAL|Assessment|Complete in-person assessment visits
223614134|NCT00169156|DRUG|Doxorubicine|50 mg/m2 D1
223614135|NCT00169156|DRUG|Cyclophosphamide|750 mg/m2 D1
223614136|NCT00169156|DRUG|Vincristine|1,4 mg/m2 D1
223614137|NCT01904045|OTHER|tacrolimus Advagraf|intake of Advagraf once daily for 3 months
223614138|NCT01904045|OTHER|tacrolimus Prograf|intake of Prograf twice daily for 3 months
223614139|NCT05429398|DRUG|Linperlisib Tablet|"1. Linperlisib Tablet Oral administration, once a day, for 21 consecutive days as a treatment cycle;~2. Camrelizumab for Injection 200 mg intravenously every 3 weeks. Camrelizumab should be administered prior to Linperlisib."
223614140|NCT00940498|DRUG|PF-05212384 (also known as PKI-587)|Intravenous dosing once weekly infusion
223614141|NCT02903498|DRUG|UFT|UFT 360mg/m2 qd po d1-14, q3w
223614142|NCT04826939|DEVICE|PFDx device and leva device|Participants will use the leva device, PFDx device and undergo ultrasound measurements during pelvic floor motion to compare the three measurements.
223614143|NCT03683953|OTHER|mesenchymal stem cells therapy|mesenchymal stem cells treatement of BPD for safety and effect evaluation0.9% sodium chloride incontrol group
223614144|NCT03683953|DRUG|0.9% sodium chloride|0.9% sodium chloride in control group
223614145|NCT00256802|DEVICE|MR-angiography, GTN|
223614146|NCT00748423|DRUG|Nitric Oxide|NO in inhalation for 3 days
223614147|NCT00748423|DRUG|Placebo|Placebo in inhalation for 3 days
223614148|NCT03589027|DRUG|Levonorgestrel two rod sub-dermal implant|Levonorgestrel (75 mg/rod), 2 rods (150 mg) inserted subdermally
223614149|NCT03589027|DRUG|Rilpivirine|Oral ripilvirine 25mg once daily
223614150|NCT03589027|DRUG|Darunavir+Ritonavir|Oral DRV/r 600/100mg twice daily
223614151|NCT02425059|PROCEDURE|Irreversible electroporation (IRE)|Irreversible Electroportion For Unresectable Rectal Neoplasms guide with ultrasound or/and CT.
223614152|NCT02425059|DEVICE|NanoKnife|
223614153|NCT00549445|DRUG|Azithromycin|250 mg daily
223614154|NCT00549445|DRUG|Placebo|Daily
223614155|NCT00158041|DRUG|Amifostine administered subcutaneously|
223614156|NCT03160820|BIOLOGICAL|Measles, mumps and rubella Combined Vaccine, Live|Subjects will be inoculated one dose of MMR vaccine and collected blood samples before and after vaccination.
223614157|NCT03963843|BEHAVIORAL|Guided ICBT|An 8-week internet- delivered cognitive behavioural therapy (ICBT) will be delivered to participants who have sustained a spinal cord injury. In addition to the online program, a health educator with experience delivering ICBT will provide support by email once a week. The health educator will spend approximately 15 minutes per week/per client.
223759899|NCT06625047|OTHER|Questionnaire Administration|Ancillary studies
223759900|NCT06625047|OTHER|Telemedicine Visit|Complete telehealth assessment visits
223759901|NCT06625047|DRUG|Temozolomide|Given PO
223614158|NCT03963843|OTHER|SCI rehabilitation mental health education|Participants will receive information provided to SCI patients in usual care at specialized SCI rehabilitation units (the Spinal Cord Injury Rehabilitation Evidence (SCIRE) Community handouts available at: https://scireproject.com/community/handouts/). The lessons will include information on spinal cord injury rehabilitation: 1)spinal cord injury basics, 2)mental health after SCI, 3)pain after SCI, 4)understanding rehabilitation 5)summary of lessons through an online platform over 8 weeks. A health educator will check in with participants once a week to answer any content related questions. The health educator will spend approximately 15 minutes per week/per client.
223614159|NCT03932760|BEHAVIORAL|UPLIFT Program|UPLIFT is based on cognitive behavioral therapy and mindfulness-based practices. Participants meet by videoconference using any electronic device (laptop, tablet, smart phone) from their own home.
223614160|NCT03932760|BEHAVIORAL|Attention Control Group|Program is based on standard prenatal, childbirth, infant feeding, and parenting education curriculum. Participants meet by videoconference using any electronic device (laptop, tablet, smart phone) from their own home.
223614161|NCT00791752|DRUG|AZD4017|ascending single doses (start dose 2 mg), oral suspension
223614162|NCT00791752|DRUG|Placebo|Placebo
223614163|NCT04499625|PROCEDURE|Sinus floor elevation|
223614164|NCT04499625|DEVICE|Sinus floor elevation using an ultrasonic device|
223614165|NCT03944512|DRUG|Pravastatin|20 mg Pravastatin taken daily
223614166|NCT03944512|OTHER|Placebo|Identical appearing placebo pill
223614167|NCT02373774|DEVICE|Ultrasound|Patients will receive an ultrasound prior to lumbar puncture procedure to help visualize and select spinal interspace.
223614168|NCT00513435|DRUG|saracatinib|Given PO
223614169|NCT00513435|OTHER|laboratory biomarker analysis|Correlative studies
223614170|NCT03707470|DEVICE|Custom fitted compression garments (CF)|Custom fitted compression garments (Isobar, Manchester, UK) designed to provide 35 mmHg at the ankle and \>20 mmHg at the mid-thigh (equivalent to European class 2 compression garments)
223614171|NCT03707470|DEVICE|Standard-sized compression garments (SSG)|Off-the-shelf, standard-sized garments (2XU, Campbelltown, Australia), typically providing pressures equivalent to European grade 1 compression or below (5 - 10 mmHg at both the ankle and thigh)
223614172|NCT03707470|PROCEDURE|Sham ultrasound (CON)|Sham ultrasound using an unplugged machine. Sham treatment for 5 minutes on each of the thighs, calves and hamstrings
223614173|NCT06337708|BEHAVIORAL|Smart Walk|Smart Walk is a culturally tailored, Social Cognitive Theory-based multi-component smartphone delivered physical activity (PA) promotion intervention that delivered through the Smart Walk application, virtual physical activity coaching, and text messages. The Smart Walk smartphone application includes four key features: 1) personal profile pages, 2) culturally relevant multi-media physical activity promotion modules, 3) discussion boards, and 4) physical activity self-monitoring/tracking feature that integrates with Fitbit activity monitors for participants to track their daily, weekly, and monthly activity. Virtual physical activity coaches will actively engage and facilitate group-based dialogue among participants on the app discussion boards and provide individualized, one-on-one PA coaching via telephone or commercially available app-based video teleconferencing software (i.e., FaceTime, Zoom, Google hangouts).
223614174|NCT06337708|BEHAVIORAL|Fitbit|This intervention group will receive a Fitbit activity monitor and be encouraged to use the commercially available device to increase physical activity.
223614175|NCT00927212|DRUG|AS101 ointment|Twice daily topical application
223614176|NCT01695356|DRUG|290-400 nm sunscreen|A broad UV spectrum sunscreen will be applied every 3 hours for 12 weeks. The affected surface will be covered with a 2 mg/cm\^2 layer of the product as indicated on the affected areas of the face.
223614177|NCT01695356|DRUG|290-800 nm sunscreen|A UV-visible light spectrum sunscreen will be applied every 3 hours for 12 weeks. The affected surface will be covered with a 2 mg/cm\^2 layer of the product as indicated on the affected areas of the face.
223614178|NCT01825967|OTHER|C-reactive protein|measured C-reactive protein in all patients with acute diverticulitis
223614179|NCT03053843|DIETARY_SUPPLEMENT|Mediterranean diet plus extra virgin olive oil|The patients in the intervention group will receive 1 liter of EVOO per week free of charge and dietary advice on how to follow a Mediterranean diet with contacts every two months. Dietary intervention will be carried out by nutritionists with previous experience in the PREDIMED study. All of them were registered, trained and certified for developing the PREDIMED intervention protocol that is similar to the one to be carried out in this study. The theoretical sessions with patients about dietary education shall be conducted in telephone form, using the internet and sending comprehensive written material to their homes that includes recipes, shopping lists, menus and explanations of typical food in the Mediterranean diet
223614180|NCT02380911|OTHER|Educational Intervention|"Physicians belonging to the PCC randomized to the intervention group receive a 3-component intervention: education workshop, Educational Outreach Visits and a mHealth application uploaded to their smartphones.~In addition, 2 intervention support tools are used at the intervention clinics:~1. A web-based platform that is tailored to send SMS messages for lifestyle modification, and prompts and reminders for clinic appointments are used to improve medication adherence for patients.~2. On-site training to pharmacist assistants at the first EOV is given by physician trainers focused on counseling to improve medication adherence among patients initiating statin therapy and at each patient visit to the clinic to refill drug prescriptions."
223614181|NCT01453010|OTHER|Self-directed Upper Limb SaeboFlex Training|"Participants undergo a 12 week self directed upper limb training programme with the SaeboFlex upper limb orthosis. Training consists of a maximum of 3 x 45 minute sessions a day.~Participants are closely monitored at least once a week by a saebo-trained therapist."
223614182|NCT00559247|DRUG|BMS-650032 or Placebo|Oral, Once daily, Single Dose
223759902|NCT05798286|OTHER|Quantra|The study plans to collect 2 additional 3 mL citrate tubes of venous blood in addition to the platelet and blood counts.
223759903|NCT05798286|OTHER|Control|The study plans to collect 1 additional 3 mL citrate tubes of venous blood in addition to the platelet and blood counts at each time.
224314296|NCT01505153|BIOLOGICAL|pbi-shRNA STMN1 LP|This is a Phase I safety trial of bifunctional shRNA-STMN1 (pbi-shRNA™STMN1) BIV (bilamellar invaginated vesicle) lipoplex (LP), pbi-shRNA™ STMN1 LP administered by a single intratumoral (IT) injection. Patients will accrue in 4-patient escalation cohorts using a modified Fibronacci escalation schema at a starting intratumoral dose of 0.010 mg/kg of DNA through a dose of 0.053 mg/kg DNA intratumoral / single dose.
224312140|NCT03947944|PROCEDURE|SMILE using manifest refraction planning|The treatments of astigmatism were planned using either the manifest refraction (manifest refraction group) or the vector planning method (vector planning group). The surgery was performed with standardized techniques with triple centration technique using the 500-KHz VisuMax system (Carl Zeiss Meditec AG, Jena, Germany). The superior cap depth was set as 120 µm, and the length of the side cut was set to 2 mm. Once the anterior (upper) and posterior (lower) planes of the lenticule were defined, the anterior and posterior interfaces were dissected using a microspatula with a blunt circular tip and extracted with microforceps. The integrity of the lenticule was assessed subsequently. The treatment plan for the vector planning group involved a combination of refractive astigmatism with 60 % emphasis and corneal astigmatism with 40 % emphasis.
223614183|NCT01091012|DRUG|Sildenafil 20mg oral vs Sildenafil 10mg intravenous|2 arms to comparation: Sildenafil 20mg oral vs intravenous Sildenafil 10mg
224201672|NCT05421715|OTHER|TELEDUC-DIAB|"* Systematic monthly remote monitoring between traditional face-to-face consultations by a medical researcher using Kidia and My Diabby digital devices:~  * With downloading by the adolescent of all data on My Diabby platform (clinical data from diabetes monitoring)~ * Evaluation of adverse events related to the treatment of diabetes (hospitalizations and concomitant treatment)~ * Analysis of data collected via My Diabby and Kidia: glycemic balance, captured data, connection frequency, alerts and alarms, diabetes knowledge)~ * The proposal of a therapeutic education session according to the needs of the adolescent via the Kidia application~ * Treatment adaptation~* A follow-up in case there is an alert identified by the teenager, the relative or My Diabby/caregiver~  * The medical orientation of the patient according to the needs identified~ * A proposal for a therapeutic education session according to the needs of the adolescent via the Kidia application"
223614184|NCT04523883|RADIATION|postoperative radiotherapy|postoperative radiotherapy with a dose of 60-66Gy
223614185|NCT04523883|DRUG|JS001|JS001 240mg every three week
223614186|NCT01925547|DIETARY_SUPPLEMENT|Micellar curcumin|80 mg micellar curcumin (oral) three times a day for six weeks
223614187|NCT01925547|DIETARY_SUPPLEMENT|Placebo|Only the excipients (without curcumin) used to prepare the curcumin micelles are given as placebo.
223614188|NCT01646606|PROCEDURE|Intermittent oxygen monitoring|Oxygen saturation and vital signs will be measured intermittently at a frequency of every 4 hours by the bedside nurse through the child's hospital stay until discharge. The nurse will attach the probe to the electrical cord which is connected to the monitor. For each measurement, the duration of monitoring will be until a steady wave form is present on the oxygen saturation monitor, indicating a reliable measurement (consistent with current standard of practice). The nurse will document the maximum and minimum reading during the period. The nurse will detach the probe from the electrical cord, leaving the probe attached to the child. Hence, the child's probe will be attached to the electrical cord intermittently as well.
223614189|NCT01646606|PROCEDURE|Continuous oxygen monitoring|Oxygen saturation will be measured continuously through the child's hospital stay until discharge. Every 4 hours the nurse will complete and document a set of vital sign measurements, including oxygen saturation level, in keeping with current clinical practice. The reading will be displayed on the bedside monitor in the participants' room. At the completion of vital signs measurement, the nurse will not detach the electrical cord from the probe. Hence, the child's probe will be attached to the electrical cord continuously as well.
223614190|NCT04489472|DIETARY_SUPPLEMENT|Beet-it Juice|Patients will ingest 1 bottle (70ml) of beet-it juice (98% concentrated beet juice, 2% lemon juice containing 400 mg/6.5 mmol nitrate).
223614191|NCT04436172|PROCEDURE|spinal anesthesia|The spinal anesthesia was given by a trained anesthetist in an equipped room, after all aseptic measures. A 20 gauge intravenous cannula was inserted for maintaining a peripheral line and 0.9% normal saline was used for loading the patient. The pulse and blood pressure were monitored non-invasively. The median approach was utilized and intrathecal space was accessed via 25 gauge Quiincke bevel(Becton Dickinson/Pakistan ) through L4-L5. A block was performed by using 5 mg hyperbaric bupivacaine (Abocain 0.5%/Abbot) after ensuring swirling. Block height was monitored via pinprick test after every three minutes, for 20 minutes until there was no progression. The couple was left alone. The couples received prior training and were explained precautions.
223614192|NCT01050244|DIETARY_SUPPLEMENT|Whole soybean soymilk powder|
223614193|NCT01050244|DIETARY_SUPPLEMENT|Whole milk powder|
223614194|NCT00672906|BEHAVIORAL|Group Parent Training|Skills group for parents that provides psychoeducation for eating disorder and skills in behavior management, self-regulation, and emotion regulation.
223614195|NCT00672906|BEHAVIORAL|Maudsley Family Therapy|Family therapy specifically adapted for the treatment of adolescent anorexia nervosa.
223614196|NCT00000706|DRUG|Quinine sulfate|
223614197|NCT00000706|DRUG|Probenecid|
223614198|NCT00000706|DRUG|Zidovudine|
223614199|NCT05641636|DIAGNOSTIC_TEST|12-lead ECG, hormone and lipid blood tests, echocardiography (Echo-CG), cardiopulmonary exercise testing (CPET) and pulse wave analysis|Echocardiography - standart protocol. Pulse wave characteristics were obtained using finger photopletysmography (PPG) (Angioscan-01, AngioScan-Electronics) from an infrared light sensor. Endothelial function was also evaluated using occlusion index and shear rate during post-occlusive reactive hyperemia (PORH). CPET was conducted on a treadmill (Intertrack 8100, Schiller, Switzerland) with a breath-by-breath algorithm of gas exchange analysis (Cardiovit CS-200 Ergo-Spiro, Schiller, Switzerland), using Bruce, modified Bruce or Naughton protocols depending on the level of physical tolerance.
223614200|NCT03320720|OTHER|Home Treatment|Patients with acute mental illness in need of inpatient care are treated at their houses by a mobile and multiprofessional care team if their health condition permits.
223614201|NCT03320720|OTHER|Treatment-as-usual|Patients with acute mental illness in need of inpatient care are treated in a psychiatric clinic.
223614202|NCT01081899|OTHER|The LCP-I Program|The LCP-I Program is a continuous quality Improvement Program of end-of-life care implemented by a Palliative Care Unit (PCU) in a hospital Medical Ward.
223614203|NCT01043991|DRUG|Darbepoetin alfa|
223614204|NCT01043991|DRUG|Placebo|
223614205|NCT04019899|DIETARY_SUPPLEMENT|control group|"* 2 g Myo-Inositol, 50 mg Alpha-Lactalbumin and 200 µg folic acid (1 sachet/day in the morning): from the first day of the menstrual cycle until 14 days after embryo transfer. If pregnancy occurs, until the 12th week of gestation.~* 600 mg Myo-Inositol, 200 µg folic acid, 1 mg melatonin (1 soft capsule/day in the evening): from the first day of the menstrual cycle until hCG administration. If pregnancy occurs, until the 12th week of gestation."
223614206|NCT04019899|DIETARY_SUPPLEMENT|study group|"* 2 g Myo-Inositol, 50 mg Alpha-Lactalbumin and 200 µg folic acid (1 sachet/day in the morning): from the first day of the menstrual cycle until 14 days after embryo transfer. If pregnancy occurs, until the 12th week of gestation.~* 600 mg Myo-Inositol, 200 µg folic acid, 1 mg melatonin (1 soft capsule/day in the evening): from the first day of the menstrual cycle until hCG administration;~* 600 mg Myo-Inositol, 200 µg folic acid, 1 mg melatonin, 50 µg vitamin D3 as cholecalciferol (1 soft capsule/day in the evening) substitutes the previous treatment at hCG administration and lasted until 14 days after embryo transfer. If pregnancy occurs, until the 12th week of gestation."
223614207|NCT01361971|PROCEDURE|Hyperbaric Oxygen Treatment|Participants will undergo 4 treatments of hyperbaric oxygen. Each treatment consists of 90 minutes compression at 2 atmospheres of pressure, with 30 minutes decompression back to 1 atmosphere, during this time, patients will be treated with 100% Oxygen delivered via a hood system.
223614208|NCT02302365|DEVICE|Spectra Optia® Apheresis System|White Blood Cell Depletion
223614209|NCT00227721|DRUG|Docetaxel|40 mg/m2, 30 minute IV infusion, Days 1 and 8, Every 21 days
223614210|NCT00227721|DRUG|Gemcitabine hydrochloride|800mg/m2, 30 minute IV infusion, Days 1 and 8, every 21 days
223614211|NCT01848665|DRUG|Indomethacin|
223759904|NCT06881693|BEHAVIORAL|Internet-delivered Cognitive Behavioural Therapy|The Wellbeing Course for New and Expecting Parents (WCNEP) is an adaptation of the Wellbeing Course (developed and evaluated at Macquaire University, Australia) and the Wellbeing Course for New Moms (a Canadian adaptation of the Wellbeing Course for new moms). The WCNEP is a transdiagnostic ICBT intervention designed for perinatal parents experiencing depression and/or anxiety, and will be offered by the Online Therapy Unit, a unit providing routine care ICBT services in Canada. The WCNEP will be evaluated in phases; phase 1 will evaluate the course for birthing parents only and phase 2 will evaluate the course for birthing and non-birthing parents. Therapist support will be offered for 8 weeks, with the possibility to extend the support to 12 weeks. Therapists will spend \~15 minutes/week communicating with each client, via secure messages. Phone calls will only be made if there is a significant clinical issue requiring attention that the therapist feel cannot be addressed in messages.
223759905|NCT07027865|BEHAVIORAL|Sip & Snack Better (SSB) Intervention|Participants (teens 12-16 years) and their parent or legal guardian will participate in a 12-week health coaching intervention to reduce added sugar intake. Parents and teens will participate in 6 health coaching sessions (in weeks 1, 3, 5, 7, 9, and 12; 30-45 minutes, online via Zoom). Teens will participate in four in-person groups sessions (in weeks 2, 4, 6, and 8) and receive text-messages to reinforce intervention content.
223759906|NCT07027865|OTHER|Sip & Snack Better (SSB) Tech-Only Comparison|Participants (teens 12-16 years) and their parent or legal guardian will participate in a 12-week technology-only comparison arm. Parents and teens will receive information about added sugar intake and healthy eating once via email or text message (based on preference) in weeks 1, 3, 5, 7, 9, and 12. Teens will receive informational text messages 3 times per week .
223759907|NCT06722443|DIETARY_SUPPLEMENT|Probiotic|Treatment with capsules with 10\^9 CFU/ day of Limosilactobacillus fermentum CECT5716 during 6 months
223759908|NCT06722443|DIETARY_SUPPLEMENT|Prebiotic|Treatment with capsules 500 mg/capsule/day of olive leaf extract, containing 35% oleuropein during 6 months
223759909|NCT06722443|DIETARY_SUPPLEMENT|Synbiotic|A pill with a combination of prebiotic and probiotic at the same doses during 6 months
223759910|NCT02777125|DEVICE|Metered Dose Inhaler|A metered dose inhaler (MDI) is a small hand held pressurized canister device that contains both a medication, in this case albuterol, and a propellant. Pressing the device delivers 90mcg of albuterol. The MDI is attached to a spacer device, which is a one way holding chamber which allows the medication to be delivered over a series of breaths.
223759911|NCT02777125|DEVICE|Breath Actuated Nebulizer|The breath actuated nebulizer (BAN) device is a device that converts liquid medication, in this case albuterol, into an aerosol. It consists of a mouthpiece, a medication reservoir, and connective tubing that attaches to a compressor. This BAN device delivers medication when the patient takes a breath, but it can be attached to a mask and set to continuous nebulization for patients that are not able to coordinate their breaths.
223759912|NCT01748253|DRUG|Telmisartan-amlodipine tablet administration group (morning)|Oral-administration of one telmisartan-amlodipine tablet once a day upon morning for 12 weeks
223759913|NCT01748253|DRUG|Telmisartan-amlodipine tablet administration group (bedtime)|Oral-administration of one telmisartan-amlodipine tablet once a day at bedtime for 12 weeks
223759914|NCT06923709|DRUG|amiloride|5mg twice daily for 7 days
223614212|NCT01848665|DRUG|Placebo|
223614213|NCT00431561|DRUG|AP 12009 10 µM|10 µM AP 12009 (trabedersen), intratumoral infusion, every other week, 11 cycles, maximum 21 weeks
223614214|NCT00431561|DRUG|AP 12009 80 µM|80 µM AP 12009 (trabedersen), intratumoral infusion, every other week, 11 cycles, maximum 21 weeks
223614215|NCT00431561|DRUG|temozolomide or PCV|temozolomide: capsules, up to 200 mg/sqm/day, 5 days per cycle; PCV (procarbazine, CCNU, vincristine): standard regimen
223614216|NCT00431561|DEVICE|Drug delivery system for administration of AP 12009|Drug delivery system for Convection Enhanced Delivery consists of a portable pump with drug reservoir and infusion line. Main implanted parts are the port access system and the intratumoral catheter.
223614217|NCT00431561|PROCEDURE|Placement of Drug Delivery System|Surgery for placement of intratumoral catheter and subcutaneous port access system as per routine clinical practice. Stereotactical catheter placement controlled by CT.
223759915|NCT06923709|DRUG|Placebo|1 tablet twice daily for 7 days
224314297|NCT04962386|DRUG|Hormone replacement therapy|HRT women were treated with an estrogen-progesterone combination therapy packaged with estradiol tablets/estradiol and dynamic progesterone (Abbott Health Products BV, Weesp, the Netherlands).Take this medicine once a day.A course of treatment was defined as 28 days of continuous treatment.One white tablet containing 1mg of estradiol was taken daily for the first 14 days and one gray tablet containing 1mg of estradiol and 10 mg of dynamic progesterone was taken daily for the remaining 14 days.
224314298|NCT00126282|BEHAVIORAL|behavior therapy|
223614218|NCT02608658|OTHER|Medical food, EnteraGam (Serum-Derived Bovine Immunoglobulin)|"Visit 1, screening (Day 0): At this visit, the investigators of the study will:~* Obtain demographic information, as will past medical history and medications.~* Perform a physical examination.~* Collect samples for labs~* Administer the Chronic Liver Disease Questionnaire (CLDQ)~* Perform a lactulose breath test~From Day 0 to 8 weeks: subjects will take the medical food twice daily~Visit 2, Week 4 (Day 28 +/- 3): At this visit, the investigators of the study will:~* Perform a physical examination~* Collect and record returned investigational product~* Dispense investigational product and instruct again regarding use~* Record any adverse events~Visit 3, Week 8 (Day 56 +/- 3): At this visit, the investigators of the study will:~* Perform a physical examination.~* Collect samples for labs~* Administer the Chronic Liver Disease Questionnaire (CLDQ)~* Perform a lactulose breath test"
223614219|NCT05699850|OTHER|ARTIFICIAL INTELLIGENCE (AI)|ARTIFICIAL INTELLIGENCE (AI) APPLICATIONS IN REPRODUCTIVE MEDICINE
223614220|NCT05324111|DEVICE|Kardia 6L|The Kardia 6L has CE marking. The purpose of this study is to extend the use of this device by a simple modification using existing equipment in the department. The device will be connected to the left leg electrodes using standard clinical crocodile clips and the other electrode applied to the chest in V1 and V6 positions to acquire the modified V1 and V6 leads
223614221|NCT02568735|DRUG|Dexketoprofen|After total hip replacement surgery patient were given either etoricoxib or dexketoprofen
223614222|NCT02568735|DRUG|Etoricoxib|After total hip replacement surgery patient were given either etoricoxib or dexketoprofen
223614223|NCT04974255|OTHER|Measuring of fibrosis in thyroid specimen and measuring of Anti-tTG in serum samples|Examination of pathology specimen and laboratory measuring
223614224|NCT05298202|BIOLOGICAL|Capsaicin|application of capsaicin gel from shoulder to wrist and mid thigh to ankle
223614225|NCT05298202|BIOLOGICAL|Control Gel|application of hypoallergenic gel from shoulder to wrist and mid thigh to ankle
223614226|NCT05298202|OTHER|Exercise|treadmill walking 3.5 mph at 5% grade
223614227|NCT05298202|OTHER|Hot environment|38°C, 60% relative humidity
223614228|NCT06053853|BIOLOGICAL|Diphtheria Antitoxin|"Dosage form: Solution for injection~Dosage:~1. Perform sensitivity tests, and desensitization if necessary.~2. Give the entire treatment dose of antitoxin IV (or IM) in a single administration (except for series of injections needed for desensitization).~3. The recommended DAT treatment dosage ranges (pediatric and adult) are:~   * Pharyngeal or laryngeal disease of 2 days duration 20,000 - 40,000 unit~  * Nasopharyngeal disease 40,000 - 60,000 unit~  * Extensive disease of 3 or more days duration, or any patient with diffuse swelling of neck 80,000 - 100,000 unit~  * Skin lesions only (rare case where treatment is indicated) 20,000 - 40,000 unit"
223614229|NCT03190395|PROCEDURE|CPVI Group|CPVI Group:The ablation strategy of Circumferential pulmonary vein isolation (CPVI)will be operated on 60 patients with paroxysmal atrial fibrillation.
223614230|NCT03190395|PROCEDURE|CPVI+LARA Group|CPVI+LARA Group: The ablation strategy of Circumferential pulmonary vein isolation combine with Left atrium roofline ablation(CPVI+LARA) will be operated on 60 patients with paroxysmal atrial fibrillation.
223614231|NCT01875159|DRUG|Caffeine citrate 6 mg/kg/day|Comparison of caffeine citrate 6 mg/kg/day versus no caffeine (usual care) on extent of intermittent hypoxia at 35, 36, 37, 38, 39, and 40 weeks postmenstrual age.
223614232|NCT03943615|DRUG|Voxelotor|
223614233|NCT01029184|OTHER|commercialized complete cereals|complete cereals suitable for the weaning period
223614234|NCT01029184|OTHER|commercialized complete cereals with additional ingredient|complete cereals suitable for weaning period
223614235|NCT02575755|DRUG|Azithromycin plus piperaquine phosphate|
223614236|NCT02575755|DRUG|Sulfadoxine-pyrimethamine|
223614237|NCT00361192|PROCEDURE|biopsy of temporal artery|
223614238|NCT00408122|PROCEDURE|PET/CT scan and EUS|
223614239|NCT04480840|DRUG|PLN-74809|PLN-74809
223614240|NCT04480840|DRUG|Placebo|Placebo
223614241|NCT06086509|OTHER|Music|Children were played music during computerized tomography.
223614242|NCT01456286|DRUG|sapropterin|two weeks of treatment: 5 mg/kg per day during first week 10 mg/kg per day during second week
223614243|NCT01916135|RADIATION|[18F]-SKI-249380|
223614244|NCT01916135|PROCEDURE|PET/CT scan|PET scans will be performed immediately, at approximately 90 minutes, and optionally at approximately 3 hours after injection of the radiotracer. This includes an initial 30-minute PET scanning period, performed. At each subsequent time-point, a 30 minute axial body image is acquired. Images will be acquired on a state-of-the-art PET-CT scanner. A 30-45 minute scanning time-period is typical for clinical PET studies. A low-dose CT will be obtained immediately-prior to PET imaging, at each time-point.
224201673|NCT05838352|OTHER|telerehabilitation exercise|The telerehabilitation program is as follows; Respiratory exercises: Chest, diaphragmatic breathing and lower basal breathing exercises will be performed with 10 repetitions.Resistance exercises: Strengthening exercises will be performed on the major muscle groups of the upper and lower extremities, using medium-hardness resistance exercise band. During the exercises, the patient's fatigue and dyspnea levels will be questioned using the Borg scale, and breaks will be given when necessary. Exercises 1st-3rd weeks with 10 repetitions; 15 repetitions in weeks 4-6; In the 7th and 8th weeks, it will be done as 2 sets of 10 repetitions.Posture exercises: Basic posture exercises will be explained. Tabletop movements will be taught in clear, various positions that concern the spine, scapula and pelvis.Gait training: In line with the data obtained from the 6-minute walking test, gait training will be given on flat ground at 60% workload (land-based walking).
224201674|NCT05838352|OTHER|Control Group|The surveys in the outcome measures section will be applied once as a pre-test. Children in both groups will receive conventional institutional rehabilitation in the rehabilitation center. Children in the conventional rehabilitation group, which is the control group, will only be included in the supervised program. This group will not receive a telerehabilitation program.
224201675|NCT05270629|OTHER|Antegrade and retrograde anastomoses|Patients who had received both antegrade and retrograde anastomoses.
224201676|NCT05270629|OTHER|Antegrade-only anastomoses|Patients who had received antegrade-only anastomoses.
224201677|NCT00900276|OTHER|immunologic technique|
224201678|NCT00900276|OTHER|laboratory biomarker analysis|
224201679|NCT00900276|OTHER|mass spectrometry|
224201680|NCT00605839|DEVICE|GlucoPak|We will be giving participants Glucopak devices and monitoring them closely over the 6 month period.
224314299|NCT00126282|DRUG|D-Cycloserine|
223614245|NCT01916135|OTHER|Blood draws|Blood will be drawn at the multiple time points for pharmacokinetic \& metabolite analyses of 18F-SKI-249380. We anticipate these time points to be approximately 1, 5, 15, 30, and 90 minutes and 3 hours (optional), post-injection.
223614246|NCT01389882|PROCEDURE|neurally adjusted ventilatory assist (NAVA) ventilator mode|Neurally adjusted ventilatory assist (NAVA) utilizes the electrical activity of the diaphragm (EAdi) to trigger and cycle-off breaths, and therefore presents a means of bypassing the ventilator circuit, and the inherent delays with pneumatic triggering. This is a processed signal, which is not artificially influenced by changes in muscle length, chest wall configuration, and/or lung volume. It represents the summation of muscle motor unit recruitment and/or firing rate, and correlates with phrenic nerve activity. In this mode, the amount of support pressure is coupled with the magnitude of the EAdi. The proportion of support pressure to EAdi (NAVA level) is adjustable.
223614247|NCT03923257|DRUG|177Lu-DOTA-tyr3-OCTREOTATE|This is a peptide receptor radiotherapy that targets somatostatin receptors on tumor cells.
223614248|NCT03923257|PROCEDURE|Peptide Receptor Radiotherapy (PRRT)|PRRT is internal radiation that is individually dosed according to patient body surface area, kidney function and bone marrow status.
223614249|NCT00436995|DRUG|Darbepoetin Alfa|Administered IV or SC, Q2W at the following unit doses: 10, 15, 20, 30, 40, 50, 60, 80, 100, 130, 150, 200 or 300ug. Initial Q2W dose calculated from pre-enrollment QW doses. Doses titrated to achieve target Hb.
223614250|NCT03014739|OTHER|Supersonic ShearWave Elastography|ShearWave Elastography (SWE) is part of routine ultrasound examination
223614251|NCT03095079|DRUG|recombinant human endostatin|"Cisplatin:dose was based on patient's weight and could be adjusted for weight change,75 mg/m\^2 by IV infusion separated in 3 different days Dacarbazine:250mg/m2,administered by intravenous (IV) infusion on the 1 to 5 day of each cycle~Hr-endostatin:dose based on body surface area as 15mg/m2,continuous intravenous infusion from day 1 to day 14"
223614252|NCT04640233|BIOLOGICAL|Gam-COVID-Vac|Vaccine for intramuscular injection
223614253|NCT04640233|OTHER|Placebo|Placebo comparator
223614254|NCT00107692|BEHAVIORAL|Physical activity and diet|
223614255|NCT00961181|DEVICE|Paclitaxel Releasing Balloon|Percutaneous coronary intervention with paclitaxel releasing balloon
223614256|NCT05532865|OTHER|Blood samples|80 ml of blood samples collected at inclusion and at 18 months
223614257|NCT05532865|OTHER|Stool samples|A stool sample for collection of digestive microbiota at inclusion
223614258|NCT05532865|OTHER|Skin swab samples|A skin swab sample for collection of skin microbiota at inclusion and at 18 months
223614259|NCT05532865|OTHER|Questionnaires on quality of life, pain and disability|At inclusion and each year for 5 years
223614260|NCT05532865|OTHER|Skin biopsies|At inclusion and 18 months
223614261|NCT06151548|DRUG|THYROX (Atlantic krill oil).|The daily content of krill oil is 2000 mg, including omega-3 fatty acids 350 mg, EPA - 240 mg, DHA - 110 mg, phospholipids - 800 mg, astaxanthin 200 mg.
223614262|NCT06151548|DRUG|Placebo|The control capsules will be made of olive oil of equal size and color.
223614263|NCT02654886|OTHER|Resistance Exercise Training|"Resistance Exercise Training: knee extension and elbow flexion each 3 times per week 3 sets each session; 10 reps/set for 6 months~Respiratory muscle strength training: 25 repetitions -twice daily, 6 days/week for 6 months"
223614264|NCT00754702|DRUG|Vinorelbine|Vinorelbine p.o (50 mg 3 times a week) until disease progression or appearance of unacceptable toxicity
223614265|NCT00754702|DRUG|Lapatinib|Lapatinib p.o every day without interruption disease progression or appearance of unacceptable toxicity
223614266|NCT01120366|DRUG|Tocilizumab plus methotrexate|Tocilizumab 8mg/kg 4weeks (i.v.) plus methotrexate up to 52weeks.The dosage of MTX will be fixed at least 24 weeks from the start of the study.
223614267|NCT01120366|DRUG|Tocilizumab|tocilizumab 8mg/kg/4weeks (i.v.) up to 52weeks.
223614268|NCT00280917|DRUG|CF101|
223614269|NCT00769886|DRUG|Ketotifen/naphazoline|One drop of ketotifen/naphazoline in study eye at visit 3 and visit 4.
223614270|NCT00769886|DRUG|Ketotifen|One drop of Ketotifen in study eye at visit 3 and visit 4.
223614271|NCT00769886|DRUG|Naphazoline|One drop of naphazoline in study eye at vist 3 and visit 4.
223614272|NCT00769886|DRUG|Vehicle|One drop of vehicle in study eye at visit 3 and visit 4.
223614273|NCT04367831|DRUG|Enoxaparin Prophylactic Dose|"Prophylactic dose anticoagulation (per Columbia University Irving Medical Center (CUIMC) Guidelines):~If eGFR ≥30 mL/min (stable kidney function):~1. BMI \< 40 kg/m2: Enoxaparin 40 mg SC daily~2. BMI 40 - 50 kg/m2: Enoxaparin 40 mg SC q12h~3. BMI \> 50 kg/m2: Enoxaparin 60 mg SC q12h"
223614274|NCT04367831|DRUG|Heparin Infusion|Unfractionated heparin infusion at 10 units/kg/hour with goal anti-Xa 0.1 -0.3U/mL.
223614275|NCT04367831|DRUG|Heparin SC|Unfractionated heparin at 5000-7500 units subcutaneous (SC) every 8 hours.
223614276|NCT04367831|DRUG|Enoxaparin/Lovenox Intermediate Dose|If estimated glomerular filtration rate (eGFR) ≥ 30 mL/min: enoxaparin 1mg/kg subcutaneous (SC) daily.
223614277|NCT04581486|OTHER|Optimal-Massive Intervention|Multimodal intervention based on 3 main measures: a) optimal fluid viscosity adaptation (with Nutilis Clear®), b) optimal nutritional support with a triple adaptation of food (texture, (Nutilis Clear®)) caloric and protein content, organoleptic) + ONS depending on nutritional status and evaluation and c) optimal treatment of oral hygiene (tooth brushing + antiseptic mouthwash + professional dental cleaning).
223614278|NCT04581486|OTHER|Control (standard clinical practice)|Standard clinical practice (fluid adaptation with Nutilis Powder® and simple texture adaptation (for solids (Nutilis Powder®))
223614279|NCT03871062|PROCEDURE|Two step anesthesia|conjunctival cul-de-sac anesthetized with 0.5% proparacaine hydrochloride drops three times + 2% lidocaine 0.2 ml subconjunctival injection
223614280|NCT03871062|PROCEDURE|topical anesthesia|conjunctival cul-de-sac anesthetized with 0.5% proparacaine hydrochloride drops three times
223614281|NCT01841905|OTHER|Observational Study|Observational Study
223614282|NCT05620095|DEVICE|drug-coated balloon|To evaluate the effectiveness and safety of drug-coated balloon angioplasty for infrapopliteal artery lesions in patients with CLTI.
223614283|NCT04796363|PROCEDURE|Erector Spinae Plane Block with Bubivacaine|Erector Spinae Plane Block with Bubivacaine 0.25% or 0.125% before breast cancer surgery
223614284|NCT04796363|PROCEDURE|Standard General Anaesthesia|Standard General Anaesthesia without ESPB
223509617|NCT02890186|DEVICE|Narcotrend|the investigator modified the effect-site target concentrations by NI.If NI fall down to 46 and keep 46 more than 30 seconds,propofol and remifentanil were infused as feedback automatically to achieve the target NI of 26-46.
224201681|NCT00605839|DEVICE|Cell Phone|We will provide cell phones and access to the clinic to facilitate communications
224201682|NCT00605839|OTHER|Usual Care|This intervention was usual care, without either device.
224201683|NCT02204839|DRUG|Basal insulin dose|
224201684|NCT00002949|DRUG|paclitaxel|Paclitaxel (qwk, starting dose of 20mg/m2 with planned dose escalation increments of 5mg/m2)
224201685|NCT00002949|DRUG|vinorelbine tartrate|Vinorelbine (qwk, 10, 15, 20 or 25 mg/m2),
223509618|NCT02890186|OTHER|experience|the investigator modified the effect-site target concentrations of both drugs without minimum or maximum concentration limits without using the Narcotrend monitor only depend on the experience of anesthesiologist.
223509619|NCT01181128|DRUG|Factor VIII (rFVIIIFc)|
223509620|NCT01181128|DRUG|Advate®|
223509621|NCT02813720|RADIATION|HR-pQCT High resolution peripheral quantitative CT-scan|"HR-pQCT is a powerful device providing low dose irradiation already used in bone field.~It is a high resolution tool (voxel size=82µm) that the investigators adapted to look after the distal joint involved by onycholysis. An anteroposterior scout view is used to define the region of interest (ROI), which spanned from the top of the distal phalange to the distal part of the intermediate phalange in order to contain the distal joint of the target finger. Images are then analysed for erosions, osteophytes and volumetric bone mineral density."
223509622|NCT01362270|DEVICE|Verum Acupuncture|DOSAGE: 25 acupoints per session FREQUENCY: 2 sessions per day DURATION: 5 days
223509623|NCT01362270|DEVICE|Sham Acupuncture|DOSAGE: 25 acupoints per session FREQUENCY: 2 sessions per day DURATION: 5 days
223509624|NCT02802085|DEVICE|VEGA Knee|TKA
223509625|NCT04681937|COMBINATION_PRODUCT|Subacromial Injection (hyaluronic acid) + Physical Therapy.|arm1: sodium hyaluronate (4ml) arm2: platelet-rich-plasma (4ml) arm3: methylprednisolone acetate (1ml methylprednisolone acetate + 3 ml serum saline) arm4: serum saline (4ml) The same physical therapy procedure will be applied to all arms after injection.
223509626|NCT04681937|COMBINATION_PRODUCT|Subacromial Injection (Platelet-Rich-Plasma) + Physical Therapy.|arm1: sodium hyaluronate (4ml) arm2: platelet-rich-plasma (4ml) arm3: methylprednisolone acetate (1ml methylprednisolone acetate + 3 ml serum saline) arm4: serum saline (4ml) The same physical therapy procedure will be applied to all arms after injection.
223509627|NCT04681937|COMBINATION_PRODUCT|Subacromial Injection (methylprednisolone acetate) + Physical Therapy.|arm1: sodium hyaluronate (4ml) arm2: platelet-rich-plasma (4ml) arm3: methylprednisolone acetate (1ml methylprednisolone acetate + 3 ml serum saline) arm4: serum saline (4ml) The same physical therapy procedure will be applied to all arms after injection.
223509628|NCT04681937|COMBINATION_PRODUCT|Subacromial Injection (Serum Saline) + Physical Therapy.|arm1: sodium hyaluronate (4ml) arm2: platelet-rich-plasma (4ml) arm3: methylprednisolone acetate (1ml methylprednisolone acetate + 3 ml serum saline) arm4: serum saline (4ml) The same physical therapy procedure will be applied to all arms after injection.
223509629|NCT03855371|DRUG|Decitabine|20mg/m2/d, intravenously, d1-d5, q4w
223509630|NCT03855371|DRUG|Arsenic Trioxide|0.16mg/kg/d, intravenously, d1-d5, q4w(maximum dose: 10mg/d)
223509631|NCT03299335|OTHER|Blood collection|assay of CPK and anti-cN-1A antibodies
223509632|NCT00185900|DRUG|Magnesium Sulfate|Preterm labor treatment with Magnesium Sulfate 4 gram bolus followed by 2 gm per hour infusion. 2 Gm bolus as needed and/or rate increase up to 4gm per hour were allowed at the discretion of the treating physician.
223509633|NCT00185900|DRUG|Nifedipine|Preterm labor treatment with Nifedipine 10 mg. sublingually every 20 minutes for three doses, followed by 20 mg. orally every 4 or 6 hours.
223509634|NCT01077895|PROCEDURE|CVVH|"CVVH is started using following parameters:~* Blood flow is started at 150 mL/min~* Anticoagulation: none, heparin or low molecular weight heparin according to local protocols in study centers.~* In both groups: dialysis dose of 25 mL/kg body weight administered using both pre- and postdilution~* Substitution fluid temperature is started at 37°C and adjusted in function of patient body temperature (which is maintained at 35-37°C)"
223509635|NCT01077895|PROCEDURE|ultrafiltration|"ultra filtration is started at 100 mL/h and increased according to following protocol~* Ultrafiltration is increased by 100 mL/h after 2h and subsequently by 100mL/h (until a maximum of 500mL/h) every 4h unless:~* Vasopressor or inotrope medication dose is increased by \> 25% (provided mean arterial pressure remains constant at 65 mmHg or another target value specified by treating physician according to standard of care)~* When above condition is not met UF should be kept constant and a passive leg raising test or stroke volume variation measurement should be performed. If SVV \> 10% or PLR is positive 100mL of albumin 20% solution or 250 mL of Hydroxyethyl Starch 130/0.4 solution is administered according to treating physician at a maximum of 4 times per 24h~* If there is no improvement after 2 colloid administration rounds, UF should be stopped for 4h and restarted at half the rate it was set at when discontinued."
223509636|NCT01077895|PROCEDURE|ultrafiltration control group|ultrafiltration is set at 100 mL/h (and fluid administration is titrated to approach 100 mL /h)
223509637|NCT02390375|DRUG|DW-0929|5/10mg
223509638|NCT02390375|DRUG|DW-0929|10/10mg
223509639|NCT02390375|DRUG|DW-0929|20/10mg
223509640|NCT02390375|DRUG|Rosuvastatin|5mg F/U study: DW-0929 5/10mg
223509641|NCT02390375|DRUG|Rosuvastatin|10mg F/U study: DW-0929 10/10mg
223509642|NCT02390375|DRUG|Rosuvastatin|20mg F/U study: DW-0929 20/10mg
223509643|NCT05418920|PROCEDURE|left-opening single-flap technique|left-opening single-flap technique
223509644|NCT05418920|PROCEDURE|double-flap group technique|double-flap group technique
223512436|NCT05411900|DRUG|BoNT-A|"A vial of 500 units of BoNT-A will be reconstituted with 2 mL of saline solution (0.9%) and 1 mL of lidocaine solution (2%) to obtain a final concentration of BoNT-A of 166.6 units/mL.~Injections will be repeated at sites 1-1.5 cm apart (0.1 ml, 16.6 units per site), up to 20 sites (333 units).~To reduce pain caused by the injection, lidocaine and prilocaine cream will be applied to the skin area 60 min before the procedure. Additionally, ice could be applied for a few seconds (4-8) before each injection of 16.6 units of BoNT-A.~Injections will be repeated at week 0 and week 12.~The active treatment and placebo solutions will be transparent and indistinguishable to maintain treatment blindness."
223614285|NCT04662359|DIAGNOSTIC_TEST|Ultrasound Assessment|Patients will undergo an ultrasound scan to assess the severity of their rheumatoid arthritis.
223614286|NCT04601935|BIOLOGICAL|LCAR-BCX cells product|In this study, LCAR-BCX CAR+ cells will be evaluated at 5 dose levels including 0.25 × 10\^6 cells/kg, 0.5 × 10\^6 cells/kg, 1.0 × 10\^6 cells/kg, 2.0 × 10\^6 cells/kg, and 4.0 × 10\^6 cells/kg, with 0.25 × 10\^6 cells/kg as the starting dose, to determine RP2D for LCAR-BCX cell therapy
223614287|NCT04513756|BEHAVIORAL|Community Reinforcement Approach|Community Reinforcement Approach (CRA) as an intervention consisting of nine sessions (each session consists of 45-minutes). Treatment is primarily based upon the guidelines by Robert Meyers and William Miller (2001). The techniques included in the sessions are functional analysis, sobriety sampling, behavioral skills, and relapse prevention techniques. The first three sessions of the intervention are based upon rapport building, induction of the rationale of CRA and Functional analysis of usage and non-usage behavior.
223614288|NCT05414890|DIAGNOSTIC_TEST|CBA-TSA|Compare the specificity, sensitivity, and clinical correlation between CBA and CBA-TSA, in detecting AQP4, MOG, and NMDAR IgG
223614289|NCT03973359|BEHAVIORAL|Hygienic recommendations|Recommendation of protective behaviours such as frequent hand washing and avoiding risky behaviours such as kissing young children on the mouth or cheeks and sharing utensils, foods etc.
223759916|NCT06890481|DEVICE|Upper-limb planar robotic intervention|"The training sessions consist of three phases.~In the first, the therapist provides the patient with the necessary information for the session.~In the second, patients undergo a pre-scenario phase, in which the parameters of the robot (ratio between virtual and physical space, viscosity, and weight) are adjusted.~In the third phase, the scenario is used for motor and cognitive exercise.~Specifically, the scenario consists of a reaching exercise involving sequential stimuli placed in different spatial areas. The scenario has adaptive characteristics regarding:~* Type of stimuli~* Size of the stimuli~* Visual and auditory cues~* Number of stimuli, related to the space in which they are displayed.~Each of these characteristics is adjusted differently according to the scenario's difficulty level. Regardless of the difficulty level, the scenario provides assistance as needed through a guided path (both visual and movement-based) toward the target."
223759917|NCT06897293|PROCEDURE|Modified Broström procedure + Suture tape augmentation operation|Patients with CLAI and GJL will accept the Modified Broström + Suture tape augmentation operation
223759918|NCT06897293|PROCEDURE|Modified Broström procedure operation|Patients with CLAI and GJL will accept the Modified Broström procedure operation
223759919|NCT06832813|DEVICE|cTBS|"Continuous θ-burst stimulation (cTBS) is characterized by plexus stimulation. The stimulation intensity was 80% resting motor threshold (RMT) at 50Hz of intra plexus pulse while the frequency of inter plexus pulse is 5Hz, the duration was 40s, and the number of stimulation pulses was 600. Two groups of stimulation were repeated in each cerebellar dentate nucleus with an interval of 5 min in each group.~1. Enhanced phase：participants received cTBS treatment for a total of 5 times a week for 2 weeks；~2. Consolidation phase：participants received cTBS treatment for a total of twice a week (at least 24 hours apart) for 8 weeks；~3. Maintenance phase：participants received cTBS treatment for a total of once a week for 8 weeks."
223759920|NCT06245473|DIAGNOSTIC_TEST|blood sample|During the blood test planned as part of the care an additional blood tube with a volume of 6mL will be takeń in an EDTA tube.
223759921|NCT06897579|DRUG|Carboplatin for injection/cisplatin for injection + etoposide injection + benmelstobart injection + Anlotinib hydrochloride capsule|Carboplatin for injection inhibits DNA synthesis, thereby preventing cancer cell division and reproduction/Cisplatin for injection binds to DNA, interfering with DNA replication and transcription processes, Thus inhibiting tumor cell proliferation/etoposide injection interferes with the division process of cancer cells to inhibit their growth and spread/Bemosubebezumab injection is a humanized recombinant anti-Programmed cell death ligand 1 (PD-L1) monoclonal antibody/Anlotinib hydrochloride capsule is a tyrosine kinase inhibitor.
223759922|NCT06897579|DRUG|Carboplatin for injection/Cisplatin for injection + etoposide injection + Tislelizumab injection|Carboplatin for injection inhibits DNA synthesis and thus prevents the division and reproduction of cancer cells/Cisplatin for injection binds to DNA and interferes with the DNA replication and transcription process, thereby inhibiting the proliferation of tumor cells/etoposide injection interferes with the division process of cancer cells to inhibit their growth and spread/Tislelizumab injection is a humanized recombinant anti-PD-1 monoclonal antibody.
224312141|NCT03947944|PROCEDURE|SMILE using vector planning|The treatments of astigmatism were planned using either the manifest refraction (manifest refraction group) or the vector planning method (vector planning group). The surgery was performed with standardized techniques with triple centration technique using the 500-KHz VisuMax system (Carl Zeiss Meditec AG, Jena, Germany). The superior cap depth was set as 120 µm, and the length of the side cut was set to 2 mm. Once the anterior (upper) and posterior (lower) planes of the lenticule were defined, the anterior and posterior interfaces were dissected using a microspatula with a blunt circular tip and extracted with microforceps. The integrity of the lenticule was assessed subsequently. The treatment plan for the vector planning group involved a combination of refractive astigmatism with 60 % emphasis and corneal astigmatism with 40 % emphasis.
224312142|NCT00376038|DRUG|GSK189075 oral tablets|
224312143|NCT00376038|DRUG|metformin tablets|
224312144|NCT01529710|DRUG|Myrrh|Subjects will be treated by Mirazid as 600 mg oral (Soft Gelatin Capsules) for 6 consecutive days or 40mg/Kg body weight of Praziquantel as a single oral dose. Subjects will be evaluated for success of treatment at 12 weeks of treatment. Evaluation will be done by examining urine or stool samples for Schistosomiasis including egg counts for the positive cases.
223614290|NCT02966808|BEHAVIORAL|cognitive and behavioural questionnaires|
223614291|NCT04903782|DIAGNOSTIC_TEST|Family-based whole genome sequencing|"1. Germline whole-genome family-based sequencing and variant identification.~2. Multidisciplinary Meeting case discussion.~3. Recommendation of referral to a Cancer Genetics Clinic for further investigation, follow up and/or genetic counselling.~4. Psychosocial study to analyse the impact of germline sequencing on families."
223614292|NCT03036410|DEVICE|standard telephone setting|without streaming function
223614293|NCT03036410|DEVICE|DECT|cordless telephone (streaming to both hearing devices)
223614294|NCT03036410|DEVICE|EasyCall|accessories for Bluetooth capable mobile telephones (streaming to both hearing devices)
223614295|NCT03036410|DEVICE|DuoPhone|streaming function, which provides the speech signal to both ears
223614296|NCT04839016|DRUG|SHR-1314|SHR-1314
223614297|NCT04839016|DRUG|Placebo|Placebo
223614298|NCT01957878|BIOLOGICAL|ProCervix|ProCervix consists of two recombinant adenylate cyclase (CyaA) proteins, CyaA-HPV 16E7 (C16-1) and CyaA-HPV 18E7 (C18-1) in a 50/50 ratio (C16C18-2 Ag mixture). ProCervix is adjuvanted by Aldara™, a cream containing 5% of imiquimod
223614299|NCT01957878|BIOLOGICAL|Placebo|Placebo matching ProCervix and adjuvanted by Aldara™, a cream containing 5% of imiquimod
223614300|NCT05313035|BIOLOGICAL|SARS-CoV-2 protein subunit recombinant vaccine|candidate vaccine manufactured by PT. Bio Farma
223614301|NCT05313035|BIOLOGICAL|placebo|the placebo is NaCl injection manufactured by PT. Bio Farma
223614302|NCT03654183|DIAGNOSTIC_TEST|Indocynine green clearance test|Indocyanine green clearance was determined by non-invasive pulse spectrophotometry (NIHON KOHDEN™; Pulse Dye Densito-Graph Analyzer, Japan).
223614303|NCT03967145|BEHAVIORAL|Determining quality of life|Quality of Life
223614304|NCT06317571|BEHAVIORAL|fertility support education|In the first module, female reproductive organs, the occurrence of pregnancy and the effect of stress on fertility are explained to women using models and training booklets. The effects of affirmation, which is one of the ways to positively affect the consciousness, and imagination, visualization and relaxation techniques, which are ways to positively affect the subconscious, on body and reproductive functions are explained. In the second module, women and their partners were also trained, and the effect of lifestyle on reproductive health was explained through the second module training booklet. In the third module, an example of a one-week program in which they could apply the methods described in the training before starting their treatments was introduced. In the fourth module, treatment process was explained to women and the practices described in the training were shared, which they could do to relax during this process.
223614305|NCT03955835|DEVICE|Treatment with Credo® stent together with the NeuroSpeed® PTA balloon catheter.|Self-expandable Credo® stent together with NeuroSpeed® PTA balloon catheter. Credo® and NeuroSpeed® are already CE approved products, for which within ACUTE an additional new indication shall be examined.
223614306|NCT00443417|DRUG|SK-PC-B70M|dosage, frequency
223614307|NCT02416843|OTHER|Consumption of a mixed meal|Participants will consume a mixed meal and postprandial responses in blood and adipose tissue will be investigated over 6 hours and compared to baseline.
223614308|NCT03833024|DRUG|Micronized Purified Flavonoid Fraction|After randomization (1:1 with stratification by centre) patients will receive 1000 mg of oral MPFF (Venixxa, one 500mg tablet BID) for 6 months, in addition to their usual PTS and DVT treatment
223614309|NCT03833024|DRUG|Placebo|After randomization (1:1 with stratification by centre) patients will receive an oral placebo (one tablet BID) for 6 months, in addition to their usual PTS and DVT treatment
223614310|NCT01794988|BEHAVIORAL|Group Cognitive Behavioral Therapy|Each CBT session will last 90 minutes and will teach participants specific skills to better cope with chronic pain. These skills will include breathing exercises, distraction, and relaxation techniques.
223614311|NCT01794988|BEHAVIORAL|Pain Education|Subjects will receive mailed educational materials to their homes on a weekly basis. Weekly materials will contain information about the nature of chronic back pain, treatment options, exercises and stretching techniques for maintaining strength and flexibility, and proper protection for a healthy back. Pain education is the standard of care for most outpatient clinics.
223614312|NCT01794988|BEHAVIORAL|Therapeutic Interactive Voice Response|Therapeutic Interactive Voice Response as a daily self monitoring and relapse prevention tool with didactic reviews and practices of recorded skills and monthly feedback based on daily calls.
223614313|NCT01794988|BEHAVIORAL|NO TIVR|Control - no intervention
223614314|NCT02599363|DRUG|Ribociclib (LEE011)|
223614315|NCT02599363|DRUG|Paclitaxel|
223614316|NCT01174407|OTHER|cd 35, cd21, cd55|Blood drawing/ 10ml/ once- duration of 1 day of full examination of the patient
223759923|NCT05980572|DRUG|Glenohumeral joint and subacromial space triamcinolone injections|"All patients will receive both glenohumeral joint and subacromial space injections. The injections will consist of a solution containing 1 ml of 40 mg/ml triamcinolone acetonide and 1 ml of 1% lidocaine in each site. The glenohumeral joint injection will be performed blindly using an anterior approach. The needle will be inserted medially to the head of the humerus, located approximately 1 cm lateral to the coracoid process, and directed posteriorly at a slight superior and lateral angle.~Patients will be educated on how to perform the 7 sets of frozen shoulder exercise. Subjects will be advised to perform all the exercises to a point that they may feel tightness but not painful and hold to the point for 2-3 seconds."
223614317|NCT00359996|BEHAVIORAL|health disparities collaborative|The HDC incorporates rapid quality improvement (QI), a chronic care model, and best practices. This study determines if the HDC improves diabetes care and whether more intensive interventions with additional learning sessions for health centers, provider training in behavioral change, and patient empowerment materials enhance care further.
223614318|NCT00359996|OTHER|No additional educational sessions|
223614319|NCT05460455|DRUG|Recombinant Humanized Anti-IL-36R Monoclonal antibody and Placebo|HB0034 and Placebo
223614320|NCT01161186|DRUG|nab-paclitaxel, gemcitabine, capecitabine|{nab-paclitaxel: Intravenous, 100 to 150 mg/m2 over 30 minutes once per cycle.} {gemcitabine: Intravenous, 750 to 1000 mg/m2 at 10mg/m2/minute once per cycle.} {capecitabine: oral, 500 to 1000 mg/m2 b.i.d. 7 days per cycle}
223759924|NCT05980572|DEVICE|App-assisted exercise|Patients will be educated on how to perform the 7 sets of frozen shoulder exercise. Subjects will be advised to perform all the exercises to a point that they may feel tightness but not painful and hold to the point for 2-3 seconds. Then the APP group will suggest performing the exercise from APP education The APP intervention group will be guided through the exercises using the mobile app, while the conventional group will be provided with a printed pamphlet illustrating the exercises.. Each set exercise will have 10 repetitions and investigators recommend 4 sessions per day.
223759925|NCT05980572|DRUG|Nonsteroidal anti-inflammatory drugs (aceclofenac)|All patients will be prescribed two weeks of nonsteroidal anti-inflammatory drugs (aceclofenac) .
223614321|NCT03919539|DIAGNOSTIC_TEST|5hmc testing|NGS
223614322|NCT01727596|OTHER|taping|Briefly, the patella was manually displaced medially, and maintained in the position by Tex Tape (Kinesio Holding Corporation, Albuquerque, NM)
223614323|NCT01729286|DEVICE|PriMatrix Moist Wound Therapy|sharp debridement, PriMatrix, a dressing regimen that maintains a moist wound healing environment, and offloading
223614324|NCT01729286|OTHER|Standard of Care Moist Wound Therapy|sharp debridement, a dressing regimen that maintains a moist wound healing environment, and offloading
223614325|NCT04220216|OTHER|H4H fitness program|4 weekly, 1 hour exercise sessions
223614326|NCT02431988|PROCEDURE|Leukapheresis|Patients will undergo leukapheresis prior to pre-conditioning chemotherapy to provide the immune cells required to produce the therapeutic product.
223759926|NCT04145778|OTHER|6-minute walk test|The 6-minute walk test is performed as part of routine practice for patients with BMDS to assess patients' overall endurance. In order to compare patients' global endurance with controls, this walking test will also be offered to 50 of the healthy subjects already recruited in the study.
223614327|NCT02431988|DRUG|Cyclophosphamide|Patients will receive a standard pre-conditioning regime with cyclophosphamide 60mg/kg/day IV over 1 hour for 2 days (day-7 and day-6).
223614328|NCT02431988|DRUG|Fludarabine|Fludarabine 25mg/m2/day IV over 15/30 minutes for 5 days (Day-5 to day-1).
223614329|NCT02431988|BIOLOGICAL|CAR19 T-Cells|"The CAR19 T-cells are to be administered on day 0 at the dose specified by the Cancer Trials Centre (CTC) at the time of registration.~Three dose cohorts are planned:~* Dose Level 1: 2x105 CAR19 T-cells/kg~* Dose Level 2: 1x106 CAR19 T-cells/kg~* Dose Level 3: 5x106 CAR19 T-cells/kg"
223614330|NCT02960516|DEVICE|MRI of 3.0T|Diffusion Tensor Testing for peripheral nerve monitoring
223614331|NCT01102088|RADIATION|Radiation Therapy|"Simultaneous integrated boost (SIB) used in combination with a fixed dose of radiation (180 cGy in 28 fractions = 5040 Gy PTV dose). Two dose levels (210 cGy and 225 cGy each in 28 fractions) of SIB will be considered in the phase I part of the study, starting at 210 cGy in 28 daily fractions.~For the phase II part of the study once the MTD has been achieved proton therapy will be allowed. Treatment dose will be identical to that of the photon treatment where the PTV is treated to 50.4 Gy(RBE) (RBE=1.1) while the CTV is boosted to 63 Gy(RBE) in 28 fractions."
223614332|NCT05449184|PROCEDURE|Balloon Eustachian Tuboplasty with Tympanostomy Tube Insertion|Under local or general anesthesia, insert a balloon into one Eaustachian tube and inflate it for up to two minutes. The balloon is then removed. Subsequently, pierce the tympanic membrane in the front and lower quadrants, suck the tympanic effusion, and then insert a tympanic ventilation tube. The tube will be removed 6 months later.
223614333|NCT05449184|PROCEDURE|Tympanostomy Tube Insertion|Under local or general anesthesia, pierce the tympanic membrane in the front and lower quadrants, suck the tympanic effusion, and then insert a tympanic ventilation tube. The tube will be removed 6 months later.
223614334|NCT03685630|DRUG|Brivaracetam|"* Pharmaceutical form: Solution for injection~* Concentration: 10 mg/ml~* Route of administration: Intravenous injection"
223614335|NCT05563610|DRUG|Amoxicillin 500mg|Patients screened to be low risk of penicillin allergy will be randomized to receive amoxicillin dose or not
223614336|NCT00210717|DRUG|paliperidone palmitate|
223614337|NCT04562181|OTHER|Bispectral index and qCON/qNOX monitoring|This study will characterise the bispectral index data and qCON/qNOX index data in 30 patients during the operation and first postoperative night
223614338|NCT04890379|DRUG|Dimethyl fumarate|Dimethyl fumarate 240mg orally twice daily for 3 consecutive days
223614339|NCT04890379|DRUG|Placebo|Placebo 240mg orally twice daily for 3 consecutive days
223614340|NCT01317758|DRUG|AS03 Adjuvant|Adjuvant/diluent manufactured by GlaxoSmithKline (GSK)
223614341|NCT01317758|OTHER|Phosphate Buffered Saline (PBS) diluent|Placebo/diluent provided by sanofi pasteur
223614342|NCT01317758|BIOLOGICAL|Sanofi H5N1 Antigen|Subvirion inactivated monovalent influenza A/H5N1 (Hemagglutinin (HA) of A/Indonesia/05/2005) virus vaccine manufactured by sanofi pasteur, at 2 doses levels 21 days apart, administered at 3.75, 7.5, or 15mcg, with either AS03 adjuvant or PBS.
223614343|NCT00000801|DRUG|Filgrastim|
223759927|NCT06867939|DIETARY_SUPPLEMENT|liposomal curcumin|Liposomal Curcumin, 400-600 mg/day taken orally for 12 weeks, plus standard of care.
223759928|NCT06867939|DIETARY_SUPPLEMENT|Liposomal Curcumin|Liposomal Curcumin, 400-600 mg/day taken orally for 12 weeks, plus standard of care.
224201686|NCT00002949|RADIATION|radiation therapy|Radiation therapy (Total pelvic RT of 45 Gy in 1.8-Gy daily fractions, 85 Gy in cervical cancer patients using intracavitary brachytherapy, 70 Gy in patients treated with interstitial brachytherapy)
224201687|NCT06343142|OTHER|Nuts|Isocaloric meal with nuts
223614344|NCT00000801|DRUG|Vincristine sulfate|
223614345|NCT00000801|DRUG|Doxorubicin hydrochloride|
223614346|NCT00000801|DRUG|Cyclophosphamide|
223614347|NCT00000801|DRUG|Cytarabine|
223614348|NCT00000801|DRUG|Dexamethasone|
223614349|NCT04643626|DEVICE|artificial intelligence dietary android mobile application|subjects use artificial intelligence dietary mobile application to monitor dietary intake
223759929|NCT06791850|BEHAVIORAL|HF-FamPALhomeCARE|Participants in HF-FamPALhomeCARE Intervention group receive standard care plus 2 home visits, 3 bi-weekly telephone call on HF home EOLPC care, and follow-up telephone calls at 3, 6, 9, and 12 months.
224201688|NCT06343142|OTHER|Nut-free meal|Isocaloric meal without nuts
224201689|NCT06073873|DRUG|Ozanimod|According to local product label
224201690|NCT05090085|OTHER|3M Adper Single Bond2|Two-step etch and rinse dental adhesive system
223614350|NCT05331560|DEVICE|Transcranial Pulse Stimulation (TPS)|"A global brain stimulation approach, which homogenously distributes the total energy of 6000 TPS pulses per session over all accessible brain areas.~Prefrontal, Temporal and Occipital brain areas were stimulated by ultrashort (3μs) ultrasound pulses with typical energy levels of 0.2-0.25 mJ/mm2 and pulse frequencies of 4-5 Hz (pulses per second)."
223614351|NCT00075712|DRUG|carboplatin|
223614352|NCT00075712|DRUG|paclitaxel|
223614353|NCT00075712|PROCEDURE|adjuvant therapy|
223614354|NCT00075712|PROCEDURE|conventional surgery|
223614355|NCT00075712|PROCEDURE|neoadjuvant therapy|
223614356|NCT02063204|DRUG|selumetinib|selumetinib 50 mg (2x25mg) administered by mouth as capsules
223614357|NCT00754377|OTHER|PBLI Curriculum|PBLI curriculum was offered on alternate rotations
223614358|NCT02362321|DRUG|Dexamethasone|Patients received a daily dosage of 12mg (4mg three times a day) of dexamethasone for three weeks. Corticosteroid treatment was then tapered off over the next week (8mg for 48 hrs, 4mg for 48 hrs, 2mg for 48 hrs and 1mg for 24 hrs).
224201691|NCT05090085|OTHER|Filtek Z350 XT, 3 M ESPE, St Paul, MN, USA)|Composite Resin
224201692|NCT05090085|OTHER|3m ESPE etch|32% phosphoric acid
223614359|NCT02362321|OTHER|Placebo|Identical oral capsules filled with lactose were administered to the control (placebo) group for 28 days.
223614360|NCT05487521|DRUG|Methylprednisolone and or prednisolone|we gave methylprednisolone and or prednisolone to patients with EEG activity and follow up the effect of the drug on language
223614361|NCT04957446|DEVICE|Sculptra Aesthetic|Injectable implant containing microparticles of poly-L-lactic acid (PLLA)
223614362|NCT04957446|OTHER|Placebo|Saline solution
223614363|NCT06111417|OTHER|Questionnaires|"3 questionnaires to allowed to assess satisfaction and acceptance of the nanopore ultrafast test by practitioners and anxiety of results by patients :~* STAI-Y (State-Trait Anxiety Inventory)~* Patient's Questionnaire~* Practitioner's questionnaire"
223614364|NCT06111417|OTHER|Communication of the results of the BRCA1/2 ultra rapid test|Communication of the results of the BRCA1/2 ultra rapid test during a consultation 1 to 2 weeks after the test
223614365|NCT01276639|DRUG|CP-690,550|10 mg oral BID, Continuous treatment for 52 Weeks
223614366|NCT01276639|DRUG|CP-690,550|5 mg oral BID, Continuous treatment for 52 Weeks
223614367|NCT01276639|DRUG|Placebo/CP-690,550|0 mg oral BID, Continuous treatment for 16 Weeks; 10 mg oral BID, Continuous Treatment for 36 Weeks (after completion of 16 Weeks of Placebo)
223614368|NCT01276639|DRUG|Placebo/CP-690,550|0 mg oral BID, Continuous treatment for 16 Weeks; 5 mg oral BID, Continuous Treatment for 36 Weeks (after completion of 16 Weeks of Placebo)
223759930|NCT06023394|DEVICE|Laryngeal Mask Airway|Laryngeal mask airway will be used as an airway device for Cohort A in the standard fashion.
223759931|NCT06023394|DEVICE|Endotracheal Tube Device|Endotracheal tube airway will be used as an airway device for Cohort B in the standard fashion.
223759932|NCT06741735|DEVICE|INVU fetal monitoring system|INVU fetal monitoring system allows for at-home non-stress testing as opposed to the typical in-clinic testing
223759933|NCT06777355|OTHER|Transthoracic and Transesophageal echography within 24 hours post cardiac surgery|Transthoracic and Transesophageal echography within 24 hours post cardiac surgery in patients at risk for postoperative complications
223759934|NCT07079072|DEVICE|Acupuncture|"The main acupoints include Guanyuan (CV4), Zhongwan (CV12), Shangyintang (EX-HN3), bilateral Tianshu (ST25), bilateral Zusanli (ST36), bilateral Hegu (LI4), and bilateral Taichong (LR3). The patient adopts a supine position, and after disinfecting the acupoints, sterile cotton pads are affixed to secure needles.~In the experimental group, filiform needles measuring Φ0.30×40mm are inserted into the skin to a depth of 0.5-1 cun, achieving De Qi sensation. Needles are retained for 30 minutes. At each acupoint (except Shangyintang), manual stimulation including lifting, thrusting, twisting, and plucking is performed once every 10 minutes. The participants received 12 acupuncture sessions over a 4-week period, with three sessions per week scheduled every other day."
223759935|NCT07079072|DEVICE|Sham Comparator|The acupoints are same with those in the experimental group. The patient adopts a supine position, and after disinfecting the acupoints, sterile cotton pads are affixed to secure needles. The control group use dull needles measuring 0.30 × 25 mm, which are inserted vertically through the fixed pad until reaching the skin surface. The needles are gently lifted, twisted, and rotated slightly three times each, without piercing the skin. The needles are retained for 30 minutes, with no manipulation during this period. The participants received 12 sham acupuncture sessions over a 4-week period, with three sessions per week scheduled every other day.
223759936|NCT07079124|BEHAVIORAL|Multi-level Social Participation Intervention|The intervention will span 12 weeks and comprises five core components: (1) a health education manual, (2) a resource information package, (3) a structured library of social activities, (4) a motivational incentive kit, and (5) a training toolkit for staff.
223759937|NCT07079124|BEHAVIORAL|Health Education|Standardized Health Education Materials
223759938|NCT06924892|BEHAVIORAL|Music Therapy|Independent music therapy 45-minute sessions provided weekly for 3 months
223759939|NCT06924892|OTHER|Wellness Concerts|Wellness Concerts provided at partner sites (Carnegie Hall Weill Music Institute, Cooper Union College, Third Street Music Settlement).
223759940|NCT01532466|DRUG|Rocuronium|All patients were given oxygen via a face mask. The patients were then administered with the following medications intravenously: the rocuronium group received rocuronium 0.06 mg kg-1, and the control group received the same volume of normal saline 30 s before the injection of an IV fentanyl bolus (1.5 mcg kg-1, within 2 s).
223759941|NCT00567775|DRUG|human insulin|
223759942|NCT00567775|DRUG|inhaled human insulin|
223759943|NCT04041869|BEHAVIORAL|MapTrek|Participants will receive a Fitbit activity monitor and access to the MapTrek game which will be visible on monitors set up in the residential facility.
223614369|NCT05271916|DRUG|Dacomitinib+Anlotinib|The dose of each drug in the combination Decomitinib and Anlotinib will be escalated or de-escalated until the recommended phase II dose (RP2D) is reached. Patients will then be treated with RP2D orally once a day.
223614370|NCT05271916|DRUG|Dacomitinib|Dacomitinib orally on a continuous daily basis at a starting dose of 45 mg once a day until progressive disease.
223614371|NCT05590052|DEVICE|Bipolar Electrosurgery|Achievement of hemostasis using bipolar electrosurgery
223614372|NCT05590052|DEVICE|Thermocautery|achievement of hemostasis using thermocautery
223614373|NCT05488639|OTHER|Registration of football exposure and occurrence of injuries and illnesses only|"Injury \& illness registration~Data on injury and illness is gathered following the recommended methodology in the football extension of the International Olympic Committee consensus statement on methods for recording and reporting of epidemiological data on injury and illness in sport. This includes characteristics such as mode of onset, injury mechanism, diagnosis and classification according to body area, tissue, and pathology type, and illness categories for organ system and etiology. Time-loss will be counted in number of days."
223614374|NCT02987465|DRUG|Darbepoetin Alfa|Darbepoetin is not a study drug and is prescribed as part of routine treatment of anaemia in CKD1. Darbepoetin is licensed for use for the treatment of anaemia in the context of CKD. It will be provided as part of the standard clinical care of the renal patients in this study. Healthy Volunteers will not be treated with Darbepoetin.
223614375|NCT02987465|DRUG|Acetylcholine|Acetylcholine is being used as a challenge agent in this study and assesses NO-mediated vasodilation
223614376|NCT02987465|DRUG|Noradrenaline|Noradrenaline is being used as a challenge agent in this study and is an endogenous a1 adrenoceptor agonist
223614377|NCT02987465|DRUG|BQ 123|BQ 123 is being used as a challenge agent in this study and is an (Endothelin A) ETA receptor agonist.
223614378|NCT03723369|DEVICE|accupuncture|accupuncture
223614379|NCT03464409|OTHER|Semi-structured interview|Semi-structured interviews to be conducted by a study team member.
223614380|NCT03464409|OTHER|Spinal Cord Independence Measure (SCIM-SR)|The Spinal Cord Independence Measure - Self Report (SCIM-SR) is a self-report instrument for assessing functional independence of persons with spinal cord injury.
223759944|NCT02782897|DRUG|Immunoglobulin Therapy|Immunoglobulin is given intravenously 0.4 g/kg per day for five consecutive days.
223759945|NCT02782897|OTHER|Standard management|Standard management includes: the use of mild sedation, blood pressure control, management of elevated intracranial pressure, glucose management, temperature management, airway maintenance, and management of medical complications.
223759946|NCT02064452|OTHER|Triple P Online System|The Triple P Online System (TPOS) is an online parenting support program designed to assist parents in developing effective parenting practices for handling their children's problem behaviors. Content focuses on positive attention and praise, teaching strategies, effective discipline, antecedent strategies to avoid problems in high-risk situations, and applying these principles to specific situations. TPOS integrates 3 different levels of program intensity to meet different levels of family need, based on severity of children's behavior problems.
223759947|NCT02064452|BEHAVIORAL|Placebo Comparator|Enhanced Usual Community Care-Waitlist
223759948|NCT02526381|DRUG|Danlou Tablets|Five tablets of Danlou Tablets (1.5g) will be given three times a day in addition to regular western medications for the 8 weeks
223759949|NCT02526381|DRUG|Tongmai Yangxin Pills|Forty pills of Tongmai Yangxin Pills (4g) will be given two times a day in addition to regular western medications for the 8 weeks
223759950|NCT02023034|OTHER|Virtual exercises|The exercises will be performed with the Nintendo ® Wii Balance Board ® platform, and consist in: 1) Table Tilt; 2) Obstacle Course; 3) Tilt City; 4) Basic step; 5) Penguin; 6) Heading Soccer; 7) Basic Run. All patients underwent 12 sessions, twice a week for a period of 06 weeks.
223759951|NCT01581593|BIOLOGICAL|Kedrion IVIG 10%|Dosage form - Intravenous (IV) infusion of Kedrion IVIG 10%; Dosage - 300 to 900 mg/kg body weight (bw); Frequency - every 21 to 28 days; Treatment duration - 12 months
223759952|NCT02355132|OTHER|Insurance Intervention|Random selection to apply for Medicaid coverage through Oregon Experiment drawings held between March and October 2008
223759953|NCT02383667|DEVICE|Electrocardiogram holter|
223759954|NCT03041259|DRUG|Rejuveinix Low Dose|A intravenous administration of Rejuveinix after standard mechanical intervention of blocked peripheral artery
223759955|NCT03041259|DRUG|Rejuveinix High Dose|A intravenous administration of Rejuveinix after standard mechanical intervention of blocked peripheral artery
223759956|NCT00887900|PROCEDURE|Deep anterior lamellar keratoplasty (DALK)|Deep anterior lamellar keratoplasty (DALK) using the big-bubble technique.
223759957|NCT00887900|PROCEDURE|Penetrated keratoplasty|Regular corneal transplant using the penetrated keratoplasty technique
223759958|NCT02970968|DRUG|VLY-686 (Tradipitant)|oral capsule
223759959|NCT02970968|OTHER|Placebo|placebo oral
223614381|NCT03464409|OTHER|SF-36|A health-related quality of life (QoL) self-reported survey.
223614382|NCT03833869|PROCEDURE|Assisted hatching|Controlled hatching of the zona pellucida in the laboratory prior to embryo transfer
223614383|NCT05156788|DRUG|PD-1+Lenvatinib+GEMOX|Tilelizumab 200mg, add 0.9% NS 100mL, d1 Q3W, Lenvatinib 8mg, po, qd Gemox chemotherapy: Gemcitabine 1000mg/m2 with 0.9% NS 100mL, 30 minutes, d1, 8, Q3W, + oxaliplatin 85mg/m2 with 5%GS 500mL, 2 hours, d1, Q3W
223614384|NCT05899140|DRUG|Clindamycin|Clindamycin will be administered at a dose of 450 mg TDS (oral) or 10 mg/kg/dose QID iv (maximum 600mg QID iv) for a maximum of 7 days
223614385|NCT05899140|OTHER|Standard of care|Standard of care
223614386|NCT00263874|DRUG|UK-500,001|
223614387|NCT01227980|DRUG|Pexacerfont|300 mg, orally, once/day during week 1, 100 mg, orally, once/day during weeks 2 and 3.
223759960|NCT04986059|OTHER|Pre-event massage|Five minutes massage, combining superficial and high-frequency techniques of massage applied with the therapist hands on gastrocnemius and hamstring muscles
223759961|NCT03976921|DIAGNOSTIC_TEST|Integration of CCTA with stress CTP when indicated|When judged indicated, functional assessment with stress CTP perfusion will be performed on top of CCTA.
223759962|NCT03976921|DIAGNOSTIC_TEST|Standard of care approach|(a) functional non-invasive tests (stress ECG, or imaging-based tests such as Stress Echo, Stress CMR, SPECT or PET) as a gatekeeper for ICA; (b) direct referral to ICA.
223759963|NCT06118294|DIETARY_SUPPLEMENT|probiotics|\>30 billion CFU/capsule
223759964|NCT06118294|DIETARY_SUPPLEMENT|Placebo|Placebo
223759965|NCT02565381|DRUG|Transdermal nicotine patch|"* ≥10 cigarettes per day: nicotine 21mg/24hr patch daily x 6 weeks, then nicotine 14mg/24hr patch daily x 2 weeks~* \<10 cigarettes per day: nicotine 14mg/24hr patch daily x 8 weeks"
223759966|NCT02565381|BEHAVIORAL|In-person smoking cessation counseling|\- One-on-one 15-minute counseling sessions once per week for 8 weeks
223759967|NCT02565381|BEHAVIORAL|Contingent financial rewards for smoking abstinence|\- Escalating-value financial rewards for smoking abstinence, verified by exhaled carbon monoxide \<8ppm
223759968|NCT02565381|BEHAVIORAL|Text messages to support smoking abstinence|\- 1-5 text messages per day starting up to 2 weeks before the quit date and continuing until 6 weeks after the quit date, delivered by SmokefreeTXT
223759969|NCT01558700|DRUG|Duloxetine|Duloxetine capsule 30mg once a day for one week, then 60mg once a day for 15 weeks, then 30mg once a day for one week.
223759970|NCT01558700|DRUG|Sugar pill|Matching capsule given once a day for a total of 17 weeks.
223759971|NCT04996303|DRUG|Routine steroid administration group|Steroid administration with routine dose - Methylprednisolone 1 mg/kg 7 days → 0.5 mg/kg 7 days → 0.25 mg kg 7 days
223614388|NCT01227980|DRUG|Placebo|300 mg, orally, once/day during week 1, 100 mg, orally, once/day during weeks 2 and 3.
223614389|NCT02398240|DRUG|Brentuximab Vedotin|Day 1 and 15 Dose: 1.2 mg/kg/dose. (Maximum dose is 120 mg)
223614390|NCT02398240|DRUG|Doxorubicin|Days: 1 and 15 Dose: 25 mg/m2/dose.
223614391|NCT02398240|DRUG|Vincristine|Days: 1 and 15 Dose: 1.5 mg/m2/dose (max: 2 mg/dose).
223614392|NCT02398240|DRUG|Rituximab|Days: 2 and 16 Dose: 375 mg/m2/dose.
223614393|NCT00001002|DRUG|Zidovudine|
223614394|NCT00001002|DRUG|Foscarnet sodium|
223614395|NCT02454023|DEVICE|Portable sleep monitor (ApneaLink Air)|Use of a portable sleep monitor that records respiratory effort, pulse, oxygen saturation and nasal flow, and reports apneas, hypopneas, flow limitation, snoring and blood oxygen saturation in order to detect obstructive sleep apnea.
223614396|NCT02454023|DEVICE|In-laboratory polysomnography|Level 1 in-laboratory polysomnography for the detection of obstructive sleep apnea.
223614397|NCT00329368|BIOLOGICAL|EC90 (KLH-FITC)|1.2mg in combination with adjuvant GPI-0100 administered subcutaneously, weekly for 4 consecutive weeks during the first treatment cycle, weekly for 2 consecutive weeks during the second cycle and once for each additional cycle.
223759972|NCT04996303|DEVICE|Steroid pulse therapy group|Steroid administration with pulse dose - Methylprednisolone 10 mg/Kg (500 mg \~ 1g) pulse 3 days -\> Methylprednisolone 1 mg/kg 7 days → 0.5 mg/kg 7 days → 0.25 mg/kg 7 days
223759973|NCT05724602|DRUG|Xevinapant|3 cycles of xevinapant + IMRT followed by 3 cycles of xevinapant as monotherapy
223759974|NCT05724602|DRUG|Placebo|3 cycles of placebo + IMRT followed by 3 cycles of placebo as monotherapy
223759975|NCT04962815|DEVICE|Electroencephalogram (EEG) Test|EEG test and delirium assessments will be performed on subjects experiencing delirium in the ICU.
223614398|NCT00329368|BIOLOGICAL|GPI-0100|3.0mg in combination with EC90 administered subcutaneously weekly for 4 consecutive weeks during the first treatment cycle, weekly for 2 consecutive weeks during the second cycle and once for each additional cycle.
223759976|NCT03205085|RADIATION|magnetic resonance imaging|assessment of right heart dimensions and function by cardiac magnetic resonance Imaging.
223614399|NCT00329368|DRUG|EC17 (Folate-FITC)|0.3mg/kg administered subcutaneously 5 days per week (Monday through Friday) for 4 consecutive weeks followed by 2 observation weeks for each cycle.
223614400|NCT00329368|DRUG|Interleukin-2|Low dose (7-12 MIU) IL-2 administered subcutaneously three times per week (MWF) for 3 consecutive weeks during the first cycle, 4 consecutive weeks during cycle 2 and additional cycles
223759977|NCT03205085|PROCEDURE|2D and 3D trans-thoracic echocardiography|assessment of right heart dimensions and function by 2D and 3D trans-thoracic echocardiography
223614401|NCT00329368|DRUG|Interferon-alpha|3.0 MIU administered subcutaneously 3 times per week (MWF) for 3 consecutive weeks during the first cycle of treatment, then 3.0 MIU administered subcutaneously 3 times per week (MWF) for 4 weeks for cycle 2 and additional cycles.
223614402|NCT04440878|BEHAVIORAL|Static stretching|Static stretching exercise will be performed under the supervision of a physiotherapist as 30 seconds of stretching and 15 seconds of rest with 10 repetitions, and the individuals will be asked to participate in the exercise actively.
223614403|NCT04440878|BEHAVIORAL|Mulligan TSLR technique|Mulligan TSLR will be applied by a physiotherapist in 3 repetitions with the patient in the supine position.
223614404|NCT00047515|DRUG|Alcon Investigational Agent|
223614405|NCT05877534|OTHER|Individual tailored exercise|A 16 week period of progressive exercise, supervised by a physiotherapist once a week.
223614406|NCT06173583|DIAGNOSTIC_TEST|Detection/screening|Using ARISCAT and LAS VEGUS risk scores for predicting PPCs
223614407|NCT02471235|BEHAVIORAL|Physiotherapy|Pulmonary rehabilitation
223614408|NCT01971541|BEHAVIORAL|Mindfulness-Based Stress Reduction|A validated 8-week group program that teaches mindfulness meditation
223614409|NCT01971541|BEHAVIORAL|Cognitive Processing Therapy|A validated group program of PTSD treatment, which focuses on cognitive processing.
223614410|NCT03373929|DEVICE|PFO Closure Rate|Suture Mediated PFO Closure and Septal Repair
223759978|NCT03205085|OTHER|Blood samples|Blood samples for assays of immune inflammatory biomarkers (InterLeukin-18, CXCL9 or interferon
223759979|NCT05910580|BEHAVIORAL|Screening, Brief Intervention, and Referral to Treatment (SBIRT)|Screening, Brief Intervention, and Referral to Treatment (SBIRT) is an evidence-based approach supported by national healthcare organizations, including the Preventative Services Task Force and the American College of Obstetrics and Gynecologists. Validated tools will efficiently screen an individual's substance use risk. Patients who screen in the risky/harmful range then receive a brief motivational interviewing-based intervention adapted from the evidence-based Brief Negotiated Interview, lasting 5-10 minutes, which provides feedback, helps explore health risks, and motivates change. Individuals who screen in the severe category, indicating a likely AUD/SUD, also receive a brief intervention, aimed at increasing motivation to accept a referral to treatment, and requiring a more intensive approach will also receive a warm-hand off referral to specialty addiction treatment. Procedures for SBIRT delivery will be adapted to the flow of telemedicine visits.
223759980|NCT02517034|OTHER|Comprehensive Geriatric Assessment|Follow geriatric assessment-driven treatment plan
223759981|NCT02517034|OTHER|Quality-of-Life Assessment|Ancillary studies
224201693|NCT05090085|OTHER|OT Primer|Dimethyl Sulfoxide DMSO \[(CH3)2SO\] is a polar aprotic solvent that dissolves both polar and non-polar compounds.
223614411|NCT03373929|DEVICE|Published PFO Device Closure|Suture Mediated PFO Closure and Septal Repair
223614412|NCT04467086|DRUG|Propranolol Hydrochloride|"Propranolol enterally at a starting dose of 20mg every 6h for 2-4 doses, and then re-assessed for upwards titration every 24 hours (+/- 6 hours) at 10mg dose increases depending on clinical response. Maximum dose of 60mg every 6h. Titration decision to be made by clinical team at daily rounds.~Daily titration will be guided by hemodynamic markers indicative of the expected sympatholysis from propranolol. Upward titration of propranolol should coincide with a downward titration in sedatives until a minimum level of sedative infusion is reached (propofol \<0.5mg/kg/h or midazolam \<1.0mg/h). Nurses will be instructed at each assessment to determine if sedative targets can be achieved with lower doses of sedatives. Daily upward titration of propranolol will be recommended if none of these conditions are met: (1)HR\<70 beats/min, (2) Mean Arterial Pressure \<70 mmHg or (3) norepinephrine or equivalent vasopressor dose increase to \>0.15 mcg/kg/min."
223614413|NCT00896298|DRUG|Leptin|Leptin injected subcutaneously twice a day, to be administered at 100% of the estimated replacement dose during the first month, which is a dosage of 0.03mg/kg for female children, 0.04mg/kg for adult females, and0.02 mg/kg for all males, and then at 200% subsequently, or placebo.
223614414|NCT00896298|DRUG|Placebo|Sugar pill
223759982|NCT02517034|OTHER|Questionnaire Administration|Ancillary studies
223759983|NCT02517034|OTHER|Survey Administration|Ancillary studies
224201694|NCT02076139|DIETARY_SUPPLEMENT|Nyaditum resae® 10e4|
224201695|NCT02076139|DIETARY_SUPPLEMENT|Nyaditum resae® 10e5|
224201696|NCT02076139|OTHER|Distilled water|
223759984|NCT05892068|DRUG|Tucatinib|Standard dose of 300mg orally twice daily for 4 days prior to surgery (day -4 to 0).
223614415|NCT01454986|DRUG|ALXN1007|Single dose, IV
223614416|NCT01454986|OTHER|Placebo|Single dose, IV
223614417|NCT00466440|DRUG|enzastaurin|1125 mg loading dose, then 500 mg po QD until disease progression, toxicity, or maximum 3 years
223614418|NCT00466440|DRUG|placebo|Loading dose, then po QD until unblinding
223614419|NCT00466440|DRUG|docetaxel|75 mg/m\^2 IV, every 21 days, six 21-day cycles, maximum 10 cycles
223614420|NCT00466440|DRUG|prednisone|5 mg po BID, six 21-day cycles
223614421|NCT02935530|DRUG|s-LMWH|2125KU, subcutaneous injection of 5-10 days
223614422|NCT02935530|DRUG|LMWH|4250KU, subcutaneous injection of 5-10 days
223614423|NCT02935530|DRUG|Argatroban|20mg, injection for 5-10 days
223614424|NCT03586713|DIAGNOSTIC_TEST|light induced fluorescence camera|The light induced fluorescence intraoral camera works with a visible blue light frequency (wavelength 450 nm) for the illumination of the dental surface and produces an overlapping image of the green fluorescence image on the image of the white light. The green fluorescence image is considered an indicator of healthy dental tissues. The colour of the fluorescence signal is green when the dentin is healthy. The healthy enamel is blue due to the scattered green light of the dentin, despite the lack of a fluorescence signal. On the other hand, caries can be easily detected by dark red fluorescence.
223614425|NCT04762732|DEVICE|NPWT|Wound of ALT donor site will be cared under PREVENA™ Incision Management System for 5 days post-operatively.
223614426|NCT04762732|DEVICE|Traditional wound care|Wound of ALT donor site will be covered by vaseline gauze coated with tetracycline ointment (Genuine Chemical Pharmaceutical, Tao-Yuan, Taiwan), and layers of gauze.
223614427|NCT00834665|BIOLOGICAL|hTERT vaccine, GM-CSF, PCV, T cell infusion|hTERT vaccine (multi-peptide vaccine), Granulocyte Macrophage-Colony Stimulating Factor (GM-CSF), Prevnar-Pneumococcal Conjugate vaccine (PCV), T cell infusion
223614428|NCT00834665|BIOLOGICAL|GM-CSF, PCV, T cell infusion|Granulocyte Macrophage-Colony Stimulating Factor (GM-CSF), Prevnar-Pneumococcal Conjugate vaccine (PCV), T cell infusion
223614429|NCT04581265|DRUG|albumin-bound paclitaxel (nab-PTX), ifosfamide and cisplatin|Participants received a single dose of albumin-bound paclitaxel (nab-PTX) 270mg/m2/d, administered intravenously (IV) on Day 1; Ifosfamide 1.2g/m2/d administered intravenously (IV) on Day 2-6; Cisplatin 20mg/m2/d administered intravenously (IV) on Day 2-6.
223614430|NCT03335410|OTHER|Non- interventional|Non- interventional
223614431|NCT04067934|BEHAVIORAL|Jumping Exercise programme|Four weeks of three jumping-based exercise sessions per week. These sessions will involve basic jumping movements, with approximately 50-100 jumps per session; incorporating 20-30 minutes of exercise.
223614432|NCT05892601|OTHER|Maternal kisses|"The parents of the children in the experimental group were informed about the process before the application. The parents were asked to approach their child immediately after the invasive procedure was over, call out Let me kiss it better and kiss the child from a point not close to the place where the invasive procedure was applied. Kisses were delivered by the mother, free of oral ulcers, with a standard 5-second pressing of both lips on the affected body part followed by an exaggerated puckering sound. Pain, fear, and anxiety scales were administered to the intervention group at the 1st and 5th minutes after the application. Invasive interventions have been applied by researchers who have been working as nurses in the emergency room for 4 years."
223614433|NCT00585117|PROCEDURE|PET-imaging with CuATSM|imaging with CuATSM
223614434|NCT00585117|PROCEDURE|PET Imaging|Imaging with CuATSM
223614435|NCT00585117|PROCEDURE|PET CuATSM|Imaging with CuATSM
223614436|NCT00585117|PROCEDURE|PET imaging|imaging with CuATSM
223614437|NCT00585117|PROCEDURE|PET imaging with CuATSM|Imaging with CuATSM
223614438|NCT00585117|PROCEDURE|PET imaging with CuATSM|Imaging with CuATSM
223614439|NCT02398305|DEVICE|TR Band standard|Diminishing the air pressure in the TR Band following standard protocol
223614440|NCT02398305|DEVICE|TR Band Quick|Diminishing the air pressure in the TR Band following a faster protocol
223614441|NCT00965081|DRUG|Duloxetine|30 milligrams (mg) dose daily (QD) by mouth (po) at the same time each day for 12 weeks
223759985|NCT03332238|DEVICE|Autologous Stomal Vascular Fraction Material|Autologous Stomal Vascular Fraction Material Prepared from the Tissue Genesis® Icellator Cell Isolation System™
223759986|NCT03332238|DEVICE|Ringer's solution|Ringer's solution
223614442|NCT00965081|DRUG|Placebo|QD po at the same time each day for 12 weeks
223614443|NCT00176774|DRUG|Irinotecan|Irinotecan by intravenous infusion (needle in a vein in your arm) over 90 minutes immediately followed by intravenous LV and 5-FU weekly for 4 weeks (days 1, 8, 15 and 22) followed by two weeks of no treatment.
223614444|NCT00176774|DRUG|5-Fluorouracil|Irinotecan by intravenous infusion (needle in a vein in your arm) over 90 minutes immediately followed by intravenous LV and 5-FU weekly for 4 weeks (days 1, 8, 15 and 22) followed by two weeks of no treatment.
223614445|NCT00176774|DRUG|Leucovorin|Irinotecan by intravenous infusion (needle in a vein in your arm) over 90 minutes immediately followed by intravenous LV and 5-FU weekly for 4 weeks (days 1, 8, 15 and 22) followed by two weeks of no treatment.
223614446|NCT00176774|DRUG|Tetrathiomolybdate|one 40 mg oral (by mouth) dose of TM three times a day with meals and one 60 mg oral dose (without food) at bedtime beginning at bedtime on day 1 of your first 6-week cycle of treatment. The between meal dose must be taken at least one hour before or one hour after a meal.
223614447|NCT01263964|PROCEDURE|coronary angiogram|coronary angiogram
223614448|NCT02060435|OTHER|EBER|EBV RNA was detected by an in situ hybridization (ISH) technique using the EBV ISH kit (Leica Microsystems, Bannockburn, IL, USA).
223614449|NCT02497924|DRUG|GBT440|GBT440 capsules followed by single dose of \[C14\] GBT440 oral suspension
223614450|NCT02961959|PROCEDURE|Surgery|Arthrodesis of SI-joints, Physiotherapy
223759987|NCT05084053|DRUG|TAK-771|Intervention description; Immune Globulin Infusion (IGI) 10% and Recombinant Human Hyaluronidase (rHuPH20)
224201697|NCT01119352|DRUG|AZD7687|Oral suspension, once daily. Starting dose of 1mg and with up to 4 dose escalations. Totally 8 doses.
224201698|NCT01119352|DRUG|Placebo|Oral suspension, once daily. Totally 8 doses
224201699|NCT04959708|OTHER|Insula treatment|he intervention will consist of twelve individual treatments. Insula method consists of the facilitation and activation of self-regulation resources, relational regulation through breathing, movement, contact, sensory stimulation and posture
223614451|NCT02961959|OTHER|Non-surgery|Physiotherapy
223614452|NCT02727829|DEVICE|pefusion index measurement|perfusion index measurement using massimo radical 7 device
223614453|NCT02541812|DEVICE|Transcranial Magnetic Stimulation|A non-invasive method for brain stimulation
223614454|NCT05665894|DEVICE|Hematoma Vaacum Assisted Biopsy|The patient was placed supine and meticulous aseptic measures were applied. Prior procedure local anesthesia (lidocaine 1%) was administered following disinfection. A 5 mm skin incision is performed to guarantee appropriate access for the needle insertion in the hematomas. The evacuation was achieved using a Mammotome® vacuum-assisted system (Devicor Medical Products, Inc., Cincinnati, OH, USA), with an 8-G needle, under the guidance of the same high-resolution US equipment (MyLabTM 9 XP; Esaote SpA, Genoa) for preoperative assessment. Empty-needle function and the tissue-biopsy option is preferred to fragment the fibrotic tissue until the hematoma empties and its walls collapsed. Once VAEv is performed, the postoperative US is carried out and VAEv is repeated until more than 90% evacuations of hematoma volume if no complication occurs.
223614455|NCT05555966|DEVICE|Electrical Activation Mapping Guided Cardiac resynchronization therapy|To study the feasibility to optimize configuration of CRT delivery for acute correction of electrical dyssynchrony using a noninvasive mapping of global electrical activation
223614456|NCT00796666|DRUG|Sitaxsentan|Sitaxsentan = 100 mg tablet administered orally, once daily Sildenafil placebo = 1 tablet administered orally, three times a day
223614457|NCT00796666|DRUG|Sitaxsentan and Sildenafil|Sitaxsentan = 100 mg tablet administered orally, once daily plus Sildenafil = 20 mg tablet administered orally, three times a day
223759988|NCT06581835|DEVICE|Observational|The study objective requires placement of a jugular venous bulb catheter in the right or left jugular venous bulb with ultrasound guidance. A venous and radial arterial line will be placed. Two INVOS™ sensors (PMSENS71-A) will be placed bilaterally on the subject's forehead. The INVOS™ device will be evaluated for a targeted range of 70-100% SpO2 levels. Hypoxic mixtures of gas are delivered, and data are collected at approximately (\~) 5-minute intervals during steady periods of increasing and decreasing oxygen concentration.
223759989|NCT05061160|OTHER|Interval Aerobic Exercise training Group|"Interval Aerobic exercise will be on upper limb Bicycle with a pause of 3 mins interval Interval Aerobic Exercises: Frequency= 3 times per week Intensity= 50% of heart rate reserve for 2 mins 80% of heart rate reserve for 1 min Type= interval aerobic exercise Time= 40 minutes~There will be 5 minutes for warm up and 5 minutes for cool down."
223759990|NCT05061160|OTHER|Continuous Aerobic Exercise training Group|"Continuous Aerobic exercise will be on upper limb Bicycle Continuous Aerobic Exercise: Frequency= 3 times per week Intensity= 50% of heart rate reserve Type= continuous aerobic exercise Time= 40 minutes~There will be 5 minutes for warm up and 5 minutes for cool down."
223759991|NCT02837432|DRUG|Hydrocortisone acetate|
223759992|NCT02837432|DRUG|Placebo|
223759993|NCT04737642|PROCEDURE|Papillary ballon dilatation|Trans cystic papillary ballon dilatation during cholecystectomy
223759994|NCT00134875|DRUG|Buprenorphine/naloxone|Acute doses of buprenorphine/naloxone in each experimental test session. Doses delivered by either sublingual or parenteral routes, and are: 4/1, 8/2, 16/4 mg.
223759995|NCT00071812|DRUG|Placebo|Placebo IV plus standard therapy (SOC) for RA; placebo administered on Days 0, 14, 28, and every 28 days thereafter through 24 weeks in the double-blind period. In the open-label extension period, placebo patients who opted to participate received belimumab 10 mg/kg IV plus SOC every 28 days for an additional 24 weeks.
223759996|NCT00071812|DRUG|Belimumab 1 mg/kg|Belimumab 1 mg/kg IV plus standard therapy (SOC) for RA; belimumab 1 mg/kg administered on Days 0, 14, 28, and every 28 days thereafter through 24 weeks in the double-blind period. In the open-label extension period, patients who opted to participate either continued on the same dose of belimumab or may have been switched to belimumab 10 mg/kg at the investigator's discretion for an additional 24 weeks.
223614458|NCT06129643|DRUG|Conventional group|conventional disinfection using 2.5% sodium hypochlorite and 17% EDTA
223614459|NCT06129643|DEVICE|Dual laser group|Er,Cr:YSGG intracanal laser irradiation to remove smear layer followed by diode laser for disinfection
223614460|NCT06129643|COMBINATION_PRODUCT|Combined group|17% EDTA was used to remove smear layer followed by diode laser for disinfection
223759997|NCT00071812|DRUG|Belimumab 4 mg/kg|Belimumab 4 mg/kg IV plus standard therapy (SOC) for RA; belimumab 4 mg/kg administered on Days 0, 14, 28, and every 28 days thereafter through 24 weeks in the double-blind period. In the open-label extension period, patients who opted to participate either continued on the same dose of belimumab or may have been switched to belimumab 10 mg/kg at the investigator's discretion for an additional 24 weeks.
223614461|NCT03116516|DRUG|Temisartan/Amlodipine+Rosuvastatin|All subjects will receive a single oral dose of temisartan/amlodipine+rosuvastatin administered in the morning.
223614462|NCT03116516|DRUG|YHP1604|All subjects will receive a single oral dose of YHP1604 administered in the morning.
223614463|NCT03211468|BEHAVIORAL|Clinical intervention program to prevent eating disorders|See previous
223759998|NCT00071812|DRUG|Belimumab 10 mg/kg|Belimumab 10 mg/kg IV plus standard therapy (SOC) for RA; belimumab 10 mg/kg administered on Days 0, 14, 28, and every 28 days thereafter through 24 weeks in the double-blind period. In the open-label extension period, patients who opted to participate continued on the same dose of belimumab (10 mg/kg) for an additional 24 weeks.
223759999|NCT04429009|DEVICE|ZEPHYRx Respiratory Therapy (RT) System|A breath controlled video game system for respiratory therapy
223760000|NCT04429009|DEVICE|Standard Incentive Spirometer|A simple (not digital) plastic device that contains a piston that rises inside the device and measures the volume of your breath
223760001|NCT01735292|DEVICE|Automatic Respiration Transfer System- Timer|
223760002|NCT05466019|DRUG|Drug: Toripalimab, FLOT(Docetaxel+oxaliplatin+leucovorin+5-FU)|FLOT: Docetaxel 50mg/m2 ivd d1 + oxaliplatin 85mg/m2 ivd d1 + leucovorin 200mg/m2 ivd d1 + 5-FU 2600mg/m2 civ, Q2W Toripalimab 3mg/kg, intravenously administered on the first day of each cycle, Q2W.
223760003|NCT04223076|DRUG|Chlorhexidine 0.2%, Corsodyl|Comparison of Corsodyl and Curasept
223760004|NCT04223076|DRUG|Chlorhexidine 0.2%, Curasept|Chlorhexidine 0.2% mouthwash with an Anti Discoloring System (ADS)
223760005|NCT05839665|DEVICE|Humidified high-flow nasal oxygen|Humidified high-flow oxygen delivered via the Optiflow device
224201700|NCT06262490|DEVICE|Traditional ultrasound therapy|Ultrasound therapy for 2 session per week for until completing 12 treatment sessions (six weeks) with frequencies up to 3 MHz are used clinically to promote healing
223760006|NCT05839665|DEVICE|Standard nasal cannula|Oxygen delivered with high flows via a standard nasal cannula
224312145|NCT06170905|DIETARY_SUPPLEMENT|Whey protein-preload OGTT|Intake of 25 g whey protein diluted in water 30 minutes prior to the start of a regular 75 g oral glucose tolerance test
224312146|NCT02776137|DRUG|Docetaxel|Docetaxel: 20mg/m2/w for 6 weeks
224312147|NCT02776137|RADIATION|Intensity-modulated radiotherapy|a total dose of 60Gy in 30 fractions over 6 weeks
224312148|NCT02003950|OTHER|Snack Condition Specification|Individuals recieve a different snack for every week of the study. This is viewed as 4 phases. Phase 1 measures of habitual chocolate candy consumption (1 week), Phase 2 assesses participants' chocolate consumption while anticipating an oncoming chocolate candy restriction (1 week), Phase 3 is the total chocolate candy restriction period, but participants will be given 3 non-chocolate-candy snack substitutes in a random order (1 week per snack type, 3 weeks total), and Phase 4 examines participants' chocolate candy consumption when the 3-week restriction is lifted (1 week).
224312149|NCT06983548|BIOLOGICAL|semen, blood and urine tests|Patients will undergo several tests, including semen analysis, spermocytogram, blood and urine tests, serology, and RT-PCR. These tests will be conducted on days 7±2, 15±2, 30±3, 60±5, 90±5, and 180±15. (Patients will only undergo the V6 if the sperm PCR result comes back positive on D90).
223760007|NCT05839665|DEVICE|Facemask|Oxygen delivered with facemask
223760008|NCT02488785|BEHAVIORAL|Virtual Diabetes Self-Care and Education Program|Participants will be able to have frequent contact in order to share physical activity and glucose data with the diabetes educator using the smartphone they will receive. Information downloaded to the Glooko Population Management tool can be shared with the diabetes educator.
223760009|NCT02488785|DEVICE|Fitbit|Participants will be given a Fitbit physical activity tracker which they can use to record their activity and share the information with the diabetes educator using the device's smartphone application.
223760010|NCT02488785|DEVICE|Smartphone|All virtual visits were performed via provided smartphone. In addition, participants will receive a Glooko MeterSync Blue cable which is able to connect to most glucose meters in order to download glucose data to the Glooko Population Management tool on their smartphones
224312150|NCT01688570|DRUG|duloxetine|Single dose, orally (pill), 30 mg, taken 6 hours prior to start of the testing session. Subjects will only take a single dose of duloxetine once.
224312151|NCT01688570|DRUG|Cyproheptadine|Single dose, orally, 8 mg, 6 hours prior to the start of the respective testing session. Subjects will take a single dose of cyproheptadine once.
224312152|NCT01688570|DRUG|Placebo|Single dose, orally, 6 hours prior to the start of the respective testing session. Subjects take a single dose once.
224312153|NCT02362555|OTHER|no intervention was used in this observational study|
224312154|NCT05648461|RADIATION|Five fraction of post operative radiotherapy|Target volume will include tumor bed \& ipsilateral level I-III levels.
224312155|NCT00637650|PROCEDURE|Ureteroscopy, Holmium Laser lithotripsy and active retrieval of fragments|
224312156|NCT00637650|PROCEDURE|Ureteroscopy, Holmium laser lithotripsy, no intent to retrieve any remaining fragment|
223760011|NCT01002144|OTHER|blood sampling|
223760012|NCT01086592|OTHER|No intervention|Daily life activities
224201701|NCT06262490|OTHER|Pelvic floor rehabilitation|Pelvic floor rehabilitation for 3 sessions per week for (six weeks) until completing 18 sessions with sessions lasting between 30-45 minutes
224201702|NCT05351606|BEHAVIORAL|Tobacco Use Cessation Counselling Sessions|Counseling sessions will be given in person
224201703|NCT05351606|DRUG|Bupropion|Given orally
224312157|NCT03603379|DRUG|C225-ILs-dox|C225-ILs-dox will be administered at a dose of 50 mg/m2. i.v., on day 1 of each cycle, cycle length is 28 days. In total, 4 cycles are planned to be applied.
223760013|NCT01086592|OTHER|Strong progressive strengthening exercises of lower limbs|Lower limb weight
223760014|NCT01086592|OTHER|Electrotherapy|Neuromuscular Electrical Nerve Stimulation
223760015|NCT01086592|OTHER|Electrotherapy+weights|Superimposed Neuromuscular Electric Nerve Stimulation
223760016|NCT02041026|DIETARY_SUPPLEMENT|probiotic yoghurt|The probiotic yoghurt will be prepared using lactobacillus NN20 isolated from Kimere (a traditional fermented food product) consumed in eastern part of kenya
223760017|NCT03612167|BEHAVIORAL|cognitive intervention|a 12 consecutive 90-minute weekly cognitive groups that included cognitive training and rehabilitation, with activity-based cognitive exercises and discussions with a focus on applications of cognitive strategies in daily lives.
223760018|NCT03612167|BEHAVIORAL|nutritional group|12 consecutive 90-minute weekly nutritional groups that included nutrition classes (lecture and discussion).
223760019|NCT02837887|BEHAVIORAL|Computerized Cognitive Behavior Therapy|Undergo computerized cognitive behavior therapy
224201704|NCT05351606|DRUG|Nicotine patch|Given transdermally
223760020|NCT01815281|DEVICE|Foot Mechanical Stimulation (GONDOLA)|
224201705|NCT05351606|DRUG|Nicotine lozenge|Given orally
224201706|NCT01023022|OTHER|Medtronic CareLink® Network|The Medtronic CareLink® Network consists of the Medtronic CareLink® Monitor and Medtronic CareLink® Clinician Website
224201707|NCT01096862|DRUG|peficitinib|oral
224201708|NCT01096862|DRUG|Placebo|oral
224312158|NCT00867997|OTHER|Chemoactive (remineralizing, neuroactive) dentifrice treatment|Chemoactive (remineralizing, neuroactive) dentifrice treatment
224312159|NCT00867997|OTHER|Clearfil S3 Bond; Clearfil Liner Bond 2 Protect Liner F|Self-etch DBA followed by a hydrophobic resin layer
224312160|NCT00867997|OTHER|Clearfil S3 Bond; Premise Flowable resin-based composite|Restoration with a dentin bonding agent (DBA) and flowable resin-based composite
224312161|NCT06396065|DRUG|AK112 Injection|Subjects will receive AK112 Plus Pemetrexed and Carboplatin via intravenous infusion (IV) Q3W, up to 4 cycles. Afterward, AK112 Plus Pemetrexed will be used for maintenance treatment (administered on Day 1 of each cycle, Q3W) up to 2 years.
224312162|NCT06396065|DRUG|Placebo Injection|Subjects will receive Placebo Plus Pemetrexed and Carboplatin via intravenous infusion (IV) Q3W, up to 4 cycles in treatment periods per the randomization schedule. Afterward, Placebo Plus Pemetrexed will be used for maintenance treatment (administered on Day 1 of each cycle, Q3W) up to 2 years.
224312163|NCT02549235|OTHER|Ultrasound|Routine 2D/3D ultrasound assessment
224312164|NCT06123923|OTHER|no intervention|no intervention, just retrospective observation
223614464|NCT06104085|DIAGNOSTIC_TEST|99mTc-MY6349 SPECT/CT scan|Triple-negative breast cancer patients underwent 99mTc-MY6349 SPECT/CT imaging to observe the binding ability of this tracer to Trop2 in the tumor and the uptake of the drug by the tumor, combined with the pathological expression level of Trop2 in the patient's lesions and 18F-FDG PET/CT imaging uptake to evaluate the efficacy of 99mTc-MY6349 in the diagnosis of triple-negative breast cancer; at the same time, combined with the treatment effect of patients using the anti-Trop2 targeted antibody gosatuzumab, the analysis of 99mTc-MY6349 SPECT/CT imaging prediction of prognosis in patients with triple-negative breast cancer treated with gosatuzumab.
223614465|NCT06375213|DIAGNOSTIC_TEST|Plasma tau phosphorylated at Thr217|Plasma concentration of tau protein phosphorylated at Thr217 as measured on the Meso Scale Discovery, single molecule array (Simoa) or the in-house mass spectrometry platform.
223614466|NCT06375213|OTHER|Neurocognitive examination|Traditional (paper and pencil) neurocognitive/neuropsychiatric examination performed by certified psychologists. This includes: Mini Mental State Examination (MMSE), Montreal Cognitive Assessment (MoCA), Clinical Dementia Rating (CDR), Wechsler Memory Scale - Fourth Edition (WMS-IV), Neuropsychiatric Inventory - Questionnaire (NPI-Q), Thai Geriatric Depression Scale (TGDS), General Anxiety Disorder - 7 (GAD-7), The Barthel activities of daily living (ADL) Index, Chula ADL Index.
223614467|NCT01303939|DIAGNOSTIC_TEST|magnetic resonance imaging (MRI) of the brain|High resolution three-dimensional T1-weighted magnetic resonance imaging (MRI) was obtained from each participant at one visit.
223614468|NCT00614679|DRUG|catheter lock solution consisting of N-acetylcystein, tigecycline and heparin|N-acetylcystein 80 mg/ml, tigecycline 1 mg/ml, and heparin 2000 units/ml. This will be a 5 ml catheter lock solution
223614469|NCT01083823|OTHER|Mental health telemetry (MHT)|Use a cell phone equipped with MHT software to complete a self-report mood symptom questionnaire daily at a fixed time of day, as well as additional discretionary questionnaires following any significantly stressful events.
223614470|NCT06009367|PROCEDURE|Fascial Manipulation by Stecco method|Fascial Manipulation (FM) is a method carefully developed by members of the Stecco family after many years of research. FM involves deep kneading of the muscle fascia at specific points called centers of coordination (CC) and centers of fusion (CF) along myofascial sequences, diagonals, and spirals. It has been proposed that the friction caused by manipulation creates localized heat and that, due to the thermosensitive characteristics of fascia, this heat facilitates the transition of hyaluronic acid within the extracellular matrix from a condensed state to a more fluid state, thus restoring the gliding properties of fascia.
223614471|NCT00256724|DEVICE|Impedance Threshold Device|Active impedance threshold device
223614472|NCT00256724|DEVICE|sham ITD|sham impedance threshold device
223614473|NCT03159559|DRUG|Lipo-PGE1|Patients received conventional therapy plus Lipo-PGE1 10μg once daily intravenous injection for 7 days
223614474|NCT01217463|DRUG|Trafermin 0.01% spray|For ulcers with a maximum diameter (longest axis) of less or equal to 6 cm, the daily dose of trafermin 0.01% spray is 5 puffs (30 microgram) sprayed onto the wound surface. If the maximum diameter (longest axis) of the ulcer is \>6 cm, the ulcer should be sprayed in two parts, i.e. 5 puffs (30 microgram) sprayed onto each half of the wound surface
223760021|NCT06955338|PROCEDURE|Music intervention|The music for the study will be the 'MusiCure® 9 Scandinavia' compositions specially developed by Inge Eje and Niels Eje (Gefion Records, Copenhagen, Denmark) (MusiCure, 2024). The compositions include melodies with harp, cello, strings and sounds from nature (birds, forest and night sounds) in a soft rhythm between 60-80 bpm for relaxation, based on research into the acoustic environment of hospitals and shown to have a positive effect on patients' symptoms such as pain, fear and anxiety. Two minutes after the child starts listening to the music, oral mucositis care will be started. Five minutes after the end of the procedure, the Child Anxiety Scale-Conditioning (CAS-D), Child Fear Scale and Visual Comparison Scale will be applied and the duration of the procedure will be recorded.
223760022|NCT06955338|PROCEDURE|Virtual reality|In this group, children will be shown a short film with virtual reality glasses. In the study, the short film 'MusiCure® The Journey' specially developed by Inge Eje and Niels Eje (Gefion Records, Copenhagen, Denmark) will be preferred in the virtual reality group. The duration of the film is 16 minutes (MusiCure, 2024). Two minutes after the child starts watching the film, oral mucositis care will be started. Five minutes after the end of the procedure, the duration of the procedure will be recorded by applying the Child Anxiety Scale-Conditioning (CAS-D), Child Fear Scale and Visual Comparison Scale.
223760023|NCT04535284|BEHAVIORAL|Coaching|"Health Coaching-in-Context that consists of up to 10 sessions, arranged once-a-week or multiple times a week based on convenience of scheduling for up to 10 weeks. The program targets improved caregiver health through occupational therapy coaching."
223760024|NCT03252821|BEHAVIORAL|High-intensity interval training|High-intensity interval training sessions will be conducted on cycle ergometers or treadmill with heart rate measured throughout each session.
223760025|NCT03252821|BEHAVIORAL|Resistance training|Resistance exercise will be performed on eight exercises targeting major muscle groups at 60% to 85% of their estimated one-repetition maximum (1RM).
223760026|NCT03759093|DRUG|Bortezomib|Standard dosing based on product insert and subjected to dose adjustments as determined by clinical care team
223760027|NCT03759093|DRUG|Cyclophosphamide|Standard dosing based on product insert and subjected to dose adjustments as determined by clinical care team
223760028|NCT03759093|DRUG|Dexamethasone|Standard dosing based on product insert and subjected to dose adjustments as determined by clinical care team
223760029|NCT03759093|OTHER|CURATE.AI-Guided dosage modulation|CURATE.AI-guided modulation of Velcade and Cyclophosphamide dosages for VCD regimen, Velcade and Thalidomide dosages for VTD regimen, and Velcade and Lenalidomide dosages for VRD regimen
223760030|NCT03759093|DRUG|Thalidomide|Standard dosing based on product insert and subjected to dose adjustments as determined by clinical care team
224312165|NCT03603548|DRUG|Envarsus|Patients after liver transplantation initially treated with traditional Tacrolimus variant- Prograf, switched on day 10 after OLTx on prolonged released Tacrolimus variant in 1:1 ratio ( Advagraf vs. Envarsus)
223614475|NCT01685775|PROCEDURE|Transvaginal/transumbilical|
223614476|NCT01685775|PROCEDURE|Needlescopic with 3 trocars|
223614477|NCT04004910|OTHER|Plasma soluble TNF receptor pulldown|The Immunoadsorption affinity column, the LW-02 column, uses a proprietary human recombinant protein, single chain TNF-α ligand, covalently linked to a bead resin, that both enhances the capture efficiency of sTNF-Rs while avoiding complications from column leaching. Reduced sTNF-R plasma levels may lead to objective tumor responses.
223760031|NCT03759093|DRUG|Bortezomib|Dose in a range of 0.7,1.0,1.3 mg/m2 subcutaneous (SC) injection on Day 1, 8, 15 ,22 for cycles 1 to 4 , as determined and guided by CURATE.AI and approved by the clinical care team
223760032|NCT03759093|DRUG|Cyclophosphamide|Dosing in a range of 100, 300, 500 mg PO on Day 1, 8, 15, 22 for cycles 1 to 4 as determined and guided by CURATE.AI and approved by the clinical care team.
224312166|NCT03603548|DRUG|Advagraf|Patients after liver transplantation initially treated with traditional Tacrolimus variant- Prograf, switched on day 10 after OLTx on prolonged released Tacrolimus variant in 1:1 ratio ( Advagraf vs. Envarsus)
223614478|NCT04004910|OTHER|Plasma soluble TNF receptor pulldown + chemotherapy|"The Immunoadsorption affinity column, the LW-02 column, uses a proprietary human recombinant protein, single chain TNF-α ligand, covalently linked to a bead resin, that both enhances the capture efficiency of sTNF-Rs while avoiding complications from column leaching. Reduced sTNF-R plasma levels may lead to objective tumor responses.~In combined treatment arm the Immunopheresis® procedure is combined with low dose chemotherapy to potentially enhancing the latter's cytotoxic effect."
223614479|NCT04004910|DRUG|Chemotherapy Drugs, Cancer|Low dose chemotherapy will be provided to patient either IV or oraly depending on the regimen used.
223760033|NCT03759093|DRUG|Thalidomide|Dose in a range of 50-200mg PO on day 1-28 for cycles 1 to 4 as determined and guided by CURATE.AI and approved by the clinical care team.
223760034|NCT03759093|DRUG|Dexamethasone|40 mg PO on Day 1 ,8 , 15, 22 for cycles 1 to 4, as determined and guided by the clinical care team according to standard of care
223760035|NCT03759093|DRUG|Lenalidomide|Standard dosing based on product insert and subjected to dose adjustments as determined by clinical care team
223760036|NCT03759093|DRUG|Lenalidomide|Dose in a range of 5-25mg PO on day 1-21 for cycles 1 to 4, as determined and guided by CURATE.AI and approved by the clinical care team.
224201709|NCT03728257|BEHAVIORAL|LTGO-Home Based Exercise|The LTGO intervention consists of two phases: Phase 1. Intensive home-based exercise training and behavioral coaching via a telerehabilitation platform, Versatile and Integrated System for Tele-Rehabilitation (VISYTER)/two-way video communication system. Interactive intervention sessions will be delivered to the home via real time video conferencing (up to 12 sessions and a behavioral contract plan to prepare for phase 2); and Phase 2. Transition to self-management. Three telephone sessions (3 monthly counseling sessions) will be delivered over 12 weeks to provide behavioral coaching and exercise reinforcement
224201710|NCT03728257|BEHAVIORAL|Enhanced Usual Care|Enhanced Usual Care (EUC) will involve delivery of monthly newsletters (6 newsletters) on the topics of post-lung transplant management, including food safety, environmental health, flu, mental health, etc. and the provision of a self-monitoring device.
224201711|NCT05560802|OTHER|WHOs Labour care guide|Guidelines for monitoring labor progress, the WHOs LCG
224201712|NCT05846152|DEVICE|Intervention|"Patient wounds will be examined:~* by eye by the principal investigator~* using a ruler by the principal investigator~* by WoundCare algorithms (AKA WoundTrack) using smartphone photography by the principal investigator~* by eye by a second investigator~* using a ruler by a second investigator~* by WoundCare (AKA WoundTrack) algorithms using smartphone photography by a second investigator."
224201713|NCT04667507|DRUG|Dexamethasone Ophthalmic implant|Dexamethasone ophthalmic insert 0.4 mg for intracanalicular use
224201714|NCT05428267|OTHER|questionnaire|Completion of questionnaires (IIEF5/FSFI, SF 36, Fatigue Scale Score, Self Esteem Inventory, Hospital Anxiety and Depression Scale) during the pre-transplant consultation, then during a consultation 6 months after transplantation
224201715|NCT05428267|OTHER|blood collection|Collection of 2 tubes of 5mL of blood during a scheduled blood draw in the patient's care pathway. This sample will also be taken after the transplant (6 months later)
224201716|NCT05018286|DRUG|Apraglutide|Apraglutide is a synthetic peptide analogue of GLP-2 under development for treatment of SBS-IF, which acts as a full agonist at the GLP-2 receptor with in vitro potency and selectivity comparable with native GLP-2
224201717|NCT06230692|DEVICE|POWERbreathe Plus IMT|"Inspiratory muscle training will be performed using the POWERbreathe Plus IMT (POWERbreathe International Ltd., Warwickshire, UK), a commercially available inspiratory pressure threshold device. In this type of training, airflow is occluded until the generated inspiratory pressure reaches the predetermined threshold, which can be set at increments of 8 cm H2O.~During the first week of training, the target intensity will be set at 50% of baseline maximal inspiratory pressure (MIP.) During the second week, the target intensity will be set at 60% of baseline MIP. Beginning at the third week and for the remainder of the training program, the target intensity will be set at 75% of the participant's baseline MIP. The target volume will be 5 sets of 6 breaths per day (total of 30 breaths per day), separated by 1-minute rest breaks between sets. The frequency of training will be 5 days per week, for a duration of 6 weeks."
224201718|NCT05794126|DEVICE|Lens 1|Soft multifocal hydrogel contact lens for 15 minutes
224201719|NCT05794126|DEVICE|Lens 2|Soft multifocal silicone hydrogel contact lens for 15 minutes.
224201720|NCT02058264|DRUG|BBI-4000|
224201721|NCT01329562|DRUG|Treximet|Tablet for oral administration contains sumatriptan 85mg / naproxen sodium 500mg.
223614480|NCT00005674|DRUG|Creatine|
223614481|NCT04821258|DIETARY_SUPPLEMENT|MICODIGEST 2.0 supplement|MICODIGEST is a nutraceutical which contains 9 different fungal extracts: Ganoderma lucidum, Agaricus blazei, Grifola frondosa, Hericium erinaceus, Cordyceps sinensis, Inonotus obliquus, Pleurotus ostreatus, Polyporus umbellatus y Lentinula edodes
224201722|NCT01329562|DRUG|Placebo|A placebo tablet matching Treximet for oral administration.
224312167|NCT05607641|DRUG|Ketorolac tromethamine, solution for injection then Neospastil, film-coated tablets|"These medicines were used for patients of Group 1 (phase II) and Group 4 (phase III).~Stage 1 (1st day of study treatment) - Ketorolac tromethamine, solution for injection, 1 ml every 8 hours.~Stage 2 (2nd day of study treatment) - Neospastil, film-coated tablets, 1 tablet every 6 hours.~Stage 3 (3rd-5th days of study treatment) - Neospastil, film-coated tablets, 1 tablet on demand with an interval of at least 6 hours, not more than 4 tablets per day."
223614482|NCT04821258|DIETARY_SUPPLEMENT|Placebo supplement|Placebo
223614483|NCT01505959|DEVICE|CPAP treatment|Usual CPAP treatment
223614484|NCT01505959|DEVICE|CPAP treatment|CPAP treatment with telemedicine system
223614485|NCT03515525|DIAGNOSTIC_TEST|Closed-suction drain fluid volume|To evaluate the clinical value of postoperative drain fluid volume for detection of hematoma, an intra-individual comparison of drain secretion volumes between sides affected by hematoma and the uneventful contralateral breasts was performed.
223614486|NCT01082692|BIOLOGICAL|PENNVAX-B|DNA plasmids delivered via IM injection + electroporation using CELLECTRA device
223614487|NCT03777761|DRUG|tucatinib|300mg oral dose
223614488|NCT03777761|DRUG|placebo|Matching placebo for tucatinib
223614489|NCT03777761|DRUG|moxifloxacin|400mg single oral dose
223614490|NCT01818102|DEVICE|Width 1000 HU/Level -450 HU|Double-lumen tube size is selected according to the internal diameter of the left mainstem bronchus measured in the chest computed tomography with width 1000 HU and level -450 HU.
223614491|NCT01818102|DEVICE|Width 400 HU/Level 25 HU|Double-lumen tube size is selected according to the internal diameter of the left mainstem bronchus measured in the chest computed tomography with width 400 HU and level 25 HU.
223760037|NCT04418206|OTHER|patients COVID 19|Exposure to SARS-Cov2 but no symptoms (patient's family, medical staff) and General population (volunteers not exposed to SARS-Cov2)
223760038|NCT06251700|DEVICE|ENDO-AID CADe|ENDO-AID CADe will be used during the withdrawal process of the colonscopy
223760039|NCT04600648|DIAGNOSTIC_TEST|Serum insulin level|Measure levels before and after weight loss related to bariatric surgery
223760040|NCT04600648|DIAGNOSTIC_TEST|Serum Leptin test|Measure levels before and after weight loss related to lifestyle change weight loss
223760041|NCT05891548|DRUG|CLS-AX|CLS-AX will be administered by suprachoroidal injection into the study eye on Day 1 and then every 12 to 24 weeks as determined by protocol-defined disease activity criteria.
223760042|NCT05891548|DRUG|Aflibercept|Aflibercept will be administered by intravitreal injection into the study eye once every 8 weeks (Q8W).
223760043|NCT04677946|OTHER|High Linoleic Acid Healthy Cookies|High Linoleic Acid Healthy Cookies (containing about 9g of linoleic acid) 1 per day for 8 weeks
223760044|NCT03186118|BIOLOGICAL|T-cell Antigen Presenting Cells expressing truncated CD19 (T-APC)|Autologous CD4 and CD8 T cells transduced to express a truncated CD19 (CD19t) Transgene
223760045|NCT05543928|DRUG|CTAP101|CTAP101 Capsules is an extended-release (ER) oral formulation of calcifediol which was approved as Rayaldee® ER Capsules in June 2016 by the United States (US) Food and Drug Administration (FDA) for the treatment of secondary hyperparathyroidism (SHPT) in adult patients with stage 3 or 4 chronic kidney disease (CKD) and vitamin D insufficiency (VDI), defined as serum total 25-hydroxyvitamin D levels less than 30 ng/mL.
223760046|NCT05543928|DRUG|Placebo|Placebo
224201723|NCT04242901|DIAGNOSTIC_TEST|Faecal Immunochemical Test - OC Sensor, Eiken, Tokyo|Quantitative Faecal Immunochemical Test - OC Sensor, Eiken, Tokyo
223614492|NCT05010096|DRUG|Copanlisib|Given IV
223614493|NCT05010096|DRUG|Elimusertib|Given PO
223614494|NCT02907762|DEVICE|Endovascular aneurysm repair EVAR|
223614495|NCT03543761|DEVICE|Dornier Aries 2 device|• Sham group: 6 sessions with placebo LiST probe, 1 session per week. A specific probe design, identical to the active one will allow the double blind fashion of the study.
223614496|NCT03543761|DEVICE|Dornier Aries 2 device|LiST groups: 6 sessions with active LiS probe, 1 session per week. The ARIES 2 device by Dornier will be used with a treatment protocol: 5000 SW, energy flux density = 0.096 mJ/mm2 (energy level 7)
223614497|NCT03543761|DEVICE|Dornier Aries 2 device|LiST groups: 6 sessions with active LiS probe, 1 session per week. The ARIES 2 device by Dornier will be used with a treatment protocol: 5000 SW, energy flux density = 0.096 mJ/mm2 (energy level 7)
223760047|NCT06003556|DIAGNOSTIC_TEST|PSMA-1007 Positron Emission Tomography (PET) scan|Additional staging PET scan prior to focal therapy to focal therapy.
223760048|NCT05143970|DRUG|IPH5301 ALONE OR IN COMBINATION WITH CHEMOTHERAPY AND TRASTUZUMAB|"Part I-Dose escalation Patients will receive IPH5301 alone on day 1 (Week 1). Treatment will be administered every 2 weeks until progression or unacceptable toxicity or other reasons requiring treatment discon-tinuation, for a maximum duration of 12 months.~Part II- Expansion cohort Patients will receive IPH5301 at a recommended dose (RP2D) or a next lower dose (RP2D-1)in combination with trastuzumab and paclitaxel, at day 1 and every 2 weeks up to 6 cycles of paclitaxel. The RP2D dose will not exceed the designated maximum tolerated dose (MTD)."
223760049|NCT04400279|BEHAVIORAL|Yoga group|At-home yoga exercise instruction provided by a mobile/tablet app or through a computer web browser
223760050|NCT04400279|BEHAVIORAL|High Intensity Interval Training group|At-home HIIT exercise instruction provided by a mobile/tablet app or through a computer web browser
223760051|NCT04400279|BEHAVIORAL|Combination|At-home yoga \& HIIT exercise instruction provided by a mobile/tablet app or through a computer web browser
224201724|NCT03128931|DEVICE|Pediatric SedLine forehead EEG sensor|Pediatric EEG sensor.
223614498|NCT03174366|DRUG|Denosumab|Subjects will receive medication once following enrollment, and will be monitored for 1 year thereafter.
223614499|NCT03169166|DRUG|Triptorelin|Triptorelin pre-filled syringes (Gonapeptyl 0.1mg; Ferring GmbH, Germany) will be administered subcutaneously in three repeated doses 12 hours apart
223614500|NCT06328673|DRUG|DM919|Anti-MICA/MICB monoclonal antibody
223614501|NCT06328673|DRUG|Pembrolizumab|Anti-PD-1 monoclonal antibody
223760052|NCT04127786|BIOLOGICAL|Purified vero rabies vaccine - serum free - VRVg-2|Pharmaceutical form: Freeze-dried Route of administration: Intramuscular
223760053|NCT04127786|BIOLOGICAL|Purified inactivated rabies vaccine - Verorab®|Pharmaceutical form:Freeze-dried Route of administration: Intramuscular
223760054|NCT04127786|BIOLOGICAL|Purified inactivated rabies vaccine - Imovax® Rabies|Pharmaceutical form: Freeze-dried Route of administration: Intramuscular
224201725|NCT04993339|DRUG|OOC|The OOC will be mixed with autologous 5cc of platelet rich plasma (PRP), and then injected using a syringe into both tibia and femoral tunnels
224201726|NCT02658578|PROCEDURE|PNS|Active PNS will be administered by 2 pairs of surface electrodes (cathode proximal). One pair will overly the median and ulnar nerves at the wrist, and the other pair will overly the radial nerve. Trains of electric stimulation will be delivered at 1 Hz by using isolation units connected to a square pulse stimulator. In sham PNS, the median, ulnar and radial nerves will not be actively stimulated.
224201727|NCT00307138|DRUG|hetastarch|
224312168|NCT05607641|DRUG|Ketorolac tromethamine, solution for injection then Ketorolac tromethamine, coated tablets|"These medicines were used for patients of Group 2 (phase II) and Group 5 (phase III).~Stage 1 (1st day of study treatment) - Ketorolac tromethamine, solution for injection, 1 ml every 8 hours.~Stage 2 (2nd day of study treatment) - Ketorolac tromethamine, coated tablets, 1 tablet every 6 hours.~Stage 3 (3rd-5th days of study treatment) - Ketorolac tromethamine, coated tablets, 1 tablet on demand with an interval of at least 6 hours, not more than 4 tablets per day."
223614502|NCT05003375|BEHAVIORAL|High-challenging cognitive protocol to provoke stress and (cognitive) fatigue|"Baseline measurement is done in two parts: 1) resting for five minutes (no talking, no movement) and 2) speaking at normal pace (2 minutes).~This is immediately followed by a measurement of the physiological response variables during the testing, in which the following protocol is performed in the order presented: 1) SDMT-NBack task-SDMT\*-NBacktask\*\*, 2) NBack task-SDMT-NBack task-SDMT. Participants will run either sequence to check for effects of the previous testing. During the conduct of the study, it will be ensured that half of the participants in each group followed Sequence 1 and the other half of the group followed Sequence 2.~During all these measurements, the participant will sit at a table with a computer on which the tests are performed.~\*SDMT: Symbol Digit Modalities Test: see description in outcome measures~\*\*N-Back Task: see description in outcome measures"
223614503|NCT01380223|DRUG|placebo|I.V. infusion of placebo for 8 hr
223614504|NCT01380223|DRUG|omecamtiv mecarbil|I.V. infusion of placebo for 2 hr followed by 6 hr infusion of omecamtiv mecarbil at 0.005 mg/kg/hr
223614505|NCT01380223|DRUG|omecamtiv mecarbil|I.V. infusion of placebo for 2 hr followed by 6 hr infusion of omecamtiv mecarbil at 0.015 mg/kg/hr
223614506|NCT01380223|DRUG|omecamtiv mecarbil|I.V. infusion of placebo for 2 hr followed by 6 hr infusion of omecamtiv mecarbil at 0.025 mg/kg/hr
223614507|NCT01380223|DRUG|omecamtiv mecarbil|I.V. infusion of placebo for 2 hr followed by 6 hr infusion of omecamtiv mecarbil at 0.0625 mg/kg/hr
223760055|NCT02400723|BEHAVIORAL|Progressive Muscle Relaxation|Progressive Muscle Relaxation is a treatment in which individuals tense and release their muscle groups in a sequential order. This helps reduce anxiety and tension. It also teaches individuals to differentiate between muscle tension and relaxation.
223760056|NCT02400723|BEHAVIORAL|Diaphragmatic Breathing|Diaphragmatic breathing is a way in which people breathe using their diaphragm. This type of breathing has been found to promote relaxation and reduce stress.
224201728|NCT01566747|DRUG|Pazopanib|Pazopanib 800mg day to be given continuously until disease progression.
224201729|NCT04877405|OTHER|No intervention|This observational study is not focused on therapeutic intervention
224201730|NCT03225950|OTHER|In vitro stimulation of blood with periodontitis-associated- and control bacteria|Peripheral mononuclear blood cells are stimulated with periodontitis-associated- and control bacteria to measure the amount of positive cytokine-producing cells.
224201731|NCT03225950|DIAGNOSTIC_TEST|Anti-CCP- and anti-P.g.-antibodies titers|Anitbody titers will be measured in saliva and serum samples.
224201732|NCT03225950|GENETIC|Analysis of selected single nucleotide polymorphisms (SNPs)|DNA obtained from saliva samples will be used to determine the genotype of the participants for selected SNPs.
224201733|NCT03225950|DIAGNOSTIC_TEST|periodontitis-associated bacteria presence|Determination of the presence of periodontitis-associated bacteria e.i. Porphyromonas gingivalis in saliva and blood samples.
223614508|NCT01380223|DRUG|omecamtiv mecarbil|I.V. infusion of placebo for 2 hr followed by 6 hr infusion of omecamtiv mecarbil at 0.125 mg/kg/hr
223614509|NCT01380223|DRUG|omecamtiv mecarbil|I.V. infusion of placebo for 2 hr followed by 6 hr infusion of omecamtiv mecarbil at 0.25 mg/kg/hr
223614510|NCT01380223|DRUG|omecamtiv mecarbil|I.V. infusion of placebo for 2 hr followed by 6 hr infusion of omecamtiv mecarbil at 0.5 mg/kg/hr
223614511|NCT01380223|DRUG|omecamtiv mecarbil|I.V. infusion of placebo for 2 hr followed by 6 hr infusion of omecamtiv mecarbil at 1.0 mg/kg/hr
223614512|NCT01380223|DRUG|omecamtiv mecarbil|I.V. infusion of placebo for 2 hr followed by 6 hr infusion of omecamtiv mecarbil at 0.75 mg/kg/hr (dose reduced)
223614513|NCT01380223|DRUG|omecamtiv mecarbil|I.V. infusion of placebo for 2 hr followed by 6 hr infusion of omecamtiv mecarbil at 0.625 mg/kg/hr (dose reduced)
223614514|NCT02418039|DIETARY_SUPPLEMENT|High protein diet|It has been suggested that administrating a high protein diet in patients with liver cirrhosis and with minimal hepatic encephalopathy could prevent the development of malnutrition, increase the detoxification of ammonia by the muscle to consequently delay the onset overt hepatic encephalopathy and prolong patient survival. However, information is scarce and inconclusive regarding the potential role of dietary protein in the prevention and treatment of minimal hepatic encephalopathy.
223614515|NCT02418039|DIETARY_SUPPLEMENT|Normal protein|A normal protein diet will be administrated in patients with MHE.
223614516|NCT03148613|DEVICE|Carbon Monoxide Breath Sensor System (COBSS)|Carbon Monoxide Breath Sensor System (COBSS): Device to measure carbon monoxide levels in one's breath and inform the user.
223614517|NCT03148613|DEVICE|Bedfont - Micro+™ Smokerlyzer®|Bedfont - Micro+™ Smokerlyzer® : Predicate Device to measure carbon monoxide levels in one's breath.
223614518|NCT03168412|BIOLOGICAL|Recombinant Hepatitis E Vaccine (Escherichia Coli)|Participants would receive 3 doses of Recombinant Hepatitis E Vaccine (Escherichia Coli) intramuscularly at 0, 7, 21 days.
223614519|NCT03168412|BIOLOGICAL|Recombinant Hepatitis E Vaccine (Escherichia Coli)|Participants would receive 3 doses of Recombinant Hepatitis E Vaccine (Escherichia Coli) intramuscularly at 0, 1, 6 month.
223614520|NCT02845817|OTHER|Qualitative research|Semi-structured interviews
223614521|NCT04934566|OTHER|ECMO flow|Dynamic changes in ECMO flow and SvO2 measurement at the 3 different sites.
223614522|NCT02894671|OTHER|blood exams|in serum will be analyzed the level of IMA, iron, transferrin, ferritin, total albumin
223614523|NCT04205526|DEVICE|Active rTMS|Patients randomized to receive actual rTMS treatment will receive 1Hz rTMS applied over contralesional M1 at an intensity of 120% resting motor threshold once daily for 30 minutes (approximately 1800 pulses) for a total of 15 sessions.
223760057|NCT02400723|OTHER|Psychoeducation (Placebo)|DVD-delivered psychoeducation. Participants will view videos that contain information about what anxiety is and information about one's well-being. This condition is an attention placebo control.
223760058|NCT00204620|DRUG|Bendamustin|
223614524|NCT04205526|DEVICE|Sham TMS|For sham-stimulation, the TMS coil will be placed over the inter-hemispheric fissure at the vertex and stimulation will be performed with low intensity (10% resting motor threshold). This will cause similar skin sensations as real stimulation but will not induce currents in motor relevant areas.
223760059|NCT03871127|PROCEDURE|Percutaneous coronary intervention|Using sirolimus eluting stent
223760060|NCT03871127|PROCEDURE|coronary artery bypass graft|coronary artery bypass graft
223614525|NCT00002963|DRUG|aminolevulinic acid hydrochloride|
223614526|NCT00002963|PROCEDURE|conventional surgery|
223614527|NCT02316561|RADIATION|Single dose ablative radiotherapy|A single dose ablative radiotherapy will be delivered prior to surgery
223614528|NCT05238389|DEVICE|AI-based upper limb robotic therapy|"Patients will be treated using MOTORE, a robotic device that allows passive, active, and active-assistive planar movements of the shoulder and elbow joints. The intervention will consist of 30 sessions, 1 per day and 5 per week. Therefore, each patient will be treated for 6 weeks~The parameters of the serious games will be proposed by a Decision Support System (DSS), based on an AI-based algorithm trained using data collected during a previous Randomized Controlled Trial.~The DSS will be fed, at the enrollment, with patient's demographics, clinical characteristics, clinical scales and kinematic/kinetic data measured by the robot during an evaluation session (unassisted reaching movements) and updated every 2 sessions with kinematic/kinetic data only, to tailor the treatment to the patient's current abilities.~The therapists will be free to use or not the suggested parameters, on the basis of their previous experience with the robot (over 3 years)."
223614529|NCT02461381|OTHER|not intervention|This is a cross-sectional study for estimation of diagnostic performance.
223614530|NCT03393234|RADIATION|Interoperative radiation by INTRABEAM using low energy X-ray|Intrabeam is a mobile Platform for Intraoperative Radiotherapy (IORT) produced by the ZEISS company in Germany.Interoperative radiation by INTRABEAM using low energy X-ray.The Intrabeam PRS appears to be a safe technique for delivering IORT in rectal cancer patients.
223614531|NCT02090426|OTHER|Link2Care|
223614532|NCT04610047|DRUG|Norketotifen|Oral capsule
223614533|NCT04610047|DRUG|Placebo|Oral capsule
223614534|NCT03228771|DRUG|PRGF/ATV|Atorvastatin loaded in PRGF fibrin scaffold
223614535|NCT03228771|DRUG|ATV gel|Atorvastatin loaded in methyl cellulose gel
223614536|NCT00182039|DRUG|Metoprolol controlled release (CR)|Patients received the first dose of the study drug (i.e., oral metoprolol CR or matching placebo 100 mg) 2-4 hours prior to surgery. Administration of the study drug at each dosing time required a patient to have a heart rate ≥ 50 beats per minute (bpm) and a systolic blood pressure (SBP) ≥ 100 mmHg. If the patient's heart rate was ≥ 80 bpm and their SBP ≥ 100 mmHg at any time during the first 6 hours after surgery, the patient received their first postoperative dose (i.e., 100 mg of the study drug) orally. Patients who did not receive the study drug during the first 6 hours after surgery received 100 mg of the study drug orally at 6 hours after surgery. Twelve hours after the first postoperative dose patients started taking oral metoprolol CR or placebo 200 mg daily for 30 days.
223614537|NCT00182039|DRUG|Placebo|Patients received the first dose of the study drug (i.e., oral metoprolol CR or matching placebo 100 mg) 2-4 hours prior to surgery. Administration of the study drug at each dosing time required a patient to have a heart rate ≥ 50 beats per minute (bpm) and a systolic blood pressure (SBP) ≥ 100 mmHg. If the patient's heart rate was ≥ 80 bpm and their SBP ≥ 100 mmHg at any time during the first 6 hours after surgery, the patient received their first postoperative dose (i.e., 100 mg of the study drug) orally. Patients who did not receive the study drug during the first 6 hours after surgery received 100 mg of the study drug orally at 6 hours after surgery. Twelve hours after the first postoperative dose patients started taking oral metoprolol CR or placebo 200 mg daily for 30 days.
223614538|NCT03531671|DEVICE|Binocular-OCT|Binocular Optical Coherence Tomographer used to assess both eyes in the same session without the need for a trained assistant.
223614539|NCT03471273|PROCEDURE|endoscopic management, surgery and follow up|endoscopic management, surgery and follow up
223614540|NCT02093507|OTHER|parents manipulation|parents perform manipulation the child foot to correct the deformity
223614541|NCT05923814|DRUG|CD25 prophylaxis|The humanized CD25 antibody was administered at 1 mg/kg iv on days+1 and +4 after HSCT.
223760061|NCT00869739|BEHAVIORAL|telephone-based intervention|
223760062|NCT00869739|OTHER|educational intervention|
223760063|NCT00869739|OTHER|partner-assisted coping skills training|
223760064|NCT00869739|OTHER|questionnaire administration|
223760065|NCT00869739|PROCEDURE|psychosocial assessment and care|
224201734|NCT05710666|DRUG|trastuzumab deruxtecan (T-DXd) (IV)|Administered as an intravenous (IV) infusion at a dose of 5.4 mg/kg on Day 1 of each 21-day cycle for up to six cycles.
224201735|NCT03389776|PROCEDURE|Anesthesia|Occurrence and severity of postoperative sore throat could be determined by various factors other than the pressure of the cuff alone. In particular, cuff pressure measurement, duration of anaesthesia, airway manipulations e.g. multiple insertion attempts, could all be factors determining the occurrence of postoperative sore throat.
224201736|NCT00386191|DRUG|clopidogrel (SR25990C)|oral administration
224201737|NCT03628872|PROCEDURE|Scaling and root planing|"A non-surgical procedure that treats periodontal disease, sometimes called a deep cleaning, is considered the gold standard (standard of care) of treatment for patients with chronic periodontitis."
223760066|NCT00869739|PROCEDURE|quality-of-life assessment|
223760067|NCT03422393|DRUG|Venetoclax|On cycle 1, day 1, patients will initiate venetoclax. The dose of venetoclax will ramp-up from 20 mg PO daily to 400 mg PO daily over a 5 week period.
223760068|NCT03422393|DRUG|Ibrutinib|"During the screening period, patients will continue on ibrutinib at their previous tolerated dose, unless required to stop (e.g.: by a preceding clinical trial).~On cycle 1, day 1, the dose of ibrutinib will be assigned based on the dose cohort. Patients in cohort 1 will receive ibrutinib 420 mg PO daily. Patients in cohort 2 will receive ibrutinib 560 mg PO daily. Cohort 3 will be 840 mg PO daily."
224312169|NCT05607641|DRUG|Neospastil, solution for injection then Neospastil, film-coated tablets|"These medicines were used for patients of Group 3 (phase II) and Group 6 (phase III).~Stage 1 (1st day of study treatment) - Neospastil, solution for injection, 2 ml every 8 hours.~Stage 2 (2nd day of study treatment) - Neospastil, film-coated tablets, 1 tablet every 6 hours.~Stage 3 (3rd-5th days of study treatment) - Neospastil, film-coated tablets, on demand 1 tablet with an interval of at least 6 hours, not more than 4 tablets per day."
224312170|NCT03423017|OTHER|Recording of data|"Recording during one hospitalization of 48 hours between birth and 2 months of life and one hospitalization of 24 hours between 6 and 10 months of life~* General data: age, term of birth, birth weight, gender, diseases, weight and size at recording, cranial perimeter, food, drugs : first and second visit~* Respiratory rate, respiratory signs, stridor : first and second visit~* 24h holter-ECG : first and second visit~* 24h impedance pH-metry : first visit~* Nocturne polysomnography : 50% prone position, 50% supine : sleep analyze, obstructive apnea hypopnea index (OAHI), central apnea index (CAI), periodical breathing, micro arousals index, non-nutritive swallowing analyze,(mental region electromyogram) : first and second visit~* 24 h gaz exchanges : mean, maximal PtcCO2 and % of time spent above 50 mmHg , SpO2 under 90%, 85% et 80% and desaturations index : first and second visit~* succimetry procedure : at first visit only between birth and 2 months"
223614542|NCT04521322|DRUG|Iota-Carrageenan|Participants will received a nasal spray with Iota-Carrageenan or placebo 4 times a day during 21 days
223614543|NCT03882892|DRUG|Ezetimibe|Ezetimibe 10 mg tablets
223614544|NCT03882892|DRUG|Atovastatin|Atorvastatin 10, 20, and 40 mg tablets at a daily dose of 10 to 80 mg
223614545|NCT03882892|DRUG|Placebo|Placebo tablets matched to ezetimibe
223614546|NCT05771649|BEHAVIORAL|Mindfulness-based intervention|A mindfulness instructor will guide focused attention meditations that will last from 15 to 30 minutes. Participants will be instructed at the beginning of the intervention and will have audio files to guide the exercises during their practice.
223614547|NCT05771649|BEHAVIORAL|Physical exercise|An instructor will guide to running with mental association strategies that will last from 15 to 30 minutes. Participants will be instructed at the beginning of the intervention and will have audio files to guide the exercises during their practice.
223760069|NCT03645668|DRUG|Meropenem Injection|Different administration types between two groups
223760070|NCT02636465|OTHER|flight simulationin obese healthy adults or obese patients with or without COPD, OHS|
223614548|NCT05605626|OTHER|the better retaining of skills|identify which teaching program has the better retaining of skills
223614549|NCT02719496|DRUG|IBEROGAST|
223614550|NCT01141712|PROCEDURE|Autologous transplant|Participants will receive the BEAM conditioning regimen followed by autologous HCT.
223760071|NCT06241027|OTHER|Nerve flossing technique|The nerve flossing technique will be perform actively with the participant sitting on the chair. The participant flexed the knee of the target lower extremity backward beside the chair as far back as possible and flexed the neck at the same time, holding both the flexed knee and neck in thisposition for 5 seconds. The participant in turn extended the neck and knee of the target lower extremity, abducted and flexed the hip until pain will feel and did not push beyond that point. This extended position will be hold for 5 seconds.
223760072|NCT06241027|OTHER|Myofascial release|Myofascial release therapy involved the application of a low load, long duration stretch along the line of maximal fascial restriction. Pressure will be applied directly on the skin toward the direction of restriction until resistance of the tissue barrier will felt, Once found , the collagenous barrier will engaged for 90-120 seconds without sliding over the skin or forcing the tissues until the fascia complex started to yield and a sensation of softening will achieved.This stage will be repeated up to 5 times for new barrier until the sensation of tissue restriction during stretching became weaker.
223760073|NCT03568942|DRUG|Gepotidacin|Gepotidacin tablets will be available at a dose strength of 750 mg. Tablets will be administered BID with water after consumption of food.
223760074|NCT00107458|DRUG|valproic acid|
223760075|NCT02843945|DEVICE|Directional Brachytherapy Source Implant|The FDA Cleared CivaSheet Directional Pd103 Brachytherapy Source is a planar radiaiton source which utilizes gold shielding in its construction. This device is radioactive on one side only, and is capable of safely delivering high doses of radiation to target areas even when placed directly adjacent to sensitive, healthy tissue or critical structures.
223760076|NCT02380651|PROCEDURE|Limb salvage|Local or free flaps
223760077|NCT01945489|BIOLOGICAL|onabotulinumtoxinA|OnabotulinumtoxinA (BOTOX®) injected into the detrusor.
223760078|NCT01945489|DRUG|Normal saline|Normal saline (placebo) injected into the detrusor.
223760079|NCT01550419|DRUG|Atorvastatin|Patients will receive 40mg atorvastatin(one tablet) over night via enteral feeding tube or per os during they stay in ICU at most thirty days.
223760080|NCT01550419|DRUG|Placebo|The smell and shape of placebo are the same as atorvastatin
223614551|NCT01141712|DRUG|BCNU|Participants will receive BCNU 300 mg/m\^2 Day -6
223614552|NCT01141712|DRUG|Etoposide|Participants will receive Etoposide 100 mg/m\^2 BID Days -5 to -2
223614553|NCT01141712|DRUG|Cytarabine|Participants will receive Cytarabine 100 mg/m\^2 BID Days -5 to -2
223614554|NCT01141712|DRUG|Melphalan|Participants will receive Melphalan 140 mg/m\^2 Day -1
223614555|NCT06117735|DEVICE|Transjugular Intrahepatic Portosystemic shunt|The experimental device is a class III implanted shunt device, which will be used to create a shunt between intrahepatic and portosystemic to reduce portal hypertension.
223614556|NCT05597033|BEHAVIORAL|Exercise|walking and handgrip exercise
223614557|NCT05597033|BEHAVIORAL|Control|seated rest
223614558|NCT06161597|BEHAVIORAL|Family Check-Up Online|Families will be provided with access to the FCO program, available in English or Spanish. Parents complete a tutorial and five different modules focused on distinct parenting skills. Each module starts with a survey and feedback to help identify relative strengths and challenges with the targeted parenting skills. Parents are then guided through various online activities including videos that model right and wrong ways to handle comm on situations and explanations of parental self-management and problem-solving strategies. Parents are complete activities to practice the parenting skills taught. Parents will have access to the online program for 8 and they are encouraged to practice the program strategies during this time period. At the end of the 8 weeks, parent re-complete the brief questions that they filled out at the beginning of each module and then receive feedback indicating which of the parent's domain scores have improved since they completed each module.
223614559|NCT03819361|DIAGNOSTIC_TEST|pulse-oximetry|Patients with suspected OSA will be monitored with 14 nights of pulse-oximetry prior to the already planned in-hospital single-night sleep study at the University Hospital Zurich
224312171|NCT03423017|OTHER|Recording of data|"Recording during one hospitalization of 48 hours between birth and 2 months of life~* General data: age, term of birth, birth weight, gender, diseases, weight and size at recording, cranial perimeter, food, drugs~* Respiratory rate, respiratory signs, stridor~* 24h holter-ECG~* 24h impedance pH-metry~* Nocturne polysomnography : 100% supine position : sleep analyze, obstructive apnea hypopnea index (OAHI), central apnea index (CAI), periodical breathing, micro arousals index, non-nutritive swallowing analyze,(mental region electromyogram)~* 24 h gas exchanges : mean, maximal PtcCO2 and % of time spent above 50 mmHg , SpO2 under 90%, 85% et 80% and desaturations index~* Succimetry procedure : at first visit only between birth and 2 months"
224312172|NCT00269243|DRUG|Quinapril|
224312173|NCT00006019|DRUG|azacitidine|
224312174|NCT00006019|DRUG|sodium phenylbutyrate|
224312175|NCT06200324|OTHER|Ready-to-Use Parenteral Nutrition|"In newborns weighing less than 1000 grams, parenteral nutrition is initiated at volumes of 70-80 ml/kg/day up to a maximum volume of 128 ml/kg/day, with a provision of 4 grams/kg/day of protein and a metabolic rate of 12 mg/kg/minute.~For newborns weighing between 1001-1500 grams, parenteral nutrition is initiated at volumes of 70-80 ml/kg/day up to a maximum of 110 ml/kg/day.~When enteral intake exceeds 70 ml/kg/day, a gradual decrease in the volume of parenteral nutrition is initiated. We discontinue parenteral nutrition in newborns weighing less than 1000 grams with enteral volume of 120 ml/kg/day, and for those between 1000 grams and 1500 grams, enteral nutrition volume of 100 ml/kg/day."
224312176|NCT03821181|DEVICE|RIC group|Patients allocated to the RIC group will undergo RIC procedure during which bilateral arm cuffs are inflated to a pressure of 50 mmHg over systolic blood pressure for five cycles of 5 min followed by 5 min of relaxation of the cuffs.
223614560|NCT06138548|DEVICE|Ossiofiber® Trimmable Fixation Nail|OSSIOfiber® Trimmable Fixation Nails are equally strong in the initial stability and fixation strength - and superior in rotational resistance to traditional metal cannulated headless compression screws.\*
223614561|NCT05258136|DRUG|low-dose CD20 monoclonal antibody injection|To comprehend the efficacy and safety of low-dose CD20 monoclonal antibody injection in preemptive treatment of EBV positive lymphoproliferative diseases after allo-HSCT in patients with EBV-HLH and CAEBV
223614562|NCT01867736|DEVICE|Passeo-18 Lux DRB|
223614563|NCT01867736|DEVICE|Standard PTA (POBA)|
223614564|NCT01175863|DEVICE|Grey scale intravascular ultrasound (Galaxy or Virtual histology-Intravascular Ultrasound)|minimal lumen area on Intravascular ultrasound
223614565|NCT01175863|DEVICE|Pressure wire(Radi Medical Systems)|Fractional flow reserve measured by pressure wire
223614566|NCT02055326|BEHAVIORAL|Cognitive Behavioral Therapy for Smoking Cessation|one hour weekly for 8 weeks. Cognitive behavioral therapy for smoking cessation
223614567|NCT02055326|BEHAVIORAL|Yoga|One hour, twice weekly for 8 weeks of vinyasa yoga
223614568|NCT02055326|BEHAVIORAL|Health & Wellness|Lectures, handouts and printed materials on general health and wellness topics including healthy eating, cancer prevention and cardiovascular disease prevention.
223614569|NCT04561895|GENETIC|DNA extraction|investigation of DNA polymorphism in patients suffering from NAFLD
223614570|NCT00634439|DRUG|atomoxetine|
223614571|NCT00634439|DRUG|Stimulants|Methylphenidate, amphetamines (including Adderall and mixed salts)
223614572|NCT00634439|OTHER|No intervention (general population)|
223614573|NCT05369663|DEVICE|mask use|face mask use
223614574|NCT01556451|BIOLOGICAL|Zoster Vaccine Live|Zoster vaccine live
223614575|NCT06420947|OTHER|atomizer|Participants received 2% lidocaine by atomizer.
223614576|NCT02624440|DRUG|Standard myeloma treatment|The choice of myeloma standard treatment is at the discretion of the treating investigator guided by the national Danish guidelines for treatment of multiple myeloma
223614577|NCT02624440|DRUG|Clarithromycin|P.o. clarithromycin 250 mg twice daily
223614578|NCT02624440|DRUG|Sulfamethoxazole/trimethoprim|P.o. sulfamethoxazole/trimethoprim 400/80 mg twice daily
223614579|NCT02624440|DRUG|Observation|Observation without prophylactic antibiotic
223614580|NCT03171337|DEVICE|Acupuncture|Acupuncture at acupoints for CTTH according to TCM theory using stainless filiform needle.
223614581|NCT03171337|DEVICE|Fu's Subcutaneous Needling (FSN)|Fu's subcutaneous needling at specific points for CTTH using soft casing needle.
223614582|NCT03171337|DEVICE|Sham acupuncture|Sham acupuncture at non-acupoints using Steinberger placebo needles
223614583|NCT03030001|BIOLOGICAL|PD-1 antibody expressing mesothelin specific CAR-T cells|Patients will receive an IV infusion of PD-1 antibody expressing mesothelin specific CAR engineered peripheral blood leukocyte. On day 21, cells will be infused intravenously (i.v.) on the Patient Care Unit over 20 to 30 minutes.
223614584|NCT02152709|BIOLOGICAL|3 dose of 10µg/0.5ml hepatitis B vaccine|3 dose of 10µg/0.5ml hepatitis B vaccine made by recombinant deoxyribonudeic acid techniques in saccharomyces cereviside were administered intramuscular injection at 0, 1, 6 momth interval.
223614585|NCT02152709|BIOLOGICAL|3 dose of 5µg/0.5ml hepatitis B vaccine|3 dose of 5µg/0.5ml hepatitis B vaccine made by recombinant deoxyribonudeic acid techniques in saccharomyces cereviside were administered intramuscular injection at 0, 1, 6 momth interval.
223614586|NCT00945282|DRUG|GSK2248761|GSK2248761 30 mg capsule once a day for 7 days. GSK2248761 is an investigational (not approved by the FDA) HIV drug in the class of non-nucleoside reuptake inhibitor class.
223614587|NCT00945282|DRUG|Lopinavir/ritonavir|Lopinavir 400 mg and ritonovir 100 mg every 12 hours for 28 days. Lopinavir/ritonavir is approved by the FDA as an HIV medication in the protease inhibitor class. Kaletra is a trademark of Abbott Laboratories.
223614588|NCT00945282|DRUG|HAART|Highly Active Antiretroviral therapy of the doctor's choice.
223614589|NCT00945282|DRUG|Placebo|Placebo is a capsule with no drug in it.
223614590|NCT00945282|DRUG|GSK2248761|GSK2248761 10 mg -20 mg or 40 mg - 90 mg once a day for 7 days. GSK2248761 is an investigational (not approved by the FDA) HIV drug in the class of non-nucleoside reuptake inhibitor class.
223614591|NCT03494920|OTHER|Direct endovascular clot retrieval|Direct endovascular clot retrieval within 4.5 hours of stroke onset
223614592|NCT03494920|OTHER|Bridging thrombolysis followed by ECR|Bridging thrombolysis followed by ECR within 4.5 hours of stroke onset
223614593|NCT00941408|PROCEDURE|Diagnostic tumor core biopsy|
223614594|NCT00808093|DRUG|GSK256073|GSK256073 100 mg study drug
223614595|NCT00854230|DRUG|Naltrexone|Naltrexone dose 25-100mg
223614596|NCT02018081|DRUG|Levofloxacin|8 blood sampling by patients between the 48th and 60th
223614597|NCT02744365|OTHER|Observational|"All women of the biobank have provided:~1. blood samples (plasma, serum and Buffy-coat)~2. urine samples~3. demographic and clinical data (maternal age, BMI, smoking status, obstetrical and medical history)~4. mean arterial blood pressure~5. ultrasound examination (datation of pregnancy at recruitment, uterine arteries doppler, placental volume, nuchal translucency in the majority of the cases)~6. access to medical record (for pregnancy/delivery outcomes, newborn birthweight, gestational age at delivery)"
223614598|NCT00973453|DRUG|PURETHAL Mites 20,000 AUeq/ml|"Group 1: slow regimen (12+2 injections) Initial treatment: incremental weekly dose of 0.05, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.8, 1.0, 1.2\*, 1.6\* and 2.0\* ml Additional maintenance: 2 two-weekly injections 2.0\* ml~\*Injection volumes larger than 1 ml will be given as 2 separate injections of equal volume within an area of 1 cm."
223614599|NCT00973453|DRUG|PURETHAL Mites 20,000 AUeq/ml|"Group 2: intermediate regimen (9+2 injections) Initial treatment: incremental weekly dose of 0.1, 0.2, 0.4, 0.6, 0.8, 1.0, 1.2\*, 1.6\* and 2.0\* ml.~Additional maintenance: 2 two-weekly injections 2.0\* ml~\*Injection volumes larger than 1 ml will be given as 2 separate injections of equal volume within an area of 1 cm."
223760081|NCT02084771|DRUG|Intravenous Saline|Patients randomized to this arm will receive intravenous isotonic (0.9%) saline. The rate of isotonic saline will be 3 mL/kg given the one hour before CT and 1 mL/kg/hour for 6 hours post-CT as per Canadian guidelines. Patients weighing more than 110 kg will receive the rate as per a 110 kg patient. The dose will be rounded up to the nearest 5 mL.
223760082|NCT02084771|BIOLOGICAL|Oral Salt and Water|Oral salt capsules and water, based on patient weight
223760083|NCT01347437|BEHAVIORAL|Positive STEPS|This intervention is given to patients in the experimental condition only. The Positive STEPS intervention-developed by our team-is based on general principles of cognitive-behavioral therapy as well as more specific principles of motivational interviewing32,33 and problem solving therapy. Informational, problem solving, and cognitive-behavioral STEPS are targeted over 5, in-person, intervention sessions with a PhD-level counselor. The intervention will also include a series of short videos related to the topics that the Positive STEPS intervention covers with participants. Participants in the experimental condition can also choose to receive text messages sent to their cell phone to remind them to take their medication.
223760084|NCT00895466|BIOLOGICAL|PEP-223/CoVaccine HT|
223760085|NCT02273843|DRUG|High-dose vitamin D 3|Will receive oral cholecalciferol (vitamin D3) in a single daily dose of 800 IU from the time of diagnosis of sepsis until discharge from the NICU
223760086|NCT02273843|DRUG|Conventional-Dose Vitamin D 3|Will receive oral cholecalciferol (vitamin D3) in a single daily dose of 400 IU from the time of diagnosis of sepsis until discharge from the NICU
223760087|NCT00358527|DRUG|Mometasone Furoate Nasal Spray (MFNS)|MFNS 50 mcg/spray: self-administered, two sprays per nostril (ie, 200 mcg QD), once daily (each morning), for 28 days.
223760088|NCT00358527|OTHER|Placebo|Matching placebo nasal spray: 2 sprays per nostril once daily for 28 days
223614600|NCT00973453|DRUG|PURETHAL Mites 20,000 AUeq/ml|"Group 3: fast initial treatment (6+2 injections) Initial treatment: incremental weekly dose of 0.2, 0.4, 0.8, 1.2\*, 1.6\* and 2.0\*ml.~Additional maintenance: 2 two-weekly injections 2.0\* ml~\*Injection volumes larger than 1 ml will be given as 2 separate injections of equal volume within an area of 1 cm."
223614601|NCT05364463|PROCEDURE|Methods for cannulating the radial artery in a cardiac catheterization|The puncture will be performed in each participant according to the method has been assigned randomly: ultrasound and hyperemia, ultrasound only, hyperemia only, palpation.
223614602|NCT02333357|BEHAVIORAL|Multimedia 12-Step Toolkit|The Multimedia 12-Step Toolkit includes counselor written guides, posters, client worksheets, engagement activities, and videos designed to be shown during group treatment sessions to explain and encourage 12-step participation.
223614603|NCT02333357|BEHAVIORAL|Treatment as Usual|Treatment as Usual is defined as five standard 12-step facilitation group sessions as counselors would normally conduct with their clients.
223614604|NCT04113317|DRUG|G-CSF (Filgrastim)|Contains 0,59 mg of acetate, 0,04 mg of polysorbate 80, 0,035 mg of sodium, 50 mg of sorbitol
223760089|NCT02674412|DRUG|Buspirone|
223760090|NCT02674412|DRUG|Placebo|Placebo Pill Manufactured by the Investigational Pharmacy at Cleveland Clinic
223760091|NCT04144166|DEVICE|capillary refill index (CRI)|a waveform analysis method using a pulse oximeter to assess peripheral perfusion
223760092|NCT03125512|DEVICE|Night Shift positional device|Night Shift is a small, positional therapy device that is worn at the back of the neck using a latex free silicone rubber strap. The strap is adjustable and is secured with a magnetic clasp. When a supine position is detected, the device vibrates with increasing intensity till the subject changes to a non-supine position.
224201738|NCT03628872|DEVICE|Er:YAG Laser|This laser is intended to be used for dental surgery. The Er:YAG Laser emits an infrared beam which is readily absorbed by water contained by both hard and soft tissues of the human body. As a result, energy of the laser beam instantly vaporizes the water molecules in soft and hard tissues of the tooth and surrounding tissues causing the tissues to crumble away or resection of the soft tissues of gingival.
224201739|NCT03628872|DEVICE|Hand instruments|11/12 and 13/14 gracey, 4R/4L curette and sickle - standard of care choices for performing scaling and root planing.
224201740|NCT03522155|BEHAVIORAL|Patient-centered communication of life expectancy|The intervention arm will test if patient-specific LE estimates via a targeted, patient-centered communication approach paired with LE-specific conjoint analysis data improves decisional conflict, quality of LE discussion, and reduces rates of overtreatment of Genitourinary malignancies.
224201741|NCT00683891|DRUG|FazaClo (clozapine, USP) ODT|
224201742|NCT04638218|DEVICE|Rehabilitation Training System|The system can capture useful biomechanical data accurately, such as the location of body centre of mass (COM), the body joint angles, and the body posture. These useful data are stored in a database and can be conveniently accessed by the therapists, which facilitate the follow-up of the patients' therapeutic progress.
224201743|NCT03081130|PROCEDURE|Intravenous laser irradiation treatment|control group
224201744|NCT00061568|PROCEDURE|Peripheral blood hematopoietic progenitor cell (PBPC) transplant|Peripheral blood hematopoietic progenitor cell (PBPC) transplant
224201745|NCT00061568|DRUG|Alemtuzumab|Alemtuzumab
223509645|NCT04236947|BEHAVIORAL|SCPP-YA|SCPP-YA includes two modules. In the first module of ten sessions, students will learn to employ a 6-step social information processing framework for solving a wide range of real-life problems. The six-step process consists of 1) stop, clam down, and think before you act; 2) say the problem and how you feel; 3) set a positive goal; 4) think of many solutions; 5) think ahead to the consequences and 6) go ahead and try the best plan. The second module offers 1) current and accurate information about the health, social, and legal consequences of substance use, 2) correct mistaken beliefs that students have about substance use, 3) enhances awareness of social and media influences; and 4) teachers assertiveness and critical thinking skills to resist peer pressure.
224201746|NCT00061568|PROCEDURE|Peripheral blood hematopoietic progenitor cell Apheresis|Donor-Peripheral blood hematopoietic progenitor cell (PBPC) apheresis
223509646|NCT03413917|OTHER|Analysis of genomic markers in uterine atony|No intervention will be performed. We will be analyzing tissue and blood samples only to identify potential association of genomic markers with uterine atony.
223509647|NCT06220266|DRUG|Phytoestrogen|consume 1 capsule twice a day for 2 months which one capsule composed of dry weight 50 mg of Pueraria Mirifica 1or Pueraria Mirifica 2 or Pueraria Mirifica 3
223509648|NCT06220266|DRUG|Diet control & life style modification|Diet control \& life style modification
223509649|NCT06964646|DRUG|Vaginal Hyal gel 2.5g|vaginal gel 2.5g
223509650|NCT06964568|DRUG|PD-1 inhibitor|PD-1 inhibitors will be administered intravenously, a fixed dose of 200 mg, once every 3 weeks for 1 year.
223509651|NCT06964568|RADIATION|TDLN-sparing radiotherapy|Tumor draining lymph nodes-sparing radiotherapy 50.4Gy/28Fx
223509652|NCT06964568|RADIATION|Unlimited radiotherapy|Unlimited radiotherapy 50.4Gy/28Fx
223509653|NCT02458300|OTHER|Nebulization of hypertonic saline|application of hypertonic saline serum through a mask fogging or a box fogging
223509654|NCT02458300|OTHER|Prolonged slow expiration technique (PSE)|Passive expiratory aid implemented baby. the child is placed supine on a hard surface. Thoracoabdominal slow manual pressure that begins at the end of a spontaneous and continuous exhalation to residual volume is exercised. Oppose reaches 2 or 3 breaths. Vibrations can accompany the art. The goal is to achieve a greater expiratory volume.
223509655|NCT02458300|OTHER|Patient coughing Provocation (TP)|Tp is based on the mechanism reflects cough induced by stimulation of the buttons on the wall of the trachea extrathoracic mechanoreceptors. The child is placed supine. A short pressure is done with the thumb on the tracheal conduit (in the sternal notch) at the end of inspiration, or at the beginning of expiration. With the other hand holding the abdominal region we prevent the dissipation of energy and make the explosion tussive more effective. It is done after the PSE.
223509656|NCT02458300|OTHER|inspiratory maneuver to rhinopharyngeal cleaning DRR|After the inspiratory reflection following the PSE, the TP or crying. At the end of expiratory time the child's mouth is closed with the back of his hand just finished his chest support, raising the jaw and forcing the child to an inspiration with the nose
223509657|NCT02458300|OTHER|Aspiration of secretions|Suctioning with a probe by a vacuum system installed on the wall.
223509658|NCT06406478|BEHAVIORAL|Schedule Change|This 4-day workweek is defined by any 4 ten hour shifts between Sunday and Saturday. It will be up to the discretion of participants in the intervention group to coordinate which 4 days they work. The 4 days will most likely be weekdays, but some participants may work weekends. If participants do any work from home, they will clock in remotely to account for the time.
223509659|NCT06406478|BEHAVIORAL|No Schedule Change|The control group will continue to work five days per week, receiving standard practice for the schedule policies at the participating study sites.
223614605|NCT00423839|BIOLOGICAL|MVA85A (Tuberculosis vaccine)|
223614606|NCT05064371|DRUG|Eptinezumab|Concentrate for solution for IV infusion
223614607|NCT04872192|OTHER|transversus thoracic muscle plane block|transversus thoracic muscle plane block by injection of 15 ml of bupivacaine 0.25% on each side combined with general anaesthesia
223614608|NCT04872192|OTHER|general anaesthesia|transversus thoracic muscle plane block by injection of 15 ml of saline on each side combined with general anaesthesia
223614609|NCT01410513|DRUG|SAR245409|Pharmaceutical form:capsule Route of administration: oral
223760093|NCT03125512|DEVICE|continuous positive airway pressure|Automated adjusting continuous positive airway pressure
224201747|NCT00061568|DRUG|Sirolimus|Sirolimus
224201748|NCT03386630|DRUG|Hyperbaric bupivacaine+Sufentanil|To evaluate in spinal anesthesia for elective cesarean section what association of hyperbaric bupivacaine 0.5% (0.06 mg Cm-1 in height) plus opioid: sufentanil (5 mcg)
223509660|NCT05656573|DRUG|CART-PSMA cells|"This study consists of 2 parts:~Part A (Dose Escalation): The investigators are looking the highest dose of the study intervention that can be administered safely without severe or unmanageable side effects in participants that advanced prostate cancer.~Part B (Expansion Cohort): Participants will be treated at the respective dose (at or below the Maximum Tolerated Dose), as determined during Part A (Dose Escalation).~Up to 4 dosing cohorts, with up to 3 subjects enrolled in each cohort, will be explored as follows:~Cohort 1： CART-PSMA cells 1-3x10\^7/M\^2 (body surface area); Cohort 2： CART-PSMA cells 1-3x10\^8/M\^2 (body surface area); Cohort 3： Lymphodepletion chemotherapy + CART-PSMA cells 1-3x10\^7/M\^2 (body surface area); Cohort 4： Lymphodepletion chemotherapy + CART-PSMA cells 1-3x10\^8/M\^2 (body surface area)."
223509661|NCT04595370|DRUG|AZD9977|Participants will receive AZD9977 as per the arms they are randomized.
223509662|NCT04595370|DRUG|Dapagliflozin|Participants will receive dapagliflozin as per the arms they are randomized.
223509663|NCT04438512|DRUG|Midomafetamine|Administration of 80 or 120 mg midomafetamine HCl in combination with manualized therapy and a supplemental dose 1.5 to 2 hrs later of 40 or 60 mg midomafetamine HCl, respectively
223509664|NCT04438512|BEHAVIORAL|Psychotherapy|Manualized therapy performed by therapist team
223509665|NCT06125548|OTHER|Lactation Management Model|The mother provides skin-to-skin contact to her baby 12 times a day, 8 times on the 2nd day, 4 times on the 3rd day, hot application to the breast (5 minutes), relaxation technique (3 minutes) and breast massage (5 minutes by hand milking, 2 minutes by breast massage). Head stimulation, stroking for 3 minutes) were asked.
223760094|NCT02203864|BIOLOGICAL|BIBW2 component A|BIBW2 without IL-2 secreting cell line
223760095|NCT02203864|BIOLOGICAL|BIBW2 component B|BIBW2 with IL-2 secreting cell line
223760096|NCT04515303|OTHER|Diverse Intervention Participation in DASH|A qualitative examination of barriers and facilitators of the DASH dietary pattern, and quantitative investigation of the types of recruitment methods effective for black adults entering a digital DASH-promoting intervention.
223760097|NCT02439112|OTHER|Exercise|"8 supervised in-hospital training sessions in a period of 10 weeks. On a general level, the intervention will follow the Danish physical activity guidelines for elderly \>65 years (Sundhedsstyrelsen 2011, see link) and consist of strength exercise, aerobic exercise and physical activity.~Bone involvement will taken into consideration in all parts of the exercise program by excluding and including specific exercises and mode of exercise according to location and extent of bone involvement (Galvão 2011; Cormie 2013)"
223760098|NCT00749463|DRUG|Nicotine Gum|2 mg or 4 mg for 12 week treatments and followed by 12 week off-treatment follow-up. Recommend subject to use 8-12 pieces daily for first 8 weeks and 4-6 pieces daily the next 2 weeks, then reduce to 1-3 pieces each day in last 2 weeks
223760099|NCT00749463|DRUG|Nicotine Patch|Each will use 15 mg/16 h patch for the first 8 weeks, 10 mg/16 h for the following 2 weeks and 5 mg/16 h for the last 2 weeks. Then followed by 12 week off-treatment follow-up.
223760100|NCT00698269|DRUG|insulin detemir|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
223760101|NCT00698269|DRUG|biphasic insulin aspart 30|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
223760102|NCT00698269|DRUG|insulin aspart|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
223760103|NCT02959281|OTHER|Providing caring physicians with hemodynamic variables|NICAS electrodes are applied to the skin of the forearm bilaterally (similar to EKG electrodes). Conductors, attached to the electrodes, connect the patient with the measuring system.
223760104|NCT01890772|DRUG|Telaprevir|
224201749|NCT03386630|DRUG|Hyperbaric bupivacaine+Morphine|To evaluate in spinal anesthesia for elective cesarean section what association of hyperbaric bupivacaine 0.5% (0.06 mg Cm-1 in height) plus opioid: morphine (0,01 mg)
223509666|NCT04560114|DRUG|Essential oils|"The patient will be invited to inhale the essential oils via the stick:~* 4 times a day before each meal and snack.~* if necessary when nausea appears, as many times as he deems necessary."
223509667|NCT03492112|DEVICE|HCV RNA Point of Care|Participants attending needle syringe programmes in Australia will be screened for hepatitis C using the finger-stick whole blood GeneXpert HCV RNA cartridge.
223509668|NCT03492112|DRUG|Sofosbuvir/velpatasvir|Participants with a detectable HCV RNA will be offered treatment with either glecaprevir/pibrentasvir or sofosbuvir/velpatasvir.
223614610|NCT02345473|GENETIC|Detection of circulating tumor cells in blood samples|Ficoll based isolation of mononuclear cells from the peripheral blood of patients undergoing radical cystectomy, nucleic acids extraction and, finally, PCR based detection of sequences specific to cytokeratins.
223614611|NCT01153737|OTHER|Manual therapy (MT)|Ten treatment sessions of 30 minutes of MT or TENS on alternate days were provided by primary care physical therapists. MT techniques: neuromuscular technique, postisometric stretching, spray and stretching and Jones technique.
223614612|NCT01153737|OTHER|TENS|Ten treatment sessions of 30 minutes of MT or TENS on alternate days were provided by primary care physical therapists. TENS electrode placement were: in the painful area, in the metamere or in the nerve´s pathway. It was applied at a frequency of 80 Hz, with ≤150 µs pulse duration and adjusted amplitude.
223614613|NCT00509470|DRUG|telmisartan plus hydrochlorothiazide|Combination therapy with telmisartan (40 mg/day) plus hydrochlorothiazide (12.5 mg/day): If blood pressure is not reach to lower than 140/90 mmHg, dose of telmisartan can be increased to 80 mg/day
223614614|NCT00509470|DEVICE|Amlodipine|
223614615|NCT03101566|DRUG|Gemcitabine|Gemcitabine 1000 mg/m2 IV
223760105|NCT01890772|DRUG|Peginterferon alfa-2a|
223760106|NCT01890772|DRUG|Ribavirin|
223760107|NCT01890772|DIETARY_SUPPLEMENT|Vitamin D|
223760108|NCT04914910|DEVICE|Minimed 780G insulin pump|This will be a 14-week, open-label, randomised, parallel-group, controlled trial comparing the efficacy of an AHCL system (MiniMed 780G, Medtronic Diabetes, Northridge, CA) with usual care (i.e., a person's usual insulin pump and CGM/isCGM system). After the 14-week trial period, the control group switches to treatment with the MiniMed 780G system. The intervention group continues with the MiniMed 780G system. Both groups are monitored for another 14 weeks.
223760109|NCT02530424|DRUG|Trastuzumab|Trastuzumab (8 mg/kg loading dose IV, then 6 mg/kg IV) will be given on day 1 q. 3 weeks for a total of 6 administrations
223760110|NCT02530424|DRUG|Pertuzumab|Pertuzumab (840 mg as an i.v. infusion) will be given on day 1 q. 3 weeks for a total of 6 administration
224201750|NCT02558075|BEHAVIORAL|MoodLifters Sessions|This program consists of 15 different sessions with a different topic for each session. These sessions will occur once a week for 15 weeks and will last approximately an hour each. These topics will be in one of five theoretically important areas: biological, cognitive, affective, behavioral and social. Each subsequent week will involve an in-depth exploration of each topic, including why it is important to mental well-being and practical ideas about how to implement positive changes into one's everyday life. Following the facilitator's brief presentation, group members will be invited to share their experiences, challenges, and provide peer support.
224201751|NCT04054934|BEHAVIORAL|Reversed Circadian Rhythm|Revered day/ night sleep cycle
224201752|NCT04054934|BEHAVIORAL|Normal Circadian Rhythm|Normal day/ night sleep cycle
224201753|NCT01381068|DEVICE|End tidal CO2 monitor|The sensor is placed in the respiratory circuit in both arms of the trial but the display is visible to the resuscitation team in the monitored arm and is covered in the control arm. The end tidal CO2 data is collected in both arms.
224201754|NCT03444909|DEVICE|cardiotocograph|Monitoring of 20 min with the cardiotocograph
224201755|NCT03444909|DEVICE|Toconaute|Monitoring of 20 min withToconaute
224201756|NCT03444909|DEVICE|electrophysiological device (Micromed)|Monitoring of 20 min with the cardiotocograph
223509669|NCT03492112|DRUG|Glecaprevir/pibrentasvir|Participants with a detectable HCV RNA will be offered treatment with either glecaprevir/pibrentasvir or sofosbuvir/velpatasvir.
223614616|NCT03101566|DRUG|Cisplatin|Cisplatin 25 mg/m2 IV
223614617|NCT03101566|DRUG|Ipilimumab|Ipilimumab 1 mg/kg IV
223614618|NCT03101566|DRUG|Nivolumab|Nivolumab 360 mg or 240 mg IV
223614619|NCT05944406|OTHER|Educational training of ER Nurses|educational intervention was conducted from 2nd to 5th May 2023 with the triage nurses. This intervention comprised of detailed explanations of how the Triage system is accurately used to categorize the patients presenting in the ED and Triage nurses were instructed to refer non-urgent cases to either the Outpatient department or to the Casualty Medical Officer. The results of the first audit were also shared. Additionally, circulars containing instructions regarding accurate usage of MTS were distributed to all triage nurses
223614620|NCT04390126|OTHER|life questionnaires|Telephone survey during the confinement period (common questionnaire and a questionnaire specific to the patient's pathology)
223614621|NCT04390126|OTHER|questionnaire|1-year telephone diary to identify complications resulting in hospitalization related to the patient's chronic disease
223614622|NCT00152893|DRUG|chromium nicotinate|
223614623|NCT00152893|DRUG|Placebo|
223614624|NCT05775016|BEHAVIORAL|Exercise|12 week resistance and cardiovascular exercise program
223614625|NCT02397304|OTHER|Exercise|Participants will complete two morning exercise sessions. One will be performed in the overnight fasted-state (i.e. no food or drink, except water, from 10pm the evening before) and the other will be performed in the fed-state having received a breakfast by the research team before exercise.
223614626|NCT02150278|BEHAVIORAL|Brief intervention|The brief intervention consist of one face to face minimal advice to reduce drinking-driving behavior and it was personalized according to the state of change of the patient (based on the Prochaska and DiClemente model). An additional informative pamphlet is offered to the participant. The intervention was done by the general practitioner or nurse that regularly attends the patient.
223614627|NCT05375591|OTHER|Non-Interventional Study|First nodule detection CT scans as per eligibility criteria will be used as input into in-house software to extract multiple radiomic features and used to develop a machine learning based classifier to differentiate nodule aetiology. Scans will also be used as input in to a deep learning/convolutional neural network models to perform automated imaging classification.
223614628|NCT04703426|DRUG|Sargramostim (GM-CSF)|Drug that binds to the protein PD-1 to help immune cells kill cancer cells better, it is given as an intravenous injection through a vein.
223614629|NCT04703426|DRUG|Pembrolizumab (anti-PD-1)|Drug that stimulates blood cells that may help support the immune system during cancer treatment, given as intravenous infusion
223614630|NCT05373446|DRUG|SSD8432 300mg|SSD8432 300mg in combination with ritonavir 100mg, day1--day5,BID
223614631|NCT05373446|DRUG|SSD8432 750mg|SSD8432 750mg in combination with ritonavir 100mg, day1--day5,BID
223614632|NCT05373446|DRUG|SSD8432Placebo|SSD8432Placebo in combination with ritonavir placebo,day1--day5,BID
223614633|NCT00986843|DRUG|HM30181AK tablet + Irinotecan tablets|HM30181AK 60 mg tablet + Irinotecan 20mg, 5 mg or 2mg tablets
223614634|NCT04592588|BEHAVIORAL|Common Elements Toolbox|COMET is an online unguided self-help intervention that lasts approximately 45-60 minutes.
223614635|NCT04592588|BEHAVIORAL|Wait-list control|Participants in the control condition will receive access to the intervention after data collection for the study has been completed.
223614636|NCT02564458|BEHAVIORAL|Interval Exercise Training/Motivational Accelerometry|During the 5-12 weeks before allogeneic stem cell transplant, the patient will participate in an at home, interval exercise training (IET) program, as well as wear a physical activity tracker, the FitBit Surge, combined with a weekly motivational call, termed Motivational Accelerometry (MA). The combined intervention is referred to as (IET/MA). The first week of the IET program consists of the participants being asked to engage in 30 minutes of aerobic exercise at any intensity for 3-4 days. For weeks two and beyond, patients be asked to undergo 3-4 sessions of IET, consisting of a 5 minute warm-up and five 2-minute intervals, with the goal of reaching 80% MHR, separated by 3 minutes of recovery/light activity in between each interval. Each exercise session is a total of 30 minutes. In addition, each week prior to transplant, the patient will receive a weekly check-in/motivational call from the study staff in order to track progress and motivate the patient to continue participation.
223614637|NCT00828230|DRUG|budesonide|One application of 2mg budesonide once daily for 8 weeks
223614638|NCT00828230|DRUG|Placebo foam|One application of placebo foam once daily for 8 weeks
224201757|NCT05046145|BEHAVIORAL|speech therapy for chewing + real tDCS|participants will be instructed to chew their food correctly during the tDCS session, but the participant does not know if the tdcs is real or sham.
224201758|NCT01070225|DRUG|Hydrocortisone/ Placebo and Propranolol|Hydrocortisone 400mcg Propranolol 10mg or 20 mg
224201759|NCT05553028|PROCEDURE|Computerised tomography|Screws placement will be evaluated for each patient by a CT scan on D1 post-intervention. The evaluation of the placement of the screws (reading of the CT images) will be carried out by 2 radiologists independent of the surgical team, blinded to the technique used for the placement of the screws (robot-assisted/conventional surgery). In case of disagreement between the 2 evaluators, a 3rd evaluator will be requested.
224201760|NCT03803514|DRUG|Recombinant EPO|Beta-epoetin (Recormon, Roche). Dosage was performed according to current recommendations.
224201761|NCT04376073|DRUG|Niraparib|Niraparib 300mg(Body Weigh ≥77 kg)/200mg (Body Weigh \<77 kg) po QD day1\~21, Anlotinib 12mg po QD day1\~14
224201762|NCT04376073|DRUG|Anlotinib|Anlotinib 12mg po QD day1\~14. Starting dose of anlotinib changed to 10mg from 2020-11-13.
223614639|NCT05441631|DRUG|Insulin|"* Preparation: 50 IU of rapidly acting insulin in 50 ml of 0.9% saline solution was delivered through a 50-ml syringe-driven pump.~* Monitoring: The insulin dose was adjusted to whole-blood glucose levels using glucometer every hour and insulin infusion was continued till BG level (Targeted level) was 80-110 mg, and then BG levels were estimated four-hourly~* Insulin dose was titrated according to the Leuven titration protocol (15)"
223614640|NCT05441631|DRUG|Subcutaneous Insulin|"* Insulin dose was titrated according to the Blood glucose level~* monitoring according to glucose in urine"
223614641|NCT03406637|DEVICE|BPK-S Integration|primary total knee endoprosthesis
223760111|NCT02530424|DRUG|Palbociclib|Palbociclib will be given at the dose of 125 mg po q.d. x 21 every 4 weeks (i.e. 1 week rest period for a total of 5 cycles
224312177|NCT03821181|DEVICE|Sham group|patients allocated to the sham group will undergo a sham RIC procedure during which bilateral arm cuffs are inflated to a pressure of 30 mmHg for five cycles of 5 min, followed by 5 min of relaxation of the cuffs.
223614642|NCT04577378|DRUG|Drug: Isotretinoin(Aerosolized 13 cis retinoic acid) plus Aerosolized Itraconazole|After randomization, erosolized 13 cis retinoic acid in gradual one dose increases froms 0.2 mg/kg/day to 4 mg/kg/day as inhaled 13 cis retinoic acid therapy for 14 days plus Aerosolized Itraconazole 5mg per day for 14 days
223760112|NCT02530424|DRUG|Fulvestrant|Fulvestrant will be administered according to local prescription guidelines and will be given intra-muscle at the dose of 500 mg every 4 weeks (repeat for 5 times) with an additional 500 mg dose given two weeks after the initial dose
223760113|NCT00726219|OTHER|Femoral perineural catheter|Comparison of 2 insertion distances (3 vs 7 cm) for a femoral perineural catheter in the context of major knee surgery.
223760114|NCT03569371|DRUG|INCB054707|INCB054707 administered once daily orally with water without regard to food for 8 weeks.
223760115|NCT01836484|DIAGNOSTIC_TEST|Diffusion-weighted MRI|
223760116|NCT01836484|DIAGNOSTIC_TEST|Fluorodeoxyglucose-18-PET/CT|
223760117|NCT01836484|DIAGNOSTIC_TEST|Fluoro-ethyl-coline-PET/CT|
223760118|NCT04114253|DIAGNOSTIC_TEST|Quantra System|Diagnostic device to monitor coagulation properties of a whole blood sample at the point-of-care.
223760119|NCT00876473|PROCEDURE|CPAP system|"Evaluating the effects of different CPAP systems on respiratory mechanics, respiratory effort and gas-exchange~CPAP systems:~Continuous high-flow CPAP with fixed value PEEP valve~Continuous high-flow CPAP with Boussignac valve~Demand flow CPAP supplied by ventilator"
223760120|NCT01515969|DRUG|Erlotinib hydrochloride|Given PO
224201763|NCT04995510|OTHER|Observational|To evaluate your chronic obstructive pulmonary disease with Chronic Obstructive Pulmonary Disease assessment test, respiratory muscle strength with intraoral pressure measurement device, respiratory muscle endurance with increasing threshold load respiratory muscle endurance test, diaphragm thickness with ultrasound device, cardiorespiratory fitness with 6 Minute Walk Test, flexibility trunk lateral flexion test , back scratch test and sit and lie down test, muscle strength and endurance will be evaluated with push-up test, sit-up test, sit and stand test and hand grip strength, body composition will be evaluated by bioelectrical impedance analysis, physical activity will be questioned with the International Physical Activity Assessment Questionnaire, shortness of breath with the Mmrc Dyspnea Scale, and perception of fatigue and shortness of breath with the Modified Borg Scale.
223614643|NCT04577378|DRUG|Drug: Isotretinoin(Aerosolized 13 cis retinoic acid)|Drug: Aerosolized 13 cis retinoic acid in gradual one dose increases froms 0.2 mg/kg/day to 4 mg/kg/day as inhaled 13 cis retinoic acid therapy for 14 days
223614644|NCT03744767|DRUG|Spironolactone 50 MG|oral administration of Spironolactone, 25mg daily for 1 week, then 50mg daily until visit Month 3, followed by 25mg daily from visit Month 3 to visit Month 4
223614645|NCT01225614|DEVICE|Bilevel pressure ventilator|Nocturnal home ventilation
223614646|NCT04117204|OTHER|Fruits and Vegetables|Fruits and Vegetable delivery, once a week for 12 weeks.
223614647|NCT01012258|BIOLOGICAL|Cetuximab + concomitant boost radiotherapy|"Cetuximab 400 milligram/square meter (mg/m\^2) intravenous (IV) infusion over 120 minutes for 1 week, subsequently followed by 250 mg/m\^2 IV infusion over 60 minutes, from week 2 to 7 along with concomitant boost radiotherapy: 72.0 Gray (Gy) total for 42 fractions in 6 weeks, initially~* Once-daily fractions: 32.4 Gy in 18 fractions of 1.8 Gy for 3.6 weeks (5 fractions/week), followed by~* Twice-daily fractions 39.6 Gy in 24 fractions for 2.4 weeks: morning dose 1.8 Gy/fraction for a total of 12 fractions 5 fractions/week; evening dose 1.5 Gy/fraction for a total of 12 fractions 5 fractions/week. Doses are separated by at least a 6-hour interval"
223614648|NCT05266612|DRUG|VG2025|"1. 1.0×108PFU Day 1 and 15~2. 2.0×108PFU Day 1 and 15~3. 3.0×108PFU Day 1 and 15~4. 4.0×108PFU Day 1 and 15"
223614649|NCT05266612|DRUG|Nivolumab Injection [Opdivo]|Flat dose of 240 mg every two weeks.
223760121|NCT01515969|DRUG|Dovitinib lactate|Given PO
223760122|NCT04145895|OTHER|Postoperative activity restrictions|Recommendations for return to full activity including return to school, sports, exercise, etc.
223760123|NCT03611569|DRUG|Lu AF82422|Lu AF82422 - concentrate for solution for infusion; vials containing 50mg/ml, single dose
223760124|NCT03611569|DRUG|Placebo|placebo - concentrate for solution for infusion, single dose
223614650|NCT01725490|DRUG|Metformin|Patients will be randomly assigned in a 2:2:1 ratio to receive metformin or identical-appearing placebo tablets orally for 7 months: metformin 500mg once and placebo twice a day in arm A, metformin 500mg three times a day in arm B, and placebo three times a day in arm C.
223614651|NCT01725490|DRUG|Metformin|Patients will be randomly assigned in a 2:2:1 ratio to receive metformin or identical-appearing placebo tablets orally for 7 months: metformin 500mg once and placebo twice a day in arm A, metformin 500mg three times a day in arm B, and placebo three times a day in arm C.
223614652|NCT01725490|DRUG|Placebo|Patients will be randomly assigned in a 2:2:1 ratio to receive metformin or identical-appearing placebo tablets orally for 7 months: metformin 500mg once and placebo twice a day in arm A, metformin 500mg three times a day in arm B, and placebo three times a day in arm C.
223614653|NCT02952599|DRUG|Edoxaban|Prescribed according to approved label
223760125|NCT02123199|DRUG|Indacaterol (Onbrez®) /QAB149|
223760126|NCT01236755|DEVICE|single-vision glasses|Daily wear of glasses to correct vision in the first seven months of the study
223760127|NCT01236755|DEVICE|ortho-k lenses|Nightly wear of lenses to correct vision in day time in the second seven months of the study
223760128|NCT04827043|COMBINATION_PRODUCT|Ultrasound guided quadratus lumborum block|prospective randomized comparative study between Group (1) : quadratus lumborum block
223760129|NCT04827043|COMBINATION_PRODUCT|Ultrasound guided thoracic paravertebral block|PVB group: will receive 0.25ml/Kg/side of 0.375% bupivacaine with epinephrine 5ug/ml, yielding the same dose of bupivacaine of 1.875mg/ml at the level of T10 as a single injection sonar guided.
223760130|NCT01388829|DRUG|Treatment A|150 mg single dose of PF 04991532 tablets (1x150 mg) manufactured from the R3 lot
223760131|NCT01388829|DRUG|Treatment B|150 mg single dose of PF 04991532 tablets (1x150 mg) manufactured from the R4 lot
223760132|NCT01665274|DRUG|Capecitabine|Capecitabine 1,000 mg/m² twice daily, d1-14, q3w
223760133|NCT01665274|DRUG|Oxaliplatin|Oxaliplatin IV infusion, 130mg/m² d1, q3w
223760134|NCT01665274|PROCEDURE|D2 resection|D2 resection
223760135|NCT00398853|DIETARY_SUPPLEMENT|chromium picolinate 1000 mcg daily vs placebo|chromium picolinate 1000 mcg daily vs placebo
223760136|NCT00398853|OTHER|Placebo|Placebo
223614654|NCT02116881|PROCEDURE|Colorectal Surgery|Application of postoperative questionnaires will be completed by patients. The intervention is the standard of care.
223614655|NCT01584310|OTHER|questionnaire STAMP and dietary|Children will undergo a complete evaluation by an investigating dietician and assessment by the STAMP tool in order to determine the extent of the nutritional risk on a numerical scale. According to findings children will get the dietary recommendations.
223760137|NCT03030027|BEHAVIORAL|Connecting Through Caregiving|The Connecting Through Caregiving intervention focuses on reappraisal exercises on intergeneration relationships in caregiving, involving the following: 1) enhancing self-awareness of the caregiver, 2) developing interpersonal empathy for the care-recipient, 3) help-seeking in caregiving, 4) balancing self-care and caring and 5) negotiating action plans.
223614656|NCT01584310|OTHER|No STAMP using|No intervention
223614657|NCT01533506|DRUG|stiripentol|Stiripentol up to 30 mg/kg/day to control seizures
223614658|NCT03600740|DEVICE|DBS Programming|DBS Programming may be temporarily altered based on imaging data to measure a change in clinical symptoms.
223614659|NCT04440748|DEVICE|T-Chair 2.0 Prototype|Participants in the experimental group will perform additional therapy with the T-Chair 2.0. Participants can train in two modes. Participants will either train in the active modus, whereby the participant has to move the seat in a certain direction, or in the passive modus, whereby the participant has to stay in a stable position while the seat is moving underneath the participant. The seat is able to move in mediolateral, anteroposterior, and diagonal and combined directions such as circles or eight-figures. The modus, the type of movement, the range of motion and speed of movement are chosen by the therapist according to the patients' abilities.Training will be coupled with a computer based exercise. During the session preparation time, and time for the questionnaires is needed, thus we expect the actual training time to be on average 30 minutes per training.
223614660|NCT04440748|OTHER|General Rehabilitation Programme|"The general rehabilitation program that is offered to all patients of Clinic Valens fits the current standards for treatment post-stroke. This program is tailored to the patients needs and consists of a 90 minute so called focus training per day, which includes physical therapy, occupational therapy, resistance training and gait training. According to the patient needs, extra therapy will be given such as robotic therapy, speech therapy and aquatic therapy. The general rehabilitation program in both groups is comparable in content, time and intensity."
223760138|NCT03030027|OTHER|Basic Skills Building|Skill building involves: 1) monitoring activities, 2) pleasant event scheduling, 3) communicating with the care recipient, 4) communicating with family members and 5) review implementation
223760139|NCT02072291|DRUG|Nifedipine|PO Nifedipine 5mg single dose
223760140|NCT00805935|DRUG|Menotropin|225 IU (up to 450 IU) by subcutaneous injection once per day for up to about 15 days.
223760141|NCT00805935|DRUG|Progesterone vaginal insert|100 mg inserted vaginally 2 or 3 times daily (BID or TID) (start on the day after oocyte retrieval) until 10 weeks gestation or confirmation of negative pregnancy test.
223760142|NCT00805935|DRUG|Follitropin beta|225 IU (up to 450 IU) by subcutaneous injection once per day for up to about 15 days.
223760143|NCT00805935|DRUG|Progesterone in oil|50 mg by intramuscular injection once per day, starting on the day after oocyte retrieval until 10 weeks gestation or confirmation of negative pregnancy test.
223760144|NCT00805935|DRUG|leuprolide acetate|Daily administration of 0.5mg of leuprolide acetate (depot formulations were not permitted) began on Day 21 following onset of menses, and then decreased to 0.25 mg when gonadotropin therapy was initiated.
223760145|NCT04904185|DRUG|Cyclophosphamide|Cyclophosphamide 500 mg/m2 is administered i.v. on day -4, -3 and -2
223760146|NCT04904185|DRUG|Fludarabine Phosphate|Fludarabine Phosphate 30 mg/m2 is administered on day -4 and -3
223760147|NCT04904185|BIOLOGICAL|Multiple Antigen Specific Endogenously derived T cells|Antigen specific, ex vivo expanded T cells derived from peripheral blood T cells
223760148|NCT04904185|DRUG|Pembrolizumab|Pembrolizumab 2 mg/kg is administered on day -1 and on day 21. The medicine is administered over 30 minutes
223760149|NCT03466502|DRUG|Oral Vancomycin|Oral vancomycin will be given concurrently with antibiotics to hospitalized patients with a history of Clostridium difficile infection to prevent recurrence
223760150|NCT03383328|DRUG|NSAID + prednisolone, preoperative|Ketorolactrometamol 5 mg/ml and prednisolone acetate 1% w/v eye drops are administered 3 times pr. day, starting 3 days prior to surgery and until 3 weeks after surgery.
223760151|NCT03383328|DRUG|NSAID + prednisolone, postoperative|Ketorolactrometamol 5 mg/ml and prednisolone acetate 1% w/v eye drops are administered 3 times pr. day, starting on the day of surgery and until 3 weeks after surgery.
223760152|NCT03383328|DRUG|NSAID, preoperative|Ketorolactrometamol 5 mg/ml eye drops are administered 3 times pr. day, starting 3 days prior to surgery and until 3 weeks after surgery.
223760153|NCT03383328|DRUG|NSAID, postoperative|Ketorolactrometamol 5 mg/ml eye drops are administered 3 times pr. day, starting on the day of surgery and until 3 weeks after surgery.
223760154|NCT03383328|DRUG|Drop-less surgery|A depot of 0.5 ml Dexamethason Krka 4 mg/ml solution for injection/infusion is administered during cataract surgery.
223760155|NCT00712088|BEHAVIORAL|Project ICARE|Group-level intervention (Project ICARE)
223760156|NCT00712088|BEHAVIORAL|HCT|Offer of HIV counseling and testing
224201764|NCT02653469|OTHER|Augmented ventilation|When the patient's PPV is within grey zone, patient's tidal volume is maintained with augmented tidal volume of 12 ml/kg (from normal ventilation of 8ml/kg) for 2min duration.
224201765|NCT02653469|OTHER|Fluid loading|We record the stroke volume index (SVI) values before and after volume expansion with 6ml/kg of balanced crystalloid
224201766|NCT00082069|BIOLOGICAL|Shigella flexneri 2a Invaplex 50|
224201767|NCT03843723|OTHER|Pre-flight evaluation|All the participants receive the interventions as part of their routine medical care during their annual visit for CF follow-up. Oxygen saturation are measured by pulse oximetry. Exercise testing is performed by 6MWT and CPET. Pre-flight evaluation is performed by HAST.
224201768|NCT04450316|DRUG|Naltrexone|4.5mg tab (low-dose) nightly
224201769|NCT04450316|DRUG|Placebo|1 tab nightly
224201770|NCT01396499|DRUG|BKM120|Starting dose 80 mg tablets by mouth daily for a 28 day cycle.
224201771|NCT01905176|OTHER|In person education on heart failure topics before discharge|Individualized in-person education on HF topics aiming to promote self-care practices by using educational electronic material and booklet
223614661|NCT03921034|DRUG|Ropivacaine|All patients will receive sedation with midazolam and/or fentanyl titrated to comfort during block procedures. Per our standard practice at Ochsner Medical Center, all patients will have either spinal or combined spinal-epidural anesthesia with mepivacaine 1.5% as the primary anesthetic during the surgery and sedation with propofol titrated to comfort. Also per our standard practice at Ochsner Medical Center, multimodal therapy will include ketamine 0.25mg/kg IV (up to 50mg) intraoperatively, dexamethasone 8mg IV intraoperatively, pregablin 150mg PO preoperatively (adjusted to 75mg for age over 70) followed by 75mg nightly (or home gabapentin dose), acetaminophen 1000mg IV followed by 100mg PO every 6 hours postoperatively, and celecoxib 400mg PO on POD #0 followed by 200mg PO daily.
223614662|NCT03921034|DRUG|Saline|All patients will receive sedation with midazolam and/or fentanyl titrated to comfort during block procedures. Per our standard practice at Ochsner Medical Center, all patients will have either spinal or combined spinal-epidural anesthesia with mepivacaine 1.5% as the primary anesthetic during the surgery and sedation with propofol titrated to comfort. Also per our standard practice at Ochsner Medical Center, multimodal therapy will include ketamine 0.25mg/kg IV (up to 50mg) intraoperatively, dexamethasone 8mg IV intraoperatively, pregablin 150mg PO preoperatively (adjusted to 75mg for age over 70) followed by 75mg nightly (or home gabapentin dose), acetaminophen 1000mg IV followed by 100mg PO every 6 hours postoperatively, and celecoxib 400mg PO on POD #0 followed by 200mg PO daily.
223614663|NCT03571204|BIOLOGICAL|3BNC117 and 10-1074|Both 3BNC117 and 10-1074 administered intravenously at 30 mg/kg dose level in 250 ml normal saline for 8 infusions at weeks 0, 2, 4, 8, 12, 16, 20, and 24. The two antibodies will be mixed in separate bags of saline for sequential administration.
223614664|NCT03571204|BIOLOGICAL|Placebo|Placebo is two separate bags of 250 ml normal saline administered intravenously for 8 infusions at weeks 0, 2, 4, 8, 12, 16, 20, and 24. The two separate bags of placebo are administered sequentially.
223614665|NCT02396212|BIOLOGICAL|Canakinumab|canakinumab was provided as a 150 mg/1 mL solution for subcutaneous injection and administered at 4mg/kg every 4 weeks.
223614666|NCT01623115|DRUG|Alirocumab|Solution for subcutaneous injection in the abdomen, thigh, or outer area of the upper arm by self-injection or by another designated person using auto-injector (also known as pre filled pen).
223614667|NCT01623115|DRUG|Placebo (for alirocumab)|Solution for subcutaneous injection in the abdomen, thigh, or outer area of the upper arm by self-injection or by another designated person using auto-injector (also known as pre filled pen).
223614668|NCT01623115|DRUG|Lipid Modifying Therapy (LMT)|Statin (rosuvastatin, simvastatin or atorvastatin) at stable dose with or without other LMT as clinically indicated.
223614669|NCT03980249|DRUG|Carvedilol|Carvedilol: Start at 6.26 mg PO twice daily for 1-2 weeks and if tolerated, will be increased to 12.5 mg PO twice daily for 6 cycles as tolerated.
223614670|NCT05932108|BEHAVIORAL|Education in TERMA|"Education of staff in TERMA. The primary aim of TERMA is to prevent aggression and violence through a system of low-effective treatment that is divided into escalating levels based on the patient's aggression level, risk of violence, and acts of violence . The TERMA model focuses on treatment, communication, and management of compassionate healthcare in forensic psychiatric settings . The levels of the TERMA model are in a cascading order, whereby if the treatment and management of one level are ineffective, the next level is initiated, and so on. The primary level involves the daily behavior and health status of the patient. The secondary level involves risk assessment and violence management, with a focus on creating an understanding of the situation for both the patient and healthcare workers. The tertiary level is utilized when violence cannot be avoided . Each level corresponds to a specific response according to the demands of the situation and environment."
223614671|NCT05932108|OTHER|Changed work routines based on TERMA|NO planned intervention but staff work routines and behavior may change after their education in TERMA. Patients are exposed to these changes.
223614672|NCT04612166|BEHAVIORAL|Medication Action Plan and Patient Empowerment (MAP-PE )|"Intervention patients (after consenting) will meet with a study health coach for an in-person meeting where the health coach will review the pharmacists Medication Action Plan (MAP) for deprescription of high-risk medication. The MAP will have previously been approved by both the patient and the patient's primary care physician. If the patient is on more than one high risk medication, the medication that puts them at the highest risk will be deprescribed first and only one medication will be decreased at a time. During this initial meeting, the health coach will use motivational interviewing and distribute materials to empower and support the patient in the reduction of the medication as outlined on their MAP. The health coach will then follow up with the patient on a schedule determined~by the type and dosage of medication being reduced. Follow ups will decrease in frequency over time (starting with at least once a week). The patients will be followed for up to 12 months."
223614673|NCT00114816|DRUG|capecitabine|
223614674|NCT00114816|DRUG|docetaxel|
223614675|NCT01155336|DRUG|Lovaza®|Lovaza® is prescription grade EPA+DHA fish oil supplement.
223614676|NCT01155336|DRUG|The placebo contained 1 gram of corn oil in each capsule.|Placebo Pill
223614677|NCT03061357|BEHAVIORAL|Activity tracker|Misfit Flash (Misfit Wearables Co., Burlingame, CA) activity tracker
223614678|NCT06106113|DRUG|GST-HG171 Tablets|150mg GST-HG171 Tablets
223614679|NCT04539600|DRUG|Camrelizumab|Camrelizumab is a type of anti-PD-1 antibody that could enhance the immune system of the patient to fight cancer.
224201772|NCT01905176|OTHER|Telephone support and education post-discharge|Individualized telephone support/education of three months duration, on HF topics, aiming to promote self-care practices while evaluating patients' current status and condition
224201773|NCT01905176|OTHER|Pre-discharge in person education and post-discharge telephone education and support|Patients receive both interventions of Arm 1 \& 2: individualized pre-discharge counseling/education along with telephone follow-up support for three months, following the same line as mentioned in Arms 1 \& 2
224201774|NCT02725840|RADIATION|Proton beam radiation therapy.|Proton bean radiation therapy interact differently with tissue with the result that protons are absorbed completely within the tissue instead of primarily passing through the entire body. The maximal depth of penetration is dependent upon the incoming velocity (energy) of the protons. Proton therapy utilizes this property to deliver radiation with very little dose beyond the targeted lesion. The dose-rate will be managed as part of the standard of care.
224312178|NCT06633575|BEHAVIORAL|exercise intervention|Patients will participate in an 8-week supervised aerobic exercise program, the intensity was set at the moderate to vigorous intensity (≥150mins/week exercise on the treadmill).
224201775|NCT02725840|RADIATION|X-ray based radiation therapy|The three-dimensional (3D) mapping of radiation dose distributions permits detailed assessment of local vascular damage as a function of treatment factors of dose, dose-rate. The dose-rate will be managed as part of the standard of care.
223614680|NCT04361734|OTHER|Blood sampling to include Deoxyribonucleic Acid (DNA) and Ribonucleic Acid (RNA)|"* Blood sampling to measure immune cell phenotypes and examine DNA/RNA and identify serum biomarkers.~* Food Frequency Questionnaires (FFQs) and/or diet recall questionnaires to assess dietary intake.~* Cardiovascular Ultrasound Scans (USS) to measure how well blood is carried around the body."
223614681|NCT01454596|BIOLOGICAL|Epidermal growth factor receptor(EGFRv)III Chimeric antigen receptor (CAR) transduced PBL|Day 0: Cells will be infused intravenously over 20-30 minutes. Patients will receive two cell doses, 2 hours apart.
223614682|NCT01454596|DRUG|Aldesleukin|Aldeskeukin 72,000 IU /kg intravenous (IV) or 720,000 IU /kg IV (based on total body weight) over 15 minutes every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum 15 doses).
223614683|NCT01454596|DRUG|Fludarabine|Days -7 to -3: Fludarabine 25 mg /m(2)/day intravenous piggyback (IVPB) daily over 30 minutes for 5 days.
223614684|NCT01454596|DRUG|Cyclophosphamide|Days -7 and -6: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml dextrose 5% in water (D5W) with Mesna 15 mg/kg /day X 2 days over 1 hr.
223614685|NCT03776695|BIOLOGICAL|Tyzivumab|Tyzivumab Injection, (100 mg/5 mL/Vial), Zika Virus (ZIKV) Monoclonal Antibody (mAb)
223614686|NCT03776695|OTHER|Placebo|0.9% Saline
223614687|NCT03997526|DEVICE|3C Patch|A platelet-rich plasma gel patch comprised of distinct fibrin, platelet, and leukocyte substantially parallel layers, prepared without the use of any added reagents through a two-step centrifugation process
223614688|NCT01671163|PROCEDURE|Endoscopic Ultrasound (EUS) for fiducial placement|Endoscopic Ultrasound (EUS) used for the placement of fiducial markers in tissue as outlined by the radiation oncologist
223614689|NCT05038865|OTHER|Malocclusion and Orthodontic Treatment|"Group 1 is exposed to malocclusion and orthodontic treatment. However, the inclusion in the study does not affect the treatment since it is an observational study.~The exposure of group 2 is no malocclusion, no orthodontic treatment."
223614690|NCT04221724|OTHER|Multicomponent physical exercise program|"The intervention consists of a combined multicomponent exercise program (EP) carried out for 6 months that includes strength, balance, flexibility and functional exercises aimed to improve functioning on daily life activities. The EP will be divided into two parts:~The first 3 months the EP aims to restore the physical condition through the multicomponent exercise program. This program will comprise of upper and lower body strengthening exercises, using external weights for 2-3sets of 8-12repetitions at a progressive intensity of 30-50% of 1RM. In addition, static balance and flexibility exercise will be performed.~From 3th to 6th months, the objective will be to improve autonomy through the functional EP. Strength exercises intensity will be increased to 60-70% of 1-RM, 2-3sets of 8-12repetitions. Attention tasks, temporal space dissociation and dynamic balance exercises will be added to increase the intensity in balance exercises. Flexibility and fine handle will be also performed"
223614691|NCT00488488|DRUG|tigecycline|The patients will be treated in accordance with the requirements of the labeling of tigecycline in Germany. The dosage and duration of therapy is to be determined by the physician to meet the patients' individual needs for treatment.
223614692|NCT05035758|OTHER|Transcendental Meditation|"In the beginning, the patients from group B will receive an introductory lecture about transcendental meditation (TM) which includes general information, the procedure itself and other techniques of relaxation and personal development.~In this first session the method is learned by practice, in the following 3 meetings additional instructions are given about the correct practice of the TM technique; TM is practiced twice a day for 20 minutes. The method is easy to learn and effortless. To guarantee the right performance of TM by the patients, there will be two group meetings per week and one individual personal meeting with the TM teacher.After discharge from the rehabilitation program (after 4 weeks) there will be meetings offered according to the patients need. This will then be arranged individually."
223614693|NCT05035758|OTHER|Yoga|"In addition to the standard rehabilitation exercise training, the patients in this group will receive a 20-minute workshop where they learn how to do the yoga exercise. The initial yoga workshop will be held by Dr. Gilda Wüst who is a yoga expert with a lot of experience based in St. Radegund.~After this, yoga sessions will be included (additionally to the regular/standard exercise) into their daily timetable. Two yoga sessions will be done every day, one in the morning (6:30-6:50) and one in the evening (16:30-16:50) and will last for about 20 minutes."
223614694|NCT04924335|PROCEDURE|Erector spinae plane block|Preoperative ultrasound-guided bilateral erector spinae plane block with 20 ml 0.025% bupivacaine.
223614695|NCT04173806|OTHER|Facebook intervention|"The intervention consists of the content of the course on telemedicine through a closed group of Facebook according to the established syllabus whose educational material is video classes, discussion forums and online questionnaires. The duration of the course will be 5 weeks, each week two classes will be uploaded to the Facebook platform in succession until the course is completed. So that the student can visualize the content progressively and continuously."
223614696|NCT04173806|OTHER|Control Training:|In this group the participants are exposed to the same course content and perform similar activities as the intervention group on Facebook during the same period but on the Moodle educational platform. The Moodle platform was chosen because it has been widely used in several institutions, with a large user community worldwide, with approximately 50,000 registrations in more than 200 countries and due to the many easy-to-use educational tools it offers. So it is one of the educational platforms that has demonstrated its efficiency in the medical educational field.
223614697|NCT01207375|BEHAVIORAL|memory retraining exercises|Memory retraining exercises will be administered on a laptop computer twice a week for 5 weeks (10 training sessions).
223614698|NCT01207375|BEHAVIORAL|placebo control memory exercises|Placebo control memory exercises will be administered on a laptop computer twice a week for five weeks (10 placebo control sessions.
224201776|NCT02725840|PROCEDURE|Computed Tomography (CT) Scan|Computed Tomography (CT) Scan of the chest will be performed at 1, 3, 6, 12, 18 and 24 months
224201777|NCT02725840|PROCEDURE|Pulmonary Function Test (PFT)|Pulmonary function test (PFT) will be performed at pre-treatment, and at 6 and 12 months.
224201778|NCT04491188|DIETARY_SUPPLEMENT|Bacillus subtilis DE111|1 x10-9 CFU Bacillus subtilis DE111 probiotic
224201779|NCT04491188|DIETARY_SUPPLEMENT|Placebo|Maltodextrin placebo
224201780|NCT00903409|DRUG|Simvastatin + Lovaza® (omega-3-acid ethyl esters)|Open-label Simvastatin + Lovaza® (omega-3-acid ethyl esters) \[formerly known as Omacor\]
224201781|NCT04526379|BEHAVIORAL|Questionnaires|Evaluation of behavioral disorders of children with PWS by questionnaires
224201782|NCT04526379|DEVICE|t-VNS|Evaluation of the influence of 6 month-stimulation by t-VNS on emotional, cognitive, and behavioral/clinical characteristics of 12 children with PWS on 30 PWS patients included.
224201783|NCT03029559|OTHER|Intermittent Hypoxia|"A single session of IH will last for 45 minutes and will consist of alternating phases of hypoxia(FiO2 :9%-11%) and hyperoxia (FiO2 :22%-38%).~Each hypoxic interval will last for 2 minutes whereas the hyperoxic interval lasts for 1 minute each (15, two-minute episodes of hypoxia and 15, one-minute episodes of hyperoxia)."
224201784|NCT03029559|OTHER|Inspiratory Threshold Loading|Subjects will undergo inspiratory threshold loading using a commercially available Threshold IMT device (Power breathe®). ITL will be administered at an intensity of 80% of the individual's maximal inspiratory pressure (MIP). The subjects will be instructed to take 10 deep, forceful breaths through the threshold device followed by at least 2 minutes of rest. The process will be repeated 4 more times for a total of 5 sets of 10 breaths each.
224201785|NCT03029559|OTHER|Sham Intermittent Hypoxia|Subjects will be exposed to a session of sham Intermittent hypoxia.This will consist of breathing room air for 45 minutes through a hypoxicator.
224201786|NCT00461396|DRUG|Interferon-1beta (Betaseron, BAY86-5046)|Male and females, 18 to 50 years of age, after a first clinical demyelinating event suggestive of multiple sclerosis or with onset of RRMS within the past 12 months
224312179|NCT03344861|DRUG|Porfimer Sodium|Porfimer sodium (Photofrin®) will be injected intravenously at a dose of 2 mg/kg.
224312180|NCT03344861|DEVICE|Fiber optic|After injection of porfimer sodium (Photofrin®), a flexible bronchoscopy with navigation guidance will be performed to confirm the location and the size of the lesion with the use of radial probe endobronchial ultrasonography (REBUS). An optical fiber diffuser length matching the tumor length will be placed in the lesion or adjacent to the lesion under fluoroscopy guidance. After the placement of the optical fiber, the laser light will be applied at a dose of 200 J/cm of diffuser length.
223509670|NCT01219075|DIETARY_SUPPLEMENT|soy isoflavones|Given orally
223509671|NCT01219075|OTHER|placebo|Given orally
223509672|NCT01219075|OTHER|questionnaire administration|Ancillary studies
223509673|NCT01219075|PROCEDURE|magnetic resonance imaging|Correlative studies
223509674|NCT01219075|PROCEDURE|biopsy|Correlative studies
223509675|NCT01219075|OTHER|immunohistochemistry staining method|Correlative studies
223509676|NCT01219075|OTHER|laboratory biomarker analysis|Correlative studies
223509677|NCT01219075|PROCEDURE|mammography|Correlative studies
223509678|NCT03383133|DRUG|SULT Allosteric Inhibition|A single, therapeutic dose of acetaminophen (APAP, 1.0 g)) or dehydroepiandrosterone (DHEA, 75 mg) is taken orally (with 375 ml of water) either alone or simultaneously with a single, oral, therapeutic dose of mefenamic acid (MEF, 0.75 g). In total, 5 experiments will be performed. Each experiment is performed in duplicate. Compounds are taken prior to eating breakfast. One hour later, the patient has a light breakfast and eats normally thereafter. Urine samples are collected at 15', 30', 1 h, 2h, 3h, 4h, 5 h, 6h, 7h, 8h, 9h, 10h, 11h, and 12h intervals following dosing. The samples are weighed. A 10 ml aliquot is taken from each time point and the aliquots are stored at -20 °C. Samples (0.5 ml) are then transferred to NMR tubes spectra are taken to assess drug metabolites in urine.
223509679|NCT01311583|BEHAVIORAL|Teach Back method of patient discharge teaching|Trained nurses will provide Teach Back to the intervention group. Appendix D lists the four questions that will be used in this study to confirm the patient's understanding. The nurses' training will focus on the concepts of Teach Back, provide coaching and guidance on how to use it as well as review the principles of conducting research. Role play will be a feature in the education sessions to improve the nurses' comfort level
223509680|NCT01341990|DEVICE|FID 114675A Multi-Purpose Disinfecting Solution (MPDS)|Investigational solution intended for use as a cleaning, rinsing, reconditioning, disinfecting, and storage solution for silicone hydrogel and soft contact lenses
223509681|NCT01341990|DEVICE|ReNu Fresh Lens Comfort Multi-Purpose Solution (MPS)|Commercially marketed prodouct indicated for cleaning, removing protein deposits, rinsing, disinfecting, and storing soft contact lenses
223509682|NCT01341990|DEVICE|Silicone Hydrogel Contact Lenses|Commercially marketed silicone hydrogel contact lenses per habitual prescription for daily wear use, at least 8 hours/day. New pair dispensed at Day 0 (Baseline Visit) and at the conclusion of Day 1 (Visit 2).
223509683|NCT06563349|DRUG|Intravenous magnesium sulfate|Intraoperative intravenous magnesium sulfate infusion.
223509684|NCT06563349|DRUG|Normal saline infusion|Intraoperative intravenous normal saline infusion.
223509685|NCT00077012|DRUG|QLT0074|
223509686|NCT00077012|DRUG|Photodynamic therapy|
223509687|NCT01701635|BEHAVIORAL|Disclosure intervention|An adherence and disclosure specialist will meet with caregiver-child dyad at each clinic visit and provide caregiver information and skills for HIV disclosure till the caregiver discloses the HIV status to the child.
223509688|NCT01701635|BEHAVIORAL|usual care|An adherence and disclosure specialist will meet with caregiver-child dyad at each clinic visit and provide caregiver with general health information without referencing HIV disclosure in their conversations till the caregiver discloses the HIV status to the child.
223509689|NCT04933227|DRUG|Atezolizumab|Atezolizumab 1200 mg will be administered intravenously (IV) on Day 1 of each 21-day cycle.
223509690|NCT04933227|DRUG|Tiragolumab|Tiragolumab 600 mg will be administered IV on Day 1 of each 21-day cycle.
223509691|NCT04933227|DRUG|Oxaliplatin|Oxaliplatin 130 mg/m\^2 will be administered IV on Day 1 of each 21-day cycle during Cycles 1-4.
223509692|NCT04933227|DRUG|Capecitabine|Capecitabine 1000 mg/m\^2/d will be administered orally (PO) twice daily (bid) on Days 1-14 during Cycles 1-4.
223509693|NCT05623514|COMBINATION_PRODUCT|Trans-vaginal ultrasound|Pre-operative trans-vaginal ultrasound in order to evaluate sliding sign between the uterus and the rectum
223509694|NCT04150757|DRUG|Intranasal ketamine|Patients with vaso-occlusive episode and sickle cell disease in moderate to severe pain determined at triage will receive intranasal ketamine while awaiting IV placement.
223509695|NCT05028660|DIAGNOSTIC_TEST|GAG score|blood and urine samples to determine GAG scores
223509696|NCT06203964|OTHER|No intervention|No intervention
223614699|NCT01485159|PROCEDURE|Spirometry|assessment of lung function by spirometry
223614700|NCT06473220|BEHAVIORAL|Narrative nursing|Narrative nursing is an intervention mode of psychological nursing.
223760157|NCT03567850|BEHAVIORAL|Problem solving Skills Training|"Participants will be encouraged to identify specific problems particularly relevant to them and to their family's situation (instead of providing them with standardized examples) to be discussed and solved during the PSST sessions. The eight sessions of PSST will be organized in a systematized, therapeutic manner. Session 1 will be face-to-face and devoted to rapport building and understanding relevant social and medical information. The therapist (RA) will introduce PSST and the Bright IDEAS paradigm, present worksheets to guide PSST homework assignments, and give an overview of subsequent sessions. Starting at session 2, participants will continue training over the phone, with the same general structure and format. In sessions 2-7, the therapist and patient, with a supportive other (SO) if available, will review the patient's identified problems and work on application of problem-solving strategies and skills learned earlier."
223760158|NCT01163409|PROCEDURE|exercise training|exercise training comprises aerobic and strength training
224312181|NCT03484143|DEVICE|Active Neuro RX Gamma device|Twenty minute treatment session, 6 days a week for 24 weeks
224312182|NCT03484143|DEVICE|Sham Neuro RX Gamma device|Twenty minute treatment session, 6 days a week for 24 weeks
224312183|NCT03462979|DEVICE|Immunochromatographic lateral flow test|The immunochromatographic lateral flow test (Gluten Detective) is an at-home test that detects gluten immunogenic peptides excreted in stool or urine. This test can detect gluten exposures which occurred either during the last 24 hours (urine) or within up to a 7 day window (stool). Minimum intake amounts of gluten for successful detection using these test are 50mg (stool) to 500mg (urine)
224312184|NCT01117493|BEHAVIORAL|Expert Patient Programme|Intervention was a disease specific Expert Patient Programme in addition to usual care. The disease specific Expert Patient Programme was delivered one session per week (lasting 2½ hours) for eight weeks and included 2 weeks disease specific education followed by 6 weeks standardised Expert Patient Programme.
223760159|NCT01163409|PROCEDURE|acupuncture|acupuncture involves two sessions per week, during 14 weeks.
223760160|NCT01163409|PROCEDURE|Exercise, Acupuncture and Fibromyalgia|Set of real acupuncture treatment and supervised aerobic exercise have better efficacy in pediatric patients with fibromyalgia versus treatment with sham acupuncture and supervised aerobic exercise, as well as treatment versus combination with aerobic exercise and resistance exercise the major muscle groups, both supervised versus group control, we just get guidance for physical activity.
223760161|NCT03780842|DEVICE|NAVA level|"A titration protocol will be used for changing NAVA levels. The NAVA level will be reduced to 0,5 cmH2O/µV for 3 minutes as a starting point. Limit peak pressure will be set to 35cmH2O (i.e. according to the standard manufacturer's settings) the maximum pressure that can be delivered to the patient is cut off at 30cmH2O). Other ventilator settings will be left unchanged and are as clinically indicated. Ventilator settings will be according to our standard of care and as following: PEEP between 4 and 7 mmHg, apnea time 2-5 sec, back-up ventilation with a pressure above PEEP between 5 and 15 mmHg and a frequency between 30 and 50 per minute.~Starting from a NAVA level of 0,5 cmH20/µV the level will be increased by 0,5 cmH2O/µV every 3 minutes until reaching a maximum NAVA level of 4,0 cmH2O/µV."
223760162|NCT02690675|DIETARY_SUPPLEMENT|Iron fortified formula milk|One group received formula milk fortified with 1.2 mg/100 mL and the other group 0.4 mg/100mL between 6 and 12 months of age.
223760163|NCT00140075|DRUG|Epirubicin with Cyclophosphamide, followed by a Taxane|"Epirubicin = 90 mg/m2 Cyclophosphamide = 600 mg/m2~Followed by a taxane; paclitaxel = 175 mg/m2 or docetaxel = 75 mg/m2"
223760164|NCT00140075|DRUG|Epirubicin with a Taxane|"Epirubicin = 75 mg/m2 per cycle~Taxane = paclitaxel = 175 mg/m2 or docetaxel = 75 mg/m2"
223760165|NCT01263288|DIETARY_SUPPLEMENT|cholecalciferol|Vitamin D3 tablet 400 IU. Once daily by mouth for 4 months
223760166|NCT01263288|DIETARY_SUPPLEMENT|cholecalciferol|Vitamin D3 tablet 1000 IU. Once daily by mouth for 4 months
223760167|NCT01263288|DIETARY_SUPPLEMENT|Placebo|Microcrystalline cellulose tablet p.o.daily. (Same color, shape and size as vitamin D tablet)
224312185|NCT01117493|BEHAVIORAL|Usual care|Usual care included reviews at a specialist respiratory clinic on a three monthly basis to monitor spirometry, inflammatory blood markers and sputum microbiology. The patients were prescribed inhaled therapy and antibiotics if required, and treatment adjusted to the needs of the patient as necessary, including hospital admission.
224312186|NCT05912270|BEHAVIORAL|Orchestra in Class|See arm/group descriptions
224312187|NCT00557089|DRUG|rhDNAse|2.5 mg rhDNase will be dispensed in 2.5 ml vials and administered once a day for 28 days. Treatment will be administered by inhalation.
224312188|NCT00557089|OTHER|Placebo|2.5 mg of the placebo will be dispensed in 2.5 ml vials and administered once a day over 28 days. Treatment will be administered by inhalation.
223614701|NCT02647307|DRUG|DS-1040b|Single 12-hour intravenous infusion of DS-1040b (20 mg)
223614702|NCT03154385|DRUG|Rituximab (Mabthera ®) Belimumab (Benlysta ®)|Rituximab (Mabthera ®): 1g IV at W0 and W2 Belimumab (Benlysta ®) : 10mg/kg IV, W0 + 2days, W2 + 2 days, W4, W8, W12
223760168|NCT02313610|DRUG|Qinbudan|Contains three kinds of traditional Chinese medicine radix scutellariae, radix stemona, liquorice
224312189|NCT03095638|DRUG|Conventional dolutegravir 10 mg tablet|Single dose of five 10 mg DTG tablets will be administered directly to mouth with 240 mL of water in the morning to randomized subjects in fasting state present in Part 1. DTG will be a white, round shaped, biconvex tablet.
224312190|NCT03095638|DRUG|Conventional dolutegravir 50 mg tablet|Single dose of one 50 mg tablet will be administered directly to mouth with 240 mL of water in the morning to randomized subjects in fasting state present in Part 1. DTG will be a white, round shaped, biconvex tablet.
224312191|NCT03095638|DRUG|Dispersible dolutegravir 5 mg tablet|Single dose of five 5 mg DTG tablets will be administered as dispersed in water or direct to mouth with 240 mL of water in the morning to randomized subjects in fasting state present in Part 2. DTG will be a white, round shaped, biconvex tablet.
223614703|NCT00857285|DRUG|olmesartan medoxomil|olmesartan medoxomil oral tablets, once daily for up to 12 weeks
223614704|NCT00857285|DRUG|losartan potassium|losartan oral tablets, once daily for up to 12 weeks
223614705|NCT00376129|DRUG|Alefacept|15 mg i.m. once weekly for 12 weeks
223614706|NCT02376764|PROCEDURE|Blood drawing (venipuncture)|Patients with Deep Vein Thrombosis will undergo blood drawing in order to collect plasma samples.
223614707|NCT05716074|OTHER|Supervised exercise|The supervised group will be given 10 minutes of warm-up, 10 minutes of breathing exercises, 20 minutes of low endurance combined exercises (stretching, strengthening, strength exercises), 10 minutes of balance and walking training, and 10 minutes of cool-down exercises. Exercise will be applied for 1 hour a day, 3 days a week for 6 weeks.
223614708|NCT05716074|OTHER|Home exercise|The home group will be given 10 minutes of warm-up, 10 minutes of breathing exercises, 20 minutes of low endurance combined exercises (stretching, strengthening, strength exercises), 10 minutes of balance and walking training, and 10 minutes of cool-down exercises. Exercise will be applied for 1 hour a day, 3 days a week for 6 weeks in the home.
223614709|NCT05770817|OTHER|N/A: SKyRoCKeT is an observational study|None; this is an observational study
223614710|NCT00430716|DRUG|Sildenafil citrate|oral, 20 mg, tid
223760169|NCT02313610|DRUG|Qinbudan Placebo|Qinbudan Placebo was the same as therapeutic drug in package,shape,size.
223760170|NCT03643003|BEHAVIORAL|Music therapy|"Music therapy consists of live singing of participant-preferred music, with guitar accompaniment, by a board-certified music therapist (i.e., MT-BC), following a protocol regarding how to manipulate the music in real time per participant responses. Dosage: participants engage in a small-group (3-6 participants) session at their nursing home, 3 times per week, across 2 consecutive weeks. Each session lasts 25 minutes and occurs in the afternoon."
224201787|NCT01124500|DRUG|methylphenidate via transdermal patch compared to placebo|The participants will start with a 10mg MPH patch on day -4, the 1st day of the titration period. This will be increased up to 20mg over 4-day titration period as needed and tolerated, and continued on the optimal dose. Subjects will be seen on day 1 of the double-blind part of the study at a patient education room or the Dr.'s office and receive 10 identical patches including 5 MPH and 5 placebo patches that will be randomly assigned over the 10-day course. The patch will be placed at 9am and removed at 4pm daily for 10 days. During the 10 days, each subject will be monitored for continuous 240 hours by actigraphy based activity monitors to follow activity levels and energy expenditure.
223614711|NCT00430716|DRUG|Sildenafil citrate|oral 1 mg, tid
223614712|NCT00430716|DRUG|Sildenafil citrate|oral 5 mg, tid
223614713|NCT00430716|DRUG|Sildenafil citrate|oral 20 mg, tid
223614714|NCT06396234|DEVICE|Safe VLM and airway management|Once the device is placed, following assessment, endotracheal intubation will be performed via the device.
223614715|NCT06396234|PROCEDURE|Endotracheal intubation using video laryngoscope|Endotracheal intubation (size 7.0 mm) using video laryngoscope
223614716|NCT06396234|DEVICE|SaCo VLM and airway management|Once the device is placed, following assessment, endotracheal intubation will be performed via the device.
223614717|NCT06116734|DRUG|Grastofil®|On day 5 after the hemopoietic stem cell transplant, one subcutaneous injection for 5 days
223614718|NCT06116734|DRUG|Lapelga|On day 5 after the hemopoietic stem cell transplant, one subcutaneous injection
224201788|NCT00797316|DRUG|Aliskiren|Aliskiren 150 mg or 300 mg taken once daily in oral form
224201789|NCT00797316|DRUG|Hydrochlorothiazide|Hydrochlorothiazide 12.5 mg or 25 mg taken once daily in oral form.
224201790|NCT01555242|DRUG|Aneustat (OMN54)|100 mg active/capsule; oral administration; 28 days/cycle (up to 6 cycles total) 1,000 mg QD 2,000 mg QD 1,500 mg BID 2,000 mg BID 2,500 mg BID
224201791|NCT01516684|DRUG|placebo administration|Given topically
224201792|NCT01516684|DRUG|EMLA|Given topically
224201793|NCT01516684|DRUG|propofol|Given IV
223614719|NCT04507243|DEVICE|Active - HD tDCS|Non-invasive neuromodulation using HD electrodes placed on the scalp to deliver a constant, low current at 2 mA.
223614720|NCT04507243|DEVICE|Sham - HD tDCS|Sham neuromodulation using HD electrodes placed on the scalp to deliver a low current ramped up/down for 20 sec.
223614721|NCT05663203|OTHER|Internet-Based Intervention|Attend CRCWeb intervention
223614722|NCT05663203|OTHER|Interview|Complete interview
223614723|NCT05663203|OTHER|Survey Administration|Complete survey
223614724|NCT05663203|OTHER|Electronic Health Record Review|Medical records are reviewed
223614725|NCT03482622|DIAGNOSTIC_TEST|Fast Raman|Fast Raman uses Raman spectroscopy to measure chemical profiles of tissue and provide a diagnostic map identifying BCC within 30 minutes.
224201794|NCT01516684|DRUG|fentanyl citrate|Given IV
224201795|NCT05787496|DRUG|NC525|Monoclonal antibody specific for LAIR-1
224201796|NCT06154772|OTHER|Color Therapy|Color therapy will be applied to the body chakras for 10-15 minutes with colored fabrics, color therapy with water and colored light lamp.
224201797|NCT02070718|DRUG|Standard Dose Kappa Agonist|
224201798|NCT02070718|DRUG|Half Dose Kappa Agonist|
224201799|NCT02070718|OTHER|Placebo|
224201800|NCT02296541|BIOLOGICAL|DNA Nat-B env|4 mg to be administered as 1 mL intramuscularly (IM) by Biojector 2000® or with a needle and syringe in the deltoid muscle of the non-dominant arm (unless medically contraindicated)
224201801|NCT02296541|BIOLOGICAL|DNA CON-S env|4 mg to be administered as 1 mL IM by Biojector 2000® or with a needle and syringe in the deltoid muscle of the non-dominant arm (unless medically contraindicated)
224201802|NCT02296541|BIOLOGICAL|DNA Mosaic env|4 mg to be administered as 1 mL IM by Biojector 2000® or with a needle and syringe in the deltoid muscle of the non-dominant arm (unless medically contraindicated)
224201803|NCT02296541|BIOLOGICAL|MVA-CMDR|1×10\^8 plaque forming units (pfu) to be administered as 1 mL IM in the deltoid muscle of the non-dominant arm (unless medically contraindicated)
224201804|NCT02296541|BIOLOGICAL|Placebo for DNA Nat-B env|Sodium Chloride for Injection, 0.9% to be administered as 1 mL IM by Biojector 2000® or with a needle and syringe in the deltoid muscle of the non-dominant arm (unless medically contraindicated)
224201805|NCT02296541|BIOLOGICAL|Placebo for DNA CON-S env|Sodium Chloride for Injection, 0.9% to be administered as 1 mL IM by Biojector 2000® or with a needle and syringe in the deltoid muscle of the non-dominant arm (unless medically contraindicated)
224201806|NCT02296541|BIOLOGICAL|Placebo for DNA Mosaic env|Sodium Chloride for Injection, 0.9% to be administered as 1 mL IM by Biojector 2000® or with a needle and syringe in the deltoid muscle of the non-dominant arm (unless medically contraindicated)
224201807|NCT02296541|BIOLOGICAL|Placebo for MVA-CMDR|Sodium Chloride for Injection, 0.9% to be administered as 1 mL IM in the deltoid muscle of the non-dominant arm (unless medically contraindicated)
224201808|NCT03626935|DEVICE|3D-printed customized guide plate|3D-printed customized guide plate will be used in the ankle arthrodesis to help reduce operation time and reduce intra-operative radiation.
224201809|NCT00482664|DRUG|CP-866,087|Tablets for oral administration
224312192|NCT03095638|DRUG|Conventional dolutegravir 25 mg tablet|Single dose of one 25 mg DTG tablet will be administered directly to mouth with 240 mL of water in the morning to randomized subjects in fasting state present in Part 2. DTG will be a white, round shaped, biconvex tablet.
223614726|NCT00804726|DEVICE|Akreos MI Five-O|Small incision cataract surgery with phacoemulsification cataract extraction and Akreos MI Five-O IOL surgical implantation
223614727|NCT02146417|PROCEDURE|Low pressure pneumoperitoneum|
223614728|NCT02146417|PROCEDURE|Normal pressure pneumoperitoneum (12 mmHg)|
223614729|NCT02146417|PROCEDURE|Deep neuromuscular block|
223614730|NCT04392817|BEHAVIORAL|Arabic Articulatory Error Remediation software program|A speech therapy computerized intervention
223614731|NCT03803189|BEHAVIORAL|Usual care plus eToolkit|The intervention arm will receive repeated e-surveys via email to collect the Edinburgh Postpartum Depression Scale (EPDS) score at baseline and 2, 4, 6, 8, and 12 weeks. Those with EPDS\<10 will be triaged as low risk. Those with EPDS 10-18 (without suicidality) will be triaged as symptomatic for non-urgent clinical assessment with a message delivered via the EMR. Those with EPDS≥19 or suicidality will be triaged as requiring immediate follow-up, with an urgent message to their PCP via EMR, phone (if suicidal) and fax. Prompts in the EMR will enable evidence-based clinical care for PPD and PPA, highlight treatment preferences to support shared decision making, and identify appropriate referrals. Intervention arm participants will receive a personalized eToolkit after the completion of each survey. Patients in the intervention group with symptoms will be invited to a telephone interview at 12 weeks postpartum to describe their experience with the intervention.
223614732|NCT05339360|PROCEDURE|Femoral fixation with intramedullary nails|Femoral fracture fixation Femoral Osteotomy
223614733|NCT01335776|BEHAVIORAL|Mindfulness-Based Stress Reduction|This intervention is provided over the course of eight, weekly, 90 minute sessions, plus one 6 hour silent retreat.
223614734|NCT01335776|BEHAVIORAL|Cognitive Behavior Therapy|This treatment is delivered to small groups over the course of 8 weekly, 90 minute sessions
223614735|NCT00675909|DRUG|Aerosolized Intranasal midazolam|"Midazolam will be administered via aerosolization (using atomizer) with half of dose in each nostril. Total dose is 0.3mg/kg."
223614736|NCT00675909|DRUG|Aerosolized Buccal Midazolam|"0.3mg/kg total dose administered with aerosolization device (atomizer) sprayed onto buccal mucosa inside the cheek on both sides of mouth."
223614737|NCT00675909|DRUG|Oral midazolam|oral midazolam 0.5mg/kg
223614738|NCT01329978|DRUG|Sofosbuvir|Sofosbuvir (SOF) administered as a 400 mg tablet orally once daily
223614739|NCT01329978|DRUG|RBV|Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)
223614740|NCT01329978|DRUG|PEG|Pegylated interferon alfa-2a (PEG) 180 μg administered once weekly by subcutaneous injection
223614741|NCT04950244|DIAGNOSTIC_TEST|High-sensitivity cardiac troponin I (hs-cTnI)|"Capillary and veinous whole blood sampling for hs-cTnI was collected. The sample was tested at the bedside with a point-of-care device (Atellica VTLi, Siemens Healthineers).~The result of both hs-c TnI values obtained was blinded to the treating physician"
224201810|NCT00482664|DRUG|CP-866,087|Tablets for oral administration
224201811|NCT00482664|DRUG|CP-866,087|Tablets for oral administration
224201812|NCT00482664|DRUG|Placebo|Tablets for oral administration
223509697|NCT05276453|DEVICE|GMove Suit|12 week, home-based programme whereby participants are encouraged to use the GMove suit daily, for at least 30 minutes a day. Recommended activities include walking, sit-to-stand and step-ups
223509698|NCT05276453|BEHAVIORAL|Normal therapy|Participants are randomized to a normal therapy (physiotherapy) only program. Participants are also advised to undertake 30 mins a day of physical activity and have active physical therapy (physiotherapy) sessions.
223509699|NCT02676427|PROCEDURE|passive leg raising|passive leg raising under echocardiographic monitoring with intravascular doppler in place
223509700|NCT02974231|RADIATION|Intensity-modulated radiation therapy|
224201813|NCT04903938|BEHAVIORAL|Primary And Secondary Abilities Among The Individuals With Antisocial Personality Disorder Within The Scope Of Positive Psychotherapy: Their Relationship With Criminal Behaviors, Aggression And Anger|Participants will be given scales with validity and reliability studies in Turkish.
224312193|NCT04642365|DRUG|RO7296682|RO7296682 will be administered as per the schedules specified in the respective arms.
223509701|NCT01751685|BEHAVIORAL|Kyphosis-specific spinal strengthening exercises|Investigator developed the intervention protocol (Kyphosis-specific spinal strengthening exercises) of targeted spine exercises during our pilot study based upon the literature and clinical experience.We standardized the protocol with a written script and a video. Each exercise session will be preceded by light aerobic activity, ended with cool-down and stretching the neck, chest and all extremities. All participants will be carefully monitored to ensure that all exercises will be performed slowly, with correct body alignment and technique to minimize risk of injury.
223509702|NCT01751685|OTHER|Control|monthly educational lectures on various topics
223509703|NCT01596244|BEHAVIORAL|Microclinic|Microclinics consist of 2-8 individuals from pre-existing social networks (friends, relatives, coworkers, neighbors, etc) that voluntarily participate in ongoing education and medical monitoring from local health care professionals, learning and practicing diabetes management strategies, sharing much-needed medical supplies, and exchanging social support in the form of regular microclinic meetings.
223509704|NCT03542357|DRUG|Calcitonin Gene Related Peptide|CGRP is given both study days to induce headache. One day the headache is treated with placebo and the other day with sumatriptan
223614742|NCT02677194|DEVICE|LED|There are 7 mini-zones of 1,5x1,5 cm at the level of forearm, one of them is allocated to control ( only laser). Dermabrasion by fractional laser CO2 ablative, evaluation of the pain on every zone by VAS post-act. Exposition to LED (630nm, 830nm and 590 nm). Water loss measure and colorimetry before and after laser and after the exposition to LED. Clinical evaluation of local tolerance post-laser and post-LED + standardized photographs.
223614743|NCT02677194|OTHER|Control device|Device without any LED exposition
223614744|NCT02952365|DRUG|Tissue sealant|Application of tissue sealant on eyes undergoing LASIK enhancement
223614745|NCT03324802|RADIATION|Hypofractionated Radiation Therapy|Undergo hypofractionated radiation therapy
223614746|NCT03324802|OTHER|Quality-of-Life Assessment|Ancillary studies
223614747|NCT03324802|RADIATION|Radiation Therapy|hypofractionated radiation therapy
223614748|NCT05984043|BEHAVIORAL|Biofeedback|Heart-rate Variability Biofeedback
223614749|NCT05984043|OTHER|Waitlist|Waitlist control group
223614750|NCT01887132|DRUG|Donepezil|
223614751|NCT01887132|DRUG|Placebo|
223614752|NCT02598206|DRUG|PF-04136309|"Treatment A (n=18): a single dose of 1000 mg PF 04136309 will be administered in a fasted state as 8 × 125 mg Tablets.~Treatment B (n=18): a single dose of 1000 mg PF-04136309 will be administered with a high fat breakfast as 8 × 125 mg Tablets."
223614753|NCT03293030|DRUG|Dupilumab|Dupilumab treatment
223614754|NCT02782286|DRUG|Ketorolac|The patients randomised to this arm will receive 30 mg intravenous ketorolac.
223614755|NCT02782286|DRUG|Morphine|The patients randomised to this arm will receive 0,1 mg/kg intravenous morphine.
223614756|NCT00924248|DRUG|Gadoxetic acid disodium (Primovist, BAY86-4873)|Patients in daily life clinical practice treatment receiving Primovist according to indication on the label.
223614757|NCT05277558|OTHER|Observational|Investigators are observing brain health over time (21 months) in these groups
223614758|NCT00821496|DRUG|ethinyl estradiol, norethindrone, VI-0521|Oral contraceptive
223614759|NCT03579706|BEHAVIORAL|Cognitive Anxiety Sensitivity Treatment|The Cognitive Anxiety Sensitivity Treatment is a computerized treatment that is a combination of psychoeducation plus interoceptive exposure for anxiety sensitivity (AS). The psychoeducational component will focus on the nature of stress and its effect on the body. Interoceptive exposure (IE) exercises, designed to correct the conditioned fear to these bodily sensations, will be explained and practiced.
223614760|NCT03579706|BEHAVIORAL|Physical Health Education Training|The Physical Health Education Training is a computerized active placebo matched in time and structure to CAST that includes information about general health and wellness (e.g. diet, exercise etc.).
223614761|NCT03015636|BEHAVIORAL|Adjusted CBT-i for ADHD|This is a version of CBT for insomnia (CBT-i) developed during the pilot phase of this Project. Traditional CBT-i is adjusted for use in the adult ADHD population. This behavioral intervention adresses not only traditional aspects of insomnia, but also sleep phase problems and other aspects of sleep specifically relevant to the ADHD-population. Treatment is given as 10 weekly group sessions with telephone calls from the therapist between sessions to increase adherence and adress individual patient needs.
223614762|NCT03015636|OTHER|Treatment as Usual|Usual care at the ADHD-clinic. This mostly entails managing pharmacological treatment for ADHD, comorbid psychiatric problems and/or sleep problems. The clinic also provides different group treatments, for instance mindfulness groups and groups for developing behavioral strategies for managing ADHD symptoms, and individual therapy.
223614763|NCT00900055|GENETIC|microarray analysis|
223614764|NCT00900055|GENETIC|polyacrylamide gel electrophoresis|
223614765|NCT00900055|GENETIC|polymerase chain reaction|
223614766|NCT00900055|GENETIC|protein expression analysis|
223614767|NCT00900055|GENETIC|reverse transcriptase-polymerase chain reaction|
223614768|NCT00900055|GENETIC|western blotting|
223614769|NCT00900055|OTHER|chromatography|
223614770|NCT00900055|OTHER|high performance liquid chromatography|
223614771|NCT00900055|OTHER|immunoenzyme technique|
223614772|NCT04394065|DEVICE|ultrasensitive positron emission tomography|A 194-cm-long total-body positron emission tomography/computed tomography (PET/CT) scanner (uEXPLORER)
223614773|NCT00393211|DRUG|MK0663, Etoricoxib / Duration of Treatment : 12 Weeks|
223614774|NCT00393211|DRUG|Comparator : placebo (unspecified) /Duration of Treatment : 12 Weeks|
223614775|NCT04725253|DIETARY_SUPPLEMENT|Nicotinamide|Nicotinamide, 1,5 gr per day for 7 days.
223614776|NCT04725253|OTHER|Placebo tablets|Placebo tablets, 1 per day for 7 days.
223614777|NCT05864222|OTHER|Aromatherapy|Elequil Aroma-Tabs are available on all clinical nursing units for staff. Instructions will be provided to participants to place the aroma tab on the back of their badge every workday for the entire duration of their shift. They will wear their badge in whatever position is most comfortable to them for the duration of the study (6 months).
223614778|NCT04789915|DRUG|Memantine|Add on treatment with memantine to aripiprazole.
223614779|NCT04789915|DRUG|Placebo|Placebo add on to aripiprazole
223760171|NCT03643003|BEHAVIORAL|Non-Music Verbal Interaction (Placebo)|"Non-music verbal interaction consists of conversation of participants' interests, without music, by a board-certified music therapist, following a protocol regarding how to respond verbally in real time per participant responses. Dosage is the same as for music therapy: participants engage in a small-group (3-6 participants) session at their nursing home, 3 times per week, across 2 consecutive weeks. Each session lasts 25 minutes and occurs in the afternoon."
223760172|NCT05402943|BEHAVIORAL|Nursing Care Program for Endometriosis|Nursing Care Program for Endometriosis, developed in line with Health Promotion Model
224201814|NCT04525066|DRUG|Hyaluronic acid|Patients in the treatment group received hyaluronic acid injection into the unaffected vocal cord intra-operatively during transoral laser microsurgery for early glottic cancer.
224201815|NCT04525066|OTHER|No Hyaluronic Acid Injection Injection|Patients in the placebo group did not receive hyaluronic acid injection into the unaffected vocal cord intra-operatively during transoral laser microsurgery for early glottic cancer.
224201816|NCT02925650|DRUG|Posiphen|oral solid dosage form capsule
224201817|NCT02925650|DRUG|Placebo|oral solid dosage form capsule
224201818|NCT01898390|PROCEDURE|Transplant|Bilateral Neural Allo-Transplantation with Fetal Ventral Mesencephalic Tissue
224312194|NCT04642365|DRUG|Atezolizumab|Atezolizumab will be administered as per the schedules specified in the respective arms.
223760173|NCT05402943|BEHAVIORAL|EHP-5 Endometriosis Health Promotion Model.|EHP-5 Endometriosis Health Promotion Model. A questionnaire used to measure the quality of life of women with endometriosis
223760174|NCT05402943|BEHAVIORAL|Healthy Life Style Behaviours Scale II.|A questionnaire used to measure the Healthy Life Style Behaviours.
224201819|NCT01932541|DRUG|Latuda (Lurasidone)|Latuda® (lurasidone) tablets taken by mouth once daily, between 20 mg and 120 mg a day.
224201820|NCT03093558|BEHAVIORAL|ECA/Kardia|Use of the ECA and Kardia daily for 30 days.
224312195|NCT01144715|DEVICE|Hand Mentor (TM) robotic stroke therapy device|The goal of the Hand Mentor ™ (TM) device is to improve Active Range of Motion in the distal musculature of the paretic limb of patients with stroke. Development of HM patient protocols are based on basic principles of motor learning: the protocols actively engage the patient in activities, progressively increase task difficulty based on patient performance, actively assist patient if necessary (i.e. patient is not passive), provide meaningful feedback at regular intervals, require sensorimotor integration and incorporate the use of tasks that that are intended to transfer to distal motor performance.
224312196|NCT01144715|DEVICE|Home Therapy Program|Subjects in the control group will be instructed in a self administered home therapy program
224312197|NCT06983704|PROCEDURE|AGV plate|AGV plate using a 27-gauge needle
224312198|NCT06983704|PROCEDURE|bevacizumab injection|subconjunctival injection of bevacizumab
223509705|NCT03542357|DRUG|Sumatriptan 50 mg|CGRP is given both study days to induce headache. One day the headache is treated with placebo and the other day with sumatriptan
223509706|NCT03542357|DRUG|Placebo Oral Tablet|CGRPis given both study days to induce headache. One day the headache is treated with placebo and the other day with sumatriptan
223614784|NCT04967196|BIOLOGICAL|Ipilimumab|Given via DoseConnect device or IV
224201821|NCT04973748|BEHAVIORAL|Conditioned open-label placebo (COLP)|"Placebo oxycodone will be formulated to have the same physical appearance as liquid oxycodone and will be dispensed by the inpatient pharmacy and administered by the nursing staff. At all times that oxycodone or placebo medication is administered on post-operative day (POD) 1-5, the patient will undergo conditioning via exposure to a clove oil scent:~1. Conditioning (i.e. exposure to clove oil scent) with each dose of oxycodone medication on POD 1-5.~2. Scheduled placebo oxycodone medication paired with conditioning (i.e. exposure to clove oil scent) 3 times per day on POD 2-5."
224201822|NCT04973748|BEHAVIORAL|Surveys about pain, opioid use and depression symptoms|"Surveys before surgery: Within 1 week prior to surgery, patients complete surveys about pain levels, opioid consumption, understanding of placebo effect and symptoms of depression.~Surveys after surgery: Through 6-months after surgery, patients complete surveys about pain levels, opioid consumption, side effects of opioids and symptoms of depression."
224201823|NCT02944097|DIETARY_SUPPLEMENT|Vineatrol 30 native powder|
224201824|NCT02944097|DIETARY_SUPPLEMENT|Vineatrol 30 micelles|
224201825|NCT03746249|DRUG|Lenvatinib|12 mg (or 8 mg) once daily (QD) oral dosing.
224201826|NCT03746249|DRUG|PD-1 antibody|3mg/kg intravenously every 2 weeks
224201827|NCT05141045|DIETARY_SUPPLEMENT|omega-3 PUFA supplement|participants were instructed to take 3.0 grams per day of omega-3 PUFA supplement
223509707|NCT04401293|DRUG|Enoxaparin|Full Dose LMWH anticoagulation therapy
223509708|NCT04401293|DRUG|Prophylactic/Intermediate Dose Enoxaparin|Prophylactic/Intermediate Dose LMWH or UFH therapy
223509709|NCT06301152|DEVICE|high intensive laser|high-intensity laser ,three times in a week, for three weeks, 9 session
223509710|NCT06301152|DEVICE|extracorporeal shock wave therapy|extracorporeal shock wave therapy, once a week, for three weeks ,3 times,
223509711|NCT00694161|DRUG|Fx-1006A|Fx-1006A 20mg soft gelatin capsules once daily (at the same time each day) for 12 months
223509712|NCT02505971|DRUG|Nadolol|"Patients will be administered twice-daily doses of medication as follows: since Day 0- 0.5 mg/kg/day ; since Day 7-1.0 mg/kg/day and since Day 14- 1.5 mg/kg/day. In all subsequent visits the dosage will be adjusted based on the current weight rather than the baseline weight to maintain 1.5 mg/kg/day. Or the dose may be escalated (by 0.5 mg/kg/day at any following study visit) up to 3 mg/kg/day based on the clinical response to maintain the dose that led to at least 75% reduction in the hemangioma size until Week 24, when unblinding happen. At Week 24 paticipants can start weaning by 10% per week or continue with the last dose, depending on the investigator's decision.~S/he will be monitored until Week 52."
223509713|NCT02505971|DRUG|Propranolol|"Patients will be administered twice-daily doses of medication as follows: since Day 0- 0.5 mg/kg/day ; since Day 7-1.0 mg/kg/day and since Day 14- 1.5 mg/kg/day.~In all subsequent visits the dosage will be adjusted based on the current weight rather than the baseline weight to maintain 1.5 mg/kg/day. Or the dose may be increased by investigator, based on clinical response by 0.5 mg/kg/day at any study visit (up to 3 mg/kg/day divided twice a day) to maintain the dose that lead to at least 75% reduction in the hemangioma size until Week 24, when unblinding happen. At Week 24 paticipants can start weaning by 10% per week or continue with the last dose, depending on the investigator's decision.~S/he will be monitored until Week 52."
223509714|NCT00837330|DRUG|ranibizumab 0.5 or 0.3 mg/0.05 cc|ranibizumab 0.5 or 0.3 mg/0.05 cc administered intraocularly on a monthly basis for 3 months, followed by monthly examination with the option of further ranibizumab treatment or other therapies at the discretion of the treating physician
223509715|NCT02186067|OTHER|Referral System|"Primary Level:~Refer patients to secondary care centre if Patients has complicated hypertension (Patients with target organ damage, CVD, CKD or more the 3 drugs)~Secondary Level:~Community health center at Aga Khan University will serve as the secondary care center.~Family physician will manage patients with CVD, CKD or more than 3 drugs.~Tertiary care:~Cardiologist at the Aga Khan University will manage secondary, resistant and difficult to treat hypertension.~Behavioral: Other Interventions CME session by Cardiologist/Consultant Family Physician : At start , and at two months Community screening by Family physicians at the primary care center (open house) once in three months Patient group education session. Once in three months"
223509716|NCT01940146|DRUG|SPARC Placebo|Placebo
223509717|NCT01940146|DRUG|SPARC1310 I|SPARC1310 I
223509718|NCT01940146|DRUG|SPARC1310 II|SPARC1310 II
223509719|NCT01940146|DRUG|SPARC1310 III|SPARC1310 III
223509720|NCT02712242|OTHER|Platelet Rich Fibrin|Immediate and delayed bleeding, pain, epithelialization, feeding habits and sensation scores were recorded after PRF placing on palatal wounds.
223509721|NCT02712242|OTHER|Butyl cyanoacrylate|Immediate and delayed bleeding, pain, epithelialization, feeding habits and sensation scores were recorded after Butyl Cyanoacrylate application on palatal wounds.
223509722|NCT02712242|OTHER|Wet gauze|Immediate and delayed bleeding, pain, epithelialization, feeding habits and sensation scores were recorded after wet gauze pressure on palatal wounds.
223614785|NCT04967196|BIOLOGICAL|Nivolumab|Given IV
223760175|NCT05402943|BEHAVIORAL|The Satisfaction Questionnaire for Nursing Care Program for women with Endometriosis.|A questionnaire used to measure the satisfaction levels of women with endometriosis who applied the Nursing Care Program for women with endometriosis.
223760176|NCT02547662|DRUG|Dexamethasone|Given PO
223760177|NCT02547662|DRUG|Ixazomib Citrate|Given PO
223760178|NCT02547662|OTHER|Laboratory Biomarker Analysis|Correlative studies
223760179|NCT02547662|DRUG|Pomalidomide|Given PO
223760180|NCT00937638|DIETARY_SUPPLEMENT|BOLD Diet|Low-fat, high fruit and vegetable diet that includes lean beef (5oz/day)
223760181|NCT00937638|DIETARY_SUPPLEMENT|BOLD-X Diet|Low-fat, moderate-high protein diet (BOLD+) that is higher in total protein (from mixed sources including lean beef, 7oz/day) than the BOLD diet. Also high in fruits and vegetables
223760182|NCT00937638|DIETARY_SUPPLEMENT|Modified DASH Diet|Low-fat, high fruit and vegetable diet which has become the Gold Standard for the management of cardiovascular disease (CVD) risk factors and metabolic syndrome
223760183|NCT00202904|DRUG|ezetimibe|ezetimibe 10 mg tablets, one tablet taken daily with atorvastatin 10 mg daily for 6 weeks
223760184|NCT00202904|DRUG|placebo|placebo tablets matched to ezetimibe, one tablet taken daily with atorvastatin 10 mg daily for 6 weeks
223760185|NCT02433834|DRUG|Glycopyrronium MDI|GP MDI
223760186|NCT02433834|DRUG|Serevent Diskus 50 μg|
223760187|NCT02433834|DRUG|Placebo|
223509723|NCT02273466|DRUG|Desipramine tablet|
223509724|NCT02273466|DRUG|Crobenetine infusion|
223509725|NCT02273466|DRUG|Placebo infusion|
223509726|NCT01019551|DRUG|ART Intensification|Current ART regimen plus raltegravir and maraviroc Raltegravir : 400 mg PO BID for 56 weeks Maraviroc : 150, 300 or 600 mg PO BID depending on concomitant ART treatment, for 56 weeks
223614786|NCT04967196|PROCEDURE|Lymph Node Assessment|Undergo lymphatic imaging with ICG
223614787|NCT04967196|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223760188|NCT06249282|PROCEDURE|Biopsy|Undergo biopsy
223760189|NCT06249282|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
223760190|NCT06249282|DRUG|Carfilzomib|Given IV
223760191|NCT06249282|PROCEDURE|Computed Tomography|Undergo CT
224201828|NCT05141045|DIETARY_SUPPLEMENT|placebo|placebo
224201829|NCT05227807|BEHAVIORAL|mouth opening exercise|The intervention group receives an oral exercise intervention, including a 30-minute individual training, a multimedia oral exercise education video along with a print education booklet, and three follow-up phone calls.
224201830|NCT05227807|BEHAVIORAL|Usual care|routine care including written mouth exercise instructions
224201831|NCT03781973|BEHAVIORAL|Data platform +Quality Performance feedback reports|Teams from each of the participating sites will attend the webinars. Each site will share an example of a QI initiative that they are executing and describe the success and challenges.
224201832|NCT05870566|DEVICE|Corneal Crosslinking|"Riboflavin isotonic, 0,1 % Vitamin B2, with Dextran 20,0%, for epi-off procedure or Riboflavin isotonic 0,1% (Vitamin B2), 1,1% HPMC without Dextran for epi-off) 0.1% riboflavin-5-phosphate and 20% dextran T-500) will be applied to the cornea after epithelial debridement every 2 min for 10 minutes before irradiation and every 2 minutes during the course of a 10 minute exposure to 365 nm UV-A with an irradiance rate of 9 mW/cm2. This dose, mode and scheme of the intervention follows the internationally recognized accelerated CXL protocol (Elbaz et al. 2014). The data existing shows equivalent outcome regarding efficacy and safety compared to the standard protocol. To avoid any damage to the limbal stem cells, the limbus will not be irradiated during the procedure, as a CXL device (with maximal diameter of 11 mm) will be used. Furthermore, the limbal area will additionally be protected by a custom-cut LSC protection shield. (Protocol V04\_0 Page 45-46)"
223509727|NCT01019551|BIOLOGICAL|Immunomodulation|Starting at Week 8, 1 cycle of 3 injections (1 per week) of recombinant human Interleukin-7 (r-hIL-7 / CYT107) at a 20 µg/kg dose.
223509728|NCT04902066|OTHER|Cognitive Behavioural Virtual Reality Therapy.|Cognitive Behavioural Therapy augmented with Virtual Reality.
223509729|NCT04902066|OTHER|Traditional Cognitive Behavioural Therapy|Traditional Cognitive Behavioural Therapy for psychosis.
223509730|NCT04779723|PROCEDURE|Comparison of two Techniques of bariatric surgery|We compared the 30 days outcomes in patients who underwent LSG procedure with those who underwent LRYGB
223509731|NCT04701320|DRUG|Conventional glass ionomer|Conventional glass ionomer with enhanced mechanical and esthetic proberties
223509732|NCT04701320|DRUG|Nano hydroxyapatite reinforced glass ionomer|Nanohydroxyapatite reinforced glass ionomer restorative material with enhanced mechanical proberties and chemical adhesion to tooth structure
223614788|NCT00041379|DRUG|beta alethine|
223614789|NCT02518763|DRUG|Vitamin D3, 100 000 IU weekly, 4 times|
223614790|NCT02518763|BIOLOGICAL|25 OH vitamin D serum concentration measurements|
223614791|NCT05267886|DRUG|Dobutamine|Dobutamine administered according to its clinical dose stage for cardiogenic shock
223614792|NCT05267886|DRUG|Milrinone|Milrinone administered according to its clinical dose stage for cardiogenic shock
223760192|NCT06249282|PROCEDURE|Echocardiography|Undergo ECHO
223760193|NCT06249282|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223760194|NCT06249282|DRUG|Sotorasib|Given PO
223760195|NCT00733720|DRUG|Suboxone|4/1mg, 8/2mg 16/4mg
223760196|NCT01024543|DRUG|Angiotensin II|Angiotensin II
223760197|NCT01024543|DRUG|Phenylephrine|Phenylephrine
223760198|NCT01024543|DRUG|Placebo|
223760199|NCT02300324|DIETARY_SUPPLEMENT|Standard broccoli and stilton soup|Participants will be randomised to eat one portion (300g) of broccoli soup for each phase.
223760200|NCT02300324|DIETARY_SUPPLEMENT|Beneforte broccoli and stilton soup|Participants will be randomised to eat one portion (300g) of broccoli soup for each phase.
223760201|NCT02300324|DIETARY_SUPPLEMENT|Beneforte Extra broccoli and stilton soup|Participants will be randomised to eat one portion (300g) of broccoli soup for each phase.
224314300|NCT00714896|BEHAVIORAL|Stepped-Care|"* stage-based expert system written intervention at baseline and 3 months~* in-person stage appropriate counseling at baseline and 3 months~* telephone counseling sessions at weeks 2,4 and 8,~* as-needed brief check-in calls on or 2 days after quit date for those who have set a quit date; and/or check-in calls on days with anticipated high risk situations for former smokers or those who have quit smoking during the study~* optional NRT nicotine replacement therapy in the forms of patch, gum or lozenge for current smokers who are ready to quit smoking and/or for former smokers who report significantly strong smoking urges"
223614793|NCT05267886|DRUG|Normal Saline|Normal saline running at a standardized rate
223614794|NCT03627871|BEHAVIORAL|Majority Norm|Participants receive information about exercise norms that apply to the majority of the population but are given no information about trends in this norm.
223614795|NCT03627871|BEHAVIORAL|Trending Minority Norm|Participants receive information about exercise norms that apply to the minority of the population and have recently been trending up.
223614796|NCT03627871|BEHAVIORAL|Minority Norm|Participants receive information about exercise norms that apply to the minority of the population but are given no information about trends in this norm.
223614797|NCT03627871|BEHAVIORAL|Control|Participants receive information about exercise that is unrelated to social norms or trends in social norms.
223614798|NCT03627871|BEHAVIORAL|Trending Majority Norm|Participants receive information about exercise norms that apply to the majority of the population and have recently been trending up.
223614799|NCT00599066|DEVICE|study cases|Application of a second M-Entropy probe on the forehead of the patient, which will happen in the OR along with the application of other monitors immediately before induction of general anesthesia.
223614800|NCT03635749|DRUG|Intensive antiplatelet|"Day 1：clopidogrel 300mg/day+ aspirin100-300mg/ day~Day2 - 21: clopidogrel 75mg/day+ aspirin 100mg/day~Day22 - 90: clopidogrel 75mg/day+aspirin placebo"
223614801|NCT03635749|DRUG|Standard antiplatelet|"Day 1: Aspirin 100-300mg/day + clopidogrel placebo~Day 2 - 90: Aspirin 100mg/day+ clopidogrel placebo"
223614802|NCT03635749|DRUG|Immediate high-intensity statin|"Day 1 - 21：Atorvastatin calcium 80mg/day~Day 22 - 90：Atorvastatin calcium 40mg/day"
223614803|NCT03635749|DRUG|Delayed high-intensity statin|"Day 1 - 3：Atorvastatin calcium placebo~Day 4 - 21：Atorvastatin calcium 40mg/day + Atorvastatin calcium placebo~Day 22 - 90：Atorvastatin calcium 40mg/day"
223614804|NCT03115762|BIOLOGICAL|bevacizumab|recombinant humanized monoclonal antibody produced by DNA technology in Chinese Hamster Ovary cells
223614805|NCT03115762|BIOLOGICAL|ASKB1202|
223614806|NCT00592488|DRUG|Acetyl-L-Carnitine|Acetyl-L-Carnitine - 4 g IV over 30 minutes, then 8 g iv over the next 12 hours
223614807|NCT05809609|DRUG|Ketamine Hydrochloride|Ketamine is a high trapping NMDA receptor antagonist which has rapid and reliable antidepressant effects in patients with major depressive disorder (MDD) who fail to respond to at least two antidepressant trials of adequate dose and duration.
223614808|NCT05809609|OTHER|No intervention (placebo)|Placebo injection (0.9% sodium chloride)
223614809|NCT01952886|DRUG|Granisetron|
223614810|NCT01952886|DRUG|Ondansetron|
223614811|NCT01987102|DRUG|Calcium Folinate|"The enrolled patients will be treated according to the MAP schedule and will receive the study drug Calcium Folinate commencing 24 hours after the administration of HDMTX and then every 6 hours (q6h) thereafter until the S-MTX levels are ≤ 0.1 µmol/L, in accordance with COG management recommendations.~All patients will receive standard o care (SOC) in the two (2) first HDMTX courses and \[6R\] 5,10-methylenetetrahydrofolate in the two (2) following courses. Patients will be enrolled in two (2) \[6R\] 5,10-methylenetetrahydrofolate dose cohort groups: with \[6R\] 5,10-methylenetetrahydrofolate start dose of 15 mg/m2 (i.e. the same as for SOC rescue) the first cohort will be administered, and 7.5 or 30 mg/m2 in the second cohort."
223614812|NCT01987102|DRUG|[6R] 5,10-methylenetetrahydrofolate (arfolitixorin)|"The enrolled patients will be treated according to the MAP schedule and will receive the study drug \[6R\] 5,10-methylenetetrahydrofolate commencing 24 hours after the administration of HDMTX and then every 6 hours (q6h) thereafter until the S-MTX levels are ≤ 0.1 µmol/L, in accordance with COG management recommendations.~All patients will receive standard o care (SOC) in the two (2) first HDMTX courses and \[6R\] 5,10-methylenetetrahydrofolate in the two (2) following courses. Patients will be enrolled in two (2) \[6R\] 5,10-methylenetetrahydrofolate® dose cohort groups: with \[6R\] 5,10-methylenetetrahydrofolate start dose of 15 mg/m2 (i.e. the same as for SOC rescue) the first cohort will be administered, and 7.5 or 30 mg/m2 in the second cohort."
223614813|NCT00643968|DRUG|EFV+TDF|
223614814|NCT00643968|DRUG|EFV+3TC+TDF|
223614815|NCT05367570|BEHAVIORAL|Cross-sectional observational study|The first work package of this project is an explanatory cross-sectional study with no intervention.
223614816|NCT06342817|BEHAVIORAL|online mindfulness based meditation program|Participants in the intervention group will attend 8 weekly online meetings lasting approximately 60 minutes each (generally structured in an initial 10 minutes for questions about the practices, 15-20 minutes of exposition on the central theme of the meeting, 5-10 minutes for class practice, 10-15 minutes for post-practice inquiry, 5 minutes for explanation of the week's informal practice and audios for daily practice). Audio in mp3 of the practice carried out at each meeting will be provided to maintain daily individual practice during the week. An online questionnaire related to weekly practices will also be left at the beginning of each meeting.
223614817|NCT04706481|PROCEDURE|Specimen Collection|Specimens obtained from surgical, phlebotomy or other non-invasive procedure
223614818|NCT02745834|OTHER|Gait analysis|Gait will be analysed while participants will walk on a treadmill at different self selected speeds, using the OPTOGait system. Spatiotemporal measures are collected without the use of any markers.
223614819|NCT02645292|DEVICE|1 mile walk using treadmill|Walk for 1 mile on treadmill (American Motion Fitness, 8800D) at self selected speed as fast as participant can without any inclination.
223614820|NCT02645292|DEVICE|Stair Climbing|Climb 14 flights of stairs at self selected speed. No double step at a time and running allowed.
223614821|NCT05246371|DRUG|Propofol, dexmedetomidine|Patients will receive maintenance of general anesthesia by TIVA using combination of propofol and dexmedetomidine.
224314301|NCT00714896|BEHAVIORAL|Control|Referral list to smoking cessation classes at Kaiser and the California Smokers Helpline
224314302|NCT00089024|DRUG|fluorouracil|2700 mg/m5 IV over 24 hr after gemcitabine weeks 1 \& 2; Repeat one 3-week cycle starting day 22
223760202|NCT04409782|OTHER|Electronic portal education|Participants will receive education via an electronic portal covering the key messages pertaining to cancer research studies and clinical trials. Data will be collected via pre- and post-tests. The post-test includes questions to pre-screen participants for eligibility into cancer research studies and clinical trials; as appropriate, study participants will be referred to those study/trial/clinical teams for follow-up.
223760203|NCT04409782|OTHER|Online educational video|Participants will receive online education via a video and written web content. Key messages will include information pertaining to cancer research studies and clinical trials. Data will be collected via pre- and post-tests. The post-test includes questions to pre-screen participants for eligibility into cancer research studies and clinical trials; as appropriate, study participants will be referred to those study/trial/clinical teams for follow-up.
223760204|NCT03228810|OTHER|Blood draw|(2) 10 mL tubes will be collected
224314303|NCT00089024|DRUG|gemcitabine hydrochloride|750 (females) or 900 (males) mg/m5 IV over 30 min (day 2)weeks 1 \& 2; Repeat one 3-week cycle starting day 22
224314304|NCT00089024|DRUG|leucovorin calcium|20 mg/m5 PO (day 1) and 20 mg/m5 IV (day 2) weeks 1 and 2; Repeat one 3-week cycle starting day 22
224314305|NCT00089024|DRUG|oxaliplatin|48 mg/m5 IV over 2 hr weeks 1, 2, 4, and 5
223509733|NCT04503200|PROCEDURE|Double guidewire|After the 3rd passage of the guidewire into the pancreatic duct, the catheter will be removed leaving the guidewire in place. The catheter will be re-inserted and a second guidewire will be used and directed above the pancreatic wire in the 11-12 o'clock direction to attempt cannulation of the common bile duct.
223509734|NCT04503200|PROCEDURE|Transpancreatic precut|After the 3rd passage of the guidewire unintentionally into the pancreatic duct, the guidewire will be left in the pancreatic duct, a sphincterotome will be used to cut in the direction of 11-12 o'clock attempting to deroof the pancreatic duct and gain access into the common bile duct. The wire will then be retracted and reinserted in the direction of the cut to attempt cannulation of the common bile duct.
223614822|NCT05246371|DRUG|Desflurane|Patients will receive maintenance of general anesthesia by desflurane.
223614823|NCT00546546|DRUG|early immunosuppressants (azathioprine, methotrexate)|azathioprine 2.5 mg/kg/day SC methotrexate 25 mg/week if aza not tolerated
223614824|NCT05751837|BIOLOGICAL|Lipopolysaccharide|One tumor will be injected with 1 ug LPS (investigational drug) over approximately one minute
223614825|NCT04751318|DRUG|Duloxetine 60mg Test Drug Enteric Coated Granules|Investigational Medicinal Product
223614826|NCT04751318|DRUG|Duloxetine 60mg Reference Product Enteric Coated Granules|Cymbalta (Eli Lilly)
223614827|NCT00110500|GENETIC|hVEGF-A|
223614828|NCT00774293|DRUG|placebo|5 placebo granules for Arnica 5 CH and 5 placebo granules for Bryonia 5 CH
223614829|NCT00774293|DRUG|Arnica and Bryonia|Arnica 5CH granules, 5 per day plus Bryonia 5CH Granules, 5 per day for 5 days
223614830|NCT01236521|DRUG|Pharmacological (MED)|"During the baseline assessment, the nurse care managers will determine current and past treatments for chronic lower back pain and establish whether or not patients have had an adequate trial (i.e., were analgesics sufficiently dosed). If not, the nurse care manager in conjunction with study doctors will recommend an adjustment of the patients' opioid or initiate treatment with a co-analgesic with appropriate dosing and scheduling.~The Patients in the MED arm will be asked to sign an opioid treatment agreement at enrollment."
223614831|NCT01236521|BEHAVIORAL|Behavioral treatment (CBT)|There will be 8 sessions of pain self-management and coping skills.
223614832|NCT05524779|DEVICE|BTL-785-7|Treatment with the BTL-785-7 applicator to the BTL-785F system.
223614833|NCT03890588|OTHER|CKD enhanced clinical decision support|The CKD-CDS intervention provides clinical recommendations at any primary care visit for patients with a deficit in any of 5 key elements of CKD care.
223614834|NCT05910216|OTHER|Dance & Music (Online)|This is a social telerehabilitation with dance and music. It will include artistic form, imageries using scenic arts, imageries using aspects of theater and storytelling, movement improvisation, choreography and sequence of movements, complex dance movements, fluidity of movement or connection between one movement and another, rhythmicity and/or movement built with music. It will include instructions for motor learning, music, and socialization
223614835|NCT05910216|OTHER|Multimodal Therapeutic Exercise & Music (Online)|This is a social telerehabilitation with multimodal therapeutic Exercise and Music. It is restricted to the execution of movements within series and standardized and fixed repetitions, with a background music. It will not include dance. It will include instructions for motor learning, music, and socialization.
223614836|NCT00893061|DRUG|anastrozole|Given orally
223614837|NCT00893061|DRUG|exemestane|Given orally
223614838|NCT00893061|DRUG|letrozole|Given orally
223614839|NCT00893061|DRUG|tamoxifen citrate|Given orally
223614840|NCT04648319|DRUG|BMS-936558|BMS-936558 followed by 30 grays of 3 to 5 fractions of high dose SBRT followed by monthly BMS-936558 until progression
223760205|NCT03228810|PROCEDURE|Tissue biopsy|Tissue biopsy of metastatic tissue if undergoing clinical care-directed biopsy
223760206|NCT03692546|DRUG|Liposomal bupivacaine (LB)|Addition of LB solution to soft tissue surgical field block to a standard interscalene block procedure
223760207|NCT03202004|DRUG|GSK2894512 1% cream|1 % (10 mg/g) GSK2894512 cream will be provided in tubes labeled in compliance with country requirements.
223509735|NCT05823454|DRUG|Different drug dosage|Choice of Anesthesia
223760208|NCT03202004|DRUG|Vehicle cream|Vehicle cream will be provided in tubes labeled in compliance with country requirements.
223760209|NCT00104533|DEVICE|Magnets|
223760210|NCT03857802|BEHAVIORAL|Sleep hygiene intervention|"An individual education will be carried out following a bidirectional feedback method. It is intended to develop skills to make conscious and autonomous decisions. The explanation will consist:~1. Information and reading with discussion of the educational sheet: The 9 tips for a healthy sleep will be read, point by point. The nurse will be open to discuss those that generate doubt.~2. Confrontation: even if the patient does not ask any questions about it, it will be necessary to ask if he has understood the advice.~3. Participated information: Questions will be asked to the patient such as: Did you already know any of these tips?.~A telephone call per month will be made as an educational reinforcement to the intervention."
223760211|NCT03734848|DRUG|Bilateral Ultrasound Guided Pectoralis Nerve Block.|Using a 20-gauge 5 cm needle. Injection bupivacaine 0.25% used as a local anesthetic. The block was performed in a supine position with the arm slightly abducted. The ultrasound probe was placed at the midclavicular level infero-laterally to locate the axillary artery and vein and then moved laterally toward the axilla until pectoralis major, pectoralis minor, and serratus anterior muscles were identified at the level of the fourth rib. The needle was inserted in-plane with respect to the ultrasound probe. A volume of 20 ml of local anesthetic solution was deposited in the fascial plane between pectoralis minor and serratus anterior muscle, followed by withdrawal of the needle to the fascial plane between the pectoralis major and pectoralis minor muscle, where a volume of 10 ml was deposited. The block was performed similarly on the opposite side. Care was taken not to cross the toxic dose of bupivacaine (3 mg/kg).
223760212|NCT03940365|DEVICE|Fetal Life tocometer device|The fetal life tocometer device is a uterine contraction monitor which is less expensive to manufacture than existing contraction monitor devices and which pairs with a smart device rather than a bulky output device.
223760213|NCT00049062|DRUG|anastrozole|
223760214|NCT00049062|DRUG|gefitinib|
223760215|NCT05580224|PROCEDURE|Radiofrequency ablation|Radiofrequency ablation is performed for peripherally located small hepatocellular carcinoma using combined energy delivery mode and triple cooled-wet electrodes. One of three electrodes is placed across the 4th or 5th portal vein branches near the target tumor which enables anatomical ablation of tumor.
223760216|NCT06099262|BEHAVIORAL|GenPMTO|GenPMTO is a parenting programme which involves trained practitioners using active teaching approaches (such as group problem-solving, role-play, and video modelling) to support caregivers in using positive parenting strategies at home. The programme is designed to improve parenting practices, as well as a range of outcomes for young people, including improving academic performance, reducing school exclusions, and reducing offending and criminal behaviour. The version of the programme investigated in this project is delivered to groups of parents.
223760217|NCT01166594|DRUG|Bevacizumab|Intrableb injection
223760218|NCT01166594|DRUG|Control|intrableb BSS injection
223614841|NCT05557344|DRUG|Acetaminophen IV|An IV infusion of 15mg/kg of acetaminophen (PrACETAMINOPHEN INJECTION, AVIR Pharma Inc.) (maximum single dose:1g) will be administered regularly every 6h as a 15-minute intravenous infusion. At the same time, an oral placebo with similar appearance as the corresponding acetaminophen oral solution will be administered.
223760219|NCT02157766|BEHAVIORAL|Intensive Meditation Practice|Long term meditators complete three days of of mindfulness or compassion/loving kindness meditation at T2 and T3 (one meditation type per visit).
223760220|NCT02157766|BEHAVIORAL|Mindfulness Based Stress Reduction|8 week class designed to enhance well-being through training in mindfulness.
223760221|NCT02157766|BEHAVIORAL|Health Enhancement Program|8 week class designed to enhance well-being through training in physical activity, functional movement, music therapy and nutrition.
223760222|NCT03373175|DEVICE|Basal record|Basal EMG record will be performed during 5 minutes. This record must be the same in both ventilators.
223760223|NCT03373175|DEVICE|PS 10 record|PS 10 EMG record record will be performed during 5 minutes. First with ventilator 1 and then with the other. The patient must be rest at least 5 minutes to recover basal record
223760224|NCT03373175|DEVICE|PS 15 record|PS 15 EMG record record will be performed during 5 minutes. First with ventilator 1 and then with the other. The patient must be rest at least 5 minutes to recover basal record
223760225|NCT03373175|DEVICE|PS 20 record|PS 20 EMG record record will be performed during 5 minutes. First with ventilator 1 and then with the other. The patient must be rest at least 5 minutes to recover basal record
223760226|NCT03246867|OTHER|Isolytic stretching group|In modified cross body position, isolytic stretching exercises will perform five times each for 15 seconds. After each stretching patient will rest for 5 seconds. When the patient contracts the agonist muscle group with 20% muscle force, the agonist muscle group is stretched at the same time for 2-4 seconds. Afterwards active-assistive stretching is done. Evaluations will be done before and just after stretching exercise.
223760227|NCT03246867|OTHER|Static stretching group|In modified cross body position, active-assistive static stretching exercises will be performed 5 times each for 15 seconds. This stretching exercise is performed 5 times with 5 seconds intervals. Evaluations will be done before and just after stretching exercise.
223760228|NCT03246867|OTHER|Control group|Control group will receive no stretching. They will be handed a brochure about the stretching techniques and its role in injury prevention. Control group will be evaluated for the first time and then will be passively waited until the duration of the stretching exercise program (approximately 4-5 min). Afterwards, second evaluation will be performed.
223614842|NCT05557344|DRUG|Acetaminophen|A liquid oral acetaminophen suspension will be administered regularly every 6h at a dose of 15mg/kg (maximum single dose: 1g). An IV infusion of NaCl 0.9% corresponding to the volume of IV acetaminophen will be administered as a 15-minute intravenous infusion at the same time as the oral dose. PrACETAMINOPHEN INJECTION ® is a clear and colorless liquid undistinguishable from NaCl 0.9%.
223760229|NCT00996762|DRUG|lapatinib|1250 mg or 1500 mg lapatinib commercial tablet
224201833|NCT01204606|PROCEDURE|Arthroscopic rotator cuff repair with intraoperative periarticular injection|"* Under general anesthesia, the patient was placed in the lazy lateral decubitus position on the operating table.~* The surgical area was prepared and draped with Betadine.~* Small stab incisions were made in the creation of 4 or 5 portals as needed.~* A scope was explored via the arthroscopic portal into the GH joint \& subacromial space.~* Repaired of rotator cuff tear was done with suture anchors.~* Mixed MMA drugs(ropivacaine 300mg;40ml, morphine 10mg;1ml, cefotetan 1g; dilution to ropivacaine, epinephrine 0.3mg;0.3ml, total volume:41.3ml) and sodium hyaluronate 20mg;2ml were injected divisionally periarticular area; intra-articular(sodium hyaluronate 20ml;2ml + 10.3ml); posterior joint capsule(10ml); subacromial space and around suprascapular nerve(11ml); anterior capsule(10ml).~* The skin was closed with Nylon or medical staples.~* Sterile dressing was applied on surgical wound.~* Peripheral intravenous PCA(Patient Controlled Analgesia) was connected."
224314306|NCT00089024|PROCEDURE|adjuvant therapy|"Patients who have undergone surgical resection, after post-operative recovery, will receive two additional cycles of gemcitabine/5-FU/leucovorin. Patients will then be followed at 3 month intervals with a history and physical exam, CT scan of the chest/abdomen/pelvis, and tumor markers.~If surgical resection is not possible, patients with stable or responsive disease will resume gemcitabine/5-FU/leucovorin and continue on it indefinitely until disease progression provided the patient tolerates it and wishes to remain on therapy."
224201834|NCT01204606|PROCEDURE|Arthroscopic rotator cuff repair with non-injection of MMA drugs|"* Under general anesthesia, the patient was placed in the lazy lateral decubitus position on the operating table.~* The surgical area was prepared and draped with Betadine.~* Small stab incisions were made in the creation of 4 or 5 portals as needed.~* A scope was explored via the arthroscopic portal into the GH joint \& subacromial space.~* Repaired of rotator cuff tear was done with suture anchors.~* 43.3ml of saline was injected divisionally periarticular area; intra-articular(12.3ml); posterior joint capsule(10ml); subacromial space and around suprascapular nerve(11ml); anterior capsule(10ml).~* The skin was closed with Nylon or medical staples.~* Sterile dressing was applied on surgical wound.~* Peripheral intravenous PCA(Patient Controlled Analgesia) was connected."
224201835|NCT00198588|DRUG|argatroban|beginning dose: 0.7microgram/kg/H
224201836|NCT03239340|DRUG|Osimertinib|Osimertinib is an oral, potent, selective, irreversible inhibitor of both EGFR-tyrosine kinase inhibitor sensitizing and resistance mutations in non-small cell lung cancer with a significant selectivity margin over wild type EGFR.
224201837|NCT06185764|DRUG|VX-670|Solution for intravenous administration.
224201838|NCT06185764|DRUG|Placebo|Solution for intravenous administration.
224201839|NCT06648603|BEHAVIORAL|Community-based larval source management|This project will foster active engagement with community stakeholders, including healthcare workers, community leaders, and other key informants, through participatory meetings aimed at co-creating and developing larval source reduction measures tailored to community's needs. This method emphasizes a participatory framework, ensuring that interventions are both community-informed and culturally relevant.
223509736|NCT02855983|PROCEDURE|Fat Grafting|Grafting of autologous fat tissue is a minimally invasive surgical technique that starts with the harvest of fat tissue from the abdomen or thighs using liposuction through incisions less than 2mm in length. The lipoaspirate is then processed to concentrate the adipose fraction and reinjected into the graft site. This surgical procedure involves the immediate transplantation of a patient's own tissue in a single operative procedure.
223614843|NCT04662008|BEHAVIORAL|Tele-coaching|This intervention arm will receive 4 one-to-one tele-coaching sessions facilitated by an advanced practice social worker. The sessions will take place over a 6-week period and will begin with a needs assessments to allow for tailoring of the intervention sessions. The sessions will include information and support in the areas of: general MS information, strategies for caring for a loved one with MS, MS and Covid (care strategies), caring for yourself, and planning for the future. The intervention will take place using Zoom videoconferencing technology or via telephone- per subject preference. In addition, all subjects will receive access to a study-specific website. The website will have links to publicly available information including general information about MS, online information, self-care, communication, caregiving, COVID-19, future planning.
223614844|NCT04662008|BEHAVIORAL|Website|This intervention arm will receive access to a study-specific website. The website will have links to publicly available information including: general information about MS, online information, self-care, communication, caregiving, COVID-19, future planning.
223614845|NCT05122728|OTHER|Post-Concussion Neuromuscular Function and Musculoskeletal Injury Risk Assessment|"Participants will complete a comprehensive biomechanical and neuromuscular assessments to elucidate the underlying neuromuscular control mechanisms that may contribute to increased MSKI risk following concussion. Participants will also complete a battery of self-report psychosocial measures.~Biomechanical Dynamic Movement Assessments:~* Jump-Landing~* Single Leg Hop~* Anticipated Cut~* Gait - Single Task~* Gait - Dual Task~Strength and Voluntary Muscle Activation Assessments:~* Interpolated Twitch Technique~* Muscular Ramp Contraction~Sensory assessments:~* Proprioception - Closed Chain~* Passive Joint Repositioning~* Light Touch Sensation~Patient Reported Outcomes:~* Self-Reported Musculoskeletal Injuries~* National Institutes of Health Patient-Reported Outcomes Measurement Information System (PROMIS) Physical Function~* PROMIS Pain Interference~* PROMIS Depression~* PROMIS Anxiety~* Brief Resilience Scale (BRS)~* Tampa Scale of Kinesiophobia (TSK-11)"
223614846|NCT06096636|OTHER|Study participants|Participants will complete study survey and dietary assessment.
223509737|NCT05132452|DIAGNOSTIC_TEST|The Test of Mastication and Swallowing Solids (TOMASS) and the Timed Water Swallow Test (TWST)|Participants swallowed one cracker for the TOMASS. They swallowed 150 mL of water for the TWST.
223509738|NCT05187637|DRUG|intravenous iron|One dose of intravenous iron carboxymaltose calculated according to ganzoni's formula. If after thirty days of the first dose, a second dose of 500mg will be administered if the patient continues to meet the inclusion criteria.
223614847|NCT05774938|PROCEDURE|Standard Endovascular aneurysm repair (sEVAR)|Standard EVAR treatment with Medtronic Endurant IIs (Medtronic, Inc. - Minneapolis, Minnesota), Gore Excluder AAA (W. L. Gore \& Associates, Inc. - Newark, Delaware), Gore Excluder Conformable AAA (W. L. Gore \& Associates, Inc. - Newark, Delaware), Cook Zenith Flex (Cook Medical, Inc. - Bloomington, Indiana).
223614848|NCT05774938|PROCEDURE|Complex Endovascular Aneurysm Repair (cEVAR)|Complex EVAR treatment with custom made devices (CMD's) from Cook Medical (Cook Medical, Inc. - Bloomington, Indiana) including fenestrated or branched devices or off-the-shelf T-branch device (Cook Medical, Inc. - Bloomington, Indiana).
223614849|NCT04502563|OTHER|Remote monitoring and predictive analytics|Subjects will undergo remote monitoring, remote monitoring data will be analyzed on a predictive platform, alerts indicating HF worsening shared with treating team, and algorithmic response to alerts implements.
223614850|NCT04502563|OTHER|Sham comparator|Subjects will wear a sensor, but data from the sensor will not generate alerts and will not be shared with the treating team.
223614851|NCT04699383|DRUG|Sodium Stibogluconate with allopurinol|Routine administration of SSG/allopurinol combination treatment, from 1-5 cycles
223614852|NCT06552650|BEHAVIORAL|Exercise|Four supervised exercise interventions after surgery: One exercise education session per week from postoperative day 5 through 1 month Subsequent home-based exercise: Home-based exercise recommendations from 1 month to 3 months post-surgery
223614853|NCT06552650|OTHER|Usual Care|The full spectrum of patient care practices in which clinicians have the opportunity (which is not necessarily seized) to individualize care
223614854|NCT03642509|DEVICE|Left atrial appendage occlusion|Interventional left atrial appendage occlusion with the Amulet or Watchman device
223614855|NCT03642509|DRUG|NOAC|Medical treatment arm. Patients will be treated with one of the available NOAC drugs; Apixaban, Dabigatran, Edoxaban or Rivaroxaban. The specific drug and dose is at the discretion of the treating physician.
223614856|NCT04991662|DRUG|metaraminol|Infusion of metaraminol adjusted according to body weight to obtain higher pH value of fetal umbilical artery blood.
223614857|NCT04991662|DRUG|Phenylephrine|Infusion of Phenylephrine adjusted according to body weight to obtain higher pH value of fetal umbilical artery blood.
223614858|NCT04991662|DRUG|Norepinephrine|Infusion of Norepinephrine adjusted according to body weight to obtain higher pH value of fetal umbilical artery blood.
223614859|NCT00214539|PROCEDURE|Bronchial Thermoplasty with the Alair System|Alair treatment plus standard-of-care therapy of high dose inhaled corticosteroids and long acting beta-agonists with or without oral corticosteroids at a dose of ≤ 30 mg/day.
223614860|NCT00214539|DRUG|Control|Standard-of-care therapy of high dose inhaled corticosteroids and long acting beta-agonists with or without oral corticosteroids at a dose of ≤30 mg/day.
223614861|NCT04494620|DIAGNOSTIC_TEST|Visual Inspection of Oral Cavity for Precancers and Cancer|Participants were invited for 3 rounds of oral cavity cancer screening, conducted 3-years apart. Screening was conducted by health workers trained to perform visual inspection of the oral mucosa and identify potential precancerous lesions or oral cancer. Lesions found were referred to a weekly clinic for further evaluation by dentists and oncologists with experience in the diagnosis of oral lesions. Oral precancerous lesions were surgically excised whenever possible and those with confirmed oral cancer were referred for appropriate treatment with surgery, radiotherapy, and/or chemotherapy.
223614862|NCT02033434|DRUG|Intranasal Ketamine|Atomized Intranasal Ketamine, 50mg
223614863|NCT06122506|PROCEDURE|Laparoscopic cerclage|Classic or robot-assisted laparoscopic cerclage in non-pregnant or early pregnant women.
223614864|NCT06122506|PROCEDURE|Vaginal cerclage|Transvaginal cerclage in pregnant women.
223614865|NCT05873608|OTHER|Educational video|Testing an educational video
223614866|NCT05873608|OTHER|Interview|Participate in interview
223614867|NCT05873608|OTHER|Observation|Undergo observation
223614868|NCT02306798|DRUG|TP05|One radio-labelled tablet given to subject after a high fat and a rich in calories breakfast
223614869|NCT06404138|OTHER|The Geriatric Activation Program (GAPP) Home version|"The rehabilitation at home intervention consists of three 45 minutes session per week (total of 18 sessions) with a different focus for each session. The therapy is goal-oriented and includes functional exercises in the home where possible (e.g. transfers such as getting out of bed, walking to the toilet etc.). There are three sessions per week: 1 for training strength, 1 for training balance and 1 for speed, coordination and endurance. Each session will start with gait rehabilitation as a warming-up.~For each session, a set of exercises with varying levels of difficulty is available. As rehabilitation needs are diverse, the therapist is expected to choose the most appropriate exercise and the difficulty level of the exercise for the individual older person. This also includes scaling the exercises to the individual progression of the older person."
223614870|NCT06404138|OTHER|Standard of care|Standard of care, without any restrictions.
223614871|NCT01826656|PROCEDURE|tooth extraction|Patients from both groups will follow the extraction of an hopeless tooth
223614872|NCT01826656|RADIATION|CBCT scan|A CBCT scan will be performed within 2 days from the tooth extraction at after 3 months (+/-2 days)
223614873|NCT01826656|RADIATION|DXA scan|DXA scan will be performed at the hip and lumbar spine in all self-reported non-osteoporotic subjects who hasn't done one within 1 year, to confirm their normal bone mineral density. Osteoporotic subjects already have a DXA scanner.
223614874|NCT01826656|RADIATION|Panoramic radiograph|As basic standard of care, a panoramic radiograph will be performed to both test and control subjects who haven't done one within the previous year, in order to give them a full-mouth dental diagnosis
223614875|NCT05171673|DRUG|Licart™ (diclofenac epolamine) topical system|The Licart™ (diclofenac epolamine) topical system was designed to deliver the nonsteroidal anti-inflammatory drug (NSAID) diclofenac to the site of a minor soft tissue injury through topical application. This investigational product (IP) is a 10 cm x 14 cm topical system comprised of an adhesive material containing 1.3% diclofenac epolamine that is bound to a non-woven polyester felt backing and covered with a polypropylene film release liner. The release liner is removed prior to topical application to the skin.
223614876|NCT05938894|OTHER|online games with various food images|Participant will play a series of online games with various food images.
223614877|NCT05938894|OTHER|online games with images of flowers and songbirds|Participant will play a series of online games with images of flowers and songbirds.
223614878|NCT05684276|DRUG|Carboplatin|"Structure: The cis-diamino (cyclobutane-1, 1 dicarboxylate) plating. Stability: 24 hours at ambient temperature in 5% glucose, sodium chloride and glucose 5% solution solution or physiologic saline. It is recommended not to dilute with chlorinated solutions for this could affect the carboplatin.~Route of administration: Intravenous infusion. Guidelines of Carboplatin administration: According to the standard of ech center."
223614879|NCT05684276|DRUG|Paclitaxel|"Structure: A diterpene whose composition is: 5b, 20-epoxy-1, 2a, 4,7b, 10b, 13a-hexa-hydroxy-11-en 9 one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)- N-benzoyl-3-phenylisoserine.~Stability: Concentrations of 0.3-1.2 mg/ml in 5% dextrose or normal saline have demonstrated chemical and physical stability for more that 27 hours at ambient temperature (25ºC approximately). The intact vial must be stored between 15º and 25ºC.~Guidelines on Paclitaxel administration: Paclitaxel must be administered by infusion over 3 hours in dextrose (D5W) or normal saline (NS). The concentration must not exceed 1.2 mg/ml."
223614880|NCT05684276|DRUG|Nivolumab|"Structure: Nivolumab is a soluble protein consisting of 4 polypeptide chains. Route of administration: Intravenous infusion. Product Description: Nivolumab (BMS-936558-01) Injection drug product is a sterile, non-pyrogenic, single-use, isotonic aqueous solution formulated in 10 mg/ml.~Storage Conditions: It must be stored at 2 to 8 degrees Cº and protected from light and freezing.~Guidelines: The administration of nivolumab infusion must be completed within 24 hours of preparation.The dose of Nivolumab for the adjuvant treatment is 360 mg administered as an intravenous infusion over 30 minutes every 3 weeks (+/-3 days) for 3 cycles.~For the maintenance adjuvant treatment the dose is nivolumab 480 mg Q4W (+/-3 days) over 30 minutes for 6 months (6 cycles).~Subjects should be carefully monitored during nivolumab administration to follow infusion reactions. Doses of nivolumab may be interrupted, delayed, or discontinued depending on how well the subject tolerates the treatment."
223614881|NCT06665828|DRUG|REGN9533|Administered per the protocol
223614882|NCT06665828|DRUG|Matching Placebo|Administered per the protocol.
223760230|NCT06366971|OTHER|The Patient Education|The patient education will be given through a brochure and the content of the education included an exercise training consisting of simple exercises for lumbar stabilization (supine bridge, cat-camel, and lumbar stretching) and the participants will be asked to perform these exercises in 3 sets of 10 repetitions 3 days a week for 6-weeks.
223760231|NCT06366971|OTHER|The Pelvic Proprioceptive Neuromuscular Facilitation Techniques Training|The content of the pelvic proprioceptive neuromuscular facilitation techniques training will include the application of the anterior depression pattern with the rhythmic initiation technique and the application of the posterior elevation pattern with the contract-relax stretch technique. All PNF techniques will be performed in 3 sets of 10 to 12 repetitions. The pelvic proprioceptive neuromuscular facilitation techniques training will be delivered face to face 3 days a week for 6 weeks by an experienced and trained physiotherapist.
223760232|NCT01993407|BEHAVIORAL|Task Switching Training|Participants will complete four, one-hour training sessions in which they will practice switching between tasks within an alternating runs task switching paradigm.
223760233|NCT01993407|BEHAVIORAL|Control Task|Participants will complete four, one-hour training sessions in which they will perform a single task each session
223760234|NCT01248026|OTHER|Buttermilk|"Consumption of the 2 experimental periods~1. buttermilk (45 g/d)~2. placebo (45 g/d,)"
223760235|NCT00004436|DRUG|leuprolide|
223760236|NCT00004436|DRUG|prednisone|
223760237|NCT01993108|DRUG|Methylphenidate|One dose 40mgs of methylphenidate one hour before fMRI scanning.
223760238|NCT01993108|DRUG|Naltrexone|One dose 40mgs of naltrexone one hour before fMRI scanning.
223760239|NCT01993108|DRUG|Placebo|One dose of placebo one hour before fMRI scanning.
223760240|NCT06218004|DRUG|Envafolimab combined with chemotherapy|envafolimab: 150 mg once every 1 week for 8 doses subcutaneously on day 1 Chemotherapy: nab-paclitaxel + cisplatin/carboplatin 3 cycles; Albumin paclitaxel 260 mg/m2, cisplatin 75 mg/m2 divided into 3 days, carboplatin AUC 5 applied on the first day.
223760241|NCT01697657|DRUG|insulin detemir|Subjects were dosed according to individual requirements. Injected subcutaneously (s.c. under the skin) twice daily in the morning and at bedtime for 10 weeks after an initial 6-week titration in treatment period 1 followed by 10 weeks after an initial 6-week titration in treatment period 2
223760242|NCT01697657|DRUG|insulin NPH|Subjects were dosed according to individual requirements. Injected subcutaneously (s.c. under the skin) twice daily in the morning and at bedtime for 10 weeks after an initial 6-week titration in treatment period 1 followed by 10 weeks after an initial 6-week titration in treatment period 2
224201840|NCT06648603|DEVICE|Enhanced Aedes adults trapping (BG-GAT)|Furthermore, the project intends to determine whether the addition of cost-effective, gravid female mosquito-targeting traps, specifically two Biogents Gravid Aedes Traps (BG-GAT) per household, can improve the overall success of these community-based intervention.
223509739|NCT04214236|DEVICE|ciNPT group|Closed-incision negative pressure therapy (ciNPT) will be applied for 7 day using continuous suction at 125 mmHg. To deliver ciNPT we will use a commercially available, FDA-approved device, used according to the manufacturer' indications (PREVENA™ Incision Management System (KCI, San Antonio, Texas, USA). After the first 7 post-operative days, subjects will discontinue the ciNPT and follow a standard wound care protocol.
223509740|NCT04214236|OTHER|Control group|Standard non-adherent surgical dressing (Vaseline petrolatum gauze) will be used for management of incisional wounds in the control group. Dressing changes will be performed per standard wound care protocol.
223760243|NCT01697657|DRUG|insulin aspart|Subjects were dosed according to individual requirements. Injected subcutaneously (s.c. under the skin) twice daily before meals for 10 weeks after an initial 6-week titration in treatment period 1 followed by 10 weeks after an initial 6-week titration in treatment period 2
223760244|NCT03995576|OTHER|thoracic sympathetic ganglion block|thoracic sympathetic ganglion block which needle reaches posterolateral vertebral body
223760245|NCT00628290|DRUG|Cannabidiol|Capsules, 3 times daily, 200 mg, 4 weeks
223760246|NCT00628290|DRUG|Amisulpride|Capsules, 3 times daily, 200 mg, 4 weeks
223760247|NCT04269967|OTHER|Receiving routine rehabilitation care via tele-rehabilitation system|Drain care education, self-massage techniques and exercise (PT and OT)
223760248|NCT03019276|DRUG|TQ-B3101|Escalating doses of TQ-B3101 will be administered orally on a continuous dosing schedule. Doses to be evaluated will range from 100 mg to 500 mg/day administered either once or twice a day. A treatment cycle is considered to be 28 days .
223760249|NCT06189456|DEVICE|BLUgel A|BLUgel A: Hyaluronic Acid Eye Drops 0.30%
223760250|NCT06189456|DEVICE|BLUyal A|BLUyal A:Hyaluronic Acid Eye Drops 0.15%
223760251|NCT01285206|DEVICE|Carbon polymer warming blanket|Routine practice ( + no carbon polymer blanket) versus use of HotDog carbon polymer warming blanket throughout day surgery procedure
224201841|NCT06648603|COMBINATION_PRODUCT|Community-based larval source management with Enhanced Aedes adults trapping (BG-GAT)|The community-based interventions and the BG-GAT deployment will be evaluated in combination to assess their individual and synergistic effects on vector control. This dual strategy combines local participation and practical, evidence-based solutions to address mosquito-borne illness transmission.
224201842|NCT06647940|DRUG|Orelabrutinib Oral Tablet|Orelabrutinib (150 mg po D1-D21) is added from the second cycle of R-CHOP regimen
223509741|NCT05177263|OTHER|Placebo|Sterile Water
223509742|NCT05177263|DRUG|10% Oral Dextrose Solution|10% Oral Dextrose Solution
223509743|NCT05177263|DRUG|20% Oral Dextrose Solution|20% Oral Dextrose Solution
223509744|NCT05177263|DRUG|30% Oral Dextrose Solution|30% Oral Dextrose Solution
223509745|NCT03460964|DEVICE|Adhesive glucose sensor|"Will assess sensor's performance by comparing readings from an adhesive glucose sensor with those from a glucometer.~pilocarpine 0.1 mL gel, applied to the skin via the glucose sensor to induce sweat"
223509746|NCT03460964|DRUG|Pilocarpine|Pilocarpine 0.1 mL gel, applied to the skin via the glucose sensor to induce sweat; will apply a minimum of 2 doses to each participant.
223509747|NCT04002557|OTHER|Interview-Questionnaire|Questionnaire
223509748|NCT04007874|DRUG|Ethinylestradiol/levonorgestrel|Ethinylestradiol/levonorgestrel 30/150 µg oral tablets once daily without a stopweek for 3 months
223509749|NCT04007874|DRUG|Vitamin E|Vitamin E 400 IU oral capsules once daily for 3 months
223509750|NCT01300065|DEVICE|Experimental- Soflens|A new pair of lenses will be worn each day while the subject is in the study
223614883|NCT00748345|DRUG|Caspofungin (drug)|pharmacokinetics of caspofungin in burn patients after a single usual dose (70 mg i.v.), in order to determine the optimal dose in this population
223614884|NCT06805331|BEHAVIORAL|Intervention group(Pelvic Floor Muscle Exercise Training)|The intervention will involve educating participants on pelvic floor muscle exercises, using the health belief model. The goal is to evaluate improvements in incontinence severity, quality of life, and pelvic floor muscle exercise self-efficacy
223614885|NCT06805331|OTHER|control group|Participants in the control group will continue to receive their current standard of care and will not receive any additional interventions.
223614886|NCT05698277|DIAGNOSTIC_TEST|Automated fetal cardiac function evaluation|"Evaluation of ultrasound parameters by automated algorithms.~Ultrasound assessed parameters are:~1. Pulsed wave Doppler Modified Left and Right Myocardial performance indices~2. Spatio-temporal image correlation Tricuspid, Mitral and Septal Annular Plane Systolic Excursion"
223614887|NCT00466531|BIOLOGICAL|therapeutic autologous lymphocytes|
223614888|NCT00466531|DRUG|cyclophosphamide|
223614889|NCT06027008|DEVICE|Mechanical Insufflation-Exsufflation|"MI-E will be applied twice a day in invasively ventilated patients. Since the severity of illness can change in the ICU, each day the attending nurse will check for clinical reasons to not apply MI-E with regard to safety. The following clinical criteria are predefined as a reason to refrain from MI-E at that day:~* severe ventilator instability (requiring \> 12 cm H2O PEEP and dependency of \> 60% FiO2);~* severe hemodynamic instability (a need for large and sustained increase in continuous administration of intravenous vasopressive medication that are adjusted on a frequent basis in each nursing shift);~* extra corporal membrane oxygenation (ECMO); and~* deeply sedated patient (RASS score ≤ -4)."
223614890|NCT04659317|DRUG|Oxycodone 5 mg Oral Tablet|Encapsulated Oxycodone 5 mg tablets x24, to take po q6 hours as needed
223614891|NCT04659317|DRUG|Placebo oral tablet|Encapsulated placebo tablets x24, to take po q6 hours as need for pain
223614892|NCT04674722|DRUG|Injection of 99mTc-NM-02|A Patient will be injected with microdose (\<100ug) of 99mTc-NM-02 radiotracer
223614893|NCT04674722|DRUG|Injection of 188Re-NM-02|A Patient will be injected with microdose (\<100ug) of 188Re-NM-02 radionuclide therapy
223509751|NCT01300065|DEVICE|Marketed - Soflens|A new pair of lenses will be worn each day while the subject is in the study.
223509752|NCT00307255|DRUG|gemcitabine hydrochloride|1000 mg/m2 on days 1 and 8 of each 21 day cycle
223509753|NCT00307255|DRUG|paclitaxel albumin-stabilized nanoparticle formulation|260 mg/m2 to 340 mg/m2 (dose will depend on when subject enters the study). Paclitaxel will be given on day 1 of each 21 day cycle (every 3 weeks)
223509754|NCT03853200|DRUG|QMix Root Canal Irrigant|Endodontic irrigant recommended for final irrigation
223509755|NCT03853200|DRUG|17%EDTA+2%Chlorhexidine|two endodontic irrigants will be used in this group in a sequential manner
223509756|NCT03853200|OTHER|EDTA|17% EDTA irrigation solution
223509757|NCT01117350|DRUG|Insulin glargine|100 Units/mL solution for injection in a pre-filled SoloStar pen
223509758|NCT01117350|DRUG|Liraglutide|6 mg/mL solution for injection in a 3-mL pre-filled pen (18mg)
223509759|NCT01117350|DRUG|Metformin|Metformin was a background treatment, mandatory for each patient randomized in the study (at the minimum dose of 1g/day). It was not supplied by the sponsor.
223509760|NCT06541028|BEHAVIORAL|Rapid-Start ART (RS-ART)|ART initiation within 7 days of HIV diagnosis. (RS-ART intervention to be informed and developed in Aims 1 and 2.) RS-ART is a strategy that focuses on clinical decision-making generally based solely on clinical criteria, and later organizing support for mental health, adherence, and management of comorbid conditions only after the patient has initiated ART.
223509761|NCT04902144|OTHER|Electronic Health Record Review|Medical data collected
223509762|NCT04902144|OTHER|Questionnaire Administration|Complete questionnaires
223509763|NCT04902144|BEHAVIORAL|Behavioral Intervention|Receive coaching
223509764|NCT03106805|PROCEDURE|early insertion|insertion at 4th postpartum week
223509765|NCT03106805|PROCEDURE|late insertion|insertion at 6th postpartum week
223509766|NCT02129556|DRUG|MK-3475|The phase Ib trial will determine the recommended dose from three MK-3475 dose levels: 1mg/kg, 2 mg/kg or 10 mg/kg.
223509767|NCT04102982|DRUG|Camrelizumab|Patients will be treated with camrelizumab alone.
223509768|NCT04102982|OTHER|Camrelizumab plus microwave ablation|In the group, microwave ablation will be administrated to the primary tumors, followed by camrelizumab.
223509769|NCT05558670|OTHER|PET-fMRI-EEG|Participants perform PET, fMRI, and EEG simultaneously using a MRI compatible EEG cap
223509770|NCT00574353|RADIATION|Fluorine-18-Labeled Fluoro-Misonidazole Positron Emission|You will be scanned 2 to 3 times on the same day, but you will only be administered one dose of the FMISO tracer. The first scan will last about 30 minutes. Then you will have 1 to 3 hours to wait before you are scanned again. Some patients will undergo a second scan approximately one-and-a-half hours after the start of the first scan. This scan will last about 10 minutes. The final scan will occur between 2-4 hours after the start of the first scan. This final scan will also last about 10 minutes. During the PET scan, you may have a separate i.v. line put into your other arm so that we can take 2 to 3 blood samples. These samples will be less than half a teaspoon each. We are taking these blood samples to see how quickly FMISO leaves your blood stream. The first sample will be taken between 2 and 40 minutes after the FMISO is injected. The other two blood samples will be taken with each subsequent scan.
223509771|NCT05587751|DIAGNOSTIC_TEST|Spirometry|Pulmonary function test to measure lung function
223509772|NCT05587751|DIAGNOSTIC_TEST|Plethysmography|Pulmonary function test to measure lung volume
223509773|NCT06181851|OTHER|Analysis of microbiome and metabolomics|Analysis of microbiome and metabolomics through the assessment of blood and semen parameters
223509774|NCT02898506|DRUG|Victoza®|Daily subcutaneous injections with increasing doses up to 1.8 mg per day. Duration of treatment 6 months and thereafter follow-up of 6 months.
223509775|NCT02898506|DRUG|Placebo|Daily subcutaneous injections with increasing doses up to 1.8 mg per day. Duration of treatment 6 months and thereafter follow-up of 6 months.
223509776|NCT07000513|BEHAVIORAL|ITEST-LAI|The ITEST-LAI intervention includes male peer-led HIVST distribution and promotion, linkage to male-friendly clinics for confirmatory testing and follow-up care, peer support and technical assistance to address implementation challenges, and continuous monitoring and feedback for male peer educators and research facilitators (MPERFs).
223614894|NCT05769023|BEHAVIORAL|Intervention test|behavioral sessions to promote vaccines
223614895|NCT05846815|DEVICE|ARVO 2.0 WEB|"Medical device software where the subject navigates in a virtual apartment, with the goal of performing the tasks given by a cartoon dragon character. The child is asked to perform the subtasks in the given order, except for the subtasks to be completed at a certain time or after a certain sound cue, but the completion order does not influence the scoring. One task scenario lasts until all subtasks are correctly performed or until the time limit of 60 s is reached.~The classification whether the subject belong to typically developed population is based on quantitative neurological performance indicators produced during the game. However, even if the activity performed is differential diagnostics, ARVO does not create any medical diagnosis. It shall be also noted that in the present clinical investigation, the interpretation of the results regarding child's ADHD susceptibility is not performed."
223614896|NCT05846815|OTHER|Conners Continuous Performance Test 3rd Edition™ (CPT 3)|"Subjects are required to respond by pressing the spacebar or the appropriate key on the mouse when any letter other than the letter X appears on the monitor. The Conners CPT 3 presents 14-minute, 360 scored stimuli trials (i.e., individual letters) on the screen, with 1, 2, or 4 sec. between the presentation of letters (i.e., the interstimulus interval; ISI). The 360 trials are divided into 6 blocks, with 3 sub-blocks each consisting of 20 trials. Each block lasts approximately 2 min and 20 sec. Scores and Score Dimensions of Attention Measured: Inattentiveness, Impulsivity, Sustained Attention and Vigilance. The Conners CPT 3 produces computer-generated reports that describe the respondent's performance.~It shall be also noted that in the present clinical investigation, the interpretation of the results regarding child's ADHD susceptibility is not performed"
223614897|NCT06420323|DEVICE|Treatment with NovoX® Cup|NovoX® Cup treatment
223614898|NCT06420323|DEVICE|Treatment with Omnistrip®|Omnistrip® treatment
223614899|NCT06009094|DRUG|VC005|VC005 group with Local topical application
223614900|NCT06009094|DRUG|VC005 Placebo|VC005 Placebo group with Local topical application
223614901|NCT03116685|BIOLOGICAL|Oxabact OC5 - Oxalobacter formigenes HC-1|Active study drug
223614902|NCT03116685|OTHER|Placebo|Placebo
223614903|NCT01200303|PROCEDURE|non-cathartic CTC|non-cathartic, CAD-assisted CT Colonography
223614904|NCT02173106|DRUG|steroid & Cyclosporin|oral methylprednisolone 0.4mg/kg/d and Cyclosporin for 6 months
223614905|NCT04466852|OTHER|telemedicine-guided consultation|Educational material is provided as short audiovisual films for understanding heart failure condition and management, how medicines work and their side effects, general advise on diets, exercise and importance of refraining from toxic exposure (smoke, alcohol, narcotics and damaging illegal medicines). Additionally, the patient (eventually assisted by their relatives and caregivers) can use this platform for learning basic important warning signs or cardiac decompensation based on feedback on recording regular measurements (weight, blood pressure and pulse and blood tests when needed) and symptoms. The cardiologist guides the patient and their Family/Basic doctors on the need for follow-up based on the parameters recorded. Videoconsultations with participation of the cardiologist, the Family/Basic doctor and the patient and relatives are used on demand.
223614906|NCT06654440|DRUG|SHR-A2102 for injection|SHR-A2102 for injection
223614907|NCT06603558|DRUG|Atogepant|Oral Tablet
223614912|NCT04232241|DRUG|Allogeneic Stem Cell Transplantation|Allogeneic Stem Cell Transplantation
223614913|NCT06662058|PROCEDURE|Audiometric Test|Undergo audiometry
223614914|NCT06662058|PROCEDURE|Audiometric Test|Undergo close to home audiometry
223614915|NCT06662058|PROCEDURE|Audiometric Test|Undergo self-administered remote audiometry
223614916|NCT06662058|OTHER|Interview|Ancillary studies
223614917|NCT06824051|DRUG|Orforglipron|Administered orally
223614918|NCT06824051|DRUG|Placebo|Administered orally
223614919|NCT02472717|DRUG|liraglutide|Liraglutide 0.6mg sc daily for 1 week, 1.2mg sc daily for 11 weeks
223614920|NCT02472717|OTHER|Placebo|Placebo sc daily for 12 weeks, volume titration at week 2 to mirror liraglutide arm
223614921|NCT06991010|DEVICE|Suction-Activated Patent Hemostasis (SAPH) Device|A compression device intended to achieve patient hemostasis of the radial artery
223614922|NCT06538662|DRUG|FID 123320 Ophthalmic Solution|Investigational sterile aqueous solution
223614923|NCT06538662|DRUG|Vehicle|FID 123320 Ophthalmic Solution inactive ingredients
223760252|NCT03025724|DRUG|Levulan Kerastick|Intervention group subjects will undergo a surgical excision of the tumor. Then a clear transparency film will be used to trace the clinical margins of the lesion, as well as any other distinctive skin markings such as nevi or birthmarks. Subjects will then undergo the study procedure where the area to be treated will be swabbed with an alcohol wipe and allowed to dry. Next, the investigator will apply topical 20% 5-ALA (Levulan Kerastick; DUSA Pharmaceuticals) to the SCCis. Then, the area will be occluded with Tegaderm film for 3 hours.
223760253|NCT03025724|DEVICE|blue light source|At the end of the incubation period, the Tegaderm will be removed and the patient will be exposed to a blue light source (BLU-U; DUSA Pharmaceuticals).
223760254|NCT03025724|OTHER|participant satisfaction survey|Participants will be asked to fill out a satisfaction survey.
223760255|NCT03604055|PROCEDURE|Endobronchial hamartomas treatment|General anesthesia was administered by an intravenous anesthesia technique. Patients were intubated with a rigid bronchoscope. Debulking procedures were performed by mechanical tumor resection (MTR) using the tip of the rigid bronchoscope, rigid pliers or argon plasma coagulation assisted MTR or cryorecanalization or electrocautery - snare probe. An innovation of our study was that cryotherapy was performed in the regions where the lesions originated after debulking
223760256|NCT00002275|DRUG|Fat Emulsion 2%|
223760257|NCT00002275|DRUG|Fat Emulsion 20%|
223614926|NCT06304207|COMBINATION_PRODUCT|Onsite Maintenance Exercise Training|Participants will receive a 60-minute supervised weekly exercise intervention for 8-weeks.Each 60-minute session will be broken down into a brief 5-minute training on inspiratory muscle training using a Threshold Inspiratory Muscle Trainer (IMT), 5-minute education on self-management of airway clearance and importance of maintaining regular physical activity; a 5-minute warm-up, and 25 minutes of aerobic training. The training intensity will be derived from the distance covered on the six-minute walk test administered at baseline. Training will be performed at 60-85% of VO2 reserve and converted to walking distance and speed using American College of Sports Medicine walking equations for treadmill and overground walking activities or a corresponding rating of perceived exertion (RPE) of 13-16 for non-walking activities. This will be followed by 15-minutes of functional strength training focusing on the lower extremity muscles, and 5 minutes of cool down with stretching exercises.
223760258|NCT03357484|PROCEDURE|Leukocyte- and platelet rich fibrin|Prior to surgery, two 9 ml glass-coated tubes (Intra-Spin, Intra-Lock International, Boca Raton, USA) of patient venous blood were collected. Tubes were transferred to a centrifuge (Andreas Hettich GmbH \& Co.KG, Tuttlingen, Germany) and processed for 12 minutes at 2800 rpm to prepare L-PRF.
223614927|NCT06304207|COMBINATION_PRODUCT|Telehealth Maintenance Exercise|Participants in the tele-rehab group will also receive the same intervention as outlined for the onsite group. The mode of aerobic exercise will vary based on availability of equipment in patient homes. The intervention will be delivered remotely via previously researched models using a tablet computer. I-pads will be provided to the participants on a need basis to take home for the duration of the study. Videoconferencing will be via Partners log in enabled Zoom videoconferencing software (San Jose, California, USA) that allows all participants to see and speak to each other. To ensure safety and understanding of equipment operation and the exercise program, the initial training session and establishment of the home exercise program will occur during the initial onsite visit in the clinic at MGH Institute of Health Professions.
223760259|NCT03357484|PROCEDURE|Blood clot|Natural blood clot formed within extraction socket
223760260|NCT04541017|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223760261|NCT04541017|PROCEDURE|Computed Tomography|Undergo PET/CT or diagnostic CT
223760262|NCT04541017|BIOLOGICAL|Magrolimab|Given IV
223760263|NCT04541017|BIOLOGICAL|Mogamulizumab|Given IV
223760264|NCT04541017|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
223760265|NCT04541017|PROCEDURE|Punch Biopsy|Undergo skin punch biopsy
223760266|NCT03140202|DEVICE|CPRmeter (feedback device) with feedback|Participants have a real time feedback and record.
223760267|NCT03140202|DEVICE|CPRmeter (feedback device) without feedback|Participants have a real time record without feedback.
223760268|NCT05418725|DEVICE|PVI and Linear lesion using PEF|PVI and Linear lesion using PEF
224201843|NCT06647940|DRUG|R-CHOP Protocol|Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone
224201844|NCT06309199|DIETARY_SUPPLEMENT|Biogaia|Biogaia is a probiotics product that contain Limosilactobacillus reuteri DSM 17938, sunflower oil and MCT oil
224201845|NCT06309199|OTHER|Placebo|Limosilactobacillus reuteri DSM 17938, sunflower oil and MCT oil
224201846|NCT02127788|DRUG|Micafungin|intravenous
223760269|NCT05418725|DEVICE|PVI and Linear lesion using CFRF|PVI and Linear lesion using CFRF
223760270|NCT04126785|OTHER|High Intensity Interval Exercise in Heated Water-Based|High intensity interval exercise will perform at controlled heated water-base (30 e 32 ºC). Subject will be submerged at the xiphoid process level. The session will consist in 4 min walking (warm-up) at 9 level of rate perceived exertion (RPE) scale, followed by 21 min of HIIE, alternating 1 min of jogging/running at 15-17 (hard-very hard) level with 2 min of walking at 9-11 (very light-fairly light) level of RPE.
224201847|NCT06650826|DIAGNOSTIC_TEST|Determination of anti-platelet factor 4 antibodies in the blood|"The anti-platelet factor 4 antibodies in the blood are determined using latex agglutination and the chemiluminescence method in the coagulation laboratory of the CCB MVZ laboratory. In addition, the platelet factor 4-induced platelet activation test (PIPA test) and the heparin-induced platelet activation test (HIPA test) as well as an ELISA-based platelet factor 4 IgG antibody test (Prof. Greinacher, Greifswald University Hospital) will be performed as part of the routine work up.~In addition a new assay for heparin-independent anti-PF4 antibody detection provided by the company Werfen using chemiluminescence will be performed."
224201848|NCT06650371|DRUG|Fentanyl infusion|opioid based anesthesia analgesia will be offered by fentanyl in induction and maintenance according to Ideal Body Weight (IBW).
224201849|NCT06650371|DRUG|Dexamedomedine and ketamine infusion|Analgesia will be offered by syringe containing ketamine and Dexmedetomidine in induction and maintenance according to IBW.
224201850|NCT01526707|DRUG|inhaled steroid|inhaled budesonide for 7 days
224201851|NCT01497860|DRUG|Vinorelbine|IV Vinorelbine (6mg/m2) provided once a week for 6 weeks followed by a 2 week rest (6 of every 8 weeks) for one year. Progression free survival will be monitored for 60 months.
224201852|NCT01860690|DRUG|Methotrexate|50 mg / meter squer Intramuscular (IM) MTX.
224201853|NCT03952962|DEVICE|Abbott Laboratories Infinity™ implantable deep brain stimulation system|Deep brain stimulation (DBS) refers to the process of delivering an electrical current to a precise location in the brain.
224201854|NCT05310578|PROCEDURE|Posterior cervical foraminotomy (with our without laminectomy)|The aim of surgery is to decrease the compression of the affected nerve. In posterior cervical foraminotomy, the foramina is expanded to create more space and with posterior cervical laminectomy the lamina is removed to create space mainly for the spinal cord.
224201855|NCT05309993|DEVICE|PTNS|See arm description
224201856|NCT05309993|DEVICE|TENS|See arm description
224201857|NCT06281184|DRUG|Methotrexate|Methotrexate 5-25 mg x 1 per week, combined with folic acid 1mg daily.
224201858|NCT06281184|OTHER|Treatment as usual|No specific treatment after MERINO-trial
224201859|NCT05968300|BEHAVIORAL|INFORMED-Living Well|1\) LHW outreach support providing responsive education and support; and 2) a 6-week automated SMS text messaging
224201860|NCT05968300|BEHAVIORAL|Text Messaging Only|A 6-week automated SMS text messaging
224312199|NCT06983002|BEHAVIORAL|Experimental group: AC-group therapy intervention.|"The aim is to increase Affect consciousness and Affect integration with 15 two hour group session interventions. Interview for 4 central affect categories to become familiar with the questions/techniques is used pre and post group. Group meeting 1 presents the AC affect theory, 13 affect categories and the group program related to each individual group meeting. Group meetings 2-14 lectures on the current affect category, bodily attentional signals and inner mood/mental content, exploration of impact, handling and the signal function of emotions and non-verbal body language and verbal descriptions related to the desire and ability to express oneself. Group meeting 15 is evaluation, clarification, repetition and closure of the group. On arrival focus on disturbances (internal and external) for each participant and performance of four body awareness exercises is used. Therapeutic writings and listening to a piece of music shared by the participants in rotation are methods i"
223614928|NCT07009015|OTHER|The oral health education intervention program|The intervention program will be designed to improve oral health knowledge, attitudes, and behaviors among students over a one-month school term, carefully scheduled to avoid disrupting regular academic activities. The program consists of initial sessions focused on building students' understanding and appreciation of oral health and healthy eating habits, followed by sessions aimed at developing practical behavioral skills. The effectiveness of the program will be evaluated at three points-before the intervention, two months after, and four months post-intervention-using a closed-ended questionnaire to assess changes in knowledge, attitudes, and practices.
223614929|NCT05404048|OTHER|89Zr-atezolizumab PET-imaging|89Zr-atezolizumab tracer injection + PET/CT-scan
223614930|NCT06870422|DRUG|Esflurbiprofen Topical System|TK-254RX will be applied for one day
223614931|NCT03066063|DEVICE|iCare|The iCare product is an action video game designed to provide home-based vision therapy for non-strabismic amblyopia and convergence insufficiency in children as young as 4 years old. Participants assigned to an iCare group will play iCare vision therapy games for approximately 20 minutes per day, five days per week.
223614932|NCT03066063|BEHAVIORAL|Amblyopia standard of Care|The amblyopia standard of care group will be prescribed patching for two or six hours per day, seven days per week. Standard of care group participants with best-corrected vision worse than 20/200 in their amblyopic eye will be prescribed six hours of patching daily
223614933|NCT03066063|BEHAVIORAL|CI standard of Care|A dosage-matched CI standard of Care group will be prescribed pencil pushups for 20 minutes per day, five days per week.
223614934|NCT06628219|DEVICE|Symani Surgical System|The Symani Surgical System (Symani) is designed for open microsurgery procedures, featuring articulated and interchangeable instruments.
223614935|NCT06631183|BEHAVIORAL|Self-help information based on principles of behavioral activation|Participants will engage with the self-help tool e-couch (https://ecouch.com.au). In the first week, they will complete the depression information submodule from the depression program. Over the following four weeks, they will complete submodules on behavioral activation and physical activity.
223614936|NCT06631183|BEHAVIORAL|Self-help information based on principles of cognitive restructuring|Participants will engage with the self-help tool e-couch (https://ecouch.com.au). In the first week, they will complete the depression information submodule from the depression program. Over the following four weeks, they will complete submodules on cognitive restructuring.
223614937|NCT06725498|DRUG|Tislelizumab-jsgr|200mg, Q3W
223614938|NCT06725498|DRUG|Cisplatin|60-75 mg/㎡, Q3W
223614939|NCT06725498|DRUG|Albumin-Bound Paclitaxel|260 mg/㎡, Q3W
223614940|NCT06725498|RADIATION|Radiotherapy|Radical Radiotherapy or adjuvant Radiotherapy per guidelines.
223614941|NCT06921109|BEHAVIORAL|Experimental: Relaxation training with VR|This group will benefit from 8 psychoeducation sessions delivered through video modules viewed alongside the psychologist. In addition, an intervention will be implemented to train the children in abdominal breathing and muscle relaxation. This training will be conducted using biofeedback equipment integrated into various virtual environments. Homework exercises will be assigned to them after each session.
223614942|NCT06921109|BEHAVIORAL|Experimental: Relaxation training without VR|This group will benefit from 8 psychoeducation sessions delivered through video modules viewed alongside the psychologist. In addition, an intervention will be implemented to train the children in abdominal breathing and muscle relaxation. This training will be conducted using biofeedback equipment displayed on a computer screen. Homework exercises will be assigned to them after each session.
223614943|NCT06921109|BEHAVIORAL|No Intervention: Control group|This group will benefit from 8 psychoeducation sessions delivered through video modules sent to their homes.
223614944|NCT02466932|DEVICE|Galilei Dual-Scheimpflug Analyzer|Measuring of Anterior Segment by Galilei Dual-Scheimpflug Analyzer
223614945|NCT06725550|DEVICE|needling acupuncture|"Acupuncture treatment will both main and supplementary acupoints. Main points include GB30; ST36; LI11- LI4, GB34-SP6; LR3, SP10, DU24, DU20, Yin Tang, Ear Shen Men which are chosen based on the unique clinical features of sickle pain. The remaining individualized acupoints will be selected and manipulated with manual acupuncture with appropriate needling techniques based on the individual Syndrome (reinforce or reduce or Non reinforce or reduce) that is determined by TCM diagnosis."
223614946|NCT06725550|DEVICE|laser acupuncture|Laser acupuncture device VitaLaser 650 (Lhasa OMS, Weymouth, MA or similar) will be positioned 1-2cm over all of the same acupoints used in verum acupuncture treatment above. No palpation is administered prior to positioning the device and there is no physical contact between device and skin.
223614947|NCT06897202|DRUG|MET097 Injection|MET097 is an ultra-long-acting, fully-biased analog of human GLP-1.
223614948|NCT06897202|DRUG|Placebo|Sterile 0.9% (w/v) saline will be used as placebo treatment during the study.
223614949|NCT07066969|GENETIC|Sophia DDM|Germline panel for patients with tumoral BRCA alteration in EC
223614950|NCT06922422|BEHAVIORAL|Sensory-Motor Integration Exercises|A structured sensory-motor integration program based on sensory play activities designed to enhance sensory processing and balance. Each session lasted 45 minutes, conducted four times per week, for a total of 64 sessions over 16 weeks. Activities targeted multiple sensory modalities, including tactile, proprioceptive, and vestibular inputs.
223614951|NCT06922422|BEHAVIORAL|Conventional therapy group|Conventional therapy sessions consisting of Applied Behavior Analysis (ABA) and massage therapy without specific sensory-motor integration activities. Each session lasted 45 minutes, conducted four times weekly, for a total of 64 sessions over 16 weeks.
223614952|NCT06921044|DRUG|R-miniMCOP:Rituximab / Mitoxantrone Liposome / Cyclophosphamide / Vincristine / Prednisone|Rituximab ：375 mg/m2，ivgtt，d0； Mitoxantrone Liposome ： The first dose level: 6mg/m2, ivgtt, d1; The second dose level: 8mg/m2, ivgtt, d1; The third dose level: 10mg/m2, ivgtt, d1; Cyclophosphamide :400 mg/m2，ivgtt，d1； Vincristine :1mg（，ivgtt，d1； Prednisone:40 mg/m2，po.，d1-5； Q3W
223614953|NCT06921096|OTHER|Tai Chi|The Tai chi group practiced 24-form simplified Tai Chi for 12 weeks, 3 times/week, 60 minutes/session (including 5-minute warm-up and 5-minute cool-down) at our university's track, under professional coaching, from 8:00-9:10 AM. The first 4 weeks were for learning, and the next 8 for consolidation.
223614954|NCT06920979|OTHER|(semi)continue monitoring of patients at risk for sepsis at home|(semi)continue monitoring of patients at risk for sepsis at home
223614955|NCT06920862|BEHAVIORAL|Multi-Modal Digital Intervention|"Participants in this group will receive a multi-modal digital intervention designed to enhance healthy weight control behaviors among overweight and obese adolescents.~1. The intervention integrates AI-driven coaching, interactive platforms, gamified applications, and real-time feedback mechanisms.~2. Participants will complete biweekly intervention sessions (2 hours each) over a 3-month period.~3. The intervention is grounded in the Theory of Planned Behavior (TPB) to target attitudes, subjective norms, and perceived behavioral control regarding weight control behaviors.~4. Participants will have access to the Virti platform, where they will receive personalized guidance and feedback."
223614956|NCT03929107|BIOLOGICAL|Interleukin-7 and Chemokine (C-C Motif) Ligand 19-expressing CD19-CAR-T cells|patient's T cells were seperated and engineered into Interleukin-7 and Chemokine (C-C Motif) Ligand 19-expressing CD19-CAR-T cells, and retransfused into the patient for treatment of their B cell lymphoma.
223614957|NCT04346992|OTHER|no intervention|no intervention
223614958|NCT02756572|DRUG|Cladribine|Given IV
223614959|NCT02756572|DRUG|Cyclosporine|Given PO
223614960|NCT02756572|DRUG|Cytarabine|Given IV
223614961|NCT02756572|BIOLOGICAL|Filgrastim|Given SC
223614962|NCT02756572|DRUG|Fludarabine Phosphate|
223614963|NCT02756572|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic hematopoietic stem cell transplantation
223614964|NCT02756572|OTHER|Laboratory Biomarker Analysis|Correlative studies
223614965|NCT02756572|DRUG|Melphalan|Given IV
223614966|NCT02756572|DRUG|Mitoxantrone Hydrochloride|Given IV
223614967|NCT02756572|DRUG|Mycophenolate Mofetil|Given PO
223614968|NCT02756572|OTHER|Questionnaire Administration|Ancillary studies
223614969|NCT02756572|DRUG|Sirolimus|Given PO
223614970|NCT02756572|RADIATION|Total-Body Irradiation|Undergo TBI
223614971|NCT02756572|DRUG|Melphalan Hydrochloride|Given IV
223614972|NCT00079573|BEHAVIORAL|Atkins diet (extremely low carbohydrate)|
223614973|NCT00079573|BEHAVIORAL|Zone diet (low carbohydrate, high protein)|
224201861|NCT05390853|PROCEDURE|Active tDCS|"tDCS application is anodic, in the M1 area (Primary Motor Cortex) right or left, contralateral to the pre-defined target limb. The cathode is positioned in the supraorbital area, contralateral to the anode.~Active stimulation is carried out with a current intensity of 2 milliAmpere. Each tDCS session lasts 20 minutes. tDCS is administered simultaneously during the first 20 minutes of the usual upper limb rehabilitation physiotherapy, which will continue for a further 20 minutes.~During the whole study period (10 weeks) each patient is not subjected to any focal treatments in the target upper limb.~In the study period, the contralateral limb is rehabilitated and evaluated according to usual practice."
224201862|NCT05390853|PROCEDURE|Sham tDCS|"tDCS application is anodic, in the M1 area (Primary Motor Cortex) right or left, contralateral to the pre-defined target limb. The cathode is positioned in the supraorbital area, contralateral to the anode.~Sham stimulation is carried out through a dedicated program, which increases the current for several seconds up to the target intensity and then decreases it gradually in a few seconds, so that subjects experience the same itching and tingling experience as in active stimulation, but they do not receive any significant therapeutic currents.~Each tDCS session lasts 20 minutes. tDCS is administered simultaneously during the first 20 minutes of the usual upper limb rehabilitation physiotherapy, which will continue for a further 20 minutes.~During the whole study period (10 weeks) each patient is not subjected to any focal treatments in the target upper limb.~In the study period, the contralateral limb is rehabilitated and evaluated according to usual practice."
223614974|NCT00079573|BEHAVIORAL|Ornish diet (very low fat)|
223614975|NCT03867643|BIOLOGICAL|hepatitis B vaccine(HepB)|Children with anti-HBs at a low level (\<10mIU/mL and \[10,100) mIU/mL) were received a dose of hepatitis B vaccine booster after informed consent.
223614976|NCT01579890|DRUG|Diclofenac|diclofenac topical lotion
223614977|NCT05890469|COMBINATION_PRODUCT|Zirconia surface implant and guided bone regeneration|"The Straumann® PURE Ceramic Implant System is made from 100 % yttria-stabilized zirconia. Its surface features a topography characterized by macro- and micro-roughness to offer a structure for cell attachment and the osseointegration of this surface has been successfully proven. Owing to the increasing aesthetic standards in the field of implant dentistry and the concerns on sensitivity to titanium, there has been a growing interest towards metal-free implant rehabilitation.~Guided bone regeneration (GBR) will be performed simultaneously with the implant placement with the aim to re-establish the bone contour. A bovine osteoconductive graft (Bio-Oss collagen®, Geistlich, Wolhusen, Switzerland) will be placed on the buccal aspect of the implant and covered with a collagen membrane (Bio-Gide®, Geistlich, Wolhusen, Switzerland)."
223614978|NCT05890469|COMBINATION_PRODUCT|Hydrophilic titanium surface implant and guided bone regeneration|"The Straumann® Standard Plus (SP) Implant is a Soft Tissue Level Implant with a smooth neck section of 1.8 mm. It has a fundamentally improved hydrophilic surface chemistry (SLActive®) which accelerates the osseointegration process in the early healing phase.~Guided bone regeneration (GBR) will be performed simultaneously with the implant placement with the aim to re-establish the bone contour. A bovine osteoconductive graft (Bio-Oss collagen®, Geistlich, Wolhusen, Switzerland) will be placed on the buccal aspect of the implant and covered with a collagen membrane (Bio-Gide®, Geistlich, Wolhusen, Switzerland)."
223614979|NCT02051322|DEVICE|Jet Nebulizer|
223614980|NCT02051322|DEVICE|Trunk Mask Nebulizer|
223614981|NCT02051322|DEVICE|Aerobika Nebulizer|
223760271|NCT04126785|OTHER|Continuous Moderate Exercise in Heated Water-Based|Continuous moderate exercise will perform at controlled heated water-base (30 e 32 ºC). Subject will be submerged at the xiphoid process level. The session will consist in 4 min walking (warm-up) at 9 level (light) of RPE, followed by 26 min of MICE, walking at 11-13 (fairly light)level of RPE.
223760272|NCT04126785|OTHER|Control Group|CON session will perform at controlled heated water-base (30 e 32 ºC). Subject will be seated in a chair and submerged at the until xiphoid process level for 30 min.
223760273|NCT04508725|DIAGNOSTIC_TEST|Doppler Ultrasound|Power Doppler measurements will be made
223760274|NCT04508725|DEVICE|SIEMENS S3000 and Verasonics Vantage 256|Vantage 256 used for power Doppler ultrasound, manufactured by Verasonics
223760275|NCT04508725|DRUG|Standard-of-care Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) tyrosine kinase inhibitor (TKI) plus immune checkpoint inhibitor (ICI)|Standard-of-care Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) tyrosine kinase inhibitor (TKI) plus immune checkpoint inhibitor (ICI).
223760276|NCT04508725|DRUG|Standard-of-care non-immune checkpoint inhibitor (ICI) such as single-agent VEGFR2 TKI|Standard-of-care non-immune checkpoint inhibitor (ICI) such as single-agent VEGFR2 TKI
223760277|NCT06249438|BIOLOGICAL|CD20/BCMA-directed CAR-T cells|Autologous 2nd generation CD20/BCMA-directed CAR-T cells, single infusion intravenously
223760278|NCT05288556|DEVICE|Placement of stoma site enteral feeding tube accessory|The study stoma site accessory will be attached at the stoma site during an enteral tube replacement procedure the patient is scheduled to have as a standard of care procedure. The study stoma site accessory is compatible with commercially available enteral nutrition feeding tubes ranging from size 16 to 20 French tubing that are adjustable to variable length.
223760279|NCT05403697|PROCEDURE|Individualized MAP|Hemodynamic optimization beginning after general anesthesia induction, and ending at the 24th hour postoperatively, which consists in obtaining a mean arterial pressure (MAP) which is at least 90% of the usual MAP of the patient.
223760280|NCT05868707|DRUG|OH2|Oncolytic Type 2 Herpes Simplex Virus
223614982|NCT01290744|DRUG|Clofazimine|Clofazimine 100mg daily for 12 months after completion of MDT.
223760281|NCT05868707|DRUG|Salvage chemotherapy or best supportive care|single or combined, including but not limited to dacarbazine, temozolomide, taxoid, or platinum
223760282|NCT04621890|BEHAVIORAL|LOAN2DOSE and COIN2DOSE|This is a behavioral economics intervention designed to help improve meal time bolusing behaviors in youth with type 1 diabetes.
223760283|NCT06383247|OTHER|transcranial magnetic stimulation|The stimulations were performed by MagStim Rapid2.
223760284|NCT02775344|DEVICE|Three dimension laparoscopy|Surgery will be performed either with three dimension laparoscopy or two dimension laparoscopy.
223760285|NCT05840146|OTHER|Kinesiotaping|"Two I-strips were used:~1. The first-third of one I-strip began at the posterior iliac crest, without tension as an anchor. Then the patient actively flexed and adducted the affected hip, thus, the middle-third of the tape was applied with approximately 50% tension. Then the hip was set in its original position and the last-third of the tape ended approximately greater trochanter without tension.~2. The first-third of the second I-strip was applied starting at the anterior iliac crest, without tension as an anchor. The patient actively extended and adducted the affected hip, thus, the middle-third of the tape was applied with approximately 50% tension. Then the hip was set in its original position and the last-third of the tape ended approximately greater trochanter without tension."
223614983|NCT01290744|DRUG|Placebo|Daily for 12 months
223760286|NCT05840146|OTHER|Sham taping|A single I-strip without tension in tape or muscle stretch. After paper backing was completely removed, tape was essentially placed on the skin across the lateral side of the hip.
223760287|NCT04205760|COMBINATION_PRODUCT|Nutrition + exercise|Patients will receive preoperative optimization consisting of oral nutrition support (Fresubin 3.2 kcal) and bed-cycling (50 minutes per day) for 5-14 days before surgery.
223760288|NCT03601806|OTHER|Laboratory Biomarker Analysis|Correlative studies
223614984|NCT01166425|DRUG|Lithium Carbonate|Participants weighing ≥ 30 kg who are randomized to receive active lithium will begin treatment at 300 mg TID at visit 1 (total dose 900 mg). Participants weighing \< 30 kg who are randomized to receive active lithium will begin treatment at 300 mg BID the day after visit 1 (total dose 600 mg). Based on the participant's response and tolerability, the dose will be increased by 300mg three days after the baseline visit and at scheduled in-office visits to the maximum tolerated dose. One mid-week dose increase will be scheduled in addition to the weekly increases at the scheduled in-clinic visits. On day 3 (+/- 2 days), a dose increase of 300 mg may occur based on the results of a telephone call placed by the study investigator to the participant's parent/guardian. During the telephone call, the prescribing clinician will assess medication adherence, adverse events, and overall improvement since baseline.
223614985|NCT01166425|DRUG|Placebo|Participants who are randomized to receive placebo during the Efficacy Phase will receive matching placebo capsules. Dosing will be titrated as described for active lithium.
223614986|NCT03015935|PROCEDURE|visual-assisted entry|First trocar entry will be performed with visual-assisted trocar
223614987|NCT03015935|PROCEDURE|Veress entry|First trocar entry will be performed with Veress
223614988|NCT06399237|DEVICE|Foot Orthoses|Three types of foot orthoses (FO), Prefabricated FO, Custom FO, Custom with a 5° varus FO
223614989|NCT05701696|DIAGNOSTIC_TEST|Central sensitization inventory|Standardized questionnaire to determine the level of central sensitization. Patients with a score of 40 and above are considered to have central sensitization.
223614990|NCT05701696|DIAGNOSTIC_TEST|Widespread pain index|Total the number of painful body areas
223614991|NCT05701696|DIAGNOSTIC_TEST|Symptom severity scale|The sum of the fatigue, waking unrefreshed and cognitive symptoms and the extent of somatic symptoms
223614992|NCT05701696|OTHER|Fibromyalgia impact questionnaire|A tool to assess health status in fibromyalgia
223614993|NCT05701696|DIAGNOSTIC_TEST|Hospital Anxiety and Depression Scale|An instrument for detecting depression and anxiety
223614994|NCT05701696|DIAGNOSTIC_TEST|Self-Leeds Assessment of Neuropathic Symptoms and Signs|An instrument used to identify pain of neuropathic origin
223614995|NCT04190732|BEHAVIORAL|Physician phone call|Often, patients will not have contact with a physician during the waiting period between embryo transfer and the pregnancy test. Participants in the intervention group will receive a phone call from one physician 3 to 4 days after fresh or frozen embryo transfer to check in. The physician will introduce themselves and state they are a part of the research team.
223760289|NCT03601806|DRUG|Pomalidomide|Given PO
223760290|NCT06491706|OTHER|the was no intervention|there was no intervention in this observational study
223760291|NCT04404777|PROCEDURE|Treatment for local recurrence with surgery or other treatments|All types of treatment for local recurrence will be evaluated
223760292|NCT04627064|DRUG|Abemaciclib|Tablet taken orally
223760293|NCT04627064|DRUG|MK-6482|Tablet taken orally
223760294|NCT03189628|BIOLOGICAL|stromal vascular fraction|The adipose tissue(no less than 40ml) in abdomen will be harvested and digested at 37 °C for (45-60) min with (0.125-1.5)mg/ml collagenase . After filtration and centrifugation at the speed of (700-1500)g, mature adipocytes are separated from the cell pellet. The pellet then is treated with saline twice to remove cell fragment and rudimental collagenase . The harvested pellet is stromal vascular fraction (SVF) The SVF was resuspended in 1 ml saline and transplanted for 3 area including the forehead、palpebra inferior and crow's-feet.
223614996|NCT06400953|OTHER|Kinetic Brain Exercises and Core Stabilization Exercises|Kinetic Brain Exercise Program Kinetic brain exercises were applied to Group 1 in groups of 8-10 people, 2 days a week for 40 minutes for 8 weeks.These exercises include warm-up, main and cool-down phases. Warm-up; These are coordination-oriented movements that include 'brain buttons', 'cross crawl' and 'the thinking cap' exercises. Main phase; These are exercises that include coordination, selective attention, audio-visual focus and balance, consisting of perceptual, independent and dependent movements. Cooling phase; It aims to ensure hand-eye coordination by consisting of double doodle, throwing balls to each other and lazy 8s exercises.Exercises were selected from the kinetic brain exercise pool, modified and applied for 2-8 weeks.The exercises were done while sitting and standing, with increasing difficulty levels. The factor that made the levels difficult was the time and complexity of the incoming command. A game ball with a diameter of 7 cm was used for the exercises.
223760295|NCT03189628|DRUG|Saline|1 ml saline was injected for 3 area including the forehead、palpebra inferior and crow's-feet.
223760296|NCT03003975|DEVICE|PVI by single cryoballoon application guided by Achieve Mapping Catheter|Pulmonary vein isolation by single cryoballoon application guided by recorded electrogram signals from an internal Mapping Catheter and by temperature drop if mapping of signals is not possible (temperature cutoff \< or = -40 degrees C)
223760297|NCT03003975|DEVICE|PVI by 2 routine cryoballoon applications|Pulmonary vein isolation by 2 cryoballoon applications guided by degree of occlusion and by temperature drop according to discretion of physician
223760298|NCT04671459|COMBINATION_PRODUCT|TTFields and SRS|SRS procedure will be delivered within 7 days after start of TTFields therapy . A 5-day SRS regimen is allowed. TTFields should be interrupted in time of SRS and start immediately after.
223760299|NCT00091299|DRUG|warfarin|
223760300|NCT02908113|BEHAVIORAL|collection data|
223760301|NCT02908113|BEHAVIORAL|IRM|
223760302|NCT03469921|DRUG|administered therapeutic regimens|administered therapeutic regimens
223760303|NCT03060746|OTHER|Newly Diagnosed|Gastric biopsy tested by composite reference method (CRM) (histology, urease, culture) and stool sample
223760304|NCT01110629|DRUG|Fosrenol (Lanthanum Carbonate, BAY77-1931)|Daily dose: 750-2250mg 3 times a dayfor 8 weeks.
223760305|NCT01110629|DRUG|Placebo|daily dose: 3 tablets TID for 8 weeks.
224201863|NCT05744388|DEVICE|Gliderite® shape modification|The stylet will be more obtuse angle than the standard shape. The stylet will be lubricated also before being fitted inside the endotracheal tube. The blade will be introduced inside the mouth midline, the tube will be held from the upper third and introduced in the midline also sliding over the blade and introduced inside the glottis.
224201864|NCT02590146|BEHAVIORAL|Non-pharmacologic pain control adjuncts|
224201865|NCT06650657|BEHAVIORAL|touchpoint method|Touchpoint is a quality approach that can be applied to increase the sense of personal connection with the instructor, ensure that students are making satisfactory progress, increase instructor-student and student-instructor interactions, and increase student satisfaction, unlike traditional learning models.
224201866|NCT06649799|DEVICE|LenSx|The patients in Group 1 conduct FLACS under LenSx
224201867|NCT06649799|DEVICE|Z8|The patients in Group 1 conducted FLACS using Z8
224201868|NCT06652477|DIAGNOSTIC_TEST|ELISA|ElISA kit to detect autoantibodies against desmoglein 3 in tissues of oral lichen planus lesions
223760306|NCT02093546|PROCEDURE|Biospecimen Collection|Undergo collection of blood and tumor
223760307|NCT01289925|DIETARY_SUPPLEMENT|Selenium|200 micrograms of selenium (in the form of selenium methionine) in tablet form taken orally daily for 8 weeks. Capsule molds with inert coating.
223760308|NCT01289925|OTHER|Sugar Pill Placebo|Placebo supplements in the same capsule mold as selenium and coated with the same inert coating. 1 tablet daily for 8 weeks.
223760309|NCT05680766|OTHER|Cardiovascular endurance training|Based on the results of a maximal effort test, investigators will provide a personalised training program. Results of a submaximal effort test after 6 weeks, will allow for adaptation of the training program for the remaining training period.
223760310|NCT06037746|OTHER|Graston|For the application, the individual was asked to lie face down, flex the knee to 90 degrees and release the ankle. The therapist took a position next to the individual on the side to be treated. Application was applied to the entire plantar fascia for 10 minutes in the longitudinal, vertical and oblique directions.
223760311|NCT06037746|OTHER|Percussive massage|For the application, the individual was asked to lie face down, flex the knee to 90 degrees and release the ankle. The therapist took a position next to the individual on the side to be treated. Application was applied to the entire plantar fascia for 5 minutes in all directions without being bound to a single direction.
223760312|NCT01148953|DRUG|ALN-TTR01|Dose levels between 0.01 and 1.0 mg/kg by intravenous (IV) infusion
224201869|NCT02357017|DIETARY_SUPPLEMENT|NaCl tablets|
224201870|NCT02038699|DRUG|ONC201|ONC201 capsules will be administered orally once every three weeks with flat dosing. Dosage will be given according to a modified Fibonacci sequence with the anticipated starting dose being 125 mg.
224201871|NCT03868059|DRUG|LPCN 1021|LPCN 1021 is gelatin capsule product provided as 112.5 mg testosterone undecanoate per capsule.
224201872|NCT02061293|DRUG|Psilocybin|
224201873|NCT02061293|DRUG|Diphenhydramine|
224201874|NCT02061293|BEHAVIORAL|Motivational Enhancement and Taking Action (META)|Manualized psychosocial intervention based on motivational enhancement therapy, functional analysis, and implementation of a change plan.
224201875|NCT01866605|DRUG|Midazolam|Intravenous midazolam 0.3 mg/kg
223614997|NCT06400953|OTHER|Core Stabilization Exercises|Core Stabilization Exercise Program in groups of 8-10 people, for 40 minutes, 2 days a week, for 8 weeks.These exercises included a 5-minute active warm-up, a 30-minute Core Stabilization exercise that included upper and lower extremity movements, and immediately followed by a 5-minute cool-down exercise.The exercises are pilates-based and in the first stage of the program. Movements were performed in standing and sitting positions.Movements were started with 6-8 repetitions, increased by 1-2 repetitions each week, and in the last week, 12-15 repetitions were performed, with contraction times increasing from 5 seconds to 10 seconds. As the exercises progressed from easy to difficult, from simple movements to complex movements, the movements were continued by adding an elastic band and 0.5 kg weight.While advancing the exercise program, the exercises were personalized by taking into account the individual's strain levels.
223614998|NCT03019094|DEVICE|The RENOVA tibial nerve stimulation system|Study participants will be implanted with the RENOVA tibial nerve stimulation system
223760313|NCT01148953|DRUG|Sterile Normal Saline (0.9% NaCl)|Calculated volume to match active comparator
223760314|NCT04708327|DRUG|STAT-205|naltrexone hydrochloride capsules 4.5 mg each
223760315|NCT01265446|DRUG|Lidocaine 8mg + CPC 2mg|one single dose
223760316|NCT01265446|DRUG|Lidocaine 1mg + CPC 2mg|one single dose
223760317|NCT02796807|DRUG|68Ga-HBED-CC-PSMA (DKFZ-11) PET/CT|
223760318|NCT04924777|OTHER|Brisk Walk|1-Brisk walk for 30 minutes 2-5 days a week 3-3months
223614999|NCT02457676|BEHAVIORAL|Alert Program for Self-Regulation|"Children attend 12 1.5 hour weekly sessions. Alert uses the analogy of a car engine to help children identify their own self-regulatory behavior. Children learn strategies to regulate their own engine speed in different situations."
223615000|NCT01047982|DIETARY_SUPPLEMENT|myo-inositol|myo-inositol 2 grams plus folic acid 400 mcg twice a day
223615001|NCT01047982|OTHER|folic acid 400 mcg|2 pills a day
223615002|NCT06379776|OTHER|Education through a 3D model|Training through a 3D model of the spine fractures
223615003|NCT06379776|OTHER|Education through a traditional pedagogical support|Training through a traditional pedagogical support
223615004|NCT04958174|DEVICE|web-application|web application for monitoring children's development
223615005|NCT02761382|OTHER|Mindfulness-based psychological treatment|
223615006|NCT02761382|OTHER|Non-specific psychological treatment|
224201876|NCT01866605|DRUG|Normal Saline|Normal saline injection will be given to groups not receiving midazolam
223615007|NCT02458833|BEHAVIORAL|Home Plate|Home Plate is a community-based, peer mentored intervention aimed at improving home food preparation practices in families with young children. Through 6 classes, this intervention explores topics related to regularly preparing healthy foods at home.
223615008|NCT02865655|PROCEDURE|Hysteroscopic|
223615009|NCT02748395|DRUG|Triamcinolone|
223615010|NCT02748395|OTHER|Placebo|
223760319|NCT04924777|OTHER|Strength training|1-Strength Training Exercises for 30 minutes. 2-5 days a week 3-3 months
223760320|NCT04924777|OTHER|Aerobic Exercises|1-Aerobic exercises for 30 minutes 2-5 Days a week 3-3months
223760321|NCT02402452|DRUG|Voxilaprevir|100 mg tablet administered orally
223760322|NCT03448315|DEVICE|tDCS|motor cortex stimulation (2 mA, 20 min for 4 sessions)
223760323|NCT00559962|DRUG|AEGR-733|3 capsules each evening for each 4-week period
223760324|NCT00559962|DRUG|placebo|3 capsules each evening for each 4-week period
224201877|NCT01866605|DEVICE|Bair Hugger|Forced air warming
224201878|NCT02866201|OTHER|Rectal swab|
223615011|NCT02748395|DRUG|Lidocaine|
223615012|NCT00890110|BIOLOGICAL|Autologous renal cell vaccine based on DNP modified cells|Primary or metastatic tumor resected in an Israeli hospital will be used to derive autologous cell lines used for vaccinations following DNP modifications in combination with the regular Sunitinib treatments. Immunological and clinical followup of the patients will be performed
223760325|NCT00559962|DRUG|AEGR-733|3 capsules each evening for each 4-week period
223760326|NCT00559962|DRUG|AEGR-733|3 capsules each evening for each 4-week period
223760327|NCT00559962|DRUG|AEGR-733|3 capsules each evening for each 4-week period
223760328|NCT00559962|DRUG|AEGR-733 and atorvastatin|3 capsules each evening for each 4-week period
224201879|NCT06353581|DRUG|Neulapeg|Participants will receive Neulapeg subcutaneously 24 hours after the end of modified FOLFIRINOX dosing. (Must be administered within a maximum of 72 hours; Neulapeg will only be given for up to 8 cycles).
224201880|NCT06353581|OTHER|Control|Patients assigned to the non-Neulapeg arm will be crossover to Neulapeg if they develop grade 3-4 neutropenia or neutropenic fever. Crossover subjects will receive up to 8 cycles of Neulapeg as a secondary treatment regardless of starting cycle.
223615013|NCT01943591|DEVICE|Endovascular coiling with standard 10-caliber platinum coils or 15-caliber platinum coils|Embolization using 15-caliber platinum coils or standard 10-caliber platinum coils.
223615014|NCT03212534|OTHER|Patient mortality prediction|Healthcare provider is notified of patient mortality prediction.
223615015|NCT02829580|PROCEDURE|Echocardiography|Measures by Doppler and study of endothelial function
223760329|NCT00559962|DRUG|AEGR-733 and fenofibrate|3 capsules each evening for each 4-week period
223760330|NCT00559962|DRUG|AEGR-733 and ezetimibe|3 capsules each evening for each 4-week period
223760331|NCT02142127|DRUG|14C-labelled GFT505 120 mg|
223760332|NCT04616807|DRUG|Mexiletine|Observational Study
223760333|NCT05414643|OTHER|Standard care|No interventions were used, as this is an observational study.
223760334|NCT01310322|DRUG|AZD5423|solution for injection, administered as intravenous infusion Corr to total dose of 250µg AZD5423
223760335|NCT01310322|DRUG|AZD5423|nebuliser suspension, inhaled via Spira, corr to approximately 300 µg lung deposited dose AZD5423
223760336|NCT01310322|DRUG|AZD5423|nebuliser suspension, inhaled via I-neb, corr to approximately 300 µg lung deposited dose AZD5423
224201881|NCT02774577|OTHER|whole body vibration training in vibrating platform in young|
224201882|NCT02774577|OTHER|whole body vibration training in vibrating platform in elderly|
224201883|NCT03512704|OTHER|Collection of possible predictors from patient data|Collection of sociodemographic and clinical parameters, from medical records, and health related quality of life data, that may predict the outcomes of interest (mortality, complications, readmissions)
223615016|NCT05830175|OTHER|manual therapy for cervikal region|Joint mobilization: In the stroke individuals included in the mobilization group, Grade 3 Central Posterior-Anterior (CPA) passive joint mobilization was applied with the Maitland method starting from the upper cervical region towards the lower cervical region, in 3 sets, 2 minutes and 1 minute rest.
223760337|NCT01310322|DRUG|AZD5423|nebuliser suspension to be administered orally, corr to a total dose of 1200 µg AZD5423
223760338|NCT01461096|BIOLOGICAL|Quadrivalent HPV Vaccine|Participants were prescribed one intramuscular (IM) injection of the quadrivalent HPV vaccine in the upper arm or thigh at baseline and Weeks 8 and 24.
223760339|NCT01461096|BIOLOGICAL|Placebo Vaccine for Male Participants Only|Participants were prescribed one IM injection of the placebo vaccine in the upper arm or thigh at baseline and Weeks 8 and 24.
223760340|NCT01461096|BIOLOGICAL|Placebo Vaccine for Female Participants Only|Participants were prescribed one IM injection of the placebo vaccine in the upper arm or thigh at baseline and Weeks 8 and 24.
223760341|NCT05657028|DRUG|Dexmedetomidine|-In the Dexmedetomidine group, patients will be given IV bolus infusion of dexmedetomidine 0.5 μg/kg over 10 min before induction of anesthesia, followed by a continuous IV infusion of dexmedetomidine 0.4 μg/kg/hour until 30 min before the end of surgery.
223760342|NCT05657028|DRUG|Lidocaine IV|In the Lidocaine group, the patients will be given an IV bolus infusion of lidocaine (2%)1.5mg/kg over 10 min before induction of anesthesia, followed by a continuous IV infusion of lidocaine 1.5 mg/kg /hour until 30 min before the end of surgery.
223760343|NCT04892576|OTHER|Physical Therapy|"The control group recieved the standard physical rehabilitation program conducted for 45 minutes, twice a week for eight consecutive weeks, and consisted of advanced balance training, gait training, postural and flexibility exercises, and strength training exercises.~The SSC group received the same program in addition to the SSC exercises for 30 minutes, two times per week for eight successive weeks"
223760344|NCT04634149|DRUG|BMS-986036|Specified dose on specified days
223760345|NCT00660062|DRUG|escitalopram|10 mg daily
223760346|NCT00660062|DRUG|escitalopram|20 mg daily dosage
223760347|NCT00660062|DRUG|escitalopram|30 mg daily dosage
223760348|NCT00660062|DRUG|nortriptyline|100 mg daily dosage
223760349|NCT05724849|DRUG|Venlafaxine|See arm/group description.
223760350|NCT05724849|DRUG|Placebo|See arm/group description.
223760351|NCT03869125|DIAGNOSTIC_TEST|Blood pressure measurement|Blood pressure monitoring using automated office blood pressure measurement (AOBPM), office blood pressure measurement (OBPM), and 24-hour ambulatory blood pressure monitoring
223760352|NCT01263548|DRUG|lisdexamfetamine dimesylate|Dosage form: Capsules; Dosage strength: 30-70mg/day, flexible dosing; Duration: 4 weeks
223760353|NCT00699010|DRUG|Acurox 5/30mg taken first|followed by oxycodone 5mg with 48 hour washout
223760354|NCT00699010|DRUG|Oxycodone 5mg taken first|followed by Acurox 5/30mg with 48 hour washout
223760355|NCT04462705|PROCEDURE|Usual physiotherapeutic intervention and Abdominal Massage|Abdominal massage is not widely applied amongst general surgery team and is not part of the recommendation. This technique refers to profound manœuvrers of visceras through abdominal palpation and breathing, and has been used as part of the local protocol of Grenoble Alps University Hospital for many years with satisfactory results. No complications have been reported.
223760356|NCT04036656|DRUG|SYHA136 0.5 mg|oral tablet
223760357|NCT04036656|DRUG|SYHA136 1 mg|oral tablet
224201884|NCT02000466|OTHER|Data collection|Initial and follow-up data will be collected using questionnaires
224201885|NCT03492489|DRUG|cemiplimab|Intravenous (IV) administration
224201886|NCT01203982|DRUG|Rosuvastatin|Rosuvastatin 5mg/day for one year
223760358|NCT04036656|DRUG|SYHA136 2.5 mg|oral tablet
223760359|NCT04036656|DRUG|SYHA136 5 mg|oral tablet
223760360|NCT04036656|DRUG|SYHA136 10 mg|oral tablet
223760361|NCT04036656|DRUG|SYHA136 20 mg|oral tablet
224201887|NCT01203982|DRUG|Rosuvastatin|Rosuvastatin 40mg/day for one year
223760362|NCT04036656|DRUG|SYHA136 35 mg|oral tablet
223760363|NCT04036656|DRUG|SYHA136 50 mg|oral tablet
223760364|NCT04036656|DRUG|Placebo matching SYHA136 0.5 mg|oral tablet
223760365|NCT04036656|DRUG|Placebo matching SYHA136 1 mg|oral tablet
223760366|NCT04036656|DRUG|Placebo matching SYHA136 2.5 mg|oral tablet
223760367|NCT04036656|DRUG|Placebo matching SYHA136 5 mg|oral tablet
223760368|NCT04036656|DRUG|Placebo matching SYHA136 10 mg|oral tablet
223760369|NCT04036656|DRUG|Placebo matching SYHA136 20 mg|oral tablet
223760370|NCT04036656|DRUG|Placebo matching SYHA136 35 mg|oral tablet
223760371|NCT04036656|DRUG|Placebo matching SYHA136 50 mg|oral tablet
223760372|NCT00113659|DIETARY_SUPPLEMENT|Probiotic|Daily dose of ten to the tenth colony-forming units of Lactobacillus GG and 225 mg of inulin for the first 6 months of life.
223760373|NCT00113659|DIETARY_SUPPLEMENT|Placebo|Daily dose of placebo supplement containing 325mg inulin for the first 6 month of life.
223760374|NCT03274479|DRUG|PBF-1129|PBF-1129 once a day by oral administration
223760375|NCT02973763|DRUG|Alflutinib|
223760376|NCT04152226|DRUG|Janthinobacterium lividum|Investigational Product
223760377|NCT05121519|OTHER|Consume coffee|Drink coffee regularly (recommend at least 1 cup of caffeinated coffee or one shot of espresso per day)
223760378|NCT05121519|OTHER|Avoid coffee|Abstain from coffee and other caffeinated products
223760379|NCT04644094|OTHER|Echocardiography (ECHO) and lung ultrasound (LUS) studies before and after Dexamethasone administration|"A. Electrocardiographic (ECG) leads will be place in the patient for electrocardiogram (ECG) recordings.~B. Echocardiography (ECHO) will be performed by an expert member of the Neonatal Echocardiography team C. Heart Rate Variability (HRV): ECG recordings D. Growth trajectory: body weight, length, head circumference, length/weight ratio at 1-, 2-weeks prior treatment, 1-, 2-, 3-, 4-,6-,8-weeks after treatment, at 36-week PMA."
224201888|NCT04066894|PROCEDURE|Explantation|Undergo lead removal
224201889|NCT04066894|OTHER|Quality-of-Life Assessment|Ancillary studies
224201890|NCT04066894|OTHER|Questionnaire Administration|Ancillary studies
224201891|NCT04066894|DEVICE|Sacral Nerve Stimulator|Undergo sacral nerve stimulator implantation
224201892|NCT04066894|DEVICE|Sacral Nerve Stimulator Battery|Undergo sacral nerve stimulator battery implantation
224201893|NCT04066894|PROCEDURE|Therapeutic Conventional Surgery|Undergo sacral nerve stimulator implantation
223760380|NCT04413123|DRUG|Cabozantinib|Cabozantinib predetermined protocol dosage po daily
223760381|NCT04413123|DRUG|Nivolumab|Nivolumab predetermined protocol dosage via IV every 3 weeks
223760382|NCT04413123|DRUG|Ipilimumab|Ipilimumab predetermined protocol dosage via IV every 3 weeks
223760383|NCT04622553|DRUG|Mexiletine|"Patients will be enrolled sequentially into 2 cohorts.~Cohort 1 - (patients aged 12 to \< 18 years):~approximately 8 weeks - 4 weeks of dose titration period + 4 weeks of maintenance period.~Cohort 2- (patients aged 6 to \< 12 years,):~approximately 8 weeks - 4 weeks of dose titration period + 4 weeks of maintenance period. Enrolment for Cohort 2 will begin after initial pharmacokinetics (PK), safety and efficacy are confirmed in this population, of patients in Cohort 1"
223615017|NCT05830175|OTHER|osteopathic suboccipital myofascial release technique|The patient lies comfortably in the supine position. The therapist's forearms are supported on the treatment table, with the metacarpophalangeal and proximal interphalangeal joints flexed to approximately 45 degrees. After the therapist places his hands on the area where the patient's suboccipital muscles connect the occiput, he asks the patient to relax and rest his head on his fingers. Therapist pays attention to positioning the fingertips in suboccipital area No traction is performed during this technique. The position is maintained until the patient is relaxed. This treatment takes approximately 3-4 minutes.
223760384|NCT03241706|DRUG|Low Fructose|IV fructose (1.3 mg/kg/min)
223760385|NCT03241706|DRUG|Saline|Saline given as a comparison to fructose.
223760386|NCT03241706|DRUG|Somatostatin|IV infusion of somatostatin (60 ng/kg/min)
223760387|NCT03241706|DRUG|Insulin|IV infusion of insulin between 20-60 mU/m2/min.
223760388|NCT03241706|DRUG|Glucagon|IV glucagon (0.65 ng/kg/min).
223760389|NCT03241706|DRUG|Dextrose solution|IV dextrose to clamp the plasma glucose at the desired level.
223760390|NCT03241706|DRUG|High Fructose|IV-fructose (6.5 mg/kg/min)
223760391|NCT05255770|DEVICE|Test condom A (NRL condom with 5% benzocaine paste)|In each assessment period (intervention duration), subjects will be provided with a condom type to use during vaginal intercourse and will report at least 4 duration records (from vaginal entry to ejaculation) over a 4-week period.
223760392|NCT05255770|DEVICE|Test condom B (NRL condom with 3% benzocaine paste)|In each assessment period (intervention duration), subjects will be provided with a condom type to use during vaginal intercourse and will report at least 4 duration records (from vaginal entry to ejaculation) over a 4-week period.
223760393|NCT05255770|DEVICE|Control NRL condom|In each assessment period (intervention duration), subjects will be provided with a condom type to use during vaginal intercourse and will report at least 4 duration records (from vaginal entry to ejaculation) over a 4-week period.
223760394|NCT05581979|DIAGNOSTIC_TEST|68-Ga PSMA PET scan|"On the scheduled visit date for the study,~* An intravenous cannula (plug) will be inserted in a vein in the participant's arm, through which the 68-Ga PSMA radiotracer for the scan will be injected. The infusion will take about 1-2 minutes.~* PET imaging will be performed with a dedicated PET/CT scanner. 2.5-6.0 mCi (depending on weight of the patient) of PSMA radiotracer will be injected intravenously."
223760395|NCT04797260|GENETIC|Gene therapy|Patients will be infused with autologous CD34+ cells transduced with the pCCL.MND.coRAG1.wpre lentiviral vector (RAG1 LV CD34+ cells).
223760396|NCT03639337|DIETARY_SUPPLEMENT|Multi-strain probiotic|30 days of administration of multi-strain probiotics containing 3.5 x 109 UFC of Bifidobacterium longum BB536, Bifidobacterium breve M-16V and Bifidobacterium infantis M-63
223760397|NCT05992792|BEHAVIORAL|App message|Participantes push App message cancer prevention from the recomendations ECAC. 2 SMS notifications (push) per week or frequency of app notifications per week.
223760398|NCT05992792|BEHAVIORAL|SMS message|Participants push SMS message cancer prevention from the ECAC. Second randomization for received 2 notifications (push) per week or frequency of 7 SMS notifications per week.
223760399|NCT05992792|BEHAVIORAL|Internet|Internet connection in their mobile phone and WI-Fi. Participants push message cancer prevention from the recomendations ECAC. Second randomization for received 2 notifications (push) per week or frequency of 7 SMS notifications per week.
223760400|NCT05992792|BEHAVIORAL|Whithout internet|Second randomization for received 2 notifications (push) per week or frequency of 7 SMS notifications per week.
223760401|NCT00639834|BIOLOGICAL|MDX-1342|One dose of active MDX-1342 (anti-CD19 fully human monoclonal antibody) will be administered to patients as an i.v. infusion. Patients will receive one dose of MDX-1342 given in combination with Methotrexate treatment.
223760402|NCT04291885|DRUG|Avelumab|Avelumab IV infusion
223760403|NCT04291885|DRUG|Placebo|Placebo IV infusion
223760404|NCT05117411|DIAGNOSTIC_TEST|OCTA and pseudophakin cystoid edema|Patients underwent OCT angiografia after cataract surgery
223760405|NCT05945316|BEHAVIORAL|Accessing Confidence levels of Nursing students|Three mock CODE BLUE training events for Spring, Summer, and Fall Nursing Residents and Nursing Fellows are scheduled for 2022 followed by an actively participated CODE BLUE event. The PI plan to collect data from all new residents meeting the inclusion/exclusion criteria with voluntary participation to complete.
223760406|NCT01452412|DRUG|Sodium bicarbonate|0.4 mEq/kg/day ideal body weight to be taken once a day
223760407|NCT01452412|DRUG|Placebo|To be taken on the same schedule as the active arm
223760408|NCT04486846|OTHER|eVisit|electronic surveillance program in lieu of in-person clinic visit
223760409|NCT04002414|BEHAVIORAL|Sufficient physical activity|Physical activity at the recommended levels by the US Health and Human Services Department: 75 minutes a week of vigorous activity or 150 minutes a week of moderate activity.
224075442|NCT06221020|BEHAVIORAL|BDI-II(Beck Depression Inventory-II)|"The BDI-II consists of 21 questions that assess the degree of depression by asking respondents about various depressive symptoms they have experienced. These symptoms include sadness, insomnia or oversleeping, changes in appetite, self-blame, self-disdain, loss of interest in daily activities, and more. Each question has four possible response options, allowing respondents to choose the answer that best fits their feelings.~Scoring on the BDI-II ranges from 0 to 63, with higher scores indicating more severe depression. Based on the scores, the severity of a respondent's depression can be classified into different levels, ranging from mild to severe. The purpose of using this scale is to help healthcare professionals assess a patient's depressive symptoms, monitor changes in condition, and evaluate the effectiveness of treatments."
223509777|NCT01887392|OTHER|Knowledge Translation Education Sessions|Two interactive sessions will be delivered to the interprofessional team at Month 1 and Month 6 and are 1 hour in length. The Clinical Consultant Pharmacist at each LTC home will lead the Knowledge Translation Sessions. Participants will watch an educational video, developed by the co-investigators with expertise in osteoporosis and geriatrics and members of the Ontario College of Family Physicians. Accompanying materials that support the topics in the video will be provided. Following the educational video, one of the experts from the video will phone the LTC home to address questions and provide the home with direct access to an expert.
223509778|NCT06696222|DIETARY_SUPPLEMENT|Vegetarian yogurt|Vegetarian yogurt alternative will be uesd.
223615018|NCT03662594|OTHER|ECMO|In this project, the investigators will apply a new technique of atomic layer deposition (ALD) to coat biocompatible and hemocompatible ZrO2/Al2O3 nanolaminate thin films on the inner surface of ECMO tubing to suppress the device-induced coagulopathy. ALD is a thin-film deposition technique for preparing high-quality oxides with atomic-layer accuracy. It offers many benefits including accurate thickness control. These characteristic clear accounts of the high-quality hemocompatible oxide thin films on the whole surface of complex 3-D structures, such as the inner surface The newly-prepared ECMO circuit will then undergo in vitro tests and animal study to carefully examine the safety and effectiveness of improvement of hemocompatibility.
223615019|NCT02566694|PROCEDURE|Implant|orthopaedic implant
223615020|NCT04456634|DRUG|20 mg/120 mg artemether-lumefantrine (AL) + 20 mg ruxolitinib phosphate (Rux)|Rux administered 2 hours after AL administration, twice daily (b.i.d) for 3 consecutive days (6 doses in total).
223760410|NCT04002414|BEHAVIORAL|Insufficient physical activity|Physical activity less than the recommended levels by the US Health and Human Services Department: 75 minutes a week of vigorous activity or 150 minutes a week of moderate activity.
223615021|NCT04456634|OTHER|20 mg/120 mg artemether-lumefantrine (AL) + Placebo|Placebo administered 2 hours after AL administration, twice daily (b.i.d) for 3 consecutive days (6 doses in total).
223615022|NCT05822882|PROCEDURE|Epidural anesthesia|Postoperative pain management by epidural anesthesia via epidural catheter and pain pump
223615023|NCT03462108|BIOLOGICAL|Rotavirus (Bio Farma) Vaccine|Rotavirus (Bio Farma) Vaccine
224201894|NCT02262507|DEVICE|Device Wearing|Q30 collar - collar designed to be worn around the neck to apply slight pressure to jugular veins. Each subject will undergo repeat oto-acoustic measures both wearing the device and not wearing the device
224201895|NCT06520761|PROCEDURE|Injectable platelet rich fibrin|blood sample obtained from the participant, centrifuged at 700 rpm to produce injectable platelet rich fibrin, this will be injected around the upper canine
224201896|NCT06520761|DEVICE|Low Level LASER|Diode LASER device is used to apply Low Level LASER around the upper canine
224201897|NCT03378999|DIETARY_SUPPLEMENT|Rhodospirillum rubrum|Capsules containing oven-dried Rhodospirillum rubrum
224201898|NCT03378999|DIETARY_SUPPLEMENT|Control|Capsules containing microcrystalline cellulose
223615024|NCT03462108|OTHER|Placebo|Placebo contains 30% sucrose in DMEM
223615025|NCT06525415|DIAGNOSTIC_TEST|DCE MRI|the recruited patients should complete pre- and post-operative DCE MRI workshops
223615026|NCT01253642|PROCEDURE|Biopsy of Prostate|Undergo transrectal ultrasound (TRUS) guided prostate biopsy OR image-guided (CT or ultrasound) core bone or soft tissue biopsy
224201899|NCT00014300|DRUG|glufosfamide|
224201900|NCT02302118|PROCEDURE|Esophagogastrectomy|Esophagogastrectomy
224201901|NCT05919771|OTHER|rock climbing|Vertical ascent of a surface specifically designed to elicit the skills that might be required to scale a naturally occurring rock formation
224201902|NCT03203746|DRUG|Lycopene + SRP|
224201903|NCT03203746|PROCEDURE|SRP only|
224201904|NCT03542253|PROCEDURE|Surgery|After surgical treatment, pathological specimens were extracted to obtain pathological results
224201905|NCT06586658|BIOLOGICAL|anti-CD70-CAR-T cells|The subjects received infusions of anti-CD70 CART cells following completion of lymphodepleting preconditioning chemotherapy. Dosage: 3×10\^6 cells/Kg; 1×10\^7 cells/Kg; 2×10\^7 cells/Kg.
224201906|NCT06604299|BEHAVIORAL|Meditation-enhanced Cognitive Behavioral Therapy|Self-guided online intervention
224201907|NCT03782688|DIAGNOSTIC_TEST|FFRCT planner|Non-invasive post-PCI fractional flow reserve prediction
224201908|NCT06656390|DRUG|ALK201|Administered intravenously, once every 3 weeks
224201909|NCT06652776|OTHER|Pharmacological treatment|"Pharmacological and non pharmacological treatments will be assessed and monitored during the retrospective and prospective phase, and will include:~* bronchodilators, inhaled steroids and their combinations~* mucolytics~* biologic therapies for COPD~* roflumilast~* pulmonary rehabilitation"
223615027|NCT01253642|DRUG|Docetaxel|Given IV
223615028|NCT01253642|OTHER|Laboratory Biomarker Analysis|Correlative studies
223615029|NCT01253642|DRUG|Phenelzine Sulfate|Given PO
223615030|NCT06139549|OTHER|Gross motor development group session|Group session for gross motor development
223615031|NCT02498301|DRUG|Rifaximin|Rifaximin will be provided to subjects either daily with placebo, or twice daily depending on which of the two experimental arms they are randomized to
223615032|NCT02498301|DRUG|Placebo|Placebo will be administered twice daily or once daily with rifaximin depending on which experimental arm they are randomized to
223615033|NCT02963454|DEVICE|Microdialysis Probe (Muscle microdialysis)|"Interstitial tissue concentrations of lactate, pyruvate, glucose and glycerol were determined at baseline and then every six hours for the following 72 hours after randomization.~During the study period, conventional treatment was continued as per usual practice. Fluid challenges were performed, and repeated as necessary, to maintain central venous pressure (CVP) ≥8 and pulmonary arterial occlusion pressure (PAOP) ≥12 mmHg. Norepinephrine was titrated to maintain mean arterial pressure (MAP) ≥65 mmHg. Packed red blood cells were transfused when Hemoglobin (Hb) concentrations decreased below 7 g/dL, or if the patient exhibited clinical signs of inadequate systemic oxygen supply."
223615034|NCT02963454|DRUG|Dobutamine|Dobutamine (5 μg/kg/min) will be used as indicated
223615035|NCT02963454|DRUG|Levosimendan|Levosimendan (0.2 μg/kg/min) will be used as indicated
223760411|NCT05216874|DEVICE|Oclusal Splint|"Cl III Laterognati volunteer group using occlusal stabilization splint before orthognathic surgery~-Splint will be used for at least two months"
223760412|NCT02040610|RADIATION|Hypofractionated Proton Therapy|
223760413|NCT06116149|BEHAVIORAL|In-person health coach delivery of the GLB|"Delivery of 24 health coaching sessions in-person by health coaches over 1 year.~Standard delivery of 24-sessions of the Group Lifestyle Balance (GLB) behavioral intervention in WIC clinics. The GLB was adapted from the original Lifestyle Balance behavioral intervention used in the original Diabetes Prevention Program trial for use in community translation and group settings. It focuses on improving diet and physical activity and promoting moderate weight loss through health coaching on behavioral change, including self-monitoring of food intake, physical activity, and weight."
223760414|NCT06116149|BEHAVIORAL|Technology-assisted health coach delivery of the GLB|"Delivery of 12 health coaching GLB sessions in-person by health coaches over one year; supplemental technology support, including tools for self-monitoring, health coach monitoring, asynchronous delivery of intervention materials, and asynchronous coach and group connection.~The GLB was adapted from the original Lifestyle Balance behavioral intervention used in the original Diabetes Prevention Program trial for use in community translation and group settings. It focuses on improving diet and physical activity and promoting moderate weight loss through health coaching on behavioral change, including self-monitoring of food intake, physical activity, and weight."
223760415|NCT00981032|BEHAVIORAL|Pre-visit Summary|The intervention is a pre-visit summary given to the patient prior to their appointment. The pre-visit summary details the patient's risk of heart attack or stroke and the benefits of daily prophylactic aspirin use.
223760416|NCT00981032|BEHAVIORAL|Clinical Decision Sharing Tool|This intervention includes a pre-visit summary and a clinical decision sharing tool. Patients will receive a pre-visit summary prior to their appointment. They will also view a clinical decision sharing tool in conjunction with the physician in the office. The pre-visit summary details the patient's risk of heart attack or stroke and the benefits of daily prophylactic aspirin use. The clinical decision sharing tool informs the physician of the patient's heart attack or stroke risk and determines if the patient would benefit from aspirin use.
223760417|NCT01506973|DRUG|Hydroxychloroquine (HCQ)|no other names
223760418|NCT01506973|DRUG|Gemcitabine|no other names
223760419|NCT01506973|DRUG|Abraxane|no other names
223760420|NCT01653093|PROCEDURE|3-Tesla magnetic resonance imaging (3T MRI)|Undergo 3T MRI
224312200|NCT06983002|BEHAVIORAL|Control group 1: Body Awareness Group.|The aim is to connect with and become more confident about the body experiences, needs and feelings, to gain an increased understanding of oneself. The Group consists of 15 group sessions. Group meeting 1 Introduces Body Awareness Therapy, group structure and content and focus on experiences and expectations. The practice of slow, simple movements for the whole body in a standing position, introduction of The Autonomous Compass model, giving an opportunity to figure out where to place themselves in the compass in the moment, exercise stimulating the feet and a relaxation exercise. Group meetings 2-14 focuses on a topic as grounding, balance, breathe, play, posture due to habitual positions, body language and emotions, self-compassion and boundaries, explored through experience by using various physical exercises, sharing body experiences and psychoeducation. Session 15 contains summary, evaluation and repetition.Reflection on the previous session and sharing homework is included.
223509779|NCT06696222|DIETARY_SUPPLEMENT|Placebo|Ordinary diet with dairy based yogurt
223509780|NCT06696222|DIETARY_SUPPLEMENT|Vegetarian meat alternative|Vegetarian meat alternative consumed
223509781|NCT06696222|DIETARY_SUPPLEMENT|Ordinary meat diet|Ordinary meat diet used as placebo
223509782|NCT05274451|BIOLOGICAL|LYL797|LYL797 is an autologous, genetically (Gen-R™) and epigenetically (Epi-R™) reprogrammed ROR1-targeted chimeric antigen receptor (CAR) T-cell therapy
223615036|NCT05927038|OTHER|Caffeinated coffee|After 2 weeks of coffee abstinence (washout), participants who were coffee drinkers were randomly allocated to receive either 4 sachets (1.8g each) of caffeinated instant coffee per day for 3 weeks. Participants were blinded to coffee contents.
223615037|NCT05927038|OTHER|Decaffeinated coffee|After 2 weeks of coffee abstinence (washout), participants who were coffee drinkers were randomly allocated to receive either 4 sachets (1.8g each) of decaffeinated instant coffee per day for 3 weeks. Participants were blinded to coffee contents.
223615038|NCT01013129|GENETIC|DNA analysis|saliva samples will be collected from men (probands) who join the study.
223615039|NCT01013129|GENETIC|polymorphism analysis|we will genotype DNA samples (buccal) from all probands and conduct a traditional case-control analysis
223615040|NCT01013129|OTHER|laboratory biomarker analysis|10ml blood specimen will be obtained and processed (on probands locally-consented and/or those who have an appointment at the VA in Portland, Oregon) to allow for analyses of erythrocyte fatty acids and future nutrient and DNA analyses
223615041|NCT01013129|OTHER|medical chart review|PSA results, prostate biopsy pathology reports and clinician notes related to the biopsy are reviewed for final data analysis
223615042|NCT01013129|OTHER|questionnaire administration|probands are asked to complete questionnaires on 1) family history of cancer, 2) diet history over the past year, 3) employment environment and risk factors and/or 4) changes to diet, medications since enrollment in originating case control study
223615043|NCT01013129|PROCEDURE|evaluation of cancer risk factors|pathology reports will be reviewed for probands whose prostate biopsies reveal cancer; these factors will be evaluated for cancer risk factors
223615044|NCT01013129|PROCEDURE|study of high risk factors|prostate biopsy pathology reports will be reviewed for high risk factors
223760421|NCT01653093|PROCEDURE|diffusion-weighted magnetic resonance imaging|Undergo diffusion-weighted MRI
223760422|NCT01653093|PROCEDURE|dynamic contrast-enhanced magnetic resonance imaging|Undergo DCE-MRI
223760423|NCT01653093|PROCEDURE|magnetic resonance spectroscopic imaging|Undergo MR spectroscopy
223760424|NCT00081614|DRUG|Avastin (bevacizumab)|
223509783|NCT00651807|DRUG|etonogestrel|Lowest dose of Org 3236 per two days, lowest dose of Org 3236 per day, highest dose of Org 3236 per day for 8 weeks
223509784|NCT00651807|DRUG|Placebo|Every day one tablet up to 8 weeks
223760425|NCT00081614|DRUG|Tarceva (erlotinib HCl)|
223615045|NCT06133335|OTHER|Periodontal examination|"Periodontal examination is performed using PCP UNC15 periodontal probe (common diagnostic method not added by research).~Gingival smear from various points in the oral cavity. This intervention consists in a smear of gingival area with an absorbent paper point into the space between the gum and the tooth (Jourdain et al. 2018). The objective of this technique is to remove the various elements of the periodontal pocket and in particular the desquamated cells."
223615046|NCT00333021|DRUG|Fondaparinux sodium|
223615047|NCT00333021|DRUG|GSK576428|
223615048|NCT02828371|DEVICE|stepping verticalization|After patient positioning, the slope of the tilt table was gradually increased from 0° to 20°, 40° and then 60° in a time span of nine minutes. The stepping frequency was set at 20 steps/min for the entire treatment. Cardiovascular and respiratory parameters were continuously monitored. The net time of the session was 30 minutes
223615049|NCT02828371|OTHER|conventional mobilization|in-bed physiotherapy (mobilization exercises in supine and sitting position on bed, without out-of-bed mobilization nor verticalization)
223615050|NCT00908453|DRUG|fosphenytoin|15mg/kg, 18mg/kg or 22.5mg/kg of loading doses of fosphenytoin
223615051|NCT06079385|OTHER|Acupuncture treatment|Acupuncture treatment with needles
223615052|NCT00567450|DRUG|ropivacaine|30ml of a mixture of ropivacaïne 0.75%
223615053|NCT00567450|DRUG|ropivacaine plus mepivacaine|30ml of a mixture of ropivacaïne 0.75% associated with mepivacaïne 1.5%
223760426|NCT04552691|DRUG|Pegunigalsidase Alfa|Pegunigalsidase alfa is a recombinant ERT (enzyme replacement therapy) used to treat Fabry disease (dosage: 1 mg/kg body weight every 2 weeks).
223615054|NCT03790111|DRUG|telotristat ethyl|XERMELO (telotristat ethyl) tablets administered as 250 mg (1 x 250-mg tablet) three times a day plus first line therapy for 7 days, then XERMELO (telotristat ethyl) tablets administered as 500 mg (2 x 250-mg tablets) three times a day plus first line therapy for the duration of the study
223615055|NCT03074409|DRUG|oxytocin|self-administration of oxytocin (nasal spray)
223615056|NCT03074409|DRUG|placebo|self-administration of placebo (nasal spray)
223615057|NCT01432405|DRUG|Exenatide|Type 2 diabetic subjects will be randomized to receive exenatide 10 micrograms injected subcutaneously twice daily for 12 months. Prior to randomization, all subjects will receive baseline measurements of fasting plasma glucose, plasma adipocytokines, Free Fatty Acids, insulin, plasma lipids, and HbA1c as well as measurement of liver fat content with magnetic resonance spectroscopy. All subjects will undergo repeat measurements of fasting plasma glucose, Free Fatty Acids, insulin and adipocytokines as well as hepatic fat content determination at the end of the 12 month treatment period.
224075443|NCT06221020|BEHAVIORAL|ERAS Patient Satisfaction Questionnaire(ERAS-PSQ)|The ERAS Patient Satisfaction Questionnaire (ERAS-PSQ) is a satisfaction survey specifically designed for patients who have undergone treatment following the Enhanced Recovery After Surgery (ERAS) protocols. This questionnaire aims to evaluate the patients' satisfaction and experience with the ERAS approach. Typically, it includes questions about various aspects of their treatment and care, such as pain management, the recovery process, the quality of nursing care, and communication with the medical team. The ERAS-PSQ is an important tool for assessing how well the ERAS protocols are received by patients and for identifying areas for improvement in patient care within the ERAS framework.
223615058|NCT01432405|DRUG|Pioglitazone|Type 2 diabetic subjects will be randomized to receive pioglitazone 45 mg daily orally for 12 months. Prior to randomization, all subjects will receive baseline measurements of fasting plasma glucose, plasma adipocytokines, Free Fatty Acids, insulin, plasma lipids, and HbA1c as well as measurement of liver fat content with magnetic resonance spectroscopy. All subjects will undergo repeat measurements of fasting plasma glucose, Free Fatty Acids, insulin and adipocytokines as well as hepatic fat content determination at the end of the 12 month treatment period.
223615059|NCT02467179|DEVICE|Amigo™ Robotic Catheter Manipulation|"Ablation is a standard procedure that patients may undergo for the atrial flutter.~In this study, this group will be assigned to robotic catheter manipulation."
223615060|NCT02467179|DEVICE|Manual Catheter Manipulation|"Ablation is a standard procedure that patients may undergo for the atrial flutter.~In this study, this group will be assigned to manual catheter manipulation."
223615061|NCT03921827|DEVICE|Enhance External Counterpulsation Therapy|EECP therapy would be administered to this group for 1-hour a day for a total of 35 sessions
223615062|NCT02494960|BEHAVIORAL|The brief smoking cessation AWARD model|"* Ask whether or not the patient currently smokes~* Warn the patients that at least one out of two smokers will be killed by smoking. Recent research shows that two out of three smokers will be killed by smoking. The 10-20-second script could be like 'I warn you that smoking can kill you by many serious diseases and that your chance to be killed prematurely by smoking is about 50% to 67%.~* Advice the patients to quit now or as soon as possible because quitting can reduce the excess risks substantially.~* Refer the patients to a smoking cessation clinic or call telephone quitlines (if available) as soon as possible, emphasizing that smoking cessation counsellors are caring and helpful.~* Do it again: Repeat the intervention among smokers who fail to quit or relapse, and encourage them to try to quit again."
223615063|NCT02494960|BEHAVIORAL|Placebo intervention|Advice the smokers to eat vegetables, and engage in regular physical activities, and offer the smokers a card which contains information about the benefits of eating vegetables and a pictorial information leaflet which shows the recommended amount of vegetables and fruits an adult should eat a day
223615064|NCT02796677|DRUG|Aclidinium bromide 400 μg/Formoterol Fumarate 12 μg (AB/FF 400/12 μg)|Inhalation powder
223615065|NCT02796677|DRUG|Aclidinium bromide 400 μg (AB 400 μg)|Inhalation powder
223615066|NCT02796677|DRUG|Formoterol fumarate 12 μg (FF 12 μg)|Inhalation powder
223615067|NCT02796677|OTHER|Placebo to AB/FF 400/12 μg, AB 400 μg and FF 12 μg|Inhalation powder
223760427|NCT03601754|DIAGNOSTIC_TEST|Treadmill/Bicycle exercise testing|"Exercise testing will be scheduled on the same day as the enrollment visit and within 30 days after post-implant visit.~The standard protocol will be typically set at an initial workload of 15Watts and go up by increments of 10 Watts every 3 minutes, as follows:~Stage 1 - 15 W Stage 2 - 25 W Stage 3 - 35 W Stage 4 - 45 W"
223615068|NCT02796677|DRUG|Tiotropium 18 μg (TIO 18 μg)|Powder in capsules for oral inhalation
223615069|NCT02796677|OTHER|Placebo to TIO 18 μg|Powder in capsules for oral inhalation
223615070|NCT02752880|DRUG|YH1 group|Participants were randomly assigned 1:1 to receive either YH1 or placebo for 12 consecutive weeks.
223615071|NCT02752880|DRUG|placebo group|Participants were randomly assigned 1:1 to receive either YH1 or placebo for 12 consecutive weeks.
223615072|NCT04921566|DRUG|Torasemide tablet 10 mg|Torasemide is manufactured by Pharmtechnology LLC, Belarus. Each tablet contains 10 mg of torasemide.
223615073|NCT04921566|DRUG|Toradiur® tablet 10 mg|Toradiur® is manufactured by MEDA Manufacturing Cologne, Germany. Each tablet contains 10 mg of torasemide.
223615074|NCT01686334|BIOLOGICAL|DC vaccine|Autologous WT1 mRNA-electroporated DCs
223615075|NCT01103765|PROCEDURE|post dilatation after stent deployment|Post-dilatation with a noncompliant balloon larger 0.25mm than stent balloon.
223615076|NCT01103765|PROCEDURE|stent deployment without post-dilatation|stent deployment without systematic post dilatation
223615077|NCT01532947|PROCEDURE|post placement|placement of an endocanalar post
223615078|NCT03372785|DRUG|aspirin, betaloc, atorvastatin, rosuvastatin, clopidogrel, ticagrelor|Optimal medical therapy includes dual antiplatelet therapy and statins (aspirin, clopidogrel, ticagrelor, atorvastatin, rosuvastatin, betaloc). And optimal medical therapy should include adequate ventricular rate-limiting medication (i.e. Beta-blocker or rate-limiting calcium antagonist) where appropriate. Anti-anginal therapy should be used if the patients have symptom.
223615079|NCT03372785|DEVICE|coronary wires. stents or coronary balloons|all species of drug-eluting stent ((such as Xience, Endeavor, Resolute) implantation or balloon expansion (POBA)
223615080|NCT01319669|DRUG|recombinant human thrombopoietin|Recombinant human thrombopoietin injection in 15000U/ml/amp.
223615081|NCT06142539|RADIATION|CT Radiation Doses|Obtaining Low CT Radiation Doses by Adjusting Dose Levels
223615082|NCT04914780|BEHAVIORAL|Education|Education intervention with mobile application for 4 weeks
223615083|NCT01045967|DRUG|Lansoprazole|30 mg delayed-release Capsule
223615084|NCT01045967|DRUG|Prevacid®|30 mg delayed-release Capsule
223615085|NCT01525836|DRUG|rituximab; recombinant human thrombopoietin (rhTPO)|patients in recombination treatment group take Rituximab( intravenously ,100 mg weekly for 4 consecutive weeks); in combination with Rh-TPO( subcutaneously , 300U/kg for 14 consecutive days,followed by flexible treating dosage so as to keep the platelet count above 50×10\^9/L until the 29th day)
223615086|NCT01525836|DRUG|Rituximab|patients in recombinant treatment group take Rituximab intravenously at 100 mg weekly for 4 consecutive weeks（Day 1,8,15,22)
223615087|NCT05582486|BEHAVIORAL|obstetric violence prevention education intervention|While the training program for the prevention of obstetric violence consisting of 16 sessions was applied by the researcher to the midwives and nurses in the experimental group, no intervention was applied to the midwives and nurses in the control group.
223615088|NCT03314493|DRUG|Spironolactone 25Mg Tablet|Patients with coronary calcium score \> 30 were treated with spironolactone for 12 months
223615089|NCT01863381|DEVICE|Tympanic membrane displacement (TMD)|"The CCFP Analyser has a passive mode and an active mode. When used in active mode, the device generates a tone burst that is transmitted to the ear to elicit contraction of the stapedius muscle. The passive mode requires no stimulus or sound burst.~For the lying, sitting, standing, and 10-degree head-down tilt conditions, the active mode will be used. Each condition comprises 13 stimuli of 0.3s duration.~Overnight recording of non-invasive ICP will be done using the passive mode of the CCFP device."
223615090|NCT01863381|DEVICE|DPOAE|DPOAE measurement uses a clinical acoustic probe to record the ear's response to two simultaneous tones. DPOAE measurements will be made for 13 tones. The total measurement time for each condition is 2-4 minutes.
223615091|NCT01248195|DRUG|Amisulpride open label|4-week open label amisulpride treatment
223615092|NCT01248195|DRUG|6-week amisulpride double blind treatment|6-week amisulpride double blind treatment
223615093|NCT01248195|DRUG|6-week olanzapine double blind treatment|6-week olanzapine double blind treatment
223615094|NCT01248195|DRUG|12-week clozapine open-label treatment|12-week clozapine open-label treatment
223615095|NCT01248195|BEHAVIORAL|Psychosocial intervention|Psychosocial intervention
223615096|NCT03042117|OTHER|periodontal probing|A periodontal probe will be inserted between the tooth and the gum in the gingival sulcus and a measurement of the pocket depth will be measured by a trained dentist in all subjects
223615097|NCT04541407|DRUG|Temozolomide plus Osimertinib|Temozolomide is an oral alkylating chemotherapy which has good CNS penetration and has demonstrated CNS responses in both primary brain tumors (e.g., glioblastoma and anaplastic astrocytoma) and in small cell lung cancer (SCLC) brain metastases. Preclinical data from glioblastoma suggests potential synergy of concurrent ALK or EGFR inhibition with temozolomide and early phase trials in glioblastoma are ongoing investigating such combinations. It is felt that combining temozolomide with osimertinib or lorlatinib may be beneficial for patients with progressive CNS disease on either of these TKIs because of the high CNS penetration of temozolomide, good CNS activity of temozolomide in other tumor types and preclinical data from glioblastoma suggesting a potential enhanced effect of concurrent EGFR and ALK/ROS1 inhibition with temozolomide.
223615098|NCT04541407|DRUG|Temozolomide plus Lorlatinib|Temozolomide is an oral alkylating chemotherapy which has good CNS penetration and has demonstrated CNS responses in both primary brain tumors (e.g., glioblastoma and anaplastic astrocytoma) and in small cell lung cancer (SCLC) brain metastases. Preclinical data from glioblastoma suggests potential synergy of concurrent ALK or EGFR inhibition with temozolomide and early phase trials in glioblastoma are ongoing investigating such combinations. It is felt that combining temozolomide with osimertinib or lorlatinib may be beneficial for patients with progressive CNS disease on either of these TKIs because of the high CNS penetration of temozolomide, good CNS activity of temozolomide in other tumor types and preclinical data from glioblastoma suggesting a potential enhanced effect of concurrent EGFR and ALK/ROS1 inhibition with temozolomide
223615099|NCT05314868|DEVICE|PhotoFix|Surgical repair with patch.
223760428|NCT03237767|OTHER|MIE|"The moderate intensity exercise (MIE) condition will begin and end with an appropriate warm-up (3 minutes at 20 W) and cool-down (2 minutes at 20 W), respectively. Throughout all exercising procedures, participants will maintain a pedal cadence of 60-80 rpm, with the average being noted and kept consistent between trials. Additionally, verbal encouragement will be given depending on the participant's preference, and kept consistent between visits.~The MIE bout will be in coherence with the physical activity guidelines for people with CF (150 min/week of moderate to vigorous physical activity). For the MIE, participants will cycle for approximately 30 minutes at 90% of their gas exchange threshold."
223760429|NCT03237767|OTHER|HIIE|"The high-intensity interval exercise (HIIE) condition will begin and end with an appropriate warm-up (3 minutes at 20 W) and cool-down (2 minutes at 20 W), respectively. Throughout all exercising procedures, participants will maintain a pedal cadence of 60-80 rpm, with the average being noted and kept consistent between trials. Additionally, verbal encouragement will be given depending on the participant's preference, and kept consistent between visits.~The HIIE will be matched for the projected work done during the MIE. The HIIE protocol has been extrapolated from recent reports which have shown improvements in glycaemic control and vascular endothelial function. Specifically, participants will cycle at 90% of their peak power output for 60 seconds, followed by 60 seconds of active recovery."
223760430|NCT03047135|DRUG|Olaparib|Olaparib will be dispensed to patients on Day 1 and every 28 days thereafter until the patient completes the study, withdraws from the study or closure of the study.
223760431|NCT05790876|PROCEDURE|SSO2 therapy|SSO2 therapy consists of overoxygenating the patient's blood and delivering it to the origin of the LAD for 60 min. Improvement in CMD will be assessed by comparing angio-IMR before and after 60 minutes of SSO2 therapy measured on conventional angiographic images
223760432|NCT04374890|DEVICE|CP308|3 weeks of baseline followed by 2x3 weeks use of the test device
223615100|NCT01777308|BIOLOGICAL|Meningococcal conjugate vaccine GSK134612|Single dose to be administrated intramuscularly in the deltoid of the non-dominant arm
223615101|NCT04381858|DRUG|Plasma from COVID-19 convalescent patient|"Infusion of 400 ml (2 units) of plasma.~Plasma donated from convalescent patients will be extracted in strict compliance with the following criteria:~* History of a clinical event with symptoms attributed to COVID-19 and a positive PCR test for COVID-19~* Further confirmation of a negative PCR test for COVID-19~* In order to be eligible plasma donors must complete at least 14 days after the last negative PCR in the absence of any symptom attributable to COVID-19 infection~* IgG antibodies for COVID-19 must be confirmed POSITIVE when a qualitative assay is being used~* When quantification of IgG antibodies for COVID-19 is available a title \> 1: 640 will be required for inclusion.~* Apheresis will be used as the only method for plasma extraction."
223760433|NCT01783951|BIOLOGICAL|DC-CIK|Patients will be receive DC-CIK cell therapy at days 15, 17 and 19 per cycle and received cycles of treatment once every 21 days.
223760434|NCT01783951|DRUG|S-1|The dose of S-1 is determined according to the body surface area as follows: \<1.25 m2, 40 mg; 1.25 to \<1.5 m2, 50 mg; and ≥1.5 m2, 60 mg, given twice daily after meals for 14 days followed by 7 days rest.
223760435|NCT01783951|DRUG|Cisplatin|Cisplatin is administered at 75 mg/m2 intravenously over 1 to 3 hours every 21 days.
223760436|NCT04889742|DEVICE|loco-regional hyperthermia|loco-regional hyperthermia by the use of microwave, capacitive, or superficial hyperthermia devices.
223760437|NCT02486380|DEVICE|Toffee full face mask/toffee nasal mask|Toffee full face mask/toffee nasal mask
223760438|NCT02162290|OTHER|Interval exercise training|Exercise bouts in low and high intensities
223760439|NCT02162290|OTHER|Continuous exercise training|
223760440|NCT02006277|DRUG|Crizotinib prototype microsphere 0.529 mg/mg|Subjects will take each sample into their mouths, swirl the sample for approximately 30 seconds, and then expectorate into an empty cup.
223760441|NCT02006277|DRUG|crizotinib prototype microsphere 0.470 mg/mg|Subjects will take each sample into their mouths, swirl the sample for approximately 30 seconds, and then expectorate into an empty cup.
223760442|NCT02006277|DRUG|crizotinib prototype microsphere 0.420 mg/mg|Subjects will take each sample into their mouths, swirl the sample for approximately 30 seconds, and then expectorate into an empty cup.
223615102|NCT04381858|DRUG|Human immunoglobulin|Human immunoglobulin 0.3 gr/kg/day (5 doses)
223615103|NCT03212326|DRUG|Perflutren Lipid Microsphere Intravenous Suspension [DEFINITY]|Perflutren 1.3mL diluted in 50 mL is infused intravenously, and intracardiac echo imaging is recorded to analyze for areas of possible myocardial scar, which is then compared with areas of abnormal electrical signal via direct catheter mapping which is performed during ablation of ventricular tachycardia.
223615104|NCT00261365|DRUG|Ipilimumab|Solution, Intravenous, 3 mg/kg, 3 weeks, 12 - 48 weeks depending on the response.
223760443|NCT02006277|DRUG|crizotinib oral solution|Subjects will take each sample into their mouths, swirl the sample for approximately 30 seconds, and then expectorate into an empty cup.
223760444|NCT02006277|DRUG|crizotinib prototype microsphere 0.529 mg/mg|Subjects will receive a single 250-mg oral dose of crizotinib.
223760445|NCT02006277|DRUG|crizotinib prototype microsphere 0.470 mg/mg|Subjects will receive a single 250-mg oral dose of crizotinib.
223760446|NCT02006277|DRUG|crizotinib prototype microsphere 0.420 mg/mg|Subjects will receive a single 250-mg oral dose of crizotinib.
224201910|NCT06652776|OTHER|Pharmacological treatment|"All pharmacological and non pharmacological treatments for COPD will be assessed and monitored during the retrospective and prospective phase of the study, and will include:~* inhaled bronchodilators (long term beta-2 agonists and cholinergic antagonists), inhaled corticosteroids and their combinations~* mucolytics~* biologics for COPD (monoclonal antibodies)~* roflumilast~* chronic oral azythromicin~* pulmonary rehabilitation~* oxygen therapy~* non invasive/invasive ventilation"
223615105|NCT00261365|DRUG|Ipilimumab|Solution, Intravenous, 10 mg/kg, 3 weeks, 12 - 48 weeks depending on the response.
223615106|NCT02016976|DRUG|EMLA Analgesic Cream|
223615107|NCT02016976|DRUG|Dormicum 2.5 mg and Pethidine 25 mg|Routine anesthesia and analgesia ( Dormicum 2.5 mg and Pethidine 25 mg )normally given to patients before and during pacemaker implantation
223615108|NCT04456023|BIOLOGICAL|Tisagenlecleucel|A single intravenous (i.v.) infusion of 0.6 - 6.0×10\^8 CAR positive viable T cells.
223615109|NCT03111303|DEVICE|mechanical ventilation|Connection to mechanical ventilator
223615110|NCT03910504|DRUG|Rocuronium 0.3 mg*kg|Patients randomized to the control group will receive rocuronium at 0.3 mg\*kg ev bolus at the induction of anesthesia.
223615111|NCT03910504|DRUG|No Rocuronium|Patients randomized to the interventional group will not receive neuromuscular blockade at the induction of anesthesia.
223615112|NCT06244004|DRUG|Antiandrogen Therapy|Undergo SOC ADT
223615113|NCT06244004|PROCEDURE|Bone Scan|Undergo bone scan
223615114|NCT06244004|PROCEDURE|Computed Tomography|Undergo CT
223615115|NCT06244004|DRUG|Cytotoxic Chemotherapy|Receive SOC cytotoxic chemotherapy
223615116|NCT06244004|PROCEDURE|FDG-Positron Emission Tomography|Undergo FDG-PET
223615117|NCT06244004|RADIATION|Radiation Therapy|Undergo MDRT
223615118|NCT04760756|OTHER|Fragility Fracture Integrated Rehabilitation Management|"* At least 2 hours of rehabilitation management per day~* Including occupational therapy (training to improve daily life performance)~* Inpatient (the first 2 weeks): daily management (body control ability, mobility ability, hygiene management, etc.)~* Outpatient (2-6 weeks): management once a week~* The management period is for 2 weeks (1 week after surgery)"
223615119|NCT04314908|PROCEDURE|Apical enlargement|"The teeth in this group will be treated according to the guidelines for retreatment in single-session. The filling will remove and cavity will be opened. The working length will be measured using apex locator and the 0 point will be based on. After standard irrigation protocol, root canals will be obturated with gutta percha and root canal sealer. Coronal restoration will complete using composite and/or fully crown if necessary."
223615120|NCT04314908|PROCEDURE|Apical enlargement + Sonic Activation Assisted Irrigation|"The teeth in this group will be treated according to the guidelines for retreatment in single-session. The filling will remove and cavity will open. The working length will be measured using apex locator and the 0 point will be based on. After standard irrigation protocol, sonic activation assisted irrigation will be applied to the root canals. Then the teeth were obturated with gutta percha and root canal sealer. Coronal restoration will complete using composite and/or fully crown if necessary."
223615121|NCT04314908|PROCEDURE|Non Apical enlargement|"The teeth in this group will be treated according to the guidelines for retreatment in single-session. The filling will remove and cavity will open. The working length will be measured using apex locator and 1 mm shorter than the 0 point will be based on. After standard irrigation protocol, root canals will be obturated with gutta percha and root canal sealer. Coronal restoration will complete using composite and/or fully crown if necessary."
223615122|NCT04314908|PROCEDURE|Non Apical enlargement + Sonic Activation Assisted Irrigation|"The teeth in this group will be treated according to the guidelines for retreatment in single-session. The filling will remove and cavity will open. The working length will be measured using apex locator and 1 mm shorter than the 0 point will be based on. After standard irrigation protocol, sonic activation assisted irrigation will be applied to the root canals. Then the teeth were obturated with gutta percha and root canal sealer. Coronal restoration will complete using composite and/or fully crown if necessary."
223615123|NCT00291135|DRUG|letrozole|Letrozole 2.5 mg daily
223615124|NCT02219464|DEVICE|Nasopharyngeal catheter|
223615125|NCT02219464|DEVICE|Nasal Cannula|
223615126|NCT02219464|PROCEDURE|Oxygen Supplementation|Initially set at 3 liters/minute
223615127|NCT02219464|PROCEDURE|Sedation|Midazolam 2mg IV, Fentanyl 100mcg IV, Propofol 100 mcg/kg/min. Additional doses of propofol at the discretion of the attending anesthesiologist.
223615128|NCT01909895|OTHER|Anger Induction|The participant is asked to recall an incident in the recent past during which they became moderately to extremely angry, or is asked to read statements out loud evoking moderate to extreme feelings of anger. The participant is asked to take a few moments to bring the details of the incident to mind and, when ready, to describe the incident in great detail to the experimenter. Participants are asked to describe key elements, such as any dialogue that transpired during the incident, along with other details of the incident, particularly regarding the feelings of that particular emotion experienced at the time. In so doing, the experimenter works to re-elicit the emotions that accompanied the original incident. The duration of the negative emotion induction task is 8 minutes.
223615129|NCT01909895|OTHER|Depressed Mood Induction|The participant will be asked to undergo a validated depression/sadness induction task.
223615130|NCT01909895|OTHER|Anxiety Induction|The participant will be asked to undergo a validated anxiety induction task.
223615131|NCT01909895|OTHER|Neutral emotion task|This is a neutral control task that each of the negation emotion induction tasks will be compared to.
223615132|NCT04834180|DIETARY_SUPPLEMENT|Hypocaloric diet plan|The hypocaloric diet is one in which there is a reduction of daily calories or foods with high caloric density usually in order to aid weight loss.
223615133|NCT04834180|OTHER|Auricular Acupuncture|Auriculotherapy is a technique derived from traditional acupuncture developed into a distinct treatment system of its own. It is based on either, the introduction of needles (auricular acupuncture), or pressure with Vaccaria seeds (acupressure). Those forms of auriculotherapy are applied on a set of anatomical maps at a specific point in the auricular region.
223760447|NCT02006277|DRUG|crizotinib capsule|Subjects will receive a single 250-mg oral dose of crizotinib.
223615134|NCT04834180|OTHER|Acupressure|Auriculotherapy is a technique derived from traditional acupuncture developed into a distinct treatment system of its own. It is based on either, the introduction of needles (auricular acupuncture), or pressure with Vaccaria seeds (acupressure). Those forms of auriculotherapy are applied on a set of anatomical maps at a specific point in the auricular region.
223760448|NCT02006277|DRUG|crizotinib oral solution|Subjects will receive a single 250-mg oral dose of crizotinib.
223760449|NCT05081856|OTHER|mobilization with moduler medical equipment carring vehicle|Mobilization of the patients was carried out with the vehicle in their modular vehicle.
223760450|NCT00886210|PROCEDURE|intra abdominal drain|Under general anesthesia, and same antibiotics (3rd generation cephalosporin). Surgery was performed using conventional four ports umbilical port, port below xiphoid and two ports below right costal margin. Pneumoperitonum at pressure 12 mmHg. In group A nelton catheter (no 20) inserted at the end of operation.
223615135|NCT03695224|DIAGNOSTIC_TEST|Topological perception test|Participants' topological perception are tested with self-designed devices. Participants are asked to respond to the figures shown on the screen, and a final score will appear after they finish all the questions.
223615136|NCT06136364|BIOLOGICAL|CAR-T|CAR-T immunotherapy targeting CD7+
223615137|NCT01138423|DRUG|Aliskiren|Once daily treatment with aliskiren for 8-weeks, according to the following regiment: once daily (morning time) 150 mg during the first 2 weeks, followed by once daily (morning time) 300 mg during the remaining 6 weeks. Coincidental intake of grapefruit(juice) should be avoided. This treatment interval is followed by a one-week tapering period: 150 mg on day 1, 2, 3, 4, 5 and 7.
223615138|NCT01138423|DRUG|Moxonidine|Once daily treatment with moxonidine for 8-weeks, according to the following regiment: once daily (morning time) 0.2 mg during the first 2 weeks, followed by once daily (morning time) 0.4 mg during the remaining 6 weeks. Coincidental intake of grapefruit(juice) should be avoided. This treatment interval is followed by a one-week tapering period: 0.2 mg on day 1, 2, 3, 4, 5 and 7.
223615139|NCT01138423|DRUG|Hydrochlorothiazide|Once daily treatment with hydrochlorothiazide for 8-weeks, according to the following regiment: once daily (morning time) 12.5 mg during the first 2 weeks, followed by once daily (morning time) 25 mg during the remaining 6 weeks. Coincidental intake of grapefruit(juice) should be avoided. This treatment interval is followed by a one-week tapering period: 12.5 mg on day 1, 2, 3, 4, 5 and 7.
223615140|NCT01138423|DRUG|Placebo (for aliskiren)|Once daily treatment with placebo tablets for 8-weeks, according to the following regiment: once daily (morning time) 1 tablet during the first 2 weeks, followed by once daily (morning time) 2 tablets during the remaining 6 weeks. Coincidental intake of grapefruit(juice) should be avoided. This treatment interval is followed by a one-week tapering period: 1 tablet on day 1, 2, 3, 4, 5 and 7.
223615141|NCT01138423|DRUG|Placebo (for moxonidine and hydrochlorothiazide)|Once daily treatment with placebo capsules for 8-weeks, according to the following regiment: once daily (morning time) 1 capsule during the first 2 weeks, followed by once daily (morning time) 2 capsules during the remaining 6 weeks. Coincidental intake of grapefruit(juice) should be avoided. This treatment interval is followed by a one-week tapering period: 1 tablet on day 1, 2, 3, 4, 5 and 7.
223615142|NCT03327909|BEHAVIORAL|TAKE vs. HOLD|All participants will be told to take once daily antihypertensive medications at night. Timing of other antihypertensive medication administration will differ depending on whether the participant is randomized to the TAKE or HOLD arm.
223760451|NCT00886210|PROCEDURE|LC without drain|Under general anesthesia, and same antibiotics (3rd generation cephalosporin). Surgery was performed using conventional four ports umbilical port, port below xiphoid and two ports below right costal margin. Pneumoperitonum at pressure 12 mmHg. In group no drain at the end of operation.
223760452|NCT03715608|OTHER|Psychological Intervention|The patients in the intervention group received psychological counseling and corresponding medication after the operation. Psychotherapy was based on the clinical expertise of the psychosocial specialist from Peking University Sixth Hospital, who selected the most appropriate plan for each patient.
223760453|NCT06321874|PROCEDURE|Oxygen|
223760454|NCT02117037|OTHER|blood sample|
223760455|NCT01807052|OTHER|laboratory biomarker analysis|Correlative studies
223760456|NCT03778151|DEVICE|REPETITIVE TRANSCRANIAL MAGNETIC STIMULATION|daily treatment session of REPETITIVE TRANSCRANIAL MAGNETIC STIMULATIO will be applied over precuneus for 20 minutes of consecutive blocks of 20Hz pulses for two seconds followed by 28 seconds of no stimulation.
223760457|NCT00144365|DRUG|Antiretroviral therapy|
223760458|NCT05520008|OTHER|Game-based exercise|Patients in the active group will put on a sensor connected to a tablet to play a game-based foot/ankle exercise twice a day for 5 minutes for four weeks.
223760459|NCT00233727|PROCEDURE|HPV DNA Testing + Cryosurgery|"Patients will undergo a Screen and Treat program utilizing HPV DNA testing of clinician-collected cervical samples, followed by cryosurgery of screen positive women."
224201911|NCT06652373|BEHAVIORAL|Behavioural change through education|The content of the perinatal grief counselling training to be used in the study will be created in 8 modules and will be applied to midwives. The planned perinatal grief counselling training for midwives will be carried out online and it is aimed that midwives gain perinatal grief counselling skills and competence and increase their competence to cope with the problems they may encounter in the counselling process.
224201912|NCT06653712|DIAGNOSTIC_TEST|Diagnostic Test|"The following clinical data sources are used:~* Personal interview (anamnesis)~* Physical examination~* Questionnaires~* Functional assessment~* Imaging techniques~The following biological materials are used:~• Max. 30 ml of blood"
224201913|NCT06653374|BEHAVIORAL|Infant, Premature|This intervention is distinct as it focuses specifically on observational monitoring and evaluation of neonatal outcomes without applying a therapeutic or procedural treatment. Unlike other interventional studies, the emphasis is on analyzing standard care practices, risk factor exposures (e.g., prematurity, maternal complications), and their impact on neonatal morbidity and mortality. The intervention involves systematic data collection and longitudinal follow-up to identify patterns and associations, rather than introducing new clinical techniques or treatment
224201914|NCT06652594|BEHAVIORAL|Eye Education Intervention|Doctors and nurses will educate parents about eye health in response to theirchild's myopia progression at baseline, 1 month, 3 months, 6 months.
224201915|NCT06652594|BEHAVIORAL|Control|Parents in the control group will not receive eye health education informationfrom doctors and nurses.
224201916|NCT06653881|OTHER|ARCHWIRE|Alignment efficiency of the archwires will be compared using little's irregularity index between the two groups
224201917|NCT06652165|DRUG|zanubrutinib combined with BEAM|zanubrutinib：160mg oral bid D-8-D-2 camustine: 300mg/m2 vgtt qd D-8 etoposide: 100mg/m2/d vgtt q12h D-7-D-4 cytarabine: 200mg/m2/d vgtt q12h D-7-D-4 melphalan: 140mg/m2 vgtt qd D3-D-2
224201918|NCT06652165|DRUG|BEAM|camustine: 300mg/m2 vgtt qd D-8 etoposide: 100mg/m2/d vgtt q12h D-7-D-4 cytarabine: 200mg/m2/d vgtt q12h D-7-D-4 melphalan: 140mg/m2 vgtt qd D3-D-2
224201919|NCT02622607|DRUG|Zoledronic acid|Zoledronic acid 4 mg in 5 mL concentrated solution prepared with 100 mL calcium free infusion solution (0.9 % sodium chloride)
224201920|NCT06593574|PROCEDURE|Robotic laminectomy|Surgical robots are used to assist with laminectomy
224201921|NCT06593574|PROCEDURE|Traditional laminectomy|Instead of relying on a surgical robot, doctors perform the laminectomy themselves with an ultrasonic osteotome
223760460|NCT00233727|PROCEDURE|VIA + Cryosurgery|"Patients will undergo a Screen and Treat program utilizing visual inspection of the cervix with acetic acid (VIA), followed by cryosurgery of screen positive women."
223760461|NCT06186778|PROCEDURE|secondary colonoscopy|After the routine colonoscopy, a repeat colonoscopy of the sigmoid colon is performed
223760462|NCT06186778|PROCEDURE|conventional colonoscopy|It starts from the rectum and progresses forward to the cecum, with observations made during withdrawal: from the cecum, ascending colon, transverse colon, descending colon, and sigmoid colon to the rectum.
223760463|NCT05706688|PROCEDURE|Anesthetic technique (regional versus general)|Anesthetic technique (regional versus general)
224201922|NCT05909007|PROCEDURE|thoracic epidural insertion|thoracic epidural for pain relief after major thoracic surgery and lung transplantation
224201923|NCT03882567|OTHER|Electro Neuro adaptative Regulator|The SCENAR device has been previously described and generates high-amplitude, pulsed, damped biphasic sinusoidal current that is delivered to the tissue via a pair of concentric electrodes placed in direct contact with the target area. The intensity of the interactive waveform adjusts in response to changes in skin impedance
224201924|NCT01580696|BIOLOGICAL|E39 peptide (100mcg)/GM-CSF vaccine plus E39 booster|"100mcg lyophilized E39 peptide is suspended in bacteriostatic water for injection in individual cryovials and frozen. At the time of vaccine administration, the suspended peptide is thawed and mixed thoroughly with 250mcg GM-CSF in the syringe. This constitutes the E39 vaccine at this dose.~Subsequently, patients will receive a booster of E39 dosed at 500mcg and mixed with 250mcg of GM-CSF. The boosters will be given at 6 and 12 months after completing the primary vaccine series above."
223615143|NCT04895254|DEVICE|Diagnostic colonoscopy|The feasibility of the motorized spiral enteroscope to achieve cecum intubation in difficult colons.
223615144|NCT04895254|PROCEDURE|Therapeutic colonoscopy|The feasibility of the motorized spiral enteroscope for performing interventions such as polypectomy
223615145|NCT05219331|PROCEDURE|Ventriculoperitoneal shunt|Treatment oh hydrocephalus
223615146|NCT06134219|OTHER|MF course|A course consisting of six 2-hour-meetings every two-weeks with 10-15 participants (12 weeks in total). The meetings have different themes related to MF, such as understanding, practices for a deeper understanding of emotions, balance in everyday life with rest and activity, meditation practice to give time for brain rest, and mindfulness).
223615147|NCT06134219|OTHER|Usual health care|The usual health care consists of one or few follow-up visits with blood tests at Sahlgrenska university hospital in Gothenburg or follow-up at the primary care after the end of treatment for Graves' treatment.
223615148|NCT04738981|DRUG|UC-MSC|UC-MSC, iv, 1×10\^6 cells/kg, once a week, for 4 weeks.
223615149|NCT04738981|DRUG|Anti-CD25 mAb|Anti-CD25 mAb, iv, 20mg，twice in first week and once a week thereafter, for 4 weeks.
223615150|NCT00381004|DRUG|Cyclophosphamide|Course 1: 250 mg/m\^2 by vein over 5-30 minutes on Days 2, 3, and 4; Course 2 - 6: 250 mg/m\^2 by vein over 5-30 minutes on Days 1 - 3
223615151|NCT00381004|DRUG|Fludarabine|Course 1: 25 mg/m\^2 by vein over 5-30 minutes on Days 2,3, and 4; Course 2 - 6: 25 mg/m\^2 by vein over 5-30 minutes on Days 1 - 3
223615152|NCT00381004|DRUG|Sargramostim|Course 1: 250 mcg/m\^2 subcutaneous (SQ) on Days -1 and Days 5 - 11; Course 2 - 6: 250 mcg/m\^2 SQ on Days -1 and Days 4 - 10
223615153|NCT00381004|DRUG|Rituximab|Course 1: 375 mg/m\^2 by vein over 2-6 Hours on Day 1; Course 2 - 6: 500 mg/m\^2 by vein over 2-6 Hours on Day 1
223615154|NCT00637065|DRUG|Bosentan|Bosentan tablets - 62.5mg bd for first 4 weeks, then 125mg bd if tolerated until trial completion.
223615155|NCT00637065|DRUG|Placebo|Placebo tables - identical to active drug but without the active ingredient -
223615156|NCT02620982|DEVICE|ARIES (Extracorporal Shock Wave Application)|The treatment protocol includes 1 treatment per week for 6 weeks and an application of 5000 shockwaves per session in 5 treatment areas with 1000 SW each at energy level 4-5 (energy flux density (0.051-0.062 mJ/mm²), while moving the applicator along the penile shaft within the treatment areas. The maximum energy applied during this treatment would be 23.35J.
223615157|NCT01379716|OTHER|skin biopsy|Using a punch biopsy, the study doctor will take a small sample of skin (3mm diameter) from a pre-defined site of the subject. For PHN patients, 4 biopsies will be obtained: 2 in an area of PHN and 2 in a contralateral control site. Biopsy sites for each PHN control subject will be matched anatomically to the corresponding PHN patient with two biopsies each from symmetrical sites in a left and right dermatome. One biopsy from each site in each subject will be fixed in a left and right dermatome. One biopsy from each site in each subject will fixed yb immersion in 4% paraformaldehyde for immunocytochemical analysis, and the second biopsy form each site will be flash frozen for assessments of mRNA expression.
223615158|NCT01579435|DEVICE|transcranial direct current stimulation|Active stimulation: duration: 20 mn, intensity: 2 mA; localisation : motor cortex or cerebellum; Placebo stimulation: duration: 9 seconds, intensity: 2 mA; localisation : motor cortex or cerebellum;
223615159|NCT01116401|DRUG|leuprolide|Leuprolide acetate is a widely used GnRH agonist. In this protocol, leuprolide will be administered at a dose routinely used for treatment of endometriosis and uterine fibroids in women (one 3.75-mg intramuscular injection).
223615160|NCT00963963|BEHAVIORAL|Healthy Futures parent education|Multi-year audio CD parent education
223615161|NCT02893241|DRUG|Cafedrine/theodrenaline|
223615162|NCT02893241|DRUG|Ephedrine|
223615163|NCT01560286|BIOLOGICAL|BMN 165 (rAvPAL-PEG)|Subcutaneous injection of rAvPAL-PEG administered from 1 time up to 5 times per week between 2.5mg up to a maximum of 375mg for 24 weeks.
223615164|NCT01521026|BEHAVIORAL|Cognitive Training|12-week compensatory cognitive training in group format
223615165|NCT01545726|DRUG|QAW039|QAW039 was supplied as capsules for oral administration.
223615166|NCT01545726|DRUG|Placebo|Placebo was supplied as capsules for oral administration.
223615167|NCT02171221|DRUG|Oral DFP-11207|
223615168|NCT04059510|PROCEDURE|rectovaginal swab|Self taken rectal and vaginal swab
223760464|NCT04446065|DRUG|Previfenon®|Every capsule of Previfenon® (patent pending) provides 250 mg EGCG ≥ 98% purity with a carefully selected set of excipients to improve flowability, stabilize EGCG against early auto-oxidation, and increase its hepatoprotective activity with prolonged use.
223760465|NCT04446065|DRUG|Placebo|Participants will receive placebo starch capsules (250 mg plus excipients) identical in appearance and taste to Previfenon® capsules in a double-blind manner.
223615169|NCT04059510|PROCEDURE|pregnancy test|Urine pregnancy test
223615170|NCT04059510|PROCEDURE|Menstrual cup|Menstrual cup vaginal fluid collection
223615171|NCT04059510|PROCEDURE|Blood test|Venous blood sample
223615172|NCT04059510|OTHER|Focus group|Focus group responses will be audio-recorded, transcribed, and analysed by developing a coding framework and identifying emerging themes
223615173|NCT03255135|DEVICE|HIFU|High intensity focused ultrasound prostate cancer therapy guided by biopsy specimens and multiparametric prostate magnetic resonance using Focal One, Edap TMS, France device.
223615174|NCT05842759|PROCEDURE|Monitoring|Continuous blood pressure monitoring
223615175|NCT05842759|PROCEDURE|Norepinephrine preparation|Norepinephrine infusion will be prepared and connected to peripheral or central venous catheter (infusion will not be started)
223615176|NCT05842759|PROCEDURE|Propofol administration|Propofol infusion will be started only when clinical effects of opioid are noticeable: 1.5 mg/kg propofol in patients less than 55 years old and 1.0 mg/kg propofol in patients 55 years or older over 90 seconds
223615177|NCT05842759|PROCEDURE|Alarm adjustment|Lower mean arterial pressure alarm threshold will be set to 75 mmHg
223615178|NCT05842759|PROCEDURE|Intervention threshold|Lower mean arterial pressure intervention threshold will be 75 mmHg: continuous norepinephrine infusion will be started when mean arterial blood decreases below 75 mmHg
223615179|NCT05275816|OTHER|Comparing the appropriateness of our practice and the usability of the AUC through comparing the actual management provided at our institution with that recommended by the AUC.|"The AUC application for carpal tunnel syndrome management requires four patients' variables to generate appropriateness ratings for six different treatment options. Each procedure is rated as appropriate, maybe appropriate, or rarely appropriate. The six procedures include splint, steroid injection, carpal tunnel release, oral steroids or Ketoprofen phonophoresis, investigation of alternative diagnoses, and further investigation using an electro-diagnostic study.~To judge the usability of the AUC for the management of carpal tunnel syndrome, the required parameters of each patient were collected and entered into the AUC application by two independent authors to generate the appropriateness rating of the provided treatment for each patient. Afterwards, the agreement between the AUC recommendations and the actual treatment that was provided at our institution was assessed."
223615180|NCT05661812|DIAGNOSTIC_TEST|Quationnaires and symptom registration|Used to collect data about symptoms potentially characterising the allergy of MB. A shortened version of the MeDALL questionnaire (mechanisms of the development of allergic diseases) will be used to collect data about allergic diseases and symptoms. POEM questionnaire (Patient-Oriented Eczema Measure) will be used to evaluate atopic eczema once in the season of MB and once outside MB and pollen seasons. The participant will also register symptoms during two periods, preferably 6 weeks during MB season autumn (August-September) 2022 and 2 weeks outside MB and pollen seasons in January/February 2023. During the 8 weeks of symptom registration the participants will receive an e-mail every other day with questions regarding symptoms and medication.
223615181|NCT05661812|DIAGNOSTIC_TEST|PNIF and spirometry|To clarify and verify the symptoms registered by the participants we will perform measurements of Peak Nasal Inspiratory Flow (PNIF) and spirometry. PNIF and spirometry will be used to assess airway obstruction through the nose and lungs, and will be performed in and outside the seasons of MB and pollen. Spirometry will be performed pre and post inhalation of bronchodilating medicine (reversibility test). Some of the participants (patients and controls) will be randomised to nasal provocation test (NPT), performed outside the seasons of MB and pollen, and for those PNIF and spirometry will be carried out before and after NPT.
223615182|NCT05661812|DIAGNOSTIC_TEST|SPT, spesific IgE, pBAT and NPT|To evaluate the symptoms as specific for allergy the participants will be tested with skin prick test (SPT) with MB and common airway allergens, serum specific IgE (sIgE) to MB and common airway allergens, nasal provocation test (NPT) with MB and passive basophil activation test (pBAT) with MB. Blood samples for the sIgE and pBAT will be performed in MD season, while SPT and NPT will be performed outside seasons of MB and pollen. We will compare the results from SPT, sIgE and pBAT with the results from NPT to calculate sensitivity and specificity of SPT, sIgE and pBAT. All those tests demand that we are able to develop MB extracts that are suitable for those tests.
223615183|NCT03471247|DEVICE|In-Bed Cycle Ergometer|Physiotherapists will place the patient's legs in a specialized in-bed cycle ergometer allowing for gentle leg exercise. Exercise can performed in passive, active-assisted, or active mode.
223615184|NCT03471247|OTHER|Routine PT|Includes, based on the patient's alertness and medical stability, activities to maintain or increase limb range of motion and strength, in- and out- of bed mobility, ambulation, and assistance with optimizing airway clearance and respiratory function.
223615185|NCT05448339|COMBINATION_PRODUCT|PVHA or TACE|PVHA or TACE
223615186|NCT01302483|DRUG|3% tetracaine HCL with 0.05% oxymetazoline HCL|1 sham injection along with 3 sprays of Kovacaine Nasal Spray in each nostril; a 4-minute interval between every set of sprays. The total dose of 3% tetracaine HCL with 0.05% oxymetazoline HCL was 18 mg/0.3 mg.
223615187|NCT01302483|DRUG|Lidocaine Injection|Each subject received both an injection along with 3 sprays of isotonic saline sham in each nostril; a 4-minute interval between every set of sprays.
223615188|NCT01758809|PROCEDURE|Pre-emptive bupivacaine wound infiltration|Pre-emptive bupivacaine wound infiltration
223615189|NCT01758809|PROCEDURE|intravenous patient controlled analgesia|postoperative pain control with intravenous patient controlled analgesia
223615190|NCT00035789|DRUG|Entecavir|
223615191|NCT01773486|DRUG|Hesperidin|Citrus polyphenol, hesperidin
223615192|NCT01773486|DRUG|Placebo|Placebo matching hesperidin
223615193|NCT05710055|DIETARY_SUPPLEMENT|Study product A (Wonderlab wonder4shape)|Partipants in this arm need to consume one bottle (2g) of this product once a day for 3 months
224201925|NCT01580696|OTHER|Non-vaccine clinically matched control group|HLA-A2-negative patients or HLA-A2-positive patients who decline the vaccine will be followed clinically as matched controls for disease recurrence/progression. No experimental treatment will be administered to this group.
224201926|NCT01580696|BIOLOGICAL|E39 peptide (500mcg)/GM-CSF vaccine plus E39 booster|"500mcg lyophilized E39 peptide is suspended in bacteriostatic water for injection in individual cryovials and frozen. At the time of vaccine administration, the suspended peptide is thawed and mixed thoroughly with 250mcg GM-CSF in the syringe. This constitutes the E39 vaccine at this dose.~Subsequently, patients will receive a booster of E39 dosed at 500mcg and mixed with 250mcg of GM-CSF. The boosters will be given at 6 and 12 months after completing the primary vaccine series above."
223760466|NCT05440292|DEVICE|Transcranial magnetic stimulation|For each stimulation day, low-frequency (1 Hz) ,1800 pulses(intensity of 100% resting motor threshold(RMT), duration 30 min) rTMS stimulation were delivered on the hotspot of unaffected hemisphere(Hotspot-rTMS Group) and the motor task activation poin of unaffected hemisphere(fMRI-rTMS Group). rTMS which guided by individualized navigation delivery 5 days a week for 4 weeks.
223615194|NCT05710055|DIETARY_SUPPLEMENT|Study product B (Wonderlab wonder4shape)|Partipants in this arm need to consume one bottle (2g) of this product once a day for 3 months
223615195|NCT05710055|DIETARY_SUPPLEMENT|Study product C (Wonderlab wonder4shape)|Partipants in this arm need to consume one bottle (2g) of this product once a day for 3 months
223615196|NCT05710055|DIETARY_SUPPLEMENT|Study product D|Partipants in this arm need to consume one bottle (2g) of this product once a day for 3 months
223615197|NCT05161416|BEHAVIORAL|Bubble Blowing|Active Distraction Methods
223615198|NCT05161416|BEHAVIORAL|Cartoon Watching|Passive Distraction Methods
223615199|NCT04675385|DRUG|0.2% hyaluronic acid gel|In this split mouth study, 733 periodontal pockets of 28 patients with moderate to severe chronic periodontitis were chosen for investigation. They were divided into 2 groups: control group and experimental group. The experimental group received sub-gingival administration of 1 ml of 0.2% hyaluronic acid gel into each pocket immediately after root planing and then after 1 week, 2 weeks and 3 weeks. Clinical parameters were assessed at baseline and 6 weeks after root planing. Subgingival plaque was assessed at baseline and 6 weeks after root planing. Quantitative real-time PCR for Porphyromonas gingivalis (Pg), Treponema denticola (Td), Fusobacterium nucleatum (Fn) Tannerella forsythia (Tf) were performed at the same time.
223615200|NCT02372877|DEVICE|Amicus Red Cell Exchange in SCD patients|Each patient will be treated with one RBCx procedure using the AMICUS RBCx System
223760467|NCT02626143|OTHER|Investigational nutrient-rich whey protein formula|
223760468|NCT02626143|OTHER|Cow's milk based formula|
223615201|NCT02700308|DEVICE|Kyphoplasty|Placement and inflation of balloon prior to cement injection
223615202|NCT02700308|DEVICE|Conventional vertebroplasty|Conventional vertebroplasty
223615203|NCT04363879|PROCEDURE|Endometrial scratch with Pipelle curette|For patients in the Pipelle curette group, physicians inserted the Pipelle curette into the uterus and removed an adequate endometrial sample using vigorous motion.
223615204|NCT04363879|PROCEDURE|Endometrial scratch with Shepard catheter|For patients in the Shepard catheter group, physicians performed a four-quadrant scratch technique by inserting the Shepard insemination catheter into the uterus at 12:00. The catheter was then turned one-quarter turn and withdrawn. This was repeated two more times so that four endometrial quadrants were touched by the catheter at 12:00, 3:00, 6:00, and 9:00.
223615205|NCT01896024|BEHAVIORAL|Psychiatric Management|
223615206|NCT01896024|BEHAVIORAL|Motive-oriented therapeutic relationship/Plan Analysis|
223615207|NCT03999515|DRUG|Abiraterone Acetate|Given PO
223615208|NCT03999515|DRUG|Enzalutamide|Given PO
223615209|NCT03999515|DRUG|Erdafitinib|Given PO
223615210|NCT04933071|BEHAVIORAL|Podcast|A list of podcasts that are specified for each rotation
223760469|NCT05551806|BEHAVIORAL|Internet-based self-help cognitive behavioural therapy|The online CBT-I course will consist of an introductory module, followed by 6 weekly modules, incorporating the key CBT-I components, including sleep hygiene education, stimulus control, sleep restriction, relaxation training, and cognitive therapy.
223760470|NCT03013543|DRUG|Setmelanotide|RM-493 QD SC injection
223760471|NCT06366880|OTHER|Parenteral nutrition cycling|"This study is a single-centre, non-blinded RCT in the NICU of Pediatric Hospital of Sinaloa, Northwest, Mexico.~A total of 66 infants born ≥34 weeks of gestation who have a high likelihood of intolerance to enteral nutrition (EN) for at least 10 days will be randomised to PNC o PNT after informed parental consent. In both groups, EN will be commenced as early as clinically feasible."
223615211|NCT06528951|OTHER|Control Phase ( 6Weeks)|The participants will perform a control phase of six weeks of resistance training using the same volume for the upper (160 repetitions) and lower limbs (230 repetitions), with relative intensities ranging from 40% to 70% of 1RM. The training sequence will be the following: i) 10 minutes of warmup walking on the treadmill, ii) 1-3 sets of 5-10 repetitions at 50-70% of 1RM in the leg press, iii) 1-3 sets of 5-10 repetitions at 40-60% 1RM in the chest press, iv) 1-3 sets of 6-10 repetitions in the sit-to-stand exercise, v) 1-3 sets of 5-7 repetitions in the 1- kg medicine ball throw, and vi) 5 minutes walking on the treadmill.
223760472|NCT02048553|DEVICE|Tablet-guided ventriculostomy|"In patients of the treatment group, ventriculostomy will be performed using a mini-tablet-guided assistance based on preoperative CT imaging. Any patient meeting the inclusion criteria and not violating the exclusion criteria may participate in the TABGUIDE study and be randomized to either a guided or freehand ventriculostomy, thus defining the two distinct groups  guided  or  freehand )."
223760473|NCT02048553|PROCEDURE|Freehand|Patients in the control group will receive standard free-hand ventriculostomy using anatomical landmarks. The catheter may be placed for external drainage or internal (ventriculoperitoneal) shunting in both groups.
223760474|NCT01503827|RADIATION|WBRT|A minimum of 30 Gy in 10 fractions given as one fraction per day within 4 weeks of randomisation
223760475|NCT03635632|GENETIC|C7R-GD2.CART cells|"Active dose levels:~C7R-GD2.CART cell without lymphodepletion (Arm A or Arm B)~Dose Level 2b = 3 x 10\^7 on day 0 and day 7~Dose Level 3b = 1 x 10\^8 on day 0 and day 7.~Day 7 dose (+- 2 days) will be omitted if patients have persistent CRS (Grade 2 or higher) experienced a DLT or for other clinical concerns at the discretion of the PI."
223760476|NCT06297707|OTHER|aquatic high intensity resistive training|The experimental group participants will involve in aquatic high intensity resistive training sessions. The participants in the intervention group will receive 1 h of supervised lower limb aquatic resistance training three times a week for 12 weeks, for a total of 36 training sessions.
223760477|NCT06297707|OTHER|usual care|The control group will maintain usual care and will be asked to continue their usual leisure time activities. They will be offered the possibility of participating in two sessions consisting of 1 h of light stretching and relaxation during the 3-month intervention period.
223760478|NCT02885155|OTHER|Echocardiography|planned at regular intervals
223760479|NCT02885155|OTHER|Hemodynamic examinations (right cardiac catheterization)|planned at regular intervals
223760480|NCT05510869|PROCEDURE|"Bimanual 1.4 mm microincision cataract surgery (B-MICS) with IOL implantation in a wound-assisted technique. In bimanual MICS group a self-sealing 1.4 mm wide incision was created supratemporally"|microincision cataract surgery (phacoemulsification) with implantation of a foldable, acrylic, hydrophilic IOL Incise® MJ14, Bausch \& Lomb
223615212|NCT06528951|OTHER|15% increase in resistance training volume (10 Weeks)|The participants will perform ten weeks of resistance training, increasing their initial volume by 15% (upper limbs - 184 repetitions; lower limbs - 268 repetitions). The number of sets will range from 1 to 3, and the relative intensities from 40% to 70% 1RM. The training sequence will be the following: i) 10 minutes of warmup walking on the treadmill, ii) 1-3 sets of 3-10 repetitions at 50-70% of 1RM in the leg press, iii) 1-3 sets of 3-10 repetitions at 40-60% 1RM in the chest press, iv) 1-3 sets of 4-10 repetitions in the sit-to-stand exercise, v) 1-3 sets of 3-8 repetitions in the 1- kg medicine ball throw, and vi) 5 minutes walking on the treadmill.
223760481|NCT05510869|PROCEDURE|Coaxial 1.8 mm microincision cataract surgery (C-MICS) with IOL implantation with an injector through the 1.8 mm wide incision created temporally.|microincision cataract surgery (phacoemulsification) with implantation of a foldable, acrylic, hydrophilic IOL Incise® MJ14, Bausch \& Lomb
223760482|NCT05510869|PROCEDURE|Coaxial 2.4 mm small incision cataract surgery (C-SICS) with IOL implantation with an injector through the 2.4 mm wide incision located temporally.|small incision cataract surgery (phacoemulsification) with implantation of a foldable, acrylic, hydrophilic IOL Incise® MJ14, Bausch \& Lomb
223760483|NCT03602937|DIETARY_SUPPLEMENT|Renastep|Renastep is a ready-to-use, high energy, low volume liquid renal specific feed that can be administered enterally via tube or oral consumption.
223760484|NCT01561768|BIOLOGICAL|Novavax Quadrivalent vaccine|Quadrivalent VLP vaccine: low dose; intramuscular injection, deltoid
223760485|NCT01561768|BIOLOGICAL|Novavax Quadrivalent vaccine|Quadrivalent VLP vaccine: medium dose; intramuscular injection, deltoid
223760486|NCT01561768|BIOLOGICAL|Novavax Quadrivalent vaccine|Quadrivalent VLP vaccine: high dose; intramuscular injection, deltoid
223760487|NCT01561768|BIOLOGICAL|Novavax Trivalent vaccine|Trivalent Dose; intramuscular injection, deltoid
223760488|NCT01561768|BIOLOGICAL|cTIV|Preconfigured dose; intramuscular injection, deltoid
223760489|NCT03904771|BEHAVIORAL|Nutrition counselling + peer support|Behavioral nutrition counselling and peer support, delivered in small groups. Includes six sessions extending over 8 weeks, with participatory activities facilitated by a nutrition therapist.
223760490|NCT03904771|BEHAVIORAL|Social activation + peer support|Social activation and peer support, delivered in small groups. Includes six sessions extending over 8 weeks, with participatory activities facilitated by group leader.
223760491|NCT06218043|BEHAVIORAL|Restrict subjects' intake of iodine-containing foods|Replace subjects' iodized salt with non-iodized salt.
223760492|NCT00482755|DRUG|sunitinib malate|
223760493|NCT00482755|OTHER|immunohistochemistry staining method|
223760494|NCT00482755|OTHER|laboratory biomarker analysis|
223760495|NCT00482755|OTHER|pharmacological study|
223760496|NCT00482755|PROCEDURE|needle biopsy|
223760497|NCT00482755|PROCEDURE|neoadjuvant therapy|
223760498|NCT00577083|DEVICE|Cap-fitted colonoscopy|Subjects will be randomized to either initial cap-fitted colonoscopy or regular colonoscopy. Patients in the initial regular arm, will undergo cap-fitted colonoscopy for their second, tandem examination. Patients in the initial cap-fitted arm, will under undergo regular colonoscopy (without the cap) for their second, tandem examination.
223760499|NCT05853133|OTHER|Erector Spinae Plane Block|Group E (ESP block), before the operation, the ESP block will be applied to the patients in the prone position under sedation by same anesthesiologist. ESP block will be applied bilaterally, 20 ml of %0.25 bupivacaine between the erector spinae muscle and transverse process at the 11th thoracic level. All patients will be equipped with an IV tramadol patient-controlled analgesia (PCA) device. In the postoperative period, the patient was evaluated by another researcher who blind to the groups at the 2st and 6th, 12th and 24th hours. Visual pain scores (VAS) in rest and movement, hemodynamic values, tramadol consumption, nausea-vomiting score, ramsey sedation scale, postoperative complications will be recorded. A 40-item recovery of quality of score will be applied in the preoperative and postoperative period to evaluate the patient's quality of life.
224201927|NCT01580696|BIOLOGICAL|E39 peptide (1000mcg)/GM-CSF vaccine plus E39 booster|"1000mcg lyophilized E39 peptide is suspended in bacteriostatic water for injection in individual cryovials and frozen. At the time of vaccine administration, the suspended peptide is thawed and mixed thoroughly with 250mcg GM-CSF in the syringe. This constitutes the E39 vaccine at this dose.~Subsequently, patients will receive a booster of E39 dosed at 500mcg and mixed with 250mcg of GM-CSF. The boosters will be given at 6 and 12 months after completing the primary vaccine series above."
224201928|NCT01580696|BIOLOGICAL|E39 peptide (100mcg)/GM-CSF vaccine plus J65 booster|"100mcg lyophilized E39 peptide is suspended in bacteriostatic water for injection in individual cryovials and frozen. At the time of vaccine administration, the suspended peptide is thawed and mixed thoroughly with 250mcg GM-CSF in the syringe. This constitutes the E39 vaccine at this dose.~Subsequently, patients will receive a booster of J65 dosed at 500mcg and mixed with 250mcg of GM-CSF. The boosters will be given at 6 and 12 months after completing the primary vaccine series above."
224201929|NCT01580696|BIOLOGICAL|E39 peptide (500mcg)/GM-CSF vaccine plus J65 booster|"500mcg lyophilized E39 peptide is suspended in bacteriostatic water for injection in individual cryovials and frozen. At the time of vaccine administration, the suspended peptide is thawed and mixed thoroughly with 250mcg GM-CSF in the syringe. This constitutes the E39 vaccine at this dose.~Subsequently, patients will receive a booster of J65 dosed at 500mcg and mixed with 250mcg of GM-CSF. The boosters will be given at 6 and 12 months after completing the primary vaccine series above."
224201930|NCT01580696|BIOLOGICAL|E39 peptide (1000mcg)/GM-CSF vaccine plus J65 booster|"1000mcg lyophilized E39 peptide is suspended in bacteriostatic water for injection in individual cryovials and frozen. At the time of vaccine administration, the suspended peptide is thawed and mixed thoroughly with 250mcg GM-CSF in the syringe. This constitutes the E39 vaccine at this dose.~Subsequently, patients will receive a booster of J65 dosed at 500mcg and mixed with 250mcg of GM-CSF. The boosters will be given at 6 and 12 months after completing the primary vaccine series above."
224201931|NCT06650085|PROCEDURE|Loop ileostomy|Patient undergoing anterior rectal resection will receive loop ileostomy
224201932|NCT06650085|PROCEDURE|Loop colostomy|Patient undergoing anterior rectal resection will receive loop colostomy
223615213|NCT06528951|OTHER|30% increase in resistance training volume (10 Weeks)|The participants will perform ten weeks of resistance training, increasing their initial volume by 30% (upper limbs - 208 repetitions; lower limbs - 300 repetitions). The number of sets will range from 1 to 3, and the relative intensities from 40% to 70% 1RM. The training sequence will be the following: i) 10 minutes of warmup walking on the treadmill, ii) 1-3 sets of 4-10 repetitions at 50-70% of 1RM in the leg press, iii) 1-3 sets of 4-10 repetitions at 40-60% 1RM in the chest press, iv) 1-3 sets of 5-10 repetitions in the sit-to-stand exercise, v) 1-3 sets of 4-7 repetitions in the 1- kg medicine ball throw, and vi) 5 minutes walking on the treadmill.
223615214|NCT06528951|OTHER|One group that performed 15% more volume and increased to 30% (10 Weeks)|The participants will perform 10 weeks of resistance training. The group that performed a 15% volume will now increase more by 15% and perform 30% (upper limbs - 208 repetitions; lower limbs - 300 repetitions). The number of sets will range from 1 to 3, and the relative intensities from 40% to 70% 1RM. The training sequence will be the following: i) 10 minutes of warmup walking on the treadmill, ii) 1-3 sets of 4-10 repetitions at 50-70% of 1RM in the leg press, iii) 1-3 sets of 4-10 repetitions at 40-60% 1RM in the chest press, iv) 1-3 sets of 5-10 repetitions in the sit-to-stand exercise, v) 1-3 sets of 4-7 repetitions in the 1- kg medicine ball throw, and vi) 5 minutes walking on the treadmill.
223615215|NCT06528951|OTHER|One group that performed 30% more volume and increased to 45% (10 Weeks).|The participants will perform 10 weeks of resistance training. The group that performed a 30% volume will now increase more by 15% and perform 45% (upper limbs - 232 repetitions; lower limbs - 334 repetitions). The number of sets will range from 1 to 3, and the relative intensities from 40% to 70% 1RM. The training sequence will be the following: i) 10 minutes of warmup walking on the treadmill, ii) 1-3 sets of 3-10 repetitions at 50-70% of 1RM in the leg press, iii) 1-3 sets of 3-10 repetitions at 40-60% 1RM in the chest press, iv) 2-3 sets of 8 repetitions in the sit-to-stand exercise, v) 2-3 sets of 8 repetitions in the 1- kg medicine ball throw, and vi) 5 minutes walking on the treadmill.
223615216|NCT06528951|OTHER|Control group ( 29 Weeks)|The participants in the control group will maintain their regular daily activities without performing any form of physical exercise.
223760500|NCT05853133|OTHER|Wound Infiltration|Group W, at the end of the operation,wound infiltration will be administered under general anesthesia in supine position by same surgeon. Subfascial and subcutaneous wound infiltration is performed (20 ml of 0.25% bupivacaine each). All patients will be equipped with an IV tramadol patient-controlled analgesia (PCA) device. In the postoperative period, the patient was evaluated by another researcher who blind to the groups at the 2st and 6th, 12th and 24th hours. Visual pain scores (VAS) in rest and movement, hemodynamic values, tramadol consumption, nausea-vomiting score, ramsey sedation scale, postoperative complications will be recorded. A 40-item recovery of quality of score will be applied in the preoperative and postoperative period to evaluate the patient's quality of life.
223615217|NCT05107895|BEHAVIORAL|online coping skills training|Young people with high levels of stress were given online coping trainings. The content of this training was primarily aimed at raising awareness about stress by giving information about stress, and then information about coping methods with stress was shared and training on problem solving skills was provided.
223615218|NCT04585724|DRUG|Abemaciclib|Given PO
223615219|NCT04585724|DRUG|Palbociclib|Given PO
223615220|NCT04585724|OTHER|Quality-of-Life Assessment|Ancillary studies
223615221|NCT04585724|DRUG|Ribociclib|Given PO
223615222|NCT04702412|OTHER|The Opal patient portal and smartphone application combined with the I-Score patient-reported outcome measure|HIV patients will complete the I-Score PROM via Opal (patient portal) prior to three consecutive clinic visits with their HIV physician who is expected to access their PROM results in time for the visit. The clinic visits will be held at Time 1, Time 2 (3 months) and Time 3 (6 months).
223615223|NCT03326804|DEVICE|H1 Hip Resurfacing Arthroplasty|A non-porous non-cemented ceramic-on-ceramic hip resurfacing arthroplasty device
223615224|NCT00930891|DRUG|Standard Chemotherapy (PCDE or PE)|"PCDE: cisPlatin 75 mg/m² D2 ; Cyclophosphamide 300 mg/m² D1 to D3; 4'-epiDoxorubicin 30 mg/m² D1; Etoposide 75 mg/m² D1 to D3, 4 cycles~PE: cisPlatin 80 mg/m², D2; Etoposide 120 mg/m² D1 to D3, 4 cycles"
223615225|NCT00930891|DRUG|Experimental Treatment (PCDE or PE + bevacizumab)|"PCDE: cisPlatin 75 mg/m² D2; Cyclophosphamide 300 mg/m² D1 to D3; 4'-epiDoxorubicin 30 mg/m² D1; Etoposide 75 mg/m² D1 to D3, 4 cycles Bevacizumab 7.5 mg/kg, D1, until progression~PE: cisPlatin 80 mg/m², D2; Etoposide 120 mg/m² D1 to D3, 4 cycles Bevacizumab 7.5 mg/kg, D1, until progression"
223615226|NCT00930891|DRUG|Prerandomization Chemotherapy (PCDE or PE)|"PCDE: cisPlatin 75 mg/m² D2; Cyclophosphamide 300 mg/m² D1 to D3; 4'-epiDoxorubicin 30 mg/m² D1; Etoposide 75 mg/m² D1 to D3, 2 cycles~PE: cisplatin 80 mg/m², D2; Etoposide 120 mg/m² D1 to D3, 2 cycles"
223615227|NCT05020509|PROCEDURE|medial branch block|lumbar medial branch block
223615228|NCT04985929|DRUG|Sildenafil 50 mg|Sildenafil is a phosphodiesterase type-5 inhibitor, which augments/prolongs the naturally occurring nitric oxide mediated vasodilatory pathway. Sildenafil pill is over-encapsulated to be identical in appearance to the placebo intervention.
223760501|NCT04388579|OTHER|Pulmonary Rehabilitation|Respiratory Physiotherapy, Exercise Therapy, Patient Education
223760502|NCT05269693|OTHER|Brief Hope Intervention|The BHI consisted of 4 one-on-one sessions: 2 (1 hr) face- to-face sessions, and 2 (30 min) telephone follow-up sessions
223760503|NCT03326427|BEHAVIORAL|Skill Training Group of the Dialectical Behavior Therapy|A 12 session version of the Skill Training Group of the Dialectical Behavior Therapy, adapted for treatment of ADHD.
223760504|NCT03326427|OTHER|Treatment as Usual|Conventional protocol using only medication (including drug adherence).
223760505|NCT00915798|BEHAVIORAL|Cigarette smoking|Participants had an fMRI scan during an experimental task consisting of mathematical problems after smoking a cigarette.
224201933|NCT06650397|OTHER|Biofortified maize|Maize that has been grown to have higher amounts of iron and zinc.
224201934|NCT06650397|OTHER|Placebo|Traditional maize
224201935|NCT06649786|PROCEDURE|Endoscopic superior rectal mucosal ligation|The patient takes the left side decubitus position, the endoscope is connected with 6 serial ligators, the cup of the sleeve is pointed at the upper edge of the straight anal line and the rectal mucosa is continuously aspirated under negative pressure. The mucosa enters the sleeve and sees a full-screen red sign. The sensing loop is successfully triggered, indicating that the loop is complete.
223615229|NCT04985929|DRUG|Placebo|Medical-grade placebo pill, over-encapsulated to be identical in appearance to the sildenafil intervention.
223615230|NCT02134223|BEHAVIORAL|Dialectical behavior therapy|"in standard DBT, we will employ all treatment modalities: a weekly individual (1 hour) and group (2 hours) session, available telephone consultation, and DBT consultation team.~DBT participants will be assigned to the next available individual therapist and relevant skills training group.~Groups have a minimum of four members before commencement and a maximum of twelve members. Entry to the skills group occurs only at the commencement of the next skills module."
223760506|NCT00915798|BEHAVIORAL|Abstinence|Participants had an fMRI scan during an experimental task consisting of mathematical problems after smoking abstinence.
223615231|NCT02134223|OTHER|Treatment as Usual: any other drug or psychotherapy offered to participants, except DBT|
223615232|NCT00178477|PROCEDURE|MRI with breath-holding|Breath holding for diminished tumor motion.
223615233|NCT01466608|DRUG|Rosuvastatin|Oral administration of rosuvastatin 20 mg once daily for 21 days.
223615234|NCT06381934|OTHER|Standard Care|Standard diagnosis and therapy procedures at physician's discretion.
223615235|NCT06381934|OTHER|aSID/ChU Guided Therapy|"Stopping of thiazide therapy. Measure aSID:~* aSID between 39 and 42 mmol/l : measure ChU~  * ChU lower than 15mmol/l : fluid administration (0.9% NaCl infusion, 250-500 ml over 2 hours followed by 10-20 ml/kg/24h)~ * ChU higher than 14.9 mmol/l : drinking restriction (of at least 50% of usual drinking volume)~* aSID higher than 42 mmol/l : fuid administration (fluid administration (0.9% NaCl infusion, 250-500 ml over 2 hours followed by 10-20 ml/kg/24h)~* aSID lower than 39 mmol/l : drinking restriction (of at least 50% of usual drinking volume)~The aSID/ChU guided therapy will take place for a minimum of 1- and a maximum of 3 days after enrolment. Treatment and adherence to the treatment will be assessed and re-evaluated at least daily for 3 days or till discharge or sodium normalization."
223615236|NCT06458790|BEHAVIORAL|AARC|This intervention will adapt an already-existing evidence-based Centering Parenting program addressing topics that are specific to African American families. There will be 7 90 min sessions via zoom. Group education topics include (parenting goals, infant feeding and sleep, self-care). Participants will complete surveys and interviews at various times to evaluate the program. The survey topics will include: parent stress, parent confidence and thoughts about the intervention. Surveys will be completed independently by participants online via redcap at a time that is convenient to them; if requested, the coordinator may complete the survey with the participant directly by phone /zoom. Interviews will be completed with a coordinator via zoom/phone.
223615237|NCT06042634|BEHAVIORAL|Online psychoeducation|Online psychoeducation aimed to enhance the knowledge and skill of family caregivers of people with dementia, who could not physically attend in-person class. Knowledge covering dementia caregiving including disease nature, communication skill, stress and coping, daily care, management of behavioral and psychological symptoms of dementia, and future planning. The intervention provided opportunities to practice through simulation and weekly home assignment. There was a total of 6 sessions and provided weekly. Each session lasted for 2 hours. Participants had discussion with peers and coached by a facilitator. Online psychoeducation wad delivered via Zoom videoconferencing.
223760507|NCT06340035|OTHER|TENS|The TENS group is subjected to transcutaneous current. Two surface electrodes are inserted at the level of the superior gluteal and inferior gluteal nerve tract. A protocol of 10 stimulations x 10 seconds of stimulations x 10 times is performed with a 10 second rest between each repetition. A maximum contraction evoked without pain is sought.
223760508|NCT06340035|OTHER|Percutaneous Peripheral Nerve Stimulation|In the pPNS group, the superior gluteal nerve and inferior gluteal nerve are stimulated percutaneously. The nerves are localized at an ultrasound-guided level and with respect to the vascular-nervous package two acupuncture needles are inserted, one for each nerve. The stimulation is the same as the TENS group: 10 stimulations x 10 times x 10 seconds, evoking the maximum contraction without pain.
223760509|NCT00437684|DRUG|LPV/r|200/50 mg 2 cpr bid monotherapy
223760510|NCT00437684|DRUG|PEG-IFNa 2a|PEG-IFNa 2a 180 mcg/week
223760511|NCT00437684|DRUG|Ribavirin|Ribavirin 1-1.2 g/day
223760512|NCT00437684|DRUG|NUCS|Nucleoside Reverse Transcriptase Inhibitors
223760513|NCT01537783|DRUG|Chlorhexidine gluconate|Scrubs applied once a day for 5 days
223760514|NCT01537783|DRUG|Mupirocin|Nasal mupirocin applied topically to both nostrils twice a day for 5 days
223615238|NCT06042634|BEHAVIORAL|Face-to-face psychoeducation|Face-to-face psychoeducation has the same content and flow of presentation as online psychoeducation.
224201936|NCT06649786|PROCEDURE|Endoscopic hemorrhoid ligation|The patient takes the left side decubitus position,the endoscope is connected with 6 serial ligators,the cup the sleeve is aligned with the base of the hemorrhoid (above the dentate line) for continuous negative pressure suction.The hemorrhoid enters the sleeve and sees a full-screen red sign. Turn the handle of the sleeve clockwise and feel that the loop is successfully triggered, the ligature is completed.
224201937|NCT06650969|OTHER|Naturalistic observation|Naturalistic observation
224201938|NCT01121224|DEVICE|Bare Metal Stent|Patients receive one or more bare metal stents in the saphenous vein graft target lesion.
223615239|NCT03172312|PROCEDURE|Different range of thyroid surgery|Observe and record parathyroid status during thyroid surgery
223760515|NCT01771432|DRUG|Antibiotic treatment|Kidney transplant recipients with asymptomatic bacteriuria will be treated with antibiotics
223760516|NCT01771432|OTHER|No treatment|Kidney transplant recipients with asymptomatic bacteriuria will be followed without antibiotic therapy
223760517|NCT06481722|OTHER|cerebral palsy|no intervention
223760518|NCT05685290|OTHER|Pushing with saline technique|Peripheral venous catheter placement by pushing with saline technique
223760519|NCT05685290|OTHER|Traditional method|Peripheral venous catheter placement with the traditional method by nurses in the clinic routinely.
223760520|NCT01528241|DRUG|ABP688|Carbon 11 labeled ABP688 will be administered intravenously as a slow intravenous push.
223760521|NCT00847444|DRUG|Drug-based intervention|Randomization A AA: 3 cycles of 5-Fluorouracil 500 mg/m² i.v. body surface area and Epirubicine 100 mg/m² i.v. and Cyclophosphamide 500 mg/m² i.v., (FEC100), each administered on day 1, repeated on day 22, subsequently followed by 3 cycles of Docetaxel 100 mg/m² body surface area i.v. (D), administered on day 1, repeated on day 22 AB: 6 cycles of Docetaxel 75 mg/m² and Cyclophosphamide 600 mg/m² i.v. body surface area i.v. (DC), administered on day 1, repeated on day 22
223615240|NCT03166241|DIAGNOSTIC_TEST|serum interleukin 21|it is cytokine used as a marker to detect it's level in patients with adverse drug reactions
223615241|NCT03166241|DIAGNOSTIC_TEST|Complete Blood Picture|It is a blood sample will taken from patients to detect any abnormalities in blood component at the start of the study
223615242|NCT03166241|DIAGNOSTIC_TEST|Liver function test|It is a blood sample will taken from patients to detect any associated liver disease at the start of the study
223760522|NCT00847444|BEHAVIORAL|Lifestyle-based Intervention|"All Patients with a Body Mass Index (BMI) of 24 - 40 kg/m² at the time of enrollment will be subsequently randomized as follows:~Second randomization B BA: Lifestyle intervention program to reduce body weight comprising individual weight loss, diet and physical activity goals in the framework of a 2-year standardized and structured telephone and mail-based intervention."
223760523|NCT05310110|DRUG|10% lidocaine spray|10% lidocaine spray 3 puff for the throat before induction
223760524|NCT05310110|DRUG|Placebo of lidocaine spray|Normal saline spray 3 puff for the throat before induction
223760525|NCT05310110|DRUG|Cisatracurium|Intravenous cisatracurium 0.12 mg/kg during induction
223760526|NCT05310110|DRUG|Placebo of cisatracurium|Intravenous normal saline during induction
223760527|NCT05310110|DRUG|Propofol|The dosage of intravenous propofol for the first subjects was predetermined for each arm, and the dosage for the subsequent subjects would be determined according to the response of the previous subjects using the Dixon's up-and-down method with a step size of 0.25 mg/kg. If the subjects had no movement and stable hemodynamic status during and after the laryngeal mask airway (LMA) placement, the predetermined dosage of propofol for the subsequent subject would be decreased by 0.25 mg/kg. On the other hand, if the subjects had obvious movement, failure to LMA placement, and significant hemodynamic changes, the predetermined dosage of propofol for the subsequent subject would be increased by 0.25 mg/kg.
224201939|NCT01121224|DEVICE|Drug-Eluting Stent|Patients receive one or more drug-eluting stents in the saphenous vein graft target lesion.
223615243|NCT03166241|DIAGNOSTIC_TEST|Random Blood Sugar|measure blood sugar in patients included in the study at the start of the study
223615244|NCT03166241|DIAGNOSTIC_TEST|Erythrocyte Sedimentation Rate|blood sample will be taken from patients to detect any abnormalities in erythrocyte sedimentation rate at the start of the study
223615245|NCT03166241|DIAGNOSTIC_TEST|Kidney function tests|blood sample will be taken from patients to detect any kidney disease before the start of the study
223615246|NCT02602093|PROCEDURE|Transforaminal Endoscopic Discectomy|Local anaesthesia is to be administered. Verification of the site to be performed by an image intensifier and depending upon the patient's posture, a line is to be drawn from the center of the herniation. The needle is to be set and position checked. After the needle has reached the correct position, a guidewire is inserted. Following that, a series of conical rods are introduced, subsequently a drill is introduced through the cannula. After drilling, the instruments are removed, but the guidewire is to remain in place. The endoscope with the working channels are introduced via an 8mm cannula. Following removal of the hernia, the cannula and endoscope are removed. The patient is to be treated on an outpatient basis.
223615247|NCT02602093|PROCEDURE|Open Microdiscectomy|General or spinal anaesthesia is to be administered. Verification is to be performed using a Carm and the patient is to be positioned prone or in the salaam position. A paramedian incision is to be performed and the level is to be indicated. Loupe or microscope magnification is to be used. Laminotomy as well as foraminotomy is to be performed, if necessary. The amount of degenerative disc material to be removed is at the discretion of the attending surgeon. Post-operative policy will be followed and it is expected that the duration of recovery in the hospital may vary from 2-7 days, but the patient will be discharged as soon as medically responsible.
223615248|NCT06423313|PROCEDURE|maintenance of anesthesia|Types used to maintain anesthesia
223615249|NCT03845647|PROCEDURE|contralateral central lymph node dissection|contralateral central lymph node dissection
224201940|NCT01121224|DRUG|Blinded clopidogrel|For non-ACS patients with no other clinical indication for open-label thienopyridine who receive one or more DES in the target lesion.
223615250|NCT01544920|BIOLOGICAL|peg-Interferon alfa-2a|peg-IFN (180 ug) was taken once weekly via subcutaneous injection.
223615251|NCT01544920|DRUG|Ribavirin|RBV 200 mg tablets taken by mouth at a total daily dose of 1,000 mg (body weight \<75 kilograms \[kg\]) or 1,200 mg (body weight ≥75 kg) with total daily dose divided into 2 dosings.
223615252|NCT01544920|DRUG|Boceprevir|Four 200 mg BOC capsules taken three times a day by mouth for a total daily dose of 2,400 mg.
223615253|NCT06262308|BEHAVIORAL|Psychological intervention along Cognitive Behavioural Therapy principles|Women who have PPROM will be offered a series of 6 sessions with a Clinical Psychologist
223615254|NCT03029468|BEHAVIORAL|cognitive behavioral therapy|CBT teaches users how to recognize negative thoughts and emotions, use cognitive skills and problem-solving, and apply coping behaviors such as distraction, activity scheduling, and relaxation.
223615255|NCT03029468|BEHAVIORAL|eEducation|Pain and sickle cell disease education delivered through a mobile electronic device
223615256|NCT00997958|DRUG|Mycophenolate mofetil|"Dose escalation increasing successively from 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, and 5.0 grams p.o. bid.~Each patient will be treated for eight weeks (56 days)."
223615257|NCT00001716|DRUG|Nitric Oxide|
223615258|NCT00001716|DRUG|Nitroglycerin|
223760528|NCT00006412|DRUG|Pravastatin sodium|
223760529|NCT00006412|DRUG|Fenofibrate|
223760530|NCT03524703|OTHER|chewing gum|Chewing gum four times per day for 5 days, 15 minutes each time.
223760531|NCT05430828|DRUG|Repatha (evolocumab); Praluent (alirocumab)|Dosage form: Injection
223760532|NCT04705285|DEVICE|Erbium Yag Laser|Subjets in the laser arm will undergo 2 sessions of vaginal erbium-yag laser, separated by a month
224201941|NCT01121224|DRUG|Placebo|For non-ACS patients with no other clinical indication for open-label thienopyridine who receive only BMS.
224201942|NCT01121224|DRUG|Thienopyridine (open-label)|For ACS patients who receive BMS or DES in their saphenous vein graft or patients for whom there is another clinical indication for open-label thienopyridine. Also for patients who receive a DES in a non-target lesion.
224201943|NCT02042573|DEVICE|rTMS|
224201944|NCT02042573|DRUG|SSRI (SEROPLEX ou ZOLOFT)|
224201945|NCT02042573|OTHER|Genetic samples|
223615259|NCT05913830|OTHER|Auricular pressure|The seeds of blancia blanc were fixed on the acupoints with patches. The intervention measure in the experimental group was auricular point sticking. The two groups received four measurements before the intervention and 2 weeks, 4 weeks, and 6 weeks after the start; while the control group received no Auricular pressure.
223760533|NCT04705285|BEHAVIORAL|Pelvic Floor Training|Patients allocated to pelvic floor training, are goin to undergo 10 sessions of pelvic floor exercises coached by an expert physiotherapist
224201946|NCT01998165|DRUG|Remifentanil|After intubation, continuous intravenous infusion of remifentanil (0.25 µg/kg/min) is started, while anesthesia is maintained with inhaled or intravenous anesthetics. In cases where sedation by general anesthetics and analgesia by lidocaine does not seem to provide a sufficient means of analgesia at the time of intubation, remifentanil may be used, beginning before intubation. The rate of infusion may be adjusted while monitoring the subject's general condition in 25% to 100% increments or in 25% to 50% decrements every 2 to 5 minutes, but should not exceed 1.3 µg/kg/min.
223615260|NCT00882232|DEVICE|Cross-linked hyaluronan gel|"Single, transperitoneal injection of 9 mL cross-linked hyaluronan gel into anterior perirectal fat under anesthesia. The gel is injected prior to the start of radiotherapy and is absorbed by the body over several months. It increases the seapartion between the prostate and rectum by 1/3 to 2/3 at the start of radiotherapy."
223615261|NCT02817126|PROCEDURE|Robot-assisted resection|Arm I: Robot-assisted resection using da vinci system.
223615262|NCT02817126|PROCEDURE|Laparoscopic resection|Arm II: Traditional laparoscopic resection.
223615263|NCT03656029|DRUG|Cannabis|Participants will smoke as much of the cigarette as they wish
223615264|NCT03656029|DRUG|Placebo|Participants will smoke a placebo cigarette
223615265|NCT00998465|OTHER|24-hour blood pressure|Blood pressure is measured every 15 minutes in the daytime and every 30 minutes at night
223615266|NCT00998465|OTHER|Echocardiography|Standard 2-D and m-mode echocardiography with determination of dimensions, systolic, and diastolic function.
223615267|NCT00998465|OTHER|Inert gas rebreathing|Cardiac output, stroke volume and total peripheral resistance are tested at rest and during exercise (bicycle ergometer) using non-invasive equipment (inert gas rebreathing - Innocor)
223615268|NCT00998465|RADIATION|Dexa-scan|Fat mass and fat free mass is determined with a whole body Dexa scan, and bone mineral density is tested with Dexa-scans of the lumbar spine and proximal femur.
223615269|NCT00998465|RADIATION|Plasma volume|The test is performed using 5 MBq technetium-labeled albumine (99mTc-albumine - Vasculosis) with several postinjection samples for accurate zero-time extrapolation.
223615270|NCT00998465|RADIATION|Glomerular filtration rate (GFR)|GFR and ECV are determined following injection of 3,7 MBq 51Cr-EDTA and postinjection samples three-four hours after injection.
223615271|NCT00998465|OTHER|Blood samples|p-glucose, p-insulin, NT-proBNP, hemoglobin, potassium, sodium, creatinine, albumine
223615272|NCT00998465|OTHER|Urine analyses|24-hour urine collections with determination of u-sodium, u-potassium and u-creatinine.
223615273|NCT00998465|DIETARY_SUPPLEMENT|Diets with low and high sodium content|Participants are subjected to 5 days of low (90 mmol/day) and high (250 mmol/day) sodium intake in a randomized order before and 1 year after laparoscopic gastric bypass surgery.
223615274|NCT06166940|OTHER|ROTEM Guided Management|ROTEM guided management of hemostasis after CPB
223615275|NCT03153514|BIOLOGICAL|Obinutuzumab|"Obinutuzumab i.v.~\[Day 0 = day of stem cell transplant\]~Cycle 1: 100 mg (d -8), 900 mg (d -7), 1000 mg (d -1, +7, +14)~Cycle 2: 1000 mg (d +1, +8, +15, +22)"
223615276|NCT02506712|DEVICE|SmartDrive assisting device|oxygen consumption
223615277|NCT02506712|DEVICE|Standard manuel wheelchair|oxygen consumption
223615278|NCT03433963|DIETARY_SUPPLEMENT|L-Arg supplement|L-Arg supplement will be prepared as pills, administered 9g each day in 3 times for 2 weeks.
223615279|NCT03433963|DIETARY_SUPPLEMENT|Placebo|Placebo will be prepared as pills (the same size, color and shape as of L-Arg), administered 3 times daily for 2 weeks.
223615280|NCT00952029|BIOLOGICAL|bevacizumab|
223615281|NCT00952029|DRUG|FOLFIRI regimen|
223615282|NCT00952029|DRUG|fluorouracil|
223615283|NCT00952029|DRUG|irinotecan hydrochloride|
223615284|NCT00952029|DRUG|leucovorin calcium|
223615285|NCT03415282|DRUG|RVT-501 0.5% topical ointment|RVT-501 0.5% topical ointment twice daily (BID) for 4 weeks.
223615286|NCT01495286|DEVICE|EMPI Select Transcutaneous Electrical Nerve Stimulation|Experimental: EMPI Select TENS unit For analgesia, StimCare electrodes will be placed on the baby's legs at specific acupuncture points and electrical stimulation will be administered via a standard EMPI Select TENS unit. For the main study, a low continuous current will be provided with voltage of 3.5 mA. The frequency will be delivered using a stimulation of 10 Hz for 10±1 minutes prior to the heelstick, with continued stimulation during and for 5±1 min after the heel stick. Two sub studies will precede the main safety study, with 6 infants in each, using electrical stimulation intensities that are a fraction of the planned intensity. Infants in sub study 1 will receive electrical stimulation at 1 mA and 2 Hz. Infants in sub study 2 will receive electrical stimulation at 2 mA and 10 Hz.
223615287|NCT00350571|BEHAVIORAL|brief (behavioral therapy)|up t 3 sessions of phone or office based counseling sessions to promote re-engagement in treatment.
223615288|NCT00350571|BEHAVIORAL|Drop out re-engagement motivational intervention|Up to 3 phone or office based counseling sessions to promote reengagement in treatment
223615289|NCT00350571|BEHAVIORAL|standard care follow up|routine counselor phone calls and letters
223615290|NCT02736058|DEVICE|Trans- abdominal sonography|
223615291|NCT02736058|DEVICE|Trans-vaginal sonography|
223615292|NCT02736058|PROCEDURE|post-operative pathological specimen examination|
223615293|NCT01246427|DRUG|BRN01|2 tablets every morning and every evening during 8 to 10 weeks. Each patient will receive 1 set of 5 treatment boxes (60 tablets/box).
223615294|NCT01246427|DRUG|Placebo|2 tablets every morning and every evening during 8 to 10 weeks. Each patient will receive 1 set of 5 treatment boxes (60 tablets/box).
223760534|NCT04359368|OTHER|collection of patient data|Data collection (history, clinical presentation, medication, complications, laboratory testing) will be performed from patient records stored in the protected electronic patient system ISMed (Integrated System for Medical Diagnostic) of patients with HSRs to NDIPs.
223760535|NCT00013663|BIOLOGICAL|ALVAC(2)120(B,MN)GNP (vCP1452)|
223615295|NCT03687788|BEHAVIORAL|Laughter Therapy|Laughter therapy program was composed of four steps. The first step, which took 10 minutes, had warm-up exercises including gentle stretching and hand clapping. The second step, which included deep breathing exercises and hand clapping, took 5 minutes. The third step involved children's games and laughter exercises. In this step, the most common laughter exercises were milkshake laughter, bugi bugi laughter techniques, lion laughter, cell phone, hot soup laughter, hug laughter, bird laughter, dialogue with nonsense, speech exercises, laugh at one's own aches and pains exercises, argument laughter, brushing teeth and mouthwash exercises. The sessions included a combination of different laughter exercises. This step took 15 minutes. The last step, which included wishes and resting by breathing, took 10 minutes.
223615296|NCT01203735|DRUG|Valproic acid|800mg per day for entire period of RT
223615297|NCT02299726|DRUG|Spironolactone|
223615298|NCT02299726|OTHER|Placebo|Matching placebo
223615299|NCT00130169|DRUG|E7974|Maximum Tolerated Dose defined as 0.35 mg/m\^2 administered on Days 1 and 15 only of a 28-day cycle; the E7974 compound is administered as a bolus infusion; no placebo is given.
223615300|NCT02531217|BIOLOGICAL|ATYR1940|Concentrate for solution for infusion
223615301|NCT00301626|BEHAVIORAL|smoking reduction intervention (including NRT)|
223615302|NCT03145740|OTHER|Intensive F.O.T.T.®|Therapeutic F.O.T.T.® intervention provided by Occupational Therapists (OTs). The intervention consists of positioning the patient, and giving sensory input to the hands and face in order to stimulate and facilitate swallowing of saliva or small amounts of food and drink, if considered safe.
223615303|NCT03145740|OTHER|Unspecific Stimulation of face and mouth|The intervention consists of positioning the patient and either washing his face, the hands, or brushing teeth, apply lipbalm, with no specific stimulation or facilitation of swallowing
223615304|NCT06015386|OTHER|inclined plane|2 parallel groups one treated with clear aligner and other treated using inclined plane
223615305|NCT06015386|OTHER|clear aligner|2 parallel groups one treated with clear aligner and other treated using inclined plane
223615306|NCT02171507|DRUG|Dabigatran etexilate|
223615307|NCT02171507|DRUG|Diclofenac|
223615308|NCT00474955|DRUG|peginterferon alfa-2a [Pegasys]|180 micrograms or 135 micrograms sc weekly for 48 weeks
223615309|NCT02576639|DRUG|CNP520|
223615310|NCT02576639|DRUG|Placebo|Matching placebo to CNP520 was supplied in capsules.
223615311|NCT00282139|DRUG|Aripiprazole|
223615312|NCT01135134|DRUG|Mometasone furoate|"The study drug is MFNS (50 μg spray device) and the dose will be:~* 5 to 11 years: one spray per nostril once daily (100 μg/day as MF) in the morning for 2 weeks~* 12 to 15 years: 2 sprays per nostril once daily (200 μg/day as MF) in the morning for 2 weeks"
223615313|NCT01135134|DRUG|Placebo|"MF Placebo nasal spray and administration will be as follows:~* 5 to 11 years: one spray per nostril once daily in the morning for 2 weeks~* 12 to 15 years: 2 sprays per nostril once daily in the morning for 2 weeks"
223615314|NCT05701007|DRUG|abiraterone|mCRPC
223615315|NCT05701007|DRUG|enzalutamide|mCRPC
223615316|NCT05701007|DRUG|docetaxel|mCRPC
223615317|NCT05701007|DRUG|apalutamide|mCRPC
223615318|NCT05701007|DRUG|cabazitaxel|mCRPC
223615319|NCT05701007|DRUG|Radium-223|mCRPC
223760536|NCT00013663|DRUG|Aldesleukin|
224201947|NCT01169116|RADIATION|hypofractionated stereotactic radiotherapy|hypofractionated stereotactic radiotherapy with 4 fractions of 7 Gy at the periphery of the brain metastasis with 3 mm margin.
224201948|NCT02996838|DRUG|TQ-B3234|TQ-B3234 p.o. qd
224201949|NCT06127862|OTHER|Education group|Students in the experimental group were educated about environmental health and microplastica, and nursing interventions were made. The training was organized for twenty minutes in each session, with a total of four sessions at two-week intervals.
223615320|NCT05701007|DRUG|Lutetium-177|mCRPC
223615321|NCT05701007|DRUG|degarelix|mCSPC
223615322|NCT05701007|DRUG|goserelin|mCSPC
223615323|NCT05701007|DRUG|leuprorelin|mCSPC
223615324|NCT05701007|DRUG|triptorelin|mCSPC
223615325|NCT01496235|DIETARY_SUPPLEMENT|Dark chocolate|Each chocolate bar provided 210 calories represented in 25 grams of carbohydrates, 3 g of proteins, 18 g of total fat and the presence of 70% cocoa solids
223615326|NCT01496235|DIETARY_SUPPLEMENT|White chocolate|Each chocolate bar provided 230 calories represented in 28 grams of carbohydrates, 3 g of proteins, 18 g of total fat, without the presence of 70% cocoa solids
223615327|NCT02255916|OTHER|Music|live sound-bed music intervention
223615328|NCT02174991|DRUG|Rho-Kinase Inhibitor (AR-12286)|
223615329|NCT04013607|DIETARY_SUPPLEMENT|fructo- and galacto-oligosaccharides|A NDC drink rich in fructo- and galacto-oligosaccharides
223615330|NCT02289677|DEVICE|ATMOS Scope|Video-laryngoscopy 1
223615331|NCT02289677|DEVICE|COOPDECH|Video-laryngoscopy-1
223615332|NCT02289677|DEVICE|AirTraq|Optical-laryngoscopy
223615333|NCT05951946|DRUG|BR3006-1|All subjects who have been fasting for at least 10 hours prior to administration will take investigational products orally with 150 mL of water at room temperature at around 8 a.m. on the administration day of each period.
223615334|NCT05951946|DRUG|BR3006-2|All subjects who have been fasting for at least 10 hours prior to administration will take investigational products orally with 150 mL of water at room temperature at around 8 a.m. on the administration day of each period.
223615335|NCT05951946|DRUG|BR3006-3|All subjects who have been fasting for at least 10 hours prior to administration will take investigational products orally with 150 mL of water at room temperature at around 8 a.m. on the administration day of each period.
223615336|NCT01915160|BEHAVIORAL|eTF-CBT|Standard treatment with the edition of in-treatment/session iPad activities.
223615337|NCT01915160|BEHAVIORAL|TF-CBT|Treatment as usual.
223615338|NCT00407186|DRUG|cisplatin+capecitabine|cisplatin 20 mg/m2 (i.v., q 1 w, 5 weeks), capecitabine 575 mg/m2 (b.i.d., oral, on radiotherapy days.
223615339|NCT00407186|RADIATION|radiotherapy|45 Gy in 25 fracions (5 days/week)
223615340|NCT00407186|DRUG|epirubicin+cisplatin+capecitabine|3 courses q 3 w: epirubicin 50 mg/m2 (i.v., day 1), cisplatin 60 mg/m2 (i.v., day 1), capecitabine 1000 mg/m2 (b.i.d., oral, day 1-14)
223615341|NCT05283551|DRUG|Famciclovir|Famciclovir (500mg BD)
224201950|NCT06127862|OTHER|No training was given|No training was given
224201951|NCT01205568|DEVICE|Transcatheter Cutting Balloon therapy|
224312201|NCT06983002|BEHAVIORAL|Control group 2: Art Psychotherapy group.|"The aim is to keep an open non-directive psychodynamic and analytical approach to explore, discover and feel ownership of creativity as a form of expression. The group consists of 15 group sessions, where session 1-4 is setting the framework by presenting art mediums to be used collectively, creating security, a sense of community and solidarity sharing common challenges. Each individual is free to choose the motive and form of expression, with a high level of sharing and learning. Creative experiences made together on the use of art materials to convey the inner world, become the starting point for further creative exploration on a individual level with their inner selves in a self-developing therapeutic process. Session 1: Introduction to projection and how to read oneself into an object by using figures and sandplay. Sessions 2 - 4: How one can transfer, animate, or create personal expressions using collage, acrylic painting and clay.Groups 5-15 allows freedom to choo"
223615342|NCT00067184|DEVICE|Toitu 320/325|Fetal monitor
223615343|NCT01877512|DRUG|Change in daily dosage of Growth Hormone|
223615344|NCT02386046|OTHER|Pulse oxymeter measurements|Pulse oxymeter measurements done at the hospital and upon discharge, weekly until 46 weeks postconceptional age
223615345|NCT00255190|DRUG|Dexlansoprazole MR|Dexlansoprazole MR 60 mg, capsules, orally, once daily for up to 12 months.
223615346|NCT00255190|DRUG|Dexlansoprazole MR|Dexlansoprazole MR 90 mg, capsules, orally, once daily for up to 12 months.
223615347|NCT02513121|OTHER|Dietary modification|The intervention is a modification of the family's habitual diet with a low sugar version of their diet.
223615348|NCT05703750|PROCEDURE|TACE ± Systemic therapy|TACE: cTACE (conventional TACE) or dTACE (drug-eluting beads TACE); Systemic therapy: PD-1/PD-L1 inhibitors, VEGF-TKI/bevacizumab, PD-1/PD-L1 inhibitors+VEGF-TKI/bevacizumab, radiotherapy or chemotherapy.
223615349|NCT06376630|DRUG|Esmolol Hcl 10Mg/Ml Inj|"the loading dose of 500 mkg/kg for 1 minute, followed by the initial rate of 50 mkg/kg/min. Individual titration depending on the desired hemodynamical effect (to the heart rate of 60 bpm or to the maximum tolerated dose maintaining stable hemodynamics) every 5-15 minutes (the maximum allowed rate of administration is 300 mkg/kg/min) for 6 hours.~Thereafter patients in both treatment arms - the IV esmolol arm and the placebo arm, will be administered oral β-adrenergic blockers, if decided so by the treating physician and unless contraindicated."
223760537|NCT02187328|OTHER|Grapefruit juice|Volunteers participate in two visits at least 5 days apart. The day of their visit they ingest 12.5 oz of grapefruit juice in the morning and 12.5 oz of grapefruit juice ingested in the afternoon, 3h before reporting to the laboratory. The order of the visits is randomized, one visit volunteers ingest apple juice only, the other visit grapefruit juice only
223760538|NCT02187328|OTHER|Apple juice|Volunteers participate in two visits at least 5 days apart. The day of their visit they ingest 12.5 oz of grapefruit juice or Apple juice ingested in the morning and 12.5 oz of grapefruit juice ingested in the afternoon, 3h before reporting to the laboratory. The order of the visits is randomized, one visit volunteers ingest apple juice only, the other visit grapefruit juice only
224201952|NCT01205568|PROCEDURE|High Pressure Balloon Angioplasty|
224201953|NCT00323830|DRUG|Capecitabine, cisplatin, Radiotherapy (+/-)|Capecitabine, cisplatin + Radiotherapy (randomized)
224201954|NCT05392699|BIOLOGICAL|human single chain IL-12 mRNA-single dose|human single chain IL-12 mRNA administered as specified in the treatment arm with injection once only
224201955|NCT05392699|BIOLOGICAL|human single chain IL-12 mRNA-multiple dose|human single chain IL-12 mRNA administered as specified in the treatment arm with injection once per week for 3 weeks
224201956|NCT00261859|BEHAVIORAL|BNI|behavioral- brief intervention
224201957|NCT04022473|DRUG|Bafiertam|Over-encapsulated capsule to mask treatment
224201958|NCT04022473|DRUG|Tecfidera|Over-encapsulated capsule to mask treatment
224201959|NCT01283282|DRUG|Clopidogrel|Clopidogrel 75 mg PO qday for 6 weeks
224201960|NCT01283282|DRUG|Placebo|Placebo PO qday for 6 weeks
224201961|NCT05583604|DRUG|secukinumab|The recommended dose is 300 mg of secukinumab by subcutaneous injection with initial dosing at weeks 0, 1, 2, 3 and 4, followed by a maintenance dose of 300 mg every 2 weeks. Each 300 mg dose is given as one subcutaneous injection of 300 mg or as two subcutaneous injections of 150 mg.
224201962|NCT00777920|DRUG|Ambrisentan|Tablet administered orally once daily
224201963|NCT02618096|DRUG|Oxytocin|
224201964|NCT02618096|DRUG|Dinoprostone|
224201965|NCT02618096|PROCEDURE|Membrane sweeping|
224201966|NCT00036868|BIOLOGICAL|trastuzumab|
224201967|NCT00036868|DRUG|CMF regimen|
224201968|NCT00036868|DRUG|cyclophosphamide|
224201969|NCT00036868|DRUG|fluorouracil|
224201970|NCT00036868|DRUG|methotrexate|
223615350|NCT02451085|BEHAVIORAL|training with video therapy|training with video therapy
223615351|NCT02451085|BEHAVIORAL|conventional exercise|training in conventional way
223615352|NCT04555395|OTHER|survival rates|survival rates
223615353|NCT05180695|DRUG|Pazopanib|"Part 1: A dose escalation part with the aim to assess the safety of the proposed combination. Eligible patients will be treated with a fixed dose of pazopanib (800mg/d, continuously) and escalating doses of HDM201. Both study drugs will be administered as long as the patient experiences clinical benefit in the opinion of the investigator or until unacceptable toxicity or symptomatic deterioration attributed to disease progression or withdrawal of consent.~Part 2: An extension part with a fixed dose of pazopanib (800mg/d, continuously) and the recommended phase 2 dose of HDM201 determined during the dose escalation part. Both study drugs will be administered as long as the patient experiences clinical benefit in the opinion of the investigator or until unacceptable toxicity or symptomatic deterioration attributed to disease progression or withdrawal of consent."
223760539|NCT00548704|DRUG|Dexrazoxane|
224201971|NCT04984304|BEHAVIORAL|Lifestyle modifications and Antireflux diet|Patients in Arm 1 - mild cough only slightly worsening the quality of life (VAS 1-3) will undergo treatment using lifestyle modifications and an Antireflux diet for 3 months.
224201972|NCT04984304|DIAGNOSTIC_TEST|Extraesophageal reflux diagnostic|Patients in Arm 2 - moderate and severe cough that significantly worsen the quality of life (VAS 4-10) will undergo extraesophageal reflux diagnostics consisting of esophageal 24-hour pH/Impedance Reflux Monitoring and peptest study on fasting
224201973|NCT00483717|DRUG|Ketorolac tromethamine|31.5 mg of ketorolac 2 x 100uL IN sprays (15% ketorolac tromethamine with 6% lidocaine hydrochloride)
224201974|NCT00483717|DRUG|Placebo|Intranasal (IN) placebo
223760540|NCT03078946|DRUG|Dexmedetomidine Hydrochloride|30 patients received a loading dose of 1 μg/kg dexmedetomidine (Precedex; Hospira, Precedex 200 mcg/2 ml, Hospira. Inc, Lake Forest, USA) diluted in 100 ml 0.9% saline infused over 10 min immediately postoperative, followed by continuous infusion of 0.2- 0.7 μg/kg/h
223760541|NCT03078946|DRUG|Morphine and Midazolam|30 patients received morphine in a dose of 10-50μg/ kg/hr as an analgesic (Morphine Sulphate ampoule; 10 mg/ 1ml, Misr Co.- Egypt) with midazolam in a dose of 0.05mg/kg up to 0.2 mg/kg (Dormicum; Roche; USA; ampoule containing 15 mg/3 ml mixed in sugar-free apple juice limiting the total volume mixed with a double volume of apple juice) repeated as needed.
223615354|NCT05180695|DRUG|HDM201|"Part 1: A dose escalation part with the aim to assess the safety of the proposed combination. Eligible patients will be treated with a fixed dose of pazopanib (800mg/d, continuously) and escalating doses of HDM201. Both study drugs will be administered as long as the patient experiences clinical benefit in the opinion of the investigator or until unacceptable toxicity or symptomatic deterioration attributed to disease progression or withdrawal of consent.~Part 2: An extension part with a fixed dose of pazopanib (800mg/d, continuously) and the recommended phase 2 dose of HDM201 determined during the dose escalation part. Both study drugs will be administered as long as the patient experiences clinical benefit in the opinion of the investigator or until unacceptable toxicity or symptomatic deterioration attributed to disease progression or withdrawal of consent."
223760542|NCT05091905|DRUG|Continuous Infusion of ropivacaine 0.2%|Patients will receive a continuous infusion of Ropivacaine 0.2% (6 mL/hr popliteal-sciatic and 8 mL/hr infraclavicular, 4 mL patient controlled bolus with 30-minute lockout) will be initiated in the recovery room.
223760543|NCT05091905|DRUG|Titratable Automated Intermittent Boluses of ropivacaine 0.2%|"Patients will receive patient-titratable intermittent boluses of Ropivacaine 0.2% (8 mL popliteal-sciatic or 11 mL infraclavicular automated bolus every 120 minutes, 4 mL patient controlled bolus with 30-minute lockout). In addition, the infusion pump will be set in a pause mode that delays initiation of the automated bolus doses by 5 hours (this can be over-ridden by patients if they would like to initiate their perineural infusion earlier than 5 hours). Lastly, subjects will be able to titrate the volume of their automated bolus up or down within the range of 1-16 mL."
223760544|NCT02722928|OTHER|Controlled Ventilation with 100% oxygen|Patients in group B will be switched from conventional 1:1 oxygen / air ventilation to 100% oxygen controlled ventilation once tumor resection is completed and hemostasis started. They will inhale 100% oxygen until extubation
223760545|NCT01398891|OTHER|Positive Psychology Exercises|At each session, the interventionalist will prepare the subject to complete a randomly-selected positive psychology exercise, lasting approximately 20 minutes, within the next 24 hours. He or she will describe the rationale for the exercise and the details of the exercise, and will answer any questions. A sheet with written instructions (matching the verbal instructions) for the exercise will be provided, with space for recording the exercise and an area to provide ratings on the exercise. On the following day, the interventionalist will review the prior day's exercise (and record whether it was completed). The exercises will be completed daily on weekdays for a maximum of 8 days.
223760546|NCT03189030|BIOLOGICAL|pLADD|via IV infusion
223760547|NCT04122573|DIAGNOSTIC_TEST|Coronary angiography|Acute chest pain patients, suspected acute coronary syndrome, are diagnosed by coronary angiography.
223760548|NCT04122573|DIAGNOSTIC_TEST|CT angiography of aorta|Acute chest pain patients, suspected acute aortic dissection, are diagnosed by gold standard of CTA.
223760549|NCT04122573|DIAGNOSTIC_TEST|CT angiography of pulmonary arteries.|Acute chest pain patients, suspected acute pulmonary embolism, are diagnosed by gold standard of CTA.
223760550|NCT04122573|DIAGNOSTIC_TEST|Electrocardiogram|All patients with acute chest pain will subject to ECG examination within 10 minutes of admission, which can quickly screen ST-segment elevation myocardial infarction.
223760551|NCT04122573|DIAGNOSTIC_TEST|Cardiac Troponin|Dynamic changes of cardiac troponin I and/or T will be used in the diagnosis of acute myocardial infarction
224201975|NCT05557201|BIOLOGICAL|Lymphocyte immunophenotyping|If the patient accepts the ancillary study, a blood sample will be taken (1 EDTA tube of 3 ml and 2 lithium heparin tubes of 10 mL each) for lymphocyte immunophenotyping in flow cytometry on fresh blood and for the constitution of the biological collection (plasma/mononuclear cells).
223615355|NCT00984984|DRUG|methylprednisolone PO|10 capsules Methylprednisolone 100 mg and 50 ml IV NaCl 0,9% (syringe pump 30 mn to 2 h, every day during 3 days
223615356|NCT00984984|DRUG|methylprednisolone IV|IV Methylprednisolone 1 g in 50 ml NaCl 0,9% (syringe pump 30 mn to 2 h) and 10 capsules of placebo, every day during 3 days
223615357|NCT02800616|OTHER|The Healthy Primary School of the Future|In two out of four intervention schools, a whole-school approach named 'The Healthy Primary School of the Future', is implemented with the aim of improving physical activity and dietary behaviour. For this intervention, pupils are offered an extended curriculum, including a healthy lunch, more physical exercises, and social and educational activities, next to the regular school curriculum.
223615358|NCT02800616|BEHAVIORAL|The Physical Activity School|In the two other intervention schools, a physical-activity school approach called 'The Physical Activity School', is implemented, which is essentially similar to the other intervention, except that no lunch is provided.
223615359|NCT02928315|DRUG|Magnesium Sulfate|The patients in the study group will receive 10 mmol of magnesium sulphate (2.47 gm). Five ampoules of 500 mg of magnesium sulphate will be dissolved in 100 ml of saline solution infused intravenously over 4 hours, once daily for 3 days starting when the patient is shifted to ICU.
224201976|NCT04490772|DIAGNOSTIC_TEST|Laboratory tests|Laboratory tests such as CBC, Liver function and CRP
224201977|NCT03599882|DEVICE|Fibroscan|Fibroscan with controlled attenuation parameter and transient elastography
224201978|NCT04269317|DEVICE|Tixel C|Thermo-mechanical technology for fractional treatment of human skin. Dermal heating and coagulative effect that occur during the treatment session provide for dermal remodeling and collagen restructuring that promote acne scar appearance improvement.
224201979|NCT00909857|DRUG|Estradiol valerate, Dienogest (Natazia, Qlaira, BAY86-5027)|Daily oral administration of one tablet SH T00658ID for 28 days per cycle in the respective treatment period; no tablet-free interval
224201980|NCT00909857|DRUG|Ethinyl estradiol, Levonorgestrel (Miranova)|Daily oral administration of one tablet for 28 days per cycle in the respective treatment period; no tablet-free interval
224201981|NCT00909857|DRUG|Placebo Match to SH T00658ID|Daily oral administration of one tablet placebo for 28 days without tablet-free interval for 3 treatment cycles.
223615360|NCT02928315|OTHER|control|100 ml of saline solution infused intravenously over 4 hours, once daily for 3 days starting when the patient is shifted to ICU.
224201982|NCT00909857|DRUG|Placebo Match to SH D593B|Daily oral administration of one tablet placebo for 28 days without tablet-free interval for 3 treatment cycles.
223615361|NCT03334032|OTHER|Inpatient treatment for Anorexia nervosa|Nutritional rehabilitation in a clinic with specialized eating disorder service
223615362|NCT02037139|OTHER|Screening|Standard care screening
223615363|NCT02037139|OTHER|Brochure|Participants are given an illustrated educational brochure
223615364|NCT02037139|BEHAVIORAL|Education|Participants undergo a in-person educational intervention
223615365|NCT02668458|PROCEDURE|High Flow nasal canula oxygen therapy|Pre-oxygenation with high-flow nasal canula oxygen therapy
223615366|NCT02668458|PROCEDURE|Noninvasive ventilation|Pre-oxygenation with non-invasive ventilation
223615367|NCT00623324|DRUG|Aplindore|Tablets .05 - 5 mg BID dosing for 14 days
223615368|NCT00623324|DRUG|Placebo|Placebo tablets to match the number of active tablets
223509785|NCT06726239|OTHER|Progressive relaxation exercises|The aim of relaxation exercises is to help individuals recognize the difference between tension and relaxation and to enable them to relax in situations of stress. These exercises are performed with light background music and verbal instructions, allowing patients to mentally focus on the process. The progressive relaxation technique involves the voluntary contraction and subsequent relaxation of muscle groups, typically starting from the hands and progressing to the feet, with each muscle group activated in sequence. During the exercise, the instructions and steps from the 'Relaxation Exercises' CD published by the Turkish Psychologists Association will be followed.
223509786|NCT02600793|DRUG|Ceftaroline|Following Ceftaroline single IV dose, 3 blood and cerbrospinal fluid samples will be collected
223509787|NCT07046455|DRUG|Sacituzumab Govitecan (SG)|After enrollment, before subjects receive TROP-2 ADC treatment, after 2 cycles of treatment, and at the time of progression, in these three phases, subjects will undergo 89Zr-DFO-hSR7 and 18F-FDG examinations once respectively (subjects will first undergo the 18F-FDG examination, and then the 89Zr-DFO-hSR7 examination within 1 week).
223509788|NCT06889493|BIOLOGICAL|Seneca Valley Virus-001 (SVV-001)|"SVV-001 will be administered intratumorally as a single dose on Day 1; or as multiple doses on Days 1, 15, 29, 43, 57, and 71. The virus dose levels per SVV-001 treatment are as follows:~* 2.2 × 10\^8 Viral Genomes (VG) (starting dose)~* 2.2 × 10\^9 VG~* 2.2 × 10\^10 VG"
223509789|NCT06889493|DRUG|Nivolumab|Nivolumab will be administered via intravenous (IV) injection at a dose of 240 mg, once every two weeks starting on Day 15 until Day 85 during SVV-001 therapy. Nivolumab will be administered once every four weeks during the maintenance period for up to 2 years.
223509790|NCT06889493|DRUG|Ipilimumab|Ipilimumab will be administered via intravenous (IV) injection at a dose of 1 mg/kg, once every six weeks starting on Day 15 until Day 85 during SVV-001 therapy. Participants will continue on 1 mg/kg ipilimumab IV every 6 weeks for two additional doses or unacceptable toxicity and/or participant withdrawal.
223509791|NCT07045961|OTHER|Supervised Station-Based Strength Circuit Training & Self-directed aerobic training|"Anaerobic training sessions follow a circuit design alternating upper body, lower body, and core exercises with dumbbells, barbells, and kettlebells. Participants complete 3 sets of 10-15 repetitions per exercise, performed consecutively without rest, at 60-80% of their one-repetition maximum (1RM). Two participants perform the same exercise simultaneously at each station. Load progression is applied by increasing resistance by 10% after successfully completing 3 sets of 12 repetitions across two consecutive sessions.~Sessions begin with a 5-minute warm-up at 50-65% of maximal heart rate (HRmax), followed by nine resistance exercises: kettlebell squats, static plank, bench press, weighted lunges, quadruped superman, seated row, weighted glute bridge, leg raises, and shoulder press. Exercises alternate muscle groups to optimize recovery.~Additionally, participants engage in self-selected aerobic exercise (walking, running, rowing, swimming, or stationary cycling) twice weekly at 65-80"
223509792|NCT07045961|OTHER|Music Medicine|During the warm-up phase, participants will engage in individual passive music listening, tailored to their personal musical preferences. The music will be delivered via MP3 players or smartphones, where a personalized playlist containing the participant's favorite tracks has been preloaded. Subsequently, during the circuit training session, a group background music playlist will be played through speakers. This heterogeneous playlist is compiled based on the collective musical preferences of all participants. Finally, during the cool-down phase, a common background music selection will be used, featuring a different repertoire from earlier phases. The cool-down will include guided muscle relaxation and breathing exercises assisted by the background music.
223509793|NCT07045129|OTHER|Cold water immersion|10 sessions of 15-minute Cold water bath (12°C) after the 10 first physiotherapy sessions.
223509794|NCT07045129|OTHER|Hot water immersion|10 sessions of 30 to 45-minute hot water bath (12°C) after the 10 first physiotherapy sessions.
223509795|NCT07045129|OTHER|Physiotherapy only|Control group. Patients of this group will follow the classic rehabilitation treatment proposed by the physiotherapist and physician of Aspetar without thermal intervention.
223509796|NCT07044921|DRUG|Irinotecan Liposomes (II)+Cetuximab+Bevacizumabl|"Irinotecan Liposomes (II) injection：Intravenous infusion, 60 mg/m2, Day 1, Q2W. The recommended initial dosage of irinotecan liposomes (II) for patients with the UGT1A1 \* 28/\* 6 homozygous mutation is 47.1 mg/m2.~Cetuximab injection：Intravenous infusion, 500 mg/m2, Day 1, Q2W. Bevacizumabl: Intravenous infusion, 5mg/kg, Day 1, Q2W."
223509797|NCT06727227|DRUG|trastuzumab deruxtecan|T-DXd
223509798|NCT07045597|DRUG|intranasal normal saline for preanasthetic sedation for Adenotonsillectomy|preschool children that will undergo adenotonsillectomy will receive intranasal normal saline equivalent volume who take midazolam intranasal by dose 1 ml saline by insulin syringe as a control group
223509799|NCT07045597|DRUG|intranasal midazolam for preanasthetic sedation for Adenotonsillectomy|preschool children that will undergo adenotonsillectomy will receive intranasal midazolam by dose 0.2 mg/kg
223509800|NCT07046247|PROCEDURE|Microvascular decompression for trigeminal neuralgia|Microvascular decompression for trigeminal neuralgia comparing two different forms to apply the Teflon implant
223509801|NCT07055750|DIAGNOSTIC_TEST|Knee Pain With High-Impact Workouts|Individuals who have been attending the gym regularly for at least 3 months having knee pain will be assessed With High-Impact Workouts
223760552|NCT06028945|DEVICE|HMD: Virtual Reality Exposure Therapy|The virtual reality exposure therapy uses 360-degree videos delivered through a head mounted display (HMD). Participants will be matched with one of three available exposure hierarchies: Social Party Scenario, Subway Scenario, or Shopping Mall Scenario. Each hierarchy comprises seven 5-min scenes ordered in increasing intensity (from low to high anxiety). Participants are gradually exposed to scenes, viewed twice per day for up to 10 days, while rating their anxiety immediately before and after the exposures. Anxiety ratings will inform when participants may advance to the next level intensity in the exposure hierarchy.
223760553|NCT06028945|DEVICE|HMD: Neutral Game|The neutral game is a virtual-reality based game that is not designed to provoke anxiety. Participants assigned to the neutral game will play for 5 minutes twice per day for up to 10 days.
223615369|NCT03955614|OTHER|pedal-controlled GoSurgeryTM|"Members of the surgical team are given operative instruction workflows to use in preparation of a specific operation and to consult during the operation if needed. The workflows are controlled by the surgical staff using pedals.~The operating theatre environment is recorded to observe how teamwork may be affected by the intervention."
223615370|NCT03955614|OTHER|ML-controlled GoSurgeryTM|"Members of the surgical team are given operative instruction workflows to use in preparation of a specific operation and to consult during the operation if needed. The workflows are projected onto screen based on the machine learning algorithm's determination of current operative step.~The operating theatre environment is recorded to observe how teamwork may be affected by the intervention."
223615371|NCT03955614|OTHER|NoGo|The operating theatre environment is recorded to observe baseline teamwork.
223615372|NCT05724992|GENETIC|Saliva swab testing|41 pancreatic cancer predisposition genes will be tested through a saliva-based swab
223615373|NCT05371925|DRUG|Sulodexide|one 250LRU sulodexide capsule twice a day for 8 weeks
223615374|NCT02956343|DEVICE|Five minutes pulse wave recording|Patients will wear a smart watch and a wristband each at one arm. A standard egg (lead I) and pig signals from the wearables will be recorded for five minutes.
223615375|NCT01569841|DRUG|insulin degludec|Administered subcutaneously (s.c., under the skin) once daily.
223615376|NCT01569841|DRUG|insulin glargine|Administered subcutaneously (s.c., under the skin) once daily.
223615377|NCT03148366|DRUG|Levofloxacin based sequential therapy|D1-D7: (esomeprazole 40mg bid + amoxicillin 1gm bid) for 7 days D8-D14: (esomeprazole 40mg bid + levofloxacin 250mg bid + metronidazole 500mg bid) for another 7 days
223615378|NCT03148366|DRUG|bismuth quadruple therapy for 10 days (BQ)|D1-D10: (esomeprazole 40mg bid + Dibismuth trioxide 120mg qid + metronidazole 500mg tid + tetracycline 500mg qid) for 10 days
223615379|NCT02028442|BIOLOGICAL|Enadenotucirev|Oncolytic virus
223615380|NCT00876161|DRUG|DAS181|DAS181 is formulated as dry powder and packaged in capsules containing DAS181. The delivered dose of DAS181 dry powder at each fill size is 5 mg, 10 mg and 20 mg.
223615381|NCT00876161|DRUG|Lactose|
223615382|NCT02327676|DRUG|Emtricitabine|emtricitabine were given to each patients for 48 weeks
223615383|NCT05783206|DRUG|MIR 19 ®|"MIR 19 ® contains anti-SARS-CoV-2 siRNAs/KK-46 (peptide dendrimer) complexes for inhalation use.~In the experimental groups treated with MIR 19 ®, the therapy included symptomatic treatment without use of any etiotropic drugs."
223615384|NCT05783206|COMBINATION_PRODUCT|Standard therapy|Therapy carried out in accordance with the current version of the temporary methodological recommendations of the Ministry of Health of the Russian Federation for the treatment of COVID-19 infection. This therapy included symptomatic treatment as well as etiotropic drugs (except MIR 19 ®)
223760554|NCT01838642|DRUG|Ponatinib|Ponatinib tablets will be administered orally, continually, once daily at a dose of 30 mg. A cycle of ponatinib is defined as 28 consecutive days starting with the first day of the treatment cycle. Treatment will be administered primarily in an outpatient setting.
224201983|NCT03573466|PROCEDURE|Muscle biopsy|A motor point biopsy of deltoid muscle will be carried out at the time of inclusion using a standardized procedure, as routinely performed. Muscle samples will be removed from the deltoid muscle by open biopsy under local anaesthesia. The region containing NMJs will be determined by the small twitch provoked by the tip of the scalpel on the surface of the muscle fascicles.
223615385|NCT06051669|DEVICE|iLivTouch|The examination with iLivTouch will be performed in each subject following the sequence determined by the randomization results.
223615386|NCT06051669|DEVICE|FibroScan|The examination with FibroScan will be performed in each subject following the sequence determined by the randomization results.
223615387|NCT03728543|DRUG|Sugammadex|"Introductory anesthesia: sevoflurane up to 8 rev /% + Air + O2 or propofol 1% 2 mg / kg intravenously.~Maintenance: sevoflurane up to 3 rev /% + Air + O2, introduction of rocuronium bromide in a dose of 0.4 mg / kg, intravenously, as a bolus injection.~At the end of anesthesia: sugammadex in a dose of 2 mg / kg, intravenously, as a bolus injection"
223615388|NCT04188938|OTHER|Evaluation of occult pneumothorax in who had a blunt or penetrating chest trauma|
223615389|NCT02041481|DRUG|MEK inhibitor MEK162|Given PO
223615390|NCT02041481|DRUG|leucovorin calcium|Given IV
223615391|NCT02041481|DRUG|fluorouracil|Given IV
223615392|NCT02041481|DRUG|oxaliplatin|Given IV
223615393|NCT02041481|OTHER|pharmacological study|Correlative studies
223615394|NCT02041481|OTHER|Laboratory Biomarker Analysis|Correlative Studies
224201984|NCT03878108|DIETARY_SUPPLEMENT|LCHF diet|low-carbohydrate, high-fat (LCHF)diet
224201985|NCT03878108|DIETARY_SUPPLEMENT|LFHC diet|low-fat, high-carbohydrate (LFHC) diet
224201986|NCT05711459|DRUG|Bicyclol tablets|Take Bicyclol tablets for the treatment of liver injury.
224201987|NCT02046655|DRUG|Corifollitropin alfa|
224201988|NCT02046655|DRUG|rFSH|
224201989|NCT00241059|DRUG|Enteric-Coated Mycophenolate Sodium (EC-MPS)|
224201990|NCT02400697|OTHER|<30 wks gestation or 1500 grams|Outcomes of preterm infants recorded
224201991|NCT00004454|GENETIC|lymphocyte gene therapy|
223615395|NCT02539641|RADIATION|Gastric emptying scintigraphy|Scintigraphy is performed to evaluate gastric emptying after eating a pancake labeled by 20 megabecquerel (MBq) Technetium-99m-Albumin (TC-99m-LyoMAA)
224312202|NCT06281171|OTHER|SkillTalk for Autistic Young Adults|A Microskills video training library on communication skills for autistic young adults.
224312203|NCT06281171|OTHER|Flyer Library|A collection of existing online resources on relationship skills
223615396|NCT02539641|OTHER|Determination of gut hormones|Gut hormone levels will be determined after eating a standard meal in the RYGB and SG groups.
223615397|NCT00638534|DRUG|Telithromycin (HMR3647)|
223615398|NCT05502913|DRUG|Antibiotics|Recipients will undergo bowel preconditioning with antibiotics (Rifaximin) following randomization.
223615399|NCT05502913|OTHER|FMT (Fecal Microbiota Transplantation)|FMT involves the transplantation of fecal bacteria from a screened donor to a recipient. This will be achieved per os in the form of a capsule containing freeze-dried stool obtained from the donor.
223615400|NCT02882594|BEHAVIORAL|Observing patient behaviors for anesthesia induction compliance|Observing patient behaviors for anesthesia induction compliance so to test reliability and validity of the CIBA Tool
223615401|NCT06097065|DIAGNOSTIC_TEST|Oral Glucose Tolerance Test|Grouping based on detected oral glucose tolerance test results without any other intervention.
223615402|NCT00670280|BEHAVIORAL|Motivational Interviewing intervention|Those randomized to receive the Motivational Interviewing intervention will meet twice over a two-week period with a trained counselor while visiting the neonatal intensive care unit. Each visit will consist of a 45 minute session in which household smoking practices will be assessed and discussed. Two weeks after the child has been discharged from the hospital, the counselor will contact participants via telephone for a third 20-30 minute telephone meeting. After the third contact with the counselor, a letter will be mailed to participants summarizing information covered in the three meetings.
223615403|NCT00670280|BEHAVIORAL|Usual Care|Those randomized to receive the Usual Care intervention will receive written information on secondary smoke and infant health and will be assessed at 1 month, 3 months, and 6 months post-intervention.
223615404|NCT00670280|BEHAVIORAL|Usual Care - Reduced Measurement|Those randomized to the Usual Care - Reduced Measurement intervention will receive the same written information on secondary smoke and infant health as the Usual Care intervention but will be assessed only at the 6-month timepoint.
223615405|NCT00644046|BEHAVIORAL|multidisciplinary predialysis education|teaching of renal knowledges, dietary support and recall of period medical visits
223615406|NCT06032169|OTHER|Patients of a surgical intensive care unit having an arterial catheter|Patients of a surgical intensive care unit having an arterial catheter undergoing noninvasive measurements of AP in the two studied positions (semi-recumbent or horizontal).
223615407|NCT01503008|DEVICE|Proteus Sustained Behavior Change system|The SBC system uses ingestible and wearable sensing devices and mobile phones to reinforce positive behaviors around medication usage, exercise and rest. Subjects will be taking their regularly prescribed oral hypoglycemics (metformin, sulfonylureas, thiazolidinediones, DPP-IV inhibitors, alpha-glucosidase inhibitors); glucometer
223615408|NCT01503008|DRUG|Regularly prescribed diabetes medicines (metformin, sulfonylureas, thiazolidinediones, DPP-IV inhibitors, alpha-glucosidase inhibitors)|Oral hypoglycemics (metformin, sulfonylureas, thiazolidinediones, DPP-IV inhibitors, alpha-glucosidase inhibitors) at subjects' regularly prescribed doses; glucometer
223615409|NCT01859923|DRUG|Delamanid|Participants received adult formulation delamanid as per regimen specified in the arm description. Morning dose of the delamanid BID regimen was given within 30 minutes after the start of a standard breakfast meal. The evening dose of the BID dose regimen was given 10 hours post morning dose and within 30 minutes after the start of a standard dinner meal.
223615410|NCT01859923|DRUG|Delamanid Pediatric Formulation (DPF)|Participants received delamanid as an extemporaneous suspension using the delamanid pediatric dispersible tablet formulation. Morning dose of the delamanid BID/once daily (QD) regimen was given within 30 minutes after the start of a standard breakfast meal. The evening dose of the BID dose regimen was given 10 hours post morning dose and within 30 minutes after the start of a standard meal.
223615411|NCT01859923|DRUG|Optimized Background Regimen (OBR)|"Selection and administration of the treatment medications (i.e. OBRs) was based on Search Results Web result with site links~World Health Organization (WHO's) Guidelines for the programmatic management of drug-resistant TB, in conjunction with national TB program guidelines. Study Investigator could change OBR for a participant based on his/her tolerability and drug susceptibility testing (DST) results."
223615412|NCT03544021|BIOLOGICAL|CART-19 cells|CD19-Targeted CAR-T cells are infused to patient received FC chemotherapy
223615413|NCT03787186|DRUG|GLPG1690 film-coated tablets|a single oral dose of GLPG1690
223615414|NCT03787186|DRUG|[14C]-GLPG1690 solution for infusion|a 15-minute IV infusion \[14C\]-GLPG1690
223615415|NCT03787186|DRUG|[14C]-GLPG1690 capsules|single oral dose of \[14C\]-GLPG1690
223615416|NCT04474678|OTHER|"My Logbook! - I know my way around!"|"Special issues/booklets of My Logbook - I know my way around! - Every booklet is based on evidence-based interventions. It illustrates psychosocial and interdisciplinary processes in a standardized way, resulting in a practical guide (My Logbook) to accompany the child throughout all stages of oncological treatment."
223615417|NCT05222828|DRUG|Carbocaine Injectable Product|One injection per patient
224201992|NCT01583465|DEVICE|Aquamantys|Primary THA via the ASI approach will be performed using the Aquamantys Malleable Bipolar Sealer. The Aquamantys is a bipolar device that combines radio-frequency energy and saline to gently reach targeted tissue and provide a biomechanical seal. The saline acts as a conduit to allow the energy to penetrate the tissue from 1 to 2 mm where the collagen is transformed thus providing the seal. The saline also helps cool the tissue which allows for gentle handling of tissue, eliminating the black char that is a port for infection. The surgeon uses the Aquamantys to assist in tissue dissection, cauterize vessels, and to pre-treat fat pad in front of capsule prior to excision, to treat the entire anterior hip capsule prior to excision, treat oozing bone surfaces not covered by an implant.
223615418|NCT00226928|BEHAVIORAL|Supportive-Expressive Group Therapy plus education|
223615419|NCT00226928|BEHAVIORAL|Education|
223615420|NCT04479826|DEVICE|Advanced hybrid closed loop system|Free living follow-up of meal handelling
223615421|NCT00057863|DRUG|Paclitaxel|Given IV
223615422|NCT00057863|DRUG|Oxaliplatin|Given IV
224201993|NCT01583465|DEVICE|standard electrocautery (Bovie)|Primary total hip arthroplasty via an anterior supine intermuscular approach will be performed with the assistance of standard electrocautery. The electrocautery is used in tissue dissection and to cauterize bleeding vessels.
224201994|NCT01682681|DRUG|Topiramate|This is an observational study. Participants with seizures receiving topiramate as per Investigator's discretion will be observed.
224312204|NCT06982755|PROCEDURE|acupuncture|acupuncture at Zusanli (ST36); sample size: 44
223615423|NCT04486534|OTHER|Musculoskeletal ultrasound|Subjects' talar cartilage, tibialis anterior and gastrocnemius muscle thickness measurements will be performed using musculoskeletal ultrasound.
223615424|NCT00764361|DRUG|doxycycline|1.0% doxycycline gel applied topically to the wound once daily for 20 weeks
223615425|NCT00764361|DRUG|placebo gel|placebo gel applied topically to the wound once daily for 20 weeks
223615426|NCT00547651|DRUG|Amrubicin|Amrubicin for injection is supplied as 50-mg vials. Patients will receive 40 mg/m2 amrubicin as a 5-minute infusion once daily for 3 consecutive days starting on Day 1 of a 21-day course
223615427|NCT00547651|DRUG|Topotecan|Topotecan for injection is supplied as 4-mg vials. Patients will receive 1.5 mg/m2 as a 30-minute infusion once daily for 5 consecutive days starting on Day 1 of a 21-day course
223615428|NCT03188107|OTHER|Video based assessment|All the infants included in this study will be assessed with Infant Motor Profile based on video recording.
223615429|NCT00367939|DRUG|valsartan + amlodipine|
223615430|NCT03074071|BEHAVIORAL|Hope Enhancement Workshop|Participants in the workshops will be prompted and guided through exercises that help them get in touch with goals that are not explicitly related to cure of disease. These goals will include symptom relief and other personal and or professional objectives.
223615431|NCT02462148|DRUG|Dexamethasone|Used in nerve block mixture
223615432|NCT02462148|DRUG|Bupivacaine|Used in nerve block mixture
223615433|NCT02462148|DRUG|Epinephrine|Used in nerve block mixture
223615434|NCT02462148|PROCEDURE|Saphenous Peripheral Nerve Block|Peripheral nerve block.
223615435|NCT06178107|DIETARY_SUPPLEMENT|LP-LDL Probiotic|LP-LDL a dietary food supplement probiotic
223615436|NCT06178107|DIETARY_SUPPLEMENT|Placebo Comparator|Placebo comparator Maltodextrin
223615437|NCT02079038|DEVICE|Totalis|
223615438|NCT02079038|PROCEDURE|Comparator Surgical Procedure|
223615439|NCT03572452|BEHAVIORAL|McKenzie Method|Treatment according to the Mechanical Diagnosis and Therapy Approach
223615440|NCT03572452|BEHAVIORAL|Advice to saty active|Physiotherapy councelling advicing to stay normally active
223615441|NCT00106314|DRUG|Dehydroepiandrosterone [DHEA]|
223615442|NCT02456155|PROCEDURE|placing nasal jejunal tube with ultrasound|bedside placing nasal jejunal tube with ultrasound confirmation versus placing endoscopically
223615443|NCT02456155|PROCEDURE|placing nasal jejunal tube endoscopically|
223615444|NCT04503746|DRUG|ALH-L1005 600mg/day|ALH-L1005 300mg 2 tablet and placebo 2 tablet
223615445|NCT04503746|DRUG|ALH-L1005 1,200mg/day|ALH-L1005 300mg 4 tablet
223615446|NCT04503746|DRUG|Placebo|Placebo 4 tablet
223615447|NCT06457061|OTHER|Survey Study|"Barthel Index for Activities of Daily Living Scale, Beck Depression Inventory and Star Cancellation Test questionnaires were applied to hemiplegia patients.~Beck Depression Inventory and Zarit Caregiver Burden Interview surveys were administered to caregivers."
223615448|NCT03986996|DRUG|amoxicillin, metronidazole and doxycycline|antibiotics: Patient weight 30-50 kg Patient weight \> 50 kg Tetracycline 50 mg X 2 Day X 2 weeks 100 mg X 2 Day X 2 weeks Amoxicillin 750 mg X 2 Day X 2 weeks 750 mg X 2 Day X 2 weeks Metronidazole 250 mg X 2 Day X 2 weeks 375 mg X 2 Day X 2 weeks
223615449|NCT03986996|DRUG|amoxicillin and doxycyclin|antibiotics: Patient weight 30-50 kg Patient weight \> 50 kg Tetracycline 50 mg X 2 Day X 2 weeks 100 mg X 2 Day X 2 weeks Amoxicillin 750 mg X 2 Day X 2 weeks 750 mg X 2 Day X 2 weeks
223615450|NCT05201508|PROCEDURE|Polyglactin mesh|Polyglactin mesh is used in keyhole manner to enforce hiatal closure
223615451|NCT05201508|PROCEDURE|Sutures only|Traditional hiatal closure with non-absorbable sutures.
223615452|NCT01952132|DRUG|OMS643762|
223615453|NCT01952132|DRUG|Placebo|
224312205|NCT06982755|DRUG|compound diclofenac sodium|intramuscular injection of compound diclofenac sodium injection; sample size: 44
223615454|NCT03096340|DRUG|IT-141|Escalating doses administered in mg/m2, IV (in the vein) on days 1 and 15 of each 28 day cycle until progression or unacceptable toxicity develops.
223615455|NCT01308736|DRUG|Varenicline|Participants randomized to receive varenicline will follow the Pfizer recommended dosing schedule (0.5 mg QD on days 1-3, 0.5 mg BID on days 4-7, and 1 mg BID thereafter.
223615456|NCT01308736|DRUG|Placebo pill|Participants randomized to receive placebo pill will follow the same dosing schedule as those randomized to receive varenicline (1 pill labelled 0.5 mg on days 1-3, pills labelled 0.5 mg BID on days 4-7, and pills labelled 1 mg BID thereafter.
223615457|NCT03634085|DRUG|BDM-2 in Bottle (50 mg - 3600 mg); oral suspension|BDM-2 in bottle will be reconstituted with a 100 mL vehicle (0.2% Sodium Dodecyl Sulfate and water) to achieve a suspension for oral administration.
223615458|NCT04764474|DRUG|HMPL-306|Administered orally QD in a 28-day continuous dosing treatment cycle
223615459|NCT06409910|RADIATION|Radiotherapy|Non-institutional-standard radiotherapy
223615460|NCT05698680|DRUG|Prednisolone 30 mg Tablet|"See treatment arm Prednisolone"
223615461|NCT05698680|DRUG|Colchicine 0.5 mg Oral Tablet|"See treatment arm Colchicine"
223615462|NCT03841422|PROCEDURE|video-assisted nasal self-packing|video-assisted nasal self-packing
223615463|NCT03246789|BEHAVIORAL|Engage-M|Engage is a stepped care psychotherapy based on what is known about how older adults respond to depression interventions. Stepped care is a model of treatment that starts with the minimum effective therapeutic techniques first, and then based on how well people respond to treatment, additional therapeutic techniques are added until people are recovered from their depression.
223615464|NCT03246789|BEHAVIORAL|Wellness in Mind and Body|An active intervention focusing on psychoeducation and de-stigmatization of health and mental health conditions. These sessions are commonly part of senior centers programs. W-MH will offer mental health referral to a clinic or primary care physician as part of senior center procedures for clients with positive PHQ-9s.
223615465|NCT00006107|DRUG|Taxotere|
223615466|NCT00006107|PROCEDURE|Surgery|
223615467|NCT00006107|RADIATION|radiation therapy|
223615468|NCT04404231|RADIATION|Delivery of infrared light to the head|Building upon the experience gathered from previous depression clinical trials, we will treat twice weekly for a total of 4-week duration consisting of 8 sessions. Each treatment will last 20 min and areas irradiated will include frontal and temporal areas bilaterally. Irradiance of 250 mW/cm2 with a fluence of 60 J/cm2.
223615469|NCT04404231|OTHER|No Infrared treatment|This is sham treatment. No light is actually given.
223760555|NCT04166838|BIOLOGICAL|CD19 UCARTcells|This study did not set up a control group. The maximum dose was determined according to the dose escalation test. Based on the number of CART cells per kg body weight which was proved to be safe and effective, all the subjects were treated with one single dose of CD19 UCART cells per treatment course. The dose escalation test was designed to evaluate the three dose levels of CD19 UCART (1 × 10 \^ 6 cells/kg,3 × 10 \^ 6 cells/kg,5 × 10 \^ 6 cells/kg). Each CD19 UCART infusion will be carried out on day 0. Each subject was observed for at least 4 weeks after the last infusion. If there was no dose-limited toxicity (DLT), it is necessary to continue multiple treatment courses at this dose level. The detailed administration time and dose were decided by the researchers.
223615470|NCT05754294|DIAGNOSTIC_TEST|Polarization of red blood cells|Pre and perioperative data blood sample were collected for each patient 5 minutes (min) before the CPB start and 5 minutes before the end of the CPB for Complete Blood Count (CBC), Erythrocyte Sedimentation Rate (ESR) and Plasma Free Hemoglobin (pFHb). At the end of CPB the residual blood from the extracorporeal circulation was treated with cell-saver and the treated and concentrated red blood cells were collected in a transfusion bag. Two milliliters (ml) was taken from the bag, one ml was subjected to a blood gas test for the evaluation of the Hemoglobin (Hb) content and one ml was subjected inside a cuvette to the release of positive ions (polarization) with a charge of 50 Millivolt (mV) for a time of 5 seconds through charge circuit, after the trend of the conserved charge was measured through a multimeter, instrument that can measure multiple electrical properties.
223760556|NCT03322228|OTHER|Music Therapy|Music therapy is tailored to subject preference. Examples are active music-making, supportive listening, and includes opportunities for legacy building to decrease caregiver distress and promote self-care.
223760557|NCT01398956|DRUG|Levetiracetam|"formulation: tablet or dry syrup~strength: 250 mg tablet, 500 mg tablet, dry syrup 50%~dosage: Sb ≥16 years and ≥4 and \<16 years (≥50 kg): 1000 mg/day, 2000 mg/day or 3000 mg/day; Sb ≥4 and \<16 years (\<50kg): 20 mg/kg/day, 40 mg/kg/day, or 60 mg/kg/day~frequency: twice daily"
223760558|NCT04693390|PROCEDURE|Acupuncture|Application of acupuncture
223760559|NCT03748199|DRUG|POL6014|"DL1 80 mg cohorts 1A and 1B (80 mg QD and 40 mg BID) DL2 160 mg cohorts 2A and 2B (160 mg QD and 80 mg BID) DL3 40 mg QD cohort C~DL = dose Level QD= quaque die (once daily) BID= bis in die (twice daily)"
223760560|NCT03748199|DRUG|Placebo|Placebo will be administered orally at a dose and frequency matched to POL6014
223760561|NCT04118309|BEHAVIORAL|Exercise|
223760562|NCT04118309|OTHER|Placebo|
223760563|NCT02653742|DRUG|Ketorolac|Ketorolac 1mg/kg sublingual is administered after induction of general anesthesia.
223760564|NCT02653742|DRUG|Fentanyl|Fentanyl 2mg/kg intranasal is administered after induction of general anesthesia
223760565|NCT06497049|DRUG|GP40221|Solution for Subcutaneous Administration 1.34 mg/ml
223760566|NCT06497049|DRUG|ozempic|Solution for Subcutaneous Administration 1.34 mg/ml
223760567|NCT00218517|DRUG|Selegiline hydrochloride|Daily oral selegiline, 5 mg po qd x 7 days, then 5 mg po bid for 7 weeks
223760568|NCT00218517|DRUG|Placebo|Matching placebo capsules using blue 00 capsules
223760569|NCT04813796|BIOLOGICAL|mRNA-1283|Sterile liquid for injection
223760570|NCT04813796|BIOLOGICAL|mRNA-1273|Sterile liquid for injection
223760571|NCT04813796|BIOLOGICAL|Placebo|0.9% sodium chloride (normal saline) injection
223760572|NCT03272451|PROCEDURE|culprit vessel intervention|ECG guided immediate culprit vessel intervention using a single transradial guiding catheter such as MAC or JL 3.5
223760573|NCT03272451|PROCEDURE|traditional approach|single diagnostic catheter for complete coronary angiography and guiding catheter selection for PCI
223760574|NCT05107258|DIAGNOSTIC_TEST|The Pine Trees Health Test System|Consists of the Pine Trees Health Reader and the Pine Trees Health COVID-19 Test Kit, which contains the Pine Trees Health Cartridge, Pine Trees Health Sample Vial containing Sample Lysis Buffer and the Pine Trees Health Nasal Swab (anterior nares) for collection. The Test System is a point-of-care test used for the qualitative detection of nucleic acid from SARS-CoV-2 viral RNA in nasal swabs taken from individuals who are suspected by a healthcare professional of having COVID-19. The COVID-19 test is a rapid molecular, in vitro diagnostic test using isothermal nucleic acid amplification technology and detection of the resulting amplicon using CRISPR-mediated collateral reporter unlocking.
223760575|NCT01020058|PROCEDURE|Mesh repair for primary inguinal hernia|Open Lichtenstein repair in local anesthesia using a polypropylene mesh compared to totally extra-peritoneal laparoscopic repair using a polypropylene mesh
223760576|NCT05134207|DIETARY_SUPPLEMENT|oral carbohydrate solution|Patients in the intervention group; Preop oral carbohydrate solution was ingested orally twice within 10 minutes, as 800 ml at 24:00 the night before the surgery and 400 ml at 06:00 2 hours before the surgery.
223760577|NCT00732810|DRUG|SCH 727965|SCH 727965 50 mg/m\^2 IV on Day 1 of each 21 day cycle until disease progression.
223760578|NCT00732810|DRUG|Capecitabine|Capecitabine 1250 mg/m\^2 orally twice daily from Day 1 to Day 14 of each 21 day cycle until disease progression.
223760579|NCT00732810|DRUG|Erlotinib|Erlotinib 150 mg orally once daily until disease progression.
223760580|NCT01557400|DRUG|Ataluren|Oral powder for suspension
223760581|NCT02630784|PROCEDURE|Non-Invasive Ventilation with Homecare ventilator|
223760582|NCT02630784|PROCEDURE|Non-Invasive Ventilation with ICU ventilator|
223760583|NCT02232581|DRUG|Alovudine - low|
223760584|NCT02232581|DRUG|Alovudine - medium|
223760585|NCT02232581|DRUG|Alovudine - high|
223760586|NCT02232581|DRUG|Placebo|
223760587|NCT02259309|DRUG|Misoprostol - buccal|buccal administration
223760588|NCT02259309|DRUG|Misoprostol - vaginal|vaginal administration
223760589|NCT04366167|OTHER|Cardiac surgery|Cardiac surgery during the COVID-19 pandemic
223760590|NCT03258827|PROCEDURE|Exercise with a towel|Exercise program composes with warm-up, strengthening exercise, cold-down, 60 minutes/time, 3 times/week. A towel is an important tool for exercise. Total duration of the program is 3 months.
223760591|NCT03258827|PROCEDURE|Home-based exercise|Home-based program focuses on walking activity at fast speed, 3 times/week, 60 minutes/times. The total duration is 3 months.
224312206|NCT06982755|COMBINATION_PRODUCT|acupuncture combined with compound diclofenac sodium|acupuncture at Zusanli (ST36) and intramuscular injection of compound diclofenac sodium injection; sample size: 44
223760592|NCT03214627|DEVICE|Anemia Control Model (ACM)|The ACM is mainly composed of 2 sub-Systems - predictor model which, depending on the input data, forecasts the response to anaemia drug therapy for a specific patient. The predictor model is implemented as a feed-forward artificial neural network. The ACM is an algorithm that extracts the optimal policy to achieve the established clinical outcome for anaemia management using the predictor model.
223760593|NCT03214627|DRUG|IV iron|IV iron given monthly as required - dose determined by the ACM and as agreed by the investigator
223760594|NCT03214627|DRUG|Erythropoiesis-Stimulating Agent (ESA)|ESA given monthly as required over 6 months - dose determined by the ACM and as agreed by the investigator
223760595|NCT05041933|DRUG|outsourcing of chemotherapy to Hospital at Home|outsourcing of chemotherapy to Hospital at Home
223615471|NCT03025646|OTHER|Mental Health care services & home based training|"From day 0 of the study period we will initiate setting up the intervention in two schools, which will include two components:~1. Implementing mental health care services at schools targeting the mothers diagnosed as having depression who have consented to participate in the study (intervention mother).~   Psychologists will provide counseling session over 4-6 months period. Every month a psychiatrist will visit each school for reviewing the records of the mothers and mothers will be referred to the National Institute of Mental Health (NIMH) if necessary~2. Organizing training sessions of the intervention mothers for supporting enhanced child care at home.~Organizing training of the intervention mothers by special educator through a parental training module in the schools. Special educator will conduct refresher training at home every month."
223615472|NCT02104453|PROCEDURE|airway maneuver|"Three-period crossover study: During general anesthesia induction, subjects are assigned to one of the 6 airway maneuver sequences (ABC, CAB, BCA, ACB, CBA, or BAC) in accordance with a randomization schedule. Each maneuver is performed 5 times in a period.~Airway maneuver A: E-C clamp mask holding technique; Airway maneuver B: two-handed mask ventilation with jaw thrust airway maneuver; Airway maneuver C: two-handed mask ventilation with triple airway maneuver(combine jaw thrust and head tilt chin lift)"
223615473|NCT01889875|DRUG|"ALK Grazax 75,000 SQ-T Phleum pratense"|
223615474|NCT01889875|DRUG|"ALK AluTard 225 Phleum pratense"|
223615475|NCT03694717|DRUG|Saline Solution for Injection|The fluid expansion will consist in a less than 10 min infusion of 500 milliliters of saline through a central venous catheter (jugular). The duration of infusion will be controlled by an airbag pressurized at 300 mmHg.
223615476|NCT01729299|DRUG|Exendin (9-39)|
223615477|NCT01729299|DRUG|acyl ghrelin|
223615478|NCT01729299|DRUG|saline|
223615479|NCT02486536|DRUG|polyethylene glycol|
223615480|NCT02486536|DEVICE|capsule endoscopy|
223615481|NCT01594320|BIOLOGICAL|Monovalent Avian Influenza VLP (H5N1)|Dose A without Adjuvant 1; intramuscular, deltoid, Day 0 \& Day 21
223615482|NCT01594320|BIOLOGICAL|Monovalent Avian Influenza VLP (H5N1)|Dose B without Adjuvant 1; intramuscular, deltoid, Day 0 \& Day 21
223760596|NCT04489706|DRUG|Arsenic trioxide for injection|Arsenic trioxide for injection, 0.16 mg/kg (maximum single dose is 10 mg), daily IV drip, d1 to d14, once every 28 days, for six cycles of treatment or until one of the following events occurs: Initiation of new anti-tumor therapy, disease progression, withdrawal of Informed consent form (ICF) and/or death.
223760597|NCT05606042|DEVICE|IM Implant|Patients that have had surgical interventions with one or more IM Implant as part of standard of care for a pelvic and/or acetabular fracture
223760598|NCT03337282|PROCEDURE|Protocolized general anesthesia|Induction and maintenance of general anesthesia, post-operative analgesia with protocolized drugs and doses. Maintenance of MAP +/- 20% of baseline with vasopressors as needed.
223760599|NCT04328376|DIAGNOSTIC_TEST|ECG coupled to phonocardiography|"A standard ECG is recorded along with a phonocardiographic recording. The phonocardiographic recording is obtained by using a specific electronic stethoscope plugged into the auxiliary port of the ECG machine. The recording takes less than 30 seconds. The two recording methods are concomitant.~QT interval is measured on the ECG recording, EMW is measured with ECG coupled to phonocardiography."
223760600|NCT06162286|DRUG|Omadacycline|Omadacycline IV/PO
223615483|NCT01594320|BIOLOGICAL|Monovalent Avian Influenza VLP (H5N1); Adjuvant|Dose B with Adjuvant 1; intramuscular, deltoid, Day 0 \& Day 21
223760601|NCT06162286|DRUG|Moxifloxacin|Moxifloxacin IV/PO
223760602|NCT05435378|DRUG|Vitamin B3 100 MG Oral Tablet|After the non surgical treatment and the oral hygiene instructions The systemically administered vitamin B3 capsules will then given to the patients under the previously mentioned dosage.
223760603|NCT05435378|DRUG|vitamin B9|After the non surgical treatment and the oral hygiene instructions the systemically administered vitamin B9 capsules will then given to the patients under the previously mentioned dosage.
223760604|NCT05435378|DRUG|Placebo|After the non surgical treatment and the oral hygiene instructions The systemically administered placebo capsules will then given to the patients under the previously mentioned dosage.
224312207|NCT06982755|COMBINATION_PRODUCT|placebo|superficial acupuncture at Zusanli (ST36) and intramuscular injection of normal saline; sample size: 44
223615484|NCT01594320|BIOLOGICAL|Monovalent Avian Influenza VLP (H5N1); Adjuvant|Dose C with Adjuvant 1; intramuscular, deltoid, Day 0 \& Day 21
223615485|NCT01594320|BIOLOGICAL|Monovalent Avian Influenza VLP (H5N1); Adjuvant|Dose D with Adjuvant 1; intramuscular, deltoid, Day 0 \& Day 21
223615486|NCT01594320|BIOLOGICAL|Saline placebo|Placebo; Intramuscular, deltoid, Day 0 \& Day 21
223615487|NCT00985465|BIOLOGICAL|Pneumococcal vaccine GSK1024850A|Intramuscular injection, 1 or 2 doses
223615488|NCT05922189|OTHER|SBS Decompression Technique|The investigator who applied the technique stood on the right side, laterally to the headboard of the table, with feet flat on the floor, at an appropriate level in relation to the volunteer's headboard, and with a glove on his right hand. Then, he contacted the volunteer's sphenoid wings with his left hand and asked the volunteer to open her mouth, contacting the upper dental arch with the second and third fingers of his right hand. Subsequently, the investigator brought both hands together, followed by an inspiration towards the floor and then a translation towards the ceiling until he felt the structures relax, with a maximum duration of 5 minutes. A second Investigator was sitting on a chair, placed on the opposite side of the head of the table with a stopwatch in his dominant hand, in order to time the application time of each technique.
224312208|NCT06982092|DRUG|sugammadex|: patients will receive the reversal drug according to the group to which they had been randomised. in the Sugammadex Group will receive 2 mg/kg sugammadex.
224312209|NCT06982092|DRUG|Neostigmine|Patients in the NEO Group will receive 50 mic/kg neostigmine and .01-.02 mg/kg atropine
224312210|NCT06102291|OTHER|Yanqing Zhitong Ointment Acupoint application|Yanqing Zhitong Ointment is a traditional external preparation of experiential prescription, which is an extract made by water extraction and concentration of Qingfengteng, Corydalis yanhusuo, Interleukin, Kansui, Asarum, etc. Clinical studies in the past ten years have preliminarily shown that it has the effects of warming meridians, promoting blood circulation, dredging collaterals and relieving pain, and has a definite effect.
223760605|NCT05435378|PROCEDURE|full mouth non surgical periodontal treatment|full mouth scaling and debridement will be done by the primary investigator using ultrasonic scaler and periodontal curettes. After the non surgical treatment patients will be given oral hygiene instructions where they will be instructed to brush twice daily and shown how to brush using the horizontal scraping technique they will also be instructed to use the dental floss and shown how to use it.
223760606|NCT04155008|DRUG|Dexamethasone|If the patient's prognosis is extremely poor (less than 12 weeks expected survival, based on discussion with the patient's treating physicians) and there is no additional disease modifying therapy planned, the patient will be prescribed 4mg dexamethasone (which is FDA approved), once daily, to be taken orally in the morning.
223760607|NCT04155008|DRUG|Dronabinol|If the patient has a history of marijuana use or has tried it in the past and had a positive experience with it, then the patient will be prescribed dronabinol (which is FDA approved) 2.5mg, twice daily before meals.
223760608|NCT04155008|DRUG|Mirtazapine|If the patient does not have any history of marijuana use, mirtazapine will be prescribed. If the patient is under the age of 70, then the patient would be prescribed 15mg of mirtazapine (which is FDA approved), once daily, to be taken orally at bedtime. For geriatric population (if the patient is over the age of 70), then the patient would be prescribed 7.5mg of mirtazapine, once daily to be taken orally at bedtime.
224312211|NCT06102291|OTHER|Acupuncture|The main acupoints are Ashi points, Shenshu (BL23), Guanyuanshu (BL26). There are three sessions per week with each session lasting for 20 min. There will be 4 weeks of treatment for each participant in total.
224312212|NCT06989268|DRUG|Linaclotide 290 micrograms|290 μg linaclotide once daily oral administration with 125mL of water
223615489|NCT05922189|OTHER|Placebo Technique|The investigator was standing, on the right side, laterally to the headboard of the table with feet flat on the floor, at an appropriate level in relation to the headboard of the volunteer's and with a glove on his right hand. Then, he contacted the participant's sphenoid wings with his left hand and asked her to open her mouth. With the second and third fingers of the right hand, he made contact with the upper dental arch. These contacts were maintained for 2 minutes, without moving. A second investigator sat on a chair, placed on the opposite side of the table with the stopwatch in his dominant hand, in order to time the application time of each technique.
223615490|NCT04648813|DRUG|tiotropium bromide monohydrate (Spiriva Respimat)|administered daily, 2 inhalations/5mcg per dose for a total of 8 doses
223615491|NCT04648813|DRUG|matching placebo|administered daily, 2 inhalations per dose for a total of 8 doses
223615492|NCT01897363|OTHER|Infants with Prader-Willi Syndrome|Participants will be admitted to the outpatient clinical research center for IV placement, blood draws from the IV, poking the participants finger to obtain small amounts of blood and monitored 6 hour fast.
223615493|NCT04832932|BIOLOGICAL|COVID-19 vaccines|Emergency-use authorized COVID-19 vaccines
223615494|NCT00756431|DEVICE|Hip Fracture reduction Screw without HA Coating (Hiploc)|Hip Fracture reduction Screw without HA Coating (Hiploc)
223760609|NCT04155008|BEHAVIORAL|Nutrition Intervention|"Nutrition intervention will be in accordance with the Academy of Nutrition and Dietetics guidelines. The intervention will involve purposefully planned action(s) designed with the intent of changing a nutrition-related behavior, risk factor, environmental condition, or aspect of health status"
223615495|NCT00756431|DEVICE|Hip Fracture reduction Screw with HA Coating (Hiploc)|Hip Fracture reduction Screw with HA Coating (Hiploc)
223615496|NCT00314743|DRUG|Ondansetron|
223760610|NCT03533387|DRUG|MN-166|an orally available small molecule drug approved in Japan and Korea for asthma and post-stroke complications and has been prescribed for these indications for more than 25 years
223760611|NCT02281552|DRUG|Tofacitinib|tofacitinib modified release 11 mg tablet administered once time a day for 12 weeks
223760612|NCT02281552|DRUG|Tofacitinib|tofacitinib immediate release 5 mg tablet administered twice a day for 12 weeks
223760613|NCT01224639|BIOLOGICAL|TDV - Low Dose|TDV is a tetravalent dengue vaccine comprised of four recombinant, live attenuated dengue virus strains: TDV-1, TDV-2, TDV-3 and TDV-4. Low dose contains: TDV-1: 8 x 10\^3 PFU, TDV-2: 5 x 10\^3 PFU, TDV-3: 1 x 10\^4 PFU, and TDV-4: 2 x 10\^5 PFU, total virus per dose 2.2 x 10\^5 PFU
223760614|NCT01224639|BIOLOGICAL|TDV - High Dose|TDV is a tetravalent dengue vaccine comprised of four recombinant, live attenuated dengue virus strains: TDV-1, TDV-2, TDV-3 and TDV-4. High dose contains TDV-1: 2 x 10\^4 PFU, TDV-2: 5 x 10\^4 PFU, TDV-3: 1 x 10\^5 PFU, and TDV-4: 3 x 10\^5 PFU, total virus per dose : 4.7 x 10\^5 PFU. TDV administered intradermally.
223760615|NCT01224639|BIOLOGICAL|Placebo|Phosphate Buffered Saline (PBS)
224312213|NCT06989268|DRUG|Placebo|Placebo, empty capsule, once daily oral administration with 125mL of water
224312214|NCT06990451|OTHER|time pressure|a set of alternative cognitive strategies that allow patients in real-life tasks to compensate for their mental slowness
224312215|NCT06990451|OTHER|step square exercise|is a form of highly specific balance training for falls prevention which directly addresses stepping capacity-a commonly executed protective strategy for maintaining balance in the everyday environment
224312216|NCT06990451|OTHER|functional care training|Intensive functional endurance, strength, and balance exercises, and selected physical therapy interventions for balance
224312217|NCT06990412|DEVICE|NEO|a Minimally Invasive Wireless Implantable Brain-Computer Interface (BCI) System NEO
224312218|NCT06989775|DEVICE|Isolator® Synergy™ EnCompass® Ablation System and AtriClip® LAA Exclusion System|Box lesion ablation with the Isolator Synergy EnCompass Clamp System and LAAE using the AtriClip LAA Exclusion System at the time of planned cardiac surgery
223615497|NCT00314743|DRUG|Dexamethasone|
223615498|NCT00314743|DRUG|Aprepitant|
223615499|NCT04701333|DRUG|Cabergoline 1 MG|Dopamine agonist
223615500|NCT04701333|DRUG|Placebo|Placebo
223615501|NCT01292187|DRUG|Oral calcitonin at dinnertime|Oral calcitonin at dinnertime.
223615502|NCT01292187|DRUG|Oral placebo at dinnertime|Oral placebo at dinnertime.
223615503|NCT01292187|DRUG|Oral calcitonin at bedtime|Oral calcitonin at bedtime
223615504|NCT01292187|DRUG|Oral placebo at bedtime|Oral placebo at bedtime
223615505|NCT00806910|DRUG|Conivaptan|IV Vaprisol initially at 20 mg IV injection over 30 minutes, followed by a 20 mg IV infusion over the next 24 hours (i.e. 20 mg bolus, 20 mg continuous infusion approximately 24 hrs).
223615506|NCT00806910|OTHER|Placebo|Placebo (will be given at the same rate of Vaprisol given in the treatment arm)
223615507|NCT03457376|DIAGNOSTIC_TEST|Hand Grip Force|Hand Grip Force
223615508|NCT03457376|DIAGNOSTIC_TEST|Maximal Inspiratory Pressure|Maximal Inspiratory Pressure
223615509|NCT03457376|DIAGNOSTIC_TEST|Maximal Expiratory Pressure|Maximal Expiratory Pressure
223615510|NCT00076414|DRUG|Acetylcholine|
223615511|NCT00076414|DRUG|L-NMMA|
223615512|NCT03062020|DEVICE|QUIPP|Information required by QUIPP tool will be introduced ( obstetrical history, cervical length and quantitative fetal fibronectin value) and a percentage of risk of preterm birth will be given. Women with a high-risk value will be managed in Preterm Birth Prevention Clinic and women with low-risk value will be followed-up in a low-risk unit.
223615513|NCT02414685|DRUG|Paclitaxel|paclitaxel, ifosfamide, cisplatin until progression, unacceptable toxicity, complete response or inability of the subject to comply with study requirements
223615514|NCT02414685|DRUG|Ifosfamide|paclitaxel, ifosfamide, cisplatin until progression, unacceptable toxicity, complete response or inability of the subject to comply with study requirements
223615515|NCT02414685|DRUG|Cisplatin|paclitaxel, ifosfamide, cisplatin until progression, unacceptable toxicity, complete response or inability of the subject to comply with study requirements
223760616|NCT03465878|DRUG|LY900014|Administered via SC injection
223760617|NCT03465878|DRUG|Insulin Lispro|Administered via SC injection
223760618|NCT01411163|DRUG|Creatine monohydrate|Up to 30 grams daily creatine monohydrate
223760619|NCT04656132|BEHAVIORAL|Physical activity assessment, promotion and monitoring in a preventive cardiology clinic|physical activity assessment promotion and remote home step-count monitoring in a clinical cardiology center
223615516|NCT00141674|PROCEDURE|Blood Transfusion|This is a single centre randomized trial in severely head injured patients requiring a blood transfusion. Randomization will be by computer generated random numbers paced in sealed envelopes. Patients would be randomized to receive either blood less than 5 days old or greater than 20 days old. The decision to transfuse and all other intensive care management will be unaltered by enrolment in the study.
223615517|NCT02996630|PROCEDURE|Sonography|Fetal Ultrasound exploration
223615518|NCT02996630|DEVICE|Magnetic Resonance Imaging|Fetal MRI for brain study
223615519|NCT02996630|OTHER|Bailey Test|Neurodevelopment paediatric assessment test performed at 2 years of age.
223615520|NCT02996630|PROCEDURE|Surgical intervention|Congenital Heart Disease repair
223615521|NCT02996630|PROCEDURE|Brain monitoring|EEG and continuous brain oximetry before surgery.
223615522|NCT02996630|PROCEDURE|cord blood sample|Cord blood samples will be taken after birth in both groups.
223615523|NCT06522789|PROCEDURE|corneal cross-linking procedure|Standard Dresden protocol corneal cross-linking procedure The CXL procedure adhered to the standard Dresden protocol. All patients received topical anaesthetic (Tetracaine HCL 0.5%, Alcon Forth Worth, Texas) and a miotic (Isopto Carpine 2% HCl, Alcon, Fort Worth, Texas) drops 30 minutes before the procedure. The periocular region and conjunctival sac were washed with 10% povidone-iodine (Betadine 10%, Alcaloid, Skopje). Manual epithelial scraping with a crescent knife followed. Pachymetry was kept over 400 μm during the procedure and measured with an ultrasound hand pachymeter (Pocket II, Quantel Medical, Cournon d'Auvergne, France). Riboflavin (Peschke D, Peschke Trade, Huenenberg, Switzerland) was applied every 3 minutes for 30 minutes. We performed corneal UV-A radiation with a wavelength of 370 nm and energy of 3mW using a UVA CXL lamp (VEGA CBM-X-Linker, Carleton Optical, Chesham, UK) for 30 minutes (6 cycles of 5 minutes each).
223615524|NCT01999296|DEVICE|Use of Thunderbeat (TM) in laparoscopic surgery|
223615525|NCT03449966|DEVICE|Confocal group|Under pCLE, target biopsy at cancer lesion will be done. 5 pieces of forcep biopsy will be obtained.
223615526|NCT03449966|DEVICE|Control group|Random biopsy around cancer lesion will be done under WLE. 5 pieces with forcep biopsy will be obtained.
223615527|NCT02360826|DRUG|Pravastatin|
223615528|NCT02360826|DRUG|Simvastatin|
223615529|NCT00898963|GENETIC|gene expression analysis|
223615530|NCT00898963|GENETIC|microarray analysis|
223615531|NCT00898963|GENETIC|polymorphism analysis|
223615532|NCT00898963|OTHER|diagnostic laboratory biomarker analysis|
223615533|NCT00898963|OTHER|immunohistochemistry staining method|
223615534|NCT00898963|OTHER|immunologic technique|
223615535|NCT03833739|DEVICE|Fixed appliance|
223615536|NCT00504088|PROCEDURE|Bypass|
223615537|NCT00504088|PROCEDURE|Silverhawk Plaque Excision|
223615538|NCT01180335|DRUG|Chemotherapy|4 cycles FEC followed by 4 cycles docetaxel
223615539|NCT01180335|DRUG|Genomic driven chemotherapy|High DLD30 receive 3 months weekly paclitaxel followed by 4 FEC, patients with high TOP2A receive 4FEC then 4 docetaxel, patients with low DLD30 and low TOP2A are treated with 6 cycles of docetaxel-capecitabine.
223615540|NCT02119871|PROCEDURE|Bilateral Open Pleurae|Both pleurae are opened Right pulmonary vein drainage
223615541|NCT02119871|PROCEDURE|Right Pleura Open|Right pleura open Left ventricular apical drainage
223760620|NCT03517709|OTHER|Primary Care Physician Management of blood pressure|"* You will receive a 30-minute education session about your blood pressure medications and the need to take them every day.~* Your primary care physician will make recommendations on your optimal target blood pressure range and medication recommendations. ."
223615542|NCT03744728|DIAGNOSTIC_TEST|Accelerate PhenoTest™ BC kit|The Accelerate PhenoTest™ BC kit with the Accelerate Pheno™ System is a fully-integrated in vitro diagnostic system. It is FDA-cleared to perform ID of bacteria and yeast in less than 90 minutes and AST in less than 7 hours, on average, directly from positive blood culture
223615543|NCT03744728|DIAGNOSTIC_TEST|Standard of Care|Standard culture and AST of positive blood culture bottles plus the Verigene® BC-GP/GN
223615544|NCT05022186|DRUG|Cannabidiol Oil|Patients will use it with specific instructions and they will be monitored at least one time in a month
223615545|NCT05022186|DRUG|Homotaurine|Patients will use it with specific instructions and they will be monitored at least one time in a month
223615546|NCT00961311|PROCEDURE|Percutaneous Coronary Intervention|Balloon angioplasty of a severely stenotic coronary lesion with the Sprinter Legend 1.25mm Balloon.
223615547|NCT00961311|DEVICE|Sprinter Legend 1.25mm Balloon Catheter|Balloon Angioplasty
223615548|NCT02489071|BEHAVIORAL|Brain Training Program|
223615549|NCT02489071|BEHAVIORAL|Brain Health Program|
223615550|NCT03075618|BEHAVIORAL|Questionnaires|Questionnaires
223615551|NCT04959747|OTHER|acupuncture|"Body acupuncture will choose eight acupoints as Yingxiang (LI20),Shangxing (GV23), BiTong, Yintang, Hegu. Disposable acupuncture needle (0.25 mm in diameter and 25-30mm in length) are inserted at a depth of 10-25 mm obliquely into scalp acupuncture points (ShangXing, YinTang) and straightly into face/body acupuncture points (Yingxiang, BiTong, Hegu).~We will also deliver electro-acupuncture will be applied to the face points at fast and dispersed waves through electric needle stimulator which is provided by Chinese Medicine Clinic (ES-160 6-Channel Programmable electro-acupuncture) for 30 minutes."
223615552|NCT03170726|DRUG|arveles|Intraoperative and postoperative pain values between these three groups will be compared.
223615553|NCT03170726|DRUG|intrafen 800 mg|ibuprofen 800 mg in normal saline 150 cc before operation will be given in 30 minutes. Intraoperative and postoperative pain values between these three groups will be compared.
223615554|NCT03170726|OTHER|plasebos|normal saline 150 cc before operation will be given in 30 minutes. Intraoperative and postoperative pain values between these three groups will be compared.
223615555|NCT02670486|OTHER|Audiovisual stimulus|Water fountain and a video (including scenes of some common triggers for OAB) played on continuous loop throughout the test on a laptop
223615556|NCT00005952|BIOLOGICAL|filgrastim|
223615557|NCT00005952|DRUG|temozolomide|
223615558|NCT00005952|PROCEDURE|peripheral blood stem cell transplantation|
223615559|NCT00744926|DRUG|placebo|sc, once weekly
223615560|NCT00744926|DRUG|taspoglutide|10mg sc, once weekly
223615561|NCT00744926|DRUG|taspoglutide|20mg sc, once weekly (after 4 weeks of taspoglutide 10mg sc once weekly)
223760621|NCT03517709|DEVICE|Withings Smart Blood Pressure Monitor|We will use the Withings Smart Blood Pressure Monitor for daily blood pressure measurements.
223760622|NCT03413059|DRUG|Morphine Sulfate|Thoracic Epidural morphine
223760623|NCT03413059|DRUG|Triamcinolone Acetonide|thoracic epidural triamcinolone acetonide
223760624|NCT00331175|DRUG|Peptide YY3-36|
224201995|NCT05156775|OTHER|Serratus Plane Block (SPB)|While the patient is in the supine position, the arm will be abducted, the ultrasound probe will be placed over the mid-clavicular region of the thoracic cage in sagittal plane. Ribs will be counted until the fifth rib will be identified in the midaxillary line. the latissimus dorsi (superficial and posterior ), teres major (superior), and serratus muscle (deep and inferior)will be identified overlying the fifth rib. As an extra reference point, thoracodorsal artery will be used, this aids in the identification of the plane superficial to the serratus muscle, 30 ml 0.25 %bupivacaine will be injected between latissimus dorsi and serratus anterior muscles at the level of the 5th rib in the mid axillary line.
223615562|NCT02530021|OTHER|Heart rate monitor|One hour non-invasive ECG heart rate variability monitoring. The results will be blinded and interpreted independantly. Study results will not effect patient management.
223615563|NCT06461663|DEVICE|Breast Cancer Locator Guided Breast Conserving Surgery|Subjects will undergo a contrast-enhanced supine MRI and two marks will be placed on the breast. The MRI images will be transmitted to the sponsor, and the images will be used to build a BCL using 3D printing. Investigators will be provided with a 3D image of the cancer in the breast. Investigators will use a BCL (a patient-specific, plastic, bra-like form that is placed on the breast and allows the investigator to mark the edges of the tumor on the skin and to place wires inside the breast which define the center of the cancer and the tumor edges. The surgeon will then attempt to surgically remove all the tissue inside the wires used to define the tumor edges.
223760625|NCT04224766|PROCEDURE|Suprascapular Nerve Block with 5ml bupivicaine 0.5%|The patient lies supine with the head turned to the contralateral side to the block. Using a linear high-frequency ultrasound probe, the proximal suprascapular nerve is visualized before it turns toward the suprascapular notch. It is blocked using 5mL of bupivicaine 0.5%.
223760626|NCT04224766|PROCEDURE|costoclavicular Block 10ml bupivicaine 0.5%|transverse ultrasound imaging of the medial infraclavicular fossa to identify the cords of the brachial plexus at the costoclavicular space (CCS) then inject 10ml bupivicaine 0.5%
223760627|NCT04224766|PROCEDURE|Interscalene Brachial Plexus Block 15ml bupivicaine 0.5%|The patient lies supine with the head turned to the contralateral side to the block. Using a linear high-frequency ultrasound probe, the interscalene groove is visualized along with the roots of the brachial plexus. The block is performed with 15mL of bupivacaine 0.5%.
223760628|NCT00754754|PROCEDURE|Brain Retraction Monitoring Sensor|This is a sensor incorporated into a brain retractor blade to monitor electrical activity and pressure applied to the brain during retraction required for the selected skull base operations.
223760629|NCT01618357|RADIATION|Radiation|Patients will receive radiation therapy at a dose of 2.35 Gy per fraction to the breast and regional nodal region for 16 fractions to a total dose of 37.5 Gy. Treatments will be given Monday through Friday. Radiation therapy will start on day 1 of Veliparib.
223760630|NCT01618357|PROCEDURE|Lumpectomy/Mastectomy|Resection of breast cancer.
223760631|NCT01618357|DRUG|Veliparib|Pills to be taken twice a day during radiation and for one week after completion of radiation for a total of 29 days.
223615564|NCT04079426|OTHER|Sampling of Blood and bronchoalveolar lavage|Multiplex assays for pro- and anti-inflammatory markers and incubation of immune cells isolated from serum and bronchoalveolar lavage fluid of patients with ARDS.
223615565|NCT06150950|BEHAVIORAL|Cardiac rehabilitation|Cardiac rehabilitation is a multifaceted, comprehensive therapeutic intervention of personalized, supervised exercise training that is beneficial and well-studied among patients with non-ACHD heart failure and has consistently been shown to improve QOL. Unfortunately, cardiac rehabilitation has been underutilized with an overall participation \<50% of eligible patients despite international guidelines advocating for more consistent deployment of cardiac rehabilitation. A major a barrier to cardiac rehabilitation is access, as CMS-mandates a physician be within 3 minutes of the rehabilitation facility to assure insurance reimbursement. This mandate limits isolated, outpatient cardiac rehabilitation programs, especially in rural communities.
223615566|NCT06150950|OTHER|Usual care|For participants randomized to the usual care (no cardiac rehabilitation group), cardiac rehabilitation will not be initiated between randomization and for up to 16 weeks following randomization. The study protocol controls only referral to cardiac rehabilitation. All other aspects of the cardiac care, such as titration of guideline directed medical therapy will be at the discretion of clinicians.
223615567|NCT01335139|BIOLOGICAL|Sublingual immunotherapy (SLIT)|Participants randomized to receive sublingual allergen tablet immunotherapy with placebo injections.
223615568|NCT01335139|BIOLOGICAL|Subcutaneous immunotherapy (SCIT)|Participants randomized to receive subcutaneous injection immunotherapy with placebo tablets. Subcutaneous immunotherapy was included as a positive control.
223615569|NCT01335139|OTHER|Placebo|Participants randomized to double-placebo tablets and injections. This group was included as a negative control.
223615570|NCT05716555|DEVICE|Deep brain stimulation|Electrical stimulation of lateral habenula
223615571|NCT01658748|DEVICE|Week 0 Medtronic 3387 electrodes/Activa PC amygdala DBS|Subjects undergo the placement of a Leksell (Elekta, Atlanta, GE) stereotactic frame. Electrode trajectory planned using stereotactic software (BrainLab, Germany). Traditional trans-frontal trajectory used to implant Medtronic #3387 DBS electrodes bilaterally in the BLn. A curvilinear incision will be made 3 cm lateral to midline and 1 cm in front of the coronal suture. A burr hole will be placed with a high-speed drill for placement of a Stimloc device to hold the electrode in place. The dura will be opened, coagulated back and the cortex exposed, coagulated, and pierced. The electrode will be introduced using a cannula. Each electrode contact will be stimulated up to 7 V to confirm the absence of immediate side effects; first left, then right. Electrode wires will be tunneled under skin to upper chest and connected to Medtronic Activa PC dual channel pulse generator. Both groups keep stimulators off until week 0, then this group has stimulators turned on.
223615572|NCT01658748|DEVICE|Week 12 Medtronic 3387 electrodes/Activa PC amygdala DBS|Subjects undergo the placement of a Leksell (Elekta, Atlanta, GE) stereotactic frame. Electrode trajectory planned using stereotactic software (BrainLab, Germany). Traditional trans-frontal trajectory used to implant Medtronic #3387 DBS electrodes bilaterally in the BLn. A curvilinear incision will be made 3 cm lateral to midline and 1 cm in front of the coronal suture. A burr hole will be placed with a high-speed drill for placement of a Stimloc device to hold the electrode in place. The dura will be opened, coagulated back and the cortex exposed, coagulated, and pierced. The electrode will be introduced using a cannula. Each electrode contact will be stimulated up to 7 V to confirm the absence of immediate side effects; first left, then right. Electrode wires will be tunneled under skin to upper chest and connected to Medtronic Activa PC dual channel pulse generator. Both groups keep stimulators off until week 0. This group has stimulators turned on at week 12.
223615573|NCT02464618|BEHAVIORAL|Social contact intervention|The social contact of the patients in this arm will be engaged to improve adherence to out-patient endoscopy
223615574|NCT04107714|BEHAVIORAL|STC|"The peer-led and web-based group program contains four lessons plus one booster session:~* Lesson 1: Consider the pros and cons of disclosing: Participants reflect on their experience of self-stigma and weight their pros and cons of (non-)disclosing their child's mental illness.~* Lesson 2: Different ways to disclose: Participants learn about different ways to disclose and their respective pros and cons. Afterwards participants discuss possible responses they might experience and develop strategies to cope with.~* Lesson 3: Communication about disclosure between parents and their child: Participants discuss pros and cons of (non-)disclosure for their children and how to negotiate whether to disclose or not.~* Lesson 4: Telling your story: Participants learn how to tell their own story.~* In a booster session, participants discuss their experiences with disclosure or non-disclosure."
223760632|NCT00189735|DRUG|FK778|
223760633|NCT04365699|DRUG|AT-001|Investigational novel Aldose Reductase Inhibitor (ARI) Product: AT-001 500mg capsule for oral administration Dosage: 1,500mg (3X500mg capsules) twice daily Mode of Administration: Oral Up to 14 days per discretion of the investigators and treatment team
223760634|NCT03603795|DRUG|Eltrombopag|Eltrombopag concomitant with induction chemotherapy in patient with AML
223760635|NCT03603795|DRUG|Placebo|Placebo concomitant with induction chemotherapy patients with AML
223760636|NCT04300569|OTHER|Non-interventional|No intervention will be administered.
223760637|NCT05145166|BIOLOGICAL|Safety group|All of the participants(N=10000) received one dose of live attenuated mumps vaccine.Vaccine will given by single intramuscular injection(0.5 ml) on day 0.
223760638|NCT03411876|DEVICE|Oxymizer® pendant nasal cannula|Supplemental oxygen is provided by an Oxymizer pendant nasal cannula.
223760639|NCT03411876|DEVICE|conventional nasal cannula|Supplemental oxygen is provided by a conventional nasal cannula.
223760640|NCT02540954|DRUG|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|A dose of 2 mg aflibercept injected intravitreally
223760641|NCT05667233|OTHER|Resistance Training Program|Participants will undergo a high exertion machine-based resistance training protocol.
223760642|NCT01005004|BIOLOGICAL|HuCNS-SC cells|intracerebral transplantation
224312219|NCT01878487|DEVICE|Thrombus aspiration (Intravascular Ultrasound catheter (Boston))|"There is a single arm in the study where all patients are undergoing primary percutaneous coronary intervention for an acute myocardial infarction.~All patients will have an Intravascular Ultrasound three times:~1. At baseline~2. After thrombus aspiration with a thrombus extraction catheter~3. After stent deployment~We are however assessing the physiological response of patients having an acute myocardial infarction and this is not a test of the devices as such."
223615575|NCT01645072|OTHER|Low glycemic index diet|Diet modification in addition to ongoing anti epileptic drug treatment. Medium and high-GI carbohydrates (GI \>55) will be eliminated from the diet and only food items with low glycemic index (GI \<55) will be allowed. Parent will be given a list of low glycemic index food items. They will also be given a list of food items (medium and high glycemic index) which should be avoided.
223615576|NCT01645072|OTHER|Control group|The ongoing anti epileptic drug treatment will be continued without change.
223615577|NCT05706311|BEHAVIORAL|Clinical Decision Support Tool (Moderate Risk)|Moderate risk patients will get brief motivational intervention for medication misuse and an offer of naloxone dispensation.
223615578|NCT05706311|BEHAVIORAL|Clinical Decision Support Tool (High Risk)|Those with high risk will receive a brief motivational intervention leading to warm handoff treatment linkage intervention to primary or specialty substance use care with an offer for naloxone dispensation.
223615579|NCT05706311|OTHER|Standard of Care|Ohio State law requires pharmacist to not dispense an opioid supply \>90 days, with a specific prohibition on dispensations ≥14 days after prescriptions are issued. Pharmacists are also required to perform a universal prescription drug medication review before initial dispensation and offer brief counseling (e.g., unstandardized information about medication safety) for new/modified prescription therapies.
223615580|NCT06063863|DIAGNOSTIC_TEST|Nurse led screening with Optos ultra-widefield retinal-imaging device|The screening will be completed by nurse trained in using an OPTOS camera, at the same time as screening for ROP by a trained ophthalmologist using standard procedure for screening for ROP using binocular indirect ophthalmoscopy (BIO). Images taken with OPTOS will then be remotely assessed by a qualified independent opthalmologist, to see if they can diagnose and grade ROP accurately using these images
223615581|NCT03226717|DRUG|Antiviral agents|combination therapy consists of Sofosbuvir,daclatasvir and ribavirin
223615582|NCT01216202|RADIATION|Preoperative radiotherapy|"Preoperative radiotherapy (RT) was administered as either short course (5Gy x5) or long-course (2Gy x25 or 1.8 Gy x25 with or without 3 fractions of boost to the primary tumor and radiologically malignant lymph nodes) treatment with or without concomitant or sequential chemotherapy. Oncological treatment was decided at a multidisciplinary team conference.~Testicular doses (TDs) was calculated from planning CT-scans and reported as mean cumulative testicular dose. Relative TD was calculated based in the assumption that RT regimens for rectal cancer are bioequivalent and referred to as proportion of prescribed dose absorbed by the testes."
223615583|NCT06187259|DEVICE|caries removal by carbide bur|caries was removed using a slow-speed handpiece and round carbide burs in sizes #12, #14, and #16, based on the lesion's size. When hard dentin was found using a dental probe, carious dentin removal was stopped.
223615584|NCT06187259|DEVICE|caries removal by polymer bur II|carious tissue was removed utilizing smart polymer burs of sizes #4, #6, and #8, depending on the cavity's size, running at a slow speed without water coolant, in circular motions from the center of the lesion outward. Carious dentin removal ceased when the instrument became macroscopically abraded and sharpened and could no longer remove tooth tissues.
223615585|NCT03093896|DIETARY_SUPPLEMENT|snack mix|commercial cereal mix with bits of beef jerky and coconut
223615586|NCT03093896|DIETARY_SUPPLEMENT|almonds, 1.5 oz|almonds, 1.5 oz/day
223615587|NCT03093896|DIETARY_SUPPLEMENT|almonds, 3 oz|almonds, 3.0 oz/day
223615588|NCT05028192|OTHER|no intervention|no intervention
223615589|NCT04564664|DRUG|Oxygen|High-flow nasal cannula oxygen therapy vs. standard oxygen therapy
223615590|NCT04968158|DRUG|Etoricoxib 90 mg / Tramadol 50 mg|One packet diluted in 100 ml of water, every 24 hours of 90 mg/50 mg.
223615591|NCT04968158|DRUG|Acetaminophen 325 mg / Tramadol 37.5 mg|One tablet, every 8 hours of 325 mg/ 37.5 m
223615592|NCT05055544|DRUG|Fosfomycin|a single dose of fosfomycin (3 g) powder dissolved in 75 ml water and 2 placebo tablets t.i.d. for 7 days (group A),
223615593|NCT05055544|DRUG|Bearberry|a single dose of placebo powder dissolved in 75 ml water and 2 bearberry tablets t.i.d. for 7 days (group B).
223760643|NCT03160053|DEVICE|NB-UVB|NB-UVB has an emission spectrum in the ultraviolet B range of 290-320 nm. The system consists of a light source, a spot handpiece, and a light guide that connects the handpiece to the light source. The light source has a Start/Stop switch for light beam activation. Activation can also be controlled remotely with a foot switch. The light source has a timer and an output level control to adjust the intensity of the ultraviolet light. This will be calibrated using a manufacturer-provided UV meter prior to every treatment to ensure accurate doses of ultraviolet light.
223760644|NCT01933906|DRUG|P1101|
223760645|NCT04023877|DRUG|E2027|E2027 oral capsule.
223760646|NCT01794091|DRUG|Eplerenone|Eplerenone 25 mg daily for 6 months
223615594|NCT03196544|BEHAVIORAL|Social Approach Training (5 sessions)|5 one-hour, clinician-administered treatment sessions focused on presenting rationale and instructions for completing positive activity exercises (e.g., gratitude, acts of kindness) designed to increase positive emotions, cognitions, and behaviors.
223615595|NCT03196544|BEHAVIORAL|Social Approach Training (10 sessions)|10 one-hour, clinician-administered treatment sessions focused on presenting rationale and instructions for completing positive activity exercises (e.g., gratitude, acts of kindness) designed to increase positive emotions, cognitions, and behaviors.
223760647|NCT01794091|DRUG|Placebo|
224312220|NCT02552212|BIOLOGICAL|Certolizumab Pegol|"* Active Substance: Certolizumab Pegol~* Pharmaceutical Form: Prefilled syringe~* Concentration: 200 mg / ml~* Route of Administration: Subcutaneous injection"
224312221|NCT02552212|OTHER|Placebo|"* Active Substance: Placebo~* Pharmaceutical Form: Prefilled syringe~* Concentration: 0.9 % saline~* Route of Administration: Subcutaneous injection"
223760648|NCT02752932|OTHER|Drug testing on PDX per Investigator's choice (upto 4)|Drug of Investigator's choice (upto 4 Ontario funded Chemotherapeutics) will be tested on PDX (Patient Derived Xenografts)
223760649|NCT02676531|OTHER|Exercise|Walking meditation exercise program
223760650|NCT00915512|DRUG|Paliperidone extended-release (ER)|Paliperidone ER tablets will be administered orally once daily as flexible dose ranging from 3 to 12 milligram (mg) per day for 12 months. The recommended dose will be 6 mg once daily.
223760651|NCT03639766|DRUG|AbobotulinumtoxinA|AbobotulinumtoxinA reconstituted in non-bacteriostatic saline solution
224312222|NCT05521659|OTHER|Standardized oral care protocol|Standardized oral care protocol (3 times a day at certain hours (06-14-22) with oral care set including chlorhexidine gluconate)
223615596|NCT04404868|OTHER|Normal clinical practice|There are no experimental interventions. The procedures are in line with normal clinical practice.
223615597|NCT02828735|DEVICE|respiration assessment|Respiration Breathing Exercise
223760652|NCT03639766|OTHER|Saline solution|Non-bacteriostatic saline solution
223760653|NCT03571919|DRUG|Lidocaine infusion|Intravenous bolus of lidocaine (1.25 mg/kg) and then infusion at 1 mg/kg/hr
223760654|NCT03571919|DRUG|Saline infusion|Intravenous bolus of saline and then infusion
223760655|NCT06357611|OTHER|Simulated technique|"The participant was in a supine position, with her upper limbs at her sides and her neck in a neutral position.~The researcher sat in a cephalic position, making contact with the participant's shoulders, without any movement, until 5 minutes had elapsed."
223760656|NCT06357611|OTHER|Muscle energy technique|"The participant was in a supine position, with her upper limbs alongside her body and her neck in a neutral position.~The researcher adopted a position homolateral to the dominant limb, contacting the lower limb with the caudal hand in the region of the malleoli. He then helped the participant to perform the movement, which consisted of flexing the hip and extending the knee passively until the motor barrier was reached, and instructed her to perform an isometric contraction of the hamstrings. She was asked to perform three 7-second contractions with a 2 to 3-second interval, using approximately 20% of her maximum strength, gaining a new motor barrier between each set, for a total of three sets."
223760657|NCT06357611|OTHER|4th ventricle technique and muscular energy technique|"The participant was in a supine position, with her upper limbs alongside her body and her neck in a neutral position.~For CV-4, the researcher contacted the squamous portion of the occiput laterally, bringing it close to the posterior convexity of the occiput, bringing the skull into extension, changing the compression movement with decompression, until 3 minutes had elapsed.~For the MET, the researcher adopted a position homolateral to the dominant limb, contacting the lower limb with the caudal hand in the region of the malleoli. She then helped the participant to perform the movement, which consisted of flexing the hip and extending the knee passively to the motor barrier, having been instructed to perform an isometric contraction of the hamstring. A total of 3 7-second contractions with a 2-3 second interval were requested, using approximately 20% of her maximum strength, and with a new motor barrier being gained between each series, for a total of 3 series."
223760658|NCT03096665|DIAGNOSTIC_TEST|blood test|Point of care blood analysis obtained from skin puncture
223760659|NCT02469116|DRUG|Docetaxel|
223760660|NCT02469116|DRUG|Carboplatin|
223760661|NCT02469116|DRUG|Pegylated G-CSF|
223760662|NCT04082988|DIAGNOSTIC_TEST|18F-FDG PET-CT|18F-FDG PET-CT scan
223615598|NCT06379165|DRUG|Meloxicam Nanocrystal Injection|30 mg (1 mL), once daily, by intravenous infusion
223615599|NCT06379165|DRUG|Placebo|1 mL Placebo, once daily, by intravenous infusion
223615600|NCT04836585|OTHER|eMBC Intervention|"The treating psychiatrist sets a flag in the patient's electronic chart that prompts them to complete self-report scales prior to each appointment:~1. Edinburgh Postnatal Depression Scale (EPDS) for symptoms of depression and anxiety~2. PROMIS Neuro-QOL and PROMIS ASCQ-Me Social Functioning Short form for measures of functional capacity~3. Adapted Frequency, Intensity, and Burden Side Effects Rating (FIBSER) Scale for participants taking antidepressant medication to measure side effects~Patient participants and providers can view the questionnaire results over time in the electronic chart item by item, and/or see them in graphical format. During the clinical encounter, the provider and patient participant review the results of the scales, as part of a collaborative re-evaluation of the treatment plan."
223615601|NCT00434226|DRUG|bevacizumab|Intravenously at a dose of 15mg/kg on the first day of each 21-day cycle
223615602|NCT00434226|DRUG|sunitinib|25 mg/day for 2 weeks, followed by 1 week of rest
223615603|NCT00434226|DRUG|carboplatin|On the first day of each cycle for 4 cycles
223615604|NCT00434226|DRUG|paclitaxel|On the first day of each cycle for 4 cycles
223615605|NCT03287401|DEVICE|Electroencephalography|Patients electroencephalogram will be recorded
223760663|NCT00006211|DRUG|Capravirine|
223760664|NCT00006211|DRUG|Nelfinavir mesylate|
223760665|NCT01750580|DRUG|Lirilumab|
223760666|NCT01750580|DRUG|Ipilimumab|
223760667|NCT04522037|OTHER|No intervention / Compare the difference in respiratory rate between H0 and H12 of the initiation of morphine between the control and interventional groups|Respiratory rate is analyzed with the scope (approved by the French national medical authorities)
223760668|NCT00917891|DRUG|dapivirine|"dosage form: vaginal gel~dosage: 1.25mg dapivirine/day~frequency: once daily~duration: 6 weeks"
223760669|NCT00917891|DRUG|placebo|"dosage form: vaginal gel~frequency: once daily~duration: 6 weeks"
223760670|NCT02199405|OTHER|Massage of chiropractic and adjusting cervical curvature|Massage of chiropractic and adjusting cervical curvature, 10 minutes, three times one week for 4 weeks
223760671|NCT02199405|OTHER|Sishi Daoyin|Sishi Daoyin, practicing during 9-11am, once a day for 4 weeks
223615606|NCT02394314|DRUG|MEDI0382|MEDI0382 administered subcutaneously
223615607|NCT02394314|DRUG|Placebo|Placebo administered subcutaneously
223615608|NCT03827135|OTHER|Traditional physical therapy|"Cervical isometrics 10 repetitions×1 set, 4 days/week and targeted muscle strechings (trapezius, scalenes and sternocleidomastoid) 10 repetitions×1 set, 4 days/week.~Total of 4 sessions were given each consisting of 40 mins."
223615609|NCT03827135|OTHER|Cyriax manipulation|"Experimental group was given cyriax manipulation protocol along with the cervical isometrics and muscle strechings.~Traction with rotation was not given in cases of bilateral arm pain. cervical isometrics 10 repetitions×1 set, 4 days/week and targeted muscle strechings (trapezius, scalenes and sternocleidomastoid) 10 repetitions×1 set, 4 days/week.~Total of 4 sessions were given each consisting of 40 mins."
223615610|NCT05806463|BEHAVIORAL|Mother's Time|Mother's Time is an evidence-based cognitive behavioral therapy (CBT) tool designed to support postpartum women experiencing mild to moderate symptoms of stress, depression, or anxiety. The intervention is designed for use by Ethiopian community health workers (CHWs) and includes CBT exercises and discussion on topics relating to family planning, such as planning for the future, speaking to the husband, and considering potential side effects.
223615611|NCT03982641|PROCEDURE|all colorectal cancer surgical procedures|colorectal cancer surgical procedures
223615612|NCT04724408|DEVICE|VieScope|see above
223760672|NCT02199405|OTHER|conventional massage|Conventional massage , 15 minutes, three times one week for 4 weeks
223615613|NCT04724408|DEVICE|Conventional|see above
223615614|NCT05136508|DRUG|Propofol|Anesthesia was induced with TCI of propofol (Ce of 4.0-4.5 μg/ml) and remifentanil (Ce of 4.0 ng/ml). Anesthesia was maintained with TCI of propofol and remifentanil. Anesthesia depth was adjusted to maintain a PSI of 25-50.
223615615|NCT05136508|DRUG|Sevoflurane|Anesthesia was induced with an intravenous bolus of propofol 1.5-2 mg/kg and TCI of remifentanil (effect-site concentration \[Ce\] of 4.0 ng/ml). Anesthesia was maintained with sevoflurane (0.8-1 age-adjusted minimum alveolar concentration) and TCI of remifentanil
223615616|NCT04757493|DRUG|Prucalopride 2mg|Both prucalopride 2mg and placebo will be administered for 6 weeks. Primary outcome will measure at 2nd and 6th week of treatment.
223615617|NCT04113850|DEVICE|Mobile Acoustic startle Reflex monitoring System (MARS)|Acoustic startle testing
223615618|NCT06059365|BEHAVIORAL|Hospitalization|Once the patient was operated and an uncomplicated appendicitis was confirmed, the patient was randomized to one of the two experimental branches: the hospitalization group (HG) or outpatient group (OG). In this group, were admitted in the hospitalization ward
223615619|NCT06059365|BEHAVIORAL|Outpatient|Once the patient was operated and an uncomplicated appendicitis was confirmed, the patient was randomized to one of the two experimental branches: the hospitalization group (HG) or outpatient group (OG). Patients in the OG were referred to the day- surgery unit where they were discharged according to ALDRETE criteria.
223615620|NCT00061659|DRUG|ABT-510 - Thrombospondin-1 mimetic|
223615621|NCT00271375|BEHAVIORAL|Caring For You, Caring For Me|5-week Education and Support Program for Caregivers of older adults.
223615622|NCT00271375|BEHAVIORAL|Caring for you, caring for me + social worker|5-week Education and Support Program for Caregivers of older adults.+ augmentation with social worker
223615623|NCT00271375|BEHAVIORAL|Control|Control group usual care
223615624|NCT04103359|OTHER|Physiological tests to measure fatigue level|Physiological tests to measure fatigue level
223615625|NCT05109780|DEVICE|My EMI, Emotional Well-being + self-applied online transdiagnostic treatment|The intervention will consist in a self-applied online transdiagnostic intervention for emotional problems together with an app-based EMI. In terms of monitoring, the My EMI, Emotional Well-being is a mobile app whose contents have been adapted to conduct ecological momentary assessments in different health conditions. The app assesses important psychological variables, namely anxiety, depressive symptoms,etc. Participants respond daily to the questions in the app. In terms of the online self-applied intervention, the Unified Protocol is a transdiagnostic extension of CBT which works on regulate emotions in a more adaptive way through 5 core treatment modules: present-focused emotional awareness, cognitive flexibility, identification and prevention of emotional avoidance patterns, increasing awareness and tolerance to emotion-elicited physical sensations, and graded (interoceptive and situational) exposure procedures.
223615626|NCT03483896|OTHER|Daylight Intervention|Staff increased the daylight exposure of participants by taking them to the perimeter zone of a daylit room from 8:00 to 10:00 AM for socialization over a period of 12 weeks. The perimeter zone was defined to be the region of the room within 3 meters from windows. The intervention was administered each day (7 days / week) over the duration of the study.
223615627|NCT02888106|DRUG|Myrcludex B|Lyophilised powder for solution for subcutaneous injection
223615628|NCT02888106|DRUG|PEG IFN alfa-2a|solution for subcutaneous injection, once per week
223615629|NCT02888106|DRUG|Tenofovir|Film-coated tablets, 300 mg, per os, once daily
223615630|NCT04618146|DRUG|Morphine Sulfate|intrathecal low dose morphine for early return to normal activity without opioid related complications.
223615631|NCT04618146|DRUG|Bupivacaine Hydrochloride|intrathecal bupivacaine 0.5%
223760673|NCT02199405|OTHER|Cervical traction|
224201996|NCT05156775|OTHER|Rhomboid intercostal nerve block (RIB)|In the rhomboid intercostal nerve block (RIB) group, the patient will be placed in a lateral position with the affected breast at the top. The ipsilateral arm will be extended to the same level as the ipsilateral chest and breast, and the scapula will be moved outward. On the oblique sagittal plane, a high frequency (6-12MHz) linear ultrasound probe will be placed on the medial edge of the scapula. The US landmarks, trapezius muscle, rhomboid muscle, intercostal muscles, pleura, and lung will be identified. Under the aseptic condition, a 22-gauge needle will be inserted in the plan to the US probe at T5 to T6 levels. Then, 0.25% bupivacaine (30 mL) will be injected into the inter-fascial plane between the rhomboid major muscle and the intercostal muscle, the diffusion of bupivacaine in the fascia between the rhomboid muscle and the intercostal muscle will be visualized. Then, the patient will be positioned in supine position.
224201997|NCT00649714|DRUG|Zonisamide Capsules 100 mg|100mg, single dose fed
224201998|NCT00649714|DRUG|Zonegran® Capsules 100 mg|100mg, single dose fed
224201999|NCT06042556|OTHER|IUD self-removal guide|We previously developed an online guide for IUD self-removal through an iterative process including advice from key expert informants, focus groups, interviews, and a pilot clinical study. It includes an online animation, step-by-step guide, troubleshooting tips, and information about pregnancy and contraception.
224202000|NCT05493748|OTHER|Bladder training|Bladder training for overactive bladder syndrome.
224202001|NCT00681447|PROCEDURE|Lumbar Interlaminar Epidural|"1. Lumbar interlaminar epidural injections under fluoroscopy~2. Epidural tray and needle~3. Drugs:~0.5% Xylocaine and non-particulate Celestone"
224202002|NCT00681447|PROCEDURE|Lumbar Interlaminar Epidural injection|"1. Lumbar interlaminar epidural injections under fluoroscopy~2. Epidural tray and needle~3. Drugs:~0.5% Xylocaine and non-particulate Celestone"
224202003|NCT06669117|DRUG|VERT-002|Route of Administration: Intravenous
224202004|NCT06995118|PROCEDURE|HUAXI hole 1|A small incision of 2mm is made at the junction of the upper outer edge of the areola and the skin, through which the scalpel is placed to assist in the resection of breast glands in reverse-sequence nipple-sparing mastectomy and direct-to-implant breast reconstruction.
224202005|NCT00975000|DRUG|Cinacalcet|Possible sequential doses are 30, 60, 90, 120, and 180 mg.
224202006|NCT00975000|DRUG|Placebo|Administered orally following the same dosing regimen as the experimental arm.
224202007|NCT06103617|DRUG|Penicillamine|Participants in this group are treated with Penicillamine (250mg each time, 4 times per day) during reradiation.
223615632|NCT05861596|DEVICE|Repetitive Transcranial Magnetic Stimulation|Participants suffered from acute stroke with dysphagia in single hospital who were determined by CT/MRI and clinical evaluation. The aim of this study is to compare the effects of rTMS, Neuromuscular electrical stimulation (NMES) and conventional swallowing therapy to those of sham rTMS, Neuromuscular electrical stimulation(NMES) and conventional swallowing therapy. One group will receive Neuromuscular electrical stimulation(NMES), to sham One group will receive Neuromuscular electrical stimulation(NMES),traditional swallowing therapy and rTMS therapy five times per week for 2 weeks ; Another group will receive Neuromuscular electrical stimulation(NMES) and traditional swallowing therapy with shame rTMS five times per week for 2 weeks. MEP character, FEES, degrees of dysphagia, FOIS, and SSA were used for evaluated swallowing function before the therapy and after 2 weeks therapy.
223760674|NCT01495845|OTHER|Pharmacogenomics testing for clopidogrel responsiveness|Patients must come to the pharmacy for all visits. At the 1st visit, the patient will provide consent, a complete list of medications, a complete pre-study questionnaire, a copy of their insurance card, and a buccal swab (collected by the pharmacist). The swab will be sent to the testing facility for genotypic testing of CYP2C19. Upon receipt of the results of the results, the pharmacist will propose an intervention to the prescriber based on the patient's indication for clopidogrel and the identification of certain genetic variations atCYP2C19. All patients will be asked to return to the pharmacy for explanation of the results and implementation of any changes approved by the prescriber and to complete a follow-up questionnaire. After the visit to explain the results of testing, the patient's insurance will be billed electronically for a medication therapy management visit; patients without insurance will not be billed. Patients may opt out of billing to insurance at any time.
223760675|NCT04752501|OTHER|Psychologically Informed Education|This arm will provide an education intervention which will attempt to address maladaptive psychological behaviors in adolescents with knee pain
223760676|NCT04752501|OTHER|Biomedical Education (Control)|This arm will provide education of basic knee anatomy, lower extremity mechanics, and simple exercises and will not address maladaptive psychological behaviors
223760677|NCT00834912|DRUG|Tramadol hydrochloride|1x300mg Tramadol Hydrochloride (HCl) tablet (Confab Laboratories), fasting condition. Taken for one treatment period only, then subjects switched treatment at each period as per randomization schedule. Results are presented per treatment group overall.
223760678|NCT00834912|DRUG|Tramadol HCl|1x300mg Tramadol Hydrochloride (HCl) tablet (Confab Laboratories), fed condition. Taken for one treatment period only, then subjects switched treatment at each period as per randomization schedule. Results are presented per treatment group overall.
223760679|NCT00834912|DRUG|Tramadol HCl|1x300mg Tramadol Hydrochloride (HCl) tablet (Trillium Healthcare) fasting condition. Taken for one treatment period only, then subjects switched treatment at each period as per randomization schedule. Results are presented per treatment group overall.
223760680|NCT03657472|DRUG|CJ-30061|Test: CJ-30061(Fixed-dose combination drug containing Amlodipine 5mg/Valsartan 160mg/Atorvastatin 20mg)
223760681|NCT03657472|DRUG|Exforge® 5/160mg & Lipitor® 20mg|Reference: Co-administration of Exforge® tab 5/160mg and Lipitor® tab 20mg
223760682|NCT00053794|DRUG|perifosine|
223760683|NCT01971658|DRUG|Thalidomide®|
223760684|NCT01971658|DRUG|Cyclophosphamide|
223760685|NCT01971658|DRUG|Velcade®|
223760686|NCT01971658|DRUG|Dexaméthasone|
223760687|NCT04953533|OTHER|no intervention|
223760688|NCT03200782|DRUG|Empagliflozin|Glucose lowering effect of empagliflozin for reducing the counter-regulatory glucose-lowering response
223760689|NCT03200782|DRUG|Anakinra|IL-1Beta blockage effect on insulin secretion and thereby influencing postprandial glucose level
223760690|NCT03200782|OTHER|oral placebo (winthrop tablet)|subcutaneous placebo (0.67 ml of 0.9% sodium chloride) 3 hours before the test meal and an oral placebo (winthrop tablet) 2 hours before the test meal will be administered by an Independent nurse to the blinded patient
223760691|NCT03200782|OTHER|subcutaneous placebo (0.67 ml of 0.9% sodium chloride)|subcutaneous placebo (0.67 ml of 0.9% sodium chloride) will be administered in arm 'Placebo-Placebo' and arm 'drug: Empagliflozin'
223760692|NCT00350766|PROCEDURE|Autologous Bone Marrow Mononuclear Cells (ABMMC) Transplantation|Catheter based stem cells delivery of 100 million cells resuspended in a 10 ml solution of saline with autologous serum. About 100 ml of Bone Marrow aspirate were harvested from iliac crest between the fifth and seventh day after myocardial infarction. ABMMC were isolated by density gradient centrifugation on Ficoll-PaqueTM plus (Amersham Biosciences) and manipulated under aseptic conditions for injection, after being filtered through 100 um nylon mesh to remove cell aggregates.
223760693|NCT01885390|DEVICE|ROX COUPLER|The COUPLER will be used to create an anastomosis in the iliac region (between the iliac artery and vein).
223760694|NCT03671291|BEHAVIORAL|self-administrated questionnaire|Persons who the biological parameters or past screening show that they were recently infected with HIV cf. eligibility criteria, will, after obtaining his consent, answer a series of questions through a self-administrated questionnaire that will take approximately 40 minutes.
223760695|NCT01892696|DEVICE|varying inspiratory flow waveforms|inspiratory flow waveform was changed, in a randomized sequence using a computer ,to one of the following modalities: 1) constant inspiratory flow; 2) decelerating inspiratory flow Each inspiratory flow waveform was maintained for 30 min. During the last 5 min of this period the physiological signals were collected and measures were performed.
223760696|NCT03829046|DRUG|Placebo|12 weeks of treatment
223760697|NCT03829046|DRUG|Evolocumab|12 weeks of treatment
223760698|NCT01037946|BEHAVIORAL|Cognitive behavioral sessions|Behavioral: Cognitive-behavioral, small group format sessions delivered in Thai to People Living with HIV and their caregivers once a week for 13 weeks (n=13 sessions).
223760699|NCT00571129|PROCEDURE|DCR with no tubes or mitomycin|"The patients were randomized into the two study groups, either with or without the insertion of a bicanalicular silicone tube after primary DCR.~In revision group patients were randomized into the two groups,ether with or without application of mitomycin C after DCR"
224202008|NCT06995729|DRUG|Zavegepant|Zavegepant 5 mg or 10 mg (dose is weight-dependent)
224202009|NCT01133366|DRUG|warfarin sodium|25 mg of warfarin oral (single dose)
224202010|NCT01133366|DRUG|mipomersen sodium; warfarin sodium|200 mg of mipomersen subcutaneous (SC) (4 doses) plus a single 25 mg of warfarin oral administered with the final mipomersen SC dose
223509802|NCT06756165|BEHAVIORAL|Mental health screening|Participants in the intervention arm will receive a mental health screening, referral, and counselling program by trained LHWs and BHU staff. LHWs will screen 120-170 WRA using PHQ-2 and GAD-2. Screen-positive WRA will be referred to BHUs, where trained doctors will reassess them using PHQ-9 and GAD-7. Those with mild to moderate anxiety or mild to moderately severe depression will receive two counselling sessions (initial and follow-up), each lasting at least 20 minutes, covering psychoeducation, awareness, and coping strategies. Severe cases will be referred to tertiary care for specialized mental health services. Mild cases will be advised to join resilience-building sessions. All WRA will attend two of three monthly group sessions by LHWs (20-25 WRA, 2 hours each), focusing on mental health literacy and coping strategies, including those related to climate change stressors like floods.
223509803|NCT01903200|DRUG|FK949E|Oral
223509804|NCT06734754|DEVICE|fetal heart sound listening|The pregnant women in the experimental group and their partners listened to fetal heart sounds for 7 days. After obtaining pre-test data from the participants in the intervention group, the midwifery intervention to be implemented was explained. A fetal heart rate monitoring device, which will be given to couples to listen to the fetal heart sound before sleep, was introduced. They were told that they had to listen to the fetal heart sound at least 7 times using this device. A supporting application was downloaded to the pregnant woman's phone for the installation of the fetal heart rate monitoring device. The way of using the application and the operation steps were introduced. It was explained to the couples that the application can detect the baby's heartbeat within seconds thanks to its smart search technology, and also provides step-by-step guidance by giving live feedback.
223509805|NCT06786052|DIETARY_SUPPLEMENT|Probiotic|After randomization, participants will consume the probiotic for 3 months.
223509806|NCT06786052|DIETARY_SUPPLEMENT|Placebo|After randomization, participants will consume the placebo for 3 months.
223509807|NCT01094093|DRUG|AMG 139|Six dose levels of AMG 139 administered as a single dose SC or IV in healthy volunteers (Part A) and subjects with moderate-severe psoriasis (Part B).
223509808|NCT04826731|OTHER|Incentive Spirometer/Respiratory Exerciser|"A patient is considered acceptable for the Incentive Spirometer Group if the patient can use an incentive spirometer and/or a respiratory exerciser at least four times per day. A pulmonary medicine specialist will confirm the proper usage of the device."
223509809|NCT04177199|OTHER|TRIAGE HF Pathway|A new care pathway (Triage-HF Plus) for the remote monitoring and management of heart failure stability in a cohort of device patients at 3 hospital sites in North West England.
223509810|NCT01104012|BIOLOGICAL|"Classification as asthmatic or rhinitis only via proteomic analysis"|Proteomic profiles are established for each patient using plasma and serum samples
223615633|NCT05861596|DEVICE|Neuromuscular electrical stimulation combined with conventional swallowing training|Participants suffered from acute stroke with dysphagia in single hospital who were determined by CT/MRI and clinical evaluation. The aim of this study is to compare the effects of rTMS, Neuromuscular electrical stimulation (NMES) and conventional swallowing therapy to those of sham rTMS, Neuromuscular electrical stimulation(NMES) and conventional swallowing therapy. One group will receive Neuromuscular electrical stimulation(NMES), to sham One group will receive Neuromuscular electrical stimulation(NMES),traditional swallowing therapy and rTMS therapy five times per week for 2 weeks ; Another group will receive Neuromuscular electrical stimulation(NMES) and traditional swallowing therapy with shame rTMS five times per week for 2 weeks. MEP character, FEES, degrees of dysphagia, FOIS, and SSA were used for evaluated swallowing function before the therapy and after 2 weeks therapy.
223615634|NCT05052034|OTHER|Music|Through headphones, the patients would listen to different types of music during the intervention.
223615635|NCT03287921|DRUG|mono bronchodilatation|within indication according to current GOLD recommendation
223615636|NCT03287921|DRUG|dual bronchodilatation|within indication according to current GOLD recommendation
223615637|NCT04653480|DRUG|Surufatinib|250mg per oral, once daily
223615638|NCT04653480|DRUG|Toripalimab|3mg/kg IV, once every 2 weeks
223615639|NCT04653480|DRUG|chemotherapy|oxaliplatin or irinotecan based regimens, according to the first line treatment
223615640|NCT03572179|DEVICE|3d printed positioning tray|3d printed positioning tray for lingual fixed retainer placement in treatment group
223615641|NCT03782519|OTHER|Dialysis frequency reduction|At initiation, frequency of dialysis will be reduced to 2 weekly sessions (incremental HD)
223615642|NCT03782519|OTHER|Frailty diagnosis|Before randomization, we will determine whether patients are frail. We will define frailty as the presence of at least three of the following five conditions: malnourished according to dietitian assessment and/or short form of Mini Nutritional Assessment (MNA), grip strength and gait speed using participants' scores on the SF-36 Physical Functioning (PF) scale, exhaustion using in the quality of life questionnaire SF-36 vitality (VT) scale and physical activity according to patient assessment (one single question)
223615643|NCT03435185|PROCEDURE|Lidocaine injections|Lidocaine injections. A mixture of 1 ml 2% lidocaine and 0.9% 1 ml saline was injected bilaterally to greater occipital nerve and supraorbital nerve in the blockade patients.
223615644|NCT03435185|PROCEDURE|Saline injections|Saline injections. Patients received 2 ml 0.9% saline in bilaterally to greater occipital nerve and supraorbital nerve
223615645|NCT00241228|DEVICE|Venovenous haemofiltration (renal replacement therapy)|High Volume ultra filtration (70 ml/kg/h)
223760700|NCT04518007|DEVICE|hyperbaric oxygen therapy|"The HBOT protocol consists of 60 daily sessions, five times per week, each session lasting 90 minutes.~Investigational product:~Multiplace hyperbaric oxygen chamber (Haux, Germany) located at the Sago l Center for Hyperbaric Medicine and Research, Shamir (Assaf-Harofeh) Medical Center, Israel."
223509811|NCT01104012|BIOLOGICAL|"Classification as asthmatic or rhinitis only according to a metacholine test"|A positive metacholine test indicating bronchial hyperresponsiveness is currently our Gold Standard for diagnosing asthma.
223509812|NCT02473874|DEVICE|Skin Spect dermoscope|Skin imaging
223509813|NCT02473874|DEVICE|Spatially modulated quantitative|Skin imaging
223509814|NCT04017975|DRUG|Fluorescite|1 mL of Fluorescite will be diluted into 1L of saline. Up to 5mLs of the 1:1000 diluted solution will be applied topically to the cardiac tissue prior to imaging.
223760701|NCT02355327|DEVICE|Laselle Kegel Exerciser|Participants use a vibrating pelvic floor muscle training ball for 12 weeks. The ball is inserted into the vagina and left for 15 minutes daily in the first week, and if well tolerated 30 minutes daily from the second week onwards. To achieve the vibrating effect, the balls are worn while moving - performing everyday tasks or going for a walk.
223760702|NCT02355327|BEHAVIORAL|Pelvic floor muscle exercises|Participants get standard care after childbirth, which is the routine recommendation of pelvic floor muscle exercises. Participants will be asked to continue/start the pelvic floor muscle exercises they routinely were recommended by customary written instructions from their health professionals after birth. Intervention duration for this study is 12 weeks.
224312223|NCT03565679|DEVICE|MEDLINE RENEWAL PULSE OXIMETRY SENSORS|An oximeter is a device used to transmit radiation at a known wavelength(s) through blood and to measure the blood oxygen saturation based on the amount of reflected or scattered radiation. Pulse oximetry monitoring is considered a standard physiological measurement and is used by clinicians in everyday situations to estimate arterial oxygen saturation. Because an arterial sample of blood is not required to make the measurement, the pulse oximeter can provide non-invasive real time information.
224312224|NCT03565679|DEVICE|CO-OXIMETRY SENSORS|A whole blood analyzer (CO-Oximeter) is used as the reference standard device for obtaining the functional SaO2 value from arterial blood samples obtained during the study.
224312225|NCT02489253|OTHER|CT coronary angiogram and carotid ultrasound|Scans in addition to routine clinical care
224312226|NCT04290195|DRUG|Ziv-Aflibercept 25 MG/ML [Zaltrap]|Intravitreal injection of 1.25 mg of ziv aflibercept in patients
224312227|NCT03263897|DEVICE|insufflation|mobile interface driven insufflation of the ear canal
223760703|NCT05962411|OTHER|Dress in Professional Attire|"Adolescents pretend to be adult e-cigarette buyers by dressing in professional attire."
223760704|NCT04709666|PROCEDURE|Endsocopic Retrograde ColangioPancreatography (ERCP)|
223760705|NCT00326664|DRUG|Cediranib Maleate|Given orally
223760706|NCT01166308|RADIATION|Carbon Ion Radiotherapy|Carbon Ion Radiotherapy in the RD determined within the Phase I part of the Study (10 x 3Gy E to 16 x 3 Gy E)
224312228|NCT03263897|DEVICE|placebo insufflation|mobile interface driven placebo insufflation of the ear canal
224312229|NCT06988917|BEHAVIORAL|the regular rehabilitation program|Each training session consists of a 10-minute warm-up (including power cycling, full-body stretching, etc.) At the same time, use the foam axis to relax the lateral oblique femoris and iliotibial band to relieve the pressure on the lateral side of the patella), 40 minutes of formal training (including wall squats with a ball, straight leg raising resistance training, terminal resistance knee extension training, bench kick ball clamping training, and balance training), and 10 minutes of relaxation (using a foam roller, foam axis and other combined techniques to relax the muscles Especially for the lower limb muscles such as the lateral femoris, iliotibial band, and tibialis anterior muscle.
224312230|NCT06988917|DEVICE|The blood flow limiting pressure band|The experimental group (LL-BFRT group) wore a flow-limiting pressure band for exercise during routine rehabilitation training. The blood flow limiting pressure band used in this study mainly consists of a 109\*10cm leg pressure band, a barometric display dial with a pressure range of 0-300mmHg, and a pressure pump. In the experiment, we fixed the blood flow restriction pressure band in the area for measuring the circumference and adjusted the blood flow restriction pressure according to the thigh circumference of the subjects to maintain it within the range of 40%-60% arterial occlusion pressure. The way to limit blood flow is intermittent inflation, that is, during the intervals of muscle strength training, the cuff deflation operation is carried out simultaneously.
224312231|NCT06990282|OTHER|microneedling|gingival microneedling (small holes in gingiva)
224312232|NCT06990282|OTHER|scaling|scaling (plaque removal)
224312233|NCT06990282|BIOLOGICAL|Ozonated olive oil|ozonated olive oil after microneedling
223509815|NCT04017975|DEVICE|Cellvizio 100 Series System with Confocal Miniprobes|The microscopy system will image cardiac tissue.
223509816|NCT04921163|DIETARY_SUPPLEMENT|sodium aluminium phospate (SALP)|1 pancake daily for 4 days
223509817|NCT04921163|DIETARY_SUPPLEMENT|Aluminium-free pancake|1 pancake daily for 4 days, without aluminium
223509818|NCT05611736|OTHER|cold saline|After standard chemo-mechanical preparation of the root canal, final irrigation will be performed using 20 milliliters of cold (at 2.5 degrees Celsius temperature) saline solution.
223760707|NCT01166308|RADIATION|Fractionated Stereotactic Radiotherapy (FSRT)|Standard Treatment as Re-Irradiation performed as Fractionated Stereotactic Radiotherapy (FSRT)up to 36 Gy in single doses of 2 Gy
223760708|NCT01930292|DRUG|Part A: Debio 1143|Adaptive doses of Debio1143 oral capsules, between 50 and 400 mg until the recommended dose (RD) is determined.
223509819|NCT05611736|OTHER|saline|After standard chemo-mechanical preparation of the root canal, final irrigation of the root canal will be done using normal saline solution at room temperature
223509820|NCT03600727|DRUG|Propofol|Propofol will be used to offer intraoperative sedation for patients in Propofol group.
223509821|NCT03600727|DRUG|Dexmedetomidine|Dexmedetomidine will be used to offer intraoperative sedation for patients in Dexmedetomidine group.
223509822|NCT03404375|DEVICE|Gauss Triton system|"The Triton system (Gauss Surgical, Inc., Palo Alto, CA) is a novel mobile monitoring platform that combines mobile computing with Gauss Feature Extraction Technology (FET) to directly assess Hb mass (mHb) absorbed by surgical sponges from an image. The device is an iPad like imaging device that will assess blood loss via imaging of the surgical sponges used in the surgery.~The device will be used to calculate blood loss on every patient enrolled in the study."
223509823|NCT00450749|OTHER|placebo|Given PO
223509824|NCT00450749|PROCEDURE|therapeutic conventional surgery|Undergo radical prostatectomy
223509825|NCT00450749|OTHER|laboratory biomarker analysis|Correlative studies
223509826|NCT00450749|DRUG|lycopene|Given PO
223760709|NCT01930292|DRUG|Paclitaxel|Paclitaxel standard of care, intravenous (IV), once on day 1 or 2 of each 21-day treatment cycle, after pre-medication to prevent severe hypersensitivity reactions.
223760710|NCT01930292|DRUG|Carboplatin|Carboplatin standard of care, intravenous (IV), once on day 1 or 2 of each 21-day treatment cycle.
223760711|NCT01930292|DRUG|Part B: Debio 1143|RD of Debio1143 oral capsules, once daily for five consecutive days starting on day 1 or 2 of each 21-day treatment cycle.
223760712|NCT00424151|DRUG|Rituximab|
223760713|NCT05452395|OTHER|Post-acute care|"A personalized care program, focusing on managing geriatric syndromes and improving functional performances.~Strength training, activities of daily living (ADL) and instrumental activities of daily living (IADL) practice, basic mobility training, reconditioning exercise, and home environment assessment and modification."
223760714|NCT05624346|OTHER|Deep-Breathing Exercises|In addition to routine care in the hospital, the patient will be taught pre-operative breathing exercises. After surgery the patients do deep-breathing exercises every hour.
223615646|NCT00241228|DEVICE|Venovenous haemofiltration (renal replacement therapy)|Conventional Volume (35 ml/kg/h)
223615647|NCT05612308|OTHER|Vertical Oscillatory Pressure (VOP)|The VOP involves a pressure from the posterior aspect of the body while patient lye prone. the pressure is exacted directly on the spine, The sustained Natural Apophyseal Glides involves pressure as well when the patient sits down on a chair. The movement is done from the posterior to the anterior as well
223615648|NCT01813916|OTHER|proteomic analysis|
223760715|NCT01831232|DRUG|pravastatin sodium|Given PO
223760716|NCT01831232|DRUG|idarubicin|Given IV
223760717|NCT01831232|DRUG|cytarabine|Given IV
223760718|NCT01831232|OTHER|laboratory biomarker analysis|Correlative studies
223760719|NCT00924911|DRUG|GSK1322322|Four different formulations of 1000mg of GSK1322322
223509827|NCT01245049|BIOLOGICAL|Boostrix PolioTM|Single dose, intramuscular administration.
223509828|NCT01245049|BIOLOGICAL|RepevaxTM|Single dose, intramuscular administration.
223509829|NCT01245049|BIOLOGICAL|PriorixTM|Single dose, intramuscular or subcutaneous administration.
223509830|NCT05343429|DRUG|Benzydamine hydrochloride|In BN group,15 ml of 0.15 % Benzydamine hydrochloride (BN) will be dissolved in 15 ml plain water in a sterile container and given to participants before anesthesia for surgery
223509831|NCT05343429|DRUG|Aspirin|In group AP, Aspirin (AP) 600 mg Aspirin tablets dissolved in 30 ml of plain water in a sterile container will be given to participants for gargling before anesthesia for surgery
223760720|NCT00924911|DRUG|GSK1322322|GSK1322322 1000mg
223760721|NCT02201303|DRUG|Danirixin|Powdered form for in-vitro administration to blood sample
223760722|NCT02201303|OTHER|CXCL1|Escalating concentrations of CXCL1 will be added to whole blood in vitro. A CXCL1/CD11b upregulation concentration response curve will determine the concentration to be used in Part 2.
223760723|NCT01638962|DRUG|Instruction on analgesic use for pain relief (acetaminophen and NSAIDs)|The PHARMA group receives instruction, by video and pamphlet, on how to best use acetaminophen and NSAID as pain management for knee OA.
224312234|NCT06990633|DIAGNOSTIC_TEST|diagnostic test|"Group 1: MMR-Proficient Group Label: MMR-Proficient~Description: Patients with normal expression of MMR proteins on IHC analysis. No indication for further genetic testing.~Type: Observational Group~Group 2: dMMR Group Label: dMMR~Description: Patients with loss of MMR protein expression (MLH1, PMS2, MSH2, or MSH6) on IHC. These patients will undergo further molecular or genetic analysis to evaluate for Lynch syndrome.~Type: Observational Group"
223509832|NCT00696150|PROCEDURE|determination of method with highest efficacy (ultrasound or nerve stimulator)|Use of ultrasound to guide the insertion of anterior psoas compartment block
223509833|NCT00696150|PROCEDURE|nerve stimulator|The use of the nerve stimulator to guide insertion of the anterior psoas compartment block
223509834|NCT00696150|PROCEDURE|loss of resistance|Use of ultrasound to guide the insertion of anterior psoas compartment block
223509835|NCT00877864|BEHAVIORAL|High volume combined aerobic/resistance exercise|High volume combined aerobic/resistance exercise
223509836|NCT00877864|BEHAVIORAL|Low volume combined aerobic/resistance exercise|Low volume combined aerobic/resistance exercise
223509837|NCT00877864|BEHAVIORAL|High volume combined A/R exercise, printouts, pedometers|High volume combined aerobic/resistance exercise, printouts, pedometers
223509838|NCT00877864|BEHAVIORAL|Low volume combined A/R exercise, printouts, pedometers|Low volume combined aerobic/resistance exercise, printouts, pedometers
223509839|NCT00877864|BEHAVIORAL|Printed PA information, pedometers and step log group|Printed PA information, pedometers and step log group
223509840|NCT00877864|BEHAVIORAL|Control|No exercise program provided by the study
223509841|NCT04230239|DRUG|CPX-351|"CPX-351 has IV administration Vyxeos contains 2.2 mg/mL and 5 mg/mL powder for concentrate for solution for infusion of Daunorubicin and cytarabine.~Each vial contains 44 mg of daunorubicin and 100 mg of cytarabine. After reconstitution, the solution contains 2.2 mg/mL daunorubicin and 5 mg/mL cytarabine"
223509842|NCT06903130|DIAGNOSTIC_TEST|Blood samples for sNfL and sGFAP levels|Blood samples for sNfL and sGFAP levels
223509843|NCT06926842|DRUG|Petrelintide|Petrelintide will be taken by participants once weekly subcutaneously.
223509844|NCT06926842|OTHER|Placebo|Matching placebo to petrelintide will be taken by participants once weekly subcutaneously.
223509845|NCT06764654|PROCEDURE|Dental implant placement|Placement of two dental implants in the jaw.
223509846|NCT06145555|BEHAVIORAL|Acute psychological sleep stabilization|See above (arm description)
223509847|NCT06145555|BEHAVIORAL|Sleep hygiene education|See above (arm description)
223615649|NCT00069446|DRUG|rhuMAb VEGF (telbermin)|
223615650|NCT05854355|OTHER|C-SLAMM Study|The intervention arm includes using innovative behavioural, pedagogical, and environmental strategies within the classroom, school, and home settings to get children moving more and sitting less. The strategies were based on strategies used in Transform-Us! involved incorporating movement into everyday class lessons - the delivery of the lesson changes, not the content. Resources included health lessons, active lessons, active breaks, active homework to do with parents, active environments, and newsletters for parents.
223615651|NCT02995356|OTHER|Collecting cervical liquid and sera samples|
223615652|NCT04703088|DRUG|Ondansetron 4 MG|2 mL of a solution of Ondansetron containing 2mg/ml in a 3 ml syringe will be given intravenously to a patient five minutes before positioning for induction of spinal anesthesia
223615653|NCT04703088|DRUG|0.9% Saline|2 mL of 0,9% Saline in a 3 ml syringe will be given intravenously to a patient five minutes before positioning for induction of spinal anesthesia
223615654|NCT05150184|OTHER|Non-interventional|observational study, thus no different arm/groups
224312235|NCT06988826|DRUG|G-CSF|G-CSF \& Antibiotic therapy in combination
224312236|NCT06988826|DRUG|Antibiotics only|Antibiotics alone
224312237|NCT06914154|DRUG|Tirzepatide|New use of tirzepatide dispensing claim is used as the exposure.
224312238|NCT06914154|DRUG|Placebo|New use of sitagliptin dispensing claim is used as the reference (active-comparator proxy for placebo).
224312239|NCT00205803|BIOLOGICAL|13-Valent Pneumococcal Conjugate Vaccine (13vPnC)|
224312240|NCT00205803|BIOLOGICAL|7-Valent Pneumococcal Conjugate Vaccine (7vPnC)|
223760724|NCT01638962|OTHER|Neuromuscular exercise|The exercise group receives 1 hour of supervised neuromuscular exercise two times a week for 8 weeks. Supervision is conducted by physiotherapists specially trained in using neuromuscular exercise and its principles.
223760725|NCT03302728|DRUG|Lenalidomide 15mg|At commencement of study : Lenalidomide will commence at 15 mg daily for days 1-14 of each cycle. Maximum number of cycles = 16. This is a dose finding study so doses will be adjusted depending on toxicity assessment over the course of the study. Dose may vary from 5 mg -25 mg daily depending on dose escalation results and recommendation of safety committee
223760726|NCT03302728|DRUG|Brentuximab Vedotin 1.8 mg/Kg|At commencement of study : Brentuximab vedotin 1.8mg/kg IV on day 1, repeated every 21 days. Maximum number of cycles = 16. This is a dose finding study so doses will be adjusted depending on toxicity assessment over the course of the study. Dose may be either 1.2 mg/Kg q21 days or 1.8 mg/kg q21 days depending on dose escalation results and recommendation of safety committee
223760727|NCT00858871|DRUG|Brivanib|Tablets, Oral, 800 mg, Once Daily, Until disease progression or unacceptable toxicity
224312241|NCT02330315|DEVICE|transcranial direct current stimulation (tDCS)|Subjects will receive 20 minutes of either active or sham tDCS at intensity of 2mA. The anodal electrode will be placed over the primary motor cortex contralateral to the most painful side, and the cathodal electrode will be placed over the contralateral supraorbital area. In the sham group, the tDCS device will not be active for the full 20 minutes.
224312242|NCT02330315|DEVICE|transcranial ultrasound (TUS)|Subjects will receive 20 minutes of either active or sham TUS. During active stimulation the ultrasound will be active for the full 20 minutes- however, during sham stimulation the ultrasound will not be active for the full 20 minutes.
224312243|NCT02302053|DIETARY_SUPPLEMENT|New Viviscal Professional Supplement|The key ingredient is AminoMar C™ marine complex, an organic form of silica derived from Equisetum sp. (horsetail), vitamin C derived from Malpighia emarginata (acerola cherry), microcrystalline cellulose (E460), natural orange flavor, magnesium stearate, hypromellose, and glycerol. The AminoMar C ™ is an active ingredient which has been trademarked and comprises of a proprietary blend of shark powder and mollusc powder. It is derived from sustainable marine sources. Viviscal provides essential nutrients to nourish hair naturally from within. The Viviscal supplement is compared to the placebo tablet which contains no active ingredients. One tablet is taken by mouth in the morning and evening with food.
223509848|NCT03020082|DRUG|Danoprevir|Danoprevir (DNV)administered orally 100mg BID for 12 weeks;
223760728|NCT00858871|DRUG|Placebo|Capsules, Oral, twice Daily, Until disease progression or unacceptable toxicity
223760729|NCT00858871|DRUG|Sorafenib|Capsules, Oral, 800 mg, twice daily, Until disease progression or unacceptable toxicity
224312244|NCT02302053|DIETARY_SUPPLEMENT|Placebo tablets|The placebo tablet contains no active ingredients. One tablet is taken by mouth in the morning and evening with food.
224312245|NCT00635232|DRUG|irbesartan|300 mg (2 x 150 mg capsules) once daily for 12 weeks
224312246|NCT00635232|DRUG|placebo|placebo capsules once daily for 12 weeks
223509849|NCT03020082|DRUG|Ritonavir|Ritonavir administered orally 100mg BID for 12 weeks;
223509850|NCT03020082|DRUG|peginterferon alfa-2a|PEG-IFN abdominal or thigh subcutaneous injection, 180μg, once a week for 12 weeks;
223509851|NCT03020082|DRUG|RBV|RBV administered orally 500mg (5 tablets)( body weight \<75Kg) BID, 600mg (6 tablets) BID body weight ≥75Kg, for 12 weeks.
223509852|NCT06936501|DIETARY_SUPPLEMENT|Traditional flavor ONS (vanilla or strawberry, by choice)|Receives a traditional flavor ONS (vanilla or strawberry, by choice) on days 1 and 2, then switches to a refreshing and stimulating flavor ONS (mango-peppermint or lemon-mint, by choice) on days 3 and 4.
223509853|NCT06936501|DIETARY_SUPPLEMENT|Refreshing and stimulating flavor ONS (mango-peppermint or lemon-mint, by choice)|Receives a refreshing and stimulating flavor ONS (mango-peppermint or lemon-mint, by choice) on days 1 and 2, then switches to a traditional flavor ONS (vanilla or strawberry, by choice) on days 3 and 4.
223509854|NCT01293877|PROCEDURE|Laparoscopy surgery for morbid obesity|The intervention will compare the 2 restrictive procedures one sleeve gastrectomy and gastric plication/
223509855|NCT01355367|DRUG|Nifedipine (Adalat, BAYA1040)|BAYA1040 CR 40mg BID
223509856|NCT04968145|OTHER|Home To Stay Mobile Health Application|"Home to stay is an integrated discharge monitoring system with a mobile application. Features of the application include a Daily Health Check to report on post-operative recovery, picture taking capability to photograph incisions/wounds and educational information on post-operative care at home.~Patients will complete a Daily Health Check on post-discharge Day #1-14, #21 and #30. The Daily Health Check consists of a series of questions specific to colorectal surgery as well as the Quality of Recovery (QoR-15) questionnaire. After completion, the participant will receive a list of recommendations tailored to their responses including relevant education modules, to contact the surgical team or in urgent cases to go to the nearest emergency room. The participants' responses will be monitored daily via a secure web site. Any participants' responses in the extreme ranges are automatically red flagged and notify the health care team that a follow up telephone call is required."
223509857|NCT06025227|DRUG|Etrasimod|tablets
223509858|NCT06214481|DRUG|Rocatinlimab|Administered SC.
223760730|NCT00858871|DRUG|Placebo|Tablets, Oral, Once Daily, Until disease progression or unacceptable toxicity
223760731|NCT04990934|BEHAVIORAL|Semistructured Interview|Patients with breast cancer (Stage I-III) will be interviewed about their experiences of telemedicine.
224312247|NCT00635232|DRUG|PS433540|200 mg (2 x 100 mg capsules) once daily for 12 weeks
224312248|NCT00635232|DRUG|PS433540|400 mg (4 x 100 mg capsules) once daily for 12 weeks
224312249|NCT00635232|DRUG|PS433540|800 mg (8 x 100 mg capsules) once daily for 12 weeks
224312250|NCT06613347|OTHER|whitening maintenance|whitening maintenance regimen
224312251|NCT06613347|OTHER|whitening maintenance MW|maintenance MW
224312252|NCT06613347|OTHER|negative control|negative control
223509859|NCT05222789|PROCEDURE|TAP|The transverse abdominal plane (TAP) block is a regional anesthesia technique performed using ultrasound that blocks the afferent nerves of the anterolateral abdominal wall, injecting local anesthetic in the fascial plane between the deep oblique and the transversus abdominis muscles.
223509860|NCT05664815|BIOLOGICAL|Human Amniotic Membrane|"After conventional/standard treatment, hAM will be applied in a single layer against the bone defect with, if possible, a burial of a few millimeters under the mucous edges.~With the idea of apprehending a possible dose effect, the hAM will be adapted to the size of the bone/mucous defect, mesenchymal side against the bone.~For closure after hAM grafting : 2 options are possible:~Edge-to-edge closure if sufficient mucosal laxity, Edge rapprochement by cross points. If necessary: possible incision of the periosteum to give laxity to the mucosa."
223509861|NCT05664815|OTHER|Conventional/Standard treatment|"Surgical procedure: Endo-oral approach:~* Trimming of the mucous edges if they are necrotic or inflamed (granulation tissue)~* For the bone: either simple sequestrectomy (the mobile sequestered bone is grabbed using forceps); either reaming until bleeding is obtained; either resection with the rongeur; either monobloc resection of the entire necrotic fragment with a saw or with a piezzotome (ultrasound); or a combination of different techniques. Rq: the resection of the necrotic bone (according to the practices of the center) will operate until the appearance of an apparently healthy bone (bone bleeding, clean appearance of the bone site)~* Closure of the mucosa with possible incision of the periosteum to provide laxity: Suture points by points separated in one plane with non-absorbable braided thread of the 3.0 silk thread type and round needle."
223509862|NCT00773110|DRUG|20% Human albumin solution|Priming of the cardiopulmonary bypass circuit with Hartmann's solution (1000 mL), 20% Human serum albumin(300 mL), 0.9% sodium chloride solution (200 mL) and heparin (10,000 IU)
223509863|NCT00773110|DRUG|Gelofusin|Priming of the cardiopulmonary bypass circuit with Hartmann's solution (1000 mL), Gelofusine (300 mL, 4% succinylated gelatin, a synthetic colloid) and heparin (10,000 IU)
223509864|NCT01932424|DEVICE|Pelorus 1500|a bedside blood propofol measurement device
223509865|NCT01932424|DRUG|Propofol 2% (Diprivan 2%, Astra Zeneca UK)|
223509866|NCT02323581|DEVICE|Endovascular treatment of Thoracoabdominal Aortic Aneurysm|"A TAAA is an abnormal enlargement (ballooning out) of the main artery (the aorta) and involves all or part of the aorta in your chest as well as all or part of the aorta in the abdomen. It also involves the part of the aorta where the arteries that bring blood to the liver, stomach and intestines and kidneys are attached.~This investigational procedure that is being studied uses stent-grafts (cylindrical fabric tubes (grafts), with metal springs (stents) attached). The stent-grafts are placed inside the aneurysmal (weakened) area of the aorta to re-line it. These customized stent-grafts have special branches attached to them or openings (called fenestrations) that are used to keep blood flowing to the arteries that supply the liver, stomach, intestines and kidneys. The investigational stent graft will be designed and custom-made specifically for your aneurysm."
223509867|NCT02323581|DEVICE|Endovascular treatment of Aortic Arch Aneurysms|"An aortic arch aneurysm is an abnormal enlargement (ballooning out) of the main artery (the aorta). The ascending aorta and aortic arch is the first part of the vessel as it exits the heart and makes a turn around the area of the collar bone. This part of the aorta gives branches that supply the head, brain and arms.~The arch branch endovascular graft includes the main aortic arch portion and one to three cuffs (side branches) that allow the graft to be located in the aortic arch. The number of cuffs is decided based on the anatomy of your aneurysm. The arteries in the aortic arch are the innominate artery (Zone 0), left common carotid artery (Zone 1) and the left subclavian artery (Zone 2). These arteries supply the right arm and right side of the brain, the left side of the brain and the left arm, respectively."
223509868|NCT05272774|BEHAVIORAL|FOREST+|The intervention will be delivered as an online stress recovery intervention consisting of six weekly modules. Modules include an introduction, psychological detachment, distancing, mastery, control, and keeping the change alive. These modules have been chosen after considering the themes that could be most useful for healthcare workers under high stress. Each module consists of a psychoeducational and an exercise component.
223509869|NCT06695676|DIAGNOSTIC_TEST|Global Longitudinal Strain|Global longitudinal strain measurement is a more objective method to determine left ventricular systolic function than traditional eyeballing method. It helps to detect and quantify subtle changes even so it is an emerging method to evaluate the cardiotoxicity of chemotherapeutic drugs. It is planned to compare each selected patient's GLS measurement before starting to use lurasidone and after six months of using it. Hereby our aim is to find if lurasidone has any effect on left ventricular systolic function.
223509870|NCT02388256|DEVICE|acupuncture|"Points of Stomach 36 (ST36), Stomach 37 (ST37), Liver 3 (LR3), Large Intestine 11 (LI11), Large Intestine 4 (LI4), Spleen 6 (SP6), Spleen 4 (SP4) and Pericardium 6 (PC6) will be used. Electrical stimulation with alternating frequency of 2 to 100 Hz will be applied to the selected points (LI4 to LI11, ST36 to ST37, and bilateral SP6).~Rationale of acupuncture treatments will include both traditional theory of harmonizing gastrointestinal function and strengthening vital energy as well as modern experimental and clinical evidence of regulating gastrointestinal motility and other symptom managements. Treatments will be provided by qualified hospital staff (Korean medical doctors) with more than 10 years of clinical experience."
223509871|NCT02388256|OTHER|early recovery program after surgery|An enhanced recovery program after surgery that was designed and is currently implemented by surgeons, anesthetists, dietitians, and nurses will be provided. The program includes preoperative education, early water/food intake, early mobilization, early removal of Foley catheter and drains, structured nursing care, and nutritional support.
223509872|NCT02883933|OTHER|Data collection|
223509873|NCT06694350|DRUG|Pembrolizumab+Flutamide|Pembrolizumab 200mg ivgtt once +Flutamide 250mg，Q8h
223509874|NCT03514693|PROCEDURE|PVI|Ipsilateral circumferential PVI is the recommended PVI strategy. The success of PVI is defined as the achievement of the dissociation of PV potentials in all PVs. Disappearance of PV potentials is reconfirmed at the end of the procedure, a minimum of 20 minutes after the initial success of PVI.
223509875|NCT03514693|PROCEDURE|PVI plus additional ablation|In addition to PVI, CFAE ablation, linear ablation, or both; the choice of which is decided by the physician
223760732|NCT02361710|PROCEDURE|frozen embryo transfer|comparison of groups according to their serum vitamin D levels on frozen embryo transfer day
223760733|NCT00684606|DRUG|Oxytocin IV|5 miu/1000ml Glu/Saline
223760734|NCT03806582|DRUG|Norepinephrine|intervention with norepinephrine to reach a MAP of 85 mmHg
223760735|NCT00347724|DRUG|Tramadol HCl ER|
223615655|NCT01101399|DRUG|Ferric carboxymaltose|"Subjects will receive a single dose of 1,000 mg iron as FCM infusion at baseline.~Subjects of bw ≤66 kg will receive a single dose of 500 mg iron as FCM infusion at baseline (Week 0) and at Visit 4 (Week 2).~Ferric carboxymaltose will be administered on the same day with chemotherapy treatment or within 24 hours before or after the chemotherapy. For subjects with bw ≤66 kg, if no chemotherapy planned for the visit 4 (Week 2), the second FCM dose should be infused independent of chemotherapy."
223615656|NCT00006269|DRUG|irinotecan hydrochloride|
223615657|NCT00006269|DRUG|octreotide acetate|
223615658|NCT04035733|DRUG|rVA576|BP subjects will be treated with 30 mg once daily rVA576 regime for 6 weeks.
223615659|NCT03811444|DEVICE|Haemolance Plus safety lancet|Haemolance Plus safety lancet type 420 is a sterile, single use medical device designed for the sampling of capillary blood from the fingertip of patients
223615660|NCT03811444|DEVICE|Prolance safety lancet|Prolance safety lancet type 430 is a sterile, single use medical device designed for the sampling of capillary blood from the fingertip of patients.
223615661|NCT03811444|DEVICE|MediSafe Solo safety lancet|MediSafe Solo safety lancet type 520 is a sterile, single use medical device designed for the sampling of capillary blood from the fingertip of patients.
223615662|NCT01188772|DRUG|Sofosbuvir|Sofosbuvir tablets were administered orally once daily.
223615663|NCT01188772|DRUG|Placebo to match sofosbuvir|Placebo tablets to match sofosbuvir were administered orally once daily.
223615664|NCT01188772|DRUG|PEG|Pegylated interferon alfa-2a (PEG) 180 μg was administered once weekly by subcutaneous injection.
223615665|NCT01188772|DRUG|RBV|Ribavirin (RBV) was administered as a tablet orally according to package insert dosing recommendations (Genotype 1: \< 75kg = 1000 mg and ≥ 75 kg = 1200 mg; Genotype 2/3: 800 mg).
223615666|NCT05003947|BIOLOGICAL|AlloRx|cultured allogeneic adult umbilical cord derived mesenchymal stem cells
223615667|NCT05696249|DEVICE|OhmTrak device.|All probands will undergo six-week outpatient therapy once a week. The intervention group will be equipped with an OhmTrak device for home self-therapy and instructed in its correct use at least 5 times a week.
224312253|NCT06428526|DEVICE|Continuous stimulation strategy|Participants will be administered stimulation with a constant frequency stimulation.
223615668|NCT05696249|OTHER|Outpatient Physiotherapy|All probands will undergo six-week outpatient therapy once a week for an hour
223615669|NCT01433172|BIOLOGICAL|Phase I - GM.CD40L.CCL21 Vaccinations|"This is a dual-agent, Phase I study with an expansion of each group at the recommended Phase II dose. Participants are entered in cohorts of 3 at the first dose level. Doses are not escalated over the course of treatment of an individual patient.~Phase I: Participants receive the GM.CD40L.CCL21 vaccine in a standard 3+3 design."
223615670|NCT01433172|BIOLOGICAL|Phase II - GM.CD40L cells Vaccinations|Patients randomized to Arm A will receive vaccinations on 3 occasions, at 2 week intervals. 7.5 X 10\^6 irradiated H1944 tumor cells, 7.5 X 10\^6 irradiated H2122 cells, and containing 15 X 10\^6 GM.CD40L cells (1.1 mL) will be injected intradermally into 4 separate sites (0.25 ml injected at each site), in bilateral proximal upper and lower extremities (in the regions of the axillary and inguinal nodal basins). Patients will be restaged approximately 2 weeks after vaccine 3. If patients show no sign of disease progression, patients will then be vaccinated at 4-week intervals.
223615671|NCT01433172|BIOLOGICAL|Phase II - GM.CD40L.CCL21 Vaccinations|"This is a dual-agent, Phase I study with an expansion of each group at the recommended Phase II dose. Participants are entered in cohorts of 3 at the first dose level. Doses are not escalated over the course of treatment of an individual patient.~Phase II: Participants are randomized to one of the 2 arms (ratio 1:1): GM.CD40L versus GM.CD40L.CCL21. Patients in Arm B will receive vaccines at the same dose and schedule as described for patients in Arm A. In addition, their vaccine will include H1944 cells expressing CCL21. Note for patients on Arms A and B: the use of steroid medication is to be avoided for 4 weeks before to the initiation of vaccine therapy and during the vaccine treatment period."
223615672|NCT00287716|DRUG|Pirfenidone|1197 or 2403 mg/day given orally, and administered in divided doses three times daily with food, for the duration of the study.
223615673|NCT00287716|DRUG|Placebo|Placebo equivalent, given orally, and administered in divided doses three times daily with food, for the duration of the study.
223615674|NCT01125982|DRUG|Propofol|Continuous intravenous infusion at 3-6 µg/mL (Ce - Target Controlled Infusion) during anaesthesia to provide sleep.
223615675|NCT01125982|DRUG|Desflurane|Continuous inhalation at 0.7-0.8 MAC (endtidal) during anaesthesia to provide sleep
223615676|NCT01894607|PROCEDURE|Contrast Enhanced Intraoperative Ultrasound|During standard of care surgery, radiologist will take images and videos with an ultrasound machine before and after patient given the contrast agent.
223615677|NCT01894607|DRUG|DEFINITY|"During standard of care surgery, radiologist will take images and videos with an ultrasound machine before patient given the contrast agent.~Patient then receives the DEFINITY contrast by vein over about 1 minute. After receiving the injection of DEFINITY, radiologist will take more images and videos of the tumor and kidney(s) to compare to those recorded earlier."
223615678|NCT01894607|BEHAVIORAL|Phone Call|Follow-up phone call 30 days after standard of care surgery is complete to review any side effects patient may be having.
223615679|NCT01398371|DRUG|Withdrawal of digoxin|Participants currently receiving digoxin for heart failure will have their digoxin stopped for 12 weeks.
223615680|NCT01398371|DRUG|Digoxin|Stable digoxin therapy which produces a digoxin plasma level of 0.4-0.8.
223615681|NCT05706948|OTHER|High Intensity Interval Training (With Face Mask)|High Intensity Interval Training on Treadmill for 4 weeks with Face mask
223615682|NCT05706948|OTHER|High Intensity Interval Training (Without Face Mask)|High Intensity Interval Training on Treadmill for 4 weeks with out Face mask
223615683|NCT05533996|DIAGNOSTIC_TEST|ultrasound|Sonographic examination to measure the maternal pre-peritoneal fat thickness and subcutaneous fat thickness and calculate body fat index
223615684|NCT02347839|PROCEDURE|Gefitinib-surgery-gefitinib|neoadjuvant gefitinib followed by surgery, followed by adjuvant gefitinib
223760736|NCT04441294|BEHAVIORAL|ACE-Plus|
223760737|NCT05651711|DRUG|Rocatinlimab|Rocatinlimab will be administered through a subcutaneous (SC) injection.
223760738|NCT05651711|OTHER|Placebo|The matching placebo will be administered through a SC injection.
224312254|NCT06428526|DEVICE|Closed-loop stimulation strategy|Participants will be administered with an activity-dependent stimulation.
224202011|NCT05661825|OTHER|phase II cardiac rehabilitation|Phase II cardiac rehabilitation was provided in the the department of physical medicine and rehabilitation in Wan Fang Hospital. The programs are two times a week, one session for 30 minutes (30 sessions in total). The training programs are focused on aerobic training with bicycles. The training intensity is calculated with 40% to 80% oxygen consumption reserve from the result of cardiopulmonary exercise test. In case of safety, heart rate, blood pressure, EKG and rate of perceived exertion will be monitored during training.
224312255|NCT06990204|DRUG|Azilsartan medoxomil 80 mg tablet|1 tablet of 80 mg of azilsartan medoxomil
224202012|NCT00845559|DRUG|Exenatide|Subjects randomized to treatment will receive a four month supply of exenatide and will be taught how to administer subcutaneous injections with their exenatide pen and instructed on the following dosing schedule: exenatide - 5 μg twice a day for 7 days, followed by exenatide 10 μg twice a day for the remainder of the four month supply.
224202013|NCT02194959|BEHAVIORAL|Peer PN|Navigation by Peer Patient Navigators
224202014|NCT02194959|BEHAVIORAL|Pro PN|Navigation by Standard Hospital Navigators
224202015|NCT01126359|DRUG|Lidocaine|Interventional dressing change: iv or po pain medication with injection of 1% lidocaine retrograde up the suction tube into the sponge.
224202016|NCT01126359|DRUG|Placebo-Saline|Control dressing change: iv or po pain medication and injection of 0.9% normal saline retrograde up the suction tube.
224202017|NCT05056740|BIOLOGICAL|Data analysis|Analysis of the data from routine care at the end of the diagnostic work-up
224202018|NCT05779059|DRUG|De-escalation to ticagrelor 60 mg at day 30|Change of P2Y12 receptor antagonist regimen to ticagrelor 60 mg bid at day 30.
224312256|NCT06990204|DRUG|Edarbi® 80 mg tablets|1 tablet of 80 mg of azilsartan medoxomil.
224312257|NCT06989749|OTHER|Anodal tDCS|Transcranial direct current stimulation (tDCS) is an experimental manipulation of brain circuitry using electrical current applied to the scalp. The equipment is commercially available (StarStim8, Neuroelectrics, Spain) and marketed for experimental research on brain function. Current is applied at 2 mA for 20 minutes. Electrodes are placed on the C3 and FP2 regions. There is a 30-second ramp-up and 30-second ramp-down of stimulation for each tDCS condition to minimize any discomfort during stimulation. In the anodal condition, real tDCS stimulation enters from the C3 electrode, and exits at the FP2 electrode.
224312258|NCT06989749|OTHER|Cathodal tDCS|Transcranial direct current stimulation (tDCS) is an experimental manipulation of brain circuitry using electrical current applied to the scalp. The equipment is commercially available (StarStim8, Neuroelectrics, Spain) and marketed for experimental research on brain function. Current is applied at 2 mA for 20 minutes. Electrodes are placed on the C3 and FP2 regions. There is a 30-second ramp-up and 30-second ramp-down of stimulation for each tDCS condition to minimize any discomfort during stimulation. In the cathodal condition, real tDCS stimulation enters from the FP2 electrode, and exits at the C3 electrode.
223509876|NCT06564766|OTHER|Debriefing|"In the experimental group, an expert instructor conducted a structured debriefing lasting about 10-15 minutes for each clinical scenario, while in the control group, no additional intervention was provided.~The debriefing used in this study has the following characteristics: brief (≤ 15 minutes), educator present, educator experienced in debriefing, focused on healthcare management or decision-making, and used the Plus-Delta method, where participants are asked to reflect on the simulation event and assess their performance by identifying what went well and areas for improvement."
223509877|NCT01153542|DRUG|VX-770|In period 1, subjects will receive a single oral dose of desipramine on Day 1.
223509878|NCT01153542|DRUG|VX-770|In period 2, subjects will receive 150 mg VX-770 q12h orally from the morning of Day 1 through the evening of Day 9. Subjects will receive 50 mg Desipramine as a single dose on Day 5 of period 2.
223509879|NCT06089746|OTHER|NIPT|Coordinated suite of DME and training to support continuous maintenance of flexion posture during the 6 week trial.
223509880|NCT06240208|BEHAVIORAL|Inactivity|Inactivity will be implemented as cessation of active commuting and all other structured exercise. Furthermore, steps will be reduced to a maximum of 1500 steps/day.
223509881|NCT05995561|OTHER|no intervention is planned.|no intervention is planned.
223509882|NCT00370955|PROCEDURE|phacoemulsification using either high vacuum or low vacuum techniques|All surgeries were performed using Sovereign phacoemulsification system (AMO) using Whitestar technology.
223509883|NCT05592743|DRUG|Vorasidenib|Oral therapy
223509884|NCT03000803|BEHAVIORAL|Early Total Caloric Intake|Provide subjects a regimented amount of calories at each meal.
224202019|NCT05779059|DRUG|De-escalation to prasugrel 5 mg at day 30|Change of P2Y12 receptor antagonist regimen to prasugrel 5 mg qd at day 30.
224312259|NCT06989749|OTHER|Sham tDCS|This is the sham (or placebo) tDCS intervention. The tDCS device is applied for one minute, for a 30-second ramp-up and 30-second ramp-down of stimulation.
224202020|NCT05779059|DRUG|Switch to ticagrelor 60 mg at day 45|Switch to ticagrelor 60 mg bid at day 45.
224202021|NCT05779059|DRUG|Switch to prasugrel 5 mg at day 45|Switch to prasugrel 5 mg qd at day 45.
224202022|NCT04116359|DRUG|Cisplatin|Given IV
224202023|NCT04116359|DRUG|Etoposide|Given IV
224202024|NCT04116359|DRUG|Etoposide Phosphate|Given IV
224202025|NCT04116359|DRUG|Molibresib|Given PO
224202026|NCT04116359|DRUG|Molibresib Besylate|Given PO
223509885|NCT03000803|BEHAVIORAL|Late Total Caloric Intake|Provide subjects a regimented amount of calories at each meal.
223509886|NCT04082442|DRUG|Evolocumab|420 mg evolocumab.
223509887|NCT04082442|DRUG|Placebos|Matching placebo.
223509888|NCT00576745|PROCEDURE|Vicryl Suture|A 4-0 vicryl suture will be used to close the subcuticular layer
223509889|NCT00576745|DEVICE|3M TM S Surgical Skin Closure System|These steri-strips will be applied to close the skin in this cohort of patients
223615685|NCT05189470|PROCEDURE|Inforatio technique|Inforatio technique is a novel minimal invasive procedure where small cuts are made on wound beds with punch biopsy tools near the wound edges but without involving wound edge epithelia. Inforatio technique is applied after the wound has been surgically debrided for slough and devitalized tissue.
223615686|NCT05189470|OTHER|Usual care of the respective outpatient clinics|Usual care of the DFUs includes local wound care and offloading treatment.
223615687|NCT02738554|OTHER|Treatment cessation|Cessation of nucleoside analogue therapy following European Association for the Study of the Liver guidelines
223615688|NCT03708978|DIAGNOSTIC_TEST|mammography|When a woman comes to the clinic to receive mammography. Then a radiologist will give a BI-RADS classification after reviewing the images. If a BI-RADS 4/5 is obtained, the woman will receive pathological biopsy to ensure there is a benign or malignant lesion. If a BI-RADS 3 is obtained, the woman will be followed up by a half-year interval until two year after the first mammography. At each follow up, she will receive mammography. If a BI-RADS 4/5 is obtained at follow up, she will receive pathological biopsy; if a BI-RADS 1/2/3 is obtained at follow up, she will be followed up by a half-year interval until two year. If a BI-RADS 1/2 is obtained at the first mammography, the woman will receive a second mammography after two year. During the study period, breast examination and results will be recorded for every subject. Radiologists will give the diagnosis with and without AI support.
223615689|NCT05187078|PROCEDURE|Allis clamp|Physicians utilized an Allis clam for cervical stabilization during IUD placement.
223615690|NCT05187078|PROCEDURE|Single-tooth tenaculum|Physicians utilized a single-tooth tenaculum clam for cervical stabilization during IUD placement.
223615691|NCT03455738|OTHER|vasoplegic syndrome|Patients with vasoplegic syndrome for whom the intensive care physician planned to decrease the norepinephrine dosage were included. Hemodynamic and uncalibrated pulse contour analysis (Volume view, FloTrac, Edwards Lifescience, Irvine) values were obtained before and after decreasing the norepineprhine dosage. Responders were defined by a \>10% decrease in mean arterial pressure (MAP).
223615692|NCT04083365|DRUG|Capecitabine|chemoradiation therapy with 825 mg/m2 twice daily capecitabine every day for 5 weeks
223615693|NCT04083365|DRUG|Radiotherapy|5040 cGy radiotherapy for 5 days per week for 5 weeks
223615694|NCT04083365|DRUG|Durvalumab|One week after the end of CT/RT patients will be treated with 1500 mg IV Q4W durvalumab for 3 administrations
223615695|NCT01824550|OTHER|home-based exercise training condition|Home based endurance exercise training
223615696|NCT06581653|BEHAVIORAL|Phone-based PERT education intervention|Participants who allocate to the intervention group will receive regular phone-based PERT education intervention by professional team.
223760739|NCT06992726|DIETARY_SUPPLEMENT|Fish oil intervention|The diet was based on the principles of a balanced diet, and subjects in this group were additionally supplemented with n-3 PUFA (provided as 1.36 g fish oil capsules), with the rest of the intervention being the same as in the control group.
223760740|NCT06992726|OTHER|Placebo intervention|Diet based on the principles of a balanced diet, taking placebo capsules with the same appearance and odor as the fish oil capsules.
223760741|NCT05466149|DRUG|Furmonertinib|240mg QD on a continuous dosing schedule.
223760742|NCT06886373|DRUG|Systane Complete|Systane COMPLETE is an artificial tears that contain nano-emulsion of mineral oil and phospholipids.
223760743|NCT06362590|DRUG|ladiratuzumab vedotin|
223760744|NCT06889545|OTHER|Assessment of frailty using multiple tools|This is an observational study without any intervention. Frailty is assessed using multiple tools and postoperative outcome is compared.
223760745|NCT06853015|DRUG|Dalfampridine|The study drug (4-AP) will be administered as a 10 mg dose twice a day.
223760746|NCT06853015|DRUG|Placebo|The placebo provided by the SRAL pharmacy that looks identical to the 4-AP, will be administered twice a day.
223760747|NCT06853015|OTHER|STDP stimulation|Paired stimulation will be given to the spinal cord and to peripheral nerves so that the signals are received at the spinal cord at a specific interval.
223760748|NCT06853015|BEHAVIORAL|Exercise training|Lower-limb exercises will involve over-ground walking, treadmill, walking and stair climbing training.
223760749|NCT06774274|DRUG|Ketamine infusion|"A 10% ketamine solution will be prepared in a 250 cc bag of 0.9% saline (1 mg/cc) using 5 cc from a vial of ketamine that has a concentration of 50 mg/cc. The infusion will be initiated at the time of surgical site closure and will proceed as follows: a bolus of 0.35 cc/kg (equivalent to 0.35 mg/kg) will be administered, followed by a continuous infusion of 0.1 cc/kg/h (equivalent to 0.1 mg/kg/h) for up to 48 hours postoperatively.~Patients in this group will have access to a PCA pump with morphine for analgesic rescue and to monitor daily opioid consumption."
224202027|NCT03141346|BEHAVIORAL|Sugar reduction health education program|A health education program incorporating sugar reduction education and monitoring provided by a trained health educator over 24 months. The intervention program will be delivered by the health educator during in-person home visits, or virtually via phone or video calls.
224202028|NCT03141346|BEHAVIORAL|Control health education program|Control health education program provided by a trained health educator over 24 months. The intervention program will be delivered by the health educator during in-person home visits, or virtually via phone or video calls.
224202029|NCT03141346|OTHER|Home water delivery|Home delivery of bottled water administered over 24 months
224202030|NCT05419635|DRUG|Asundexian (BAY2433334)|Study intervention BAY2433334 will be administered as tablet taken orally.
224202031|NCT04078893|OTHER|telephone recruitment|using telephone to recruit inactive donors on two different methods
224202032|NCT02831478|DRUG|BAY987517|Applied liberally to the skin (Formulation: RB# Z16-071)
223615702|NCT02733445|DRUG|dasatinib|
223615703|NCT02733445|DRUG|nilotinib|
223615704|NCT04393493|DRUG|Furosemide intravenous solution|Administrated as an 80 mg intravenous bolus every 24 hours in both arms and then as a continuous infusion dosed according to the experimental arm.
223615705|NCT04393493|DRUG|Chlortalidone|One 50 mg pill administrated every 24 hours in group B
223615706|NCT04393493|DRUG|Spironolactone|One 50 mg pill administrated every 24 hours in group B
223615707|NCT05759689|DIETARY_SUPPLEMENT|Dietary Supplement: Resource Energy|Carbohydrate Supplement
223615708|NCT05759689|DIETARY_SUPPLEMENT|Dietary Supplement: Calogen|Polyunsaturated liquid fat supplement
223615709|NCT04303559|DRUG|Eloctate Injectable Product|This is a factor VIII-Fc fusion protein.
223615710|NCT04303559|DRUG|Emicizumab Injection [Hemlibra]|This is a bispecific monoclonal antibody FVIII mimic.
223615711|NCT00421681|BEHAVIORAL|Fit and Strong! Exercise Program|Fit and Strong! is an 8-week (24 sessions) multi-component exercise and health education intervention, including flexibility, aerobic conditioning, strength training, and group discussion/problem solving for lifestyle change. Following participation in Fit and Strong!, all study participants are randomly assigned to one of 2 maintenance treatment follow-up groups.
223615712|NCT00419731|DRUG|Bupropion|"Sustained-release, 150 mg, q.d., for days 1-3, 150 mg, b.i.d., for balance of 7 weeks.~Placebo, 25 mg, q.d., for 7 weeks."
224202033|NCT02831478|DRUG|Sunscreen Lotion (RB# T78-190B)|Applied liberally to the skin
224202034|NCT00902486|DRUG|INCB028050|4 mg capsules QD
224202035|NCT00902486|DRUG|INCB028050|7 mg capsules QD
224202036|NCT00902486|DRUG|INCB028050|10 mg capsule QD
224202037|NCT00902486|DRUG|Placebo|Placebo matching INCB028050 QD
223615713|NCT00419731|DRUG|Bupropion + Naltrexone|"Bupropion, Sustained-release, 150 mg, q.d., for days 1-3, 150 mg, b.i.d., for balance of 7 weeks.~Naltrexone, 25 mg, q.d., for 7 weeks."
223615714|NCT02625805|DEVICE|EEG monitoring (MindWave by NeuroSky)|EEG evaluation will be conducted for duration of 10 minutes. 5 minutes without auditory stimulation and 5 minutes with auditory stimulation performed using standard headphone or earphones to reduce external noises. Additional EEG monitoring will be performed during performance of a computerized test using MindWave Headset.
223615715|NCT02625805|DEVICE|EEG monitoring (EPOC by Emotiv)|EEG evaluation will be conducted for duration of 10 minutes. 5 minutes without auditory stimulation and 5 minutes with auditory stimulation performed using standard headphone or earphones to reduce external noises.
224202038|NCT00364416|OTHER|Any treatment used to treat CHF|Clinical Outcomes of Chronic Decompensated Heart Failure patients
224202039|NCT03328286|BEHAVIORAL|Weekly group meeting w/psychotherapist|Introduce a Psychotherapist in a work Integration program to further support Young adults in Job search and at the same time offering psychotherapeutic counselling. The participants will have a weekly meeting lasting 1.5 hour and additionally the can have 5 private counselling sessions with the psychotherapist if they wish
224202040|NCT00488007|DEVICE|Hearing aids used : PHONAK Savia and Valeo|5 hours per day during the first 6 months (active or inactive upon randomization) 5 hours per day during the last 6 months (active)
224202041|NCT03951701|OTHER|Evaluation of the supportive care|Evaluation of interest of a systematic screening for oncological supportive care needs
224202042|NCT03998852|DRUG|Positron Emission Tomography (PET) with [18F]-FDOPA|Positron Emission Tomography (PET) with \[18F\]-FDOPA
224202043|NCT03998852|DRUG|Positron Emission Tomography (PET) with [18F]-FEOBV|Positron Emission Tomography (PET) with \[18F\]-FEOBV
224202044|NCT03998852|DEVICE|Magnetic Resonnance Imaging (MRI)|MRI protocol will be performed on the same day that the \[18F\]-FEOBV PET imaging, using a 3T scanner (Philips Medical System). Different types of images will be acquired.
224202045|NCT03998852|OTHER|Neuropsychological evaluation|Neuropsychological evaluation will be performed, consisting in an assessment of apathy by actigraphy (social or physical activities will be recorded during seven days) and a complementary assessment of apathy using the Lille Apathy Rating Scale (LARS)
224202046|NCT03906773|OTHER|Patient Centered Medical Home Based Electronic Framework for Advance Care Planning|The intervention tested a pre-visit ACP workflow centered around a framework sent via secure Electronic Health Record (EHR)-linked patient portal in a real world clinical setting. The primary objectives were to determine its impact on frequency and quality of ACP documentation.
224202047|NCT02332655|DRUG|Cannabidiol|"Initiation of treatment will begin with 2mg/kg/day. The dose will be increased by 3 mg/kg/day after seven days and then by 5 mg/kg/day every seven days up to a maximum dose of 25 mg/kg/day given.~The dose of concomitant antiepileptic drugs will remain unchanged during the first 12 weeks of CBD treatment (or until 8 weeks after steady state at final dose), unless symptoms of toxicity and/or significant changes in blood levels are observed."
224202048|NCT01912469|DRUG|Traumeel|oral, Day 1: one tablet every 15 minutes for two hours after the exercise test, 6 hours and 10 hours after the exercise test; Day 2 and 3: two tablets thrice daily; Day 4: two tablets in the morning
224202049|NCT01912469|DRUG|Placebo|oral, Day 1: one tablet every 15 minutes for two hours after the exercise test, 6 hours and 10 hours after the exercise test; Day 2 and 3: two tablets thrice daily; Day 4: two tablets in the morning
224202050|NCT06874855|DRUG|Lemborexant|Lemborexant tablet administered orally once daily
224202051|NCT06874855|DRUG|Placebo|Placebo to match Lemborexant tablet administered orally once daily
224202052|NCT01298661|OTHER|Six-minute Step Test|The patients underwent a test where they need to step up and down a 20cm test during six minutes.
224202053|NCT07040267|DIAGNOSTIC_TEST|Thumb evaluations|"There is no therapeutic or experimental intervention in this study. All procedures will be limited to diagnostic evaluations. The study will include non-invasive biomechanical and sensory assessments to compare the thumb muscle characteristics and sensory discrimination between smartphone-addicted and non-addicted university students.~Specifically, muscle tone, stiffness, and elasticity will be measured using the MyotonPro™ device, and thumb sensory sensitivity will be evaluated using a Baseline Aesthesiometer with a two-point discrimination test. These assessments will be conducted during a single laboratory visit and will not involve any treatment, medication, or behavioral intervention.~This is a purely observational study aimed at identifying potential associations between smartphone usage patterns and thumb neuromuscular or sensory changes."
223615716|NCT02625805|DRUG|Methylphenidate|Methylphenidate will be administered to each of the study participants in both groups in one of the two days on the study selected randomly.
223615717|NCT02687464|OTHER|Non-operative treatment|"will receive a minimum of 12 hours intravenous antibiotics and then receive oral antibiotics once they have shown clinical improvement (a total course of 10 days of antibiotics (intravenous and oral). They will be discharged home once they meet a standardized set of criteria to be used in all centers.~The choice of antibiotics will vary between centers and will be the antibiotic regimen that is current standard of care in that center allowing each center to maintain current protocols will improve study feasibility and increase generalization of the results."
223615718|NCT02687464|PROCEDURE|Appendectomy|"will undergo laparoscopic appendectomy within 18 hours of randomization and will receive intravenous antibiotics per each site's standard care, from the time of randomization and post-operatively according to a defined and standardized treatment regimen based on consensus for this trial.~Children with a visibly normal appendix or non-perforated acute appendicitis will receive no further antibiotics; children with perforated appendicitis will continue to receive intravenous antibiotics for a minimum of 3 days, and then per local practice. The type of antibiotics used in each center will be identical to those used in the non-operative treatment group and are not specified by the study."
223615719|NCT03904121|PROCEDURE|Curative operation|Postoperative morbidity, mortality, functional outcome, survival
223615720|NCT00398658|DRUG|gentamycin and clindamycin|
223615721|NCT02408588|OTHER|Pulse oximeter|Place a pulse oximeter on the subject which will record the pulse oximeter waveform.
223615722|NCT02238119|DRUG|Tiotropium + formoterol combination|
223615723|NCT02238119|DRUG|Tiotropium|
223615724|NCT02238119|DRUG|Formoterol|
223615725|NCT06062654|OTHER|Hospital-assisted Rehabilitation|Patients are assisted by a physical therapist to perform commuting exercises and active and passive mobilization of the glenohumeral joint in anterior elevation, external rotation, internal rotation, retroposition and abduction.
223615726|NCT06062654|OTHER|Home-based Rehabilitation|Patients were educated by a physical therapist to perform commuting exercises and active and passive mobilization of the glenohumeral joint in anterior elevation, external rotation, internal rotation, retroposition, and abduction, which they perform at home independently.
223615727|NCT01572480|DRUG|Carfilzomib|Carfilzomib intravenous (IV) 20-36 mg/m\^2 per dose on days 1, 2, 8, 9, 15, and 16 of each cycle based on arm; until disease progression or unacceptable toxicity.
223615728|NCT01572480|DRUG|Revlimid|Revlimid by mouth (PO) 25 mg/day, days 1-21 every 28 days of each cycle based on arm; until disease progression or unacceptable toxicity.
223615729|NCT01572480|DRUG|Dexamethasone|Dexamethasone by mouth (PO) 20 mg per dose on days 1, 2, 8, 9, 15, 16, 22, and 23 of each cycle based on arm; until disease progression or unacceptable toxicity.
223615730|NCT06128304|OTHER|Core Implementation strategies|"Core Implementation Strategies~1. Ongoing consultation~2. Educational meetings~3. Strengthen referral system~4. Prepare patients to be active participants"
223615731|NCT06128304|OTHER|Core+ Enhanced Implementation Strategies|"Includes all of the Core implementation strategies and adds:~5\. Community engagement using Health Beginning Initiative Model~6\. Smart Cards to facilitate patient engagement"
223615732|NCT06148597|PROCEDURE|Modified thoracoabdominal nerves block through perichondrial approach (M-TAPA)|application local anesthetic between internal oblique and transversus abdominis muscle at the level of 10th costal cartilage
223615733|NCT04807686|DEVICE|Auditory simulation|Each patient will be delivered each of the 2 auditory stimulation protocols considered in the context of the research: stimulation with a traditional algorithm called AT and stimulation with a notched-type algorithm called AE. The order in which will be carried out, for the same patient, each of these 2 protocols (AT then AE or AE then AT) will be randomized.
223615734|NCT06360393|DEVICE|Smart spacer|Participants' inhalation medication adherence and inhalation technique will be monitored using a smart spacer. Their usual medication regime will be continued and they will not receive information about their adherence or inhalation technique measured by the spacer during the follow-up year (except for any interventions that will be done in standard care).
223615735|NCT04037891|DRUG|rVA576|Part 1: The first 3 patients selected for the study will be treated with the active drug in open-label.
223615736|NCT04037891|OTHER|Placebo|Part 2: Sixteen patients will be randomised 1:1. between active and placebo and patients allocated to either group will receive the appropriate product throughout the trial.
223615737|NCT04037891|DRUG|rVA576|Part 2: Sixteen patients will be randomised 1:1. between active and placebo and patients allocated to either group will receive the appropriate product throughout the trial.
223615738|NCT05974098|OTHER|Observational study|This study intends to use correlation analysis and mediation analyses to assess the mediating effects of self-efficacy, coping, depression and anxiety on the quality of life of patients with paroxysmal atrial fibrillation.
224202054|NCT06720948|DEVICE|ION 3D Facet Screw System|Observational study of subjects previously implanted with ION 3D Facet Screw System.
224202055|NCT06722963|DRUG|fentanyl|Fentanyl used as an adjuvant to bupivacaine for intraperitoneal instillation during laparoscopic cholecystectomy, a dose is 50 micrograms is commonly added to the local anesthetic solution.
224202056|NCT06722963|DRUG|Nalbuphine|Nalbuphine in doses ranging from 10 mg have been studied as adjuvants to bupivacaine
224314307|NCT00089024|PROCEDURE|conventional surgery|Restaging with repeat imaging studies will be performed four weeks after completion of the chemo-radiation. If no contraindication for surgical resection is identified, resection will be performed six to eight weeks after completing chemoradiation. At the time of surgical resection, an extensive examination of the abdomen will be performed to exclude the presence of metastatic disease. All operations will be performed with curative intent with resection of all gross tumor (ie R0 \[negative margins\] or R1 \[positive microscopic margins\]). Resection of adjacent involved organs or vascular structures will be performed as clinically indicated.
223615739|NCT06598475|OTHER|Facilitator-driven provider- and practice-level implementation strategies for influencing provider recommendations and practice-level HPV vaccination rates|"The practice facilitator (UTHealth research staff) will implement the following 4 strategies with providers and immunization navigators at each practice:~* Facilitator-driven provider education: The practice facilitator will conduct one provider education module (5 total modules) over three months with health care providers using a booklet and resource binder.~* Facilitator-driven clinical practice plan: The practice facilitator will assist the implementation team in creating their clinical practice in two additional modules and encourage providers to identify strategies to increase HPV vaccination.~* Training and education for staff (Immunization Navigators): The facilitator will train immunization navigators to implement the plan, and practice immunization navigators will implement the plan.~* Technical assistance plus assessment and feedback: During implementation of the plan, the facilitator will provide technical assistance, ongoing assessment and feedback, and booster trainings."
223615740|NCT06087224|OTHER|Teleneonatology|Real-time, two way, audio-video telemedicine connection between the neonatologist located in the regional neonatal intensive care unit (NICU) and the physician located at the community hospital.
223615741|NCT06817031|DRUG|VE818|VE818, is an 11-strain bacterial consortium rationally designed by Vedanta Biosciences Inc., to displace enteropathogens and reduce intestinal inflammation in pregnant women
223615742|NCT06817031|DRUG|Placebo|Enteric Capsules filled with approximately 400mg of Microcrystalline Cellulose (bulking agent)
223615743|NCT06817031|DRUG|Oral Vancomycin|Oral vancomycin in capsule form will be administered three times daily for 5 days at 250mg per dose. Because oral vancomycin is a non-absorbable antibiotic, the likelihood of systemic absorption is minimal and therefore, it is not associated with the adverse events attributable to the intravenous formulation
223615744|NCT03446313|BEHAVIORAL|Movn Mobile App|The Movn app will have each participant's personalized instructions for post-cardiac rehab integrated into it including medication reminders, physical activity prompts, educational materials, and patient-reported outcomes.
223760750|NCT06774274|DRUG|PCA Ketamine|"A mixture of 5% ketamine and 5% morphine will be prepared in a 100 cc bag of 0.9% saline. This will be achieved by using 1 cc of a ketamine vial (50 mg/cc) and 5 cc of a morphine ampule (10 mg/cc). This results in a final concentration of 0.5 mg of ketamine and 0.5 mg of morphine per cc in the 100 cc saline bag.~The pump settings will be configured as follows:~* PCA (Patient-Controlled Analgesia) dose: 2 cc (which delivers 1 mg of ketamine and 1 mg of morphine)~* Lockout interval: 6 minutes~* Maximum dose limit: 15 doses over a 4-hour period~The pump will be available for patient use for up to 48 hours postoperatively."
223760751|NCT04949750|OTHER|Paper - based cognitive training|Cognitive training
223760752|NCT06901726|DRUG|Human insulin enteric coated capsules in dose 32mg|Single oral administration of human insulin enteric coated capsules in dose 32mg (16 mg per capsule, two capsules).
223760753|NCT06901726|DRUG|Human Insulin Injection in dose 5IU|Single subcutaneous administration of Human Insulin Injection in dose 5IU.
223760754|NCT06903546|DRUG|Propolis drops|The intervention given is propolis drops that are approved by Indonesian Food and Drug Authority
223760755|NCT06903546|OTHER|Placebo|The given placebo are look-alike substance with no effect
223760756|NCT07087249|BEHAVIORAL|Ultrasound Visual Feedback|Speech therapy using real-time ultrasound imaging to provide visual feedback on tongue placement and movement. Aimed at improving speech accuracy and motor planning in children with Childhood Apraxia of Speech (CAS). The intervention follows principles of motor learning and includes 12 individual sessions over 6 weeks (twice per week). Practice alternates between ultrasound-assisted and non-assisted phases to promote generalization.
223760757|NCT07087249|BEHAVIORAL|Traditional Speech Therapy|Standard speech motor therapy for children with Childhood Apraxia of Speech (CAS), based on evidence-based motor learning approaches. No visual feedback tools are used. Therapy focuses on blocked and random practice, varied feedback, and increasing speech complexity. Delivered in 12 sessions over 6 weeks (twice per week).
223615745|NCT04183205|DIAGNOSTIC_TEST|LDAEP|This is an ERP task in which participants hear a series of tones ranging from 74dB to 104dB and electrophysiological activity is measured throughout. For each participant average P2 scores are derived for the 74dB tones, 84dB tones, 94dB tones, and 104dB tones. Then, LDAEP is defined as the slope of these average P2 scores.
223760758|NCT06902142|DEVICE|Adherence measured by MEMS caps|The methodological choices made in this study are justified by the need to assess the effectiveness of bictegravir, taking into account the varying levels of adherence among PLHIV. The use of electronic antiretroviral caps (MEMS caps: https://aardexgroup.com/medication-event-monitoring-system/ ) and the intra-cellular TAF assay to measure drug concentrations will enable a combined, precise and objective assessment of treatment adherence, and constitute the originality of this research.
223615746|NCT04183205|DRUG|Placebo|placebo pills of the same size, color and taste as the active drug will be administered
223760759|NCT06924047|OTHER|Beautifil Flow Plus X|Shofu's Beautifil Flow Plus X F00 a advanced bioactive injectable composite
223760760|NCT06924047|OTHER|EverX Flow|Short fiber reinforced composite
223760761|NCT02416882|OTHER|Aerobic Exercise|Subjects will sample and rate their liking of three cardiovascular machines (treadmill, cycle ergometer, elliptical step ergometer) to determine which one will be used during the test.
223760762|NCT02416882|OTHER|Resistance Exercise|Subjects will sample and rate their liking of three different resistance training circuits (upper body, lower body, core) to determine which one will be used during the test.
223760763|NCT02416882|OTHER|Sedentary Option|Subjects will rate their liking of three sedentary activities (reading magazines, playing puzzles, completing word games) as an alternative to exercise.
223760764|NCT06922864|OTHER|thermal stimulation|contact heat stimulation at 54℃
223760765|NCT06922864|OTHER|itch|itch the sole of the foot
223760766|NCT06924684|DRUG|Statin monotherapy (rosuvastatin or atorvastatin)|Tab Rosuvastatin 40mg (weight) at presentation. Tab Rosuvastatin 20mg at night for 30 days.
223760767|NCT06924684|DRUG|Placebo|Placebo caspule
223760768|NCT06922981|BEHAVIORAL|resistance training program|"Thirty-eight male and female patients aged 18-45 years, diagnosed with NSCLBP will be recruited through direct referrals from orthopedic surgeons, based on their availability to participate, thus a sample of convenience will be used, Participants will be randomly assigned as follows:~Group A:~Patients in group (A) (n=19) will receive a periodized resistance exercise program.~Group B:~The patients in group (B) (n=19) will receive a periodized aerobic exercise program"
223760769|NCT06923995|OTHER|AI-driven clinical interview|AI-driven clinical interview
224312260|NCT05686473|BEHAVIORAL|Program of psychoeducation of parents and professionals|"The program consists of a standardized manual-based treatment package as an easily accessible treatment tool for use by professionals in the specialist health services, who have treatment responsibilities for children diagnosed with FASD in Norway.~The intervention program will last for about 2 months and includes eight sessions, including six digitally based, interactive psychoeducational sessions.~Topics will be:~1. General information about FASD~2. Intervention strategies in kindergartens/schools for children with FASD~3. Families living with FASD - activities of daily living~4. Self-regulatory deficits - how to cope~5. Executive functions in daily life~6. Social development in children with FASD~7. Guidance in social settings~8. Challenging behavior - what can be done"
223760770|NCT06924723|PROCEDURE|tear duct probing|"In-office tear duct exploratory surgery was performed on the study participants, and the children were closely monitored for healing after the procedure.~The children were closely monitored for healing afterward, and the patients were also examined at 1 week, 1 month, and 2 months after the start of treatment."
223615747|NCT04183205|DRUG|sertraline|Sertraline is an FDA approved SSRI for treatment of PTSD.
223615748|NCT05516953|DRUG|Baclofen Tablets|10 mg oral baclofen 1 h before anesthesia
223615749|NCT06695546|OTHER|VExUS evaluation ultrasound|"VExUS evaluation by ultrasound will be performed before the filling/bleeding/cleaning procedure, and again after the procedure:~* Inferior vena cava measurement in Time-Motion (TM) mode, 1-2 cm from the right atrial orifice.~* Hepatic venous Doppler measurement in pulsed Doppler mode.~* Renal vein Doppler measurement in pulsed Doppler mode. Each measurement is performed three times consecutively (to average the results), then the ultrasound measurements are compiled into a score according to the degree of doppler severity."
224312261|NCT06534528|DRUG|Human umbilical cord mesenchymal stem cell injection|Different doses of human umbilical cord mesenchymal stem cell injection were infused to the focus of patients with idiopathic pulmonary fibrosis through bronchoscope, and the tolerance of subjects to different doses of human umbilical cord mesenchymal stem cell injection was observed, and the curative effect was preliminarily observed.
224312262|NCT06616064|BEHAVIORAL|personalised feedback and brief motivational|personalised feedback and brief motivational
224312263|NCT06616064|OTHER|routine lifestyle advice|routine lifestyle advice
224312264|NCT06616064|OTHER|questionnaire CliniCAP|questionnaire CliniCAP
224312265|NCT06617169|DRUG|MNPR-101-PCTA-177Lu|MNPR-101-PCTA-177Lu administered intravenously over approximately 20 minutes, followed by a normal saline flush. Dosing will occur on Cycle 1 Day 1, Cycle 1 Day 15, and Cycle 2 Day 1.
224312266|NCT05656001|OTHER|Real-time functional magnetic resonance imaging Neurofeedback and Real-time Biofeedback|Participants will take part in three runs of real-time functional magnetic resonance imaging feedback (rt-fMRI-NF) training with 4-8 days apart, which will be conducted at the Center for Medical Image Science and Visualization (CMIV) at the university hospital in Linköping. Participants who receive biofeedback will take part in three runs of biofeedback with 4-8 days apart conducted in the lab at the Center for Social and Affective Neuroscience (CSAN) at Linköping university. Participants will be given instructions and basic psychoeducation of brain function and the rational for down-regulating the area of the brain that drives emotion, as well as the physiological reaction that is triggered in response to emotional stimuli. The emotional stimuli are emotional pictures from the International Affective Picture System (IAPS) and the Open Affective Standardized Image Set (OASIS).
224312267|NCT05656001|OTHER|Sham functional magnetic resonance imaging neurofeedback and sham biofeedback|Participants will take part in three runs of sham neurofeedback with 4-8 days apart, which will be conducted at the Center for Medical Image Science and Visualization (CMIV) at the university hospital in Linköping. Participants who receive sham biofeedback will take part in three runs of sham biofeedback with 4-8 days apart conducted in the lab at the Center for Social and Affective Neuroscience (CSAN) at Linköping university. Participants will be given instructions and basic psychoeducation of brain function and the rational for down-regulating the area of the brain that drives emotion, as well as the physiological reaction that is triggered in response to emotional stimuli. The emotional stimuli are emotional pictures from the International Affective Picture System (IAPS) and the Open Affective Standardized Image Set (OASIS).
224312268|NCT02436967|OTHER|Carotid endarterectomy in clinical healthcare.|For the this study itself there is no intervention caused by the extra CT or MRI. The patients are scheduled for surgery as the routine intervention to reduce the risk of a new stroke in clinical practice. The performed extra diagnostic CT and MRI in this study before surgery will compare the vessel wall images with histology regardless of the patients status or medication.
224312269|NCT05300828|DRUG|Genexl PM|Every three weeks, after intravenous infusion of 260 mg/m2 for 3 hours, followed by carboplatin AUC 5 for 3 hours.
224312270|NCT06411379|DRUG|Sonelokimab|Sonelokimab
224312271|NCT06411379|DRUG|Placebo|Placebo
224312272|NCT06678854|OTHER|Training about Aphasia|Training will include direct teaching, aphasia simulations, scenario-based training and a panel with persons with aphasia with the goal of increasing confidence for law enforcement officers and first responders providing services to and communicating with persons with aphasia.
224312273|NCT05278650|OTHER|Senior PharmAssist^TM Program Implementation|"Representatives from three diverse communities will participate in co-design workshops to refine the Senior PharmAssistTM (SPA) implementation toolkit, which will then be delivered to agency staff from these partnering communities through a series of learning collaborative sessions to facilitate implementation of SPA core components in each community.~Community champions will be trained to deliver a community-based program to deliver the core components of SPA:~1. Medication Therapy Management (MTM);~2. Medication co-payment assistance;~3. Tailored community referrals; and~4. Medicare insurance counseling"
224312274|NCT06870968|BEHAVIORAL|Exercise Training|The Exercise Training will follow a progressive interval-based training program designed for youth with MS. Participants will engage in three weekly exercise sessions. Participants will be given access to links to live virtual structured exercise sessions. The sessions will be scheduled weekly in partnership with a coach. A trained fitness instructor will lead the participants in a 10-minute warm-up, followed by 30 minutes of interval training, and a 10-minute stretching and cool down activity. Intervals will progress in intensity over the course of the 20-week program and progression will be based on individualized target heart rate zones. The session will be delivered via a live feed in order to foster social support from the participants peers enrolled in the program. Participants will have the option of completing the class in real-time and make up classes will also be available through a repository of sessions accessible through links to the repository cloud.
223615750|NCT06725407|BEHAVIORAL|Cesarean section|In the study, the participants' postoperative hypothermia development status was monitored.
223615751|NCT06727201|DRUG|Ondansetron (Zofran)|Ondansetron will be given intravenously in a dose of 0.1mg/kg 10 minutes before spinal anaesthesia as single shot.
223615752|NCT06727201|DRUG|Saline (NaCl 0,9 %) (placebo)|normal saline infusion will be given intravenously 10 minutes before spinal anaesthesia
223615753|NCT06725745|OTHER|Survey|Survey containing a primary survey regarding basic demographic features, medical treatment and organization of care and two validated questionnaires.
223615754|NCT06727383|PROCEDURE|peripheral blood collection|standard blood test procedures
223615755|NCT06727383|PROCEDURE|leukapheresis|"Leukapheresis is the procedure that allows the separation and collection of hematopoietic stem cells (HSCs) from peripheral blood. The collection takes place through a machine called a cell separator: it uses centrifugal force to separate the mononuclear cells from all the other cells in the blood and plasma."
223615756|NCT06726603|PROCEDURE|Assisted Reproductive Technology|Assisted Reproductive Technology for the purposes of this study include IVF and IVF+ICSI. Ovulation induction methods are not considered Assisted Reproductive Technology
223615757|NCT06921187|BEHAVIORAL|Psychoacoustic test|Natural sounds will be presented at different decibels (dB), and the subject will be asked to rate the pleasantness/unpleasantness of the sound heard on a visual analogue scale, as well as the loudness (subjective intensity) of the sound heard.
224312275|NCT06870968|BEHAVIORAL|Mobility and Flexibility Training|The Mobility and Flexibility Training will be focused on improving mobility and flexibility through three times a week stretching and mobility program. A 5-minute warm up will be followed by a series of stretches and mobility patterns that will be repeated as a circuit four times. Each session will focus on a specific muscle group - upper body, lower body or core. The classes will be led by a fitness instructor in the same manner as the exercise intervention arm with a virtual link sent to the participants.
223615758|NCT06921187|OTHER|semi-structured interviews|interview, designed under the supervision of a psychologist and using the methodology of micro-phenomenological interviews the aim of these interviews is to gain access to the participants' experiences, as they describe them in the first person, during misophonic episodes
223615759|NCT06921187|OTHER|Exposure to unpleasant sounds|"Home exposure is a practice whereby participants voluntarily subject themselves to SMs in a controlled environment.~Participants will be asked to complete two tasks: firstly, they will have to expose themselves to all 10 sounds at least twice a week; secondly, they will have to record the annoyance felt for each sound and the subjective loudness (loudness) of each SM using VAS."
223615760|NCT06922513|DEVICE|digital health (Application and Smart Measuring Tape)|For lymphedema management, we use a smart measuring tape to measure arm circumference and provide analysis results along with self-management strategies.
223760771|NCT06924723|PROCEDURE|Lacrimal sac massage|At the time of the visit, the patient's parents (one of them) were given Standardized tear duct massage (Crigler massage)Teaching and hands-on practice were performed, with the researcher confirming the standardization of movements.Subsequent massages were performed by the family member who received the training, and the child's family swiped the card to access the program.completed by the family member of the child, who scanned the code to enter the small program punch card group, according to the standardized process of massage (the frequency of massage was not less than 3 times/day, each time no less than 4 eight beats)And complete the punch card on time (each punch card interval should be greater than 2 hours).(each clock interval should be more than 2 hours).
223760772|NCT05023811|DRUG|[14C]RIST4271|\[14C\]RIST4271 oral solution
223760773|NCT00006028|DRUG|cisplatin|
223760774|NCT00006028|DRUG|gemcitabine hydrochloride|
223615761|NCT06921122|DEVICE|IOWA ORAL PERFORMANCE INSTRUMENT|"In the first session all protocols and assessments will be carried out as a way of observing the responses and previous measures of all participants. The group in this study must appear weekly for six weeks to verify if necessary, reinsufflate the bulb, carry out force measurement and lingual press with the IOPI, as well as receive or reinforce the guidance provided at the beginning of the treatment.~The participants in the group will study that will have a mobile phone and an instant message application will receive weekly, on scheduled days, a letter containing the following text message: Here is the day of performing the last exercise by the Speech Pathologist. Participants who do not have a mobile phone will be notified through a telephone connection or contact with a responsible family member/caregiver.~After the end of the sixth week of training, patients will be subjected to the last set of data on the two protocols and evaluations proposed in this study."
223615762|NCT06921122|DEVICE|Placebo Group - Without Treatment|"The group in study, without treatment, supported by the same schedule of the patients treated, will represent the natural progression of failure disorders in PD. A decision was made not to include a false treatment, in order to adhere to the principle of balance and not to place an undue burden of time and effort on patients who receive a treatment with low therapeutic potential. Furthermore, the researchers considered that given the questions regarding the adequacy of simulations as comparators of treatment in behavioral studies, research in this work between the group in the study and the placebo group (without treatment) can provide more useful contrasts than a group with therapeutic simulation.~If the intervention clearly aims to provide direct benefits to the participants, this group will be contacted to carry out the same intervention later."
224312276|NCT04469816|BEHAVIORAL|Family Check-Up 4 Health|A parent-training intervention to improve child health, school readiness and manage obesity.
224312277|NCT04469816|OTHER|Services as Usual|Services/Treatment as usual.
224312278|NCT06595277|DIAGNOSTIC_TEST|Neuromuscular blockade|Neuromuscular blockade will be measured in all patients using a quantitative measurement (TOFScan, IdMed, Marseille, France) during surgery and after surgery until either full neuromuscular recovery or time of scheduled extubation.
224312279|NCT06681935|PROCEDURE|Oral Cavity Reconstruction|This procedure includes a planned surgical connection from the oral cavity to the neck soft tissues which is repaired through free or pedicled flap reconstruction.
224312280|NCT06082674|DEVICE|Vayu bCPAP|The Vayu bCPAP uses a constant flow of dry oxygen from the source with an adjustable flow meter. Oxygen is blended by Venturi blender with ambient air to create a source of oxygen-enriched air of adjustable concentration.
224312281|NCT06082674|DEVICE|Mechanical Ventilator Driven CPAP|Mechanical Ventilator Driven CPAP
224312282|NCT05491876|OTHER|Chest physiotherapy with breathing exercises and ACBT|Group A got chest physiotherapy with breathing exercises and ACBT
224312283|NCT05491876|OTHER|Chest physiotherapy with breathing exercises|Group B got chest physiotherapy with breathing exercises.
224312284|NCT00290160|BEHAVIORAL|Protein supplementation|
224312285|NCT06680414|OTHER|Supportive Vaccine Communication Using Motivational Interviewing|Supportive Vaccine Communication using Motivational Interviewing will be administered to the pregnant mothers in the experimental group by the researcher. The training will take place in 3-part and 6-sessions, one week apart, and each session will last approximately 40 minutes. The training will be carried out as group training with 3-5 people. Data collection forms will be applied before and after the program.
224312286|NCT02369458|DRUG|Mitomycin-C|
224312287|NCT02369458|DRUG|Pegfilgrastim|
224312288|NCT04572893|DRUG|danicamtiv|Myosin activator
224312289|NCT03784053|OTHER|Immersive virtual reality|At the start of every session, the participants' top five occupational problems will be reviewed, and a list of apps corresponding to the desired occupational problem will be offered through the immersive virtual reality device (Oculus Go). There will be eight 30-minute virtual reality sessions.
224312290|NCT00121134|DRUG|Bevacizumab|Group A: Once every 3 weeks for 12 months Group B: Once every 3 weeks for 12 months
224312291|NCT00121134|DRUG|Cyclophosphamide|Once a day for 6 months
224312292|NCT00121134|DRUG|Methotrexate|Twice daily for the first two days of every week for 6 months
223615763|NCT06921161|DEVICE|TongueFit|"TongueFit is a newly orofacial manometer. This device is specifically developed for children to measure and improve tongue strength and endurance which includes a complementary application. Participants will do a series of tongue exercise therapy using TongueFit. The exercise therapy will be performed once per day, three times a week, for eight weeks."
223615764|NCT06921161|OTHER|OSMS|Patients will receive OSMS therapy, conducted for 15 minutes per session, three times a week, over a duration of eight weeks.
224312293|NCT00121134|DRUG|Capecitabine|"Capecitabine: 2000 mg/m2 a day, on Days 1-14 of a 21 day cycle, for at total of 6 cycles (18 weeks)~Bevacizumab: 15 mg/kg IV day 1 every 3 weeks x 1 year (17 cycles)"
224312294|NCT02909283|PROCEDURE|Physical exams and blood analyzes|Blood samples collection (for DNA, plasma and cells analyzes) ; Hemorheologic analyzes ; ASL sequence on MRI ; Near Infra Red Spectroscopy (NIRS) and associated cardiofrequency analyze.
224312295|NCT04410237|DEVICE|Med-Jet|"One half of each psoriasis plaque will be treated with a Med-Jet device and Triamcinolone acetonide (TAC) while the control half will be untreated.~One side of the body will be treated using a conventional syringe and the opposite side of the body will be treated using the Med-Jet needle-free injection device to verify efficacy, safety, and pain score"
223615765|NCT06922045|DRUG|STSP-0601 for Injection|Evaluation of the Efficacy of Single-Dose and Continuous Administration of STSP-0601 Injection for the Treatment of Bleeding in Patients with Hemophilia A or B with Inhibitors
223615766|NCT00451971|DRUG|LEFLUNOMIDE|
223615767|NCT07064980|PROCEDURE|Endoscopic Retrograde Cholangiopancreatography|Performed under intravenous anesthesia. A duodenoscope was advanced to the major duodenal papilla. After cannulation and cholangiography, purulent bile was aspirated. Biliary sphincterotomy was performed in most patients (95.2%), followed by stone extraction using a balloon catheter or basket. A 7-10 Fr nasobiliary tube was placed for drainage in all patients. Prophylactic rectal indomethacin (100mg) was also administered.
223615768|NCT07064980|PROCEDURE|Percutaneous Transhepatic Biliary Drainage|Performed under general anesthesia with endotracheal intubation and ultrasound guidance. An 18G needle was used to puncture a dilated intrahepatic bile duct. After guidewire placement, an 8-10 Fr drainage catheter was inserted for either internal-external drainage (if the guidewire could pass into the duodenum) or purely external biliary drainage.
223615769|NCT06795490|BEHAVIORAL|Online program|Families in Balance Online is a 6-week online program that includes 6 weekly group discussions and 3 individual support sessions, all held over Zoom. Program activities will focus on improving parent and child self-regulation as a means to encourage healthy family mealtime, sleep, and screentime routines. Participants will engage in in person and online data collection activities to understand whether the program is impactful.
223615770|NCT06795490|BEHAVIORAL|Control Condition|Families in Balance is an asynchronous program in which participants will be sent materials weekly over 6 weeks to encourage healthy family mealtime, sleep, and screentime routines. Participants will engage in in person and online data collection activities to understand whether the program is impactful.
223615771|NCT06901583|OTHER|Mindfulness-oriented psycho-education|The program, consisting of six sessions and developed by evaluating studies in the literature, covers topics such as mindfulness, anger, and interpersonal relationships
223615772|NCT04485195|DRUG|Vernakalant|an initial infusion of 3 mg/kg infused over a 10-minute period by a pre-programmed IV pump
223615773|NCT04485195|DRUG|Procainamide|15 mg/kg in 500 mL of normal saline given over 60 minutes
223615774|NCT06915246|DRUG|VI-0609|Carmustine with Propylene Glycol
223615775|NCT06915246|DRUG|BiCNU|Carmustine with Ethanol
223615776|NCT06917755|OTHER|Virtual Reality Training in Thyroid Surgery|Participants will use an application in an Immersive Virtual Reality environment. In this module, the participant will be the chief surgeon and will be guided to accomplise the first steps of thyroidectomy: from neck incision until continious neuromonitoring device placement in vagus nerve.
223615777|NCT06917755|OTHER|Convetional Training|This intervation consists of traditional methods of training. Participants will read specific chapters of a technical book specialised in Endocrine Surgery (Atlas of Thyroid Surgery- Alexander Shifrin). Also, they will be provided with videos of the clinic's archive which will support them with specific surgical steps : neck incision up to Continious Neuromonitoring Device placement on Vagus nerve.
224312296|NCT04410237|OTHER|Traditional Syringe|"One half of each psoriasis plaque will be treated with a traditional syringe and Triamcinolone acetonide (TAC) while the control half will be untreated.~One side of the body will be treated using conventional syringe and the opposite side of the body will be treated using the Med-Jet needle-free injection device to verify efficacy, safety, and pain score"
224312297|NCT04080544|DRUG|[18F]AV-1451|The subject will receive up to a target dose of 370 megabecquerel (MBq) as a single IV bolus of \[18F\]AV-1451.
224312298|NCT04080544|PROCEDURE|Positron Emission Tomography|Approximately 80 minutes after injection subjects will be placed in the UTSW PET/CT scanner for a 20-minute brain scan.
223615778|NCT06920966|OTHER|Cold Water Immersion (CWI)|Participants undergo five intermittent immersions of 2 minutes each in cold water (11°C), with 2-minute rest periods in between.
223615779|NCT06920966|OTHER|Hot water immersion (HWI)|Participants undergo a continuous immersion of 18 minutes in hot water (38°C)
223615780|NCT06920966|OTHER|Thermography-Guided Immersion (TI)|Based on thermographic assessments, participants with a hypothermic profile (decreased temperature) receive hot water immersion, while those with a hyperthermic profile (increased temperature) receive cold water immersion.
223615781|NCT06920758|DIETARY_SUPPLEMENT|USPlus DERM Bioactive Fatty Acids 160 mg Softgels|"USPlus® DERM Bioactive Fatty Acids (160 mg) Ingredient List (Per Softgel)~Active: 100% Concentrated Lipidosterolic Extract of Saw Palmetto (Serenoa repens).~Shell: Bovine Gelatin, Glycerin, Water"
223615782|NCT06920758|OTHER|Placebo softgel|"Placebo Ingredient List:~Palm oil Gelatin Glycerin Water Caramel color"
223615783|NCT06922136|DEVICE|Hyalo Gyn Vaginal Gel|Hyalo Gyn® is uniquely formulated with Hydeal-D®, a proprietary HA derivative component manufactured by Fidia Farmaceutici S.p.A.
223615784|NCT06922136|OTHER|Placebo|Placebo
223615785|NCT06922084|DEVICE|Clareon PanOptix|Bilateral Clareon PanOptix IOL implantation
223615786|NCT06922084|DRUG|Clareon PanOptix PRO|Bilateral Clareon PanOptix PRO IOL implantation
223760775|NCT06901778|BEHAVIORAL|DEAR weight management|"In the DEAR weight management model:~D (Diet) refers to dietary management, primarily based on a calorie-restricted balanced diet; E (Exercise) refers to exercise management, guided by the 10th edition of the ACSM Exercise Testing and Prescription Guidelines and the 2017 National Fitness Guidelines. Exercise prescriptions are tailored to the patient's daily activity levels (light, moderate, and vigorous) to match the corresponding intensity levels; A (Accompany) refers to peer education, which involves using peer education methods to provide health education for patients, build confidence, and alleviate anxiety; R (Refresh) refers to rejuvenation, which involves correcting unhealthy dietary and exercise habits and establishing good lifestyle practices."
223760776|NCT06901778|BEHAVIORAL|Standardized discharge care plan and follow-up schedule|Standardized discharge care plan and follow-up schedule providing patients and their families with professional and feasible pre-discharge education on disease-related knowledge, dietary and exercise recommendations, daily living advice, and psychological support to help patients establish healthy behaviors. Patients are provided with printed health education materials and a handbook on health and disease knowledge. A WeChat communication group is established to promptly answer patients' questions, encourage peer-to-peer experience sharing, and conduct regular telephone follow-ups and questionnaire surveys after discharge.
223760777|NCT06901778|BEHAVIORAL|Implementation of the weight management mobile health application|Patients undergoing weight management are instructed to download the app from the app store (compatible with both iOS and Android platforms). Users in the control group can independently register and log in using their mobile phone numbers to access and use the app. The app will create an electronic health record for weight management for each user. Users can input their weight-related information, and the app features a data analysis function that displays weight trends through charts (e.g., BMI calculation and personal weight change curves). The app interface also provides professional guidance on diet and exercise, such as food calorie information, customized nutritional meal plans, and specialized exercise programs with training courses. By offering educational articles and instructional videos, the app aims to promote correct weight management concepts, disseminate scientific health knowledge, and enhance self-efficacy in weight loss.
223760778|NCT06901778|BEHAVIORAL|Implementation of the weight management mobile health application + Enhance the regular interaction, feedback, and supervision mechanism between medical teams and apps|Based on the intelligent app's comprehensive coverage on the user side and integrating the ABI concept, the app dynamically adjusts intervention strategies. This is achieved by real-time collection and analysis of user behavior data, providing users with all around and personalized weight management support across diet, exercise, psychological support, etc., thereby enhancing the effectiveness and sustainability of interventions. The research team has formed a professional and experienced medical team. All members hold a bachelor's degree or above and possess rich clinical weight management experience. Through the app, they provide users with scientific and rigorous supervision and guidance. During weight loss, users can obtain accurate, professional answers and personalized adjustment advice in real-time via the app's question-asking column if they encounter any problems.
223760779|NCT06908408|DIAGNOSTIC_TEST|Corrrelation between metabolic acidosis severity in patients on admission to the ICU and platelet count trend in 2 days following admission was investigated|The aim of the study was to investigate if there exists any correlation between metabolic acidosis severity in patients upon admission to the ICU and platelet count trend in 2 days, following admission.
223760780|NCT06909747|BEHAVIORAL|Posture Training|Training program consists of three sessions. It will cover proper body posture, the importance of spinal health, and targeted exercises to support spinal well-being.
223760781|NCT06903117|BIOLOGICAL|Targeted CEA CAR-T|Subjects meeting the transfusion criteria will receive pre-treatment, which is as follows: fludarabine 25mg/m2/d×3day and cyclophosphamide 300mg/m2/d×3day, and intravenous CEA CAR-T therapy after 1-2 days of rest
223760782|NCT06903117|BIOLOGICAL|Targeted CEA CAR-T|Subjects meeting the reinfusion criteria will receive pre-treatment with fludarabine 25mg/m2/d×3day and cyclophosphamide 300mg/m2/d×3day, rest for 1-2 days, and intraperitoneal reinfusion targeted CEA CAR-T therapy
223760783|NCT06908837|DRUG|Bupivacaine|Applied perineurally using a 22-gauge, 80-mm block needle (Temena, Felsberg, Germany) under ultrasound guidance.
223760784|NCT06909474|BIOLOGICAL|Anti-CD5 CAR NK cells|Each patient will initially receive a single infusion of CAR-NK cells on Day 0. If a suboptimal response is observed after the first infusion (assessed by Day 28) and the safety profile remains acceptable, a second infusion may be administered as a remedial dose after Day 28. CAR-NK cells need to be controlled within 70 minutes from thawing to infusion completion.
224312299|NCT06694753|BIOLOGICAL|mRNA-1645-eODGT8|eOD-GT8 60mer is a self-assembling nanoparticle composed of 60 subunits of the engineered HIV-1 gp120 outer domain germline targeting version 8 (eOD-GT8) fused to an engineered form of a bacterial enzyme, Lumazine Synthase, through a 15-amino acid Glycine-Serine linker. eOD-GT8 60mer will be delivered using an mRNA lipid nanoparticle (LNP) platform. To be administered by intramuscular (IM) injection at doses of 10 or 30 mcg.
224312300|NCT06694753|BIOLOGICAL|mRNA-1645-CoreG28v2|core-g28v2 60mer is a nanoparticle composed of 60 protein subunits of an engineered core-gp120 fused to an engineered form of a bacterial enzyme, Lumazine Synthase, through a 21-amino acid Glycine-Serine linker. Core-g28v2 60mer will be delivered using an mRNA-LNP platform. To be administered by IM injection at doses of 10 or 30 mcg.
224312301|NCT06694753|BIOLOGICAL|mRNA-1645-N332GT5|"N332-GT5 gp151 is an HIV envelope glycoprotein gp151 trimer based on BG505 SOSIP MD39 (clade A) trimer with germline-targeting mutations added that confer the ability to bind germline precursors of BG18 class B cells. N332-GT5 gp151 will be delivered using an mRNA-LNP platform. To be administered by IM injection at doses of 10 or 30 mcg."
224312302|NCT06694753|BIOLOGICAL|Placebo|Saline
223615787|NCT06922084|DRUG|Mix-and-Match PanOptix/Vivity|Clareon PanOptix Pro in the non-dominant eye and Clareon Vivity in the dominant eye
223615788|NCT06921421|DIAGNOSTIC_TEST|Spatial Frequency Domain Imaging|Spatial Frequency Domain Imaging captures at specific timepoints.
224312303|NCT04967508|DRUG|Stelara® (Ustekinumab)|Subjects randomised into Stelara® group will receive Stelara® (45 mg) via subcutaneous injection at Week 0, 4, and then every 12 weeks up to Week 40.
224312304|NCT04967508|DRUG|SB17 (Proposed Ustekinumab Biosimilar)|"Subjects randomised into SB17 group will receive SB17 (45 mg) via subcutaneous injection at Week 0, 4, and then every 12 weeks up to Week 40.~Starting at Week 28, subjects transited from Stelara® to SB17 will receive SB17 via subcutaneous injection."
224312305|NCT06876454|PROCEDURE|Gastrostomy Tube|Feeding gastrostomy tube insertion
223615789|NCT06921343|DRUG|Iron (III) Hydroxide Polymaltose (50 mg/5 mL)|"Participants randomized to the intervention group will receive oral iron supplementation in addition to a gluten-free diet. The specific iron formulation used in this study is Iron (III) Hydroxide Polymaltose (50 mg/5 mL) at a dosage of 6 mg/kg/day, up to a maximum of 100 mg/day, for 3 months.~The iron supplement will be given once daily, preferably on an empty stomach or with vitamin C-containing foods to enhance absorption. Parents/caregivers will be instructed on proper administration, and adherence will be monitored through weekly self-reported intake logs and pharmacy dispensing records.~This intervention is specifically targeted at children with newly diagnosed celiac disease and iron deficiency without anemia.~The study follows a non-inferiority design, comparing the effect of iron supplementation versus a gluten-free diet alone on ferritin levels."
223760785|NCT06915662|DEVICE|Tulavi allay Nerve Cap|"The Tulavi allay Nerve Capfirst and only fully absorbable in situ forming technology designed to protect transected nerves, prevent axonal escape, and reduce the risk of neuroma formation.~https://tulavi.com/allay-nerve-cap/"
223615790|NCT06921343|OTHER|Gluten-free diet|Participants in the control group will follow a strict gluten-free diet, the standard-of-care treatment for celiac disease. No iron supplementation will be given. Compliance will be monitored through self-reported adherence and TTG antibody levels at follow-up.
223615791|NCT06921902|DEVICE|FreeStyle Libre 3|Abbott Sensor Based Glucose Monitoring System (FreeStyle Libre 3 System)
223760786|NCT06922968|PROCEDURE|TRUS-Guided TURP and enucleation|realtime TRUS guidance during the procedure (TURP and enucleation)
223760787|NCT06922968|PROCEDURE|Standard TURP and enucleation|No TRUS guidance during the procedure (TURP and enucleation)
223760788|NCT06924359|DIAGNOSTIC_TEST|Multimodal Ophthalmic Imaging and plasma biomarker|Multimodal Ophthalmic Imaging and plasma biomarkers (Aβ42/40, p-tau181, p-tau217, NfL and GFAP）.
223760789|NCT06923475|DRUG|Pembrolizumab|Patients will initiate with 2 sets of 3 cycles of neoadjuvant gemcitabine and cisplatin in combination with perioperative pembrolizumab (up to total of 1 year immunotherapy treatment)
223760790|NCT06923475|DRUG|Gemcitabine, Cisplatin|Patients will initiate with 2 sets of 3 cycles of neoadjuvant gemcitabine and cisplatin in combination with perioperative pembrolizumab (up to total of 1 year immunotherapy treatment)
223615792|NCT06921291|DRUG|Salbutamol (Ventolin®)|Randomized controlled trials
223615793|NCT06922487|PROCEDURE|Karolinska Sleepiness Scale, KSS|Assessment of sleepiness during resection using KSS
223615794|NCT06939712|BEHAVIORAL|Online Positive Psychology Intervention|A 6-week online psychological support program, held once a week, primarily organized by a facilitator, with patient-led discussions and communication.
223615795|NCT06939712|OTHER|Routine Care|A 6-week program of health education provided by IBD specialists and nurses during patient follow-ups, tailored to individual patient circumstances and needs. Topics include IBD disease knowledge, medication management, diet, exercise, lifestyle, psychological support, and follow-up care. Patients in this group will also join a control group WeChat group for study-related communication.
223615796|NCT01603485|DRUG|Lersivirine Immediate-Release (fasted)|Single 500 mg dose of Lersivirine Immediate-Release Tablets (2 x 250 mg)
223615797|NCT01603485|DRUG|Lersivirine Modified-Release #1 (fasted)|Single 500 mg dose of Lersivirine Modified-Release Tablet #1
223615798|NCT01603485|DRUG|Lersivirine Modified-Release #2 (fasted)|Single 500 mg dose of Lersivirine Modified-Release Tablet #2
223615799|NCT01603485|DRUG|Lersivirine Modified-Release #3 (fasted)|Single 500 mg dose of Lersivirine Modified-Release Tablet #3
223615800|NCT01603485|DRUG|Lersivirine Modified-Release (fed)|Single 500 mg dose of Lersivirine Modified-Release Tablet dosed with food.
223615801|NCT02154256|BEHAVIORAL|Increasing incentives|Offer incentives that increase over time.
223760791|NCT06924190|DRUG|Budiair® 200ug/puff inhalation aerosol|The subjects randomly received one puff Budiair®(budesonide inhalation aerosol 200ug/puff )
223615802|NCT02154256|BEHAVIORAL|Decreasing incentives|offer incentives that decrease over time
223615803|NCT02154256|BEHAVIORAL|stable incentives|offer incentives that are stable over time, but higher than usual care
223760792|NCT06924190|DRUG|budesonide 200ug/puff inhalation aerosol|The subjects randomly received one puff budesonide inhalation aerosol(200ug/puff )
223760793|NCT03607916|DRUG|Hyperbaric prilocaine 2%|Varying dose according to sensitive response of previous subjects. All study doses of hyperbaric prilocaine 2% will be administrated intrathecally with 100µg of morphine
223760794|NCT03607916|DRUG|Hyperbaric prilocaine 2%|The dose of 60 mg of Hyperbaric prilocaine 2% will be administrated intrathecally with 100µg of morphine
223760795|NCT03607916|DRUG|Morphine|100µg morphine
223760796|NCT03212703|BEHAVIORAL|Mindfulness-Based Skills Training (MBST)|8-week mindfulness skills training sessions based on Mindfulness-Based Cognitive Therapy (MBCT) program by Zindel Segal, Mark Williams and John Teasdale
223760797|NCT03212703|OTHER|Waitlist control (WLC)|Observation surveys at baseline, mid-point and end-point of an 8-week period
223615804|NCT06937658|DEVICE|Alert-based care|Alert-based care is an alternative strategy for longitudinal management of patients with wireless pacemakers and implantable defibrillators
223615805|NCT06937658|DEVICE|Guideline-based care|Guideline-based care is the current typical standard for longitudinal management of patients with wireless pacemakers and implantable defibrillators
223615806|NCT04491136|DRUG|ACEI/ARB|Oral ACE/ARB drug according to the investigator's discretion for the first 6 months in this study
223615807|NCT04491136|DRUG|ARNI|Oral sacubitril/valsartan at the dosage of investigators discretion, whit a target dose of 200mg bid for the next 6 months of this study
223615808|NCT00587717|DRUG|simvastatin|Two 80 mg pills simvastatin taken 24 hours prior to surgery
223760798|NCT02881294|DRUG|SUVN-G3031|
224075444|NCT06221020|BEHAVIORAL|Quality of Recovery-40(QoR-40)|The Quality of Recovery-40 (QoR-40) is a widely used questionnaire designed to assess the quality of recovery after surgery. It comprises 40 questions that cover both physical and psychological aspects of a patient's recovery, such as pain, nausea, anxiety, dietary habits, and social functioning. The QoR-40 provides a comprehensive view of a patient's postoperative recovery, encompassing a range of factors crucial to understanding the effectiveness of surgical procedures and the overall patient experience during the recovery phase. This tool is instrumental in evaluating and improving post-surgical care and patient outcomes.
224075445|NCT00207415|BEHAVIORAL|ASHC and CDSMP|
224075446|NCT00778037|DRUG|Cyclobenzaprine hydrochloride 10 mg tablet|
223760799|NCT04020302|BEHAVIORAL|Self-monitoring shopping intervention|Intervention will occur once per week for a duration of 8 weeks. The intervention format will alternate between individual and group sessions, so that the first week of intervention will be provided in a group format, the second week will be provided in an individual format, and so forth. Sessions will be 90 minutes in duration. Data will be collected during individual sessions, which will occur every other week. During individual sessions, each participant will meet at the facility for the first 15 minutes, will travel to a local grocery store for 45 minutes, and then reconvene at the facility for the final 30 minutes. Group sessions will follow the same structure; however, all ten participants will be present. Each of the 8 sessions will consist of the following: awareness training; facilitation of strategy generation; facilitation of error detection; reinforcement of self-monitoring techniques; and opportunity for participants to practice self-monitoring techniques.
223615809|NCT00587717|DRUG|placebo|take 2 80 mg pills placebo 24 hours prior to surgery
223615810|NCT01611194|DRUG|Hyperbaric oxygen (HBO2) at 1.5 atms|The Hyperbaric oxygen (HBO2) at 1.5 atms (active) group (hyperbaric oxygen-chamber compressed to 1.5 atm abs and breathing 100% oxygen). Each participant should complete 40 sessions over the course of 12 weeks, one session per day, five per week.
223615811|NCT01611194|DRUG|Sham control 1.2 atms|The chamber will be compressed with air to 1.2 atm abs to simulate the active group. Participants will don a hood and breathe 21% oxygen (room air). Each participant will complete 40 sessions, one session per day, five sessions per week, within 12 weeks following randomization. Breathing air at a pressure of 1.2 atm abs is equivalent to inhaling 25% oxygen at sea level pressure (1.0 atm abs).
223615812|NCT03999060|DEVICE|Electric Current Stimulation|Electric stimulation with a Digitimer DS7AH HV Current Stimulator delivered with 4 shielded electrodes mounted on the participants head
223615813|NCT00348673|DRUG|UK-453,061|Placebo BID, Placebo QD, UK-453,061 10 mg BID, 30 mg BID, 100 mg BID or 500 mg QD for 7 days
223615814|NCT00348673|DRUG|UK-453,061|Placebo BID, Placebo QD, UK-453,061 100 mg QD, 500 mg BID or 750 mg QD for 7 days
223615815|NCT00293995|PROCEDURE|Repair of unilateral inguinal hernia|
223615816|NCT04359485|PROCEDURE|Glycolic acids peel 70%|Glycolic acid peel 70% applied in 3 coats medium depth
223760800|NCT03479866|OTHER|Dietary intervention|To carry out an interventional dietary study using standardised meals to predict for an individual their metabolic response to certain foods using the gut microbiome and their metabolic profile. Responses will include post-prandial appetite, levels of satiety, circulating glucose, insulin, ketone bodies and lipid levels.
223760801|NCT00667238|BEHAVIORAL|Questionnaire|
223760802|NCT02643251|DRUG|Clonidine Hydrochloride Topical Gel, 0.1%|Clonidine Gel is supplied as an aqueous gel formulation for topical use.
223760803|NCT02643251|DRUG|Clonidine Hydrochloride Gel Comparator|Clonidine Gel Comparator is supplied as an aqueous gel formulation for topical use.
223760804|NCT05374811|OTHER|Neuropathic Pain|Neuropathic pain degrees of the patients will be evaluated with the Douleur Neuropathic-4 (DN4) questionnaire.
223760805|NCT02129075|BIOLOGICAL|DEC-205/NY-ESO-1 Fusion Protein CDX-1401|Given SC or ID
223760806|NCT02129075|DRUG|Poly ICLC|Given SC
223760807|NCT02129075|BIOLOGICAL|Recombinant Flt3 Ligand|Given SC
223760808|NCT00333229|DRUG|Zoledronic Acid|4 mg zoledronic acid in 5 mL concentrate solution. Plastic vials.
223760809|NCT00333229|DRUG|Placebo|Matching Placebo
223760810|NCT00348556|DRUG|Nesiritide|Nesiritide 0.005 ug/kg/min IV for 6 hours, then to 0.01 ug/kg/min for 6 hours then to 0.02ug/kg/min for 6 hours then to 0.03 ug/kg/min for the last 6 hours.
223760811|NCT05664997|BEHAVIORAL|playing assessment|Investigators used Edinburgh Handedness Inventory, the Wong-Baker Faces Pain Rating Scale, the Disability of Arm, Shoulder and Hand - Sports/Musicians (DASH-SM), the Rapid Upper Limb Assessment, and the 11-item revised version of the Occupational Balance Questionnaire (OBQ11 - T). All have their Turkish validity studies. A correlation analysis was performed to examine the relationship between the variables.
223760812|NCT06097884|OTHER|Main study intervention-Salt substitute|replacing regular salt with salt substitute in school meals
223760813|NCT06097884|OTHER|Main study control-Usual salt|Use usual salt in school meals
223760814|NCT06097884|OTHER|Ancillary study intervention-Meal trays|Replacing bowls with trays in school cafeteria
223760815|NCT06097884|OTHER|Ancillary study control-Bowls|Use bowls in school cafeteria
223760816|NCT04742738|BIOLOGICAL|GBP510 adjuvanted with Alum (RBD 10μg/dose) - Stage 1|Participants will receive intramuscular (IM) injections of GBP510 adjuvanted with Alum (RBD 10μg/dose) on Days 0 and 28.
223760817|NCT04742738|OTHER|Normal saline (0.9% sodium chloride solution) - Stage 1|Participants will receive intramuscular (IM) injections of Normal saline on Days 0 and 28.
224312306|NCT06876454|DEVICE|Self Expanding Metal esophageal Stent|Fully covered SEMS in the esophagus
224312307|NCT02954926|DRUG|IVIG|IVIG at a dose of 500mg/kg within 12 h and 3 days of birth
223615817|NCT04359485|OTHER|Saline|Sodium chloride
223615818|NCT06267534|DEVICE|mindfulness-based mobile applications program|Every two days is the same practice sound file, which must be practiced in order, so each sound file will be locked, for example: 9/9, 9/10 listen to the first sound file practice, 9/11, 9/12 listen to the second Practice with two sound files... and so on. After two days, the sound files will be automatically unlocked, and the subjects can continue to practice. The first ten days need to be practiced in order. From the eleventh day, each sound file will be unlocked. You can choose an audio file to practice, and the page will record the time and items of the practice, and you can also use text to record your experience after the practice
223615819|NCT02345213|DRUG|E2020|E2020 tablets will be orally administered once daily after breakfast
223615820|NCT02345213|DRUG|Placebo|Matching placebo tablets will be orally administered once daily after breakfast
223615821|NCT03833414|PROCEDURE|triceps lifting and olecranon osteotomy approaches|two different surgical approaches for distal humerus fracture
223615822|NCT02404818|PROCEDURE|Cardiac Magnetic Resonance Imaging|A cardiac MRI will be performed.
223760818|NCT04742738|BIOLOGICAL|GBP510 adjuvanted with Alum (RBD 25μg/dose) - Stage 1|Participants will receive intramuscular (IM) injections of GBP510 adjuvanted with Alum (RBD 25μg/dose) on Days 0 and 28.
224312308|NCT02927977|OTHER|control|Individuals with neck pain will receive a multimodal rehabilitation program composed by pain education, exercises and manual therapy. Participants will receive 4-6 treatments during 4 weeks.
223615823|NCT02404818|PROCEDURE|Echocardiogram|An echocardiogram will be performed for the following information: M-mode, two-dimensional, Doppler blood flow measurements, and longitudinal strain and strain rate imaging
224312309|NCT02927977|OTHER|dry needling|Individuals with neck pain will receive a multimodal rehabilitation program composed by pain education, exercises, manual therapy and dry needling in neck muscles. Participants will receive 4-6 treatments during 4 weeks.
224312310|NCT00376194|DRUG|DMSA|
223760819|NCT04742738|OTHER|Normal saline (0.9% sodium chloride solution) - Stage 1|Participants will receive intramuscular (IM) injections of Normal saline on Days 0 and 28.
223760820|NCT04742738|BIOLOGICAL|GBP510 adjuvanted with Alum (RBD 10μg/dose) - Stage 2|Participants will receive intramuscular (IM) injections of GBP510 adjuvanted with Alum (RBD 10μg/dose) on Days 0 and 28.
224312311|NCT04714229|BIOLOGICAL|Meningococcal(Groups A, C, W-135, and Y) Conjugate Vaccine|0.5mL single intramuscular dose on Day 0
223615824|NCT05633888|DEVICE|CATAMARAN SI Joint Fusion System|Placement of the Catamaran Fixation Device
224312312|NCT04714229|BIOLOGICAL|Meningococcal(Groups A, C, Y, and W-135) Conjugate Vaccine|0.5mL single intramuscular dose on Day 0
224312313|NCT00118131|DRUG|cisplatin|
224312314|NCT00118131|DRUG|docetaxel|
224312315|NCT03589235|PROCEDURE|A free gingival graft|A free gingival graft will be used for the treatment of gingival recession
224312316|NCT03589235|DEVICE|A Platelet-Rich Fibrin dressing|A Platelet-Rich Fibrin dressing (PRF) will be applied in both donor and receiving sites after the free gingival graft.
224312317|NCT03589235|DEVICE|A non-eugenol-based dressing|A non-eugenol-based dressing (Coe-Pak™) will be applied in both donor and receiving sites after the free gingival graft.
223615825|NCT03009799|DRUG|Iota-Carrageenan|One drop in each eye 8 times per day for 7 days (mandatory), then 4 to 8 times/day for the next 14 days until Day 21
223615826|NCT03009799|DRUG|Carmellose|1 drop in each eye 8 times/day for 7 days (mandatory), then 4 to 8 times/day for the next 14 days until day 21
223615827|NCT03583970|DEVICE|Left Ventricular Assist Device Implantation|Veno-arterial extracorporeal membrane oxygenation prior to left ventricular assist device implantation : initial patients characteristics and 6 Month Follow-up
223615828|NCT06288074|DIAGNOSTIC_TEST|Multi-omics tests|Biological sample collection for Multi-omics tests
223615829|NCT02648568|BEHAVIORAL|Hypnosis plus relaxation|The patient will have 20 min of Jacobson 's type relaxation, with sequential contraction and relaxation of limb muscles followed by an induction of hypnosis based on the preferential channel of each patient and, during trance, recommendation to assimilter the bed room and bed to a safe place
223760821|NCT04742738|BIOLOGICAL|GBP510 adjuvanted with Alum (RBD 25μg/dose)- Stage 2|Participants will receive intramuscular (IM) injections of GBP510 adjuvanted with Alum (RBD 25μg/dose) on Days 0 and 28.
223760822|NCT04742738|OTHER|Normal saline (0.9% sodium chloride solution)- Stage 2|Participants will receive intramuscular (IM) injections of Normal saline on Days 0 and 28.
223760823|NCT02720926|DRUG|Xeloda,|Capecitabine (xeloda): 2000mg/m2, twice a day on Day 1-14;
223760824|NCT02720926|DRUG|Oxaliplatin|Oxaliplatin: 130mg/m2 day 1 every 21days
223760825|NCT02720926|DRUG|TKI258|4 dose levels of TKI258: 200mg, 300mg, 400mg, 500mg once daily, 5days on and 2 days off;
223760826|NCT01726010|DEVICE|22-G Procore Needle|
223760827|NCT01298024|OTHER|Early Neuromuscular Exercise|30 patients are randomized to early neuromuscular exercise (n=15) or treatment as usual, i.e., late exercise (n=15). Both groups are given an orthosis and are instructed to wear this for eight weeks. The experimental group starts with a structured exercise program one week after the diagnosis. The patients attend one training session/week during eight weeks, guided by a physical therapist. The level of training is progressed during this time. The patients in the control group (treatment as usual) are given exercise instructions and information at one occasion; 2 weeks after diagnosis. Both groups are followed up, by a blinded assessor, with valid and reliable self-reported and physical function outcomes at 1, 4, 8 and 16 weeks after injury.
223760828|NCT05372016|BIOLOGICAL|Experimental: Experimental: 9-valent Human Papillomavirus (Types 6, 11, 16, 18, 31, 33, 45, 52, 58)|9vHPV vaccine ,0.5mL, three doses, 0,2,6 months
223760829|NCT05372016|BIOLOGICAL|Active Comparator: GARDASIL ®9|GARDASIL®9 vaccine, 0.5mL, three doses, 0,2,6 months
224075447|NCT02105532|OTHER|Restrictive transfusion policy|Participants allocated to this group will be eligible for transfusion once their Hb level is ≤ 8 g/dL after presentation to hospital. The objective for the attending clinician is to maintain the Hb level between 8.1-10 g/dL for the duration of hospital stay.
224075448|NCT02105532|OTHER|Liberal Transfusion Policy|Participants allocated to this group will be eligible for transfusion once their Hb level is ≤ 10 g/dL after presentation to hospital. The objective for the attending clinician is to maintain the Hb level between 10.1-12 g/dL for the duration of hospital stay.
224075449|NCT02668718|RADIATION|Adjuvant radiotherapy|The radiation therapy will be given in 37 fractions of 1.8 Gy per day, five days per week. The total dose of radiation will be 66.6 Gy.
224075450|NCT05528627|OTHER|Pectoral Nerve (PECs) block|Pectoral Nerve (PECS) blocks were performed on the side of surgery, using the ultrasound-guided technique 30 min before the implantable cardiac electronic device (pacemaker, implantable cardioverter defibrillator) insertion procedure
224312318|NCT04254939|DRUG|CS3007 (BLU-285)|"A modified 3+3 dose escalation design will be adopted. Each group will enroll 3-6 subjects. Avapritinib will be administered orally at the starting of 200 mg QD. A cycle consists of 28 consecutive days."
224312319|NCT00534014|DIETARY_SUPPLEMENT|Vitamin C|Arm A = 0 mg Vitamin C, Arm B = 250 mg Vitamin C, Arm C = 500 mg Vitamin C, Arm D = 1000 mg Vitamin C
224312320|NCT02803229|DRUG|Adderall-XR|
224312321|NCT02803229|DRUG|Matched placebo|matched placebo provided for placebo arm
223615830|NCT02648568|BEHAVIORAL|Relaxation|The patient will have 20 min of Jacobson 's type relaxation, with sequential contraction and relaxation of limb muscles
224075451|NCT02467530|OTHER|AGE|
224312322|NCT02995876|PROCEDURE|Glaze layer|A coating of a glaze layer will be used at the inner surface of the bridge to improve adhesion
224312323|NCT02995876|PROCEDURE|E-max Press layer|A coating of E-max Press layer will be used at the inner surface of the bridge to improve adhesion
224312324|NCT04995692|BEHAVIORAL|Telehealth Education for Asthma Connecting Hospital and Home|TEACHH aims to provide educational support to families managing childhood asthma throughout the transition from hospital to home, and includes several core components: 1) Health literacy-informed inpatient teaching for child and caregiver including pictorial materials, hands-on demonstration, and use of teach-back/show-back techniques; 2) Facilitated identification of rescue and controller medications using color- and shape-coded medication labels and a pictorial asthma action plan; and 3) A pair of virtual follow-up visits after discharge to reinforce inpatient teaching and support families during the shift from acute exacerbation to preventive care management. Virtual visits will be completed using the Zoom platform on smartphones or other compatible devices, 2-4 days after discharge (first visit) and 3 weeks after discharge (second visit). All intervention activities will be completed within 1 month of discharge.
224312325|NCT04995692|BEHAVIORAL|Standard Care (SC) Comparison Group|Patients in the SC group will receive standard impatient management, including pre-recorded asthma education videos shown prior to discharge and the hospital action plan. PCP follow-up with be scheduled within a week of discharge. All SC measures will also be provided to subjects randomized to TEACHH.
224312326|NCT01519986|DIETARY_SUPPLEMENT|Vitamin D3|Supplement of vitamin D3
224312327|NCT01519986|DIETARY_SUPPLEMENT|Placebo|Placebo
224312328|NCT01024686|BIOLOGICAL|p52-/p36- GAP Vaccine|Administered by five bites from GAP-infected Anopheles mosquito
224312329|NCT01024686|BIOLOGICAL|p52-p36- GAP Vaccine|Administered by 200 bites from GAP-infected Anopeles mosquito
224312330|NCT01024686|BIOLOGICAL|p52-/p36- GAP Vaccine|Five doses separated by 4-weeks, each administered by 200 bites from GAP-infected Anopheles mosquito
224312331|NCT03967587|DEVICE|Neosense Umbilical Catheter|The Neosense umbilical catheter is used instead of the routinely used umbilical catheter
224312332|NCT00612430|DRUG|Bevacizumab and Etoposide|32 pts w recurrent WHO grade III MG \& 27 pts w recurrent WHO grade IV MG will be enrolled in this study. Estimated rate of accrual is 10 pts per month. The estimated date of study completion is 6-9 months from study initiation. Bevacizumab administered intravenously at dose 10 mg/kg every two weeks. If pt tolerates 1st bevacizumab dose, subsequent doses may be given by local oncologists under direct supervision of Duke investigators. Etoposide administered orally, once daily for 1st 21 days of each 28-day treatment cycle. Dose of Etoposide will be 50 mg/m2/day. The Duke investigators will review all la data \& order treatment. Treatment will continue until either evidence of progressive disease, unacceptable toxicity, non-compliance w study follow-up, or withdrawal of consent.
224312333|NCT01102374|DRUG|High Dose Vitamin D|Vitamin D3 100,000 IU monthly
224312334|NCT01102374|DRUG|Standard Dose Vitamin D|Vitamin D 12,000 IU monthly
224312335|NCT01102374|DRUG|Placebo|Placebo monthly
224312336|NCT01102374|DIETARY_SUPPLEMENT|Usual Care|Usual care of 0-1000 IU vitamin D daily. This is present in both study arms.
224312337|NCT00418821|BIOLOGICAL|Laronidase|dose of 0.58mg/kg body weight intravenously (IV) every week
223509890|NCT02754037|RADIATION|Fluorodeoxyglucose (FDG) positron emission tomography (PET)|This imaging method uses radiotracers for functional analysis of liver inflammation. It does involve placement of an intravenous catheter and a radiotracer. One blood sample (10cc) will be drawn after PET scan using a butterfly method with the time recorded. The blood sample will be centrifuged in the Main Hospital to get the plasma and a well counter will be used to calculate the radioactivity in the plasma as per established protocol. Potential risks from an intravenous catheter insertion and blood draw include pain, minimal blood loss and local erythema. Radiotracer exposure from FDG-PET is minimal and has been well-characterized. Radiation Use Committee approval has been obtained for FDG-PET use.
223509891|NCT02754037|OTHER|Magnetic resonance imaging (MRI)|Novel non-invasive MRI based tools to assess liver fat and fibrosis. Potential risks include a sensation of claustrophobia. No contrast dye is used and thus no risk of contrast allergy. Inflammation of the liver may be assessed by MRI software after processing of images and does not require additional patient involvement or change in MRI protocol.
223509892|NCT02754037|RADIATION|PET Explorer|Similar to the regular PET-Scan, this imaging method uses radiotracers to scan multiple organs of the body. It does involve placement of an intravenous catheter and a radiotracer. One blood sample (10cc) will be drawn after PET scan using a butterfly method with the time recorded. The blood sample will be centrifuged in the Main Hospital to get the plasma and a well counter will be used to calculate the radioactivity in the plasma as per established protocol. Potential risks from an intravenous catheter insertion and blood draw include pain, minimal blood loss and local erythema. Radiotracer exposure from FDG-PET is minimal and has been well-characterized. Radiation Use Committee approval has been obtained for FDG-PET use.
223509893|NCT06027892|RADIATION|Two-fraction stereotactic radiotherapy|Definitive prostate radiotherapy will be delivered to a dose biologically comparable to 40 Gy in 5 treatments, but in only 2 treatments
223509894|NCT06027892|RADIATION|Five-fraction stereotactic radiotherapy|Definitive prostate radiotherapy will be delivered to a standard stereotactic dose of 40 Gy in 5 treatments
223615831|NCT05858372|DIETARY_SUPPLEMENT|Chios Mastiha essential oil|1 soft gel capsule containing 200 mg of CMO and 100 mg of other excipients being medium chain triglycerides, while the shell was made of bovine gelatin and glycerol
223615832|NCT05858372|OTHER|Placebo|Placebo
223615833|NCT04057521|OTHER|Care Coordination|Comprehensive care coordination.
223615834|NCT03928795|PROCEDURE|elective caesarean section|elective caesarean section
223615835|NCT04277065|PROCEDURE|BULLDOG ,A Useful Vascular Occlusion Tourniquet In Laparoscopic Liver Resection|Bulldog is an effectively performed approach for vascular occlusion during laparoscopic hepatectomy than traditional Pringle manuever.
224312338|NCT01469702|DRUG|prednison and azithromycin|Patients with typical cat-scratch disease will be treated with a 5-day course of prednison and azithromycin.
224312339|NCT01469702|DRUG|prednison, azithromycin|Cap Azithromycin 500 mg qd (first day), then 250 mg qd for 4 days and Tab prednison 1 mg/kg/day, not exceeding 60 mg/day, qd, for 5 days.
224312340|NCT01469702|DRUG|prednison, Azenil|Cap Azenil 500 mg qd (first day), then 250 mg qd for 4 days and Tab prednison 1 mg/kg/day, not exceeding 60 mg/day qd, for 5 days.
224312341|NCT02071849|DEVICE|HAART 200 Aortic Valve Annuloplasty Device|Surgical repair of bicuspid aortic valve using the HAART 200 Aortic Valve Annuloplasty Device .
223615836|NCT04277065|PROCEDURE|cotton tourniquet|cotton tourniquet
223760830|NCT02821884|DEVICE|Combination of tDCS and NMES|Both tDCS and NMES conduct simultaneously for 30 minutes. The anodal electrode of tDCS is placed on the scalp site corresponding to primary motor cortex (M1) of the hemisphere affected by stroke. The cathodal electrode of tDCS is placed on the scalp site corresponding to unaffected primary motor cortex. The current is initially increased in a ramp-like fashion over 30 seconds until reaching 2 mA and is decreased ramp-like fashion over 30 seconds until reaching 0 mA. The NMES electrodes are placed over the following muscle: extensor digitorum communis, extensor carpi radialis to produce wrist and hand extension. The settings for the NMES is frequency at 50 Hz, pulse width of 200μs,duty cycle of 10 seconds on and 10 seconds off,current amplitude is adjusted to patients comfort (10-20mA).
223760831|NCT02821884|DEVICE|Combination of tDCS and sham NMES|Both tDCS and sham NMES conduct simultaneously for 30 minutes. The anodal electrode of tDCS is placed on the scalp site corresponding to primary motor cortex (M1) of the hemisphere affected by stroke. The cathodal electrode of tDCS is placed on the scalp site corresponding to unaffected primary motor cortex. The current is initially increased in a ramp-like fashion over 30 seconds until reaching 2 mA and is decreased ramp-like fashion over 30 seconds until reaching 0 mA. Sham NMES electrodes are placed away from all extensor digitorum communis, extensor carpi radialis motor points, and the patients receive cutaneous stimulation just above the sensory threshold without motor activation(wrist extension).
224312342|NCT01513382|PROCEDURE|Pilonidal sinus excision|The dyed portion of the excised pilonidal sinus and non-dyed cavity excision specimen will be studied histopathologically to detect any remnant of pilonidal sinus.
224312343|NCT05318274|RADIATION|Hypofractionated radiotherapy|Ultra hypofractionated 26 Gy in 5 fractions applied once with daily port film.
223760832|NCT02821884|DEVICE|Combination of sham tDCS and sham NMES|Both sham tDCS and sham NMES conduct simultaneously for 30 minutes. Sham tDCS electrodes are placed in the same position on patients receiving the sham stimulation. Just like during real tDCS, stimulation is started in a ramp-like fashion but fade out slowly after 30 seconds. Sham NMES electrodes are placed away from all extensor digitorum communis, extensor carpi radialis motor points, and the patients receive cutaneous stimulation just above the sensory threshold without motor activation(wrist extension).
223760833|NCT03161561|OTHER|capacity of primary phagocytes|measurement of capacity of primary phagocytes (neutrophils, monocytes and macrophages) isolated from COPD patients' blood or alveolar macrophages isolated from patients' lungs to carry out key host defence functions and compare these to similar cells isolated from age and sex-matched non-smokers or smokers without COPD as controls.
223760834|NCT05488899|DIAGNOSTIC_TEST|Half iodine Spectral CT|Patients receive half dosage of iodine contrast agent, and Spectral CT acquisition with Virtual Monoenergetic Images at 40 and 50 keV.
223760835|NCT05488899|DIAGNOSTIC_TEST|Standard iodine conventional CT|Patients receive standard dosage of iodine contrast agent, and conventional 120 kv Polychromatic CT acquisition.
223760836|NCT02007928|OTHER|Rispéridone, aripiprazole, olanzapine|"Study:~We propose a prospective, interventional multicenter study.~Method:~Both in and out patients may be included in the study Patients will be recruited over a period of 24 months. They will be followed up for 12 months. Each patient will receive one year of therapeutic monitoring after the introduction of the antipsychotic drug.~The therapeutic monitoring will include clinical, electrocardiographical, and laboratory assessments. These assessments are performed at baseline (before prescribing treatment) and at 1 month (M1), at 3 months (M3), 6 months (M6), 9 months (M9), and at 12 months (M12) after the first prescription of the antipsychotic drug."
223760837|NCT03744377|OTHER|The Endometriosis Health Profile EPH-30|Self-reported questionnaires
223760838|NCT02229877|DRUG|Omeprazole|40 mg oral capsules administered twice daily for 8.5 days
223760839|NCT02229877|DRUG|Gefapixant|Gefapixant oral tablet (25 mg administered as a divided 50 mg tablet) administered twice daily for 2 days
223760840|NCT02229877|DRUG|Gefapixant|Gefapixant oral tablet (50 mg tablet) administered twice daily for 8 days
223760841|NCT02229877|DRUG|Gefapixant|Gefapixant oral tablet (150 mg administered as three 50 mg tablets) administered twice daily for 8 days
223760842|NCT03294603|DRUG|CC-220|1mg \[14C\]-CC-220 will be administered as a single dose
223760843|NCT03294603|RADIATION|[14C]|Single dose of \[14C\]-CC-220 will contain approximately 1.4 μCi of radioactivity
223760844|NCT03646721|DRUG|DA-1241|"\[Part1\] Administration once daily for 28 days; Dose strength for each cohort (Cohort 1, 2 and 3) is planned as 50mg, 100mg and 200mg, respectively.~\[Part2\] Administration once daily for 56 days; Dose strength for each cohort (Cohort 4, 5 and 6) is planned as 25mg, 50mg and 100mg, respectively.~(Dose escalation and dose level decisions for subsequent cohorts will be made via interim dose escalation review meetings.)"
223760845|NCT03646721|DRUG|Placebo|\[Part1\] Administration once daily for 28 days. \[Part2\] Administration once daily for 56 days.
223760846|NCT03646721|DRUG|Sitagliptin|\[Part2\] Administration of Sitagliptin 100mg once daily for 56 days.
223760847|NCT04723199|DEVICE|Electrocautetery LAMS|Electrocautetery LAMS
223760848|NCT01332617|DRUG|Simvastatin,Zoledronic Acid,Bortezomib,Bendamustine,Methylprednisolone.|"1. Simvastatin 80 mg PO daily starting day -2 through day 10.~2. Zoledronic acid 4 mg IV over 15 minutes on day 1 and then monthly~3. Bortezomib 1.3 mg/m2/day IV bolus on days 3,6 and 10.~4. Bendamustine 100 mg/m2/day IV over 30 minute infusion on days 3 and 10.~5. Methylprednisolone 1g/m2 IV over 30 minutes on days 1 and 8."
224312344|NCT04619992|DEVICE|Currently marketed Hydrophillic Intermittent Catheter|Currently marketed Hollister standard with tip hydrophilic intermittent catheter
224312345|NCT04619992|DEVICE|Test Hydrophilic Intermittent Catheter|Hollister standard with tip hydrophilic intermittent catheter with design enhancements
224312346|NCT01558180|BEHAVIORAL|Telephone Care Management|series of phone calls from registered nurse to discuss behavioral suggestions for pediatric insomnia
224312347|NCT01558180|BEHAVIORAL|Usual Care|educational handouts on pediatric insomnia
224312348|NCT04465773|PROCEDURE|general anesthesia for scheduled gynecological surgery|
224312349|NCT04465773|DRUG|Propofol|continuous infusion, target concentration adjusted to maintain bispectral index between 45 and 55
224312350|NCT04465773|DRUG|Remifentanil, Ultiva®|continuous infusion, target concentration 1 ng/ml
224312351|NCT04465773|PROCEDURE|tetanic stimulations|10-20-30-40-50-60 milliamps, 5 seconds, 100 Hertz 2 minutes between stimulations delivered via the standard neuromuscular blocking agents monitor
223509895|NCT06123676|DEVICE|Y90-PET-CT scan|40 min extra PET-CT scan - no extra injection of radiotracer. We image the Y90-microspheres administered to these patients during the therapy
223509898|NCT03885206|OTHER|Level of healthcare services|Patiens judged to be eligible for admittance to a municipal acute care wrad will be admitted to hospital as an intervnetion, to be able to compare same patient groups.
223509899|NCT05761483|PROCEDURE|ERCP|Endoscopic Retrograde Cholangiopancreatography, placement of stents using a duodenoscope and making an access through the papilla of Vater
223509900|NCT02605538|BIOLOGICAL|Vaccination with vaccine against hepatitis A and B|Vaccination against hepatitis A and B
223509901|NCT01027754|DRUG|Varenicline|Days 1-3: 0.5 mg once a day Days 4-7: 0.5 mg twice a day Days 8-84: 1 mg twice a day
223509902|NCT01027754|DRUG|Placebo|Days 1-3: 1 pill daily Days 4-7: 2 pills daily Days 8-84: 2 pills daily
223509903|NCT06119204|OTHER|Oviva programme|Total diet replacement for insulin-treated patients
223509904|NCT06119204|OTHER|Usual care|NHS 12 week weight loss programme
223509905|NCT01213251|DEVICE|Single Site Pacing|Subjects will be implanted with a CRT-D that delivers pacing via the Left Ventricular lead.
223509906|NCT01213251|DEVICE|Dual Site Pacing|Subjects will be implanted with a CRT-D that delivers pacing via the Left Ventricular and Right Ventricular lead.
223509907|NCT03084900|OTHER|Arm 1|Patient-Centered Decision Support to Improve Diabetes Mgmt. We will use a computerized decision support system to aid clinicians to provide standard of care management while introducing patient-centered guidelines and outcomes measures.The intervention is the use of an electronic decision support tool. The decision support tool consists of a series of questions answered by the patients that will then allow the health care provider to address specific needs during the visit.
223509908|NCT02459600|OTHER|instulling cyclopentolate drops in the eye|measuring refraction with and wirthout cyclopentolate drops under general anesthesia
223509909|NCT03796286|OTHER|Medium-fiber bar|Each subject will receive one control and two active treatments in a crossover design. The two active treatments are dietary fiber-containing bars at two doses of fiber. The control bar will not contain fiber.
223509910|NCT03796286|OTHER|High-fiber bar|Each subject will receive one control and two active treatments in a crossover design. The two active treatments are dietary fiber-containing bars at two doses of fiber. The control bar will not contain fiber.
223509911|NCT03796286|OTHER|Control bar (0 g fiber)|Each subject will receive one control and two active treatments in a crossover design. The two active treatments are dietary fiber-containing bars at two doses of fiber. The control bar will not contain fiber.
223509912|NCT02637674|PROCEDURE|Uterus Transplant|
223509913|NCT06355141|OTHER|oral assessment|observational oral assessment
223509914|NCT00693511|BEHAVIORAL|Circuit Training|Circuit Training (aerobic + strength training 2 times per week for 16 weeks)
223509915|NCT00693511|BEHAVIORAL|Circuit training + motivational interviewing|Circuit training (aerobic + strength training 2 times per week for 16 weeks) + motivational interviewing (4 individual + 4 group sessions)
223509916|NCT06372041|DEVICE|transcranial Alternating Current Stimulation|tACS will be performed by using a Conformite Europeenne (CE) marked stimulator device (Starstim ®, Neuroelectrics, Barcelona, Spain). By applying alternating current at the gamma frequency band (range 30-80), known to be associated to motor performance, tACS can entrain or synchronize neural oscillations in the targeted brain regions. By modulating cortical excitability of the cerebellum, a region strongly involved in motor learning and coordination, tACS is expected to influence the strength and coordination of motor responses elicited during the training. tACS will be delivered through two saline-soaked surface sponge electrodes (dimension: 25cm2 each), one placed over F3 (left frontal region) and the other over the right cerebellar hemisphere. The intensity will be set to 1mA, and this value will be gradually reached with a ramping-up phase of 30 secs. The frequency of the stimulation will match the IGF identified during the EEG recording performed at rest.
223509917|NCT02411045|BEHAVIORAL|Take and send a selfie|Direction to take and send a selfie.
223509918|NCT02411045|BEHAVIORAL|Workout gears|Direction to wear workout gears.
223509919|NCT02411045|BEHAVIORAL|Exercise|Direction to complete a 30 minute workout.
223509920|NCT01557244|DRUG|Fesoterodine PR 4 mg|Fesoterodine 4 mg tablet once daily for 24 weeks
223509921|NCT01557244|DRUG|Fesoterodine PR 8 mg|Fesoterodine PR 8 mg tablet once daily for 24 weeks, the first week being 4 mg.
223509922|NCT01557244|DRUG|Fesoterodine PR 8 mg|Fesoterodine 8 mg tablet once daily for 24 weeks, the first week being 4 mg.
223509923|NCT01557244|DRUG|Oxybutynin|Oxybutynin extended release tablets according to approved pediatric labeling for 12 weeks with dose titration phase for first 4 weeks to achieve dose optimisation.
223509924|NCT01557244|DRUG|Fesoterodine PR|Fesoterodine 4 mg or 8 mg tablets once daily for 12 weeks after 12 weeks of oxybutinin. Those assigned to 8 mg will take 4 mg for the first week.
223509925|NCT01557244|DRUG|Fesoterodine BIC 2 mg|Fesoterodine BIC 2 mg tablet once daily for 24 weeks.
223509926|NCT01557244|DRUG|Fesoterodine BIC 4 mg|Fesoterodine BIC 4 mg tablet once daily for 24 weeks, with the first week being 2 mg.
223509927|NCT00438282|BEHAVIORAL|home visitation|Home visitation from midway through pregnancy until child age 2. Group 2 is visitation by Paraprofessionals; group 3 is home visitation by Nurses.
223509928|NCT06325631|PROCEDURE|Intra-articular injection to lumbar facet joint|to treat low back pain caused by facet joint syndrome
224202057|NCT07047573|BIOLOGICAL|PBMCS were isolated from the peripheral blood of hospitalized patients with pulmonary nodules and incubated with nanoparticles loaded with tumor antigens for a specific period of time to detect cancer|Research on the in vitro Stimulation of Pbmc by Tumor Antigen Nanoparticles PBMCS were isolated from the peripheral blood of hospitalized patients with pulmonary nodules and incubated with nanoparticles loaded with tumor antigens for a specific period of time to detect cancer-related T cells or cytokines in vitro. The content of this type of T cells or cytokines is positively correlated with tumors. On the contrary, the content of T cells or cytokines in patients with benign pulmonary nodules is negatively correlated with the tumor. Furthermore, the benign and malignant nature of pulmonary nodules in patients is determined through the combination of patient imaging data and clinicopathological data.
224312352|NCT04465773|DEVICE|VideoAlgesiGraph|non invasive infrared camera placed in front of the left eye of the patients during the study period, connected to a laptop. No part of the device touches the eye.
224312353|NCT00501501|PROCEDURE|Cesarean section|
224312354|NCT00501501|PROCEDURE|Vaginal delivery|
223509929|NCT05183984|DRUG|Chemotherapy|Chemotherapy (carboplatin + paclitaxel) will be administred by intravenous infusion, AUC 5-6 q3w - 5 cycles during the treatment period
223509930|NCT05183984|DRUG|Bevacizumab-Awwb|"MVASI (bevacizumab biosimilar) will be administrated by intravenous infusion at the second chemotherapy cycle for 5 cycles.~the administration will continue during maintenance phase. Total bevacizumab duration therapy is 15 months."
223509931|NCT05183984|DRUG|Niraparib|niraparib will be administered orally once daily continuously after chemotherapy (+/- bevacizumab) cycles (maintenance treatment period). Total niraparib duration mainance treatment period is 2 years.
223509932|NCT03312114|DRUG|Avelumab|Avelumab\* (MSB0010718C; anti-PD-L1 is a fully human anti-PD- L1 IgG1 antibody)
223509933|NCT02295579|OTHER|lactobacillus (EcoVag)|Probiotic human lactobacillus (L. gasseri and L rahmnosus)
223509934|NCT01313676|DRUG|fluticasone furoate/vilanterol|100/25mcg given once daily via novel dry powder inhaler
223509935|NCT01313676|DRUG|fluticasone furoate|100mcg given once daily via novel dry powder inhaler
223509936|NCT01313676|DRUG|vilanterol|25mcg given once daily via novel dry powder inhaler
223509937|NCT01313676|OTHER|Placebo|placebo comparator once daily via novel dry powder inhaler
223509938|NCT00944645|DRUG|niacin (+) laropiprant (Source 1)|Single dose of MK0524A (ER Niacin/laropiprant 1000/20 mg) from Source 1 in one of two treatment periods.
223509939|NCT00944645|DRUG|Comparator: niacin (+) laropiprant (Source 2)|Single dose of MK0524A (ER Niacin/laropiprant 1000/20 mg) from Source 2 in one of two treatment periods.
223509940|NCT04441515|DEVICE|Ipod with music|music of patient's preference provided 2 hours daily
224312355|NCT00005727|BEHAVIORAL|Intervention|Classroom-based nutrition education curriculum designed for individuals with low literacy skills.
224312356|NCT03008876|DRUG|Acetaminophen|infants receive acetaminophen for treatment of their PDA
224312357|NCT03008876|DRUG|Ibuprofen|infants receive ibuprofen, standard of care in our unit, for treatment of a PDA
224312358|NCT04220931|DRUG|botulinum toxin injection|injection of Botulinum toxin A 100 UI, single dose administration, in the major papilla, in the Oddi sphincter, during upper gastrointestinal endoscopy.
224312359|NCT04682769|OTHER|Other|Patients with Coronary Heart Disease and Depressive Disorder are receiving routine treatment by their physician.
224312360|NCT00106340|DRUG|vildagliptin|
224312361|NCT00106340|DRUG|glimepiride|
224312362|NCT00106340|DRUG|Metformin|
224312363|NCT00106340|DRUG|Vildagliptin matching placebo|
223509941|NCT04441515|DEVICE|ipod with books to listen|2 hours of daily listening to books
223509942|NCT04441515|DEVICE|ipod only with usual care|participants given device only
223509943|NCT03995147|DRUG|Pembrolizumab|"Pembrolizumab will be administered at a fixed dose of 200mg intravenously every 3 weeks in combination with R-CHOP for 6 cycles.~Participants that respond to the combination regiment will continue to receive pembrolizumab 200 mg IV every 3 weeks for additional 35 cycles (2 years)."
223509944|NCT03995147|DRUG|R-CHOP Protocol|R-CHOP chemo-immunotherapy will be administered in combination with Pembrolizumab
223509945|NCT05988229|OTHER|Toolkit to improve discharge equity|Linguistically appropriate discharge teaching aids: a medication calendar, pictographics added to the after visit summary (AVS), and an audio recording of the discharge teaching.
223509946|NCT03537729|BEHAVIORAL|Salient Cues|Salient cues are those that capture the individual's attention. Information that is complex, novel, and difficult to identify takes more processing resources than those that are simple and familiar. Cues such as pictures and wall hangings, along with bright and meaningful signs, will be placed at key decision points within the senior communities.
223509947|NCT03537729|BEHAVIORAL|Spaced Retrieval Education|Spaced Retrieval (SR) is an evidence-based memory strategy that is used to teach individuals with memory loss new or previously known information. In this study, participants in Arm 3 will receive twelve 30-minute educational sessions to help them use the salient cues to find their way.
223509948|NCT05968742|BEHAVIORAL|Abstinence of oral hygiene on select teeth|Study participants abstain from oral hygiene on a select set of four teeth for a period of 21 days
223509949|NCT04668599|OTHER|Cardiopulmonary rehabilitation|Patients will undergo standardized cardio-pulmonary rehabilitation program.
223615837|NCT04371965|DRUG|Povidone-Iodine|Patients in the experimental group will be asked to gargle with a 1% povidone-iodine solution, spray their nose with the same antiseptic solution, and finally applied 10% povidone-iodine cream in each nostril, all four times a day for five days.
223615838|NCT01065038|DRUG|Anagrelide|
223615839|NCT01065038|DRUG|Hydroxyurea|
223615840|NCT02168114|OTHER|Exercising|This arm will only include subjects that have a confirmed diagnosis of Duchenne Muscular Dystrophy. Subjects in this arm will not undergo any exercising, and will only be imaged by Optical and Magnetic Resonance Imaging and Spectroscopy techniques at a single time point.
223615841|NCT02168114|PROCEDURE|Optical and Magnetic Resonance Imaging and Spectroscopy|This arm will contain subjects that are not affected by Duchenne Muscular Dystrophy. These subjects will undergo concentric exercising of one forearm, and eccentric exercising of the contralateral forearm. Two days following the exercising, subjects will undergo Optical Imaging and Magnetic Resonance Imaging and Spectroscopy.
223615842|NCT04957797|PROCEDURE|round tunnel|reamed with round tunnel
223615843|NCT04957797|PROCEDURE|flat tunnel|reamed with flat tunnel
223615844|NCT04437485|BEHAVIORAL|Good Days Ahead (GDA)|GDA (Empower Interactive) is an empirically supported, HIPAA compliant, computerized CBT for depression appropriate for primary care patients and people with little computer experience. GDA uses an interactive, multimedia format to deliver 9 45-minute sessions, the structure and content of which mirror face-to-face CBT. General topics include identifying and modifying automatic thoughts, using behavioral activation and other behavioral methods, identifying and modifying schemas, using effective coping strategies, and employing other core CBT methods. GDA is empirically supported - it is acceptable to patients, achieves superior depression outcomes to waitlist comparators, and yields equivalent (noninferior) depression outcomes to standard face-to-face CBT. To minimize time/transportation barriers, GDA sessions occur at the PI's lab or a location with internet access selected by the patient (patient's, family member's, or friend's home).
223615845|NCT04437485|BEHAVIORAL|Problem Solving Treatment in Primary Care (PST-PC)|PST-PC is an established, manualized, empirically supported CBT developed for primary care. During the 6-10 30-minute sessions, patients are taught skills for solving problems contributing to depression. We will deliver PST-PC by phone, which has been found to be feasible and efficacious.
223615846|NCT04437485|DRUG|Antidepressant Medications|We first considered all FDA-approved antidepressants and excluded those with weight gain effects (tricyclics, paroxetine, mirtazapine) and those rarely used in primary care (MAOIs). Then, we used existing evidence to inform the structure. We made bupropion (an aminoketone) and fluoxetine (an SSRI) our first-line and second-line antidepressants, as meta-analyses indicate that their use is associated with weight loss. We made other SSRIs (escitalopram, sertraline) and SNRIs (desvenlafaxine, duloxetine, venlafaxine) our third-line antidepressants, given their negligible effects on weight. Our team will make recommendations to the patient's PCP, who will write prescriptions. Our team and the PCP will then collaboratively manage pharmacotherapy.
223760849|NCT01944059|DRUG|Theramine (medical food/old drug)|Theramine® is a prescription medical food that is composed of variety of amino acids and/or their precursors.
223760850|NCT01944059|OTHER|Placebo (l-alanine)|Theramine like placebo comparator
224202058|NCT07048067|PROCEDURE|Carotid endarterectomy (CEA)|carotid endarterectomy (CEA) with the use of Baxter VASCU-GUARD vascular patches
224202059|NCT06736743|DIAGNOSTIC_TEST|SMART Tool for Feeding Skill Assessment|Infant Oral Feeding Skill Assessment (FSA) done using SMART Tool
224202060|NCT07047989|BIOLOGICAL|NWRD09 injection|NWRD09 administered by intramuscular injection
224202061|NCT02198209|DRUG|Liraglutide|"1. acute study: one injection of 0.6 mg s.c. before IVGTT~2. chronic study: 6 weeks of daily liraglutide administration (1 week at 0.6 mg, 1 week at 1.2 mg, 4 weeks at 1.8 mg, s.c)."
223509950|NCT06023264|PROCEDURE|Dry needling|It is a minimally invasive treatment modality. Its effectiveness has been confirmed in numerous studies. It consists of applying an antiseptic in the puncture area and inserting the needle in the required aseptic conditions. During puncture, the patient's physical response is observed at all times, in order to control the local spasmodic responses in each muscle. After applying the technique, we assessed jaw pain, mouth opening, and the appearance of headaches. The adverse effects of the technique are the following: pain after puncture (1.7%), local bleeding at the puncture site (6.1%) and syncopal responses (0.7%).
223509951|NCT06306157|DRUG|Low dose naltrexone|While naltrexone is FDA-approved for treatment of alcohol or opioid addition, this study will be looking at how naltrexone, when dosed very low, may reduce the painful symptoms associated with CRPS. Naltrexone is not FDA-approved for pain management treatment of CRPS at this time, and therefore the study intervention is using the drug in an off-label manner.
223509952|NCT06306157|DRUG|Placebo sugar capsules|The external appearance of the capsules prepared by the pharmacy will be identical to the LDN capsules. The inactive capsule ingredients will be microcrystalline cellulose (MCC) and Magnesium stearate
223509953|NCT02562040|PROCEDURE|Early Adenotonsillectomy (eAT)|Standard clinical adenotonsillectomy within 4 weeks post randomization in addition to information about healthy sleep habits for children and appropriate clinical referrals for management of co-morbidities.
223509954|NCT02562040|BEHAVIORAL|Watchful Waiting with Supportive Care (WWSC)|Information about healthy sleep habits for children and appropriate clinical referrals for management of co-morbidities.
223509955|NCT02845349|DRUG|Vortioxetine|The study drug, vortioxetine received approval from the U.S. Food and Drug Administration (FDA) to treat adults with major depressive disorder. This study is being done to determine its effectiveness in a specialized population, i.e. those who have developed major depression after a traumatic brain injury. As patients who have sustained a TBI are medically fragile and sensitive to side-effects of medications, it is important to test the effectiveness and safety of vortioxetine in this population.
223509956|NCT02845349|DRUG|Placebo|A placebo comparator will be used in one subset of patients.
223509957|NCT04997421|DEVICE|Combined HA380 hemoadsorption and continuous veno-venous hemodiafiltration (CVVHDF) with Oxiris®-AN69 membranes|Combined HA380 hemoadsorption and continuous veno-venous hemodiafiltration (CVVHDF) with Oxiris®-AN69 membranes (intervention arm)or mere CVVHDF using the Oxiris®-AN69 membrane (control arm).
223509958|NCT04997421|DEVICE|Continuous veno-venous hemodiafiltration (CVVHDF) with Oxiris®-AN69 membranes|Continuous veno-venous hemodiafiltration (CVVHDF) with Oxiris®-AN69 membranes (control arm)
223509959|NCT00523666|DRUG|Galantamine (Reminyl®)|8mg - 24mg
223509960|NCT00523666|DRUG|Placebo/Galantamine (Reminyl®)|"Patients are treated double-blind with placebo for 6 months, followed by treatment with Galantamine (Reminyl®) for another 6 months.~Dose scheme: 8mg-24mg"
223509961|NCT04775524|BEHAVIORAL|Storytelling Through Music (STM)|6 week expressive arts-based program
223509962|NCT04775524|BEHAVIORAL|Wait List / Storytelling Through Music-Hybrid|2 week song listening program
223509963|NCT03342794|PROCEDURE|cataract surgery|To diagnose the preexisting posterior capsule defects in congenital cataracts after the cataracts are removed by surgery and observe the characteristics
223509964|NCT05121922|BEHAVIORAL|Metacognitive Therapy|Psychological treatment provided by the patient's regular general practitioner
223509965|NCT00863460|RADIATION|cranial radiotherapy|40 Gy
223509966|NCT00863460|DRUG|intensive chemotherapy and hematopoietic stem cell rescue|intensive chemotherapy and hematopoietic stem cell rescue
223509967|NCT00863460|DRUG|MTX based chemotherapy|R-MBVP 2 cycles day1 and day28 followed by R-Aracytine 2 cycles days58\&59 and days79\&80
223509968|NCT02684474|BIOLOGICAL|HBOC-201|Intravenous administration of a hemoglobin based oxygen carrier (HBOC) in patients with life-threatening anemia, for whom allogeneic blood transfusion is not an option.
224202062|NCT01525407|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo myeloablative allogeneic PBSC transplant
223615847|NCT04437485|OTHER|Active Control|(1) The graduate research assistant (RA) will have a 50-minute call with AC patients to review depression materials. The RA will provide a list of Eskenazi Health mental health services and will encourage patients to follow-up with their PCP. We will then send an electronic health record message to the PCP encouraging them to address their patient's depression, note that there are no care restrictions, and provide the same list of services. (2) The RA will call AC patients every 4 weeks to assess depressive symptoms and will notify clinical staff to encourage additional care when indicated. (3) AC patients will receive current primary care for depression. The Eskenazi Health primary care clinics utilize a team care approach, with PCPs supported by embedded behavioral health clinicians and affiliated psychiatrists.
224202063|NCT01525407|DRUG|Atorvastatin Calcium|Given PO
223509969|NCT05504083|DRUG|D-0120|Part A: Randomized in a 1:1:1 ratio through the randomization system, and assigned to D-0120 group 1, D-0120 group 2 or benzbromarone control group. Part B: Subjects will be assigned to D-0120 group 3.
223509970|NCT05504083|DRUG|Benzbromarone|Part A: Randomized in a 1:1:1 ratio through the randomization system, and assigned to D-0120 group 1, D-0120 group 2 or benzbromarone control group.
223509971|NCT03735901|DRUG|IMP Levodopa 100mg/Carbidopa 25mg|"Study treatment will comprise 3 phases:~1. Dose escalation phase: On day 1-3, patients will receive IMP solely in the morning; on day 4-6 in the morning and at lunch time;~2. full study treatment phase: from day 7 to day 34, 3 times per day (tid).~3. Treatment will stop with a tapering phase: On day 35-37, patients will receive IMP in the morning and at lunch time; on day 38 and 39 solely in the morning."
223615848|NCT04049487|OTHER|Exercise|Both groups will participate in group exercise as previously described
223615849|NCT02954107|OTHER|MRI|
223615850|NCT02954107|OTHER|24h-EEG + video|
223615851|NCT02954107|OTHER|Neuropsychological tests|
223615852|NCT04533724|DRUG|Amisulpride|The amisulpride treatment group was given amisulpride tablets. The dose: the initial dose was 50 mg/d. The doctor titrated the dose to the therapeutic amount within 1 to 2 weeks according to the patient's condition. The maximum dose was 300 mg/d, taken with a single meal. Observe for 8 weeks.
223615853|NCT03727815|OTHER|Mindfulness Pain Management Arm|Mindfulness Pain Management intervention: patients will be asked to complete a guided mindfulness meditation intervention using a phone application for 2 weeks prior to participant's scheduled procedure and continue with the pain management mindfulness module for 4 weeks postoperatively with periodic survey assessments using validated psychometric tools.
224202064|NCT01525407|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo myeloablative allogeneic PBSC transplant
223509972|NCT03735901|DRUG|Matching placebo|"Study treatment will comprise 3 phases:~1. Dose escalation phase: On day 1-3, patients will receive Placebo solely in the morning; on day 4-6 in the morning and at lunch time;~2. full study treatment phase: from day 7 to day 34, Placebo capsules 3 times per day (tid).~3. Treatment will stop with a tapering phase: On day 35-37, patients will receive Placebo in the morning and at lunch time; on day 38 and 39 solely in the morning."
223509973|NCT00355550|DRUG|Tricaprilin|Powder formulation will be mixed in a liquid (approximately 8 oz).
223509974|NCT00355550|OTHER|Placebo|Powder formulation will be mixed in a liquid (approximately 8 oz).
223509975|NCT01902303|DRUG|Matching Placebo|Sublingual micro dosing of placebo for 7 days
223509976|NCT01902303|DRUG|BTL-TML-HSV|Sublingual micro dosing of BTL-TML-HSV for 7 days
223509977|NCT03274349|PROCEDURE|whole body electromyostimulation exercise|whole body electromyostimulation exercise training twice a week for 20 min each, bipolar, 85 Hz, intermittent pulse/pause, pulse width 350 µsec
223509978|NCT03274349|PROCEDURE|protein-rich nutrition therapy|protein-rich nutrition therapy with an objective of reaching 1,2 to 1,5 g protein/kg body weight and day
223509979|NCT02821000|BIOLOGICAL|Pembrolizumab|Intravenous infusion
223509980|NCT05673655|DRUG|intraoral trigger point injection by botox|intraoral injection of trigger point of masseter muscle by botulinum toxin
223509981|NCT05673655|DRUG|transcutaneous trigger point injection by botox|transcutaneous injection of masseter muscle by botulinum toxin
223509982|NCT00326495|DRUG|Cetuximab|Cetuximab is a recombinant human/mouse chimeric monoclonal antibody which binds specifically to the extracellular domain of the epidermal growth factor receptor (epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 1 (HER1), c-ErbB) in normal and tumor cells, and competitively inhibits the binding of epidermal growth factor (EGF) and other ligands, such as transforming growth factor-alpha.
223509983|NCT00326495|DRUG|BAY 43-9006|Is a potent inhibitor of proto-oncogene c-Raf (c-raf), and wild-type and mutant proto-oncogene b-Raf (b-raf) in vitro
223509984|NCT03189511|DRUG|Fluvastatin|Fluvastatin 40 mg twice daily per mouth for 14 days.
223509985|NCT05386836|DEVICE|Pulse oximeter validation population|Evaluation of the SpO2 accuracy performance of the Sunrise Sensor 2 placed at the tip of the chin during non-motion conditions over the range of 70-100% by comparison to SaO2 values determined from arterial blood sample specimen analyzed by a CO-oximeter.
223509986|NCT05328544|PROCEDURE|ACL reconstruction of the knee joint by arthroscopic technique, with the tibial fixation method using a bioabsorbable screw (Arthrex) with the use of autogenous cancellous bone grafts|Reconstruction of the anterior cruciate ligament (ACL) of the joint the knee stabilization method, a bioabsorbable screw with the use of an autogenous spongy bone graft taken during drilling of the tibial canal into the tibial canate before inserting the screw.
223760851|NCT03645629|DIAGNOSTIC_TEST|skin test with food at different storage times|Perform skin tests to each foods at 0, 3, 6 months after preparation and compare the results
223760852|NCT00839293|DRUG|ABT-335|Once, see arm description for more information
224202065|NCT06761469|OTHER|Implementing active-case finding strategies|Implementation of a multifactorial active-case finding strategy, including: (1) raising awareness among the population about leprosy; (2) theoretical and practical educational training for healthcare workers; (3) georeferencing of historical and existing cases in the municipality (from 2012 to 2023) and of new cases diagnosed throughout the study (dynamic changes); (4) screening tools for signs/symptoms of the disease (application of Leprosy Suspicion Questionnaire); and (5) serological profile (rapid test) of patients with reported signs/symptoms (positive answers Leprosy Suspicion Questionnaire).
224312364|NCT00106340|DRUG|Glimepiride matching placebo|
223760853|NCT00808288|DRUG|PF-00610355|oral, inhaled, dry powder, 600ug, OD
223760854|NCT00808288|DRUG|PF - 00610355|oral, inhaled, dry powder, 300ug, OD
223615854|NCT03727815|OTHER|Mindfulness Self Esteem Arm|Mindfulness Self Esteem intervention: patients will be asked to complete a guided mindfulness meditation intervention using a phone application for 2 weeks prior to participant's scheduled procedure and continue with the self esteem mindfulness module for 4 weeks postoperatively with periodic survey assessments using validated psychometric tools.
223615855|NCT03303326|BEHAVIORAL|Immediate interview|A women's health interview that obtains information about physical, mental, and sexual health, particularly relatively private sexual health-related attitudes and experiences, as well as conflicts and stress related to sexuality.
223615856|NCT02602535|BEHAVIORAL|Mindfulness-Oriented Recovery Enhancement|Mindfulness-Oriented Recovery Enhancement (MORE) is a group behavioral intervention that unites mindfulness training, cognitive reappraisal, and positive psychological principles into an integrative intervention strategy targeting mechanisms of pain and opioid misuse.
223615857|NCT02602535|BEHAVIORAL|Support Group|A conventional support group will allow participants to express emotions, share experiences, and receive social support under the guidance of a skilled therapist.
223615858|NCT04324671|DEVICE|nasofibroscopy|"Flexible videorhinolaryngoscope, PAL 11101VP\*, 4.2 mm diameter. Using a computerized system including:~Light source: Explor ENT (HAL250). The software allowed audio, video recording and retrieval of recorded material."
223615859|NCT03222635|PROCEDURE|Endoscopic follow-up|Endoscopic follow-up by means of regular upper endoscopies and endoscopic ultrasounds
223615860|NCT02182323|DRUG|BI 201335 NA|
223615861|NCT02182323|DRUG|Placebo solution|
223615862|NCT00110539|BEHAVIORAL|Complementary and alternative medicine education|
223760855|NCT00808288|DRUG|PF- 00610355|oral, inhaled, dry powder, 100ug, OD
223760856|NCT00808288|DRUG|Placebo|oral, inhaled, dry powder, placebo, OD
223760857|NCT00808288|DRUG|Salmeterol|salmeterol, 50ug, BID
223760858|NCT01405638|BEHAVIORAL|Motivational Interviewing|One-on-one client-centered counseling for lifestyle changes related to blood pressure control
223760859|NCT01405638|BEHAVIORAL|Patient Navigation|One-on-one navigation to guide participants through the process of being screened for colorectal cancer.
223760860|NCT04237077|OTHER|telephone coaching program|telephone coaching program : 7 phone calls by nurse
223760861|NCT04237077|OTHER|no telephone coaching program|no telephone coaching program : 7 phone calls by nurse
223760862|NCT02993575|DRUG|Flucloxacillin|Dose according to summary of product characteristics (SPC) or local protocols: intermittent and continuous infusion
223760863|NCT02365636|DRUG|TV-45070|TV-45070 is an ointment applied topically twice daily to area of pain.
223760864|NCT02365636|DRUG|Placebo|The matching placebo ointment contained only the excipients of the active treatment; also applied topically twice daily to area of pain.
223760865|NCT03490266|PROCEDURE|Robotic Repair|The surgeon will be utilizing a robotic system to repair the hernia.
223760866|NCT03490266|PROCEDURE|Laparoscopic Repair|The surgeon will be repairing the hernia laparoscopically.
223760867|NCT04379167|DRUG|YY-20394|YY-20394 is a selective inhibitor of the delta isoform of phosphatidylinositol 3 kinase (PI3K-δ) which differs structurally from idelalisib, a PI3K-δ inhibitor approved for patients with relapsed chronic lymphocytic leukemia and indolent lymphoma. PI3K-δ signaling pathways are frequently hyperactive in B-cell cancers, making inhibition of PI3K-δ a promising target for B-cell malignancies. YY 20394 has high potency against PI3K-δ, but with markedly improved selectivity in in vitro assays compared to idelalisib. This higher selectivity for PI3K-δ may decrease the risk of serious infection seen with idelalisib and duvelisib (a PI3K-γ/δ dual inhibitor) due to strong immune suppression.
223760868|NCT03427658|BEHAVIORAL|Sweet food consumption|Comparison of the impacts of sweet and non-sweet food consumption
223615863|NCT04260893|DEVICE|Tixel|Peri-Orbital fractional treatment on the Eye-Lid to assess the effect on Dry Eye symptoms
223615864|NCT00428766|DRUG|MORAb-003|
223615865|NCT02289495|DRUG|GSK2838232|GSK2838232 will be available as oral suspension dispersion in hydromellulose acetate succinate bulk powder/10, 20 and 50 mg which is to be administered orally QD for 8 days (Part A) or 11 days (Part B), morning dose, following an overnight fast of at least 10 hours
223615866|NCT02289495|DRUG|Placebo|Matching placebo of Suspension to active dose, administered orally QD for 8 days (Part A) or 11 days (Part B), morning dose, following an overnight fast of at least 10 hours
223615867|NCT02289495|DRUG|Ritonavir|Ritonavir will be available as white film-coated ovaloid tablets of 100 mg tablet/100mg to be administer orally, QD
223615868|NCT05244616|OTHER|arabic version of the postoperative Quality of Recovery Score 15|The Arabic version of the Postoperative Quality of Recovery Score 15 to be completed twice by the patients: once preoperatively and once within 24 to 48 hours postoperatively.
223615869|NCT02719171|DRUG|risankizumab|Risankizumab administered by SC injection
223760869|NCT06382987|DRUG|Deucravacitinib|According to the product label
223760870|NCT06382987|DRUG|Apremilast|According to the product label
223760871|NCT00003491|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Stage IV Lung Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
223760872|NCT05098639|BEHAVIORAL|BASICS|In the BASICS condition, individuals receive information about alcohol use on campus and discuss safe drinking practices. They also receive personalized normative feedback based on their alcohol use and their use of protective behavioral strategies.
224075452|NCT05946473|DIETARY_SUPPLEMENT|Gum base containing xylitol and essencial oils|Participants will be asked to chew 2 pieces of chewing gum containing additives for 10 minutes after eating in the morning, and after one meal in the evening, for a four-week period
224075453|NCT05946473|DIETARY_SUPPLEMENT|Gum base with no additives|Participants will be asked to chew 2 pieces of pure gum base for 10 minutes after eating in the morning, and after one meal in the evening, for a four-week period
224075454|NCT03736512|DEVICE|GreenLight XPS™ 532 nm Laser System with MoXy™ laser fiber|observational registry
224202066|NCT06828887|DRUG|LV232 40mg|LV232 capsules 2 capsules (20 mg/capsule) + LV232 capsule placebo 1 capsule + escitalopram oxalate tablet placebo 1 tablet
224202067|NCT06828887|DRUG|LV232 60mg|LV232 capsules 3 capsules (20 mg/capsule) + escitalopram oxalate tablet placebo 1 tablet
224202068|NCT06828887|DRUG|Escitalopram|LV232 capsule placebo 3 capsule + escitalopram oxalate tablet 1 tablet
223509987|NCT05328544|PROCEDURE|ACL reconstruction of the knee joint by arthroscopic technique, with the tibial fixation method using a bioabsorbable screw (Arthrex) without the use of autogenous cancellous bone grafts|Reconstruction of the anterior cruciate ligament (ACL) of the joint the knee stabilization method, a bioabsorbable screw without the use of an autogenous spongy bone graft taken during drilling of the tibial canal into the tibial canate before inserting the screw.
223509988|NCT04162314|DRUG|Beta-1,3/1,6-D-Glucan Ganoderma lucidum|Beta-1,3/1,6-D-Glucan capsule three times daily for 90 days
224202069|NCT06828887|DRUG|Placebo|LV232 capsule placebo 3 capsule + escitalopram oxalate tablet placebo 1 tablet
224202070|NCT06926426|BEHAVIORAL|oral function training|A 12-week program including oral muscle strengthening, pronunciation drills, and swallowing-related exercises designed to improve oral function in older adults.
223509989|NCT04162314|DRUG|Placebos|Placebos
223509990|NCT04457778|DRUG|M6223|Participants will receive an intravenous (IV) infusion of M6223 at escalated doses every 2 weeks (Q2W) or every 3 weeks (Q3W) on Day 1 of each Cycle (Each cycle is of 14 days) according to the recommendation of the SMC(Safety Monitoring Committee) until the maximum tolerated dose(MTD) has been reached or confirmed disease progression.
223509991|NCT04457778|DRUG|Bintrafusp alfa|Participants will receive an IV infusion of bintrafusp alfa Q2W on Day 1 of each Cycle (Cycle is 14 days) until confirmed disease progression.
223509992|NCT04457778|DRUG|M6223|Participants will receive an IV infusion of M6223 at escalated doses Q2W on Day 1 of each Cycle (Each cycle is of 21 days) according to the recommendation of the SMC until the MTD has been reached or confirmed disease progression.
223509993|NCT05311410|OTHER|Non-bloody dental procedures (control group)|Control group composed of 30 positive patients for SARS-CoV-2, from the same ICU, submitted to non-bloody procedures.
223509994|NCT05311410|PROCEDURE|Bloody dental procedures (study group)|Study group consisting of 30 patients who require open dental treatment and with a positive PCR test for SARS-CoV-2 prior and admitted to the Intensive Care Unit.
223509995|NCT00002482|BIOLOGICAL|antibody therapy|
223509996|NCT00002482|BIOLOGICAL|biological therapy|
223509997|NCT00002482|BIOLOGICAL|muromonab-CD3|
223509998|NCT00002482|DRUG|cyclophosphamide|
223509999|NCT03153293|DRUG|rAAV2-ND4|a Single IVT Injection
223510000|NCT00344669|DRUG|Albendazole 400 mg, given 6 monthly|
223510001|NCT04359680|DRUG|Nitazoxanide|Nitazoxanide 600 mg administered orally twice daily for six weeks
223510002|NCT04359680|DRUG|Placebo|Placebo administered orally twice daily for six weeks
223510003|NCT04359680|DIETARY_SUPPLEMENT|Vitamin Super B-Complex|Vitamin Super B-Complex administered orally twice daily to maintain the blind
223510004|NCT01855568|PROCEDURE|Single-dose Methotrexate|"Participants in the single-dose protocol group received intramuscular methotrexate at single dose of 50 mg/m2 on day 0 (the initial day of treatment). The β-hCG levels were then measured on day 4 and 7. If there was at least 15% β-hCG drop between day 4 and 7, the treatment was deemed successful and the participants were then followed with weekly β-hCG measurements until the results was negative. If a 15% drop on day 4 and 7 did not occur, a second dose was administrated on day 7 and β-hCG levels were then measured on day 11 and 14. Participants were referred for surgical treatment if β-hCG levels fell \<15% between day 11 and 14."
223510005|NCT01855568|PROCEDURE|Two-dose methotrexate protocol|"Participants in the two-dose protocol group received intramuscular methotrexate twice at dose of 50 mg/m2 on day 0 and 4. A third dose of methotrexate was given on day 7 if β-hCG levels did not fall 15% between day 4 and 7 after two-dosing. A fourth dose was administered on day 11 if β-hCG levels fell \<15% between day 7 and 11. Then, a final β-hCG level was checked on day 14. If a 15% drop was not seen, the medical treatment was deemed refractory and the patients were referred for surgical treatment."
223510006|NCT03211845|OTHER|Nutritional telemonitoring|Participants receive a weighing scale, pedometer and television channel in order to perform self-measurements and receive guidance on nutrition and physical activity. Nurses use a website in order to receive telemonitoring measurements and decide about proper follow-up. In case of risk of undernutrition, nurses provide personal advice to optimize nutritional status of the participant.
223510007|NCT02245893|PROCEDURE|open reduction internal fixation (ORIF)|The study design is a prospective, randomized pilot clinical trial of the treatment of unstable syndesmosis injuries sustained with Weber C type fractures. Comparison will be made between two syndesmosis stabilization methods: 1) Percutaneous (closed) reduction using syndesmosis fixation by SCREW 2) Open reduction (ORIF) with ART repair of the anterior ligament and stabilization of the syndesmosis by use of a syndesmosis screw.
223510008|NCT00893581|DRUG|Quetiapine & Placebo|Bipolar adolescents will be initiated on 100 mg per day of quetiapine (or placebo) and 30 mg/kg (maximum starting dose of 600 mg twice daily) of lithium carbonate (or placebo), depending on randomization assignment. Patients will be given placebo for the medication to which they were not assigned. Quetiapine will be adjusted based on tolerability and response to a target dose of 400-600 mg and lithium will be adjusted to a target dose based on achieving a serum level of 1.0-1.2 mEq/L.
223615870|NCT02719171|DRUG|placebo for risankizumab|Placebo for risankizumab administered by SC injection
223615871|NCT02614729|OTHER|Standard Protein-Plant, Even Distribution (SP-PLANT-EVEN)|Diet contains all plant proteins. Meals are evenly distributed throughout the day.
223615872|NCT02614729|OTHER|Standard Protein-Beef, Even Distribution (SP-BEEF-EVEN)|Diet contains combination of beef and plant proteins. Meals are evenly distributed throughout the day.
223615873|NCT02614729|OTHER|High Protein-Beef, Even Distribution (HP-BEEF-EVEN)|Diet contains combination of beef and plant proteins. Meals are evenly distributed throughout the day.
223615874|NCT02614729|OTHER|High Protein-Beef, Uneven Distribution (HP-BEEF-UNEVEN)|Diet contains combination of beef and plant proteins. Meals are unevenly distributed throughout the day.
224202071|NCT04548401|DRUG|Antiplatelet Drug|aspirin and/or clopidogrel or ticagrelor
224202072|NCT05213065|OTHER|Sphenopalatine ganglion block with 0.5% bupivacaine|Repetitive SPG blockade using 0.5% bupivacaine delivered with the Tx360® device.
224202073|NCT05213065|OTHER|Sphenopalatine ganglion block with saline|Repetitive SPG blockade using saline delivered with the Tx360® device.
224202074|NCT00381667|DRUG|GW642444M|M salt
223615875|NCT03984110|DRUG|Ozurdex|Intravitreal injection
223615876|NCT03984110|DRUG|Eylea|Intravitreal injection
223615877|NCT04510714|DEVICE|Image guided percutaneous microwave ablation|Lung metastasis from sarcoma will be treated with microwave antennas (SOLERO) and Ablation System and microwave generators (Angiodynamics), with power settings of 35-45W and an average ablation time of 15 minutes (range 10-30 minutes). The ablation time will be recorded for all procedures. The manufacturer's recommendations will be observed in all cases, since it is assured that patients are able to tolerate the total ablation time.
223510009|NCT00893581|DRUG|Lithium and Placebo|Bipolar adolescents will be initiated on 100 mg per day of quetiapine (or placebo) and 30 mg/kg (maximum starting dose of 600 mg twice daily) of lithium carbonate (or placebo), depending on randomization assignment. Patients will be given placebo for the medication to which they were not assigned. Quetiapine will be adjusted based on tolerability and response to a target dose of 400-600 mg and lithium will be adjusted to a target dose based on achieving a serum level of 1.0-1.2 mEq/L.
223510010|NCT00893581|OTHER|Healthy Controls|Healthy control (patients given placebo -- sugar pill intended to mimic drug)
223615878|NCT00034775|DRUG|risperidone|
223615879|NCT06153134|DRUG|10% Curcuma xanthorriza Roxb.|Patients in experimental arms will receive 10% Curcuma xanthorriza Roxb. cream for 2 months
223615880|NCT06153134|DRUG|2% Kojic Acid|Patients in experimental arms will receive 2% Kojic Acid cream for 2 months
223615881|NCT05489848|DRUG|Paclitaxel|Paclitaxel: paclitaxel dose of 135\~175mg / m2, about 3 hours after the infusion, the use of pretreatment drugs before the infusion according to the drug instructions. Every 21 days is one session.
223615882|NCT05489848|DRUG|Carboplatin|Carboplatin: Doses were given at AUC=5 - 6 and used after paclitaxel. Based on the calculated amount, the maximum dose of carboplatin per chemotherapy does not exceed 750mg.
223615883|NCT05489848|DRUG|Cisplatin|Concurrent cisplatin intravenous chemotherapy on radiotherapy days 1 and 29,50mg / m2, a total of 2 times.
223615884|NCT05489848|RADIATION|EBRT|50.4Gy/28 / 6 weeks; common iliac node positive or paraaortic node positive plus extended field.The radiation extension field should include the entire pelvic cavity, the common iliac vessels and the paraaortic lymph node area.The range above the extension field is determined based on the clinical status, but at least 1-2cm above the renal vascular level.
223615885|NCT05489848|RADIATION|VBT|Subnormal vaginal mucosa was 0.5cm, 30Gy / 5times /5weeks.
223615886|NCT00602212|BEHAVIORAL|relaxation with virtual reality (VR)|VR relaxing environment and audio-visual mobile narratives will be used to teach patients how to relax themselves
223615887|NCT00602212|BEHAVIORAL|relaxation and biofeedback virtual reality|The patients experienced the same protocol described above, but with the biofeedback support. Specifically, in the sessions with the therapist, HR variations were used to modify specific features of the virtual environment:
223615888|NCT00025597|DRUG|carboplatin|
223615889|NCT00025597|DRUG|cyclophosphamide|
223615890|NCT00025597|DRUG|doxorubicin hydrochloride|
223615891|NCT00025597|DRUG|etoposide|
223615892|NCT00025597|DRUG|vincristine sulfate|
223615893|NCT00025597|PROCEDURE|conventional surgery|
223615894|NCT05588349|OTHER|Dry needling|Dry needling + stretching exercise
223615895|NCT05588349|OTHER|Stretching exercise|Stretching exercise only
223760873|NCT05098639|BEHAVIORAL|Deviance Regulation Theory (DRT)|The Deviance Regulation Intervention comprises tailored intervention messages based on perceived norms. Participants complete an initial session that focuses on perceived norms of protective behavioral strategy (PBS) use and heavy drinking among peers. The therapist engages participants in a tailored discussion based on their perceived norms. If individuals believe PBS use is uncommon, the therapist discusses the positive social image that PBS use portrays. If the participant believes PBS is common, the therapist engages the participant in discussion of the negative aspects of non-PBS use. A similar strategy is taken for common and uncommon heavy alcohol use. Finally, the participant carries a mobile device which provide real-time adaptive positive or negative messages (consistent with the initial session) based on the perceived drinking and PBS norms of their current drinking environment.
224202075|NCT00381667|DRUG|GW642444H|H salt
224202076|NCT00381667|OTHER|placebo|placebo
223615896|NCT00981097|GENETIC|polymerase chain reaction|determination of elevated serum FLC and clonal Ig detection rates in plasma and tumor
223615897|NCT00981097|OTHER|laboratory biomarker analysis|determination of elevated serum FLC and clonal Ig detection rates in plasma and tumor
223615898|NCT00867516|BIOLOGICAL|ALD518|Two doses of ALD518, each given in an infusion of normal saline, IV over 1 hour, at Weeks 1 and 8
223615899|NCT00867516|BIOLOGICAL|Infusion without ALD518'|250 cc Normal saline IV over one hour Weeks 1 and 8.
223510011|NCT04178863|DEVICE|CATS Tonometer|latanoprost vs. timolol
223510012|NCT04178863|DRUG|Latanoprost|latanoprost IOP reduction
223510013|NCT03092011|DRUG|Clonidine|Clonidine at 0.38 mcg/kg/dose every 3 hours or 0.5 mcg/kg/dose every 4 hours Clonidine dose will be increased by 25% of the previous dose if needed. It will be decreased by 10% of the highest dose using the original/birth weight (same amount each time) every 24 to 48 hours, provided the scores remain below 8.
223510014|NCT03092011|DRUG|Morphine Sulfate|Morphine at 0.03 mg/kg/dose every 3 hours or 0.04 mg/kg/dose every 4 hours Morphine dose will be increased by 25% of the previous dose if needed. It will be decreased by 10% of the highest dose using the original/birth weight (same amount each time) every 24 to 48 hours, provided the scores remain below 8.
223510015|NCT01654250|DRUG|NWP09|Methylphenidate, variable dose, daily dosing, 1 week duration
223510016|NCT01654250|DRUG|Placebo|Placebo
223510017|NCT05142644|PROCEDURE|ultrasound|An extra ultrasound performed during pregnancy
223510018|NCT01862029|DRUG|Roflumilast|Selective phosphodiesterase 4 (PDE4) inhibitor
223510019|NCT00660959|DRUG|lixivaptan|oral capsule
223510020|NCT00660959|DRUG|placebo|oral capsule
223615900|NCT05644314|DEVICE|The drug-eluting stent|Vertebral artery drug-eluting stents Maurora® was approved for marketing in 2020 and has been shown to be effective in reducing restenosis in clinical trials.
224202077|NCT06901713|OTHER|cognitive behaviour thearpy|Participants will access the CBT text materials through a dedicated platform
224202078|NCT06901713|OTHER|mindfulness|Participants will access the mindfulness audio via a compatible device
223510021|NCT01723839|DRUG|Fludarabine, Cyclophosphamide, Rituximab, Lenalidomide|19 subjects are treated in stage-1 with FCR plus 5mg lenalidomide increasing to 10mg and 15mg in subsequent cycles depending on toxicity.
223510022|NCT01534715|DRUG|IMGN529|
223510023|NCT03357172|BIOLOGICAL|Blood Sample|Additional blood sample before graft, D0, D7, D15, D21, D30, D60, D90, D180, Y1, Y2
223510024|NCT03357172|BIOLOGICAL|Bone marrow aspiration|Additional bone marrow aspiration before graft, D30, D90, Y1
223510025|NCT03357172|BIOLOGICAL|Blood sample|Before donation
223510026|NCT03357172|BIOLOGICAL|Allogeneic hematopoietic stem cell sample|Allogeneic hematopoietic stem cell sample
223510027|NCT03788928|DIAGNOSTIC_TEST|serum mitochondrial DNA|serum mitochondrial DNA will be measured using RT-PCR within first 72 hours of symptoms of acute pancreatitis
223510028|NCT04987450|DRUG|Methylprednisolone, prednisone|The patients receive intravenous pulses of methylprednisolone 20-30 mg/kg/day for three consecutive days followed by oral prednisone 0.8-1.0 mg/kg/day.
223510029|NCT03002857|DEVICE|LMA-C|LMA-C will be placed into the patients airway following anesthesia induction. The placement will be done as suggested in supine position with a standard gel pillow under patients head.
223510030|NCT03002857|DEVICE|Baska Mask|Baska Mask will be placed into the patients airway following anesthesia induction. The placement will be done as suggested in supine position with a standard gel pillow under patients head.
223510031|NCT03002857|DEVICE|I-gel|I-gel LMA placement will be done as suggested in supine position with a standard gel pillow under patients head.
223510032|NCT01265147|DRUG|Cisplatin|40mg/m2/w
223510033|NCT01265147|DRUG|Nedaplatin|40mg/m2/w
223510034|NCT02225795|OTHER|Hematopoietic stem cell transplantation|"Immuno-ablative regimen for HSCT:~Day Treatment~* 6 r-ATG 2 mg/kg~* 5 r-ATG3 2 mg/kg~* 4 r-ATG3 2 mg/kg~* 3 Cyclophosphamide with Mesna~* 2 Cyclophosphamide with Mesna~* 1 REST 0 PBSC infusion~  * 3 Cyclophosphamide with Mesna~ * 4 Cyclophosphamide with Mesna~ * 6 Start GCSF"
223510035|NCT05179005|DEVICE|RibFix Advantage|Intrathoracic rib fracture stabilization
223510036|NCT02500342|DRUG|Levothyroxine|The intervention will start with Levothyroxine 50 mcg daily (reduced to 25 mcg in subjects \<50 kg of body weight or if known coronary heart disease - previous myocardial infarction or symptoms of angina pectoris) vs. matching placebo; at 3 months, if the serum TSH level is \<0.4 mU/L, dose will be reduced by 25 mcg; TSH \>=0.4 and \<4.6 mU/L, no change to dose; TSH \>=4.6 mU/L, additional 25 mcg. The process will be repeated at 12 months, then annually; mock titration will be performed in the placebo group. The maximum possible dose of Levothyroxine which will be prescribed is 150 mcg (after 4 increments of 25 mcg at 3 months, 1, 2, 3 years; from the starting dose of 50 mcg).
223510037|NCT02500342|DRUG|Placebo|"Control patients will obtain a placebo pill of the same characteristics as the intervention drug, and mock titration will be carried out identically to the intervention drug.~Pharmaceutical composition of placebo (100 mg): Lactose monohydrate 66 mg, Maize starch 25 mg, Gelatin 5 mg, Croscarmellose sodium 3.5 mg, Magnesium stearate (vegetable source) 0.5 mg."
223510038|NCT03747263|PROCEDURE|Catheter ablation|Electrophysiology studies are performed during conscious sedation using boluses of midazolam and fentanyl and a continuous infusion of propofol. Vital parameters are continuously monitored. One 7F standard diagnostic catheter is positioned inside the coronary sinus (CS) via the femoral vein. One 8,5-F sheath is advanced to the left atrium (LA). After transseptal catheterization, intravenous heparin is administered to target an activated clotting time of ≥300 seconds. PV angiographies are obtained for each PV and PV recordings are registered at baseline in SR. The 8.5F transseptal sheath (TS) is changed over the wire for a 12F steerable TS.
224312365|NCT03756467|BEHAVIORAL|Girl Empower Program|Girl Empower (GE) encourages adolescent girls living in rural areas of Nimba County, Liberia to partake in weekly mentored community-based workshops on life skills, selfcare, and financial literacy.
223510039|NCT03486106|OTHER|Music|Music will be provided via Spotify, which is an Internet streaming music service, and will be played through headphones; this way, no other individual in the operating room will be distracted or influenced by the patient's music selection.
223510040|NCT03486106|OTHER|Headphones|All participants will receive noise-cancelling wireless headphones that they will wear in the operating room during the procedure.
223510041|NCT03486106|DRUG|Propofol|All participants will receive intravenous doses of propofol; the timing and frequency of the doses will be given when the patient indicates (by squeezing a rubber duckie) that he/she wants sedation medication.
223510042|NCT01031615|BEHAVIORAL|Child and Family Traumatic Stress Interv (CFTSI)|4 sessions involving both the target child and a parent/caregiver
223510043|NCT01031615|BEHAVIORAL|Psychoeducational Comparison|4 individually focused sessions including psychoeducation and relaxation.
223510044|NCT06353516|DRUG|Propofol|delivered via intravenous route
223510045|NCT06353516|DRUG|Sevoflurane|delivered via inhalation route
223510046|NCT04040855|OTHER|Medication review|Multi-professional medication review
223510047|NCT01534403|BIOLOGICAL|Epratuzumab|Epratuzumab 600 mg infusions delivered weekly for a total of 4 consecutive weeks (cumulative dose 2400 mg) over eight 12-week treatment cycles (ie, Weeks 0, 1, 2, 3, 12, 13, 14, 15, 24, 25, 26, 27, 36, 37, 38, 39, 48, 49, 50, 51, 60, 61, 62, 63, 72, 73, 74, 75, 84, 85, 86, and 87)
223510048|NCT01530256|BIOLOGICAL|ALD518|160 mg IV q 4 weeks for 4 doses
223510049|NCT01530256|BIOLOGICAL|ALD518|320 mg IV q 4 weeks for 4 doses
223510050|NCT01530256|BIOLOGICAL|ALD518|640 mg IV q 4 weeks for 2 doses
223510051|NCT00946036|DRUG|Sertraline Hydrochloride|
223510052|NCT01528774|OTHER|Blood Draw|Approximately 40 cc of blood will be drawn from participants at a time when they are having blood drawn for routine or treatment-related purposes. Sequential samples may be obtained in the same manner from selected patients to allow exploration of potential correlation of CTC with response to treatment, progression-free survival and overall survival.
223510053|NCT02596984|DRUG|Caspofungin|Either preemptive, empirical or curative prescription of Caspofungin by one of the ICUs' attending physician. Caspofungin will be administered according to the international recommendation
224312366|NCT03654469|OTHER|questionnaires and electronic mini-spirometry|prospective screening study based on questionnaires and electronic mini-spirometry (Néo-6(®)) that includes a representative sample of dairy farmers from the departments of Morbihan and Île-et-Vilaine in Brittany
224312367|NCT02368574|PROCEDURE|Class II hysterectomy|Class II hysterectomy
223510054|NCT06039800|OTHER|No intervention|No intervention
223510055|NCT04919551|DRUG|vicagrel|Oral administration after fasting/high-fat meal/low-fat meal
223615901|NCT01848158|DEVICE|acupuncture|Patients randomized to active treatment will receive acupuncture treatment with press needles (small acupuncture needles manufactured with attached bandage that makes the needle flush with skin) at sites GV 24.5 or GV20, Ht 7 or Ht 3, Ki 3, Lr 3, LI 4 or LI 11, Lu 7 or Lu 5, Sp6, ST 36, using up to 15 points per patient three days per week for the duration of mechanical ventilation (maximum of 14 calendar days from the time of the first acupuncture treatment). We will also apply a seed magnet at ear shen men position for 4 hours on treatment days.
223615902|NCT01848158|DEVICE|sham acupuncture|Patients randomized to sham treatment will receive sham acupuncture with similarly appearing bandages placed without press needles attached at sites GV 24.5 or GV20, Ht 7 or Ht 3, Ki 3, Lr 3, LI 4 or LI 11, Lu 7 or Lu 5, Sp6, ST 36, using up to 15 points per patient three days per week for the duration of mechanical ventilation (maximum of 14 calendar days from the time of the first acupuncture treatment). We will also apply a similarly appearing bandage without seed magnet underneath at ear shen men position for 4 hours on treatment days.
224202079|NCT06446973|OTHER|35 patients with meniscus tear|Have meniscus pathologies in one or both knees confirmed by MRI.
223510056|NCT00370136|DRUG|ultrasound contrast|
223510057|NCT03690999|DIETARY_SUPPLEMENT|Placebo|Placebo product
223510058|NCT03690999|DIETARY_SUPPLEMENT|Prebiotic supplement|Prebiotic supplement
223510059|NCT02004275|DRUG|pomalidomide|given PO
223510060|NCT02004275|DRUG|ixazomib|given PO
223510061|NCT02004275|DRUG|dexamethasone|given PO
223510062|NCT03908008|DRUG|Botox (Botulinum toxin type A)|20U of the investigational drug will be intramuscularly injected to 5 sites of the glabella line. Treatment will be conducted just once in visit 2.
223510063|NCT03908008|DRUG|MT10107 (Botulinum toxin type A)|20U of the investigational drug will be intramuscularly injected to 5 sites of the glabella line. Treatment will be conducted just once in visit 2.
223510064|NCT00841074|DRUG|chlorhexidine|0.12% chlorhexidine mouthwash spray, \~1.3 ml, twice a day.
223510065|NCT00841074|DRUG|Placebo mouthwash|Placebo mouthwash spray application of \~1.3 ml twice a day.
223510066|NCT04356001|PROCEDURE|Socket preservation|'One-Piece' autologous tuberosity graft combining hard and soft tissue, harvested from the maxillary tuberosity, placed in extraction sockets.
223510067|NCT05257161|DEVICE|Emboshield NAV6™|Embolic Protection System for Carotid Artery Revascularization ( distal - filter) + stent CGuardTM™
223510068|NCT05257161|DEVICE|Mo.Ma™|Embolic Protection System for Carotid Artery Revascularization ( proximal - occlusion) + stent CGuardTM™
223510069|NCT03899597|DRUG|Oxytocin|The intervention group (ARTCON) will receive the standard assignment for the elective caesarean section, but at least one hour before surgery oxytocin exposure will be performed with cardiotocographic (CTG) monitoring and obstetrical supervision.
223510070|NCT03899597|OTHER|Normal saline|The control group (SA) will receive the standard assignment for the elective caesarean section, but at least one hour before surgery placebo exposure will be performed with cardiotocographic (CTG) monitoring and obstetrical supervision.
223510071|NCT05130957|OTHER|Massage Application with clove oil|The experimental group is given a massage with clove oil,
223510072|NCT05130957|OTHER|Massage Application without any oil|The control group is given a massage without any oil as a standard midwifery care.
223510073|NCT00752362|DEVICE|Milennium Matrix® (Control)|Percutaneous coronary intervention with bare metal stent
223510074|NCT00752362|DEVICE|Infinnium®|Percutaneous coronary intervention with paclitaxel-eluting stent
223510075|NCT00752362|DEVICE|Supralimus®|Percutaneous coronary intervention with sirolimus-eluting stent
223510076|NCT00782379|DRUG|busulfan|110 mg/m2 infused over 3 hours once daily on 4 consecutive days (Days -7, -6, -5, -4)
223510077|NCT00782379|DRUG|cyclophosphamide|14.5 mg/kg infused over 1-2 hours once daily on 2 consecutive days (days -3,-2).
223510078|NCT00782379|DRUG|fludarabine phosphate|30mg/m2 infused over 30 minutes once daily on three consecutive days (days -5, -4, -3)
223510079|NCT00782379|DRUG|mycophenolate mofetil|15 mg/kg po three times a daily with a maximum dose of 3gm/day starting D+5. To be discontinued on Day +35 in the absence of clinically significant GVHD.
223510080|NCT00782379|DRUG|tacrolimus|0.03 mg/kg/day infuse over 24 hours starting on day +5 (adjusted to maintain trough level of 5-15 ng/ml). Switch to oral (twice daily divided dose) on day +21 or when able to tolerate PO. Discontinue on day +180 in the absence of clinically significant GVHD.
223510081|NCT00782379|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Patients to received unmanipulated PBSCs on Day 0
223510082|NCT00782379|PROCEDURE|peripheral blood stem cell transplantation|patients to receive unmanipulated PBSCs on day 0
223510083|NCT01901757|DRUG|HCP1201, Fasted followed by fed|There are 2 administration periods with 7 days of wash-out. In period 1, the subjects will receive a single oral dose of HCP1201 under fasted condition. In period 2, the subjects will receive a single oral dose of HCP1201 under fed condition.
223510084|NCT01901757|DRUG|HCP1201, Fed followed by fasted|There are 2 administration periods with 7 days of wash-out. In period 1, the subjects will receive a single oral dose of HCP1201 under fed condition. In period 2, the subjects will receive a single oral dose of HCP1201 under fasted condition.
223510085|NCT00151463|DRUG|sildenafil citrate|
223510086|NCT04343768|DRUG|Hydroxychloroquine|This Drug will be used in all arms.
223510087|NCT04343768|DRUG|Lopinavir / Ritonavir|This Drug will be used in all arms.
223510088|NCT04343768|DRUG|Interferon Beta-1A|This drug will be only used in Arm 1.
223510089|NCT04343768|DRUG|Interferon Beta-1B|This drug will be only used in Arm 2.
224202080|NCT06034067|PROCEDURE|Osseodensification osteotomy preparation|The implant site will be prepared by raising a mucoperiosteal flap. Implant osteotomy will be prepared by using osseodensification technique using Versah burs and a dental implant will be placed. The flaps will then be replaced and sutured with 4/0 polyglycolic acid interrupted and mattress sutures.
224202081|NCT06034067|PROCEDURE|Standardized osteotomy preparation|The implant site will be prepared by raising a mucoperiosteal flap. Implant osteotomy will be prepared by using either conventional surgical drills provided by Straumann implant systems and a dental implant will be placed. The flaps will then be replaced and sutured with 4/0 polyglycolic acid interrupted and mattress sutures.
223760874|NCT02961907|PROCEDURE|PEPCI|"Both parents will receive:~* consultation with a psychiatrist then psychologist follow-up if required, addiction specialist physician consultation then liaison nurse follow-up if required~* endocrinologist consultation then dietitian follow-up if required~* actiphysician consultation and follow-up if required This program will be added to the usual routine course Both parents will receive a 3 months personalized follow-up if required from the multi disciplinary consultation and before the first ART attempt."
223760875|NCT03906669|DRUG|Letrozole|PO daily for 14 days
224202082|NCT06322355|DIAGNOSTIC_TEST|Coronary angiography, Fractional Flow Reserve measurement, Intravascular ultrasound|Invasive CAG was conducted following standard clinical procedures, encompassing multiple projections of both the left and right coronary arteries. The FFR was precisely measured using either an intracoronary pressure wire (Pressure Wire X; Abbott Vascular, Santa Clara, USA) or a rapid-exchange pressure microcatheter (Insight Lifetech, Shanghai, China) during peak hyperemia. This state of maximal hyperemia was achieved through the intravenous infusion of adenosine triphosphate (ATP) at a concentration of 150 μg/kg/min, administered via the forearm vein. Upon completion of the FFR assessment, the pressure wire or microcatheter was carefully retracted to the tip of the guiding catheter for a routine drift check. IVUS imaging was meticulously conducted using the iLab™ IVUS system, coupled with a 40-MHz OptiCross IVUS catheter (Boston Scientific, Fremont, USA), at a steady pullback speed of 0.5 mm/s.
224202083|NCT06935149|DRUG|18-PSMA|Intravenous push 4 MBq/kg per patient (for a 70 kg patient, 280 MBq of \[18F\]FPSMA needs to be intravenously injected), and the maximum dose cannot exceed 400 MBq. After the injection of \[18F\]FPSMA, intravenous flushing was performed with 20 ml of normal saline.
224202084|NCT06936540|OTHER|Virtual Tour|The intervention group will be trained by the researcher with a virtual tour material about surgical environments via a tablet computer.
224202085|NCT06936540|OTHER|No Interventions|The control group will not receive any intervention other than verbal training in the routine of the organization.
224202086|NCT06932588|DIAGNOSTIC_TEST|Biomarker Testing using the Alinity Whole-blood TBI biomarker i-STAT|"The i-STAT TBI cartridge is a point-of-care, whole-blood, biomarker-based assay that measures the level of biomarkers associated with brain injury in the bloodstream 24 hours after injury. Blood samples (5-10cc of whole blood) will be collected upon admission during a routine blood draw in the ED. These samples will be tested using the iSTAT system for mild TBI biomarkers.~In a subset of admitted patients, serial blood draws and iSTAT testing will be performed at 4, 8, 16, and 24 hours, depending on the patient's length of stay."
224202087|NCT05816213|DEVICE|Portable low-field MRI|"Three FDA-approved low-field (LF) portable MRI commercialized by Hyperfine Research Inc. (www.hyperfine.io) will be employed. Patients will undergo LF-MRI in the CT suite during the downtime of preparation which usually occurs after urgent imaging in the CT suite (mean time, as calculated basing on the current door to imaging time: \~20-25 minutes), thus not delaying the conventional diagnostic processes and treatment administration. LF-MRI will be also repeated by the study staff at predefined time-points: 24 h, 72 h, at the discharge and 4 weeks after the event.~A prespecified acquisition of Fast-Spin Echo (Fast-SE) essential stroke sequences will be performed, starting with diffusion weighted imaging (DWI) + apparent diffusion coefficient (ADC) mapping and fluid attenuated inversion recovery (FLAIR)."
224202088|NCT06942624|BIOLOGICAL|Phage Therapy|Our phage is an investigational treatment for bacterial infections. Our lytic phage preparation was provided by Cytophage Technologies (CIP-200).
224202089|NCT06942325|DEVICE|OTC self-fitting hearing aid|OTC hearing aid to be compared to prescription hearing aid
224202090|NCT06942325|DEVICE|Prescription hearing aid|Prescription hearing aid used as active comparator to the OTC self-fitting hearing aid
224202091|NCT06942117|OTHER|Experimental|Approximately 280 grams of caffeine containing coffee will be given
224202092|NCT06942117|OTHER|Placebo|Decaffeinated coffee will be given.
224202093|NCT06943170|OTHER|Aerobic Exercise and Low Calorie Diet|Group A: Aerobic Exercise with Low calorie diet Group B: Aerobic Exercise without Low Calorie Diet
224312368|NCT02636192|DRUG|No Intervention|This is an observational study and participants did not receive any intervention in this study.
223510090|NCT04714177|DRUG|Edaravone Dexborneol|Edaravone Dexborneol 37.5 mg, containing Edaravone 30 mg and Dexborneol 7.5 mg, Edaravone Dexborneol 37.5 mg BID, 14 days, addition to standard of care of Intracerebral Hemorrhage
223760876|NCT03906669|DRUG|Letrozole and Prometrium|PO daily for 14 days
223760877|NCT03906669|DRUG|Tamoxifen and Prometrium|PO daily for 14 days
223760878|NCT04240899|OTHER|Tele-yoga|Subjects will undergo 30-minute yoga sessions delivered remotely 2-3 times/week for 6-weeks. The yoga sessions will be delivered one-on-one and will include 5-7 minutes of breathing exercises 15-20 minutes of postures, and 5-7 minutes of relaxation and meditation exercises.
223760879|NCT00006219|DRUG|clarithromycin|
223760880|NCT00006219|DRUG|prasterone|
223760881|NCT06153446|DIAGNOSTIC_TEST|Synovasure® Comprehensive Infection Panel|The Synovasure Comprehensive PJI Test Panel (PJI Panel) is a laboratory-developed test (LDT) panel (CD Laboratories, CLIA Registration No.: 21D0216863) intended to aid the diagnosis of PJI.
223760882|NCT04828655|BEHAVIORAL|Use of a mobile application based on machine learning with the aim of improving health and body composition parameters.|Specific diet program and moderate physical activity, all guided and mediated by a mobile application. As well as the recording and monitoring of periodic evaluations of health indicators.
223760883|NCT04541875|OTHER|MAR-Scale|The MAR-Scale is a 20-item questionnaire based on commonly reported reasons for non-adherence to medications.
223760884|NCT00463060|DRUG|sunitinib malate (Sutent)|Sutent administered PO QD from days 1 to 28 Two weeks after completion of any chemotherapy, maintenance Sutent in 6 week cycles (consisting of Sutent 50 mg PO QD weeks 1-4 followed by no treatment weeks 5-6) until progression or death If no chemotherapy is planned, maintenance Sutent (as described above) will start on day 43.
223760885|NCT00463060|PROCEDURE|radiotherapy|Radiation is to be delivered to each site over 10 fractions separated by at least 16 hours. Up to 5 sites may be treated
223510091|NCT04714177|DRUG|Placebo|Edaravone Dexborneol matching injection, addition to standard of care of Intracerebral Hemorrhage
223510092|NCT00780598|DRUG|Tosedostat|"In Part A, approximately 70 subjects will be randomized to one of 2 dose regimens of tosedostat which will be administered orally, once daily. The dose regimens of tosedostat will be:~* 120 mg for 6 months once daily, OR~* 240 mg (induction dose) once daily for 2 months, followed by 120 mg(maintenance dose) for 4 months~In Part B a further 130 subjects will receive the dose regimen of tosedostat identified in Part A as being appropriate, based on the interim analysis during Part A."
223510093|NCT03177070|DRUG|Methylene Blue|As described above. Intravenous injection with visualisation via fluorescence enabled laparoscope.
223510094|NCT04105257|DIAGNOSTIC_TEST|All patients|Comparison of the results of the CTP with MRI
223510095|NCT03146793|DRUG|Sodium Thiosulfate|25g intravenously 3 times per week
223510096|NCT04658680|DRUG|BCG vaccination at first health facility contact|"Intradermal injection at first health facility contact: 0.05 ml dose Mycobacterium bovis BCG live attenuated vaccine in the left deltoid region.~The strain supplied by the national vaccination programme is provided through UNICEF. Different strains are used interchangeably. The additional BCG vaccines provided through this study will be procured by the Bandim Health Project. Vaccines will be from the WHO list of prequalified vaccines and the same strain will be used in intervention and control health centres."
223510097|NCT02595437|DRUG|Triferic|
223510098|NCT04477512|DRUG|Cabozantinib|Supplied by Exelixis
223510099|NCT04477512|DRUG|Nivolumab|Supplied by Bristol-Myers Squibb
223510100|NCT04477512|DRUG|Abiraterone acetate|Commercially available
223510101|NCT04477512|DRUG|Prednisone|Commercially available
223510102|NCT04477512|PROCEDURE|Peripheral blood collection|Prior to start of treatment, after 8 weeks of combination therapy, with every subsequent imaging (every 12 weeks), end of treatment
223510103|NCT02758080|OTHER|Matching on the basis of molecular analysis|
223510104|NCT02758080|OTHER|Matching on the basis of physician's choice|
223510105|NCT04238182|OTHER|wet cupping|This smoker group will receive single wet cupping session. The first site is between the two scapulae (interscapular), opposite the T1-T3 scapular spine. This area is called Al-Kahil in Arabic. The second site is located on the spinous process of seventh cervical vertebra and it is called GV14 in Chinese medicine. The third site is BL-17 (Ge Shu Diaphragm Shu) is located 1.5 cun lateral to the lower border of the spinous process of the seventh thoracic vertebra (T7). BL 17 can directly act on the septum transversum of diaphragm . Cupping of BL 17 will be done bilaterally.
223615903|NCT04589858|OTHER|Supervised exercise protocol|Strengthening exercises:It included a sets/group of exercises such as a static quad set in knee extension, standing terminal knee extension, seated leg-press, partial squats weight-lessened with arm support as needed, and step-ups Stretching Exercises:A slow, sustained stretching was performed in different positions for different group of muscles with holding time 30-seconds, a gap of 1-minute between two repetitions, and repeated 3-times per session on alternate day for 2-weeks. The stretching performed for the calf muscle, hamstring muscle, and quadriceps femoris muscle in standing, supine, and prone positions respectively.
223615904|NCT04589858|OTHER|Specified Manual Therapies|"Myofascial Mobilization: Patellar glide performed in all available ROM and direction such as superior-inferior and lateral-medial translation/glides of patella over patellar fossa.~Myofascial manipulation technique: Manipulation of knee joint. An impulse type thrust was delivered, directed in the caudal direction to mobilize the joint in a near-full extension position."
223615905|NCT03880539|DRUG|bezlotoxumab|Adding BEZLO to SOC oral VAN pulse/taper
223615906|NCT03880539|DRUG|Vancomycin Oral|SOC vancomycin pulse/taper
223615907|NCT02539797|DEVICE|tDCS|comparing anodal, cathodal, and sham tDCS
223615908|NCT02762695|OTHER|Case Management|"A model of health care for chronic patients, based on Case Management and guided by a nurse which targets the patient´s risk.~The core elements of this strategy are: a. processes to identify specific population and their risk; b. evidence-based practice guidelines according to risk (higher risk, more interventions and monitoring by a nurse, lower risk, higher emphasis on self-care); c. Practice models based on collaboration between health team members leaded by a nurse; d. self-management education for patients; e. monitoring patients face to face or by telephone to ensure to follow the care program (blood test, medical consultation, for example); e. measurement of process and outcomes."
223615909|NCT02762695|OTHER|Usual Care|Usual Care at Primary Health Care Center
223615910|NCT05651100|BIOLOGICAL|CD19 and CD22 targeted CAR-T cells|CAR-T cells were manufactured from peripheral blood mononuclear cells collected by leukapheresis and frozen for multiple uses. Before each CAR T-cell infusion (day 0), patients received lymphodepleting chemotherapy composing of Fludarabine (30 mg/m2/day) and Cyclophosphamide (300 mg/m2/day) on days -5 to -3. No bridging chemotherapy was given between enrollment and infusion. In sequential CAR-T clinical trials, CAR-T cells will be given.（anti-CD19 CAR-T first, then anti-CD22 CAR-T).
223615911|NCT02335619|BEHAVIORAL|Early palliative care|
223615912|NCT02495129|DRUG|VAY736 lower dose|Patients will receive a total number of 3 monthly subcutaneous injections with the lower dose of VAY736
223615913|NCT02495129|DRUG|VAY736 higher dose|Patients will receive a total number of 3 monthly subcutaneous injections with the higher dose of VAY736
223615914|NCT01775644|DRUG|Bevacizumab|Administration of treatment will be as used in normal daily routine under local labeling.
223510106|NCT04238182|OTHER|dry cupping|The smoker group will receive single dry cupping session. The first site is between the two scapulae (interscapular), opposite the T1-T3 scapular spine. This area is called Al-Kahil in Arabic. The second site is located on the spinous process of seventh cervical vertebra and it is called GV14 in Chinese medicine. The third site is BL-17 (Ge Shu Diaphragm Shu) is located 1.5 cun lateral to the lower border of the spinous process of the seventh thoracic vertebra (T7). BL 17 can directly act on the septum transversum of diaphragm. Cupping of BL 17 will be done bilaterally.
223510107|NCT01183182|DEVICE|ActiSight Needle Guidance System|Three different groups of patients defined per lesion size
223510108|NCT04226105|DRUG|GP40081|1 ml of the GP40081 contains 100 units soluble insulin aspart/protamine-crystallised insulin aspart in the ratio 30/70. Insulin aspart 30 mix is self-administered drug by SC injection 1-3 times per day before meal intake.
223615915|NCT01139814|DEVICE|Amigo catheter robot|The Amigo Catheter System is intended to facilitate manipulation, positioning and control of a Diagnostic Catheter.
223615916|NCT05091658|DEVICE|LH Urine Test|Test for qualitative detection of LH in urine
223760886|NCT01595360|DRUG|Placebo|It is applied directly to the bleeding site after tooth extraction
223615917|NCT03798717|DIAGNOSTIC_TEST|Heating|Warm water immersion
223615918|NCT00942903|DEVICE|Provox Xtra HME|Heat and Moisture Exchanger for pulmonary Rehabilitation after total laryngectomy
223615919|NCT04002960|DEVICE|INVSENSOR00036|Noninvasive regional oximeter
223615920|NCT02529540|OTHER|Adjustable glasses|The glasses will be used for refraction and wearing within professional instructions.
223615921|NCT02529540|OTHER|Custom standard glasses|The custom standard glasses are made by the traditional standards after refraction.
223615922|NCT02529540|OTHER|Ready-made glasses|The glasses have been made already before the refraction in the hospital. And they will be chosen by prescription after refraction.
223760887|NCT01595360|DRUG|TT-173|It is applied directly to the bleeding site after tooth extraction
223615923|NCT01250106|DIETARY_SUPPLEMENT|Lactobacillus reuteri|twice daily
223615924|NCT03958175|OTHER|Alouette test (reading test)|The alouette test was assessed at a fixed distance of 40 centimeters on a fixed surface to avoid errors related to hand tremors.
223615925|NCT06274463|BEHAVIORAL|Exercise therapy including a trunk stabilization exercise program|All patients will undergo 30 sessions of exercise therapy, including a trunk stability exercise program, for 30 minutes per day, 5 days a week for 6 weeks
223615926|NCT00379665|DRUG|Cisplatin|1 mg/ml at a dosage of approximately 2 mg per cubic cm of tumor. Weekly up to 6 injections.
223615927|NCT02962258|DRUG|Torrent's Olmesartaan medoxomil, Amlodipine and Hydrochlorothiazide Tablets|oral, crossover
223615928|NCT02962258|DRUG|Tribenzor of Daichi Sankyo Inc. USA|oral, crossover
223760888|NCT00347152|DRUG|Divalproex|Divalproex, 8-20% taper
223760889|NCT00347152|DRUG|Divalproex|Divalproex, 8-20% taper
223760890|NCT02093572|OTHER|3 standard meals/day|
223615929|NCT00515151|DRUG|0.1% Octenidine with 30% 1-propanol and 45% 2-propanol|Before insertion of the catheter, the entry site was disinfected with the assigned solution over an area of \>200 cm² for at least one minute. The assigned solution was then applied for care of the entry site during the change of dressings, usually every 2 to 3 days.
223615930|NCT00515151|DRUG|74% Ethanol with 10% 2-propanol|Before insertion of the catheter, the entry site was disinfected with the assigned solution over an area of \>200 cm² for at least one minute. The assigned solution was then applied for care of the entry site during the change of dressings, usually every 2 to 3 days.
223615931|NCT04147689|DEVICE|DESIRIAL® PLUS|"DESIRIAL® PLUS is a cross-linked hyaluronic acid gel to restore volume by filling the labia majora, to rehydrate and to add tone and tension to the area of connective tissue.~The baseline injection is performed at V1, with a maximum volume to be injected per labium of 2 ml. The exact volume will be determined by the physician in order to reach optimal volume correction.~One optional touch-up injection of DESIRIAL® PLUS is allowed at V2 (4 weeks after Baseline), with a maximum volume to be injected per labium of 1 ml. No other touch-up injections are allowed until the end of the study."
223615932|NCT06112574|BEHAVIORAL|Visuomotor force control training|Single-task training involves visuomotor finger force tracking and dual-task has an additional cognitive components including visual distraction and working memory.
223760891|NCT02093572|OTHER|2 meals/day (omit breakfast)|
223760892|NCT04989049|DRUG|Folic Acid 5 MG|folic acid tablet of 5mg will be placed on the ulcers 2 times per day for 7 days
223760893|NCT04989049|OTHER|placebo|an inactive drug looking exactly like active drug will be given, patients will be asked to put it on ulcers 2 times per day
223760894|NCT04338711|DRUG|tofacitinib modified release (MR)|"Single oral 10 mg multi particulate dose of dose of tofacitinib MR with different levels of enteric coating (MR E1, MR E2, and MR E3) in the fasted state. Additionally, the lowest and highest enteric coating levels will also be evaluated in the fed state.~Treatment F: a 10 mg oral dose of tofacitinib IR solution"
223760895|NCT03374826|DIAGNOSTIC_TEST|Dedicated axillary hybrid PET-MRI|All clinically node negative patients will undergo a hybrid PET-MRI axilla preoperatively, followed by breast surgery and SLNB.
223615933|NCT01649895|DRUG|D-Cycloserine|Predicted to enhance the effects of exposure in internet-based cognitive-behaviour therapy
223615934|NCT01649895|DRUG|Placebo|Placebo pills as adjunct to internet-based cognitive-behaviour therapy
223615935|NCT01804478|BEHAVIORAL|Mild pneumatic compression|
223760896|NCT03160963|OTHER|Power Testing|Chair stand, vertical jump, computerized squat
224202094|NCT06941675|OTHER|Hybrid Closed-Loop Artificial Pancreas System|Hybrid Closed-Loop Artificial Pancreas System Group: Uses an open-source system with Novo Nordisk ultra-rapid-acting insulin (approval: J20050097, 3 mL: 300 U). Daily insulin dose calculated at 0.3-0.6 U/(kg\*d) based on weight; system auto-adjusts basal rate. Physicians prescribe bolus doses, entered by nurses via AAPS software. Glucose correction uses CGM + 4 daily capillary tests (fasting, 2h post-meal). AAPS features hypoglycemia prediction suspend (pauses basal if glucose ≤4.4 mmol/L, resumes upon recovery) and alarms (\<3.9 mmol/L, ensures nighttime alert).
224202095|NCT06943326|OTHER|nutrition monitoring|There is no investigator intervention in the study. Patients' nutrition is recorded for one week from the beginning of the study.
223615936|NCT01609348|DRUG|Placebo|Capsule matching active drug to be taken once a day for 12 weeks
223615937|NCT01609348|DRUG|Venlafaxine|225 mg daily for 12 weeks
223615938|NCT01879917|DRUG|Liraglutide|
223615939|NCT01879917|DRUG|Placebo|Saline
223760897|NCT03337633|BEHAVIORAL|Menu design|Participants were given 5 minutes to order a hypothetical meal from the assigned test menu by circling all items they wanted to order.
223760898|NCT01236196|BEHAVIORAL|Telephone cognitive behavior therapy|Cognitive behavior therapy aimed at teaching pain coping skills was conducted by telephone (12 sessions over a 6-month period).
223760899|NCT01236196|BEHAVIORAL|Telephone pain education|Participants received information on the management of chronic pain during 12 telephone sessions conducted over a 6-month period).
223760900|NCT01802775|DRUG|edoxaban|
223760901|NCT01802775|DRUG|Clopidogrel|75mg tablet
223760902|NCT01802775|DRUG|Aspirin|
223615940|NCT01799707|BEHAVIORAL|vision restoration training|visual stimuli repetitively presented to stimulate areas of residual vision. The training consists of luminance increment stimuli similar to perimetry and the task isa simple detection task (pressing a key whenever a target stimulus was detected).
223615941|NCT01799707|BEHAVIORAL|Discrimination Training|the stimulus is a line segment (bar) which is always presented within the central ±5° visual field in one of four possible random orientations: horizontal, vertical, oblique to the right or oblique to the left. If the patient has visual field defects in this central area, 80% of the stimuli are presented in the intact part of the training region. The task is to identify the orientation of the line segment and press, as fast as possible, one of 4 assigned buttons on the keyboard.
223760903|NCT00386256|DEVICE|Health Buddy, Home telehealth technology|Exercise questions, educational messages, and clinical reminders have been programmed into the home telehealth technology and are administered daily via the Health Buddy(R) to evaluate the program's feasibility based on adherence rates, program completion rates, and safety.
223760904|NCT00386256|OTHER|Telephone counseling|
223760905|NCT05429450|DRUG|Methotrexate|Three periocular injections of methotrexate at week 0, week 3 and week 6.
223760906|NCT05429450|DRUG|Triamcinolone Acetonide|Three periocular injections of triamcinolone acetonide at week 0, week 3 and week 6.
223760907|NCT03438435|DRUG|QRH-882260 Heptapeptide|Imaging agent
223760908|NCT01375218|OTHER|Pavlik Brace|Pavlik Brace
224202096|NCT06941688|DRUG|Decitabine with GemOx|Each treatment cycle consists of 3 weeks, and a total of 6 cycles will be administered. The drugs will be administered sequentially in the following order: decitabine, gemcitabine, and oxaliplatin. Decitabine will be administered at a dose of 7.5 mg/m² on days 1 to 5; gemcitabine at 1000 mg/m² on days 1 and 8; and oxaliplatin at 100 mg/m² on day 1 of each cycle.
223615942|NCT03410628|DEVICE|gammaCore|Non-invasive vagal nerve stimulator
223615943|NCT02942212|BEHAVIORAL|Questionnaire|Participants complete a computerized questionnaire to assess demographics and smoking history.
223510109|NCT04226105|DRUG|NovoMix 30|1 ml of the NovoMix 30 contains 100 units soluble insulin aspart/protamine-crystallised insulin aspart in the ratio 30/70. Insulin aspart 30 mix is self-administered drug by SC injection 1-3 times per day before meal intake.
223615944|NCT02942212|BEHAVIORAL|In-Depth Interviews|Participants take part in individual in-depth interviews discussing smoking history, attempts to quit, and suggestions for smoking cessation program. The interview should last 30-45 minutes and is audio-recorded.
223615945|NCT02942212|OTHER|Breath Test|Participants complete a breath test to assess the amount of cigarette smoke inhaled at baseline, weekly during study, and at 3 month follow up.
223615946|NCT02942212|DRUG|Nicotine Patches|Participants receive a 6-week supply of nicotine patches and instructions on how to use them. Patch therapy for participants who smoke \>10 cigarettes/day consists of 4 weeks of 21 mg patches, 1 week of 14 mg patches, and 1 week of 7 mg patches. Patch therapy for participants who smoke 5-10 cigarettes/day consists of 4 weeks of 14 mg patches and 2 weeks of 7 mg patches.
223615947|NCT02942212|BEHAVIORAL|Advice plus Phone Counseling|Participants receive brief advice to quit smoking, as well as phone counseling for support in quitting smoking (5 sessions over the course of 6 weeks) with a counselor at the Texas Quitline.
223615948|NCT02942212|BEHAVIORAL|Advice plus Counseling Sessions|Participants receive brief advice to quit smoking, as well as 5 individual, in-person smoking cessation treatment counseling sessions.
223760909|NCT01375218|OTHER|Plastizote Brace|Plastizote Brace
223760910|NCT02994342|DEVICE|Vaginal gel, Medical Device Class 2A|Application twice a day of vaginal gel for 56 consecutive days
223760911|NCT04935151|PROCEDURE|holmium laser enucleation of the prostate|cystoscopic transurethral enucleation of the prostate using Holmium laser
223760912|NCT04935151|PROCEDURE|Bipolar resection of the prostate|cystoscopic transurethral resection of the prostate using bipolar energy
224202097|NCT06941688|DRUG|GemOx|Each treatment cycle spans 3 weeks, with a total of 6 cycles planned. Gemcitabine will be administered at a dose of 1000 mg/m² on days 1 and 8, and oxaliplatin at 100 mg/m² on day 1 of each cycle.
223510110|NCT00676637|DRUG|Travoprost 0.004%/timolol 0.05% fixed combination eye drops (DuoTrav)|One drop in study eye(s) once daily in the evening for four months
223510111|NCT00676637|DEVICE|Travalert Dosing Aid|Approved device used with DuoTrav and intended to provide an objective system for quantifying dosing and improving patient adherence
223510112|NCT01531803|DRUG|Kedbumin 25%|"Albumin (Human) 25% solution for intravenous (IV) infusion in the dosage strength of 250g human albumin /L, supplied in 50 mL type II vial (each vial containing 12.5g human albumin).~The dose will be 0.5 to 1g/kg body weight (2 to 4 mL/kg of 25% albumin)."
223510113|NCT01531803|DRUG|Normal Saline Solution|Normal (0.9%) saline solution administered via IV infusions of 10 to 20 mL/kg as appropriate per standard of care based on the subject's clinical status and response to treatment.
223510114|NCT04403893|OTHER|HANARO biliary stent placement|HANARO biliary stent placement
223510115|NCT05914259|OTHER|No Intervention|Following the manner of observational study, no intervention will be provided in the study.
223510116|NCT00538278|OTHER|Database|database
223510117|NCT02898675|DEVICE|Platelet rich fibrine|Platelet rich fibrin increases the growth factors. So it was applied for treatment of periodontal bone loss.
223510118|NCT02898675|DEVICE|Open Flap Debridement|Only open flap debridement treatment the bone loss limitedly
223760913|NCT04199429|BEHAVIORAL|Relationship-Based Care|
223760914|NCT04226716|BEHAVIORAL|Assessment of postural control, body perception, psychosocial factors and inflammation|Behavioral assessment of postural control, lumbar proprioceptive use during postural control, back-specific body perception, psychosocial factors (incl. perceived harmfulness of daily activities, pain-related fear of movement, fear-avoidance beliefs, (pregnancy-related) depression, anxiety and stress, optimism/pessimism, pain coping and coping with stressful life events) and inflammatory mediators
223760915|NCT03641573|DRUG|[14C] ASN002|\[14C\] ASN002
223760916|NCT00774098|DRUG|dextrose 10% (D10W ®) infusion|Started at 8pm the day before surgery until the procedure begins
223760917|NCT00774098|DRUG|hyperinsulinemic normoglycemic clamp|Started as the procedure begins, decreased at the end of the procedure and continued until 16 hours postoperatively
223760918|NCT00774098|DIETARY_SUPPLEMENT|high calorie diet 35 kcal/kg|High Calorie meals start the day before the surgery and are given 5 hours apart. The last meal is given at 7 pm the day before surgery
223615949|NCT02942212|BEHAVIORAL|Self Assessment Questionnaires|Participants complete self assessment questionnaires the week before quitting smoking, the day that they quit, and 1, 2, and 4 weeks after quitting, and at 3 month follow up.
223615950|NCT04333914|DRUG|Autophagy inhibitor (GNS651)|Cohort 1 (arm B): 200mg q.d. orally for 10 consecutive days. If for any reason a treatment is not given within the allowed treatment window (± 12h) it will be cancelled (i.e., missed for that time point), and treatment will be resumed at the next dosing day.
223615951|NCT04333914|OTHER|Standard of care|"In cohorts 1 and 2, patients allocated in the standard of care arms should receive best supportive care, as per the investigator's discretion and the local routine practices. With regards to the respiratory symptoms and medical resoures at investigational site, the following should be given according to the patient's condition: oxygen supplementation, non-invasive ventilation, invasive ventilation, antibiotherapy, vasopressor support, renal replacement therapy, or extracorporeal membrane oxygenation.~Additional care and medications should be administered in the patient's best interest."
223615952|NCT04333914|DRUG|Avdoralimab|Cohorte 2 (arm H): 500mg, intravenously, at Day 1 then 200mg once daily every 2 days during 14 Days
223615953|NCT04333914|DRUG|Monalizumab|Cohorte 2 (arm G) : 50mg (flat dose),intravenously, single infusion at Day 1.
223615954|NCT03533673|BIOLOGICAL|ACTUS-101|Adeno-associated virus serotype 8 carrying the human GAA gene under the control of the LSP promoter.
223510119|NCT05296655|OTHER|Reflux Symptom Index Inventory (diagnostic survey)|Kazakh versions of the Reflux Symptom Index Inventory will be filled patients
223510120|NCT05296655|OTHER|Reflux finding score|laryngoscopy with a score RFS
223615955|NCT03430791|DRUG|Nivolumab 240 mg IV|Nivolumab IV 240mg IV every 2 weeks for maximum of 24 months.
223615956|NCT03430791|DRUG|Nivolumab 3 mg/kg|Nivolumab IV 3mg/kg every 2 weeks for maximum of 24 months.
223615957|NCT03430791|DRUG|Ipilimumab 1 mg/kg|Ipilimumab IV 1 mg/kg every 6 weeks for maximum of 4 doses.
223510121|NCT04704128|OTHER|Salivic sample|Collection of total saliva not stimulated
223510122|NCT05795712|OTHER|Therapy Change from Baseline|The patient will be followed up from the point of view of therapy according to symptoms and flare-ups irrespective of systemic or peripheral eosinophil assessment
223510123|NCT04990310|DRUG|[14C]-CORT113176|\[14C\]-CORT113176 450 mg lipid formulation capsule for oral administration containing not more than 3.37 megaBequerel 14C.
223510124|NCT03606213|BIOLOGICAL|PENNVAX-GP|PENNVAX®-GP is a circular, double stranded, deoxyribonucleic acid consisting of expression plasmids that encode synthetic HIV-1 multiclade consensus Gag, Pol and Env proteins.
223510125|NCT03606213|BIOLOGICAL|INO-6145|INO-6145 is a circular, double stranded, deoxyribonucleic acid consisting of expression plasmids that encode synthetic HIV-1 multiclade consensus Gag and Pol proteins.
223510126|NCT03606213|BIOLOGICAL|INO-9012|The IL-12 DNA adjuvant (INO-9012) consists of a single plasmid containing a dual promoter system for expression of both the IL-12 p35 and p40 genes necessary for production of the active heterodimeric (p70) IL-12 protein.
223510127|NCT03606213|DEVICE|CELLECTRA® 2000|Electroporation (EP) is a technology in which an electrical field is applied to increase the permeability of cell membranes and thereby enhance the uptake of drugs, vaccines, or other agents into target cells. This technology has been used in the last decade in both therapeutics and vaccinations. EP is currently being used to deliver cancer vaccines and therapeutics as well as in gene therapy. The expression levels are increased by as much as 3 orders of magnitude over plasmid injection alone.
223510128|NCT01251211|DRUG|botulinum toxin type A|BTX A : 5 units/0.2 ml, maximum 300 units will be injected subcutaneous in the painful area ; this will be performed after randomization and within a minimum of 3 months interval depending on the duration of efficacy (maximum 6 months) Saline will be injected in the same volume in the painful area within the same frequency
223510129|NCT02993341|DRUG|Tranexamic Acid|
223510130|NCT02993341|OTHER|Saline Wash|
223510131|NCT03748563|DIAGNOSTIC_TEST|ds-MCE and EGD|"Procedure of ds-MCE:~The ds-MCE system mainly consists of two parts: the NaviCam magnetically maneuvered capsule endoscopy system and the detachable string part. The capsule, which is partially enclosed within the sleeve, can be actively moved in the esophagus through the control of string. Investigator can examine the entire esophagus several times under real time views. After completing the esophageal examination, the capsule could be detached from the string through injecting air into the hollow string with the syringe. Then, the examination of stomach under magnetic control and small bowel under the natural action of gastrointestinal peristalsis follows.~Procedure of EGD:~The esophagogastroduodenoscopy (EGD) will be performed using conventional upper gastrointestinal video endoscopy, according to the standard procedure at individual centers. EGD will be performed within 48 hours after ds-MCE procedure and usually during the same endoscopic session."
223510132|NCT05919251|BEHAVIORAL|Ageless Grace|This unique program attempts to combine multiple aspects that easily fit together including music and a group setting for socialization. The use of music to improve cognition as has been shown in other research studies to improve participation in exercise program. By linking cognitive retraining, low intensity exercise, group activities and music, the researchers of this project can determine if a movement program with these attributes can benefit individuals as a program of wellness once their rehabilitation plans have been completed. The researchers are specifically interested in the effect on balance, activity and incidence of falls in people with chronic stroke. Additionally, the researchers will investigate the differences that this structured program will make on older adults who will act as a comparison group. This will bring insight into some of the additional challenges that people with stroke encounter on a daily basis.
223615958|NCT03430791|DEVICE|NovoTTF200A (Optune)|A device to be worn continuously for a goal of 75% of the time, ranging from 18 hours daily nonstop or 22 hours daily with 2-3 days off monthly.
223615959|NCT05581602|DEVICE|Wearing bracelets (3-Axis Logging Accelerometer)|Participants will be required to wear wristbands containing an accelerometer on each wrist. The bracelets will be kept on both wrists for 7 days with permission to remove them from time to time.
223615960|NCT02918617|DRUG|Control toothpaste containing Novamin® technology|
223615961|NCT02918617|DRUG|Control toothpaste containing 1500 ppm fluoride as MFP|
223615962|NCT02918617|DRUG|Test toothpaste with nano-HAP (high concentration)|
223615963|NCT02918617|DRUG|Test toothpaste with nano-HAP (low concentration)|
224312369|NCT06303479|OTHER|Non-Instrumental breathing exercise group|Before starting the exercises, participants will be told about diaphragmatic breathing exercises, maximum inspiratory holding technique and thoracic expansion exercises through the Zoom program by telerehabilitation method, and people will be checked by the physiotherapist who manages the program during the practice. The program will last for 8 weeks and will be planned to be implemented 5 days a week in total, including 2 days of telerehabilitation, 3 days of home program. The participant will be asked to start the exercises in a reclining position with his back to the chair. He will be asked to place his right hand on his upper abdomen and his left hand on the upper side of his chest. In each session, the exercises will be performed with 1 set of 10 repetitions for each of the diaphragmatic breathing and thoracic expansion exercises and will progress with progression.
224312370|NCT06303479|OTHER|Instrumental breathing exercise group|The volume-oriented spirometer works with pressure and its indicator changes during breathing. When the participants breathe, the pressure in the tube decreases and the piston of the spirometer rises. The inhaled breath volume is seen at the top of the piston. In our study, participants will be told about the exercises through the Zoom program using the telerehabilitation method, and people will be checked by the responsible physiotherapist who manages the program during the application. The program will last for 8 weeks, 2 days of telerehabilitation, 3 days of home program will be planned to be implemented 5 days a week in total. Participants will be instructed to breathe up to their total lung capacity and maintain continuous inspiration for at least 3 seconds. The exercises will start with 1 set of 15 repetitions and the program will progress with progression.
224202098|NCT06942000|DRUG|dexmedetomidine 3mcg group|3mcg of preservative-free dexmedetomidine in (0.5 ml) preservative-free 0.9% saline.
224202099|NCT06942000|DRUG|dexmedetomidine 5mcg|5mcg of preservative-free dexmedetomidine in (0.5 ml) preservative-free 0.9% saline.
224202100|NCT06942000|DRUG|preservative-free 0.9% saline.|(0.5 ml) preservative-free 0.9% saline
224202101|NCT06942520|GENETIC|RGX-314 Dose 1|AAV8 vector containing a transgene for anti-VEGF fab (Dose 1)
224202102|NCT06942520|GENETIC|RGX-314 Dose 2|AAV8 vector containing a transgene for anti-VEGF fab (Dose 2)
224202103|NCT06942520|BIOLOGICAL|Aflibercept (2.0 mg)|Commercially available Active Comparator
223510133|NCT06369051|OTHER|Self-employment support intervention|A new intervention developed to assist stroke survivors in becoming self-employed by developing entrepreneurial skills. It consists of one home visit, three online individual sessions, and four online group sessions held once a week for eight weeks.
223510134|NCT05112588|BEHAVIORAL|Intervention|The women randomized to intervention will get support from the Child Health Care unit (CHCU) at every visit with the baby. Before the visit the women will have blood-samples taken and waist and weight measured. The women will also get support from a digital solution, specially developed for this purpose (MyMOWO). The nurse at the CHCU will include information and support to the mother at every visit accort´ding to a special protocol. All women will be carefully examined at baseline, after one and four years will blood-tests, anthropometric measurements and maximal oxygen uptake (VO2max).
223510135|NCT03275610|GENETIC|Blood sample|5 mL of blood withdrawn from patients with history of pulmonary embolism post total hip arthroplasty or total joint arthroplasty
223510136|NCT02487355|DRUG|Dexmedetomidine|Dexmedetomidine 1 μg/ kg
223510137|NCT02487355|DRUG|Magnesium Sulphate|Magnesium Sulphate 50 mg
223510138|NCT02487355|DRUG|Bupivacaine|1ml/kg of 0.25%of bupivacaine
223510139|NCT02487355|DRUG|Dexmedetomidine + Magnesium Sulphate + Bupivacaine|Dexmedetomidine 1 μg/ kg + Magnesium Sulphate 50 mg + 1ml/kg of 0.25%of bupivacaine
223510140|NCT02491060|DRUG|IDP-121 Lotion|Investigational Product: IDP-121 Lotion
223510141|NCT02491060|DRUG|IDP-121 Vehicle Lotion|Comparator Product: IDP-121 Vehicle Lotion
223510142|NCT05849974|OTHER|Structural and fonctional phynotyping|"The additioan acts in this research are:~Fonctionnal phenotyping:Retinal sensitivity and fixation stability assessment using microperimetry, assessment of long-term fixation stability Structural Phenotyping: Anterior segment examination with OCT anterior Blood sample collection"
223510143|NCT04914000|BEHAVIORAL|Self-help Materials|Self-help booklet targeted by cancer type to increase smoking cessation motivation
223510144|NCT04040673|PROCEDURE|thyroid lobectomy|routine surgical removal of thyroid for biopsy
223510145|NCT04040673|DEVICE|Raman spectroscopy probe measurement|The measurement of Raman spectra from the excised tissue
223510146|NCT01429623|DRUG|ladostigil hemitartrate|10mg ladostigil base administered once daily as hard gelatin capsule
223510147|NCT01429623|DRUG|Placebo|Placebo comparator
223510148|NCT06433011|DEVICE|The Bashir™ Endovascular Catheter|The Bashir™ Endovascular Catheter is a device intended for the localized infusion of therapeutic agents into the pulmonary artery and peripheral vasculature.
223510149|NCT06433011|DRUG|r-tPA|Pulse spray and infusion
223510150|NCT02217553|DRUG|Cholecalciferol|The study participants will receive 180 soft gel cholecalciferol capsules, to be taken 2 capsules once a day for 90 days
223510151|NCT05714228|PROCEDURE|Surgical Mitral Valve Repair|Mitral valve is repaired using open surgical approach
223510152|NCT05714228|PROCEDURE|Transcatheter Mitral Valve Repair|Mitral valve is repaired using Mitraclip transcatheter device
223510153|NCT06401772|BEHAVIORAL|Intracranial Hypotension Targeted(IHT) Body Posture|IHT therapy requires CSDH patients to raise their lower limbs 30° higher over the horizontal level of their head.For patients with unilateral CSDH, the head should be tilted towards the hematoma affected side and opposite side lying should be avoided as much as possible. For patients with bilateral CSDH, there is no need for the head lateralization.To avoid food reflux and aspiration pneumonia, IHT therapy was strictly prohibited within 2 hours after each meal
223510154|NCT00004931|DRUG|leucovorin calcium|Given IV
223510155|NCT00004931|DRUG|fluorouracil|Given IV
223510156|NCT00004931|DRUG|oxaliplatin|Given IV
223510157|NCT00004931|OTHER|laboratory biomarker analysis|Correlative studies
223615964|NCT02918617|DRUG|Test toothpaste with nano-HAP and (Potassium Nitrate) KNO3|
224202104|NCT06941662|DIAGNOSTIC_TEST|computer vision, remote monitoring, blood, urine, wrist bands, mobile-app|This is a low burden study that relies on a combination of cutting edge remote monitoring methods to deliver individualized evaluations to participants in their homes.
223510158|NCT01750281|DRUG|Selumetinib 75 mg|Three selumetinib capsules (Hyd-Sulfate) 25 mg will be administered orally, twice daily, (75 mg dose bd) on an uninterrupted schedule.
223615965|NCT02918617|DRUG|Control toothpaste without nano-HAP|
223615966|NCT02918617|DRUG|Test toothpaste with nano-HAP (medium concentration)|
223615967|NCT02918617|DRUG|Test cream with nano-HAP (higher concentration)|
223615968|NCT02918617|DRUG|Control cream without nano-HAP|
223615969|NCT00791063|OTHER|18F ML-10|Patients will undergo 2-3 brain PET/CT sessions; A pre-treatment session and 1-2 sessions post WBRT treatment. Each PET/CT session will be done following intravenous administration of 18F-ML-10, to assess tracer uptake by the tumor.
223615970|NCT05390372|OTHER|human milk|For skin damage care of preterm newborns randomly assigned to the breast milk group, their own breast milk will be applied topically once every 60 minutes until complete healing. Skin damage in newborns will be evaluated by an independent nurse and specialist doctor for 60 minutes during the treatment, and the score will be given and recorded. A minimum decrease of 1 point in the skin condition assessment scale score will be considered to indicate 'improvement'. The decision that the skin integrity of the newborn is completely healed will be made by the neonatal doctor independent of the trial. Areas between 0-3 on the newborn skin condition assessment scale will be considered healed. Breastfeeding does not have any side effects in preterm newborns.
223615971|NCT05390372|OTHER|Routine care group|cream applied as part of hospital routine practice
223615972|NCT03840317|BIOLOGICAL|Autologous CD19-targeting CAR T cells|Autologous CD19-targeting CAR T cells
223615973|NCT02964221|OTHER|Cognitive Testing|Computerized CogState Brief Battery (CBB), Cognigram, assesses changes in four cognitive domains including psychomotor function, attention, learning and memory, and working memory. The CBB is a computerized test based on card games that can be administered online. .
223615974|NCT05441826|DRUG|VB119|Humanized, immunoglobin (Ig) G1 monoclonal antibody (mAb) to be administered as intravenous infusion at multiple timepoints during the study.
223615975|NCT05118646|DEVICE|sublingual microcirculation,|Avoiding pressure artifacts, clear stable microvascular images were taken for a minimum of 20 seconds of the left, middle, and right sections of the tongue.
223615976|NCT05118646|DEVICE|hemodynamic monitoring|Arterial blood lactic acid (Lac), central venous oxygen saturation (ScvO2), hematocrit (HCT) and entral venous-to-arterial carbon dioxide partial pressure difference (Pcv-aCO2) will be measured employing a bedside blood gas machine on admission and six hours following admission.
223615977|NCT05317104|OTHER|Aerobic exercise|For 6 weeks, 3 times a week, aerobic exercise will be performed with a treadmill at 55-74% of the maximal heart rate.
223615978|NCT05062122|OTHER|vibration group|Hand skills were evaluated before and after 10 minutes of vibration application.
223615979|NCT05062122|OTHER|kinesiology tape group|Dexterity was assessed before and after kinesiology tape application.
223615980|NCT05062122|OTHER|control group|Manual dexterity was assessed before and after traditional physiotherapy.
223615981|NCT02937337|DEVICE|Laryngeal mask insertion with videostylet guided technique|
223615982|NCT02937337|DEVICE|Laryngeal mask insertion with standard blind technique|
223615983|NCT06453408|PROCEDURE|Punción seca con aguja retráctil|"The placebo dry needling protocol will be performed in the same position, with identical antiseptic measures and the same number of simulated incisions as the real dry needling protocol, using DONGBANG AcuPrime® 0.30 x 30mm blunt-tipped placebo needles with a retractable handle. These needles simulate the sensation of needle contact without penetrating the skin. The therapist will hold the needle and guide tube, pressing the tube against the skin and simulating needle manipulation. Changes in pressure direction will mimic the real technique. The protocol will end with compression using an alcohol swab and an upper trapezius stretch.~Participants in both groups will receive the same information about the sensations of the dry needling procedure. At the beginning, they will be informed that they may or may not feel the needle insertion. They will also be told that the physiotherapist will manually manipulate the needle multiple times during the procedure."
223615984|NCT06453408|PROCEDURE|Punción seca con aguja normativa.|To perform the actual SP, patients shall be asked to lie prone with arms close to the body. The dry needling shall be performed with a 0,30 × 30 mm DN needle (APS Regular Agupunt) with a guide tube. The therapist shall first clean the area with alcohol. The trapezius muscle is then firmly grasped with a clamp between the thumb and index finger, so that the needle is directed deep into the index finger until the tip of the needle is felt to be approaching (33). This procedure involves an approximate insertion of the needle to a depth of 30 mm and ensures the intramuscular penetration necessary for dry needling. Puncture of the PGM shall be performed using the Hong technique (34), performing up to 12 inlets and outlets, at a frequency of 1 Hz. When the needle is withdrawn, the area is firmly compressed with cotton wool for 60 seconds. Finally, the upper trapezius muscle is stretched, following the technique originally described by Simons (35).
223510159|NCT01750281|DRUG|Docetaxel 75 mg/m2|Docetaxel 75 mg/m2 will be administered intravenously on day 1 of each 21 day cycle.
223510160|NCT01750281|DRUG|Docetaxel 60 mg/m2|Docetaxel 60 mg/m2 will be administered intravenously on day 1 of each 21 day cycle.
224312371|NCT02086903|DRUG|Ticagrelor 90 mg|The subjects administer Ticagrelor 90 mg as loading dose (LD) follow by 90 mg/day as maintenance dose (MD) for 5 days, following a 2-week washout period, to receive the alternate thienopyridine (Clopidogrel 600 mg as LD follow by 75 mg/day as MD for 5 days).
223510161|NCT01750281|DRUG|Placebo|Three placebo capsules will be administered orally uninterrupted twice daily.
223510162|NCT02728726|DRUG|Sugammadex|Sugammadex will be administered intravenously at 2 mg/kg after routine reversal of anesthesia is performed and subject is extubated.
223510163|NCT02728726|DRUG|Placebo|Placebo will be administered intravenously at 2 mg/kg after routine reversal of anesthesia is performed and subject is extubated.
223615985|NCT02754973|BEHAVIORAL|an integrated experiential training program with coaching|The intervention will be implemented to each participant by a designated coach who is a trained nursing student during 28 home visits throughout a 6-month period (24 weeks) and each visit will last for about 1 hour. The 1-hour program consists of a 30-minute English tutorial session, and a 30-minute physical activity session with the coach. The same coach will pay a visit to a participant at twice a week for the first 4 weeks and then once a week for the subsequent 20 weeks. 4 levels of physical activity will be taught to the participants gradually according to their ability.
224202105|NCT06943560|BEHAVIORAL|Emotion Regulation Selection Flexibility Training|7 online computerized regulatory selection training sessions that includes a fully computerized part, and an interactive, human operated part guided by a clinician and home assignments between intervention session to be completed on days without sessions. Psychoeducation includes information on selection of appropriate strategy according to the regulatory selection flexibility rule (i.e., distraction for high intensity vs reappraisal in low intensity). In the computerized task participants are exposed to emotional words and are asked to select a regulatory strategy in a flexible matter according to the regulatory selection flexibility rule, and receive feedback on whether they chose flexibly or not. Following , they are instructed to implement the chosen strategy. Homework includes choosing two daily events one of high intensity and a second one of low intensity, and describe which strategy they selected and how they implemented their chosen strategy according to the flexibility rule.
224312372|NCT02086903|DRUG|Clopidogrel 600 mg|The subjects administer Clopidogrel 600 as loading dose (LD) follow by 75 mg/day as maintenance dose (MD) for 5 days, following a 2-week washout period, to receive the alternate thienopyridine (Ticagrelor 90 mg/day as LD, follow by 90 mg/day as MD for 5 days).
224312373|NCT01264536|DIETARY_SUPPLEMENT|lactoferrin|Infants will receive oral bovine lactoferrin (200 mg/Kg/day divided in three dosis) for 4 weeks. Lactoferrin will be dissolved in human milk or infant formula or in a 5% glucose solution. Each dose will be dissolved in a small volume so the maximum lactoferrin concentration will be 25mg/mL.
224312374|NCT01264536|DIETARY_SUPPLEMENT|Maltodextrin|Infants will receive oral maltodextrin (200mg/Kg/day in three divided dosis) for 4 weeks. Maltodextrin will be dissolved in human milk or infant formula or in a 5% glucose solution. Each dose will be dissolved in a small volume so the maximum maltodextrin concentration will be 25mg/mL.
224312375|NCT05892692|BEHAVIORAL|Ecological Momentary Intervention|Participants will receive hypothetical and real-time behavioral feedback using a smartphone application which provides ecological momentary responses to their current behaviors. By providing safety tips and advice, the intervention may decrease incidences of sexual assault and risky sex compared to a control group.
224312376|NCT02302547|DRUG|triple therapy|Dosage treatment and usual prescription
224312377|NCT02302547|DRUG|dual therapy|1 tablet (200mg/245mg) daily for 48 weeks
224312378|NCT04719962|PROCEDURE|Targeted proteomics in skin +/- cerebrospinal or synovial fluid to diagnose disseminated Lyme disease|"Following a 2-days course of local daily clobetasol propionate 0,05% cream application, a skin biopsy (3 mm punch-biopsy ) of healthy-looking skin of the upper part of the thigh will be performed in all patients,.~Arthrocentesis (in patients with Lyme arthritis only) and lumbar puncture to collect cerebrospinal fluid (in patients with neuroborreliosis only) will be performed in the usual care setting as appropriated.~All biological samples will be subject to Borrelia culture, PCR and SRM-MS proteomics."
224312379|NCT04684004|OTHER|To report number of HF events and deaths|In these two cohorts of study authors will evaluate at 2 years of follow-up the number of HF events and of deaths.
224312380|NCT04888598|DIAGNOSTIC_TEST|Optical Coherence Tomography (OCT) Angiography|Measurement of retinal vessel density and distribution in the macula using new generation OCT device
223510164|NCT01060969|DRUG|Tadalafil and acetazolamide|Experimental arm: Tadalafil 20 mg daily + acetazolamide 125 mg BID beginning above 3000 m altitude.
223510165|NCT01060969|DRUG|Acetazolamide|Active comparator arm (control): acetazolamide 125 mg BID beginning above 3000 m altitude
223510166|NCT01169909|DRUG|Ranibizumab|Subtenon injections of Ranibizumab 0.5mg will be given, and repeated twice with 30 day intervals between each dose. Note, after an amendment in February 2011, this dose was increased to 2mg with the same schedule.
223510167|NCT00000778|DRUG|Isoniazid|
223510168|NCT00000778|DRUG|Pyridoxine hydrochloride|
223510169|NCT00000778|DRUG|Levofloxacin|
223510170|NCT00793611|BEHAVIORAL|Behavioral therapy standard of care|controls will receive usual interventions for overactive bladder: voiding diary, bladder drills, pelvic floor exercises
223510171|NCT00793611|OTHER|hypnotherapy|Patients will receive 3 hypnotherapy sessions in addition to usual behavioral treatment of overactive bladder
223510172|NCT02256800|GENETIC|UGT1A1 genotyping (6,6)|"The investigators will use the regimen as following:~Regimen for treatment consisted of bevacizumab (Avastin) 5mg/Kg (IV infusion) on day 1, follow by irinotecan (180 mg/m2 as a 120-min IV infusion), Leucovorin (400 mg/m2 IV infusion over 2 hours), and 5-FU (2800 mg/m2 IV infusion over a 46-hour period), repeated every 2 weeks.~After 2 cycles of each different dose of irinotecan, we will observe the adverse effects (AEs) of hematological / non-hematological. If the grade is under the grade 2, we will escalate the dose of 30 mg/m2 gradually. The estimated maximal dose of irinotecan is 260 mg/m2."
223510173|NCT02256800|GENETIC|UGTIA1 genotyping (6,7)|"The investigators will use the regimen as following:~Regimen for treatment consisted of bevacizumab (Avastin) 5mg/Kg (IV infusion) on day 1, follow by irinotecan (180 mg/m2 as a 120-min IV infusion), Leucovorin (400 mg/m2 IV infusion over 2 hours), and 5-FU (2800 mg/m2 IV infusion over a 46-hour period), repeated every 2 weeks.~After 2 cycles of each different dose of irinotecan, we will observe the adverse effects (AEs) of hematological / non-hematological. If the grade is under the grade 2, we will escalate the dose of 30 mg/m2 gradually. The estimated maximal dose of irinotecan is 240 mg/m2."
223510174|NCT02256800|GENETIC|UGTIA1 genotyping (7,7)|"The investigators will use the regimen as following:~Regimen for treatment consisted of bevacizumab (Avastin) 5mg/Kg (IV infusion) on day 1, follow by irinotecan (120 mg/m2 as a 120-min IV infusion), Leucovorin (400 mg/m2 IV infusion over 2 hours), and 5-FU (2800 mg/m2 IV infusion over a 46-hour period), repeated every 2 weeks.~After 2 cycles of each different dose of irinotecan, we will observe the adverse effects (AEs) of hematological / non-hematological. If the grade is under the grade 2, we will escalate the dose of 30 mg/m2 gradually. The estimated maximal dose of irinotecan is 180 mg/m2."
223510175|NCT02256800|GENETIC|UGT1A1 non-genotyping|"The investigators will use the regimen as following:~Regimen for treatment consisted of bevacizumab (Avastin) 5mg/Kg (IV infusion) on day 1, follow by irinotecan (180 mg/m2 as a 120-min IV infusion), Leucovorin (400 mg/m2 IV infusion over 2 hours), and 5-FU (2800 mg/m2 IV infusion over a 46-hour period), repeated every 2 weeks."
223510176|NCT02256800|DRUG|bevacizumab (Avastin)|bevacizumab as target therapy
223510177|NCT02256800|DRUG|irinotecan|irinotecan as escalating dose according to UGT1A1 genotyping
223510178|NCT02256800|DRUG|Leucovorin|combined with 5-FU
223510179|NCT02256800|DRUG|5-FU|combined with irinotecan
223615986|NCT02754973|BEHAVIORAL|Placebo Control|When discharged home, participants will receive an amount of time and attention (home visits by research assistants) that mimicked that received by the experimental group, but which is thought not to have any specific effect on the outcome measures. The placebo activities during the home visits may include playing cards or chess games, health advice on the prevention of influenza and healthy diet which will be conducted for 30 minutes.The participants will also receive a 30-minute English tutorial session with the research assistants in each home visit.
223615987|NCT04471519|BIOLOGICAL|BBV152A - Phase I|0.5 ml of the vaccine will be administered intramuscularly twice at Day 0 and Day 14
223615988|NCT04471519|BIOLOGICAL|BBV152B - Phase I|0.5 ml of the vaccine will be administered intramuscularly twice at Day 0 and Day 14
223615989|NCT04471519|BIOLOGICAL|BBV152C - Phase I|0.5 ml of the vaccine will be administered intramuscularly twice at Day 0 and Day 14
223615990|NCT04471519|BIOLOGICAL|Placebo - Phase I|0.5 ml of the Placebo will be administered intramuscularly twice at Day 0 and Day 14
223615991|NCT04471519|BIOLOGICAL|BBV152A - Phase II|0.5 ml of the vaccine will be administered intramuscularly twice at Day 0 and Day 28
223615992|NCT04471519|BIOLOGICAL|BBV152B - Phase II|0.5 ml of the vaccine will be administered intramuscularly twice at Day 0 and Day 28
223615993|NCT00291616|DRUG|Pegylated Interferon-alpha2a|180 microgram s.c. injection weekly
223615994|NCT00291616|DRUG|Thymosin alpha1 & Pegylated Interferon-alpha2a|Pegylated interferon 180 microgram s.c. injection weekly Thymosin 1.6 mg s.c. injection twice per week
223615995|NCT04849208|OTHER|Presentation of fast and slow trials|"In each task trial participants will solve a reasoning problem. Half of the trials will be traditional Slow trials in which participants get ample time to deliberate (i.e., 20 s). The other half of the trials will be Fast trials in which people do not get sufficient time to deliberate (i.e., 4 s deadline) and need to rely on intuitive processing"
223615996|NCT02763306|DEVICE|Dermal Cooling System|Treatment with dermal cooling system.
223615997|NCT04154436|OTHER|Sodium Bicarbonate (NaHCO3) Plus Solution|Alkaline Solution
223615998|NCT04154436|OTHER|Water (H2o)|Alkaline Solution
223615999|NCT06182878|BEHAVIORAL|Tender loving care intervention|Receiving weekly prenatal care counseling messages
223616000|NCT00032669|DRUG|HAART|
223616001|NCT02582528|BEHAVIORAL|Cognitive remediation treatment|Cognitive remediation treatment consisting of a novel computerized training called My Brain Solutions (MBS)
223616002|NCT02582528|BEHAVIORAL|Motivational Interviewing|A client-centered, directive method for enhancing intrinsic motivation to change.
223616003|NCT04839510|DRUG|MRG002|Administrated intravenously
223616004|NCT04239001|DRUG|PEG-rhG-CSF|24 hours after the completion of intravenous infusion of albumin paclitaxel during the treatment period, patients with pancreatic cancer who met the input / discharge criteria were given secondary prophylactic administration of the tested drug PEG-rhG-CSF.
223616005|NCT04921202|OTHER|Metabolic syndrome and meniscus injuries|Metabolic syndrome
223616006|NCT00383786|DRUG|NK1 Antagoist (GR205171)|
224312381|NCT03579927|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo ASCT
224312382|NCT03579927|DRUG|Carmustine|Given IV
224312383|NCT03579927|DRUG|Cytarabine|Given IV
223616007|NCT00383786|PROCEDURE|Psychophysiology (Trauma Script)|
223616008|NCT00383786|PROCEDURE|Psychophysiology (Verbal Threat)|
223616009|NCT00383786|PROCEDURE|Psychophysiology (Fear Conditioning)|
223616010|NCT00383786|PROCEDURE|Psychophysiology (Affective Modulation)|
223616011|NCT00383786|PROCEDURE|Psychophysiology (Heart rate variability)|
223616012|NCT00383786|PROCEDURE|Lumbar Puncture|
223616013|NCT00383786|PROCEDURE|24-hour plasma sampling|
223616014|NCT00383786|PROCEDURE|MRI|
223616015|NCT00051870|DEVICE|Magstim Rapid Magnetic Stimulator|
223616016|NCT03588663|DEVICE|Baseline Bionic Leg Assessment|The 'Bionic Leg' (BL) \[Alter G, Fremont, CA, USA; approved by the Food and Drug Administration (FDA) in 2014\], is an externally-wearable, battery-operated robotic device that assists patients and therapists during rehabilitation by providing adjustable and progressive functional mobility training. A patient or therapist can programme the BL to provide motor assistance during sit-to-stand exercises, over-ground walking, and stair climbing, with either more or less robotic-assistance, as desired by the therapist. As the BL increases stability and actively engages the affected leg during functional tasks, it enables patients to undertake more repetitions of specific tasks than when not wearing a BL.
223616017|NCT03588663|OTHER|Baseline Control Condition Assessment|Participants will complete identical tasks as that undertaken with the Bionic Leg, but will complete the tasks without wearing the Bionic Leg.
223616018|NCT03588663|OTHER|Training|Participants will take -part in a 30-minute training session whilst wearing the Bionic Leg. The training programme will ask participants to engage in a variety of walking, balance and stair exercises. The training programme will include a 15-minute rest period after completion of the 30 minutes of exercises. This will take 45 minutes in total.
223616019|NCT03588663|OTHER|Follow-up Assessment|45 minutes after the baseline assessment, immediately following the Training programme, the following tests (PCI, TUG, postural sway, 6-min walk, sit-to-stand) will be completed. These tests will be undertaken whilst not wearing the Bionic Leg. It is anticipated that this session will last approximately 2 hours.
223616020|NCT00058396|BIOLOGICAL|lumiliximab|
223616021|NCT00985673|BIOLOGICAL|GSK2340274A|Two intramuscular injections
223616022|NCT00985673|BIOLOGICAL|GSK2340273A|Two intramuscular injections
223616023|NCT00985673|BIOLOGICAL|Seasonal trivalent influenza vaccine (TIV)|Single intramuscular injection
223616024|NCT00985673|BIOLOGICAL|Saline placebo|Single intramuscular injection
223616025|NCT04519736|DEVICE|Single Band vs. Dual Band Pulsed Light Technology for the Treatment of Photodamage|
224312384|NCT03579927|DRUG|Etoposide|Given IV
224312385|NCT03579927|BIOLOGICAL|Filgrastim|Given SC
224312386|NCT03579927|DRUG|Melphalan|Given IV
224312387|NCT03579927|BIOLOGICAL|Rituximab|Given IV
224312388|NCT03579927|BIOLOGICAL|Umbilical Cord Blood-derived Natural Killer Cells|Given CAR.CD19-CD28-zeta-2A-iCasp9-IL15-transduced CB-NK cells IV
224312389|NCT05933980|DRUG|Rego+Tori+Cele|combination of Toripalimab,regorafenib and celecoxib
223760919|NCT00774098|DRUG|Intravenous normal saline (NS 0.9)|Intravenous normal saline (NS 0.9) started just before induction, and titrated to hemodynamic parameters and urine output
223760920|NCT01067352|DRUG|Recombinant human growth hormone (r-hGH)|Recombinant human GH were administered subcutaneously (s.c) at the daily dose of 0.067 mg/kg of body weight to Group A1.
223760921|NCT04995640|PROCEDURE|open cardiovascular repair or endovascular treatment (TEVAR)|Surgery type: open cardiovascular repair and endovascular treatment (TEVAR)
223760922|NCT02090816|PROCEDURE|Surgery of liver and lung|Simultaneous resection of liver and right lung metastases in a single surgical session through a new approach
223760923|NCT01096784|DRUG|rhIGF-I/rhIGFBP-3|Continuous intravenous infusion
223760924|NCT03052582|OTHER|Milk type|
223510180|NCT03444688|OTHER|Conventional Gait Training|Subjects allocated to the CT group will first perform active assisted or passive range of motion of the lower limbs including ankle, knee, and hip joint in the supine position for 10 minutes. They will then perform conventional gait and balance therapy based on the proprioceptive neuromuscular facilitation (PNF) concept for 15 minutes. They will be given a 5 minutes rest. Finally, the CT subjects will undergo the over-ground gait training with or without aid or orthoses and with manual assistance from senior physiotherapist for 15 minutes, depending on the individual subject's abilities.
223616026|NCT02252146|DRUG|IMO-8400|MO-8400 given subcutaneously twice weekly
223616027|NCT04034368|DRUG|Tenofovir Alafenamide (TAF)|Tenofovir alafenamide (TAF) 25 mg QD, oral administration, 48 weeks；
223616028|NCT03715517|PROCEDURE|Continuous thoracic epidural analgesia|"Needle/catheter: 17 Ga. × 80 mm Tuohy epidural needle (Perican®, B. Braun Medical Inc., Bethlehem, PA, USA); Arrow FlexTip Plus® 19 Ga. epidural catheter (Arrow International Inc., Reading, PA, USA)~Level of insertion and patient positioning: T6-T8, upright sitting position for insertion of needle and catheter (to 5 cm beyond loss-of-resistance point) and for injection of test dose (3 mL 2% lidocaine with epinephrine 1:200,000); supine for injection of bolus dose~Confirmation of correct placement: Loss of resistance to air or saline; negative aspiration of the epidural catheter; negative test dose; and ease of injection of an initial bolus dose"
223616029|NCT03715517|PROCEDURE|Spinal anesthesia with intrathecal morphine|"Needle/catheter: 25 Ga. × 90 mm high-flow Whitacre spinal needle (Becton-Dickinson, Franklin Lakes, NJ, USA)~Level of insertion and patient positioning: L2-L3, lateral decubitus position during injection; immediately post-injection, patient is placed supine in \<5% degree of Trendelenburg~Confirmation of correct placement: Aspiration of cerebrospinal fluid"
223616030|NCT03715517|DRUG|Bupivacaine 0.75% in Dextrose Inj 8.25%|0.25 mg⋅kg-¹ hyperbaric bupivacaine 0.75%
223616031|NCT03715517|DRUG|Morphine|3 mcg⋅kg-¹ intrathecal morphine (preservative-free)
223616032|NCT03715517|DRUG|Bupivacaine 0.25% Preservative-Free Injectable Solution|0.25 mg⋅kg-¹ bupivacaine 0.25%
223616033|NCT03715517|DRUG|Bupicavaine 0.125% epidural solution|Epidural solution, bupivacaine 0.125% with hydromorphone 10 mcg·mL-¹, infusion range 0.075-0.125 mL⋅kg-¹⋅h-¹
223616034|NCT03715517|DRUG|Hydromorphone 10 mcg/mL epidural solution|Epidural solution, bupivacaine 0.125% with hydromorphone 10 mcg·mL-¹, infusion range 0.075-0.125 mL⋅kg-¹⋅h-¹
223760925|NCT03903627|OTHER|verbal instruction|Verbal instruction for pelvic floor contraction will be given to participants. Ultrasound examination will be conducted to asses urinary bladder displacement being a marker for pelvic floor muscle function.
223760926|NCT01474642|DRUG|Capecitabine/Cisplatin(XP)|Capecitabine/Cisplatin(XP) D1-D14 Capecitabine 2000mg/m2 D#2 PO D1 Cisplatin 75mg/m2 iv q 3 weeks
223760927|NCT01474642|DRUG|Capecitabine/Paditaxel(XG)|Capecitabine/Paditaxel(XG) D1-D14 Capecitabine 2000mg/m2 D#2 PO D1,D8 Paditaxel(genexol) 80mg/m2 iv q 3 weeks
223760928|NCT01097837|OTHER|Non-interventional|This is an observational study conducted by anonymous survey. There is no intervention.
223760929|NCT03756220|DRUG|Combination therapy of vitamin C and thiamine|Vitamin C (50 mg/kg up to 3 g, every 12 hours) and thiamine (200 mg every 12 hours) intravenously administered mixed in 50 mL solution bags of normal saline for 2 days
223760930|NCT03756220|DRUG|Normal saline solution|Normal saline solution in a volume to match the treatment components administered mixed in 50 mL solution bags of normal saline for 2 days
223616035|NCT05736874|DRUG|Fluticasone|Fluticasone furoate is an inhaled powder drug product composed of fluticasone furoate. It is a synthetic trifluorinated corticosteroid that is insoluble in water. Fluticasone furoate is a white powder and will be provided in a two tone grey inhaler with a mouthpiece cover and separate foil blister strips. The inhaler will be packaged in a moisture-protective foil tray with a desiccant and a peelable lid.All packaging will be labeled to indicate that the product is for investigational use. Participants will self-administer 200 µg (1 blister) of fluticasone furoate once daily for 14 days.
223616036|NCT05736874|OTHER|Placebo|Each study arm will contain a placebo comparator. Placebo will look similar to study drug and will be administered via the same route of administration and dose. However, placebo will be an inactive substance, containing no study drug.
223616037|NCT03065322|OTHER|To assess risk of OSA|The risk of OSA will be assessed using the Berlin questionnaire and the Epworth Sleepiness Scale (ESS). Women with at high risk of OSA will have home-based sleep studies performed. Study participants will be divided based on the results of the Berlin and ESS questionnaires and sleep studies into two groups: 1) PCOS low risk OSA: women with normal ESS and normal Berlin questionnaire (no sleep studies performed), or women with normal sleep studies; and 2) PCOS OSA: women with OSA proven by sleep studies.
223616038|NCT00531284|DRUG|Carfilzomib|Administered by intravenous (IV) bolus (2-10 minute) infusion or 30 minute infusion
223616039|NCT00531284|DRUG|Dexamethasone|Administered orally or by IV infusion prior to carfilzomib
223616040|NCT00433641|DRUG|sibutramine|placebo
223616041|NCT00433641|DRUG|sibutramine|oral 15 mg sibutramine once per day
223616042|NCT00433641|DRUG|sibutramine|oral sibutramine 10 mg once per day
223760931|NCT03377335|DRUG|Dapagliflozin 10mg|"The subjects in this arm will receive dapagliflozin (10mg daily) as add-on to metformin therapy (doses ranging from 1500 to 3000 mg daily).~Number of patients to be randomized: 93~Number of patients expected to complete the study: \>87~All the other medications (including lipid-lowering, anti-hypertensive and anti-platelet agents) will be maintained at fixed doses during the treatment."
224312390|NCT05527574|OTHER|Resistance Exercise|Participants are enrolled in 30-40 minutes of resistance exercise training using elastic bands for 30-40 minutes/session three times per week over six months
223760932|NCT03377335|DRUG|Metformin|"All the subjects in this arm will be on metformin therapy only (doses ranging from 1500 to 3000 mg daily).~Number of patients to be randomized: 93~Number of patients expected to complete the study: \>87~All the other medications (including lipid-lowering, anti-hypertensive and anti-platelet agents) will be maintained at fixed doses during the treatment."
223760933|NCT04865497|BIOLOGICAL|S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine|Group 1:3/2/1 dose(s) according to age of subjects. Single intramuscular dose contains 10 µg S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine.
223760934|NCT04865497|BIOLOGICAL|S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine|Group 2:3/2/1 dose(s) according to age of subjects. Single intramuscular dose contains 5 µg S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine.
223760935|NCT04865497|BIOLOGICAL|S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine|Group 1:3/2/1 dose(s) according to age of subjects. Single intramuscular dose contains 10 µg adjuvant-free S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine.
223760936|NCT04865497|BIOLOGICAL|Haemophilus b Conjugate Vaccine|Group 1:3/2/1 dose(s) according to age of subjects. Single intramuscular dose contains 10 µg Haemophilus b Conjugate Vaccine.
223760937|NCT01835249|OTHER|Intensive BP Arm|Participants in the Intensive arm have a goal of SBP \<120 mmHg.
223760938|NCT01835249|OTHER|Standard BP arm|Participants in the Standard BP arm have a goal of SBP \<140 mmHg.
224312391|NCT04175535|PROCEDURE|Percutaneous Posterior Endoscopic Cervical Discectomy|The most common alternative in the case of soft cervical disc herniations.
223510181|NCT03444688|DEVICE|Gait rehabilitation with walker|For WT group, subjects will first go through active assisted or passive range of motion of the lower limbs including ankle, knee, and hip joint in the supine position for 10 minutes. The main therapy consists of 2 parts with 5 minutes rest in between. During part 1, subjects will be trained on the robotic walker with the help of active body weight support (BWS) and functional electrical stimulation (FES) for 15 minutes with pelvic motion support function and lateral balance function being continuously provided. During part 2, subjects will also receive resistance/assistance forces on top of the BWS and FES training for 15 minutes.
223510182|NCT03944005|PROCEDURE|Spinal Anesthesia + ACB continious catheter + iPACK + Sham LIA|"ACB - On identification of adductor canal,10ml ropivacaine 0.5% with 1:400,000 epinephrine will be injected to surround the femoral artery.Following catheter placement, another 10ml of the same solution will be injected. Continuous infusion of 5ml/hr 0.2% ropivacaine will be infused till considered ready to discharge.~Ipack - Posterior knee infiltration will be performed following ACB. On visualization of femoral condyle and popliteal artery, 20ml ropivacaine 0.5% with 1:400,000 epinephrine will be infiltrated in muscular space between popliteal artery and posterior femoral condyle.~Spinal anesthesia will be performed following nerve blocks. All patients will receive 2-3ml of 0.75% preservative-free bupivacaine at the level of L2-3 or L3-4 intervertebral space.~LIA - Patients in Group 1 will receive local infiltration 100ml of normal saline around the knee capsule of 100ml of normal saline by the surgeons as a Sham injection."
223616043|NCT05904158|BIOLOGICAL|Platelet-Rich Fibrin during Standard ACL reconstruction surgery|Plateleth-rich fibrin was obtained from patients own blood (40 cc) and applied to the tunnels which were drilled for ACL graft
223616044|NCT05904158|OTHER|Standard ACL reconstruction surgery|This was a control group where patients received Standard ACL reconstruction surgery
223616045|NCT02805686|DEVICE|spectral domain optical coherence tomography|
223616046|NCT02805686|DEVICE|multifocal electroretinogram|
223616047|NCT03194906|DRUG|Memantine|Medication dosing will be overseen by one of the study neurologists, with step-wise dose reductions (5 mg intervals) allowable in the case of side effects.
223616048|NCT03194906|OTHER|Placebo|A placebo that appears exactly like the study drug, memantine, will be given in a manner identical to the study drug.
223616049|NCT03194906|OTHER|Cognitive Assessment|Cognitive and neurologic examinations will be conducted to assess cognitive, social, quality of life, and neurological outcomes associated with memantine will be completed at baseline prior to medication start, and at 6 weeks (end of radiation therapy), 12 weeks (discontinuation of study medication or placebo), and one year post radiation therapy.
223616050|NCT00984256|DRUG|Atovaquone Proguanil|Volunteers will receive doses of atovaquone/proguanil (Malarone) or matching sugar pills.
223616051|NCT00984256|OTHER|Procedure - malaria challenge|2\) Procedure- Malaria Challenge- Volunteers will be exposed to bites of infectious mosquitoes with the intention of causing malaria infection. Volunteers infected with malaria will undergo approved treatments for malaria.
223616052|NCT01500590|DRUG|Renin-angiotensin system blockers|ramipril 2.5mg to 10mg once daily if patient experience cough, we will use irbesartan 150 mg to 300mg once daily
223616053|NCT01500590|DRUG|non-renin angiotensin system blockers|amlodipine 2.5 to 10 mg once daily nifedipine retard 20mg to 40mg twice daily indapamide 2.5mg once daily metoprolol 25mg to 100mg daily methyldopa 125 mg to 500mg twice daily
223616054|NCT00002682|DRUG|Amoxicillin|
223616055|NCT00002682|DRUG|Bismuth Subsalicylate|
223616056|NCT00002682|DRUG|Clarithromycin|
223616057|NCT00002682|DRUG|Metronidazole Hydrochloride|
223616058|NCT00002682|DRUG|Omeprazole|
223616059|NCT00002682|DRUG|Tetracycline Hydrochloride|
223616060|NCT05525377|BEHAVIORAL|Better living with non-memory led dementia course|Caregivers online training and educational phenotype-specific programme on how to support people with non-memory-led dementia.
223616061|NCT01493193|OTHER|Endurance training with constant work load|Endurance training with constant work load(n=15): 31min at 65-75% HRmax
223616062|NCT01493193|OTHER|Pyramid-Training|Pyramid-Training (n=15): One Pyramid consists of 8 one-minute blocks. Those are grouped starting with one block of 70-75% HRmax, followed by one block at 75-80% HRmax and another one at 80-85% HRmax. The top of the pyramid are 2 blocks of 85-90% HRmax. Intensity is lowered afterwards with one block at 80-85% HRmax, followed by one block at 75-80% HRmax and last one at 70-75% HRmax. Two more pyramids follow, each divided by 2min of active recovery at 65-70% HRmax, making it a total of 28min.
223616063|NCT01493193|OTHER|High-intensity interval training|HIT (n=15): 4x4min intervals at 85-95% HRmax divided by 3x3min of active recovery at 60-70% HRmax, making it a total of 25min
224312392|NCT04175535|PROCEDURE|Anterior cervical decompression and fusion|The standard procedure for operation of cervical disc herniations.
224312393|NCT04049110|DRUG|Forxiga 10mg|Dapagliflozin 10mg per 24 hours, oral, for 7 consecutive days
224312394|NCT04049110|DRUG|Placebo|Placebo 1 tablet per 24 hours, oral, for 7 consecutive days
223616064|NCT03057496|DEVICE|Collision warning device|The collision warning device is a pocket-sized, electronic system that includes a micro-computer, a clip-on miniature camera, a gyro-sensor, an accelerometer, and a rechargeable battery, all contained within a shoulder bag. It is about the size of a smart phone. When a potential collision is detected by the device it emits a warning to the user, either in the form of an audible beep or a tactile warning through bracelets worn on the wrist. The time to collision will be coded in both the auditory and tactile domains. The device is designed to only give warnings about high risk collisions, so the users will not be continually bombarded by warnings for every potential collision object in the environment.
223616065|NCT02040623|DRUG|R348 Ophthalmic Solution, 0.2%|R348 Ophthalmic Solution 0.2% 2 drops per eye twice a day
223616066|NCT02040623|DRUG|R348 Ophthalmic Solution, 0.5%|R348 Ophthalmic Solution, 0.5% 2 drops per eye twice a day
223616067|NCT02040623|OTHER|Placebo Ophthalmic Solution|Placebo Ophthalmic Solution 2 drops per eye twice a day
223616068|NCT00259545|DRUG|Retarded Release Phosphatidylcholine (rPC)|
223616069|NCT05245435|DIAGNOSTIC_TEST|FDHT-PET Scan|\[18F\]-fluoro-5α-dihydrotestosterone (FDHT)- positron emission tomography (PET)
223616070|NCT05245435|DIAGNOSTIC_TEST|liquid biopsies|circulating tumor cell count and circulating tumor DNA abundance in blood of prostate cancer patients
223616071|NCT01722019|DEVICE|Tulip fiber|Laser ablation with a wavelength of 1470 nanometers will be performed, in combination with a new sort of fiber: the tulip tip fiber.
223616072|NCT01722019|DEVICE|VNUS closure fast|Radiofrequent ablation will be performed in combination with the catheter 'VNUS closure fast'.
223760939|NCT02350205|BIOLOGICAL|Self assembled skin substitute (SASS)|All patients in Phase B will receive Self assembled skin substitute (SASS)
223760940|NCT05923229|BEHAVIORAL|Mindfulness Based Walking Therapy (MBWT)|MBWT is a modified version of the Mindfulness Based Stress Reduction (MBSR) program that incorporates more walking mediations and is acceptable for people with Parkinson disease and freezing of gait.
223760941|NCT05923229|OTHER|Freezing of Gait (FOG) Education|Participants will receive materials to read weekly about FOG and track their usual care regimens.
223760942|NCT03064126|DEVICE|RANGER™ Paclitaxel Coated Balloon|"A procedure that utilizes a balloon coated with paclitaxel (drug) which can open up a blocked blood vessel using a small, flexible plastic tube, or catheter, with a balloon at the end of it. When the tube is in place, it inflates to open the blood vessel, or artery, so that normal blood flow is restored. The tube is then removed. The blood vessels that will be treated in the RANGER II SFA study include the superficial femoral arteries and the proximal popliteal arteries."
223760943|NCT03064126|DRUG|Paclitaxel|The RANGER™ Balloon is coated with the drug Paclitaxel.
224202106|NCT06943560|BEHAVIORAL|Emotion Regulation Active control Training|"All the interventional sections are similar to the experimental group except that in the control group we omit the regulatory selection rule that defines which strategy is compatible with which emotional situation.~7 online computerized regulatory selection training sessions that includes a fully computerized part, and an interactive, human operated part guided by a clinician and home assignments between intervention session to be completed on the days without sessions. Psychoeducation explicitly included information on regulatory strategies (without the regulatory selection flexibility rule). In the computerized task participants are exposed to the same emotional words and are asked to choose freely a regulatory strategy (without the regulatory selection flexibility rule or feedback), and implement it. Homework includes choosing two daily events and selecting and implementing a regulatory strategy (without the regulatory selection flexibility rule)."
224202107|NCT06943339|OTHER|Standard enteral nutrition|It will include the baseline and 15-day follow-up data of the patients in the standard enteral nutrition group for standard product (1kkal/1ml) intake. No intervention will be made by the researchers during the treatment process of the patients.
224312395|NCT02511821|OTHER|Computer-Assisted Intervention|Complete online surveys
224312396|NCT02511821|DEVICE|Vivofit watch|Wear Vivofit watch
223760944|NCT03064126|PROCEDURE|Standard Balloon Angioplasty|"A procedure that utilizes an uncoated balloon which can open up a blocked blood vessel using a small, flexible plastic tube, or catheter, with a balloon at the end of it. When the tube is in place, it inflates to open the blood vessel, or artery, so that normal blood flow is restored. The tube is then removed. The blood vessels that will be treated in the RANGER II SFA study include the superficial femoral arteries and the proximal popliteal arteries."
223760945|NCT05925517|OTHER|Graded Motor Imagery (GMI)|"GMI includes three stages. Each session will be 30 minutes, and the GMI program will span over 8 weeks. The first 3 weeks will focus on lateralization, followed by 3 weeks of motor imagery, and the final 2 weeks will involve mirror therapy.~Lateralization: Patients will be asked to differentiate whether the extremities shown in the Recognise™ Knee application belong to the right or left side of their body.~Motor Imagery: Patients will be instructed to imagine slowly and smoothly moving their affected extremities to the posture depicted in the photos in the Recognise™ Knee application and then returning to the starting position.~Mirror Therapy: Using a mirror measuring 90x60 cm² placed between the lower extremities, patients will be instructed to progressively move only their unaffected extremity, then their affected extremity, and finally both extremities."
223760946|NCT05925517|OTHER|Transcutaneous Electrical Nerve Stimulation (TENS)|Application will be performed using a TENS device and four separate 2 × 2 inch self-adhesive electrodes. The current will be applied to the most painful area of the affected knee. The four self-adhesive electrodes will be positioned in a square pattern, approximately 5 cm apart, centered over the pain point. Conventional TENS will be applied for 30 minutes at a frequency of 100 Hz, pulse width of 100 μs, and intensity below 10% of the motor threshold.
224312397|NCT02511821|OTHER|Quality-of-Life Assessment|Ancillary studies
224312398|NCT02511821|OTHER|Questionnaire Administration|Ancillary studies
223512437|NCT05411900|DRUG|Placebo|"Placebo will consist of equal volume of saline solution (0.9%). Injections will be repeated at sites 1-1.5 cm apart (0.1 ml, 16.6 units per site), up to 20 sites (333 units).~To reduce pain caused by the injection, lidocaine and prilocaine cream will be applied to the skin area 60 min before the procedure. Additionally, ice could be applied for a few seconds (4-8) before each injection.~Injections will be repeated at week 0 and week 12.~The active treatment and placebo solutions will be transparent and indistinguishable to maintain treatment blindness."
223760947|NCT05925517|OTHER|Conventional Physiotherapy Program|The routine 60-minute program for OA patients in conventional physiotherapy includes warming up, core stability, pelvic and hip stability, gluteus medius strengthening, knee control and stability (knee flexion and extension control, lunge exercises), knee strengthening exercises (wall-assisted leg press with a ball, step-ups with elastic bands), and functional exercises.
223760948|NCT05925517|OTHER|Home Exercise Protocol|The home exercises will include a warm-up consisting of a 10-minute walk at a normal pace on a flat surface while gently stretching the hamstring and calf muscles. The exercises will also involve straight leg raises, terminal knee extension, isometric contractions of the quadriceps femoris and adductor muscles using a pillow for support, toe raises, single-leg standing, toe taps, and quadriceps strengthening exercises included in the session.
223760949|NCT05415267|BIOLOGICAL|diphtheria and tetanus toxoids (adsorbed) vaccine|The diphtheria/tetanus toxoids vaccine will be given to participants enrolled into Group 1 as a comparator vaccine to the mRNA COVID-19 booster vaccine with the aim of determining whether the results related to COVID-19 vaccine timing also apply to more traditional protein-based vaccines.
223760950|NCT05415267|BIOLOGICAL|COVID-19 vaccine|All participants will receive a COVID-19 booster vaccination at either week 0 or week 24 depending on their randomised study arm
223760951|NCT06799403|BEHAVIORAL|Therapist-assisted online stress management|Participants gain access to an online program comprised by 14 modules covering psychoeducation on stress, sleep, and communication, cognitive behavioral restructuring, and exercises and tools for dealing with stress and preventing relapse. Participants are followed by a therapist providing feedback on exercises and progress. The program extends over approx. 12 weeks.
223760952|NCT06799403|BEHAVIORAL|Group-based face-to-face stress management|The group-based format consists of 8 sessions of each 3 hours spread across 12 weeks. The sessions cover psychoeducation on stress, sleep, and communication, cognitive behavioral restructuring, and exercises and tools for dealing with stress and preventing relaps. A group includes 8-9 participants
223760953|NCT05778188|DRUG|RLS-0071|RLS-0071 (unit strength 10 mg/mL) will be administered by infusion for a dose level of 3 or 10 mg/kg. Planned infusion duration is 10 minutes for all dose levels.
223760954|NCT05778188|DRUG|Placebo|Placebo control (commercial sterile saline) will be administered by infusion at a volume matched to RLS-0071 (3 or 10 mg/kg). Planned infusion duration is 10 minutes for all matched dose levels.
223760955|NCT04156815|RADIATION|1,565nm NAFL|1,565nm M22-ResurFx NAFL can deliver additional benefits to existing acne scar and skin texture. Patients were first treated by the 1,565nm M22-ResurFx NAFL on inflammatory papules and boxcar atrophic scars using round or rectangle light spots with similar sizes of individual lesional papules or scars. The energy fluence was 60 mJ and spot density was 150 spots/cm2. A whole face pass treatment was followed using hexagon or rectangle light spots with fluences of 40-45 mJ, density of 200 spots/cm2 and no overlap on light spots. The end points of the treatment were appearance of localized erythema, edema and bruise on treated areas.
223760956|NCT04156815|DRUG|Oral isotretinoin|Oral isotretinoin has remained the most effective medication for moderate-to-severe AV.Subjects received oral isotretinoin (Xingyi Yan'an Pharmaceutical, Shanghai, China) (1mg/kg/d for the first 2-4 weeks and 0.5mg/kg/d for the next 12-14 weeks) for a total of 16 weeks. Serum triglycerides, cholesterol and levels of liver enzymes were monitored every month during oral isotretinoin medication.
224202108|NCT06943339|OTHER|High energy and protein enteral nutrition|It will include the baseline and 15-day follow-up data of the patients in the high energy and protein enteral nutrition group for the intake of high energy and protein containing product (1.5kkal/1ml + protein content increased). No intervention will be made by the researchers during the treatment process of the patients.
223510183|NCT03944005|PROCEDURE|Spinal Anesthesia + LIA + Sham Blocks|"ACB - On identification of adductor canal, 10ml of saline as a sham solution will be injected to surround the femoral artery. Following catheter placement, another 10ml of the same solution will be injected. Continuous infusion of 5ml/hr of saline will be infused till considered ready to discharge.~Ipack - Posterior knee infiltration will be performed following ACB. On visualization of the femoral condyle and popliteal artery, 20ml of saline will be infiltrated in the muscular space between popliteal artery and posterior femoral condyle.~Spinal anesthesia will be performed following the nerve blocks. All patients will receive 2-3ml of 0.75% preservative-free bupivacaine injected at the level of L2-3 or L3-4 intervertebral space.~LIA - Patients will receive local infiltration by the attending surgeon intraoperatively with 300mg of ropivacaine (100ml of 0.3% ropivacaine),30 mg of ketorolac, and 10mg of morphine around the knee capsule."
223510184|NCT02597361|DRUG|Irbesartan|Irbesartan: 150 or 300 mg o.d. The up-titration of irbesartan from 150 mg to 300 mg o.d. occur during the first 8 weeks following randomization
223510185|NCT02597361|DRUG|Placebo|Placebo o.d. to match 150mg or 300mg irbesartan tablets
223510186|NCT03592992|DRUG|Spinal Hydromorphone|75 mcg of hydromorphone will be prepared in a non-identifiable syringe by central hospital pharmacy. The resulting solution will then be added to the spinal anesthetic mixture(fentanyl 15 mcg and 0.75% hyperbaric bupivacaine 1.4-1.6 mcg at the discretion of the attending anesthesiologist, adjusted to height and weight)
223510187|NCT03592992|DRUG|Spinal Morphine|150 mcg of morphine will be prepared in a non-identifiable syringe by central hospital pharmacy.The resulting solution will be added to the spinal anesthetic mixture (fentanyl 15 mcg and 0.75% hyperbaric bupivacaine 1.4-1.6 mcg at the discretion of the attending anesthesiologist, adjusted to height and weight)
223510188|NCT02882893|DRUG|Clostridium Botulinum A Toxin|
223510189|NCT02882893|DRUG|Clostridium Botulinum A Toxin|
223510190|NCT05446155|DIAGNOSTIC_TEST|Imaging|Diagnostic and prognostic imaging, omics and machine learning methods will be applied
223510191|NCT04289272|BEHAVIORAL|Dove Confident Me|Dove Confident Me is a school-based intervention co-created by researchers at La Trobe University (Australia), the Centre for Appearance Research UWE, teachers, students, and education experts, and the Dove Self-Esteem Project (the social mission for personal care brand Dove). The five-session intervention is aimed at adolescents aged between 11-13 years, and targets recognised risk factors for body dissatisfaction, by addressing societal appearance ideals (Session 1), media literacy (Session 2), appearance comparisons (Session 3), appearance-related conversations and teasing (Session 4), and promoting 'body activism' (Session 5). The intervention consists of classroom-based discussion and small group activities, and uses audio-visual materials and worksheets to facilitate learning.
223510192|NCT02011997|PROCEDURE|patients undergo cVATS segmentectomy|
224312399|NCT04320654|OTHER|exercise|The aim of this intervention is to increase patients average daily step count. The walking program is a behavior change intervention in which the pedometer will be used as a tool to help the patients monitor their activity levels.
224312400|NCT00000212|DRUG|Desipramine|
224312401|NCT00906386|DRUG|Varenicline|oral, 1 mg twice daily, 12 weeks
224202109|NCT04962659|BEHAVIORAL|Mindfulness-Based Music and Songwriting|The Mindfulness-Based Music and Songwriting (MBMS) program involves up to 8 weekly sessions (\~1 hour each) delivered via telehealth. During sessions, the participant works with a therapist (e.g., board-certified music therapist) to learn and apply mindfulness practices via music-based meditations and mindful songwriting. Supported by the therapist, participants write two songs during the program.
224202110|NCT03899220|BEHAVIORAL|Project Matter|This intervention includes 5 face-to-face therapy sessions with a trained clinician plus a bidirectional text component that queries mood, substance use, and medication adherence. Both the intervention group and the enhanced treatment as usual (E-TAU) involve a one-session behavioral engagement in care intervention as well as substance use treatment counseling.
224202111|NCT01584050|DIETARY_SUPPLEMENT|L-5-methyltetrahydrofolate (Metafolin ®)|dosage: 1000 μg, frequency: once daily, duration: 12 weeks
224202112|NCT01584050|DIETARY_SUPPLEMENT|folic acid|dosage: 1000 μg, frequency: once daily, duration: 12 weeks
224202113|NCT01584050|DIETARY_SUPPLEMENT|Placebo|frequency: once daily, duration: 12 weeks
224202114|NCT00330772|DRUG|Aspirin|
224202115|NCT00330772|DRUG|Clopidogrel|
224202116|NCT02729545|OTHER|Tung's acupuncture|The study took Tung's acupoints as main acupuncture points, which were Fuke, Huanchao, Tianhuang, Renhuang, as well as the traditional acupoints Guanyuan (CV4) and Zigong (EX-CA1).
224202117|NCT02729545|DRUG|Cyproterone acetate/ethinylestradiol (CPA/EE)|Cyproterone acetate/ethinylestradiol (CPA/EE) contains 2mg cyproterone acetate (an anti-androgenic progestin) and 0.035mg ethinylestradiol (CPA/EE). The pills were administered for 21 days consecutively. The patients then stopped taking the pills for seven days and, on the eighth day, continued to take the pills again for three menstrual cycles (28 day cycles).
224202118|NCT04313686|BEHAVIORAL|Mindfulness-based therapy|Based on randomization, those who first receive the mindfulness training program are the intervention group. Participants would meet weekly for 2-3-hour long sessions for six weeks at the patient's usual follow-up clinic.
224312402|NCT00906386|DRUG|placebo|oral, 1 mg twice daily, 12 weeks
224202119|NCT04313686|BEHAVIORAL|No-intervention|Participants who were randomized into this group would continue to receive their usual follow-up care at the usual neurology outpatient clinic.
224202120|NCT00118196|DRUG|arsenic trioxide|
224202121|NCT00118196|DRUG|azacitidine|
224202122|NCT06539780|BEHAVIORAL|Imagery Rescripting|In Imagery Rescripting participants imagine a different sequence of events based on missed emotional needs and rescript until needs are fulfilled. Duration of sessions is up to 60 minutes.
223510193|NCT02011997|PROCEDURE|Patients undergo cVATS lobectomy|
223510194|NCT03154112|DEVICE|Measurement of oxygen consumption and caloric expenditure|This study will involve an \~1 hour, single point in time measurement of oxygen consumption, carbon dioxide production, resting energy expenditure, and respiratory quotient using two methods while patients are breathing an FiO2 of 40%. These measurements will be measured using the novel, responsive device and compared with gas collected simultaneously collected from a Douglas bag.
223510195|NCT00183612|DRUG|Olanzapine|
223510196|NCT00948935|DRUG|Gemcitabine, Irinotecan, Panitumumab|Gemcitabine 1000 mg/m2 over 100 minutes(Days 1, 8), irinotecan 100 mg/m2 IV over 60 minutes(days 1, 8) and panitumumab 9 mg/kg IV (day 1) every 3 weeks as a cycle. Continue until disease progression or unacceptable toxicities.
223510197|NCT02594852|DEVICE|+ laser|Use of laser in the treatment
223510198|NCT04727827|OTHER|Pharmacogenomic-guided supportive care|Patients undergoing hematopoietic stem cell transplantation will be genotyped and supportive care therapies tailored to identified drug-gene pairs and guideline recommendations
223510199|NCT01634750|DRUG|ManNAc|Single dose
223510200|NCT04559672|PROCEDURE|Cervical laminoplasty surgery|The posterior standard cervical laminoplasty procedure with ARCH mini-plate fixation
223510201|NCT04559672|PROCEDURE|Cervical laminectomy and fusion surgery|The posterior standard cervical laminectomy and fusion surgery procedure with lateral mass screws fixation
223510202|NCT01061710|DRUG|varenicline|Dosage form: tablet 0.5mg, tablet 1mg. The usual adult dosage for oral use is 0.5 mg once daily after eating on Days 1 to 3; 0.5 mg twice daily after eating in the morning and evening on Days 4 to 7, and 1 mg twice daily after eating in the morning and evening on Day 8 and thereafter. The drug should be administered to subjects for 12 weeks.
223510203|NCT04071483|PROCEDURE|Cervical transforaminal epidural steroid injection|Cervical transforaminal epidural steroid injection is a useful option in the diagnosis and treatment of cervical radicular pain.
223510204|NCT00482456|DRUG|Nitrous oxide|
223510205|NCT00201773|DRUG|Exemestane|25 mg orally once per day for 16 weeks.
223510206|NCT00201773|DRUG|Celecoxib|given orally at two 200 mg capsules (400 mg) twice per day. Patients assigned to receive 400 mg twice per day should be instructed to take the drug with food.
223510207|NCT00201773|OTHER|Correlative studies|
223510208|NCT03087123|BEHAVIORAL|P-Mobile App|The behavioral strategies are based on Social Cognitive Theory. The following topics will be covered: self-monitoring, goal setting, stimulus control, making time for exercise, exercising in- and outdoors, problem-solving, reinforcing PA, reducing sedentary behaviors, relapse prevention, parental modeling, lifestyle exercise, self-efficacy, self-management, parental PA modeling, parental co-participation, and establishing PA rules. Parents will be provided with adapted step goals (based on principles of shaping). Text messages will be designed to prompt PA, remind parents of concepts from the lessons, and motivate behavioral change.
223510209|NCT02533128|DRUG|Liberal blood pressure management|Protocolized hemodynamic management to maintain mean arterial pressure (MAP) \> 60 mmHg
223510210|NCT02533128|DRUG|Tight blood pressure management|Protocolized hemodynamic management to maintain mean arterial pressure (MAP) \> 75 mmHg
223510211|NCT03757715|DRUG|Bupivacaine|20 mL of 1.3% bupivacaine
223510212|NCT03757715|DRUG|Dexamethasone|2 mg dexamethasone
224312403|NCT00085475|DRUG|imatinib mesylate|
224312404|NCT00085475|PROCEDURE|conventional surgery|
224312405|NCT02472327|BEHAVIORAL|Pre-operative support|
223616073|NCT06525428|DRUG|standard systemic therapy combined with high/low-dose radiotherapy plus toripalimab|"First-line standard systemic therapies in cohort A include: FOLFOX/XELOX+ bevacizumab, FOLFOX/XELOX+cetuximab (KRAS/NRAS/BRAF WT and left-sided tumors only), FOLFIRINOX+ bevacizumab.~Second-line standard systemic therapies in cohort B include: FOLFOX/XELOX+ bevacizumab, FOLFOX/XELOX+cetuximab (KRAS/NRAS/BRAF WT), FOLFIRI/irinotecan+raltitrexed/irinotecan/+bevacizumab, FOLFIRI/irinotecan+raltitrexed/irinotecan/+cetuximab (KRAS/NRAS/BRAF WT), based on the previous first-line chemotherapy and adverse events.~Toripalimab will be given at 240 mg q3w. Radiotherapy regimes include 4-8 fractions of 4-12Gy via SABR or hypofractionated radiotherapy (HFRT) and 5 fractions of 0.5-2Gy via LDRT"
224312406|NCT01325727|OTHER|Brief computerized feedback|Brief computerized feedback
223616074|NCT05587816|DEVICE|Validation of the PortionSize app|The investigators will recruit 40 dyads (40 children aged 7-12 years old and 40 parents or caregivers) using a convenience sample for this pilot study. Children and their parents or caregivers will be trained to use the PortionSize app at Pennington Biomedical Research Center (PBRC). Children will use the PortionSize app and estimate food intake from pre-weighed meals (simulated meals) at PBRC clinic. Children will not consume the simulated meals. Children's parents or caregivers will also use the PortionSize app and estimate the food intake of their children (at least one meal and a snack each day) for two consecutive days at home.
223616075|NCT00786383|BIOLOGICAL|IMC-1121B|"Cohort 1~6 mg/kg I.V., once every other week for 4 weeks"
223616076|NCT00786383|BIOLOGICAL|1121B|"Cohort 2~8mg/kg I.V., once every other week for 4 weeks"
223616077|NCT00786383|BIOLOGICAL|1121B|"Cohort 3~10 mg/kg I.V., once every other week for 4 weeks"
223616078|NCT00786383|BIOLOGICAL|1121B|"Cohort 4~15 mg/kg I.V., once every 3 weeks for 6 weeks"
223616079|NCT00786383|BIOLOGICAL|1121B|"Cohort 5~20 mg/kg I.V., once every 3 weeks for 6 weeks"
223616080|NCT01512134|DEVICE|Deep Brain Stimulation Device|Deep brain stimulation surgery
223616081|NCT03033277|BIOLOGICAL|Placebo transplantation|Intraovarian injection of placebo through vagina under the guidance of ultrasonic.
223616082|NCT03033277|BIOLOGICAL|HUC-MSCs transplantation|Intraovarian injection of HUC-MSCs through vagina under the guidance of ultrasonic.
223616083|NCT02383563|DRUG|metformin extended release|
223616084|NCT01447654|DRUG|Losartan|100 mg for 12 months.
223616085|NCT01447654|DRUG|Placebo|100 mg for 12 months.
223616086|NCT01033981|DRUG|Sunitinib|Treatment for mRCC as indication approved and physician criterium
223616087|NCT01925885|PROCEDURE|PVI Ablation|PVI ablation for atrial fibrillation specifically targets areas in the left atrium in the area just outside the pulmonary veins to eliminate triggers of atrial fibrillation.
223616088|NCT01925885|PROCEDURE|FIRM Ablation|Ablation for atrial fibrillation specifically targets areas in the left or right atrium to eliminate areas that maintain atrial fibrillation without isolating the pulmonary veins
223616089|NCT05254665|DRUG|Docetaxel Polymeric Micelles for Injection|Docetaxel polymeric micelles，usage and quantity of Docetaxel polymeric micelles follows the clinical study proctol，not published.
223616090|NCT06440473|DRUG|Roflumilast|Roflumilast 0.3% cream
223616091|NCT06440473|OTHER|Vehicle (Roflumilast 0.3% vehicle cream)|Vehicle (Roflumilast 0.3% vehicle cream)
223616092|NCT02136979|DRUG|Propofol|group of patients with propofol-based anesthesia
223616093|NCT02136979|DRUG|Sevoflurane|group of patients with sevoflurane-based anesthesia
224202123|NCT05526924|RADIATION|Chemoradiation|A combination of chemotherapy and radiation given at the same time to treat cancer.
224202124|NCT05526924|DRUG|Pamiparib|An anti-cancer drug that targets specific cells to help fight cancer given by IV (through a needle inserted into a vein).
224202125|NCT05526924|DRUG|Hydroxyurea|A chemotherapy drug given in pill form; used to treat leukemia and head and neck cancer.
224202126|NCT05526924|DRUG|Fluorouracil (5FU)|A chemotherapy drug used to treat different types of cancer.
224202127|NCT05526924|DRUG|Tislelizumab|An anti-cancer drug.
224312407|NCT01325727|OTHER|Resources only (control)|Participants randomized to the control group will discuss the option of quitting smoking, along with an information sheet, highlighting resources available to assist participants with smoking cessation, such as the Virginia Quitline (1-800 QUIT NOW) and nicotine replacement therapy.
223616094|NCT06074848|DEVICE|Transcranial Direct Current Stimulation (tDCS)|tDCS deliver low-intensity electrical currents (2 mA) through electrodes placed on the scalp. It is used to influence brain function, modulating the neuronal activity in specific areas, in a non-invasive way, as the stimulation may not be perceived sensorially due to the low intensity. In some cases, it can provide mild tingling and bring minimal discomfort. It has the ability to increase or decrease the cortical excitability of neurons, influencing the polarization of neuronal membranes, with the anodal pole (positive) facilitating depolarization that results in increased neuronal excitability in the area, and the cathodal pole (negative) promoting a hyperpolarization of the neuronal resting membrane potential that reduces cortical excitability, used to inhibit activity in a particular cortical area.
223616095|NCT06074848|BEHAVIORAL|Motor Training|Motor training will be performed on the treadmill with the speed respecting the limits of the patient's maximum heart rate. To determine the maximum heart rate, the calculation must be performed: maximum heart rate = 208 - (0.7\*age). For participants who use beta-blockers, the following formula will be used: maximum heart rate = 164 - (0.7\*age). Just for the arms of fatigue and pain.
224202128|NCT00398632|DRUG|Duloxetine|dosage form: capsule. dosage: 60 mg. frequency: once daily, or twice daily if 120 mg/day is needed to control symptoms of major depression. duration: 12 weeks
224202129|NCT02139085|DEVICE|GSV Electrocoagulation|The energy source will be the Electrosurgical Generator (FX-Valley Lab; USA) and the GSV thermo ablation will be performed with 60 Watts per 10 seconds. The catheter and electrocoagulation device head will be pulled back in increments of 2 cm also to overlap the treatment sites.
224312408|NCT05148260|BEHAVIORAL|Learning Through Play plus (LTP+)|Group-1: Experimental (n=40 participants) will receive the LTP+ which consist of a total of 12-group integrated treatment sessions lasting approximately 60-90 minutes per session every fortnight with 10 mother/child pair per sub-group.
224312409|NCT05148260|BEHAVIORAL|Psychoeducation|Group-2: Controlled (n=40 participants) will receive 'psychoeducation' which consist of a total of 12-group sessions lasting approximately 60-90 minutes per session every fortnight with 10 mother-child pair per sub-group.
223616096|NCT06074848|BEHAVIORAL|Cognitive Training|an n-Back task will be performed online at PsyToolkit (https://www.psytoolkit.org/). Just for the arms of cognitive impairment and depressed mood.
223616097|NCT03270943|BEHAVIORAL|MFY|Mindful Self-Compassion course for teens
223616098|NCT03270943|BEHAVIORAL|HLG|Healthy Lifestyles course for teens
223616099|NCT03342586|DIAGNOSTIC_TEST|Resting State fMRI (rsfMRI)|rsfMRI before receiving High-dose chemotherapy with autologous stem cell transplantation/HDC-ASCT (pre-HDC-ASCT), at approximately 3 months (+/- 2 weeks) after HDC-ASCT (early post-HDC-ASCT) and approximately 6months (+/- 2 weeks) after HDC-ASCT (late post-HDC-ASCT).
223616100|NCT03342586|OTHER|Auditory Attention and Executive Functions Test|"* Trail Making Test (Parts A \& B): Part A is a timed test of visual scanning and graphomotor speed; AT: 3 minutes. Part B is a timed measure of set-shifting; Administration Time (AT): 5 minutes. Test-retest reliabilities=0.64-0.94.~* Brief Test of Attention-BTA assesses auditory working memory; AT: 10 minutes. Test-re-test reliability=0.70.~* Controlled Oral Word Association Test-COWAT is a timed measure of phonemic verbal fluency. It requires the subject to generate as many words as possible, beginning with a given letter of the alphabet (i.e., F, A, and S). The subject is allowed 60 seconds per letter, and the resultant score is the total number of words produced. Test-retest reliability=0.88. AT: 5 minutes."
223616101|NCT03342586|OTHER|Memory Test|The Hopkins Verbal Learning Test-Revised (HVLT-R): The HVLT-R is a test of verbal learning and memory.
223616102|NCT03342586|OTHER|Motor Speed Test|Grooved Pegboard Test (GPT)-Dominant Hand and Non-Dominant Hand. It is a timed test of manual dexterity, in which the time to completion is scored separately for each hand.
223616103|NCT03342586|OTHER|Self Reported Quality of Life Questionnaire|The Functional Assessment of Cancer Therapy-Brain Cancer (FACT-BR Version 4) consists of 46 questions with five domains assessing physical well-being, social/family well-being, emotional well-being, functional well being, additional concerns. The neuropsychological and QOL assessments will be performed by a neuropsychologist or by a trained RSA under the neuropsychologist's direct supervision.
223616104|NCT05980728|OTHER|No Intervention|No Intervention
223616105|NCT02981368|DRUG|18F-DCFPyL Injection|A single dose of 9±1 mCi (333±37 MBq) IV injection of 18F-DCFPyL
223616106|NCT02981368|DIAGNOSTIC_TEST|PET/CT imaging|PET/CT imaging will be acquired 1-2 hours post-PyL injection
224075455|NCT06195020|OTHER|Metaverse|"The research consists of two stages (preparation and implementation). In the first stage of the research, the educational material planned to be used in the education of parents (video of navigation in the metaverse) will be developed in the form of modules. The topics in the training materials to be developed are listed below.~Module 1: Information about Epilepsy (What is epilepsy?, What are the causes of epilepsy? Module 2 Diagnostic Methods in Epilepsy (Neurological examination, blood tests, electroencephalogram, screening tests 3rd Module Treatment of Epilepsy (Things to consider in patients receiving antiepileptic drug therapy) Module 4: First Aid in Epilepsy (first aid in seizures with convulsions, first aid in seizures without convulsions) Module 5: Life with Epilepsy (Epilepsy and school, epilepsy and career choice, epilepsy and home safety, epilepsy and exercise, epilepsy and healthy nutrition, epilepsy and sleep) The intervention will last 3 months."
224202130|NCT02139085|DEVICE|GSV Radiofrequency|The second generation RF device (Closure FAST; Covidien, USA) will be used. The treatment component of the device is 7 cm in length and works with a segmental pullback protocol. Once the catheter is in position, activation of the generator delivers 20- seconds cycles of energy to the catheter tip, which heats the vein wall to 120 o C.
224202131|NCT03403920|OTHER|Questionnaire|Profile Fitness Mapping Low Back Questionnaire
224202132|NCT05644938|PROCEDURE|Standard workflow|The SW group was either transferred to angiosuite or received rTPA, if indicated, after the results of Magnetic resonance imaging (MRI) and Magnetic resonance angiography (MRA) at admission.
224202133|NCT05644938|PROCEDURE|One-stop|The OS group transferred directly to ﬂat-detector computed tomography to consider recanalization by either intervention or recombinant Tissue Plasminogen Activator (rTPA) in the angiosuite.
224202134|NCT04906473|DRUG|KY100001|KY100001; Tablet; Oral route; Dose escalation and dose extension
224202135|NCT00197184|BIOLOGICAL|Twinrix™ Adult|Intramuscular injection in the left deltoid, 2 doses, Adult formulation in primary study.
223616107|NCT06059235|OTHER|pharmaceutical care|"consultation with a pharmacist performing advanced pharmaceutical care : Package of clinical pharmacy activities including :~Medication history (during assessment consultation) Medication review and consultation with the geriatrician Therapeutic education (during results consultation) Shared decision (at results consultation) One-week follow-up call + usual care"
223616108|NCT03684616|DRUG|Statin|continuous statin treatment for 3 months prior to cardiac arrest
223616109|NCT05308992|DEVICE|HydroGlyde Condom|The latex HydroGlyde condom has a hydrophilic coating which maintains its lubricity when in contact with water. Improved lubrication during intercourse may lead to improved user satisfaction and increased condom use which would help prevent the spread of Sexually Transmitted Infections and unwanted pregnancies.
223616110|NCT04412577|DRUG|TQB3473|TQB3473 tablets administered orally once. Then TQB3473 tablets administered orally, once daily in 28-day cycle after 3 days of first administration.
223616111|NCT05348902|OTHER|In this study, only cases were collected and reported without any intervention or adverse reactions|In this study, only cases were collected and reported without any intervention or adverse reactions
223616112|NCT03189186|DRUG|Pembrolizumab Injection [Keytruda]|Same as arm description
223616113|NCT03189186|PROCEDURE|Cryoablation|Cryoablation uses liquid argon in metal needles to freeze tumors. Tumor cells are ruptured due to the forming ice crystals and die. Cryoablation is standardly used in tumors less then 4cm in diameter.
223616114|NCT03189186|PROCEDURE|Nephrectomy|Nephrectomy is the surgical excision of either the entire kidney or a small portion of the kidney. Nephrectomy is standardly used to treat renal cell cancer.
223616115|NCT03991312|DRUG|itraconazole|Participants will receive an oral solution as described in the arm description.
223510213|NCT00281580|DRUG|Amlodipine 5 mg|Amlodipine 5 mg once daily for two weeks
224202136|NCT00197184|BIOLOGICAL|Twinrix™ Junior|Intramuscular injection in the left deltoid, 3 doses, junior formulation in primary study.
224202137|NCT05200507|DEVICE|High Frequency Percussive Ventilation|High Frequency Percussive Ventilation will be applied for 10 minutes at an oscillation frequency of 10 Hz, superimposed to the ventilatory assistance
224202138|NCT00366678|BIOLOGICAL|13-valent pneumococcal conjugate vaccine|Single 0.5 mL dose given at 2, 3, 4, and 12 months of age.
224202139|NCT00366678|BIOLOGICAL|7-valent pneumococcal conjugate vaccine|Single 0.5 mL dose given at 2, 3, 4, and 12 months of age.
224202140|NCT00366678|DRUG|Pentavac|The Pentavac was administered by intramuscular injection 0.5 ml into the anterolateral thigh muscle of the right leg at 2, 3, and 4 months (infant series) and 12 months of age (toddler dose).
224202141|NCT04292171|DRUG|Gabapentin|Preoperative treatment with Gabapentin
224202142|NCT04292171|DRUG|Placebos|Preoperative treatment with Placebo
224202143|NCT02816554|BIOLOGICAL|JEVAX|JEVAX - VABIOTECH Vietnam Liquid form Subcutaneous injection 0.5ml/dose, 2 doses, 10-12 days interval
224202144|NCT02816554|BIOLOGICAL|JECEVAX-1|JECEVAX - VABIOTECH Vietnam Liquid form Composition: 1 BR209 Subcutaneous injection 0.5ml/dose, 2 doses, interval 10-12 days
224202145|NCT02816554|BIOLOGICAL|JECEVAX-0.8|JECEVAX - VABIOTECH Vietnam Liquid form Composition: 0.8 BR209 Subcutaneous injection 0.5ml/dose, 2 doses, interval 10-12 days
224202146|NCT02816554|BIOLOGICAL|JECEVAX-0.5|JECEVAX - VABIOTECH Vietnam Liquid form Composition: 0.5 BR209 Subcutaneous injection 0.5ml/dose, 2 doses, interval 10-12 days
224202147|NCT00317083|PROCEDURE|Cough reflex test|
224202148|NCT04296461|GENETIC|Welgenaleucel|Welgenaleucel (UWC19) is a CD19-directed immunotherapy consisting of autologous T cells, which is reprogrammed to target cells that express CD19.
224202149|NCT02337426|DRUG|Dimethyl Fumarate|Given PO
224202150|NCT02337426|DRUG|Temozolomide|Given PO
224202151|NCT02337426|RADIATION|Radiation Therapy|Undergo radiation therapy
224202152|NCT06204536|OTHER|Tech-enabled ABA treatment planning|The tech-enabled ABA treatment planning will involve the use of a proprietary MLA integrated within a proprietary software application for use on a tablet, phone, or other smart device by BCBAs (one proprietary software application, one non-proprietary software application). The proprietary application provides functionality for treatment plan development, including templates and centralized resource availability. This tech will be used as adjunct or auxiliary tools to develop and manage ABA treatment plans. The proposed period of time for this intervention (the latter portion of the study subsequent to the non-interventional phases) will be 24 months.
223510214|NCT00281580|DRUG|Placebo|Placebo to Telmisartan and Amlodipine once daily for eight weeks
223510215|NCT00281580|DRUG|Telmisartan 20 mg|Telmisartan 20 mg once daily for eight weeks
223510216|NCT00281580|DRUG|Telmisartan 40 mg|Telmisartan 40 mg once daily for eight weeks
223616116|NCT03991312|DRUG|rifampin|Participants will receive oral capsule(s) as described in the arm description.
224202153|NCT03596086|DRUG|ADV/HSV-tk (gene therapy)|The investigational adenovirus gene therapy injected at tumor site followed by valacyclovir, radiotherapy, and chemotherapy
223510217|NCT00281580|DRUG|Amlodipine 10 mg|Amlodipine 10 mg once daily for six weeks
223510218|NCT00281580|DRUG|Telmisartan 20 mg|Telmisartan 20 mg once daily for eight weeks
223510219|NCT00281580|DRUG|Telmisartan 80 mg|Telmisartan 80 mg once daily for eight weeks
223510220|NCT00281580|DRUG|Amlodipine 10 mg|Amlodipine 10 mg once daily for six weeks
223510221|NCT00281580|DRUG|Telmisartan 20 mg|Telmisartan 20 mg once daily for eight weeks
223510222|NCT00281580|DRUG|Amlodipine 5 mg|Amlodipine 5 mg once daily for two weeks
223510223|NCT00281580|DRUG|Amlodipine 5 mg|amlodipine 5g once daily for eight weeks
223510224|NCT00281580|DRUG|Telmisartan 20 mg|Telmisartan 20 mg once daily for eight weeks
223510225|NCT00281580|DRUG|Amlodipine 5 mg|Amlodipine 5 mg once daily for eight weeks
223510226|NCT00281580|DRUG|Amlodipine 5 mg|amlodipine 5mg once daily for eight weeks
223510227|NCT00281580|DRUG|Amlodipine 2.5 mg|Amlodipine 2.5 mg once daily for eight weeks
223510228|NCT00281580|DRUG|Amlodipine 2.5 mg|Amlodipine 2.5 mg once daily for eight weeks
223510229|NCT00281580|DRUG|Amlodipine 10 mg|Amlodipine 10 mg once daily for six weeks
223616117|NCT03991312|DRUG|mitapivat sulfate|Participants will receive an oral tablet as described in the arm description.
223616118|NCT00048412|DRUG|FLUDARABINE|
224202154|NCT04720573|DRUG|Neostigmine|50 mcg/kg neostigmine was used under the guidance of TOF monitoring after cessation of anesthesia.
224202155|NCT04720573|DRUG|Sugammadex|2 mg/kg sugammadex was used under the guidance of TOF monitoring after cessation of anesthesia.
224202156|NCT02397174|OTHER|mediterranean diet, restricted calorie|50 pcos women will be assigned to hypocaloric mediterranean diet for 6 months
223616119|NCT00048412|DRUG|CAMPATH 1H|
223616120|NCT00048412|DRUG|FK50|
224202157|NCT02397174|OTHER|hypocaloric diet, restricted calorie|50 pcos women will be assigned to standardized hypocaloric diet for 6 months
224202158|NCT04794582|DEVICE|ProGrip™ Self-Gripping Polyester Mesh|Supra-aponeurotic placement of ProGrip® macroporous polyester mesh in the supra-aponeurotic position
224202159|NCT01658982|OTHER|cardiopulmonary exercise testing|3 minute step test compared to 6 minute bicycle test
224202160|NCT01467401|DRUG|biphasic insulin aspart|Individually adjusted dose. Injected subcutaneously (s.c., under the skin) twice daily
224202161|NCT01467401|DRUG|biphasic human insulin|Individually adjusted dose. Injected subcutaneously (s.c., under the skin) twice daily
224202162|NCT04711512|BEHAVIORAL|Encouragement/Support|Messages that focus on improving self-efficacy and motivation for physical activity
223510230|NCT00281580|DRUG|Amlodipine 2.5 mg|Amlodipine 2.5 mg once daily for eight weeks
223510231|NCT00281580|DRUG|Telmisartan 80 mg|Telmisartan 80 mg once daily for eight weeks
223616121|NCT00048412|PROCEDURE|Stem Cell Collection and Infusion|
224202163|NCT04711512|BEHAVIORAL|Social Comparison|Messages that provide exposure to another person's physical activity engagement data (for comparison)
224202164|NCT00334269|BEHAVIORAL|Health messaging at weekly home visits by health counsellor|
224202165|NCT00334269|BEHAVIORAL|Weekly home delivery of bottled spring water|
224202166|NCT00334269|BEHAVIORAL|Weekly afterschool physical activity program for 5-18y.o.|
223510232|NCT00281580|DRUG|Telmisartan 80 mg|Telmisartan 80 mg once daily for eight weeks
223510233|NCT00281580|DRUG|Amlodipine 5 mg|Amlodipine 5 mg once daily for two weeks
223510234|NCT00281580|DRUG|Amlodipine 2.5 mg|Amlodipine 2.5 mg once daily for eight weeks
223510235|NCT00281580|DRUG|Telmisartan 40 mg|Telmisartan 40 mg once daily for eight weeks
223510236|NCT00281580|DRUG|Telmisartan 40 mg|Telmisartan 40 mg once daily for eight weeks
223510237|NCT00281580|DRUG|Amlodipine 5 mg|amlodipine 5g once daily for two weeks
223510238|NCT00281580|DRUG|Amlodipine 5 mg|Amlodipine 5 mg once daily for eight weeks
223510239|NCT00281580|DRUG|Telmisartan 40 mg|Telmisartan 40 mg once daily for eight weeks
223510240|NCT00281580|DRUG|Telmisartan 80 mg|Telmisartan 80 mg once daily for eight weeks
223510241|NCT00281580|DRUG|Amlodipine 10 mg|Amlodipine 10 mg once daily for six weeks
223510242|NCT03640988|DEVICE|dermaPACE|Shockwave application
223510243|NCT00337688|DEVICE|isometric joystick|isometric joystick
223510244|NCT01655212|DRUG|Valganciclovir|Infants will be treated with valganciclovir for 6 weeks, 32 mg/kg daily dose in two doses, oral solution.
223510245|NCT01266057|DRUG|Hydroxychloroquine|Starting dose of 200 mg by mouth every day for a 21 day cycle.
223510246|NCT01266057|DRUG|Sirolimus|Starting dose of 2 mg by mouth every day for a 21 day cycle.
223510247|NCT01266057|DRUG|Vorinostat|Starting dose of 200 mg by mouth per day for a 21 day cycle.
223616122|NCT02875379|PROCEDURE|Measurements|Measurements of respiratory mechanics and parameters, arterial blood gases and comfort
223616123|NCT01414894|OTHER|Fluid manipulation|Patients are treated with conventional fluid replacement (Normovolemia) or increased the fluid replacement (Hypervolemia) for 10 days.
223616124|NCT01414894|OTHER|Blood Pressure Manipulation|Patients are treated with maintenance of blood pressure in a normal range (Conventional Blood Pressure) or increased the blood pressure (Augmented Blood Pressure) for 10 days.
223616125|NCT01913951|DRUG|vosaroxin|Given IV over 10 minutes on Day 1 and 4
223616126|NCT01913951|DRUG|Azacitidine|Given SC or IV over 15 minutes on days 1-7
223616127|NCT01626924|DRUG|2-Iminobiotin|2-Iminobiotin is formulated as a 0.75 mg/ml isotonic, iso-osmotic, saline solution with a pH of 4. It is administered as a solution for I.V.infusion through a central catheter. Six pulse doses will be given in 20 hours. Dosage will starts with 0.2 mg/kg/dose, but may be adapted during the study.
223616128|NCT04557540|BEHAVIORAL|Lifestyle Therapy|Receive The WORD lifestyle CER weight loss intervention
223616129|NCT04557540|OTHER|Quality-of-Life Assessment|Ancillary studies
223616130|NCT04557540|OTHER|Questionnaire Administration|Ancillary studies
223616131|NCT04557540|OTHER|Short-Term Fasting|Receive Fasting WORD intermittent fasting weight loss intervention
223616132|NCT02723773|BIOLOGICAL|Herpes Zoster Vaccine GSK1437173A|Intramuscular injection
223510248|NCT04385836|DRUG|alpha one antitrypsin inhalation|\- we will give 8 ml of intravenous alpha one antitrypsin (alpha1-proteinase inhibitor (AATD)Glassia 50 ml) as nebulizer every 12 hours for 5 days
223510249|NCT03302936|DRUG|Phenazopyridine|to be given preoperatively
223510250|NCT03107299|OTHER|Communication methods to encourage adherence|Prospective randomized controlled study in intention to treat in open monocentric in 3 arms: all patients benefiting from the current management (medical consultation every 4 to 6 months in the department of rheumatology)
223510251|NCT02520947|DEVICE|BIS|Bispectral index monitoring
223510252|NCT02520947|DRUG|Desflurane|volatile agent for maintenance of anesthesia
223510253|NCT05130021|DRUG|MAX-40279-01|MAX-40279-01 50mg/70mg
223510254|NCT05130021|DRUG|regorafenib|regorafenib
223510255|NCT04739774|DRUG|CHF6001 DPI|Single dose of CHF6001
223510256|NCT04739774|DRUG|Itraconazole|Repeated doses of oral Itraconazole
223510257|NCT01433965|DRUG|Lenalidomide|Lenalidomide will be taken orally once a day for 21 days continuously in 28 day cycles. The dose of the lenalidomide administered to each patient will be based on the group that the patient is enrolled. The dose cycles will be 21 days of a 28 day cycle.
223510258|NCT00170365|BEHAVIORAL|Restorative Yoga|
223510259|NCT04656431|DRUG|Hyperpolarized pyruvate (13C)|Given intravenously (IV) injection prior to imaging
223510260|NCT04656431|PROCEDURE|Magnetic resonance imaging (MRI)|MRI scan takes an image of brain and/or spinal cord and will take up to 45 minutes to complete
223510261|NCT01550965|BIOLOGICAL|Adalimumab|Adalimumab pre-filled syringe, administered by subcutaneous injection
223510262|NCT03240432|DEVICE|Dexcom CGM|CGM group will be instructed on how to utilize the CGM data for diabetes management. Participants will be encouraged to use CGM values for making diabetes management decisions and will be provided guidelines for when to confirm with a study BGM fingerstick.
223616133|NCT05401162|OTHER|Autologous blood transfusion with haematopoietic stem cells|Transfusion of autologous blood containing haematopoietic stem cells for haematopoietic reconstruction after chemotherapy.Blood tests were performed weekly, if the patient's neutrophils were less than 1.0 × 109 / L during chemotherapy, G-CSF was given as a remedial treatment. If fever occurs, antibiotics were given promptly.Monitor peripheral blood after transfusion. If peripheral blood leukocyte count does not reach 1.0 x 109/L, administer G-CSF 150 μg subcutaneously daily until peripheral blood leukocyte count reaches 1.0 x 109/L.Patients were tested monthly for peripheral blood cells for 6 months after the end of treatment.
223616134|NCT06523335|OTHER|Neuromuscular coordination-guided rehabilitative training|During training exercise, post-stroke participants will be asked to match the targets on the screen. The experimental group will match them by activating a specific set of muscle. During assessment trials, a physical therapist or occupational therapist will rate the functional level of arm impairment using FMA and ARAT.
223616135|NCT06523335|OTHER|Force strengthening-guided rehabilitative training|During training exercise, post-stroke participants will be asked to match the targets on the screen. The active comparator group will match them by generating isometric force in a desired target direction. During assessment trials, a physical therapist or occupational therapist will rate the functional level of arm impairment using FMA and ARAT.
223616136|NCT03789916|DRUG|Ticagrelor|90 mg bis in die
223616137|NCT03789916|DRUG|acetylsalicylic acid|100 mg die
223616138|NCT00481819|DRUG|FK506MR|oral
223616139|NCT00481819|DRUG|Prograf|oral
223616140|NCT00481819|DRUG|Mycophenolate Mofetil|oral
223616141|NCT00481819|DRUG|Methylprednisolone|oral
223616142|NCT00481819|DRUG|Prednisolone|oral
223616143|NCT05915845|OTHER|Laura Mitchell's Relaxation technique|This technique was used to eliminate muscular tension. Patients were taught to contract muscles opposite to the strained muscle groups, eventually to 'cease' shrunken them, and then to roster the position adaptation of the body structure. Patient was comfortably positioned.
223616144|NCT05915845|OTHER|Papworth exercise|"The Papworth Method integrates five components, the principal one being specific breathing training:~• Breathing training, including teaching of appropriate minute and tidal volume and the development of a pattern of breathing suitable to current metabolic activity.~Elimination of dysfunctional breathing, including hyperinflation and hyperventilation patterns is discussed. A specific Papworth method diaphragmatic breathing technique is taught to replace the use of inappropriate accessory muscles of respiration. When relaxed, is placed on calm slow nasal expiration. Patients are encouraged to nose-breathe rather than mouth-breathe and eradication or reduction of habits such as yawning, sighing, etc. is taught and practiced."
223616145|NCT05077930|BIOLOGICAL|Convalescent plasma|The intervention group will receive 200 or 400 mL of high-titer COVID-19 convalescent plasma, ABO compatible with the patient, within 24 hours of randomization.
223616146|NCT05077930|DRUG|Standard of care|The active comparator group will receive oxygen supplementation, corticoids, antiretrovirals, and/or monoclonal antibodies according to the institutional protocol.
223616147|NCT04296656|BEHAVIORAL|The 5 S's infant calming intervention|5 simple steps to calm a fussy or crying infant. Steps include swaddling, side position, sound (white noise), swing and suck.
223510263|NCT05897502|BEHAVIORAL|multimedia education|"The experimental group use multimedia education, 20 minute nutrition education courses each time, a total of 8 courses.~The control group use routine education."
223510264|NCT01235416|DRUG|AMG 706|In each of these 3 planned treatment cohorts, approximately 6 evaluable subjects will be treated with gemcitabine (1000-mg/m2 intravenously over 30 minutes, once weekly starting on day 1, week 1 of cycle 1) and erlotinib (100 mg orally once daily starting on day 1, week 1 of cycle 1)
223510265|NCT03760640|DRUG|LY900014|Administered SC
223616148|NCT01982734|DIETARY_SUPPLEMENT|curcumin|80 mg curcumin were given orally either as native powder, native powder plus phytochemicals,micelles or micelles plus phytochemicals
224075456|NCT06195020|OTHER|Polyclinic information|This group will be informed only at the outpatient clinic. The intervention will last 3 months.
223510266|NCT03760640|DRUG|Insulin Lispro|Administered SC
223510267|NCT03683498|BIOLOGICAL|Regulatory T-cell enriched infusion|Enrichment of CD25hi regulatory T cells from CD8 and/or CD19 pre-depleted leukapheresis products.
223510268|NCT03016403|BEHAVIORAL|Stepped-Care Intervention|The intervention delivered evidence-based CBT and stress management across eight counseling sessions.
223510269|NCT03016403|BEHAVIORAL|Enhanced Usual Care|Consists of a list of standard mental health resources offered at the participating hospital, local community, or national non-profit organizations.
223510270|NCT04495998|DIAGNOSTIC_TEST|Brief Motor Scale_portuguese version (BMS_pt)|translate, adapt and validate Brief Motor Scale for portuguese population with schizophrenia
223510271|NCT05463705|BEHAVIORAL|Intervention to address diffusion of responsibility|PCPs will receive an email from a peer offering encouragement and support in prescribing SGLT-2is and GLP-1RAs that includes specific components designed to reduce diffusion of responsibility. Specifically, these elements will be adapted from interventions that mitigate diffusion of responsibility in other contexts, including: (1) assigning responsibility to individuals or smaller groups, (2) increased perceived harm of the situation to be addressed (3) highlighting competence to act, and (4) modeling the desired behavior. The email will also contain a link to clinical and administrative information to support prescribing and an offer for direct support from the peer.
223510272|NCT05463705|BEHAVIORAL|Intervention to address diffusion of responsibility + simplification of prescribing|"PCPs will receive the same contact addressing diffusion of responsibility as in the Intervention to address diffusion of responsibility arm, but will additionally have access to an experienced administrative team for diabetes medication insurance authorization support, by routing their clinic note through the EHR. PCPs will be informed, suing the same email outreach, how to access the administrative team, which consists of medical and administrative assistants and currently supports prescribing within the endocrinology division. The team will follow up with the pharmacy to determine coverage, complete prior authorizations, determine alternate covered options, and track progress."
223510273|NCT02812537|OTHER|patients with conduct disorders|interview with a specialist
224075457|NCT02123485|DEVICE|Low frequency (1 hz) rTMS, as add-on to ECT|Right prefrontal Low frequency (1 hz) repetitive transcranial magnetic stimulation as add-on to ECT.
224075458|NCT02123485|DEVICE|Sham-rTMS|Right prefrontal Low frequency (1 hz) sham-stimulation using af double blind placebo coil as add-on to ECT.
224075459|NCT04741724|DEVICE|TEDS|An non-invasive intervention. During the intervention, the electrode was placed on the skin stimulated muscle.
224075460|NCT06311474|BEHAVIORAL|Parent-Child Interaction Therapy (PCIT)|PCIT is a dyadic therapy that focuses on enhancing the parent-child relationship and improving child behavior through positive parenting and limit setting skills. All PCIT sessions are delivered remotely via Zoom once per week for up to 20 weeks. Session length is about 1 hour. There are two distinct phases of PCIT, the Child Directed Interaction and the Parent Directed Interaction. Each phase begins with a Teach session, where parents learn about the skills they will practice during that portion of PCIT, and is followed by Coach sessions, in which the PCIT therapist provides direct feedback and live coaching on the use of the skills. An additional component is Daily Play practice. Parents are instructed to spend five minutes per day playing with their child, during which they practice skills learned during sessions. Adaptations have been made to the standard approach to increase suitability for the TSC population.
224075461|NCT03423342|DIETARY_SUPPLEMENT|nicotinamide riboside|nicotinamide riboside capsule
224075462|NCT03423342|DRUG|Placebo|matching placebo capsule
224075463|NCT06437873|PROCEDURE|Total Thyroidectomy (TT)|TT:Surgical removal of the entire thyroid gland.
224075464|NCT06437873|RADIATION|Radioactive iodine treatment(RAIT)|RAIT:Administration of radioactive iodine to eliminate remaining thyroid tissue or cancer cells.
223616149|NCT04929535|DRUG|Hydrogen Peroxide 30 % Topical Solution|Patients will be seen by the radiation therapists involved with the study after randomization. Prior to application of hydrogen peroxide solutions, the patients' lesions will be prepared and debrided of keratinous debris and oils using sterile 70% isopropyl alcohol. Then, the appropriate hydrogen peroxide solution (30% for Arm 1 or 3% for Arm 2) will be rubbed into the lesion and a 1cm border all around the lesion until blanching of the lesion is observed. Hydrogen peroxide will be reapplied after one hour. This process will be repeated weekly for three additional applications for this study. If there is complete clinical response, further hydrogen peroxide will not be done. Patients will be accessed for definitive treatment 4 weeks later.
223616150|NCT05261555|DEVICE|NoObesity app|The NoObesity system consists of two linked apps - the NoObesity Family app and the NoObesity Professional app.
223616151|NCT06527898|DRUG|hypofractionated radiotherapy with immunotherapy|hypofractionated radiotherapy with Adebrelimab consolidation
223616152|NCT00420485|DRUG|gimatecan|
223616153|NCT02768766|DRUG|Selumetinib, 100mg|"100mg, oral capsules, twice daily~An orally active, small molecule with potential antineoplastic activity. Selumetinib is an ATP-independent inhibitor of mitogen-activated protein kinase kinase (MEK) or MAPK/extracellular-signal-regulated kinase (ERK) kinase) 1 and 2. Inhibition of both MEK1 and 2 by selumetinib prevents the activation of MEK1/2 dependent effector proteins and transcription factors, thereby leading to an inhibition of cellular proliferation in various cancers."
224075465|NCT03243994|DIAGNOSTIC_TEST|Absorption test with D-xylose and zink|Absorption of D-xylose (25 g) and zinc (132 mg), administered as a single dose. The concentration of D-xylose and zinc was measured in peripheral blood one, two and three hours after ingestion and used as markers of absorption. Furthermore, urine was collected for five hours to determine the amount of excreted D-xylose.
223510274|NCT05344274|DIAGNOSTIC_TEST|Indocyanine Green Angiography|Erythrocyte Mediated Angiography with indocyanine green as well as conventional indocyanine green angiography will be conducted to determine retinal blood flow
223510275|NCT05344274|BIOLOGICAL|Isocapnic Oxygen|Investigators will evaluate retinal blood flow (RBF) in response to oxygen supplementation at a constant level of carbon dioxide (isocapnic hyperoxia) to isolate the vascular autoregulatory response to oxygen.
223510276|NCT05344274|DIAGNOSTIC_TEST|Ocular Imaging with Optical Coherence Tomography (OCT) and Adaptive Optics (AO)|Investigators will image subjects with OCT as well as AO technology to determine retinal ganglion cell density, vessel density, and vessel flowrates
223510277|NCT01602458|PROCEDURE|Silicone Only Therapy (SOT)|SOT group will be instructed to wear the silicone for 23 hours/day, removing only for bathing. A new piece of Mepiform™ silicone should be replaced weekly and applied to clean, dry skin. Compression free medical tape will be used to secure the silicone in place. Patients will be provided with 6 months of topical silicone therapy. If optimal results are achieved prior to 6 months of therapy, the treatment will be discontinued. Patients will also be provided with Scar Management for Skin Grafts Homecare Instructions: Silicone.
223510278|NCT01602458|PROCEDURE|Silicone Pressure Garment Therapy (SPGT)|"SPGT group will be instructed to use the Mepiform™ silicone only for 2 weeks during the interim before final fitting with the custom compression garment. A new piece of Mepiform™ silicone should be replaced weekly and applied to clean, dry skin. The patients will be instructed to wear the silicone for 23 hours/day, removing only for bathing.~The patient will continue to use the Mepiform™ silicone under the compression garment for the entire length of the study. The garment will be replaced after 3 months of wear, in order to ensure that optimal pressure and silicone management is applied to the area. Patients will be provided with Scar Management for Skin Grafts Homecare Instructions: Silicone and Compression Garment."
223510279|NCT00930332|DRUG|methadone hydrochloride|"Level 1: 1 mg q8h, breakthrough 1 mg q2h\* (maximum 6 BTA\*\* per day)~Level 2: 2 mg q8h, breakthrough 1 mg q2h\* (maximum 6 BTA per day)~Level 3: 3mg q8h, breakthrough 1 mg q2h\* (maximum 6 BTA per day)~OR~Level 1: 2 mg q8h, breakthrough 1 mg q2h\* (maximum 6 BTA per day)~Level 2: 3 mg q8h, breakthrough 1 mg q2h\* (maximum 6 BTA per day)~Level 3: 4 mg q8h, breakthrough 1 mg q2h\* (maximum 6 BTA per day)"
223510280|NCT00930332|OTHER|questionnaire administration|within 48 hours of registration
223510281|NCT00930332|PROCEDURE|management of therapy complications|if required
223510282|NCT00621322|BIOLOGICAL|GSK Biologicals' AS01B adjuvant|Intramuscular injection, 2 doses
223510283|NCT00621322|BIOLOGICAL|GSK Biologicals' Candidate Tuberculosis Vaccine (692342) - Formulation 1|Intramuscular injection, 2 doses
223510284|NCT00621322|BIOLOGICAL|GSK Biologicals' Candidate Tuberculosis Vaccine (692342) - Formulation 2|Intramuscular injection, 2 doses
223510285|NCT00621322|BIOLOGICAL|GSK Biologicals' Candidate Tuberculosis Vaccine (692342) - Formulation 3|Intramuscular injection, 2 doses
223510286|NCT00621322|BIOLOGICAL|GSK Biologicals' Candidate Tuberculosis Vaccine (692342) - Formulation 4 - Dosage 1|Intramuscular injection, 2 doses
223510287|NCT00621322|BIOLOGICAL|GSK Biologicals' Candidate Tuberculosis Vaccine (692342) - Formulation 4 - Dosage 2|Intramuscular injection, 2 doses
223510288|NCT05447858|OTHER|SWEA|Managers with one or several l staff experiencing WRNP will be educated in the Prehab guide. The manager should read and listen to all modules and a 1-h lecture recorded by the research team before participating in two workshops (4 h each), together with other managers and an experienced expert in work environmental health and rehabilitation. In the workshops, different themes will be discussed, such as physical, psychological, and organisational work-related health, prevention, and rehabilitation, how to lead problem-solving dialogue, how work-related adaptations can be performed related to WRNP, and questions about the Prehab guide. The Prehab guide will be used to deliver managerial support in the work with the Swedish Work Environment Authority's regulations regarding SWEA and the prevention of ill health, sick leave, and accidents, work adaptations, and workplace-oriented rehabilitation.
223510289|NCT05447858|OTHER|Neck-specific exercise|NSEs will be performed based on a well-structured framework of evidence-based exercises for facilitation of deep neck muscles, improved interaction between the different muscle layers of the neck, increased neck muscle endurance, and improved postural control .
223510290|NCT01514435|DEVICE|Electroconvulsive therapy|treatment for major depression
223510291|NCT01514435|DEVICE|18-Fluoro-desoxy-glucose positron emission tomography|"intravenous injection of 18-FDG, after 30 min PET-Scan of the brain for aprox. 40 min.~It´s a neuroimaging technique."
223616154|NCT02768766|DRUG|Selumetinib, 125mg|"125mg, oral capsules, twice daily~An orally active, small molecule with potential antineoplastic activity. Selumetinib is an ATP-independent inhibitor of mitogen-activated protein kinase kinase (MEK) or MAPK/extracellular-signal-regulated kinase (ERK) kinase) 1 and 2. Inhibition of both MEK1 and 2 by selumetinib prevents the activation of MEK1/2 dependent effector proteins and transcription factors, thereby leading to an inhibition of cellular proliferation in various cancers."
223616155|NCT02768766|DRUG|Selumetinib, 150mg|"150mg, oral capsules, twice daily~An orally active, small molecule with potential antineoplastic activity. Selumetinib is an ATP-independent inhibitor of mitogen-activated protein kinase kinase (MEK) or MAPK/extracellular-signal-regulated kinase (ERK) kinase) 1 and 2. Inhibition of both MEK1 and 2 by selumetinib prevents the activation of MEK1/2 dependent effector proteins and transcription factors, thereby leading to an inhibition of cellular proliferation in various cancers."
223616156|NCT02768766|DRUG|Selumetinib, 175mg|"175mg, oral capsules, twice daily~An orally active, small molecule with potential antineoplastic activity. Selumetinib is an ATP-independent inhibitor of mitogen-activated protein kinase kinase (MEK) or MAPK/extracellular-signal-regulated kinase (ERK) kinase) 1 and 2. Inhibition of both MEK1 and 2 by selumetinib prevents the activation of MEK1/2 dependent effector proteins and transcription factors, thereby leading to an inhibition of cellular proliferation in various cancers."
223616157|NCT02768766|DRUG|Selumetinib, 200mg|"200mg, oral capsules, twice daily~An orally active, small molecule with potential antineoplastic activity. Selumetinib is an ATP-independent inhibitor of mitogen-activated protein kinase kinase (MEK) or MAPK/extracellular-signal-regulated kinase (ERK) kinase) 1 and 2. Inhibition of both MEK1 and 2 by selumetinib prevents the activation of MEK1/2 dependent effector proteins and transcription factors, thereby leading to an inhibition of cellular proliferation in various cancers."
223760957|NCT04156815|OTHER|Pricking blood therapy|Pricking blood therapy (PBT) is a modified acupuncture strategy that is adapted to treat inflammatory related diseases. It has been shown to be effective in treatment of many chronic and acute inflammatory conditions including vasomotor rhinitis, acute herpes zoster and acute gouty arthritis,suggesting a potential efficacy for AV as well. At the end point of each session of laser treatment, an acupuncture practitioner performed a PBT in the areas within 1.5 cm radius of the five facial acupoints (Yintang, Zhukong, Sun, Yingxiang, Cuanzhu) (Figure 1). These areas usually appeared intensive erythema. A facial sheet mask was used to clean the face after PBT, and the face was cooled by air cooler for 10 minutes.
223616158|NCT02768766|DRUG|Selumetinib, 225mg|"225mg, oral capsules, twice daily~An orally active, small molecule with potential antineoplastic activity. Selumetinib is an ATP-independent inhibitor of mitogen-activated protein kinase kinase (MEK) or MAPK/extracellular-signal-regulated kinase (ERK) kinase) 1 and 2. Inhibition of both MEK1 and 2 by selumetinib prevents the activation of MEK1/2 dependent effector proteins and transcription factors, thereby leading to an inhibition of cellular proliferation in various cancers."
223616159|NCT02539771|OTHER|Polysomnography and blood sample|"Blood collection is a specific intervention of protocol for the 3 arms. Polysomnography is a specific intervention for the arms  Diurnal VOC  and  Slightly symptomatic "
223616160|NCT02564666|OTHER|telephone counseling|regular telephone counseling for compliance and advese event
223616161|NCT03041948|PROCEDURE|Ilioinguinal/iliohypogastric nerve block|See arm description
224075466|NCT02933697|DRUG|Apixaban|Patients will be instructed to take one tablet of 2.5 mg twice daily: one tablet in the morning and one in the evening at approximately the same time every day (with about 12 hours gap) irrespective of the time of dialysis.
224075467|NCT02933697|DRUG|Phenprocoumon|Subjects in phenprocoumon treatment group will receive phenprocoumon individually adjusted to an INR of 2.0-3.0 as recommended in the appropriate SmPC for AF patients.
224075468|NCT02296242|DRUG|BVD-523|Oral, multiple escalating doses, twice daily, for 21 days in each treatment cycle
223616162|NCT03041948|PROCEDURE|Caudal-epidural nerve block|See arm description
223616163|NCT03041948|DRUG|Acetaminophen|See arm description
223616164|NCT03041948|DRUG|Sevoflurane|See arm description
223616165|NCT03041948|DRUG|Remifentanil|See arm description
223616166|NCT03041948|DRUG|Propofol|See arm description
223616167|NCT03041948|DRUG|Morphine|See arm description
223616168|NCT03041948|DRUG|Ondansetron|See arm description
223616169|NCT03041948|DRUG|Dexamethasone|See arm description
223616170|NCT03041948|DRUG|Ketorolac|See arm description
223616171|NCT02495701|PROCEDURE|Hip arthroscopic surgery|Hip arthroscopic surgery
223616172|NCT01912066|DRUG|Stillen|
223616173|NCT01912066|DRUG|Cytotec (reference drug)|
223616174|NCT01912066|DRUG|NSAID (Aceclofenac)|
223616175|NCT03347123|DRUG|Epacadostat|Phase 1: Epacadostat at the protocol-defined dose twice daily. Phase 2: Epacadostat at the recommended dose from Phase 1.
223616176|NCT03347123|DRUG|Nivolumab|Nivolumab at the protocol-specified dose and schedule.
223616177|NCT03347123|DRUG|Ipilimumab|Ipilimumab at the protocol-specified dose and schedule.
223760958|NCT02465528|DRUG|Ceritinib (LDK378)|Ceritinib was to be administered orally once daily at a dose of 750 mg (5 capsules of 150 mg) on a continuous dosing schedule. A complete treatment cycle was defined as 28 days of once daily continuous treatment with ceritinib.
223760959|NCT06006559|DRUG|EYU688|EYU688 administered by oral route
224202167|NCT00334269|BEHAVIORAL|Cooking classes and grocery store tours with dietician|
224202168|NCT00334269|BEHAVIORAL|Pedometers to track/increase weekly physical activity|
224202169|NCT03795064|PROCEDURE|Foam sclerotherapy|Foam sclerotherapy is used to all patients for endovenous ablation of insufficient veins in subulcer plexus area.
224202170|NCT03795064|PROCEDURE|Endothermal ablation|Endothermal ablation is performed in early setting when truncal vein(s) anatomy is suitable.
224202171|NCT06126523|DEVICE|Radial Extracorporeal Shock Wave Therapy ONCE|"rESWT application ONCE The points where rESWT will be applied will be determined under ultrasonography guidance. The pressure pulses will be focused on the injection site in the medial and lateral heads of the gastrocnemius muscle and the soleus muscle.~Number of pulses: 1500 pulses Frequency: 6 Hz Energy level/Pressure: 2.2 bar air pressure Duration: 12 minutes~Device to be used in research ELMED VIBROLITH ESWT SW. Give. 3.3 It is based on the principle that currents produced outside the body spread in the tissue in the form of sound waves."
223616178|NCT03347123|DRUG|Lirilumab|Lirilumab at the protocol-specified dose and schedule.
223616179|NCT03018444|DRUG|Atorvastatin|Atorvastatin tablet
223616180|NCT03018444|OTHER|Placebo|Placebo tablet
223616181|NCT05638932|DRUG|Initiation of IL6Ri (tocilizumab or sarilumab) versus JAKi (baricitinib or tofacitinib) added to systemic corticosteroids of interest (CSI)|Real world use of either IL6Ri (TCZ or SAR) or JAKi (BAR or TOF)
223616182|NCT01982123|DIAGNOSTIC_TEST|SPECT/CT|Undergo 99mTc-MAA and 99mTc-DTPA SPECT/CT mid-radiation and post-radiation
223616183|NCT01982123|PROCEDURE|Single Photon Emission Computed Tomography|Undergo 99mTc-MAA and 99mTc-DTPA SPECT/CT
223616184|NCT01982123|RADIATION|Technetium Tc-99m Albumin Aggregated|Undergo 99mTc-MAA SPECT/CT
223616185|NCT01982123|DRUG|Technetium Tc-99m DTPA|Undergo 99mTc-DTPA SPECT/CT
223616186|NCT02046707|OTHER|initial evaluation|
223616187|NCT02046707|OTHER|Period of cardiac rehabilitation|
223616188|NCT02046707|OTHER|final evaluation|
223616189|NCT02046707|OTHER|Concentric and eccentric exercise sessions|
223760960|NCT06006559|DRUG|Placebo|Matching placebo administered orally as capsules
223760961|NCT02036034|DEVICE|forced air warmer (Bair Hugger)|forced air warmer placed under the chin before draping, forced air warmer inflated after draping is completed.
223760962|NCT02036034|DEVICE|warming blanket|warming blanket placed on torso of patient under the drape.
223760963|NCT05876182|DRUG|Oral Vancomycin|The investigator will identify potential participants and confirm the diagnosis of PSC. Subjects will be screened within 10 weeks before randomization to determine the eligibility. Study participants will be consecutively randomized to oral vancomycin or placebo and investigational drug and placebo dispensed.
223760964|NCT05876182|OTHER|Placebo|The investigator will identify potential participants and confirm the diagnosis of PSC. Subjects will be screened within 10 weeks before randomization to determine the eligibility. Study participants will be consecutively randomized to oral vancomycin or placebo and investigational drug and placebo dispensed.
224075469|NCT01976559|DEVICE|Tympanic Membrane Displacement (TMD)|"The CCFP Analyser has a passive mode and an active mode. When used in active mode, the device generates a tone burst that is transmitted to the ear to elicit contraction of the stapedius muscle. The passive mode requires no stimulus or sound burst.~For each ICP level during the CSF infusion testing, the active mode will be used. Each condition comprises 13 stimuli of 0.3s duration."
223510292|NCT04299425|DEVICE|NIRAF Detection Technology|"Near Infrared Autofluorescence (NIRAF) detection technology or 'PTeye' consists of a disposable fiber-optic probe that emits non-ionizing radiation from a NIR 785 nm laser source, and also transmits the resulting tissue NIRAF to a photo detector. The 785 nm laser source emits a maximum power of 20 mW. The device is FDA cleared for clinical use in general surgeries and dermatological use (Class 2 device).~After surgeon identifies a potential parathyroid gland in the surgical field, the surgeon places the fiber-optic probe of PTeye on suspect tissue and presses the device foot-pedal to activate tissue NIRAF measurement. Auditory beep at high frequency with a Detection Ratio \> 1.2 is interpreted by device as the suspect tissue being positive for parathyroid."
223510293|NCT06483217|BEHAVIORAL|Patient-directed follow up|Patients will be instructed to follow up for repeat injection based on bladder symptomatology at their own self-determined time interval.
223510294|NCT00310479|DEVICE|Magnetic Resonance Spectroscopy (3Tesla)|
223510295|NCT05235828|BEHAVIORAL|Sudarshan Kriya Yoga (SKY)|This is the experimental arm of the study, where participants will be trained in a form of breathing based meditation that incorporates different breathing techniques centred around controlling arousal and attention. Participants will be encouraged to learn all of the techniques that are covered during these sessions and also utilize the techniques that are most appropriate for their personal needs. After some initial training sessions, participants will be encouraged to practice their new SKY techniques in environments and situations that they have been avoiding. They would begin with situations that are less triggering, and progress to more difficult situations. At each group session, participants will describe their experiences and discuss ways to continue to incorporate the SKY techniques into their daily lives, until it reaches a point of being natural to use these skills throughout the day, both in practice, and in application.
223510296|NCT06522529|OTHER|Multifaceted implementation strategy|The multifaceted implementation strategy consist in a process of improvement by reference to a prior baseline clinical audit. It implies a local context analysis, identifying barriers to improvements in clinical practice, and developing and implementing a plan of action for improving adherence to pre-established criteria. The goal is to establish interprofessional processes within the teams, in order to: examine the barriers that hinder the use of evidence in fostering best practices; and contribute to the development of implementation programmes for overcoming such obstacles.
223510297|NCT03686982|OTHER|Active Nitrate Bar|Bar containing Nitrate, L-citrulline; epicatechin; vitamin C and glutathione
223510298|NCT03686982|OTHER|Placebo Bar|No active ingredients
223510299|NCT05488353|DRUG|Disitamab Vedotin for Injection,Penpulimab Injection|"After completion of all screening activities, patients confirmed to be eligible will enter the study and receive the following treatments.~Neoadjuvant regimen (up to 4 cycles): Disitamab Vedotin for Injection, 2.0 mg/kg, given as an IV infusion on day 1, and Penpulimab Injection, 200 mg, on every 21 days On day 1 of the cycle, it is given as an intravenous infusion. Order of use: Disitamab Vedotin for Injection → Penpulimab Injection."
223510300|NCT02591407|PROCEDURE|TAP Block|This is a one time injection of Exparel in the plane between the internal oblique and transversus abdominis muscles
223510301|NCT02591407|PROCEDURE|Continuous Epidural Analgesia|Epidural catheter placed prior to the operation in the standard fashion
223510302|NCT03367351|BEHAVIORAL|Web-Based Education|Completion of a CGM specific web-based educational intervention that includes a series of online learning modules.
223510303|NCT03367351|BEHAVIORAL|Social Support|Engagement in peer-led CGM specific discussion boards
223510304|NCT03367351|BEHAVIORAL|Standard of Care|Standard of Care - serves as the control group for the treatment arm
223510305|NCT00705965|BEHAVIORAL|Psychotherapy|Stepwise, manualized individual and group psychotherapy in addition to usual cardiological care.
223510306|NCT00705965|BEHAVIORAL|Information session|One information session about living with heart disease.
223616190|NCT00183131|BEHAVIORAL|Brief Personalized Feedback|
223616191|NCT00760682|PROCEDURE|Hyperbaric oxygen|30 preoperative and 10 postoperative HBO sessions 90 minutes each. Sequestrectomy is performed after 30 sessions.
223616192|NCT03138421|DRUG|ABX-1431 HCl|ABX-1431 HCl, capsules, 20 mg
223616193|NCT03138421|DRUG|Placebo|Matching placebo
223616194|NCT01822197|DEVICE|Phototherapy|light will be administered at a minimum distance of 12 inches away to provide 10,000 lux
223616195|NCT05448040|PROCEDURE|Socket preservation|Tooth extraction and preservation with a biomaterial
223616196|NCT00175513|DRUG|Valacyclovir (Valtrex)|
223616197|NCT01963195|DRUG|Icotinib|Patients can accept the treatment with Icotinib (250/375/500mg tid) until disease progression or unacceptable toxicities occurred. The overall study period takes about 24 months
223616198|NCT01132807|BIOLOGICAL|Bleomycin Sulfate|Given IV
223616199|NCT01132807|DRUG|Doxorubicin Hydrochloride|Given IV
223616200|NCT01132807|DRUG|Procarbazine Hydrochloride|Given PO
223616201|NCT01132807|DRUG|Vinblastine Sulfate|Given IV
223616202|NCT01132807|DRUG|Dacarbazine|Given IV
223616203|NCT01132807|DRUG|Cyclophosphamide|Given IV
223616204|NCT01132807|DRUG|Etoposide phosphate|Given IV
223616205|NCT01132807|DRUG|prednisone|Given PO
223616206|NCT01132807|DRUG|Radiation Therapy|Undergo radiation therapy
223616207|NCT01132807|RADIATION|Fludeoxyglucose F-18|Undergo FDG PET/CT
223616208|NCT01132807|PROCEDURE|computed tomography|Undergo FDG PET/CT
223616209|NCT01132807|PROCEDURE|Positron Emission Tomography|Undergo FDG PET/CT
223616210|NCT05408962|OTHER|Blood and urine collection, anthropometric analysis and answering to questionnaires|During the visit to the recruitment center, participants will sign an informed consent. They will have to be in fasting condition for blood and urine collection. In addition they will answer the lifestyle questionnaire and the Food Frequency Questionnaire and will be submitted to an anthropometric analysis and evaluation of blood preassure and heart rate.
223616211|NCT00955214|DEVICE|TAXUS Liberté paclitaxel-eluting coronary stent system|diameter is 2.5mm
223616212|NCT02436525|DEVICE|conventional stainless steel orthodontic brackets ligated with stainless steel ligature (Oromco - USA)|
223616213|NCT02436525|DEVICE|passive self-ligating stainless steel orthodontic brackets (Oromco - USA)|
223616214|NCT02436525|DEVICE|active self-ligating stainless steel orthodontic brackets (Oromco - USA)|
223616215|NCT05625984|DEVICE|Fascigel|The product is a Class III Medical Device. Structure is made by 1% sodium hyaluronate polysaccharide in normal saline solution.
223616216|NCT00763412|DRUG|placebo|CF pancreatic insufficient patients with impaired glucose tolerance (IGT) or CFRD without fasting hyperglycemia (CFRD-No FH) by OGTT will be treated with placebo by taking 1 pill before each meal that contains more than 20 grams of carbohydrate 3-4 times a day for 2 years.
223616217|NCT00763412|DRUG|repaglinide|CF pancreatic insufficient patients with impaired glucose tolerance (IGT) or CFRD without fasting hyperglycemia (CFRD-No FH) by OGTT will be treated with repaglinide 0.5 mg before each meal that contains more than 20 grams of carbohydrate 3-4 times a day for 2 years.
223616218|NCT00314730|DEVICE|handheld Personal Digital Assistant (PDA)|
223616219|NCT03908333|DRUG|Ascorbic Acid|25, 37.5, 56.25 or 75 grams/m2
223616220|NCT03908333|DRUG|Paclitaxel protein-bound|125mg/m2 over 30 minute IV infusions on days 1 and 8 repeated every 21 days
223616221|NCT03908333|DRUG|Cisplatin|25mg/m2 in 500 mL of NS over 60minute IV infusion on days 1 and 8 repeated every 21 days
223616222|NCT03908333|DRUG|Gemcitabine|1000mg/m2 in 500 mL over 30 minute IV infusion on days 1 and 8 repeated every 21 days
223616223|NCT01731912|DRUG|Degarelix|Given SC
223616224|NCT01731912|RADIATION|External Beam Radiation Therapy|Undergo standard EBRT
223616225|NCT01731912|OTHER|Laboratory Biomarker Analysis|Correlative studies
223616226|NCT02757144|DRUG|DWP14012|DWP14012 tablets
223616227|NCT02757144|DRUG|Placebo|DWP14012 placebo-matching tablets, Active control placebo-matching tablets
223616228|NCT02757144|DRUG|Esomeprazole|Nexium®
223616229|NCT03646877|DRUG|Ozone|Subjects will perform alternating 15 minutes rest with 15 minutes treadmill walk exercise periods for 135 minutes in while breathing Ozone (O3).
223616230|NCT03646877|OTHER|Filtered Air|Subjects will perform alternating 15 minutes rest with 15 minutes treadmill walk exercise periods for 135 minutes in while breathing filtered air.
223616231|NCT04507607|DRUG|Tenofovir Alafenamide 25 MG|TAF was administered to pregnant women with CHB during pregnancy for mother-to-child interention.Women with chronic hepatitis B who are not pregnant receive TAF for antiviral treatment.
223616232|NCT06000124|OTHER|Plyometric exercises|High knee lifts, squat jumps, lunge cross jumps, squat jumping lunges, and squat jump twists are examples of plyometric exercises suitable for older adults.
223616233|NCT06000124|OTHER|Regulation Exercises Program|The regulated exercise program includes the use of elastic bands, Qigong, and dance et al.
223616234|NCT05583487|OTHER|Nurse-led progressive mobility protocol|The nurse-led mobility progression protocol incorporates a checklist for four primary team members belonging to each discipline to follow before, during, and after providing mobility for each patient. It outlines steps to progress patient mobility from in-bed mobility activities to out-of-bed activities as tolerated. This protocol intervention was created and designed based upon a review of previously conducted studies' interventions and findings, as well as expert guidelines established in the literature. Furthermore, multidisciplinary experts at the medical center who work with ventilated neurosurgery patients were consulted to form the protocol to further establish hemodynamic, neurological, respiratory, and physiological patient safety parameters. This intervention has not been implemented in previous studies and will be piloted for this study.
223616235|NCT05583487|OTHER|Standard of Care|For the purposes of the current study, the control group of multidisciplinary teams requested to mobilize the ventilated neurosurgery patient, may also consist of the primary nurse, RT, PT, and PCT. They will be asked to progressively mobilize the patient to the best of their ability according to standard of care procedures, incorporating any resources the medical center provides including, but not limited to, written information, equipment, ThinkLift, etc.
223616236|NCT02222558|DRUG|TSX-002|TSX-002 are capsules with testosterone as the active ingredient.
224312410|NCT04493086|DIAGNOSTIC_TEST|FFRCT-angio|According to invasive coronary angiography (CAG) images, image databases of critical lesions, diffuse lesions, left main trunk lesions, ostium lesions and bifurcation lesions were established. In order to ensure that the position of the pressure guide wire sensor is consistent with that of FFRCT-angio, a professional with unknown FFR results is used to mark the position of the pressure wire sensor on the CAG image. The clinical information and characteristics of coronary artery lesions were collected, and the baseline data of patients were completed. The accuracy and diagnostic performance of FFRCT-angio in the diagnosis of functional stenosis (FFR \< 0.8) were evaluated with FFR value measured by pressure guide wire as reference standard.
223510307|NCT00705965|OTHER|Usual cardiological care|Usual cardiological care
223510308|NCT05685407|DRUG|Caffeine|300mg caffeine will be administered orally via capsules to participants with female sexual arousal disorder.
223510309|NCT05685407|OTHER|Placebo|A placebo pill that matches in size, shape, and color will be administered to participants with female sexual arousal disorder.
223510310|NCT02694055|OTHER|Proactive Community Case Management|CHWs will be trained and deployed to conduct daily active case finding home visits door-to-door for at least two hours each day, with the goal of visiting each household at least two times each month. At these active case finding home visits, CHWs will screen each household of sick children and will offer home pregnancy testing and family planning services to reproductive aged women. For patients they identify, they will offer counselling, diagnostic services, care, accompaniment, and referral according to an iCCM service delivery package.
223510311|NCT02694055|OTHER|Integrated Community Case Management|CHWs will be trained offer counselling, diagnostic services, care, accompaniment, and referral according to an iCCM service delivery package to patients that visit them at their work post.
223510312|NCT02694055|OTHER|Removal of point-of-care user fees|User fees will be removed across the catchment areas for both study and control villages. No fees will be charged for care by CHWs or at all primary care centres.
223510313|NCT02694055|OTHER|Infrastructure improvements at primary health centre|Targeted infrastructure improvements to rehabilitate, expand and equip the capacity of the seven government primary care centres in the study area. Each health center will be equipped with solar power.
223510314|NCT02694055|OTHER|Training of primary health centre staff|"Health center staff will receive targeted training in~* Integrated management of childhood illness~* Diagnosis and treatment of simple and severe cases of malaria~* Helping babies breathe~* Managing post-partum haemorrhage~* Gestational dating using frontal height, last menstrual period and ultrasound~* Family planning counselling and administration of long-acting contraceptives~* Pharmacy stock management~* Health center management"
223510315|NCT00180700|BEHAVIORAL|Hypnosis|
223510316|NCT00892450|DRUG|Oxybutynin and darifenacin|Participants with overactive bladder will take each medication for 4 weeks.
223510317|NCT05196503|BIOLOGICAL|Treatment|"Experimental product: product derived from autologous blood, obtained after centrifugation.~Treatment modalities: intraoperative periradicular administration of autologous PRF."
223510318|NCT04494737|BEHAVIORAL|Active Comparator: Program 1|A well-established behavioral method for reducing stress. To maintain blinding, details will be given to participants after randomization.
223510319|NCT04494737|BEHAVIORAL|Active Comparator: Program 2|A well-established behavioral method for reducing stress. To maintain blinding, details will be given to participants after randomization.
223510320|NCT03834662|DRUG|AVID200|A TGFβ receptor ectodomain-IgG Fc fusion protein inhibitor of TGFβ
223510321|NCT01326637|OTHER|Patient Overview Document|"The Intervention has two components:~1. Pre-visit care coordination:~   * 5-7 days prior to a study patient's appointment with the doctor, the doctor's nurse/MA will call the study patient and collect pertinent clinical information using a data collection form we call a Patient Overview Document or POD. The purpose of the POD is to comprehensively inform the doctor about the patient before the doctor enters the exam room.~  * The nurse/MA will ensure that lab results, consultant reports, ER reports, imaging studies, etc., needed by the physician during the patient's visit, are available to the doctor in their usual place.~2. Team Meeting:~On the day of the patient's appointment, prior to the beginning of the clinic session, the nurse/MA and doctor will jointly review the POD."
223510322|NCT01578746|PROCEDURE|Direct lateral approach in total hip arthroplasty|The use of direct lateral approach in total hip arthroplasty
223510323|NCT01578746|PROCEDURE|Anterior approach|The use of anterior approach in total hip arthroplasty
223510324|NCT01501500|DRUG|BOTOX|once injection of BTA 3oU into hallux oblique and transverse heads each
223510325|NCT01501500|DRUG|Normal Saline (0.9% NaCl)|Normal saline 0.3ml to oblique and transverse heads each
223510326|NCT06035549|BEHAVIORAL|Culturally Tailored Digital Resilience-Building|The Culturally Tailored Digital Resilience-Building intervention consists of 6 modules, including an introduction of advance care planning and resilience skills that specifically address cultural beliefs and barriers.
223510327|NCT03241550|DRUG|isavuconazonium sulfate - intravenous|IV infusion
223510328|NCT03241550|DRUG|isavuconazonium sulfate - oral|Oral
223510329|NCT01391299|BIOLOGICAL|botulinum toxin Type A|Botulinum toxin Type A (total dose 30 Units or 40 Units) injected into bilateral forehead and frown line areas on Day 1.
223510330|NCT01391299|DRUG|Normal Saline|Normal Saline (placebo) injected into bilateral forehead and frown line areas on Day 1.
223510331|NCT02319915|DRUG|Tranexamic Acid|
223510332|NCT02319915|DRUG|Adrenalin|
223510333|NCT06642779|BEHAVIORAL|VFQ- 25 (Visual Function Questionnaire)|VFQ-25 questionnaire was used to evaluate patient satisfaction at the M3 and M12 visits.
223510334|NCT06642779|DIAGNOSTIC_TEST|Optical Biometry|Axial length, anterior chamber depth and corneal keratometric values K1-K2. All these parameters were measured at the screening visit and at the month 3 follow-up visit, using the ARGOS® Biometer or the ANTERION® Cataract App
223510335|NCT06642779|DIAGNOSTIC_TEST|Slit lamps / Fundoscopy / Biomicroscopy|The fundus and other ocular structures, such as the cornea, anterior chamber, iris, pupil, crystalline lens / IOL alignment, corpus ciliare and choroid were examined at screening visit, on the day of the surgery, and at the follow up visits D1, M1, M3, M6, and M12, using the slit lamp binocular indirect ophthalmoscopy.
223510336|NCT06642779|DIAGNOSTIC_TEST|UDVA|Monocular and binocular Uncorrected Distance Visual Acuity (UDVA) was evaluated at all visits (preoperative, D1, M1, M3, M6 and M12), using the ETDRS chart.
224312411|NCT00124761|PROCEDURE|Surgery + WBRT|Surgery - complete excision of Solitary Brain Metastasis with 30 Gy in 10 fractions over 2 2 1/2 weeks
223616237|NCT06144463|DIAGNOSTIC_TEST|lung ultrasound-guided fluid resuscitation|For the LUGFR group, therapy was applied based on the same treatment guidelines, and initial lung ultrasonography was performed after enrollment as baseline assessment of lung. The lung ultrasound was conducted using the Doppler ultrasound diagnostic instrument (Philips CX50) at a probe frequency range of 8 to 12 MHz. Lung ultrasonography was conducted using the 12-region method that included the anterior, lateral, and posterior walls on both sides of the lung, which was focused on the condition of A-lines, B-lines (including confluent B-line and compact B-lines), lung consolidation and pleural effusion
223616238|NCT05134558|RADIATION|Xenon-enhanced Ventilation CT-guided Radiotherapy|Xenon-enhanced Ventilation CT-guided Radiotherapy for functional protection of the lung
223616239|NCT02528708|DRUG|fibrinogen concentrate|The dose of fibrinogen concentrate needed to achieve this target will be calculated using a formula that accounts for the baseline FIBTEM® - A10 value and the patient's body weight assessed at hospital admission . In general, a 70-kg patient requires a fibrinogen dose of approximately 0.5 g to increase the MCF by approximately 1 mm.
223616240|NCT02528708|DRUG|Placebo|0.9% saline solution
223616241|NCT04690140|PROCEDURE|Epithelialized free gingival graft|The Epithelialized free gingival graft placed on the prepared bed.
223616242|NCT04690140|PROCEDURE|Modified coronally advanced tunnel technique|Connective tissue graft placed under the prepared tunnel
223616243|NCT06268054|DRUG|DEH113|Tablets
223616244|NCT06268054|DRUG|Placebo Comparator|Tablets
223616245|NCT06288555|DIAGNOSTIC_TEST|Ipswich touch test|"Ipswich touch test: A simple test to screen for diabetic peripheral neuropathy (DPN) by lightly touching the patient's toes with the index finger and asking them to identify which foot is touched.~10g monofilament test: A more sensitive test to confirm DPN by applying a thin nylon fiber to different sites on the patient's feet and asking them to indicate when they feel the pressure.~Test procedure: The patient closes their eyes and the examiner performs both tests in a specific sequence and records the results. The tests are done on healthy skin and not on wounds or calluses."
223616246|NCT01762553|BEHAVIORAL|The TEA intervention|TEA Gathering is a small group training session for PLH and their family members to deal with HIV-related challenges at individual level; TEA Time is home based family activities for PLHs and their family members to interact with their children after each TEA Gathering to promote family positive interaction; TEA Garden is the community events that built social integration for HIV affected families to live a healthy social life and to build sustained, supportive relationships in their communities. There will be reunions once a month for 12 months after the completion of the TEA intervention.
223616247|NCT03421522|OTHER|ICBN preservation surgery|"For participants randomized to the ICBN preserving technique, surgeons will perform axillary dissection in which the second ICBN, just inferior to the axillary vein, will be preserved. Surgeons will be asked to indicate whether the ICBN nerve was fully preserved, partially preserved, or sacrificed.~All study participants will receive anesthetic management at the discretion of the attending physician, which will be documented."
223616248|NCT05551858|DRUG|Proglumide|(CAS: 6620-60-6.)
223616249|NCT05551858|DRUG|Placebo|Avicel fiber filled capsule taken by mouth three times daily
223616250|NCT03493555|BEHAVIORAL|Peer Health Navigator for PrEP|Peer health systems navigator to improve adherence to PrEP
223616251|NCT01169948|RADIATION|Computed tomography scan|Computed tomography will be performed using a 320 multidetector computed tomography scanner and may include coronary calcium score, coronary angiography and myocardial perfusion scanning.
223616252|NCT02759757|OTHER|Kinesio Taping|This is a tape that can be placed in different parts of the body using different shapes and tensions. In theory, this tape can change muscle activity.
223616253|NCT02759757|OTHER|Placebo|A micropore tape will be used as placebo
223616254|NCT05905094|OTHER|Postural correction exercises|Exercises to improve posture like shoulder shrugging, chin tuckin, neck isometrics
223616255|NCT00481702|DRUG|Comparator: ceftriaxone sodium / Duration of Treatment: 8 Weeks|
223616256|NCT00481702|DRUG|MK0826, /Duration of Treatment : 8 Weeks|
223616257|NCT00481702|DRUG|Comparator: metronidazole / Duration of Treatment: 8 Weeks|
223616258|NCT00992758|BIOLOGICAL|Iodine-131 Anti-B1 Antibody|"Dosimetric Dose: 450 mg unlabeled Anti-B1 Antibody infused over 1 hour or longer followed by 35 mg of Anti-B1 Antibody of which 1-2 mg has been labeled with 5 mCi of Iodine-131 infused over 20 minutes.~Therapeutic Dose: 7-14 days after dosimetric dose, 450 mg Anti-B1 Antibody infused over 1 hour or longer followed by 35 mg of Anti-B1 Antibody labeled with the subject-specific dose of Iodine-131 to deliver the desired total body radiation, infused over 20 minutes The dose escalation will be initiated at 45 cGy and will be increased in 10 cGy increments until the maximum tolerated dose (MTD) is reached."
223616259|NCT03432507|OTHER|PCR|PCR for proinflammatory cytokines (IL-1b, IL-6, IL-8, IL-17, TNF-a, INF-g) and bacteria
223616260|NCT05876481|DRUG|Psilocybin|Product name: Psilocybin Pharmaceutical form: capsule, hard Dose number and units: 25 mg per day (8-hour dosing session) x 2 Route of administration: oral
223616261|NCT05230940|BIOLOGICAL|TURKOVAC|Inactive COVID-19 Vaccine - TURKOVAC
223616262|NCT05230940|BIOLOGICAL|CoronaVac|It has 600 subunit of SARS-CoV-2 virus antigen
223616263|NCT02621112|BIOLOGICAL|Intradermal HBVv with imiquimod|Intradermal hepatitis B vaccine with imiquimod pretreatment
223616264|NCT02621112|BIOLOGICAL|Intradermal HBVv with aqueous cream|Intradermal hepatitis B vaccine with aqueous cream pretreatment
223616265|NCT02621112|BIOLOGICAL|Intramuscular HBVv with aqueous cream|Intramuscular hepatitis B vaccine with aqueous cream pretreatment
223616266|NCT01285401|DRUG|VigantOL oil plus interferon beta-1a (Rebif)|VigantOL oil 6,670 International Units per day (IU/d) (167 microgram per day \[mcg/day\]), was administered orally for 4 weeks followed by 14,007 IU/d (350 mcg/d) administered orally for 44 weeks on top of Rebif 44mcg three times per week (tiw) administered subcutaneously.
223616267|NCT01285401|DRUG|Placebo plus interferon beta-1a (Rebif)|Matching placebo daily, orally administered matched placebo for 48 weeks on top of Rebif 44 mcg tiw.
223616268|NCT01285401|BIOLOGICAL|Interferon beta-1a (Rebif®) alone|Rebif® 44 mcg tiw, sub-cutaneously alone.
223616269|NCT02322281|DRUG|Rociletinib|
224312412|NCT00124761|RADIATION|Radiosurgery + WBRT|Radiosurgery - Marginal dose based on maximum tumour diameter
224312413|NCT05653284|DRUG|AK130|IV infusion, specified dose on specified days.
224312414|NCT06754176|BEHAVIORAL|Alcohol Consumption Randomized Instructions|"Alcohol Avoidance: In this intervention assignment, participants will be instructed to avoid drinking alcohol for this day.~Alcohol Non-Avoidance: In this intervention assignment, participants will be allowed to drink alcohol for this day."
224314308|NCT00089024|PROCEDURE|neoadjuvant therapy|Eligible patients will receive an initial two cycles of chemotherapy with gemcitabine 750 (females) or 900 (males) mg/m5 over 30 minutes followed by a 24-hour infusion of fluorouracil 2700 mg/m5 on days 2 and 9 of a 21-day cycle . Calcium leucovorin 20 mg/m5 will be given orally on days 1 and 8 and by IV push on days 2 and 9 prior to the 5-FU. A window of -2 up to +7 days will be allowed to start planned cycles of therapy provided all other criteria to restart the new cycle has been met. Patients will require a central venous catheter (Port, Hickman or Groshong catheter) for the administration of 5-FU.
223616270|NCT02322281|DRUG|Pemetrexed or gemcitabine or paclitaxel or docetaxel|
223616271|NCT02925897|BEHAVIORAL|Behaviour change and motivational interviewing|nurses will help patients to identify health behaviours that they would like to change and to explore their motivation and strengths to achieve this.
223616272|NCT03354949|OTHER|Measurement of sitting postural control of the adult (MCPAA)|"The Adult Seated Postural Control Measure 2.0 (MCPAA 2.0) is a clinical evaluation tool for sitting postural control of adult clients using a locomotion aid. It thus allows the evaluation of the two variables inherent to the postural control sit, the alignment of body segments and the influence between movement and posture.~It can also be used to evaluate the changes in seated postural control due to changes over time or to an adaptation of the sitting posture.~Assessment of wheelchair pain in the spine and ischia by a self-evaluation scale (EVA).~the speed of propulsion by a wheelchair."
223616273|NCT06159088|DIETARY_SUPPLEMENT|Feihe Investigational Formula|Participants in this arm will receive stage 1 and stage 2 Feihe investigational formulas. At the first (up to) 6 months, they will be fed with stage1 formula, and then switch to stage 2 formula until 12 months.
223616274|NCT06159088|DIETARY_SUPPLEMENT|Control Formula|Participants in this arm will receive stage 1 and stage 2 Control formulas. At the first (up to) 6 months, they will be fed with stage1 formula, and then switch to stage 2 formula until 12 months.
223616275|NCT06159088|OTHER|Breastfeeding|Exclusively breastfed for the first 4 months and continue with supplement food without any marketed infant formula.
223616276|NCT05724940|OTHER|clinical and serological differences among juvenile, adult, and late-onset systemic lupus erythematosus in a cohort of SLE patients|"All patients will be subjected to the following:~1. Thorough medical history of the patients~2. Full clinical examination including:~   1. General examination and vital signs.~  2. Complete rheumatological examination.~  3. SLE disease activity index SLEDAI (ref).~  4. SLICC( Systemic Lupus International Collaborating Clinics) damage index (ref).~3. Routine investigations (complete blood picture, erythrocyte sedimentation rate and liver functions).~4. Renal investigations:~   1. Kidney functions~  2. Urine analysis~  3. 24 hours protein in urine and/or A/C ratio~  4. Renal biopsy if indicated.~5. ANA (Antinuclear Antibodies)test.~6. ANA profile for the most common 19 autoantibodies by immunoblot."
223616277|NCT00974649|BEHAVIORAL|self-report questionnaire|validated self-report questionnaires on psychosocial determinants
223616278|NCT04033744|PROCEDURE|extraction of mandibular third molar|After loco-regional anesthesia was administered, a full-thickness mucoperiosteal flap was raised. The flap incision was extended from the vestibular side of the retromolar trigon to the second molar, corresponding to its distolingual cusp. The incision continued intrasulcular at the second molar and proceeded with a release incision distally to the papilla between the first and second molars, on a 45° angle. An osteotomy using a Lindemann burr under constant irrigation, followed by an odontotomy using a diamond burr was performed, if necessary
223616279|NCT00502554|PROCEDURE|photopheresis|2-day cycles of photopheresis every 3 weeks for 3 months
223616280|NCT04019353|GENETIC|cf-DNA Collection|"For all consenting recipients undergoing kidney biopsy between 1 and 12 months post-transplant, a single tube of blood will be drawn (at the time of other blood draws so that there is no additional needle stick) to measure cf-DNA. The tube will be shipped to the California lab for determination of donor cf-DNA. For recipients whose biopsy shows AR, a tube of blood will be drawn at 2, 4, 6, and 8 weeks after initiation of anti-rejection treatment and similarly will be shipped to the California lab for determination of cf-DNA.~Recipients whose exit biopsy shows ongoing inflammation and receiving additional anti-rejection therapy will have an additional exit biopsy additional cf-DNA determinations."
223616281|NCT02436018|DEVICE|WEI NASAL JET|Oxygen is supplied through WEI NASAL JET by a manual jet ventilator
223616282|NCT02436018|DEVICE|Nasopharyngeal airway without jet ventilator|Oxygen is supplied directly through WEI NASAL JET without jet ventilator
223616283|NCT05977400|DRUG|Ampicillin|Intravenous Ampicillin
223616284|NCT05977400|DRUG|Gentamicin|Intravenous Gentamicin
223616285|NCT05977400|DRUG|Placebo|Intravenous Normal Saline
223616286|NCT05874284|DRUG|Gelofusin|In the experimental group, the wound will be washed with gelofusine as prolotherapy, and the wound will be closed with sterile sponge and fixative tape. In the control group, the wound will be covered with sterile sponge and fixative tape by washing with physiological saline.
223616287|NCT04945187|OTHER|Nurse-led consultations based on electronic patient-reported outcomes|The patients will weekly answer electronic patient-reported outcomes during chemotherapy and the answers will be used proactive in nurse-led consultations.
223616288|NCT00936702|DRUG|carboplatin|Given IV
223616289|NCT00936702|DRUG|everolimus|Given PO
223616290|NCT00936702|DRUG|paclitaxel|Given IV
223616291|NCT01636635|OTHER|Calorie Restriction|Intervention consists of a calorically restricted diet regime designed and administered at the Weight and Wellness Center at Tufts University
223616292|NCT03915171|DIAGNOSTIC_TEST|Next generation sequencing|NGS can provide genetic and MSI test for patients
223616293|NCT02532465|DEVICE|Air-Q|
223616294|NCT02532465|DEVICE|i-gel|
223616295|NCT00793858|DRUG|placebo, isotonic ciclesonide, hypotonic ciclesonide|200mcg/nostril
223616296|NCT04567641|DIETARY_SUPPLEMENT|postoperative nutrition|Forty patients (50%) received enteral nutrition 6 hours after surgical procedures and 40 patients (50%) received parenteral nutrition 6 hours after surgical procedures.
223616297|NCT00790192|DRUG|Lurasidone|Lurasidone 80 mg tablets
223616298|NCT00790192|DRUG|Lurasidone|Lurasidone 4 40 mg tablets
223616299|NCT00790192|DRUG|Quetiapine XR|Quetiapine XR 600mg
223616300|NCT00790192|DRUG|Placebo|Matching Placebo to Lurasidone or Quetiapine
223616301|NCT00354679|BIOLOGICAL|bevacizumab|
223760965|NCT06423053|BEHAVIORAL|Biology Course with Integrated Mindfulness|The intervention, Mindful Physiology, is an undergraduate-level biology course embedded with mindfulness practices. There will be 19 class sessions, each 1 hour and 50 minutes long, over 10 weeks. Students will be taught human physiology through didactic lectures, laboratory activities, and written quizzes typical for a college course. Each class meeting will have \~20 minutes of mindfulness practice in Thích Nhất Hạnh's Plum Village tradition. Students will also be encouraged to practice mindfulness for 15 minutes daily outside the class. Students will complete a daily log of their mindfulness practice and be given credit for each log completion regardless of the minutes of mindfulness practice. Students will be assigned a weekly written reflection on the physiology course content and/or their mindfulness practice. All students in the class are required to attend a 4.5-hour or a two-day (16-hour) on-campus mindfulness retreat.
223616302|NCT00354679|DRUG|cisplatin|
223616303|NCT00354679|DRUG|irinotecan hydrochloride|
223616304|NCT00354679|GENETIC|proteomic profiling|
223616305|NCT00354679|OTHER|diagnostic laboratory biomarker analysis|
223760966|NCT06050746|OTHER|Systematic screening|Included children will be followed prospectively during five years through clinical visits and medical records, where need for additional treatment (casting, braces and/or surgery) is the primary endpoint.
223760967|NCT05847153|BEHAVIORAL|MASC|"The intervention arm will be comprised of:~1. Six Virtual Group Sessions. The sessions will teach mindfulness, self-compassion and behavioral management skills.~2. At Home Practice. After each group session, participants will have the opportunity to integrate the practices learned into their everyday life."
223760968|NCT06138756|DEVICE|Nerivio|Nerivio is a remote electrical neuromodulation (REN) device for the treatment of migraine
224314309|NCT00089024|RADIATION|radiation therapy|A re-staging CT scan, which will be obtained as part of the radiation simulation, will be used to assess any possible response to the initial two cycles of chemotherapy. Unless the patient has developed evidence of metastatic disease, chemoradiation will proceed. Patients who required no treatment delays will commence chemoradiation on day 42. If a one-week delay is needed before cycle 2 of neo-adjuvant chemotherapy can be delivered, the patient will begin chemoradiation on day 49 provided treatment-related toxicity has resolved. If cycle 2 could not be given (2 or more week delay for resolution of treatment-related toxicity), then chemoradiation will begin once toxicity has resolved (may be earlier than day 42).
223616306|NCT00354679|OTHER|mass spectrometry|
223616307|NCT00354679|PROCEDURE|adjuvant therapy|
223616308|NCT00354679|PROCEDURE|neoadjuvant therapy|
223616309|NCT00354679|PROCEDURE|therapeutic conventional surgery|
223616310|NCT00354679|RADIATION|radiation therapy|
223616311|NCT02938195|RADIATION|radiotherapy|The clinical target volume of radiotherapy only includes the visible tumor and lymph nodes and the investigators wouldn't do any prophylactic radiation treatment.
223616312|NCT02938195|PROCEDURE|Surgery|Surgery would be done 4-8 weeks after neoadjuvant chemoradiotherapy.
223616313|NCT02089919|BIOLOGICAL|cancer stem cell vaccine|
224314310|NCT04472676|DRUG|LY3473329|Administered orally.
223616314|NCT04115384|DRUG|Novolin-R insulin|Insulin (Novolin-R) 20 IU/IN (0.1ml/10 units IN in each nostril), twice per day, once in the morning and again in the evening (at least 8 hours between doses) for 4 weeks.
223616315|NCT02019732|OTHER|Data collection|Data collection from existing electronic healthcare databases (Marketscan Commercial database, MarketScan Medicare Supplemental database).
223616316|NCT06421038|OTHER|Thyme honey|Thyme honey is a rich monofloral honey variety formed by bees that collect nectar from thymus vulgaris flowers. thyme honey application (100% pure natural honey, applied by themselves) on their ulcers three times a day for 7 days
223616317|NCT06421038|DRUG|Kenalog|kenalog in orabase (Triamcinolone acetonide 0.1% in oral paste 5g)
223616318|NCT05527665|PROCEDURE|Midurethral sling surgery|This treatment consists of the placement of a sub-urethral sling, usually made of polypropylene, in order to support the urethra during efforts and thus to avoid leaks linked to its hyper mobility. This is a frequent and rapid surgery, which is performed on an outpatient basis. The sling is placed under the patient's urethra with the help of an awl.
223616319|NCT05315102|OTHER|Sham intervention|The participants head and/or spine will be moved in ways that include passive and active movements, similar to what is done when assessing the spine by a chiropractor. The sham intervention will also include the participants moving into adjustment setup positions similar to how the chiropractor would typically set up a patient with no joint pre-loading or adjustive thrust
223616320|NCT05315102|OTHER|Chiropractic Care|A registered chiropractor will assess the entire spine, and both sacroiliac joints will be assessed for vertebral subluxation by a registered chiropractor. The clinical indicators that will be used to assess the function of the spine before spinal adjustment intervention include assessing for joint tenderness to palpation manually palpating for a restricted intersegmental range of motion, assessing for palpable asymmetric intervertebral muscle tension, and any abnormal or blocked joint play and end-feel of the joints.
223616321|NCT05315102|OTHER|Physical therapy intervention|The standardized treatment protocol will be provided according to the guidelines, which will include various modalities and treatment approaches, including stretching exercises; massage; strengthening exercises of weak muscles, weight-bearing, balance (static and dynamic) and gait training; electrical stimulation; treadmill use; and endurance training for the improvement of gait, motor function, strength and functional mobility in Cerebral Palsy children, where Conventional Therapy will be provided according to the respective needs of the individual patient.
223616322|NCT03678064|DEVICE|Lokomat|16 sessions total. Provided by study PT twice weekly for a period of 8 weeks
223616323|NCT04722341|BEHAVIORAL|Time-Restricted Eating (TRE)|8-hour daily eating period, starting 1-3 hours after waking up
223616324|NCT04722341|BEHAVIORAL|Control|More than equal to a 12-hour daily eating period
223616325|NCT05870891|OTHER|Food|Food
223616326|NCT04590560|DIAGNOSTIC_TEST|screening for breast cancer with tomosynthesis and synthetic 2D mammography performed at different interval compared to actual clinical practice|women will be screened for breast cancer using tomosynthesis and synthetic 2D mammography with an interval defined according to their randomization arm for a follow-up period of 6 years;
223760969|NCT06305299|BIOLOGICAL|iC9-CAR.B7-H3 T cells|iC9-CAR.B7-H3 T cells will then be administered intraperitoneally
223616327|NCT03938896|OTHER|platelet rich plasma|Patients were put in supine position. Betadine was used to disinfect the skin of the heel. 1 ml of local anesthesitic (lidocaine) was injected;then, by the same syringe, 2.5 ml of PRP was injected in the tenderestarea.After extraction of the needle, a bandage was puton the injected area. The patient was kept in the supine position for twentyminutes and then discharged
223616328|NCT03938896|OTHER|corticosteroid|Patients were put in the supine position. Injection was done usingthe medial technique. Identification of the tenderest point of the heel was done by palpation. Antiseptic solution was used to disinfect the skin overlying theheel. Then1ml of 40 mg methylprednisolone acetate and 1 ml of local anaesthetic as lidocaine 2% were injected into the plantar fascia by a 22gauge needle. After injection, participants were advised to stay sitting without foot movement for 15 minutes
224312415|NCT04815889|BEHAVIORAL|PRIMUS parent training Group|"The parents offered a PRIMUS Group-based parent support program for 5 half days. This parenting education for preschool children with developmental problems but without the requirement of diagnosis Hellström (2019) has been designed and tested in other parts of the country but not scientifically validated, which can be done in this study. The teachers will be offered a teacher group for half a day together with the parents.~For those families who need more intervention the PLUSS toddler team (from the specialist Healthcare) is established.~The PLUSS toddler team makes a management plan as referral to Habilitation Center, Child and Adolescent Psychiatry, Speech Therapist, or interventions eg:~* Support in the child's everyday environment home / preschool~* Targeted Parent Groups: toilet, sleep, food, everyday structure, handle behavioural problems~* Web courses"
224312416|NCT05132036|OTHER|lung ultrasound|"Subjects are enrolled during their usual session in the hemodialysis unit of the Amiens University Hospital. Before starting the hemodialysis, lung ultrasound according to the 8 sites score and a measure of bioimpedance will be performed in dorsal decubitus. In a 2nd time, an echocardiography is realized. During haemodialysis session, biological analysis and clinical score will be assessed"
224312417|NCT06902350|DRUG|CS231295|oral tablet. Only one dose on C0D1 in single-dose period. Once daily from C1D1 until disease progression, death, intolerable toxicity, loss to follow-up, withdrawal of informed consent, or the end of the trial, whichever occurs first, in multiple-dose period in both escalation and cohort expansion phases.
224312418|NCT04006210|COMBINATION_PRODUCT|ND0612 Solution for SC infusion|Levodopa/Carbidopa (LD/CD) solution administered SC via infusion pump
224312419|NCT04006210|COMBINATION_PRODUCT|Placebo for SC infusion|Placebo solution administered SC via infusion pump
224312420|NCT04006210|DRUG|Oral IR-LD/CD|Encapsulated LD/CD 100mg/25mg
224312421|NCT04006210|DRUG|Placebo for Oral IR-LD/CD|Encapsulated Placebo for LD/CD 100mg/25mg
224312422|NCT06907342|DRUG|FOLFOX or FOLFIRI|Treatment allocation from tumouroid readout
224312423|NCT06935162|DRUG|Teclistamab (Tec)|Teclistamab will be administered via a subcutaneous injection
224312424|NCT06936878|BEHAVIORAL|BOLSTER Program|This supportive care program includes six telehealth sessions led by a trained nurse to help patients with advanced gynecological or gastrointestinal cancers and their care partners build skills, manage symptoms, and cope with challenges. Two additional sessions will be help support care partners. Participants will also get access to the BOLSTER website, which offers personalized educational materials to support their well-being
224312425|NCT05999812|DRUG|all trans Retinoic Acid|ATRA orally 45 mg/m2 QD in 2 divided doses days 1-7, repeat every 14 days
224312426|NCT05999812|DRUG|Atezolizumab|Atezolizumab IV D1, 840 mg every 14 days
224312427|NCT05999812|DRUG|Bevacizumab|Bevacizumab IV D1, 10 mg/kg every 14 days
224312428|NCT02248038|PROCEDURE|open surgery|Patients in this arm undergo radical resection of colon cancer in open surgery.Open surgery is a conventional technique for colorectal cancer patients.
224312429|NCT02248038|PROCEDURE|laparoscopic surgery|Patients in this arm undergo radical resection of colon cancer in laparoscopic surgery.Laparoscopic surgery is a new and minimum invasive technique for colorectal cancer patients.
224312430|NCT02658838|DRUG|Ticagrelor|Patients were treated with full amount low molecular weight heparin randomly after PCI,All patients are treated with ticagrelor one year.
224312431|NCT02658838|DRUG|full amount low molecular weight heparin|Patients were treated with half amount low molecular weight heparin randomly after PCI,All patients are treated with ticagrelor one year.
224312432|NCT02658838|DRUG|half amount low molecular weight heparin|Patients were treated with half amount low molecular weight heparin randomly after PCI,All patients are treated with ticagrelor one year.
223616329|NCT03566706|BEHAVIORAL|Discussion Tool: Unhealthy Eating|Parents will randomly be assigned to one of three discussion tools that will provide parents with tools on how to communicate with their children about unhealthy eating, marijuana use, or sedentary behavior.
223616330|NCT03566706|BEHAVIORAL|Discussion Tool: Marijuana Use|Parent Discussion Tools
223616331|NCT03566706|BEHAVIORAL|Discussion Tool: Sedentary Behavior|Parent Discussion Tools
223616332|NCT00622505|DRUG|zoledronic acid|Zoledronic acid concentrate (4 mg/5 milliliters \[ml\]) was diluted in 100 mL sterile 0.9% calcium-free sodium chloride or 5% dextrose injection, administered IV, either 4 or 12 weeks for 96 weeks.
223616333|NCT04294602|OTHER|Exercise|Exercise therapy intended in reducing muscle spasm, improving coordination of the mastication muscles and alter the jaw closure pattern.
224312433|NCT02658838|DRUG|No low molecular weight heparin|Patients were treated with no low molecular weight heparin randomly after PCI,All patients are treated with ticagrelor one year.
224312434|NCT03679052|DRUG|Mirtazapine|Each patient received 30 mg mirtazapine tablet and a placebo tablet for clonidine orally with sips of water 2 h preoperatively.
224312435|NCT03679052|DRUG|Clonidine|Each patient received 150 µg clonidine tablet and a placebo tablet for mirtazapine orally with sips of water 2 h preoperatively.
224312436|NCT03679052|DRUG|Placebo|Each patient received two placebo tablets for mirtazapine and clonidine orally with sips of water 2 h preoperatively.
224312437|NCT06948968|OTHER|Social Role Participation Questionnaire|Validity and Reliability of the Turkish Version of the Adapted Social Role Participation Questionnaire in Ankylosing Spondylitis
224312438|NCT06954727|OTHER|No intervention; Observational study|No intervention; observational study
224314311|NCT04472676|DRUG|Placebo|Administered orally.
224314312|NCT00103220|DRUG|SJG-136|Given IV
224314313|NCT03513055|OTHER|nurse inject premixed insulin|nurse inject premixed insulin，coaching in the injection technique
223616334|NCT04294602|OTHER|Low Level Laser Therapy|LLLT (max output power: 1200mW, wavelength: 808 nm, dosage: 10j/ cm2 Electronica Pagani Laser Tower Light, Italy) 2.5-4j/TrP dosage was applied to MTrP or sensitive points.
223616335|NCT04294602|OTHER|Manuel Pressure Release|MPR technique is a noninvasive method based on pressure on the trigger point in accordance with the patient's tolerance and technique applies supine position relax as much as possible, manuel pressure applied trigger point in neck and mactication muscles
223616336|NCT04294602|OTHER|Patient Education|Some suggestions were made to TMD people who should pay attention to in daily life. These suggestions were given in writing.
223616337|NCT00056693|DRUG|Sunitinib|Sunitinib 50 mg by oral capsule daily for 4 weeks in every 6 week cycle until progression or unacceptable toxicity
223760970|NCT06305299|DRUG|Cyclophosphamide|cyclophosphamide 300 mg/m2 IV will be given.
223760971|NCT06305299|DRUG|Fludarabine|fludarabine 30 mg/m2 IV will be given.
223760972|NCT06519734|OTHER|Questionnaire|"Questionnaire intended for patients on contraceptive modalities and use of menstrual hygiene products.~Consultation of the medical records of patients who have reported infectious complications linked to the use of intrauterine devices, tampons or menstrual cups."
223760973|NCT06188702|DRUG|S095035|S095035 will be taken orally once daily in 28-day cycles.
224202172|NCT06126523|DEVICE|Radial Extracorporeal Shock Wave Therapy TWİCE|"rESWT application TWİCE The points where rESWT will be applied will be determined under ultrasonography guidance. The pressure pulses will be focused on the injection site in the medial and lateral heads of the gastrocnemius muscle and the soleus muscle.~A total of 2 sessions of rESWT will be applied on the same day after BTX-A injection and on the 7th day after BTX-A.~Number of pulses: 1500 pulses Frequency: 6 Hz Energy level/Pressure: 2.2 bar air pressure Duration: 12 minutes~Device to be used in research ELMED VIBROLITH ESWT SW. Give. 3.3 It is based on the principle that currents produced outside the body spread in the tissue in the form of sound waves."
224202173|NCT06126523|DEVICE|Radial Extracorporeal Shock Wave Therapy SHAM|"Radial Extracorporeal Shock Wave Therapy- SHAM The points where rESWT will be applied will be determined under ultrasonography guidance. The pressure pulses will be focused on the injection site in the medial and lateral heads of the gastrocnemius muscle and the soleus muscle.~Sham ESWT will be administered with the r-ESWT probe. The device will be switched on, the frequency, pressure and duration values will be set and then the device will be switched off and the probe will be kept in equal time with the active treatment, by playing a sound previously recorded during the real application."
224202174|NCT06533891|DIETARY_SUPPLEMENT|DPA enriched n-3|4 g/d DPA enriched n-3 concentrate (\~980 mg DPA, 380 mg EPA, 1720 mg DHA)
224202175|NCT06533891|DIETARY_SUPPLEMENT|n-3 control|4 g/d n-3 control (\~980 oleic acid, 380 mg EPA, 1720 mg DHA)
224202176|NCT06533891|DIETARY_SUPPLEMENT|Placebo|"4 g/d placebo control (light olive oil)"
224202177|NCT01776619|DRUG|PF-06305591|14 day repeated 20mg BID doses
224202178|NCT01776619|DRUG|Placebo|14 day repeated BID doses
224202179|NCT01776619|DRUG|PF-06305591|14 day repeated 80mg BID doses
224202180|NCT01776619|DRUG|Placebo|14 day repeated BID doses
224202181|NCT01776619|DRUG|PF-06305591|14 day repeated 40mg BID doses
224202182|NCT01776619|DRUG|Placebo|14 day repeated BID doses
224202183|NCT01776619|DRUG|PF-06305591|14 day repeated BID doses
224202184|NCT01776619|DRUG|PF-06305591|relative bioavailability tablet vs. solution and food effect at 50mg dose
224202185|NCT06292910|DIAGNOSTIC_TEST|arterial and central venous blood gas analysis, lactate|blood gas analysis
224202186|NCT02814669|DRUG|Atezolizumab|Atezolizumab will be given at a dose of 840 milligrams (mg) via intravenous (IV) infusion on Days 1 and 15 of each 28-day cycle until loss of clinical benefit, unacceptable toxicity, or disease progression.
223616338|NCT04322188|OTHER||this is an observational study. No intervention is applicable; patients are managed as per clinicians' best judgement and best practice
223616339|NCT00933322|DIETARY_SUPPLEMENT|diet enriched with industrial trans fatty acids|After run-in phase of 2 weeks with margarine without TFA, 4 weeks with margarine enriched with industrial trans fatty acids following. TFA-percentage of total energy consumption is 2% or 6% of total fat energy consumption.
224202187|NCT02814669|DRUG|Radium-223 Dichloride|Radium-223 dichloride will be administered at a dose of 55 kilobecquerels per kilogram (kBq/kg) via slow IV bolus on Day 1 of each 28-day cycle for up to 6 cycles.
224202188|NCT02897453|DEVICE|The Spinal Tethering System|An implant comprised of: vertebral body screws, vertebral body staples (washers), and a PET (polyethylene-terephthalate) cord.
224202189|NCT03300232|BEHAVIORAL|Computer-based VC-CBT|Computer-based VC-CBT: Three, one-hour computerized therapy sessions delivered on an interactive computerized platform with therapy blocks dedicated to each of three primary modules/goals: 1) psycho-education, 2) skills learning, and 3) individualized practice
223616340|NCT00933322|DIETARY_SUPPLEMENT|diet enriched with ruminant trans fatty acids|After run-in phase of 2 weeks with margarine without TFA, 4 weeks with butter enriched with ruminant trans fatty acids following. TFA-percentage of total energy consumption is 2% or 6% of total fat energy consumption.
223616341|NCT00933322|DIETARY_SUPPLEMENT|diet without any trans fatty acids|6 weeks with margarine without any trans fatty acids.
223616342|NCT01135615|DRUG|Sevelamer|The starting dose for sevelamer was 1-2 capsules (800 mg) three times a day
223616343|NCT01135615|DRUG|calcium acetate|calcium acetate (1000 mg) 1 tablet three times a day
223616344|NCT00250237|DRUG|Haloperidol|Haloperidol 1mg twice daily during 72hours
223616345|NCT00250237|DRUG|placebo|Placebo 1mg twice daily during 72hours
223760974|NCT06188702|DRUG|TNG462|TNG462 will be taken orally once daily in 28-day cycles.
223760975|NCT06287203|BEHAVIORAL|Addiction Risk Feedback Program|This novel prevention/intervention program will be accessed via an on-line interactive website where individuals receive their personalized risk estimates, based on their genetic, behavioral, and environmental risk factors (part 1 of the program), accompanied by information to help them reduce risk (part 2 of the program). The information in part 2 of the program will vary between arms.
224202190|NCT01823237|DEVICE|Transcranial Magnetic Stimulation|
224314314|NCT00905710|PROCEDURE|Chromoendoscopy|Chromoendoscopy: spraying of the mucosa of the right colon with indigo-carmine
224314315|NCT03348735|DRUG|Lidocaine patch 5%|Application of Lidocaine 5% patch for 12 hours.
224314316|NCT03348735|DRUG|Capsaicin 8% Patch|Application of Capsaicin 8% patch for
223510337|NCT06642779|DIAGNOSTIC_TEST|CDVA|Monocular and binocular Corrected Distance Visual Acuity (UDVA) was evaluated at all visits (preoperative, D1, M1, M3, M6 and M12), using the ETDRS chart.
223510338|NCT06642779|DIAGNOSTIC_TEST|UIVA / DCIVA|Uncorrected and Distance Corrected Intermediate Visual acuity (UIVA / DCIVA) was evaluated postoperatively at M1, M3, M6 and M12, using an intermediate chart from 67 cm.
223510339|NCT06642779|DIAGNOSTIC_TEST|UNVA / DCNVA|Uncorrected and Distance Corrected Near Visual acuity (UNVA / DCNVA) was evaluated postoperatively at M1, M3, M6 and M12, using a near chart from 40 cm.
223616346|NCT01839058|OTHER|Esophageal Manometry|Both cohorts will undergo standard high resolution esophageal manometry testing. This entails a catheter passed through the nose into the esophagus and measures pressure changes with a series of wet swallows. As part of the study, we will also be instilling both weak acid and saline into the esophagus.
223616347|NCT06189326|PROCEDURE|non-penetrating deep sclerectomy|Non-penetrating deep sclerectomy (NPDS) is a non-perforating filtration procedure used for the surgical treatment of medically uncontrolled open angle glaucoma. This procedure was developed in an attempt to avoid many of the postoperative complications of trabeculectomy
223616348|NCT06189326|PROCEDURE|primary combined trabeculotomy-trabeculectomy|Combining trabeculotomy with trabeculectomy is one of the preferred surgical options, which showed favorable results in congenital glaucoma, and is advised mainly for treating moderate to severe forms of the disease, as the procedure provides dual pathways for aqueous drainage
223616349|NCT04979676|BEHAVIORAL|Cognitive Therapy|Experimental psychotherapy based on the cognitive model for social anxiety disorder, applied individually and remotely to participants fulfilling inclusion criteria.
223616350|NCT04979676|BEHAVIORAL|Compassion-focused Therapy|Experimental psychotherapy based on the principles of the compassion-focused model, applied individually and remotely to participants fulfilling inclusion criteria.
223616351|NCT04979676|BEHAVIORAL|Acceptance and Commitment Therapy|Experimental psychotherapy based on the principles of the acceptance and commitment model, applied individually and remotely to participants fulfilling inclusion criteria.
223616352|NCT01395576|DEVICE|Genu Neurexa orthosis|Knee orthosis for the prevention of knee hyper extension
223616353|NCT00414141|BIOLOGICAL|Grass MATA MPL|4 subcutaneous injections
223616354|NCT00414141|BIOLOGICAL|Placebo|4 subcutaneous injections
223616355|NCT05734755|BEHAVIORAL|The Individualized Dietary Behavioural Change Programme (IDBC)|The first three weekly face-to-face sessions will be during the 'goal initiation' and 'planning' phases. The remaining seven face-to-face sessions will be offered once to twice per month between weeks 4 and 24 during the program at the 'action execution' phase. Family members will be encouraged to join the dietary consultations. Strategies will be discussed with the family members to facilitate the participant's adherence to the recommended diet regimen.Phase I Goal Initiation is aimed at motivating the participants to actively manage their sarcopenic obesity. Phase II Plan Formulation is aimed at guiding the participants in transforming their (sub-) goals into detailed individualized action plans.Phase III Action Execution is aimed at encouraging the participants to continually execute the action plan. The IDBC guidebook will be given to the participants to guide them on how to gradually adopt our dietary recommendations in their daily life.
223616356|NCT05734755|BEHAVIORAL|The Exercise Training|The group size will be \< 10. They will be used in the resistance exercise in this study to improve muscle strength (20 mins). Brisk walking (20 mins) will be employed in the aerobic exercise in this study. Each session will include 10 minutes of warm-up and cool-down exercises at the beginning and at the end. A YouTube video and a pamphlet describing the different types of exercises used in this programme will be disseminated to all participants to encourage them to continually practise their exercises at home for 30 minutes at least 5 times per week.
223616357|NCT02361333|BEHAVIORAL|Teaching Intervention|Patients will be taught how to install and use a remote monitor
223616358|NCT02420093|DEVICE|"Pelvis Support Assembly"|"Use of a portable and adjustable Pelvis Support Assembly in the seat of the subject's work or home desk chairs as tolerated during the 3 weeks intervention interval. This pelvic support device supports the user from the pelvis and aids in maintaining a more anatomically neutral lumbar and pelvic position in sitting. This device is not officially named at this time but is as represented in US Patent number is US 8,857,906 B2."
223616359|NCT04105049|OTHER|Observation of psychological aspects|Motivational, socioeconomic, family, stress, and other aspects are tested.
223616360|NCT00980356|DRUG|Vildagliptin|Patients receive once daily 50 mg Vildagliptin
223616361|NCT03292224|DIAGNOSTIC_TEST|- Microscopic examination and culture of collected specimens|"1. Unstained wet mount with 10%-20% KOH.~2. Wet mounts stained with:~   * Lactophenol cotton blue.~  * India ink~  * Gram stain Culturing on Sabouraud´s dextrose agar ."
223616362|NCT00819936|PROCEDURE|forward walking|comparison forward walking vs backward walking in the physiotherapy after after abdominal surgery
223616363|NCT00819936|PROCEDURE|backward walking|physiotherapy with use a backward walking type of physiotherapy
223616364|NCT00411749|BIOLOGICAL|Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine (V501)|V501; Gardasil, 0.5 ml injection in 3 dosing regimen
223616365|NCT00411749|BIOLOGICAL|Comparator: Placebo (unspecified)|Placebo 0.5 ml injection in 3 dosing regimen
223616366|NCT00651781|DRUG|Bortezomib|2 times per week of Velcade administration.
223616367|NCT02768493|DRUG|1.0 ml/kg of 0.15% ropivacaine|Randomly selected patients of the high dose group are given 1.5 ml/kg of 0.15% ropivacaine for caudal block before their surgery. In contrast, patients in the low dose group are given 1.0 ml/kg of 0.15% ropivacaine for caudal block before surgery.
223616368|NCT02768493|DRUG|1.5 ml/kg of 0.15% ropivacaine|Randomly selected patients of the high dose group are given 1.5 ml/kg of 0.15% ropivacaine for caudal block before their surgery. In contrast, patients in the low dose group are given 1.0 ml/kg of 0.15% ropivacaine for caudal block before surgery.
223616369|NCT01648634|DRUG|Nebivolol|A 1.25mg-test dose will be administrated to assess the treatment tolerance before randomization. A forced titration of nebivolol will be performed with 2 weeks periods. Full dose of nebivolol is 5mg/day (7.5mg/day for patients whose weight is\>60kg)
223616370|NCT01648634|DRUG|Placebo|A 1.25mg-test dose of nebivolol will be administrated to assess the treatment tolerance before randomization. A forced titration of placebo will be performed with 2 weeks periods. Full dose of placebo is 5mg/day (7.5mg/day for patients whose weight is\>60kg)
223616371|NCT01645254|DRUG|Argemone mexicana|30g, the powder decoction 2 times a day for 14 days
223616372|NCT02820454|DRUG|AGuIX|A single intravenous injection on day 1. Dose level 1: 15mg/kg; Dose level 2: 30mg/kg, Dose level 3: 50mg/kg; Dose level 4: 75mg/kg; Dose level 5: 100mg/kg
224202191|NCT04591600|DRUG|Ivermectin and Doxycyline|Ivermectin 200ug/kg PO per day for two days, and in some patients who needed more time to recover, a third dose 200ug/kg PO per day was given 7 days after the first dose. Doxycycline 100mg capsule PO every 12h per day was given for 5-10 days, based on the clinical improvement of patients. In addition, standard care was given to the patients of Ivermectin-Doxycycline group based on the clinical condition of each patient.
224312439|NCT06955117|OTHER|Physical Therapy Exercises|"Experimental - McKenzie Technique (Group A) Intervention Type: Other: Physical Therapy Exercises~Other Names:~Intervention for low back pain~Description:~Soft Tissue Mobilization: Manual massage to release muscle tension (5-10 mins)~Lumbar Mobilization Techniques:~PA Mobilization (Posteroanterior glide) on the lumbar spine (Grade I-IV, 3-5 min per segment)~Side-lying Rotational Mobilization (3 sets × 10 reps)~Muscle Energy Techniques (METs):~Pelvic Tilts (3 sets × 10 reps)~Hip Flexor Stretch with Isometric Hold (3 sets × 10 sec per side)~Core Stabilization Exercises:~Bridge Exercise (3 sets × 10-15 reps)~Dead Bug Exercise (3 sets × 10 reps per side)~Modalities:~Hot Pack (15-20 mins) for relaxation before therapy~TENS (10 mins) for pain relief before mobilization"
224312440|NCT06955117|OTHER|Group B|"Manual Therapy (Group B)~Description:~Soft Tissue Mobilization: Manual massage to release muscle tension (5-10 mins)~Lumbar Mobilization Techniques:~PA Mobilization (Posteroanterior glide) on the lumbar spine (Grade I-IV, 3-5 min per segment)~Side-lying Rotational Mobilization (3 sets × 10 reps)~Muscle Energy Techniques (METs):~Pelvic Tilts (3 sets × 10 reps)~Hip Flexor Stretch with Isometric Hold (3 sets × 10 sec per side)~Core Stabilization Exercises:~Bridge Exercise (3 sets × 10-15 reps)~Dead Bug Exercise (3 sets × 10 reps per side)~Modalities:~Hot Pack (15-20 mins) for relaxation before therapy~TENS (10 mins) for pain relief before mobilization"
224312441|NCT06236139|BIOLOGICAL|Anti-STEAP1 CAR T-cells|Given IV
224312442|NCT06236139|PROCEDURE|Biopsy|Undergo tumor biopsy
224202192|NCT04591600|DRUG|Standard of care|"Standard care~* Acetaminophen 500mg on need~* Vitamin C 1000mg twice/ day~* Zinc 75-125 mg/day~* Vitamin D3 5000IU/day~* Azithromycin 250mg/day for 5 days~* Oxygen therapy/ C-Pap if needed~* dexamethasone 6 mg/day or methylprednisolone 40mg twice per day, if needed~* Mechanical ventilation, if needed"
224202193|NCT03649607|OTHER|Accelerated Resolution Therapy|ART was developed to treat both physiological and cognitive aspects of PTSD, which has been described as a consequence of failed memory processing. The use of Voluntary Image Replacement (VIR) parallels imaging re-scripting in which a preexisting negative mental image is transformed into a more benign image. This has been successfully used to treat survivors of traumatic industrial accidents suffering from PTSD. Participants will complete five sessions over a 21-day period.
224202194|NCT04442178|DRUG|CYT107|IM administration at 10μg/kg twice a week for three weeks and up to 7 administrations according to Hospital length of stay
224202195|NCT04442178|DRUG|Placebo|IM administration at 10μg/kg twice a week for three weeks and up to 7 administrations according to Hospital length of stay
224202196|NCT02838329|OTHER|warming of ropivacaine for BT|
224202197|NCT02838329|DRUG|Ropivicaine|
224202198|NCT01909817|PROCEDURE|Routine coronary angiogram|
223616373|NCT02820454|RADIATION|whole brain radiation therapy|30Gy in 10 sessions of 3Gy (5 days a week in weeks 1-2); first session 4 hours after AGuIX injection.
224202199|NCT00713713|PROCEDURE|Mechanical ventilation with low and high tidal volume|Tidal volume of 6 or 12 ml.kg-1, calculated on ideal body weight
223616374|NCT02373488|OTHER|lifestyle advice|lifestyle advices such as increasing fluid and fibre intake, improving physical activity level, and taking the ideal posture for defecation (squatting position) with a two-pages document.
224202200|NCT05567588|COMBINATION_PRODUCT|Drug: Pembrolizumab|200mg(body weight \>75kg) or 100mg(body weight≤75kg) given intravenously over 30 minutes day 1 of every 3 week cycle until progression as per immune related response criteria.
224202201|NCT02594137|PROCEDURE|Without watertight duraplasty|After standard craniectomy and dural opening, provided there is no brain contusions or hematomas requiring surgical evacuation, no watertight duraplasty is performed. The dura is left opened and the brain parenchyma is covered with Surgicel. Usual closure is then performed.
224312443|NCT06236139|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
224312444|NCT06236139|PROCEDURE|Bone Scan|Undergo NM bone scan
224312445|NCT06236139|PROCEDURE|Computed Tomography|Undergo CT scan
224312446|NCT06236139|DRUG|Cyclophosphamide|Given IV
223616375|NCT02373488|OTHER|connective tissue manipulation|CTM wil be applied five days per week, a total of 20 sessions for 4 weeks. Each session lasted around 15-20 minutes. While patients are in a sitting position, starting from the lumbosacral region, lower thoracic, scapular, inter-scapular and cervical regions will be included in the treatment, respectively.
223616376|NCT02373488|OTHER|abdominal massage|Abdominal massage will be applied five days a week for four weeks. Each session will last around 15-20 minutes.
223616377|NCT02088450|DRUG|Active treatment with nitrendipine (10-40 mg/day).|If necessary, the dihydropyridine calcium-channel blocker was combined with or replaced by enalapril maleate (5-20 mg/day), hydrochlorothiazide (12.5-25 mg/day), or both drugs.
223616378|NCT05963620|OTHER|percutaneous coronary intervention vs bypass graft surgery|retrieve long term follow up data on clinical outcome of study population, no intervention
224312447|NCT06236139|PROCEDURE|Echocardiography|Undergo ECHO
224312448|NCT06236139|DRUG|Enzalutamide|Given PO
224312449|NCT06236139|DRUG|Fludarabine|Given IV
224312450|NCT06236139|PROCEDURE|Leukapheresis|Undergo leukapheresis
224312451|NCT06236139|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
224312452|NCT06236139|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
224312453|NCT06236139|PROCEDURE|Positron Emission Tomography|Undergo PET scan
224312454|NCT06832410|BIOLOGICAL|Biological/Vaccine|Infused into the hepatic portal vein.
224312455|NCT04876092|DRUG|JNJ-67856633|Participants will receive JNJ-67856633 orally.
223616379|NCT04006093|DRUG|Apixaban Oral|one Tablet 5mg
224312456|NCT04876092|DRUG|Ibrutinib|Participants will receive Ibrutinib orally.
224314317|NCT03348735|DRUG|Pregabalin|Oral treatment with pregabalin (75mg capsules) will be used at optimized doses to best match clinical practice in Europe.
223616380|NCT03560336|DRUG|Liraglutide|Patients will initiate treatment with liraglutide according to the approved label in Korea. Patients will initiate 0.6 mg daily and weekly increase the dose by 0.6 mg until reaching 3.0 mg daily. Patients will then continue to stay on 3.0 mg/day (total treatment duration: 26 weeks).
223616381|NCT04499937|BEHAVIORAL|Streak incentive|Participants will receive prompts 3 times a day for 21 days prompting them to complete surveys. They will start with a $0 balance and will earn a fixed amount for each response.
223616382|NCT04499937|BEHAVIORAL|Loss-based incentive|Participants will receive prompts 3 times a day for 21 days prompting them to complete surveys. They will start with the maximum balance and will lose a fixed amount for each response they do not complete.
223616383|NCT04499937|BEHAVIORAL|Flat-fee control status quo condition|Participants will receive prompts 3 times a day for 21 days prompting them to complete surveys. They will receive the maximum compensation at the end of the study.
223616384|NCT04499937|BEHAVIORAL|Flat-Fitbit control status quo condition|Participants will receive prompts 3 times a day for 21 days prompting them to complete surveys. They will keep the Fitbit at the end of the study.
223616385|NCT05762497|OTHER|Moldable adhesive|Patients were provided with the new adhesives and a short questionnaire on current ASV use. After a week, they were contacted by telephone to verify any doubts/problems. At the end of the two weeks, the patient was again administered a questionnaire to evaluate the new moldable adhesive (while using the ASV).
223616386|NCT01509755|DRUG|placebo|Once daily injection, under the skin (s.c.) for 12 weeks
223616387|NCT01509755|DRUG|liraglutide|Once daily injection, under the skin (s.c.) for 12 weeks
223616388|NCT01509755|DRUG|glimepiride|Tablets administered orally according to current treatment guidelines. Dose adjusted according to the glycaemic response
223616389|NCT01809522|PROCEDURE|Posterior reconstruction of the rhabdosphincter|
223616390|NCT01360320|DIETARY_SUPPLEMENT|Green tea extract of Camellia Sinensis|"Powdered decaffeinated green tea extract of Camellia Sinensis, packed in hard gelatine capsules containing either 150 mg EGCG~* Run-in period with 150mg EGCG two times daily (p.o) for 4 weeks~* 150mg EGCG two times daily (p.o.) over the course of three years.~* Colonoscopy after 3 years"
223616391|NCT01360320|DIETARY_SUPPLEMENT|Green tea extract of Camellia Sinensis followed by placebo|"Powdered decaffeinated green tea extract of Camellia Sinensis, packed in hard gelatine capsules containing either 150 mg EGCG~* Run-in period with 150mg EGCG two times daily (p.o.) for 4 weeks~* Placebo two times daily (p.o.) over the course of three years~* Colonoscopy after 3 years"
223616392|NCT06273150|OTHER|Positive genetic test for pathological expansion in ATN1|Positive genetic test for pathological expansion in ATN1
223616393|NCT02426463|DRUG|propofol|
223616394|NCT02426463|DRUG|oxycodone|
223616395|NCT04869865|DIETARY_SUPPLEMENT|9-day detoxification cleanse and 1 week of pre-cleanse transition|Subjects will participate in the full 9-day Springtime Home Cleanse, including the week prior to a pre-cleanse transition period. The cleanse includes a transition week, 9 days of a monodiet, internal oleation with ghee, external oleation, herbs, purgation, and an enema. During this time, subjects will also attend daily online meetings on Facebook Live throughout the cleanse and on AyurPrana's AyurLearn online portal to participate in guided mediation and yoga. Subjects will also use these platforms to access daily cleanse instructions and journaling topics.
223616396|NCT03444493|OTHER|Exercise|Exercises were basically performed in 3 phases in this study. In the first phase; effectively and correctly contraction of TrA and multifidus muscles and how the patients adapted to daily life activities was taught. In the second phase; was aimed that the protection of stabilization by counteracting more muscle activation, in the third phase neutral position along with the activities required high level control.
223616397|NCT02532608|OTHER|Acute sleep deprivation|Participants will stay awake for 36 hours
223616398|NCT03287999|DIAGNOSTIC_TEST|Thrombophilia screen|Thrombophilia screen (including antithrombin activity (AT:Ac), protein S antigen (PS:free), protein C activity (PC:Ac) , genetic analysis for FV Leiden and Prothrombin 3'UTR mutations and screening for lupus anticoagulant.
224202202|NCT03962660|OTHER|HaRTS-TRENDS|"HaRTS-TRENDS comprises 4, individual sessions delivered in the context of the interventionist's pragmatic harm-reduction mindset paired with a compassionate, advocacy-oriented heart-set or style. It comprises the delivery of 4 manualized components, including a) participant-led tracking of preferred smoking outcomes, b) elicitation of participants' harm-reduction goals and their progress toward achieving them, c) discussion of the relative risks of various nicotine delivery systems, and d) instruction in using ENDS. Additionally, HaRTS-TRENDS entails provision of commercially available ENDS."
224314318|NCT02485119|DRUG|BAY94-9343|Cohort 1: 4.5 mg/kg of BAY 94-9343 at Q3W dose regimen. Cohort 2: 6.5 mg/kg of BAY 94-9343 at Q3W dose regimen.
223616399|NCT03287999|DIAGNOSTIC_TEST|Initiation pathway analysis|Evaluation of inter-individual variability in regulation of TF.VIIa.Xa.TFPI complex (tissue factor, activated Factor VII, activated factor X, tissue factor pathway inhibitor)
223616400|NCT00295191|PROCEDURE|high-flux membrane|high-flux dialyser
223616401|NCT00295191|PROCEDURE|low-flux membrane|low-flux dialyser
223616402|NCT00295191|PROCEDURE|conventional dialysate|conventional dialysate
223616403|NCT00295191|PROCEDURE|ultrapure dialysate|ultrapure dialysate
223616404|NCT01865760|DIETARY_SUPPLEMENT|Oral Glucose tolerance test (OGGT)|At baseline subjects will consume 50 g glucose dissolved in water in 10 minutes
223616405|NCT01865760|DIETARY_SUPPLEMENT|Liquid mixed meal|At baseline subject will consume the liquid mixed meal in 10 minutes
223616406|NCT01865760|DRUG|Octreotide|At baseline subjects will receive Octreotid 100 µg subcutaneous
223760976|NCT05741125|BEHAVIORAL|DSME + ASE intervention (Centering Appetite)|The intervention will enable participants to relearn their stomach's hunger and fullness signals and monitor their appetite. Participants will also learn strategies for glucose monitoring and carbohydrate management. Monthly booster sessions will be devoted to problem-solving, addressing barriers to emotion management, and self-monitoring type 2 diabetes mellitus symptoms. Participants will also receive weekly lessons with interactive activities delivered via a digital app.
223760977|NCT05999578|OTHER|Hypnosis|Hypnosis support before, during and at the end of cardiac MRI exam
224202203|NCT03962660|OTHER|Standard Care (SC)|The 4-session, individual standard care control condition entails the well-documented and evidence-based 5 As intervention (i.e., Ask about nicotine use, Assess use, Advise to quit smoking, Assist with exploring current smoking/planning smoking cessation, Arrange follow-up). Part of arranging follow-up is the recommendation to call the smoking quit line, which can supply additional counseling and nicotine replacement therapy.
224202204|NCT04059276|DIAGNOSTIC_TEST|MRI|We will examine chronic (\>3 months post stroke) patients using functional, structural, and metabolic MRI in both the brain and the spinal cord.
224202205|NCT04059276|DIAGNOSTIC_TEST|MRI|We will examine healthy control participants using functional, structural, and metabolic MRI in both the brain and the spinal cord.
224202206|NCT03976076|DRUG|JBPOS0101|JBPOS0101 (investigational product)
224202207|NCT01095029|DEVICE|Medtronic InterStim II - 3058|Stimulation with optimal pacemaker settings unilateral and bilateral with standard pacemaker settings: Amplitude sensory treshold, frequency 14 Hz and impulsduration 210 μsec.
224202208|NCT00295308|DRUG|Clonidine|clonidine up to 0.3 mg/day oral
224202209|NCT00295308|DRUG|Placebo|oral capsules daily
223616407|NCT03244917|BEHAVIORAL|TRAIN-AD|The study intervention is a multi-component training and education program targeting direct care providers and healthcare proxies for advanced dementia NH residents, intended to improve the management of urinary and lower respiratory tract infections in advanced dementia patients. There are two components to this practice intervention: 1. Provider Training, and 2. Proxy Education. Intervention components aimed at the provider include: Professionally led infection management training seminars, online infection management course, and infection management guidance algorithms. Additionally participating prescribing providers will be sent bimonthly infection management feedback reports. Proxy Education is completed by providing an infection management in Advanced Dementia booklet to proxies of patients with AD upon resident enrollment in study.
223616408|NCT05888675|DRUG|Weifuchun|The treatment group#Weifuchun group#was given Weifuchun tablets, 4 tablets each time, 3 times a day, and 1 hour after meals. The control group(chemotherapy group)#Chemotherapy regimen was based on the Chinese Clinical Oncology Association Guidelines for the Diagnosis and Treatment of Gastric Cancer (2018), including oxaliplatin +5-FU/CF, SOX regimen, XELOX regimen, and Ticeo monotherapy regimen.
223616409|NCT00964496|DRUG|Thalidomide|Patients were randomly assigned to receive a four-month course of 25 mg of thalidomide (Pharmaceutical Co., Ltd. of Chang-zhou, China). Medications were taken orally four times daily at 6 a.m., 12 noon, 6 p.m., and 10 p.m.
223616410|NCT00964496|DRUG|Iron|Patients were randomly assigned to receive a four-month course of 100 mg of iron (Pharmaceutical Co., Ltd. of Nanjing, China). Medications were taken orally four times daily at 6 a.m., 12 noon, 6 p.m., and 10 p.m.
223616411|NCT00896766|GENETIC|loss of heterozygosity analysis|
223616412|NCT00896766|GENETIC|microarray analysis|
223616413|NCT00896766|GENETIC|polymorphism analysis|
223616414|NCT00896766|GENETIC|tumor replication error analysis|
223616415|NCT02750774|BEHAVIORAL|Low-glycemic index group|"The dietary intervention consisted of the prescription of a Mediterranean style, low-glycaemic, low-fat, exchange diet (3 main meals and 3 snacks) with a total intake of 1500 kcal/day. In light of the PA, the dietitian adds 200 kcal/day for obese, 300 kcal/day for overweight women. The diet had a target macronutrient composition of 55% carbohydrates (80% complex carbohydrates with a low glycaemic index and 20% simple carbohydrates), 20% protein (50% animal and 50% vegetable) and 25% fat (12% mono-unsaturated, 7% polyunsaturated and 6% saturated) with moderately low saturated fat levels. The daily intake of carbohydrates was at least 225 g/day. The exercise intervention was focused on developing a more active lifestyle. The PA prescription is consistent with recommendations by the ACOG and ACSM for pregnant women. The talk test (being able to maintain a conversation during activity) was suggested to monitor the exercise intensity."
223616416|NCT02750774|OTHER|Standard Care Group|Women randomized to the Standard Care Group received general information about healthy lifestyle during pregnancy, according to the Guidelines
223616417|NCT05878834|DIETARY_SUPPLEMENT|Beta-glucan supplement group|Take 1 capsule 1 time per day for 12 weeks.
223616418|NCT05878834|DIETARY_SUPPLEMENT|Placebo group|Take 1 capsule 1 time per day for 12 weeks.
223616419|NCT01147666|DRUG|Roxadustat|Roxadustat will be administered per dose and schedule specified in the arms.
223616420|NCT01147666|DRUG|Epoetin Alfa|Epoetin Alfa will be administered per dose and schedule specified in the arms.
223616421|NCT01147666|OTHER|Placebo|Placebo matching to roxadustat will be administered per schedule specified in the arm.
223616422|NCT02159066|DRUG|LGX818|Combination of LGX818 and MEK162 (Part I)
223616423|NCT02159066|DRUG|MEK162|Combination of LGX818 and MEK162 (Part I)
223616424|NCT02159066|DRUG|LEE011|Combination of LGX818 + MEK162 + LEE011 (Part II)
223616425|NCT02159066|DRUG|BGJ398|Combination of LGX818 + MEK162 + BGJ398 (Part II)
223616426|NCT02159066|DRUG|BKM120|Combination of LGX818 + MEK162 + BKM120 (Part II)
224202210|NCT01908998|OTHER|Sandal|Subjectes will be scored on the Y-Balance Test wearing an Orthaheel Sandal
224202211|NCT05804240|DIAGNOSTIC_TEST|3D TEE RVEF|With TEE package software, the investigators measure and calculate 3D TEE RVEF using mid esophageal 4 chamber view
224202212|NCT03292731|DRUG|17-Hydroxyprogesterone caproate 250mg or 500 mg.|For the pharmacodynamic study, subjects receiving either 250mg or 500 mg dose will be studied to relate the plasma concentration at 26-30 to the rate of sPTB. For the safety study, subjects will be randomized to either the 250mg or 500 mg dose.
224202213|NCT03292731|DRUG|Safety study of 500 mg dose.|Subjects randomized to 250 mg or 500 mg dose
224202214|NCT06522828|DRUG|SSGJ-707|SSGJ-707 is a bispecific antibody against human PD-1 and VEGF
224202215|NCT06522828|DRUG|carboplatin|chemotherapy
224202216|NCT06522828|DRUG|paclitaxel|chemotherapy
224202217|NCT05229783|PROCEDURE|Electronic chromoendoscopy|Inspection of the Barrett's esophagus using the electronic chromoendoscopy modality of the endoscope for the detection of high-grade dysplasia and adenocarcinoma lesions.
224312457|NCT05219474|DIAGNOSTIC_TEST|Cochlear implant Computer Model Implementation|"The computer model will use standard Cochlear Implant settings to evaluate psychophysical and speech understanding abilities and sound quality with standard CI settings and then use these measures to build subject-specific models and determine experimental active electrode conditions to be tested: model-optimized, and two best-electrodes settings (2 types); 3) evaluate speech understanding and sound quality measures after using experimental settings regularly for 1.5 months; and 4) compare performance across experimental and clinical conditions.~The analysis will include four levels of repeated measures with active CI electrode conditions. These levels include the clinical baseline condition (all available electrodes active) and three experimental conditions (model-optimized, best-electrodes, and restricted best-electrodes)."
223616427|NCT02159066|DRUG|INC280|Combination of LGX818 + MEK162 + INC280 (Part II)
223616428|NCT05220878|BIOLOGICAL|GNR-069|Once a week as a subcutaneous injection. The initial dose is 1 mcg/kg.
224202218|NCT05229783|PROCEDURE|White light endoscopy with Seattle protocol|Inspection of the Barrett's esophagus using the white light modality of the endoscope for the detection of high-grade dysplasia and adenocarcinoma lesions, and then systemic quadrantic biopsies every 2 centimeters from the esogastric junction to the top of the Barett's esophagus (Seattle protocol)
224312458|NCT05307731|DRUG|Fingolimod|0.5mg daily for 90-180 days, in addition to guideline-based treatment for DM
223616429|NCT05220878|BIOLOGICAL|Nplate|Once a week as a subcutaneous injection. The initial dose is 1 mcg/kg.
223616430|NCT00462007|DRUG|Stalevo|Oral 3-4 daily doses for 6 weeks
223616431|NCT00217932|DRUG|Divalproex Sodium (Depakote)|
224202219|NCT06215872|OTHER|Therapeutic Exercises|Participants who have inclusion criterias after DRF reconstrontion pos-op 4. week will included this study. Certified Physiotherapist who have master of science degree and doctorate student will assessed them before and after treatment with face to face. Also exercise education will give face to face with same therapist. After that first sessions patients will progress their standardize or structered exercises pragram with telerehabilition during 4 weeks and 16 sessions. All sessions will be supervised with physiotherapist. End of study assessments will perform again with same therapist.
224202220|NCT05031975|DRUG|Irinotecan|Irinotecan 100 mg/smq intravenous infusion every 14 days
224202221|NCT05031975|DRUG|Temozolomide|Oral temozolomide 150 mg/sqm over days 1-5 every 28 days.
224202222|NCT03811652|DRUG|MEDI7247|Subjects with advanced solid tumors will enroll into the respective arms to receive Medi7247 IV at prescribed dose and schedule
224202223|NCT04492488|DRUG|MRG002|Administrated intravenously
224202224|NCT03449277|DRUG|Oral Tablet|oral labetalol tablets and oral nifedipine tablets
224202225|NCT02448212|DRUG|TS-121|Oral
224202226|NCT02448212|DRUG|[11C]TASP0410699|Intravenous radiotracer
224202227|NCT02448212|RADIATION|Positron Emission Tomography (PET)|Imaging scanning procedure
224202228|NCT04561973|BEHAVIORAL|numerical rating scale|Patients seen for routine planned visits complete a self-administered retrospective questionnaire about pain during the last 3 months, and a prospective diary during the two weeks following the visit.
224202229|NCT04426019|BEHAVIORAL|CLS Intervention|Community health workers (or promotoras) will deliver the CLS program either in face-to-face and/or group sessions to all women within 2 months of the baseline interview. Each session will last approximately 1 to 2 hours, and will include CLS materials adapted for this study.At the conclusion of the CLS program, promotoras will provide information about local and affordable providers delivering low-cost or free breast and cervical cancer screening services. Should a woman require follow-up for abnormal results, referrals will be given to programs,which provides assistance accessing cancer diagnostic and treatment services. Two weeks after delivering the education component of the CLS program, promotoras will call women to provide any further assistance needed. During these follow-up calls promotoras will provide on-going navigation support to women in need of mammography and Pap test screening
224202230|NCT04426019|BEHAVIORAL|No CLS intervention|This control arm will receive only usual practice care (print education) and will not receive the CLS intervention. They may receive the intervention after the study has been completed
224312459|NCT05307731|DRUG|guideline-based treatment for DM|guideline-based treatment for DM
224312460|NCT06322784|DIETARY_SUPPLEMENT|Oat bran (dietary fiber)|"Dietary fiber, known as the seventh type of nutrients, refers to carbohydrate polymers that have health benefits for the human body, mainly derived from plant cell walls such as grains, fruits, and vegetables.Mediterranean cuisine is a dietary pattern"
224312461|NCT03283267|DRUG|Sodium Zirconium Cyclosilicate (ZS)|Sodium zirconium cyclosilicate (ZS) is a non-absorbed, inorganic crystalline compound that selectively captures potassium ions in exchange for sodium and hydrogen ions in the gastrointestinal tract after oral administration.
223616432|NCT02869399|DIETARY_SUPPLEMENT|dietary intervention in addition to standard recommendations|"The diet of the intervention group will be based on the AICR/WCRF recommendations for cancer prevention and for the prevention of recurrences (www.dietandcancerreport.org):~* avoid or limit alcoholic drinks (2 drinks men, 1 drink women)~* increase consumption of a variety of non-starchy vegetables, fruits (at least 400g per day) and dietary fibers (at least 25g per day)~* eat mostly food of plant origin~* eat lean meat, limit intake of red meat and avoid processed meat~* increase consumption of anti-inflammatory foods, such as fish and whole grain cereals, f.e. brown rice and barley creams~* avoid high glycaemic and high insulinemic foods, such as refined flours, white breads, and pastries"
223616433|NCT00746278|PROCEDURE|Laparoscopic ovarian cystectomy using bipolar|Laparoscopic ovarian cystectomy using bipolar
223616434|NCT00746278|PROCEDURE|Laparoscopic ovarian cystectomy using ultrasonic scalpel|Laparoscopic ovarian cystectomy using ultrasonic scalpel
223616435|NCT00746278|PROCEDURE|Laparoscopic ovarian cystectomy using suture|Laparoscopic ovarian cystectomy using suture
223616436|NCT04266808|DEVICE|An interactive telehealth monitoring and biofeedback system|A pressure sensitive mat located under the user's wheelchair seat cushion and a wheelchair propulsion monitoring device attached to the chair which are interfaced with a phone App based user interface to provide feed back to promote physical activity and pressure relief maneuver performance among wheelchair users.
223616437|NCT04266808|BEHAVIORAL|Education Control|Participants will receive education on importance of pressure relief maneuvers and physical activity and the recommended amounts of each for prevention of pressure ulcer/injury and for physical health.
223760978|NCT04589676|BEHAVIORAL|Naloxone training|The naloxone training will teach participants about how to appropriately use naloxone in the event of an opioid overdose.
223510340|NCT06642779|DIAGNOSTIC_TEST|Manifest Refraction|Manifest refraction was the monocular subjective refraction (Sph, Cyl, Axis) giving the best distance corrected visual acuity. It was measured at the screening visit and the follow-up visits Day 1, Month 1, Month 3, Month 6 and Month 12.
223510341|NCT06642779|DIAGNOSTIC_TEST|IOP|Intraocular pressure (IOP) was measured at all visits (preoperative, D1, M1, M3, M6 and M12), using a non-contact tonometer.
223616438|NCT05768100|DIETARY_SUPPLEMENT|1,3-Butanediol|1,3-Butanediol
223616439|NCT05768100|DIETARY_SUPPLEMENT|Placebo|Isovolumic placebo
223760979|NCT04798352|OTHER|6-minute walk test|6-minute walk test
223760980|NCT04798352|OTHER|WIQ functional questionnaire|WIQ functional questionnaire
224202231|NCT03684473|BEHAVIORAL|Online Mindfulness-Based CBT & Trauma-Informed Yoga Intervention|"8 Weekly Online modules consisting of one weekly video of yoga postures combined with breath awareness and daily guided meditation audios, and a breath technique manual form the foundation of the intervention. The trauma-informed component of the program uses specific language, movement cues, teacher qualities, and physical assists. The yoga intervention will emphasize full choice and control of the participant through invitational language such as, when you are ready, if you like before each body posture cue. Based on trauma-informed yoga best practices, a predictable foundation of yoga postures (with variations) will be followed in a consistent order each session to allow participants to anchor to the series."
224202232|NCT05278975|DRUG|RSO-021|A naturally-occurring, sulfur-rich, cyclic oligopeptide antibiotic of the thiopeptide class.
223510342|NCT06642779|DIAGNOSTIC_TEST|VADC|Visual Acuity Defocus Curve (VADC) was taken monocularly at M3, monocularly and binocularly at M6 and binocularly at M12, using the Multifocal Lens analyzer - MLA application.
223510343|NCT06642779|DIAGNOSTIC_TEST|CSDC|Contrast Sinsitivity Defocus Curve (CSDC) was taken under photopic conditions at M6 and M12, using the Multifocal Lens Analyzer - MLA application
223510344|NCT06642779|DIAGNOSTIC_TEST|CSV-1000|"Contrast Sensitivity was measured using the CSV-1000 with distance correction in place at spatial frequencies of 3, 6, 12, and 18 cycles per degree (cpd). Measurements were taken under four different light conditions:~* Photopic (M3 monocular and binocular, M6 binocular and M12 monocular)~* Mesopic (M6 binocular)~* Photopic with backlight (M6 binocular)~* Mesopic with backlight (M6 binocular)"
223510345|NCT06642779|DIAGNOSTIC_TEST|Tear film stability|Tear film stability was assessed at screening visit and at follow-up visits M1, M3, M6, and M12 using the non-invasive Tear break Up Time (TBUT) with fluorescein dye.
223510346|NCT06642779|DEVICE|IOL implantation|The investigational device (877PEY) and the comparator (877PAY) intraocular lens models were implanted, using sutureless, small-incision phacoemulsification surgery.
223510347|NCT06641622|DIAGNOSTIC_TEST|Prediction of delayed graft function|Donor plasma CIRBP levels were measured using an ELISA kit to evaluate their association with DGF incidence
223510348|NCT06641934|OTHER|No intervention; Observational study|No intervention
223510349|NCT01704989|PROCEDURE|SLT Laser|At the first treatment, SLT treatment will be delivered to 360 degrees of trabecular meshwork. At the first escalation of treatment, the superior 180 degrees will be retreated. Twenty-five non-overlapping shots per quadrant will be used with a starting power of 0.8 mJ and increments of 0.1 mJ (titrated to avoid large bubbles) with standard other settings (400 nm spot size, 3 nanosecond duration) using a Latina single-mirror goniolens. The IOP will be checked 1 hour post treatment and five days of guttae acular tds will be administered to the treatment eye following treatment. After 2 treatments of SLT, the laser treated arm of the study will follow the same pathway as the medical treatment arm.
223510350|NCT01704989|DRUG|Prostagladin|Treatment will be initiated with latanoprost 0.005%. At the first IOP check (1-2 months), if the IOP has not reached target IOP, a second line agent will be added (β-Blocker unless contraindicated). If target IOP is still not reached, a third agent will be considered (topical carbonic anhydrase inhibitor). Treatment may be switched, instead, at the discretion of the clinician if the reduction of IOP with an agent is deemed to be no different than the pre-treatment IOP. Surgical therapy will be considered if target IOP is not met, or there is high IOP (\>35 mmHg) or advanced damage at presentation.
223510351|NCT05500534|DEVICE|Laser lithotripsy with stone recognition|Application of Revolix HTL+ which features automatic real-time stone recognition
223616440|NCT05716061|PROCEDURE|Sacral ESPB|Cadaver study
223616441|NCT01744249|DRUG|Axitinib|Orally, 5mg, twice daily, until progression or until unacceptable toxicity, with or without food intake.
224202233|NCT01965431|DRUG|BI 207127|Medium dose oral administration
224202234|NCT01965431|DRUG|BI 207127 placebo|
224202235|NCT01965431|DRUG|Faldaprevir placebo|
224202236|NCT01965431|DRUG|Faldaprevir|Medium dose oral administration
223616442|NCT01744249|DRUG|Sandostatin LAR|Intramuscular, 30mg, single injection every 28 days, until disease progression or unacceptable toxicity
224202237|NCT01965431|DRUG|Moxifloxacin (Avalox®)|
224202238|NCT02894060|OTHER|blood tests|"Blood tests done by the nurse in the CRC (clinical research center). The quantity of blood taken wil be (3 5-mL tubes):~2 plain tubes and 1EDTA tube Arterial blood pressure will be measured at the CRC. Then, an X-ray of the profile of the abdomen will be taken without preparation to evaluate aortic calcification (in the radiology department of the Amiens hospital)"
224202239|NCT03582657|DEVICE|dental implant (KONTACT N)|Implant-supported prosthetic restoration
223616443|NCT01744249|DRUG|Placebo|orally, twice daily, until disease progression or unacceptable toxicity, with or without food intake.
223616444|NCT01712126|DRUG|Irbesartan and Hydrochlorothiazide|
223616445|NCT01712126|DRUG|Avalide|
223616446|NCT01630915|DRUG|Torrent's Clopidogrel Tablets USP 75 mg|
223760981|NCT04798352|OTHER|quality of life questionnaires (EQ5D5L and SF-36)|quality of life questionnaires (EQ5D5L and SF-36)
223760982|NCT00846742|DRUG|Stanford V Chemotherapy|The Stanford V regimen is an abbreviated, multi-agent, dose-intensive regimen that utilizes many of the most active chemotherapy agents for Hodgkin lymphoma: Vinblastine, Doxorubicin, Vincristine, Bleomycin, Mechlorethamine, Etoposide, and Prednisone
224312462|NCT04697836|PROCEDURE|ST|"After a computer-generated randomization list with a 1:1 intergroup ratio, ensuring equal distribution in the two groups, 30 opaque sealed envelopes numbered 1-30 were prepared. The patients were randomly divided into the Group with bilateral CPB with 15 ml 0.5% bupivacaine or the patients with translaryngeal block with 5 ml 2% lidocaine in addition to bilateral CPB.~Following inclusion, two research assistants, with no further involvement in the study, prepared 15mL syringes and 5 ml syringes according to the envelope's specifications. The syringes were marked with the patient's randomization number. All other investigators, staff, and patients were blinded to group allocations. Before surgery, the patients were transferred to the specified block room area monitored with 3-lead electrocardiography, pulse oximetry, and non-invasive blood pressure. All patients had two intravenous cannula lines, and then bilateral CPB block procedures were performed in awake non-sedated patients."
223616447|NCT01658007|DRUG|Sirolimus|Adding sirolimus to established induction and consolidation chemotherapy for relapsed/refractory acute lymphoblastic leukemia
223760983|NCT00846742|RADIATION|Radiation Therapy|Patients who achieve less than a complete response after 8 weeks of chemotherapy will receive 25.5 Gy to individual nodal sites (tailored fields) starting 2-3 weeks following completion of all chemotherapy and recovery of ANC to at least 1000.
223760984|NCT05225935|DEVICE|image-guided VT ablation strategy|Catheter ablation procedure performed as part of standard care, although with the addition of an image-based 3D heart model including detailed anatomy and primary ablation targets
224312463|NCT05231330|DRUG|silvernanoparticles|silvernanoparticles in fluoride varnish
224312464|NCT05231330|DRUG|SDF|silver diamine fluoride
224312465|NCT03928730|PROCEDURE|resection and removal|Surgical resection or removal for histopathological examination
224312466|NCT00625625|DRUG|isosulfan blue|
224312467|NCT00625625|GENETIC|polymerase chain reaction|
224312468|NCT00625625|OTHER|diagnostic laboratory biomarker analysis|
224312469|NCT00625625|OTHER|immunohistochemistry staining method|
224312470|NCT00625625|PROCEDURE|diagnostic lymphadenectomy|
223510352|NCT05500534|OTHER|Laser lithortripsy|Standard laser lithotripsy
223510353|NCT06642870|OTHER|Non-interventional study|The study will consist of focus groups and a large scale patient survey
223510354|NCT01655069|DRUG|Solifenacin succinate suspension|Oral suspension
223510355|NCT06367153|DRUG|BI 1569912|BI 1569912
223510356|NCT06367153|DRUG|repaglinide|repaglinide
223510357|NCT06367153|DRUG|midazolam|midazolam
223510358|NCT06367153|DRUG|bupropion|bupropion
224202240|NCT02168569|DRUG|Coartem™ (Artemether-lumefantrine combination)|AL (Coartem™) was administered twice daily for three days (six doses in total) with dosage determined according to body weight: one tablet (20mg artemether and 120mg lumefantrine) for children 5 to \<15kg, two tablets per dose for those 15 to \<25kg, and three tablets per dose for those 25 to \<35kg.
224202241|NCT02168569|DRUG|Coarsucam™ (Amodiaquine-artesunate combination)|AQ-AS (Coarsucam™) was administered once daily according to body weight: one 25mg artesunate and 67.5mg amodiaquine tablet in children \<9kg, one 50mg artesunate and 135mg amodiaquine tablet in children 9-17.9kg; and one 100mg artesunate and 270mg amodiaquine tablet in children \>18-35kg.
223510359|NCT06582771|DRUG|Sotorasib|Sotorasib 960 mg (8 pills) daily
224202242|NCT06274697|DEVICE|Evaluation by magnetic sensor|Evaluation by magnetic sensor on arm and leg
224202243|NCT03046966|PROCEDURE|Intervention: Receives Training|"• Complete a Hands-on Intubation in the Simulation Lab with PI instructing:~* Using state of the art technology, a Storz C-MAC video laryngoscope~* Identifying anatomical landmarks~* Practice on the manikin until intubation occurs within 15 seconds"
224202244|NCT03046966|OTHER|Intervention: Control No Training|• Does not receive simulation training with PI. Only standard training.
224202245|NCT00472004|DRUG|17B Estradiol (1mg) / (0.125 mg) TMG Continuous combined (Totelle)|17B Estradiol (1mg) / (0.125 mg) TMG Continuous combined, 1 Daily, 1 year duration
224202246|NCT00472004|DRUG|Tibolone (Livial)|Tibolone 2.5 mg 1 daily, 1 year duration
224202247|NCT05134545|DEVICE|Genoss® DCB|Peripheral Drug Coated Balloon
224202248|NCT05134545|DEVICE|IN.PACT Admiral® DCB|Peripheral Drug Coated Balloon
224202249|NCT03700515|DRUG|Erythropoietin|Subjects receive weekly infusions of EPO
224202250|NCT03700515|DRUG|Placebo|Subjects receive weekly infusions of saline
224202251|NCT06124534|DEVICE|Neurostimulation of the Occipital Nerve Field|BliStim Neurostimulation system
224202252|NCT03916692|DIETARY_SUPPLEMENT|Carbohydrate drink|Meal replacement drink containing 200 kcal
223510360|NCT05694208|BEHAVIORAL|Education Group|In the first pre-operative interview at the gynecological oncology outpatient clinic of the relevant hospital, the purpose of the research will be explained to the patients and an informed consent form will be filled. The patients in the experimental group will use the mobile-based care support application developed within the scope of the research.
223510361|NCT03041870|DEVICE|PET-fMRI scan|fMRI scan include MR sequences: BOLD and fMRI. The PET acquisition will be carried out in dynamic for 90 consecutive minutes following intravenous administration of 4 MBq / kg dose of \[11C\]DASB bolus.
223510362|NCT05075681|DRUG|Modified By/Cy conditioning regimen intensified by Ruxolitinib and Chidamide|"Drug: modified By/Cy conditioning regimen intensified by Ruxolitinib and Chidamide.~Day -15 # Ruxolitinib 70mg bid, Chidamide 30 mg once; Day -14 # Ruxolitinib 70mg bid; Day -13 # Ruxolitinib 70mg bid; Day -12 # Ruxolitinib 70mg bid, Chidamide 30 mg once; Day -11 # Ruxolitinib 70mg bid; Day-10# Cytarabine 4g/m2/day CI (only for Haploidentical and unrelated donor), Ruxolitinib 60mg bid; Day- 9# Cytarabine 4g/m2/day CI, Ruxolitinib 60mg bid; Day- 8 # Busulfan 0.8mg/ kg Q6h iv, Ruxolitinib 50mg bid, Chidamide 30 mg once; Day- 7# Busulfan 0.8mg/ kg Q6h iv, Ruxolitinib 50mg bid; Day-6# Busulfan 0.8mg/kg Q6h iv, Ruxolitinib 40mg bid; Day-5# Cyclophosphamide 1.8 g/m2/day CI, Ruxolitinib 30mg bid, Chidamide 30 mg once; Day-4# Cyclophosphamide 1.8 g/m2/day CI,Ruxolitinib 20mg bid; Day-3# Carmustine 250mg/m2/ day iv, Ruxolitinib 10mg bid; Day-2# Ruxolitinib 5mg bid, Chidamide 30 mg/day; Day-1# Ruxolitinib 5mg qd;"
223510363|NCT04249739|DRUG|Pembrolizumab|Pembrolizumab is a potent and highly selective humanized monoclonal antibody (mAb) of the IgG4/kappa isotype designed to directly block the interaction between PD-1 and its ligands, PD-L1 and PD-L2. Keytruda ™ (pembrolizumab) has recently been approved in the United Stated for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor.
223760985|NCT05225935|DEVICE|conventional VT ablation strategy|Catheter ablation will be performed using conventional mapping techniques to identify targets. The ablation strategy will be left to the local investigator's decision, based on the clinical scenario and operator's habits.
224312471|NCT00625625|PROCEDURE|therapeutic conventional surgery|
224312472|NCT00625625|PROCEDURE|therapeutic lymphadenectomy|
224312473|NCT00213135|DRUG|Cladribine 5.25 mg/kg|Cladribine tablet will be administered as cumulative dose of 0.875 milligram per kilogram (mg/kg) over a course of 4 or 5 consecutive days of 28-day period at Week 1, 5, 9, 13, 48, and 52 resulting in total cladribine dose of 5.25 mg/kg during the treatment period of 96 weeks.
223760986|NCT05546697|OTHER|Online- Yoga-based Intervetion|See arms description
223760987|NCT05546697|BEHAVIORAL|Online- BA|See arms description
223760988|NCT05563064|DRUG|Karika Syrup|To evaluate the effects of Karika syrup on complete blood count specifically thrombocytes (platelets) collected from blood samples of patients after treatment of 15 days long period.
223760989|NCT04063761|DEVICE|esophageal cooling device (Attune Medical, Chicago, IL)|Prospective, single center pilot study
224312474|NCT00213135|DRUG|Cladribine 3.5 mg/kg|Cladribine tablet will be administered as cumulative dose of 0.875 mg/kg over a course of 4 or 5 consecutive days of 28-day period at Weeks 1, 5, 48, and 52 and placebo matched to cladribine tablet will be administered at Week 9 and 13 resulting in total cladribine dose of 3.5 mg/kg during the treatment period of 96 weeks.
223760990|NCT05237258|BEHAVIORAL|Specialty Palliative Care|Participants assigned to specialty palliative care will be cared for by both oncology and palliative care clinicians during their hospital stays for AML.
223760991|NCT05237258|BEHAVIORAL|Primary Palliative Care|Participants assigned primary palliative care will be cared for by oncology clinicians who have been trained in palliative care during the hospital stays for AML.
223760992|NCT06178341|DEVICE|Kata Inhalations-App|"The Kata Inhalations-App is a digital product that bears a CE mark. The application provides algorithms to run an inhalation trainer. The inhalation trainer shows patients how to improve their inhalation maneuver in a simple and understandable way. For this purpose, the signals from the camera and microphone of the patient's smartphone are used to evaluate the individual steps of the inhalation maneuver in real-time to provide automatic, personalized feedback. Additional functions of the Kata Inhalations-App include the possibility to document health parameters and to receive inhalation reminders.~After set-up, subjects will use the application on their own as an add-on to their usual therapy for asthma. The total duration of application use will be 13 weeks, 1 week use of the Messinstrument (Measurement)-App for all subjects (Baseline period), followed by 12 weeks use of the Kata Inhalations-App (intervention) or the Messinstrument-App (control)."
223760993|NCT04843852|DRUG|Hepatitis B Vaccine Recombinant, Adjuvanted Intramuscular Solution [HEPLISAV-B]|one 0.5ml intramuscular injection on day 0 and week 4.
223760994|NCT04703218|OTHER|olfactory rehabilitation|Olfactory rehabilitation consists of smelling 4 scents twice a day using scent sticks, for 12 weeks
223760995|NCT03795610|DRUG|IPI-549|40mg by mouth (PO) every day (QD) for at least 14 days
224075470|NCT01976559|DEVICE|DPOAE|DPOAE measurement uses a clinical acoustic probe to record the ear's response to two simultaneous tones. DPOAE measurements will be made for 13 tones. The total measurement time for each condition is 2-4 minutes.
224075471|NCT01639833|DEVICE|Veriset Hemostatic Patch|Topical hemostat
224202253|NCT03916692|DIETARY_SUPPLEMENT|Energy smart Carbohydrate blend|Carbohydrate blend drink designed for low glycemic responses containing 200 kcal
224202254|NCT03916692|DIETARY_SUPPLEMENT|Liquid Dextrose|Liquid Dextrose drink of 200 kcal
224312475|NCT00213135|OTHER|Placebo|Placebo matched to cladribine tablet will be administered over a course of 4 or 5 consecutive days of 28-day period at Weeks 1, 5, 9, 13, 48 and 52 during the treatment period of 96 weeks.
224312476|NCT01328379|DRUG|Dalfampridine-ER 5mg|5mg, twice daily
224312477|NCT01328379|DRUG|Dalfampridine-ER 10mg|10mg, twice daily
224312478|NCT01328379|OTHER|Placebo|placebo, twice daily
224312479|NCT01820234|OTHER|In-person dermatology evaluation|Every patient will be evaluated by an in person dermatologist present at the screening.
224075472|NCT01639833|DEVICE|TachoSil®|Topical Hemostat
224312480|NCT01820234|OTHER|Store-and-forward teledermatology evaluation|Every patient will be evaluated online via a store and forward teledermatology modality.
224312481|NCT03523078|PROCEDURE|Breast reconstructive surgery|All sorts of breast reconstructive surgery are allowed in this study in terms of timing, autologous/prosthetic and so forth.
224312482|NCT02656888|DRUG|Irlanda-1-Association|For children 2 to 6 years old: take 2,5 mL every 12 hours (2x/day), oral route. For children 6 to 12 years old: take 5 mL every 12 hours (2x/day), oral route. For children 12 to 17 years old: take 10 mL every 12 hours (2x/day), oral route.
224312483|NCT02656888|DRUG|Placebo|For children 2 to 6 years old: take 2,5 mL every 12 hours (2x/day), oral route. For children 6 to 12 years old: take 5 mL every 12 hours (2x/day), oral route. For children 12 to 17 years old: take 10 mL every 12 hours (2x/day), oral route.
224312484|NCT00318877|BEHAVIORAL|After school team sports program|
224312485|NCT00318877|BEHAVIORAL|After school health education program|
224312486|NCT03706937|OTHER|Semi directive interview|Semi directive interview will be performed to try to define the management of addictions in the oncology care course. Thus, an approach in terms of social representations among paramedical professional actors involved in the care of patients treated for cancer and with an unresolved addictive disorder sounds the best way for this research.
224312487|NCT04351633|OTHER|questionnaire assesment|questionnaire assesment
224075473|NCT02679469|DRUG|nalmefene hydrochloride 10 mg|
224075474|NCT00653237|DEVICE|I-gel and LMA Supreme: supraglottic airway devices|Insertion of a supraglottic airway device
224075475|NCT00415779|DRUG|docetaxel|given IV in subsequent cohorts of patients at 30, 40, or 50mg/m2
224202255|NCT06567067|DEVICE|Pulsenmore ES home ultrasound|Fetal Ultrasound scanning using Pulsenmore ES device followed with an interview by a human factoring researched
224202256|NCT02286284|DEVICE|Apheresis for extracorporal removal of sFlt-1|
224202257|NCT04934969|DIETARY_SUPPLEMENT|Adjunctive use of lavender and peppermint essential oils|passive inhalation aromatherapy following joint surgery
224312488|NCT06416956|DRUG|Caffeine|We will record infant\&#39;s brain activity and vital signs when caffeine dose is changed or caffeine treatment is stopped. The decision to change dose/stop treatment will be made by the clinical team as part of routine care. No changes in caffeine treatment will be carried out solely for research purposes.
224312489|NCT05326048|OTHER|cytof analysis|cytof analysis of biological samples of CIS patients. Genomic analysis
224312490|NCT00588588|PROCEDURE|Bronchoscopy|Bronchoscopy procedure
224312491|NCT00588588|PROCEDURE|Clinical pulmonary infection score (CPIS)|Calculate CPIS
224312492|NCT04778085|BEHAVIORAL|Illness management and recovery|Treatment given in groups, weekly for 10-12 months.
224312493|NCT04778085|OTHER|Semi-structured interviews|Semi-structured individual or group interviews conducted three times with staff on each participating outpatient clinic.
224312494|NCT00660907|DRUG|dapagliflozin|Tablet oral 2.5, 5, or 10 mg total daily dose once daily 208 weeks
224312495|NCT00660907|DRUG|glipizide|Capsule oral 5, 10, or 20 mg total daily dose once or split/twice daily 208 weeks
224312496|NCT00660907|DRUG|metformin hydrochloride|Tablet oral 1500, 2000, or 2500 mg total daily dose split/twice daily 218 weeks
224312497|NCT03973307|DIAGNOSTIC_TEST|UroX bladder cancer biomarker test|Urine test using novel UroX biomarker test for bladder malignancy
223616448|NCT04963283|DRUG|Cabozantinib|Cabozantinib is a multi-targeted inhibitor of RTKs. The targets of cabozantinib include several RTKs known to play important roles in tumor cell proliferation and/or tumor neovascularization, namely MET, VEGFR2 (also known as KDR), AXL, and RET. Other recognized targets of cabozantinib include ROS1, TRKA, TRKB, TIE2, TYRO3, and MER, two additional members of the VEGFR family (VEGFR1, VEGFR3), and the closely related RTKs KIT and FLT-3. The mode of action for cabozantinib is similar to other drugs targeting RTKs: binding in a fully reversible manner to a region of the kinase domain (including the ATP-binding site) which forces the kinase activation loop into a pseudo-inactive conformation, thereby inhibiting subsequent catalytic activity.
224202258|NCT02756169|OTHER|Intervention|Three actions since pregnancy until the first year of life of the baby for helping the women with obesity to increase the probability of a successful breastfeeding.
224202259|NCT06107127|PROCEDURE|STOP|Using their symptomatic arm participants will be asked to push against a fixed force dynamometer (hand held force gauge), starting with a low level of effort and gradually increasing their effort stopping either at the point that they start to feel pain or when they feel they have pushed as forcefully as they can.
224202260|NCT00462241|PROCEDURE|chiropractic treatment|Participants in the therapy group undergo a physical examination by an experienced, primary sector chiropractor, lasting up to one hour. The chiropractors choose an individual treatment strategy based on a combination of their findings, the patient history, and a standardized protocol reflecting routine practice. The standardized treatment protocol includes high velocity, low amplitude manipulation directed towards the thoracic and/or cervical spine in combination with any of the following: Joint mobilisation, soft tissue techniques, stretching, stabilising or strengthening exercises, heat or cold treatment, and advice. The protocol specifies up to ten treatment sessions of approximately 20 minutes, 1-3 times per week, or treatment until the patient is pain free. The chiropractors record the types of treatment rendered at sessions.
224202261|NCT00462241|OTHER|Self-management|Advice group: Advice is directed towards promoting self-management. The participants are told that their chest pain generally has a benign, self limiting course. The participants receive individual instructions regarding posture and two or three exercises aiming to increase spinal or muscle stretch based on clinical evaluation. They are advised to seek medical attention for re-evaluation (general physician, chest pain clinic or emergency department) in case of severe or unfamiliar chest pain. The session lasts on average 15 minutes. Further, the advice group is also asked not to seek any manual treatment for the next four weeks.
224202262|NCT03801200|DRUG|Apatinib|radiotherapy with Apatinib
224312498|NCT00237640|DRUG|Cinnamon or placebo 500 mg capsule twice daily|Cinnamon 500 mg capsule twice daily or placebo capsule twice daily
224312499|NCT02218801|OTHER|Evaluation of treatment for liver metastasis|
224312500|NCT02813265|DRUG|KPI-121 0.25% Ophthalmic Suspension|
224312501|NCT02813265|DRUG|Vehicle of KPI-121 0.25% Ophthalmic Suspension|
224312502|NCT04975191|BEHAVIORAL|Resources|Participants will be provided a list of resources available at VCU that are intended to support student success
224312503|NCT04975191|BEHAVIORAL|Personalized Feedback Program (PFP)|Participants will complete an interactive online program that explores their personality-related traits to provide personalized recommendations for success
224312504|NCT04975191|BEHAVIORAL|Substance Use Feedback Program (BMI)|Participants will complete an online program based on brief motivational intervention (BMI) content/principles that explores their current substance use patterns to make personalized recommendations for success
224312505|NCT01815476|RADIATION|Radiation Therapy Positioning Intervention|All participants will receive an adjuvant XRT dose to the breast of 50Gy in 25 fractions using an IMRT technique. In both arms, boost to the surgical bed using a mini-tangent technique will be delivered at the treating oncologist's discretion. Acceptable boost doses are 1600cGy/8 fractions, 1000cGy/5 fractions or 1325cGy/25 fractions as a simulatenous integrated boost. Participants randomized to the supine arm will be positioned supine on an angled breast board, with the ipsilateral arm abducted over her head. Participants randomized to the prone arm will be positioned prone on a prone breast board with both arms immobilized above the participant's head. The us of a cushion-like VaclocTM device is permitted at the treating physician's discretion. Radiation beams will be shaped to encompass the breast volume requiring treatment in both arms.
224312506|NCT00668694|BEHAVIORAL|Stimulation|Stimulation given to the child by mother
224312507|NCT05264129|DRUG|Atogepant|Oral Tablet
224312508|NCT05264129|DRUG|Ubrogepant|Oral Tablet
224312509|NCT01393886|PROCEDURE|Laparoscopic Greater Curvature Plication (LGCP)|This procedure creates a small sized stomach by folding the stomach twice into itself vertically. The functional capacity of the stomach is decreased by 80% of its normal(At least two rows of five continuous stitches are placed laparoscopically about the greater curvature of the stomach starting at or near the angle of His and ending in the antrum).
224312510|NCT03593538|DRUG|Metformin|Metformin capsule
224312511|NCT03593538|DRUG|Placebo|Sucrose filler in gel capsules
224312512|NCT00999323|DEVICE|stent implantation in coronary artery|Percuatenous Coronary Intervention with implanatation of a stent
224312513|NCT02173314|OTHER|SAFE FC|SAFE - FC, a combination of SAFE (developed by ACTION for Child Protection) and Family Connections (developed by Ruth H. Young Center for Families and Children, University of Maryland School of Social Work) for Populations 1 and 2.
224312514|NCT05435937|BEHAVIORAL|Partnering for change (P4C-Swe)|"P4C focuses on the collaboration and a intersectional partnership between teachers and occupational therapists/special educators to create physical, social and learning environments that facilitate successful participation for all pupils. The intervention tiered model provides interventions in a school context in levels; class, group, and individual level to students with participation restrictions.~Dynamic Performance Analysis (DPA), which focuses on pupils' occupational performance, is used in P4C model to identify and analyze were and why pupils' occupational performance is breaking down in school-based occupations in the natural context, followed by collaboration and coaching between the occupational therapist and teacher in setting up goals, planning, implementing and monitoring intervention at the different intervention levels, to support participation."
224312515|NCT05435937|BEHAVIORAL|Treatment as usual|Treatment as usual is provided by the Student health services that consists of a school doctor, school nurse, psychologist and counselor, and staff with special educational competence
224312516|NCT02053337|DEVICE|Self adhesive foam dressing|Self adhesive foam dressing
224312517|NCT00618332|DRUG|mometasone furoate nasal spray|2 puffs in each nostril once a day for 2 weeks
224312518|NCT00618332|DRUG|placebo|2 puffs in each nostril once a day for 2 weeks
224312519|NCT02692144|OTHER|Test Cluster|Test cluster is an optimized savory cluster made through a proprietary baking process combined with slow digestible carbohydrates and fiber
224312520|NCT06176729|DRUG|Polatuzumab Vedotin, Rituximab, Lenalidomide|polatuzumab vedotin 1.8 mg/kg ivgtt D1, rituximab375 mg/m2 ivgtt D1, lenalidomide 25mg po D1-14, one cycle every 21 days
224312521|NCT02645903|DRUG|Transversus Abdominis Plane Block|Cases to whom used bupivacaine with ultrasound guided transversus abdominis plane block was applied after standard general anesthesia were determined as Group 1
223616449|NCT04963283|DRUG|Nivolumab|Nivolumab is a human monoclonal antibody that targets the programmed death-1 (PD-1) cluster of differentiation 279 (CD279) cell surface membrane receptor. Nivolumab binds specifically to the human PD-1 receptor and inhibits the interaction of PD-1 with its ligands, programmed death ligands-1 (PD-L1) and 2 (PD-L2), which promotes immune responses and antigen-specific T-cell responses to foreign- and self- antigens. Nivolumab is expressed in Chinese hamster ovary (CHO) cells and is produced using standard mammalian cell cultivation and chromatographic purification technologies.
223616450|NCT05490862|BEHAVIORAL|Lifestyle Modification|"An individualized low-calorie diet is characterized by sugars and starchy food intake restriction, 500 kcal daily energy deficit for 12 weeks (3 months).~Regular physical activity is represented by individualized 30 minutes trainings on an anti-gravity treadmill 3 workouts per week for 12 weeks with individual targets of stepping activity, which will be evaluated according to personal fitness monitoring data"
224202263|NCT02663999|DRUG|diazepam nasal spray|diazepam nasal spray at two dose levels (DL). One dose of diazepam nasal spray is administered as two intranasal sprays; one in each nostril using a nasal spray device.
224202264|NCT04012008|OTHER|Comprehensive care|"* Regular follow-up by nephrologists every 1-3 month~* Multidisciplinary team consisting pharmacists, nurses, and dieticians"
224202265|NCT04012008|OTHER|Standard care|"* Regular follow-up by internists every 3 month~* May consult nephrologists case-by-case"
224202266|NCT05552391|DRUG|Bupivacaine|Group bupivacaine(Control) (B) received 0.5 ml/kg bupivacaine 0.25% diluted with isotonic saline (total volume15 ml).
224202267|NCT05552391|DRUG|Ketamine Hydrochloride|Group bupivacaine - ketamine (K) received 0.5 ml/kg bupivacaine 0.25% with ketamine 2 mg/kg, diluted with isotonic saline (total volume15 ml).
224202268|NCT05552391|DRUG|Dexmedetomidine Hydrochloride|Group bupivacaine - Dexametomedine (D) received 0.5 mL/kg bupivacaine 0.25% with dexmedetomidine 1 µg/kg. diluted with isotonic saline (total volume 15ml).
224202269|NCT00132600|DRUG|bacitracin (allergen)|
224202270|NCT03911882|DIETARY_SUPPLEMENT|Celergen Administration|The food supplement Celergen was administered on a daily basis for a total of 3 months (90 days) to participating fibromyalgia patients
224312522|NCT02645903|DRUG|standard general anesthesia|Cases to whom applied alone standard general anesthesia were determined as Group 2
223616451|NCT05490862|BEHAVIORAL|Traditional Recommendations|The list of traditional diet and physical activity recommendations for patients with obesity
223616452|NCT06018948|DRUG|Dexmedetomidine 0.6|Patients received a bolus dose of 1μg/kg Dexmedetomidine, 15 minutes after endotracheal intubation over 10 minutes followed by infusion of 0.6 μg/kg/hr for one hour.
223616453|NCT06018948|DRUG|Dexmedetomidine 0.3|Patients received a bolus dose of 1μg/kg Dexmedetomidine, 15 minutes after endotracheal intubation over 10 minutes followed by infusion of 0.3 μg/kg/hr for one hour.
223616454|NCT06018948|DRUG|Saline|Patients received over 10 minutes comparable volume of normal saline (0.9%) 15 min after endotracheal intubation followed by infusion.
223616455|NCT04163029|PROCEDURE|Preoperative oral care|tooth brushing and mouthwash with chlorhexidine 0,2% five day before surgery
224202271|NCT00759668|DEVICE|Acrysof Natural ReSTOR SN60D3|Bilateral implantation with the AcrySof Natural ReSTOR Intraocular Lens (IOL) SN60D3 following cataract removal.
224202272|NCT00759668|DEVICE|Acrysof Natural Monofocal SN60AT|Bilateral implantation with the AcrySof Natural Intraocular Lens (IOL) Model SN60AT following cataract removal.
224202273|NCT04112615|DEVICE|Blood measurement|Single fingerprick to measure haemoglobin and haematocrit measurements using a potential haemoglobin home monitoring system.
224202274|NCT02922439|BEHAVIORAL|Tailored Intervention|The intervention will focus on improving the health literacy of low literacy individuals by providing chronic disease self-management information tailored to cultural and linguistic characteristics of participants.
224312523|NCT00644930|DEVICE|the application of NPPV|ARDS patients in the NPPV group showing no indications for urgent intubation received NPPV in addition to standard medical therapy, and those with indications were intubated. BIPAP Vision machine (Respironics, PA, USA) were used for NPPV.
224312524|NCT00644930|DEVICE|invasive ventilation|Standard therapy group (invasive ventilation). Patients in need of endotracheal intubation were mechanically ventilated with Amadeus (Hamilton, Via Nova, Switzerland) and Esprit (Respironics, PA, USA) ventilators in the assist-control or synchronized intermittent mandatory ventilation (SIMV) mode.
224312525|NCT02028741|OTHER|Transverse vertebral pressures|Graded transverse mobilization directed to the thoracic spine
224202275|NCT02922439|BEHAVIORAL|Control Intervention|This intervention will provide information similar to that provided in the control condition, but will not utilize tailoring.
224312526|NCT00245687|DEVICE|Tiger Tube|
223616456|NCT00631358|DRUG|Maxidex|Maxidex (0.1% Dexamethasone) 1 drop in each eye 2 times daily
223616457|NCT00631358|OTHER|No treatment|Healthy normal control group receiving no treatment
223616458|NCT00802516|DIETARY_SUPPLEMENT|stanol ester|enriched margarine
224312527|NCT05395286|BEHAVIORAL|Innovation Lab|An Innovation Lab is a facilitated 5-day residential event designed to create novel, transdisciplinary and potentially transformative research ideas and proposals to address a specific grand challenge. Participants, along with a director, organizers, subject matter guides, and KI facilitators communally explore the problem space, generate a broad range of ideas, and form transdisciplinary teams to pursue research projects.
224312528|NCT01194063|DRUG|Omega-3 fish oil lipid emulsion|daily intravenous administration of Omegaven fish oil emulsion
224312529|NCT00948324|DRUG|CSII,ALA,MET,RSG|CSII along.ALA:CSII combined with two weeks α- thioctic acid (600mg/500ml NaCl, 0.9%), ivdrip QD. RSG:CSII combined with three months rosiglitazoneor 4mg QD. MET:CSII combined with metformin 500mg BID-TID.
223510364|NCT02159404|BIOLOGICAL|Immunotherapy|
223616459|NCT00802516|DIETARY_SUPPLEMENT|sterol ester|enriched margarine
224202276|NCT00410839|PROCEDURE|ALA rich diet|
224202277|NCT00783939|DRUG|Lactic Acid|Lactic Acid (Dermacyd PH\_DETINBACK Tangerine Mix)
224202278|NCT02689609|RADIATION|Intensity-modulated radiation therapy|All patients will receive intensity-modulated radiation therapy with or without chemotherapy as usual standard of care in our institution.
224202279|NCT06173674|OTHER|Music intervention|"The music intervention will consist of three components including:~1. Playlist composition Six music genres playlists will be offered to patients, including Classical Music, Country Music, Folk Music, Hymns and Reglious Music, Jazz and Swing Music, Popular/Easy Listening/RNB and Soundtrack Music. Patients can also add their favourite music to the list as well.~2. Music Intervention Delivery The general criteria for intervention delivery are:1) Each session lasts at least 20 minutes; 2) The music will be delivered by a comfortable, wireless, on/off switch noise-cancelling headphone; 3) The volume will be adjusted according to the patient's preference and controlled at 65dB or lower; 4) The order of music in the playlists will be decided by the patient; 5) Music will be delivered in inpatient room and/or waiting area before surgery/procedure.~3. Cleaning and infection of the equipment We will comply with guidelines on disinfection of materials in the hospital."
224202280|NCT06652269|OTHER|Psychopharmacology intervention|Psychotherapy with horses
224202281|NCT06283069|BEHAVIORAL|compilation of a questionnaire about LifeStyle|compilation of a questionnaire about LifeStyle
224202282|NCT01892813|DRUG|Nicotine replacement therapy - Transdermal nicotine patch|Medication selection will be determined based on individual participant preferences, medical history, and contraindications.
223510365|NCT04771871|DRUG|Epirubicin|Epirubicin is an antitumor antibiotics with good activity on breast cancer. It has less cardiotoxic effect than doxorubicin
223510366|NCT04771871|DRUG|Cyclophosphamide|Cyclophosphamide is a cytoxic drug indicated for the treatment of many malignancies including breast cancer
223616460|NCT00802516|DIETARY_SUPPLEMENT|No intervention|placebo margarine
223616461|NCT05646134|DEVICE|Repetitive Transcranial Magnetic Stimulation|Repetitive transcranial magnetic stimulation (rTMS) is a form of non-invasive brain stimulation therapy that modulates brain excitability.
224202283|NCT01892813|DRUG|Nicotine replacement therapy - Nicotine gum|Medication selection will be determined based on individual participant preferences, medical history, and contraindications.
223616462|NCT05646134|DEVICE|Sham Transcranial Magnetic Stimulation|During Sham Transcranial Magnetic Stimulation the coil will be facing the wall making the stimulation inactive
223510367|NCT04771871|DRUG|Paclitaxel|Paclitaxel is a taxane chemotherapy agent indicated for the treatment of many cancers including breast cancer. It can be used alone or in combination with other drugs
223510368|NCT04771871|DRUG|Carboplatin|Carboplatin is a platinum compound indicated for the treatment of many types of malignancies including breast cancer
223510369|NCT03883451|OTHER|Helmet Model|helmet model worn by football players
223510370|NCT06380530|PROCEDURE|Deformity correction|Surgeries to correct bone defomity, supported by the use of preoperative planning and/or patient-specific instruments
223616463|NCT01122602|DRUG|Acetylsalicyclic acid (Fast acting Aspirin, BAY1019036)|Single dose of fast acting aspirin 2 x 325 mg = 650 mg total
223616464|NCT01122602|DRUG|Acetylsalicyclic acid (Aspirin, BAYE4465)|Single dose of regular aspirin 2 x 325 mg = 650 mg total
223616465|NCT01122602|DRUG|Placebo|Two placebo tablets
223616466|NCT01007357|DEVICE|Body MR imaging|Body MR imaging will be performed to optimize sequences
223616467|NCT00889135|DRUG|droxidopa|Droxidopa (L-DOPS) comes in capsule form, 100 mg or 200 mg strength and is usually administered 2 - 3 times per day. It would be taken indefinitely to improve symptoms of orthostatic hypotension
224075476|NCT00415779|DRUG|zoledronic acid|2 mg IV every 2 weeks
224075477|NCT04342728|DIETARY_SUPPLEMENT|Ascorbic Acid|Readily available marketed open label ascorbic acid
224075478|NCT04342728|DIETARY_SUPPLEMENT|Zinc Gluconate|Readily available marketed open label zinc gluconate
224075479|NCT04342728|DIETARY_SUPPLEMENT|Ascorbic Acid and Zinc Gluconate|Readily available marketed open label ascorbic acid and zinc gluconate
224075480|NCT04342728|OTHER|Standard of Care|Readily available prescribed medications/ supplements- None study supplements
224075481|NCT03541005|DIETARY_SUPPLEMENT|Obex|After concluded the six months of treatment, patients will be follow-up during six months without consumption of Obex
224075482|NCT03541005|DIETARY_SUPPLEMENT|Placebo|After concluded the six months of treatment, patients will be follow-up during six months without consumption of the placebo.
224075483|NCT00803504|PROCEDURE|ocular blood flow measurement|
224075484|NCT02618447|DEVICE|4Dimensional Phase Contrast Magnetic Resonance Angiography|4D PC MRA is a new non-contrast MRA technique that can measure flow of blood within vessels of interest over time.
223760996|NCT06105905|BEHAVIORAL|"Healthy futures (Futuros Saludables)"|The developed intervention will be delivered in a workshop format by facilitators, over 8 sessions for teens and parent/guardian(s). Feedback on delivery mode (virtual, in-person, or hybrid) during the co-development sessions. If in-person/hybrid is suggested, feedback will be elicited about preferred location (e.g., a local community center, sports club, etc.). Participants will complete sessions, in either Spanish or English depending on participants' preference, using video conference tools. After the delivery of the intervention, facilitators will take field notes and complete a debriefing questionnaire to assess practicality and fidelity. Teens and parent/guardian(s) will complete a 20-minute survey pre-intervention, immediately post-intervention, three-month, six-month, and twelve-month post-intervention. Surveys will assess acceptability and risk behaviors.
223760997|NCT03655002|DRUG|Cyclophosphamide|Given IV
223760998|NCT03655002|BIOLOGICAL|Cytokine-based Biologic Agent IRX-2|Given SC
223760999|NCT03655002|BIOLOGICAL|Nivolumab|Given IV
223761000|NCT05080309|DIETARY_SUPPLEMENT|carbohydrate oral intake|During labor the women will have free access to water and 20 ml commercial fruit juice bricks containing between 430 or 660 kcal/l. Every 2 hours the midwife or the nurse will measure the fruit juice oral intake volume and will advise women to drink the planned volume (1 brick/2hours)
224312530|NCT04208958|BIOLOGICAL|VE800|VE800 is an orally administered (PO) live biotherapeutic product (LBP) consisting of 11 distinct nonpathogenic, nontoxigenic, commensal bacterial strains manufactured under Good Manufacturing Practice (GMP) conditions. These strains were selected for their ability to induce an immune response.
224312531|NCT04208958|DRUG|Nivolumab|Nivolumab is an approved medication that blocks antibodies for certain types of cancer.
224312532|NCT04208958|DRUG|Vancomycin Oral Capsule|Vancomycin is an antibiotic used to treat or prevent infection.
224312533|NCT05773794|DIETARY_SUPPLEMENT|Soymilk, green tea, or blueberry|One dose of soymilk, green tea, or blueberry blends (460mL) with breakfast.
224312534|NCT05773794|DIETARY_SUPPLEMENT|Control group|Breakfast with milk or water, without soymilk, green tea, or blueberry blends.
224312535|NCT03669185|DRUG|Pentalong|Pentalong, 2 x daily 1 tablet, intake max. 133 days
224312536|NCT03669185|DRUG|Placebos|Placebos, 2 x daily 1 tablet, intake max. 133 days
224312537|NCT01239108|DRUG|SGI-1776|SGI-1776 will be administered orally at escalating dose levels ranging from 350 to 1600 mg/day based on the dose escalation levels of the ongoing, first-in-human study.
224312538|NCT05274555|OTHER|Assessment|"The Upper Limb Short Questionnaire was administered by the researcher in face-to-face sessions with the children and their caregivers.~The lower extremity functions and ambulation levels of the children were evaluated by the researcher using the Vignos Scale.~The Brooke Upper Extremity Functional Rating Scale and ABILHAND-Kids were used to evaluate children's upper extremity functions."
224312539|NCT01027195|DEVICE|Bipolar Radiofrequency (Aquamantys 6.0)|
224312540|NCT01027195|DEVICE|Standard Bovie Electrocautery|
224312541|NCT02387411|OTHER|High-intensity interval exercise training|High-intensity interval exercise training \[4 reps \* (4 min at 80% VO2peak + 3 min at 50% VO2peak)\]
224312542|NCT02387411|OTHER|Combined exercise training|High intensity \[2 reps \* (4 min at 80% VO2peak + 3 min at 50% VO2peak)\] and strength exercise training (2-4 sets, 10-12 reps, 60-65% 1RM, for quadriceps and hamstrings, 14 min in total)
224312543|NCT01917916|DRUG|Placebo|Solution for subcutaneous (s.c.) injection.
223761001|NCT05080309|OTHER|free water only|Women will have free access to water only
223761002|NCT06554327|DEVICE|Multiplex PCR|In the intervention group (Multiplex PCR performed and results communicated to the clinician), bronchoalveolar lavage will be examined directly after Gram staining by the laboratory, followed by quantitative culture. A multiplex PCR will be performed.
223761003|NCT06576830|DRUG|Methadone|Single-dose intraoperative intravenous methadone with initial dose at 0.15 mg/kg in children and 0.2 mg/kg in adolescents.
223761004|NCT06576830|DRUG|Fentanyl/Hydromorphone|Per routine care, given as needed
223761005|NCT06088810|OTHER|CoMPoSER intervention group|Participants in the intervention will use a mobile application that plays calming music personalized for sleep enhancement, relaxation techniques and nighttime routine guidance.
223761006|NCT06088810|OTHER|Sleep Education|Participants in this intervention will receive sleep education based on the NIH/NIA guide, which includes tips for getting a good night's sleep.
223761007|NCT05748340|PROCEDURE|Unilateral cleft lip repair|Surgical repair unilateral cleft lip
223761008|NCT05329103|DRUG|PEEL-224|Lyophilized powder reconstituted with D5W
223761009|NCT05329103|DRUG|FOLF+B|infusional 5-FU, LV, and bevacizumab
223761010|NCT03817320|DRUG|Ixazomib|"Days 1, 4, 8, and 11. Note: at least 72 hours must have elapsed between doses~Dose Phase 1 - Assigned upon study entry.~Phase 2 - PO formulation at RP2D"
223761011|NCT03817320|DRUG|Vincristine|"IV push over 1 minute or infusion via minibag as per institutional policy~Days 1, 8, 15 and 22~Dose: ≥ 1 year: 1.5mg/m2/dose (maximum dose 2mg)~≥ 6 months and \< 1 year: 1.2mg/m2/dose~\< 6 months: 1mg/m2/dose"
223761012|NCT03817320|DRUG|Dexamethasone|"Days 1-14~Dose: ≥ 1 year: 10mg/m2/day, divided BID (i.e., 5mg/m2/dose, BID)~≥ 6 months and \< 1 year: 8mg/m2/day, divided BID (i.e., 4 mg/m2/dose, BID)~\< 6 months: 7mg/m2/day, divided BID (i.e., 3.5 mg/m2/dose, BID)"
224075485|NCT02618447|PROCEDURE|Portal vein embolization|
224075486|NCT06436885|DRUG|Iruplinalkib tablets|Iruplinalkib tablets should be administered orally at a roughly fixed time each day. Once daily, on an empty stomach or with food, 60mg per dose for days 1 to 7, 180 mg per dose from day 8 if tolerated. Swallow the tablet whole, do not crush, divide or chew the tablet
224075487|NCT01997879|DRUG|AR-13324 Ophthalmic Solution, 0.02%|Eyedrop
224075488|NCT03343015|PROCEDURE|complete dentures|therapy with maxilla and mandible dentures
224075489|NCT02020486|DRUG|Perampanel|2 mg up to 4 mg
224075490|NCT02020486|DRUG|Perampanel|2 mg up to 6 mg
224075491|NCT05019001|PROCEDURE|Laminoplasty|A posterior approach surgical method to treat patients with Ossification of the Posterior Longitudinal Ligament
224075492|NCT05019001|PROCEDURE|Laminectomy With Fusion|Another posterior approach surgical method to treat patients with Ossification of the Posterior Longitudinal Ligament
224075493|NCT03877172|DEVICE|High-flow nasal cannula|To provide high-flow nasal cannula in the immediate postoperative period after lung resection surgery as compared to conventional face-mask therapy, in a randomized sequence, for 30 minutes.
224075494|NCT00119158|DRUG|Combination of pimecrolimus and fluticasone|Pimecrolimus cream twice a day and fluticasone cream once a day
224075495|NCT00119158|DRUG|pimecrolimus|apply daily with fluticasone cream for flares
224075496|NCT04338958|DRUG|Ruxolitinib|2 x 10mg Ruxolitinib with defined response adapted dose escalation up to 2 x 20mg for a duration of 7 days with clinical and/or radiographic response assessment
224075497|NCT00035594|DRUG|pegfilgrastim|Growth factor (GCSF) administered to promote neutrophil development post-chemotherapy.
224075498|NCT05125250|OTHER|Motor Control Group|will received treatment which comprises of therapeutic exercises, During the first 4 weeks, motor control and ROM exercises will be prescribed in order to improve muscular endurance of deep flexors muscles and to improve the ROM of cervical spine in flexion, extension, rotation and side bending and lateral rotation in. These exercises will be performed at a rate of 3 sets and an intensity of 15 repetitions per day .
224075499|NCT05125250|OTHER|Vestibular Group|will receive vestibular exercises which comprises of postural awareness training, balance board exercises, Foveal vision exercises .
224075500|NCT03368183|OTHER|Care delivery algorithim|SCAMP
224075501|NCT00434564|PROCEDURE|Stress nuclear scan|
224075502|NCT00419328|DRUG|NGR-hTNF|"Drug: NGR-hTNF~NGR-hTNF was administered every 3 weeks by a 1 hour intravenous iv infusion. NGR-hTNF in PBS was diluted in 0.9% NaCl, containing human serum albumin.~Step 1:~* starting dose: 0.2 μg/m2~* following doses: 0.4, 0.8 and 1.6 μg/m2.~* number of patients: 4 per dose level~Step 2:~* starting dose: 3.2 μg/m2~* following doses: 6.4 and 12.8 μg/m2~* number of patients: 3 per dose level~Step 3:~* starting dose: 19.2 μg/m2~* following doses: 28.8, 43.2 and 64.8 μg/m2~* number of patients: 3 per dose level~Step 4:~* starting dose: 86.2 μg/m2~* following doses: 114.6 and 152.4 μg/m2~* number of patients: 3 per dose level"
224075503|NCT05872087|DRUG|Nebulised Dexmeditomidine|premedication by dexmeditomidine 3mcg/kg in children undergoing lower abdominal surgeries
224075504|NCT05872087|DRUG|Nebulised Midazolam|premedication by nebulised midazolam 0.3mg/kg in children undergoing lower abdominal surgeries
224075505|NCT03033745|DRUG|IgPro20|A liquid formulation of normal human IgG at a concentration of 20% administered as a subcutaneous infusion at a dose prescribed by subject's physician prior to study entry.
224075506|NCT00726466|DRUG|Efalizumab, Ranibizumab|
224202284|NCT01892813|DRUG|Nicotine replacement therapy - Nicotine lozenge|Medication selection will be determined based on individual participant preferences, medical history, and contraindications.
224202285|NCT01892813|DRUG|Bupropion|Medication selection will be determined based on individual participant preferences, medical history, and contraindications.
224202286|NCT01892813|DRUG|Varenicline|Medication selection will be determined based on individual participant preferences, medical history, and contraindications.
224312544|NCT01917916|DRUG|BI 655064|Solution for subcutaneous (s.c.) injection.
224312545|NCT02918812|DRUG|Intracervical lidocaine|Intracervical lidocaine injected at four different points
224312546|NCT02918812|DRUG|Intramuscular Diclofenac|Intramuscular Diclofenac 30 mins before HSG
224312547|NCT00098358|DRUG|Zileuton|
223510371|NCT06031051|DEVICE|Pillcam Crohn's Capsule Endoscopy|Patients with scheduled colonoscopy are invited to a previous exploration with capsule endoscopy
223510372|NCT05639803|DRUG|PEGIFNα1b|100μg/vial
223510373|NCT05639803|DRUG|Placebo|0.5ml/vial
223510374|NCT06362642|DRUG|PC14586|First-in-class, oral, small molecule p53 reactivator that is selective for the TP53 Y220C mutation.
223510375|NCT06362642|DRUG|Itraconazole|Antifungal treatment that is a potent inhibitor of CYP3A4.
223510376|NCT05093166|DRUG|"Ex vivo expanded autologous human oral epithelium containing stem cells"|The treatment includes a single administration of investigational product through a dedicated surgical procedure of penis wound bed preparation, epithelial surface adaption and product application followed by urethra tubularization and penis reconstruction.
223510377|NCT05373836|DIAGNOSTIC_TEST|prognostic nutritional index calculated from laboratory parameters|Calculated nutritional index using laboratory results of serum albumin, lymphocyte count, and cholesterol
223510378|NCT01595178|BEHAVIORAL|Combined BNI|Combination brief negotiated interview (BNI) for patients who smoke and drink
223510379|NCT05477641|PROCEDURE|Pericapsular Nerve Group Block with Lateral Femoral Cutaneous Nerve Block|Local anesthetic will be deposited along the lower pelvis to block 3 nerves that innervate the anterior hip capsule
223510380|NCT05477641|PROCEDURE|Fascia Iliaca Compartment Block|Local anesthetic is deposited between the fascia iliaca and the internal oblique muscle in an attempt to block 3 nerves that innervate the hip.
223510381|NCT03288935|BEHAVIORAL|TICM|The TICM will be designed to include the seven domains of trauma-informed care articulated by SAMHSA (2014): 1) early screening and comprehensive assessment; 2) consumer driven care and services; 3) trauma-informed, responsive and educated workforce; 4) emerging and evidence-informed best practices; 5) safe and secure environments; 6) trauma-informed community partnerships; and 7) a performance monitoring system. The trained agency case managers and staff will provide the TICM to 50 newly resettled refugees during their regular R\&P service period (i.e., 60 days).
223510382|NCT03288935|BEHAVIORAL|TICO|The community-based TICO will be based on the Im's CHW that comprises 8 sessions (2 hour per session), co-facilitated by trained refugee peer mentors and community service providers. The TICO sessions will include interactive sessions on healthy eating, healthy body and healthy mind, acculturation \& resettlement stress, understanding trauma and stress, healthy coping, helping others, and community building.
223510383|NCT03062436|OTHER|Stopping the standard drug therpy|Stopping the standard drug therapy of CML patients and monitoring their treatment free remission status
223510384|NCT03062436|DIAGNOSTIC_TEST|Quantitative bcrabl recording every month for first 6 months|Monthly recording of quantitative bcrabl by RQPCR on patients peripheral blood derived RNA. RQPCR will have minimum sensitivity of log4.5
223510385|NCT06399471|DEVICE|Microprocessor prosthetic knee|Microprocessor prosthetic knees for use in a transfemoral prosthesis
223510386|NCT05347797|DIAGNOSTIC_TEST|therascreen® KRAS RGQ PCR Kit|To utilize a Clinical Study assay, the therascreen® KRAS RGQ PCR Kit, as a screening test in Phase 3 of Clinical Study (Protocol No. 20190009), in order to identify patients with NSCLC with KRAS G12C mutation positive tumours.
223510387|NCT06083467|DIAGNOSTIC_TEST|Brain MRI Scan|MRI scan of the brain
223510388|NCT06083467|BEHAVIORAL|Neurologic exam|Neurologic exam and assessments, including video interview
223761013|NCT03817320|DRUG|Asparaginase|"Days 2, 15~Dose ≥ 1 year: 2,500 International units (IU)/m2/dose~≥ 6 months and \< 1 year: 2,000 IU/m2/dose~\< 6 months: 1,750 IU/m2/dose~Patient with allergic reaction to Pegaspargase can be given Erwinase IM/IV on Mon/Wed/Fri (or every other day per institutional standard) x 6 doses for each dose of Pegaspargase.~Dosing guideline for Erwinase:~* 1 year: 25,000 IU/m2/dose~* 6 months and \< 1 year: 20,000 IU/m2/dose~\< 6 months: 17,500 IU/m2/dose"
224312548|NCT00583388|DIETARY_SUPPLEMENT|L-arginine|Each subject will be exposed to three treatments, a) 5 g of L-arginine, b) 15 g of L-arginine, and c) placebo, the sequences will be randomly assigned to the 42 volunteers. The washout period between interventions will be from one to two days.L-arginine will be mixed in 60 cc of dextrose-based syrup to blind the taste and color of the L-arginine powder.
224312549|NCT00583388|DEVICE|Ultrasound|Ultrasound from the brachial artery will be done on 3 occasions: at 9 pm after 4hs of fasting, at 6 am and at 11 am. The brachial artery images will be acquired above the antecubital fossa in the longitudinal plane of the artery with an ultrasound machine using a 6-MHz linear transducer. Flow-mediated vasodilatation will be assessed by the reactive hyperemia method (inflation of a blood pressure cuff around the forearm to 200 mmHg for 5 minutes and then released). The diameter of the brachial artery will be assessed 60 to 90 s after deflation of the cuff. After a 10min period a second baseline image of the brachial artery will be obtained. Non-low-mediated vasodilatation will be measured by an administration of a sublingual dose of nitroglycerin (0.4 mg).
224312550|NCT01733810|OTHER|Cessation of Acid Suppressing Medications|Acid-suppressing medications are stopped for all participants the day after baseline assessment. Subsequent evaluations performed while participant is not on acid-suppressing medications.
224312551|NCT00216138|DRUG|Docetaxel|Docetaxel 60 mg/m2 for 60 minutes, day 1 of each cycle
224312552|NCT00216138|DRUG|Capecitabine|Capecitabine 825 mg/m2 po bid, days 1-14
224312553|NCT00216138|DRUG|Premedication|Dexamethasone and antiemetic premedication
223616468|NCT04692623|DRUG|Moxifloxacin 400mg|Blood will be checked for glucose levels and ECG at Baseline(Day Ist) and at Steady state Steady state(Tmax) via Glucometer and ECG machine will be used for determination of serum insulin levels.
224312554|NCT02487303|DRUG|Acetaminophen Intravenous|IV 1 gram f3 doses over 24 hours
224312555|NCT02487303|DRUG|Acetaminophen Oral|Oral 1 gram 3 doses over 24 hours
223616469|NCT04692623|DRUG|Gemifloxacin 320 MG|Blood will be checked for glucose levels and ECG at Baseline(Day Ist) and at Steady state(Tmax) via Glucometer and ECG machine will be used for determination of serum insulin levels.
223616470|NCT02609308|OTHER|Short leg cast|Immobilization with short leg cast with a dorsiflexed foot for two weeks
223616471|NCT02609308|PROCEDURE|Platelet-rich plasma|Will be applied 5 mL of autologous platelet-rich plasma under the lateral malleolus, over the anterior talofibular ligament
223616472|NCT00304174|BEHAVIORAL|Motivation to eat|Participants will use a computer program to earn food (a yogurt shake) by tapping on the keyboard. More taps on the keyboard will result in a larger amount of food earned by the end of the day. Once experimentation is complete on Day 1, participants will be instructed to eat as much as they can. On Days 2 and 3, participants will be given a small serving of the yogurt shake prior to beginning the computer task. Following the computer task, they will be instructed to either eat until they are comfortable (without restricting or binging), or eat as much as they can.
223616473|NCT00105911|BEHAVIORAL|Cognitive Behavioral Therapy|
223616474|NCT03326778|PROCEDURE|AVR and CABG|Combined AVR with CABG
223616475|NCT00815217|PROCEDURE|injection of lipoaspirate|Small volume lipoaspiration will be performed. This technique involves harvesting small amounts of fat by making a small incision in the donor site (usually the abdomen) and infiltrating 25-75cc of tumescence solution (1 liter of LR, 30 cc of 1% lidocaine, 1 ampule of 1:1,000,000 epinepherine) into the adipose layer with a blunt infiltrator. The Coleman aspiration Cannulae, approximately 2-3 mm in diameter and 15 cm in length attached with a Luer-Lok suction syringe will be used to harvest up to 100 cc of fat. Gently pulling back on the syringe provides a small amount of negative pressure to allow for aspiration into the syringe.For the intervention wound, the adipose tissue will be implanted using the infiltration Cannulae (blunt end, 7 cm- COL-17) or the both approx. 1mm in diameter. The implantation will be in single tunnels radially around each wound spaced at 5-10 mm apart and approximately 3 - 5 cm in length.
223616476|NCT00815217|OTHER|control|For the control wound, only the sterile injectable tumescence solution (1 liter of LR, 30 cc of 1% lidocaine, 1 ampule of 1:1,000,000 epinepherine) will be used. The solution will be injected in a similar fashion with single tunnels radially around the control wound spaced at 5-10 mm apart and approximately 3 - 5 cm in length.
223616477|NCT05413785|BEHAVIORAL|Telehealth in Parole/Probation Office|Onsite (telehealth) linkage toHep C treatment in a Probation and Parole office setting via an onsite nurse navigator. The navigator will provide Hep C education, draw labs, and facilitate a telemed visit with a UK GI provider.
223616478|NCT02610582|DRUG|rAAV.hCNGA3|Single subretinal injection of rAAV.hCNGA3
223616479|NCT02254473|OTHER|Wedge Insert|
223616480|NCT02254473|OTHER|Flat Insert|
224312556|NCT01708668|PROCEDURE|Epidural analgesia|
224312557|NCT01708668|PROCEDURE|Combined spinal-epidural analgesia|
223616481|NCT01018277|OTHER|Mobilization (walking)|25 meters twice
223616482|NCT02241564|OTHER|Referral to a multidisciplinary expert panel at the Uppsala University Hospital after tumor detection|
223616483|NCT02241564|DRUG|Switch from calcineurin inhibitor to an mTOR inhibitor|
223616484|NCT04619615|OTHER|Asynchronous self-directed digital training|Resident participants will be able to complete the digital training at their own pace.
224312558|NCT01708668|PROCEDURE|Continuous epidural infusion|
224312559|NCT01708668|PROCEDURE|Intermittent epidural bolus|
224312560|NCT01741168|OTHER|TLSO|Patients in the TLSO arm will remain on bed rest until fitted with a TLSO. They will wear the TLSO for 8-10 weeks and mobilized in the brace by a physiotherapist.
224312561|NCT01741168|OTHER|No Orthosis|Patients in the No Orthosis group will be mobilized immediately as tolerated by a physiotherapist with restrictions to limit bending or rotating through their trunk. They will be encouraged to return to normal activities after 8 weeks.
224312562|NCT05568667|BEHAVIORAL|Low risk|"* remote support in physical activity and nutrition via digital media~* monthly collective physical activity sessions~* logbook"
223616485|NCT04619615|OTHER|Synchronous large group online workshop|Resident participants will complete the digital training platform in real time over the course of a one day, live workshop (4.5 hours of online instruction).
223616486|NCT02197702|DIETARY_SUPPLEMENT|vitamin D|Two doses of cholecalciferol 100,000 unit (2 mL) given 3.5 months apart, once in the fall, once in the winter
223616487|NCT02197702|DIETARY_SUPPLEMENT|placebo|Two doses of identical placebo (2 mL) given 3.5 months part, once in the fall, once in the winter
223616488|NCT01285817|DRUG|celecoxib, Vinblastine, Cyclophosphamide , methotrexate ,|
223761014|NCT03817320|DRUG|Doxorubicin|"Day 1~Dose ≥ 1 year: 60mg/m2/dose~≥ 6 months and \< 1 year: 48 mg/m2/dose~\< 6 months: 42mg/m2/dose"
224202287|NCT01892813|DRUG|Combination pharmacotherapy - Transdermal nicotine patch + nicotine gum|Medication selection will be determined based on individual participant preferences, medical history, and contraindications.
224202288|NCT01892813|DRUG|Combination pharmacotherapy - Transdermal nicotine patch + nicotine lozenge|Medication selection will be determined based on individual participant preferences, medical history, and contraindications.
224202289|NCT01892813|DRUG|Combination pharmacotherapy - Transdermal nicotine patch + bupropion|Medication selection will be determined based on individual participant preferences, medical history, and contraindications.
224202290|NCT01892813|BEHAVIORAL|Tobacco quitline referral|Participants assigned to this condition will receive a referral to their state tobacco quitline. The specific behavioral treatment that is provided will differ slightly depending upon the services available through the participant's state of residence.
224202291|NCT01892813|BEHAVIORAL|Tailored behavioral intervention|Participants will receive a standard six session cognitive behavioral intervention for smoking cessation combined with supplemental treatment modules based on individual need and preference.
224202292|NCT01892813|BEHAVIORAL|Alcohol use risk reduction|Participants engaging in risky alcohol use may receive this six-session telephone-based behavioral intervention for reducing alcohol use.
224202293|NCT01892813|BEHAVIORAL|Behavioral activation for depressive symptoms|Participants with elevated depressive symptoms may receive this six-session telephone-based behavioral activation intervention.
224202294|NCT01892813|BEHAVIORAL|Behavioral management of postcessation weight gain|Participants with concerns about gaining weight after quitting smoking may receive this six-session telephone-based behavioral self-management intervention designed to help attenuate post-cessation weight gain.
224202295|NCT03890835|PROCEDURE|MTA Pulpotomy.|Pulpotomy using MTA.
224202296|NCT03890835|PROCEDURE|Biodentine Pulpotomy|Pulpotomy using Biodentine
224202297|NCT02591602|OTHER|Teleradiology Service|Teleradiology Service at home or in nursing homes
224202298|NCT06566352|PROCEDURE|Laparoscopic myomectomy with intramyometrial injection of diluted epinephrine|intramyometrial injection of epinephrine 1mg diluted in 200mg of NaCl solution
224202299|NCT06566352|PROCEDURE|traditional laparoscopic myomectomy|traditional laparoscopic myomectomy
224202300|NCT06566352|PROCEDURE|laparoscopic myomectomy with temporary bilateral uterine artery occlusion|Experimental: laparoscopic myomectomy with temporary bilateral uterine artery occlusion
224202301|NCT06566352|DRUG|injection of epinephrine 1mg diluted in 200mg of NaCl|injection of epinephrine 1mg diluted in 200mg of NaCl
224202302|NCT01803464|DEVICE|Low-magnitude vibration|Children will receive a daily low-magnitude vibration treatment.
223616489|NCT03725631|DIAGNOSTIC_TEST|Imaging and serologic evaluation of fibrosis and steatosis|Imaging evaluation: Fibroscan, MRI scan for evaluation of fibrosis and steatosis in biopsy proven NAFLD patients Serologic evaluation: serologic test for evaluation of fibrosis and steatosis in biopsy proven NAFLD patients
224202303|NCT01803464|DRUG|Botox|Children who are candidates to receive Botox as part of their standard of care.
224202304|NCT02424851|DRUG|Bortezomib|"1.3 mg/m2 subcutaneously\* days 1, 4, 8 and 11 of each cycle. Number of cycles: Four 21 day cycles (participants not suitable for ASCT (autologous stem cell transplant) will continue up to 6 cycles on the treatment regimen to which they were randomised).~\*intravenous infusion available in case of patient intolerance to subcutaneous bortezomib"
224202305|NCT02424851|DRUG|Thalidomide|100 mg daily orally, preferably at night, days 1-21 of each cycle. Four 21 day cycles (participants not suitable for ASCT will continue up to 6 cycles on the treatment regimen to which they were randomised)
223616490|NCT06192849|DRUG|Furmonertinib|This arm plans to enroll 20 subjects, treating with furmonertinib 160mg/d, until disease recurrence, death or intolerability. The maximum duration of treatment is three years.
223761015|NCT03817320|DRUG|Methotrexate (IT)|For patients with CNS 1 or CNS 2, on Days 1, 15, and 29
223761016|NCT03817320|DRUG|Triple IT (Methotrexate, Hydrocortisone, Cytarabine)|For patients with CNS 3, on Days 1, 8, 15, 22, and 29
223761017|NCT03817320|DRUG|Leucovorin|For patients with Down syndrome only, on Days 2, 9, 16, 23, and 30 (based on dates when IT Methotrexate or Triple IT is given)
224202306|NCT02424851|DRUG|Bendamustine|60 mg/m2 i.v. days 1 and 8 of each cycle. Four 21 day cycles (participants not suitable for ASCT will continue up to 6 cycles on the treatment regimen to which they were randomised)
224202307|NCT02424851|DRUG|Dexamethasone|40mg orally days 1-2, 4-5, 8-9 and 11-12 of each cycle
224202308|NCT03427827|DRUG|Camrelizumab|Camrelizumab is an antibody targeting PD-1 developed by Jiangsu Hengrui Medicine, China.
224202309|NCT02091388|DRUG|LY03004|
224202310|NCT02091388|DRUG|Risperdal® Consta®|
224202311|NCT02159573|BIOLOGICAL|natalizumab|Administered as per routine clinical practice
224202312|NCT02159573|DRUG|dimethyl fumarate|Administered as per routine clinical practice
224312563|NCT05568667|BEHAVIORAL|Moderate risk|"* remote support in physical activity and nutrition via digital media~* monthly collective physical activity sessions~* one collective health education session~* logbook"
223616491|NCT04262726|BEHAVIORAL|REMOTION|REMOTION is an internet-based intervention aimed at transdiagnostically reducing symptom severity and improving emotion regulation of psychotherapy patients. The structure of REMOTION is based on the idea of an extended process model of emotion regulation as postulated by J.J. Gross (2015). The program includes the following modules: introduction, psychoeducation, identification, selection, implementation and monitoring/modification. A variety of elements based on different psychotherapy approaches (Cognitive Behavioral Therapy, Emotion Focused Therapy, Dialectical Behavior Therapy etc.) are integrated in the program. Participants should work through one module per week. REMOTION is administered as an add-on to treatment as usual (TAU), which is psychotherapy at the outpatient clinic of the Department of Clinical Psychology and Psychotherapy at the University of Bern.
223616492|NCT04262726|BEHAVIORAL|TAU|Treatment as usual (TAU) refers to psychotherapy at the outpatient clinic of the Department of Clinical Psychology and Psychotherapy at the University of Bern. Psychotherapy at the outpatient clinic is based on Psychological Therapy (Grawe, 1998) principles, which are largely rooted in academic psychology and which mainly draw on interventions from Cognitive Behavior Therapy. Individual case conceptualization are key in Psychological Therapy, along with general therapeutic factors and a focus on the therapeutic relationship.
223616493|NCT06375070|PROCEDURE|PFO closure|PFO closure
224202313|NCT01410565|DRUG|Apaziquone|Apaziquone 4 mg in 40 mL diluent
224202314|NCT01410565|DRUG|Placebo|Placebo for Double Blind Phase
224202315|NCT02860039|BIOLOGICAL|Trivalent Influenza Vaccine|High dose Trivalent Influenza Vaccine given intramuscular
224202316|NCT02860039|BIOLOGICAL|Quadrivalent Influenza Vaccine|Standard dose Quadrivalent Influenza Vaccine given intramuscular
224202317|NCT02860039|OTHER|Laboratory Biomarker Analysis|Correlative studies
224202318|NCT01254357|OTHER|Questionnaire self report|Burn specific outcome measurement and global health measurement
224202319|NCT02394379|DEVICE|Trulign™ Toric IOL|Trulign™ Toric Posterior Chamber IOL is a modified plate haptic lens
224202320|NCT06226064|DRUG|VES001|VES001 is an oral, blood brain barrier penetrating ligand of sortilin.
224202321|NCT06226064|DRUG|Placebo|A matching dosage form, indistinguishable from the active treatment will be used as the placebo treatment.
224202322|NCT04298008|DRUG|AZD6738|AZD6738 (240 ) mg bid on D15-D28 Every 4 weeks
224202323|NCT04298008|DRUG|Durvalumab|Durvalumab 1500 mg iv on D1 Every 4 weeks
224202324|NCT00270179|DRUG|epoetin alfa|
224202325|NCT03121664|DRUG|PF06649751, Itraconazole|PF-06649751 0.25 mg on Days 1,2,3 PF-06649751 0.5 mg on Days 4,5,6 PF-06649751 1 mg on Days 7 to Day 25 Itracoanzole 200 mg on Days 12 to Day 25
224202326|NCT03857308|BEHAVIORAL|Mindfulness Training|"This stress reduction training will last 14 days and teach participants skills in concentration, monitoring of present-moment bodily experience, and acceptance of experience. Participants are encouraged to mentally welcome all physical and emotional experience. Each day will consist of approximately 25 to 30 minutes of training.~A full explanation of the mindfulness training compared to the reappraisal training could interfere with study blinding procedures. A complete description can be provided after data collection is complete."
224202327|NCT03857308|BEHAVIORAL|Reappraisal Training|"This stress reduction training will last 14-days. Each day consists of 25 to 30 minutes of daily practice in Coping control. Participants are encouraged to reframe and reappraise life events, both past and present, and encouraged to solve personal problems through active change.~A full explanation of the reappraisal stress reduction program compared to the mindfulness program could interfere with study blinding procedures. A complete description can be provided after data collection is complete."
224202328|NCT01360021|DRUG|Symbicort|Breath actuated metered dose inhaler
224202329|NCT01360021|DRUG|Symbicort|Actuation counter pressured metered dose inhaler
224202330|NCT01360021|DRUG|Budesonide|Actuation counter pressured metered dose inhaler
224312564|NCT05568667|BEHAVIORAL|High risk|"* remote support in physical activity and nutrition via digital media~* monthly collective physical activity sessions~* one collective health education session~* 3 individual sessions of motivational coaching~* connected watch~* logbook"
223616494|NCT06375070|DRUG|anticoagulant|rivaroxaban
223616495|NCT03836768|DRUG|DTRMWXHS-12|DTRMWXHS-12 capsules: 150 mg, 300 mg
223616496|NCT00706446|DRUG|tiotropium bromide|tiotropium bromide one inhalation a day for one year, along with inhaled steroids at variable dosing based on patient's prior inhaled steroid dosing and treating physician's judgement.
224202331|NCT04060979|DRUG|Nitric Oxide|Nitric Oxide given intermittently via inhalation
224202332|NCT04060979|OTHER|Standard Supportive treatment|Standard Supportive treatment (including oxygen)
224202333|NCT02446496|DRUG|Cefadroxil tablets manufactured by GSK|Cefadroxil tablets manufactured by GSK contains 1 mg of Cefadroxil
224202334|NCT02446496|DRUG|Cefadroxil tablets manufactured by NP|Cefadroxil tablets manufactured by NP contains 1 mg of Cefadroxil
224202335|NCT04999137|DRUG|Vitamin C|Vitamin C (ascor), infused intravenously in 50 mls sodium chloride (NaCl) over 30 minutes every 6 hours for 16 doses
224202336|NCT04999137|DRUG|Vitamin B1|Vitamin B1 (200 mg) administered intravenously every 12 hours for 8 doses
224202337|NCT01537809|DIETARY_SUPPLEMENT|Vitamin D3|Subjects are told to take vitamin D daily for 6 months.
224202338|NCT01537809|DIETARY_SUPPLEMENT|Vitamin D3|Subjects are asked to take vitamin D orally, daily for six months.
224202339|NCT00631709|OTHER|CareLink Remote Monitoring|Substitution of CareLink Remote Monitoring of Pacemakers for in-clinic pacemaker follow-up visits
224202340|NCT04401709|DRUG|Gemcitabine/Capecitabine|gemcitabine 1,000 mg / m2 IV on day 1, 8, and 15 of each cycle Capecitabine 1,660mg / m2 PO twice daily 1 \~ 21 days for 4 weeks
224202341|NCT04401709|DRUG|Capecitabine|total 8 cycles Capecitabine 1,250 mg / m2 PO twice daily 1 \~ 14 days for 3 weeks
224202342|NCT00369798|PROCEDURE|PET scan|
224202343|NCT00369798|DRUG|Rolipram|
224312565|NCT00102947|DRUG|daptomycin (up to 14 days)|
224312566|NCT04192461|PROCEDURE|Tooth guided immediate implant placement|The technique of implant insertion consisted of a progressive preparation of the implant site using the anatomy of the root of the multi-radicular mandibular molars to be extracted as a reference and as an aid to engage the inter-radicular septum
223761023|NCT03909165|DRUG|Sugammadex 2 mg/kg|For moderate NMB reversal, a single IV bolus of sugammadex (2 mg/kg) will be given after final dose of neuromuscular blocking agent (NMBA; rocuronium or vecuronium) and within 2 minutes of the reappearance of a second twitch (T2) in response to train-of-four (TOF) stimulations.
224312567|NCT04587999|OTHER|bladder stimulation|"The bladder stimulation technique requires the presence of 2 people:~* The child must be held by an adult (caregiver or parent) under the armpits, legs dangling.~* the first person (the investigator), performs the stimulation technique consisting of: rapid tapping (frequency of about 100 / min), over the pubic area, at the level of the bladder, alternated with external rotational movements of the pits lumbar, in the kidneys. Alternate these 2 maneuvers every 30 seconds.~* The second person starts the stopwatch at the start of the stimulation, and is about to collect the urine, 2nd jet in a sterile pot~* The maneuver ends as soon as urine is obtained, and will be stopped after 5 minutes in case of failure."
223616497|NCT00706446|DRUG|Salmeterol|salmeterol diskus 1 puff twice a day for 1 year, depending on which medication the patient was on before the start of the trial. The goal of this intervention is to continue the patient's current therapy of long-acting beta-agonists. In addition, the patients will be on inhaled steroids at variable doses, depending on what dose they were on at the start of the trial and based on the judgement of their treating physicians.
223616498|NCT00706446|DRUG|Formoterol|formoterol aerolizer 12 mcg 1 puff twice a day for 1 year, depending on which medication the patient was on before the start of the trial. The goal of this intervention is to continue the patient's current therapy of long-acting beta-agonists. In addition, the patients will be on inhaled steroids at variable doses, depending on what dose they were on at the start of the trial and based on the judgement of their treating physicians.
223616499|NCT00706446|DRUG|Fluticasone propionate|Either fluticasone propionate diskus 100 mcg 1 puff twice a day or fluticasone propionate aersol in 44 mcg, 110 mcg, 2 puffs twice a day OR fluticasone propionate 220 mcg 2 puffs once a day for one year, depending on which dose the patient was on before the start of the trial.
223616500|NCT00706446|DRUG|budesonide|Either budesonide 90 mcg 2 puffs twice a day or 180 mcg 2 puffs twice a day for one year, depending on which dose the patient was on before the start of the trial.
223616501|NCT01908686|BEHAVIORAL|Pivotal Response Training|Behavioral intervention for autism
223616502|NCT06437262|DRUG|0.20% CHX gel on saliva|In vivo application of a gel on the vestibular and palatal/lingual gingival mucosa of both arches at minute 0 for posterior saliva collection at different time-points.
223616503|NCT06437262|DRUG|0.20% CHX and Cymenol gel on saliva|In vivo application of a gel on the vestibular and palatal/lingual gingival mucosa of both arches at minute 0 for posterior saliva collection at different time-points.
223616504|NCT06437262|DRUG|0.20% CHX gel on oral biofilm|Ex vivo application of a gel on the glass disks of the removable intraoral appliance at minute 0 for subsequent one-by-one disk removal from the device at different time-points.
223616505|NCT06437262|DRUG|0.20% CHX and Cymenol gel on oral biofilm|Ex vivo application of a gel on the glass disks of the removable intraoral appliance at minute 0 for subsequent one-by-one disk removal from the device at different time-points.
223616506|NCT00172211|DRUG|Physioneal|
223616507|NCT00293917|DRUG|Tacrolimus Cream|
223616508|NCT00429949|DRUG|Dasatinib|
223616509|NCT04143867|DEVICE|Nolix Device|For temporary management of SUI
223761024|NCT03909165|DRUG|Sugammadex 4 mg/kg|For deep NMB reversal, a single IV bolus of sugammadex (4 mg/kg) will be given after final dose of NMBA (rocuronium or vecuronium) and within 2 minutes of detection of a target of 1 to 2 post-tetanic counts and no response to TOF stimulations (TOF=0).
224075507|NCT00608985|DRUG|almorexant|2 100 mg almorexant tablets and 1 placebo matching over-encapsulated zolpidem
224075508|NCT00608985|DRUG|almorexant|1 100 mg almorexant tablet, 1 placebo matching almorexant tablet, and 1 placebo matching over-encapsulated zolpidem
224075509|NCT00608985|DRUG|Placebo|2 placebo matching almorexant tablets and 1 placebo matching over-encapsulated zolpidem
224075510|NCT00608985|DRUG|zolpidem|2 placebo matching almorexant tablets and 1 zolpidem 10 mg over-encapsulated
224075511|NCT03064139|BEHAVIORAL|MCG|Community-based in person group training n mindful walking over 11 sessions in 6-months+ Activity monitor with feedback on activity levels
224075512|NCT03064139|BEHAVIORAL|SCG|Community-based in person group education in management of knee osteoarthritis (importance of physical activity, weight management, etc.) over 11 sessions in 6 months + Activity monitor with feedback on activity levels
224075513|NCT02562326|DRUG|BioChaperone insulin lispro|Injection immediately before the start of the individualised standard meal
224075514|NCT02562326|DRUG|Humalog®|Injection immediately before the start of the individualised standard meal
224075515|NCT03631823|OTHER|Chemotherapy with temozolomide or no chemotherapy|This study is just an observational study.
224075516|NCT03786549|OTHER|pediatric-adult care transition program|"Three structured axes of multidisciplinary interventions are added to the usual follow-up for the patients drawn in this interventional arm. Those axes integrate the bioclinical medical care and include the parents of the adolescent~Three axes are :~* Educative, family (patient and parent), at home~* Psychological, with the patient individually~* Medico-social orientation, group of patients"
224075517|NCT04519723|DEVICE|Assess the safety and efficacy of light-laser therapy using the Harmony XL and Dye-VL (500-600nm), Q-Switched 1064nm, Er:YAG 2940nm modules in combination .|
224075518|NCT00133380|DRUG|PPAR alpha|
224075519|NCT00133380|DRUG|atorvastatin|
224075520|NCT00133380|DRUG|placebo|
224075521|NCT01999803|DRUG|sNN0029|
224075522|NCT01999803|DRUG|Placebo|
224075523|NCT03052452|OTHER|My Nutritional Health App|The My Nutritional Health app built in LifeData will be used as the data collection platform for this study. We will use the data collected in the app testing to develop population-level FAST scores.
224075524|NCT01726946|DRUG|VX-135|12 weeks of VX-135
224075525|NCT01726946|DRUG|ribavirin|12 weeks of ribavirin
224075526|NCT04975061|DRUG|YY-20394|YY-20394 is a small molecule inhibitor.
224075527|NCT05156827|DRUG|TB006|TB006 diluted in normal saline, administered through IV infusion over an hour
224075528|NCT05156827|DRUG|Placebo|Normal saline administered through IV infusion over an hour
223616510|NCT03269149|OTHER|Adapted Tango Dance|20 improvisational, 90-minute adapted tango dance sessions over a 12-week period. Classes begin with a 20-minute standing warm-up followed by partnering and rhythmic exercises. Next, novel step elements are introduced and participants will be taught how to combine the new steps with previously learned steps via improvisation. Caregivers will dance with each other or undergraduate /graduate student volunteers. Music will be played throughout classes and artistic expression, i.e., attention to aesthetics, and improvisation, will be encouraged.
223616511|NCT03269149|BEHAVIORAL|Educational lectures|Participants will take part in at least 20 educational lectures offered twice per week over 12 weeks. Classes will also be 1.5 hours long and will involve lecture, partnered and group learning and extensive Q\&A will be encouraged.
223616512|NCT06386523|DIAGNOSTIC_TEST|Passage of olfactory tests|test TODA2 and Sniffin Stick Test
223616513|NCT00296816|DRUG|Bevacizumab (Avastin®)|15 mg/kg bevacizumab administered intravenously (IV) over 30 to 90 minutes on Day 1 of every 3 week cycle for 12 months or until disease progression or unacceptable toxicity
223616514|NCT00296816|DRUG|Docetaxel (Taxotere®)|75 mg/m\^2 docetaxel was administered IV over 1 hour on Day 1 of every 3 week cycle for 6 cycles or until disease progression or unacceptable toxicity
223616515|NCT00296816|DRUG|Oxaliplatin (Eloxatin®)|85 mg/m\^2 Oxaliplatin was administered IV over 2 hours on Day 1 of every 3 week cycle for 6 cycles or until disease progression or unacceptable toxicity
223616516|NCT01187940|BEHAVIORAL|PEGASUS|PEGASUS - a psychoeducational group intervention with parallel parent and child sessions.
223616517|NCT04203511|DRUG|Retifanlimab|INCMGA00012 administered intravenously every 3 weeks on Day 1 of each 21-day cycle for 4 cycles, followed by a consolidation part of INCMGA00012 administered intravenously on Day 1 of each 28-day cycle for up to12 cycles.
224202344|NCT01257737|DRUG|HPN-100|Participants received individualized doses of HPN-100 orally, three times daily (TID) with meals. The initial dose was the same dose administered at the end of the HPN-100-005SE, HPN-100-007, or HPN-100-012SE studies. Dose adjustments (including frequency adjustments) were permitted as judged clinically appropriate by the investigator based on assessment of ammonia-scavenging needs (e.g., severity of the UCD defect, dietary protein intake, and urinary phenylacetylglutamine \[PAGN\] excretion). The maximum recommended dose of HPN-100 in participants weighing less than 20 kg was 0.53 mL/kg/day (equivalent to 600 mg/kg/day of NaPBA), and was 11.48 mL/m²/day in heavier subjects (equivalent to 13g/m²/day of NaPBA). The maximum HPN-100 dose recommended per protocol was 17.4 mL/day, which is equivalent to 20 g/day of NaPBA.
224312568|NCT04587999|OTHER|Quick wee|"The Quick wee technique requires the presence of only one person:~Stimulation of the suprapubic area by circular movements, with a cold and wet compress held by sterile forceps.~Collection of urine in a sterile container."
224312569|NCT04659759|OTHER|COVID-19 exposure|COVID-19 exposure during pregnancy
223616518|NCT04203511|DRUG|Placebo|Placebo administered intravenously every 3 weeks on Day 1 of each 21-day cycle for 4 cycles, followed by a consolidation part of placebo administered intravenously on Day 1 of each 28-day cycle for up to 12 cycles.
223616519|NCT04203511|DRUG|Pemetrexed|Pemetrexed administered intravenously every 3 weeks on Day 1 of each cycle with either carboplatin or cisplatin (nonsquamous NSCLC only) for 2 cycles (if radiation therapy is started on Cycle 1 Day 1) or 3 cycles (if radiation therapy is started after Cycle 1).
223616520|NCT04203511|DRUG|Cisplatin|Cisplatin administered intravenously every 3 weeks on Day 1 of each cycle with either etoposide or pemetrexed (nonsquamous NSCLC only) for 2 cycles (if radiation therapy is started on Cycle 1 Day 1) or 3 cycles (if radiation therapy is started after Cycle 1).
223616521|NCT04203511|DRUG|Carboplatin|Carboplatin administered intravenously every 3 weeks on Day 1 of each cycle with either pemetrexed (nonsquamous NSCLC only) or paclitaxel for 2 cycles (if radiation therapy is started on Cycle 1 Day 1) or 3 cycles (if radiation therapy is started after Cycle 1).
223616522|NCT04203511|DRUG|Paclitaxel|Paclitaxel administered intravenously every 3 weeks on Days 1, 8, and 15 of each cycle with carboplatin for 2 cycles (if radiation therapy is started on Cycle 1 Day 1) or 3 cycles (if radiation therapy is started after Cycle 1).
223616523|NCT04203511|DRUG|Etoposide|Etoposide administered intravenously every 3 weeks on Days 1-3 of each cycle with cisplatin for 2 cycles (if radiation therapy is started on Cycle 1 Day 1) or 3 cycles (if radiation therapy is started after Cycle 1).
223616524|NCT04203511|RADIATION|Radiotherapy|Total dose of 60 Gy ± 10% (54 to 66 Gy) in 2 Gy daily fractions.
223616525|NCT04370158|OTHER|disease history|Clinical progression and prognosis of patients with interstitial lung diseases
223616526|NCT01473290|DIETARY_SUPPLEMENT|live freeze-dried lactic acid bacteria probiotic|Given orally (PO)
223616527|NCT01473290|OTHER|placebo|Given PO
223616528|NCT01721161|BIOLOGICAL|BIIB033 (anti-LINGO-1 mAb)|100 mg/kg via IV infusion once every 4 weeks for 20 weeks (a total of 6 doses).
223616529|NCT01721161|DRUG|Placebo|via IV infusion once every 4 weeks for 20 weeks (a total of 6 doses)
224075529|NCT06182488|OTHER|ERAS protocols|ERAS protocols for emergency abdominal surgery
224075530|NCT06182488|OTHER|Conventional protocols|Conventional protocols for emergency abdominal surgery
224075531|NCT04976894|OTHER|open|open
224075532|NCT02574637|DRUG|Brazikumab IV Infusion|Brazikumab IV infusion as per protocol specified dosing schedule.
224075533|NCT02574637|DRUG|Brazikumab SC Injection|Brazikumab IV infusion as per protocol specified dosing schedule.
224075534|NCT02574637|DRUG|Placebo|Placebo-matching Brazikumab IV infusion as per protocol specified dosing schedule.
224075535|NCT05450679|PROCEDURE|Cervical Radiofrequency Ablation (RFA)|"During the cervical RFA procedure, all patients will undergo sensory and motor stimulation testing prior to receiving radiofrequency lesioning, which is a standard and recommended practice.~During the motor stimulation testing step, the pain physicians performing the procedure will assess the presence or absence of cervical paraspinal muscle twitching by using a standardized grading scale (per radiofrequency electrode: 0 = no twitches observed or palpated; 1 = twitches palpated but not observed; 2 = twitches observed and palpated at 1-2 levels; 3 = twitches observed at \> 2 levels). A total score and a weighted score (total score divided by the number of radiofrequency lesion sites), will be recorded for each patient, and the RFA procedure will be completed per usual practice.~RFAs will be performed in the usual manner and as per standard of care. Providers will not use any new or experimental devices to perform the RFA."
224075536|NCT04291937|DRUG|Lurbinectedin|Powder for concentrate for solution for infusion in 4 mg vials
224312570|NCT04659759|BIOLOGICAL|COVID-19 vaccine|Receipt of any COVID-19 vaccine
223761025|NCT03909165|DRUG|Neostigmine + Glycopyrrolate|For moderate NMB reversal, a single i.v. bolus containing both neostigmine (50 μg/kg; up to 5 mg maximum dose) as well as glycopyrrolate (10 μg/kg) will be given after final dose of NMBA (rocuronium or vecuronium) and within 2 minutes of the reappearance of T2 in response to TOF stimulations.
223761026|NCT03909165|DRUG|Neostigmine + Atropine|For moderate NMB reversal, a single i.v. bolus containing both neostigmine (50 μg/kg; up to 5 mg maximum dose) as well as atropine (20 μg/kg) will be given after final dose of NMBA (rocuronium or vecuronium) and within 2 minutes of the reappearance of T2 in response to TOF stimulations.
223761027|NCT04609020|DEVICE|JUVÉDERM|JUVÉDERM VOLBELLA with Lidocaine Treatment of any fine lines and medium-sized skin depressions. Can also be used for enhancement and pouting of the lips to correct structural defects such as asymmetry, contour deformities, volume loss. JUVÉDERM VOLIFT with Lidocaine Intended for the treatment of any deep skin depressions due to conditions such as premature aging. Can also be used for face contouring and volume restoration to correct facial structural defects such as asymmetry, contour deformities, volume loss in the lips, cheeks, chin, lower face. JUVÉDERM VOLUMA with Lidocaine Intended to restore volume of the face JUVÉDERM VOLITE with Lidocaine Intended for treatment, by filling, of superficial cutaneous depressions such as fine lines and for additional improvement of skin quality attributes such as hydration and elasticity. JUVÉDERM VOLUX with Lidocaine Intended to restore and generate facial volume in chin and mandible areas
223761028|NCT04609020|DRUG|BOTOX|Indicated for the treatment of hyperkinetic facial lines.
224202345|NCT01626209|DRUG|BKM120|This is a single arm study, with a starting dose of BKM120 at 80mg/day. Two dose levels: 80mg/day and 100mg /day will be tested in the dose escalation phase. At least 3 patients will be enrolled at each dose level and at least 6 evaluable patients required to be treated at the recommended Phase II dose(RP2D)/MTD dose. After dose escalation the 80mg/day and the 100mg /day dose levels will be expanded to evaluate up to approximately a total of 15 patients each (if 100mg is determined as the RP2D/MTD).
224202346|NCT06565871|DRUG|HRS9531 Injection|Titration administration, SC
224202347|NCT06565871|DRUG|HRS9531 Injection|Titration administration, SC
224202348|NCT06565871|DRUG|Placebo Injection|SC
224202349|NCT03853980|DEVICE|Focal Contouring System|Single treatment of skin resection (removal of loose skin)
224202350|NCT01618903|DRUG|Levetiracetam|Levetiracetam 1.500 mg (500 mg/ 5 mL vials) administered as a 45 minutes intravenous infusion diluted in 100 mL 0.9 % saline solution in the morning of Day 1.
224202351|NCT01618903|DRUG|Levetiracetam|Levetiracetam single oral administration of 3 tablets of 500 mg immediate release tablet.
224202352|NCT03300882|OTHER|Procedure|Serial blood draws. Participants will be enrolled either pre-transplant or within 45 days post-transplant and will be followed over the course of 18 months post transplant. Protocol mandated serial measurement of cytomegalovirus (CMV)-specific immune signature will occur pre-transplant (as applicable) and at post-transplant timepoint months 2, -3, -6, -9, -12 and -18.
224202353|NCT04785027|DRUG|PSORI-CM01 formula|PSORI-CM01 formula will be orally administrated once a day for 12 weeks excpet the day for the infusion of AD-MSCs
224202354|NCT04785027|DRUG|Gu Ben Hua Yu formula|Gu Ben Hua Yu formula will be orally administrated once a day for 12 weeks excpet the day for the infusion of AD-MSCs
224202355|NCT04785027|BIOLOGICAL|adipose-derived multipotent mesenchymal stem cells|AD-MSCs (adipose-derived multipotent mesenchymal stem cells) will be infused intravenously at a dose of 2 million cells/kg
224202356|NCT04185025|DRUG|Ceramides|"On the 0th day, it is determined that one of the leg extensions of the participant is the test side using CeraVe Moisturising Lotion and the opposite side is the control side using Half Mu ceramide body milk by the random table. Participants are required to use the product in the morning and evening according to the Product Use Procedures, during which other moisturizing products or emollients are prohibited. And the follow-up tests are conducted at the prescribed time. At each visit, empty packaging of products used during this period must be collected; if they are not used up as required, the remaining products must be collected."
224202357|NCT02122939|DRUG|Escitalopram|
224202358|NCT01600612|DRUG|carbetocin|10 ug of carbetocin will be given intravenously to patients with atonic postpartum hemorrhage
224202359|NCT01600612|DRUG|misopristol|600 ug of misopristol will be given sublingually to patients with atonic postpartum hemorrhage
224202360|NCT01600612|DRUG|oxytocin|30 IU of oxytocin will be given intravenously to patients with atonic postpartum hemorrhage
224202361|NCT03267316|BIOLOGICAL|CAN04|A fully humanized monoclonal immunoglobulin G1 (IgG1) antibody (hmAb) in aqueous solution administered by i.v. infusion.
224202362|NCT03267316|DRUG|Cisplatin|Standard of care treatment
224202363|NCT03267316|DRUG|Gemcitabine|Standard of care treatment
224202364|NCT03267316|DRUG|Nab-paclitaxel|Standard of care treatment
224202365|NCT03267316|DRUG|Carboplatin|Standard of care treatment
224202366|NCT03267316|DRUG|Pemetrexed|Standard of care treatment
224202367|NCT06393816|DRUG|Durvalumab with etoposide and Carboplatin/Cisplatin|"Combination of durvalumab with etoposide and Carboplatin/Cisplatin as First Line Treatment in Patients With Large-cell Neuroendocrine Carcinomas of the Lung.~All patients (either with confirmed diagnosis or not) will be treated and followed-up:~* During the induction: every 3 weeks for 12 weeks (4 cycles)~* During the maintenance: every 4 weeks for 24 months"
224202368|NCT04061655|DRUG|Iron Isomaltoside 1000|Apatients (n= 40) received single dose intravenous infusions of iron isomaltoside 1000 mg over 15 min with a maximum single dose of 20 mg/kg.
224202369|NCT04061655|OTHER|placebo|Patients in the placebo group (n=40)received as a single-dose of saline (Natriumklorid 9 mg/ml; Fresenius Kabi, Copenhagen, Denmark) 100 ml infused over 15 min.
224202370|NCT01131208|GENETIC|gene expression analysis|
224202371|NCT01131208|OTHER|laboratory biomarker analysis|
224202372|NCT02399410|DRUG|perioperative chemotherapy plus bevacizumab|preoperative and postoperative combination chemotherapy with bevacizumab
224202373|NCT02399410|PROCEDURE|cytoreductive surgery|complete or nearly complete removal of synchronous or metachronous peritoneal carcinomatosis from CRC.
224202374|NCT02399410|DRUG|Intraperitoneal Oxaliplatin|Pump-driven intraperitoneal administration of oxaliplatin
224312571|NCT01806571|DRUG|Cytarabine|Given IV
224312572|NCT01806571|DRUG|Daunorubicin Hydrochloride|Given IV
224312573|NCT01806571|OTHER|Laboratory Biomarker Analysis|Correlative studies
223616530|NCT04247386|DRUG|PEG-Mizone|"The evening before the colonoscopy:60gPEG-4000 was mixed with 0.6LMizone and 0.4L water.~On the day of the colonoscopy:4-6 hours before colonoscopy, 120gPEG-4000 was mixed with 1.2LMizone and 0.8L water."
223616531|NCT04247386|DRUG|PEG-ELS|The evening before the colonoscopy:60gPEG-4000 was mixed with 1L water. On the day of the colonoscopy:4-6 hours before colonoscopy, 120gPEG-4000 was mixed with 2L water.
223616532|NCT04506541|OTHER|Kangaroo Care|Kangaroo care application started in the first minute after giving birth in mothers who were in the kangaroo care group and came to the delivery room.
223616533|NCT02223780|OTHER|early palliative care|the patients will benefit from an early palliative care consultation
224202375|NCT00983255|DRUG|TR-701 FA for injection, 200 mg/vial|TR-701 FA for injection will be given as a single infusion at doses of 50 mg, 100 mg, 200 mg, and 400 mg in SAD/Part A (Pilot and Cohorts 1 to 3). TR-701 FA for injection will be given as once daily infusions at doses of 200 mg and 400 mg for 7 days in MAD/Part B (Cohorts 4 \& 5). TR-701 FA for injection will be given once as a 200 mg IV infusion in BA/Part C (Cohort 6). TR-701 FA 200 mg will be given daily for 3 days in Venous Tolerability/Part D
224202376|NCT00983255|DRUG|TR-701 FA tablets|TR-701 FA will be given once orally as a 200 mg tablet in Part C.
224202377|NCT02023723|DIETARY_SUPPLEMENT|Energy Drink|16oz energy drinks - 2 consumed within 60 minutes
224202378|NCT02023723|DIETARY_SUPPLEMENT|Active Control|16oz control drink: Caffeine 160mg, Sucrose 115g consume 2 - 16oz drinks within 60 minutes
224202379|NCT01143610|PROCEDURE|Newly forming bone technique for root coverage|A granulation tissue will be obtained 21-25 days after the creation of an alveolar socket and grafted to receptor site.
224202380|NCT01143610|OTHER|Subepithelial connective tissue graft for root coverage.|A subepithelial connective tissue graft will be used for the treatment of Miller class I or II deep recessions.
224202381|NCT05260658|DRUG|CFTX-1554|CFTX-1554 is a new chemical entity that binds to the angiotensin II type 2 receptor (AT2R).
224202382|NCT05260658|DRUG|Placebo|CFTX-1554 matching placebo
224202383|NCT00124579|DRUG|bortezomib|induction: 1 mg/m2 IV push days 1, 4, 8, 11 every 21 days
224312574|NCT01806571|DRUG|Nilotinib|Given PO
224312575|NCT01806571|OTHER|Pharmacological Study|Correlative studies
224312576|NCT02198183|DEVICE|Casmed Fore-Sight Elite|
224312577|NCT02198183|DEVICE|Non-invasive Cardiac Output Monitor (NICOM)|
224312578|NCT01947998|DRUG|Rivaroxaban (Xarelto, Bay59-7939)|"The treatment of deep vein thrombosis (DVT) or pulmonary embolism (PE), and prevention of recurrent DVT and PE in adult patients (15 mg rivaroxaban twice daily \[bid\] for 3 weeks, then 15 mg or 20 mg once daily \[od\], tablets).~The prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (stroke prevention in atrial fibrillation \[SPAF\]) with one or more risk factors (20 mg rivaroxaban \[od\], tablets).~The prevention of venous thromboembolism (VTE) in adult patients undergoing elective hip or knee replacement surgery (recommended dose: 10 mg rivaroxaban \[od\] tablets for 35 days following hip replacement surgery and 14 days following knee replacement surgery).~Co-administered with acetylsalicylic acid (ASA) alone or with ASA plus clopidogrel or ticlopidine, for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (ACS) with elevated cardiac biomarkers (recommended dose 2.5 mg rivaroxaban tablets \[bid\])."
224312579|NCT01947998|DRUG|Warfarin|For VTE prevention, DVT/PE treatment and SPAF, standard of care is treatment with the most widely used vitamin K antagonist, warfarin.
223616534|NCT01775774|BIOLOGICAL|Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells|Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells will be administered intravenously.
223616535|NCT00017602|BIOLOGICAL|oblimersen sodium|
223616536|NCT00017602|DRUG|dexamethasone|
223616537|NCT00071227|DRUG|Triamcinolone Acetonide (TAC-PF)|
223761029|NCT04609020|DEVICE|HArmonyCA Lidocaine|HArmonyCa Lidocaine injectable gel is a dermal filler intended for facial soft tissue augmentation.
224202384|NCT00124579|DRUG|dexamethasone|induction: 20 mg/d PO days 1, 2, 4, 5, 8, 9, 11, 12 every 21 days maintenance: 40 mg days 1-4 every 28 days until progression
224202385|NCT00124579|DRUG|thalidomide|100 mg/d PO days 1-21 every 21 days
224202386|NCT06496984|OTHER|Nutritional intervention|Diet changes with different dietary therapies, such as oral nutritional supports (ONS), extra nutritional cares, diet changes without supplements and artificial nutrition.
224202387|NCT00874042|DRUG|Treatment with ARQ 197 in combination with gemcitabine|"Enrollment of an initial cohort of 3 or 6 patients will follow the traditional 3 + 3 dose escalation scheme. These patients will be treated with ARQ 197 and gemcitabine. ARQ 197 will be administered by mouth BID continuously. Gemcitabine will be administered by intravenous infusion over 30 minutes once weekly for 3 consecutive weeks followed by a week of rest."
224202388|NCT02253199|DRUG|intranasal dexmedetomidine|"Children who were not adequately sedated ( no evidence of adequate sedation within 30 min after administration of Initial dose of chloral hydrate) received a bolus of intranasal dexmedetomidine which adjusted by the Dixon up-and-down method for rescue sedation.~The first child received 0.8mcg/Kg of intranasal dexmedetomidine dose (100mcg/ml), and the dose interval was set at 0.1mcg/Kg."
224202389|NCT04747678|DRUG|Ivermectin|retrograde study of common and rare adverse effects of multiple doses of ivermectin used during the coivd 19 pandemic in egypt
224202390|NCT02417207|DRUG|Entecavir combined long-term low-dose HBIG group intramuscular|HBIG scheme is: the use of intraoperative muscle injection of 800 IU HBIG, postoperative week 1 intramuscular injection HBIG 400 IU 1 times a day, 1 week after intramuscular injection HBIG 400 IU 2 times per week, dosage and time interval according to the HBsAb drops in patients with degree of level adjustment, target drops for 3 months or more after 500 IU/mL, 3 \~ 6 months or 300 IU/mL, after six months of 100 IU/mL or more.
224312580|NCT01947998|DRUG|Antiplatelet drugs|For the secondary prevention of ACS, standard of care is antiplatelet drug(s) such as low-dose acetylsalicylic acid, clopidogrel, dipyridamole, prasugrel, ticlopidine and ticagrelor
224312581|NCT01570114|DEVICE|Fully covered metallic colonic stent|Endoscopically insertion of fully covered metallic colonic stent
224312582|NCT00337337|BEHAVIORAL|Multiple grain|
224312583|NCT00337337|BEHAVIORAL|Ordinary Asian- rice|
224312584|NCT06583161|BEHAVIORAL|Moderate drinking|Drink up to 16 grams of alcohol daily or almost daily \[repeated assessment center visit\] or 8-16 grams of alcohol 4 or more times per week \[web-based mental health questionnaire\]
224312585|NCT06583161|BEHAVIORAL|Quitting|No alcohol consumption
224202391|NCT02417207|DRUG|Entecavir combined HBIG group short-term high-dose intravenous|Preoperative HBV DNA level is less than 1000 IU/ml, intraoperative intravenous drip of 2500 IU HBIG static note type, postoperative 1 and 15 days respectively to give 2500 IU HBIG static note type, a total of three times, then no longer apply. Preoperative HBV DNA level greater than 1000 IU/ml, the use of HBIG solution for: intraoperative intravenous drip of 5000 IU HBIG static note type, postoperative day 1, 15 days and 30 days respectively to give 2000-2500 IU HBIG static note type, a total of four times, since then no longer apply. Preoperative HBV DNA level of the unknown, preoperative immediate detection of DNA, intraoperative intravenous drip of 5000 iu HBIG static note type, choose according to test results after dosing frequency.
223761030|NCT06224244|RADIATION|Ten-fraction hypofractionated breast radiotherapy with 40 Gy simultaneous integrated bed boost|Patients undergo BCS followed by ten-fraction adjuvant breast irradiation (34Gy) with a risk adapted SIB dose of 40 Gy
223761031|NCT06224244|RADIATION|Ten-fraction hypofractionated breast radiotherapy with 43 Gy simultaneous integrated bed boost|Patients undergo BCS followed by ten-fraction adjuvant breast irradiation (34Gy) with a risk adapted SIB dose of 43 Gy
223761032|NCT02107599|DRUG|Florbetapir (18F)|No Florbetapir (18F) will be administered in this study.
223761033|NCT06049888|BEHAVIORAL|Restricted Social Media|Participants (N = 500) will be randomly assigned to either have no study-imposed restrictions on social media use (naturalistic social media condition) or have no access to social media apps on their phones (restricted social media condition). This manipulation will last three months, after which both groups will have no study-imposed restrictions on social media for three more months.
223761034|NCT00779103|DRUG|Histrelin Subcutaneous Implant|histrelin subcutaneous 50 mg implant
224202392|NCT02459756|OTHER|Beverage: Spray dried blackcurrant powder dissolved in water|
224202393|NCT02459756|OTHER|Beverage: Placebo (sucrose, glucose, fructose, maltodextrin, malic acid, citric acid, vitamin C, artificial blackcurrant flavouring and low-nitrate water)|
224202394|NCT05455593|BEHAVIORAL|Water aerobics|1-hour session of water aerobics per week, for 3 months. A specialized trainer will carry out water aerobics sessions and will focus on motor coordination, strength and cardiovascular workout.
224202395|NCT05455593|BEHAVIORAL|Metacognitive Training (MCT)|1-hour session of MCT per week, for 3 months. A trained psychologist will carry out the MCT sessions. MCT addresses the most common cognitive biases in psychosis. Each session will focus on one topic, such as attributional style, jumping to conclusions, theory of mind, emotion recognition, memory or empathy.
224202396|NCT05455593|BEHAVIORAL|Combined intervention|Patients in this arm will participate in both in water aerobics and MCT sessions, once a week for each intervention.
224202397|NCT03170271|DRUG|Benralizumab (Medi-563)|30mg Benralizumab administered as a subcutaneous injection at Visit 4 (day 0), Visit 6 (day 28 +/- 3 days), Visit 7 (day 56 +/- 3 days) and Visit 9 (day 112 +/- 3 days) In the open label ANDHI IP sub study, all patients will receive benralizumab subcutaneously at Day 168 (Week 24), Day 196 (Week 28), Day 224 (Week 32), Day 280 (Week 40), Day 336 (Week 48), Day 392 (Week 56), Day 448 (Week 64), and Day 504 (Week 72).
224312586|NCT06583161|BEHAVIORAL|Social drinking|Drink up to 16 grams of alcohol 1-2 days per week or drink 1-3 times per month or only on special occasions \[repeated assessment center visit\], or drink 8-16 grams of alcohol 2-3 times per week or drink 4 times per month or less \[web-based mental health questionnaire\]
224312587|NCT06583161|BEHAVIORAL|Heavy/binge drinking|Drink more than 16 grams of alcohol daily or almost daily or more than 40 grams of alcohol 1-2 days per week \[repeated assessment center visit\], or 24 grams of alcohol or more 4 or more times per week or 40 grams of alcohol or more 2-3 times per week \[web-based mental health questionnaire\]
224312588|NCT02618759|DRUG|DSXS|active treatment
224312589|NCT02618759|DRUG|Placebo|placebo treatment
224312590|NCT02446756|OTHER|acupuncture|
223510389|NCT05792462|DRUG|Baricitinib|Baricitinib will be taken orally with a dose of 4mg once daily until the disease relapses or week 48, with a final evaluation at week 52.
223510390|NCT06007248|DIAGNOSTIC_TEST|Protocol-defined Examinations|Lab tests (blood and urine and stool routine tests, hepatic and renal and thyroid function tests, tests for metabolic markers, tests for cardiac biomarkers, thrombosis-related tests, rheumatology tests, tests for inflammation markers), electrocardiography, echocardiography, Birmingham Vasculitis Activity Score (BVAS-3), 6-minute walk test, 1-minute squat test, vascular ultrasound, fibroblast activation protein inhibitor (FAPI) positron emission tomography/computed tomography (PET/CT), coronary angiography, optical coherence tomography (OCT), tests for exploratory biomarkers.
223510391|NCT05965466|PROCEDURE|Distal gastrectomy and radical resection|Distal gastrectomy and Roux-en-Y anastomosis
223761035|NCT03509038|OTHER|Exploratory pathophysiology Study|Urodynamic tests before and after bariatric surgery in obese incontinent women before and after bariatric surgery
224202398|NCT03170271|DRUG|Placebo|Placebo administered as a subcutaneous injection at Visit 4 (day 0), Visit 6 (day 28 +/- 3 days), Visit 7 (day 56 +/- 3 days) and Visit 9 (day 112 +/- 3 days)
224202399|NCT04589793|BEHAVIORAL|Life Style|Life Style intervention including physical activity, diet, sleep and stress
224312591|NCT02446756|OTHER|physiotherapy|
224312592|NCT00269230|DEVICE|Pacing Lead|Left ventricular pacing lead
224312593|NCT02690987|DRUG|Exenatide|"Exenatide is a commercially available GLP-1 receptor agonist. It is a synthetic form of exendin-4, a protein extracted from the saliva of a Gila monster lizard, which exhibits 53% sequence identity to human GLP-1.~The planned intravenous Exenatide infusion dose is expected to be 0.06 pmol/kg/min aiming for maintenance plasma concentrations of \~130-190 pg/mL."
223510392|NCT05965466|PROCEDURE|Total gastrectomy and radical resection|Total gastrectomy and Roux-en-Y anastomosis
223510393|NCT03371225|DEVICE|Active tDCS|Active tDCS: A 1x1 Low-intensity DC Stimulator will be used to deliver direct current through rubber electrodes in saline soaked sponges. The anode will be placed over the left primary motor cortex (M1) while the cathode will be placed over the contralateral supra-orbital area. 20 minutes of tDCS will be applied.
223510394|NCT03371225|PROCEDURE|Active Exercise|Participants will walk briskly in a treadmill (as to keep at 60-70% maximum heart rate) for 30 minutes
224202400|NCT02231671|DRUG|ALS-008176|
224202401|NCT02231671|DRUG|ALS-008112|
223761036|NCT06034613|BEHAVIORAL|internet-based mindfulness intervention for emotional distress(iMIED）|The iMIED program integrates the rationales and practices from the UP and MBIs. Formal mindfulness exercises (e.g., body scan, mindful breathing, and mindful stretching) and informal mindfulness practices (e.g., mindful tooth brushing) were adapted from MBIs. In addition, the iMIED program selected several important tasks from the UP, like practicing tolerating uncomfortable feelings by interoceptive exposure practices (e.g., rapid breathing), identifying avoidant behaviors and emotion-driven behaviors and reducing them step by step, identifying common maladaptive automatic thoughts (e.g., overestimating probability and catastrophizing), and using the above strategies in daily life by completing challenging tasks. In total, it took about 30 min per day to finish all the tasks. The program lasted for 49 days.
223761037|NCT02983006|BIOLOGICAL|DS-8273a|"* Starting Dose: 4 mg/ kg IVQ 3 weeks (Cohort 1)~* Dose Escalation: 8 mg/kg IV Q 3 weeks (Cohort 2), 16 mg/kg IV Q 3 weeks (Cohort 3), 24 mg/kg IV Q 3 weeks (Cohort 4), 2 mg/kg IV Q 3 weeks (Cohort -1), 4 mg/kg IV Q 3 weeks (Cohort -2)"
223616538|NCT02307708|DEVICE|8° incline shoe|"Wearing inclined shoes for 6 weeks, walking 15 minutes (2 times/day).~The shoe is inclined from front to back and from top to bottom of 8 °. This causes a controlled and an eccentric contraction during the passage.~During the walk we will have:~In support tardigrade : an ankle dorsiflexion with a stretching the Achilles tendon (eccentric contractions).~In support digitigrade: plantar flexion of ankle with a muscle contraction of triceps surae (concentric contraction)."
223616539|NCT02307708|OTHER|kinesitherapy|Daily eccentric contraction at home and once per week for 6 weeks with the physiotherapist
223616540|NCT04363203|DRUG|Hydroxychloroquine|Hydroxychloroquine: 2x200mg mg .PO in the AM and 2x200mg PO in the PM on Day 1, followed by 200mg PO in the AM and 200 mg PO in the PM on Days 2-5.
223616541|NCT04363203|DRUG|Azithromycin|Azithromycin: 2x250mg by mouth (PO) in the AM on Day 1, followed by 250mg PO every day on Days 2-5.
223616542|NCT04363203|DRUG|Placebo oral tablet|Placebo in pill packs identical to study drugs
223761038|NCT02983006|BIOLOGICAL|Nivolumab|5 mg/kg IV Q 3 weeks
223761039|NCT04098458|BEHAVIORAL|NDURE|NDURE consists of 6 key functions including (1) Improve patient knowledge about guidelines for timely PORT and associated care processes; (2) Minimize the burden of travel for HNSCC care; (3) Improve communication between patients and providers regarding intentions and goals for timely, guideline-adherent PORT; (4) Enhance coordination of care between healthcare teams during care transitions and about treatment sequelae; (5) Track referrals to ensure timely scheduling of appointments and patient attendance across fragmented healthcare systems; (6) Restructure the organization to clarify roles and responsibilities for care processes associated with PORT delivery to avoid duplication and gaps in care. Direct contact between the NDURE navigator and patient occurs via three clinic-based, face-to-face NDURE sessions lasting 30-60 minutes each at the pre-surgical consult, hospital discharge, and first postoperative visit.
224202402|NCT01144988|DRUG|Bevacizumab / Irinotecan|Bevacizumab (10mg/kg KG) Irinotecan (125 mg/ m2 or 340 mg/m2 depending on usage of EIAED)
224202403|NCT05131893|DRUG|Tamoxifen|endocrine therapy
224202404|NCT05131893|DRUG|Goserelin|endocrine therapy
224202405|NCT05131893|DRUG|Letrozole 2.5Mg Tab|endocrine therapy
224202406|NCT05131893|DRUG|Epirubicin|chemotherapy
224202407|NCT05131893|DRUG|cyclophosphamide|chemotherapy
224202408|NCT05131893|DRUG|Docetaxel|chemotherapy
224202409|NCT05131893|DRUG|paclitaxel|chemotherapy
224202410|NCT05131893|DRUG|trastuzumab|biological treatment
224202411|NCT05131893|DRUG|pertuzumab|biological treatment
224202412|NCT05131893|DRUG|Capecitabine|chemotherapy
224312594|NCT02690987|BIOLOGICAL|Desacyl ghrelin|"Ghrelin is a 28 amino acid stomach-derived peptide hormone, with the desacyl ghrelin (DAG) form inactive at the GHSR1a receptor. Good Manufacturing Practice (GMP)-grade DAG is obtained from Clinalfa (Bachem AG, Bubendorf, Switzerland).~The planned intravenous DAG infusion dose is expected to be 4.0 mcg/kg/hour aiming for maintenance plasma concentrations of \~13-19 ng/mL."
224312595|NCT02690987|BIOLOGICAL|Saline|The placebo visit will involve an intravenous infusion of normal saline.
223616543|NCT03262220|RADIATION|Volumetric Arc Therapy (VMAT)|Total Marrow Irradiation: 12 Gy in 3 fractions of 4 Gy on 3 consecutive days with a concomitant simultaneous integrated boost (SIB) of 4.5 Gy x 3 fractions delivered to active bone marrow (ABM).
224202413|NCT01080911|DRUG|Morphine|spinal morphine 0.05 mg
224202414|NCT01080911|DRUG|Morphine|spinal morphine 0.1 mg plus 0.5% heavy marcaine 3.5 ml
223616544|NCT04204707|OTHER|PROMS|Patient Reported Outcomes after different types of surgery for rectal endometriosis
223616545|NCT01847963|DRUG|Sindhuvallathy mezhugu ( SVM)|500 mg capsules per oral twice daily for 45 days a Siddha classical literature preparation
223616546|NCT01847963|DRUG|Kalladaippu Kudineer (KK) -|130 ml decoction twice daily-per oral for 45 days, a Siddha classical literature preparation
223616547|NCT00860730|DEVICE|Aortic valve replacement with Perceval aortic heart valve|Replacement of diseased or malfunctioning native aortic valve via traditional surgery (open chest) with the Perceval S prosthesis
224202415|NCT01915485|RADIATION|Lu 177|Patients will be submitted to 4 cycles of 177-Lu with 200mCi each
224202416|NCT01048411|DRUG|Naja-comp.|homeopathic remedy
224202417|NCT01048411|DRUG|Placebo|s.c. injection of NaCl-solution three times a week
224202418|NCT00915980|PROCEDURE|gastric bypass surgery and testing|The patients will be tested with OGTT and meal testing before and after undergoing gastric bypass surgery.
224202419|NCT05912153|DIAGNOSTIC_TEST|SPECT/CT|SPECT/CT of the foot and ankle
224202420|NCT05912153|DIAGNOSTIC_TEST|MRI|MRI of the foot and ankle
224202421|NCT05778227|DRUG|Ethylene Diamine Tetra Acetic acid|Final irrigation will be done with 5ml of EDTA for 1min which is the gold standard and compare it with experimental irrigants.
224202422|NCT05778227|DRUG|smearOFF|Final irrigation of root canal treatment procedure will be done with 5ml of smearOFF for 1min.
224202423|NCT05778227|DRUG|Etidronic acid /sodium hypochlorite|During whole procedure of cleaning and shaping combination product of HEBP/NaOCl will be used
224202424|NCT05778227|DRUG|Maleic acid|Final irrigation of root canal treatment procedure will be done with 5ml of maleic acid for 1min.
224202425|NCT00535873|DRUG|Lenalidomide|Starting dose of 5 mg (capsules) by mouth daily for 28 days, one cycle.
224202426|NCT03753893|OTHER|No intervention used|no intervention used
224312596|NCT03074344|DEVICE|XLHA+CoQ10|XLHA+CoQ10 for four times a day for 12 weeks.
224202427|NCT06565520|DEVICE|transcranial direct current stimulator|"The total amount of participation time per qualified subject will be approximately 150 minutes over two sessions. The participant screening session will take approximately 30 minutes, which is an appropriate amount of time to complete all screening tasks. The tDCS and sham sessions will take approximately a total of 120 minutes over two sessions.~The first session will include a screening (30 minutes) to ensure they qualify for the study, followed by a treatment session (60 minutes): including non-invasive brain stimulation combined with hip strengthening exercises and functional movement testing at UNLV Maryland Campus. Subjects will return for a second treatment session (60 minutes) 2 weeks after the first."
224312597|NCT03074344|DEVICE|Hyaluronic acid (HA)|Hyaluronic acid (HA) for four times a day for 12 weeks.
224202428|NCT02466776|DEVICE|Absorbable subcuticular suture|Patients will receive absorbable subcuticular suture for skin closure at time of cesarean delivery (CD).
224312598|NCT01823497|DRUG|Morphine|Morphine will be used to control pain post-surgery.
224312599|NCT02474277|OTHER|30 sec chair stand test|diagnostic test for functional impairment
224202429|NCT02466776|DEVICE|Stainless steel staples|Patients will receive stainless steel staples for skin closure at time of cesarean delivery (CD).
224202430|NCT00632476|OTHER|Placebo|Placebo capsule once a day
224202431|NCT00632476|DIETARY_SUPPLEMENT|Vitamin C|A 500-mg vitamin C capsule once a day
224202432|NCT03724591|PROCEDURE|a high ligation of IMA|total mesorectal excision (TME) for rectal cancer by a high ligation of IMA without preservation of left colic artery
224202433|NCT03724591|PROCEDURE|a low ligation of IMA|total mesorectal excision (TME) for rectal cancer by a low ligation of IMA with preservation of left colic artery
224202434|NCT03123120|DRUG|Spesolimab|12 weeks treatment
224202435|NCT03123120|DRUG|Placebo|12 weeks treatment
224312600|NCT04403828|OTHER|Survey|a cross-sectional, online survey-based study administered to Dentist in Egypt. A 20-item questionnaire developed and distributed using Google Forms.
224312601|NCT05884944|PROCEDURE|Sham- Light touch, not reaching restrictive barrier|Sham- Light touch, not reaching restrictive barrier For the control group, the subjects hip, knee, and ankle joints will be moved bilaterally 3 times into each plane to mimic the OMM muscle energy treatment. The joint will be moved in each plane of motion without reaching the joint barrier. The hip joint will be moved into adduction, extension, and flexion, the knee joint will be moved into extension and flexion, and the ankle will be moved into plantarflexion and dorsiflexion 3 times in each direction without reaching the barrier passively.
224312602|NCT05884944|PROCEDURE|Experimental: Interventional Group- OMM- Muscle energy|The interventional group will received Osteopathic Manipulative Medicine, specifically Muscle energy treatment. An osteopathic manipulative treatment protocol will be applied to the lower extremity joints bilaterally. Muscle energy technique (MET) will be applied to the hip, knee, and ankle bilaterally based on the protocol from Atlas of Osteopathic Techniques. The adductor, extensor, and flexor muscles of the hip joint will be treated, the extensors and flexors of the knee joint will be treated, and the plantar and dorsiflexion muscles of the ankle will be treated. Muscle energy is a direct active treatment asking the subject to move their joint in a direction against a counterforce by the treatment provider for 3 times for 3 seconds and repeating the procedure 3 times and afterwards a passive stretch to the joint is applied by the provider.
224312603|NCT02500043|DRUG|TAS-102|35 mg/m2/dose of TAS-102 orally, twice daily on days 1-5 and days 8-12 of each 28-day cycle.
224312604|NCT02500043|DRUG|Placebo|35 mg/m2/dose of placebo orally, twice daily on days 1-5 and days 8-12 of each 28-day cycle.
224312605|NCT02856555|DRUG|Firsocostat|Capsules orally once daily.
224312606|NCT02856555|DRUG|Placebo|Placebo matched to firsocostat orally once daily.
223510395|NCT03371225|DEVICE|Sham tDCS|Active tDCS: A 1x1 Low-intensity DC Stimulator will be used to deliver direct current through rubber electrodes in saline soaked sponges. The anode will be placed over the left primary motor cortex (M1) while the cathode will be placed over the contralateral supra-orbital area. Only 30 seconds of current will be applied for the sham condition.
223510396|NCT03371225|PROCEDURE|Sham Exercise|Participants will walk in a treadmill (as to keep at 10% within their baseline heart rate) for 30 minutes.
223510397|NCT00986102|DRUG|doripenem|500mg vial by injection every 8 hours for 5 to 14 days
223510398|NCT06325852|OTHER|DBS programing|The physician will utilize the Boston Scientific Chronos Clinician Programmer (software) to make adjustments to the Deep Brain Stimulation (DBS) settings for the patients.
223510399|NCT06800183|DRUG|Four-Chamber Tartrazine Patch across 3 Body Sites|This is a chamber patch comprising four increasing doses of tartrazine (0.15M, 0.3M, 0.6M, 1.2M). This will be applied on the forearm, abdomen, and back to represent different skin thicknesses.
223510400|NCT06083493|DEVICE|LIFUP excitation|The experimental will consist of a 10-minute baseline period (LIFUP-OFF) followed by four 10-minute sessions of stimulating (LIFUP-ON-excitation) four thalamic areas. The order of thalamic area stimulation will be counterbalanced across participants and will include the ventral anterior (VA), dorsal anterior (DA), ventral posterior (VP), and dorsal posterior (DP) sections of the thalamus.
223510401|NCT06083493|DEVICE|LIFUP inhibition|The experimental will consist of a 10-minute baseline period (LIFUP-OFF) followed by four 10-minute sessions of stimulating (LIFUP-ON-inhibition) four thalamic areas. The order of thalamic area stimulation will be counterbalanced across participants and will include the ventral anterior (VA), dorsal anterior (DA), ventral posterior (VP), and dorsal posterior (DP) sections of the thalamus.
223510402|NCT06378190|BIOLOGICAL|CAR-T cells therapy|CAR-T cells therapy
223510403|NCT02060188|DRUG|Ipilimumab|Specified dose on specified days
223510404|NCT02060188|DRUG|Nivolumab|Specified dose on specified days
223510405|NCT02060188|DRUG|Cobimetinib|Specified dose on specified days
223510406|NCT02060188|DRUG|Daratumumab|Specified dose on specified days
223510407|NCT02060188|DRUG|BMS-986016|Specified dose on specified days
223510408|NCT03270163|DIAGNOSTIC_TEST|Transcutaneous electrical stimulation|"The following tests and measurements will be carried out on the patient within 3 days of inclusion and again between the 4th and 6th day after inclusion and upon awakening:~* three simple electrical stimulations,~* three electrical doublets at the frequency of 100Hz~For each type of electrical stimulation, the stimulations will be carried out 3 times and reproduced at 1 hour intervals."
224202436|NCT00203892|BIOLOGICAL|modified CEA peptide (10mcg)|Vaccine contained the modified CEA peptide (10mcg), Montanide ISA-51, and sargramostim (GM-CSF) 250mcg. Vaccine was administered on Day 1 of each 14 day cycle until progressive disease or dose-limiting toxicity for a maximum of 24 cycles. Vaccine administration site was the proximal thigh.
224202437|NCT00203892|BIOLOGICAL|modified CEA peptide (100mcg)|Vaccine contained the modified CEA peptide (100mcg), Montanide ISA-51, and sargramostim (GM-CSF) 250mcg. Vaccine was administered on Day 1 of each 14 day cycle until progressive disease or dose-limiting toxicity for a maximum of 24 cycles. Vaccine administration site was the proximal thigh.
224202438|NCT00203892|BIOLOGICAL|modified CEA peptide (1000mcg)|Vaccine contained the modified CEA peptide (1000mcg), Montanide ISA-51, and sargramostim (GM-CSF) 250mcg. Vaccine was administered on Day 1 of each 14 day cycle until progressive disease or dose-limiting toxicity for a maximum of 24 cycles. Vaccine administration site was the proximal thigh.
224202439|NCT05922592|PROCEDURE|crestal sinus lift using ballon technique|The sinus membrane will be elevated by using balloon technique with simultaneous Implant placement.
224202440|NCT05922592|PROCEDURE|crestal sinus lift using densah burs|The sinus membrane will be elevated by using Densah burs with simultaneous Implant placement
224202441|NCT00137462|DRUG|torcetrapib/atorvastatin|
224202442|NCT00137462|DRUG|atorvastatin|
224202443|NCT06150001|DRUG|rocuronium-normal-saline mixture|rocuronium will be pre-diluted with 2mL of normal saline. Researchers will inject the mixture into intravenous catheter.
224202444|NCT06150001|DRUG|rocuronium-lidocaine mixture|rocuronium will be pre-diluted with 2mL of 2%lidocaine. Researchers will inject the mixture into intravenous catheter.
224202445|NCT06150001|DRUG|rocuronium-blood mixture|Researchers will connect a syringe which contains 0.8mg/kg of rocuronium intravenous catheter, and then withdraw blood into the syringe. Finally inject the mixture into intravenous catheter.
224202446|NCT05477368|DIETARY_SUPPLEMENT|D-β-hydroxybutyric acid with R-1,3-butanediol|Pre-intervention (baseline) and post-intervention measurements will be obtained before and after the 90-day period respectively.
224202447|NCT05477368|OTHER|Inert placebo|Pre-intervention (baseline) and post-intervention measurements will be obtained before and after the 90-day period respectively.
224202448|NCT00806416|DRUG|alendronate sodium (+) cholecalciferol|A single dose tablet of 70 mg alendronate/2800 IU (international unit) vitamin D in one treatment period of each sequence. There will be a 12 day interval between each treatment period.
224202449|NCT00806416|DRUG|Comparator: alendronate|A single dose table of 70 mg alendronate in one treatment period of each sequence. There will be a 12 day interval between each treatment period.
224202450|NCT00806416|DIETARY_SUPPLEMENT|Comparator: cholecalciferol (Vitamin D)|A single dose tablet of 2800 IU vitamin D in one treatment period of each sequence. There will be a 12 day interval between each treatment period.
224202451|NCT00143416|DRUG|Pegvisomant|
224202452|NCT05598619|DIETARY_SUPPLEMENT|Vitamin C|Colon delivered vitamin C (ascorbic acid) for 12 weeks
224202453|NCT05598619|OTHER|placebo|Colon delivered placebo once a day for 12 weeks
223761040|NCT06801535|DEVICE|Splint|Patients will use the splint at home 3 times daily for 10 minutes per session for 3 months total.
223761041|NCT06385587|DEVICE|Oleena|Oleena™ is a software medical device for patients and their healthcare team which digitalizes some aspects of their supportive care, allows remote monitoring by healthcare professionals (HCP) and supports the management of targeted symptoms in adult cancer patients while they are being actively treated for their cancer.
224202454|NCT01596049|DEVICE|Self-fixating Mesh|Using Self-fixating Mesh for Inguinal Hernia Repair
224202455|NCT06014008|OTHER|Test product consumption group|Participants will take one bottle (80 ml) of Yakult® drink daily for a period of 4 weeks. Yakult is a branded probiotic drink with 8x10\^9 CFU Lacticaseibacillus paracasei strain Shirota. Subsequently, a two-week follow-up period will follow.
224202456|NCT01735864|DRUG|Indirubin 200μg/g|"1. Dosage form: Ointment~2. Dose(s): Each gram of ointment containing 200 μg of indirubin~3. Dosing schedule: apply 0.5 g of ointment per 10 x 10 cm psoriatic lesion twice daily"
224202457|NCT01735864|DRUG|Indirubin 100 μg/g|"1. Dosage form: Ointment~2. Dose(s): Each gram of ointment contains 100 μg of indirubin~3. Dosing schedule: apply 0.5 g of ointment per 10 x 10 cm psoriatic lesion twice daily"
224202458|NCT01735864|DRUG|Indirubin 50 μg/g|"1. Dosage form: Ointment~2. Dose(s): Each gram of ointment contains 50 μg of indirubin~3. Dosing schedule: apply 0.5 g of ointment per 10 x 10 cm psoriatic lesion twice daily"
224202459|NCT01735864|DRUG|Indirubin 10 μg/g|"1. Dosage form: Ointment~2. Dose(s): Each gram of ointment contains 10 μg of indirubin~3. Dosing schedule: apply 0.5 g of ointment per 10 x 10 cm psoriatic lesion twice daily"
224312607|NCT03333941|DEVICE|ReCell® Autologous Cell Harvesting Device|RES (Regenerative Epithelial Suspension) derived from the use of the ReCell® device will be applied over skin grafts meshed more widely than conventional autografting.
224312608|NCT03955458|DRUG|EXPAREL|FICB with EXPAREL + Bupivacaine HCL (single dose)
224312609|NCT03955458|DRUG|Ropivacaine|FICB with continuous infusion of ropivacaine
224202460|NCT06567132|PROCEDURE|Non-surgical periodontal treatment|Non-surgical periodontal treatment was performed in a single session using an ultrasonic device and a manual scaler. Polishing was done using polishing paste and rubber cup. Clinical periodontal indices, saliva and gingival crevicular samples were repeated after six weeks follow-up period.
224202461|NCT00513578|BIOLOGICAL|PR1 leukemia peptide vaccine|
224202462|NCT00513578|BIOLOGICAL|incomplete Freund's adjuvant|
224202463|NCT00513578|BIOLOGICAL|sargramostim|
224202464|NCT03914209|OTHER|EHL clotting factor|This study shall not implement any intervention that might alter the normal development of the daily life activities of hemophilia patients included in the study. They will continue with the prophylactic regimen prescribed by their hematologist. Patients will also be asked to continue to develop their physical, work, entertainment and leisure activities in the same way as at baseline.
224202465|NCT02310815|DEVICE|ReSure Sealant|
224202466|NCT00722007|DEVICE|Cormet Hip Resurfacing|Cormet Hip Resurfacing implant
224202467|NCT00081978|DRUG|TMC125|
224202468|NCT01596088|DRUG|Dexrazoxane|
224202469|NCT02149277|DRUG|Filgrastim|The fertility specialist will inject the study medication or its placebo on the 6th day of gonadotrophin stimulation for IVF subjects. For the subjects undergoing embryo transfer, the injection will be done once the endometrial lining measure more than 8mm.
224202470|NCT00670527|PROCEDURE|[18F] Fluorocholine PET/CT|"The patients fast 6 hours before the \[18F\]Fluorocholine PET/CT scan. \[18F\]Fluorocholine will be used as tracer with a dosage of 4 MBq per kg bodyweight. PET/CT imaging will be performed after 15 and 60 after the intravenous injection of the tracer. The patient will receive 2 full body FCH PET/CT. The CT scan is with contrast.~The radiation exposure from the CT scan is 9 mSv and from the PET scan it is 3 mSv, giving a total of 12 mSv, which equals 4 times the yearly background radiation in Denmark."
224202471|NCT01394120|DRUG|Targeted Therapy Tailored Treatment|"Targeted therapy tailored treatment, based on molecular determination in pancreas cancer specimen~* Tim Synthase (TS) (neg), ERCC-1 (neg), Topoisomerase I (Topo I) (pos) : FOLFIRINOX~* TS (neg), ERCC-1 (neg), Topo I (neg): FOLFOX~* TS (neg), ERCC-1 (pos), Topo I (pos): FOLFIRI~* TS (neg), ERCC-1 (pos), Topo I (neg): Capecitabine/Gemcitabine~* TS (pos), EGFR Not Amplificate, K-Ras Mutation (pos) : Gemcitabine single agent~* TS (pos), EGFR Ampl or K-Ras mut (neg): Gemcitabine plus Erlotinib"
224202472|NCT01394120|DRUG|Standard Chemotherapy|Patients treated based on investigator´s criteria: : FOLFIRINOX, FOLFOX, FOLFIRI, Capecitabine-Gemcitabine, Erlotinib-Gemcitabine or Gemcitabine single agent
224202473|NCT02989922|BIOLOGICAL|SHR-1210|SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody
224202474|NCT01244516|DEVICE|galyfilcon A, BC 8.30|galyfilcon A, BC 8.30 soft contact lens
224202475|NCT01244516|DEVICE|lotrafilcon B, BC 8.60|lotrafilcon B, BC 8.60 soft contact lens
224202476|NCT01244516|DEVICE|comfilcon A, BC 8.60|comfilcon A, BC 8.60 soft contact lens
224202477|NCT05982158|BEHAVIORAL|Avatar therapy|Seven 50-minute therapy sessions conducted by videoconferencing.
224202478|NCT05982158|BEHAVIORAL|Cognitive behavioural therapy (CBT)|Seven 50-minute therapy sessions conducted by videoconferencing.
224202479|NCT04045834|DEVICE|68Ga-DOTA-TATE PET/MR and PET/CT imaging|Intravenous access is established in advance, intravenous bolus injection, 68Ga-DOTA-TATE dose is about 2 MBq/kg body weight (0.054 mCi/kg) up to 200 MBq (5.4 mCi), 18F-FDG dose is about 3.7-5.4 MBq/kg (0.1 -0.15 mCi/kg), rinsed with 0.9% saline, and hydrated after drinking more water.
224202480|NCT02215434|DRUG|Biolipid B2 (blanked/placebo)|the intervention will be the comparison effects of both emulsions
224202481|NCT02215434|DRUG|Testosterone, Transdermal, Behavior|Transdermal 0.5% testosterone Biolipid/B2
224202482|NCT01700335|DRUG|SyB L-1101|"SyB L-1101（rigosertib sodium） will be administered to two cohorts at either 1200 mg/day or 1800 mg/day.~The dose will be administered intravenously for 72 continuous hours (3 days), followed by 11-day observation period. The treatment period of 14 days (3 days of administration + 11 days of observation) constitutes 1 cycle.~The study will involve treatment through the second cycle, but treatment can be continued for 3 or more cycles if conditions for continued administration are satisfied."
224202483|NCT04256135|OTHER|Mulligan mobilization|Mobilization will be performed while the patient actively performs knee flexion and/or extension depending on the patient's painful or limited movements. Three series of ten repetitions will be performed.
224202484|NCT04256135|OTHER|AP Maitland mobilization|The joint mobilization, will be carried out in the knee with both hands, with displacement of the tibia from the front to the back of the femur in an oscillatory way without pain, will be carried out in blocks of 2 minutes with rests of 30 seconds with a duration of about 6 minutes.
224202485|NCT00878735|BEHAVIORAL|Zen meditation|Zen meditation retreat (7 days: 5 days from 5:30 to 9:30 plus one day for adaptation and the departure day). The program starts everyday at 5:30 and finish at 9:30. In silence, the volunteers perform seating and walking meditation, stretching exercises, eating and all tasks in mindfulness.
224202486|NCT05105035|DRUG|Ceftazidime or meropenem|Patients will be prescribed ceftazidime or meropenem intravenously as per standard of care for at least 14 days while in the hospital
224202487|NCT05105035|DRUG|ARV-1801|Patients will be prescribed ARV-1801 at 1500mg 12 hours apart on Day 1 and 600mg every 12 hours for Days 2-14.
224202488|NCT05105035|DRUG|Placebo|Patients will be prescribed placebo every 12 hours for Days 1-14.
224202489|NCT01402193|DRUG|Pre-radiotherapy commencement of Arimidex|Arimidex:1mg P.O. daily will be prescribed for 8 weeks in post-mastectomy patients and 9 weeks in BCT patients within the study period. Arimidex starts 3 weeks before adjuvant radiotherapy and throughout the course of radiotherapy.Total duration of adjuvant hormonotherapy is prescribed by the investigators at the completion of study, 5 years in principle.
224312610|NCT03955458|DRUG|Bupivacaine Hydrochloride|FICB with EXPAREL + Bupivacaine HCL (Single dose)
223510409|NCT03270163|DIAGNOSTIC_TEST|Magnetic stimulation|"The following tests and measurements will be carried out on the patient within 3 days of inclusion and again between the 4th and 6th day after inclusion and upon awakening:~* three simple magnetic stimulations,~* three magnetic doublets at the frequency of 100Hz~For each type of magnetic stimulation, the stimulations will be carried out 3 times and reproduced at 1 hour intervals."
223510410|NCT03270163|DIAGNOSTIC_TEST|ultrasound measurement|The ultrasound measurement of the thickness of the quadriceps muscle will be carried out on the patient within 3 days of inclusion and again between the 4th and 6th day after inclusion and upon awakening.
223510411|NCT06639113|BEHAVIORAL|Self-administration medicines|Management of drugs' administration by the patient
223510412|NCT06643910|BIOLOGICAL|Single drug group A|9x10\^10 BST08 cells, Intravenous infusion，3 subject is planned to be enrolled
223510413|NCT06643910|BIOLOGICAL|Combined treatment group B|9x10\^10 BST08 cells+ Pembrolizumab Injection，200mg，Q3W, Intravenous infusion，6subject is planned to be enrolled
223510414|NCT02430610|PROCEDURE|Irreversible electroporation (IRE)|Irreversible Electroportion For Unresectable Uterine Cervical Neoplasms guide with ultrasound or/and CT.
223510415|NCT02430610|DEVICE|NanoKnife|
223616548|NCT04045327|DRUG|Normal saline + Standard Treatment|Normal Saline to be Used as Vehicle in the Phase-III Study to Assess Efficacy of PMZ-2010 as a Resuscitative Agent for Hypovolemic Shock
223616549|NCT04045327|DRUG|Centhaquine + Standard Treatment|Phase-III Study to Assess Efficacy of PMZ-2010 as a Resuscitative Agent for Hypovolemic Shock
223616550|NCT02426840|DIETARY_SUPPLEMENT|High dose vitamin D and calcium|participants will receive a FDC tablet containing 1500 mg of calcium carbonate (equivalent to 600 mg of elemental calcium) and 200 IU of vitamin D3. This drug will be administered as 1 tablet orally twice daily and is to be taken with food. In addition, participants will receive vitamin D2 capsule containing 20,000 IU of ergocalciferol, which will be administered as 1 capsule orally once weekly at any time (not related with meal).
223761042|NCT00006489|BEHAVIORAL|Cognitive-Behavioral Therapy|Twelve weekly 90-minute individual therapy sessions followed by (6) 90-minute sessions every other week
223761043|NCT00006489|DRUG|Naltrexone|Daily dosing 100 mg for 24 weeks
223761044|NCT00006489|DRUG|Placebo|Pill Placebo daily dosing 24 weeks
223761045|NCT00984581|DRUG|Avotermin|Intradermal injection, 5ng/100ul/linear cm wound margin administered on Day 0, Day 1 and month 6
223761046|NCT00984581|DRUG|Avotermin|Intradermal injection, 50ng/100ul/linear cm wound margin administered on Day 0, Day 1 and month 6
223761047|NCT00984581|DRUG|Placebo|Intradermal injection, 100ul/linear cm wound margin administered on Day 0 and Day 1
223761048|NCT01968018|DRUG|Tramadol HCI/acetaminophen|Participants will receive tablet of tramadol HCI (37.5 mg)/acetaminophen (325 mg) on Day 1. Participants may increase their daily dosage of study medication is 1 to 2 tablets every 4 to 6 hours as needed for pain relief up to maximum of 8 tablets per day.
223761049|NCT05583903|OTHER|Virtual Reality Software|The ReCognition virtual reality software is delivered via an Oculus Quest 2 device. This three-dimensional simulated software was designed to improve attention and executive functions.
223761050|NCT01533246|DRUG|linsitinib|Oral Linsitinib 150mg, twice a day, days 1- 28
223761051|NCT01533246|OTHER|laboratory biomarker analysis|Correlative studies
223761052|NCT05180903|OTHER|X-tra base & GrandioSO reinforced by Ribbond|The missing peripheral tooth structure will be built up via 2-mm wedge-shaped a universal hybrid resin composite, GrandioSO . Then the polyethylene fibers will be wetted with an unfilled resin first . After removing the excess resin, fibers will be covered with a very thin layer of flowable composite X-tra base . After that, fibers will be bonded immediately against the peripheral missing walls and cured for 20 seconds. Then a bulk-fill flowable resin composite lining X-tra base will be applied in approximately 4 mm thick in bulk increments as needed to fill the cavity 2 mm short of the occlusal cavosurface and each increment will be light cured for 20 s. The remaining occlusal part of the cavity will be restored with a universal hybrid resin composite, GrandioSO . The shade of the composite will be selected according to the teeth to be restored. All cavities will be restored with open-sandwich technique (Deliperi, et al. 2017).
223761053|NCT02567513|BEHAVIORAL|Supplement Intervention|Supplements given twice/day, 5 days/week, for 24 weeks by research staff.
223761054|NCT02567513|BEHAVIORAL|Snack Intervention|Snacks given twice/day, 5 days/week for 24 weeks by research staff.
223761055|NCT01546116|DRUG|ADEFOVIR, LAMIVUDINE|Adefovir/10mg tablet/once a day/52week Lamivudine/100mg tablet/once a day/52week
223761056|NCT01217918|DRUG|1 mg|1 mg or placebo a material sparing tablet per day for 10 days
223761057|NCT01217918|DRUG|5 mg|5 mg or placebo as material sparing tablet per day for 10 days
223761058|NCT01217918|DRUG|10 mg|10 mg or placebo as a material sparing tablet per day for 10 days
224312611|NCT01342601|DEVICE|ect4allergy Nasal Spray (ANS01) and Eye Drops (AAT01)|Comparison of ANS01 and AAT01 with placebo
223761059|NCT04498962|DRUG|Danzhu Fuyuan Granule|Danzhu Fuyuan Granules，2 times / day, 1 bag / time, one time in the morning and one time in the evening. It is recommended to add the same amount of boiling water as the particles to soak for 30 seconds, and then add 5 times boiling water to dissolve until completely dissolved.The treatment cycle of each arm: 8 weeks for Chronic Stable Angina, 6 months for Vascular Dementia and 6 months for Idiopathic Membranous Nephropathy.
223761060|NCT01427205|DRUG|Cetuximab|Loading dose 400 mg/m2 by vein once followed by 250 mg/m2 weekly (+/- 7 days).
223761061|NCT01427205|DRUG|OSI-906|150 mg by mouth twice a day.
223761062|NCT01427205|OTHER|Placebo|Placebo taken by mouth twice daily.
223761063|NCT03491150|DRUG|Crenezumab|Crenezumab was administered by intravenous (IV) infusion at 60mg/kg as per the dosing schedule described above.
223761064|NCT03012854|PROCEDURE|short-myotomy|"1. Entry to submucosal space. After submucosal injection, a 2-cm longitudinal mucosal incision is made at approximately 8-10 cm proximal to the gastroesophageal junction (GEJ).~2. Submucosal tunnelling. A long submucosal tunnel is created to 3 cm distal to the GEJ.~3. Endoscopic myotomy is carried out in a proximal to distal direction to a total length less than 7 cm. The expected end point of myotomy is 2 cm distal to the GEJ.~4. Myotomy of inner circular muscle bundles and outer longitudinal muscle layer is done.~5. Closure of mucosal entry: the mucosal incision is closed using hemostatic clips."
223761065|NCT03012854|PROCEDURE|long-myotomy|"1. Entry to submucosal space. After submucosal injection, a 2-cm longitudinal mucosal incision is made at approximately 8-10 cm proximal to the gastroesophageal junction (GEJ).~2. Submucosal tunnelling. A long submucosal tunnel is created to 3 cm distal to the GEJ.~3. Endoscopic myotomy is carried out in a proximal to distal direction to a total length more than 7 cm. The expected end point of myotomy is 2 cm distal to the GEJ.~4. Myotomy of inner circular muscle bundles and outer longitudinal muscle layer is done.~5. Closure of mucosal entry: the mucosal incision is closed using hemostatic clips."
223761066|NCT03012854|PROCEDURE|full-thickness myotomy|"1. Entry to submucosal space. After submucosal injection, a 2-cm longitudinal mucosal incision is made at approximately 8-10 cm proximal to the gastroesophageal junction (GEJ).~2. Submucosal tunnelling. A long submucosal tunnel is created to 3 cm distal to the GEJ.~3. Endoscopic myotomy is carried out in a proximal to distal direction to a total length more than 7 cm. The expected end point of myotomy is 2 cm distal to the GEJ.~4. Myotomy of inner circular muscle bundles and outer longitudinal muscle layer is done.~5. Closure of mucosal entry: the mucosal incision is closed using hemostatic clips."
223510416|NCT00777673|DRUG|Bevacizumab, nab-paclitaxel, carboplatin, doxorubicin hydrochloride, cyclophosphamide, PEG-Filgrastim|"Eligible patients will receive:~* nab-paclitaxel IV on days 1, 8, and 15. Treatment will be repeated every 28 days 28 days for 4 courses.~* Carboplatin IV on day 1. Treatment will be repeated every 28 days for 4 courses.~* Bevacizumab IV on days 1 and 15. Treatment will be repeated every 28 days for 4 courses.~After completion of the above regimen, patients will receive:~* Doxorubicin IV on day 1. Treatment will be repeated every 14 days for 4 courses.~* Cyclophosphamide IV on day 1. Treatment will be repeated every 14 days for 4 courses.~* Bevacizumab IV on day 1. Treatment will be repeated every 14 days for 2 courses.~Patients will then proceed with:~\- Surgery including axillary staging~A minimum of 4 weeks post operatively, patient will receive:~\- Bevacizumab IV on days 1 and 15. Treatment will be repeated every 28 days for 8 courses."
223510417|NCT05052307|DRUG|Pfizer/BioNTech BNT162b2 mRNA COVID-19 vaccine|Pfizer/BioNTech BNT162b2 mRNA COVID-19 vaccine
224312612|NCT01342601|DEVICE|Placebo products|Nasal Spray and Eye drops without Ectoin
224312613|NCT04984343|RADIATION|Radiation Therapy|"Eligible subjects will be randomly assigned to 5 or 2 fraction treatment groups in a 1:1 ratio using a computer-generated randomization scheme.~After consent and eligibility verification, patients will undergo CT/MRI simulation and radiotherapy planning. Patients will receive treatment to the prostate +/- seminal vesicles per treating physician's discretion in either 37.5 Gy in 5 fractions or 25 Gy in 2 fractions. SIB use is at treating physician's discretion and should be concordant with imaging and biopsy findings with no PTV expansion.~Subjects on 5 fraction arm should be treated on non-consecutive days. Subjects on the 2 fraction arm must have \>72 hours between beginning of each fraction."
224312614|NCT03155321|OTHER|It's an observational study - no intervention is planned|No intervention is planned
224312615|NCT02932306|DRUG|IDP-121 Lotion|IDP-121 lotion will be applied as per the instructions provided by the investigational center staff.
224312616|NCT02932306|DRUG|IDP-121 Vehicle Lotion|IDP-121 vehicle lotion will be applied as per the instructions provided by the investigational center staff.
224312617|NCT03163524|OTHER|e-Coupon Text Modification and Reminders|The treatment group will receive a modified text of the current e-coupon. They will also receive notification that they have been enrolled in the study via a second text. They will also receive a series of text message reminders to redeem their e-coupons at intervals of 6, 13 and 18 days after coupon origination.
224312618|NCT03163524|OTHER|e-Coupon standard text|Participants receive control text (SMS) message, which contains a numeric coupon code and no additional text to the standard coupon.
223510418|NCT05052307|DRUG|CoronaVac COVID-19 vaccine|CoronaVac COVID-19 vaccine
223510419|NCT05052307|DRUG|ChAdOx1 nCoV-19 Covid-19 Vaccine|ChAdOx1 nCoV-19 Covid-19 Vaccine
223510420|NCT05052307|DRUG|Ad26.COV2.S COVID-19 Vaccine|Ad26.COV2.S COVID-19 Vaccine
223510421|NCT00445120|DRUG|Lactobacillus Rhamnosus GG|patients are treated with oral Lactobacillus Rhamnosus GG once daily for six months
223510422|NCT00445120|DRUG|placebo (sugar)|Placebo will be administered to patients once daily for six months
223510423|NCT00510471|DRUG|autologous immunoglobulin idiotype-KLH conjugate vaccine|
223510424|NCT03422471|OTHER|Hyperinsulinemic Hypoglycemic Clamp|Participants will receive two 90 minute sessions of hypoglycemia. Baroreflex sensitivity will be assessed before, after, and during the sessions.
223510425|NCT06131593|DRUG|TAPB with dexamethasone as an adjuvant to local anesthetics|patients will receive TAPB with dexamethasone as an adjuvant to bupivacaine and lidocaine local anesthetics
223510426|NCT06131593|DRUG|TAPB with methylprednisolone as an adjuvant to local anesthetics|patients will receive TAPB with methylprednisolone as an adjuvant to bupivacaine and lidocaine local anesthetics
223510427|NCT03587103|BEHAVIORAL|Protocol initiate with A|The BP-lowering medication adjustment and titration will follow A-AC-ACD or A-AD-ADC for individuals randomized to A or two-drug combination therapy with full dose of A in their initial medication assignment.
223510428|NCT03587103|BEHAVIORAL|Protocol initiate with C|The BP-lowering medication adjustment and titration will follow C-CA-CAD or C-CD-CDA for individuals randomized to C or two-drug combination therapy with full dose of C in their initial medication assignment.
223510429|NCT03587103|BEHAVIORAL|Protocol initiate with D|The BP-lowering medication adjustment and titration will follow D-DA-DAC or D-DC-DCA for individuals randomized to D or two-drug combination therapy with full dose of D in their initial medication assignment.
223510430|NCT04506710|BEHAVIORAL|Audio recording of the counseling conversation|The patient will have an audio-recorded counseling conversation. Audio recording will be carried out using a portable recorder ZOOM H2n. The audio recordings of the counseling conversations will be performed by the health workers selected to participate in the study.
223510431|NCT00655798|DIETARY_SUPPLEMENT|Placebo|plain yogurt and capsules containing cellulose
223510432|NCT00655798|DIETARY_SUPPLEMENT|Plain Yogurt + mix of anti-oxidants capsules|plain yogurt and capsules containing mix of anti-oxidants
223510433|NCT00655798|DIETARY_SUPPLEMENT|Yogurt containing Lactobacillus helveticus|Yogurt containing the probiotic Lactobacillus helveticus
223616551|NCT02426840|DIETARY_SUPPLEMENT|Normal dose vitamin D and calcium|participants will receive a FDC tablet containing 1500 mg of calcium carbonate (equivalent to 600 mg of elemental calcium) and 200 IU of vitamin D3. This drug will be administered as 1 tablet orally twice daily and is to be taken with food
223616552|NCT00055835|DRUG|carboplatin|\*AUC=5 (by modified Calvert formula), IV, over 15 minutes; given q 21 days for a maximum of 3 cycles (1 cycle = 21 days)
223616553|NCT00055835|DRUG|cisplatin|75 mg/m2 (maximum dose 150 mg), IV, rapid infusion; given q 21 days for 2 cycles (1 cycle = 21 days)
223616554|NCT00055835|DRUG|gemcitabine hydrochloride|800 mg/m2, IV, over 30 minutes; given on Days 1 \& 8, q 21 days, for a maximum of 3 cycles (1 cycle = 21 days)
223616555|NCT00055835|DRUG|paclitaxel|200 mg/m2, IV, over 3 hours; given q 21 days for a maximum of 3 cycles (1 cycle = 21 days)
223616556|NCT00055835|PROCEDURE|neoadjuvant therapy|Neoadjuvant chemotherapy (paclitaxel, carboplatin, and gemcitabine)
223616557|NCT00055835|RADIATION|radiation therapy|Radiation treatments will be delivered once daily. Treatment will be given 5 days per week at a dose of 180 to 200 cGy per day. All fields will be treated everyday.
223616558|NCT02588326|DRUG|Mometasone furoate drug formulation (MFF) 1|Mometasone furoate drug formulation (MFF) 1 will be administered by suspension-based nasal spray.
223616559|NCT02588326|DRUG|Mometasone furoate drug formulation (MFF) 2|Mometasone furoate drug formulation (MFF) 2 will be administered by suspension-based nasal spray.
223616560|NCT04579471|DIAGNOSTIC_TEST|SARS-CoV-2 IgG|Collection of clinical variables, assessment of IgG antibodies for SARS-CoV-2, plasma collection for translational immunology studies
223616561|NCT00431626|DRUG|Dutasteride (Avodart)|
223616562|NCT00431626|DRUG|Placebo|Placebo before and after treatment of TURP
223761067|NCT03012854|PROCEDURE|circular myotomy|"1. Entry to submucosal space. After submucosal injection, a 2-cm longitudinal mucosal incision is made at approximately 8-10 cm proximal to the gastroesophageal junction (GEJ).~2. Submucosal tunnelling. A long submucosal tunnel is created to 3 cm distal to the GEJ.~3. Endoscopic myotomy is carried out in a proximal to distal direction to a total length more than 7 cm. The expected end point of myotomy is 2 cm distal to the GEJ.~4. Myotomy of inner circular muscle bundles is done, leaving the outer longitudinal muscle layer intact.~5. Closure of mucosal entry: the mucosal incision is closed using hemostatic clips."
223761068|NCT04333680|DIAGNOSTIC_TEST|Focused Assessment of Sonography for Trauma Exam|Speed and image quality of ultrasound exams performed with either transducer specified in the arms.
223761069|NCT03915288|OTHER|Group continuous training at moderate intensity|70 minutes for intervention, where 10 minutes were warm up (breathing exercises, walking, stretching), 30 minutes of continuous aerobic training at moderate intensity (60-80% FCM), with fast walking or endless tread with the floor inclined to reach the desired intensity. Also on bicycle, rowing and elliptical; Then, 20 minutes of strength training (40-60% maximum strength) with dumbbells and theraban. Ends with 10 minutes of cooling with walking and breathing exercises.
223761070|NCT03915288|OTHER|Group high Intensity Interval Training|70 minutes for intervention, where 10 minutes were for warm-up (Respiratory exercises, walking, stretching), 30 minutes consisted of an intensity of interval training. That is, the participants who underwent 30 minutes of aerobic exercise consisted of a protocol created for this experimental group that we named 30-30. 30 seconds at moderate intensity (60-80% FCM) and 30 seconds at high intensity (80-90%). ; Then, 20 minutes of strength training (40-60% maximum strength) with dumbbells and theraban. Ends with 10 minutes of cooling with walking and breathing exercises.
223761071|NCT03915288|OTHER|Group control|This group did not perform supervised exercise nor were they given exercise recipes or formal intervention programs. Only continued with the usual care and gave directions to maintain a healthy lifestyle based on proper nutrition and usual activities.
223761072|NCT06091553|DRUG|Duloxetine alone|30 mg once daily for 1 week, then 60 mg once daily
223761073|NCT06091553|DRUG|Duloxetine augmented with gabapentin|30 mg once daily for 1 week, then 60 mg once daily 300 mg at bedtime
223761074|NCT06091553|DRUG|Duloxetine augmented with amitriptyline (as combined therapy)|10 to 25 mg once daily at bedtime 30 mg once daily for 1 week, then 60 mg once daily
223761075|NCT00786695|DRUG|esomeprazole|esomeprazole (40 mg o d) for 14 days
223761076|NCT00786695|DRUG|Placebo|Identical looking Placebo, same regimen, for 14 days
223761077|NCT04262336|DRUG|DB-020|Injectable sterile viscous solution of DB-020 and sodium hyaluronate in sterile water
223761078|NCT04262336|DRUG|Placebo|Injectable sterile viscous solution of sodium hyaluronate in sodium chloride
223761079|NCT02735070|DRUG|Resfenol|Patients should take the study medication without breaking or chewing together with a cup containing approximately 200 ml of water. The patient should ingest the study drug after fasting for at least 30 minutes.
223761080|NCT02735070|DRUG|Coristina d|Patients included in the study will take the drugs 4 times a day, orally. Patients should take the study medication without breaking or chewing together with a cup containing approximately 200 ml of water. The patient should ingest the study drug after fasting for at least 30 minutes.
223761081|NCT02315768|DRUG|GA101|
223761082|NCT02315768|DRUG|Ibrutinib|
223761083|NCT04237961|PROCEDURE|Botox and brow lift|Botox injection
223761084|NCT04237961|PROCEDURE|Injection|Fat injection and botox
223761085|NCT04237961|PROCEDURE|Suture|Suspension suture
223761086|NCT06802757|DRUG|Posaconazole|Posaconazole 120mg/m2 po bid d1-14 q21d
223761087|NCT06802757|DRUG|Nab-paclitaxel|Nab-paclitaxel 260mg/m2 d1 q21d
223761088|NCT06802757|DRUG|Carboplatin|Carboplatin AUC=6 d1 q21d
223761089|NCT06802757|DRUG|Anthracycline|Epirubicin 90-100mg/m2 d1 q21d or Doxorubicin 50-60mg/m2 d1 q21d
223510434|NCT00655798|DIETARY_SUPPLEMENT|Yogurt containing Bifidobacterium animalis ssp.|Yogurt containing the probiotic Bifidobacterium animalis ssp.
223510435|NCT05683275|OTHER|IASTM|IASTM will be applied to the affected extremity twice a week for 4 weeks, in total 8 sessions. Participants will be asked to sit comfortably in a chair with back support. IASTM will be applied to the wrist extensor muscles of the participants for 90 seconds in the position where the muscle is tense, with a frequency of 60 beats per minute.
223510436|NCT05683275|OTHER|ESWT|ESWT will be applied to the affected elbow two days a week for 4 weeks, a total of 8 sessions, each session 2000 shock 10 Hz frequency, 2.5 bar intensity point and circumferential application.
223510437|NCT05683275|OTHER|Home Exercise|Special static stretching and eccentric strengthening exercises for the forearm muscles will be taught and they will be asked to perform 2 sets (morning-lunch-evening) 10 repetitions per day, 5 days a week, for 4 weeks.
223510438|NCT02221297|DIETARY_SUPPLEMENT|Supplement product with plant stanol ester|2 grams plant stanols consumed with a meal daily for 3 to 4 weeks
223510439|NCT03839680|PROCEDURE|Endoscopy|The endoscopy procedure uses an endoscope to examine the interior of a hollow organ or cavity of the body.
223761090|NCT06802757|DRUG|Cyclophosphamide|Cyclophosphamide 1000mg/m2 d1 q21d
223761091|NCT06802757|DRUG|Pembrolizumab|Pembrolizumab 200mg d1 q21d
223761092|NCT02877784|PROCEDURE|Videofluoroscopic swallowing study|Videofluoroscopic swallowing study will be performed to measure the oropharyngeal swallowing.
224202490|NCT01402193|DRUG|Post radiotherapy commencement of Arimidex|Arimidex：1mg P.O. daily will be prescribed at 2 weeks after the end of radiotherapy.Total duration of adjuvant hormonotherapy is prescribed by the investigators at the completion of study, 5 years in principle.
224202491|NCT01402193|RADIATION|Radiotherapy|Radiotherapy is delivered to the whole breast/chest wall +/- regional lymph nodes to a total dose of 50Gy/25 fractions/5weeks, an additional tumor bed boost of 10Gy/5 fractions/1week is delivered to patients with breast conservative surgery
223761093|NCT02877784|OTHER|Functional Oral Intake Scale|The Functional Oral Intake Scale (FOIS) will be used for participants to report their food intake habits.
223761094|NCT02877784|OTHER|Eating Assessment Tool-10|The Eating Assessment Tool-10 will be used for participant reporting of swallowing system severity.
223761095|NCT04277988|DEVICE|Ultrasonography|Length of Posterior Longitudianl Ligament, Ligamentum Flavum and Interlaminar distance visible in paramedian longitudinal view during lumbar spine ultrasonography in cross legged position will be compared to standard sitting position.
223761096|NCT02647034|OTHER|no intervention|no intervention
223761097|NCT01125215|DRUG|0.75% capsaicin nanoparticle cream|0.75% capsaicin nanoparticle cream apply to area with neuropathic pain twice daily for 12 weeks
223761098|NCT01125215|DRUG|Placebo|Identical cream base of nanoparticle apply to area with neuropathic pain twice daily for 12 weeks
223761099|NCT04995016|DRUG|Pembrolizumab|PD-1 inhibitor，Pembrolizumab 200mg IV, every 3 weeks.
223761100|NCT04995016|DRUG|Axitinib|Tyrosine kinase inhibitor，licensed for use in treatment of renal cell carcinoma. Oral treatment Axitinib given 5 mg PO BID.
224202492|NCT01402193|RADIATION|Radiotherapy|Radiotherapy is delivered to the whole breast/chest wall +/- regional lymph nodes to a total dose of 50Gy/25 fractions/5weeks, an additional tumor bed boost of 10Gy/5 fractions/1week is delivered to patients with breast conservative surgery
224202493|NCT04692753|OTHER|Training and education|Training and education of health care workers in the form of online seminars and bed side demonstration of care and maintenance of venous access devices
224202494|NCT03837340|OTHER|CMHT|Community mental health teams (CMHTs) delivering evidence-based interventions to people with SMI, inspired by the Flexible Assertive Community Treatment (FACT) service delivery model.
224202495|NCT03837340|OTHER|CAU|Care as usual (CAU) usually consisting of inpatient psychiatric care or outpatient care prescribing medication.
224202496|NCT00023426|DRUG|rifapentine|
224202497|NCT03910101|PROCEDURE|Hand surgery and intensive rehabilitation|Spasticity-correcting upper-limb surgery comprised lengthening of tendons, release of muscles, and occasionally correction of deformities. Rehabilitation starts the first post-operative day and comprised physiotherapy and occupational therapy. Patients are also taught a home-training program. Up to 1 week of intensive in-hospital rehabilitation followed 3 weeks after surgery and a new home-training program are designed.
224202498|NCT06105008|DRUG|Disitamab Vedotin|2.0 mg/kg intravenous (lV) infusion every 2 weeks
224202499|NCT06105008|DRUG|Toripalimab|3.0 mg/kg intravenous (lV) infusion every 2 weeks
224312619|NCT05462431|BEHAVIORAL|Deep relaxation exercises intervention|Deep relaxation exercises intervention: breathing exercise, suitable positions for rest, and relaxation exercise instructions.
224312620|NCT05776862|DRUG|Ursolic Acid|Subjects will take an oral 400mg (8 capsules - 4 in the morning/200mg and 4 at night/200mg) supplement of UA every day for 12 weeks.
224312621|NCT05776862|OTHER|Strength Training|Subjects will perform 3 sets of 10 repetitions of concentric and eccentric upper body exercises (bicep curls and tricep extensions) each session. Each session will last approximately 10-15 minutes of weightlifting with a 2-minute rest period between sets. The arm selected for exercise will be randomized.
223510440|NCT06410807|OTHER|Focus groups|The present study consists of 5 focus groups over 3 waves to inform the development and refinement of internet-based mindfulness (iMBSR) and lifestyle education (iLifeEd) protocols for use in future clinical trials. 50% females and 50% minoritized participants will be recruited to ensure representation across sex and race. For all focus groups, adults (over the age of 50 years) who report SCD will be recruited. Specifically, the Everyday Cognition Questionnaire (E-Cog) will be administered to quantify informant-reported deficits in cognitive functioning.
223510441|NCT05839821|BEHAVIORAL|noF-noRAS|resting state, that is, without finger-tapping and without listening to RAS
223510442|NCT05839821|BEHAVIORAL|F-noRAS|finger-tapping without listening to RAS
223510443|NCT05839821|BEHAVIORAL|noF-100RAS|listening to RAS with the 100% of the baseline tempo and without finger-tapping
223510444|NCT05839821|BEHAVIORAL|F-100RAS|finger-tapping and listening to RAS with 100 % of baseline tempo
223510445|NCT05839821|BEHAVIORAL|F-105RAS|finger-tapping and listening to RAS with 105 % of baseline tempo
223510446|NCT05839821|BEHAVIORAL|F-110RAS|finger-tapping and listening to RAS with 110 % of baseline tempo
223510447|NCT05714631|OTHER|Placebo Patch|Transdermal placebo patch
223510448|NCT05714631|DRUG|4% Lidocaine Patch|Transdermal patch
223510449|NCT03464448|DRUG|Teriflunomide|AUBAGIO® (teriflunomide) is a prescription medicine used to treat relapsing forms of multiple sclerosis (MS), which inhibits pyrimidine de novo synthesis by blocking the enzyme dihydroorotate dehydrogenase.
223510450|NCT02241772|DRUG|TA-8995|
223510451|NCT02241772|DRUG|Placebo|
223510452|NCT04785807|OTHER|Post traumatic, Anxiety and depression evaluation|Family member of person or trust of patient who had a limitation or discontinuation of treatments will be identified and asked to fulfilled a hospitalized anxiety and depression scale and the revised Impact Event scale 7 and 30 days after the limitation or discontinuation of treatments announcement
223510453|NCT01982227|DRUG|indocyanine green|intravenous injection (0.25mg/kg) of the indocyanine green 24h before the surgery.
223510454|NCT01906164|DRUG|ALS-008176|
223510455|NCT01906164|DRUG|Placebo|
223510456|NCT04667429|OTHER|Food|HEC83518 40mg will be taken orally fasted or with food
223510457|NCT04667429|DRUG|HEC83518|HEC83518 will be taken orally before sleep for 15 days
223510458|NCT04667429|DRUG|placebo|The placebo will be administered before sleep for 15 days.
223761101|NCT05179421|DRUG|Low dose oxytocin|10 minute IV infusion of saline followed by a 10 minute infusion of oxytocin 1.3 micrograms
224202500|NCT01950338|OTHER|Dry needling|Once the most painful spot is located within a palpable spastic taut band, the overlying skin is cleaned with alcohol. The needle will be inserted, penetrating the skin about 15-20mm, until the first local twitch response is obtained. Once the first local twitch response is obtained, the needle will be moved up and down (4 to 5 mm. vertical motions with no rotation) in the muscle at approximately 1Hz for 25-30 seconds.
224202501|NCT06454695|BEHAVIORAL|Future-oriented imagery rescripting|In this pilot study, in the screening phase, negative or catastrophic future-oriented images will be explored for all patients, including ratings of distress. The future-oriented imagery rescripting consists of 3-5 sessions; each image will be treated in one session, starting with the image that causes highest distress. The protocol is largely based on Hackmann (1998), with minor adaptations from other protocols.
224202502|NCT06454695|OTHER|Treatment as Usual|Psychotherapy and/or medication
224202503|NCT05049902|DRUG|Amoxicillin|Use according to the drug combination options selected by each center.
224202504|NCT05049902|DRUG|Clarithromycin|Use according to the drug combination options selected by each center.
224202505|NCT05049902|DRUG|Tetracycline|Use according to the drug combination options selected by each center.
224202506|NCT05049902|DRUG|Metronidazole|Use according to the drug combination options selected by each center.
224202507|NCT05049902|DRUG|Bismuth Potassium Citrate|Use according to the drug combination options selected by each center.
224202508|NCT05049902|DRUG|Colloidal Bismuth Pectin|Use according to the drug combination options selected by each center.
224202509|NCT05049902|DRUG|Vonoprazan fumarate|Use according to the drug combination options selected by each center.
224202510|NCT06109402|DRUG|TQB2450|Specified dose on specified days
224202511|NCT06109402|DRUG|Carboplatin|Specified dose on specified days
224312622|NCT00084032|BEHAVIORAL|Structured treatment interruption|Treatment interruption schedule is dependent on the Arm in which participants are enrolled in Step 2
224312623|NCT00084032|DRUG|Antiretroviral regimen|Participants will take any combination of FDA-approved ARV medications prescribed by their physician
224312624|NCT02627248|DRUG|Huaier Granule|20g tid, orally
224312625|NCT02627248|DRUG|Epirubicin|70 mg/m² ivdrip, d1 for both TEC and ET regimes
224312626|NCT02627248|DRUG|Docetaxel|75 mg/m² ivdrip, d2 for both TEC and ET regimes
224312627|NCT02627248|DRUG|Cyclophosphamide|600 mg/m² ivdrip, d2 for TEC regimes
224312628|NCT05637346|PROCEDURE|Intra-operative ultrasound measurement|A patient-specific 3D model will be created using an available pre-operative CT scan. Anatomical target points are selected on this virtual model before the start of the surgery. Prior to surgery, a patient-reference electromagnetic (EM) sensor will be placed between the patient and the matrass on the operating table to account for patient movement during acquisition. Intra-operatively, an initial point registration of the 3D model with the electromagnetic tracking system (EMTS) will be performed based on ultrasound (US) imaging of the arterial bifurcations by the surgeon. Then, the surgeon will acquire multiple US sweeps of the pelvic arteries (abdominal aorta and left and right iliac arteries). For validation purposes, the pre-operatively defined anatomical target points will be visualized on US imaging and by pinpointing the EM tracked pointer. All tracking and US data will be recorded and stored for post-operative analysis.
224202512|NCT06109402|DRUG|Pemetrexed|Specified dose on specified days
224202513|NCT06109402|DRUG|Nab-paclitaxel|Specified dose on specified days
224202514|NCT06109402|PROCEDURE|Surgery|Surgery for II-IIIB (N2) non-small cell lung cancer
224202515|NCT03345485|DRUG|Tinostamustine 60mg/m2 over 30min|Tinostamustine as a single agent was administered at doses of 60mg/m2 by intravenous infusion over 30 minutes on Days (D) 1 and 15 of each 28-day cycle.
224312629|NCT02518516|DRUG|Rosuvastatin (≥10 mg)|"Current cumulative exposure to high dose rosuvastatin (ATC C10AA07) will be defined as a prescription for ≥10 mg of rosuvastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-365 days, or 366-730 days).~Past exposure to high dose rosuvastatin (ATC C10AA07) will be defined as a prescription for ≥10 mg of rosuvastatin dispensed \>120 days of the index date (i.e. no exposure within 120 days of the index date)."
224312630|NCT02518516|DRUG|Atorvastatin (≥20 mg)|"Current cumulative exposure to high dose atorvastatin (ATC C10AA05) will be defined as a prescription for ≥20 mg of atorvastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-365 days, or 366-730 days).~Past exposure to high dose atorvastatin (ATC C10AA05) will be defined as a prescription for ≥20 mg of atorvastatin dispensed \>120 days prior to the index date (i.e. no exposure within 120 days of the index date)."
224312631|NCT02518516|DRUG|Simvastatin (≥40 mg)|"Current cumulative exposure to high dose simvastatin (ATC C10AA01) will be defined as a prescription for ≥40 mg simvastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-365 days, or 366-730 days).~Past exposure to high dose simvastatin (ATC C10AA01) will be defined as a prescription for ≥40 mg simvastatin dispensed \>120 days prior to the index date (i.e. no exposure within 120 days of the index date)."
223510459|NCT05111769|DRUG|Recombinant human brain natriuretic peptide|1\. To determine the effect of rhBNP on hemodynamics in sepsis based on PiCCO hemodynamic monitoring; 2. To collect and sort out the relevant data to determine the effects of rhBNP on cardiac function and kidney function, including cardiac ultrasound, kidney blood flow index and related laboratory tests. 3. To determine the effect of rhBNP on the final prognosis of patients, including ICU mortality and hospital mortality, ICU time, hospital stay, ventilator use time, kidney replacement therapy time, vasoactive drug dosage and time.
223510460|NCT03465605|DIAGNOSTIC_TEST|frailty test|questionnaire
223510461|NCT00224354|BIOLOGICAL|IL-2 secreting and hCL4OL-expressing autologous B-CLL cells|Patients will be treated with six subcutaneous injections of their IL-2-secreting and hCD40L-expressing autologous B-CLL cells, separated by one to two weeks in an immunological treatment window
223510462|NCT00224354|BIOLOGICAL|IL-2|subcutaneous (SC) injections of autologous leukemic cells modified ex vivo to secrete human interleukin-2 (hIL-2) and to express human CD40 ligand (hCD40L).
223510463|NCT00224354|BIOLOGICAL|CD40L|subcutaneous (SC) injections of autologous leukemic cells modified ex vivo to secrete human interleukin-2 (hIL-2) and to express human CD40 ligand (hCD40L).
223510464|NCT00224354|DRUG|ONTAK|an interleukin-2 immunotoxin directed to the CD25 antigen (denileukin diftitox, ONTAK
223510465|NCT00224354|BIOLOGICAL|immunotoxin dose|Days 0, 2, and 4 (18 ug/kg) i.v
223510466|NCT00700089|BEHAVIORAL|Assertive intervention|8-20 assertive contacts after suicide attempt
223510467|NCT00700089|OTHER|Standard treatment|In standard treatment there is no procedure for ensuring that the patient will actually receive the recommended treatment. Patients are often referred to available treatment modalities such as general practitioner, psychological treatment, treatment for alcohol abuse, and most often, the patients are themselves responsible for getting into contact with the treatment to which they are referred.
223510468|NCT00776425|DRUG|Epoetin beta|Epoetin beta subcutaneously or intravenously at a dose of 150 IU per kg of body weight thrice weekly or 30000 IU once weekly.
223510469|NCT03112850|DEVICE|Hearing aid|LOF hearing aid
223510470|NCT03112850|BEHAVIORAL|Auditory Training|
223510471|NCT05303974|OTHER|Ultrasound guided joint injection|The participants will perform two ultrasound guided joint injections on a mannequin. The performance of both procedures are videorecorded. All videos will be rated by two blinded raters using the modified IUSE assessment tool.
223510472|NCT05431751|DIETARY_SUPPLEMENT|Whole Algae|Whole Euglena gracilis algae, produced by proprietary fermentation.
223510473|NCT05099276|DRUG|Tranexamic Acid Pill|1950 mg tranexamic acid (three capsules) given in post-anesthesia room and three capsules for postop day one and three capsules for postop day two
224202516|NCT03345485|DRUG|Tinostamustine 80mg/m2 over 30min|Tinostamustine as a single agent was administered at doses of 80mg/m2 by intravenous infusion over 30 minutes on Days (D) 1 and 15 of each 28-day cycle.
224202517|NCT03345485|DRUG|Tinostamustine 100mg/m2 over 30min|Tinostamustine as a single agent was administered at doses of 100mg/m2 by intravenous infusion over 30 minutes on Days (D) 1 and 15 of each 28-day cycle.
223616563|NCT02673918|OTHER|Home-based upper-body rehabilitation with online support|"Participants will be given written educational material, in which the physiotherapist marks the exercises specifically recommended for the individual patient. In addition, participants will get a personal password giving access to the BRECOR website for 12 weeks. The website contains professionally filmed videos of upper-body rehabilitation exercises (joint mobility and muscle strength) and instructions in scar tissue massage and manual lymph drainage. Furthermore, mindfulness sessions and additional information about prevention and early detection of late effects after breast cancer treatment are available on the website.~On average, participants will complete three rehabilitation exercises 5-7 times weekly with an anticipated duration of approximately 20 minutes."
223616564|NCT00485017|DRUG|THR-4109|THR-4109 maximum dose in study is 115 mg via oral capsule daily in a.m. and 115 mg via oral capsule daily in p.m. for 24 weeks
223761102|NCT05179421|DRUG|High dose oxytocin|10 minute IV infusion of oxytocin 0.3 micrograms followed by a 10 minute infusion of oxytocin 7 micrograms
223616565|NCT00485017|DRUG|Placebo|Oral capsules daily in a.m. and in p.m. for 24 weeks
223616566|NCT05586919|PROCEDURE|Direct Puncture Repair / Ethanol|Ethanol is an organic compound that will be injected in the venous malformation as a sclerotherapy by Direct Puncture Repair
223616567|NCT05586919|PROCEDURE|Direct Puncture Repair / Polidocanol|Polidocanol is a sclerosing agent that will be injected in the venous malformation by Direct Puncture Repair
223616568|NCT00881114|DRUG|Cisplatin|Intensity modulated radiation therapy with concurrent chemotherapy. Cisplatin will be administered at a dose of 100 mg/m2 during weeks 1, 4, and 7 of radiation therapy. Post treatment neck dissection will be performed if clinically indicated.
223510474|NCT05099276|DRUG|Placebo|Three capsules of cellulose given in post-anesthesia room and three capsules for postop cay one and three capsules for postop day two
223510475|NCT04168138|DRUG|rhTPO|D: Decitabine(15mg/m2) d1-5 G: G-CSF（300ug/d） d0-9(stop using when White Blood Cell (WBC)\>20\*109/L) T: rhTPO(15000U/d) d3,5,7,9, d11- (Platelet\>50\*109/L) A: Aclarubicin(10mg/d) d3-6 C: Cytarabine(15mg Q12h) d3-9
223510476|NCT05615961|DIETARY_SUPPLEMENT|Probiotics (Lab4 probiotics, Cultech, Port Talbot, Wales, UK)|The intervention is a unique blend of probiotic cultures from a well-established manufacturer.
223616569|NCT00881114|DRUG|Cetuximab|Intensity modulated Radiation Therapy with concurrent chemotherapy. Cetuximab will be administered beginning at a dose of 400 mg/m2 the week before radiation commences, then at a dose of 250 mg/m2 weekly during weeks 1 to 7. Post treatment neck dissection will be performed if clinically indicated.
223616570|NCT05287828|OTHER|Surgeons CT scan analysis|Surgeons extract indicators using standard methods of analysis
223510477|NCT05615961|DIETARY_SUPPLEMENT|Placebo|Placebo Tablets
223510478|NCT00676962|BEHAVIORAL|External facilitation|Study facilitator meets regularly with therapists to aid implementation of CBT
223510479|NCT02257021|DRUG|BILR 355 BS|
223510480|NCT02257021|DRUG|Tipranavir|
223616571|NCT05287828|DEVICE|PRAEVAorta CT scan analysis|CT scans are analysed using PRAEVAorta Suite which is composed of the software PRAEVAorta 2 and PRAEVAorta Web. Indicators extraction is fully automatic.
223616572|NCT01862913|OTHER|Computer-assisted cognitive-behavioral therapy|The intervention arm will receive eight sessions of computer-assisted CBT plus usual medical treatment, as described in the AUGE Clinical Guidelines for Depression. Computer-assisted CBT sessions will be delivered on a weekly basis and assisted by trained psychologists in face-to-face meetings. The program is called 'Yo pienso, siento y actúo mejor' (YPSA-M); in English, 'I think, feel, and behave better'. Topics covered in the program will include information on symptoms and causes of depression, treatment options, problem-solving techniques and other cognitive-orientated strategies to challenge negative thoughts.
223510481|NCT02257021|DRUG|Low dose of ritonavir|
223510482|NCT02257021|DRUG|High dose of ritonavir|
223510483|NCT00147537|DRUG|CP-751,871|"Phase 2 Arm A:~CP-751,871 20 mg/kg IV over 2.5 hours up to 17 cycles"
223510484|NCT00147537|DRUG|paclitaxel|"Phase 2 Arm A:~Paclitaxel 200 mg/m2, IV over 3 hours up to 6 cycles~Phase 2 Arm B:~Paclitaxel 200 mg/m2, IV over 3 hours up to 6 cycles"
223510485|NCT00147537|DRUG|carboplatin|"Phase 2 Arm A:~Carboplatin AUC 6, IV over 15-60 minutes up to 6 cycles~Phase 2 Arm B:~Carboplatin AUC 6, IV over 15-60 minutes up to 6 cycles"
223616573|NCT01862913|OTHER|Usual care treatment|The control arm will receive treatment as usual from the primary care clinics. The professionals in the primary care centers will be instructed to follow the AUGE Clinical Guidelines for Depression.
223616574|NCT03546582|DRUG|Pembrolizumab|Anti-PD-1 targeted immunotherapy
224202518|NCT03345485|DRUG|Tinostamustine 60mg/m2 over 60min|Tinostamustine as a single agent was administered at doses of 60mg/m2 by intravenous infusion over 60 minutes on Days (D) 1 and 15 of each 28-day cycle.
223510486|NCT00147537|DRUG|CP-751,871|Phase 1b Dose Escalation/Expansion: CP-751,871 20 mg/kg IV over 2.5 hours (up to 17 cycles) Phase 1b Erlotinib Extension: CP-751,871 20 mg/kg IV over 2.5 hours (up to 17 cycles)
223510487|NCT00147537|DRUG|paclitaxel|Phase 1b Dose Escalation/Expansion: paclitaxel 200 mg/m2, IV over 3 hours (up to 6 cycles) Phase 1b Erlotinib Extension: paclitaxel 200 mg/m2, IV over 3 hours (up to 6 cycles)
223510488|NCT00147537|DRUG|carboplatin|Phase 1b Dose Escalation/Expansion: carboplatin AUC 6, IV over 15-60 minutes (up to 6 cycles) Phase 1b Erlotinib Extension: carboplatin AUC 6, IV over 15-60 minutes (up to 6 cycles)
224202519|NCT03345485|DRUG|Tinostamustine 80mg/m2 over 60min|Tinostamustine as a single agent was administered at doses of 80mg/m2 by intravenous infusion over 60 minutes on Days (D) 1 and 15 of each 28-day cycle.
223510489|NCT00147537|DRUG|erlotinib|Phase 1b Erlotinib Extension: erlotinib 150 mg/day orally every day (up to 17 cycles)
223510490|NCT02844712|OTHER|Evaluation of reexposure to a negatively tested betalactam|
223510491|NCT05922735|BEHAVIORAL|Questionnaire|Serology from remaining blood sample Self-questionnaire about sexual behavior during the epidemy mpox
224202520|NCT03345485|DRUG|Tinostamustine 100mg/m2 over 60min|Tinostamustine as a single agent was administered at doses of 100mg/m2 by intravenous infusion over 60 minutes on Days (D) 1 and 15 of each 28-day cycle.
224202521|NCT03345485|DRUG|Tinostamustine 80mg/m2 over 80min|Tinostamustine as a single agent was administered at doses of 80mg/m2 by intravenous infusion over 80 minutes on Days (D) 1 and 15 of each 28-day cycle.
223616575|NCT03546582|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|High-precision radiotherapy
223616576|NCT05005975|DRUG|MT-7117|MT-7117
223616577|NCT04998955|BEHAVIORAL|Maximal strength training|Exercise intervention utilizing 4 x 4 repetitions heavy resistance training
223761103|NCT01561066|PROCEDURE|Autologous platelet-rich fibrin glue (PRFG)|"1. Preparation of autologous platelet-rich fibrin glues (PRFG) The platelet-rich plasma (PRP) was separated by centrifugation from 300-400 ml whole blood for 6 min at 1000g, 22°C twice, keeping most of the platelets (50%-60%) in the plasma fraction. For 50g PRP from each patient, with citric acid (2.84mM) lowering and NaHCO3 (75mM) adjusting the PH value, thrombin solution was produced. On the other hand, cryoprecipitate was produced from the rest of the plasma. Frozen at -80°C for at least 6h and then thawed at 4°C, PRP went through centrifugation at 4000rpm/min for 5min.~2. PRFG application The application of the glues through the external opening of the fistula was controlled by the drainage tube through a double-syringe system with distal mixing device. The distance was based on fistulography to assure total occlusion of the internal hole. After the FG was instilled, any redundant glue was removed from the external openings."
223761104|NCT01561066|DRUG|Octreotide|subcutaneous injection, 0.3mg/8h until enteral nutrition resolution
223761105|NCT01171716|OTHER|Meal Patterning|LP intake 3 meals and 6 meals HP intake 3 meals and 6 meals
223761106|NCT05052190|BEHAVIORAL|Text Message R/R with Direct Appointment Schedule Link|Participants in this arm will receive up to 3 R/R messages by text reminding them to get a flu vaccine with a Direct Appointment Scheduling link and instructions to make a flu vaccine appointment.
223761107|NCT05052190|BEHAVIORAL|Text Message R/R without Direct Appointment Schedule Link|Participants in this arm will receive up to 3 R/R messages by text reminding them to get a flu vaccine without a Direct Appointment Scheduling link and instructions to make a flu vaccine appointment.
223761108|NCT05052190|BEHAVIORAL|Text Pre-Appointment Reminder|Participants will receive a Pre-Appointment Reminder via text when they schedule a visit during the study period advising them to get the flu vaccine at their upcoming appointment.
223761109|NCT05052190|BEHAVIORAL|Portal Message R/R with Direct Appointment Schedule Link|Participants in this arm will receive up to 3 R/R messages by portal. R/R message will be sent with a Direct Appointment Scheduling link and instructions to make a flu vaccine appointment.
223761110|NCT05052190|BEHAVIORAL|Portal Message R/R without Direct Appointment Schedule Link|Participants in this arm will receive up to 3 R/R messages by portal. R/R message will be sent without a Direct Appointment Scheduling link and instructions to make a flu vaccine appointment.
223761111|NCT05052190|BEHAVIORAL|Portal Pre-Appointment Reminder|Participants will receive a Pre-Appointment Reminder via the portal advising them to ask their doctor for the flu vaccine at their upcoming appointment via text when they schedule a visit during the study period.
223761112|NCT03700359|DRUG|Anlotinib Hydrochloride|Anlotinib: Maintenance therapy 12mg/day P.O., day 1-15 every 21 days (2 weeks on, 1 week off) until progressive disease or treatment discontinuation
223761113|NCT03700359|DRUG|Lobaplatin|Lobaplatin:30 mg/m2 IV every 21 days for up to 4 cycles of 21 days
223761114|NCT03700359|DRUG|Etoposide|Etoposide: 60 mg/m2 IV every 21 days for up to 4 cycles of 21 days
223761115|NCT06474494|PROCEDURE|Application of one layer|35 non-carious cervical lesions (NCCL) will receive composite resin restorations applying one layer of Scotchbond Universal Plus adhesive
223761116|NCT06474494|PROCEDURE|Application of double layer|35 non-carious cervical lesions (NCCL) will receive composite resin restorations applying double layer of Scotchbond Universal Plus adhesive
223761117|NCT06474494|PROCEDURE|Etch-and-rinse application mode|35 non-carious cervical lesions (NCCL) will receive composite resin restorations applying Scotchbond Universal Plus adhesive applied as etch-and-rinse application mode
223761118|NCT06474494|PROCEDURE|Selective enamel etching application mode|35 non-carious cervical lesions (NCCL) will receive composite resin restorations applying Scotchbond Universal Plus adhesive applied as selective enamel etching mode
223761119|NCT01173302|BIOLOGICAL|Rabies vaccine, manufactured by ChengDa|1 dose before the antibody is tested
223761120|NCT03746522|DRUG|Setmelanotide|SC injection of setmelanotide
224202522|NCT06539585|PROCEDURE|Meiotic spindle status observation in polarized light|In patients older than 35 years and younger than 40 years, we will use a microscope with a polarizing filter to evaluate the position of meiotic spindles and polar bodies in oocytes collected from patients who were indicated for IVF and ICSI. Using an optical microscope with a Nikon CEE GmbH polarizing filter, the angle between PB and MS together with MS visibility will be determined.
224202523|NCT06539585|PROCEDURE|ICSI|ICSI will be performed according to standard protocol using ICSI/holding micropipettes (#002-5-30/#001-120-30, Microtech IVF, Czech Republic), polyvinylpyrrolidone (ICSI™, Vitrolife, Sweden), and Eppendorf (Hamburg, Germany) micromanipulation system equipped with thermoplate (Tokaohit, Japan). The oocytes will be cultivated individually, and their order preserved, so that the other outcomes (data from timelapse, clinical results) can be associated with individual oocytes. Oocytes will be denuded (HYASE-10X™, Vitrolife, Sweden) after OPU, and the maturation stage will be examined.
224202524|NCT05517707|DEVICE|Nasogastric Tube|Temperature and impedance data will be collected from sensors embedded within the feeding tube wall.
224202525|NCT05907044|BIOLOGICAL|RQ3013|0.15mL/dose containing mRNA 30μg
224202526|NCT05907044|BIOLOGICAL|RQ3025|0.15mL/dose containing mRNA 30μg
223761121|NCT03746522|DRUG|Placebo|SC injection of placebo
223616578|NCT03374579|DIAGNOSTIC_TEST|Fluid challenge|Fluid challenge and measure change in co2 gap
223616579|NCT02927392|DRUG|Leuprolide acetate|A subset of premenopausal women will receive GnRHAG (leuprolide acetate) 3.75 mg/mo by intramuscular injection every 4 weeks for 24 weeks (6 doses).
223616580|NCT05184530|DRUG|Evolocumab 140 MG/ML|140 mg per two weeks, subcutaneous injection
223616581|NCT00278733|BEHAVIORAL|Brief intervention (physician advice)|
223616582|NCT04287621|DRUG|DUPIXENT®|There is no investigational product provided by the study sponsor and no therapeutic intervention regulated by this protocol. As a condition for eligibility, patients are required to initiate DUPIXENT® for asthma, according to the country-specific prescribing information, prescribed by their physician as part of their normal care (ie, not for the purpose of enrolling in the registry). Once patients enter the study, there are no protocol requirements regarding DUPIXENT® or any other treatments.
223616583|NCT00512876|DRUG|Bevacizumab (Avastin)|Bevacizumab 10mg/mL 1 drop BID x 3 weeks
223761122|NCT04026919|OTHER|OK EN CASA-ZAINDOO|Intervention based on cognitive- behavioural techniques offered in an online format.
223761123|NCT04917055|DRUG|ropivacaine 0.25% with epinephrine and 6mg dexamethasone|Regional Nerve block behind the knee for posterior knee pain following total knee arthroplasty using ultrasound guidance, to be done distally between femoral chondyles
223761124|NCT04917055|DRUG|Saline|Injection of Saline behind knee using ultrasound guidance
223761125|NCT01479621|DRUG|Fp MDPI|"Fp MDPI is an inhalation-driven multidose dry powder inhaler (MDPI) containing fluticasone propionate (Fp) dispersed in a lactose monohydrate excipient and contained within a reservoir. A metered dose of drug is delivered to a dose cup via an air pulse activated when the cap is opened.~During the treatment period, participants were randomized to 12.5, 25, 50 or 100 mcg of Fp one inhalation twice a day for a total daily dose of 25, 50, 100 or 200 mcg. Study drug was administered in the morning and in the evening"
223761126|NCT01479621|DRUG|Flovent Diskus|Flovent Diskus contains the active ingredient fluticasone propionate (Fp). Flovent Diskus 100 mcg was used twice a day, once in the morning and evening, for a total daily dose of 200 mcg of Fp. This therapy was not blinded as the inhaler device was different than the MDPI used in the other treatment arms.
223761127|NCT01479621|DRUG|albuterol/salbutamol|A short-acting β2-adrenergic agonists (SABA), albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI), was provided to be used as needed for the relief of asthma symptoms during both the run-in and treatment periods (to replace the subject's current rescue medication).
223761128|NCT01479621|DRUG|Placebo MDPI|Placebo multidose dry powder inhaler in the morning and evening. Placebo MDPI was provided in devices identical in appearance to Fp MDPI.
223761129|NCT02140034|PROCEDURE|Extensive Peritoneal Lavage|
223761130|NCT05077254|BIOLOGICAL|Pfizer-BioNTech COVID-19 Vaccine 2023-2024|Administration: One dose administered intramuscularly.
223761131|NCT05077254|BIOLOGICAL|Moderna COVID-19 Vaccine 2023-2024|Administration: One dose administered intramuscularly.
223761132|NCT05077254|DRUG|SOC IS Regimen|Participants will continue to take their prescribed immunosuppression (IS) medications without alterations in schedule and dosing, per protocol instruction.
223761133|NCT05077254|DRUG|SOC IS Reduction|Participants will reduce their standard of care immunosuppression medications (IS) before and after the COVID-19 vaccine booster (1 dose), per protocol instruction.
223761134|NCT05197270|BIOLOGICAL|4D-150 IVT|4D-150: AAV-based gene therapy comprised of miRNA targeting VEGF-C and codon-optimized sequence encoding aflibercept
223761135|NCT05197270|BIOLOGICAL|Aflibercept IVT|Commercially available Active Comparator Other Name: Eylea
223616584|NCT06410014|OTHER|No intervention is performed|The study is observational
223761136|NCT01771133|BEHAVIORAL|Lifestyle intervention group|The lifestyle intervention will be delivered within an empowerment framework which promotes behavioral changes by facilitating health self-efficacy, utilizing self-praise and using active coping skills to address and manage emotions. A nutrition component primarily focuses on total calories, for which energy requirements will be individually calculated for each pregnant women and on general diet quality with an emphasis on carbohydrate quality. It will also promote an overall healthy diet, emphasizing improvement of fat quality and reducing salt intake. A physical activity component focuses on promoting regular movement and minimizes the duration of bouts of sitting or lying during waking hours as well as non-exercise activity.
223761137|NCT06094270|DEVICE|EndoMind|Withdrawal time is calculated and an image report is generated using the EndoMind system.
223761138|NCT05634278|BEHAVIORAL|Preoperative mindfulness|A seven-minute, audio-guided, mindfulness meditation practice.
223761139|NCT05634278|BEHAVIORAL|Postoperative mindfulness|A seven-minute, audio-guided, mindfulness meditation practice.
223761140|NCT05634278|BEHAVIORAL|Mind wandering|"A timed, seven-minute mind wandering period during which participants are instructed: For the next 7 minutes, allow your mind to wander."
223761141|NCT00046033|DRUG|Lopinavir/ritonavir|
223761142|NCT00046033|DRUG|Ritonavir|
223761143|NCT00046033|DRUG|Saquinavir|
223616585|NCT03674632|BEHAVIORAL|Relaxation meditation tape|The tape used in this study is based on a meditation CD designed for breastfeeding mother (Menelli, 2004). The recording will be transcribed and translated into Chinese language by a certified yoga therapist.
223616586|NCT03342417|BIOLOGICAL|Nivolumab|Nivolumab 240 mg administered by IV infusion over 30 minutes
223616587|NCT03342417|BIOLOGICAL|Ipilimumab|Ipilimumab 1 mg/kg administered by IV infusion over 30 minutes.
223761144|NCT00046033|DRUG|Tenofovir disoproxil fumarate|
223761145|NCT00046033|DRUG|Amprenavir|
223761146|NCT06197789|BIOLOGICAL|TPX-105|Subjects will be administered with autologous fibroblasts through injection
223761147|NCT06197789|BIOLOGICAL|Placebo|Subjects will be administered with Placebo through injection
223761148|NCT01064557|DRUG|all-trans retinoic acid (ATRA)|
223761149|NCT02180282|DEVICE|M22-IPL|"The M22 is an advanced computer-controlled light emission system that incorporates several different light modules.~The IPL hand piece operates at a spectrum of 400-1200nm with 7 different filters that can be easily inserted to the hand piece to treat different conditions. The IPL hand piece also includes 2 different sapphire cooled light guides of 8x15mm and 15x35mm. The cut-off filter that will be used for this evaluation is the Acne Filter that cuts off all light with the wavelength of 400-600 and 800-1200nm."
223761150|NCT00319826|OTHER|No intervention|This is an observational study with no intervention
223761151|NCT05422053|DEVICE|t:slim X2 insulin pump with Control-IQ technology 1.5|t:slim X2 insulin pump with Control-IQ technology 1.5, and wearing the Dexcom G6 CGM.
224202527|NCT05907044|BIOLOGICAL|RQ3027|0.15mL/dose containing mRNA 30μg
224202528|NCT03359473|DRUG|GSK2881078|GSK2881078 will be available as capsules for oral administration. GSK2881078 will be administered once daily by the oral route at a dose of 1 mg and 2mg to post-menopausal female subjects and male subjects, respectively.
224202529|NCT03359473|DRUG|Matching Placebo|Subjects will be administered two capsules of GSK2881078 matching placebo once daily by the oral route.
223761154|NCT02439775|DEVICE|Symplicity Spyral™ multi-electrode renal denervation system|After a renal angiography according to standard procedures, subjects remain blinded and are immediately treated with the renal denervation procedure after randomization.
224312632|NCT02518516|DRUG|Fluvastatin|"Current cumulative exposure to fluvastatin (ATC C10AA04) will be defined as a prescription for any dose of fluvastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-365 days, or 366-730 days).~Past exposure to fluvastatin (ATC C10AA04) will be defined as a prescription for any dose of fluvastatin dispensed \>120 days prior to the index date (i.e. no exposure within 120 days of the index date)."
223510492|NCT03041480|DIAGNOSTIC_TEST|serum lipid levels and Lp-PLA2|Estimation of Total Cholesterol, triglyceride, High density lipoprotein, Low density lipoprotein, very low density lipoprotein and Lipoprotein associated lipophosphase A2 in chronic periodontitis
223510493|NCT05469178|DRUG|Bemcentinib|Bemcentinib capsules will be administered orally.
223510494|NCT05469178|DRUG|Pembrolizumab|Pembrolizumab will be administered as an intravenous (IV) infusion as part of CIT every 3 weeks.
223510495|NCT05469178|DRUG|Pemetrexed|Pemetrexed will be administered as an IV infusion as part of CIT every 3 weeks.
223761155|NCT02439775|PROCEDURE|Sham Procedure|After a renal angiography according to standard procedures, subjects remain blinded and remain on the catheterization lab table for at least 20 minutes prior to introducer sheath removal.
223761156|NCT06517290|OTHER|Non applicable|Non applicable
223761157|NCT05007782|DRUG|Denikitug|Administered Intravenously
223510496|NCT05469178|DRUG|Carboplatin|Carboplatin will be administered as an IV infusion as part of CIT every 3 weeks up to 4 cycles. Each cycle = 21 days.
223510497|NCT06130033|DEVICE|Neuromonitoring|"Multimodal Neuromonitoring:~Transcranial Doppler - middle cerebral artery blood flow velocity Jugular venous bulb oximetry - hemoglobin oxygen saturation at the jugular venous bulb Arterial blood pressure monitoring - mean arterial, systolic and diastolic pressure monitoring at the radial artery via an in situ radial arterial line catheter Pulmonary artery catheter - to measure continuous cardiac output and mixed venous oxygen saturation Near infrared spectroscopy - to measure regional cerebral saturation of oxygen"
223510498|NCT00406731|DRUG|NG-monomethyl-L-arginine (L-NMMA)|bolus 6 mg/kg over 5 minutes followed by a continuous intravenous infusion of 60 µg/kg/min over 12 minutes; twice on 1 study day
223510499|NCT00406731|DRUG|Endothelin-1 (ET-1)|5 ng/kg/min intravenous infusion over 17 minutes; twice on 1 study day
223510500|NCT00406731|DRUG|Physiologic saline solution (placebo control)|intravenous infusion over 20 minutes; twice on 1 study day
223510501|NCT00406731|DEVICE|Laser Doppler flowmetry|blood flow measurements at the temporal neuroretinal rim of the optic nerve head
223510502|NCT00406731|DEVICE|Goldmann applanation tonometer|Intraocular pressure measurements
223510503|NCT00406731|DEVICE|HP-CMS patient monitor|blood pressure and pulse rate measurements
223510504|NCT00406731|PROCEDURE|Suction cup method|The IOP will be raised by an 11 mm diameter, standardized suction cup placed on the temporal sclera with the anterior edge at least 1 mm from the limbus.
223510505|NCT00013299|DEVICE|Prevention of Diabetic Ulcers|
223510506|NCT00699166|DRUG|DNK333|25 mg and 100 mg oral doses, each taken twice daily
223510507|NCT05866601|OTHER|Role-playing for learning the clinical interview|"Thirty-one first-year physiotherapy students will carry out the role-playing methodology to learn how to take a clinical history in physiotherapy.~Before and after the realization, they will be measured by means of a validated questionnaire in Spanish, the language in which they study, the variable of empathy and anxiety."
223510508|NCT05151965|PROCEDURE|Bankart Repair and Remplissage|"Arthroscopic Bankart repair with a minimum of 3 anchors~1 or 2 anchor Remplissage subsequently performed with percutaneous anchor insertion in the base of the Hill-Sachs defect, and sutures passed in a horizontal mattress configuration 1 cm apart, tied in the subacromial space."
223510509|NCT05151965|PROCEDURE|Latarjet Coracoid Transfer|Coracoid transfer performed via deltopectoral approach with horizontal subscapularis split. Graft placed in the conventional orientation, secured with 2 screws, ensuring the graft is not lateral to the glenoid rim.
223510510|NCT00345592|DEVICE|Dual (atrial and ventricular) implantable defibrillator|The devices automatically applies therapy (shock) for atrial fibrillation, when atrial fibrillation is confirmed.
223510511|NCT00345592|DEVICE|Dual (atrial and ventricular) implantable defibrillator|In hospital application of anti arrhythmic therapies via the device
223510512|NCT00345592|DEVICE|Dual (atrial and ventricular) implantable defibrillator|Therapy for atrial arrhythmias will be delivered from the device through command of the physician and in a hospital environment
223510513|NCT06021379|DRUG|Trastuzumab|AryoTrust (AryoGen Pharmed Trastuzumab) is given at a dosing of 6 mg/m2 after adjuvant chemotherapy completion every 3 weeks for 9 cycles.
223510514|NCT05351489|DRUG|Dexmedetomidine|Patients will receive intrathecal 2 mL heavy bupivacaine 0. 5% together with either dexmedetomidine 5 μg or10 μg dexmedetomidine .
223510515|NCT02523040|DRUG|Lenalidomide|
223510516|NCT01183637|DEVICE|Kensey Nash Corp. Cartilage Repair Device|To perform the Cartilage Repair Device implantation procedure, the surgeon first removes the damaged cartilage. Then, the surgeon creates a cylindrical hole in the bone below the area of damaged cartilage. The Cartilage Repair Device is then implanted into the hole so that the surface is level with the surrounding native cartilage. The Cartilage Repair Device will then absorb blood and bone marrow from the bone to begin the healing process.
223510517|NCT01183637|PROCEDURE|Microfracture|To perform the microfracture technique, the surgeon will first remove the damaged cartilage. Then, the surgeon will make a number of small fractures in the bone below the area of damaged cartilage. The fractures cause the bone to bleed and a clot to form over the exposed bone. Over time, the clot forms a layer of fibrocartilage over the bone.
223510518|NCT05217966|RADIATION|Radiation: Single Pre-Operative Radiation Therapy|Ablative preoperative partial breast radiation therapy
223761158|NCT05007782|DRUG|Zimberelimab|Administered Intravenously
223510519|NCT02006654|DRUG|Placebo|Once daily, matching placebo capsules, orally
223761159|NCT05162911|BEHAVIORAL|Ask, advise, Assist and refer to the Quitline|A nurse will ask, advise, assist and refer patient to the Quitline
223761160|NCT05162911|BEHAVIORAL|Ask, advise, Assist and referral to onsite counselor|A nurse will ask, advise, assist and refer patient to a counselor
223761161|NCT05162911|BEHAVIORAL|Ask, advise, Assist and referral to onsite counselor and NRT|A nurse will ask, advise, assist and refer patient to a counselor and provide nicotine replacement therapy in the form of gum
223761162|NCT01216475|PROCEDURE|Femtosecond LASIK|LASIK consists of two steps: the first step involves the formation of a corneal flap and the second one is when the excimer ablation is performed in the corneal stromal bed. Femtosecond lasers (FL) have been widely used in LASIK surgery to fashion the corneal flap. The laser will cut a lamellar followed by a vertical corneal incision. We are able to produce a vertical cut since the Femtosecond laser can deliver laser pulses of 1 micron diameter at a preselected depth in the cornea, which then expands to 2 to 3 microns with the formation of a cavitation bubble. These pulses create micro-photodisruption of the corneal tissue by the formation of an expanding bubble of carbon dioxide and water, which in turn cleaves the tissue and creates a plane of separation. The flap is then removed to expose the stroma and the refractive treatment is done by the excimer laser over the denuded stroma.
224202530|NCT04432129|BEHAVIORAL|IBBIS II|"The IBBIS-II service consists of:~1. Mental health assessment.~2. Planned integrated service. The participant has the same employment specialists and care manager throughout the intervention. A joint plan is made with shared decisions between the participant, the employment specialist and the care manager. There is a focus on disclosure (openness about illness) and involvement of relatives and significant others.~3. Vocational rehabilitation. Focus on return to work with ongoing assessment of job goals, competencies and need of support. Participants receive help in contacting existing employers (employed) and potential employers (unemployed). Unemployed participants are offered an individualized job search effort. The focus is on competitive jobs within the community.~4. Treatment consists of stepped care with structured treatment guidelines.~5. When the participant has obtained work the team continues to offer support."
224202531|NCT04432129|BEHAVIORAL|Service as Usual|Service as usual consists of standard mental health care and vocational rehabilitation
224202532|NCT06080191|DRUG|CD19-CAR_Lenti_ALLO|"Biological/Vaccine: CD19-CAR\_Lenti\_ALLO~A single infusion of CD19-CAR\_Lenti\_ALLO on Day 0"
224202533|NCT05262894|OTHER|extreme hypercapnia induced by ventilation insufficiency|Re-breathing of gas by breathing into the simulated avalanche snow
224202534|NCT00870714|DRUG|Docetaxel|Docetaxel 55mg/m2 to be given IV as a one-hour infusion to be repeated every 21 days for four treatment cycles.
224202535|NCT00870714|DRUG|Ketoconazole|Ketoconazole 400mg P.O. BID daily to start on day 2 following the first docetaxel treatment. In patients who experience no grade 2 or higher toxicity, the ketoconazole dose will be increased to 400mg TID on day 2 following cycle #2 of docetaxel. This will be continued daily until completion of study treatment.
224202536|NCT05302414|BEHAVIORAL|Board game-based learning|The team of PGY doctors and nurses received 3 hours training intervention in resuscitation teamwork skills through a board game-based teaching approach.
224202537|NCT05302414|BEHAVIORAL|Simulation-based learning|The team of PGY doctors and nurses received 3 hours training intervention in resuscitation teamwork skills through a simulation-based teaching approach.
224202538|NCT05302414|BEHAVIORAL|Lecture-based learning|The team of PGY doctors and nurses received 3 hours training intervention in resuscitation teamwork skills through an interactive lecture-based approach.
224202539|NCT04716816|PROCEDURE|Stripping massage|Stripping massage for rhomboid myofascial trigger points
223510520|NCT02006654|DRUG|Idalopirdine|Once daily, encapsulated tablets, orally
223510521|NCT05396391|DRUG|IAP0971|IAP0971 should be subcutaneous injected，q2w
223510522|NCT03176199|DRUG|Oxycodone|Every 12 hours for control-released oxycodone (OxyContin®)
223510523|NCT03176199|DRUG|Oxycodone|Every 6 hours for immediate-released oxycodone (OxyNorm®)
223510524|NCT06447051|OTHER|Kasai Surgery|As per institute treatment protocol
223510525|NCT02852746|BEHAVIORAL|Performance measures of the upper extremity|Athletes will perform the unilateral seated shot put test (USSPT) and the upper quarter Y balance test (UQYBT) bilaterally.
223510526|NCT01391949|BEHAVIORAL|Detailed feedback|Once a week subjects will receive feedback about the total time spent cycling and walking in the previous week. Subjects in this intervention group will also receive feedback about average cycling speed, distance pedaled, average walking speed, and distance walked in the previous week.
223510527|NCT01391949|BEHAVIORAL|Basic feedback|Once a week subjects will receive feedback about total time spent cycling and walking in the previous week.
223510528|NCT01298466|DRUG|Pregabalin|The investigator will administer pregabalin in a flexible dose-escalation regimen as follows: 150 mg per night for 1 week, 300 mg per day for 1 week, 450 mg per day for 1 week, then 600 mg per day through to the end of the study. Patients may change the dose of medication based on individual response and tolerability as determined by the investigator.
223510529|NCT04803903|DEVICE|Flotraq Sensor with EV1000 incorporating the HPI algorithm|"The HPI algorithm is only available on the EV1000, Hemosphere and Flotrac monitoring systems and requires the use of a Flotrac sensor connected to an arterial line (Edwards Lifesciences Corp., Irvine, CA, USA). The Flotrac sensor has a splitter which enables the splitting of the arterial blood pressure signal to facilitate a blood pressure signal on both the anesthesia machine monitor (standard care) and the HemoSphere monitor (study).~In the intervention arm we asked the anesthesiologist and anesthesia nurse to use the study treatment flowchart . If the HPI alarm goes off, which entails both a sound and a flickering light, we ask the anesthesiologist to act upon this alarm immedietaly. Use of the study treatment flowchart ensures that the anesthesiologist has to think about the underlying cause. The HemoSphere/EV1000 with HPI software has a second screen with variables that provide information about the underlying cause of the predicted hypotension."
223510530|NCT04825899|OTHER||
223510531|NCT00004015|DRUG|sodium borocaptate|
223510532|NCT00004015|PROCEDURE|adjuvant therapy|
223510533|NCT03116815|OTHER|Direct input of home blood pressure readings via MyChart|Participants will record home blood pressure readings directly into the electronic health record via the MyChart application
223510534|NCT01823887|DEVICE|Vagus Nerve Stimulation (VNS)|Electrical Stimulation of the Vagus Nerve
223510535|NCT03864549|DIETARY_SUPPLEMENT|Femina II|2 capsules per day until delivery
223510536|NCT03864549|OTHER|Placebo|2 capsules per day until delivery
223761163|NCT01216475|PROCEDURE|Small incision lenticule extraction (SMILE)|Patient's eye will be centered and docked with the curved interface cone before application of suction fixation. First, the posterior surface of the refractive lenticule (spiral in), then the lenticule border is created. The anterior surface of the refractive lenticule (spiral out) is then formed which extended beyond the posterior lenticule diameter by 0.5mm to form the anterior flap and is followed by a rim cut. After the suction is released, a Siebel spatula is inserted under the flap near the hinge before the flap is seperated and reflected. The edge of the refractive lenticule is separated from the stromal bed with a sinsky hook and the posterior border of the lenticule gently separated with the Siebel spatula and removed through small incision.
223761164|NCT06494384|BEHAVIORAL|Problem Solving Treatment as usual (PST as usual)|PST is a skills-based intervention that teaches clients a 7-step approach in which they 1) select a specific problem and define it in concrete terms,2) select a goal that is feasible to reach before next session, 3) brainstorm various ways to accomplish the goal, 4) evaluate pros and cons of each solution, including the likelihood they can actually implement it, 5) select the best solution, 6) create a plan to implement the solution, and 7) evaluate the plan afterward to ascertain the effectiveness of the solution. Practitioners teach and illustrate the PST process to clients at each session and encourage clients to implement action plans developed using the PST process. Clients are also encouraged to practice the PST process with additional problems between sessions, in order to gain mastery over the PST skills, enhance behavioral activation and as a result improve their belief in their ability to solve problems on their own (self efficacy).
223761165|NCT06494384|BEHAVIORAL|Problem Solving Treatment Aid (PST-Aid)|PST-Aid is an internet-based tool to support the delivery of PST. PST-Aid incorporates decision support for the practitioner as well as client and provides PST treatment support functions (i.e., scaffolding), including patient problem lists and session worksheets. PST-Aid was designed to be used during remote sessions, such that practitioners and clients can interact throughout the session while collaboratively viewing and editing worksheets on their own browsers.This system was developed into a prototype that was piloted and found to be acceptable and with adequate usability.
223761166|NCT00132418|DRUG|Enbrel|Enbrel
223761167|NCT00132418|DRUG|Placebo|Placebo
223761168|NCT05927792|DEVICE|repeated transcranial magnetic stimulation (continuous theta-burst stimulation)|Participants in intervention group will receive cTBS over the left M1for 5 consecutive days. The detailed parameters as follows: 80% of resting motor threshold (RMT), 60 cycles of 10 bursts of three pulses at 50 Hz were delivered in 2-second trains (5 Hz) with no intertrain interval (i.e. triplet standard cTBS, 1800 pulses, 120s). Stimulation sessions were delivered hourly, 10 sessions were applied per day (18,000 pulses/day).
223761169|NCT05927792|DEVICE|sham repeated transcranial magnetic stimulation|The sham group will be stimulated with a pseudo-stimulation coil, which emitted sounds with the same intensity, rhythm and vibratory sensation as the real stimulation, and the intervention target, duration and frequency are the same as the real intervention group.
223761170|NCT02578784|DEVICE|Angioplasty with drug-coated balloon|"Angioplasty with drug-coated balloon Elutax (Aachen Resonance, Germany)"
223761171|NCT02578784|DEVICE|Angioplasty with plain old balloon|"Angioplasty with plain old balloon Sterling (BostonScientific, Switzerland)"
223761172|NCT05325593|DRUG|romiplostim plus dexamethasone|Patients will be reviewed weekly for 8 weeks (56 days). After Week 8, patients will be reviewed every 2 weeks (14 days) for 8 additional weeks and then monthly until Week 52 (365 days) from randomization.
223761173|NCT05325593|DRUG|Dexamethasone|Patients will be reviewed weekly until the completion of dexamethasone cycles and for a minimum of 8 weeks (56 days). After that, every 2 weeks (14 days) for 8 additional weeks and then monthly until Week 52 (365 days) from randomization.
223761174|NCT05634525|DRUG|MRTX849|Given By PO
223761175|NCT03058133|OTHER|fMRI study|Functional brain activations of face-voice processing during a gender task
224202540|NCT01534390|DEVICE|In-line microfilter (Supor IV Filter; Pall Corporation, Port Washington, New York)|use of in-line microfilters with a pore size of 0,2 mcm and 1,2 mcm (only if parenteral nutrition is administered) at all intravenous accesses
224202541|NCT03750916|DRUG|Anlotinib Hydrochloride plus Docetaxel|Anlotinib Hydrochloride (12mg QD PO d1-14, 21 days per cycle) and Docetaxel (75mg/m2 IV d1)
224202542|NCT01610284|DRUG|Fulvestrant|Intramuscular fulvestrant 500 mg (Day 1 and Day 15 of Cycle 1 and Day 1 of every cycle thereafter)
224202543|NCT01610284|DRUG|BKM120|BKM120 100 mg once daily
224202544|NCT01610284|DRUG|BKM120 matching placebo|BKM120 matching placebo, once daily
224202545|NCT04014296|BEHAVIORAL|High Protein Diet|16 week group-based weight loss program with high protein diet. Approximate macronutrient distributions (carbohydrate:protein:fat) will be 32%:40%:28%. Because this protocol uses a sequential, multiple assignment, randomized trial (SMART) design, response will be assessed after 8 weeks. Non-responders will be randomized to either combine the HP diet with supervised resistance training counseling (2 days per week) or add a protein supplement.
223510537|NCT05174702|RADIATION|Irradiation collected at the end of the operation on the active dosimeter|Mesure of the irradiation collected at the end of the operation on the active dosimeter for the surgeon, the patient and the operating team
223510538|NCT04999293|DRUG|Ticagrelor|Patients were survivors and treated with DAPT (aspirin \[100 mg once daily\], cilostazol, or indobufen)combined with a P2Y12 receptor antagonist \[clopidogrel (75 mg once daily) or ticagrelor (90 mg twice daily)\]) at the time of hospital discharge.All patients were followed for 1 year in the outpatient clinic after hospital discharge.
223510539|NCT04108260|DRUG|Albutrepenonacog Alfa 1 UNT [IDELVION]|Clinical data will be collected from patients who suffered from hemophilia B, and switch from other FIX products to Idelvion as prophylaxis, prevention of bleeding (e.g. surgery) or treatment of bleeding.
223510540|NCT03438656|BEHAVIORAL|Behavioral Activation|The Adolescent Behavioral Activation Program (ABAP) will be used as the BA protocol. ABAP was developed and validated by McCauley, Dimidjian et al. to adapt BA to adolescents. ABAP is a 12-week protocol that utilizes an idiographic approach to foster rewarding experiences, effective problem solving, and goal attainment, and decrease avoidance, barriers to activation, and depressive rumination that may be contributing to depression severity and maintenance.
223616588|NCT04844502|OTHER|Physical rehabilitation|Rehabilitation can be applied to the intervention group in two ways: in person or by home orientation. The face-to-face form will correspond to 5 weeks of intervention, 3 sessions per week, which should include: a) aerobic resistance training of 30 minutes in total, five minutes of cooling down); b) strengthening of peripheral muscles using 20-minute sessions of calisthenic exercises; and c) maintained active stretching, for 10 minutes, for the main muscle groups. The home-based intervention will correspond to three months of daily activities, monitored twice a week in the first month and once a week in the second and third months, by telephone or video conference, and will follow an exercise protocol that includes: a) aerobic resistance training for 15 uninterrupted minutes; b) anaerobic training to strengthen the peripheral muscles for 15 minutes at intervals with breathing exercises; and c) maintained active stretching, for 10 minutes, for the main muscle groups.
223616589|NCT06164574|OTHER|Survival analysis|Immunotheray responses and long-term survival were evaluated in classical and other EGFR-mutant lung adenocarcinomas
223616590|NCT01708317|BEHAVIORAL|ACASI|Youth who participated in this study completed the ACASI -- they provided details about their sexual history, and the software program used their responses to create a recommendation for chlamydia/gonorrhea testing. The information obtained through the ACASI was integrated into the emergency department (ED) electronic medical record. ED physicians and nurses were able to review the information and order chlamydia/gonorrhea testing if needed.
223616591|NCT02493686|DIAGNOSTIC_TEST|audiogram|hearing test
223616592|NCT02401347|DRUG|Talazoparib Tosylate|Participants receive Talazoparib tosylate at 1 mg by mouth daily.
223616593|NCT05037474|PROCEDURE|TLE group|all patients underwent a transvenous lead extraction/explantation (TLE) procedure
223616594|NCT02936674|DEVICE|Light - standard|Light will be given during the night to determine its effects on melatonin suppression. This light will be an LED with standard spectral distribution
223616595|NCT02936674|DEVICE|Light - alternate|Light will be given during the night to determine its effects on melatonin suppression. This light will be an LED with an altered spectral distribution (different color)
223616596|NCT00363636|DRUG|Galiximab in combination with rituximab|Galiximab (500mg/m2 IV) in combination with Rituximab (375 mg/m2 IV), weekly x 4
223616597|NCT00363636|DRUG|Rituximab in combination with placebo|Rituximab (375 mg/m2 IV) in combination with placebo, weekly x 4
224202546|NCT04014296|BEHAVIORAL|Resistance Training|16 week weight loss program with normal protein diet and resistance training counseling. Approximate macronutrient distributions (carbohydrate:protein:fat) will be 53%:20%:26%. Because this protocol uses a sequential, multiple assignment, randomized trial (SMART) design, response will be assessed after 8 weeks. Non-responders will be randomized to either combine resistance training with HP/protein supplement or add supervised sessions with a personal trainer (2 days per week) to the resistance training regimen.
223510541|NCT00730600|PROCEDURE|Thai Traditional massage|Thai traditional massage for 2 hours by a single masseuse.
223616598|NCT02660164|DEVICE|Nautilus BrainPulse Recording|Comparison of Nautilus BrainPulse recordings in subjects who have a concussive event (Cohort A) to Nautilus BrainPulse recording in subjects who do not experience a concussive events (Cohort B or matched subjects to Cohort A). Recordings are obtained over a 2 week period every 2 to 3 days (at least 5 recordings per subject).
223616599|NCT00957879|DIETARY_SUPPLEMENT|Ergocalciferol|Ergocalciferol 50000 international units by mouth weekly for 12 weeks
223616600|NCT00957879|DIETARY_SUPPLEMENT|Calcitriol|Calcitriol 0.5 mcg by mouth daily for 12 weeks
223616601|NCT01111695|DEVICE|ApisSept|honey and ionic silver based dressing
223510542|NCT04799717|BEHAVIORAL|Gaming session|Participants will be provided the option to play an online game with the clinician for the first half of the session through an online platform.
223616602|NCT02354534|DRUG|Artesunate Suppositories|
223616603|NCT00174902|DRUG|inderal (drug), acetylsalicylic acid (drug)|
223616604|NCT00374439|BEHAVIORAL|Cognitive-behavioral|Cognitive-behavioral approach
223616605|NCT00374439|BEHAVIORAL|Interpersonal Therapy|Interpersonal therapy approach
223616606|NCT03169335|DRUG|QL1101|targeted vascular endothelial growth factor (VEGF) monoclonal antibodies
223616607|NCT03169335|DRUG|Avastin®|targeted vascular endothelial growth factor (VEGF) monoclonal antibodies
223616608|NCT03169335|DRUG|Paclitaxel|175 mg/m2, IV (in the vein) following investigational product on day 1 of each 21 day cycle. Number of cycles 4-6.
223616609|NCT03169335|DRUG|Carboplatin|AUC 5 IV, (in the vein) following paclitaxel on day 1 of each 21 day cycle. Number of cycles: 4-6.
223616610|NCT03458312|BEHAVIORAL|Family and Network Consultations|"Family and Network Consultation' (FNC) seek to identify and address patients' symptoms/concerns and caregiver burden on one side and identify the resources and opportunities to ease their burdens on the other side.~Intervention: FNC IG will receive four family consultations over 52 weeks relying on the Calgary model and Patient-reported outcome on symptom management and concerns."
223616611|NCT06526416|OTHER|Anterior segment optical coherence tomography|Imaging of the anterior segment of the eye using optical coherence tomography
223616612|NCT02972203|BEHAVIORAL|Mindfulness Training for Primary Care|• MPTC is a primary care adaptation that includes core common Mindfulness-Based Intervention (MBI) elements. MTPC is a referral-based, insurance-reimbursable 8-week group psychotherapy delivered primarily by Patient-Centered Medical Home-integrated behavioral clinicians. MTPC groups are 2 hours long for 8 weeks, with a 7-hour day of silent group practice on a weekend. MTPC also emphasizes psychoeducational skills for self-regulation including a collaborative primary care provider (PCP) action-planning appointment during week 6.
223616613|NCT02972203|BEHAVIORAL|Mindfulness Intro. +resources +waitlist|Control arm: Participants receive a 60-minute introduction to mindfulness group plus referral to a list of community mindfulness resources such as private-pay community mindfulness classes, mobile mindfulness applications, books, and online recordings. These participants are added to a 6-month waitlist for a Cambridge Health Alliance mindfulness-based intervention group. All participants are scheduled to meet with their primary care provider during week 6 for a collaborative action planning visit.
223616614|NCT04469972|OTHER|Breathing Exercises|Breathing exercise is defined as therapeutic intervention to create a particular form of breathing.The application of the breathing exercise program is as follows; I. Pursed Lip Breathing Exercise (Total 10 minutes) II. Diaphragmatic breathing exercise (10 minutes in total), III. Cough exercise (Total 10 minutes)
223616615|NCT03259555|DRUG|Brexpiprazole|Brexpiprazole was administered orally with flexible dosing from 2 to 4 mg/day; titrated to a maximum of 4 mg/day for 3 weeks.
223616616|NCT03259555|DRUG|Placebo|Administered orally daily for 3 weeks.
223616617|NCT05057663|DRUG|Bleomycin and 5-fluorouracil|"In the bleomycin-treated group, bleomycin vial will be diluted first with 5 ml distilled water At time of treatment session 2 ml of lidocaine 2% and 1 ml of the bleomycin stock solution will be taken in 100-unite insulin syringe. Thus, the working bleomycin solution will be used in treatment 1 mg/ml. The bleomycin solution will be injected intralesional till blanching of the wart will be occurred. The amount of injection ranging from 0.2, 0.5, 1 ml according to size of warts; (5 mm, 10 mm, \>10 mm) maximum for 1 ml in single wart and 2ml in treatment session. Treatment session will be done every two weeks maximum four sessions.~In 5-fluorouracil treated group, 5-fluorouracil vial ( 1 ml of 50 mg/ml 5-FU will be mixed with 0.25 ml of lidcaine 2% Every wart will be injected with 0.1 ml of the previous mixture into it base using an insulin syringe till blanching of the warts maximum 2ml of 5-FU per session. Treatment session will be done every two week for maximum 6 sessions"
223616618|NCT00000346|BEHAVIORAL|counseling|
223616619|NCT03850860|OTHER|empirical antibiotherapy|comparison of the outcome in the 2 groups having had 2 different empirical antibiotherapies
223616620|NCT06303921|DRUG|11C-M503 PET|2 hour Positron Emission Tomography (PET) scan using new radiotracer 11C-M503
223616621|NCT06303921|DIAGNOSTIC_TEST|Brain MRI|MRI scan of brain.
223616622|NCT06303921|DIAGNOSTIC_TEST|Amyloid PET|PET scan with Florbetaben F18 or 11C-PiB
223616623|NCT06303921|BEHAVIORAL|Neurological assessments|Neurological assessments, including a video interview.
223616624|NCT06731088|DRUG|Midazolam|Midazolam, a benzodiazepine sedative commonly used in ICU, acts on GABA receptors in the central nervous system to produce dose-related hypnosis, anti-pyroanxiety and anterograde amnesia, and has corresponding competitive antagonists \[8\]. It has rapid onset and short duration, but its deficiency lies in that the metabolites are still active. Thus easy accumulation, prolong the recovery time of patients
223616625|NCT06731088|DRUG|Remazolam besylate|Remazolam besylate is a new type of benzodiazepine sedative drug metabolized by tissue esterase. It is not metabolized by liver and kidney, and is metabolized by tissue esterase rapidly in vivo to produce inactive metabolites.
223616626|NCT01363089|DRUG|Ketorolac tromethamine|30 mg of intranasal ketorolac tromethamine (one 100 µL spray into each nostril of a 15%, pH 7.2 solution)
223510543|NCT05692557|DEVICE|Virtual reality|"The Oculus Rift's (Lenovo, Beijing, China) Fujii - Mystical Journey was the game played by the VRD group on a tablet. The game is a peaceful, ethereal voyage that passes through several surreal, natural locations.~The game combines elements of adventure, agriculture and revitalizing music. It alternates between outdoor exploration and inventive gardening. Players explore three different magical biomes. The life force in each biome is restored by interacting with the plants and animals there."
223510544|NCT05692557|PROCEDURE|Progressive muscle relaxation|The patients of the control group performed Progressive muscle relaxation technique, a relaxation technique used to control pain. It is believed that anxiety-inducing thoughts result in muscle tension and hence muscle relaxation can reduce anxiety. The relaxation technique consisted of tensing and relaxing different muscles, starting from the toes and finally involving muscles of the head and neck. It was recommended that this be done in a peaceful, distraction-free environment. The muscle groups were tensed for a period of 5 seconds and then relaxed for 30 seconds.
223510545|NCT03931811|DEVICE|Short wave diathermy|SWD group took short wave diathermy with specifications of 400 watt power output, 27.12 MHz frequency, 11.06m wave length, using condensators and electrodes of 12 cm diameter parallel to the knee for 20 minutes(Enraf-Nonius, Curapuls 970 Short wave diathermy device).
223510546|NCT03931811|OTHER|Prolotherapy|Prolotherapy solutions were injected to the knee by a blinded physician in the group, using 25 gauge needle, with solutions being 6 ml 25 % dextrose (3 ml 20% dextrose + 3 ml 30% dextrose) for intraarticular, and 20 ml 15% dextrose (10 ml 0,9% NaCl + 10 ml 30% dextrose) for periarticular. Injection points wwere defined as medial collateral ligaments, adhesion points of quadriceps tendon, adhesion points of patellar tendon, tuberositas tibia, pes anserinus, lateral collateral ligaments, coronal ligaments, medial and lateral tibia plateaus. Patients were blinded to their treatment groups
223510547|NCT06446323|DRUG|0.2 ml dose of sucrose|Both interventions aim to provide pain relief to neonates following minor procedures by administering sucrose solution orally. The study evaluates the efficacy of each dose (0.2 ml vs. 0.5 ml) in reducing post-procedural pain intensity, as measured by the Premature Infant Pain Profile (PIPP). Additionally, any adverse events associated with the administration of sucrose solution are documented and analyzed as part of the study.
223510548|NCT03721965|DRUG|Itacitinib|Phase 1: Itacitinib administered orally once daily at the protocol-defined dose according to age cohort, with dose reductions or modifications based on safety assessments. Phase 2: Itacitinib administered orally once daily at the recommended dose from Phase 1.
223510549|NCT03721965|DRUG|Corticosteroids|Phase 1 and 2: Methylprednisolone 2 mg/kg IV daily (or prednisone equivalent) or at a dose that is appropriate for the severity of disease as outlined per local treatment guidelines as background treatment.
223510550|NCT06377592|OTHER|Sample collection without intervention|No Intervention
223510551|NCT00563316|DRUG|Panitumumab|The first infusion of panitumumab will occur on Cycle 1 Day 4. On Cycle 2 Day 1, panitumumab will be administered on the same day as irinotecan and every 2 weeks thereafter.
223510552|NCT00563316|DRUG|Irinotecan|The first infusion of irinotecan will occur on Cycle 1 Day 1. Irinotecan will be administered on the same day as panitumumab on Cycle 2 Day 1 and every 2 weeks thereafter.
223616627|NCT01363089|DRUG|Oxymetazoline hydrochloride|Single intranasal dose of oxymetazoline hydrochloride (Afrazine®) (3 sprays of a 0.05% solution into each nostril) followed 30 minutes later by 30 mg of intranasal ketorolac tromethamine (one 100 µL spray into each nostril of a 15%, pH 7.2 solution)
223616628|NCT04532034|BEHAVIORAL|Peer-Delivered Decision Support Intervention|An intervention provided by a trained peer interventionist to facilitate treatment decision making among emerging adults with early psychosis. Specific components of this intervention may include facilitating access to information, clarifying values, helping a person obtain the needed support to make a decision, and screening for implementation barriers. Due to having lived experience of a mental health condition, the peer interventionist will also be able to provide unique types of information and support within the coaching process.
223616629|NCT05894785|PROCEDURE|External cephalic version|An ECV attempt is made on the study group
224202547|NCT03262519|DIAGNOSTIC_TEST|Computer based neurocognitive testing|Iowa Gambling Task, The Balloon Task, Intertemporal choices task, Cognitive Reflection Test, Physiological and self-reported measures of OSA/sleep related symptoms, General health and physiological measures.
224312633|NCT02518516|DRUG|Pravastatin|"Current cumulative exposure to pravastatin (ATC C10AA03) will be defined as a prescription for any dose of pravastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-365 days, or 366-730 days).~Past exposure to pravastatin will be defined as a prescription for any dose of pravastatin (ATC C10AA03) dispensed \>120 days prior to the index date (i.e. no exposure within 120 days of the index date)."
224312634|NCT02518516|DRUG|Lovastatin|"Current cumulative exposure to lovastatin (ATC C10AA02) will be defined as a prescription for any dose of lovastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-365 days, or 366-730 days).~Past exposure to lovastatin will be defined as a prescription for any dose of lovastatin (ATC C10AA02) dispensed \>120 days prior to the index date (i.e. no exposure within 120 days of the index date)."
224312635|NCT02518516|DRUG|Atorvastatin (<20mg)|"Current cumulative exposure to low dose atorvastatin (ATC C10AA05) will be defined as a prescription for \<20 mg of atorvastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-365 days, or 366-730 days).~Past exposure to low dose atorvastatin (ATC C10AA05) will be defined as a prescription for \<20 mg of atorvastatin dispensed \>120 days prior to the index date (i.e. no exposure within 120 days of the index date)."
224312636|NCT02518516|DRUG|Simvastatin (<40 mg)|"Current cumulative exposure to low dose simvastatin (ATC C10AA01) will be defined as a prescription for \<40 mg simvastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-365 days, or 366-730 days).~Past exposure to low dose simvastatin (ATC C10AA01) will be defined as a prescription for \<40 mg simvastatin dispensed \>120 days prior to the index date (i.e. no exposure within 120 days of the index date)."
224312637|NCT01730066|DIETARY_SUPPLEMENT|L. plantarum 299 and L. plantarum 299v (+maltodextrin)|"Patients will be given a mixture of maltodextrin ( a starch product often used i alimentary products) and two strains of probiotic bacteria ( L. plantarum 299 and L. plantarum 299v ) dissolved in water. They will gurgle and swallow the suspension from the day before surgery. Postoperatively they will be given the probiotic mixture via a nasogastric tubing twice a day and when the responsible surgeon find it suitable also orally as described above. When they can swallow no study product is given through the nasogastric tube.~Patients randomized 1:1 between groups"
224312638|NCT00003324|PROCEDURE|conventional surgery|
224312639|NCT00003324|RADIATION|radiation therapy|
223510553|NCT01171937|DRUG|Risperidone|children get randomized to either placebo or active risperidone
223510554|NCT01171937|DRUG|Placebo|Children get randomized to either placebo or risperidone
224202548|NCT05596552|DRUG|hyperbaric bupivacaine and dexmedetomidine|In a 3 ml syringe, 5 µg dexmedetomidine was added to the 2 ml of 10 mg hyperbaric bupivacaine, to have a total volume of 2.5 ml for intrathecal spinal injection over 3 minute without barbotage
224202549|NCT05596552|DRUG|Bupivacaine-Fentanyl group|In a 3 ml syringe, 25 μg fentanyl was added to the 2 ml of 10 mg hyperbaric bupivacaine, to have a total volume of 2.5 ml for intrathecal spinal injection over 3 minute without barbotage
223510555|NCT05610150|DEVICE|Myobrace Functional Appliance|An Appliance for treating growing Class II patients with mandibular deficiency
223510556|NCT05610150|DEVICE|Twin Block|An Appliance for treating growing Class II patients with mandibular deficiency
223510557|NCT04972175|DRUG|50-Hour Intervention - Rapid Insulin lispro|Subcutaneous-delivery of insulin lispro using pump therapy.
223510558|NCT04972175|DRUG|50-Hour Intervention - BC LisPram|Subcutaneous-delivery of BC LisPram using pump therapy.
223510559|NCT02468700|DRUG|Dexamethasone|
223510560|NCT02468700|OTHER|Placebo Vehicle|
223510561|NCT01217411|PROCEDURE|Cognitive Assessment|Ancillary studies
223510562|NCT01217411|DRUG|Gamma-Secretase Inhibitor RO4929097|Given PO
223510563|NCT01217411|OTHER|Laboratory Biomarker Analysis|Correlative studies
223510564|NCT01217411|RADIATION|Stereotactic Radiosurgery|Undergo SRS
223510565|NCT01217411|RADIATION|Whole-Brain Radiotherapy|Undergo WBRT
223510566|NCT02573896|DRUG|Dinutuximab|17.5 mg/m2/day of dinutuximab will be given for 4 consecutive days (days 1-4 of each course) via intravenous infusion over ten hours.
223510567|NCT02573896|BIOLOGICAL|NK Cells|The designated dose of NK Cells will be infused on Day 5 by IV drip using a Y infusion set with a filter-less chamber. Cells should not be delivered at a rate faster than 10 ml/kg/hr (as determined by drip rate or syringe push rate), and should not take longer than one hour for total infusion time if possible.
223510568|NCT02573896|DRUG|Lenalidomide|25 mg/m2/day of Lenalidomide will be given at Dose Level 4, once daily with or without food by mouth on days -6 through +14.
224202550|NCT03519152|DRUG|low dose diclofenac|it is a split mouth design in which one side recieved low dose diclofenac(25mg) after periodontal flap surgery and in next week second side will recieve diclofenac 50mg after flap surgery.
224202551|NCT04537052|PROCEDURE|Ven Restoration Therapy|This is a novel and promising method, applied percutaneously, in the treatment of deep venous insufficiency . In this method, developed based on the effects of compression garments, a polymer consisting of cyanoacrylate and hyaluronic acid is injected, with ultrasound-guidance, percutaneously around the femoral vein. In this way, the diameter of the vein is reduced, and function is restored to the inadequately functioning valve. The procedure is also called percutaneous valvuloplasty. The underlying idea in the development of this product was that hyaluronic acid might cause an increase in connective tissue, while cyanoacrylate could serve as an exoskeleton by forming heavy tissue.
224202552|NCT03327532|PROCEDURE|Clinical examination centered on congestion|Clinical examination centered on congestion will be performed within 72 hours of admission and before discharge from hospital
224312640|NCT04981496|OTHER|Observational Study during Clinical and Simulated arrhythmias in patients with ICDs|Observational Study during Clinical and Simulated arrhythmias in patients with ICDs
224312641|NCT06387602|PROCEDURE|Cryotherapy|Take an icepack and wrap it in a moisture-absorbing towel. The temperature of the icepack should be between 1˚ to 10˚. Any temperature below 0˚ can damage the skin. The icepack will be on strained adductors for 5-7 minutes. Patients will be advised to do cryotherapy at home for 24-42 hours after every 2 hours.
224202553|NCT03327532|PROCEDURE|Cardio-pulmonary and peritoneal ultrasound|Cardio-pulmonary and peritoneal ultrasound will be performed within 72 hours of admission and before discharge from hospital
224202554|NCT03327532|BIOLOGICAL|Blood sample retrieved for biological assessment and biobanking|Blood sample collection will be performed within 72 hours of admission and before discharge from hospital
224202555|NCT03327532|OTHER|Telephone interview|Telephone interview will be performed 3, 12 and 24 months after discharge from hospital
224202556|NCT03327532|BIOLOGICAL|Urinary sample retrieved for biological assessment and biobanking|Urinary sample collection will be performed within 72 hours of admission and before discharge from hospital
224202557|NCT03327532|PROCEDURE|jugular and renal ultrasound (optional)|optional jugular and renal ultrasound performed within 72hours of admission and before discharge from hospital
224202558|NCT06700694|OTHER|Technology-assisted, family-engaged in-bed activities|Technology-assisted, family-engaged in-bed activities include handgrip interactive games, virtual reality butterfly catching, virtual reality magic cube games, and immersive in-bed cycling, performed 20 minutes per session, twice daily, five days a week, primarily assisted by family members.
224202559|NCT06700694|OTHER|Protocol-oriented early mobilization program|The protocol-oriented early mobilization program is implemented based on the patient's muscle strength and the Intensive care unit Mobility Scale (IMS), including lying, sitting, standing, stepping, and walking, once daily for 20-60 minutes, five days a week, carried out by physiotherapist and researcher.
224202560|NCT02405494|DIETARY_SUPPLEMENT|Beverage 1|
224202561|NCT02405494|DIETARY_SUPPLEMENT|Beverage 2|
224202562|NCT02405494|DIETARY_SUPPLEMENT|Beverage 3|
224202563|NCT02405494|DIETARY_SUPPLEMENT|Beverage 4|
224202564|NCT02405494|DIETARY_SUPPLEMENT|Beverage 5|
224202565|NCT02405494|DIETARY_SUPPLEMENT|Beverage 6|
224202566|NCT02405494|DIETARY_SUPPLEMENT|Beverage 7|
224202567|NCT02405494|DIETARY_SUPPLEMENT|Beverage 8|
224202568|NCT02405494|DIETARY_SUPPLEMENT|Beverage 9|
224202569|NCT05672394|PROCEDURE|Continuous Serratus anterior plane block|in lateral position a linear transducer (10-12MHz, M-Turbo) will be used, The 5th rib is identified in the mid-axillary line. The following muscles are overlying the rib latissimusdorsi ,teres major, and serratus muscle.The needle (22G, 50-mm Tuohy needle) is introduced in-plane targeting the plane superficial to serratus muscle. local anesthetic is injected then a catheter is threaded and . Ultrasound-guided SAPB was done using a serratus anterior catheter Group DL (n=20) received a bolus of 30 mL of 0.25% bupivacaine followed by a continuous infusion of 0.125% bupivacaine at a rate of 7-12 ml/hr according to patient response upon ICU arrival after the stabilization of the clinical status. The infusion was continued until the end of the 1st 24 hours postoperatively .
223510569|NCT04910503|DRUG|Dexamethasone intravitreal implant|Implant every 4 months if necessary
223510570|NCT04910503|DRUG|Fluocinolone Acetonide Intravitreal Implant|Implantation
223510571|NCT05736614|BEHAVIORAL|Stage 1 Strength Based Case Management (SBCM) Condition|Intervention participants will receive a trained SBCM to motivate, support, and assist in linkage to PrEP prescribers to help facilitate obtaining PrEP medication to initiate treatment.
223510572|NCT05736614|BEHAVIORAL|Stage 2 PrEPare for Work Intervention Condition|Intervention participants will receive 1-on-1 adherence counseling and personalized daily text messaging reminders to increase PrEP adherence. Intervention participants will undergo three adherence intervention sessions (once per week for 3 weeks) with interventionist.
223510573|NCT05026619|OTHER|Information about age-related fertility|"The following information is provided:~Age and fertility IVF success rates and side effects"
223510574|NCT05026619|OTHER|Information about policy initiatives|"The following information is provided:~Assisted reproductive technology treatment subsidies Other fertility-related policies"
223510575|NCT05026619|OTHER|Information about diabetes|"The following information is provided:~Diabetes risk factors and treatment Diabetes-related policies"
223510576|NCT05554003|DRUG|Temozolomide capsule|Metronomic temozolomide 60 mg/die continuously
223510577|NCT04899466|DEVICE|ActiGraft|Whole blood clot (WBC) gel
223510578|NCT06358443|DIETARY_SUPPLEMENT|Jarlsberg cheese|Jarlsberg cheese + Vitamin D ampulles + Calcium
223510579|NCT03503799|OTHER|Observation|"Visit 1 Informed consent Medical history Demographics Result of EndoPredict® Test Status of menopause Disease status Tumor board decision Planned anti-tumor-therapy~Visit 2, 1 year after inclusion This visit will be documented at the study site Status of menopause Disease status Anti-tumor therapy Survival~Following visits For these visits, patients will be asked directly through the Center for Clinical Trials of the Philipps-University Marburg (KKS Marburg) via phone.~Status of Menopause Disease status Anti-tumor therapy Survival~Treatment after end of the study The patient will be treated during and after end of study by physician's choice."
223510580|NCT04332393|DRUG|Metformin|Metformin tablets according to glycemic control. Initial dose: 425 mg before meals (breakfast, lunch and supper) and 1700 mg around 22:00. Modifications may take place according to glycemic control
223510581|NCT05272696|DRUG|Nab-paclitaxel, cisplatin and Pembrolizumab combination|Pembrolizumab in combination with Nab-paclitaxel and cisplatin as induction therapy
223510582|NCT05272696|PROCEDURE|surgery|Patients with PR but the maximum diameter of tumor \> 3cm or SD or PD can receive surgery directly.
223510583|NCT05272696|RADIATION|Adjuvant Chemoradiotherapy|After surgery, adjuvant Chemoradiotherapy or radiotherapy will be given for patients with high-risk factors.
223510584|NCT05272696|DRUG|Radical concurrent chemoradiotherapy|Patients with PR and maximum tumor diameter ≤ 3cm or CR evaluated by MDT after 2 courses induction therapy can receive Radical concurrent chemoradiotherapy. Evaluation was performed 3 months after CRT. After MDT discussion, patients with high-risk factors need maintenance treatment.
223510585|NCT06963593|DRUG|Nanocrystal Megestrol Acetate in Combination with First-Line Standard Immuno-Chemotherapy Regimen|Megestrol Acetate Nanocrystal Oral Suspension Group: Nanocrystal Megestrol Acteate Oral Suspension (QD, up to 16 weeks from the initiation of immuno-chemotherapy) + PD-1 inhibitor (Q3W, until PD) + Chemotherapy regimen (TP regimen or XELOX regimen or SOX regimen selected based on cancer type, Q3W, as per package insert)
223510586|NCT06963593|DRUG|First-Line Standard Immuno-Chemotherapy Regimen|PD-1 inhibitor (Q3W, until PD) + Chemotherapy regimen (TP regimen or XELOX regimen or SOX regimen selected based on cancer type, Q3W, as per package insert)
223510587|NCT06964334|DRUG|Lansoprazole|oral lansoprazole (1 mg/kg per day, max. 30 mg bid)for 14 day
223761176|NCT03932396|OTHER|Observational study|No intervention is planned outside of usual clinical practice. Only active screening for hepatotropic virus infection, mainly hepatitis C virus, HIV, and mental illness will be carried out. If any disease is detected, patients will be referred to the corresponding specialized care following the usual clinical practice.
223616630|NCT02194595|DRUG|Basal insulin and exenatide|
223616631|NCT02194595|DRUG|Basal insulin only|
224202570|NCT05672394|PROCEDURE|Thoracic Epidural|A thoracic epidural catheter was done to the patient while sitting. Tuohy needles are used. Epidural space can be identified by loss of resistance. Injection begins with a negative aspiration and a test dose (3 ccs of 1.5% lidocaine with 1:200,000 epinephrine) .A Continuous epidural technique through the placement of a catheter 3-5 cm beyond the needle is applied. Injection in 5ml increments of 0.25% bupivacaine is used until the block of the required segments achieved ( 10 to 15ml). sensory testing is via pinprick and cold test to detect sympathetic block . Throughout the technique hourly injection of 5 ml 0.25% bupivacaine for maintenance.
224202571|NCT05672394|DRUG|Bupivacaine|bupivacaine
224202572|NCT05672394|DRUG|lidocaine with epinephrine|3 ccs of 1.5% lidocaine with 1:200,000 epinephrine
223616632|NCT02194595|DRUG|Basal insulin and bolus insulin|
223616633|NCT05943886|DRUG|HEC88473 injection|HEC88473 will be provided as a 17 mg/mL solution and will be administered by subcutaneous injection in the abdomen.
223616634|NCT05943886|DRUG|Placebo|Placebo will be administered by subcutaneous injection in the abdomen.
223616635|NCT02552030|DEVICE|cuff device (Omron HBP-1300-E Pro)|Comparison of systolic blood pressure results measured with an oscillometric cuff device (Omron HBP-1300-E Pro) and iPhone 4s
223616636|NCT02552030|DEVICE|iPhone 4s|
223761177|NCT00223106|DEVICE|Vaginal Sling|
224202573|NCT04035694|OTHER|Media Aware Sexual Health - High School|Media Aware is an online media literacy and sexual health education program developed for high school students that addresses the influence of media on sexual behaviors explicitly using established message processing theory. The program consists of 4 self-paced modules each with two to three lessons. Broadly, the modules cover healthy and unhealthy relationships, sexually transmitted infections, consent, substance use, pregnancy, protection and contraception, and communication between adolescents and their partners, parents, or health providers. Users also learn media literacy skills including message deconstruction to help examine the truth behind media messages.
223510588|NCT06964334|DRUG|amoxicillin|amoxicillin (50 mg/kg per day, max. 1 g bid) for 14 day
223510589|NCT06964334|DRUG|clarithromycin|oral clarithromycin (15 mg/kg per day, max. 500 mg bid) for 14 day
223510590|NCT06964334|DRUG|vitamin D|vitamin D therapy of 4000-5000 units daily in patients over 12 months old.
223510591|NCT03589053|DEVICE|Limb remote ischemic conditioning|The LRIC treatment consisted of 5 cycles of bilateral upper limb ischemia for 5 minutes followed by reperfusion for another 5 minutes performed twice a day for a total of 90 consecutive days.The procedure was performed by using an electric autocontrol device with cuffs that inflated to a pressure of 200 mmHg during the ischemic period and deflated during the reperfusion.
223510592|NCT03589053|DEVICE|Control group|Participants in the control group receive both sham LRIC and standard clinical therapy.
223510593|NCT06380504|BEHAVIORAL|R-SWITCH integrated intervention package|"1. Monthly group meetings of Alliance for Development (AFD) community groups) and their members (caregivers of children 0-59 months of age):~   * Introduction and refresher of Family-led MUAC~  * Active screening of wasting by AFD~  * Group SBCC on Infant and Young Child Feeding (IYCF), health and Water, Sanitation and Hygiene (WaSH) with a focus on SAM~  * Promotion of health services such as GMP~2. Introduction of weight-for-age Z-score \<-3 as screening criterion for passive screening by health extension workers at any contact with children (e.g. during GMP)~3. Promotion of Family-led MUAC screening and SAM awareness to fathers during male agricultural/pastoralist extension activities and by community and religious leaders (creating social support)~4. Follow-up and counselling during home visits by AFD leaders of i) earlier referred cases of SAM, ii) cases enrolled in SAM OTP, iii) and recovered SAM cases discharged from OTP~5. Strengthening communication between HEW and AFDs"
223510594|NCT06084286|BIOLOGICAL|Dual-targeting CLDN18.2 and PD-L1 CAR-T cells|The trial consists of a traditional '3 + 3' pattern dose-escalation phase and a dose-expansion phase.
223510595|NCT03925714|OTHER|life style|life sryle control only
223510596|NCT03925714|DRUG|Metformin|metformin twice daily
223510597|NCT03925714|DRUG|Nigetella salivata|NS twice daily
223510598|NCT02745405|OTHER|Fat Suit|Participants wear a fat suit.
223510599|NCT02745405|OTHER|Control Condition|Participants wear same clothing as intervention, but in their own size.
223510600|NCT05497882|BEHAVIORAL|E-Learning Prototype for Dementia Care|Usability testing System Usability Scale
223510601|NCT03536065|BEHAVIORAL|Opioid Reduction Intervention|Patient education discharge sheet, nursing education, opioid prescription reduction based on Pre-Intervention data
223510602|NCT03536065|BEHAVIORAL|Current Care|Current unchanged care provided; unchanged provider prescribing and unchanged education of patients prior to intervention
223510603|NCT05791149|DIAGNOSTIC_TEST|saliva tube|1 tube of saliva (\~2 ml) will be collected from all patients enrolled in the study. For operated OSCC patients a second tube will be collected during the routine hospital visit 4 weeks after surgery
223510604|NCT05199155|BIOLOGICAL|NerVFIX|Decellularized, freeze-dried and sterile allogeneic graft of artery or vein from umbilical cord use by the investigator as a nerve regeneration conduit
223510605|NCT03269786|DIAGNOSTIC_TEST|Liver function tests (ALT,AST,ALBUMIN,BILIRUBIN,INR,PC,CBC)|Liver function tests will be assessed after endoscopic varisceal treatment for 6 monthes
223510606|NCT03269786|DEVICE|biannual ultrasonography|portal vein diameter , portal vein velocity and flow direction, volume flow in portal vein , congetive index, spleen size.will be assessed after endoscopic varisceal treatment by using biannual ultrasonography for 6 monthes
223510607|NCT03014388|OTHER|autogenous bone|Autogenous bone graft (gold standard). sinus lift with autogenous bone.
223510608|NCT03014388|OTHER|Mineralized plasmatic matrix|By using venoud blood from the patient, together with bone graft, a centrifuge will be used to obtain the top layer after centrifuging blood at 3000 RPM.
224202574|NCT05272267|OTHER|AI-assisted models providing diagnosis and prognostic information|AI-assisted models providing diagnosis and prognostic information in the ED, including triage, ICD coding, chest x ray alerts, critical event alerts, readmission prediction, and post-cardiac arrest prognostication.
224202575|NCT05272267|PROCEDURE|Critical treatment|Critical treatment of the emergency room
224202576|NCT06061601|DEVICE|Exoskeleton stroke group|The exoskeleton stroke group will receive gait rehabilitation with the TWIN-Acta exoskeleton
224202577|NCT02395601|DRUG|CPI-1205|Small molecule inhibitor of the enzyme EZH2
224202578|NCT02657746|OTHER|multi-component interventions|The multi-component interventions (MCI) is comprised of all the following five components: 1) home health education (HHE) by government community health workers (CHWs), plus 2) blood pressure (BP) monitoring and stepped-up referral to a trained general practitioner (GP) using a checklist, plus 3) training public and private providers in management of hypertension and using a checklist, plus 4) designating hypertension triage counter and hypertension care coordinators in government clinics, plus 5) a financing model to compensate for additional health services and provide subsides to low income individuals with poorly controlled hypertension.
224202579|NCT01296269|DRUG|Oxytocin|one-time intranasal administration, 24 International Units, 5 puffs for each nostril
224202580|NCT01296269|DRUG|Arginine Vasopressin|one-time intranasal administration, 20 International Units, 5 puffs in each nostril
224202581|NCT01296269|DRUG|placebo|contains all the ingredients as in the oxytocin and vasopressin conditions, save for the active ingredient, one time intranasal administration, 5 puffs in each nostril
224202582|NCT06564155|DEVICE|carotid duplex|measure Carotid intima media thickness
224202583|NCT06439316|BEHAVIORAL|Sedentary behavior|Total sedentary time was assessed by self-reported daily hours of sitting
224202584|NCT06439316|BEHAVIORAL|Depressive symptoms|depressive symptoms were assessed by Patient Health Questionnaire 9 scale
224202585|NCT00442338|DRUG|montelukast sodium|Montelukast 7 mg single injection (IV bolus administration) over 2-3 minutes
224202586|NCT00442338|DRUG|montelukast sodium|Montelukast 14 mg single injection (IV bolus administration) over 5 minutes
224202587|NCT00442338|DRUG|aminophylline hydrate|Aminophylline 250 mg IV drip infusion over 60 minutes
224202588|NCT00448110|DRUG|Intravenous Diclofenac (DIC075V)|Intravenous Diclofenac (DIC075V): 1 of 2 dosage levels
224202589|NCT00448110|DRUG|Intravenous Ketorolac|Intravenous Ketorolac
224202590|NCT00448110|DRUG|placebo|placebo
224202591|NCT05760638|DEVICE|Nerivio|Remote electrical neuromodulation (REN) device for the acute treatment of migraines. The device delivers transcutaneous electrical stimulation to the upper arm to induce conditioned pain modulation (CPM) that activates a descending endogenous analgesic mechanism. The treatment is self-administered and controlled by a smartphone application
224202592|NCT01125358|DRUG|LY2140023|Administered orally, twice daily for up to 7 weeks of treatment
224202593|NCT01125358|DRUG|Placebo|Administered orally, twice daily for up to 7 weeks of treatment
224202594|NCT04434235|OTHER|axial load|With a helmet with Velcro fastener we will add additional weight to produce axial load on the cervical spine
224202595|NCT03976817|PROCEDURE|aortic valve replacement|After median sternotomy, cardiopulmonary bypass (CPB) was established between the ascending aorta and the right atrium. The aorta was cross-clamped and a high potassium warm cardioplegia was infused and repeated every 15 minutes. The aortotomy was made above the sinuses and the aortic valve was removed. The prosthesis was chosen one size larger than the maximal sizer that could be inserted, which was also used to determine the appropriate height for insertion of the sutures along the wall of the non-coronary sinus.
224202596|NCT01157065|DRUG|AL-78898A|Investigational treatment
223510609|NCT01282554|DEVICE|electrostimulation program (Rehab 400)|"electrostimulation program (Rehab 400) : electrostimulation program during dialysis sessions for 3 months.~Electrostimulation modalities have been chosen to seek both slow and fast muscle fibers : 35 Hz ; impulsion time: 400 µsec ; on/ off : 7'' contraction / 8'' relaxation. Stimulated muscles are quadriceps. Electrostimulation time will be 30 minutes. Each patient will individually regulate work intensity, maximal intensity should be the maximal tolerable intensity.~Electrostimulation will be done 3 times per week. In case of asthenia or medical condition, electrostimulation can be delayed. The program will take place for 3 months."
223510610|NCT01678690|DRUG|Gemcitabine HCl Oral Formulation|Gemcitabine HCl Oral Formulation 80 mg/vial Subjects will be treated on Day 1 of the 7-day study treatment period
223616637|NCT02147756|DEVICE|CO2RE|"Subjects will be randomly assigned to three different time-points of laser treatment: immediately, 1 week or 4 weeks prior the scheduled abdominoplasty. Subjects will be required to attend between 2 to 3 visits depending on the interval between the treatment and the abdominoplasty procedure. One side of the abdomen will be treated using the CO2RE device and the other side with the RePair device. The investigator will also leave an untreated area (control).~Punch biopsies will be obtained before or during the abdominoplasty procedure from the two treated areas (CO2RE and RePair) and one control (un-treated) areas (on the abdominoplasty area) for histological evaluation."
223616638|NCT02147756|DEVICE|Repair|
223616639|NCT05772624|DRUG|low dose nivolumab in combination with AVD|Nivolumab as an standard dose of 40mg in combination with AVD.
223616640|NCT04339816|DRUG|Azithromycin|orally or into nasogastric tube for 5 days
223616641|NCT04339816|DRUG|Hydroxychloroquine|orally or into nasogastric tube for 5 days
223616642|NCT04339816|DRUG|Placebo|orally or into nasogastric tube for 5 days
223616643|NCT03420872|OTHER|Nutrient mixtures|consumption of a mixture of beneficial nutrients
223616644|NCT00148148|DRUG|caspofungin|
223616645|NCT00148148|DRUG|liposomal amphotericin B|
223616646|NCT01190501|DEVICE|complier device|"The procedure of use of complier has to follow the recommendations for standardization of subject conditions.~Assessment of arterial distensibility: pulse wave velocity (PWV), aortic stiffness is assessed by PWV which is a classic index of arterial stiffness. A semi-automatic device is used to measure carotid-femoral PWV. The distance covered by the pulse wave is measured on the surface of the body and represented the distance between the 2 recording sites."
223616647|NCT05137964|DIAGNOSTIC_TEST|Vitamin D|Serum Biochemical routine lab workup and gynaecological ultra sound AFC
223616648|NCT03392220|PROCEDURE|Unilateral Neck Dissection|patient undergo unilateral (affected side) neck dissection, along with the excision of the laryngeal primary tumor
223761178|NCT03364088|PROCEDURE|Spinal anesthesia with tourniquet|Operation is done under spinal anesthesia and surgical tourniquet is used.
224202597|NCT01157065|DRUG|Ranibizumab|Anti-vascular endothelial growth factor (VEGF) treatment
224202598|NCT01764776|DRUG|LDE225|LDE225
224202599|NCT01060007|RADIATION|External beam radiation|
224202600|NCT01060007|DRUG|Oxaliplatin|
224202601|NCT01060007|DRUG|Leucovorin|
224202602|NCT01060007|DRUG|5-FU|
224202603|NCT01060007|DRUG|Capecitabine|
224202604|NCT04352621|DRUG|intranasal ketamine|Ketamine 0.5 mg/kg will be administered intranasally using an atomization device with a maximum dose of 40 mg followed by 6 weeks of rTMS treatment. .
224202605|NCT04352621|DEVICE|rTMS treatment|patients will begin the open label trial of rTMS per the FDA-approved method on day 1 (the day after the Baseline Visit).
224202606|NCT05428059|OTHER|mobile education|The training content prepared by the researchers will be presented to the expert opinion. After the necessary arrangements, it will be installed on the mobile application. The mobile application will be downloaded to the patients' phones for one month. It will be in live consultation.
224202607|NCT04978194|OTHER|University-based intervention to promote better management of emotions and learning|It included 9 video capsules (that take place over 9 weeks), with the following themes: stress information, learning information, emotion and stress regulation strategies, cognitive and metacognitive learning strategies, motivation for learning, physical activity, diet, sleep, and managing worry and uncertainty. It is based on previous online student mental health intervention studies. It presents two innovative aspects: elements and examples specific to the COVID-19 pandemic and the addition of modules focused on learning strategies. The different modules were designed by 5 associate professors, 2 Master students in clinical psychology and 2 undergraduate students in psychology. For the control group, the videos will be posted every week on a You Tube channel and broadcast on a private discord group. For the hybrid group, student will have to attend 10 lessons of 2 hours. These courses include the viewing of videos and a time for discussion between students and the teacher.
224202608|NCT00002680|BIOLOGICAL|filgrastim|
224202609|NCT00002680|DRUG|cyclophosphamide|
224202610|NCT00002680|DRUG|megestrol acetate|
224202611|NCT00002680|DRUG|melphalan|
224202612|NCT00002680|DRUG|tamoxifen citrate|
224202613|NCT00002680|DRUG|thiotepa|
224202614|NCT00002680|PROCEDURE|conventional surgery|
223510611|NCT04351815|BEHAVIORAL|Short term prehabilitation (2 weeks)|"* Initial assessment visit with a dietitian, a psychologist, a physiotherapist, a doctor (physical medicine) and a geriatrician (for patients over 75 years old)~* Patient will be asked to follow a 2 weeks prehabilitation program~* 2 months post-surgery assessment visit with a dietitian, a psychologist, a physiotherapist, a doctor (physical medicine)~* 6 months post-surgery assessment visit with a dietitian, a psychologist, a physiotherapist, a doctor (physical medicine)"
223510612|NCT04351815|OTHER|No specific intervention|"* Standard care: Initial assessment visit with a dietitian, a psychologist, a physiotherapist, a doctor (physical medicine) and a geriatrician (for patients over 75 years old)~* Patients will be asked to maintain regular physical activity without support~* 2 months post-surgery assessment visit with a dietitian, a psychologist, a physiotherapist, a doctor (physical medicine)~* 6 months post-surgery assessment visit with a dietitian, a psychologist, a physiotherapist, a doctor (physical medicine)"
223510613|NCT06305065|PROCEDURE|KUNWU Navigation TKA procedure|"In terms of technical specifications, KUNWU is the only robotic arm with seven degrees of freedom, while other systems have a maximum of six. The ergonomic and user-friendly design of the system contributes to physical relief and simplified instrument handling, which enhances surgical precision and reduces cognitive stress.~KUNWU's navigation system boasts a refresh rate of 335Hz, which is significantly higher than the current 60Hz rate of other navigation systems. This high refresh rate provides a clear and visually captivating display of the navigation procedure, eliminating blurriness and indecipherable output. It enables surgeons to react promptly during live procedures, enhancing safety for both clinicians and patients and reducing potential complications and hospitalization."
223510614|NCT06305065|PROCEDURE|CORI Surgical System TKA procedure|The CORI Surgical System (Smith and Nephew®) represents one of such recent advances in robotics that it can assist surgical planning, and increase the accuracy of implant position due to real-time feedback during the procedure (bone resection, implant position, ligamentous balance).
223616649|NCT03392220|PROCEDURE|Bilateral Neck Dissection|patient undergo bilateral neck dissection, along with the excision of the laryngeal primary tumor
223616650|NCT06361589|DRUG|Lorlatinib|lolatinib 100mg qd po
223616651|NCT03406273|RADIATION|Cerebral Spinal (CS) radiation|Surgery plus Cerebral Spinal (CS) radiation
223616652|NCT03406273|RADIATION|Focal radiotherapy (SRS)|Surgery plus focal radiotherapy (stereotactic radiosurgery to the tumor bed \[SRS\])
223616653|NCT02654548|OTHER|Sebutape|Women who consent to the study will have a sebutape attached to their and their babies foreheads to measure the levels of androgens.
223616654|NCT01125800|DRUG|LDE225|LDE225/sonidegib capsules were supplied to the Investigators at dose strengths of 50 mg, 100 mg, 200 mg, and 250 mg.
223761179|NCT03364088|PROCEDURE|Spinal anesthesia without tourniquet|Operation is done under spinal anesthesia and without the use of surgical tourniquet.
224202615|NCT00002680|PROCEDURE|peripheral blood stem cell transplantation|
224202616|NCT00002680|RADIATION|radiation therapy|
224202617|NCT06385873|DRUG|RC48|RC48: 2.5 mg/kg, intravenous infusion, on day 1, every 3 weeks (Q3W);
224202618|NCT06385873|DRUG|Adebrelimab|Adebrelimab：1200 mg, intravenous infusion, on day 1, every 3 weeks (Q3W);
224202619|NCT06385873|DRUG|Apatinib|Apatinib: 250mg, oral administration, once daily (qd), every 3 weeks (Q3W);
224202620|NCT06385873|DRUG|S-1|S-1：For patients with a body surface area (BSA) ≤1.5m², use 50mg each time; for patients with BSA \>1.5m², use 60mg each time, oral administration, twice daily (bid), on days 1-14, every 3 weeks (Q3W);
224202621|NCT05168657|DEVICE|Bionic Pancreas|14 days using the insulin-only configuration of the iLet Bionic Pancreas (Beta Bionics, Inc.), which automates insulin delivery, as the only intended mode of insulin delivery.
224202622|NCT05168657|OTHER|Usual Care|14 days of the participant's usual care of their type 1 diabetes
224202623|NCT04935931|DRUG|Naltrexone|naltrexone 50 mg PO x 1
224202624|NCT06393673|DRUG|HS-10384 tablet Dose 1|Administered orally QD
224202625|NCT06393673|DRUG|HS-10384 tablet Dose 2|Administered orally QD
223616655|NCT01152528|DEVICE|VA-SENSE|The VA-SENSE contains a strip of pH indicator (color indicator) that is sensitive to the acidity level. A change in the color of the strip due to changes in the acidity level of vaginal secretions absorbed in the panty liner clearly indicates high probability of bacterial or parasitic vaginal infection. Any color change that results from contact with urine will disappear 10 minutes of drying out, and then the color of the indicator strip will fade back to the original color (yellow).
223616656|NCT01492205|DRUG|insulin human|All subjects were treated with human insulin administered either by using the NovoLet® pre-filled insulin system or the conventional vial and syringe method. Doctors and nurses must personally administer at least 10 insulin doses to each patient under their individual clinical supervision for assessment of the NovoLet® pre-filled insulin system
223616657|NCT04885335|OTHER|PAS (Pediatric Appendicitis Score) survey|Score ≤ 5: appendicitis unlikely. Score ≥ 6: probable appendicitis. core ≥ 7: very probable appendicitis
223616658|NCT00055692|BIOLOGICAL|bevacizumab|Given orally
223616659|NCT02534363|DRUG|Aripiprazole|Oral, dose range 5-30 mg/day, once or twice a day, during study duration
223616660|NCT02534363|DRUG|Quetiapine|Oral, dose range 100-600 mg/day, once or twice a day, during study duration
224202626|NCT06393673|DRUG|HS-10384-matched placebo tablets|Administered orally QD
224202627|NCT04344782|DRUG|Bevacizumab Injection|Treatment includes the administration on day 1 (D1) of an infusion of Bevacizumab 7.5 mg / kg in 100 ml saline for all patients weighing 100 kg or more. In control arm, patient receives standard care.
224202628|NCT04083274|OTHER|Erector spinae plane block (Group E)|"Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. Postoperative patient evaluation will be performed by an anesthesiologist blinded to the procedure.~Postoperative pain assessment will be performed using the VAS score (0 = no pain, 10 = the most severe pain felt). The VAS scores at rest and during cough will be recorded at postoperative 1, 2, 4, 8, 16, 24 and 48 hours. If the VAS score will be ≥ 4, 0.5 mg/ kg meperidine IV will be administered. Sedation level will be assessed with a 4-point sedation scale (0 = awake, eyes open, 1 = sleepy but responding to verbal stimulus, 2 = sleepy and hard to evoke, 3 = sleepy, not aroused by shaking). The first time of the use of rescue analgesic, intraoperative and postoperative opioid consumption, side effects such as nausea, vomiting, itching and block related complications will be recorded."
223510615|NCT06305065|PROCEDURE|Conventional TKA procedure|Total knee arthroplasty (TKA) is a highly successful and frequently performed surgical treatment to reduce disability caused by end-stage osteoarthritis and other conditions affecting articular cartilage. Technical outcomes for TKA are excellent, with favorable postoperative health-related quality of life. Also, survivorship of primary knee replacements is excellent with reported survivorship of 82.3% at 25 years. TKA has traditionally been indicated in the elderly population with relatively sedentary lifestyles, but more active, younger patients (\<55) are receiving TKA due to the desire for a pain-free, active lifestyle with the demand projected to continue to increase for this group. A recent systematic review has shown that functional outcomes are similar in this population compared to elderly patients with no increase in the burden of revision.
223510616|NCT04481282|DRUG|Terbutaline|2.5mg po tid for 12 weeks
223510617|NCT04481282|DRUG|Danazol|200mg po bid for 12 weeks
223510618|NCT00002051|DRUG|Thymopentin|
223510619|NCT05095337|DRUG|[14C]SHR1459|Patients will receive single dose of orally \[14C\]SHR1459 on Day 1.
223510620|NCT05181657|BEHAVIORAL|COVID-19 education|This session will be completed within 45 minutes. The LinkUP intervention will be available in English and Spanish.
223510621|NCT06114966|OTHER|CADCAM|Milling of Final prosthesis over dental implants using CADCAM milling machine
223510622|NCT04726488|PROCEDURE|Periareolar Approach in Minimally Invasive Cardiac Surgery (PAMI Technique)|"To study the feasibility and safety of periareolar minimally invasive surgery protocol in patients undergoing periareolar minimally invasive surgery vs. Control group (inframammary approach)."
223510623|NCT04726488|PROCEDURE|inframammary approach|"To study the feasibility and safety of periareolar minimally invasive surgery protocol in patients undergoing periareolar minimally invasive surgery vs. Control group (inframammary approach)."
223510624|NCT01978574|BEHAVIORAL|Intellectual Enrichment daily activities|A daily program of intellectually enriching, iPad/tablet-based activities: games, reading/writing, hobby activities, or a documentary video (control).
223510625|NCT01978574|BEHAVIORAL|Intellectual Enrichment documentary videos|Participants watch daily documentary videos.
223510626|NCT01594684|DEVICE|balloon angiolplasty - drug coated balloon (Cotavance, Medrad Inc.)|balloon inflation
223510627|NCT01594684|DEVICE|drug coated balloon inflation (Cotavance, Medrad Inc.)|Balloon inflation
223510628|NCT01594684|DEVICE|uncoated balloon (e.g. Admiral, Medtronic)|balloon inflation
223510629|NCT01594684|DEVICE|balloon inflation, drug coated balloon (Cotavance, Medrad Inc.)|ballon inflation
223510630|NCT01108055|DRUG|Pazopanib (GW786034)|Cycle of 28 days. Pazopanib: 800mg/day
223510631|NCT01108055|DRUG|Paclitaxel|Cycle of 28 days Paclitaxel: 80mg/m2 days 1,8 and 15
223510632|NCT00964444|DEVICE|Peisner device|The doctor/midwife stands on the device while the baby is delivered. The device measures how much force is exerted on the baby.
223510633|NCT03339453|DRUG|Nasal Glucagon|Administered nasally
223510634|NCT03339453|DRUG|Intramuscular Glucagon|Administered IM
223510635|NCT00328809|DRUG|spironolactone|spironolactone administered to ESRD patients at low dose
223510636|NCT03043469|OTHER|Short-form survey instrument|Questionnaire with questions about quality of life. Takes about 5 minutes to be completed.
223510637|NCT03043469|OTHER|Demographic data|height, weight, age, gender, list of comorbidities, health history, level of physical activity, medicines in use. Takes about 10 minutes to be completed.
223616661|NCT02534363|DRUG|Ziprasidone|Oral, dose range 40-160 mg/day, once or twice a day, during study duration
223616662|NCT02534363|BEHAVIORAL|Cognitive battery|Completed in the following standardized sequence: 1-the Rey Auditory Verbal Learning Test (RAVLT); 2-WAIS-III digit symbol subtest; 3-Grooved Pegboard Test; 4-The Zoo Map Test; 5-Tower of London Test (ToL); 6-Rey Complex Figure (RCF); 7-Trail Making Test (TMT); 8-WAIS-III digits forward and backward subtests; 9-WAIS-III letter-number sequencing subtest; 10-WAIS-III vocabulary subtest that was used as measure of premorbid intelligence quotient (IQ); 11-Stroop Test; 12-letter (FAS) and semantic (animal) fluency tests; 14-Eyes Task; 15-Continuous Performance Test (CPT).
224202629|NCT04083274|OTHER|Sham block group (Group S)|"Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. Postoperative patient evaluation will be performed by an anesthesiologist blinded to the procedure.~Postoperative pain assessment will be performed using the VAS score (0 = no pain, 10 = the most severe pain felt). The VAS scores at rest and during cough will be recorded at postoperative 1, 2, 4, 8, 16, 24 and 48 hours. If the VAS score will be ≥ 4, 0.5 mg/ kg meperidine IV will be administered. Sedation level will be assessed with a 4-point sedation scale (0 = awake, eyes open, 1 = sleepy but responding to verbal stimulus, 2 = sleepy and hard to evoke, 3 = sleepy, not aroused by shaking). The first time of the use of rescue analgesic, intraoperative and postoperative opioid consumption, side effects such as nausea, vomiting, itching and block related complications will be recorded"
224202630|NCT04522310|OTHER|MR-Pro-ADM|Dosage of MR-pro-ADM
224202631|NCT05752396|OTHER|Conditioned Pain Modulation|Conditioned pain modulation (CPM) procedure evaluates the change in mechanical and heat pain sensitivity by a contralateral conditioning stimulus (cold immersion). This psychophysical paradigm investigates inhibitory pain modulation processes.
224202632|NCT05752396|OTHER|Offset Analgesia|Offset analgesia (OFA) procedure evaluates the disproportionate change in heat pain sensitivity after a slight decrease in stimulus intensity. This psychophysical paradigm investigates inhibitory pain modulation processes.
224202633|NCT05752396|OTHER|Spatial Summation|Spatial summation (SS) procedure evaluates the change in heat pain sensitivity when applying two painful stimuli simultaneously compared to one stimulus alone. This psychophysical paradigm investigates facilitatory pain modulation processes.
224202634|NCT05752396|OTHER|Temporal Summation|Temporal summation (TS) procedure evaluates the change in mechanical pain sensitivity after exposure to a series of noxious stimuli of the same intensity. This psychophysical paradigm investigates facilitatory pain modulation processes.
224202635|NCT06542224|PROCEDURE|Deep Brain stimulation|All subjects will receive bilateral surgical implantation of DBS system.
224202636|NCT03864367|DEVICE|Device - Prism Medical FGA-700 Bariatric Floor Lift|This group will be using a Mobile Weight-Support Therapy (MWeST) device (the Prism Medical FGA-700 Bariatric Floor Lift) to determine if it improves mobilization of older patients with traumas of their legs.
224202637|NCT02960724|OTHER|68Ga-NOTA-AE105 PET/CT|One injection of 68Ga-NOTA-AE105 (app. 200 Mbq) followed by Positron Emission Tomography Scan.
224202638|NCT01288417|DRUG|boceprevir|10 days of boceprevir 800mg TID
224202639|NCT01288417|DRUG|raltegravir|raltegravir 400mg single dose
224202640|NCT03287141|DIAGNOSTIC_TEST|Shuttle walk test|A shuttle walk test was performed without any previous intervention.
224202641|NCT03287141|DEVICE|Noninvasive ventilation (Bi-pap)|After 30 minutes of the mentioned intervention, the subject performed a shuttle walk test.
224202642|NCT03287141|DEVICE|Noninvasive ventilation (CPAP)|After 30 minutes of the mentioned intervention, the subject performed a shuttle walk test.
223616663|NCT01876355|DRUG|Clonidine|o The concentration of clonidine in the solution is 12.5 µg/ml. Continuous iv infusion of 0.02 ml/kg/h results in a dosage of 0.25 µg/kg/h. The maximum dosage achieved is 25 µg/h. The total amount of clonidine given to a person with a body weight 100 kg or more will be 600 µg a day. Since the doses chosen are in the low range, there will be no dosage adjustment for renal- or liver failure.
223616664|NCT01876355|DRUG|SodiumChloride|Placebo. Pharmaceutical form: Injection. Route of administration: Intravenous use.
223616665|NCT05355064|DRUG|Trehalose|Enrolled subjects will daily take 4 g of trehalose in oral administration for 24 weeks.
224202643|NCT01638416|OTHER|Blood transfusion|Blood transfusion in ICU patients aged 18 and over.
224202644|NCT04998188|PROCEDURE|Collagen|Patients will be treated with a single injection of collagen (2 ml) in the knee joint affected by osteoarthritis
224202645|NCT04998188|PROCEDURE|Placebo (saline solution)|Patients will be treated with a single injections of saline solution (2 ml) in the knee joint affected by osteoarthritis
223510638|NCT03043469|OTHER|Hospital Anxiety and Depression Scale|Questionnaire with questions about anxiety and depression. Takes about 5 minutes to be completed.
223510639|NCT03043469|OTHER|Nijmegen questionnaire|Answering questions about symptoms related to breathing. Takes about 5 minutes to be completed.
223510640|NCT03043469|OTHER|The Self-evaluation of breathing questionnaire|Answering questions about self-evaluation of breathing. Takes about 5 minutes to be completed
223510641|NCT03043469|OTHER|six-minute exercise test|Cycling against certain load in a bicycle for 6 minutes. Takes about 16 minutes to be completed together with indirect calorimetry, oxygen saturation monitoring, heart rate variability analysis and continuous monitoring of arterial blood pressure).
223510642|NCT03043469|OTHER|Indirect calorimetry|Breathing through a mask that measures levels of oxygen, carbon dioxide, breathing frequency and others (non-invasively). Takes about 16 minutes to be completed, together with the 6-minute exercise test.
223510643|NCT03043469|OTHER|Oxygen saturation monitoring|The measurement of the amount of oxygen which is attached to haemoglobin molecules (non-invasively). Takes about 16 minutes to be completed, together with the 6-minute exercise test.
223510644|NCT03043469|OTHER|Heart rate variability analysis|Measurement of the variation in the beat-to-beat interval (non-invasively). Takes about 16 minutes to be completed, together with the 6-minute exercise test.
223510645|NCT03043469|OTHER|Continuous measurement of arterial blood pressure|Measurement of blood pressure based on the peripheral pulse using a finger cuff (non-invasively). Takes about 16 minutes to be completed, together with the 6-minute exercise test.
223510646|NCT03043469|DIAGNOSTIC_TEST|Lung function test|Breathing through a mouth-piece in many different ways in order to measure the function of the lungs (non-invasively).
223510647|NCT03043469|OTHER|Respiratory muscle function|Breathing through a mouth-piece in many different ways in order to measure the function of the respiratory muscles (non-invasively).
223510648|NCT03043469|OTHER|Manual assessment of respiratory motion|Measure of the movements of the thorax while the participant is breathing (non-invasively).
223616666|NCT00966615|OTHER|double-chamber bag Stay-Safe Balance system|2-L exchange; three times a day
223616667|NCT00966615|OTHER|glucose-based dialysis solution|2-L exchange; three times a day
224202646|NCT00424632|DRUG|PF-03814735|1, 5, and 25 mg gelatin capsules administered orally once a day from day 1 to day 5, or from day 1 to day 10 every 3 weeks until disease progression or unacceptable toxicity.
223616668|NCT01168726|BEHAVIORAL|Protective Behavioral Strategies|Personalized feedback on use of protective behavioral strategies.
223616669|NCT01168726|BEHAVIORAL|Personalized Normative Feedback|Personalized feedback on how one's own drinking compares to relevant norms.
223616670|NCT01168726|BEHAVIORAL|Alcohol Education|Educational information about harms associated with heavy drinking.
223616671|NCT01908452|DRUG|Pyridoxine|1200 mg/d during 12 weeks
223616672|NCT05279287|OTHER|Video and kinematic data recording of minimally invasive surgical procedure|Analysis of video and kinematic data through validated methodology in order to analyse technical performance and errors enacted intraoperatively.
223616673|NCT03823183|BEHAVIORAL|Cognitive training|Group-based cognitive training on iPads with commercially available video games (Lumosity) designed to enhance executive control, memory functions and processing speed. Difficulty will be automatically adjusted to the performance level of the participant. Participants will train for 40 min 2 days/wk over 3 months.
223616674|NCT03823183|BEHAVIORAL|Physical training|Group-based fitness program (senior-friendly adaption of BodyAttack) that combines aerobic, strength and coordination training to a music soundtrack. Participants will train for 40 min, 2 days/wk over 3 months.
223761180|NCT03364088|PROCEDURE|General anesthesia with tourniquet|Operation is done under general anesthesia and surgical tourniquet is used.
223761181|NCT03364088|PROCEDURE|General anesthesia without tourniquet|Operation is done under general anesthesia and without the use of surgical tourniquet.
223761182|NCT03364088|DRUG|Oxycodone by patient-controlled analgesia (PCA)|PCA device (CADD Legacy PCA Pump, Smiths Medical, Kent, UK) is programmed to give intravenous oxycodone in doses of 0.04 mg/kg (ideal body weight). The minimum time between doses is set to 10 minutes and no more than 4 doses per hour are allowed.
223761183|NCT02051465|DEVICE|LumenR Retractor|Polyp removal using LumenR Retractor Modified overtube
224202647|NCT04457531|DRUG|LiuWeiLuoBi Granule|LiuWeiLuoBi Granule is a Chinese medicine made from 6 herbal medicine, including Shaji(Sea-buckthorn), Honghua (Safflower), Jinyinhua(Honeysuckle),etc.
224202648|NCT04457531|OTHER|Standard medical treatment|Standard medical therapy is adhered to the guidline issued by American Diabetes Association and Chinese Diabetes Society at 2017, including keeping an appropriate diet, doing some exercises, the pharmacological therapy to control the blood glucose, blood pressure and blood lipids.
224202649|NCT04393831|PROCEDURE|Retzius sparing|Retzius nerve sparing is a specific approach that avoids disrupting the structures involved in urinary and sexual function.
224202650|NCT06144931|PROCEDURE|PENG Block|With the patient in the supine position, the ultrasound probe is placed on a transverse plane over the anterior superior iliac spine (ASIS). Once the ASIS is identified, the transducer is aligned with the pubic ramus and rotated at approximately 45 degrees, parallel to the inguinal crease. The transducer then slides medially along this axis until the anterior inferior iliac spine (AIIS), iliopubic eminence (IPE), and the psoas tendon is clearly identified, serving as anatomic landmarks. Sliding the probe distally or gently tilting the caudal will expose the head of the femur. Returning to the initial starting position, a standard 22 gauge spinal needle is inserted in-plane, from lateral to medial, in the plane between the psoas tendon and the pubic ramus. 20 ml 0.25% bupivacaine diluted with preservative free normal saline then deposited in this plane, lifting the psoas tendon. Care should be taken to avoid puncturing the psoas tendon.
224202651|NCT02437929|PROCEDURE|Mobilization|
224202652|NCT02437929|PROCEDURE|Positioning|
224202653|NCT02437929|PROCEDURE|Personal Hygiene Care|
224202654|NCT02437929|PROCEDURE|Bladder catheterization|
224202655|NCT02437929|PROCEDURE|Wound care|
224202656|NCT02437929|PROCEDURE|Subcutaneous drugs administration|
224202657|NCT06420427|DIAGNOSTIC_TEST|Assess the risk of recurrence and the efficacy of medication|Evaluation of recurrence risk and medication efficacy through liquid biopsy
224202658|NCT05813665|DRUG|Narlumosbart|Administered by subcutaneous injection. Dietary Supplement: Calcium/Vitamin D. All patients should be adequately supplemented with calcium and vitamin D (at least 500 mg of calcium and 400 IU of vitamin D), except in the case of pre-existing hypercalcemia.
224202659|NCT05813665|DRUG|Denosumab|Administered by subcutaneous injection. Dietary Supplement: Calcium/Vitamin D. All patients should be adequately supplemented with calcium and vitamin D (at least 500 mg of calcium and 400 IU of vitamin D), except in the case of pre-existing hypercalcemia.
224202660|NCT00686231|DRUG|Nitroglycerin 15mg|15mg Nitroglycerin applied topically to one wrist
223510649|NCT03043469|OTHER|Breath-hold test|Holding the breath a few times for as long as possible.
223510650|NCT03043469|OTHER|Physical Activity monitoring|Wearing a light-weight activity monitor to be wore on the hip for 7 consecutive days during, at least, 8 hours per day.
224202661|NCT00686231|DRUG|Nitroglycerin 30mg|30mg Nitroglycerin applied topically to one wrist
224202662|NCT00686231|DRUG|Lidocaine 20mg|20mg Lidocaine applied topically to one wrist in combination with nitroglycerin or placebo
224202663|NCT00686231|DRUG|Lidocaine 40mg|40mg Lidocaine applied topically to one wrist in combination with nitroglycerin or placebo
223510651|NCT03043469|OTHER|Asthma Control Questionnaire|Only for asthmatics: answering questions about the control the participant has over this respiratory condition/symptoms.
223510652|NCT03377127|BEHAVIORAL|Pharmacy Managed Diabetes Clinic (PMDC)|The PMDC visit encounters will focus on patient identified goals for the management of their diabetes. Initial visit in the PMDC will be 60-90 minutes with follow up visits lasting 30-45 minutes.
224202664|NCT00686231|DRUG|Placebo|Topical skin moisturizing cream with same appearance as active agent
224202665|NCT00445458|DRUG|HKI-272|
224202666|NCT00445458|DRUG|Paclitaxel|
224202667|NCT05339542|OTHER|platelet rich plasma|derived from patient own blood
224202668|NCT05339542|DRUG|MethylPREDNISolone 40 MG|active comparative intervention
224202669|NCT01527942|DRUG|Acetaminophen|Intravenous Acetaminophen 1,000 mg IV
224202670|NCT01527942|DRUG|Placebo|Placebo - IV administration 0.9% 100 ml Sodium Chloride (NaCl)
224202671|NCT03634007|BIOLOGICAL|LX1001|LX1001 is a serotype rh.10 AAV gene transfer vector expressing the cDNA coding for human APOE2.
224202672|NCT04203888|OTHER|Swedish Massage|60-minute Swedish Massage delivered in-home by a licensed massage therapist, 2 times per week with at least 48-hours between massage interventions.
224202673|NCT04203888|OTHER|Yoga|"60-minute yoga session delivered in-home by a certified yoga instructor, 2 times per week with at least 48-hours between yoga interventions.Yoga sessions will be based on the yoga postures available in the appendix of the December 2005 Annals of Internal Medicine article, Comparing Yoga, Exercise, and a Self-Care Book for Chronic Low Back Pain (Sherman KJ et al., 2005)."
224202674|NCT01071083|DRUG|natalizumab|300 mg intravenous every 4 weeks
224202675|NCT01071083|DRUG|interferon beta 1-a|30 ug intramuscular once per week
224202676|NCT01071083|DRUG|methylprednisolone|1000 mg intravenous every 4 weeks
224202677|NCT01071083|OTHER|IV placebo|placebo intravenous every 4 weeks
224202678|NCT01071083|DRUG|glatiramer acetate|20 mg subcutaneous once daily
224202679|NCT04095975|DIETARY_SUPPLEMENT|Baking Soda|Standard baking soda that can be bought from stores.
224202680|NCT04095975|DIETARY_SUPPLEMENT|LithoLyte|LithoLyte is considered a medical food and consists of: potassium citrate, magnesium citrate, sodium bicarbonate, and erythritol.
224202681|NCT03987737|PROCEDURE|small urinary catheter placement in the rectum|The MRI technician will place a small urinary catheter in the rectum prior to MRI of the prostate to evacuate excessive gasses. This catheter will stay in the rectum during the whole MRI examination.
224202682|NCT03539939|PROCEDURE|Coronally Advanced Flap|The coronally advanced flap (CAF) is a procedure frequently used in periodontal plastic surgery. The main objective of this surgical technique is to mobilize the gingival margin and reposition it at a level more coronal (incisal direction) than its original location. CAF is mainly used for the treatment of gingival recessions.
224202683|NCT00116207|DRUG|ORAL ANTIOXIDANT|Comparison of triple antioxidant combination therapy vs placebo.
224202684|NCT00728988|DRUG|Atorvastatin|80mg 12 hours pre-Percutaneous Coronary Intervention (PCI), 40mg 2 hours pre-PCI and 40mg daily after PCI for 30 days.
224202685|NCT00728988|DRUG|Atorvastatin|40mg daily after PCI for 30 days.
224202686|NCT00029042|DRUG|Infliximab|
224202687|NCT01247753|BEHAVIORAL|Walking group|Internet-mediated pedometer-based walking program with gradually increasing step count goals and feedback on step counts. Also includes nutritional coaching course consisting of 1 individual session with a dietician, 4 group sessions, and monthly follow-up. Oral glucose tolerance tests pre and post-intervention.
224202688|NCT03412994|DRUG|Apatinib|Apatinib in combination with standard second-line chemotherapy for advanced colorectal cancer
224202689|NCT03412994|DRUG|standard second-line chemotherapy|The second line standard chemotherapy regimen recommended by the NCCN
224202690|NCT00764816|OTHER|grain (soy) protein diet|The patient is to eat a grain (soy) protein diet for 7 days. The food is prepared by a registered dietitian.
224202691|NCT00764816|OTHER|casein (meat) protein diet|The patient is to eat a casein (meat) protein diet for 7 days. The food is prepared by a registered dietitian.
224202692|NCT00710060|BEHAVIORAL|Community Popular Opinion Leader (C-POL)|The C-POL intervention will teach identified opinion leaders to share personalized HIV prevention messages in conversations with peers in an effort to change community norms. Opinion leaders will be taught skills for sharing HIV risk-reduction messages during four to five weekly training sessions. At least 15% of the community population will be trained as opinion leaders. After the initial training, opinion leaders will attend six to nine booster sessions over the next 2 years to reinforce and support continued conversation efforts.
224202693|NCT00710060|BEHAVIORAL|HIV/STD educational materials|Communities will receive HIV/STD educational materials and treatment referral information to distribute to community members.
224202694|NCT00937859|DRUG|SER120|SER120
224202695|NCT00937859|DRUG|Placebo|Placebo
224202696|NCT01225601|BEHAVIORAL|Tabacco discontinuation|Tabacco discontinuation
224202697|NCT05181501|DRUG|Fully human BCMA chimeric antigen receptor autologous T cell injection (CT103A)|"CT103A is a customized, BCMA-targeted genetically modified autologous T cell immunotherapy, which can identify and eliminate malignant and normal cells expressing BCMA. CAR specifically recognizes BCMA with single chain fragment variable (ScFv), and promotes the activation, proliferation, cytokine secretion and target cell killing of CAR-T through the CD3ζ domain. And 4-1BB enhances the expansion and persistence of CT103A.~CT103A will be infused at 1.0×10\^6 /kg via intravenous drip within 24h to 72h after chemotherapy conditioning regimen at the recommended infusion rate of 3-5 mL/min."
224202698|NCT01166126|DRUG|temsirolimus|Given IV
224202699|NCT01166126|DRUG|selumetinib|Given orally
224202700|NCT01166126|OTHER|laboratory biomarker analysis|Correlative studies
224202701|NCT01433029|OTHER|Surgical Video Assessments|Rate performance of the surgeon/trainee in each CAB video performance (5 recorded procedures) using two rating scales, a checklist and the Global Rating Scale. Up to 38 different recorded procedures rated while on the study, each procedure lasting about 15 minutes.
223761184|NCT02051465|DEVICE|Removal without overtube|Endoscopic removal of polyp without overtube
224202702|NCT01433029|OTHER|Video Recording of CAB|Each video begins when dissection of a coronary artery has begun and ends when all manipulation of anastomosis is complete. At least 6 separate anastomoses will be recorded, or at least 2-3 procedures. A ProXennon Surgical Headlight Camera System (a small camera that is mounted in place directly over a high-intensity light that is worn on the head) records the performance of the coronary artery bypass (CAB) procedures.
224202703|NCT05548270|DRUG|DPI-386 Nasal Gel|Subjects will self-administer DPI-386 Nasal Gel or Placebo
224202704|NCT05548270|DRUG|Placebo|Subjects will self-administer DPI-386 Nasal Gel or Placebo
224202705|NCT04237831|DRUG|BMS-986259|Specified Dose on Specified Days
224202706|NCT00605969|PROCEDURE|Motion analysis|Participants will undergo a motion analysis procedure: a dynamic assessment of the movement in their hip.
224202707|NCT00605969|DIAGNOSTIC_TEST|Computed Tomography|Participants will undergo computed tomography (CT) scan of their hip.
224202708|NCT00370929|BEHAVIORAL|Meditation|
224202709|NCT03832426|DRUG|Narlaprevir|100 mg film-coated tablets
224202710|NCT03832426|DRUG|Ritonavir|100 mg film-coated tablets
224202711|NCT02279602|DRUG|fosbretabulin|fosbretabullin, 60 mg/m2 weekly for up to 1 year
224202712|NCT00003401|DRUG|carmustine|
224202713|NCT00003401|DRUG|cisplatin|
224202714|NCT00003401|DRUG|cyclophosphamide|
224202715|NCT00003401|DRUG|dexamethasone|
224202716|NCT00003401|DRUG|etoposide|
224202717|NCT00003401|DRUG|gemcitabine hydrochloride|
224202718|NCT00003401|DRUG|melphalan|
224202719|NCT00003401|DRUG|paclitaxel|
224202720|NCT00003401|PROCEDURE|bone marrow ablation with stem cell support|
224202721|NCT00003401|PROCEDURE|peripheral blood stem cell transplantation|
224202722|NCT05947981|DIETARY_SUPPLEMENT|Dextrose 5%, normal saline|Decrease fasting hours
224202723|NCT02333110|RADIATION|spatially fractionated radiation therapy|A single dose of 15-20Gys of spatially fractionated radiation therapy
224202724|NCT01734109|DEVICE|Quantum Negative Pressure Wound Therapy Device|To compare the additional benefit of Quantum Negative pressure wound therapy device with and without simultaneous irrigation.
224202725|NCT01927159|BIOLOGICAL|ID93 + GLA-SE|
224202726|NCT01927159|OTHER|Placebo|
224202727|NCT03223506|DRUG|Paracetamol|
224202728|NCT03545568|OTHER|Neu5Ac supplementation|Sialic acid as N-Acetyl-neuraminic acid dehydrate (Neu5Ac) 150 mg/kg/d (max 12g/d) in three doses orally in subjects with NANS deficiency compared to controls
224202729|NCT03319368|OTHER|Targeted gown and glove use|Gown and glove use for high risk care activities in high risk residents
224202730|NCT01535872|DIETARY_SUPPLEMENT|Dehydroepiandrosterone|DHEA in 25mg capsule. 1 capsule taken 3 times daily for up to 5 months.
224202731|NCT03000075|DRUG|risankizumab|Risankizumab pre-filled syringe, administered by subcutaneous (SC) injection
224202732|NCT03000075|DRUG|placebo for risankizumab|Placebo for risankizumab pre-filled syringe, administered by subcutaneous (SC) injection
224202733|NCT00666952|OTHER|Video Decision Aid|Participants randomized to the video decision aid group will be asked to view the video portion of the decision aid, Weight loss surgery: Is it right for you? in a private room The content of the video and accompanying booklet was based on a systematic-review of the efficacy and safety of bariatric surgery, input from experts in bariatric surgery, internal medicine, psychology, nutrition, and nursing, and from a series of focus groups and interviews with 30 morbidly obese patients, some of whom had elected not to have bariatric surgery.
224202734|NCT00666952|OTHER|Booklet Decision Aid|General educational booklet on gastrointestinal surgery developed by the NIH titled, 'Gastrointestinal Surgery for Severe Obesity'.
224202735|NCT05917080|OTHER|Manual Therapy|"Manual Therapy: Manual therapy is the use of hands-on techniques to evaluate, treat, and improve the status of Neuro-musculoskeletal conditions.~Augmented Low-Dye Taping: Augmented Low-Dye taping is designed to off-load the plantar fascia \& applied below the ankle and is hypothesised to generate a supinating force that controls the amount of pronation at the subtalar joint.~Neuromuscular Exercises: Neuromuscular training could be defined as training enhancing unconscious motor responses by stimulating both afferent signals and central mechanisms responsible for dynamic joint control.~Strengthening Exercises:The strengthening of the muscles promotes better overall functioning of the foot and thereby can help to take some of the tension out of the fascia.~Stretching exercises:Static stretching is defined as passively stretching a given muscle-tendon unit by slowly placing it maximal position of stretch and sustaining it there for an extended period of time."
224202736|NCT06650488|DRUG|Clopidogrel|Patients will change from aspirin to clopidogrel (without loading dose)
224202737|NCT06650488|DRUG|Aspirin|Patients will continue their existing aspirin.
224202738|NCT00715052|PROCEDURE|Hyperbaric Oxygen Therapy (HBOT)|40 consecutive one hour treatments at 1.5 ATA with 100% O2
224202739|NCT01797068|BEHAVIORAL|Patient Navigator|Patients in the intervention group will be offered patient navigation and timely access to comprehensive care and services through Project Access-New Haven (PA-NH), a local non-profit organization that coordinates the provision of donated medical care and services to underserved patients through a network of participating hospitals and volunteer physicians.
224202740|NCT01797068|OTHER|Standard of Care|Patients in the standard of care group will experience the usual intake process in the ED setting.
224202741|NCT00111007|DRUG|Sorafenib (Nexavar, BAY43-9006)|Sorafenib, 400 mg po (per os), 2 tablets (200 mg each) bid Study Days 2-19
224202742|NCT00111007|DRUG|Carboplatin/Paclitaxel|Paclitaxel (225 mg/m\^2 iv) and Carboplatin (AUC 6 iv) on Study Day 1
224202743|NCT00111007|DRUG|Placebo|Placebo, 2 tablets bid Study Days 2-19
223616675|NCT03823183|BEHAVIORAL|Cognitive control|Group-based cognitive control activity consisting of playing on iPads non-cognitively demanding video games during 40 min 2 days/wk over 3 months and exercises based on relaxation and stretching for 40 min, 2 days/wk over 3 months.
223616676|NCT03823183|BEHAVIORAL|Physical control|Group-based exercises program (based on relaxation and stretching) for 40 min, 2 days/wk over 3 months.
223616677|NCT02840708|DRUG|Sargramostim|
223616678|NCT01212861|DEVICE|Suprachoroidal Dissection Instrument (SDI)|The Suprachoroidal Dissection Instrument (SDI) is a manually operated, non-powered, re-usable ophthalmic surgical instrument. The SDI is designed to enter a surgically exposed Schlemm's canal and be advanced up to 90 degrees around the canal from the entry site.
223616679|NCT02883231|OTHER|taking peripheral blood|taking peripheral blood of no more than 3ml
224202744|NCT00778193|DRUG|Naproxen|1 tablet 500mg BID for 8 days
224202745|NCT00778193|DRUG|Aspirin|1 tablet 81mg QD for 8 days
224202746|NCT00778193|DRUG|Celecoxib|1 capsule 200mg QD for 8 days
224202747|NCT00778193|DRUG|Clopidogrel|Day 0: 4 tablets QD for 1 day; Days 1-7: 1 tablet QD for 7 days
224202748|NCT00778193|DRUG|Placebo|1 capsule BID for 8 days
224202749|NCT00824993|DRUG|Ibandronate|Infusion of 3 mg by vein over 15 to 30 seconds for 4 doses at 3-6 weeks after transplant, and at Months 3, 6, and 9 after the transplant.
224202750|NCT00824993|DRUG|Vitamin Supplements|"Calcium 500 mg by mouth everyday for 12 months~Vitamin D 400 units by mouth 2 times a day for 12 months"
224202751|NCT00440193|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|During the first 3 weeks patients will receive 15 mg rivaroxaban twice-daily. Thereafter, patients will receive rivaroxaban 20 mg once-daily. Rivaroxaban will be administered orally and should be taken with food.
224202752|NCT00440193|DRUG|Enoxaparin followed by VKA|Enoxaparin 1.0 mg/kg twice daily with a minimal duration of 5 days. This 5 days treatment could include the period up to 36 h before randomization if enoxaparin twice-daily was used. VKA should be started as soon as possible but not later than 48 hours after randomization.
224202753|NCT06516783|DEVICE|Full Body Blue GEN 1.0 device|Full body blue irradiation in the treatment of inflammatory skin diseases and chronic pruritus
224202754|NCT01100398|PROCEDURE|possible liver biopsy and serum collection|All patients with a positive ultrasound for hepatic steatosis offered a liver biopsy after obtaining fasting blood work that included a complete blood count, coagulation studies, liver function tests, fasting lipid panel, glucose and insulin. Patients with a negative ultrasound for fatty liver are not referred for liver biopsy and are considered as completed study patients. Serum is also stored for adipokine and cytokine analysis. A study investigator using a 14g Bard Monopty biopsy gun performs the liver biopsy.
224202755|NCT01756651|DRUG|Fentanyl pectin|comparison of Intranasal fentanyl 100mcg vs 200 mcg.
224202756|NCT02329951|PROCEDURE|Facet intervention|Diagnostic block of the nerves innervation the lumbar facet joint. If this block is positive (greater or equal to 50% relief), the participant will proceed to radiofrequency nerve ablation when the pain returns
224202757|NCT02329951|PROCEDURE|Sacroiliac joint injection|Injection of steroid and local anesthetic into SI joint
224202758|NCT02329951|PROCEDURE|Epidural steroid injection|Transforaminal or interlaminar injection of steroid epidurally
224312642|NCT06387602|PROCEDURE|Strengthening of adductors|"Both groups will perform the following strengthening of adductors which includes adductor isometrics, Side-lying adductor strengthening, and Adductor resistance with a stepper and will be done 10 repetitions, 3 times a week.~After the performance of the Adductor strengthening protocol, Group A will be given the Active release technique while Group B will be given post-isometric relaxation by the therapist."
223510653|NCT03377127|OTHER|Standard of Care (SOC)|Standard of care will be delivered at the physician discretion per the current American Diabetes Association recommendations
223510654|NCT01236807|PROCEDURE|MR perfusion guidance|Coronary revascularization guided by MR perfusion imaging
223510655|NCT01236807|PROCEDURE|FFR guidance|Coronary revascularization guided by invasive angiography and FFR
224202759|NCT06367998|DRUG|Pregabalin|Pregabalin oral intake from the day before surgery to six weeks postoperatively
224202760|NCT06567171|PROCEDURE|This descriptive correlational study was conducted among 102 parents with children aged between 2 and 12 undergoing elective surgical procedures.|This descriptive correlational study was conducted among 102 parents with children aged between 2 and 12 undergoing elective surgical procedures. Parental use of pain relief strategies (PURPS) and parental postoperative pain management (PPPM) tools were used to collect data on the adequacy of knowledge of the use of different pain relief strategies and the skill of parental pain assessment, respectively. We used Spearman's rank correlation coefficient was used to determine the relationships between pain score given by parents and nurses. The statistical tests were performed at a 95% confidence interval and a 5% significance level.
224202761|NCT05351437|DRUG|MTx-COVAB36|MTx-COVAB36 is a fully human monoclonal IgG1 antibody derived from the memory B cells of convalescent COVID-19 donors and directed against SARS-CoV-2 spike protein with potent virus neutralising activity.
224202762|NCT05351437|DRUG|Placebo|0.9% saline
224202763|NCT01976637|OTHER|no compression|no compression stockings worn during the study
224202764|NCT01976637|DEVICE|compression|compression stockings class II (23-32 mm Hg) worn during the day for up to 3 weeks
224202765|NCT02477462|OTHER|Clinic visit|Blood draw every 3 months; quality of life surveys and imaging annually
224202766|NCT02477462|OTHER|Baseline visit|Blood draw and quality of life surveys
223510656|NCT05605080|DEVICE|Gelfoam|Use Gelfoam as a hemostatic agent after anal surgery.
224202767|NCT00240786|DRUG|acetaminophen extended release|
223510657|NCT05605080|OTHER|Bosmin gauze|Use bosmin gauze as a hemostatic agent after anal surgery.
223510658|NCT02734914|DEVICE|SF-URS with automatic control of RPP|A new F-URS monitoring and control of RPP using intelligent pressure control device
223510659|NCT02734914|DEVICE|conventional F-URS|Ureteroscopy will be conducted using the ureteral access sheath from Cook Medical to treat renal calculi.
223510660|NCT02769052|DEVICE|Transcutaneous Electrical Nerve Stimulation (TENS)|Electrotherapy through self-applied device .
223510661|NCT03298100|OTHER|Scoring model|Determining risk factors an calculating the risk score, recurrent vaginal bleeding 3, hypertension 2, age and endometrial thickness 1 for each
223510662|NCT05231941|DRUG|Lidocaine IV|Bolus and infusion of lidocaine will be administered
224202768|NCT06648499|OTHER|Evaluation of lower extremity muscle strength, physical activity, exercise capacity, balance, quality of life, and fatigue in POMS|The demographic information of the patients will be taken with the form prepared for the people in this group. Patients will be assessed using the FTSTS test to evaluate lower extremity muscle strength, the Godin Leisure Time Exercise Questionnaire (GLTEQ) for physical activity, the 2-Minute Walk Test (2MWT) for exercise capacity, the Timed Up and Go (TUG) Test for functional mobility, the Pediatric Quality of Life Inventory (PedsQL) for quality of life, and the PedsQL Multidimensional Fatigue Scale for fatigue. All assessments will be completed on the same day and will not be repeated after a certain period of time.
223510663|NCT05231941|DRUG|Ropivacaine|Bilateral TAP block will be given to these patients
223510664|NCT02863172|BEHAVIORAL|Questionnaires|"Consenting Proband Group: Participants fill out questionnaires about work, family history, medical history, and health habits at baseline. It should take about 20 minutes to complete the questionnaires. Participants also complete a health and lifestyle questionnaire, which contains 20 questions for men and 22 questions for women. Questionnaire should take about 10 minutes to complete. Follow-up questionnaire at least 1 time in 5 years to update medical, cancer, and family history.~Family Members (MDA Registered Patients) Group and Family Members (Not MDA Registered Patients) Group: Participants complete a health questionnaire, which collects information about their personal medical history, demographics (age, race, sex, and so on), and questions about their alcohol and tobacco use at baseline. Questionnaire should take about 20 minutes to complete. Participants complete follow-up questionnaire at least 1 time in 5 years to update their medical, cancer, and family history."
223510665|NCT02863172|PROCEDURE|Blood Draw/Saliva Sample|About 2-3 tablespoons blood drawn. Participants may give a saliva sample instead.
223616680|NCT03370718|DRUG|Cabozantinib|Given PO
223616681|NCT03370718|OTHER|Pharmacogenomic Study|Correlative studies
223616682|NCT03370718|OTHER|Pharmacokinetic Study|Correlative studies
223616683|NCT05038631|DRUG|Ribociclib|Patients receive ribociclib
223616684|NCT04354324|DRUG|Radioiodine|The test group: low dosage (30mci). The control group: high dosage (100mci).
223761185|NCT00323414|DRUG|Polyunsaturated fatty acid (Opti-EPA)|Active experimental arm to patients with diabetes mellitus and non alcoholic steatohepatitis: Eicosapentaenoic acid (EPA):Docosahexaenoic acid (DHA)\[360 mg EPA and 240 DHA in each capsule\] 6 capsules-3 capsules by mouth 2 x per day x 48 weeks
223761186|NCT00323414|DRUG|Placebo|Placebo gelcaps containing corn oil identical to the PUFA gelcaps 6 capsules-3 capsules by mouth 2x per day x 48 weeks
223761187|NCT05047991|DRUG|Irinotecan Liposome Injection|Irinotecan Liposome Injection, intravenously, over 90 min on day 1and day 15 of every 28-day cycle
223761188|NCT05047991|DRUG|Fluorouracil|5-Fluorouracil (5-Fu), intravenously, over 46 h on day 1 and day 15 of every 28-day cycle
224202769|NCT06648499|OTHER|Evaluation of lower extremity muscle strength, physical activity, exercise capacity, balance, quality of life, and fatigue in healthy controls|The demographic information of the healthy controls will be taken. Healthy controls will be assessed using the FTSTS test to evaluate lower extremity muscle strength, the Godin Leisure Time Exercise Questionnaire (GLTEQ) for physical activity, the 2-Minute Walk Test (2MWT) for exercise capacity, the Timed Up and Go (TUG) Test for functional mobility, the Pediatric Quality of Life Inventory (PedsQL) for quality of life, and the PedsQL Multidimensional Fatigue Scale for fatigue. All assessments will be completed on the same day and will not be repeated after a certain period of time.
224202770|NCT01912391|DRUG|Selegiline|The Study Drug known as either selegiline 12 mg patch or matching placebo patch will be administered daily beginning at Visit 2 for the duration of 12 weeks.
224202771|NCT01912391|DRUG|Placebo (for Selegiline)|Transdermal Placebo patch manufactured to mimic Transdermal Selegiline 12 mg. patch
224202772|NCT05246150|BEHAVIORAL|nursing care practices|To determine the effect of nursing care practices on Near Infrared Spectroscopy (NIRS) levels in premature babies
223616685|NCT05301517|DRUG|SEPO®|SEPO® will be administered per dose and schedule specified in the arm description.
223616686|NCT05301517|DRUG|Roxadustat|Roxadustat will be administered per dose and schedule specified in the arm description.
223616687|NCT04106609|OTHER|Supervised, individualized exercise oncology program|The study intervention is a supervised, individualized exercise oncology program described in previous literature2,3,12 and provided by Maple Tree Cancer Alliance, a non-profit organization providing exercise training to individuals with cancer (https://www.mapletreecanceralliance.org/). This organization was founded in 2011 and currently operates in 9 hospitals serving Ohio and Pennsylvania, offering free exercise programs and nutritional guidance to approximately 500 patients annually to help relieve side effects related to cancer treatment.
224202773|NCT01408836|PROCEDURE|Plasma exchange|Plasma exchange
224202774|NCT01408836|DRUG|Intravenous methyl prednisolone|Intravenous methyl prednisolone
224202775|NCT01408836|DRUG|Methyl prednisolone|methyl prednisolone
224202776|NCT02864953|DRUG|BIIB093|Administered as specified in the treatment arm.
223616688|NCT04106609|OTHER|Current standard of care|Resource guide with various options available to cancer survivor. Within this guide are tips for healthy eating and pictures of standard exercises to improve fitness.
223616689|NCT04665271|BEHAVIORAL|Zemedy App|Digital smart phone app that delivers cognitive-behavioral therapy for IBS
223616690|NCT04970654|DRUG|somapacitan|Somapacitan (0.16 mg/kg/week) will be administered subcutaneously (s.c.; under the skin) once weekly by PDS290 pen-injector. Somapacitan can be injected any time during the once weekly dosing day. The dose will be calculated based on the subject's current body weight.
223616691|NCT04970654|DRUG|Norditropin®|Norditropin® (0.034 mg/kg/day) will be administered s.c. once daily by FlexPro® pen-injector. Norditropin® should be injected daily in the evening. The dose will be calculated based on the subject's current body weight.
224202777|NCT02864953|DRUG|Placebo|Administered as specified in the treatment arm.
224202778|NCT02487407|DRUG|ODM-109|ODM-109 1 mg capsule for oral administration.
223761189|NCT05047991|DRUG|Leucovorin|Leucovorin (LV), intravenously, over 30 min on day 1 and day 15 of every 28-day cycle
223761190|NCT05047991|DRUG|Oxaliplatin|Oxaliplatin, intravenously, over 2 h on day 1 and day 15 of every 28-day cycle
223761191|NCT05047991|DRUG|Nab paclitaxel|Paclitaxel (albumin bound), intravenously, over 30 min on day 1, day 8 and day 15 of every 28-day cycle
224202779|NCT02487407|DRUG|Placebo for ODM-109|Placebo capsule for oral administration.
224202780|NCT05440175|OTHER|EMS, Mirror therapy & exercises|EMS will be applied with frequency between 20-100 Hz and pulse width between 20 to 450us and Mirror therapy for 30 minutes and four days per week for a total duration of 12 weeks. Exercises include the flexion, extension of the wrist and elbow, ulnar and radial deviations , place any cylindrical object in patients palm and ask to lift the object off the table. other exercises includes external and internal rotations with different task orientations.
223761192|NCT05047991|DRUG|Gemcitabine|Gemcitabine, intravenously, over 30 min on day 1, day 8 and day 15 of every 28-day cycle
223761193|NCT05323955|DRUG|Trastuzumab|Administer per current package insert based on site standard of care guidelines
223761194|NCT05323955|DRUG|Trastuzumab Emtansine (T-DM1)|Administer per current package insert based on site standard of care guidelines
223761195|NCT05323955|DRUG|Pertuzumab|Administer per current package insert based on site standard of care guidelines
223761196|NCT05323955|DRUG|Tucatinib|300 mg orally twice daily (21 Day Cycle)
223761197|NCT04891029|DIAGNOSTIC_TEST|DOvEEgene test|Women participating in the study will undergo a genomic uterine pap test, DOvEEgene test, for the screening of ovarian and endometrial cancers. Clinical tests will also be administered as a comparator (CA-125 blood test and TVUS).
223761198|NCT05876091|OTHER|Vaping|Undergo vape puffing regimen
223761199|NCT05876091|PROCEDURE|Biospecimen Collection|Undergo collection of saliva samples and oral cell samples
223761200|NCT05876091|OTHER|Questionnaire Administration|Administer Quesitonnaire
223761201|NCT01619033|DRUG|BF2.649|single dose 20 mg
224202781|NCT05440175|OTHER|CIMT & exercises|Constraint induced movement therapy will be applied for 30 minutes and four days per week for a total duration of 12 weeks, it is a form of rehabilitation therapy that improves upper limb movement, it claims to improve the arm motor ability and the functional use of a paretic arm- hand. Exercises include the flexion, extension of the wrist and elbow, ulnar and radial deviations , place any cylindrical object in patients palm and ask to lift the object off the table. other exercises includes external and internal rotations with different task orientations.
224202782|NCT05440175|OTHER|Mirror therapy & exercises|Mirror therapy will be given for 30 minutes and four days per week for a total duration of 12 weeks. The exercises include the flexion, extension of the wrist and elbow, ulnar and radial deviations , place any cylindrical object in patients palm and ask to lift the object off the table. other exercises includes external and internal rotations with different task orientations.
224202783|NCT05186688|BEHAVIORAL|Braining|"Braining is a clinical invention that helps patients in psychiatry to start and execute physical exercise (PE) regularly in psychiatric care. The core components are basic moderate to vigorous aerobic group training session and motivational work led by the psychiatric staff. Braining is used as add-on treatment to regular psychiatric care and is included in the patient care plan."
223616692|NCT05730582|BEHAVIORAL|Parkland Diabetes Detection Program (PDDP) Screening Invitation|"The PDDP is designed to supplement and close screening gaps that persist despite opportunistic screening. Program staff order diabetes screening tests for randomized patients, then mail screening invitation letters to inform patients that they are at risk for diabetes. The letter informs them that a screening test has been ordered, and requests that they complete testing at their clinic lab. Patients who were mailed the letter but have not completed screening after 30 days are tracked and are send a second reminder invitation. Patients randomized to the targeted-tailored intervention study arm receive an additional phone call after 30 days."
224202784|NCT01518296|DEVICE|Medtronic-Dantec Urodynamic System|Urodynamic test is test performed in order to assess whether there is a urinary incontinence and underlying cause. During this test the woman is asked to empty her bladder and then two transducers are inserted, one into the bladder and the other into the rectum, then the bladder is filled with physiological solution and the patient is asked to urinate. During bladder emptying urinary flow velocity is measured and the pressures in the abdomen and bladder are recorded for later evaluation
224202785|NCT00621309|DRUG|Rifampicin|Rifampicin, an antibiotic used to treat TB, is administered at a dose of 300 mg day x 7 days to induce CYP3A5.
224202786|NCT00621309|DIETARY_SUPPLEMENT|sulforaphane plus rifampicin|Sulforaphane (SFN) is an isothiocyanate derived from the plant phytochemical, glucoraphinin. It appears to inhibit ligand binding to the ligand activated nuclear transcription factor, Pregnane X-Receptor (PXR). This arm tests the hypothesis that SFN can block ligand binding to the PXR, thereby inhibiting transcriptional activation of PXR-regulated genes. Sulforaphane is administered daily for 7 days as a broccoli sprout extract, at a dose rate of 75 mg (\~420 umoles)per day for 7 days. Rifampicin is also administered once per day at a dose rate of 300 mg/day for 7 days.
224202787|NCT00621309|DIETARY_SUPPLEMENT|sulforaphane alone|Sulforaphane (SFN) is an isothiocyanate derived from the plant phytochemical, glucoraraphinin. It appears to inhibit ligand binding to the ligand activated nuclear transcription factor, Pregnane X-Receptor (PXR). This arm tests the hypothesis that SFN can block ligand binding to the PXR, thereby inhibiting transcriptional activation of PXR-regulated genes
224202788|NCT04184882|DRUG|Bocidelpar|Oral
224202789|NCT04184882|DRUG|Placebo|Oral
224202790|NCT06005077|OTHER|Perineal Massage Group|While the pregnant woman was in the lithotomy position, massage was applied with two fingers and rhythmic U-shaped movements starting from the side walls 3-4 cm inside the vagina and towards the rectum. This implementation was done for 10 minutes in three stages according to cervical dilatation. It was applied when the cervical dilatation was 3-4 cm, 5-7 cm, and 8-10 cm.
223510666|NCT06375720|BEHAVIORAL|Lower frequency, shorter period of Tai Chi Chuan|Participants would take 24-form simplified Tai Chi Chuan 1 hour/session, 3 sessions/week for 12 weeks. There were 10 minutes warm-up, 40 minutes Tai Chi Chuan lesson and 10 minutes cool-down exercises in the Tai Chi Chuan training. Besides, they would also take standard health education 0.5 hour/session, 2 sessions/month for 6 months.
223510667|NCT06375720|BEHAVIORAL|Higher frequency, shorter period of Tai Chi Chuan|Participants would take 24-form simplified Tai Chi Chuan 1 hour/session, 5 sessions/week for 12 weeks. There were 10 minutes warm-up, 40 minutes Tai Chi Chuan lesson and 10 minutes cool-down exercises in the Tai Chi Chuan training. Besides, they would also take standard health education 0.5 hour/session, 2 sessions/month for 6 months.
223510668|NCT06375720|BEHAVIORAL|Lower frequency, longer period of Tai Chi Chuan|Participants would take 24-form simplified Tai Chi Chuan 1 hour/session, 3 sessions/week for 24 weeks. There were 10 minutes warm-up, 40 minutes Tai Chi Chuan lesson and 10 minutes cool-down exercises in the Tai Chi Chuan training. Besides, they would also take standard health education 0.5 hour/session, 2 sessions/month for 6 months.
223616693|NCT02912715|DEVICE|Paclitaxel releasing angioplasty balloon|Paclitaxel releasing angioplasty balloon catheter is advanced through an introducer sheath and tracked over the wire until reaching the target lesion. The balloon can be precisely positioned by means of the radiopaque markers crimped on the inner shaft of the catheter. The catheter is dilated up to its intended diameter by inflating the balloon with a solution containing contrast media, causing a compression of the arterial plaque against the inner lining of the arterial wall and improving blood flow. After balloon inflation, the drug-carrier adheres to the arterial wall and facilitates the drug release to surrounding tissue. As there is no need for sustained release of Paclitaxel after the inflation, the drug carrier dissolves rapidly.
223616694|NCT06523894|RADIATION|SBRT|Adapted to tumor volume BC SBRT
223616695|NCT03095248|DRUG|Selumetinib|Continuous twice daily dosing; oral agent
223616696|NCT06339658|PROCEDURE|Targeted axillary dissection (TAD) by ICG|Use of ICG during the targeted axillary dissection (TAD)
223616697|NCT06339658|PROCEDURE|Targeted axillary dissection (TAD) by Blue patent|Use of Blue patent during the targeted axillary dissection (TAD)
223616698|NCT06172348|DRUG|Ritlecitinib|Ritlecitinib 100 milligrams (mg) will be provided as either solution or capsule formulation (2 capsules of 50 mg)
223616699|NCT01006759|OTHER|exercise and orientation|guidances for prevention of disability in leprosy with focus on hands, eyes and feet.
223616700|NCT06419062|DEVICE|Frontier X2|Frontier X2 device will be used to measuring for physiological changes (breathing rate, heart rate, ECG, and heart rate variabilities) in people with COPD.
223616701|NCT06713330|DEVICE|BioFLX crown|Device: BioFLX crown
224202791|NCT06005077|OTHER|Perineal Warm Compress Application Group|Sterile compresses kept in hot water of 40 C were placed on the perineum. Compresses that cooled down and became dirty were changed every 5-8 minutes. This implementation was done for 30 minutes in three stages according to cervical dilatation. It was applied when the cervical dilatation was 3-4 cm, 5-7 cm, and 8-10 cm.
224202792|NCT06005077|OTHER|Perineal Massage and Perineal Warm Compress Application Group|When the cervical dilatation was 3-4 cm, 30 minutes of warm compress and 10 minutes of perineal massage were performed. These two methods were applied when the cervical dilatation was 5-7 cm and 8-10 cm as well .
223616702|NCT06713330|DEVICE|3M Stainless Steel Crown|3M Stainless Steel Crown
223616703|NCT06706141|BEHAVIORAL|PowerPoint presentation.|The training included topics such as breast anatomy; breast cancer incidence in Somalia, mortality, morbidity rates; breast cancer risk factors, importance of screening methods; The messages on breast self-examination, health belief models, breast cancer awareness, confidence for BSE, and perceived barriers/benefits for BSE were presented in a PowerPoint presentation. The procedure for performing breast self-examination was described using the English edition of Bristol-Myers Squibb Oncology. In the movie, BSE was made simpler with schematics showing the breast area that needed to be covered. Simple directions on which fingers to use and how to move them over the breast were provided. After the film, the emphasis shifted to helping students gain more self-assurance in their ability to accurately complete each BSE step. Students were encouraged to use proper palpation technique to find lumps by performing a breast examination on a silicone breast model.
223616704|NCT06725914|BEHAVIORAL|kangaroo care|Transport practice with paternal kangaroo care in preterm infants
223616705|NCT06725758|DRUG|ODM-212|ODM-212 5mg and/or 40mg tablets
223616706|NCT06725511|BEHAVIORAL|Opt-out framing|Outreach notifies those eligible that they are enrolled in the program and invites them to start participating.
223616707|NCT06725511|BEHAVIORAL|Opt-in framing|Eligible participants are invited to enroll
223616708|NCT02264158|DRUG|Telmisartan high|
223616709|NCT02264158|DRUG|Telmisartan low|
223616710|NCT02264158|DRUG|Lacidipine high|
223616711|NCT02264158|DRUG|Lacidipine low|
223616712|NCT02264158|DRUG|Placebo|
223616713|NCT06413602|OTHER|Acute Intermittent Hypoxia|During AIH, the participant will be equipped with a non-rebreathing face mask, and provided with the AIH intervention. The AIH intervention involves alternating breathing cycles. One cycle involves breathing air with lower oxygen concentration (9-10% oxygen) for 30 and 90 seconds, followed by breathing normal room air (21% oxygen) for a similar duration. This cycle is repeated 15 times in one session. Blood oxygen and heart rate are monitored throughout.
223616714|NCT06413602|OTHER|Neuromuscular Electrical Stimulation|During NMES, participants will receive electrical stimulation to the common peroneal nerve. Stimulation will be done with a 50% duty cycle, duration of 0.5-1ms for each pulse and a frequency 25-40 Hz. The stimulus intensity will be adjusted to produce approximately 50% of the maximum M-wave (compound muscle action potential) for each participant.
223616715|NCT01232868|BIOLOGICAL|trivalent Influenza vaccine (TIV)|0.5 ml IM as a single dose in a prefilled syringe.
223616716|NCT01538069|OTHER|Exercise training|It consisted of three sessions/week, on non-consecutive days. The aerobic protocol consisted of a warm-up (strengthening exercises, 10 minutes), aerobic exercise (30 minutes in the first month and 45 minutes in the last two months) and cool-down (strengthening exercises, 10 minutes). The aerobic exercise intensity was established by heart rate levels that corresponded to anaerobic threshold, 10 heart rates down and 10 heart rates up, assessed by cardiopulmonary exercise testing. The strength training consisted of eight exercises attending the major muscle groups and the intensity was determined by 50-60% of one-repetition maximum (1-RM) and the progression of the training will be monthly: first month (a series of 12 repetitions with 50% 1-RM), second month (1 set of 15 repetitions with 60% 1-RM) and third months (2 sets of 10 repetitions with 60% 1-RM).
223616717|NCT01538069|OTHER|CPAP group|The CPAP treatment will be according to protocol of the Department of Psychobiology. Titration will be perform after randomization with ventilation device servo-assisted so as to ensure positive pressure within the first 24 hours of treatment. The treatment will be for three months.
224202793|NCT05716516|DRUG|Estradiol|Estradiol is a therapeutic option for the treatment of advanced ER+ breast cancer
224202794|NCT02604849|DRUG|Neomycin|
223616718|NCT01538069|OTHER|Exercise and CPAP group|The patients randomized for this group will perform both Exercise protocol and CPAP treatment at the same time for three months.
223616719|NCT04575194|DRUG|Liraglutide 6 MG/ML [Saxenda]|3 mg of sc liraglutide daily plus lifestyle intervention
224202795|NCT02604849|DRUG|Streptomycin|
224202796|NCT02604849|DRUG|Gentamicins|
224202797|NCT00519909|OTHER|Dairy calcium|Diets with different content of calcium and fat
224202798|NCT01256229|DEVICE|cochlear implantation|This is the experimental therapy for deaf children with developmental delays, and the conventional therapy for deaf children without developmental delays.
224202799|NCT01256229|DEVICE|hearing aids|This is the conventional therapy for deaf children with developmental delays.
224202800|NCT01998659|DRUG|Px-102|Px-102 drinking solution, 7 single ascending doses from 0.15 mg/kg up to 4.5 mg/kg
223510669|NCT06375720|BEHAVIORAL|Higher frequency, longer period of Tai Chi Chuan|Participants would take 24-form simplified Tai Chi Chuan 1 hour/session, 5 sessions/week for 24 weeks. There were 10 minutes warm-up, 40 minutes Tai Chi Chuan lesson and 10 minutes cool-down exercises in the Tai Chi Chuan training. Besides, they would also take standard health education 0.5 hour/session, 2 sessions/month for 6 months.
223510670|NCT06375720|BEHAVIORAL|Standard Health Education|Participants would take standard health education 0.5 hour/ session, 2 sessions/month for 6 months.
223510671|NCT02521194|BEHAVIORAL|Questionnaire|Questionnaire completion regarding opinion of the inpatient occupational therapy session patient received.
223510672|NCT03661580|BEHAVIORAL|Behavioural Activation|The BA intervention will be the outpatient version of the Life Enhancement Treatment for Substance Use (LETS ACT; Daughters et al., 2008). This brief, manualised BA intervention has been specifically developed to meet the needs of patients with comorbid substance misuse and depression in drugs and alcohol treatment settings. LETS ACT targets the link between mood, substance use and behaviour, and focuses on identifying and increasing rewarding, substance-free activities that are based on the patient's own personal values.
224312643|NCT06387602|PROCEDURE|Active release technique|"Step 1: Place the body in a position (Dorsiflex ankle, flex the knee, extend the hip, flex the spine) so that the nerve is moved proximally. In this position, the nerve is relaxed on the distal side of the entrapment site and the nerve is tractioned on the proximal side.~Step 2: Place contact between the distal Gracilis and the Sartorius and push the muscle proximally. The contact should not compress the nerve.~Step 3: Move each joint so that the nerve moves distally past the muscle. The new position (Plantarflex and evert the ankle, extend the knee, flex the hip, extend the spine) will be achieved.~Step 4: Move the contact to the proximal side of the muscles and push the muscle distally.~Step 5: Move the nerve proximally again by pushing the muscle distally. This brings the position of the patient back to Step 1.~Contact will be held for a short time 5-20 seconds with repetitions 3-5 times to the injury site and 2 sessions per week."
224312644|NCT06387602|PROCEDURE|Post-Isometric Relaxation|"Step 1: Position the patient's limb at a point with the highest resistance felt during abduction.~Step 2: The patient is asked to bring the leg back into adduction using only 20% of strength against firm resistance given by the therapist.~Step 3: The patient will contract the agonist (the muscle that needs to be released) while holding an inhaled breath. Contraction should be held between 7-10 seconds without any jerking, bouncing, or wobbling.~Step 4: The patient is asked to release their effort slowly and completely. As the patient relaxes, the limb is guided into a new resistance barrier where a bind is felt again.~Step 5: After PIR, a 10-20-second latency period exists and the muscle can be stretched more easily.~Contract adductor muscle for 7-10 seconds and relax the same for 7-10 seconds with repetitions 7 times and 2 sessions per week."
224312645|NCT02065700|DRUG|Filgotinib|Administered as Oral Tablets
224312646|NCT00191971|DRUG|Gemcitabine|
224312647|NCT02782793|PROCEDURE|Endoscopic Mucosal Resection|
224312648|NCT02760992|DRUG|IV Baclofen|Baclofen intravenous solution 2 mg/mL manufactured and provided by Allaysis, LLC
224312649|NCT02760992|DRUG|Oral Baclofen|10 mg tablet
223616720|NCT04575194|DRUG|Naltrexone-Bupropion Combination|32/360 mg of oral lnaltrexone-bupropion daily plus lifestyle intervention
224202801|NCT01998659|DRUG|Placebo|Oral drinking solution
224202802|NCT04536818|PROCEDURE|Laparotomy|Exploratory laparotomy.
224202803|NCT00456027|DRUG|rhGAD65 formulated in Alhydrogel® (Diamyd®)|20 micrograms of rhGAD65 formulated in Alhydrogel® administered subcutaneously twice 4 weeks apart
224202804|NCT01692470|DRUG|No intervention|Patients will be taking rilpivirine hydrochloride as per the dosing regimen given on product insert approved in Philippines (ie, 1 tablet of 25 mg orally once a day) in combination with anti-retroviral (ARV) medications.
224202805|NCT06063980|PROCEDURE|Conventional sinus lift surgery|After graft reflection, sinus membrane is separated from bone or oral mucosa and then bone graft is inserted in between the two structures.
224202806|NCT06063980|PROCEDURE|Two-stage-sinus-lift procedure|Procedure is performed in two stages with the purpose of stage one to separate the oral mucosa from the sinus membrane using a small amount of bone graft and stage two as actual sinus augmentation, which is performed similar to that of conventional sinus lift procedure.
224312650|NCT05657392|DEVICE|repetitive Transcranial Magnetic Stimulation (rTMS)|Repetitive Transcranial Magnetic Stimulation (rTMS) is a noninvasive intervention that uses magnetic fields to stimulate nerve cells to improve the symptoms of a variety of disorders, including stroke-related motor impairment. Last few decades, it has been revealed that rTMS accelerates motor recovery and may reduce stroke-related symptoms.
224312651|NCT05657392|OTHER|32 electrode electroencephalography (EEG)|32-electrode EEG will be non-invasively recorded from electrodes placed in a montage over the scalp while the participant is resting
224312652|NCT03612557|DRUG|penicillin G benzathine|2.4 million units (IM) of benzathine benzylpenicillin
224312653|NCT01037296|PROCEDURE|catheter ablation|ablation procedure performed with Hansen robotic navigation system
224312654|NCT01037296|PROCEDURE|catheter ablation|Ablation will be performed as normal treatment
223616721|NCT03128515|DRUG|Hydroxyurea|Administered once a day in tablet form (100mg or scored 1000mg) for 24 months
223616722|NCT00774761|DRUG|fluticasone propionate/formoterol fumarate|inhalation suspension
223616723|NCT00774761|DRUG|fluticasone propionate|inhalation suspension
223616724|NCT00774761|DRUG|formoterol fumarate|inhalation solution
223616725|NCT04481243|BIOLOGICAL|Pneumovax 23- pneumococcal polysaccharide|PPSV23 is a vaccine to help protect against serious infection due to the Streptococcus pneumoniae bacteria. One dose administered intramuscularly or subcutaneously.
223616726|NCT04481243|PROCEDURE|Blood draw|6 ml blood draw at baseline and 6 months post immunization
224202807|NCT04566965|DIAGNOSTIC_TEST|SARS-CoV-2|"1. Testing weekly samples from nasal swabs to promptly diagnose acute COVID-19 infection.~2. Testing monthly serum samples to document post-viral infection."
224202808|NCT03881748|OTHER|Manual acupuncture|"Manual acupuncture twice a week for 20 treatments.~Acupuncture will be administered on an outpatient basis in private rooms with participants lying supine. The acupuncturist will disinfect the selected acupuncture points with alcohol and then needle them so that the participant achieves a de qi sensation if possible, which is often described as a pressure or achiness feeling. Acupuncture needles will be left in place for approximately 20 minutes."
224312655|NCT05214703|OTHER|cold therapy application|cold therapy
224312656|NCT06394700|BEHAVIORAL|written exposure therapy|Written Exposure Therapy (WET) is a manualized exposure-based therapy involving five sequential weekly individual sessions. Each session lasts approximately 40 minutes except the first, which is one hour. In the initial session, the therapist explains the treatment rationale and guides the participant to write about their traumatic experience uninterrupted for 30 minutes. Subsequent sessions start with a brief discussion about the previous session's writing, followed by another 30-minute writing session, concluding with a short check-in. There is no homework between sessions.
224312657|NCT06394700|BEHAVIORAL|Written Exposure Therapy plus Mindfulness-Based App (WET + MBA)|"WET + MBA combines the standard WET protocol with the addition of a mindfulness practice facilitated through a mobile app called Now Meditation. This app is among the most downloaded mindfulness apps in China, used to help manage symptoms of insomnia commonly comorbid with PTSD. Participants are instructed to engage in daily mindfulness exercises according to the app's 7-Day Basic Meditation program and continue practicing mindfulness throughout the duration of the therapy. This is intended to supplement the therapeutic effects of WET by providing tools to manage insomnia and potentially enhancing the therapeutic process by fostering greater mindfulness and relaxation."
224312658|NCT06394700|BEHAVIORAL|Minimal Contact Control (MCC)|MCC contains weekly phone calls from a study therapist to monitor their status and provide support as needed, without introducing any specific therapeutic interventions. These calls are brief, generally lasting between 10 to 15 minutes, and are strictly for the purpose of engagement and safety monitoring rather than therapeutic intervention.
223616727|NCT03564717|OTHER|Segmented three dimensionally printed transfer tray|Segmented indirect bonding transfer tray
223616728|NCT05872685|DRUG|S1|S-1 orally intake as perioperative chemotherapy
223616729|NCT05872685|DRUG|Oxaliplatin|Oxaliplatin (130 mg/m2) infusion as perioperative chemotherapy
223616730|NCT05872685|DRUG|Serplulimab|Perioperative serplulimab, 300 mg IV infusion
223616731|NCT05872685|DRUG|Placebo|Perioperative placebo, 300 mg IV infusion
223616732|NCT00786292|OTHER|Assisted mechanical ventilation|Patients will be mechanically ventilated with noisy PSV and PSV in random sequence
223616733|NCT02191462|DIETARY_SUPPLEMENT|Niagen 100mg|
223616734|NCT02191462|DIETARY_SUPPLEMENT|Niagen 300mg|
224202809|NCT03881748|OTHER|Electro-acupuncture|"Electro-acupuncture twice a week for 20 treatments.~Acupuncture will be administered on an outpatient basis in private rooms with participants lying supine. The acupuncturist will disinfect the selected acupuncture points with alcohol and then needle them so that the participant achieves a de qi sensation if possible, which is often described as a pressure or achiness feeling. Acupuncture needles will be left in place for approximately 20 minutes.~Electrical stimulation will be applied to the needles concomitantly and continuously to acupuncture points by placing lead wires on the needles connected to an electro-acupuncture stimulator such as the Model IC-1107. The stimulator will be set on the Dense-Disperse wave setting with low frequency at 2-10 Hz and high frequency at 100-110 Hz. The needles will not be manually stimulated after electrical stimulation is applied."
223616735|NCT02191462|DIETARY_SUPPLEMENT|Niagen 1000mg|
224202810|NCT04625634|OTHER|2 days of work heat stress|2 consecutive days of identical simulated structural firefighting tasks.
224202811|NCT05290636|OTHER|Teaching intervention program|Using an action research approach, The investigators designed a pair of geriatric nursing and practicum courses and recruited a class of in-service nursing students through convenience sampling in a college setting. The intervention was an 18-week course in geriatric nursing that meets once a week in the classroom and internship practice in settings used for training nursing students. The investigators collected data using quantitative indicators (attitude measurements) and qualitative textual analysis. The quantitative data were analyzed by paired t-testing using SPSS 21.0 software.
223510673|NCT03661580|BEHAVIORAL|Treatment as Usual|The control intervention in this study is Treatment as Usual at the CDAT service. Treatment as Usual consists of planned key-working sessions every 2-4 weeks with an allocated caseworker plus monthly prescribing review appointments with a medical practitioner for patients who require drug treatment medication. Key-working sessions are primarily focused on addressing substance misuse issues using a range of intervention techniques such as motivational interviewing and brief solution-focused therapy.
223510674|NCT05697003|DRUG|Fluticasone propionate 1000 mcg and salmeterol xinafoate 50 mcg/Respirent Pharmaceuticals|2 inhalations in one study period
223616736|NCT02831764|DRUG|Dolutegravir (DTG)|DTG is available as 50 mg white, round, biconvex, film coated tablet debossed on one side with 'SV 572' and on the other side with '50'. The tablets are packaged into high density polyethylene (HDPE) bottles with induction seals and child resistant closures. Each 45 ml bottle contains 30 tablets and a desiccant. DTG 50 mg tablet will be orally administered once daily with or without food upto 148 weeks.
223616737|NCT02831764|DRUG|Lamivudine (3TC)|Lamivudine is available as swedish orange, 'AA' sized elongated double blind HPMC capsules containing 300 mg lamivudine to visually match overencapsulated TDF/FTC FDC tablet. The capsules are packaged into HDPE bottles with induction seals and child resistant closures. Each 150 mL bottle contains 30 capsules and a desiccant. Overencapsulated 3TC 300 mg tablet will be orally administered once daily with or without food upto 96 weeks. From Week 96 to Week 148, lamivudine will be dispensed as 300 mg white, diamond shaped, scored, film coated tablets debossed with 'GX CJ7' on both sides, packed in over labelled HDPE bottles with child-resistant closures each containing 30 tablets.
223616738|NCT02831764|DRUG|Tenofovir disoproxil fumarate/Emtricitabine (TDF/FTC FDC)|Tenofovir disoproxil fumarate and Emtricitabine are available as swedish orange, 'AA' sized elongated double blind HPMC capsules containing 300 mg TDF and 200 mg FTC to visually match overencapsulated 3TC tablet. The capsules are packaged into HDPE bottles with induction seals and child resistant closures. Each 150 mL bottle contains 30 capsules and a desiccant. Overencapsulated tenofovir disoproxil fumarate/emtricitabine tablet will be orally administered once daily with or without food upto 96 weeks. From Week 96 to Week 148, tenofovir disoproxil fumarate/emtricitabine will be dispensed as 300/200 mg white, blue, capsule shaped, film coated tablets debossed with 'GILEAD' on one side and '701' on another side, packed in overlabelled HDPE bottles with polypropylene childresistant closures each containing 30 tablets and a desiccant.
223616739|NCT00004858|BIOLOGICAL|B43-genistein immunoconjugate|
223616740|NCT05360927|DRUG|BDB-001 injection|Intravenous injection
223616741|NCT05360927|DRUG|Placebo|Intravenous injection
223616742|NCT05721495|OTHER|freeze all strategy embryo transfer|criopreservation of all viable embryos in order to transfere the best one in a posterior cycle
223616743|NCT05721495|OTHER|fresh embryo transfer strategy|transfer of the best embryo two or three days after the fecundation technique
223616744|NCT01459588|DRUG|Carboxymethylcellulose Based Eye Drop Formulation A|Carboxymethylcellulose Based Eye Drop Formulation A (Refresh Optive® Advanced Sensitive Eye Drops) 1-2 drops in each eye as needed, at least 2 times daily for 30 days.
223616745|NCT01459588|DRUG|Carboxymethylcellulose Based Eye Drop Formulation B|Carboxymethylcellulose Based Eye Drop Formulation B (Refresh Optive® Advanced Eye Drops) 1-2 drops in each eye as needed at least 2 times daily for 30 days.
224202812|NCT00790270|DRUG|Cyclobenzaprine|5 mg orally every 8 hours as needed
224202813|NCT00790270|DRUG|Ibuprofen|Ibuprofen 400 mg every 8 hours as needed
224312659|NCT00000259|DRUG|15 % Nitrous oxide|
224312660|NCT00000259|DRUG|0.3 % Sevoflurane|
224312661|NCT00000259|DRUG|30% Nitrous oxide|
224312662|NCT00000259|DRUG|0.6% Sevoflurane|
224312663|NCT00000259|OTHER|Placebo|
224312664|NCT00307918|DEVICE|acupuncture|
224312665|NCT04176406|DEVICE|rTMS|excitatory 5Hz rTMS will be used
223616746|NCT01459588|DRUG|Carboxymethylcellulose Based Preservative-Free Lubricant Eye Drops|Carboxymethylcellulose Based Preservative-Free Lubricant Eye Drops (Optive® Sensitive Preservative-Free Lubricant Eye Drops) 1-2 drops in each eye as needed at least 2 times daily for 30 days.
224202814|NCT00790270|DRUG|Ibuprofen plus Cyclobenzaprine|Ibuprofen 400 mg plus cyclobenzaprine 5 mg every 8 hours as needed
224202815|NCT05416346|BEHAVIORAL|Digital Cognitive Behavioral Therapy|Cognitive behavioral therapy for insomnia (CBT-i) has been showed to be effective in reducing insomnia symptoms and insomnia-related symptoms, including sleepiness, dysfunctional beliefs and attitudes about sleep, anxiety and depressive symptoms
224202816|NCT05416346|BEHAVIORAL|Sleep Hygiene Education (SHE)|The SHE group received sleep hygiene education delivered in text form, and the same intervention as the dCBT-i group did after four weeks.
224202817|NCT03522285|OTHER|investigation: erythrocyte sedimentation rate|investigations will be done to detect presence of infection and x-ray also for detection of infection or loosing of hip components
224202818|NCT01238523|PROCEDURE|Long leg cast in full extension|Long leg cast in full extension with instructions to begin immediate weight bearing as tolerated on the injured extremity
224202819|NCT01238523|PROCEDURE|Long leg cast with 45 degrees of flexion|Long leg cast with 45 degrees of flexion at the knee with instructions not to bear weight on the injured extremity
224202820|NCT00838175|PROCEDURE|suture mediated closure|Suture mediated closure of femoral venous access
224202821|NCT00005886|DRUG|arzoxifene hydrochloride|
224202822|NCT00005886|DRUG|tamoxifen citrate|
224202823|NCT02496442|DEVICE|Aqueduct|Using Aqueduct in procedures to continuously supply the irrigation solutions
224202824|NCT05434767|DEVICE|Mobile application|Participants will be instructed on the installation and use of the mobile application on their personal mobile phones. Participants will then have to perform the assigned exercises using the mobile application 3 times daily. Physiotherapists will still perform the required assessment/review, education, and intervention.
224202825|NCT05434767|OTHER|Standard rehabilitation program|All participants will be seen by physiotherapists in the ward post-TKR surgery and undergo standard inpatient rehabilitation. Patients will be given instructions to perform assigned exercises 3 times daily. Physiotherapists will perform the required assessment/review, education, and intervention.
224202826|NCT02300272|DEVICE|Polysomnograph|Participants will be screened for sleep disorders other than chronic insomnia with an in-home overnight sleep monitoring. Monitoring will consist of six electroencephalography (EEG) measures, two electrooculography (EOG), and chin electromyography (EMG) according to standard placements. Other channels will include oxygen saturation level, bilateral anterior tibialis EMG, heart rate (EKG), thoracic strain gauge, and a nasal/oral thermistor. A single night of polysomnography will be collected during the 2 weeks of assessment.
224202827|NCT02300272|DEVICE|Actiwatch|This device will be worn on the wrist for 14 continuous days to measure limb movements and ambient light.
224202828|NCT02175927|DRUG|Lansoprazole|antisecretory drug of each quadruple therapy
224202829|NCT02175927|DRUG|Bismuth Potassium Citrate|one component of each quadruple therapy
224202830|NCT02175927|DRUG|Metronidazole|antibiotic of each quadruple therapy
224202831|NCT02175927|DRUG|Amoxicillin|antibiotic of high dose amoxicillin based quadruple therapy
223510675|NCT05697003|DRUG|ADVAIR DISKUS 100/50|2 inhalations in one study period
223510676|NCT04595578|DEVICE|Cerebellar repetitive transcranial magnetic stimulation|rTMS was delivered on the scalp for over 2 cm under the inion, which is the scalp over the cerebellum area, using a double-cone coil connected to a Magstim Rapid2® stimulator with two Booster Modules (Magstim, Spring Gardens, Wales, UK) in accordance with safety recommendations. Stimulation was delivered to the cerebellum at 10 Hz with 90% of the mean resting motor threshold intensity for 5 seconds at 55 second intervals to deliver 1000 pulses in 20 minutes. Immediately after rTMS, the combination treatment group received balance and gait training by a physical therapist for 30 minutes/day and underwent aerobic exercise using a stationary bicycle at moderate intensity (12 to 14 rating of perceived exertion) for 30 minutes/day and 5 days/week for two weeks. In the control group, no participants received physical therapy or rTMS for two weeks.
223510677|NCT06603831|PROCEDURE|patients treated using 3D technology and Patient-Specific Instrumentation|"3D Digital surgery includes:~* 3D Surgical Planning using biomedical engineering software; 3D visualization of the patients anatomy and surgical simulation.~* Use of personalized surgical guides created through additive manufacturing.~* Use of personalized implants created through additive manufacturing.~  3 surgical procedures are studied in this study; radius osteotomy, acetabular arthroplasty and spinal arthrodesis"
223510678|NCT06603831|PROCEDURE|Patients treated with conventional surgery, without using 3D technology|"Conventional surgery includes:~* 2D planning using TC and x-rays~* Free-hand surgery~* Use of generic, non-personalized implants~  3 surgical procedures are studied in this study; radius osteotomy, acetabular arthroplasty and spinal arthrodesis"
223510679|NCT01491165|PROCEDURE|stem cell transplantation through interventional procedures|one time interventional procedures
223510680|NCT00394537|DRUG|Labetalol 10mg iv|
223510681|NCT00666471|PROCEDURE|MICE|MICE
223510682|NCT00666471|PROCEDURE|SPA ligation|SPA ligation
223510683|NCT04928404|PROCEDURE|tongue base suspension using barbed suture|all patients will undergo multi-level surgeries .Therefor, Anterolateral advancement pharyngeoplasty (ALA) or Barbed Reposition Pharyngoplasty (BRP) will be applied to improve retro-palatal obstruction and tongue base suspension using barbed suture for retro-lingual obstruction.
223510684|NCT00800384|DEVICE|Implantable defibrillator|Implantable defibrillator to detect and terminate ventricular arrhythmias
223510685|NCT02119000|DRUG|PEG/electrolytes 2L/2L split dose|Polyethylene glycol 17gm X 4 At 18h00 the day prior the colonoscopy, dilute 2 sachets in 2 L of water and drink 240 mL every 10 minutes On the day of the procedure, 4-5 hours prior the colonoscopy, dilute 2 sachets in 2 L of water and drink 240 mL every 10 minutes
223510686|NCT02119000|DRUG|Bisacodyl 15 mg and PEG/electrolytes 1L/1L split dose|"Bisacodyl 15 mg x 3~At 14h00 the day prior the endoscopic procedure: take 3 tablets of Bisacodyl ER (15 mg) orally then 5 hr later:~PEG/electrolytes 1L/1L Polyethylene glycol 17gm Dilute one sachet of Polyethylene glycol 17gm in 1 L of water Start drinking at around 19h00 the night prior the colonoscopy Drink 240 ml every 10 minutes The day of the colonoscopy. At (4 hrs prior the procedure). Dilute on sachet of PEG and drink 240 ml every 10 minutes"
223616747|NCT01459588|DRUG|Carboxymethylcellulose Based Lubricant Eye Drops|Carboxymethylcellulose Based Lubricant Eye Drops (Optive® Lubricant Eye Drops) 1-2 drops in each eye as needed, at least 2 times daily for 30 days.
223616748|NCT02264275|BEHAVIORAL|Aerobic Exercise Training|The aerobic exercise training uses a television attached to a Nintendo Wii videogame console with a dance game to be played by participants on 5 days per week using a ramped-duration schedule (from 10-30 minutes of moderate physical activity daily).
223616749|NCT00860873|DIETARY_SUPPLEMENT|EMS Chondroitin Sulfate + Glucosamine Sulfate (Oral powder)|Chondroitin Sulfate 1200mg Glucosamine Sulfate 1500mg
223616750|NCT00860873|DIETARY_SUPPLEMENT|EMS Chondroitin Sulfate 1200mg + Glucosamine Sulfate 1500mg (hard capsules)|Chondroitin Sulfate 1200mg Glucosamine Sulfate 1500mg
223616751|NCT00860873|DIETARY_SUPPLEMENT|Zodiac: Chondroitin Sulfate 1200mg + Glucosamine Sulfate 1500mg (Oral powder)|Chondroitin Sulfate 1200mg + Glucosamine Sulfate 1500mg
223616752|NCT00860873|DIETARY_SUPPLEMENT|Zodiac Chondroitin Sulfate 1200mg + Glucosamine Sulfate 1500mg (hard capsules)|Chondroitin Sulfate 1200mg + Glucosamine Sulfate 1500mg
223616753|NCT02544321|DRUG|Bromocriptine|
223616754|NCT02544321|OTHER|Placebo|
223616755|NCT04978896|DEVICE|Self-guided program on stress coping|This is an 8-day program that provides psychoeducation on the negative effects of stress and effective stress-management skills to combat stress. Guided by principles of CBT, the program targets the thoughts and behaviours of participants and equips them with skills to alter negative cognitions pertaining to stress. Participants are engaging with a series of exercises involving reflection and mindfulness where they are required to spot and write down their stressors, the negative thoughts associated with the stressors, as well as positive affirmations. Participants will also be taught breathing exercises and are encouraged to practice them during 2 check-ins.
224202832|NCT02175927|DRUG|Tetracycline|antibiotic of classical quadruple therapy
224202833|NCT04478188|OTHER|Measuring Pressure Volume Loop Pre and Post Device Placement|To measure simultaneous pressure and volume of the heart (pressure volumes loops) before and after ventricular assist device placement for cardiogenic shock (a severe form of heart failure) and before and after device removal.
223616756|NCT04978896|DEVICE|Self-guided program on cooperation|The 8-day program on cooperation aims to provide psychoeducation for participants to understand and improve collaboration and interpersonal relationships. Short quizzes and practice exercises on feedback-giving will be included. The time and duration of the cooperation SGA is matched to the stress-coping SGA to ensure that participants spend a similar amount of time and effort across both the intervention and active-control conditions.
223616757|NCT02583919|DRUG|ISIS-GCGRRx- Dose Level 1|once weekly dosing for 26 weeks
223616758|NCT02583919|DRUG|ISIS-GCGRRx- Dose Level 2|once weekly dosing for 26 weeks
223616759|NCT02583919|DRUG|Placebo|once weekly dosing for 26 weeks
223616760|NCT00675181|DRUG|Melatonin|5mg per os
223616761|NCT00675181|DRUG|Placebo|per os
224202834|NCT05423769|DRUG|Fingolimod|0.5 mg hard gelatine capsules
224202835|NCT00227734|DRUG|capecitabine and oxaliplatin + cetuximab|cetuximab
224202836|NCT00227734|DRUG|capecitabine and oxaliplatin|capecitabine and oxaliplatin without cetuximab
224202837|NCT04109768|BEHAVIORAL|nutrition and activity|16 sessions; nutrition 8; activity 8- 45 minutes to improve health and nutrition literacy
224202838|NCT06584708|OTHER|Low-volume high intensity interval training|"Week 1 \& 2:~Warm-up: 10 minutes at 50% THR Work: 1x4 minutes at 80% THR followed by 1\*4 minutes Recovery at 50% THR Cool down: 5 minutes at 50% THR Total exercise time: 23 minutes~Week 3 \& 4:~Warm-up: 10 minutes at 50% THR Work: 2x6 minutes at 80% THR followed by 1\*6 minutes Recovery at 50% THR Cool down: 5 minutes at 50% THR Total exercise time: 33 minutes"
224202839|NCT06584708|OTHER|Moderate intensity continuous exercise|"Week 1 \& 2:~Warm-up: 5 minutes at 50% THR Work: 20 minutes at 60% VO 2 THR Cool Down: 5 minutes at 50% THR Total exercise time: 30 minutes~Week 3 \& 4:~Warm-up: 5 minutes at 50% THR Work: 30 minutes at 60% THR Cool Down: 5 minutes at 50% THR Total exercise time: 40 minutes"
224202840|NCT04632134|DEVICE|Transcutaneous vagal nerve stimulation (tVNS)|Transcutaneous vagal nerve stimulation (tVNS) will be performed using a noninvasive battery powered Transcutaneous Electrical Nerve Stimulation device (Nemos ©; Cerbomed, Germany). Electrical stimulation will be delivered by external electrodes through the skin surface at the conca of right external ear. Electrical current will be applied continuously with a pulse width of 200 μs and pulse frequency of 25 Hz. Stimulation amplitude will be adjusted between 0.1-6 mA, to a maximal amplitude level without causing patient discomfort.
224202841|NCT04632134|OTHER|Placebo|tVNS electrodes will be positioned in the right ear of the POTS patients without delivering stimulus (Sham)
224202842|NCT04632134|DEVICE|Home daily transcutaneous vagal nerve stimulation|The home stimulation will consist of 4 hours of stimulation by the tVNS device organized as a 4 sessions of 1 hour. The home stimulation will last for 14 consecutive days.
224202843|NCT00381134|DRUG|losartan 100 mg orally once daily|
224202844|NCT00381134|DRUG|spironolactone 25 mg orally once daily|
224202845|NCT00381134|DRUG|placebo once orally once daily|
224202846|NCT05078359|DIAGNOSTIC_TEST|Prostate Magnetic resonance Imaging|Magnetic resonance imaging (MRI) uses a magnetic field, radiofrequency pulses, and a computer to produce detailed pictures of the organ. Prostate MRI evaluate the presence and extent of prostate cancer and determine whether it has spread around the organ
224202847|NCT06202950|BEHAVIORAL|Yoga|Applying yoga for one hour a week for eight weeks to an adolescent with type 1 diabetes
224202848|NCT06202950|BEHAVIORAL|Mindfulness|Applying mindfulness for one hour a week for eight weeks to an adolescent with type 1 diabetes
224202849|NCT02792088|DRUG|Besifovir 150mg|Besifovir 150 mg q.d. + Placebo of Tenofovir Disoproxil Fumarate 300 mg q.d. + L-carnitine (L-Carn Tab. 330 mg) 660 mg q.d.
223616762|NCT01517750|DEVICE|ICON Auto CPAP™ with Thermosmart heated tube|ICON Auto CPAP™ with heated humidification and the use of a heated tube
223616763|NCT01517750|DEVICE|ICON Auto CPAP™ without Thermosmart heated tube|ICON Auto CPAP™ without heated humidification or the use of a heated tube.
223616764|NCT01298479|OTHER|Uniject|single use container
223616765|NCT00001572|DRUG|Id-KLH Vaccine|
223616766|NCT00001572|DRUG|QS-21 (Stimulation-QS-21) Drug|
223616767|NCT01584232|DRUG|LY2189265|
223616768|NCT01584232|DRUG|Insulin glargine|
223616769|NCT01584232|DRUG|Sulfonylureas (SU)|
223616770|NCT01584232|DRUG|Biguanide (BG)|
224202850|NCT02792088|DRUG|Tenofovir 300mg|Placebo of Besifovir 150 mg q.d. + Tenofovir Disoproxil Fumarate 300 mg q.d. + Placebo of L-carnitine (L-Carn Tab. 330 mg) 660 mg q.d.
224202851|NCT01352871|BEHAVIORAL|Concentration / meditation|from 30 minutes before endotoxin administration to 1,5 hrs after endotoxin administration the subject is concentrating / meditating with the goal to influence the innate immune response
224202852|NCT01352871|DRUG|lipopolysaccharide|lipopolysaccharide 2ng/kg intravenously
224202853|NCT03434873|OTHER|magnetic stimulation|Twenty trains of 50 stimuli at 5 Hz (train duration: 10 seconds) separated by a 40-second pause were delivered for a total of 1000 pulses, once a day for four consecutive days for two weeks
224202854|NCT04933708|BEHAVIORAL|Labor Podcast|"Listening to podcasts.~Topics include:~Labor Anesthesia, Induction of Labor, Second Stage of Labor, Reasons for Cesarean Section, Postpartum Recovery, Complications of Labor and Birth"
224202855|NCT05312801|DRUG|BAFF CAR-T|Autologous CAR-T cell therapy expressing the BAFF-ligand.
224202856|NCT02143479|DRUG|Tacrolimus|oral
224202857|NCT04141761|DIETARY_SUPPLEMENT|Visbiome|This group will receive Visbiome probiotic in powder form.
224202858|NCT04141761|OTHER|Placebo|This group will receive a placebo in powder form.
224202859|NCT06653738|DRUG|Empagliflozin 25 MG|Once daily per os for 3 years
224202860|NCT06653738|DRUG|Placebo|Once daily per os for 3 years
224202861|NCT06653738|BEHAVIORAL|Personalized dietary counseling|Personalized dietary counseling based on repeat 24-hr urine collections and dietary assessments for 3 years
224202862|NCT06653738|BEHAVIORAL|Generic dietary counseling|Generic dietary counseling based on current guidelines without 24-hr urine collection results and without specific dietary assessments for 3 years
224202863|NCT06653673|BEHAVIORAL|ChatGPT supported Online Guided Self-Help Program (GSHP)|"Guided Self-Help Program (GSHP)~The Guided Self-Help Program (GSHP) was developed by Fairburn and Carter for patients with binge eating disorder and later adapted to address various eating behaviors, forming an intervention protocol. GSHP modules consist of:~Starting self-monitoring, Establishing regular eating patterns, Applying the mindful eating rule and developing alternatives to emotional eating, Practicing problem-solving exercises, Addressing diet-related issues and body image, and Termination modules.~Session Structure:~Session 1 focuses on tracking eating patterns and raising self-awareness about eating habits. Individuals are asked to maintain a daily record via a shared Google Forms link. This food diary is later processed through ChatGPT, and personalized feedback is provided.~Session 2 provides psychoeducation on developing regular eating patterns. It emphasizes recognizing hunger and satiety cycles and reducing triggers. Participants are asked to log their meals daily"
224202864|NCT06652711|BEHAVIORAL|2-month access to mental health app|Participants will have access to the well-being app for two months.
224202865|NCT06652711|BEHAVIORAL|Direct incentive|A $10 gift card are given to participants at the end of the study if they used the app sufficiently.
224312666|NCT04176406|DEVICE|Sham rTMS|an electrical sham coil reproducing the same clicking sound and tactile sensation than the active rTMS will be used
224312667|NCT01489631|DRUG|naropin|ropivacaine 0,2%, 3x 50 ml during surgery
224312668|NCT01489631|DRUG|marcaine|bupivacaine 0,125%
223616771|NCT01810484|DEVICE|Ultherapy® treatment only|Focused ultrasound energy delivered below the surface of the skin
224202866|NCT06652711|BEHAVIORAL|4-month access to mental health app|Participants will have access to the well-being app for four months.
224202867|NCT06652711|BEHAVIORAL|Lottery incentive|Participants can participate in a draw of $150 gift cards at the end of the study if they used the app sufficiently.
224202868|NCT05603000|BEHAVIORAL|Emotion Focused Family Therapy|"The Emotion Focused Family Therapy (EFFT) intervention for this study will be delivered to groups of four to ten parents over six weekly sessions of two hours each. The goal of EFFT is to teach and empower parents to coach their child to process the emotions at the source of their mental health symptoms, to increase their child's adaptive behaviours, and to repair emotional injuries within the parent-child relationship. EFFT also targets parents' own emotional challenges that may prevent them from feeling capable or being able to support their child's treatment.~Each EFFT session will include introductions, psychoeducation about emotion and psychopathology, introduction of skills, experiential activities (e.g., chair work), open discussion and feedback, and homework activities covering the foci of EFFT: emotion coaching, behaviour coaching, therapeutic apology, and parental emotion blocks."
224202869|NCT05385783|DRUG|CYB003|CYB003 is a synthetic psilocybin analog.
224202870|NCT05385783|BEHAVIORAL|Psychotherapy|Manualized psychotherapy (called EMBARK) performed by facilitators
224312669|NCT01489631|DRUG|sufentanil|sufentanil 1mcg/ml
223616772|NCT01810484|DEVICE|Ultherapy® treatment and CO2 laser treatment|"Ultherapy® treatment: Focused ultrasound energy delivered below the surface of the skin;~CO2 Laser: Fractionated energy delivered to the surface of the skin for ablative and thermal injury to the skin layers for resurfacing the skin."
223616773|NCT01810484|DEVICE|CO2 Laser treatment only|CO2 Laser: Fractionated energy delivered to the surface of the skin for ablative and thermal injury to the skin layers for resurfacing the skin.
224312670|NCT01489631|DRUG|neurontin|gabapentin 600 mg pre-operative 3 dd 300 mg
224312671|NCT06344663|OTHER|motivational interview|Before starting the interview, mothers will be informed about the interview intervals, duration, how many times it will be held, and that, unlike other interviews, the topic will be determined and the mother's opinions on this subject will be obtained. Each meeting will last approximately 15-30 minutes
224312672|NCT02763371|OTHER|Dietary: high GI lunch|High GI: High-GI rice lunch ad libitum on test day 1 and low GI-rice lunch on test day 2. Water at libitum was constantly available on both days.
224312673|NCT02763371|OTHER|Dietary: low GI lunch|Low-GI: Low GI-rice lunch ad libitum on test day 1 and high GI-rice lunch on test day 2. Water at libitum was constantly available on both days.
224312674|NCT05782127|DRUG|Onureg + Venetoclax|Combination of Onureg and Venetoclax
224312675|NCT04674865|OTHER|Standardized Physical therapy protocol|Standardized Phase 1 protocol without for 7 days without ANB sessions.
224312676|NCT04674865|OTHER|Alternate nostrils breathing|Alternate nostrils breathing 2 sessions per day
224202871|NCT05385783|DRUG|Placebo|Placebo
224202872|NCT05385783|BEHAVIORAL|Psychological Support|Manualized psychological support performed by facilitators
224202873|NCT00763126|BEHAVIORAL|stress level|Stress levels
224312677|NCT03285100|DIAGNOSTIC_TEST|Venipuncture|"* Approximately 6 months after discontinuation of VKAs one additional venipuncture will be performed for determination of dp-ucMGP and desmosine.~* At baseline two additional blood collection tubes will be drawn for determination of dp-ucMGP, desmosine and VKORC1 polymorphisms. Since this is during one of the last regular International Normalized Ratio (INR) testing at the anticoagulation clinic, no additional venipuncture has to be performed at this moment."
224312678|NCT02036359|DRUG|erlotinib|150mg/day for 9 weeks unless disease progression, unacceptable toxicity or death.
224312679|NCT02036359|DRUG|docetaxel|receive 3 cycles (9 weeks) of chemotherapy with docetaxel 35mg/m2 IV on day 1 and day 8, and cisplatin 75mg/m2 on day 8.
224202874|NCT01243853|DIETARY_SUPPLEMENT|Alpha-galactosidase|3 months intervention, daily 3 x 3 capsules alpha-galactosidase enzyme (400 GalU/capsule) or 3 x 3 capsules placebo
224202875|NCT02270021|OTHER|Provider Mobile Application (ProvAPP)|Mobile phone application to maneuver clinicians through the cervical cancer screening and treatment guidelines based on patient age and condition.
224202876|NCT02270021|OTHER|ProvAPP + Patient Educational Tool (Tab)|"Patient Educational Tool (Tab): A patient educational tool (mobile tablet) will educate women on cervical cancer screening and treatment. Patients' self-assessment using a tablet at the time of clinic check-in will help them to understand current guidelines and their choices for treatment if they have abnormal cytology. It will allow them to assess the risks and benefits of screening intervals and of treatment choices.~ProvAPP: Mobile phone application to maneuver clinicians through the cervical cancer screening and treatment guidelines based on patient age and condition."
224202877|NCT05751824|OTHER|AI based automatic surveillance (AS) system (ENDOANGEL-AS)|An automatic surveillance (AS) system to accurately identify post-polypectomy patients, assign surveillance intervals for different risks of patients and proactively follow up with patients at certain times.
224312680|NCT05584592|OTHER|Intergrate early palliatuve care + Conventional chemotherapy|Sixty patients with gastric and pancreatic cancer will be eligible, and 30 patients will be randomly assigned to the exercise therapy + high protein supplement group and 30 patients to the exercise therapy + placebo supplement group.
223510687|NCT06401551|DEVICE|CPO Pro IOL|Intraocular lens (IOL) implanted in the eye for the visual correction of aphakia in adult patients with less than 1 diopter of preexisting corneal astigmatism in whom a cataractous lens has been removed. The IOL is intended to mitigate the effects of presbyopia on intermediate and near visual acuity while maintaining comparable distance visual acuity.
223510688|NCT06401551|DEVICE|CPO IOL|Intraocular lens (IOL) implanted in the eye for the visual correction of aphakia in adult patients with less than 1 diopter of preexisting corneal astigmatism in whom a cataractous lens has been removed. The IOL is intended to mitigate the effects of presbyopia on intermediate and near visual acuity while maintaining distance visual acuity.
223510689|NCT06401551|PROCEDURE|Cataract Surgery|Extraction of the cataractous lens by phacoemulsification, followed by implantation of the IOL.
223510690|NCT03772340|DRUG|Tradipitant|Oral capsule
223510691|NCT03772340|DRUG|Placebo|Oral capsule
223510692|NCT02857959|DRUG|Benzathine Penicillin G|
223510693|NCT06695897|DRUG|Dupilumab|This study will not administer any treatment, only observe the treatment as prescribed in real-world clinical practice.
223510694|NCT01275937|DRUG|Esomeprazole|Esomeprazole 40 mg IV daily is given for three days. Thereafter, the patients receive 40 mg Esomeprazole orally daily for two months.
223510695|NCT01275937|DRUG|esomeprazole|esomeprazole 160 mg/day continuous infusion is given for three days. Thereafter, the patients receive 40 mg nexium orally daily for two months.
223510696|NCT03614780|BEHAVIORAL|30 minutes outdoors|Participants were asked to add an additional 30 minutes of time spent outdoors during the last 5 days of participation
223510697|NCT02355470|BEHAVIORAL|GIFTSS|Universal education and brief counseling regarding sexual violence
224202878|NCT05751824|OTHER|Manually remind the patients to review.|Medical staff remind patients to review by telephone.
224202879|NCT01440075|OTHER|Cardiac evaluation|"complete cardiac evaluation with :~Electrocardiogram Echodoppler Echodoppler with dobutamine stress Carotid Echodoppler Coronary scan Positron emission tomography with adenosine stress Blood test (search for early atherosclerosis marker Genotyping"
224202880|NCT05422105|DRUG|18F-PSMA-1007|18F-PSMA-1007 PET/CT
224202881|NCT05109169|COMBINATION_PRODUCT|FINGER 2.0 multidomain lifestyle-based intervention|"Multimodal lifestyle-based precision prevention intervention, including:~* Optimized FINGER multidomain lifestyle intervention (diet, physical activity, cognitive training and cardiovascular/metabolic risk monitoring and social interaction)~* Metformin (Glucophage® XR)"
224312681|NCT05584592|OTHER|Conventional chemotherapy|patients to receive routine palliative care when they want it or when it is needed by health care providers. In other words, if a patient assigned to the control group desires palliative care, they can receive conventional palliative care.
223510698|NCT02355470|BEHAVIORAL|Brief alcohol use intervention|Brief education and counseling intervention to promote safer alcohol use, reduce binge drinking
223510699|NCT07045038|DEVICE|Acupuncture LLLT:|"Acupuncture LLLT:~This mode of therapy will be conducted for study group B as follows:~A therapeutic unit (M6 MLS from ASA laser, Italy) with wavelength 905 nm, output 5-20 MW, laser beam spot size 0.785 cm2, energy density 91 J/cm2, energy delivered 28 J, and frequency 500HZ. Laser probe will be placed in intercostal space both anteriorly and posteriorly on chest wall.~Each acupuncture point will be stimulated with a laser for 60 s, three weekly sessions over 12 successive weeks. Anterior chest wall acupuncture points are {LU1, LU2, CV17, (Ren17)}, posterior chest wall from a prone or setting position of the patient {UB13, (BL13), UB 17(BL17)}."
223510700|NCT07045038|OTHER|Blood flow restricted resistance exercise:|"The subject will warm up and cool down for at least five to seven minutes each, (before and after exercise).~The patients will perform blood flow restricted resistance exercise (BFRRE) at 40-80% of 1RM with 50% limb occlusion pressure (LOP), while placing cuff on midthigh and perform four sets of bilateral knee extension exercise, each set consist of 15 repetitions with 30-60 second rest in between sets and relieve cuff pressure in rest period, three weekly sessions over 12 successive weeks"
224312682|NCT06359106|DRUG|80% Oxygen|After successful anesthesia induction, the fraction of inspired oxygen (FiO2) will be adjusted to 80%, and the total gas flow rate will be set at 2L/minute.
224312683|NCT06359106|DRUG|40% Oxygen|After successful anesthesia induction, the fraction of inspired oxygen (FiO2) will be adjusted to 40%, and the total gas flow rate will be set at 2L/minute.
224312684|NCT06632899|BEHAVIORAL|combined physical and cognitive training and 1 hour of risk factor prevention and healthy lifestyle development|"Dosage: a 2-hour session once a week for 12 weeks. Each multidomain intervention session includes 1 hour of combined physical (balance, strength and aerobic exercises) and cognitive (attention, memory, calculation, visual-spatial ability, processing speed and executive function) training and 1 hour of risk factor prevention (nutrition, chronic disease management, oral health, fall prevention and transportation safety, psychosocial factors and sleep) and healthy lifestyle development (Discussion and sharing on topics such as self-health management, goal setting, and the health journal.)"
224312685|NCT01723618|DRUG|CRD007|
223616774|NCT04554420|BEHAVIORAL|Youth Participatory Action Research-Mental Health Curriculum|The mental health curriculum will focus on enhancing the knowledge, critical consciousness (i.e., exploration of systemic/racial problems), research self-efficacy, and other skills of youth to integrate their lived experiences and identity to learning about the intersection of system and community level issues in mental health. Activities will center on participatory action approaches to engaging youth in culturally/community responsive ways.
223616775|NCT01307319|DRUG|BDP HFA|BDP (beclomethasone dipropionate) HFA (hydrofluoroalkane) nasal aerosol administered as a single actuation in each nostril daily for the 15 day treatment period. Each actuation contains either 40 or 80 mcg for a total daily dose of either 80 or 160 mcg depending upon the assigned treatment arm.
223616776|NCT01307319|DRUG|Placebo nasal aerosol|Placebo formulated as a nasal aerosol spray and administered as a single actuation in each nostril daily for the 15 day treatment period.
223616777|NCT03689582|DRUG|68Ga-PSMA|"Positron Emission Tomography/Computed Tomography (PET/CT) imaging with 68Ga-PSMA:~68Ga-PSMA is an investigational radioactive drug that binds to receptors on prostate cancer cells. The intravenously administered drug dose will be about 5 mCi (range 3-7 mCi)."
224202882|NCT05109169|OTHER|Self-guided multidomain lifestyle intervention|Participants build their own healthy lifestyle program based on standard healthy lifestyle advice on diet, physical activity, cognitive training and cardiovascular/metabolic risk
224202883|NCT05303727|DRUG|Anti Thymocyte Globulin|2.5 mg/kg/day；2 doses on day -3 and day -2 for matched sibling donor transplantation；3 doses on day -4，-3 and day -2 for unrelated donor transplantation；4 doses on day -5，-4，-3 and day -2 for haploidentical donor transplantation
224202884|NCT05303727|DRUG|Fludarabine|30 mg/m2/day for 5 days
224202885|NCT05303727|DRUG|Cyclophosphamide injection|60 mg/kg/day for 2 days in cord blood stem cell transplantation
224202886|NCT05303727|DRUG|Topotecan|2mg/m2/day for 3 days in cord blood stem cell transplantation
224202887|NCT05303727|DRUG|Melphalan|70mg/m2/day，for peripheral stem cell transplantation or haploidentical bone marrow combined with peripheral stem cell transplantation；2 doses on day -3 and day -2 when conditioning regimen containing thiotepa；3 doses on day -4，-3 and day -2 when conditioning regimen not containing thiotepa；
224202888|NCT05303727|DRUG|Thiotepa|5 mg/kg/day for 2 days in peripheral stem cell transplantation or haploidentical bone marrow combined with peripheral stem cell transplantation
224202889|NCT05303727|DRUG|Busulfan|0.8mg/kg/dose；8 doses in cord blood stem cell transplantation；12 doses in peripheral stem cell transplantation or haploidentical bone marrow combined with peripheral stem cell transplantation when conditioning regimen containing thiotepa；16 doses in peripheral stem cell transplantation or haploidentical bone marrow combined with peripheral stem cell transplantation when conditioning regimen not containing thiotepa；
224202890|NCT05303727|DRUG|Cyclosporine|2.5\~4 mg/kg/dose every 12 hours orally；1.5\~2 mg /kg/dose every 12 hours intravenously; trough concentration maintained at 150\~250ng/ml
224202891|NCT05303727|DRUG|Tacrolimus|0.02\~0.03 mg/kg/day as continuous infusion or 12 hour divided doses
224202892|NCT05303727|DRUG|Mycophenolate Mofetil|15 mg/kg/dose every 12 hours
224202893|NCT05303727|DRUG|Methotrexate|15 mg/m2/dose on d+1 and 10 mg/m2/dose on d+3，d+6 in peripheral stem cell transplantation
224202894|NCT02159534|OTHER|Primebrain|Primebrain stimulation programme aims to facilitate the infant's self-organization of postural competences by proposing varied sensorimotor experiences in a context supporting parent-child interaction.
224202895|NCT06425601|DEVICE|SIL drain|Silicone chest tube used for pleural space drainage after VATS lobectomy
224202896|NCT06425601|DEVICE|PVC drain|Polyvinyl chloride chest tube used for pleural space drainage after VATS lobectomy
224202897|NCT02949219|OTHER|Laboratory Biomarker Analysis|Correlative studies
224202898|NCT02949219|BIOLOGICAL|Pembrolizumab|Given IV
224202899|NCT03494816|DRUG|Axitinib Oral Tablet|"Axitinib is an oral VEGF-receptor inhibitor. Patients are prescribed a starting dose of 5mg twice daily, escalating to 10mg in absence of dose limiting toxicities and blood pressure.~Doses should be taken approximately 12 hours apart and patients should be instructed to take their doses at approximately the same times each day with or without food as per instruction. On clinic days only, patients will be advised to fast for 6 hours prior to their clinic visit.~Patients should be advised to stop axitinib treatment a minimum of 36 hours and maximum of 7 days prior to week 9 nephrectomy and thrombectomy surgery.~Dose adjustments, including dose increase or dose reduction, are permitted and should be based on clinical judgement and the guidelines provided in the protocol."
224202900|NCT04297254|DRUG|Lenvatinib|Lenvatinib capsules.
224202901|NCT03932474|COMBINATION_PRODUCT|SAMEUp|One tablet per day of food supplements containing S-adenosyl methionine (SAMe) 200 mg and Lactobacillus plantarum HEAL9 1x109 CFU.
224312686|NCT06231056|DIETARY_SUPPLEMENT|Probiotic iNatal®|iNatal® (Enterococcus faecium L3, Bifidobacterium animalis subsp. lactis BB-12, Lactococcus lactis SP38, Lacticaseibacillus casei R0215)
224312687|NCT05551871|DRUG|Simvastatin|the patient will receive Simvastatin for 7 days
224312688|NCT05551871|DRUG|Placebo drug|the patient will receive Placebo drug for 7 days
224312689|NCT04084093|DEVICE|Surfactant Gel|This device is helps in the creation of an optimal moist wound healing environment that aids in protecting healthy tissues and provides an environment conductive to autolytic debridement. The device is 100% water-soluble, biocompatible, and non-ionic. The dressing is a surfactant based gel.
224312690|NCT00359593|BEHAVIORAL|Knowledge translation intervention package|
224312691|NCT02346266|OTHER|SMART Education|
223616778|NCT02099240|DRUG|oral antibiotics|intravenous antibiotics with early switch to oral antibiotics, antibiotic type will be dependent on bacteria type
223616779|NCT02099240|PROCEDURE|intravenous antibiotics|intravenous antibiotics for the full duration of therapy, antibiotic type will be dependent on bacteria type
223616780|NCT04813588|OTHER|Pantomiming|Pantomiming with fluency shaping techniques
223616781|NCT04813588|OTHER|Easy onset|Easy onset method with breathing exercises
223616782|NCT01476059|OTHER|Telephone follow-up|Asthmatic children being treated, who will be given medical guidance and therapeutic guidance through telephone calls at every fifteen days to the parents or guardians, performed by trained professionals.
223616783|NCT01476059|OTHER|No telephone follow-up|Asthmatic children being treated, who will be given medical guidance without telephone follow-up calls to parents or guardians.
223616784|NCT02038816|DRUG|Deferasirox + Azacitidine|"Deferasirox:~20 mg/kg/d for \< 14ml/kg/mo pRBCs (\~ \<4U/mo), 30mg/kg/d for ≥14ml/kg/mo pRBCs(≥4U/mo), 10mg/kg/d for transfusion-independent patients"
223761202|NCT02471521|OTHER|Mask ventilation|Mask ventilation is performed after administration of rocuronium or not. Initial inspiratory pressure is set as 10 cmH2O and increased gradually by 2 cmH2O until gastric insufflation is detected by either of two methods. Tracheal intubation is done after detection of gas.
224202902|NCT03932474|OTHER|Placebo|One tablet per day identical in shape, size, colour and taste to the SAMEUp tablet
223761203|NCT02471521|DRUG|Rocuronium|Rocuronium 0.6 mg/kg is injected before mask ventilation in muscle relaxant group or after finish of study in non-relaxant group.
224202903|NCT04819282|DIAGNOSTIC_TEST|Senior Fitness Test|Senior Fitness Test, simple and easy to use, was used to evaluate physical performance.
223761204|NCT02396836|OTHER|6 step technique|Hand decontamination with alcohol hand rub using the World Health Organizations 6 step technique
223761205|NCT02396836|OTHER|3 step technique|Hand decontamination with alcohol hand rub using the 3 step technique
223761206|NCT04389411|DRUG|Montelukast 10mg|10mg oral Montelukast will be taken daily for 60 days
223761207|NCT05248516|DIETARY_SUPPLEMENT|Simplified dose of ready-to-use therapeutic food (RUTF)|"In the simplified arm all children receive the same dose: 1 sachet of RUTF/day. This until discharge from treatment.~Recovery from treatment will be defined as WAZ\>= -3 on 2 consecutive visits. A maximum of 12 treatment weeks are allowed before declaring non-response. Defaulting will be declared after 2 consecutively missed visits."
224202904|NCT06394427|OTHER|cycles of neoadjuvant therapy and duration of waiting for surgery|We intended to explore the cycles of neoadjuvant therapy and duration of waiting for surgery on the perioperative outcomes and long-term prognosis of locally advanced NSCLC in the real world
224202905|NCT02660775|BEHAVIORAL|schizophrenia|"The battery (ClaCoS) is composed by 6 tests and several scores will be recorded for each:~* for emotion perception : Facial emotions recognition task (TREF)~* for theory of mind : Movie for the assessment of social cognition ( MASC-VF)~* for attributional bias : Ambiguous Intentions Hostility Questionnaire ( AIHQ)~* for social perception and knowledge : interpretation score - with and without index, comprehension score ( PerSo )~* for empathy :Questionnaire of cognitive and affective empathy ( QCAE) for people with schizophrenia~* for self assessment : Self - assessment of social cognition (ACSo)"
224202906|NCT02660775|BEHAVIORAL|Autism|"The battery (ClaCoS ) is composed by 6 tests and several scores will be recorded for each:~* for emotion perception : Facial emotions recognition task(TREF ): total score, score per emotion, detection levels~* for theory of mind : Movie for the assessment of social cognition (MASC ) :total score, error type~* for attributional bias : Ambiguous Intentions Hostility Questionnaire (AIHQ) :hostility score, attribution score, aggression score~* for social perception and knowledge : interpretation score - with and without index, comprehension score ( PerSo )~* for empathy : Empathy quotient (EQ)~* for self assessment : Self - assessment of social cognition ( ACSo ): total score and scores per processes"
224202907|NCT02660775|BEHAVIORAL|Healthy controls|only social cognitive measures
224202908|NCT04037683|DRUG|Misoprostol Oral Tablet|Misoprostol 25mcg orally given 2-hourly
224202909|NCT04037683|DRUG|Oxytocin|Oxytocin infusion
224202910|NCT05646342|OTHER|Measure of CO by ECHocardiac Machine|we will realise ETT before and after PLR in all women that eligible of crieria inclusion , in obstetric consultation
224202911|NCT02765139|BEHAVIORAL|Engaging Men through Accountable Practice|Engaging Men through Accountable Practice aims to engage men as agents of change through structured, weekly discussions with committed groups of men. It aims to address entrenched views of gender roles and identify positive models of masculinity. The approach follows a structured series of discussions designed to explore existing understandings of masculinity and create more positive models of what it means to be a 'good' man, promoting self-reflection and pushing men to analyze and change their own power and privilege. This methodology begins with a series of discussions with women to inform men's dialogue groups, and includes continuous feedback loops with women throughout the process so that the work with men is grounded in, and accountable to, women's views and objectives.
224202912|NCT02765139|OTHER|Alternative intervention|Control communities will receive an alternative intervention focused on a non-gender topic of 16 weekly sessions for men only.
223616785|NCT02038816|DRUG|Azacitidine|Azacitidine 75mg/m2 sc daily X 7 days (5-2-2 schedule permitted) on a 28 day cycle for 6 cycles
223616786|NCT02300792|DIETARY_SUPPLEMENT|honey|Each patient in the intervention group (group 1) took oral honey in a dose of 5 ml/kg/day (with a maximum dose of 150 ml/day) for four weeks.
223616787|NCT02300792|DIETARY_SUPPLEMENT|molasses|Each patient in the molasses (placebo) group took 5 ml molasses/kg/day for four weeks, with a maximum of 150 ml/day
223616788|NCT05490017|DRUG|KP104|Participants will receive KP104 intravenous (IV) dose approximately for 1 hour or subcutaneous (SC) dose.
223616789|NCT05490017|DRUG|Placebo|Participants will receive matching placebo which is KP104 vehicle containing sodium phosphate, sodium chloride, and L-Lysine Hydrochloride (L-Lys-HCL).
223616790|NCT01275352|DRUG|Eplerenone|Eplerenone 50 mg/day
223616791|NCT01275352|DRUG|placebo|placebo
223616792|NCT03629886|BIOLOGICAL|HPV (Types 16, 18) Vaccine, Adsorbed|Three doses of Human Papillomavirus (Types 16, 18) Vaccine, Adsorbed administered intramuscularly in the deltoid region of the upper arm, according to a 0, 1, 6-month schedule.
223616793|NCT06217965|OTHER|survey|The study will involve patients completing a questionnaire on a secure online platform (such as RedCap)
223616794|NCT00333008|DRUG|Doxil|
223616795|NCT00333008|DRUG|Cyclophosphamide|
223616796|NCT00333008|DRUG|Vincristine|
223616797|NCT00333008|DRUG|Prednisone|
223616798|NCT00333008|DRUG|Rituximab|
223616799|NCT00333008|DRUG|Pegfilgrastim|
223616800|NCT02831621|BEHAVIORAL|lifestyle intervention (diet OR diet+exercise)|diet or diet+fitness training
223616801|NCT01179724|DRUG|high dose proton pump inhibitor|IV loading PPI before 2hr to conduct ESD, and IV 8mg/h continuous infusion within 48hr, and then 40mg oral pantoprazole for one month
223616802|NCT01179724|DRUG|H2RB|IV 50mg loading H2 receptor antagonist before 2hr to conduct ESD, and IV 13mg/h continuous infusion within 48hr, and then 300mg oral H2 receptor antagonist for one month
224202913|NCT05044143|OTHER|Monitoring the length of the uterine cervix using transvaginal ultrasound|Cervical length is measured with a 7-9 MHz transvaginal probe by trained obstetricians-gynecologists following the same standardized approach (Berghella 2003). Transvaginal CL measurement is largely used in current obstetric practice, and it is considered the 'gold standard' measurement when assessing the uterine cervix. In contrast to transabdominal US, the transvaginal approach is highly reproducible, and measurements are unaffected by maternal obesity, cervical position, and shadowing from fetal parts (Berghella 2003, Hassan 2000, ACOG 2012, Berghella 2012).
224202914|NCT06651320|OTHER|The patients in the interventional arm will be introduced to video will be introduced to a concise, animated video explaining the steps they are about to undergo in the department, the OR, recovery|"The patients in the interventional arm will be introduced to video will be introduced to a concise, animated video explaining the steps they are about to undergo in the department, the OR, recovery and discharge. How to prepare for the procedure, what to expect during and after the procedure and what are the possible follow up scenarios.~In order to overcome language berries videos would be available in basic 6th grader language and translated into English, Arabic and Russian for the non-Hebrew speaking population.~There would be one staff member aware of the patient's allocation the international Vs nonintervention arm while the rest of the staff would be masked to the research arm the patient was allocated to.~Once they have watched the video they would be asked to fill up a questionnaire their anxiety level concerning the procedure (STAI-S)."
224202915|NCT01101269|DRUG|ACEI or ARB|Subjects will be asked to discontinue their usual ACE inhibitor or Angiotensin Receptor Blocker (ARB) for ten days, undergo a CEU using Definity (for renal blood flow assessment) as the contrast agent, then resume their usual ACEI or ARB for ten days, then undergo another CEU using Definity as the contrast agent.
224202916|NCT01101269|DRUG|Lisinopril|Subjects will be undergo a CEU using Definity (for renal blood flow assessment) as the contrast agent, then take Lisinopril 10 mg every day for 7 days, after which they will undergo another CEU using Definity as the contrast agent.
224202917|NCT00940329|DRUG|Roflumilast|Treatment A (500 μg/d roflumilast from day 2 to day 18 and 48 μg/d formoterol from day 12 to day 18)
224202918|NCT00940329|DRUG|Roflumilast|Treatment B (48 μg/d formoterol from day 2 to day 18 and 500 μg/d roflumilast from day 9 to day 18)
224202919|NCT01245829|OTHER|Swabbing of observation chart|The observation charts to be studied will be stored on the DMH critical care unit and all existing non-laminated white charts removed for the duration of the study period. The observation charts will thereafter be used in the normal way as defined by nursing practice; blue charts from patient admission (irrespective of time) and white charts for each 24 hour period thereafter commencing at 8 am. On placement and after 24 hours of use, a standardised section of the patient observation area will be swabbed by the data collection researcher. The standardised area is defined as the section of the chart that is most comprehensively completed during the patient episode and is therefore most likely to become contaminated through contact. Use of white charts only is required in order to standardise the length of time each chart is in place between the two points of swabbing (white charts present at 8 am have been in use for exactly 24 hours).
224202920|NCT03494452|OTHER|No intervention|There is no intervention in this cross-sectional study
224202921|NCT03712462|BEHAVIORAL|Acceptance-Based Behavioral Weight Loss Therapy for BED|ABBT group therapy incorporates standard behavioral and acceptance-based strategies and was adapted to meet suit the unique needs of BED.
224202922|NCT03712462|BEHAVIORAL|Standard Behavior Therapy|SBT group therapy will be adapted from the gold-standard standard behavioral therapy manuals used from previous weight loss studies.
224202923|NCT03397576|BEHAVIORAL|ATHENA|Adherence Through Home Education and Nursing Assessment (ATHENA), is an evidence-based ART adherence intervention delivered in the patient's home by nurses and peer educators working in teams.
224202924|NCT02594566|DRUG|CyMVectin|CyMVectin will be delivered by unilateral intramuscular (IM) injection at Day 0, Day 28(+4 days), and Day 56 (+4 days) in alternating arms. Each dose of CyMVectin will be administered in a 1.0-mL volume
224202925|NCT00186082|DRUG|Cefotetan or Cefoxitin vs placebo|"Cefotetan or Cefoxitin, 1 g intravenously, or Clindamycin, 900 mg intravenously.~Normal Saline, 100 ml intravenously for placebo arm."
223616803|NCT00463255|BEHAVIORAL|diet|
223616804|NCT00942565|DRUG|tramadol/acetaminophen|
223616805|NCT00942565|DRUG|acetaminophen|
223616806|NCT05133024|DIETARY_SUPPLEMENT|concentrated beetroot juice|Nitrate supplementation; natural source of dietary nitrate
223616807|NCT04098523|DIAGNOSTIC_TEST|Duplex ultrasound|A one-time carotis and abdominal aorta duplex ultrasound will be performed on-site by a skilled site staff to determine the prevalence of, and risk factors associated with, CAS and AAA. A diameter measurement will be performed of the abdominal aorta as well as a determination of the carotid arteries.
223616808|NCT02472860|BEHAVIORAL|Targeted Cognitive Training (TCT)|The investigators have selected a set of computer exercises designed to specifically target aspects of cognition relevant to autism spectrum disorder (including attention and executive functions). The tasks were designed to benefit subjects through principles of learning dependent plasticity.
223616809|NCT02472860|OTHER|Youth Appropriate Online Games|Engaging games not designed to improve cognition
223616810|NCT01288755|DRUG|TMC278|One 25 mg tablet, once daily, for 11 days (TrtA and C)
223616811|NCT01288755|DRUG|Raltegravir|One 400 mg tablet, twice daily, for 4 days (Trt B) and for 11 days (TrtC)
223616812|NCT01757314|BEHAVIORAL|ultrasound technique|instruction in the ultrasound technique
223616813|NCT01757314|OTHER|palpation technique|placement of a line via palpation technique
223616814|NCT04497649|DRUG|Sofosbuvir|Sofosbuvir once daily
223616815|NCT04497649|DRUG|Daclatasvir|daclatasuvir once daily
224202926|NCT02937727|DEVICE|3T MRI compatible and LFP recordable G106R of Beijing Pins medical.|
224202927|NCT06323265|DRUG|Adebrelimab + chemotherapy|Adebrelimab: 1200mg, d1, iv (30-60min), Q3W ,up to progressive disease or toxicity intolerable Chemotherapy: etoposide 100mg/m2，d1-3，iv；carboplatin AUC=5-6，d1，iv；or cisplatin 75mg/m2，d1，iv，Q3W，4 cycles；
224202928|NCT06323265|RADIATION|±chest radiotherapy|Chest radiotherapy: 3Gy/15f-18f or 2Gy/20f-25f
224202929|NCT03083457|DRUG|Fluid resuscitation or amine administration|Fluid administration or amine administration if deemed necessary by the attending physician. Haemodynamics will be monitored through noninvasive cardiac output assessment by arterial pulse contour analysis
223510701|NCT07045038|DRUG|Medical treatment|"All patients will enroll to maximum doses guideline medical treatment that include (Beta blockers-Aspocid- Ator-Concor-Tritace).~Also all patients will adhere to routine cardiac rehabilitation:~The patients will enroll in CR program for 12 weeks, three times per week for 12 week. Moderate-intensity treadmill exercise training achieving a target heart rate of 40-60% of HR reserve (calculated from pre-exercise symptom-limited treadmill exercise stress test by modified Bruce protocol). The duration of each session was 30- 45 minutes (5-10 minutes of treadmill warm up, followed by 20-30 minutes of aerobic continuous treadmill training and terminated by 5-10 minutes of cooling down"
224202930|NCT03083457|DRUG|General anesthetic|Total intravenous anesthesia with a standard protocol
224202931|NCT03083457|DRUG|Fluid administration|3-5 ml/kg of balanced crystalloids will be administered throughout the whole surgical procedure
223510702|NCT07056478|DRUG|Denosumab (Prolia)|60mg subcutaneous Denosumab (1mL solution) every 6 months and intravenous placebo (100mL normal saline) once yearly
223510703|NCT07056478|DRUG|Zoledronic acide (Aclasta)|5mg intravenous Zoledronic Acid (100mL solution) once yearly and subcutaneous placebo (1mL normal saline) every 6 months
223510704|NCT07056413|PROCEDURE|BRILMA block|20 ml 0.25 % bupivacaine was injected into the fascial plane between the serratus anterior muscle and the external intercostal muscle at T4 level.
224202932|NCT03083457|PROCEDURE|Low-tidal volume ventilation|Volume-control ventilation with tidal volume=7 ml/kg of predicted body weight for the entire surgical procedure. Respiratory rate will be set to maintain EtCO2 within a physiological range and kept unchanged for the entire duration of the study
224202933|NCT03083457|PROCEDURE|Scheduled recruiting maneuvers|Pressure-control ventilation inspiratory pressure=10 cmH2O. Steplike 5-cmH2O-PEEP increase every 30 seconds to achieve a peep of 35 cmH2O, followed by 5-cmH2O-PEEP reduction every 30 seconds to set PEEP
224202934|NCT05688137|PROCEDURE|Abdominal drainage|The patients with intervention will take an abdominal drainage.
224202935|NCT01701180|DRUG|Oxytocin|24 IU; 3 puffs per nostril, each with 4 IU OXT
224202936|NCT01701180|DRUG|Placebo|
223510705|NCT07056413|OTHER|Standard intravenous analgesia.|Standard intravenous analgesia.
223510706|NCT06751992|DRUG|Conversion to extended-release tacrolimus|Conversion from immediate-release tacrolimus (Prograf) to extended-release tacrolimus (Envarsus XR) as a part of the maintenance immunosuppressive treatment
223510707|NCT06751992|DRUG|Maintenance of immediate-release tacrolimus|Continuing immediate-release tacrolimus (Prograf) as a part of the maintenance immunosuppressive treatment
223510708|NCT00710788|DRUG|sevelamer phosphate-binders|1600 mg/day for 2 years
223510709|NCT00710788|DRUG|Calcium Carbonate|Calcium carbonate 1 g/day for 2 years
223510710|NCT03380481|OTHER|observational only-no intervention|Observational only and no predesigned interventions in this study.
223510711|NCT00403065|DRUG|dexamethasone|
223510712|NCT00403065|PROCEDURE|quality-of-life assessment|
223510713|NCT00403065|RADIATION|radiation therapy|
223510714|NCT04422834|OTHER|Questionnaire|A group of students who studying at the Faculty of Health Sciences will be asked to fill the Turkish version of JSE-HPS and ETS. JSE-HPS will be asked to re-fill after seven days for retest analysis.
223510715|NCT01919476|OTHER|Bagel|
223510716|NCT01919476|OTHER|Cream Cheese|
223510717|NCT01919476|OTHER|Almond Butter|
223510718|NCT04880889|DRUG|BL 3000|capsule 500 mg
223510719|NCT04880889|DRUG|Reference Pantogar|capsule
223510720|NCT04880889|DRUG|BL3000 Placebo|capsule 500 mg
223510721|NCT04880889|DRUG|Pantogar - Placebo|capsule
223510722|NCT00504556|DRUG|Edoxaban (DU-176b)|30mg tablet once daily
223510723|NCT00504556|DRUG|Edoxaban (DU-176b)|60mg tablet once daily
223510724|NCT00504556|DRUG|Edoxaban (DU-176b)|30mg tablet two times a day
223510725|NCT00504556|DRUG|Edoxaban (DU-176b)|60mg tablet two times a day
223510726|NCT00504556|DRUG|warfarin|warfarin tablets
224202937|NCT02392377|DRUG|Paclitaxel|Given IV or IVPB
224202938|NCT02392377|DRUG|Carboplatin|Given IV or IVPB
224202939|NCT02392377|DRUG|Oxaliplatin|Given IV
224202940|NCT02392377|DRUG|Leucovorin Calcium|Given IV
224202941|NCT02392377|DRUG|Fluorouracil|Given IV
224202942|NCT02392377|RADIATION|Radiation Therapy|Undergo radiation therapy
224202943|NCT02392377|PROCEDURE|Therapeutic Conventional Surgery|Undergo esophagectomy
224202944|NCT02392377|OTHER|Laboratory Biomarker Analysis|Correlative studies
224202945|NCT04518527|DEVICE|Tape|The tape is an elastic cotton strip with an acrylic adhesive that is used with the intent of treating pain and disability
224202946|NCT03667781|DIAGNOSTIC_TEST|Therapeutic drug monitoring|Blood assay to evaluate for the presence of medications that the patient is prescribed. This is not being used for therapeutic purposes. It has already been validated in prior papers.
224202947|NCT00985127|DRUG|placebo|administered daily for 21 days
224202948|NCT00985127|DRUG|BCX4208|Administered daily for 21 days.
224202949|NCT04993937|OTHER|Intervention|Interventional group will receive 6 weeks of plyometric training and receive training for week and three sessions in a week.
224202950|NCT04993937|OTHER|Control Group|Control group will follow their daily routine activities and may involve in any other exercise program rather than plyometric exercises.
224202951|NCT00757198|DRUG|remifentanil|remifentanil infusion
224202952|NCT00757198|DRUG|remifentanil|remifentanil infusion
224202953|NCT01340807|OTHER|Specialized Functional Prosthetic Training|Each subject receives specialized functional prosthetic training
224202954|NCT02048059|DRUG|ANG1005|
224202955|NCT01643967|OTHER|sunflower oil|The research subjects allocated to this treatment arm will receive Sunflower Oil supplied by Philozon. Sunflower oil should be applied once daily for 60 days, it immediately after cleansing site where the lesion is present.
224202956|NCT01643967|OTHER|Ozone Therapy|The research subject will receive topical and rectal insufflation of ozone three times a week on alternate days for two months or at least 12 sessions.
224202957|NCT03205163|BIOLOGICAL|Advate (Low Dose)|Participants received a single IV low dose of Advate 25 IU/kg.
224202958|NCT03205163|BIOLOGICAL|Advate (High Dose)|Participants received a single IV high dose of Advate 65 IU/kg.
224202959|NCT03205163|BIOLOGICAL|BIVV001 (Low Dose)|Participants received single IV low dose of BIVV001 25 IU/kg.
224202960|NCT03205163|BIOLOGICAL|BIVV001 (High Dose)|Participants received single IV high dose of BIVV001 65 IU/kg.
224202961|NCT00730067|DRUG|sildenafil|Sildenafil 50 mg three times daily
224202962|NCT00730067|DRUG|placebo|tablet with Laetose mono hydrat, talc,Potato tarch, Gelatin, Magnesium stearate.
224202963|NCT02472431|OTHER|Intracavernosal administration of autologous ADRC|Subjects will undergo liposuction under local anesthesia. Lipoaspirate will be processed to isolate and concentrate adipose-derived regenerative cells (ADRC). After isolation autologous ADRC suspension will be injected intracavernosally.
224202964|NCT02472431|PROCEDURE|Liposuction|
224202965|NCT02472431|DEVICE|ADRC isolation|ADRC isolation performed using Celution 800/CRS System (Cytori Therapeutics Inc) according to manufacturer's protocol
224202966|NCT06167798|OTHER|biopsy|two 2 mm gingival biopsies were obtained.
224202967|NCT00003276|DRUG|irinotecan hydrochloride|
224202968|NCT01845194|DRUG|Codeine|"Treatment period 2:~5 mg Codeine once"
224202969|NCT01845194|DRUG|Midazolam|"Treatment period 1:~0.2 mg Midazolam 3x~Treatment period 2:~1 mg Midazolam once"
224202970|NCT01845194|DRUG|Pravastatin|"Treatment period 2:~5 mg Pravastatin once"
224202971|NCT01845194|DRUG|Torsemide|"Treatment period 1:~2.5 mg Torsemide 3x~Treatment period 2:~0.25 mg Torsemide once"
224202972|NCT01845194|DRUG|Talinolol|"Treatment period 1:~50 mg Talinolol 3x~Treatment period 2:~2.5 mg Talinolol once"
224202973|NCT01845194|DRUG|Caffeine|"Treatment period 1:~50 mg Caffeine 3x"
224202974|NCT01845194|DRUG|Metoprolol|"Treatment period 1:~5 mg Metoprolol 3x"
224202975|NCT03872908|DEVICE|Chilled gloves|Chilled glove for non-dominant hand (patients treated with paclitaxel)
223510727|NCT01778231|DIETARY_SUPPLEMENT|Nutrof Total|Antioxidant and trace element supplement
223510728|NCT01778231|DIETARY_SUPPLEMENT|Placebo|
223510729|NCT01713322|BEHAVIORAL|Pain management education|Parents are provided with educational material on how to manage child pain during immunization.
223510730|NCT01713322|BEHAVIORAL|No pain management education|Control - parents receive general information about childhood immunization.
223510731|NCT04957927|DRUG|Effectiveness of Montelukast Versus Intranasal Fluticasone Propionate in the Management of Allergic Rhinitis Among Children 02 to 05 Years of Age|Effectiveness of Montelukast Versus Intranasal Fluticasone Propionate in the Management of Allergic Rhinitis Among Children 02 to 05 Years of Age
223510732|NCT03280615|DIETARY_SUPPLEMENT|Omega 3 fatty acids|Omega 3 fatty acids will be provided in a dose of 3.7 g/day, that should be enough to rise red blood cell levels of eicosapentanoic and docosahexanoic acids
223510733|NCT03280615|DIETARY_SUPPLEMENT|Corn oil|Corn oil will be the placebo comparator for omega 3 fatty acids supplement
223510734|NCT05356429|OTHER|Small molecule LCDM|The cocktail of small molecules includes four chemical components of LCDM were added to GV oocyte culture medium.
223510735|NCT05671679|OTHER|SNAQ app|SNAQ is a smartphone food analysis app that estimates the macronutrient content of a meal, based on a single image. The app first determines meal content in terms of food components with input from the user to correct or add further components (e.g. foods, ingredients, sauces, herbs or seasonings). Then, the total macronutrient and energy content of the meal is determined based on the estimated volume and information from a nutritional database. Of note, the application also allows for assessing nutritional content of packaged foods by means of a barcode scanning function. The user can always adapt proposed nutritional contents at their own discretion. Meal macronutrients alongside the food pictures are collected in a detailed log which allows users to review their dietary choices. The product is not conceived by its manufacturer to be used for medical purposes and can thus not be considered a medical device.
223510736|NCT05671679|OTHER|Traditional carbohydrate counting|Patients will follow their traditional methods of carbohydrate counting during the control period. In addition to assess sustainability of the intervention, following the control period, the control group will also go an intervention period of 3 weeks using the SNAQ App.
223510737|NCT05041582|DEVICE|tDCS|dual tDCS with ipsilesional primary motor cortex (M1) anodal stimulation and contralesional M1 cathodal stimulation, 2 weeks after SSRI treatment
224202976|NCT03872908|DEVICE|Surgical gloves|Surgical gloves (patients treated with oxaliplatine)
223510738|NCT05041582|DRUG|Citalopram|total 3 months, since 2-4 weeks after stroke
223510739|NCT05041582|BEHAVIORAL|Rehabilitation|hospitalized rehabilitation, 3 hours daily
223510740|NCT00144508|DRUG|MRA (Tocilizumab)|8mg /kg /4week for 52 weeks
223510741|NCT00144508|OTHER|current treatment|continue current treatment
223510742|NCT03373513|PROCEDURE|Robotic single-site Hysterectomy|Robotic assisted Periumbilical single incision hysterectomy
223510743|NCT03373513|PROCEDURE|Laparoscopic hysterectomy|Multiport laparoscopic hysterectomy
223510744|NCT01693237|OTHER|Group psychotherapy|20 sessions of systemic and narrative group therapy
223510745|NCT01693237|OTHER|Group psychotherapy with feedback|20 sessions of systemic and narrative group therapy
223510746|NCT01138306|GENETIC|gene expression analysis|
223510747|NCT01138306|GENETIC|mutation analysis|
223510748|NCT01138306|OTHER|flow cytometry|
223510749|NCT01138306|OTHER|laboratory biomarker analysis|
223510750|NCT00339365|BEHAVIORAL|Promoting First Relationships Program|Participants assigned to PFR will receive ten weekly home visits that will focus on promoting the development of a secure attachment between foster parents and infants.
223510751|NCT00339365|BEHAVIORAL|Early Education Support Program|EES will consist of three monthly home visits, during which infants will be assessed and referred for additional care if necessary. EES participants will not receive any training.
224312692|NCT00746876|DEVICE|Unipolar hip hemiarthroplasty|Unipolar hip hemiarthroplasty for the treatment of femoral neck fractures
224202977|NCT06723600|OTHER|Information|Nurse-led family member information
224202978|NCT06723483|PROCEDURE|Distraction Plate|This technique deals with comminuted distal radius fracture using a distraction plate. The plate was inserted by minimally invasive skin incisions, fixed from the 2end metacarpal distally to the 2end extensor compartment at intact radius proximally Spaning the comminution, Restoring the Radial Length, Radial Inclination, Volar Tilt
223510752|NCT03967574|DEVICE|Transcranial direct current stimulation|"The tDCS anode was applied on the primary motor cortex area responsible for the control of the rotator cuff, as determined using transcranial magnetic stimulation and surface electromyography. The cathode was applied on the contralateral forehead, just above the eyebrow. The electrodes were soaked in saline solution to improve conductivity and the montage was secured with rubber bands and adhesive tape.~The tDCS device (Soterix Medical 1x1 tDCS device) was then gradually turned to an intensity of 2mA. This stimulation was continued for a total of 20 minutes, after which it was gradually stopped."
223510753|NCT01013870|DRUG|Atorvastatin|In this Phase II randomized clinical trial of 200 MTBI subjects to evaluate atorvastatin as a neuroprotective agent, subjects will receive either active drug or placebo (1:1 randomization) for 7 days, starting within 24 hours of the brain injury. The dosage for subjects in the treatment group will be weight-based at 1mg/kgm, up to 80 mg, which will be the maximal dose. Subjects will be monitored at 3-4 days after injury by phone, then with follow-up visits at 1 week, 1 month, 3 months.
223510754|NCT01013870|DRUG|Placebo|In this Phase II randomized clinical trial of 200 MTBI subjects to evaluate atorvastatin as a neuroprotective agent, subjects will receive either active drug or placebo (1:1 randomization) for 7 days, starting within 24 hours of the brain injury. For the placebo group, subjects will take a daily dose of an inert preparation, visually indistinguishable from the active agent. They will take this preparation for seven days, started within 24 hours of MTBI, and their outcome will be compared with the group of subjects receiving active drug. Subjects will be monitored at 3-4 days after injury by phone, then with follow-up visits at 1 week, 1 month, 3 months.
223510755|NCT01386645|OTHER|low glycemic index (LGI) diet|Following a 2 week medium glycemic index control diet (glycemic index 50-55), subjects will be provided with a weight stable low glycemic index diet (glycemic index \<35) for 4 weeks with all food provided by the Human Nutrition Lab
223510756|NCT01386645|OTHER|high glycemic index (HGI) diet plus placebo (PLAC)|Following a 2 week medium glycemic index control diet (glycemic index 50-55), subjects will be provided with a weight stable high glycemic index diet (glycemic index \>70) for 4 weeks, all food provided by the Human Nutrition Lab. They will take placebo capsules (matching for active N-acetylcysteine (NAC) in arm 3) twice daily for the 4 weeks on the high GI diet. The NAC vs. placebo arms (arms 2 and 3) will be double-blinded.
223510757|NCT01386645|DRUG|high glycemic index diet plus N-acetylcysteine|Following a 2 week medium glycemic index control diet (glycemic index 50-55), subjects will be provided with a weight stable high glycemic index diet (glycemic index \>70) for 4 weeks, all food provided by the Human Nutrition Lab. They will take N-acetylcysteine (NAC) two 600 mg capsules twice daily for the 4 weeks on the high GI diet. The NAC vs. placebo arms (arms 2 and 3) will be double-blinded.
223510758|NCT02441816|DRUG|Aflibercept|
223510759|NCT02441816|OTHER|Extend Treatment|In year 2 of the study a treat and extend protocol will be applied, if a patient has signs of disease activity (eg macular fluid on SDOCT) they will be brought back at 8 weeks after the visit and given an intravitreous injection. They will then be reviewed 8 weeks post treatment for a further treatment with follow-up and treatment interval extended to 10 weeks if the disease is quiescent (if no macular fluid at the subsequent visit the patient could be extended to 12 weeks interval with treatment).
223510760|NCT00785447|OTHER|Mouth-to-mouth or mouth-to-nose breathing|Patients undergoing elective surgery under general anesthesia will be given mouth-to-mouth and mouth-to-nose breaths. The respiration process will be measured and recorded by the help of elastic bands put around the chest and abdomen. The efficiency of the breathing methods will be evaluated.
223510761|NCT03977298|PROCEDURE|Chlorhexidine|Inflammatory tissue, excess cement or plaque deposits will be removed using titanium curettes and the implant surface will be cleaned by copious irrigation with sterile saline and surgical gauze soaked in chlorhexidine
223510762|NCT03977298|PROCEDURE|CTG|CTG will be positioned in the buccal aspect of the peri-implant tissue
223616816|NCT04057066|BEHAVIORAL|Physical activity counseling|Physical activity counseling consists of two phone or video calls with a therapists, two group video calls with a therapist and a complementary e-learning course.
224202979|NCT07048639|DIAGNOSTIC_TEST|4D-CT (Four-Dimensional Computed Tomography)|To assess tumor and organ motion during breathing
224202980|NCT06024876|BIOLOGICAL|CS-101|Autologous CD34+ hematopoietic stem cell suspension modified by ex vivo base editing technique
224202981|NCT05883020|OTHER|Experimental Interventions|One session per week of rSWT will be applied using the BMI-1120 SHOCK MED device (BIO-MED-INC- ITALY). The following parameters will be used: Shocks number: 1500 per muscle, will be applied over the belly of the calf muscle using the 15 mm applicator head. The pressure will be 2 bar and the frequency will be 4 Hz. Patients will receive shock wave from prone position.
224202982|NCT05883020|OTHER|Standard physical therapy program|Regular rehabilitation procedures consist of strengthing, stretching, facilitation and inhibitory techniques, splinting, developmental techniques, gait and balance training, and advice to parents. The duration of each session will be 1 hour, 3 times per week for 4 weeks
224202983|NCT03356769|DRUG|Aspirin|low-dose of aspirin, 5mg/Kg/d, once every day, 25mg per tablets
224202984|NCT03356769|DRUG|AED|maintain the dosages and the drugs throughout the 3-month observation time
224202985|NCT03356769|DRUG|Placebo|placebo, 5mg/Kg/d, once every day, 25mg per tablets
224202986|NCT01444469|DRUG|Zithromax|250mg \* 2 capsules once daily for three days
224202987|NCT01444469|DRUG|Placebo|Lactose powder
224202988|NCT03647280|DRUG|Abraxane|Tailored neoadjuvant chemotherapy with 4 cycles of PE(weekly Abraxane 125mg/m2, Q3week Epirubicin 100mg/m2, 21day/cycle) is planned for early breast cancer patients(stage of T2-4N0-3M0) who are eligible for primary systemic therapy.
224202989|NCT03647280|DRUG|Epirubicin|Tailored neoadjuvant chemotherapy with 4 cycles of PE(weekly Abraxane 125mg/m2, Q3week Epirubicin 100mg/m2, 21day/cycle) is planned for early breast cancer patients(stage of T2-4N0-3M0) who are eligible for primary systemic therapy.
223616817|NCT04057066|BEHAVIORAL|Exercise|Participants will agree with their therapist on an exercise plan (endurance and resistance training) that will be made available through the studies mobile app. Frequency and duration of endurance and strength training shall be prescribed in accordance with exercise guidelines for pwMS. However, they can be adjusted according to participants prior physical activity level and their available time slots for exercise during the week.
223616818|NCT05947188|OTHER|prostate cancer diagnosis|prostate cancer diagnosis
223616819|NCT05982990|DRUG|Fluticasone propionate 250 mcg and salmeterol xinafoate 50 mcg/Respirent Pharmaceuticals|2 inhalations in one study period
223616820|NCT05982990|DRUG|ADVAIR DISKUS® 250/50|2 inhalations in one study period
223616821|NCT01239069|DRUG|DE-110 ophthalmic suspension high dose|ophthalmic suspension; high dose; QID
223616822|NCT01239069|DRUG|DE-110 ophthalmic suspension low dose|ophthalmic suspension; low dose; QID
223616823|NCT01239069|OTHER|Placebo|DE-110 ophthalmic suspension vehicle;QID
223616824|NCT02632292|DEVICE|Absorb GT1|Bioresorbable vascular scaffold
224202990|NCT02703974|BEHAVIORAL|Early handwashing station|"A handwashing station will be a dedicated location for handwashing in each selected school and will include:~1. A raised concrete platform (built to child height)~2. A plastic container with a lid and spigot~3. Soap~The early handwashing stations will be constructed in weeks 1 and 2 of the study, after the baseline observations (Phase I) are complete."
223616825|NCT02632292|DEVICE|Promus|Everolimus-eluting stent
223616826|NCT01911611|DRUG|RO6870868|Single ascending doses
223616827|NCT01911611|DRUG|placebo|Single ascending doses
223616828|NCT05198817|DRUG|SHR-2002 injection、Camrelizumab for Injection, SHR-1316 injection, SHR-1701 injection|Firstly Dose Escalation and Dose Expansion of SHR-2002 injection monotherapy should be conducted. After RP2D and MTD of the SHR-2002 injection monotherapy were confirmed, Dose Escalation, Dose Expansion and Efficacy Expansion of SHR-2002 injection in combination with other anti-cancer treatment would be completed, including Camrelizumab for Injection, or SHR-1316 injection, or SHR-1701 injection.
223616829|NCT02730728|DRUG|20ml bolus of 0.5% ropivicaine|Local anesthetic
223616830|NCT02730728|DRUG|0.2% Ropivicaine at 8 milliliter/hour|Local anesthetic
223616831|NCT02730728|DRUG|5ml bolus of 0.5% ropivicaine|Local anesthetic
223616832|NCT03354117|DRUG|Ulipristal Acetate 30 MG Oral Tablet|Each study participant will receive one dose of the study medication (ulipristal acetate 30mg plus meloxicam 15mg) at peak fertility in the treatment cycle.
223616833|NCT03148535|DRUG|Lithium Carbonate|bipolar depression recieve lithium Carbonate treatment
223616834|NCT03148535|DRUG|lithium carbonate combined with SSRI antidepressant treatment|lithium carbonate combined with SSRI antidepressant treatment
223616835|NCT04531761|BEHAVIORAL|Parent Support Program|The parent support program includes three modules aimed at increasing knowledge, positive attitudes, and supportive behaviors towards trans youth. Each online module includes several activities including writing prompts, videos, interactive quizzes, and other educational activities.
223616836|NCT01855412|OTHER|PAD endovascular treatments|All FDA-cleared endovascular PAD treatments
223616837|NCT02932137|DRUG|Interleukin-2|Patients receive low dose recombinant human Interleukin-2（HrIL-2）
224202991|NCT02703974|BEHAVIORAL|Late handwashing station|"A handwashing station will be a dedicated location for handwashing in each selected school and will include:~1. A raised concrete platform (built to child height)~2. A plastic container with a lid and spigot~3. Soap~The late handwashing stations construction will begin after Phase 2 data collection has been finished at the end of week 3."
224312693|NCT00746876|DEVICE|Bipolar hip hemiarthroplasty|Bipolar hip hemiarthroplasty for the treatment of femoral neck fractures
223616838|NCT04535635|OTHER|Active Release Techniques®|The ART® procedure will consist of identifying and treating manipulatable lesions as per their protocols, while the sham group will receive a passable version of this technique. This information is under copyright and cannot be copied or outlined specifically in any form, including a research paper. The overarching procedure used by ART® will be explained however specific details referring to each protocol cannot be described. Muscles are shortened, and the therapist applies sufficient digital pressure to be in contact with the tissue in question. Directional tension is applied proximally along the muscle fiber direction, and then the structure is lengthened while the contact remains as described.
223616839|NCT04535635|OTHER|Sham Active Release Techniques®|"For the sham treatment, the muscle(s) in question will be taken from a lengthened to a shortened position (opposite of the protocol direction as per the ART® manual) with a broad light contact on the skin - the treating therapist will not achieve tissue depth as specified by ART® and will not attempt to take tension as is outlined in the ART® manual."
223616840|NCT04197830|PROCEDURE|Thrombectomy for stroke|Patients who have had thrombectomy for acute stroke.
223616841|NCT00072007|BIOLOGICAL|filgrastim|filgrastim
223616842|NCT00072007|BIOLOGICAL|rituximab|rituximab
223616843|NCT00072007|DRUG|CHOP regimen|CHOP regimen
223616844|NCT00072007|DRUG|cladribine|cladribine
223616845|NCT00072007|DRUG|cyclophosphamide|cyclophosphamide
223616846|NCT00072007|DRUG|doxorubicin hydrochloride|doxorubicin hydrochloride
223616847|NCT00072007|DRUG|prednisone|prednisone
223616848|NCT00072007|DRUG|vincristine sulfate|vincristine sulfate
223616849|NCT00262496|DRUG|Botox|
223616850|NCT04569877|DRUG|Molgramostim nebuliser solution|300μg molgramostim nebuliser solution nebulised seven times within 7 days via rapid nebuliser system
223616851|NCT04569877|OTHER|Placebo nebuliser solution|Placebo nebulised seven times within 7 days via rapid nebuliser system
223616852|NCT02463916|OTHER|Exercise|8 week structured exercise programme
223616853|NCT05332600|OTHER|drop-jump test|The participants will be submitted to a kinematic evaluation protocol before and after fatigue protocol and after two weeks they will be submitted again to the same protocol, however, they will be guided and trained on the correct execution of the tested movement.
223616854|NCT04895449|BIOLOGICAL|MVA-SARS-2-ST|i.m. vaccine administration
223616855|NCT00569712|DRUG|budesonide/formoterol fumarate dihydrate inhalation aerosol|
223616856|NCT00569712|GENETIC|DNA methylation analysis|
223616857|NCT00569712|GENETIC|comparative genomic hybridization|
223616858|NCT00569712|GENETIC|microarray analysis|
224312694|NCT05496660|OTHER|NHE+KT|the Nodic hamstring exercise plus the kinesio taping with tension during 4-week consisting 12 sessions
224312695|NCT05496660|OTHER|NHE|the Nodic hamstring exercise plus the kinesio taping without tension during 4-week consisting 12 sessions
224312696|NCT04842786|OTHER|Coconut oil|Coconut oil, Parachute oil composition: 92% lauric (C12) fatty acid, 6% oleic fatty acid, 2% linoleic fatty acid
224312697|NCT03718312|PROCEDURE|clamping with pre-conditioning (PCl)|"PCI procedure: clamping of the supracellular thoracic aorta for 5 minutes followed by a 5-minutes de-clamping period.~PCI procedure is repeated twice."
224312698|NCT02119923|BEHAVIORAL|Working memory training|The WM consisted of two tasks; the Number-letter task (Rogers \& Monsell, 1995) and an Updating task. The Number-letter task trains the ability to shift between task relevant stimuli. Participants need to shift between four categories. In the Updating task participants receive a set of three words in which they have to compare the two consecutive words on emotional valence (positive or negative) to train their updating skills. Participants executed the training three times a week during four weeks.
224202992|NCT02703974|BEHAVIORAL|Nudge|"A nudge will be built in each randomly selected school and will consist of:~1. Connecting latrines to the handwashing station via paved pathways that are painted bright colors~2. Painting footprints on infrastructure guiding students to the handwashing stations and handprints on stations~The nudges will be constructed at the end of week 3 and 4, after Phase II data collection is complete within each randomly assigned nudge school."
224202993|NCT02703974|BEHAVIORAL|Education|"Hand hygiene education-based program: the hygiene promotion element will include a one month program of handwashing education involving weekly facilitator led sessions. Each session will be about 30-45 minutes long, and will cover the following topics:~* Importance of handwashing~* Method of handwashing~* Critical times of handwashing~* Finding solutions for handwashing in school and at home The sessions will involve use of flipcharts, and other IEC materials (e.g. videos) and participative learning methods.~The Hand hygiene education-based program will begin at the beginning of weeks 4 and 5, after Phase II data collection is complete in each randomly assigned education school."
224202994|NCT01281631|DRUG|NP001|Low dose of NP001
224202995|NCT01281631|DRUG|NP001|High dose of NP001
224312699|NCT02119923|BEHAVIORAL|Placebo training|Both the WM and the placebo training consisted of two tasks; the Number-letter task (Rogers \& Monsell, 1995) and an Updating task. To prevent training WM the placebo training was a simplified version of the Number-letter task in which shifting was not required. In the Updating task the placebo group only had to count the number of positive or negative words. Participants executed the training three times a week during four weeks.
224312700|NCT02009514|OTHER|Glucose-containing compared to glucose-free hemodialysate|Comparison of effects on glucose variation
224312701|NCT04293328|DEVICE|orthokeratology|Nightly wear of orthokeratology lenses to correct vision in the daytime
224312702|NCT04293328|DEVICE|Menicon Progent A+B|Menicon Progent A+B is a commercially available protein remover for rigid lenses. It has received FDA clearance and been launched in Hong Kong for over a decade. The product contains two separate sterile solutions, one with sodium hypochlorite and the other with potassium bromide. By mixing the two solutions in a special vial, it can clean and remove protein deposits on the lenses. Parents of subjects assigned to use weekly protein remover will be required to soak the cleansed lenses in the solution mixture for not more than 30 mins every week. All lenses must be rinsed thoroughly with saline and cleansed with daily cleaner again before daily disinfection.
224312703|NCT04591223|BEHAVIORAL|Competency-based physical training (CbM)|The intervention to be added to online social work treatment as usual (OSW) is a well-designed, one-on-one structural physical workout module which will be offered by a licensed senior physical trainer in public sports ground or gymnasium. The aim is to strengthen participants' sense of competence, improve their physical fitness, self-confidence and self-image through an outcome-driven Circuit training. One of the chief advantages of Circuit training is its adaptability. Circuit training can be performed with gym equipment and/or bodyweight exercises which is deemed to be suitable for beginner and easy to practice at home on oneself. Participants can continue to replicate the exercise with or without any equipment. The program will be delivered in six one-hour sessions, including face-to-face and online mode, over one month.
224312704|NCT05519319|PROCEDURE|RFA|RFA will be performed
224312705|NCT05519319|PROCEDURE|PDT|PDT will be performed
224312706|NCT05519319|PROCEDURE|RFA combined with PDT|RFA and PDT will be performed
224312707|NCT03858543|DRUG|Poly-L Lactic Acid|After initial treatment, reassessment will be conducted at 3 follow-up visits. Photographs will be taken for blinded evaluators to compare post-treatment to the original pre-treatment photographs. At final visit, a questionnaire will be administered to rate treatment satisfaction.
223510763|NCT06521593|PROCEDURE|Applying a tourniquet for either a short or long time during total knee replacement|All patients underwent spinal anesthesia and the tourniquet was applied to the middle of the thigh; in group one who underwent long-duration application of a tourniquet, it was applied only before the skin incision by inflating it to 150 mmHg above the systolic blood pressure of the patients and deflation finishing of bone cementation while in group two who underwent short duration application of a tourniquet, the tourniquet was only applied just before cementation, was inflated also to 150 mmHg above the systolic blood pressure of the patients, and was deflated after bone cementation.
223510764|NCT01972178|DRUG|PRC-4016|
223510765|NCT01972178|DRUG|Placebo|
224202996|NCT01281631|DRUG|Placebo|normal saline
224202997|NCT02539472|OTHER|Blood sampling|Blood sampling for quantitative evaluation of nine candidate biomarkers (CD158k/KIR3DL2, KIR2DL4, KIR2DS1, KIR2DS3, KIR3DL1, NKp46, PLS3/T-Plastin, Twist and TOX) by quantitative RT-PCR.
224202998|NCT03944538|BEHAVIORAL|Lifestyle Physical Activity|The intervention consists of two primary components: a dedicated Internet website and one-on-one video chats with a behavioral coach via Zoom. The intervention focuses on the skills, techniques, resources and strategies for becoming and staying physically active with MS, but does not provide a prescription for exercise or physical activity itself.
224202999|NCT03944538|BEHAVIORAL|General Wellness|The control condition provides an Internet website and one-on-one video chats that discuss materials about self-managing MS consequences and health indicators through methods other than physical activity.
224203000|NCT01585064|OTHER|DAS28-IOMS|Investigators randomized to DAS28-IOMS will be expected to adapt their therapeutic approaches in relation to the defined targets, i.e. to optimize adalimumab treatment according to individual patient's responses to treatment in order to achieve a DAS28 score of \< 2.4.
224203001|NCT01585064|OTHER|0SJ-IOMS|Investigators randomized to 0SJ-IOMS will be expected to adapt their therapeutic approaches in relation to the defined targets, i.e. to optimize adalimumab treatment according to individual patient's responses to treatment in order to achieve a swollen joint count of 0.
224203002|NCT01585064|OTHER|Routine Care (RC)|Investigators randomized to RC will NOT be expected to adapt their therapeutic approaches to a pre-defined target. They will optimize adalimumab treatment according to individual patient's responses to treatment as per routine care and according to their own judgment.
224203003|NCT03582059|PROCEDURE|High Frequency Spinal cord stimulation|An electrode will be implanted into the patients back. A defined stimulation patter will be applied. The patient will be randomised to received 7-10 days of high frequency stimulation.
224203004|NCT03582059|PROCEDURE|Burst Frequency Spinal cord stimulation|An electrode will be implanted into the patients back. A defined stimulation patter will be applied. The patient will be randomised to received 7-10 days of burst frequency stimulation.
224203005|NCT00264082|DRUG|Zometa(drug)|
224203006|NCT00189696|DRUG|YM060|
224203007|NCT01386619|BIOLOGICAL|CD3-depleted/CD56+ selected natural killer cells collected from apheresis products|NK DLI products containing \>1 10e7 NK cells/kg bodyweight (BW) and \< 1 x 10e5 T-cells/kg BW are administered at days +4 (Frankfurt only), and on days +40 and +100 (both centers)
224203008|NCT01245595|DRUG|Aminophylline|5 mg/kg IV bolus then 1.8 mg/kg IV Q6 hours
224203009|NCT01245595|DRUG|Placebo|Normal Saline
224203010|NCT03574194|DIETARY_SUPPLEMENT|Methionine-restricted diet|The methionine-restricted diet diet (MRD) will begin 2 weeks prior to radiation therapy to deplete methionine stores in the body, continue during radiation, and extend for approximately 2 weeks after the last radiation fraction for a total of 6-10 weeks (depending on duration of radiation course).
224203011|NCT04242368|DRUG|Isotonic saline|Nasal isotonic saline irrigation (240 mL, 0.9% NaCl) administered through nasal rinse bottle.
224203012|NCT04242368|DRUG|Hypertonic Nasal Wash|Nasal hypertonic saline irrigation (240 mL, 1.8% NaCl) administered through nasal rinse bottle.
224203013|NCT04242368|DRUG|Fluticasone Propionate|Fluticasone nasal spray administered two sprays to each nare twice a day
224203014|NCT02545868|BIOLOGICAL|23-PPV|The 23-PPV vaccine will be given as a 0.5-milliliter (mL) intramuscular (IM) injection in the deltoid muscle on Day 112 (Group A) or Day 28 (Group B).
224203015|NCT02545868|BIOLOGICAL|13-PCV Booster|The 13-PCV booster will be given as an IM injection in the deltoid muscle on Day 140 (select participants in Group A).
223510766|NCT01972178|DRUG|Statins|Any statin allowed (i.e. rosuvastatin, simvastatin, pravastatin, atorvastatin etc)
223510767|NCT00432991|DRUG|Ephedrine [Synonyms: Ephedra, Ephedrinum]|25 mg, IM (in the muscle), one time
223510768|NCT00432991|DRUG|Saline Placebo|0.5 mL, IM (in the muscle), one time
223510769|NCT03759197|DRUG|188-0551 Spray|Topical Spray containing active drug
223510770|NCT03759197|DRUG|Vehicle Spray|Topical Spray containing no active drug
223510771|NCT04738669|OTHER|mHealth|The mHealth intervention includes telephonic call and SMS.
223510772|NCT04738669|BEHAVIORAL|Teach-back|While the teach-back includes counselling session related to discharge instruction including medication adherence.
223510773|NCT00974532|DIETARY_SUPPLEMENT|High calcium diet 2000 mg/day|High calcium (2000 mg elemental calcium) diet x 9 days
223510774|NCT00974532|DIETARY_SUPPLEMENT|Low calcium diet, 800 mg/day|Low calcium (800 mg elemental calcium) diet x 9 days
223510775|NCT04109482|BIOLOGICAL|MB-102|"The study drug, MB-102 consists of adoptively transferred T cells that are genetically modified using a self-inactivating (SIN) lentiviral vector to express a CD123-specific, CD28-costimulatory chimeric antigen receptor (CAR) as well as a truncated human epidermal growth factor receptor (EGFRt) (CD123.CD28.CD3ζ.EGFRt+T cells) derived from autologous leukapheresis which is administered after a lymphodepletion regimen.~Single dose of MB-102 up to 600 x 10 6 CART-T+ cells (Day 0) as defined by Phase 1 will be administered."
223510776|NCT04109482|DRUG|Fludarabine|"Fludarabine 30 mg/m2/day IV (3 days) on days -5, -4, and -3~* A 20% dose reduction (24 mg/m2/day IV (3 days) on days -5, -4, and -3) is required for patients with moderately impaired renal function (creatine clearance ≤ 70 mL/min)."
223510777|NCT04109482|DRUG|Cyclophosphamide|Cyclophosphamide 300 - 500 mg/m2/day IV (3 days) on days -5, -4, and -3
223510778|NCT01489826|DRUG|Dexanabinol|Patients will (initially) be given a slow intravenous (i.v.) infusion of Dexanabinol over 3 hours on Days 1, 8 and 15 of a three weekly (21 day) cycle.
223510779|NCT01489826|OTHER|Cremophor|Drug vehicle.
223510780|NCT03418480|DRUG|BNT113|Intradermal vaccine
223510781|NCT01991574|DRUG|Calcium acetate|
223510782|NCT01991574|DIETARY_SUPPLEMENT|Iron Hydroxide Adipate|
223510783|NCT01991574|DRUG|Placebo|methylcellulose capsules
223510784|NCT03142451|DRUG|FMX103 minocycline foam 1.5%|Dosage form description: Foam containing minocycline HCl 1.5%. Once daily application of a sufficient amount of foam to cover the entire face. Estimated maximum is 0.5 g of drug product containing 7.5 mg (1.5% active) of minocycline. Participants will apply a small amount of the drug as a thin layer over all areas of the face. Participants should apply the drug at approximately the same time each day, about 1 hour before bedtime.
223510785|NCT03142451|DRUG|Vehicle foam|Dosage form description: Foam containing minocycline vehicle foam. Once daily application of a sufficient amount of foam to cover the entire face. Estimated maximum is 0.5 g of drug product containing 0.0 mg (vehicle) of minocycline. Participants will apply a small amount of the drug as a thin layer over all areas of the face. Participants should apply the drug at approximately the same time each day, about 1 hour before bedtime.
223510786|NCT00090402|DIETARY_SUPPLEMENT|Fish Oil|Fish oil capsule
223510787|NCT00090402|DIETARY_SUPPLEMENT|Lipoic Acid|Lipoic acid capsule
223510788|NCT00090402|OTHER|Fish Oil Placebo|Soybean oil placebo capsule
224203016|NCT02545868|BIOLOGICAL|Influenza Vaccine|The influenza vaccine will be given as an IM injection in the deltoid muscle at any time between Day 85 and Day 144 (select participants in Group A) or any time between Day 1 and Day 85 (Group B).
224203017|NCT02545868|BIOLOGICAL|KLH|KLH will be given as a 1-mg subcutaneous (SC) injection on Days 84, 112, and 140 (Group A) or Days 1, 28, and 56 (Group B).
224203018|NCT02545868|DRUG|OCR|OCR will be given as an intravenous (IV) infusion at a dose of 600 mg, with the first dose given as two infusions of 300mg 14 days apart, according to the specifications described in the corresponding Group A and Group B arms.
224312708|NCT03858543|DEVICE|Fractional laser treatment|After initial treatment, reassessment will be conducted at 3 follow-up visits. Photographs will be taken for blinded evaluators to compare post-treatment to the original pre-treatment photographs. At final visit, a questionnaire will be administered to rate treatment satisfaction.
224312709|NCT04008849|OTHER|Safety and efficacy assessments|Long term safety and clinical outcomes
224312710|NCT01544179|DRUG|Gefitinib|Investigational Drug
224312711|NCT01544179|DRUG|Placebo|Matching placebo as comparator
224312712|NCT01544179|DRUG|Pemetrexed|Chemotherapy (concomitant therapy)
224312713|NCT01544179|DRUG|Cisplatin|Chemotherapy (concomitant therapy)
223510789|NCT00090402|OTHER|Lipoic Acid Placebo|Lipoic acid (LA) placebo capsule containing no LA
224203019|NCT02545868|BIOLOGICAL|TT Vaccine|The TT-containing adsorbed vaccine will be given as a 0.5-mL IM injection in the deltoid muscle on Day 85 (Group A) or Day 1 (Group B).
224203020|NCT06459076|DEVICE|Transnasal humidified rapid-insufflation ventilatory exchange (THRIVE)|Immediately after ceasing assisted ventilation, before intubation the age-appropriate nasal prongs were applied and weight-specific high flow rates delivered using the Optiflow THRIVETM system. The flow rates applied were as follows: 0-15 kg, 2 litres kg-1 min-1；15-30 kg, 35 litres min-1; 30-50 kg, 40 litres min-1; and\>50 kg, 50 litres min-1.
224203021|NCT02147262|DRUG|doxycycline orally, 100 mg, bid, 14 days|
224203022|NCT02147262|DRUG|doxycycline orally, 100 mg, bid, 28 days|
224203023|NCT02102529|PROCEDURE|laparoscopic colonic surgery|women with typical symptoms including pelvic pain, infertility and endometriotic bowel lesions who underwent laparoscopic surgery including colonic resection performed from 2009 to 2012
224203024|NCT00591526|DRUG|Arac|Ommit ARAC in the chemotherapy
224203025|NCT04946474|DRUG|Xingnaojing injection + Shuxuetong oral liquid|Xingnaojing injection (administered immediately after joining the group, once a day, treatment for 10 days) + Naoxueshu oral liquid treatment (administered on the 4th day of onset, 3 times a day, treatment for 30 days ).
224203026|NCT00696631|DRUG|Dronedarone (SR33589)|oral administration
224203027|NCT00696631|DRUG|Placebo|oral administration
224203028|NCT04443673|DIETARY_SUPPLEMENT|Glycine|Along with habitual treatment for their severe condition, participants will receive 0.5 g/kg/day glycine by nasogastric tube, divided in four equal doses in a day, since their enrollment and until they are weaned from mechanical ventilator or die.
224203029|NCT03165331|OTHER|Ung Face IT|Ung Face IT is an online intervention tool (programme) that provides easy access to specialist advice and support via a home computer/tablet, using illustrations, information, videos, and interactive activities, and a discussion forum for participants only (supervised by the research team). Through these tools, it provides advice and teaches coping skills based on cognitive behavioural therapy and social interaction skills training.
224203030|NCT00154830|BEHAVIORAL|cerebral palsy|
223616859|NCT00569712|OTHER|bronchoalveolar lavage|
223616860|NCT00569712|OTHER|immunoenzyme technique|
223616861|NCT00569712|OTHER|laboratory biomarker analysis|
224203031|NCT00154830|BEHAVIORAL|crouch gait|
224203032|NCT01932801|DRUG|XR-NTX|
224203033|NCT01932801|OTHER|Placebo|
224203034|NCT01932801|BEHAVIORAL|HRC|
224203035|NCT01926301|PROCEDURE|continuous veno-venous hemodialysis|
224203036|NCT00174486|DRUG|UK0369,003|
224203037|NCT00174486|DRUG|Cialis (Tadalafil)|
224203038|NCT04465916|DRUG|EYP001a|Oral tablets
224203039|NCT04465916|DRUG|Placebo|Oral tablets
224203040|NCT04465916|DRUG|Nucleotide analogue (Entecavir or Tenofovir Disoproxil)|Oral tablets
224203041|NCT02015286|DEVICE|easypod™|Saizen® (Somatropin) as per Summary of Product Characteristics administered by easypod™
224203042|NCT00732784|DRUG|Imatinib mesylate|Dosage form: tablets Dosage: 400 mg Frequency \& duration: On an 18-day schedule, one dose administered once on day 1 and once on day 15 (2 doses total)
224203043|NCT00732784|DIETARY_SUPPLEMENT|calcium carbonate|Dosage form: tablets Dosage: 4000 mg (4 x 1000 mg tablet) Frequency: On an 18-day schedule, once daily day 15 (for Arm 1); or once daily day 1 (for Arm 2)
224312714|NCT06633484|OTHER|functional magnetic resonance imaging|non-diagnostic, non-invasive, passive measurement of the brain\&#39;s structure and function
224312715|NCT03466268|DRUG|Gumarontinib Tablets|Either at 100mgSD、100mgQD、200mgSD、200mgQD、400mgSD、400mgQD、300mgBID、400mgBID
224312716|NCT00049530|BIOLOGICAL|PEG-interferon alfa-2b|Patients receive PEG-interferon alfa-2b subcutaneously (SC) once weekly. Treatment continues until basic fibroblast growth factor level is suppressed to normal or until a maximum weekly dose is reached. If there is disease progression, patients then discontinue treatment. If there is no disease progression, patients receive PEG-interferon alfa-2b SC weekly for up to 1 year in the absence of disease progression or unacceptable toxicity.
224312717|NCT01279083|DRUG|DE-112|Topical ocular solution
224312718|NCT01279083|DRUG|DE-112|Topical ocular solution
224312719|NCT01279083|DRUG|DE-112|Topical ocular solution
223616862|NCT00569712|PROCEDURE|bronchoscopy|
224312720|NCT01279083|DRUG|DE-112|Topical ocular solution
224312721|NCT01279083|DRUG|DE-112 Vehicle Solution|Topical ocular solution
224312722|NCT01279083|DRUG|Timolol Maleate Solution|Topical ocular solution
224312723|NCT01635283|BIOLOGICAL|tumor lysate-pulsed autologous dendritic cell vaccine|Given ID
224312724|NCT01635283|OTHER|laboratory biomarker analysis|Correlative studies
224312725|NCT01433549|DEVICE|Lotrafilcon B|Commercially marketed, silicone hydrogel, single-vision contact lens FDA-approved for daily wear and extended (overnight) wear up to 6 nights.
224312726|NCT01433549|DEVICE|Senofilcon A|Commercially marketed, silicone hydrogel, single-vision contact lens FDA-approved for daily wear and extended (overnight) wear up to 6 nights.
224312727|NCT01639196|OTHER|Self-compassion writing|Participants are instructed to write about their chronic pain in a way that elicits self-compassion for 20 minutes once a week for three consecutive weeks.
224312728|NCT01639196|OTHER|Self-efficacy writing|Participants are instructed to write about their chronic pain in a way that elicits self-efficacy for 20 minutes once a week for three consecutive weeks.
224312729|NCT01438996|BIOLOGICAL|NVGH Vi-CRM197|Vi-CRM197 glycoconjugated vaccine
224312730|NCT04496115|BEHAVIORAL|Mindfulness|Mindfulness training
224312731|NCT00479778|DRUG|Bazedoxifene/conjugated estrogens|
224203044|NCT00605397|RADIATION|PET Imaging With Cu-64 Labeled Trastuzumab|The first 8 patients enrolled will undergo two complete PET studies, up to 3-6 weeks apart, to assess for reproducibility of measures of tracer uptake into individual organs and known sites of metastatic disease.
224203045|NCT00605397|RADIATION|PET Imaging With Cu-64 Labeled Trastuzumab|The remaining 20 patients will undergo one PET study.
224203046|NCT00817869|OTHER|New flooring|8.3mm thick vinyl floor covering with foam backing, manufactured by Tarkett and installed by Tyndale Flooring Ltd.
224203047|NCT01635127|DRUG|Canakinumab|150mg s.c.
224203048|NCT01635127|DRUG|Placebo|Constituent of canakinumab
224203049|NCT05515627|DRUG|Atezolizumab|Atezolizumab 1200 mg administered via intravenous infusion every 3 weeks
224203050|NCT03519360|OTHER|UFR-restricted dialysis|UFR's are limited to a maximum of 10 mL/kg/hr for the duration of the session. In order to prevent progressive volume overload and the need for additional hemodialysis sessions to manage volume gains in this scenario, subjects will crossover weekly between the restricted and unrestricted UFR interventions.
224203051|NCT03519360|OTHER|UFR-unrestricted dialysis|UFR's will be unlimited and prescribed according to the standard of care.
224203052|NCT05088980|DEVICE|VOLBELLA with Lidocaine|Facial Injection
224203053|NCT03576469|BIOLOGICAL|C1-esterase inhibitor [recombinant] (C1-INH-R)|C1-INH-R is FDA approved and indicated for the treatment of acute attacks of angioedema in adolescent and adult patients with Hereditary Angioedema (HAE) as a replacement for low levels of C1-esterase inhibitor or low function of C1-esterase inhibitor
224203054|NCT00387868|DRUG|cisplatin and etoposide|Cisplatin: 50mg/m2 - administered on days 1,8,29\&36 Etoposide: 50 mg/m2 - administered on days 1-5 \& 29-33
224203055|NCT00387868|PROCEDURE|Surgical Resection|Resection will take place 4-8 weeks after completion of radiotherapy.
224203056|NCT00387868|RADIATION|Concurrent Radiotherapy|Preoperative External Beam Radiotherapy
224203057|NCT00484120|DRUG|3%-Diclofenac-Nano-Emulsion Cream|3%-Diclofenac-Nano-Emulsion Cream
223510790|NCT00382928|DEVICE|Defibrillation of pulseless VT/VF by AECD|In case of cardiac arrest caused by shockable rhythms the automatic external cardioverter defibrillator (AECD) will automatically deliver defibrillation. Automated External Cardioverter Defibrillator (AECD; The PowerHeart CRM, Cardiac Science Inc., Seattle, WA) is a device attached to the chest wall by pads, monitors the electrocardiogram, and is capable of automatically delivering electric countershock to appropriate rhythms without operator intervention. The device will deliver only one shock of 150 Joules for pulseless ventricular tachycardia and ventricular fibrillation.
223616863|NCT01702844|DRUG|Nab-Paclitaxel|Administer 2 cycles of Nab-Paclitaxel 100 mg/m2 IV on days 1 8 and 15
224203058|NCT00484120|DRUG|Placebo cream|Placebo cream
224203059|NCT00115466|PROCEDURE|Non-surgical autologous implant of ASCs|
224203060|NCT01906580|DRUG|Peg-IFNα-2a|180ug peg-IFNα-2a, subcutaneous injection per week
224203061|NCT01906580|DRUG|Entecavir|0.5mg,oral administration every day
224203062|NCT00448630|OTHER|No intervention|Non-interventional study
224203063|NCT03991065|DIAGNOSTIC_TEST|high digestive endoscopy|high digestive endoscopy with biopsies performed according to the sydney protocol
224203064|NCT00800722|DRUG|Rapamycin Treatment of Port Wine Stain|Treatment of Port Wine Stain
224203065|NCT04691739|OTHER|occupational therapy|occupational therapy sessions include a set of standardized test exercises plus additional modalities that are optimized to each patient's needs according to the clinical judgement of the treating therapist
223510791|NCT02691377|DEVICE|acupuncture group|Acupoints include 11 on the head, two on the upper extremities, and two on the lower extremities. Before performing acupuncture, a small pad will be pasted on each acupoint. All the needles will insert the acupoints through these pads. Then, they will be twirled, lifted and thrust three times to elicit the Deqi sensation. Each session will last 30 minutes.
223510792|NCT02691377|DEVICE|Sham Acupuncture group|The same acupoints with acupuncture group are selected.A placebo needle with a blunt tip will be used to perform sham acupuncture. They will only insert the pad and no skin penetration. The same procedure with acupuncture group will be performed.
223616864|NCT00500916|DEVICE|ProSeal LMA|GEB vs digital vs introducer tool
224203066|NCT02107963|BIOLOGICAL|Anti-GD2-CAR engineered T cells|Administer anti-GD2 CAR T cells 1 x 105 transduced T cells/kg; 1 x 106 transduced T cells/kg; 3 x 106 transduced T cells/kg; and 1 x 107 transduced T cells/kg
224203067|NCT02107963|DRUG|AP1903|If unacceptable toxicity occurs that is possibly, probably or likely related to anti-GD2-CAR T cells, AP1903, a dimerizing agent, may be administered to mediate clearance of the genetically engineered cells and resolve toxicity
224203068|NCT02107963|DRUG|Cyclophosphamide|1800mg/m2/d X 2 days as a lymphodepleting regimen
224203069|NCT01594580|OTHER|Antimicrobial impregnated scrubs|Scrubs are impregnated with an antimicrobial product
224203070|NCT01594580|OTHER|Non-impregnated scrubs|
224203071|NCT04740801|DEVICE|Ablation procedure|Catheter ablation of pulmonary veins with the Rhythmia HDx mapping system, IntellaMap Orion mapping catheter and IntellaNav StablePoint ablation catheter
224203072|NCT01325701|DRUG|ibrutinib|ibrutinib is an inhibitor of BTK
224203073|NCT00997672|DRUG|Lithium Carbonate|Lithium Carbonate will be dosed based on lithiemy, which will be in the range 0.9-1.2 mEq/L. Maximum allowed dose will be 1500mg/day.
224203074|NCT00997672|DRUG|Placebo|
224203075|NCT02812368|DRUG|Clonidine|
224203076|NCT02812368|DRUG|Placebo (for clonidine)|Placebo pill manufactured to mimic clonidine
224203077|NCT02378467|DRUG|7% Hypertonic Saline (HS)|Administered via inhalation twice daily for 48 weeks. The delivery system is a PARI Sprint Junior nebulizer with a PARI Baby face mask or mouthpiece driven by a PARI Vios® compressor.
224203078|NCT02378467|DRUG|0.9% Isotonic Saline (IS)|Administered via inhalation twice daily for 48 weeks. The delivery system is a PARI Sprint Junior nebulizer with a PARI Baby face mask or mouthpiece driven by a PARI Vios® compressor.
224203079|NCT04924946|OTHER|Inventory of prescribing habits and detect any differences in efficacy and tolerance of antihypertensive drugs|"* Time to monitor blood pressure values in target targets~* Need for administration of another antihypertensive drug~* Disappearance of organ failure attributable to hypertension~* Weaning from an extra-renal purification~* Weaning from mechanical ventilation~* Improved kidney function~* Iatrogenic hypotension~* Need for suspension of treatment~* Other side effect"
224203080|NCT04650516|DEVICE|Virtual reality|20 minutes treatment in virtual reality
224203081|NCT04650516|DEVICE|Digital control|20 minutes digital control movie on tablet without virtual reality
223510793|NCT01084759|DRUG|Testosterone injection|Patients will receive an intramuscular gluteal injection with testosterone cypionate at a dose of 400 mg every month for a total of 3 injections (i.e. 3 months of therapy). This route and dose of testosterone was selected based on data demonstrating that it produces an initial supraphysiologic serum level of testosterone (i.e. \> 3-5 times normal level) with eugonadal levels achieved at the end of two weeks.
224203082|NCT06515717|DIETARY_SUPPLEMENT|ketone ester|oral supplement
224203083|NCT06515717|DIETARY_SUPPLEMENT|dextrose (placebo)|oral supplement calorie and taste matched to ketone supplement
224203084|NCT01898858|DEVICE|Hypercapnia inhalation (Altitrainer NP 190)|Hypercapnia inhalation using an Altitrainer NP 190
224203085|NCT01898858|DEVICE|Hypoxia and hypercapnia (Altitrainer NP 190)|Hypoxia and hypercapnia inhalation using an Altitrainer NP 190
223510794|NCT01084759|DRUG|Etoposide|On the day of testosterone injection (i.e. day 1 of each cycle) patients will begin therapy with oral etoposide at a dose of 100 mg/day given in divided doses (one 50 mg etoposide capsule q 12 h) for 14 consecutive days. This dose was selected based on Phase II studies of the combination of oral estramustine and oral etoposide. In these trials, myelosuppression was observed when etoposide was given for 21 days out of a 28 day cycle. Therefore, to minimize toxicity, in this study etoposide will be administered for 14 days of a 28 day cycle.
223510795|NCT01758471|DRUG|Glipizide|glipizide 5mg per pill 5mg tid p.o. for 3 month
223510796|NCT01758471|DRUG|Acarbose|Acarbose 50mg per pill 100mg to 150mgtid p.o.（oral） for 3 month
223510797|NCT01755754|COMBINATION_PRODUCT|Silicone Elastomer Vaginal Ring|Silicone Elastomer Vaginal Ring
223510798|NCT01755754|DEVICE|Female Condom|Female condom
223510799|NCT00901563|DRUG|Rotigaptide|Prior to 20 mins of ischaemia induced by a blood pressure cuff inflated to 200 mmHg around the upper non-dominant arm, rotigaptide will be infused for 30mins. During the ischaemic period no drug will be infused but the infusion will be restarted once the blood pressure cuff has been deflated and blood flow returns to the limb.
223510800|NCT00901563|OTHER|Forearm vascular study|Forearm blood flow measured by venous occlusion plethysmography during interarterial infusion of substance P (2,4,8 pmol/min) or Acetylcholine (5, 10 , 20 micromol/min) . Venous blood sampling via cannula in antecubital fossa.
223510801|NCT01141790|OTHER|Music and voice message|
223510802|NCT00941395|OTHER|Survey Administration|Complete surveys
223510803|NCT06032598|DIETARY_SUPPLEMENT|Berry extract 1|The study foresees the intake of 1 capsule per day during 84 days
223510804|NCT06032598|DIETARY_SUPPLEMENT|Berry extract 2|The study foresees the intake of 1 capsule per day during 84 days
223510805|NCT06032598|DIETARY_SUPPLEMENT|Placebo|The study foresees the intake of 1 capsule per day during 84 days
223510806|NCT04859231|OTHER|Control|Cow's milk-based formula
223510807|NCT04859231|OTHER|Investigational|Cow's milk-based formula with added source of enriched whey protein
223510808|NCT04461535|DRUG|Adrenocorticotropic hormone|Patients divided into Intervention group need to undergo stimulation with a continuous cosyntropin infusion (50 μg/h started 30 minutes before sampling during AVS). Right and left adrenal venous blood and corresponding peripheral venous blood should be sampled sequentially.
223510809|NCT02016885|DRUG|glycopyrrolate, 1.0%|glycopyrrolate Topical Wipes, 1.0%
223510810|NCT02016885|DRUG|glycopyrrolate, 2.0%|glycopyrrolate Topical Wipes, 2.0%
223510811|NCT02016885|DRUG|glycopyrrolate, 3.0%|glycopyrrolate Topical Wipes, 3.0%
223510812|NCT02016885|DRUG|glycopyrrolate, 4.0%|glycopyrrolate Topical Wipes, 4.0%
223510813|NCT02016885|OTHER|Vehicle|Vehicle Topical Wipes
223510814|NCT02244528|DRUG|Sildenafil|
223510815|NCT05224648|DEVICE|TOF scan train of four ratio monitoring|Device : TOF Scan For each included patient, 2 monitorings (TOF Scan and ITF device) will be placed, one on each hand. Once 4 contractions of the adductor pollicis muscle will be observed on the TOF Scan side following train of four stimulation, 40 µg/kg neostigmine will be injected. Train of four ratio (delivered every minute) will be recorded. This sequence (tetanus 100 Hz followed by tetanus 50 Hz) will be repeated 6 times. For each tetanus stimulation, the ratio between the residual force and the maximum force generated by the adductor pollicis muscle will be recorded (this ratio illustrates the fade phenomenon). At the end of this period lasting 30 minutes after neostigmine administration, anesthetic drug delivery will be stopped and the patient wil be allowed to recover.
223510816|NCT05224648|DEVICE|ITF device tetanus stimulation monitoring|Device ITF For each included patient, 2 monitorings (TOF Scan and ITF device) will be placed, one on each hand. Once 4 contractions of the adductor pollicis muscle will be observed on the TOF Scan side following train of four stimulation, 40 µg/kg neostigmine will be injected. Train of four ratio (delivered every minute) will be recorded. This sequence (tetanus 100 Hz followed by tetanus 50 Hz) will be repeated 6 times. For each tetanus stimulation, the ratio between the residual force and the maximum force generated by the adductor pollicis muscle will be recorded (this ratio illustrates the fade phenomenon). At the end of this period lasting 30 minutes after neostigmine administration, anesthetic drug delivery will be stopped and the patient wil be allowed to recover.
223510817|NCT06570499|OTHER|Implant impression|definitive impressions on implants
223510818|NCT05539911|DRUG|Fentanyl|50 mic fentanyl added as an adjuvant
223510819|NCT03912805|BIOLOGICAL|botulinum toxin, Type A|topical liniment
223510820|NCT03912805|BIOLOGICAL|Vehicle|Vehicle Formulation
223510821|NCT04621786|DEVICE|Mecta Spectrum 5000Q paired with Soterix Medical 4X1 HD - ECT Multi-Channel Stimulation Interface|The Mecta Spectrum 5000Q paired with Soterix Medical 4X1 HD-ECT Multi-Channel Stimulation Interface will reduce ECT current amplitude for amplitude-seizure titration.
223510822|NCT02440399|DRUG|Tramadol hydrochloride|Please see arm description
223510823|NCT02440399|DRUG|Morphine|Please see arm description
224203086|NCT01898858|DEVICE|Hypoxia inhalation (Altitrainer NP 190)|Hypoxia inhalation using an Altitrainer NP 190
224203087|NCT06349434|DEVICE|MyoMo|To evaluate the usefulness of extended utilization of an upper extremity assistive device, called (MyoPro) in improving upper extremity (UE) activities in people with spinal cord injury (SCI).
223510824|NCT02440399|DRUG|Paracetamol|
223616865|NCT04761601|DRUG|UCT-01-097|Orally available kinase inhibitor
223510825|NCT02440399|DRUG|Diclofenac|
223510826|NCT02440399|DRUG|TAB. Percocet (Oxycodone 5MG/Paracetamol 325 MG)|
223510827|NCT03815604|BEHAVIORAL|Independent Housing and Support (IHS)|Direct placement of people with SMI in an independent accommodation in the community, usually in a flat rented by the service user. Support is provided by a coach according to individual needs in a permanent housing situation without time limit.
223616866|NCT04761601|DRUG|Gemcitabine|Gemcitabine injection for intravenous use.
223616867|NCT04761601|DRUG|Paclitaxel|Paclitaxel protein-bound particles for injectable suspension (albumin-bound).
224203088|NCT06349434|OTHER|conventional therapy|To evaluate the usefulness of extended conventional therapy compared to the utilization of an upper extremity assistive device called (MyoPro) in improving upper extremity (UE) activities in people with spinal cord injury.
224203089|NCT06217835|OTHER|To evaluate the response of an orthopedic insole|To evaluate the response of an orthopedic insole of different heights on gait.
223616868|NCT05346120|BIOLOGICAL|allogeneic marrow stromal cells (MSCs)|stem cell infusion
223616869|NCT03431441|DEVICE|JJVC Marketed Contact Lens|Female subjects that are habitual contact lens wearers between the ages of 18 to 39 will be dispensed 1 treatment of the JJVC Marketed Contact Lens during the 2-visit study.
223616870|NCT00346216|DRUG|celecoxib|100 to 200 mg twice daily, taken by mouth
223616871|NCT00346216|DRUG|Ibuprofen|ibuprofen 600 mg to 800 mg three times daily, taken by mouth
223761208|NCT05248516|DIETARY_SUPPLEMENT|Standard dose of ready-to-use therapeutic food (RUTF)|"In the standard arm, children will receive different doses of RUTF depending on their WHZ category and weight.~1. children with a WHZ\<-3 will receive the equivalent of 200kcal/kg/d of RUTF until discharge.~2. children with a WHZ between -3 and -2 will receive 1 sachet (500kcal) of RUTF per day until discharge.~3. children with a WHZ\>=-2 will receive no nutritional treatment.~Recovery from treatment will be defined as WHZ\>= -2 on 2 consecutive visits. A maximum of 12 treatment weeks are allowed before declaring non-response. Defaulting will be declared after 2 consecutively missed visits."
223761209|NCT05248516|DIETARY_SUPPLEMENT|No nutritional treatment|no nutritional treatment will be provided to children in the control arm.
224203090|NCT06217835|OTHER|evaluate activation of musculature|To evaluate the response caused by an orthopedic insole of different heights on the indicated musculature.
224203091|NCT02255734|DRUG|Acyclovir|
224203092|NCT04616079|DRUG|REGN6490|Single dose of REGN6490
224203093|NCT04616079|DRUG|Placebo|Placebo matching single dose of REGN6490
224203094|NCT04511884|DIAGNOSTIC_TEST|Next-generation sequencing|The patient who may be diagnosed with cryptogenic organizing pneumonia will be detected through next-generation sequencing.
224203095|NCT04918810|DRUG|Docetaxel intermittent|After 3 or 4 cycles of docetaxel chemotherapy (75mg/m\^2 every 21 days or 50mg/m\^2 every 14 days) in combination with an undetectable mGSTP1 level, patients will stop docetaxel treatment. Plasma mGSTP1 is measured every 21 days or 28 days (depending on Docetaxel regimen) and docetaxel treatment will be recommenced if it mGSTP1 becomes detectable again.
224203096|NCT01483612|BEHAVIORAL|Interdisciplinary lifestyle intervention|"Individual meetings with a dietitian and a kinesiologist at 0, 3, 6 weeks and then every 6 weeks for 18 months or until delivery. A reminder phone call/email will also take place once between each meeting.~The program also includes 12 group sessions discussing subjects about nutrition, psychology and demonstration of physical activity."
224203097|NCT00976313|PROCEDURE|Assessment of urinary micturition after thoracotomy|Post residual urine volume and voided volume will be assessed with Bladder Scan™ BVI 6100 (Bladder scan, Bothell, WA, USA) will be performed the day before surgery and on day 2 after surgery, with epidural analgesia within segments T2-4 to T10 21,22. Bladder sensitivity will be assessed at strong desire to void. On day 2 the bladder will be filled through the transurethral catheter till the patient signalised a strong desire to void, then the catheter will be removed and spontaneous micturition will be attempted. Voided volume and post void residual will be assessed.
224203098|NCT00976313|OTHER|International Prostate Symptom Score|International Prostate Symptom Score (IPSS) for assessment of lower urinary tract symptoms (LUTS) preoperatively
224203099|NCT04957914|DRUG|Insulin Glargine|Administered SC
224203100|NCT04957914|DRUG|LY3209590|Administered SC
224203101|NCT00500695|BEHAVIORAL|Motivational Interviewing|Motivational Interviewing
224203102|NCT00500695|BEHAVIORAL|Psychoeducation|Psychoeducation
224203103|NCT01570218|BEHAVIORAL|Music therapy|Music therapy arm: Intervention with 10 sections of music therapy will be performed, twice a week, during 45 days
224203104|NCT05124990|DIAGNOSTIC_TEST|thermal imaging|no risk infrared thermal image would be used to capture pictures of the patients joints that are reported to be painful during a rheumatoid arthritis flare along iwth labs such as esr and crp. these will then be fed to a machine learning algorithm that will learn to predict the DAS 28 score for the RA patient and their flare.
224203105|NCT06023303|DEVICE|Potenza|The Radiofrequency microneedling device will be used for treating several skin problems. It is mostly used on the face and neck, specifically to treat jowls and firm the jawline, under aye area, and around the mouth.
224203106|NCT06023303|DEVICE|Morpheus|The Radiofrequency microneedling device will be used for treating several skin problems. It is mostly used on the face and neck, specifically to treat jowls and firm the jawline, under aye area, and around the mouth.
224203107|NCT02469675|DEVICE|Transcranial magnetic stimulation|One TMS pulse every 10 seconds for 20 minutes
224203108|NCT02469675|DEVICE|Median nerve stimulation|One median nerve pulse every 10 seconds for 20 minutes
223510828|NCT03815604|BEHAVIORAL|Residential Care Settings and other Treatment as Usual (RCS/TAU)|Placement in a common residential home or supportive housing setting with the aim to gain psycho-social stability before being able to maintain independent housing.
223616872|NCT00346216|DRUG|Naproxen|naproxen 375mg to 500 mg twice daily, taken by mouth
223616873|NCT01866371|PROCEDURE|Retinal imaging|Retinal imaging procedures include adaptive optics imaging, optical coherence tomography and fundus photography.
223616874|NCT02166099|PROCEDURE|Choledochoscopy using Digital Spyglass|Choledochoscopy using Digital Spyglass during Endoscopy
223761210|NCT02196272|BEHAVIORAL|Nurse-led reminder program through email|"Both groups will receive an educational program and usual care. The educational program will consist of:~\- 1-hour session, during which the NCM give advices and enphasize the importance of the correct procedure of glycemic control, report non-pharmacological strategies for a healty lifestyle and instruction on how to fill a self assessment form."
224312732|NCT02398383|OTHER|Oral Glucose Tolerance Test|Subjects will be instructed to fast after midnight the night prior to the study. Subjects will be admitted to the research unit on the morning of the test for placement of blood-drawing IV for frequent sampling. Patients will drink 1.75 gm/kg glucose (Glucola) to a maximum of 75 gm. Venous samples for glucose and c-peptide will be drawn from the IV at 0, 30, 60, 90 and 120 minutes. Subjects will be instructed to eat at least 75 gm carbohydrates daily in the week prior to this test.
224203109|NCT02469675|DEVICE|Cervical transcutaneous stimulation|One cervical pulse every 10 seconds for 20 minutes
223510829|NCT01649583|DEVICE|Jaw Dynasplint System|Patients on the intervention arm will wear the Jaw Dynasplint® System for 30 minutes, 3 times per day each day during the cancer treatment period and for the first 3 months after primary or adjuvant based-radiation treatment (recovery period) is completed. Patients will maintain a daily patient log indicating the amount of time they used the Jaw Dynasplint® System.
224203110|NCT01715259|DRUG|Abiraterone acetate: participants with end-stage renal disease|abiraterone acetate 1000 mg (4 x 250 mg tablets) taken by mouth as a single dose in the fasted state on Day 1
224203111|NCT01715259|DRUG|Abiraterone acetate: matched control participants with normal renal function|abiraterone acetate 1000 mg (4 x 250 mg tablets) taken by mouth as a single dose in the fasted state on Day 1
223510830|NCT01210911|DRUG|gemcitabine|Gemcitabine at a dose of 1000 mg/m2 (iv, 30 minutes) will be given weekly, for 3 weeks, followed by one week without gemcitabine
223510831|NCT01210911|DRUG|erlotinib|Erlotinib will be administered at a daily dose of 100 mg at least one hour before or 2 hours after the ingestion of food
223510832|NCT01210911|DRUG|metformin|Metformin will be administered at a dose of 500 mg twice daily for the first week. If tolerated well, the dose will be increased up to 1000 mg twice daily in the second week.
223761211|NCT01147185|DEVICE|Locomotor training using a robotic device|50min walking time, 3-5 trainings/week.
223761212|NCT01147185|DEVICE|Locomotor training using a robotic device|25min walking time, 3-5 trainings/week.
223761213|NCT05714488|DEVICE|blue halo coil catheter|device inserted with coil at the bladder and straight arm in the prostatic urethra proximal to the external sphincter
223761214|NCT01155895|DRUG|Amlodipine Besylate / Benazepril Hydrochloride|10 mg Amlodipine Besylate / 20 mg Benazepril Hydrochloride Capsules
224203112|NCT05202600|PROCEDURE|Appendectomy|Surgical removal of the vermiform appendix.
224203113|NCT05349032|DIETARY_SUPPLEMENT|Curcumin|Oral supplement
224203114|NCT00864409|DRUG|ropivacaine 0,2%|Local wound infiltrtation with 170 mL ropivacaine 2 mg/mL
224203115|NCT00864409|DRUG|saline.9%|Wound infiltration with 170 mL sterile saline
224203116|NCT00254488|DRUG|Lithium (LI)|The starting LI dose will be 150 mg in the morning and evening. The dose of medication will be adjusted to achieve plasma LI level ranges between 0.40 and 0.99 mEq/L (target 0.80 to 0.99 mEq/L).
224203117|NCT00254488|DRUG|Divalproex (DV)|Dosage of DV will be 250 mg in the morning and evening. The dose of medication will be adjusted to achieve plasma DV level ranges between 40 and 99 mcg/mL (target 80 to 99 mcg/ml).
224203118|NCT05776732|OTHER|3M CaviionTM|3M CaviionTM is mainly composed of acrylate trimer, non-toxic, alcohol-free, and compatible with chlorhexidine gluconate and povidone iodine.
224203119|NCT03540407|DIETARY_SUPPLEMENT|Oncoxin-Viusid®|Administration of the Oncoxin-Viusid® oral solution 25 mL three times a day during the concurrent Radiotherapy and Chemotherapy treatment and up to 3 weeks after the end of the onco-specific treatment
224203120|NCT03540407|DIETARY_SUPPLEMENT|Placebo|Administration of the Oncoxin-Viusid® oral solution placebo 25 ml three times a day during the concurrent Radiotherapy and Chemotherapy treatment and up to 3 weeks after the end of the onco-specific treatment
224203121|NCT02491307|OTHER|Ginger.io Smartphone Application|Daily use of the Ginger.io smartphone application
224203122|NCT05066607|DRUG|Isatuximab|Patient will receive the association of Isatuximab, Pomalidomide and Dexamethasone during 9 or 12 cycles.
224203123|NCT02470078|DEVICE|Phagenyx-Catheter, Phagenesis Limited, UK.|Pharyngeal electrical stimulation via an intraluminal catheter (Phagenesis Ltd.) once daily for 10 minutes on three consecutive days. The intensity of the electrical stimulation is determined following the calculation of suitable sensory threshold, tailored to the individual patients. After determining the optimal stimulation intensity, 10 minutes of stimulation are delivered.
224203124|NCT02470078|DEVICE|Sham stimulation|The intraluminal catheter (Phagenesis Ltd.) for pharyngeal electrical stimulation is placed. In the sham group the optimisation procedure was imitated as closely as possible to mitigate any bias or effect of time spent interacting with the patient during PES, but no current was applied. After this procedure 10 min of sham stimulation were delivered.
224203125|NCT00561093|DRUG|pentoxiphylline|pentoxiphylline 400 mg daily, anti-inflammatory and appetite-stimulating while subjects undergo thrice weekly hemodialysis and during the following non-dialysis day (6 days per week)
224203126|NCT00561093|DIETARY_SUPPLEMENT|Nepro|Nepro (8 ounces) one can while undergoing thrice weekly hemodialysis and during the following non-dialysis day (6 days per week)
224203127|NCT00561093|DIETARY_SUPPLEMENT|anti-inflammatory module (similar to Oxepa)|Oxepa-similar anti-inflammatory module (2 ounces) while undergoing thrice weekly hemodialysis and during the following non-dialysis day (6 days per week)
224203128|NCT00561093|DRUG|Placebo pill imitating pentoxiphylline|Placebo pill imitating pentoxiphylline 400 mg daily, to imitate the anti-inflammatory and appetite-stimulating pill while subjects undergo thrice weekly hemodialysis and during the following non-dialysis day (6 days per week)
224203129|NCT00561093|DIETARY_SUPPLEMENT|Placebo to imitate Nepro|Placebo to imitate Nepro (8 ounces), with less protein and calorie, one can while undergoing thrice weekly hemodialysis and during the following non-dialysis day (6 days per week)
224203130|NCT00561093|DIETARY_SUPPLEMENT|Placebo to imitate anti-inflammatory module (similar to Oxepa)|Placebo to imitate Oxepa-similar anti-inflammatory module (2 ounces), without anti-inflammatory or anti-oxidative ingredients, while undergoing thrice weekly hemodialysis and during the following non-dialysis day (6 days per week)
223616875|NCT00904813|RADIATION|Short-course RT|Preoperative radiotherapy (RT) given 5 times 5 Gray during five consecutive days, preferably Monday - Friday, with a four-field box technique, including the primary tumour and the primary and secondary lymph nodes in the pelvis.
223616876|NCT00904813|RADIATION|Long-course RT|Preoperative radiotherapy (RT) given 2 Gy in 25 fractions during 5 weeks, total dose 50 Gy with a four-field box technique, including the primary tumour and the primary and secondary lymph nodes in the pelvis.
223616877|NCT03909893|RADIATION|Adaptive Radiation Therapy|Cone-beam CT images as well as MRI scans will be used to make any changes to the radiation treatment plan, part of the way through the treatment. Adaptation of treatment plans may allow smaller target volumes to be treated with higher doses, while minimizing the side effects to surrounding organs.
223616878|NCT00509184|DRUG|Rituximab|375 mg/m\^2, weekly (4 weeks), repeated after 4 weeks gap
223616879|NCT01198197|DRUG|NOP-1A|
223616880|NCT05681650|BIOLOGICAL|HypoSti.CAR-HER2 T cells|Dose escalation: dose -1 (1×10\^6 cells/kg) ,dose 1 (3×10\^6 cells/kg) , dose 2 (6×10\^6 cells/kg), dose 3 (1×10\^7 cells/kg), dose 4 (1.5×10\^7 cells/kg). Dose expansion: RP2D
223616881|NCT05681650|DRUG|Albumin-bound paclitaxel|Administered intravenously at dose of 100-200mg/m2 on day -5
223616882|NCT05681650|DRUG|Cyclophosphamide|Administered intravenously at a total dose of 15-30mg/kg on day -3 and day-2
223616883|NCT05681650|DRUG|Fludarabine|Administered intravenously at dose of 30mg/m2/d on day -3 and day -2 only in the first infusion of HypoSti.CAR-HER2 T cells
223616884|NCT04213300|OTHER|Low carbohydrate diet|"Study duration: 13 weeks (run in phase = 1 week; low carbohydrate diet phase = 12 weeks).~Each participant will be provided with an individualised meal plans to meet their energy needs as per the Schofield formula and a macronutrient distribution of 20% for carbohydrate, 25% for protein and 55% for fat.~Participants will self-report quality of life using a validated diabetes specific quality of life questionnaire for Australian adults and HbA1c (pre and post intervention phase of 13 weeks duration) ."
223616885|NCT01624116|DRUG|Acarbose|Tab.Acarbose 50mg BD for one day in addition to existing medication to 10% of patients in each treatment arm.
223616886|NCT01624116|OTHER|Diet and lifestyle|Patients would follow a 1200 KCal Ramadan diet plan, and exercise for 30 minutes per day
223616887|NCT01624116|DRUG|Metformin|Patients on metformin monotherapy prior to Ramadan will continue on it, in the same dose
223616888|NCT01624116|DRUG|Metformin/ Glimepride|Metformin 500mg and Glimepride 1mg in a combination tablet. Dosage frequency BD
223616889|NCT01624116|DRUG|Metformin/Sitagliptin|Metformin 500 and sitagliptin 50mg in a combination tablet,dosage frequency BD.
224203131|NCT06513988|DEVICE|MI-BCI combined with tDCS treatment|The treatment intervention was carried out in an independent and quite room and included following steps: During the MI-BCI based training, MI of leg flexion and extension training was first performed 10 times to accurate the training threshold, and then later in the formal BCI training, if the attention was reached the threshold, functional electrical stimulator was trigger to stimulate the corresponding muscle to execute the actual action. Additionally, the patient was given a brief training about how to operate tDCS device until he felt comfortable using it, and then asked to show and give feedback to the researcher. For motor function and pain improvement, tDCS is typically delivered with the anode electrode placed over the primary motor cortex (M1), and the cathode over the supraorbital area (SO) to trigger neuroplastic changes\[5\]. The MI-BCI combined with tDCS treatment was performed five days per week (in the late afternoon), and MI-BCI training for 30min.
223616890|NCT02043938|DEVICE|SedLine EEG sensor|Test subjects in each group will receive the same device intervention (SedLine EEG) to monitor their EEG waves.
223616891|NCT03202407|DRUG|Calcium acetate and sevelamer hydrochloride|receive the conventional renal replacement therapy including calcium-based phosphate (calcium acetate) and active form of vitamin D for 3 months with regular follow up of serum phosphate ,calcium, parathyroid hormone and alkaline phosphate every month
224203132|NCT01053078|DRUG|Naltrexone|1 month treatment; Naltrexone 25mg once daily for 5 days, then 50 mg once daily for 23 days
223616892|NCT02339311|OTHER|Educational intervention of Lifestyle and patient activation in diabetics|Participants underwent a one hour group didactic session led by Community Health Representatives (CHRs) who subsequently carried out monthly home-based educational interventions to encourage healthy lifestyles, including diet, exercise, and alcohol and cigarette avoidance until follow up at 6 months, when clinical phenotyping and the PAM survey were repeated.
223616893|NCT01107951|DRUG|Rituximab and dexamethasone|"Rituximab 100mg IV days 1,8,15,22.~Dexamethasone 40mg PO days 1-4 (four days)"
223616894|NCT03200119|BEHAVIORAL|Daily health-related lifestyle modification prescription|Daily health-related lifestyle modification prescription
223616895|NCT05098028|DRUG|Low Dose Rifaximin ER|Low Dose Rifaximin Extended Release Twice Daily
223616896|NCT05098028|DRUG|Low Dose Rifaximin DER|Low Dose Rifaximin Delayed Extended Release Twice Daily
223616897|NCT05098028|DRUG|High Dose Rifaximin ER|High Dose Rifaximin Extended Release Twice Daily
223616898|NCT05098028|DRUG|High Dose Rifaximin DER|High Dose Rifaximin Delayed Extended Release Twice Daily
223616899|NCT05098028|DRUG|Placebo|Placebo Twice Daily
223616900|NCT03788057|OTHER|ICS dose reduction|"If control of symptoms is maintained (evaluation based on clinical symptoms solely), every 3 months the dose of ICS is halved according to GINA guidelines, until the control is lost or the lowest daily dose is reached (200 mcg, calculated as budesonide equivalent).~In the case of loss of asthma control, beta-mimetic will be administered (temporarily) and return to the chronic administration of the previous, twice higher dose of ICS is restored (or further increase of treatment). In severe exacerbations, inclusion of oral steroids will be considered."
223761215|NCT00739752|BEHAVIORAL|Non-Framed-Offered|Subjects received information only and are offered the vaccine.
223761216|NCT00739752|BEHAVIORAL|Non-Framed-Recommended|Subjects receive information only and are recommended the vaccine.
223761217|NCT00739752|BEHAVIORAL|Gain-Framed-Offered|Subjects receive gain-framed messages and are offered the vaccine.
224203133|NCT01053078|OTHER|Placebo|1 month treatment; placebo tablet once daily for 28 days
223761218|NCT00739752|BEHAVIORAL|Gain-Framed-Recommended|Subjects receive gain-framed messages and are recommended the vaccine.
223761219|NCT00739752|BEHAVIORAL|Loss-Framed-Offered|Subjects receive loss-framed messages and are offered the vaccine.
223761220|NCT00739752|BEHAVIORAL|Loss-Framed-Recommended|Subjects receive loss-framed messages and are recommended the vaccine.
224203134|NCT00471588|DRUG|Pramipexole, Amisulpride|Study Drug
224203135|NCT01642693|RADIATION|Low power laser in teeth after intrusive movement|Low power laser was aplied to premolar teeth under an intrusive movement to study histological changes and root resorption
224203136|NCT01642693|OTHER|Simulated laser in teeth with intrusive movements|Simulated laser in teeth with intrusive movements for histological and root resorption changes
224203137|NCT06568328|BIOLOGICAL|Chimeric Natural Killer Receptor Universal T-cells (CNK-UT)|"OUTLINE: This is a dose-escalation study of CNK-UT cells followed by a dose-expansion study.~1. Dose Escalation (Single Ascending Dose Study, SAD): During SAD study stage, the participants will be intravenous infused with CNK-UT cells (1\~10×10\^7 CNK+ cells/kg)with a3 +3 design to determine the maximum tolerated dose. During single ascending dose (SAD) study stage, the participants will receive a single dose of CNK-UT cells before the DLT observation period (21 days). If the participants do not experience DLT, they will be able to enter a multiple ascending dose (MAD) study stage.~2. Dose Expansion (multiple ascending dose study, MAD): During MAD study stage, the participants will receive multiple doses of CNK-UT cells. The dosage and frequency of drug administration in the dose expansion stage can be adjusted and determined according to the SAD study."
224203138|NCT06540183|PROCEDURE|Percutaneous intramyocardial septal radiofrequency ablation|Percutaneous intramyocardial septal radiofrequency ablation (PIMSRA) is an innovative minimally invasive ablation treatment. Under the real-time transthoracic echocardiography guidance, a radiofrequency electrode needle is introduced into the hypertrophied interventricular septum via the percutaneous intramyocardial approach. Then the needle tip is pushed to the target region of the interventricular septal (IVS) basal segment 8 to 10 mm from the subaortic valve. The main objective of PIMSRA is to reduce ventricular septal hypertrophy and left ventricular outflow tract obstruction by means of thermal ablation.
224203139|NCT05725577|OTHER|care via the telemedicine system|Care via the telemedicine system
224312733|NCT02398383|OTHER|Mixed Meal Tolerance Test|Subjects will be instructed to fast after midnight the night prior to the study. Subjects will be admitted to the research unit on the morning of the test for placement of blood-drawing IV for frequent sampling. Subjects will consume 6 kcal/kg (6 ml/kg) Boost High Protein Nutritional Energy Drink (Mead-Johnson) over five minutes to a maximum of 360 ml. Venous samples for glucose, glucagon, GLP-1, GIP, and c-peptide will be drawn at -10, 0, 15, 30, 60, 90, 120, 150, 180, 210, and 240 minutes.
224312734|NCT02398383|OTHER|Hypoglycemic Clamp|All subjects with CF and adult (but not pediatric) controls will undergo one-step hypoglycemic clamp. Subjects will be instructed to fast after midnight the night prior to the study. Subjects will be admitted to the research unit on the morning of the test for placement of blood-drawing IV for frequent sampling and a second IV for infusion of insulin and dextrose.
224312735|NCT05156905|DRUG|Cirmtuzumab|Cirmtuzumab will be given in combination with docetaxel.
224312736|NCT00000978|DRUG|Zidovudine|
224312737|NCT00000978|DRUG|Zalcitabine|
224312738|NCT01004653|BIOLOGICAL|H1N1 influenza A Vaccine (Split virion), Inactivated|100 elders were assigned to receive one dose of 15μg H1N1 influenza A Vaccine (Split virion), Inactivated
224312739|NCT06324851|DRUG|Drospirenone / Estetrol|Endometrial polyps underwent hysteroscopic polipectomy after starting 14-day treatment with oral Drospirenone/Estetrol at any time of the menstrual cycle
223616901|NCT03985761|BEHAVIORAL|Home Telerehabilitation using HoVRS|The Home Virtual Rehabilitation System (HoVRS) integrates a Leap Motion controller, a passive arm support and a suite of custom designed hand rehabilitation simulations. The Leap Motion provides camera based measurement of finger joint positions, allowing for integrated virtual arm and finger training. If the patient's arm is severely impaired, a forearm orthosis that counter-balances gravity to provide graded support to the arm during activity is issued to the subject. In this study, we utilize 3 task-based simulations that train hand manipulation and arm transport. One simulation trains hand opening integrated with pronation and supination, a second trains wrist movement, by presenting targets that subjects navigate a plane over and around buildings to collect, a third simulation, trains shoulder and elbow disassociation in a horizontal plane integrated with hand opening.
223616902|NCT00127023|BIOLOGICAL|Measles, Mumps, Rubella and Chickenpox (live vaccine)|
223616903|NCT03400852|DRUG|MNK-1411|MNK-1411 (1 mg/mL suspension) for subcutaneous injection
223616904|NCT03400852|OTHER|Placebo|Placebo suspension for subcutaneous injection
223616905|NCT02803736|DEVICE|acupuncture|Acupuncture involves the insertion of extremely thin needles through skin at strategic points on human body. Many Western practitioners view the acupuncture as a device to stimulate nerves, muscles and connective tissue, and believe that it can increases blood flow.
224203140|NCT05725577|OTHER|Routine care|Routine care
224203141|NCT03232554|DRUG|Buxue Yimu Pills|Buxue Yimu Pills 12g pill by mouth, twice daily.
224203142|NCT03232554|DRUG|Buxue Yimu Pills &Ferrous Sulfate|Buxue Yimu Pills 12g pill by mouth, twice daily and Ferrous Sulfate 0.3g tablet by mouth, three times daily
224203143|NCT03232554|DRUG|Ferrous Sulfate|Ferrous Sulfate 0.3g tablet by mouth, three times daily
224203144|NCT06568653|PROCEDURE|exosome|human placenta mesenchymal stem cell-derived exosome
224203145|NCT06568653|PROCEDURE|routine conventional fistulotomy|routine conventional fistulotomy
224203146|NCT06541483|PROCEDURE|Ultra-Fast-Track Cardiac Anesthesia(UFTCA)|(UFTCA)The researcher removed the endotracheal tube either immediately or within 1 hour of the end of the procedure.
224203147|NCT06541483|PROCEDURE|conventional general anesthesia (CGA)|(CGA)The researcher not extubated at the end of the operation and were admitted to the ICU under anesthesia with an endotracheal tube.
224312740|NCT06324851|DRUG|Nomegestrol Acetate / Estradiol|Endometrial polyps underwent hysteroscopic polipectomy after starting 14-day treatment with oral Nomegestrol Acetate/Estradiol at any time of the menstrual cycle
224312741|NCT06324851|DRUG|Ethinylestradiol / Dienogest|Endometrial polyps underwent hysteroscopic polipectomy after starting 14-day treatment with oral Ethinylestradiol/Dienogest at any time of the menstrual cycle
224312742|NCT03831165|COMBINATION_PRODUCT|Melatonin 3 mg|melatonin and placebo
223761221|NCT04222582|DEVICE|Transcranial direct current stimulation (tDCS)|Transcranial direct current stimulation (tDCS) is a non-invasive form of brain stimulation which uses a weak current (2mA direct current) to temporarily excite or inhibit underlying brain regions with small electrodes placed on the scalp.
224312743|NCT03831165|DRUG|Acyclovir|Only acyclovir 200 mg twice a day
224312744|NCT02573844|DRUG|Proklama|
224312745|NCT02573844|DRUG|Placebo|
223616906|NCT02484066|DEVICE|VBN|VBN is carried out by a VBN software（DirectPath; Olympus, Japan) which can automatically create virtual bronchoscopic images.
223616907|NCT02484066|DEVICE|EBUS-GS|EBUS is performed using an endoscope ultrasound system , which is equipped with a 20-MHz mechanical radial-type probe (UM-S20-17S;Olympus) with an external diameter of 1.4 mm and a GS (K-201; Olympus).
223616908|NCT02484066|DEVICE|X-ray|The radiograph fluoroscopy are performed when the probe and GS are confirmed to reach the lesion by EBUS images ,cytologic and pathologic specimens are obtained under fluoroscopic guidance.
223616909|NCT05117736|DRUG|Sacubitril / Valsartan Oral Tablet|For the first phase of the trial, each patient will be randomized to active therapy (50, 100, or 200 mg bid of Sacubitril/Valsartan based on the run-in phase) or the corresponding placebo (matching tablets for the 50,100 or 200mg of Sacubitril/Valsartan), with the sequence reversed in the second phase.
223616910|NCT05117736|DRUG|Placebo|Corresponding placebo: matching tablets for the 50,100 or 200mg of Sacubitril/Valsartan.
223616911|NCT03941496|DRUG|Azacitidine Injection|"In Phase Ib dose escalation stage, 24 participants will receive AZA subcutaenously once a day for 5 days as follows:~1. 5 mg/m\^2~2. 15 mg/m\^2~3. 30 mg/m\^2~4. 50 mg/m\^2~5. 75 mg/m\^2~Results from Phase Ib are sent to FDA/IRB for approval before proceeding to Phase IIa. 36 subjects will receive AZA treatment in total (Phase Ib/IIa). Subjects in Phase II will receive a dose that induces two of the three following:~1. a decrease DNA methylation levels in genes previously identified to be persistently hyper-methylated despite successful anti-TB therapy~2. an increase in TNF and IFN-γ signaling pathways~3. an increase in ex vivo mycobacterial growth inhibition assay"
223616912|NCT00248495|DRUG|cisplatin|Given IV
223616913|NCT00248495|DRUG|pemetrexed disodium|Given IV
224312746|NCT04043130|BEHAVIORAL|Pulse|The intervention provides participants access to Pulse, a web-based mobile health app designed for Black and Latinx women ages 18-20. Participants can access the app autonomously and on their own schedule. The app for the experimental arm, the Pulse treatment app, provides information on birth control, healthy relationships, sexual health and physiology, pregnancy, and utilization of clinical services. The app for the comparator arm, the Pulse control app, provides information on general health topics, such as the importance of sleep, healthy eating, and friendships. Participants receive MMS messages that reinforce app content and remind them to visit the app.
223616914|NCT00248495|PROCEDURE|adjuvant therapy|Metastasis prevention/control
223616915|NCT00248495|PROCEDURE|conventional surgery|Undergoing tissue removal
223616916|NCT00248495|PROCEDURE|neoadjuvant therapy|Tumor Reduction
223616917|NCT03812380|DRUG|EffCaMgCit|Each sachet of EffCaMgCit will contain 19 meq or 380 mg calcium, 10 meq (122 mg) magnesium, and 50 meq total citrate.
223616918|NCT03812380|OTHER|Placebo|Each sachet of Placebo will contain microcrystalline cellulose, but no calcium, magnesium or citrate. Placebo will be added to 6 oz water for 1-2 minutes, to be dissolved/suspended before swallowing. The placebo will contain 400 units of vitamin D.
223616919|NCT03065777|DEVICE|ONE ENDO|single file rotary system
223616920|NCT03065777|DEVICE|F6 SKYTaper|single file rotary system
223616921|NCT03065777|DEVICE|ProTaper Universal|multi-file rotary system
224203148|NCT04404530|DRUG|Palynziq|Participants will take Palynziq as prescribed by their genetics doctor. In accordance with the Palynziq Risk Evaluation and Mitigation Strategy (REMS) protocol, patients will have their first injection of Palynziq at the Emory Genetics Clinic under the supervision of a physician. After initiating therapy, patients will continue to mail in blood spot filter papers and 3-day dietary records to their clinic providers as standard components of clinical care.
224203149|NCT01033201|OTHER|Confocal imaging|At the time of the standard of care bronchoscopy, confocal images will be obtained from each consented patient.
224203150|NCT04061057|DRUG|Lidocaine|"Drug: 1. Lidocaine Intravenous lidocaine bolus of 1.5mg/kg immediately after anesthesia induction followed by infusion at 2.0mg/kg/hr up to 1 hr after end of surgery.~2\. Fentanyl IV infusion via PCA (patient controlled analgesia) machine of fentanyl 10 μg/ml, ramosetron 0.3 mg, normal saline, total 100 ml, infusion rate 1 ml/hr, 1 ml bolus and lockout time 7 min."
224203151|NCT04061057|DRUG|Normal saline|"Drug: 1. Normal saline Intravenous normal saline bolus of immediately after anesthesia induction followed by infusion up to 1 hr after end of surgery. Volume of normal saline is equal to lidocaine.~2\. Fentanyl IV infusion via PCA (patient controlled analgesia) machine of fentanyl 10 μg/ml, ramosetron 0.3 mg, normal saline, total 100 ml, infusion rate 1 ml/hr, 1 ml bolus and lockout time 7 min."
224203152|NCT02312531|DRUG|Hepatitis B immunoglobulin|Hepatitis B immunoglobulin 200 IU injection at gestational week 20, 24, 28, 32, 34, 36, 38, 39, and 40 in HBIG group mothers.
224203153|NCT00388674|DRUG|entecavir|Tablets / Oral Solution, Oral, ETV = 0.5 mg - 1 mg, once daily, Investigator/Patient decision
224203154|NCT00388674|DRUG|Other anti-HBV medication|Tablets / Oral Solution, Oral, depends on chosen active comparator, depends on chosen active comparator, Investigator/Patient decision
223616922|NCT03617952|BEHAVIORAL|P3 Bio Intervention|Two types of improved biomass burning cookstoves (ACE1 and Greenway Jumbo) are offered to participants in both arms at varying prices.
223616923|NCT00308477|DRUG|dexamethasone|
223616924|NCT03662958|DRUG|Lutrate|a novel leuprolide acetate 3.75mg depot
223616925|NCT03662958|DRUG|Enantone|market reference leuprolide acetate 3.75 mg depot
223616926|NCT03318835|DRUG|Thalidomide combined with R-CHOP|rituximab 375 mg/m2,ivgtt D1 cyclophosphamide 750 mg/m2 iv D2 vincristine 1.4 mg/m2 \[capped at 2.0 mg\], iv D2 doxorubicin 50 mg/m2 iv D2 prednisone 100 mg/m2 per day PO D2-6 Thalidomide 200mg PO QN D1-21
223616927|NCT03318835|DRUG|R-CHOP|rituximab 375 mg/m2,ivgtt D1 cyclophosphamide 750 mg/m2 iv D2 vincristine 1.4 mg/m2 \[capped at 2.0 mg\], iv D2 doxorubicin 50 mg/m2 iv D2 prednisone 100 mg/m2 per day PO D2-6
223616928|NCT01683708|DIETARY_SUPPLEMENT|Symbiotic therapy|Patients randomized into the Symbiotic group received Prebiotic® in a dose of one sachet twice a day for at least 1 week preoperatively. Postoperatively the medication was reintroduced as tolerated, and continued until discharge from hospital. One 4,5 gr sachet of Prebiotic® contains at least 1010 living Bifidobacterium bifidum, 1010 living Streptococcus Thermophilus, 1010 living Streptococcus Salivarius, 3 109 Lactobacillus Acidophilus, 1010 living Lactobacillus Casei, 1010 living Lactobacillus bulgaricus and galactooligosaccharides (4,5 gr).
223616929|NCT04319367|DRUG|Investigational Medicinal Product|Recombinant human monoclonal antibody (mAb) or placebo
223616930|NCT03011281|DRUG|Tofacitinib|
223616931|NCT02648204|DRUG|semaglutide|Administered subcutaneously (s.c., under the skin) once-weekly.
223616932|NCT02648204|DRUG|Dulaglutide|Administered subcutaneously (s.c., under the skin) once-weekly.
223616933|NCT05625698|DRUG|MagTrace only|see information in arm descriptions
223616934|NCT05625698|COMBINATION_PRODUCT|MagTrace and Magseed|see information in arm descriptions
223616935|NCT00659802|DRUG|HMPL-004 low dose|HMPL-004, 400 mg (2 x 200 mg) t.i.d. (total of 1200 mg/day).
223616936|NCT00659802|DRUG|Placebo|Matching dose of Placebo
223616937|NCT00659802|DRUG|HMPL-004 high dose|HMPL-004, 600 mg (3 x 200 mg) t.i.d. (total of 1800 mg/day).
223616938|NCT01512199|DRUG|U3-1287|U3-1287: 18 mg/kg administered intravenously once every three weeks
223616939|NCT01512199|DRUG|Trastuzumab|Trastuzumab: 6 mg/kg up to 8 mg/kg administered intravenously once every three weeks
223616940|NCT01512199|DRUG|Paclitaxel|Paclitaxel: 175 mg/m\^2 administered intravenously once every three weeks
223616941|NCT01512199|DRUG|U3-1287|The maximum tolerated dose as determined in Phase 1b portion (between 9 mg/kg and 18 mg/kg) administered intravenously once every three weeks
223616942|NCT01512199|DRUG|Trastuzumab|Trastuzumab: 6 mg/kg up to 8 mg/kg administered intravenously once every three weeks
223616943|NCT01512199|DRUG|Paclitaxel|Paclitaxel: 175 mg/m\^2 administered intravenously once every three weeks
224312747|NCT00581126|DRUG|Recombinant Factor IX Coagulation|Benefix IV each 12 hours for 2 a 5 days
223616944|NCT01512199|DRUG|Placebo|Placebo: Dose corresponding to U3-1287 administered intravenously once every three weeks
223616945|NCT03002441|DEVICE|Same-Day Dilapan-S|Dilapan-S cervical dilators placed the same day as the D\&E procedure
223616946|NCT03002441|DEVICE|Overnight Dilapan-S|Dilapan-S cervical dilators placed the day prior to D\&E procedure
223616947|NCT01359345|DRUG|gadollinum|use of on injection gadollinum Iv for imaging
224203155|NCT02454322|DRUG|Magnesium Sulfate|Standard of care Magnesium Sulfate given to women with a diagnosis of a hypertensive disorder of pregnancy.
224203156|NCT02726672|DEVICE|respiratory rehabilitation using Powerbreathe|10 minutes 2 times a day : 30 inspirations per session during 10 weeks
224312748|NCT01399567|BEHAVIORAL|Algorithm|The NH pain management algorithm is a series of decision-making tools that begin with regular, comprehensive pain assessment matched to residents' cognitive status and proceed through analgesic therapy appropriate to the character, severity, and pattern of pain.
224312749|NCT02432053|DRUG|Advagraf|
223616948|NCT02161835|OTHER|Training|30 minutes of home based pulse watch regulated cycle-ergometer exercise, three times a week at 75% of maximal oxygen consumption.
223616949|NCT01909999|PROCEDURE|Osteogenic markers Evaluation|"The collection of peri-implant crevicular fluid (PICF) was performed immediately after implant insertion (Baseline) and after 7, 15, 30, 60, 90 and 120 days. The site to be collected was dried and isolated with sterile gauze. PICF was collected at four sites per implant using absorbent paper strips (Periopaper, Oralflow, Smithtown, New York). The volume of fluid was measured immediately with the aid of Periotron (Oraflow, Smithtown, New York) and conditioned at 400uL of PBS buffer + 0.05% Tween and then frozen at -80°C.~The levels of the peri-implant osteogenic markers (OPG, OCN, OPN, TGF-α, and PTH) were determined using the LUMINEX/Magpix system (HBN1A-51K and HCCBP1MAG-58K, Millipore Corporation, Billerica, MA, USA)."
223616950|NCT01909999|PROCEDURE|Clinical parameters evaluation|"The following parameters were assessed:~1. Peri-implant sulcus depth (PISD): distance from the margin of the peri-implant mucosa to the bottom of the peri-implant sulcus;~2. Modified Bleeding on Probing Index: the presence or absence of bleeding after 10 seconds on probing around implants."
223616951|NCT01909999|PROCEDURE|Implant instalation|The surgeries, as well as all postoperative follow-up, were performed at the dental clinic of UNIP-SP. Surgical areas were anesthetized (2% mepivacaine with 1:100,000 epinephrine) and mucoperiosteal incisions in the alveolar ridge mucosa were made. The surgical sequence follow the protocol described by the implant company supplier of implants (SIN - São Paulo, SP, BR). In all cases, for maxilla rehabilitation, 6 implants were installed, while, for mandible, 5 were used.
223616952|NCT01909999|PROCEDURE|Prosthesis installation|The patients in the IM Group received Brånemark protocol prosthesis within 3 days after the implant. The implants were first molded and the models sent for prosthesis confection (LABDENTAL, São Paulo, SP, Brazil). All prosthesis used straight mini-abutments (SIN, São Paulo, SP), that ranged from 1mm to 4mm in height, whose were tightened with 20N of torque, followed by occlusal adjustment and clinical monitoring
223616953|NCT01909999|PROCEDURE|Suture|Soft tissues sutures were done using absorbable polygalactin 910 suture.
223616954|NCT01909999|DRUG|Post-operative care|"Postoperative care were: amoxicillin 500 mg (8-8 hours/7 days); sodic dipyrone 500mg (6-6 hours/3 days); 0.12% Chlorhexidine mouthwash"
223616955|NCT00494585|DRUG|CEP-701|80 mg orally twice a day for 30 days
223616956|NCT04557800|DRUG|DNL151|oral dose(s)
223616957|NCT04557800|DRUG|Placebo|oral dose(s)
224312750|NCT00256113|DRUG|Saredutant succinate (SR48968C)|
223616958|NCT00112372|DRUG|Ridaforolimus|10 mg tablet of ridaforolimus administered orally according to one of several different dosing regimens for a four-week treatment cycle.
223616959|NCT02248805|DRUG|MGD007|MGD007 is a gpA33 x CD3 bi-specific antibody-based molecular construct referred to as a DART molecule. MGD007 will be administered as a single agent.
224203157|NCT01728363|DRUG|Antibiotic|Ticarcillin-clavulanate/Timentin is an antibiotic used to treat a wide variety of bacterial infections. Rifampin/Rifadin/Rimatane is an antibiotic and first line antituberculotic. Clindamycin/Cleocin is an antibiotic used to treat a wide variety of bacterial infections and serious bacterial infections.
224203158|NCT00002902|DRUG|irinotecan hydrochloride|
224203159|NCT00002902|DRUG|raltitrexed|
224203160|NCT00504842|DRUG|MRX-801|
224203161|NCT00504842|DRUG|Placebo|
224203162|NCT00219752|DRUG|Imatinib mesylate 400 mg|
224203163|NCT04058600|BEHAVIORAL|Virtual Reality Software|Patients will be exposed to a virtual reality software that simulates the hospital environment, from admission to the operating room and the recovery room.
224312751|NCT03551821|DRUG|ATI-50002|Topical Solution
224312752|NCT03857750|DRUG|Rocuronium|0.6 mg/kg
224312753|NCT02826772|DRUG|GT0918|anti-tumor activity
224203164|NCT03686137|OTHER|Data collection|Colelction of pre-operative, surgical and post-surgical data
224203165|NCT06672198|PROCEDURE|ERAC protocol|our study aimed to evaluate pre-peri-post operative practices in women who underwent elective cesarean section (CS) according to the ERAC protocol. In this context, this study aimed to describe the implementation status of the recommendations regarding the ERAC protocol in CS operations, to identify the missing aspects of the ERAC protocol and to raise awareness about its benefits.
224203166|NCT01474148|DEVICE|IRS-8 (8-Channel implanted stimulator-telemeter)|Surgical implantation of the 8-channel neuroprosthesis
224203167|NCT03435822|OTHER|asthma action plan management group|Patients will follow the directions in asthma action plan when their asthma get worse.
224203168|NCT03435822|OTHER|conventional management group|Patients will follow the directions in conventional strategy when their asthma get worse.
224203169|NCT01068795|DRUG|enoxaparin|enoxaparin dosage will be adjusted according to anti-factor Xa plasma levels
224312754|NCT06634186|DIETARY_SUPPLEMENT|Dietary intervention|The aim of the dietary intervention is the implementation of a fiber-enriched diet. Therefore, patients receive dietary counseling, supplemented with propionate, that functions as fiber-surrogate.
223510833|NCT01210911|DRUG|placebo|Placebo will be administered at a dose of 500 mg twice daily for the first week. If tolerated well, the dose will be increased up to 1000 mg twice daily in the second week.
223510834|NCT00132912|DRUG|SCH 530348|
223510835|NCT00949078|DRUG|omalizumab|omalizumab subcutaneously every 2-4 weeks depending on participant weight and total IgE
223510836|NCT05342688|BEHAVIORAL|Task-specific practice of upper extremity functions|The intervention will consist of training of items from the Wolf motor function test.
223510837|NCT04743895|DEVICE|Stainless Steel Wire Cerclage|Wire cerclage used to close sternum after cardiothoracic surgery.
224203170|NCT06542549|DRUG|AK104|The study treatment was followed by a 3-week treatment cycle. The dosing time window is ±3 days. Within 72 hours before each dosing cycle, subjects are required to complete various examinations, including vital signs, physical examination, laboratory examination, and physical status score, to evaluate the safety and tolerability of continued treatment.
224203171|NCT05430282|OTHER|Only vestibular rehabilitation|Vestibular adaptation exercises, static and dynamic balance exercises, proprioceptive and conditioning exercises.
224203172|NCT05430282|OTHER|Cervical exercises in addition to vestibular rehabilitation|Cervical range of motion exercises, stretching exercises for the trapezius muscle, isometric and isotonic strengthening exercises in addition to conventional vestibular rehabilitation exercises.
224203173|NCT05292079|DEVICE|CAPTURER|Patients in whom treatment with (CAPTURER) has been attempted
223510838|NCT04016428|BEHAVIORAL|OPTIMISM|Six-week online program that emphasizes mindfulness and skills for improving sleep during pregnancy.
223510839|NCT04016428|BEHAVIORAL|Sleep Education|Six-week online program that provides education on sleep during pregnancy.
223510840|NCT02365064|DEVICE|AirCurve 10 ASV|Device is able to provide both ASV therapy and CPAP therapy modes.
224203174|NCT04219956|OTHER|Polyamine Deficient Diet|Diet low in polyamines: the estimated calculated dose is 20 times lower that in an usual diet
224203175|NCT03568929|DRUG|Idelalisib|Tablets administered according to the product information and treatment guidelines in routine clinical practice
224203176|NCT06385665|BEHAVIORAL|Graded companionship|Accompanying levels are divided into beginner, intermediate and advanced
224203177|NCT00265863|DRUG|mitomycin C|Mitomycin C is infused into the abdominal cavity by hyperthermic perfusion over 60 minutes.
224203178|NCT00776269|PROCEDURE|argon laser and radiofrequency|
224203179|NCT05355987|OTHER|Early oncological supportive care|Several appointments (at diagnosis, 3 months, 6 months and 9 months) with nursing coordinator to define the needs in oncological supportive care. Different appointments will be planned according to patient's needs, with several possibilities: oncological supportive care nurse, social worker, psychologist, physiotherapist, adapted physical activity, medication reconciliation, oncologic geriatric medicine, dietician, nutritionist, smoking cessation advisor, sexologist, sophrologist, pain management nursing and palliative care, socio-aesthetician and religious cult coordinator.
224203180|NCT05355987|OTHER|Delayed oncological supportive care|Two appointments (6 months and 9 months) with nursing coordinator to define the needs in oncological supportive care. Different appointments will be planned according to patient's needs, with several possibilities: oncological supportive care nurse, social worker, psychologist, physiotherapist, adapted physical activity, medication reconciliation, oncologic geriatric medicine, dietician, nutritionist, smoking cessation advisor, sexologist, sophrologist, pain management nursing and palliative care, socio-aesthetician and religious cult coordinator.
224203181|NCT04955873|DEVICE|Treatment of the dental extraction socket using newly-released biomaterials|Treatment of the dental extraction socket with the combined use with the combined use of a newly-released xenogenic bone granules and a resorbable collagen membrane.
224203182|NCT04955873|DEVICE|Treatment of the dental extraction socket using well-known biomaterials|Treatment of the dental extraction socket with the combined use of a well-known xenogenic bone granules and a resorbable collagen membrane
224203183|NCT04628143|DRUG|Nafamostat Mesilate|Administered intravenously as a continuous infusion
224312755|NCT01696058|DRUG|Tiotropium|marketed product
224312756|NCT01696058|DRUG|Placebo matching Olodaterol|one dose
223510841|NCT06532344|DRUG|ONO-7913|Specified dose on specified days
223510842|NCT06532344|DRUG|ONO-4538|Specified dose on specified days
223510843|NCT06532344|DRUG|Oxaliplatin|Specified dose on specified days
223510844|NCT06532344|DRUG|Levofolinate|Specified dose on specified days
223510845|NCT06532344|DRUG|Irinotecan|Specified dose on specified days
223510846|NCT06532344|DRUG|Fluorouracil|Specified dose on specified days
223510847|NCT01688401|DRUG|Melphalan hydrochloride|"Drug administered intra-arterially (injection in the artery).~Standard dose: Cycle 1: 1 mg, intra-arterial (IA) delivery. Cycle 2: 2 mg, intra-arterial (IA) delivery.~Duration of treatment: Eight weeks total - two cycles of IA chemotherapy, separated by four weeks."
223510848|NCT00562198|DRUG|entacapone and carbidopa|Entacapone 200mg carbidopa 50mg
223510849|NCT00562198|DRUG|Sinemet 200mg/50mg|Sinemet 200mg/50mg once
223510850|NCT05889000|OTHER|questionnaire responses|questionnaire responses - Pelvic Varicose Veins Questionnaire (PVVQ) and Pelvic Venous Clinical Severity Score (PVCSS)
223616960|NCT06579430|DRUG|Indocyanine Green near infrared fluorescence imaging|ICG-NIRF was performed using the Quest Spectrum Platform 2.0. The camera lens was positioned at a fixed distance of 30 cm to the wound bed, at a perpendicular angle, with the gain set at 22.5 decibels (dB) and an exposure time of 50 milliseconds (ms). ICG was dissolved in sterile water at a concentration of 2.5 mg/mL as recommended by the manufacturer (Verdye). 1.5 mg of ICG per liter of circulating blood volume was then administered through manual bolus intravenous injection. Blood volume estimation was based on the patient\&amp;#39;s height and weight.
223616961|NCT06579430|DRUG|Indocyanine Green near infrared fluorescence imaging|"ICG-NIRF was performed using the Quest Spectrum Platform 2.0. The camera lens was positioned at a fixed distance of 30 cm to the wound bed, at a perpendicular angle, with the gain set at 22.5 decibels (dB) and an exposure time of 50 milliseconds (ms). ICG was dissolved in sterile water at a concentration of 0.5 or 2.5 mg/mL as recommended by the manufacturer. 1.5 mg of ICG per liter of circulating blood volume was then administered through manual bolus intravenous injection. Blood volume estimation was based on the patients height and weight. Different administration rates (fast: 2s, slow: 15-20s) and a different camera system were tested.~Group 1: Quest Platform 2.0; Fast/Slow; 2.5 mg/mL Group 2: Quest Platform 2.0; Slow/Fast; 2.5 mg/mL Group 3: Quest Platform 2.0; Fast/Fast; 2.5 mg/mL Group 4: Stryker Spy-Elite; Fast/Fast; 2.5 mg/mL Group 5: Quest Platform 2.0; Fast/Fast; 0.5 mg/mL"
223616962|NCT01578681|PROCEDURE|Low Expiration Open glottis inferolateral (ELTGOL)|Place the affected lung in infralateral, asks the patient to make an inspiration without being forced to medium volume, and then a slow expiration with the glottis open, down to residual volume. If the therapist is present place the abdominal caudal hand at putting pressure cranial head and hand is placed over the rib cage at a pressure of closing the rib cage. Otherwise, the patient self-administered intertwining arms and abdominal rib at top exerting the same pressure. In case you have two lungs affected the art will take place on one side and then the opposite.
223616963|NCT01578681|PROCEDURE|Stretching|Patient will be instructed to do muscle stretching of the thorax
223616964|NCT01507688|BEHAVIORAL|Stroke Self-Management|Stroke self-management program- Participants randomized to this program will receive 6 bi-weekly telephone sessions during the first 3 months followed by 3 monthly reinforcement telephone sessions coupled with 3 monthly group sessions during months 4-6.
223616965|NCT04402424|DIAGNOSTIC_TEST|Faecal Immunochemical Testing|Stool samples for both point of care and laboratory based faecal immunochemical testing via device specific sampling sticks
223616966|NCT01333228|OTHER|Autologous bone marrow-derived endothelial progenitor cells|Intraarterial administration (hepatic artery) of autologous bone marrow-derived endothelial progenitor cells
223616967|NCT02534415|DRUG|Periodontal dressing material|Procedure:Palatal wound area was covered with periodontal dressing material at baseline and 3rd day
223616968|NCT02534415|DRUG|0.2% Hyaluronic acid gel|0.2% topical hyaluronic-acid gel was applied to palatal wound area and covered with periodontal dressing material (Peripac®) at baseline and 3rd day
223616969|NCT02534415|DRUG|0.8% Hyaluronic acid gel|0.8% topical hyaluronic-acid gel was applied palatal wound area and covered with periodontal dressing material (Peripac®) at baseline and 3rd day
223616970|NCT05178199|BEHAVIORAL|RPSG|The RPSG program include sharing successful experience, progressive muscle relaxation (PMR), and mindfulness-based stress reduction (MBSR). The duration is at last 8 weeks and includes 1 hour per week of RPSG activities.
223761222|NCT04939285|PROCEDURE|PEEP|The patients who met the withdrawal screening criteria were randomly divided into low pressure support level PSV spontaneous respiration test.The duration of the spontaneous breathing test was 30 minutes, and the results of the spontaneous breathing test were evaluated at the end of the test.
223616971|NCT05178199|BEHAVIORAL|AVMBM|"The duration is also at last 8 weeks and includes encouraging to use 5 minutes Audio and Video Mindfulness of Breathing Meditation (AVMBM) per week."
223616972|NCT01514019|DRUG|Acebutolol|Acebutolol
223616973|NCT01514019|DRUG|Placebo|Placebo capsule(Capsules filled up with lactose)
223616974|NCT04966260|OTHER|Standardized Virtual Reality|This is a one session intervention, where participants will be asked to wear a VR headset and view a three-dimensional standard VR video. The activity session will be approximately 15 minutes in length. Prior to starting the intervention, the therapeutic recreation staff will explain the activity and familiarize participants with the VR headset.
224312757|NCT01696058|DRUG|Tiotropium|marketed product
223616975|NCT04966260|OTHER|Control|This is a one session intervention, where participants will be asked to view a two-dimensional video on an iPad. The activity session will be approximately 15 minutes in length. Prior to starting the activity session, the therapeutic recreation staff will explain the activity.
223616976|NCT04966260|OTHER|Personalized Virtual Reality|This is a one session intervention, where participants will be asked to wear a VR headset and view a three-dimensional personalized VR video. The activity session will be approximately 15 minutes in length. Prior to starting the intervention, the therapeutic recreation staff will explain the activity and familiarize participants with the VR headset.
223616977|NCT00580736|DEVICE|Optical Clearing|Optical Clearing
223761223|NCT00153400|BEHAVIORAL|Enhanced Lifestyle Intervention|Three face-to-face counseling sessions for nutrition and physical activity. Used a Spanish culturally tailored materials. These interventions were delivered by community health workers (CHWs) who are trained.
223761224|NCT03488212|BEHAVIORAL|Training to Identify Eligible Patients and Direct them to Online Obesity Treatment Program|Primary care clinic staff are trained to identify patients who meet study inclusion and exclusion criteria. They are then trained to provide patients with the information necessary to enroll in the study and access the online behavioral obesity treatment.
223761225|NCT03488212|BEHAVIORAL|Training to Motivate and Support Patients' Weight Loss|Primary care clinic staff are trained in psychological and behavioral strategies for: talking to patients about weight and weight loss in a way that patients find acceptable and helpful, increasing motivation for weight loss, overcoming common barriers to weight loss, and persevering with a weight loss attempt. They are trained in strategies to provide this support by telephone in addition to during clinic visits.
224312758|NCT01696058|DRUG|Olodaterol|one dose
224312759|NCT03482258|DIETARY_SUPPLEMENT|Prebiotic|A daily dose for 3 weeks -14.5g per day in powder form dissolved in 200ml water. This equates to 10g GOS (VGOS is primarily 69% GOS, 23% Lactose).
223616978|NCT02341235|BEHAVIORAL|Game intervention|The game will target motivation via narrative and game mechanics. It will also encourage self-regulation by providing monitoring and feedback of activity. Counseling will be adapted to specifically reference concepts related to narrative and games.
223616979|NCT02341235|BEHAVIORAL|Standard intervention|The electronic activity monitor will monitor steps, and the mobile device will provide basic feedback on progress toward goals. Counseling will be standard and concentrate on self-regulatory skill-building.
223616980|NCT02163824|DRUG|KPI-121 0.25%|KPI-121 drug product will be supplied as 0.25% as a suspension in identically packaged opaque dropper bottles. KPI-121 drug product is a sterile, aqueous, submicron suspension of loteprednol etabonate.
223616981|NCT02163824|DRUG|KPI-121 1.0%|KPI-121 drug product will be supplied as 1.0% as a suspension in identically packaged opaque dropper bottles. KPI-121 drug product is a sterile, aqueous, submicron suspension of loteprednol etabonate.
223616982|NCT02163824|DRUG|Vehicle of KPI-121 0.25%|Placebo control arms will receive the same bottles containing vehicle of KPI-121 including all components at the concentrations used in the KPI-121 drug product with the exception of the active component, loteprednol etabonate.
223616983|NCT02163824|DRUG|Vehicle of KPI-121 1.0%|Placebo control arms will receive the same bottles containing vehicle of KPI-121 including all components at the concentrations used in the KPI-121 drug product with the exception of the active component, loteprednol etabonate.
223616984|NCT04110912|OTHER|This is a registry and no interventions are taking place.|
223616985|NCT03470480|DEVICE|Real Repetitive transcranial magnetic stimulation|A real magnet will be used during rTMS treatments, which will look identical to the sham magnet. The participants and treatment facilitator will be blinded to which magnet will be used. High frequency repetitive transmagnetic stimulation (rTMS) will be directed at left dorsolateral prefrontal cortex (DLPFC) during 10 daily treatments within two weeks then 6 more treatments during the following month.
223761226|NCT03488212|BEHAVIORAL|Online Behavioral Weight Loss Intervention|For 3 months, participants receive: a weekly online lessons for training in behavioral skills for losing weight; online self-monitoring of daily weight, diet, and physical activity; weekly feedback on the self-monitoring record.
224312760|NCT03482258|DIETARY_SUPPLEMENT|Maltodextrin|A daily dose for 3 weeks -14.5g per day in powder form dissolved in 200ml water. This will be matched to VGOS for lactose (3.3g per dose of maltodextrin will be lactose).
223616986|NCT03470480|DEVICE|Sham Repetitive transcranial magnetic stimulation|A sham magnet will be used during rTMS treatments, which will look identical to the real magnet. The participants and treatment facilitator will be blinded to which magnet will be used. The sham rTMS treatments will be directed at left dorsolateral prefrontal cortex (DLPFC) during 10 daily treatments within two weeks then 6 more treatments during the following month.
223616987|NCT03470480|BEHAVIORAL|Methamphetamine visual cues|Just before each rTMS session, participants will be shown methamphetamine-related pictures
223616988|NCT03470480|BEHAVIORAL|Neutral visual cues|Just before each rTMS session, participants will be shown neutral pictures
223616989|NCT02726763|DEVICE|Transcranial Direct Current Stimulation (tDCS)|
223616990|NCT02726763|BEHAVIORAL|Questionnaires|
223616991|NCT02366312|DRUG|vismodegib|vismodegib is a synthetic, small molecule inhibitor of the sonic Hh pathway, which is involved in tumorigenesis, thus providing a strong rationale for its use in the treatment of a variety of cancers.
223616992|NCT03518294|BEHAVIORAL|Aerobic Exercise|Subjects in the aerobic exercise group will be supervised to exercise 30 minutes, 5 times per week at a moderate intensity. Formal exercise instruction and supervision will be provided by ACSM certified fitness professionals at the Penn State University Fitness Center. Aerobic exercise can be completed on either the treadmill, exercise bike, rowing machine or the elliptical machine.
223616993|NCT04254224|PROCEDURE|colon resection, stoma|oral or intravenous antibiotics treatment with or without percutanous or transrectal or transvaginal drainage
224312761|NCT03815734|PROCEDURE|motor imagery|motor imagery during the postoperative immobilization period
223616994|NCT03324243|DRUG|Crenolanib|66.7 mg/m2 three times a day (TID)
223616995|NCT03324243|DRUG|Fludarabine|30 mg/m2/day, intravenous infusions over 30 mins.
223616996|NCT03324243|DRUG|Cytarabine|2000 mg/m2/day, intravenous infusions over 1-3 hours.
223616997|NCT05147376|DRUG|Curcumin mouthwash|Rinse with 10 ml for 1 minute, twice a day for 28 days after brushing in the morning and at night, following proper oral hygiene and avoid taking any liquid or food for 30 minutes after rinsing.
223616998|NCT05147376|DRUG|Placebo mouthwash|Rinse with 10 ml for 1 minute, twice a day for 28 days after brushing in the morning and at night, following proper oral hygiene and avoid taking any liquid or food for 30 minutes after rinsing.
223616999|NCT04222296|DEVICE|Fitting strategy of cohlear implant of hearing aid|To determine whether new hardware and fitting strategy provides better sound quality or ease of use than generic hardware and fitting methods
223617000|NCT02581306|OTHER|Exercise session|There is no drug or device intervention in this study. Subjects will exercise at a moderate intensity for 60 minutes and a blood sample will be obtained before and after the exercise session
223617001|NCT06357702|BEHAVIORAL|Physical Self Regulation Telehealth|2 sessions of an intervention delivered via telehealth. Session 1 includes awareness and strategies for monitoring habits and 4 exercises to practice 5 times per day. Session 2 will be 2 weeks later and is a review of session 1 and an introduction to diaphragmatic breathing. Breathing is practiced for 15 minutes twice per day.
223761227|NCT03488212|BEHAVIORAL|Control Intervention for Weight Loss Maintenance and Weight Gain Prevention|After completing the 3-month Online Behavioral Weight Loss Intervention, participants receive 9 months of: monthly online newsletters with educational information pertaining to healthy weight, diet, and physical activity habits.
223761228|NCT03488212|BEHAVIORAL|Monthly Lessons and Feedback Intervention for Weight Loss Maintenance and Weight Gain Prevention|After completing the 3-month Online Behavioral Weight Loss Intervention, participants receive 9 months of: monthly online lessons for training in behavioral skills for maintaining weight loss and preventing weight gain; online self-monitoring of daily weight, diet, and physical activity; monthly feedback on the self-monitoring record.
224203184|NCT06567288|PROCEDURE|spencer mscle energy technique|The effectiveness of MET found in chronic capsulitis is due to its effect on relieving pain, ensuring ROM incretions, and developing functional activities due to the muscle contraction in a precise direction and in a monitored position over resistance to assist in improving joint range by advancing joint flexibility. This procedure is suggested for all joints with limited ROM (Butt \& Tanveer, 2022).
224203185|NCT01777607|DEVICE|IMPELLA® RP|
224203186|NCT04243005|PROCEDURE|Supramarginal resection|Aim of supramarginal resection, where a margin of at least 10 mm is considered feasible prior to surgery. The resection is guided by the T2 volume (i.e. zone of edema) where removal of as much as possible of this zone (or beyond) is attempted as long as considered safe
224203187|NCT04243005|PROCEDURE|Conventional surgery|Aim of gross total resection (i.e. removal of contrast enhancing tumor) according to institutional practice. No limit in use of technical adjuncts in this arm.
224203188|NCT06701227|OTHER|In Situ Simulation|"The simulation scenario included briefing (5 min), scenario (10 min), and debriefing (20 min).~Materials and Simulators: neonatal mannequin, with its crying controlled by a smartphone; breastfeeding simulator that had the function of ejecting liquid imitating human milk.~Team: One facilitator and one actor playing a Community Health Worker."
224203189|NCT02426827|DEVICE|Spinal Cord Stimulation|
224203190|NCT04552080|DRUG|Amoxicillin|Preoperatively antibiotics of 2 g amoxicillin 1 hour prior to standard implant placement and sinus floor Elevation will be administered. An additional single dose of 500 mg of amoxicillin will be administered 8 hours after surgery and 500 mg thrice daily (8 hourly) on days 1 to 3 following implant placement and sinus floor elevation.
223510851|NCT04799639|DRUG|Sindilimab +paclitaxel+ cisplantin|standard dose paclitaxel + cisplantin + Sindilimab every 3 weeks for 3 cycles
223510852|NCT00465283|DRUG|Donepezil|Tab.Donepezil 5 mg once daily during ECT treatment and the month after the last ECT treatment
223510853|NCT00440739|DRUG|etoricoxib|etoricoxib 120 mg
223510854|NCT00440739|DRUG|flavoxate|flavoxate 200 mg 3 times
223510855|NCT00440739|DRUG|etoricoxib, flavoxate|etoricoxib 120 mg once and flavoxate 200 mg 3 times
223510856|NCT00440739|DRUG|placebo|placebo once and placebo 3 times
223510857|NCT01232842|GENETIC|cytogenetic analysis|
223510858|NCT01232842|OTHER|HUMARA assay|
223510859|NCT01232842|OTHER|fluorescence activated cell sorting|
223510860|NCT01232842|OTHER|laboratory biomarker analysis|
223510861|NCT04760236|BIOLOGICAL|Oral Cholera Vaccine Simplified (OCV-S)|"* Manufacturer: EuBiologics Co., Ltd.~* Oral administration"
223510862|NCT04760236|BIOLOGICAL|Shanchol™|"* Manufacturer: Shantha Biotechnics~* Oral administration"
223510863|NCT00005078|DRUG|carboplatin|
223510864|NCT00005078|DRUG|paclitaxel|
223510865|NCT00005078|DRUG|tirapazamine|
223510866|NCT05810649|DRUG|Freshly manufactured 35 kDa hyaluronan fragment|One hundred milligrams of the freshly made 35 kDa low molecular weight HA fragment HA35 was injected into the tissue under the heath skin immediately surrounding the chronic wounds once a day for 10 days.The pain associated with the wounds and degree of wound healing, including the size of the fresh granulation area on the wound; the degree to which the surface of the skin surrounding the wound was dark, red, dry or broken; and the size of the wound, were observed and recorded.
223510867|NCT05775575|DRUG|TQB3909 tablets|TQB3909 is an inhibitor targeting BCL-2 protein
223510868|NCT05667402|DRUG|TBF regimen|The subjects receive TBF conditioning regimen (Thiotepa, Busulfan, Fludarabine) before allo-HSCT.
223510869|NCT05667402|DRUG|modified BuCY2 regimen|The subjects receive modified BuCY2 conditioning regimen (Busulfan, Cytarabine, ATG, Cyclophosphamide, CCNU) before allo-HSCT.
223510870|NCT04744129|DRUG|NN414|To investigate the role of NN414 on cerebral hemodynamic in migraine patients
223510871|NCT04744129|DRUG|Saline|To investigate the role of NN414 compared with saline cerebral hemodynamic in migraine patients.
223510872|NCT01594814|PROCEDURE|RFA|radiofrequency ablation of slow pathway or accesory pathway
223510873|NCT03881878|DRUG|TAHP and AHP|"(A, Neoadjuvant setting): D1 X 6 cycles, q3weeks~* Docetaxel (75mg/m2, IV)~* Atezolizumab (1200mg, IV)~* Tastuzumab (600mg, SC)~* Pertuzumab (840mg loading dose at Cycle 1 followed by 420mg, IV)~(B, Adjuvant setting) : patients with pCR:D1 X 11-12 cycles, q3weeks~* Atezolizumab (1200mg, IV)~* Trastuzumab (600mg, SC)~* Pertuzumab (420mg, IV)"
223510874|NCT03881878|DRUG|TAHP plus AC and AHP|"(A, Neoadjuvant setting): D1 X 6 cycles, q3weeks~* Docetaxel (75mg/m2, IV)~* Atezolizumab (1200mg, IV)~* Tastuzumab (600mg, SC)~* Pertuzumab (840mg loading dose at Cycle 1 followed by 420mg, IV)~(B, Adjuvant setting) : patients with non-pCR~* Doxorubicin(60mg/m2) plus cyclophosphamide (600mg/m2) D1 X 4cycles q3weeks followed by~* Atezolizumab (1200mg, IV), Trastuzumab (600mg, SC) and Pertuzumab (420mg, IV) D1 X 11-12 cycles q3weeks"
223510875|NCT02062255|DRUG|Aspirin|
223761229|NCT03488212|BEHAVIORAL|Refresher Courses for Weight Loss Maintenance and Weight Gain Prevention|After completing the 3-month Online Behavioral Weight Loss Intervention, participants receive two month-long refresher courses with weekly online lessons for training in behavioral skills for maintaining weight loss and preventing weight gain; online self-monitoring of daily weight, diet, and physical activity; weekly feedback on the self-monitoring record; weekly challenges focuses on specific behavior change and weight loss goals.
223510876|NCT02062255|DIETARY_SUPPLEMENT|Omega 3 FFA|
223510877|NCT03023683|BIOLOGICAL|FluMist®|Influenza Virus Vaccine Live, Intranasal Spray
223510878|NCT01133977|DRUG|Lenvatinib|Lenvatinib tablets administered orally at doses of 16 mg, 20 mg, or 22 mg, once daily continuously over 3 weeks (21 days) during each 21-day cycle
223510879|NCT01133977|DRUG|Lenvatinib|Lenvatinib 20 mg (MTD/recommended Phase 2 dose as determined in Phase 1b of the study) administered once daily continuously over 3 weeks (21 days) during each 21-day cycle
223510880|NCT01133977|DRUG|Dacarbazine|Dacarbazine (1000 mg/m2) infusion over 60 minutes on Day 1 of each 21-day cycle.
223510881|NCT04314180|DEVICE|Taking slit-lamp images|The participant only needs to take several slit-lamp images as usual.
223617002|NCT06357702|BEHAVIORAL|Psycho-education Telehealth|2 sessions of an intervention delivered via telehealth. Session 1 includes discussing trigeminal nerve function, jaw and muscle anatomy, posture, pain referral patterns, and stress biology. Participants rate pain and jaw fatigue 5 times per day. Session 2 will be 2 weeks later and consists of checking on the homework and information from session 1,followed by a discussion of autonomic nervous system activity, and a discussion of sleep quality and sleep hygiene. Participants will be instructed to rate their stress levels, pain, and mood several times per day, similar to the times when participants in the PSR-TH condition would be practicing diaphragmatic breathing
224203191|NCT04552080|OTHER|Placebo|Preoperatively a placebo of 2 g will be administered. An additional single dose of 500 mg of placebo will be administered 8 hours after surgery and 500 mg thrice daily (8 hourly) on days 1 to 3 following implant placement and sinus floor elevation.
224203192|NCT04441801|OTHER|stretching exercise|Static stretching consists of stretching a muscle (or group of muscles) to its farthest point and then maintaining or holding that position
224203193|NCT00355680|DEVICE|Green Laser (Aurolas, Aurolab)|Green laser developed by Aurolab
224203194|NCT00355680|DEVICE|Green Laser (Iridex)|Already available green laser
224203195|NCT01058044|OTHER|"Evaluation of adherence to 3 oral anticancer treatment using a  Medication Event Monitoring System "|"Evaluation of adherence using a  Medication Event Monitoring System  (MEMS®) for oral anticancer treatment delivered by dispensary pharmacy"
224203196|NCT00568776|DRUG|Placebo Control|ELND005 matched placebo capsules for oral administration, bid for 78 weeks
224203197|NCT00568776|DRUG|ELND005|ELND005 capsules for oral administration at a dose of 2000 mg bid for 78 weeks
224203198|NCT00568776|DRUG|ELND005|ELND005 capsules for oral administration at a dose of 250 mg bid for 78 weeks
224312762|NCT05284487|DEVICE|Jalosome® soothing gel|Jalosome® Soothing gel is a phospholipid based vesicular system based on hyaluronic acid (HA). HA supports the process of formation of extracellular matrix and collagen synthesis by fibroblasts, favoring the formation of a well-vascularized granulation tissue and thus accelerating the healing process. Jalosome® Soothing gel contains other active ingredients: Acetyl-L-carnitine which plays an important role as shuttle for energy production and is involved in cellular metabolism. It is an effective cytoprotective, anti-inflammatory, neuroprotective, metal chelator, anti-apoptotic and anti-oxidant agent. Allantoin is a key constituent of comfrey (Symphytum officinale L), it has moisturizing and keratolytic effect, increasing the water content of the extracellular matrix and enhancing desquamation of upper layers of dead skin cells. Hydrogenated phosphatidylcholine is a permeation enhancers, which increases the solubilization of active ingredients, improving their skin permeation ability.
223761230|NCT05939492|BEHAVIORAL|Mindfulness-Based Intervention|"Participants in the mindfulness-based intervention (MBI) group will be asked to use the Headspace app to sequentially complete the Basics, Basics 2, and Basics 3 courses. Each of these courses lasts 10 days, and participants have the ability to choose how long daily sessions last. Participants can choose between 3, 5, or 10-minute sessions for the Basics course; 10 or 15-minute sessions for the Basics 2 course; and 10, 15, or 20-minute sessions for the Basics 3 course. These daily sessions are audio recordings that prompt users to engage in a variety of mindfulness techniques, including focusing on their body and breathing, as well as acknowledging thoughts and emotions in a non-judgmental manner."
224203199|NCT00568776|DRUG|ELND005|ELND005 capsules for oral administration at a dose of 1000 mg bid for 78 weeks
224203200|NCT00379366|DEVICE|External ionizing radiations|14 Gy in one time
224203201|NCT00488839|DRUG|IPX056 20 mg|IPX056 Extended Release capsule containing 20 mg baclofen
224203202|NCT00488839|DRUG|IPX056 40 mg|IPX056 Extended Release capsule containing 40 mg baclofen
224203203|NCT00488839|DRUG|Encapsulated Baclofen 20 mg|Baclofen 20mg tablet was encapsulated for blinding.
224203204|NCT00488839|DRUG|Placebo Baclofen Tablet|Placebo capsule encapsulated placebo Baclofen tablet
224203205|NCT00488839|DRUG|IPX056 10 mg|IPX056 Extended Release capsule containing 10 mg baclofen
224203206|NCT00488839|DRUG|IPX056 30 mg|IPX056 Extended Release capsule containing 30 mg baclofen
224203207|NCT00488839|DRUG|IPX056 35 mg|IPX056 Extended Release capsule containing 35 mg baclofen
224203208|NCT00488839|DRUG|Placebo IPX056 20 mg|Placebo capsule for IPX056 20 mg
224203209|NCT00488839|DRUG|Placebo IPX056 40 mg|Placebo capsule for IPX056 40 mg
224203210|NCT01674959|RADIATION|concurrent chemoradiation|"postoperative Intensity-modulated radiotherapy (IMRT) combined with capecitabine for high risk gastric cancer patients Radiation: concurrent chemoradiotherapy Postoperative radiotherapy regimen: Therapy plan system was formulated by Computed tomographic (CT) simulation. Radiation was delivered with 6MV photons. Radiotherapy consisted of 4500 cGy of radiation at 180 cGy per day, five days per week for five weeks, to the tumor bed, to the margins of resection or the stoma, to the regional nodes. Protection of spinal cord, heart, liver and kidney should be considered.~Postoperative chemotherapy regimen: capecitabine( 1,600 mg/m2 per day for 5 weeks)."
224203211|NCT01385670|DEVICE|Transcatheter PFO closure with the SeptRx Intrapocket PFO Occluder (IPO)|Transcatheter PFO closure
224203212|NCT02111382|OTHER|CV4 Cranial (4th ventricle technique) Osteopathic Manipulative|"The participant will be in supine position during the whole procedure. The practitioner sits behind the participant's head, contacts participant's lateral protuberances of the squama occipitalis (medially to the occipitomastoid suture) with the thenar eminence of both hands.~When the practitioner feels the PRM (a pulsating rhythm caused by liquor production and reabsorption), the flexion phase will be resisted and the extension phase exaggerated. The compressive force is held until the PRM stops (event known as 'Still point'). The compression will be held until the practitioner feels PRM gradual return; the compression will be slowly diminished, and then, the practitioner remove the hands from the occipital bone, laying the participant's head on the table.~The CV4 technique will be performed by an osteopath D.O. - member of the Brazilian Register of Osteopaths."
224203213|NCT02111382|OTHER|CV4 (4th ventricle technique) manual therapy sham technique|"The participant will be in supine position and the practitioner will be seated behind the participant's head. The practitioner places the fingers (2nd to 5th) under the occipital bone, touching only the squama occipitalis. The practitioner will hold this position for 5 minutes, and after this period the participant's head will be placed on the table.~The CV4 sham will be performed by a registered physiotherapist."
224203214|NCT06539494|DRUG|Omeprazole 40 MG|Proton pump inhibitor twice a day for 4 weeks
223617003|NCT05651945|OTHER|Cardiac rehabilitation program|The cardiac rehabilitation program is an outpatient exercise intervention consisting of 36 sessions (30-50 minutes) of a progressive exercise program. Participants are closely monitored throughout the sessions using a telemetry monitor and are supervised by a team of cardiac rehabilitation nurses and exercise physiologists. In addition to the exercise program, participants will receive educational sessions for cardiovascular disease (CVD) risk factors including: 1) Diet/Nutrition, 2) Smoking cessation, 3) Physical activity, 4) Medication management/adherence and 5) Behavior change. As a part of the program, based on the initial assessment results, patients are referred to a rehabilitation psychologist or a dietician for consultation and evaluation if needed. In addition, participants will also receive their standard of care therapies as prescribed by their treating physicians.
223617004|NCT05682326|DRUG|Daprodustat|Daprodustat will be administered up to Week 52.
223761231|NCT02583932|DRUG|Meaning-Making intervention (MMi)|The MMi is a brief, individualized and manualized therapeutic approach based on post-trauma literature and designed to facilitate a search for meaning following a cancer diagnosis.
223761232|NCT02583932|BEHAVIORAL|Empathic Visitor|They will provide the basic ingredients for fostering a good therapeutic relationship (i.e., trust, warmth, empathy, neutrality and authenticity) without further intervention or probing.
223617007|NCT05200143|DRUG|Ipilimumab|Ipilimumab is a fully human IgG1 kappa monoclonal antibody that binds the co-inhibitory receptor CTLA-4. Antibody binding prevents interaction with the CTLA-4 ligands CD80 and CD86. Blockade of CTLA-4 results in increased T cell activation and proliferation. Ipilimumab was the first immune checkpoint inhibitor to receive FDA approval as a cancer therapy. Treatment of patients with advanced metastatic melanoma with ipilimumab monotherapy resulted in improved overall survival. Subsequent clinical trials with ipilimumab alone and in combination with anti-PD-1 antibodies have demonstrated impressive clinical activity in patients with melanoma, renal cell carcinoma, non-small cell lung cancer and other cancers. Side effects of ipilimumab result from autoimmune attack on healthy tissues. Side effects may include dermatitis, colitis, hepatitis, hypophysitis, pneumonitis, endocrinopathies, nephritis, arthritis, neuropathies and others.
223617008|NCT05200143|DRUG|Nivolumab|Nivolumab is a fully human IgG4 kappa monoclonal antibody that binds the co-inhibitory receptor PD-1. Nivolumab binding to PD-1 blocks interaction with the PD-1 ligands PD-L1 and PD-L2. PD-1 blockade can lead to reinvigoration of exhausted T cells and prevent T cell exhaustion of newly activated T cells. Nivolumab has been shown to have excellent clinical efficacy in treating a wide range of cancers as monotherapy and in combination with ipilimumab.
223617009|NCT05200143|DRUG|Cabozantinib|Cabozantinib is a potent small molecule inhibitor of multiple receptor tyrosine kinases. Cabozantinib inhibits VEGFR2, MER, KIT, and MET at single digit nanomolar IC50 concentrations. Other kinases including ROS1, RET, FLT3, RON, AXL, and TIE2 are also inhibited with nanomolar concentrations of cabozantinib. Cabozantinib has been shown to have clinical activity in a variety of solid tumors and has been approved by the FDA for treatment of medullary thyroid cancer, renal cell carcinoma and hepatocellular carcinoma.
223617010|NCT03719131|DRUG|Nivolumab|Receive standard of care nivolumab therapy
223617011|NCT03719131|BIOLOGICAL|Rituximab and Hyaluronidase Human|Given IV or SC
223617012|NCT03719131|DRUG|Ipilimumab|Receive standard of care ipilimumab therapy
223617013|NCT03077191|OTHER|Quality of life measurement|The quality of life of breast cancer patients treated with conservative surgery and adjuvant whole breast hypofractionated radiotherapy, without boost, will be evaluated.
223617014|NCT05257278|DEVICE|MonoPlus®|MonoPlus® is indicated for use in general soft tissue approximation, specially in cases where extended wound support of more than 4 weeks is desirable
223617015|NCT05555329|DRUG|Pomalidomide 4 mg every day in cycle 1|Pomalidomide 4 mg every day, on days 1-21 in a cycle of 28 days
223617016|NCT05555329|DRUG|Pomalidomide 4 mg every other day in cycle 2|Pomalidomide 4 mg every other day, on days 1-21 in a cycle of 28 days
223617017|NCT05555329|DRUG|Pomalidomide 2 mg every day in cycle 2|Pomalidomide 2 mg every day, on days 1-28 in a cycle of 28 days
223617018|NCT05555329|DRUG|Pomalidomide 2 mg every day in cycle 3|Pomalidomide 2 mg every day, on days 1-28 in a cycle of 28 days
223617019|NCT05555329|DRUG|Pomalidomide 4 mg every other day in cycle 3|Pomalidomide 4 mg every other day, on days 1-21 in a cycle of 28 days
224203215|NCT01005680|DRUG|Pemetrexed|500 milligrams/square meter (mg/m²) administered intravenously on Day 1 of each 21-day cycle, for 6 cycles
224203216|NCT01005680|DRUG|Gemcitabine|1250 mg/m² administered intravenously on Day 1 and Day 8 of each 21-day cycle, for 6 cycles
224203217|NCT01005680|DRUG|Cisplatin|75 mg/m² administered intravenously on day 1 of each 21 day cycle, for 6 cycles
224203218|NCT01130701|OTHER|Neoadjuvant capecitabine, panitumumab and radiation|"Patients will receive six weekly doses of panitumumab (2.5mg/kg) in conjunction oral capecitabine 825 mg/m2 PO bid Mon-Friday and external beam radiation therapy. Panitumumab and oral capecitabine will begin on the first week of external beam radiotherapy and will continue throughout the course of external beam radiation therapy, and will be discontinued following the conclusion of external beam radiation therapy.~Patients will be reevaluated for surgical resection 4-6 weeks after completion of neoadjuvant therapy.~After surgical resection, adjuvant systemic chemotherapy with gemcitabine for six months is strongly recommended for all patients."
223617020|NCT04653285|BEHAVIORAL|motor skill practice|Motor learning task on a stability platform (stabilometer). Participants try to keep the tiltable platform in a horizontal position in trials of 30s.
223617021|NCT04653285|BEHAVIORAL|aerobic exercise|A bout of moderate intensity aerobic exercise on a cycle ergometer following motor skill practice.
223617022|NCT04653285|BEHAVIORAL|rest|Seated rest following motor skill practice.
223617023|NCT05992064|OTHER|Measuring gait|"Measurements are performed by PA trackers. The measurements include:~* Lower limb 3D linear accelerations according to gait bouts collected and stored as time-series of linear accelerations with a frequency of 12.5 Hz.~* Details on the amount of time spent lying down, sitting, and standing, as well as the number of steps and sit-to-stands completed throughout the day. This information will be stored in 15-minute epochs and then summarized into daily summaries for analysis."
223617024|NCT03777943|PROCEDURE|Sampling peritoneal tissue|Resection specimen will be obtained during CRS from normal peritoneum at a distance, normal peritoneum close to a peritoneal metastasis, miliary peritoneal carcinomatosis, and established peritoneal carcinomatosis.
223617025|NCT04748614|OTHER|Cost|ICU cost
223617026|NCT04192955|DRUG|Acetyl Salicylate|Tablets
224203219|NCT03548324|DEVICE|HHHFNC|Application to HHHFNC to treat respiratory distress syndrome in preterm infants previously demonstrated to be stable on a non-invasive respiratory support (HHHFNC or NCPAP).
224203220|NCT03548324|DEVICE|NCPAP|Application to NCPAP to treat respiratory distress syndrome in preterm infants previously demonstrated to be stable on a non-invasive respiratory support (HHHFNC or NCPAP).
224203221|NCT01862718|PROCEDURE|Thermal Ablation|On Thursday in the first week, subject will receive the radiofrequency ablation.
224203222|NCT01862718|PROCEDURE|Standard External Beam Radiation Therapy|During those 2 weeks, subject will receive radiation on Monday, Wednesday and Friday.
224203223|NCT00704990|DIETARY_SUPPLEMENT|Zinc, Magnesium, Vitamin B6, Vitamin C (Compound Natural Health Product for ADHD)|Weight based dosing of a chewable natural health product containing 15-35 mg zinc citrate, 150-350 mg magnesium lactate, 30-70 mg pyridoxine hydrochloride and 150-350 mg calcium ascorbate. Participants will take weight based dose two times during the day with meals for a 10 week period
224203224|NCT06538103|PROCEDURE|Eye soft surgery|Early lower eyelid surgery will be performed in accordance with the protocol previously described by Di Stadio, with medial or lateral eyelid lifting surgery as indicated. The indication for eye surgery are in case of ectropion (exposure of the conjunctiva due to a reduction in tension of the anterior compartment of the eye muscle) and lagophthalmos (incomplete /abnormal closure of the eye with eyelid in closed position) a lateral lower eyelid lifting surgery is performed. otherwise, in presence of epiphora (the eversion of the lachrymal point) and lagophthalmos medial lower eyelid lifting surgery is done.
224203225|NCT06538103|OTHER|Physical Rehabilitation|Kabat therapy and neuromuscular reeducation (NMR) at home Kabat therapy involved thrice-weekly 35-minute sessions.
224203226|NCT05074602|DRUG|SHR8008|Dosing frequency: During Part 1, administered orally once daily for 2 days. During Part 2, administered orally once weekly for 11 weeks starting from Week 3, Route of administration: oral
224312763|NCT05284487|DEVICE|Placebo|The placebo does not contain the active ingredients of Jalosome, only the co-formulants.
224312764|NCT01773837|DRUG|methylphenidate|methylphenidate (pill) p.o. 15 to 25 mg daily for six days
223510882|NCT06535776|OTHER|Matrix Rhythm Therapy|Individuals in this group will be taught home exercises face-to-face in a single session as in the home-based exercise group and will be asked to perform the exercises themselves at home for 3 non-consecutive days a week for 6 weeks. In addition to home-based exercises, a total of 12 sessions of face-to-face matrix rhythm therapy will be performed, 2 non-consecutive days a week for 6 weeks. Matrix rhythm therapy applications will be applied by a specialist physiotherapist who has received training with the matrix rhythm therapy vibromassage device.
223510883|NCT06535776|OTHER|Home-based Exercise|Home-based exercise program will be explained to patients diagnosed with axSpA by a physiotherapist. All exercises will be repeated with the physiotherapist and explained until understood. Patients will be asked to perform these exercises on their own 3 non-consecutive days a week for 6 weeks. Patients will be called by the physiotherapist on each exercise day and their home exercises will be monitored and recorded in the exercise tracking chart created for each patient. In addition, the patients will be given an exercise follow-up chart and they will be asked to fill in the existing chart and submit it at the end of the 6-week training.
223510884|NCT03902483|DEVICE|renal doppler ultrasound|renal doppler ultrasound measuring renal resistive index
223510885|NCT03958097|COMBINATION_PRODUCT|NK cell and PD-1 antibody|Each patient enrolled the study will received both NK cell and PD-1 antibody.
223510886|NCT00450840|DRUG|Simvastatin|
223510887|NCT04869410|PROCEDURE|Modification Broselow Tape|Intubation using modified Broselow Tape prediction for predicting ETT size
223510888|NCT04869410|PROCEDURE|Cole Formula|Intubation using Cole Formula prediction for predicting ETT size
223510889|NCT02540902|DEVICE|All-polyethylene tibia (Aesculap AG)|Implantation of an all polyethylene tibial component.
223510890|NCT05532163|DRUG|Natalizumab|Administered as specified in the treatment arm
223510891|NCT02773537|DRUG|Femoral nerve catheter and sciatic nerve block|This nerve block is believed to cause both muscle weakness and numbness. A catheter remains in place for up to 36 hours after surgery for the purpose of adding additional medication should the patient require it. This technique causes both the front and the back of the knee to be numb.
223510892|NCT02773537|DRUG|Adductor canal catheter and selective tibial block|This nerve block is believed to cause numbness only, without any muscle weakness. A catheter remains in place for up to 36 hours after surgery for the purpose of adding additional medication should the patient require it to control pain. This technique causes both the front and the back of the knee to be numb.
223510893|NCT02773537|DRUG|Adductor canal catheter only|This nerve block is believed to cause numbness only, without any muscle weakness. A catheter remains in place for up to 36 hours after surgery for the purpose of adding additional medication should the patient require it. This technique causes only the front of the knee to be numb
223510894|NCT05996705|OTHER|Determining the relationship of fatigue with some parameters|Determining the relationship of fatigue with physical function, pain values at rest and in motion, gender, age, pain, disease activity, gender and disease duration in RA patients.
223510895|NCT02542579|GENETIC|16S rRNA pyrosequencing analysis|Next generation sequencing analysis will be done for 16S rRNA V1,2 hypervariable regions at Biocore (Seoul, Korea).
223617027|NCT00619515|OTHER|questionnaire administration|Patients complete 4 questionnaires at baseline and periodically during study to assess acute and late toxicities and quality of life (e.g., overall health status, patient function, sexual function, and urinary symptoms).
223617028|NCT00619515|PROCEDURE|implanted fiducial-based imaging|Undergo fiducial placement imaging
223617029|NCT00619515|RADIATION|stereotactic radiosurgery|Patients undergo fiducial placement using ultrasound. At least 5-10 days later, patients undergo CyberKnife® stereotactic radiosurgery once daily for 5 days.
223617030|NCT00637078|OTHER|Treatment algorithm:caduet, Amlodipine, ACEI-ARB combo dose, a-blocker, b-blocker or spironolactone, dyslipidemic therapy with ezetamide|initial treatment with a low dose diuretic/ACE-inhibitor or ARB combination followed by a low dose DHP-CCB/statin combination
224312765|NCT01773837|DRUG|placebo|placebo (pill) p.o.
224203227|NCT05074602|DRUG|Fluconazole|Dosing frequency: During Part 1, administered orally 3 sequential doses (every 72 hours), During Part 2, administered orally once weekly for 6 Months starting from Week 3. Route of administration: oral
224203228|NCT00145652|DRUG|Neo-Recormon and Venofer|
224312766|NCT05805215|COMBINATION_PRODUCT|Non-invasive Temporal Interference stimulation and Face-name association training task targeting the hippocampus|"TIS relies on high frequencies which can penetrate with relatively low loss. High-frequency carriers (\>1 kHz) emitted by two (or more) pairs of cutaneous electrodes can temporally interfere at deep peripheral nerve targets. The effective stimulation frequency is equal to the offset frequency between the carriers. By controlling field orientation and frequency offset, the hot spot of constructive interference can be precisely targeted. The key aspect of this method is the use of carrier waves at frequencies higher than 1 kHz. Frequencies above this range are regarded as non-stimulating and pass-through tissues with relatively low loss. While these higher frequencies do not stimulate neural tissue, the interference envelope of two phase-shifted frequencies can elicit action potentials because the offset (aka beat) frequency can be tuned accordingly to \< 100 Hz."
224312767|NCT05805215|COMBINATION_PRODUCT|Non-invasive Temporal Interference stimulation and Face-name association training task targeting the Precuneus|"TIS relies on high frequencies which can penetrate with relatively low loss. High-frequency carriers (\>1 kHz) emitted by two (or more) pairs of cutaneous electrodes can temporally interfere at deep peripheral nerve targets. The effective stimulation frequency is equal to the offset frequency between the carriers. By controlling field orientation and frequency offset, the hot spot of constructive interference can be precisely targeted. The key aspect of this method is the use of carrier waves at frequencies higher than 1 kHz. Frequencies above this range are regarded as non-stimulating and pass-through tissues with relatively low loss. While these higher frequencies do not stimulate neural tissue, the interference envelope of two phase-shifted frequencies can elicit action potentials because the offset (aka beat) frequency can be tuned accordingly to \< 100 Hz."
224312768|NCT05805215|COMBINATION_PRODUCT|High-frequency stimulation (placebo) with Face-name association training task|High-frequency (\>1 kHz) stimulation; Standardly used as a carrier frequency; Effects are expected to he high-pass filtered by neurons
224312769|NCT04028193|DIETARY_SUPPLEMENT|Calogen|Polyunsaturated liquid fat supplement
224312770|NCT04028193|DIETARY_SUPPLEMENT|Resource Energy|Carbohydrate Supplement
224312771|NCT01167101|DRUG|Rebamipide|Rebamipide 100mg Tid for 28days
223510896|NCT00662038|DRUG|pirfenidone|Pirfenidone, 2403 mg/d, administered as 801-mg doses, three times daily.
223510897|NCT01840163|OTHER|Static version of CanSORT tool|
223510898|NCT01840163|OTHER|CanSORT Online Tool|
223510899|NCT05591287|PROCEDURE|Contrast enhanced harmonic Endoscopic Ultrasound|Solid pancreatic masses suspected for PDAC detected by cross-sectional imaging and confirmed at EUS will be enrolled. The
223510900|NCT01560559|PROCEDURE|Peroral endoscopic myotomy|"An endoscopy is performed under anesthesia with orotracheal intubation. After submucosal saline injection, an entry point in the submucosal space is created at 10 cm above the cardia. The endoscope will create a 12cm long tunnel in the caudal direction by submucosal dissection, stopping at 2cm below cardia. Then the muscular circular internal layer is sectioned on a 9cm length, starting 3 cm below the submucosal entry point. At the end the submucosal entry point is closed with metallic clips. A scanner is performed after the procedure so as to check the esophageal wall integrity. Alimentation is progressively introduced at day 1.~This is a study of a procedure - peroral endoscopic myotomy (POEM). No new, unapproved device is used. All endoscopic tools are already approved for endoscopic submucosal dissection and associated complications (hemorrhage or perforation): dissection knifes, hot biopsy forceps, endoscopic metallic clips."
223510901|NCT06564480|DEVICE|MI-R1 lower limb walking machine assisted training device|The training is conducted under partial weight support training conditions, performing passive movements on the lower limbs through motor drive, improving the joint activity of the patient's hip and knee joints, and achieving sitting, standing, and walking functions.
224312772|NCT01167101|DRUG|pantoprazole|pantoprazole 40mg qd for 28days
224312773|NCT03223844|DRUG|Dextroamphetamine Sulfate|Repeated oral administration of dexamphetamine 0.4mg/KG bodyweight four times.
224312774|NCT02278055|DRUG|Radium-223|
224312775|NCT00000108|BEHAVIORAL|Exercise|
224312776|NCT01934335|DRUG|Vandetanib|
224312777|NCT01934335|OTHER|Placebo|
223510902|NCT06564480|OTHER|Walking rehabilitation training under the guidance of therapists|Each patient undergoes training under the guidance of a rehabilitation therapist
223617031|NCT03494296|DRUG|patients received D-COP regimen chemotherapy|patients received D-COP regimen chemotherapy
223761233|NCT05970315|BEHAVIORAL|PPC|Participants will have an encounter with a facilitator who will identify priorities (outcome goals and care preferences) from the dyads and transmits them in the electronic health records (EHR), and a follow-up encounter with their usual geriatric care provider to decide upon changes in their care that align with the identified priorities.
224203229|NCT00996632|PROCEDURE|ultrasonic knife (Ultracision®, Ethicon Endo Surgery)|mastectomy or quadrantectomy and axillary dissection by an ultrasonic knife (Ultracision®, Ethicon Endo Surgery)
224203230|NCT00996632|PROCEDURE|conventional diarthermy knife|mastectomy or quadrantectomy and axillary dissection using conventional diarthermy knife
224203231|NCT02952937|DRUG|GLA5PR GLARS-NF3 tablet 300mg|A new formulation(3rd.) of Pregabalin CR tablet
224203232|NCT02952937|DRUG|GLA5PR GLARS-NF1 tablet 300mg|A new formulation(1st.) of Pregabalin CR tablet
224203233|NCT02049554|OTHER|Preconception Care Screener|
224203234|NCT01372254|BEHAVIORAL|Standard Treatment|Participants will receive a standard smoking cessation treatment in individual format. Treatment will be delivered in five, 90-minute individual sessions, and with two booster sessions assessed scheduled 2 and 4 weeks post quit. Participants will also receive 8 weeks of the transdermal nicotine patch.
224312778|NCT02974179|BIOLOGICAL|Subjects from Study AG-CLI-0206 who received AMG0001|Subjects from Study AG-CLI-0206 who received the study product AMG0001
224312779|NCT00405808|DRUG|Rimonabant|Once daily in the morning
224312780|NCT00405808|DRUG|Placebo|Once daily in the morning
224312781|NCT02810379|PROCEDURE|written informed consent|
224312782|NCT02810379|PROCEDURE|video+written informed consent|
224312783|NCT05384171|BEHAVIORAL|Measurement-Based Transition Assistance (MBTA)|Measurement-Based Transition Assistance (MBTA) asks Veterans about their well-being and then provides Veterans with individualized feedback on areas in which they would benefit from additional support with regard to their health, vocational, financial, and social circumstances, along with personalized recommendations for relevant programs, services, and supports.
224312784|NCT01421511|DRUG|TR-701 FA|"* TR-701 FA 200 mg once daily in 250 mL sterile saline for injection as a 60 minute IV infusion~* TR-701 FA Tablets, 200 mg, orally once daily"
224312785|NCT01421511|DRUG|Linezolid|"* Linezolid 600 mg IV Injection twice daily in 300 mL sterile saline for injection as a 60 minute IV infusion~* Linezolid Tablets, 600 mg, orally every 12 hours"
224203235|NCT01372254|BEHAVIORAL|BAD-AS|The Behavioral Activation for Drug Abusing Smokers (BA-DAS) treatment protocol will incorporate elements of the ST along with behavioral activation strategies, modified for smoking. Treatment will consist of five, 90-minute individual sessions, and with two booster sessions scheduled 2 and 4 weeks post quit. Participants will also receive 8 weeks of the transdermal nicotine patch.
224203236|NCT01372254|DRUG|Transdermal Nicotine Patch|8 weeks of the Transdermal Nicotine Patch Nicoderm CQ at 24 hour doses of 21, 14, and 7 mg respectively depending on participant's initial level of nicotine use. Nicotine patch dose will decrease at 2 or 4 week increments also specific to the participant's initial nicotine level. Participants in both intervention arms will receive transdermal nicotine patch.
224203237|NCT02600273|OTHER|Usual brand cigarettes|Usual brand cigarettes
224203238|NCT02600273|OTHER|Lower nicotine content cigarettes|SPECTRUM research cigarettes
224203239|NCT02600273|OTHER|Electronic cigarettes 1|Electronic cigarette with 0 g/mL e-liquid
224203240|NCT02600273|OTHER|Electronic cigarettes 2|Electronic cigarette with 18 g/mL e-liquid
224203241|NCT04166877|DRUG|Magnesium Sulfate in Parenteral Dosage Form|IV bolus followed by continuous infusion for 24 hours
224203242|NCT04166877|DRUG|Normal saline placebo|IV bolus followed by continuous infusion for 24 hours
224203243|NCT05501002|DEVICE|eShunt® Implant|The eShunt® Implant is intended to drain excess cerebrospinal fluid from the intracranial subarachnoid space to the venous system as a less invasive therapy for treating hydrocephalus.
224203244|NCT04305184|DRUG|ASP0598|ASP0598 Otic solution was administered onto the Tympanic Membrane (TM) through the external auditory canal via syringe.
224203245|NCT04305184|OTHER|Placebo|Placebo matched to ASP0598 Otic solution was administered onto the TM through the external auditory canal via syringe.
224312786|NCT00163488|DRUG|Ciclesonide|
224312787|NCT01236911|OTHER|Calcium Measurement|after moderate-severe TBI (less as 24 hrs)
224312788|NCT00749892|DRUG|Erlotinib Hydrochloride|Given PO
223761234|NCT05970315|BEHAVIORAL|Usual care|Participants will have a geriatric clinic visit with a geriatrician that acts as their primary care provider (PCP) , in which the dyads will be encouraged by an unblinded study coordinator to ask about reducing medication burden.
224203246|NCT05358392|OTHER|emotional freedom technique (EFT)|EFT is an energy psychotherapy derivative application, consisting of cognitive and somatic components, used to heal personal negative emotions and related emotional and physical disorders. Stress hormones are secreted in response to the stress response in the person, and then the amygdala and other cerebral parts that respond to stress are activated. There are basic steps to be followed in EFT application; By giving a message to the emotional body (subconscious) with suggestion sentences, clicks are made on the twelve energy meridian endpoints (acupressure points).
224203247|NCT05623449|OTHER|Clinical examination|Current medications (only those prescribed to treat pain, anxiety and depression), non-drug treatment(s) prior to treatment in hypnosis as well as any ongoing treatment(s).
224203248|NCT05623449|OTHER|Anxiety and Depression Scale (HAD)|To screen for anxious and depressive symptoms
224203249|NCT05623449|PROCEDURE|pain scale|Measurement of pain intensity
224203250|NCT05623449|PROCEDURE|hypnosis consultation|5 hypnosis consultation
224203251|NCT05623449|PROCEDURE|Maintenance|Qualitative assessment
224203252|NCT05623449|OTHER|Data collection|Age, sex, socio-professional category, level of education, comorbidities, date of diagnosis of chronic peripheral neuropathic pain, distance between home and hospital.
224203253|NCT06201598|DEVICE|Group 1 - Intervention 1|Endovascular treatment of cerebral aneurysms through the implantation of p64MW HPC and p48MW HPC devices.
224312789|NCT01799369|BEHAVIORAL|Surgical Apgar Score|Post-operative care influenced by Surgical Apgar Score
224312790|NCT04460508|DRUG|Pegylated rhG-CSF|Pegylated rhG-CSF:6mg
224312791|NCT04460508|DRUG|rhG-CSF|rhG-CSF:5ug/kg/d
224312792|NCT06360055|DRUG|Dabigatran Etexilate|Subjects will receive a single oral dose of 110mg (low dose specification in the instructions) or lower of dabigatran etexilate on an empty stomach on the morning of day 1 and day 16 of the trial period.
224312793|NCT06360055|DIETARY_SUPPLEMENT|D-mannose|Subjects will take 3g (1g\*3 tablets) of D-mannose tablets every morning and evening from the 2nd day to the 15th day of the trial period, with a total of 6g/day (medium dose specification in the instructions).
223761235|NCT03385252|OTHER|Eggs|Eggs provided as complementary food for the infant
224203254|NCT03401762|BEHAVIORAL|MCI|EMG-controlled game
224312794|NCT01371812|DRUG|GSK2239633|Drug will be orally administered at the doses and time points detailed in the 'arms' section.
224312795|NCT01371812|DRUG|Placebo|Placebo will be orally administered to 4 subjects in each treatment period of each cohort.
224312796|NCT04992208|BIOLOGICAL|Experimental Group|SARS-CoV-2 Inactivated Vaccine 600SU inactivated virus in 0·5 mL of aluminium hydroxide solution per injection
224203255|NCT03401762|BEHAVIORAL|Sham MCI|Sham control game
224312797|NCT06130423|DRUG|Music intervention|Music therapy carried out with Music Care
224312798|NCT06130423|DRUG|Nicotine replacement|NRT: Nicotine Patch, Nicotine Gum
224312799|NCT02870010|BIOLOGICAL|blood samples (5 ml) will be taken|blood samples (5 ml) will be taken
224312800|NCT02870010|RADIATION|Chemoembolization|Chemoembolization will take place in the Interventional Radiology room: the syringe, prepared at the pharmacy, will contain microspheres loaded with a defined dose of idarubicin. Then five millilitres of Visipaque® will be added to visualize the injection
224312801|NCT06338124|DIAGNOSTIC_TEST|Triglyceride glucose index|To evaluate the role of various laboratory biomarkers ( TyG , RAR , CAR, N\\L ratio, CRP, Serum lactate )in prediction of sepsis outcome.
224312802|NCT06343064|DRUG|Vebreltinib|Phase Ib is a dose escalation study, the initial dose of Vebreltinib is 100mg/150mg/200mg,according to the result of Phase Ib, will confirm the RP2D.
224203256|NCT05098444|BEHAVIORAL|Cognitive behavioral psychotherapy|Internet-based Cognitive Behavioural Therapy aims to reduce the impairment due to endometriosis by using cognitive behavioural intervention techniques. Furthermore, therapy should enable the patients in coping with symptoms in the future.
224203257|NCT05098444|OTHER|Waiting list|Participants of the waiting list receive no treatment for 5 months. Afterwards they receive the same treatment as the experimental group.
224203258|NCT03425786|BEHAVIORAL|Diagnostic training|Training in the Dix-Hallpike maneuver and the supine head roll test to diagnose BPPV.
224203259|NCT03425786|BEHAVIORAL|Diagnostic and treatment training|Training in the Dix-Hallpike maneuver and the supine head roll test to diagnose BPPV. Training in the Epley and Barbecue maneuvers to treat BPPV.
224203260|NCT03506646|DIETARY_SUPPLEMENT|Placebo|Participants will be given a gelatin tablet to serve as the control condition. This will be a double-blinded, randomized, cross-over design to examine the effects of beetroot juice on endothelial function, leg function, and thermoregulation.
224312803|NCT06343064|DRUG|PLB1004|Phase Ib is a dose escalation study, the initial dose of PLB1004 is 80mg/160mg,according to the result of Phase Ib, will confirm the RP2D.
224312804|NCT02669030|DRUG|suvorexant|an FDA-approved sleep aid
224312805|NCT02669030|DRUG|Placebo|control group
223510903|NCT03223805|OTHER|Respiratory Distress Symptom Intervention|"The RDSI comprises of four components~1. Controlled breathing techniques - consists of diaphragmatic breathing exercises and calming techniques practised twice a day and used as needed for episodes of intense breathlessness and/or anxiety~2. Cough suppression techniques - includes education (capacity for voluntary cough easing, identifying warning signs for cough and replace with modified swallow technique or relaxed throat breath~3. Acupressure: a small number of acupressure points are taught: L7, L9, LI4 (located on the hand and wrist areas), CV21 and 22 (sternum), and ST36 (knee). Patients can select any of these points in any combination to apply pressure for one-minute at least twice a day for symptom relief~4. Exercise: Individually-tailored exercise plan, for example, walking incrementally increasing distances in their local environment, incorporating breathing techniques as required"
223510904|NCT05531344|DEVICE|Composite Steep-pulse Treatment Device|Applying the Composite Steep-pulse Treatment Device to treat the patients with Benign Prostatic Hyperplasia
223510905|NCT05531344|DRUG|Tamsulosin Hydrochloride Capsules|Applying Tamsulosin Hydrochloride Capsules to treat the patients with Benign Prostatic Hyperplasia
223510906|NCT06055699|OTHER|Fecal sampling|"Stool samples are a collection of products derived from the human body that is not invasive in any way and samples not taken as part of usual care.~Stool samples will be collected at home within 7 days of the visit M0, M3 and M6 and within 14 days of the visit M12 in an ethanol tube and in DNA/RNA shield, and transported at room temperature to Saint-Antoine Hospital (CRB SAT, AP-HP, Pr. SIMON ), samples will be aliquoted (3 aliquots per tubes) and stored at -80°C for a period of 5 years (renewable) At the end of the research, stool samples will be analysed using metagenomics sequencing.~DNA extraction will be performed following the standards of the The International Human Microbiome Standards . DNA will be stored at -80°C."
223510907|NCT06055699|OTHER|Blood sampling|"Blood samples (serum, 15 ml) are an additional and minimal collection performed following a sample taken as part of usual care.~Blood samples (serum) will be collected during the visit at M0, M3 (± 7 days), M6 (± 7 days) and M12 (± 7 days).~In the hours following collection, the samples must be aliquoted and stored at -80°C in a secure place in the participating centre."
223510908|NCT00397046|DRUG|neratinib|HKI-272
223510909|NCT06107686|DRUG|YL202 should be intravenously infused|For each patient, YL202 should be intravenously infused over 60±10 min.
223510910|NCT01366014|DRUG|ARRY-371797, p38 inhibitor; oral|multiple dose, single schedule
223510911|NCT01366014|DRUG|Oxycodone hydrochloride (HCl) extended release (ER), opioid agonist; oral|multiple dose, single schedule
223510912|NCT01366014|DRUG|Placebo; oral|matching placebo
223510913|NCT00383565|DRUG|romidepsin|Given IV
223510914|NCT00276315|BIOLOGICAL|Botulinum toxin type A|
223510915|NCT03990337|DEVICE|Ultrasound|Ultrasonography of cricoid cartilage.
223510916|NCT05820555|BEHAVIORAL|Timed evening technology and digital media use (tablet use)|timing of children's evening tablet device use relative to bedtime
223510917|NCT05820555|BEHAVIORAL|no technology and digital media use (screen media use)|no screen media use relative to bedtime (Tablets, computers, TV, moble devices, smart phone)
223510918|NCT03090542|DIETARY_SUPPLEMENT|clinoptilolite|randomized, open-label, cross-over study of control vs clinoptilolite with a washout period separating the 2 phases
223510919|NCT00748527|DRUG|carboplatin|Given IV
223617032|NCT05663021|DIAGNOSTIC_TEST|Ultrasound-guided core needle biopsy in breast|For patients who were not evaluated as progressive disease by the latest imaging measurement, repeated core needle biopsy is conducted within the baseline tattooed area after 2 to 4 cycles of neoadjuvant chemotherapy, depending on the total cycles of chemotherapy. Tissue is acquired from different sections of the lesion from different angles to minimize the impact of tumor heterogeneity. For each patient, 3 to 4 tissue specimens are collected and sent for pathological review to examine whether there is residual malignancy (residual cancer, pleomorphic tissue) in the tumor site that is tattooed.
223510920|NCT00748527|DRUG|decitabine|Given IV
223617033|NCT01412528|OTHER|Allergen extracts|
223617034|NCT03294590|OTHER|OHT Parent targeted text messages|For the Oral health text message (OHT) group, the parent targeted text messaging program will include two core topics and a menu of options to choose from, all of which pertain to oral health.
223617035|NCT03294590|OTHER|CWT Parent targeted text messages|For the CWT group, the parent targeted text messaging program will include two core topics and a menu of options to choose from, all of which pertain to child wellness.
224312806|NCT04939376|PROCEDURE|IVF|In vitro fertilization
224312807|NCT06270186|DIAGNOSTIC_TEST|Type 1 myotonic dystrophy|"To compare classical neuropsychological test and on Good Diag NMD software in Type 1 myotonic dystrophy patients"
224312808|NCT02329938|PROCEDURE|Lichtenstein tension free reair|a mesh is apllied on the posterior wall of the inguinal canal and sutured to the inguinal ligament below, to the internal oblique muscle above , and to rectus sheath medially.
223617036|NCT01844388|DRUG|carboxymethylcellulose based eye drop formula|1-2 drops of carboxymethylcellulose based eye drop formula in each eye, a minimum of 4 times a day for 90 days. One of the 4 times a day may be to prepare the contact lens for insertion.
223617037|NCT01844388|DRUG|carboxymethylcellulose sodium based eye drop solution|1-2 drops carboxymethylcellulose sodium based eye drop solution (REFRESH CONTACTS®) in each eye, a minimum of 4 times a day for 90 days. One of the 4 times a day may be to prepare the contact lens for insertion.
223617038|NCT06396819|DRUG|collagen-povidone solution|Application of collagen-povidone solution at a dose of 0.2 cc, compared with the application of physiological solution in the control group
224203261|NCT03506646|DIETARY_SUPPLEMENT|Beet root juice|Beet root juice serves as a mode of dietary nitrate supplementation. This will be a double-blinded, randomized, cross-over design to examine the effects of beetroot juice on endothelial function, leg function, and thermoregulation.
224203262|NCT03011385|BEHAVIORAL|Individual Planning|"Participants are filling in the planning forms, referring to their individual physical activity. Both members of the dyad form their own, interdependent plans.~The following behavior change techniques (BCT) are included in the planning intervention protocol: action planning, barrier identification, prompting self-talk, relapse prevention/coping planning. Applications of all BCT included references to planning."
224203263|NCT03011385|BEHAVIORAL|Dyadic Planning|"Participants are filling in the planning forms jointly. Planning refers to physical activity of only one person in the dyad. The other person in the dyad is actively participating in forming plans by the target person.~The following BCT are included in the planning intervention protocol: action planning, barrier identification, prompting self-talk, relapse prevention/ coping planning. Applications of all BCT included references to planning."
224203264|NCT03011385|BEHAVIORAL|Collaborative Planning|Participants are filling in the planning forms jointly. Planning refers to physical activity of both persons in the dyad. Physical activity may be performed jointly by both persons in the dyad. The following BCT are included in the planning intervention protocol: action planning, barrier identification, prompting self-talk, relapse prevention/ coping planning. Applications of all BCT included references to planning.
224312809|NCT02329938|PROCEDURE|Desarda's repair|the repair is done using a flap of the external oblique aponeurosis sutured to the inguinal ligament below and to the aponeurotic part of the internal oblique muscle above.
224312810|NCT01756079|DRUG|boceprevir|
224312811|NCT01756079|BIOLOGICAL|PegIFN-2b|
223617039|NCT05580822|DRUG|Tenecteplase for Injection|intra-arterial TNK infusing after successful thrombectomy for patient with acute basilar artery occlusion via support/access catheter
223617040|NCT05580822|DRUG|Saline|intra-arterial saline infusing after successful thrombectomy for patient with acute basilar artery occlusion via support/access catheter
223617041|NCT01061970|DRUG|Fispemifene|once daily for 4 weeks
223617042|NCT02802566|DIETARY_SUPPLEMENT|BMI-based prenatal vitamin|The intervention group receives additional antioxidant micronutrients that we have found to be decreased in obese pregnant women.
223617043|NCT02802566|DIETARY_SUPPLEMENT|Standard prenatal vitamin|Standard prenatal vitamin
223617044|NCT00088140|DRUG|IDN-6556|
224312812|NCT01756079|DRUG|RBV|
224312813|NCT00106964|BIOLOGICAL|Engerix-B 20 mcg|A single dose of 1 mL (20 mcg/mL) will be administered in the deltoid muscle at Entry, Weeks 4 and 24.
224312814|NCT00106964|BIOLOGICAL|Engerix-B 40 mcg|A single dose of 2 mL (20 mcg/mL) will be administered in the deltoid muscle at Entry, Week 4 and 24.
224312815|NCT00106964|BIOLOGICAL|Twinrix 720 EIA HAV Ag plus 20 mcg HBsAg|"Arm 3: 720 EIA HAV Ag, 20 mcg HBsAg/ml:~A single dose of 1 mL will be administered in the deltoid muscle."
224312816|NCT02654119|DRUG|Cyclophosphamide|Given IV
224312817|NCT02654119|OTHER|Laboratory Biomarker Analysis|Correlative studies
224312818|NCT02654119|DRUG|Paclitaxel|Given IV
224312819|NCT02654119|BIOLOGICAL|Trastuzumab|Given IV
224312820|NCT02492659|PROCEDURE|femtosecond laser-assisted cataract surgery|the femtosecond laser platform was used to generate capsulotomy with a diameter as described above in the control group, and lens fragmentation into 6 segments.
224312821|NCT02492659|PROCEDURE|conventional phacoemulsification|continuous curvilinear capsulorhexis was performed with capsulorrhexis forceps. Following hydrodissection, phacoemulsification of the nucleus, aspiration of the residual cortex and capsular polishing were performed using a phacoemulsification machine
223512438|NCT03733782|DIETARY_SUPPLEMENT|Modular enteral protein - Prosource|Supplemental protein (2 gm/kg/day of Prosource; Medtrition, Lancaster, PA) was administered via the nasal/oral feeding tube in 60 - 180 ml bolus infusions 2 - 4 times per day, independently of the enteral formula received. That is, the daily target amount of protein was initially administered as the supplement boluses and only after the enteral formula infusion approached the target rate was the amount of supplement decreased. Supplemental protein was reduced by 50% once the patient received 75% of targeted caloric intake over the previous day (0700 - 0700). Once the patient reached the target caloric intake for 48 hours, the amount of supplemental protein was decreased in order that the total protein prescribed equaled 2 gm/kg/day.
223617045|NCT00088140|DRUG|Placebo|
223617046|NCT04862065|DEVICE|Alinity s Anti-HCV II|For all donor specimens with investigational Alinity s Anti-HCV II results that are discordant with final status after supplemental testing, an attempt will be made to obtain a follow-up whole blood specimen approximately 4 to 6 weeks after initial donation for further analysis.
223617047|NCT05098730|BEHAVIORAL|Strategy Training|Strategy training is comprised of participant-selected activity based goals, self evaluation, global problem solving strategies, and therapist-delivered guided training. The strategy training therapist will guide participants using prompting questions, as well as work sheets that facilitate learning and aid the participants in implementing the process.
223617048|NCT06299449|PROCEDURE|free-hand socket shield|Immediate Implant Placement Using Socket Shield Technique with autogenous whole tooth graft after immediate implantation using Socket Shield Technique, the palatal root portion and the decoronated crown will be converted to autogenous whole tooth graft and used for grafting the defect between the socket shield and the implant fixture
223761236|NCT03385252|BEHAVIORAL|Visits|Twice weekly household visits by study staff
223761237|NCT02803918|DRUG|Lixisenatide (AVE0010)|"Pharmaceutical form: solution~Route of administration: subcutaneous"
224312822|NCT05390593|DEVICE|iTBS-1800|Participants in the 1800-pulse intermittent TBS (iTBS-1800) active stimulation group will receive three-pulse 50-Hz pulses for 2 weeks at an intensity of 80% active motor threshold (MT) to Left DLPFC, twice a day. Stimulation will use a MAG \& More stimulator.
224312823|NCT05390593|DEVICE|iTBS-1200|Participants in the 1200-pulse intermittent TBS (iTBS-1200) active stimulation group will receive three-pulse 50-Hz pulses for 2 weeks at an intensity of 80% active motor threshold (MT) to Left DLPFC, twice a day. Stimulation will use a MAG \& More stimulator.
224312824|NCT01329783|OTHER|maraviroc|No intervention is distributed during this trial.
224312825|NCT02581397|DRUG|Transpulmin suppository|01 suppository in the morning and 01 at night, via rectal, for 03 or 07 days
224312826|NCT02581397|DRUG|Guaiacol suppository|01 suppository in the morning and 01 at night, via rectal, for 03 or 07 days
224312827|NCT02581397|DRUG|Transpulmin syrup|7,5ml every 4 hours, orally, for 03 or 07 days
223510921|NCT06549127|DEVICE|Soft Wearable Robot|This study aims to enroll 20 participants who will receive assistance in flexion and extension of the knee and hip during overground walking adaptation training. Following the initial assessment, participants will undergo three 30-minute sessions of overground walking adaptation training with a powered hip assistive device over two weeks. After completing these sessions, Post-intervention Assessment 1 will be conducted. Then, participants will undergo three 30-minute sessions of overground walking adaptation training with a powered knee assistive device over two weeks, followed by Post-intervention Assessment 2. Each participant will have a total of nine visits, including three functional assessments and six adaptation training sessions. The first visit will involve scheduling subsequent visits. The familiarization process will occur two to three times per week, adjustable for participants' convenience, with each set of three visits completed within three weeks.
223617049|NCT06299449|PROCEDURE|AI/guided socket shield|"The patient specific guides will be placed at the pre-planned positions at the labial buccal mucosa.~using artificial intelligence the socket shield approach will be planned to keep the buccal shield and using surgical guide the shield will be preciesly prepared followed by guided implant placement and whole tooth grafting of the jumping gap"
224203265|NCT03011385|BEHAVIORAL|Education|The education group participants receive extended physical activity and healthy nutrition education program. The education includes: (1) the guidelines for physical activity and healthy nutrition, tailored to age and health status of the participants, (2) the examples of exercises and their metabolic equivalent; (3) information about healthy body mass and body composition.
224203266|NCT04793815|PROCEDURE|Cryo-activation|The cryo-activation procedure involves the insertion of a cryoprobe in the tumor bed with subsequent application of very low temperatures leading to cell necrosis and tumor antigens release.
224203267|NCT04793815|DRUG|Pembrolizumab|Following the cryo-activation procedure, patients will sequentially be treated with pembrolizumab (anti-PD-1) monotherapy.
223510922|NCT02607163|DRUG|dexmedetomidine|Immediately after the induction of anesthesia, patients in the dexmedetomidine group received dexmedetomidine continuous intravenous (IV) infusion of 0.4 mcg/kg/h until 24 hours after surgery.
223510923|NCT02607163|DRUG|saline|same infusion rate (received equal volume of normal saline), IV, The infusion of study drug is started after anesthesia induction and continued until 24 hours after surgery.
223617050|NCT02304900|OTHER|white implant|"1. st intervention (in the month following the inclusion): Randomization of the color of the implant~2. nd operation (1 to 3 months after the first surgery): Installation of a same color as the first implant operated eye"
223617051|NCT02304900|OTHER|yellow implant|"1. st intervention (in the month following the inclusion): Randomization of the color of the implant~2. nd operation (1 to 3 months after the first surgery): Installation of a same color as the first implant operated eye"
223761238|NCT02803918|DRUG|Placebo|"Pharmaceutical form: solution~Route of administration: subcutaneous"
223761239|NCT02803918|DRUG|Basal Insulin|"Pharmaceutical form: solution~Route of administration: subcutaneous"
223761240|NCT02803918|DRUG|Metformin|"Pharmaceutical form: tablet~Route of administration: oral"
223761241|NCT03900299|PROCEDURE|oncoplastic breast surgery|oncoplastic breast surgery with level 1 or 2 according to the case using intra operative frozen section to assess the margin
223761242|NCT03919461|DRUG|Propranolol and etodolac|A perioperative combined drug regimen
224203268|NCT02118896|DRUG|FK506E|oral
224203269|NCT06095362|DRUG|Bevacizumab-IRDye800CW|All patients will receive a dose of Bevacizumab-IRDye800CW, in a dose of 4.5, 10, or 25mg
224203270|NCT00288106|OTHER|Follow-up|No additional drug was given; clinical observation of men diagnosed with prostate cancer who were previously randomized and treated on PCPT
224203271|NCT03947632|DIAGNOSTIC_TEST|serum ferritin and hemoglobin test|Five milliliter of blood samples were collected in two tubes (ethylenediaminetetraacetic acid and gel) at Fatimid foundation by a trained phlebotomist prior to blood transfusion to determine hemoglobin and serum ferritin.
224203272|NCT00011999|DRUG|cisplatin|
224312828|NCT01620294|PROCEDURE|abdominal wall closure|triclosan-coated (PDS-Plus) and non-coated (PDS) suture to close the abd. wall
223761243|NCT03919461|OTHER|Placebo|Placebo
224203273|NCT00011999|DRUG|paclitaxel|
224203274|NCT00011999|PROCEDURE|conventional surgery|
224203275|NCT00011999|RADIATION|radiation therapy|
224203276|NCT03130634|DRUG|Silymarin|During six cycles of FOLFIRI chemotherapy, the patients will take silymarin (150mg) three times daily from day 1 to day 7 during one cycle of treatment.
224312829|NCT01620294|PROCEDURE|surgical site infection|triclosan-coated (PDS-Plus) and non-coated (PDS) suture to close the abd. wall
224203277|NCT01722058|DRUG|Peptide application|
224203278|NCT01861431|BEHAVIORAL|HIV Sexual Risk reduction|4 sessions of HIV sexual risk reduction
224312830|NCT03827720|DEVICE|SENSE Device|Non-invasive radiofrequency (RF) sensor
224312831|NCT05204082|DEVICE|Single Use Vein Entry Indicator Device|Electronic pressure sensing device, integrated to a conventional needle catheter, and which indicates continuously during intravenous cannulation whether the tip of the needle is inside or outside of a vein, to assist a clinician in intravenous cannulation.
224312832|NCT00245830|PROCEDURE|Ischemic Preconditioning|Experimental: Hepatic Ischemic Preconditioning blood flow to the liver will be cut off by hilar clamping for ten minutes followed by release of the clamp prior to removal of the liver from the donor.
223510924|NCT06536855|BIOLOGICAL|Gardasil 9|"GARDASIL 9 is a vaccine indicated in females 9 through 45 years of age for the prevention of cervical, vulvar, vaginal, anal, oropharyngeal and other head and neck cancers caused by human papillomavirus (HPV) Types 16, 18, 31, 33, 45, 52, and 58; cervical, vulvar, vaginal, and anal precancerous or dysplastic lesions caused by HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58; and genital warts caused by HPV Types 6 and 11.~GARDASIL 9 is indicated in males 9 through 45 years of age for the prevention of anal, oropharyngeal and other head and neck cancers caused by HPV Types 16, 18, 31, 33, 45, 52, and 58; anal precancerous or dysplastic lesions caused by HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58; and genital warts caused by HPV Types 6 and 11."
223510925|NCT03364257|DIAGNOSTIC_TEST|iDTECT Blood|Next generation sequencing-based shot-gun metagenomic test for the diagnosis of viral or bacterial infections using blood samples
224203279|NCT01861431|BEHAVIORAL|HIV Sexual Risk reduction plus Microfinance|4 sessions of sexual risk reduction plus 12 sessions of financial literacy, 12 sessions of business development training, 10 sessions of business mentorship; matched savings throughout course of intervention
224203280|NCT00812045|DRUG|AZD1236|Oral tablet, 75 mg twice daily during 4 weeks
224203281|NCT00812045|DRUG|Placebo|
224203282|NCT02188667|OTHER|Providers of Novel Care|Providers in the treatment group will be asked (1) to complete a series of six online education modules in pain care, (2) will be given access to new patient reported outcomes questionnaire data collected from patients within the electronic health record, (3) asked to review this data and related care recommendations during the patient visit, and (4) asked to complete baseline and monthly online surveys related to experiences and satisfaction with providing care to patients with chronic noncancer pain.
224203283|NCT02188667|OTHER|Providers of Usual Care|Providers in the control group will provide care as usual to patients and will be asked to complete baseline and monthly online surveys related to experiences and satisfaction with providing care to patients with chronic noncancer pain.
224203284|NCT03901352|DRUG|Placebo|Matching placebo tablets for oral administration
224203285|NCT03901352|DRUG|Mirogabalin|Mirogabalin tablets for oral administration
223510926|NCT03636269|DRUG|CR845 0.5 mcg/kg|IV CR845 0.5 mcg/kg administered three times/week
223510927|NCT03636269|DRUG|Placebo|IV placebo administered three times/week
223510928|NCT03992482|DRUG|Intravenous Immune Globulin (IVIG)|Intravenous Immunoglobulin (IVIG), 4 mg/ml (0.4%) eye drops two times a day for eight weeks
223510929|NCT03992482|DRUG|Placebo|Normal Saline Eye Drops (0.9% NaCl) two times a day for eight weeks
223510930|NCT05441345|OTHER|questionnaires with collection of stool and urine|questionnaires will be completed (GPAQ, SarQoL, EQ-5D-3L, SF36), with collection of stool (for care and research) and urine
223510931|NCT02063438|PROCEDURE|Pericostal suture technique|
223510932|NCT02063438|PROCEDURE|Intracostal suture technique|
223510933|NCT02940119|DEVICE|Multi Radiance Medical®|Volunteers received all procedures of the study with active or placebo phototherapy (PBMT) in 9 sites of the neck and shoulders, twice a week. The PBMT was applied in all sessions.
223510934|NCT01507103|BIOLOGICAL|Tecemotide (L-BLP25)|Subjects will receive 8 consecutive weekly subcutaneous vaccinations with 806 microgram (mcg) of tecemotide (L-BLP25) at Weeks 1, 2, 3, 4, 5, 6, 7 and 8, which will be administered concomitantly with the chemoradiotherapy, followed by a 9th subcutaneous injection 7 to 11 days prior to surgery.
223510935|NCT01507103|DRUG|cyclophosphamide (CPA)|A single intravenous infusion of 300 milligram per square meter (mg/m\^2) (to a maximum 600 mg) of CPA will be given 3 days before the first tecemotide (L-BLP25) administration.
223510936|NCT01507103|OTHER|Chemoradiotherapy|Radiotherapy of 45-52 grays (Gy) will be applied 5 times per week, over a minimum period of 5 weeks. Capecitabine at a dose of 825 mg/m\^2, twice daily or equivalent dose of 5-fluorouracil (5-FU) will be given orally, starting at the first day of radiotherapy and given 5 to 7 days per week during the time of radiotherapy.
223510937|NCT06541080|DIAGNOSTIC_TEST|Shallow Whole Genome Sequencing (sWGS)-GIPXplore|GIPXplore will be used to mine shallow whole genome sequencing cell free DNA data for identification of signatures.
223510938|NCT06541080|DIAGNOSTIC_TEST|methylation-sensitive restriction enzymes (MSRE)-Single-molecule molecular inversion probes (smMIP)-seq assay|Aberrant methylation in ccfDNA will be analyzed using the novel, highly sensitive MSRE-smMIP-seq technology.
223510939|NCT02250573|BIOLOGICAL|Replenine®-VF (High Purity Factor IX)|
223761244|NCT01433432|DRUG|80 mg DR-6MP|All subjects from the original study, Protocol C2/13/DR-6MP-02, whether they received test drug for 12 weeks or Purinethol for 12 weeks, will now receive an additional 12 weeks of 80 mg DR-6MP drug to be administered as 2 x 40 mg DR-6MP test tablets, once nightly, before bedtime.
223761245|NCT05970432|DRUG|TQH2722 injection 300mg-150mg|TQH2722 injection is a fully human monoclonal antibody that interfering with the signal cascade.
224203286|NCT05830123|DRUG|HS-20093|IV administration of HS-20093 Q3W; Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and confirmed disease progression.
224203287|NCT06246630|OTHER|Chemotherapy and targeted-therapy guided by organoid drug sensitivity test|this study conducts drug sensitivity tests on various clinically approved drugs. The most sensitive drug for the patient is selected for treatment, and the study aims to evaluate the clinical effectiveness of the drug and its consistency with in vitro organoid drug sensitivity.
224203288|NCT02860026|OTHER|Marketed cow's milk-based infant formula|
224203289|NCT02860026|OTHER|Cow's milk-based infant formula with added nutrients|
224203290|NCT06455163|OTHER|Eerder Erbij|The intervention (Eerder Erbij, EE) is a person-centred, manual-based intervention consisting of education, information and a support group for persons in the early stage of dementia and their main informal caregiver (e.g. spouse, relative), who receive little or no formal care. The intervention will discuss the effects of dementia, and how to cope and adjust to those effects. It will take place in small group sessions led by a health care professional (e.g. casemanager) and is intended for both the person with dementia and the caregiver. The intervention will be personalised to meet needs, interests and strengths of the dyad by discussing the sessions content at the start of the intervention.
224203291|NCT06471738|DRUG|Zanubrutinib|BTK inhibitor
224203292|NCT06471738|BIOLOGICAL|Rituximab|Monoclonal antibody to CD20
224203293|NCT06471738|DRUG|Venetoclax|BCL-2 inhibitor
223510940|NCT02044146|DRUG|Ticagrelor, Prasugrel, Clopidogrel|
223510941|NCT05579522|PROCEDURE|Fat graft injection|Fat graft injection in the interdental papilla.
223761246|NCT05970432|DRUG|TQH2722 injection 600mg-300mg|TQH2722 injection is a fully human monoclonal antibody that thereby interfering with the signal cascade.
224203294|NCT01845181|DRUG|PBF-680|Dose: 10, 20, 40 ,60 mg/day (making combination of 5 y 20 mg forms).
224203295|NCT01845181|DRUG|Placebo|1 or 2 or 3 capsules of placebo.
224203296|NCT05725473|DEVICE|Eso-Flip|Dilatation with Eso-FLIP
224203297|NCT04668131|DRUG|Sodium hyaluronate eye drops|eye drops, three times a day
224203298|NCT04668131|OTHER|acupuncture|three times a week
224203299|NCT06400095|DIAGNOSTIC_TEST|Poccl, Time constant, driving pressure|Ventilatory parameters
224203300|NCT04635631|DRUG|talazoparib|Talazoparib will be administered orally on a continuous basis. Each cycle will consist of 28 days.
224203301|NCT06566001|PROCEDURE|control group|socket shield technique and allogenic bone graft
224203302|NCT02393066|DRUG|Propofol|Sedation
224203303|NCT02393066|DRUG|Dexmedetomidine|Sedation
224203304|NCT04189666|DRUG|Rivastigmine Transdermal System [Exelon]|compare the ability of the drug in preventing postoperative delirium
224203305|NCT04189666|DRUG|Melatonin|compare the ability of the drug in preventing postoperative delirium
224203306|NCT04477473|OTHER|Questionnaire-based observational study|"Questionnaire focusing on practical health care issues regarding respiratory support, health status and perception of the COVID-19 issue:~* Symptom score (related to noninvasive ventilation: NIV)~* Thymic disturbances (score of anxiety and depression)~* Compliance to treatment (assessed via tele-monitoring: routine procedure)"
224203307|NCT02050373|RADIATION|Low-Level laser|Application of laser therapy in low power mucosa jugal right and left upper and lower labial mucosa, floor of the mouth, tongue side of the right and left and belly of the tongue.
224203308|NCT00811031|DRUG|Taxotere|75 mg/m\^2 Day 1 of every 21-day cycle by vein for 4 cycles prior to surgery.
224203309|NCT00811031|DRUG|Prednisone|5 mg twice a day by mouth.
224203310|NCT05829746|DEVICE|Tubridge|Intracranial stent for wide-necked aneurysms
224203311|NCT02341872|OTHER|Clinpro White Varnish (fluoride + calcium varnish)|Clinpro White Varnish will be applied to the teeth with brush.
224203312|NCT02341872|OTHER|Curodont Repair|Curodont Repair solution be applied to the teeth in the form of drops
224203313|NCT04342130|DRUG|Morphine|30 mg oral tablet
224203314|NCT03901339|DRUG|Sacituzumab Govitecan-hziy|Administered intravenously
224203315|NCT03901339|DRUG|Eribulin|Administered intravenously per NCCN guidelines
223761247|NCT05970432|DRUG|TQH2722 injection 900mg-450mg|TQH2722 injection is a fully human monoclonal antibody that thereby interfering with the signal cascade.
223761248|NCT05970432|DRUG|TQH2722 injection matching Placebo|Placebo without active substance.
223761249|NCT03531216|OTHER|Rosemary essential oil|Topically-applied oil to both dorsal and palmar aspects of the hands
224203316|NCT03901339|DRUG|Capecitabine|Administered orally per NCCN guidelines
224203317|NCT03901339|DRUG|Gemcitabine|Administered intravenously per NCCN guidelines
224203318|NCT03901339|DRUG|Vinorelbine|Administered intravenously per NCCN guidelines
224203319|NCT05125822|OTHER|Meal replacement and lifestyle modification|Meal replacement and lifestyle modification
224203320|NCT00761566|OTHER|Real preconditioning followed by Sham preconditioning|Subjects in this arm of the study will first receive four 5 minute cycles of upper limb ischemia interspaced with 5 minutes of reperfusion by using a blood-pressure cuff inflated to a pressure of 15 mmHg greater than systolic arterial pressure. The subjects will then cross-over to the other arm of the study and receive four 5 minute cycles of upper limb ischemia interspaced with 5 minutes of reperfusion by using a sham procedure consisting of inflating the blood pressure cuff to 10 mmHg.
224203321|NCT00761566|OTHER|Sham preconditioning followed by Real preconditioning|Subjects in this arm of the study will first receive four 5 minute cycles of upper limb ischemia interspaced with 5 minutes of reperfusion by using a sham procedure consisting of inflating the blood pressure cuff to 10 mmHg. They will then cross-over to the other arm of the study and receive four 5 minute cycles of upper limb ischemia interspaced with 5 minutes of reperfusion by using a blood-pressure cuff inflated to a pressure of 15 mmHg greater than systolic arterial pressure.
224203322|NCT01199510|OTHER|FID 112903 (SYSTANE® ULTRA Lubricant Eye Drops) plus standard of care|Patients will dose 4 times daily for 30 days with FID 112903 and follow routine standard of care post-operatively
224203323|NCT01199510|OTHER|Standard of Care|Post Cataract Surgery Standard of Care
224203324|NCT03896373|OTHER|Blood samples|Blood samples
224203325|NCT02560207|DRUG|Cefotaxime|To assess the influence of administration route on target attainment cefotaxime is administered via two IV routes.
224203326|NCT02084329|DEVICE|Weighted Compression Vest|
224203327|NCT05349760|BIOLOGICAL|AMB-05X|A fully human monoclonal immunoglobulin (IgG2) directed against c-fms
224203328|NCT05349760|DRUG|Placebo|Saline/D5W
223510942|NCT05579522|PROCEDURE|Hyaluronic acid injection|Hyaluronic acid injection in the interdental papilla
223510943|NCT03008213|DRUG|Netupitant and Palonosetron|300 mg of netupitant and 0.5 mg of palonosetron
224203329|NCT00075101|DRUG|Dexamethosone|10 day study cycle: 5 day observation pre-steroid,5 day observation post-steroid
224203330|NCT02741609|DEVICE|Borrelia Diagnostic Test|The ALSI BDT is a high-yield in vitro cultivation method for Borrelia burgdorferi from venous whole blood samples.
224203331|NCT00572910|BIOLOGICAL|Comparator: Placebo (PBO)|Group 6: Placebo (PBO / PBO / PBO)
224203332|NCT00572910|BIOLOGICAL|V710 Comparator: Placebo (PBO)|"Group 5A: V710 (90 mcg / 90 mcg / 90 mcg) with MAA~Group 5B: V710 (90 mcg / 90 mcg / PBO) with MAA"
224203333|NCT00572910|BIOLOGICAL|V710 Comparator: Placebo (PBO)|"Group 4A: V710 (60 mcg / PBO / 60 mcg) with MAA~Group 4B: V710 (60 mcg / PBO / PBO) with MAA"
224203334|NCT00572910|BIOLOGICAL|V710 Comparator: Placebo (PBO)|"Group 3A: V710 (60 mcg / 60 mcg / 60 mcg) with MAA~Group 3B: V710 (60 mcg / 60 mcg / PBO) with MAA"
224203335|NCT00572910|BIOLOGICAL|V710 Comparator: Placebo (PBO)|"Group 2A: V710 (60 mcg / PBO / 60 mcg) without MAA~Group 2B: V710 (60 mcg / PBO / PBO) without MAA"
224203336|NCT00572910|BIOLOGICAL|V710 Comparator: Placebo (PBO)|"Group 1A: V710 (60 mcg / 60 mcg / 60 mcg) without MAA~Group 1B: V710 (60 mcg / 60 mcg / PBO) without MAA"
224312833|NCT01679717|OTHER|Early mobilisation after CMC1-surgery|Comparison of early (two weeks) and conservative (six weeks) mobilisation after operation. Comparison of rigid and soft thumb splint.
224312834|NCT03207243|DRUG|GSK3772847|GSK3772847 10 mg/kg will be administered as IV infusion once every 4 weeks to randomized subjects.
224312835|NCT03207243|DRUG|Placebo|Placebo sterile normal saline will be administered as IV infusion once every 4 weeks to randomized subjects.
224312836|NCT03207243|DRUG|Fluticasone propionate/salmeterol|FP/Sal 500/50 mcg will be administered via inhalation route twice daily to all subjects.
224312837|NCT03207243|DRUG|Fluticasone propionate|FP 500, 250, 100 or 50 mcg will be administered via inhalation route twice daily to all subjects.
224312838|NCT05418114|DRUG|Magnesium sulfate|. One group (Group A) will be given local infiltration with 9 ml (180 mg) of 2% lignocaine + 1 ml (500 mg) of 50% Magnesium sulphate. Other group (Group B) will be given local infiltration with 9 ml (180 mg) of 2% lignocaine.
224312839|NCT06290908|PROCEDURE|RPE-P/TLIF|patients with lumbar spinal stenosis and instability who met the inclusion and exclusion criteria were treated with RPE-P/TLIF
224312840|NCT03747510|DEVICE|CarpX Device|Transverse carpal ligament release with CarpX Device
223510944|NCT04125719|BIOLOGICAL|PVSRIPO|Intralesional injection of PVSRIPO
223617052|NCT01030029|DEVICE|electrical auricular acupuncture|Patients in the acupuncture group received titan disposable needles (27-gauge, 3 mm length; Biegler GmbH, Mauerbach, Austria), which were inserted in the dominant ear at the following acupuncture points: shen men, thalamus and one segmental organ-specific point \[2\]. Acupuncture points were identified by measuring skin resistance, using an electrical conductance meter (multipoint selection pen™, Biegler GmbH, Mauerbach, Austria). The needles were connected to the P-Stim™ device and received continuous low frequency electro acupuncture using P-Stim™ (constant current: 1 Hz biphasic, 2 mA) for 72 hours postoperatively. Acupuncture was performed by a specialist with 15 years experience in this technique.
223617053|NCT01030029|DEVICE|P-Stim™ devices were applied without electrical stimulation and acupuncture.|Patients in the control group received electrodes without needles and the P-Stim™ devices were applied without electrical stimulation.
223617054|NCT02525653|DRUG|albumin-bound paclitaxel|
223617055|NCT02525653|DRUG|gemcitabine|
223617056|NCT04365621|OTHER|we enrolled ultra-high risk of psychosis (UHR) patient to describe|there is no intervention because we study only the prevalence of patients meeting UHR criteria
223617057|NCT03170661|DRUG|Deep neuromuscular block|Deep neuromuscular block will be achieved with high dose rocuronium to achieve a depth of 1-2 twitches post tetanic count
223510945|NCT04125719|DRUG|Nivolumab|Nivolumab infusion
223510946|NCT00298701|BIOLOGICAL|ALK Grass tablet|
223510947|NCT05001555|DRUG|Dexketoprofen/Vitamin B|1 capsule containing 25 mg of dexketoprofen / vitamin B (thiamine mononitrate 100 mg, Pyridoxine hydrochloride 50 mg, Cyanocobalamin 0.50 mg), orally, every 8 hours, for 7 days.
223510948|NCT05001555|DRUG|Dexketoprofen|1 tablet of dexketoprofen 25 mg, orally, every 8 hours, for 7 days.
223510949|NCT06005636|DIAGNOSTIC_TEST|Test delirium state|use scale to test whether ischemic stroke patients have post-stroke delirium
223510950|NCT01291160|DEVICE|Epiflo|During the Treatment Period, subjects will be administered EPIFLO (either working units or sham units per randomization schedule) in conjunction with standard wound therapy regimen consisting of aggressive debridement, wound cleansing, wound dressing, for a period of 12 weeks, or until the wound completely closes, whichever event occurs first.
223510951|NCT01291160|OTHER|Moist Wound Therapy|During the Treatment Period, subjects will be administered EPIFLO (either working units or sham units per randomization schedule) in conjunction with standard wound therapy regimen consisting of aggressive debridement, wound cleansing, wound dressing, for a period of 12 weeks, or until the wound completely closes, whichever event occurs first.
223510952|NCT05674565|DRUG|Magnesium sulfate loading with maintenance dose|4 gm MgSo4 loading over 20 minutes followed by 1 gm per hour maintenance till delivery
223617058|NCT00269308|PROCEDURE|Chiropractic Manual treatment + home exercise ( procedure+behavior)|"The number of treatments will be determined by the individual chiropractor. Chiropractic manual treatment will be limited to gentle spinal manipulation and mobilization with light soft tissue massage as indicated to facilitate the manual therapy.~Patients will attend 4, 1-hour small-group sessions at weeks 1, 2, 4 and 8. At the first two sessions they will be given information about neck pain and shown exercises to perform at home. Emphasis will be placed on the importance of staying active"
223761250|NCT03531216|OTHER|Placebo|Topically-applied oil to both dorsal and palmar aspects of the hands
223761251|NCT06310850|DRUG|Ketamine|Patients will be administered 0.15 mg kg-1 intravenous ketamine (The sample provided contains equal proportions of two enantiomers, S and R ketamine hydrochloride.) 3 minutes before thoracic epidural catheter placement.
224312841|NCT00168818|DRUG|dabigatran etexilate|daily dose 150 mg once daily, half a dose on the day of surgery
223510953|NCT05674565|DRUG|Magnesium sulfate loading dose only|4 gm MgSo4 loading over 20 minutes within one hour before delivery
223510954|NCT00493285|BIOLOGICAL|MEDI-534|Multiple doses of MEDI-534 or Placebo at 10\^4 TCID50
223510955|NCT00493285|BIOLOGICAL|MEDI-534|Multiple doses of MEDI-534 or Placebo at 10 \^5 TCID50.
223510956|NCT00493285|BIOLOGICAL|MEDI-534|Multiple doses of MEDI-534 or Placebo at 10\^6 TCID50.
223510957|NCT04304248|DRUG|Albumin-bound paclitaxel, Carboplatin, Toripalimab|Eligible patients will receive Toripalimab 240mg + Albumin-bound paclitaxel 260mg/m2 + Carboplatin AUC5 for 3 cycles every 21 days (+/-3 days) as neoadjuvant treatment
223510958|NCT05213221|DRUG|Envafolimab|300mg, subcutaneous injection, q3w
223510959|NCT05213221|PROCEDURE|TACE|The first TACE will be started on d1, and the subsequent TACE will be performed on demand.
223510960|NCT05213221|DRUG|Lenvatinib|8mg,QD (body weight \<60kg); 12mg, QD (body weight ≥ 60kg)
223510961|NCT00324545|BEHAVIORAL|Medium-intensity Minimally-directive Counseling|
224312842|NCT00168818|DRUG|dabigatran etexilate|daily dose 150 mg once daily, half a dose on the day of surgery
224312843|NCT00168818|DRUG|enoxaparin|40 mg once daily
224312844|NCT00159237|PROCEDURE|blood test|
224312845|NCT05416788|OTHER|cervical manipulation|high-velocity, low-amplitude cervical manipulation
224312846|NCT05416788|OTHER|Sham intervention|lateral flexion and cervical rotation without manipulation
224312847|NCT05408585|OTHER|Regional Anesthesia Techniques|Fascial Plane Blocks
224312848|NCT06629844|OTHER|The VR dementia education group|The intervention group will receive the VR dementia education program, which will be conducted once for each participant, and each session will accommodate a maximum of 20 participants. The VR dementia education program will follow the flow below, integrating video dramatizations, VR experiences, lectures, and discussions. The program is designed to simulate real-life dementia care situations, encourage reflection, and enhance nursing students' understanding of dementia management. The following are the steps for intervention: Introduction (3 minutes), Pre-Program Questionnaire (10 minutes), Lecture Introduction (2 minutes), Bad Drama (Unfriendly Communication) (10 minutes), Bad VR (10 minutes), Discussion (5 minutes), Lecture 1: What is Dementia? (10 minutes), Good VR (10 minutes), Good Drama (10 minutes), Lecture 2: What Can We Do to Support PLWD? (5 minutes), N-impro (10 minutes), Post-Program Questionnaire (10 minutes), Conclusion (5 minutes).
224312849|NCT06629844|OTHER|The control group|The intervention begins with an introduction to the VR dementia program, outlining its objectives and setting participant expectations. A pre-program questionnaire follows to assess baseline knowledge, attitudes, and intention to assist people with dementia. A brief lecture introduces a dramatization showing ineffective communication with a PLWD, followed by a VR scenario highlighting poor care practices. After discussing these observations, participants attend a lecture explaining dementia's symptoms and progression, with culturally adapted video content for Indonesian audiences. Next, a positive VR scenario demonstrates best practices in dementia care, followed by a video on supportive communication. A second lecture offers practical strategies for caregiving and communication, complemented by an N-impro session to deepen understanding. The session concludes with a post-program questionnaire and final reflection to encourage real-world application of the learned skills.
224312850|NCT04471129|OTHER|HFO/O2C/NIV|High-flow oxygen therapy + O2C + Non invasive ventilation
224312851|NCT04471129|OTHER|NIV/O2C/HFO|Non invasive ventilation + O2C + High-flow oxygen therapy
224203337|NCT04537130|BIOLOGICAL|IN01 vaccine|"INO1 vaccine is a biological compound comprising generated and purified from recombinant bacteria culture that contains a protein consisting of EGF-4-EGF portion and the Cholera Toxin B-Subunit Domain G33D sequence (CTB-G33D) separated by 4 amino acids and 14 amino acids respectively glycine/serine-rich linkers.~IN01 is a recombinant growth factor fusion molecule which, once injected into the patient, stimulates the immune system to produce polyclonal anti-Epidermal Growth Factor (anti-EGF) neutralizing antibodies. This vaccine-led active immunisation is a new approach to target the growth factor pathways allowing for combinations with other small molecule inhibitors in order to obtain a sustained efficacy with an acceptable toxicity.~The vaccine inhibits binding of circulating Epidermal Growth Factor (EGF) to its receptor, EGF-R to block downstream activation of cell signaling pathways contributing to tumor growth or other pathophysiologies such as fibrosis."
224203338|NCT00194116|DRUG|Divalproex Sodium ER|Tablets will be available in 250mg and 500mg strengths. Divalproex will be titrated to a minimum blood level of 50 mg/L. However, the investigators will titrate divalproex to the maximum tolerable dose with an expected average dose of 2000mg per day. By dosing in this manner, all subjects will have a minimum blood level of 50 mg/L, but the mean level is likely to be considerably higher.
224203339|NCT00194116|DRUG|Placebo|. Tablets will be available in 250mg and 500mg strengths. Divalproex will be titrated to a minimum blood level of 50 mg/L. However, the investigators will titrate divalproex to the maximum tolerable dose with an expected average dose of 2000mg per day. By dosing in this manner, all subjects will have a minimum blood level of 50 mg/L, but the mean level is likely to be considerably higher.
224203340|NCT02148835|OTHER|Sausage: Triomeg|Commercial sausages enriched with 330 - 510 mg EPA+DHA / 100 g Approximate average composition of active product per 80 g Sausage (Triomeg): 250 mg EPA+DHA as ethyl-ester Energy content 500 kJ (120 kcal), protein 12 g, Carbohydrates 0.8 g, total fat 9 g, of which 2.8 g saturated fatty acids, 4.5 g monounsaturates, 1.4 g polyunsaturates. sodium 0.66 g.
224203341|NCT02148835|OTHER|Sausage: Control|Control sausage: as active, but no EPA+DHA ethyl-ester.
224203342|NCT03367949|OTHER|Surgical guide designed from Impression inversion with markers|Rather than using optical scan of the cast , We will use impression inversion technique with VPS impression and adding CBCT Markers on the tray
224203343|NCT03715335|OTHER|Targeted STI Screening|GC/CT screening will be offered to those who screen at risk or at high risk for STIs.
224203344|NCT03715335|OTHER|Universally Offered STI Screening|GC/CT screening will be offered to all patients who meet the age eligibility criteria.
224203345|NCT01825421|OTHER|Intervention is to stop antibiotics at 24h .|Stoppage of antibiotics at 24h in the intervention arm, randomization based on neutrophil CD64 values.
224312852|NCT04854044|DRUG|Akt/ERK Inhibitor ONC201|Given orally
224312853|NCT04854044|RADIATION|Radiation Therapy|Undergo radiation therapy
224312854|NCT04854044|PROCEDURE|Resection|Undergo surgical resection
224312855|NCT02937389|DIAGNOSTIC_TEST|Patients after esophagectomy|Endoscopic examinations are performed at 1 and 8 postoperative days. Endoscopic examination is added when abnormal findings are demonstrated.
223510962|NCT03844035|DIAGNOSTIC_TEST|Periimplant crevicular fluid (PICF) collection|Prior to PICF sampling, supragingival plaque was removed by sterile curets and, after air drying, the surfaces were isolated by cotton rolls. Filter paper strips (periopaper, proflow Inc., Amityville, New York, USA) were placed in sulcus for 30s. Care was taken not to avoid mechanical trauma and strips contaminated with blood or saliva were discarded. The absorbed PICF volume was estimated by a calibrated instrument (periotron 8000, proflow Inc., Amityville, NY, USA). Then, the strips were sealed into sterile tubes before freezing at -80⁰C. The readings were converted to an actual volume (µl) by reference to the standard curve.
223510963|NCT03837535|PROCEDURE|Surgery|Neuro, Lung/thorax, GI, Gynecologic, Urologic, Orthopedic, Vascular surgery
223510964|NCT03641677|DEVICE|Centralized Lung Evaluation System|Assessment of allograft lung for transplant suitability
223510965|NCT03641677|PROCEDURE|Lung Transplant|Orthotopic single or double lung transplantation.
223510966|NCT01390519|OTHER|everolimis|
223510967|NCT04535362|DRUG|Nicotine|session will include 3 infusions in the same order: nicotine (1 mg per 70 kg body weight) delivered over 5 minutes, saline and nicotine (1 mg/ 70 kg) delivered over 2.5 minutes.
223510968|NCT02419911|PROCEDURE|Laparoscopic surgery|gastrointestinal, gynecologic, urologic or bariatric laparoscopic surgery;
223761252|NCT06310850|OTHER|Placebo|Intravenous saline will be administered to patients 3 minutes before the thoracic epidural catheter is placed.
224312856|NCT02733380|DRUG|Chidamide|30mg , Oral twice a week(with an interval of no less than 3 days,;e.g. Monday and Thursday，Tuesday and Friday) until disease progression or unacceptable toxicity develops
224312857|NCT02733380|DRUG|Vinorelbine|20mg/m2， IV on day 1 of each 14 day cycle until disease progression or unacceptable toxicity develops, up to 12 cycles
224312858|NCT02733380|DRUG|Liposomal Doxorubicin or mitoxantrone|20mg/m2, IV on day 1 of each 14 day cycle（Note：for patients who can not afford the liposomal doxorubicin，may be replaced into mitoxantrone 8mg/m2, IV on day1 of each 14 day cycle） until disease progression or unacceptable toxicity develops, up to 12 cycles
224312859|NCT02733380|DRUG|Dexamethasone|10mg/m2 , IV on day 1-5 of each 14 day cycle until disease progression or unacceptable toxicity develops, up to 12 cycles
224312860|NCT02733380|DRUG|Thalidomide|100mg,Oral at night on each day until disease progression or unacceptable toxicity develops, up to 24 weeks
224312861|NCT00469144|DRUG|Busulfan|"Fixed Dose = 130 mg/m\^2 IV Daily Over Three Hours x 4 Days.~Adjusted Dose = 32 mg/m\^2 IV Over 2 Hours Test Dose x 1 Day.~Proceeding dosage level determined by pharmacokinetic studies to achieve a daily area under curve (AUC) of 6,000 microMol-min ± 10%."
224203346|NCT03624049|OTHER|Exercise|Community based exercise programs held 2-3 times per week
224203347|NCT03624049|OTHER|Health Class|Community based health class held 1 time per week
224203348|NCT04511975|DRUG|IBI188|IBI188: 100 mg/mL, intravenous infusion once a week
224203349|NCT04511975|DRUG|Azacitidine|Azacitidine (VIDAZA) for Injection:100 mg per vial, subcutaneous injection will be administered for 7 days in each 28 day cycle
224203350|NCT06170632|DEVICE|Biliary drainage|Biliary drainage with FC-SEMS Niti-S FLARE TYPE
224203351|NCT01104935|DRUG|trastuzumab monotherapy|
224312862|NCT00469144|DRUG|Fludarabine|40 mg/m\^2 IV Daily Over 1 Hour x 4 Days
224312863|NCT05128760|DIAGNOSTIC_TEST|characterization of aPL|characterization of aPL profile, GT profile and leukocytes activations markers (NETs, TREM-1)
224312864|NCT02000765|DRUG|GSK2140944 for Injection|GSK2140944 (1 gram) for Injection will be supplied as powder for injection containing \[14C\] GSK2140944. Non sterile powder is to be dissolved aseptically in sterile water for injection to a concentration of 4 mg/mL free base equivalent. IV solution is prepared by sterile filtration. 250 mL of IV solution, equivalent to 1000 mg GSK2140944, is then administered intravenously.
224312865|NCT02000765|DRUG|GSK2140944 Capsule|GSK2140944 Capsule (2 gram) will be supplied as powder in capsule containing \[14C\] GSK2140944. Powder is to be filled in empty capsule to achieve 200-400 mg strength per capsules as free base equivalent. Sufficient capsules are administered to provide the required total dose of 2 gram as free base.
224312866|NCT02794246|BIOLOGICAL|CART-19 cells|
224203352|NCT01104935|DRUG|trastuzumab and chemotherapy|
224203353|NCT01436942|BEHAVIORAL|Exercise|"The exercise intervention will be carried out at a fitness center with supervision from a physiotherapist.~A cardiorespiratory and muscle strengthening exercise program following the American College of Sports Medicine (ACSM) recommendations for maintenance and improvement of physical fitness. Cardiorespiratory fitness: two interval sessions (4 x 4 min), one continuous moderate exercise session (40 min) on a treadmill. The muscle strength exercises will consist of: 15-20 repetitions, large muscle groups as thighs, back and abdomen.~Dose: 12 weeks. Three times a week, 60 minutes."
224203354|NCT04038307|DRUG|paracetamol|1gm
224203355|NCT04038307|DRUG|Saline Solution|100ml
224203356|NCT03843307|DEVICE|Avazzia Tennant Biomodulator® PRO|High-voltage pulsed current (HVPC) electrical stimulation with Reactions and BEST™ (Bio-Electric Stimulation Technology) microcurrent that measure and change with tissue electrical characteristics.
224203357|NCT00363428|BEHAVIORAL|exercise intervention|life style
224312867|NCT04602546|DEVICE|BIS Complete Monitoring System|The BIS™ EEG complete monitoring system is intended for use under the direct supervision of a licensed healthcare practitioner or by personnel trained in its proper use. The system and its associated parameters are intended for use on adult patients within a hospital or medical facility, providing patient care to monitor the state of the brain by data acquisition of EEG signals.
224312868|NCT06455540|PROCEDURE|Superior hypogastric plexus block|Prior to the laparoscopic hysterectomy and any additional procedures, the superior hypogastric plexus block will be performed on all the patients. The block will contain 20 mL of 0.75% ropivacaine hydrochloride or 0.9% normal saline. The injection will be performed by tenting the presacral peritoneum, aspirating with a laparoscopic needle-tip syringe to ensure extravascular placement, and injecting the block.
223510969|NCT02419911|DEVICE|FloShield Defogging and Cleaning System|Sterile, single-use in vivo device to clean and defog the laparoscope camera lens
223510970|NCT02419911|DEVICE|Clearify Defogging and Cleaning System|Single-use, ex vivo device to clean and defog the laparoscope camera lens
223510971|NCT05470296|BEHAVIORAL|Move & Eat 2 Live|American Indians suffer disproportionately from several chronic diseases that may be prevented with healthier modifiable factors. Nutrition, physical activity and a healthy weight are key factors that may prevent and reduce risk of disease incidence. The major goals of this project are to develop a culturally adapted intervention that addresses barriers and uses positive cultural values as guiding principles for behavior changes to enhance program retention and improve behaviors. This project will pilot a 12-week standard lifestyle intervention in American Indians.
223761253|NCT04395937|OTHER|exercises|One hour twice a week to practice respiratory exercises, postural exercises, muscular exercises
223761254|NCT03773731|BEHAVIORAL|High intensity interval training (HIIT)|Exercise training on bicycle ergometer with high intensity bouts of 1 min interspersed by low intensity recovery intervals
224203358|NCT00363428|BEHAVIORAL|smoking cessation intervention|Life style
224203359|NCT00363428|OTHER|counseling intervention|life style
224203360|NCT00363428|OTHER|educational intervention|life style
224203361|NCT00363428|PROCEDURE|conventional surgery|life style
224203362|NCT00363428|PROCEDURE|pulmonary complications management/prevention|life style
224312869|NCT00186940|DRUG|Rasburicase|Rasburicase 0.2 mg/kg/dose by the intravenous route for up to 7 days.
224312870|NCT04467450|DRUG|botulinum toxin type A|ultrasound guided injection of the botulinum toxin type A in the inflamed subacromial subdeltoid bursa
224312871|NCT04467450|DRUG|Methyl Prednisolonate|ultrasound guided injection of Methyl Prednisolonate in the inflamed subacromial subdeltoid bursa
224312872|NCT01722422|DRUG|oxygen and saline|
224312873|NCT04439617|BIOLOGICAL|blood examination|use of the remaining 1-2 ml of blood in samples taken as part of routine care to study mitochondrial function
224312874|NCT03951025|DIETARY_SUPPLEMENT|Melatonin oral administration|One tablet with1 mg of melatonin and 82 mg of excipients
224312875|NCT03951025|DIETARY_SUPPLEMENT|Melatonin sublingual administration|One tablet with 1 mg of melatonin and 82 mg of excipients
224312876|NCT06362694|DRUG|Dabrafenib + Trametinib|Dabrafenib is an inhibitor of some mutated forms of BRAF kinases. Trametinib is a reversible inhibitor of mitogen-activated extracellular signal-regulated kinase 1 (MEK1) and MEK2 activation and of MEK1 and MEK2 kinase activity. Dabrafenib and trametinib target two different kinases in the RAS/RAF/MEK/ERK pathway. Use of dabrafenib 623 and trametinib in combination resulted in greater growth inhibition of BRAF V600 mutation-positive tumors.
224312877|NCT03289273|DRUG|Regorafenib (Stivarga, BAY73-4506)|As per the treating physicians discretion
224203363|NCT01827553|DRUG|Induction chemotherapy with gemcitabine or FOLFIRINOX|According to medical recommendation, induction chemotherapy is performed with gemcitabine (3 cycles a 3 administrations, 1000 mg/m\^2/d)or FOLFIRINOX (6 cycles; 1 cycle: oxaliplatin 85 mg/m\^2 2 h infusion, folinic acid 400 mg/ m\^2 2h infusion completed after 30 min with irinotecan infusion 180 mg/m\^2 for 90 minutes, bolus application 5-FU 400 mg/m\^2 followed by 46h infusion of 5-FU 2400 mg/m\^2)
224203364|NCT01827553|RADIATION|Radiotherapy, 28 x 1.8 Gy|Radiotherapy combined with chemotherapy starts on day 1 of chemotherapy. Radiation volume is restricted to macroscopic visual tumor region. Radiation is performed in 28 fractions with 1.8 Gy resulting in a total dose of 50.4 Gy.
224203365|NCT01827553|DRUG|Chemotherapy, gemcitabine|5 cycles of 300 mg/m\^2/d gemcitabine infusions and than 3 administrations of 1000 mg/m\^2/d
224312878|NCT05916274|BIOLOGICAL|Blood and fecal samples|Blood and fecal samples will be performed
224312879|NCT05916274|PROCEDURE|Coolonic biopsies|colonic biopsies will be analysed
224312880|NCT05494476|PROCEDURE|implant insertion|after flap detachment, implant bed will be prepared with twist-drill, implant will be inserted according to randomization (1 or 2 mm under bone)
224312881|NCT04379791|OTHER|Data collection from routine medical records|Data collection from routine medical records for criteria for fracture related infections (FRI) and for wound complications. Data collection from routine medical records for risk factors.
224312882|NCT01994291|DRUG|Ranibizumab|"Intravitreal Injection supplied as:~* 10 mg/mL in a 0.2 mL vial with instructions on preparation and administration of the 0.5 mg (0.05 mL) dose.~* 6 mg/mL in a single use vial with instructions on preparation and administration of the 0.3 mg (0.05 mL) dose.~* Adminstered once a month for 12 weeks"
224312883|NCT01994291|DRUG|Placebo|"Oral Placebo is provided in tablet form to match the 50mg dose of PF-04634817.~Dose is 4 tablets each day for 12 weeks"
224312884|NCT01994291|DRUG|PF-04634817|Four 50mg tablets PF-04634817 once a day for 12 weeks.
224312885|NCT01994291|DRUG|Masked Sham Therapy|Empty, needle-less syringe is used by the unmasked team once a month.
224203366|NCT01827553|DRUG|Chemotherapy with gemcitabine or FOLFIRINOX according to induction chemotherapy|Chemotherapeutic administration started with during induction chemotherapy is continued; Gemcitabine: 3 cycles a 3 administrations of 1000 mg/m\^2/d gemcitabine infusions FOLFIRINOX: 6 cycles
224203367|NCT06045377|DIETARY_SUPPLEMENT|Effect of Armolipid on Lipid Profile in Children With Hypercholesterolemia|A prospective single center cohort study
224312886|NCT01775189|DRUG|ALO-02 weight-matched placebo|crushed sugar spheres (powder) x 1 dose
224312887|NCT01775189|DRUG|crushed ALO-02 30 mg/3.6 mg|crushed ALO-02 30 mg/3.6 mg capsule x 1 dose
224312888|NCT01775189|DRUG|oxycodone weight-matched placebo|crushed lactose tablets (powder) x 1 dose
224312889|NCT01775189|DRUG|crushed oxycodone IR 30 mg|Three (3) crushed immediate-release (IR) oxycodone 10 mg tablets x 1 dose
224312890|NCT05209165|DRUG|Semaglutide|weekly Semaglutide (increased from starting dose of 0.25 mg at four-week intervals (0.5 mg, 1.0 mg, 1.7 mg) to a target dose of 2.4 mg) for 52 weeks with intake visit for the VA MOVE program
224312891|NCT05209165|DRUG|Placebo|Matching placebo and intake visit for VA MOVE
223510972|NCT03791060|DRUG|Secukinumab|Secukinumab is selective for human IL-17A and potently neutralizes the bioactivity of this cytokine. IL-17A is the central cytokine in multiple autoimmune and inflammatory processes. It is being recognized as one of the principal pro-inflammatory cytokines in autoimmune diseases such as psoriasis, PsA and AS, uveitis and is thought to play a role in other inflammatory conditions.
223510973|NCT03774810|DRUG|Zolpidem tartrate|Zolpidem Tartrate, 5mg for men older than 60 and women of all ages. 10 mg for men younger than 60.
223510974|NCT00200083|DEVICE|Transcend II Model 8848|"All subjects will be implanted with the IGS device and then randomized to on or off for 12 months. After 12 months all subjects will be turned on through 24 month follow up."
223510975|NCT03074643|BEHAVIORAL|Weight loss intervention months 0-6|All participants will undergo a dietary weight loss intervention designed to elicit behavioral changes leading to decreased caloric intake sufficient to yield a \~10% loss of initial body mass. The weight loss intervention will incorporate nutrition education (via group and individual meetings with the study dietitian), self-monitoring skills, cognitive-behavioral strategies for promoting lifestyle behavior modifications, and planned meals. Behavioral and educational group and individual sessions will be held weekly in a 3:1 ratio (3 group and 1 individual session per month).
224312892|NCT02996292|DEVICE|Traditional brackets|Treating of crowding using traditional brackets
224312893|NCT02996292|DEVICE|Active self-ligating brackets|Treating of crowding using active self-ligating brackets
224312894|NCT02996292|DEVICE|Passive self-ligating brackets|Treating of crowding using passive self-ligating brackets
224312895|NCT04608435|OTHER|Video-Assisted Thoracoscopic Surgery|patients receive Video-Assisted Thoracoscopic Surgery under general anesthesia
223761255|NCT03773731|BEHAVIORAL|Moderate intensity continuous training (MICT)|Exercise training on bicycle ergometer with moderate intensity (60 - 65 % of individual maximal power output)
224312896|NCT03585634|BEHAVIORAL|Dads in Gear Program|
224312897|NCT00085384|BIOLOGICAL|PEG-interferon alfa-2b|Starting dose 1.0 mg/kg/week given subcutaneously
224312898|NCT00085384|DRUG|PEG-interferon alfa-2b|"Biological/Vaccine: PEG-interferon alfa-2b~Dose 1.25 mg/kg/week given subcutaneously"
224312899|NCT00085384|BIOLOGICAL|PEG-interferon alfa-2b|"Biological/Vaccine: PEG-interferon alfa-2b~Dose 1.5 mg/kg/week given subcutaneously~EG-Intron"
224312900|NCT01017796|DRUG|N-acetylcysteine and ascorbic acid|1200mg acetylcysteine and 2g ascorbic acid in 200 ml 0,9% normal saline at least 2 hours before the start of the index procedure, followed by 1200mg acetylcysteine and 1,5g ascorbic acid the night and the morning after the examination.
224312901|NCT06413043|DRUG|Selenium|Add on Selenium (100mcg once daily) with Vitamin B Complex and Standard Treatment for Grave's Disease
224312902|NCT05629975|DIETARY_SUPPLEMENT|Oral Nutritional Supplements|"Each package contained L-arginine (750 mg), methionine (300 mg), glutamine (5 g), plant protein (10 g), vitamin B12 (1 ug), vitamin C (50 mg), vitamin D (2000 IU), vitamin A (300 mg), folic acid (5 mg), omega-3 fatty acid (1 g), zinc (20 mg), magnesium (400 mg), selenium (100 mcg), whole wheat fiber (5 g), carotenoid (3 mg), curcumin supplement (500 mg).~Probiotics included orally administration of clostridium butyricum\& bifidobacterium (500 mg) every day for 7 days."
224312903|NCT00856375|DRUG|NKTR-102|IV every 3 weeks
223617059|NCT00269308|PROCEDURE|Supervised rehabilitative exercise + home exercise|"The rehabilitative exercise program will consist of 20, 1 hour small-group sessions. It is a modification of exercise protocols used in previous studies by the investigators and others and incorporates recommendations of leading rehabilitative exercise specialists. The program will include exercises that reduce joint stiffness and relax elastic structures resulting in lower joint loads during movements.~Patients will attend 4, 1-hour small-group sessions at weeks 1, 2, 4 and 8. At the first two sessions they will be given information about neck pain and shown exercises to perform at home. Emphasis will be placed on the importance of staying active"
224203368|NCT04051840|DRUG|ClinOleic (Baxter Healthcare, Deerfield, IL, USA)|ClinOleic group: Patients using ClinOleic or Structolipid-based lipid parenteral nutrition regimen. From day 0 to day 5, the goal of treatment is to deliver 25kcal/kg/day, 1.05g/kg/day amino acids, and 1.1g/kg/day lipid.
224203369|NCT04723667|BEHAVIORAL|13-week multimodal intervention|The experimental intervention was a 13-week multimodal intervention consists of five-weekly, 90-minute, face-to-face sessions to be delivered in a group format (six to eight participants per group), followed by two weekly and three biweekly telephone follow-ups. The five face-to-face sessions covered brain health information, booster memory power, reducing stressors, optimizing strength and active lifestyle engagement.
224203370|NCT04723667|BEHAVIORAL|5-week health education programme|The health education program consisted of three topics (fall prevention, oral care and home hygiene), with two tele-booster follow up
224203371|NCT04406129|BIOLOGICAL|FMT capsules|Intervention: FMT capsules containing extensively screened donor stool.
224203372|NCT04406129|OTHER|Placebo capsules|Intervention: Placebo capsules that do not contain donor stool or any active drug.
224203373|NCT00331604|DRUG|inhaled human insulin|Treat-to-target dose titration scheme, inhalation.
224203374|NCT00331604|DRUG|insulin detemir|Injection s.c., 50% of daily dose.
224203375|NCT00331604|DRUG|insulin aspart|Treat-to-target dose titration scheme, injection s.c.
224203376|NCT00331604|DRUG|insulin aspart|Treat-to-target dose titration scheme, injection s.c. After 2 years.
224203377|NCT04051658|DEVICE|Transcranial direct current stimulation|tDCS will be applied in 1.5 mA, 20 mins before conventional physical therapy for 5 days. All experiments will be performed in random order for each subject.
224203378|NCT00708656|DRUG|mesalazine (Asacol®)|800 mg tablets
224203379|NCT00649155|DRUG|Ciprofloxacin Extended-Release Tablets 500 mg|500mg, single dose fasting
224203380|NCT00649155|DRUG|Cipro® XR Tablets (500 mg|500mg, single dose fasting
224203381|NCT00592007|DRUG|Fulvestrant and Erlotinib|Upon enrollment, patients will continue to receive erlotinib daily orally at 150 mg/day or at 100 mg/day if 150 mg was associated with adverse events requiring dose reduction before enrollment in this study. Doses less than 100 mg/day will not be allowed. Fulvestrant will be added intramuscularly 500 mg Day 0, 250 mg Days 14 and 28. In cycles 2 and up, fulvestrant will be given 250 mg on day 28. Patients will receive this therapy until they progress.
224203382|NCT03570307|OTHER|medical VS surgical evacuation of the uterus|mentioned above
224203383|NCT01466907|OTHER|Secondary prevention, supportive counselling|Patients' self-reports on Mobility, Self Care, Usual activities, Pain/Discomfort, Anxiety/Depression, Health Outcome were registered. Health problems were assessed. Secondary prevention was controlled by measuring blood pressure, Cholesterol levels, HbA1c, Weight to estimate nutritional status. Functional status was assessed. Supportive counselling was provided. Referral was sent to physician if medical interventions were needed.
223617060|NCT00269308|BEHAVIORAL|Home exercise|Patients will attend 4, 1-hour small-group sessions at weeks 1, 2, 4 and 8. At the first two sessions they will be given information about neck pain and shown exercises to perform at home. Emphasis will be placed on the importance of staying active.
224312904|NCT00856375|DRUG|irinotecan|IV every 3 weeks
224312905|NCT02794597|BEHAVIORAL|SHINE intervention group|Includes all substance treatment services as well as the brief peer-led behavioral intervention focused on contraceptives, reproductive needs, and motivational interviewing: Sexual Health Initiative for Navigation and Empowerment (SHINE).
224312906|NCT01455298|OTHER|Transient Elastography and fibrotest|a Transient Elastography and an ultrasound are performed.
223617061|NCT01272232|DRUG|liraglutide|Liraglutide 3.0 mg for subcutaneous (under the skin) injection once daily for 56 weeks.
224203384|NCT01466907|OTHER|Standard care until one year follow-up|No intervention three months after stroke. Assessment one year after stroke and comparison with the intervention group.
224203385|NCT00457418|DRUG|PEG-Intron|
224203386|NCT01456598|PROCEDURE|Laparoscopic gastrectomy|"* After laparoscopic observation, the possibility of surgery can be considered by examining inside of abdomen.~* The surgeon undergoes laparoscopic subtotal gastrectomy and D2 lymph node dissection~* After lymph node dissection, it is possible to undergo gastrectomy on appropriate part and reconstruction under small incision or laparoscopic view.~* As the reconstruction, one of the techniques like Billroth I, Billroth II and Roux en Y and so on is applied and there is no limitation on use of appliance."
224312907|NCT04020783|OTHER|NO Intervention|NO Intervention
224312908|NCT00221377|DEVICE|Intubation using tracheal tubes with or without cuff|
224312909|NCT02268968|DRUG|Lidocaine 2% Gel|Lidocaine 2% gel will be applied to nostrils and nasal CPAP prong 5 minutes prior to application of nasal CPAP
224312910|NCT00154869|DRUG|Peginterferon Alfa-2a plus Ribavirin|
224312911|NCT05798910|OTHER|ALS VR (VR based serious gaming module for advanced life support training)|Using VR based serious gaming module for advanced life support training instead of taking part in a classical lecture about advanced life support.
224312912|NCT05798910|OTHER|Lecture based training for advanced life support|Taking part in a classical lecture about advanced life support.
224312913|NCT02638025|DEVICE|OCT|Anterior Segment Spectral-domain Optical Coherence Tomography
224312914|NCT05856006|OTHER|upper trapezius stretching plus neck isometrics|upper trapezius stretching plus neck isometrics
224312915|NCT05856006|OTHER|upper trapezius stretching with mid-lower trapezius strengthening exercises plus neck isometrics|"Mid-Lower Trapezius strengthening exercise includes:~1. Latissimus pull down~2. Prone V- raise~3. Modified Prone Cobra"
224203387|NCT01456598|PROCEDURE|Open gastrectomy|"* After laparotomy, the possibility of surgery can be considered by examining inside of abdomen.~* The surgeon undergoes open subtotal gastrectomy and D2 lymph node dissection~* After lymph node dissection, one of the techniques likes Billroth I, Billroth II and Roux en Y and so on is applied and there is no limitation on use of appliance."
224312916|NCT01693796|OTHER|blood and urine samples ; Echography|
223510976|NCT03074643|BEHAVIORAL|Exercise intervention months 0-6|All participants will be expected to participate in a supervised, center-based exercise program involving moderate-intensity aerobic exercise (e.g., treadmill walking) 3 days/wk during the 6-month weight loss intervention in accordance with the American Heart Association and the American College of Sports Medicine physical activity recommendations for older adults.
223510977|NCT03074643|DIETARY_SUPPLEMENT|Carbohydrate supplement for months 0-6|Participants in the lower protein / higher CHO diet group (RecProt) will be provided a carbohydrate supplement (\~50 g of carbohydrate and 220 calories) to consume daily during the 6 month weight loss intervention.
224203388|NCT03092115|DEVICE|HIV medication adherence app|A medication adherence mobile application for HIV+ youth. It is a theory-driven, patient-centered, mobile phone-based intervention targeting medication adherence and engagement in care among HIV+ youth with features including, but not limited to: custom avatar, medication reminders, calendar tracking of medication adherence, and anonymous chat function for social support.
224203389|NCT05859893|BEHAVIORAL|Classical Turkish Music Sessions|The participants attended an interactive livestreamed music performance. In selecting the mode, tempo, and songs to be performed, recommendations were obtained from the Applied Music Therapies Association, and the pieces with copyrighted recordings presented by the Edirne State Turkish Music Ensemble, under the leadership of the General Directorate of Fine Arts of the Ministry of Culture and Tourism. As part of the project, examples of traditional Turkish songs were presented to the elderly. The recommended genres and songs consist of vocal and instrumental works belonging to major and minor scales from the Classical Period, which spans from the 14th to the 20th century. In this respect an assembly of eight-musican consisting of five artists playing kanun, tanbur, ney, classical kemençe, and bendir, as well as two vocal soloists performed.
224203390|NCT01785472|DRUG|LCZ696|LCZ696 200 mg tablet
224203391|NCT01785472|DRUG|Olmesartan|Olmesartan 20 mg capsule
224203392|NCT01785472|DRUG|Placebo of LCZ696|Placebo tablet of LCZ696 200 mg once daily
224203393|NCT01785472|DRUG|Placebo of Olmesartan|Placebo capsule of olmesartan 20 mg once daily
224203394|NCT01459679|DEVICE|KXL System (15 mW/cm2)|UVA irradiation for 8 minutes at 15 mW/cm2
224203395|NCT01459679|DEVICE|KXL System (30 mW/cm2)|UVA irradiation for 4 minutes at 30 mW/cm2
224203396|NCT01459679|DEVICE|KXL System (45 mW/cm2)|UVA irradiation for 2 minutes 40 seconds at 45 mW/cm2
224203397|NCT01459679|DRUG|riboflavin ophthalmic solution|Drops of riboflavin ophthalmic solution will be applied in the eye every two minutes for 20 minutes
224203398|NCT00595127|DRUG|Cyclophosphamide|Cyclophosphamide (10mg/kg/day x 4days)
224203399|NCT00595127|DRUG|Fludarabine|Fludarabine (30mg/m\^2/day x 5 days)
224203400|NCT00595127|RADIATION|Total body irradiation (TBI)|TBI (450 cGY in a single fraction)
224203401|NCT06330467|DIAGNOSTIC_TEST|psychometric assessment|Psychometric testing to assess trauma and dissociative disorders, and in particular dissociative identity disorder.
224203402|NCT06330467|DIAGNOSTIC_TEST|semi-structured clinical interview|Semi-structured interview for the assessment of dissociative disorders (SCID-D : Semi-structured Clinical Interview for diagnosing DSM-5 and ICD-11 Dissociative Disorders)
224203403|NCT03259646|BEHAVIORAL|Universal Education|Clinic provider/staff training on implementing universal education into clinical practice to: 1.) provide all women information about IPV/SA, harm reduction, and available safety resources; 2) provide trauma-informed counseling to women who disclose IPV/SA; includes access to the myPlan safety decision aid to develop a tailored safety action plan; 3) provide warm referrals in partnership with local domestic violence and sexual assault (DV/SA) advocacy agencies; 4) integrate documentation and quality improvement templates and measures into clinical settings.
224203404|NCT02601326|PROCEDURE|Laparoscopic ventral mesh Rectopexy|Laparoscopic fixation of rectum to sacral promontory using mesh
224203405|NCT02601326|PROCEDURE|Delorme's procedure|Transanal excision of rectal mucosa and plication of muscle layer
224203406|NCT04413357|OTHER|Balanced Nutritional Drink|Drink 1 cup of liquid nutrition product that contains protein, carbohydrate and fat intended for use as Supplemental Nutrition.
224203407|NCT04413357|OTHER|Diabetes Specific, Balanced Nutritional Drink (DMA)|Drink 1 cup of liquid nutrition product that contains protein, carbohydrate and fat, designed for people living with diabetes and intended for use as Supplemental Nutrition available in retail setting.
224312917|NCT06421883|DIETARY_SUPPLEMENT|Lactobacillus containing probiotic|"Patients will be randomized into two groups each group includes 40 patients:~Control group: 40 patients will receive their standard therapy only. Intervention group (probiotic group): 40 patients will receive probiotic 5 billion unit per day with their standard therapy for 3 months."
224312918|NCT00408083|DRUG|MultiHance|0.5 mmol/kg as a single dose administration
224312919|NCT00408083|DRUG|Magnevist|0.5 mmol/kg as a single dose administration
224312920|NCT03270878|DRUG|Glasdegib Oral Tablet|Subjects will receive a single 100 mg oral tablet of glasdegib under fasted conditions, either in study period 1 or 2, depending on randomization.
224312921|NCT03270878|DRUG|Glasdegib IV infusion|Subjects will receive a 50 mg IV infusion of glasdegib over approximately 1.25 hours, in the fasted state, in either period 1 or 2 based on randomization.
223510978|NCT03074643|DIETARY_SUPPLEMENT|Protein supplement for months 0-6|Participants in the higher protein / lower CHO diet groups (6-mon HiProt and 18-mon HiProt) will be provided a protein supplement (\~50 g of protein and 220 calories) to consume daily during the 6 month weight loss intervention.
223510979|NCT03074643|DIETARY_SUPPLEMENT|Protein supplement for follow-up months 7-18|Participants in the higher protein / lower CHO diet (18-mon HiProt) will be provided a protein supplement (\~50 g of protein and 220 calories) to consume daily during the 12-month follow-up.
223617062|NCT01272232|DRUG|liraglutide|Liraglutide 1.8 mg for subcutaneous (under the skin) injection once daily for 56 weeks.
223617063|NCT01272232|DRUG|placebo|Liraglutide placebo of either 3.0 mg or 1.8 mg for subcutaneous (under the skin) injection once daily for 56 weeks.
223617064|NCT04852861|DIAGNOSTIC_TEST|immunogenicity after first and second dose|Humoral and cellulair immunity after first and second dose of the different vaccines administrated.
223617065|NCT01227798|DRUG|Interferon alfacon-1|15 mcg at fill volume of 0.5mL
223617066|NCT01227798|DRUG|Placebo|Normal Saline
223510980|NCT02212977|DEVICE|Octylcyanoacrylate|Skin incision closure with topic skin adhesive Octylcyanoacrylate
223510981|NCT02212977|PROCEDURE|Suture|Skin incision closure with standard subcuticular technique using a running 4-0 Polysorb suture
223510982|NCT01604031|BIOLOGICAL|B-CLL Vaccine|Patients will receive a fixed dose (2X10\^7) of IL-2 secreting B-cells together with (2X10\^7) of hCD40L expressing B-cells. Patients will receive doses of vaccine at 2 week intervals for 5 doses. Barring adverse events, an additional 11 doses of vaccine will be given, at 4 weekly intervals beginning on week 12 for a total period of one year or 16 vaccinations in total.
223617067|NCT03041571|BEHAVIORAL|Patient Provider Orientation Scale|Investigators are interested in the impact that our activity has on the students' patient-centeredness. Investigators will use the Patient-Practitioner Orientation Scale (PPOS), which will be completed by both the student and the patient prior to the encounter. Following the interview, the co-investigators will lead a discussion with the patient and student. Investigators will discuss differences in patient and student PPOS scores, and how each party felt the interview went. Investigators will examine if the patients feel the interview differed from typical interactions with health care providers, and how this made the patient feel. The students will describe what was learned from the patients story as well as try to explore reasons why providers may not always learn the patient's illness story.
223617068|NCT03041571|BEHAVIORAL|Interview performed by MHP student|"The MHP students took a course called Medical Humanities in the fall of 2016. MHP students learned patient interviewing skills and the importance of gathering the patients illness story. The students will conduct an interview with a patient with chronic illness, which will be focused on gather information about how the patients illness affects daily life as well as interactions with the health care system."
223617069|NCT04291846|DRUG|SHR1459 fasted in P1, high-fat diet in P2|SHR1459 administration in fasted condition in period 1, SHR1459 administration after high-fat diet in period 2
224203408|NCT04413357|OTHER|Diabetes Specific, Balanced Nutritional Drink DMB|Drink 1 cup of liquid nutrition product that contains protein, carbohydrate and fat, designed for people living with diabetes and intended for use as Supplemental Nutrition.
224203409|NCT01327989|DEVICE|Solitaire™ FR device|Mechanical Thrombectomy
224203410|NCT05398731|OTHER|Covid_19|Duration, type of response, and the time period between the begining of drug and the emergence of symptoms of COVID-19
224203411|NCT06326112|DRUG|Furosemide Injection|o.5 mg/kg bid or tid IV
224203412|NCT06326112|DRUG|Metolazone Tablets|Diuretic as needed
224203413|NCT03858660|OTHER|No intervention|No intervention
224203414|NCT02086968|DRUG|Injectafer|2 doses of Injectafer, at 15mg/kg for a maximum single dose of 750mg given on days 0 and 7 for a total of up to 1500mg
224203415|NCT02086968|DRUG|Ferrous Sulfate tablets|325mg (1 tablet) three times a day for 28 days
224203416|NCT03915041|DEVICE|VR + active brain stimulation|Active Brain stimulation (tDCS) is applied during exposition to virtual reality (20 minutes)
223510983|NCT01604031|DRUG|Lenalidomide|Subjects will begin lenalidomide 5 mg orally daily on day zero and will continue daily dosing until week 60 (4 weeks after the final dose of vaccine).
223510984|NCT00092469|BIOLOGICAL|V441, diptheria, tetanus, acellular pertussis, inactivated poliomyelitis, hepatitis B (recombinant), & Haemophilus influenza type b conjugate vaccine|
223510985|NCT04767412|DEVICE|aerobic exercise training, inspiratory muscle training|All participants received 30 min of aerobic exercise training thrice per week for a period of 12 weeks, whereas the group B received an additional 30 min of IMT before each aerobic exercise session.
223617070|NCT04291846|DRUG|SHR1459 high-fat diet in P1, fasted in P2|SHR1459 administration after high-fat diet in period 1, SHR1459 administration in fasted condition in period 2
223761256|NCT01876069|DEVICE|22 gauge ProCore needle aspiration|Pancreatic mass evaluation through the 22 gauge ProCore needle aspiration
223761257|NCT01876069|DEVICE|22 gauge Fine needle aspiration|Pancreatic mass evaluation through the 22 gauge Fine needle aspiration
223761258|NCT06018558|GENETIC|OCU410|Subretinal administration of OCU410
223761259|NCT04887662|OTHER|Fermented vegetable|Participants will be asked to consume 100 g of fermented vegetables per day, at least 5 days per week, for 8 weeks
223761260|NCT00542581|DEVICE|The Acrysof toric SN60T3 IOL|Intraocular Lens
224203417|NCT03915041|DEVICE|VR +sham brain stimulation|Sham Brain stimulation (tDCS) is applied during exposition to virtual reality (20 minutes)
224203418|NCT01211873|DRUG|Dotarem (gadoterate meglumine)|0.1 mmol/kg by body weight, single IV injection
224203419|NCT01211873|DRUG|Magnevist (gadopentetate dimeglumine)|0.1 mmol/kg by body weight, single IV injection
224203420|NCT04496765|PROCEDURE|Total mesorectal excision|Radical resection of rectal cancer and draining lymph nodes
224203421|NCT03480165|DRUG|Parecoxib 20 MG/ML|1 ml of injectable parecoxib (Dynastat®, Pfizer) at a concentration of 20 mg/mL is given concurrently with 19 ml of 0.75% ropivacaine (Naropin®, Astra Zeneca)
224203422|NCT03480165|DRUG|Ropivacaine|19 ml of 0.75% ropivacaine (Naropin®, Astra Zeneca)) is given concurrently with 1 ml of normal saline
224203423|NCT01569074|DRUG|Fostamatinib|Fostamatinib 100mg twice daily for 12 weeks
224203424|NCT01569074|DRUG|Fostamatinib|Fostamatinib 100mg twice daily for 4 weeks, followed by150mg once daily up to Week 12
224203425|NCT01569074|DRUG|Fostamatinib|Fostamatinib 75mg twice daily for 12 weeks
223617071|NCT04713488|BIOLOGICAL|Sputnik Light|solution for intramuscular injection Composition for 1 dose (0.5 ml)
223617072|NCT04140396|DRUG|Saline infusion|Normal saline infusion at 10mL/hour
223617073|NCT04140396|DRUG|Lidocaine infusion|Lidocaine infusion at 1.0mg/kg/hr
223510986|NCT00330278|DRUG|Cefazolin|
223510987|NCT00554580|PROCEDURE|Continuous Positive Airway Pressure (CPAP)|"Usual treatment of acute pulmonary oedema (see arm A) + CPAP will be administered without interruption for at least one hour and will be stopped for efficacy:~stade I or II KILLIP classification and FR less or equal to 25 /min and SpO2 larger than 90 % ambient air and patient willing the stop of CPAP because of improvement of his clinical status."
223510988|NCT00554580|PROCEDURE|usual care of acute pulmonary oedema|"Usual treatment of acute pulmonary oedema including :~Oxygen, diuretic minimum one bolus IV of 40 mg FUROSEMIDE (LASILIX) possibility to repeat the dose every 15 minutes with a maximum 120 mg.~Bolus of ISOSORBIDE DINITRATE (RISORDAN) of 1 mg maybe repeated every 3 minutes.~As soon as possible perfusion of ISDN with flow adapted to the clinical status If necessary administration of DOBUTAMINE continuous perfusion of to 5 to 20 µg/kg/min."
223617074|NCT05616468|BIOLOGICAL|BGT007 Cell Injection|BGT007 cells (d0) were infused intravenously once, and the dose group was 5.0 × 10\^5cells/kg，1.0 × 10\^6cells/kg，3.0 × 10\^6cells/kg，6.0 × 10\^6cells/kg，1.0 × 10\^7cells/kg。
223617075|NCT05616468|DRUG|Fludarabine|Fludarabine 25\~30mg/m2/d was infused intravenously for 3 consecutive days. (- 5 days to - 3 days)
223617076|NCT05616468|DRUG|cyclophosphamide|250\~350mg/m2/d cyclophosphamide was infused intravenously for 3 consecutive days. (- 5 days to - 3 days)
223617077|NCT05313789|DEVICE|Analgesia Nociception Index (ANI)|Monitorization of Analgesia Nociception Index in Intensive Care Patients
223617078|NCT05936489|DRUG|Aceclidine + Brimonidine|LNZ101 (Aceclidine/Brimonidine) non-preserved ophthalmic solution
223617079|NCT05936489|DRUG|Aceclidine|LNZ100 (Aceclidine) non-preserved ophthalmic solution
223617080|NCT01730521|BEHAVIORAL|Exercise (Running)|the study foresees a measurement of iron biavailability in a resting and in a exercising phase and subjects will act as their own control during the study.
223617081|NCT01936571|OTHER|Blood samples|Blood samples, that were collected, processed and stored in the Maastro biobank in a standardized way, will be used to measure CRP, LDH, Osteopontin, CA-9 IL-6, IL-8, CEA, CYFRA 21-1, and α-2M. Clinical data will be retrieved from the electronic medical files.
223617082|NCT06216067|DEVICE|CALLISTO eye|Cataract toric lens placement tool
223617083|NCT06216067|DEVICE|Wavetec AnalyzOR|Cataract toric lens placement tool
223617084|NCT03679065|DRUG|Paracetamol|Each patient received 1g paracetamol tablet orally with sips of water and 100 ml 0.9% sodium chloride (normal saline \[NS\]) (IVI) over 15 minutes as a placebo for Dex solution 2 hours preoperatively.
224203426|NCT01569074|DRUG|Fostamatinib|Fostamatinib 50mg twice daily for 12 weeks
224203427|NCT01569074|DRUG|Placebo|Placebo twice daily for 12 weeks
223510989|NCT02692261|PROCEDURE|Maxillary Sinus Augmentation|Each 0.5 cc Collagenated Heterolog Bone Graft, mixed with two bundles of Hyalossᵀᴹ matrix and a few drops of sterile saline solution
223617085|NCT03679065|DRUG|Dexamethasone|Each patient received a placebo tablet identical to paracetamol tablet orally with sips of water and Dex 8 mg ampoule diluted in 100 ml 0.9% NS IVI over 15 minutes, 2 hours preoperatively.
223617086|NCT03679065|DRUG|Placebo|Each patient received a placebo tablet identical to paracetamol tablet orally with sips of water and 100 ml 0.9% NS IVI over 15 minutes as a placebo for Dex solution 2 hours preoperatively.
224203428|NCT02696304|OTHER|Adipose tissu repartition|absorptiometry,
224203429|NCT02696304|OTHER|Visceral and liver adipose tissue repartition|MRI,spectroscopy,
224203430|NCT02696304|OTHER|Preadipocyte quantification and adipose tissue inflamation|biopsy
224203431|NCT02696304|OTHER|Inflamation blood markers quantification|blood drawn,
223510990|NCT02692261|PROCEDURE|Maxillary Sinus Augmentation|Control group sinuses filled with heterolog bone graft alone
223617087|NCT01881516|DEVICE|acupuncture|once per week for 6 weeks，30 mins for each treatment and for seven main acupoints
223617088|NCT01881516|DEVICE|sham acupuncture|the same acupoints and time as in acupuncture arm, but use a Park Sham Device
223617089|NCT02394535|DRUG|Capecitabine|Given PO
223617090|NCT02394535|OTHER|Laboratory Biomarker Analysis|Correlative studies
224203432|NCT05263869|DRUG|MRG002|Administrated intravenously
224203433|NCT04530422|DRUG|Sofosbuvir plus Ledipasvir|"Sofosbuvir plus Ledipasvir, once daily for 15 to 21days~* Oseltamivir 150 mg q 12 hours for 10 days ;~* HCQ 400 q 12 hours for one day followed by 200mg q 12 hours for 9 days ; and~* Azithromycin 500mg once daily for 1 day , followed by 250mg once daily for 6 days."
224203434|NCT03813966|DIAGNOSTIC_TEST|Sofia Influenza A+B FIA|The Nasal Swab Home Collection Kit (NSHC Kit) provides the materials and training needed for you to safely collect a nasal swab at home. The sample can then be delivered to a designated test site for influenza testing.
224203435|NCT03099161|DRUG|preladenant|Administered as an oral capsule BID on Days 1 through 21 of each 21-day cycle
224203436|NCT03099161|BIOLOGICAL|pembrolizumab|Administered as IV infusion on Day 1 of each 21-day cycle
224203437|NCT02514031|DRUG|ARQ-761|"Dose Level 1:~ARQ761 195 mg IV D1, D15 Gemcitabine 1000 mg/m2 D1, 8, 15 Nab paclitaxel 125 mg/m2 D1, 8, 15~Dose Level 2:~ARQ761 290 mg IV D1, D15 Gemcitabine 1000 mg/m2 D1,8,15~Dose Level 3:~ARQ761 390 mg IV D1, D15 Gemcitabine 1000 mg/m2 D1,8,15 Nab-paclitaxel 125 mg/m2 D1,8,15~Expansion Dose Level:~ARQ761 390 IV mg or as tolerated D1, 15 Gemcitabine 1000 mg/m2 D1,8,15 Nab-Paclitaxel 125 mg/m2 D1,8,15"
223617091|NCT02394535|DRUG|Nab-paclitaxel|Given IV
223617092|NCT02394535|OTHER|Questionnaire Administration|Ancillary studies
224203438|NCT02514031|DRUG|Gemcitabine|"Therapy after lead in Phase:~You will receive Gemcitabine (1000mg/m2) administered intravenously on Days 1,8, 15-every 28 days. All cycles are 28 days in duration and there are no rest periods between cycles. You may continue treatment after cycle 6 until disease progression."
223617093|NCT02394535|RADIATION|Radiation Therapy|Undergo radiation therapy
223617094|NCT00628030|BEHAVIORAL|NOURISH|Participants in the NOURISH intervention will have 6 weekly face-to-face parent group sessions regarding healthy eating and physical activity.
224203439|NCT02514031|DRUG|nab-paclitaxel|"Therapy after lead in phase:~You will receive nab-paclitaxel (125 mg/m2) administered intravenously on Days 1,8, 15-every 28 days. All cycles are 28 days in duration and there are no rest periods between cycles. You may continue treatment after cycle 6 until disease progression."
223617095|NCT00628030|OTHER|Wellness Group|Participants in the Wellness Group will have one face-to-face group meeting and information regarding healthy eating and physical activity will be provided on a regular basis via mail.
223617096|NCT03392935|DEVICE|1540 nanometer Erbium glass laser|Subjects will receive laser treatment by dermatologist at week 0 and week 4.
223617097|NCT02486575|OTHER|Self-learning|Every resident will train following the video instruction included in the FLS course material and related written instruction only
223617098|NCT02486575|OTHER|Mentoring|A tutor will follow each resident during learning, giving instruction, examples and any kind of suggestions.
223617099|NCT03568981|RADIATION|Partial breast irradiation|After breast- conservating surgery, all patients are allowed to receive partial breast irradiation or whole breast irradiation after surgery according to the international guidelines and physician's discretion.
223617100|NCT03568981|RADIATION|Whole breast irradiation|After breast- conservating surgery, all patients are allowed to receive partial breast irradiation or whole breast irradiation after surgery according to the international guidelines and physician's discretion.
223617101|NCT01536717|DRUG|Articaine hydrochloride 2% solution|"* 4 ml/h periosteal wound infusion~* duration of 72 h"
223617102|NCT01536717|DRUG|Sodium Chloride|Placebo Sodium chloride 0,9%
223617103|NCT01732744|OTHER|Physiological solution|The volunteers were instructed to brush the internal surface of complete dentures for 2 minutes, 3 times a day, after meals (breakfast, lunch and dinner) and use the following chemical immersion methods, only once a day after dinner: A - Control (Co): Physiological solution, for 20 minutes. B) 1% Sodium Hypochlorite, for 20 minutes. C) Polident Alkaline Peroxide, for 3 minutes. D) 2,0% Castor bean solution Ricinus communis, for 20 minutes. In addition, the participants were instructed to immerse their dentures in water during the night period, before going to sleep.
223617104|NCT01732744|OTHER|Sodium hypochlorite|The volunteers were instructed to brush the internal surface of complete dentures for 2 minutes, 3 times a day, after meals (breakfast, lunch and dinner) and use the following chemical immersion methods, only once a day after dinner: A - Control (Co): Physiological solution, for 20 minutes. B) 1% Sodium Hypochlorite, for 20 minutes. C) Polident Alkaline Peroxide, for 3 minutes. D) 2,0% Castor bean solution Ricinus communis, for 20 minutes. In addition, the participants were instructed to immerse their dentures in water during the night period, before going to sleep.
223617105|NCT01732744|OTHER|Alkaline Peroxide|The volunteers were instructed to brush the internal surface of complete dentures for 2 minutes, 3 times a day, after meals (breakfast, lunch and dinner) and use the following chemical immersion methods, only once a day after dinner: A - Control (Co): Physiological solution, for 20 minutes. B) 1% Sodium Hypochlorite, for 20 minutes. C) Polident Alkaline Peroxide, for 3 minutes. D) 2,0% Castor bean solution Ricinus communis, for 20 minutes. In addition, the participants were instructed to immerse their dentures in water during the night period, before going to sleep.
223617106|NCT01732744|OTHER|Castor bean solution|The volunteers were instructed to brush the internal surface of complete dentures for 2 minutes, 3 times a day, after meals (breakfast, lunch and dinner) and use the following chemical immersion methods, only once a day after dinner: A - Control (Co): Physiological solution, for 20 minutes. B) 1% Sodium Hypochlorite, for 20 minutes. C) Polident Alkaline Peroxide, for 3 minutes. D) 2,0% Castor bean solution Ricinus communis, for 20 minutes. In addition, the participants were instructed to immerse their dentures in water during the night period, before going to sleep.
223617107|NCT01156480|DRUG|hydrocortisone|Subjects in hydrocortisone group will receive 3mg/kg/day divided every 8 hours via IV route for 3 days, followed by 2mg/kg/day divided every 8 hours IV for 1 day, followed by 1.5mg/kg/day divided every 8 hours IV for 1 day, followed by 1mg/kg/day divided every 12 hours for 1 day, followed by 0.5mg/kg/day in single dose for one day. The first dose of study drug will be given within 6 hours of diagnosis of NEC, once informed consent is obtained, and subjects will continue to receive study drug until all doses have been given (total of 18 doses) or consent is withdrawn.
223617108|NCT01156480|DRUG|placebo|Subjects in placebo group will receive a volume of placebo equal to the hydrocortisone group, on the same dosing schedule, with doses given every 8 hours via IV route for 3 days, followed by placebo every 8 hours IV for 1 day, followed by placebo every 8 hours IV for 1 day, followed by placebo every 12 hours for 1 day, followed by placebo in single dose for one day. The first dose of study drug will be given within 6 hours of diagnosis of NEC, once informed consent is obtained, and subjects will continue to receive study drug until all doses have been given (total of 18 doses) or consent is withdrawn.
223617109|NCT01235013|DRUG|Maraviroc|150 mg of Maraviroc every 12 hours (300 mg daily) orally for 24 weeks
223617110|NCT04816084|DIAGNOSTIC_TEST|Anti-SARS-CoV2 Serology|"Diagnostic Test: Anti-SARS-CoV2 Serology A blood sample is collected by venipuncture at Day 0. The anti-SARS-CoV2 serological status is measured by with fully automated MAGLUMI 2019-nCoV IgG and IgM chemiluminescence immunoassays (EUROBIO®)~Other: Questionnaire~Data concerning personal exposure factors are collected in a questionnaire:~* Socio-demographic factors: sex, age,~* known risk-factor for Covid-19~* Professional factors: Employment (type, work time, location), protective measures put in place to reduce the risk of contamination~* Non-professional factors: Contact with infected individuals, carrying of protective equipment and compliance with barrier measures, transport and accomodation modalities during holidays"
223617111|NCT03997461|DEVICE|BPro|BPro and Oscar 2 comparison for 24 hours
224203440|NCT03003858|DEVICE|0.1% HA-based film-forming device (Gengigel Prof® Fluid)|0.1% HA-based film-forming device (Gengigel Prof® Fluid, Ricerfarma, Milano, Italy) administered (oral rinses for 3-5 min.) three to five times a day over a 4-week period as an adjunct to domiciliary care and oral hygiene instructions and motivation
224203441|NCT02502084|DEVICE|3NT flexible endoscope|The nasal anatomy will be accessed and viewed with the device during functional endoscopic sinus surgery (FESS) procedure.
224203442|NCT02780817|OTHER|Error enhancement|Participants will sit in front of a 3D robotic device and grab the robotic arm handle. The participants will carry out arm reaching tasks appear on a screen on front of them. Each game of tasks will lasts 2 minutes. The participants will carry out one game to be accustomed to device, followed by one game with null force field, followed by 5 games as the main intervention with error enhancement force field, and another last game with null force field.
224203443|NCT02780817|OTHER|Control group|Participants will sit in front of a 3D robotic device and grab the robotic arm handle. The participants will carry out arm reaching tasks appear on a screen on front of them. Each game of tasks will lasts 2 minutes. The participants will carry out one game to be accustomed to device and another 7 games with null force field.
223617112|NCT01726894|DEVICE|Irreversible Electroporation|
223617113|NCT03301883|DRUG|Tocilizumab|Tocilizumab will be administered as per the schedule specified in the arm description.
224203444|NCT00171899|DRUG|imatinib mesylate|
224203445|NCT01793285|DRUG|ETANERCEPT|"During the LoadET study (0881A3-102090), subjects were treated with etanercept 100 mg versus 50 mg weekly. After completing this study, the subjects were allowed to continue the treatment with etanercept 50 mg weekly, etanercept 100 mg weekly, another drug, or abandoned medication at the discretion of their physician.~This is a non-interventional study in which historic data will be collected retrospectively from the patient's clinical history. During the historical period covered in the Study, patients would have received the treatment and the medical care that their treating physicians considered appropriate under the conditions of standard clinical practice."
224203446|NCT03520582|DEVICE|Tube placement|Placement of enteral feeding tubes
223510991|NCT06477510|PROCEDURE|non-surgical periodontal therapy|change in self perception of esthetics and clinical periodontal parameters will be assessed after non-surgical periodontal therapy.
224203447|NCT02554331|RADIATION|FP-CIT single-photon emission computed tomography|FP-CIT radiolabeled is used as a surrogate marker to examine the integrity of the dopaminergic nigrostriatal neurons.
224203448|NCT02554331|BEHAVIORAL|neuropsychological evaluation|"Assessment of:~* overall cognitive function~* executive functions~* visuospatial functions~* Nonverbal memory~* verbal memory~* Evaluation of hearing ability of time perception and sensorimotor synchronization from selected tasks the Battery of assessment of auditory sensorimotor and timing abilities~* Beck Depression Inventory"
224203449|NCT02554331|OTHER|Gait recording with sensors|Gait recording with sensors
224203450|NCT03330977|DEVICE|Compression garments|"Patients will wear the compression garments since 4 months after inclusion in order to have a comparison before and after use.~Usual practice would give to the patient the compression garments at inclusion."
224203451|NCT02723786|BIOLOGICAL|GSK1070806|Injectable solution of 100 milligram/millilitre (mg/mL), administered as a single dose of 3 milligram/kilogram (mg/kg) (maximum of 10 mg/kg) diluted in 100 mL sterile IV infusion bag of 0.9% Sodium Chloride.
224203452|NCT02723786|DRUG|1) basiliximab 2) mycophenolate mofetil (MMF) OR azathioprine 3) tacrolimus 4) corticosteroids|This immunosuppressant regimen may be revised based on the clinical judgment of the investigator including titration of tacrolimus levels.
224203453|NCT03055286|DRUG|CWP232291|"For cohort 1-3, a fixed dose of ara-C at 1 G/m2 will be administered IV over 2 hours daily from Day 1 to Day 5 following CWP232291 infusion.~For cohort 4, a fixed dose of ara-C at 1 G/m2 will be administered IV over 2 hours daily from Day 1 to Day 7 following 250 mg/m2 CWP232291 infusion."
224203454|NCT05990946|DEVICE|ePRO based Remote Symptom Management provide by a mobile phone app|"Alerts are triggered if any of 5 core symptoms scored ≥4, prompting remote clinician feedback and guidance on symptom management. This is facilitated through the Shuyu mobile application, which serves as the platform for monitoring symptoms and communication."
224203455|NCT01146886|DRUG|Placebo to BI 135585|Part 1 - oral doses given to approximately 9 parallel groups of 8 subjects (6 on active and 2 on on placebo) on Day 1
224203456|NCT01146886|DRUG|BI 135585|Part 1 - oral doses given to approximately 9 parallel groups of 8 subjects (6 on active and 2 on placebo) on Day 1; Part 2 - oral doses given to 12 subjects on Day 1
224203457|NCT05109416|DRUG|Bupivacaine Hydrochloride 0.5% Injection Solution|Local anesthetic
224203458|NCT05109416|DRUG|Saline 0.9%|Isotonic crystaloid
224312922|NCT05168683|DRUG|Each ALLN-346 treatment will be radiolabelled to contain 4 MBq 99mTc at time of dosing with light meal|Dosing or radiolabelled ALLN-346 fast or slow release tablets or capsules. Scintigraphic images will be taken
223510992|NCT02105870|DRUG|Abciximab|This drug will be administered intracoronary before percutaneous coronary intervention.
223510993|NCT02920567|DRUG|Octreotide|After pancreatoduodenectomy, octreotide was injected to patients every 8 hours subcutaneously for 7 days
223510994|NCT02920567|DRUG|Placebo|After pancreatoduodenectomy, normal saline was injected to patients every 8 hours subcutaneously for 7 days
223510995|NCT03061851|BEHAVIORAL|conventional treatment|the treatment plan by the investigators according to the patient's condition may be, this study does not interfere.
223617114|NCT03301883|DRUG|NSAIDs|Participants may receive NSAIDs up to the maximum recommended stable daily dose. Study protocol does not enforce any particular NSAID.
223617115|NCT03301883|DRUG|CSs|Participants may receive CSs at a stable dose of 30 milligrams per day (mg/day) or 0.5 milligrams per kilogram per day (mg/kg/day), whichever is less. Study protocol does not enforce any particular CS.
223617116|NCT03301883|DRUG|MTX|Participants may receive MTX at a stable dose of less than or equal to (\</=) 20 milligrams per square meter (mg/m\^2).
223617117|NCT06457724|DIETARY_SUPPLEMENT|Levilactobacillus brevis CNCM I-5566|Participants will take four Mucomixx tablets (containing Levilactobacillus brevis CNCM I-5566) daily for 28 days. The tablets should be taken after each of the following meals: breakfast, lunch, afternoon break, and dinner.
224203459|NCT04678700|OTHER|Chest physiotherapy post-covid19|"The sessions are divided into the following modules;~* Directed abdominal-diaphragmatic ventilation (10 times).~* Costal expansion exercises with the help of flexion and abduction of the upper limbs. (10 times)(1).~* Self-passive stretching of the ribcage and neck muscles, accessory to inspiration. The purpose of the stretching will be to increase the flexibility of the muscles to improve the vital capacity as has already been evidenced in other respiratory diseases such as chronic obstructive pulmonary disease (COPD) and cystic fibrosis (25)(26).~Relaxation time;Jacobson's progressive relaxation; we scan the body's condition.~Post-session evaluation by taking the respiratory frequency/ min and the Borg's dyspnea index, and level oxigen after the exercises."
224203460|NCT02672488|DRUG|Sorafenib|Standard treatment for advanced HCC
224203461|NCT02672488|DRUG|Metformin|To evaluate the safety and efficacy of the combined treatment of Metformin and Sorafenib for advanced HCC
224203462|NCT06538571|DIAGNOSTIC_TEST|Near infrared spectroscopy|Noninvasive monitor for venous saturation
224203463|NCT04950673|DEVICE|Cognivue|Computerized Cognitive Assessment Device
224203464|NCT00163527|DRUG|Roflumilast|
224203465|NCT02989467|DRUG|Aprepitant|Subjects will receive one tablet daily for 5 consecutive days. On Day 1 subjects will take a 125mg tablet, on Days 2-5, subjects will take an 80 mg tablet.
224203466|NCT02989467|DRUG|Placebo|Subjects will receive one placebo tablet daily for 5 consecutive days.
224203467|NCT01977560|BEHAVIORAL|Intensive Lifestyle Intervention|Participants will be instructed to consume \~500 kcal/day less than their calculated estimated total daily energy requirements. The supervised exercise program will include both endurance and resistance exercise training sessions. The doses of diabetes medications will be adjusted by study physicians every 1-2 weeks, as needed to avoid hypoglycemia.
224203468|NCT01977560|BEHAVIORAL|Standard Care|After receiving dietary and physical activity instructions as recommended by the American Diabetes Association (ADA) guidelines participants will meet approximately every month for about 7 months with a study team member to record body weight, review diet and physical activity behaviors, and document medication use. Participants will continue their routine medical management, including regular clinic visits with their personal physician and/or diabetes educator during their participation in this study. Any changes medications will made by the participants' personal physician(s).
223510996|NCT03061851|OTHER|Maltose app|"1. Weekly diabetes-related science articles.~2. Patients reported hypoglycemia or other adverse reactions, the competent physician to deal with.~3. Questionnaires published out the hospital (2 weeks 1), the feedback for the problem.~4. monitoring of abnormal blood glucose data or the presence of related discomfort, can communicate with the competent physician online.~5. Personalize the development of diet, exercise program.~6. different insulin and oral hypoglycemic drug medication time to remind.~7. hypoglycemic drug side effects query."
223510997|NCT01641783|DRUG|nanoparticle Albumin-Bound paclitaxel|nanoparticle Albumin-Bound paclitaxel:125mg/m2 d1 iv
223510998|NCT02715752|DIETARY_SUPPLEMENT|Gene-Eden-VIR/Novirin|
223510999|NCT03709589|OTHER|Modified Early Warning Score|Modified Early Warning Score
223511000|NCT02848352|OTHER|Placebo nasal spray|
223511001|NCT02848352|OTHER|Film Sequence|
223511002|NCT01401075|DRUG|mistletoe extract|subcutaneous injections thrice weekly with 1 ml in 4 increasing doses
223511003|NCT01401075|DRUG|doxifluridine|600 - 900 mg per day orally, depending on weight and status of the patient
223511004|NCT03116087|DRUG|Testosterone patch|300 mcg testosterone patches or placebo applied twice weekly
223511005|NCT03116087|DRUG|Placebo|Placebo patch
223511006|NCT00943202|BIOLOGICAL|Inactivated H1N1 Vaccine|Inactivated influenza H1N1 vaccine, 15 micrograms per dose. Vaccines will be administered as a single 0.5 mL intramuscular injection in the deltoid muscle of the arm or in the anterolateral thigh muscle (1 injection in each arm or each thigh if receiving 2 doses).
223511007|NCT00943202|BIOLOGICAL|Trivalent Inactivated Influenza Vaccine|Licensed seasonal trivalent influenza vaccine (TIV) (2009-2010 season). For subjects greater than or equal to 6 - \<36 months, licensed TIV will be administered as a single 0.25 mL intramuscular (IM) injection in the deltoid muscle of the arm or in the anterolateral thigh muscle. For subjects greater than or equal to 36 months - 17 years, licensed TIV will be administered as a single 0.5 mL IM injection in the deltoid muscle of the arm or in the anterolateral thigh muscle.
223511008|NCT05942989|OTHER|Reiki implementation|Reiki is implied by putting hands on the patient and it is believed that energy is transferred to patients by hands.
223511009|NCT03286803|BIOLOGICAL|Inactivated Poliovirus vaccine|we will administer either full dose (0.5ml) or fractional dose (0.1ml) of inactivated poliovirus vaccine
223511010|NCT04250974|OTHER|electroacupuncture|acupuncture with electricity
223511011|NCT00499538|DRUG|SKI-606|
223511012|NCT05328232|OTHER|Olive oil|The parents of the babies included in the experimental group were asked to fill in the questionnaires. The infant's skin condition was assessed using the Scale for Assessing the Severity of Uncomplicated Diaper Dermatitis in Infants. Each time the diaper was changed, the diaper area was cleaned with water and cotton wool and dried, 1-2 cc of natural extra virgin olive oil was applied, and the new diaper was fastened. At the end of each day, the diaper area was evaluated by the researcher and a nurse by using the Scale for Assessing the Severity of Uncomplicated Diaper Dermatitis in Infants.
223511013|NCT00593073|BEHAVIORAL|Electronic tailored messaging|Tailored CRC message based on patient screening barriers, preferences and attitudes and reminder to get screened.
223511014|NCT00593073|BEHAVIORAL|General Reminder Message|General CRC health education message and reminder to get screened.
223511015|NCT03675555|DRUG|Mirtazapine|Each patient received 30 mg Mirta tablet orally with sips of water and 100 ml 0.9% sodium chloride (normal saline \[NS\]) (IVI) over 15 minutes as a placebo for Dex solution 2 hours preoperatively.
223511016|NCT03675555|DRUG|Dexamethasone phosphate|Each patient received a placebo tablet identical to Mirta tablet orally with sips of water and Dex 8 mg ampoule diluted in 100 ml 0.9% NS IVI over 15 minutes, 2 hours preoperatively.
223511017|NCT03675555|DRUG|Placebo|Each patient received a placebo tablet identical to Mirta tablet orally with sips of water and 100 ml 0.9% NS IVI over 15 minutes as a placebo for Dex solution 2 h preoperatively.preoperatively.
223511018|NCT02567292|OTHER|Human Milk|Participants will receive an exclusive human milk diet comprised of mother's own milk (MOM, pasteurized donor human milk (DM) fortified with a donor-milk based fortifier (DMBF): Prolact+ for infants \<37 weeks PMA and/or or weight \<2,200g or PBCLN-002 for infants \>37 weeks PMA and/or weight \>2,200g)
223511019|NCT00290758|DRUG|placebo|Given orally
223511020|NCT00290758|DRUG|genistein|Given orally
223511021|NCT00290758|OTHER|laboratory biomarker analysis|Correlative studies
223511022|NCT06190015|BIOLOGICAL|Advanced platelet rich fibrin (APRF) clots|15 minutes before surgery, phlebotomy will be performed and two vacutainers containing 10ml of blood will be placed in the centrifuge for 8 min and 200g. Acquired APRF clots will be placed in the extraction alveolus
223511023|NCT06190015|DEVICE|Enamel matrix derivative (EMD) group|After third molar removal, Pref Gel (EDTA) will be placed on the root surface for 2 min and then removed. Emdogain (EMD) will be placed on the collagen sponge (Botiss, Collacone) and then applied in the wound so that the side of the sponge which is covered with Emdogain is in contact with the root surface.
224203469|NCT03147040|DRUG|Carboplatin|Chemotherapy treatment with carboplatin and atezolizumab
224203470|NCT03147040|DRUG|Atezolizumab|Chemotherapy treatment with carboplatin and atezolizumab
224203471|NCT02439801|PROCEDURE|PEEP 0|0 cmH2O positive end expiratory pressure
224203472|NCT02439801|PROCEDURE|PEEP 5|5 cmH2O positive end expiratory pressure
224203473|NCT02439801|PROCEDURE|PEEP 8|8 cmH2O positive end expiratory pressure
224203474|NCT04681001|DEVICE|nasal spray|application of nasal spray into nostrils and mouth
224312923|NCT05168683|DRUG|Each ALLN-346 treatment will be radiolabelled to contain 4 MBq 99mTc at time of dosing in fasted/fed state|Selected dosing of Part One treatments in fasted and/or fed states
224312924|NCT00442871|DRUG|eltrombopag|eltrombopag 50 mg oral
224312925|NCT01586793|DEVICE|Magstim Rapid2 Stimulator|1 Hz in 1 train of 20-minute duration (1,200 pulses per session) at 120% of the rMT.
224203475|NCT03080272|OTHER|no intervention will take place|Only registration and data collection of patients' care and treatment will take place. There will be no changes in patients' treatment. No intervention will take place
224203476|NCT02871336|OTHER|Data collection|
224203477|NCT02701049|OTHER|Methods to collect SO/GI information in the ED|In Mode 1, all patients presenting to the ED will have SO/GI information collected verbally by the nurse, which is standard of care. In Mode 2, all patients presenting to the ED will have SO/GI information collected in a non-verbal manner, in which the registrar will ask them to complete an electronic form.
224312926|NCT01586793|DEVICE|Magstim Rapid2 Stimulator|10 Hz in 75 trains of 4-seconds duration, with 26-seconds intertrain intervals (3,000 pulses per session) at 120% of the rMT.
224312927|NCT00641615|BIOLOGICAL|RNF43-721|Doses of 0.5mg, 1.0mg, 3.0mg/body/week
224312928|NCT02006329|DEVICE|acupuncture|
223511024|NCT05573360|OTHER|NGF5-A test formulation|One drop of investigational product instilled on the eye
223511025|NCT05573360|OTHER|NGF4-B test formulation|One drop of investigational product instilled on the eye
223511026|NCT05573360|OTHER|NGF6-B test formulation|One drop of investigational product instilled on the eye
223511027|NCT05573360|OTHER|NGF6-E test formulation|One drop of investigational product instilled on the eye
224203478|NCT02709759|BEHAVIORAL|Motivational intervention|Involves 60 minutes of counseling delivered by videoconferencing. Provides feedback on drinking and HIV and related behaviors.
224203479|NCT02709759|BEHAVIORAL|Brief Advice|Involves 5-10 minutes of brief counseling to reduce drinking
224203480|NCT02709759|BEHAVIORAL|Interactive text messaging|Involves receiving daily text messages that enable participants to track their drinking and related consequences. Provides feedback on drinking and allow setting of goals.
224203481|NCT01654211|DRUG|danoprevir|single iv infusion
224203482|NCT01654211|DRUG|danoprevir|single oral dose
224203483|NCT01654211|DRUG|placebo|single iv infusion
224312929|NCT00637767|DRUG|melphalan|
224312930|NCT00637767|PROCEDURE|autologous hematopoietic stem cell transplantation|
224312931|NCT00637767|RADIATION|yttrium Y 90 anti-CD66 monoclonal antibody BW 250/183|
224312932|NCT03544944|DRUG|TJP-008-1|Subjects who are randomized into group TJP-008-1 will receive bowel preparation on the same-day.
224312933|NCT03544944|DRUG|TJP-008-2|Subjects who are randomized into group TJP-008-2 will receive bowel preparation from evening to next morning.
224312934|NCT03544944|DRUG|Coolprep powder|Subjects who are randomized into group Coolprep will receive bowel preparation from evening to next morning.
224312935|NCT01238380|OTHER|patient care pathway|"Stage 1: Urinary c-peptide creatinine ratio (UCPCR); if positive progress to Stage 2.~Stage 2: Pancreatic auto-antibodies measurement (GAD65 \& IA2); if negative progress to genetic testing.~Genetic testing for HNF1A, HNF4A, GCK. If positive, progress to Stage 3.~Stage 3: review and potential change of diabetes treatment. Monitor success via use of three standardised health and quality of life questionnaires and Hba1c pre-treatment change and at 1, 3, 6 and 12 months post-treatment change."
223511028|NCT05573360|OTHER|Systane eye drop|One drop of commercial product instilled on the eye
223511029|NCT00441740|DRUG|Vinorelbine|Vinorelbine (oral) 70 mg/m2, on days 1 and 15 every 4 weeks for 6 cycles
224312936|NCT04585230|DRUG|CBD|CBD oil Roll-On Stick
224312937|NCT04585230|DRUG|Mineral Oil|Mineral Oil- Roll on Stick
223511030|NCT00441740|DRUG|Gemcitabine|Gemcitabine 900 mg/m2 on days 1 and 15 every 4 weeks for 6 cycles
223511031|NCT00441740|DRUG|Docetaxel|Docetaxel 75 mg/m2 intravenous on day 8 every 3 weeks for 6 cycles
223511032|NCT00441740|DRUG|Gemcitabine|Gemcitabine 1000 mg/m2 intravenous, on days 1 and 8 every 3 weeks for 6 cycles
223511033|NCT00003812|BIOLOGICAL|filgrastim|
223511034|NCT00003812|DRUG|carboplatin|
223511035|NCT00003812|DRUG|etoposide|
224203484|NCT01654211|DRUG|ritonavir|oral doses
224203485|NCT03165253|DRUG|Bifidobacterium Animalis Oral Product|The synbiotic group will receive this product.
224203486|NCT03165253|DRUG|Amoxicillin Oral Tablet|50mg/kg/day B.I.D.
224203487|NCT03165253|DRUG|Clarithromycin Oral Tablet|15 mg/kg/day B.I.D.
224203488|NCT03165253|DRUG|Omeprazole|1 mg/kg/day
224203489|NCT02461147|PROCEDURE|Cholecystectomy with intraoperative cholangiogram|cf. arm/group description. This intervention is not assigned by the investigators: it is the standard treatment at the investigators institution.
224203490|NCT02633462|PROCEDURE|scaling and root planing , Myo-inositol|scaling and root planing along with Myo-inositol supplementation (1 gm twice a day)
224203491|NCT02633462|DRUG|Myo-inositol|only provided treatment with Myo-inositol supplementation (1 gm twice a day)
224203492|NCT01508286|DRUG|Telaprevir + peginterferon alfa + ribavirin|During the first 12 weeks of the early access program, all eligible patients will receive telaprevir 750 mg every 8 hours in combination with peginterferon-alfa and ribavirin.
224203493|NCT01508286|DRUG|peginterferon alfa + ribavirin|Patients with severe fibrosis who are treatment naïve or prior treatment relapsers will subsequently be treated with peginterferon-alfa and ribavirin alone for either an additional 12 or 36 weeks.
224203494|NCT01508286|DRUG|peginterferon alfa + ribavirin|Previously treated patients with prior partial or null response, or who had viral breakthrough, with severe fibrosis and all subjects with cirrhosis will subsequently be treated with peginterferon-alfa and ribavirin alone for an additional 36 weeks.
224203495|NCT01291186|DRUG|BPV6NO|intrathecal bupivacaine 6 mg for BMI less than 27.5 kg/m2
224203496|NCT01291186|DRUG|BPV7NO|intrathecal bupivacaine 7 mg for BMI less than 27.5 kg/m2
224203497|NCT01291186|DRUG|BPV8NO|intrathecal bupivacaine 8 mg for BMI less than 27.5 kg/m2
224312938|NCT04585230|DRUG|Placebo|Roll- On stick with no CBD and no Mineral Oil
223511036|NCT00003812|DRUG|paclitaxel|
223617118|NCT06457724|DIETARY_SUPPLEMENT|Placebo|Participants will take four placebo tablets daily for 28 days. The tablets should be taken after each of the following meals: breakfast, lunch, afternoon break, and dinner.
224203498|NCT01291186|DRUG|BPV9NO|intrathecal bupivacaine 9 mg for BMI less than 27.5 kg/m2
224203499|NCT01291186|DRUG|BPV10NO|intrathecal bupivacaine 10 mg for BMI less than 27.5 kg/m2
224203500|NCT01291186|DRUG|BPV11NO|intrathecal bupivacaine 11 mg for BMI less than 27.5 kg/m2
224203501|NCT01291186|DRUG|BPV6O|intrathecal bupivacaine 6 mg for BMI over 27.5 kg/m2
224203502|NCT01291186|DRUG|BPV7O|intrathecal bupivacaine 7 mg for BMI over 27.5 kg/m2
224203503|NCT01291186|DRUG|BPV8O|intrathecal bupivacaine 8 mg for BMI over 27.5 kg/m2
224203504|NCT01291186|DRUG|BPV9O|intrathecal bupivacaine 9 mg for BMI over 27.5 kg/m2
224203505|NCT01291186|DRUG|BPV10O|intrathecal bupivacaine 10 mg for BMI over 27.5 kg/m2
224203506|NCT01291186|DRUG|BPV11O|intrathecal bupivacaine 11 mg for BMI over 27.5 kg/m2
224203507|NCT03490539|DRUG|Mycophenolate Mofetil|oral tablets
224203508|NCT03490539|DRUG|Azathioprine|oral tablet
224203509|NCT00232778|DEVICE|GAMMA-Iridium-192 catheter|
224203510|NCT04501809|PROCEDURE|compare misoprostol with combined oxytocin and cervical foly catheter|we will compare using misoprostol alone in one group with oxytocin and cervical catheter in the other group
224203511|NCT05372211|OTHER|not use of any intervention|not use of any intervention
224203512|NCT04727580|DRUG|HSK7653 10mg Q2W|HSK7653 5mg (2 tablets) and placebo of HSK7653 25mg (1 tablet) Q2W, oral, Day1 to week12
224203513|NCT04727580|DRUG|HSK7653 25mg Q2W|HSK7653 25mg (1 tablet) and placebo of HSK7653 5mg (2 tablets) Q2W, oral, Day1 to week12
224203514|NCT04727580|DRUG|Placebo|Placebo of HSK7653 25mg (1 tablet) and placebo of HSK7653 5mg (2 tablets) Q2W, oral, Day1 to week12
224203515|NCT00556166|DEVICE|Enterra Therapy Gastric Stimulator|"The intramuscular stomach leads, implanted in a minimally invasive surgical procedure lasting 1-3 hours, are placed on the greater curvature of the stomach. The implanted pulse generator (IPG) is about 2 1/2 x 2 x 1/2 and is implanted in a subcutaneous pocket, generally created in the abdominal area, and is then connected to the leads. The IPG provides the energy source that delivers the electrical pulse to the stomach muscle through the stomach leads to improve the symptoms of gastroparesis.~The doctor will use an external programmer to change the settings of the neurostimulator and control the neurostimulator after implantation. Part of the programmer is held outside the body over the implant site and can adjust or change the settings of the neurostimulator using radio remote control."
224203516|NCT05005130|OTHER|TASKPEN|"TASKPEN is the name of the package of implementation strategies proposed by the investigators that are intended to deliver the WHO PEN intervention in routine HIV clinical practice settings in Zambia. TASKPEN has five components which will be the subject of stakeholder consultation and adaptation in this formative research protocol. The package of integrated HIV/NCD services includes:~1. WHO PEN protocols, algorithm, \& training materials adapted for Zambia~2. Access to cardio-metabolic condition screening \& laboratory monitoring~3. Non communicable disease-focused electronic medical record module~4. Integrated non-communicable/HIV care (one stop shop for services)~5. Strengthened non-communicable disease (NCD) medication supply chain, including multi-month dispensing (MMD)"
224203517|NCT04395040|OTHER|Semi-structured interview|Semi-structured interview
224203518|NCT06547814|BEHAVIORAL|Standard implementation webinar and online training|The one-hour webinar (either live or pre-recorded) will include updated information about the COVID-19 virus, variant nomenclature, vaccine eligibility, mechanisms of action, and outcomes. The 30-minute online training addresses how to communicate about COVID-19 vaccinations, presents a 5-step process for initiating conversations, includes example verbiage about how to address specific concerns, and has example videos that show how to implement the 5-step process with vaccine hesitant patients.
224203519|NCT06547814|BEHAVIORAL|Virtual facilitation|This intervention involves a 30-minute virtual facilitation site visit and at least 8, 30-minute virtual facilitator coaching sessions. The virtual site visit over Zoom will establish the personnel and workflows at each pharmacy and allow the facilitator to establish rapport. Weekly Zoom calls will allow the virtual facilitator to work with a participant to review overall implementation challenges associated with approaching patients, delivering the intervention, and documenting results. Lastly, either the facilitator or the participant can request and schedule a Zoom call to go over any pressing implementation issue in need of rapid attention (e.g., technical difficulties with the website).
224203520|NCT00335985|DRUG|GB-0998|8 mL (400 mg of GB-0998)/kg per day is intravenously administered for five successive days
224203521|NCT00335985|DRUG|Placebo of GB-0998|8 mL/kg per day is intravenously administered for five successive days
224203522|NCT03016988|DRUG|Bortezomib|Bortezomib(V) 1.3mg/m2, subcutaneously,day 1,4,8,11;
224203523|NCT03016988|DRUG|Fludarabine|Fludarabine(F) 25mg/m2, intravenously day 1-3;
224203524|NCT03016988|DRUG|Cytarabine|Cytarabine(A) 500mg/m2 for 3 days(day1-3)
224203525|NCT05736809|OTHER|Low-dye taping|Low-dye taing using 4 tapes around calcaneam
224203526|NCT05736809|OTHER|Plantar fascia stretching|out of 21 participants 7 will be included in the study design as an active participants group using plantar fscia stretching in acute stage
224203527|NCT05736809|OTHER|sham taping|out of 21 participants 7 will be included in the study design as an plecebo group using sham taping in acute stage
224203528|NCT02985515|BEHAVIORAL|Smell training|Participants will be provided with 4 vials of essential odors. Participants will sniff each scent for 20-30 seconds, twice daily, for 12 weeks. The participant will take 30 seconds of rest between each scent. All participants will undergo this smell training regimen for 12 weeks.
223511037|NCT00003812|DRUG|topotecan hydrochloride|
223511038|NCT00003812|RADIATION|radiation therapy|
223511039|NCT01386320|PROCEDURE|Ultrasound guided ankle block|Under ultrasound guidance, block of the tibial nerve, superficial and deep branches of the common peroneal nerve and saphenous nerves will be carried out using 12 mls 0.5% levobupivacaine and 12 mls 0.75% levobupivacaine.
223617119|NCT06159452|DRUG|SAR153191-P3 drug product|Pharmaceutical form:Solution for injection-Route of administration:Subcutaneous injection
223511040|NCT01386320|PROCEDURE|Medial forefoot block|Using peripheral nerve stimulator guidance, the tibial and common peroneal nerves will be blocked ( plus the saphenous nerve ), using a total of 12 mls 0.75% levobupivacaine and 12 mls 0.5% levobupivacaine.
224203529|NCT05503160|BEHAVIORAL|Intervention|Structured (video-)call by qualified nursing staff with breast cancer patients, with the intention to overcome side effects, distress or non-adherence to endocrine therapy.
224203530|NCT02875431|PROCEDURE|Patients undergo ACDF or cervical vertebral body replacement|
224203531|NCT00568516|DRUG|ASP3550|subcutaneous administration
224203532|NCT01129518|BIOLOGICAL|Glyco-conjugate Neisseria meningitidis serogroup C (MenC) vaccine|"In order to ensure proper intramuscular injection of the study vaccines, a 23G (0.5mm in diameter) needle of at least 1 inch (2.54 cm) length will be used. All vaccines will be administered intramuscularly.~Then MenC vaccine will administered either once (at 3 months) or twice (at 3 and 4 months) depending on treatment group to either the thigh, deltoid or a combination of the two."
224203533|NCT01129518|BIOLOGICAL|Routine schedule immunisations except monovalent MenC vaccine|Routine schedule immunisations will be given according to NHS guidelines.
224203534|NCT03310606|OTHER|Dosage of serum and peritoneal of the B lactam used for antibiotic treatment|Dosage of serum and peritoneal of the B lactam used B lactam concerning are : CEFTRIAXONE, CEFOTAXIME, PIPERACILLINE/TAZOBACTAM, IMIPENEM
224203535|NCT06543095|OTHER|Pain level|Post-operative pain levels of the patients with detected using VAS score.
224203536|NCT02854722|DRUG|Deferasirox and calcium-vitamin D3|"deferasirox and calcium-vitamin D3 Deferasirox is an orodispersible tablet and should be taken daily 30 minutes before breakfast, with a dose of 10 mg/Kg/day ± 5 mg/Kg/day during 12 month.~Calcium 500 mg and vitamin D3 800 IU should also be taken daily as a basic therapy."
224203537|NCT02854722|DRUG|Calcium-vitamin D3|Calcium 500 mg and vitamin D3 800 IU are taken daily as a basic therapy.
224203538|NCT05550025|DRUG|camrelizumab& apatinib|"TACE（transcatheter arterial chemoembolization） combined with Apatinib and Camrelizumab Camrelizumab 200mg every 3 weeks. Taking Apatinib-Mesylate Tablets (250 mg/tablet) orally after meals, once a day, for continuous medication.~The cumulative maximum drug use period is up to 1 years. The patient is concurrent on medication until the treatment discontinuation criteria specified in the protocol appear."
224203539|NCT01184781|DEVICE|Comparison of capsule endoscopy Pillcam II™ versus colonoscopy|On the same patient, we compare both methods (video-colonoscopy vs capsule endoscopy)
224203540|NCT03312881|DIAGNOSTIC_TEST|quantitative sensory testing|multiple modality testing of generalized and localized changes in somatosensory perception
224203541|NCT03312881|DIAGNOSTIC_TEST|neuroimaging|magnetic resonance imaging (MRI)
224312939|NCT02121392|DEVICE|Adductor Canal Nerve Block Catheter|ACNB catheter will be placed by anesthesia residents under the supervision of board-certified anesthesiologists familiar with regional anesthesia techniques, who are part of the anesthesia pain service. They will be performed at the bedside, aseptically, with the patient's vital signs monitored throughout the procedure. 1% lidocaine will be infiltrated in the skin and subcutaneous tissues overlying the adductor canal as visualized on ultrasound. Via a 17 gauge touhy needle a closed tip non-stimulating, epidural catheter will be placed after 1% lidocaine is used to hydrodissect the space lateral to the superficial femoral artery within the adductor canal. The catheter will be secured to the skin. All catheters will be connected to infusion pumps with opaque plastic bags covering the pumps. The functional ACNB pumps will run 8cc/h.
224312940|NCT02121392|DEVICE|Adductor Canal Nerve Block Sham Catheter|Patients randomized to the sham catheter will have a chlorhexidine prep of the skin and ultrasound examination of the adductor canal on postoperative day #1. To minimize patient risk, a wooden applicator will be used to apply 10 seconds of pressure to the leg followed by catheter securing to the skin with the same tegaderm and paper tape dressing used on functional catheters. All catheters will be connected to infusion pumps with opaque plastic bags covering the pumps. The sham catheter pumps will not be turned on.
224312941|NCT02121392|DRUG|Bupivacaine|In the functioning continuous adductor canal block, 0.125% bupivacaine will be infused at a rate of 8cc/hr.
224203542|NCT03312881|OTHER|Patient Reported Outcome Measures|neuropathic pain screening tool; validated questionnaires
224203543|NCT02964910|BIOLOGICAL|Recombinant Hepatitis E Vaccine (Escherichia Coli)|Participants would receive 3 doses of Recombinant Hepatitis E Vaccine (Escherichia Coli) intramuscularly at 0, 1, 6 month.
224203544|NCT04924738|BEHAVIORAL|Monitoring and lifestyle|Dietary and lifestyle modification recommended for pregnant women with hyperglycemia detected in pregnancy.
224312942|NCT03021863|BEHAVIORAL|Group A Reminder|Tone of reminder email (duty 14 days followed by duty 28 days for non-responders)
224312943|NCT03021863|BEHAVIORAL|Group B Reminder|Tone of reminder email (encouragement 14 days followed by encouragement 28 days for non-responders)
223617120|NCT06159452|DRUG|SAR153191-P2 drug product|Pharmaceutical form:Solution for injection-Route of administration:Subcutaneous injection
224203545|NCT01508923|DRUG|liraglutide|6 mcg/kg injected subcutaneously daily in each treatment period in random order. In total, subjects are treated 9-10 days
224312944|NCT03021863|BEHAVIORAL|Group C Reminder|Tone of reminder email (encouragement 14 days followed by duty for non-responders 28 days)
224312945|NCT03021863|BEHAVIORAL|Group D Reminder|Tone of reminder email (duty 14 days followed by encouragement for non-responders 28 days)
224312946|NCT03021863|BEHAVIORAL|Group E Reminder|Tone of reminder email (generic reminders 14 days followed by 28 days for non-responders)
223617121|NCT06159452|DRUG|SAR153191-C1F3 drug product|Pharmaceutical form:Solution for injection-Route of administration:Subcutaneous injection
223617122|NCT02470221|OTHER|Applying goal-directed fluid therapy by continuous hemodynamic monitoring system|Applying continuous hemodynamic monitoring system ( Vigileo/Flotrac) to monitor Stroke Volume Variation and Cardiac Output and further manage intra-operative fluid therapy.
224203546|NCT01508923|DRUG|placebo|6 mcg/kg injected subcutaneously daily in each treatment period in random order. In total, subjects are treated 9-10 days
224203547|NCT01614158|DEVICE|perimetry|perimetric examination using static stimuli, assessing the entire (80 degree) visual field with a fast thresholding algorithm (GATE) \[Schiefer 2008\] to know the extent/ magnitude of the visual field defect and its variability within the cohort and over time
224203548|NCT01614158|OTHER|D-BCVA|D-BCVA using EDTRS chart
224203549|NCT01614158|OTHER|RAPD|RAPD using swinging flashlight test
224203550|NCT01614158|DEVICE|IOP|IOP using applanation tonometer
224203551|NCT01614158|DEVICE|Spectralis OCT|RNFT and RNFV using Spectralis OCT (star scan, ring scan 2,8 mm and volume scan)
224203552|NCT01614158|OTHER|Fundus photography|Optic disk morphology will be documented by fundus photography
224312947|NCT03021863|BEHAVIORAL|Group F Reminder|Tone of reminder email (generic 14 days followed by duty for non-responders 28 days)
224312948|NCT03021863|BEHAVIORAL|Group G Reminder|Tone of reminder email (generic 14 days followed by encouragement for non-responders 28 days)
224312949|NCT03021863|BEHAVIORAL|Group H Reminder|Tone of reminder email ( duty14 days followed by generic for non-responders 28 days)
223617123|NCT02470221|OTHER|Conventional fluid therapy|Applying conventional fluid therapy according to Peking Union Medical College Hospital standard.
224203553|NCT03112096|DRUG|[18F]THK-5351|Imaging for evaluating the biodistribution, pharmacokinetics and safety of abnormal tau protein in the brain
224203554|NCT05629117|BEHAVIORAL|Personalized Diabetes Text Messaging (DB-TEXT) combined with Peer Support Education|Patients who are assigned to the DB-TEXT+PSE group will receive personalized short text message services twice weekly at approximately noon on Monday and Thursday for three months (12 weeks). Furthermore, they will receive the peer support education weekly from the peer supporter by telephone during three months
224203555|NCT05629117|BEHAVIORAL|Personalized Diabetes Text Messaging (DB-TEXT)|Personalized Diabetes Text Messaging (DB-TEXT)
224203556|NCT04332835|DRUG|Plasma|Day 1: CP-COVID19, 250 milliliters. Day 2: CP-COVID19, 250 milliliters.
224203557|NCT04332835|DRUG|Standard Therapy|Standard therapy defined by institutional protocol.
224203558|NCT00318409|DRUG|Bupropion|
224203559|NCT00318409|DRUG|Placebo|
224203560|NCT01304017|OTHER|Virtual Reality|The VR-therapy will include the playing of various virtual reality or video-games which encourages the use of the extremities while sitting and standing
224203561|NCT01304017|OTHER|Traditional Therapy|The traditional therapy will include exercise for balance and walking and for the upper extremity using traditional therapeutic tools such as balls, weights, chairs, bands, steps, etc.
224203562|NCT06440044|OTHER|Data collection|A prospectively maintained database query of all patients with CRC and VTE was initially performed, and then each patient's electronic record was reviewed for inclusion criteria.
224203563|NCT01637064|DRUG|Acthar|Physicians will prescribe Acthar at their own discretion; however the recommended dose is 80 units subcutaneously twice a week.
224203564|NCT00742859|DRUG|betrixaban|orally, once daily for at least 3 months
224312950|NCT03021863|BEHAVIORAL|Group I Reminder|Tone of reminder email (encouragement 14 days followed by generic non-responders 28 days)
223511041|NCT00474968|DEVICE|e2 Cell Collector [SoftPAP(R)]|Cervical cells collected using the e2 Cell Collector \[SoftPAP(R)\]
223511042|NCT00474968|DEVICE|Spatula/Brush|Cervical cells collected using a combination of a cervical spatula and an endocervical brush
223511043|NCT00270075|DRUG|epoetin alfa|
223511044|NCT02681432|DRUG|HIPEC|Cytoreductive surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) with Paclitaxel (175 mg/m2) for 60 minutes at 42-43 degrees.
223511045|NCT02681432|PROCEDURE|No HIPEC|Cytoreductive surgery without HIPEC
223511046|NCT01911325|DRUG|Buparlisib|
224203565|NCT00742859|DRUG|Warfarin|Warfarin will be prescribed by the investigator according to the standard of care.
224203566|NCT06251154|DEVICE|Lens 1|Daily disposable silicone hydrogel contact lens (diameter=14.0mm) for 15 minutes
223511047|NCT01911325|DRUG|Buparlisib matching placebo|
223511048|NCT01911325|DRUG|Docetaxel|
224203567|NCT06251154|DEVICE|Lens 2|Daily disposable silicone hydrogel contact lens (diameter=14.1mm) for 15 minutes
224203568|NCT06132100|DEVICE|digitalized incentive spirometry|digitalized incentive spirometry
224203569|NCT06132100|DEVICE|traditional incentive spirometry|traditional incentive spirometry
224203570|NCT06567184|BEHAVIORAL|Strong Hearts Urban|A 12-week multi-level intervention targeting behavior modification, nutrition education, strength training, aerobic exercise, and stress reduction activities
223511049|NCT03720275|GENETIC|Systematic screening of TTR mutations|The diagnosis of TTR-FAP requires genetic analysis using direct sequencing of TTR gene.The diagnosis of TTR-FAP will be performed using standard procedures following international recommendations, requiring genetic analysis of the TTR gene.
223511050|NCT03719937|DEVICE|weight on the anterior chest of the patient|The investigators aim at assessing whether and to what extent an artificial increase in chest wall elastance, while the patient is in the supine position, may yield a significant benefit to oxygenation. The increase in chest wall elastance will be will be achieved placing a 100 g/kg weight on the anterior chest wall of the patient while he/she is in the supine/semirecumbant position. The weights will be placed on the patients' chest for 120 minutes, and then removed. A number of measurements will be recorded before and after the procedure.
223511051|NCT00981175|BIOLOGICAL|Live attenuated Japanese encephalitis virus, then ChimeriVax diluent|ChimeriVax™-JE, 0.5 mL subcutaneous on Day 0; ChimeriVax diluent 0.5 mL subcutaneous on Day 28
223617124|NCT03268785|DIAGNOSTIC_TEST|Intraoperative identification method|After needle pucture of suspicious nodes, Diff-quik staining was used to distinct lymph nodes and parathyroid glands. PTH test assay was used for parathyroid identification. Postoperative HE staining were applied as golden standard.
224203571|NCT03501407|DIAGNOSTIC_TEST|Blood samples|1 or 2 blood samples will be collected from the patient.
224203572|NCT03501407|DIAGNOSTIC_TEST|skin biopsy|A skin biopsy will be performed on the periphery of the erythema migrans
224203573|NCT00956709|DRUG|levobupivacaïne 0,5 %|20mL de levobupivacaïne 0,5 % 20mL de ropivacaïne 0,5 %
224203574|NCT00956709|DRUG|ropivacaïne 0,5 %|20mL de ropivacaïne 0,5 %
224203575|NCT04064931|DIAGNOSTIC_TEST|Detection of niacin and other vitamins in plasma|Detection of niacin and other vitamins in plasma
224203576|NCT05589649|PROCEDURE|Erector spinae plane block|Ultrasound-guided erector spinae plane block
224203577|NCT05589649|PROCEDURE|Paravertebral block|Ultrasound-guided paravertebral block
224203578|NCT00962013|DEVICE|Restoration® Modular Revision Hip System|Restoration® Modular Revision System
224203579|NCT00868816|DRUG|12 cycles of oxaliplatine based adjuvant chemotherapy|oxaliplatine 85 mg/㎡ d1, lv 200 mg/㎡ d1, 5-fu 1300 mg/㎡ ivgtt maintain for 48hr, every 3 weeks/cycle, 12 cycles
224203580|NCT00868816|DRUG|8 cycles of oxaliplatine based adjuvant chemotherapy|oxaliplatine 85 mg/㎡ d1, lv 200mg/㎡ d1, 5-fu 1300 mg/㎡ ivgtt maintain for 48hr, every 3 weeks/cycle, 8 cycles
224203581|NCT00486642|DRUG|Bicalutamide|Given PO
224203582|NCT00486642|OTHER|Laboratory Biomarker Analysis|Correlative studies
224203583|NCT00486642|DRUG|Pazopanib Hydrochloride|Given PO
224312951|NCT04283604|DRUG|MPH|The treatment will include taking the patient's own medication by the patient himself in the treatment session 60-180 minutes before the beginning of the tests, according to their prescription given by their own physician. Participants must have consumed this medication at least 3 months before the first session as their regular treatment for ADHD. Note, we are not planning on giving the medication to the participant, rather he/she will consume their own prescribed MPH by them self.
224312952|NCT01352416|DRUG|Ranolazine|Ranolazine 1000mg (2-500mg tablets) twice daily. Starting 2 days prior to surgery, morning of surgery and up to 14 days post operative depending when the breathing tube is removed from the patient post operative. If intolerant to the study drug due to adverse effects or the patient is started on diltiazem or verapamil post operative then the dose will be reduced to 500mg (1-500mg tablet) twice daily
224312953|NCT01352416|DRUG|Placebo|Placebo 1000mg (2-500mg tablets) twice daily. Starting 2 days prior to surgery, morning of surgery and up to 14 days post operative depending when the breathing tube is removed from the patient post operative. If intolerant to the study drug due to adverse effects or the patient is started on diltiazem or verapamil post operative then the dose will be reduced to 500mg (1-500mg tablet) twice daily
224312954|NCT02497638|DRUG|Metformin|One month run-in of 850 mg metformin once daily, followed by 850 mg twice daily of metformin until progression.
224312955|NCT02497638|DRUG|Atorvastatin|Atorvastatin 20 mg once daily until progression.
224312956|NCT02497638|DRUG|Placebo (corresponding to metformin)|One month of one placebo tablet (corresponding to metformin) once daily, followed by one placebo tablet twice daily until progression.
224312957|NCT02497638|DRUG|Placebo (corresponding to atorvastatin)|One placebo tablet (corresponding to atorvastatin) once daily until progression.
224312958|NCT02390024|DEVICE|Invasive Mechanical Ventilation|"Mechanical ventilation parameters will be monitorized during the ICU stay in all patients Four types of ventilators will be used:~Servo Dräger Evita XL Dräger Evita 4 Puritan Bennet 840"
224312959|NCT02597127|DRUG|ALN-PCSSC|ALN-PCSSC is a small interfering ribonucleic acid (RNA) that inhibits PCSK9 synthesis and is given as SC injections
224312960|NCT02597127|DRUG|Normal Saline|Saline (sterile, normal, 0.9%) solution given as SC injections
224312961|NCT03231566|BEHAVIORAL|Pain Neuroscience Education|See arm/group description
224312962|NCT03097848|PROCEDURE|RFA|for eligible cases, radiofrequency ablation will be given only.
224312963|NCT03097848|DRUG|Sorafenib|for eligible cases, combination treatment with RFA and Sorafenib will be given.That is sorafenib for 2 week,then radiofrequency ablation
224312964|NCT03960125|DEVICE|Photodynamic Therapy|Blue Light Therapy Exposure
224312965|NCT03960125|DRUG|4% Imipramine|A tricyclic antidepressant (TCA) medication. Though it is usually taken orally, topical preparations (4%) has use in topical anesthetics and anti-pain medicaments.
223511052|NCT00981175|BIOLOGICAL|ChimeriVax diluent, then Live attenuated Japanese encephalitis virus|ChimeriVax diluent, 0.5 mL subcutaneous on Day 0 and ChimeriVax™-JE, 0.5 mL subcutaneous on Day 28.
223512439|NCT05468177|COMBINATION_PRODUCT|neoadjuvant chemotherapy|"Cetuximab: 500mg/m2,day1, every 2 weeks. mFOLFOX: oxaliplatin 85mg/m2, day 1;LV 400mg/m2, day 1;5-FU 400mg/m2, day 1, then 1200mg/ (m2•d) ×2days(total 2400mg/m2, infusion 46-48h) (every 2 weeks).~Anti-PD-1(Sintilimab Injection):200mg every 3 weeks. Surgery will be performed after 4 cycles for locally advanced or initially resectable metastatic right colon cancer.If the initial unresectable metastatic right colon cancer were converted into resectable metastases, and surgery will be performed. Patients who failed to convert after 6 cycles of treatment will be withdrawn from the study.Cetuximab +mFOLFOX was treat for 8 cycles, and Anti-PD-1 was treated for one year in the perioperation period unless disease progression, toxicity intolerance, initiation of new anti-tumor therapy."
224203584|NCT00486642|OTHER|Pharmacological Study|Correlative studies
224203585|NCT03074916|DEVICE|DIP arthroplasty or arthrodesis|Arthroplasty of the DIP Joint or arthrodesis of the DIP joint
224203586|NCT02284152|BEHAVIORAL|infant-led feeding|mothers' feeding practices and infant intakes were compared between a typical feeding condition and an infant-led feeding condition, where the experimenter ensured the feeding was in response to infant hunger and fullness cues.
224203587|NCT04681807|BEHAVIORAL|Emotion Recognition Training|Participants will undergo 2 fMRI scans, one before and one after the training sessions. There will be 4 visits consisting of an emotion recognition training exercise on iPad, lasting for a period of \~1 hour each. (More details about each condition will be added after study completion to protect the blinding of participants) .
224312966|NCT03960125|DRUG|Base Cream|Control to 4% Imipramine
224312967|NCT00823810|OTHER|PET/CT|18F-FDG PET/CT
224312968|NCT03938623|OTHER|Training|Teaching general practitioners to use the patient-centered approach when suggesting colorectal cancer screening
224312969|NCT00645632|DRUG|cisplatin|
224312970|NCT00645632|DRUG|doxorubicin hydrochloride|
224312971|NCT00645632|DRUG|ifosfamide|
224312972|NCT00645632|DRUG|methotrexate|
224312973|NCT00645632|PROCEDURE|adjuvant therapy|
224312974|NCT00645632|PROCEDURE|neoadjuvant therapy|
224312975|NCT00645632|PROCEDURE|therapeutic conventional surgery|
224312976|NCT02394093|DRUG|Aspirin (Acetylsalicylic acid, BAYe4465)|One stick pack containing 500 mg acetylsalicylic acid dry powder
224312977|NCT02394093|DRUG|Aspirin (Acetylsalicylic acid, BAYe4465)|One tablet containing 500 mg acetylsalicylic acid
224312978|NCT02394093|DRUG|Aspirin (Acetylsalicylic acid, BAYe4465)|One effervescent tablet containing 500 mg acetylsalicylic acid
224312979|NCT05456230|DRUG|Midazolam|Midazolam as a premedication was given as the patient is taken to the operating room and typically within 15 minutes of anesthetic induction.
224312980|NCT02679638|OTHER|Factors and perceptions questionnaire|A detailed questionnaire inquiring about demand factors, supply factors and perceptions affecting patients' treatment choices in 5 key decision points: participation role in the decision making process, hospital choice, treatment regimen choice, surgical extent and surgeon choice.
224312981|NCT02679638|OTHER|Qualitative interview|Depth interviews with 20 breast cancer patients, 2 spouses and 3 staff members.
223761261|NCT01184274|DRUG|SB939|"Dose Levels for Part A~-1 - 20mg/m2 - oral - Every other day three times/week1 for three consecutive weeks, followed by one week off-dosing~1. (starting dose) 25mg/m2 - oral - Every other day three times/week1 for three consecutive weeks, followed by one week off-dosing~2. \- 35mg/m2 - oral - Every other day three times/week1 for three consecutive weeks, followed by one week off-dosing~3. \- 45mg/m2 - oral - Every other day three times/week1 for three consecutive weeks, followed by one week off-dosing~4+ - Previous level + 10mg/m2 - oral - Every other day three times/week1 for three consecutive weeks, followed by one week off-dosing"
223761262|NCT02022228|DRUG|triptorelin|0.2 mg triptorelin, ih
223761263|NCT02022228|DRUG|hCG|1000 IU hCG, im
223761264|NCT02022228|DRUG|hCG|500IU hCG, im
223761265|NCT06097208|BEHAVIORAL|community-based health promotion and obesity prevention intervention|The intervention involving measurements of children aged three- to four-years old in kindergartens, parents of the children had the opportunity of individual contact with a community health nurse, and education to kindergartens manager and employees e.g. pedagogues and kitchen staff. as well to parents of children in kindergartens.
223761266|NCT01970839|DEVICE|tourniquet, sensory nerve conduction abnormality|
224203588|NCT04681807|BEHAVIORAL|Active Control Training|Participants will undergo 2 fMRI scans, one before and one after the training sessions. There will be 4 visits consisting of a control training exercise on iPad, lasting for a period of \~1 hour each. (More details about each condition will be added after study completion to protect the blinding of participants) .
224203589|NCT03706209|DRUG|MP1032|hard gelatin capsules containing 50mg MP1032 as active ingredient
224203590|NCT03706209|DRUG|Placebo|hard gelatin capsules containing no active ingredient
224203591|NCT00163371|DRUG|Ciclesonide|
224203592|NCT03003793|DIAGNOSTIC_TEST|Hyperinsulinemic euglycemic clamp|Hyperinsulinemic euglycemic clamp to detect insulin sensitivity
224203593|NCT06567951|DIETARY_SUPPLEMENT|Extra Virgin Olive Oil (EVOO)|This is the first time that prengnt women with maternal supraphysiological hypercholesterolemia will be suplemented with EVOO during pregnancy. The intervention will be daily EVOO suplementation (36mL) form gestational week 28 until delivery
224203594|NCT03635021|DRUG|FOLFOX regimen|oxaliplatin 85 mg/m2 administered by IV infusion over 120 minutes on Day 1, L-leucovorin 200 mg/m2 administered as a 2-hour IV infusion on Day 1 and 5-FU 400 mg/m2 administered as IV bolus over approximately 2 to 4 minutes on Day 1 followed by 5-FU 2400 mg/m2 administered as IV infusion over 46- 48 hours on Days 1 and 2
224203595|NCT03635021|DRUG|Panitumumab|6 mg/kg administered by intravenous (IV) infusion over 60 minutes on Day 1 of each 14-day cycle
224203596|NCT03635021|DRUG|Bevacizumab|5 mg/kg administered by IV infusion over 60 minutes on Day 1 of each 14-day cycle
224203597|NCT03635021|DRUG|FOLFIRI regimen|irinotecan 180 mg/m2 administered as a 90 minutes IV infusion on Day 1, L-leucovorin 200 mg/m2 administered as a 2-hour IV infusion on Day 1 and 5-FU 400 mg/m2 administered as IV bolus over approximately 2 to 4 minutes on Day 1 followed by 5-FU 2400 mg/m2 administered as IV infusion over 46-48 hours on Days 1 and 2
224203598|NCT01895829|PROCEDURE|Magnetic Resonance Imaging (MRI)|On Day 1, patient will have 2 standard MRIs, as part of standard of care. About an hour after these 2 scans, patient receives ferumoxytol by vein. Right after that, first study MRI performed. On Day 2, about 24 hours after patient receives ferumoxytol, second study MRI performed.
224203599|NCT01895829|DRUG|Ferumoxytol|On Day 1, patient will have 2 standard MRIs, as part of standard of care. About an hour after these 2 scans, patient receives ferumoxytol by vein.
224203600|NCT05634629|PROCEDURE|Anterior Lamellar Recession|ALR is a common surgical treatment that splits the skin and orbicularis oculi muscle from the tarsus and conjunctiva to recede the anterior lamella and expose the tarsus. Interlamellar separation can be accomplished via a grey line technique, an eyelid crease approach, or a combination of the two
224203601|NCT05634629|PROCEDURE|Bilamellar Tarsal Rotation|the full-thickness transverse blepharotomy combined with everting sutures to rotate the inferior portion of the upper lid outwards and this procedure has a low recurrence risk
224312982|NCT05062213|OTHER|Moisturizer Body Lotion|Moisturizer Body Lotion
224312983|NCT01860352|DIETARY_SUPPLEMENT|Fish OIl|
223512440|NCT00605657|DRUG|Valproic Acid|Oral administration of valproic acid
223512441|NCT00605657|PROCEDURE|CT Scan|CT scans were done before and after treating the patient with valproic acid
223512442|NCT00605657|PROCEDURE|Blood Sample|Blood samples were collected before and after the intervention to monitor blood counts and biomarkers of ALPS
223512443|NCT02156505|PROCEDURE|placement of double bare stent|
223512444|NCT02156505|DEVICE|DoubleBare stent|
223512445|NCT01053065|DRUG|Atorvastatin - Cholestyramine - Sitosterol|
223512446|NCT02925143|OTHER|E-learning course in neuromuscular monitoring|An e-learning course designed to assess the challenges and common problems experienced by anesthetists when monitoring the neuromuscular blockade during general anesthesia.
223512447|NCT01218256|OTHER|Physical exercise training|aerobic endurance training (cycle ergometer, 60-70% heart rate reserve) hypertrophy resistance training (2sets, 10-12 repetitions, 70% of the one-repetition maximum) endurance resistance training (2 sets, 25-30 repetitions, 40% of the one-repetition maximum)
223512448|NCT04524429|PROCEDURE|Bariatric Surgery|Bariatric surgery includes sleeve gastrectomy and gastric bypass.
223512449|NCT05127200|DEVICE|Starstim (Neuroelectrics)|Anodal transcutaneous spinal direct current stimulation (a-tsDCS)
223512450|NCT05305703|OTHER|cervical stretching|Heating therapy for 10 minutes Passive stretching of neck muscles including Sub-occipital muscles, Trapezius upper boarder and Sternocleidomastoid muscle with 10 reps each
223512451|NCT05305703|OTHER|soft tissue mobilization|Heating therapy for 10 minutes Soft tissue mobilization for 8 minutes and trigger point release of sub-occiptal muscles with 5 repetitions each.
223512452|NCT01234376|DEVICE|Confocal laser endomicroscopy|Confocal laser endomicroscopy
223512453|NCT06292507|OTHER|MYOFASCIAL STRETCH|Group A 10 participants will receive Myofascial Stretching
223512454|NCT06292507|OTHER|CONTRACT-RELAX TECHNIQUE|group B 10 participants will receive Control-Relax Stretching Technique.
223512455|NCT02718482|DRUG|Gemcitabine and Docetaxel|Treatment with gemcitabine and docetaxel at day 1 and day 8 n a 3 weeks cycle
223512456|NCT02718482|DRUG|Ifosfamide|Treatment arm with high doses of ifosfamide continous infusion for 14 days in a 3 weeks cycle
224203602|NCT00345826|DRUG|dasatinib|
224203603|NCT02815189|PROCEDURE|Ibuprofen for post operative pain|All treatment sessions were approximately 50 minutes in length to allow for acceptable time for completion of treatment and retreatment in one or two visits. All the clinical procedures were performed by the author. Following local anesthesia with 2% lidocaine with 1:100,000 epinephrine (Septodont Saint-Maur des Fossés, France) and rubber dam isolation the tooth was disinfected with 5.25% NaOCl (Ultra bleach, Bentonville, AR, USA).
224203604|NCT02815189|DRUG|Acetaminophen 325 mg for Flare up|Each patient will be evaluated a week after completion the clinical procedures.
224203605|NCT06701292|DEVICE|PVS-PVI targeted ablation|"Omnipolar technology will be used to analyze all PVs and delineate the PVMS. Once identified, PVMS will be marked and described in a clockface fashion using a lateral view of the vein.Ablation will target the PVMS using the same power and force parameters as described for the WACA procedure. Effective ablation lesions and distance between ablation spots will be represented in the same manner too. Lesions should cover at least 5 mm outside the PVMS delineation on both PVMS borders of each myocardial sleeve. PVI will be demonstrated with the same technique described in the WACA procedure.~The PVI will be verified for each vein 10 minutes after the initial achievement of PVI."
224203606|NCT06701292|DEVICE|Wide area circumferential ablation (WACA)|After generating the 3D electroanatomical map of the heart to understand where treatment needs to be applied,using a tool called radiofrequency (RF) ablation, small burns will be made around the veins to block abnormal electrical signals. Each burn is applied with up to 50 watts of power and lasts up to 10 seconds.The ablation tool will press down with a force of around 10-20 grams.The mapping system (NAVX software) shows the burns on the 3D map
224203607|NCT04125160|DEVICE|Continuous glucose monitoring|Continuous glucose monitoring over 16 days
224203608|NCT04125160|DIAGNOSTIC_TEST|Glycaemic markers|Measurement of HbA1c, glycated albumin and fructosamine.
224203609|NCT02890966|DRUG|SHR4640|Day1\~Day7:oral administration
224203610|NCT02890966|DRUG|placebo|Day1\~Day7:oral administration
224203611|NCT04451109|DEVICE|Dilapan-S|Application of Dilapan-S and all other procedures regarding cervical ripening and induction of labor will be carried out as per the hospital's standard practice.
223511053|NCT03831555|BEHAVIORAL|PREP-C|"The Psychosocial Readiness Evaluation and Preparation for Hepatitis C Treatment (PREP-C) tool assesses a patient's psychosocial readiness to start HCV treatment. There are nine sections in the survey:~1. Motivation: reasons client wants to begin HCV treatment, concerns about treatment, and the importance of treatment~2. Information: knowledge about HCV treatment and one's own HCV disease status~3. Medication Adherence: current prescribed medications and adherence to them in the prior month~4. Self-efficacy: self-confidence about adhering to HCV treatment~5. Social Support and Stability: stability of financial, housing, and social support resources~6. Alcohol and substance use: alcohol and substance use behaviors and current treatment~7. Psychiatric Stability: current psychiatric status, previous and current treatment~8. Energy Level: sleep and fatigue~9. Cognitive Functioning: perceived difficulty with communication in health care setting, problem-solving ability, and memory."
223511054|NCT02619812|OTHER|Serum-derived bovine immunoglobulin/protein isolate (SBI)|SBI 10 grams (The subject will take a total of 4 packets of SBI; taken as two packets of SBI twice a day mixed with water or blended with certain foods)
223617125|NCT02271464|DRUG|Maintenance:BEVACIZUMAB|"Patients will be randomly assigned to receive induction chemotherapy with the G.O.N.O. FOLFOXIRI regimen plus bevacizumab:~* BEVACIZUMAB 5 mg/kg over 30 minutes, day 1~* IRINOTECAN 165 mg/sqm IV over 1-h, day 1~* OXALIPLATIN 85 mg/sqm IV over 2-h, day 1~* L-LEUCOVORIN 200 mg/sqm IV over 2-h, day 1~* 5-FLUOROURACIL 3200 mg/sqm IV 48-h continuous infusion, starting on day 1~with cycles repeated every 2 weeks for 4 months (8 cycles), followed after 2 weeks by (if no progression occurs):~\- BEVACIZUMAB 7.5 mg/kg over 30 minutes, day 1 (every three weeks)"
224203612|NCT00713765|DRUG|AZD3480|18 total doses of 40 mg, on days 1-18
224203613|NCT00713765|DRUG|Donepezil|One single dose of mg on day 5
224203614|NCT02454699|DRUG|MBX400|MBX-400, a white to off-white crystalline powder, will be given orally x 7 days to 4 cohorts. Cohort 1 receives 100 mg/day, Cohort 2 receives 350 mg, Cohort 3 receives 750 mg, Cohort 4 receives 1000 mg.
224203615|NCT02454699|OTHER|Placebo|Placebo capsules are supplied as white opaque, hard gelatin capsules filled with microcrystalline cellulose. 2 subjects from each cohort receive Placebo orally once per day x 7 days.
224203616|NCT02367807|DRUG|Emtricitabine and tenofovir disoproxil fumarate|This study will enroll 50 subjects who are offered TDF/FTC for 48 weeks as part of a combined biomedical/behavioral intervention offered in a community-based setting serving high-risk youth in an urban setting.
224203617|NCT05192954|DEVICE|LigaSureTM vessel sealing device|Device will be used to clamp, cauterize, seal, and transect tissue during vaginal hysterectomy.
224203618|NCT03833856|PROCEDURE|colonoscopy perforation|The development of perforation after colonoscopy
224203619|NCT06652230|OTHER|Smile Arc Marginal Ridge Approach (SAMRA)|Smile Arc Marginal Ridge Approach (SAMRA) is a new orthodontic bonding technique proposed by Dr. Dalia El Bokle where she stated that it provides more accurate orthodontic results and less time and effort needed during finished. No randomized clinical trials are done on this new approach yet so our study is the first one to test it. 0.018-inch MBT brackets will be used in our study.
224203620|NCT06652230|OTHER|MBT Chart Method|For our comparator group MBT Chart Method will be used. Using charts during orthodontic bonding procedures is considered the gold standard. 0.018-inch brackets will be used.
224203621|NCT03003728|DRUG|Elotuzumab|Elotuzumab 10 mg/kg via intravenous infusion on days -16, -3, 12, and 26
224203622|NCT03003728|DRUG|Melphalan|Melphalan 200 mg/m2 Ivia intravenous infusion on day -3
224203623|NCT03003728|PROCEDURE|Autologous Stem Cell Transplant (ASCT)|ASCT on day -2
224203624|NCT03003728|BIOLOGICAL|Expanded Natural Killer (ENK) Cells|ENK cell infusion on day 0
224203625|NCT03003728|DRUG|ALT-803|ALT-803 (Interleukin-15 superagonist) 10 ug/kg via subcutaneous injection on days 1, 8, 15, and 22
224203626|NCT03049371|OTHER|No Intervention for both groups|No Intervention for both groups However, computer-administered questionnaire will collect quantitative demographic information and details about surgical history, neovaginal health, neovaginal practices, and sexual behavior including neovaginal intercourse and drug use history from each participant
224203627|NCT05188807|DIAGNOSTIC_TEST|Airway ultrasonography|we will measure hyomental distance, skin-epiglottis distance, skin-hyoid distance, epiglottis-vocalcords distance
224203628|NCT02513693|DRUG|Standard neuromuscular blockade|Standard neuromuscular block provided by rocuronium to TOF-count 1-2. Reversal of the block with neostigmine.
224203629|NCT02513693|DRUG|Deep neuromuscular blockade|Deep neuromuscular block provided by rocuronium to PTC 1-2. Reversal of the block with sugammadex.
224203630|NCT01984229|DRUG|Alectinib|Alectinib will be administered as a single oral dose on Day 1 (Period 1) and Day 15 (Period 3) with an identical standardized meal (identical meal on Day 1 and Day 15 across all participants).
223511055|NCT02619812|DRUG|Colesevelam|Colesevelam 1.875 g (The subject will take a total of 12 capsules of Welchol 1.875g per day; taken as 6 capsules twice a day by mouth).
223511056|NCT02619812|OTHER|Double Placebo|Double placebo twice per day (The subject will take a total of 4 packets of placebo and 12 capsules daily taken as 6 capsules twice a day by mouth and two packets of placebo twice a day mixed with water or blended with certain foods).
223511057|NCT01834651|DRUG|Cabozantinib|Cabozantinib 60 mg daily (oral). Subjects may continue to receive study treatment until they experience unacceptable drug-related toxicity or disease progression.
223511058|NCT01242046|DIETARY_SUPPLEMENT|Caffeine|400 mg of caffeine in tablet form
223511059|NCT01242046|DIETARY_SUPPLEMENT|Placebo|Inert tablet
223511060|NCT05961384|DRUG|baxdrostat|a blood pressure lowering drug, oral dose
223511061|NCT01197105|BIOLOGICAL|Use of natural product (Schinus terebinthifolius)|Mouthwash (0,3125% of schinus terebinthifolius) 10mL per day during 14 days.
223511062|NCT03556280|DEVICE|GammaSense Stimulation System (Active Settings)|Proprietary auditory and visual sensory stimulation device.
223511063|NCT03556280|DEVICE|GammaSense Stimulation System (Sham Settings)|Proprietary auditory and visual sensory stimulation device.
223511064|NCT02884960|PROCEDURE|Uterine Fibroid Embolization|This procedure involves the administration of the study device into the uterine arteries to block the flow of blood in these vessels. This deprives fibroid tumors within the uterus of their blood flow, which can cause the tumors to die. This in turn can lead to the relief of symptoms associated with fibroids.
223511065|NCT04189588|DRUG|Cetirizine HCl 10 mg/mL|Comparison of two injectable products: cetirizine HCl 10 mg/mL and diphenhydramine 50 mg/mL, both administered during a 1 to 2-minute period by IV push using a 1 mL syringe
223511066|NCT04189588|DRUG|Diphenhydramine 50 mg/mL|Comparison of two injectable products: cetirizine HCl 10 mg/mL and diphenhydramine 50 mg/mL, both administered during a 1 to 2-minute period by IV push using a 1 mL syringe
223511067|NCT04189588|DRUG|anti-CD20 such as Rituximab or Paclitaxel|Compare the number of infusion reactions to treatment with an anti-CD20 such as Rituxan® (Rituximab) or Taxol® (Paclitaxel) after premedication with intravenous (IV) QUZYTTIR™ cetirizine hydrochloride (HCl) or IV diphenhydramine during first-cycle infusion or re-treatment. Re-treatment is defined as re-treatment with Rituxan® (Rituximab) or Paclitaxel after 6 months in patients with persistent infusion reactions while on maintenance or re-treatment.
223511068|NCT06291961|GENETIC|CS-101 injection|Autologous CD34+ hematopoietic stem cell suspension modified by in vitro base editing technique
223511069|NCT05813483|OTHER|Skinceuticals skin care product(CE)|fraxel laser therapy combined with Skinceuticals skin care product(CE) and routine moisturizing and sun protection
223511070|NCT05813483|OTHER|fraxel laser therapy|fraxel laser therapy combined with routine moisturizing and sun protection
223511071|NCT02334254|DRUG|rivaroxaban and ticagrel therapy|Antiplatelet therapy are mandatory at least 1 month after bare metal stent implantation, and 6 months after drug-eluting stent implantation.
223511072|NCT02334254|DRUG|triple antithrombotic regimen with warfarin, asipirin and clopidogrel|
223511073|NCT05616780|OTHER|Physiological test|Lung volume measurements will be obtained using nitrogen washout and body plethysmography
224203631|NCT01984229|DRUG|Posaconazole|Posaconazole will be administered as a 400-mg BID oral dose after a high-fat meal on Days 8 to 14 (Period 2) and Days 15 to 18 or 21 (Period 3).
224203632|NCT04620863|OTHER|t-DCS group|All the participants received daily stimulation sessions for 5 consecutive days, starting from the first Monday after hospital admission (Monday to Friday). The primary motor cortex (M1) was identified using the International 10-20 system for C3 (left M1) or C4 (right M1). For the stimulation, the anode was placed over the primary motor cortex (M1) ipsilateral to the side of trunk deviation, and the cathode was placed over the primary motor cortex (M1) contralateral to the side of trunk deviation (bi-hemispheric stimulation).
224203633|NCT04620863|OTHER|Sham group|The stimulation setting was exactly the same but the stimulation intensity was set according to a ramping up/ramping down method and delivered only in the first and last 30 seconds of each session. This stimulation paradigm is insufficient to produce a meaningful therapeutic effect, but it is necessary to guarantee the blind condition as it mimics the possible initial tingling sensation associated with active stimulation.
224203634|NCT02334046|DRUG|Remifentanil|Remifentanil was maintained at predetermined effect-site concentration during the periextubation period (initial concentration: 1.8 ng/ml) in elderly patients (65-80 years) .
224203635|NCT02334046|DRUG|Remifentanil|Remifentanil was maintained at predetermined effect-site concentration during the periextubation period (initial concentration: 1.8 ng/ml) in adult patients (20-60 years) .
223511074|NCT02326246|OTHER|multi-parametic MRI|
223511075|NCT03569007|DRUG|Larazotide|Synthetic 8-amino acid peptide formulated as enteric-coated beads in gelatin capsules
223511076|NCT03569007|DRUG|Matching Placebo|enteric-coated beads in gelatin capsules
223511077|NCT01681303|DRUG|AST-120|
223511078|NCT03502772|OTHER|Pilates exercises|Clinical Pilates training program will be given one session in a week for 8 weeks plus two days home exercise program. Group exercise sessions will be performed. The sessions will be supervised by a physiotherapist who is certified.
223511079|NCT03502772|OTHER|Home exercise program|written exercises that matched the aims of the Pilates exercises, 3 times per week for 8 weeks. These exercises reflect routine clinical practice (flexibility, strength, and balance exercises).
223511080|NCT05099588|OTHER|Other: observational study|Observational study
223511081|NCT00567801|PROCEDURE|conventional embolectomy/thrombectomy|
223511082|NCT00567801|PROCEDURE|embolectomy/thrombectomy with controlled reperfusion|
223511083|NCT03578263|DRUG|Carbetocin|Group (A): included 100 patients who received carbetocin 100 µg diluted in 10 ml normal saline and administered slowly (over 30-60 seconds) intravenously by anesthetist after the birth of the baby.
224312984|NCT00994578|BEHAVIORAL|CHESS|Patients randomized to the CHESS intervention will be trained to access the website. After being trained in usage of the site, they will use the available resources as desired without further input from the study team, except for technical support
224312985|NCT00994578|BEHAVIORAL|COPE|Participants in the COPE arm will receive training and access to the COPE patient intervention, an interactive web program based on Social Cognitive Theory that includes automated, tailored email reminders and encouragement prior to each of two oncologists visits over a maximum of a 9 month period, and access to the patient's audio-recorded conversations for review.
224312986|NCT00994578|BEHAVIORAL|CHESS/COPE|Participants in the CHESS/COPE arm will be given access to the University of Wisconsin CHESS modified specifically for this study. After being trained in usage of the site, they will use the available resources as desired and receive technical support. COPE arm will receive training and access to the COPE patient intervention an interactive web program based on Social Cognitive Theory that includes automated, tailored email reminders and encouragement prior to two oncologists visits over a maximum period of 9 months, and access to the patient's audio-recorded conversations for review.
223511084|NCT03578263|DRUG|oxytocin|Group (B): included 100 patients who received a combination of intraoperative oxytocin 5 I.U which was diluted in 10 ml normal saline and administered slowly over (30-60 seconds) intravenously by anesthetist and
223511085|NCT03578263|DRUG|ergometrine|intramuscular ergometrine 0.2 mg.
223511086|NCT02303938|BEHAVIORAL|physical exercise|Patients in the intervention group will undergo a 6-month home-based exercise intervention. Patients will exercise (e.g., running, biking, swimming) three times per week for 6 months. Session duration will vary between 20 minutes and 45 minutes.
223511087|NCT05986058|BEHAVIORAL|Golden Circle|The original Golden Circle project was deployed in response to the COVID-19 pandemic and the need to implement remote social services in South Korea. Golden Circle had the aim of building a case management model using a healthcare-oriented automation system based on wearable devices (smartwatches and mobile applications). Through innovative system expansions, the goals were to promote healthful CVH and physical function and cultivate self-care management skills in older Korean adults.
224312987|NCT00220831|DRUG|Natural source Vitamin E 400IU/day|
224312988|NCT02008435|BEHAVIORAL|Enriched GLB|Habit formation techniques, namely if-then plans and their mental practice are being added to the standard Group Lifestyle Balance program.
223511088|NCT02526316|BIOLOGICAL|P16_37-63 peptide combined with Montanide® ISA-51 VG|Patients will receive P16\_37-63 peptide (100 µg) combined with Montanide® ISA-51 VG vaccination subcutaneously once a week for four weeks, followed by a 4 week rest period
223617126|NCT02271464|DRUG|Maintenance:BEVACIZUMAB+CAPECITABINE+CYCLOPHOSPHAMIDE|"Patients will be randomly assigned to receive induction chemotherapy with the G.O.N.O. FOLFOXIRI regimen plus bevacizumab:~* BEVACIZUMAB 5 mg/kg over 30 minutes, day 1~* IRINOTECAN 165 mg/sqm IV over 1-h, day 1~* OXALIPLATIN 85 mg/sqm IV over 2-h, day 1~* L-LEUCOVORIN 200 mg/sqm IV over 2-h, day 1~* 5-FLUOROURACIL 3200 mg/sqm IV 48-h continuous infusion, starting on day 1~with cycles repeated every 2 weeks for 4 months (8 cycles), followed after 2 weeks by (if no progression occurs):~* BEVACIZUMAB 7.5 mg/kg over 30 minutes, day 1 (every three weeks),~* CAPECITABINE 500 mg/tid orally, continuously,~* CYCLOPHOSPHAMIDE 50 mg/day orally, continuously."
223617127|NCT05034913|OTHER|Digital photography measurements|"The participant will be instructed to take off any thick outer layers and leave on shirt and pants. Tops will be gathered to make cloth tight to body. The participant will stand next to an 8 ½ x 11 piece of paper taped to a wall, to use as a reference for linear regression calculations."
224203636|NCT02334046|DRUG|Sevoflurane|Anesthesia was maintained with sevoflurane with 1.5-2.0 vol% in air/50%oxygen mixture, and sevoflurane was adjusted to about 1.0 vol% 10 min before end of surgery.
224203637|NCT05216289|DIETARY_SUPPLEMENT|Probiac|Oral probiotic composed of Lactobacillus acidophilus, Bifidobacterium lactis, vitamins and minerals - Exímia Probiac® (EP), in combination with 2.5% benzoyl peroxide plus 0.1% adapalene (PBA) for topical use.
224203638|NCT05216289|OTHER|Placebo|Placebo + 2.5% benzoyl peroxide plus 0.1% adapalene (PBA) for topical use.
224203639|NCT02717910|BEHAVIORAL|Health game|Health game intervention consists of 20 minutes guided training session with the health game at school and 2 weeks free usage of the health game via own smart phone or tablet computer during free time. The health game includes textual information about the consequences of tobacco use, but also visualized elements that aim at supporting understanding of the information, and motivation and ability to use the information in daily life situations. The visualized content is presented in a format of a game including tasks, rules, goals, rewards and opponents. There are also sound effects and background music included in the game.
224203640|NCT02717910|BEHAVIORAL|Web page|Web page intervention consists of 20 minutes guided training session with the web page at school and 2 weeks free usage of the web page via own smart phone or tablet computer during free time. The web page includes textual information about the consequences of tobacco use, but also visualized elements that aim at supporting understanding of the information, and motivation and ability to use the information in daily life situations. The visualized elements are presented with pictures and video clips. These visualized elements do NOT contain game elements (NO activating tasks, rules, goals, rewards or opponents). The video clips contain sound effects, but no background music.
224312989|NCT02008435|BEHAVIORAL|Standard GLB|This arm is the standard Group Lifestyle Balance program
223511089|NCT02526316|BIOLOGICAL|P16_37-63 peptide without Montanide® ISA-51 VG|Patients will receive 30 mcg P16\_37-63 peptide injected intradermally for test on delayed-type hypersensitivity (DTH) reactions.
223511090|NCT00885898|PROCEDURE|Non-invasive-ventilation|increased oxygen fraction, continuous positive pressure ventilation, if necessary pressure support ventilation or even intermittent positive pressure ventilation
223511091|NCT00885898|PROCEDURE|conventional treatment|oxygen, diuretics, bronchodilators, positive inotropic drugs
223511092|NCT04431778|DRUG|Ethosuximide|"Taking the treatment (1 daily intake during the evening meal) according to increasing dosage:~Step 1: 2.5 ml (125 mg) / day for 7 days Step 2: 5 ml (250 mg) / day for 7 days Step 3: 7.5 ml (375 mg) / day for 7 days Step 4 (final): 10 ml (500 mg) / day for the remainder of the study (12 weeks)."
223511093|NCT04431778|DRUG|Placebo|"Taking the treatment (1 daily intake during the evening meal) according to increasing dosage:~Step 1: 2.5 ml (125 mg) / day for 7 days Step 2: 5 ml (250 mg) / day for 7 days Step 3: 7.5 ml (375 mg) / day for 7 days Step 4 (final): 10 ml (500 mg) / day for the remainder of the study (12 weeks)."
224203641|NCT03186794|OTHER|Treadmill exercise training|30 minutes of continuous treadmill walking at a target intensity or use of an interval approach in which walking at the target will be sustained at smaller training interval durations of no shorter than 5 minutes followed by an active rest interval that is no longer than 1.5 times the training interval until the subject achieves a total exercise time of 30 minutes, excluding the rest intervals. Each session will last about 60 minutes but slightly longer if an interval approach is used.
224203642|NCT02871869|DRUG|vindesine|3 mg/㎡ (maximum dosage: \<4mg), d1, 21 d as a cycle, for 4～6 cycles
224203643|NCT02871869|DRUG|cyclophosphamide|750 mg/㎡, d1, 21 d as a cycle, for 4～6 cycles
224203644|NCT02871869|DRUG|Epirubicin|60 mg/㎡, d1, 21 d as a cycle, for 4～6 cycles
224203645|NCT02871869|DRUG|prednisone tablets|100 mg, d1～5, 21 d as a cycle, for 4～6 cycles
223511094|NCT01081938|DRUG|INSULIN GLARGINE|"Pharmaceutical form: Lantus® (100 U/ml)~Route of administration: Subcutaneous injection with SoloStar® (3 ml) pen device.~Dose regimen: Single daily dose of Insulin Glargine"
223511095|NCT01081938|DRUG|INSULIN GLULISINE|"Pharmaceutical form: Apidra® (100 U/ml)~Route of administration: Subcutaneous injection with SoloStar® (3 ml) pen device~Dose regimen:~Arm1: Every 6 hours Arm2: several daily dose according to sliding scale of Insulin Glargine"
223511096|NCT05875610|DRUG|Venlafaxine 75 MG|Venlafaxine 75 mg extended release capsules for a 7-days duration
223511097|NCT05875610|DRUG|Gabapentin 400 mg|Gabapentin 400 mg capsules
223511098|NCT01141543|DRUG|Plerixafor (mozobil)|"Cohort 1: Administration of PLERIXAFOR (240mcg/kg sc) before the first dose of FLUDARABINE and BUSULFAN Cohort 2: Administration of PLERIXAFOR (240mcg/kg sc) before the first and second dose of FLUDARABINE and BUSULFAN.~Cohort 3: Administration of PLERIXAFOR (240mcg/kg sc) before the first, second, and third dose of FLUARABINE and BUSULFAN Cohort 4: Administration of PLERIXAFOR (240mcg/kg sc) before all four doses of FLUDARABINE and BUSULFAN"
223511099|NCT06032975|OTHER|Questionnaires|The PROFFIT questionnaire is a PRO instrument composed by 16 items encompassing all the major life domains where FT can be expressed and is formed by two type of items: (1) outcome (items 1-7) and (2) determinants (items 8-16); EORTC QLQ-C30 questionnaire (items 29-30) and OV28 (items 55-58); PRO-CTCAE: short list of 43 symptoms relevant for ovarian cancer
223511100|NCT02104011|DRUG|Propranolol|
223511101|NCT02985775|BIOLOGICAL|Donor-derived CMVpp65-specific T cells|About 1 million per kg CMVpp65-specific T cells will be infused once acute GVHD ocurred post haploidentical transplantation.
223511102|NCT06172049|OTHER|treatment|the actual treatment CRC patients have reveived
223511103|NCT03917264|PROCEDURE|Peri-implantitis debridement|Mechanical cleaning of titanium implants, peri-implantitis debridement.
223511104|NCT03917264|OTHER|Dental hygiene procedures|Titanium scalers and nylon brushed used for implant cleaning
223511105|NCT05391087|OTHER|Mean arterial pressure based management|Mean arterial pressure group: Low MAP will be intervened in accordance with the protocol as described in the arm
223511106|NCT05391087|OTHER|Cardiac index based management|Cardiac index group: Low CI will be intervened in accordance with the protocol as described in the arm. Additionally, if MAP is lower than target MAP along with a normal CI, this will be intervened with noradrenalin infusion/titration
223511107|NCT01658735|DEVICE|H-Wave|Proprietary electrotherapy device using electrical stimulation of unique wave form and energy level that is delivered through transcutaneous electrodes to nerves and soft tissue for analgesic effect.
223511108|NCT01658735|DEVICE|Transcutaneous Electrical Nerve Stimulation (TENS)|Electrotherapy device that delivers current at different frequency, amplitude, and wave form through cutaneous electrodes placed near body parts with pain for temporary analgesic effect. The study device is installed inside the same housing as the H-Wave Device and Sham Device, so that all appear the same. There are no identifying marks on the case that participants will recognize in order to maintain blinding.
224203646|NCT02871869|DRUG|Cinobufacini Tablets|0.3 g per tablet, 3 tablets per time, tid., p.o., until progressive disease or intolerable drug toxicities
224203647|NCT02871869|DRUG|Rituximab|375mg/㎡,one day before CHOP protocol
223511109|NCT01658735|DEVICE|Sham|The sham device is a TENS unit modified to have minimal electrical output. The device is installed in the same housing as the two active arms with equal weight, so that each device in the study appears identical.
223511110|NCT01851304|DIETARY_SUPPLEMENT|Satiety of breads|One separate breakfast session to consume each bread along with 125 mL skim milk. The session will start after an overnight fast followed by 5 separate blood draws over a 3 hour period before a provided lunch.
223511111|NCT01851304|DIETARY_SUPPLEMENT|Satiety of puddings|One separate breakfast session will be used to evaluate satiating efficacy of puddings after an overnight fast. After pudding consumption, five separate blood draws will be taken over a 3 hour period before a provided lunch.
223511112|NCT03156621|DRUG|Alirocumab|Alirocumab SC Q2W
223511113|NCT03156621|DRUG|Placebo|Matching placebo SC Q2W
223511114|NCT05023174|PROCEDURE|Hiatal Hernia Repair with Platelet Rich Plasma|Platelet rich plasma will be injected into the crura of the diaphragm and coating the mesh placed during surgery.
223511115|NCT05023174|PROCEDURE|Hiatal Hernia Repair without Platelet Rich Plasma|Surgery will be performed without the addition of platelet rich plasma injection
223511116|NCT03065738|OTHER|tibial reduction osteotomy in total knee replacement|reduction osteotomy :downsizing of tibial tray with lateralization
224203648|NCT01448070|DRUG|human insulin|Single dose of 0.2 IU/kg, administered subcutaneously (under the skin)
224203649|NCT00394862|DRUG|multivitamin|
224203650|NCT02203773|DRUG|Posaconazole|Posaconazole will be administered orally twice a day on Cycle 1 Day 21 and once daily from Cycle 1 Day 22 to Cycle 1 Day 28.
224203651|NCT02203773|DRUG|ABT-199|ABT-199 is taken orally once daily starting on Day 2 of cycle 1 and begin on day 1 of every other cycle thereafter. This is a dose escalation study, therefore the dose of ABT-199 will change.
224203652|NCT02203773|DRUG|Decitabine|Decitabine will be administered by IV infusion over 1 hour beginning on Day 1 thru Day 5 of each Cycle for a minimum of 4 Cycles
224203653|NCT02203773|DRUG|Azacitidine|Azacitidine will be administered by IV infusion over 10 to 40 minutes or subcutaneously based on the institutional guidelines, beginning on Day 1 through Day 7 of each Cycle, for a minimum of 4 Cycles.
224203654|NCT02549391|DRUG|KHK7580|Oral administration
224203655|NCT02549391|DRUG|KRN1493|Oral administration
224312990|NCT05914688|DRUG|LY3209590 (Formulation 1)|Administered SC.
223617128|NCT03367858|BEHAVIORAL|Motivational Interviewing (MI)|Motivational interviewing introduced a conversation about alcohol use, and the personally-experienced consequences of problem drinking. The MI sessions explored youths' stories around their substance use, the factors in youths' lives that support problem drinking (e.g., what they like about drinking), and the consequences of their recent or previous problem drinking (e.g., getting in trouble). Youth were provided personalized feedback about how their problem drinking compared to age-matched norms in the U.S. The ultimate goal of the MI sessions was to engage youth in a thoughtful conversation about their problem drinking with an eye to bolstering and supporting youths' own inherent drive for behavior change.
223617129|NCT03367858|BEHAVIORAL|Brief Adolescent Mindfulness (BAM)|Brief Adolescent Mindfulness introduced a conversation about what mindfulness is, and ways that it might be personally-relevant to adolescents' current experiences. This manualized treatment introduced concepts of eastern thought in a manner articulated to adolescents. Treatment included a discussion of factors in the youth's life that could be positively impacted by using or engaging mindful approaches (e.g., current experiences of stress) and a link to how mindful approaches might be applicable or relevant to the adolescent's problem drinking. The ultimate goal was to engage youth in a thoughtful conversation about BAM and how eastern thought and mindful approaches could unburden some aspects of their current lived experiences.
223617130|NCT04598022|OTHER|cross-sectional observation|observation of dietary patterns, body weight status, microbiome and metabolome profiles at the start of the first semester
223617131|NCT04598022|OTHER|cross-sectional follow-up observation|follow-up observation of dietary patterns, body weight status,microbiome and metabolome profiles after one year
223617132|NCT00232622|DRUG|Streptokinase|Accelerated infusion of streptokinase
223617133|NCT00232622|DRUG|Streptokinase|Standard dose streptokinase
223617134|NCT01119053|DEVICE|VNS Pulse Model 102|Individual dosage within the realm of 0,25 mA - 3,5 mA. Uninterrupted stimulation of 24 h.
223617135|NCT01119053|DEVICE|VNS Pulse Model 102|Within this branch, study participants obtain the VNS therapy after a defined space of time of 12 weeks.
223617136|NCT00027625|DRUG|gefitinib|
223617137|NCT00027625|DRUG|temozolomide|
223617138|NCT01022021|DRUG|Rituximab|Day 1 - rituximab, 375 mg/M2 IV (drug dosage is based on body weight)
223617139|NCT01022021|DRUG|Bendamustine|Days 2 and 3 bendamustine, 90 mg/M2 IV over 30-60 minutes (drug dosage based on body weight)
223617140|NCT00430469|DRUG|human lactoferrin (hLF1-11)|intravenous 0.5mg in NaCl-solution
223617141|NCT04386369|OTHER|Airway pressure release ventilation|Ventilator management strategy
224203656|NCT04548336|BEHAVIORAL|Motor Imagery|Motor imagery group will have to imagine motor gestures of static and dynamic balance
224203657|NCT04548336|BEHAVIORAL|Action observation|Action observation group will have to observe static and dynamic equilibrium motor gestures
224203658|NCT04548336|BEHAVIORAL|Placebo group|This group will watch a video of nature without a human component.
224203659|NCT00300261|BEHAVIORAL|Telehealth monitoring|Experimental group receives telehealth monitoring equipment in their homes for the duration of home care. Equipment includes blood pressure cuff, scale, and pulse oximeter, or glucometer as needed. Two home care nurses provide video visits with subjects on the days when the home care nurse does not visit. Patients use the equipment daily and the results are downloaded to the nurse's computer at the home care agency where they are checked daily. The nurse acts on any abnormal readings by calling the patient, the home care nurse, or the physician.
224203660|NCT00327080|PROCEDURE|MRI|
224203661|NCT00327080|DRUG|L-NMMA|
224203662|NCT00327080|DRUG|Acetylcholine|
224203663|NCT04469868|BEHAVIORAL|No opioids at discharge|"Patients who are being scheduled for any major urologic cancer surgery (open or laparoscopic) will be counselled regarding post-operative pain and measures taken during surgery and during hospital stay.~They will be provided written information on these pain mitigation efforts and the adverse effects associated with opioids use and outpatient prescriptions.~Patients will be discharged from the hospital without any opioids prescriptions and instructions to use non-opioids analgesics.~Patients will complete a visual analog pain scale daily for 7 days after discharge from the hospital.~Patients will be able to call the clinic at anytime for any post-operative pain issues."
224203664|NCT04144309|PROCEDURE|Electroacupuncture (EA) and Auricular Acupressure (AA)|"EA: Ten points will be used, including GV24 (Shenting), GV20 (Baihui), EX-HN1 (Sishenchong), PC6 (Neiguan), CV12 (Zhongwan), CV4 (Guanyuan), ST25 (Tianshu), ST36 (Zusanli), SP6 (Sanyinjiao), KI3 (Taixi).~AA: Vaccaria seeds will be embedded by acupuncturists on three auricular points (Shenmen, Sympathetic and Heart) and maintained between EA treatments."
224312991|NCT05914688|DRUG|LY3209590 (Formulation 2)|Administered SC.
223617142|NCT03006146|DRUG|Sargramostim|Participants will receive a single administration of inhaled sargramostim (either 125 mcg or 250 mcg dose)
223617143|NCT05377853|BEHAVIORAL|Cognitive-Kinesthetic Navigational Training|Training with tactile maps to improve spatial memory capability for enhanced navigational capabilities.
223617144|NCT03625284|DIETARY_SUPPLEMENT|Placebo|Edible oil
223617145|NCT03625284|DIETARY_SUPPLEMENT|FucoVital|Microalgae oil extract
223617146|NCT01250366|DRUG|INX-08189|Capsules, Oral, 9 mg, Once Daily, 7 Days
223617147|NCT01250366|DRUG|INX-08189|Capsule, Oral, 25 mg, Once Daily, 7 days
223617148|NCT01250366|DRUG|INX-08189|Capsules, Oral, 50 mg, Single Dose, 1 day
223617149|NCT01250366|DRUG|INX-08189|Capsules, Oral, 9 mg, Once daily, 6 days
223617150|NCT01250366|DRUG|INX-08189|Capsules, Oral, 50 mg, Once daily, 7 days
223617151|NCT01250366|DRUG|INX-08189|Capsules, Oral, 9 mg, Once daily, 7 days
223617152|NCT01250366|DRUG|INX-08189|Capsules, Oral, 100 mg, Once daily, 7 days
223617153|NCT01250366|DRUG|Placebo matching with INX-08189|Capsules, Oral, 0 mg, Once daily, 7 days
223617154|NCT01250366|DRUG|Ribavirin|Capsules, Oral, 1000 or 1200 mg daily (delivered in weight-adjusted am/pm divided dose), 7 days
223617155|NCT03363516|DIAGNOSTIC_TEST|Cerebral 3 Tesla MRI|Subjects will be examined using a 3 Tesla MR750 GE MRI scanner with an eight-channel head coil. All participants will undergo the same MRI protocol, including: whole-brain 3D T1-weighted spoiled gradient recalled (SPGR) (BRAVO, voxel size of 1 × 1 × 1 mm3), DTI (voxel size 2 × 2 × 2 mm3, 27 directions with gradients at a b-value of 1,000 s/mm2 and 4 b = 0 images) and conventional 2D T2-weighted,T2 (FLAIR) and T2 gradient echo.
223617156|NCT02197117|DEVICE|Remote ischemic conditioning|
223617157|NCT02197117|DEVICE|Control|
224203665|NCT04144309|PROCEDURE|Sham Electroacupuncture (SE) and Sham Auricular Acupressure (SA)|"SE: The sham acupuncture treatment procedure, including the acupoint selection principle, sterilization procedure and treatment schedule, will be the same as in the acupuncture treatment group, except that sham points 1 to 2 cm exterior and inferior to the real points will be used, and no needle penetration or electric stimulation will be performed.~SA: Three sham auricular points in the helix region (HX7, HX8, HX9) will be selected. Instead of Vaccaria seeds, soft Junci Medulla (1 to 2 mm in length, dyed black) will be used to mimic real AA with no pressure."
224312992|NCT04045483|OTHER|Virtual reality based cognitive training|The VR-based cognitive training consists of a three-dimensional simulation of home, a mart, bus stop, and street. It provides an integrative cognitive training experience where participants are required to accomplish some common ADL's in three frequently visited places: home, a supermarket, and bus stop.
223511117|NCT02427217|BIOLOGICAL|FCH|FCH is a heat-treated, lyophilized fibrinogen (coagulation factor I) powder made from pooled human plasma. FCH is administered as an IV infusion.
223511118|NCT01436890|DRUG|Revamilast|Tablet. Low dose, Once daily for 12 weeks
223511119|NCT01436890|DRUG|Revamilast|Medium dose, Once daily for 12 weeks
223511120|NCT01436890|DRUG|Revamilast|High dose, Once daily for 12 weeks
223511121|NCT01436890|DRUG|Placebo|Placebo tablet in triple dummy format, Once daily for 12 weeks
223511122|NCT02998125|PROCEDURE|Total knee arthroplasty|prospective assessments for the functional outcome before and after the total knee arthroplasty
223511123|NCT01379937|BIOLOGICAL|Influenza vaccine GSK1562902A Formulation 1|Intramuscular injection, two doses each in GSK1562902A Formulation 1 and 2 - Havrix / Havrix Jr Group and GSK1562902A Formulation 1 - Havrix / Havrix Jr Group
223511124|NCT01379937|BIOLOGICAL|Influenza vaccine GSK1562902A Formulation 2|Intramuscular injection, one dose each in GSK1562902A Formulation 1 and 2 - Havrix / Havrix Jr Group and GSK1562902A Formulation 2 - Havrix / Havrix Jr Group
223511125|NCT01379937|BIOLOGICAL|Havrix™|Intramuscular injection, one dose in GSK1562902A Formulation 1 and 2 - Havrix / Havrix Jr Group and two doses each in GSK1562902A Formulation 1 - Havrix / Havrix Jr Group, GSK1562902A Formulation 2 - Havrix / Havrix Jr Group and Havrix / Havrix Jr Group
223511126|NCT01379937|BIOLOGICAL|Havrix™ Junior|Intramuscular injection, one dose in GSK1562902A Formulation 1 and 2 - Havrix / Havrix Jr Group and two doses each in GSK1562902A Formulation 1 - Havrix / Havrix Jr Group,GSK1562902A Formulation 2 - Havrix / Havrix Jr Group and Havrix / Havrix Jr Group
223511127|NCT05020119|DRUG|Neoantigen-expanded cell therapy.|Infusion of personalized neoantigen-expanded T (CIK) cells
223511128|NCT06467058|DEVICE|DABQ questionnaire versus Actigraph as reference method|"In this study, participants will have one contact session with the researcher, which will be held either at Ghent University Hospital or at the participants' home. During this session, participants will be provided with an accelerometer device and two questionnaires (to be filled in after wearing the Actigraph), namely the Daily Activity Behavior Questionnaire (DABQ) and general information questionnaire.~The participants will receive an Actigraph wGT3X+BT accelerometer which will be worn for seven consecutive days. Instructions will be given on how to wear the accelerometer (e.g. during the day at the hip and during the night at the wrist). At the end of this week, the participants will fill in both questionnaires. After wearing the accelerometer for seven consecutive days and filling in both questionnaires, the researcher will visit the participants to collect the devices, or the participants will send them back by postal package."
223511129|NCT05566054|DRUG|Chidamide|Chidamide 10mg orally daily for 7 days (d1-d7)
223511130|NCT05566054|DRUG|Azacitidine|azacytidine 75mg/m2 daily for 7 days (d1-d7)
223511131|NCT05566054|DRUG|Venetoclax|Venetoclax orally once daily (100 mg d1, 200 mg d2, 400 mg d3-28)
223511132|NCT01431573|BEHAVIORAL|Wake Therapy|Maintaining wakefulness on alternating nights over 7 days, with continued sleep deprivation the next day.
223511133|NCT01431573|DEVICE|light box|use of a lightbox titrated between 15-60 minutes (typically 30 minutes), timed according to chronotype score on the Morningness-Eveningness Questionnaire
223511134|NCT01431573|DRUG|Lithium|For patients not already taking lithium, dose will start at 600 mg daily (all in the evening) and be adjusted in 300 mg/d increments according to weekly blood levels (i.e., lithium dose may be changed once a week if most recent blood level is too low; if too high, it will be decreased or temporarily discontinued as clinically indicated; 150 mg increments will be utilized if multiples of 300 mg result in intolerance or blood levels outside the target range (0.6 - 1.0 mEq/L)
223511135|NCT04693715|DRUG|RNS60|RNS60 injection solution
223511136|NCT04693715|DRUG|Placebo|Placebo injection solution
223511137|NCT06497829|DIETARY_SUPPLEMENT|geranylgeraniol|GG Pure (Extendlife Natural Products) containing GG gold®30 Annatto Extract, 500 mg capsule, use for 3 months, once daily
223617158|NCT04075344|OTHER|Multimodal Infection control programme|12 weekse educational programme with 6 sessions, 45 minutes per session will be provided to experimental group RCHEs staff
223511138|NCT02631031|DRUG|Valsartan|single oral dose of 160 mg valsartan under fasting conditions
223511139|NCT03015779|OTHER|cultured autologous oral mucosal epithelial cell sheet|a prospective study,Before and after self control
223511140|NCT00063362|DRUG|Lithium|Lithium monotherapy was initiated at 450 mg once daily and titrated slowly over three weeks to a minimum blood level of 0.5 milliequivalent /L (mEq/L).
223617159|NCT00508326|DRUG|Paclitaxel|Starting dose 150 mg/m\^2 HAI once every 4 weeks
223617160|NCT00596986|DRUG|Duloxetine|Duloxetine 30mg up to 120mg per day.
223617161|NCT00596986|BEHAVIORAL|Cognitive Behavioural Analysis System of Psychotherapy|Cognitive Behavioural Analysis System of Psychotherapy (CBASP): 20 sessions of psychotherapy, beginning with twice weekly, then weekly sessions.
223617162|NCT00377793|DRUG|Levitra (Vardenafil, BAY38-9456)|
223617163|NCT00377793|DRUG|Placebo|
223617164|NCT03493295|DRUG|Levonogestrel IntraUterine System (LNG-IUS)|At the routine clinical practice. Jaydess, Mirena, Kyleena Or any other levonogestrel intrauterine system (LNG-IUS) commercialized in Spain at the start of the study, only for contraception indication.
223617165|NCT04276233|DRUG|Mepolizumab|Mepolizumab will be available as a lyophilized cake in sterile vials and will be reconstituted with sterile water for injection, just prior to use.
224203666|NCT00700037|DRUG|high-dose atorvastatin|20mg/day
224203667|NCT00700037|DRUG|low-dose atorvastatin|5mg/day
223617166|NCT04276233|DRUG|Salbutamol|Salbutamol metered dose inhalers (MDIs) will be provided as rescue medication during treatment period.
223617167|NCT02251626|DIETARY_SUPPLEMENT|coenzyme Q10|It is a randomized and double blind study so patients or his/her doctor will not know which group s/he is in.
223617168|NCT02251626|DIETARY_SUPPLEMENT|Placebo|It is a randomized and double blind study so patients or his/her doctor will not know which group s/he is in.
223617169|NCT01946139|PROCEDURE|comparison of screening methods|Undergo HPV screening using HC2, APTIMA and OncoHealth HPV E6/E7 assays
223617170|NCT01946139|OTHER|laboratory biomarker analysis|Correlative studies
223617171|NCT01946139|OTHER|questionnaire administration|Ancillary studies
223617172|NCT01946139|PROCEDURE|quality-of-life assessment|Ancillary studies
223617173|NCT01191723|DRUG|MAP0004|3.0mg orally inhaled MAP0004 administered in Treatment B as per protocol
223617174|NCT01191723|DRUG|Inhaler Placebo|Placebo for Inhaler administered in Treatments A and C
223617175|NCT01191723|DRUG|Moxifloxacin|400mg encapsulated tablet administered in Treatment A as per protocol
223617176|NCT01191723|DRUG|Placebo Capsule|Placebo for Moxifloxacin administered in Treatment B and Treatment C
223617177|NCT03117816|DRUG|AOP2014 / Pegylated-Proline-interferon alpha-2b|AOP2014 as pre-filled auto-injection pen for subcutaneous injection, containing 250 µg AOP2014 / 0.5 ml. The solution also contains inactive ingredients (sodium chloride, polysorbate 80, benzyl alcohol, sodium acetate, and acetic acid). The solution is colorless to light yellow.
223617178|NCT03117816|OTHER|Surveillance|For patients randomized into this treatment arm stopp their standard treatment and will just be under observation.
223617179|NCT01676987|DRUG|Fixed combination of budesonide and formoterol|Delivered dry powder inhaler for 12 weeks.
223617180|NCT01676987|DRUG|Budesonide|Delivered dry powder inhaler for 12 weeks.
223617181|NCT03275740|DRUG|PF-06755347 intravenous healthy participant|Single doses of PF-06755347 will be administered intravenously dose levels 1, 2, 3, 4, 5, and 6.
223617182|NCT03275740|DRUG|Placebo intravenous healthy participant|Placebo comparator
224203668|NCT04667793|DRUG|Toripalimab + Chemotherapy|"Toripalimab: 200mg, q3w, i.v., 2-4 cycles~Chemotherapy:~Thymoma: Cisplatin+Amycin+Cyclophosphamide Thymic carcinoma: Carboplatin+Paclitaxel"
224203669|NCT00834366|DRUG|Tramadol HCl|Single oral administration in fasting conditions of 1x200mg Tramadol HCl 200 mg Film-coated Tablet or Tramadol HCl 200 mg Uncoated Tablets based on randomization schedule.
224203670|NCT05450900|DRUG|Choriogonadotropin Alpha|drug, active
224203671|NCT05450900|DIETARY_SUPPLEMENT|biotin|supplement, oral
223617183|NCT03275740|DRUG|PF-06755347 subcutaneous healthy participant|single doses of PF-06755347 will be administered subcutaneously at dose levels of SC1, SC2, SC3, SC4, and SC5.
223617184|NCT03275740|DRUG|Placebo subcutaneous healthy participant|placebo comparator
223617185|NCT03275740|DRUG|PF-06755347 subcutaneous ITP|single doses of PF-06755347 will be administered subcutaneously at 2 dose levels tested in healthy participants
223617186|NCT00486369|DRUG|Oral salmon calcitonin|
223617187|NCT01388517|DRUG|Tacrolimus|0.1% tacrolimus ointment to apply twice a day for 9 weeks on pytiriasis alba plaques.
223617188|NCT01388517|DRUG|Calcitriol|0.0003% calcitriol ointment to apply twice a day for 9 weeks on pytiriasis alba plaques.
223617189|NCT01388517|DRUG|Petrolatum|Petrolatum ointment to apply twice a day for 9 weeks on pytiriasis alba plaques.
223617190|NCT03880058|DRUG|SLI-F06|Active treatment
224203672|NCT05450900|OTHER|Microcellulose filler|supplement, oral
224203673|NCT04690959|OTHER|neural mobilization|Neural mobilization, or neurodynamics, is a movement-based intervention aimed at restoring the homeostasis in and around the nervous system.
224203674|NCT04690959|OTHER|Sham intervention|it is faked neural mobilization that mimic the neural mobilization treatment but believed not to stress the neural tissues in the upper extremity.
223617191|NCT03880058|DRUG|Formulation buffer|Placebo treatment
223617192|NCT04179006|DIETARY_SUPPLEMENT|LF/Erinacine A-enriched Hericium/Plain chocolate + antidepressant(s)|3 pieces per day
223617193|NCT00750724|DRUG|"25 mg sodium hyaluronate GO ON"|25 mg sodium hyaluronate, 2 ml., intraarticular weekly for 5 weeks
223617194|NCT00750724|DRUG|normal saline,2 ml., intraarticular weekly for 5 weeks|
223617195|NCT00002164|DRUG|Nelfinavir mesylate|
223617196|NCT03178435|OTHER|Measures to prevent AKI among critically ill patients|"1. Meticulous optimization of the fluid balance~2. Avoidance of nephrotoxic medications where possible~3. Optimisation of the hemodynamic status~4. Avoidance of blood transfusion unless marked acute blood loss or symptomatic anemia~5. Optimization of the underlying medical condition~6. Seek expert renal advise when necessary"
223617197|NCT03639363|DRUG|4% chlorhexidine gluconate soap-like solution|"1. humidify the whole body surface with the exception of the face using water-impregnated washcloths~2. use 4% CHG-impregnated washcloths to bath the whole body surface with the exception of the face; use at least 30 ml of 4% CHG~3. wait for at least 30 seconds~4. rinse using water-impregnated washcloths"
223617198|NCT03639363|OTHER|standard soap|"1. humidify the whole body surface with the exception of the face using water-impregnated washcloths~2. use standard soap-impregnated washcloths to bath the whole body surface with the exception of the face~3. wait for at least 30 seconds~4. rinse using water-impregnated washcloths"
223617199|NCT02604446|DRUG|Tapentadol|
223617200|NCT02604446|DRUG|Oxycodone|
223617201|NCT02604446|DRUG|Placebo|
223617202|NCT02604446|DRUG|usual pain treatment|premedication of Dexamethasone, Paracetamol, Vimovo; postoperative Paracetamol and Vimovo
224203675|NCT04195867|DRUG|Salmeterol Xinafoate|Subjects receive a daily inhaled dose of 200 μg (4 inhalations of 50 μg each).
224203676|NCT05641246|DRUG|(CARBAMIDE®)|Urea is used to treat dry/rough skin conditions (such as eczema, psoriasis, corns, callus) and some nail problems (such as ingrown nails). It may also be used to help remove dead tissue in some wounds to help wound healing. Urea is known as a keratolytic. It increases moisture in the skin by softening/dissolving the horny substance (keratin) holding the top layer of skin cells together. This effect helps the dead skin cells fall off and helps the skin keep more water in.
224203677|NCT05641246|DRUG|(VOLTAREN®) Emulgel 1%|(VOLTAREN®) Emulgel 1% contain the active ingredient diclofenac which belongs to the NSAIDS.it has analgesic and anti-inflammatory properties and due to its alcohol base it has a cooling effect.
223617203|NCT02977000|DRUG|Propranolol|Propranolol was administered orally as a dose of 1.5 mg/kg.d divided q8h.investigators used powdered drug, dissolved in 5% dextrose. The treatment was continued until complete development of retinal vascularization, although administration was not permitted for more than 90 days.
223617204|NCT06410898|DEVICE|Punch Biopsy 5mm|Disinfect the skin, inject local anesthesia ,insert the punch and extract the biopsy
223617205|NCT03827655|DRUG|TAK-954 Placebo|TAK-954 placebo-matching intravenous infusion.
223761267|NCT02394938|OTHER|MUSIC|In addition to the standard care,patients assigned to the music group will listen recorded classical music. Music will be delivered with a mp3 Player and headphones Music will be listened by the patient in his home.The music play list will be formed by a classical repertoire.During the intervention patients will be recommended to listen to the music for 3 months. Also patients will be asked to listen to the music once or more than once per day, at any time, for a total of 30 minutes per day.Music will be listen at 50-60 decibels below the threshold of 85 db established for listening to portable media devices such as compact disc and MP3 players.Music in this protocol will have a tempo/rhythm in a range of 60-80 beats per minute (bpm).
224203678|NCT01016184|DIETARY_SUPPLEMENT|Vitamin D|Oral vitamin D 100,000 IU
224203679|NCT01016184|DIETARY_SUPPLEMENT|Placebo|Placebo
224203680|NCT00406497|DRUG|Difluprednate Ophthalmic Emulsion|
224203681|NCT04828551|DEVICE|Ultrasound based shear wave speed and fat quantification methods|Ultrasound based imaging parameters will be collected from all patients in two visits. These will include but may not be limited to SWE results, Quantitative ultrasound parameters,where available,including Attenuation Coefficient, Backscatter Coefficient, Shear Wave Dispersion, Speed of Sound, Ultrasound derived fat fraction Conventional Bmode (gray-scale) and Doppler ultrasound images,including An image of the liver and right kidney on the same image for hepatorenal index calculation Right liver lobe for skin to liver capsule distance calculation Portal vein Doppler for portal vein pulsatility index measurement VCTE and Controlled Attenuation Parameter measurements with the Fibroscan system
224203682|NCT04828551|DIAGNOSTIC_TEST|Blood collection|"Blood will be collected by trained phlebotomists at each site using routine methods and standard collection tubes.~Total volume is expected to be about 10 mL or less Blood collected at MGH will be analyzed by the MGH clinical laboratory. Blood collected at UCSD will be analyzed by the UCSD clinical laboratory. Blood results obtained within the 3-month interval prior to the screening visit at the MGH or UCSD laboratories will be considered acceptable for study analyses and may be used at PI discretion. For each laboratory, the normal ranges for each blood test will be recorded and filed"
224203683|NCT04828551|OTHER|Physical measurements|Height will be recorded at Screening. Weight and vital signs will be recorded at each visit. Body mass index will be calculated at each visit. All measurements will be made by trained coordinators using standard and calibrated instruments.
224203684|NCT04828551|OTHER|Clinical history and medication reviews|"The following questionnaires will be administered at Screening:~Medical history questionnaire Medication use questionnaire Alcohol consumption questionnaire Physical activity questionnaire~The following questionnaires will be administered at Visit 1 and Visit 2:~Interim medical history questionnaire Change in medication use questionnaire Change in alcohol consumption will be recorded using a modified version of the alcohol use followback. Alcohol use for the 7 day period prior to Visit 1 and for all days between Visit 1 and Visit 2 will be recorded. Change in physical activity questionnaire"
224203685|NCT02525380|PROCEDURE|Device(DC Bead)|Doxorubicin-Eluting-Bead Embolization (DEBDOX), DC Bead are a novel drug delivery embolization system
224203686|NCT00390091|DRUG|abetimus sodium (LJP 394)|
224203687|NCT01615900|OTHER|Teleconsultation / Standard consultation|"Stage 1: randomization. Two arms: teleconsultation and standard consultation~Stage 2: calculation of Kidney Transplant Failure Score which will determine 4 sub-groups: teleconsultation high risk, teleconsultation low risk, standard consultation high risk and standard consultation low risk.~Stage 3: follow-up (2 years) according to the group:~* Standard consultation low risk: consultation every 2 months during one year and then every 3 months during one year~* Standard consultation high risk: consultation every 6 weeks during one year and then every 2 months during one year~* Teleconsultation low risk: same follow-up as standard consultation low risk group but all the consultations are teleconsultations~* Teleconsultation high risk: same follow-up as standard consultation high risk group but the follow-up will be intensified by the addition of an intermediate teleconsultation (between 2 consultations)"
224203688|NCT02362243|OTHER|Experimental Intervention|Participants will perform the back and core exercises that were tested in our previous firefighter study (Mayer, 2015), in addition to their usual physical fitness routine. All participants at a given fire station will receive the same intervention and all interventions will be completed at the fire station. Participants will perform 2 exercise sessions each week (each time they are on duty) throughout the study's 12-month duration. The back and core exercise program consists of 1 set of 5 exercises - 4 core exercises on a floor mat and 1 back extension exercise on a variable angle Roman chair - which will take approximately 10 minutes to complete for each session (Mayer, 2015).
224203689|NCT02362243|OTHER|Placebo Comparator|Participants will receive a 45-60 minute, one-time educational session, which will be delivered to delivered by an exercise specialist in a 1-on-1 format while the participant is on-duty at the fire station, in addition to their usual physical fitness routine. Content for the educational session on evidence-based guidelines for exercise, physical fitness, and general physical activity will be derived from the American College of Sports Medicine (ACSM) Position Stand - Quantity and Quality of Exercise for Developing and Maintaining Cardiorespiratory, Musculoskeletal, and Neuromotor Fitness in Apparently Healthy Adults: Guidance for Prescribing Exercise (Garber, 2011).
224203690|NCT02380248|OTHER|Polyethylene Glycol, 0.4%, Propylene Glycol, 0.3% eye drops|
224312993|NCT02922738|OTHER|VisualDx|VisualDx is a computerized clinical information technology with medical image and text content in dermatology.
223617206|NCT03827655|DRUG|TAK-954|TAK-954 intravenous infusion.
223617207|NCT06124365|OTHER|Shock wave therapy and core stability exercises|20 post-partum women with SIJP will be treated by ESWT once weekly combined with core stability exercises 3 times per week for 6 weeks.
223617208|NCT06124365|OTHER|core stability exercises only|20 post-partum women with SIJP will be treated by core stability exercises 3 times per week for 6 weeks.
223761268|NCT00677807|DRUG|Indacaterol|Indacaterol once-daily (o.d.) via single-dose dry-powder inhaler (SDDPI)
223761269|NCT00677807|DRUG|Placebo|Placebo once-daily (o.d.) via single-dose dry-powder inhaler (SDDPI)
224312994|NCT01010113|OTHER|Standard infant formula with prebiotics|From 0-6 months of age. As per standard requirement
224312995|NCT01010113|OTHER|Infant formula with synbiotics|From 0-6 months of age as per standard requirement
224312996|NCT00811928|DRUG|Posaconazole|"40 mg/mL; 200 mg (5 mL) TID~Treatment was continued with each cycle of chemotherapy until:~* The onset of a proven or probable diagnosis of invasive fungal infection (IFI)~* 3 chemotherapy cycles or~* Total treatment duration up to 12 weeks (84 days)"
224312997|NCT00811928|DRUG|Fluconazole|"50 mg/capsule (2 capsules), 150 mg/capsule (2 capsules);~400 mg QD~Treatment was continued with each cycle of chemotherapy until:~* The onset of a proven or probable diagnosis of invasive fungal infection (IFI)~* 3 chemotherapy cycles or~* Total treatment duration up to 12 weeks (84 days)"
224203691|NCT01608048|DEVICE|transcutaneous electrical acupoint stimulation (TEAS);EA|TEAS group (conventional IVF + TEAS), electro-acupuncture (EA) group (conventional IVF + electro-Acu.), and control group (only conventional IVF) Parameter of TEAS or EA: frequency of 2/100 Hz；moderate electrical current. Treatments start from the day 3 of menstruation，once every two days, 30 min for each for two continuous weeks.
224203692|NCT02687763|BIOLOGICAL|ProQuad|"2\) Patients 6 months to 24 months of age who are being considered and/or evaluated for any solid organ transplant within the next five (5) years who are willing:~1. to receive two doses of ProQuad® at least 30 days but no more than 365 days apart.~2. to participate in the three (3) antibody titer blood draws."
224203693|NCT06014359|DRUG|Saline|Patients will be Nebulized with 3 mL of 0.9% saline 15 minutes before shifting the patients to operation room with face mask 6 L/min in sitting position.
224203694|NCT06014359|DRUG|Dexmedetomidine|Patients will be Nebulized with Dexmedetomidine (1 mcg/kg) in 3mL of 0.9% saline 15 minutes before shifting the patients to operation room with face mask 6 L/min in sitting position.
224203695|NCT04551859|OTHER|Dynamic Pelvic Floor MRI|6 months after surgery, a Dynamic Pelvic Floor MRI is performed
224203696|NCT01275170|DRUG|MK-7655|125 mg intravenous (IV) over 30 minutes as a single dose
224203697|NCT01275170|DRUG|Imipenem + Cilastatin|250 mg IV over 30 minutes as a single dose
224203698|NCT01275170|DRUG|Caffeine|Caffeine caplet, single 200 mg dose, orally
224203699|NCT01275170|DRUG|Midazolam|Midazolam hcl syrup single 2.0 mg dose by mouth.
224203700|NCT01275170|DRUG|Omeprazole|Omeprazole tablets, single 40 mg dose (as two 20 mg tablets), orally
224203701|NCT01934062|PROCEDURE|Surgery|"All surgeries performed at Nationwide Children's Hosp. between 1/1/2013 \& 7/31/2013.~\--------------------------------------------------------------------------------"
224203702|NCT03361540|DRUG|ASP8302|ASP8302 will be administered orally.
224312998|NCT06548997|DRUG|GZR18|5 μg/kg-maximum tolerated dose (MTD), single dose or two doses
224312999|NCT06548997|OTHER|Placebo|administered the same volume as GZR18
224313000|NCT03431545|BEHAVIORAL|PALS and|"Play and Learning Strategies (PALS) include web-based parent training courses with remote coaching and in-person meetings that support the adults' developing a set of core behaviors that comprise a responsive interactive style including responses contingent to children's needs and interests with rich language input.~Parents will begin their 11 week (infant) or 14 week (toddler) parenting program in October and complete it by April. There will be monthly Parent Meetings related to the content they are learning online. Post-assessments will occur in late April and May. Each weekly online parent session will take approximately 30 minutes to complete with a 40 - 60 minute weekly remote coach call."
224313001|NCT03431545|BEHAVIORAL|BEECH|"Beginning Education: Early Childcare at Home (BEECH) includes web-based teacher training courses with remote coaching and in-person meetings that support the adults' developing a set of core behaviors that comprise a responsive interactive style including responses contingent to children's needs and interests with rich language input.~Teachers will complete the 20 online sessions weekly, except for planned center closings due to holidays or agency-related events. The three in-person trainings will occur before Session 1 and after Sessions 8 and 14. Each weekly online teacher session will take approximately one-hour for a teacher to complete with a 30 minute weekly remote coach call. Each in-person teacher training will be 6-hours in duration."
224313002|NCT03431545|BEHAVIORAL|Control condition|Parents and teachers conduct business as usual in regards to care-giving in the school and at home.
224313003|NCT00171951|DRUG|Pasireotide|Pasireotide 600 μg or 900 μg was administered as an SC injection.
224313004|NCT05231005|BIOLOGICAL|BNT162b2 vaccine|fourth dose of the BNT162b2 vaccine (30 microgram) adminstered IM
224313005|NCT03420586|DRUG|Nitrous Oxide|The nitrous oxide group (GN2O) will receive 70% N2O in 30% O2 at the end of surgery.
224313006|NCT00396812|DRUG|Rituximab|"Participants to receive an intravenous infusion of rituximab (1 gram ) fourteen days apart, at baseline (Day 0) and at Week 2.~Concomitant treatments to be administered at a dose and frequency prescribed per protocol include methotrexate (MTX) and folic or folinic acid."
224313007|NCT04839484|DEVICE|Study Product|up to 2cc per injection of filler placed into nasolabial fold.
224203703|NCT03361540|DRUG|Placebo|Placebo will be administered orally.
224313008|NCT04839484|DEVICE|Active Control|up to 2cc per injection of filler placed into nasolabial fold.
224203704|NCT01338909|DRUG|Prasugrel|Prasugrel 60mg immediate loading dose (Day 0)followed by 10mg/day starting from Day 1 until Day 5
223617209|NCT04781166|BEHAVIORAL|Calm program|7 online modules designed to teach cognitive behavioral skills
223617210|NCT03168620|PROCEDURE|Restoration|
223617211|NCT05543954|DRUG|68Ga-FAPI-RGD|Intravenous injection of 68Ga-FAPI-RGD with a dosage of approximately 1.8-2.2 MBq (0.05-0.06 mCi)/kg.
224203705|NCT01338909|DRUG|Clopidogrel|Clopidogrel 150mg/d starting from Day 1
224203706|NCT06506526|PROCEDURE|Sodium hypochlorite irrigating solution|2 ml 1% NaOCl after each file
224203707|NCT06506526|PROCEDURE|one minute NaOCL+Chitosan|2 ml 1% NaOCl after each file then with 5 ml of 0.2% chitosan for one minute.
224203708|NCT06506526|PROCEDURE|Three minute NaOCL+Chitosan|2 ml 1% NaOCl after each file then with 5 ml of 0.2% chitosan for three minute.
224203709|NCT01934777|DRUG|Docosahexaenoic Acid plus Vitamin E plus choline|DHA 250 mg plus Vitamin E (39 UI) plus Choline 201 mg
224203710|NCT01934777|DRUG|placebo pearls|placebo
224203711|NCT00232245|DRUG|Fish oil|
224203712|NCT01031342|PROCEDURE|Early colonoscopy|Colonoscopy within 12 hours of presentation
224313009|NCT02695784|DIETARY_SUPPLEMENT|Probiotic Continuation|This arm will continue to receive probiotics beyond 34 weeks corrected gestation until two months after discharge
224313010|NCT04873973|OTHER|Telemedical support|The nursing homes participating in the project will be equipped with telemedical equipment. This will allow teleconsultations to take place when needed. In addition, an early warning system will be introduced and, within the framework of the teleconsultation, a trained medical assistant can be sent to the care facility if necessary, who can carry out medical activities on site under a physician's delegated instructions. In addition, an electronic patient file will be introduced which can be accessed by the telemedicine physician and the general practitioner.
224313011|NCT04935684|DRUG|Fecal Microbiota Transplantation|"Patients randomized in the FMT group will received FMT within 4 weeks following neutrophils recovery after the allo-HSCT procedure. The stool transplant will be done by enema. The day before FMT, patient will undergo bowel cleansing by ingestion of two liters of polyethylene glycol solution. The day of FMT, a colon cleanse enema will be performed in the morning and FMT will be delivered around two hours after the cleanse enema. This colic preparation is essential to optimize the results of FMT.~The enema (50g of stools diluted in 250mL of NaCl 0.9%) will be performed by a qualified member of the study team (nurse) by using a rectal cannula (within 6 hours of thawing). The enema will have to be kept by the patient for as long as possible and at least 30 minutes."
224313012|NCT06301906|DRUG|LipoCol Forte Capsule 600mg bid|LipoCol Forte Capsule 600mg bid for 12 months
224313013|NCT00534456|DRUG|Placebo|Placebo group to receive volume and dose frequency changes resembling titration dosing in the treatment group.
224313014|NCT00534456|DRUG|Darbepoetin alfa|Starting dose: 0.75 mcg/kg subcutaneously Q2W. Subsequent doses: Darbepoetin alfa group to receive darbepoetin alfa titrated to achieve Hb target of 13.0 g/dL, not to exceed 14.5 g/dL.
224313015|NCT03153033|BEHAVIORAL|Fatigue protocol|The figure 8 protocol (fatigue intervention) requires the participants to propel three times as many laps as possible for four minutes each with their wheelchair. The protocol has been developed and used previously. Every bout of four minutes is separated by 90 seconds of rest. Each lap consists of a right and left turn and two complete stops after half a lap. Measurements during the protocol include the Rate of Perceived Exertion (RPE) scale, heart rate, and propulsion kinetics.
224313016|NCT05577195|DEVICE|Impella|To provide active left ventricular unloading in the experimental arm
224313017|NCT05577195|DEVICE|VA-ECMO|To provide circulatory support in both arms
224313018|NCT03998397|BIOLOGICAL|blood alcohol concentration withdrawal|The blood alcohol concentration is systematically performed in all intoxicated patients admitted in Emergency Department
224313019|NCT04590105|DEVICE|"Smartphone App SB Colonoscopy Prep"|We created a smartphone app that informs patients about their colonoscopy procedure, alerts them when to take their medications throughout the hours-long colonoscopy prep process and tells them when to arrive to the endoscopy suite.
224313020|NCT04590105|OTHER|Written Instruction|Written Instruction
224203713|NCT01031342|PROCEDURE|Elective colonoscopy|Colonoscopy 36-60 hours after presentation
224203714|NCT06650436|DIAGNOSTIC_TEST|EEG|The phase lag index will be used to assess functional connectivity between time series based on the consistency with which one signal is leading or lagging with respect to another signal.The PLI characterizes the asymmetry in the distribution of instantaneous phase differences between signals. If such an asymmetry is present, a phase coupling is assumed between signals, reflecting synchronized activity. Importantly, zero-phase coupling is discarded in the PLI as this may represent activity from common sources picked up at different electrodes. Based on the MST, network measures can be calculated. It is a measure of network efficiency. Leaf fraction quantifies the fraction of nodes in the whole network that have only one connecting edge, which is a measure of network integration.
224313021|NCT06968468|BEHAVIORAL|Resilient Together ALS|This intervention will teach resiliency and coping skills (mindfulness, meaning making, etc) to dyads soon after ALS diagnosis in order to manage distress associated with an ALS diagnosis. These sessions will take place over Zoom with both the person diagnosed with ALS and their primary informal caregiver.
223511141|NCT00063362|DRUG|Lamotrigine|Patients were assigned in a one to one ratio to adjunctive lamotrigine versus placebo after stratification for illness type (bipolar I versus bipolar II), historical response to lithium (response versus non-response), and length of current exposure to combination treatment with lithium and divalproex (\< 2 months versus ≥ 2 months). During Phase 2, patients were continued on the same doses of lithium and divalproex as during the open-label treatment phase and equal capsules of double-blind lamotrigine or matching placebo were gradually added per a structured dosing schedule up to a minimum dose of 150 mg and a maximum dose of 200 mg per day.
223511142|NCT00063362|DRUG|Divalproex|Divalproex was then initiated at 250 mg twice daily and increased slowly over five weeks to a minimum blood level of 50 μg/mL.
223511143|NCT00063362|DRUG|Placebo|Patients were assigned in a one to one ratio to adjunctive lamotrigine versus placebo after stratification for illness type (bipolar I versus bipolar II), historical response to lithium (response versus non-response), and length of current exposure to combination treatment with lithium and divalproex (\< 2 months versus ≥ 2 months). During Phase 2, patients were continued on the same doses of lithium and divalproex as during the open-label treatment phase and equal capsules of double-blind lamotrigine or matching placebo were gradually added per a structured dosing schedule up to a minimum dose of 150 mg and a maximum dose of 200 mg per day.
223511144|NCT03477591|OTHER|Evidence-based information|Evidence-based information on PSA testing such as blog posts, plain language evidence summaries and web resource ratings (quality-appraised online resources).
223511145|NCT03477591|OTHER|Patient Decision Aid|Patient Decision Aid for prostate cancer screening decision
223511146|NCT03477591|OTHER|Sham information|Educational information not specific to PSA testing or cancer screening
223511147|NCT00087672|DRUG|CC-5013|10 mg orally (2 capsules) daily
223511148|NCT04993768|DRUG|TPN-101, 100 mg/day|100 mg/day of study investigational drug TPN-101 once daily for 24 weeks (double-blind treatment) followed by 400 mg/day TPN-101 for 24 weeks (open-label treatment).
223511149|NCT04993768|DRUG|TPN-101, 200 mg/day|200 mg/day of study investigational drug TPN-101 once daily for 24 weeks (double-blind treatment) followed by 400 mg/day TPN-101 for 24 weeks (open-label treatment).
223761270|NCT05638646|OTHER|Intervention group|Practice standard for clinical diagnosis and treatment of chronic obstructive pulmonary disease
223617212|NCT05543954|DRUG|18F-FDG|Intravenous injection of 18F-FDG with a dosage of approximately 3.7-5.55 MBq (0.1-0.15 mCi)/kg.
223617213|NCT05543954|DRUG|68Ga-FAPI|Intravenous injection of 68Ga-FAPI with a dosage of approximately 1.8-2.2 MBq (0.05-0.06 mCi)/kg.
223617214|NCT05543954|DRUG|68Ga-RGD|Intravenous injection of 68Ga-RGD with a dosage of approximately 1.8-2.2 MBq (0.05-0.06 mCi)/kg.
223617215|NCT06256172|DEVICE|Medlink|The 10 Patients enrolled in this arm tested the ue of Medlink in Measuring and reporting their Physiological Paramters in Oder to remotely obtain access to health care for the following diseases: Myasthenia Gravis, Hypertension, Chronic Heart Failure, Diabetes Mellitus, and Chronic Obstruction Pulmonary Disorder.
223617216|NCT00778778|DRUG|cefprozil 500mg tablets|
223617217|NCT02544568|OTHER|Meals|At 4 different occasions the participants will receive meals with the same amount of calories and different composition of fat, protein, carbohydrate and fiber.The composition of the meals is: Low-fat / high-carbohydrate meal (18 E% proteins, 28 E% fat and 54% carbohydrates), high-fat meal (18 E% protein, 50 E% fat and 31 E% carbohydrate), high-protein meal (40 E% protein, 30 E% fat and 30 E% carbohydrates) and low-fat / high-carbohydrate and high fiber (18 E% proteins, 28 E% fat and 54 E% carbohydrates and 15 gram of fibers).
223761271|NCT05638646|OTHER|control group|Maintain current treatment
223761272|NCT01336686|DRUG|Arhalofenate|Arhalofenate 400 mg once daily for 4 weeks
223761273|NCT01336686|DRUG|Arhalofenate|Arhalofenate 600 mg once daily for 4 weeks
223761274|NCT01336686|DRUG|Placebo comparator|Matching placebo once daily for 4 weeks
224203715|NCT06650436|DIAGNOSTIC_TEST|MRI|"Manual segmentation of the acute ischemic lesion will be performed on MRI of the brain. Support vector regression-based lesion symptom mapping (SVR-LSM) will be performed to determine the association between AIL location and PSD. We will also perform an assumption-free region of interest (ROI)-based analysis by using support vector regression. The ROIs will be determined by the AAL atlas and ICBM-DTI-81 white matter tract atlas in MNI-152 space.~The MRI's will be performed within 72 hours of the stroke onset with a follow-up of 12 months."
224203716|NCT06650436|DIAGNOSTIC_TEST|Depression screening and neuropsychological tests|"Screening post-stroke delirium (during first 72hours after stroke symptom onset):~4AT test score: 0-12 (\>/= 4: diagnosis of (post-stroke) delirium) RASS score: from -5 until +4 Screening post-stroke cognitive impairment (3months, 12 months): MOCA score: 0-30~Screening post-stroke depression:~Patient Health Questionnaire-2: score 0-6 Hospital Anxiety and Depression Scale: score 0-21Anxiety and 0-21Depression"
224203717|NCT06651723|DEVICE|Toothbrush type|The participants will use either an electric soft brush (test) and soft manual brush (control).
224203718|NCT06652581|PROCEDURE|Modified Thorachoabdominal Nerve Block Perichondrial Approach(M-TAPA|USG Guided Bilateral Modified Thorachoabdominal Nerve Block Perichondrial Approach (M-TAPA) using 20 ml Bupivacaine 0,25%.
224203719|NCT06652581|DEVICE|Opioid Intravena|Opioid Intravenous post Surgery without M-TAPA Block delivered with PCA Machine
224203720|NCT06651996|DEVICE|one session of face-to-face telerehabilitation tutorial (OST)|The first group participated in a face-to-face tele-rehabilitation session in the hospital on the use of sensors and rehabilitation software before the home-rehabilitation session. Thereafter, the tele-rehabilitation program included muscle strengthening, flexibility stretching, and movement quality training every Tuesday, Thursday, and Saturday.
224203721|NCT06651996|DEVICE|Three session of face-to-face telerehabilitation tutorials (TST)|The second group participated in three face-to-face tele-rehabilitation sessions in the hospital on the use of sensors and rehabilitation software before the home-rehabilitation session. Thereafter, the tele-rehabilitation program included muscle strengthening, flexibility stretching, and movement quality training every Tuesday, Thursday, and Saturday.
224203722|NCT06651996|DEVICE|Six session of face-to-face telerehabilitation tutorials (SST)|The third group participated in six face-to-face tele-rehabilitation sessions in the hospital on the use of sensors and rehabilitation software before the home-rehabilitation session. Thereafter, the tele-rehabilitation program included muscle strengthening, flexibility stretching, and movement quality training every Tuesday, Thursday, and Saturday.
224203723|NCT06175468|DRUG|Formosa 1-Breath Free (NRICM101)|After screening, the treatment of this study is divided into two groups: The treatment group is Formosa 1-Breath Free (NRICM101) granule 5g/bag, 3 times a day.
223617218|NCT04903210|DIETARY_SUPPLEMENT|Nicotinamide mononucleotide supplied as 400mg capsule|NMN10000 WRIGHT LIFE® + lifestyle modification NMN10000 WRIGHT LIFE®: 800mg, qd, for two months. Lifestyle modification: intake 1400-1600 kcal/day: 54% carbohydrates, 24% proteins, 22% lipids, 108 mg cholesterol, 35 g fiber; avoid smoking and alcohol consumption; performing aerobic activity 4 days per week such as 45 min on a stationary bicycle.
223617219|NCT04903210|BEHAVIORAL|Lifestyle modification|Lifestyle modification: intake 1400-1600 kcal/day: 54% carbohydrates, 24% proteins, 22% lipids, 108 mg cholesterol, 35 g fiber; avoid smoking and alcohol consumption; performing aerobic activity 4 days per week such as 45 min on a stationary bicycle.
223617220|NCT02318563|DRUG|Cannabidiol Oral Solution|An oral solution containing pharmaceutical grade cannabidiol (nonplant-based)
223617221|NCT02318563|DRUG|Placebo Solution|A matching oral solution containing no cannabidiol
223617222|NCT02336607|DRUG|Felodipine tablet (Plendil) alone|Felodipine sustained release tablet single drug therapy (1st week- 2nd week) Eligible subjects will first take felodipine tablet 5mg, once daily, orally for 2 weeks. If blood pressure is controlled after 2 weeks, then the subjects will continue the treatment until the end of primary therapy stage (14th week).
223617223|NCT02336607|DRUG|Felodipine tablet (Plendil)+Hydrochlorothiazide|"Step 1: Eligible subjects will first take felodipine tablet 5mg, once daily, orally for 2 weeks.~If blood pressure is not controlled after 2 weeks, then the subjects will go to Step 2: Felodipine sustained release tablet 5mg once daily combined with hydrochlorothiazide 12.5mg, once daily. If blood pressure is not controlled after 4 weeks, then the subjects will go to Step 3: The dosage of felodipine sustained release tablet will be escalated to 10mg, once daily, while the dosage of the combined drug remains the same. If blood pressure is not controlled after 4 weeks, then the subjects will go to Step 4: The dosage of felodipine sustained release tablet keeps 10mg, once daily, while the dosage of different combined drug is doubled."
223761275|NCT01336686|DRUG|Colchicine|0.6 mg colchicine daily for flare prophylaxis
223761276|NCT01358604|GENETIC|polymerase chain reaction|
223761277|NCT01358604|GENETIC|protein expression analysis|
223761278|NCT01358604|GENETIC|western blotting|
223761279|NCT01358604|OTHER|flow cytometry|
223761280|NCT01358604|OTHER|immunohistochemistry staining method|
223761281|NCT01358604|OTHER|laboratory biomarker analysis|
223761282|NCT04019041|DRUG|bermekimab|bermekimab 2 mL (200 mg/mL) pre-filled syringe
224203724|NCT06175468|DRUG|Placebo control drug|After screening, the treatment of this study is divided into two groups: The placebo control group is the placebo (dummy) 5g/bag, 3 times a day.
224203725|NCT00069069|DRUG|Intransal instillation of E-selectin|Intranasal recombinant human E-selectin
224203726|NCT01280760|OTHER|Device: Neurally Adjusted Ventilatory Assistance|"Device: Neurally Adjusted Ventilatory Assistance~In ICU following extubation NIV was performed as follows:~facial mask with PSV/NIV mode to define settings for NAVA ventilation facial use with NAVA/NIV mode"
224203727|NCT02460861|PROCEDURE|biopsies of the prostatic fossa in Magdeburg|intraoperative Open surgical biopsies of the prostatic fossa after prostatevesiculectomy in Magdeburg
224203728|NCT02460861|PROCEDURE|RPVE|Open Radical prostatovesiculectomy in Magdeburg
224203729|NCT02460861|PROCEDURE|ETRARP|Robotassisted Radical prostatovesiculectomy in Gronau
224203730|NCT02460861|PROCEDURE|CE|Open cystectomy in Magdeburg/Gronau
224203731|NCT02460861|PROCEDURE|biopsies of the prostatic fossa in gronau|intraoperative endoscopic robotassisted biopsies of the prostatic fossa after prostatevesiculectomy in Gronau
224203732|NCT05451407|DRUG|TQB2618 injection|Humanized IgG4 mab targeting TIM-3
224203733|NCT05451407|DRUG|Toripalimab injection|Monoclonal antibody against Programmed death factor receptor 1
224203734|NCT01379365|DEVICE|Cryo-Touch III|Percutaneous treatment with the device
224203735|NCT01679418|DEVICE|Placement of a wound drain post surgery (Redon; Medicoplast)|The wound drain, type Redon Drainage 3.0 mm in diameter
224203736|NCT01679418|OTHER|No-drain after surgery|After surgery, no drain was put
224203737|NCT02606864|DRUG|Nifurtimox (BAYa2502)|Oral Intake of 4 x 30 mg nifurtimox tablets
223511150|NCT04993768|DRUG|TPN-101, 400 mg/day|400 mg/day of study investigational drug TPN-101 once daily for 24 weeks (double-blind treatment) followed by 400 mg/day TPN-101 for 24 weeks (open-label treatment).
223511151|NCT04993768|DRUG|Placebo|Placebo once daily for 24 weeks (double-blind treatment) followed by 400 mg/day TPN-101 for 24 weeks (open-label treatment).
224203738|NCT02316743|DRUG|Levothyroxine supplementation|T4 supplementation for heart failure patients with subclinical hypothyroidism.
224203739|NCT06650904|OTHER|simulation based training|Simulation practice enables the acquisition of realistic skills. Semi-structured scenarios used in the training allow nurses to demonstrate their real communication skills.
223511152|NCT04645030|DIAGNOSTIC_TEST|Ultra low-dose computer thermography|The ULD-CT scan will be executed according to a standardized predeveloped technical protocol. The technical protocol will differentiate between patients with BMI \<25 and \>25 to insure optimal ULD-CT image quality.
223511153|NCT04645030|DIAGNOSTIC_TEST|lung ultrasound|"LUS will be performed by trained researchers. Before inclusion researchers preforming LUS scans, will undergo a training program and will complete 25 supervised LUS scans to be certified in LUS. At the end of the training program, researchers will be tested to insure proficiency in LUS.~LUS will be performed according to LUS protocol with seven scanning's zones on each side; 2 anterior, 2 lateral and 3 posterior."
223511154|NCT00968045|DRUG|Fibrinogen|Fibrinogen 2 gr in 100 ml sterile water. The infusion is given during 15 minutes
223511155|NCT03568123|DEVICE|MC polyethylene bearing|"Zimmer Biomet Persona Total Knee System with MC polyethylene bearing. Femoral component: Only cemented femoral components will be used for this study. Both standard as well as narrow femoral components will be used, depending on the patient anatomy.~Tibial component: Only cemented tibial components will be used for this study. Polyethylene materials: Conventional polyethylene will be used for patients \>65 years old and Vitamine-E infused poly insert for patients ≤ 65 years old."
223511156|NCT03568123|DEVICE|CR polyethylene bearing|"Zimmer Biomet Persona Total Knee System with CR polyethylene bearing. Femoral component: Only cemented femoral components will be used for this study. Both standard as well as narrow femoral components will be used, depending on the patient anatomy.~Tibial component: Only cemented tibial components will be used for this study. Polyethylene materials: Conventional polyethylene will be used for patients \>65 years old and Vitamine-E infused poly insert for patients ≤ 65 years old."
223511157|NCT04179656|DRUG|Pyrotinib|400 mg administered orally, once daily, continuously in 21 day cycles
223511158|NCT00808756|DIETARY_SUPPLEMENT|Fermentable carbohydrates.|Infant formula enriched with fermentable carbohydrates.
223761283|NCT04019041|DRUG|placebo|placebo 2 mL pre-filled syringe
223761284|NCT02839616|PROCEDURE|orthotopic liver transplantation|
223761285|NCT04278521|DEVICE|Transcranial Magnetic Stimulation|Transcranial magnetic stimulation uses a rapidly changing magnetic field to induce current in brain tissue non-invasively. It is common procedure in both clinical and research settings, and it has well established guidelines for safe an ethical use which maximize safety for all subjects.
224203740|NCT06650735|PROCEDURE|BMR resection|"Lid speculum will be applied. Fornix conjunctival incision will be used to expose medial rectus muscle. Area that will be resected will be marked using calipers. Double-armed polyglactin 910 suture (6/0 Vicryl) will be used in securing the muscle.~The muscle then excised anterior to the sutures and the stump cut flush to the sclera.~The muscle will be sutured again to the original insertion by scleral sutures which will be tied together.~Conjunctiva will be closed using polyglactin 910 suture (6/0 Vicryl)."
224203741|NCT06650735|PROCEDURE|BLR recession|"Lid speculum will be applied. Fornix conjunctival incision will be used to expose lateral rectus muscle. Double-armed polyglactin 910 suture (6/0 Vicryl) will be used in securing the muscle close to the insertion.~The muscle will then be cut anterior to the sutures flush with the sclera. Calipers will used to mark the new insertion on sclera measured from the stump. The muscle will be sutured again to the new insertion by scleral sutures, which will be tied together.~Conjunctiva will be closed using polyglactin 910 suture (6/0 Vicryl)."
224203742|NCT06376812|BEHAVIORAL|Physical activity intervention|Physical activity
224203743|NCT03226574|DRUG|Resiniferatoxin|single dose (0.4, 1, 2, 4, 8,15, 25 or 35 mcg), epidural injection
224203744|NCT03804060|DEVICE|Thermogard XP3|Cooling with the ZOLL® Circulation catheter and the ZOLL® Intravascular Temperature Management system to initiate and maintain hypothermia for 6 hours as an adjunct to endovascular Recanalization.
224203745|NCT03804060|PROCEDURE|Recanalization only|Standard of Care for recanalization
224075537|NCT05582642|DEVICE|Inspiratory Muscle Training (IMT)|"The training itself includes 2 x 30 breathing cycles per day. The whole training should take place daily, 7 days a week. The initial training intensity in the treatment arm (resistance of the respiratory muscle training) is set to 50% of the maximum respiratory muscle strength (measured using PImax). Once a week the present investigators get a picture of patient's training, pay attention to shortness of breath, potential for adaptation.~In the control arm of the study, this force adjustment would not take place, i.e. it is an endurance training of the diaphragm (10% of PI Max over the whole 6 weeks) with, however, also the control dates of the training twice a week. At least in the 6 weeks of the study (see above)."
224203746|NCT02689973|BEHAVIORAL|Self-Efficacy|"The introductory part included an abbreviated version of the education materials used in the control group. The self-efficacy materials and forms had four sections: (a) definitions of self-efficacy beliefs, (b) information on the importance of self-efficacy for goal pursuit, (c) recollecting a mastery experience, (d) persuasive statements evoking self-persuasive statements about self-efficacy beliefs. The materials ended with instructions for the following 7 days to recollect self-efficacy enhancing statements every morning. The procedures are based on a self-efficacy intervention by Luszczynska, Tryburcy et al. (2007).~Group and individual components were included. Setting: secondary and high schools."
224313022|NCT01774708|DEVICE|Pressure sensitive pad|"The proposed research uses an investigational device from EarlySense consisting of a pressure sensitive piezoelectric pad 350 mm x 226 mm x 12 mm or a little less than 9 by 13 inches and under a half inch thick connected to a cord resembling a phone cord to a controller 10.3 by 10.5 by 5.5 inches which in turn plugs into a standard electrical outlet. The power cord is modu¬lar, so it is possible to select a cord that is long enough without having excessive extra length. The con¬nec¬tion between the pad and the monitor has a quick release like a modular telephone.~This system is designed to very unobtrusively collect heartbeat patterns, respiratory patterns, motion in bed, and bed-exit data with no risk or inconvenience to the patient."
223511159|NCT00808756|OTHER|Standard infant formula.|Standard infant formula.
223511160|NCT00619242|DRUG|sorafenib|2 tablets with water by mouth twice a day for two weeks.
223511161|NCT01250327|DEVICE|Melody|insertion of a pulmonic valved stent
223511162|NCT01250327|DEVICE|bare stent|insertion of a bare metal stent
223511163|NCT01250327|PROCEDURE|Surgery|conventional surgery methode
223511164|NCT05877365|DIETARY_SUPPLEMENT|Standard Process 21-Day Purification Program|Purification, also known as detoxification, may help remove natural toxins from the body, while maintaining a healthy weight. The toxin load humans are exposed to daily may take a toll on physical and emotional well-being. Internally, human bodies produce waste byproducts because of normal metabolic function. Although the body is designed to rid itself of these toxins naturally, it can become overburdened. Purification may offer the body additional support to expel these toxins and manage weight, which is important to maintaining health and vitality.
223511165|NCT02621853|DEVICE|Raman spectroscopy of the liver|Liver will be illuminated by the Raman spectroscope optic probe in order to assess fat content
223511166|NCT04797481|PROCEDURE|Exercise|Group A participants will be invited to attend up to 24 exercise sessions (2 sessions per week and a 3rd optional) and 2 virtual (online; a 3rd will be optional) HF workshops over 8 weeks. All sessions will be delivered via online platforms, with 1 facilitator supporting up to 8 participants simultaneously in each session.
223511167|NCT04797481|PROCEDURE|Self-managed exercise|Group B participants will be provided with a self-care exercise programme. The exercise programme will be home-based with a mixture of online video calls and telephone support contacts, alternating once every other week. The video or telephone contacts will be mutually agreed by the patient and the facilitator at a mutually convenient time and will aim to support Group B participants, by offering advice and tracking progress. Patients will be provided with two exercise programmes: I) a chair-based exercise programme (DVD will be provided), and ii) a progressive walking training programme (a manual will be provided). Patients will be advised to exercise ≥3 times per week, starting from their own personal level and gradually building up over 8 weeks in session's duration, frequency of sessions per week, and walking pace.
223511168|NCT03133780|DRUG|Ketamine|Patient will receive IV ketamine 0.5 mg/kg diluted in normal saline to a volume of 50 ml over 10 min
223511169|NCT03133780|DRUG|Midazolam|Patient will receive IV midazolam 0.03 mg/kg diluted in normal saline to a volume of 50 ml over 10 min
223511170|NCT04991597|OTHER|Cold Compress Pack|Palmar aspect of forearm will have a cold compress pack placed on it.
223511171|NCT04991597|OTHER|Room Temperature Compress Pack|Palmar aspect of forearm will have a room temperature compress pack placed on it.
223511172|NCT04991597|DRUG|Lidocaine Epinephrine|Lidocaine with epinephrine will be buffered 3:1 with sodium bicarbonate
223511173|NCT04991597|DRUG|Lidocaine Epinephrine|Lidocaine with epinephrine will be buffered 9:1 with sodium bicarbonate
223511174|NCT04034056|DRUG|Obinutuzumab|Induction phase: 1000 milligram (mg) intravenously (IV) on Day 1, 8, 15 of Cycle 1 an Day 1 of Cycles 2-6 or 2-8. Maintenance phase: 1000 mg IV every 2 months for 2 years or until disease progression (whatever occurs earlier).
223511175|NCT05887661|PROCEDURE|hypovolemic phlebotomy|hypovolemic phlebotomy was performed after induction of anesthesia and before the star of parenchymal division, with a goal-directed low central venous pressure drop to 5mmHg.
223511176|NCT04578418|DIETARY_SUPPLEMENT|Hydrolyzed collagen|Hydrolyzed collagen supplementation twice daily
223511177|NCT04578418|OTHER|Heavy slow resistance training|Heavy slow resistance training 3 times weekly
223511178|NCT04578418|DIETARY_SUPPLEMENT|Placebo|Placebo supplementation twice daily
223511179|NCT06636851|DEVICE|Pacemaker and defibrillator|Permenant pacemaker implantation with lead fixed to the RV Septal location
223511180|NCT06636851|DEVICE|Pacemaker and defibrillator|Description: Permenant pacemaker implantation with lead fixed to the RV Apical location
223511181|NCT06644872|OTHER|Bedrest|Investigation of the effect of short-term bed rest (3 hours) on heart function, measured by cardiac magnetic resonance, in healthy participants ( males and females)
223511182|NCT04401475|BIOLOGICAL|SOC plus 15mg/kg EB05 IV|Standard of care plus single IV infusion of 15mg/kg of EB05.
223511183|NCT04401475|OTHER|SOC plus Placebo IV|Standard of care plus a single IV infusion of placebo.
223511184|NCT02921282|GENETIC|Genotype dopamine|Laboratory investigations of nicotine reinforcement
223511185|NCT02921282|GENETIC|Genotype cannabinoids|Laboratory investigations of nicotine reinforcement
223617224|NCT02336607|DRUG|Felodipine tablet (Plendil)+Metoprolol tablet (Betaloc ZOK)|"Step 1: Eligible subjects will first take felodipine tablet 5mg, once daily, orally for 2 weeks.~If blood pressure is not controlled after 2 weeks, then the subjects will go to Step 2: Felodipine sustained release tablet 5mg once daily combined with metoprolol succinate prolonged-release tablet (Betaloc ZOK) 47.5mg , once daily. If blood pressure is not controlled after 4 weeks, then the subjects will go to Step 3: The dosage of felodipine sustained release tablet will be escalated to 10mg, once daily, while the dosage of the combined drug remains the same. If blood pressure is not controlled after 4 weeks, then the subjects will go to Step 4: The dosage of felodipine sustained release tablet keeps 10mg, once daily, while the dosage of different combined drug is doubled."
224075538|NCT01179958|BEHAVIORAL|aerobic training|24 weeks of aerobic training, 4X/week
224313023|NCT03203564|DRUG|Modufolin (arfolitixorin)|Thirty-three eligible and consenting subjects will be included in 3 cohorts, 11 subjects in each cohort, Within each cohort, subjects will be randomized to receive either placebo (3 subjects) or Modufolin® for injection, 100mg (8 subjects)
224313024|NCT02377050|OTHER|Higher Volume Feeding Goal|feeding volume goal of 180-200 ml/kg/day
224313025|NCT06199063|OTHER|Self-Streching Exercises|The participants in the SSE group; received 1 session SSE with 10 repetitions, about 30 min. The assessments were applied before and after the session.
224313026|NCT06199063|OTHER|Post-Isometric Relaxation Exercises|The participants in the PIRE group; received 1 session PIRE with 10 repetitions, about 30 min. The assessments were applied before and after the session.
224313027|NCT06199063|OTHER|Reciprocal-Inhibiton Exercises|The participants in the RIE group; received 1 session RIE with 10 repetitions, about 30 min. The assessments were applied before and after the session.
224313028|NCT00499421|PROCEDURE|Computed Tomography (CT) Scan|CT scan of the prostate three times a week, just before the delivery of radiation.
224313029|NCT06060379|OTHER|GiochiAMO a 626|The subjects of the intervention group will play three different games: a role-playing game, a card game and a board game.
223511186|NCT03227627|DEVICE|VitalStim|One group of children (Group A) will receive 24 sessions of NMES for combined with traditional therapy including oral motor exercises and laryngeal exercises will be performed to the participants. The equipment to be used for NMES is VitalStim®. VitalStim is a product of Empi®.
223511187|NCT03227627|OTHER|Traditional Therapy|The other group (Group B) will be receiving 24 sessions of traditional dysphagia therapy.
223511188|NCT02767687|OTHER|Noninvasive ventilation|Twenty minutes after extubation all subjects will receive noninvasive ventilation delivered through a facial mask with an ICU ventilator with NIV option for 60 minutes. NIV associates pressure support ventilation (PSV: 5 to 15 cmH2O) and positive end expiratory pressure (PEEP: 5 to 10 cmH2O).
223511189|NCT02155972|DIETARY_SUPPLEMENT|Bifidobacterium infantis|Probiotic supplement
224075539|NCT01179958|BEHAVIORAL|stretching/toning|stretches and toning exercises designed to promote flexibility and improved core strength
224075540|NCT04714541|DRUG|Ketamine Hcl 50Mg/Ml Inj|Racemic Ketamine Will Be Infused At A Starting Dose of 0.75 mg/kg Over A Period of 45 Minutes. The Dose Will be Titrated, Based on Clinical Signs With Changes of 0.3mg/kg Up to Maximum of 0.95 mg/kg, and Lowest Dose of 0.3 mg/kg
224075541|NCT04016311|BEHAVIORAL|Mindful Drinking/Eating Intervention|Participants will be individually guided during their dialysis session through: 1) a mindful drinking exercise, a meditation focused on the sensory experience of 3 sips of fluid, along with a discussion of the experience; and 2) a mindful eating exercise with select foods that are recommended for controlling thirst (i.e., hard candy, frozen fruits). Participants will be given directions for mindful drinking/eating and asked to practice mindful drinking/eating as often as possible but least once each day.
224075542|NCT04311086|DEVICE|Renal Denervation (Symplicity Spyral™)|Device: Symplicity Spyral™ multi-electrode renal denervation system. After a renal angiography according to standard procedures, subjects are treated with the renal denervation procedure.
224075543|NCT02653222|PROCEDURE|Renal sympathicolysis|
224075544|NCT02653222|PROCEDURE|Ambulatory Blood Pressure Monitoring|1 month before and after surgery the patient will have an ABPM over 24h
224075545|NCT02653222|RADIATION|Magnetic Resonance Angiography|1 month before and after surgery the patient will have a MRA
224075546|NCT02653222|BIOLOGICAL|Blood test|complete blood count, blood platelets, coagulation profile, irregular agglutinins search
224075547|NCT02706730|DRUG|OTO-104|Single intratympanic injection of 12 mg OTO-104
224075548|NCT02064387|DRUG|GSK2857916|A clear or opalescent solution for IV infusion with unit dose strength of 20 mg/mililiter (mL) for multiple dose levels.
224075549|NCT05875259|DRUG|BR1019-1|Treatment group A : One tablet of BR1019-1 administered alone once daily for 7 days.
224075550|NCT05875259|DRUG|BR1019-2|Treatment group B : One tablet of BR1019-2 administered alone once daily for 7 days.
224075551|NCT05875259|DRUG|BR1019-1 + BR1019-2|Treatment group C : One tablet each of BR1019-1 and BR1019-2 administered in combination once daily for 7 days.
224075552|NCT00794560|BEHAVIORAL|patient education|"Possible, individualized interventions:~* Improvement of patient's knowledge about medication, therapy and drug application by providing detailed written information material~* Providing a complete equipment package for self-injection (disinfection patches, patches, plasters, waste disposal box for used syringes)~* Patient training: oral instructions for self-injection (and application, if required), exercising the injection technique on a phantom~* First self-injection under control of a specially trained pharmacist"
224075553|NCT01584245|OTHER|Amino Acid formula|
224075554|NCT02499029|DRUG|N-acetylcysteine|NAC pills were administered each week. NAC is a N acetyl pro-drug of the naturally-occurring amino acid cystine. NAC is a white, crystalline powder with the molecular formula C5H9NO3S and with a molecular weight of 163.2.
224075555|NCT02499029|DRUG|Placebo|Identical looking placebo pills were administered each week.
224313030|NCT04269681|DEVICE|High Flow Nasal Cannula|"Experimental intervention (HFNC) The HFNC (AIRVO 2 - Fisher \& Paykel Healthcare, Auckland, New Zealand) consists of a device that allows FiO2 adjustable from 21 to 100% and that delivers a flow of humidified and heated gas up to 60 l / min and 37 degrees C of temperature.~The HFNC will be offered until resolution of the ARF or until decision by the assisting team and the patient and/or their legal guardian, for the suspension of the treatment due to intolerance, and/or worsening of the discomfort and / or dyspnea.~The HFNC should be offered to the patient in ARF as follows:~* Initial parameters: Flow 45 ml / L, FiO2 50%, AIRVO 37oC temperature;~* Titrate the flow up to 60ml / L or up to the maximum tolerated;~* Titrate FiO2 to maintain SatO2 between 92% to 98%, starting with 50%;~* Keep the AIRVO temperature at 37oC, if not possible, acceptable down to 34oC."
223617225|NCT02336607|DRUG|Felodipine tablets (Plendil)+Lisinopril (Zestril)|"Step 1: Eligible subjects will first take felodipine tablet 5mg, once daily, orally for 2 weeks.~If blood pressure is not controlled after 2 weeks, then the subjects will go to Step 2: Felodipine sustained release tablet 5mg once daily combined with Lisinopril (Zestril) 10mg, once daily. If blood pressure is not controlled after 4 weeks, then the subjects will go to Step 3: The dosage of felodipine sustained release tablet will be escalated to 10mg, once daily, while the dosage of the combined drug remains the same. If blood pressure is not controlled after 4 weeks, then the subjects will go to Step 4: The dosage of felodipine sustained release tablet keeps 10mg, once daily, while the dosage of different combined drug is doubled."
223617226|NCT02587741|DRUG|Metformin|start with metformin，from 500mg bid,if metformin reach the biggest dosage，added gliclazide modified release tablets，afterthat，add acarbose
223511190|NCT02155972|OTHER|Placebo|Placebo capsules
223511191|NCT04213339|BEHAVIORAL|Kegel Exercises|"Kegel exercise group will get exercise within duration of 3 to 6 weeks based on age factor. Kegel exercise can be performed at any time and at any place without any restrictions.~following steps will be followed by kegel exercises group members:~1. Tighten and hold pelvic floor muscles for five seconds (count 1 one thousand, 2 one thousand, 3 one thousand, 4 one thousand, 5 one thousand).~2. Relax pelvic muscles and perform 10 to 20 Kegel exercises three to four times each day.~3. Squeeze the muscles in anus like holding a bowel movement focus penile area~4. Relax the pelvic floor muscles after each attempt.~5. Repeat this exercise 10 to 20 times.~6. While performing Kegel exercises:~Do not hold the breath. Do not push down. Squeeze the muscles together tightly and imagine, trying to lift this muscle up. Do not tighten the muscles in the stomach, buttocks, or thighs.~While the control group did not participate in any kegel exercises"
223511192|NCT01843504|BIOLOGICAL|platelet rich plasma|A blood draw of 15 mL of the subject's own blood will be performed. The study coordinator will then place the sample in the Platelet Separator System (a centrifuge) and spin the blood sample in using a two-stage spinning: the 1st separates red blood cells from platelets, and the 2nd concentrates the platelets. This will be spun by centrifuge to yield 6 mL of concentrated autologous platelet. Under continuous ultrasound evaluation, 1.0-2.0 mL of the prepared PRP will be injected onto the origin of the patella tendon itself will be peppered along a short segment of the tendon into the areas of palpated tenderness and US-documented pathology.
223617227|NCT02587741|DRUG|Lantus|started with insulin glargine 0.2 u/kg subcutaneous injection ，add dosage if glucose dose not reach the target.after that,you can add oral drugs（like oral drug group）
223617228|NCT02587741|DRUG|Novomix30|started with premixed insulin subcutaneous injection(0.4-0.6 u/kg divided into half before breakfast and dinner),and add dosage if glucose dose not reach the target.after that,you can add oral drugs ,as Group Oral Drugs
224075556|NCT01392820|DRUG|TC-5214|Tablet, Oral, twice daily
224075557|NCT01392820|DRUG|Placebo|Tablet, Oral, twice daily
224075558|NCT02681016|DEVICE|"DES Calypso"|A standard endovascular procedure is carried out under local anesthesia and under fluoroscopic control. Stenosis of coronary artery is passed by the hydrophilic coronary wire. Then balloon angioplasty of target lesion (if required) is provided. After the angiographic control coronary stent is implanted. After coronary wire removing control angiographic study is provided. Medical therapy includes aspirin(acid acetylsalicylic) 125 - 300 mg/d and plavix(clopidogrel) in dose 300-600 mg prescription before the procedure and heparin (heparin sodium) injection during the procedure(5000 U iv). After the procedure aspirin(acid acetylsalicylic) in dose 100 mg/d within long period should be prescribed in all the patients, and plavix(clopidogrel) in dose 75/d should be prescribed within 12 months.
224075559|NCT02681016|DEVICE|"DES Xience Prime"|A standard endovascular procedure is carried out under local anesthesia and under fluoroscopic control. Stenosis of coronary artery is passed by the hydrophilic coronary wire. Then balloon angioplasty of target lesion (if required) is provided. After the angiographic control coronary stent is implanted. After coronary wire removing control angiographic study is provided. Medical therapy includes aspirin(acid acetylsalicylic) 125 - 300 mg/d and plavix(clopidogrel) in dose 300-600 mg prescription before the procedure and heparin (heparin sodium) injection during the procedure(5000 U iv). After the procedure aspirin(acid acetylsalicylic) in dose 100 mg/d within long period should be prescribed in all the patients, and plavix(clopidogrel) in dose 75/d should be prescribed within 12 months.
224075560|NCT02681016|PROCEDURE|Coronary angioplasty|
224075561|NCT03161756|DRUG|Denosumab|Denosumab is a fully human monoclonal immunoglobulin type 2 (IgG2) antibody that binds with high affinity and specificity to RANK ligand (RANKL) and neutralises the activity of human RANKL, similar to the action of endogenous osteoprotegerin (OPG). Denosumab binding prevents the activation of RANK and inhibits the formation, activation, and survival of osteoclasts. As a consequence, bone resorption and cancer-induced bone destruction are reduced.
224075562|NCT03161756|DRUG|Nivolumab|Nivolumab is a human monoclonal antibody that targets the programmed death-1 (PD-1) cluster of differentiation 279 (CD279) cell surface membrane receptor. Nivolumab inhibits the interaction of PD-1 with its ligands, PD-L1 and PD-L2, resulting in enhanced T-cell proliferation and interferon-gamma (IFN-γ) release in vitro.
224075563|NCT03161756|DRUG|Ipilimumab|Ipilimumab is a fully human monoclonal immunoglobulin specific for human cytotoxic T-lymphocyte antigen 4 (CTLA-4), which is expressed on a subset of activated T cells. Ipilimumab is a monoclonal antibody(mAb) that binds to CTLA-4 and blocks the interaction of CTLA-4 with its ligands, cluster of differentiation antigen 80 / cluster of differentiation antigen 86 (CD80 / CD86). Blockade of CTLA-4 has been shown to augment T-cell activation and proliferation, including the activation and proliferation of tumor-infiltrating T-effector cells.
224075564|NCT00180960|DRUG|Oxaliplatin and irinotecan|
224313031|NCT04269681|OTHER|Standard respiratory support|The patient randomized to standard respiratory support will be placed on conventional low flow oxygen therapy according to the center's standard of care aiming at SpO2 90 - 98% and improvement of dyspnea. For cases refractory to oxygen therapy, keeping SpO2 below 90% or if dyspnea does not improve, non-invasive positive pressure ventilation (NIPPV) may be offered at the discretion of the assistant team. NIPPV will be performed with the patient in a supine position at 45 degrees. The mask will be facial (oronasal or full face) with an appropriate size for each patient and adapted in a way to minimize leakage. A hydrocolloid dressing can be placed over the nose in order to avoid ulcerations and increase comfort. The NIPPV will be performed with the help of a ventilator with inspiratory and expiratory circuits or with Bilevel devices with a single circuit and exhalation valve according to the availability of each center.
224313032|NCT02612259|DIETARY_SUPPLEMENT|TRYPTOPHAN|at the dose of 3,5 m/kg/ day divided in two capsules
224313033|NCT02612259|OTHER|PLACEBO|at the dose of 3,5 m/kg/ day divided in two capsules
224313034|NCT04292652|PROCEDURE|AAA surgery|EVAR is a mini invasive procedure to exclude aortic aneurysms with the intention to prevent rupture. Open repair is the traditional open surgical procedure for the same condition.
224313035|NCT04962152|DRUG|Nalbuphine Sebacate or Sesame oil (placebo)|ultrasound-guided intramuscular injection after the induction of anesthesia immediately
224313036|NCT06532851|OTHER|Progressive Resistance Exercise (PRE)|A structured exercise regimen focusing on increasing muscular strength and endurance through progressive resistance.
224313037|NCT06532851|OTHER|Aerobic Exercise|An exercise program focusing on cardiovascular conditioning using a stationary bike.
224313038|NCT06532851|OTHER|Control|A set of general strength and balance exercises that do not target the specific therapeutic goals of the other interventions.
224313039|NCT03357653|DRUG|Losartan group|Losartan 50 mg daily
223617229|NCT04748666|BEHAVIORAL|Problem Solving Training|Problem Solving Training (PST) is a metacognitive strategy training approach, grounded in self-management theory, that teaches a simple, systematic method for evaluating problems, generating and selecting solutions, developing specific goals and action plans, and evaluating and revising plans as needed.
224203747|NCT02689973|BEHAVIORAL|Planning|"The introductory part included an abbreviated version of the education materials used in the control group. The planning materials and forms had four sections: (a) information on the importance of planning, including examples of how planning works and what it affects, (b) instructions of what should be included in a good plan (the when, where, and how components), (c) formulating action and coping plans. The materials ended with instructions for the following 7 days to recollect/redo plans every morning.The procedures are based on a planning intervention by Luszczynska, Sobczyk, et al. (2007).~Group and individual components were included. Setting: secondary and high schools."
224203748|NCT02689973|BEHAVIORAL|Education|"Participants received a set of educational materials about types of physical activity (PA), PA intensity, exercise calorie expenditure, myths about PA, strength and endurance training, stretching, and general healthy nutrition guidelines. The materials excluded planning and self-efficacy statements.~The materials ended with instructions for the following 7 days to recollect forms of MVPA every morning.~Group and individual components were included. Setting: secondary and high schools."
224203749|NCT03750058|DEVICE|Implant test procedure|Implant test procedure with new LV quadripolar lead before a standard implantation for Cardiac resynchronisation therapy
224203750|NCT05244902|DRUG|5% Dextrose|All the patients will receive oral 3mL/kg 5%Dextrose
224203751|NCT00576940|DRUG|Reconvan|isocaloric, immunomodulating entral diet
224203752|NCT00576940|DRUG|Peptisorb|isocaloric, isopeptic standard diet
224203753|NCT04544748|BIOLOGICAL|GNR-051|Anti-PD1 monoclonal antibody
224203754|NCT00000856|DRUG|Foscarnet sodium|
224203755|NCT00000856|DRUG|Ganciclovir|
224203756|NCT00314262|DRUG|Erlotinib & Celecoxib|"Erlotinib given orally, once daily (dose escalation from 50 mg, 75 mg, or 100 mg) continuously for 6 months in the phase I portion.~Celecoxib given 400 mg orally BID continuously for 6 months."
224203757|NCT01704482|DRUG|N-acetylcysteine|NAC bolus of 150 mg/kg in 250 mL of 5% glucose over 15 mins, followed by continuous intravenous infusion of 50 mg/kg in 250 mL of 5% glucose over 4 hrs, then 100 mg/kg in 1000 ml of 5% glucose over 20 hrs
224203758|NCT01704482|DRUG|placebo|
224313040|NCT03357653|DRUG|Placebo group|Placebo 1 pill daily
224313041|NCT06462560|OTHER|Vivo Online Exercise Program|Virtual online exercise programs conducted by the Vivo team consisting of multiple time a week group live programs
224313042|NCT06462560|OTHER|Medbridge Home program|At home exercise program accessed through exercise descriptions and short vidoes
224313043|NCT00763061|DRUG|Travoprost 0.004% Ophthalmic Solution (Travatan)|Travoprost at 9 AM + Placebo \& 9 PM
223617230|NCT04139226|DRUG|CC-11050|CC-11050
223617231|NCT00339586|DRUG|Erlotinib|
223617232|NCT04590807|DEVICE|Posterior spinal fusion with pedicle screws|Implanting pedicle screws and rods
223617233|NCT04590807|DEVICE|Anterior vertebral body tethering|Vertebral screws and cable
224203759|NCT00083226|DRUG|doxorubicin|Given IV
224203760|NCT00083226|DRUG|bortezomib|Given IV
224203761|NCT04661865|OTHER|Health Information Package Program (HIP program )|"Fifteen minutes PowerPoint presentation will be introduced to women to increase women's educational experience and raise their level of engagement and commitment.~The principal investigator will narrate the video record with PowerPoint slides and it was recorded as a video and will include information regarding the introduction to pregnancy, causes and predisposing factors of iron deficiency anemia during pregnancy, signs and symptoms, prevention, management of iron deficiency anemia during pregnancy that includes iron therapy, iron supplementation, dietary management. Content validity for the information in the video will be done by sending it to three experts in maternity nursing. Iron supplementation will be given to all participants who will start by sixteen weeks of pregnancy and they will receive information regarding the proper usage of iron supplements."
224203762|NCT06037148|BIOLOGICAL|DM-101PX|subcutaneous injection of DM-101PX
224203763|NCT06037148|BIOLOGICAL|Placebo to Match DM-101PX|Placebo to match DM-101PX administered subcutaneously
224313044|NCT00763061|DRUG|Timolol 0.5% Ophthalmic Solution (Timoptic)|Timolol in each eye, twice daily at 9 AM \& 9 PM
224313045|NCT03661697|DEVICE|Laser Therapy|"Clear and Brilliant Permea is a 1927nm fractional laser with 3 settings; low, medium, high.~All interventions were done at low with four passes to each participant's full face."
223511193|NCT01843504|OTHER|saline|A blood draw of 15 mL of the subject's own blood will be performed to maintain blinding. Under continuous ultrasound evaluation, 1.0-2.0 mL of the saline solution will be injected onto the origin of the patella tendon itself will be peppered along a short segment of the tendon into the areas of palpated tenderness and US-documented pathology.
223511194|NCT02145611|DRUG|Glibenclamide|Glibenclamide
223511195|NCT02145611|DRUG|Vildagliptin|Vildagliptin
223617234|NCT02763423|PROCEDURE|umbilical cord mesenchymal stem cell|allogeneic umbilical cord mesenchymal stem cell transplantation by intravenous injection
223617235|NCT02552966|DEVICE|UESAD|Device designed to provide modest cricoid pressure to reduce reflux
223617236|NCT02643459|BEHAVIORAL|suPAR measurement|The biomarker suPAR will be measured on all patients included in the study. Before the study period the doctors will receive information on suPAR. We want to study if the information provided by suPAR is useful in emergency medicine. Interventions depends on the clinical issue, as suPAR is an unspecific marker of disease. Usually a elevated suPAR level could result in more investigation e.g. diagnostic procedures or follow up, while a low suPAR could result in faster discharge.
223617237|NCT04983966|DRUG|Desﬂurane|"General anesthesia for patients will be inducted and maintained with desflurane inhalation and remifentanil infusion.~Remimazolam group will be started with remiamazolam at 6 mg/kg/h and TCI Minto model of remifentanil for the time of anesthesia induction, and maintained at 0.5"
223617238|NCT04983966|DRUG|Remimazolam|"General anesthesia for patients will be inducted and maintained with desflurane inhalation and remifentanil infusion.~Remimazolam group will be started with remiamazolam at 6 mg/kg/h and TCI Minto model of remifentanil for the time of anesthesia induction, and maintained at 0.5"
223617239|NCT02232217|BEHAVIORAL|Cognitive Behavior Therapy Sleep|Children in this arm will receive instructions on the use of 'coping thoughts.' Common elements across the CBTcs sessions include reviewing progress, setting goals for change, problem solving to address challenges/barriers, and reinforcing progress
224203764|NCT04800510|DEVICE|Carbon Fiber Custom Dynamic Orthosis (CDO)|The CDO will consist of a semi-rigid foot plate, a posterior carbon fiber strut, and a proximal cuff below the knee.
223511196|NCT01235117|DRUG|azacitidine|
223511197|NCT01235117|OTHER|laboratory biomarker analysis|
223511198|NCT00997191|PROCEDURE|Laser photocoagulation|Focal / grid photocoagulation for diabetic macular edema according to ETDRS guidelines
223511199|NCT00997191|DRUG|Intravitreal triamcinolone|Intravitreal preservative-free triamcinolone (4mg) associated to focal photocoagulation for diabetic macular edema on baseline; Re-treatment at weeks 20 and 40 if CMT\>275um
223511200|NCT00997191|DRUG|Intravitreal bevacizumab|Intravitreal bevacizumab (1.5mg) associated to focal photocoagulation for diabetic macular edema at baseline; Re-treatment at weeks 20 and 40 if CMT\>275um
223511201|NCT03073304|DRUG|Crystalloid based prime solution|Crystalloid based prime solution
223511202|NCT03073304|DRUG|Erythrocyte based prime solution|Erythrocyte based prime solution
223511203|NCT00002135|DRUG|Ganciclovir|
223511204|NCT04957082|BEHAVIORAL|Culturally Targeted SARS-CoV-2 Communication|SARS-CoV-2 video tutorial includes a one minute video based messaging adjunct meant to enact a culturally targeted framing of health information presented to African Americans.
223511205|NCT04957082|BEHAVIORAL|General SARS-CoV-2 Communication|SARS-CoV-2 video tutorial is for general consumption and does not include culturally targeted information
223511206|NCT03897010|DEVICE|Socket Graft|5 patients had bilateral decayed upper premolar or anterior teeth, in one side SCPC graft was inserted in socket and in the contralateral site was a control, 5 months months postoperative core biopsies were taken from both grafted sockets and control ungrafted sockets during implant insertion. The biopsy samples from SCPC-grafted and control ungrafted sockets were fixed, decalcified and embedded into paraffin wax. All samples were serially sectioned in serial 5μm-thin sections were stained separately with Hematoxylin and Eosin staining, Sirius red and Mason trichrome and immunostaining with osteopontin.
223511207|NCT01260311|DRUG|Fesoterodine|Any dose of Fesoterodine
223617240|NCT02232217|OTHER|Education Control|Children in this arm will receive sleep and dietary education, as well as general coping strategies and controls for staff attention and seasonal effects that could influence changes in sleep and health outcomes.
223617241|NCT01495208|DRUG|Aflibercept|intravitreal aflibercept injection 2mg
223617242|NCT01167803|DRUG|Desflurane|Patients undergo anesthesia using remifentanil associated with desflurane
223617243|NCT01167803|DRUG|Xenon|Patients undergo anesthesia using remifentanil associated with xenon
224203765|NCT00604175|BIOLOGICAL|Quadrivalent HPV vaccine|Quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine. All participants received the vaccine via intramuscular injection at baseline, Week 8 and Week 24.
224203766|NCT02044094|DRUG|Buprenorphine|A subcutaneous depot injection of buprenorphine 300 mg was delivered using the ATRIGEL® Delivery System on study days 1 and 29. As the depot degrades, buprenorphine is released into systemic circulation over an extended period of time.
224203767|NCT02044094|DRUG|buprenorphine and naloxone|Buprenorphine and naloxone (SUBOXONE® sublingual film) is given to participants on days -14 to day -1 (the SUBOXONE sublingual film stabilization period) or as soon as they start to experience withdrawal symptoms. SUBOXONE sublingual film may be initially administered several times daily until a stable dose between 8 mg and 24 mg daily is established.
223617244|NCT03930693|DIETARY_SUPPLEMENT|Beetroot juice|Beetroot juice shot (70mL containing 400mg inorganic nitrate)
224313046|NCT03661697|OTHER|Basic Skin Care Regimen|Skin Medica brand cleanser, sunscreen, moisturizer as directed for 12 weeks
224313047|NCT03661697|OTHER|Lytera|cosmeceutical serum applied to face daily for 12 weeks
224313048|NCT03638414|OTHER|ePainQ questionnaire|This is a questionnaire which will be given to the intervention group about their perceptions of treatment. It will be online.
223511208|NCT04898543|BIOLOGICAL|M-CENK, Suspension for Infusion, Cryopreserved (M-CENK) (Cohort 2 part B)|M-CENK will be administered up to 10 times weekly via intravenous (IV) infusion starting on study day 1 with a minimum of 7 days between each M-CENK dose. The dose of MCENK will be 0.25 - 0.75 × 10e9 cells per infusion.
223511209|NCT04898543|BIOLOGICAL|N-803 (Cohort 2 part B)|N-803 15 μg/kg will be administered subcutaneously prior to every other dose of M-CENK for up to 5 doses of N-803.
223511210|NCT04898543|OTHER|Apheresis collection of MNCs (part A)|Subjects in cohort 1A will participate in apheresis collection of lymphocytes (part A) and will not receive any investigational therapy in this study.
223617245|NCT01186666|DEVICE|Coronary intervention using IVUS-VH & FDG PET-MDCT|All the patients will undergo percutaneous coronary intervention of culprit vessels after imaging of the entire coronary tree (culprit and non-culprit lesions) using intravascular ultrasound with radiofrequency data analysis (IVUS-VH). Before discharge, fluorodeoxyglucose positron emission tomography combined with multidetector computed tomography (FDG PET-MDCT) of the carotid arteries and the thoracic aorta, along with MDCT coronary angiography, will be performed and a blood sample will be obtained for subsequent measurements of emerging or new biomarkers.
223617246|NCT01186666|DEVICE|Coronary intervention using IVUS-VH & FDG PET-MDCT|All the patients will undergo percutaneous coronary intervention of culprit vessels after imaging of the entire coronary tree (culprit and non-culprit lesions) using intravascular ultrasound with radiofrequency data analysis (IVUS-VH). Before discharge, fluorodeoxyglucose positron emission tomography combined with multidetector computed tomography (FDG PET-MDCT) of the carotid arteries and the thoracic aorta, along with MDCT coronary angiography, will be performed and a blood sample will be obtained for subsequent measurements of emerging or new biomarkers.
223617247|NCT03780049|PROCEDURE|HAIC of FOLFOX|administration of Oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries
223617248|NCT03780049|DRUG|H101|Patients receive H101 0.5ml dissolved in 10ml normal saline in each session of HAIC
223617249|NCT03780049|DRUG|Placebos|Patients receive normal saline 10ml in each session of HAIC
224075565|NCT05966285|OTHER|suture repair|Suture repair was used to reinforce the abdominal wall, including Bassini, Ferguson, McVay, or Halsted technique.
224075566|NCT05966285|OTHER|mesh repair|Mesh repair was conducted using a synthetic and biological mesh in the Lichtenstein or open preperitoneal techniques.
224075567|NCT04634266|DEVICE|Transcatheter tricuspid valve treatment (TTVT)|Percutaneous CE-mark approved techniques for transcatheter tricuspid valve treatment (TTVT): These include (I) transcatheter annuloplasty devices (Tricuspid Cardioband) and (II) transcatheter edge-to-edge repair (TriClip, PASCAL).
224075568|NCT04758585|PROCEDURE|Arthroscopy|Shoulder Arthroscopy
224075569|NCT02436876|DRUG|MBN-101|MBN-101 is a locally administered, anti-infective drug product
224075570|NCT02436876|OTHER|Placebo|The placebo is comprised of the vehicle/excipients used to formulate MBN-101, but does not contain the active pharmaceutical ingredient
224075571|NCT04455373|PROCEDURE|pediatric vascular bypass grafting|pediatric vascular bypass grafting
224075572|NCT02702648|DRUG|AC-082|Hard gelatin capsules for oral administration
224075573|NCT02702648|DRUG|Placebo|Matched placebo capsules for oral administration
224075574|NCT04444622|BIOLOGICAL|AlloStim|Living bioengineered, non-genetically manipulated, activated Th1-like immune cells differentiated and expanded from precursor cells purified from blood of healthy unrelated donors
224075575|NCT01367522|DRUG|SC Methylnaltrexone (MNTX)|
224075576|NCT02931721|DIAGNOSTIC_TEST|MRI|Pelvis MRI
224075577|NCT03439033|DRUG|PET/MRI with Gallium-68 labeled PSMA-HBED-CC|Subjects have one visit, during which they will undergo one PET/MRI with the study drug, Gallium-68 labeled PSMA-HBED-CC, a radiopharmaceutical
224075578|NCT03439033|DRUG|Multiple PET/MRI with Gallium-68 labeled PSMA-HBED-CC|Subjects have two visits (the second visit being optional) within two years. During each visit, they will undergo one PET/MRI with the study drug, Gallium-68 labeled PSMA-HBED-CC, a radiopharmaceutical
224075579|NCT03439033|DRUG|PET/CT with Gallium-68 labeled PSMA-HBED-CC|Subjects have one visit, during which they will undergo one PET/CT with the study drug, Gallium-68 labeled PSMA-HBED-CC, a radiopharmaceutical
224075580|NCT00149578|DRUG|Gemcitabine Oxaliplatin 5FU and Leucovorin|
224075581|NCT06247891|PROCEDURE|ECS Group|Patients underwent endoscopic and endocytoscopic evaluations.
224075582|NCT00927095|DRUG|Continuous OC (EE/DROS)|Continuous EE(20ug)+DROS(3mg) daily for 3 months
224075583|NCT00927095|DRUG|Intermittent OC (EE/DROS)|Intermittent EE(20ug)+DROS(3mg) daily for 21 days each month
224075584|NCT00927095|DRUG|placebo|daily placebo
224075585|NCT04894929|OTHER|multi component exercise in the clinic|"Patients randomly assigned to this group have a pre-fragile or fragile SPPB condition, so they will perform:~3 days of empowerment work, 4 days of flexibility work, and daily walking aerobic work and balance work."
224075586|NCT04894929|OTHER|vestibular exercise in the clinic|"Patients randomly assigned to this group have a pre-fragile or fragile SPPB condition, so they will perform. sessions of about 20 minutes with 5 weekly sessions (Monday to Friday) consisting of 5 repetitions without fatigue of:~to. Head and eye movements while sitting. b. Head and body movements while sitting. c. Exercises standing. d. Combined exercises of modifications in steps, unstable surfaces and in progress.~and. Along with push up 30sec and squat 30sec"
224075587|NCT04894929|OTHER|vestibular exercise at home telerehabilitation|"Patients randomly assigned to this group have a pre-fragile or fragile SPPB condition, so they will perform with the help of a video. sessions of about 20 minutes with 5 weekly sessions (Monday to Friday) consisting of 5 repetitions without fatigue of:~to. Head and eye movements while sitting. b. Head and body movements while sitting. c. Exercises standing. d. Combined exercises of modifications in steps, unstable surfaces and in progress.~and. Along with push up 30sec and squat 30sec"
224075588|NCT04894929|OTHER|multi component exercise at home telerehabilitation|"Patients randomly assigned to this group have a pre-fragile or fragile SPPB condition, so they will perform with the help of a video:~3 days of empowerment work, 4 days of flexibility work, and daily walking aerobic work and balance work."
224075589|NCT04931992|OTHER|No intervention|Retrospective analysis
224075590|NCT06202300|OTHER|Inflammation burden|Coronary artery disease patients undergone multimodality imaging with different level inflammation burden
224075591|NCT05462509|DEVICE|bCPAP with blenders|The intervention device is a low-cost bCPAP kit which includes two fixed-ratio oxygen blenders that do not require a source of pressurized air. These simple and inexpensive devices sit in-line from the oxygen source and dilute the flowing stream of oxygen with room air, obviating the need for a pressurized source of air. The oxygen may be supplied from either high-pressure sources or low-pressure sources such as oxygen concentrators. Each of the two blenders are single plastic parts, injection moulded from a biocompatible, medical-grade polyethylene resin. No electricity is required for the blenders to provide a stable and constant mix of air and oxygen over the full range of clinically relevant pressure and flows for newborns.
224075592|NCT02556255|DEVICE|B-Laser™ Atherectomy Catheter|Laser atherectomy catheter based on 355 nm
223617250|NCT05262257|DRUG|Metformin|Take it regularly for 12 weeks
223617251|NCT05262257|DRUG|Dapagliflozin|Take it regularly for 12 weeks
223617252|NCT05262257|BEHAVIORAL|Lifestyle intervention|patients did not take any hypoglycemic drugs and adopted diet, exercise and other lifestyle intervention measures to control blood sugar.
223617253|NCT01338337|DRUG|Azacitidine|Azacitidine 75 mg/m2, for 5 days of each 20 day cycle. Transfusional support will be applied for symptomatic anaemia using clinical discretion and chelation therapy when ferritin is ≥ 1000 μgr/ml with the chelating agents allowed
223617254|NCT00510159|DRUG|Artesunate+Sulfamethoxypyrazine/pyrimethamin|
223761286|NCT03501095|DIAGNOSTIC_TEST|Vocal analysis and Laryngostroboscopy|"Vocal analysis study the acoustic emission of the pneumo-phono-articulatory system, i.e. the vocal signal. Currently, digital technology instruments enable the processing and analysis of the verbal signal quickly and reliably, also offering graphical products and numerical data. Among the various existing software products for the study of the vocal signal, PRAAT is available. In practice, the vocal parameters are acquired in a non-invasive way with a microphone.~Laryngostroboscopy is one of the most widely used techniques for laryngeal clinical evaluation. This is a non-invasive endoscopic practice performed by means of a flexible fibroscope, which, through a pulsed light source, allows visualization of the chordal movement."
223761287|NCT05530122|BIOLOGICAL|infliximab, adalimumab, golimumab, vedolizumab, ustekinumab|
223761288|NCT06392243|DEVICE|Intracardiac ultrasound imaging system|The control group was treated with SOUNDSTAR 3D Diagnostic Ultrasound catheter (SNDSTR10G) and Vivid IQ, intracardiac and macrovascular imaging of the heart, assessment of intracardiac Doppler flow, and guidance for intracardiac intervention
223617255|NCT00510159|DRUG|Praziquantel|
223761289|NCT05839457|BEHAVIORAL|Empowerment Pilot|The Empowerment Pilot is a school-based program aimed to raise awareness and change attitudes around SRGBV among students and teachers and promote gender equality. This intervention includes training provided by Teacher Mentors to other teachers in school, learning sessions delivered via safe spaces for student learners, and guidance for engaging parent-teacher committees.
223761290|NCT01401933|DRUG|Linifanib|QD on Days 1 and 13
224203768|NCT02044094|DRUG|hydromorphone|"Hydromorphone IM challenges are administered during the screening period (days -17 to -15), on days -3 to -1 during the buprenorphine and naloxone (SUBOXONE sublingual film) stabilization period, and weekly during the 12-week treatment period after administration of RBP-6000. Each challenge consists of 3 days during which participants are randomly administered 0 mg (placebo), 6 mg and 18 mg hydromorphone via intramuscular (IM) injection daily in varying blinded sequences.~Additionally, hydromorphone can also be earned during the afternoon Reinforcing effects tasks sessions up to the same randomized dose received in the hydromorphone challenge that morning (or money can be chosen)."
224203769|NCT02044094|DRUG|placebo|Placebo for hydromorphone administered via intramuscular injection during each challenge.
224203770|NCT01801306|DEVICE|NeMo Probe|A new minimal-invasive brain tissue probe applying near infrared spectroscopy
224203771|NCT01477775|DRUG|Oral P2Y12 receptor blocker|Free choice among clopidogrel, prasugrel or ticagrelor
224203772|NCT01477775|DRUG|Customized choice for the oral P2Y12 receptor blocker|one drug among clopidogrel, prasugrel or ticagrelor based on an algorithm integrating phenotype information.
224313049|NCT05233111|BEHAVIORAL|Brief Prolonged Exposure Therapy|Brief PE will include 3 therapy sessions, each lasting approximately 60 minutes.
223617256|NCT06034288|DRUG|Xeomin 100 UNT Injection|intravesical injection
223617257|NCT06034288|DRUG|Botox 100 UNT Injection|intravesical injection
223617258|NCT02091817|DRUG|Oxytocin|Intervention will be examined on control group, and on experimental group as well.
223617259|NCT02091817|DRUG|Placebo|Placebo will be given to control group and experimental group as well.
223617260|NCT05642585|DRUG|MY008211A tablets|Single oral
223617261|NCT05642585|DRUG|Placebo|Single oral
223617262|NCT02191371|DRUG|propofol|Patients are randomized to receive intravenous anesthetic (propofol) or inhalational anesthetic (desflurane) as a maintenance anesthetic.
223617263|NCT02191371|DRUG|desflurane|Patients are randomized to receive intravenous anesthetic (propofol) or inhalational anesthetic (desflurane) as a maintenance anesthetic.
223617264|NCT00230126|DRUG|erlotinib|Arm A: 150 mg/day cycles 1 - 3. Arm B: Cycle 1 - 175 or 200 mg/day depending on body weight; Cycle 2 - if rash developed, then 150 mg/day; if no rash, then 175 mg/day; Cycle 3 - if rash developed, then 175 mg/day; if no rash, then 200 mg/day.
223617265|NCT03767647|BEHAVIORAL|Emotional Intelligence lessons|6 lessons were given to the students in separated weeks by the same investigator. Lessons were 45-60 minutes long and each one was dedicated to one of the main aspects of emotional intelligence.
223617266|NCT01679496|OTHER|Food items|Food items with different fatty acid composition
223617267|NCT00115505|OTHER|quality-of-life assessment|Complete Subjective Significance Questionnaire, MOS Social Support Survey, Patient Preferences, CALGB Background Information, and EQ-5D and QOL Assessment Form, EORTC QLQ-C30 and EORTC QLQ-BR23
223761291|NCT01401933|DRUG|Rifampin|QD on Days 5-16
223761292|NCT00881192|PROCEDURE|IABP|preoperative IABP placement
223761293|NCT01388842|DRUG|inhaled nitric oxide|Study drug will be administered using an INOpulse delivery system that delivers small pulses of study drug to the patient via a nasal cannula. Subjects randomized to the intervention arm will receive a dose equivalent to 80 ppm iNO in air for 24 hours per day for a minimum of two days and until clinical improvement (coma recovery), death or a maximum of 5 days.
223761294|NCT01388842|DRUG|Placebo|The placebo will be administered using an INOpulse delivery system that delivers small pulses of study drug to the patient via a nasal cannula. Subjects randomized to the placebo arm will receive nitrogen in air for 24 hours per day for a minimum of two days and until clinical improvement (coma recovery), death or a maximum of 5 days.
223761295|NCT01464515|DEVICE|H-Coil Deep TMS|this group will receive high frequency treatment of deep TMS with 10Hz
224313050|NCT05233111|BEHAVIORAL|Treatment as Usual|This may include an evaluation by a licensed psychologist and continued follow-up psychotherapy as needed. Treatment as usual participants will have follow-up assessments at 1, 3, and 6 months.
224313051|NCT04590638|OTHER|tumescent with adrenaline|skin graft donor site of patients enrolled in this group will be injected subcutaneously with tumescent solution containing adrenaline to see the bleeding control of donor site.
223511211|NCT03237312|PROCEDURE|Laparoscopic ovarian drilling|The electric current used was set at 40 Watts. The power was activated just before touching the ovary, and then the needle electrode was held against the antimesenteric surface of the ovary for 4 seconds until penetration of the ovarian capsule. Four or eight puncture points were made through the ovarian capsule of each ovary according to the study protocol. The ovaries were cooled in the pool of the Ringer's lactate after each cauterization both to minimize adhesion formation and to prevent heat trauma to the adjacent viscera. Complete hemostasis was ensured. At the end of the procedure, the ovaries were copiously rinsed with Ringer's lactate (Aqua-purator, Storz, Germany). An amount about 200 ml of heparinized Ringers lactate (5000 IU/1000 ml) was left in the pelvis to avoid postoperative adhesions.
223511212|NCT03237312|BIOLOGICAL|Antimullerian hormone|"1. In patients with Antimullerian hormone between 4-8 ng/ml 4 punctures in each ovary were performed.~2. In patients with Antimullerian hormone above 8 ng/ml 8 punctures in each ovary were performed."
223511213|NCT01237405|DRUG|99mTc-EC20|Study participants underwent a one-time evaluation by FolateScan which entailed a single intravenous injection of 99mTc-EC20 (total volume of 1.0 to 2.0 ml administered over a period of 30 seconds with radioactive dose between 20 and 25 mCi). A total of three imaging scans were acquired: an early phase (at \~1 minute) SPECT/CT of both knees; a late phase (at \~60 minutes) SPECT/CT image of both knees; and a late phase (at \~80 minutes) planar image of the whole body was performed (anterior-posterior, and postero-anterior).
223511214|NCT05154162|DIAGNOSTIC_TEST|PSMA PET/CT|PSMA PET/CT (limited to the pelvis)
223511215|NCT05154162|PROCEDURE|Transperineal template prostate biopsy|Transperineal template prostate biopsies will be performed as per treating urologist's usual practice. No specific template for biopsy is prescribed for the purposes of the study. However, template sampling of the prostate is required, with a minimum of 12 cores, dependent on prostate volume. MRI will be available for any additional targeted biopsies required. Transperineal template biopsies must be labelled appropriately and sent for histopathological analysis.
223511216|NCT05154162|PROCEDURE|Transperineal targeted prostate biopsy|If the PSMA PET/CT is normal, transperineal prostate biopsy would be omitted If the PSMA PET/CT is abnormal, transperineal prostate biopsies would be performed targeting the MRI (done prior to study) and PSMA PET/CT images
223511217|NCT03584386|DEVICE|V-CAMS (aka Jaspr)|V-CAMS is an integrated software system for use on any device by suicidal patients.
223511218|NCT03186924|BEHAVIORAL|Take a STAND for health|The Take a STAND for health is a newly developed 4-month goal-setting intervention aimed at reducing sedentary behavior
223511219|NCT05456217|OTHER|admission to ICU|admission to an intensive care unit or high dependency unit in Kenya
223511220|NCT00198744|BEHAVIORAL|Medifast FIT! for Kids|
223511221|NCT00198744|BEHAVIORAL|standard recommendations for dietary intake in children|
223511222|NCT00198744|BEHAVIORAL|both diet plans with and without a parent dieting|
223761296|NCT01464515|DEVICE|SHAM Coil TMS|this group will receive SHAM treatment of deep TMS
224075593|NCT00467454|DRUG|Naltrexone|daily
224075594|NCT00467454|DRUG|Placebo|daily
224075595|NCT02475811|RADIATION|3D ultrasonography|The angle of volume sampling varied throughout gestational age with a maximum limit of 75° in the third trimester. After scanning the volume, multiplanar imaging in the 3 orthogonal ultrasonographic sections was analyzed to reconstruct the 3D ultrasound image. Before its volume was analyzed, each lung was carefully identified on the 3 orthogonal multiplanar imaging sections. We used the rotational technique that entails the VOCAL imaging program to measure lung volume. A transverse section of the multiplanar imaging was chosen as the reference image for volume analyses
224075596|NCT01849770|DRUG|Mexiletine|
224075597|NCT01849770|DRUG|Placebo|
224075598|NCT01290692|BIOLOGICAL|TVI-Brain-1|Following surgery, tumor tissue is used to generate a cancer vaccine. Patients are vaccinated with neutralized cells to initiate an immune response. Following vaccinations, the patient's white blood cells are collected, the white blood cells are stimulated and expanded, and are then reinfused into the patient's blood.
224075599|NCT04799886|OTHER|Semi structured interview|Interviews are performed by one research group member and based on beforehand decided questions and sub-questions. The interview material is transcribed and analysed on a theme level.
224075600|NCT04534660|DEVICE|SMI-01|SMI-01 is a device consisting of silk particles in a hydrogel carrier.
224075601|NCT03279003|DEVICE|LED light|An exposure to LED light will be carried out twice a week until improvement, maximum 8 weeks.
224075602|NCT03396965|OTHER|Mini-c-arm|Fluoroscopy used to aid reduction of distal radius fracture
224075603|NCT05116124|OTHER|dosing of inflammatory parameters|View and register the dosing of inflammatory parameters
224075604|NCT03353857|DRUG|levonorgestrel/ Microlut|In Period 1, 0.03 mg single dose administered as 1x0.03 mg tablet on Study Day 1, In Period 2, 0.03 mg single dose administered as 1x0.03 mg tablet on Study Day 15 In Period 3, 0.03 mg single dose administered as 1x0.03 mg tablet at Study Day 26
224075605|NCT03353857|DRUG|Norethindrone/ Noriday|In Period 1, 0.35 mg single dose administered as 1x0.35 mg tablet on Study Day 1, In Period 2, 0.35 mg single dose administered as 1x0.35 mg tablet on Study Day 15 In Period 3, 0.35 mg single dose administered as 1x0.35 mg tablet at Study Day 26
224075606|NCT03353857|DRUG|Desogestrel/ Cerazette|In Period 1, 0.075 mg single dose administered as 1x0.075 mg tablet on Study Day 1, In Period 2, 0.075 mg single dose administered as 1x0.075 mg tablet on Study Day 15 In Period 3, 0.075 mg single dose administered as 1x0.075 mg tablet at Study Day 26
224075607|NCT03353857|DRUG|Dienogest/ Visanne|In Period 1, 2 mg single dose administered as 1x2 mg tablet on Study Day 1, In Period 2, 2 mg single dose administered as 1x2 mg tablet on Study Day 15 In Period 3, 2 mg single dose administered as 1x2 mg tablet at Study Day 26
224075608|NCT03353857|DRUG|Drospirenone, Ethinylestradiol/ Yasmin|In Period 1, 3 mg drospirenone, 0.03 mg ethinylestradiol single dose administered as 1x3mg drospirenone, 0.03 mg ethinylestradiol tablet on Study Day 1, In Period 2, 3 mg drospirenone, 0.03 mg ethinylestradiol single dose administered as 1x3mg drospirenone, 0.03 mg ethinylestradiol tablet on Study Day 15, In Period 3, 3 mg drospirenone, 0.03 mg ethinylestradiol single dose administered as 1x3mg drospirenone, 0.03 mg ethinylestradiol tablet on Study Day 26,
224075609|NCT03353857|DRUG|Midazolam/ Midazolam-ratiopharm|In Period 1, 1 mg single dose administered as 1x0.5 ml oral solution on Study Day 1, In Period 2, 1 mg single dose administered as 1x0.5 ml oral solution on Study Day 15 In Period 3, 1 mg single dose administered as 1x0.5 ml oral solution at Study Day 26
224203773|NCT04216992|DEVICE|Cone beam computed tomography|The contrast agent (Omnipaque, GE Healthcare, Ireland) was instilled to conﬁrm the epidural space. With use of a calibrated angiographic C-arm system and a postprocessing workstation, we acquired volume data sets from two dimensional digital projection images obtained to reconstruct the 3D-RE during a C-arm rotation around the patient axis.
224203774|NCT03908840|BIOLOGICAL|TBI 302|TBI 302 administered once a week in first 3 weeks and no treatment in week 4 (28 days is 1 cycle). Followed once weekly treatment of TBI 302 for 3 weeks followed by no treatment in week 4 (cycle 2)
224203775|NCT01153659|DRUG|E3810|RAB ER 50 mg capsule once per day on Days 1-5
224203776|NCT01153659|DRUG|Aciphex (rabeprazole)|Aciphex (rabeprazole) 20 mg tablet once per day on Days 1-5
224313052|NCT04590638|OTHER|tumescent without adrenaline|skin graft donor site of patients enrolled in this group will be injected subcutaneously with tumescent solution not containing adrenaline to see the bleeding control of donor site.
223511223|NCT00624078|DRUG|Antivenin Centruroides (scorpion) F(ab)2 Anascorp™|three vials diluted in 20 to 50 mL normal saline administered intravenously. Subsequent single vial doses of Anascorp, up to a total of five vials administered at thirty minutes intervals until resolution of symptoms.
223511224|NCT01444170|DIETARY_SUPPLEMENT|dicreatinol sulfate|nutritional supplement
223511225|NCT01444170|DRUG|placebo sugar pill|
223511226|NCT05740592|PROCEDURE|micro-osteoperforations ,microincision|Patients in MOPs group will be subjected to minimal 6 MOPs 2mm apart and corticoperforation will be conducted by using drilling bure and only 1 or 2mm bicortical in the mid-palatal suture area. Patients with the piezocision group will be subjected to minimal 3 micro incisions spaced 4mm apart and a piezoelectric device with diamond surgical tip (size: 4 mm, thickness: 0.5mm) will be used.. The MARPE technique comprises the insertion of four bicortical miniscrews adjacent to the mid-palatal suture, being two mesial and two distal to the expanding screw. Each MARPE have two arms and will be fixed to molar band by soldering.
224203777|NCT01153659|DRUG|Nexium (esomeprazole)|Nexium (esomeprazole) 40 mg capsule once per day on Days 1-5
223511227|NCT05345158|PROCEDURE|Robotic Retroperitoneal Lymph Node Dissection (RPLND)|Robotic RPLND performed using the DaVinci robotic surgical system.
223511228|NCT00369863|DRUG|Triamcinolone acetonide|
223511229|NCT03817515|DRUG|ABI-009|Sirolimus Albumin-bound Nanoparticles
223511230|NCT02742974|DEVICE|FloTrac™ and EV1000™|Interventions to improve cardiovascular performance will be made in all patients whose cardiovascular function is sub-optimal in accordance with routine clinical management during trauma resuscitation. Patients who meet inclusion criteria will be assigned to the intervention or control arm of the study based on the process outlined in the protocol. Patients assigned to the intervention arm will have intra-operative hemodynamic monitoring performed by the anesthesia staff and cardiovascular interventions will be based off of the algorithm described in the protocol. Members of anesthesia or the surgical team can initiate interventions as indicated during routine ICU care or intra-operatively.
223511231|NCT01730976|DIETARY_SUPPLEMENT|Vitamin D 2,000 I.U.|
223511232|NCT01928576|DRUG|Azacitidine|
223511233|NCT01928576|DRUG|Entinostat|
223511234|NCT01928576|DRUG|Nivolumab|
223511235|NCT01928576|DRUG|CC-486 300|
223511236|NCT03325803|DRUG|lidocaine/prilocaine (5%) application|For AFL pre-treatment, lidocaine/prilocaine (5%) cream (EMLA; Astra Pharmaceuticals, LP, Westborough, MA, USA) was applied to the treatment area under occlusion for 30 min
223511237|NCT03325803|DEVICE|2940-nm Er:YAG AFL pretreatment|After the anaesthetic cream was removed, AFL therapy was performed using a 2940-nm Er:YAG AFL (Joule; Sciton Inc., Palo Alto, CA, USA) at 150 µm ablation depth, level 1 coagulation, 22% treatment density and a single pulse
223511238|NCT03325803|DRUG|MAL application|Immediately after AFL treatment, an approximately 1- mm-thick layer of MAL (Metvix, PhotoCure ASA, Oslo, Norway) was applied to the lesion and on 5 mm of surrounding normal tissue. Incubation time is 3 hours
223511239|NCT03325803|OTHER|Measurements of the fluorescence intensity|After 3 hours of application with MAL, saline wash was performed and fluorescence imaging analysis was performed with ultraviolet examination light (model 31602,356 nm; Burton Medical Products Crop.) at 10 cm height above the base of each lesion. The red fluorescence (610 nm-700 nm) was separated and extracted by Matlab program and then used to measure the amount of 633 nm fluorescence of protoporphyrin IX.
223511240|NCT03325803|DEVICE|irradiation with red light-emitting diode lamp|After incubation for 3 hours, the dressing and cream were removed, and the area was cleansed with saline. The area was irradiated with a red light-emitting diode lamp (Aktilite CL 128; PhotoCure ASA, Oslo, Norway) with peak emission at 632 nm, placed 5 cm away from the skin surface, and a total light dose of 37 J/cm-2. All patients wore protective goggles during illumination.
223511241|NCT04883554|OTHER|Olfactory therapeutic|The sessions of the olfactory sensory therapy group take place according to the care framework at a frequency of one session of 45 minutes per week
223511242|NCT04883554|OTHER|Body therapy|very specific stages at a weekly frequency and lasts 1 hour. Kinesic time or time to set the body in motion (20 min) Kinesthetic time: time of slow movements (20 min) Talk time (20 min)
223511243|NCT01089543|DRUG|Rabeprazole|Rabeprazole 10 mg tablet taken orally once daily after breakfast for 8 weeks.
223511244|NCT01089543|DRUG|Rabeprazole|Rabeprazole 20 mg tablet taken orally once daily after breakfast for 8 weeks.
223511245|NCT01089543|DRUG|Rabeprazole|Rabeprazole 40 mg tablet taken orally once daily after breakfast for 8 weeks.
223511246|NCT01089543|DRUG|Placebo|Rabeprazole Placebo tablet taken orally once daily after breakfast for 8 weeks.
224203778|NCT04838132|PROCEDURE|Bilateral transversus thoracis muscle plane and rectus sheath block with ropivacaine|A linear array transducer (6-13 MHz) with a sterile cover and a 22-gauge (G) block needle (KDL™, Kindly group, Shanghai, China) will be used. Place the ultrasound probe on the longitudinal plane 1 cm outside the edge of the sternum in the fourth intercostal space, and identify the T3-T4 intercostal space under ultrasound. Use the plane technique to place a 22-gauge, 80-mm needle obliquely upwards until the needle tip is located at the plane between the internal intercostal muscles and the transverse pectoralis muscle. After general anesthesia, all subjects were injected with 0.3% ropivacaine 15ml and 10ml respectively after insertion of a needle into bilateral transverse thoracic muscle plane and rectus sheath guided by B-ultrasound.
224203779|NCT04838132|PROCEDURE|Bilateral transversus thoracis muscle plane and rectus sheath puncture with saline|A linear array transducer (6-13 MHz) with a sterile cover and a 22-gauge (G) block needle (KDL™, Kindly group, Shanghai, China) will be used. Place the ultrasound probe on the longitudinal plane 1 cm outside the edge of the sternum in the fourth intercostal space, and identify the T3-T4 intercostal space under ultrasound. Use the plane technique to place a 22-gauge, 80-mm needle obliquely upwards until the needle tip is located at the plane between the internal intercostal muscles and the transverse pectoralis muscle. After general anesthesia, all subjects were injected with 0.9% saline 15ml and 10ml respectively after insertion of a needle into bilateral transverse thoracic muscle plane and rectus sheath guided by B-ultrasound.
224203780|NCT05417477|DEVICE|use of an e-health application|Use of the e-health application throughout the duration of the study combined with the usual management of the disease and 20 physiotherapy sessions.
224203781|NCT00939367|DRUG|Zolpidem Tartrate Tablets 10 mg|
224203782|NCT00939367|DRUG|'Sanofi-Synthelabo Inc's Ambien® Tablets 10 mg|
224203783|NCT00706927|DRUG|latanoprost 0.005% + timolol 0,5% fixed combination|1 drop per day and eye for 6 weeks
224203784|NCT00706927|DRUG|brimonidine 0,2% + timolol 0,5% fixed combination|1 drop twice a day per eye for 6 weeks
224203785|NCT01211158|DRUG|Ketofol|Syringes containing ketofol (mixed propofol-ketamine) will contain propofol 5mg/ml and ketamine 5 mg/ml. Patients will receive an initial intravenous dose of 0.075 millilitres per kilogram of pre-prepared medication. Patients in the propofol-ketamine group will receive 0.375 mg/kg each of ketamine and propofol as an initial bolus and 0.188 mg/kg each of ketamine and propofol as necessary until reaching deep sedation (Ramsay score = 5 or greater).
224203786|NCT01211158|DRUG|Propofol alone|Propofol-only syringes will contain propofol 10 mg/ml. Patients in each group will receive an initial intravenous dose of 0.075 millilitres per kilogram of pre-prepared medication (0.75 mg/kg). One minute after the initial dose of sedative, and every minute thereafter, the attending physician will assess the patient's level of sedation using the Ramsay Sedation Scale (RSS). If the attending physician determines the level of sedation to be inadequate (RSS\<5), additional study drug will be administered at a dose of 0.0375 millilitres per kilogram (0.375 mg/kg) every minute until deep sedation is achieved (RSS=5 or greater).
224203787|NCT03945929|BEHAVIORAL|Distraction|"Distraction-1 Group: Cards containing approximately six optical illusion pictures were shown to the patients and as a method of distraction during the PIC insertion procedure they were asked what they saw in these cards.~Distraction-2 Group: Underwater 3D audial videos were played with visual reality (VR) goggles during PIC insertion until the procedure was completed."
224203788|NCT00034593|DRUG|ALIMTA|
224203789|NCT00034593|DRUG|gemcitabine|
224203790|NCT04607265|DIAGNOSTIC_TEST|Cardiac MRI|Comparison of scar characteristics on cardiac MRI between the two groups.
224203791|NCT02831686|DRUG|Selinexor|
223511247|NCT03954873|OTHER|Glucagon-like peptide 2|Human glucagon-like peptide 2
223511248|NCT03954873|OTHER|Saline|Placebo
223511249|NCT03954873|OTHER|Glucose|20% (w/v) glucose infusion for regulating plasma glucose
223511250|NCT03954873|OTHER|Insulin|Actrapid (insulin) for lowering plasma glucose
223511251|NCT04065854|BEHAVIORAL|Intervention|Assessment, tailored strength and balance exercise programme, activity analysis and risk enablement advice, and assessment for environmental hazards. Tailored adherence support and supervision.
223511252|NCT06356597|DRUG|Tislelizumab with Fruquintinib, Metronidazole|"Metronidazole tablets: One administration cycle is every 6 weeks, and metronidazole tablets are given orally on the 1st to 7th day of each cycle. The medication method is two tablets three times one day.~Teralizumab: Every 3 weeks is a dosing cycle, with 200mg of Teralizumab administered intravenously on the first day of each cycle."
223511253|NCT02222181|OTHER|Pharmacotherapy Management|"* assessment of patient characteristics as alcoholic, smoker, food, drugs~* Pharmacotherapy follow-up~* to evaluated medication adherence~* Assessment of the individual clinical parameters each patient at baseline and after the educational or pharmacy intervention."
223511254|NCT03206385|RADIATION|Radiation treatment|50 Gy will be delivered in the PTV 1 and 60 Gy in the PTV 2 simultaneously in 28 fractions (5 fractions a week) in no more than 40 days. Anytime, 95% of the prescribed dose will have to cover at least 90% of the PTV 1 and PTV 2.
223511255|NCT03206385|RADIATION|CK Boost Pelvis|Two high CyberKnife dose sessions will deliver a pelvic boost of 6.5 Gy each to the initial GTV or eventually to the residual GTV in case of too close vicinity of the OAR
223511256|NCT06539377|PROCEDURE|Living donor liver transplantation|"Liver transplantation from living donor donation (SII/III as left-lateral donation during a two stage-procedure or left lobe donation or right lobe donation) in patients with unresectable intrahepatic cholangiocarcinoma."
223511257|NCT02100033|DEVICE|acupuncture|
223511258|NCT05507164|DRUG|Temporomasseteric Nerve Block|The TMNB injection is a local anesthetic injection technique that targets the anterior deep temporal and masseteric branches of the mandibular division of the Trigeminal Nerve. The surface landmark for the twin block injection site is located by palpating for the depression created by the greater wing of the sphenoid bone at the superior border of the zygomatic process and approximately 1 cm posterior to the posterior border of the frontal process of the zygomatic bone. This site is first disinfected with alcohol wipes prior to inserting a 27- or 25-gauge long dental needle (32 mm). Angled 35-45° away from the calvarium (skull) and perpendicular to the zygomatic arch (along the coronal plane), the needle is advanced to its length before injecting 1.8 mL of 2% lidocaine with 1:100,000 epinephrine.
223511259|NCT03931512|DEVICE|transcranial direct current stimularion|aplication of direct current stimulation on the scalp wiht sponge electrodes
223511260|NCT00240773|DRUG|acetaminophen|4 grams daily for six months
223511261|NCT00240773|DRUG|naproxen|750 mg daily for 12 months
223511262|NCT00240773|DRUG|acetaminophen|4 grams daily for 12 months
223511263|NCT00240773|DRUG|naproxen|750 mg daily for six months
223511264|NCT01742052|DRUG|MT-1303-Low|
223511265|NCT01742052|DRUG|MT-1303-Middle|
223511266|NCT01742052|DRUG|MT-1303-High|
224203792|NCT02831686|DRUG|Ixazomib|
224203793|NCT02831686|DRUG|Dexamethasone|
224203794|NCT05782309|DRUG|Flavanol|Assessement, supplementation for 30 days with either Placebo or Flavanols, Re-assessment
224203795|NCT05782309|DRUG|Placebo|Assessement, supplementation placebo for 30 days with either Placebo or Flavanols, Re-assessment
224203796|NCT02242331|DRUG|Micardis®|
224203797|NCT00288782|DRUG|Mirtazapine|
224203798|NCT07006129|PROCEDURE|Perineorrhaphy|Concomitant perineorrhaphy
224203799|NCT07006129|PROCEDURE|No perineorrhaphy|No concomitant perineorrhaphy
224203800|NCT07042542|OTHER|Mulligan Spinal Mobilization with Arm Movement|In the neurodynamic SNAGs technique, participants sat on a chair. The therapist placed the medial border of the distal phalanx of one thumb under the facet joints of the C5, C6, and C7 levels, respectively. Then, the therapist placed the tip of the other thumb on the lateral side of the first thumb. In neurodynamic spinal mobilization combined with arm movement, the therapist provided manual contact to the affected spinous process level by supporting the medial aspect of one thumb with the index finger of the other hand. The therapist applied a transverse shift from the affected side to the unaffected side, but only in the transverse plane. While the glide was in progress, the patient was asked to perform neurodynamic movements for the median nerve, including scapular depression, shoulder abduction, elbow extension, forearm supination, and wrist and finger extension, all without crossing the pain limit for the affected side.
224203801|NCT07042542|OTHER|Conventional Neurodynamic Mobilization|A neurodynamic mobilization technique involving a specific sequence of movements along the median nerve line was applied. For the right side, the procedure was performed as follows: The individual was placed supine on a stretcher. The therapist stood on the right side of the stretcher, facing the participant, with their right leg in front of their left leg. The individual's arm rested on the therapist's right thigh, and the therapist held the individual's right hand with his left hand. During the procedure, the therapist placed one hand on the individual's shoulder to depress the shoulder girdle by pressing the scapula downward. The individual's shoulder was abducted 90° and laterally rotated, and the forearm was supinated. The wrist, thumb, and fingers were extended. In this position, the therapist dynamically alternated between simultaneous elbow flexion/wrist extension and simultaneous elbow extension/wrist flexion.
224313053|NCT05179538|BEHAVIORAL|Cued picture-naming therapy|The proposed study will administer Cued Picture-Naming Treatment (CPNT) four days per week for four weeks (i.e. 16 sessions). During therapy, participants will attempt to name eight consecutive presentations of the same black and white picture, for each of the 20 pictures, with cueing from the administrator. Trials will include (1) independent naming, (2) orthographic cueing (i.e. the written word beneath the picture.), (3) repeating, (4) naming after a short delay (i.e. approximately three seconds), (5)semantic cueing (i.e. three cues providing semantic information about the target will be spoken to the participant by the clinician), (6) phonological cueing (i.e. the first sound and letter will be spoken by the clinician), (7) repeating, and (8) naming after a short delay. The administrator will provide the correct response for each incorrect participant response and will ask the participant to repeat it.
224313054|NCT06633055|DRUG|JH013 injection|JH013 injection is a BAFF-R inhibitor monoclonal antibody
224313055|NCT06633055|DRUG|Placebo|JH013 injections placebo
224313056|NCT00843635|DRUG|Tadalafil|Given orally
223511267|NCT01742052|DRUG|Placebo|
223511268|NCT05592730|GENETIC|AMHR2 polymorphism in blood|1 tube of blood taken at the first application
223511269|NCT05592730|GENETIC|AMHR2 polymorphism in granulosa cell|Extraction of granulosa cell from the follicle fluid obtained during OPU
223511270|NCT06359535|DRUG|HSK21542|This study is an economic study and does not interfere with patients' medical treatment.
223511271|NCT06359535|DRUG|Placebo|Placebo
223511272|NCT01248468|DRUG|Aspirin, acetaminophen and caffeine|2 tablets each containing Aspirin (250mg), acetaminophen (250mg) and caffeine (65mg)
223511273|NCT01248468|DRUG|Sumatriptan|100 mg Sumatriptan
223617268|NCT00115505|OTHER|Questionnaire Administration|Complete the Employment and Informal Care Cost Assessment and Peripheral Neuropathy Assessments
224313057|NCT00843635|OTHER|Placebo|Given orally
224313058|NCT00140348|BIOLOGICAL|Immunotherapy allogeneic GM-CSF secreting cellular vaccine|
224313059|NCT06310304|DRUG|Ruxolitinib IR|Tablet
224313060|NCT06310304|DRUG|Ruxolitinib XR|Tablet
224313061|NCT02457663|PROCEDURE|Blood Draw|Blood is to be collected at admission, prior to the 1st operating procedure, once daily for the following 7 consecutive days, at day 15, and at discharge (11 blood draws total). Blood will be taken from IV catheter or routine venipuncture if the catheter is not in place. The blood draw will occur prior to the induction of anesthesia or operating surgical procedure.
224313062|NCT03496610|DRUG|Liposomal Bupivicaine|Patient will receive liposomal bupivicaine mixed with non-liposomal bupivicaine directly to wound
224313063|NCT03496610|PROCEDURE|QL Block|Patient will receive ultrasound guided QL Block
224313064|NCT02143921|BEHAVIORAL|Training intervention|Intervention group service providers received intervention training
224313065|NCT02803424|OTHER|Volume controlled ventilation|During anesthesia and surgical procedure, volume-controlled ventilation will be applied with an inspiration:expiration ratio of 1:2 and a tidal volume of 8 mL per ideal body weight (kg) without ventilatory mode change.
223511274|NCT01248468|DRUG|Placebo|placebo
223511275|NCT03124602|DEVICE|Red Diamond Disposable Pulse Oximeter Sensor|Noninvasive Pulse Oximeter Sensor
223511276|NCT02608346|PROCEDURE|Blood sampling|"Patients will have a blood draw at each visit to the hospital,~* with a maximum of 1 blood draw every 3 months, in absence of any abnormal clinical/radiological exam~* with a maximum of 1 blood draw every week, in case of abnormal clinical/radiological exam that requires further investigation"
223511277|NCT00468546|DRUG|MabThera/Rituxan|1
223511278|NCT00468546|DRUG|Methotrexate|2
223511279|NCT00468546|OTHER|Placebo|3
223511280|NCT00540761|DEVICE|OFDI imaging|Intervention of OFDI system and Imaging of the culprit lesion using the OFDI system.
223511281|NCT04088292|DRUG|Alteplase 20 Mg Powder for Solution for Injection Vial|Low dose alteplase delivered IV or bu Ultrasound Assisted Thrombolysis device
223511282|NCT04088292|DEVICE|Ultrasound assisted Thrombolysis|Ultrasound assisted thrombolysis (USAT)
223511283|NCT05732363|DEVICE|Ultrasonography|The US muscle measurement will be performed with the handheld portable Philips Lumify Sonography connected to a Samsung tablet. The measurement will take approximately 5-10 minutes. A seven-point measurement has to be performed based on the seven-site Jackson Pollock Generalized Prediction Equations for circumference and skinfold thickness measurements.6,7
223617269|NCT04502537|DRUG|Roxadustat|Oral
223617270|NCT04502537|DRUG|erythropoietin|injection
223761297|NCT03925727|DRUG|Tavilermide ophthalmic solution|BID topical dosing
224203802|NCT07042542|BEHAVIORAL|Tendon Gliding and Hand Strengthening Exercises|Tendon glide exercises were performed in five consecutive positions. Each position was practiced for seven seconds, with three sets of five repetitions and one minute of rest between sets. Participants were asked to perform the exercises three times during the day. Hand muscle strengthening exercises were performed by placing a tire on the fingertips, abducting the fingers, and stretching the tire to strengthen the intrinsic muscles and fingers. Resistance could be increased by thickening the tire or adding a second one. Participants were given a grip strength exercise. The hand grip exercise strengthened the extrinsic muscles. Finger flexion and extension exercises strengthened the hand and finger muscles. Participants were asked to perform 10 repetitions of each exercise in each session and to perform the strengthening exercises three times during the day.
224203803|NCT00178763|DEVICE|Heckel Infrared Radiant Heat Device|thermotherapy, maintain a core temperature of 40 degrees centigrade for 6 hours duration
224203804|NCT00178763|OTHER|cisplatin, gemcitabine, interferon-alpha|cisplatin 60 mg/m2 administered over 3 hours intravenously 36 hours before heat. gemcitabine 600 mg/m2 administered intravenously over 1 hour during 40 degree heat. interferon-alpha 1 million international units subcutaneously daily during protocol.
224203805|NCT00178763|OTHER|thermochemotherapy|fever-range whole-body thermal therapy to 40 degrees centigrade combined with cisplatin 60 mg/m2 + gemcitabine 600 mg/m2 + daily interferon alpha 1 million units.
224203806|NCT05660837|BEHAVIORAL|T1: Mixed mode social support group|"This group will receive programs in both online and off-line setting. There will be one face-to-face group session to get to know participant's peer group members. After the in-person group meeting, participants will meet in WhatsApp group. In WhatsApp group, facilitator will provide the following program~1. In person get to know your group member activities~2. Nutrition information through WhatsApp~3. Tips and advice to maintain good mental health through WhatsApp~4. Motivational messages through WhatsApp~5. Reminder through WhatsApp~6. In-person baking class x 1 session"
224203807|NCT05660837|BEHAVIORAL|T2: Online mode social support group|"This group will receive the same program as mixed mode social support group. The key differences would be delivery of all program components online.~1. Online get to know your group member activities~2. Nutrition information through WhatsApp~3. Tips and advice to maintain good mental health through WhatsApp~4. Motivational messages through WhatsApp~5. Reminder through WhatsApp~6. Online baking class x 1 session through WhatsApp"
224203808|NCT03993288|DRUG|Ferrum Lek® (iron (III) hydroxide polymaltosate), 100 mg chewable tablets (Lek d.d., Slovenia)|Participants received Ferrum Lek® 2 tablets daily (200 mg) for 12 weeks
224203809|NCT03993288|DRUG|MALTOFER® (iron (III) hydroxide polymaltosate), 100 mg chewable tablets (Vifor S.A., Switzerland)|Participants received MALTOFER® 2 tablets daily (200 mg) for 12 weeks
224203810|NCT00830271|DEVICE|Vicryl plus and Monocryl plus|closure of skin and subcutaneous tissues
224203811|NCT00830271|DEVICE|wound closure with Vicryl and Monocryl|wound closure skin and subcutaneous tissues
224203812|NCT05036447|OTHER|Moderate-Heavy Resistance Exercise|"Leg press: 3 x 8 repetitions at 75% of 1 repetition maximum, 3 minutes rest between sets.~Knee extension: 3 x 6 repetitions at 85% of 1 repetition maximum, 3 minutes rest between sets."
224203813|NCT02791581|DIAGNOSTIC_TEST|Cardiac MRI|"Breast Cancer Patients Cardiac MRIs will be performed baseline, 3 months (for cancer patients only), and 24 months.~Non-Cancer Controls Cardiac MRIs will be performed baseline and 24 months."
224203814|NCT00915473|DRUG|bupivicaine|2.5 mL 0.5% bupivicaine
224203815|NCT00915473|DRUG|normal saline|2.75 mL normal saline
224203816|NCT00915473|DRUG|methylprednisolone|0.5 mL 20 mg methylprednisolone
224203817|NCT00915473|DRUG|lidocaine|0.25 mL 1% lidocaine
224203818|NCT06159439|DIAGNOSTIC_TEST|Contrast enhanced ultrasound scan|Contrast enhanced ultrasound using Sonovue microbubble contrast
224203819|NCT06159439|DIAGNOSTIC_TEST|MRI scan|Arterial-spin labelling magnetic resonance imaging
223511284|NCT05732363|RADIATION|Dual-energy X-ray Absorptiometry|The brand of the DXA scanner is the Hologic Discovery A, which has a weight limit of 204 kilograms. During the DXA scan, patients will be exposed to radiation, which is approximately 0.2 micro Sievert (µSv) for measuring body composition. For comparison: the average amount of background radiation per hour is approximately 0.23 µSv. The DXA body composition scan will be performed according to standard protocol by a specialized technician.
223511285|NCT03776240|DRUG|HD201|Single-dose 6mg/kg body weight by 90 minute intravenous infusion
223511286|NCT03776240|DRUG|EU-Herceptin|Single-dose 6mg/kg body weight by 90 minute intravenous infusion
223511287|NCT03776240|DRUG|US-Herceptin|Single-dose 6mg/kg body weight by 90 minute intravenous infusion
223511288|NCT01392196|PROCEDURE|Renal Denervation|Renal Denervation using the Symplicity Catheter in Heart Failure Population
223511289|NCT04352530|OTHER|Health Communication|Spoken word poems set to images performed by youth who wrote the poems. Videos were produced by The Bigger Project and were posted publicly to the Bigger Picture Project website and YouTube. Duration of videos ranges from 2 minutes to 6 minutes.
223511290|NCT03838705|PROCEDURE|hypoxia|It was accepted that hypoxia developed in patients with SpO2\< 92 or falling over 20% compared to preoperative values.
224203820|NCT06383143|OTHER|no intervention|no intervention
224203821|NCT06200688|OTHER|PEANUT BALL|"Experimental Group: Pregnant women who were applied with a peanut ball were informed about the necessary information related to the ball by the midwife with a visual representation of the positions. A total of 5 positions were shown to the pregnant women. Peanut ball was started to be used when the cervical dilation reached 6 cm. Pregnant women in the active phase, the transition phase, and the second stage of labor where the peanut ball was applied were directed to change positions every 30-45 minutes. Importance was given to selecting positions where the pregnant woman felt comfortable.~Control Group: No intervention was made other than routine practices within the clinic for pregnant women. It was generally observed that pregnant women spent the time until delivery lying down and connected to electronic fetal monitoring."
224203822|NCT02319954|PROCEDURE|Direct compression|Direct compression by the surgeon with their hands on the nasal sidewall
224203823|NCT06540573|DIAGNOSTIC_TEST|Laboratory tests (examination)|Laboratory tests (examination) to be performed include complete blood count, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), liver function tests and kidney function tests; rheumatoid factor (RF), anti-cyclic citrullinated peptide antibody (anti-CCP antibody) and C-C Motif Chemokine Ligand 21 (CCL21).
223761298|NCT03925727|OTHER|Placebo|BID topical dosing
224203824|NCT06540573|DIAGNOSTIC_TEST|Western Ontario and McMaster Universities Osteoarthritis (WOMAC) Index|Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) This questionnaire is used to assess the health status of osteoarthritis patients introduced in 1988 (13). It is consisted of 33 items which evaluates the health and function of the patient from various aspects including: clinical symptoms (5 questions), severity of joint stiffness (2 questions), degree of pain (9 questions), and activity of daily living (17 questions).The test questions are scored on a scale of 0-4, which correspond to: None(0),Mild (1),Moderate (2),Severe(3),and Extreme (4).The scores for each subscale are summed up, with a possible score range of 0-20 for Pain, 0-8 for Stiffness, and 0-68 for Physical Function. Usually a sum of the scores for all three subscales gives a total WOMAC score, however there are other methods that have been used to combine scores.Higher scores on the WOMAC indicate worse pain, stiffness, and functional limitations.
224203825|NCT06540573|DIAGNOSTIC_TEST|The Disease Activity Score28 (DAS28)|The Disease Activity Score (DAS) was created as a numerical tool for quantifying and assessing disease activity in rheumatoid arthritis (RA).The DAS28 (Disease Activity Score using 28 joint counts) was developed from the original DAS (Disease Activity Score).The DAS28 evaluates the disease activity by assessing the number of tender and swollen joints in a patient. Specifically, it considers 28 joints. The DAS28 also takes into account a blood marker of inflammation, typically the erythrocyte sedimentation rate (ESR) or the C-reactive protein (CRP) level.A patient with a DAS28 score of less than 2.6 is in remission; a score greater than or equal to 2.6 and less than 3.1 indicates low activity; a score greater than or equal to 3.1 and \<5.1 indicates moderate activity and a score 5.1 or more indicates high activity
224203826|NCT06540573|DIAGNOSTIC_TEST|Patient global assessment (PGA)|Patient global assessment (PGA) of disease activity will be reported by patients. PGA was developed in the late 1970s and was initially designed for the measurement of self-assessed pain in RA \[8\], although it has since been used to evaluate RA more globally. It is interesting to note that the way PGA is used in clinical practice covers, in fact, two very different concepts, one related to global health and the other to overall disease activity. They are both usually used under the heading of PGA without further specification for which is being assessed.
224203827|NCT06540573|DIAGNOSTIC_TEST|Physician global assessment (PhGA)|Physician global assessment (PhGA)of disease activity will be reported by the physician.The Physician Global Assessment (PhGA) of treatment response measures the overall response to treatment as assessed by the physician. The PhGA is a well accepted and commonly used scale for evaluating treatment response in clinical trials both in adults and children. PhGA is a simple instrument and the result is easily understood. However, assigning a score for PhGA requires a very detailed evaluation. To perform this assessment a physician/health care provider would use extensive data from every aspect of ICF.
224313066|NCT02803424|OTHER|Autoflow-volume controlled ventilation|After tracheal intubation, volume-controlled ventilation will be initiated with an I:E ratio of 1:2 and a tidal volume of 8 mL per ideal body weight (kg). Immediately after CO2 pneumoperitoneum with steep Trendelenburg positioning, Autoflow-volume controlled ventilation will be applied instead of volume-controlled ventilation. Immediately after CO2 desufflation and supine positioning, volume-controlled ventilation will be applied again.
224313067|NCT01727726|DRUG|Brexpiprazole|tablet/capsule
224313068|NCT01727726|DRUG|Seroquel XR|tablet/capsule
224313069|NCT01727726|DRUG|Placebo|tablet/capsule
223511291|NCT03838705|PROCEDURE|normooxy|It was accepted that patients with SpO2 between 100-92 mmHg
223511292|NCT02214732|BEHAVIORAL|Mindfulness Based Cognitive Therapy|The modified MBCT program for pregnant women is an 8-session group intervention that aims to help women change their relationship to the thoughts, feelings, and bodily sensations that can lead to psychological distress. Participants are guided to recognize and disengage from unhelpful mind states characterized by self-perpetuating patterns of ruminative thought. The intervention was modified to address pregnant women's physical and emotional needs, as well as their risk of perinatal mood episodes.
223511293|NCT00472641|DRUG|Ziprasidone/Geodon|Ziprasidone/Geodon
223511294|NCT05158803|RADIATION|ultrasound and C.T|lung ultrasound in comparison to C.T
223511295|NCT00176215|PROCEDURE|survival failure of more than 20 %|
223511296|NCT01025895|PROCEDURE|acl reconstruction - double bundle technique|
223511297|NCT01025895|PROCEDURE|acle reconstruction - single bundle technique|
223511298|NCT05206435|DRUG|Electronic Cigarette|Electronic Cigarettes are provided to replace tobacco cigarettes
223511299|NCT05206435|DRUG|Nicotine Lozenge|Nicotine Lozenges are provided to replace tobacco cigarettes
223511300|NCT04509011|DEVICE|Fluobeam® LX|Fluobeam®-LX is used to identify and evaluate parathyroid glands using auto-fluorescence during thyroid surgery.
223511301|NCT02325895|OTHER|Dried Plum|Three doses of dried plum (0 g, 50 g and 100g) were used as intervention.
223511302|NCT04144764|OTHER|Workplace-based exercise|Participants will have to perform 10-week of workplace-based exercise programme which consist of 5 sessions of 10 minutes per week. The workplace-based exercise programme will consist of general stretching and strengthening exercise using resistance tubing for both the neck and upper limb. Specific rotator cuff and scapular muscles strengthening exercise were also included to enhance glenohumeral and scapular kinematics (Appendix). Each participant will receive a set of elastic resistance tubing that comprise red (2kg), green (3kg) and blue (4kg). The exercise programme will be taught by physiotherapist during their baseline assessment. They will be asked to train at the workplace during workdays (Monday to Friday), five times a week during the 10-week intervention. The program built on the principle of progressive overload.
223511303|NCT04144764|OTHER|Ergonomic advice and education|Participants will receive ergonomic training and education on how to adjust their workstations to reduce the ergonomic risk factors when using computers.
223511304|NCT00239980|DRUG|dalteparin|50, 100, 150 IU/kg administered subcutaneously once daily for 3 cycles of chemotherapy
223511305|NCT00377806|DRUG|Diclofenac gel|
223511306|NCT05865249|OTHER|Spirometry decision support software (ArtiQ.Spiro)|ArtiQ.Spiro is a decision support software that combines two sub-components - one focussing on quality assessment (ArtiQ.QC), and one on spirometry interpretation (ArtiQ.PFT). It is intended to be used as an adjunct to spirometry to assist with the grading of spirometry quality and the interpretation of spirometry by providing the probability of six disease / or no disease categories.
224203828|NCT06540573|DIAGNOSTIC_TEST|Health Assessment Questionnaire (HAQ)|Functional impairment will be assessed with the Health Assessment Questionnaire (HAQ). It is a self-assessment tool used to measure functional ability in eight different areas: rising, dressing and grooming, hygiene, eating, walking, reach, grip, and activities of independent living. Each item or question is rated on a scale of 0 to 3, with 0 (normal/no difficulty), 1 (some difficulty), 2 (much difficulty), and 3 (unable to do). The 8 category scores are averaged, which represent an overall score from 0 (no disability) to 3 (completely disabled). If the questionnaire is slightly changed to reflect a certain disease, this does not affect the respective scoring.Scores 0-1 indicates mild to moderate disability, 1-2 indicates moderate to severe disability, and 2-3 indicates severe to very severe disability.
224313070|NCT02714426|BEHAVIORAL|Mindfulness-inspired treatment|Eight weekly group MIT sessions lasting 90-120 minutes, along with a ½ day Mindfulness Retreat at the end of the training period, will include 1) psychoeducation, 2) formal exercises in the form of guided practice mentioned above, and 3) thoughtful exploration of ideas and questions. Formal MIT training will follow 21 guided pre-recorded meditative Moving Picture Experts Group Layer-3 Audio (MP3) tracks from the authors for use in class and at home, promoting both fidelity to the model and uniformity in intervention across training groups. MIT activities in the protocol include mindful breathing, eating, walking, and various other practices well documented in the literature to promote mindfulness. Participants will be asked to practice MIT on their own time, and to log this.
223511307|NCT05907499|DRUG|Decitabine|Decitabine 6 mg/m2 daily subcutaneously for consecutive 3 days (day 1 to day 3)
223511308|NCT05907499|DRUG|Granulocyte Colony-Stimulating Factor|5ug/kg/d when absolute neutrophil count ≤ 1.5 × 109/L
223511309|NCT05907499|DRUG|Thrombopoietin Receptor Agonist|Eltrombopag initial dose: 25 mg orally once a day, may increase to up to 75 mg/day, when platelet count ≤ 30 × 109/L; Avatrombopag initial dose: 20 mg orally once a day, may increase to up to 60 mg/day, when platelet count ≤ 30 × 109/L.
223511310|NCT05907499|DRUG|Recombinant human erythropoietin|10000 U/day when hemoglobin ≤ 85 g/L
223511311|NCT02588534|DEVICE|etanercept (ENBREL®) via auto-injector device|single 50 mg subcutaneous dose of liquid etanercept (ENBREL®) in a 1.0 ml pre-filled syringe administered via an auto-injector device manufactured by Scandinavian Health Limited (SHL)
223511312|NCT02588534|OTHER|Etanercept (ENBREL®) via Manual injection|single 50 mg subcutaneous dose of liquid etanercept (ENBREL®) in a 1.0 ml pre-filled syringe administered via manual injection (reference treatment) to compare to the auto-injection
223511313|NCT04044287|DRUG|200 micrograms of misoprostol|200 micrograms of powdered misoprostol applied sublingually together with standard parenteral oxytocic therapy
223511314|NCT04044287|DRUG|Placebo Oral Tablet|200 micrograms of powdered placebo applied sublingually together with standard parenteral oxytocic therapy
223617271|NCT01091675|DRUG|Etoricoxib|Etoricoxib 90 mg/day/PO during 4 weeks Positive response to the therapy (in investigator opinion): Ongoing treatment with 90 mg/day/PO until 24 weeks.
223617272|NCT00408850|DRUG|Pioglitazone|15 mg per day for 6 weeks and 30 mg per day for further 6 weeks
223617273|NCT00408850|DRUG|sugar pill|One capsule daily for 6 weeks followed by two capsules per day for next 6 weeks
223617274|NCT00614380|DRUG|telmisartan/amlodipine 40/5 mg fixed combination|
223617275|NCT00614380|DRUG|telmisartan/amlodipine 80/5 mg fixed combination|
223617276|NCT05312593|OTHER|Aftoral Oral Gel|Patients will use Aftoral® Oral Gel solution for the domiciliary application once a day for 15 days after the visits (no rinsing and eating for 30 minutes after gel solution application).
223617277|NCT05312593|OTHER|Unidea Chlorhexidine mouthwash|Patients will use chlorhexidine mouthwash 0,20% for the domiciliary application once a day for 15 days after the visits (no rinsing and eating for 30 minutes after mouthwash application).
223617278|NCT02161796|DRUG|FG-4592|Oral
223617279|NCT02161796|DRUG|Placebo|Oral
223617280|NCT02314936|DIETARY_SUPPLEMENT|Litesse powder containing 12 g polydextrose|12 g polydextrose
223617281|NCT02314936|DIETARY_SUPPLEMENT|Litesse powder containing 8 g polydextrose|8 g polydextrose, 4 g maltodextrin
223617282|NCT02314936|DIETARY_SUPPLEMENT|Litesse powder containing 4 g polydextrose|4 g polydextrose, 8 g maltodextrin
223617283|NCT02314936|DIETARY_SUPPLEMENT|Placebo|12 g Maltodextrin
223617284|NCT01577017|DRUG|Letrozole|Women in group L will be assigned with Letrozole on night at day 5 to day 9 of the cycle
223617285|NCT04001712|DRUG|Caffeine Citrate|caffeine citrate is given early to preterm neonates in need of respiratory support
223617286|NCT00165880|DRUG|E7070|
223617287|NCT04471077|PROCEDURE|bariatric surgery|(Laparoscopic Sleeve Gastrectomy, laparoscopic Roux-en-Y gastric bypass)
223617288|NCT01528059|PROCEDURE|Stomach-small intestine reconstruction|Billroth II or Roux en Y reconstruction will be performed after gastric resection in stomach patients co-morbid with type 2 diabetes
223617289|NCT03913858|PROCEDURE|Obesity Surgery with Low-Flow Anesthesia|Group 1 had 1 liter/minute (50% O2, 50% air) flow administered.
223617290|NCT03913858|PROCEDURE|Obesity Surgery with High-Flow Anesthesia|Group 2 had 4 liter/minute (50% O2, 50% air) flow administered.
223617291|NCT05853146|DEVICE|Oxitone 1000M|World's First FDA-cleared Wrist-Sensor Pulse Oximetry Monitor
223617292|NCT03853330|DEVICE|Ultrasound|Ultrasound-guided Thoracic Epidural Analgesia and Erector spinae plane block.
223617293|NCT03853330|DRUG|Bupivacaine HCl Inj 0.25%|Bupivacaine HCl Inj 0.25% will be used in both blocks by the same dose of 7.5-12 ml
223617294|NCT03853330|DRUG|Bupivacaine Hydrochloride, 0.125%-0.9% Injectable Solution|infusion of Bupivacaine Hydrochloride, 0.125%-0.9% Injectable Solution at 5-7 ml/h will be used in both blocks and also for breakthrough pain after both blocks as a bolus of 5-10 ml.
223617295|NCT03476135|BIOLOGICAL|MenACYW conjugate vaccine|Meningococcal polysaccharide (serogroups A, C, Y, and W) tetanus toxoid conjugate vaccine 0.5 mL, intramuscular
223617296|NCT00930696|PROCEDURE|Extensive abdominal lavage|Extensive lavage of the abdomen with 8 liters of saline at the end of the surgical procedure
223617297|NCT00930696|PROCEDURE|Rinsing of the abdomen|Standard rinsing of the abdomen with some 0,5 liters of saline at the end of the surgical procedure
223761299|NCT02800330|DRUG|Esomeprazole 40mg concomitantly|During phase B the patients will use esomeprazole 40mg concomitantly with regorafenib for 5 days.
223761300|NCT02800330|DRUG|Esomeprazole 40mg before|During phase C the patients will use esomeprazole 40mg 3 hours before regorafenib for 5 days.
223761301|NCT02800330|DRUG|Regorafenib 160mg or 120mg|Patients will use regorafenib 160mg or 120mg during all phases (A, B, C)
223761302|NCT02832869|OTHER|short message service based re-education|The patients will receive standard written instructions on preparing for a colonoscopy plus intervention such as short message system based re-education by one investigator on the day before colonoscopy.
223761303|NCT02832869|OTHER|Wechat based re-education|The patients will receive standard written instructions on preparing for a colonoscopy plus intervention such as Wechat based re-education by one investigator on the day before colonoscopy.
223761304|NCT01203592|DRUG|Albuterol|4 mg twice daily by mouth for adults. The dose for children 6 to 12 years is 2 mg two or three times daily; the dose for children 2 to 6 years is 0.1 mg/kg/day (maximum 2 mg) three times daily.
223761305|NCT01652391|DEVICE|Transcranial direct current stimulation (tDCS); DC-STIMULATOR (NeuroConn GmbH, Ilmenau, Germany)|
223761306|NCT00903812|OTHER|No intervention|No intervention as observational study
224313071|NCT02714426|OTHER|Brain health|Eight weekly group brain health sessions lasting 90-120 minutes. The intervention is psychoeducational, and each week presents information from NIH regarding factors that may promote cognitive health in late life (e.g., sleep, physical activity, social engagement and leisure, cognitive training). Weekly sessions are supplemented with educational videos and group discussion. Weekly homework consists of readings about brain health.
224075610|NCT03353857|DRUG|Rifampicin|In period 2, 10 mg (suspension, 0.5 ml) for 11 days at 10 mg/day In period 3, 600 mg (film-coated tablets) for 11 days at 600 mg/day
224075611|NCT02397850|BEHAVIORAL|phone calls 30 min|Patients receive either seven 30 minutes phone calls over 6 months (psychotherapy/continuation treatment)
224313072|NCT05046743|OTHER|Colonic gas load|Colonic infusion of gas via an anal cannula
224313073|NCT05046743|OTHER|Sham load|Sham infusion of gas via an anal cannula
223511315|NCT02451735|BEHAVIORAL|Video and Booklet|Printed and DVD materials about Genetic Counseling. Self-reported feedback will be collected and reviewed to compare to the control group response.
223511316|NCT02451735|BEHAVIORAL|Factsheet|Patient factsheet about Genetic Counseling. Self-reported feedback will be collected and reviewed to compare to the intervention group response.
223511317|NCT00150527|DRUG|Citalopram|40 mg, pill, single dose
223511318|NCT00150527|DRUG|Escitalopram|20 mg, pill, single dose
223511319|NCT00150527|DRUG|Dexamethasone|1 mg, pill, single dose
223511320|NCT00150527|BEHAVIORAL|Cold Pressor Test|single test
223511321|NCT00451984|BIOLOGICAL|Twinrix|
223511322|NCT00451984|BIOLOGICAL|interleukin-2|
223511323|NCT00139035|DRUG|cyclosporine A|
223511324|NCT00478140|BIOLOGICAL|trastuzumab|For HER-2/neu positive biopsies, trastuzumab was administered intravenously, once every 3 weeks, at a loading first dose at 8 mg/kg over 90 minutes, and subsequent maintenance doses of 6 mg/kg over 90 minutes then every 30 minutes starting at the third dose.
223511325|NCT00478140|OTHER|laboratory biomarker analysis|Correlative studies
223511326|NCT02178189|OTHER|High Calorie Infant formula|Infants were randomized to be fed high calorie formula from 72 hours of life until age 21 days.
223511327|NCT02178189|OTHER|Standard Calorie Infant Formula|Infants were randomized to be fed standard calorie formula from 72 hours of life until age 21 days.
223511328|NCT02988557|PROCEDURE|walking on a treadmill with a sloped surface|walking on a treadmill with a sloped surface
223511329|NCT02988557|DEVICE|treadmill|walking on a treadmill with a sloped surface
223511330|NCT02077712|DRUG|intranasal dexmedetomidine|1 or 2 ug/kg of intranasal dexmedetomidine
223511331|NCT02979158|PROCEDURE|CPB Low Dose|Performing CPB with low dose heparin and coated equipment
223511332|NCT02979158|PROCEDURE|CPB High Dose|Performing CPB with high dose heparin and uncoated equipment
223511333|NCT03693508|DRUG|Genvoya®|Patents treated with elvitegravir (EVG) 150mg / cobicistat (COBI) 150mg / emtricitabine (FTC) 200mg / tenofovir (TAF) 10mg once a day as the first line treatment.
223511334|NCT04615988|OTHER|blood draw and questionnaire completion|questionaires provided to subjects during visits while on study and baseline one tube of blood drawn
223511335|NCT04615988|OTHER|questionnaire completion, blood collection|questionnaire provided to subject during study visits. One tube blood collected for research purposes at baseline
223511336|NCT00103753|DRUG|deferiprone|
223511337|NCT01933425|DRUG|rocuronium|
223511338|NCT01933425|DRUG|sugammadex|
223511339|NCT01933425|DRUG|placebo|
223511340|NCT05706675|PROCEDURE|Non surgical periodontal therapy|Manual root planning+Ultrasonic subgingival debridement
224075612|NCT02397850|BEHAVIORAL|phone calls 50 min|Patients receive either seven 50 minutes phone calls over 6 months (psychotherapy/continuation treatment)
224075613|NCT04961606|OTHER|interview|semi-structured individual interview
224075614|NCT04434144|DRUG|Ivermectin + Doxycycline|SARS-CoV-2 infection was confirmed by RT PCR in every case. For group A, Ivermectin 200mcg/kg single dose and Doxycycline 100mg BID for 10 days were given. For group B, Hydroxychloroquine 200mg BID for 10 days and Azithromycin 500mg single daily dose for 5days was given. Before advising the contraindications and possible adverse effect and drug interactions were kept in consideration. Incase of asymptomatic patients, repeat sample collection (nasopharyngeal and throat swab) for PCR was done on 5th day. For the symptomatic patients, this duration was on the 3rd nonsymptomatic day from the first day of drug intake. In the case of positive PCR, the test was repeated after 2days and onward.
224075615|NCT04434144|DRUG|Hydroxychloroquine + Azithromycin|SARS-CoV-2 infection was confirmed by RT PCR in every case. For group B, Hydroxychloroquine 400mg first day then 200mg BID + Azithromycin 500mg BID for 5 days were given. For group B, Hydroxychloroquine 200mg BID for 10 days and Azithromycin 500mg single daily dose for 5days was given. Before advising the contraindications and possible adverse effect and drug interactions were kept in consideration. Incase of asymptomatic patients, repeat sample collection (nasopharyngeal and throat swab) for PCR was done on 5th day. For the symptomatic patients, this duration was on the 2nd nonsymptomatic day from the first day of drug intake. In the case of positive PCR, the test was repeated after 2days and onward.
224203829|NCT06540573|DIAGNOSTIC_TEST|Clinical disease activity index (CDAI)|Clinical Disease Activity Index (CDAI) is a composite index (without acute-phase reactant) for assessing disease activity. CDAI is based on the simple summation of the count of swollen/tender joint count of 28 joints along with patient and physician global assessment on VAS (0-10 cm) Scale for estimating disease activity. The CDAI has range from 0 to 76
224313074|NCT04435184|DRUG|Crizanlizumab|Crizanlizumab 5.0 mg/kg in 100 ml IV once.
224313075|NCT04435184|OTHER|0.9% saline|0.9% saline 100 ml IV once.
224313076|NCT03360084|PROCEDURE|Percutaneous lung biopsy under CT guidance|Percutaneous lung biopsy under CT guidance
224313077|NCT05318430|DEVICE|Subcutaneous closed-suction drainage device|This subcutaneous closed-suction drainage device was designed to be placed subcutaneously when surgeons have completed all intra-abdominal operations and are about to suture subcutaneous layer and skin
224313078|NCT03939715|BIOLOGICAL|DermaPure®|Surgical intervention using DermaPure®
224313079|NCT03939715|PROCEDURE|native tissue|Surgical intervention using native tissue
224313080|NCT04333030|OTHER|questionnaire|Tobacco Use and Risk Questionnaire
224313081|NCT02985216|DRUG|YHD1119|"YHD1119 150mg, PO YHD1119 300mg, PO~YHD1119 600mg, PO"
224203830|NCT06540573|DIAGNOSTIC_TEST|The Simplified Disease Activity Index (SDAI)|The Simplified Disease Activity Index for Rheumatoid Arthritis (SDAI) is a scoring system that has been validated in both research and clinical settings. It has been shown to have the highest sensitivity and specificity for predicting a physicians' decisions to change DMARD therapy when compared to other scores.Remission is defined as an SDAI of \<3.3, low disease activity as ≤11, moderate disease activity as ≤26 and high disease activity as \>26. Response to therapy is considered moderate if SDAI decreases by ≥7 and major if decreases by ≥17
224203831|NCT06540573|DIAGNOSTIC_TEST|Knee Radiography|Knee osteoarthritis (gonarthrosis) will be evaluated using Kellgren-Lawrence (KL) staging on direct radiographs (anteroposterior and lateral views).Numerous variations of the Kellgren and Lawrence classification system have been used in research. Grade 0 (none): definite absence of x-ray changes of osteoarthritis. Grade 1 (doubtful): doubtful joint space narrowing and possible osteophytic lipping.Grade 2 (minimal): definite osteophytes and possible joint space narrowing. Grade 3 (moderate): moderate multiple osteophytes, definite narrowing of joint space, some sclerosis and possible deformity of bone ends Grade 4 (severe): large osteophytes, marked narrowing of joint space, severe sclerosis and definite deformity of bone ends. Osteoarthritis is deemed present at grade 2 although of minimal severity
224203832|NCT01609127|DRUG|Tesetaxel|Tesetaxel 27 mg/m2 orally once on Day 1 of each 21-day cycle
224203833|NCT01609127|DRUG|Tesetaxel|Tesetaxel 15 mg/m2 orally once every 7 days for 3 consecutive weeks on Day 1, Day 8, and Day 15 of each 28-day cycle
224313082|NCT02985216|DRUG|Lyrica|Lyrica 75mg, PO Lyrica 150mg, PO Lyrica 300mg, PO
224313083|NCT01131468|DRUG|N-acetylcysteine|N-acetylcysteine 600 mg twice daily or vancomycine+amikacin alone
224313084|NCT04627987|DIAGNOSTIC_TEST|Cardiac MRI scan|Cardiac MRI scan pre- and post- aortic valve replacement to assess degree of left ventricular remodelling, fibrosis and myocardial blood flow.
224313085|NCT04627987|DIAGNOSTIC_TEST|Serum biomarkers (High sensitivity troponin, NT-proBNP|Blood tests looking evidence of cardiac structural remodelling and function.
224313086|NCT04627987|PROCEDURE|Implantable Loop Recorder|Determine post-AVR arrhythmia burden
224313087|NCT04627987|DIAGNOSTIC_TEST|6 minute walk test|Validated assessment of functional capacity - distance walked over 6 minute time frame.
224313088|NCT04627987|DIAGNOSTIC_TEST|Echocardiogram|Ultrasound assessment of heart structure and function. Standard of care in valve surgery pathway.
224313089|NCT01476332|DRUG|cis-urocanic acid 0,5% eye drops|one drop three times a day, applied on one eye at Part 1 and on both eyes at Part 2
224313090|NCT01476332|DRUG|cis-urocanic acid 2.5% eye drops|one drop three times a day, applied on one eye at Part 1 and on both eyes at Part 2
224313091|NCT01476332|DRUG|Placebo for cis-UCA, eye drops|one drop three times a day, applied on one eye at Part 1 and on both eyes at Part 2
224313092|NCT04760496|DRUG|Oxytocin 4 mIU/mL|Oxytocin at 4 mIU/mL administrated by IV infusion controlled by pump or electric syringe.
224313093|NCT04760496|DRUG|Oxytocin 2 mIU/mL|Oxytocin at 2 mIU/mL administrated by IV infusion controlled by pump or electric syringe.
223511341|NCT03374904|BEHAVIORAL|Video Feedback|first, a play interaction between the child and caregiver is recorded (5 to 10 minutes), then the therapist and caregivers watch together a selected part of the video (1 to 2 minutes) and provide feedback with a six step protocol.
223511342|NCT03374904|BEHAVIORAL|Control Group|Play therapy will be administered once a week plus inpatient treatment as usual for 4 weeks
224313094|NCT00258700|BIOLOGICAL|Haemophilus influenzae type b- and meningococcal (vaccine)|
224313095|NCT03259412|DIETARY_SUPPLEMENT|Fish Oil|Fish Oil Capsule
224313096|NCT03259412|DIETARY_SUPPLEMENT|Placebo|Olive Oil capsule manufactured to mimic fish oil capsule
224313097|NCT03306446|DRUG|Start adalimumab in monotherapy|Discontinuation of Adalimumab in patients who achieved deep remission
224313098|NCT03810326|DEVICE|CTR device (tradename named Xtend)|Non invasive active splint
224313099|NCT00770081|DRUG|vildagliptin|50mg qd
224313100|NCT00770081|DRUG|sitagliptin|25mg qd
223511343|NCT05697692|DRUG|Heparin sodium|Lung transplantation on central veno-arterial ECMO with standard additional heparin
223511344|NCT05697692|DRUG|Placebo|Lung transplantation on central veno-arterial ECMO without additional heparin
223511345|NCT04492293|DRUG|ICP-192|ICP-192 is a white, round, uncoated table
223511346|NCT02622594|DRUG|Aminolevulinic Acid (ALA)|
223511347|NCT02622594|DEVICE|Environ Cosmetic Roller|
223511348|NCT02622594|DEVICE|BLU-U IIlluminator|
224313101|NCT01869855|PROCEDURE|Subdural Drainage|
224313102|NCT01869855|PROCEDURE|Subperiosteal Drainage|
224313103|NCT01405014|BEHAVIORAL|Hold Me Tight|Relationship enhancement group
224313104|NCT01882972|BEHAVIORAL|Exercise|
224313105|NCT01882972|BEHAVIORAL|Meditation|
223511349|NCT03471949|OTHER|CGM in a population with normal OGTT|The population with normal OGTT will use CGM and document their values as well as be documenting a capillary blood glucose value
224313106|NCT05769257|DRUG|IS-001|Intravenous injection of IS-001 investigational drug
224313107|NCT00010530|PROCEDURE|Meditation|
224203834|NCT01609127|DRUG|Capecitabine|Capecitabine 1250 mg/m2 orally twice daily (in the morning and evening after a meal; equivalent to a total daily dose of 2500 mg/m2) on Day 1 through Day 14 of each 21-day cycle
224203835|NCT05635773|DEVICE|Use of Alexa Visual Cognitive aid|The intervention is the use of of a cognitive aid to determine the efficacy of the aid in completing the steps correctly.
224203836|NCT05385276|PROCEDURE|Transverse supraumbilical incision|The skin incision will be performed as a straight transverse skin incision 3-5cm above umbilicus after maximum retraction the panniculus caudally using two towel clips, to facilitate the approach to the lower uterine segment The skin incision is a transverse upward concavity, typically initiated two finger-breadths above the symphysis pubis and extended in the direction of the anterior superior iliac spine below and medial to it about (2 - 3 cm) .
224203837|NCT05385276|PROCEDURE|Pfannenstiel Incision|The skin incision is a transverse upward concavity, typically initiated two finger-breadths above the symphysis pubis and extended in the direction of the anterior superior iliac spine below and medial to it about (2 - 3 cm).
224203838|NCT06318091|BIOLOGICAL|platelet poor plasma gel|injection of platelet poor plasma gel in the dark circles around the eye to rejuvenate and improve pigmentation
224203839|NCT06318091|BIOLOGICAL|nanofat|injection of nanofat in the dark circles around the eye to rejuvenate and improve pigmentation
224203840|NCT04245930|PROCEDURE|Bovine Pericardial Patch in Immediate Implant Breast Reconstruction|Patients will receive immediate breast implant reconstruction using Bovine Pericardial Patch
224203841|NCT04245930|PROCEDURE|TiLOOP® Bra Mesh in Immediate Implant Breast Reconstruction|Patients will receive immediate breast implant reconstruction using TiLOOP® Bra Mesh
224203842|NCT00413465|DRUG|Escherichia Coli Endotoxin|
224203843|NCT05496101|PROCEDURE|Intraoperative CLI + FAR LightPath imaging|"Imaging System: The LightPath Imaging System is an in vitro diagnostic device which has CE mark in Europe, in line with In Vitro Diagnostic Medical Devices 98/79/EC (post marketing study).~Radiopharmaceutical:~18F-FDG is a routinely used Positron Emission Tomography (PET) / Computed Tomography (CT) radiopharmaceutical"
224203844|NCT05234619|DRUG|Group one ( lidocaine or control LE ) Early deflation|"This will be conducted on 20 trauma patients group one who will be present for both elective and emergency Hand and Forearm surgery After establishing noninvasive arterial blood pressure, ECG, peripheral oxygen saturation monitoring, two venous cannulae will be inserted: one in a vein in the dorsum of operative hand and the other in the opposite hand for crystalloid infusion.~The opposite arm will be elevated for 2 minutes, and using an Esmarch bandage, the venous capacitance of the arm will be emptied. Then, a double-pneumatic tourniquet will be applied. The proximal tourniquet will be inflated to a pressure of 250 mmHg and circulatory isolation of the arm will be confirmed by inspection, lack of radial pulse and failure of pulse oximetry tracing of ipsilateral index finger then Esmarch bandage will be released then induction of lidocaine for intravenous regional anesthesia ( Bier block ) and Early deflation of distal tourniquet occurs after 20 minutes of IVRA induction"
224203845|NCT05234619|DRUG|Group two ( lidocaine , ketorolac LKE ) Early deflation|As the first intervention this will be conducted on group two but ketorolac will be combined with lidocaine in intravenous regional anesthesia
224203846|NCT05234619|DRUG|Group three ( lidocaine or control LL ) Late deflation|As the first intervention this will be conducted on group three but late deflation of distal tourniquet in intravenous regional anesthesia after 40 minutes of induction of lidocaine for IVRA .
224203847|NCT05234619|DRUG|Group four ( lidocaine , ketorolac LKL ) Late deflation|As the first intervention this will be conducted on group four but late deflation of distal tourniquet in intravenous regional anesthesia after 40 minutes of induction of lidocaine and ketorolac for IVRA .
224203848|NCT03526679|DRUG|Eribulin|lenvatinib 14mg po daily; eribulin 1.1mg/m2 D1, D8, every 21 days
224313108|NCT00323466|PROCEDURE|IMRT versus conventional radiotherapy|Comparing MRT versus conventional radiotherapy
224313109|NCT03357718|DRUG|Precedex|2 µg/kg oral
224313110|NCT03357718|DRUG|Midazolam|0.5 mg/kg
224313111|NCT00048737|DRUG|Zevalin Radioimmunotherapy|Escalating single dose of 90Y Zevalin 0.2-0.3-0.4 mCi/kg
224313112|NCT00048737|DRUG|Rituximab|250 mg/m\^2 on day 1 and day 8
224313113|NCT00048737|DRUG|Fludarabine|30 mg/m\^2/day for 3 days
224313114|NCT00048737|DRUG|Cyclophosphamide|750 mg/m\^2/day for 3 days, given on the same days as fludarabine, at 4-hour intervals
224203849|NCT03526679|DRUG|Lenvatinib|lenvatinib 14mg po daily; eribulin 1.1mg/m2 D1, D8, every 21 days
224203850|NCT01738490|DEVICE|Bone anchored hearing implant|
224313115|NCT00048737|PROCEDURE|Allogeneic Stem Cell Transplantation|Allogeneic stem cell transplantation 2 days after chemotherapy
224313116|NCT04496284|OTHER|Vitrification via slush nitrogen|blastocyst stage embryos will be vitrified via slush nitrogen
224313117|NCT00776087|DEVICE|Home Monitoring provided by Biotronik ICD and CRT-D devices|Remote monitoring of ICD and CRT-D function and patient status may result in more effective follow-up and increased patient safety
224313118|NCT00776087|DEVICE|No Home Monitoring|Home Monitoring option is switched off (in the same kind of devices as used in the other study arm).
224313119|NCT06015763|PROCEDURE|Endoscopy|Endoscopic biopsy
224313120|NCT03190902|BEHAVIORAL|Attention Processing Training program (APT)|
224313121|NCT03190902|BEHAVIORAL|nonspecific computer training (n-ST)|
224313122|NCT01019668|DRUG|Verteporfin PDT, half-dose|half the regular dose or half the regular laser fluence to treat prolonged unresolved CSCR
224313123|NCT01019668|DRUG|verteporfin PDT, half-fluence|half the regular dose or half the regular laser fluence to treat prolonged unresolved CSCR
224203851|NCT04024852|OTHER|Intervention group|When Air Quality Health Index is below level 5, the intervention group did daily mild exercise (walking) outdoors for 30 minutes. When Air Quality Health Index is equal to or above level 5, the group is advised to do mild exercise indoors for 30 minutes.
224313124|NCT02588495|OTHER|Food intake|Either drinking a cup of clear liquid, or having a cup of coffee and a muffin
224313125|NCT06550466|OTHER|Breakfast only|Participants will attend a breakfast-only arm without the exercise protocol.
224313126|NCT06550466|OTHER|FAST|Participants will be exercised for 90 minutes following a 12-hour overnight fast
224313127|NCT06550466|OTHER|FED|Participants will be exercised 90 minutes after a breakfast
224313128|NCT05011045|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
224313129|NCT05011045|OTHER|Neurocognitive Assessment|Undergo neurocognitive function assessment
224313130|NCT05011045|OTHER|Quality-of-Life Assessment|Complete questionnaires
224313131|NCT05011045|OTHER|Questionnaire Administration|Complete questionnaires
224313132|NCT06974357|DIAGNOSTIC_TEST|Genetic testing|blood draws for genetic testing
224313133|NCT04546880|OTHER|Breathing exercises|"Breathing exercises consist of the techniques of diaphragmatic and pursed-lip breathing. During the diaphragmatic breathing, attention is focused on the correct abdominal breathing.~The pursed-lip breathing is one step further to the diaphragmatic breathing and a technique designed to have control time and volume over breathing."
224313134|NCT04546880|OTHER|Stabilization exercises|"Training about the concepts of stabilization and abdominal bracing is given before starting to the study. The motor control tests for local muscles transversus abdominus and multifidi are performed after the training. The abdominal bracing test is performed in the quadruped position, in prone, and in hook lying position with the patient's spine supine with hips and knees flexed and knees in contact with the surface.~The second stage consists of closed-chain segmental control exercises. It is a series of weight-bearing exercises are performed on stable and unstable surfaces. The last stage of the stabilization program is an open kinetic chain exercise to promote distal stability."
224313135|NCT04711616|BEHAVIORAL|physical therapy intervention|physical therapy interventions include thermal therapy, electrical therapy, manual therapy, and therapeutic exercise.
224203852|NCT05764837|OTHER|Foam Rolling|Foam rolling was performed for 4 minutes with the goal of affecting the entire myofascial posterior chain.
224203853|NCT06202807|DEVICE|Intermittent Oro-esophageal Tube Feeding|The observation group was given enteral nutritional support with Intermittent Oro-esophageal Tube according to the following procedure: Before each feeding, inside and outside of the tube was cleaned with water. During feeding, the patient should maintain a semi-reclining or sitting position with mouth opened, and the tube was inserted slowly and smoothly into the upper part of the esophagus by medical staffs while the appropriate depth of intubation was checked with the calibration markings on the tube wall. The distance from the incisors to the head part of the tube should be between 22-25 cm. However, the specific depth should be evaluated based on patients' feedback and adjusted accordingly. After insertion, the tail part of the tube should be put into a container full of water and the absence of continuous bubbles indicated a successful intubation. Then, the feeding was to be conducted three times per day with 50 ml per minute and 400-600ml for each feeding.
224203854|NCT06202807|DEVICE|Nasogastric Tube Feeding|The control group was given enteral nutritional support with Nasogastric Tube Feeding according to the relevant guidelines. Within 4 hours after admission, the placement of the feeding tube was conducted by professional medical staffs and after intubation, the tube was secured to the patient\&#39;s cheek with medical tape. The feeding was conducted once every 3-4 hours, with 200-300ml each time. The total feeding volume was determined based on daily requirements. The feeding content was formulated by the nutritionists based on the patient\&#39;s condition and relevant guidelines to reach the energy demand as 20-25 kcal/kg/day and protein supplementation of 1.2-2.0 g/kg/day for both two groups. For patients with limited tube feeding compliance, we made appropriate adjustments to ensure that they were not at risk of severe malnutrition as much as possible.
224203855|NCT06202807|BEHAVIORAL|comprehensive rehabilitation therapy|"Including：~1. Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~2. Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training.~3. Pulmonary function training, including standing training, cough training, and diaphragm muscle training."
224203856|NCT00418509|DRUG|Mometasone furoate|
224313136|NCT05360940|DIAGNOSTIC_TEST|H.pylori stool antigen rapid test and stool parasitological examination|200 stool samples ( 100 positive and 100 negative for H.pylori) after performance of H.pylori stool rapid antigen test then parasitological stool examination will be done
224313137|NCT01695863|DRUG|comparing 2 drugs on their effect on the bowel preparation for colonoscopy|the effects of the drug on the colon preparation for colonoscopy
224313138|NCT00813800|DRUG|Varenicline|Varenicline (Chantix®, Pfizer) is an oral medication with a recommended dosage of 0.5 mg once daily for 3 days, increasing to 0.5 mg twice daily for days 4-7, and then to the maintenance dose of 1 mg twice daily for the 12 weeks of treatment.
224313139|NCT03456453|BEHAVIORAL|NIDA Standard for HIV Prevention|The NIDA Standard is a manualized, HIV prevention education intervention focused on reducing risky sexual and drug use practices. It will be adapted for Facebook in this pilot trial.
224313140|NCT00720252|DEVICE|Ultrasound|To measure intratracheal flow volume (and peak velocity) displaced during breathing cycle in premature fetuses.
224313141|NCT04762277|DRUG|Spesolimab - solution for infusion|Solution for infusion
224313142|NCT04762277|DRUG|Placebo matching spesolimab - solution for infusion|Solution for infusion
224203857|NCT00418509|DRUG|Formoterol fumarate|
223511350|NCT00429455|BEHAVIORAL|Survey|3-Part Questionnaire
223511351|NCT03702374|DRUG|Combined antioxidant therapy|It consists in a tablet with lutein (10 mg), astaxanthin (4 mg), Zeaxanthin (1mg), vitamin C (L-ascorbic acid 180mg), vitamin E (DL-alpha tocopherol 30mg), zinc (zinc oxide 20mg), copper (copper sulfate 1mg), taken once a day for 12 months
223511352|NCT03702374|OTHER|Placebo|It consists in a capsule with 100mg of magnesium oxide.
223511353|NCT03807167|OTHER|Mattis Dementia Rating Scale|This scale was developed to assess the cognitive status of patients with neurodegenerative diseases. There are 37 items that are presented in a fixed order and grouped into five sub-scales: attention, initiation, construction, conceptualization and memory. Patients and healthy subjects with a score below 125 are not included because of major cognitive impairment.
224203858|NCT03208218|DRUG|SYP-1512|Lenalidomide 25mg/tablet, PO, 1 tablet once daily for I\&II D1(crossover)
224203859|NCT03208218|DRUG|Revlimid cap|Lenalidomide 25mg/capsule, po, 1 capsule once daily for period I\&II D1(crossover)
224203860|NCT03443973|DRUG|Gantenerumab|Gantenerumab will be administered as per the schedule specified in the respective arm.
224203861|NCT03443973|DRUG|Placebo|Placebo matching to gantenerumab will be administered as per the schedule specified in the respective arm.
224203862|NCT03282617|BIOLOGICAL|CD137L-DC-EBV-VAX|Patients will receive CD137L-DC-EBV-VAX at a dose of approximately 5-50 millioncells every 2 weeks, for a total of 5-7 times.
224203863|NCT01956123|DRUG|Follitropin Delta (FE 999049)|
224203864|NCT01956123|DRUG|Follitropin Alfa (GONAL-F)|
224313143|NCT04762277|DRUG|Spesolimab- solution for injection|Solution for injection
224203865|NCT05388136|PROCEDURE|Conventional follow up schedule with imaging|Frequent of follow up visit and imaging
224313144|NCT04762277|DRUG|Placebo matching to spesolimab- solution for injection|Solution for injection
224203866|NCT05388136|PROCEDURE|Deintensified follow up schedule without imaging|Less intense follow up visit without imaging
224203867|NCT02268019|PROCEDURE|tourniquet application|
224203868|NCT02268019|DRUG|epinephrine injection|
224203869|NCT01945554|PROCEDURE|Cervical nerve root infiltration|4mg Mephamesone followed by 1ml of 0.5% bupivacaine (Bupivacain®) will be administered.
224203870|NCT01945554|PROCEDURE|Lumbar nerve root infiltration|40mg triamzinolone (Kenacort®) followed by 2ml of 0.5% bupivacaine (Bupivacain®) will be administered.
224313145|NCT01860677|DEVICE|Fisher Wallace Cranial Stimulator|The Fisher Wallace Cranial Stimulator device generates micro currents of electricity using a patented series of radio frequencies.
224313146|NCT06975631|DEVICE|TrHCROSS®|Single injection of 4.4 ml of viscoelastic sodium hyaluronate solution crosslinked.
224203871|NCT01945554|DRUG|Mephamesone|
224313147|NCT06975631|DEVICE|Hyalone®|Single injection of 4.4 ml of viscoelastic sodium hyaluronate solution crosslinked
224313148|NCT06267859|COMBINATION_PRODUCT|The use of a combination of microelements and vitamins against the background of physiotherapy|If necessary, necessary microelements and vitamins will be added to the treatment process. At the same time, physiotherapeutic procedures will be added at the rehabilitation stage.
224313149|NCT06852755|OTHER|Blood Sample Collection|Collection of peripheral blood samples for mitochondrial analysis, including the extraction of mononuclear cells and plasma for further assessment of mitochondrial quality and quantity.
224313150|NCT06654687|DEVICE|Transthoracic Echocardiography|Transthoracic Echocardiography will be used to measure the changes in stroke volume and cardiac output.
224313151|NCT06654687|DRUG|Ringer lactate 1000 ml|Patients will receive 1000 mL of Ringer's lactate solution over 15 minutes.
224313152|NCT06654687|DRUG|Albumin|Patients will receive 250 mL of human albumin 5% over 10 minutes
224313153|NCT06654687|DRUG|Ringer lactate 750 ml|Patients will receive 750 mL of Ringer's lactate solution over 15 minutes.
224313154|NCT06978010|OTHER|Platelet-Rich Plasma (PRP) intraoperatively|Patients receive platelet-rich plasma (PRP) intraoperatively during cesarean section (5 ml before hysterography, 5 ml subcutaneously before skin closure).
224313155|NCT06979427|DIAGNOSTIC_TEST|NIFFR|Fractional flow reserve derived from CT angiography from lesion between 50-70%
223617298|NCT03592316|OTHER|Lower Extremity Amputation Pathway|"Pre-operatively: Subjects will meet with social work/case management, physical therapy, anesthesiology, and the prosthetist for the following: discuss expectations and rehabilitation; pain control options and consideration for epidural or nerve block; prosthetic treatment and care timeline.~Post-operatively: Physical therapy will begin on post-op day 1 with increasing complexity through post-op day 3. On post-op day 3 the wound will be examined by the surgeon and subjects will be cleared for discharge.~Quality of life surveys will be given at several time points during post-operative care."
223617299|NCT05007522|DRUG|Ketotifen/Indomethacin|2 mg tablet, 75 mg SR tablet
223617300|NCT05007522|DRUG|Placebo|Matching placebo tablet
223617301|NCT00867230|DRUG|FTS|Starting dose of 100 mg twice a day by mouth, Days 1 through 21 of a 28-day cycle.
223617302|NCT00790946|DRUG|Valsartan|Valsartan 80 to 160 mg
223617303|NCT00694616|DEVICE|AutoSet Spirit|3 months of therapeutic CPAP (auto-titrating CPAP) followed by 3 months of non-therapeutic sham-CPAP with 1 month of wash-out in between
223617304|NCT00694616|DEVICE|Modified-AutoSet Spirit|3 months of non-therapeutic sham-CPAP followed by 3 months of therapeutic CPAP (auto-titrating CPAP) with 1 month of wash-out in between
223617305|NCT02885688|DIETARY_SUPPLEMENT|Liquid Nutrition|Participants receive liquid nutrition by vein non-stop for up to 7 days.
223617306|NCT02885688|PROCEDURE|Insulin Drip|"Insulin drip by vein to keep serum glucose level between 140 and 180 mg/dL as per ICU protocol.~The interventions required in the current standard management of patients with septic shock is based on the MD Anderson Evidence-Based Protocol (EBP) for management of Severe Sepsis initiated on admission to the ICU."
224203872|NCT01945554|DRUG|0.5% bupivacaine (Bupivacain®)|
224203873|NCT01945554|DRUG|Kenacort®|
224203874|NCT03151967|DRUG|Lactobacillus crispatus CTV-05|vaginal applicator with medium containing drug
224203875|NCT03151967|DRUG|Placebo|vaginal applicator with medium containing no drug
224203876|NCT01308073|DEVICE|Hemodialysis with EMIC 2 filters|Patients with indication for routine continuous hemodialysis due to acute renal insufficiency
224203877|NCT01777191|DRUG|Ixekizumab Auto-Injector|Administered SC by auto-injector
224203878|NCT01777191|DRUG|Ixekizumab Prefilled Syringe|Administered SC by prefilled syringe
224203879|NCT04350073|DEVICE|Q-NRG Metobolic Cart Device|COVID-19 ICU patients will be measured using the Q-NRG device for up to 30 mins. These measurements will take place every other day while the patients are in the ICU. Then they will occur a minimum of 3 times a week until discharge.
224203880|NCT04350073|DEVICE|MuscleSound Ultrasound|COVID-19 ICU patients will have muscle mass, muscle glycogen, and muscle quality measured at rectus femoris (leg), intercostal, and temporal muscle. These measurements will take place every other day while the patients are in the ICU. Then they will occur a minimum of 3 times a week until discharge.
224313156|NCT06983106|OTHER|body composition calculate|The goal of this observational study is to learn about the value of body composition as predictors of pathological grading and prognosis in patients with gastroenteropancreatic neuroendocrine neoplasms. The volume of abdominal skeletal muscle and fat tissue is calculated based on CT scans at diagnosis.
224313157|NCT06982703|DIETARY_SUPPLEMENT|Food Supplement DBZ (acronym for: DIBUZIN) containing calcium butyrate, vitamin D and zinc,|In this prospective pilot study, we plan to evaluate the effects of a Food Supplement DBZ (acronym for: DIBUZIN) containing calcium butyrate, vitamin D and zinc, on the variation of intestinal microbiota and prevention of antibiotic-induced diarrhea, in individuals who have been prescribed antibiotic therapy.
224313158|NCT06982703|DIETARY_SUPPLEMENT|Placebo|The intervention with Placebo involves the intake of a product free of bityrate, zinc and vitD
224313159|NCT06983717|PROCEDURE|lacrimal deroofing|After infiltration anesthesia, patient underwent proximal lacrimal deroofing. Proper punctal dilatation is done, followed by combined 1 snip punctoplasty with a lateral canaliculotomy/ Punctotomy and posterior canaliculotomy of the lateral third. En-bloc expulsion of the concretion was done in case of canaliculitis.
224313160|NCT06982443|BEHAVIORAL|Mindfulness based relapse prevention|"Mindfulness-based relapse prevention (MBRP) is a group-based treatment to provide individuals with skills intended to foster increased awareness of triggers, destructive habitual patterns, and automatic reactions to triggering experiences. Mindfulness practices in MBRP are designed to help individuals pause, observe present experience, and bring awareness to the range of choices available in every moment. Through MBRP individuals learn to respond in ways that serve them, rather than react in ways that are detrimental to their health and happiness."
224313161|NCT06982950|OTHER|Manipulation of Sleep Duration|After a baseline assessment of sleep, participants will undergo either 2 nights of restricted sleep (4 hour time in bed) followed by a recovery sleep, OR 3 nights of an extended sleep opportunity (10 hour time in bed)
224313162|NCT06982638|DEVICE|TMS+ Gait training|"Participants in this single-arm study will receive a personalized, accelerated course of continuous theta burst stimulation (cTBS) over a functionally defined subregion of the supplementary motor area (SMA), which is individually targeted using resting-state functional MRI. The stimulation will be delivered using a MagPro Cool-B65 A/P figure-of-eight coil at 110% of resting motor threshold.~Each participant will undergo 6 treatment visits over 2 weeks , receiving 8 rTMS sessions per day (600 pulses/session), totaling 28,800 pulses across the study. TMS sessions will be interleaved with dual-task gait training involving cognitive walking exercises. Gait training will be conducted for 30 minutes per visit, immediately following stimulation blocks. Safety, tolerability, adherence, gait performance, and neuroplasticity will be evaluated pre- and post-intervention using clinical scales, motor evoked potentials (MEPs), and functional MRI."
224075616|NCT04172558|BIOLOGICAL|OnabotulinumtoxinA|a single ICI of BTX-A 100 units one day after the penile Doppler/trimix test.
224075617|NCT04172558|DRUG|Trimix|on demand ICI of Trimix
224075618|NCT04617158|PROCEDURE|Adjustable strabismus surgery|Adjustable surgery will be done using sliding nose technique using fornix approach
224075619|NCT02189135|DEVICE|Telemedicine|The glucometer acts by automatically uploading any glucose readings to an online portal. A summary of the patient's glycaemic and metabolic control, self-management skills as well as compliance to other key measures such as eye examination, screening for microvascular complications would also be provided if available. All patients in this intervention arm would be given a system-driven guidance on when to test their blood glucose based on their disease status, medication regimen, and time of poorest control so that the most useful, patient specific blood profile can be created and used for future self-management coaching for patient
224075620|NCT04307108|DEVICE|Magic Glass|MAGIC-GLASS is a VR-based home system for stroke rehabilitation, developed by Ulster University (UK) in collaboration with Tech4Care srl (Italy) and miThings AB (Sweden) in the context of the EU-funded Project Magic (grant agreement No 687228). It includes a number of mini-games grounded on rehabilitation paradigms such as mirror therapy \[29\] and can adapt to the capability of a person. In addition, the games will include an automatic coaching system for giving feedback both on rehabilitation results (e.g. achievement of exercise goals) and performance (during the exercise itself, the system will give real time advice on the execution of the exercise).
224075621|NCT02634723|BIOLOGICAL|Octocog alfa (recombinant human coagulation factor VIII)|
224075622|NCT04925752|DRUG|Oral Lenacapavir (LEN)|Tablets administered orally without regard to food
224075623|NCT04925752|DRUG|F/TDF|Tablets administered orally
224075624|NCT04925752|DRUG|Sub-cutaneous (SC) Lenacapavir (LEN)|Administered via SC injections
224075625|NCT04925752|DRUG|Placebo SC LEN|Administered via SC injections
224075626|NCT04925752|DRUG|PTM F/TDF|Tablets administered orally
224075627|NCT04925752|DRUG|PTM Oral LEN|Tablets administered orally
224075628|NCT04925752|DRUG|F/TAF (for US participants only)|F/TAF tablets administered orally once daily
224075629|NCT02238444|DRUG|Warfarin|From postoperative day 3, patients will receive oral Warfarin 2.5mg qd with titration of dose to maintain a target INR of 2-3 for 1 year.
224075630|NCT02238444|DRUG|Dipyridamole|From postoperative day 3, patients will receive oral dipyridamole 25mg tid for three months.
224075631|NCT02238444|DRUG|Aspirin|From postoperative day 3, patients will receive oral Aspirin Enterie Ccoated Tablets 100mg qd for 1 year.
224075632|NCT02238444|DRUG|Low Molecular Weight Heparin|From postoperative day 3, Patients will receive subcutaneous injection of Low Molecular Weight Heparin (4100 IU) once daily for first five days.
224075633|NCT00373204|DRUG|Motexafin Gadolinium|"On Day 1 of each 3 week cycle for up to 12 cycles:~MGd 10 mg/kg infused over approximately 30 to 60 minutes, followed ≥ 30 minutes later by Docetaxel 75 mg/m2 administered IV over approximately 1 hour."
224075634|NCT04581980|OTHER|Exercise|Participants will exercise on a cycle ergometer
224075635|NCT06050044|DRUG|Group A (hyperbaric bupivacaine)|Patients were injected intrathecally with 20 mg hyperbaric bupivacaine 0.5% solution
224075636|NCT06050044|DRUG|Group B (Mixture of Hyperbaric and Isobaric Bupivacaine)|Patients received 10 mg hyperbaric bupivacaine and 10 mg isobaric bupivacaine 0,5 % solution
224075637|NCT02163174|DRUG|Pentoxifylline (PTX)|Patients were randomly assigned to receive intravenous Pentoxifylline 5 mg/kg/hr for 6 hours on 6 successive days in addition to antibiotics
224075638|NCT02163174|DRUG|Placebo|Patients were randomly assigned to receive intravenous normal saline 5 mg/kg/hr for 6 hours on 6 successive days as a placebo in addition to antibiotics.
224075639|NCT00782769|DRUG|Oxybutinyn Vaginal Ring 4mg|
224075640|NCT00782769|DRUG|Oxybutinyn Vaginal Ring 6mg|
224075641|NCT00921700|DRUG|Ibuprofen + Paracetamol|Single oral dose of ibuprofen 400 mg combined with paracetamol (acetaminophen) 1000 mg in gelatine capsules
224075642|NCT00921700|DRUG|Ibuprofen + Paracetamol + Codeine|Single oral dose of ibuprofen 400 mg combined with paracetamol (acetaminophen) 1000 mg and codeine 60 mg in gelatine capsules
224075643|NCT00921700|DRUG|Paracetamol + Codeine|Single oral dose of paracetamol (acetaminophen) 1000 mg combined with codeine 60 mg in gelatine capsules
224075644|NCT00921700|DRUG|Placebo|Single oral dose of lactose as placebo in gelatine capsules
224075645|NCT03467958|DRUG|Ozanimod|Specified dose on specified days
224313163|NCT06977490|DRUG|Amphotericin B Liposome for Injection (strength: 50 mg, Sichuan Huiyu Pharmaceutical Co., Ltd.)|Single intravenous administration of 3.0 mg/kg in each period.
224313164|NCT06977490|DRUG|Amphotericin B Liposome for Injection (trade name: Ambisome®, strength: 50 mg, MAH: Gilead Sciences)|Single intravenous administration of 3.0 mg/kg in each period.
224313165|NCT06983860|PROCEDURE|Application and demonstration of endoscope-assisted low-temperature plasma radiofrequency ablation resection of tonsils|Low temperature plasma radiofofency ablation of tonsil under 70° nasal endoscope can directly view the lesion area on the monitor, clearly enlarge the operating field, and has the advantages of small surgical trauma, good hemostatic effect, light postoperative pain, low probability of postoperative bleeding and quick postoperative recovery of patients, etc. It is a good surgical mode integrating surgery and teaching, and has brought great benefits to patients, and is worth promoting and applying.
223511354|NCT03807167|OTHER|Unified Parkinson 's Disease Rating Scale-III|This scale is used to rate the severity of extra-pyramidal symptoms (akinesia, rigidity and tremors). These symptoms may be the cause of reduction of motor activity apart from any reduction in motivation, they onstitute a confounding factor that it should be controlled.
223511355|NCT03807167|OTHER|Mini Neuropsychiatric Investigation|This is a structured interview that allows rapid screening in about 20 minutes of troubles Psychiatric. It is based on short questions to which the patient must answer yes or no and on a decision tree. Patients must validate clinical diagnoses of depression.
224075646|NCT02692209|DEVICE|FFDM Plus DBT|"FFDM + DBT Images~FujiFilm Aspire Cristalle System"
224075647|NCT02692209|DEVICE|FFDM Alone|FFDM Alone Images
224075648|NCT00866307|DRUG|Cyclophosphamide|Given IV
224075649|NCT00866307|DRUG|Cytarabine|Given IT and IV or SC
224075650|NCT00866307|DRUG|Daunorubicin Hydrochloride|Given IV
224075651|NCT00866307|DRUG|Dexamethasone|Given IV
224075652|NCT00866307|DRUG|Doxorubicin Hydrochloride|Given IV
224075653|NCT00866307|OTHER|Laboratory Biomarker Analysis|Correlative studies
224075654|NCT00866307|DRUG|Mercaptopurine|Given PO
224075655|NCT00866307|DRUG|Methotrexate|Given IT and PO
224075656|NCT00866307|DRUG|Pegaspargase|Given IV
224075657|NCT00866307|DRUG|Prednisone|Given IV or PO
224075658|NCT00866307|RADIATION|Prophylactic Cranial Irradiation|Undergo radiation
224075659|NCT00866307|DRUG|Thioguanine|Given PO
224075660|NCT00866307|DRUG|Vincristine Sulfate|Given IV
224075661|NCT04793256|DEVICE|Fluoride varnish (3M Clinpro White Varnish 5% sodium fluoride).|5% sodium fluoride Varnish is a fluoride varnish which is applied to tooth surfaces
224075662|NCT04793256|DEVICE|Resin based fissure sealant (3M Clinpro Sealant)|teeth will be isolated with cotton rolls and saliva ejector than etching for pits and fissure sealant
224075663|NCT03726164|DEVICE|Remote Conditioning|A Blood pressure cuff will be placed on the arm and inflated to 200mm hg for 5 minutes, and then deflated for 5 minutes, a cycle repeated 3 times.
224075664|NCT03726164|DEVICE|Sham protocol|An un-inflated blood pressure cuff will be placed on the arm for 20 minutes.
224075665|NCT02286947|DRUG|Eteplirsen|Eteplirsen solution for IV infusion
224075666|NCT00500526|OTHER|Singing practice|
224075667|NCT00500526|OTHER|Singing classes|
224075668|NCT00500526|OTHER|Hand craft classes|
224075669|NCT02108431|DEVICE|balloon catheter for suprapubic bladder-drainage|suprapubic tube removal was allowed when the anastomosis was watertight, Day 5
224075670|NCT02108431|DEVICE|balloon catheter for transurethral bladder-drainage|transurethral catheter withdrawal was allowed when the anastomosis was watertight, Day 5
224075671|NCT03308396|DRUG|Guadecitabine|Days 1-5 Dose 0: 60 mg/m\^2 Dose -1: 45 mg/m\^2
224075672|NCT03308396|DRUG|Durvalumab|Day 8 Durvalumab (1500 mg IV)
224075673|NCT00361595|DRUG|zoledronic acid|5 mg zoledronic acid administered in a single 15 minute IV
224075674|NCT05654129|OTHER|saliva samples|saliva samples (non-invasive, in the sites evaluated during the partial survey) will be perform by one of the investigators .
224075675|NCT05654129|OTHER|medical questionnaire|a complete medical questionnaire will be carried out (general, lifestyle and quality of life) will be perform by one of the investigators .
224075676|NCT03528512|DRUG|Ketamine|Intranasal ketamine 3mg/kg (max 100 mg) + saline 0.03 ml/kg (max 2ml)
224075677|NCT03528512|DRUG|Midazolam and fentanyl|Intranasal midazolam 0.3 mg/kg (max 10 mg) + fentanyl 1.5mcg/kg (max 100 mcg)
224075678|NCT02689830|DEVICE|Bead Block|Prostate embolization
224075679|NCT03790280|DIAGNOSTIC_TEST|HFO analysis|We hypothesize that the strategy of incorporating HFO data to a standard ECoG-guided resection in pediatric epilepsy surgery will result in improved postoperative seizure outcome than the traditional approach.
224075680|NCT02797886|OTHER|FES + VOL|Electrical stimulation is applied in concert with the subject's volitional movement.
224075681|NCT02797886|OTHER|FES|Electrical stimulation is applied to the subject while they are asked to do nothing.
224075682|NCT02797886|OTHER|VOL|The subject initiates and completes the movement without electrical stimulation.
224075683|NCT00164294|BEHAVIORAL|Brief intervention|
224075684|NCT01147146|DRUG|propofol, fentanyl, atracurium|general anesthesia
224075685|NCT01147146|DRUG|bupivacaine|spinal anesthesia
224075686|NCT01147146|DRUG|bupivacaine, Midazolam|spinal anesthesia \& sedation
224075687|NCT01918670|PROCEDURE|catheter ablation of atrial fibrillation|electric pulmonary vein disconnection
224075688|NCT00002693|BIOLOGICAL|filgrastim|
224075689|NCT00002693|DRUG|carboplatin|
224075690|NCT00002693|DRUG|topotecan hydrochloride|
224075691|NCT01353742|DRUG|Lamivudine|100mg tablet
224075692|NCT01353742|DRUG|Adefovir dipivoxil|10mg tablet
224075693|NCT01353742|DRUG|Fixed dose combination (Lamivudine and Adefovir dipivoxil)|100mg/10mg capsule
224075694|NCT04490837|DIAGNOSTIC_TEST|ELISA and Rapid test to detect antibodies against COVID-19|Ycovid-19 aims to be a rapid diagnostic test for SARS-CoV-2 infection, which will allow a reliable diagnosis to be made in 10 minutes, and on easy-to-use devices
224313166|NCT06981910|BEHAVIORAL|Psychoeducation program|Each psychoeducation session included informational components, a preliminary group discussion of the topic, structured education on the discussed topic, awareness-raising activities within the group, opportunities for sharing, and emotional support. When participants' attention waned during sessions, breathing exercises were introduced. Depending on the group's preference, sessions concluded with a 2-3-minute poetry listening session and/or breathing exercises. At the end of each session, educational booklets prepared specifically for that session were distributed to the participants.
224313167|NCT06982040|DRUG|NTQ5082 capsules 100 mg|NTQ5082 capsules 100 mg
224313168|NCT06982040|DRUG|NTQ5082 capsules 200 mg|NTQ5082 capsules 200 mg
224313169|NCT06982040|DRUG|NTQ5082 capsules 300 mg|NTQ5082 capsules 300 mg
224313170|NCT06982040|DRUG|Placebo|Placebo
224313171|NCT06982339|OTHER|Air Conditioner|Air conditioners will be window-mounted units powered by 110v AC.
224313172|NCT06982339|OTHER|Electricity subsidy|Electricity subsidies will consist of a single block subsidy of USD 100, intended to provide support for the electricity costs associated with operating an air conditioning unit.
224313173|NCT06982989|DEVICE|use LED to treat pelvic pain|Use led to treat pelvic pain
224313174|NCT06983834|BEHAVIORAL|Psychoeducation|Mindfulness Based Psychoeducation
224313175|NCT06983652|DEVICE|THz scanning using THz Imaging system.|The THz scanning system is non-invasive and non-contact. It is a prototype developed by Institute of Materials Research and Engineering (IMRE), A\*STAR, Singapore and is performed for the purpose of research. THz scanning will provide safety data in human and the measurement of cornea hydration status. Each THz scan will take approximately 1 second. Real-time data will be generated when participants are positioned in front of the device.
224313176|NCT06983132|DIAGNOSTIC_TEST|Cerebral imaging (MRI) according to a dedicated protocol with central MRI reading|Cerebral MRI according to dedicated protocol, central MRI reading.
224313177|NCT06983132|DIAGNOSTIC_TEST|Determination of circulating biomarkers|High-throughput molecular analysis will be performed on plasma samples collected assessing a selected panel of biomarkers, associated with endothelial cell profiles using automated and high-throughput ELISA. The interactions between mutation profile, protein biomarkers, and clinical variables will be correlated with patients' outcomes.
224313178|NCT06983951|GENETIC|BCMA CART|"The cell product used in this study is a targeted BCMA autologous CART cell injection.~Research drug name: Targeted BCMA Autologous CART Cell Injection Drug code: BJBR-BCMA-006 Administration method: single intravenous injection"
224313179|NCT06804876|DEVICE|the COMBO Endoscopy Oropharyngeal Airway|Using the COMBO Endoscopy Oropharyngeal Airway for oxygenation.
224313180|NCT06982326|OTHER|MF+|During the MF+ session, before each physical testing phase, participants completed a 30-min Colour Word Stroop task (CST) to trigger MF. The paper-based version of the CST was completed in quiet rooms following the same protocol as in previous studies. This prolonged cognitive task was reported to require sustained attention and automatic response inhibition and effectively induced MF through cognitive manipulation. ThyIt had ben Four colour words (red, blue, green and yellow) were randomly printed and participants were asked to verbalise the colour of each word.
223511356|NCT03807167|OTHER|Montgomery and Asberg depression Rating Scale|This scale is composed of 10 items from 0 to 6 from a semi-structured interview, to obtain a total depression score of 0 to 60 (0 no depression, 60 maximum intensity of depression).
224313181|NCT06982326|OTHER|MF-|During the control session, before each physical testing phase, participants watched emotionally neutral documentaries for 30 min.
224313182|NCT06982534|BIOLOGICAL|UTAA91 injection|CAR-modified gamma delta T cells
224313183|NCT06981858|DRUG|Enlonstobart Injection|Sequential Enlonstobart Injection with concurrent chemoradiotherapy
224313184|NCT06982391|BEHAVIORAL|Resilience-Focused Acceptance and Commitment Therapy (ReACT) Program|The Resilience-Focused Acceptance and Commitment Therapy (ReACT) program is a structured, group-based psychological intervention specifically designed for women who have undergone mastectomy following breast cancer. The program consists of three weekly 90-minute sessions integrating core ACT processes, including acceptance, defusion, mindfulness, values clarification, and committed action, with an emphasis on building psychological resilience, self-compassion, and enhancing perceived social support. The program uniquely combines evidence-based ACT techniques with group exercises focused on post-cancer psychosocial adjustment.
224313185|NCT06982391|OTHER|No intervention|Standard Care
224313186|NCT06983236|BEHAVIORAL|AI-enabled patient education material|Students in the intervention group will be asked to prepare patient education material for a patient using an artificial intelligence (AI) tool on 'infection care'. First, the intervention group will receive 2 hours of training on artificial intelligence. This training will take place in a classroom environment with internet access. All students in the intervention group will be trained at the same time and their questions will be answered. The students will not receive any additional counselling after the training. It will be explained to the students in the intervention group that they will first have to prepare the educational material using the AI tool and that they can use support tools such as books, magazines and websites while preparing the educational material. Students will be given five days and will be asked to submit their patient education materials at the end of the five days and will be asked to complete the patient education information form.
224313187|NCT06983236|BEHAVIORAL|Traditional patient education material|"Students in the control group will be interviewed and asked to prepare a patient education material about infection care for a patient. Students will be informed that they can use additional tools such as books, magazines, and websites to prepare educational materials. Students will be given five days and at the end of the five days, they will be asked to submit their patient education materials and fill out the Patient Education Information Form. Students will be asked to write down the references they used in detail and include direct links to the websites of the Internet resources."
224313188|NCT06982612|OTHER|Hot environment|Participants exercising in a 36 degrees celsius environment
224313189|NCT06982612|OTHER|Temperate condition|Participants exercising in a 18 degrees celsius environment
223511357|NCT03807167|OTHER|Clinical Global Impression|heterosexual assessment that rates the severity of symptoms suicidal and changes in suicidal symptoms. Any subject with a score greater than 4 is not included.
224313190|NCT06981897|BEHAVIORAL|early cognitive therapy program in addition to selected physical therapy program (positioning, chest care exercise).|"A.Positioning for head injury patients~B.Chest clearance intervention~C.Procedure for cognitive therapy All these exercises are given to patients even when they are on ventilator support of around 20-30 minutes six days /week .~1. coma stimulation incorporated with cognition training such as : i. Multimodal Sensory stimulation, including :~   1. Visual~  2. Auditory~  3. Olfactory~  4. Gustatory~  5. Tactile- Administered by rubbing different textures like satin, silk, fur, smooth metal, sandpaper, or cool or warm items over the patient's body surfaces.~   ii. Calling out their names, using patient's relatives help for transferring were used for improving the cognition and conscious levels.~2. Kinesthetic Stimulation~   1. Passive movements~  2. Joint approximation Each movement two times, allowing 1 minute to respond. This will be performed either in bed or in the wheelchair, one extremity at a time."
224313191|NCT06981897|BEHAVIORAL|selected physical therapy program (Chest care exercise, passive movement of the four limbs) in addition to early cognitive therapy program|"The patient was placed in a comfortable position with a head-up position Passive range of movement for all four limbs \& positioning for head injury patients,. Joint approximation and Chest clearance intervention and Procedure for cognitive therapy~Multimodal Sensory stimulation, including :~Visual Auditory- Olfactory-. Gustatory- Tactile- Calling out their names, using patients relative help for transferring were used for improving the cognition and conscious levels."
224313192|NCT06981897|BEHAVIORAL|Control group|The patient was placed in a comfortable position with a head-up position , Passive range of movement for all four limbs and positioning for head injury patients,. Joint approximation and Chest clearance intervention
224313193|NCT00866190|DRUG|SQ109|SQ109 150 mg is an oval, coated, white, scored tablet. Dosages: 75 mg administered once daily for 14 days; 150 mg administered once daily on Days 1-5, 9, and 14; and 150 mg administered once daily for 14 days.
224313194|NCT00866190|DRUG|Placebo|Placebo is an oval, coated, white, scored tablet administered once daily for 14 days or on Days 1-5, 9, and 14.
224203881|NCT04350073|DEVICE|Multifrequency Bioimpedance Spectroscopy|COVID-19 ICU patients will have body composition and phase angle measured using Multifrequency Bioimpedance Spectroscopy. These measurements will take place every other day while the patients are in the ICU. Then they will occur a minimum of 3 times a week until discharge.
224203882|NCT01581073|DRUG|Darbepoetin alfa|Darbepoetin alfa is used for targeting Hb level of 11-13g/dL in high Hb group, and 9-11g/dL in low Hb group.
224203883|NCT00315328|DRUG|Atropine|Atropine 1% each weekend day in the sound eye
224203884|NCT00315328|DEVICE|Patching|Patching 2 hours per day
224313195|NCT01163630|DRUG|esomeprazole/ASA Fixed Dose Combination (FDC)|esomeprazole 20 mg/ASA 81 mg oral capsule
224313196|NCT00491140|GENETIC|Gene mutations analysis and FISH|FISH and mutation analysis of multiple genes
224313197|NCT03045991|BEHAVIORAL|aerobic exercise training|The aerobic exercise program using progressive resistive stationary bicycle training which will contain warm-up, resistive physical exercise, and cool-down. The training resistance will increase with improvement of participants' performance.
224203885|NCT00315328|PROCEDURE|Near activities|near visual activities for at least one hour per day
224203886|NCT00753909|DRUG|Carboplatin|Carboplatin (IV) 3 AUC on day 1 and day 15 every 4 weeks for 6 cycles
224203887|NCT00753909|DRUG|Bevacizumab|Bevacizumab (IV) 10 mg/kg on day 1 and day 15 every 4 weeks for 6 cycles Followed by Bevacizumab (IV) 15 mgr/Kgr on day 1 every 3 weeks until disease progression
224203888|NCT00753909|DRUG|Paclitaxel|Paclitaxel (IV) 140 mg/m2,on day 1 and day 15 every 4 weeks for 6 cycles
224313198|NCT03045991|BEHAVIORAL|control training|The control training program will receive 30 minutes non-aerobic exercise training, including stretching muscle skills, joint mobility exercises; in addition to one 30-minute session of unstructured mental activities, such as reading books or reading educational films.
224313199|NCT03045991|BEHAVIORAL|cognitive training|The computerized cognitive training program will be implemented with the brainHQ to target abilities of visuospatial processing, attention, memory, and executive function. The level of the training program will become more difficult with progress in participants' targeted cognitive abilities.
224313200|NCT04249544|DRUG|Pramipexole|1mg of pramipexole
224203889|NCT03603405|DRUG|ADV/HSV-tk (gene therapy)|The investigational adenovirus gene therapy injected at tumor site followed by valacyclovir, radiotherapy, and chemotherapy
224313201|NCT04249544|DRUG|Placebo|1mg equivalent of placebo
224313202|NCT00896480|BIOLOGICAL|Immunotherapeutic GSK2132231A|Administration by intramuscular injection
224313203|NCT06284447|OTHER|Non-Interventional Study|Non interventional study
223511358|NCT03807167|OTHER|Apathy diagnostic criteria|The clinical criteria make it possible to make a diagnosis of apathy with a functional repercussion. It is based on a lack of motivation felt by the patient, causing a functional or social impact that is not the consequence of a disturbance of consciousness or a disability engine. The cognitive, emotional and behavioral dimensions are affected.
224203890|NCT03478345|BEHAVIORAL|endocrine disruptor chemical reduction intervention|Participants will take part in a 4-week intervention consisting of a modified (shortened) version of the Diabetes Prevention Program diet and physical activity group education program, with instructions to reduce endocrine disruptor chemical exposure through changes in food handling and personal care products.
224203891|NCT02139930|BEHAVIORAL|Normal Nicotine Control Group|Participants will smoke experimental cigarettes for a period of 20-weeks.
224203892|NCT02139930|BEHAVIORAL|Immediate Nicotine Reduction Group|Participants will smoke experimental cigarettes for a period of 20-weeks.
224203893|NCT02139930|BEHAVIORAL|Gradual Nicotine Reduction Group|Participants will smoke experimental cigarettes for a period of 20-weeks.
224203894|NCT00479739|DRUG|Salmeterol/fluticasone propionate or formoterol/budesonide|
224203895|NCT04871724|DRUG|EDP-938|Subjects will receive EDP-938 once daily on Days 1 and 14
224203896|NCT04871724|DRUG|Fluconazole|Subjects will receive fluconazole once daily on Days 5 to 18
224203897|NCT01950195|PROCEDURE|Stereotactic Radiosurgery (SRS)|
224203898|NCT01950195|BIOLOGICAL|Ipilimumab|
224203899|NCT01424618|DRUG|Leuprolide|leuprolide 10 units daily, decreased to 5 units daily once suppression achieved for a total of approximately 4 weeks. Once suppression achieved, estradiol and progesterone administered to mature uterine lining.
224203900|NCT01424618|DRUG|Ganirelix|Ganirelix 250 mcg daily will be used to suppress pituitary-ovarian function and is administered concurrently with estradiol and progesterone for approximately two weeks.
224203901|NCT04201418|DRUG|Patisiran|Patisiran-lipid complex injection, for intravenous use
223511359|NCT03807167|OTHER|walking speed test|The patient is timed to walk 10m. A speed \<1m / sec is a criterion exclusion because it shows severe sarcopenia and constitutes a bias.
224203902|NCT06346600|GENETIC|SKG0106|Non-interventional (observational) study, long-term follow-up safety and efficacy assessments up to 5 years post SKG0106 injection.
224203903|NCT06541236|PROCEDURE|Alveolar Ridge Preservation After Tooth Extraction Using Autologous Dentin Matrix|Incorporation of various bone grafting materials for alveolar ridge preservation
223511360|NCT03807167|OTHER|accelerometer presentation|accelerometer presentation and pose
223511361|NCT03807167|OTHER|data acquisition from the accelerometer|withdrawal of the accelerometer and data acquisition from the accelerometer
223511362|NCT03807167|OTHER|Apathy Evaluation Scale,|clinician version and near-helping version. It's a hetero rating scale from an interview semi structured by a trained clinician. It assesses cognitive, emotional and behavioral apathy than three items of various apathy. The total score ranges from 18 (total absence of apathy) to 72.
224203904|NCT02587000|DRUG|Ulipristal acetate|
224203905|NCT02587000|DRUG|Placebo|
224203906|NCT00153868|BIOLOGICAL|darbepoetin alfa|The allocation to the treatment arms will be dependent on the schedule of chemotherapy (i.e. weekly, every 2 week, or every 4 week chemotherapy schedules will receive a starting dose of 200 mcg darbepoetin alfa and every 3 week chemotherapy schedule will receive a starting dose of 300 mcg). Non-responders are defined as patients who experience \<1.0 g/dL increase in hemoglobin concentrations after 6 weeks. Darbepoetin alfa will be held for hemoglobin concentrations \>13.0 g/dL.
224203907|NCT05673369|DRUG|CKD-387|1 Tablet
224203908|NCT05673369|DRUG|D484|1 Tablet
224203909|NCT00949572|BIOLOGICAL|Human Papillomavirus 6,11,16,18 Vaccine Recombinant alum ads|1 intramuscular dose (0.5 ml) on month 0, 1 and 4 containing approximately: Human Papillomavirus Type 6 L1 protein 20 micrograms Human Papillomavirus Type 11 L1 protein 40 micrograms Human Papillomavirus Type 16 L1 protein 40 micrograms Human Papillomavirus Type 18 L1 protein 20 micrograms
224203910|NCT00949572|BIOLOGICAL|Human Papillomavirus 6,11,16,18 Vaccine Recombinant alum ads|1 sublingual application on month 0, 1 and 4 of 0.5 ml containing approximately: Human Papillomavirus Type 6 L1 protein 20 micrograms Human Papillomavirus Type 11 L1 protein 40 micrograms Human Papillomavirus Type 16 L1 protein 40 micrograms Human Papillomavirus Type 18 L1 protein 20 micrograms
224203911|NCT05587517|BEHAVIORAL|EMPOWER|"EMPOWER is a manualized treatment delivered based in cognitive behavioral and acceptance and commitment therapies delivered by a trained mental health professional that utilizes breathing and grounding exercises, mindfulness meditation, psychoeducation, imaginal dialogue with the patient, and coping rehearsal techniques.~The total amount of time EMPOWER intervention is about 90 minutes, about 15 minutes each module. It can either be administered in one session or many sessions to accommodate the dynamic nature of ICU, and has two booster follow-up calls (roughly 45 minutes each) in the month following initial treatment."
224203912|NCT05587517|OTHER|Supportive Conversation|The Supportive Conversation will match the time and attention offered through EMPOWER, so will be about 1.5-2 hours and will have two additional follow-up calls.
224203913|NCT00717158|BEHAVIORAL|Usual medical care|
224203914|NCT00717158|BEHAVIORAL|Lifestyle Case management|Intervention participants were assigned to one registered dietitian who they met with over a one year period for 6 session (four hours) of individual care, 6- one-hour group classes, and had monthly email contact for follow up and checking in
224203915|NCT01304563|BIOLOGICAL|TIV 2010/2011 influenza vaccine|TIV 2010/2011 influenza vaccine Intramuscular: 15 mcg TIV 2010/2011 vaccine x 1: Control
223511363|NCT03807167|OTHER|fatigue Visual Analog Scale|To date, there is no valid fatigue scale in the depression of the elderly subject, a fortiori in French. The fatigue scale in adult depression includes has been validated with an EVA (Visual Analogue Scale) (38). We therefore propose to use this type of evaluation to control this aspect.
223511364|NCT03807167|OTHER|executive function|"* Modified Card Sorting Test MCST(Modified Card Sorting Test) (Wisconsin Test): This test assesses conceptualization, attention and mental flexibility using a deck of cards.~* Trail Making Test (TMT): This test is used to assess mental flexibility.~* Fluences verbal: This test tests the capacities of setting up search strategies in memory semantics and oral language.~* Stroop Paradigm: This test is used to evaluate the resistance to interference, ie the patient's ability to inhibit some over-learned and automated responses."
224203916|NCT01304563|BIOLOGICAL|TIV 2010/2011 influenza vaccine|Low dose TIV 2010/2011 influenza vaccine delivered via intradermal injection x 1: Experimental
224203917|NCT01304563|BIOLOGICAL|TIV 2010/2011 influenza vaccine|Higher lower dose TIV 2010/2011 influenza vaccine delivered via intradermal injection x 1: Experimental
224203918|NCT01304563|BIOLOGICAL|INT|Low dose TIV 2010/2011 influenza vaccine delivered via a short needle intradermal device x 1: Experimental
224203919|NCT03906786|BEHAVIORAL|motivational interviewing|The intervention will consist of 4 structured medical consultations in the form of a motivational interviewing compared to usual care, covering a 12-month intervention period. In both groups, the frequency of visits (c / 3 months) and the variables collected will be the same.
224203920|NCT00869141|DRUG|glaucoma medications (Timolol, Brimonidine, Dorzolamide, Brinzolamide)|Subjects may receive glaucoma medications after Ahmed valve implantation
224203921|NCT01954784|DRUG|fludarabine phosphate|
223511365|NCT03807167|OTHER|MRI|An MRI lasting 30 minutes is programmed
224203922|NCT01954784|RADIATION|total-body irradiation|Undergo TBI
224203923|NCT01954784|PROCEDURE|nonmyeloablative allogeneic hematopoietic stem cell transplantation|Undergo nonmyeloablative allogeneic hematopoietic SCT
224203924|NCT01954784|DRUG|cyclosporine|Given PO
224203925|NCT01954784|DRUG|mycophenolate mofetil|Given PO
224203926|NCT01954784|DRUG|bortezomib|Given SC
224203927|NCT01954784|DRUG|lenalidomide|Given PO
224203928|NCT01954784|OTHER|laboratory biomarker analysis|Correlative studies
224203929|NCT06540755|GENETIC|genetic polymorphism analysis|Genotype for IL-6 rs1800795 and PAPP-A rs7020782 polymorphisms were determined using real-time polymerase chain reaction with allele-specific probes.
224203930|NCT00212810|DRUG|Topiramate|
224313204|NCT05604456|PROCEDURE|secondary ear reconstruction based on Nagata method|Secondary auricular reconstructions based on Nagata method were conducted on patients who sought for secondary revision.
224313205|NCT03734315|DEVICE|Ostenil®|Ostenil® is a CE-certified viscoelastic solution for injection into the joint cavity, containing 1.0 % sodium hyaluronate from fermentation.
224313206|NCT06662227|BIOLOGICAL|Single dose injection of certain dose of UWD-19|Eligible participants will undergo FC lymphodepleting chemotherapy preconditioning after signing an informed consent form, followed by a one-time injection of certain dose of universal UWD-19 cells
224313207|NCT02898753|DRUG|VAL-1221|VAL-1221 3, 10, or 30 mg/kg as per the dose and schedule specified in the arm group description
224313208|NCT02898753|DRUG|RhGAA|Active comparator
224313209|NCT00642278|DRUG|Canagliflozin (JNJ-28431754)|One 50 mg, 100 mg, 200 mg, or 300 mg over-encapsulated tablet orally (by mouth) once daily for 12 weeks or one 300 mg over-encapsulated tablet orally twice daily for 12 weeks.
224313210|NCT00642278|DRUG|Sitagliptin|One 100 mg over-encapsulated tablet orally (by mouth) once daily for 12 weeks.
223511366|NCT03807167|OTHER|Apathy Motivation Index|"This is a self-questionnaire of 18 items, each side on a 5-level Likert scale (0: not everything at 4: very often). It differentiates between behavioral apathy and social apathy.~Emotional."
224203931|NCT04896723|DIAGNOSTIC_TEST|Sexual function questionnaire|Sexual function questionnaire and cognitive screening assessments
224203932|NCT01614808|OTHER|laboratory biomarker analysis|Correlative studies
223511367|NCT05516407|DRUG|FEN164|Oil based. Full-spectrum medicinal cannabis plant extract with less than 0.08% THC.
224203933|NCT03390452|BEHAVIORAL|Mobile Phone Messaging|"Parents of primary school children will receive Mobile Phone Messages regarding their children's oral hygiene maintenance and their positive dietary habits."
224203934|NCT05947799|OTHER|Baseline questionnaires|Questionnaires asking about the participant's familiarity with heart failure medication and management before watching/reading the educational modules.
224203935|NCT05947799|OTHER|Post-questionnaire|Questionnaires asking about the participant's familiarity with heart failure medication and management after watching/reading the educational modules.
224203936|NCT04253756|DEVICE|20-gauge BD Nexiva Diffusics|The BD Nexiva Diffusics catheters are suitable for use with power injectors when a direct connection is made.
223511368|NCT00225602|BEHAVIORAL|Assertive Community Treatment|
224203937|NCT04861415|RADIATION|Sterotactic Body Radiotherapy|Hypofractionated stereotactic radiation treatment.
224203938|NCT04861415|RADIATION|Conventionally Fractionated Radiation|External beam radiation therapy treatment
224203939|NCT01910597|DRUG|SBG|
224203940|NCT02561013|DEVICE|3M™ Coban™ Custom Fit Compression System|"3M Coban™ Fit is a compression system that consists of two components: 1. A Compression Stocking and 2. Coban™ Fit Sleeve.~The stocking provides compression to the foot and improves wearing comfort in the calf area under the sleeve. The compression sleeve is intended to provide the therapeutic compression to the calf, with the initial fitting to be done by a health-care professional. The compression sleeve is customized according to the anatomy of the patient's leg; both components are designed to be used together."
224313211|NCT00642278|DRUG|Placebo|One matching placebo capsule orally (by mouth) once or twice daily for 12 weeks.
224313212|NCT00006043|DRUG|temozolomide|
224313213|NCT02635113|DEVICE|Gait Synchronized Vibration System|A wearable vibratory shoe that delivers stimulus to the soles that is synchronized with step resulting in improved gait.The shoe consists of two externally mounted vibration units (tactors). The vibration units allow for variation of both frequency and amplitude of stimulation independently. Using the pressure sensors and timing data, gait velocity, cadence, swing time, stance phase and double support time will be analyzed to assess features of their gait performance during the Dynamic Gait Index with and without vibratory stimuli.
224313214|NCT00090363|DRUG|ZD4054 15 mg|15 mg oral tablet once daily
224313215|NCT00090363|DRUG|Placebo|
224313216|NCT00090363|DRUG|ZD4054 10 mg|10mg oral tablet once daily
224313217|NCT06190418|OTHER|Loaded sit to stand strengthening exercise|This Group will be given with the wieghted vest equal to that of 1RM for each child and Sit-to-Stand Strengthening Excerise will be given 3 times per week for 6 weeks
224313218|NCT06190418|OTHER|Unloaded sit to stand strengthening exercise|This Group will be given with the Sit-to-Stand Strengthening Excerise without any external load for 3 times per week for 6 weeks
224313219|NCT03580486|OTHER|The squares test|The squares test (ST) originally used in handedness is modified. The ST is a reliable, not time-consuming and easy to administer test for evaluated hand function.
224313220|NCT01802450|DRUG|Dasatinib|
223511369|NCT00225602|BEHAVIORAL|Treatment in Community Mental Health Center|
224075695|NCT03711643|PROCEDURE|Periprostatic nerve block|4 injections of 2 cc of lidocaine for a Periprostatic nerve block
224075696|NCT03711643|DEVICE|hypnosis mask|"The mask HYPNOS pro stimulates the imagination of the user by means of 6 diodes among 3 by eye.~Just before the introduction of ultrasound probe, the patient put the hypnotic mask and choose a session.Twenty minutes after the removal of the probe, an healthworker assess the painful patient with the visual analogue scale VAS, after this the patient fulfill the STATE- TRAIT Anxiety Inventory (STAI) form Y-A."
224075697|NCT02067039|DEVICE|OraQuick in home & Sure Check HIV tests|Provision of OraQuick in home \& Sure Check HIV tests
224075698|NCT01972074|DRUG|Memantine|Capsule
224075699|NCT01972074|OTHER|Placebo|Capsule
224075700|NCT06507163|OTHER|The post-surgical breathing exercise group|Individuals in the Intervention-1 group were asked to perform 10 breathing exercises with IS every waking hour in addition to the routine practices of the clinic for 5 days in the postoperative period.
224313221|NCT03713619|DRUG|secukinumab|Secukinumab 300mg every 2 or every 4 weeks
224313222|NCT03713619|DRUG|Placebo|Placebo 300mg every 2 or every 4 weeks
224313223|NCT01069874|DIETARY_SUPPLEMENT|Cholecalciferol (Vitamin D/Vigantol oil)|Cholecalciferol will be administered as 2-monthly oral bolus doses of Vigantol oil over a period of one year
224313224|NCT01069874|DIETARY_SUPPLEMENT|Miglyol oil|Miglyol oil will be administered as 2-monthly oral bolus doses of Miglyol oil over a period of one year
224313225|NCT00700297|DRUG|Colchicine|100 mg Colchicine per day for 4 months
224313226|NCT00700297|DRUG|Placebo|One tablet placebo per day for 4 months
224313227|NCT02012348|OTHER|Antibacterial soap with triclocarban|
224313228|NCT02012348|OTHER|Antibacterial soap + benzalkonium chloride|
224313229|NCT02012348|OTHER|Control soap|
224313230|NCT06060067|BIOLOGICAL|TDV|TDV SC injection on Day 1 and Day 90 of the study
224313231|NCT06060067|BIOLOGICAL|Placebo|Normal Saline (0.9% NaCl) SC injection on Day 1 and Day 90 of the study
224313232|NCT06982079|DRUG|Dapagliflozin 10 mg|Dapagliflozin 10 mg will be added in addition to standard of care
223511370|NCT01570582|DRUG|carboplatin and paclitaxel|Subjects assigned to Arm I Neople taksoljuwa Latin week the first day of the week based outpatient / inpatient treatment receive it. The subjects first received taksoljureul given over 3 hours followed by 30 minutes will be administered Neople Latin week.
223511371|NCT05285150|OTHER|Survey|It´s a survey
224075701|NCT06507163|OTHER|The pre- and post- surgical breathing exercise group|Individuals in the Intervention-2 group were asked to perform 10 breathing exercises with IS every waking hour in addition to the routine practices of the clinic for a total of 10 days, 5 days in the preoperative period and 5 days in the postoperative period.
224075702|NCT00286676|DRUG|Nutropin|
224075703|NCT00286676|PROCEDURE|Oral Glucose Tolerance Test|
224203941|NCT02561013|DEVICE|Profore|PROFORE is a multi-layer compression bandaging system developed to apply sustained graduated compression for the management of venous leg ulcers and associated conditions. Multi-layer compression bandaging is the first choice in treatment for venous leg ulcers.
224203942|NCT05366153|DIAGNOSTIC_TEST|Coronary CT|Screening/Management Plan
224203943|NCT04215653|DRUG|Anaprazole Sodium|administered orally once every 30-60 minutes before breakfast for 4 weeks
224203944|NCT04215653|DRUG|Rabeprazole|administered orally once every 30-60 minutes before breakfast for 4 weeks
224203945|NCT04215653|DRUG|Rabeprazole Placebo|administered orally once every 30-60 minutes before breakfast for 4 weeks
224203946|NCT04215653|DRUG|Anaprazole Sodium Placebo|administered orally once every 30-60 minutes before breakfast for 4 weeks
224203947|NCT02726373|OTHER|type of walking|Subjects walked either intermittently or continuously twice a week for 4 weeks, then crossed over
224203948|NCT04760574|DIAGNOSTIC_TEST|Testosterone|Serum total testosterone and free testosterone level
224313233|NCT05846230|DRUG|BI 1291583|Tablet
224313234|NCT05846230|DRUG|Placebo matching BI 1291583|Tablet
224313235|NCT03646058|DRUG|Buprenorphine|Buprenorphine, 0.4mg pills, sublingual
224313236|NCT03646058|DRUG|Placebo|Placebo pills, sublingual, specifically made to mimick buprenorphine pills
224313237|NCT05291260|PROCEDURE|Cast immobilization|A cast to immobilize the MCP, in 10-30 degrees (slight) flexion (neutral position), and the CMC joint, in 30-40 degrees palmar abduction, is applied (IP joint is free).
224313238|NCT05291260|PROCEDURE|Surgical treatment|"In general, two surgical techniques are described in literature and used in daily clinical practice:~* If the UCL is ruptured in the middle of the ligament, sutures are used to reattach the ligament remnants together.~* When no viable UCL ligaments are present, the UCL is reattached directly to the bone using suture anchors."
224313239|NCT06529757|OTHER|Whole body cooling|Subjects will exercise for 60 minutes in the indicated environmental condition while being exposed to whole body skin wetting. Skin wetting will be performed by spraying water onto the whole body throughout the exercise bout.
224075704|NCT00286676|PROCEDURE|Dual Energy X-ray Absorptiometry (DEXA)|
224075705|NCT00286676|PROCEDURE|Computed Tomography (CT) Scan|
224075706|NCT05595044|DRUG|Vitamin D|ASD children with vitamin D insufficiency and deficiency will receive vitamin D with dose 300 IU/KG/ day not exceed 5000IU/day for 6 weeks then revaluate serum level of vitamin D if they reach normal level of vitamin D they will receive vitamin D 1000IU/ day till the end of 4 months.
224313240|NCT06529757|OTHER|Non-cooling|Subjects will exercise for 60 minutes in the indicated environmental condition while being exposed to no cooling modalities.
224313241|NCT06850753|PROCEDURE|Liver transplantation after en bloc resection of the liver and pancreas|Exenteration of the upper right part of the abdomen, including the liver and pancreas en bloc in locally advanced hilar cholangiocarcinoma, followed by liver transplantation
224075707|NCT05595044|OTHER|Habilitation|Habilitation
224075708|NCT04916405|OTHER|Standardized management of pregnancy weight of twin pregnancy|Standardized management of pregnancy weight of twin pregnancy
224075709|NCT06537115|BEHAVIORAL|exercise|progressive resistance exercise
224075710|NCT06537115|DIETARY_SUPPLEMENT|whey protein powder|The protein intake is 60 grams per day, taken in three divided doses for 12 consecutive weeks. Attention should be paid to monitoring liver and kidney function, and the dosage of protein powder should be adjusted according to the condition of the patient.
224075711|NCT06537115|DRUG|Eldecalcitol|Eldecalcitol soft gel capsules are taken at an oral dose of 0.75μg once a day for 12 consecutive weeks.
224075712|NCT02113631|DRUG|Telaprevir|
224075713|NCT02113631|DRUG|Boceprevir|
224075714|NCT02113631|DRUG|Peg-IFN|Administration 45-180mcg in 0.5 ml solution s.c. weekly for 24-48 weeks
224075715|NCT02113631|DRUG|Ribavirin|Administration: 200 mg capsules; 800 mg-1200 mg daily for 24-48 weeks
224075716|NCT03899662|OTHER|Cognitive Training|Cognitive training included memory, attention, velocity, intelligence
224075717|NCT03899662|OTHER|Physical Training|Physical training included aerobic, strength, flexibility and balance.
224075718|NCT04791046|DRUG|antihypertensive therapy|Personalized evidence-based antihypertensive therapy in patients with comorbidities
224075719|NCT00051155|DRUG|Travoprost (0.004%)|
224075720|NCT00051155|DRUG|Latanoprost (0.005%)/Timolol (0.5%)|
224075721|NCT04761211|DEVICE|smart bra|This is a patented infrared breast examination bra
224075722|NCT03068156|RADIATION|308-nm excimer laser|monochromator UVB laser (308nm)
224075723|NCT06143748|DRUG|Cadonilimab|Patients received cadonilimab 10 mg/kg every 3 weeks for up to 16 cycles.
224075724|NCT06143748|DRUG|Paclitaxel and cisplatin|Patients received 2 cycles of induction chemotherapy with paclitaxel/cisplatin (paclitaxel 135 mg/m2 and cisplatin 75 mg/m2) prior to radiotherapy. Then patients will not receive chemotherapy during radiotherapy.
224313242|NCT06671457|DEVICE|Active transcranial direct current stimulation|"The intervention uses transcranial direct current stimulation (tDCS). The targeted brain regions are identified by conducting simultaneous fMRI-EEG data collection and sleep staging, comparing fMRI data between wakefulness and sleep states. Brain regions that show differences are calculated as potential targets for electrical stimulation. If no differentiated regions are found in a participant, specific areas are chosen based on individualized modeling results from previous experiments, targeting areas such as the dorsolateral prefrontal cortex (DLPFC), orbitofrontal cortex (OPFC), medial prefrontal cortex (mPFC), and posterior cingulate cortex (PCC). Two regions are selected within each brain area for parameter scanning (with each stimulation lasting 10 seconds and EEG data recorded 10 seconds before and after stimulation).~In our prior studies, we observed a decrease in EEG microstate complexity during sleep, with electrical stimulation influencing this complexity reduction to some"
224313243|NCT06671457|DEVICE|Sham transcranial direct current stimulation|In the sham stimulation group, the placement of the tDCS electrodes is identical to that of the active stimulation group. After the stimulation begins, the current gradually increases over 15 seconds. However, upon reaching the therapeutic current level, it immediately begins to decrease, lowering to 0 mA within 15 seconds and remaining at 0 mA throughout the rest of the session. During the last 15 seconds of the stimulation, there is another gradual decrease in current to 0 mA. This approach creates a similar subjective sensation to the real stimulation, making it difficult for participants to discern which type of electrical stimulation they are receiving.
224313244|NCT04201964|DRUG|Intra-arterial administration of tenecteplase|Intra-arterial administration of tenecteplase (0.2-0.4 mg/min) immediately after thrombectomy device pass for 30-40 minutes.
224313245|NCT06433414|OTHER|PAUSE App|Participants receiving the intervention will receive access to the PAUSE App, a self-management tool for SDMG intended for patients to use during an acute illness. The app asks users a series of questions regarding signs and symptoms that identify a qualifying sick day illness, and screens for 'red flags' that would require emergency, or HCP or urgent care referral, and help patients identify which of their medications they should temporarily withhold or adjusted, tailored to a patients' current medication list. This aims to provide patients with interactive support for managing medication during a sick day event. As part of the intervention, patients will also receive a SDMG patient handout. The intervention addresses the previously identified challenges described above via an interactive and individualized electronic application designed to facilitate provision of SDMG.
224203949|NCT01284231|DRUG|MEDI-565|MEDI-565 will be administered by IV infusion
224203950|NCT01284231|DRUG|MEDI-565|20 subjects with selected gastrointestinal tumor type to receive MEDI-565 at the maximum tolerated dose or optimum biologic dose by IV infusion over 3 hours per day for 5 consecutive days every 28 days.
224203951|NCT01284231|DRUG|MEDI-565|20 subjects with selected gastrointestinal tumor type to receive MEDI-565 at the maximum tolerated dose or optimum biologic dose by IV infusion over 3 hours per day for 5 consecutive days every 28 days.
224203952|NCT01284231|DRUG|MEDI-565|20 Subjects with refractory Gastroesophageal cancer to receive MEDI-565 at the maximum tolerated dose or optimum biologic dose by IV infusion over 3 hours per day for 5 consecutive days every 28 days.
224203953|NCT04254731|DRUG|Same individuals treated with racemic methadone and switched to levomethadone (R-methadone)|
224203954|NCT05582200|DIAGNOSTIC_TEST|Positron Emission Tomography (PET) using two PET tracer under IND|Positron Emission Tomography
224203955|NCT01225237|DRUG|Ramosetron|oral
224203956|NCT01225237|DRUG|Placebo|oral
224203957|NCT02028156|OTHER|Partially Hydrolyzed Infant Formula|Commercially available infant formula
224313246|NCT02438904|BIOLOGICAL|CD34 Positive Stem Cell Infusion|Participants infused by vein with around 1 - 4 million/kg CD34+ selected cells.
224313247|NCT02438904|DEVICE|Miltenyi device|Miltenyi device is used for CD34+ cell infusions) to patients who experience poor graft function after stem cell transplantation (SCT).
224313248|NCT04513288|DIETARY_SUPPLEMENT|Experimental treatment L-citrulline (Protéocit®)|Enteral administration of citrulline for 5 days.
224203958|NCT00540007|DRUG|Lenalidomide|
224203959|NCT03745573|BEHAVIORAL|Empateach|Empateach is a behavioural intervention for teachers.
224203960|NCT05257174|DIETARY_SUPPLEMENT|Jing Si Herbal Tea LIQUID PACKETS|intake Jing Si Herbal Tea LIQUID PACKETS twice daily for three months
224203961|NCT05257174|DIETARY_SUPPLEMENT|Placebo|intake Placebo twice daily for three months
223617307|NCT02643108|PROCEDURE|Lateral episiotomy|When the woman is randomized to episiotomy, lateral episiotomy is performed with scissors on the left or right side of the vaginal opening. Origin of incision is 1.0 - 3.0 cm from the midline/posterior forchette and is cut 3.0 cm or more towards the ischial tuberosity at an angle of 60 degrees from the midline.
223617308|NCT03865446|DRUG|Dacomitinib|anti-cancer agent
223617309|NCT01244685|DEVICE|Deltex CardioQ Probe|Deltex CardioQ probe will be placed nasally in the operating room by the anesthesia team and fluid management will be administered via anesthesia protocol.
223617310|NCT05515731|BIOLOGICAL|Autologous platelet-rich plasma (PRP) eye drops|Autologous platelet-rich plasma (PRP) eye drops are used as a sole or adjunctive therapy in many ophthalmological conditions including dry eye, macular holes, retinitis pigmentosa and perforated corneal ulcers. Actions of PRP in these conditions are attributed to the plethora of growth and healing factors concentrated in different PRP preparations.
223617311|NCT04033562|DRUG|Lidocaine patch|Lidocaine patch will be applied at time of Cesarean delivery for post-operative pain control.
224203962|NCT05808894|PROCEDURE|extended pancreatic neck transection during laparoscopic pancreaticoduodenectomy|Transect the pancreatic neck at ≥5mm and ≤10mm beyond the left side of the portal vein.
224203963|NCT04261322|RADIATION|x ray exposure|exposure of whole body to x ray
224203964|NCT04976387|DRUG|Hydrocodone/Acetaminophen 5 Mg-325 Mg ORAL TABLET|Patients are instructed to take Hydrocodone/acetaminophen 5 mg-325 mg oral tablets every 6 hours as needed for treatment of severe pain
224203965|NCT04976387|DRUG|Ibuprofen 600 mg|Patients will take ibuprofen 600 mg every 6 hours as needed
224203966|NCT04976387|DRUG|Acetaminophen 650 MG|Patients will take Tylenol 650mg every 6 hours as needed
224203967|NCT04715737|DRUG|Vasopressin|Administration of vasopressin (20IU) intranasally
224203968|NCT04715737|DRUG|Oxytocin|Administration of oxytocin (24IU) intranasally
224203969|NCT04715737|DRUG|Placebo|Administration of placebo intranasally
224313249|NCT04513288|OTHER|Placebo treatment|Enteral administration of iso-nitrogenous placebo for 5 days.
224313250|NCT01208987|OTHER|Medication History was printed|
224203970|NCT03455647|BEHAVIORAL|ASF promotion plus Girinka|Behavior change communication promoting the consumption of milk produced in the household and other optimal maternal and child nutrition practices. The intervention will be implemented by government of Rwanda Community Health Workers.
224203971|NCT02080065|PROCEDURE|living donor liver transplantation|
224203972|NCT06003491|DEVICE|Intra-articular Cages|Using reduction using posterior intra-articular distraction and fusion technique with cages.
224203973|NCT03105882|DEVICE|Neuro-Spinal Scaffold|Experimental: Neuro-Spinal Scaffold
224203974|NCT06377969|DEVICE|ECAP (Evoked Compound Action Potential)-controlled Closed-Loop Spinal Cord Stimulation|The patients will receive externalized epidural leads connected to external pulse generator for 5-14 days during trial phase. If the trial results in \>50% reduction in pain, they will undergo a minor surgery to receive implantable spinal cord stimulator
224203975|NCT02453867|OTHER|Reduced immunosuppression|Stop steroids at month 3 Stop mycophenolate at month 6 continue tacrolimus once daily (Advagraf, trough levels \> 5ng/ml) Stop mycophenolate at month 6
224203976|NCT02453867|DRUG|Tacrolimus|Tacrolimus is used in both the acitve comparator arm and the interventional arm
224203977|NCT02453867|DRUG|mycophenolate|Mycophenolate is used in the acitve comparator arm for the whole study period; Mycophenolate is stopped at month 6 after Transplantation (month 3 of the study) in the experimental arm
224203978|NCT02453867|DRUG|Steroids|Steroids are used continually in the active comparator arm and are stopped at the beginning of the study (month 3 after Transplantation) as an Intervention in the experimental arm
224203979|NCT02331069|DRUG|Dextrose 5% (D5W)|0,1,2, and 3 week injection sessions consisting of injection of 2 ml of D5W into the D-T groove at the point of maximal pain at 1-2 cm depth, followed by subcutaneous injection of D5W at 4 cm intervals along the course of the PACN if tenderness is present.
224203980|NCT02331069|OTHER|Physical therapy|Three times weekly X 3 week sessions to include myofascial release, exercise, and one modality.
224203981|NCT05383976|OTHER|Machine Learning Algorithm with Existing Penn Medicine CRC Patient Navigation Program|This intervention will utilize the existing Penn Medicine CRC patient navigation program. There will be a monthly list of patients with unfilled coloscopies provided, that are risk-stratified according to the machine learning algorithm and select high-risk criteria. The navigation team will prioritize timely outreach and navigation to high-risk patients according to a script that communicates risk.
224203982|NCT00712660|DRUG|antipsychotic dose increase|20% increase in the dose of current antipsychotic medication
224203983|NCT00712660|OTHER|no intervention|Treatment as usual
224313251|NCT01908907|DIETARY_SUPPLEMENT|DHA oil|Therapy Group:DHA oil administered at 50 mg/d (0.18ml) as an oil emulsion enterally with feedings or by gavage tube if the infant has one.
224313252|NCT01908907|DIETARY_SUPPLEMENT|(MCT) Control oil|Placebo Group:MCT oil administered at 0.18 ml as an oil emulsion enterally with feedings or by gavage tube if the infant has one.
224313253|NCT00761657|DRUG|Roxadustat|Capsule
224313254|NCT00761657|DRUG|Placebo|Capsule
224313255|NCT05329324|OTHER|Questionnaire for study group|Demographic features, Stage and Type, The LANSS Pain Scale and Pain Detect Questionnaire to assess patients' pain characteristics,the Nottingham Health Profile to assess quality of life, and the Hospital Anxiety and Depression Scale to detect the presence of depression and anxiety will be completed by patients.
223512457|NCT05638217|COMBINATION_PRODUCT|Silver diamine fluoride 38% followed by Sodium fluoride varnish 5%|"1)Completely drying of the affected area 2)10 microliters of silver diamine fluoride 38% (CaviGuard®) will be placed on the affected area 3)The affected area should be immediately covered with 20 microliters of fluoride varnish 5% (CaviGuard®) 4)Repeat steps 1-3 one or two more times for large caries at intervals of at least 2 days apart 5)Follow up evaluation of treatment success visits will be conducted at 6 and 12 months from the initial treatment.~NOTE: This is a single intervention using the device registered as Caviguard® to apply both products (Silver diamine fluoride 38% followed by Sodium fluoride varnish 5% (®)) in sequence."
224203984|NCT00092651|DRUG|MK0653A, ezetimibe (+) simvastatin|
224313256|NCT05329324|OTHER|Questionnaire for control group|Demographic features, The LANSS Pain Scale and Pain Detect Questionnaire to assess patients' pain characteristics,the Nottingham Health Profile to assess quality of life, and the Hospital Anxiety and Depression Scale to detect the presence of depression and anxiety will be completed by patients.
224313257|NCT02989324|DRUG|MisoprostoL|Vaginal MisoprostoL
223617312|NCT04033562|DEVICE|Ambu ACTion pump, 0.125% bupivacaine at 8cc/hr|Infusion pump will be placed at time of Cesarean delivery for post-operative pain control.
224203985|NCT00092651|DRUG|Comparators: simvastatin and ezetimibe|
224203986|NCT01576627|DIETARY_SUPPLEMENT|zinc citrate|10 mg of zinc as either zinc citrate
224203987|NCT01576627|DIETARY_SUPPLEMENT|Zinc Gluconate|10 mg of zinc as either zinc gluconate
224203988|NCT01576627|DIETARY_SUPPLEMENT|Zinc oxide|10 mg of zinc as either zinc oxide
224203989|NCT02036827|DRUG|Rocuronium|We will administrate neuromuscular blocking agent until moderate or deep neuromuscular blockade stabilized.
224203990|NCT01365676|DRUG|GAMALINE® + HIPERICIN®|GAMALINE® 900mg + HIPERICIN 300mg T0 = 2 soft caps of each / day (1st month) T1-T6 = 1 soft caps of each / day (2nd - 6th month)
224313258|NCT02989324|DEVICE|Foley Catheter|Misoprostol Plus Foley Catheter
224313259|NCT05968118|DRUG|NL003|Day 0: 8mg of NL003 (32 injections of 0.5ml of NL003) Day 14: 8mg of NL003 (32 injections of 0.5ml of NL003) Day 28: 8mg of NL003 (32 injections of 0.5ml of NL003)
224313260|NCT05968118|DRUG|Placebo|Day 0: 16ml of Normal Saline (32 injections ) Day 14: 16ml of Normal Saline (32 injections ) Day 28: 16ml of Normal Saline (32 injections ) Other Name: Placebo
224313261|NCT03601130|DEVICE|HydroxyColl Bone Graft Substitute|The intervention involves the use of Open Wedge High Tibial Osteotomy with DePuy Synthes TomoFix Medial High Tibial Plate (MHT) fixation (Standard of Care) with the HydroxyColl bone graft substitute i.e. bone graft substitute vs. no bone graft substitute.
224313262|NCT03601130|DEVICE|DePuy Synthes TomoFix Medial High Tibial Plate (MHT) fixation (Standard of Care)|The intervention involves the use of Open Wedge High Tibial Osteotomy with DePuy Synthes TomoFix Medial High Tibial Plate (MHT) fixation (Standard of Care) without the HydroxyColl bone graft substitute i.e. bone graft substitute vs. no bone graft substitute.
224203991|NCT01365676|DRUG|GAMALINE®|GAMALINE® 900mg T0= 2 soft caps / day (1st month) T1-T6 = 1 soft caps / day (2nd - 6th month)
224203992|NCT04783844|DIAGNOSTIC_TEST|Virtual modelization.|3D-MSP technology is used to make virtual 3D models based on conventional CT.
224313263|NCT01793948|DRUG|metformin hydrochloride|Given PO
224313264|NCT01793948|OTHER|placebo|Given PO
224313265|NCT01793948|OTHER|laboratory biomarker analysis|Correlative studies
224203993|NCT03576131|BIOLOGICAL|GEN1029 (HexaBody®-DR5/DR5)|GEN1029 will be administered intravenously. The dose levels will be determined by the starting dose and the escalation steps taken in the trial.
224203994|NCT01339858|DRUG|N-Acetyl Cysteine|NAC and matched placebo will be supplied in unmarked capsules. Each NAC capsule will contain 480 mg of NAC. Dosing will begin at 480 mg/d and titrated up by 480 mg/d each week until a maximum dose of 2880 mg/d (BID) is reached. This approximate dose was effective and well tolerated in a recent study of treatment refractory obsessive-compulsive disorder by Krystal and colleagues at Yale (16). In addition, a double-blind placebo controlled trial recently completed at IUSM Riley Hospital in children (age 4 to 12 years) with autism spectrum disorders used doses ranging from 900 mg/day to 4200 mg/day and reported no serious adverse events and found the agent well tolerated (15). Dose adjustments downward to 1920 mg/d will be permitted if tolerability issues are encountered at the maximum dose
224203995|NCT01339858|OTHER|sugar pill|matched placebo will be supplied in unmarked capsules. Dosing regimen will be the same as in the N-Acetyl Cysteine arm.
224203996|NCT00002338|DRUG|Raluridine|
224203997|NCT05512286|RADIATION|Preoperative radiotherapy|Radiotherapy followed by mastectomy and DIEP flap reconstruction
224203998|NCT05512286|RADIATION|Postmastectomy radiotherapy|Radiotherapy after mastectomy and DIEP flap reconstruction
224203999|NCT01456000|DEVICE|EAS-AC (HeartLight)|Pulmonary vien isolation
224204000|NCT01456000|PROCEDURE|Control Arm Ablation|Treatment with standard ablation.
224204001|NCT06539637|COMBINATION_PRODUCT|OMIDRIA (*Registered Product) {10.16 mg/mL (1% w/v) of phenylephrine and 2.88 mg/mL (0.3% w/v) of ketorolac}|10.16 mg/mL (1% w/v) of phenylephrine {Generic Name: Biorphen} (Adrenergic Receptor Agonist) and 2.88 mg/mL (0.3% w/v) of ketorolac {Generic Name: TORADOL} (Nonsteroidal Anti-inflammatory) - via intracameral delivery
224313266|NCT04060095|PROCEDURE|standardized noxious stimulus under general anesthesia.|"50 adult patients undergoing general anesthesia for any types of surgery and who have been chronically treated with β1-adrenergic antagonists for at least three months. .Induction of anesthesia will be standardized.~At least 10 min after the post-intubation decrease of the remifentanil infusion rate, the OR team will stop any physical contact/stimulation of the patient allowing at least 3-minutes.~At this point, the standardized electrical (tetanic) stimulation will be applied on the area of the ulnar nerve at the wrist level, at a frequency of 100 Hz and a current of 70 mA for a duration of 30 seconds, followed by 3 minutes of observation period without any other stimulation of the patient by the anesthesia or the surgical team. At the end of the observation period, the study is discontinued and the anesthesia will be conducted at the discretion of the anesthesiologist in charge of the patient."
224313267|NCT01707264|DRUG|NEOD001|Monoclonal antibody administered by intravenous infusion every 28 days.
224313268|NCT00359801|DRUG|Randomization to Exubera (insulin human [rDNA origin] inhalation powder) or Usual Diabetes Care|Subjects are randomized to use Exubera. Following initial use of randomized treatment, physicians and subjects are free to change regimens and dosing based on subject response to assigned treatment (as consistent with routine practice). Enrolling physicians are provided with the approved local label for Exubera to guide prescribing and treatment decisions.
224313269|NCT00359801|DRUG|Randomization to Exubera (insulin human [rDNA origin] inhalation powder) or Usual Diabetes Care|Subjects are randomized to use usual diabetes care. Following initial use of randomized treatment, physicians and subjects are free to change regimens and dosing based on subject response to assigned treatment (as consistent with routine practice).
223617313|NCT01774032|BIOLOGICAL|H5N1 Influenza Vaccine (Whole Virion, Vero Cell-Derived, Inactivated), non-adjuvanted formulation|
224075725|NCT06143748|RADIATION|intensity-modulated radiotherapy|All patients received external-beam radiation using intensity-modulated radiotherapy. The prescribed dose is 50.4 Gy in 28 fractions over 5-6 weeks.
224075726|NCT01009476|DRUG|Galantamine|Therapeutic measures were not predefined in the protocol but remained at the discretion of the treating physician. The treatment regimen of galantamine (8 mg,16 mg, 24 mg retard capsule) was to be in accordance with the recommendations given in the summary of product characteristics.
224075727|NCT01009476|DRUG|Nootropics (ginkgo biloba, nicergoline, piracetam, or others)|Therapeutic measures were not predefined in the protocol but remained at the discretion of the treating physician. The treatment regimen of nootropics was to be in accordance with the recommendations given in the relevant summary of product characteristics.
224075728|NCT06355232|BIOLOGICAL|Covid-19 vaccine|Recombinant SARS-CoV-2 spike protein with Advax-CpG55.2 adjuvant
224075729|NCT06355232|BIOLOGICAL|Influenza vaccine|Inactivated seasonal influenza vaccine with Advax-CpG55.2 adjuvant
224075730|NCT01699555|BIOLOGICAL|GNbAC1|Single dose intravenous (IV) GNbAC1 of 0.0025mg/kg, 0.025mg/kg, 0.15mg/kg, 0.60mg/kg, 2.00mg/kg or 6.00mg/kg
224075731|NCT01699555|BIOLOGICAL|GNbAC1 placebo|Single dose intravenous (IV) GNbAC1 placebo
224075732|NCT02439658|DRUG|Dofetilide and/or sotalol|This is an observational study of patients receiving Dofetilide and/or sotalol as part of their routine clinical care. Patients receiving either of these medications will be compared with population controls for genetic analysis.
224075733|NCT06962839|DRUG|BI 1815368|BI 1815368
224075734|NCT06962839|DRUG|Placebo|Placebo matching BI 1815368
224075735|NCT06413511|BIOLOGICAL|Belantamab|Belantamab will be administered
224075736|NCT03757104|BEHAVIORAL|micro-incentive|Residents in these communities are eligible to receive a R50 food voucher conditional on undergoing a home-based HIV test. If diagnosed with HIV, residents are eligible to receive a second R50 food voucher when they link to care within 6 weeks of the HIV test
224075737|NCT03757104|BEHAVIORAL|EPIC-HIV|Men in these communities are eligible to receive a tablet-based male-sensitive HIV decision support app (EPIC-HIV 1)to encourage them to test for HIV at home. If diagnosed with HIV and do not link to care within a month of HIV test, they become eligible to receive a tablet-based male HIV specific decision support app (EPIC-HIV 2) to encourage them to link to HIV care.
224313270|NCT06223386|BEHAVIORAL|Designed on-line course A with 3-month consultation with the dietitian|Educational materials on weight reduction will be provided at the beginning of the 3-month intervention. Participants can consult with the dietitian via the APP on their mobile phones during the intervention period. These materials will encompass dietary and physical activity guidelines by the government in Taiwan.
224313271|NCT06223386|BEHAVIORAL|Designed on-line course B with 3-month consultation with the dietitian|Educational materials on weight reduction will be provided every weekday for 8 weeks. Participants can consult with the dietitian via the APP on their mobile phones during the 3-month intervention period. These materials will encompass various aspects such as dietary habits, physical activity, and daily routines, all designed to impart online lifestyle education.
224313272|NCT06223386|BEHAVIORAL|Designed on-line course B with 3-month consultation with the dietitians + 3-month daily dietary assessment by the dietitians|Educational materials on weight reduction will be provided every weekday for 8 weeks. Participants can consult with the dietitian via the APP on their mobile phones during the 3-month intervention period. These materials will encompass various aspects such as dietary habits, physical activity, and daily routines, all designed to impart online lifestyle education. In addition, dietitians assess participants' daily diet for 3 months.
224313273|NCT06223386|BEHAVIORAL|Designed on-line course B with 6-month consultation with the dietitians + 6-month daily dietary assessment by the dietitians|Educational materials on weight reduction will be provided every weekday for 8 weeks. Participants can consult with the dietitian via the APP on their mobile phones during the 6-month intervention period. These materials will encompass various aspects such as dietary habits, physical activity, and daily routines, all designed to impart online lifestyle education. In addition, dietitians assess participants' daily diet for 6 months.
224313274|NCT01188512|BIOLOGICAL|BPZE1|Individuals will be vaccinated once intranasally with the designated dose of BPZE1 Dose 2 x 0.1 mL (0.1 mL per nostril).
224313275|NCT01188512|BIOLOGICAL|Placebo|Individuals will get placebo once intranasally. Dose 2 x 0.1 mL (0.1 mL per nostril).
224313276|NCT02420912|DRUG|Ibrutinib|Given PO
224313277|NCT02420912|OTHER|Laboratory Biomarker Analysis|Correlative studies
224313278|NCT02420912|BIOLOGICAL|Nivolumab|Given IV
224204002|NCT06539637|OTHER|Ketorolac Tromethamine {TORADOL} (0.5%) - Topical Eyedrop|Topical ketorolac tromethamine {TORADOL, Nonsteroidal Anti-inflammatory} (0.5%) administered 4 times daily for the 3 days leading up to surgery. The last drop is to be given at least 2 hours prior to surgery.
224204003|NCT04391400|DIAGNOSTIC_TEST|nasal pharyngeal (NP) swab samples|These donors will be from a population of patients who are already providing nasal pharyngeal (NP) swab samples in universal transport media (UTM) for COVID-19 testing at LabPMM LLC.
224204004|NCT04391400|DIAGNOSTIC_TEST|peripheral blood draw|"From patients suspected of SARS-CoV-2 viral infections.~* At least 2mL to 5mL of peripheral blood.~* Collected in EDTA tubes.~* Shipped to ambient LabPMM, LLC within 2 days.~* Specimen Collections:~* Collected at the same time as the NP specimen sent for COVID-19 testing.~* Collected two to three weeks post the original patient's COVID-19 testing."
224204005|NCT03975088|PROCEDURE|Sub-macular injection of Ranibizumab|In this study, authors describe a new surgical technique for the treatment of refractory non tractional DME. The technique consists of vitrectomy with ILM peeling with subretinal injection of Ranibizumab.
224204006|NCT00334828|DRUG|eritoran tetrasodium|Intravenous infusion at a total dose of 105 mg.
224204007|NCT00334828|DRUG|Placebo|Matching placebo; intravenous infusion.
224204008|NCT03823677|PROCEDURE|Hypoxia|hypoxia
224204009|NCT03409497|OTHER|Concord Grape Juice|Concord Grape Juice
224204010|NCT03409497|OTHER|Low flavonoid low essence beverage|Low flavonoid low essence beverage
224204011|NCT03409497|OTHER|Low flavonoid beverage|Low flavonoid beverage
224204012|NCT04590898|DEVICE|Peri-device leakage closure after left atrial appendage occlusion|Peri-device leakage closure after left atrial appendage occlusion
224204013|NCT05769322|DEVICE|Nerivio|Remote electrical neuromodulation (REN) device for the acute treatment of migraines. The device delivers transcutaneous electrical stimulation to the upper arm to induce conditioned pain modulation (CPM) that activates a descending endogenous analgesic mechanism. The treatment is self-administered and controlled by a smartphone application.
224313279|NCT02673814|BIOLOGICAL|durvalumab|
224313280|NCT02673814|BIOLOGICAL|bavituximab|
224204014|NCT05489380|DEVICE|AccuMeasure|intracolonoscopy measurement of polyps using a laser-based device
224204015|NCT03004963|DEVICE|Body composition monitor|Both body composition monitor (BCM) is used to evaluate the volume status of patients.
224204016|NCT03004963|DEVICE|clinical indexes|The investigators evaluate the volume status of patients according to clinical indexes.
224204017|NCT04928794|PROCEDURE|Erector Spinae Plane Block|Regional anesthesia with injected local anesthetic solution, placed in space underlying erector spinae muscles
224204018|NCT04928794|PROCEDURE|Paravertebral Block|Regional anesthesia with injected local anesthetic solution, placed in space adjacent to vertebrae
224204019|NCT05880485|RADIATION|online adaptive radiotherapy|PTV with 5-10 margins covers CTV
224313281|NCT00610610|DRUG|Paroxetine CR|Those in the active treatment group will receive doses of Paxil CR in the following manner: week 1: 12.5 mg per day, week 2: 25 mg per day, week 3: 37.5 mg per day, wk 4: 50 mg per day and week 5: 62.5 mg per day.
224313282|NCT00610610|DRUG|Placebo|Same shape Placebo
224313283|NCT02291640|DEVICE|MIL|direct laryngoscopy
224313284|NCT02291640|DEVICE|CoPilot|video laryngoscopy
224204020|NCT04018937|DRUG|Alemtuzumab|Alemtuzumab will be administered by either subcutaneous (SQ) injection or IV. A test dose of alemtuzumab, 3 mg, is administered on the first day. If the test dose is tolerated, administration of three treatment doses will begin within 24 hours. The three treatment doses will be administered on consecutive days. On the first day, 10 mg/m2 will be given, 15 mg/m\^2 the second and 20 mg/m\^2 the third. Alemtuzumab will be started between Days -22 and -20, but all doses (test dose and three treatment doses) should be completed by Day -18.
224204021|NCT04018937|DRUG|Fludarabine|Fludarabine will be administered at 30 mg/m\^2 IV daily for five days (Days -7 to -3).
224204022|NCT04018937|DRUG|Melphalan|Melphalan will be administered at 140 mg/m\^2 IV on Day -3 following fludarabine administration.
224204023|NCT01598740|DRUG|CLP|Oral administration
224204024|NCT01598740|DRUG|Spironolactone|oral administration
224313285|NCT04412278|OTHER|Online Survey|Volunteer individuals enrolled the study after approval an online informed consent form. Sociodemographic data of the participants recorded as an online survey. Then, patient reported outcomes were used to assess physical activity level (International Physical Actvity Questionairre) and Exercise Benefits and Barriers (Exercise Benefits and Barriers Scale).
224313286|NCT01635348|BEHAVIORAL|motor skill gait exercise|The motor skill gait exercise is a task-oriented motor sequence learning approach to exercise to improve walking. The approach involves goal-directed stepping and walking patterns to facilitate use of the appropriate muscles at the appropriate timing relative to body position during gait through the task performance. Treadmill-assisted walking in brief intervals of small increased speed walking interspersed with usual walking speed are performed to induce the automatic rhythm and timing of gait. The exercise sessions are about 60 minutes, 2-3 times a week for 12 weeks or a total of 30-36 sessions.
224313287|NCT01635348|BEHAVIORAL|aerobic gait intervention|The aerobic gait intervention approach involves treadmill and overground walking with the gradual increases in the distance walked and speed of walking. The exercise approach provides walking practice, including on the treadmill to facilitate the timing of stepping during gait, while also facilitating a fitness or conditioning response, and endurance for walking activities. The exercise sessions are about 60 minutes, 2-3 times weekly for 12 weeks, or about 30-36 sessions.
224204025|NCT04273763|DRUG|Bromhexine Hydrochloride Tablets|Bromhexine Hydrochloride Tablets
224204026|NCT04273763|DRUG|Arbidol Hydrochloride Granules|Standard treatment refers to the latest edition of Pneumonia Diagnosis and Treatment Scheme for Novel Coronavirus Infection. Arbidol Hydrochloride Granules is recommended but not enforced to use.
224204027|NCT04273763|DRUG|Recombinant Human Interferon α2b Spray|Standard treatment refers to the latest edition of Pneumonia Diagnosis and Treatment Scheme for Novel Coronavirus Infection.
224204028|NCT03069365|DRUG|Glecaprevir/pibrentasvir|Film-coated tablet
224204029|NCT01910701|BEHAVIORAL|Family Spirit|The Family Spirit intervention consists of 52 sessions (30-60 minutes in duration) delivered during a 39-month intervention phase and designed to positively impact a number of maternal and child behavioral and health outcomes.
224204030|NCT05252273|OTHER|Observational, No intervention|Open-label observational study that will evaluate the reliability and responsiveness of patient-reported symptoms and endoscopic and histologic items for assessing pouchitis disease activity in 43 patients undergoing standard of care (SOC) antibiotic therapy.
224204031|NCT01856348|DRUG|Vitamin D|
224204032|NCT06564272|DRUG|KC1036|For patients weighing between 30 kg and less than 50 kg, administer 40 mg QD of KC1036. For patients weighing between 50 kg and less than 70 kg, administer 50 mg QD of KC1036. For patients weighing 70 kg or more, administer 60 mg QD of KC1036. 4 weeks as a cycle.
224204033|NCT03508466|BEHAVIORAL|hypersensitivity reaction|Previous hypersensitivity reaction
224204034|NCT06262581|DRUG|Tisleizumab(BGB-A317)|200mg i.v. q3w
224204035|NCT02724176|DRUG|carbon nanoparticles|0.1 ml of CN suspension was injected per spot into the tissue surrounding the tumor using a skin test syringe. Two or three randomly selected spots were injected slowly for each tumor, and the total amount injected was no more than 0.5 mL per lobe.
224313288|NCT04063085|DEVICE|PROTAHERE Absorbable Adhesion Barrier|40 mg/ml (4%) cross-linked hyaluronan
224313289|NCT04063085|DEVICE|Hyalobarrier Gel|Laparotomy: 40 mg/ml (4%) cross-linked hyaluronan Endoscopy: 30 mg/ml (3%) cross-linked hyaluronan
224313290|NCT04063085|OTHER|No treatment|No anti-adhesion agent applied
224313291|NCT04063085|DEVICE|Seprafilm Adhesion Barrier|a hyaluronate carboxymethylcellulose-based bioresorbable membrane
224204036|NCT04480502|BIOLOGICAL|Envafolimab|PD-L1 single domain antibody for subcutaneous injection.
224204037|NCT04480502|DRUG|Ipilimumab|CTLA-4 monoclonal antibody
224204038|NCT02886494|DRUG|BAC treatment|BAC, topical application on external nasal skin, scalp, and neck, 2 times daily, 30 g/day for 12 weeks
224204039|NCT02886494|DRUG|Matched vehicle|BAC matched vehicle, topical application on external nasal skin, scalp, and neck, 2 times daily, 30 g/day for 12 weeks
224204040|NCT05490160|DRUG|Tranexamic acid|During the total knee arthroplasty, the patients received a 2-g retrograde injection of tranexamic acid through the drain after closure, with subsequent clamping of the drain for 6 hours.
224204041|NCT02867748|PROCEDURE|TVT-Abbrevo|
224204042|NCT02867748|PROCEDURE|Serasis|
224204043|NCT02712736|OTHER|quality of life survey|subjects with PSC will be administered a survey to assess their quality of life
224204044|NCT00576849|DRUG|Balanced HES 130/0.42|Volume is administered perioperatively and during the first 48 hrs after surgery when mean arterial pressure (MAP) was \<60mmHg and pulmonary capillary wedge pressure (PCWP) or central venous pressure (CVP) is \<10 mmHg
224204045|NCT00576849|DRUG|Balanced HES 130/0.42|Volume will be administered perioperatively and during the first 48 hrs after surgery when mean arterial pressure (MAP) is \<60mmHg and pulmonary capillary wedge pressure (PCWP) or central venous pressure (CVP) is \<10 mmHg
224313292|NCT04063085|DEVICE|Gynecare Interceed (TC7) Absorbable Adhesion Barrier|an oxidized regenerated cellulose absorbable membrane
224313293|NCT03900455|DEVICE|Hydrocellular polyurethane foam multilayer dressing|Application of a multilayer foam with 4 flaps that can be adapted to several areas of the body (including the sacrum) and consists of: an external polyurethane film, which is impermeable to liquids and bacteria using dynamic transpiration, which can form an impenetrable barrier to protect the skin; a protective layer that shields the skin against accidental knocks and helps to spread the pressure; a highly absorbent and leak-proof layer that traps the exudate inside; a layer of hydrocellular polyurethane foam; and, finally, in contact with the skin, a perforated evenly covered layer of silicone gel adhesive. in addition to Standard preventive care
224204046|NCT00576849|DRUG|6% HES 130/0.4 prepared in saline solution|Volume will be administered perioperatively and during the first 48 hrs after surgery when mean arterial pressure (MAP) is \<60mmHg and pulmonary capillary wedge pressure (PCWP) or central venous pressure (CVP) is \<10 mmHg
224204047|NCT06232135|OTHER|CBCT scan|analysis of the CBCT scan to assign a calcification stage to the subject's lower left third molar and accordingly calculate the estimated age of each subject
224204048|NCT02780115|DRUG|AGN-199201 ophthalmic solution|1 drop of AGN-199201 ophthalmic solution Doses A, B, C in the eye.
224313294|NCT03900455|PROCEDURE|Standard preventive care|Pressure Ulcer risk assessment using the Braden scale within 8 hours of admission. Place patient on pressure mattress (static or alternating pressure) if Braden score \<17, daily inspection of the skin in the various pressure points and moving the patient at list every 4 hours. Management of possible incontinence, humidity control and prevention of skin damage and rubbing/friction during postural changes as per hospital procedure
224204049|NCT02780115|DRUG|AGN-190584 ophthalmic solution|1 drop of AGN-190584 ophthalmic solution Doses A, B, C in the eye.
223617314|NCT06239740|PROCEDURE|Electroacupuncture group|The acupuncture needle was placed on the scalp at a Chinese traditional acupuncture point. Subsequently, a small electrode was attached to the needle. A minor amount of electricity runs through the electrode, producing a slight vibration or soft hum during the treatment.
223761307|NCT05949138|DEVICE|ECG-Less Cardiac CT using SmartPhase|"Administration of medications and biologic products (such as contrast agent administration, and potentially beta-blockers and other medications) will be given according to standard hospital care.~This is a prospective research study evaluating an investigational workflow on an existing CT device that has regulatory clearance. The investigational workflow includes preforming the CT acquisition according to the hospital's usual care with the exception that the ECG signal which triggers the scan will be coming from an ECG simulator based on an estimate of the patient's heart rate, rather than through ECG leads connected to the subject. Clinically-indicated Cardiac CTs take approximately 30-60 minutes. No additional imaging is needed as part of the study."
224204050|NCT02780115|DRUG|AGN-199201 Vehicle|Vehicle to AGN-199201
224204051|NCT02780115|DRUG|AGN-190584 Vehicle|Vehicle to AGN-190584
224204052|NCT01179191|DRUG|morphine sulfate and naltrexone hydrochloride (EMBEDA)|Capsules in dose strengths ranging from 20 to 100 mg morphine sulfate with 0.8 to 4 mg of naltrexone hydrochloride taken either once or twice daily with a starting dose calculated using the total daily dose of the current opioid being converted from until a stable dose is achieved or six weeks which ever comes first.
224204053|NCT05592704|DEVICE|Usage of a wearable heart rate monitor and a smartphone with the application for home-based exercises|Physical activity self-monitoring using a wearable heart rate monitor and a smartphone with specially designed application
224204054|NCT03863925|DEVICE|Target controlled infusion, Schnider model|Target controlled infusion (TCI) is an intravenous drug delivery system estimating pharmacokinetics after input of patient's data, e.g. age, sex, body height, body weight. Schnider model is one of TCI model to deliver Propofol. After target concentration at effect site (e.g. the brain) is keyed in, the computerized infusion pump will calculate dosage of bolus and infusion rate for each individual, and calculated concentration of propofol at plasma and brain will be displayed. The clinicians should evaluate the patient's sedation level in response to calculated propofol concentration and titrate target concentration to achieve desired sedation level.
224204055|NCT03863925|BEHAVIORAL|Bolus injection of Propofol|Bolus intravenous injection is a traditional way to deliver anesthetic, and the dosage and amount of medication is based on clinical experience and patients' response.
224204056|NCT03029104|COMBINATION_PRODUCT|CXLO Corneal Strengthening Solution and UVA Illumination Device|CXLO Corneal Strengthening Solution
224204057|NCT03297801|DIETARY_SUPPLEMENT|Fish oil supplements|Women who chose to supplement with fish oil during gestation or lactation.
224204058|NCT06346756|OTHER|Treatment of dental caries.|The researchers used G-aenial Universal Injectable (GCI), G-aenial A'CHORD (GCA), Tetric Prime (TP), and Filtek Ultimate (FU) composites for premolar Class II restorations.
224204059|NCT04929834|OTHER|Hydrating emollient + body lotion for immunotherapy-related side effects|Hydrating, hypo-allergenic, and anti- itching emollient and body lotion for immunotherapy-related skin reactions
224204060|NCT04749121|DEVICE|UVC Irradiation|We used the Porcine epidemic diarrhea virus (PEDV) as the indicator virus .An N99 mask was contaminated by spraying or applying with the virus on the exterior and interior surface of each silicone mask. Also, 100 μl of the viral suspension was spotted onto the filter part of N99 masks. Following 20-30 minutes of drying, the silicone masks underwent each of the decontamination procedures which are ultraviolet-C (UV-C) irradiation and 70% alcohol treatment. For UV irradiation, N99 masks were placed in an UV-C incubator ) and were exposed for different times at 1, 10 and 20 minutes, respectively.Untreated control and treated N99 masks were analyzed for viral infectivity in VERO cell cultures. At 48 hours post-infection, cells were examined for evaluation the viral infectivity via observation of cytopathic effect. Results for each treatment express mean ± standard deviations of 3 biological replicates.
224204061|NCT04749121|DRUG|UVC Irradiation|Bacterial and fungal sampling were obtained from the inside and outside surface areas likely to the frequently touched and close contact with the face of hospital personnel. The cultures were then isolated onto the blood agars and Mac Conkey agars, respectively. After incubation, the total number of bacterial and fungal colonies were counted, recorded, and selected different colonies.
224204062|NCT04749121|DEVICE|Fit test|All the participants had to pass the initial fit test.After decontamination with UVC irradiation for 60 minutes, fit testing was conducted using qualitative fit test (Bittrex Solution aerosol),
224204063|NCT04749121|DEVICE|Tensile strength|We measured the tensile strength of the strap of the Silicone mask before and after the UVC irradiation to study the strength and reliliency of the strap
224204064|NCT06537479|OTHER|Buteyko breathing technique|Participants will be advised to sit in a comfortable and relaxed position and take a shallow breath through nose, partially filling the lungs. Hold breath for 2-3 seconds and exhale slowly through the nose and emptying the lungs.
224204065|NCT06537479|OTHER|Chest Wall Mobilization|It started with positioning, sitting or standing with good posture, and relaxing shoulders and arms. Hands were placed on the chest with fingers wide and thumbs on side of ribcage. Inhale deep breaths with expansion of chest and hands move outward. Exhale slowly allowed the chest to drop and the hands to move inward.
224204066|NCT05026879|BIOLOGICAL|Inactivated COVID-19 vaccine (CoronaVac)|The adverse events due to an inactivated COVID-19 vaccine.
223617315|NCT06239740|PROCEDURE|Sham acupuncture|participants received acupress or a brief needle insertion at He gu on both hands during the first and 10th weeks, marking the endpoint of the study
224204067|NCT05644899|PROCEDURE|Interlaminar ultrasound-assisted intrathecal administration of nusinersen|All procedures were performed with patients either seated or placed in a lateral decubitus. After skin disinfection with 2% chlorhexidine in 70% alcohol, using a convex array, the L3-4 or L4-5 intervertebral space was identified and a left paramedian sagittal oblique view was obtained; the probe was rotated 90° into a transverse orientation, centered on the neuraxial midline, and moved in either the cephalad or caudal direction to obtain a transverse interlaminar view; the intersection between the two markings of the spinal midline and interspinous space was identified as the spinal entry point of the needle. After local anesthesia (LA) with lidocaine 2%, a 25-gauge non-traumatic 90 mm Whitacre spinal needle or a traumatic 90 mm Quincke spinal needle was used to access the subarachnoid space. After confirmation of cerebrospinal fluid (CSF) flow, 5 mL of CSF were removed. Subsequently, nusinersen was administered intrathecally over 1-3 min.
224204068|NCT05644899|PROCEDURE|Landmark-based intrathecal administration of nusinersen|All procedures were performed with patients placed in their most comfortable position (either seated or placed in a lateral decubitus). After skin disinfection with 2% chlorhexidine in 70% alcohol, conventional palpation of the superior aspect of iliac crest was performed and the palpated intercristal line was assumed to cross the spine at L4 vertebral body or L4-L5 interspace. The skin was marked with horizontal and vertical lines at the L3-L4 or L2-L3 interspaces and was referred as entry point of the needle. The procedure was then completed in the same fashion as for US-assisted technique.
224204069|NCT02742818|DEVICE|Upper body blanket, Bair Hugger|Upper body warming blanket will be used in patients undergoing LEA and EVAR.
224204070|NCT02742818|DEVICE|Underbody blanket, Bair Hugger|Underbody warming blanket will be used in patients undergoing LEA and EVAR.
224204071|NCT02249065|DRUG|Brimonidine|
224204072|NCT05560594|DEVICE|Coloplast SpeediCath CH12 standard male intermittent catheter|Drainage of the bladder through the urethra when using the SpeediCath standard male intermittent catheter.
224204073|NCT00432367|DRUG|Amodiaquine plus artesunate combination; sulphadoxine-pyrimethamine|"Eligible women will be allocated randomly to one of three groups and treated as follows:~Arm 1 (OptiMAL® antigen screening and treatment with SP plus LLIN group) - a woman in this will receive 1500mg/75mg (S/P) administered at the ANC as single dose on enrollment if her screening test is positive.~Arm 2 (OptiMAL® antigen screening and treatment with AQ+AS plus LLIN) - a woman in this will receive 300mg of AQ and 100mg co-administered two times a day for 3 days if her screening test is positive. The first dose is observed on enrolment day at the ANC.~Arm 3 (SP-IPTp plus LLIN group) - a woman in this will receive 1500mg/75mg (S/P) administered at the ANC as single dose on enrollment as recommended by national policy.~All enrolled women will be given one long lasting insecticide treated bed net each for use."
224204074|NCT01068093|DRUG|Ezetimibe|10mg daily
224204075|NCT06264271|BEHAVIORAL|structured nutrition intervention|Structured nutrition education on carbohydrate counting and flexible insulin dosing by qualified nutritionist.
224204076|NCT02405351|BEHAVIORAL|Adaptive Working Memory Training|"The working memory training task will consist of an online adaptive working memory program that will test and extend patients' working memory capacity.~Adaptive refers to the increase in the number of items that the patient is required to remember."
224204077|NCT03922984|PROCEDURE|MRI with Arterial Spin Labeling (ASL)|Week 0 (Before initiation of chemoradiation): MRI with ASL will be performed along with patient's standard of care imaging session Week 3: contrast-enhanced research MRI with ASL Week 6: contrast-enhanced research MRI with ASL Week 10: MRI with ASL will be performed along with patient's standard of care imaging session Week 18: MRI with ASL will be performed along with patient's standard of care imaging session Week 26: MRI with ASL will be performed along with patient's standard of care imaging session Week 34: MRI with ASL will be performed along with patient's standard of care imaging session
224204078|NCT00969267|OTHER|ear-acupuncture A|with needle stimulation
224204079|NCT00969267|OTHER|stimulation B|with bread stimulation on ear acupuncture point
224204080|NCT00969267|OTHER|stimulation C|without needle stimulation
224313295|NCT03830372|DEVICE|VR Tier One|"10 sessions of 20 minutes virtual terapeutic game~Thanks to using VR googles and the phenomenon of total immersion VR Tier One terapy game allows to completely separate the patient from the hospital environment and provides an intense visual, auditory and kinesthetic stimulation. Depending on the stage of therapy it can have a calming and mood-improving effect or it can motivate and cognitively activate the patient. The additional aim of the game is to help the patients regain their emotional balance, let them recognize their resources in order to bring them to power in the rehabilitation process and trigger the natural recovery mechanisms."
224313296|NCT03830372|OTHER|Control|10 sessions of 20 minutes of Schultz Autogenic Training
224313297|NCT04934059|DRUG|Yuxuebi tablet|0.5g/ tablet
224313298|NCT04934059|DRUG|Placebo tablet|0.5g/ tablet
223511372|NCT06478615|PROCEDURE|Coring out Fistulectomy with Closure of Internal Sphincter Opening|The patient was laid in the lithotomy position. Skin preparation and draping were done. Normal saline irrigation was performed. The anal canal was sufficiently dilated to permit the introduction of a self-retaining retractor. With H2O2 injection into the fistula tract, the internal opening and tract of the fistula will be identified. The incision was made around the external opening, and the tract was all cored out along the tract from the external opening to the internal sphincter. Meticulous hemostasis will be performed, stay suture by PDS 4/0 around fistiolous opening at the internal sphincter, excision of fistulous tract above stay suture, then closure of internal sphincter defect by PDS 3/0. Anal packing with 4 × 4 epinephrine gauze and sterile protective dressing was performed. After the operation, a stool softener and pain controller were prescribed, and patients were discharged.
223511373|NCT06478615|PROCEDURE|Lay Open Fistulotomy and Primary Sphincter Repair|Patients were put in a lithotomy position and the skin was then draped. After identification of the external fistula orifice probing of the fistula tract with identification of the fistulous tract and internal orifice with H2O2 injection into the fistula tract. The fistula was laid open and fistulectomy was then conducted and dissected with diathermy cautery help. Then Primary repair of the sphincter with PDS 3/0 with proper hemostasis using coagulation diathermy.
223511374|NCT01189227|PROCEDURE|Postoperative chemotherapy|Patients undergo hepatic resection. Beginning 31-56 days after surgery, patients receive mFOLFOX6 or FOLFIRI chemotherapy IV on day 1 over 3 hours. Patients receive an additional dose of fluorouracil over 46 hours using a portable pump. Treatment repeats every 2 weeks for 12 cycles.
224204081|NCT01873131|DRUG|topical timolol maleate|Timolol maleate 0.5% ophthalmic solution will be used. The dose will be 1 drop per square centimeter of hemangioma, rubbed into the area by the parent/guardian twice daily. The intent is to cover the entire lesion without excess of medication. Therefore, the dose can be lowered from 1 drop/cm2 at the discretion of the investigators, but not increased. This dose should not have significant systemic side effects given that the normal systemic intravenous dose for propanolol is 2mg/kg/day and there would be much less systemic absorption if the solution is applied topically. It is well established that the stratum corneum greatly slows the transport of timolol.
224313299|NCT06064578|BEHAVIORAL|Project SOLVE|Project SOLVE is a \~30-minute self-guided digital intervention designed to teach children and adolescents how to set goals and solve problems systematically. Specifically, Project SOLVE is based on problem solving, a core component of cognitive behavioral therapy, a gold standard treatment for internalizing disorders. Project SOLVE uses vignettes, interactive activities, and engaging graphics to teach youth a systematic strategy for solving problems. Project SOLVE was previously found to be effective in reducing mental health symptoms among American children (https://link.springer.com/article/10.1007/s12310-023-09598-7).
224313300|NCT00132860|DRUG|azithromycin|
224313301|NCT04326114|DEVICE|Inspiratory training device|Inspiratory training by a Power-breath device
224313302|NCT04326114|DEVICE|Expiratory training device|Expiratory training a Winner-flow device
224313303|NCT00822796|DEVICE|Thermogard™|Those who have a Thermogard™ central venous warming catheter placed prior to surgery
224313304|NCT00822796|DEVICE|Standard central venous catheter|Those who have a standard central venous catheter placed prior to surgery
224313305|NCT03413293|DIAGNOSTIC_TEST|Diagnosis of bacterial infections|Cultures
224204082|NCT01873131|DEVICE|Pulsed dye laser|A 595-nm PDL (V-beam Perfecta, Candela Corp, Wayland, MA, USA) with a dynamic cooling device (DCD) will be utilized for all treatments. This device is cleared by the FDA for clinical treatment of vascular lesions. Protective eyewear for patient and all participants in the treatment room will be provided. A spot size of 7 or 10 mm will be used with an average fluence (energy delivered per unit area, in J/cm2) of 9 J/cm2 (range 8-10.0 J/cm2). Fluence will vary according to patient and hemangioma characteristics, including age, skin type, location, lesion thickness and response to treatment. A 30-50 ms cryogen spray cooling (CSC) duration will precede the laser pulse duration of 0.4 ms.
224204083|NCT04074122|DIAGNOSTIC_TEST|Adenosine and epinephrine, isoprenaline provocation|High-resolution electromechanical mapping at baseline and after provocative measures.
224204084|NCT06469476|BEHAVIORAL|depression post partum|visit post partum
224204085|NCT00118222|DRUG|porfimer sodium|All patients receive porfimer sodium IV.
224204086|NCT00118222|PROCEDURE|adjuvant therapy|All patients receive porfimer sodium IV.
224204087|NCT00118222|PROCEDURE|conventional surgery|All patients receive porfimer sodium IV. One day later, patients undergo craniotomy and tumor resection.
224204088|NCT02878239|OTHER|Steps 1|Kinematic characteristics are obtained by the portal gait analysis system in the patients. Kellgren-Lawrence Scores are obtained according to their radiography.
224204089|NCT02878239|OTHER|Steps 2|Kinematic characteristics are obtained by the portal gait analysis system in the subjects.Physical examinations are taken to avoid other diseases.
224204090|NCT01302639|DIETARY_SUPPLEMENT|Comparison of different combinations of polyphenols with respect to effects on fat oxidation|EGCG, resveratol and genistein
224313306|NCT03151408|DRUG|Pracinostat|60 mg capsule
224313307|NCT03151408|DRUG|Placebos|capsule
224313308|NCT03151408|DRUG|Azacitidine|SC or IV injection
224313309|NCT02938559|BEHAVIORAL|Cognitive Therapy (CT) for depression|There is evidence that CT for major depressive disorder (MDD) can be as effective as antidepressant medication for the initial treatment of moderate to severe MDD. Moreover, following the withdrawal of treatment, patients treated with CT are significantly less likely to relapse than patients treated with antidepressant medication and CT is at least as effective as antidepressant medication in preventing subsequent relapse. CT aims to alter the symptomatic expression of depression and reduce risk for subsequent episodes by correcting the negative beliefs and maladaptive information processing presumed to underlie the disorder and alter the systematic tendency to misperceive reality in a pessimistic fashion.
224313310|NCT02938559|BEHAVIORAL|Cognitive Therapy (CT) for depression + Memory Support|The Memory Support Intervention will be delivered interwoven with CT. The Memory Support Intervention is designed to improve patient memory for treatment and involves a series of specific procedures that support the encoding and retrieval stages of episodic memory. It is comprised of eight memory promoting strategies: attention recruitment, categorization, evaluation, application, repetition, practice remembering, cued-based reminder and praise recall. These strategies are proactively, strategically and intensively integrated into treatment-as-usual to support encoding. Memory support is delivered alongside each 'treatment point', defined as a main idea, principle, or experience that the treatment provider wants the patient to remember or implement as part of the treatment.
224313311|NCT04933448|OTHER|Ketogenic Diet|The ketogenic diet (KD) is an alternative feeding regimen that has been in use since 1921. It is a high-fat, low carbohydrate, and moderate protein diet. There are various forms of the KD. The classic KD consists of long-chain triglycerides with a fat-to-combined-protein-and-carbohydrate ratio that can vary. At the investigating institution, it is standard of care to initiate a ketogenic diet at a ratio of 2:1, and to increase the ratio to 3:1 or 4:1 as needed to achieve ketosis.
223511375|NCT01189227|PROCEDURE|Perioperative chemotherapy|Patients receive mFOLFOX6 or FOLFIRI chemotherapy IV over 3 hours on day 1. Patients receive an additional dose of fluorouracil over 46 hours using a portable pump. Treatment repeats for every 2 weeks for 6 cycles. Patients then undergo hepatic resection. Beginning 31-56 days after surgery, patients receive an additional 6 cycles of mFOLFOX6 or FOLFIRI chemotherapy.
223511376|NCT02245724|BIOLOGICAL|Stem Cell|Autologous bone marrow mononuclear cell transplantation
223761308|NCT00314366|BIOLOGICAL|Stem Cell Therapy|Cells are injected under electromechanical guidance and delivered by the Myostar catheter after NOGA mapping.
224204091|NCT05137639|PROCEDURE|Platelet-rich fibrin (PRF)|PRF was only applied in the experimental arm to improve wound bed conditions
224313312|NCT02744118|OTHER|5A's Model|"The adapted 5A's model will include the following elements:~1. Ask the patient about their marijuana use~2. Advise every patient to quit/reduce marijuana use using clear, specific personalized advice~3. Assess factors affecting choice of behavior and behavior change~4. Assist abstinence/reduction in in marijuana use using behavior change techniques to aid the patient~5. Arrange follow-up for ongoing assistance and support, and to adjust treatment plans"
224313313|NCT02744118|OTHER|Healthy Internet Use Model|"The Healthy Internet Use Model provides a framework for conversations between pediatric practitioners and their adolescent patients. It focuses on 3 key areas of social media behavior:~1. Balance~2. Boundaries~3. Communication"
224204092|NCT01366365|DRUG|methylnaltrexone|
224204093|NCT01366365|DRUG|placebo|
224313314|NCT04540679|OTHER|VIP4SCI|Technology-enabled self-management \& rehabilitation solution
224313315|NCT03578575|DRUG|Danggui Buxue Tang|Danggui Buxue Tang is an extracted powder of traditional Chinese medicine formula.
224204094|NCT00545493|DRUG|Tacrolimus|tacrolimus capsules, dosing according to blood trough levels: 12-15 ng/ml during months 1-6, 5-10 ng/ml during months 7-12 and 5-8 ng/ml thereafter
224204095|NCT00545493|DRUG|i.v. immunoglobulins|infusions, dosing: initially on three consecutive days 0,4 g/kg KG, thereafter 0,4 g/kg KG every month, after 12 months of treatment every two months).
224313316|NCT03578575|DRUG|Placebo|Placebo is a very low dose Danggui Buxue Tang powder.
224204096|NCT01940276|DRUG|Abiraterone acetate|
224204097|NCT01940276|DRUG|Prednisone|
224313317|NCT03730818|OTHER|Water-based Exercise Group|The intervention consist will of a water-based exercise protocol
224313318|NCT03730818|OTHER|Land-based Exercise Group|The intervention will consist of a land-based exercise protocol
224204098|NCT04473339|PROCEDURE|CRS+HIPEC|"Patients will undergo only CRS, HIPEC and IVCT.Patients will receive standard platinum-based combination doublet chemotherapy for 6-8 cycles after CRS and then followed by maintenance therapy.~A single drug lobaplatin(30mg/m2)will be administered in normal saline via HIPEC and it will be continued for 60 minutes in the hyperthermic phase (41°C-43°C). HIPEC will be performed at the 1st, 3rd and 5th day after CRS. The intravenous chemotherapy(IVCT) will start from 7th-14th day after CRS."
224204099|NCT04473339|PROCEDURE|CRS alone|Patients will undergo only CRS and IVCT.Patients will receive standard platinum-based combination doublet chemotherapy for 6-8 cycles after CRS and then followed by maintenance therapy.
224313319|NCT00493415|DRUG|nitroglycerin iv|loading dose of 4mg/h iv in the first 30 minutes, 2 mg/h iv in the next 23 hours and 30 minutes
224313320|NCT00493415|DRUG|placebo = nacl 0.9%|4 ml/h iv in the first 30 minutes, 2 ml /h iv in the next 23 hours and 30 minutes
224313321|NCT02235090|OTHER|Direct current stimulation of cervical spinal cord|10 minutes direct current stimulation of 0, 100 microamperes, 1 milliampere strengths applied through dermal electrodes to cervical spinal cord
224313322|NCT01478165|DRUG|Total intravenous anesthesia|Total intravenous anesthesia plus normal saline 1.5 ml immediately before induction of anesthesia
224313323|NCT01478165|DRUG|Total intravenous anesthesia plus palonosetron|Total intravenous anesthesia plus palonosetron 0.075 mg(1.5 ml)immediately before induction of anesthesia
224313324|NCT03206463|DRUG|4 mg Delta-9-THC|Subject will have 1/3 chance of receiving 4 mg THC administered through a vaporizer, over approximately 20 minutes, followed by approximately 45 minutes of neuropsychological and physiological testing.
224313325|NCT03206463|DRUG|Placebo|Subject will have 1/3 chance of receiving the inhaled placebo condition administered through a vaporizer, over approximately 20 minutes, followed by approximately 45 minutes of neuropsychological and physiological testing. The placebo condition will include no active cannabinoids.
223617316|NCT06214975|DEVICE|EXOPULSE Mollii Suit Stimulation|"We designed a randomized crossover, sham-controlled, double-blind trial to demonstrate the improvement of motor functions and stroke related symptoms following a single session of active versus sham EXOPULSE Mollii suit stimulation. in phase 1, the patient will receive two stimulations separated by a two-week washout period. The patients will be randomized to receive either active/sham or sham/active and both patients and investigators will be blinded to the order in which the stimulation will be given. A 2-week washout period should be enough to prevent a potential carry over effect. Two weeks after the end of phase 1, a second open label phase (phase 2) of this trial will be proposed to all patients where they will receive active stimulation every other day at home over four weeks (for a total of 14 sessions). This will help understand the long term effects of EXOPULSE Mollii suit stimulation on stroke related symptoms."
223617317|NCT04265196|OTHER|cognitive behavioral group therapy|A unique protocol that includes cognitive-behavioral psychological therapy with emphasis on coping with pain
223617318|NCT04265196|OTHER|Mindfulness-based group therapy|Unique protocol that includes mindfulness-based psychological therapy with emphasis on coping with pain
223617319|NCT01069432|OTHER|No Intervention|No Intervention
223617320|NCT00498459|BEHAVIORAL|Physical activity|Physical promotion according to socio-ecological model Limitation of sedentary behaviour
223617321|NCT00334217|BEHAVIORAL|Cognitive Remediation|PSS Cogrehab
223617322|NCT04602403|PROCEDURE|rigid ureteroscopy|endoscopic treatment of ureteric stones by extraction or peumatic desintegration or laser
223617323|NCT00128895|DRUG|azathioprine|azathioprine 2 mg/kg oral once daily, duration according to arm
223617324|NCT01587144|DRUG|Lucanthone|Lucanthone will be given as an oral at 10-15 mg/kg/day for 6 weeks during the concomitant phase. In the maintenance phase, placebo will be administered on days 1-5 of a 28-day cycle for 6 cycles.
223617325|NCT01587144|DRUG|Temozolomide (TMZ)|"TMZ is administered at 75mg/m2 daily for 42 days during the concomitant phase. TMZ is administered for an additional 6 cycles of maintenance treatment. Dosage in Cycle 1 (maintenance) is 150 mg/m2 once daily for 5 days followed by 23 days without treatment.~Cycles 2-6: At the start of Cycle 2, the dose can be escalated to 200 mg/m2, if the common terminology criteria (CTC) nonhematologic toxicity for Cycle 1 is Grade ≤2 (except for alopecia, nausea, and vomiting), absolute neutrophil count (ANC) is ≥1.5 x 109/L, and the platelet count is ≥100 x 109/L. The dose remains at 200 mg/m2 per day for the first 5 days of each subsequent cycle except if toxicity occurs."
223617326|NCT01587144|RADIATION|Radiation|60 Gy administered in 30 fractions for 42 days in the concomitant phase.
224204100|NCT04925531|DRUG|Antibiotics|to examine if either the utility of antibiotics administered for 3 days or 5 days make a difference in the clinical outcomes after facial fractures in trauma patients.
224313326|NCT03206463|DRUG|2 mg Delta-9-THC|Subject will have 1/3 chance of receiving 2 mg THC administered through a vaporizer, over approximately 20 minutes, followed by approximately 45 minutes of neuropsychological and physiological testing.
224313327|NCT01235195|DRUG|sertraline hydrochloride|50 mg capsule, single-dose
224204101|NCT03423914|BEHAVIORAL|Expressive writing|The emotional or expressive writing therapy developed by James Pennebaker has been used as a method of self-understanding in people with high levels of stress, chronic diseases, sexual and physical abuse, natural disasters and job loss, among others. Expressive writing allows and implies revealing the deepest thoughts and feelings of the person about a stressful or traumatic event in life translate emotions into words, and with that, reduce mental stress (decrease in levels of depression, stress and anxiety), strengthen self-esteem and even strengthen the immune system
224204102|NCT03423914|OTHER|Only Writing|Participants write about knowledge related to infant care during four days
224204103|NCT06516133|RADIATION|Intensity modulated radiation therapy (IMRT) with conventional planning target volume (PTV) margin and without online adaptive radiotherapy|"Radiation: Complete the full course of radiotherapy using the original treatment plan.~Planning target volume (PTV) margin: 3mm;"
224204104|NCT06516133|DRUG|Chemotherapy|Chemotherapy: If given, platinum-based.
224204105|NCT06516133|RADIATION|Intensity modulated radiation therapy (IMRT) with smaller planning target volume (PTV) margin and online adaptive radiotherapy|"Radiation: During the course of radiotherapy, the treatment plan is adjusted online based on the anatomical and dosimetric changes in the target volumes and organs at risk of patients.~planning target volume (PTV) margin: smaller."
224204106|NCT06516133|DRUG|Chemotherapy|Chemotherapy: If given, platinum-based
224204107|NCT06694168|PROCEDURE|Periodontal Regeneration, clinical and radiographic results, modified minimal invasive surgery|The Entire Papilla Preservation Technique (EPP) is a minimally invasive surgical approach for the treatment of intraosseous defects allowing access to the defect maintaining the integrity of the interproximal papilla. Studies have evaluated its efficacy for the regeneration of intraosseous periodontal defects with or without the use of regenerative biomaterials to fill the defect.
224204108|NCT06694168|PROCEDURE|REGEND001 Autologous Therapy Product|L-PRF is an autologous concentrate of platelet- and leukocyte-rich fibrin derived from blood, which through a centrifugation process allows to stimulate, improve and accelerate healing. The growth factors in the concentrates, together with pro-inflammatory and anti-inflammatory molecules, actively participate in the stimulation of the processes associated with tissue and bone repair and regeneration. Due to its high content of fibrin, platelets, leukocytes, monocytes and stem cells, L-PRF acts in immune regulation by controlling inflammation, with a continuous release of growth factors and presents an analgesic effect, which gives greater postoperative comfort to the patient. In addition, being an autologous product, it greatly reduces the risk of infection or rejection by the patient. Due to its beneficial biological effects, low costs and ease of preparation its use as a filling material in intraosseous defects will be evaluated.
224204109|NCT04074798|BEHAVIORAL|assessment of hyperventilation, postural control and psychological behavior|assessment of hyperventilation, postural control and psychological behavior
224204110|NCT03972709|DRUG|Galegenimab|Intravitreal (ITV) injections of galegenimab
224204111|NCT03972709|DRUG|Sham Control|Sham control
224204112|NCT00852072|PROCEDURE|Single-operator cholangioscopy-guided laser lithotripsy|Ability to clear the bile duct of all stones in one ERCP session using laser lithotripsy-based technique, including use of mechanical lithotripsy
224204113|NCT00852072|PROCEDURE|Balloon Sphincteroplasty|Ability to clear the bile duct of all stones in one ERCP session using large balloon sphincteroplasty-based technique, including use of mechanical lithotripsy
224204114|NCT05225116|DRUG|Sintilimab|Sintilimab will be at a dose of 200mg,Q3W
224204115|NCT05225116|DRUG|Lenvatinib|On the first day of the trial, Lenvatinib will be taken orally once daily （8mg/day ≤ 60kg or 12mg/day ≥60kg).
224204116|NCT05225116|RADIATION|radiotherapy|Radiotherapy will be completed within two weeks at a dose of 300cGy× 10 fraction
224204117|NCT05538039|OTHER|Distract with play dough|Distract with play dough
224204118|NCT05538039|OTHER|Distract with play kaleidoscope|Distract with play kaleidoscope
224204119|NCT05538039|OTHER|Control group|Routine nursing care
224204120|NCT02962869|DRUG|BAY987517|50 μl/ cm\*2 of the test article is applied directly to two sites on the skin and covered with the appropriate patch. Twenty-four (24) hours later, the patches are removed. The test sites are lightly wiped with a dry cloth/tissue and 3μl/ cm\*2 of test article is reapplied directly to the skin of the test site designated for irradiation, and lightly spread over the test site. Forty-eight (48) hours later the procedure is repeated to the same test sites. This process is repeated twice weekly for a total of six exposures. (Formulation number: Z43-078)
224313328|NCT01235195|DRUG|sertraline hydrochloride|50 mg tablet, single-dose
224313329|NCT02936414|DRUG|Berberine|Berberine (300 mg/tid), as an adjuvant therapy will be used on the basis of the SGAs monotherapy.
224313330|NCT02936414|DRUG|Placebo|Accept placebo(300 mg/tid)+SGAs monotherapy.
223617327|NCT01587144|DRUG|Placebo|Placebo will be given as an oral at 10-15 mg/kg/day for 6 weeks during the concomitant phase. In the maintenance phase, placebo will be administered on days 1-5 of a 28-day cycle for 6 cycles.
223617328|NCT01329627|DRUG|Paclitaxel/doxorubicin/cyclophosphamide|"Metronomic chemotherapy as described below:~1. Paclitaxel 100 mg/m2 once a week for 8 weeks followed by;~2. Doxorubicin 24 mg/m2 once a week concomitant to oral cyclophosphamide 100 mg/day (fix dose) for 9 weeks."
223617329|NCT01329627|DRUG|Paclitaxel/doxorubicin/cyclophosphamide|"Metronomic chemotherapy as described below:~Paclitaxel 100 mg/m2 once a week for 8 weeks followed by; Doxorubicin 24 mg/m2 once a week concomitant to oral cyclophosphamide 100 mg/day (fix dose) for 9 weeks."
224313331|NCT02771535|BEHAVIORAL|D-MCT|Metacognitive Training for Depression (D-MCT), 8 sessions (60min); twice a week over a period of 4 weeks. Metacognitive Training for depression (D-MCT) is a low-threshold, easy to administer group intervention. It aims at the reduction of depressive symptoms by changing cognitive biases; not only biases targeted in cognitive behavioral therapy but also those identified by basic research.
224313332|NCT02771535|BEHAVIORAL|Health Training|Health Training Group (Walking/ Psychoeducation on health); 8 sessions (60min), twice a week over a period of 4 weeks
223617330|NCT04388254|DRUG|Simufilam 100 mg oral tablet|Simufilam 100 mg oral tablet for b.i.d. administration
223511377|NCT03211832|OTHER|Dissemination of public health knowledge|Participating local health departments will help develop and choose dissemination strategies they prefer for their staff working in and supporting diabetes and chronic disease prevention and control to receive. Dissemination strategies may include multi-day in-person training workshops, electronic information exchange modalities, remote technical assistance, and information on ways to enhance organizational climates favorable to evidence-based diabetes prevention and control.
223511378|NCT00684554|DRUG|Buprenorphine|Dose is determined according to the participants' individual need.
224204121|NCT02962869|OTHER|Untreated skin|One site is patched without treatment as control
224204122|NCT01883531|DRUG|Inhaled Mannitol|Active treatment is inhaled mannitol with a particle size of 3-4 microns
224204123|NCT01883531|DRUG|Inhaled Placebo|The PLacebo is non respirable mannitol due to the big size particle
223511379|NCT00052897|BIOLOGICAL|HspE7|
223761309|NCT00314366|OTHER|Control (plasma)|Placebo patients receive an injection of plasma (control) containing 5 % albumin the the same quantity as the stem cell arm. A total of 15 injections of 0.2 ml to total 3.0 ml.
223761310|NCT01393743|DRUG|Perampanel|
223761311|NCT01393743|DRUG|Placebo comparator|
223761312|NCT04296981|OTHER|video-based patient information|explanatory video (8 minutes) concerning communication, stroke issues and stages of the continuum of care
224204124|NCT01885507|OTHER|Pass recommendations on ventilation factors and extubation|"* the use of tidal volume \< 7 ml/kg and of a positive expiratory pressure = 6 to 8 cmH20 (centimeter of water)~* extubation as soon as ventilatory weaning is associated with a glasgow coma scale equal or above 10 and cough"
224204125|NCT03433807|DRUG|Idebenone|900 mg idebenone/day (2 tablets to be taken 3 times a day with meals)
224204126|NCT04474288|DIAGNOSTIC_TEST|SARS-CoV-2 antibody testing|venipuncture for SARS-CoV-2 IgG
224204127|NCT00533585|DRUG|BAY 43-9006|Starting Dose of 200 mg orally twice a day on Day 3 through Day 19 of Cycle 1 and Days 2 through 19 of Cycle 2 and remaining cycles. Cycle is 21 days.
224204128|NCT00533585|DRUG|Paclitaxel|200 mg/m\^2 By Vein Over 3 Hours on Day 1.
224204129|NCT00533585|DRUG|Carboplatin|Area under curve (AUC) 6 By Vein Over 30 Minutes on Day 1.
224204130|NCT00533585|DRUG|Bevacizumab|Starting Dose of 5 mg/kg By Vein Over 90 minutes on Day 1.
224204131|NCT03544606|DRUG|isosorbide mononitrate|40 mg tablet of intra-vaginal IMN (Effox; MINAPHARMA, Cairo, Egypt) will be placed into the posterior fornix of the vagina, through a digital vaginal examination, every 4 h for a maximum of four doses.
224204132|NCT03544606|DRUG|Placebos|In placebo group (group 2) 40 mg intra-vaginal pyridoxine placebos every 4 h for a maximum of four doses will be given
224204133|NCT05409807|DEVICE|Ultrasound guided smart glasses assisted|Ultrasound guided smart glasses assisted interscalene nerve block
224204134|NCT05409807|DEVICE|Ultrasound guided|Ultrasound guided interscalene nerve block
224204135|NCT00446771|DRUG|Mannitol|
224204136|NCT03501017|OTHER|physical activity program|"The 12-week physical activity program was implemented under the guidance of nurse, in outdoors with the group, 5 days a week with warm up and cooling down for 10 minutes and normal walking tempo at a moderate pace for 30-45 minutes (3-6 km/hour).~Application of WHO Smoking Cessation Algorithm: After fagerström test was applied, the modified smoking cessation algorithm of WHO was applied to the individuals and those who decided to quit smoking were referred to smoking cessation outpatient clinics."
224204137|NCT03501017|OTHER|Routine Practice|As routine practice, a brochure provided from the Public Health Directorate on protection from CVD was delivered to the individuals in the control group.
224204138|NCT00091507|DRUG|GIK|Intravenous solution, 1.5ml/kg/hour, continuous infusion for total of 12 hours.
224204139|NCT00091507|DRUG|Placebo|Intravenous solution of Dextrose 5 percent at 1.5 ml/kg/hour for a total of 12 hours.
224204140|NCT04437407|DEVICE|PB2-1 prototype|PB2-1 prototype is a belt-like wearable device similar to the original PrenaBelt designed for pregnant women that permits supine positioning of the pelvis but, when in this position, provides subtle pressure points to the user's body and thereby activates the body's natural mechanism to reposition itself to relieve discomfort. It is expected to significantly decrease the amount of time a pregnant woman's pelvis is in the supine position overnight while promoting comfortable sleep.
224204141|NCT04437407|DEVICE|PB2-2 prototype|PB2-2 prototype is a belt-like wearable device designed for pregnant women. When placed on the woman's back, this device prevents the pelvis from achieving a supine orientation by maintaining at least fifteen degrees of right or left lateral pelvic tilt. It is expected to significantly decrease the amount of time a pregnant woman's pelvis is in the supine position overnight while promoting comfortable sleep.
224204142|NCT04437407|DEVICE|PB2-3 prototype|PB2-3 prototype is a belt-like wearable device designed for pregnant women. When placed on the woman's back, this device prevents the pelvis from achieving a supine orientation by maintaining at least fifteen degrees of right or left lateral pelvic tilt. It is expected to significantly decrease the amount of time a pregnant woman's pelvis is in the supine position overnight while promoting comfortable sleep.
224204143|NCT04437407|DEVICE|PB2-4 prototype|PB2-4 prototype is a belt-like wearable device designed for pregnant women that prevents the user from achieving a supine position as the device allows right and left lateral pelvic tilt but prevents the user's pelvis from settling supine due to virtue of its design. It is expected to significantly decrease the amount of time a pregnant woman's pelvis is in the supine position overnight while promoting comfortable sleep.
224204144|NCT04437407|DEVICE|PB2-5 prototype|PB2-5 prototype is a belt-like wearable device designed for pregnant women that does not provide positional therapy. It can be worn anytime as a maternity support belt.
224204145|NCT04437407|DEVICE|Ajuvia-Active|Ajuvia Sleep Monitor senses the user's body position and can be used in passive or active mode with or without the PB2 prototypes. In the active mode, it alerts the woman when her pelvis is in the supine position through a gentle vibratory alarm.
224204146|NCT04437407|DEVICE|Ajuvia-Passive|Ajuvia Sleep Monitor senses the user's body position and can be used in passive or active mode with or without the PB2 prototypes. In the passive mode, it measures and records the position of the pelvis but does not alert the woman.
224204147|NCT03449420|DIAGNOSTIC_TEST|thromboelastography|TEG5000® : Kaolin and Functional Fibrinogen tests on native blood sample
224313333|NCT03870867|OTHER|No intervention|No intervention
224313334|NCT01473524|DRUG|Obeticholic Acid (OCA)|OCA was administered orally once daily and provided in tablet form in 2 strengths: 5 mg and 10 mg.
224204148|NCT01879709|BEHAVIORAL|Yoga Training|Participants will be imparted yoga training for twenty-one days, for one hour a day. This will include postures or Asanas (exercises) and Pranayam (Breathing protocols). The training starts with 'Om' chanting followed by warm up exercises and then breathing exercises. The Breathing exercises (Pranayama) are practiced before practice of Asana.
224313335|NCT01473524|DRUG|Placebo|Matching placebo tablets were administered orally once daily.
224313336|NCT00140218|DRUG|R(+) pramipexole dihydrochloride monohydrate|10 mg tid oral
224313337|NCT04287335|DIAGNOSTIC_TEST|Multitarget stool FIT-DNA test - ColoClear|Multitarget stool FIT-DNA test
223511380|NCT01269320|DRUG|Femarelle|Study treatment will consist of Femarelle, two 530mg oral tablets (equivalent to 322 mg of DT56a and 108 mg of Linum Usitatissimum extract each) twice a day for 90 days
223511381|NCT04808895|DRUG|Acetylsalicylic acid|administration of one tablet daily for 15 days. On the first day a loading dose of 300 mg will be administered
224204149|NCT01879709|BEHAVIORAL|Physical Exercise|This group will take part in a general physical exercise program incorporating simple physical exercises for one hour daily, including Saturdays. The schedule will include fifteen minutes of brisk walking followed by light exercises adapted from the National Fitness Corps - Handbook for Middle High and Higher Secondary Schools as used by Duraiswamy et al. (2007).
224204150|NCT01879709|OTHER|Treatment as Usual|"Placebo Comparator: Treatment as Usual Group~Participants who will continue in the department with clinical treatment as usual. No supplementation will be provided"
223511382|NCT04808895|DRUG|Placebo|administration of one tablet daily for 15 days. On the first day 3 tablets will be administered
223511383|NCT01155310|DRUG|Helium/Oxygen 78%/22%|"The Helium/Oxygen mixture will be administered during NIV and NIV-free sessions for a maximum of 72 hours using study dedicated devices.~Patients will then receive the Air/Oxygen mixture with usual devices."
223511384|NCT01155310|DRUG|Air/Oxygen|"The Helium/Oxygen mixture will be administered during NIV and NIV-free sessions for a maximum of 72 hours using study dedicated devices.~Patients will then receive the Air/Oxygen mixture with usual devices."
223511385|NCT05336760|DIAGNOSTIC_TEST|Iowa Oral Performance Instrument (IOPI)|IOPI measures the peak pressure of the tongue strength and endurance using a disposable bulb placed on a hard palate behind the front teeth or at the base of the tongue. The participants will be asked to press the bulb with their tongue with maximum pressure, three times. To measure the endurance, the participants will be asked to hold the pressure for as long as they can.
223511386|NCT05336760|DIAGNOSTIC_TEST|Mann Assessment of Swallowing Ability (MASA)|MASA is a standard clinical swallowing assessment protocol including general patient examination, on-the-outside visible signs of oral preparatory and transportation phase and pharyngeal phase of swallowing function.
223511387|NCT05336760|DIAGNOSTIC_TEST|Fiberoptic Endoscopic Evaluation of Swallowing|The subjects will ingest up to 10 boluses ranging in thickness and volume (from thin to extremely-thick and a cookie).
223511388|NCT05336760|DIAGNOSTIC_TEST|Respiratory function measurements|Respiratory function measurements will include forced vital capacity (FVC), maximum inspiratory pressure (MIP), and maximum expiratory pressure (MEP), all expressed in percentage of predicted values. Conventional methods of testing will be applied.
224204151|NCT04918927|DRUG|Favipiravir|Oral Favipiravir 1800 mg twice daily on Day 1, followed by 400 mg four (4) times daily from Day 2 to Day 7
224204152|NCT04918927|DRUG|Nitazoxanide|Nitazoxanide at 1000 mg twice daily on Day 1 followed by 500 mg four (4) times daily from Day 2 to Day 7
224204153|NCT04918927|OTHER|Nitazoxanide Placebo|Nitazoxanide matched placebo at 1000 mg twice daily on Day 1 followed by 500 mg four (4) times daily from Day 2 to Day 7.
224204154|NCT00633009|BIOLOGICAL|Leishmania tropica Skin Test Antigen (LtSTA)|Administer 15 ug, 30 ug or 50 ug of LtSTA into DTH positive volunteers. Repeat drug administration 30 days after initial injection and 60 days after initial injection. Read and interpret reaction 48 hours after each injection. Observe subjects for conversion or adverse reaction.
224204155|NCT00633009|BIOLOGICAL|Leishmania tropica Skin Test Antigen Placebo (Placebo)|Administer Placebo concurrently with 15 ug, 30 ug and 50 ug doses of LtSTA. Read and interpret the reaction 48 hours after injection. Observe subjects for reaction to Placebo
224204156|NCT06568965|OTHER|De-stress & happy gut powder-U001|Take one sachet daily, 30 minutes before breakfast, for 60 days
223511389|NCT02660346|DRUG|Daptomycin|Control Arm Treatment if used as monotherapy. Study Arm Treatment if used in combination with ceftaroline.
224204157|NCT06568965|OTHER|De-Stress & Happy Gut powder-I001|Take one sachet daily, 30 minutes before breakfast, for 60 days
224204158|NCT06568965|OTHER|Placebo Powder 001|Take one sachet daily, 30 minutes before breakfast, for 60 days
224204159|NCT03933982|DRUG|Pyrotinib Plus Vinorelbine|Pyrotinib: 320mg/d, q.d., p.o. A course of treatment need 21 days. Vinorelbine: 60mg/m2 q.d. d1,8,15, p.o. A course of treatment need 21 day.
224204160|NCT00203931|DRUG|Cetuximab|
224204161|NCT00203931|DRUG|Pemetrexed|
224313338|NCT04287335|DIAGNOSTIC_TEST|FIT|fecal immunochemical test
224313339|NCT04287335|PROCEDURE|Colonoscopy|diagnostic colonoscopy
224313340|NCT00006216|BIOLOGICAL|PA-1-STK ovarian carcinoma vaccine|
224313341|NCT00006216|DRUG|ganciclovir|
224313342|NCT06447311|OTHER|Hyaluronic acid gel|Hyaluronic acid is involved in tissue repair and wound healing by stimulating cell proliferation, migration and interaction with several growth factors. Furthermore, HA has a crucial role in space-filling owing to its hygroscopic nature.
224313343|NCT06633328|DRUG|CD7 CAR-T cells injection|CD7 CAR T cells treat patients with severe aplastic anemia
224313344|NCT06633328|OTHER|Allogeneic hematopoietic stem cell transplantation|In this study, Allogeneic hematopoietic stem cell transplantation is used as a bridge therapy to CD7 CAR T cells infusion to treat patients with severe aplastic anemia
224313345|NCT02410980|DRUG|Tretinoin cream 0.1%|Assessment of the skin change
224313346|NCT02383810|DRUG|Elsiglutide|
224313347|NCT02383810|DRUG|Placebo|
224313348|NCT01046786|BIOLOGICAL|Umbilical Cord Blood Mononuclear Cell|The cord blood mononuclear cells are obtained from thawed units of HLA-matched human umbilical cord blood. The cells will be slowly injected into the posterior gray matter after laminectomy and opening of the dura.
223511390|NCT02660346|DRUG|Vancomycin|Control Arm Treatment
223511391|NCT02660346|DRUG|Ceftaroline|Study Arm Treatment
223617331|NCT04388254|DRUG|Placebo|Matching placebo oral tablets
224204162|NCT01057160|DRUG|Rizatriptan|use of rizatriptan 10 mg for one migraine attack, in comparison to previously used analgetic
224313349|NCT01046786|DRUG|Methylprednisolone|30 mg/kg methylprednisolone
224313350|NCT01046786|DRUG|Lithium|oral lithium, titrated to maintain 0.6-1.0 mM serum level
224313351|NCT05794360|BEHAVIORAL|ACtive Children Enhance LEaRning and AttenTION (ACCELERATION)|A diverse group of key informants (i.e., PE teachers, school athletic department director) and community stakeholders (i.e., professional soccer coaches, Houston Dynamo Academy director) were engaged to help the research team design, modify, and implement the ACCELERATION curriculum to ensure program relevance and appeal. There are several components that described below make our program design both comprehensive and highly adaptable for optimal reach and effectiveness. These include staff development training, parent workshops, on-site and virtual developmental programs, delivery and implementation support from community stakeholders, online resources, family engagement events, equipment donations to improve activity, and on-going support and mentoring services for parents and school-based educators.
224313352|NCT01911286|PROCEDURE|Apnea test - Standard|
224313353|NCT01911286|PROCEDURE|Apnea test - CPAP|
224313354|NCT01782235|DRUG|Tocilizumab|
224204163|NCT01579292|BEHAVIORAL|Mobile phone based physical activity with intervention|This group will receive a mobile phone software program and a pedometer. Over a 5-month period, participants in this group will be asked to participate in 6 in-person sessions, wear a pedometer, use a mobile phone physical activity and diet diary, and respond to daily physical activity and diet messages or video clips.
224313355|NCT01782235|DRUG|Placebo|
224313356|NCT01194986|OTHER|[11C]AZ12807110|Radioligand
224313357|NCT01194986|DRUG|AZD5213|
223761313|NCT04246385|BEHAVIORAL|CO-OP Group|"Participants in the intervention group will attend one 1:1 session where one goal will be selected from their COPM results to focus on during the group, group expectations will be reviewed, caregivers will be invited, and questions answered. The group will run six sessions as supported by the literature (Chan, 2007; Lee, Fischer, Zera, Robertson, \& Hammel 2017).~Day Rehab CO-OP Group Curriculum Session Content~Introduction One on one session. COPM, introduction to group, education for caregiver. Session 1 Introduction to group and CO-OP approach, homework. Session 2 Review CO-OP approach, practice, homework. Session 3 Review CO-OP approach, plan outing, homework. Session 4 Review CO-OP approach, experiential learning according to participants' alternate COPM goals, homework. Session 5 Review CO-OP approach, outing, homework. Session 6 Review CO-OP approach, focus group, lessons learned, final COPM, homework"
223761314|NCT02581384|RADIATION|Stereotactic Body Radiotherapy (SBRT)|
223761315|NCT01076504|DRUG|Amrubicin|30 mg/m2 IV on Days 1-3 of each 3-week treatment cycle
224313358|NCT02549586|DRUG|Autologous Hematopoietic Stem Cell Transplant|"Step 1: Participants will receive intravenous chemotherapy and cytokine-based treatment for mobilization of hematopoietic stem cells (HSC) into the circulation, followed by collection using peripheral vein leukopheresis. The HSC graft product will undergo ex vivo purification with CD34 selection using Miltenyil CliniMACS and cryopreserved.~Step 2: Intravenous busulphan, cyclophosphamide and anti-thymocyte globulin will be administered to participants to achieve immune ablation prior to the infusion of the participants' own thawed HSC graft product (HSC transplant). Routine supportive measures will be employed during the recovery from the chemotherapy and HSCT. Participants' immune suppression will be stopped at the time of immunoablative therapy and will be switched to everolimus which will be discontinued at 6 months post HSCT."
224313359|NCT00282919|DRUG|Azithromycin plus chloroquine|dose of 2000 mg Azithromycin plus 600 mg chloroquine base
223761316|NCT01076504|DRUG|Carboplatin|AUC=5 IV, Day 1 of each 3-week treatment cycle
224313360|NCT01327508|DEVICE|TRIGEN SURESHOT Distal Targeting Instrumentation.|image-guided localization system
224313361|NCT01327508|OTHER|Free-hand technique|Free-hand technique utilizes x-rays to find screw holes.
223511392|NCT00908908|DRUG|eribulin|Cycle 1 day 1: radio-labeled dose of 2 mg radioactive eribulin, followed by 1.4 mg/m\^2 of non-radio-labeled eribulin thereafter on days 1 and 8 every 21 days.
223511393|NCT02277366|PROCEDURE|Fluorescence Bronchoscopy/Narrow Band Bronchoscopy|Fluorescence Bronchoscopy and Narrow Band Bronchoscopy are used in the Fluorescence/Narrow Band Bronchoscopy group to make a diagnosis of lung cancer.
223761317|NCT01076504|DRUG|Pegfilgrastim|6 mg SQ on Day 4 of each 3 week treatment cycle
224204164|NCT01579292|BEHAVIORAL|Pedometer Only|This group will receive a pedometer. Over a 5-month period, participants in this group will be asked to wear a pedometer.
224204165|NCT05672160|DIAGNOSTIC_TEST|CT evaluated sarcopenia|At L3 level of CT scan we will measure the area and density of muscles and fat tissue. We devided the patients to sarcopenia and non-sarcopenia groups according to these values.
224204166|NCT00893230|DIETARY_SUPPLEMENT|probiotic L sakei KCTC 10755BP|freeze-dried, 50,0000,0000 colony-forming units, twice daily, for 12 weeks
224204167|NCT00893230|DIETARY_SUPPLEMENT|microcrystalline cellulose (placebo)|freeze-dried, 50,0000,0000 colony-forming units, twice daily, for 12 weeks
224313362|NCT04840537|PROCEDURE|endoscopic retrograde cholangiopancreatography with cholangioscopy in the first procedure of ERCP|endoscopic retrograde cholangiopancreatography with cholangioscopy in the first procedure for exploration of an indeterminate biliary stenosis and biliary drainage
224313363|NCT01413607|DEVICE|Quill knotless tissue-closure device|The Quill knotless tissue-closure device is a barbed suture that allows the surgeon to keep tissue approximation without maintaining tension on the suture.
224313364|NCT01413607|DEVICE|2-0 absorbable vicryl suture|In the control group a traditional 2-0 absorbable vicryl suture (Ethicon) will be used to close the central defect in the kidney.
224313365|NCT06048965|OTHER|No intervention to be performed|No intervention to be performed. Anonymous survey only.
223511394|NCT04217057|DRUG|64Cu-DOTA-ECL1i|Will be produced by the Cyclotron Facility at Washington University School of Medicine
223511395|NCT06097988|DEVICE|ABIO3419|Intra-articular injection
223512458|NCT03611361|DEVICE|SpectralMD DeepView Wound Imaging System 2.0|The DeepView is an imaging device which simultaneously performs multispectral imaging (MSI) measurements across the visible and infrared spectrum to obtain a quantitative tissue viability assessment. These optical measurements are integrated using a machine learning (ML) algorithm to categorize microvascular blood flow and provide a quantitative assessment for selection of tissue healing.
223761318|NCT03738371|OTHER|In situ simulation|Team involved in thrombectomy procedures will be trained by in situ simulation. Simulation will reproduce the initial step of a thrombectomy procedure, i.e from from the installation of the patient to the percutaneous punch by the neuroradiologist. Simulation will be followed by a debriefing focused on the team performance. Three in situ simulation sessions will be realized by each team.
224204168|NCT03622086|OTHER|Foundations of Fitness Program|The Foundations of Fitness Program is a 12 week, bi-weekly community intensive lifestyle program which focuses on healthy diet, daily physical activity, self-esteem and support for individual and family behavior change, components supported by USPSTF evidence review. Class sessions, which involve both parent/caregiver and child will include structured fitness activities, hands on nutrition, cooking, shopping and meal planning and facilitated discussions about goal setting, self-monitoring, stimulus control and healthy homes and families. Content will be offered in a context that supports self-esteem and behavior change. The program was developed by the Carter Community Building Association (CCBA) in collaboration with the Dartmouth-Hitchcock Weight \& Wellness Center research core.
224204169|NCT01872858|DRUG|Aspirin|Aspirin, 100mg, Q.D, p.o, 2yr
224204170|NCT01872858|DRUG|Cilostazol|cilostazol, 100mg, B.I.D, p.o, 2yr
224204171|NCT00935415|DRUG|Montelukast|Montelukast 5 mg
224204172|NCT00935415|DRUG|Placebo|capsules of matching placebo
224204173|NCT06538909|DEVICE|VR|Virtual reality that simulates obstacles on the road during walking
224204174|NCT01947257|OTHER|the measure TRVMAX|by transthoracic echocardiography
224204175|NCT01947257|OTHER|the measure of the pulmonary artery|by transesophageal ultrasound
224204176|NCT01947257|OTHER|the direct measure of the pulmonary pressures|by right catheterization
224204177|NCT05357209|DEVICE|Avidhrt Sense Heart Monitor|Use of Avidhrt Sense Heart Monitor review ECG signals.
224204178|NCT05254093|OTHER|Quadratus lumborum block|quadratus lumborum block, anterior approach using a curvilinear (5-8MHz) transducer. The transducer will be positioned transverse above the iliac crest at the posterior axillary line and slided posteriorly till the Shamrock sign is identified (the transvers process represent the stem and the attached erector spinae, QL and Psoas major muscles represent the three leaves). A 22 G, 100 mm needle will be advanced in-plane from lateral to medial through the QL muscle to reach the inter-fascial plane between the QL and psoas major muscles, posterior to the transversalis fascia. After ensuring negative aspiration, the local anesthetic solution (20 ml of 0.25% isobaric bupivacaine) will be injected anterior to the QL muscle. The procedure will be repeated on the opposite side of the back
224204179|NCT05254093|OTHER|erector spinae plane block|the block will be given at the level of the 9th thoracic transverse process using a linear 6-13 MHz ultrasound transducer. The transducer will be positioned vertically 3 cm to the side of the midline to visualize the muscles of the back, the transverse process, and the pleura between the two transverse processes. Then, a 22G 10-mm needle will be introduced in the cranial-caudal direction toward the transverse process (T9) using the in-plane method till the needle tip crosses all the muscles. The tip of needle should be in the plane between the transverse process and the erector spinae muscle. After ensuring negative aspiration, the local anesthetic solution (20 ml of 0.25% isobaric bupivacaine) will be injected below the muscle. The procedure will be repeated on the opposite side of the back
224204180|NCT00351078|DRUG|PTC124|4-,4-, and 8-mg/kg PO first 14 days 10-, 10-, and 20-mg/kg TID second 14 days
224204181|NCT06123494|DRUG|SHR-A1811|SHR-A1811 6.4 mg/kg IV infusion every 3 weeks on Day 1 of each 21-day cycle
224204182|NCT06123494|DRUG|Ramucirumab / Paclitaxel/ Docetaxel/ Irinotecan|Ramucirumab 8mg/kg，D 1,15 + Paclitaxel 80mg/m2，D1,8,15，Q4W; Paclitaxel 80mg/m2，D1,8,15，Q4W; Docetaxel 75mg/m2，D1，Q3W; Irinotecan 150mg/m2，D1，Q2W.
224204183|NCT03392415|PROCEDURE|CTO PCI|attempted percutaneous coronary intervention of the chronic total coronary occlusion
224204184|NCT01073059|DRUG|Valproic acid and Ertapenem|
224204185|NCT00200590|DRUG|acetaminophen and nalbuphine|
224204186|NCT00200590|DRUG|acetaminophen and morphine|
224204187|NCT00200590|DRUG|acetaminophen and reduced dosage of prostaglandin|
224204188|NCT00877214|DRUG|Rituximab|Follicular Lymphomas: induction therapy with bendamustine + rituximab. If CR or PR: Maintenance therapy with rituximab every 2 months for 4 years Immunocytomas, marginal zone and mantle cell lymphomas: induction therapy with bendamustine + rituximab If CR or PR: Maintenance therapy with rituximab every 2 months for 2 years
224204189|NCT00877214|DRUG|Rituximab / observation|Follicular Lymphomas:induction therapy with bendamustine + rituximab If CR or PR: Maintenance therapy with rituximab every 2 months for 2 years (standard) Immunocytomas, marginal zone and mantle cell lymphomas: induction therapy with bendamustine + rituximab If CR or PR: observation (standard)
223512459|NCT02046876|OTHER|Multimodal Physiotherapy Program|Multimodal Physiotherapy Program integrates: physical land-based therapeutic exercise, adapted swimming and health education
224204190|NCT04200781|DRUG|Granules of Shengdi Dahuang Decoction|Shengdi Dahuang Decoction contains Shengdi (rehmannia) and Dahuang ( rhubarb). Each pack of the granules of Shengdi Dahuang Decoction contains 15 grams of rehmannia and 5 grams of rhubarb.
224204191|NCT04200781|DRUG|Placebo|Placebo granules has the same appearence, weight, shape and color as the experimental drug.
224204192|NCT00246441|DRUG|Paroxetine|16 weeks treatment; dosing will start at 20 mg/day paroxetine and will increase gradually to a maximum dose of 60 mg/day
224204193|NCT00246441|DRUG|Placebo|treatment phase will last 16 weeks; dosing will start at 20 mg/day (placebo) and will increase gradually to a maximum dose of 60 mg/day.
224204194|NCT00003119|BIOLOGICAL|filgrastim|
224204195|NCT00003119|BIOLOGICAL|sargramostim|
224204196|NCT00003119|DRUG|carboplatin|
224204197|NCT00003119|DRUG|cyclophosphamide|
224204198|NCT00003119|DRUG|doxorubicin hydrochloride|
224204199|NCT00003119|DRUG|etoposide|
224204200|NCT00003119|PROCEDURE|adjuvant therapy|
224204201|NCT00003119|PROCEDURE|conventional surgery|
224204202|NCT00003119|RADIATION|radiation therapy|
224313366|NCT02935153|BIOLOGICAL|Anti-CD22-CAR-transduced T cells|The first 3 enrolled patients will receive autologous-derived CD22-targeted CAR-T cells on day 1, 2 and 3 with respective 10%, 30% and 60% of the total expected dosage after receiving lymphodepleting chemotherapy. If the 3 patients don't display severe toxicity, the next patients enrolled will get infused in 2 days with respective 40% and 60% total dosage.
224313367|NCT01967914|OTHER|PVI|Measurement of PVI (plethysmography variability index)
223511396|NCT06964074|DEVICE|Nebulization with OPEP device|"During hospitalization due to exacerbation of the bronchopulmonary disease, patients performed inhalations twice a day using one of two devices: PARI PEP® S System (produced by PARI, Germany) with a dedicated Pari LC Sprint nebulizer or the Aerobika\*OPEP Device (produced by TRUDELL MEDICAL INTERNATIONAL) with a dedicated Aero Eclipse XL nebulizer, or they were in the control group where they performed inhalations in the standard way using the Pari LC Sprint nebulizer (produced by PARI, Germany). Frequency: twice daily. Inhalation duration: 10 minutes. Immediately after inhalation, each patient performed physiotherapy in the same scheme using the Pari OPEP device, 15 exhalations, and autogenic drainage technique according to the method's concept, with the drainage duration ranging from 15 to 30 minutes."
224204203|NCT05013749|PROCEDURE|Hysterectomy|Hysterectomy: An incision will be made above the level of the placenta, delivering the newborn. Uterotonics will be administered, and spontaneous delivery of the placenta will be awaited using gentle traction. The absence of spontaneous separation of the placenta will confirm the diagnosis of PAS, the patient will undergo to hysterectomy. The complete removal of the uterus will be attempted, including the cervix, the duration of the intervention and intraoperative blood loss will be recorded, as well as the damage to organs neighboring the uterus. In this arm of the study, to hysterectomy will be performed in 100% of patients
224204204|NCT05013749|PROCEDURE|Partial Myometrial Resection|Partial myometrial resection: The technique described by Palacios-Jaraquemada et al5. will be followed. Briefly, the uterus will be dissected to free it from the posterior wall of the bladder to the cervix. The vesico-uterine vessels will be ligated and the parametrial space will be visualized. The hysterotomy will be performed in the upper segment, immediately above the area of invasion of the myometrium. The entire invaded myometrium and the entire placenta will be removed. The uterus will repair itself in one or two layers. Intrauterine balloon tamponade will be used if indicated.
224204205|NCT02017535|DRUG|Fluoxetine|Prozac (fluoxetine capsules, USP) is a selective serotonin reuptake inhibitor for oral administration.
224204206|NCT02017535|BEHAVIORAL|Interpersonal Psychotherapy|Type of talk therapy that focuses on an adolescents relationship and communication skills in the context of of their depression.
224204207|NCT02806635|BEHAVIORAL|OurRelationship|
224204208|NCT02806635|BEHAVIORAL|PREP Online|
224204209|NCT02421770|OTHER|Chamaemelum nobile 2%|"Experimental Chamaemelum Nobile 2% gel Active During the 6-week double-blind phase, all patients will be randomly assigned to receive Chamaemelum Nobile 2% gel Active or its vehicle twice daily with occlusion on the affected are"
224204210|NCT02421770|OTHER|placebo|
224204211|NCT06169020|DEVICE|Resting and maximal oxygen consumtion|All subjects will undergo tests for resting and maximal oxygen consumption while simoultaneously wearing a number of wearables and a heart rate monitor. They will also be tested for health related physical fitness and resting blood pressure. Their body composition will also be measured.
224204212|NCT06169020|DEVICE|Free living energy expenditure|All subjects will ingest a dose of doubly labelled water after which they will be fitted with several wearables. They will live their ordinary lives except that they will collect daily urine samples.
224204213|NCT05613920|BEHAVIORAL|diet management program based on the nudge strategy|The intervention group received a 12-week dietary management intervention based on the nudge strategy. The MINDSPACE framework was used, which has nine intervention categories. Face-to-face intervention and telephone follow-up were used to provide targeted dietary management.
224204214|NCT02421107|OTHER|Glysure CGM|
224204215|NCT02421107|OTHER|iStat intermittent testing|
224204216|NCT05785026|OTHER|Menthol inhalation|300 milligrams of L-menthol will be deposited on to a cellulose swab and secured inside the lower portion of a sealed facemask.
224204217|NCT05785026|OTHER|Strawberry scent|600 microliters of 100% natural strawberry flavoring will be deposited onto on to a cellulose swab and secured inside the lower portion of a sealed facemask.
224204218|NCT06435598|OTHER|video-based health education|The video- based health education program guided by the Health Belief Model will be designed to provide tailored information on insulin therapy in diabetes. Health Belief Model(HBM) emphasizes changes in people's behavior are acquired through awareness of risk factors and perceived health benefits. The video will provide general information on insulin, types of insulin, its administration technique and storage.
224204219|NCT01393626|DRUG|Placebo|oral tablets twice daily
224204220|NCT01393626|DRUG|CP-690,550|oral tablets twice daily
224204221|NCT01393626|DRUG|CP-690,550|oral tablets twice daily
223617332|NCT04104386|OTHER|Telomere Disclosure Impact|Participants were either provided or not provided information about their personal telomere length and how they compared to the rest of the sample.
224313368|NCT01750489|DEVICE|non-invasive ventilation (NIV)|
224313369|NCT02378792|DEVICE|Vagus Nerve Stimulation|Vagus Nerve Stimulator
224313370|NCT03479567|OTHER|Gait accelerometry|accelerometric assessment of gait (Dynaport Hybrid): 7m walk in 3 conditions (normal pace, fast, double task)
223511397|NCT06964074|DEVICE|Nebulization with PEP device|"During hospitalization due to exacerbation of the bronchopulmonary disease, patients performed inhalations twice a day using one of two devices: PARI PEP® S System (produced by PARI, Germany) with a dedicated Pari LC Sprint nebulizer or the Aerobika\*OPEP Device (produced by TRUDELL MEDICAL INTERNATIONAL) with a dedicated Aero Eclipse XL nebulizer, or they were in the control group where they performed inhalations in the standard way using the Pari LC Sprint nebulizer (produced by PARI, Germany). Frequency: twice daily. Inhalation duration: 10 minutes. Immediately after inhalation, each patient performed physiotherapy in the same scheme using the Pari OPEP device, 15 exhalations, and autogenic drainage technique according to the method's concept, with the drainage duration ranging from 15 to 30 minutes."
223617333|NCT03965013|DRUG|NNC0268-0965|2 to 3 dose levels will be tested in Part 1. 3 to 5 dose levels will be tested in Part 2
223617334|NCT03965013|DRUG|Placebo|A single dose of placebo given in Part 1
223617335|NCT03965013|DRUG|insulin glargine|Insulin glargine given at a fixed dose level of 0.5 U/kg
223617336|NCT01670721|DRUG|AFLIBERCEPT|Pharmaceutical form:Concentrate for solution for infusion; Route of administration: Intravenous
223617337|NCT01670721|DRUG|Irinotecan|Pharmaceutical form:Concentrate for solution for infusion; Route of administration: Intravenous
223617338|NCT01670721|DRUG|Fluorouracil|Pharmaceutical form:Concentrate for solution for infusion; Route of administration: Intravenous
224313371|NCT03479567|OTHER|balance accelerometry|accelerometric assessment of balance (Dynaport Hybrid) during 10 seconds trial in 3 conditions (side-by-side, semitandem, tandem)
224313372|NCT03479567|OTHER|Fine motor skill test|assessment of fine motor skills with Purdue Pegboard, with dominant hand, non-dominant hand and bimanual
224313373|NCT03479567|DIAGNOSTIC_TEST|Paratonia Assessment Instrument (PAI)|diagnosis of paratonia based on passive movement of the four limbs
224313374|NCT03479567|OTHER|myotonometric measurement of muscle tone|MyotonPRO measurement of muscle tone
224313375|NCT04395144|PROCEDURE|Awake Prone Positioning|Patients will receive instruction to remain in prone position as long and as often as possible, up to 16h/24h
224313376|NCT04395144|PROCEDURE|Standard care|Patients will not receive any special instructions with regards to proning.
224313377|NCT03608865|DRUG|Durvalumab with Tremelimumab|Trial treatment should be administered on Day 1 of each cycle after all procedures/assessments have been completed as detailed on the Trial Flow Chart. Trial treatment may be administered up to 3 days before or after the scheduled Day 1 of each cycle due to administrative reasons. All trial treatments will be administered on an outpatient basis. Durvalumab 1500mg + tremelimumab 750 mg will be administered as a 60 minute each one IV infusion every 4 weeks. Sites should make every effort to target infusion timing to be as close to 60 minutes as possible. However, given the variability of infusion pumps from site to site.
224313378|NCT03278392|BEHAVIORAL|Trier Social Stress Test|Task instructions provided to subject (5mins), subject prepares speech on their strengths and weaknesses (5 mins), subject delivers speech before a stern evaluative committee while being video-taped (5 mins), subject completes a mental arithmetic challenge task before the evaluative committee with critiques if errors are made (5mins).
224313379|NCT03278392|BEHAVIORAL|Placebo Non-stress task|Subject engages in a friendly conversation about a neutral or happy topic (e.g. recent holiday, favorite past-times) for 15 minutes with a familiar research staff member.
224313380|NCT05800158|DIAGNOSTIC_TEST|Applied Biosystems™ TaqPath™ COVID-19 Diagnostic PCR Kit|A reverse transcription, real-time polymerase chain reaction (RT-qPCR) test for the qualitative detection of SARS-CoV-2.
224313381|NCT00581165|DRUG|Etanercept|recommended dose of enbrel is 25mg administered twice weekly.
224313382|NCT02456935|DRUG|CJ-12420 100 mg QD|CJ-12420 100 mg tablets will be orally administered, once daily, for up to 8 weeks. For subjects whose erosive esophagitis is not endoscopically healed at Week 4, subjects will receive additional 4 week treatment of CJ-12420 100 mg.
224204222|NCT02935946|OTHER|Cold Liquid Barium|Cold Liquid is defined as being between 4-9 °C. One liter bottles of Poland Spring Natural Spring Water will be kept in the radiology suite to remain at room temperature. As described by Fink and colleagues,(42) the bottled water will be used to mix the barium powder to create a thin liquid consistency, with 50% dilution, which is found to be most similar to human milk and infant formula. After the barium is prepared, 2oz will be poured into a bottle and placed in a refrigerator set to 36°F; this will allow the barium to cool to approximately 4-9°C. Before oral administration, the barium mixture will be measured with a thermometer (TP3001 Digital Thermometer from Red Lantern®) to document the exact temperature.
224204223|NCT02426125|DRUG|Ramucirumab|Administered IV
224204224|NCT02426125|DRUG|Docetaxel|Administered IV
224204225|NCT02426125|DRUG|Placebo|Administered IV
224313383|NCT02456935|DRUG|Esomeprazole 40 mg QD|Esomeprazole 40 mg tablets will be orally administered, once daily, for up to 8 weeks. For subjects whose erosive esophagitis is not endoscopically healed at Week 4, subjects will receive additional 4 week treatment of Esomeprazole 40 mg.
224313384|NCT02861014|BIOLOGICAL|Ocrelizumab|Ocrelizumab will be administered as two 300 mg IV infusions on Days 1 and 15 followed by one 600 mg IV infusions administered at Weeks 24, 48, and 72.
224313385|NCT00002780|BIOLOGICAL|aldesleukin|
224313386|NCT00002780|BIOLOGICAL|cytokine therapy|
224313387|NCT00002780|BIOLOGICAL|sargramostim|
224313388|NCT00002780|DRUG|carboplatin|
223512460|NCT01034657|DRUG|LBH589|LBH589 was supplied at dose strengths of 5 mg or 20 mg hard gelatin capsules.
223512461|NCT01034657|DRUG|Epoetin Alfa|Epoetin alfa was supplied as 10000 IU/1 mL in a ready-to-use syringe.
223512462|NCT00930800|OTHER|Exercise|Using a video game so-called Dance Dance Revolution (DDR)
223512463|NCT05294146|DRUG|Clofazimine|"All participants will receive an (experimental) oral loading dose regimen of 300 mg clofazimine once daily (= 3 capsules of 100 mg) for 4 weeks. Afterwards, all participants will continue with a standard oral dose of 100 mg clofazimine once daily (= 1 capsule of 100 mg) until a total 4 months of treatment with CFZ.~Blood samples will be taken at Day 28 (+/- 2 days), Day 29 (Day 28 +1) and after 4 months of treatment to assess the pharmacokinetics of CFZ, both with the loading dose and the standard dose. In addition, the safety/tolerability of CFZ will monitored."
223512464|NCT01941342|PROCEDURE|Pancreatoduodenectomy|
223512465|NCT01941342|PROCEDURE|ENBD and Pancreatoduodenectomy|
223512466|NCT01941342|PROCEDURE|EBD and Pancreatoduodenectomy|
223512467|NCT01941342|PROCEDURE|PTCD and Pancreatoduodenectomy|
224313389|NCT00002780|DRUG|cyclophosphamide|
224313390|NCT00002780|DRUG|thiotepa|
224313391|NCT00002780|PROCEDURE|peripheral blood stem cell transplantation|
224313392|NCT00926783|PROCEDURE|CFAE ablation|CFAE ablation (targeted vs. generalized)
224313393|NCT00236912|DRUG|levofloxacin; metronidazole|
224313394|NCT05577221|DEVICE|High Flow Nasal Air|Administration of air at high flow by using a high flow nasal oxygenation (FiO2 21%) device
224313395|NCT04321681|OTHER|no intervention|no intervention
224313396|NCT03914092|DRUG|triamcinolone acetonide injection|,1 mm percutaneous intralesional injection
224313397|NCT03914092|BEHAVIORAL|Smith Accent method of voice therapy|regular sessions of smith accent voice therapy (about 24 sessions, twice session / week) for 3 months
224313398|NCT01819870|DRUG|Dilatrend SR capsule 32mg|"* 1 capsule, oral, once daily, 7days~* over the period I\&II(crossover)"
224313399|NCT01819870|DRUG|Dilatrend IR tablet 25mg|"* 1 tablet, oral, once daily, 7days~* over the period I\&II(crossover)"
224313400|NCT03600987|BEHAVIORAL|Simultaneous music and reading lyrics|listening to music with singing of the lyrics simultaneously with reading the written lyrics.
224313401|NCT03600987|BEHAVIORAL|Priming with music|priming by listening to music and singing of the lyrics followed by reading the written lyrics.
224313402|NCT03600987|BEHAVIORAL|Control|control condition using reading materials without music.
224204226|NCT01578343|DRUG|Fludarabine, Mitoxantrone, Dexamethasone, Vorinostat|"1. Induction treatment (Total 4 cycles) FND D1-3 Fludarabine 25mg/m2 + NS 100mL iv over 30 min D1 Mitoxantrone 10mg/m2 + NS 100mL iv over 30 min D1-5 Dexamethasone 20mg IV or PO every 4 weeks Vorinostat D1-10 Vorinostat 200mg once daily PO (When vorinostat is concurrently administered with FND regimen, vorinostat will be administered 3 hours before chemotherapy)~2. Consolidation treatment for responders Patients not eligible for transplantation~   * Vorinostat maintenance up to 6 cycles~  * 200mg twice daily for 14 consecutive days from D1 - 14 in a 21 day cycle~  * Delay of the start of the next cycle by up to 7 days will be acceptable.~  * If relapse or progression during maintenance, it will be stopped. Patients eligible for transplantation~  * High-dose chemotherapy followed by autologous stem cell transplantation"
224204227|NCT01179139|OTHER|Biopsy|Percutaneous 2-3 mm biopsies of middle turbinate mucosae and nasal polyps will be obtained with 5 mm Thrucut® (Smith \& Nephew, Memphis, TN) biopsy forceps. Generally, 2-3 specimens will be obtained from each side as in previous studies. Healthy controls and subjects with CRS without NP will have biopsies from both middle turbinates. Subjects with CRS with NP will have two nasal polyp biopsies and one middle turbinate biopsy.
224204228|NCT01902524|DRUG|Fentanyl-TTS|All of the participants will receive the study drug at least once transdermally, administration dosage starts at 12.5 microgram/hour.
223511398|NCT06964074|DEVICE|Nebulization with Pari LC Sprint|"During hospitalization due to exacerbation of the bronchopulmonary disease, patients performed inhalations twice a day using one of two devices: PARI PEP® S System (produced by PARI, Germany) with a dedicated Pari LC Sprint nebulizer or the Aerobika\*OPEP Device (produced by TRUDELL MEDICAL INTERNATIONAL) with a dedicated Aero Eclipse XL nebulizer, or they were in the control group where they performed inhalations in the standard way using the Pari LC Sprint nebulizer (produced by PARI, Germany). Frequency: twice daily. Inhalation duration: 10 minutes. Immediately after inhalation, each patient performed physiotherapy in the same scheme using the Pari OPEP device, 15 exhalations, and autogenic drainage technique according to the method's concept, with the drainage duration ranging from 15 to 30 minutes."
223511399|NCT06964295|DEVICE|Macintosh videolaryngoscope|Used to perform nasotracheal intubation under general anesthesia. The Macintosh videolaryngoscope is introduced orally to visualize the glottis, and a preformed nasotracheal tube is inserted through the nostril.
224204229|NCT05941299|DEVICE|REGENERA breast implant implantation|"Each patient will perform 13 study visits, and at each visit, all necessary study procedures will be performed according to the clinical investigation plan:~* Screening~* Pre-surgery treatment~* Surgery and study device implant~* Post-surgery follow-up"
224204230|NCT04959006|DIETARY_SUPPLEMENT|Antioxidant supplement|Short term (16d) supplementation of either the antioxidant supplement (Oliphenolia) or placebo. Participants required to consume 2x25ml drinks, one mid-morning, one mid-afternoon between meals.
224204231|NCT04959006|DIETARY_SUPPLEMENT|Placebo|Placebo
224204232|NCT04345887|DRUG|Spironolactone 100mg|2x100 mg spironolactone for 5 consecutive days
223511400|NCT06964295|DEVICE|Flexible bronchoscope|Used to perform nasotracheal intubation under general anesthesia. The bronchoscope is inserted through a lubricated nasotracheal tube and advanced into the trachea.
223761319|NCT02825303|OTHER|Workplace consisting of two height-adjustable desks|Desk arrangements: self-determined by the participants Desk equipment: depending on pre-intervention condition - 1 or 2 screens per desk Build-up: one day prior to the intervention period at the location of the workplace Adjustment: together with the study leader
223761320|NCT02165046|DRUG|Budesonide|
223761321|NCT02165046|DRUG|Procaterol|
223761322|NCT02321462|DRUG|Eziclen|Eziclen solution administered orally as split-dose the day before and on the day of colonoscopy.
224204233|NCT04345887|DRUG|Placebo oral tablet|2 x1 placebo tablet
224204234|NCT03820999|OTHER|Oral and written information on tick-bites and Lyme disease|See under study arm descriptions
224204235|NCT05214599|DRUG|Budesonide Gel|Twice daily regimen
224204236|NCT01898117|DRUG|Carbo/cyclo|
224204237|NCT01898117|DRUG|Carbo/cyclo + atezolizumab|
224204238|NCT01898117|DRUG|Paclitaxel|
224204239|NCT01898117|DRUG|Paclitaxel + Atezolizumab|
224204240|NCT04871178|BEHAVIORAL|Mindfulness-based intervention|"Eight, 2-hour instructor-led MBI group sessions once a week for 8 weeks, combined with formal meditative training at home for 20 minutes per day, 6 days a week.~Course material consists of facts booklet, weekly training manuals, audio recordings on a CD, with the five formal guided meditative exercises (body scan, breathing anchor, breathing space, mindful movements, sitting meditation).~The weekly home-work also included informal training of being present in daily life activities.~The program is provided according to the standard MBI protocol. Compared to MBSR and MBCT durations of formal meditative practices are shorter and no 'all-day in silence' session is included. Because of participants' physical limitations and safety, the 'mindful movements' sequence, is adapted and performed in a sitting position.~Adherence to the MBI was followed by self-reported weekly training in manuals asked to be submitted at group sessions."
224204241|NCT02602561|DIETARY_SUPPLEMENT|HMB|
224204242|NCT02602561|DIETARY_SUPPLEMENT|Placebo|
223511401|NCT06964347|DEVICE|Ropivacaine 0.2% + nerve stimulator set|Patients will receive a continuous local anesthetic (LA) infusion through the popliteal sciatic nerve block catheter using an infusion of ropivacaine 0.2% at a rate of 8-12 ml/h for at least 3 postoperative days. In addition, patients will receive a low-frequency peripheral nerve stimulation (PNS) via a nerve stimulator set to the pre-determined setting of adequate clinical response (determined in the preoperative area).
223761323|NCT02321462|DRUG|Fortrans®|Fortrans® solution administered orally as split-dose the day before and on the day of colonoscopy.
223511402|NCT06964347|DRUG|Ropivacaine 0.2%|Patients will receive a continuous local anesthetic infusion through the popliteal sciatic nerve block catheter using an infusion of ropivacaine 0.2% at a rate of 8-12 ml/h for at least 3 postoperative days. In addition, patients will have an inactive PNS button for the purposes of blinding.
223761324|NCT04434885|OTHER|Clinical and imaging examination of symptoms and signs suggestive of axial involvement|Clinical and imaging examination including X-rays and magnetic resonance imaging of sacroiliac joints and spine
223761325|NCT02724904|PROCEDURE|Allogeneic stem cell transplantation|Reduced intensity allogeneic stem cell transplantation from a fully matched related or unrelated donor
223761326|NCT02724904|DRUG|Fludarabine|Standard Treatment
223761327|NCT02724904|DRUG|Thiotepa|Standard Treatment
223761328|NCT02724904|DRUG|Methotrexate|IV Bolus
224313403|NCT02023294|PROCEDURE|Convetional laparoscopic Sleeve Gastrectomy|Convetional laparoscopic sleeve gastrectomy using 5 ports (incisions) in the abdominal wall
224313404|NCT02023294|PROCEDURE|SILS Sleeve gastrectomy|Single incision Sleeve gastrectomy using only one port (incision) on the abdominal wall assisted by an special Traction Device for single port surgery (Endograb)
224204243|NCT04717232|OTHER|Blended learning approach to mentoring education for dental health care professionals|The participants in the intervention group are dentists´ and dental hygienists´. The mentoring education for dental health care professionals (3 ECTS credits) will be organized by the program leader in Dentistry at the place-blinded. The aim of the mentoring education is to build understanding of how to support a student's professional development (both basic education and specialization) and transfer skills that are relevant to working as an independent expert in oral health care.
224204244|NCT04717232|OTHER|The interprofessional online mentoring education|The participants in the intervention group are dentists´ and dental hygienists´. The interprofessional online mentoring education (3 ECTS credits) will be organized in collaboration with the Finnish Dental Association in an online environment. The aim of the intervention is to in-crease mentors' competence in guidance processes and interactions, supporting students´ goal-oriented learning and professional evaluation, and providing constructive feedback.
224204245|NCT00004232|BIOLOGICAL|filgrastim|
224204246|NCT00004232|DRUG|cyclosporine|
224204247|NCT00004232|DRUG|methylprednisolone|
224204248|NCT00004232|DRUG|prednisone|
224204249|NCT00004232|PROCEDURE|allogeneic bone marrow transplantation|
224204250|NCT00004232|PROCEDURE|peripheral blood stem cell transplantation|
224204251|NCT06537245|OTHER|Massage|Massage was applied in the both quads during 5 or 10 minutes, with differents pressures.
224204252|NCT06003673|COMBINATION_PRODUCT|neoadjuvant therapy|The enrolled patients undergo 2 cycles of neoadjuvant therapy, with each cycle consisting of treatment every 3 weeks. On the first day of the first treatment cycle, conventional transarterial chemoembolization (TACE) is performed, and concomitant intravenous infusion of tislelizumab at a dose of 200mg is given, followed by oral administration of lenvatinib at a dose of 8/12mg once daily. On the first day of the second cycle, tislelizumab is again administered intravenously at a dose of 200mg, TACE is not repeated, and lenvatinib treatment is continued. Within 2-4 weeks after the completion of neoadjuvant therapy, the investigator evaluates the tumor's suitability for surgical resection based on a comprehensive assessment of imaging results. Subsequently, eligible patients undergo tumor resection surgery, followed by follow-up for survival and safety monitoring.
224204253|NCT05760482|DIAGNOSTIC_TEST|Metobolites serum level measurement|Blood samples will be taken from all volunteer participants in 1 yellow cap tube of 10 cc. After the blood has cooled and the clot development process (approximately 15 minutes), the serum will be separated by centrifugation at 2000 g for 5 minutes. Separated sera will be aliquoted and stored at -40°C until analysis. The tryptophan and tryptophane metabolite levels of the participants will be measured by Liquid Chromatography-Tandem Mass Spectrometer API 3200 device. The kynurenine, kynurenic acid, 3-HK, 3-HAA, 3-HOA, and QA values obtained as a result of this test will be recorded.
224204254|NCT05760482|BEHAVIORAL|Anxiety and stress level measurement|Anxiety and stress levels will be evaluated by applying State-Trait Anxiety Inventory and Perceived Stress Scale Tests by all volunteer participants. Scores from these tests will be recorded.
224313405|NCT04522817|BIOLOGICAL|CLBS119|Peripheral blood derived autologous CD34+ cells
224313406|NCT00578266|DRUG|Cyclophosphamide,Campath IH and TBI|"DAY 5 TREATMENT~* 6 5 CYTOXAN 50 mg/kg WITH MESNA~* 5 CYTOXAN 50 mg/kg WITH MESNA;~* 4 CYTOXAN 50 mg/kgWITH MESNA; CAMPATH 3-10 mg~* 3 CYTOXAN 50 mg/kg WITH MESNA; CAMPATH;~* 2 TBI; CAMPATH; TACROLIMUS~* 1 TBI (second fraction); CAMPATH (am) 0 STEM CELL INFUSION (pm)"
224313407|NCT06112496|DEVICE|EMG|Neuro-EMG-Micro, Neurosoft, Ivanovo, Russia, will be used for the assessment of muscle activity for muscles.
224313408|NCT00235209|DEVICE|Collagen ORC Antimicrobial Matrix (CAM)|
224313409|NCT06240195|OTHER|data collection|Collection of data relating to the effectiveness of sacituzumab govitecan and evaluation in a real-world context and planned research of predictive biomarkers of efficacy/tolerability
224313410|NCT00613886|DEVICE|Programmable Shunt Insertion (Codman, Medtronic)|Medical Device - Shunt insertion surgery of adjustable valve and laparoscopic assistance for placement of peritoneal catheter. Patient will be brought to operating room suite where general anesthesia is induced. Patient will be placed with a small roll on shoulder, supine, on the operating room table. Patient's head will be turned with the parietal area uppermost in the field. Patient will be prepared and draped in the usual sterile fashion. Site prep includes parietooccipital area, side of neck, chest, and entire abdomen. Ventricular catheter placed and then attached to shunt valve. Catheter is then fitted over grooved blue burr hole guide. Excess catheter pulled down to pull valve into pocket on the skull. Sterile dressings applied.
224313411|NCT00613886|BEHAVIORAL|Assessments in physical therapy, occupational therapy, and speech therapy|Follow-up testing to be administered by trained Physician Assistant in the outpatient setting on an approximately monthly basis: 10m walk, timed up-and-go, Mini-Mental Status Exam, 9-hole Grooved Pegboard, Motor Visual Perception Test (MVPT), Modified Rankin Score (MRS)
223511403|NCT06964477|BEHAVIORAL|XR-Based Leisure Intervention|"The XR-based leisure intervention was developed based on occupational therapy principles and the therapeutic use of leisure to support engagement, volition, and emotional regulation in individuals with chronic mental illness. The intervention content was designed using the AR2VR platform and the MAKAR marker-based AR development system. Leisure scenarios were created by capturing real-world environments using 360-degree panoramic video and embedding interactive elements, such as contextual prompts, virtual objects, and multimedia cues, to enhance immersion and engagement.~Sessions are guided by trained occupational therapists and follow a standardized protocol to ensure consistency. A simple cardboard VR viewer is used to reduce sensory overload and avoid adverse effects common with electronic head-mounted displays, such as dizziness or nausea. Activities target various leisure domains, including physical movement, creative expression, social activities, and cognitive play. Weekly con"
223512468|NCT06517511|DRUG|Selinexor Oral Tablet [Xpovio]|Selinexor (60mg po D1, 8) is added from the second cycle of R-CHOP regimen.
223761329|NCT05233436|DRUG|PF-07265028|PF-07265028 will be administered orally
223761330|NCT05233436|BIOLOGICAL|Sasanlimab|Administered subcutaneously
224313412|NCT05018312|BEHAVIORAL|Modified Collaborative Assessment (MCA)|The Modified Collaborative Assessment (MCA) will be assessment of the patients that Is more thoroughly-done, and which will be inspired by the school of Therapeutic Assessment and Collaborative Assessment. It will include the EASE, SCID-interview, PSE, ADOS and SCIP-interviews.
224313413|NCT05018312|BEHAVIORAL|Assessment as Usual (AAU)|Assessment as usual is the standard assessment the patients will receive in the clinic. It includes one or more interviews with a mental health professional in the clinic.
224313414|NCT03021889|BEHAVIORAL|Nutritional therapy|The nutritional therapy intervention group received monthly nutritional guidelines for 12 weeks focusing on the diet for dyslipidemia, based on the recommendation of the type I diet of the Clinical Protocol and Therapeutic Guidelines for Management of HIV Infection in children and adolescents. In addition, participants in the intervention group received weekly phone calls for nutritional counseling.
224313415|NCT03021889|BEHAVIORAL|Control group|The control group was followed according to the ambulatory care routine, which consists of medical follow-up by the assistant team.
224313416|NCT03684967|DRUG|Fruquintinib|Fruquintinib treatment: 4mg in the Cycle 1,administration for 3 weeks followed by 1 week break, and administration every day for the first 21 days.5mg ,administration for 3 weeks followed by 1 week break, and administration every day for the first 21 days
224313417|NCT04569669|DIAGNOSTIC_TEST|FFR and FFRCT|All the patients will undergo computed coronary tomography angiography to analysis FFRCT . Then FFR will be measured during invasive cardiac catheterization.
224313418|NCT00740012|OTHER|Continuous glucose monitoring|Glucoday S (microdialysis system). Continuous glucose monitoring all three nights
224313419|NCT00740012|OTHER|alarm- clock intervention, patient perform blood glucose self monitoring|Alarm clock intervention at midnight, 2 a.m., 4 a.m. and 6:45 a.m.
224204255|NCT02902107|DEVICE|CivaSheet|
224204256|NCT02902107|RADIATION|Brachytherapy|
224204257|NCT02902107|PROCEDURE|surgical resection|
224204258|NCT02858076|DRUG|2-mg Intravitreous Aflibercept Injection|Soluble decoy receptor fusion protein that has a high binding affinity to all isoforms of VEGF as well as to placental growth factor.
224313420|NCT00740012|OTHER|nurse intervention|Nurse intervention: gently drawing capillary sample (blood glucose)at midnight, 2 a.m., 4 a.m. and 6:45 a.m. .
224313421|NCT00740012|OTHER|Taking the patients pulse|In nights (a) and (b) the doctoral candidate takes the patients pulse 5-7 minutes after the alarm clock or the nurse.
224313422|NCT00740012|OTHER|Venous blood drawing|Venous blood drawing for the determination of epinephrine, norepinephrine, cortisol, glucagon, growth hormone, and prolactin (determined by specific immunoassays at Biocientia laboratories, Jena, Germany) (6-10 minutes after midnight, 2 a.m., 4 a.m. and 6:45 a.m.)in night (a) and (b)
224313423|NCT00740012|OTHER|Other capillary sample|5-7 minutes after the alarm clock or the nurse the doctoral candidate takes another capillary sample for a laboratory glucose determination (EBIOS, Eppendorf, Hamburg, Germany) analyzer.
224313424|NCT03850314|DIETARY_SUPPLEMENT|Glycine|Glycine powder to be dissolved in water.
224313425|NCT01323712|DIETARY_SUPPLEMENT|Vitamin D Cholecalciferol|Cholecalciferol 100,000 Units 6 doses; 0,4,8,12,24,42 weeks
224313426|NCT06097455|GENETIC|ARI0003|Treatment with ARI0003 cells
224313427|NCT03927014|OTHER|thiol/disulfide levels|Venous blood will sample from the antecubital veins for measuring the serum concentration of thiol/disulfide levels. The serum thiol/disulfide levels will measure using commercially available reagent kits, which is produced to detect human thiol/disulfide levels (Rel Assay Diagnostics Gaziantep, Turkey). The thiol/disulfide levels measurements were performed in accordance with the company's protocol.
224313428|NCT03240835|DRUG|cisplatin and docetaxel|"NACt：cisplatin 75 mg/m2 intravenous infusion in day1，docetaxel 75 mg/m2 intravenous infusion in day1，both drugs are given every 3 weeks, two cycles.~CCRT: cisplatin (100mg/m2 on day 1) every three weeks for two cycles."
224313429|NCT03240835|RADIATION|IMRT|intensity modulation radiation therapy
224313430|NCT01343316|DEVICE|Transpyloric feeding tubes (Nasogastric Tube (NG tube), Tiger2, Syncro BlueTube)|To determine the benefits of utilizing one type of transpyloric tube over another.
224313431|NCT00099879|DRUG|BMS-275183|
224313432|NCT05011747|PROCEDURE|single-site rigid probe viscotrabeculotomy (VT)|single-site VT by the rigid probe trabeculotome is performed through a superonasal triangular scleral flap.
224313433|NCT05011747|PROCEDURE|two-site rigid probe viscotrabeculotomy (VT)|Two-site VT by the rigid probe trabeculotome is performed through a superonasal and an inferotemporal triangular scleral flap.
224313434|NCT02360176|PROCEDURE|Sleeve gastrectomy single port|Bariatric surgery: one incision of 2.5 to 3 cm
224313435|NCT02360176|PROCEDURE|Sleeve gastrectomy multi trocar|Bariatric surgery: 4 to 7 incisions of 1 to 2 cm
224313436|NCT05260060|BEHAVIORAL|Treatment as usual: Control|Treatment usually delivered in service that may include but is not limited to cognitive behaviour therapy, exposure, eye movement desensitisation and reprocessing , behaviour therapy, family therapy.
223761331|NCT02110316|OTHER|Dosage form of voriconazole|Instead of an oral dose of voriconazole, patients receive one intravenous dose of voriconazole (in the same dose as the oral dose).
224204259|NCT02858076|PROCEDURE|Prompt Vitrectomy Plus Panretinal Photocoagulation|Surgical removal of the vitreous gel and associated hemorrhage, concurrent delivery of panretinal endolaser
224204260|NCT00410592|DRUG|Esomeprazole 40mg|
224204261|NCT00410592|DRUG|Pantoprazole 40mg|
224204262|NCT00410592|DRUG|Lansoprazole 30mg|
224204263|NCT00478634|DRUG|RAD001, Cetuximab, Irinotecan|
224313437|NCT05260060|BEHAVIORAL|Group Metacognitive Therapy (Group-MCT): Experimental|Group metacognitive therapy (Group-MCT) focuses on developing adaptive control of worry, repetitive negative thinking and attention and modifies beliefs that maintain unhelpful thinking patterns. Treatment is 6 to 8 weekly sessions delivered by two trained mental health professionals, guided by a treatment manual, lasting approximately 90 minutes each session.
224313438|NCT04581369|OTHER|Care Coordinator Intervention for Direct Intervention Group|"The First Visit: The care coordinator will conduct a visit within 72 hours of hospital discharge to assess the patient's physical, cognitive, and psychological status, and will complete a needs assessment for both the patient and family caregiver. These measures will be used to guide the use of care protocols and development of the individualized care plan. The care plan will be developed with an emphasis on coordinating services with the patient's providers.~The Second Visit: During the second visit, the coordinator will review the individualized care plan with both the patient and the family caregiver and will make revisions to the plan based on assessment outcomes.~The 6-month Interaction Period: Approximately every 2 weeks, the coordinator will meet with the participant to revisit the care plan and to facilitate care.~At the end of 6 months, all patients will be transitioned to receive full care by their primary care and specialty physicians."
224313439|NCT04581369|OTHER|Care Coordinator Intervention for Standard of Care Group|For participants randomized to this arm, a consultation with the care team will be arranged prior to hospital discharge. Outcome measures will be obtained by blinded research staff from all enrolled subjects at baseline, 3 months, and 6 months. This is the extent of interventions received for participants in this arm.
223617339|NCT01670721|DRUG|Leucovorin|Pharmaceutical form:Concentrate for solution for infusion; Route of administration: Intravenous
224204264|NCT05818163|DEVICE|electroencephalography spectral analysis|"Before inducing general anesthesia in the patient entering the operating room, an anesthesia depth monitoring patch is attached to the forehead, and EEG data during anesthesia is collected using the currently used anesthesia depth monitoring device.~The EEG data is transformed into a frequency and energy distribution and density spectral array (DSA) graph using Fourier transform (FFT) for spectral analysis."
224204265|NCT04587856|OTHER|bone marrow withdrawal|bone marrow samples evaluation
224313440|NCT04581369|OTHER|Caregiver Intervention|Caregivers of the participants will be assessed for caregiver burden at 3 time points.
224204266|NCT05166473|OTHER|Telerehabilitation group (n=21)|"This group was conducted with a physiotherapist for video conference-based vestibular rehabilitation exercises, was called the telerehabilitation group (TR). In terms of ease of Use and applicability, the WhatsApp app was preferred. Patients were individually searched for two days a week, 25-30 minutes. The exercises were performed gradually from easy to difficult, initially in a sitting position in accordance with the levels of the patients."
224204267|NCT05166473|OTHER|Control Group (n=21)|"After the home exercise program, which should be applied twice a day for six weeks, was shown in practice, the home exercise program was given, in which the exercises were visual and written, this group was called the control group. All participants were given a phone number to consult when there were any problems, and were phoned to decry whether they were continuing the exercises."
224204268|NCT05402865|DRUG|Denosumab|Denosumab, subcutaneous injection, specific usage to see the medical records. Non-denosumab, specific usage to see the medical records.
224204269|NCT06692166|DRUG|9MW2821|1.25mg/kg of 9MW2821 by intravenous infusion on days 1, 8 and 15 of every 28-day cycle
224204270|NCT06692166|DRUG|Chemotherapy|1.0 or 1.25 mg/m \^2 topotecan by intravenous infusion on days 1 to 5 or 1000 mg/m \^2 gemcitabine by intravenous infusion on days 1 and 8 or 500 mg/m \^2 pemetrexed by intravenous infusion on day 1 of every 21 days
224204271|NCT03506425|DRUG|Triheptanoin|Triheptanoin is a medium chain triglyceride (MCT) that can improve mitochondrial function and energy production and therefore has potential for slowing ALS progression. Indeed, triheptanoin slowed motor neuron loss and delayed the onset of weakness in a mutant SOD1 model of ALS. The Triheptanoin we will use is a colorless to light yellow oil. The target triheptanoin dose for this study is 1g/kg/d. This target dose was selected because it was safe and tolerable and altered brain MR spectroscopy in patients with Huntington's Disease.
224204272|NCT01804530|DRUG|PLX7486 TsOH|PLX7486 TsOH capsules, 50mg
224204273|NCT06493110|PROCEDURE|Gastric ultrasound|To compare gastric volumes in standard fasting state before surgery in diabetic and non-diabetic pregnant women by evaluating the gastric antrum with ultrasound.
224313441|NCT01360463|BEHAVIORAL|Behavioral Drug and Risk Counseling (BDRC)|"The BDRC counseling is rooted in cognitive behavioral theory. During one hour sessions, the counselors help participant identify short term behavioral goals and work with the participant to develop strategies to achieve their goals. These plans are referred to as contracts and these contracts are reviewed and revised at each subsequent session."
223617340|NCT03971461|DRUG|Lutathera|administered intravenously every 8 weeks for a total of 4 doses
224204274|NCT04789811|OTHER|Stretching exercise|Stretching exercise: Stretching exercises were planned for 30 seconds, ten repetitions for each stretching, 10 minutes in total, four days a week, for two weeks.
224204275|NCT04789811|OTHER|Dry needling|Dry needling: A total of 3 sessions of dry needling, once a week, were applied to the gastrocnemius muscle.
224204276|NCT06060639|DIAGNOSTIC_TEST|transthoracic echocardiography|E wave, A wave, e' and vdi measurement
224204277|NCT00209495|DRUG|Pregabalin; Dexamethasone|Comparing combinations of paracetamol + pregabalin 300 mg + dexamethasone 8 mg
224204278|NCT01141049|DRUG|Gabapentin|During week 1 the dosage will be increased 3 times. Days 1 and 2, participants will receive 400 mg of Gabapentin three times daily. During days 3 and 4 the dosage will be increased to 800 mg three times daily. On day 5 through 7, participants will receive a dose of 1200 mg three times daily, which will continue from week 2 through 8. During week 9 patients will be tapered off for the duration of the week.
224204279|NCT01141049|OTHER|Placebo|Placebo, TID
224313442|NCT01360463|BEHAVIORAL|methadone maintenance treatment|daily individualized doses of methadone will be provided by the program staff.
224313443|NCT00780910|DRUG|MP-424|750 mg every 8 hours for 12 weeks
224313444|NCT00780910|DRUG|Ribavirin|600 - 1000 mg/day based on body weight for 24 weeks
223617341|NCT05171192|BEHAVIORAL|CMAP Plus LTP|The LTP Plus CMAP intervention will be delivered for a period of 12 weeks, including 8 weekly sessions and 2 sessions fortnightly. First 6 sessions will be for a duration of 60-90 minutes and remaining 4 sessions will take approximately 50-60 minutes. All sessions will be delivered by female therapists trained in CMAP and LTP intervention.
223617342|NCT06468995|OTHER|Surveys completion|Completion of surveys: the Feasibility of Implementation Measure (FIM), the Acceptability of Intervention Measure (AIM), the Intervention Appropriateness Measure (IAM), a Likert scale, the EQ-5D-5L questionnaire, the HIV/AIDS-Targeted Quality of Life (HAT-QoL) questionnaire and the HIV Treatment Satisfaction Questionnaire (HIVTSQ).
224204280|NCT02284295|OTHER|exposure to respirable silica dust|History of exposure to respirable silica dust due to job
224204281|NCT02284295|OTHER|exposure to aromatic hydrocarbons|history of exposure to aromatic hydrocarbons due to job
224204282|NCT03839784|COMBINATION_PRODUCT|Neurocognition Interventions|EEG, Neurocognitive Battery Testing, and Immune Profiles
224204283|NCT06030479|DRUG|Topical adrenaline|"Skin is incised midline sub-umbilical incision , bladder dissection will be done , uterus will be incised by vertical upper segment incision , followed by delivery of the baby.~Surgical assessment and decision for either conservative management or CS hysterectomy will be done.~After completion of surgical procedure , surgical field is observed for major bleeding and patients are subjected to intervention Packing the pelvic surgical field with towels fully saturated with adrenaline 1:10000 solution."
224204284|NCT06030479|DRUG|Warm saline|"Skin is incised midline sub-umbilical incision , bladder dissection will be done , uterus will be incised by vertical upper segment incision , followed by delivery of the baby.~Surgical assessment and decision for either conservative management or CS hysterectomy will be done.~After completion of surgical procedure , surgical field is observed for major bleeding and patients are subjected to intervention Packing the surgical field with towels fully saturated with warm saline solution ( 50 degrees)."
224204285|NCT04526249|DEVICE|rapid pulse confirmation device|device used to detect pulsatile blood blood during and after cardiac arrest
224204286|NCT01925378|DRUG|Nelfinavir|"All medications which a patient is taking will be reviewed at each visit, including the screening, day 1, weeks 4,12, 24.~All patients enrolled in the study will receive 1,250 mg twice PO daily for a 24 week duration."
224204287|NCT05605457|DEVICE|PRG barrier coat + nanohybrid composite|It is a light cured surface-partially reacted glass (S-PRG) filler particles with a multifunctional glass core embedded in a resin matrix.
224204288|NCT05605457|DEVICE|resin modified glass ionomer|RMGIC are glass-ionomer cements with small quantity of monomers and initiators so the acid-base reaction is supplemented by a second polymerization reaction
224204289|NCT06066866|OTHER|endoscopic sampling of luminal fluid|We will collect luminal fluid via endoscopic sampling
224313445|NCT00780910|DRUG|Peginterferon Alfa-2b|1.5 mcg/kg/week for 24 weeks
224313446|NCT06382610|DIETARY_SUPPLEMENT|Melatonin|Melatonin will be administered in three different forms
224313447|NCT03879434|DEVICE|Ostenil® Mini|Ostenil® Mini is a CE-certified viscoelastic solution for injection into the Joint cavity, containing 1.0 % sodium hyaluronate from fermentation
224313448|NCT04680858|OTHER|DECT|Use of a digital enhanced telecommunication headset for team communication
224313449|NCT01053000|DRUG|Tazorac|compare the safety and efficacy of broad area photodynamic therapy with aminolevulinic acid (ALA-PDT) following topical retinoid pre-treatment with Tazorac vs ALA-PDT with occlusion only (no pretreatment) in subjects with dorsal hand/forearm actinic keratoses, with an incubation time of 60 minutes, using blue light.
224313450|NCT01111825|DRUG|Temsirolimus|"28 day treatment cycle Phase 1~* Weekly intravenously (IV) on days 1, 8, 15, and 22~* Starting dose 8 mg IV weekly (dose level 1). Three patients initially enrolled in each cohort~Phase 2~* Dose escalation cohort - 8 mg IV weekly on Days 1, 8, 15, and 22, and then 15 mg IV weekly starting on Day 29~* HER2-amplified and Triple negative - 8 mg IV weekly on Days 1, 8, 15, and 22"
224313451|NCT01111825|DRUG|Neratinib|"28 day treatment cycle~• 240 mg orally daily"
224313452|NCT04462211|PROCEDURE|Implementation of management pharmacological protocol of constipation|"first 48 hours:~* polyethylene glycol 3350 (about 17 grams) 1 every 8 hours enterally.~* Patients who have vomiting and / or gastric residue greater than 500 mL (in a timely measurement every 6 hours) will also be given domperidone 10 mg every 8 hours intravenously.~* Patients who have excessive abdominal distension will be administered in addition, levosulpiride 25 mg every 8 hours intravenously.~  48 hour evaluation:~* Patients who do not have bowel movements will be administered lactulose or sodium phosphate enema.~* For patients who do not have a bowel movement, administration of neostigmine intravenously or of naloxone enterally will be evaluated.~* Every patient who uses one or more prokinetics will have an electrocardiogram.~* Any patient who has bowel movements during management, doses of polyethylene glycol 3350 will be adjusted according to the daily goal of bowel movements, the days of treatment of the prokinetics will be adjusted, for a maximum of 5 consecutive days."
224204290|NCT00892424|DRUG|Sorafenib|Sorafenib doses will be 200mg twice daily orally for 28 days in level I, 400 mg in the morning and 200mg in the evening in level II, and 400mg twice daily orally for 28 days in level III . Radiotherapy will be started at day 8, patients will receive a total of 6 fractions over 2 weeks. Patients will be assessed weekly during treatment, 1 month post-tx, then at 3-month intervals for up to a year after tx, and then followed-up at 6-month intervals up to 3 years.
224313453|NCT04462211|PROCEDURE|Implementation of bundle of prevention and non-pharmacological management|"Bundle of prevention:~* Start early enteral nutrition.~* Optimize and / or decrease opioid doses.~* Start early mobilization.~Non-pharmacological management bundle~* Select laxative and/or prokinetic/s to manage constipation.~* Optimize and / or decrease doses of opioids and sedatives.~* Start early mobilization.~* Pharmacological reconciliation."
224204291|NCT02233881|DRUG|Atrovent® - inhalets|
224204292|NCT00405210|DRUG|sorafenib (200 or 400mg bid) and taxotere iv|200 mg BID, day 3-19 cycle 1, day 2-19 other cycles 200 mg BID, day 3-21 Cycle 1, day 1-21 other cycles 400 mg BID, day 3-19 cycle 1, day 2-19 other cycles 400 mg BID, day 3-21 cycle 1, day 1-21 other cycles
223511404|NCT05784597|DRUG|[68Ga]Ga-OncoFAP administration|All patients will receive a single intravenous bolus administration of 250 MBq (225 - 275 MBq)
223511405|NCT04619888|DIAGNOSTIC_TEST|HeartLogic|In case of HeartLogic index ≥16, the investigator will contact the patient to assess the patient's clinical condition and possibly adjust the heart failure treatment. The management will be standardized across centers according to the Manage-HF protocol.
224204293|NCT02484235|OTHER|HIIT|Group training with HIIT 3 times per week during 10 sessions
223511406|NCT03346317|DEVICE|disposable balloon uterine stent|The disposable balloon uterine stent is heart-shaped that resembled the shape of the uterine cavity and could fully separate the two sides of the uterine wall and the corners of the uterus compare to Foley catheter.
223511407|NCT03346317|PROCEDURE|dried biological amnion graft|Uterine application of amnion membrane following hysteroscopic adhesiolysis. Other Name: Human amnion membrane
223511408|NCT03346317|DRUG|estradiol valerate tablets+dydrogesterone tablets|oral estradiol valerate tablets+dydrogesterone tablets
223761332|NCT03496688|PROCEDURE|Sinus floor augmentation|
223617343|NCT06468995|DRUG|Home administration of CAB+RPV|Drug treatment and follow-up at home (home arm).
223617344|NCT06468995|DRUG|Hospital administration of CAB+RPV|Drug treatment and follow-up in hospital (hospital arm)
223617345|NCT06418594|DRUG|Adebrelimab|Adebrelimab: 1200mg, ivgtt, administered on the first day of each cycle, with a cycle of 21 days
224204294|NCT02484235|OTHER|Strength|Group training with strength exercises 3 times per week during 10 sessions
224204295|NCT03952663|PROCEDURE|inferior alveolar nerve lateralization and dental implant placement.|inferior alveolar nerve lateralization for placement of sufficiently long dental implants.
224204296|NCT03952663|PROCEDURE|platelet rich fibrin membrane around the nerve|platelet rich fibrin membrane is prepared from the patient's blood and placed around the nerve.
224204297|NCT02677675|BEHAVIORAL|Intervention (reminder module)|Reminder module (delivered via SMS and telephone call reminders)
224204298|NCT03468374|DEVICE|lymphoscintigraphy|Nuclear Medicine diagnostic device using radioactive material
224204299|NCT03468374|DEVICE|Single Photon Emission Tomography|Nuclear Medicine diagnostic device using fusion technique between SPECT and CT
224204300|NCT04427956|PROCEDURE|Corneal crosslinking: CXL (UVA 9mW/cm2)|CXL treatment with UVA-radiation (9mW/cm2) with a 10 minute irradiation protocol.
224204301|NCT04427956|DRUG|Isotonic riboflavin|CXL protocol with isotonic riboflavin
224204302|NCT04427956|DRUG|Hypotonic riboflavin|CXL protocol with hypotonic riboflavin
224204303|NCT04427956|PROCEDURE|Iontophoresis|CXL protocol with iontophoresis and ricrolin
224204304|NCT04539158|DEVICE|Direct Current Cardioversion|The patient is sedated and shocked using an external defibrillator to terminate the arrhythmia and restore a normal intrinsic rhythm (i.e., normal sinus rhythm).
224204305|NCT04471558|OTHER|Music|A part of the RCT will be performed with music in the room. The music will be switch on just before anesthesia and off after the postoperative rest.
224204306|NCT04088734|DRUG|ABO-102|Single dose of ABO-102 (scAAV9.U1a.hSGSH) administered by intravenous injection through a peripheral limb vein at a dose of 3 X 10\^13 vg/kg
224204307|NCT01345890|PROCEDURE|electrical stimulation|sub motor threshold stimulation of mylohyoid muscles
224204308|NCT01222559|DRUG|co.don chondrosphere®|co.don chondrosphere® are spheroids in suspension, developed from autologous chondrocytes. The dose depends on the size of the defect, recommended dose is 10-70 spheroids/cm2 defect.
224204309|NCT01222559|PROCEDURE|Microfracture|A procedure in which the subchondral bone is perforated to allow a bloodcloth to form new tissue.
224204310|NCT05341076|PROCEDURE|Amniotomy|Amniotomy, artificial rupture of membranes, is done with an initial delay of labor (in partograph: extension beyond the alert line, in labor scale: when progress reaches the membrane line)
224204311|NCT05341076|DRUG|Oxytocin|oxytocin augmentation: given with further delay of labor (according to the point of intervention of the partograph or the scale)
224204312|NCT05341076|PROCEDURE|Cesarean Section|Cesarean section: done when progress is deemed arrested (according to the definition of the partograph or the scale)
224204313|NCT06566066|OTHER|no intervention|register study without intervention
224204314|NCT03506854|DRUG|ISIS 681257|Xmg dose administered as a subcutaneous injection
224204315|NCT06472375|DIAGNOSTIC_TEST|holter|ambulant heart rate monitor (holter) for 24 hour.
223511409|NCT02552654|BEHAVIORAL|Stress Film|Film scene with severe physical and sexual violence.
223511410|NCT02552654|DRUG|Hydrocortisone|10mg
223511411|NCT02552654|DRUG|Placebo|
223511412|NCT01327365|PROCEDURE|trans-radial PCI (TRI)|TRI performed using the sheathless guiding approach
223511413|NCT01327365|PROCEDURE|trans-radial PCI (TRI)|TRI performed using a conventional guiding approach
223511414|NCT05236465|BEHAVIORAL|A 3-day course|The course is built on the LP manual (Parker, 2013) and includes stress theory, Positive Psychology and knowledge about regulating thoughts, feelings and behavior, and through that positively influencing physiology.
223511415|NCT05236465|BEHAVIORAL|Waiting list|Treatment as usual (TAU) in the first 10 weeks. After 10 weeks: Behavioural: A 3-day course. The course is built on the LP manual (Parker, 2013) and includes stress theory, Positive Psychology and knowledge about regulating thoughts, feelings and behavior, and through that positively influencing physiology.
223511416|NCT06081465|DRUG|VG290131|The study drug and matching placebo will be administered orally.
223511417|NCT03531502|PROCEDURE|Ventricular Tachycardia Ablation|Ventricular Tachycardia Ablation
223511418|NCT03531502|OTHER|Standard Medical Therapy|For the antiarrhythmic naïve patients, the attending physician may initiate therapy with sotalol or amiodarone. For patients already on therapy with sotalol or amiodarone, the attending physician may choose to either increase the dosage/ frequency of these medications and/or add mexiletine to the regimen. Other alterations to medical therapy, such as adjusting the dose of beta-blockers, calcium-channel blockers, anti-hypertensive, diuretic or anti-anginal medications may be performed at the discretion of the attending physician.
223617346|NCT06418594|DRUG|Apatinib|Apatinib: 250 mg, oral, once daily, continuous use, with a cycle of 21 days
223617347|NCT06418594|DRUG|Etoposide|Etoposide: 50mg/day, oral, administered on days 1-14 of each cycle, with a cycle of 21 days
223617348|NCT05844280|PROCEDURE|BFR+NMES at therapeutic level|This group will receive therapy with BFR+NMES devices used at settings that are deemed by prior studies to be therapeutic.
224204316|NCT00096200|DRUG|Carboplatin|Given IV
224204317|NCT00096200|DRUG|Paclitaxel|Given IV
224204318|NCT00096200|DRUG|Sorafenib Tosylate|Given orally
224204319|NCT03821831|DEVICE|Continuous Positive Airway Pressure|CPAP machine
224204320|NCT03821831|DEVICE|Orthodontic intervention|Mandibular advancement or Rapid maxillary expansion devices
224204321|NCT01850901|PROCEDURE|Renal sympathetic denervation|
224204322|NCT06283745|OTHER|Platelet-rich Plasma (PRP)|Platelet-rich plasma (PRP) intranasal injection in the treatment of qualitative olfactory dysfunction (parosmia). This is taken from a blog draw from the patient themselves, and thus no external drug/biologic product will be given - only the concentrated plasma portion from the patient's own blood.
224204323|NCT06283745|OTHER|Saline|Saline intranasal injection (sham injection)
224204324|NCT05324709|BEHAVIORAL|Yoga Based Stress Management Program|Yoga-based stress management program is applied to the intervention group.
224313454|NCT06265194|BEHAVIORAL|EMDR|The fibromyalgia protocol applied to the patients in the study was developed specifically for fibromyalgia by Konuk, and colleagues (Konuk et al.). In addition to the article, the details of the protocol and the study sheet are presented supplementary. After a short introduction, the participants were informed about the protocol, their -consent was obtained for registration, and a visual, tactile and audio bilateral stimulus that will be used in the application was introduced.
224313455|NCT06265194|BEHAVIORAL|TAU|Treatment as Usual (TAU): Routine fibromyalgia treatments, referred to as Treatment as Usual (TAU) in this study, were initiated in the outpatient clinic conditions. TAU are treatments designed by rheumatologists in accordance with current rheumatology guidelines.
224204325|NCT03438474|PROCEDURE|Standard surgical procedure for endometrial cancer|total hysterectomy, bilateral salpingo-oophorectomy, omentectomy (type 2 cancers)
224204326|NCT03438474|PROCEDURE|systematic lymphadenectomy (LNE)|systematic pelvic and para-aortic lymphadenectomy (LNE) up to the renal vessels
224204327|NCT05799859|DEVICE|Use of coronally advanced flap (CAF) and collagen matrix (CM)|
224204328|NCT05799859|DEVICE|Use of coronally advanced flap (CAF) and collagen matrix (CM) and additional application of enamel matrix derivatives (EMD).|
224204329|NCT00213031|DRUG|Carraguard (PC-515)|
224204330|NCT04193033|OTHER|FLOW intervention|The FLOW program, including internal and external facilitation, use of the FLOW online report to identify patients, patient and provider education materials, a medical record template, and regular data tracking and feedback about the process.
224313456|NCT02691143|OTHER|TheraBand Kinesiology Tape|One approach to treating musculoskeletal conditions is a elastic therapeutic taping technique designed to target muscles and lymphatic system. Limited research on the efficacy of elastic therapeutic taping (ETT) is available for specific patient populations, including neck pain. ETT it is theorized to impact muscle function by inhibiting or facilitating the muscle, improve blood flow, reduce pain, and improve joint alignment. In a study by Gonzalez-Iglesias et al. the investigators reported that neck pain and range of motion significantly improved immediately and 24 hours after the application of ETT in acute whiplash patients as compared to a sham taping.
224313457|NCT06422910|OTHER|Telerehabilitation|"Home exercises will be delivered through a video mobile application. In this application, exercises for knee osteoarthritis will be presented according to their types (stretching, strengthening, etc.). Videos deemed appropriate by the physiotherapist will be added to the exercise prescription and sent to the patients via message. Patients will have the opportunity to remotely access their own exercise prescription with visual, auditory and written commands.~Translated with DeepL.com (free version)"
224313458|NCT04074616|DEVICE|High Dose|Electrodes 2 inch by 2 inch will be placed according to anatomic landmarks,with the negative electrode behind the internal malleolus and the positive electrode 10cm superior to the negative electrode, verified with rhythmic flexion of the toes secondary to stimulation of the flexor digitorum and hallicus brevis. The intensity level will be set to the amperage immediately under the threshold for motor contraction. If the patient perceives pain, the intensity will be lowered until comfortable. Stimulation frequency of 10 Hz and pulse width of 200ms in continuous mode will be used.
224313459|NCT04074616|DEVICE|Low dose|Toe flexion will be attempted, as in the TTNS protocol. Then the stimulation will be reduced to 1 mA for 30 minutes
224313460|NCT05113433|OTHER|conventional physical therapy|"muscle strengthening i.e. isometrics of lower limb muscles. 5 sets/rep and 2 sets/ session.~stretching of lower limb muscles . 5sets/rep and 2 sets/session."
224313461|NCT05113433|OTHER|standing frame.|"muscle strengthening i.e. isometrics of lower limb muscles. 5 sets/rep and 2 sets/ session.~stretching of lower limb muscles . 5sets/rep and 2 sets/session. sanding on standing frame for different time period according to group with upper limb activities lie box and blocks , cones and theraputty ."
223511419|NCT03531502|PROCEDURE|Non-Invasive Programmed Stimulation (NIPS)|All patients will receive this procedure in attempt to induce ventricular tachycardia. The outcome of this procedure determines if a patient will be randomized.
223511420|NCT02551107|DEVICE|Measurement of nasal Nitric Oxide level|ECO MEDICS CLD 88 sp Nitric Oxide Analyzer
223511421|NCT01151631|DEVICE|occipital nerve stimulation|Low occipital bilateral Quad Plus, midline to laterally directed, secured by titan anchors, connected to Versitrel. No trial stimulation. Suggested stimulation parameters: Pulse width: 450, Amplitude: protocol, Rate: 60
223512469|NCT06517511|DRUG|R-CHOP Protocol|Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone
223512470|NCT04295928|BEHAVIORAL|PPP|Personalized Pharmaceutical Plan on therapeutic adherence to immunosuppressive treatments after the transplantation
223761333|NCT01519856|DRUG|piribedil (Clarium)|oral tablets, 50 mg
224204331|NCT06439615|DRUG|Baricitinib 4 MG|Baricitinib will be administered orally (or crushed for nasogastric tube delivery) at a daily dosage of 4mg for three consecutive days following SAH.
224204332|NCT06439615|OTHER|Standard treatment|Participants will receive standard treatment and care according to the current management guidelines for subarachnoid hemorrhage.
223761334|NCT01183169|DRUG|Alisporivir|ALV 200 mg soft gel capsules administered orally
224204333|NCT04843501|BEHAVIORAL|CATCH My Breath (CMB) program for E-cigarette prevention among adolescents|CMB has 4 developmentally appropriate e-cigarette lessons, 20-30 minutes in each of 6th-8th grades. Strategies include small and large group discussions, parent interviews, role-plays, media literacy, and goal setting. E-cigarette focused science and humanities activities (2 per school year) are also provided. An informational tool kit will be provided to parents. Finally, 8 activity-based E-cig PE lessons are intended for either 7th or 8th grades, depending on school calendar. CMB provides study materials to teachers through an online access portal. A site-based management team will oversee program implementation. Teachers in CMB intervention schools will be provided with CMB-specific training for implementing the lessons with fidelity through a one-hour live webinar, offered at multiple times to accommodate teaching schedules. Project staff will meet routinely with participating schools to answer study questions.
224204334|NCT04843501|BEHAVIORAL|Texas Education Agency (TEA) required tobacco prevention program|The TEA tobacco prevention program is a state-supported program that meets the mandates of the state. It includes TEA developed online lessons and support materials and also includes elements of the CDC Know the Risks e-cigarette prevention program. This can be considered 'usual care'
224313462|NCT01056315|DRUG|GRT3938Y|Overencapsulated tablets of GRT3983Y, 100 to 300mg daily dose, 16 weeks treatment.
224313463|NCT01056315|DRUG|Placebo|Overencapsulated tablets of placebo, 16 weeks treatment.
224204335|NCT04220723|OTHER|Frailty Assessment|"Liver Frailty Index measurements:~1. Grip strength: the average of three trials, measured in the subject's dominant hand using a hand dynamometer~2. Timed chair stands: measured as the number of seconds it takes to do five chair stands with the subject's arms folded across the chest~3. Balance testing: measured as the number of seconds that the subject can balance in three positions (feet placed side-to-side, semitandem, and tandem) for a maximum of 10 seconds each."
223511422|NCT02014454|DRUG|Propranolol eye drops|"All the enrolled preterm newborns will receive propranolol as ophthalmic solution (0,1%): 3 microdrops of 6 microliters (μL) propranolol solution (= 6 μg propranolol/microdrop) will be topically applied with a calibrated pipette, in each eye, three times daily (every 8 hours).The treatment will continue until the complete development of retinal vascularisation, but no more than 60 days.~The propranolol treatment will be always associated to the conventional approach adopted by the ETROP Cooperative Group."
223761335|NCT01183169|DRUG|Peginterferon alfa-2a|PEG 180 μg administered via subcutaneous (s.c.) injection once weekly
223761336|NCT01183169|DRUG|Ribavirin|RBV 200 mg tablets (weight-based dose: \< 75 mg = 1000 mg/day; ≥ 75 kg = 1200 mg/day) administered orally in a divided daily dose
223761337|NCT01183169|DRUG|Placebo|ALV placebo soft gel capsules administered orally
223761338|NCT01514396|DEVICE|Surgiseal|surgical glue
223761339|NCT03814954|DRUG|Salbutamol|At first day of admission, patients will receive 3 doses of nebulized salbutamol every 20 minutes. Then after 24 hours patients will receive standing dose according to clinical status
223761340|NCT03814954|DRUG|Epinephrine|At first day of admission, patients will receive 3 doses of nebulized epinephrine every 20 minutes. Then after 24 hours patients will receive standing dose according to clinical status
223761341|NCT00161707|DRUG|Aerosolized, Recombinant Alpha 1-Antitrypsin|
223761342|NCT04361461|DRUG|Hydroxychloroquine Sulfate|400 mg orally, every 12 hours x 2 doses (loading dose) and then 400 mg, once daily, orally, for 10 days.
224204336|NCT04220723|OTHER|Functional Capacity Assessment|Shuttle Walk Test: The patient is required to walk around two cones set 9 metres apart (so the final track is 10 metres) in time to a set of auditory beeps played on a CD. Initially, the walking speed is very slow, but each minute the required walking speed progressively increases. The patient walks for as long as they can until they are either too breathless or can no longer keep up with the beeps, at which time the test ends. The number of shuttles is recorded. Each shuttle represents a distance of ten metres (i.e each time the patient reaches a cone is 1 shuttle).
224204337|NCT04532489|DRUG|FNP-59|FNP-59, a radiotracer, is administered for PET/CT scans.
224204338|NCT06017362|DRUG|Insulin|Topical insulin 1UI/ml 4 times a day
224204339|NCT06017362|DRUG|Artificial tear|Artificial tears 4 times a day
224204340|NCT03648385|DRUG|DHEA tablet|DHEA tablet (50 mg) taken by mouth once a day for 18 weeks.
224204341|NCT03648385|OTHER|Placebo|1 placebo tablet taken by mouth once a day for 18 weeks
224204342|NCT06254963|OTHER|sand jump training|A series of progressive jumping activities on sand increasing in difficulty over the 6 week period
224204343|NCT06254963|OTHER|land jump training|A series of progressive jumping activities on land increasing in difficulty over the 6 week period
224204344|NCT06282263|OTHER|"Awareness Development Program on Suicide Prevention for Oncology Nurses"|"While developing the Awareness Development Programme on Suicide Prevention for Oncology Nurses applied to the nurses in the experimental group, literature information on suicide risk management and suicide prevention in oncology was included in the study content by the researchers. Awareness Development Programme on Suicide Prevention for Oncology Nurses includes 3 sessions and the titles of the programme are as follows:~Session 1: Introduction to Understanding Suicide Awareness and Development Session 2: Assessing Suicide Risk Session 3: Management of Suicide Risk Communication and Referral The programme was submitted to the opinions of 5 experts before starting the study and the programme was finalised after the feedbacks."
224204345|NCT04704752|DIAGNOSTIC_TEST|Swallowing Evaluation|Study Evaluation includes basic test batteries. These are observational.
224204346|NCT03259867|DRUG|Nivolumab Injectable Product|a PD-1 immune check inhibitor
224204347|NCT03259867|COMBINATION_PRODUCT|Trans-arterial tirapazamine embolization|Embolization with Lipiodol and Gelfoam
224204348|NCT05250609|OTHER|"Endocrown composite."|It is a type of restoration has been shown a great success in adult and recently has been suggested for children
224204349|NCT03023007|PROCEDURE|Loco-regional anaesthesia|Loco-regional anaesthesia
224204350|NCT04426188|PROCEDURE|Heading series|10 headers from machine-projected soccer balls at standardized speeds
224204351|NCT04426188|DEVICE|Magnetic Resonance Imaging (MRI)|Brain MRI before and after a series
224204352|NCT04426188|OTHER|Cognitive computerized assessment|Cognitive evaluation carried out with two computerized tools
224204353|NCT04426188|PROCEDURE|Electrophysiological records|Electrophysiological recording of Motor Evoked Potentials consisting of the application of transcranial magnetic stimulations (TMS) and the collection of muscle activity by electromyogram (EMG)
224204354|NCT04426188|DEVICE|Dynamometer|Measure of the strength of the neck muscles using a dynamometer
224204355|NCT04036786|BEHAVIORAL|study group|We prepared a preeclampsia education booklet in accordance with the literature,The content of the booklet was guided by the opinion of experts. It was written in easily understandable language and contained attractive and colorful illustrations. This booklet contents were definition and risk factors for the development of preeclampsia, maternal and fetal damages, recommendations for preventing its development (diet, rest, study, exercise, coping with stress techniques), follow-up of symptoms at home (blood pressure, weight and edema follow-up, counting fetal movements), danger signs, drug use, follow up in hospital, risk of developing in subsequent pregnancies, and its results. Pregnant women in the study group were given education and counseling at four times in addition to standard care, using the preeclampsia education booklet, in a special place. The participants' questions were answered, and each received a copy of the booklet.
224204356|NCT04036786|BEHAVIORAL|standard care|standard pregnancy follow up
224313464|NCT01401556|OTHER|case management|
224313465|NCT01401556|OTHER|Multifaceted quality improvement intervention|
223511423|NCT01216085|DRUG|high-dose imatinib|Study patients will receive 400 mg twice daily oral administration in the morning and the evening.
223511424|NCT04849000|DRUG|SHR-1209|SHR-1209
223511425|NCT04849000|DRUG|SHR-1209 Placebo|SHR-1209 Placebo
223511426|NCT03997734|DRUG|AB001|single and repeated dosing
224313466|NCT02482961|DRUG|colistimethate sodium|At least once a week, all patients with carbapenem-resistant Acinetobacter baumannii infection were screened from the database at the clinical microbiology laboratory
224204357|NCT05117073|DIAGNOSTIC_TEST|ASCITIC FLUID CULTURE|Ten milliliters of ascitic fluid will be collected at the bedside and inoculated into aerobic and anaerobic blood culture bottles. Bacterial culture will be performed manually using MacConkey and blood agar plate
224204358|NCT05008419|BEHAVIORAL|Narrative discourse treatment|The protocol will incorporate elements from prior treatment studies that showed some promise: 1) hierarchical training, 2) variety of discourse stimuli, 3) development of skills and strategies for discourse processing, 4) structured training prompts, 5) meta-cognitive and meta-linguistic strategies, and 6) integration of learning principles. Novel treatment elements will include: 1) targeting both story content and story organization, 2) use of a discourse model to guide treatment, and 3) functional communication training. Treatment will be delivered twice a week over 8 weeks. There will be four treatment phases: education, story organization, story content, and integration of story organization and content.
224204359|NCT02121405|PROCEDURE|Rectectomy|Include anterior resection or abdominoperineal resection by open or laparoscopy with Total Mesorectal Excision (TME).
224204360|NCT02121405|RADIATION|Radiotherapy|45-50 Gy in 25-28 fractions to the pelvis. After 45 Gy a tumor bed boost with a 2 cm margin of 5.4 Gy in 3 fractions for preoperative cancers or 5.4-9.0 Gy in 3-5 fractions for postoperative cancers could be considered. Radiotherapy is used only for patients with pathological confirmed positive circumferential margin in Group primary surgery. Radiotherapy is used to all of the patients in Group preoperative radiochemotherapy.
224204361|NCT02121405|DRUG|Capecitabine|Capecitabine 825 mg/m2 twice daily 5 or 7 days/week with concurrent radiotherapy in Group primary surgery and Group preoperative radiochemotherapy. Capecitabine 1250 mg/m2 twice daily 1-14 every 3 weeks to a total of 6 weeks after preoperative radiochemotherapy in Group preoperative radiochemotherapy. Capecitabine 1250 mg/m2 twice daily 1-14 every 3 weeks to a total of 6 months postoperative therapy for a part of stage II patients in Group of primary surgery. Capecitabine 1000 mg/m2 twice daily 1-14 every 3 weeks with oxaliplatin day 1 to a total of 6 months postoperative therapy for stage III patients in Group of primary surgery.
224204362|NCT02121405|DRUG|Oxaliplatin|Oxaliplatin 130 mg/m2 over 2 hours, day 1, with capecitabine every 3 weeks. Repeat every 3 weeks to total of 6 months postoperative therapy.
224313467|NCT03775044|DEVICE|Medherent Device|The Medherent Medication Management Device (MMD) is intended to enable patients to self-manage their medication at home when it may otherwise require assistance.
224313468|NCT06174597|PROCEDURE|UCA-PSCs/bFGF or bFGF Intramuscular injection|After skin disinfection, according to the distribution characteristics of blood vessels around the vascular lesion area, the site that is most likely to establish a new collateral circulation in vascular anatomy is selected. According to the vascular lesion of each subject, 40 reasonable injection sites are selected for Clusters of umbilical cord artery-derived perivascular stem cells with bFGF or bFGF only.
224313469|NCT01927198|DRUG|Placebo|
224313470|NCT01927198|DRUG|RDEA3170 5 mg|
224313471|NCT01927198|DRUG|RDEA3170 10 mg|
224313472|NCT01927198|DRUG|RDEA3170 12.5 mg|
224313473|NCT04141930|DRUG|Baloxavir Marboxil|Individuals willing and able, will receive a weight-based oral dose of baloxavir within 48 hours of symptom onset
224313474|NCT03763357|DEVICE|Heat Therapy (HT)|Water at 42-43 degrees C will be circulated through the water circulating trousers to obtain calf skin temperature 39 degrees C followed by PET/CT imaging of generator-based 62Cu-ETS.
224313475|NCT05719792|PROCEDURE|Transforaminal Epidural Steroid Injection|In the TFESI group, all patients were positioned prone. The injection site was cleaned with povidone-iodine 3 times and a sterile drape was applied. Short-acting local anesthesia (3 mL of 2% prilocaine) was applied to the skin and subcutaneous tissue. A 3.5-inch, 22-gauge spinal needle was inserted just below the pedicle. It was advanced into the subpedicular space using the coaxial technique under the intermittent guidance of fluoroscopy. The needle position was confirmed through a lateral view. Using lateral views, the needle was placed at the posterior one-third of the foramen. Using the anteroposterior view, one to 2 mL of the contrast agent (300 mg/50 mL iohexol) was given and the distribution pattern was visualized. Once the epidural distribution of the contrast agent was confirmed without vascular flow, a mixture of 8 mg (two mL) of dexamethasone, 2 mL of physiological saline, and 1 mL (0.5%) of bupivacaine hydrochloride was injected.
224313476|NCT05719792|PROCEDURE|Erector Spina Plane Block|Patients are placed in the prone position to determine the vertebrae in the middle of the involved area. Following the provision of aseptic conditions, the spinous process of the vertebral midline is visualized using a high-frequency (8 MHz) linear ultrasound (USG) probe. The transverse process is, then, visualized approximately at the 3 cm lateral from the midline and the erector spinae muscle is visualized on it. The 22-gauge 50 mm block needle is advanced towards the in-plane section craniocaudally and the transverse process is touched. Then the needle is then withdrawn minimally to confirm that it is between the erector spinae muscle and the transverse process through hydrodissection. Following that, 5 mL from 0.5% bupivacaine hydrochloride, 8 mg dexamethasone and 3 ml saline is administered and local anesthetic spread is confirmed by USG.
223511427|NCT03997734|DRUG|oral capsule|single dose
223511428|NCT03997734|DRUG|positive comparative patch|single and repeated dosing
223511429|NCT03997734|DRUG|Placebos|single and repeated dosing
223511430|NCT00641212|DRUG|Budesonide|
223511431|NCT00641212|DRUG|Placebo|
223617349|NCT05844280|PROCEDURE|BFR+NMES at sub therapeutic level|This means that the BFR tourniquet and the NMES device will be at such low settings as to not create the treatment effect but subject will have the equipments on their thigh during exercise
223617350|NCT06533280|DRUG|Part A, C and D: VH3739937 500 mg|Oral administration of VH3739937 in moderate fat/moderate calorie conditions
223617351|NCT06533280|DRUG|Part A: VH3739937 100 mg|Oral administration of VH3739937 in moderate fat/moderate calorie conditions.
223617352|NCT06533280|DRUG|Part A and C: Placebo|Oral administration of Placebo in moderate fat/moderate calorie conditions
223511432|NCT03238157|DRUG|Fluocinolone Acetonide (FA) implant|Fluocinolone Acetonide (FA) implant is designed to release FA at an initial rate of approximately 0.6 g/d, decreasing over the first month to a steady rate of 0.3 to 0.4 g/d with a duration of approximately 30 months.
223617353|NCT06533280|DRUG|Part B: Treatment A|VH3739937, 500 mg(single dose given as 5 x 100 mg tablets). administered under moderate fat/moderate calorie conditions (reference)
224204363|NCT05991401|DRUG|DA-8010 5mg|\[Period 1\] DA-8010 5mg \[Period 2\] DA-8010 5mg, Clarithromycin 500mg \[Period 3\] DA-8010 5mg, Rifampicin 600mg
224204364|NCT05991401|DRUG|Clarithromycin 500mg|\[Period 2\] DA-8010 5mg, Clarithromycin 500mg
224204365|NCT05991401|DRUG|Rifampicin 600mg|\[Period 3\] DA-8010 5mg, Rifampicin 600mg
224204366|NCT01914289|PROCEDURE|Resection|
224204367|NCT01914289|RADIATION|Radiotherapy|
224204368|NCT04755088|DRUG|Surufatinib|Subjects to receive Surufatinib 300mg on Day 1
224204369|NCT04755088|DRUG|Surufatinib|Subjects to receive Surufatinib 300mg on Day 1
224204370|NCT06448611|OTHER|Blood Test|Research and quantification of Circulating Tumor Cells
224204371|NCT00938015|OTHER|Questionnaire|This is a non-interventional study
224204372|NCT00938015|OTHER|Questionnaire|This is a non-interventional study
224204373|NCT02568111|DRUG|peginterferon beta-1a|SC administration as prescribed by the physician- initial dose of 63 μg followed by 94 μg dose on day 15 and 125 μg on day 29
224204374|NCT02568111|DRUG|brimonidine tartrate|Applied to injection site as specified in the treatment arm. Commercially available Mirvaso (Brimonidine tartrate) gel will be provided by Galderma.
224204375|NCT02568111|DRUG|Vehicle Gel|Matched placebo applied to injection site as specified in the treatment arm. Matching vehicle gel will be provided by Galderma.
224204376|NCT01338311|DRUG|salbutamol|200mcg twice daily for a total of 7 doses
224204377|NCT01338311|DRUG|Placebo|200mcg twice a day for a total of 7 doses (3.5 days).
224313477|NCT00741286|DRUG|Aspirin|Asprin (100mg) plus placebo
224313478|NCT00741286|DRUG|cilostazol|Aspirin (100mg) plus cilostazol (200mg)
224204378|NCT00053911|DRUG|anastrozole|
224313479|NCT06467110|DEVICE|transcatheter mitral valve clip delivery system and steerable guide catheter (Shenqi Medical)|The principle of this product is the transcatheter interventional edge-to-edge repair technology (edge-to-edge repair). The core technology is to treat the regurgitation by edge-to-edge suturing the mitral valve. The double holes are set in the mitral valve (A2/P2 zone) or the edges in A1/P1 or A3/P3 zones are apposed and closed to treat regurgitation.
223511433|NCT04044248|DEVICE|TIPS-obliteration|Transjugular intrahepatic portosystemic shunt (TIPS) decompression of portal hypertension coupled with transvenous obliteration of gastric varices (GVs).
224204379|NCT00053911|DRUG|cyclophosphamide|
224204380|NCT00053911|DRUG|docetaxel|
224204381|NCT00053911|DRUG|epirubicin hydrochloride|
224204382|NCT00053911|DRUG|fluorouracil|
224204383|NCT00053911|DRUG|goserelin acetate|
223511434|NCT05549882|OTHER|no intervention|no intervention
224204384|NCT00053911|DRUG|tamoxifen citrate|
224204385|NCT00053911|PROCEDURE|adjuvant therapy|
224204386|NCT04213001|DIAGNOSTIC_TEST|ultrasonographic measurement|ultrasonographic measurement- Subcutaneous ultrasound echogenicity (SEG) and Skin and subcutaneous thickness measurement
224204387|NCT04156009|OTHER|Activated Lavender Elequil aromatabs® (#372)|Activated Lavender aromatherapy tablets wrapped in tape
224204388|NCT04156009|OTHER|Unactivated Lavender Elequil aromatabs® (#372)|Unactivated Lavender aromatherapy tablets wrapped in tape
224204389|NCT02341482|DRUG|PF-04958242|Administered as specified in the treatment arm
224204390|NCT02341482|DRUG|Itraconazole|Administered as specified in the treatment arm
224204391|NCT01476891|OTHER|Immediate MBSR|Immediate Online MBSR Group. Participation in a standardized manual-based 8-week online MBSR program.
224204392|NCT01476891|OTHER|Wait-list Control Group.|Wait-list Control Group. The control group will receive the next available online MBSR program.
224313480|NCT01831258|DEVICE|SensAwake On|
224313481|NCT01831258|DEVICE|SensAwake Off|
224313482|NCT02943135|DRUG|lidocaine in-situ gel|lidocaine in-situ gel
223511435|NCT03375164|GENETIC|delandistrogene moxeparvovec|Single IV infusion of delandistrogene moxeparvovec.
223511436|NCT00484328|DRUG|Ribavirin|different dosing regimes of Ribavirin
223617354|NCT06533280|DRUG|Part B: Treatment B|VH3739937, 500 mg (single dose given as 500 mg tablet) administered under moderate fat/moderate calorie conditions (test)
224204393|NCT00077870|DRUG|ocrelizumab|
224204394|NCT00118209|BIOLOGICAL|rituximab|IV
224204395|NCT00118209|DRUG|cyclophosphamide|IV
224204396|NCT00118209|DRUG|doxorubicin|IV or CIVI
224204397|NCT00118209|DRUG|vincristine|IV or CIVI
224204398|NCT00118209|DRUG|prednisone|oral
224204399|NCT00118209|DRUG|etoposide|CIVI
224204400|NCT00118209|DRUG|filgrastim|IV
224204401|NCT00118209|DRUG|pegfilgrastim|IV
224204402|NCT03509766|DEVICE|Histamine skin testing|skin testing using histamine
224204403|NCT03597620|DRUG|Metaderm|Metaderm cream and spray will be apply to subjects scalp and body.
224204404|NCT05127707|BEHAVIORAL|Words Matter - Visual Campaign|Visual campaign emphasizing the importance of using non-stigmatizing language related to substance use and opioid use disorder in clinical settings.
224204405|NCT05127707|BEHAVIORAL|Words Matter - Visual Campaign & Narrative Vignette (Messenger: Person with Opioid Use Disorder) Experimental: Words Matter - Visual Campaign & Narrative Vignette (Messenger: Clinician)|Visual campaign emphasizing the importance of using non-stigmatizing language related to substance use and opioid use disorder in clinical settings combined with a narrative vignette told from the perspective of a person with opioid use disorder
224313483|NCT02943135|DRUG|placebo in-situ gel|placebo in-situ gel
224313484|NCT06552013|OTHER|MERV 13 filter|This is an environmental intervention consisting of a low-cost box fan with a MERV 13 filter placed behind it. The company Lasko makes these fans and other environmental appliances.
224313485|NCT06552013|OTHER|Sham filter|This is an environmental intervention consisting of a low-cost box fan with a sham filter (MERV 1) placed behind it. The company Lasko makes these fans and other environmental appliances.
224313486|NCT05115487|DIAGNOSTIC_TEST|digital dynamometer|Hand grip strength will be measured using a hand-held digital dynamometer with the patient sitting in a hard chair and elbow flexed to 90°. All assessments and measurements will be made by the same experienced physician blinded to patients' clinical data.
224313487|NCT03803982|PROCEDURE|Deep Neuromuscular Blockade|The proposed intervention in this study is delivery of an anesthetic with Deep Neuromuscular Blockage (NMB), which will be defined as a TOF of 0 and 2-3 twitches in the post-tetanic count.
224204406|NCT05127707|BEHAVIORAL|Words Matter - Visual Campaign & Narrative Vignette (Messenger: Clinician)|Visual campaign emphasizing the importance of using non-stigmatizing language related to substance use and opioid use disorder in clinical settings combined with a narrative vignette told from the perspective of a clinician working with patients with opioid use disorder
223511437|NCT01440751|DEVICE|Use of ologen Collagen Matrix in trabeculectomy (ologen)|Place ologen CM on the top of the loosely-sutured scleral flap under conjunctiva before suturing. It is recommended to suture the scleral flap with 1 or 2 stiches loosely for the convenience of future suture lysis and to coordinate with the tamponading effect of ologen CM to create a fluctuating scleral flap that prevents bleb wound adhesion and modulates aqueous humor outflow for ideal IOP control without leakage.
223511438|NCT01440751|DRUG|Use of Mitomycin-C (MMC) in trabeculectomy|After outlining and creating a superficial scleral flap, a cellulose sponge soaked with MMC(0.4mg/mL) is applied for up to 3 mins according to physician's routine method of application. The area treated is copiously irrigated with balanced isotonic solution. Alternatively, 15mcg of MMC may be injected intra-Tenon's at the end of the procedure. Patients receiving mitomycin will be billed as per operating room practice.
223511439|NCT05249348|DRUG|PC14586|An oral dose of PC14586 will be used in Arms A and B (Part 1) and a different dose will be used for Arms C and D and the Japanese cohort (Part 2).
223511440|NCT06964139|OTHER|Surgical video grading|Videos of fellow surgical cases will be randomized in sequence and provided to a masked grader who will review cases and record primary and secondary endpoints.
223511441|NCT05306145|PROCEDURE|High freqnence Irreversible electroporation|High freqnence Irreversible electroporation will be performed via the perineum with the guidance of ultrasound under general anaesthesia to the patient with benign prostatic hyperplasia
223511442|NCT05306145|PROCEDURE|Trans Urethral Resection Prostate|Trans urethral resection prostate will be performed under general anaesthesia to the patient with benign prostatic
223511443|NCT03306290|DRUG|Serum dosage of antibiotic prophylaxis CEFOXITIN|"Three blood samples will be collected. These samples are specific for the research, and will be performed on the forearm opposite to the one used for Cefoxitin infusion.~1. Blood sample at the start of surgery (t0): at the end of the Cefoxitin infusion (\~30 min), 1 tube (5 ml) of blood will be withdrawn~2. Blood sample at half way surgery (t1): 1 tube (5 ml) of blood will be withdrawn (if applicable)~3. Blood sample at skin closure (t2): 1 tube (5 ml) of blood will be withdrawn"
223511444|NCT02393469|OTHER|pulmonary rehabilitation|Exercises breathing exercises are performed on a cycle ergometer for 30 minutes, monitored by 50% of your maximum heart frequency, strengthening exercises for major muscle groups of the upper and lower limbs with charges based on 70% of one repetition maximum, muscle stretching test, and in expiratory pattern
223511445|NCT02393469|OTHER|Education and self-management for COPD|Two months of continuous and self management for COPD where patients know their disease, pathophysiology, treatment, exacerbation of symptoms, and better ways pharmacological treatment education will be conducted through a system of multidisciplinary lessons with professional Physiotherapists, Psychologists, Dieticians, Pharmacists , Physical Education Professionals and Doctors
223617355|NCT06533280|DRUG|Part B: Treatment C|VH3739937, 500 mg single tablet administered under fasted conditions.
224204407|NCT05127707|BEHAVIORAL|Words Matter - Visual Campaign & Narrative Vignette (Messenger: Health System Administrator)|Visual campaign emphasizing the importance of using non-stigmatizing language related to substance use and opioid use disorder in clinical settings combined with a narrative vignette told from the perspective of a health system administrator/leader
224204408|NCT05127707|BEHAVIORAL|Medication Treatment for Opioid Use Disorder Works - Visual Campaign|Visual campaign emphasizing the effectiveness and value of medications to treat opioid use disorder in saving lives
224204409|NCT05127707|BEHAVIORAL|Medication Treatment for Opioid Use Disorder Works - Visual Campaign & Narrative Vignette (Messenger: Person with Opioid Use Disorder)|Visual campaign emphasizing the effectiveness and value of medications to treat opioid use disorder in saving lives combined with a narrative vignette told from the perspective of a person with opioid use disorder
224204410|NCT05127707|BEHAVIORAL|Medication Treatment for Opioid Use Disorder Works - Visual Campaign & Narrative Vignette (Messenger: Clinician)|Visual campaign emphasizing the effectiveness and value of medications to treat opioid use disorder in saving lives combined with a narrative vignette told from the perspective of a clinician who treats people with opioid use disorder
224204411|NCT05127707|BEHAVIORAL|Medication Treatment for Opioid Use Disorder Works - Visual Campaign & Narrative Vignette (Messenger: Health System Administrator)|Visual campaign emphasizing the effectiveness and value of medications to treat opioid use disorder in saving lives combined with a narrative vignette told from the perspective of a health system administrator/leader
224204412|NCT05401552|OTHER|Meal|Comparison of two breakfast meals containing the same amount of phosphorus but one in the form of inorganic additives
224204413|NCT00066586|DRUG|exemestane|exemestane 25 mg once daily x 1 year
224204414|NCT00066586|DRUG|Placebo|placebo once daily x 1 year
224204415|NCT00139802|DEVICE|Coronary Stent Implantation|
224204416|NCT02804659|OTHER|microRNA|Extraction of the microRNA using the mirVana miRNA isolation kit and quantification using real-time PCRs
224204417|NCT01240109|DRUG|Remifentanil|"* propofol group : propofol effect site-TCI 2-4mcg/ml + remifentanil effect site-TCI 2-4ng/ml~* sevoflurane group: sevoflurane end-tidal concentration 0.5-1.0 MAC + remifentanil effect site-TCI 2-4ng/ml"
224204418|NCT05925478|PROCEDURE|Ptergyopalatine Fossa Block|Injection of local anesthetic (e.g. Bupivacaine) into the pterygopalatine fossa to treat headache related to aneurysmal subarachnoid hemorrhage
224204419|NCT05925478|DRUG|Bupivacaine 0.25% Injectable Solution|Injection of local anesthetic (e.g. Bupivacaine) into the pterygopalatine fossa to treat headache related to aneurysmal subarachnoid hemorrhage
224204420|NCT04503031|DEVICE|TaperGuard endotracheal tube|TaperGuard endotracheal tube is intubated
224204421|NCT04503031|DEVICE|cylindrical endotracheal tube|endotracheal tube is intubated
224204422|NCT00090259|DRUG|Losartan 50 mg|50-mg losartan oral tablet
224204423|NCT00090259|DRUG|Losartan 150 mg|100-mg losartan oral tablet + 50-mg losartan oral tablet
224204424|NCT01935882|DRUG|Artemether-lumefantrine combination|
224204425|NCT01935882|DRUG|Artemether-Lumefantrine with a single dose of 0.25mg/kg primaquine|
224204426|NCT01935882|DRUG|Artemether-Lumefantrine with a single dose of 0.4mg/kg primaquine|
224313488|NCT03803982|DRUG|Sugammadex|Sugammadex will be used to reverse the deep neuromuscular blockade in the experimental group.
224204427|NCT04262024|DRUG|cabergoline 1.5-2 mg/week).orally daily for 1 month plus health education|Women with hyperprolactiemia scheduled for cabergoline therapy 1.5-2 mg/week). for one month will be offered health education to help minimize prolactin level(group A)
224204428|NCT04262024|DRUG|cabergoline 1.5-2 mg/week).orally daily for 1 month without health education|Women with hyperprolactiemia scheduled for cabergoline 1.5-2 mg/week).for one month will not be offered health education (group B)
224204429|NCT01387360|DEVICE|Supracor|"The presbyopic treatment consists of a standard treatment for distance vision and the procedure known as SUPRACOR addition to correct near vision.~The SUPRACOR addition provides a multifocal ablation with a central near addition with an aberration controlled transition zone towards the periphery, thereby allowing good focus over a range of object distances."
224204430|NCT00061646|DRUG|ABT-510/Thrombospondin-1 mimetic|
224204431|NCT00061646|DRUG|Carboplatin/Taxol|
224204432|NCT05647200|DRUG|Treatment: additional albumin during cardiopulmonary bypass|Treatment group (T): administration of 100 mL Human Albumin (20%), first dose directly after aortic cross clamping and blood cardioplegia administration, second dose after the third blood cardioplegia administration (± 30 min after the first dose).
224204433|NCT05647200|DRUG|control: additional ringers during cardiopulmonary bypass|Control group (C): administration of 100 mL of Ringer's solution, first dose directly after aortic cross clamping and blood cardioplegia administration, second dose after the third blood cardioplegia administration (± 30 min after the first dose).
224204434|NCT01269671|DRUG|Melatonin, Peppermint Oil (mentharil), and Simethicone|Dosing will be dependent on patient's age during time of enrollment. Patients 8-12 years of age will receive Melatonin 3mg tab at night, Peppermint oil 1 capsule (0.2ml) 30-60 minutes prior to meal twice daily, and Simethicone 80mg tab 30-60 minutes prior to meal twice daily. Patients 13-18 years of age will receive Melatonin 3mg tab at night, Peppermint oil 2 capsules (0.4ml) 30-60 minutes prior to meal twice daily, and Simethicone tab 125mg 30-60 minutes prior to meal twice daily
224204435|NCT01269671|OTHER|Sugar pill|Patients in the placebo group will receive one placebo tab to be taken at night, one placebo capsule to be taken 30-60 minutes prior to meal twice daily, and one placebo tab to be taken 30-60 minutes prior to meal twice daily.
224204436|NCT04807231|BIOLOGICAL|Blood withdrawal|Blood withdrawal in order to perform a bioavailable testosterone RIA (Radio-Immuno Assay).
224204437|NCT04024527|DRUG|Esomeprazole|Proton pump inhibitor
224204438|NCT04024527|DRUG|Amoxicillin|Antibiotic for H. pylori eradication
224313489|NCT03918460|DEVICE|ANEUFIX|ANEUFIX is administered through translumbar injection into the AAA using imaging techniques to guide the place of injection.
224313490|NCT03458260|DRUG|Pixantrone|6 cycles - dose = 80mg/m²
224313491|NCT03458260|OTHER|Ifosfamide|6 cycles - 1500 mg/m2
223761343|NCT04361461|DRUG|Hydroxychloroquine Sulfate + Azythromycin|400 mg, orally, every 12 hours x 2 doses (loading dose) and then 400 mg, once a day, orally, for 10 days associated with azithromycin, intravenously or orally, 500 mg / day, for 1 day and then 250mg / day for another 4 days.
224313492|NCT03458260|OTHER|Etoposide|6 cycles - 150 mg/m2
224313493|NCT03458260|OTHER|Rituximab|6 cycles - 375 mg/m2
224313494|NCT03458260|PROCEDURE|Transplant|after 2 or 6 cycles
224204439|NCT04024527|DRUG|Metronidazole|Antibiotic for H. pylori eradication
223511446|NCT02489045|DRUG|SHAPE measurement (Sonazoid ultrasoud contrast agent)|Three vials with 48 µl of Sonazoid (GE Healthcare, Oslo, Norway) microbubbles (6 ml) will be prepared and drawn into a 10 ml syringe, placed in a syringe pump. Sonazoid will be co-infused at a rate of 0.024 µl/kg body weight/minute (suspension infusion rate of 0.18 ml/kg/hour) together with a 0.9% NaCl solution infused at a rate of at least 2 ml/min.
223511447|NCT02970812|DEVICE|Electrical Muscle Stimulation|Participants were under EMS 5 times a week for 12 weeks. Pads were applied on participants' abdomen, rectus abdominis and external oblique abdominal muscle areas without any recent wound, infection, scar, and warts while lie on their back.
224204440|NCT00912327|BIOLOGICAL|Imprime PGG|Imprime PGG, 4 mg/kg, i.v. over 2 hr, weekly in 6 week cycles and Cetuximab, initial dose will be 400 mg/m2 via i.v., and subsequent doses will be 250 mg/m2 via i.v., weekly in 6 week cycles
224204441|NCT00345969|DRUG|Transdermal Testosterone gel (1%)|Transdermal testosterone replacement therapy with Androgel(TM). Daily application of gel at 5 mg, 7.5 gm, or 10 gm for six months. Target serum total testosterone level between 500-900 ng/dl.
224204442|NCT00345969|BEHAVIORAL|Supervised exercise training|Supervised exercise training performed on site at academic medical center exercise facility. Exercise training consisted of 2 months of flexibility, balance, treadmill walking, and physical therapy-type exercises, followed by 4 months of progressive resistance training.
224204443|NCT04874701|DRUG|Capsimax|Capsimax, 2 capsules per day, for 12 weeks Medicinal ingredient: Capsicum annuum Quantity (per capsule): 100.0 mg
224204444|NCT04874701|OTHER|Energy restriction|Personalised diet plan targeting a 500 kcal/day energy restriction
224204445|NCT00131326|DEVICE|Synvisc (hylan G-F 20)|
224204446|NCT00003892|DRUG|ISIS 5132|4mg/kg/day IV for 21 days every 4 weeks.
224204447|NCT03936946|BEHAVIORAL|Audio Content 1|\~30 minute daily audio recordings of content 1 for 28 days
224313495|NCT02564887|DEVICE|Iowa Oral Performance Instrument|the IOPI device is being used to increase tongue strength and endurance
224313496|NCT00658047|DRUG|CH-1504|Comparison of different doses of CH-1504
224313497|NCT00658047|DRUG|Methotrexate (MTX)|10mg/week for 2 weeks escalated to 15mg/week for 2 weeks escalated to 20mg/week for 8 weeks
224313498|NCT02850731|DEVICE|plate-forme Hu360®|the innovative technology (plate-forme Hu360®) will be used in the experimental arm
224313499|NCT01851330|DRUG|LDV/SOF|LDV 90 mg/SOF 400 mg FDC tablet administered orally once daily
224313500|NCT01851330|DRUG|RBV|Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
224313501|NCT06003296|PROCEDURE|Calcaneocuboid arthrodesis|Calcaneocuboid arthrodesis in triple arthrodesis
224313502|NCT00309803|DEVICE|FiberNet Embolic Protection Device|
224313503|NCT01616342|DEVICE|Spinal cord stimulator|Precise (TM) spinal cord stimulator from boston scientific, and comprehensive mdedical management.
224313504|NCT03395457|DRUG|Care as usual|Application of usual pharmacological care for chronic migraine
224313505|NCT03395457|OTHER|Manual Therapy|5 sessions of manual therapy over 12 weeks
223617356|NCT06533280|DRUG|Part B: Treatment D|VH3739937, 500 mg single tablet administered under low-fat/ low calorie conditions.
224313506|NCT06256107|DEVICE|Virtual Reality Headset|Virtual Reality Headset
224313507|NCT04001946|DEVICE|Button Huggie|low profile, external securement device for G-buttons
224313508|NCT01902225|DRUG|Istodax|
223617357|NCT06533280|DRUG|Part B: Treatment E|VH3739937, 500 mg single tablet administered under high-fat/ high calorie conditions.
223617358|NCT06533280|DRUG|Part D: Probe cocktail|Oral administration of probe cocktail (Midazolam, Digoxin, Total Dabigatran etexilate, Rosuvastatin) in moderate fat/moderate calorie conditions.
223617359|NCT04837833|DIAGNOSTIC_TEST|ultrasound|Participants will undergo research ultrasound (rUS1) within three days of their routine CECT scan. A subset of participants (up to 10) will undergo a second research US (rUS2) at 3-4 weeks after rUS1 and at least one month prior to the next planned clinical CECT
223617360|NCT02825615|PROCEDURE|Radial artery cannulation|Radial artery cannulation done with conventional and ultrasound guidance in two respective groups of patients and their first pass success and ultimate success rates compared in different hemodynamic subsets of the patients.
223617361|NCT02378545|DRUG|Oxygen|"On the Hyperoxia arm: Oxygen will be administered using a non-re-breathe oxygen mask applied over the face and nose.~On the Normoxia arm: In many cases oxygen will not be administered. If required the minimum percentage required to reach the target saturations will be administered. In a majority of cases this will be via a venturi mask."
223617362|NCT04655573|PROCEDURE|Breast Cancer Tumor Resection|Patients with ABC will be receiving a biopsy, and a PDMO from the patient's biopsies will be generated from it. It is a model correlating clinical response with PDMO sensitivity to the most common forms of chemotherapy used in advanced breast cancer care.
224313509|NCT01902225|DRUG|Doxil|
224204448|NCT03936946|BEHAVIORAL|Audio Content 2|\~30 minute daily audio recordings of content 2 for 28 days
224204449|NCT06343922|BEHAVIORAL|oral motor facilitation technique group|oral motor facilitation technique
224204450|NCT06343922|OTHER|traditional oral motor exercises group|traditional oral motor exercises
224313510|NCT05972330|DIETARY_SUPPLEMENT|VRx MyBiotics Oral Lozenges|VRx MyBiotics Oral Lozenges are composed of prebiotics, probiotics, and postbiotics.
224313511|NCT02468856|DRUG|armodafinil|Armodafinil 250 mg tablet single dose administration. Outcome measures: Driving simulator performance, Electroencephalogram activity, Area under the plasma concentration versus time curve (AUC), Motor Praxis Task, the Visual Object Learning Test, the Fractal-2-Back, the Abstract Matching, the Line Orientation Test, the Digit-Symbol Substitution Task, the Balloon Analog Risk Test, and the Psychomotor Vigilance Test
224313512|NCT02468856|DRUG|Placebo (for armodafinil)|Placebo tablet single dose administration. Outcome measures: Driving simulator performance, Electroencephalogram activity, Motor Praxis Task, the Visual Object Learning Test, the Fractal-2-Back, the Abstract Matching, the Line Orientation Test, the Digit-Symbol Substitution Task, the Balloon Analog Risk Test, and the Psychomotor Vigilance Test
223617363|NCT03458949|OTHER|awareness campaign|awareness campaign for colorectal cancer screening in the workplace
223617364|NCT00191334|DRUG|gemcitabine|1250 mg/m2, intravenous (IV) day 1 and day 8, every 21 days x 6 cycles or disease progression or unacceptable toxicity
223617365|NCT00191334|DRUG|cisplatin|75 mg/m2, intravenous (IV), every 21 days x 6 cycles or disease progression or unacceptable toxicity
223761344|NCT02484703|DRUG|Placebo|Participants will receive matching placebo PO BID. Study medication will first be administered on Day 1, and only the morning dose will be given on the last day of treatment (Week 26).
223761345|NCT02484703|DRUG|RO5186582|Participants will receive 1 of 3 dosages of RO5186582 PO BID, including 40 mg, 60 mg, or 120 mg. Study medication will first be administered on Day 1, and only the morning dose will be given on the last day of treatment (Week 26).
224204451|NCT04762212|PROCEDURE|Mobilization with movement and stretching, stretching or control|The participants will receive a therapist performed mobilization with movement and then instructed in a stretching program to be followed for one week or only receive instruction in a stretching program to be followed for one week on the hip with the greatest limitation in motion. The hip with the least amount of limitation will not receive an intervention.
224204452|NCT05694026|DEVICE|Intense pulsed light|IPL treatment intensity was chosen based on the Fitzpatrick scale as follows: Fitzpatrick scale I, II, III, 10-15 J/cm2 with a 570-nm filter.
224313513|NCT03687411|PROCEDURE|Neuraxial ultrasonography|Ultrasound gel is applied to lower back lumbar spine of patient and placed with an ultrasound probe around the sacral region. The graphical interface of the software integrated with ultrasound machine will help identify the sacrum. The probe is moved in until the L3/4 interspinous space is identified for skin surface marking. Once the longitudinal scan is completed, the investigator will turn the probe 90° clockwise for transverse scan to identify ligamentum flavum.
224313514|NCT03523338|DRUG|Apalutamide|Participants will receive apalutamide 240 mg orally once daily.
224313515|NCT03523338|DRUG|ADT (Standard of Care)|Participants who did not undergo surgical castration, should receive and remain on a stable regimen of ADT according to local standard of care.
224313516|NCT00385008|DRUG|Combination Product (sumatriptan succinate / naproxen sodium)|sumatriptan/naproxen sodium
224313517|NCT00385008|DRUG|RELPAX(eletriptan) 40mg Tablet|eletriptan tablets
224313518|NCT03353883|DRUG|Triptorelin SR|GnRH agonist depot( Decapeptyl) will be taken in the previous mid luteal cycle in group A and the first day in group B
224313519|NCT00641069|DEVICE|Automated load-distributing band device|Blood pressure recording before and after starting up the automated band device
224313520|NCT05537350|DIETARY_SUPPLEMENT|Lumenato|Supplementation of 12 weeks
224313521|NCT02234219|PROCEDURE|Heart-shape anastomosis|a new operation approach for Hirschsprung disease
224313522|NCT02234219|PROCEDURE|Soave anastomosis|traditional approach for Hirschsprung disease
224313523|NCT05593419|DEVICE|TIIC signature|Collect tumor tissue of 300 gastric cancer patients at treatment baseline, samples will be transferred to central lab to detect the density and spatial proximity of certain immune cells infiltrated in tumor by multi complex immunohistochemistry, and evaluate patients' TIIC signature.Tumor response evaluation will be performed after two cycles of therapy by CT/MRI based on RECIST.Clinical data, including tumor stage,metastaticorgan ,regimen, objective response, progression free survival, overall survival, etc, will be collected according to study protocol.
223511448|NCT02970812|DEVICE|Transcutaneous Electrical Nerve Stimulation|Participants were under TENS 5 times a week for 12 weeks. Pads were applied on participants' abdomen, rectus abdominis and external oblique abdominal muscle areas without any recent wound, infection, scar, and warts while lie on their back.
223511449|NCT00827307|DRUG|tamoxifen|In the monotherapy arm, patients receive once-daily oral dose of tamoxifen 20 mg.
223511450|NCT00827307|DRUG|Goserelin|In the combination arm, patients receive ZOLADEX 3.6 mg by subcutaneous injection every 4 weeks along with once-daily oral dose of tamoxifen 20 mg
223511451|NCT02464358|BEHAVIORAL|IMB Intervention Group|Participants in the IMB group received information specific to HPV, cervical cancer, and the HPV vaccine. This information was delivered in a group setting, and it was delivered via a PowerPoint presentation that included short video clips.
223761346|NCT05019222|DRUG|Sevoflurane based inhalation anesthesia|Sevoflurane group will be inducted with bolus of propofol 1% and maintained with sevofulrane as inhalation and TCI Minto model of remifentanil for general anesthesia.
223761347|NCT05019222|DRUG|Remimazolam based total intravenous anesthesia|Remimazolam group will be inducted with remiamazolam at 6 mg/kg/h and maintained with remimazolam at 0.5-1.5 mg/kg/h and TCI Minto model of remifentanil for general anesthesia.
224204453|NCT05694026|DRUG|Diquafosol tetrasodium|3% Diquafosol tetrasodium eye drops will be used to assess its usefulness in dry eye signs and symptoms
224204454|NCT04361552|OTHER|Best Practice|Receive standard of care
224204455|NCT04361552|BIOLOGICAL|Tocilizumab|Given IV
224204456|NCT05917314|OTHER|Slimbiotic Probiotic|"SlimBiotics Probiotic formula contains three probiotic strains of L. fermentum:~* Limosilactobacillus fermentum K7-Lb1~* Limosilactobacillus fermentum K8-Lb1~* Limosilactobacillus fermentum K11-Lb3 The product also contains Microcrystalline cellulose."
224204457|NCT05917314|OTHER|Placebo|The placebo capsule contains microcrystalline cellulose.
224204458|NCT00928785|BIOLOGICAL|REPEVAX|1 dose of 0.5 mL at Day 0
224204459|NCT00928785|BIOLOGICAL|Monovalent Tetanus vaccine|1 dose of 0.5 mL at Day 0
224204460|NCT00358670|BIOLOGICAL|infliximab|"Infliximab maintenance therapy~intravenous (IV) infusion every 8 weeks, 5 mg/kg body weight (first infusion at Week 4/Visit 2)."
224204461|NCT00358670|BIOLOGICAL|infliximab|"Infliximab intermittent therapy:~Paricipants will receive no infliximab treatment until the Week 26 improvement in PASI from Baseline (original Study P04271 \[NCT00251641\] Baseline) is reduced by more than 50%. At that time, participants will receive an infliximab infusion, 5 mg/kg body weight. Participants may receive additional infusions at 0, 2, 6, and 14 weeks after the first infusion of the cycle (ie, a maximum of 4 infusions in each infusion cycle) as needed until they respond, defined as a \>=75% improvement in PASI from the original Baseline in Study P04271. Subjects will receive no further treatment until they relapse again (ie, improvement in PASI from Baseline is reduced by more than 50%), at which time participants will receive another infusion cycle of up to 4 infusions, as described above. Throughout the study, intermittent treatment infusion cycles will be repeated whenever participants relapse."
224204462|NCT06274385|DIETARY_SUPPLEMENT|Betalain-rich concentrate (AltRed)|"A single dose of 100 mg (2 x 50 mg) 120 min before exhaustive exercise.~Supplement instructions:~All treatments will be administered in similar capsules (smell, color, and size) to ensure both the participants and researcher are blinded to the treatment. All treatments will be administered in an opaque lidded container.~The participants will be instructed to close their eyes and carefully open the container, keeping their heads forward. They will be asked to place the container to their lips, tipping the container to pour the contents into their mouth. Immediately after, they will be instructed to drink water to help them swallow the pill and instructed not to chew or manipulate the pill inside their mouth."
224204463|NCT06274385|OTHER|Placebo|"A single dose (2 x empty capsules) 120 min before exhaustive exercise.~Supplement instructions:~All treatments will be administered in similar capsules (smell, color, and size) to ensure both the participants and researcher are blinded to the treatment. All treatments will be administered in an opaque lidded container.~The participants will be instructed to close their eyes and carefully open the container, keeping their heads forward. They will be asked to place the container to their lips, tipping the container to pour the contents into their mouth. Immediately after, they will be instructed to drink water to help them swallow the pill and instructed not to chew or manipulate the pill inside their mouth."
224204464|NCT01347983|DRUG|Tocilizumab+Methotrexate(MTX)|Tocilizumab: 8 mg/kg every 4 weeks, IV infusion Methotrexate: 10-20 mg/week
224204465|NCT00960687|DRUG|Fenofibric Acid (Fibricor™) 105 mg Tablet|1 x 105 mg fenofibric acid (Fibricor™) tablet administered 30 minutes after the initiation of a standard breakfast.
224204466|NCT00960687|DRUG|Fenofibrate (Tricor®) 145 mg Tablet|1 x 145 mg Fenofibrate (Tricor®) tablet administered 30 minutes after the start of a standard breakfast.
224204467|NCT05121779|DRUG|68Ga-FAPI|Intravenous injection of one dosage of 18.5-22.2MBq (0.5-0.6 mCi)/Kg 68Ga-FAPI. Tracer doses of 68Ga-FAPI will be used to image lesions of pulmonary fibrosis by PET/CT.
224204468|NCT05121779|DRUG|18F-FDG|Intravenous injection of one dosage of 4.44-5.55 MBq(0.12-0.15mCi)/Kg 18F-FDG. Tracer doses of 18F-FDG will be used to image lesions of pulmonary fibrosis by PET/CT.
224204469|NCT06700603|DRUG|Irinotecan liposome (Nal-IRI) in combination with 5-FU/sodium levofolinate|Irinotecan liposome (Nal-IRI) in combination with 5-FU/sodium levofolinate，Every 2 weeks until disease progression or patient develops intolerable toxicity
224204470|NCT04493099|DRUG|Alvocidib Hydrochloride|Given IV
224204471|NCT04493099|DRUG|Decitabine|Given IV
224204472|NCT04493099|DRUG|Venetoclax|Given PO
224204473|NCT00143546|DRUG|Defibrotide|Defibrotide to be administered approximately every 6 hours at an initial dose of 6.25 mg/kg/dose. Subsequent doses will be escalated with a plateau of 15 mg/kg/dose (or 60 mg/kg/day total). For patients with persistent VOD, the dose may be escalated by 10 mg/kg/day as needed to a maximum of 110 mg/kg/day total.
224204474|NCT06652048|DRUG|Furmonertinib 160mg QD|All patients enrolled into this group will receive furmonertinib 160mg p.o qd.
224204475|NCT06652048|DRUG|Furmonertinib 240mg QD|All patients enrolled into this group will receive furmonertinib 240mg p.o qd.
224313524|NCT00314951|DRUG|Fidaxomicin|200 mg oral capsules two times daily (q12h regimen)
223761348|NCT06424080|PROCEDURE|laparoscopic partial nephrectomy|cases amenable for partial nephrectomy
223761349|NCT06424080|PROCEDURE|robotic partial nephrectomy|cases amenable for partial nephrectomy
224313525|NCT00314951|DRUG|Vancomycin|125 mg capsules q6hr (4 times a day)
224313526|NCT00314951|DRUG|Matching Placebo to Fidaxomicin|Matching Placebo to Fidaxomicin administered two times daily (intermittently with fidaxomicin dosing)
224313527|NCT05063032|OTHER|Radiofrecuency ablation|Radiofrequency ablation to treat left atrial flutter, guided by high-density mapping versus linear ablation.
224313528|NCT04387942|DRUG|IL-2|For all patients,rhIL-2 infusions seven days;recurrent patients was applied again for 7 days;patients who were diagnosed HSPN were treated on a routine basis for 7 consecutive days, and then once every two week for 3months.
224313529|NCT02658799|DRUG|cataflam (diclofenac potassium)|Cataflam (diclofenac potassium, 50 mg) b.i.d. after a meal for 6 months in a cyclic regimen. Administration of diclofenac potassium was undertaken from baseline to 2 months, no drug (diclofenac potassium or placebo) was administered from 2 to 4 months, then diclofenac potassium or placebo therapy was reinstituted (b.i.d.) from 4 to 6 months. To promote compliance, each patient was recalled monthly.
223617366|NCT02747810|DEVICE|NewTENS Design|This device functions the same as the FDA approved TENS unit, but provides a small, inexpensive unit that will be easy for a child to use. The stimulation characteristics include a continuous frequency of 5 Hz, pulsewidth 0.2 ms, and intensity 2-4 times the threshold voltage required for inducing toe twitching - or the intensity that the subject feels comfortable with. The subjects will also be instructed how to use the stimulator and where to attach the electrodes on the foot at the beginning of the study. The investigator will provide the stimulator and electrodes. The subjects will be asked to wear socks to prevent the electrodes from detachment and to stop the stimulation during walking or in any non-resting situation. Subjects will be asked to use the stimulator for a MINIMUM of 60 minutes in the evening prior to bedtime at home for two weeks. They will be encouraged to use the stimulator for more time than the minimum as long as they accurately record the total duration.
224204476|NCT06652048|DRUG|Furmonertinib 160mg QD plus Chemotherapy|All patients enrolled into this group will receive furmonertinib 160mg furmonertinib p.o qd plus chemotherapy\[(carboplatin AUC 5 / cisplatin 75mg/m2+ pemetrexed 500mg/m2) every 21 days ×4 cycles + pemetrexed 500mg/m2 every 21 days maintenance\]
224313530|NCT02658799|DRUG|placebo|"Placebo gel caps (containing inactive filler of starch flour and carboxymethylcellulose) b.i.d. after a meal for 6 months in a cyclic regimen.~Administration of placebo was undertaken from baseline to 2 months, no drug (diclofenac potassium or placebo) was administered from 2 to 4 months, then diclofenac potassium or placebo therapy was reinstituted (b.i.d.) from 4 to 6 months. To promote compliance, each patient was recalled monthly."
224313531|NCT06457893|OTHER|The health belief model-based exercise training program and health belief model-based education|The health belief model-based exercise training program and education program will implement with the students in the experimental group for 5 weeks and follow-ups will be made at the 3rd and 6th months.
224313532|NCT03008317|DEVICE|PEEK|a metallic denture base
223617367|NCT04140630|OTHER|No intervention|No intervention; 1 week observational study
224313533|NCT03783325|BEHAVIORAL|UV Counseling|This is a sub-study that involves a behavioral intervention. Participants will wear a UV dosimetry for 3 weeks, return the device and receive feedback. After the feedback, they will re-wear the device for an additional 3 weeks.
224313534|NCT03783325|OTHER|UV Photo|Technically, this arm is a sub-study that does not involve an intervention. Patients are not receiving an intervention; they are simply providing data to the study team.
223617368|NCT01817504|PROCEDURE|Systematic transplantectomy|Transplantectomy within two months after return to dialyse. Antiproliferatives stop at the start of dialysis. Maintenance basic immunosuppressive treatment without dose reduction up to two weeks after transplantectomy. Abrupt discontinuation of the basic immunosuppressive treatment ttwo weeks after transplantectomy. Maintenance corticosteroids at 5mg per day until one month after transplantectomy then stop corticosteroids within one month.
224313535|NCT03783325|OTHER|Biological Sample|Technically, this arm is a sub-study that does not involve an intervention. Patients are not receiving an intervention; they are simply providing data to the study team.
223617369|NCT01817504|PROCEDURE|Progressive reduction of immunosuppression|"Progressive reduction of immunosuppression. Transplantectomy for cause only. Antiproliferatives withdrawn at the start of dialysis. Maintenance of anticalcineurin or mTOR inhibitors half dose for 3 months, ¼ dose for 3 months and then stop. Maintenance corticosteroids for 6 months up to 5 mg per day, and then soft stop in 3 months.~In case of transplantectomy by reason in the control group, basic immunosuppression will be continued at the maintenance dose during the current surgical procedure, and withdrawn two weeks later, similary to the strategy used in the study group."
223761350|NCT05409235|DRUG|OTT166|Participants will receive OTT166 ophthalmic solution
223761351|NCT05409235|DRUG|Vehicle control|Participants will receive vehicle control
224204477|NCT03979339|PROCEDURE|Blood sample collection|A total volume of 32 ml of blood will be collected in each subject and separated in 4 10-mL EDTA vacutainer tubes EDTA tubes of 8 mL each.
224204478|NCT00530452|DRUG|CG100649|Dual-acting COX-2 inhibitor \& carbonic anhydrase inhibitor in gelatin capsules. Oral loading doses (2, 4, or 8 mg vs. placebo) followed by daily oral maintenance doses (0.3, 0.6, or 1.2 mg vs. placebo) for 20 days (total 21 days therapy).
224313536|NCT04601571|DEVICE|CORTRAK Stylet|The stylet is a component of the CORTRAK feeding tube system used to confirm the correct placement of the feeding tube
224313537|NCT05178342|DRUG|CA-4948|"Patients will be treated orally with CA-4948 at 300 mg BID (2x200mg) over 4 cycles. One cycle consists of 28 days, 21 of which are treatment days, followed by 7 days off.~Patients with erythroid response (HI-E) after 4 cycles who tolerate CA-4948 may continue to receive CA-4948 until loss of HI-E response."
224313538|NCT00131599|DRUG|5FU/LV|5FU/LV
224313539|NCT06079320|DRUG|Sisunatovir|Participants will receive tablets from Day 1 to Day 5
224313540|NCT06079320|DRUG|Placebo|Participants will receive matching placebo tablets from Day 1 to Day 5
224313541|NCT03218124|OTHER|Remifentanil Effect site concentration|"After skin suture, a predetermined Effect site remifentanil concentration will be achieved. Starting from 1.5 ng/ml in the first patient and increased or decreased by 0.2 ng/ml intervals based on the previous patient response: up if cough present, down otherwise (Dixon's up and down method)."
224313542|NCT00259233|DRUG|peripheral Peptide YY administration|
224313543|NCT00233402|DRUG|Hexvix|Single Instillation, Transurethral Resection of the Bladder
224313544|NCT00233402|PROCEDURE|Standard white light cystoscopy|
223617370|NCT05957965|DEVICE|Wii fit|Nintendo Wii console (Nintendo Co., Ltd, Kyoto, Japan) is the main power unit of Nintendo Wii Fit. Its software includes an interactive video games that is played with a handheld, wireless remote that senses motion and requires the participant to mimic the action of their on - screen character. These games are played using a special Wii balance board in order to perform activities like yoga, balance and aerobics. The Wii remote is the primary controller for Nintendo's Wii console. The motion sensing capability is the main feature of it. It allows the user to interact with and manipulate items on screen via pointing.
223617371|NCT05957965|OTHER|Strengthening, proprioceptive exercises.|"-Strengthening exercise: Ankle Dorsiflexion and Plantar Flexion \& inversion and eversion Strengthening with Exercise Bands~-Proprioceptive exercise using wobble board"
223617372|NCT04266132|PROCEDURE|General anaesthesia|General anaesthesia will be induced with 8% sevoflurane in oxygen and maintained with 1 MAC sevoflurane via a laryngeal mask.
223617373|NCT04266132|PROCEDURE|Ultrasound-guided RLB|The suggested ultrasound transducer orientation is sagittal paramedian (cephalacaudad direction). We begin our ultrasound scanning in a paramedian sagittal plane by finding desired level (T12- L1).The transverse process view, the costotransverse ligament can be visualized above the paravertebral space. Continuing to scan from lateral to medial, the vertebral laminae come into view.
224204479|NCT00530452|DRUG|Silicified microcrystalline cellulose + talc|Gelatin capsules containing cellulose/talc matched for weight and color to experimental medication. Placebo administered orally 1x/day.
224204480|NCT02704130|DEVICE|Transarterial embolization|In transarterial bland embolization, beads are delivered directly into the arterial vessels feeding the tumor, usually by a percutaneous coaxial catheter system guided by ultrasound or fluoroscopy through the common femoral artery.
224204481|NCT02704130|PROCEDURE|Microwave Ablation|Microwave ablation is a form of thermal ablation used to treat cancer. In this procedure, electromagnetic waves in the microwave energy spectrum (300 MHz to 300 GHz) are applied to tumor tissue. The oscillation of polar molecules produces frictional heating, ultimately generating tissue necrosis within solid tumors.
224204482|NCT06521138|BEHAVIORAL|Motivational interviewing group|The intervention group will receive motivational interviewing based on the transtheoretical model in addition to routine care. Motivational interviews are structured in line with the stages of change and behavioral change processes, which are the basic structures of the transtheoretical model. Three sessions of motivational interviewing with a session duration of 30 min will be implemented. Two sessions of motivational interviewing in the prenatal period and one session of motivational interviewing in the postnatal period.
224204483|NCT06521138|OTHER|Control group|Participants in the control group will receive routine care at the center.
224204484|NCT06701708|OTHER|Participants are not assigned to interventions based on a protocol.|Participants are not assigned to interventions based on a protocol.
224204485|NCT04807634|DRUG|Intravenous Lipid Emulsion (Intralipid 20%)|Lipid emulsion or fat emulsion refers to an emulsion of lipid for human intravenous use. It is often referred to by the brand name of the most commonly used version, Intralipid, which is an emulsion of soy bean oil, egg phospholipids and glycerin, and is available in 10%, 20% and 30% concentrations. The 30% concentration is not approved for direct intravenous infusion, but should be mixed with amino acids and dextrose as part of a total nutrient admixture.
224204486|NCT01770639|PROCEDURE|MFB|Surgical arthrodesis of the midfoot with the Midfoot Fusion Bolt (MFB)
224204487|NCT06108297|DIETARY_SUPPLEMENT|Lithium|Elemental lithium as lithium aspartate.
224204488|NCT01065545|DRUG|Clofarabine|dose escalation, administered orally, once a day for 21 days per cycle (cycles begin every 28-49 days)
224204489|NCT00509340|BEHAVIORAL|Cognitive behavioral therapy (CBT)|Participants in this group will receive individual sessions of cognitive-behavioral training for improvement of medication adherence and reduction of depression.
224204490|NCT04120714|DEVICE|Active tDCS|active D.C. transcranial stimulation (delivers a low current (1 to 2 mA)) for 10 to 30 minutes, during 5 sessions
224204491|NCT04120714|DEVICE|Placebo tDCS|inactive DC transcranial stimulation (delivering a non-significant current at the beginning and end of the stimulation, simulating active stimulation) for 10 to 30 minutes, during 5 sessions
224204492|NCT04120714|OTHER|Questionnaires|"* visual analogue scale (VAS)~* impulsivity scale: Barratt Impulsiveness Scale - version 11 (BIS-11)~* Decision-making scales: Iowa Gambling Task (IGT) and Balloon Analogue Risk Task (BART)~* Go-No go test~* HAM-D scale~* SF-12 quality of life scale"
224204493|NCT05529641|OTHER|Diaphragmatic resistance training|6 weeks home exercise of diaphragmatic resistance training will be emphasized.
224204494|NCT05529641|OTHER|Cervical stabilization exercise|Participants will finish 6 weeks supervised cervical stabilization exercise in person by physical therapist. Dissociated movement and movement control will be emphasized during cervical stabilization exercise.
224204495|NCT06280794|DEVICE|Laser acupuncture|"Patients in the laser acupuncture group (LA group) received 12 sessions of laser acupuncture (3 times per week). Laser aucpuncture used a class IV Multiwave Locked System (MLS) laser (Mphi laser, ASA Srl, Vicenza, Italy).~In LA group, we choose 5 acupoints on the affected side. It includes ST2(Si Bai), ST4(Di Cang), ST6(Jia Che), GB14(Yang Bai), GB20(Feng chi). We choose 6 acupoints, including LI4 (He Gu), LI11(Qu Chi), ST36 (Zu San Li), SP6 (San Yin Jiao), KI3 (Tai Xi), LR3 (Tai Chong).~Laser acupuncture used have wavelength of 808 nm and 905nm, 1.2 W power (808nm is 1 W, 905 nm is 200 mW), continuous mode emission (808 nm) and pulsed mode emission (905 nm), 500 Hz, 50% power level, 50% duty cycle, 8.35 J/cm2 dosimetry, 26.22 J for each point, administered for 3 times per week in the first 2 weeks, and 1500 Hz, 50% power level, 50% duty cycle, 8.35 J/cm2 dosimetry, 26.22 J for each point, in the last 2 weeks, 12 times total treatment."
224204496|NCT06280794|DRUG|Steroids|Prednisolone as 5 mg tablets (Tianjin Lisheng Pharmaceutical Co., Ltd., China) were given as a single dose of 30 mg daily for the first 3 days; 15 mg daily for the following 3 days; 10 mg daily for the after 3 days; 5 mg daily for the final 3 days, with a total treatment time of 9 days.
224204497|NCT05524714|DIETARY_SUPPLEMENT|solubilized Xanthohumol low dose|single administration of 2 soft gelatine capsules each containing 43 mg micellar solubilized Xanthohumol and 2 soft gelatine capsules containing only micelles
224204498|NCT05524714|DIETARY_SUPPLEMENT|solubilized Xanthohumol high dose|single administration of 4 soft gelatine capsules each containing 43 mg micellar solubilized Xanthohumol
224204499|NCT05524714|DIETARY_SUPPLEMENT|native Xanthohumol low dose|single administration of 2 hard gelatine capsules each containing 43 mg native Xanthohumol and 2 hard gelatine capsules containing silicon dioxide
224204500|NCT05524714|DIETARY_SUPPLEMENT|native Xanthohumol high dose|single administration of 4 hard gelatine capsules each containing 43 mg native Xanthohumol
224313545|NCT04084457|DIETARY_SUPPLEMENT|Wild Blueberry powder|Powdered extract obtained from wild blueberries. A daily administration of 27g wild blueberry powder will be administered.
224313546|NCT04084457|DIETARY_SUPPLEMENT|Placebo|Identical formulation as the treatment matched for fibre and vitamin C
224313547|NCT06975501|BEHAVIORAL|Exercise Intervention|Participants will receive twice-weekly aerobic and balance training sessions, with medication compliance education.
224313548|NCT06975501|BEHAVIORAL|Cognitive Intervention|Participants will participate in twice-weekly structured cognitive training sessions, with medication compliance education.
224313549|NCT01963286|DEVICE|ICD with enhanced SVT discriminators|ICD will be programmed to uniform device settings with enhanced SVT discrimintators enabled.
224313550|NCT04034563|PROCEDURE|1) Risk of metachronous advanced neoplasia at 3-year, beyond 3 years surveillance colonoscopy|"3-year group: High-risk subjects who have baseline colonoscopy done in 2014, 2015 and 2016 and will be eligible for 3-year surveillance colonoscopy in 2017-2019.~Beyond 3 years group: High-risk subjects who had screening colonoscopy prior 3 years, but not received or scheduled for a surveillance colonoscopy- either due to non-adherence or limited access to surveillance colonoscopy will be eligible for surveillance colonoscopy in 2017-2019.~For the surveillance interval beyond 3 years group, recruitment will be prioritizing to subjects who had the screening colonoscopy at the earliest date. This will in part ensure that subjects in this group will consist those with the longest surveillance interval, leading to an applicable estimation of the risk of metachronous advanced neoplasia beyond 3 years surveillance interval."
224313551|NCT03663634|OTHER|Cytochalasin B use in ICSI handling medium|A medium with in-house supplementation of Cytochalasin B to decrease oocyte degeneration after ICSI and improve survival rate
224313552|NCT06007066|DRUG|HSK16149 capsule|Subjects will be given 40mg or 60mg of HSK16149 orally.
224313553|NCT06007066|DRUG|Placebo|Subjects will be given HSK16149 placebo orally.
224313554|NCT04091711|DEVICE|ReX-C system|Oral oncolytic medications are dispensed to patients via ReX-C system
224313555|NCT04016220|DRUG|Budesonide|first nebulization of 0.5 mg of budesonide in association with terbutaline and ippratropium bromide followed by repetitive nebulization of 5 mg of terbutaline with 0.5 mg of budesonide at 20, 40, 60 and 120 min.
224313556|NCT04016220|DRUG|normal saline|first nebulization of 2ml of normal saline as placebo comparator in association with terbutaline and ippratropium bromide followed by repetitive nebulization of 5 mg of terbutaline with 2 ml of normal saline at 20, 40, 60 and 120 min.
224313557|NCT04278950|DRUG|Povidone-Iodine|For the PVP-I group, the final concentration of available iodine in the solution will be 0.01%, (from diluting 10% PVP-I solution), as previously demonstrated to be below ciliotoxic levels of 1.25% and greater than 0.01% which is the lower limit of active potency.
224313558|NCT04278950|DRUG|Placebos|The placebo will be 2.5mL of saline with brown food coloring.
224313559|NCT02581722|DEVICE|PrePex Device|The PrePex device is designed to enable conducting male circumcision procedure that is bloodless with no anesthesia and no sutures. For contraindicated subjects, a preparation procedure will take place.
224313560|NCT06182761|DRUG|Sunvozertinib combination with Anlotinib|Sunvozertinib 300 mg once daily (QD) with Anlotinib 12mg once daily （QD in Day 1-14） ，21 days in one cycle.
224204501|NCT04938102|DRUG|Botulinum Toxin Type A Injection [Botox]|Injection of 100 units of botulinum toxin into the lower esophageal sphincter (25 units in each quadrant).
224313561|NCT04032249|BEHAVIORAL|Control Group (CG)|The control group is subjected to follow a hypocaloric diet and receives information about the benefits of having healthy habits in relation to decision making and food
223511452|NCT02464358|BEHAVIORAL|Attention Control|Participants in the attention control arm watched a PowerPoint that contained a series of short video clips encompassing aspects of women's general and sexual health. This was also conducted in a group setting.
223511453|NCT05562921|BEHAVIORAL|Controls-ususal care|Controls: patients who did not receive remote patient monitoring for blood pressure prescribed during routine care delivery, with multivariable matching to cases
223511454|NCT05562921|BEHAVIORAL|Cases-remote patient monitoring prescribed|Cases: patients prescribed remote patient monitoring for blood pressure during routing care delivery
223511455|NCT02690376|DEVICE|Magnetic Assisted Capsule Endoscopy|Swallowed magnetic capsule for endoscopy purposes
223511456|NCT01309191|OTHER|Minoxidil|Over the counter Rogaine, twice a day for 8 weeks
223511457|NCT01309191|OTHER|Placebo|
223511458|NCT01993758|PROCEDURE|Low tourniquet pressure|Tourniquet pressure set as 120mmHg above the systolic blood pressure just before tourniquet inflation
223511459|NCT01993758|PROCEDURE|Conventional tourniquet pressure|Tourniquet pressure set as 150mmHg above the systolic blood pressure just before tourniquet inflation
224204502|NCT05744219|DRUG|Ferric carboxymaltose|Active drug
224204503|NCT05744219|DRUG|Placebo|Placebo
224204504|NCT04318041|DRUG|Artrodar|"Diacerein (Artrodar):~D1-D28 (1 month): Artrodar (50 mg) 1 x 1 with evening meal D29-end of study (23 months): Artrodar (50 mg) 1 x 2 with meal"
224204505|NCT04318041|DRUG|Placebos|"Placebo:~D1-D28 (1 month): Placebo 1 x 1 with evening meal D29-end of study (23 months) Placebo 1 x 2 with meal"
224313562|NCT04032249|BEHAVIORAL|Intervention Group (IG)|The control group is subjected to follow a hypocaloric diet and receives information about the benefits of having healthy habits in relation to decision making and food, but also, they will have monitored the self-control of the weight in order to compare the impact of self-weighing versus not doing it
224313563|NCT04810949|DIETARY_SUPPLEMENT|Vitamine D3 supplementation|1\. The supplementation treatment will consist of prescribing vitamin D3 consumption of 4000 U 13 single dose tablets each month (52,000 IU).
224313564|NCT04810949|DIETARY_SUPPLEMENT|Diet and sun exposure|"2\. Hygienic-dietary recommendations will consist of 2 steps~1. Sun exposure at least 10 minutes a day from 10: 00-6: 00 pm~2. Consumption of foods rich in vitamin D: milk, fish, almonds, mushrooms"
224204506|NCT06197698|DIAGNOSTIC_TEST|F18-FDG, Tc-99m TRODAT-1|In this project, 18F-FDG PET is used as an imaging marker of gut microbiota composition evaluation in PD patients, and the nigrostriatal dopamine system is assessed by Tc-99m TRODAT-1 SPECT.
224204507|NCT05495425|DRUG|NPC-12Y gel|NPC-12Y gel is applied twice a day for 12 weeks. After the double-blind evaluation period, NPC-12Y gel is applied twice a day for 52 weeks.
224204508|NCT05495425|DRUG|NPC-12Y placebo gel|NPC-12Y placebo gel is applied twice a day for 12 weeks. After the double-blind evaluation period, NPC-12Y gel is applied twice a day for 52 weeks.
224204509|NCT02666768|DRUG|Interferon gamma-1b|gamma interferon-1b dose escalation over first 4 weeks of study to 100 mcg SC 3 times weekly
224313565|NCT06484725|GENETIC|Oncotype DX assay|Oncotype DX assay (Genomic Health, Inc, Redwood City, Calif) is a 21 gene panel developed to predict the risk of tumor recurrence in patients with ER-positive and human epidermal growth factor 2 (HER2)- negative breast cancer (BC); nowadays, this test represents a standard of care to guide adjuvant chemotherapy decision recommended in several guidelines. According to Oncotype DX Recurrent Score (RS)® a high RS shows a worse prognosis and predicts chemotherapy benefit in patients with ER-positive HER2-negative BC.
224313566|NCT06407986|DIAGNOSTIC_TEST|pulmonary function test|Whether the estimated value of FEV1 and FVC is greater than 80%.
224313567|NCT04181723|DRUG|Trofinetide|Trofinetide solution administered based on the subject's weight at Baseline, twice daily for 12 weeks
224313568|NCT04181723|OTHER|Placebo|Trofinetide placebo solution administered based on the subject's weight at Baseline, twice daily for 12 weeks
224313569|NCT05509816|DRUG|Midazolam|Administered orally.
224313570|NCT05509816|DRUG|Imlunestrant|Administered orally.
224313571|NCT05161247|OTHER|Zona pellucida sperm selection|Sperm selection for ICSI based on the spermatozoa ability to adhere to immobilized zona pellucida proteins.
224313572|NCT05161247|OTHER|Conventional sperm selection|Sperm selection for ICSI based on the sperm morphology.
224313573|NCT05161247|OTHER|Intracytoplasmic Sperm Injection (ICSI)|Normal ICSI procedure.
223511460|NCT05759364|DRUG|IV Papaverine 80 mg|Opium alkaloid antispasmodic drug
223511461|NCT05759364|DRUG|Placebo|Placebo
223511462|NCT03116269|DRUG|Cilostazol 100mg|
223511463|NCT03116269|DRUG|Aspirin|
223511464|NCT01813643|DRUG|Risperidone|Risperidone group,1mg/pill,2mg-6mg/day non-forced titration method,last 2-4weeks
223511465|NCT01813643|DRUG|Aripiprazole|Aripiprazole group,5mg/pill,20mg-30mg/day non-forced titration method,last 2-4weeks
223511466|NCT02713620|BIOLOGICAL|recombinant HBV vaccine (Hepavax-Gene® Berna, Korea)|Different HBV vaccine regimen in each group
223511467|NCT04042428|DRUG|Somatropin injection|Subjects receive a daily subcutaneous dose of 0.2 IU/kg (0.067 mg/kg) of recombinant somatropin (rhGH) during 14 days.
223511468|NCT06293144|DRUG|Ciprofol|Ciprofol was injected intravenously, and was pumped during operation to maintain sedation
223511469|NCT00291226|DRUG|Glycine|Glycine 0.4 g/kg bid
223511470|NCT00291226|DRUG|Placebo|Placebo
223511471|NCT00557102|BIOLOGICAL|cetuximab|
223511472|NCT00557102|BIOLOGICAL|filgrastim|
223511473|NCT00557102|DRUG|fluorouracil|
223511474|NCT00557102|DRUG|irinotecan hydrochloride|
223511475|NCT00557102|DRUG|leucovorin calcium|
223511476|NCT06285903|PROCEDURE|internal sinus lift surgery|surgery approach
223511477|NCT01666613|DRUG|AZD8683|Solution for injection, administered as intravenous infusion Total dose of 100µg AZD8683
223511478|NCT01666613|DRUG|AZD8683|Solution to be administered orally Total dose of 950 µg AZD8683
223511479|NCT01666613|DRUG|AZD8683|Dry powder inhaled via New Dry Powder Inhaler, 540 µg delivered dose AZD8683
223511480|NCT01666613|DRUG|AZD8683|Dry powder inhaled via Turbuhaler™, 600 µg delivered dose AZD8683
223511481|NCT03111732|BIOLOGICAL|Pembrolizumab (MK-3475)|200 mg will be administered as an IV infusion on Day 1 of each 21 day cycle
223511482|NCT03111732|DRUG|Oxaliplatin|130mg/m(2) IV Infusion will be administered as an IV infusion on Day 1 of cycles 1-6
223511483|NCT03111732|DRUG|Capecitabine|750 mg/m(2) will be administered orally twice a day on Days 1-14 of cycles 1-6
223511484|NCT06163638|BEHAVIORAL|GRANDPACT Project|To investigate whether grandparents and grandchildren are more co-physically active, have a better cognitive and physical function, psychosocial well-being, quality of the family relationship due to the intervention, we compare the intervention phase (B) with a pre phase (A), a in between period (A) and another intervention period (B)
223511485|NCT02504385|DEVICE|Virtual Reality Timocco|Timocco virtual reality system is a motion based comuter games that was designed for child development therpay. The children will play Timocco for 15 minutes every session.
223511486|NCT02504385|OTHER|Conventional OT intervention|Traditional Occupational Therapy intervention will be givven to the control group.
223511487|NCT01366105|DEVICE|V.A.C. by K.C.I.|Negative Pressure Wound Therapy, Delivered by Vacuum Assisted Closure (KCI) across closed surgical incision at completion of surgery
224204510|NCT05217901|DRUG|14C-labeled ASP0367|Oral
224204511|NCT05558189|DEVICE|Vibrotactile Coordinated Reset (vCR)|The purpose of this study is to test the efficacy of vibrotactile coordinated reset stimulation on human subject participants who have refractory Parkinson's disease post surgical treatment
224204512|NCT06646991|DEVICE|Nasal canula - up to 6 liters per minute|"Oxygen will be administered via nasal cannula up to 6 liters per minute during this period.~Oxygen flow rates will be adjusted manually, with a gradual increase in flow rates to achieve a oxygen flow rates for reach the peripheral oxygen saturation (SpO2) target (92% for non chronic obstructive pulmonary disease (non COPD) patient and 90% for chronic obstructive pulmonary disease (COPD) patient).~The steady state will be defined by a fixed oxygen flow rate and a stable SpO2 around the target ±2% for 15 minutes. The average oxygen flow rate during the last five minutes will be used."
224313574|NCT02087189|DEVICE|First ICD/CRT-D implantation or upgrade from pacemaker|
224204513|NCT06646991|DEVICE|Nasal canula - up to 15 liters per minute|"Oxygen will be administered via nasal cannula up to 15 liters per minute during this period.~Oxygen flow rates will be adjusted manually, with a gradual increase in flow rates to achieve a oxygen flow rates for reach the SpO2 target (92% for non COPD patient and 90% for COPD patient).~The steady state will be defined by a fixed oxygen flow rate and a stable SpO2 around the target ±2% for 15 minutes. The average oxygen flow rate during the last five minutes will be used."
224204514|NCT06646991|DEVICE|Open oxygen mask|"Oxygen will be administered via an open during this period. Oxygen flow rates will be adjusted manually, with a gradual increase in flow rates to achieve a oxygen flow rates for reach the SpO2 target (92% for non COPD patient and 90% for COPD patient).~The steady state will be defined by a fixed oxygen flow rate and a stable SpO2 around the target ±2% for 15 minutes. The average oxygen flow rate during the last five minutes will be used."
224313575|NCT05375877|DEVICE|iATROS|"The digital eHealth platform of iATROS in combination with a wearable will be used independently by the subjects of the study. In particular, the reminder function is used to remind patients to record their ECGs, take medication and perform other tasks they may have created themselves, or to use other iATROS functions, such as teleconsultation or remote medical data reporting. Furthermore, the designed training program for atrial fibrillation patients teaches them how to deal with their own disease.~If unhealthy or dangerous vital signs are detected during the use of these medical devices over a longer period of time, the patient receives feedback through the application for medical presentation. This includes the detection of atrial fibrillation recurrences."
224313576|NCT04570462|OTHER|Hypothermia Via Cooling Machine- Arctic Sun 5000|"Initiate hypothermia using the Arctic Sun.The Arctic Sun 5000® is set to a temperature of 34.5 C to lower the body temperature.~Duration of hypothermia will be 48 hours after which the subject will be rewarmed. Metabolic rate, or indirect Calorimetry, will be assessed at baseline, day 1 of hypothermia, day 2 of hypothermia before rewarming, and after full rewarming. CBC, basic metabolic profile, magnesium, phosphorus, coagulation profile, ABG, inflammatory markers would be drawn every 12 hours during hypothermia until subject has achieved full rewarming and once after full rewarming.~The entire hypothermia procedure will last 48 hours. Acceptable rewarming range is a temperature of 36.5C to 37.5C. The subject body temperature rewarming is typically set over 6-8 hours. Therefore, the final 6-8 hours of the 48 hour time period is set to rewarm the subject."
224313577|NCT00500136|PROCEDURE|mortality salience|
223617374|NCT04266132|PROCEDURE|Ultrasound-guided INB|A high-frequency probe is placed medial to the anterior superior iliac spine with the axis facing the umbilicus. A needle is inserted toward the ilioinguinal nerve as it runs between the transversus abdominis and internal oblique.
224313578|NCT04429438|BIOLOGICAL|4SCAR19 and 4SCAR20/22/70/PSMA/13/79b/GD2|Patients who have relapsed and refractory B cell lymphoma (BCL) after conventional chemotherapy will be treated with multiple 4SCAR gene-engineered T cells
224313579|NCT05129007|DEVICE|Oura ring|Photopletysmography based noninvasive device
224313580|NCT04810637|DRUG|GX-I7|Recombinant human interleukin-7 hybrid Fc
224313581|NCT05434429|OTHER|mobile application|Participants in the intervention group are able to access the intervention materials 5 days after enrollment. Two main self-guided intervention modules are available. Short-term self-guided intervention module include mainly audio-guided sessions on gratitude, thoughts management, auto-empathy, and relaxation. Moreover, there based on breath relaxation exercises, craving management, and motivation to change. Long-term self-guided intervention module include CBT-based interventions, meditations, mindfulness, and journaling.
224313582|NCT05865730|OTHER|Live Bacterial Product - Akkermansia muciniphila|Oral administration of Oncobax-AK to patients deficient in Akkermansia by stool metagenomic analysis.
224313583|NCT04869215|OTHER|EverVita Pro|EverVita Pro is composed of barley and corn, grown and mechanically processed in Europe, with non-GMO grains.
224313584|NCT04869215|OTHER|Control bread|Bread baked with normal Bakers flour
224313585|NCT01189487|DRUG|ampicillin sodium/sulbactam sodium|ampicillin sodium/sulbactam sodium is administered 12g/day (3 g four times a day) intravenously for 3 to 14 days
223511488|NCT04674800|BIOLOGICAL|MYL-1701P, a proposed biosimilar to Eylea|Open label and single arm
223511489|NCT00063232|DRUG|Metformin|After complete medical evaluation and liver biopsy, patients who qualified for therapy were started on metformin in an initial dose of 500 mg once daily. After 2 weeks, the dose was increased to 500 mg twice daily and after 4 weeks to the full dose of 1000 mg twice daily. Subsequent dose reductions were carried out based on tolerance, with particular attention to gastrointestinal upset and abdominal bloating. Patients were seen in the out-patient clinic, had a brief medical history and examination and routine blood tests at 2 and 4 weeks after enrolment and every 4 weeks thereafter. The oral and intravenous glucose tolerance tests were repeated after 40 and 44 weeks respectively and liver biopsy and imaging tests at 48 weeks. Metformin was discontinued after 48 weeks in patients without diabetes on the pre-treatment evaluation.
223511490|NCT02644811|DRUG|Topical anesthesia (buccal and palatal)|Saliva is removed with a sterile swab followed by application of 5% Lidocaine gel (APL, Sweden) on the gingiva.
223511491|NCT02644811|DRUG|Local anesthesia (buccal and palatal)|Injection of 1,5 ml Xylocaine Dental Adrenaline (Lidocaine hydrochloride 20 mg/ml, adrenaline 12.5 µg/ml, Dentsply Pharmaceutical, Weybridge, Surrey, UK).
223511492|NCT02644811|PROCEDURE|Extraction of the maxillary first premolars|Careful extraction of the maxillary first premolars after mobilization.
223511493|NCT02644811|DRUG|Topical anesthesia (buccal)|Saliva is removed with a sterile swab followed by application of 5% Lidocaine gel (APL, Sweden) on the gingiva.
223511494|NCT02644811|DRUG|Local anesthesia (buccal)|Injection of 0.3 ml Xylocaine Dental Adrenaline (Lidocaine hydrochloride 20 mg/ml, adrenaline 12.5 µg/ml, Dentsply Pharmaceutical, Weybridge, Surrey, UK).
223511495|NCT02644811|DEVICE|Molarblock|Molarblock is a Stainless steel ligature connecting the maxillary second premolar with the maxillary first and second molar.
224204515|NCT06646991|DEVICE|Simple oxygen face mask|"Oxygen will be administered via simple oxygen face mask during this period. Oxygen flow rates will be adjusted manually, with a gradual increase in flow rates to achieve a oxygen flow rates for reach the SpO2 target (92% for non COPD patient and 90% for COPD patient).~The steady state will be defined by a fixed oxygen flow rate and a stable SpO2 around the target ±2% for 15 minutes. The average oxygen flow rate during the last five minutes will be used."
224204516|NCT05534698|PROCEDURE|PCI|Revascularization by PCI
224204517|NCT05534698|PROCEDURE|CABG|Revascularization by CABG
223617375|NCT04266132|DRUG|Bupivacaine|0.3 ml.kg of 0.25% bupivacaine will be injected under visualization.
224204518|NCT05726409|OTHER|Mobile application|Participants will use the meal planner function on the mobile application to plan and cook at least 3 meals a week for 12 weeks.
224204519|NCT03054675|DIAGNOSTIC_TEST|Spirometry|Absolute FEV1 is measured in every patient using a handheld spirometer
224204520|NCT03690375|DEVICE|Broad Band Light (BBL)|Sciton's BBL treatment using a new protocol that utilizes a 590nm, 560nm, and skintyte filter
224204521|NCT01103375|DRUG|erlotinib hydrochloride|Given PO
224204522|NCT01103375|DRUG|isotretinoin|Given PO
224204523|NCT01103375|OTHER|laboratory biomarker analysis|Correlative study
224204524|NCT01103375|GENETIC|protein expression analysis|Correlative study
224204525|NCT06623526|DRUG|YHR2402|Test Drug: YHR2402
224204526|NCT06623526|DRUG|YHR2402+YHR2403|Test Drug: YHR2402+YHR2403
224204527|NCT01527786|DRUG|Desvenlafaxine|50mg-100mg everyday for 12 weeks over 7 study visits
224204528|NCT06369077|DRUG|dorzolamide/timolol|Compare half-frequency dosing of latanoprost and dorzolamide/timolol to full dosing. Compare also to timolol/brimonidine/dorzolamide/bimatoprost
224204529|NCT04054323|BEHAVIORAL|Physical Activity Intervention|The physical activity intervention will include basic skill training during which the participant will be instructed on the use of (1) the activPAL physical activity device for the tracking of time spent sitting, standing, and walking, (2) tools to monitor exercise intensity, including ratings of perceived exertion, (3) an exercise calendar for setting a specific schedule for the completion of the home exercise program using the exercise videos posted on our website, (4) use of the exercise equipment that will be used in the home program (Therabands), and (5) strategies for reduction of sedentary behavior that target prolonged sitting and encourages frequent activity breaks. Duration of intervention is 6 months.
224204530|NCT02008955|DIETARY_SUPPLEMENT|Lysine intake provided as a milkshake|There are 7 different lysine test levels ranging from 10 to 80 mg of lysine per kilogram body weight per day (10 - 80 mg/kg/d)
224204531|NCT00050050|BEHAVIORAL|Cognitive behavioral therapy|
224204532|NCT00050050|DRUG|Drug therapy|
224204533|NCT02973282|OTHER|Recording of Infants and Children's Cough Sounds|Smartphone recordings of the cough sounds of infants and children presenting to a participating site with signs or symptoms of respiratory disease
224204534|NCT00285012|DRUG|placebo|1mg (placebo) by mouth twice daily for 12 weeks (first week is up titration schedule---0.5mg once daily for 3 days, 0.5mg twice daily for 4 days)
224204535|NCT00285012|DRUG|Varenicline Tartarate|1 mg by mouth twice daily for 12 weeks (first week is up titration schedule---0.5mg once daily for 3 days, 0.5mg twice daily for 4 days)
224204536|NCT00127296|DEVICE|FlexPen®|
224204537|NCT00127296|DEVICE|vial and syringe|
224204538|NCT05871853|BEHAVIORAL|Improved breastfeeding support|Cross-sectoral intervention to improve breastfeeding support among women giving birth at Slagelse Hospital, Region Zealand, Denmark
224204539|NCT02843529|OTHER|Altoida: neuropsychological, MRI, EEG and CSF biomarkers|"Data collection at baseline: clinical (neurological, activity of the daily life, instrumental activity of the daily life, depression scale), standard neuropsychological exam, ALTOIDA and neurophysiology (EEG/ERPs) in both Prodromal and Preclinical AD subjects. In both Prodromal and Preclinical AD subjects, APOE genotyping. The local clinical Unit should document the positivity at the baseline session of at least one of the biomarkers of AD mentioned above.~Data collection at 6, 12, 24 and 36 months of follow up: clinical (neurological, activity of the daily life, instrumental activity of the daily life, depression scale), standard neuropsychological exam, ALTOIDA and neurophysiology (EEG/ERPs) in both Prodromal and Preclinical AD subjects."
224204540|NCT02850783|PROCEDURE|89Zr-nanocoll and Indocyanine Green|
224204541|NCT02873195|DRUG|Atezolizumab|Given IV
224204542|NCT02873195|BIOLOGICAL|Bevacizumab|Given IV
224204543|NCT02873195|DRUG|Capecitabine|Given PO
224204544|NCT02873195|OTHER|Laboratory Biomarker Analysis|Correlative studies
224204545|NCT02873195|OTHER|Placebo|Given IV
224204546|NCT01005186|BEHAVIORAL|Eating habits, diet and exercise|Programme of change to eating habits, diet and exercise
224204547|NCT03076307|BEHAVIORAL|Procedural Motor Skills with mirror-drawing of figures|Evaluation of error rate and speed for completion of a procedural motor task
224204548|NCT02174549|DRUG|Tirapazamine|Intra-arterial injection into the tumor feeding artery
224204549|NCT02174549|PROCEDURE|Conventional Transarterial Embolization (TAE)|Lipiodol and Gelfoam used to embolize tumor vessels and induce tumor hypoxia
224204550|NCT06550440|BEHAVIORAL|family integrated care|Trained NICU nurses give effective education to parents of children, and regard parents as a part of NICU team, so that they can actively provide positive care for babies instead of passive caregivers. Parents mainly participate in nursing care such as bottle feeding, changing diapers, skin contact and so on.
224204551|NCT06405048|OTHER|Mobile Weibo post screenshot with mock-up Chinese fact-checking extension|The intervention in this survey experiment involves mobile Weibo post screenshots equipped with a mock-up Chinese fact-checking browser extension. All screenshots are based on actual Weibo posts. The fact-checking content is generated by a Large Language Model (LLM), tailored to relevant knowledge and prompts, and subsequently validated by experts. The Weibo posts cover a range of popular topics known to contain misinformation, including infertility, safety, vaccine ingredients, high-risk cervical cancer types, regular check-ups, transmission routes, and others.
224204552|NCT01711814|DRUG|peficitinib|oral
224204553|NCT05004181|BIOLOGICAL|BNT162b2|Intramuscular (IM)
224204554|NCT05004181|BIOLOGICAL|Multivalent BNT162b2 (B.1.1.7 + B.1.617.2)|Intramuscular (IM)
224204555|NCT05004181|BIOLOGICAL|Monovalent BNT162b2 (B.1.1.7)|Intramuscular (IM)
224204556|NCT05004181|BIOLOGICAL|Monovalent BNT162b2 (B.1.617.2)|Intramuscular (IM)
224204557|NCT05004181|BIOLOGICAL|Monovalent BNT162b2 (B.1.1.529.1)|Intramuscular (IM)
224204558|NCT05004181|OTHER|Observational|No vaccination within 3 months after Visit 1.
224204559|NCT03620201|DRUG|Bintrafusp Alfa|Given IV
224204560|NCT06653595|OTHER|Programme to Support Breastfeeding|The intervention consists of active support for breastfeeding by a lactation expert and IBCLC until the premature baby is 6 months old. The intervention includes: 1 face-to-face pre-discharge session, 8 home sessions up to 4 months and 3 telephone sessions up to 6 months.
224204561|NCT04210882|BEHAVIORAL|Moderate-Intensity Exercise|See description of study arm.
224313586|NCT01879748|DRUG|Rasagiline|"Each subject will be enrolled into 1 of 4 cohorts:~* cohort 1 (16 Japanese subjects): 4 subjects each for 0.5, 1, and 2 mg of rasagiline and placebo~* cohort 2 (16 Caucasian subjects): 4 subjects each for 0.5, 1, and 2 mg of rasagiline and placebo~* cohort 3 (16 Japanese subjects): 4 subjects each for 0.5, 1, and 2 mg of rasagiline and placebo~* cohort 4 (16 Caucasian subjects): 4 subjects each for 0.5, 1, and 2 mg of rasagiline and placebo~Each subject will then be randomly assigned to 1 of the following groups:~* rasagiline at 0.5 mg (8 Japanese and 8 Caucasian subjects)~* rasagiline at 1 mg (8 Japanese and 8 Caucasian subjects)~* rasagiline at 2 mg (8 Japanese and 8 Caucasian subjects)~* placebo (8 Japanese and 8 Caucasian subjects)"
224313587|NCT01879748|DRUG|Placebo|"Each subject will be enrolled into 1 of 4 cohorts:~* cohort 1 (16 Japanese subjects): 4 subjects each for 0.5, 1, and 2 mg of rasagiline and placebo~* cohort 2 (16 Caucasian subjects): 4 subjects each for 0.5, 1, and 2 mg of rasagiline and placebo~* cohort 3 (16 Japanese subjects): 4 subjects each for 0.5, 1, and 2 mg of rasagiline and placebo~* cohort 4 (16 Caucasian subjects): 4 subjects each for 0.5, 1, and 2 mg of rasagiline and placebo~Each subject will then be randomly assigned to 1 of the following groups:~* rasagiline at 0.5 mg (8 Japanese and 8 Caucasian subjects)~* rasagiline at 1 mg (8 Japanese and 8 Caucasian subjects)~* rasagiline at 2 mg (8 Japanese and 8 Caucasian subjects)~* placebo (8 Japanese and 8 Caucasian subjects)"
224313588|NCT04386486|OTHER|Bathe anamnesis method|BATHE anamnesis (BA) is applied to first group and preoperative examinations are completed.
224204562|NCT03935451|DRUG|Apixaban 2.5 milligram|2.5 milligram daily dosing of Apixaban beginning on the first day of hospital discharge for a total of 30 days
224204563|NCT03935451|DRUG|Placebo Oral Tablet|placebo oral tablet that resembles the experimental drug. To be taken with the same frequency and duration
224313589|NCT04386486|OTHER|standart anamnesis|standart anamnesis is applied to second group and preoperative examinations are completed.
224204564|NCT02329496|DEVICE|Lotus Valve and LOTUS Edge Valve System|Transcatheter aortic valve replacement (TAVR) with the Lotus Valve System with the Next Generation Delivery System and LOTUS Edge Valve System, with either the Lotus Introducer or iSleeve Introducer Sets
224313590|NCT05886387|OTHER|High PEEP + Recruitment maneuvers|The use of a High PEEP (positive end-expiratory pressure) level after recruiting collapsed alveoli can protect from mechanical ventilation associated lung injury
224204565|NCT00435240|BEHAVIORAL|Paleolithic diet|
224204566|NCT04278872|DRUG|SJX-653|administered orally once daily
224204567|NCT04278872|DRUG|Placebo|administered orally once daily
224204568|NCT05437718|OTHER|Ropivacaine|Thoracic paravertebral block(TPVB) is performed on the patients who undergo the thermal ablation therapy.
224204569|NCT04900415|DRUG|Vitamin A|Metabolic supplement for neurogenesis at the olfactory apparatus
224204570|NCT04900415|DEVICE|Electronic portable aromatic rehabilitation (EPAR) diffuser|Handheld essential oil ultrasonication diffuser technology
224204571|NCT03470896|PROCEDURE|preanesthesia teleconsultation|According to his allocated group, patient will have a teleconsultation at home/at work with an anaesthesiologist.
224313591|NCT05886387|OTHER|Standard PEEP. Low positive end-expriatory pressure|Mechanical ventilation is managed with a low standard PEEP without recruitment manneuvers
224313592|NCT04630158|OTHER|SAF312 Placebo|Topical ocular, suspension eye drops
224313593|NCT04630158|DRUG|SAF312|Topical ocular, suspension eye drops
224313594|NCT06112392|DIAGNOSTIC_TEST|Treatment （Stellate ganglion block；Oral standard anti-Parkinson's drugs）|Treatment （Stellate ganglion block；Oral standard anti-Parkinson's drugs）
224313595|NCT06112392|DIAGNOSTIC_TEST|Treatment （Oral standard anti-Parkinson's drugs）|Treatment （Oral standard anti-Parkinson's drugs）
224313596|NCT00120679|DRUG|darbepoetin alfa|
223511496|NCT02644811|DEVICE|Spider Screw K1 short neck|The Spider Screw K1 (Health Development Company, Sarcedo, Italy) is a self-drilling and self-tapping screw. Short neck screws (SCR-1508 and SCR-1510) with a diameter of 1.5 mm and length 8 or 10 mm are used.
223511497|NCT06460909|OTHER|Psychological support|An interview with the psychologist before surgery.
223617376|NCT05396300|BIOLOGICAL|CEA CAR-T cells|Administration method: intravenous infusion or intraperitoneal injection； Subjects will be treated with Fludarabine and Cyclophosphamide before cell infusion.
223617377|NCT02551341|PROCEDURE|higher PEEP ventilation|
223617378|NCT05349630|DRUG|Ferrous sulfate 325mg|Participants will take one tab of ferrous sulfate 325 mg (equivalent to 65 mg elemental iron) daily for 30 days.
224204572|NCT03470896|PROCEDURE|preanesthesia traditional consultation|According to his allocated group, patient will have a traditional consultation with an anaesthesiologist in the surgical center Emile Galle.
224204573|NCT06658275|OTHER|Constraint-induced movement therapy|During the first routine checkup, therapists will educate caregivers on how to perform the exercises and activities at home. Caregivers will place the childrens less-affected hands in slings and guide them through exercises designed to engage their weaker, paretic hands. The sling will be fastened around the childrens trunks, with the end securely closed.After the initial session, the intervention will be provided by the caregiver at home, with progress monitored by the therapist through Zoom meetings or WhatsApp video calls. Children will engage in play-based activities as part of the CIMT program to improve upper limb functions.These activities will include painting, pin the tail on the donkey for sensory awareness and proprioception, card games, bubble activities, squeezing sponges, building towers with blocks, playing a curtained box game, using tongs, and picking up coins. Exercises will be gradually progressed from easier to more challenging tasks as the child improves.
224313597|NCT00120679|DRUG|recombinant human erythropoietin (rHuEPO)|
223511498|NCT00093223|DRUG|Paclitaxel Nanoparticle Albumin Bound|Single or duel doses of 35mg/m\^2 ABI-007, administered IV, administered after placement of denovo stent(s).
223511499|NCT00093223|DRUG|Paclitaxel Nanoparticle Albumin Bound|
223511500|NCT00093223|DRUG|Paclitaxel Nanoparticle Albumin Bound|35mg/35 infusion time is 3.5 minutes
223511501|NCT03397758|DEVICE|Study population|First, periorbital area was treated with the short needles (exposure time 150ms, power 9W) to tighten the overlying dermis. Then, the fat pocket itself was treated additionally with the long needle (exposure time 400ms, power 9W).
224313598|NCT05269979|BEHAVIORAL|Prevention of hip fractures|Physical exercise and lifestyle advice on diet, smoking, walking and outdoor activities. Recommendations to use calcium and Vitamin D and do exercise at home by written instructions. Home visit by rehab team when needed. Group training with a physiotherapist. Gymnastics group and walking group. Walking aides and instructions of anti-slip protection. Home environment risk reduction was offered.
224313599|NCT04594317|DEVICE|low level laser therapy|buccal application of diode laser on non-contact mode
224313600|NCT00912925|BIOLOGICAL|rhIDU (recombinant human-Alpha-L-Iduronidase)|Patients in the active treatment group received Aldurazyme intravenously at a dose of 100 units/kg (approximately 0.58mg/kg) administered intravenously over approximately 4 hours once weekly for 26 weeks.
224313601|NCT00912925|BIOLOGICAL|Placebo|Patients in the Placebo-control group were administered a solution of 100mM sodium phosphate , 150mM sodium chloride, and 0.001% polysorbate-80, adjusted to a pH of 5.8 administered intravenously over a time period of approximately 4 hours once weekly for 26 weeks.
224313602|NCT03103139|PROCEDURE|Transpapillary Stent|ERCP with placement of short stent
224313603|NCT03103139|PROCEDURE|Stent across bile leak|ERCP with long stent
224313604|NCT03136965|BIOLOGICAL|PRP|Injection of autologous platelet rich plasma (PRP)
224313605|NCT03136965|PROCEDURE|Dry Needling|This is a therapeutic procedure that involves the same injection procedures under ultrasound guidance as in the PRP group but no PRP will be injected inside the patellar tendon.
224313606|NCT03136965|PROCEDURE|Dry Needling - Sham|This is a sham procedure that involves similar injection procedures under ultrasound guidance as in the PRP and DN groups with no injection of PRP or needle placement inside the patellar tendon.
223617379|NCT03226743|OTHER|collaborative and stepped care model|"Including elements:~* collaborative and stepped care of patients with mental disorders~* treatment in a multiprofessional network consisting of primary care physicians, psychologists, psychiatrists and inpatient facilities~* initial training of participating health care providers~* formalized and standardized screening procedure for early recognition of depressive, anxiety, somatoform and alcohol abuse disorders~* formalized ICD-diagnostics~* guideline-oriented treatment recommendations~* bibliotherapy or internet-based self-help for patient with mild to moderate disorders~* online referral platform~* case management for patients with severe disorders~* systematic and regular monitoring~* regular quality circles for participating health care providers"
223617380|NCT05441267|DRUG|Semaglutide Oral Tablet|Oral semaglutide 14mg daily (option to reduce to 7mg daily)
224204574|NCT06658275|OTHER|Hand Arm Bimanual Intensive Training -HABIT|For the Bimanual Intensive Training group, a strategy similar to HABIT will be used. At the first routine checkup, therapists will educate caregivers on the exercises, which will then be conducted at home. Caregivers will guide children through specially designed bimanual activities without slings, focusing on tasks like reaching, grasping, manipulation, releasing, and bearing weight on the upper limb. Progress will be monitored remotely through Zoom or WhatsApp video calls.Exercises will include catching and throwing a ball to improve reaching, grasp, and release; squeezing a textured ball for sensory awareness and sustained grip; stabilising and reorienting paper while drawing and cutting to enhance forearm supination and wrist extension. Additional tasks like sticker peeling for pincer grip and dough playing for hand manipulation will also be included.Exercises will progress from easy to more difficult as the child improves
224313607|NCT04152187|OTHER|Inspiratory muscle training|The treatment group will receive inspiratory muscle training.
224313608|NCT00390559|DRUG|nicotine transdermal system|21 mg nicotine transdermal system
223617381|NCT05441267|DRUG|Placebo oral tablet|Placebo oral semaglutide
223617382|NCT04947696|DIAGNOSTIC_TEST|Blood sampling|Blood sampling preoperatively and sequentially up to 30 days post op
223617383|NCT00597688|DRUG|Chlorhexidine gel|Oral mucosal application of chlorhexidine gel
223617384|NCT00597688|DRUG|Placebo gel|Oral mucosal application of placebo gel
223617385|NCT05274958|BEHAVIORAL|Patient-rated outcome measures and educational videos|PROMs are scales that are validated in behavioral health for tracking symptoms of depression, anxiety, and other conditions. They can be self-administered or given by a clinician. Mytonomy videos are short, educational videos about the patient's primary condition. All patients receive PROMs on entering our clinic. The difference in this intervention is those randomized to the active treatment will receive monthly PROMs and mytonomy video(s) until their appointment with the clinician. Usual care patients will only have PROMs at the intake and then at the appointment with their assigned clinician.
224204575|NCT04494334|PROCEDURE|Bronchoscopy for Probable Idiopathic Pulmonary Fibrosis and Sarcoidosis|Blood samples and Nasosorption sampling
224204576|NCT05082922|BEHAVIORAL|Hybrid treatment|Transdiagnostic emotion-focused treatment provided by a psychologist with, when needed, support of a medical doctor (ensuring adherence to medical guidelines) and a physiotherapist (providing assessment and treatment support in exposure for physical activities). Depending on the length of the waiting period (randomly assigned to be either 4, 5 or 6 weeks), the treatment period varies between 14-16 weeks and contains 10-15 sessions.
224313609|NCT00390559|DRUG|Nicotine transdermal system|Placebo nicotine patch
224313610|NCT00390559|OTHER|Nicotine containing cigarette|Nicotine containing cigarette
224313611|NCT00390559|OTHER|Placebo cigarette|Non nicotine containing cigarette
224313612|NCT01527812|PROCEDURE|Femoral nerve block|We will perform an ultrasound guided femoral nerve block. For locating the nerve a 5 cm, 6-13 MHz linear probe (Sonosite Turbo M, Bothwell WA, USA) will be used. After the examination of the anatomy of the femoral artery we will fix the probe transversal to the thigh below the inguinal crease and above the ramification of deep femoral artery and make skin marks on this position. A 22 G 50 mm long Stimuplex BBraun needle will be used. 15 ml 2 % lignocaine will be injected.
224313613|NCT04868968|DRUG|DFV890|100 mg of DFV890 film coated tablets twice daily (b.i.d.). for 3 days starting in the morning of Day 1 and 100 mg of DFV890 in the morning on the fourth day.
224313614|NCT00767624|DRUG|Antidepressant|Possible antidepressants are sertraline, escitalopram, desvenlafaxine, based on past history, response and tolerance
224313615|NCT00767624|BEHAVIORAL|Desensitization Therapy for Insomnia|
224313616|NCT00767624|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|
224313617|NCT01410643|OTHER|Macronutrient Modification|reduced carbohydrate versus standard carbohydrate diet
224313618|NCT01349777|DRUG|Pregrel®|Pregrel® 75mg daily for 12 months
224313619|NCT01349777|DRUG|Plavix®|Plavix® 75mg daily for 12 months
224313620|NCT02563392|PROCEDURE|uterine myomectomy with preventive uterine arteries occlusion|laparoscopic uterine myomectomy with preventive uterine arteries occlusion
224313621|NCT02563392|PROCEDURE|laparoscopic uterine myomectomy without preventive uterine arteries occlusion|laparoscopic uterine myomectomy
224313622|NCT01740050|DIETARY_SUPPLEMENT|Very Low Calorie Diet (VLCD)|One subject group will lose 10% of initial body weight using a VLCD. There are no risks for the subjects in consuming the VLCD (Modifast, together with the recommended fruit and vegetables) as the macronutrient composition and vitamins/minerals content meet the Dutch recommended daily allowance.
224313623|NCT01740050|PROCEDURE|RYGB|
224204577|NCT04198974|BEHAVIORAL|PreVenture Training (PTtT)|"PreVenture TtT model will involve identifying local expert trainers to be trained to train school-based professionals on the PreVenture program. Steps include:~1. PreVenture Facilitator certification: Trainers participate in training workshops and deliver the program to eligible youth in Cohort 1 and are rated on quality of implementation using the PIFA.~2. Reliable use of the PIFA: Each trainer demonstrates convergence with the Montreal Team's ratings on a set of previously-recorded PreVenture sessions.~3. PreVenture Training Workshop Certification: Trainers participate in a one-day TtT workshop to review the main aims and exercises of PreVenture Training. Trainers then record mock TtT sessions in which key components of the PreVenture Training Workshop are delivered to an audience of 4-10 individuals (e.g., class of graduate students). These sessions are rated by the Montreal Team the PreVenture Implementation Fidelity and Adherence-Trainer Scale (PIFA-T)."
224313624|NCT01740050|PROCEDURE|LAGB|
224313625|NCT00343356|DRUG|Trement|
224313626|NCT03460392|DRUG|Antibiotic therapy|To evaluate the effects of a specific event (i.e. surgical operation) or therapy (i.e antibiotic treatment) over time;
224313627|NCT00776750|BIOLOGICAL|trivalent split influenza vaccine|standard dose of 0.5 ml commercially available trivalent split influenza vaccine (Vaxigrip®, Aventis Pasteur MSD) by intramuscular injection
223617386|NCT06670755|BIOLOGICAL|ID93/GLA-SE|"ID93/GLA-SE is a protein-adjuvant vaccine which has been purposefully designed to elicit a diverse immune response against M.tb bacterial antigens, improve treatment outcomes and prevent TB disease in people already infected with M.tb.~ID93/GLA-SE will be administered intramuscularly."
224313628|NCT04523935|OTHER|Placebo|Fructose powder identical with the drugs was used
224313629|NCT04523935|DRUG|Baclofen, Diazepam, Clonazepam, Trihexyphenidyl, Tetrabenazine, Gabapentin, Topiramate, Lamotrigine, Amitriptyline.|Drugs were used either singly or in combination guided by clinical findings and investigations.
224313630|NCT03013855|DEVICE|FIT-SOC|Study subjects will be given a standard kit for fecal immunochemical test by their primary healthcare provider. As per standard practice, the patient will take the kit home and use the included FIT applicator to collect a stool sample from spontaneously passed stool during a regular bowel movement. The patient will then mail the stool sample to the lab in a pre-paid envelope, which is provided in the kit.
224313631|NCT03013855|DEVICE|FIT-DRE|Study subjects will have a digital rectal exam completed by their primary care providers during the physical exam portion of a routine clinic visit. The stool collected on the examiner's finger will be applied to the FIT applicator in the standard kit, which will then be sent to the lab for processing.
224313632|NCT05738044|OTHER|No intervention|No intervention
224313633|NCT03486366|OTHER|non interventional trial|other
224313634|NCT02508129|BEHAVIORAL|Brief Behavioral Treatment for Insomnia|BBTI employs behavioral strategies for treating insomnia, including stimulus control and sleep restriction. The BBTI interventionist contacts occur by telephone or web conferencing. It is administered in an initial session, followed by 3 brief weekly contacts, each guided by a printed workbook. During an initial 60 minute session, the sleep interventionist will review the participant's insomnia symptoms, discuss sleep regulation, and develop an individualized prescription of sleep wake times.
224313635|NCT02508129|BEHAVIORAL|Sleep Healthy Using the Internet|"SHUTi is a self-guided, automated, interactive, and tailored web-based program modeled on the primary tenets of Cognitive Behavioral Treatment for Insomnia (CBT-I): sleep restriction, stimulus control, cognitive restructuring, sleep hygiene, and relapse prevention. Intervention content is metered out over 6 Cores based on a time and event-based schedule. SHUTi uses online sleep diaries to track progress and to tailor treatment (e.g., assign a sleep restriction window). Each Core acts as an online analog for the weekly sessions of traditional CBT-I and follows the same structure."
224313636|NCT02508129|BEHAVIORAL|Enhanced Usual Care|Participants randomized to EUC will complete the standard panel of self-report assessments and home blood pressure monitoring at baseline. The study team will generate an individualized report based, which will be sent to the participant and physician. The report will also contain publically-available educational resources (websites, books) and contact information for treatment resources. Participants in EUC will be given a link to a website containing an educational video on insomnia and its treatment, produced by Emmi Solutions, Inc. Participants in EUC will complete outcome assessments on the same schedule as participants in the other conditions. Participants who complete the EUC intervention will be offered the CBT-I/ SHUTi intervention following study completion.
224313637|NCT02018575|DIETARY_SUPPLEMENT|Crystalline Lysine Amino Acid Mix|Crystalline Lysine from Amino Acid Mixture in amount of 29, 37, 46 and 54% of the mean Lysine requirement of 35 mg/kg/d will be given to subjects.
224313638|NCT02018575|DIETARY_SUPPLEMENT|White corn meal porridge|A cornmeal porridge including 29, 37, 46 and 54% of the mean Lysine requirement of 35 mg/kg/d will be given to subjects.
224313639|NCT06126341|OTHER|Lecture on the role of cellular therapies in relapse/refractory multiple myeloma/RRMM|Physician investigators will review a lecture on the role of cellular therapies in relapse/refractory multiple myeloma/RRMM that discusses current information in regards to available cellular therapies in RRMM and a proposed treatment algorithm.
224313640|NCT06126341|BEHAVIORAL|Hospital Anxiety and Depression Scale|Depression and anxiety will be assessed using the Hospital Anxiety and Depression Scale (HADS), a 14-item self-rated questionnaire
224313641|NCT06126341|BEHAVIORAL|Duke-UNC Functional Social Support Questionnaire|A 14-item, self-administered, multidimensional, functional social support questionnaire has been reduced to an 11 items to a brief and easy-to-complete two-scale, eight-item functional social support instrument.
224313642|NCT06126341|BEHAVIORAL|Distress Thermometer|The Distress Thermometer is a single-item visual analog scale used to screen cancer patients for the presence of psychological distress
224313643|NCT06126341|BEHAVIORAL|FACT-BMT|The FACT-BMT Version 4.0 is a 37 item self-report questionnaire that measures the effect of cancer on Quality of Life domains
224313644|NCT06126341|BEHAVIORAL|Psychosocial Assessments of Candidates for Transplantation|The PACT scale is a single page 10-item rating scale with high inter-rater reliability that has been used extensively in solid organ transplantation
223617387|NCT06670755|BIOLOGICAL|BCG Danish|"BCG Danish 1331 is on the WHO list of pre-qualified vaccines and has a well-defined side effect profile. BCG is licensed for delivery via the intradermal route. It is not licensed for delivery via the aerosol route.~For the challenge, aerosol BCG will be administered via nebulizer."
224204578|NCT04198974|BEHAVIORAL|PreVenture Training+Implementation Facilitation|"PreVenture TtT model + Implementation Facilitation Package:~1. Youth advisors identified the role of older youth to support program implementation. Youth will help promote PreVenture to students and families and help Facilitators optimize attendance at sessions.~2. Trainer-led coaching sessions will focus on enhancing program fidelity and acceptability by Facilitators. 'Best practice' supervision elements from efficacy trials will be integrated. Fidelity and symptom monitoring will be conducted in real-time during program implementation.~3. Performance metrics have been developed based on youth qualitative feedback to PreVenture sessions in previous trials. Analysis indicates key responses that are predictive of students most likely to benefit from PreVenture on 12-month substance use outcomes and indicates the extent to which Facilitator's interventions are leaving students with impressions consistent with positive long-term outcomes."
224204579|NCT00752895|DIETARY_SUPPLEMENT|American ginseng|Given orally
224204580|NCT00752895|DIETARY_SUPPLEMENT|Placebo|Given orally
224204581|NCT03821519|BIOLOGICAL|donor-derived CIK cells|Treatment plan will be based on three infusions of donor derived CIK cells given by 3 weeks intervals at increasing dose levels. No dose changes are allowed and the following planned dose levels will be administered to each patient enrolled: 5x106, 5x106 and 10x106 cells/Kg according to the dose escalating program
224204582|NCT06050031|DIETARY_SUPPLEMENT|Intake of antioxidant supplement|All participants will supplent oral antioxidants (individual or combined which can be obtained without prescription, and which are not regulated as a pharmaceutical drug) over three months.
224204583|NCT00096031|BIOLOGICAL|cetuximab|1 time Cetuximab 400mg/m2 IV over 120 minutes followed by weekly Cetuximab 250mg/m2 IV over 60 minutes.
224204584|NCT02869204|OTHER|Leucocyte - Platelet rich Plasma|Autologous L-PRP are studied regarding it's accelerating effect on tissue repair.
224204585|NCT02869204|DIETARY_SUPPLEMENT|Vitamin C|A daily dietary supplement of 500 mg Vitamin C. Provided from POD2-3 until POD30
224204586|NCT02869204|DIETARY_SUPPLEMENT|Zinc|A daily dietary supplement of 44 mg Zinc. Provided from POD2-3 until POD30
224204587|NCT02869204|DIETARY_SUPPLEMENT|L-Arginine|A daily dietary supplement of 5 g L-Arginine. Provided from POD2-3 until POD30
224204588|NCT05201898|OTHER|control:usual medical management|with regular doctor visits every 3 months
224204589|NCT05201898|BEHAVIORAL|intervention 1:usual medical management+individual dieting consultation|with regular doctor visits every 3 months and dietitian visits every 3 months
224204590|NCT05201898|BEHAVIORAL|intervention 2:usual medical management+individual dieting consultation+ daily tea drinking|with regular doctor visits every 3 months and dietitian visits every 3 months and daily tea drinking
224204591|NCT04080362|DEVICE|MitralStitch|With transesophageal echocardiographic guidance,implanting ePTFE sutures as artificial neochordae or ege-to-ege repair using MitralStitch System
224204592|NCT01592526|OTHER|Endotoxin|Bolus injection of LPS 2 ng/kg IV at time = 2 hours (Study day A).
224204593|NCT01592526|OTHER|Endotoxin + Nicotine|Transdermal application of nicotine patch applied at time = -8 hours (midnight the day before Study day B) + bolus injection of LPS 2 ng/kg at time = 2 hours (Study day 2)
223617388|NCT05414292|DRUG|Rapamune (sirolimus) 1Mg Tablet|Take Rapamune to see the effect on muscle structure and function during a 14 week unilateral resistance exercise training programme.
224204594|NCT04025866|OTHER|Conventional rehabilitation|1h/day for 5 days/week of conventional rehabilitation for femur fracture
223617389|NCT05414292|BEHAVIORAL|Unilateral resistance exercise training|Participants will complete unilateral leg extension resistance training 3 times per week for 14 weeks at 75% of their 1 repetition maximum
223617390|NCT04372251|PROCEDURE|Sinus tarsi approach (STA)|Osteosynthesis
223617391|NCT04372251|PROCEDURE|Percutaneous Arthroscopically Assisted Osteosynthesis (PACO)|Osteosynthesis
224204595|NCT04025866|OTHER|Aerobic exercise|30 min/day of aerobic exercise with arm cycle ergometer added to 1h/day for 5 days/week of conventional rehabilitation for femur fracture
224204596|NCT04249557|BEHAVIORAL|exercise is medicine|a 12-week exercise classes program combined with other motivational skills, including feedback and information technology support. The whole program lasts for 1 year for each participant
224204597|NCT00689494|OTHER|Nanopaz contraception device|levonorgestrel and levonorgestrel device for cervical contraception-nantechnolgy method
224204598|NCT05375110|DEVICE|NoYA™ Radiofrequency Interatrial Shunt System|NoYA™ Radiofrequency Interatrial Shunt System include Adjustable Interatrial Shunt System and Radiofrequency Ablation Generator.
224204599|NCT05406310|DEVICE|Ablation Index-guided ablation|Radiofrequency catheter ablation guided by Ablation Index software.
224204600|NCT05406310|DEVICE|High-power, short-duration ablation using QDOT Micro catheter|Radiofrequency catheter ablation guided by high-power, short-duration ablation using QDOT Micro catheter
224204601|NCT03515681|BEHAVIORAL|Text messages|Subjects randomized to intervention will receive text messages to promote seeking care and improving compliance with blood pressure treatment.
224204602|NCT05199649|DRUG|SintilimabCombined With Chemotherapy|Sintilimab and chemotherapy are carried out at the same time for every 3 weeks
224204603|NCT00608075|DRUG|lithium|600 mg - 1800 mg per day
224204604|NCT00608075|DRUG|Lithium|600 - 1800 mg
224204605|NCT03718559|DRUG|Edoxaban Monotherapy|Taking edoxaban (Lixiana™, Daiichi-Sankyo Inc.) 60mg once daily. The dose of edoxaban will be reduced to 30mg once daily in patients with estimated creatinine clearance 15≤CrCL≤50mL/min by Cockcroft-Gault equation or weight is ≤60kg.
224313645|NCT04384653|DRUG|Furosemide Injection Solution for subcutaneous administration (80 mg)|Furosemide Injection Solution for subcutaneous administration (80 mg)
224313646|NCT04384653|DRUG|Furosemide Injection, USP|Furosemide Injection, USP (10 mg/mL), 80 mg by intravenous administration
224313647|NCT04384653|DEVICE|Medfusion 3500 (v6) precision infusion pump|Furosemide Injection Solution for subcutaneous administration (80 mg)
224313648|NCT06977867|DEVICE|Stress Ball|All hemodialysis patients who meet the inclusion criteria will be asked to squeeze a stress ball during their dialysis sessions (3 times a week for 1 month, totaling 12 sessions). Anxiety, comfort, and patient satisfaction levels will be assessed using three measurements: a pre-test before the intervention, a mid-test at the end of the 6th session (2nd week), and a post-test after the 12th session. Patients will be instructed to use the stress ball throughout their dialysis session. They will be asked to squeeze the ball for at least 10-15 minutes during each session.
224313649|NCT06977867|OTHER|standard care|The hemodialysis patients in the control group will not use the stress ball and will receive standard care throughout the study period. Similar to the intervention group, levels of anxiety, comfort, and patient satisfaction will be assessed at three time points: prior to the intervention (pre-test), at the end of the second week (after the 6th session), and at the end of the fourth week (post-test, after the 12th session).
224313650|NCT06041217|DRUG|Semaglutide|Subcutaneous injections of semaglutide once-weekly at escalating doses every fourth week until maintenance dose of 2.4 mg of semaglutide is reached.
224313651|NCT06041217|DRUG|Placebo|Subcutaneous injections of placebo once-weekly at escalation doses manner as semaglutide every fourth week until maintenance dose of placebo matched to 2.4 mg is reached.
224313652|NCT06983691|BEHAVIORAL|Patient Navigation Program|The patient navigation program will integrate 1) education to enhance understanding of the treatment regimen, follow-up care, and the importance of adherence, 2) symptom management and adherence strategies, and 3) skills and resources to enhance women's symptom coping and self-management abilities.
224313653|NCT06982248|DRUG|NSP and chitosan nanoparticles gel loaded by quercetin|NSP and chitosan nanoparticles gel loaded by quercetin
224313654|NCT06982248|DRUG|NSP and chitosan nanoparticles gel|NSP and chitosan nanoparticles gel
224204606|NCT03718559|DRUG|Edoxaban plus Single Antiplatelet Agent|Type of antiplatelet agent is dependant upon the investigator's discretion, but aspirin 100mg once daily or clopidogrel 75mg once daily was recommended.
224204607|NCT03371095|DRUG|Infliximab|Use of infliximab instead of cyclophosphamide
224204608|NCT03371095|DRUG|Cyclophosphamide|Use of cyclophosphamide
224313655|NCT06982248|PROCEDURE|scaling and root planning|NSPT
224313656|NCT06983457|COMBINATION_PRODUCT|Therapeutic ultrasound|Participants in Group A will receive therapeutic ultrasound (TUS) as the primary intervention for managing chronic heel spur pain. The TUS treatment will be administered using a frequency of 1 MHz, which is effective for targeting deeper tissues. The intensity will range from 0.8 to 2.0 W/cm², depending on patient tolerance, and will be applied in a continuous mode to maximize thermal effects. Each treatment session will last for 4 minutes, and Treatment sessions will be conducted daily Monday through Friday for a period of 2 weeks in a series of ten treatments. The TUS application will focus on the medial calcaneal tubercle and the surrounding inflamed soft tissues to reduce pain and promote tissue healing.
224313657|NCT06983457|COMBINATION_PRODUCT|Shockwave Therapy|Group B (Shockwave therapy) Participants in Group B will receive extracorporeal shockwave therapy to perform the shock wave treatments, an apparatus generating a shock wave in a pneumatic manner was used, i.e., BTL-5000 SWT POWER + HIGH INTENSITY LASER 12 - to perform the shock wave treatments, an apparatus generating a shock wave in a pneumatic manner was used. Before starting the procedure, each patient was informed about the principles of the shock wave action and the possibility of side effects. Each of the project participants underwent a series of 5 treatments at 7-day intervals.
224313658|NCT03457935|OTHER|blood samples|Blood samples
224204609|NCT03353415|DEVICE|Dexcom CGM masked|"The CGM will monitor sensor glucose levels in all participants. (Initially the Dexcom G4 was worn by participants (n=13); however, when the G4 became unavailable, the G6 was worn by the subsequent participants (n=10)).~The duration of the Dexcom G4 sensor was 7 days (2 sensors placed during each phase of participation) versus the Dexcom G6 whose sensor duration is 10 days (1 sensor placed during each phase of participation)."
224204610|NCT03353415|DEVICE|Dexcom CGM unmasked|"During the second phase (2 weeks for the Dexcom G4 and 10 days for the Dexcom G6), participants are able to see the sensor glucose levels displayed from the CGM. Participants will be instructed to use this information to treat low glucose levels before symptoms or severely low glucose levels develop.~The duration of the Dexcom G4 sensor was 7 days (2 sensors placed during each phase of participation) versus the Dexcom G6 whose sensor duration is 10 days (1 sensor placed during each phase of participation)."
224204611|NCT04259307|DRUG|Omapone Peri 724mL or Winuf Peri 654mL|Additional intravenous nutrition of 500 kcal per day for 3 weeks
224204612|NCT04122339|DRUG|MAX-10181|"Part 1: Dose escalation, MAX-10181 once or twice daily with dose modifications based on tolerability criteria.~Part 2: Dose expansion, Recommended doses from Part 1."
224204613|NCT03531684|DIETARY_SUPPLEMENT|MMFS-205-SR|Twice daily, oral, 500 mg tablets
224204614|NCT03531684|DIETARY_SUPPLEMENT|Placebo|Twice daily, oral
224204615|NCT07047534|DEVICE|Real-time EEG-triggered Repetitive Transcranial Magnetic Stimulation (rTMS)|Stimulation target: left dorsolateral prefrontal cortex (DLPFC; F3 electrode position, 10-20 EEG system); Frequency: 10 Hz; Intensity: 110% of resting motor threshold (RMT); Pulse number: 2000 pulses/session (20 trains of 100 pulses, 30-second inter-train interval); EEG triggering: Stimulation pulses synchronized to the peak of the participant's ongoing θ-wave (4-7 Hz) activity. Duration: 20 sessions over 4 weeks.
224204616|NCT07047534|BEHAVIORAL|Group Therapy|Semi-closed group therapy; 10 participants/group, 2 sessions/week, 90 minutes/session for 4 weeks (total 8 sessions). Content included: Sessions 1-2: Emotional recognition and expression training; Sessions 3-4: Cognitive restructuring; Sessions 5-6: Impulse control training; Sessions 7-8: Self-esteem building and future planning.
224204617|NCT06724120|OTHER|No interventions|No interventions
224204618|NCT03560466|DRUG|Dupilumab (SAR231893/REGN668)|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous (sc)"
224204619|NCT03560466|DRUG|Asthma controller therapies (incl. prednisone/prednisolone)|"Pharmaceutical form: powder, or solution, or pill~Route of administration: inhaled, oral or parenteral"
224204620|NCT03560466|DRUG|Asthma reliever therapies|"Pharmaceutical form: powder or solution~Route of administration: inhaled"
224204621|NCT06937281|RADIATION|SABR|Prescription dose/fractionation: 26Gy/5 with 40Gy/5 +/- 35Gy/5 Boost Radiation Technique: VMAT Treatment Frequency: Every other day (EOD)
223511502|NCT02922660|DRUG|desflurane|method of anesthesia maintenance with desflurane ranged from 0.5\~1.5 MAC during the procedure
224204622|NCT06943690|PROCEDURE|Single-port robotic surgery|In this group, patients will be operated using a single-port surgical robot system. In the single-port configuration, a four-channel trocar shall be used. The surgical tools are steered through the curved access channels in the trocar to enter a patient's abdomen. The surgical procedure followed the principle of total mesorectal excision.
224204623|NCT06943690|PROCEDURE|Multi-port robotic surgery|In this group, patients will be operated using a multi-port surgical robot system. Surgical instruments enter the abdominal cavity through 4 separate trocars. The surgical procedure followed the principle of total mesorectal excision.
224204624|NCT06942312|DIAGNOSTIC_TEST|Ketoisocaproic acid breath test|13C-alpha-ketoisocaproic acid breath test to estimate hepatic mitochondrial reductive stress (1 mg/kg body weight; oral dose; study duration 390 min)
224313659|NCT04492826|PROCEDURE|Postoperative infections rate|Assess the postoperative infection rate after otolaryngology bone flap surgery.
224313660|NCT01478386|OTHER|Orthovisc|Subjects will receive a series of three Orthovisc injections into their affected knee
224313661|NCT01478386|DEVICE|DonJoy HA lite knee brace|Subjects will be fitted and educated on using the DonJoy HA lite knee brace to treat their affected knee
224313662|NCT01478386|DEVICE|Orthovisc injections and DonJoy HA lite knee brace|Subjects will receive a series of three Orthovisc injections and be fitted and educated on using a DonJoy HA lite knee brace
224313663|NCT04220424|DIAGNOSTIC_TEST|MR and Histopathology images based prediction of molecular pathology and patient survival|MR and Histopathology images based prediction of molecular pathology and patient survival in gliomas by leverage artificial intelligence algorithms
224313664|NCT03887312|BEHAVIORAL|t-CETA|Cognitive Behavioural Therapy (CBT) based approach delivered over the telephone. Components are available for common problems, including anxiety, depression, PTSD, conduct problems, substance abuse, and safety issues (including self-harm or suicidal ideation), and a tailored treatment package is produced for each child based on the presenting problem(s) and response to treatment. There are components for use with both child and caregiver.
224313665|NCT03887312|BEHAVIORAL|Médecins du Monde treatment as usual|Case manager-led care, with referral to a psychotherapist or psychiatrist as necessary. Médecins du Monde's approach is based on a joint collaboration between mental health trained case managers (who undergo extensive training by experts in the field on topics including Psychological First Aid, Child Protection, Gender Based Violence, etc.) and psychotherapists from different schools (providing Eye Movement Desensitization and Reprocessing \[EMDR\] for trauma, Interpersonal Therapy \[IPT\] for depression, Cognitive Behavioural Therapy \[CBT\], motivational counselling, familial or systemic therapy, and integrative approaches). Thus the number and content of sessions, and the person delivering treatment (case manager, psychotherapist, psychiatrist) vary.
224313666|NCT05183386|PROCEDURE|dental socket regeneration|after a dental extraction the fresh socket is filled with graft materials and compared with the spontaneous healing (control)
224313667|NCT05068154|DIAGNOSTIC_TEST|Myovista® WavECG™|The MyoVista wavECG Device uses wavelet signal processing to extract frequency information from the acquired 12-lead ECG signal which is then analysed using artificial intelligence to provide information relating to left ventricular relaxation abnormalities
224204625|NCT06942312|DIAGNOSTIC_TEST|Ammonium Chloride|15N-ammonium chloride stable isotope test to estimate ureagenesis (20 mg/kg body weight; oral dose; study duration 390 min)
224204626|NCT06942312|DIAGNOSTIC_TEST|Bicarbonate de sodium|13C-bicarbonate breath test to estimate body bicarbonate pool size and gastric emptying (0.5 mg/kg body weight; oral dose; study duration 390 min)
224204627|NCT06942312|DIAGNOSTIC_TEST|Deuterated Water|Deuterated water stable isotope test to estimate hepatic de novo lipogenesis and gluconeogenesis (3 g/kg body water; oral dose; duration: overnight)
224204628|NCT06942312|DIAGNOSTIC_TEST|Oral Glucose Tolerance Test|A standard 2-hour 75-gram oral glucose tolerance test to assess glucose tolerance and whole body metabolism
223511503|NCT02922660|PROCEDURE|total intravenous anesthesia|method of anesthesia in group TIVA is total intravenous anesthesia(TIVA) during the procedure
223511504|NCT02922660|PROCEDURE|inhalation anesthesia|method of anesthesia in group DES is inhalation anesthesia with desflurane during the procedure
223511505|NCT02922660|DRUG|Propofol|using propofol as sedative during the procedure of anesthesia and maintaining with propofol Cp 2-4 μg/ml in TCI
223511506|NCT02922660|DRUG|Remifentanil|using remifentanil as analgesics during the procedure of anesthesia and maintaining with remifentanil 2-4 ng/ml in TCI
223511507|NCT00483392|DRUG|metformin, rosiglitazone|
223511508|NCT00000446|DRUG|sertraline (Zoloft)|
223512471|NCT03757117|DRUG|Feminizing hormone therapy|"Estradiol valerate was initiated at 2 mg PO daily and increased to 4 mg after 4 to 12 weeks~Antiandrogen therapy with spironolactone started at a dose of 50 mg PO daily and increased every 4 weeks to 200 mg daily"
223512472|NCT03757117|BEHAVIORAL|Peer navigation|Transgender women community peer navigation
223512473|NCT00379379|DEVICE|electroacupuncture|
223512474|NCT02544087|DRUG|Ixeris of sonchifolia Hance|KDZ40ml+0.9%N.S.250ml,ivdrip,qd of each 14-day cycle.Number of cycles:one.
223512475|NCT02544087|DRUG|Panax notoginseng saponins|Xueshuantong450mg+0.9%N.S.250ml,ivdrip,qd of each 14-day cycle.Number of cycles:one.
223512476|NCT02544087|DRUG|Ixeris of sonchifolia Hance combined with Panax notoginseng saponins|KDZ40ml+0.9%N.S.250ml,ivdrip;Xueshuantong450mg+0.9%N.S.250ml,ivdrip,qd of each 14-day cycle.Number of cycles:one.
224313668|NCT00818987|OTHER|Open reduction internal fixation; reduction and immobilization|
224313669|NCT02760745|OTHER|Ancillary tests|Blood culture, complete blood count, crp, urinalysis for all patients. If clinically indicated: Urine culture, chest x ray, csf culture, stool culture, joint fluid culture
224313670|NCT03915509|DEVICE|Evaluation of the effect of surface properties on the stability of the different implants with resonance frequency analysis|Lasak Impladent Implants (sandblasted)
224313671|NCT05358080|DRUG|Entelon Tab. 50mg|twice daily for 24months
224313672|NCT05358080|DRUG|Placebo|twice daily for 24months
223512477|NCT05542901|DIAGNOSTIC_TEST|Joint Position Sense Analysis|The Xsens DOT Motion Capture System will be used to analyze joint position sense.
224313673|NCT06608550|OTHER|short video film|Children will be trained with a short movie to prepare for the endoscopy procedure. The content of the short movie video training will include; introduction of the outpatient clinic, things to be considered before the procedure, preparation for the procedure, introduction of the endoscopy room, introduction of the service to come after endoscopy, issues to be considered after the procedure. The short movie training is expected to last approximately 5 minutes.
224313674|NCT06983067|DEVICE|Cornerstone C1000 Robotic Surgery System|Minimally invasive surgical instruments are controlled by the physician using a master-slave operating system for urologic laparoscopic surgical operations.
224313675|NCT06982001|BEHAVIORAL|Brachial line guided hemodynamic management|Anesthesiologists in charge of the patients will guide their hemodynamic management based on the monitoring of brachial/humeral arterial line, instead of the most frequently used radial line.
224313676|NCT06982001|BEHAVIORAL|Radial line guided hemodynamic management|The anesthesiologist will guide their hemodynamic management on the classically used radial arterial line.
224313677|NCT06982001|DEVICE|Radial line catheterization|An arterial line will be inserted in the radial artery of the patient.
224313678|NCT06982001|DEVICE|Brachial line catheterization|An arterial line will be inserted in the brachial artery of the patient.
223617392|NCT05118139|OTHER|P1211216|Flavor variant P1211216 of a 1.5% nicotine ENDS product
224313679|NCT06982690|PROCEDURE|Spinal Anesthesia|A total of 10-12 mg of 0.5% bupivacaine will be administered into the cerebrospinal fluid of the subarachnoid space using a 25-gauge Quincke spinal needle via an 18-gauge introducer (adjusted by body height). Midazolam (2-5 mg) may be used to decrease anxiety.
224313680|NCT06982690|PROCEDURE|General Anesthesia|Induction will be performed with propofol (0.5-1.5 mg/kg) and fentanyl (1-2 µg/kg), and anesthesia will be maintained with sevoflurane (1-3 vol %) via a laryngeal mask or endotracheal intubation. Rocuronium (0.5-0.6 mg/kg) will be used for induction, maintenance and occurrence of obturator jerk.
224313681|NCT06595264|PROCEDURE|embolization therapy|Embolization in the neuroradiological department is the Golden Standard for the treatment of vein of Galen malformations.
224313682|NCT06587217|DRUG|Carbidopa 25 mg|Participants will take one 25mg Carbidopa tablet 3 times a day for 10 days.
224313683|NCT06587217|DRUG|Carbidopa-Levodopa 25/100 mg|Participants will take one 25/100mg carbidopa-levodopa tablet 3 times a day on days 4-6, then increase to 1.5 tablets 3 times a day on days 7-10.
223617393|NCT05118139|OTHER|P1213416|Flavor variant P1213416 of a 1.5% nicotine ENDS product
224313684|NCT06982170|DEVICE|A physical activity and reminiscence therapy|There were two parts in this study, one was co-design (participants co-designed the device) and the other was a pilot intervention. The two parts were iterative. In the interventional part, participants were asked to cycling the co-design rehabilitation bike and also did reminiscence or any cognitive therapy at the same time. The intervention session lasted at least 15 minutes, twice a week for 12 weeks.
224313685|NCT00860392|DRUG|Stable isotope tracer (13-C(4)-BHB)|A stable isotope tracer (13-C(4)-BHB), a commercially available lipid emulsion, and heparin will be administered intravenously. Ketone body concentrations will be measured before beginning the infusion, at approx. 135 minutes, and at approx. 255 minutes.
224313686|NCT06982209|DEVICE|Analgesia/Nociception Index (ANI)|ANI was monitored using the ANI monitor (MetroDoloris, France) in both groups, but only guided adjustments in the ANI group
223617394|NCT05118139|OTHER|P1213716|Flavor variant P1213716 of a 1.5% nicotine ENDS product
223617395|NCT05118139|OTHER|P1213616|Flavor variant P1213616 of a 1.5% nicotine ENDS product
223617396|NCT05118139|OTHER|P1213816|Flavor variant P1213816 of a 1.5% nicotine ENDS product
224204629|NCT06236373|OTHER|Focus Groups or Interviews|Focus groups and qualitative interview will be conducted with patients, caregivers and stake-holders trying to identify unmet needs of cancer survivors after the acute treatment phase. Individual interviews (in presence or online) will be hold as alternative if it will not be possible (due to logistical or personal problems) to participate in a focus group or if the number of people who would have agreed to participate in that focus group is less than 3
224204630|NCT05257109|OTHER|Water Concentration 1|E-liquid containing 36mg/ml pronated nicotine will be administered with no alteration to water concentration.
224204631|NCT05257109|OTHER|Water Concentration 2|E-liquid containing 36mg/ml pronated nicotine will be administered with 5% total water concentration of e-liquid.
224204632|NCT05257109|OTHER|Water Concentration 3|E-liquid containing 36mg/ml pronated nicotine will be administered with 10% total water concentration of e-liquid.
224204633|NCT05257109|OTHER|Water Concentration 4|E-liquid containing 36mg/ml pronated nicotine will be administered with 20% total water concentration of e-liquid.
224204634|NCT05171712|DEVICE|Transcatheter Aortic Valve Replacement|Transcatheter Aortic Valve Replacement for the treatment of patients with severe aortic stenosis
224204635|NCT00584831|DEVICE|senofilcon A|toric contact lens
224204636|NCT00584831|DEVICE|balafilcon A|toric contact lens
224204637|NCT00584831|DEVICE|omafilcon A|toric contact lens
224204638|NCT00584831|DEVICE|lotrafilcon B|toric contact lens
224204639|NCT03840031|OTHER|High Fe OFSP meal labelled with Fe-58|400 gram steamed, mashed OFSP high Fe with 0.33 mg FeSO4-58 daily for 10 days
224204640|NCT03840031|OTHER|Control OFSP meal labelled with Fe-57|400 gram steamed, mashed OFSP control with 0.33 mg FeSO5-57 daily for 10 days
224313687|NCT06981871|OTHER|Evaluation of the gingival phenotype of the incisors in the upper and lower jaws|Assessment of gingival thickness (Kan et al 2015) and keratinised tissue height of the incisors with UNC-15 peridontal probe (Hu-Freidy, USA) and clinical photography.
223617397|NCT05118139|OTHER|P1211916|Flavor variant P1211916 of a 1.5% nicotine ENDS product
223617398|NCT05118139|OTHER|P1210016|Flavor variant P1210016 of a 1.5% nicotine ENDS product
223617399|NCT05118139|OTHER|P1211217|Flavor variant P1211217 of a 2.4% nicotine ENDS product
223617400|NCT05118139|OTHER|P1213417|Flavor variant P1213417 of a 2.4% nicotine ENDS product
223617401|NCT05118139|OTHER|P1211222|Flavor variant P1211222 of a 5% nicotine ENDS product
224204641|NCT02468167|PROCEDURE|Balloon-occluded retrograde transvenous obliteration|Balloon-occluded retrograde transvenous obliteration
224313688|NCT06988722|DEVICE|650 nm Diode Laser PBM|A 650 nm red diode laser applied at three points (buccal, palatal, and crestal) around the implant site using 100 mW power for 60 seconds per point (total dose 18 J). Applied immediately post-op and repeated within 48 hours. Used for photobiomodulation to reduce pain and improve healing.
224204642|NCT02468167|PROCEDURE|Endoscopic cyanoacrylate injection|Endoscopic cyanoacrylate injection
224204643|NCT02468167|DRUG|N-butyl-2-cyanoacrylate|
224204644|NCT02468167|DRUG|Lauromacrogol|
224204645|NCT05477940|DEVICE|Absorbable zinc alloy drug eluting coronary stent system|"Absorbable zinc alloy drug eluting coronary stent system (hereinafter referred to as stent system) consists of delivery system and drug stent (hereinafter referred to as stent) pressed on the balloon end of the delivery system"
224204646|NCT03300804|DRUG|20-herb formulation|Two daily dosages will be investigated. The lowest dosage condition will be 17gm daily, followed by an escalation to 34gm. Participants will be treated for 8 weeks
224313689|NCT06988722|DEVICE|810 nm Diode Laser PBM|A 810 nm red diode laser applied at three points (buccal, palatal, and crestal) around the implant site using 100 mW power for 60 seconds per point (total dose 18 J). Applied immediately post-op and repeated within 48 hours. Used for photobiomodulation to reduce pain and improve healing.
224313690|NCT06988722|DEVICE|Sham Laser PBM|Identical laser handpiece applied at the same locations and durations as the active PBM groups, but without laser emission. Used to maintain blinding and simulate treatment without therapeutic effect.
224313691|NCT06989281|BEHAVIORAL|FLOW Lifestyle Medicine Clinic|The FLOW Lifestyle Medicine Clinic is a 12-month multidisciplinary program for improving obesity and obesity-related chronic conditions. FLOW is an evidence-based program that aligns with USPSTF recommendations for intensive behavioral counseling for obesity and cardiovascular disease risk reduction. There are at least 12 clinician/patient encounters in the FLOW clinic over 12 months including 6 with a registered dietitian and 6 with a FLOW physician. Behavioral Health assessments and visits are also offered as part of FLOW but are optional.
224313692|NCT06991023|DIETARY_SUPPLEMENT|Prebiotic (Bimuno®)|The prebiotic supplement (Bimuno®) is a galactooligosaccharide (GOS) supplement derived from lactose which is publicly available and sold in the UK. Subjects will consume a daily dose of 2.75g GOS (3.65g total powder) which will be administered in sachets and consumed with breakfast by mixing into water, tea or coffee, or sprinkling on top of/mixing into food.
224313693|NCT06991023|DIETARY_SUPPLEMENT|Placebo|A matched placebo for the prebiotic intervention, containing 3.65g of maltodextrin. Consumed in the same manner as the prebiotics.
224313694|NCT06989450|DEVICE|Sidekick digital patient support program for patients with breast cancer|A digital health program delivered through an app that provides holistic lifestyle intervention and medication adherence support.
224313695|NCT06989450|OTHER|Standard of care for breast cancer patients|Standard of care includes adjuvant breast cancer treatment and optional cancer rehabilitation
224204647|NCT03300804|DRUG|Placebo|Placebo herb formulation
224204648|NCT02359409|DEVICE|goggle balloon|Colonoscopy will be performed using the water immersion technique.
224204649|NCT02359409|OTHER|water immersion only|Colonoscopy will be performed using a goggle balloon at the tip of the scope with water immersion technique.
224204650|NCT00359073|DRUG|montelukast|10 mg everyday
224204651|NCT00359073|DRUG|placebo|like placebo
224204652|NCT04698252|RADIATION|Radiotherapy|Radiation therapy for oligometastatic sites
224204653|NCT04698252|PROCEDURE|Surgery|Surgery for oligometastatic sites
224204654|NCT04698252|OTHER|Radiofrequency ablation|Radiofrequency ablation for oligometastatic sites
224204655|NCT03907709|BEHAVIORAL|In-Home Addiction Treatment Program|"* Treatment was delivered per treatment protocol~* Primary IHAT Care Team consisted of a licensed Care Coordinator (LPN, RN, MSW, LPC, or LMFT) and two Recovery Advisors~* Urine drug screens administered randomly~* Appointments were scheduled per protocol for 52 weeks~* Within first two weeks of care, all clients are provided an evaluation by a psychiatrist to ensure fitness for program"
224204656|NCT04212624|OTHER|Human retinal pigment epithelial (HuRPE) cell injection|Human retinal pigment epithelial cell injection Dosage form and specifications: injection; 600,000 cells / branch (200μl), 1 million cells / branch (200μl), 2 million cells / branch (200μl) Transportation and storage: sealed, stored at 2-8 ° C, valid for 6 hours
224204657|NCT03387423|DRUG|Tofacitinib|Patients who are started on Tofacitinib treatment according to the drug label
224204658|NCT01371006|DRUG|low dose|efavirenz single dosing once daily
224204659|NCT01371006|DRUG|normal dose|efavirenz once daily
224204660|NCT01371006|DRUG|low dose|Efavirenz single dosing once daily
224204661|NCT03356366|OTHER|MRI 3T|Magnetic Resonance Imaging 3 Tesla
223512478|NCT04214444|BIOLOGICAL|Anti-pneumococcal vaccination with prime-boost strategy in patients with diffuse large B cell lymphoma|The investigators aim to describe efficiency and tolerability of prime-boost vaccination against pneumococcus in patients with Diffuse large B-cell Lymphoma. The investigators search to evaluate immunogenicity of prime-boost depending on the time of prevenar administration (before or after immunochemotherapy) and on the dose (single or double dose).
223512479|NCT01862965|DRUG|PredEver|Firstline treatment with prednisone and Everolimus
224204662|NCT03356366|OTHER|MRI 1,5T|Magnetic Resonance Imaging 1,5 Tesla
224204663|NCT03356366|OTHER|MRI 7T|Magnetic Resonance Imaging 7 Tesla
224204664|NCT03530007|DRUG|Normal saline|normal saline used for prevention of spinal shivering
224204665|NCT03530007|DRUG|Ondansetron 4 MG|ondansetron 4 MG used for prevention of spinal shivering
224204666|NCT03530007|DRUG|Ondansetron 8mg|ondansetron 8 MG used for prevention of spinal shivering
224204667|NCT02973178|DEVICE|Scanadu Urine Device|Device to allow lay user to perform urinalysis test at home.
224313696|NCT06989138|OTHER|Stabilitation Exercise|Patients will be included with the guidance of a physician specialized in the relevant field. After randomization, the patients included in the groups will be given 1 session of training before the start of treatment. In this training, soft orthosis use and home exercise programs will be explained to the patients in the intervention group. Soft orthoses; It will be explained that they should use for 10-12hours during the day for 4-6weeks, take them off during rest, sleep and exercise, and use them during active hours. Home exercise program; as in the classical approach, stretching and strengthening exercises will first be explained to the patient practically by the physiotherapist and then the patient will be asked to practice. Participants will be accompanied by a physiotherapist in the clinical environment 2 days a week for 10 weeks according to the groups they are divided into. Patients will be asked to practice the home exercise program taught in the training session 6 days a week.
224204668|NCT01935557|DRUG|Continuous heparin infusion|continuous group is given an initial intravenous heparin 100u/kg and then maintain heparin infusion during procedural.
224204669|NCT01935557|DRUG|Intermittent heparin infusion|Intermittent group is given an initial intravenous heparin 100u/kg. Then The ACT is tested every 30min with administration of additional heparin boluses and titration of the heparin drip based on the results and according to the judgment of the operating physician.
224204670|NCT00101140|DRUG|anti-thymocyte globulin|
224204671|NCT00101140|DRUG|fludarabine phosphate|
224204672|NCT00101140|DRUG|thiotepa|
224204673|NCT00101140|PROCEDURE|biological therapy|
224204674|NCT00101140|PROCEDURE|bone marrow ablation with stem cell support|
224204675|NCT00101140|PROCEDURE|chemotherapy|
224313697|NCT06989138|OTHER|Conventional Exercise|Patients will be included with the guidance of a physician specialized in the relevant field. After randomization, the patients included in the groups will be given 1 session of training before the start of treatment. In this training, soft orthosis use and home exercise programs will be explained to the patients in the intervention group. Soft orthoses; It will be explained that they should use for 10-12hours during the day for 4-6weeks, take them off during rest, sleep and exercise, and use them during active hours. Home exercise program; as in the classical approach, stretching and strengthening exercises will first be explained to the patient practically by the physiotherapist and then the patient will be asked to practice. Participants will be accompanied by a physiotherapist in the clinical environment 2 days a week for 10 weeks according to the groups they are divided into. Patients will be asked to practice the home exercise program taught in the training session 6 days a week.
224313698|NCT06989138|OTHER|Orthosis|Patients will be included with the guidance of a physician specialized in the relevant field. After randomization, the patients included in the groups will be given 1 session of training before the start of treatment. In this training, soft orthosis use and home exercise programs will be explained to the patients in the intervention group. Soft orthoses; It will be explained that they should use for 10-12hours during the day for 4-6weeks, take them off during rest, sleep and exercise, and use them during active hours.
223617402|NCT05118139|OTHER|P1213422|Flavor variant P1213422 of a 5% nicotine ENDS product
223617403|NCT05118139|OTHER|P1213722|Flavor variant P1213722 of a 5% nicotine ENDS product
223617404|NCT05118139|OTHER|P1213622|Flavor variant P1213622 of a 5% nicotine ENDS product
223617405|NCT05118139|OTHER|P1213822|Flavor variant P1213822 of a 5% nicotine ENDS product
223617406|NCT05118139|OTHER|P1211922|Flavor variant P1211922 of a 5% nicotine ENDS product
223617407|NCT05118139|OTHER|P1210022|Flavor variant P1210022 of a 5% nicotine ENDS product
224204676|NCT00101140|PROCEDURE|non-specific immune-modulator therapy|
224204677|NCT00101140|PROCEDURE|peripheral blood stem cell transplantation|
224204678|NCT00101140|PROCEDURE|radiation therapy|
224204679|NCT00880867|DRUG|Poly-ICLC|An accessible site of disease (lymph node, cutaneous, subcutaneous, etc.) will be selected by the principal investigator. Patients will then receive two doses of low dose irradiation (2 Gy per day) to that single site on days 1 and 2. Intratumorally or peritumorally Poly-ICLC will be dosed on days 3 and 4 by the physician during weeks 1, 2, 3, 4, and 8.
224204680|NCT03642886|BEHAVIORAL|Prescribed Detraining|Detraining is the deliberate act of reducing volume of exercise to observe subsequent changes in cardiac indices over time or the partial or complete loss of training of induced anatomical, physiological and performance adaptions. Detraining is primarily employed as a diagnostic tool to help differentiate Athletes' heart from cardiac pathology.
224204681|NCT05784363|DRUG|NT 201|Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9 percent (%) Sodium Chloride (NaCl).
224204682|NCT05784363|DRUG|Placebo|Solution for injection prepared by reconstitution of powder with 0.9% NaCl.
224204683|NCT01317069|DRUG|Fluorouracil implant|Before the abdomen was closed, fluorouracil implant 1000mg was sprayed evenly on the surface of tumor resection area, and some of the drugs were put into mesenteric root based on the location
224204684|NCT00946556|DRUG|Valacyclovir|1g po od for 2 months
224204685|NCT00946556|DRUG|Placebo|Placebo po od for 2 months
224204686|NCT01583400|OTHER|RESPECT-D|The RESPECT-D (Re-engineering Systems of Primary Care Treatment of Depression) intervention is a systematic approach to the assessment and management of depression within Primary Care. The essential components of the Collaborative Care model include prepared PCPs and practices, the Care Manager, and a Behavioral Health specialist all working in partnership with the patient. The trained depression care manager closely coordinates with primary care clinicians, supports treatment recommendations, patient education, appropriate follow-up to ensure adequate treatment, and coordination with a consulting psychiatrist.
224204687|NCT01583400|OTHER|RESPECT-D-E (Enhanced)|The RESPECT-D-E intervention includes all of the components of the RESPECT-D model, but also incorporates the enhanced digital health coaching program for depressive symptoms tool, is an on-line program with education, coaching, self-management techniques, symptom, side effect and medication adherence tracking for depression. Depressive symptoms, medication side effects and adherence data are automatically delivered to the Care Manager for use in treatment planning. The program provides tailored feedback, provides coaching on skills related to depression treatment (such as changing negative thoughts and avoiding relapse), and offers tools for tracking behavior change.
223617408|NCT04588116|BEHAVIORAL|Strategies Empowering activities in Everyday life (SEE 1.0)|"The patients are provided a person-centered activity-based intervention on the web aiming at facilitating the level of engagement in a variety of activities, at different places in society, together with other people to support an active life. In the long-term, the change to an active life will be reflected in a healthy and balanced pattern of activities.~The program provide the patients with tools to see their activities in everyday life in a new light and, also, tools to identify activity-based strategies that can empower them to take an active role to prevent and overcome challenging situations in everyday life."
223617409|NCT03189537|DRUG|Ingavirin (Imidazolyl Ethanamide Pentandioic Acid)|Broad-spectrum antiviral agent
223617410|NCT03189537|DRUG|Placebo oral capsule|Placebo capsule to match Ingavirin capsule
223617411|NCT04757116|DEVICE|iTind|The iTind is implemented for 5-7 days
223617412|NCT04757116|PROCEDURE|UroLift|UroLift is a minimally invasive procedure where permanent implants are placed in the prostate.
224204688|NCT04444362|DRUG|Intestinal Microbiota Transplant (IMT) Capsules|Intestinal Microbiota Transplant (IMT) Capsules tid immediately after cardiovascular surgery for at least 7 days
224204689|NCT06063291|DRUG|ID110521156|subjects will receive a single oral dose of IMP. In the morning (all procedures must be performed at the similar clock time) on Day 1
224204690|NCT06063291|DRUG|Placebo of ID110521156|subjects will receive a single oral dose of IMP. In the morning (all procedures must be performed at the similar clock time) on Day 1
224204691|NCT02682173|OTHER|MR Abdomen|
224204692|NCT05088382|DEVICE|LH Urine Test|Test for the qualitative measurement of LH in urine
224204693|NCT00897039|OTHER|flow cytometry|
223617413|NCT05289986|DRUG|DELSTRIGO 100Mg-300Mg-300Mg Tablet|"Delstrigo (300 mg of tenofovir disoproxil fumarate equivalent to 245 mg of tenofovir disoproxil, 300 mg of lamivudine and 100 mg of doravirine~\- TDF/3TC/DOR)"
223617414|NCT06727422|DRUG|rifaximin 66mg + N-acetylcysteine 560mg three times daily|RNIB21 containing rifaximin 66mg + N-acetylcysteine 560mg three times daily
223617415|NCT06727422|DRUG|RNIB21 containing rifaximin 132mg + N-acetylcysteine 560mg three times daily|RNIB21 containing rifaximin 132mg + N-acetylcysteine 560mg three times daily
223617416|NCT06727422|DRUG|Placebo|placebo three times daily
224204694|NCT00897039|OTHER|immunohistochemistry staining method|
224204695|NCT05681104|DIAGNOSTIC_TEST|Waist-height ratio|Waist-height ratio as early predictors of metabolic syndrome in primary school obese children
224204696|NCT05681104|DIAGNOSTIC_TEST|body mass index|Body mass index as early predictors of metabolic syndrome in primary school obese children
224204697|NCT05681104|DIAGNOSTIC_TEST|Bio-electrical impedance analysis|Bio-electrical impedance analysis as early predictors of metabolic syndrome in primary school obese children
224204698|NCT03586986|DIAGNOSTIC_TEST|Brain MRI|Perform brain MRI; draw blood; fill out bioscreen questionnaire; perform SDMT
224204699|NCT04571164|DRUG|LY03003(Rotigotine,extended-release microspheres)|During the intervention, the initial dose was 14mg, and then was incremented in weekly units, 14mg each time, until the maximum dose of 56mg set in this study was reached 4 weeks after titration, the optimal therapeutic dose or the maximum tolerated dose was entered into the dosing maintenance period. After entering the maintenance period, no dose adjustment was performed, and the stable dose was maintained for 24 weeks
224204700|NCT04571164|DRUG|Placebo,extended-release microspheres|During the intervention,the initial does was 14mg,and then was incremented in weekly units,14mg each time,until the maximum does of 56mg set in this study was reached 4 weeks after titration,the optimal therapeutic does or the maximum tolerated does was entered into the dosing maintenance period.After entering the maintenance period,no does adjustment was performed,and the stable does was maintained for 24 weeks.
224204701|NCT05005000|BIOLOGICAL|Micro-Fragmented Adipose Tissue (MFAT)|1ml of autologous micro-fragmented adipose tissue will be used.
224204702|NCT05005000|DRUG|Triamcinolone Acetonide 10mg/mL|The control group will receive a 1ml intraarticular injection of triamcinolone acetonide 10mg/ml.
224204703|NCT03121560|DEVICE|Hysteroscopy|Hysteroscopy allows a direct visualization of the interior of the uterine cavity in order to invalidate or confirm the presence of uterine pathologies.In the pre-menopausal period, it is preferable to perform a hysteroscopy at the beginning of the follicular phase (just after the menstruations, when the endometrium is atrophic). Use of a rigid hysteroscope comprising a 2.9 mm optics and a 4.3 mm sheath with a 5 - bit operator channel allowing the realization of a biopsy.
224204704|NCT03121560|DEVICE|Hysterosonography|Hysterosonography (SIS) is an endovaginal ultrasound performed along with an injection of saline in order to observe the uterine cavity and detect any endometrial pathology. A 3D image can be associated with it to define the topography of a lesion. It is ideally performed in the first part of the cycle. Use of the GE Voluson E8 Ultrasound System.
224204705|NCT03955718|BEHAVIORAL|Motherly App|The Motherly app is a behavioral intervention aimed at preventing maternal depression and promoting child development.
224204706|NCT03955718|BEHAVIORAL|Educational App (Active Control)|An app with educational content about gestation, maternal health and mental health, child development, etc.
224313699|NCT06989502|BEHAVIORAL|Co-creation (2016 to 2019) + Co-design (2023 to 2024)|"It includes interventions implemented in a sequential way: a) The co-creation intervention (between 2016 and 2019), and b) the co-design intervention (between 2023 and 2024).~In this group of sequential interventions, relevant stakeholders have already been engaged in the project and they would be familiar with the intervention components. Their participation this time will enable updating and refining the previous co-creation intervention through the co-design process.~The intervention will encompass activities with the health service users and healthcare workers, in Peru, Nepal, and Mozambique"
224313700|NCT06989502|BEHAVIORAL|Co-design only (2023 to 2024)|"The same intervention activities of the first group (between 2023 and 2024), but without having them involved in the previous co-creation process. In consequence, relevant stakeholders in the corresponding sites are not expected to be as engaged in the project (in contrast to the intervention that includes co-creation), and they would not be very familiar with the intervention components of COHESION-I.~As in the first group, the intervention will encompass activities with the health service users and healthcare workers, in Peru, Nepal, and Mozambique"
224313701|NCT06989684|PROCEDURE|Osseodensification|Osseodensification uses specially designed burs to densify osteotomy site
224313702|NCT06989684|PROCEDURE|Underdrilling|In underdrilling the osteotomy is smaller than implant diameter to be placed
223617417|NCT06725342|GENETIC|Combined DNA/RNA sequencing on clinical FFPE material (technically challenging; innovative); immuno-genomics test.|"Dual extractions (DNA/RNA) will be carried out from macrodissected thick unstained FFPE sections; samples will be measured for adequate quality / quantity; libraries will be constructed separately with each panel and samples will be sequenced in the same chip in an Ion Torrent Proton System, according to the manufacturer's instructions.~Sequencing results will be called with the Variant Caller for each panel and submitted for initial analysis and annotation to the Ion Reporter pipeline with each DNA and RNA panel"
223617418|NCT06921447|OTHER|Clinical Cases|Seven clinical cases that have to be analysed
223617419|NCT06726525|DEVICE|HPMC+GlicoPro eyedrops|HPMC+GlicoPro eyedrops, artificial tears for dry eye disease
223617420|NCT06726525|DEVICE|Hydroxypropyl-methylcellulose|Hydroxypropyl-methylcellulose eyedrops, artificial tears for dry eye disease
223617421|NCT05935592|BEHAVIORAL|Web-based comic and newsletters|Web-based comic and health messages (child component) and health newsletters (parent component)
223617422|NCT05935592|BEHAVIORAL|Didactic health information|Web-based newsletters (for child and parent) by email and/or text
223617423|NCT06756490|DRUG|HY-2003 (10 mg/ml), BELKYRA and placebo|Participants received HY-2003 (10 mg/ml), or BELKYRA, or placebo administered up to 10 mL per treatment session at intervals of approximately 4 weeks for up to a maximum of 6 treatments.
223617424|NCT06756490|DRUG|HY-2003 (5 mg/ml) and placebo|Participants received HY-2003 (5 mg/ml) or placebo administered up to 10 mL per treatment session at intervals of approximately 2 weeks for up to a maximum of 6 treatments.
224204707|NCT02428959|DRUG|Amyl Nitrite|Amyl nitrite is the chemical compound with the formula C5H11ONO. It relaxes vascular smooth muscle; decreases venous ratios and arterial blood pressure; reduces left ventricular work; decreases myocardial oxygen consumption. The method of administration is via inhalation with onset of action within of 30 seconds and ends 2-3mins. In a study by Dodds et al., amyl nitrite is used as part of radiologic esophagram test in order to distinguish patients with pseudoachalasia from those with idiopathic achalasia since amyl nitrite has transient effect on the lower esophageal sphincter (LES). The study revealed that the LES pressure in achalasia patient decreases substantially in response to amyl nitrite with the measurable increase in LES diameter of 3 mm to an average of 4.6m. In contrast, amyl nitrite does not relax the LES segment in pseudoachalasia and has no change in LES diameter. Thus, the investigators anticipate amyl nitrite inhalation will be beneficial at the LES during HREM.
224204708|NCT01929837|DEVICE|E-fied navigated rTMS|1 hz on the superior temporal gyrus contralateral/left side with E-field navigated rTMS (Nexstim) targeted at the tonotopic representation area of the main frequency content of tinnitus
224204709|NCT01929837|DEVICE|non-navigated rTMS|1 hz on the superior temporal gyrus contralateral/left side with non-navigated rTMS according to external landmarks (between T3/T4 and P3/P4 EEG-electrode locations)
224204710|NCT01929837|DEVICE|sham E-field navigated rTMS|
224204711|NCT01929837|DEVICE|Navigated rTMS|1 hz on the left superior temporal gyrus with (MRI) navigated rTMS (Visor)
224204712|NCT00034359|DRUG|ACH-126,443|
224204713|NCT00034359|DRUG|Lamivudine|
224204714|NCT00034359|DRUG|Placebo|
224204715|NCT03509688|DRUG|entecavir+resveratrol|entecavir+resveratrol
224204716|NCT03509688|DRUG|Entecavir|Entecavir
224204717|NCT03509688|DRUG|entecavir+thymosin α1|entecavir+thymosin α1
224204718|NCT00547209|DRUG|air|60% air combined with 40% oxygen for ventilation
224204719|NCT00547209|DRUG|Nitrous oxide|60% nitrous oxide combined with 40% oxygen for ventilation
224204720|NCT00583128|DRUG|AST-120|oral, sachet, 2 grams three times daily for 8 weeks
224204721|NCT00583128|DRUG|Celphere® CP-305|oral, placebo, sachet, 2 grams three times daily for 8 weeks
224204722|NCT05231161|DIAGNOSTIC_TEST|Index of Microvascular Resistance|The invasive diagnostic procedure will be performed in at least one coronary artery. The left anterior descending coronary artery will be the preferred target vessel; however, if technical factors precluded guidewire-based assessment of this artery (e.g., tortuous anatomy), then the left circumflex or right coronary artery can be selected. In the case of multiple measurements per patient, the lowest FFR or highest IMR will be used for analysis. A coronary wire with a pressure and temperature sensor (PressureWire X, Abbott Vascular, Santa Clara, CA, USA) will be advanced to the mid to distal segment of the coronary artery. Bolus thermodilution technique with three 3-cc saline injections in rest and hyperemia will be used.
224204723|NCT03291847|DEVICE|fetal monitoring|Maternal fetal monitoring
224204724|NCT03291847|DRUG|Buprenorphine Naloxone|Treatment for opioid use disorder
224204725|NCT06583148|OTHER|Best Practice|Receive usual care
224204726|NCT06583148|BEHAVIORAL|Smoking Cessation Intervention|Receive the smoke-free home program
224204727|NCT06583148|OTHER|Survey Administration|Ancillary studies
224204728|NCT01987843|DRUG|MT-1303-Low|
224204729|NCT01987843|DRUG|MT-1303-Middle|
224204730|NCT01987843|DRUG|MT-1303-High|
224204731|NCT01987843|DRUG|Placebo|
224204732|NCT02488473|DRUG|Dexmedetomidine|100 ug dexmedetomidine added to the ropivacaine nerveblock
224204733|NCT02488473|DRUG|Ropivacaine|20 ml Ropivacaine 5mg/ml
224204734|NCT02488473|DRUG|Isotonic Saline|Placebo
224204735|NCT00242450|DRUG|Metoclopramide|
224204736|NCT00739687|DRUG|ALT-711|200 mg tablet BID for 9 months.
224204737|NCT00739687|DRUG|Placebo|200 mg tablet BID for 9 months.
224204738|NCT03515837|BIOLOGICAL|pembrolizumab|IV infusion
224204739|NCT03515837|DRUG|pemetrexed|IV infusion
224204740|NCT03515837|DRUG|carboplatin|IV infusion
224204741|NCT03515837|DRUG|cisplatin|IV infusion
224204742|NCT03515837|DRUG|saline solution|IV infusion
224204743|NCT00665509|BIOLOGICAL|Trivalent influenza subunit vaccine Influvac|3x 15mcg HA per 0.5 ml, trivalent one injection at Day 1
224204744|NCT01964898|BEHAVIORAL|Behavioral Activation (BA)|5 to 9 Behavioral Activation (BA) counseling sessions focused on cessation and mood management. BA sessions will occur over the 12 weeks after hospital discharge.
224204745|NCT01964898|BEHAVIORAL|Standard Smoking Cessation Counseling|1 hour of in hospital counseling based on clinical guidelines
224204746|NCT01964898|DRUG|Nicotine patch|An 8 week supply of the nicotine patch will be provided if the patient is cleared by their MD.
224204747|NCT01964898|OTHER|Printed Self-help materials for Smoking Cessation|
224313703|NCT03799328|OTHER|multi-OIT|low dose OIT to multiple foods
224313704|NCT04129671|GENETIC|No intervention was applied|No intervention was administered
224313705|NCT02985190|DRUG|Azacitidine|Azacitidine at 75mg/m²/j for 7 days.
224313706|NCT00654290|DRUG|Amiodarone + Propranolol|Amiodarone and Propranolol 7 days pre-operation to 5 days post CABG
224313707|NCT00654290|DRUG|Amiodarone|Amiodarone treated 7 days pre-operation to 5 days post CABG
223761352|NCT04697979|OTHER|Questionnaire|"Selection of patients for a discharge interview in the stroke unit with collection of non-opposition and scheduling of telephone interviews or by teleconsultations at one week and then at two months after hospitalization.~Data collection through interviews using a telephone questionnaire (or by teleconsultation) one week and then at two months after discharge. Elements on knowledge of treatment, dietary measures and warning signs and recurrence of stroke will be collected and re-explained if necessary."
223511509|NCT04264195|OTHER|Constraint-induced movement therapy: PEPS-MIT|"All participants of control and experimental groups received standard stroke rehabilitation. After regular office time, a 2 hours' peer group session was provided, 5 days/week, 4 consecutive weeks, to both groups. One patient 'leads' the group exercises under a therapist's supervision. The therapist is mainly helping and correcting patients during the various exercise tasks.~• Specific for the experimental group was that patients performed all manipulation tasks with forced use of the paretic hand/arm by wearing a soft-padded mitten at the non-paretic hand, preventing manipulation with that hand. Patients were encouraged to wear the mitten also for 3 hours/day at home, while performing ADL and learned exercises. Behavioural strategies included a treatment contract and daily use of the home activity checklist which was checked by patient's caregiver and signed by both patient and caregiver. Each treatment day the activity checklist was submitted to the therapist who gives feedback."
223761353|NCT01221961|DEVICE|Masimo Radical-7|The Masimo device will be placed on one finger of the patient. To see whether or not the hemoglobin values recorded at the same time matches between the standard clinical practice (CSMC Lab and outside Lab) and the Masimo device
224204748|NCT00276965|DRUG|Sertraline|Sertraline or placebo for sertraline starting at 25 mg per day, up to maximum of 200 mg per day
224204749|NCT00276965|DRUG|Lithium carbonate|Lithium or placebo for lithium starting at 150 mg per day; target dose of 900mg per day. Maximum dose based on clinical response and serum levels (maximum serum level of 1.2 mEq/L).
224204750|NCT00429091|DRUG|ABT-894|Subjects will take 1 mg QD, 2 mg QD, 4 mg QD, 4 mg BID for up to four weeks.
224204751|NCT00429091|DRUG|atomoxetine|Subjects will take 40 mg BID or placebo for up to four weeks.
224204752|NCT00429091|DRUG|placebo|Subjects will take BID for up to four weeks
224204753|NCT04309760|OTHER|MRI|Subjects will receive structural and functional (resting state) MRI
224204754|NCT04881331|OTHER|Analysis of electrosurgical smoke.|Patients undergo standard of care surgical removal of the malignant breast tumor. Electrosurgical knife is used to cut tissues according to standard practice. Fraction of the surgical smoke is captured for analysis and video record of the point of view of the surgeon is captured with a head-mounted camera.
224204755|NCT02629380|BIOLOGICAL|hyaluronic acid|A single injection of 3 ml hyaluronic acid to be performed under arthroscopic view at the end of meniscectomy
224204756|NCT02629380|PROCEDURE|meniscectomy alone|The patients randomized in this group will receive arthroscopic meniscectomy alone
224204757|NCT02056431|BEHAVIORAL|IVR Intervention Group|Participants will receive 3 interactive voice response (IVR) calls (2nd, 4th, and 6th month post-treatment start date) to collect information on medication use, side effects, rating of side effects, and pain symptoms to be fed back to their physicians.
224204758|NCT02325401|DRUG|Metformin|Escalating doses of 2000mg, 2550 mg and 3000mg. Starting 1 week prior to the initiation of chemoradiation and ending the final day of chemo or radiation.
224204759|NCT02325401|DRUG|Cisplatin|Dosed at 100mg/m2 on days 1, 22, and 43
224204760|NCT02325401|RADIATION|Radiation Therapy|70 Gy in 2 Gy once daily fractions of 35 fractions
224204761|NCT06675695|DRUG|New use of osimertinib|New use of osimertinib described in electronic health records is used as the exposure.
224204762|NCT06675695|DRUG|New use of erlotinib or gefitinib|"New use of standard of care described in electronic health records (erlotinib or gefitinib) dispensing claim is used as the reference."
224204763|NCT01072318|DRUG|Letrozole|Letrozole 2.5mg
224204764|NCT05831787|OTHER|Patient Reported Outcomes|Patients will be asked to complete baseline, 30-day, and 6-month clinical and patient reported outcome health surveys.
224204765|NCT03257137|OTHER|Diet Quality|Diets matched for calorie intake and macronutrient distribution but differing by overall diet quality will be provided in a random order, cross-over design study.
224204766|NCT00310700|BIOLOGICAL|Meningococcal C conjugate vaccine|
224204767|NCT02855788|DRUG|Paclitaxel 60mg/m2, Oxaliplatin 50mg/m2, Leucovorin 20mg/m2, and 5-FU 425mg/m2 IV weekly|metronomic chemotherapy
224204768|NCT05789511|DEVICE|High Resolution Electrogastography|a new generation 64- channel high-resolution electrogastrography recording technology by Alimetry Limited that is able to record and analyze body surface gastric mapping/ HR-EGG
224313708|NCT00654290|DRUG|Propranolol|Propranolol from 7 days pre-operation to 5 days post CABG
224313709|NCT03429400|DRUG|Morphine Sulfate|Morphine every 4 hours as needed for up to a maximum of 5 days
224313710|NCT00771459|DRUG|Ropivacaine 0.5 %|Local infiltration analgesia
224313711|NCT00771459|DRUG|Isotonic NaCl|Local infiltration analgesia
224313712|NCT03535389|DIAGNOSTIC_TEST|Knee 4DCT|Dynamic knee 4DCT
224313713|NCT03020589|DRUG|Tacrolimus|See description in arm/group sections
224313714|NCT02379572|DEVICE|iMRI-guided surgery|For iMRI-guided glioma resections the surgery can be paused and a direct intraoperative resection control is possible by performing an intraoperative MRI scan. If residual tumor is found, the resection might be continued.
224313715|NCT02379572|DRUG|5-ALA-guided surgery|For 5-ALA guided glioma resections patients have to drink 100ml of a solution with 5-Aminolevulinic acid 4-6 hours before surgery. Intraoperatively the light source of the surgical microscope can be switched to a certain wave length to enable fluorescence of the glioma cells, which helps resecting the tumor as radical as possible.
224313716|NCT06330272|PROCEDURE|Application of dental mousse based on CPP-ACPF|"Treatment will begin with pumice prophylaxis of incisors with IMH lesions. After this step, the teeth will be dried before applying dental foam based on CPP-ACPF (Tooth Mousse PlusTM, GC Corporation, Tokyo, Japan).~The application of Tooth Mousse PlusTM to the MIH lesion will be carried out under relative isolation and with the aid of a microbrush. The cream will remain on the surface for 1 minute, which will be timed. The application will be carried out once a week, for four consecutive weeks."
224313717|NCT06989385|OTHER|This is an observational study. Interventions are standard of care and include: High-flow nasal oxygen (HFNO) Non-invasive ventilation (NIV) Pnose monitoring|No experimental interventions are administered as part of the study.
224313718|NCT01064154|DRUG|Carvedilol|Carvedilol Tablets 25 mg
224313719|NCT02093130|DIETARY_SUPPLEMENT|Pomegranate Juice|
224313720|NCT02093130|DIETARY_SUPPLEMENT|Placebo|
224313721|NCT00401986|DEVICE|Bronchial thermoplasty with the Alair System|Treatment of airways with the Alair System in PREDECESSOR STUDY (NCT00214539).
224313722|NCT00946686|DRUG|Leflunomide 20 mg Tablets (Geneva Pharmaceutical)|
223617425|NCT06756490|DRUG|HY-2003 (5 mg/ml) and placebo|Participants received HY-2003 (10 mg/ml) or placebo administered up to 10 mL per treatment session at intervals of approximately 4 weeks for up to a maximum of 6 treatments. It is possible to explore the maximum number of administrations exceeding six treatment sessions.
223617426|NCT06752239|RADIATION|Modified delineation|Modified delineation (MD) of cervical lymphatic drainage areas, sparing the common carotid artery within the clinical target volume (CTV)
223617427|NCT06752239|RADIATION|Standard delineation|Standard delineation
223617428|NCT06906978|PROCEDURE|blood sampling|Patients will be seen in hospital as part of their routine care, during which a blood test will be prescribed. On this occasion, an additional 20 mlof blood will be collected for research purposes.
223617429|NCT05524220|DEVICE|Standard care with a facemask.|The anesthesia provider will supply oxygen via the closed facemask at 10 liters per minute (LPM)
224204769|NCT05831267|OTHER|Fibrin Glue|Blood samples were collected from the antecubital vein of the right or left arm of the patient and drawn into sterile Titanium tubes immediately. The tubes were then centrifuged for 12 minutes at 2800 rpm and room temperature
224204770|NCT05831267|OTHER|T-PRF|The contents of the two containers (human fibrinogen, human thrombin) will be mixed with distilled water and then aspirated by two syringes after that, the two solutions will be mixed together and injected into the empty compartment around the dental implant under the sinus mucosal lining using auto mixing applicator.
224313723|NCT00946686|DRUG|Arava 20 mg Tablets (Aventis Pharmaceutical, Inc.)|
224313724|NCT05419609|PROCEDURE|Limited facelift|A limited procedure under local anesthesia that addresses signs of aging in the lower face and neck
224313725|NCT05419609|PROCEDURE|Full facelift|A full face and neck lift that addresses signs of aging in the face and neck
224204771|NCT05831267|OTHER|Negative control|this group will not receive any material.
224204772|NCT06701695|PROCEDURE|Periarticular Injection (PAI)|Patients in the periarticular injection group were administered a 100 mL periarticular solution comprising 200 mg of bupivacaine (40 mL), 60 mg of ketorolac (2 mL), 8 mg of dexamethasone (2 mL), 2 mg of 1:1000 epinephrine (2 mL), and standard saline solution (54 mL). This solution was prepared in two 50 mL syringes. The first syringe containing 50 mL of the cocktail was injected into the capsule and gluteal muscles prior to femoral stem insertion. Following joint capsule closure, the second syringe containing 50 mL of the periarticular injection cocktail was infiltrated into the fascia lata muscle, subcutaneous tissue, and wound layers.
224313726|NCT05419609|OTHER|"FACE-Q | Aesthetics - Satisfaction With Lower Face and Jawline"|"Completed by patients. The FACE-Q \| Aesthetics - Satisfaction With Lower Face and Jawline is a 5-item questionnaire. Each item is rated 1-4, with 1 being Very Dissatisfied and 4 being Very Satisfied. Lower scores suggest the person may be less pleased with the appearance of their lower face and jawline."
224313727|NCT05419609|OTHER|"FACE-Q | Aesthetics - Recovery Early Symptoms"|"Completed by patients. The FACE-Q \| Aesthetics - Recovery Early Symptoms is a 17-item questionnaire. Each item is rated 1-4, with 1 being Not at all and 4 being Extremely. Lower scores suggest the person may be experiencing fewer symptoms early in their recovery following an aesthetic facial procedure."
223617430|NCT05524220|DEVICE|SuperNO2VA™EtCO2 (Nasal Oxygenating Ventilating Apparatus)|The anesthesia provider will attach the SuperNO2VA™ EtCO2 circuit port to the hyperinflation bag with the oxygen flow rate to 10 L/min. The oxygenation, continuous positive airway pressure, and ventilation of the subject will be done via SuperNO2VA™EtCO2 (Nasal Oxygenating Ventilating Apparatus)
223617431|NCT04088006|DEVICE|Injection of STYLAGE® HydroMax|"STYLAGE® HydroMax is a hyaluronic acid injectable gel intended to improve skin moisturization and elasticity of the face and neckline area in this study.~A total of 3 injection sessions will be performed one month apart for each subject.~At each injection session, 1 mL of product will be injected in the mid to deep dermis of one cheek and another 1 mL in one site of neckline area for each subject."
224204773|NCT06701695|PROCEDURE|Control (Standard treatment)|The control group received the conventional treatment protocol.
224204774|NCT02733601|OTHER|NIS (Non Interventional Study) observational study|NIS observational study : Epidemiologic registry
224204775|NCT00704717|BIOLOGICAL|PegIntron (peginterferon alfa-2b; SCH 54031) pen|PegIntron pen administered in accordance with approved labeling
224313728|NCT05419609|OTHER|"FACE-Q | Aesthetics - Satisfaction with Outcome"|"Completed by patients. The FACE-Q \| Aesthetics - Satisfaction with Outcome is a 6-item questionnaire. Each item is rated 1-4, with 1 being Definitely disagree and 4 being Definitely agree. Lower scores suggest the person may be less pleased with their final appearance following surgery and the decision to have an aesthetic facial procedure."
224313729|NCT05419609|OTHER|"FACE-Q | Aesthetics - Adverse Effects: Cheeks, Lower Face, Neck"|"Completed by patients. The FACE-Q \| Aesthetics - Adverse Effects: Cheeks, Lower Face, Neck is a 15-item questionnaire. Each item is rated 1-3, with 1 being Not at all and 3 being A lot. Lower scores suggest the person may be experiencing fewer chronic symptoms following an aesthetic facial procedure."
224313730|NCT02623985|DEVICE|Sofia|Patients who presented with sore throat will be performed throat swab and sent for Sofia for rapid test.
224313731|NCT02623985|DEVICE|QuickVue|Patients who presented with sore throat will be performed throat swab and sent for QuickVue for rapid test.
224313732|NCT02623985|DEVICE|Throat swab culture|Patients who presented with sore throat will be performed throat swab and sent for throat swab culture for gold standard.
224313733|NCT05038800|BIOLOGICAL|MK-0482|IV infusion
224313734|NCT06695572|DRUG|CKD-383|QD, PO
224313735|NCT03011190|BEHAVIORAL|Emotional regulation|Educate people with difficulty in regulating their emotions and help them acquire skills to do so
224313736|NCT03338842|DEVICE|Distractor and Lower limb VR|In the first phase (A), subjects will receive the Distraction VR treatment during 5, 6, or 7 one-hour-long sessions occurring twice weekly. After the A phase, the remaining sessions (B phase) will consist of Lower-Limb VR treatment. This number includes a mean of 6 (range 5-7) phase A sessions and mean of 11 (range 10-12) phase B sessions.
224313737|NCT00002241|DRUG|Indinavir sulfate|
224204776|NCT00704717|DRUG|Rebetol (ribavirin; SCH 18908)|Rebetol administered in accordance with approved labeling.
224313738|NCT00002241|DRUG|Ritonavir|
224313739|NCT00002241|DRUG|Lamivudine|
224204777|NCT01476345|DRUG|LY2963016|Administered subcutaneously
224204778|NCT01476345|DRUG|Lantus|Administered subcutaneously
224204779|NCT02209454|DRUG|Enantyum® oral solution|One dose of 25 mg DKP oral solution
224204780|NCT02209454|DRUG|Keral® tablet|One dose of 25 mg DKP tablet
224313740|NCT00002241|DRUG|Stavudine|
224313741|NCT05464849|DIAGNOSTIC_TEST|Evaluation of systemic skin microvascular endothelial function|Laser-based method for evaluating non-invasive, operator-independent systemic microvascular function that detects microvascular flow in the skin for the evaluation of systemic vascular endothelial function.
224313742|NCT03273491|BEHAVIORAL|daily self-weighing|Participants are provided with a wifi-enabled scale and asked to weigh themselves daily, first thing in the morning.
224313743|NCT03273491|BEHAVIORAL|daily temperature-taking|Participants are provided with a wifi-enabled thermometer and asked to take their temperature daily, first thing in the morning.
224313744|NCT06695598|DRUG|CKD-383|QD, PO
224313745|NCT06464432|BEHAVIORAL|Enhanced Skills Training in Affective and Interpersonal Regulation|Enhanced Skills Training in Affective and Interpersonal Regulation combined with Modified Prolonged Exposure (ESTAIR); Psychotherapeutic manual for the treatment of Complex Post-Traumatic Stress Disorder (CPTSD) consisting of 4 therapeutic modules: 1. Emotion Regulation, 2, Self-concept, 3. Relationship Patterns, 4. Prolonged Exposure.
224313746|NCT00197496|PROCEDURE|Body weight supported treadmill training|hip fracture patients walk on a treadmill with body weight support
224313747|NCT02606214|DRUG|TBA-354|
224313748|NCT02606214|DRUG|TBA-354 Placebo|
224313749|NCT04819035|DIAGNOSTIC_TEST|CBC-DIFF Monocyte Volume Width Distribution (MDW)|MDW measurement will be used to detect sepsis. Results will not be used to manage patients.
224204781|NCT04622488|DRUG|Diclofenac Potassium|\- In the form of Insitu gel system can be applied as solution or suspension that undergoes gelation after administration. Applied once inside the root canal after chemo-mechanical preparation.
224204782|NCT00736060|OTHER|Observational|Summary of clinical and laboratory data
224313750|NCT00857584|DRUG|Extended release quetiapine (quetiapine XR)|"Flexible dose from 300 to 600 mg/d (combination of tablets of 50mg, 200mg and 300mg) oral, daily, 8 weeks length.~Quetiapine XR was initiated at 50 mg/day and titrated to 100 mg on day 2, 200 mg on day 3, 300 mg on day 4, and flexible doses of 300 to 600 mg/d from day 5 to the end of the study."
224075738|NCT03757104|BEHAVIORAL|micro-incentive and EPIC-HIV|"micro-incentives: Residents in these communities are eligible to receive a R50 food voucher conditional on undergoing a home-based HIV test. If diagnosed with HIV, residents are eligible to receive a second R50 food voucher when they link to care within 6 weeks of the HIV test.~EPIC-HIV 1:~Men in these communities are eligible to receive a tablet-based male-sensitive HIV specific decision support app (EPIC-HIV 1) to encourage them to test for HIV at home. If diagnosed with HIV and do not link to care within a month of HIV test, they become eligible to receive a tablet-based male HIV specific decision support app (EPIC-HIV 2) to encourage them to link to HIV care."
224075739|NCT01211379|BEHAVIORAL|FLU-FOBT Program|Primary care patients who came in for flu shots were assessed by nurses for colorectal cancer screening eligibility and offered FOBT if due.
224204783|NCT04829422|DRUG|Lazertinib 240 mg|The initial dose of lazertinib 240 mg (3 tablets of 80 mg lazertinib) once daily can be reduced to 160 mg once daily (2 tablets of 80 mg lazertinib) under specific circumstances
224204784|NCT06410573|BEHAVIORAL|Breast Self-Examination and Practice|In the training, women will be divided into 5 groups and the training will be held in 5 separate sessions in one day. A training program will be completed with 9 women. All trainings will be conducted under the same conditions in the school's training room. Before the training, women will be informed about the training and their permission and consent will be obtained. The training prepared by the researcher will be presented to the women in the experimental group of the study. The presentation used in the training will include information about breast cancer, breast cancer screening programs and breast self-examination. In the presentation, the steps of breast self-examination will be shown step by step using visual materials.
224313751|NCT00857584|DRUG|Sertraline|"Flexible dose from 50 to 200 mg/d (combination of tablets of 50mg and 100mg) oral, daily, 8 weeks length.~Sertraline titration: 50 mg on day 1-3, 100 mg on day 4, and flexible doses of 50 to 200 mg/d from day 5 to the end of the study."
224313752|NCT00857584|DRUG|adequate mood stabilizer|An adequate mood stabilizer treatment with lithium or valproate(defined as a serum concentration of 0.5-1.2 mEq/L or 50-100 microg/ml, respectively).
224313753|NCT00696579|DRUG|BCG|6 weekly instillations of Tice-strain BCG (Organon Teknika Corp.) as induction chemotherapy, with a dose of 5 x 108 CFU diluted in 50 mL of saline held in the bladder for 2 hours.
224313754|NCT00696579|DRUG|gemcitabine|14 days after II look-TURB the patients received 6 weekly instillations of Gemcitabine (Gemzar, Eli Lilly SpA), using a dose of 2000 mg diluted in 50 mL of saline held in the bladder for 2 hours
224313755|NCT05185401|OTHER|Observational study|Retrospective data-analysis
224313756|NCT01432379|BIOLOGICAL|botulinum toxin Type A|155-195 U of botulinum toxin Type A administered intramuscularly in the face, head, and neck areas as directed by physician (approximately every 12 weeks) for 1 year.
224313757|NCT01236586|DRUG|RO4929097|
224313758|NCT01236586|DRUG|Dexamethasone|
224313759|NCT04677296|OTHER|VS002A|Amino acid based ORS/Medical food
224313760|NCT04677296|OTHER|WHO-ORS|WHO Oral rehydration solution, which is glucose based
224313761|NCT03866720|OTHER|Carbohydrate rich breakfast|A porridge breakfast meal fed at a carbohydrate delivery rate of 7.3 mg/kJ of each participants resting metabolic rate.
224313762|NCT03866720|DIETARY_SUPPLEMENT|Whey protein enriched breakfast|A porridge breakfast meal in which 15 grams of whey protein is substituted in place of carbohydrate and a small portion of fat.
224313763|NCT02116959|DRUG|Melphalan|
224313764|NCT02116959|DRUG|Carboplatin|
224204785|NCT03025659|OTHER|Pyruvate levels|An additional 1 ml of arterial blood will be drawn at each routine postoperative blood draw (Hour 0, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, and 48 for participants 10kg and above or only at Hour 0, 2, 4, 6, 8, and 12 for infants under 10 kg) to measure the concentration of pyruvate in blood.
224204786|NCT03618082|DRUG|Anesthesic agent guided by ANI (Interventional Group)|Anesthesic agent guided by ANI (Interventional Group) The remifentanil administration will be piloted by the ANI, as well as the prophylactic administration of morphine at the end of the intervention.
224204787|NCT03618082|DRUG|Administration of the lowest effective concentration of desflurane (Interventional Group)|Administration of the lowest effective concentration of desflurane (Interventional Group) Desflurane will be administered with a targeted purpose of minimal alveolar concentration (MAC).
224204788|NCT04921046|DRUG|lignocaine|After giving lignocaine to a group of people, myoclonus was observed after the dose of etomidate given two minutes after lignocaine.
224204789|NCT04921046|DRUG|Midazolam 1 milligram Prefilled Syringe|after giving midazolam to the second group of people two minutes before etomidate dose, myoclonus was observed for one minute.
224204790|NCT05697107|DRUG|Ripretinib Oral Tablet|Oral kinase inhibitor
224204791|NCT03313154|OTHER|Neuropsychiatric screening|"Psychiatric diagnosis through:~1. clinical interview~2. the Advanced Neuropsychiatric Tools and Assessment Schedule (ANTAS), based on the SCID-I-NP (Structured Clinical Interview for the Diagnostic and Statistical Manual for Mental Disorders-Non Patient Version);~3. HAM-D (Hamilton Scale for Depression);~4. PHQ-9 (Patient's Health Questionnaire-9 items);~5. MDQ (Mood Disorders Questionnaire);~6. YMRS (Young Mania Rating Scale);~7. ASRM (Altman Self Rating Mania scale);~8. BRIAN (Biological Rhythms Interview of Assessment in Neuropsychiatry).~   Assessment of Quality of Life:~9. SF-12 (Short Form Health Survey-12 items).~Neuropsychological screening:~l) Addenbrooke's Cognitive Examination (ACE-R)."
224204792|NCT00795483|DRUG|Zoledronic acid|Zoledronic Acid 5mg/year
224204793|NCT00795483|BEHAVIORAL|Lifestyle modifications|Lifestyle modifications
224204794|NCT00795483|DRUG|Zoledronic acid|Zoledronic acid (5mg/2years)
223617432|NCT06910748|BEHAVIORAL|E-training for Medical Professionals On Wellbeing and Effective Resolutions (E.M.P.O.W.E.R.)|The EMPOWER programme aims to help participants acquire problem-solving skills adapted into the context of MPs' workplace and daily life to address their work-related, personal, and interpersonal problems, including self-neglect, work-life imbalance, patient communication problems, as well as stress during emerging public health crises. The session elements include video introduction, metaphors, daily examples, and narrative stories with prototype MP characters depicting the targeted problems to demonstrate how the taught problem-solving skills could be applied in a variety of situations. Brief exercise and homework will be assigned after each session and personalized written feedback will be provided.
223617433|NCT06910748|OTHER|Education Materials|The waitlist control receive education materials covering (1) introduction of mental health problems; (2) signs, symptoms, causes, and consequences of anxiety and depression, and (3) treatment approaches and available community resources.
223617434|NCT06319898|BEHAVIORAL|Lavender aromatherapy sticker|Lavender aromatherapy during procedure, music and dim lighting
223617435|NCT06914544|RADIATION|Hypofractionated Radiosurgery|"Image-guided stereotactic Linac based RT preferable with dedicated radiosurgery system such as CyberKnife"
224204795|NCT04504097|BEHAVIORAL|m-Health|Participants receive a weekly bidirectional text message (SMS) asking how they are doing. They are requested to reply fine, or not fine, in which case they will be contacted with support by a peer navigator. If they do not reply to the message within the specified timeframe a peer navigator will follow up with them.
224204796|NCT04504097|DIAGNOSTIC_TEST|HIV self-testing|Participants will receive HIVST kits so that they can perform their HIV testing.
224204797|NCT02494947|BEHAVIORAL|high intensity interval-based aerobic exercise|Interval exercises done 3 times weekly during 6 months according to standard procedures at the Department of Circulation and Medical Imaging.
223617436|NCT05321927|DEVICE|Trancutaneous Electrical Nerve Stimulation|Transcutaneous Electrical Nerve Stimulation produces an electrical current to stimulate the nerves for therapeutic purposes. continuous high frequency (≥ 50 Hz) stimulation for 5 minutes followed by high frequency (≥ 50 Hz) bursts with 7 pulses per burst for the last 5 minutes.
223617437|NCT05321927|OTHER|Strength training|Three training sessions for 10 minutes per muscle, per week, for four weeks in total.
224204798|NCT02494947|OTHER|Usual care|
224204799|NCT04231994|DEVICE|TPE|singular Therapeutic Plasma Exchange using fresh frozen Plasma as replacement fluid
224204800|NCT06413589|OTHER|SMOF lipid 20%|Drug: SMOF lipid 20% SMOF 20%, a blend of soybean oil, medium-chain triglycerides, olive oil, and fish oil, is a new lipid emulsion product that was provided as a bolus dose of 1.5ml/kg for one hour, followed by a maintenance dose of 6 ml/kg for a period of four hours to the active comparator group
224313765|NCT02116959|DRUG|Etoposide|
224313766|NCT02116959|DRUG|Vincristine|
224313767|NCT02148289|DIETARY_SUPPLEMENT|Nitrate rich beverage|Following randomisation on day 1, subjects will consume either the nitrate or nitrate-free beverage and then the crossover beverage on day 8.
224313768|NCT02148289|DIETARY_SUPPLEMENT|Nitrate free beverage|Following randomisation on day 1, subjects will consume either the nitrate or nitrate-free beverage and then the crossover beverage on day 8.
224313769|NCT00674557|DRUG|SOD1 inhibitor ATN-224|
224313770|NCT00674557|DRUG|exemestane|
224313771|NCT00674557|GENETIC|protein expression analysis|
224313772|NCT00674557|GENETIC|proteomic profiling|
224313773|NCT00674557|OTHER|laboratory biomarker analysis|
224313774|NCT00674557|OTHER|pharmacological study|
224313775|NCT03862066|OTHER|Blood collection|5 milliliters (mL) of blood will be collected at the time of surgery
224313776|NCT03862066|OTHER|Tissue collection|Left over tissue will be collected at the time of surgery
224313777|NCT03852173|BEHAVIORAL|Wasserschulen|"Schools receive following materials and trainings:~* one training sessions for teachers (at the beginning of the intervention)~* refillable water bottles for each school student~* drying rack for water bottles for each classroom~* educational material for each class and for school events~* informational material for parents"
224204801|NCT06413589|OTHER|standard treatment for clozapine toxicity|"Hypotension was initially treated with isotonic crystalloid; vasopressors were utilised if intravenous fluids failed to restore the hypotension. This was in the form of norepinephrine with a dose of 0.05 μg/kg/min and titrated till reaching the goal mean arterial pressure (\>65 mmHg) \[29\].~Those experiencing seizures due to CBZ overdose were treated with benzodiazepines (diazepam) at a dose of 10-20 mg. Benzodiazepines are considered allosteric modulators of the gamma-aminobutyric acid channel.~MDAC (50 grammes every six hours) was given to all patients in the current study. Those with severe poisoning were given the MDAC after securing the airway with a cuffed endotracheal tube"
224204802|NCT02797626|PROCEDURE|Primary retroperitoneal lymph-node dissection (pRPLND)|Open or laparoscopic robotic-assisted nerve-sparing retroperitoneal lymph node dissection (modified template RPLND, if possible ipsilateral nerve-sparing)
224204803|NCT01652573|DRUG|nasal salmon calcitonin|400 IU daily in two sprays (one to each nares)
224204804|NCT01652573|DRUG|Saline Nasal Spray Placebo|
224313778|NCT06884215|OTHER|Mitopure Topical Formula 3|Topical skin cream containing Mitopure
224313779|NCT06884215|OTHER|Mitopure Topical Formula 4|Topical skin cream containing Mitopure
224313780|NCT03457155|OTHER|VS-I dosing in plasma samples|"VS-I dosing in plasma samples using ELISA protocol :~* At intensive care admission time~* 24h after admission time~* In case of FA occurrence~* In case of sinusal rhythm recovery (in patients with new onset FA)"
224313781|NCT03911518|PROCEDURE|Loop drainage|Loop drainage will occur via 2 small incisions, approximately 2 cm, with the cuff from the base of a sterile glove pulled through and then tied off.
223617438|NCT05321927|DEVICE|Sham stimulation|Continuous stimulation at 1 Hz for 2 seconds, then no stimulation for 10 seconds. This will alternate for 10 minutes. The intensity equals the intensity that is just felt by the individual.
223617439|NCT06914947|BEHAVIORAL|Brain Health Together|Each week, the program included a 1-hour group brain health education class, a 1-hour group Moving Together class, and a 30-minute individual brain health coaching session (total: 2.5 hours/week). Before the first session, participants were asked to complete a brief online survey about lifestyle behaviors and medical conditions related to dementia risk. The first 4 brain health education classes focused on general content to introduce and reinforce the concept that healthy lifestyle behaviors and management of chronic medical conditions can improve cognitive function, delay cognitive decline, and potentially prevent dementia. Another goal was to introduce participants to health coaching and to help participants each set specific, measurable, achievable, realistic, time-limited (SMART) goals to improve brain health. The remaining 8 weeks were adjusted to accommodate participant feedback in the early portion of the pilot study.
223617440|NCT04894669|DEVICE|INVSENSOR00045|Noninvasive sensor will be fitted to the subject's hand, foot, or toe to measure oxygen saturation and pulse rate.
223617441|NCT06911736|OTHER|Trendelenburg position|In addition to the management described above, the postoperative position was modified in the intervention group (trendelenburg). After admission to the hospital unit (general ward, special care, or intensive care unit), the patient's position was adjusted with a 30° leg elevation and a 10° downward head tilt. Proper positioning was verified with a goniometer. This position was maintained until the drains were removed, and the patient was then positioned according to usual care. If the patient decided to get out of bed, the nurse occluded the drains and reopened them when the patient returned to the position described for each group.
223617442|NCT06922565|DEVICE|acupuncture|Subjects in the acupuncture group received traditional acupuncture. The needles were inserted to induce a sense of 'getting qi' and left in place for 30 minutes.
223617443|NCT06922565|DEVICE|sham acupuncture|Sterile disposable retractable needles and a fake placebo acupuncture device are used for sham acupuncture. The acupuncturist attached the base of the sham acupuncture device to the acupoints, and then inserted sterile disposable blunt-tipped retractable needles into the tubes; when the blunt tips touched the skin, the needles retracted into the handles, and there was no sensation of getting qi.
223617444|NCT06918366|DRUG|Part A - single rising dose 1|Inhaled XQ-001
224204805|NCT03614065|DRUG|endostar|endostatin
223617445|NCT06918366|DRUG|Part A - single rising dose 2|Inhaled XQ-001 or Placebo
224204806|NCT03614065|DRUG|Placebos|saline solution
224204807|NCT03614065|RADIATION|radiotherapy|radiotherapy
224204808|NCT00934622|DEVICE|AcrySof® ReSTOR® Aspheric IOL|AcrySof® ReSTOR® Aspheric Intraocular Lens (IOL) implanted into the study eye following the cataract extraction surgery
224204809|NCT02148731|OTHER|Frailty markers|Brief screening assessment, CGA and frailty markers will be evaluate at inclusion. CGA and frailty markers will be evaluated at 3, 6, 12 and 18 months after the beginning of chemotherapy. Criteria for toxicity and adverse outcomes will be recorded at each cycle or visits
224204810|NCT05780944|BEHAVIORAL|Paced Bottle-Feeding Education|Participants will be asked to review an educational handout that outlines how to implement PBF during bottle-feeding interactions. Participants will then be asked to watch a video that further describes PBF and illustrates how to implement it with a live infant. A trained research assistant will then answer questions, further explain PBF, and demonstrate PBF with a baby doll, using a standardized script
224313782|NCT03911518|PROCEDURE|Incision and drainage|The wound will be incised with a #11 blade scalpel along the point of maximal fluctuance, approximately 2-3 cm, and then all loculations bluntly dissected with a set of Kelly clamps. After drainage of pus, the wound will be loosely packed with gauze.
224313783|NCT01212354|RADIATION|Radiotherapy|7 weeks Radiation dose escalation (5 x 2.3 Gy up to 80.5 Gy total dose)
224313784|NCT00259272|DRUG|olanzapine|5 to 20 mg (flexible dose) administered orally as disintegrated tablets, daily for 24 weeks.
224313785|NCT06367491|OTHER|Registration in a database|All patients with bone metastasis enrolled at the centre will be entered into the database and followed until death or interruption of follow-up for any another cause
224313786|NCT00792363|DRUG|Irinotecan|350 mg/m2 intravenously on day 1 every 3 weeks
224313787|NCT00792363|DRUG|Panitumumab|9 mg/kg intravenously on day 1 every 3 weeks
224313788|NCT04051112|DRUG|SCB-313|10mg group: Intraperitoneal injection single dose on Day 0, safety observation for 7 days, then 3 continuous doses on Day7, Day8, Day9, 21 days for 1 cycle
224313789|NCT04172116|DEVICE|Continuous glucose monitoring|see arm/group descriptions
224313790|NCT04164914|DIETARY_SUPPLEMENT|Prebiotic|Soluble prebiotic fiber (resistant dextrin 14 g/d x 4 weeks)
224313791|NCT00658021|DRUG|Placebo|Subcutaneous injection, twice a day
224204811|NCT02449967|PROCEDURE|interventional therapy|pancreatic cancer patients received HepaSphere interventional therapy using the digital subtraction angiography（DSA）
224313792|NCT00658021|DRUG|Exenatide|Subcutaneous injection, 5 µg, twice a day
224075740|NCT01502904|DEVICE|Sirolimus-eluting stent|2x2 randomization by the treatment of dyslipidemia and hypertension(In patients of dyslipidemia: pitavastatin 2mg/day vs. pravastatin 20mg/day, in patients of hypertension: eporsartan 600mg/day vs. Non-ARB) and the types of the implanted DES, SES vs BES.
224075741|NCT01502904|DEVICE|Biolimus-eluting stents|2x2 randomization by the treatment of dyslipidemia and hypertension(In patients of dyslipidemia: pitavastatin 2mg/day vs. pravastatin 20mg/day, in patients of hypertension: eporsartan 600mg/day vs. Non-ARB) and the types of the implanted DES, SES vs BES.
224204812|NCT04662086|DRUG|Acebilustat|100 mg capsule administered orally once daily
224204813|NCT04662086|DRUG|Camostat|200 mg (2 x 100 mg tablet) administered orally four times daily (800 mg total daily dose).
224204814|NCT06418932|DEVICE|UrgoK2 / UrgoK2 Lite|Multicomponent compressive bandage system consisting of an internal bandage of short traction and an external cohesive bandage of long traction, with pressure indicators on both bandages, which provides a sustained ankle pressure of \~20/40mmHg.
224204815|NCT06418932|OTHER|Controll|Administration of parenteral diuretics only
224204816|NCT01856686|DRUG|BP22042013|This group of patients receive 2.000 kilo-calories diet (60 g. carbohydrates, 144 gr of fat and 107 gr of proteins), including 2 protein shakes.
224204817|NCT01856686|DIETARY_SUPPLEMENT|Low carbohydrate diet|the second group of patients receive diet of 2.000 Kilo-calories without rapidly absorbed carbohydrates and without proteins supplements
224204818|NCT04372563|OTHER|aortic prosthetics|aortic prosthetics
224204819|NCT06514924|OTHER|height and weight measurement|Height and weight measurements and socioeconomic status survey
224204820|NCT04647279|DIAGNOSTIC_TEST|Dual-emission X-ray Absorptiometry|The recruiters were divided into osteoporosis, osteopenia and normal by dual emission X-ray absorptiometry.
224204821|NCT02706041|PROCEDURE|Definitive Closure Laparotomy|Subjects randomized to the definitive closure laparotomy arm will have the incision closed at the end of the exploratory laparotomy.
224204822|NCT02706041|PROCEDURE|Damage Control Laparotomy|Subjects randomized to the damage control laparotomy arm will have the incision left open at the end of the exploratory laparotomy. The trauma team will evaluate the patient's clinical course to determine when the incision can be closed.
224204823|NCT00602979|DEVICE|Macintosh laryngoscope|Used during laryngoscopy to facilitate intubation.
224204824|NCT00602979|DEVICE|Airtraq® Optical Laryngoscope|Used during laryngoscopy to facilitate intubation.
224204825|NCT00602979|DEVICE|Storz DCI Video Laryngoscope®|Used during laryngoscopy to facilitate intubation
224204826|NCT00602979|DEVICE|GlideScope® Video Laryngoscope|Used during laryngoscopy to facilitate intubation
224204827|NCT00602979|DEVICE|McGRATH® Video Laryngoscope|Used during laryngoscopy to facilitate intubation
224204828|NCT04252690|DEVICE|MOBIDERM® autofit : auto-adjustable compression stocking|"The experimental protocol will require 2 visits during usual reduction phase performed at the hospital (5 days of hospitalization).~Visit 1 will be performed the first day of hospitalization and will consist of inclusion visit and some evaluations (lymphoscintigraphy, edema volume, cutaneous characteristics).~Between visit 1 (D1) and visit 2 (D3), patients will wear Mobiderm Autofit continually.~Visit 2 will be performed the third day of hospitalization and will consist of evaluations (lymphoscintigraphy, edema volume, cutaneous characteristics, satisfaction survey)."
224204829|NCT06072755|DEVICE|Finger pulse oximetry probe|This finger probe will be used to make noninvasive measurements of systemic arterial and central venous oxygen saturations.
223617446|NCT06918366|DRUG|Part A - single rising dose 3|Inhaled XQ-001 or Placebo
223617447|NCT06918366|DRUG|Part A - single rising dose 4|Inhaled XQ-001 or Placebo
224204830|NCT06072755|DEVICE|Transreflectance oximetry probe|This neck probe will be used to make noninvasive measurements of systemic arterial and central venous oxygen saturations.
224204831|NCT00468312|DRUG|Mometasone furoate nasal spray|Two sprays (50 mcg/spray) in each nostril (200 mcg daily) in the morning
224204832|NCT00468312|DRUG|Placebo|Two sprays in each nostril in the morning
224204833|NCT04304846|OTHER|Questionnaires and interviews|List of questionnaires: ASQ, PSI, PPQ, SDQ, GSA and AMMI score obtained from mother during two separated interviews for the mother and the child at 3 and 5 years old
224204834|NCT00431236|DRUG|Oral Casopitant (GW679769)|
224204835|NCT00431236|DRUG|IV Casopitant (GW679769)|
224204836|NCT00431236|DRUG|IV ondansetron hydrochloride|
224313793|NCT00658021|DRUG|Exenatide|Subcutaneous injection,10 µg, twice a day
224313794|NCT00727766|DRUG|Clofarabine|
224313795|NCT03349008|DRUG|Entecavir|Glycyrrhizin for the treatment of patients with chronic hepatitis B combined with entecavir-based
224313796|NCT03349008|DRUG|Magnesium Isoglycyrrhizinate|Magnesium Isoglycyrrhizinate Injection treat for two weeks with entecavir-based
224313797|NCT03349008|DRUG|Diammonium Glycyrrhizinate|Diammonium Glycyrrhizinate for oral after Magnesium Isoglycyrrhizinate Injection treatment with entecavir-based
224313798|NCT03349008|DRUG|Magnesium Isoglycyrrhizinate Placebo|Magnesium Isoglycyrrhizinate Injection Placebo
224313799|NCT03349008|DRUG|Diammonium Glycyrrhizinate Placebo|Diammonium Glycyrrhizinate Enteric-coated Capsules Placebo
224313800|NCT00416702|DRUG|QAB149|
223617448|NCT06918366|DRUG|Part A - single rising dose 5|Inhaled XQ-001 or Placebo
223617449|NCT06918366|DRUG|Part A - single rising dose 6|Inhaled XQ-001 or Placebo
223617450|NCT06918366|DRUG|Part B - mutiple rising dose 1|Inhaled XQ-001 or Placebo
223617451|NCT06918366|DRUG|Part B - mutiple rising dose 2|Inhaled XQ-001 or Placebo
224075742|NCT01502904|DRUG|pravastatin 20mg/day after DES implantation|2x2 randomization by the treatment of dyslipidemia and hypertension(In patients of dyslipidemia: pitavastatin 2mg/day vs. pravastatin 20mg/day, in patients of hypertension: eporsartan 600mg/day vs. Non-ARB) and the types of the implanted DES, SES vs BES.
224075743|NCT01502904|DRUG|pitavastatin 2mg/day after DES implantation|2x2 randomization by the treatment of dyslipidemia and hypertension(In patients of dyslipidemia: pitavastatin 2mg/day vs. pravastatin 20mg/day, in patients of hypertension: eporsartan 600mg/day vs. Non-ARB) and the types of the implanted DES, SES vs BES.
224204837|NCT00431236|DRUG|Oral dexamethasone|
224204838|NCT04950803|DIETARY_SUPPLEMENT|Microbiome immunity formula|Microbiome immunity formula contains probiotics blend (3Bifidobacteria, 20 billion CFU daily)
224204839|NCT04950803|DIETARY_SUPPLEMENT|Active placebo|Active placebo contains active vitamin
224204840|NCT05112679|DEVICE|PROPRIO FOOT® by Ossur|Active prostheses like the PROPRIO FOOT® offer great potential to more completely restore the locomotor capabilities of individuals with transtibial amputation, perhaps enhancing RTD for military personnel. The investigators will examine factors of socket loading and direct measures of residual limb health so as to inform the optimization of prosthesis fit. The testing will consist of walking on a treadmill and the use of a 3D motion capture camera to track movement and angles of the participant's upper and lower extremities. Ascending and descending on stairs and ramps with the device will be completed. Participants will also have laser speckle imaging to measure blood flow to skin and transepidermal water loss measurement to check skin health.
224313801|NCT01123837|OTHER|Intravenous fluid|"The treatment group will receive a 250cc bolus over 2 hrs of D5LR prior to the end of surgery and continued in the PACU. Blood glucose will be checked 3 different times using an Accu-chek monitor along with the type and number of rescue medications given at 30, 60, and 120 minutes after anesthesia and the post-op morning.~The control group will receive a 250cc bolus over 2 hours of LR. Blood glucose will be monitored 3 times along with the type and how much of rescue medications are given at 30, 60 and 120 minutes post-op and the morning after surgery."
223617452|NCT06922682|BEHAVIORAL|Training with Sudden Infant Death Syndrome Training Booklet|Sudden Infant Death Syndrome Training Booklet was prepared. Prgenant women who agreed to participate were provided a face-to-face training on the risk factors triggering sudden infant death syndrome through the booklet. Following the educational session, they received the safe sleep handout to use at home and were informed that the researcher would call them two months later to check on their adherence to safe sleep practices. Following the training, participants were re-administered the Knowledge Level on Sudden Infant Death Syndrome and Risky Behavior Identification Questionnaire and the training booklet was given to them as a gift. Two months after the training, the pregnant women were contacted via phone and they were required to fill out the Knowledge Level on Sudden Infant Death Syndrome and Risky Behavior Identification Questionnaire once again.
224204841|NCT05112679|DEVICE|Empower ankle by Ottobock|Active prostheses -such as the Empower ankle offer great potential to more completely restore the locomotor capabilities of individuals with transtibial amputation, perhaps enhancing RTD for military personnel. The investigators will examine factors of socket loading and direct measures of residual limb health so as to inform the optimization of prosthesis fit. The testing will consist of walking on a treadmill and the use of a 3D motion capture camera to track movement and angles of the participant's upper and lower extremities. Ascending and descending on stairs and ramps with the device will be completed. Participants will also have laser speckle imaging to measure blood flow to skin and trans epidermal water loss measurement to check skin health.
224204842|NCT01052038|DRUG|Placebo administration|Placebo administration
224204843|NCT01052038|DRUG|Dexamethasone 0.05mg/kr administration|Dexamethasone 0.05mg/kr administered in 100ml of sterile saline solution prior to the start of surgery.
224204844|NCT01052038|DRUG|Dexamethasone 0.1mg/kg|Dexamethasone 0.1mg/kg administered in 100ml of sterile saline solution prior to the beginning of surgery.
224204845|NCT03650179|OTHER|Observational study : No intervention|Observational study : No intervention. Only exporting data
224204846|NCT00791284|DRUG|Intermediate release (IR) Paliperidone|
223511510|NCT04264195|OTHER|Bimanual manipulation exercises (PEPS-Bimanual)|"All participants of control and experimental groups received standard stroke. After regular office time, a 2 hours' peer group session was provided, 5 days/week, 4 consecutive weeks, to both groups. One patient 'leads' the group exercises under a therapist's supervision. The therapist is mainly helping and correcting patients during the various exercise tasks.~Specific for the control group was that patients performed all manipulation tasks bimanually, as they used to do in occupational therapy activities. Patients were also asked to document their 'at home' activities in an activity checklist that was regularly checked by the therapists."
223511511|NCT04933058|DRUG|IV acetaminophen|Pain management
223511512|NCT04933058|DRUG|IV fentanyl|Pain management
223511513|NCT05756907|BIOLOGICAL|SON-1010|SON-1010 +/- Atezolizumab
224204847|NCT06123975|OTHER|Venous blood collection|Peripheral blood was collected on the day of embryo transfer. And if the pregnancy test was positive at 14 days after embryo transfer, peripheral blood was collected at 21 days after the transfer and every 2 weeks thereafter until 12 weeks of gestation.
224204848|NCT04098159|DEVICE|duplex ultrasound|regular duplex follow up every three months with subsequent intervention either diagnostic venography , angioplasty or surgery according to the type of the lesion
223511514|NCT02151604|DRUG|Inhalation of hyperpolarized xenon gas|The xenon gas is inhaled immediately before acquisition of an MR image to enable the lung structure to be seen.
224204849|NCT01277406|DRUG|4SC-201(Resminostat)|oral administration
224204850|NCT01277406|DRUG|FOLFIRI|i.v. administration
224204851|NCT03500887|DEVICE|intragastric bag|
224204852|NCT04656171|RADIATION|MRI of the hand and forearm,|MRI of the hand and forearm,
224204853|NCT04731909|DRUG|Toripalimab|Toripalimab 240mg,ivgtt,d1,q3w.
224204854|NCT04731909|DRUG|Anlotinib|Anlotinib 12 mg/d,d1-14,q3w,4-6 cycles in total. In maintenance treatment period, Anlotinib 12 mg/d,d1,Oral for 2 weeks and stop for 1 week.
223511515|NCT01572688|DRUG|Melphalan|powder for injection, 200mg/m2, uses after reconstituted within 24 hours
223511516|NCT00991562|DRUG|IMGN901|dose escalation study. dosing on days 1, 8 and 15 every 28 days
223511517|NCT05860530|DRUG|The test olaparib tablet (T)|The test olaparib tablet (Qilu Pharmaceutical Co., Ltd., Jinan, China) 300mg, every 12 hours
223511518|NCT05860530|DRUG|The reference olaparib tablet (R)|The reference olaparib tablet (Lynparza®; AstraZeneca PLC, Cambridge, England, UK) 300mg, every 12 hours
223511519|NCT01279993|PROCEDURE|Kerato refractive Surgery|This interventional case series was performed on 297 eyes of 150 patients who were candidates for PRK. Complete ophthalmic evaluations focusing on orthoptic examinations were performed before and 3 months after PRK.
223617453|NCT06922500|DEVICE|depth of anesthesia|Time spent within recommended pEEG-levels
224204855|NCT04731909|DRUG|Cisplatin|75mg/m2,d1,q3w,4-6 cycles in total.
224204856|NCT04731909|DRUG|Carboplatin|AUC=5,d1,q3w,4-6 cycles in total.
224313802|NCT01123837|OTHER|D5LR or lactated ringers|"The purpose of the study is to see if giving dextrose fluid in the veins (IV) decreases the risk of postoperative nausea and vomiting (PONV) in female urologic, gynecologic and breast outpatient surgery patients and at what blood sugar level.~The reason for this study is that IV dextrose may decrease the incidence of PONV and the use of medications to treat PONV, while leading to sooner discharge after surgery. This can decrease overall healthcare cost and improving patient satisfaction."
224204857|NCT02534207|DRUG|Basmisanil|Single oral dose: Basmisanil doses between 20 milligrams (mg) and 960 mg may be used in this study. The planned doses for the first two participants are 160 mg and 480 mg, respectively. Basmisanil dose for subsequent participants will be decided by the investigator and sponsor during the study, based on on-going review of emerging data.
224204858|NCT04979078|DEVICE|Photobiomodulation therapy (PBMT)|Patients will receive PBM on the sole of their feet and palms of their hands
224204859|NCT05805956|DRUG|IMM2902|a recombinant bispecific monoclonal antibody with high affinity to the dual targets, HER2 and CD47
224204860|NCT05747261|GENETIC|ANB-004, dose 1|Adeno-associated viral vector carrying the SMN gene single infusion at dose 1. The duration of the infusion is about 60 minutes.
224204861|NCT05747261|GENETIC|ANB-004, dose 2|Adeno-associated viral vector carrying the SMN gene single infusion at dose 2. The duration of the infusion is about 60 minutes.
224204862|NCT05747261|GENETIC|ANB-004, dose 3|Adeno-associated viral vector carrying the SMN gene single infusion at dose 3. The duration of the infusion is about 60 minutes.
224204863|NCT01426828|BIOLOGICAL|CD3/CD28|CD3/CD28 activated autologous lymphocytes intravenously
224313803|NCT03336177|OTHER|Semi-structured face to face interviews.|Patients will be interviewed by open-ended questions face to face concerning their past experiences. The recorded interview will be transcribed and analyzed by psychodynamic and semio-pragmatic approach.
224313804|NCT04121754|DEVICE|MR-001|Participants will walk using the investigational device (foot sensors, mobile device with mobile app and headphones) for thirty (30) minutes at a time, 3 times a week for 5 weeks.
224313805|NCT04121754|OTHER|Active Walking|Participants will walk for thirty (30) minutes at a time, 3 times a week for 5 weeks. No mobile devices, music players or headphones will be allowed. They will wear foot sensors during their active walking sessions to measure gait biomechanics.
224204864|NCT02040207|DRUG|AM-101|AM-101 gel for intratympanic injection
224313806|NCT02838654|PROCEDURE|cervical epidural injection|sensitivity, specificity, positive predictive value, negative predictive value
223511520|NCT00563563|DRUG|NB32|All subjects are to complete a 4 week titration period at which time subjects will be titrated up to a maintenance level of study drug. Subjects will then take the maintenance dose of study drug for an additional 20 weeks.
223511521|NCT00563563|BEHAVIORAL|Ancillary therapy|During the study, subjects will receive ancillary therapy including counseling on smoking cessation, diet and exercise.
223511522|NCT04469283|OTHER|caffeine and movement disorders|Caffeine efficacy on movement disorders in patients with ADCY5-related dyskinesia.
224204865|NCT02133911|DRUG|Ranolazine|
224204866|NCT02446197|OTHER|Patient Directed Exercise Group|Combination of PT and OT activities that will be individually prescribed based on an evaluation by the therapy team completed pre-intervention. The activities will be added to the comprehensive inpatient rehabilitation program.
223511523|NCT04495478|DRUG|Ramucirumab - IV|Administered IV.
223511524|NCT04495478|DRUG|Placebo - IV|Administered IV.
223511525|NCT04495478|DRUG|Ramucirumab - SC|Administered SC.
223511526|NCT04495478|DRUG|Placebo - SC|Administered SC.
223511527|NCT02783937|BIOLOGICAL|Filgrastim|"Each case will have two intervention phases done blindly at random with a wash-out period of 6 months:~Phase A:~Filgrastim vial (30 million IU/ml) SC injection twice daily for five consecutive days.~Phase B:~Injection of saline SC injection twice daily for five consecutive days."
223511528|NCT02783937|DRUG|Saline|Injection of saline SC injection twice daily for five consecutive days
223511529|NCT07056829|DEVICE|Mandibular Advancement Appliance (Invisalign MA)|"Clear aligner system with integrated buccal precision wings to posture the mandible forward.~Advancement protocol: 2 mm increments every 8 weeks. Total active treatment duration: \~8.15 months, followed by retention phase. Patients instructed to wear aligners ≥20 h/day, removing only for eating and oral hygiene."
223511530|NCT07056829|DEVICE|Activator Appliance|"Traditional removable functional appliance fabricated on a standardized bite registration.~Patients instructed to wear appliance 24 h/day except during meals and sports. Total active treatment duration: \~7.15 months, followed by retention phase."
224204867|NCT03203005|DRUG|IMA970A plus CV8102 and Cyclophosphamide|"Study treatment starts with a single intravenous infusion of 300mg/m2 Cyclophosphamide.~Three days later patients start vaccination therapy with IMA970A plus CV8102 Each vaccination consists of a dose of 6.80 milligrams (mg) IMA970A (containing approx. 400 micrograms \[µg\] of each individual peptide) followed by a dose of 50 µg CV8102. First IMA970A is injected intradermally (i.d.) and about 10 minutes later CV8102 is injected i.d. at the same vaccination site in close proximity. Patients will receive 4 vaccinations at weekly intervals followed by 5 vaccinations at 3-weekly intervals for a total duration of about 4.5 months."
224204868|NCT04143997|DIAGNOSTIC_TEST|A clinical Transthoracic echocardiogram|A previously clinically completed transthoracic echocardiogram will be utilized to assess for diastolic dysfunction in the presence of normal systolic function for patients with previously diagnosed peripartum cardiomyopathy.
223511531|NCT07055763|COMBINATION_PRODUCT|Nigella sativa (black seed)|Participants in Group 1 (intervention group) will receive Nigella sativa (black seed) oil at a dosage of 0.5 ml, administered orally twice daily-once before breakfast and once before bedtime-for a duration of 12 weeks. The oil, sourced from a standardized local supplier, is rich in thymoquinone, known for its antioxidant and vasodilatory properties. Blood pressure will be measured at baseline and biweekly intervals using a calibrated digital sphygmomanometer to monitor changes in systolic and diastolic values. Participants will also be monitored regularly for any adverse effects.
223511532|NCT07055958|DRUG|Metformin|Metformin's chemical name is 1,1-Dimethylbiguanide, a molecular formula of C4H11N5. Beyond its well established antihyperglycemic impact, metformin demonstrated anti-oxidant and anti-inflammatory activities contributing its potential benefits in conditions associated with inflammation and oxidative stress. Furthermore, metformin rapidly crosses the blood brain barrier and disperses into several brain regions presenting an ideal therapeutic option for the treatment of PD.
223511533|NCT07055958|OTHER|placebo|placebo of tab. Metformin of same shape
224313807|NCT05352347|DRUG|NuSepin® 0.2 mg/kg|NuSepin® 0.2 mg/kg in 100mL NS bid
224204869|NCT03541798|PROCEDURE|positions of patients for combined spinal-epidural anesthesia|Patients in groups will be positioned according to the study groups for performing combined spinal epidural anesthesia.
224204870|NCT03541798|PROCEDURE|Combined spinal epidural anesthesia|After positioning, a combined spinal epidural anesthesia (CSE) will be applied using a CSE Tuohy Needle (18 G) and 27 G Whitacre spinal needle via needle - through needle technique. The epidural space will be located with loss of resistance to saline. 3 ml hyperbaric bupivacaine 0.5% (15 mg) will be given for spinal anesthesia after identification of subarachnoidal space.
224204871|NCT02263586|BEHAVIORAL|Education in nutrition|Athletes were given a 45 min lesson on the proper diet and fluid intake to prevent hyponatremia in long-distance triathlon.
224204872|NCT03349437|DEVICE|Vitabreath Device|The VitaBreath device is designed for non-continuous use only and typical device use is expected to be for 2-3 minutes. The device should only be operated for less than 10 minutes at a time. After such time, the device should be turned off for at least 30 minutes
224204873|NCT03349437|OTHER|Pursed Lip Breathing|Pursed lip breathing (PLB) is the standard of care and will be used as the control condition comparator.
224204874|NCT06541977|BEHAVIORAL|Behavioral to reduce sedentary behvaior|This intervention will also utilize a geographical time app to raise awareness about participants' sedentary lifestyles, helping them identify opportunities to incorporate more movement into their daily routines. Furthermore, the program will implement the Wheel of Change behavior technique, which serves as a structured approach to facilitate lasting changes in health behaviors, empowering participants to take control of their physical activity levels and overall well-being.
224204875|NCT06541977|BEHAVIORAL|Physical activity|This intervention will be conducted with two weekly days of supervised and structured physical activity sessions, held at the university's facilities, providing participants with expert guidance and a supportive environment to enhance their physical fitness and overall health.
224204876|NCT06541977|PROCEDURE|Bariatric Surgery|In this intervention, bariatric surgery will be performed, accompanied by the usual hospital care, which includes comprehensive nutritional and physical activity advice. This standard care ensures that participants receive essential guidance and support for their dietary and exercise routines, complementing the surgical intervention.
224204877|NCT03525327|OTHER|Line Dance Class|"Line or party dances to be taught will include:~Electric Slide (Mainland USA)Hukilau (Hawaii)Cupid Shuffle (Mainland USA)Poco Poco (Philippines)Cha Cha Slide (Mainland USA)Tush Push (Mainland USA)Trojan Crawl (Mainland USA)Wobble (Mainland USA)Goyang Maumere (Indonesia)"
224204878|NCT04033627|PROCEDURE|In Vitro T cells depletion using CliniMCAS system|Use the CliniMACS TCRα/β and CD45 Systems to deplete TCRα/β+ and CD45RA+ cells from the mobilized peripheral blood stem cells of a haploidentical donor in patients with leukemia.
224313808|NCT05352347|DRUG|NuSepin® 0.4 mg/kg|NuSepin® 0.4 mg/kg in 100mL NS bid
224313809|NCT05352347|DRUG|Placebo|Normal saline (NS) 100mL bid
224313810|NCT05653024|DRUG|Salbutamol|8 puffs of 100 mcg inhaled salbutamol administered with spacer
224313811|NCT05653024|DRUG|Placebo|8 puffs of placebo inhaler administered with spacer
224313812|NCT04197427|DEVICE|Experimental Oral Rinse|Experimental Oral Rinse is a proprietary formulation of GRAS ingredients
224313813|NCT04197427|DEVICE|Placebo|Placebo formulation without the active ingredients
224313814|NCT03258073|OTHER|Medical simulation using scenario execution|Each team of students will be exposed to simulation two times in a semester totaling to four times a year. In a scenario execution, participants are placed in a simulated experience of a medical emergency. Participants are required to respond and their reactions are observed by the investigators. After the experience, participants will have a debriefing session to learn from their experience of handling this emergency.
223511534|NCT06901089|OTHER|Manual therapy|This technique involves a low-amplitude, high-velocity push on the hip joints with an additional two-second tension
224204879|NCT00504127|DRUG|Naproxcinod 375 mg bid|Naproxcinod 375 mg bid
224204880|NCT00504127|DRUG|Naproxcinod 750 mg bid|Naproxcinod 750 mg bid
224204881|NCT00504127|DRUG|Naproxen 500 mg bid|Naproxen 500 mg bid
224204882|NCT00504127|DRUG|placebo|placebo
224204883|NCT05796531|BEHAVIORAL|Therapeutic Evaluative Conditioning|"Participants are told which pictures are matched pairs. They find the matched pairs among 4 or 8 pictures. By associating pictures and words associated with SITB (e.g., pictures of cut skin, pictures of people engaging in potentially suicidal behaviors, and the word death) with naturally aversive images (e.g., snakes and spiders), it increases the aversion to SITB. The second goal is to increase liking toward the self by pairing self-relevant stimuli (e.g., the participant's name or other self-relevant details, as well as words like I and me)."
224204884|NCT05796531|BEHAVIORAL|Neutral comparison condition|Match neutral pictures to account for doing an intervention.
224313815|NCT01058460|PROCEDURE|HPV-cytology co-testing|Subjects will receive HPV testing and conventional cytology testing at baseline. Follow up management will be based on both results.
224313816|NCT04544501|BEHAVIORAL|Culturally-Targeted Video|"Culturally targeted narrative video: Is My Cancer Hereditary? Rosa Visits a Genetic Counselor. With R03 funding (R03CA191543) we developed a culturally targeted narrative video for at-risk Latinas. A multidisciplinary team of researchers collaborated with filmmakers to develop the script and video. The script was informed by health behavior conceptual models, evidence-based risk communication strategies, and formative research (40 interviews with providers and at-risk Latinas). The script addressed identified knowledge gaps (e.g., incorrect belief that pap smears screen for ovarian cancer), facilitators (e.g., inform family cancer risk), barriers (e.g., emotional concerns), and cultural factors (e.g., respect). The 18-minute video illustrates the GCRA process with the story of Rosa, a Latina cancer survivor at increased risk of HBOC. Rosa learns about HBOC risk factors, overcomes barriers, and attends genetic counseling."
223511535|NCT06901089|OTHER|Placebo|This technique involves a low-amplitude, high-velocity push on the shoulder and elbow joints with an additional two-second tension
223511536|NCT06901089|OTHER|Exercise|The following exercise will be performed: lunges
224313817|NCT04544501|OTHER|FORCE Fact Sheet|A publically available Spanish-language fact sheet about HBOC and GCRA developed by FORCE.
224313818|NCT00393965|DRUG|MPC-6827|2-hour IV infusion given once weekly for 3 consecutive weeks on a 28-day cycle.
224313819|NCT01550627|OTHER|extra fluid/iv fluid supplementation during phototherapy|The study group received an extra intravenous fluid intake of 20% of the total fluid demand per 24 hours of NaCl 0,9% during each two hour period of phototherapy (12h total per day). The extra fluid intake was interrupted during the 12 hours break of phototherapy.
224313820|NCT01550627|OTHER|Non extra fluid|Control placebo The control group received the previous fluid regime, as intravenous fluid was given constantly, without a specific guideline according to extra fluid intake.
223511537|NCT02743858|OTHER|Bilateral arm measurements|Pts treated with ALND, bilateral arm measurements will be obtained using the Perometer (Model 350 NT Perometer, Per-System) circumferential arm measurements with elastic tape taken at 4-cm intervals from the wrist to the shoulder \& the L-Dex U400 (Impedimed, Brisbane, Australia) for bioimpedance measurements. Measurements will be performed before surgery, post-operatively \& at timepoints of 6,12,18, \& 24 months after surgery for 2 years will be obtained using the Perometer (Model 350 NT Perometer, Per-System) for bioimpedance measurements. Pts who have not yet developed lymphedema by 2 years, an additional measurement at approx 3 years post-surgery will be performed. If pt is diag with lymphedema at the 3-year visit, she will be asked to continue on study for an additional year. Pts treated with SLNB alone, following re-consent, a long-term follow-up volumetric arm measurement will be obtained using the perometer \& circumferential arm measurements at a minimum of 2 years post-surgery.
224075744|NCT01502904|DRUG|Non-ARB /day after DES implantation|2x2 randomization by the treatment of dyslipidemia and hypertension(In patients of dyslipidemia: pitavastatin 2mg/day vs. pravastatin 20mg/day, in patients of hypertension: eporsartan 600mg/day vs. Non-ARB) and the types of the implanted DES, SES vs BES.
224075745|NCT01502904|DRUG|Eposartan 600mg/day after DES implantation|2x2 randomization by the treatment of dyslipidemia and hypertension(In patients of dyslipidemia: pitavastatin 2mg/day vs. pravastatin 20mg/day, in patients of hypertension: eporsartan 600mg/day vs. Non-ARB) and the types of the implanted DES, SES vs BES.
224075746|NCT02813772|DIETARY_SUPPLEMENT|Milk formula NAN Sensitive, Nestle|Infants randomized to group 1 will receive the milk formula NAN Sensitive, Nestle for a period of 4 weeks.
224075747|NCT02813772|DIETARY_SUPPLEMENT|Milk formula Optipro, Nestle|Infants randomized to group 1 will receive the milk formula NAN Optipro, Nestle for a period of 4 weeks.
224075748|NCT06450197|DRUG|AZD7798|AZD7798
224075749|NCT06450197|OTHER|Placebo|Placebo
224075750|NCT05574062|DEVICE|MiniMed 780G Auto Mode with G4S sensor|MiniMed™ 780G system in Auto Mode with G4S sensor.
224075751|NCT05574062|DEVICE|MiniMed 780G Manual Mode with G4S sensor|MiniMed™ 780G system in Manual Mode.
224075752|NCT05574062|DEVICE|MiniMed 780G Auto Mode with DS5 sensor|MiniMed 780G Auto Mode with DS5 sensor
224075753|NCT00368576|DRUG|SB 480848, tablets|
224075754|NCT04999579|DEVICE|T scan|Occlusal load analysis
224075755|NCT05752214|OTHER|WEB Register|Observational, non-profit, multicentre longitudinal study on the assessment of quality of life and its association with demographic variables and visual function of visually impaired patients attending the visual rehabilitation service.
224075756|NCT05615636|DRUG|Mosunetuzumab|Given by IV (vein)
224075757|NCT05615636|DRUG|Polatuzumab vedotin|Given by IV (vein)
224075758|NCT05615636|DRUG|Tafasitamab|Given by IV (vein)
224075759|NCT05615636|DRUG|Lenalidomide|Given by PO
224075760|NCT03356184|DEVICE|The Rhea Vital Sign Vigilance Device Group|The RHEA device and Philips Patient Monitor MX400 are used to monitor the heart rate (HR) and respiratory rate (RR) of participants.
224075761|NCT03356184|DEVICE|The Earlysense System Device Group|The reference device Earlysense 2.0 system(vital sign monitoring system) and Philips Patient Monitor MX400 are used to monitor the heart rate (HR) and respiratory rate (RR) of participants.
224075762|NCT06282848|DRUG|Atropine 0.05%|Topical application
224075763|NCT06282848|DEVICE|DIMS lens|Spectacle wear
224075764|NCT05986097|BEHAVIORAL|Breakfast|We will provide participants recipes and information to support this dietary change.
224075765|NCT06802393|OTHER|Intervention|The intervention incorporates a multifaceted pharmacist-led approach to addressing health-related social needs (HRSN) during transitions of care in the emergency department (ED) at Buffalo General Medical Center (BGMC). The intervention includes: 1) pharmacist-led medication reconciliation, and 2) HRSN screening using the Accountable Health Communities (AHC) HRSN tool. Based on the results, patients receive tailored referrals to community-based organizations using the 211 WNY database, which provides localized resources aligned with their social needs. Each patient is given a printed handout detailing the referral information. Within one month, a follow-up phone call is conducted to follow up with patients and assess additional needs as well as collect feedback through a patient satisfaction survey.
224075766|NCT06802393|OTHER|Control|The control arm of the study consists of a historical cohort of patients who were admitted to or discharged from the emergency department (ED) at Buffalo General Medical Center (BGMC) during the same timeframe as the intervention arm but did not receive the pharmacist-led health-related social needs (HRSN) screening or referral intervention. These patients are identified through the electronic health record (EHR) based on the same inclusion criteria as the intervention group, such as age, geographic location, and discharge disposition. Control participants are matched 1:1 with intervention participants using demographic and clinical characteristics, including age (within 5 years), zip code, insurance type, discharge status, and race. Data for the control arm include healthcare utilization metrics such as 30- and 90-day unplanned hospital readmissions and emergency department visits. The control arm serves as a comparator to evaluate the effectiveness of the intervention
224075767|NCT06323161|DRUG|Cagrilintide|Participants will receive once-weekly cagrilintide subcutaneously.
224075768|NCT06323161|DRUG|Semaglutide|Participants will receive once-weekly semaglutide subcutaneously.
224075769|NCT06323161|DRUG|Placebo|Participants will receive placebo matched to cagrilintide and semaglutide subcutaneously.
224075770|NCT04403165|PROCEDURE|Nocturnal polysomnography (NPSG)|Nocturnal polysomnography (NPSG) to measure REM sleep and sleep spindles characteristics.
224075771|NCT04403165|PROCEDURE|Lumbar Puncture (LP)|Lumbar puncture (LP) to measure CSF P-Tau, T-Tau and Aβ42/40 ratio.
224075772|NCT04403165|OTHER|PET-MR measurement with a norepinephrine transporter (NET)-selective radiotracer (S,S)-[11C]Omethylreboxetine ([11C]MRB)|PET-MR measurement with a norepinephrine transporter (NET)-selective radiotracer (S,S)-\[11C\]O-methylreboxetine (\[11C\]MRB) to measure NET availability.
224204885|NCT01222182|DRUG|atorvastatin|All patients desired to change atorvastatin 10, 20mg to an equivalent that is covered by their prescription plan. This is accomplished by either pharmacists by MD/Pharmacist practice agreement or physicians in usual practice
224204886|NCT03154931|OTHER|CBT-SG|To support the group.
224204887|NCT03154931|OTHER|CFT-G|Teach compassionate skills.
224204888|NCT04156282|PROCEDURE|knot burial technique|surgical suturing intervention
224204889|NCT04156282|PROCEDURE|classical closure|surgical suturing intervention
224204890|NCT05436301|OTHER|Pain Catastrophizing Scale|"Personal and disease-related inquiries of the participants will be recorded in the demographic registration form. To assess the validity of the Pain Catastrophizing Scale-Child (PCS-C) scale, the Pediatric Quality of Life Questionnaire (PEDSQL) 3.0 Arthritis Module, Childhood Health Assessment Questionnaire (CHAQ), and Juvenile Idiopathic Arthritis Disease Activity Score (JADAS) will be administered to the participants. In this way, the consistency of the developed scale with similar questionnaires that were previously reported to be valid will be examined. In order to determine the reliability of the Pain Catastrophizing Scale-Child (PCS-C) scale, test-retest will be performed at one week intervals for the participants whose treatment has not undergone any change. The consistency of the scale will be determined by the data of the participants who have the first and second scale scores. Interviews will be conducted by face-to-face method."
224204891|NCT01385501|OTHER|Video intervention along with educational hand out|The interventional group will be shown an 8 minute video addressing common concerns of vaccine hesitant parents. Then, they will be provided with a handout describing how to find accurate vaccine information on the internet and a handout on more common questions from vaccine hesitant parents.
224204892|NCT05137301|DEVICE|X-ray bone age instrument|Bone age films were taken by X-ray bone age instrument
224204893|NCT05005676|DIAGNOSTIC_TEST|acceleromyography|Simultaneous measurement of the time course of a neuromuscular block with 2 acceleromyographs
224204894|NCT01461369|DRUG|Diclofenac|35 mg bid Capsules
224204895|NCT01461369|DRUG|Diclofenac|35 mg tid Capsules
224204896|NCT01461369|DRUG|Placebo|Capsules
224204897|NCT05719844|DIAGNOSTIC_TEST|Neuropsychological tests|"List of neuropsychological tests:~* Matrix reasoning~* D2-R~* Coding~* Symbol search~* Digit span~* Alertness (computerized TAP battery)~* Divided Attention (computerized TAP battery)~* Go / No go (computerized TAP battery)~* Incompatibility (computerized TAP battery)~* Working memory (computerized TAP battery)~* 16-item Free and Cued Recall or Stories subtest of the Children Memory Scale (CMS) for children only (\< 17 years old)~* complex figure of the memory efficiency battery 144 or Word pairs of the Children Memory Scale for children only (\< 17 years old)"
224204898|NCT04889794|OTHER|GPS clinical intervention|Nurses and doctors in exposed FMGs and home care teams (HCTs) will be asked to refer to the FMG pharmacist all seniors undergoing cognitive evaluation OR referred to a memory clinic OR recently diagnosed with a cognitive disorder, for a complete and critical review of their medication therapy. FMG pharmacists will be asked to conduct an interview with each referred senior and his or her caregiver, if applicable, in order to establish the best possible treatment regimen. They will compare the information collected with another reliable data source (e.g., pharmacy records) in order to perform medication reconciliation and will then evaluate the medication related problems. Pharmacist will establish a care plan and the follow-ups to be carried out with the patient in collaboration with the health care team. There will be no drug or devices tested, it is a human clinical intervention by a pharmacist.
224204899|NCT02738489|BIOLOGICAL|SHR-1210|A fully human monoclonal immunoglobulin (IgG4 subtype)
224313821|NCT01196676|DRUG|AZD4451|1 mg capsules, 5 mg capsules, and 25 mg capsules
224313822|NCT01196676|DRUG|Placebo|1 mg capsules, 5 mg capsules, and 25 mg capsules
224313823|NCT00309894|BIOLOGICAL|sargramostim|
224313824|NCT00309894|DRUG|ketoconazole|
224313825|NCT00309894|DRUG|therapeutic hydrocortisone|
223511538|NCT02743858|OTHER|Body mass index (BMI)|Height and weight will be obtained for each patient at baseline and at each scheduled visit for the purpose of calculating BMI. BMI will be correlated with the presence of inflammatory biomarkers in the tissue, as well as with lymphedema development.
223511539|NCT02743858|BEHAVIORAL|Quality of Life Questionnaire|
223511540|NCT02743858|OTHER|Blood draw|Patients enrolled in the translational study (Cohort 3) will undergo blood draws for serum collection preoperatively and 12-24 months postoperatively to test for FGF2, IL4, IL10, TGFB, Leptin, IL6, and CRP. At both timepoints, up to 20 mL of blood will be collected.
223511541|NCT05270902|DEVICE|CytoSorb Adsorber|Polymer based adsorber system for the elimination of cytokines
223511542|NCT04405388|DRUG|Placebo|Placebo will be given orally as capsule (same size and weight as Spermidine capula)
223511543|NCT04405388|DRUG|Spermidine|Spermidine will be given orally as capsule (4mg/day)
223511544|NCT02805348|DRUG|Bixalomer|Oral
223511545|NCT03812172|DRUG|99mTc-PYP or 99m Tc-HDP|10-25 mCi of 99mTc-PYP (or 99m Tc-HDP) will be administered intravenously and imaging will be performed after 3 hours.
224204900|NCT04209244|DIETARY_SUPPLEMENT|Eskimo-3 Pure Fish Oil|Dosage: 10 ml/day (2.6 g EPA+DHA)
224204901|NCT04209244|DIETARY_SUPPLEMENT|Rapeseed Oil|Dosage: 10 ml/day (0 g EPA+DHA)
224204902|NCT01247974|DEVICE|CorMatrix ECM for Pericardial Closure|Circumferential closure of the pericardium following CABG surgery using the CorMatrix ECM for Pericardial Closure
224204903|NCT00364273|DRUG|GSK159802|GSK159802 will be available with dosing strengths of 75 microgram per blister and 300 microgram per blister administered using DISKUS inhaler.
224204904|NCT00364273|DRUG|Placebo|Subjects will receive placebo administered using DISKUS inhaler.
224204905|NCT00364273|DRUG|Salmeterol|Salmeterol will be available with dosing strength of 50 micrograms per blister administered using DISKUS inhaler.
224204906|NCT04144231|BEHAVIORAL|iCBT-I|Internet-Based Cognitive Behavioral Therapy for Insomnia (ICBT-I) with the support of a therapist, delivered by mobile application (HUS iCBT-I)
224204907|NCT04144231|BEHAVIORAL|GCBT-I|Cognitive Behavioral Group Therapy for Insomnia (GCBT-I)
224313826|NCT02001831|DIETARY_SUPPLEMENT|Supplement|
224313827|NCT02001831|DIETARY_SUPPLEMENT|Placebo|
223617454|NCT06921252|DRUG|chemotherapy agents|Overall, data of 276 patients (144 men and 132 women, 224 Rec-PC and 51 PM-PC) were retrospectively analyzed. The median patient age was 70 (range; 29-91) years. Serum carbohydrate antigen (CA) 19-9 among Rec-PC group (median; 207 U/mL) and PM-PC group (median; 1680 U/mL) was statistically different. Rec-PC patients received gemcitabine plus nab-paclitaxel (106), S-1 (37), gemcitabine (22), FOLRIFINOX (18) and other (8) regimen as a first line chemotherapy. 67 Rec-PC patients underwent any local treatment. PM-PC patients received gemcitabine plus nab-paclitaxel (34), FOLRIFINOX (8), gemcitabine (5), S-1 (2) and other (2) regimen as a first line chemotherapy.
223617455|NCT05688696|DRUG|Orelabrutinib (Low Dose)|Subjects will be administered with lower dose of Orelabrutinib orally once daily in combination with SOC therapy
224204908|NCT03569566|OTHER|Age, Genes, Training, Tickbourne Disease and Endurance|Testing of genes, exosomes, physiological variables, tick-bourne disease markers, observation of training modality and performance
223617456|NCT05688696|DRUG|Orelabrutinib (High Dose)|Subjects will be administered with higher dose of Orelabrutinib orally once daily in combination with SOC therapy
223617457|NCT05688696|DRUG|Orelabrutinib Placebo|Subjects will be administered with Orelabrutinib Placebo orally once daily in combination with SOC therapy
223617458|NCT06920927|OTHER|Decision aid|Decision aid for use by physicians and patients with CKD when deciding upon an invasive vs a conservative approach to management of coronary artery disease.
223617459|NCT06921889|PROCEDURE|Autologous Chondrocyte Implantation (ACI)|ACI is a two-stage process that utilises the patient's own chondrocytes to repair damaged chondral tissue. After a harvesting procedure to obtain the cells, the chondrocytes are cultured and expanded in a specialised laboratory. A second procedure is then performed to implant the cells into the defect to replace and regenerate the injured cartilage. ACI allows the knee to generate durable and hyaline-like repair tissue.
223617460|NCT06922201|OTHER|SmartCoach|Participants will receive a tailored life-skills training program over four months, which includes 2-4 personalized messages per week via Whatsapp. These messages, in the form of microdialogues generated by an automated system, will focus on self-management skills, social skills and substance use resistance skills. The program will use interactive elements such as quiz questions, behavioural plans, message contests and multimedia content (audio testimonials, motivational podcasts, videos, images and links to relevant websites).
223617461|NCT06919601|BEHAVIORAL|Grief-Informed Healing Circles|Eight one-hour sessions delivered in a group setting
223617462|NCT06921629|OTHER|Menstruatie Educatie Kalender (Menstrution Education Calendar) application (MEK-app)|The MEK-APP is a mHealth application to evaluate menstrual complaints like heavy menstrual blood loss and dysmenorrhea. The MEK-APP is a calendar and facilitates daily monitoring of pain intensity using a Visual Analogue Scale (VAS), the amount of blood loss through a pictorial blood loss assessment chart (PBAC), and the impact of these complaints on daily life. The MEK-APP followed the waterfall methodology for software development and the usability was evaluated by both adults and adolescents(4). Furthermore, the MEK app has been approved by the privacy and security officers of Amsterdam UMC
224075773|NCT04403165|BEHAVIORAL|Psychomotor Vigilance Task (PVT)|Psychomotor vigilance task (PVT) and the OddBall to measure test taskattention performance.
224075774|NCT04278131|DRUG|BS01|Non-replicating, rep/cap-deleted, recombinant adeno-associated virus vector expressing an enhanced light-sensitive channelrhodopsin gene (ChronosFP)
224075775|NCT05953337|DEVICE|EYE90 Microspheres Treatment|Y90 glass microspheres
224075776|NCT05401617|OTHER|additional information via the computerized tool|additional information delivered via the computerized tool
224075777|NCT03949972|OTHER|Biosampling|Biosampling at initial visit and follow-up visits
224075778|NCT06134492|DRUG|Acyclovir|"Dosage: 10mg/kg (current) body weight every 8 hours, dose adjustment to renal function according to technical information.~Mode of administration: intravenous (i.v.)"
224075779|NCT06567015|DRUG|STX-241|"Film-coated tablet~Route of administration: Oral"
224075780|NCT01777581|DRUG|Milnacipran|
224075781|NCT01777581|DRUG|Placebo|
224075782|NCT01211600|OTHER|Staples|Interrupted Ethicon Staples
224075783|NCT01211600|OTHER|Suture|Subcuticular continuous suture (4-0 Monocryl Plus on PS2 needle or 4-0 Vicryl Plus on FS2 or PS2 needle)
224075784|NCT04906668|PROCEDURE|Cryoballoon pulmonary-vein isolation|Electrical isolation of the pulmonary-veins using cryoenergy
224075785|NCT04906668|PROCEDURE|Pacemaker implantation and ablation of atrioventricular-node|Pacemaker implantation and ablation of atrioventricular-node
224075786|NCT06386887|BEHAVIORAL|Intermittent Fasting|Intermittent fasting (IF) also known as time restricted eating regimen consisting of 16 hours of fasting and 8 hours of ad libitum feeding for 5 days followed by ad libitum feeding for 2 days has been proposed. With this type of intervention, there are no dietary restrictions to the type or quality of food and it decreased daily energy intake by 20%. Participants will be asked to follow an IF schedule consisting of 16 hour of continuous fasting per day for 5 days a week. This will be started 2 days prior to chemotherapy (cycle 2).
224075787|NCT06386887|DRUG|Neoadjuvant chemotherapy|Chemotherapy will be given as standard treatment every 3 weeks (21 days) and continue for 3 to 4 cycles per routine care. As chemotherapy is not part of this research study, participants will begin standard chemotherapy as decided by their physician.
224075788|NCT05721482|BEHAVIORAL|Caregiver Training|"A trained MIM provider and dietitian will deliver the MIM DASH group intervention in eight weekly 1-hour sessions via telehealth. Participants will receive session materials so they can follow along. Each MIM session consists of material related to mindfulness-the somatic mind/body connection, relaxation, yoga, meditation, self-awareness, and bodily cues relating to emotional reactivity. Group interaction centers on sharing ideas toward effective practice and practical daily challenges to being mindful. Each class begins with a prompt for participant contemplation during the next hour that reference a unique weekly theme which will be reiterated in the session materials.~The DASH portion, led by the Registered Dietitian, focuses on education to increase vegetables, fruits, whole grains and decrease intakes of fat and sodium, sugar sweetened beverages and sweets. Education includes adapting traditional Soul food dishes to meet the DASH dietary guidelines."
224075789|NCT06182579|DRUG|RiMO-401|• Single intratumoral injection of RiMO-401 followed by palliative radiotherapy
224075790|NCT06152731|GENETIC|tests to determine HRD status|"Test Giscar AND test myChoice will be performed.~If one or two tests identifies a HRD status :~a PARP inhibitor treatment may be initiated according to current recommendations"
223617463|NCT06921629|OTHER|Questionnaires|"After registration for this study via www.mijnmenstruatie.nl (which has also been approved by the privacy and security officers of Amsterdam UMC), participants received the first digital questionnaire. This questionnaire consisted of a baseline questionnaire, the electronic self bleeding assessment tool (e-self-BATH) and the Menstrual Health Literacy questionnaire.~After using the MEK-app for at least one month, participants received an e-mail with the second questionnaire. This questionnaire consisted of the Menstrual Bleeding Questionnaire; Period ImPact and Pain Assesment; Pelvic Pain Impact Questionnaire; ENDOPAIN-4D; Endometriosis Health Profile 5 and iMTA Productivity Cost Questionnaire."
223617464|NCT06922253|DRUG|Sacubitril and Valsartan-Test product|1 tablet of 97 mg Sacubitril / 103 mg Valsartan
223617465|NCT06922253|DRUG|Sacubitril and Valsartan-Reference product|1 tablet of 97 mg Sacubitril / 103 mg Valsartan
223617466|NCT06921369|OTHER|Compassionate Care Education Level|Compassionate Care Education Level
224204909|NCT01031225|DRUG|STA 9090|STA-9090 IV infusion once per week for three consecutive weeks followed by a 1 week dose-free interval
224204910|NCT02764073|DEVICE|Bioimpedance spectroscopy|The technique involves attaching electrodes to the patient's forearm and ipsilateral ankle, with the patient in a supine position. The BCM® measures the body resistance and reactance to electrical currents of 50 discrete frequencies, ranging between 5 and 1000 kHz. Based on a fluid model using these resistances, the extracellular water (ECW), the intracellular water (ICW) and the total body water (TBW) are calculated. All calculations are automatically performed by the software of the BCM® device. Absolute fluid overload (AFO) is is defined as the difference between the expected patient's ECW under normal physiological conditions and the actual ECW, whereas the relative fluid overload (RFO) is defined as the absolute fluid overload AFO to ECW ratio.
224204911|NCT02764073|DEVICE|Lung Ultrasonography|Examinations will be performed in the supine position. Scanning of the anterior and lateral chest will be performed on both sides of the chest, from the second to the fourth (on the right side to the fifth) intercostal spaces, at parasternal to mid-axillary lines. B-lines will be recorded in each intercostal space and were defined as a hyperechoic, coherent US bundle at narrow basis going from the transducer to the limit of the screen. B-lines starting from the pleural line can be either localized or scattered to the whole lung and be present as isolated or multiple artifacts (with a distance 7 mm between 2 artifacts). The sum of B-lines produces a score reflecting the extent of lung water accumulation (0 being no detectable B-line).
224204912|NCT02764073|DEVICE|Echocardiography|All echocardiographic measurements will be carried out according to the recommendations of the American Society of Echocardiography by an observer unaware of the lung ultrasound and bioimpedance results. Echocardiographic evaluation will provide information about cardiac anatomy (e.g. volumes, geometry, mass) and function (e.g. left ventricular function and wall motion, valvular function, right ventricular function, pulmonary artery pressure, pericardium).
224204913|NCT01103401|DRUG|Drug: Tobramycin 0.3% - Dexamethasone 0.1%|one drop four times per day
224204914|NCT01103401|DRUG|Drug: Tobramycin-Dexamethasone plus Ketorolac tromethamine|Tobramycin-Dexamethasone one drop four times per day and Ketorolac tromethamine one drop three times per day
224204915|NCT02228369|DRUG|AZD3759|Starting dose 50 mg, administered twice daily. If tolerated subsequent cohorts will test increasing doses of AZD3759, until a maximum tolerated dose or an effective dose is defined
224204916|NCT02228369|DRUG|AZD9291|AZD9291 160mg once daily
224204917|NCT03628001|PROCEDURE|ERCP|Pts will be randomized with or without sphinterectomy.
224204918|NCT02962739|DRUG|emtricitabine 200 mg/tenofovir alafenamide 25mg|1 tablet of Descovy contains emtricitabine 200 mg/tenofovir alafenamide 25mg
224204919|NCT00734617|DRUG|Nicotine Patch|"Groups 1 \& 3 1-21mg Nicotine patch and 1-placebo for 2 wks pre quit day and 4 wks post quit day~Groups 2 \& 4 2-21mg Nicotine Patches for 2 wks pre quit day and 4 wks post quit day"
224204920|NCT02125617|DRUG|Abiraterone|1000 mg/day
224204921|NCT02125617|DRUG|Prednisolone|10 mg/day
224204922|NCT06257186|OTHER|Art Therapy|Participants assigned to the Intervention (Art Therapy) arm will be offered a series of three to five art therapy sessions, depending on the participants' needs/preferences. The art therapy sessions will be given anytime after consent has been obtained till approximately 36 weeks of gestation. The Art Therapy is given in addition to routine antenatal care.
224204923|NCT05399186|OTHER|Early preoperative assessment and optimization|The interventional group received early preoperative assessment and optimization (6-12 months) prior to total joint arthroplastic surgery in cooperation between hospital and primary care
224204924|NCT02803190|BEHAVIORAL|ICG|All participants received a CD-ROM and one hour education on osteoporosis, sarcopenia, frailty, fall prevention, nutrition, low back pain, good posture, and coping strategy and another hour of professional led exercise program with focus on central muscle groups. ICG subjects received once weekly group exercise.
223511546|NCT05680636|DIAGNOSTIC_TEST|temperature measurement|Differential Leg Skin Temperature Measured With Handheld Low-cost Infrared Thermometers.
223511547|NCT03004183|BIOLOGICAL|ADV/HSV-tk|Replication-defective recombinant adenovirus vector
223511548|NCT03004183|DRUG|Valacyclovir|Prodrug of the antiviral drug acyclovir
223511549|NCT03004183|RADIATION|SBRT|Low-dose SBRT
223511550|NCT03004183|DRUG|Pembrolizumab|Humanized immunoglobulin G4 anti-programmed death-1 (PD-1) monoclonal antibody
223511551|NCT04964466|BIOLOGICAL|Amount of PDGF-BB in PRF preparation vs. GEM21|The quantification will be performed at 60 minutes, 8 hours, 1 day, 3 days, and 10 days. The samples will each be placed in a cell incubator at 37°C to allow for growth factor release into a phosphate-buffered saline. At each desired time point assessment, 2 ml of the sample will be collected, frozen, and replaced with 2 ml of additional phosphate-buffered saline. The protein quantification will be carried out using ELISA assay according to manufacturer's protocol.
223617467|NCT06921369|OTHER|Question Form Created for Nurses' Compassionate Care Attitudes|Question Form Created for Nurses' Compassionate Care Attitudes
223617468|NCT06921369|OTHER|Nurse Opinion Form on Compassionate Care Education to be Given According to Watson's Human Caring Model|Nurse Opinion Form on Compassionate Care Education to be Given According to Watson's Human Caring Model
223617469|NCT05579977|DRUG|PF-07081532|Oral glucagon-like peptide-1 receptor agonist
223617470|NCT05579977|OTHER|Placebo|No drug
223617471|NCT05579977|DRUG|Rybelsus|Oral Semaglutide
224204925|NCT02803190|BEHAVIORAL|MTG|All participants received a CD-ROM and one hour education on osteoporosis, sarcopenia, frailty, fall prevention, nutrition, low back pain, good posture, and coping strategy and another hour of professional led exercise program on central muscle groups. MTG subjects received twice weekly machine-based resistance training on major and central muscle groups.
224204926|NCT02686710|DRUG|Sevoflurane|
224204927|NCT02686710|DRUG|Propofol|
224204928|NCT02515981|BEHAVIORAL|NH Medicaid Incentives Program|
224204929|NCT00881595|DRUG|Chemoradiotherapy Temozolomide|Temozolomide: 75 mg/m2 five days per week during radiotherapy for 5 weeks.Temozolomide: 75 mg/m2 five days per week during radiotherapy for 5 weeks. Temozolomide should be taken orally 1 hour before each session of radiotherapy during weekdays (Monday through Friday). The dose will be determined using the body surface area (BSA) calculated at the beginning of the concurrent treatment. The BSA will be calculated from the height obtained at the pretreatment visit and the weight obtained before the first day of treatment. The concurrent treatment will last until the end of radiotherapy.
224204930|NCT00881595|RADIATION|Proton therapy|50 cobalt gray equivalent(CGE), 25 daily fractions, 5 weeks (2 CGE/fx)
224204931|NCT00881595|PROCEDURE|Proton Chemoradiotherapy followed by surgery|Proton Chemoradiotherapy followed by surgery. Resection of tumor at 4-6 weeks post-treatment.
224204932|NCT01293318|OTHER|No intervention|No intervention
224204933|NCT02029313|DRUG|Montelukast|
224204934|NCT02029313|DRUG|Montelukast sodium|
224204935|NCT01398449|RADIATION|Elective nodal irradiation (ENI)|
224204936|NCT01398449|OTHER|Adjuvant chemotherapy only|
224204937|NCT03849079|OTHER|Hyponut|Prick tests with hyponut
224204938|NCT01778452|PROCEDURE|endometrial biopsy|endometrial biopsy
224204939|NCT02406742|DRUG|CC-122|CC-122 will be administered daily starting at Cycle 1 Day 1 in 28-day cycles until disease progression, unacceptable toxicity, or discontinuation for any other reason.
224204940|NCT02406742|DRUG|Ibrutinib|
224204941|NCT02406742|DRUG|Obinutuzumab|Obinutuzumab will be administered as an intravenous (IV) infusion at a dose of 100 mg on Cycle 1 Day 1 and 900 mg on Cycle 1 Day 2 and 1000 mg on Cycle 1 Days 8 and 15. The dose of obinutuzumab on Days 1 and 2 of Cycle 1 may be adjusted per institutional practice as long as the combined dose equals 1000 mg. Obinutuzumab will be administered at a dose of 1000 mg on Day 1 of Cycles 2 through 6.
224204942|NCT00053599|DRUG|Simvastatin|
224204943|NCT03816956|DRUG|AR-301|AR-301 (tosatoxumab) 20 mg/kg administered once intravenously the day of enrolment.
224204944|NCT03816956|OTHER|Placebo|Placebo comparator
224204945|NCT03319693|GENETIC|Somatic Genetic|NGS analysis
224204946|NCT03797573|DEVICE|tDCS|tDCS will be applied during 20 minutes with a current of 1 mA preceded and followed by a behavioral assessments (Modified Ashworth Scale and Coma Recovery Scale Revised) and an EEG. The anodes will be placed over F3 and F4 and the cathodes over C3 and C4.
224204947|NCT03797573|DEVICE|sham tDCS|Indentical to the active tDCS, except that the stimulation is terminated after 5 seconds.
224204948|NCT02367729|DEVICE|Neurostimulator|Non-invasive, battery operated neurostimulator of the external ear worn for 5 days each week x 4 weeks.
224204949|NCT02367729|DEVICE|Sham|Inactive neurostimulator device pre-programmed to be inactive. To be worn for 5 days each week x 4 weeks.
224204950|NCT01208168|DRUG|NAB001|nail lacquer, once daily, 52 weeks
224204951|NCT01208168|DRUG|Vehicle alone|nail lacquer, once daily, 52 weeks
224204952|NCT00438932|DRUG|Lanthanum Carbonate|Lanthanum carbonate 1000mg 3x/day
224204953|NCT00438932|DIETARY_SUPPLEMENT|Low Phosphorus Diet|Low phosphorus diet will consist of 800 mg of phosphorus per day.
224204954|NCT00438932|DIETARY_SUPPLEMENT|Unrestricted Phosphorus Diet|Unrestricted diet will contain 1550 mg of phosphorus per day - 800 mg of which is dietary and 750mg of Neutraphos (3 packets/day); each packet is 250mg.
224204955|NCT00438932|DRUG|Placebo|Lanthanum Carbonate placebo given three times a day with meals.
224204956|NCT02301962|DRUG|Panitumumab|Panitumumab is available as a concentrate for solution for infusion (sterile concentrate). It is a colorless solution that may contain, translucent to white, visible amorphous, proteinaceous panitumumab particles. Each milliliter (mL) of concentrate contains 20 mg panitumumab. Each vial contains 100 mg of panitumumab in 5 mL.
224204957|NCT02077660|DIETARY_SUPPLEMENT|Four green tea bags per day for 12 weeks|Four green tea bags per day for 12 weeks
224204958|NCT02077660|OTHER|4 daily placebo tea bags for 12 weeks|4 daily placebo tea bags for 12 weeks
224204959|NCT00400426|PROCEDURE|Radiotherapy|20 Gy in 4 fx
224204960|NCT00354731|DRUG|pentoxifylline|Oral pentoxifylline 1,200 mg/day (for estimated GFR ≧60 ml/min) or 800 mg/day (estimated GFR 59-30 ml/min) x 6 months, followed by stepwise reduction (800 mg/day x 6 M, 400 mg/day x 6 M and discontinued at 18 M
224204961|NCT00354731|DRUG|Corticosteroid|Oral prednisolone (1 mg/kg/day) x 3 M, followed by gradual tapering (0.5 mg/kg/day at 6 M, 0.25 mg/day at 12 M, and discontinued at 18 M
224204962|NCT02585973|DRUG|AZD1775|AZD1775 given twice daily (BID) for three consecutive days (M-W) concomitantly with standard of care cisplatin and radiation. AZD1775 doses will be escalated in 50 mg increments up to 200 mg BID (M-W) in subsequent cohorts to determine the MTD.
224204963|NCT02585973|DRUG|Cisplatin|40 mg/m2 IV infused over 1 hour D1 of each week of radiation
224204964|NCT02585973|RADIATION|Intensity Modulated Radiotherapy Treatments|Total dose will be 70 Gy at 2Gy/fx, 35 fractions, M to Fri, for 7 weeks
224204965|NCT00759174|DRUG|No intervention|No intervention occurs in this observational study.
224204966|NCT01890109|BIOLOGICAL|Erenumab|Administered via subcutaneous injection.
224204967|NCT01890109|DRUG|Placebo|Administered via subcutaneous injection
223617472|NCT06665438|DRUG|Normal Saline (Placebo)|the 18 ml of normal saline will injected intra articular in the knee joint by the surgeon through the arthroscope after completing the procedure
223617473|NCT06665438|DRUG|Bupivacaine 0.25%|the 18ml 0.25% bupivacaine. will injected intra articular in the knee joint by the surgeon through the arthroscope after completing the procedure
223617474|NCT06665438|DRUG|Dexmedetomidine|Dexmedetomidine 1 μg/kg will injected intra articular in the knee joint by the surgeon through the arthroscope after completing the procedure.
223617475|NCT06151522|DRUG|Alpha-Agonist|An initial infusion dose of prophylactic phenylephrine (0.625 ug/kg/min) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 0.125 ug/kg/min of prophylactic phenylephrine according to the responses of previous patients according to the up-down sequential allocation.
223617476|NCT06151522|DRUG|α-adrenergic receptor agonist|An initial infusion dose of prophylactic phenylephrine (0.625 ug/kg/min) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 0.125 ug/kg/min of prophylactic phenylephrine according to the responses of previous patients according to the up-down sequential allocation.
223617477|NCT06939296|DRUG|VCT220|A small molecule GLP-1R drug, film coated tablet
224204968|NCT04546737|OTHER|Magnetic Resonance Spectroscopy (MRS).|This is a Nuclear Magnetic Resonance (NMR) technique which can detect the NMR signal allowing to measure under curves areas, amplitudes, ratios and concentrations of various metabolites contained in a biological tissue, in addition to water and lipids. This offers the possibility, in addition to the contribution of MRI imaging, to better characterize pathological processes (inflammatory, infectious, etc.) through spectral and metabolic changes that can be quantitatively evaluated. Spectroscopic measurements will be carried out with a mono-voxel spectroscopy using a PRESS \[Point RESolved Spectroscopy\] sequence with a short Echo Time (TE) of 35 ms, an intermediate TE of 144 ms and a long TE of 288 ms.
224204969|NCT01638637|DEVICE|APTIMA Assays; PANTHER System|APTIMA Assays; PANTHER System
224204970|NCT01643928|BIOLOGICAL|Rituximab-Pfizer (PF-05280586) x 3 courses|1000 mg intravenous infusion \[IV\] on Days 1 and 15 of each 24 week treatment course for up to 3 treatment courses
224204971|NCT01643928|BIOLOGICAL|Rituximab-EU+ Rituximab-Pfizer x 2 Courses|Subjects will receive Rituximab-EU x 1 course followed by Rituximab-Pfizer x 2 courses. 1000 mg IV infusion of Rituximab-EU on Days 1 and 15 of a 24 week treatment course followed by 1000 mg IV infusion of PF-05280586 on Days 1 and 15 of each 24 week course for up to 2 additional treatment courses
224204972|NCT01643928|BIOLOGICAL|Rituximab-US + Rituximab-Pfizer x 2 Courses|Subjects will receive Rituximab-US x 1 course followed by Rituximab-Pfizer x 2 courses. 1000 mg IV infusion of Rituximab-US on Days 1 and 15 of a 24 week treatment course followed by 1000 mg IV infusion of PF-05280586 on Days 1 and 15 of each 24 week course for up to 2 additional treatment courses
224204973|NCT00999245|OTHER|High Demand / Low Infusion|HDLI dosing plan will administer either morphine or hydromorphone using PCA. Dosing will be based on body weight.
224204974|NCT00999245|OTHER|PCA Dosing Plan|LDHI dosing plan will administer either morphine ot hydromorphone using PCA. Dosing will be based on body weight.
224204975|NCT00053027|BIOLOGICAL|rituximab|
224204976|NCT00053027|DRUG|cladribine|
224204977|NCT05652894|DRUG|HX008|Drug: HX008 200 mg ,Q3W
224204978|NCT05652894|DRUG|Investigator's Choice Chemotherapy|"Drug: bevacizumab 5mg/kg given by IV every 14 days. Other Name: Avastin~Drug: cetuximab 400 mg/sqm initial dose, then 250 mg/sqm once weekly thereafter. Other Name: Erbitux~Drug: oxaliplatin 8 5 mg/sqm by IV, day1. Component of mFOLFOX6.~Drug: irinotecan 180 mg/sqm by IV, day1.Component of FOLFORI.~Drug: calcium Folinate 400 mg/sqm by IV, day1.Component of mFOLFOX6 or FOLFORI.~Drug: 5-fluorouracil 400 mg/sqm, day1,followed by 2400 mg/sqm iv infusion over 46\~48 h.Component of mFOLFOX6 or FOLFORI."
224204979|NCT05335473|DRUG|Eribulin and Tucidinostat|phase 1b： 3+3 trial design will be used for Tucidinostat dose escalation cohorts phase 2: Eribulin+Tucidinostat
224204980|NCT02532140|DRUG|WCK 5107 250 mg to 2000 mg|
224204981|NCT02532140|DRUG|Cefepime 2000 mg|
224204982|NCT02532140|DRUG|WCK 5107 1000/2000 mg with Cefepime 2000 mg combination|
224204983|NCT02532140|DRUG|Placebo|
224204984|NCT02700074|OTHER|No Intervention|Intervention is not a part of this study.
224204985|NCT03701490|DRUG|Progesterone subcutaneous|25 mg/twice a day.
224204986|NCT03701490|DRUG|Progesterone Vaginal Product|200 mg three times a day.
224204987|NCT04118855|DRUG|Toripalimab|240mg, IV (in the vein) on on day 1 of 3-week, 6-week and 9-week for a total of 3 doses prior to partial nephrectomy or radical nephrectomy
224204988|NCT04118855|DRUG|Axitinib|5 mg by mouth twice each day for 12 weeks prior to nephrectomy
224204989|NCT01097850|DRUG|henna paste|Henna paste will be applied to either the left hand/foot or right hand/foot, along with CeraVe moisturizer to both hands/feet
224204990|NCT04434638|OTHER|Transitions of Care Coordinator|We developed the Transition of Care Coordinator (TOCC) program to aid in the completion of the diagnostic evaluations as well as in the transition out of the acute care hospital setting. In the TOCC intervention, the stroke nurse navigator completed eight specific tasks: (1) met the patient and family within 48 hours of admission, (2) identified patient home location and insurance status, (3) coordinated communication between treating providers (neurologists, cardiologists, etc.) regarding pending diagnostic tests, (4) followed up physical, occupational, and speech therapy teams' recommendations for rehabilitation, (5) attended daily multi-disciplinary rounds, (6) facilitated referrals to acute and subacute rehabilitation facilities with case managers, (7) assisted beside nurses in providing tailored stroke education and discharge instructions to patients and families, and (8) arranged stroke clinic follow-up appointments.
224204991|NCT04434638|OTHER|Usual Care|Patients received the current, ongoing method of care coordination by members of the multi-disciplinary stroke team. The current practice is that members of this multi-disciplinary team meet with each other every weekday morning to discuss the discharge plan of care for each stroke patient on the inpatient stroke service. Physicians, nurses, rehabilitation therapists and case managers are then individually responsible for talking to patients and their families/caregivers about the different aspects of the plan of care.
224204992|NCT01318200|PROCEDURE|Transarterial Chemoembolization|Transarterial Chemoembolization will be given within 12 weeks and up to 3 staged procedures, depending on the architecture of the tumor vasculature.
224204993|NCT01318200|RADIATION|CyberKnife SBRT|Dose is 45 Gy (15 Gy in 3 fractions) or 36 Gy(12 Gy in 3 fractions). Tumors should receive the higher dose unless normal tissue constraints cannot be met.
224204994|NCT00415142|DRUG|saredutant (SR48968)|oral administration (capsules)
223617478|NCT06939296|DRUG|Placebo|Placebo tablets
224204995|NCT00415142|DRUG|placebo|oral administration (capsules)
224204996|NCT00415142|DRUG|escitalopram|oral administration (capsules)
223617479|NCT06938841|DEVICE|Transcranial Magnetic Stimulation (TMS) - Standard maintenance rTMS:|In this approach, patients who were treated with rTMS five days per week during their acute episode receive less frequent treatments during a taper period (for example treatment three days per week followed by two sessions per week) with a gradual transition into a maintenance schedule. For example, the maintenance schedule might begin with a single weekly session for one or two months and then the intensity is reduced to one session every two weeks (and possibly then one session every three or four weeks).
223761354|NCT01416168|OTHER|McCorkle Model Intervention|The intervention will consist each week in a home visit and a phone call. The GNP conducting the home visit will identify current problems using a comprehensive geriatric assessment (CGA) and record problems on the Intervention and Recommendation Data Sheet. In addition, the cases will be reviewed at a weekly Intervention Team meeting between the intervention GNP (VM, CV), the geriatrician (VP), and the intervention PI (JO). That team meeting will also record how intervention goals for the various problems are met, using the instruments and criteria developed during our pilot study5. To ensure optimal consistency and an up-to-date evidence-based approach over the 4 years of the intervention, treatment recommendations will be offered according to national evidence-based treatment guidelines.
223761358|NCT00004918|BIOLOGICAL|PR1 leukemia peptide vaccine|Given SC
223761359|NCT00004918|DRUG|Montanide ISA 51 VG|Given SC
223761360|NCT00004918|BIOLOGICAL|sargramostim|Given SC
223761361|NCT00004918|OTHER|laboratory biomarker analysis|Correlative studies
223761362|NCT01358617|OTHER|diagnostic laboratory biomarker analysis|Correlative studies
223761363|NCT02957175|OTHER|Immunophenotyping|Multiplex assays for screening pro- and anti-inflammatory markers and RNA will be analysed using a next generation sequencing approach
223761364|NCT04436523|DEVICE|Blood flow restriction (Delfi Personalized Tourniquet System)|The Delfi Personalized Tourniquet System will be utilized to apply the blood flow restriction protocol.
224204997|NCT03801759|DRUG|Vadadustat|Oral dose 600 mg
224204998|NCT03801759|DRUG|Furosemide|Oral Furosemide
224204999|NCT03801759|DRUG|Adefovir|Oral Adefovir
224205000|NCT03801759|DRUG|Digoxin|Oral Digoxin
224205001|NCT05741775|OTHER|Aerobic training|The warm-up exercise will include light aerobic activity and some dynamic stretching movements. Similarly, the cool down exercises will include buttock stretch, hamstring stretch, inner thigh stretch, calf stretch and thigh stretch. Each stretch to be performed for 5 repetitions with a hold time of 15 seconds for each. An elastic band secured around the head will be used to apply local pressure over the area. Kettler Computeranleitung Advanced display will be used to train static cycling. ProAction BH Treadmill G6700 instrument will be used for aerobic training.
224205002|NCT05741775|OTHER|Biofeedback Training|Neurotrac myoplus 4 pro instrument will be used for EMG biofeedback training.
224205003|NCT06058507|DIAGNOSTIC_TEST|CT angiography|No intervention was made
224205004|NCT01188005|DEVICE|n-CPAP|administration of continuous positive airway pressure through a nasal device
224205005|NCT01188005|DEVICE|Oxygen supplementation|Oxygen supplementation (3L) through nasal spectacles
224205006|NCT01188005|DRUG|Vitamin A, Vitamin C, Vitamin E, Allopurinol, N-Acetylcysteine|Vitamin A 50,000 IU, Vitamin C 1000 mg , Vitamin E 200 mg, Allopurinol 600 mg, N-Acetylcysteine 2 g. Duration is set for 60 days
224205007|NCT00850005|BIOLOGICAL|Intravenous immunoglobulin|2 g/kg divided over five days
224205008|NCT00850005|BIOLOGICAL|Normal Saline|Same volume as experimental arm
224205009|NCT04160676|DRUG|Hydrocortisone, Ascorbic acid, Thiamine|Combination of hydrocortisone, ascorbic acid, and thiamine
224205010|NCT04160676|DRUG|Normal saline|Normal saline
224205011|NCT03692078|OTHER|OTDN product 1|Oral tobacco-derived nicotine product
224205012|NCT03692078|OTHER|OTDN product 2|Oral tobacco-derived nicotine product
224205013|NCT03692078|OTHER|Tobacco Cessation|Tobacco Cessation
224205014|NCT03620773|DRUG|Aminohippurate Sodium Inj 20%|Diagnostic aid/agent used to measure effective renal plasma flow (ERPF)
224205015|NCT03620773|DRUG|Iohexol Inj 300 mg/mL|Diagnostic aid/agent used to measure glomerular filtration rate (GFR)
224205016|NCT03620773|PROCEDURE|Vertical Sleeve Gastrectomy|Participants will undergo vertical sleeve gastrectomy surgery, a laparoscopic bariatric surgery procedure designed for weight loss in obese patients
224205017|NCT03620773|PROCEDURE|Renal Biopsy|Minimally invasive outpatient procedure in interventional radiology to obtain renal tissue cores.
224205018|NCT03358342|OTHER|ePneumonia CDS|ePneumonia clinical decision support system for community-onset pneumonia
224205019|NCT01979588|OTHER|What's Going Around tool|Provider has access to the What's Going Around tool
224205020|NCT01979588|OTHER|Control|Provider does not have access to the What's Going Around tool but received information regarding the tool prior to study initiation
224205021|NCT05038410|DRUG|Wobenzym®|Wobenzym®
224205022|NCT05038410|OTHER|Placebo|Microcrystalline cellulose
224205023|NCT04645732|BEHAVIORAL|Personalized exercise therapy and self-management support program|See description under Arms
224205024|NCT04645732|OTHER|Usual care|See description under Arms
224205025|NCT06102824|DRUG|Organoid-guided treatment|The drugs predicted to be the most sensitive through organoid drug sensitivity screening. The drugs selected for sensitivity screening are from the following options: taxane, anthracycline, 5-fluorouracil, gemcitabine, vinorelbine, eribulin, utidelone, carboplatin, sacituzumab govitecan, and trastuzumab deruxtecan (for HER2-low patients).
224205026|NCT06102824|DRUG|Taxane|Albumin-bound paclitaxel 260mg/m2, IV, q3w, or 100-125mg/m2, IV, days 1, 8, and 15, q4w OR Liposomal paclitaxel 175mg/m2, IV, q3w
224205027|NCT06102824|DRUG|Capecitabine|1000-1250mg/m2, PO, bid, days1-14, q3w
224205028|NCT06102824|DRUG|Gemcitabine|800-1200mg/m2, IV, days 1, 8, q3w
224205029|NCT06102824|DRUG|Vinorelbine|20-35mg/m2, IV, days 1 and 8, q3w
224205030|NCT06102824|DRUG|Eribulin|1.4mg/m2, IV, days 1 and 8, q3w
224205031|NCT06102824|DRUG|Anthracycline|Liposomal doxorubicin 50mg/m2, IV, q3w OR Liposomal doxorubicin 40mg/m2+Cyclophosphamide 600mg/m2, IV, q3w
224205032|NCT06102824|DRUG|Carboplatin|Carboplatin AUC 6, IV, q3w or q4w OR Carboplatin AUC 2+Gemcitabine 1000mg/m2, IV, days 1 and 8, q3w OR Carboplatin AUC 2+Albumin-bound paclitaxel 125mg/m2, IV, days 1 and 8, q3w
223511552|NCT04964466|BIOLOGICAL|Amount of PDGF-BB available in PRF + bone substitutes vs. rhPDGF-BB+ bone substitutes following preparation|Growth factor release assessments will be made to determine the PDGF-BB present in the six prepared samples of the following: 1) PRF + mineralized freeze-dried corticocancellous allograft, 2) PRF + xenograft, and 3) PRF + B-TCP. Assessments will also be made for one sample of each of the following: 1) rhPDGF-BB + freeze-dried bone allograft, 2) rhPDGF-BB + xenograft, and 3) rhPDGF-BB+ B-TCP preparation. This assessment will be made at 60 minutes following the incorporation of the bone graft materials. During this time period, the samples will each be placed in a cell incubator at 37°C to allow for growth factor release into a phosphate-buffered saline. At 60 minutes after preparation, 2 ml of the sample will be collected, frozen, and replaced with 2 ml of additional phosphate-buffered saline. The protein quantification will be carried out using ELISA assay according to manufacturer's protocol.
223761365|NCT04436523|OTHER|Standard rehabilitation|Post-operative physical therapy as guided by a standardized protocol for patients undergoing meniscus repair.
224205033|NCT06102824|DRUG|Utidelone|30mg/m2, IV, once per day on days 1-5, q3w
224205034|NCT06102824|DRUG|Trastuzumab deruxtecan|5.4mg/kg, IV, q3w
224205035|NCT06102824|DRUG|Sacituzumab govitecan|10mg/kg, IV, days 1 and 8, q3w
224205036|NCT06492018|DIAGNOSTIC_TEST|Panbio™ HCV Self Test|Rapid diagnostic test (self-test and professional) plus laboratory reference tests
224205037|NCT06568848|COMBINATION_PRODUCT|EKKO therapy|In this group 6 particepents will be included .the interventions will be given for 10 seconds on each finger tips . the session will be 30 mins. 4 to 5 sessions per week
224205038|NCT06568848|DIAGNOSTIC_TEST|Conservative Treatment|In this group 6 participants will be included .: Conservative treatment, which includes ROM isometric exercises (20 repetitions per limb), stretching exercises (10 seconds per limb with 3 repetitions), balance training (standing without belts for 20 minutes), and gait training (walking with a frame). The session will be 30 mins
224205039|NCT02206256|DRUG|Omega-3 fatty acid capsules|2 times a day 1 capsule for 4 weeks before gastric bypass surgery
224205040|NCT02206256|BEHAVIORAL|Low calorie diet|A low calorie diet of 600 kcal/day during 2 weeks, using Modifast or an adjusted normal diet.
224205041|NCT06224387|DRUG|CTS2190 capsules|4-6 dose groups are pre-specified in Dose Escalation,and 4 arms in Dose Expansion.
224205042|NCT02235415|DRUG|Motens® (lacidipine)|
224205043|NCT02636166|OTHER|Clearblue Investigational Pregnancy test|Clearblue Investigational Pregnancy test
224205044|NCT02636166|OTHER|Professional pregnancy test|Alere Professional use pregnancy test
224205045|NCT02636166|OTHER|Clearblue Marketed Pregnancy test|Clearblue Marketed Pregnancy test
224205046|NCT05365594|DEVICE|Controlled Ankle Movement Boot|Walking boot used for orthopaedic foot injuries
224205047|NCT05365594|DEVICE|EVENUp Lift|Orthotic shoe lift worn on contralateral foot to increase leg length
224205048|NCT04404816|DRUG|heliox|NIV-NAVA with a conventional gas mixture (air-oxygen) at baseline, 3 hours of NIV-NAVA with heliox and return to NIV-NAVA with air-oxygen.
224205049|NCT05116761|BIOLOGICAL|Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles|Intravenous administration of Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles
224205050|NCT05116761|OTHER|Saline|Placebo Saline
224205051|NCT05968664|DEVICE|Spinal Cord Stimulator|Spinal Cord Stimulator modified to deliver Time Variant Pulse (TVP) stimulation.
224205052|NCT05968664|DEVICE|Spinal Cord Stimulator|Spinal Cord Stimulator to deliver standard of care Time Invariant Pulse (TIP) stimulation.
224205053|NCT02106793|DRUG|Mitomicin C|Mitomicin C (0.4 mg/ml) will be provided in a sterile vial and prepared by pharmacist at the Faculty of Medicine Ramathibodi Hospital.The treatment solution will be drawn and soaked ono two one inch neurosurgical cotton pledgets. Each pledget will be placed on each side of the nose for 5 minutes. The nurse will set the alarm for removal of the cotton pledgets, then normal saline will be used to irrigate both sides of the nose, using 100 ml on each side.
224205054|NCT02106793|DRUG|Identical placebo solution|Identical placebo solution
224205055|NCT04901182|DIAGNOSTIC_TEST|the effect of consuming diets on the swallowing capacity by using Flexible Endoscopic Evaluation of Swallowing (FEES)|the effect of consuming white sesame soy milk smoothie (WS), Chicken shitake smoothie (CS) vs. Ensure on the swallowing capacity by using Flexible Endoscopic Evaluation of Swallowing (FEES)
224205056|NCT01563029|DRUG|Fluticasone Furoate|current asthma medicine
224205057|NCT01563029|DRUG|Fluticasone Propionate|Fluticasone propionate
224205058|NCT01563029|DRUG|Placebo|placebo
224205059|NCT01569594|DEVICE|CorMatrix ECM for Carotid Repair|Subjects must be undergoing carotid endarterectomy with patch angioplasty closure
224205060|NCT05242406|OTHER|Expiratory muscle trainig|This exercise will be used to strengthen forced expiratory muscles.
224205061|NCT02963909|BIOLOGICAL|IXIARO|An inactivated vaccine indicated for active immunization for the prevention of disease caused by Japanese encephalitis virus (JEV).
223761366|NCT00819416|DRUG|5% albumin|5% albumin for the first 7 days of care in the ICU
223761367|NCT00819416|DRUG|Normal Saline|Normal Saline for the first 7 days of care in the ICU
224205062|NCT02963909|OTHER|Placebo|0.9% Sodium Chloride 5 mcg
224205063|NCT02963909|BIOLOGICAL|YF Vax 17D Strain|A stabilised Yellow Fever Vaccine (Live) that is an injectable suspension of the attenuated 17D strain of yellow fever virus. The vaccine is injected by the subcutaneous route.
224205064|NCT02963909|BIOLOGICAL|Zika Virus Purified Inactivated Vaccine (ZPIV)|Zika Virus Purified Inactivated Vaccine with aluminum hydroxide adjuvant.
224205065|NCT00131573|DEVICE|bion|battery powered bion microstimulator
224205066|NCT01920841|OTHER|Cream A applied to left thigh and Cream B to right thigh|Half the participants will receive Cream A applied to the left thigh, and Cream B applied to the right thigh
224205067|NCT01920841|OTHER|Cream B applied to left thigh and Cream A to right thigh|Half the participants will receive Cream B applied to the left thigh and Cream A applied to the right thigh
224205068|NCT02204527|DIETARY_SUPPLEMENT|supplementation of 100.000 IU of vitamin D3|supplementation of vitamin D ( with 2 pills of Addera D3 (50.000IU each pill))
224205069|NCT02204527|DIETARY_SUPPLEMENT|placebo pill|Placebo
224205070|NCT04375735|DRUG|Bovine Lipid Extract Surfactant|BLES will be administered in doses of 50mg/kg ideal bodyweight, at a concentration of 27mg/ml so a total volume of approximately 2ml/kg will be administered. The material will be instilled via the suction catheter through the ET tube so that the ventilation circuit is not broken. Half of the material will be instilled with the patient positioned on their left and right sides, with a pause to allow 5 min of MV between. The procedure will be repeated at, 24 and 48 hours while intubated, so the patient will receive up to 3 doses. To minimize aerosol generation, all patients will be paralyzed during surfactant administration and the ventilator will be paused. The proposed administration technique, surfactant concentration, volume and dosing schedule is based on previous studies, and has shown to be safe in patients with ARDS.
224205071|NCT01826201|DRUG|MOL4239|10% MOL4239 ointment to one target lesion twice a day for 28.5 consecutive days
224205072|NCT01826201|DRUG|Placebo|placebo ointment to the contralateral target lesion twice a day for 28.5 consecutive days
224205073|NCT04683874|DEVICE|3D printed tray|3D printed tray
224205074|NCT01615822|DRUG|OZ439 100mg|OZ439 100mg oral suspension, single dose
224205075|NCT01615822|DRUG|OZ439 400mg|OZ439 400mg oral suspension, single dose
224205076|NCT01615822|DRUG|MQ 250 mg, single dose|Mefloquine 250 mg tablet, single dose
224205077|NCT01615822|DRUG|MQ 750mg, single dose|Mefloquine 750mg oral tablet, single dose
224313828|NCT00813631|OTHER|silver-releasing dressings|Experimental group are accepted primary dressing the AQUACEL Ag. control group are provided with the AQUACEL on the wound surface. Wound specialist or primary nurses undertaking wound care are informed by inclusion criteria that the treatment shall be adhered to during the two-week study period.All wounds are cleansed with sterile saline prior to assessment and dressing application.The sterile, non-woven sodium carboxymethylcellulose primary AQUACEL Ag with 1.2% ionic silver.Each secondary dressing is covered a sterile gauze.Dressings are changed between daily assessments when judged necessary.Patients attended the wound ward weekly for treatment evaluation. All participating clinics used the same wound management guidelines and data collection forms.
224313829|NCT02884401|DEVICE|Dental implant placement (Straumann® Bone Level Tapered, BLT, Roxolid® SLActive®)|A tapered bone level implant (Straumann® BLT Roxolid® SLActive®, Basel, Switzerland) will be placed according to the manufactures guidelines trying to achieve primary stability in the correct prosthetic position
224313830|NCT02490267|OTHER|Quality of Life questionnaire|
224313831|NCT00238706|DEVICE|Radiofrequency ablation|
224313832|NCT04808466|DRUG|Paclitaxel|Paclitaxel is used as drug for hyperthermic intraperitoneal chemotherapy. Choice of perfusate: Normal saline. Drug selection and dose: Paclitaxel 75 mg/m2 . Treatment course: 2 times (the first time is after surgery, the second time is 48h after first time).
224313833|NCT04808466|DRUG|Lobaplatin|Lobaplatin is used as drug for hyperthermic intraperitoneal chemotherapy. Choice of perfusate: Normal saline. Drug selection and dose: lobaplatin 50 mg/m2 . Treatment course: 2 times (the first time is after surgery, the second time is 48h after first time).
224313834|NCT02414438|OTHER|FirstStepDX PLUS and NextStepDX PLUS Webinar|A pre-recorded 20-minute webinar on FirstStepDX PLUS and NextStepDX PLUS
224313835|NCT02414438|OTHER|FirstStepDX PLUS and NextStepDX PLUS Test Results|Physicians receive a prompt to order and download FirstStepDX PLUS and NextStepDX PLUS Test Results
224313836|NCT05922475|DIETARY_SUPPLEMENT|Protein|"Post-exercise protein group consumed protein immediately after exercise sessions.~Pre-sleep protein group consumed protein 30 minutes before sleep."
223617480|NCT06938841|DEVICE|Transcranial Magnetic Stimulation (TMS) - Clustered maintenance rTMS:|Clustered maintenance rTMS typically involves around 4 TMS sessions applied over 2 days, at 1-month intervals. Our team initially developed this approach based upon preclinical TMS studies (for example (Maeda et al. 2000)) suggesting that rTMS treatment effects may accumulate when applied over multiple sessions in a shorter period of time (Maeda et al. 2000).
223617481|NCT06938841|DEVICE|Transcranial Magnetic Stimulation (TMS) -- Sham maintenance rTMS|Sham treatment will be administered as either standard or clustered maintenance rTMS for 6 months period using a sham coil. The intervention target will be located via a Brainsight TMS Navigator (Brainsight, Montreal, Canada). For safety reasons, the individual TMS intensity will be limited to 130% of the individual resting motor threshold.
223617482|NCT06938334|GENETIC|Autologous CD34+ cell enriched population containing HSPCs transduced ex vivo using a LVV encoding the hPD-L1 DNA|The intervention is intended for newly diagnosed T1D patients with residual beta-cell function, who can receive the Drug Product (DP) within 180 days from the first insulin administration. Mobilized autologous HSPCs, collected by leukapheresis, are ex vivo transduced with a LVV encoding for hPD-L1 and formulated in a cryopreservation medium containing DMSO (DP). After release, the DP is thawed and administered to the patient at a dose ranging between 5 and 20 million of cells per kilogram of body weight. The intervention plans for a single DP injection.
224205078|NCT01615822|DRUG|Placebo|
224205079|NCT06470841|DRUG|CHG Combined With Venetoclax and Azacytidine|"Patients were treated by CHG Combined With Venetoclax and Azacytidine:~Venetoclax 100mg po qd d1, 200mg po qd d2, 400mg po qd d3-14; Azacytidine 75 mg/m2 subcutaneous injection qd d1-7; Homoharringtonine 1mg/m2 iv qd d1-14; Cytarabine 10mg/m2 subcutaneous injection q12h d1-14; G 250ug/m2 subcutaneous injection qd d0-14."
224205080|NCT03978897|DEVICE|Blood flow restriction tourniquet|A blood flow restriction tourniquet, which impedes arterial flow to extremity at 50% of usual flow.
224205081|NCT03978897|OTHER|Evidence based physical/occupational therapy|Up to date physical/occupational therapy for lateral epicondylitis
224313837|NCT05922475|OTHER|Placebo|Resistance exercise training only group did not consume supplemental protein.
224313838|NCT04141475|DIETARY_SUPPLEMENT|Physiomance acide lipoïque gold|1 capsule of 300 mg in the morning outside a meal and 1 capsule of 300 mg in the evening outside a meal during 12 weeks
224313839|NCT04141475|DIETARY_SUPPLEMENT|Placebo - Physiomance acide lipoïque gold|1 capsule of 300 mg in the morning outside a meal and 1 capsule of 300 mg in the evening outside a meal during 12 weeks
224313840|NCT03681327|OTHER|Sensory stimulation during sleep|Sensory stimulation during sleep
224313841|NCT06405282|OTHER|Manual Lymphatic Drainage|MLD is a gentle manual technique used to decongest swollen areas and redirect lymphatic flow to non-congested areas
224313842|NCT06405282|DEVICE|Near infrared spectroscopy|Oxygen saturation measurement
224313843|NCT06405282|DEVICE|Temperature|Thermal imaging
224313844|NCT06405282|DEVICE|Tissue Dialectic Constant|TDC captured by lymphatic fluid scanning device
223617483|NCT06939452|DRUG|anlotinib +TQB2450 + Oxaliplatin+S-1|"Anlotinib: 10mg, po, d1-14,q3w,until disease progression or unacceptable toxicity.~TQB2450: 1200mg, iv, d1, q3w,until disease progression or unacceptable toxicity. Oxaliplatin: 130mg/㎡, iv, d1,6 cycles.~S-1:40mg, po, bid, d1\~14,6 cycles."
223617484|NCT06939205|DIAGNOSTIC_TEST|Assessment of body surface area and assessment ventricular dilatation prevalence|Estimation of body surface area and quantification of absolute and relative values of echocardiographic variables
224205082|NCT01905007|DEVICE|Defibrillation testing|Defibrillation testing at initial ICD implantation
224205083|NCT04317547|BEHAVIORAL|Steering Teens Safe (STS)|The goal of STS is to provide intervention parents with guidance and communication skills, which will enable parents to effectively communicate with their teens about specific driving safety topics (e.g., speeding, seatbelt use, distracted driving). Our proposed parent training has two components: an individualized virtual communication training (provided to parents via Skype by a trained research team member) and a parent-teen safe driving communication guide (available online).
224313845|NCT06311162|BEHAVIORAL|Life-Style app|The modules of the Life-Style app are introduced and unlocked sequentially during the first weeks of the intervention phase. Afterwards the modules are fully available. Duration and frequency of app-use is not limited. The parents are accompanied by a coach through the app, who gives regular structured feedback and individual inputs. The coach has access to all data collected in the app.
224313846|NCT06311162|OTHER|Sham Comparator|The parents get a flyer with information on second-hand smoke exposure and references to smoking cessation programs, and do not have an active app during the main intervention period.
224313847|NCT06884852|DRUG|Erector spinae plane block (ESPB)|"Erector spinae plane block (ESPB) using multilevel injections of bupivacaine 0.25%.~We will inject 15ml at the level of T2 and 15ml at the level of T5."
224205084|NCT04317547|BEHAVIORAL|Driving Feedback Technology.|The driving feedback technology will include the Azūga™ in-vehicle device and smartphone app.
224205085|NCT06566248|DRUG|TQA3810 tablets+NUC|TQA3810 is a novel, effective and highly selective small-molecule oral Toll-like receptors-8 agonist.
224205086|NCT06566248|DRUG|Placebo+NUC|"NUC:~Entecavir Dispersible Tablets, Inhibit viral replication; Tenofovir Disoproxil Fumarate Tablets, Nucleotide reverse transcriptase inhibitors; Tenofovir Alafenamide Fumarate Tablets, Inhibit HBV replication."
224205087|NCT02861534|DRUG|Vericiguat|2.5, 5.0, or 10.0 mg orally once daily
224205088|NCT02861534|DRUG|Placebo for vericiguat|2.5, 5.0, or 10.0 mg orally once daily
224205089|NCT05458791|DEVICE|Intra-arterial Perfusion|All patients will undergo standard of care locoregional intra-arterial (IA) treatment for HCC. The procedure will take place utilizing fluoroscopic and CT guidance. Following catheterization of the femoral or radial artery, CT angiography of the hepatic circulation will be performed to define the hepatic vascular anatomy. Intra-arterial CT perfusion will be performed prior to IA treatment by the interventional radiologist to understand the dynamics of hepatic circulation or to manage the IA treatment strategy.
224205090|NCT01092676|DRUG|Ibuprofen Regular Dosing|Regular dosing
224205091|NCT01092676|DRUG|PRN dosing Ibuprofen|PRN dosing Ibupofen
224205092|NCT06205940|BEHAVIORAL|Audioguided Nature tour|Listening to audio instructions by an app while visiting nature. The instructions emphasize the connection between self and nature and direct attention to the present moment experience by guiding focus towards sensory experiences and specific natural elements.
224205093|NCT06205940|BEHAVIORAL|Non audio guided nature tour|Visiting nature without listening to audio instructions by an app
224205094|NCT02708940|OTHER|Participatory technology development|Creating mobile support tools by patients and their therapists
224205095|NCT02708940|OTHER|Usual Care|Usual care as part of the UCLA PHP and IOP programs
224205096|NCT03199924|DRUG|Diclofenac|Intramuscular injection of 75mg / 3ml of Diclofenac solution
224313848|NCT06884852|DRUG|Thoracic epidural block|Thoracic epidural block at level of T5 -T6 using 10 ml of bupivacaine 0.25% as a bolus followed by 5 ml bupivacaine 0.25% every 1-2 hours depending on the duration of surgery and the response of the patient.
224313849|NCT06050473|PROCEDURE|Nerve-sacrificing procedure|Surgical fixation of the clavicle fracture will be performed through a horizontal incision over the clavicle. During the incision and soft tissue dissection, the surgeon will not attempt to identify the supraclavicular nerve branches. Instead, the surgeon will cut the nerve branches during the dissection.
224205097|NCT03199924|DRUG|Magnesium Sulfate|intravenous injection of 1 g magnesium solution diluted in 10ml of saline solution administered over 2 minutes
224205098|NCT03199924|DRUG|Lidocaine|intravenous injection of 10ml lidocaine 1% solution administered over 2 minutes
223617485|NCT06937697|DRUG|Test toothpaste|A commercially available fluoride toothpaste
223617486|NCT06937697|DRUG|Control toothpaste|A commercially available fluoride toothpaste
223617487|NCT06938958|OTHER|Video and Motion Analysis|"1. Measurements of joint angle, body segment position, static and dynamic postures and posture duration.~2. Video of Surgeon and Procedure."
223617488|NCT00964652|OTHER|Treadmill walking training with additional body load|"The training program was divided into three phases (A1-B-A2):~treadmill training with additional body load (A1), control condition (conventional physical therapy) (B). and treadmill training with additional body load again (A2). Each phase lasted six weeks, totaling 18 weeks. Both evaluations and training were performed during on-phase of the medication cycle."
223617489|NCT06939270|BIOLOGICAL|CD73/AXL.HypoSti.CAR-T cells|Dose escalation: Dose1 (1×10\^6 cells/kg) , Dose 2(3×10\^6 cells/kg) ,Dose 3 (1×10\^7cells/kg); Dose expansion: RP2D.
223617490|NCT06939270|DRUG|Albumin-Bound Paclitaxel|Administered intravenously at dose of 100-200mg/m2 on day -5 .
223617491|NCT06939270|DRUG|Cyclophosphamide|Administered intravenously at a total dose of 15-30mg/kg on day -3 and day -2 .
223617492|NCT06939270|DRUG|Fludarabine|Administered intravenously at dose of 30mg/m2/d on day -3 and day -2.
223617493|NCT06937554|OTHER|observational follow up aimed at evaluating functional, physical, cognitive, and nutritional parameters|observational follow up aimed at evaluating functional, physical, cognitive, and nutritional parameters
224205099|NCT05415618|OTHER|Manual lymphatic drainage|Manual lymphatic drainage will be applied 5 days a week for about 15 minutes every day for 4 weeks.
224313850|NCT06050473|PROCEDURE|Nerve preserving procedure|Surgical fixation of the clavicle fracture will be performed through the same horizontal incision over the clavicle. The surgeon will attempt to dissect out, identify and preserve all branches of the supraclavicular nerve throughout the fracture reduction, fixation and closure.
224313851|NCT02954263|DRUG|TD-1439|
224313852|NCT02954263|DRUG|Placebo|
224313853|NCT02573090|PROCEDURE|Non-invasive resin based fissure sealing|The dentists use resin based fissure sealants of own choice, and follow their usual clinical procedures based on the instructions from the manufacturer and the guidelines from The Department of Cariology and Endodontics, University of Copenhagen, DK
224313854|NCT02573090|PROCEDURE|Invasive resin based restoration|The dentists use preparation design and resin composites of own choice, and follow their usual clinical procedures based on the instructions from the manufacturer and the guidelines from The Department of Cariology and Endodontics, University of Copenhagen, DK
224313855|NCT04358289|OTHER|Basic antimicrobial stewardship education|Commune health center: Revision of guidelines for antibiotic prescribing for respiratory infections in primary care, Training primary healthcare doctors in the application of the new guidelines
223617494|NCT06200753|PROCEDURE|Mechanical Thrombectomy|"Mechanical Thrombectomy: A stroke treatment method involving the use of a device to extract a blood clot from the blood vessels, restoring blood flow and reducing brain damage.~Ischemic Post-conditioning: After thrombectomy, a procedure involving inflating and deflating a balloon in situ for four cycles of 2 minutes each, reducing reperfusion injury and minimizing neural damage.~Selective Hypothermia: Administering cold saline either intra-arterially or within the cerebral sinus to lower brain temperature, mitigating ischemia-induced injury."
223617495|NCT06939192|OTHER|Intervention Group (APP)|Combination of app-based information and diagnostic screening for parents of premature babies.
224313856|NCT04358289|OTHER|Participatory action research group in commune health center and community|"* Establish a participatory action research group~* Engagement with the group through participatory action research involving problem identification, planning change strategies, implementing strategies, and evaluation"
224313857|NCT04358289|OTHER|Antimicrobial stewardship program in hospitals|"The intervention activities in hospitals will include: training a health-worker in each of the participating hospitals to act as a facilitator or activator; forming an antibiotic stewardship group; meeting regularly and following an action-research cycle that includes problem identification, planning change strategies, implementing strategies, and evaluating strategies"
224313858|NCT04358289|OTHER|Community education|Development of educational materials for the community and farmers; Disseminated of messages through posters, leaflets and local media channels
224313859|NCT00021580|PROCEDURE|human cadaveric islet cell transplantation|
224313860|NCT01830491|DRUG|Clopidogrel|
224205100|NCT05415618|DEVICE|splint|In splint treatment, a volar-supported splint that keeps the wrist in a neutral position will be preferred and it will be recommended to both groups to be used only at night for 4 weeks.
224205101|NCT05415618|OTHER|Nerve gliding|Median nerve gliding exercises as a home exercise program will be performed by the patient 5 days a week for 4 weeks. It will be performed in 6 different consecutive positions of the hand and wrist.
224205102|NCT01810575|DRUG|WC3036-11F/Alprostadil in Vehicle 2.5%|330 mcg alprostadil in 2.5% vehicle
224205103|NCT01810575|DRUG|WC3036-12F/Alprostadil in Vehicle 0.5%|330 mcg alprostadil in 0.5% vehicle
224313861|NCT01830491|DRUG|aspirin 100mg|
224313862|NCT02067273|DEVICE|Transcranial Magnetic Stimulation (TMS)|
223617496|NCT06939192|OTHER|Treatment as usual-Group (TAU)|No intervention. Treatment in the form of usual aftercare service is possible.
223617497|NCT06937489|DEVICE|Hydrogel conventional toric lenses with -10° axis misalignment|The assessment visits interval is 1 week and completed exactly on day 14 after their first baseline visit. At each assessment visit, three different cylinder power were tested: 1) full cylinder power, 2) under-correction of cylinder power by 0.5 D, and 3) under-correction of cylinder power by 1.0 DC. Axis was also misaligned by -10° and +10° for each cylinder power alteration. The powers and axis assigned to the participants were randomized during every assessment visit. Baseline assessments and treatment allocations were masked to both patients and physician. All assessments were carried out on the day of observation and recorded on the subject evaluation sheet in accordance with the sample data, in which examinations results.
224205104|NCT01810575|DRUG|WC3036-13P/Vehicle Only 0.5%|100 mg cream vehicle 0.5%.
224205105|NCT04222218|DEVICE|repetitive transcranial magnetic stimulation|Cerebellar repetitive theta Burst stimulation will be performed as detailed in the Real arm description
224205106|NCT05563142|PROCEDURE|deploying vascular closure device versus manual compression|patients will be randomized to either group 1 or group 2 in a 1:1 ratio:
224205107|NCT02835664|DIETARY_SUPPLEMENT|Nicotinamide Riboside (Niagen)|
224205108|NCT02835664|DIETARY_SUPPLEMENT|Placebo|
224313863|NCT00151112|PROCEDURE|Positioning and plexus anesthesia|positioning during plexus anesthesia
224313864|NCT01595386|DRUG|Hydrocortisone|The drug will be bolused at 50mg/m2 followed by a continuous infusion that will start at 50mg/m2 for the first 48 hours and then be tapered as follows: 40mg/m2/day over 24 hours, 30mg/m2/day over 12 hours, 20 mg/m2/day over 12 hours, 10mg/m2/day over 24 hours, then off.
224313865|NCT01595386|DRUG|Normal Saline|This will be bolused and infused in the same manner as the hydrocortisone arm to ensure blinding of study arm.
224313866|NCT05778487|DIETARY_SUPPLEMENT|Gatorade Thirst Quencher|Gatorade Thirst Quencher, 710ml (45g of carbohydrates, 6.3% carbohydrates, 25.4kcal/100ml)
224313867|NCT00678197|OTHER|Access Intervention|
224313868|NCT00678197|OTHER|Bonus/Pay-for-Performance Intervention|
224313869|NCT01831401|PROCEDURE|Operating table position 0° head down (Horizontal)|
224313870|NCT01831401|PROCEDURE|Operating table position 7° head down.|
224313871|NCT01831401|PROCEDURE|Operating table position Y° head down|Operating table position Y° head down (angle required to obtain vertical Transverse Pelvis Lines).
224313872|NCT01831401|DEVICE|Standard straight acetabular component introducer without alignment guide.|
224313873|NCT01831401|DEVICE|Modified 35° acetabular component introducer.|
224313874|NCT01831401|DEVICE|Inclinometer-assisted acetabular component introducer.|
224205109|NCT05238701|DRUG|LPM3770164 sustained release tablet|LPM3770164 sustained release tablet will be administrated orally single-dose on day 1
224205110|NCT05238701|DRUG|LPM3770164 sustained release tablet simulant|LPM3770164 sustained release tablet simulant will be administrated orally single-dose on day 1
224205111|NCT02866409|PROCEDURE|scalp block|"In this group following nerves were blocked-~1. Supra-orbital nerve~2. Supra-trochlear nerve~3. Zygomatico-temporal nerve~4. Auriculo-temporal nerve~5. Posterior auricular branches of the greater auricular Nerve~6. The greater, lesser, and third occipital nerves"
224205112|NCT02866409|PROCEDURE|infiltration|The incision site was infiltrated with drug. {1/3rd in the muscle and 2/3rd in the subcutaneous tissue}.
224205113|NCT02866409|DRUG|Dexmedetomidine|Dexmedetomidine was administered as a dose of 1 µg/kg in 20 ml 0.25% bupivacaine for scalp block or infiltration.
224205114|NCT02866409|DRUG|Bupivacaine|20 ml of Bupivacaine 0.25% was administered to the patients either in the form of scalp block or infiltration
224205115|NCT05315986|DIETARY_SUPPLEMENT|Saffr'Inside; 30mg|Ingestion of one gummy sweet of Saffr'Inside; 30mg, on a daily basis for 4 weeks.
224205116|NCT05315986|BEHAVIORAL|Enhanced Sleep Education|Psycho-education based multi-component sleep intervention
224075791|NCT06289985|DEVICE|Endovascular thrombectomy with any FDA-approved category POL or NRY device|Endovascular thrombectomy with any FDA-approved category POL or NRY device - Neurovascular Mechanical Thrombectomy Device For Acute Ischemic Stroke Treatment (POL), and/or Catheter, Thrombus Retriever (NRY)
224075792|NCT06289985|OTHER|Medical Management|Medical Management (MM) may involve any combination of the following: intravenous thrombolysis, antiplatelets, anti-hypertensives, cholesterol-lowering medications, and rehabilitative care.
224075794|NCT01331356|DRUG|Botox|One injection of botulinum toxin type A in the ganglion Impar in patients with chronic proctalgia
224075795|NCT04621695|PROCEDURE|RBL|Both arms are standard care procedures in the Netherlands
224075796|NCT04621695|PROCEDURE|Hemorrhoidectomy|Both arms are standard care procedures in the Netherlands
224205117|NCT05315986|DIETARY_SUPPLEMENT|Placebo food supplement|Placebo food supplement identical to the active gummy sweet of Saffr'Inside; 30mg, on a daily basis for 4 weeks.
224205118|NCT02001285|DRUG|Remifentanil|During intubation, remifentanil will be infused to prevent change arterial blood pressure and heart rate.
224075797|NCT01352806|PROCEDURE|identification of the lumbar interspinous space using fluoroscopy versus ultrasound versuspalpation|Copmarison of multiple technique for identification of the lumbar interspinous space,which is fluoroscopy,ultrasound and palpation
224075798|NCT04312698|DRUG|D013, D326, D337|Experimental: Group 1 Patients assigned to this group are treated with D013, D326, D337
224075799|NCT04312698|DRUG|placebo of D013, D326, D337|Placebo Comparator: Group 1 Patients assigned to this group are treated with D326, D337, placebo of D013
224075800|NCT04312698|DRUG|D013, placebo of D326, placebo of D337|Placebo Comparator: Group 2 Patients assigned to this group are treated with D013, placebo of D326, placebo of D337
224075801|NCT06179888|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
224075802|NCT06179888|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
224075803|NCT06179888|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
224075804|NCT06179888|PROCEDURE|Computed Tomography|Undergo PET/CT and/or CT
224075805|NCT06179888|DRUG|Iberdomide|Given PO
224075806|NCT06179888|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
224075807|NCT06179888|PROCEDURE|Patient Monitoring|Undergo disease monitoring
224075808|NCT06179888|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
224075809|NCT06179888|PROCEDURE|Skeletal Survey X-Ray|Undergo skeletal survey x-ray
224205119|NCT02801838|DRUG|Morphine|If the physician in charge of the patients judges it necessary, after the optimization of the ventilators settings, if the patient remains uncomfortable, a second therapeutic intervention using a maximum of 10mg morphine titration may be performed. After this second therapeutic intervention, a third non-verbal measure of respiratory discomfort will be performed with the IC-RDOS. Concomitantly, EEG and EMG will be again recorded over a of 15-minutes period.
224205120|NCT00916617|DRUG|bapineuzumab|5 mg/week subcutaneous bapineuzumab
224205121|NCT06062758|BEHAVIORAL|ECT Simulation Training|Simulation training will consist of three stages. The first stage is preliminary preparation. At this stage, students who review the resources identified and come prepared for the simulation scenario will be asked questions appropriate to the simulation objectives to help them remember the subject. In the second stage, the simulation will be realized. A high-fidelity mannequin/simulator will be used during the simulation, and the responsible faculty will give patient responses in the cabin. While the students taking roles during the simulation provide care to the patient, other group members will watch their teammates in the cabin or in a The simulation will be finalized by discussing the critical points of the case, the care to be given, communication skills and patient safety.
224205122|NCT00623441|DEVICE|Endeavor Zotarolimus Eluting Coronary Stent|Drug eluting stent
224205123|NCT01177735|DRUG|Pomalidomide|Only enough CC-4047 for 1 cycle of therapy may be provided to the patient each cycle. Participants will receive CC-4047 4 mg/day for 21 days, every 28 days. Treatment will continue until disease recurrence or untoward toxicity.
224205124|NCT02768935|PROCEDURE|blood sample|blodd sample at 12 months
224205125|NCT04368117|BEHAVIORAL|Physical Therapy|Directed and prescribe physical therapy program for severely burned patients
224205126|NCT02628821|OTHER|Preterm Infants treated with non-invasive ventilation.|
224205127|NCT03224741|BEHAVIORAL|Monetary Incentive|Subjects in this condition will be read a script informing them of the benefits and importance of routine HIV/AIDS testing for themselves, the benefits for one's partner and loved ones, and for the broader community; they are also given a flyer including the same information.Iin addition, they will be told that if they will get tested for HIV/AIDS within the next two weeks, they will receive $10 (the US dollar became Ecuador's official currency in 2001).
224205128|NCT03224741|BEHAVIORAL|Information|Subjects assigned to this condition are read a script informing them of the benefits and importance of routine HIV/AIDS testing for themselves, the benefits for one's partner and loved ones, and for the broader community; they are also given a flyer including the same information. Then, they are invited to get tested in the next two weeks.
224313875|NCT04102280|DEVICE|Dialyser|Three consecutive treatment weeks and one follow-up week per patient. Each treatment week includes three hemodiafiltration HDF sessions and is assigned to one type of dialyzer: FX P600 Fresenius Medical Care, comparator Xevonta Hi 15 (B. Braun) and comparator Elisio 150H (Nipro)
224313876|NCT01119794|DRUG|Ofatumumab and Bortezomib|Ofatumumab 1000 mg IV Cycle 1 on day 1, 8, 15 and 22 Bortezomib 1.6 mg/m2 IV Ofatumumab 1000 mg IV on day 1 maintenance phase Patients will remain until progression
224205129|NCT03224741|BEHAVIORAL|Active Choice|"Subjects in this condition will receive the same information and flyer as in T1; in addition, they are told that they have the opportunity to express their intention to get tested for HIV/AIDS. To this aim, they will be given a sheet of paper and asked to tick one of two boxes. The first box will say I intend to get tested within the next two weeks, and the second will say I will consider getting tested within the next two weeks but I am not ready to commit at this time. They will also be asked to write their initials at the bottom of the sheet, and will be told to keep it. This is a form of soft commitment which has proven effective in other contexts (Bryan et al. 2010)."
224205130|NCT02432521|OTHER|Conventional rehabilitation program from IMREA|The IMREA rehabilitation program lasts about 18 weeks and consists of two weekly sessions of 60 minutes of physical therapy, occupational therapy, as well as weekly sessions of speech therapy, nursing, nutrition, psychology and social work. Conventional therapies are typically composed of stretching and strengthening exercises both upper and lower limbs, mobilizations, functional training. The only fact that differ the subjects from the protocol from the patients from the IMREA Institute are the clinical and neurophysiological evaluations that will be performed before and after the end of the conventional rehabilitation program previously described.
224205131|NCT04450979|DIETARY_SUPPLEMENT|Bioactive hydrolysate|Participants given a bioactive vegetable hydrolysate to take one dose each morning and one dose each evening for the duration of the study.
224313877|NCT05182320|DEVICE|OrthoPath|unilateral TKA and THA patients using the BPMpathway rehabilitation sensor system
224313878|NCT05182320|DEVICE|Control|unilateral TKA and THA patients not using the BPMpathway rehabilitation sensor system
224313879|NCT02167373|OTHER|Cogito Companion Intervention|
224313880|NCT02167373|DEVICE|mobile phone application|
224313881|NCT01147263|OTHER|Evaluation of autonomic parameters|Physical examination, ECG, Loop recorder, Heart rate variability evaluation
224313882|NCT03869086|OTHER|Freeze dried blueberry powder|36 g of freeze-dried blueberry powder to be mixed with milk and served together with an energy-dense meal.
224313883|NCT03869086|OTHER|Anthocyanin free, sugar-matched placebo|36 g of isocaloric placebo, matched for sugars to be mixed with milk and served together with an energy-dense meal.
224313884|NCT05600790|BEHAVIORAL|Mindfulness Intervention for Emotional Distress|Mindfulness Intervention for Emotional Distress (MIED) program provide standard audio instructions for mindfulness exercises, introduce the nature and law of anxiety, depression and other emotions, the source of anxiety, depression and other emotional distress, and the strategies and methods to alleviate emotional distress. These exercises, knowledge and strategies are based on the latest progress in the field of psychological counseling and treatment, and their application in daily life can help alleviate anxiety, depression and other emotional problems.
224313885|NCT04689555|PROCEDURE|Novel method without manual compression|Novel method for femoral artery hemostasis without manual compression. After sheath removal, four or five sterile gauzes were overlaid layer by layer and then bandaged without the procedure of manual compression.
224313886|NCT04689555|PROCEDURE|Standard method with manual compression.|Standard method for femoral artery hemostasis with manual compression.After sheath removal, manual compression was continued for at least 10 minutes or until hemostasis. After that four or five sterile gauzes were overlaid layer by layer and then bandaged without the procedure of manual compression.
224313887|NCT04013984|OTHER|Accupuncture|In experimental groups (A), acupuncture will be applied for 30 minutes in each session and will be started from the month prior to onset of ovarian stimulation (two sessions of a weekly), and during the ovarian stimulation cycle (two sessions of a weekly), totally 7 acupuncture sessions will be carried out. Acupuncture will be performed using sterile needle on specific points (CV 3 (Zhongji), CV 4 (Guanyuan), ST 25 (Tianshu), ST 28 (Shuidao), ST 29 (Guilai), and LR 3 (Taichong), BL 23 (Shenshu), BL 32 (Ciliao), GV 20 (Baihui), GV 24 (Shenting), GB 13 (Benshen), ST 36 (Zusanli), SP 6 Sanyinjiao), SP 8, SP 10 and KI 3 (Taixi)). The needles were inserted to a depth of 15-30 mm, depending on the region of the body. No sham acupuncture is considered in the control group for ethical and practical reasons
224313888|NCT03330210|PROCEDURE|3D printing|Manufacturing and use of a model printed in 3D
224313889|NCT02418481|BIOLOGICAL|DC-CIK|DC-CIK cells will be used against tumor cells.
224313890|NCT02418481|BIOLOGICAL|γδ T Cell|γδ T cells will be used against breast tumor.
224313891|NCT02418481|BIOLOGICAL|Combination|γδ T/DC-CIK cells will be used against breast tumor.
223617498|NCT06937489|DEVICE|Hydrogel conventional toric lenses with +10° axis misalignment|The assessment visits interval is 1 week and completed exactly on day 14 after their first baseline visit. At each assessment visit, three different cylinder power were tested: 1) full cylinder power, 2) under-correction of cylinder power by 0.5 D, and 3) under-correction of cylinder power by 1.0 DC. Axis was also misaligned by -10° and +10° for each cylinder power alteration. The powers and axis assigned to the participants were randomized during every assessment visit. Baseline assessments and treatment allocations were masked to both patients and physician. All assessments were carried out on the day of observation and recorded on the subject evaluation sheet in accordance with the sample data, in which examinations results.
223617499|NCT06937489|DEVICE|Hydrogel conventional toric lenses with undercorrection of 0.5 D|The assessment visits interval is 1 week and completed exactly on day 14 after their first baseline visit. At each assessment visit, three different cylinder power were tested: 1) full cylinder power, 2) under-correction of cylinder power by 0.5 D, and 3) under-correction of cylinder power by 1.0 DC. Axis was also misaligned by -10° and +10° for each cylinder power alteration. The powers and axis assigned to the participants were randomized during every assessment visit. Baseline assessments and treatment allocations were masked to both patients and physician. All assessments were carried out on the day of observation and recorded on the subject evaluation sheet in accordance with the sample data, in which examinations results.
224205132|NCT01487018|PROCEDURE|Navigation Surgery|To evaluate the feasibility and accuracy of a new method for planning and realizing zygomatic osteotomies in cases of established post-traumatic deformities using computer assisted navigation.
224313892|NCT06632314|DIETARY_SUPPLEMENT|Enteral feeding|Enteral feeding will be withheld or continued in very low birthweight neonates during packed red blood cell transfusion. Regional cerebral and splanchnic oxygenation will be measured using near-infrared spectroscopy (NIRS) for 48 hours. Cerebral and splanchnic oxygenation parameters, including cerebral regional oxygen saturation (crSO2), splanchnic regional oxygen saturation (srSO2), the ratio of crSO2 to srSO2 (CSOR), cerebral fractionated tissue oxygen saturation (cFTOE) and splanchnic fractionated tissue oxygen saturation (sFTOE) will be measured immediately before PRBCT (baseline) and at the first, sixth, 12th, 24th, and 48th hours after PRBCT using near-infrared spectroscopy.
224313893|NCT00006458|RADIATION|indium In 111 monoclonal antibody MN-14|
224313894|NCT00006458|RADIATION|yttrium Y 90 monoclonal antibody MN-14|
224313895|NCT00000535|BEHAVIORAL|diet, reducing|
224313896|NCT00000535|BEHAVIORAL|diet, sodium-restricted|
224313897|NCT04320121|DIETARY_SUPPLEMENT|Nelutri™|Nelutri™ 2,000 mg/day for 12 weeks
224313898|NCT04320121|DIETARY_SUPPLEMENT|Placebo group|Placebo 2,000 mg/day for 12 weeks
224313899|NCT02952898|DRUG|GDC 695|GDC 695 is a topical gel.
224313900|NCT02952898|DRUG|Diclofenac Sodium Gel, 3%|Diclofenac sodium gel, 3% is an FDA-approved drug.
224313901|NCT02952898|DRUG|Vehicle gel|Vehicle topical gel contains 0.0% of active drug and is color matched to the other two active test drugs.
224313902|NCT01062867|DRUG|ORG25435|Intended doses: 0.25, 0.5, 1.0, 2.0, 3.0, 4.0, 5.0 and 6.0 mg/kg by intravenous infusion over 1 min Up to 25mg/kg by infusion over 30min
224313903|NCT05423795|OTHER|Telemedicine-based intervention|Telemedicine-based intervention Multifaceted intervention including daily videoconferences with audit and feedback, educational interventions, and dissemination of published works
223617500|NCT06937489|DEVICE|Hydrogel conventional toric lenses with undercorrection of 1.0 D|The assessment visits interval is 1 week and completed exactly on day 14 after their first baseline visit. At each assessment visit, three different cylinder power were tested: 1) full cylinder power, 2) under-correction of cylinder power by 0.5 D, and 3) under-correction of cylinder power by 1.0 DC. Axis was also misaligned by -10° and +10° for each cylinder power alteration. The powers and axis assigned to the participants were randomized during every assessment visit. Baseline assessments and treatment allocations were masked to both patients and physician. All assessments were carried out on the day of observation and recorded on the subject evaluation sheet in accordance with the sample data, in which examinations results.
223617501|NCT06938789|OTHER|Blood Transfusion|Blood transfusion is given without delay (within 4 hours) in case of hemoglobin below our threshold.
224205133|NCT01487018|PROCEDURE|Traditional Surgery|To compare with the experamental group.
224205134|NCT04575987|OTHER|Questionnaire|"Questionnaires will be sent by email or by post, in which questions about PFD, obstetrical history or dietetic follow-up will be asked.~Some obstetrical issues will be get from women medical files."
224313904|NCT05423795|OTHER|Standard of care arm|Classic expertise (as routinely performed in the participating ICU)
224313905|NCT05068453|DRUG|Recombinant Oncolytic HSV-2 Therapeutic Injecta (Vero Cell) for Human Use (rHSV2hGM-CSF)|OH2：less than 8mL/time，Q2W，i.t.；
223617502|NCT06938789|OTHER|Standard care|These patients recieve our standard care including blood transfusion as usual. Vital parameters and delirium screening are collected three times a day.
224313906|NCT05068453|DRUG|Recombinant humanized anti-PD-1 monoclonal antibody for injection|HX-008：200mg/time，Q3W，i.v.；
224313907|NCT05068453|RADIATION|RT|3 times radiation，totally 24-30 Gy for each lession.
224313908|NCT03958253|OTHER|Toolbox for Lung Cancer Screening|"-Toolbox of evidence-based elements that a primary care or referral site could implement to address known barriers to screening and referral, as well as required elements for screening. These elements will be designed to be adaptable to the unique needs and screening processes of the participating practices.~* Patient education materials~* Primary care practice educational materials~* Pack-years/eligibility calculator~* Local referral process guide~* Smoking cessation materials and support~* Shared decision-making guide~* LDCT best practice guidelines"
224313909|NCT06167863|DIAGNOSTIC_TEST|radiomics|extracted image features from CT or MRI
224313910|NCT01246063|DRUG|carfilzomib|
223617503|NCT06938321|DRUG|AK112|Following a predefined dose and date.
223617504|NCT06938321|DRUG|AK130|Following a predefined dose and date.
223617505|NCT06937736|DIAGNOSTIC_TEST|blood glucose measurement by subject|blood glucose measurement by subject using finger tip capillary blood
223617506|NCT06937671|PROCEDURE|Cold EMR|Cold EMR with cold forceps (regular or jumbo forceps) removal of any visible neoplasia that cannot be ensnared.
223617507|NCT06937671|PROCEDURE|Hybrid EMR|Cold EMR with hot avulsion of any visible residual neoplasia within the resection bed, in addition to precise APC of the fibrotic bands that may harbor invisible neoplasia within the resection bed.
224205135|NCT00960232|DRUG|Cholecalciferol|40.000 IU cholecalciferol per week for 6 months
224205136|NCT00960232|DRUG|placebo|placebo
224313911|NCT01246063|DRUG|pegylated liposomal doxorubicin (PLD)|
224313912|NCT01246063|DRUG|Dexamethasone|
224313913|NCT03694600|DIAGNOSTIC_TEST|Multi-analyte blood Test|intended for the qualitative detection of DNA methylation profiles associated with hepatocellular carcinoma in cell-free DNA derived from patient whole blood specimens.
224313914|NCT02332954|DRUG|vortioxetine|The starting and recommended dose of vortioxetine is 10 mg once daily; film-coated 10 mg tablets for oral use once daily for 52 weeks.Depending on individual patient response, the dose may be increased to a maximum of 20 mg daily.
224313915|NCT03993782|OTHER|A19010-R|A snus product
224313916|NCT03993782|OTHER|B19010-O|A snus product
224313917|NCT03364868|DRUG|Oral Insulin|treatment starting at 4 months - 7 months until age 3.0 years; dose escalation scheme: daily treatment with 7.5 mg or placebo for 2 months; increasing to daily treatment with 22.5 mg or placebo for the following 2 months; increasing to daily treatment with 67.5 mg or placebo until the end of the treatment period.
224313918|NCT03364868|OTHER|Placebo|treatment starting at age 4 months - 7 months until age 3.0 years; daily treatment with insulin or placebo capsules containing filling substance (microcrystalline cellulose).
224313919|NCT01485744|DRUG|LDE225; Fluorouracil; Leucovorin; Oxaliplatin; Irinotecan|LDE225 200-800 mg daily orally. Fluorouracil 2400 mg IV every other week. Irinotecan 180 mg/m2 IV every other week. Oxaliplatin 85 mg/m2 IV every other week. Leucovorin 400 mg/m2 IV every other week.
224205137|NCT01988337|DEVICE|Resin infiltration|The study is a split-mouth design. One tooth with a proximal caries lesion will randomly receive the infiltrating resin (Icon) while the other will receive a placebo, according to the manufactures´ instruction for Icon. In short, teeth will be isolated with a rubber dam and the tooth surface cleaned with non-fluoride prophylactic paste and pumice. The Icon material will be applied following the manufacturer's instructions and light cured, followed by polished using interproximal finishing/polishing strips (Sof Lex, 3M ESPE, St Paul, MN). Subjects will be given a letter to take to their local dentist asking them not to treat the selected lesions without informing the investigator first.
224313920|NCT03125980|DRUG|capecitabine plus oxaliplatin before and after surgery|"Subjects will receive systemic CapeOX chemotherapy both before and after the radical surgery for at most 4 cycles respectively. They shall have rest after the surgery for at least four weeks before the post-operative chemotherapy. CapOX regimen will be administered as follows:~1. Oxaliplatin 130 mg/m2 iv continue for 2 hours.D1~2. Capecitabine 1000mg/m2/d PO Bid,once every morning and evening D1-14~3. Repeat every 3 weeks (Q3W)"
224313921|NCT03125980|DRUG|capecitabine plus oxaliplatin after surgery|"Subjects will first receive radical surgery, then have rest for at least four weeks. Thereafter, subjects will receive systemic CapeOX chemotherapy for at most 8 cycles. CapOX regimen will be administered as follows:~1. Oxaliplatin 130 mg/m2 iv continue for 2 hours.D1~2. Capecitabine 1000mg/m2/d PO Bid,once every morning and evening D1-14~3. Q3W"
224313922|NCT00483483|BEHAVIORAL|Individual and group HIV risk behavior counseling sessions|Healthy Relationships Intervention (HRI) culturally adapted and modified to address substance use and associated risk behaviors; subjects will attend three 2-hour structured group sessions in addition to two 1-hour individualized sessions over the course of 10 days.
224313923|NCT00483483|BEHAVIORAL|health education and support group|general health information (nutrition, stress reduction) in 2 individual sessions and 3 group sessions.
224313924|NCT00815360|DRUG|intravitreal injection of ranibizumab|intravitreal injection of 0.5 mg ranibizumab
224313925|NCT00815360|PROCEDURE|peripheral laser|ultra-widefield fluorescein angiography guided peripheral laser
224313926|NCT00815360|DRUG|intravitreal injection of triamcinolone acetonide|intravitreal injection of 4.0 mg triamcinolone acetonide
224313927|NCT00815360|PROCEDURE|macular laser|macular laser to areas of retinal thickening or leakage
224313928|NCT04676659|DRUG|TNK-tPA|Experimental arms for low, middle, and high dosing; and active control arm for the standard protocol
224313929|NCT04123561|DRUG|TLC599|TLC599 is a proprietary (Bioseizer) lipid formulation containing DSP (active ingredient)
223511553|NCT04964466|BIOLOGICAL|Release kinetics of PDGF-BB in PRF + bone substitutes vs. rhPDGF-BB + bone substitutes|The release kinetics of PDGF-BB will be assessed for six preparations of each of following: 1) PRF+ mineralized freeze-dried corticocancellous allograft, 2) PRF + bone xenograft, and 3) PRF + B-TCP. The release kinetics of PDGF-BB will also be assessed for one preparations of each of following: 1) rhPDGF-BB + mineralized freeze-dried corticocancellous allograft, 2) rhPDGF-BB + bone xenograft, 3) rhPDGF-BB + TCP. The quantification will be performed at 60 minutes, 8 hours, 1 day, 3 days, and 10 days. The samples will each be placed in a cell incubator at 37°C to allow for growth factor release into a phosphate-buffered saline. At each desired time point assessment, 2 ml of the sample will be collected, frozen, and replaced with 2 ml of additional phosphate-buffered saline. The protein quantification will be carried out using ELISA assay according to manufacturer's protocol.
223511554|NCT04964466|BIOLOGICAL|Release kinetics of PDGF-BB in rhPDGF-BB + PRF + bone substitutes|The quantification will be performed at 60 minutes, 8 hours, 1 day, 3 days, and 10 days. The samples will each be placed in a cell incubator at 37°C to allow for growth factor release into a phosphate-buffered saline. At each desired time point assessment, 2 ml of the sample will be collected, frozen, and replaced with 2 ml of additional phosphate-buffered saline. The protein quantification will be carried out using ELISA assay according to manufacturer's protocol. The samples will each be placed in a cell incubator at 37°C to allow for growth factor release into a phosphate-buffered saline. At each desired time point assessment, 2 ml of the sample will be collected, frozen, and replaced with 2 ml of additional phosphate-buffered saline. The protein quantification will be carried out using ELISA assay according to manufacturer's protocol.
223511555|NCT04288531|DIETARY_SUPPLEMENT|Iodine supplementation|Recommendation, issued by the National Health Authorities, on supplementing with iodine (200 ug/day) women during preconception, pregnancy and lactation.
223511556|NCT05063136|DRUG|Capecitabine+endocrine therapy|Capecitabine (500mg, tid) (for 1 year)+ standard endocrine therapy (at least 5 years)
223511557|NCT05063136|DRUG|Placebo+endocrine therapy|Placebo (tid) (for 1 year)+ standard endocrine therapy (at least 5 years)
224205138|NCT01988337|OTHER|Mock treatment|"For the mock treatment the procedure will be identical to the Resin Infiltration intervention, with the exception that a placebo will be used. Essentially, syringes identical to the Icon materials will be supplied by DMG for the placebo procedure. The syringes will be filled with solutions having the same consistency and color as the Icon material."
224313930|NCT04123561|DRUG|DSP|Dexamethasone sodium phosphate (DSP) is a glucocorticoid widely used in the treatment of joint pain such as gout, osteoarthritis and rheumatoid arthritis via IA injection.
224313931|NCT04123561|OTHER|Normal Saline|0.9% normal saline
224313932|NCT05236283|DIAGNOSTIC_TEST|Blood Culture|Blood Culture
224313933|NCT02454127|BEHAVIORAL|Atkins Diet|Dietary counseling for 1 year
224313934|NCT02454127|BEHAVIORAL|Zone Diet|Dietary counseling for 1 year
224313935|NCT02454127|BEHAVIORAL|Weight Watchers Diet|Dietary counseling for 1 year
224313936|NCT02454127|BEHAVIORAL|Ornish Diet|Dietary counseling for 1 year
224313937|NCT05614427|DIAGNOSTIC_TEST|Innova Lateral Flow Test|Lateral flow test performed on anterior nasal or buccal swabs
224313938|NCT05734612|DRUG|Colchicine|Patients in the intervention group receive loading dose of colchicine 1 x 2 mg followed by colchicine 2 x 0,5 mg daily for two consecutive days.
224313939|NCT05734612|DRUG|Placebo (lactose)|Patients in the control group receive loading dose of placebo (lactose) 1 x 2 mg followed by lactose 2 x 0,5 mg daily for two consecutive days.
224313940|NCT01178528|DRUG|ivabradine|7.5 mg bd
224313941|NCT01178528|DRUG|"Drug:Carvedilol and Drug:Ivabradine"|up to 12.5/5 mg bd
223617508|NCT06938178|OTHER|Mindfulness treatment|The Mindfulness treatment will consist of a series of 8 weekly meetings in small groups . An experienced therapist will guide patients and during the sessions they will be encouraged to close their eyes, assume a relaxed posture, focus on breathing and the present moment in order to improve awareness of mental and bodily sensations. Patients will also be encouraged to add a regular, practice at home of about 10 minutes to the group treatment. If necessary, patients in both groups can take the medication they normally take for acute events. These occurrences will be reported in the headache diary given to each subject. Before conducting the study protocol, the investigator will explain the study to each participant and collect a signed copy of the written informed consent. All participants will undergo a clinical, neurophysiological and neuropsychological evaluation before the first session and after the last. In both groups, the usual drug therapies in case of crisis will be allowed.
224205139|NCT02936349|OTHER|Transthoracic Contrast Echocardiogram|A transthoracic contrast echocardiogram (TTCE) is a still or moving image of the internal parts of the heart using ultrasound following the injection of microbubble contrast (agitated saline) into a vein in the arm, which then travels to the heart.
224313942|NCT01178528|DRUG|Carvedilol|25 mg bd
224205140|NCT02844088|OTHER|Meningococcus C conjugate vaccine|
224205141|NCT00293605|PROCEDURE|Total Hip Replacement|Implantation of one of 3 stem designs
224313943|NCT03854682|PROCEDURE|Radiofrequency microtenotomy|A longitudinal incision of about 3 cm will be made over the most tender part of the foot taking care to avoid the weight bearing part of the sole, and the tissues dissected down to the affected plantar fascia. After initiating sterile isotonic saline flow of 1 drop every 1-2 s from a line connected to the RF system, the TOPAZ tip will be placed onto the fascia and the micro debridements carried out in a grid like pattern on and throughout the symptomatic fascia area. After debridement, the wound will be irrigated with copious amounts of normal saline solution and closed in layers. A local anaesthetic will be injected into the skin and subcutaneous tissues around the wound and standard wound dressings will be applied
224205142|NCT01260194|DRUG|trastuzumab [Herceptin]|Loading dose of 8 mg/kg on day 1, followed by 6 mg/kg intravenous infusion every 3 weeks until disease progression in combination with standard chemotherapy
224205143|NCT06393907|DEVICE|Hemostatic Forceps|The experimental device will be used for control bleeding in high risk gastroduodenal ulcers.
224313944|NCT03854682|BEHAVIORAL|Strength training|Non-surgical treatment consists of one-legged heel lift to primarily activate the windlass effect and increase the mechanical stress on the tendon. The exercise is performed on a step, a thick book or the like, so the heel movement finishes below the horizontal level. The exercise is performed every other day with as many sets as possible and as heavy as possible, but not heavier than eight repetitions can be performed per. set. The load progressed from two to one leg +/- backpack. The exercise is performed as 3 s/2 s / 3 s concentric, isometric and eccentric respectively followed by 2 min rest. Patients continue to exercise 4 weeks after patient acceptable symptom state (PASS) has been achieved
224313945|NCT04228016|DEVICE|Device: nastent™|Patients with Nasal obstruction at night, will be used intrasal stent during 15 nights. These are flexible silicone tubes that are lubricated and easy to insert into the nasal cavities, which would restore the permeability of the nasal cavities.
224313946|NCT05439083|BIOLOGICAL|9-valent HPV vaccine|All participants will receive the immunization schedule according to guidelines: immunosuppressed patients will receive a three-dose schedule: 0.5 mL intramuscular injection of 9vHPV at entry plus an additional dose at month 2 and month 6. Healthy controls aged 9-14 years will receive a two-dose schedule: 0 and 6 months.
224313947|NCT06129305|OTHER|Comparison of the distance of the Erector Spina muscle from the skin at different thoracal levels and different posıtıons under ultrasonography|Comparison of the distance of the Erector Spina muscle from the skin at different thoracal levels and different posıtıons under ultrasonography
224313948|NCT05017597|OTHER|Rehabilitation|Exercises completed, and rate of perceived exertion (RPE) will be reviewed during \& after each exercise session. Exercises will be modified by either increasing or decreasing the intensity. Decisions will be made based RPE, physical symptoms \& any identified barriers or supports. Weeks 1, 3, 5, \& 7, Cancer-related fatigue (CRF) education will be assigned. During weeks 2, 4, 6, \& 8, CRF education will be reviewed and a plan for how to apply the information will be developed. Participant will be guided through 6 steps of problem solving to address one occupational performance problem identified by participant within Canadian Occupational Performance Measure. Goal \& action plan for the week will be shared with the participant electronically. At the beginning of each session, participant will describe progress on previous week action plan. Based on participant's response, either a new goal will be developed or the current one modified..
224313949|NCT05607654|DEVICE|active iTBS|"Participants in the active stimulation group will receive the accelerated intermittent TBS to left DLPFC. The L-DLPFC will be targeted utilizing the neuronavigation system. Stimulation intensity will be standardized at 90% of RMT.~Stimulation will be delivered to the L-DLPFC using an NTK-TMS-II100 TMS device,is compatible with the Brainsight TMS navigation system."
224313950|NCT05607654|DEVICE|sham rTMS|The parameters in the sham arm will be as above with the internal randomization of the device internally switching to sham in a blinded fashion.
223511558|NCT04583553|DIAGNOSTIC_TEST|Vikor Scientific Urine-IDTM|Urine samples will be collected for both standard laboratory culture at KUMC Lab and expedited delivery to Vikor Scientific Lab for Urine-IDTM analysis. Vikor Scientific will cover all costs associated with sample delivery. If insufficient urine volume is collected for both standard laboratory culture at KUMC Lab and Vikor Scientific Urine-IDTM, urine will be preferentially used for standard laboratory culture at KUMC Lab.
223617509|NCT06938815|OTHER|Pigment Balancing Peel|Chemical Peel
223617510|NCT06938815|OTHER|Discoloration Defense Serum|Dark spot correcting serum
223617511|NCT06938815|OTHER|LHA Cleansing Gel|exfoliating gel facial cleanser
223617512|NCT06938815|OTHER|Hydrating B5 Gel|Vitamin B5 serum with hyaluronic acid
224205144|NCT06393907|DEVICE|Bipolar Electrocautery Probes|The active comparator devices will be used for control bleeding in high risk gastroduodenal ulcers.
224205145|NCT03740828|DEVICE|KIDScore D3|Embryos are scored using the KIDScore D3 algorithm based on annotated morphokinetic parameters.
224205146|NCT02724215|DEVICE|Sleep Apnea Screening (Out of Center Polysomnography Device)|
224205147|NCT02776215|DRUG|tasimelteon|Melatonin receptor agonist
224205148|NCT04365907|DRUG|Zafatek tablets|Once weekly new anti-diabetic drug approved only in Japan
224313951|NCT04669847|OTHER|Trunk-oriented exercise program|The trunk-oriented exercise program was performed by a physiotherapist two days of the week for 8 weeks.Trunk-oriented exercises were specially adapted to the patient based on the patient's functional status and active participation in the exercises.
224313952|NCT04669847|OTHER|Conventional exercise program|Conventional exercise program was performed daily for 8 weeks, twice a day, on average 45 minutes, each exercise 5-10 repetitions. The program formed stretching exercises, and active or active-assisted strength exercises (upper extremity, lower extremity, abdominal muscles, back muscles).
224313953|NCT06871722|BEHAVIORAL|Plant based diet|"The plant-based diet in this study is defined as a predominantly vegetarian dietary pattern, consisting of two vegetarian meals per day and one meal that includes animal-derived protein. The diet is based on whole foods while avoiding ultra-processed foods.~Macronutrient Composition Caloric Intake: 30-35 kcal per kilogram of body weight per day Protein Intake: 0.8-1 g per kilogram of body weight per day Fat Sources Animal-derived fats are to be avoided. Plant-based oils are recommended as the primary source of dietary fats. Protein Sources Emphasis is placed on plant-based protein sources, including nuts, beans, edamame, tofu, and tempeh.~Dairy consumption is permitted, but cow's milk is discouraged. Instead, plant-based alternatives such as almond milk and soy-based milk (e.g., tofu milk) are recommended.~Egg consumption is allowed but limited to no more than one egg per day"
224205149|NCT03840473|BEHAVIORAL|MET|The patient was in a supine position with the cervical spine in the opposite lateral flexion to the treating part so that the upper trapezius muscle fibers were in a lengthened position.19 The moderate isometric contraction (approximately 75% of maximal) of the upper trapezius muscles was elicited for a period of 5 seconds followed by 3 seconds of relaxation while reaching the new barrier. The technique was repeated four times in each session.
223617513|NCT06938815|OTHER|Daily Brightening Sunscreen|daily moisturizing sunscreen SPF 30
223617514|NCT06937515|OTHER|Cosmetic topical products|Cosmetic topical products efficacy evaluation
224205150|NCT03840473|BEHAVIORAL|ICT|The patient lying in the supine position with the cervical spine in opposite lateral flexion to the treating part so that the upper trapezius muscle fibers were kept in a lengthened position.18,22 The physiotherapist applied gradually increasing pressure to the MTrPs until the subject perceived the first noticeable pain. At that moment, the pressure was maintained until the discomfort and/or pain eased by around 50% as perceived by the patient, at which time the pressure was increased until the discomfort appeared again. This process was maintained for 90 seconds.
224205151|NCT03840473|BEHAVIORAL|Conventional Intervention|Hot packs (75°C) for 20 minutes and active stretching exercises for the upper trapezius muscle (slow, 5 repetitions per session, 10-second hold and 10-second relaxation between two repetitions). Active stretching exercises were done by all the participants under the supervision of the physical therapist. This approach was standardized for all participants.
224205152|NCT04859647|OTHER|Method of Levels Therapy|MOL is a flexible, client-led psychological therapy that allows people to talk freely about important problems and life goals.
224205153|NCT05611710|DRUG|Placebo|"Drug: Placebo, with visually matched clear syringes~* Adults (≥16 years) and children (12-16 years, \> 50Kg) will receive 2 syringes of placebo via IV route, twice daily for 4 days~* Children (12-16 years, \< 50Kg) will receive no more than 1 syringe of placebo via IV route, twice daily for 4 days"
224205154|NCT05611710|DRUG|Anakinra|"Drug: Anakinra~* Adults (≥16 years) and children (12-16 years, \> 50Kg) will receive 200mg of anakinra (2 syringes) via IV route, twice daily for 4 days~* Children (12-16 years, \< 50Kg) will receive 2mg/Kg of anakinra via IV route, twice daily for 4 days (no more than 1 syringe of anakinra, twice daily for 4 days)"
224205155|NCT00421486|PROCEDURE|Oral swabs for HPV-typing and high-risk HPV-determination|Oral swabs for HPV-typing and high-risk HPV-determination
224205156|NCT02111265|DRUG|Remifentanil|"1. Remifentanil 0.1-0.2μg/ ( kg•min) is continuously pumped at steady speed for analgesia for induction and maintenance of anesthesia.~2. Remifentanil is stopped before skin closure"
223617515|NCT06938087|DEVICE|3D printed prosthesis foot|Energy storage and restoration 3D printed prosthesis foot
223617516|NCT06938087|DEVICE|Current prosthesis foot|Energy storage and restitution prosthesis foot made in carbon fibers blades
224205157|NCT02111265|DRUG|Cisatracurium|"1. Cisatracurium 0.15 mg/kg for induction and 0.12 mg/kg/h continuous infusion for maintenance of anesthesia.~2. Cisatracurium is stopped before skin closure."
224205158|NCT02111265|DRUG|Sufentanil|Before skin closure, remifentanil is stopped and sufentanyl 0.1μg/kg is given by intravenous injection.
224205159|NCT02111265|DEVICE|Bispectral index(BIS) monitor|BiS is maintained at 40-60 during anesthesia.
224205160|NCT03252665|DRUG|Alprostadil|alprostadil,2ug, dilivered by targeted perfusion catheter in the culprit vessel after PCI in STEMI patients
224205161|NCT03252665|DRUG|Nicorandil|Nicorandil,2mg, dilivered by targeted perfusion catheter in the culprit vessel after PCI in STEMI patients
224205162|NCT03252665|DRUG|Nitroglycerin|Nitroglycerin,200ug, dilivered by targeted perfusion catheter in the culprit vessel after PCI in STEMI patients
224205163|NCT06114017|BEHAVIORAL|Social Media Abstention|People will stop or reduce their social media use for one week.
224205164|NCT06041269|DRUG|Rosnilimab|PD-1 agonist antibody
223617517|NCT06938711|DRUG|Elacestrant|Elacestrant 200mg once daily oral dosing in cycles of 28 days.
223617518|NCT06938711|DRUG|Onapristone|Onapristone 40mg twice daily oral dosing in cycles of 28 days.
223617519|NCT00866814|DEVICE|Bard Ventrio Hernia Patch|The Ventrio Hernia Patch is a self-expanding, non-absorbable, sterile prosthesis for use in the reconstruction of soft tissue deficiencies, such as for the repair of hernias.
223617520|NCT06939387|OTHER|Observational study, no intervention|Observational study, no intervention
224205165|NCT06041269|DRUG|Placebo|Placebo
224205166|NCT03780101|DIAGNOSTIC_TEST|Multi-parametric renal MRI|Multi-parametric functional magnetic resonance imaging of a transplant kidney including sequences for T1, T2, diffusion-weighted imaging, diffusion tensor imaging and arterial spin labelling.
224205167|NCT00004123|DRUG|Doxorubicin hydrochloride (DOX)|Doxorubicin IV bolus followed immediately by IV over 4 days every week for 5 weeks concurrently with external beam radiotherapy 5 days a week for 4 weeks.
224205168|NCT00004123|PROCEDURE|Conventional surgery|Surgical resection of primary tumor and all adjacent gross disease approximately 6 weeks after chemoradiotherapy
224205169|NCT00004123|RADIATION|Intraoperative radiation therapy (IORT)|Intraoperative radiotherapy (IORT) to tumor bed if all gross disease has been resected and if area of maximal tumor adherence to retroperitoneum can be encompassed within a single IORT field (maximum 15 cm).
224205170|NCT00004123|RADIATION|Radiation Therapy (RT)|5 days a week for 4 weeks
224205171|NCT01294709|DRUG|telcagepant|
224313954|NCT05006391|OTHER|Tele-Coaching (Online) Community-Based Exercise|"PHASE 1-Intervention Phase (6 months): Participants will engage in an individual tailored home-based exercise program involving aerobic, resistance, balance and flexibility training \~60min, 3 times per week for 24 weeks. Intervention will include: Component 1) biweekly 60 min personal online coaching with a certified trainer from the YMCA (13 sessions) who will monitor and progress exercise intensity; Component 2) weekly online group-based exercise classes \~60 min each led by a trainer at YMCA; Component 3) monthly online evidence-based self-management education sessions focused on topics related to self-management and health, and physical activity living with HIV; and Component 4) a wireless physical activity monitor (WPAM) to self-monitor steps, distance, calories burned, and active minutes.~PHASE 2: Post-Intervention (6 months): Participants will be encouraged to continue with unsupervised home / outdoor-based exercise 3 times per week and to continue using their WPAM throughout."
224313955|NCT06821633|PROCEDURE|Targeted laser photocoagulation guided by OCTA (Optical Coherence Tomography Angiography)|The patient's eyes were first scanned using the Topcon OCTA (five-field montage) with a 24×20mm and a 6×6mm scan range. After enrollment, the patient underwent treatment on the same day in the retinal laser room. The laser treatment was performed by the same ophthalmologist. After obtaining baseline fundus images, the treating ophthalmologist overlaid the OCTA images onto the fundus images using retinal vessel alignment to guide targeted photocoagulation of the retinal non-perfusion (NP) areas under OCTA guidance. The specific photocoagulation method involved applying a grid pattern of spot laser (3×3) to the NP area once, with the treatment area extending beyond the NP boundary by one laser spot diameter. The total procedure duration was 10-20 minutes.
224313956|NCT06347705|BIOLOGICAL|2141-V11 Antibody|2141-V11 Antibody: Intratumor injection
224313957|NCT06831552|BEHAVIORAL|RISE Intervention|Income-poverty targeted, supportive care intervention that includes direct cash transfers delivered by the Fund for Guaranteed Income, a non-profit organization, along with benefits counseling to discuss the risk of means-tested benefits loss or reduction. Funds will be dispersed to families via debit card or through personal banking, PayPal, or Venmo on a twice monthly basis for a total of twelve disbursements (6-months). Meetings with a benefits counselor will be conducted by the HIPAA-compliant video conference platform, Zoom.
224313958|NCT06234202|DEVICE|Bioactive Sleeve|Pitchers will wear a bioactive sleeve immediately post-game through overnight.
224313959|NCT06234202|DEVICE|Control Sleeve|Pitchers will wear a non-bioactive sleeve immediately post-game through overnight.
224313960|NCT00604136|BIOLOGICAL|tumor infiltrating lymphocytes|Patients will have a melanoma metastasis resected and cultured in IL-2 in vitro. Tumor infiltrating lymphocytes from these cultures will be assessed for tumor reactivity and those with such activity will be further expanded and adoptively transferred. Patients will receive a non-myeloablative lymphocyte-depleting preparative regimen consisting of cyclophosphamide (60 mg/kg/day x2 days IV)and fludarabine (25 mg/mE2/day IV x5days). Following this regimen, patients will receive an intravenous adoptive transfer of at least 10E9 tumor-reactive lymphocytes followed by high dose IL-2 (720,000 IU/kg/dose IV every 8 hours for up to 15 doses).
224313961|NCT06115044|PROCEDURE|Intermittent diurnal nutrition|Calculated daily nutritional requirement given as three equal bolus feeds in daytime with prolonged overnight fast
224313962|NCT06115044|PROCEDURE|Continuous|Calculated daily nutritional requirement given over 24 hours
224313963|NCT00187382|DRUG|Multiple vs. single courses of antenatalcorticosteroids|
224313964|NCT04157127|BIOLOGICAL|Autologous DC Therapy|Autologous DC Therapy
224205172|NCT01294709|DRUG|Placebo to telcagepant|
224205173|NCT06521281|BEHAVIORAL|Chan-Chuang qigong|Twice daily, every 15 minutes Chan-Chuang qigong
224205174|NCT05322421|OTHER|Topical Olive Oil|Olive oil will be placed in 200 ml opaque glass containers. For each application, a new stick with a sponge will be submerged into one of the agents to absorb then coat the tongue, buccal mucosa, lips, and hard palate. Patients will be instructed to refrain form eating for 1 hour after the application
224205175|NCT05322421|OTHER|Sodium bicarbonate 5% solution|Sodium bicarbonate 5% solution will be placed in 200 ml opaque glass containers. For each application, a new stick with a sponge will be submerged into one of the agents to absorb then coat the tongue, buccal mucosa, lips, and hard palate. Patients will be instructed to refrain form eating for 1 hour after the application
224205176|NCT04470856|DIAGNOSTIC_TEST|End-expiratory occlusion test (EEOT)|An occlusion manoeuvre during the end of expiration for 20 seconds
224205177|NCT04155775|OTHER|Computer electronic health record alert (Best Practice Alert - BPA)|Upon ordering platelets in patients with recent platelet count \>50,000, a pop-up within the electronic health system will recommend to not continue with transfuse product order and provide clinical exceptions to continue. Importantly, the alert does not trigger in operating areas, emergency medicine treatment areas, for certain specialties like neurosurgery or for massive transfusion orders.
224205178|NCT04854707|DRUG|Follitropin Alfa|Subcutaneous injection of follitropin alpha biosimilar only, with daily dose 100-300 IU for 10 days, maximum of 15 days, using antagonists of GnRH or agonist of GnRH.
224205179|NCT04854707|DRUG|Follicle Stimulating Hormone/Luteinizing Hormone|Subcutaneous injection of follitropin alpha biosimilar, with daily dose 100-300 IU for at least 5 days, than added another gonadotropin for a maximum of 10 days, using antagonists of GnRH or agonist of GnRH.
224205180|NCT04854707|DRUG|Follitropin Alfa|Subcutaneous injection of follitropin alpha biosimilar only, with daily dose 100-300 IU for 10 days, maximum of 15 days, using antagonists of GnRH only for suppression.
224205181|NCT04854707|DRUG|Follitropin Alfa|Subcutaneous injection of follitropin alpha biosimilar only, with daily dose 100-300 IU for 10 days, maximum of 15 days, using agonists of GnRH only for suppression.
224205182|NCT04854707|DRUG|Follicle Stimulating Hormone/Luteinizing Hormone|Overall ovarian stimulation protocols with follitropin alpha biosimilar for at least 5 days+other recombinant and menotropins and short (antagonists of GnRH) or long protocol (agonist of GnRH).
224205183|NCT04917029|DRUG|Bupivacaine hydrochloride perineurally|Arm 1; Bupivacaine hydrochloride 40 ml 0.25% perineurally in FICB
224205184|NCT04917029|DRUG|Dexmedetmidine infusion|Arm 1: infusion of Dexmedetmidine 0.5 µg/kg/h
224205185|NCT04917029|DRUG|Dexmedetomidine perineurally|Arm 2:Dexmedetomidine perineurally in FICB 80µg
224205186|NCT03254407|OTHER|Screening medical record|Communicating possible IV/PO switch to prescriber by phone or e-note in medical record
224313965|NCT06906081|DRUG|Kerendia (Finerenone, BAY94-8862)|"Titration of finerenone will be based on baseline eGFR. Participants with eGFR \> 60 mL/min/1.73m² will start on a 20mg dosage. Medication dosage will be increased to 40 mg after one month if serum potassium \< 4.8 mmol/l. If side effects occur at any dosage, the dosage will be reduced to the previous level.~Participants with eGFR \< 60 and \>25 Participants with eGFR \< 60 mL/min/1.73m² (and eGFR \< 25 mL/min/1.73m²) will start on a 10mg dosage. Medication dosage will be increased to 20 mg after one month if serum potassium \< 4.8 mmol/l. Subsequently, Medication dosage will be increased to 40 mg after an additional one month if serum potassium \< 4.8 mmol/l. If side effects occur at any dosage, the dosage will be reduced to the previous level.~Finerenone is administered orally as immediate release tablets."
224313966|NCT06906081|DRUG|Placebo|Placebo tablets matching BAY94-8862 are administered orally.
224313967|NCT06135051|DEVICE|Diadem prototype|The device delivers low-intensity ultrasonic waves into specific brain targets.
224313968|NCT06399432|BEHAVIORAL|Mediterranean Diet|"In the Mediterranean Diet, all foods are included. Red meat will be limited to 1/week, poultry to ≤3 times/week and fish to 2-3 times/week. Supplementation with extra-virgin olive oil and nuts, providing 1 liter of olive oil per week and 30 gr a day of nuts.~The dietician will personalize the dietary advice by adapting it to the patient's condition, preferences and beliefs, will encourage adherence, and transmit a sense of empowerment. A change in diet with specific, attainable goals will be negotiated between the dietician and the participant.~Dieticians will conduct a phone call once in every 2-week period to assess dietary compliance using a 24-hour food recall, the Mediterranean Diet Adherence Form. MD patients will keep a diet diary for 3 days every two weeks, which they will discuss with the dietician during their scheduled dietician assessment. The Baseline Visit with the dietician can occur either in-person or via video communication software."
224313969|NCT03462459|DRUG|Vancomycin|Vancomycin capsule, 125 mg
224313970|NCT03462459|DRUG|Placebo|Capsule containing inert (nonactive) material to mimic 125 mg vancomycin capsule
224313971|NCT01449097|PROCEDURE|Adductor-Canal-Blockade|US-guided Adductor-Canal-blockade with Ropivacaine
224313972|NCT01449097|PROCEDURE|The femoral nerve block|US-guided femoral nerve block with ropivacaine
224313973|NCT01449097|PROCEDURE|Placebo|US-guided Adductor-Canal-Blockade/femoral nerve block with saline
224313974|NCT03441282|DRUG|Fentanyl|"After the patient is attached to an ASA non-invasive monitor, a dose (2mcg/kg) of Fentanyl will be administered.~Groups compared would include patients experiencing respiratory depression vs those not experiencing respiratory depression after fentanyl administration. Their samples would be evaluated for any differences in genetic make-up concerning selected, known sequences affecting opioid-induced analgesia."
223511559|NCT06212323|OTHER|Patients with smoldering myeloma undergoing active surveillance with diffusion weighted whole body MRI.|"Patients with high-risk smoldering myeloma will be prospectively followed and chart review will be performed to determine if progression events happen, and how they happen.~All patients on the study are recommended to undergo the following standard of care surveillance protocol:~* Complete Blood Count (CBC), Complete Metabolic Panel (CMP), myeloma blood tests (serum kappa/lambda light chains, monoclonal protein evaluation, immunoglobulin levels), to be done monthly for first year, and then every two months for the second year.~* WB DW-MRIs every 6 months during the study period.~* 24-hour urine Immunofixation/electrophoresis is expected to be completed approximately every 6 months.~* Bone marrow biopsy will be performed annually during the study time-period."
223511560|NCT04953169|OTHER|Biobank Video|The video describes the process of biobanking with visuals
223511561|NCT04953169|OTHER|Non-Video|The non-video group will receive a written informed consent
223511562|NCT06369545|OTHER|EXERCISE|All participants included in this group will receive Exercises
223511563|NCT06369545|OTHER|TENS|All participants included in this group will receive TENS
223511564|NCT06369545|OTHER|ESWT|All participants included in this group will receive ESWT
223617521|NCT06938360|PROCEDURE|breast-conserving surgery combined with radiotherapy|The experimental group received breast-conserving surgery combined with radiotherapy
224205187|NCT01948011|DRUG|Racecadotril suspension|Racecadotril suspension at 10, 30 and 60mg. Single oral dose.
224205188|NCT01948011|DRUG|Racecadotril granules|Racecadotril granules at 60mg. Single oral dose.
224205189|NCT00259311|DRUG|LY2422347|
224205190|NCT00259311|DRUG|placebo|
224205191|NCT06566053|OTHER|Observation|Observation
224205192|NCT02822612|DEVICE|Binocular OCT prototype|Testing will begin using a prototype binocular OCT system. Subjects will undergo the full suite of diagnostic assessments offered by the system at that time (i.e., visual acuity, ophthalmic history, pupillometry, ocular motility, perimetry, anterior segment and posterior segment OCT imaging).
224313975|NCT06659718|DRUG|Oral semaglutide|New use of oral semaglutide dispensing claim is used as the exposure.
224313976|NCT06659718|DRUG|Sitagliptin|New initiation of sitagliptin dispensing claim is used as the reference.
224313977|NCT06865131|DEVICE|StrataXRT|StrataXRT being a silicone-based cream forming a film, it is very flexible and can be applied easily to the prone position and to the contours of the large breast unlike some other barrier film skin interventions
224205193|NCT05761522|OTHER|transthoracic echocardiography|"* Concerning the main judgment criterion and the secondary judgment criteria:~  * Left ventricular ejection fraction (LVEF) by the Simpson Biplane method,~ * Cardiac output and cardiac index by continuity equation (measurement of left ventricular outflow chamber (mm) and sub-aortic time-velocity integral (cm/s)).~ * Tricuspid Annular Systolic Excursion (TAPSE) (mm)~ * S wave at the tricuspid ring (cm/s)~* Other parameters collected systematically:~  * Surface of the left ventricle (end-systolic and end-diastolic),~ * Global strain of the left ventricle~ * Mitral Annular Plane Systolic Excursion (MAPSE) (mm)~ * Left ventricular filling pressure (LVRP) (at the mitral annulus, E, A, e', S' waves, E/A ratio, E/e');~ * Maximum tricuspid regurgitation velocity (m/s) to estimate systolic pulmonary arterial pressure (PAPs) (mmHg)"
224205194|NCT03878056|DEVICE|Vaginal: UpholdTM Lite Vaginal Support - Boston Scientific|Apical prolapse reconstructive surgery by Transvaginal mesh vs Robotic sacral colpopexy
224313978|NCT03739645|BEHAVIORAL|Skin conductance levels and slopes over time in conditioned fear as metrics.as metrics for anxiety|After fear conditioning the cue induces autonomic responses like skin conductance and cognitive ratings like expectancy of the unconditioned stimulus after cueing or conditioning. Activity across blocks in the conditioning stage shows that the skin conductance can be described by levels, and slopes which might be related to state anxiety and trait anxiety (Spielberger trait and state anxiety inventory or questionnaire). These skin conductance measures may be concrete metrics for psychological processes in healthy subjects. We will carry out a partial correlation analysis of levels, state anxiety and trait anxiety, and then a similar analysis of slopes, state anxiety and trait anxiety. These results may show that concrete skin conductance levels and slopes are related to metrics of subjective self report measures of state and trait anxiety.
224313979|NCT06498869|DRUG|Ketamine Hcl 50Mg/Ml Inj|This group will be administered ketamine (0.25-0.50 mg/kg)
224313980|NCT04666805|DRUG|Tamoxifen|20 mg/d, oral administration
224313981|NCT04666805|DRUG|Toremifene|60 mg/d, oral administration
224313982|NCT04666805|DRUG|Anastrozole|1 tablet (1 mg) per day, oral administration
224313983|NCT04666805|DRUG|Letrozole|Adjuvant therapy with letrozole for 5 years or until the disease relapses. Patients who have received tamoxifen adjuvant therapy for 5 years should continue to take Letrozole until the disease relapses. The recommended dose of Letrozole tablets is one 2.5 mg tablet administered once a day, without regard to meals. For patients with advanced breast cancer, treatment with Letrozole should continue until tumor progression is confirmed. Patients with liver and/or renal dysfunction (creatinine clearance rate ≥ 10 mL/min) do not need to adjust the dosage.
224313984|NCT04666805|DRUG|Exemestane|The recommended dose of Exemestane for adult and older patients with early and advanced breast cancer is one 25 mg tablet administered orally once a day after a meal. After 2-3 years of tamoxifen treatment, patients with early breast cancer should continue to use Tamoxifen in the case of no recurrence or contralateral breast cancer, until the completion of 5-year sequential adjuvant therapy with tamoxifen and exemestane. Patients with advanced breast cancer should continue to take Exemestane until the tumor progresses.
224313985|NCT06758661|DRUG|D352|1 tablet
224313986|NCT06758661|DRUG|D794|4 capsule
224313987|NCT06907537|DIETARY_SUPPLEMENT|Food containing plasmalogen|Take four capsules per day in the morning.
224313988|NCT06907537|DIETARY_SUPPLEMENT|Food without plasmalogen|Take four capsules per day in the morning.
224313989|NCT04465552|OTHER|Patients received standard of care treatment during hospitalization|All patients admitted with covid-19 will be enrolled and followed for the duration of their hospitalization as well as during outpatient follow for up to 6 months, in those recovered, to assess clinical outcomes.
223511565|NCT06413134|DEVICE|TheraPAP|TheraPAP is a novel CPAP-based therapy in which pressure is dropped as much as 5 cmH2O starting at the beginning of inspiration and extending through the end of expiration where it rises back up to the true therapy pressure for a short period. It improves comfort by providing pressure only when it is needed and maintaining it at a low level the rest of the time. Normal CPAP/APAP therapy keeps pressure at the therapy level during the entire breath cycle, except with some alternate approaches where pressure is decreased but only during the expiratory phase.
223511566|NCT06413134|DEVICE|APAP|Standard CPAP therapy where therapy pressure is automatically adjusted to prevent respiratory events from occurring. The TheraPAP prototype device will be used to operate in the APAP mode in addition to the TheraPAP intervention mode.
223511567|NCT04785352|DIETARY_SUPPLEMENT|Nutrition Intervention|One egg per day for six months
223511568|NCT04785352|BEHAVIORAL|Grandi Byen|Multicomponent intervention on responsive parenting, nutrition, hygiene + one egg per day for 6 months
223511569|NCT02762890|DRUG|Deep neuromuscular blockade|neuromuscular blockade will be performed using a continuous infusion of rocuronium. Post-tetanic count 1-2 will be maintained during surgery. After the end of surgery, sugammadex of 4 mg/kg will be administered to reverse neuromuscular blockade.
223511570|NCT02762890|DRUG|Moderate neuromuscular blockade|neuromuscular blockade will be performed using a continuous infusion of rocuronium. Train-of-four 1-2 will be maintained during surgery. After the end of surgery, sugammadex of 2 mg/kg will be administered to reverse neuromuscular blockade.
223511571|NCT05994534|DRUG|Cysteamine Bitartrate|Single dose, tablets at current therapeutic dose
223511572|NCT05994534|DRUG|N-Acetylcysteine Amide|Single dose, oral solution
223511573|NCT00495781|PROCEDURE|%-hypo (laboratory parameter, functional iron deficiency)|
223511574|NCT00495781|PROCEDURE|CHr (laboratory parameter, functional iron deficiency)|
223511575|NCT00495781|PROCEDURE|RET-HE (laboratory parameter, functional iron deficiency)|
223511576|NCT02576704|DEVICE|semi conductor gamma camera|we use a new mathematic technique from entropy analysis to provide precise, objective, automated quantification of perfusion heterogeneity at stress with camera SPECT. This method may be a non-invasive imaging to assess coronary microvascular dysfunction.
224313990|NCT03623178|OTHER|Assertive Community Treatment|The intervention program is a type of very flexible community treatment. This is facilitated by a small case load ratio per health care professional (1:10). The healthcare workers are specialized in SUD treatment. The time of the intervention differs, there is no prefixed limitation but the duration of the intervention depends on the goals agreed on with the patient. The main objective of this intervention is to ensure an adherence to an addiction treatment program and establish or consolidate a stable healthcare and social network for the patient. The intervention aims to prevent service disengagement. The healthcare workers will explore specific patient needs and ensure that health and social services are better coordinated to fit their needs.
224205195|NCT03284515|BIOLOGICAL|Vaccination with a pertussis containing vaccine|Vaccination with a pertussis containing vaccine
224205196|NCT05648097|DEVICE|Baldachin|"Environmental intervention: Equipment of a patient space of a patient with confirmed COVID-19 in open-space multiple bed Intermediate Care Unit areas with a mobile, optimally placed high efficiency particulate air (HEPA)-equivalent air filtration unit (Baldachin) in addition to existing room ventilation and hospital policy infection prevention and control measures."
224205197|NCT05311215|DRUG|SL-1002|SL-1002 injectable solution
224205198|NCT05311215|DRUG|Placebo|Matching placebo injectable solution
224205199|NCT00954694|DEVICE|NuStep fitness apparatus|The NuStep is a mode of exercise that has recently been used in clinical settings to determine appropriate intensity recommendations and energy expenditures. The NuStep exercise implement provides simultaneous upper and lower body movement while in a seated position. The machine stimulates all major muscle groups while putting minimal strain on joints. Ten resistance settings are offered and the device is fully adjustable to accommodate users of varying sizes (NuStep, 2009).
224205200|NCT04365829|DEVICE|"virtual reality headset Occulus GO"|"Use of a virtual reality headset for one week at a frequency of 3 days per week (D1, D3 and D5). During each session (1 hour), the subject will visualize a scene of natural virtual environment (a garden, animals in the wild, a grand Canyon) lasting 7 min using an virtual reality headset Occulus GO."
224205201|NCT01612780|DEVICE|XprESS Multi-Sinus Dilation Tool|Sinus balloon dilation
224205202|NCT03466060|DEVICE|Opti-Free : RevitaLens / Clear Care : RevitaLens|Subjects between the ages of 18-69 will be randomized to 1 of 3 lenses. Solutions will be administered contralaterally with 1 test solution and 1 of 2 control solutions prior to the subjects' follow-up visits.
224205203|NCT03466060|DEVICE|Opti-Free : RevitaLens / RevitaLens : Clear Care|Subjects between the ages of 18-69 will be randomized to 1 of 3 lenses. Solutions will be administered contralaterally with 1 test solution and 1 of 2 control solutions prior to the subjects' follow-up visits.
224205204|NCT03466060|DEVICE|Clear Care : RevitaLens/ Opti-Free : RevitaLens|Subjects between the ages of 18-69 will be randomized to 1 of 3 lenses. Solutions will be administered contralaterally with 1 test solution and 1 of 2 control solutions prior to the subjects' follow-up visits.
224205205|NCT03466060|DEVICE|Clear Care : RevitaLens / RevitaLens : Opti-Free|Subjects between the ages of 18-69 will be randomized to 1 of 3 lenses. Solutions will be administered contralaterally with 1 test solution and 1 of 2 control solutions prior to the subjects' follow-up visits.
224313991|NCT06915857|DEVICE|Topical Betamethasone|Betamethasone a TC, reduces RD by promoting the synthesis of anti-inflammatory proteins while also preventing other inflammatory proteins from being synthesized
224313992|NCT06927700|BEHAVIORAL|Modified Risk Claim Type - None|Participants will view smokeless tobacco ads with no modified risk claim (control)
224313993|NCT06927700|BEHAVIORAL|Product Brand - General Snus|Participants will views ads for the smokeless tobacco brand General Snus
224313994|NCT06927700|BEHAVIORAL|Product Brand - Copenhagen|Participants will views ads for the smokeless tobacco brand Copenhagen
224313995|NCT06927700|BEHAVIORAL|Modified Risk Claim Type - Multiple Diseases|Participants will view smokeless tobacco ads with a claim about lower risks for multiple diseases
224205206|NCT03466060|DEVICE|RevitaLens : Clear Care/ Opti-Free : RevitaLens|Subjects between the ages of 18-69 will be randomized to 1 of 3 lenses. Solutions will be administered contralaterally with 1 test solution and 1 of 2 control solutions prior to the subjects' follow-up visits.
224205207|NCT03466060|DEVICE|RevitaLens : Clear Care / RevitaLens : Opti-Free|Subjects between the ages of 18-69 will be randomized to 1 of 3 lenses. Solutions will be administered contralaterally with 1 test solution and 1 of 2 control solutions prior to the subjects' follow-up visits.
223511577|NCT01543230|DEVICE|Total hip replacement|Total hip arthroplasty (THA) using CoMplete™ Acetabular Hip System
223511578|NCT05457205|OTHER|Electrical neuromodulation|Electrical neuromodulation intervention using transcutaneous spinal stimulation: two self-adhesive semicircle electrodes (forming a 5cm round electrode) will be centered midline over the T11-12 spinal processes, and two 8×13 cm electrodes will be placed paraumbilical and interconnected to serve as a counter electrode. A current-controlled stimulator will deliver symmetric biphasic pulses (500-μs/phase). Electrical stimulation will be applied according to the description in each study arm.
224205208|NCT03466060|DEVICE|RevitaLens : Opti-Free / Clear Care : RevitaLens|Subjects between the ages of 18-69 will be randomized to 1 of 3 lenses. Solutions will be administered contralaterally with 1 test solution and 1 of 2 control solutions prior to the subjects' follow-up visits.
224313996|NCT06927700|BEHAVIORAL|Modified Risk Claim Type - Lung Cancer|Participants will either view smokeless tobacco ads with a modified risk claim about lower risks for lung cancer only
224313997|NCT04215991|DRUG|Cefiderocol|Administered intravenously over 3 hours
224313998|NCT04215991|DRUG|Standard of Care|Standard of care administered will be selected by the investigator based on the suspected or confirmed pathogen(s) for the infection in accordance with local standards.
224205209|NCT03466060|DEVICE|RevitaLens : Opit-Free / RevitaLens : Clear Care|Subjects between the ages of 18-69 will be randomized to 1 of 3 lenses. Solutions will be administered contralaterally with 1 test solution and 1 of 2 control solutions prior to the subjects' follow-up visits.
224205210|NCT00012194|DRUG|7-hydroxystaurosporine|Given IV
224205211|NCT00012194|DRUG|cisplatin|Given IV
224205212|NCT00012194|OTHER|laboratory biomarker analysis|Correlative studies
224205213|NCT06402890|DIETARY_SUPPLEMENT|Resistance training with collagen supplementation|"Participants performed 24 lower limb resistance training sessions over under supervision from the principal investigator. Participants were pair-matched, then allocated to hydrolysed collagen (COL) or a calorie-matched beverage comprising maltodextrin and non-caloric sweetener (PLA). Both COL and PLA consumed their respective supplements in conjunction with each resistance training session.~Baseline assessments of strength were used to set initial training loads. An example of weekly training is included below for indicative purposes:~Week 1 protocol:~Day 1:~* Barbell squat, 4 sets @ 90% 10-RM~* Romanian deadlift, 4 sets @ 90% 10-RM~Day 2:~* Hex bar deadlift, 4 sets @ 90% 10-RM~* Dumbbell goblet squat, 4 sets @ 90% 10-RM~Linear progression adjusted weekly loads. If participants completed the prescribed sets and reps, loads increased by 2.5-5 % the following week."
224205214|NCT06422832|OTHER|HeartLogic or TriageHF Algorithms for implantable devices|Activation of the HeartLogic and TriageHF algorithms for implantable devices and correctly act according to its design
224205215|NCT02784002|DRUG|Ridinilazole|
224314004|NCT06943222|OTHER|Traditional Play|"The intervention for the traditional play group included activities such as Shtapu and skipping rope. Both traditional play activities were scheduled 3 times per week (3 Session/week) over the 6-month period.~Both activities took place outdoors and in the institutional gymnasium, depending on the prevailing weather conditions. Each session lasted 35 minutes and took place in the morning hours (8-11 a.m.). Prior to each type of activity, a specific warm-up was conducted, following methodological guidelines for preschoolers' physical education."
224314005|NCT06954532|BEHAVIORAL|Interoceptive training|There will be 6 interoceptive training sessions. Each training session will comprise two blocks, between which participants will undergo a self-paced, light physical activity that aims to enhance heartbeat perception and lasts 2 to 3 minutes. During the pre- and post-exercise block, each participant will complete cardiac interoceptive tasks, and for each trial, note their confidence in their answer on a visual analogue scale and then be given accurate feedback about their objective heartbeat perception accuracy, relative to their objective accuracy.
224314006|NCT05927363|OTHER|Therapeutic educational consolidation program in Phase 3 of cardiac rehabilitation associating a patient & caregiver partnership|"In the experimental group, patients benefit from the usual management as part of the phase 2 post-CR follow-up, with the provision of an information booklet on the benefits of physical activity, and a telephone contact in the event of any questions. In addition, they benefit from the Consolidation therapeutic education program in phase 3 of CR associating a patient \& caregiver partnership, which consists of two teleconsultation sessions at 2 and 4 months, followed by a remote group education workshop co-facilitated by the patient and caregiver partnership at 5 months.~Discussions during teleconsultations will be recorded to identify the main barriers to physical activity mentioned by patients, and the responses provided by the healthcare professional-peer helper pair during the therapeutic education sessions."
224205216|NCT02784002|DRUG|Fidaxomicin|
224205217|NCT05298215|BIOLOGICAL|UB-221|UB-221 is a recombinant humanized IgG1 monoclonal antibody with neutralizing capability against soluble human IgE and CD23-bound IgE for the treatment of allergic diseases. The activity of UB-221 is directly through the high-affinity binding with soluble and membrane bound IgE. The neutralization of soluble IgE will desensitize the activation of mast cells and basophils by inhibiting IgE cross-linking and down-regulation of FcεRI (high affinity IgE receptor) expression on those cells. The binding to CD23-bound IgE may inhibit IgE synthesis by stabilization of membrane-bound CD23 on B lymphocytes.
224205218|NCT05298215|OTHER|sterile saline solution|sterile saline solution (0.9% NaCl) for intravenous (IV) infusion
224205219|NCT02297607|DIETARY_SUPPLEMENT|Tube Feeding|
224314007|NCT05927363|OTHER|Teleconsultation at 2 months|Discussions during teleconsultations will be recorded to identify the main barriers to physical activity mentioned by patients, and the responses provided by the healthcare professional-peer helper pair during the therapeutic education sessions.
224314008|NCT05927363|OTHER|Teleconsultation at 4 months|Discussions during teleconsultations will be recorded to identify the main barriers to physical activity mentioned by patients, and the responses provided by the healthcare professional-peer helper pair during the therapeutic education sessions.
224314009|NCT05927363|OTHER|Remote group education workshop|This remote workshop will be co-facilitated by the patient and caregiver partnership at 5 months
224314010|NCT05927363|OTHER|Administration of self-questionnaires: IPAQ, EMAPS, the Exercise Confidence Survey, EQ-5D-5L and the Mediterranean diet adherence score.|Patients are then randomly assigned to either the control group (usual management) or the experimental group (management with Patient and Caregiver partnership).
223511579|NCT01063803|DRUG|ATN-103|A single subcutaneous injection of ATN-103 every 4 weeks (approx 13 SC injections during the study)
223511580|NCT01063803|DRUG|ATN-103|A single subcutaneous injection of ATN-103 every 4 weeks (approx 13 SC injections during the study)
224314011|NCT05927363|DIAGNOSTIC_TEST|6-minute walk test and administers the modified Borg scale at its conclusion.|What is a modified Borg scale? The Modified Borg Dyspnea Scale is a 0 to 10 rated numerical score used to measure dyspnea as reported by the patient during submaximal exercise and is routinely administered following a six-minute walking test, one of the most common and frequently used measures to assess disease severity in patients with pulmonary arterial hypertension. Upon conclusion of the 6-minute walking test, the modified Borg scale will be recorded.
223511581|NCT04409769|OTHER|Description of use of ceftaroline and ceftobiprole|Ceftaroline and ceftobiprole are the only betalactam active on methicillin-resistant staphylococci. Description of condition of use of thoses antibiotics in PJI and BJI
223511582|NCT03355092|DEVICE|vBloc Therapy|The vBloc device will be placed using a laparoscopic procedure. The participants will be followed according to standard clinical practice and vBloc therapy protocol under the supervision of study surgeons. . Pre-operative testing will be conducted per surgeon's evaluation. Participants will receive weight management education according to the vBloc Therapy protocol.
223617522|NCT06937151|PROCEDURE|Rocabado approach exercise program 6×6 and manibulation .|Rocabado's approach (Rocabado's 6 × 6 Exercises and manipulation). This program included 6 exercises to be performed 6 times a day, repeated 6 times, and three gliding exercises.
224205220|NCT02312752|DEVICE|Intra-epidermal stimulation electrode|"A small piece of plastic with a tiny sharp protruding tip (the intra-epidermal stimulation electrode) will be applied to the foot and hand. Small sticker electrodes will be placed over nerves on the forearm or ankle. A stimulus will be applied to the electrode for intra-epidermal stimulation. The stimulus will be gradually increased from no stimulus to a stimulus that is barely felt as a pin-prick type of sensation. Thereafter, the stimulus will be applied 5-15 times per second for 10 periods of 40-60 seconds."
224205221|NCT05494580|DRUG|Pamiparib|Oral
224205222|NCT05494580|DRUG|Surufatinib|Oral
224205223|NCT05268523|BEHAVIORAL|Education and Strategies Intervention|Sessions will be led by registered therapists and clinicians in the fields of psychology, rheumatology, cardiology and neurology. The sessions will be comprised of educational presentations on the nature of persisting symptoms after COVID-19 and associated recommendations for self-management.
224205224|NCT05268523|BEHAVIORAL|Mindfulness Skills Intervention|The Mindfulness Skills Intervention is an 8-week program designed to provide an introduction to some basic mindfulness skills. Each session begins with a brief breath focus practice followed by discussion of the experience and sharing/discussion of the previous week including participants' experiences. Each session also includes some didactics, and a new, related mindfulness skill is introduced and practiced, followed by another discussion.
224205225|NCT05282810|OTHER|tympanoplasty|use of cartilage versus tempotalis fascia in tympanoplasty for recuurent perforation
224205226|NCT04007406|DRUG|dexfadrostat phosphate|DP13 systemic administration
224205227|NCT03870061|BEHAVIORAL|All Babies Are Equal Initiative (conditional cash transfer program)|New Incentives, an NGO, offers cash incentives to caregivers for bringing their child to clinics for the first five visits of the Nigerian Routine Immunization schedule. These small cash transfers can provide some material benefit to new caregivers from poor communities. At a minimum, they help offset time and transport costs. The following vaccines are directly incentivized by the New Incentives' program: tuberculosis (BCG vaccine); diphtheria, tetanus, pertussis, hepatitis B and Haemophilus influenzae Type B (Pentavalent Vaccine), pneumococcal bacteria (PCV vaccine), measles vaccine.
224205228|NCT04253028|DEVICE|NERv's Inline Device|NERv's Inline Device attaches to existing catheters or peritoneal drains that are currently being used in the medical industry. This allows the device to measure the pH and conductance of intraperitoneal fluids that typically get drained through peritoneal drains.
224205229|NCT00263393|DRUG|ASA, Atenolol, hydrochlorothiazide, ACE inhibitor, Statin|The first intervention was a clinical algorithm designed to enhance the identification and treatment of high-risk individuals compared to continued usual care. The algorithm was designed to be used by either physician or non-physician health care workers.
224205230|NCT00263393|BEHAVIORAL|Health Promotion|The second intervention was a health promotion program designed to increase knowledge of cardiovascular risk factors compared to continued usual practices.
224314012|NCT05927363|DIAGNOSTIC_TEST|Biological check-up|This check-up includes total cholesterol, LDL, HDL, triglycerides, HbA1c.
224314013|NCT05927363|DEVICE|Accelerometer|"An accelerometer is given to the patient, with instructions to wear it for 7 days following the visit (it will then be returned by post).Pre-stamped bubble envelopes are given to the patient to return their accelerometer to the measurement points specified in the follow-up."
224314014|NCT05927363|OTHER|Administration of a logbook|The patient is given a logbook for daily monitoring of non-measurable physical activities, treatments and medical procedures carried out, as well as any intercurrent events.
224314015|NCT05978141|OTHER|Optional Blood Sample and Nail Sample|Participants may provide optional research blood and nail samples for biobanking and future use
224314016|NCT04802564|OTHER|regular hand therapy|edema control, scar management, stretching regimen, tendon gliding exercise, blocking exercise, muscle strengthening protocols
224314017|NCT00072787|DRUG|S-1|
224314018|NCT00072787|DRUG|cisplatin|
224314019|NCT02302989|DRUG|Ranibizumab 0.5mg|
224314020|NCT00154518|PROCEDURE|Orthodontic treatment|
224314021|NCT04618640|BIOLOGICAL|DTaP-IPV combination vaccine|Dosage and administration: A single intramuscular injection of 0.5 mL will be given to healthy children aged 4 to 6 years
224314022|NCT03106389|DRUG|Misoprostol|400 micro grams misoprostol administered vaginally followed every 6 hours by 400 micro grams orally until complete expulsion
224314023|NCT03106389|DEVICE|Misoprostol/Transcervical catheter|Foleys' catheter introduced into the cervix and inflated with 30 ml. of fluid; weighted traction applied by using a 1000 ml fluid-filled bag
224314024|NCT02836314|OTHER|Anorganic Bovine Bone Mineral (ABBM)|In the control group, periodontal intrabony defects were treated with ABBM alone.
224314025|NCT02836314|OTHER|Anorganic Bovine Bone Mineral and Platelet Rich Fibrin (PRF)|In the test group, periodontal intrabony defects were treated with ABBM and PRF combination.
224314026|NCT00750581|DRUG|Indomethacin|Infants randomized to Escalating Dose group will receive indomethacin (0.2 mg/kg/dose) at 12 hr intervals for 2 doses, followed by indomethacin (0.3 mg/kg/dose) at 12 hr interval for 2 doses, then Indomethacin (0.4 mg/kg/dose) at 12 hr interval for 2 doses, increased to indomethacin (0.5 mg/kg/dose) at 12 hour interval for 2 doses and finally indomethacin 0.6 mg/kg/dose at 12 hourly interval for 2 doses.
224314027|NCT00373633|PROCEDURE|Thoracic Epidural|Gold standard for post thoracotomy pain
224314028|NCT00373633|PROCEDURE|Extrapleural Intercostal Catheter|Continuous extra-pleural intercostal local anesthesia
224314029|NCT06142318|DRUG|Pirfenidone|Dose climbing started two weeks before the start of radiotherapy, and the maintenance dose of 600mg bid was reached in the third week until the end of radiotherapy.
224314030|NCT06142318|DRUG|Placebo|Dose climbing started two weeks before the start of radiotherapy, and the maintenance dose of 600mg bid was reached in the third week until the end of radiotherapy.
224314031|NCT03778684|DIAGNOSTIC_TEST|Visceral fat thickness|An initial longitudinal sweep will be done from the xiphoid process to the umbilicus to determine the area of maximum pre-peritoneal fat thickness.
224314032|NCT03778684|DIAGNOSTIC_TEST|Body mass index|Weight and height will be measured with subjects in a standing position wearing light clothes and no shoes.
224314033|NCT03252561|PROCEDURE|Ultrasound guided Transversus Abdominis Plane (TAP) bock|Ultrasound guided TAP bock with Bupivacaine 0.25% 20ml per side or to a maximum 1mg/kg per side and the skin puncture will be covered with a small plaster
224205231|NCT06414265|DEVICE|Transcatheter mitral valve replacement|The SATURN TS TMVR System will be implanted through a transcatheter approach in patients with symptomatic mitral regurgitation.
224205232|NCT00157040|DRUG|Antihemophilic factor, recombinant, manufactured protein-free|
223761368|NCT04527861|PROCEDURE|Single-incision Laparoscopic Surgery|In this group，the surgery is performed through a single incision. The surgeon will adjust surgical position to expose the operative field with the help of gravity. Besides，hand over hand cross and parallel techniques are needed to achieve the SILS. All the other operative procedures are the same as conventional laparoscopic surgery.
223761369|NCT04527861|PROCEDURE|Conventional Laparoscopic Surgery|In this group，the surgery is performed through 3-5 ports according to the surgeons habits and specific conditions.
224314034|NCT03252561|PROCEDURE|Local anaesthetic infiltration of laparoscopic port sites|Laparoscopic port sites will be infiltrated with a total of 20 mls 0.5% bupivacaine subcutaneously at the end of the procedure in the control group and plasters will be stuck on either side approximately where a skin puncture for tap block would be made.
224314035|NCT02647385|DRUG|Block with lidocaine for SAM and PEC I block|"Patients could be submitted to general anesthesia or general anesthesia associated with SAM and PEC I block with lidocaine before mastectomy.~Interventions: include pain assessment, inflammatory response and opioid consumption."
224314036|NCT01533012|PROCEDURE|Pressure difference|Peak inspiratory pressures difference between two lungs
224314037|NCT05860855|PROCEDURE|Augmentative craniotomy|Expansion of the skull
224314038|NCT05860855|PROCEDURE|Decompressive craniotomy|Standard hemicraniectomy
224314039|NCT03132155|DRUG|AMG 337|6-{(1R)-1-\[8-fluoro-6-(1-methyl-1H-pyrazol-4-yl)\[1,2,4\]triazolo\[4,3-a\]pyridin-3-yl\]ethyl}-3-(2-methoxyethoxy)-1,6-naphthyridin-5(6H)-one•hydrate (1:1)
224314040|NCT04584762|DEVICE|Automated Variable Pressure Insufflation|Acute migraine treatment
224314041|NCT01654016|DRUG|Detralex|Detralex 500 mg twice daily for three month prior to surgery
224314042|NCT00538369|OTHER|Ramsay Scale|While receiving sedation, subjects will be monitored with the Ramsay scale
223761370|NCT06242210|OTHER|pursed lip|pursed lip breathing technique for group A through videos on smart phones and a brochure given to patients. Each session takes 15-20 minutes until researchers ensure that patients understand how to perform exercises and re-demonstrate them. • Each group applied it twice per day for a period of 4 weeks. Telephone follow-up was used for patients in both groups
224314043|NCT00538369|DEVICE|Bispectral index monitor|While receiving sedation, subjects will receive BIS monitoring
224314044|NCT04638101|BEHAVIORAL|Mindfulness-based intervention|Mindfulness-based intervention: The proposed MBI was designed based on well-known MBI programs including Mindfulness-Based Stress Reduction and Mindfulness-Based Cognitive Therapy and adapted to adolescents' needs and language. The program consisted of 8 weekly sessions in groups of up to 8 participants, lasting 1h30. Two MBI groups were offered per week (Wednesdays and Fridays) and participants had the possibility to choose the most convenient day for them. Two instructors were present for each group throughout the intervention.For each session one theme was addressed, such as attention and the stabilisation of the focus of attention, bodily sensations, breath, emotions, thoughts, compassion, stress, stress reactivity and coping strategies.
224314045|NCT05089669|OTHER|Interactive e-book|The nasogastric tube feeding interactive e-book has a lot of elements such as text content, videos, pictures, links, and other interactive content with which the students can interact. The participants can use the interactive e-book to learn nasogastric tube feeding.
223617523|NCT06937151|PROCEDURE|Arthrocentesis|"Participants in the Control Group underwent arthrocentesis of the affected temporomandibular joint. The procedure was performed as follows:~Anesthesia: Local anesthesia was administered to the area surrounding the TMJ.~Needle Insertion: A 20-gauge needle was inserted into the upper joint space approximately 10 mm anterior to the tragus.~Lavage: The joint was lavaged with lactated Ringer's solution to reduce inflammation and remove debris. The joint was irrigated with lactated Ringer's solution."
223617524|NCT06937567|BIOLOGICAL|CDH17 CAR-T|The initial dose of cell therapy in this clinical study was set at 1.0×106/Kg and the maximum dose was set at 6.0×106/Kg.
223617525|NCT03628976|OTHER|tVNS|Intervention
223761371|NCT06242210|OTHER|Stacked Breathing|The technique will be administered to the patient under supervision for 10 minutes, and the patient will be instructed to use this trained exercise in his daily routine as per needed
224205233|NCT02143401|OTHER|Laboratory Biomarker Analysis|Correlative studies
224205234|NCT02143401|BIOLOGICAL|Navitoclax|Given PO
224205235|NCT02143401|OTHER|Pharmacological Study|Correlative studies
224205236|NCT02143401|DRUG|Sorafenib|Given PO
224205237|NCT02143401|DRUG|Sorafenib Tosylate|Given PO
224205238|NCT01825499|OTHER|Registry|
224205239|NCT05738083|DIAGNOSTIC_TEST|Machine Leaning Models|"Area Under the Curve (ROC): Measures the overall performance of the model across all classification thresholds. A higher AUC value indicates better performance.~Accuracy: The proportion of correctly predicted outcomes (both positive and negative) out of all predictions made.~Precision (Positive Predictive Value, PPV): The proportion of correctly predicted positive outcomes out of all predicted positive outcomes.~Sensitivity (True Positive Rate, TPR): The proportion of actual positive outcomes that are correctly identified by the model.~Specificity (True Negative Rate, TNR): The proportion of actual negative outcomes that are correctly identified by the model."
224205240|NCT06701604|DIETARY_SUPPLEMENT|Single Strain Probiotic + Milk Protein|• Both conditions matched flavor, color, and serving size
224314046|NCT05089669|OTHER|paper textbook|The paper textbook has text content and pictures. The participants can use the paper textbook to learn nasogastric tube feeding.
224314047|NCT05790603|DEVICE|Intervention group with PHD-Band|The initial compression pressure was systolic blood pressure plus 10mmHg. Pressure will be released by 20mmHg and 40mmHg 1 hour and 2 hours respectively after the surgery and then the band will be removed after 3 hours if no bleeding occurs. The compression will continue if bleeding occurs.
224314048|NCT05790603|DEVICE|Control group with TR-Band|TR-Band will be inflated with 15 mL of air The band will be deflated with 1 mL of air hourly for the following 2 hours after the procedure. After 3 hours, the band will be removed if no bleeding occurs. If rebleeding occurs, the band will be inflated with appropriate volume of air until bleeding stops .
224314049|NCT03763305|DRUG|Propofol continuous infusion|Propofol intravenous continuous infusion for anesthetic induction and maintenance
224205241|NCT06701604|DIETARY_SUPPLEMENT|Placebo + Milk Protein|• Both conditions matched flavor, color, and serving size
224205242|NCT05894668|OTHER|ECIRS|Endoscopic Combined Intrarenal Surgery
224205243|NCT00045396|DRUG|tipifarnib|Given orally
224205244|NCT01761617|BEHAVIORAL|Yoga class once per week|"The protocol consists of one 75-minute yoga class per week for 12 weeks. The 12 weeks are divided into four 3-week segments, each with a theme (e.g., Listening to the Wisdom of the Body, Engaging your Power). The number of postures learned and degree of difficulty increases with each segment. The protocol provides variations and uses various aids (e.g., chair, yoga strap, yoga block) to accommodate a range of physical abilities. Classes are taught by a team of yoga instructors to ensure a low participant-to-teacher ratio."
224205245|NCT01761617|BEHAVIORAL|Yoga class twice per week|"The protocol consists of two 75-minute yoga classes per week for 12 weeks. The 12 weeks are divided into four 3-week segments, each with a theme (e.g., Listening to the Wisdom of the Body, Engaging your Power). The number of postures learned and degree of difficulty increases with each segment. The protocol provides variations and uses various aids (e.g., chair, yoga strap, yoga block) to accommodate a range of physical abilities. Classes will have eight participants at a time and are taught by a team of two yoga instructors to ensure a low yoga participant-to-teacher ratio."
224205246|NCT05552235|DEVICE|Elbow SOFT 300|15 patients will be included in this group and will used the medical device ElbowSOFT 300 during sport practice (at least 2 sport sessions per week), for 6 weeks.
224205247|NCT05552235|OTHER|Control group|15 patients will be included in this control group and will performed their sport sessions as usual (without the medical device), for at least 2 sport sessions per week during 6 weeks.
224205248|NCT04454619|DRUG|Hand antisepsis with Clorhexidine and solution|Hand antisepsis by scrub Surgical Hand scrubbing using chlorhexidine digluconate with the addition of an alcoholic solution of chlorhexidine digluconate and potassium sorbate. both hands using a sterile disposable surgical scrub brush with plastic bristles on one side and a foam sponge on the other side
224205249|NCT04885816|DEVICE|Drug Eluting Balloon (DEB)|"Size (diameter and length) will be chosen at operator's discretion aid by simple angiography, quantitative coronary analysis (QCA), or intravascular image; so that the lesion previously prepared and 2 mm at each end are covered by DEB, and the diameter and pressure used aims a balloon to artery ratio of 1. In case of significant recoil (more than 30% for main vessels and 50% for side vessels), coronary perforation or flow limiting dissection, provisional stent will be implanted with a stent to artery ratio of 1.1 with stent post-dilatation when indicated. Device will be used in accordance with the CE mark instructions.~DAPT will be given for a month with aspirin and a P2Y12 inhibitor (clopidogrel will be favored). Single anti-platelet therapy (SAPT) with aspirin will be continued thereafter."
224205250|NCT04885816|DEVICE|Drug Eluting Stents (DES)|"Size (diameter and length) will be chosen at operator's discretion aid by simple angiography, quantitative coronary analysis (QCA), or intravascular image; so that the lesion previously prepared and 2 mm at each end are covered by DES with an stent to artery ratio of 1.1. Post-dilatation will be performed when indicated. Devices will be used in accordance with the CE mark instructions.~DAPT will be indicated according to actual international guidelines."
224205251|NCT02360059|DRUG|Metformin|Metformin dose starts at 500 mg daily for 5 days, followed by 500 mg twice daily for 5 days, followed by 1,000 mg twice daily for 2 days. Participants reach required study medication dose of 2,000 mg daily 2 days prior to commencement of Paclitaxel therapy and continue this dose for remainder of intervention.
224205252|NCT02360059|OTHER|Placebo|Participants take placebo by mouth twice daily starting 12 days before, and 12 weeks during Paclitaxel treatment.
224205253|NCT02360059|BEHAVIORAL|Questionnaires|Questionnaires completed about numbness and/or symptoms about 2 weeks before start of Paclitaxel, 1 -2 days before Paclitaxel, every week while taking Paclitaxel, and at end of study visit. At week 12, questionnaire completed regarding satisfaction with Paclitaxel.
224205254|NCT02360059|OTHER|Sensory and Fine-Motor Tests|Three sensory and fine-motor tests completed 2 weeks before Paclitaxel, every 3 weeks while taking Paclitaxel, and at end of study visit.
224205255|NCT05189145|DRUG|estradiol valerate|8mg orally on daily basis for 13 days beginning with the first day of either a spontaneously or induced menstrual cycle then assess by ultrasound
224205256|NCT05189145|OTHER|Hormonal monitoring progesterone, estradiol, luteinizing hormone|Serum Progesterone, estrogen \& LH measured on day 13 after priming endometrium with 8mg estradiol valerate on a daily basis beginning as early as the first day of menstrual cycle.
224205257|NCT05189145|DIAGNOSTIC_TEST|transvaginal ultrasound examination|Patients examined using transvaginal ultrasonography on day 13 of exogenous estrogen supplementation to measure endometrial thickness and to detect signs of escape ovulation
224205258|NCT05189145|DRUG|Progesterone 400 Mg Vaginal Suppository|Progesterone supplements given in form of daily two vaginal prontogest suppositories400 mg each
224205259|NCT05189145|OTHER|Hormonal monitoring progesterone and estradiol|Measuring the serum Progesterone \& Estradiol in the early morning on the day of embryo transfer an progesterone supplementation adjusted as follows: Group II A: If P4 levels \< 5ng/dl, one 100 mg intramuscular injection daily added, Group II B: If P4 levels 5-10ng/dl, dydrogesterone three times daily added. Group II C: If P4 levels \>10ng, continued on 400 mg prontogest suppositories twice daily
224205260|NCT05189145|DRUG|Progesterone|group II A: 100 mg intramuscular injection daily Group II B: If P4 levels 5-10ng/dl dydrogesterone added
224205261|NCT04557982|PROCEDURE|A painful procedure (peripheral venepuncture)|The child will undergo a peripheral venepuncture during a scheduled visit to a hospital clinic and routinely provided care.
224314050|NCT03763305|DRUG|Remifentanil|Remifentanil intravenous continuous infusion for anesthetic induction and maintenance
223617526|NCT03628976|OTHER|Motor training|Same finger training for both arms
223617527|NCT06262724|PROCEDURE|Breast auto-augmentation|Single group assignment. All patients included were subjected to utilizing chest wall perforator flaps for breast reshaping.
223617528|NCT04730856|DRUG|Tinzaparin|"day subcutaneously • Follow-up phase 1 (Day 15 to day 30): The information is obtained at discharge and on day +14, + 28 on 30 days. The latter information is obtained from patients, from medical records or by telephone contact at the patient's home.~• Follow-up phase 2 (At 3 months: Information is obtained from patients, medical records, or by telephone contact at the patient's home."
224314051|NCT03763305|DRUG|Sevoflurane|Study participants receive fentanyl 1mcg/kg and propofol 1.5\~2mg/kg for induction of general anesthesia. For maintenance of anesthesia, desflurane is used to maintain 1 age-related minimum alveolar concentration (MAC).
224205262|NCT01136044|OTHER|septocutaneous perforator flap|Perforator flaps can be based on septocutaneous or musculocutaneous perforators. If septocutaneous perforators are present, the harvest of these flaps is more straight forward and the dissection of the pedicle is easy.
224205263|NCT02297724|OTHER|Oxygen|Administration of oxygen will last for no more than 10 min, with flow rate 15L/min via non-rebreather facial mask. Each subject will have once of the administration per scan.
224205264|NCT05161559|PROCEDURE|Etching with phosphoric acid gel (3M ESPE, St. Paul, MN, USA)|Etching enamel surface using phosphoric acid gel (3M ESPE, St. Paul, MN, USA)
224205265|NCT05161559|PROCEDURE|Self-etch adhesive (Kuraray, Tokyo, Japan)|No Etching enamel surface using phosphoric acid (self-etch technique) (Kuraray, Tokyo, Japan)
224205266|NCT05161559|PROCEDURE|Chemical bond adhesive (GC, Corporation, Tokyo, Japan)|Chemical bond with hydroxyapatite crystals of Enamel (GC, Corporation, Tokyo, Japan)
224205267|NCT01339000|DRUG|Glycosylated Recombinant Human Interleukin-7|Interleukin-7 (CYT 107) 20 microgram/kg / dose, by intramuscular (IM) injection
224205268|NCT01339000|BIOLOGICAL|Diphtheria/Tetanus Vaccine|Diphtheria/Tetanus Vaccine will be administered according to the random schedule per protocol.
224205269|NCT01339000|BIOLOGICAL|Polio Vaccine|Polio Vaccine will be administered according to the randomized schedule per protocol.
224205270|NCT01339000|BIOLOGICAL|Pneumococcal Vaccine|Pneumococcal Vaccine will be administered according to the randomization schedule per protocol.
224205271|NCT01339000|BIOLOGICAL|Hepatitis A Vaccine|Hepatitis A Vaccine will be administered according to the randomization schedule per protocol.
224205272|NCT01339000|BIOLOGICAL|Hepatitis B Vaccine|Hepatitis B vaccine will be administered according to the randomization schedule per protocol.
224205273|NCT05151796|DRUG|Aspirin|Daily aspirin intake for cardiovascular prevention
224205274|NCT03001869|DRUG|68Ga-HBED-CC-PSMA PET/CT|68Ga-HBED-CC-PSMA PET/CT Scan
224205275|NCT03712046|DIAGNOSTIC_TEST|18F-FDG PET-CT|Patient will receive one injection of 18F-FDG and then undergo PET-CT imaging
224205276|NCT05785416|OTHER|Proprioceptive Neuromuscular Stretching - Contract Relax stretching (PNF-CR)|PNF-CR utilized the concept of autogenic inhibition of the muscle for improving the flexibility of the muscle. It includes stretching a muscle after a brief period of activation.
224205277|NCT05785416|OTHER|Static Stretching (SS)|The SS technique utilized the concept of creep for improving the hamstring flexibility. The stretch was maintained for a prolonged period passively by the therapist.
224314052|NCT03763305|DRUG|Desflurane|1 age-related minimum alveolar concentration (MAC) of desflurane inhalation for anesthetic maintenance
223511583|NCT01121029|PROCEDURE|Autologous hematopoietic stem cell transplantation|Patients will receive a stimulation with filgrastim 10mcg/Kg per day during 4 days and cyclophosphamide 1.5g/m2 per day during 2 days and mesna 300mg/m2 i.v. in 4 hours for prophylaxis (uroprotection). Lately, the stem cells will be recollected by apheresis. After that, the patients will receive a conditioning regimen with cyclophosphamide 500mg/m2 per day during 4 days and fludarabine 30mg/m2 per day during 4 days. After the last dose of cyclophosphamide, the autologous hematopoietic stem cell transplantation will be done on day 0, by peripheral vein. Then, a standard regimen of prophylaxis with oral ciprofloxacin 500mg every 12 hours, acyclovir 400mg every 8 hours, fluconazole 100mg per day and omeprazole 20mg per day for the recovery time of each patient.
223511584|NCT01825252|BEHAVIORAL|Social Network Intervention|Approximately 20% of people are trained to have discussions endorsing less risky behaviors with members of their social network.
224205278|NCT06565598|PROCEDURE|Single-layer robot-assisted transperitoneal retroperitoneal tubeless radical nephrectomy|Free through the single layer of the posterior abdominal cavity
224205279|NCT00601276|DRUG|leuprorelin|Subcutaneous injection, 3.75 mg every 4 weeks
224205280|NCT00601276|DRUG|Cyproterone acetate|2.0 mg/kg/day, tablet, per os
224205281|NCT02072174|DRUG|Anaferon for Children|Anaferon for children: For oral use.
224205282|NCT02659826|DEVICE|anodal tsDCS|Transcutaneous spinal cord stimulation will be delivered through a direct current (DC) stimulator (NeuroConn Plus, Germany) using a pair of saline-soaked sponge electrodes (35cm²). The active electrode (anode) will be placed between the eleventh and the twelfth thoracic vertebra) and the reference electrode, over the right arm (deltoid muscle). Will be delivered a current intensity of 2.5 milliampere (mA), fade in and fade out of 10 seconds, during 20 minutes.
224205283|NCT02659826|DEVICE|cathodal tsDCS|Transcutaneous spinal cord stimulation will be delivered through a DC stimulator (NeuroConn Plus, Germany) using a pair of saline-soaked sponge electrodes (35cm²). The active electrode (cathode) will be placed between the eleventh and the twelfth thoracic vertebra) and the reference electrode, over the right arm (deltoid muscle). Will be delivered a current intensity of 2.5 mA, fade in and fade out of 10 seconds, during 20 minutes.
224314053|NCT03763305|DRUG|Propofol bolus injection|Propofol intravenous injection for anesthetic induction
224314054|NCT03763305|DRUG|Fentanyl|Fentanyl intravenous injection for anesthetic induction
224314055|NCT01650584|DRUG|ISTA Tears|sterile ophthalmic solution
224314056|NCT01650584|DRUG|Systane|Sterile ophthalmic solution
224314057|NCT03655314|OTHER|NEWT|The Newborn Weight Tool (NEWT) is publicly available at www.newbornweight.org. For this intervention, NEWT will be embedded into the electronic medical record along with a flag for weight loss greater than or equal to the 75th centile of birth weight.
224314058|NCT03655314|OTHER|Usual care|The electronic medical record will display the weight only as weight in grams and percent weight lost from birth weight.
224314059|NCT06185881|PROCEDURE|restoration of cervical carious teeth|restoration of carious cervical lesions by glass ionomer
224314060|NCT02009592|DRUG|Rifaximin|Both arms receive Rifaximin
224314061|NCT02521272|OTHER|Breathing in the simulated avalanche snow.|Breathing in the simulated avalanche snow with zero air pocket and one-liter air pocket.
224314062|NCT02521272|DEVICE|air pocket|Zero air pocket or one-liter air pocket in the snow.
224314063|NCT02218554|GENETIC|BRONJ|collection of the blood sample from the subject for evaluation of the Micromedic BRONJ Risk Assessment in vitro Diagnostic Assay
224314064|NCT04533997|DRUG|Hypertonic saline solution plus intravenous furosemide|"Intravenous 60-minutes of hypertonic saline therapy plus furosemide:~Furosemide:~125 mg if home oral furosemide ≤160 mg, 250 mg if home oral furosemide \> 160 mg~Hypertonic saline solution:~Na+ 125-134: 3.4%, Na+ 135-145: 2.6%"
224314065|NCT04533997|DRUG|Intravenous furosemide|"Intravenous 60-minutes infusion of furosemide:~125 mg if home oral furosemide ≤ 160 mg, 250 mg if home oral furosemide \> 160 mg"
224205284|NCT02659826|DEVICE|sham tsDCS|sham transcutaneous spinal cord stimulation will be delivered through a DC stimulator (NeuroConn Plus, Germany) using a pair of saline-soaked sponge electrodes (35cm²). The electrode anode will be placed between the eleventh and the twelfth thoracic vertebra) and the reference electrode, over the right arm (deltoid muscle). Will be delivered a current intensity of 2.5 mA, fade in and fade out of 10 seconds, during only 30 seconds but the volunteers will continue with electrodes montage for 20 minutes.Thus, early sensations (eg. mild to moderate tingling or itch) on stimulation site will be experienced without inducing any modulatory effects.
224314066|NCT00199147|DRUG|Cytarabine|
224205285|NCT02659826|DEVICE|Gait training|It consists of moderate gait training exercise for 20 minutes. To ensure that the exercise will be performed at moderate intensity will be used the 64% - 76% of maximum heart rate (HRmax = 220-age). Heart rate will be monitored every three minutes through a heart polar. In addition will be monitored perceived effort, gait speed and inclination of the treadmill. The Borg scale will be used to evaluate perceived effort. This is an analogue scale graded from 6 (light exercise) to 20 points (exhaustive exercise). Information about the exercise on the treadmill will be noted in the evolution record.
224205286|NCT02659826|DEVICE|High frequency rTMS|Initially, the higher cortical representation area (hotspot) of first right dorsal interosseous (FDI) muscle will be determined through a figure-eight coil connected to the magnetic stimulator (Rapid2, Magstim, UK) held manually and positioned over the scalp (C3 - 10/20 System) at an angle of 45 degrees from the midline pointed to the target muscle (FDI). Thereafter, RMT will be measure. rTMS protocols was based on previous studies. High frequency protocol: 20 hertz (Hz), 90% RMT, 45 trains, 40 stimuli per train, inter interval of 28 seconds, 1800 stimuli. After each rTMS session, presence of adverse effects will be computed.
224205287|NCT02659826|DEVICE|Low frequency rTMS|Initially, the higher cortical representation area (hotspot) of first right dorsal interosseous (FDI) muscle will be determined through a figure-eight coil connected to the magnetic stimulator (Rapid2, Magstim, UK) held manually and positioned over the scalp (C3 - 10/20 System) at an angle of 45 degrees from the midline pointed to the target muscle (FDI). Thereafter, RMT will be measure. Low frequency protocol: 1Hz, 90% RMT, 1500 stimuli (1 train). After each rTMS session, presence of adverse effects will be computed.
224314067|NCT00199147|DRUG|Etoposide|
224314068|NCT00199147|DRUG|Idarubicin|
224314069|NCT00199147|DRUG|G-CSF|
224314070|NCT00199147|DRUG|Fludarabine|
224314071|NCT00199147|PROCEDURE|Stem cell apheresis|
224314072|NCT00199147|PROCEDURE|Stem cell transplantation|
224314073|NCT05188677|BIOLOGICAL|Candidate vaccine, SCB-2019|a recombinant SARS-CoV-2 trimeric S-protein subunit vaccine for COVID-19; intramuscular injection
224314074|NCT05188677|BIOLOGICAL|Comirnaty Vaccine|intramuscular injection
224314075|NCT05188677|BIOLOGICAL|Vaxzevria Vaccine|intramuscular injection
224314076|NCT05188677|BIOLOGICAL|CoronaVac Vaccine|intramuscular injection
224314077|NCT01547702|BEHAVIORAL|Teacher Help for ADHD|"Teachers will review powerpoints other materials online and will have access to a study coach to assist with their understanding and practical application of the materials. Session descriptions follow:~* Session 1: Provide information about ADHD characteristics, impact, diagnosis, etiology~* Session 2: Help establish teacher's role; goal setting; introduce behaviour planning~* Session 3: Help develop and implement behaviour program specific to the needs of students with Session 2 goals~* Session 4: Help develop strategies re: classroom structure, work assignments, teacher-student relationship~* Session 5: Help to use instructional interventions for ADHD~* Session 6: Help to teach these students self-monitoring and self-evaluation skills; help teachers to evaluate progress, phase out behaviour program, and plan for relapses in unwanted behaviours"
223511585|NCT01825252|BEHAVIORAL|Counsel, Test, and Treat|People receive standard-of-care HIV/STD counseling, testing, and treatment
223511586|NCT01992939|OTHER|Specialized pulse oximetry probe with external heat pack|Pulse oximetry will be obtained using the specialized pulse oximetry probe with external heat pack for 45 minutes.
223511587|NCT01992939|OTHER|Standard of Care Pulse Oximetry Probe|Pulse oximetry will be obtained using a standard of care pulse oximetry probe for 45 minutes.
223511588|NCT06098352|BEHAVIORAL|PEBL Continuous Performance Task|A PEBL version of the Conners Continuous Performance Task
223511589|NCT00666614|OTHER|Sleep Environment Intervention|Patients randomized to the sleep environment intervention months will experience a relaxation period before nighttime sleep, white noise as selected by the patient, stimulus control strategies, a window covering to diminish hallway light from entering the room, and a nurse-protected 90-minute uninterrupted sleep period at night.
223511590|NCT00666614|OTHER|Normal Hospital Environment|Normal Hospital Environment
223511591|NCT04216550|DRUG|Apatinib|Apatinib 0.5g orally daily until the untolerable toxicities, disease progression or death
223511592|NCT02529488|DEVICE|AcrySof® IQ PanOptix™ Presbyopia-Correcting IOL|Multifocal IOL(near, intermediate, distance) implanted for long-term use over the lifetime of the cataract patient
223617529|NCT00475189|DRUG|loestrin 24/4 vs loestrin 1/20|One month of loestrin 1/20 then randomized to Loestrin 24/4 or Loestrin 1/20 x 3 months. After 3 months if randomized to 1/20 will be switched to 24/4 if already on 24/4 will be given a choice which OC they want to continue for 3 more months.
223617530|NCT00475189|DRUG|loestrin 1/20|loestrin 1/20 1 tab 21/7 x 3mo and then changed to Loestrin 24 FE
223617531|NCT00788788|DRUG|HELIOX|HELIOX is a mixture of Helium in Oxygen with a low density and the ability to reduce the work of breathing in subjects with airway obstruction. The fractions of Helium was altered in a different order depending on the arm of the study
224314078|NCT05982002|DEVICE|shock wave|ESWT (Chattanooga, Intelect RPW, USA) continues mode, hand piece transmitter R SW D20 /20mm, with the following Parameter: Shock pressure of 3-4 bars, wave frequency of 12 Hz.
224314079|NCT05982002|OTHER|Moderate intensity aerobic exercise|Treadmail training exercise 60%-75% of Maximum heart rate MHR 2 times/ week
224314080|NCT05982002|OTHER|Energy-restricted diet|energy intake was 500K calorie below daily requirements on average three meals at the same time of the day
224314081|NCT00839397|DRUG|Paroxetine|"Subjects will take the treatment phase medication once daily after an evening meal. All subjects will be maintained at Dose Level II (20 mg/day) for the first 2 weeks. If a sufficient clinical response (1. Very much improved or 2. Much improved based on the CGI Global Improvement) is achieved, the subject will continue on the same dose level. When the clinical response is not sufficient but the investigational product is well tolerated, the dose will be increased to Dose Level III (30 mg/day) and then to Dose Level IV (40 mg/day) at intervals of at least 2 weeks until a sufficient response is reached. Once a sufficient response is obtained, the treatment will be continued at that dose. The treatment phase will last for a total of 52 weeks. In those patients receiving Dose Level III or IV, dosage reductions to the next lowest level (Dose Level II or III) consequent to an adverse event are permitted.~Dosage adjustment will be made at the discretion of the PI or Sub-PI"
224314082|NCT04394039|OTHER|Public space exposure|landscapes with nature and/or classified as contemplative (through a CLM psychometric measure) are expected to elicit different brainwave oscillations as compared to noncontemplative ones.
224314083|NCT01860625|DRUG|Donepezil patch|
224314084|NCT01860625|DRUG|placebo|
224314085|NCT00270855|PROCEDURE|Arm Crank Ergometry|Use of an upper body cycle to perform exercise. 10-minute warm up, 40 minutes @ 70%HRMax (50RPM), 10 minute cool down 5x/week x 16 weeks
223511593|NCT03768050|OTHER|Advanced care for frail elderly|"Home-based case management group receives advanced nursing care meeting the health and social needs of patient and/or carer. It is carried out through a process of evaluation, planning\&coordination, facilitating the provision, monitoring and evaluation of the options and resources necessary for the resolution of the case. It is person-centred. The service also provides palliative care.~Home hospitalisation/early discharge dispenses medical and nursing care at home on a transient basis after hospitalisation when patients still need surveillance and assistance. It is done in the acute, subacute or post-acute phase. In the last phase the focus is on functional recovery.~The geriatric residences group is assisted by health care teams with expertise in geriatrics. They coordinate with primary care and health professionals of the residences to improve the attention. They are highly accessible, have high-resolutive capacity and can activate the resources of the healthcare network."
223511594|NCT02698787|DEVICE|Experimental sound coding strategy (FAST)|Commercially available Cochlear™ Nucleus® CI24RE with Contour Advance™ Electrode or Cochlear™ Nucleus® CI512 cochlear implant with FAST sound coding strategy using crossover design in newly implanted subjects. Both groups will receive the experimental and control strategy
223511595|NCT02698787|DEVICE|Commercially available ACE sound coding strategy|Commercially available Cochlear™ Nucleus® CI24RE with Contour Advance™ Electrode or Cochlear™ Nucleus® CI512 cochlear implant with FAST sound coding strategy using crossover design in newly implanted subjects. Both groups will receive the experimental and control strategy
224314086|NCT00270855|PROCEDURE|FES Cycle Ergometer|Use of an FES cycle ergometer to perform exercise. 10-minute warm up, 40 minutes @ 70%HRMax (50RPM), 10 minute cool down 5x/week x 16 weeks
224314087|NCT01794455|DRUG|Sertraline|50mg - 200mg daily
224314088|NCT01794455|DRUG|Candesartan|4mg - 32mg daily
224314089|NCT05424679|BEHAVIORAL|Safety Planning Intervention|The Safety Planning Intervention is a brief intervention that directly targets suicide risk with demonstrated efficacy and is a recommended best practice for suicide prevention. The intervention aims to provide participants with an individualized set of steps that can be used progressively to both reduce risk and maintain safety when under particular stress. It also includes a series of brief telephone calls to revise the safety plan and facilitate connections to care. The study team will adapt the intervention to target a larger range of mental health distress.
223511596|NCT00324857|BEHAVIORAL|Decision Aid Video|"The research interventionist will show the participant the Dartmouth Knee OA Decision Aid video entitled Treatment Choices for Knee Osteoarthritis. The video gives a detailed explanation of 1) the damage to the knee joint caused by OA; 2) treatment options including lifestyle changes, medications, injections, complementary therapy, and surgery; 3) the risks, benefits, and known efficacy of each treatment option."
223511597|NCT00324857|BEHAVIORAL|Motivational Interviewing|The research intervention will conduct the fact-to-face MI session with the participant. The MI session will do the following things: 1) Assessing Readiness, Importance, and Confidence; 2) Eliciting Barriers, Concerns and Positive Motivational; 3) Summarizing Pros and Cons; 4) Assess Patient Values and Goals; 5) Provide a Menu of Options.
223511598|NCT00324857|BEHAVIORAL|MI plus Decision aid|Patient viewed the video and then underwent MI.
223511599|NCT00324857|OTHER|Attention control|patients received a booklet.
223511600|NCT03696186|DRUG|Luminal type-1|Goserelin (3.75mg, once every 4 weeks)+Docetaxel (75 mg/m2 on day 1 every 3 weeks)+Prednisone (5 mg, twice daily)
223511601|NCT03696186|DRUG|Luminal type-2|Goserelin (3.75mg, once every 4 weeks)+Abiraterone (1000 mg, once daily)+Prednisone (5 mg, twice daily)
223511602|NCT03696186|DRUG|Neuroendocrine type-1|Goserelin (3.75mg, once every 4 weeks)+Docetaxel (75 mg/m2 on day 1 every 3 weeks)+Prednisone (5 mg, twice daily)
223511603|NCT03696186|DRUG|Neuroendocrine type-2|Goserelin (3.75mg, once every 4 weeks)+Carboplatin (area under the curve 5 on day 1 every 3 weeks)+Docetaxel (75 mg/m2 on day 1 every 3 weeks)+Prednisone (5 mg, twice daily)
223511604|NCT03696186|DRUG|Atypical type-1|Goserelin (3.75mg, once every 4 weeks)+Docetaxel (75 mg/m2 on day 1 every 3 weeks)+Prednisone (5 mg, twice daily)
223511605|NCT03696186|DRUG|Atypical type-2|Goserelin (3.75mg, once every 4 weeks)+Abiraterone (1000 mg, once daily)+ targeted therapy according to next Generation Sequencing (NGS)+ Prednisone (5 mg, twice daily), or Goserelin (3.75mg, once every 4 weeks)+Abiraterone+ Prednisone (5 mg, twice daily) if no druggable gene mutation detected.
223511606|NCT02661347|DRUG|Risperidone|The dosage for risperidone will be 1 mg to 6 mg per day. The dose of the risperidone will be based on the participant's clinical improvement and side effects.
223511607|NCT02661347|DEVICE|tDCS|Transcranial direct current stimulation (tDCS) is a form of non-invasive brain stimulation in which sub-threshold transcranial electric current (in the range of 0.4-2 mA) is applied via two conductive saline soaked electrodes placed on the scalp using a Soterix Medical 1x1 line tDCS Model 1300 low-intensity stimulator.
223511608|NCT04245579|OTHER|Multifactorial Memory Training Program (UMAM method)|
224314090|NCT05424679|BEHAVIORAL|Caring Contacts|Caring contacts is a cost and time effective suicide prevention intervention. It traditionally utilizes letters and postcards that are sent to an individual to remind them that they are cared about and that they matter. Research suggests that this intervention significantly reduces the likelihood of dying by suicide and suicide attempt over a person's lifetime. This intervention has the potential to reach more individuals at risk in the community. In this study, the research team will allow participants to receive these messages by postcard/MMS and will adapt the intervention to align with cultural values.
224314091|NCT05531110|DEVICE|Cataract surgery with insertion of Eyhance ICB00|Cataract surgery with insertion of Eyhance ICB00
223617532|NCT02416154|PROCEDURE|Reproductive tract and blood sampling|Reproductive tract and blood sampling will be performed at enrollment only in this cross-sectional parallel cohort study.
223617533|NCT04368780|OTHER|Effect of Progressive Muscle Relaxation Combined With Music|The CD on relaxation exercises developed by the Turkish Psy-chological Associationwas used.In the second of CD 30-min section; relaxation exercises are explained to the accompaniment ofrunning water sounds and verbal instructions. Progressive relaxation technique includes stretching and relaxing the bigmuscle groups (hands, arms, neck, shoulders, face, chest, abdomen,hip, feet andfingers) in the human body on purpose. When steps ofProgressive Relaxation Exercises are analyzed, it is observed thatlearning how to take correct and deep breaths is the most impor-tant step towards learning relaxation. In addition, taking correct breaths is used as a part of the exercise among all relaxation exercises.Steps of Progressive Relaxation Exercise:- breathing exercises- lower extremity exercises- upper extremity exercises- exercise of respiratory muscles.
224314092|NCT05531110|DEVICE|Cataract surgery with insertion of Alcon SN60WF|Cataract surgery with insertion of Alcon SN60WF
224314093|NCT04292041|OTHER|Fasting mimicking diet|"3 cycles of programmed nutrition using a fasting mimicking diet (Chemolieve (R)), each cycle consisting of 4 days. Pre and post nutritional cycles, clinical and metabolic assessments are taken, as per protocol. Allowing for a 3 month washout time, the 'post' assessment is planned approximately 6 months from the initial (pre) assessment."
224314094|NCT00292890|DEVICE|insulin needle|
224314095|NCT02027532|DRUG|Cefazolin|
223617534|NCT01755871|DRUG|Fingolimod|0,5mg Fingolimod once a day
223617535|NCT04957121|OTHER|on-hours|"If the begin time of anesthesia was between 8:00 to 17:59, it was defined as on-hours."
224314096|NCT02027532|DRUG|Vancomycin|
224314097|NCT00719875|DRUG|Vorinostat|BID days -7, 1-7 and 15-21, 200 mg
224314098|NCT06582030|BEHAVIORAL|Assessment|Ancillary studies
224314099|NCT06582030|OTHER|Educational Activity|View the chronically relapsing brain disease vignette
224314100|NCT06582030|OTHER|Educational Activity|View the brain disease vignette
224314101|NCT06582030|OTHER|Educational Activity|View the disease vignette
223617536|NCT04957121|OTHER|off-hours|"If the start time of anesthesia was between 18:00 to 7:59 or the end time of anesthesia was later than 20:00, it was defined as off-hours."
224314102|NCT06582030|OTHER|Educational Activity|View the illness vignette
223617537|NCT04247737|OTHER|gluten free diet|Participants keep a gluten free diet for six weeks
223617538|NCT03004235|DEVICE|Observational data collection|Observational data collection
223617539|NCT00005644|DRUG|gemcitabine hydrochloride|
223617540|NCT00005644|DRUG|paclitaxel|
223617541|NCT01420926|DRUG|Bortezomib|Given SC
224205288|NCT02659826|DEVICE|sham rTMS|The hotspot of first right dorsal interosseous (FDI) muscle will be determinate through a figure-eight coil connected to the magnetic stimulator positioned over the motor primary cortex (C3). Then, the motor threshold (RMT) of FDI will be measure. Sham rTMS will be performed with low frequency (1Hz, 90% RMT, 1500 stimuli) protocol using two coils. The first one - connected to the stimulator - will be positioned on a coil support close to the volunteer but not visible. Therefore, characteristic stimulation noises will be audible. The second - disconnected to the stimulator - will be placed over left primary motor area. After each rTMS session, presence of adverse effects will be computed.
224205289|NCT01544816|OTHER|Snack Product|control food product
224205290|NCT01544816|OTHER|Snack Product|Experimental food product containing ingredient 1
224205291|NCT01544816|OTHER|Snack Product|Experimental food product containing ingredient 2
224205292|NCT03446716|BEHAVIORAL|Sleep Extension|Child attempted to go to bed 90 mins in advance of their normal bedtime.
224314103|NCT06582030|OTHER|Educational Activity|View the disorder vignette
224314104|NCT06582030|OTHER|Educational Activity|View the problem vignette
223617542|NCT01420926|DRUG|Decitabine|Given IV
223617543|NCT01420926|OTHER|Laboratory Biomarker Analysis|Correlative studies
223617544|NCT01420926|OTHER|Pharmacological Study|Correlative studies
223617545|NCT01420926|OTHER|Quality-of-Life Assessment|Ancillary studies
223617546|NCT01420926|OTHER|Questionnaire Administration|Ancillary studies
223617547|NCT02285387|PROCEDURE|Rhythm control|"1. Start AAD right after evaluating for LA size, EF, LA thrombus, and presence of CAD during anticoagulation~2. Cardioversion after 1 month~3. Rhythm FU schedule (2012 ACC/AHA/ESC guidelines)~4. If AF recur, RFCA"
224314105|NCT06582030|OTHER|Training|Attend a SAS workshop
224314106|NCT06582823|OTHER|Health belief model-based community educational program|"The 5-week intervention includes two weekly 60-minute face-to-face sessions for 8-10 participants, two weekly telephone follow-ups, and a booster session.~Week 1: Focuses on increasing knowledge about atrial fibrillation (AF), its risks, complications, and treatment benefits. The principal investigator (PI) provides education using interactive methods and colored visuals.~Week 2: Emphasizes skill building for pulse palpation to detect irregular pulses. Participants learn through demonstrations and practice using a simulated arm.~Weeks 3-4:Telephone follow-ups monitor adherence to pulse checking and address barriers. Support and advice are provided by the PI.~Week 5: A booster session reinforces knowledge and skills with scenario-based practice and use of a simulated arm."
224314107|NCT06582823|OTHER|Control|The control group will receive an information leaflet presenting information about AF, health risks and complications associated with AF, common methods to screen for AF, and follow-up actions if positive screening results are suspected.
224205293|NCT06417723|PROCEDURE|Maxillary nerve block|It is aimed to reach the maxillary nerve trace with a peripheral nerve block needle using the suprazigomatic approach and to create a temporary block in the maxillary nerve with local anaesthetic injection.
224205294|NCT04272255|DRUG|scopolamine HBr|Nasal Gel
224205295|NCT04272255|DRUG|Transdermal Scopolamine|Patch
224205296|NCT02379442|BIOLOGICAL|MSC|MSC are an adherent, fibroblast-like cell population found in the bone marrow. Allogeneic MSC for treatment can be grown from bone marrow aspirates or biopsies of normal donors.
224205297|NCT05531838|DEVICE|Fu Lishan instant sense hospital dynamic glucose monitoring system|Using CGM Technology (dynamic glucose monitoring system used in Fu Lishan instant sense hospital), on the basis of patients' original eating habits, according to the guidelines and the training of MMC center, patients are guided to adjust their eating patterns according to the glucose map monitored by the dynamic glucose monitoring system.
224205298|NCT02582359|DRUG|MLN9708|Dose of 1.5 mg or 2.3 mg or 3.0 mg taken by mouth on days 2, 5, 9, 12 of each cycle.
224314108|NCT04862910|OTHER|Kinect Based Virtual Reality Training|The participant will receive the game instructions from the examiner.Protocol will be implemented 3 steps Warm Up phase Activity phase and cool down phase. The games will be played under the supervision and guidance of the therapist.Games are selected from Kinect games Kinect Sports Kinect Adventures and Your Shape Fitness Evolved. Three treatment sessions per week will be given to each participant. Total duration of each treatment session will be 45 Minutes.Participants will be instructed to walk outdoors for 30 Minutes daily. Routine Medication and routine diet will be continued.
224314109|NCT04862910|OTHER|Control Group|"* They will be instructed to walk outdoors daily for 30 Minutes.~* They will continue their daily activities with a routine diet and routine Medication"
224314110|NCT04653025|DEVICE|Implant placement|After tooth extraction implants were placed either immediate or delayed approach
224314111|NCT01396512|BIOLOGICAL|Live attenuated Japanese encephalitis chimeric virus vaccine|0.5 mL, Subcutaneous
224314112|NCT01396512|BIOLOGICAL|Japanese encephalitis live attenuated vaccine (SA14 14 2 vaccine)|0.5 mL, Subcutaneous
224314113|NCT02755649|DRUG|Dupilumab|
224314114|NCT02755649|DRUG|Matching Placebo|
224314115|NCT00098605|DRUG|lapatinib ditosylate|Given orally
224314116|NCT00098605|OTHER|laboratory biomarker analysis|Correlative studies
224314117|NCT00098605|PROCEDURE|quality-of-life assessment|Ancillary studies
224314118|NCT00098605|OTHER|questionnaire administration|Ancillary studies
224314119|NCT03420911|DRUG|dexketoprofen trometamol|
224314120|NCT03420911|DRUG|Midazolam|
224314121|NCT00142389|BIOLOGICAL|pneumococcal polysaccharide and protein conjugate vaccines|
224314122|NCT06435689|OTHER|Sampling|Blood and surgical specimen sampling the day of surgery
224314123|NCT03365557|PROCEDURE|Airway peak pressure|Air was injected into LMA cuff during expiration phase to make intracuff pressure achieve the level of airway peak pressure. If there's any leakage, increase 5 cmH2O every time till there's no air leakage from the mouth.
224314124|NCT01822106|OTHER|Placebo|
223511609|NCT04562805|DEVICE|DynamX Bioadaptor|DynamX Bioadaptor Treatment
223511610|NCT04562805|DEVICE|Resolute Onyx|Resolute Onyx Treatment
224205299|NCT02582359|DRUG|Cytarabine|Induction: cytarabine 100 mg/m2/day continuous infusion, days 1-7 Consolidation: cytarabine 2000 mg/m2/day, 3 hour infusion, on days 1-5
223511611|NCT00594308|DRUG|Cyclophosphamide|60mg/kg/day for two consecutive days (-7,-6).
223511612|NCT00594308|DRUG|Fludarabine|25mg/m2/day for 5 consecutive days
224205300|NCT02582359|DRUG|Daunorubicin|Daunorubicin 60 mg/m2, IV bolus, on days 1-3 of induction, only.
224205301|NCT05674721|DRUG|Advil PM Liqui-Gels Minis|Ibuprofen/diphenhydramine hydrochloride 200 mg/25 mg, Oral capsule which is a size reduction of the currently marketed reference product.
223511613|NCT00594308|DRUG|Cyclosporine|3mg/kg/day will be given by continuous intravenous infusion beginning on Day -1.
223511614|NCT00594308|DRUG|Mycophenolate mofetil|1000 mg will be administered through day +60 and then discontinued if there is no GVHD.
224314125|NCT01739049|DRUG|Liraglutide|liraglutide
224314126|NCT01739049|BEHAVIORAL|Diet and Exercise|diet and exercise
224314127|NCT02152605|DRUG|UMEC/VI|Dry white powder delivered via DPI (2 strips with 30 blisters each, first containing UMEC 62.5 mcg per blister and second containing VI 25 mcg per blister), administered as one inhalation of UMEC/VI 62.5/25 mcg
224314128|NCT02152605|DRUG|Placebo|Dry white powder delivered via DPI (2 strips with 30 blisters each, both containing lactose with magnesium stearate), administered as one inhalation of placebo
224314129|NCT05864989|PROCEDURE|Non-incised papila surgical approach only|Reconstructive periodontal surgery
224314130|NCT05864989|PROCEDURE|Non-incised papila surgical approach with connective tissue grafting|Reconstructive periodontal surgery
224314131|NCT05366140|OTHER|Prospective follow-up of patients who have received instrumented lumbar arthrodesis supplemented the Implanet Jazz System(TM)|To assess the clinical outcomes of patients receiving standard of care Implanet Jazz System(TM) at the time of their instrumented lumbar arthrodesis.
224314132|NCT02271347|DRUG|CMX001|CMX001 administered as initial dose of 200mg then 100mg BIW for a total of 5 doses.
224314133|NCT04419753|BEHAVIORAL|attention focus walking training|Use different attention focus instructions or no attention focus instruction during walking training in older adults to examine whether the attention focus instructions can ameliorate conscious motor processing and optimize rehabilitation outcome measurements.
224314134|NCT03647085|DEVICE|Wearable cardiac monitor|Participants will be fitted with a wearable cardiac monitor placed on the skin that measures physiologic signals.
224314135|NCT04458285|DRUG|Sacubitril / Valsartan Oral Tablet [Entresto]|Patients in experimental group will receive sacubitril/valsartan with the recommended starting dose: 50mg twice daily (if previous ACEI, ensure 36-hour washout period), after 2-4 weeks, the dose will be doubled to the target maintenance dose of 100mg twice daily(if tolerated) for 12 weeks.
224314136|NCT04458285|DRUG|Valsartan 80mg Tablet|Patients in active comparator group will receive Valsartan with an dose of 80 mg once daily.
224314137|NCT04524208|DRUG|Cabozantinib|Cabozantinib is administered orally at the dose of 60 mg per day..
224314138|NCT02692443|DEVICE|Magnetic Resonance Imaging|Brain MRI without Contrast
224314139|NCT02692443|BEHAVIORAL|Neurodevelopmental Testing|Validated battery of neurodevelopmental and psychological tests.
224205302|NCT05674721|DRUG|Advil PM Liqui-Gels|Ibuprofen/diphenhydramine hydrochloride 200 mg/25 mg, Oral capsule.
224205303|NCT02285452|DRUG|Zingiberis Rhizoma plv.|
224205304|NCT02285452|DRUG|Sinapis nigrea semen|
224205305|NCT02285452|DRUG|Placebo|
224205306|NCT01831518|DEVICE|CRT Implant|
224205307|NCT01831518|DEVICE|Body Surface ECG Mapping|
224205308|NCT02256059|PROCEDURE|Plate osteosynthesis|Plate osteosynthesis using LCP plate (Synthes)
224205309|NCT02388607|OTHER|measurements|performance measurements
224205310|NCT01895088|DEVICE|AcuFocus Corneal Inlay ACI 7000 PDT|Inlay implanted in cornea for improvement of near vision
224205311|NCT02067585|DIETARY_SUPPLEMENT|Standardized Lipid meals|Standardized Lipid meals: 240 ml of Hormel Great Shake Plus liquid nutritional supplement, 203 Kcal/100mL; 49% calories from fat, mostly unsaturated fatty acids of soy origin; 38% calories from carbohydrates, 13% calories from proteins.
224205312|NCT01506570|BIOLOGICAL|TetraVax-DV Vaccine - Admixture TV003|One SC injection at Day 0 and Day 180 of the TetraVax-DV Vaccine, Admixture TV003 (10\^3 plaque-forming unit \[PFU\] of rDEN1Δ30, 10\^3 PFU of rDEN2/4Δ30\[ME\], 10\^3 PFU of rDEN3Δ30/31-7164, and 10\^3 PFU of rDEN4Δ30)
224205313|NCT01506570|BIOLOGICAL|TetraVax-DV Vaccine - Admixture TV005|One SC injection at Day 0 and Day 180 of the TetraVax-DV Vaccine, Admixture TV005 (10\^3 PFU of rDEN1Δ30, 10\^4 PFU of rDEN2/4Δ30\[ME\], 10\^3 PFU of rDEN3Δ30/31-7164, and 10\^3 PFU of rDEN4Δ30)
224205314|NCT01506570|BIOLOGICAL|Placebo|One SC injection at Day 0 and Day 180 of placebo
224314140|NCT03063411|OTHER|Executive Function Intervention|In the executive function training group, children will complete computerised tasks requiring working memory and inhibitory control over four weekly sessions lasting 15-20 minutes. The aim is to improve their executive function skills. In the active control group, children will complete computerised tasks requiring simple decision making and visual search skills over four weekly sessions lasting 15-20 minutes.
224314141|NCT03063411|OTHER|Active Control Group|This is the active control condition. Children will complete computerised tasks requiring simple decision making and visual search skills over four weekly sessions lasting 15-20 minutes.
224314142|NCT03301649|DRUG|Generic Ivermectin Lotion 0.5%|Topical lotion, generic formulation of the brand product.
223761372|NCT01616186|DRUG|Everolimus and sorafenib|"* Starting doses: everolimus 5 mg daily and sorafenib 400 mg BID - taken fasting, no food 1 hour before or 2 hours after dosing~* Everolimus and sorafenib are dosed continuously~(Note: everolimus and sorafenib are typically dosed in 28 day cycles, and sunitinib is typically dosed in 42 day cycles; for the purposes of this protocol to keep timing consistent, a cycle will be defined as 42 days of therapy)"
224205315|NCT04466956|DEVICE|Virtual reality|Virtual reality headset worn with short relaxing video played during MVA procedure
224314143|NCT03301649|DRUG|Sklice® (Ivermectin) Lotion 0.5%|Topical lotion, brand product.
223511615|NCT00594308|DRUG|Basiliximab|20mg , will be given by intravenous infusion (without an in-line filter) over at least 15 minutes beginning 3 days after engraftment.
223511616|NCT00295503|DRUG|bevacizumab|15 mg/kg IV every 3 weeks
224205316|NCT00197470|PROCEDURE|IL-1, TNF-alpha, Il-10|
223511617|NCT00295503|DRUG|cisplatin|75 mg/m2 IV every 3 weeks
224205317|NCT00255476|DRUG|gefitinib|
224205318|NCT00255476|DRUG|cisplatin|
224205319|NCT00255476|DRUG|5-flourouracil|
224205320|NCT00872365|BEHAVIORAL|Regular aerobic physical exercise|Walking (10 minutes), aerobic exercise (30 minutes), stretching (10 minutes) and relaxation exercise (10 minutes). Exercise will be performed at three sessions per week. All sessions will be supervised by a physical therapist and a physical educator.
224205321|NCT00872365|DIETARY_SUPPLEMENT|Micronutrients|Zinc 30mg, Magnesium 400mg, Beta-carotene 9 mg, Tocopherol 30mg, vitamin C 200mg y Niacin 100mg.
224205322|NCT00872365|OTHER|Activities of daily living + placebo|"Basic activities of daily living (bathing, dressing, eating, walking) without counseling by a physical therapist and prenatal care.~Placebo Comparator: Equivalent to placebo (maltodextrin)."
224205323|NCT05391607|DRUG|Hyperoncotic Albumin 20%|Intravenous administration during removal of the bladder (i.e. the bleeding part) of cystectomy procedures.
224205324|NCT05391607|DRUG|Isooncotic Albumin 5%|Intravenous administration of Albumin 5% 12ml/kg (ideal body weight) completed by a Ringer-lactate crystalloid ratio 1:1 to total amount of blood loss during removal of the bladder (i.e. the bleeding part) of cystectomy procedures.
224205325|NCT05391607|DRUG|Ringer's Lactate Crystalloid Solutions (control group)|Intravenous administration of Ringer-lactate ratio 3:1 of total of blood loss during removal of the bladder (i.e. the bleeding part) of cystectomy procedures.
224205326|NCT02689726|DRUG|GTL001+|
224205327|NCT02689726|DRUG|Aldara|5% imiquimod cream
223511618|NCT00295503|DRUG|pemetrexed|500 mg/m2 every 3 weeks
223511619|NCT03453515|BEHAVIORAL|HEART|Interactive web-based intervention with five modules: motivation, knowledge, attitudes/norms, self-efficacy, and sexual communication skills.
223511620|NCT03453515|BEHAVIORAL|Growing Minds|Interactive web-based intervention with five modules: mindsets introduction, growth mindsets of intelligence, growth mindsets of self-control, growth mindsets of people, and integrative summary.
223511621|NCT01245023|PROCEDURE|Laparoscopic adhesiolysis|Laparoscopic adhesiolysis and Sprayshield
223511622|NCT01245023|PROCEDURE|Placebo-surgery|skin incisions without laparoscopy or related procedures
223511623|NCT02571881|PROCEDURE|Caesarean section|After caesarean section oxycodone or oxycodone-naloxone prolonged release tablet twice a day is started for pain medication
223511624|NCT02571881|DRUG|Oxycodone|
223511625|NCT02571881|DRUG|oxycodone-naloxone|
224205328|NCT03814213|OTHER|CGA|Multi-level Health assessment
224205329|NCT03814213|OTHER|tailored care|Tailored care based on problems identified by CGA
224205330|NCT01093716|DEVICE|Magstim Rapid® (rTMS)|Ten daily sessions of rTMS treatments using Magstim Rapid® device (10 Hz, 110% of the MT, 4.9 seconds per train, inter-train interval of 30 seconds, and 20 trains per session) with an air cooled figure-of-eight coil over either right or left DLPFC
224205331|NCT02269501|OTHER|Exercise treatment|
224205332|NCT02643394|DRUG|Oral Acetaminophen|1000mg oral acetaminophen + 400mg oral celecoxib given within one hour of incision
224205333|NCT02643394|DRUG|Intravenous acetaminophen|400mg oral celecoxib given within one hour of incision + 1000mg IV acetaminophen within one hour prior to anesthetic emergence.
224205334|NCT00664066|DRUG|DYNEPO (epoetin delta)|dose, dose frequency, route of administration (iv or sc) and duration will be determined by the investigator according to their normal prescribing habits, as this is an observational study
224205335|NCT04756466|DIETARY_SUPPLEMENT|Placebo|Each participant will consume 1 capsule per day in one of the main meals without any restriction in the diet or in their life habits
224205336|NCT04756466|DIETARY_SUPPLEMENT|Lactobacillus|Each participant will consume 1 capsule per day in one of the main meals without any restriction in the diet or in their life habits
223511626|NCT02673060|DRUG|MBC-11|0.5 mg/kg-10 mg/kg , IV (in the vein) on day 1-5 of each 28 day cycle. Number of cycles: 2, in case of partial metabolic reaction or stable metabolic reaction - up to 4.
223511627|NCT04627974|DEVICE|Evoke Spinal Cord Stimulation (SCS) System|A spinal cord stimulation system that measures and records evoked compound action potentials (ECAPs) and automatically adjusts the stimulation current to maintain a consistent ECAP amplitude
224205337|NCT04469101|PROCEDURE|Lumbar Epidural|Parturients will have an epidural placed in the upright seated position as per institution standard. After epidural placement, they will be positioned as per their randomization. They will then have a total of 20 cc of epidural solution (0.08% ropivacaine with 2 mcg per cc of fentanyl) injected into the epidural in boluses of 5 cc every 5 minutes.
224205338|NCT05986708|OTHER|interview|In addition to routine treatment and care, the patients in the application group were interviewed by the researcher once a week for 6 weeks, within the first hour of HD treatment, for a total of 6 sessions, each session being approximately 30 minutes-1 hour, within the scope of the guided self-determination method.
224205339|NCT00925795|OTHER|consumption 1. EVOO; 2. ROO|EVOO in doses of 50 mL/daily for 20 days; 14 days of wash-out period without olives and olive oil; followed by ROO in doses of 50 mL/daily for 20 days
223511628|NCT06564727|PROCEDURE|Uniportal VATS approach|Uniportal VATS resection for simple pulmonary aspergilloma
223511629|NCT06564727|PROCEDURE|VATS approach|VATS resection for complex pulmonary aspergilloma
223511630|NCT04560296|BEHAVIORAL|Community-based E-Health Program|Community-based E-Health Program will be developed to engage and empower older adults to manage the chronic conditions effectively.
223511631|NCT04560296|BEHAVIORAL|usual self-management and follow up with doctors/nurse|usual self-management and follow up with doctors/nurse as planned in the community nurse post.
223511632|NCT03829488|DRUG|Plasma-Lyte 148 (approx. pH 7.4) IV Infusion|Plasma-Lyte 148 (approx. pH 7.4) IV Infusion is a sterile, clear, non-pyrogenic isotonic solution and when administered intravenously is a source of water, electrolytes and calories. Plasma-Lyte 148 intravenous infusion is indicated as a source of water \& electrolytes or as an alkalinising agent.
223617548|NCT02285387|PROCEDURE|Rate control|"1. No AAD, just anticoagulation~2. HR control between 60\~110bpm (with beta blocker, calcium channel blocker, digoxin)~3. Without the treatment about antiarrhythmia and rhythm control, deification of rate control, the subject will be drop out for study."
223617549|NCT02860104|DEVICE|microwave ablation|ultrasound guided percutaneous microwave ablation for breast lesions
223617550|NCT02606331|PROCEDURE|Piezosurgery|Corticotomy cuts will be performed by this technique.
223617551|NCT02606331|RADIATION|ER:YAG laser|Corticotomy cuts will be performed by this technique.
224205340|NCT00925795|OTHER|consumption 1. ROO; 2. EVOO|ROO in doses of 50 mL/daily for 20 days; 14 days of wash-out period without olives and olive oil; followed by EVOO in doses of 50 mL/daily for 20 days
224205341|NCT06650332|DRUG|cadonilimab|Cohort 1:10 mg/kg, iv, Q3W, D1; Cohort 2/3:6 mg/kg, iv, Q2W, D1
224205342|NCT06650332|DRUG|Trastuzumab|loading dose 8 mg/kg, iv, Q3W, D1; maintenance dose 6 mg/kg, iv, Q3W, D1
224205343|NCT06650332|DRUG|XELOX|Oxaliplatin: 130 mg/m\\(\^2\\), IV, D1; Capecitabine: 1000 mg/m\\(\^2\\), oral (PO), twice daily, D1-14.
224205344|NCT06650332|DRUG|Disitamab Vedotin|1.5、2.0、2.5mg/kg，IV，D1，Q2W
224205345|NCT06650332|DRUG|mFOLFOX6|Oxaliplatin 85 mg/m\\(\^2\\), IV, d1; Leucovorin (folinic acid) 400 mg/m\\(\^2\\), IV, d1; 5-FU 400 mg/m\\(\^2\\), IV, d1, followed by 2400 mg/m\\(\^2\\), continuous intravenous infusion over 46 hours.
224205346|NCT01419405|DRUG|Pregabalin|hard capsule, 150 mg, 2 times, 2 days
224205347|NCT01419405|DRUG|Remifentanil|50-90 min: TCI 0.6 ng/mL, 100-140 min: 1.2 ng/mL, 150-190 min: TCI 2.4 ng/mL
224205348|NCT01419405|DRUG|sugar pill, saline infusion|hard capsule, 150 mg, 2 times, 2 days, saline infusion
224205349|NCT04059900|DRUG|STW5 (Iberogast®, BAY98-7411)|The medication was applied daily per os (orally, p.o.) from day 0 to day 28. The dosage was 20 drops three times daily before the meals.
224205350|NCT04059900|DRUG|Placebo|The medication was applied daily p.o. from day 0 to day 28. The dosage was 20 drops three times daily before the meals
224205351|NCT03701516|DEVICE|etafilcon A with novel molding process|TEST Lens
224205352|NCT03701516|DEVICE|etafilcon A with current molding process|CONTROL Lens
224205353|NCT05286931|DRUG|Ciprofloxacin 500 mg|Ciprofloxacin 500 MG, taken once orally.
224205354|NCT01924572|PROCEDURE|cord clamping at 2 minutes|
224205355|NCT01924572|PROCEDURE|cord clamping at 5 minutes|
224205356|NCT01924572|PROCEDURE|cord milking|
224205357|NCT03960268|DRUG|Brodalumab|interleukin 17 receptor A antagonist
224205358|NCT01842516|DRUG|LCB01-0371 800mg|LCB0-0371 800mg
224205359|NCT01842516|DRUG|LCB01-0371 1200mg|LCB01-0371 1200mg
224205360|NCT01842516|DRUG|Placebo|Placebo
224205361|NCT05749549|DRUG|BR1733|Subjects will receive oral administration of BR1733.
224205362|NCT05531695|BEHAVIORAL|Exercise (either aerobic or flexibility)|
224205363|NCT03609970|DIETARY_SUPPLEMENT|Vitamin D|Daily 4X 1000IU cholecalciferol
224205364|NCT03609970|RADIATION|UVR (Solar simulated radiation)|1.25 SED Solar simulated radiation twice weekly
224205365|NCT05929040|BEHAVIORAL|mindful cognitive intervention|Mindfulness based cognitive intervention based on the behavioural change techniques taxonomy
224205366|NCT03826446|PROCEDURE|Surgery|laparoscopic and open complete mesocolic excision with central vascular ligation in right colon cancer.
224205367|NCT02980939|OTHER|iv fluid infusion|Intravenous isotonic saline infusion
224205368|NCT01764594|BIOLOGICAL|CDP7657|"CDP7657 100 mg/ ml solution~30 mg/ kg initial dose~15 mg/ kg every other week~10 weeks"
224205369|NCT01764594|OTHER|Placebo|Placebo comparator
224205370|NCT03083639|DRUG|Esomeprazole Capsule|Esomeprazole Capsule
224205371|NCT03083639|DRUG|Esomeprazole Tablet|Esomeprazole Tablet
224205372|NCT02765958|DEVICE|portable ECG devise|
224205373|NCT04619134|OTHER|NCSR Program|flexibility exercise,strengthening exercise,dynamic strengthening exercise,endurance training,counselling session
224205374|NCT04619134|OTHER|conventional physical therapy|hot pack,flexibility training,strengthening exercise.
224205375|NCT01743664|BEHAVIORAL|EMDR|Patients in the experimental group will undergo 10 weekly sessions of 60 minutes each with EMDR following Shapiro's protocol for traumatic events
224205376|NCT01743664|BEHAVIORAL|Relaxation|The patients in the control group will undergo 10 weekly relaxation sessions that include diaphragmatic breathing, progressive muscle relaxation, visualization and rapid relaxation.
224205377|NCT02002949|PROCEDURE|Short daily hemodialysis|5 or 6 treatments per week for approximately 3 hours (range 2 to 4 hours) per treatment, to be performed at the patient's home, using any hemodialysis machine as chosen by the responsible clinician in each participating center
224205378|NCT02002949|PROCEDURE|Conventional hemodialysis|3 treatments per week for approximately 4 hours (range 3 hours and 30 minutes to 4 hours) per treatment, to be performed in a dialysis clinic using any hemodialysis machine as chosen by the responsible clinicians in each participating center
224205379|NCT01591499|DEVICE|BIOFINITY® MF - AIR OPTIX® AQUA MF|During the first period, the participant will be allocated at random either the test lens pair (Biofinity) or a comparator lens pair (Air Optix or Purevision); during the second period, the participant will crossover to the alternate lens pair. (Biofinity crossover to Air Optix or Purevision) (Air Optix or Purevision crossover to Biofinity)
224314144|NCT03301649|DRUG|Vehicle Lotion|Topical lotion, placebo. Has no active ingredient.
224314145|NCT00646334|DEVICE|Mesh Implantation|An elective incisional Hernia repair is performed by using Optilene® Mesh Elastic, a lightweight and large pore mesh, knitted from monofilament polypropylene. Due to the multidirectional elasticity the mesh is able to adapt to all movements taking place in the abdominal wall.
224314146|NCT00646334|DEVICE|Mesh Implantation|Ultrapro® Mesh is a knitted, partly absorbable, lightweight mesh, consisting of equal parts of nonabsorbable polypropylene and absorbable polyglecaprone (Monocryl®). Polyglecaprone is fully absorbed in the body by hydrolysis. The addition of polyglecapron filament is only intended to reinforce the mesh to allow a convenient intraoperative handling and mesh placement, without additional function. Ultrapro® is an elastic mesh having enlarged elasticity cross to the blue strips.
224314147|NCT00762918|DIETARY_SUPPLEMENT|cholecalciferol|cholecalciferol 5000 IU capsule by mouth daily for 3 months
224314148|NCT02159313|DRUG|Riociguat(Adempas,BAY63-2521)|Single dose of a whole 2.5 mg riociguat tablet
223511633|NCT03829488|DRUG|0.9% SODIUM CHLORIDE 9g/L injection BP|Sodium chloride (0.9% saline) infusion is a sterile, non-pyrogenic solution of sodium chloride in Water for Injections. The concentration of sodium chloride is 154mmol/L. Sodium chloride (0.9%) intravenous infusion is indicated for extra-cellular fluid replacement and in the management of metabolic alkalosis in the presence of fluid loss, and for restoring or maintaining the concentration of sodium and chloride ions.
223511634|NCT01480765|DRUG|Pregabalin|150mg (2hrs) pre operatively and twice daily post operatively for 10 days, followed by dose reduction to 75mg twice daily for 2 days and finally to 50 mg twice daily for 2 days
223511635|NCT01480765|DRUG|Ketamine infusion|0.1mg/kg/hr for 48 hours post operatively
223511636|NCT01480765|DRUG|Placebo capsules|Single capsule (2hrs) pre operatively and twice daily post operatively for 10 days, followed by dose reduction to single capsule twice daily for 2 days and finally to single capsule twice daily for 2 days
223511637|NCT01480765|DRUG|Placebo infusion|Normal saline placebo intravenous infusion for 48 hours
223511638|NCT05599321|DIAGNOSTIC_TEST|Virtual Navigation System|The Virtual Navigator guidance computer is interfaced to the bronchoscopy hardware to tap off the live bronchoscopy and EBUS video feeds. The standard OR medical team (technicians, clinical fellows, et al.) is on hand, and standard clinical facilities (e.g., fluoroscopy, CT/PET image viewer) are available. Our technical team is also present to record all procedural video and computer display information. It also operates the guidance computer during the guided procedure and offers any assistance in case of unanticipated issues. The participant's clinical bronchoscopy will be recorded by the radiology imaging management system.
224205380|NCT01591499|DEVICE|BIOFINITY® MF - PUREVISION® MF|During the first period, the participant will be allocated at random either the test lens pair (Biofinity) or a comparator lens pair (Air Optix or Purevision); during the second period, the participant will crossover to the alternate lens pair. (Biofinity crossover to Air Optix or Purevision) (Air Optix or Purevision crossover to Biofinity)
224205381|NCT06653452|DIAGNOSTIC_TEST|18F-FDG PET/CT and PET/MR scan, 68Ga-FAPI-04 PET/CT and PET/MR scan|Patients with Locally Advanced Rectal Cancer underwent 68Ga-FAPI-04 PET/CT and PET/MR scan after injection of 0.02 to 0.04 mCi/Kg×patient weight (Kg). Within 1 week before and after the examination, 18F-FDG PET/CT and PET/MR is completed.
224314149|NCT03564158|DRUG|meropenem-vaborbactam|Meropenem-Vaborbactam being studied for effects on TQT
224314150|NCT03564158|DRUG|Placebo|Placebo
224314151|NCT03564158|DRUG|Moxifloxacin|Active Comparator
224314152|NCT01564537|DRUG|Ixazomib|Ixazomib capsules
224314153|NCT01564537|DRUG|Lenalidomide|Lenalidomide capsules
224314154|NCT01564537|DRUG|Dexamethasone|Dexamethasone tablets
223511639|NCT06457217|DIAGNOSTIC_TEST|Magnetic resonance spectroscopic imaging|High-resolution 3D metabolic imaging was performed using the SPICE 1H-MRSI sequence.
223617552|NCT02698150|DEVICE|HERMES tablet|Tablet, sensors and wearables for daily collection of clinical data
223617553|NCT00294294|BIOLOGICAL|Prevenar|
223617554|NCT00294294|BIOLOGICAL|Infanrix hexa|
224314155|NCT01564537|DRUG|Placebo|Ixazomib placebo-matching capsules
224314156|NCT02816606|PROCEDURE|Flexible reamers|These reamers allow creation of the femoral tunnel to be made in reduced knee flexion and potentially maximise tunnel length
224314157|NCT02816606|PROCEDURE|70-degree arthroscope|Using this arthroscope (rather than the more traditional 30-degree) gives improved visualisation of the femoral and tibial footprints. This may translate into better positioning of the tunnel within these regions
224314158|NCT05076357|BEHAVIORAL|Caloric Restriction|-30% of participants total energy requirements
224314159|NCT05076357|OTHER|Cold intervention|Sessions of 90min each every 2nd day involving cold exposure
224314160|NCT01909856|DRUG|Palonosetron|Palonosetron 0.25mg d1,d3
224205382|NCT06700642|OTHER|Educational intervention|"In this study, 3 intervention tools were developed by the researchers. The first of these, 'Rational Drug Use Trainer Guide', was used for trainer training and standardisation of the education given to patients. The sample rational drug use presentations prepared by the Ministry of Health, Turkiye Medicines and Medical Devices Agency, Department of Rational Drug Use were combined in terms of content, enriched with information obtained from the literature and developed for the use of family physicians working in primary health care institutions in their clinical practices.~'Rational Drug Use Individual Education Presentation' was prepared by the researchers in line with the 'Rational Drug Use Trainer Guide'. It has been prepared in a format suitable for individual education presentation with the most concise and understandable content suitable for use during primary healthcare service delivery.~'Rational Drug Use Patient Brochure' was prepared by the researchers in a similar content."
224205383|NCT01135316|DRUG|Ablavar|One dose of Ablavar will be administered for use during a contrast MRI examination
224205384|NCT05164562|OTHER|Data collection|Description: musculoskeletal disorders of upper limb evaluation
224205385|NCT00973531|DEVICE|Autotitrating Positive Airway Pressure (APAP)|Then subjects will use Autotitrating Positive Airway Pressure machine for 90 days
224314161|NCT01909856|DRUG|Granisetron|Granisetron 3mg d1-3
224205386|NCT00973531|DEVICE|Traditional Split Titration Polysomnogram|Then subjects will use Continuous Positive Airway Pressure (CPAP) machine for 90 days
224205387|NCT02801201|DRUG|Midazolam|
224205388|NCT02801201|DRUG|Bupivacaine|
224314162|NCT01909856|DRUG|Dexamethasone|Dexamethasone 10mg d1-3
224314163|NCT01909856|DRUG|Cisplatin|3-day chemotherapy regimens including cisplatin, cisplatin: 25mg/m2 d1-3
224314164|NCT02525900|PROCEDURE|Wound Infiltration|Wound Infiltration with 0.25% Bupivacine
224314165|NCT02525900|PROCEDURE|TAP Blocks|bilateral TAP block with 0.25% Bupivacaine
224314166|NCT02525900|PROCEDURE|TAP Catheters|bilateral TAP Catheter with repeat bolus of 0.25% Bupivacaine
224314167|NCT03275116|DRUG|Tiotropium 'Respimat' 5 mcg|Once daily single bronchodilation
224314168|NCT03275116|DRUG|Aclidinium Bromide/Formoterol Fumarate 340/12 mcg|Twice daily dual bronchodilation
224205389|NCT06426186|PROCEDURE|Right-stellate ganglion block|The experimental group was given right stellate ganglion block 30 minutes before anesthesia
224205390|NCT04653701|COMBINATION_PRODUCT|Chemoembolization with preloaded microparticles 100 micron and reflux control microcatheter|We will perform chemoembolization technique in those patients (during 1 year) with indications for this treatment in relation with guidelines (early and intermediate hepatocellular carcinoma). Specific microcatheter and microparticles will be use (Mentioned above)
224205391|NCT00000282|DRUG|Pemoline|
224314169|NCT01551108|BEHAVIORAL|Intervention: limited behavioral strategies|Parents are given access to a website, formatted for a mobile phone. The website provides parents with a target steps/day goal for their child and parents are instructed to use their mobile phone to access the study website to record their child's step count each night. Parents are also sent monthly healthy nutrition tips via text message targeting the child in order to provide these families with potentially health promoting information.
224314170|NCT01551108|BEHAVIORAL|Intervention: advanced behavioral strategies|Parents are given access to a website, formatted for a mobile phone. The website provides parents with a target steps/day goal for their child and parents are instructed to use their mobile phone to access the study website to record their child's step count each night. Parents also receive additional behavioral strategies based on the Social Cognitive Theory. The strategies are delivered through weekly articles posted on the website. Text messages are designed to prompt parents to encourage their child's physical activity, remind parents of behavioral concepts presented in the articles (article tip), and motivate parents to foster behavioral change in their child.
224314171|NCT04149106|DRUG|Sulfadoxine pyrimethamine + Amodiaquin|Monthly dose of SPAQ over three days for SMC
224314172|NCT04149106|DRUG|Dihydroartemisinin piperaquin|Monthly dose of DHAPQ for SMC
224314173|NCT00837473|DEVICE|Plexur-P used as a Bone Void Filler in Iliac Crest Harvesting Procedures|Plexur-P used as a Bone Void Filler in Iliac Crest Harvesting Procedures
224314174|NCT04405843|DRUG|Ivermectin Oral Product|Ivermectin oral suspension, 6 mg/mL
224314175|NCT04405843|DRUG|Placebo|Substance with similar physical and organoleptic characteristics as ivermectin, without the active drug ingredient
224314176|NCT05030558|BEHAVIORAL|Web-assisted patient education intervention designed according to the common-sense model|Implementation of patient education with the website created about fibromyalgia disease in 4 weeks according to the disease perception themes reached as a result of the qualitative research.
224314177|NCT05030558|BEHAVIORAL|The website where the Turkish Physical Medicine and Rehabilitation Association Fibromyalgia patient booklet is available as pdf.|The website where the Turkish Physical Medicine and Rehabilitation Association Fibromyalgia patient booklet is available as pdf.
224314178|NCT01286935|DRUG|Safinamide|
224314179|NCT01286935|DRUG|Safinamide|
223511640|NCT02933151|DIETARY_SUPPLEMENT|Nutritional Supplement|Selection of which supplement to give to the patients will be left to the dialysis unit's governing body as this study is not interested in a specific supplement's effect on nutrient restoration and subsequent outcomes but rather on oral replacement of amino acids regardless of the agent used.
223617555|NCT04027894|DRUG|Rifamycin SV MMX|200 mg Rifamycin SV-MMX® (CB-01-11)
224314180|NCT01286935|DRUG|Placebo|
224314181|NCT01635218|DRUG|Individualized homeopathic treatment|A single dose of the individualized homeopathic remedy in C-potency was dissolved in a 60 ml bottle of 30% alcohol-distilled water:15 drops PO two times per day following agitation plus fluoxetine-dummy loaded PO daily during 6 weeks. The homeopathic remedy could be changed at every follow-up (week 4) according to patient´s symptoms.
224314182|NCT01635218|DRUG|Fluoxetine|20 mg per day PO during 6 weeks plus individualized homeopathic dummy-loaded (60 bottle of 30% alcohol-distilled water: 15 drops PO two times per day following agitation). The individualized homeopathic dummy-loaded was repeated at week 4.
224314183|NCT01635218|DRUG|Placebo|Fluoxetine placebo (capsules containing sucrose microgranules) PO daily during 6 weeks plus individualized homeopathic placebo (60 ml bottle of 30% alcohol-distilled water: 15 drops PO two times per day following agitation). The individualized homeopathic placebo was repeated at week 4.
224314184|NCT03559400|DRUG|local gentamicin injection|Treatment includes debridement and administration of the local antibiotic which will consist of 80mg of liquid gentamicin diluted in 40mL normal saline injected after inserting a 22 gauge needle down to bone after wound closure. The injection will continue until either all 40cc are injected or there is fluid extravasation from the wound.
224314185|NCT03559400|DRUG|placebo saline injection|Treatment includes debridement and administration of the local antibiotic which will consist of 40mL normal saline injected after inserting a 22 gauge needle down to bone after wound closure. The injection will continue until either all 40cc are injected or there is fluid extravasation from the wound.
224314186|NCT04285593|OTHER|Bulgarian squats|The intervention using Bulgarian squat exercises will consist in the application of the protocol described by Aguilera-Castells et al. The technique will be done with the footballer standing. The athlete with one foot in front and the other behind the body, arms crossed over her chest, and her upper body, will remain upright with a natural swing in the lower back during the entire exercise. The players will lower the body (eccentric phase) until the front knee flexes to 90º. Subsequently, they will return to the initial position with a full extension of the knee of the front leg (concentric phase), maintaining an erect trunk position. The front foot will be placed in a fixed position contacting the ground, and the rear foot will rest on a horizontal press bench.
224205392|NCT06541925|DEVICE|Injection with the needle-free (NF) system|Before the injection procedure, the children were demonstrated the popping sound produced by device to prevent reflex reactions, and they informed that they would feel as if their gum were punched. The NF injection device was prepared according to the manufacturer's instructions, placed in full contact with the buccal mucosa and a pre-withdrawn dose of 0.1 ml was applied to the buccal region for topical purposes by the pushing the top of the device. After 10-15 seconds, the same procedure was repeated with withdrawn dose of 0.3 ml. After 5 min the treatment commenced, and the children were instructed to raise their hand if they experienced pain during the procedure. Each time the child indicated pain, in accordance with the same protocol an additional 0.3 ml of anesthetic solution was administered, until the sufficient anesthetic effect was obtained and the final amount of anesthetic solution were recorded. Precautions were taken to prevent tissue ballooning.
224205393|NCT06541925|DEVICE|Injection with the traditional method (TM)|The depth of penetration was only a few millimeters and 0.3ml of anesthetic solution was deposited. After 5 min the treatment commenced, and the children were instructed to raise their hand if they experienced pain during the procedure. Each time the child indicated pain, in accordance with the same protocol an additional 0.3 ml of anesthetic solution was administered, until the sufficient anesthetic effect was obtained and the final amount of anesthetic solution were recorded. Precautions were taken to prevent tissue ballooning.
224205394|NCT05083559|DEVICE|MPC AP algorithm|The Model Predictive Control (MPC) insulin infusion algorithm contains a model within the controller that takes as an input the aerobic metabolic expenditure in addition to the CGM and meal inputs. The algorithm uses heart rate and accelerometer data collected on the patient's body to calculate metabolic expenditure. The metabolic expenditure then acts on the model for the insulin dynamics, whereby more energy expenditure and longer duration exercise can lead to a more substantial effect of insulin on the CGM.
224205395|NCT05083559|DEVICE|Robust R-AP algorithm|The R-AP is a modified MPC algorithm. A new feature in the algorithm includes a model for missed meal insulin detection. The model includes estimations for carbohydrate consumption based glucose patterns to determine if that person has consumed a meal without announcing it to the system.
224314187|NCT04707976|DEVICE|Navina Smart|CE-marked NavinaTM Smart including Navina Smart App.
224205396|NCT03907540|DRUG|Belumosudil 200 mg tablet|Belumosudil 200 mg tablet, development candidate
224205397|NCT03907540|DRUG|[14C]-KD025 at a dose of 100 μg in a 5 mL solution IV microdose|test investigational medicinal product
224205398|NCT03907540|DRUG|[14C]-KD025 200 mg capsule|test investigational medicinal product
224205399|NCT06520722|DIAGNOSTIC_TEST|Prolapse scoring system|"A FIXED APCD classification system :~A: Associated symptoms:~FIXED:~F: frequency I: infection X: sex problems E: everted mass(external protrusion of mass from the valva as PV lump sensation ,heaviness,itching and ulceration) D: digitation(patient need to digitate to complete the act of micturation or defecation)~APCD:~A: Dependent point on anterior wall. P: Dependent point on posterior wall. C: Cuff point either cervix or vault. Distance to hymen in centimeters (minus above or plus below) after pushing the opposite wall during maximal straining D: Dimensions; base diameter of vestibule/ perineal length.~The staging system will be interpreted as follows:~Normal:~A-3 P-3 C-8 D 2/2~Stages:~0: No prolapse.~A/P-2 OR C-7 to C-2 A,P or C-1 to +1 A,P or C ˃ +1~X component: (alone or with any stage):~Dimension disruption: ˃2 or \<2"
224205400|NCT01721824|BEHAVIORAL|The IPS-MA method|During the first 6 months participants are usually offered 3 meetings with their mentor per month, lasting approximately 1 1/2 hours each. The following 6 months they are offered 1 meeting per month, lasting approximately 1 hour. The estimated duration of the IPS-MA intervention is 12 months, but since the needs of the participants are very individual, this may vary.
224314188|NCT04707976|OTHER|Standard Bowel Care|Bowel care will be scheduled at least every 2nd day according to a defined study specific standard bowel care protocol. Diet, fluids, abdominal massage, regular physical activity and medications will be used if non-interventional treatment is insufficient.
224314189|NCT03401125|OTHER|Medical file data collection|The information described in the 'outcome measures' section will be collected from the medical files of the patients.
223617556|NCT04027894|DRUG|Placebo to Rifamycin SV-MMX|Placebo to Rifamycin SV-MMX® Placebo tablets correspond to active tablets with respect to size, taste, and appearance.
223617557|NCT01151488|OTHER|Resistance Training|RT 3x/wk for 4 months
223617558|NCT03710148|OTHER|Natural exposure of deficient or excessive iodine|Natural exposure of deficient iodine from diet \& drinking water, and of excessive iodine intake from drinking water
223761373|NCT01616186|DRUG|Sunitinib monotherapy|"Starting dose: sunitinib 50 mg daily 4 weeks on, 2 weeks off - taken fasting, no food 1 hour before or 2 hours after dosing~(Note: sunitinib is typically dosed in 42 day cycles described above: 28 days treatment, 14 days off. For the purposes of this protocol, to keep timing consistent, a cycle will be defined as 42 days of therapy)"
223617559|NCT04393675|DRUG|LT5001|Administered twice daily
223617560|NCT04393675|DRUG|Placebo|Administered twice daily
224314319|NCT05635032|OTHER|Comprehensive clinical assessment and biological samples collection|To establish the first Portuguese registry and biobank of PF-ILDs, comprising both extensive patient-level data, and systematic biological sampling (DNA, RNA, plasma, serum, bronchoalveolar lavage, lung tissue) at baseline and repeated biological sampling of blood and pharyngeal swabs performed at 6, 12 and 18 months, or whenever progression criteria are met or an acute exacerbation occurs. Participants will have regular visits at maximum intervals of 6 months, when their clinical condition and lung function tests are reassessed. A high resolution computed tomography (HRCT) scan of the lung will be performed every 12 months. Progressive fibrosis will be diagnosed based on meeting at least two of the following three criteria, occurring within the last year: (i) worsening of symptoms; (ii) absolute decline in FVC ≥5% predicted or absolute decline in DLCO (corrected for Hb) ≥10% predicted; (iii) increased extent of fibrotic changes on HRCT.
224314320|NCT05853042|DIAGNOSTIC_TEST|high-sensitivity cardiac troponin testing|Lithium heparin plasma samples will be measured with Mindray Bio-Medical CL-1200i Chemiluminescence Immunoassay Analyzer.
224314321|NCT04093375|PROCEDURE|Radical Prostatectomy|Radical prostatectomy with or without androgen deprivation therapy
224314322|NCT04093375|OTHER|Radical Radiotherapy|Radical Radiotherapy with adjuvant androgen deprivation therapy
224314323|NCT06558149|PROCEDURE|Those whose opioids were adjusted according to hemodynamic parameters|Patient who will be adjusted according to hemodynamic parameter
224314324|NCT06558149|PROCEDURE|Those whose opioids were adjusted according to NOL monitoring|Patient who will be adjusted according to NOL monitoring
224314325|NCT02529215|BEHAVIORAL|Just-in-time training (JITT)|The JITT training is a 20 minute simulation-based teaching session targeting: (1) CPR quality and (2) medication administration.
224314326|NCT00018356|PROCEDURE|exercise|
224314327|NCT00018356|DRUG|testosterone|
224260305|NCT04936581|PROCEDURE|Robotic Total Mesorectal Excision|Robotic approach for Total Mesorectal Excision
224260306|NCT04936581|PROCEDURE|Transanal Total Mesorectal Excision|Transanal approach for Total Mesorectal Excision
224260307|NCT01694212|DRUG|Perioperative Diclofenac eye-drops administration|
224260308|NCT01694212|DRUG|placebo|
224260309|NCT02836821|DRUG|Apatinib Mesylate Tablets|apatinib was administered in the morning after an overnight fast of at least 10 h
224260310|NCT02836821|DRUG|Rifampicin Capsules|rifampicin was administered in the morning 2 hours after breakfast
224260311|NCT06562621|BIOLOGICAL|ON-01|ON-01 consists of a yeast cytosine deaminase (CD) gene. The CD gene converts the antifungal 5-flurocytosine (5-FC) to the anticancer drug 5-FU in cells that have been infected by ON-01.
224260312|NCT06562621|DRUG|ONF|ONF is an extended-release formulation of flucytosine.
224260313|NCT00835263|DRUG|Lamotrigine|200 mg Tablet
224260314|NCT00835263|DRUG|Lamictal®|200 mg Tablet
224260315|NCT03664063|DRUG|Azithromycin|Treatment with Azithromycin single dose - weight based dosing max 2gm
224260316|NCT03664063|DRUG|Albendazole|"Single dose of Albendazole weight based dosing~\- 400mg"
224260317|NCT03664063|DRUG|Ivermectin|Ivermectin weight based dosing - max 21mg
224260318|NCT03664063|DRUG|Diethylcarbamazine|Diethylcarbamazine weight based dosing - max 500mg
224260319|NCT00848536|DRUG|Travoprost 0.004% (POLYQUAD-preserved) Eye Drops, Solution|One drop once daily in the evening for 3 months
224260320|NCT00848536|DRUG|Travoprost 0.004% (BAK-preserved) Eye Drops, Solution|One drop once daily in the evening for 3 months
224260321|NCT02748707|DRUG|Arm1|Drug (Celecoxib as 200mg twice daily) given orally for 21 days after confirmation by biopsy and before definitive treatment by surgery
224260322|NCT02748707|DRUG|Arm 2|Drug (ERLOTINIB 150 mg daily) given orally for 21 days after confirmation by biopsy and before definitive treatment by surgery
224260323|NCT02748707|DRUG|Arm 3|Drugs (Celecoxib 200mg twice daily and Erlotinib 150mg once daily) given orally for 21 days after confirmation by biopsy and before definitive treatment by surgery
224260324|NCT02748707|OTHER|Arm 4|Patients randomized to this arm will be observed for 21 days before definitive treatment by surgery.Having a control group is ethically justifiable because the average waiting time in our hospital prior to definitive treatment is 30 days after diagnosis.
224260325|NCT01131637|DRUG|rhNRG-1|day1\~day10:0.6ug/kg/day,10hours per day for vein infusion; week3\~week25:0.8ug/kg/day,10minutes per time per week for vein injection
224260326|NCT01131637|DRUG|placebo|day1\~day10:0.6ug/kg/day,10hours per day for vein infusion; week3\~week25:0.8ug/kg/day,10minutes per time per week for vein injection
224260327|NCT03249454|DEVICE|Anodal tsDCS|During Anodal tsDCS intervention the positive end of the battery will be connected to the electrode on participant's back and negative end of the battery will be connected to the electrode on participant's shoulder. The battery will be turned on for 15 minutes, and the stimulation strength will be adjusted a couple of times per tolerance level.
224260328|NCT03249454|DEVICE|Cathodal tsDCS|During Cathodal tsDCS intervention the negative end of the battery will be connected to the electrode on participant's back and positive end of the battery will be connected to the electrode on participant's shoulder. The battery will be turned on for 15 minutes, and the stimulation strength will be adjusted a couple of times per tolerance level.
224260329|NCT03249454|DEVICE|Sham tsDCS|During Sham tsDCS intervention, battery will be turned off and no current will pass through the electrodes.
224260330|NCT05281861|OTHER|Zirconia reinforced Lithium disilicate (Vita Ambria) ceramic onlay restoration|In experimental group, Participants will be restored with onlay ceramic restorations constructed from zirconia reinforced Lithium disilicate (Vita Ambria) glass ceramic
224260331|NCT05281861|OTHER|Lithium disilicate (IPS e-max press) ceramic onlay restoration|In control group, Participants will be restored with onlay ceramic restorations constructed from Lithium disilicate (IPS e-max press) glass ceramic
224260332|NCT03972683|OTHER|Handgrip Exercise Training|Signaling mechanisms that regulate blood flow will be studied before and after 7 weeks of handgrip exercise training with the non-dominant forearm. Training sessions will consist of 30 min of rhythmic contractions using a handgrip exercise device, and participants will complete four training sessions per week.
224260333|NCT03972683|DRUG|Acetylcholine|Vasodilatory sensitivity to acetylcholine will be assessed in dose-response fashion as a standard test of vascular function. Doses of 0.5, 1.5, and 15 μg/dl forearm volume/min will be infused via a brachial artery catheter for 4 min per dose.
224314328|NCT06427707|DRUG|Intravenous Infusion of propofol, lidocaine, Magnesium sulfate|intravenous infusion of propofol 6-10 mg.kg-1.h-1, lidocaine (lidocaine 2% 400mg in 20 ml) bolus of 1.5 mg.kg-1 followed by infusion with a rate of 1.5 mg.kg-1.h-1 and magnesium sulfate 40 mg.kg-1 loading followed by infusion of 20 mg.kg-1.h-1. the effect of either Propofol injection, or ketamine injection or dexmeditomidine injection on intraoperative bleeding
224314329|NCT06427707|DRUG|Intravenous infusion of ketamine, lidocaine, Magnesium sulfate|Patients will receive intravenous infusion of Ketamine 0.1-0.2 mg.kg-1.h-1 (intravenous infusion of propofol 6-10 mg.kg-1.h-1, lidocaine (lidocaine 2% 400mg in 20 ml) bolus of 1.5 mg.kg-1 followed by infusion with a rate of 1.5 mg.kg-1.h-1 and magnesium sulfate 40 mg.kg-1 loading followed by infusion of 20 mg.kg-1.h-1. dose of 1 mg.kg-1), lidocaine bolus of 1.5 mg.kg-1 followed by infusion with a rate of 1.5 mg.kg-1.h-1 and magnesium sulfate 40 mg.kg-1 loading followed by infusion of 20 mg.kg-1.h-1.
224314330|NCT06427707|DRUG|Intravenous infusion of dexmedetomidine, lidocaine, Magnesium sulfate|Dexmeditomidine (Precedex® 200 mcg.2ml-1) with a rate of 0.2-0.6 mcg.Kg-1.h-1. lidocaine bolus of 1.5 mg.kg-1 followed by infusion with a rate of 1.5 mg.kg-1.h-1 and magnesium sulfate 40 mg.kg-1 loading followed by infusion of 20 mg.kg-1.h-1
224314331|NCT01797237|DEVICE|PFNA|
224314332|NCT01797237|DEVICE|InterTAN|
224314333|NCT01247883|DRUG|PF-04634817|single dose, 20mg, tablet
224314334|NCT01247883|DRUG|PF-04634817|single dose, 20mg, solution
224314335|NCT03548701|DIAGNOSTIC_TEST|Thromboelastometry testing|Thromboelastometry testing - a form of testing in whole blood for coagulation abnormalities
224314336|NCT00000246|DRUG|Flumazenil|
224314337|NCT03578549|DEVICE|Pulse Oximetry|Pulse Oximeter is being applied with a special holding tool to test the oximeter for its ability to measure pulpal blood flow, but no effect of the oximeter is being measured. Thus, to that degree the use is observational rather than interventional.
224314338|NCT05708989|PROCEDURE|Caudal Block|Injectable 1 ml/kg of 0.25% ropivacaine with 1mcg/kg dexmedetomidine into caudal spinal space. First attempt will be landmark-guided into the caudal spine region. Subsequent attempt(s) may be done using ultrasound.
224314339|NCT05708989|PROCEDURE|Ultrasound-guided Pudendal Block|Injection of 0.5 ml/kg per side of injectable 0.2-0.3% ropivacaine with 0.5 mcg/kg dexmetomedine. Ultrasound-guided injection into each pudendal nerve region through skin of buttocks.
223618280|NCT05548946|DIAGNOSTIC_TEST|Clinical Ratings of the dimensional model|"Clinical ratings of criteria A and B will also be collected. Only a small part of the patients will be selected for this, in order to make the research more feasible. The rater (a clinician or researcher) assesses the patient (in terms of level of personality functioning and personality traits) by means of (structured) clinical interviews. Given clinical ratings of the dimensional criteria are not part of the standard care in either institution, the ratings can be conducted by the doctorandus and Master Thesis students, trained by the doctorandus (in order not to overburden the clinicians).~The clinical interviews that will be used for the ratings are:~* The Semigestructureerd Interview voor Persoonlijkheidsfunctioneren DSM-5 (STIP) (Hutsebaut et al., 2014).~* The Structured Clinical Interview for the DSM-5 (SCID-5-AMPD) (First et al., 2018), only if a Dutch translation is available by the time of this intervention."
223618281|NCT05548946|OTHER|PID-5-BF+M and LPFS-BF 2.0 (Informant questionnaires)|In the clinical population, participants will be asked to include an informant (family member, partner, friend, acquaintance), to fill in an informant version of the PID-5-BF+M and LPFS-BF 2.0 questionnaires. It is also possible for the patient to participate in the study without giving permission to include an informant. The informant will be asked to fill in the informant versions of the questionnaires, which contain the exact same items as the self-report versions, adjusted to the third person.
223618282|NCT05173896|DRUG|Tadalafil 20 MG|Daily dose of oral over-encapsulated tadalafil tablets (20 mg) for three months.
223618283|NCT05173896|DRUG|Placebo|Daily dose of oral over-encapsulated placebo tablets for three months.
223618284|NCT03009851|BEHAVIORAL|OBCHI|Occupation-based cultural heritage intervention emphasizing the cultural background of residents in LTC settings.
223680750|NCT01490723|DRUG|Methotrexate|5 mg/m2 by vein on Day +1, +3 and +6. Patients receiving an unrelated graft will also be given methotrexate on Day +11 after the transplant.
224314340|NCT05708989|DRUG|Injectable 1 ml/kg of 0.25% ropivacaine with 1mcg/kg dexmedetomidine|Injectable 1 ml/kg of 0.25% ropivacaine with 1mcg/kg dexmedetomidine into caudal spinal space. First attempt will be landmark-guided into the caudal spine region. Subsequent attempt(s) may be done using ultrasound.
224314341|NCT05708989|DRUG|Injection of 0.5 ml/kg per side of injectable 0.2-0.3% ropivacaine with 0.5 mcg/kg dexmetomedine.|Injection of 0.5 ml/kg per side of injectable 0.2-0.3% ropivacaine with 0.5 mcg/kg dexmetomedine. Ultrasound-guided injection into each pudendal nerve region through skin of buttocks.
224314342|NCT02600689|BEHAVIORAL|Physical exercise training|
224314343|NCT02600689|BEHAVIORAL|Cognitive exercise training|
224314344|NCT02305160|DRUG|Butantan|Use of Butantan surfactant 100 mg/kg, IT, maximum of 3 doses
224314345|NCT02305160|DRUG|Control|The pulmonary surfactants commercially available in Brazil Survanta or Curosurf: 100 mg/kg, IT, maximum of 3 doses.
224314346|NCT01776931|DIETARY_SUPPLEMENT|Lysine intake|Oral consumption of Eight hourly experimental meals- Includes 4 tracer-free experimental meals containing a mixture of free amino acids, calories from a flavored liquid and protein free cookies and 4- labeled amino acid experimental meals.
224314347|NCT04603157|BEHAVIORAL|Hybrid Exercise Training|Personalized exercise program completing at least 3 aerobic exercise sessions a week and receive eight supervised training sessions over the 3-months
224314348|NCT00461201|PROCEDURE|Nurse practitioner care of patients|
224314349|NCT03668392|DRUG|Asparaginase|Measurement of serum Asparaginase activities during therapy, in terms of intensity and duration, as surrogate parameter for asparaginase depletion.
223680751|NCT01490723|DRUG|Mycophenolate|15 mg/kg (actual body weight with a maximum dose of 1 gram twice daily) by vein or by mouth administered from Days -3 to +45 and then tapered to end by day 100 if there is no Graft versus Host Disease (GVHD).
224314350|NCT02046486|DRUG|Ticagrelor 180mg whole tablets|
224314351|NCT02046486|DRUG|Ticagrelor 180mg crushed and dispersed|
224314352|NCT00900835|OTHER|educational intervention|
224314353|NCT00900835|OTHER|questionnaire administration|
224314354|NCT00900835|OTHER|study of socioeconomic and demographic variables|
224314355|NCT00900835|PROCEDURE|assessment of therapy complications|
224314356|NCT00900835|PROCEDURE|fatigue assessment and management|
223618285|NCT04726722|BEHAVIORAL|internet-based cognitive behavioral theraphy|"When determining the content of the I-CBT program, the participants and therapist will be allowed to choose from a library of treatment modules.~Therapist controlled support and feedback are given weekly and in a structured manner. Participants will be able to contact the therapist when support and feedback is desired"
223618286|NCT05626530|DRUG|Letermovir|Open label 480 mg given daily for 60 days
224205962|NCT04331392|BEHAVIORAL|Spatial Navigation Intervention|"The 16-week intervention is completed daily, 5 days/week, remotely from home on a designated study website. Each week participants learn a new city through navigation tasks which increase in difficulty day-to-day and have a total of 4 levels of difficulty, with the goal of being able to independently navigate the city by the end of the week via Google Street View. Participants complete end-of-day multiple-choice tasks, testing what they learned with 3 types of allocentric questions: 1) predicting the next street/landmark, 2) distance judgement and 3) vector mapping. Participants also complete a map placement task, which involves reporting the locations of all studied landmarks/streets.~Participants are presented with auditory rewards in the forms of short audio clips about landmarks, written encouragement in the form pop-ups (e.g., Good work, keep it up!), and coffee card rewards based on adherence to the intervention (e.g.,$5 bi-weekly if 100% of intervention is completed)."
224205963|NCT04331392|BEHAVIORAL|Educational Videos|The 16-week active control, remote video intervention is completed daily, 5 days a week by participants on a designated website. Participants placed in the active control group are trained on educational topics by watching videos of Ted Talks, to control for the effects of generalized environmental enrichment of the same dose as targeted navigation training. For each day of training, participants are asked to select between an option of 2 possible videos, watching a total of three videos per day. To ensure compliance and sufficient attention to the videos, at the end of each video, participants are asked to rate 5 aspects of the content (relevance, interest, comprehensibility, complexity, informative), and speaker (persuasiveness, quality of delivery, facial expression, convincingness, captivation), on a scale of 1 (lowest) to 5 (highest). Additionally, as with remote navigation participants, they are given written and monetary rewards.
224205964|NCT04690946|BEHAVIORAL|Cognitive Behavioral Therapy|14-18 sessions of CBT
224205965|NCT04690946|BEHAVIORAL|Emotion-Focused Therapy|14-18 sessions of EFT
224205966|NCT04914559|OTHER|Oral nutrition supplement - control|Drink 1 cup of liquid nutrition product that contains protein, carbohydrate and fat intended for use as supplemental nutrition.
224205967|NCT04914559|OTHER|Oral nutrition supplement - test|Drink 1 cup of liquid nutrition product that contains protein, carbohydrate and fat designed for people living with diabetes and intended for use as supplemental nutrition.
224205968|NCT03687580|DEVICE|B-Cure Laser Pro|The B-Cure Laser Pro is a portal, non-invasive low-level laser therapy device, that emits light in the near infrared (808nm) over an area of 1X4.5 cm2 with power output of 250mW, and energy dose of 5J/min
224205969|NCT03687580|DEVICE|Sham laser|The sham laser device is externally identical to the B-Cure Laser Pro and emit the same guiding light, but does not emit the therapeutic near infrared rays
224205970|NCT05924672|DRUG|Radium-223|Given IV
224205971|NCT05924672|PROCEDURE|PSMA Positron Emission Tomography (PET) Scan|Undergo PSMA PET/CT
224205972|NCT05924672|DRUG|Technetium Tc 99M Medronate|Undergo MDP
224205973|NCT02160054|DRUG|Graceptor®|oral
224205974|NCT05134740|BIOLOGICAL|TAA-specific CTLs|"Each patient will receive 2 infusions at the same dose, 14 days apart, according to the following dose level:~2 x 10\^7/m2"
224205975|NCT04308382|BEHAVIORAL|Health Risk Assessment|"Heath Risk Assessment consists of:~* Survey to include questions about physical activity, stress, hope, household hunger and demographics.~* Lipid panel and HbA1c~* Height and Weight, blood pressure and resting pulse"
224205976|NCT06643975|OTHER|One-piece zirconia dental implants|One-piece zirconia dental implants with zirconia ball attachments, these implants are metal free made of oxide ceramics with cutting-edge Selective laser melting(SLM) surface treatment technology
224205977|NCT06643975|OTHER|One-piece titanium dental implants|One-piece Titanium dental implants with titanium ball attachments, these implants are gold standard compatible implants
224205978|NCT02603341|RADIATION|Photon|Photon Therapy:once a day, 5 days a week, for 5 to 7 weeks
224205979|NCT02603341|RADIATION|Proton|Proton Therapy: once a day, 5 days a week, for 5 to 7 weeks
224205980|NCT06650540|DRUG|Levofloxacin Plus Metronidazole Suppositories|Administer a two-week course of Levofloxacin Plus Metronidazole Suppositories to patients diagnosed with chronic endometritis.
223618287|NCT05820282|BEHAVIORAL|Volitional help sheet|Participants are asked to choose from a list of strategies for increasing delivery of behaviour change interventions
224205981|NCT06650540|BIOLOGICAL|Levofloxacin co-administered with Metronidazole tablets|Administer a two-week course of Levofloxacin in combination with Metronidazole tablets to patients diagnosed with chronic endometritis.
224205982|NCT06650280|OTHER|Hyaluronic Acid (HA)|hyaluronic acid coated implants will be placed in posterior maxilla to evaluate rapid osseointegration
224205983|NCT06650280|OTHER|nano-hydroxyapatite|nano-hydroxyapatite coated implants will be placed in posterior maxilla to assess rapid osseointegration
224205984|NCT06650280|OTHER|sandblasted acid etched|SLA coated implants will be placed in posterior maxilla and implant stability will be evaluated
224205985|NCT06649734|OTHER|Delphi Study|A Delphi study will be conducted with several rounds up to stable expert consensus or dissensus
224205986|NCT06651424|DIETARY_SUPPLEMENT|Combination of Lactobacillus probiotics (no comercial)|Each participant will consume 1 capsule per day in one of the main meals without any restriction in the diet or in their life habits
224205987|NCT06651424|DIETARY_SUPPLEMENT|Placebo|Each participant will consume 1 capsule per day in one of the main meals without any restriction in the diet or in their life habits
224205988|NCT06651307|DEVICE|Lifting with elbow sleeves|Lifting with elbow sleeves
224205989|NCT06164886|OTHER|Waiting list|patient on the waiting list for scheduled surgical admissions
224205990|NCT03594175|DRUG|CUSA-081|Participants received 1 or 2 doses of CUSA-081 0.7 mg/2 mL directly into the catheter lumen
224205991|NCT03594175|DRUG|Placebo|Participants received 1 or 2 doses of placebo (normal saline) directly into the catheter lumen
224314357|NCT00900835|PROCEDURE|quality-of-life assessment|
224314358|NCT00900835|PROCEDURE|standard follow-up care|
224314359|NCT02040441|DRUG|Spironolactone|
223618288|NCT05820282|OTHER|Control condition|Participants are asked to identify situations and solutions and place a tick next to each one they think would be useful to them. Therefore, participants in the control condition are not asked to form implementation intentions.
223618289|NCT01001247|DRUG|TMC278; Omeprazole|
223618290|NCT05233033|DRUG|KT-413|KT-413 will be supplied as 10mg/mL concentration frozen solution to be administered intravenously per the protocol defined dose level.
224205992|NCT03594175|DRUG|Alteplase|Participants received 1 or 2 doses of alteplase, 2 mg/2 mL, directly into the catheter lumen
224205993|NCT06489847|DIAGNOSTIC_TEST|SPPB++ Application|Participants will have video data collected as they perform the SPPB test one time.
224205994|NCT03413722|DRUG|Tacrolimus|The patient's physician will prescribe drug according to standard practice.
224205995|NCT03413722|DRUG|Everolimus|The patient's physician will prescribe drug according to standard practice.
224205996|NCT05416125|DRUG|Lisdexamfetamine Dimesylate|Vyvanse treatment
224205997|NCT05416125|BEHAVIORAL|Lifestyle therapy|Lifestyle treatment
224205998|NCT01915498|DRUG|Enasidenib|Enasidenib tablets administered orally every day of 28-day treatment cycles until disease progression or unacceptable toxicities.
224205999|NCT01907516|DEVICE|Cell phone-internet home glucose reporting system|Glucose monitoring via cell phone and internet using the Confidant Diabetes Management Application and the Confidant Connector.
224206000|NCT01907516|BEHAVIORAL|Voicemail home blood glucose reporting|Glucose monitoring via standard telephone and fax reporting.
224206001|NCT04719728|DIAGNOSTIC_TEST|Aided pure tone audiometry|aided response, speech, evoked potential
224206002|NCT06406894|OTHER|Conventional physical therapy|"lower limb muscle stretching ( pelvic bridging, Knee to chest,cat and camel stretch) (30 seconds hold and 3 sets of 5 repetitions with 1 min rest interval in between each set, per session on daily basis for only one week for immediate results and for long term effect on alternate 3 days in remaining 2nd ,3rd week).~Treatment protocol will be given on daily basis to check immediate effect and for long term effect treatment will be given in alternating 3 days for remaining 2 weeks. Total 12 session were given (3 weeks)."
224206003|NCT06406894|OTHER|Superficial back line relaxation (SMIT & CCFE)|Experimental group was given superficial back line relaxation includes SMIT \& CCFE along with conventional therapy includes lower limb muscle stretching. SMIT For short term effect 10-12 repetitions per session, on daily basis for 1st week. For long term effect 10-12 repetitions per session, for 3 alternate days in remaining 2nd\&3rd week. CCFE For short term effect 3 sets of 10 reps , 10 sec hold , 1 min rest after each set, on daily basis for 1st week. For long term effect 3 sets of 10 reps, 10 sec hold , 1 min rest after each set, for 3 alternate days , remaining 2nd \& 3rd week. Conventional therapy lower limb muscle stretching ( For short term effect 30 seconds hold , 3 sets of 5 repetitions , 1 min rest after each set, per session on daily basis for 1st week , for long term effect on alternate 3 days in remaining 2nd ,3rd week). Total 12 sessions were given (3 weeks).
224206004|NCT01137643|OTHER|biologic sample preservation procedure|All samples collected during routine clinical care.
224206005|NCT01137643|OTHER|cytology specimen collection procedure|All Samples collected during routine clinical care.
224206006|NCT04983095|RADIATION|stereotactic body radiotherapy|30 Gy in 3 fractions alternatively 40 Gy in 5 fractions delivered with stereotactic radiotherapy-principles
224206007|NCT04983095|COMBINATION_PRODUCT|androgen deprivation therapy|Medical castration and next-generation Hormonal Agent along with radiotherapy to the prostate in de novo oligometastatic prostate cancer
224206008|NCT04983095|RADIATION|Radiotherapy|RT to the prostate for de novo patients
224206009|NCT06147856|DRUG|mRNA-3210|IV infusion
224206010|NCT05254041|OTHER|Menstrual Cup Removal|Participants will be asked to remove Menstrual cup by breaking the seal.
224206011|NCT02159651|DRUG|tacrolimus|oral
224206012|NCT05027425|DRUG|Durvalumab|1500 mg IV, Q4W
224206013|NCT05027425|DRUG|Tremelimumab|300 mg IV, 1 dose on day 1 of only the first cycle
224206014|NCT05027425|PROCEDURE|Liver Transplant|minimum 72-day washout from the end of immunotherapy, patients will undergo liver transplant.
224206015|NCT05494151|DIAGNOSTIC_TEST|Investigation of the metabolic substrate|A blood sample will be received from each patient to assess novel metabolomic biomarkers' levels at the time of acute myocardial infraction
224206016|NCT04233788|DEVICE|MR-scans using a 3T Prisma and a 7T Terra scanner (Siemens, Erlangen Germany)|The MR-scans performed at 3T and 7T are performed to evaluate whether high field MR-examinations bring an advantage to the patient in determining the IDH-status of the glioma. Two MRSI/CEST sequences will be tested against each other.
224206017|NCT06173713|DEVICE|Emphasys Hip Solutions|Emphasys Acetabular Shell, Emphasys AOX Polyethylene Liner, Articul/eze 12/14 metal head and Emphasys fem. stem
224206018|NCT04824560|BEHAVIORAL|Blood pressure education|One page teaching protocol performed by pharmacy students; phone follow-up
224206019|NCT03692767|BIOLOGICAL|Anti-CD22 CAR NK Cells|Anti-CD22 CAR NK Cells injection
224206020|NCT05631652|DEVICE|PillSense System|The device is composed of an orally ingested PillSense capsule and a wireless handheld PillSense receiver for real-time display of sensor data. The capsule contains an optical sensor for in-vivo detection of blood. The sensor capsule is used for diagnosis in patients with suspected acute bleeding in the upper gastrointestinal tract.
224206021|NCT06348823|DIAGNOSTIC_TEST|volume survey|All subjects received oral hygiene instructions and, if needed, a dental cleaning of plaque and calculus. After calibration using digital photographs, intraoral scans, and CBCT, one dentist, who was not involved in the screening phase to avoid any bias, obtained all clinical parameters (gingival biotype, probing depth, gingival thickness, gingival width). Two test subjects were examined prior starting with enrollment and data collection.
224206022|NCT05362955|DRUG|Intravaginal 5-Fluorouracil (5-FU)|Participants will self-administer 2 g of 5% 5-FU intravaginally using an applicator, one night per week (every other week), on weeks 1, 3, 5, 7, 9, 11, 13, 15, for a total of 8 applications.
224206023|NCT04873830|BIOLOGICAL|volume stable collagen matrix placement|volume stable collagen matrix placement to augment the buccal defect.in class I siebert at the same time of implant placement
224206024|NCT04873830|PROCEDURE|connective tissue grafting|connective tissue placement to augment the buccal defect.in class I siebert at the same time of implant placement
223618291|NCT03400475|DRUG|Simvastatin|One topical application in peri-implant gingival crevice
223618292|NCT03400475|OTHER|Placebo|One topical application in peri-implant gingival crevice
223618293|NCT00966511|PROCEDURE|Lung resection surgery|The study is designed in a way that will not alter the surgeon's decision based on routine assessment of candidates for resection (lobectomy or greater). Namely, the VRI data will be gathered prospectively; however, the analyses using VRI data will be performed retrospectively.
223618294|NCT06867289|DEVICE|EEG|EEG monitoring will be performed in addition to the usual practice, before DEX administration and for 20 minutes before NMRI, to enable calculation of the PSI sedation score (at 0, 10, 20 minutes). Sedation will also be assessed by the PSSS clinical score at 0, 10, 20 minutes after DEX administration, as well as at 150 minutes after DEX.
224206025|NCT06146517|OTHER|Clevr Sleeptime|Participants will trial Clevr Blends Sleeptime during weeks 1-4.
224206026|NCT06146517|OTHER|Clevr Matcha|Participants will trial Clevr Matcha during weeks 5-8.
224206027|NCT06146517|OTHER|Clevr Chai|Participants will trial Clevr Chai during weeks 9-12.
224206028|NCT06054750|DRUG|Ropivacaine|800 mg ropivacaine in continuous infusion adductor canal block (400 mL total volume)
224206029|NCT06054750|DRUG|Normal saline|400 mL normal saline in continuous infusion adductor canal block (400 mL total volume)
224206030|NCT04951895|DIAGNOSTIC_TEST|MRI|MRI of TMJ
224206031|NCT02181127|DEVICE|Glucagon-only Bionic Pancreas|A computer algorithm will automatically deliver glucagon based on the signal from a minimally invasive continuous glucose monitor.
224206032|NCT00334477|DRUG|tadalafil|
224206033|NCT02707718|BIOLOGICAL|blood sampling|during the usual blood sampling performed in the ED in patients suspected of sepsis, two additional tubes will be sampled for a panel of biomarkers measurement
224206034|NCT05187507|OTHER|Evaluation of the effectiveness of low- fluoridated toothpaste.|"Children will be given low- fluoridated toothpaste, plaque score in groups will be assess pre given toothpaste in baseline,aweek,2week,and after 3weeks by using the TMQHPI for both buccal and lingual surface.~Gingivalitis will be assess pre given toothpaste,aweek,2weeks,and after 3weeks by using gingival index (loe and silness)."
224206035|NCT05187507|OTHER|Evaluation of the effectiveness of fluoridated toothpaste.|"Children will be given e fluoridated toothpaste, plaque score in groups will be assess pre given toothpaste in baseline,aweek,2week,and after 3weeks by using the TMQHPI for both buccal and lingual surface.~Gingivalitis will be assess pre given toothpaste,aweek,2weeks,and after 3weeks by using gingival index (loe and silness)."
224206036|NCT05187507|OTHER|Evaluation of the effectiveness of theobromine toothpaste (2%) toothpaste.|"Children will be given theobromine toothpaste(2%),plaque score in groups will be assess pre given toothpaste in baseline,aweek,2week,and after 3weeks by using the TMQHPI for both buccal and lingual surface.~Gingivalitis will be assess pre given toothpaste,aweek,2weeks,and after 3weeks by using gingival index (loe and silness)."
224206037|NCT05187507|OTHER|Evaluation of the effectiveness of theobromine toothpaste(4%) toothpaste.|"Children will be given theobromine toothpaste(4%),plaque score in groups will be assess pre given toothpaste in baseline,aweek,2week,and after 3weeks by using the TMQHPI for both buccal and lingual surface.~Gingivalitis will be assess pre given toothpaste,aweek,2weeks,and after 3weeks by using gingival index (loe and silness)."
224206038|NCT00351156|PROCEDURE|Blood sample|
224206039|NCT01205542|BEHAVIORAL|Training|Training of scapular function with strengthening exercises using bodyweight and elastic resistance
224206040|NCT01205542|BEHAVIORAL|Reference|Health check and advice to continue ordinary physical activity
224206041|NCT06232538|DIAGNOSTIC_TEST|The level of CNV|The extracted DNA from bile will be analyzed by UCAD to determine the level of CNV. And the patient will be followed more than 1 year.
224206042|NCT00191620|DRUG|Gemcitabine|
224206043|NCT00191620|DRUG|cisplatin|
224206044|NCT06653829|DEVICE|SPARK|A gamified augmented reality activity to recapitulate the beginning activation and engagement phase of each recovery-oriented cognitive therapy (CT-R) session
224206045|NCT04059861|DIAGNOSTIC_TEST|Ultrasound|enrolled patients will be investigated by ultrasound two times, awake in the clinic and in narcosis before the surgery. For those with tongue cancer ultrasound will be used during the surgery to visualise the deep margin of the tumour.
224206046|NCT06607692|DRUG|Olaparib; 177Lu-DOTATATE|7Lu-DOTATATE will be administered intravenously, on day 1, every 8 weeks, at a fixed dose of 200 mCi (7.4 GBq) for children \&gt;= 12 years old infused intravenously over a period of 30 minutes. For children younger than 12 years old, the dose that will be administered is 200 MBq per kilogram of body weight (maximum 7.4 GBq) infused intravenously over a period of 30 minutes. Concomitant to 177Lu-DOTATATE, patients will receive IV fluids and an IV infusion of amino acid solution for renal protection23. Patients will receive four infusions every 8 weeks (maximum cumulative radioactivity, 29.6 GBq \[800 mCi\]). Olaparib will be administered PO, BID, days 2-29, every 8 weeks at a fixed dose of 187.5mg/m2 twice daily (BID).
224206047|NCT01642862|DRUG|Simvastatin|Comparison of pharmacokinetic parameters of different formulations (liquid vs tablet) and doses (20 or 40 mg) of simvastatin after single oral administration of the drug
224314360|NCT02040441|DRUG|Placebo|
224206048|NCT06064110|BEHAVIORAL|Pictou County Person Empowerment Program|The 6 month home-based program focuses on aerobic and strength training, meditation/relaxation techniques, social connection, and overall healthy lifestyle practices supported with daily email reminders. The aerobic (5 times/week) and strength (2 times/week) program will comprise of a single 30-minute session daily, the meditation/relaxation practice is 10 minutes daily, the intimacy and connection component consists of engaging in at least one form of intimacy practice prescribed, per day. Optional social connection components will be offered, such as pairing participants up with peers from the study, monthly Zoom videoconferences, and monthly in-person events in Pictou County to further promote healthy lifestyle habits.
224206049|NCT00633217|DRUG|Fluticasone Propionate/Salmeterol DISKUS 250/50mcg|treatment drug
224206050|NCT00633217|DRUG|Fluticasone Propionate/Salmeterol Hydrofluoroalkane 134a MDI 230/42mcg|treatment drug
224206051|NCT05025891|OTHER|Teleconsultation|Patients are randomized into groups in which there are either teleconsultations alone or with the help of a mediator to carry out their follow-up care
224206052|NCT06012357|DIAGNOSTIC_TEST|Nociception Coma Scale-Revised|Nociception Coma Scale-Revised Recorded after personalized painful stimulus
224206053|NCT01953523|PROCEDURE|Administration of autologous adipose derived SVF|Intra-venous, intra-articular, and soft tissue injection delivery of SVF
224314361|NCT02040441|DRUG|Standard care|Standard diabetes care
224314362|NCT04799938|BEHAVIORAL|Exercise|180 minutes of moderate-intensity exercise per week
223618295|NCT06216938|BIOLOGICAL|Vusolimogene oderparepvec (RP1)|Vusolimogene Oderparepvec is a genetically modified oncolytic viral strain of the herpes simplex type 1 (HSV-1) virus, with potential oncolytic, immunostimulating and antineoplastic activities.
223618296|NCT06692140|DEVICE|Ultra-low strut thickness everolimus-eluting biodegradable polymer Evermine50 stent(s)|Percutaneous coronary intervention with Ultra-low strut thickness everolimus-eluting biodegradable polymer Evermine50 stent(s)
223618297|NCT06692140|DEVICE|PCI with Everolimus-eluting stents (durable polymer everolimus-eluting Xience or Promus stent(s))|Percutaneous coronary intervention with Everolimus-eluting stents (durable polymer everolimus-eluting Xience or Promus stent(s))
223618298|NCT06726564|DRUG|MT027 cells suspension|MT027: CRISPR/Cas9 edited B7H3-specific allogeneic CAR-T cells
223618299|NCT06726967|DIAGNOSTIC_TEST|vitamin D 25(OH)D|Thyroid functions (thyroid-stimulating hormone (TSH), serbest triiodothyronine (fT3), serbest thyroxine (fT4)); Thyroid antibodies (Anti-thyroid peroxidase (anti-TPO), anti-thyroglobulin (anti-TG))
223618300|NCT06725628|DIAGNOSTIC_TEST|Thy_CLNM_multi_omics|Surgery
223618301|NCT06726005|DEVICE|functional appliance twin block|3D facial scans will be taken (prior to the treatment, at rest and at mandible moved forward to class I dental relation (Fraenkel manouver)) and at the end of treatment, one year later.
223618302|NCT06725654|OTHER|Diagnostic Procedures|To evaluation the oral and dental health of orphaned children, DMFT, deft, GI, PI and CPITN indices were used to assess dental caries experience, gingival inflammation, the amount of plaque on the tooth surface and periodontal status, respectively.
223618303|NCT06726317|BEHAVIORAL|Early palliative care integration|The early palliative care intervention package was developed following the guidelines provided by the UK Medical Research Council for the development of complex interventions. The early palliative care intervention for patients with oral cancer had six components: 1) providing information, 2) addressing acute and functional issues, 3) nutritional care, 4) psychological support, 5) mindfulness therapy, and 6) coordination of the financial allowance. The package was formulated by triangulating literature review findings and several independent studies: a case-control study; in-depth interviews with experts in the field of oncology and palliative care in Sri Lanka; key-informant interviews with patients with oral cancer and their caregivers; and an observation study at the National Cancer Institute Sri Lanka- Apeksha Hospital). The intervention package was finalized through a
224206054|NCT05853081|DIAGNOSTIC_TEST|Bioelectrical impedance analysis|The Fat-free mass index (FFMI) will be measured using bioelectrical impedance analysis. Exacerbations and mortality will be recorded during follow-up to evaluate the prognostic value of the FODE scale.
224206055|NCT05190562|DRUG|Zinc Sulfate 110 MG (Zinc 25 MG) Oral Tablet|Zinc sulfate is an inorganic compound. It is used as a dietary supplement to treat zinc deficiency and to prevent the condition in those at high risk
224206056|NCT01827072|DRUG|NPB-01|
224206057|NCT04881448|DIAGNOSTIC_TEST|collection of serum/capillary creatinine values|collection of serum/capillary creatinine values
224206058|NCT05779046|OTHER|HIT 1:1|The participants received a high-intensity interval exercise program of walking or running on a treadmill for approximately 40 minutes. The training included a 10-minute warm-up at low intensity. High-intensity interval exercise at a ratio of 1:1 (high intensity for 1 minute at 85-90% of maximum heart rate, then alternating with low intensity 50-55% of maximum heart rate for 1 minute).
224206059|NCT05779046|OTHER|HIT 1:2|The participants received a high-intensity interval exercise program of walking or running on a treadmill for approximately 40 minutes. The training included a 10-minute warm-up at low intensity. High-intensity interval exercise at a ratio of 1:2 (high intensity for 1 minute at 85-90% of maximum heart rate, then alternate with low intensity 50-55% of maximum heart rate for 2 minutes).
224206060|NCT02861729|OTHER|Vita Suprinity|zirconia reinforced lithium silicate partial coverage restorations
224206061|NCT02861729|OTHER|IPS e.max|lithium disilicate partial coverage restorations
224206062|NCT00807859|DRUG|AMG 386 30 mg/kg, Paclitaxel and Trastuzumab|AMG 386 30 mg/kg IV QW, paclitaxel 80 mg/m2 IV QW, trastuzumab: initial dose 8 mg/kg IV week 1, then 6 mg/kg IV Q3W
224206063|NCT00807859|DRUG|AMG 386 30 mg/kg, Capecitabine and Lapatinib|AMG 386 30 mg/kg IV QW, capecitabine 2000 mg/m2 divided into 2 doses given PO Q12 hrs, days 1-14 every 21 days, lapatinib 1250 mg PO QD
224206064|NCT00807859|DRUG|AMG 386 10 mgkg, Paclitaxel and Trastuzumab|AMG 386 10 mg/kg IV QW, paclitaxel 80 mg/m2 IV QW, trastuzumab: initial dose 8 mg/kg IV week 1, then 6 mg/kg IV Q3W
224206065|NCT00807859|DRUG|AMG 386 10 mg/kg, Capecitabine and Lapatinib|AMG 386 10 mg/kg IV QW, capecitabine 2000 mg/m2 divided into 2 doses given PO Q12 hrs, days 1-14 every 21 days, lapatinib 1250 mg PO QD
224206066|NCT01135147|BEHAVIORAL|Diet|Dietary therapy and physical education
224206067|NCT01135147|PROCEDURE|Surgery|Adenotonsillectomy along with diet and physical therapy
224206068|NCT00967707|DRUG|gabapentin and venlafaxine|"Week 1-6: Gabapentin monotherapy (titration to individual maximum tolerated dose or maximum 800 mg 3 times daily).~Week 7-12: Venlafaxine 75 mg once daily is added."
224206069|NCT00967707|DRUG|gabapentin and donepezil|"Week 1-6: Gabapentin monotherapy (titration to individual maximum tolerated dose or maximum 800 mg 3 times daily).~Week 7-12: Donepezil 5 mg once daily is added."
224206070|NCT04252040|DEVICE|Active tDCS with guided imagery|The subject will be positioned in the sitting/reclining position in a quiet room with lights dimmed. The tDCS device and audio headphones will be placed on the subject's head. The tDCS device to be used is the Soterix Medical 1X1 device using 2.0 mA of current. The electrodes that will be used will be standard sponge electrodes. The subject will listen to a scripted guided imagery CD specifically developed for women with chronic pelvic pain through the audio headphones. The guided imagery plus active tDCS arm will have 20 minutes of stimulation with 25 minutes of guided imagery.
224206071|NCT01916759|DRUG|Seasonal trivalent inactivated influenza vaccine (Vaxigrip®)|Administer seasonal trivalent inactivated influenza vaccine (Vaxigrip®) and collect blood specimens at 0, 1, 3, 7, 14, 28 and 100 days following vaccination.
224206072|NCT00058045|BIOLOGICAL|aldesleukin|
224206073|NCT00058045|BIOLOGICAL|recombinant human stem cell factor|
224260334|NCT03972683|DRUG|Adenosine Triphosphate|Vasodilatory sensitivity to adenosine triphosphate will be assessed during infusion of a dose of 10 μg/dl forearm volume/min administered via a brachial artery catheter over a total of 4 min.
224314363|NCT01016470|DIETARY_SUPPLEMENT|VIUSID/ALZER|VIUSID/ALZER, 3 per day, oral, one year
224314364|NCT01016470|DIETARY_SUPPLEMENT|Placebo|Placebo Viusid and Placebo Alzer, 3 per day, oral, one year
224314365|NCT06091670|OTHER|No intervention|There is no intervention. The research is cross-sectional-descriptive type.
224314366|NCT04380597|DRUG|Calcipotriene and betamethasone dipropionate aerosol foam|Prescribed according to clinical practice and following Product Data Sheet instructions
224314367|NCT02506283|DEVICE|Zamar Therapy CT clinic|Zamar Therapy is a certified medical product (directive 93/42/EEC and ISO 134 85:2012) (www.zamarmedical.com)
223618304|NCT06725381|DRUG|SKB571|SKB571 for injection is administered every 3 weeks (q3w) until radiographic disease progression (PD), intolerable toxicity, death, or discontinuation of treatment, whichever occurs first.
224314368|NCT02723747|OTHER|myocardial perfusion with magnetic resonance imaging|
224314369|NCT01807247|PROCEDURE|Intensive lower limbs muscles strengthening|
224314370|NCT06050304|BEHAVIORAL|Observation of behavior and search of biomarkers with 3 blood tests.3 weeks wearing an actimeter|In the form of a small watch, which collects the level of motor activity throughout the day and night. Patients will be asked to indicate each moment of crack-cocaine use by pressing the button in the center of the watch. We want to know if certain uses lead to more behavioral problems (especially after periods of cessation).
224314371|NCT06050304|BIOLOGICAL|3 blood tests|We will try to identify biomarkers of BS: blood proteins, genetic markers passed on by your parents, or the expression of proteins in particular situations
224314372|NCT05742035|PROCEDURE|Venipuncture|Bloodletting of 450 mL, followed by separation of the whole blood in 2 blood components: 1 red blood cell concentrate and 1 plasma. Measurement of the outcomes in the red blood cell concentrate.
224314373|NCT04837924|PROCEDURE|fascia iliaca compartment block, (FICB) (levobupivacaine hydrochloride 0,25% 40 ml)|Land mark technique will be used to perform FICB on the side of the hip fracture. The injection site is one centimetre caudal from the junction between medial 2/3 and lateral 1/3 in the imaginary line between anterior superior iliac spine and ipsilateral pubic tubercle. The goal is to administer local anesthetic in the fascia iliaca compartment.
224314374|NCT04837924|DRUG|paracetamol 1 gram IV|paracetamol 1 gram IV every six hours, 4 times in 24 hours
224314375|NCT04837924|DRUG|Rescue analgesic tramadol 100 mg IV if needed|Rescue analgesic, if needed, tramadol 100 mg in 100 ml saline (0,9% Sodium chloride) IV, up to 4 times in 24 hours
224314376|NCT04837924|PROCEDURE|Sham injection|Sting with blunt needle, (without piercing the skin), same site as fascia iliaca compartment block
224314377|NCT05616637|DIAGNOSTIC_TEST|Navicular Drop Test|While participants in sitting position, the navicular tuberosity (NT) will be palpated.The most distal protruding portion of the medial NT will be marked. Participants will be asked to stand with equal weight on both feet. The new distance will be measured. The navicular drop test (NDT) results will then be obtained by comparing the measured values between the sitting and standing positions. Each measurement will be repeated three times and the average of the 3 measurements will be calculated. The expression in mm of the distance between the two marks will be considered the amount of ND. The amount of navicular fall of 10 mm or more will be interpreted as pes planus. Measurements will be made on both extremities. As a result of the measurements, if pes planus is present in a single extremity, that extremity, if it is present in both extremities, the extremity with higher NDT or if it is equal on both sides, the dominant extremity will be tested.
224314378|NCT05616637|OTHER|Lower Extremity Length Measurement|Lower extremity length will be recorded to normalize dynamic balance test data. The person will lie in the supine position. The distance between the umbilicus and the anterior superior of the spina iliaca will be measured in cm with the help of a tape measure. If there is no asymmetry, it will be assumed that there is no rotation in the pelvis, and it will be started to measure the length of the lower extremity. If pelvic asymmetry is detected, the pelvic position will be corrected manually. Then, the most inferior point of the spina iliaca anterior superior and the most distal point of the medial malleolus will be marked and measured and recorded. Lower extremity length and data in 3 different directions will be used in cm. The purpose of using formulas is to easily provide comparisons with other studies using the same type of data. The data obtained from the formula is expressed as a percentage of the length of the limb.
223618305|NCT06705543|GENETIC|multi-omics genetic analyses included exome|"Genetic analysis will be carried out on amniotic fluid from the volume collected as part of the by obstetricians working in the fetal medicine unit. These genetic analyses will include :~* Study of free RNA circulating in the LA,~* Methylome study.~* Trio exome study (parents-fetus)."
223618306|NCT06705543|GENETIC|multi-omics genetic analyses|"Genetic analysis will be carried out on amniotic fluid from the volume collected as part of the by obstetricians working in the fetal medicine unit; These genetic analyses will include :~* Study of free RNA circulating in the LA,~* Methylome study."
223618307|NCT06727175|BEHAVIORAL|non-invasive neuromodulation therapy|Patients with subjective tinnitus were treated using non-invasive neuroregulation therapy. That is, to generate personalized, non-invasive acoustically stimulated neuroregulation regimens for six montns. Each participant was treated three times a day (morning, noon and bedtime) for 30 minutes each time.
224323203|NCT03458676|PROCEDURE|Standard of Care Brain Biopsy and Tumor Removal|"During the surgery, the neurosurgeon(s) uses the information collected from the AMRI to decide what area of the brain tumor will be biopsied.~Biopsies from up to 5 locations taken before the tumor is surgically removed."
223618308|NCT06727175|OTHER|before any intervention|before any intervention
223618309|NCT06718543|DRUG|AK112 with SCRT and CapeOX|In the 1st week, neoadjuvant short-course radiotherapy will be administered (25 Gy in 5 fractions over 5 days). After a 7day interval, patients will receive 2 cycles of CapeOX chemotherapy combined with AK112 (every 3 weeks; Day 1: Oxaliplatin, 130 mg/m², IV infusion; Day 1: AK112, 20 mg/kg, IV infusion; Day 1 to Day 14: Capecitabine, 850-1000 mg/m², BID, orally).
223618310|NCT06718543|DRUG|AK112 with SCRT|In the 1st week, neoadjuvant short-course radiotherapy will be administered (25 Gy in 5 fractions over 5 days). After a 7-day interval, patients will receive 2 cycles of AK112 treatment (Day 1: AK112, 20 mg/kg, IV infusion).
223618311|NCT00004164|BIOLOGICAL|filgrastim|
223618312|NCT00004164|DRUG|cisplatin|
223618313|NCT00004164|DRUG|docetaxel|
223618314|NCT00004164|DRUG|fluorouracil|
223618315|NCT00004164|DRUG|leucovorin calcium|
223618316|NCT00004164|RADIATION|radiation therapy|
224206074|NCT04293601|OTHER|interventional nursing care|"The infants enrolled will receive different intervention according to a defined risk factor level:~Low:~* NCPAP duration \< 48 hours (h)~* Gestational Age (GA) \> 32 weeks (wks)~* Current weight \> 1500 g~Interventions:~* alternating mask or nasal prongs once per shift~* skin assessment (excoriation, erythema or skin breakdown) once per shift~Medium:~* NCPAP duration from 48 to 72 h~* GA from 32 to 28 wks~* Current weight from 1500 to 1000 g~Interventions:~* alternating mask or nasal prongs twice per shift~* skin assessment (excoriation, erythema or skin breakdown) twice per shift~* repositioning of device once per shift~High:~* NCPAP duration \> 72 h~* GA \< 28 wks~* Current weight \< 1000 g~Interventions:~* alternating mask or nasal prongs twice per shift~* skin assessment (excoriation, erythema or skin breakdown) every 3 h per shift~* repositioning of device every 3 h per shift"
223618317|NCT05657990|DRUG|Tamsulosin|Tamsulosin 0.4 mg one time daily after a meal for seven days prior to surgery. Post-surgery, an ultrasound of the bladder will be completed approximately six hours after surgery to assess the bladder. If the bladder ultrasound shows more than 400 cc of urine in the bladder, or if the study subject passes urine on his own and there is more than 100cc or less than 400 cc of urine left in the bladder, he will be encouraged to try to pass urine. Study subject will be monitored for two additional hours. If a study subject is unable to pass urine at this time or the bladder has 400 cc or more of urine left in it, he will have an intermittent catheter (in and out) to drain urine. If the bladder has greater than 500 cc (which is approximately 16 and two-thirds ounces) per catheterization for more than 24 hours, and the study subject cannot pass urine, an indwelling catheter may be considered.
223618318|NCT00434187|DRUG|ERB-041|
223618319|NCT06920849|BIOLOGICAL|SRP+iPRF|SRP (scaling and root planing) with iPRF (injectable platelet-rich fibrin)
223618320|NCT06920849|PROCEDURE|SRP|SRP (scaling and root planing)
223618321|NCT06922773|DIAGNOSTIC_TEST|Completion of questionnaires; child psychiatric screening; faecal sample analysis|"Completion of questionnaires:~* FFQ (Food Frequency Questionnaire) - completed by child~* KIDSCREEN-10 - completed by child~* CRIES-13 (Child Revised Impact of Events Scale) - completed by parents/guardian and child~* CTES (Childhood Trust Events Survey) - completed by parents/guardian~* RCADS-25 (Revised Children's Anxiety and Depression Scale) - completed by parents/guardian and child~Child psychiatric screening using SCID-5-Junior - semi-structured interview conducted with child and parent(s)/guardian~Faecal sample analysis:~* Beta-diversity (UniFrac and Bray-Curtis distance index)~* Firmicutes/Bacteroidetes ratio~* Abundance of Prevotella, Lactobacillaceae, Bifidobacteriacae and Lachnospiraceae~* Short-chain fatty acid metabolites"
223680752|NCT01490723|DRUG|G-CSF|5 mcg/kg/day subcutaneously beginning Day +7 for patients receiving related and matched unrelated donor (MUD) grafts and on Day 0 for patients receiving a cord blood (CB). G-CSF will continue until the absolute neutrophil count (ANC) is \> 500 \* 10/L for 3 consecutive days.
223680753|NCT01490723|PROCEDURE|Stem Cell Transplantation|Stem Cell Transplantation on Day 0
224206075|NCT04293601|OTHER|Standard nursing care|"* Use of hydrocolloid as nasal barrier dressing~* Appropriate size of headbands, indicated by production company~* Appropriate size of mask or binasal prongs, indicated by production company~* Frequently assess skin integrity, every 4 hours~* Replace hydrocolloid if it's dirty or displaced~* Humidity and heat gases"
224206076|NCT03441373|DRUG|XC8 20 mg|once daily during 5 days.
224206077|NCT03441373|DRUG|XC8 100 mg|once daily during 5 days.
224206078|NCT03441373|DRUG|XC8 200 mg|once daily during 5 days.
224206079|NCT03441373|DRUG|Placebo|once daily during 5 days.
224206080|NCT00213629|OTHER|transcriptome analysis|transcriptome analysis from muscle biopsy
224206081|NCT00213629|OTHER|T cell repertoire analysis|blood T cell repertoire analysis
224206082|NCT00788008|DRUG|inhalation anesthesia with isoflurane vs. TIVA with propofol|variable depending upon patient
224206083|NCT06538714|OTHER|MIIT|"12-week supervised exercise program consisting of moderate-intensity interval training (MIIT)~MIIT: 3 series of 4-8 repetitions of 30-s of work at 70-75% of MAS and 30-s of active recovery at 50% of MAS.~3 exercise sessions per week.~Additionally, participants receive no individualized nutritional counseling."
224206084|NCT06538714|OTHER|MIIT + HIIT|"12-week supervised exercise program consisting of moderate-intensity interval training (MIIT) (6-week) and high-intensity interval training (HIIT) (6-week).~MIIT: 3 series of 4-8 repetitions of 30-s of work at 70-75% of MAS and 30-s of active recovery at 50% of MAS.~HIIT: 3 series of 5 repetitions of 30-s of work at 100% of MAS and 30-s of active recovery at 50% of MAS for weeks 7-9, as well as two series of 10 repetitions of 30-s of work at 100% of MAS and 30-s of active recovery at 50% of MAS for weeks 10-12.~3 exercise sessions per week. Additionally, participants receive no individualized nutritional counseling."
224206085|NCT06538714|OTHER|Control group|"Habitual physical activity No additional physical intervention~Additionally, participants receive no individualized nutritional counseling."
224206086|NCT06056323|DRUG|HB0045 Drug Product|Patients will be assigned to dose regimens in the order of enrollment and receive their assigned fixed dose of HB0045 via intravenous infusion, Q3W.
224206087|NCT02175472|DEVICE|Spectramax light therapy device|Spectramax light therapy device emits a specific combination of bandwidths and intensities of light.
224206088|NCT02175472|DEVICE|Control light device|The control light device is identical in appearance to the Spectramax light therapy device, except that when turned on, emits a different combination of bandwidths and intensity, not believed to produce a therapeutic response.
224206089|NCT01038531|OTHER|low-tidal-volume ventilation|goal tidal volume of 6 cc/kg ideal body weight
224206090|NCT01038531|OTHER|APRV|APRV is a time cycled, inverse-ratio, pressure controlled strategy that allows spontaneous breathing through the respiratory cycle.
224206091|NCT05207176|DRUG|DWP16001|Subjects should fast except for drinking water after 10 p.m. in order to maintain a fasting state for at least 10 hours before administration. On dosing days (5d to 10d), except for 1d and 11d, breakfast can be consumed from about 1 hour after administration of the clinical trial drug. Subjects should swallow the investigational drug whole with 150 mL of water, and should not chew the drug before swallowing. Subjects should fast for 4 hours after dosing, and can drink water freely from 2 hours after dosing.
224206092|NCT00005879|DRUG|arzoxifene|one tablet daily
224206093|NCT00005879|DRUG|Placebo|matched tablet dialy
224206094|NCT00363935|DRUG|Dexmedetomidine|
224206095|NCT02352207|OTHER|identification of a pulmonary malformation in the fetus|
223618322|NCT06920732|PROCEDURE|VLNT（Vascularized Lymph Node Transfer）|VLNT is a physiologic surgical procedure in which vascularized lymph nodes are harvested from a donor site (e.g., groin or submental region) and transplanted to the affected limb to restore lymphatic drainage. The transferred lymph nodes are anastomosed to recipient vessels to ensure perfusion, aiming to reconstruct lymphatic flow and reduce lymphedema-related swelling and fibrosis.
223618323|NCT06920732|PROCEDURE|LVA（Lymphaticovenular Anastomosis）|LVA is a supermicrosurgical technique designed to improve lymphatic drainage by creating anastomoses between functional lymphatic vessels and nearby venules. Under high magnification, lymphatic vessels (typically \<0.8 mm) are identified and connected to subdermal venules to bypass obstructed lymphatic pathways, facilitating improved lymph flow and symptom relief in patients with early-stage lymphedema.
223618324|NCT06920732|PROCEDURE|LS（Liposuction）|LS is a volume-reduction procedure used in the management of advanced lymphedema characterized by fibroadipose tissue hypertrophy. Tumescent liposuction is performed to remove excess subcutaneous adipose tissue, thereby reducing limb volume and improving limb contour. This procedure is often combined with physiologic surgical techniques for optimal long-term outcomes.
223618325|NCT06937216|DEVICE|Volara therapy|Oscillation and Lung Expansion (OLE) therapy, is a respiratory airway clearance intervention including continuous high-frequency oscillation and continuous positive expiratory pressure
224206096|NCT00689273|DRUG|PF-04136309|125 mg capsules. Dose will be 4 capsules BID for 2 weeks for a total of 500 mg for each dosing interval.
224206097|NCT00689273|DRUG|Placebo|Placebo will be matched to PF-04136309. Dose, frequency, and duration same as PF-04136309.
224206098|NCT06430307|DRUG|Saussurea Involucrata Liquid Tonic|This product is a single preparation of Saussurea Involucrata Liquid Tonic. It is used for rheumatoid arthritis, rheumatoid arthritis and dysmenorrhea caused by insufficient kidney yang and cold-damp stasis.
224206099|NCT03138135|BEHAVIORAL|HOME Study intervention|Access to home HIV test kits, home STI self-collection kits, the HOME Study website, and the SexPro HIV risk assessment tool.
224206100|NCT03138135|BEHAVIORAL|Control|Counseling about the importance of quarterly HIV/STI testing and a PrEP information pamphlet.
224206101|NCT04794725|PROCEDURE|Blood sampling|blood samples from venepuncture (10mL)
224206102|NCT06259760|DRUG|Nitroglycerin|during surgery, the patient received nitroglycerin infusion or nitroglycerin with labetalol to decrease blood pressure and to decrease blood loss. During the procedures and management, patients were executed of continuously monitoring of arterial blood pressure, hemodynamic changes such as cardiac output, stroke volume variation, peripheral oxygen saturation, and cerebral oximeter.
224206103|NCT02790619|DEVICE|tDCS via Chattanooga Ionto Iontophoresis System-Phoresor|Small electrical current delivered non-invasively to the scalp. 1mA electrical current to Meditation and Active Stimulation 1 condition. 2mA to Meditation and Active 2 Stimulation condition.
224206104|NCT02790619|DEVICE|Sham tDCS Chattanooga Ionto Iontophoresis System-Phoresor|Blinds participants to meditation condition by applying 30 seconds of real stimulation and then turning the device off.
224206105|NCT02953873|DRUG|Tacrolimus Extended Release Capsule|goal trough 5 - 12ng/mL
224206106|NCT02953873|DRUG|Mycophenolate mofetil|≥500mg twice a day
224206107|NCT02953873|DRUG|Prednisone|goal dose 5mg daily
224206108|NCT02953873|DRUG|Mycophenolate Sodium|≥360mg twice a day
224206109|NCT00306800|PROCEDURE|Photodynamic therapy with methyl aminolevulinate cream|
224206110|NCT03676673|OTHER|Psychiatric diagnosis|Kiddie Schedule for Affective Disorders \& Schizophrenia (K-SADS) for DSM-5
224206111|NCT01238172|OTHER|dietary education and counseling|
224206112|NCT01238172|OTHER|prostate cancer foundation booklet|
224206113|NCT05354999|DIETARY_SUPPLEMENT|Sodium bicarbonate and caffeine|On experimental days subjects ingest a combination of sodium bicarbonate, caffeine and placebo.
224206114|NCT04498260|DRUG|Local steroid - triamcinolone acetonide|(triamcinolone acetonide)
224206115|NCT04498260|DRUG|Oral steroid - predonisolone|(predonisolone)
224206116|NCT03635970|PROCEDURE|celular therapy|application of cell therapy with a concentrate of hematopoietic progenitor cells or celular therapy
224206117|NCT04655339|DRUG|Bilateral abdominal Lap-TAP|A total of 30ml of anesthetic (0.25% Bupivacaine HCL), 0.25% Liposomal Bupivacaine (Exparel®) or control will be injected into the transversus abdominis plane bilaterally. A long spinal needle attached to a 30cc syringe with the TAP block solution or control will be used to inject the patient. The needle puncture will be halfway between the subcostal margin and anterior superior iliac spine at the midclavicular line. With laparoscopic guidance, needle will enter through the skin, external oblique and internal oblique. Once the needle is in place, injection of 30 ml on each side will be applied between the internal oblique and transversus abdominis muscle. The injection of bupivacaine into this abdominal wall induces an observable bulge, indicating accuracy of the procedure. These steps will be repeated on the contralateral side of the abdomen. All patients will receive 10 ml bupivacaine 0.25% pre-incision infiltration.
224206118|NCT03980561|DRUG|Varenicline|Active medication
224206119|NCT03980561|DRUG|Placebo|Inactive medication
224206120|NCT06542809|OTHER|Questionnaire|Recruitment will take place through routine paediatric endocrinology consultations with physicians registered with BELSPEED. These doctors will take the time to explain the questionnaire. And allow the patient to complete it.
224206121|NCT00230217|DRUG|Rasburicase (SR29142)|
224206122|NCT05022121|BEHAVIORAL|Supported Biopsychosocial Self-Management (SBSM)|Participants receive training and instruction in skills to engage in healthy physical, psychological, and social self-management behaviors. This will be accomplished through 6-12 sessions with a trained chiropractor or physical therapist. Patients will receive training and instruction in exercises targeting posture, strength, stabilization, and mobility based on their individual needs. They will learn psychological strategies including problem solving and cognitive restructuring to address unhelpful thoughts and emotions. Social strategies include pleasant activity planning with a social focus, and communication techniques for navigating relationships to garner support for self-sufficiency. Other elements include providing key evidence based information about BRLP and spinal manipulation therapies (SMT). SMT will include manipulation, mobilization and soft-tissue treatment. Other intervention elements include enablement, persuasion, and resources and materials to support the patient.
223618326|NCT06937684|BEHAVIORAL|Early Oral Fluid Intake|Participants receive clear fluids up to 10 ml/kg at 1 hour after anesthesia.
223618327|NCT06937684|BEHAVIORAL|Traditional Oral Fluid Intake|Participants receive clear fluids up to 10 ml/kg at 2 hours after anesthesia.
223618328|NCT03842670|BEHAVIORAL|Cognitive Behavior Therapy|The CBT condition will include 8 weekly, 60-minute sessions, and will be delivered according to the Epstein \& McCrady (2009) cognitive-behavioral treatment manual, excluding material provided in the platform treatment. The treatment manual and accompanying client workbook provide detailed therapist instructions for each session, client exercises, worksheets, and homework assignments. The treatment focuses on cognitive and behavioral coping skills training, and emphasizes problem-solving as an overall approach to dealing with drinking. Treatment sessions may be audio-recorded for supervision and to ensure that the treatment is being delivered as intended.
223618329|NCT03842670|BEHAVIORAL|Mindfulness Based Relapse Prevention|The MBT condition will be adapted from the 8-week version of the mindfulness-based relapse prevention (MBRP) manual (Bowen et al., 2011; Witkiewitz et al., 2005). The main adaptation will be to eliminate the relapse prevention/CBT components and focus attention on mindfulness practices. The mindfulness practices in MBT are designed to increase awareness of triggers and decrease reactivity to distress or discomfort in the presence of triggers (Witkiewitz \& Bowen, 2010). The relevant worksheets and homework assignments focusing on mindfulness tools will be maintained from the MBRP manual. Treatment sessions may be audio-recorded for supervision and to ensure that the treatment is being delivered as intended.
224206123|NCT05022121|DRUG|Medical Care|Medical care will be comprised of primarily medication management, which is a standard first-line approach for back-related leg pain in primary care. Choice of medications is informed by the current evidence and the American College of Physicians guidelines on noninvasive treatment for LBP which balances evidence for risks and benefits when making recommendations. Decisions regarding medication selection will be made collaboratively between the study provider and patient after a discussion of risk/benefit profiles and patient preferences, including prior response. Study providers licensed to prescribe FDA-approved medications will call-in the prescription for the medication of choice to the participant's preferred pharmacy, as is typical in clinical practice.
224206124|NCT03965507|OTHER|Evaluation of the prevalence of sacroiliac joint dysfunction in lumbar disc herniation|
224206125|NCT05832242|OTHER|Ultrasound|Point-of-care ultrasound in the emergency department
224206126|NCT06395584|DEVICE|White Light LED|Participants will be exposed to white LED lights (4 lux) in a dark room for 1-2 hours per day for 10 weeks.
224206127|NCT06395584|DEVICE|Green Light LED|Participants will be exposed to green LED lights (4 lux) in a dark room for 1-2 hours per day for 10 weeks.
224206128|NCT03934242|OTHER|Questionnaire on new born's bedding|Questionnaire on new born's bedding (Child's position in the bed : dorsal, ventral or lateral, presence of pillow or stuffed in bed, presence of coverage and presence of the bed sharing) at two times (during hospitalisation and one month later)
224206129|NCT02639195|OTHER|Treatment|Retrospective chart review of patients treated with manual therapy.
224206130|NCT06360679|DEVICE|Endoscopic gastric restriction and biliodigestive diversion|The BariTon™ is endoscopically implanted and retrieved once treatment is completed
224206131|NCT05406596|DEVICE|LiquID GCE Use|Use of the LiquID GCE to aid in percutaneous coronary intervention (PCI)
224206132|NCT03896802|PROCEDURE|Physiological assesment|"1. Arterial and mixed venous blood gas analysis.~2. Alveolar and physiologic dead space via volumetric capnometry, as well as carbon dioxide (CO2) production, end-tidal CO2 and mixed expired CO2~3. Respiratory system (Crs), chest wall (Ccw) and lung (Cl) compliance measurement via an end-inspiratory and end-expiratory pause.~4. Arterial blood pressure, central venous pressure (CVP), heart rate, cardiac output through the arterial pulse contour and transpulmonary thermodilution methods (PiCCO technology). Global end-diastolic volume, Intra-thoracic blood volume, Extravascular lung water will also be assessed. Respiratory hold maneuvers (at PEEP, and +10, +15 and +20 cmH2O) will be performed and CVP and cardiac output will be measured in the last 3 s of the 12 s inspiratory hold. Venous return curve will constructed and the zero-flow pressure recorded as the mean systemic filling pressure.~5. Urine flow in 1h and determination of the fractional excretion of sodium and creatinine."
224206133|NCT03162120|DRUG|Ranolazine plus Metoprolol Combination|Ranolazine plus Metoprolol Combination in ATrial Fibrillation Recurrences FOllowing PhaRmacological or Electrical CardioverSion of AtRial Fibrillation
224206134|NCT03162120|DRUG|FlecainidE pluS Metoprolol Combination|FlecainidE pluS Metoprolol Combination in ATrial Fibrillation Recurrences FOllowing PhaRmacological or Electrical CardioverSion of AtRial Fibrillation
224206135|NCT02531698|BIOLOGICAL|Bivalent rLP2086 Vaccine|1 dose of 120 μg of bivalent rLP2086 by intramuscular injection at Months 0, 2, and 6 into the upper deltoid muscle of the arm.
224206136|NCT02531698|BIOLOGICAL|Licensed pediatric hepatits A vaccine|1 0.5 mL dose by intramuscular injection at Months 0 and 6 into the upper deltoid muscle of the arm.
224206137|NCT02531698|OTHER|Normal Saline|Sterile saline solution for injection (0.85% sodium chloride) in a 0.5 mL dose at Month 2.
224206138|NCT03979586|OTHER|Laser-assisted hyaluronic acid delivery|The facial skin remodeling corresponds to a request for repair treatment on the stigmas of heliodermia, irregularity of cutaneous texture, dyschromias, loss of radiance of the complexion, fine lines, as well as on the fine scars of the face for example, the finely depressed cicatrices sequellaires acne.
224206139|NCT05549986|OTHER|Observational|Observational
224206140|NCT02085798|OTHER|Either Wait and See, or Supportive Treatment, or Active Treatment at physician discretion|As described above
224206141|NCT01988194|PROCEDURE|Acupuncture|Acupuncture treatments will be provided in patient rooms up to four days per week for the duration of their hospital stay. Treatments will be consistent with how acupuncture is typically practiced: acupuncturists will diagnosis patients according to principles of traditional Chinese medicine (TCM); and treatments will be individualized to the patients. Duration of assessment, needle placement and retention will be 20-30 minutes.
224260335|NCT03972683|DRUG|Atropine|Atropine will be used to inhibit muscarinic acetylcholine receptors in order to determine the contribution of acetylcholine to vasodilation during exercise. An initial dose of 0.2 mg will be infused via a brachial artery catheter over 3 min, then a maintenance dose of 0.067 mg will be infused over 1 min prior to each of 5 subsequent experimental trials.
224206142|NCT04591327|PROCEDURE|The Effect of General Anesthesia and Spinal Anesthesia on Postoperative Atelectasis by Lung Ultrasonography in Cesarean Sections|Preoperative lung ultrasound will be performed on all patients and baseline values will be recorded. The sensory block level under T10 of the patients who underwent spinal anesthesia in the postoperative period lung ultrasonography will be done after regression. In the postoperative period, lung ultrasonography will be performed in patients undergoing spinal anesthesia when the sensory block level is below T10. In the general anesthesia group, when the neuromuscular block is completely reversed and the Aldrete score is\> 9, lung ultrasonography will be performed. The degree of atelectasis will be determined according to the modified LUS score.
224206143|NCT00228878|PROCEDURE|Effects of Pulsatile IV insulin on Diabetic Quality of Life|Patients receive weekly treatments of Pulsatile Intravenous insulin therapy. The patient's Endocrinologist determines the insulin dosage each week based upon the patient's response to treatment and their insulin resistance.
224206144|NCT02334839|OTHER|Observational only|Endothelial function will be assessed using ENDO-PAT (Itamar medical LTD, Caesarea, Israel) device, which evaluates the change in peripheral vascular tone in reaction to temporal ischemia in a process called Reactive Hyperemia (RH) .The RH-PAT is a blood pressure measurement-like cuff which is placed on the non-dominant arm. A pneumatic probe is placed on the index finger bilaterally (one serves as a control). After a baseline assessment for a 5 minutes period, the cuff is inflated to a 60mm Hg pressure above the systolic pressure in order to occlude the arterial flow distal to the brachial artery. After 5 minutes of occlusion, a prompt deflation of the cuff results in a RH response and vasodilatation in the distal arteries including those monitored in the index finger. The sensor translates the change in vascular tone and the ENDO-PAT V3.0.4 device analyzes the data automatically. The results are given in a RH index scale that reflects the level of reactive hyperemia.
224206145|NCT02616341|BEHAVIORAL|Team ERP (T-ERP) Intervention|
224206146|NCT02616341|BEHAVIORAL|Treatment as Usual (TAU)|
224206147|NCT05193578|DRUG|Semaglutide, 1.34 mg/mL|Semaglutide, 1.34 mg/mL
224206148|NCT05193578|OTHER|Placebo|Semaglutide-Placebo
224206149|NCT02651974|BEHAVIORAL|Control condition|Patients will be mailed a control invitation letter to complete a home fecal immunochemical test (FIT) for colorectal cancer screening.
224206150|NCT02651974|BEHAVIORAL|Cost condition|Patients will be mailed a cost condition invitation letter to complete a home fecal immunochemical test (FIT) for colorectal cancer screening.
224206151|NCT02651974|BEHAVIORAL|Cost/Future condition|Patients will be mailed a cost/future condition invitation letter to complete a home fecal immunochemical test (FIT) for colorectal cancer screening.
224206152|NCT01699100|OTHER|device|Experimental: insole In-shoe plantar pressure measurements were performed in 26 patients with diabetic neuropathic feet at baseline condition, and 52 regions of interest (ROIs, with mean peak pressure \> 200kPa or with the highest mean peak pressure in the forefoot area) were identified as suitable areas for removal of pegs. Data of in-shoe plantar pressures of the three insole conditions (pre-peg removal, post-peg removal, and post-peg removal plus arch support) were collected. Mean peak pressure (MPP) and pressure-time integral (PTI) were recorded for analysis.
224206153|NCT04491773|DRUG|Tadalafil 20 MG|To study retinal and choriocapillary features in patients undergoing Tadalafil 20 mg orally, on alternate days, for more than 6 months.
224206154|NCT03441620|DIETARY_SUPPLEMENT|strawberries|Freeze-dried strawberry powder
224206155|NCT03441620|OTHER|Control powder|Control powder matched for fiber and strawberries
224206156|NCT03611920|PROCEDURE|Tetracycline|Teeth were soaked in topical tetracycline 5% for 5 minutes before replantation
224206157|NCT03611920|PROCEDURE|Dexamethasone|Teeth were soaked in topical dexamethasone (60μ ml-1) for 20 minutes before replantation
224206158|NCT02328170|OTHER|EUROIMMUN Allergy|Immunoblot assay
224206159|NCT02328170|OTHER|ImmunoCap|Fluoroallergosorbent test
224206160|NCT00106613|DRUG|FK228 (romidepsin)|Patients receive 13 mg/m2 of romidepsin (FK228) intravenously over 4 hours on Days 1, 8, and 15 of each 28-day cycle.
224206161|NCT02049931|DEVICE|No brace treatment|Patients in the no brace group were allowed to ambulate without any braces as long as it would be tolerable.
224206162|NCT02049931|DEVICE|Rigid brace|In rigid brace group, brace is required to be worn at all times except when lying. All patients were instructed to wear the rigid brace for a total of 8 weeks.
224206163|NCT02049931|DEVICE|Soft brace|In soft brace group, brace is required to be worn at all times except when lying. All patients were instructed to wear the soft brace for a total of 8 weeks.
223618330|NCT00765804|DRUG|EGP-437 with EyeGate® II System|Transscleral iontophoretic delivery of EGP-437 (dexamethasone phosphate ophthalmic solution 40 mg/mL) delivered via EyeGate® II Drug Delivery System
223618331|NCT00765804|DRUG|Sodium citrate buffer solution with EyeGate® II System|Transscleral iontophoretic delivery of sodium citrate buffer solution 100 mM delivered via EyeGate® II Drug Delivery System
224206164|NCT03198819|DRUG|Local Rifampisin and İnrtravenous cefotaxime|
224206165|NCT00230113|DIETARY_SUPPLEMENT|Omega-3 fatty acid diet supplementation|4 gm fish oil per day
224206166|NCT00230113|DIETARY_SUPPLEMENT|safflower oil|4 gm per day safflower oil
224206167|NCT02041000|OTHER|Adipose Derived Stem Cells|
224206168|NCT05268965|BEHAVIORAL|Experimental: group comparison|"* Standardized psychiatric interview (Mini International Neuropsychiatric Interview MINI)~* State-Trait-Anxiety Inventory (Spielberger, 1993)~* Beck Depression Inventory (BDI-II, 1998)~* Cognitive Emotional Regulation Questionnaire (Jermann \& al., 2006) Participant installation and testing: 2 stages (forecasting on a computer, and exposure in virtual reality)~Task / affective forecasting:~* Step 1: forecasting about one's own emotional responses regarding pleasant, neutral and unpleasant scenarios~* Step 2: experience of the same scenarios in virtual reality"
223618332|NCT02001935|DRUG|theophylline|After oral theophylline 200mg per day for two weeks,bood sample will be collected for determining plasma concentrations of theophylline and it's metabolites and the genotypes of CYP1A2 and CYP2E1
223618333|NCT02145117|BEHAVIORAL|MBSR|Behavioral
223618334|NCT00001146|DRUG|Ethyl Eicosapentaenoic Acid|
223618335|NCT00001146|DRUG|OmegaBrite|
223618336|NCT01663012|DRUG|Etirinotecan pegol|
223618337|NCT05030168|DRUG|Ketosteril|ketoanalogues of essential amino acid
223618338|NCT01202630|DIETARY_SUPPLEMENT|Lactobacillus acidophilus CL1285® and Lactobacillus casei|2 capsules of Lactobacillus acidophilus CL1285® and Lactobacillus casei (50 billion cfu/capsule), consumed once daily for 60 days
224314379|NCT05616637|OTHER|Y Balance Test|While the individual tries to balance on one bare foot at the midpoint of the assembly, the individual will also be asked to reach as far as possible with the other foot in the anterior, posteromedial and posterolateral directions, touch the tip of the toe, and then immediately return to the starting position without disturbing the balance. The test will be evaluated for 3 repetitions. Situations where the participant will be requested to repeat the test: the foot on the ground passes the reference point or the heel lifts off the ground, perturbations caused by the environment, contact of the foot with the ground, and loss of balance when returning to the starting position. 10 seconds between 3 repetitions during testing will be given. Each participant will be given the right to try 6 times before starting the test in order to eliminate the possible learning parameter. The test will be repeated 3 times in each direction and the closest distance in cm will be recorded.
224206169|NCT02805673|PROCEDURE|Osteopathy|
224314380|NCT04718948|DEVICE|Urinary Multimodal Fiber Optic Spectroscopy|"Approach based on a physical principle, mainly spectroscopy, which is rapid non-invasive and does not require the use of additional substances or contrast media in the diagnosis of urothelial neoplasms in urine samples.~It will be administered through a appositely designed device"
224314381|NCT04718948|DIAGNOSTIC_TEST|Urine Cytology|An expert cytopathologist will analyze urine samples to detect urinary tract cancer cells. It is the current golden standard to detect urothelial cancer in urine
224206170|NCT00901420|PROCEDURE|Urodynamics Test|90 Minute videotaped bladder function procedure involving pressure-monitoring catheters in bladder and rectum.
224314382|NCT04718948|PROCEDURE|Surgery|It will provide a reliable information on the presence/absence of cancer in the urinary tract (from direct visualization to pathological analysis)
224314383|NCT02156167|DEVICE|CP810 and Codacs™ system test|Nucleus® CP810 Sound Processor for the Codacs™ system (CE marked) and Codacs™ Test System (CE marked)
223618339|NCT01202630|DIETARY_SUPPLEMENT|Placebo|2 capsules of placebo (no live cells), consumed once daily for 60 days
223618340|NCT04767503|DRUG|Propofol|Maintence of anestheisa with propofol guided by the bispectral index in the range 40-60.
224206171|NCT00901420|BEHAVIORAL|Questionnaire|Survey of urinary function and quality-of-life (regarding daily living after surgical treatment for prostate cancer), taking 30 minutes to complete.
224206172|NCT02395536|OTHER|office setting|An office setting was defined as a procedure or office room with controlled entry and hard floors outside the walls of the hospital and not including ambulatory surgical centers
224206173|NCT02395536|OTHER|hosptial setting|A hospital setting was defined as an operating room or electrophysiology lab inside the walls of a hospital.
224206174|NCT00187174|DRUG|Everolimus|The drug is given orally in 28 day courses.
224206175|NCT05475535|BEHAVIORAL|Cognitive Behavioural Therapy|Cognitive Behavioural Therapy
224206176|NCT05475535|BEHAVIORAL|Self-Compassion|Self-Compassion focused exercises
224206177|NCT05475535|BEHAVIORAL|Active Control|Engagement in a mobile application (Cooperation skills)
224206178|NCT02407483|DEVICE|Laser Visual Guidance|Laparoscopic simulator training, tested with laser visual guidance
224206179|NCT02407483|DEVICE|2 D vision|Laparoscopic simulator training, tested without laser visual guidance
224206180|NCT04282733|BEHAVIORAL|Mindfulness Rounds|"Throughout the 8-week study period, a different mindfulness practice will be introduced weekly in 3 separate 15-minute live sessions. Posters describing the particular practice of the week will be placed around the Unit as visual reminders to encourage actual practice."
224206181|NCT03943407|DRUG|Zyclara 3.75 % Topical Cream|The cream will be applied on 4x4 cm squared areas on the volar forearm. The cream will be left in place for 2h, 1 h or 30 min (sub-study 1) after which it will be removed. The technical and security procedures will be conducted in accordance with the manufacturer's instructions.
224206182|NCT03943407|DRUG|Prudoxin|The anti-histamine cream Prudoxin, containing 5% doxepin hydrochloride (1 g contains 50 mg of doxepin) (Healthpoint, San Antonio, TX) will be applied on the volar forearm. Two adhesive patches 4×4 cm (1mm thick, 3M foam adhesive tape, 3M, St. Paul, MN) each with a 3.5×3.5 cm center cut out (to deposit 1.2 grams of cream) will be each placed 3 cm distal and 3 cm proximal to the center of the volar aspect of each arm. Each patch will be covered with Tegaderm I.V., an occlusive, adhesive dressing (3M), for at least 1 h and 30 minutes.
224206183|NCT03943407|OTHER|Histamine|To deliver histamine, standard allergy skin prick test (SPT) lancets are applied. The lancets have a 1 mm shouldered tip adapt to introduce a small amount of test substance extremely locally and approximately at the dermo-epidermal junction. . A small drop of histamine dihydrochloride (1%, in saline) will be applied to a previously determined area on the volar forearm followed by a prick through the drop.
224314384|NCT03372291|OTHER|Usual Care|Usual leukemia care with all the supportive care measures instituted by the leukemia team
224314385|NCT03372291|OTHER|Psychological intervention|Psychological intervention is focused on educating patients about leukemia and how to cope with its treatment
224314386|NCT05248165|DEVICE|PCI|Percutaneous coronary intervention
224314387|NCT00391963|DEVICE|Bispectral index, Entropy|
224314388|NCT05689957|DRUG|Deep neuromuscular block using intravenous rocuronium induction at 1.2mg/kg and maintainance of 8-12mcg/kg/min for deep neuromuscular block|both arm are using low pressure pneumoperitoneum in laparoscopic surgery, moderate and deep neuromuscular block are monitor with neuromuscular monitoring. if surgical condition is inadequate, surgeon are allowed to increase intraabdominal pressure as per standard care
224314389|NCT02896790|OTHER|Interviews with 2 oncologists and 10 patients|
224314390|NCT02896790|OTHER|Interviews with 15 patients|
224314391|NCT03138590|DEVICE|Transcranial Direct Current Stimulation- Neuroconn DC Stimulator PLUS|Transcranial Direct Current Stimulation targeting the trigeminal nerve
223618341|NCT04767503|DRUG|Desflurane|Maintence of anestheisa with desflurane guided by the bispectral index in the range 40-60.
223618342|NCT01154777|BEHAVIORAL|Neurofeedback training|60 sessions of Neurofeedback on 6-18 year olds with Autism
223618343|NCT01385657|DRUG|Placebo|A total of 4 doses were administered.
223618344|NCT01385657|DRUG|Dupilumab|A total of 4 doses were administered.
223618345|NCT01385657|OTHER|Background treatment|Participants were required to apply stable doses of an additive-free, basic bland emollient on the affected areas of the skin twice daily throughout the study.
224206184|NCT03943407|OTHER|Cowhage|Cowhage spicules are 1-2 mm in length and have diameter of 1-3 um at their tip. The active substance delivered (mucunain) has been calculated to be in the nanogram range. The insertion of cowhage spicule(s) rapidly and consistently produces itch with no or very little flare reaction. This insertion is conducted by forceps using a stereo-microscope, and 30-35 spicules are gently rubbed into a 1 cm diameter skin area.
223618346|NCT00556816|BEHAVIORAL|on demand clinic|Outpatient on demand clinic
223618347|NCT00556816|BEHAVIORAL|Control|conventional outpatient clinic
224314392|NCT05110820|DIAGNOSTIC_TEST|Automated quantitative pupillometer|Quantitative measurement of pupillary variables was performed at the time of arrival at the ED (0 h), and at the 6-, 12-, and 24-h time points on hospital day (HD) 1. The worst value among those recorded within 24 h and during the total measurement period was selected as the 24-h and total lowest values. If a patient was discharged before HD 3, measurements were taken only until discharge. The initial value was measured within 1 h after arrival at the ED because of the requisite time for obtaining informed consent before enrollment. At each time point, the lowest values for the NPi and qPLR of each eye were retained for analysis. The sPLR (standard PLR) was serially measured in the ED and after admission by emergency physicians using a manual penlight. We classified the reactivity of the sPLR as reactive, sluggish, or non-reactive. Non-reactive sPLR was defined when pupillary reactivity was not identified bilaterally.
224314393|NCT00043628|PROCEDURE|Stem Cell Mobilization|
224314394|NCT04352868|DEVICE|Intelliwave multifocal, toric, soft contact lens|This is a quarterly disposable, multifocal, toric soft contact lens commercially available from Art Optical Contact Lens, Inc.
224314395|NCT04352868|DEVICE|Intelliwave toric, soft contact lens|This is a quarterly disposable toric soft contact lens commercially available from Art Optical Contact Lens, Inc.
224314396|NCT03238612|DRUG|FFA, clarithromycin, oseltamivir|2-day course of triple combination of clarithromycin 500mg, flufenamic acid 200mg and oseltamivir 75mg twice daily followed by oseltamivir 75mg twice daily for 3 days
224206185|NCT03943407|OTHER|L-menthol|L-menthol (≥99.9%, TRPM8 agonist; (Sigma Aldrich, Broendby, Denmark) is dissolved in 96% ethanol at concentrations of 40%(w/v) L-menthol. A 1 mL aliquot is dispensed onto a 3 × 3 cm cotton pad and placed on a 6 × 6 cm sheet of medical tape. In between the cotton pad and the medical tape, a layer of parafilm will be added to avoid evaporation. This configuration was subsequently applied for 1 h.
224206186|NCT03943407|OTHER|Trans-cinnamaldehyde (CA)|CA will be obtained from Sigma Aldrich (Brøndby, Denmark) and dissolved in 90% ethanol at a concentration of 10% (vol/vol) CA. One ml aliquot of CA is dispensed onto a 3x3 cm cotton pad and placed on a 5x5 cm sheet of medical tape. Between the cotton pad and the tape, a layer of plastic film will be added to inhibit the evaporation of the solutions. This configuration will be applied for 1 h.
224206187|NCT06317870|PROCEDURE|Intrathecal morphine|"Spinal anesthesia will be performed as follows: patient will be placed in the lateral decubitus position on the non-operative side. Using sterile gloves red chlorhexidine 2% alcohol solution will be used for skin disinfection. The site will be secured with a sterile drape, and the L4-L5 lumbar space identified. After subcutaneous local infiltration with 1% lidocaine, a 25G Whitacre pencil point spinal needle will be used to access the intrathecal space with free flow of cerebrospinal fluid as confirmation. A mixture of 12.5 mg of isobaric bupivacaine and 100 mcg of morphine will be administered intrathecally.~After the spinal anesthesia, the intrathecal morphine (ITM) group will receive a sham PENG block with the block needle inserted subcutaneously, the anesthesiologist using the same verbal block confirmation commands aspirate, inject but the needle withdrawn without injection. This will create the appearance of an identical cutaneous injection site to ensure patient blinding."
224314397|NCT03238612|DRUG|Oseltamivir alone|2-day course of oseltamivir 75mg plus placebo capsules twice daily followed by oseltamivir 75mg twice daily for 3 days as control
224314398|NCT01199016|PROCEDURE|Tympanocentesis|To be performed as needed on children presenting with acute otitis media
224314399|NCT01199016|PROCEDURE|Nose/throat swab|To be performed at every study visit
224314400|NCT01199016|BIOLOGICAL|Observational|Observational Study Only
223618348|NCT05899374|BEHAVIORAL|KindMap|The KindMap is a stand-alone, cost-free e-mental health tool presenting a low-intensive psychological intervention adapted from the MBPI to fit a web app format. KindMap is to be used at users' own time and pace, and includes ten modules addressing psychoeducation, mindfulness and compassion guided practices, and ACT-based experiential exercises. These components are delivered through text, videos, audio, experiential exercises, and interactive contents.
224314401|NCT02318303|DRUG|GSP 301-1 NS (QD)|GSP 301-1 NS (665 μg olopatadine hydrochloride/50 μg mometasone furoate) administered as 2 sprays/nostril
224314402|NCT02318303|DRUG|GSP 301-2 NS (BID)|GSP 301-2 NS (665 μg olopatadine hydrochloride/25 μg mometasone furoate) administered as 2 sprays/nostril
224314403|NCT02318303|DRUG|GSP 301 Placebo NS|GSP 301 placebo NS administered as 2 sprays/nostril
224314404|NCT02318303|DRUG|Olopatadine HCl-1 NS (QD)|Olopatadine HCl-1 NS (665 μg) administered as 2 sprays/nostril
224314405|NCT02318303|DRUG|Olopatadine HCl-2 NS (BID)|Olopatadine HCl-2 NS (665 μg) administered as 2 sprays/nostril
224314406|NCT02318303|DRUG|Mometasone Furoate-1 NS (QD)|Mometasone furoate -1 NS (50 μg) administered as 2 sprays/nostril
224314407|NCT02318303|DRUG|Mometasone Furoate-2 NS (BID)|Mometasone furoate-2 NS (25 μg) administered as 2 sprays/nostril
224314408|NCT01480362|DEVICE|Negative Pressure Wound Therapy|"Used therapy systems:~KCI. V.A.C. Freedom; Acti V.A.C.; INFO V.A.C. to be used with the V.A.C. Granufoam (black), V.A.C. Granufoam Silver and V.A.C. WhiteFoam Smith \& Nephew: Renasys GO and Renasys EZ Plus to be used with the Renassys-F/P and Renassys-G Use of the medical devices and applicable consumption items according to manufacturers guidelines and FDA regulations."
224314409|NCT01480362|OTHER|Standard Wound Therapy|Standard wound therapy according to current evidence-based guideline(basic and advanced methods of wound treatment)
224314410|NCT02971098|PROCEDURE|Reduced activity|Participants will reduced their physical activity level to approximately 2000 steps or 75% of their normal activity levels.
224314411|NCT06551376|OTHER|Ovarian Stimulation Start|To compare ovarian response accordin to ovarian stimualtion start
223618349|NCT05958849|DRUG|Sovalteinib Solutumab Tegeo|Soventinib in combination with solutumab and tegeo for advanced pancreatic cancer
223618350|NCT03787797|DIAGNOSTIC_TEST|Echocardiography|Assessment of epicardial adipose tissue thickness
223618351|NCT01630291|DEVICE|Electrode device|Lacrimal gland stimulation
223618352|NCT06422013|DIETARY_SUPPLEMENT|GTB1|oral administration of GTB1 powder packet once daily
224314412|NCT00843895|BIOLOGICAL|pneumococcal conjugate vaccine(prevenar)|to see the vaccine impact on pneumococcal diseases
224314413|NCT00832156|BIOLOGICAL|Cultured autologous keratinocytes|The experimental wound site will be covered with cultured keratinocytes on a collagen/elastin carrier after the application of a meshed split skin autograft. The control wound site will be covered with a meshed split skin autograft alone.
223618353|NCT06422013|DIETARY_SUPPLEMENT|Placebo|oral administration of placebo powder packet once daily
223618354|NCT06231979|DRUG|Dexmedetomidine|1 μg/kg Dexmedetomidine per side in erector spinae block
223618355|NCT06231979|DRUG|Bupivacain|18 mL of bupivacaine 0.25 % per side in erector spinae block
223618356|NCT06231979|DRUG|Normal saline|2 ml normal saline 0.9% per side in erector spinae block
223618357|NCT02623621|DRUG|chemotherapy plus bevacizumab|Every chemotherapy regimen combined with bevacizumab is allowed
223618358|NCT01063153|DRUG|Osmotic Release Methylphenidate|During a 6 week treatment period, adult subjects with ADHD are prescribed, in an open label fashion, once daily doses of osmotic release methylphenidate to a maximum daily dose of 144 mg. Efficacy and tolerability assessments are completed, in addition to EEG and cognitive testing. Healthy adults without ADHD will not receive medication.
223618359|NCT05708456|OTHER|Mobile application with symptom management|In this study, patients will be given evidence-based advice via a mobile application to manage their symptoms.
224314414|NCT04628897|BEHAVIORAL|Exposures|"1. Total area of available floor space inside the home (m2)~2. Frequency that child plays outdoors~3. Total number of physical hazards in the home (presence of open stairwells, stove height)~4. Total number of fine-motor activity items available to the child~5. Presence of gross-motor activity items available to the child across each category (e.g., fixed, portable: ball equipment, push/pull equipment, riding equipment, rocking and twisting equipment)~6. Hemoglobin concentration (g/L)."
224314415|NCT03791463|DRUG|salvianolic acid A|Following an overnight fast of at least 10 hours, a single dose of 90 mg salvianolic acid A will be administered on 2 separate occasions (fasting and after meal) in a randomized crossover fashion with different food restrictions.
223618360|NCT00411255|PROCEDURE|repetitive transcranial magnetic stimulation (rTMS)|Three arms on three different days 180 stimuli will be delivered to the AC with a sham coil, with the H-coil and with a standard circular coil in separate sessions.
224314416|NCT03140371|DIETARY_SUPPLEMENT|High energy high protein peptide feed study|"Each patient will receive the high energy, high protein peptide-based feed for a period of up to 4 weeks (28 days). The feed will be available as an enteral tube feed in a 500ml bottle, and as a Vanilla flavoured oral nutritional supplement in a 200ml plastic bottle. The appropriate feed presentation (tube feed or oral nutritional supplement) and prescription will be determined on an individual basis by the Dietitian responsible for the patient's nutritional management, based on the patient's clinical requirement and preference, and the Dietitian's clinical judgement.~The study feed is classed as a 'Dietary Food for Special Medical Purposes' (EC Directive 1999/21/EC, 1999) ."
223618361|NCT04304872|BEHAVIORAL|Gamification|"Participants sign a pledge agreeing to try their best to meet their goals.~Participants are entered into a game. Each week they receive 70 points. Each day they're told their step count and points. If the step goal was met they keep their points, but if not, they lose 10 points. At the end of the week if they have at least 40 points they move up a level, but if not, they drop a level. Participants start in the middle of 5 levels.~Participants choose a support partner who gets a weekly email with the participant's progress. We hold a 3-way phone call with the participant and supportive sponsor to discuss ways they can help the participant meet their goal. At 6 weeks, we have a follow up call if the participant is stuck in a lower level and restart them back at the middle level."
223618362|NCT04304872|BEHAVIORAL|Loss-Framed Financial Incentives|Participants are informed that each week $14 is placed in a virtual account for them. Each day the participant is informed of their step count on the prior day. If the step goal was achieved, the balance remains. Each day the goal is not achieved, the participant is informed that $2 was taken away.
223618363|NCT02607943|DRUG|Insulin Glargine|Insulin Glargine Versus Regular Insulin Based Regimens in Glycemic Control
224314417|NCT00986050|DRUG|Abciximab|Abciximab bolus 0,25mg/kg, 10-60 minutes before PCI. Infusion 0,125ug/kg/min for 12 hours after PCI.
224206188|NCT06317870|PROCEDURE|Pericapsular nerve group block (PENG)|"Spinal anesthesia with intrathecal injection of 12.5 mg of isobaric bupivacaine will be performed, followed by a PENG block.~After skin disinfection, a low frequency curvilinear ultrasound probe (2-5 MHz 8870, BK ultrasound, Peabody Massachussets, US) with a sterile covering will be used to identify the anterior inferior iliac spine, the pubic eminence and the psoas tendon with its fascial plane. A 22 gauge 10cm block needle (Sonoplex® Pajunk, Geisingen, DE), will be used to enter the fascial plane and 20ml of 0.75% Ropivacain (Fresenius Kabi, Krienz CH) will be injected."
224206189|NCT05021120|DRUG|AK127|Subjects will receive AK127 by intravenous administration
224206190|NCT05021120|DRUG|AK104|After AK127 infusion, on the same day subjects will receive AK104 by intravenous administration
224206191|NCT02366026|BIOLOGICAL|IR103|REMUNE HIV/AIDS Vaccine with two adjuvants IFA + Amplivax
224206192|NCT04889378|OTHER|prehabilitation|very low calories diet (800-1000kcal/day) with moderate intensive aerobic exercise (1 hour per section; 3 sections per day)
224206193|NCT02108366|DRUG|Celecoxib|Celecoxib 200mg daily
224206194|NCT02108366|DRUG|Oseltamivir|Oseltamivir 75mg bid
224206195|NCT02108366|DRUG|Placebo|Placebo capsule identical in appearance to celecoxib capsule, containing corn starch
224314418|NCT00986050|DEVICE|bare metal stent prokinetic, chrono, skylor or bluemedical|bare metal stent in culprit artery in acute myocardial infarction
224314419|NCT00986050|DEVICE|drug eluting stent (sirolimus eluting) - CYPHER stent|stent implantation in culprit artery in acute myocardial infarction
224314420|NCT02368314|DRUG|Sodium Enoxaparine|30 mg (0,3 ml), subcutaneously, twice a day (every 12 h).
223618364|NCT02607943|DRUG|Regular Insulin|Insulin Glargine Versus Regular Insulin Based Regimens in Glycemic Control
223618365|NCT05154253|DEVICE|Biomotum Spark: Robotic ankle assistance|A lightweight assistive wearable ankle robotic device.
223618366|NCT05154253|DEVICE|Biomotum Spark: Robotic ankle resistance|A lightweight resistive wearable ankle robotic device.
223618367|NCT05154253|OTHER|Standard gait training|Standard gait training without a device.
223618368|NCT05154253|DEVICE|Ankle foot orthosis|Standard ankle foot orthosis
223618369|NCT05154253|OTHER|Standard physical therapy|Physical therapy without a device.
223618370|NCT05154253|OTHER|Standard walking|Walking without a device
223618371|NCT05235542|DRUG|AK104|IV infusion,Specified dose on specified days
223618372|NCT05235542|DRUG|AK117|IV infusion,Specified dose on specified days
223618373|NCT05235542|DRUG|Capecitabine tablets|Oral,Specified dose on specified days
223618374|NCT05235542|DRUG|Oxaliplatin|IV infusion,Specified dose on specified days
224206196|NCT04499391|OTHER|Project ECHO|Project ECHO utilizes case-based, collaborative learning to support discussion of learners' challenges and barriers to guideline implementation. This differentiates ECHO from traditional learning and facilitates rapid dissemination of medical knowledge and increased capacity to deliver best-practice care.studying innovative approaches.
223618375|NCT05235542|DRUG|Cisplatin|IV infusion,Specified dose on specified days
223618376|NCT05235542|DRUG|Paclitaxel|IV infusion,Specified dose on specified days
223618377|NCT05235542|DRUG|Irinotecan|IV infusion,Specified dose on specified days
223618378|NCT05235542|DRUG|Docetaxel|IV infusion,Specified dose on specified days
223618379|NCT05235542|DRUG|5-FU|IV infusion,Specified dose on specified days
223618380|NCT01612130|DRUG|100 mg of Valeriana officinalis L|A single dose of 100 mg of Valeriana officinalis L., 1 hour prior to surgical procedures
224206197|NCT05577819|DIAGNOSTIC_TEST|99mTc-pyrophosphate Scintigraphy|Cardiac Imaging Technique used to diagnose Transthyretin Cardiac Amyloidosis by use of 15 mCi of 99mTC-Pyrophosphate tracer
224206198|NCT03313401|DRUG|Aflibercept|Intravitreal aflibercept injection
224206199|NCT03313401|DEVICE|Specular microscopy|Specular microscopy measurement after intravitreal aflibercept injection
224206200|NCT06429891|DRUG|18F-FDG|All study participants will undergo one 18F-FDG PET/CT scan.
224206201|NCT06702475|DIAGNOSTIC_TEST|Home Sleep Test with Watch PAT-one|Each participant will have a Watch-PAT one home sleep test, recording pulse oximetry, pulse tonometry, wrist actigraphy, snoring (by microphone), and chest motion by accelerometer.
224206202|NCT06723353|OTHER|Visceral Manipulation Therapy|Visceral Manipulation (VM) is a manual therapy consisting of gentle, specifically placed manipulations that encourage normal mobility, tone, and inherent tissue motion of the viscera and their connective tissues. These manipulations can potentially improve the structural integrity of the abdominal cavity and enhance the physiological functioning of the organs. VM will be administered by certified therapists trained in this specialized technique, focusing on reducing the Inter-Recti Distance (IRD) and associated symptoms of DRA.
224206203|NCT06723353|OTHER|Abdominal Kinesio Taping|Kinesio Taping (KT) involves the application of a thin, stretchable tape over and around muscles to enhance function, reduce inflammation, and support muscles in movement on a 24hr/day basis. It is non-restrictive, allowing for full range of motion. In this study, KT will be applied in a crisscross pattern across the abdomen to support the abdominal muscles affected by DRA, potentially aiding in muscle function and reducing pain and discomfort.
224206204|NCT06723353|OTHER|Combined Visceral Manipulation and Kinesio Taping|This intervention combines Visceral Manipulation and Kinesio Taping to leverage the benefits of both modalities. The combination aims to enhance the functional and structural support of the abdominal region by improving organ function through VM and providing muscular support through KT. This dual approach is hypothesized to offer a synergistic benefit, potentially providing a more effective treatment for reducing IRD and improving overall abdominal function.
224206205|NCT06723353|OTHER|Postpartum Core Strengthening Program|The Core Strengthening Program is designed to strengthen the deep core muscles, including the transverse abdominis, multifidus, and the pelvic floor muscles. Exercises will be tailored to accommodate postpartum women and will be progressively adjusted to match improvements in strength and endurance. The program includes supervised training sessions focusing on enhancing core stability, which is crucial for postpartum recovery and long-term spinal and pelvic health.
224206206|NCT05366725|DRUG|Avelumab|As provided in real world practice
224206207|NCT02316704|DEVICE|THA with G7 PPS coted acetabular component|
223618381|NCT01612130|DRUG|Placebo 100mg|A single dose of 100 mg of placebo orally, 1 hour prior to surgical procedures
223618382|NCT04340453|OTHER|Exercise with Blood Flow restriction training|3 times a week for 4 weeks to a total of 12 sessions. BFR cuff (Sports Rehab Tourniquet©) will be used, with a width of 10cm and a length of 116cm or 84cm depending on the diameter of the participants thigh. Therapy sessions will be supervised and in groups. Exercises focus on strengthening the hip extensors and abductors, as well as the quadriceps both in open and closed kinetic chain. Exercises will be carried out using will be set at a load of 30% of 1RM with a limb occlusion pressure (LOP) of 70%. The first set will consist of 30reps. followed by 3 sets of 15reps. at 2:2 (con/ecc) at 60bpm by Metronome app. with auditory cue. Rest between sets will be 30sec and between exercises 2min. Cuffs will be deflated during the resting period between exercises and re-inflated at the beginning of the next exercise. Exercise progression will be individualized based on assessments at the beginning of each week. The duration has been estimated to be approximately 60min. including LOP estimation.
223618383|NCT04340453|OTHER|Hip and Knee Exercise Program|A supervised hip and knee strengthening exercise protocol with a combination of stretching, 3 times a week for 4 weeks to a total of 12 sessions. Exercises focus on hip extensors, abductors, as well as the quadriceps and hamstrings strength. Open Kinetic Chain (OKC) exercises will be executed first followed by CKC exercises. Exercises using weights or mechanical resistance will be set at a load of 70% of 1RM and 3 sets of 10 rep. for each exercise. Elastic band exercises will be set at 10RM for 3 sets. Tempo will be set by the Metronome app installed on a Smartphone at 1:2 (con/ecc) at 60bpm with auditory cue. Rest between sets will be 30sec and between exercises 2min. Exercise progression will be individualized based on assessments at the beginning of each week. The duration of each session is estimated to be approximately 45min, with the exception of the first session of each week which is estimated to be 80min due to the addition of strength testing
223618384|NCT04340453|OTHER|stretching|Both groups will receive stretching of the hamstrings, plantar flexors, quadriceps and Iliotibial Band (ITB) in the same manor at the end of each session. Passive stretching will be executed by the physiotherapist with 3x30sec stretch for each muscle group
223618385|NCT00350844|DRUG|Hydroxyurea|20 mg/kg/day and dose escalating every 2 months until maximum tolerated dose.
223618386|NCT00932321|DRUG|Norethindrone Acetate/Ethinyl Estradiol 24 Days|One tablet per day for 24 days of each 28 day cycle followed by 4 placebo tablets
223618387|NCT00932321|DRUG|Norethindrone Acetate /Ethinyl Estradiol 21 Days|One tablet per day for 21 days of each 28 day cycle followed by 7 placebo tablets
224206208|NCT02316704|DEVICE|THA with G7 OsseoTi coted acetabular component|
224206209|NCT06548529|RADIATION|HER2 expression of PET imaging|Evaluate the diagnostic potential of HER2 imaging using 18F-labelled HER2 affibody , evaluate the predictive and prognostic value of HER2 PET imaging in bladder cancer patients treated with ADC
224206210|NCT00228332|DRUG|Administration of zinkgluconaat or placebo|
224206211|NCT03538314|DRUG|UV1|UV1 (300 microgram)
224206212|NCT03538314|DRUG|GM-CSF|GM-CSF (37,5 or 75 microgram)
224206213|NCT06082609|PROCEDURE|Removable partial denture|All patients will receive Removable partial denture by two different impression techniques
224206214|NCT06271941|PROCEDURE|Hybrid Argon Plasma Coagulation (h-APC)|The hybrid argon plasma coagulation (h-APC) combines an ablation technique (APC) with the option for submucosal saline injection using a high-pressure water jet. The technique allows for the lifting of dysplastic epithelium, creating a cushion under the mucosa to facilitate the ablation of larger areas more thoroughly and with higher energy settings, while posing a low risk for side effects or complications.
224206215|NCT06271941|PROCEDURE|Snare tip soft coagulation (STSC)|The Snare tip soft coagulation (STSC) involves using a snare to remove polyps, while simultaneously applying soft coagulation to the surrounding tissue using a specialized tip on the snare.
224206216|NCT03920527|DRUG|Itraconazole 400 mg|Duration of itraconazole
224206217|NCT00891527|DRUG|Bevacizumab (Avastin) and Imatinib Mesylate (Gleevec)|"Imatinib Mesylate Orange to grayish orange, opaque, 100mg capsules dissolved in 50-100mls of mineral water or apple juice. Given at 340mg/m2 once daily, preferably with a meal.~Bevacizumab Clear to slightly opalescent liquid. Given at 10mg/kg once every 2 weeks IV. The calculated dose should be placed in an IV bag and diluted with 0.9% sodium chloride to obtain a final volume of 25-100mls. The vials contain no antibacterial preservatives. Once diluted, must be administered within 8 hrs. Initially administered over 90 mins. If no adverse reactions occur, 2nd dose administered over 60 mins. If still no adverse reactions, subsequent doses administered over 30 mins. If infusion-related adverse reactions occur, further infusions administered over the shortest period that was well tolerated."
224206218|NCT05073276|OTHER|Physical Therapy|Patient is randomized to the weightbearing group the day after surgery.
224206219|NCT05589246|DEVICE|regional analgesia with cryolesia|The regional analgesia (erector spine plane block) will be added to intraoperative cryolesia of intercostal nerves
224206220|NCT01186744|DRUG|CP-690,550|10 mg of CP-690,550 oral BID or placebo oral BID, as appropriate based on treatment withdrawal/retreatment design
224206221|NCT01186744|DRUG|CP-690,550|10 mg oral BID
224206222|NCT01186744|DRUG|CP-690,550|5 mg of CP-690,550 oral BID or Placebo oral BID, as appropriate based on treatment withdrawal/retreatment design
224206223|NCT01186744|DRUG|CP-690,550|5 mg oral BID
224206224|NCT05572424|OTHER|Adaptated Physical Activity (APA) + pedometer watch|"Adapted physical activities program : 12 weeks, 2 40-minutes sessions per week ( one broadcast live via online video conferencing and other one in autonomy according to a sequence of different personalized exercises defined by the APA's professional). Children are divided into 6 groups. Each session will be broken down into three parts: the warm-up (10mins), the session's corps alternating between five to eight of muscle strengthening, proprioception, and endurance exercises (20mins) and a cool-down with stretching (10mins). The physical activity performed during the sessions will be quantified with a heart rate monitor and the range of 60-70% of the maximum theoretical heart rate for each child will be respected.~A pedometer watch will wear during 1 year and will provide the number of steps."
224206225|NCT04542902|BIOLOGICAL|Dermatophagoides pteronyssinus allergen|Dermatophagoides pteronyssinus allergen is required to perform allergen bronchial challenge test.
224206226|NCT04542902|PROCEDURE|Blood sampling|An amount of a person's blood taken from their body for use in medical.
224206227|NCT04542902|PROCEDURE|Bronchial challenge with allergen|Bronchial challenge is performed with D. pteronyssinus allergen. Measurements of differences in eosinophils activity after allergen challenge.
224206228|NCT02547779|OTHER|0.9% Saline|0.9% Saline will be used whenever an isotonic crystalloid is ordered
224206229|NCT02547779|OTHER|Physiologically-balanced isotonic crystalloid|Lactated Ringers or Plasma-Lyte© A will be used whenever an isotonic crystalloid is ordered
224206230|NCT05302700|BEHAVIORAL|Early Parental Sensitivity Intervention|Parental sensitivity intervention include (1)Establish an emotional connection：Using the VR tour to introduce the environment, instruments and equipment of the neonatal intensive care unit, appearance of premature infants and pipeline wires on their bodies .(2)maintain physical proximity:proactively provide mothers with the opportunity to touch the body of preterm infants.(3) parents must understand their infant's cues:Using the Premature Infant Behavioral Clues Teaching Materials to play video and we will discuss and respond to the mother's questions.(4)engage in his/her care and communicate appropriately with him/her:We will discuss the behavioral clues of the preterm infant with the mother next to the incubator, encourage the mother to ask questions and participate in care activities such as changing diapers and stamping the baby's footprints on the card, asking the mother to write down the number of days of birth, corrected age, weight and what she wants to say for her baby.
224206231|NCT04275232|BIOLOGICAL|Allogenic plasma aliquots, a source of plasminogen|Plasma eye drops, a source of plasminogen
224206232|NCT06317337|OTHER|focused ultrasound cavitation augmented with aerobic exercises|Ultrasound cavitation single session per week along with the Aerobic exercises. Aerobic Exercise was Treadmill walk for 30 min with moderate intensity
224206233|NCT05673915|DEVICE|ActivaDose II 0.1 mA transcranial direct current stimulation (tDCS)|Stimulation setting 0.1 mA daily for a 2-month period. Each daily treatment will last for approximately 30 minutes.
224314421|NCT05042895|PROCEDURE|Group A|"Office diagnostic hysteroscopy for assessment of the following:~* cervical canal: arborvitae, mucous, any abnormal pathology like a polyp.~* Endometrium cavity: vascularity, thickness, color, gland openings, any abnormal pathology.~* Darwishhysterscopic triad: shape, caliber, depth, abnormal pathology, flow patency, bubble flow patency, and peristalsis.~Endometrial sample by a Novak's curette Histopathologic assessment: will be sent for the routine out-patient Pathology lab to comment on the endometrial pattern and abnormalities.~Physical and laboratory examinations follicle-stimulating hormone \[FSH\], LH, thyroid-stimulating hormone \[TSH\], prolactin, and pre ovulatory LH LH levels of the patients will be measured on day 3 of the menstrual cycle."
224206234|NCT05673915|DEVICE|ActivaDose II 2.0 mA transcranial direct current stimulation (tDCS)|Stimulation setting 2.0 mA daily for a 2-month period. A Each daily treatment will last for approximately 30 minutes.
224314422|NCT05042895|PROCEDURE|Group B|"Office diagnostic hysteroscopy for assessment of the following:~* cervical canal: arborvitae, mucous, any abnormal pathology like a polyp.~* Endometrium cavity: vascularity, thickness, color, gland openings, any abnormal pathology.~* Darwishhysterscopic triad: shape, caliber, depth, abnormal pathology, flow patency, bubble flow patency, and peristalsis.~Endometrial sample by a Novak's curette Histopathologic assessment: will be sent for the routine out-patient Pathology lab to comment on the endometrial pattern and abnormalities.~Physical and laboratory examinations follicle-stimulating hormone \[FSH\], LH, thyroid-stimulating hormone \[TSH\], prolactin, and pre ovulatory LH LH levels of the patients will be measured on day 3 of the menstrual cycle."
224314423|NCT05396235|BIOLOGICAL|MT-3921|Solution for infusion; Intravenous (IV)
224314424|NCT05396235|BIOLOGICAL|Placebo|Solution for infusion; Intravenous (IV)
224314425|NCT02352935|DEVICE|NanoKnife LEDC System|90 pulses of 70 microseconds each in duration will be administered per electrode pair
224206235|NCT01020773|BEHAVIORAL|spontaneous breathing trial|
224206236|NCT00769782|PROCEDURE|therapeutic conventional surgery|All patients undergo suegery to achieve macroscopic complete resection within 28 days after enrollment (including enrollment day). As long as tumor free margin is ensured, all resection margin distances and all surgical procedure are accepted. Surgical treatment in this study excludes the following, radiofrequency ablation (RFA) without resection of liver only or microwave coagulation therapy (MCT) only; for RFA or MCT is used as additional treatment under judgment of primary physician for new liver tumor which comfirmed during surgery in different parts of liver except portion scheduled for resection, RFA and MCT are included. After histological curative resection, patients are observed without treatment until comfirming recurrence. Patients with incomplete tumor removal are withdrawn from protcol treatment and receive imatinib treatment, 400 mg/day orally. For reccurrence is comfirmed, patients receive imatinib treatment, 400 mg/day orally.
224206237|NCT02026882|DEVICE|Supreme Laryngeal Mask Airway|Supreme Laryngeal Mask Airway. Preoxygenation, rapid sequence induction and cricoid pressure. Induction of general anaesthesia.
224206238|NCT05983029|DIAGNOSTIC_TEST|Intergluteal Cleft|Marking of intersection between inferior aspect of the intergluteal cleft and the horizontal intercristal line
224206239|NCT05983029|DIAGNOSTIC_TEST|Neuraxial Midline|Marking of intersection between the neuraxial midline, as established with the transverse spinous process view on ultrasound, and the horizontal intercristal line
224206240|NCT05983029|DIAGNOSTIC_TEST|Horizontal Distance between Vertical Markings|The horizontal distance between these two vertical marks will be measured at the level of the intercristal line
224206241|NCT04445129|DEVICE|Portable EEG Device|Portable EEG device is lightweight and designed for nighttime wear.
224206242|NCT04445129|DEVICE|Portable ECG Device|Portable ECG device is waterproof and will be adhered to the chest of the participant.
224206243|NCT04445129|DEVICE|Accelerometry|Portable accelerometry device is noninvasive and will capture data on participant activity level, including intensity of movement, rest, and sleep.
224314426|NCT02381184|DRUG|clomiphene citrate|receive100 mg of clomiphene citrate (Clomid®; Hoechst Marion Russel, Cairo, Egypt) daily starting on day 3 of spontaneous or progestin induced cycle for 10 days.
224206244|NCT05292430|OTHER|Specimen Collection|collection of diseased and non-diseased tissue, blood, and other body fluids
224206245|NCT02815930|OTHER|HCU Status|Total healthcare expenditures in the top 5% of Ontarians
224314427|NCT02381184|PROCEDURE|laparoscopic ovarian drilling (LOD)|Laparoscopy was performed under general anesthesia, using three-puncture technique
224206246|NCT01280565|DRUG|Masitinib|Masitinib 7.5 mg/kg/day
224206247|NCT01280565|DRUG|Dacarbazine|IV bolus at 1,000 mg/m2 once every 3 weeks
224206248|NCT05812222|BEHAVIORAL|Skin-to-Skin contact.|Skin to skin contact: It is the laying of the newborn in the prone position on the mother's bare chest with only a diaper on.
224206249|NCT00831467|BIOLOGICAL|CV9103|Over a period of 23 weeks 5 vaccinations with CV9103 will be administered.
224206250|NCT01389024|DRUG|Hydroxyurea|Hydroxyurea solution 100 mg/ml with a starting dose of 20 mg/kg/day by mouth once daily and escalation by 5 mg/kg/day every 8 weeks until hematological toxicity, an Absolute Neutrophil Count of 2000 to 4000/ul, or a maximum dose of 35 mg/kg/day.
224206251|NCT01389024|DRUG|Placebo|Sucrose solution 0.2 ml/kg/day by mouth once a day with blinded dose escalation of 0.05 ml/kg/day to match the frequency of dose escalation in the hydroxyurea arm.
224206252|NCT01393717|DRUG|brentuximab vedotin|Given IV
224206253|NCT01660490|PROCEDURE|ORIF|Open reduction internal fixation of the proximal femur
224206254|NCT04252508|OTHER|Animated film|An animated film depicts the child and the caregivers in the form of avatars and retraces his journey from his room to the transfer area, then to the the operating room and finally to the post-intervention ward.
224314428|NCT00242632|DRUG|Namenda|Namenda has already been shown to offer cognitive benefits to patients suffering from Alzheimer's disease, but it's potential for treating those at risk for cognitive decline without Alzheimer's disease or other dementia has yet to be evaluated. It is possible that memantine may offer neurocognitive benefits to this population, as well. Participants are asked to take medication for six months, complete neuropsychological testing, and one blood draw.
224314429|NCT01638585|DRUG|urokinase|daily short infusions, i. e. i. v. application of 1.000.000 I.E. urokinase over 30 min. for at least 10 and up to 21 days during the 30 days after randomization
224314430|NCT02565212|DRUG|Montelukast,mometazon froat|
224314431|NCT06626295|OTHER|exercise-snack group|Adolescents in the exercise-snacks group will perform 4 \&amp;amp;amp;#34;exercise-snacks\&amp;amp;amp;#34; sessions per day during 3 weeks in addition to multidimensional care program. These sessions will consist of 1-min various intense supervised exercises . They will also receive information about their attitudes to physical activity.
224206255|NCT03149965|OTHER|transperineal ultrasound|transperineal ultrasound was used by placing a vaginal ultrasound probe towards the vaginal distal wall pointing to the anus, measuring the anovaginal distance.
224206256|NCT04794400|OTHER|oxygen mask|All patients fulfilling inclusion criteria would be offered to test the intervention as part of their care. The intervention consisted only of a standardised way to evaluate this new clinical routine.
224206257|NCT04739852|OTHER|Fasting|Patients undergo a 5-10 day fasting period with a dietary energy supply 350-400kcal per day with fruit and vegetable juices or, if not feasible, an established fasting-mimicking diet of 600-800 kcal according to Longo et al.
224206258|NCT04461652|PROCEDURE|prophylactic air-extraction catheter drainage|This is a kind of venous catheter commonly used in clinic. It may bring less pain after being inserted into the chest, with an equivalent drainage effect with traditional thick drainage tube from our experience, especially in the aspect of gas drainage effect.
224206259|NCT01739088|OTHER|Remote ischemic pre-conditioning stimulus.|Forty eight to 24 hours prior to the surgery, patient assigned to remote ischemic pre-conditioning stimulus (RIPC) will have blood pressure cuffs placed on both lower limbs around the upper thigh, and will then have the cuff inflated around the lower limb to a pressure 10 mmHg above systolic blood pressure for 5 minutes, followed by 5 minutes of cuff deflation. This will be done sequentially on each lower limb for two cycles on each limb. In the operating room, after induction of anesthesia, the exact same procedure will be performed in the RIPC group. For each intervention, the legs will be covered by a drape, so that whether the cuff is being inflated around the leg or underneath the leg is not seen by any member of the health care team.
224206260|NCT01739088|OTHER|Sham Ischemic Pre-conditioning|In the control (sham Ischemic Pre-conditioning) group 48 to 24 hours prior to the surgery a cuff will be placed just underneath the upper thigh and the cuff will be inflated for 5 minutes, followed by 5 minutes of cuff deflation, done sequentially for two cycles on each side.In the operating room, after induction of anesthesia, the exact same procedure will be performed in the RIPC group.
224206261|NCT05318807|OTHER|Assessment of level of readiness and need for personalised prehabilitation|"Patients asked to complete five validated questionnaires to assess their level of need and readiness:~1. Cancer Behaviour Inventory brief form - to measure self-efficacy for coping with cancer~2. Patient Activation Measure - to measure patient activation~3. Modified Godin Leisure Time Exercise Questionnaire - to monitor activity~4. Patient Generated Subjective Global Assessment - to identify malnutrition risk~5. Emotions thermometer - to detect emotional disorders and identify risk"
224206262|NCT05318807|OTHER|Formation of a personalised prehabilitation plan|"Prior to starting treatment, at week three and at week six, each patient will be invited to see a specialist dietitian for a one hour face-to-face personalised prehabilitation appointment to:~* Review the initial questionnaires to inform the personalised plan and goal setting~* Complete a further four questionnaires related to quality of life, diet and exercise~* Measure handgrip strength~* Assess functional capacity by completing the six minute walk test~A personalised plan is then agreed using SMART goals, taking into account the patient's priorities as indicated in their Patient Generated Index."
224206263|NCT05318807|OTHER|Daily diary|Each patient will be asked to keep a daily diary to record their symptoms, appetite, mobility and mood throughout their treatment as well as their adherence to goals. This will provide an indication of the impact of symptoms.
224314432|NCT01320384|OTHER|O2 conventional|standard low flow therapy
224314433|NCT01320384|DEVICE|O2-HFN : high flow nasal oxygen therapy|The patient will receive high flow nasal of humidified oxygen, set between 30 to 50 l/min. The inspired fraction of oxygen (FiO2) will be adjusted in order to obtain a SpO2 \>92%.
224314434|NCT01320384|DEVICE|O2-HFN/NPPV : association of high flow nasal oxygen therapy and non invasive positive pressure ventilation|The patient will receive successively in a day NPPV and O2-HFN. The NPPV will be applied with an airway humidification achieved by using a heated humidifier and a facial mask adapted to the morphology of the patient. The settings will be adjusted as follow : an inspiratory pressure between 6 to 14 cmH2O, in order to obtain a tidal volume between 7 to 10 ml/kg of predicted weight, a positive expiratory pressure between 0 to 10 cmH2O in order to obtain a SpO2 \>92% with the minimal FiO2.
224206264|NCT01286688|DRUG|Terbinafine Hydrochloride Tablets, 250 mg|Terbinafine Hydrochloride Tablets, 250 mg of Dr. Reddy's Laboratories Limited.
224206265|NCT00005578|BIOLOGICAL|bleomycin sulfate|
224206266|NCT00005578|BIOLOGICAL|filgrastim|
224206267|NCT00005578|DRUG|cyclophosphamide|
224314435|NCT01992718|PROCEDURE|Evaluation of MRI, US for pelvic and uterine conditions|"Pelvic ultrasound with transabdominal and transvaginal imaging. The transvaginal ultrasound will include elastography (TVUS-E). Also, a pelvic MRI will be performed if not done in the last 6 months. The MRI is performed with IV gadolinium-based contrast (MultiHance ®).~A patient survey will be included."
224314436|NCT01992718|PROCEDURE|Patient preference between MRI and Ultrasound|"Subjects may take part in this arm because they have recently had a MRI performed and scheduled for, or have recently undergone a pelvic ultrasound.~Subjects will also be asked to complete a survey that will state their preference with regards to examination/imaging. This will be done over the phone and will take no longer than 30 minutes to complete."
223618388|NCT05152771|OTHER|KETOGENIC DIET|"This will be a prospective cohort study. All families with children who have been newly diagnosed with confirmed SSPE (based on Dyken's Criteria) will be approached to start the low glycemic index diet (liberalized kind of KD). A thorough dietary history will be taken from the parents/caregivers, and they will be counseled by a trained dietitian on the diet, all pros and cons, and the format. After the verbal agreement, formal consent will be taken from the parent/ caregiver for initiation of the diet.~These patients are usually already admitted in the hospital for initial diagnosis and management. Therefore the initiation of the diet will be in the hospital during their admission if the parents/ caregivers agrees. A minimum of 2-3 days would be required to train the parents/caregivers."
223618389|NCT00158288|BEHAVIORAL|LAAM|
223618390|NCT01792037|DRUG|Etomidate|
224314437|NCT01739699|DRUG|Acetaminophen|
224314438|NCT01739699|DRUG|Placebo|
224314439|NCT02248883|DRUG|TPV low|
224314440|NCT02248883|DRUG|Placebo|
224314441|NCT02248883|DRUG|Moxifloxacin|
224314442|NCT02248883|DRUG|TPV high|
224314443|NCT02248883|DRUG|RTV|
224314444|NCT01767038|PROCEDURE|OCT Spectralis|
224314445|NCT01767038|PROCEDURE|microperimetry|
223618391|NCT01792037|DRUG|Midazolam|
224206268|NCT00005578|DRUG|dexrazoxane hydrochloride|
224206269|NCT00005578|DRUG|doxorubicin hydrochloride|
224206270|NCT00005578|DRUG|etoposide|
224206271|NCT00005578|DRUG|prednisone|
224206272|NCT00005578|DRUG|vincristine sulfate|
224206273|NCT00005578|RADIATION|radiation therapy|
224206274|NCT00646256|BEHAVIORAL|COGPACK training, psychoeducation|Bifocal psychoeducation group program (Munich Psychoses Information Program - PIP) with preceding computerbased cognitive training program (COGPACK)
224206275|NCT04901871|DRUG|0.02 mg/kg, age<65|Remimazolam of 0.02 mg/kg will be infused in patients aged\<65.
224206276|NCT04901871|DRUG|0.07 mg/kg, age<65|Remimazolam of 0.07 mg/kg will be infused in patients aged\<65.
224206277|NCT04901871|DRUG|0.12 mg/kg, age<65|Remimazolam of 0.12 mg/kg will be infused in patients aged\<65.
224206278|NCT04901871|DRUG|0.17 mg/kg, age<65|Remimazolam of 0.17 mg/kg will be infused in patients aged\<65.
224206279|NCT04901871|DRUG|0.22 mg/kg, age<65|Remimazolam of 0.22 mg/kg will be infused in patients aged\<65.
224206280|NCT04901871|DRUG|0.27 mg/kg, age<65|Remimazolam of 0.27 mg/kg will be infused in patients aged\<65.
224206281|NCT04901871|DRUG|0.02 mg/kg, age≥65|Remimazolam of 0.02 mg/kg will be infused in patients aged≥65.
224206282|NCT04901871|DRUG|0.07 mg/kg, age≥65|Remimazolam of 0.07 mg/kg will be infused in patients aged≥65.
224206283|NCT04901871|DRUG|0.12 mg/kg, age≥65|Remimazolam of 0.12 mg/kg will be infused in patients aged≥65
224206284|NCT04901871|DRUG|0.17 mg/kg, age≥65|Remimazolam of 0.17 mg/kg will be infused in patients aged≥65.
224206285|NCT04901871|DRUG|0.22 mg/kg, age≥65|Remimazolam of 0.22 mg/kg will be infused in patients aged≥65.
224206286|NCT04901871|DRUG|0.27 mg/kg, age≥65|Remimazolam of 0.27 mg/kg will be infused in patients aged≥65.
224206287|NCT01638754|PROCEDURE|Image guided Cardiac Resynchronization Therapy (CRT) device lead placement.|Participants will have a cardiac MRI scan prior to insertion of CRT device and an image guided map will be created to guide placement of Cardiac Resynchronization Therapy (CRT) pacing leads to the most optimal target on the patients heart.
224206288|NCT01638754|PROCEDURE|optimizing myocardial lead placement for Cardiac Resynchronization Therapy (CRT) devices|optimal lead placement will be determined by 3D model of coronary vein anatomy, myocardial scar and mechanical dyssynchrony
224206289|NCT01136005|OTHER|dexpanthenol 5% cream|Apply at least two times a day on face, chest and upper arms during the 6 week treatment period
224206290|NCT01136005|OTHER|Cetomacrogol cream|Apply at least two times a day on face, chest and upper arms during the 6 week treatment period
224206291|NCT00245427|DRUG|all macrolide antibiotics|Varies based on antibiotic
224206292|NCT00245427|DRUG|all beta-lactam antibiotics|Varies based on antibiotic
224314446|NCT04218734|DRUG|DBPR108|DBPR108: 100 mg, once daily for 24 weeks.
224314447|NCT04218734|DRUG|metformin hydrochloride|metformin hydrochloride: 500 mg, 1-3 times daily for 24 weeks.
224314448|NCT04218734|DRUG|placepo|placebo:100 mg, once daily for 24 weeks.
224314449|NCT05432661|DEVICE|HİGH-FLOW NASAL OXYGEN USE (HFNO)|It is aimed to show that the use of HFNO can improve oxygenation compared to the use of nasal cannula in ERCP procedures performed under sedation in the prone position.
224314450|NCT06206798|BEHAVIORAL|Resourcefulness Group|The content of the Resourcefulness intervention group includes 6 sessions such as session 1 to introduce resourcefulness skills; sessions 2-4 to discuss personal resourcefulness skills including planning daily activities, and positive self-talk; sessions 4-5 to discuss social resourcefulness skills including relying on family or friends, and seeking professional assistance.
224314451|NCT01663883|OTHER|Isometric exercise|use of a handgrip for 3x2 minutes
224314452|NCT05453097|DIAGNOSTIC_TEST|Selvester QRS Score with Preoperative ECG|Selvester QRS score will be calculated with the preoperative ECG of the patients.
224314453|NCT05503511|DRUG|NPT 2042 (bumetanide analog) or Matching Placebo|Soft gelatin capsules
224314454|NCT02842073|DRUG|Naltrexone|Standard clinical doses of naltrexone 50 mg/d dispensed by the UNC Investigational Drug Services. Naltrexone will be initiated at 25 mg/d from Days 7-9 and then go to 50 mg/d for Days 10-84.
224314455|NCT02842073|DRUG|Bupropion|Standard clinical doses of bupropion-XL 300 mg/d (lower seizure risk) dispensed by the UNC Investigational Drug Services. Bupropion XL will be initiated at 150 mg/d on Days 1-4 and increased to 300 mg/d for Days 5-84.
224314456|NCT00195338|DRUG|etanercept|
224314457|NCT00100308|DRUG|Unfractioned heparin|Low-dose continuous-infusion, 500 units/hour per seven days
223618392|NCT01792037|DRUG|methylprednisolone|
223618393|NCT02775916|DRUG|CDZ173|
223618394|NCT02775916|DRUG|Placebo|
224206293|NCT03533920|DEVICE|UNI-DEB|Applicate the TACE with UNI-DEB to unresectable hepatocellular carcinoma patient
224206294|NCT02759627|OTHER|Robotic-Assisted Gait Training|"There were three intervention arms in this study,~1. Robotic-Assisted Gait Training,~2. Conventional Training,~3. Combined Training."
224260336|NCT03972683|DRUG|Phenylephrine|Vasoconstriction to phenylephrine will be used to assess sensitivity to alpha 1 adrenergic stimulation. Phenylephrine will be infused via a brachial artery catheter at 0.125 or 0.25 μg/dl forearm volume/min (18-35 and 60-85 age groups, respectively), adjusted according to forearm blood flow, for a total of 16 min.
224314458|NCT00100308|DRUG|saline|Saline placebo
224314459|NCT04032717|DRUG|Q-Griffithsin (Q-GRFT) enema|Investigational enema composed of 4.2mL Q-Griffithsin (Q-GRFT) 9.6mg/mL combined with approximately 120.8mL of 0.9% sodium chloride solution to yield an active enema study product that will contain and deliver a dose of approximately 40mg of Q-GRFT
224314460|NCT04032717|OTHER|Placebo enema|Approximately 125mL of 0.9% sodium chloride solution
224314461|NCT03100123|DRUG|Aspirin 81 mg|Aspirin 81 mg po daily in tablet form.
224314462|NCT03100123|DRUG|Low-molecular-weight heparin|The LMWH regime will be at the discretion of the treating physician, with a suggested regime as follows: tinzaparin 4,500 IU sc daily until 20 weeks gestation, and then 4,500 IU sc twice daily until 37 weeks gestation.
224314463|NCT00378495|DRUG|Miltefosine: initially 2.5 mg/kg/day for 28 days|
224206295|NCT02757131|OTHER|Ambulation|"Patients randomized to the intervention group will be asked to participate in the ambulation protocol outlined by the PT staff 3 times daily under the supervision of the dedicated ambulator PCNA. This protocol will involve four exercise levels (mobilization, standing, walking, stairs) that may be implemented depending on the current physical capacity of the patient. The cohort of patients randomized to ambulator protocol will also receive the usual care by primary nursing.~In an effort to best characterize mobility in these patients, the team will collect Braden Scale Activity data from the electronic health record, and provide each patient a mobility tracking device to directly record daily steps taken while the patient is in the hospital. Daily step counts will be collected on a weekly basis from each device. The Braden Scale is entered by nursing on each patient at least daily and measures current activity level on a 4-point scale."
224206296|NCT03725267|DRUG|Melatonin Pill|Patients will receive 1 pill of melatonin each day during polymyxin B therapy for a maximum of 14 days.
224314464|NCT00469664|DRUG|Guanfacine/Tenex|
224206297|NCT03725267|DRUG|Placebo oral capsule|Patients will receive 1 pill of placebo each day during polymyxin B therapy for a maximum of 14 days.
224314465|NCT00039702|DRUG|[123] 5-I-A-85380|
224206298|NCT04619472|DEVICE|Pulmonary Radiofrequency Ablation System and the Disposable Pulmonary Radiofrequency Ablation Catheter|The conjunction of the pulmonary RFA system with the disposable pulmonary RFA catheter developed by Hangzhou Broncus Medical Co., Ltd. is aim to specifically target lung tumors. The ablation catheter is designed to reach the tumor through the bronchial pathway.
224314466|NCT05019443|DEVICE|Wedge Scoring Balloon|Scoring balloon
224206299|NCT05543863|DIAGNOSTIC_TEST|Platelet function testing|platelet function testing (Platelet function analyzer-100 (PFA-100) collagen epinephrine closure time, VerifyNowⓇ Assays (aspirin, P2Y12)) before surgery and 5 days, 3 months after surgery
223618395|NCT02753166|DRUG|Dexamethasone|After six (6) hours of the accident, subject will take 5 mg of DEX in the Emergency Department (ED). Within twenty-four (24) hours, the subjects will send in a saliva sample. After sexen (7) days, subjects will participate in a phone interview. After thirty (30) days, subjects will participate in an online assessment and return for a one month follow-up visit. Subjects will then participate in online assessments at months 3,6,9, and 12 months.
223618396|NCT03974048|DIAGNOSTIC_TEST|Blood samples for DNA methylation analysis|DNA from blood samples will be isolated and analyzed for genome-wide DNA methylation patterns using the Infinium HumanMethylationEPIC BeadChip (Illumina, San Diego, CA, USA).
224206300|NCT00545441|DEVICE|Surgisis Biodesign Anal Fistula Plug (Surgisis® AFP)|Surgical placement of the Surgisis AFP is performed under general anesthesia.
224206301|NCT00545441|DEVICE|Flap|Advancement flap surgery is performed; no anal fistula plug is placed
224314467|NCT05019443|DEVICE|Conventional Balloon|Conventional balloon
224314468|NCT02072603|OTHER|HITSystem|"Online, automated program designed to overcome current EID barriers by providing efficient prospective tracking of HIV-exposed infants and triggering electronic action alerts for both EID providers and lab technicians when time sensitive interventions are overdue for specific infants."
224314469|NCT02072603|OTHER|Standard of Care|current procedures that follow Kenyan National EID guidelines to diagnose and manage HIV infection among HIV-exposed infants.
224314470|NCT04223375|BEHAVIORAL|Nutrition Training|Postpartum women were educated on postpartum healthy and regular nutrition.
223618397|NCT01773681|DRUG|Cimzia|"For the loading phase, it consists of the first 3 doses. During the loading phase, the recommended dose of Cimzia for adults with rheumatoid arthritis is 400mg initially followed by 400mg again at week 2 and week 4. A 400mg dose requires 2 subcutaneous injection of 200mg; the injections should occur at separate sites in the thigh or abdomen.~After the loading dose, will be follow with 200mg every other week. The injection should occur at either the thigh or abdomen."
223618398|NCT01773681|DEVICE|Magnetic Resonance Imaging (MRI)|MRI of the dominant wrist, before, during and after the gadolinium contrast injection will be acquired. The dose of the gadolinium agent for this study is 0.1mmol/kg body weight. This gadolinium contrast agent will increase the image contrast in the joints in the wrist and surrounding tissues and will make the MRI pictures stand out better.
223618399|NCT01773681|DEVICE|High-resolution peripheral quantitative computed tomography (HR-pQCT)|HR-pQCT scan of the hand and wrist will be acquired to look at the bone quality. The scan uses special x-ray equipment to make detailed pictures of bone structure.
223618400|NCT00585481|PROCEDURE|Samples collection for viral diagnosis|"At Enrollment and Termination Visits all subjects will have phlebotomy performed for RSV antibody levels (3 mL of blood).~Subjects diagnosed with an LRTI during the study will have a nasopharyngeal lavage (NPL) for viral diagnosis. Phlebotomy for antibody levels will be performed if the current episode represents the first LRTI since study enrollment."
224314471|NCT04010552|DRUG|NALRINOX combination|NALRINOX: combination of three chemotherapy agents: 5- FU/LV, nal-IRI, and oxaliplatin
224314472|NCT01382537|DEVICE|InterX 5000|A computer driven electrical stimulation unit that contains a cutaneous impedance sensor.
224314473|NCT01382537|DEVICE|InterX 5000|Placebo treatment
224314474|NCT05320887|OTHER|Normal Nicotine Content Vape with all flavor e-liquids|Participants are randomly assigned to the order of each marketplace Group
224314475|NCT05320887|OTHER|Normal nicotine content vape with tobacco e-liquids|Participants are randomly assigned to the order of each marketplace Group
224314476|NCT05320887|OTHER|Low nicotine content vape with all flavor e-liquids|Participants are randomly assigned to the order of each marketplace Group
224314477|NCT05320887|OTHER|Low nicotine content vape with tobacco e-liquids|Participants are randomly assigned to the order of each marketplace Group
224314478|NCT03790371|DRUG|Misoprostol|vaginal misoprostol prior IUD insertion
224314479|NCT03790371|DRUG|Placebos|vaginal placebo tablet prior IUD insertion
224314480|NCT02052193|DRUG|Dabrafenib|Measurement of toxicity related to UV exposure
224314481|NCT02052193|DRUG|Vemurafenib|Measurement of toxicity related to UV exposure
224314482|NCT01577771|BIOLOGICAL|Prevnar13 (manufactured by Pfizer)|Prevnar13 administered IM in the antero-lateral thigh
224314483|NCT02289456|DRUG|nab-Paclitaxel|
224314484|NCT02289456|DRUG|Carboplatin|
224314485|NCT05511311|PROCEDURE|Resistance Training|Resistance training developed by the researcher (SCR-RSCM) for 12 weeks
224314486|NCT05511311|PROCEDURE|Standard Therapy|Standard therapy for 12 weeks
223618401|NCT00585481|PROCEDURE|Lung Function Analysis|Subjects enrolled in one study site (located in Porto Alegre city) will perform Lung Function Analysis. First measurement will be performed up to Visit 6 and repeated at Termination Visit. Measurements collected in the first analysis will include respiratory compliance and resistance by passive deflation pressure - volume curve, lung volumes by gas dilution method (washout with SF6), lung clearance index with SF6, and maximal flows (rapid thoracic compression from raised volumes).
223618402|NCT02741622|BEHAVIORAL|High aerobic intensity training (HIT)|One training session, high aerobic intensity training (HIT) at 90-95 % of the maximal heart rate (HRmax)
223618403|NCT02741622|BEHAVIORAL|Long slow distance training (LSD)|One training session, long slow distance training (LSD) at 70 % of the HRmax
223618404|NCT02836912|OTHER|Exercise|Besides the same information for the education group, exercise of upper extremity without loading, exercise of lower extremity, and training of respiratory muscles are used for the exercise group
223618405|NCT00670553|DRUG|panobinostat|
223618406|NCT01131988|DRUG|Tacrolimus Capsules|Tacrolimus Capsules, 5 mg of Dr. Reddy's Laboratories Limited
223618407|NCT04434079|OTHER|Regular critical care|Clinical demographic data, daily and cumulative FB (input minus output) with and without insensible fluid losses, and daily and total BW changes are recorded, as well as survival outcome.
224206302|NCT04095819|PROCEDURE|Middle Meningeal Artery procedure|Seal off the blood supply to the middle meningeal artery to prevent growth of the Subdural Hematoma
224206303|NCT04095819|PROCEDURE|Traditional Surgery|Drainage of Subdural Hematoma using Craniotomy or Burr Hole
224206304|NCT02298595|DRUG|cisplatin|75 mg/m2 IV day 1 of each cycle
224206305|NCT02298595|DRUG|Cetuximab|XXXX day 1, 8, and 15 of each cycle
224206306|NCT02298595|DRUG|BYL719|200, 250, 300, or 350 mg/day by mouth every day
224206307|NCT05877235|DIETARY_SUPPLEMENT|Quercetin|Trans-quercetin, 1000 mg daily for 60 days
224206308|NCT05877235|DIETARY_SUPPLEMENT|Placebo|Starch, 1000 mg daily for 60 days
224206309|NCT02803138|DRUG|Ombitasvir/paritaprevir/ritonavir|Co-formulated tablet
224206310|NCT02803138|DRUG|Dasabuvir|Tablet
224206311|NCT02803138|DRUG|Ribavirin|Tablet
224206312|NCT02803138|BEHAVIORAL|Patient support program|Supportive services provided to participants included reminder calls, emails, text messages, a Care Coach, and educational/informational materials.
223618408|NCT04822675|PROCEDURE|Percutaneous mitral valve repair|Percutaneous mitral repair will be performed using the MitraClip system.
223618409|NCT04822675|PROCEDURE|Surgical mitral valve repair/replacement|All mitral valve surgeries will be performed either via sternotomy or right thoracotomy, and with cardioplegic arrest and cardiopulmonary bypass. Mitral valve repair may include annuloplasty and adjunctive procedures as determined by the operating surgeon. For mitral valve replacement, the choice of mitral valve prosthesis will be left at the surgeon's discretion.
223618410|NCT03737123|DRUG|Carboplatin|Carboplatin AUC 4 IV Day 1 of each 21 day cycle
223618411|NCT03737123|DRUG|Gemcitabine|Gemcitabine 1,000 mg/m2 IV Day 1 and Day 8 of each 21 day cycle
224206313|NCT06576375|DRUG|Dapagliflozin|oral Dapagliflozin
224206314|NCT06576375|DRUG|Metformin|oral metformin
224260337|NCT03972683|DRUG|Sodium Nitroprusside|Sodium nitroprusside will be infused via a brachial artery catheter as a control vasodilator to elevate resting forearm blood flow to a level similar to that during exercise. The dose will be adjusted to match forearm blood flow to a similar level as during handgrip exercise, with an anticipated average dose of 1 μg/dl forearm volume/min. The dose will be infused for a total of 14 min.
224260338|NCT01910753|PROCEDURE|APA|A 3-month program for physical activity and diet education will be followed. An exercise specialist will supervise patients twice per week, during the first six weeks. They will also follow nutrition counselling and therapeutic education by a dietician once per week. During the last six weeks, they will just follow a guide for safe and appropriate exercise regimen. The dietician will call patient weekly during this final period.
224260339|NCT04376190|RADIATION|low level laser therapy|In the laser group, patients received LLLT from a semiconductor Gallium Aluminum Arsenide diode laser (SMARTMPRO, LASOTRONIX, Poland) with the following set parameters; 635 nm wavelength in continuous-wave mode, 50 mw power output, 4.5 J/cm2 energy density, 11.25 J total dose per side, 45 seconds/ point, and 8 mm fiber optic tip diameter. Laser was applied (Fig.2) at five points located within TMJ region on both right and left sides in contact with skin as follows: lateral, superior, anterior, posterior, and posterior- inferior points.
224260340|NCT01009229|DIETARY_SUPPLEMENT|Low and high salt diets|High salt diet: 150mmol/d Low salt diet: 30mmol/d
224260341|NCT05172947|DRUG|Resveratrol|This group received resveratrol with the conventional therapy
224260342|NCT05172947|DRUG|Placebo|This group received placebo with the conventional therapy
224260343|NCT05172947|OTHER|Resveratrol plus Pharmaceutical care|This group received Resveratrol with Pharmaceutical care in addition to the conventional therapy
224260344|NCT05172947|OTHER|Placebo+Pharmaceutical care|This group received placebo with Pharmaceutical care in addition to the conventional therapy
224260345|NCT00170547|BIOLOGICAL|Trivalent inactivated influenza vaccine|A synthetic vaccine consisting of three inactivated influenza viruses: two different influenza type A strains and one influenza type B strain.. Group 4: 382 subjects receive Fluzone 15 mcg IM on day 0
224260346|NCT00170547|BIOLOGICAL|Trivalent inactivated influenza vaccine|A synthetic vaccine consisting of three inactivated influenza viruses: two different influenza type A strains and one influenza type B strain. Group 1: 382 subjects receive 6 mcg ID with BD system. Group 2: 382 subjects receive 9 mcg ID with BD system, all doses on day 0.
224260347|NCT00170547|BIOLOGICAL|Trivalent inactivated influenza vaccine|A synthetic vaccine consisting of three inactivated influenza viruses: two different influenza type A strains and one influenza type B strain..Group 3: 382 subjects receive 3 mcg Fluzone ID using Mantoux technique on day 0.
224260348|NCT00151593|OTHER|Celsior®|Graft preservation solution
224260349|NCT04890353|DRUG|Dimethyl fumarate|Dimethyl fumarate 240mg orally twice daily for 3 consecutive days
224260350|NCT05723393|PROCEDURE|Erector spinae plane block|fascial plane injection guided by ultrasound
224260351|NCT00489177|DEVICE|A|QuickOpt intra-cardiac electrogram optimization
224260352|NCT00489177|DEVICE|B|Single optimization in initial month post-implant
223618412|NCT03737123|DRUG|Atezolizumab|Atezolizumab 1,200 mg IV Day 1 of each 21 day cycle
223618413|NCT03737123|DRUG|Docetaxel|Docetaxel 75 mg/m2 IV Day 1 of each 21 day Cycle.
223618414|NCT00633971|OTHER|complex lymphedema therapy|Patients with established post thrombotic syndrome will be randomized to either compression stocking use or complex lymphedema therapy.
223618415|NCT04715113|OTHER|Normobaric hypoxia (FiO2 15%)|"Inhalation of deoxygenated air through an altitude simulator (Altitrainer), for approx. 1/2 hour given by a facemask, first at rest and then during exercise."
223618416|NCT04715113|OTHER|Placebo-ambient air (FiO2 21%)|"Inhalation of room air through an altitude simulator (Altitrainer), for approx. 1/2 hour given by a facemask, first at rest and then during exercise."
223618417|NCT04715113|OTHER|Normobaric hypoxia (FiO2 15%) under Sildenafil|"Inhalation of deoxygenated air through an altitude simulator (Altitrainer), for approx. 1/2 hour given by a facemask, first at rest and then during exercise under Sildenafil."
223618418|NCT04715113|OTHER|Placebo-ambient air (FiO2 21%) under Sildenafil|"Inhalation of room air through an altitude simulator (Altitrainer), for approx. 1/2 hour given by a facemask, first at rest and then during exercise under Sildenafil."
223773656|NCT05940675|BEHAVIORAL|Physical Activity (FitFirst)|To ensure that all children reach the recommended 3x30 minutes of vigorous activity per week, we will implement three weekly 40-minute sessions in the school curriculum. These sessions will be carried out throughout the study period and will encompass modified and varied sporting activities and games, which promote motivation, physical literacy, active involvement of all children, and high training intensity.
224206315|NCT05723042|OTHER|EMS with CIMT|The interventions are consisted of 3weeks of casting the unaffected limb followed by 5 weeks of transference activities.The assisting hand assessment AHA was used to measure bimanual activity performance at baseline,8 weeks, 16 weeks. 20-minute application of currents and resistance exercises for the respective muscles of the area. The intervention group with 11 patients underwent a program of CIMT for one hour daily for 14 consecutive days or two hours per day, six days per week and a total of 12 weeks. A follow-up will be performed 12 weeks after the intervention. The healthy upper limb will be immobilized by orthosis or cast for six hours a day . Electrotherapy will be applied with TENS for 15 minutes at intervals of 1000ms and with a pulse duration of 50ms. The square wave will be chosen to ensure that there will be sufficient muscle contraction
224206316|NCT05723042|OTHER|EMS|this group will only receive baseline exercises (ROM and flexibility exercises) than apply electrical stimulations at specific motor points. Electrotherapy will be applied with TENS for 15 minutes at intervals of 1000ms and with a pulse duration of 50ms. The square wave will be chosen to ensure that there will be sufficient muscle contraction
224206317|NCT00792675|OTHER|Aerobic and resistance exercise training|Exercise was performed 3 times per week. It consisted of 30 minutes of treadmill exercise at approximately 85% of heartrate max and 2 sets of 6 resistance weight lifting exercises resulting in volitional fatigue at 12 to 15 repetitions.
224206318|NCT06408454|DIAGNOSTIC_TEST|Gingival crevicular fluid collection|Samples were taken from two mandibular molar teeth. Before sampling, the sites were isolated with cotton rolls and then carefully dried with an air syringe to avoid saliva contamination. GCF was collected using sterile periodontal strips by gently inserting them into the gingival sulcus or pocket until slight resistance was noticed. After 30 s, the strips were collected into sterile tubes and immediately transported to the laboratory for storage (-40 °C) and posterior analysis.
224206319|NCT06408454|DIAGNOSTIC_TEST|periodontal test|A periodontist conducted the periodontal evaluation, which included a comprehensive assessment of clinical periodontal status, a full mouth manual periodontal charting, measurement of probing depth, clinical attachment level, bleeding on probing, and evaluation of mobility using a periotest device. Additionally, information regarding the patient's smoking status, frequency of smoking, and oral hygiene habits was obtained.
224206320|NCT03402165|DRUG|Sofosbuvir and Ledipasvir or sofosbuvir and daklatasuvir|Response to DAAD's and developing HCC
224206321|NCT02095626|DRUG|AP-301|orally delivered doses of 87.6 mg AP301 (dose per subject, 5 ml nebulizer filling dose) are inhaled every 12 hours for a total of 7 days
224206322|NCT02095626|DRUG|saline solution|placebo solution (0.9 % physiologic NaCl, 5 ml nebulizer filling dose) is inhaled every 12 hours for a total of 7 days
224206323|NCT04256057|DRUG|Magnesium Sulfate|After the induction of anesthesia, a loading dose of magnesium sulfate 50mg/kg in 100mL of isotonic saline as within 5 to 10 minutes(23) followed by a maintenance dose of 10 mg/kg/hr up to the end of surgery
224206324|NCT01283373|DRUG|DSTP3086S|DSTP3086S administered intravenously
224206325|NCT01283373|DRUG|DSTP3086S|Escalating intravenous dose
224206326|NCT00276731|DRUG|carboplatin|
224206327|NCT00276731|DRUG|cisplatin|
224206328|NCT00276731|DRUG|cyclophosphamide|
224206329|NCT00276731|DRUG|etoposide|
224206330|NCT00276731|DRUG|vincristine sulfate|
223618419|NCT00273338|DRUG|calcitriol|
223618420|NCT00273338|DRUG|docetaxel|
224206331|NCT00276731|PROCEDURE|conventional surgery|
224206332|NCT00276731|PROCEDURE|neoadjuvant therapy|
224206333|NCT00276731|RADIATION|radiation therapy|
224260353|NCT03036748|DIETARY_SUPPLEMENT|Standardized sodium diet|Dietary Supplement: Standardized salt diet 150 mmol NaCl per day given as three meals daily for 5 consecutive days.
224260354|NCT03036748|DRUG|Tbl amiloride|Drug: Amiloride Amiloride tablet 10 mg two times daily (morning and afternoon) for one day
224260355|NCT01328652|DRUG|dexlansoprazole|dexlansoprazole 60 mg once daily for 3 months
224260356|NCT01913405|BIOLOGICAL|PEGylated Recombinant factor VIII (rFVIII)|Lyophilized powder and solvent for solution for injection
224260357|NCT05896995|OTHER|Pilates Exercise|Pilates exercises target the deep muscles of the core, including the abdomen, lower back, hips, and glutes, while also engaging the whole body.
224260358|NCT05896995|OTHER|Mckenzie Exercise|The McKenzie Method emphasizes self-treatment and active patient involvement in the management of their condition. It involves a systematic assessment process to determine the most appropriate exercises and interventions for an individual based on their specific symptoms and movement responses.
224314487|NCT06125730|OTHER|DIME Beauty Eyelash Boost Serum|The test product contains Water, Glycerin, Amino Acids (Sodium PCA, Sodium Lactate, Arginine, Aspartic Acid, PCA, Glycine, Alanine, Serine, Valine, Proline, Threonine, Isoleucine, Histidine, Phenylalanine), Hyaluronic Acid, Panthenol, Aloe Leaf Extract, Niacinamide, Purslane, Chebulic Fruit Extract, Apple Fruit Extract, Tocopherol, Phenoxyethanol, Hexanediol, Ethylhexylglycerin, Biotinoyl Tripeptide-1, Myristoyl Pentapeptide-4.
223618421|NCT02173769|DRUG|Spiriva® Respimat®|Spiriva® Respimat® plus Striverdi® Respimat® or Spiriva® 18 Microgramm plus Striverdi® Respimat®
223618422|NCT02173769|DRUG|Striverdi® Respimat®|Spiriva® Respimat® plus Striverdi® Respimat® or Spiriva® 18 Microgramm plus Striverdi® Respimat®
224314488|NCT02590965|DRUG|Fruquintinib|After checking eligibility criteria, subjects will be randomized into Fruquintinib plus best supportive care group (treatment group) or placebo plus best supportive care group (control group) in a ration of 2:1.
223618423|NCT03382886|DRUG|Nivolumab|"Nivolumab will be administered as a 240mg IV infusion given once every two weeks (+/- 3 days).~Subjects will remain on study treatment for up to two years or until progression or excessive toxicity"
223618424|NCT03382886|DRUG|Bevacizumab|"Bevacizumab will be administered as an IV infusion from 1-10mg/kg in accordance with the appropriate subject cohort being examined as described below:~Dose level 1: 5 mg/kg intravenously once every two weeks Dose level 2: 10 mg/kg intravenously once every two weeks Dose level -1: 1 mg/kg intravenously once every two weeks~Dosing is based on actual body weight. There is no dose adjustment for obese or frail individuals. Dosing is recalculated if patient weight changes by more than 10% as reviewed by the principal investigator.~Subjects will remain on study treatment for up to two years or until progression or excessive toxicity"
223618425|NCT04123886|DRUG|SCB-313|SCB-313 Intrapleural injection, once daily. Single dose on Day 1 in Cycle 0 followed by 7-day safety assessment, then dose on Day 1,2,3 in Cycle 1 followed by 21-day observation .
223618426|NCT02490436|DRUG|Cetuximab|Randomized cross-over between cetuximab and placebo
223618427|NCT02490436|DRUG|Placebo|Randomized cross-over between cetuximab and placebo
223618428|NCT03534609|DEVICE|Lutronic Genius System|Treatment of the neck using the Lutronic Genius System
224206334|NCT06084273|OTHER|Bobath Exercises|"The Bobath approach aims to enhance postural and neuromotor control goal-directedly, leading to functional improvement. Our study selected the Bobath 30 exercises from the fundamental exercises to create a program specific to the goal and targeting functionality.~The ten Bobath exercises performed by all participants in the study are as follows: Bridging Exercise, Latissimus Stretch Exercise, Autoinhibition Exercise, Dorsiflexion Training, Sitting Balance Training, Upper Extremity Weight Shifting Exercise, Lower Extremity Weight Shifting Exercise, Oblique Abdominal Strengthening Exercise, Knee Control Training, and Walking Training."
224206335|NCT06084273|OTHER|Breathing Exercises,Breathing Exercises, Bobath Exercises|"The puckered lip breathing exercise aims to prevent the closure of the small airways by creating pressure during expiration. During the exercise, the individual is asked to follow these steps:~1. Breathe calmly and slowly through the nose.~2. Pucker the lips as if whistling or inflating a balloon.~3. Exhale the breath with puckered lips. Relaxation exercises Progressive Muscle Relaxation Technique: Progressive muscle relaxation is one of the easiest methods to learn and apply, developed by Jacobson. It involves voluntarily tensing and relaxing large muscle groups regularly and sequentially. The participant was encouraged to wear comfortable clothing, breathe deeply, and exhale. The technique can be performed in a sitting or lying position. Music can be played to contribute to the participant's relaxation."
224206336|NCT00357474|PROCEDURE|Transarterial chemoembolization|lipiodol, adriamycin and/or mitomycin
224206337|NCT00357474|PROCEDURE|Percutaneous ethanol injection therapy|99% ethanol 2-4cc per one session, two to three sessions per single procedure for one week
224206338|NCT04071366|DRUG|Itacitinib|Part 1: Itacitinib 200 mg once daily for 30 days. Part 2: Itacitinib 200 mg twice daily for 30 days.
224314489|NCT02590965|DRUG|Placebo|Placebo is a capsule in the form of 1mg and 5mg, orally, once daily, 3 weeks on/1 week off
224314490|NCT05717465|OTHER|Anatomy diagrams|"The visual aids used included:~* An anatomical diagram illustrating how a lumbar puncture is carried out~* Paling palette, diagram illustrating the number of individuals affected by a particular condition~* Paling perspective scale, diagram comparing the risk of an event occurring in comparison to other 'everyday' risks"
223618429|NCT02832544|DRUG|Rivaroxaban (20 mg)|Rivaroxaban is non-inferior to VKAs for the prevention of stroke or systemic embolism in patients with AF/flutter and RVHD and potentially superior to VKAs.
223618430|NCT02832544|DRUG|Vitamin K antagonists (VKA)|
223618431|NCT00132574|BEHAVIORAL|Minimization of milk and dairy products in the diet|
223618432|NCT05647135|OTHER|Medical food|enteral formulas with different protein composition
223618433|NCT03112681|DRUG|Saroglitazar magnesium 2 mg|Saroglitazar magnesium 2 mg once daily in the morning before breakfast without food, for a period of 16 weeks.
223618434|NCT03112681|DRUG|Saroglitazar magnesium 4 mg|Saroglitazar magnesium 4 mg once daily in the morning before breakfast without food, for a period of 16 weeks.
223618435|NCT03112681|DRUG|Placebo Oral Tablet|Placebo once daily in the morning before breakfast without food, for a period of 16 weeks.
223618436|NCT06552273|BEHAVIORAL|Emotional Reasoning bias correction training|Emotional Reasoning Bias correction training involves 12 daily self-applied sessions focusing on psychoeducation about emotions and identifying ER biases and their impact on behaviour.
223618437|NCT06552273|BEHAVIORAL|Module of Mindfulness of the Transdiagnostic treatment|Module based on mindfulness using techniques for training in awareness and acceptance of experiences, observing experiences as they arise without judgment.
223618438|NCT05489341|DIAGNOSTIC_TEST|Histopathology and Magnetic Resonance Imaging with Follow-Up|Reference standard establishes histologically-confirmed (ISUP ≥ 2) cases of csPCa as positives, and histopathology- (ISUP ≤ 1) or MRI- (PI-RADS ≤ 2) with follow-up (≥ 3 years) confirmed cases of indolent PCa or benign tissue as negatives.
223618439|NCT05489341|DIAGNOSTIC_TEST|Histopathology and Magnetic Resonance Imaging|Reference standard establishes histologically-confirmed (ISUP ≥ 2) cases of csPCa as positives, and histopathology- (ISUP ≤ 1) or MRI- (PI-RADS ≤ 2) confirmed cases of indolent PCa or benign tissue as negatives.
223618440|NCT00318084|DRUG|Esomeprazole|
223618441|NCT00318084|PROCEDURE|Ambulatory 24-hour esophageal pH-monitoring|
223618442|NCT02701517|DRUG|Cyclosporine + METHOTREXATE|MTX days +1, +3, +6 and +11 followed by rescue with folinic Ac. All patients receive CSA from day -7.
223618443|NCT02701517|DRUG|Cyclosporine + CAMPATH-1H|CAMPATH-1H at a dose of 20 mg / day at 8-hour intravenous infusion on days -8 to -4. All patients will receive CSA from day -7.
223618444|NCT02682381|DRUG|Teduglutide 0.05mg/kg|0.05 mg/kg
223618445|NCT02682381|DRUG|Teduglutide 0.025 mg/kg|0.025 mg/kg
223618446|NCT02682381|OTHER|Standard of Care|Observational cohort for the 24-week treatment period and 4 week follow-up.
224206339|NCT04071366|DRUG|Immune effector cell therapy|Participants will receive IEC therapy that is approved by the health authority in the country where the study is being conducted for any approved hematologic indication.
224206340|NCT04071366|DRUG|Placebo|Participants will receive placebo twice daily.
224206341|NCT04071366|BIOLOGICAL|Yescarta|Eligible participants are receiving Yescarta (An infusion of chimeric antigen receptor (CAR)-transduced autologous T cells) for relapsed or refractory larbe B-cell lymphoma or follicular lymphoma intravenously.
224206342|NCT02162901|BEHAVIORAL|Choice-Class with IVR Calls|The intervention for this arm consists of an educational program which is an adaptation of the 16 lessons from the original Diabetes Prevention Program, both Core and After-Core sessions. After attending one 2-hour class to be introduced to the program and set goals, these lessons are delivered to the participant through 22 Interactive Voice Response telephone call over a period of 12 months.
224206343|NCT02162901|BEHAVIORAL|Random-Class with IVR calls|The intervention for this arm consists of an educational program which is an adaptation of the 16 lessons from the original Diabetes Prevention Program, both Core and After-Core sessions. After attending one 2-hour class to be introduced to the program and set goals, these lessons are delivered to the participant through 22 Interactive Voice Response telephone calls over a period of 12 months.
224206344|NCT02162901|BEHAVIORAL|Random-Class only|The intervention for this arm consists of an educational program which is an adaptation of the 16 lessons from the original Diabetes Prevention Program, both Core and After-Core sessions. After attending one 2-hour class to be introduced to the program and set goals, these lessons are delivered to the participant through a printed workbook.
224206345|NCT02162901|BEHAVIORAL|Choice-DVD with IVR calls|The intervention for this arm consists of an educational program which is an adaptation of the 16 lessons from the original Diabetes Prevention Program, both Core and After-Core sessions. After watching a DVD at home to be introduced to the program and set goals, these lessons are delivered to the participant through 22 Interactive Voice Response telephone calls over a period of 12 months.
224206346|NCT02162901|BEHAVIORAL|Random-DVD with IVR calls|The intervention for this arm consists of an educational program which is an adaptation of the 16 lessons from the original Diabetes Prevention Program, both Core and After-Core sessions. After watching a DVD at home to be introduced to the program and set goals, these lessons are delivered to the participant through 22 Interactive Voice Response telephone calls over a period of 12 months.
224206347|NCT05570968|PROCEDURE|C-arm device|Percutaneous Transluminal Angioplasty
224206348|NCT00858234|DRUG|Vorinostat|Vorinostat (MK-0683) three or four 100 mg capsules taken by mouth with food.
224206349|NCT00858234|DRUG|Bortezomib|Bortezomib (1.0 or 1.3 mg/m\^2) intravenous infusion.
224206350|NCT06317363|OTHER|Base Line + ACEPELLA|Group A (baseline treatment + acapella) consisting of 15 participants will receive (baseline treatment aerosol therapy, ACBT, Mobilization, breathing with arm elevation with addition to using Acapella). The primary and secondary outcome measures will be assessed at baseline post-op day 1, and after 1 week of surgery.
224206351|NCT06317363|OTHER|Base Line + Manual Chest Physiotherapy|The group B consisting of 15 participants will receive base line treatment. aerosol therapy, ACBT, Mobilization, breathing with arm elevation with addition chest physiotherapy percussing for 20 minute. The s primary and secondary outcome measures will be assessed at baseline post-op day 1, and after 1 week of surgery.
224206352|NCT01629134|DEVICE|Crosslinked hyaluronic acid gel|All treatments are carried out according to the physician's experience and the Directions for Use
224206353|NCT04264663|DRUG|Furazolidone|Furazolidone-tetracycline-containing quadruple regimens
224206354|NCT04264663|DRUG|Tinidazole|tinidazole-tetracycline-containing quadruple regimens
223618447|NCT05301985|DIETARY_SUPPLEMENT|preoperative nutrition|The participants of experimental group consumed 400 ml of a clear carbohydrate drink (12,5 gr/100 ml carbohydrate, 50 kcal/100 ml, pH 5.0) at 10:00 pm the evening before surgery and 200 ml of the carbohydrate drink on the day of surgery, 2 hours before induction of anesthesia. After surgery the participants fasted until the recovery of function of the bowel.
223618448|NCT02155634|DRUG|Lenalidomide|Treatment with lenalidomide capsules 10 mg, 5mg daily or 5mg every other day given on days 1-21 of each 28 day cycle.
223618449|NCT03985241|DIAGNOSTIC_TEST|Functional Assessment of Myocardial Ischemia by icECG|
223618450|NCT04354792|DIAGNOSTIC_TEST|Serum SARs COV 2 IGg screening in health care workers|Blood samples will be collected from the enrolled HCWs. Sample collection, processing, and laboratory testing will follow guidance from the World Health Organization
223618451|NCT04956536|OTHER|Demographic data and MRI images were extracted and analyzed|Demographic data and MRI images were extracted and analyzed. Related factors for anterior tibial subluxation were examined in anterior cruciate ligament-injured patients.
223618452|NCT04796597|DEVICE|Subcutaneous implantation of Epios sub-scalp leads|The sub-scalp Epios Leads will be implanted by a trained neurosurgeon and will provide epicranial EEG recording of specific cortical areas identified by the neurologist.
223618453|NCT03016312|DRUG|Atezolizumab|Atezolizumab will be administered at a fixed dose of 1200 milligrams (mg), intravenous (IV) infusion on Day 1 of each 21-day cycle.
223618454|NCT03016312|DRUG|Enzalutamide|Enzalutamide capsules will be administered orally at a dose of 160 mg daily.
223618455|NCT05412147|DIETARY_SUPPLEMENT|RECO-18|4 pills daily, oral
223618456|NCT05412147|DIETARY_SUPPLEMENT|Multi-vitamins|one tablet daily, oral
223618457|NCT00308139|DRUG|exenatide, long acting release|
223618458|NCT00308139|DRUG|exenatide|
223618459|NCT00721006|BIOLOGICAL|MESENDO|40 subcutaneous injections of biological product
223618460|NCT00721006|BIOLOGICAL|Placebo|40 subcutaneous injections of placebo
223618461|NCT04718623|DIAGNOSTIC_TEST|Quantitative determination of serum Presepsin (sCD-14), and Syndecan-1 concentrations|Quantitative determination of serum Presepsin (sCD-14), and Syndecan-1 concentrations by ELISA technique
223618462|NCT00823862|DRUG|SD-101|Intramuscular (IM)
223618463|NCT00823862|DRUG|ribavirin|oral, 2 times per day, for 2 months
223618464|NCT05656339|DIETARY_SUPPLEMENT|CHO+WP|Oral supplement containing carbohydrates plus whey protein
223618465|NCT05656339|DIETARY_SUPPLEMENT|CHO|Oral supplement containing carbohydrates
223618466|NCT05656339|DIETARY_SUPPLEMENT|Fast|Fast condition of 12 hours
224206355|NCT02808663|BIOLOGICAL|fecal calprotectin concentration|
224206356|NCT02808663|BIOLOGICAL|blood collection|
224206357|NCT01207063|OTHER|Radiotherapy and concurrent chemo-therapy|Radiotherapy and concurrent chemo-therapy
224206358|NCT04023318|BEHAVIORAL|Integrated Lifestyle Intervention|This program is grounded in data demonstrating the dysregulation across multiple domains and considerable life stressors experienced by this population. The central hypothesis is that by simultaneously ameliorating psychological dysregulation and directly targeting proinflammatory behaviors, ILI operates on multiple proposed mediators of poor treatment outcomes in this population, thereby enhancing treatment outcomes. As such, the overall framework emphasizes integration of self-regulation as it applies to both psychological functioning and weight control. Content will highlight the interconnectedness of mood, stress, eating and exercise behaviors, and risk for inflammation and disease. Each treatment session will present a combination of behavioral and psychological content, representing a truly integrated approach. Participants will meet for 75-minute group sessions weekly for months 1-2, followed by bi-weekly groups in months 3-4, for a total of 12 groups.
224206359|NCT01379079|DRUG|Acetylsalicylic acid|aspirin intake at bedtime
224206360|NCT01379079|DRUG|Acetylsalicylic acid lysinate|aspirin intake on awakening
224206361|NCT03711669|BEHAVIORAL|Immunosuppression withdrawal|IS will be tapered gradually over a period of 6 months. Azathioprine will be stopped during the first 3 months, reducing the dose 50% every month. Prednisone will be tapered 2.5mg monthly until total withdrawal. During withdrawal and the first year after stopping treatment patients will undergo laboratory tests on a monthly basis, afterwards follow-up will be done every 3 months until the end of the project.
224206362|NCT01523769|PROCEDURE|Umbilical Cord Milking|Approximately 10 cm of umbilical cord was milked toward the baby immediately following delivery. (The blood remaining in the umbilical cord after delivery is squeezed in the direction from the placenta (remaining inside the uterus) toward the newborn baby.)
224206363|NCT05110950|PROCEDURE|No suction EBUS-TBNA|"The needle is moved from a side to side of the lymphnode for 15 times. Each lymphnode is sampled three times.~The samples obtained will be examined on-site by experienced blinded cytopathologist.All specimens obtained will be send to definitive cytological and histological evaluation and the final diagnosis will be collected and reported on CRFs."
224206364|NCT05110950|PROCEDURE|Passive suction through dedicated EBUS-TBNA syringe|"The needle is moved from a side to side of the lymphnode for 15 times. Each lymphnode is sampled three times.~The samples obtained will be examined on-site by experienced blinded cytopathologist.All specimens obtained will be send to definitive cytological and histological evaluation and the final diagnosis will be collected and reported on CRFs."
224206365|NCT05110950|PROCEDURE|Manual applied suction EBUS-TBNA through a pistol-grip syringe holder|"The needle is moved from a side to side of the lymphnode for 15 times. Each lymphnode is sampled three times.~The samples obtained will be examined on-site by experienced blinded cytopathologist.All specimens obtained will be send to definitive cytological and histological evaluation and the final diagnosis will be collected and reported on CRFs.."
224206366|NCT00640614|BIOLOGICAL|T.R.U.E. TEST® Skin Patch Test: Dose Response Allergens|"Polyvinylpyrrolidone (PVP; excipient 1) Hydrocortisone-17-butyrate, 0.020 mg/cm2 in PVP Hydroxypropylcellulose (HPC; excipient 2) MDBGN, 0.0055 mg/cm2 in PVP Bacitracin, 0.60 mg/cm2 in HPC Gold sodium thiosulfate, 0.075 mg/cm2 in HPC Parthenolide, 0.0030 mg/cm2 in PVP Disperse Blue 106, 0.050 mg/cm2 in PVP Bronopol, 0.25 mg/cm2 in PVP~Test patches, with allergens, are placed at day one and removed 48 hours later. The duration of the study lasts 21 days. However, the subject is only exposed to the study allergens for 48 hours."
224206367|NCT00529802|DRUG|RAD001|take 2 tablets of RAD001 once a day by mouth (10 mg per day)
224206368|NCT03446079|OTHER|Topical Anti Aging Cream|Primary Subjects will take a saliva based genetic test and apply a topical anti aging cream for 6 weeks.
224206369|NCT02692352|OTHER|Goal Management Training|Goal Management training, 8 sessions of 2 hours
224206370|NCT02692352|OTHER|Brain Health Workshop|Brain Health Workshop training, 8 sessions of 2 hours
224206371|NCT05736952|DRUG|Oral Topotecan Combined With Anlotinib|Topotecan hydrochloride capsules: 2 mg, once daily, oral with dinner for 5 days, discontinued for 16 days, that is, 21 days (3 weeks) as a course of treatment, a total of 6 courses of administration.；Anlotinib hydrochloride capsules: 10mg once a day, oral before breakfast, continuous administration for 14 days, discontinuation for 7 days, that is, 21 days (3 weeks) as a course of treatment.
224206372|NCT04366778|DIAGNOSTIC_TEST|TEM-tPA|325 patients with Covid-19 hospitalized in Lyon University Hospitals will have TEM-tPA measurements in parallel to D-dimers every 3 days during the hospitalization period. TEM-tPA of patients with and without thrombosis will be compared and their fibrinolysis (PAI-1, TAFI, tPA, thrombin) will be further explored.
224206373|NCT00003583|DRUG|amifostine trihydrate|
224206374|NCT00003583|DRUG|cisplatin|
224206375|NCT00003583|DRUG|etoposide|
224206376|NCT00003583|RADIATION|radiation therapy|
224314491|NCT05717465|OTHER|Standard informed consent|Audio narration of a video containing text information relating to the lumbar puncture procedure (including risks) and an image of a consent form
224314492|NCT06381557|DRUG|Zhengyuan Capsules|Zhengyuan capsules, 4 capsules at a time, 3 times per day;
224314493|NCT06381557|DRUG|Placebo contains 5%-10% Zhengyuan Capsule total mixed powder|Zhengyuan capsules simulator（Placebo contains 5%-10% Zhengyuan Capsule total mixed powder）, 4 capsules at a time, 3 times per day;
223618467|NCT06304961|BIOLOGICAL|Tozorakimab|Tozorakimab will be administered as a single SC dose on Day 1.
223618468|NCT06792708|DRUG|LUMRYZ|Prescribed for narcolepsy in accordance with product label.
223618469|NCT05957679|DIAGNOSTIC_TEST|Magnetic Resonance Elastography|Undergo MRE and routine MRI
223618470|NCT05957679|PROCEDURE|Assessment and Recording|Undergo grading and recording of tumor stiffness and adhesion during surgery
223618471|NCT06840015|DEVICE|Airpod Pro as hearing assistive technology|All participants will use and evaluate four types of assistive technology: hearing aids, Airpod pro 2nd and 3rd generation, dedicated wireless remote microphones, and Smartphone wireless remote microphone.
224206377|NCT03185247|BEHAVIORAL|Transdiagnostic Group-Based Treatment|10 week 90-minute weekly therapy sessions including both the adolescent and caregiver. Treatment will consist of psychoeducation about dysautonomia, motivational interviewing techniques to promote readiness for change, support around lifestyle and behavioral changes, core CBT components (e.g., relaxation training, linking thoughts, feelings, and behaviors, minimizing catastrophizing thoughts, cognitive coping, and exposure), and components of ACT aiming to increase cognitive flexibility (e.g., mindfulness, experiential avoidance, values, cognitive defusion, committed action), and relapse prevention and maintenance. Most sessions will involve homework assigned to the adolescent and their parent/legal guardian(s) to encourage practice at home.
224314494|NCT00904657|DRUG|sunitinib (Sutent)|50 mg capsule Sutent, one application a day for five days
224314495|NCT02279108|DRUG|indocyanine green|One injection, 2.5 milligrams per patient, intradermal use
223618472|NCT04935957|DEVICE|GLUCUBE device|device to monitor and measure the blood glucose compared to the standard glucometer in a group subjects
223618473|NCT06296589|BEHAVIORAL|Trauma Informed Guilt Reduction Therapy|Behavioral therapy for trauma related guilt and shame
223618474|NCT06296589|BEHAVIORAL|Prolonged Exposure Therapy|Behavioral exposure therapy for PTSD
224206378|NCT03715673|DIAGNOSTIC_TEST|von willebrand antigen and activity|Measuring von Willebrand antigen and activity (VWF: RCo and VWF: CB)
224206379|NCT02185235|DEVICE|Electrical Stimulation|"The Chartered Society of Physiotherapy recommends the following standard for electrical devices.~Frequency: 35 Hertz. Pulse width: 250µs (0.25ms). Current type: bi-phasic rectangular. Intensity: maximum tolerated. Duty-cycle: 5 seconds on/10 seconds off. Very weak muscles: 5 seconds on/15 seconds off.~Treatment time: 5 minutes initially, gradually increasing to 20 minutes."
224206380|NCT02185235|DEVICE|Biofeedback|Biofeedback is a treatment technique in which people are trained to improve their health by using signals from their own bodies
224206381|NCT02185235|OTHER|Pelvic Floor Training|"First, as you are sitting or lying down, try to contract the muscles you would use to stop urinating To contract the pelvic muscles, squeeze for 3 seconds and then relax for 3 seconds.~Repeat this exercise to 20 minutes each session."
223618475|NCT05191394|DIAGNOSTIC_TEST|Evolution of antibodies titre|For each patient included in this study, 3 blood samples of 5 ml(serum) will be collected at well-defined time points: at the beginning of an TPE session, at the end of the same session, and at the beginning of the consecutive TPE session.
223618476|NCT03301558|DRUG|Low dose sodium bicarbonate|1500 mg sodium bicarbonate
224206382|NCT04386668|OTHER|Let It Out (LIO)-C|Participants complete three online 20-minute writing sessions in response to prompts asking them to write about their experiences during the COVID19 pandemic from a self-compassionate perspective
224206383|NCT04386668|OTHER|Neutral writing control|Participants complete three online 20-minute writing sessions in response to neutral writing prompts
224206384|NCT01573494|OTHER|Sampling of blood|7,5 ml of blood
224206385|NCT02278731|OTHER|training program|Participants were randomly allocated to 1 of 3 groups: Pilates group (n=20), which underwent one-month (three times per week) training program with the Pilates method; PNF group (n=20), that underwent one-month (three times per week) training program using the PNF method; and Control group (n=18), that received no intervention during that one month and continued with their daily activities.
224206386|NCT04093726|OTHER|lollipop|chewing lollipop for 20min
224206387|NCT02675426|DRUG|Placebo|Tablet; Oral
224206388|NCT02675426|DRUG|Upadacitinib|Tablet; Oral
224206389|NCT05467865|OTHER|ZELIAKIDE|"The nutrition education program will be adapted to the curriculum of the schools. The intervention will consist of 8 sessions and the main topics will be: (1) to understand the balanced diet and to apply it to one´s own diet, (2) to learn what celiac disease and gluten are, (3) to promote social inclusion.~Each session will last 60 minutes and they will take place during school hours. The whole intervention will last 4 weeks, 2 sessions per week. Teaching-learning process will be developed through games and experiments.~Designed activities are based on IBL methodology, which has proven to be very effective in science teaching-learning processes. As a result, inquiry-oriented TLS has been developed, focused on facilitating children's understanding of the research process."
224206390|NCT06310473|DRUG|Cadonilimab|10mg/kg intravenous (IV) every 3 weeks ;
224206391|NCT06310473|DRUG|Oxaliplatin|130mg/m², iv drip for 2h, d1, q3w;
224206392|NCT06310473|DRUG|Capecitabine|1000mg/m² po, Bid, d1-14, q3w ;
224206393|NCT04911673|BEHAVIORAL|music|Participants listened a song with headphones that lasts 29 minutes and 32 seconds for four days (three days before menstruation and the first day of menstruation).
224206394|NCT04911673|DIETARY_SUPPLEMENT|Chocolate group|Participants ate 40 mg of dark chocolate with 60% cocoa per a day for four days (three days before menstruation and the first day of menstruation) that was given by researchers to them.
224206395|NCT02830230|DRUG|Tab cefixime,Tab Azithromycin|The women with clinical cervicitis will receive treatment for cervicitis.
224314496|NCT02279108|DRUG|isotope|One injection, 20 MBq techntium99, intradermal use
224314497|NCT03446807|DRUG|Droxidopa|Droxidopa in 100, 200, and 300mg capsules. Maximum dose to be used in this study is 600mg.
224314498|NCT03446807|DRUG|Placebo Oral Tablet|Placebo capsules to match Droxidopa 100, 200, and 300mg capsules.
224314499|NCT03885115|BEHAVIORAL|Intervention|Involves 12-weeks of education related to healthy behaviors, nutrition, and exercise from certified fitness instructors.
224314500|NCT03915405|DRUG|KHK2455|orally, once daily.
224314501|NCT03915405|DRUG|Avelumab|IV Administration
224314502|NCT01661062|OTHER|Cone Beam Computed Tomography (CT) Scan|Cone beam CT scan is considered a noninvasive procedure (meaning that the procedure does not require breaking the skin or any tools that physically enter the body). It will add a small amount of additional radiation dose (less than 1%) to the head and neck. The increase in the amount of radiation is only a very small amount more than what patients who get standard daily imaging receive. The amount of radiation from the cone beam CT scans is not significant (less than 1%) when compared to the amount of radiation generally received for treatment of head and neck cancer.
224314503|NCT04410614|PROCEDURE|Free epithelial (gingival) graft|1mm thickness epithelial layer harvested from the palate (1st molar area) is grafted and stabilised at the dental or implant area deficient of keratinized mucosa
224314504|NCT03281759|DEVICE|Transcranial LED Therapy (Active coil helmet)|The patients will undergo 18 sessions of repetitive transcranial LED stimulation.
223618477|NCT03301558|DRUG|High dose sodium bicarbonate|3000 mg sodium bicarbonate
223618478|NCT02246049|BIOLOGICAL|Bevacizumab|Given IV
223618479|NCT02246049|DRUG|5-fluorouracil|Given IV
223618480|NCT02246049|DRUG|Irinotecan hydrochloride|Given IV
223618481|NCT02246049|DRUG|Leucovorin calcium|Given IV
223618482|NCT02246049|DRUG|Oxaliplatin|Given IV
223618483|NCT01884077|DEVICE|Reverse Shoulder Arthroplasty|REVERSE In a Reverse Total shoulder the ball is located on the shoulder blade (glenoid) and the socket is located on the arm bone (humerus), exactly the opposite of the situation in a conventional total shoulder. The ball (glenosphere) is screwed to the bone of the shoulder blade. The cup (humeral sock¬et) is fixed to a stem that is cemented down the inside of the arm bone (humerus).
223618484|NCT01884077|DEVICE|Total Shoulder Arthroplasty|TOTAL In a conventional Total shoulder, the arthritic surface of the ball is replaced with a metal ball with a stem that is press fit in the inside of the arm bone (humerus) and the socket is resurfaced with a component.
223618485|NCT01052155|OTHER|Urine Drug Testing|LC/MS/MS Laboratory Evaluation
223618486|NCT04508881|DEVICE|Ahmed Glaucoma Valve|To compare the prevalence of postoperative hypotony between the 2 arms
223618487|NCT05580523|DRUG|75 mg acetylsalicylic acid|75 mg acetylsalicylic acid (C9H8O4, CAS number 50-78-2) daily, Oral
223618488|NCT05580523|DRUG|1.5g Metformin|up to 1.5 g metformin (C4H11N5, CAS number 657-24-9) daily, Oral Dose increases from 0.5g to 1.0g to 1.5g
224206396|NCT02277639|DEVICE|CliniMACs device|Reduced intensity conditioning with chemotherapy followed by stem cell transplant using the CliniMACs device to deplete CD3+ CD19+ peripheral stem cells.
224206397|NCT04052074|OTHER|Music Therapy|We are aiming to use music therapy, with pre-recorded favoured music, as a complementary treatment in oncological patients in palliative care, as well as on the carer. It will be performed using mp3 players or mobile phones.
224206398|NCT04052074|OTHER|simulation with therapeutic education|Basic therapeutic education repetition performed to all caregivers and oncological patients in palliative care, through earphones
224206399|NCT02156466|DRUG|MSB0010841|MSB0010841(Anti- IL-17A/F Nanobody) will be administered at a dose of 30 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.
224206400|NCT02156466|DRUG|MSB0010841|MSB0010841 will be administered at a dose of 60 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.
224206401|NCT02156466|DRUG|MSB0010841|MSB0010841 will be administered at a dose of 120 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.
224206402|NCT02156466|DRUG|MSB0010841|MSB0010841 will be administered at a dose of 240 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.
224206403|NCT02156466|DRUG|Placebo|Placebo matched to MSB0010841 will be administered as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.
223618489|NCT05580523|DRUG|150 mg acetylsalicylic acid|150 mg acetylsalicylic acid (C9H8O4, CAS number 50-78-2) daily, Oral
223618490|NCT05580523|DRUG|Placebo of acetylsalicylic acid and Metformin|Pills with shape, color and smell same with acetylsalicylic acid and metformin, daily, oral
223618491|NCT00981149|DRUG|duloxetine|Evaluate the analgesic effect of 30 mg duloxetine twice daily in comparison to matching placebo at baseline (BL) and follow up over a six week period
224206404|NCT05226468|DRUG|NEI-01|"Part1:~Single dose period: Intravenous single dose of NEI-01 with 4 ascending dose levels.~Multiple dose period: Intravenous weekly dose of NEI-01 for 9 weeks with 4 ascending dose levels.~Part2:~Intravenous weekly dose of NEI-01 at the recommended dose obtained from Part 1"
224206405|NCT01462552|DRUG|Lapatanib|Prescription of lapatinib (Tykerb)
223618492|NCT00981149|DRUG|Placebo|Placebo match duloxetine for 6 week period.
223618493|NCT00303823|DRUG|placebo|Given orally
223618494|NCT00303823|DIETARY_SUPPLEMENT|defined green tea catechin extract|Given orally
223618495|NCT00303823|OTHER|laboratory biomarker analysis|Correlative studies
223618496|NCT06135961|DEVICE|eCTG monitoring with the NFMS|Device: Nemo Fetal Monitoring System (Nemo Healthcare B.V., Veldhoven, the Netherlands)
223618497|NCT01826396|DRUG|Irinotecan|Comparison of standard and high dose irinotecan
223618498|NCT03497065|PROCEDURE|non-surgical periodontal treatment|scaling, root planing, polishing, and oral hygiene education was performed
223618499|NCT05925946|DIETARY_SUPPLEMENT|CURE-DM|"1. This randomized controlled prospective trial will be of 2 years duration where 150 patients with T2DM from urban areas of Delhi will be screened.~2. These subjects will be randomized into two groups by computer-generated randomization list using variable block size.~3. Group A (n, 60, test group)will be received a low-calorie diet along with appropriate exercise counseling; and group B (n, 60, Control group) will be received balanced diet along with exercise advice."
223618500|NCT05757648|DRUG|Non-buffered Anesthetic|non-buffered LA, 2% lidocaine with epinephrine 1:100,000
223618501|NCT05757648|DRUG|Buffered Anesthetic|A cartridge of 2% lidocaine with epinephrine 1:100,000 alkalinized at 9:1 ratio with a resulting pH of 7.21 using 8.4% sodium bicarbonate solution per manufacturer.
223618502|NCT05757648|DEVICE|Onset|"The test solution will be made by a mixing pen called Onset- This mixing pen Onset will deliver 0.18 mL of sodium bicarbonate solution into the anesthetic cartridge."
224206406|NCT00637052|DRUG|ARRY-520, KSP(Eg5) inhibitor; intravenous|Part 1: multiple dose, escalating; Part 2: multiple dose, single schedule; Part 3: multiple dose, single schedule.
224206407|NCT02010970|DRUG|Group 1 AZD3293|AZD3293 oral solution
224206408|NCT02010970|DRUG|Group 2 AZD3293|AZD3293 oral solution
224206409|NCT02010970|DRUG|Group 3 AZD3293|AZD3293 oral solution
224206410|NCT02010970|DRUG|Group 1 Itraconazole|itraconazole capsule
224206411|NCT02010970|DRUG|Group 2 Diltiazem|Diltiazem ER tablet
224206412|NCT02010970|DRUG|Group 3 Midazolam|midazolam syrup
224206413|NCT05539599|DIAGNOSTIC_TEST|Comprehensive evaluation|Non-ultrasound parameters: Central venous pressure, hand-grip strength evaluation, P0.1, Maximal inspiratory pressure, Blood gas analysis ultrasound parameters: Diaphragmatic displacement, thickening fraction, TFmax, E/e', Triscuspidal annular Plane Systolic Excursion, Lung score
224206414|NCT01001715|DRUG|REGN475/SAR164877|"Pharmaceutical form: solution~Route of administration: intravenous infusion over 30 minutes"
224206415|NCT01001715|DRUG|Placebo (for REGN475/SAR164877)|"Pharmaceutical form: solution~Route of administration: intravenous infusion over 30 minutes"
224206416|NCT00080288|DRUG|Armodafinil 150 mg/day|Armodafinil 150 mg taken 30 minutes to 1 hour before the start of the night shift, but no later than 2300, only on nights worked.
224206417|NCT00080288|DRUG|Placebo|Matching placebo tablets once daily
224206418|NCT03582007|DRUG|Murepavadin|Murepavadin + ertapenem
223618503|NCT00721448|DRUG|AZD6140|90mg tablet, oral, once daily for the first day and twice daily from day 4 to 9
224314505|NCT03281759|DEVICE|Transcranial LED Therapy (Inactive coil helmet)|The patients assigned to this group will undergo 18 sessions of transcranial LED but with an inactive coil, which will not generate LED emissions, only a similar red light color.
223618504|NCT00721448|DRUG|AZD6140|90 x 2 mg tablets, oral, once daily for the first day and twice daily from day 4 to 9
223618505|NCT02071199|DRUG|1X ACCS (Amnion-derived Cellular Cytokine Solution)|1X ACCS will be applied to the gingival margin daily 5 days per week for 2 weeks
223618506|NCT02071199|DRUG|Normal saline|Saline will be applied to the gingival margin daily 5 days per week for 2 weeks
223618507|NCT02071199|DRUG|0.3X ACCS|0.3X ACCS will be applied to the gingival margin daily 5 days per week for 2 weeks
224206419|NCT03582007|DRUG|One anti-pseudomonal antibiotic|Either meropenem or piperacillin-tazobactam
224206420|NCT01794156|BEHAVIORAL|Cognitive behavior therapy|
224206421|NCT01794156|BEHAVIORAL|Mindfulness-based stress reduction|
224314506|NCT03247179|OTHER|PTSD Coach mobile application|The PTSD Coach app is publicly available for free, and draws on cognitive behavioral therapy components to help participants learn, manage, and cope with their PTSD symptoms in real time.
224314507|NCT00599053|DRUG|Azithromycin|10 mg/kg IV per dose given for 10 days
224314508|NCT05456958|OTHER|MRI Biofeedback|We will use state-of-the-art fMRI and neurofeedback of brain signals in order to teach patients with PTSD to self-regulate pathological brain activity that is associated with their symptoms. Indeed, feedback information is crucial for learning, where rt-fMRI-based neurofeedback makes information about brain activity accessible to our consciousness (Ros et al., 2014; Sitaram et al., 2017). It thus provides a reinforcement signal to induce personalized learning mechanisms, allowing individuals to search for appropriate cognitive strategies to voluntarily control brain activity. The feedback signal will come from activity within either the amygdala or PCC.
224314509|NCT05456958|OTHER|Sham-MRI Biofeedback|In the sham-control arm (N=20), individuals will receive fake neurofeedback signal, i.e., from a successful participant in one of the experimental arms.
224314510|NCT05906524|DRUG|KD6001|KD6001 will be administered intravenously.
224314511|NCT05906524|DRUG|Tislelizumab|Tislelizumab will be administered intravenously.
224314512|NCT05906524|DRUG|Bevacizumab|Bevacizumab will be administered intravenously.
224314513|NCT00381433|DRUG|AVI-4065 Injection|
223618508|NCT01220167|DRUG|Ondansetron 8 mg ODFS without water|Single dose of Ondansetron 8 mg (ODFS) administered without water
224206422|NCT01794156|BEHAVIORAL|Inference-based therapy|
224206423|NCT06520228|BEHAVIORAL|Active video games|The experiment was divided into two groups. One experimental group, one control group. The experimental group received an active video game intervention for 12 weeks, 40 minutes twice a week. The control group underwent 12 weeks of traditional physical activity, 40 minutes twice a week.
224206424|NCT06520228|BEHAVIORAL|Traditional sports games|The experiment was divided into two groups. One experimental group, one control group. The experimental group received an active video game intervention for 12 weeks, 40 minutes twice a week. The control group underwent 12 weeks of traditional physical activity, 40 minutes twice a week.
224314514|NCT02734407|PROCEDURE|Assigned Intervention|All subjects receiving PRN IVT aflibercept injections will be evaluated for focal laser treatment beginning at week 12 through the end of the study as assigned intervention. If the subject meets any of the criteria for focal laser treatment (FLT), fluorescein angiography (FA) will be performed to guide the focal laser treatment. Focal laser treatment and focal laser re-treatment will be administered no more than once every 90 days.
224314515|NCT02734407|DRUG|aflibercept 2.0 mg|If a subject has recurrent CR-DME they will receive an IVT aflibercept injection
224314516|NCT05291611|BEHAVIORAL|Online-based Cognitive-behavioral Therapy for OCD|26 patients with obsessive-compulsive disorder (OCD) receive treatment with cognitive-behavioral therapy. 14 sessions will take place via the internet.
223618509|NCT01220167|DRUG|Ondansetron 8 mg ODFS with water|Single dose of Ondansetron 8 mg (ODSF) was orally administered, allowed to dissolve, swallowed with saliva, followed with water
223618510|NCT01220167|DRUG|Zofran ODT (ondansetron 8 mg) without water|Single dose of Zofran ODT (containing ondansetron 8 mg) administered without water
223618511|NCT04674007|OTHER|3D analysis of landing task|Landing tasks (anticipated, unanticipated and cognitive dual task) are investigated with 3D analysis by using an opto-electronic system
223618512|NCT01028417|DEVICE|Platinum microcoil|Coil Name: Vortx-18, Diamond Shape, Boston Scientific, Cork, Ireland; Coil Description: 80 mm long, fibre coated 0.018 inch diameter platinum microcoil
223618513|NCT00395655|DRUG|Hydralazine and magnesium valproate administration|
223618514|NCT00395655|PROCEDURE|Core-needle biopsy of the breast|
223618515|NCT05599750|PROCEDURE|Incisional hernia repair|Participants will undergo incisional hernia repair
223618516|NCT05789745|DRUG|Recombinant human plasma gelsolin|intravenous administration of either 6, 12, 18, or 24 mg/kg at time 0, 12, 36, 60 and 84 hours
223618517|NCT05789745|OTHER|placebo|intravenous administration of saline control at time 0, 12, 36, 60 and 84 hours
223618518|NCT05400655|DRUG|L9LS|Administered subcutaneously.
223618519|NCT05400655|OTHER|Normal Saline|Administered subcutaneously.
223618520|NCT03203252|OTHER|Reconstruction BREAST-Q|Validated Patient reported outcome measure specifically designed to assess Quality of life domains and satisfaction following breast reconstruction.
223618521|NCT03203252|OTHER|3-dimensional Surface Image|Non-invasive 3-dimensional photograph using VECTRA® XT 3D imaging system.
223618522|NCT03203252|OTHER|Treatment Questionnaire|Online questionnaire pertaining to treatment received pertaining to breast cancer or risk reduction for breast cancer.
224206425|NCT01066273|DEVICE|P-Stim|The P-Stim is a battery-powered, transcutaneous electrical stimulator that delivers 1 per second bipolar 1 millisecond pulses to three points on the auricle. The device connects via three fine insulated stainless steel wires to three needles (each 0.4 mm diameter, 2 mm long) that have been applied to three different points on the auricle. The device is powered by three zinc air batteries, each with a voltage of 1.4 V. The device is on for 180 minutes, then off for 180 minutes, for a maximum period of up to 96 hours. The battery and electronics are contained in a 6 mm by 2.5 mm pack that has one adhesive surface which is applied to the skin behind the ear. The adhesive is conductive and acts as the return for the device. The battery pack is secured with tape.
224206426|NCT01325857|PROCEDURE|Bilateral superficial cervical plexus block|Bilateral superficial cervical plexus block with 0.525% ropivacaine 20ml
224314517|NCT03296111|OTHER|Questionnaires on pain and quality of life|"Patients will be asked to complete several questionnaires about their pain and the impact on their quality of life.~They will complete the questionnaires in the ophthalmology consultation room or at home and return it by mail (or present it at the next consultation).~Patients will be asked to complete several questionnaires :~* Questionnaire about the characteristics of ocular neuropathic pain (7 items)~* DEQ-5 (Dry Eye Questionnaire)~* ODI (Ocular Surface Disease Index)~* BPI (Brief Pain Inventory)~* HADS (Hospital Anxiety and Depression Scale)"
224314518|NCT00377832|DRUG|Acetaminophen 975 mg|Acetaminophen 975 mg by mouth once only
224314519|NCT02108093|PROCEDURE|retrograde autologous priming|Retrograde autologous priming (RAP) is a technique where, the patient's own circulating blood partially replaces the priming solution in the CPB.
224314520|NCT04969731|DRUG|Immuncell-LC|IV
224206427|NCT01325857|PROCEDURE|placebo|Procedure: Bilateral superficial cervical plexus block with normal saline 20ml
224206428|NCT01325857|PROCEDURE|Control group|Procedure: Local anesthetic infiltration at incision site with 0.525% ropivacaine 20ml
224206429|NCT05744531|OTHER|Internet-based Parenting Education based on the information -Motivation-Behavioral Skills (IMB) Model|Internet-based Parenting Education based on the information -Motivation-Behavioral Skills (IMB) Model
224206430|NCT04470622|DRUG|Aprepitant injectable emulsion|Aprepitant injectable emulsion, once daily (QD) for 14 days.
224206431|NCT04470622|DRUG|Saline Placebo|Saline Placebo, once daily (QD) for 14 days.
224206432|NCT05274399|OTHER|surveys and questionnaires|The data containing the questions determining the relationship between the self-care power and hopelessness of the patients who voluntarily participated in the study were collected through a questionnaire.
224206433|NCT04121299|DRUG|Carvedilol|Carvedilol 40mg Extended Release Once Daily
224206434|NCT04121299|DRUG|Amlodipine|Amlodipine 10mg Once Daily
224206435|NCT02614937|DRUG|ranibizumab|0.5 mg IVT ranibizumab
224206436|NCT02614937|DRUG|Squalamine Lactate Ophthalmic Solution, 0.2%|Squalamine Lactate Ophthalmic Solution BID
224206437|NCT03719729|DRUG|Rifaximin|Administer daily rifaximin to modify intestinal microbiome to alter the course of the disease.
224206438|NCT06334978|OTHER|Osteopathic intervention|The experimental group received the same treatment as the control group and one osteopathic intervention per week for the 21 days of the study (days 2, 9 and 16). Each session was performed on a different day from the conventional treatment to prevent interactions. The physiotherapist performed an osteopathic assessment involving a static/dynamic inspection and palpation and other osteopathic tests: Mitchell test, Quick Scanning, standing flexion (Piedallu) test, Gillet test, sphenobasilar synchondrosis (SBS) test, sutural palpation test and diaphragm test. Techniques used: the dog technique in flexion, scalene muscle energy technique, Jones' first rib adjustment, first rib trust in posterior subluxation, occipitomastoid thrust, Sutherland's posterior needle-scratch, SBS decompression, semi-direct thrust for the sacrum, Sutherland's sacrum, posterior occipital condyle thrust, SBS equilibration.
224206439|NCT01286337|PROCEDURE|bipolar vessel sealing|
224206440|NCT01286337|PROCEDURE|control|
224206441|NCT04768829|DRUG|Moringa oleifera leaf 10mg/100ml|ear drops
224206442|NCT04768829|DRUG|Ear Drop|plain ear drop formulation without moringa
224206443|NCT02321215|OTHER|Introductory Disease Education|This intervention will consist of two one-on-one education sessions, each lasting 30 minutes.
224206444|NCT01990079|DRUG|Bupropion|All participants who are medically eligible will be prescribed bupropion, which they will start two weeks prior to their quit day. Dosage will be 150 mg/daily for days 1-7 and 300 mg/daily (administered in two daily doses) until the 3-month follow-up.
224206445|NCT01990079|DRUG|nicotine replacement therapy|Participants will be prescribed NRT patch and one nicotine rescue method (e.g., nicotine gum, lozenge, inhaler) for use during the post-quit phase of the study. Participants will be given the choice between nicotine gum, nicotine inhaler, or nicotine nasal spray, and will be instructed to use the rescue method as needed to reduce cigarette cravings
224206446|NCT01990079|OTHER|Smoking cessation counseling|Participants will receive four 20-minute smoking cessation counseling sessions and a participant manual. The four sessions are based on standard cognitive-behavioral therapy techniques shown to be efficacious for smoking cessation.
224206447|NCT01990079|BEHAVIORAL|mobile contingency management|Participants will be asked to provide video recordings of themselves taking carbon monoxide readings in order to confirm smoking abstinence. Participants are asked to upload these videos to the study's secured server, and are provided monetary reward for videos that suggest smoking abstinence.
224206448|NCT01990079|OTHER|Stay Quit Coach|Stay Quit Coach is a smart phone application that serves as a source of readily available support and information for adults who are already in treatment to quit smoking and to help them stay quit after treatment. The app guides user in creating tailored plans that include their personal reasons for quitting, interactive tools to help users cope with urges to smoke, motivational messages, support contacts to help users stay smoke free and how to address lapses. Participants assigned to this condition will be asked to use Stay Quit Coach from Session 2 through the 6-month follow-up.
224314521|NCT04969731|DRUG|Gemcitabine|IV
224206449|NCT03759418|DEVICE|exclusion of the left atrial appendage|A trans esophageal echocardiogram will be performed to assess the Atriclip device in the closure of the left atrial appendage in patients that had surgery at least 12 months ago.
224314522|NCT04048291|BEHAVIORAL|Brisk walking and balance training|6 months of combined brisk walking and balance training
224314523|NCT04048291|BEHAVIORAL|Upper limb exercise|6 month of hand dexterity training
224314524|NCT06434974|OTHER|Interview|Interviewer administered questionnaire
224206450|NCT02953262|BEHAVIORAL|My HealtheVet Brochure|Participants will receive a mailed brochure with basic My HealtheVet content.
224206451|NCT02953262|BEHAVIORAL|My HealtheVet Training Guide for Veterans Living with Diabetes|Participants will be mailed a bound My HealtheVet training guide with step by step instructions on how to register, upgrade to Premium account, refill prescriptions, use secure messaging, download their Blue Button reports, and other features
224206452|NCT02953262|BEHAVIORAL|My HealtheVet Group Training|Participants will be invited to participate in a scheduled group training to learn how to use My HealtheVet to help manage their diabetes
224206453|NCT02953262|BEHAVIORAL|My HealtheVet Individual Training|Participants will be invited to participate in a one-on-one training to learn how to use My HealtheVet to help manage their diabetes at a time of their convenience.
224206454|NCT03225066|DEVICE|Poly-L-lactic acid - Sculptra|Participants using Sculptra - Poly-L-lactic acid 3 sessions in the first side and 3 sessions on the second side
224206455|NCT01453101|DRUG|Fludarabine monophosphate, melphalan, Bortezomib|"* Fludarabine will be administered at a dose of 30/mg/m2 IV daily for 4 days starting on transplant day -5.~* Melphalan will be administered at a dose of 140 mg/m2 on transplant day-2~* Bortezomib will be administered by rapid IV push at a dose of 1.6mg/m2 on days-4 and -1. The bortezomib should be given at least 20 hours after the melphalan."
224206456|NCT02177864|DIETARY_SUPPLEMENT|Fiber|
224206457|NCT02177864|OTHER|Placebo (low fiber bar)|
224206458|NCT01506063|DRUG|Levocetirizine DiHCl|Levocetirizine DiHCl Tablets 5 mg
224206459|NCT01838863|BIOLOGICAL|Type AB plasma|The plasma is thawed and administered to subjects in the experimental (plasma) arm.
224206460|NCT01838863|DRUG|Crystalloid fluid (standard of care for resuscitation)|Normal saline will be give to subjects in the standard arm as the current standard of care for an initial resuscitation fluid
224206461|NCT00729703|DEVICE|Ovatio DR 6550|Dual-chamber ICD therapy with minimized ventricular pacing
224206462|NCT00729703|DEVICE|OVATIO DR 6550|Single-chamber device therapy with settings which are common in clinical practice.
224206463|NCT05633095|DEVICE|Neuclare|It is used to stimulate the brain for a certain period of time to improve cognitive impairment in patients with cognitive disorder. In this clinical trial, it is used for patients with mild cognitive disorder and demincia symptoms.
224206464|NCT00004288|DRUG|olsalazine|
224206465|NCT02214004|DRUG|Trastuzumab|"\- Eight times IV administration of trastuzumab per 3 weeks~* Trastuzumab 8mg/kg on Day 1 of Cycle 1~* Trastuzumab 6mg/kg from Day 1 of Cycle 2 to Day 1 of Cycle 8"
224206466|NCT02214004|DRUG|Letrozole|\- Daily letrozole 2.5 mg/day for 24 weeks
224206467|NCT00695604|DRUG|Placebo|Placebo via MDI.
224206468|NCT00695604|DRUG|Fluticasone|Fluticasone MDI.
224206469|NCT04604496|DRUG|PF-06882961 20MG|PF-06882961 in 20 mg oral tablet will be administered on Day 1
224206470|NCT01835808|DEVICE|Fractional flow reserve (St. Jude Medical pressure-wire)|CAD patients submitted to coronary angiography and in which coronary lesions are to be evaluated with pressure-wire (FFR functional evaluation)
224206471|NCT00765999|DRUG|Linaclotide|Linaclotide capsules, oral, once daily each morning at least 30 minutes before breakfast for the duration of the study.
224206472|NCT00148473|DRUG|Misoprostol|
224206473|NCT06371547|OTHER|Stretching Exercise|Participants will perform different types and durations of gastrocnemius muscle stretching exercises according to their assigned groups for two weeks.
224206474|NCT00532454|DRUG|Tamoxifen|tamoxifen 20mg, PO, QD until disease progression
224206475|NCT01608776|DEVICE|MIST Therapy|The MIST Therapy System is used as a non-contact method of delivering ultrasound to treat chronic wounds.
224206476|NCT01608776|OTHER|SOC - Standard of Care|Standard of Care includes wound cleansing and debridement as needed, moist wound healing dressings, and offloading
224206477|NCT00694031|PROCEDURE|Hemodialysis|3 times per week
224206478|NCT00694031|PROCEDURE|On-line hemodiafiltration|3 times per week
224206479|NCT02410031|DRUG|Cyproterone acetate 2mg/ethinylestradiol 35 μg (Diane-35)|Cyproterone acetate 2mg/ethinylestradiol 35 μg
224206480|NCT05829473|OTHER|Breathing Exercise Group|A total of 1 times day diaphragmatic breathing exercise will be made on 3 consecutive days (5 minutes diaphragmatic breathing exercise, 5 minutes relaxation exercise). Diaphragmatic breathing exercises will be performed at least 4 hours after the use of antiemetic drugs in the service. 20 minutes from the diaphragmatic breathing exercise application. Afterward, post-test data will be obtained using the Nausea-Vomiting Severity Evaluation Test During Pregnancy and Pregnancy-Related Anxiety scales. A total of 6 measurements will be made using the scales on the 1st, 2nd, and 3rd days.
224206481|NCT05829473|OTHER|Guided Imagery Group|10 minutes once a day for pregnant women with hyperemesis gravidarum who meet the research criteria the guided imagery compact disc will be played with the computer. A guided imagery compact disc will be watched at least 4 hours after the use of antiemetic drugs in the service.10 minutes once a day for pregnant women with hyperemesis gravidarum who meet the research criteria the guided imagery compact disc will be played with the computer. A guided imagery compact disc will be watched at least 4 hours after the use of antiemetic drugs in the service. Afterward, 20 minutes from the application post-test data will be obtained by using the Nausea-Vomiting Severity Assessment Test in Pregnancy and Pregnancy-Related Anxiety Scale-R2 scales. A total of 6 measurements will be made using the scales on the 1st, 2nd, and 3rd days.
224206482|NCT02069886|DRUG|deferasirox|125, 250, 500 mg dispersable tablets
224206483|NCT02039817|DRUG|IDN-6556|
224206484|NCT05294770|OTHER|Optisource® Plus: Very Low Calorie Diet treatment|Patients randomized to this group will receive a VLCD, which consists of a replacement diet based on a liquid enteral formula (46% carbohydrates, 19% fat and 32% protein; 654 Kcal/day): OPTISOURCE® PLUS, taken as 3 shakes a day. In addition, participants may consume 2 pieces of fruit/day (about 250 g/day) and up to 300 g/day of non-starchy vegetables according to the list of foods that will be provided to patients; this will constitute a total daily energy intake of about 800 Kcal. In addition, protein intake (0.8 to 1.3 g/kg/day of adjusted weight) will be adjusted by adding Resource® Instant Protein individually, depending on the anthropometry and the renal function of the patients (to preserve fat free mass, whose loss has been correlated with subsequent weight recovery)
224206485|NCT05294770|OTHER|Hypocaloric Mediterranean Diet|Randomized participants in this group will be recommended to follow a Mediterranean Diet, based on the use of olive oil as the main source of visible fat and regular consumption of vegetables (≥2 servings/day), fruits (≥3 servings/day), legumes (≥3 servings/week) and fish (≥3 times a week), reducing the consumption of red meat or sausages (\<2 times a week) and eliminating the consumption of sugary drinks, pastries or industrial pastries. In this Mediterranean Diet, an energy restriction of 30% of the estimated energy needs (Harris-Benedict equation) will be established.
224206486|NCT00197509|BEHAVIORAL|Sit-To-Stand Protocol and Extra Practice in Sit-To-Stand|
224206487|NCT06224478|OTHER|Measurement of palatal mucosa thickness on CBCT scans|Measurement of palatal mucosa thickness on CBCT scans in hypodovergent, normodivergent and hyperdivergent patients
224314525|NCT05341830|BEHAVIORAL|Recovery housing|Recovery housing provides housing and other services to individuals who are recovering from substance-use disorders. They provide a substance-free living environment, as well as services to assist residents with life in recovery. These services include connections to employment and educational opportunities, help obtaining documentation such as a driver's license, connection to mutual aid, and assistance building life skills.
224314526|NCT05309018|OTHER|Interviews|Semi-structured interview about perceptions and expectations of APN participation in AML monitoring according to patient and to care team.
224314527|NCT00271401|OTHER|Angioplasty|
224314528|NCT00271401|OTHER|Intracoronary Stent|
224206488|NCT02039583|OTHER|Smoke-free legislation|The intervention under study is the smoke-free legislation in England introduced overnight on 1 July 2007. As of this date virtually all enclosed public places and workplaces were by law required to be smoke-free. More detail can be found via the link provided at the end of this protocol.
224314529|NCT00271401|DRUG|Abxicimab|
224314530|NCT00271401|DRUG|Heparin|
224314531|NCT00271401|DRUG|Placebo|
224314532|NCT05567510|DRUG|BMS-986369|Specified dose on specified days
224314533|NCT00014352|DRUG|docetaxel|
224314534|NCT00014352|DRUG|doxorubicin hydrochloride|
224314535|NCT00014352|DRUG|estramustine phosphate sodium|
224314536|NCT00014352|DRUG|ketoconazole|
224314537|NCT00014352|DRUG|warfarin|
224314538|NCT02015065|DRUG|Vandetanib|Vandetanib administered orally once per day continuously using a 28 day cycle until disease progression or unacceptable toxicity
224314539|NCT01120704|DRUG|Short Term Combination Nicotine Replacement Therapy (patch + gum)|"IF participant smokes \>10 cigs/day AND is randomized to a 8 week condition: they will be asked to take one 21 mg patch/day for 4 weeks, THEN one 14 mg patch/day for 2 weeks, THEN one patch 7mg/day for 2 weeks.Participants will also be asked to use 4-mg gum every 1-2 hours (9 pieces maximum per day)for 6 weeks and decrease gum use over the 2 weeks prior to medication termination until down to one gum piece every 4-8 hours by the last week of treatment.~IF participant smokes 5-10 cigs/day AND is randomized to the 8 week medication condition: they will be asked to take one 14 mg patch/day for 4 weeks, THEN one 7 mg patch/day for 4 weeks. Participants will also be asked to use 2-mg gum every 1-2 hours (9 pieces max per day)for 6 weeks and decrease gum use over the 2 weeks prior to medication termination until down to one gum piece every 4-8 hours by the last week of treatment."
224314540|NCT01120704|DRUG|Long Term Combination Nicotine Replacement Therapy (patch + gum)|"IF the participant smokes \>10 cigs/day AND is randomized to a 26 week medication condition: they will be asked to take one 21 mg patch per day for 22 weeks, THEN one 14 mg patch per day for 2 weeks, THEN one patch 7 mg patch per day for 2 weeks. Participants will also be asked to use one piece of one 4-mg- gum every 1-2 hours (9 pieces maximum per day)for 24 weeks and decrease gum use over the 2 weeks prior to medication termination until they are down to one gum piece every 4-8 hours by the last week of treatment.~IF the participant smokes 5-10 cigs/day AND is randomized to a 26 week medication condition: they will be asked to take one 14 mg patch per day for 22 weeks, THEN one patch 7 mg patch per day for 4 weeks. Participants will also be asked to use one piece of 2-mg gum every 1-2 hours (9 pieces maximum per day)for 24 weeks and decrease gum use over the 2 weeks prior to medication termination until they are down to one gum piece every 4-8 hours by the last week of treatment."
223512559|NCT05287685|BEHAVIORAL|School Readiness Parenting Program|The SRPP is an 8-week parenting program for parents of preschool aged children with externalizing behavior problems. The SRPP targets child externalizing behavior problems specifically, as well as to help parents promote children's school readiness skills. The SRPP follows a group Parent-Child Interaction Therapy (PCIT) model and also uses motivational interviewing and modelling problem solving approaches. The SRPP utilizes a large group format (10-15 parents) with weekly sessions lasting 1.5 hours. The SRPP curriculum contains traditional aspects of behavioral management strategies (e.g., improving parenting skills and the parent-child relationship; discipline strategies such as time out). Specific sessions of the SRPP also directly target parental interactions during children's learning activities and setting up homework and household structure and routines. In its original form, SRPP does not address children's screen time.
223512560|NCT00920270|DRUG|nebulized colistin|nebulized colistin 75 mg every 12 hours
223512561|NCT00920270|DRUG|antibiotics|conventional parenteral antibiotics
223512562|NCT04541693|DEVICE|Full revision|Both cup and stem require revision
223512563|NCT04541693|DEVICE|Cup revision|Only the cup requires revision
223512564|NCT04541693|DEVICE|Stem revision|Only the stem requires revision
224206489|NCT03888131|DRUG|CHF 1535 100/6 µg pMDI plus Symbicort® Turbohaler® Placebo|Fixed combination of beclometasone dipropionate 100 µg plus formoterol fumarate 6 µg (BDP/FF)
224206490|NCT03888131|DRUG|Symbicort® Turbohaler® plus CHF 1535 pMDI Placebo|Fixed combination of 160 µg budesonide + 4.5 µg formoterol fumarate (BUD/FF)
224206491|NCT06234124|DEVICE|Variable Friction Shoe Training|The experimental group (A) will be given a pair of VF shoes and instructed to use shoes on both feet. This group will be instructed to walk on hard surfaces to engage auditory feedback of the VF shoes. This group group will be monitored daily using actigraphy and will receive weekly check-up telephone calls by a member of the research team to record number of steps, walking time, a scale for self-identified effort and perceived safety levels.
224206492|NCT06234124|DEVICE|Ankle Foot Orthosis (AFO) Training|The control group (B) will be provided an AFO to use on the paretic limb. This group will be instructed to walk on hard surfaces. This group group will be monitored daily using actigraphy and will receive weekly check-up telephone calls by a member of the research team to record number of steps, walking time, a scale for self-identified effort and perceived safety levels.
224314541|NCT01120704|BEHAVIORAL|Intensive Maintenance Counseling|Participants randomized to this condition will receive eight 15-minute phone counseling sessions at Weeks 3, 4, 6, 8, 10, 14, 18 \& 22. The counseling will encourage continued practice of coping skills, and avoidance of danger situations. Another emphasis will be the continued provision of social support as a means of enhancing motivation. Participants who have relapsed will receive counseling aimed at motivating and planning renewed quit attempts. Other aims are enhancing motivation, especially competence self-appraisals, providing intratreatment support, and encouraging pleasurable activities.
224314542|NCT01120704|BEHAVIORAL|Cognitive Medication Adherence Counseling (CAM)|Participants randomized to this condition will be given a brief (10 minute) session of CAM treatment at both Visits 1 and 2. CAM will include information on NRT such as the following: NRT reduces withdrawal and urges; sustained use reduces the likelihood of relapse; willpower and medication make a good combination; NRT will help a lapsing smoker reachieve abstinence. The tailored counseling component of the CAM intervention is based on brief evaluation of the smoker's beliefs, concerns, and possible misconceptions about smoking cessation medications.
224314543|NCT01120704|BEHAVIORAL|Electronic Medication Monitoring Device (the Helping Hand) + Feedback|If randomized to this condition, the case manager will give patients a computer-generated feedback sheet showing the patient's medication self-administration since the last visit. The case manager will provide problem-solving counseling regarding barriers to medication use. This problem-solving counseling intervention will be given in brief in-person sessions (three in-person sessions for those in the 8 week medication condition and five in-person sessions for those in the 26 week medication condition). Medication monitoring counseling will also occur via phone (two 10-minute sessions for those in the 8 week medication condition and four 10-minute sessions for those in the 26 week medication condition).
224314544|NCT01120704|BEHAVIORAL|Automated Adherence Prompting Phone Calls|"Participants in this condition will receive fully automated prompts with messages designed to encourage participants to take their medication.~Adherence prompting calls will occur two times in the first week of the quit attempt, and then once a week in weeks 2, 3, 4, 5, and 7. Those in the 26-Week medication condition who are assigned to the active adherence prompting calls intervention, will receive one prompting call a week during Weeks 11, 15, 19 \& 23."
224314545|NCT05810584|DEVICE|Revision LR femoral stem|Revision LR is a modular femoral stem used for hip replacement
224314546|NCT01061268|DRUG|No topical artificial tear|40 patients randomized to not using a topical artificial tear.
224314547|NCT01061268|DRUG|Blink® Tears Lubricant Eye Drops|Blink® Tears Lubricant Eye Drops
223618524|NCT04410172|DIAGNOSTIC_TEST|Mirror and prope|Mirror and probe will be used for each patient. Mirrors for proper visualization especially for maxillary teeth, explorers will be used to aid in tactile sensation.
223618525|NCT03140397|DIETARY_SUPPLEMENT|Placebo|
223618526|NCT03140397|DIETARY_SUPPLEMENT|6-prenylnaringenin|
223618527|NCT03140397|DIETARY_SUPPLEMENT|8-prenylnaringenin|
223618528|NCT03482531|OTHER|mathematical model|mathematical model: regression equation that calculates the mean time from insert placement to delivery for each patient, based on every patient's characteristics (parity, BMI, cervical dilation and state of membranes)
224206493|NCT03430037|DIETARY_SUPPLEMENT|Fisetin|Flavonoid Family
224206494|NCT03430037|DRUG|Placebo oral capsule|Placebo
224206495|NCT04458428|OTHER|SMS|"Patients who are randomized to the intervention arm will be signed up for the automated SMS program. This cohort will receive text messages after surgery, timed from the day of discharge through 14 days post-op. Patients in this cohort will receive text messages each day. The number of text messages varies on patient interest and yes responses to see additional information."
224206496|NCT04069208|DRUG|Idarubicin and cytarabine induction|Idarubicin 14mg/m2 for 3 days cytarabine 100mg/m2 every 12 hour for 7 days
224206497|NCT03949634|DRUG|PLD|pegylated liposomal doxorubicin is 35 mg/m2 intravenously on Days 1 of each 21-day cycle followed by cyclophosphamide.
224206498|NCT03949634|DRUG|CTX|cyclophosphamide is 600 mg/m2 intravenously on Days 1 of each 21-day cycle, followed by docetaxel or paclitaxel.
224206499|NCT03949634|DRUG|Docetaxel|docetaxel is 100 mg/m2 intravenously on Days 1 of each 21-day cycle.
224314548|NCT05141617|PROCEDURE|Endoscopic treatment|Patients in the endoscopic treatment receive endoscopic variceal ligation and N-butyl-cyanoacrylate according to the type of varices
224314549|NCT05141617|PROCEDURE|TIPS|Patients in the TIPS group receive Transjugular Intrahepatic Portosystemic Shunt
224314550|NCT02675569|PROCEDURE|Catheter|A method of vascular access for hemodialysis that all participants will have in place prior to randomization.
224314551|NCT02675569|PROCEDURE|Fistula|A type of vascular access strategy for hemodialysis which involves connecting the artery and the veins in the participant's arm.
224314552|NCT00755443|DEVICE|Drug eluting stent|Drug eluting stent implantation
224314553|NCT00755443|DEVICE|Bare metal stent|
224314554|NCT00109408|DRUG|Methotrexate|7.5-20mg po weekly
224314555|NCT00109408|DRUG|tocilizumab [RoActemra/Actemra]|8mg/kg iv every 4 weeks
224314556|NCT06012461|OTHER|Closed-loop DBS stimulation for 24 hours|Continuous closed-loop modulation for 24 hours
224314557|NCT06012461|OTHER|Open-loop DBS stimulation for 24 hours|Continuous open-loop modulation for 24 hours
224314558|NCT06012461|OTHER|Closed-loop DBS stimulation for 72 hours|Continuous closed-loop modulation for 72 hours
224314559|NCT06012461|OTHER|Open-loop DBS stimulation for 72 hours|Continuous open-loop modulation for 72 hours
224314560|NCT03363386|PROCEDURE|Proprioceptive Exercises|Patients trained for proprioceptive exercises
224314561|NCT03363386|PROCEDURE|Resistive Exercises|Patients trained for resistive exercises
224314562|NCT03363386|PROCEDURE|Aerobic Exercise|Patients were educated with treadmill walking for 30 minutes of each exercise session
223618529|NCT03242694|DIAGNOSTIC_TEST|LA pressure, voltage map, strain, scar-map, blood sampling|invasive LA pressure monitoring, LA voltage map creation, LA strain evaluation by transthoracal echocardiography, LA scar-mapping by cardiac MRI, defining biomarkers from blood samples during atrial fibrillation and after pulmonary vein isolation in sinus rhythm
223618530|NCT03242694|PROCEDURE|pulmonary vein isolation|pulmonary vein isolation without creating additional ablation lesions
223618531|NCT03232346|DRUG|Vivitrol|Oral naltrexone induction procedure followed by Vivitrol
224314563|NCT05162014|DRUG|empagliflozin|empagliflozin
224314564|NCT05162014|DRUG|Oral non-incretin/non-sodium glucose co-transporter-2 inhibitors (SGLT2)-containing hypoglycaemic agents|Oral non-incretin/non-sodium glucose co-transporter-2 inhibitors (SGLT2)-containing hypoglycaemic agents
224206500|NCT03949634|DRUG|Paclitaxel|paclitaxel is 80mg/m2 intravenously on Days 1, 8 and 15 of each 21-day cycle.
224314565|NCT02074618|OTHER|Physical exercise.|Physical exercises were held three times a week on alternate days to hemodialysis sessions, with duration of 45 to 90 minute, supervised by a physiotherapist. In all the sessions the following measurements were performed: body weight and blood pressure, heart rate and peripheral oxygen saturation in the pre, during and post session. The exercises were: heating and stretching during 5 minutes, followed by aerobic physical exercise on treadmill and/or bike (about 30 minutes), muscle strengthening exercises (15 to 20 minutes), cooling and stretching (5 minutes). The time for aerobic and strengthening varied according to the tolerance of the patient. The resistance exercises have been conducted for the major muscle groups of the lower limbs.
224314566|NCT03485365|DRUG|GSK3858279 IV|GSK3858279 will be available as solution for injection to be administered via IV route.
224314567|NCT03485365|DRUG|GSK3858279 SC|GSK3858279 will be available as solution for injection to be administered via SC route.
224314568|NCT03485365|DRUG|Placebo matching to GSK3858279 (SC or IV)|Placebo will be available as sodium chloride solution to be administered via SC or IV route.
224314569|NCT03485365|DRUG|Placebo matching to GSK3858279 (SC)|Placebo will be available as sodium chloride solution to be administered via SC route.
223618532|NCT03232346|DRUG|Buprenorphine|5-week buprenorphine taper
224314570|NCT00486941|BEHAVIORAL|Exercise and diet - based on DPS and DPP|
224314571|NCT02361242|DRUG|PXT00864|PXT00864 is a fixed-dose combination of baclofen and acamprosate
223618533|NCT01095432|PROCEDURE|PWS Testing|Partial wave spectroscopy (PWS)has been developed to allow scientists to learn about any changes to the cells that may indicate a risk of developing colon cancer.
223618534|NCT00327106|DRUG|Tranexamic acid (Exacyl)|15 mg/kg IV (in the vein), just before surgery and 3 hours after surgery
223618535|NCT00327106|DRUG|Placebo|NaCl 9‰, 0,15 ml/kg IV (in the vein), just before surgery and 3 hours after surgery.
223618536|NCT00139074|DRUG|Quetiapine fumarate|oral variable dose
223618537|NCT00139074|DRUG|sodium valproate|oral
223618538|NCT03371472|DEVICE|Visualisation and measuring of paravalvular leak.|Visualisation and measurements of PVL by investigational sizing ballons made by Balton. The balloon is a modification of diameter and length of existing sizing ballons (AcuMark™, AMPLATZER™, Occlutech®).
223618539|NCT02634333|PROCEDURE|Prompt Sham|A sham injection (syringe without a needle pressed against the injection site) is performed on the day of randomization and visits at 1, 2, and 4 months and then every 4 months thereafter.
223618540|NCT02634333|DRUG|Prompt aflibercept|Intravitreal injection of 2.0mg aflibercept is performed on the day of randomization and visits at 1, 2, and 4 months and then every 4 months thereafter.
223618541|NCT02634333|PROCEDURE|Deferred laser|Laser (either focal/grid laser for diabetic macular edema or panretinal photocoagulation for proliferative diabetic retinopathy) is added following initiation of anti-vascular endothelial growth factor injections for center-involved diabetic macular edema or proliferative diabetic retinopathy only if certain criteria are met
223618542|NCT02634333|DRUG|Deferred aflibercept|Intravitreal injection of 2.0mg aflibercept performed once proliferative diabetic retinopathy or center-involved diabetic macular edema develops and then up to every 4 weeks using defined treatment criteria.
223618543|NCT02646631|OTHER|Usual Care|Participants assigned to this treatment will receive the usual care as determined by their physician
223618544|NCT02646631|BEHAVIORAL|Management of Risks in Epilepsy (MORE)|MORE is a smartphone application which participants use to record information on a daily basis about seizures (severity, type), medications, and mood and stress levels. It also includes a camera-based application which uses a pill scanner and photo to record the identity and quantity (dose) of medications just prior to them being taken. Also included in the app are medication reminders, educational video clips, and self-management tips.
224206501|NCT03949634|DRUG|Doxorubicin|doxorubicin is 60 mg/m2 intravenously on Days 1 of each 21-day cycle followed by cyclophosphamide.
224314572|NCT04159870|DRUG|Rifaximin|Rifaximin pills 400 mg x 3/day
224314573|NCT04159870|DRUG|Norfloxacin|Norlfloxacin 400 mg 1 pill/day
224314574|NCT00339092|BEHAVIORAL|Modified Directly Observed Therapy|Treatment includes storefront modified directly observed therapy (MDOT) of prescribed antiretrovirals. Participants in the MDOT program will report to the study site each morning for 3 months, Monday through Friday, to take their HIV medication and any other medications prescribed by their primary care doctors. At the end of 3 months, participants will no longer attend the study site for medication assistance. Participants will then attend Action Point, a county program that helps participants adhere to taking medication, for an additional 3 months.
224314575|NCT00339092|BEHAVIORAL|Standard Care|Participants assigned to standard care will report to the study site once a month for 9 months, but will not receive any assistance with taking HIV medications. Information about medication adherence, housing, income, use of health services, drug use, sexual practices, and mental health services will be collected at each visit.
224314576|NCT06043687|DRUG|Dentifrice Paste|Scaling and Root planing followed by dentifrice usage
224314577|NCT05147324|BEHAVIORAL|"MyPlan - Individualized Planned Eating Pattern"|Sessions involve a structured behavior change counseling module derived from FLEX (NCT01286350), DASH-4-Teens (NCT00585832), and a Social Cognitive Theory and Transtheoretical Model informed conceptual framework, which uses education, motivation and self-efficacy enhancement, goal setting, and problem-solving skills training to initiate and sustain eating pattern adherence. Sessions support incremental progress towards meeting all five eating behavior goals by helping youth develop action plans, troubleshoot barriers to adherence, and refine action plans to improve adherence. Youth log in MyFitnessPal at least three days per week. Logs are used to assess and troubleshoot adherence, support youth in developing and refining action plans, and reward youth with points. Incentives are allocated using a point scheme designed to promote logging and goal achievement. Formal adjustment of the eating pattern is based on adherence according to logs and youth/guardian acceptability.
224314578|NCT04204473|DRUG|TY-9591(10mg,40mg) qd. po|Increased dose cohorts from low dose to MTD(20mg Cohort1, 40mg Cohort2, 80mg Cohort3,120mg Cohort4, 160mg Cohort5, 200mg Cohort6)
224314579|NCT03975231|DRUG|Dabrafenib|Given PO
224314580|NCT03975231|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
223618545|NCT02646631|BEHAVIORAL|Telephone-based motivational interviewing (MORE+MI)|Participants will receive a total of 4 motivational interviewing sessions over the phone. These sessions last approximately 20 minutes each and build on the educational materials already provided within the MORE app.
224314581|NCT03975231|DRUG|Trametinib|Given PO
223618546|NCT02646631|OTHER|Educational Materials|Printed educational materials on the management of epilepsy
223618547|NCT01546558|DRUG|Metformin|Metformin 1000 mg bid on Days 1-10
223618548|NCT01546558|DRUG|Ranolazine|Ranolazine 500 mg bid on Days 6-10
223618549|NCT02140515|DRUG|Lutropin alfa|Administration of Gonal-F or recombinant Follicle Stimulating Hormone (rFSH)
223618550|NCT02140515|DRUG|Follitropin alfa and Lutropin alfa|Administration of (rFSH) and (rLH)
224206502|NCT05254691|PROCEDURE|Sprinting|"The ventilator mode is switched to PS ventilation. The level of PS is set to meet the level of PS set when the patient is ventilated in the SIMV-PS mode. The patient will be in the PS mode until he or she clinically shows increased work-of-breathing (tachypnoea and the presence of nasal flaring and intercostal and/or interjugular retractions indicate increased work of breathing). This sprinting is performed on the theory that the respiratory muscles can be slowly trained to sustain complete spontaneous breathing. Also, theoretically this sprinting allows a better global and regional distribution of the tidal volume in the lung."
224206503|NCT00319488|DRUG|Inhaled Corticosteroid (Budesonide)|Participants will receive inhaled corticosteroid for 7 days, at the first sign of RTI-associated symptoms.
224206504|NCT00319488|DRUG|Leukotriene Receptor Antagonist (Montelukast Sodium)|Participants will receive leukotriene receptor antagonist for 7 days, at the first sign of RTI-associated symptoms.
224206505|NCT00319488|DRUG|Inhaled Albuterol|All participants will receive inhaled albuterol treatments four times a day.
224206506|NCT00490399|DRUG|gemcitabine|
224206507|NCT00490399|DRUG|cisplatin|
224206508|NCT02492009|BEHAVIORAL|Standard Resource Sheet|Women allocated to the control intervention will login to the study website and receive a printable PDF containing references to standard published information on antidepressant use in pregnancy. This ensures women have access to accurate information on the benefits and risks of antidepressant medication in pregnancy (even though they will not receive the PDA).
224314582|NCT01547130|DRUG|Normal (0.9%) saline|A total of 2L solution at lukewarm temperature (37.2-38.8 degrees Centigrade)consumed as bolus intake (8-16 oz in one to two minutes) alternating with yoga exercises.
224314583|NCT01547130|DRUG|HalfLytely|A total of 2L solution prepared as per manufacturers instructions and sipped until bowel movements are clear.
223618551|NCT03308916|DIAGNOSTIC_TEST|transient elastography|Ultrasound elastography using shear-wave elastography to measure liver stiffness as a marker of liver fibrosis. Patients with transient elastography above 8.0 kPa selected for liver biopsy to detect advanced liver fibrosis
223618552|NCT03308916|DIAGNOSTIC_TEST|Enhanced liver fibrosis test|Patented, commercially available algorithm of hyaluronic acid (HA), N-terminal propeptide of collagen type 3 (P3NP) and tissue inhibitor of metalloproteinase 1 (TIMP-1)
223618553|NCT03308916|DIAGNOSTIC_TEST|Indirect serum markers of liver fibrosis|Diagnostic markers using combination of routine liver biochemistry: age, AST, ALT, platelet count, cholesterol, GGT
223618554|NCT03308916|DIAGNOSTIC_TEST|Direct serum markers of liver fibrosis|Serum markers that reflect liver extracellular matrix turnover and -accumulation
223618555|NCT03308916|DIAGNOSTIC_TEST|LiverTRAIL|Software that contain 199 diagnostic algorithms, containing combinations of routine tests: age, AST, albumin, alkaline phosphatase, bilirubin, GGT, INR, platelet count, cholesterol and sodium, and specialist tests: transient elastography and direct serum markers of fibrosis.
224314584|NCT03408535|OTHER|Eriksholm Guide to Better Hearing|Online rehabilitation program.
224314585|NCT06050343|DRUG|Humulin® Regular|subcutaneous injection at a dose of 0.3 IU / kg
224314586|NCT06050343|DRUG|Rinsulin® R|subcutaneous injection at a dose of 0.3 IU / kg
224314587|NCT01324505|DRUG|semaglutide|Semaglutide will be administered once weekly by s.c. (under the skin) injections in the abdomen. A total of 13 doses of semaglutide will be administered according to a predefined dosing scheme
224314588|NCT01324505|DRUG|placebo|Placebo semaglutide will be administered once for securing eligibility of subjects (willingness and ability to self inject) at the screening visit.
224314589|NCT01324505|DRUG|Microgyn®|Microgyn® will be given as once daily oral dosing in two periods, each of 8 days' duration. One tablet contains levonorgestrel 0.15 mg and ethinylestradiol 0.03 mg.
224314590|NCT02965586|DRUG|intrathecal|intrathecal block will be performed in sitting position using 25 G spinal needle at either the L3-L4 or L4-L5 intervertebral spaces.
224314591|NCT05369312|DRUG|BPI-442096|Subjects will receive BPI-442096 until disease progression
223618556|NCT03308916|DIAGNOSTIC_TEST|Cytokeratin 18|Cytokeratin 18 from liver cell cytoskeleton; when cells undergo apoptosis, caspase-cleaved CK18 is released (M30), whereas full-length CK18 is realised during necrosis (M65)
223618557|NCT03308916|DIAGNOSTIC_TEST|Omics markers|Markers combining signatures of liver fibrosis and hepatic inflammation from many 'omics technologies
223618558|NCT03361085|PROCEDURE|nvHAP Prevention Bundle|oral care, (early) mobilization, diagnosis and treatment of dysphagia, respiratory physiotherapy, stop Proton pump Inhibitors (PPI) if reasonable
223618559|NCT06264011|BEHAVIORAL|Salaat|While Muslims perform mandatory salaat (prayer) 5 times daily, the Duha salaat is an optional daily prayer consisting of 4 cycles of standing, bowing, standing again, prostrating, kneeling, and prostrating again. Research has shown that salaat may influence physiological relaxation.
223618560|NCT06264011|OTHER|Sham comparator|Participants will count while mimicking the movements of the Duhaa salaat. This is a no-prayer condition in which the recitation of Qur'an is omitted for the sake of comparison.
223618561|NCT00902681|DRUG|Fesoterodine|A fesoterodine extended-release tablet (ER) formulation once daily administration of 8 mg
224314592|NCT05924607|OTHER|Standard clamshells method|The patient is asked to lie in a side-lying position with the weak limb up, both hips flexed at 45°, the knees flexed at 90°, and neither the feet nor back not in contact with the wall. Keeping both their heels and the first metatarsal head together, the patient separated their knees and rotated the weak limb upward. The patients is instructed not to tip it backward and to hold the pelvis in a neutral position
224206509|NCT02492009|BEHAVIORAL|Patient Decision Aid|"The electronic Patient Decision Aid (PDA) is an interactive website with 3 main sections:~1. Evidence-based information on (a) depression in pregnancy, (b) each treatment option and procedure;~2. (a) Evidence-based information on the risks and benefits of both untreated depression and antidepressant treatment, (b) exercises to help women determine which risks and benefits are most important to them; and~3. A summary section that outlines the information reviewed and which benefits and risks they deemed most important.~At the end of the PDA, women allocated to this intervention will ALSO receive the standard resource sheet which is being used as the placebo comparator."
224314593|NCT05924607|OTHER|Targeted VMO strengthening|Targeted VMO strengthening The patient is asked to lie in a supine lying position with arm next to the body. After that asked the patient to perform SLR exercise in an external hip rotation with the simultaneous contraction of the ankle dorsiflexors. Common treatment will be given to each patient includes hot pack for 10 minutes and knee isometric contraction exercises and SLR( 3-5 sets of 10 repetitions
224206510|NCT00256841|DRUG|Chemotherapy|
224206511|NCT00256841|PROCEDURE|Radiation Therapy|
224206512|NCT02185027|OTHER|complications and compliance with GIHP recommendations|Description of complications, compliance, major bleeding events, treatments, reversal strategies.
224206513|NCT05150340|DRUG|TAK-771|Intervention description; Immune Globulin Infusion (IGI) 10% and Recombinant Human Hyaluronidase (rHuPH20)
224206514|NCT05550259|PROCEDURE|protocolized postextubation support|The intervention corresponds to a protocolized use of HFNO or NIV after extubation in accordance with the risk of extubation failure: a) 24H HFNO in patient at low risk of extubation failure b) 48H NIV+/-HFNO in patients at high risk of extubation failure
224206515|NCT03681925|DIAGNOSTIC_TEST|Nutrition Literacy Assessment Instrument (NLit)|The NLit is a 64-question survey broken into 6 subscales. each subscale examines a different aspect of nutrition literacy (Nutrition and Health, Energy Sources in Food, Household Food Measurement, Food Label and Numeracy, Food Groups, and Consumer Skills). Global and subscale NLit scores will be generated for each participating patient.
224206516|NCT03981614|DRUG|Binimetinib|Given PO
224314594|NCT00229177|DRUG|ONO-2506|Once daily one-hour intravenous infusion at 12/mg/kg/hr for 7 days
224314595|NCT00229177|DRUG|ONO-2506|Once daily one-hour intravenous infusion at 0 mg/kg/hr for 7 days
224314596|NCT00229177|DRUG|ONO-2506|Once daily one-hour intravenous infusion at 8 mg/kg/hr for 7 days
224314597|NCT06983444|PROCEDURE|TURP|Using bipolar loop diathermy via cystoscopy, excess prostate tissue is resected piecemeal to remove obstruction to the prostatic urethra due to BPH.
224314598|NCT06983444|PROCEDURE|TUEP|Using bipolar enucleation loop diathermy via cystoscopy, to anatomically enucleate prostate.
224314599|NCT06982781|DEVICE|Flow Re-Direction Endoluminal Device System(FRED)|Flow Diverter (FD) devices are developed based on reconstructing the parent artery's lumen. FDs are designed with a denser mesh compared to conventional intracranial stents. By covering the aneurysm neck, these stents redirect blood flow away from the aneurysm, promoting intra-aneurysmal flow stagnation and subsequent thrombosis formation. Currently, FDs are primarily used for the treatment of wide-neck aneurysms.
224314600|NCT03553576|DRUG|Low volume bolus|Administration of a low-volume bolus (6.25 mL) of greater density solution (0.1% bupivacaine with fentanyl 2.0 mcg/mL) at 250 mL per hour given by CADD pump.
224314601|NCT03553576|DRUG|High volume bolus|Administration of a high-volume bolus (10 mL) of lower density local anesthetic (0.0625% bupivacaine with fentanyl 2.0 mcg/mL) at 250 mL per hour given by CADD pump.
224314602|NCT06983093|OTHER|Rain Stick|The rain stick to be used in the study is a toy made of wood, ranging in length from 20 to 120 cm. It is also a very entertaining musical instrument that imitates the sound of real rain. It is suitable for use by children aged 4 to 6. It has spiral shapes and colorful beads inside. When the rain stick is turned up and down, it produces a perfect rain sound that drizzles and patters. It is also known as a rain sound stick. The visual and auditory nature of the rain stick can distract the child during the blood collection process.
224314603|NCT06983093|OTHER|Musical Egg|The musical egg to be used in the study is a toy made of wood, approximately 6.5-7 cm in size. These wooden shaker eggs are a fun and interesting musical instrument. It is suitable for use by children aged 4-6. It is filled with iron sand and when shaken, it makes a clear sound and adds a unique rhythm to the music. This egg imitates the sound of maracas when shaken. Maracas are a musical instrument that makes a sound when shaken thanks to the parts in its hollow body. It is also known as musical eggs, egg shakers, musical egg maracas, Easter egg percussion instruments. The visual and auditory nature of the musical egg can distract the child during the blood collection process.
224314604|NCT01413490|DRUG|rimantadine|12 weeks of rimantadine therapy in addition to standard combination therapy with interferon and ribavirin
224314605|NCT05498779|PROCEDURE|Ablation therapy|Radiofrequency or microwave ablation
224314606|NCT00345657|DRUG|Niacin Extended Release/Lovastatin|
224206517|NCT03981614|DRUG|Palbociclib|Given PO
224206518|NCT03981614|DRUG|Trifluridine and Tipiracil Hydrochloride|Given PO
224206519|NCT05469776|PROCEDURE|bicruciate-retaining total knee arthroplasty|
224206520|NCT05469776|PROCEDURE|posterior-stabilized total knee arthroplasty|
224206521|NCT00182208|DEVICE|Veno-device (Venowave)|
224206522|NCT02404272|OTHER|Educational oral feeding nurse program|"A multidisciplinary group composed of childcare assistants, nurse guardians, speech therapist, physiotherapist, psychologist, and pediatricians will develop and implement the educational oral feeding program. They will provide the 2-day theoretical session as well as the three 2-hour practical sessions including reviews of video recording preterm neonates during bottle or breast feedings.~The program will focus on non-nutritive sucking for all neonates from 24 up to 34 weeks' of gestation, early oral feeding from 29 weeks' of gestation and oral stimulation for all preterm neonates admitted to the unit. Additionally, all preterm neonates presenting feeding difficulties symptoms will be evaluated weekly by a physiotherapist or speech therapist.~Each program session is composed of 20 nurses or childcare assistants. Six sessions will be organized in total and all nurses and childcare assistants will be trained"
224206523|NCT02836704|DRUG|INSULIN GLARGINE|"Pharmaceutical form: solution~Route of administration: subcutaneous injection"
224206524|NCT02836704|DRUG|metformin|"Pharmaceutical form: table or capsule~Route of administration: oral administration"
224206525|NCT02836704|DRUG|acarbose|"Pharmaceutical form: table or capsule~Route of administration: oral administration"
223773657|NCT05940675|BEHAVIORAL|Sleep and screen media|The aim of this component is to promote healthy sleep and screen media behaviours. Sleep and screen media recommendations will be presented for parents at three parent workshops and in electronic infographics. Teachers/pedagogues will facilitate small assignments on screen media and sleep practices with children during school time. Children will talk about and reflect upon screen media and sleep practices in their family, based on assignments and material from e.g., Medierådet (The Danish Media Council). The results of the children's assignments will be presented to their parents at later workshops. This is done to integrate the children's perspective in the parent workshops, especially in relation to screen media habits.
224206526|NCT06540820|DIAGNOSTIC_TEST|Dexa or Biompedance analysis with clinical and biochemical evaluations|All patients will undergo body composition study with DXA or Bioimpedance analysis which are the gold standard to determine % of fat mass and fat free mass, basal biochemical examinations and oral glucose tolerance test (OGTT), and clinical evaluation with waist circumference measurement. Moreover, all patients will undergo REMS ultrasound, TBS and BSI evaluation at DXA scan and hand grip test. In addition, all patients will undergo to clinical evaluation with specific nutritional, physical activity and sleep quality questionnaire assessments and an additional volume of blood.
224206527|NCT02425358|OTHER|BMC therapy within 24 hours|The BMCs were isolated by Ficoll density gradient centrifugation on Lymphocyte Separation Medium. BMCs were infused into IRA at the site of the previous occlusion. This was accomplished with the use of a microtubular. After positioning of the microtubular into the distal segment vessel of the stent position in the infarct-related artery, 15 milliliter of the whole cell suspension was slowly administered via microtubular. The usual time should be over 10min to prevent back-flow and to prolong cellular contact time for cellular migration into the tissue. Patients in BMC therapy group within 24 hours remained in the cath-lab until the entire procedure, including primary PCI and intracoronary BMC infusion, was completed.
224206528|NCT02425358|OTHER|BMC therapy within 3-7 days|Patients in this group, who underwent a second procedure, to receive BMC transplantation in the cath-lab during the same hospitalization or returned for a second hospitalization.
224206529|NCT02425358|OTHER|BMC therapy within 7-30 days|Patients in this group, who underwent a second procedure, to receive BMC transplantation in the cath-lab during the same hospitalization or returned for a second hospitalization.
224206530|NCT02425358|OTHER|PCI only|The saline was intracoronary infusion with the use of microtubular.
224206531|NCT03716804|DRUG|Tablet Nitrofurantoin|Tablet Nitrofurantoin (100 mg), two times daily in 12 hours interval for 7 days
224206532|NCT03716804|DRUG|Tablet Ciprofloxacin/ Tablet Cefixime/ Tablet Cefuroxime|Tablet Ciprofloxacin (500 mg), two times daily in 12 hours interval for 7 days or, Tablet Cefixime (200 mg), two times daily in 12 hours interval for 7 days or, Tablet Cefuroxime (250 mg), two times daily in 12 hours interval for 7 days
224206533|NCT00863239|DRUG|ribavirin|Co-administered in all arms: oral ribavirin, 200 mg capsules. Subjects with body weight \< 65 kg: 800 mg/day; Subjects with body weight 65-85 kg: 1000 mg/day; Subjects with body weight \> 85 kg: 1200 mg/day.
224206534|NCT00863239|DRUG|Locteron™ (controlled-release interferon alpha 2b)|investigational controlled-release recombinant interferon alpha 2b formulated in 1500/77/23 PolyActive microspheres as a lyophilized powder, reconstituted with carboxymethyl cellulose immediately before subcutaneous injection every other week as part of the treatment of chronic hepatitis C
224206535|NCT00863239|DRUG|PEG-Intron™|commercially available pegylated interferon alpha 2b injected subcutaneously weekly in a dose of 1.5 ug/kg as part of the treatment of chronic hepatitis C
224206536|NCT03654365|OTHER|Bulk ordering and bulk messaging|Patients in the intervention group had the hepatitis screening test ordered for them in bulk and then a bulk message sent to them through the personal health record describing hepatitis C and how they could be tested.
224206537|NCT03654365|OTHER|Routine alerting|Passive alerting to providers (during face-to-face encounters using the electronic health record) and to patient (when they review preventative screening recommendations through their personal health record).
224206538|NCT01062100|DEVICE|nuclear breast imaging using MBI Gamma camera|nuclear breast imaging using MBI Gamma camera in addition to MRI
224206539|NCT03777800|BEHAVIORAL|Body therapy|"Body therapy involving direct physical treatments, conversations, breathing exercises and relaxation in the sessions. Moreover, the participants are taught how to practice vipassana or awareness meditation every day at home.~The body therapist works directly with the muscle armour and the treatment sessions have focus on creating a safe environment and enabling cognitive realisation and awareness of symptoms.~Each participant is assigned a practitioner who acts as contact person and 'lifeline'. Furthermore, a coordinator is assigned in ManuVision who will also act as contact person when needed for the veterans. This provides peace of mind, trust, and ensures retention. The coordinator or the practitioner follows up on the veteran's progress prior to each session."
224206540|NCT03777800|BEHAVIORAL|Treatment as usual|Standard treatment
224206541|NCT00499252|DRUG|Paclitaxel Albumin-Stabilized Nanoparticle Formulation|
224206542|NCT04629300|BEHAVIORAL|Supportive Care Mobile Application|Tablet computer with application providing modules on skills for managing symptoms and coping.
224206543|NCT04629300|OTHER|Usual Care|Standard oncology care with monitoring of supportive care services usage
224206544|NCT01687777|BIOLOGICAL|Mesenchymal Stem Cells (MSCs)|20.000.000 autologous MSCs included in the OrthADAPT membrane. Single dosage.
224206545|NCT01687777|BIOLOGICAL|OrthADAPT|
224206546|NCT03667742|DIAGNOSTIC_TEST|analysis of sweat and serum samples for protein markers|collection of blood and sweat samples (with Macroduct Sweat Collecting System) in patients with suspected tuberculosis or proven acute tuberculosis or pulmonary diseases (pneumonia, bronchitis, COPD) and analyzing serum and sweat for protein markers (Early Secretory Antigenic Target (ESAT-6) and Culture Filtrate Protein 10 (CFP-10) and C-reactive protein (CRP) and Amyloid A2 and complement component 1q (C1q)) by mass spectrometry and enzyme-linked immunosorbent assay (ELISA)
224206547|NCT00397072|DRUG|ZK 219477|
224206548|NCT02964052|OTHER|Brain CT imaging|Investigators will analyzed the CT image that was performed in patients with hyperacute stroke. The CT protocol includes CT thrombus, collateral, core images. Investigators also obtain detailed history and laboratory and imaging result for comorbidity. The comorbidity index protocol is based on the Charlson comorbidity index.
224314607|NCT03741699|DRUG|Pre-treatment with rLH (Luveris 75 IU),|Treatment with 150 IU/day rLH (Luveris 75 IU), administered subcutaneously for 4 consecutive days prior to COS (Controlled ovarian stimulation)
224314608|NCT06616844|DEVICE|InnovaMatrix® AC|SOC plus weekly application of the study device
224314609|NCT01867983|BEHAVIORAL|Weight gain prevention and smoking cessation|"The two intervention groups will receive weight gain prevention either:~Simultaneous: weight control treatment simultaneous with cessation treatment (5 proactive calls with a quit coach combined with weight coach/nutritionist followed by 5 'contact control calls'), or Sequential: weight control treatment added after cessation treatment (5 proactive calls with a quit coach followed by 5 weight coach/nutritionist calls). All three study arms will include a total of 10 phone counseling calls, interactive web, mailed support materials, access to nicotine replacement therapy (NRT) and unlimited participant initiated calls."
224314610|NCT01867983|BEHAVIORAL|Smoking cessation|The control group will receive cessation treatment calls (5 proactive calls with a quit coach followed by 5 contact control calls.
223618562|NCT00902681|DRUG|Fesoterodine|A fesoterodine extended-release tablet (ER) formulation once daily administration of 8 mg
223618563|NCT06270069|OTHER|Excercise-based therapy|An individual 60-min motor training sessions twice a week for eight-week outpatient program, that included exercises aimed at improving postural control, strengthening and stabilizing the back muscles, and stretching
223761395|NCT05791461|BEHAVIORAL|MARS (Measures Against Work-related Stress)|"The stress management intervention is based on cognitive behavioral therapy and aims to change the way patients perceive and cope with stressful situations at work.~It is group sessions over 3 months with approximately 9 participants. Participants meet 9 times (once a week the first 3 weeks and once every second week the last 5 times) and for a follow-up session 3 months after the intervention has ended. Each session lasts for 3 hours and is led by a trained psychologist. The participants perform tasks at home between the sessions. In the first session the rationale behind the intervention is introduced. In session 2 and 3 the patients work with enhancing self-regulation. In session 4 and 5 the focus is on modifying intermediate beliefs. In session 6 the focus is on improving interaction. Session 7 and 8 focuses on consolidation of learning and strategies to prevent relapse, and session 9 is a follow-up session 3 months after the intervention has ended."
223761396|NCT06775678|RADIATION|Spatially Fractionated Radiation Therapy Combined With Low-dose Radiotherapy|Spatially Fractionated Radiation Therapy Combined With Low-dose Radiotherapy
224206549|NCT00566631|DRUG|Paliperidone|Paliperidone ER tablet in flexible daily dose of 3, 6, 9 or 12 milligram (mg) as per Investigators' discretion will be given once daily orally for 6 weeks in the core treatment phase and no longer than 12 months in the extension phase after the completion of core treatment phase.
224206550|NCT00003786|DRUG|irofulven|
224206551|NCT02076230|DRUG|[14C] TH-302 (Label 1)|\[14C\]-labeled TH-302 (Label 1) will be administered as intravenous infusion over 30 minutes on Day 1 of Part A.
224206552|NCT02076230|DRUG|[14C] TH-302 (Label 2)|\[14C\]-labeled TH-302 (Label 2) will be administered as intravenous infusion over 30 minutes on Day 1 of Part A.
224206553|NCT02076230|DRUG|Unlabeled TH-302|Unlabeled TH-302 will be administered along with labeled TH-302 at the dose of 340 milligram per square meter (mg/m\^2) as intravenous infusion over 30 minutes on Day 1 of Part A, followed by recommended Phase 2 dose (RP2D) of 480 mg/m\^2 as monotherapy infusion over 30 minutes on Days 8 and 15 of Part A; and on Days 1, 8 and 15 of Part B, until progression of the disease, unacceptable toxicity, withdrawal of consent by the subject, loss to follow up, or death.
224206554|NCT03801018|OTHER|Questionnary and Interviews|"An internet platform dedicated to the anonymous survey will be set up by the communication department and the digital System Department of the promoter Public assistance hospitals in Marseille, the data Processing manager. It would deplore anonymous questionnaires accessible from a dedicated web page. People will therefore respond to a national survey on the basis of volunteering and anonymity.~Interviews, lasting one to two hours, will be fully transcribed and processed anonymously.~The interviews will seek to collect data on the modalities, conditions and effects of the circulation (or retention) of information on the use of donation, throughout the lives of individuals and families, in a cross-analysis of Viewpoints of parents and people born of donation."
224206555|NCT04335565|OTHER|sugar replacements|Participants will receive a solution of stevia before being administered a fixed meal (lunch). Glucose and insulin levels, and Visual analogue scale data will be collected.
224314611|NCT05697016|DRUG|Sivelestat Sodium for Injection|Sivelestat, a specific inhibitor of neutrophil elastase; sodium N-\[2-\[4-(2,2-dimethylpropionyloxy) phenyl-sulfonylaminobenzoyl\]amino-acetate tetrahydrate\]
224314612|NCT05697016|DRUG|The Placebo|Excipients used for the sivelestat sodium
224314613|NCT00017823|PROCEDURE|Acupressure|
224314614|NCT01104792|DRUG|Cariprazine|Cariprazine was supplied in capsules.
224314615|NCT04703582|DIAGNOSTIC_TEST|Activated clotting time|Relationship between elongated baseline activated clotting time and comorbidity
224314616|NCT00937482|DRUG|cediranib maleate|Given orally
224314617|NCT00937482|RADIATION|whole-brain radiation therapy|Undergo whole-brain radiotherapy
224314618|NCT05710939|OTHER|exercises|
223618564|NCT01344902|DRUG|hexaminolevulinate HCl|200mg hexaminolevulinate HCl capsule 6 hours before colonoscopy
223618565|NCT06171958|DRUG|Iodine-containing Contrast Media|Patients will receive or not receive ICM depending on their medical need.
223618566|NCT04537793|DRUG|ELX/TEZ/IVA|Fixed dose combination granules for oral administration.
223618567|NCT04537793|DRUG|IVA|Granules for oral administration.
223761397|NCT06775678|RADIATION|Conventional fractionated radiotherapy|Conventional fractionated radiotherapy
223761398|NCT04448717|DIAGNOSTIC_TEST|COVID-19 Antibody testing|COVID-19 Antibody testing in venous blood and/or saliva samples.
223761399|NCT05847569|BIOLOGICAL|Belantamab Mafodotin|Given IV
223761400|NCT05847569|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
223761401|NCT05847569|PROCEDURE|Bone Marrow Aspirate|Undergo bone marrow aspirate
223761402|NCT05847569|PROCEDURE|Bone Marrow Biopsy|Undergo biopsy
223761403|NCT05847569|PROCEDURE|Computed Tomography|Undergo CT scan
223761404|NCT05847569|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI scan
224206556|NCT02968641|DRUG|Lonafarnib|antiviral farnesyltransferase inhibitor
224314619|NCT02831647|DIETARY_SUPPLEMENT|AYMES PRAGUE|AYMES PRAGUE is a ready to drink, high energy, low volume oral nutritional supplement drink. It provides 300 kcal and 12g protein per 125ml serving. It is a Food for Special Medical Purposes (FSMP) and must therefore be used under medical supervision. It is not designed as a sole source of nutrition.
223618568|NCT02414815|DEVICE|Monophasic action potential(MAP) catheter|After ordinary procedure for electrophysiologic study or catheter ablation, the investigators will replace conventional catheter to monophasic action potential (MAP) recording catheter through right femoral sheath. MAP recording catheter is introduced to endocardial surface of atrium, and we record atrial MAP at variable pacing cycle lengths: steady state cycle lengths of 600, 400, 300, 240, 220, 240, 260, 300, 400 and 600 ms. At each cycle length, pacing was applied for 20 sec. It takes less than 5 min to acquire MAP recordings.
223761405|NCT05847569|PROCEDURE|Positron Emission Tomography|Undergo PET/CT scan
224206557|NCT02968641|DRUG|Ritonavir|CYP 3A4 inhibitor, lonafarnib booster
224206558|NCT05954338|DRUG|DWC202307|DWC202307
223761406|NCT05524545|DRUG|Evorpacept|Fusion protein that blocks CD47-SIRPalpha pathway
224206559|NCT05954338|DRUG|DWJ1543|DWJ1543
224206560|NCT05954338|DRUG|DWC202216|DWC202216
224206561|NCT04718727|DRUG|Placebo|oral Placebo tablets one-hour preoperatively
224206562|NCT04718727|DRUG|5 mg Olanzapine Tablets|oral 5 mg Olanzapine tablets one-hour preoperatively
224206563|NCT04718727|DRUG|10 mg Olanzapine Tablets|oral 10 mg Olanzapine tablets one-hour preoperatively
224206564|NCT03387735|OTHER|Treatment as usual (TAU) + Internet|Patients in this group will receive TAU+internet and links to helpful websites.
224206565|NCT03387735|BEHAVIORAL|TAU + ElderTree|"For the patient, ElderTree provides tools, motivation, and social support to help them manage their specific set of chronic conditions and communicate with peers and their primary care physician.~For the clinic, ElderTree has a Clinician Report (CR), a visual dashboard of health-tracking data that can be customized based on the needs of the clinic. The CR provides alerts to the clinician when a patient passes a certain threshold. The dashboard is intended to help clinicians prepare for patient office visits."
224206566|NCT01817335|PROCEDURE|psychosocial assessment and care|Participate in psycho-educational program
224206567|NCT01817335|OTHER|educational intervention|Participate in psycho-educational program
224206568|NCT01817335|OTHER|communication skills training|Participate in psycho-educational program
224206569|NCT01817335|OTHER|questionnaire administration|Ancillary studies
224206570|NCT01771419|DEVICE|Loop-tip wire (Cook Medical) for the cannulation of the CBD|
224206571|NCT01771419|DEVICE|Cannulotome CT-25mm Cook Medical|
224206572|NCT00110084|DRUG|Gemcitabine|1000 mg/m2 (IV over 30 min) (days 1 and 8) on 21 day cycle
224206573|NCT00110084|DRUG|Paclitaxel protein-bound particles for injectable suspension (albumin-bound)|125 mg/m2 (IV over 30 min) (days 1 and 8) on 21 day cycle
224206574|NCT05829382|DIETARY_SUPPLEMENT|DailyColors™|Capsule containing active ingredient administred daily by the participant during the trial period
224206575|NCT05829382|DIETARY_SUPPLEMENT|Placebo|Capsule containing placebo administered daily by the participant during the trial period
224206576|NCT05204849|DEVICE|IRRAflow|Ventriculostomy using IRRAflow with active irrigation and aspiration
224206577|NCT05204849|PROCEDURE|Standard ventriculostomy|Standard passive external ventricular drainage
224206578|NCT00537056|PROCEDURE|FDG PET CT|nuclear medicine imaging technique which produces a three-dimensional image or picture of functional processes in the body
224206579|NCT00537056|PROCEDURE|DCE MRI|DCE MRI will be acquired using rapid intravenous bolus of gadolinium-DTPA (0.1 mmol/kg).
224206580|NCT00537056|DRUG|F-18 Fluoro-deoxi-glucose|15 mCi iv
224206581|NCT00537056|DRUG|Gadolinium-DTPA|0.1 mmol/kg iv
224206582|NCT00537056|DRUG|Sunitinib|50 mg/day po
224206583|NCT00986609|BIOLOGICAL|MUC-1 peptide vaccine|Given subcutaneously
224206584|NCT00986609|BIOLOGICAL|poly ICLC|Given intramuscularly
224206585|NCT00986609|BIOLOGICAL|MUC1 peptide-poly-ICLC adjuvant vaccine|Receive adjuvant vaccination
224206586|NCT00986609|OTHER|laboratory biomarker analysis|Correlative studies
224206587|NCT00986609|OTHER|enzyme-linked immunosorbent assay|Correlative studies
224206588|NCT00986609|OTHER|flow cytometry|Correlative studies
224206589|NCT02449109|PROCEDURE|interventional therapy|Liver cancer patients received drug interventional therapy using the digital subtraction angiography（DSA）
224206590|NCT02816658|OTHER|Laparoscopic Inguinal Hernia Repair|Laparoscopic Inguinal Hernia Repair
224206591|NCT02816658|OTHER|Robotic Inguinal Hernia Repair|Robotic Inguinal Hernia Repair
223618569|NCT02976337|DRUG|Naloxone|active drug infusion
223618570|NCT02976337|DRUG|Normal Saline|placebo comparator
223618571|NCT01255423|DRUG|Diclofenac sodium topical gel 1%|Diclofenac sodium topical gel 1%, 4 times daily
223618572|NCT01255423|DRUG|Placebo|Placebo, 4 times daily
224206592|NCT00506558|PROCEDURE|Ventral Surgical Decompression with Instrumented Fusion|Multi-level discectomy or Corpectomy are performed at surgeon's discretion. After decompression an instrumented fusion is performed.
224206593|NCT00506558|PROCEDURE|Dorsal Decompression With or Without Fusion|Dorsal decompressive laminectomy, laminoplasty, or laminectomy with lateral mass instrumented fusion
224206594|NCT00703261|DRUG|atorvastatin|Participants will be asked to self-administer one atorvastatin 10 mg or 80 mg tablet at approximately the same time each day.
224206595|NCT00703261|DRUG|placebo|Participants will be asked to self-administer one tablet of placebo to atorvastatin 10 mg or 80 mg at approximately the same time each day.
224206596|NCT05145647|RADIATION|Add-on Brachytherapy|Brachytherapy protocol starts within 2 weeks after consolidative EBRT, subjects who are enrolled will receive brachytherapy with specified balloon applicator. High-dose-rate (HDR) brachytherapy system will be used in the treatment, 5-Gy per fraction is delivered to the pre-treatment esophageal length of primary tumor(s), second treatment if applicable will be finished within 2 weeks after the first one, a total of 5-10Gy in 1-2 fractions will be delivered.
224206597|NCT05145647|DEVICE|"BRAXX Esophageal Brachytherapy Applicator"|The device is intended for use with commercially available afterloader during brachytherapy. The purpose of the device is for delivery of radioactive source to the esophagus. This device is sterile, disposable and single-use.
224206598|NCT02163278|DRUG|DBPR108|DBPR108 capsules in four doses beginning at 25 mg and rising to 600 mg.
224206599|NCT02163278|DRUG|matching placebo|Matching placebo capsules in four doses beginning at 25 mg and rising to 600 mg.
224206600|NCT02953418|DEVICE|Radiofrequency ablation|RFA
224206601|NCT03020966|DRUG|Acetaminophen|Oral acetaminophen, intravenous placebo
224314620|NCT01190943|OTHER|Laboratory Biomarker Analysis|Correlative studies
223618573|NCT05470387|DRUG|LB1148|A total of 700 mL of drug product will be administered orally as a split dose before surgery.
223761407|NCT05524545|DRUG|Enfortumab Vedotin|Nectin-4 directed antibody and microtubule inhibitor conjugate
224206602|NCT03020966|DRUG|Acetaminophen|Intravenous acetaminophen, oral placebo
224206603|NCT06423937|DRUG|combination therapy Combination: Fruquintinib plus Camrelizumab and HAIC (TOMOX/TOMIRI) Maintenance: Fruquintinib plus Camrelizumab|"Procedure/Surgery: HAIC After successful percutaneous hepatic artery cannulation, superior mesenteric arteriogram and hepatic arteriogram were performed, and after confirming that the subjects were eligible for enrollment according to the results, the hepatic artery was cannulated to the predetermined position. The catheter was connected to a syringe pump in the ward for continuous pumping of drugs.~TOMOX（Raltitrexed 2 mg/m2, Oxaliplatin 85mg/m2）/ TOMIRI（Raltitrexed 2 mg/m2 ，Irinotecan 120mg/m2） Drug: Fruquintinib 3mg, qd, po, 21 days for a cycle, Suspend medication on the day of HAIC Drug: Camrelizumab 200mg, ivgtt,, 21 days for a cycle"
224206604|NCT04361006|DEVICE|Radiofrequency (RF)|Will be evaluated if percutaneous radiofrequency catheter ablation is superior to cryotherapy as treatment modality of para-hisian accessory pathways.
224206605|NCT04361006|DEVICE|Cryotherapy (CRYO)|Will be evaluated if percutaneous cryotherapy catheter ablation is superior to radiofrequency as treatment modality of para-hisian accessory pathways.
224206606|NCT00792142|DRUG|bortezomib|Given IV
224206607|NCT00792142|DRUG|dexamethasone|Given orally
224206608|NCT00792142|DRUG|melphalan|Given IV
224206609|NCT00792142|DRUG|thalidomide|Given orally
224206610|NCT00792142|GENETIC|cytogenetic analysis|Performed on baseline and post transplant bone marrow specimens
224206611|NCT00792142|GENETIC|fluorescence in situ hybridization|Performed on baseline and post transplant bone marrow specimens
224206612|NCT00792142|OTHER|laboratory biomarker analysis|Baseline, post transplant and prior to start of bortezomib, every 3 months post transplant for the first year, after 6 cycles of bortezomib, every year after transplant for 2-4 years.
224206613|NCT00792142|OTHER|questionnaire administration|Completed at baseline (within 6 weeks prior to enrollment) and at 2 months post transplant and once a month after that for the first year. For the second year the questionnaire will be completed every 3 months as long as on thalidomide for the duration of the study.
224206614|NCT00792142|PROCEDURE|autologous hematopoietic stem cell transplantation|Minimum dose of 2 X 10(6) CD34 + cells/kg day 0 after two days of treatment with Melphalan
224206615|NCT00792142|PROCEDURE|peripheral blood stem cell transplantation|Minimum dose of 2 X 10(6) CD34 + cells/kg day 0 after two days of treatment with Melphalan
224206616|NCT00527527|PROCEDURE|flexion distraction|Chiropractic treatment using the flexion distraction apparatus
224206617|NCT00527527|OTHER|placebo control|Placebo for comparison with flexion distraction treatment
224206618|NCT02115373|DRUG|Tepotinib|Participants received a single oral dose of Tepotinib 300 milligram (mg) in each 21 days treatment cycle until progressive disease, intolerable toxicity, death, or withdrawal from treatment.
224206619|NCT02115373|DRUG|Tepotinib|Participants received a single oral dose of Tepotinib 500 mg daily in each 21 days treatment cycle until progressive disease, intolerable toxicity, death, or withdrawal from treatment.
224206620|NCT05243810|DEVICE|EPC Silver Wound Gel|Re-application of EPC-123 will occur within 48 hours of the initial application. Secondary dressings will be selected at the discretion of the clinician or home care provider, based upon best practice guidelines for moisture management and will consist of a selection between the following secondary dressings: Mesorb® (Molnyke), Gauze, Cling (self-adherent gauze), or MediporeTM (3M). Application of EPC-123 will be executed at the Lawson Health Research Institute every second visit, where interim applications will be facilitated by home care. To support home care applications, a study kit will be provided to home care professionals inclusive of the EPC Silver Wound Gel, secondary dressings required, and instructions for removal/re-application.
224206621|NCT06565975|DRUG|Oral azacitidine|As per product label, prescribed by treating physician
224206622|NCT02676518|OTHER|serum|Serum for serum anti-Mullerian hormone, 2-hour 75 gram oral glucose tolerance test and lipid profiles
224314621|NCT03559166|DRUG|BLD-2660|Randomized to active product or placebo
224314622|NCT01175031|OTHER|Manipulation of Positive Airway Pressure (PAP)|Positive airway pressure (PAP) will be manipulated throughout the night to induce breathing events. PAP will be set to the participant's prescribed pressure, increased until breathing events are induced , and then returned to the prescribed pressure. This cyclic pattern will continue throughout the night.
224314623|NCT06240520|DRUG|Panobinostat 20 MG Oral Capsule|Panobinostat 20mg will be administered once orally
224314624|NCT06240520|DRUG|Pyrimethamine 200mg Oral Tablet|Pyrimethamine 200mg will be administered once orally
224314625|NCT06240520|DRUG|Lenalidomide 25 MG Oral Capsule|Lenalidomide 25mg will be administered once orally
224314626|NCT00555360|BEHAVIORAL|HITCM+CP|Weekly automated assessment calls with follow-up by a care manager and a CarePartner for 12 months. Baseline, 6-month and 12-month follow-up.
224314627|NCT00555360|BEHAVIORAL|HITCM only|Weekly automated assessment calls with follow-up by a care manager for 12 months. Baseline, 6-month and 12-month follow-up.
223618574|NCT05470387|DRUG|Placebo|A total of 700 mL of placebo will be administered orally as a split dose before surgery.
223618575|NCT00006275|DRUG|calcitriol|
223618576|NCT03567772|DEVICE|Wiifit Nintendo video game|
223618577|NCT03567772|OTHER|Pulmonary rehabilitation program|
223618578|NCT05794035|OTHER|Surgery with additional moderate hypofractionation RT (15 fractions)|"After randomization, patients will then be followed-up at 3 months post randomization and at each surveillance visit (M6, M12, M24 and M36).~Adjuvant Radiotherapy:~-Arm B: Surgery followed by moderate hypofractionation RT (15 fractions): 45Gy in 15 fractions, 3 fractions per week over 5 weeks to the operative bed."
223618579|NCT05794035|OTHER|Surgery alone, without radiation post surgery|Arm A: Surgery alone followed by surveillance
223761408|NCT04744454|DRUG|Isauvuconazole group|Patients who are treated with Isavuconazole according to its protocol label.
223761409|NCT05702216|OTHER|Rehabilitation|Hybrid approach in cardiac telerehabilitation. Patients underwent 20 cardiac rehabilitation sessions: alternatively, patients underwent 10 classical cardiac rehabilitation sessions in the clinic and 10 cardiac telerehabilitation sessions at home.
223618580|NCT05794035|RADIATION|Surgery with extreme hypo fractionation treatment (HF)|"After randomization, patients will then be followed-up at 3 months post randomization and at each surveillance visit (M6, M12, M24 and M36).~Adjuvant Radiotherapy:~-Arm C= Surgery followed by extreme hypofractionation RT (5 fractions, 2 fractions/week): 30Gy in 5 fractions of 6Gy over 5 weeks to the operative bed."
223618581|NCT02638766|DRUG|regorafenib|Treatment with regorafenib 160mg once a day, 3 weeks on / 1 week off in cycles of 28 days
223618582|NCT03890068|DRUG|Anlotinib Hydrochloride|48 subjects with advanced soft tissue sarcoma will receive anlotinib at a dose of 12 mg once daily (day1-14 PO) in 21-day cycles until disease progression (defined by RECIST version 1.1) or unacceptable toxicity.
224206623|NCT05420818|PROCEDURE|Transversalis Fascia Inversion|This study will be carried out at SBU Istanbul Training and Research Hospital, General Surgery Clinic. Patients diagnosed with M2 and M3 direct primary inguinal hernia according to EHS classification and who will undergo TEP repair surgery will be randomized into 2 groups. After direct hernia reduction in the patients in the first group, the transversalis fascia at the hernia site will be pulled inward and fixed to the Cooper ligament with 2 or 3 absorbable tackers. Standard surgery will then be continued. The patients in the second group will undergo standard surgery without any seroma prevention procedure. Demographic data of patients in both groups, postoperative pain (VAS values) at postoperative 1st, 7th day and 3rd month, clinical/radiological seroma rate, postoperative pain, QOL, recurrence and other complications will be recorded. When the desired number of patients and follow-up period are reached, the data in the 2 groups will be compared.
223618583|NCT01612975|DRUG|Naproxen|Intervention arm involves administering 500mg Naproxen BID to participants and 40mg of Pantoprazole in tandem. Pantoprazole will negate gastrointestinal consequences of Naproxen and reduce the likelihood of a complication occurring. Participants will take Naproxen at the above dosage from the time of surgery to four weeks following surgery. They will attend scheduled check-ups where their vitals will be recorded, as well as laboratory indicators of gastrointestinal complications (creatinine levels, etc) for their safety. This experiment is double-blinded so neither investigators nor participants will know which arm of the study they belong to.
224206624|NCT02628418|OTHER|General Rehabilitation|All patients underwent basic rehabilitation following the guidelines according to the Bobath concept. Mobilization performed by physiotherapist of the lower and upper limbs through passive and/or active manoeuvres, gait training, standing and functional exercises and speech rehabilitation.
224206625|NCT02628418|DEVICE|Specific hand rehabilitation by Gloreha device|"Each training session consisted of six parts:~1. A sequence of digital joint flexion/extension exercises, from the thumb to the fifth finger (7 min);~2. 7 min of a number sequence (counting from one to five);~3. A sequence of thumb-finger opposition movements from the 2nd to the 5th finger (7 min)~4. A sequence of wave-like finger movements (7 min)~5. A sequence of fist opening/closing (7 min)~6. A sequence of flexion-extension of the fingers alternated with flexion-extension of the thumb (5 min)."
224206626|NCT02628418|OTHER|Specific hand rehabilitation performed by physiotherapist|"The activities were:~1. Flexion-extension of the fingers (10 min);~2. Thumb opposition with the other fingers keeping the forearm in supine position (10 min);~3. Adduction and abduction of the fingers (10 min);~4. Global movement of the hand consisting in reaching for a 0.5l bottle of water, taking hold of it, pouring water into a glass, and then putting the bottle down and letting go of it (10 min)."
224206627|NCT00397293|DRUG|AT-101|40 mg of AT-101 (by mouth) on days 1-5 of each 21 day cycle with topotecan 1.25 mg/m2, IV (in the vein) on days 1-5 of each 21 day cycle for approx. 4 cycles or until progression or unacceptable toxicity develops.
224206628|NCT00397293|DRUG|topotecan|40 mg of AT-101 (by mouth) on days 1-5 of each 21 day cycle with topotecan 1.25 mg/m2, IV (in the vein) on days 1-5 of each 21 day cycle for approx. 4 cycles or until progression or unacceptable toxicity develops.
224206629|NCT04130594|BIOLOGICAL|BVRS-GamVac|a vector vaccine for the prevention of the Middle East respiratory syndrome, lyophilisate for the preparation of a solution for intramuscular administration
224206630|NCT04130594|OTHER|placebo|placebo
224206631|NCT04512391|PROCEDURE|Ultrasound guided Erector Spinae Plane Block (ESPB)|Ultrasound guided ESPB is applied at T4 vertebrae level, 3 cm lateral to mid-line where transverse process lies. After identification of transverse process, needle is advanced in plane and real time visualisation on ultrasound screen. When bonny contact is encountered, normal saline is injected for verification of placement, then, 25 ml %0,25 bupivacaine is injected plane between transverse process and erector spinae muscles.
224206632|NCT05855473|OTHER|Auricular acupuncture|The NADA protocol used in this study uses five specific points on the ear: Shen men, sympathetic autonomic, lung, liver, and kidney. Using this protocol, semi-permanent needles and seeds were placed unilaterally at five specific points in the ear by a specialist physician certified in acupuncture.
224206633|NCT02502565|OTHER|Uric acid level|
224206634|NCT03747939|DRUG|Apremilast (CC-10004)|"Subjects randomized to apremilast will receive dose-titration for the initial 5 days. Apremilast subjects will receive dummy titration at wk. 16 (for early escape subjects) and again at week 24 to maintain the blinding of the original treatment assignments. Investigational product (IP) will be dispensed in blinded dose cards until Week 28. Thereafter, IP will be dispensed in open-label bottles."
224206635|NCT03747939|OTHER|Apremilast (CC-10004) Placebo|"Subjects randomized to placebo will receive dummy dose-titration for the initial 5 days. Placebo subjects who meet the criteria for early escape at wk. 16 may receive apremilast beginning at wk. 16 and will receive active titration. Remaining placebo subjects will receive active dose titration at week 24. Beginning at wk 24 all subjects will be dispensed active apremilast. Investigational product will be dispensed in blinded dose cards until Week 28. to maintain the blinding of the original treatment assignments. Thereafter, IP will be dispensed in open-label bottles"
224206636|NCT04511923|DRUG|Nebulised heparin|Nebulised unfractionated heparin 25000 units administered 6 hourly for 10 days
224206637|NCT02379650|DRUG|Hydroxychloroquine (HCQ)|
224206638|NCT02379650|DRUG|Placebo|
224206639|NCT01215955|DRUG|Insulin lispro|Administered subcutaneously, up to three times daily for 24 weeks
224206640|NCT01215955|DRUG|Glargine|Administered subcutaneously, dosage determined by investigator once daily for 24 weeks
224206641|NCT00604734|DEVICE|ReCap Total Hip Resurfacing System|This is a hip resurfacing system.
223618584|NCT01612975|DRUG|Placebo|Inert, inactive placebo pill similar in appearance to naproxen allocation. To be taken twice daily for 4 weeks total along with 40mg pantoprazole.
224314628|NCT00103610|DRUG|Granulocyte colony-stimulating factor plus plerixafor|Participants underwent mobilization with granulocyte colony-stimulating factor (G-CSF) (10 µg/kg/day) for 4 days, administered by subcutaneous (SC) injection. On the evening of Day 4, participants received plerixafor (240 µg/kg), administered by SC injection. On Day 5, participants received a morning dose of G-CSF (10 µg/kg) and underwent apheresis approx. 10 to 11 hours after the dose of plerixafor (within 60 minutes of G-CSF administration). Participants continued to receive an evening dose of plerixafor followed by a morning dose of G-CSF and apheresis for up to 4 aphereses or until ≥ 5\*10\^6 CD34+ cells/kg were collected. Participants who participated in the rescue procedure underwent an additional daily treatment with plerixafor (240 µg/kg) and apheresis for up to 4 days.
224314629|NCT00103610|DRUG|Granulocyte colony-stimulating factor plus placebo|Participants underwent mobilization with granulocyte colony-stimulating factor (G-CSF) (10 µg/kg/day) for 4 days, administered by subcutaneous (SC) injection. On the evening of Day 4, participants received placebo, administered by SC injection. On Day 5, participants received a morning dose of G-CSF (10 µg/kg) and underwent apheresis approx. 10 to 11 hours after the dose of placebo (within 60 minutes of G-CSF administration). Participants continued to receive an evening dose of placebo followed by a morning dose of G-CSF and apheresis for up to 4 aphereses or until ≥ 5\*10\^6 CD34+ cells/kg were collected. Participants who participated in the rescue procedure underwent an additional daily treatment with plerixafor (240 µg/kg) and apheresis for up to 4 days.
224314630|NCT03301623|OTHER|Clinical Decision Support|The CDS intervention will test the use of existing guideline-based EHR alerts related to the prescription of opioids. CDS alerts employ computer algorithms that account for patient characteristics and diagnoses to deliver reminders of appropriate use when a provider enters an order for a medication.
224314631|NCT03301623|OTHER|Patient Education and Activation Tools|"The patient education materials selected for this study: Pain Management: Which Treatment is Right for You, Preparing for Your Health Care Visit, and a video from the American Chronic Pain Association (ACPA) named A Car with Four Flat Tires, which helps to give patients a better understanding of how multi-modal treatment can be more effective than relying on one source of treatment (e.g., pain medication)."
224314632|NCT01866059|DEVICE|Calcium silicate cement|Calcium silicate cement
224314633|NCT01866059|DEVICE|Glass Ionomer Cement|Glass Ionomer Cement
224314634|NCT01866059|DEVICE|Resin Modified Glass Ionomer Cement|Resin Modified Glass Ionomer Cement
224314635|NCT00003920|BIOLOGICAL|filgrastim|
224314636|NCT00003920|DRUG|cyclosporine|
224314637|NCT00003920|PROCEDURE|peripheral blood stem cell transplantation|
224314638|NCT00003920|RADIATION|indium In 111 monoclonal antibody m170|
224206642|NCT00350818|DRUG|Azacitidine|8 mg/m\^2 Subcutaneously Once Daily for 5 Days
224206643|NCT04196699|BEHAVIORAL|self-management program|"Our intervention will be based on the following framework and will consist of 3 phases :~Phase I: At the end of a medical consultation, the doctor will offer the patient the opportunity to benefit from a nursing consultation and remote monitoring to better manage his COPD. A nursing consultation will be scheduled during which the nurse will explain the procedure, obtain the written consent of the patient, and develop an educational diagnosis with the participation of the patient.~Phase II: During the next six weeks education sessions will be provide to the participants and a telephone number will be available in case of emergency and for any additional information.~Phase III: A final consultation will be scheduled at the nurse office to evaluate the patient's achievements and modify his/her educational assessment. A telephone follow-up will be conducted after one month to assess the maintenance of learning."
224206644|NCT02507271|OTHER|Brain Fitness Program|This intervention involves work on a computer by responding to sounds for five hours a week, approximately one hour a day five days a week at the Rusk Institute for Rehabilitation.
224206645|NCT02507271|OTHER|Weekly Telephone Contact|This intervention involves weekly telephone calls over a period of approximately 8 weeks to inquire about the participant's involvement in cognitively stimulating activities (such as reading, working on the computer, puzzles, etc.)
224206646|NCT04011904|OTHER|Cross-over study|Traditional Inuit Diet vs Westernized Diet
224314639|NCT00003920|RADIATION|yttrium Y 90 monoclonal antibody m170|
224314640|NCT02304627|DRUG|insulin 338 (GIPET I)|Each subject will be randomly allocated to a fixed treatment sequence of four single-dose administrations of oral insulin 338 in a GIPET® I tablet, administered on four separate dosing visits. The subjects will be dosed in the morning in the fasting state prior to four different post-dose fasting periods.
224314641|NCT03449927|OTHER|Specialized menu|-Specialized menu that will guide participant food choices if the participant experiences nausea or diarrhea
224314642|NCT03449927|OTHER|Standard of care menu|-Standard registered dietitian support
224314643|NCT03449927|OTHER|Self report dietary intake worksheet|-Self report nausea and diarrhea
224314644|NCT03449927|OTHER|Post study questionnaire|-Completed upon count recovery and prior to discharge
224314645|NCT05896930|DRUG|Meropenem 6g IV over 6 hours|Meropenem 6g intravenously over 6 hours once daily on days 1-14.
224314646|NCT05896930|DRUG|Ertapenem 1g IM|Ertapenem 1g intramuscularly once daily on days 1-14.
224314647|NCT05896930|DRUG|Meropenem 3g IV|Meropenem 3g intravenously twice daily over 60 minutes on days 1-14.
224314648|NCT05896930|DRUG|Ertapenem 1g IV|Ertapenem 1g intravenously once daily on days 1-14.
224314649|NCT05896930|DRUG|Amoxicillin/CA twice daily|Amoxicillin/CA 2 tablets x 1000mg/62.5mg orally 12-hourly on days 1-14.
224314650|NCT05896930|DRUG|Rifampicin 35 mg/kg|Rifampicin 35 mg/kg once daily on days 1-14.
224314651|NCT05896930|DRUG|Meropenem 6g IV over 60 minutes|Meropenem 6g intravenously once daily over 60 minutes on days 1-14.
224314652|NCT05896930|DRUG|Rifafour e-275|Rifafour e-275 will be supplied as fixed dose combination tablets and administered orally once daily for 14 days as The daily dose is dependent on the participants' weight as follows: 40 - 54kg: 3 tablets; 55 - 70kg: 4 tablets; 71kg and over: 5 tablets.
224314653|NCT05896930|DRUG|Meropenem 4g IV|Meropenem 4g intravenously once daily over 60 minutes on days 1-14.
224314654|NCT05896930|DRUG|Amoxicillin/CA once daily|Amoxicillin/CA 2 tablets x 1000mg/62.5mg orally once daily on days 1-14.
224314655|NCT01176708|DRUG|dipeptidyl peptidase 4 (DPP4) inhibitor|One tablet (50 mg)of DPP4 inhibitor is to be taken 12 and 1 hours before start of the oral glucose tolerance test (50 g glucose and 1.5 g paracetamol dissolved in 300 ml water)on day 3
224314656|NCT01176708|OTHER|oral glucose|50 grams glucose dissolved in 300 ml water with 1.5 grams paracetamol
224206647|NCT03406611|DRUG|Pegtibatinase|Pegtibatinase sterile solution for subcutaneous injection
224206648|NCT03406611|DRUG|Placebo|Normal saline for subcutaneous injection
224206649|NCT05485571|DEVICE|derma pen|"Group 1: Taking aseptic condition, 15 Patients were subjected to therapy with microneedling, patient will take session weekly for 12 weeks.~Group 2: Taking aseptic condition, 15 patients were subjected to combined therapy with Microneedling and methotrexate After microneedling we applied methotrexate topically (25mg/ml) at dose 0.02ml/cm2 , A maximum of 0.1-0.2ml (2.5-5 mg) on the affected areas and rub it gently then Microneedling again, patient will take session weekly for 12 weeks"
224206650|NCT06700577|DIAGNOSTIC_TEST|Gene expert|Gene expert and XDR to detect multidrug resistance between tb patient
224206651|NCT06700577|GENETIC|Ultra xpert and xdr xpert|Detect resistance between tyberculous patient
224206652|NCT05309031|OTHER|Water Immersion|Participants will enter the pool, which has a thermoneutral temperature of 33°C (92°F), warm enough to be comfortable, but cool enough to avoid an increase in HR with similar ambient air temperature. A maximum depth of 4 to 4 feet 6 inches allows ample room participants to be immersed to the chest, float vertically and move in the pool. During 45 min of immersion, they will be instructed to stand, walk and move ad lib. Noodles will be available to hang or rest on in a vertical position. Taller participants will remain at the pool's deep end. The timeframe was chosen to approximate our previous immersion intervention length.
224206653|NCT01523301|DRUG|Rotigotine|"Transdermal Patch~Content:~2 mg /24 h (10 cm\^2), 4 mg /24 h (20 cm\^2), 6 mg /24 h (30 cm\^2), 8 mg /24 h (40 cm\^2)~* For early-stage Parkinson's disease, Subjects received Rotigotine patches in escalating weekly dose (starting with daily doses 2 mg/24 h to 8 mg/24 h) for a maximum 4-week Titration Period, then 8 week Maintenance period~* For advanced-stage Parkinson's disease, Subjects received Rotigotine patches in escalating weekly dose (starting with daily doses 4 mg/24 h to 16 mg/24 h) for a maximum 7-week Titration Period, then 8 week Maintenance period"
224206654|NCT01523301|DRUG|Placebo|"Transdermal Patch~Size:~10 cm\^2, 20 cm\^2, 30 cm\^2, 40 cm\^2~Subjects randomized to placebo received matching placebo patches"
224206655|NCT02517346|OTHER|Standard follow-up|Standard management according to Spanish Respiratory Society guidelines in Sleep Unit.
224206656|NCT02517346|OTHER|Telemonitoring|Follow up by telemonitoring system during 3 months
224206657|NCT04394572|BIOLOGICAL|Blood sample|All patients included in the study will have blood sample
224206658|NCT00093067|DRUG|daptomycin|
224314657|NCT01176708|OTHER|intravenous glucose|1.5 g paracetamol dissolved in 50 ml water is to be ingested orally within the first 2 minutes. Intravenous glucose is supplied in an amount to match the plasma glucose during the oral glucose tolerance test
224314658|NCT06490614|DRUG|Dexmedetomidine in superficial cervical plexus block|While the patient is in the supine position, the head will be turned to the opposite side of the surgical incision, and a line extending from the mastoid process to the clavicular head of the sternomastoid muscle will be marked. Aseptic preparation of this area will be done, and then the block needle will be inserted at the midpoint of this line with injection of bupivacaine 0.25%, dexmedetomidine 1 μg/kg (precedex 100mcg/ml), and adrenaline 1:200,000 in a total volume of 10ml normal saline in the above, below, and middle directions subcutaneously, creating a sausage-shaped swelling. The sensory block will be assessed with ice chips in the dermatome corresponding to the block, which included the skin of the neck, upper chest, shoulder, and ear, until the completion of the sensory blockade.
223512565|NCT04559464|DEVICE|AeriSeal|The AeriSeal Foam functions by blocking both small airways and collateral channels causing absorption atelectasis in the treated region of the lung. Occlusion with the foam also yields a targeted fibrotic response which durably reduces lung hyperinflation. The reduction in hyperinflation allows the healthier parts of the lung to re-inflate and improve breathing mechanics and gas exchange. In this study, the AeriSeal delivery will be limited to three segments that contain the collateral channel(s) between lung lobes. A minimum 10 mL volume of AeriSeal will be delivered per segment, with a total delivered volume limit of 40 mL per subject (including re-treatment, if needed) in a total of three segments.
223512566|NCT04559464|DEVICE|Zephyr Valves|The Zephyr Valves are implantable bronchial valves intended to control airflow in order to improve lung function in patients with hyperinflation associated with severe emphysema and/or to reduce air leaks.
223512567|NCT03254641|DRUG|human chorionic gonadotropin|5000 IE times one
223512568|NCT04869124|DRUG|Dapagliflozin|Dapagliflozin propanediol (FORXIGA) tablet: 10 mg once daily p.o. on top of recommended standard therapy, duration of administration: 12 weeks.
223512569|NCT04869124|DRUG|Placebo|Placebo tablet, matching Dapagliflozin, once daily p.o. on top of recommended standard therapy, duration of administration: 12 weeks.
223512570|NCT04284436|BEHAVIORAL|Treadmill walking|Treadmill walking 4 days per week for 30 minutes in the target heart rate
223512571|NCT04592562|DEVICE|the Terumo Hydropearl® microspheres device|"Genicular artery embolization (GAE) is a new, minimally invasive investigational not yet approved therapy. In previous studies, this procedure has provided pain relief in patients with mild to moderate OA in the short to midterm. We will be utilizing the Terumo Hydropearl® microspheres particle beads during the GAE procedures. The procedure will take place utilizing fluoroscopic and ultrasound guidance. Following catheterization of the femoral artery, angiography of the affected limb will be performed to define the genicular arterial anatomy. Genicular arteries demonstrating abnormal vascularity and corresponding to the site of the patient's pain will be catheterized and embolized using microspheres. Prior to and after embolization, parametric imaging will be performed utilizing proprietary software to quantify changes in blood flow to the target area~The intended use of the Terumo Hydropearl® microspheres device is to embolize the geniculate artery branch."
223512572|NCT05222581|DEVICE|Prototypes of breast shield and Freedom Double Electric Breast Pump|Prototypes of breast shield and Freedom Double Electric Breast Pump.
223512573|NCT06225531|OTHER|Autobiographical Memory Based Intervention|"The intervention involves 6 sessions of therapeutic input based around autobiographical memories. Memory based activities will broadly follow the 5 stages outlines in the broad-minded affective coping (BMAC) procedure, but with a focus on specific memories. It will follow the following structure:~Session 1 - Introduction and Familiarisation Session 2 - Neutral Memories Session 3 - Positive Memories Session 4 - Memories of Moves Away from Suicidality Session 5 - Practice of Preferred Memory (from Sessions 2-4) Session 6 - Continued Practice and Post-Intervention Planning"
223618585|NCT03309566|DRUG|Efavirenz, tenofovir disoproxil fumarate and emtricitabine|Two period administration of a formulation containing a combination of efavirenz 600 mg, emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg.
223618586|NCT05745311|DRUG|The KPCXM18 injection|Intravenous infusion
223618587|NCT05745311|DRUG|Placebo|Intravenous infusion
223618588|NCT03762031|DRUG|GC4711 30mg|single dose given via a 15 minute intravenous infusion
223618589|NCT03762031|DRUG|GC4711 60mg|single dose given via a 15 minute intravenous infusion
223618590|NCT03762031|DRUG|GC4711 90mg|single dose given via a 15 minute intravenous infusion
223618591|NCT03762031|DRUG|GC4711 120mg|single dose given via a 15 minute intravenous infusion
223618592|NCT03762031|DRUG|Placebo|single dose of normal saline given via a 15 minute intravenous infusion
223618593|NCT03762031|DRUG|GC4711 75mg|single dose given via a 15 minute intravenous infusion
223761410|NCT00745914|DRUG|Pioglitazone|oral Pioglitazone 15mg daily for 12 weeks, then 30mg daily for 36 weeks
223761411|NCT00745914|DRUG|Placebo comparator|Placebo comparator
223761412|NCT04741165|DRUG|HX008|200 mg administered as IV infusion on Day 1 of each 21-day cycle.
224206659|NCT05425823|OTHER|Health Belief Model Based Intervention|In intervention group-1, Information Form and PAVS-HBM will be applied as a pre-test to pregnant women who have completed their 28th gestational week. Childhood Vaccination Training Based on the Health Belief Model will be given in the prenatal period by organizing 2 face-to-face and individual sessions for the researcher's pregnant women. Each session will take approximately 30-45 minutes, with each session being in a different week. In addition, at the end of each session, HBM-based short messages will be sent to the pregnant woman's husband and recorded with the Short Message Tracking Form. Intervention group-2 will receive the same training, but no text messages will be sent.
224206660|NCT05943158|DRUG|myoinositol and folic acid|The pregnant women were given myoinositol+folic acid starting from initial examination of pregnancy until 24-28 weeks of gestation (time of oral glucose tolerance test)
224206661|NCT05943158|DRUG|folic acid|The pregnant women were given only folic acid starting from initial examination of pregnancy until 24-28 weeks of gestation (time of oral glucose tolerance test)
224206662|NCT01805258|DRUG|Nevirapine|The regimen containing Nevirapine: 3TC/ZDV 150/300 mg 1 tablet BID + NEVIRAPINE 200 mg qD for 2 weeks then 200mg BID
224206663|NCT01805258|DRUG|Efavirenz|The regimen containing Efavirenz: 3TC/ZDV 150/300 mg 1 tablet BID + EFAVIRENZ 600 mg qD
224206664|NCT05314413|PROCEDURE|Single Leg Immobilization|7-days of single leg immobilization to induce muscle atrophy
224206665|NCT05996549|DRUG|Quadrivalent Influenza Vaccine|All high-risk groups have been getting one dose of seasonal influenza vaccination (Inactivated Influenza Vaccine ), except children aged six months to 8 years, who will receive two doses four weeks apart. All vaccines are in the southern hemisphere, as Bangladesh's influenza season matches the southern hemisphere areas.
224206666|NCT00486213|DIETARY_SUPPLEMENT|pyridoxine hydrochloride|Pyridoxine (200mg) or placebo once daily orally for 21 days out of each treatment cycle
224206667|NCT00486213|OTHER|Placebo|
223618594|NCT03762031|DRUG|GC4711 105mg|single dose given via a 15 minute intravenous infusion
223618595|NCT04540965|DRUG|Telaglenastat|Glutaminase inhibitor
223618596|NCT04540965|DRUG|Famotidine|Histamine-H2 Receptor Antagonist
223618597|NCT04540965|DRUG|Placebo for famotidine|Placebo for Histamine-H2 Receptor Antagonist
223618598|NCT03004365|DRUG|C16G2 Varnish|Antimicrobial Peptide
223618599|NCT03004365|DRUG|Placebo Varnish|Placebo
223618600|NCT01858363|DEVICE|CVI Paclitaxel-coated Percutaneous Transluminal Angioplasty Balloon Catheter|
223618601|NCT01858363|DEVICE|Bare Percutaneous Transluminal Angioplasty Balloon Catheter|
223618602|NCT00491413|DRUG|epoetin|
223618603|NCT03992352|DIAGNOSTIC_TEST|Age 60+ with planned HCT for Hematologic Malignancy|questionnaires, geriatric assessments
223618604|NCT02016196|DRUG|Rifaximin|"6 rifaximin caps of 200 mg morning and night, 15 days before and 6 months after TIPS~\--------------------------------------------------------------------------------"
223618605|NCT02016196|DRUG|placebo|6 placebo caps per day morning and night, during 15 days before TIPS and 6 months after TIPS
223618606|NCT06634875|DRUG|isunakinra|Isunakinra is a potent IL1R1 inhibitor
223618607|NCT03776799|DEVICE|Stent-avoiding|Percutaneous transluminal angioplasty (PTA), in which a balloon is advanced and inflated in the obstructed artery for several seconds to minutes, has become the standard endovascular treatment for peripheral arteries
223618608|NCT03776799|DEVICE|Stent-based|Stenting, in which a stent is advanced and implanted in the obstructed artery, has become the standard endovascular treatment for peripheral arteries
223618609|NCT00970918|PROCEDURE|Measurement of the Carotid Intima Media thickness|one time, radiological procedure on both sides of the neck
223618610|NCT00970918|BIOLOGICAL|Blood sample testing for hs-CRP|one time, blood sample taking
223618611|NCT05154084|BEHAVIORAL|Performance feedback and education|Hospitals and surgeons will have an online interactive performance feedback dashboard provided to them along with educational components.
223618612|NCT05024435|DEVICE|Surfactant Administration|Laryngoscopy, intratracheal catheter placement and surfactant administration
223761413|NCT04741165|DRUG|Bevacizumab|15 mg/kg administered as IV infusion on Day 1 of each 21-day cycle.
223761414|NCT04741165|DRUG|Lenvatinib|Administered orally once a day during each 21-day cycle
224206668|NCT06562335|OTHER|Booster|See description of arm. The Booster intervention has evolved from the PROfeel intervention. PROfeel is described in: https://doi.org/10.1186/s13063-022-06620-2
224206669|NCT06568900|OTHER|cigarette smoking|continue smoking usual brand of cigarette
224206670|NCT06568900|OTHER|tobacco flavored and unflavored pouch|provide tobacco flavored and unflavored options of nicotine pouch
224206671|NCT06568900|OTHER|unrestricted flavor options pouch|provide unrestricted flavor options of nicotine pouch
224206672|NCT02912884|DRUG|No cytoreductive vs cytoreductive drugs|No cytoreductive treatment vs cytoreductive drugs (hydroxycarbamide, alpha-interferon, ruxolitinib).
224206673|NCT06229379|DEVICE|"Digital twin patient"|"Digital twin patient can serve as patients with specific diseases for medical students to acquire disease history and thus practice clinical questioning skills."
224206674|NCT06229379|BEHAVIORAL|Interaction with real patients|As in traditional medical education, medical students need to interact with real patients to practice history collection skills.
224206675|NCT02258399|BEHAVIORAL|Exercise|Moderate intensity exercise
224206676|NCT02258399|DIETARY_SUPPLEMENT|Breakfast|Breakfast consumption
224206677|NCT01447628|DRUG|Saline|intravenous, no active drug
224206678|NCT01447628|DRUG|Ferinject or CosmoFer|Intravenous, 1000 mg iron
224206679|NCT05455411|BEHAVIORAL|Group-based Parent-implemented Training|A group-based social communication training for parents of preschoolers with autism spectrum disorder will be taught by a speech therapist online (approximately 25 hours distributed over 6 months), with up to 8 parents in a group.
224206680|NCT05455411|BEHAVIORAL|Individual-based Parent-implemented Training|An individual-based social communication training for parents of preschoolers with autism spectrum disorder will be taught by a speech therapist online in a one-on-one format (approximately 25 hours distributed over 6 months).
224206681|NCT03087773|DRUG|Empagliflozin 10 mg|The subject will receive Empagliflozin 10 mg orally once daily for 26 weeks.
224206682|NCT03087773|DRUG|Placebo Oral Tablet|The subject will receive Placebo orally once daily for 26 weeks.
224206683|NCT00185731|DRUG|Atorvastatin|80 mg orally once daily
224206684|NCT02341794|DRUG|Rosuvastatin|Rosuvastatin (5mg) will be orally administrated once daily. Dose of rosuvastatin will be adjusted to control serum LDL-c level under 1.8 mmol/L.
224206685|NCT00571220|PROCEDURE|gastric bypass surgery|weight loss bariatric surgery
224206686|NCT00571220|OTHER|Diet induced weight loss|low calorie diet with meal replacements. weekly outpatient visits with nutritionist.
224206687|NCT04656782|OTHER|Imaging survey|Participation as expert panelist in the imaging survey.
224206688|NCT04656782|OTHER|Facilitation|Moderation and evaluation of the expert panel's answers. Adoption and moderation of further survey rounds.
224206689|NCT00396981|DEVICE|Matrix 2® coils for endovascular aneurysm occlusion|endovascular aneurysm occlusion coil
224206690|NCT00396981|DEVICE|GDC® coils for endovascular aneurysm occlusion|endovascular aneurysm occlusion coil
224206691|NCT06540924|OTHER|single nucleotide polymorphisms|The LBX1 (Ladybird Homeobox 1), TIMP2 (Tissue Inhibitor of Metalloprotease 2), GPR126 (G Protein-Coupled Receptor 126) and CHD7 (Chromodomain Helicase DNA Binding Protein 7) gene polymorphisms in adolescent idiopathic scoliosis patients and the control group were analyzed using real-time PCR with TaqMan probe SNP (single nucleotide polymorphism) primers (rs625039, rs11598564, rs6570507, rs121434341, rs11190870, rs8179090).
223512574|NCT05821088|PROCEDURE|Biopsy|Undergo tissue biopsy
223512575|NCT05821088|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223512576|NCT05821088|DRUG|Carboplatin|Given IV
223512577|NCT05821088|PROCEDURE|Computed Tomography|Undergo CT
223512578|NCT05821088|DRUG|Etoposide|Given IV
223512579|NCT05821088|DRUG|Ifosfamide|Given IV
223512580|NCT05821088|DRUG|Lenalidomide|Given PO
223512581|NCT05821088|PROCEDURE|Positron Emission Tomography|Undergo PET
223512582|NCT05821088|BIOLOGICAL|Tafasitamab|Given IV
223512583|NCT06162312|OTHER|Antenatal perineal massage|Participants at 34-35 weeks of gestation were received training in self-perineal massage and performed a daily 5-minute massage using water-based jelly until delivery to compare with standard obstetric care on postpartum morbidities
223512584|NCT00940121|DRUG|mirabegron|oral tablet
223512585|NCT00940121|DRUG|mirabegron|IV solution
223512586|NCT05522972|BEHAVIORAL|Video Game Vision Training|A new approach for improving amblyopic vision using video games
223512587|NCT05522972|BEHAVIORAL|Perceptual Learning|A new approach for improving amblyopic vision with perceptual learning
223512588|NCT05522972|BEHAVIORAL|Occlusion Therapy|Conventional treatment for amblyopia
223512589|NCT04135352|DRUG|200 mg of pembrolizumab|Participants receive 200 mg of pembrolizumab intravenously Q3W for a maximum of 35 21-day cycles.
223512590|NCT04135352|BIOLOGICAL|V938|Participants receive V938 intratumorally in cycles 1-7. Each cycle is 21 days.
223512591|NCT06639321|DEVICE|Percutaneous Ventricular Assist System|Percutaneous Ventricular Assist System provides intraoperative circulatory support during high-risk PCI.
223512592|NCT06639321|DEVICE|extracorporeal membrane oxygenation (ECMO)|ECMO provides intraoperative circulatory support during high-risk PCI.
223761415|NCT02444091|DRUG|Cyclophosphamide|Cyclophosphamide intravenous infusions four weeks apart, in total six infusions. First infusion: cyclophosphamide 600mg/m2. Infusions 2 to 6: cyclophosphamide 700 mg/m2 . Follow-up for 12 months.
224206692|NCT02624817|DRUG|Sulfonylurea|See Arm description.
224206693|NCT01931501|DRUG|Torrent's Montelukast Sodium Chewable Tablets 5mg|
224206694|NCT01931501|DRUG|Singulair® (Montelukast Sodium) Chewable Tablets 5mg|
224206695|NCT04916067|DEVICE|Mesh Implantation|Implantation of Phasix™ Soft Mesh - a knitted monofilament mesh scaffold using Poly-4-hydroxybutyrate (P4HB), a biologically derived material - to prevent hernia formation
224206696|NCT01749618|BEHAVIORAL|Education and Feedback|Rheumatologists are rated on how systematically they assess their patients, and receive six sessions of university accredited education about systematic assessments of patients with seronegative arthritis.
224206697|NCT03210142|PROCEDURE|Transvenous hypoglossal nerve stimulation|Transvenous hypoglossal nerve stimulation to open upper airway.
224206698|NCT00934778|PROCEDURE|Confocal microscopy and endocytoscopy|2 probe based imaging systems for use via the working channel of the bronchoscope. 0.5ml of methylene blue injected into airways for endocytoscopy. Each procedure takes about 2-3 minutes.
224206699|NCT00639158|DRUG|ABT-335|135 mg capsule, daily, 12 weeks
224206700|NCT00639158|DRUG|placebo|placebo capsule, daily, 12 weeks
224206701|NCT00639158|DRUG|atorvastatin|40 mg, tablet, daily, 12 weeks
224206702|NCT00639158|DRUG|ezetimibe|10 mg capsule, daily, 12 weeks
224206703|NCT03403712|DRUG|fosnetupitant/ palonosetron|intravenous fosnetupitant/ palonosetron (260 mg/0.25 mg) fixed-dose combination
224206704|NCT03403712|DRUG|netupitant/palonosetron|oral netupitant/palonosetron (300 mg/0.50 mg) fixed-dose combination
224206705|NCT03403712|DRUG|dexamethasone|Oral dexamethasone (12 mg)
224206706|NCT02232685|DEVICE|18F-Choline PET/CT|18F-Choline PET/CT
223618613|NCT00101686|DRUG|Modified Bolus 5-FU/LV with Irinotecan|Day 1 \& 8: Irinotecan (125 mg/m2 IV over 90 minutes), LV (20 mg/m2 IV bolus), 5-FU (500 mg/m2 IV bolus). All chemotherapy cycles repeated every 3 weeks. Celecoxib/placebo treatment will commence on the same day as chemotherapy treatment (i.e. Day 1 of treatment on study). Celecoxib/placebo will be taken at a dose of 400 mg po BID \[two times a day\] (800 mg/day) and will continue daily without interruption (no rest period for celecoxib/placebo treatment).
224206707|NCT04264988|PROCEDURE|Stopping of pelvic bleeding via several surgical methods|Those surgical methods were pelvic packing, electrocautery, energy devices, suturing, fastener, muscle welding, procoagulant chemicals, and combination of those
224206708|NCT05728918|DIETARY_SUPPLEMENT|Antrodia cinnamomea mycelia|Antrodia cinnamomea mycelia capsule, two capsules/day (600 mg/day) for 3 months
224206709|NCT05728918|DIETARY_SUPPLEMENT|Placebo|Placebo capsule, two capsules/day (600 mg/day) for 3 months
224206710|NCT03455114|DEVICE|AssiAnchor|"The novel device, the capsular Anchor, was designed to secure the capsular bag to the scleral wall. The device is a one-piece, one-plane intraocular implant . It works like a paper clip; holding the anterior capsule between a central rod, placed in front of the capsule, and the two lateral arms, inserted through the eye surgery and placed behind the capsule."
224206711|NCT03147521|OTHER|Care bundle|Risk fall assessment at hospital admission with Conley scale or with findings of specific risk characteristics (previous falls, cognitive impairment, neuropsychological damage, increased need to go to the bathroom for increased evacuative needs, neuroleptic or cardiovascular drugs assumption); if risk is found shear the information with the team, writing it in patient chart, and positioning a specific symbol on patient bed. Inform patient and family about fall risk and ask, if possible, a continuous caregiver presence. Universal strategy application for the environmental safety and patient safety. Periodic assessment of drugs therapy, with the aim of reduce those that acts on central nervous system and cardiovascular system. If patient is at risk and alone, verify each 2 hours the need to go to the bathroom, change position or drink.
224206712|NCT03891875|COMBINATION_PRODUCT|Subcutaneous elamipretide through the elamipretide delivery system|Subjects will be randomized in a 2:1 ratio to receive either elamipretide or placebo through the elamipretide delivery system. Subjects will dose daily for up to 48 weeks.
224206713|NCT03891875|COMBINATION_PRODUCT|Subcutaneos placebo through the elamipretide delivery system|Subjects will be randomized in a 2:1 ratio to receive either elamipretide or placebo through the elamipretide delivery system. Subjects will dose daily for up to 48 weeks.
224206714|NCT04331418|DRUG|Dexmedetomidine|1 mcg/kg IV over 10 minutes followed by 0.5 mcg/kg/hr
224206715|NCT04331418|PROCEDURE|caudal block|After negative aspiration of blood or cerebrospinal fluid, 2 mg/ kg of bupivacaine at concentration of 0.5% (volume 0.5ml/kg) was given as per the group assigned, then the site of injection was dressed, and the patient was turned supine.
224206716|NCT00661791|BEHAVIORAL|Massage therapy without exercise|Infants will receive massage twice a day; 15 minutes each.
224206717|NCT00661791|BEHAVIORAL|Massage therapy with exercise|Infants will receive massage with exercise twice a day; 15 minutes each.
224206718|NCT03884907|PROCEDURE|The patients will receive human bone graft screws surgically|All patients undergo Hallux valgus correction according to the Austin procedure using human bone graft screws.
224206719|NCT03821688|PROCEDURE|SAS-JB|single anastomosis sleeve jejunal bypass
224206720|NCT03821688|PROCEDURE|OAGB|one anastomosis gastric bypass
224206721|NCT03821688|PROCEDURE|LSG|laproscopic sleeve gastrectomy
224206722|NCT00921765|DRUG|Saline|Saline single bolus dose followed by saline single bolus dose iv
224206723|NCT00921765|DRUG|Saline + Ketamine|Single bolus dose of saline followed by ketamine 0.2 mg/kg bw
224206724|NCT00921765|DRUG|Naloxone + Placebo|Single bolus dose of naloxone 0.2 mg/kg bw followed by single bolus dose of saline
224206725|NCT00921765|DRUG|Naloxone + Ketamine|Single bolus dose of naloxone 0.2 mg/kg bw followed by single bolus dose of ketamine 0.2 mg/kg bw
224206726|NCT05467709|DRUG|Midazolam|2 mg Day 1 and Day 16
224206727|NCT05467709|DRUG|CTP-543|12 mg q12 hour for 14 consecutive days starting on Day 3
224206728|NCT02127229|PROCEDURE|Endoscopist informed of cost per procedure|Following each procedure, endoscopists will get a cost report regarding the amount spent on disposable accessories.
224206729|NCT00960310|DRUG|Bicalutamide 50 mg Film-Coated Tablets (Sandoz Inc., USA)|
224206730|NCT00960310|DRUG|Bicalutamide 50 mg Film-Coated Tablets (Casodex) (Astrazeneca Pharmaceutical LP, USA)|
224206731|NCT04752085|DIAGNOSTIC_TEST|Chitotriosidase activity|The chitotriosidase activity will be measured in all the subjects
224206732|NCT02460133|DRUG|Paritaprevir|
223512593|NCT06639945|DEVICE|transcranial MR-guided focused ultrasound|MRI-guided transcranial focused ultrasound (MRgFUS) combines magnetic resonance imaging (MRI) with focused ultrasound to target specific areas in the brain non-invasively. MRgFUS allows for treatment without surgical incisions, leading to fewer risks and a quicker recovery. MRI provides real-time imaging that helps precisely locate and treat affected brain regions, such as the thalamus or globus pallidus.The procedure allows for continuous monitoring of the treatment effects, enabling adjustments as needed.
223618614|NCT00101686|DRUG|FOLFIRI + bevacizumab|"Day 1 Bevacizumab 5mg/kg IV 90 minutes prior to irinotecan/LV Irinotecan 180 mg/m2 IV 90 minutes Leucovorin 400 mg/m2 IV 2 hours - given with irinotecan without mixing.~I m m e d i a t e l y f o l l o w e d b y :~5-FU 400 mg/m2 IV bolus 5-FU 2400 mg/m2 IV Continuous infusion over 46 hours Every 2 weeks~Amendment 2 Bevacizumab 5mg/kg IV 90 minutes prior to irinotecan/LV Irinotecan 180 mg/m2 IV 90 minutes Leucovorin 400 mg/m2 IV 2 hours - given with irinotecan without mixing.~I m m e d i a t e l y f o l l o w e d b y :~5-FU 400 mg/m2 IV bolus 5-FU 2400 mg/m2 IV Continuous infusion over 46 hours Celecoxib/placebo 400 mg BID \[two times a day\] oral Every 2 weeks"
224206733|NCT02460133|DRUG|Ritonavir|
224206734|NCT02460133|DRUG|Dasabuvir|
224206735|NCT02460133|DRUG|Ombitasvir|
224206736|NCT02460133|DRUG|Ribavirin|In genotype 1b individuals without cirrhosis, treatment will NOT include ribavirin.
224206737|NCT04143477|DRUG|peficitinib|Oral
224206738|NCT00425282|DRUG|RWJ-333369|
224206739|NCT01272739|DIETARY_SUPPLEMENT|IHBG-10|500 mg of IHBG-10 taken 15 minutes prior to the three main meals of the day
224206740|NCT01272739|DIETARY_SUPPLEMENT|Placebo|Placebo taken 15 minutes prior to the three main meals of the day
223618615|NCT00101686|DRUG|miFL + bevacizumab|Day 1 Bevacizumab 7.5mg/kg IV \*over 90 minutes - given prior to irinotecan, 5-FU, and leucovorin Irinotecan 125 mg/m2 IV over 90 minutes Leucovorin 20 mg/m2 IV bolus 5-FU 500 mg/m2 IV bolus Day 8 Irinotecan 125 mg/m2 IV over 90 minutes Leucovorin 20 mg/m2 IV bolus 5-FU 500 mg/m2 IV bolus Every 3 weeks Amendment 2 Day 1 Bevacizumab 7.5mg/kg IV over 90 minutes - given prior to irinotecan, 5-FU, and leucovorin Irinotecan 125 mg/m2 IV over 90 minutes Leucovorin 20 mg/m2 IV bolus 5-FU 500 mg/m2 IV bolus Celecoxib/placebo 400 mg BID \[two times a day\] oral Day 8 Irinotecan 125 mg/m2 IV over 90 minutes Leucovorin 20 mg/m2 IV bolus 5-FU 500 mg/m2 IV bolus Celecoxib/placebo -- 400 mg po BID \[two times a day\] continues daily without interruption Every 3 weeks
223618616|NCT00101686|DRUG|Infusional 5-FU/LV with Irinotecan|Day 1: Irinotecan (180 mg/m2) IV over 90 minutes, LV (racemic mixture 400 mg/m2) over 2 hours during irinotecan infusion but without mixing, immediately followed by 5-FU IV bolus (400 mg/m2) and 5-FU continuous infusion (2400 mg/m2) over 46 hours. FOLFIRI regimen is repeated every 2 weeks. Celecoxib/placebo treatment will commence on the same day at a dose of 400 mg po BID \[two times a day\](800 mg/day) and will continue daily without interruption (no rest period for celecoxib/placebo treatment).
223618617|NCT00101686|DRUG|Oral Capecitabine with Irinotecan|Day 1: Irinotecan (250 mg/m2 IV) over 90 minutes; Day 1-14: capecitabine 1000 mg/m2 PO BID \[two times a day\] (28 single doses). All chemotherapy cycles repeated every 3 weeks. Celecoxib/placebo treatment will commence on the same day as chemotherapy treatment (i.e. Day 1 of treatment on study). Celecoxib/placebo will be taken at a dose of 400 mg po BID (800 mg/day) and will continue daily without interruption (no rest period for celecoxib/placebo treatment).
223618618|NCT03599206|DRUG|Ozone|Subjects will perform alternating 15 minutes rest with 15 minutes treadmill walk exercise periods for 135 minutes in while breathing Ozone (O3).
223618619|NCT03599206|OTHER|Filtered Air|Subjects will perform alternating 15 minutes rest with 15 minutes treadmill walk exercise periods for 135 minutes in while breathing filtered air.
223618620|NCT05923840|DIAGNOSTIC_TEST|Chemoreflex Testing|The carotid body chemoreflex can be tested by holding carbon dioxide (CO2) constant (isocapnic) and applying hypoxia and hyperoxia. Measurements are then made of expiratory minute volume and of sympathetic activity. The central chemoreflex measures isocapnic and hypercapnic responses in the presence of hyperoxia to suppress the carotid body chemoreflex.
223618621|NCT05923840|DIAGNOSTIC_TEST|Baroreflex testing|Baroreceptors are measured by the change of heart rate (HR) and sympathetic activity with changing blood pressure using the modified Oxford technique. Blood pressure is lowered an amount by a bolus of sodium nitroprusside and then raised by a bolus of phenylephrine. When standing baroreflexes are activated and the investigators will measure chemoreflex activity upright to see how baroreflex effects the chemoreflexes. Similarly chemoreflexes affect the baroreflexes best observed when the patients are supine.
223618622|NCT05923840|DIAGNOSTIC_TEST|Orthostatic stress testing|Orthostatic Stress tests are administered in two forms: a standing test to evoke the initial orthostatic hypotensive response that sensitizes and triggers the carotid body chemoreflex by intermittent stagnant ischemia. And the 70 degree upright tilt test that best identifies causal changes in regional blood volumes and flows and in respiratory patterns of hyperpneic hypocapnia.
223761416|NCT05733143|OTHER|cardiopulmonary exercise stress test (CPEST)|The study is observational and purely exploratory. We will utilise cardiopulmonary exercise stress testing to assess levels of fitness and causes for symptoms in proposed groups.
223761417|NCT06227377|DRUG|QTX3034|QTX3034 will be administered at protocol defined dose
223761418|NCT06227377|COMBINATION_PRODUCT|Cetuximab|Cetuximab will be administered at protocol defined dose.
224206741|NCT06290258|PROCEDURE|Fecal microbiota transplantation|Fecal microbiota transplantation has been applied to patients with autism spectrum disorder in recent years. Fecal microbiota of healthy donors can be transplanted to patients through colonoscopy. Before donation, donors were comprehensively screened to rule out gastrointestinal symptoms and infections. Patients will receive colon preparation before transplantation. After the intervention, patients will have to stay in bed and be monitored for 24 hours to assure safety.
224206742|NCT01456871|PROCEDURE|Guided insertion of electrodes|Fine-wire needle electrodes (30mm x 27gauge needle with a pairs of 0.051mm, insulated, hooked wires, Motion Lab Systems, Baton Rouge, LA) guided by sonographic evaluation of the pulley system using a Philips iU22 Ultrasound Machine (Philips Ultrasound Systems, Bothell, WA), a 17-5 MHz linear array transducer, and standard ultrasound gel.
224206743|NCT01456871|PROCEDURE|Electromyographic (EMG) recording|EMG signal recording, performed with an MA 300 EMG system (Motion Lab Systems, Baton Rouge, LA).
224206744|NCT02357407|DRUG|Patients in intensive care : infection treated with ciprofloxacin IV|8-10 samples per patients on day-4 of their treatment
224206745|NCT02357407|DRUG|Osteoarticular infected patients : infection treated with oral ofloxacin|8-10 samples per patients on day-4 of their treatment
224206746|NCT02079428|OTHER|No interventions|
224206747|NCT05860608|DEVICE|Us2.ai (AI-enabled report) handheld echocardiogram|NT-proBNP will be performed in all individuals randomized to the ACTIVE arm at the same visit as informed consent, and those with elevated NT-proBNP (≥125pg/ml) will be invited to attend a visit for an Us2.ai (AI-enabled) echocardiogram which will be controlled with a standard echocardiographic study if the AI-echo is non-diagnostic.
224206748|NCT01370434|DRUG|PAD combination|"* Bortezomib 1.3 mg/m2/d iv on D 1, 4, 8, 11~* Doxorubicin 9 mg/m2/d iv on D 1-4~* Dexamethasone 40mg/d po or iv on D1-4, 8-11"
224206749|NCT00943384|DEVICE|chronOS Strip|chronOS strip combined with bone marrow aspirate plus local bone
224206750|NCT05807347|DRUG|Venetoclax|VA regimen Drug: Venetoclax orally once daily (100 mg d1, 200 mg d2, 400 mg d3-21); Drug: Azacitidine 75 mg/m2 subcutaneously once daily on days 1-7. CAG regimen Drug: Cytarabine 10mg/m2 subcutaneously q12h on days 1-7 Drug: Aclacinomycin 12-14mg/m2 on days 1,3,5,7 Drug: Granulocyte colony-stimulating factor 5ug/kg on days 0-8, discontinue if WBC \>20×109/L
224206751|NCT00553033|PROCEDURE|Laparoscopic liver surgery|Ultrasonic dissector, harmonic scalpel
224206752|NCT01920074|DRUG|Nitroglycerin Ointment 0.4%|
224206753|NCT04004273|BEHAVIORAL|Exercise|24 moderate-intensity exercise training sessions over six weeks (four times per week; \~50 min per session)
224206754|NCT04937452|DRUG|Rotigotine 4Mg/24Hrs Patch|Rotigotine 4 mg/24Hrs administration for 24 weeks
224206755|NCT04937452|DRUG|Rotigotine 6Mg/24Hrs Patch|Rotigotine 6 mg/24Hrs administration for 24 weeks
224206756|NCT04937452|DRUG|Placebo|Placebo administration for 24 weeks
223618623|NCT02525471|DRUG|RNS60|"RNS60 will be administered in two ways: by intravenous (IV) infusion one day a week (infusion dose: 375ml, infused over a 40-min period) and by inhalation (the remaining 6 days a week, 4 ml/day) for 23 weeks.~In addition, subjects will be given the option to continue to receive drug for approximately an additional 24 weeks, for a total of approximately 48 weeks on study drug. Study drug will be given by intravenous (IV) infusion one day a week (infusion dose: 375ml, infused over a 40-min period) and by inhalation (the remaining 6 days a week, 4 ml/day) during the extension phase."
223618624|NCT04390451|BEHAVIORAL|Whole Health STEPS|A peer-delivered package of Whole Health services.
223618625|NCT05904197|OTHER|Gamified Cards about Nephrotic Syndrome|"* The study intervention Spin to Win - Nephro Cards will include the following items with simple Arabic language and graphic designation appropriate to children's developmental levels including; nephrotic syndrome, hygiene practices, weight control, fluids, blood pressure control, diet, medication…etc.~* A spin wheel with numbers and images similar to the educational gamified cards will be designed. Children will request to spin the wheel. After the spin, the educational gamified Nephro Cards will reveal and discuss with the child."
223618626|NCT00867165|DRUG|ezetimibe|oral tablets: ezetimibe 10 mg once daily for 12 weeks
223618627|NCT00867165|DRUG|Placebo|oral tablets: placebo to match ezetimibe 10 mg; administered once daily during the 5-week, single-blind, placebo run-in and diet stabilization period and 12-week double-blind treatment period
223618628|NCT04138992|DRUG|bevacizumab|bevacizumab will be used during neoadjuvant and concurrent chemoradiotherapy
223618629|NCT04138992|DRUG|DDP|DDP will be used during neoadjuvant and concurrent chemoradiotherapy
223761419|NCT01454921|BEHAVIORAL|Evolution: Young Women Taking Charge and Growing Stronger|The intervention aims to address the following concerns: 1) reducing the risk of young women infected with HIV transmitting the virus to their sexual partners, and 2) preventing young women infected with HIV from re-infection with a new viral strain or co-infection with another sexually transmitted disease (STD).
224206757|NCT01890018|BEHAVIORAL|Electronic Pill Bottle tracking|All 4 groups will use the GlowCaps, a remote monitoring bottle, to take their statin medications
224206758|NCT01890018|BEHAVIORAL|Adherence Messaging|Some arms will receive adherence messages if they have not used the Glowcap bottles for 2 of the last 3 days.
223618630|NCT04138992|DRUG|Docetaxel|used in neoadjuvant chemotherapy
223618631|NCT04138992|RADIATION|radiotherapy|standard treatment includes pelvic external beam radiation and brachytherapy
223618632|NCT02183857|DEVICE|Ultrasound|
223618633|NCT02183857|OTHER|Landmark|
223618634|NCT04125043|DIAGNOSTIC_TEST|Direct ophthalmoscope|Red reflex test
223761420|NCT02582853|PROCEDURE|Lumbar puncture|Lumbar puncture for spinal fluid
223761421|NCT02582853|PROCEDURE|Blood Sample|Blood sample
223773658|NCT05940675|BEHAVIORAL|Community capacity building|Community capacity building in selected local communities. To promote healthier eating, children and families need to be supported within their local community by food environments that make the healthy choice the easy choice and not a challenge in their everyday life. To promote physical activity, the children will be invited to participate in activities in the local sports clubs including camps in the holidays.
224206759|NCT01890018|BEHAVIORAL|Social Influence|Some arms will select their own adherence feedback partner who will provide support in taking their medication as scheduled.
224206760|NCT03199989|DRUG|CapeOX（Capecitabine+Oxaliplatin）|Patients enrolled in the chemotherapy group would receive postoperative chemotherapy CapeOX（Capecitabine+Oxaliplatin）for 6 months
224206761|NCT03199989|OTHER|Observation|Patients enrolled in the observation group would not receive any chemotherapy drugs just for observation
223618635|NCT04441411|DEVICE|NEMOST system|Minimal invasive double rod posterior Non-Fusion Scoliosis Surgery
223618636|NCT05806437|DIETARY_SUPPLEMENT|sideremil vita cp|assunzione per 30 giorni dell'integratore
223618637|NCT00890825|DRUG|AZD6244|oral capsules, 75mg twice daily
223618638|NCT00890825|DRUG|docetaxel|75mg/m2 iv on day 1 of every 21 day cycle
223618639|NCT00890825|DRUG|Placebo|placebo
223618640|NCT01054456|DRUG|palonesetron|One dose administered intravenously 30 minutes pre-chemotherapy
223618641|NCT00611689|DRUG|Imatinib and PTK/ZK222584|Imatinib and PTK/ZK will each be administered orally daily. Two dose levels of imatinib (400 mg and 600 mg) will be tested with 4 dose levels of PTK/ZK (250 mg, 500 mg, 750 mg, and 1000 mg). 3 patients will be accrued at each individual dose level. If dose-limiting toxicities are reported in ≤ 1/3 patients, the dose level will be expanded to 6 patients. If dose-limiting toxicities are reported in \< 2/6 patients, then dose escalation will continue. If ≥ 2/6 patients experience dose-limiting toxicity, the next lower dose will be considered the maximum tolerated dose and will be expanded to a total of 12 patients. There will be no intrapatient dose escalations. Patients may continue to receive treatment until unacceptable toxicity or disease progression is encountered.
223618642|NCT02498288|DRUG|Isotretinoin: Reference Medication 1|Isotretinoin reference medication 1 will be 40 mg in the pharmaceutical form of capsule (2 capsules of 20 mg each)
224206762|NCT00101374|DRUG|Leflunomide|
224206763|NCT02205281|BEHAVIORAL|Lifestyle Intervention|The intervention is a multi-component program designed to prevent excessive gestational weight gain in overweight and obese women and to promote weight loss in their non-pregnant overweight and obese partners through modifications of diet, exercise, and behavioral strategies during pregnancy.
224206764|NCT05972954|DRUG|OMT-28|once daily
224206765|NCT01955473|DRUG|Sym004|Part-A (dose-escalation): Sym004 will be administered intravenously either weekly at 6 to 12 milligram per kilogram (mg/kg) or biweekly at 18 mg/kg from Week 1 until unacceptable toxicity, disease progression, or consent withdrawal. Part-B (dose-expansion): After the maximum tolerated dose (MTD) is determined in Part-A, up to 30 additional subjects will continue to receive treatment in Part-B.
224206766|NCT02837250|BEHAVIORAL|Pos4Health|This is a personalized, interactive, patient-centered Internet intervention targeting nonadherence to ART among substance users living with HIV.
224206767|NCT02837250|BEHAVIORAL|Patient Education|This is a patient education website with content about nonadherence to ART pertinent to substance users living with HIV.
224206768|NCT04011111|PROCEDURE|Intubation tube and voice analysis|After the ıntubation tube application, done voice analysis early postoperative period
224206769|NCT01584804|DRUG|Su-Huang antitussive capsule|Su-Huang antitussive capsule (0.45g) 3 capsules Tid for 2 weeks (swallowed by warm water at 0.5-1h after each meal)
223618643|NCT02498288|DRUG|Isotretinoin: Reference Medication 2|Isotretinoin reference medication 2 will be 40 mg in the pharmaceutical form of capsule (2 capsules of 20 mg each)
223618644|NCT02498288|DRUG|Isotretinoin: Test Medication|Isotretinoin test medication will contain isotretinoin 40 mg (2 capsules of 20 mg each) in the same type of pharmaceutical presentation, containing the same drug but possible to have a different excipients.
223618645|NCT03781661|OTHER|Extended information|The extended information consists out of an information leaflet and a visual go-through of the participants calcium score images. The patients are then given the normal examination result.
223618646|NCT04711785|BEHAVIORAL|Multicomponent exercise program|"The exposed group will carry out the following program of specific muscle strength and cardio physical activity aimed at reducing frailty.~For 2.5 hours per week."
224206770|NCT01584804|DRUG|Sugar pill|Sugar pill 3 capsules Tid for 2 weeks (swallowed by warm water at 0.5-1h after each meal)
223618647|NCT05016466|OTHER|Standard Care|Patients will followed during 5 years, and only 2 visits , baseline and 5 years
224206771|NCT06539286|DEVICE|Laser Irradiation|three different laser wavelengths will be used
224206772|NCT03422796|DRUG|Cilostazol 200mg|Cilostazol is given both study days to induce headache. One day the headache is treated with placebo and the other day with sumatriptan
224206773|NCT03422796|DRUG|SUMAtriptan 6 MG/ML|Cilostazol is given both study days to induce headache. One day the headache is treated with placebo and the other day with sumatriptan
224206774|NCT03422796|DRUG|Placebo|Cilostazol is given both study days to induce headache. One day the headache is treated with placebo and the other day with sumatriptan
224206775|NCT00481871|DRUG|Pralatrexate Injection|"Intravenous (IV) push administration over 30 seconds to 5 minutes into a patent IV line containing normal saline (0.9% sodium chloride).~Sequential Dosing: 10 mg/m2 every 2 weeks (days 1 and 15) of a 4-week cycle until criteria for discontinuation per the protocol are met.~Same Day Dosing: 15 mg/m2 every 2 weeks (days 1 and 15) of a 4-week cycle until criteria for discontinuation per the protocol are met."
224206776|NCT00481871|DRUG|Gemcitabine Hydrochloride|"Gemcitabine will be prepared and administered as an IV infusion as per manufacturer instructions.~Sequential Dosing: 400 mg/m2 every 2 weeks (days 2 and 16) of a 4-week cycle until criteria for discontinuation per the protocol are met.~Same Day Dosing: 600 mg/m2 every 2 weeks (days 1 and 15) of a 4-week cycle until criteria for discontinuation per the protocol are met."
224206777|NCT00481871|DIETARY_SUPPLEMENT|Vitamin B12|"1 mg intramuscular injection~Administered within 10 weeks of enrollment, every 8-10 weeks throughout the study and for at least 30 days after last dose of pralatrexate."
224206778|NCT00481871|DIETARY_SUPPLEMENT|Folic Acid|"1 mg orally~Administered daily for at least 7 days prior to start of pralatrexate, throughout the study and for at least 30 days after last dose of pralatrexate."
224206779|NCT03125239|DRUG|Merestinib|Oral, once a day, Merestinib Only- Lead in period on week. The followed by cycles on combination therapy with Merestinib and LY2874455 (28 days long)
224206780|NCT03125239|DRUG|LY2874455|This will be followed by cycles of combination therapy with merestinib and LY2874455. Each of these cycles are 28 days long. • LY2874455 will be taken by mouth twice a day. You may take LY2874455 twice daily for 14 days, 21 days, or 28 days each cycle depending on the dose level you are assigned.
224206781|NCT04292756|PROCEDURE|Subtenon injection of 40 mg triamcinolone acetonide|Subtenon injection of 40 mg triamcinolone acetonide: 1 initial injection of 40 mg triamcinolone acetonide, further injections will be base at month 3 examination.
224206782|NCT04292756|PROCEDURE|Intravitreal injection of 4 mg triamcinolone acetonide|Intravitreal injection of 4 mg triamcinolone acetonide: 1 initial injection of 4 mg triamcinolone acetonide, further injections will be base at month 3 examination.
224206783|NCT04292756|DIAGNOSTIC_TEST|Visometry|Ophthalmic examination
223618648|NCT05016466|OTHER|Standard Care plus oxidative stress study plus inflammation biomarkers study|Patients will followed during 5 years, Annual follo-up visits will be carried out during this period
223618649|NCT05591092|PROCEDURE|Computed Tomography|Undergo a SPECT/CT scan
223618650|NCT05591092|RADIATION|Iodine I-123|Given PO
223618651|NCT05591092|PROCEDURE|Planar Imaging|Undergo planar imaging
223618652|NCT05591092|PROCEDURE|Single Photon Emission Computed Tomography|Undergo a SPECT/CT scan
223618653|NCT00017511|DRUG|cevimeline hydrochloride|
223618654|NCT02124733|PROCEDURE|Aminolevulinic acid based photodynamic therapy|The PDT treatments will be done in two stages. ALA (Levulan® Kerastick™) will be applied to the entire treatment area, and then the longer light exposure (lasting up to 1 hr) will be performed on one-half of the treatment area (Side A). After that, a shorter (16 min 40 sec) light exposure will be done on the other half (Side B).
223761422|NCT06842875|BEHAVIORAL|RI-SPHERES|Participants assigned to the RI-SPHERES group will be introduced virtually or in-person to the care manager (CM), who demonstrate how to communicate directly with patients through the app for medical or non-medical needs. Each participant will learn how to obtain SMBP, sync the LTE-enabled BP cuff to the RI-SPHERES app, and respond to adaptive messaging pertaining to BP measurements, which include the ability to receive on-demand education on postpartum topics (e.g., HDP, breastfeeding, mood disorders) per participant preference. During the study period, the CM will respond to needs elicited from the SDoH screening by facilitating referrals to community resources. After six weeks, the focus of RI-SPHERES will transition to preventive care in addition to SMBP. The CM will engage monthly with each study participant to ensure they have a primary care provider and to facilitate preventive care visits or specialist appointments, if needed.
224206784|NCT04292756|DIAGNOSTIC_TEST|Fluorescent angiography|Ophthalmic examination
224206785|NCT04292756|DIAGNOSTIC_TEST|Refractometry|Ophthalmic examination
224206786|NCT04292756|DIAGNOSTIC_TEST|Slit lamp examination|Ophthalmic examination
224206787|NCT04292756|DIAGNOSTIC_TEST|Ophthalmoscopy|Ophthalmic examination
224206788|NCT04292756|DIAGNOSTIC_TEST|OKT|Ophthalmic examination
224206789|NCT04292756|DIAGNOSTIC_TEST|IOP|Ophthalmic examination
223618655|NCT00881517|DRUG|HCMV-specific hyperimmune globulin (Cytotect®)|100U (2.0ml)/Kg i.v. every 4 weeks up to 38 weeks' gestation or HCMV-positive amniocentesis or pregnancy termination.
223618656|NCT00881517|DRUG|Isotonic solution of sodium chloride (placebo)|2.0ml/Kg i.v. every 4 weeks until 38 weeks'gestation or HCMV-positive amniocentesis or pregnancy termination
224314659|NCT06490614|DRUG|Nalbuphine in superficial cervical plexus block|While the patient is in the supine position, the head will be turned to the opposite side of the surgical incision, and a line extending from the mastoid process to the clavicular head of the sternomastoid muscle will be marked. Aseptic preparation of this area will be done, and then the block needle will be inserted at the midpoint of this line with injection of bupivacaine 0.25%, 10 mg of Nalbuphine (nalufin 20mg/ml), and adrenaline 1:200,000 in a total volume of 10ml normal saline in the above, below, and middle directions subcutaneously, creating a sausage-shaped swelling. The sensory block will be assessed with ice chips in the dermatome corresponding to the block, which included the skin of the neck, upper chest, shoulder, and ear, until the completion of the sensory blockade.
224314660|NCT04885465|BEHAVIORAL|web-based psychoeducational support|Caregivers in the experimental group will have access to psycho-educational support through a web-based plattform during 3 months.
223512594|NCT04082273|DEVICE|Femtosecond Laser for Cataract Surgery|Cataract Surgery on study eye according to conventional procedure, with the exception of three steps (Capsulotomy, Lens Fragmentation and Clear Corneal Incisions) which are performed with a Femtosecond Laser in the laser treatment group. Equipment uesd for measurements is the same for both groups and in line with the normal equipment used for the conventional cataract treatment
224206790|NCT03451474|PROCEDURE|Upper extremity nerve transfer surgery|Upper extremity nerve transfer surgery is a surgical procedure where axons from an intact, functioning upper extremity peripheral nerve are moved to a target muscle that demonstrates significant weakness or paralysis as a result of spinal cord injury. After allowing time for recovery from surgery and for nerve growth to occur, the patient undergoes hand/occupational therapy in order to retrain motor skills.
224206791|NCT04681495|BEHAVIORAL|STAC|STAC is a brief, stand-alone bullying bystander intervention for middle school students, to reduce bullying and mental health risks for bystanders. The primary outcome will be showing usability for the technology-based program (STAC-T) prototype.
224206792|NCT05593783|PROCEDURE|lithotripsy|lithotripsy
224206793|NCT03039205|DRUG|Clopidogrel|Clopidogrel 600 mg loading dose + 75 mg q.d. for 7 to 9 days
224206794|NCT03039205|DRUG|Ticagrelor|Ticagrelor 180 mg loading dose + 90 mg b.i.d. for 7 to 9 days
224206795|NCT04737811|OTHER|Turkish Version of Swallowing Disturbance Questionnaire|The Turkish Version of Swallowing Disturbance Questionnaire consists of 15 questions related with dysphagia.
224206796|NCT05069428|DRUG|Ramelteon 8mg|administered crushed, orally at 20:30
224206797|NCT06525155|DRUG|Triptorelin Embonate|Treatment 1: 3.75 mg twice before surgery (baseline and week-6) and once after surgery at week-12
224206798|NCT06525155|DRUG|Triptorelin Embonate|Treatment 2: 3.75 mg once after surgery at week-12
224206799|NCT04754919|OTHER|Transition intervention group|Support and on-going treatment intervention; monitoring the uptake of routine annual diabetes tests and encouraging to access where default observed General specialist diabetes support and provision of education and referral to other specialist healthcare agencies as individual requires
224206800|NCT04754919|OTHER|Post transition group|The previous fifty eligible young people who have transitioned to adult service, will be compared with the active comparator group.
224206801|NCT03974516|DRUG|Careseng 1370|Careseng 1370 should be taken around 1 hour before meal.
224206802|NCT03454672|DEVICE|Tixel|Tixel treatment. Between 3-5 treatment sessions according to investigator's review of subject response.
224206803|NCT03454672|DEVICE|Laser|Tixel treatment. Between 3-5 treatment sessions according to investigator's review of subject response.
224206804|NCT02351297|DIETARY_SUPPLEMENT|casein supplementation|After the run-in period, volunteers will receive casein supplementation (15 % of energy intake) for 3 weeks.
224206805|NCT02351297|DIETARY_SUPPLEMENT|soy protein supplementation|After the run-in period, volunteers will receive soy protein supplementation (15 % of energy intake) for 3 weeks.
224206806|NCT02351297|DIETARY_SUPPLEMENT|maltodextrin supplementation|After the run-in period, volunteers will receive maltodextrin supplementation (15 % of energy intake) for 3 weeks.
224206807|NCT01301248|OTHER|Chemoradiation plus Cetuximab|Radiotherapy 65-70 Gy (1.8 Gy fractionation) Chemotherapy delivered weekly (cisplatin; 40mg/m2)concurrently with weekly cetuximab 250mg/m2 (following initial loading dose of 400mg/m2 a week before radiotherapy initiation)
224314661|NCT02015429|DIETARY_SUPPLEMENT|Pasta meal with added fractions or control with no fractions|
224314662|NCT03577548|OTHER|Auto- questionnaires|10 auto-questionnaires are submitted to the patient during his/her consultation (which is part of the standard care).
224314663|NCT01205386|DEVICE|1. CROSSER System|The Crosser system will be used to recanalize the chronic total occlusion in the SFA (superficial femoral artery). The IVUS (Intravascular Ultrasound Imaging) System will be used in the treated occlusion after the Crosser to generate real-time images of the artery.
223512595|NCT04082273|OTHER|Conventional Cataract Surgery|Cataract surgery will be performed conventionally, this means the clear corneal incisions will be performed manually by a blade, the capsulorhexis will be performed manually by a hook, and the lens extraction will be done by phacoemulsification
223512596|NCT03093870|DRUG|Varlitinib|Varlitinib:300mg, oral tablets, twice daily. Number of cycles: until disease progression, unacceptable toxicity, withdrawal of consent, or death.
223512597|NCT03093870|DRUG|Capecitabine|1000mg/m2, oral tablets, twice daily for 2 weeks followed by a 1-week rest period in 3-week cycles. Number of cycles: until disease progression, unacceptable toxicity, withdrawal of consent, or death.
223512598|NCT03093870|DRUG|Placebo (for Varlitinib)|oral tablets, twice daily. Number of cycles: until disease progression, unacceptable toxicity, withdrawal of consent, or death
223512599|NCT01660685|BEHAVIORAL|Tracking|Participants will record their daily weight, physical activity steps and meal replacements online
223512600|NCT01660685|BEHAVIORAL|Journaling|Participants will journal to two online writing prompts: one on positive focus and one on goal setting
223512601|NCT01660685|BEHAVIORAL|Website|Participants will have access to resource website with stories and tips from people who successfully lost weight, blogs from investigators, quotes from other participants.
223512602|NCT01660685|BEHAVIORAL|Enhanced Usual Care|Participants will receive standard care of monthly height, weight and blood pressure measurements. Participants will also receive a pedometer and a diet plan book on pre-portioned items.
223512603|NCT00980629|DRUG|M516102|Twice a day
223512604|NCT00980629|DRUG|placebo|Twice a day
224314664|NCT05944380|DRUG|Ropivacaine 0.5% Injectable Solution|20 mL 0.5% ropivacaine will be injected for the PENG block
224314665|NCT05944380|DRUG|0,9% normal saline|20 mL 0.9% normal saline will be injected for the PENG block
224206808|NCT01301248|OTHER|Chemoradiation|Radiotherapy 65-70 Gy (1.8 Gy fractionation) Chemotherapy delivered weekly (cisplatin; 40mg/m2
224206809|NCT03004417|DRUG|CHF 6001 Dose1|CHF 6001 plus placebo
224206810|NCT03004417|DRUG|CHF 6001 Dose2|CHF 6001 only (high dose)
224206811|NCT03004417|OTHER|Placebo|Placebo only
224206812|NCT05496595|DRUG|DCBY02|A monoclonal antibody that binds to CD93, DCBY02 will be administered as a single intravenous (IV) infusion on Day 1 in each 21-day cycle.
224206813|NCT06567158|OTHER|Moderate carbohydrate diet|During the moderate carbohydrate diet, participants will be asked to limit his/her carbohydrate intake to no more than 30% of their total energy intake.
224206814|NCT06567158|OTHER|Traditional diet|During the traditional diet, participants do not follow any diet, however their carbohydrate intake must be at least 50% of their total energy intake.
224206815|NCT01058876|DRUG|Deuterated nicotine and cotinine|used as a marker for pharmacokinetic studies
224206816|NCT03890861|BEHAVIORAL|Physical activity|Promotion of physical activity to the current federal physical activity guidelines.
224206817|NCT03890861|BEHAVIORAL|Successful Aging|Seminars of health topics related to aging in African Americans with light stretching and low intensity activites
224206818|NCT04730973|DRUG|Evolocumab|Evolocumab 140 mg s.c. every two weeks on top of optimal lipid lowering therapy
224206819|NCT04730973|OTHER|lipid-lowering therapy (LLT)|lipid-lowering therapy (LLT)
224206820|NCT00348049|PROCEDURE|Laser in Situ Keratomileusis (LASIK)|
224206821|NCT00348049|PROCEDURE|Photorefractive Keratectomy (PRK)|
224206822|NCT06025487|BIOLOGICAL|Bexsero|two doses of Bexsero are applied intramuscularly with a one-month interval between doses
224206823|NCT06390423|DIAGNOSTIC_TEST|Passive leg raise, SVI via bioreactance, Echo based VTI|No interventions other than fluid challenge
224206824|NCT06565377|BEHAVIORAL|Multimodal biopsychosocial teleprehabilitation|"Multimodal biopsychosocial teleprehabilitation containing (pain science and lifestyle) education, stress management and physical activity promotion, guided by shared decision making, motivational interviewing and solution focused therapy principles.~Format: 4 preoperative and 1 postoperative one-on-one (tele-)conferencing sessions with a physical therapist, supplemented by an informational booklet."
224206825|NCT06565377|OTHER|Best-evidence prehabilitation advice|Best-evidence prehabilitation advice in accordance with the NICE guideline on Joint Replacement (Primary): hip, knee and shoulder (2020), by means of an informational booklet.
224260359|NCT05882630|DRUG|Surufatinib,Serplulimab,Etoposide,Carboplatin|"In dose escalation, Surufatinib will be administered orally (PO) once daily (QD) ,d1-21,q3w + Serplulimab 4.5 mg/kg ivgtt,d1,q3w+Etoposide 100mg/m2,d1-3,q3w + Carboplatin AUC=5,d1,q3w; 4-6 cycles in total.~At the indication-specific expansion portion of the study, patients will receive surufatinib RP2D,d1-21,q3w+Serplulimab 4.5 mg/kg ivgtt,d1,q3w+Etoposide 100mg/m2,d1-3,q3w + Carboplatin AUC=5,d1,q3w, 4-6 cycles in total. After the end of the first-line treatment, patients with CR, PR, and SD can continue to maintenance treatment with Surufatinib RP2D,d1-21,q3w＋Serplulimab 4.5 mg/kg ivgtt,d1,q3w until the disease progressed."
224260360|NCT00754455|BIOLOGICAL|Influenza VLP Vaccine (recombinant)|Single injection Day 0; 0.5mL
224260361|NCT00754455|BIOLOGICAL|Placebo|Placebo as a single injection of 0.5 mL.
224314666|NCT01498731|BEHAVIORAL|Discharge home|Patients who test negative for Copeptin at admission will be considered low-risk and will be discharged home. To secure the patients safety they will be transferred into our co-operating network of resident cardiologists preferably the next day (but latest within the next three days). In case of any findings suggestive of acute coronary syndrome or worsening of the patient's condition, the patient will immediately be re-admitted to our Emergency Room.
224314667|NCT04211727|DIAGNOSTIC_TEST|Capillary finger prick blood sample|Patients will have a blood finger prick sample
224314668|NCT02092467|DRUG|tofacitinib|Oral tablet, 5 mg BID
224314669|NCT02092467|DRUG|tofacitinib|Oral tablet, 10 mg BID
223512605|NCT00005775|DRUG|Glutamine|Infants randomized to glutamine supplementation will receive glutamine any time that parenteral nutrition is required during the first 120 days of hospitalization.
223512606|NCT00005775|DRUG|Placebo|TrophAmine given any time that parenteral nutrition is required during the first 120 days of hospitalization.
223512607|NCT06542341|DEVICE|decoLITE (TN2037)|Red/Near infra red light therapy
223512608|NCT06563752|OTHER|Participants will use 3D glasses to view VR educational information|"Participants will use 3D glasses to view VR educational information, which includes:~1. Understanding of psychiatric symptoms, including symptoms, disease course, treatment, and prognosis.~2. Knowledge about medications, their relationship with symptom stabilization, and handling of side effects.~3. Schizophrenia as a chronic illness, with analogies to other chronic diseases.~4. Signs of disease relapse.~5. How to manage ongoing psychiatric symptoms of schizophrenia, including delusions, hallucinations, paranoia, and negative symptoms.~6. Strategies for interacting and communicating with patients.~7. Stress management and adjustment, as well as suicide prevention.~8. Available resources."
223512609|NCT06563752|OTHER|routine care|Before discharge, provide routine discharge preparation instructions and offer a disease education booklet with relevant health information. Follow up with two phone calls after discharge, on the 7th and 30th days.
223512610|NCT05383898|DRUG|D-1553|D-1553 is a novel, targeted KRasG12C inhibitor that is being developed as a potential oral agent for advanced or metastatic solid tumors with KRasG12C mutation.
223512611|NCT05431179|DRUG|Zilovertamab|After 16 weeks in the open-label Ibrutinib phase, participants will receive zilovertamab (600mg) administered by IV every 2 weeks for 3 administrations and then every 4 weeks thereafter.
223512612|NCT05431179|DRUG|Ibrutinib|All participants will receive oral Ibrutinib (560mg) daily.
223512613|NCT05431179|DRUG|Placebo|After 16 weeks in the open-label Ibrutinib phase, participants will receive placebo administered by IV every 2 weeks for 3 administrations and then every 4 weeks thereafter.
224314670|NCT02092467|BIOLOGICAL|adalimumab|Pre-filled syringe, 40 mg subcutaneous injection, every other week
224314671|NCT02092467|BIOLOGICAL|etanercept|Pre-filled syringe, 50 mg subcutaneous injection, every week
224314672|NCT01104467|DRUG|Desmoteplase|1 bolus injection of desmoteplase 70 µg/kg intravenous (IV)
223618657|NCT01622621|PROCEDURE|Sublobar Resection|Undergo surgery which removes a sublobar resection of the lung
223618658|NCT01622621|RADIATION|Stereotactic Body Radiotherapy (SBRT)|54 Gy in 3 fractions
223618659|NCT04283071|DEVICE|Boxed infrared gross kinematic assessment tool|An optical motion capture system, which records the movements of infrared emitting diodes (IREDs) in three-dimensional (3D) space by triangulating images from a pair of infrared cameras
224314673|NCT01104467|DRUG|Desmoteplase|1 bolus injection of desmoteplase 90 µg/kg (IV)
224314674|NCT01104467|OTHER|Placebo|1 bolus injection of placebo IV
224314675|NCT04180631|DIAGNOSTIC_TEST|Quantitative ultrasound imaging parameter (QUS)|Quantitative ultrasound imaging parameters (QUS) are analyzed to evaluate hepatic steatosis
223618660|NCT04641845|OTHER|Cork inlay wedge|
224314676|NCT05819216|DEVICE|Treadmill|Gait training on treadmill training
224314677|NCT05201196|OTHER|Conventional physical therapy|Targeted muscle stretching and Strengthening (flexors, Extensors, abductors, internal and external rotators, of Shoulder, Elbow, forearm (supination \& pronation) and hand 10 repetitions×1 set, 4 days/ week. Transcutaneous Electrical nerve Stimulation for 10-20 min, 4 days/ week. Total of 16 sessions were given each consisting of 45 mins.
223618661|NCT03935126|DIAGNOSTIC_TEST|Diagnostics|Diagnostics
223618662|NCT03649217|DEVICE|wearing the iStride device|The device mimics the actions of the split-belt treadmill, but can be used during over-ground walking and in one's own home, thus enabling long-term training. This device does not require any external power and is completely passive; all necessary forces are redirected from the natural forces present during walking since it utilizes the wearer's weight to generate its movements. This research aims to test the iStride on individuals with stroke in their own home in order to determine if the related effects that we saw in the clinic, can also benefit patients at home.
223618663|NCT02520726|DRUG|Sertraline|\< 65years: sertraline 50mg PO qday increasing by 50mg per day per week until 200mg for one week, then stop.
223618664|NCT02520726|DRUG|Placebo oral capsule|Matched encapsulated placebo from 1-4 capsules daily
223618665|NCT00734435|DRUG|zonisamide SR plus olanzapine|zonisamide SR 90 mg given twice daily and olanzapine 10 mg to 20 mg daily for 10 weeks (maintenance period)
223618666|NCT00734435|DRUG|Placebo plus olanzapine|Placebo given twice daily and olanzapine 10-20 mg for 10 weeks (maintenance period)
223618667|NCT04827108|OTHER|PeNAT validation|Children will be required to fill in a set of questionnaires including the Chinese version of the Pediatric Nausea Assessment Tool (PeNAT), the Chinese version of the Pediatric Quality of Life Inventory 4.0 Cancer Module (PedsQL 4.0), and the Chinese version of Center for Epidemiological Studies Depression Scale for Children (CES-DC)
223618668|NCT00586859|DEVICE|NDO Full-thickness Plicator|The Plicator and gastroscope assembly were passed into the stomach. The stomach was distended with air. The gastroscope was advanced and retroflexed so that the instrument could be visualized and accurately positioned. The Plicator was retroflexed to within 1cm below the GE junction, and the helical tissue retractor was advanced deeply into the gastric wall. The gastric wall was retracted into the Plicator instrument arms. The arms were then closed, and the suture-implant was deployed to secure the full-thickness plication. The tissue retractor is then disengaged and the suture-implant released from the instrument. Additional sutures were placed in the same manner described above, with each additional implant placed incrementally closer to the GE junction in a linear configuration along the anterior gastric cardia. All plications were placed de novo, and re-treatment was not permitted.
223618669|NCT03741465|PROCEDURE|The SFP technique|The USG, and the 5-point NRS evaluation in the SFP
224260362|NCT03856320|BEHAVIORAL|Educational Video|An educational video describing obesity treatment options available in the VA.
224260363|NCT05887427|OTHER|Neural Mobilisation|Transcutaneous Electrical Stimulation, hotpack, ultrasound and neural mobilization(radial,ulnar,median)
224260364|NCT05887427|OTHER|Conservative physiotherapy|Hotpack,Transcutaneous Electrical Stimulation ,Ultrasound
224260365|NCT03432182|DIAGNOSTIC_TEST|electroencephalography|Sleep states definition by electroencephalograpy
224260366|NCT06561594|DRUG|recombinant human follicle-stimulating hormone-CTP Fusion protein injection|IF Weight \> 60kg，150ug, H. Administer the drug once every 14 days for 64 weeks；IF Weight \>≤60kg，100ug, H. Administer the drug once every 14 days for 64 weeks
224260367|NCT06561594|DRUG|recombinant human follicle-stimulating hormone-CTP Fusion protein injection Placebo|0.5ml, H. Administer the drug once every 14 days for 64 weeks
224260368|NCT01293591|OTHER|Control|Subjects will consume a garlic-free diet for 10 days. On day 11, subjects will consume 270 kcal white bread with 15 g margarine.
224260369|NCT01293591|OTHER|Garlic treatment|Subjects will consume a garlic-free diet for 10 days. On day 11, subjects will consume 270 kcal white bread with 15 g margarine and 5 g crushed garlic.
224260370|NCT03987191|DRUG|Multiple daily ijnection using Insulin Degludec and Insulin Aspart|Drug: Insulin Degludec and insulin Aspart Pharmaceutical form: Solution for injection Route of administration: Subcutaneous
224260371|NCT06562231|OTHER|quality of life scale|This study will be conducted on women diagnosed with symptomatic isthmocele after cesarean section. Researchers will prepare scale questions, and the survey questions will be developed after obtaining an expert opinion from 20 experts to be evaluated by psychiatry, obstetrics, and public health experts. The patient will fill out the questionnaire form with the diagnosis of isthmocele. Oral and written consent will be obtained from the patients.
224260372|NCT01065740|OTHER|Patient education|
224260373|NCT00372086|DRUG|Rosiglitazone|
224260374|NCT01148186|BEHAVIORAL|knowledge transfer tool|knowledge transfer tool for empowering patients to engage in collaborative discontinuation of potentially inappropriate medication with their pharmacist and/or physician
224260375|NCT04684186|PROCEDURE|Endovascular fiducial marker insertion|Fiducial markers will be inserted using an endovascular route
224260376|NCT04684186|PROCEDURE|Bronchoscopic fiducial marker insertion|Fiducial markers will be inserted using an endoscopic route
224260377|NCT03261167|DRUG|Botulinum toxin A (GSK1358820)|GSK1358820 is sterile, purified type A botulinum neurotoxin complex. GSK1358820 injection will contain botulinum toxin A (100 units), sodium chloride (0.9 milligrams \[mg\]), and human serum albumin (0.5 mg). It will be available with doses of 400 units and 240 units.
224260378|NCT03261167|DRUG|Placebo|Placebo injection will contain sodium chloride (0.9 mg).
224260379|NCT01490567|DRUG|Donepezil|5 mg/day
224260380|NCT01490567|DRUG|placebo|placebo 5mg/d
223618670|NCT03741465|PROCEDURE|The ASP technique|The USG, and the 5-point NRS evaluation in the ASP
224314678|NCT05201196|OTHER|Task Oriented Training|"Experimental group was given Task oriented protocol including activities such as Table-top polishing, Arm cradling, Reach forward and pick-up or touch an object, Reached sideway to pick-up an object and transferring it to a table in front, Pouring~½ cup of water from a measuring pot into wide mouth glass held in opposite hand, Picking up pen from thumb and first two fingers, lifting a basket and placing it on the table 10 repetitions×1 set for each activity, 4-5days/week. Total of 16 sessions were given each consisting of 45 mins"
224314679|NCT05259995|DEVICE|Sustained Acoustic Medicine|The SAM device emits continuous ultrasound at 3 megahertz (MHz) frequency and 0.132 watts/cm2 intensity delivering 18,720 Joules of ultrasound per 4 hour treatment.
224314680|NCT00005614|DRUG|Gemcitabine hydrochloride|Gemcitabine via IV
224314681|NCT02906566|DRUG|Retinol|Retinol in the form of vitamin A lotion
223618671|NCT04337424|DIAGNOSTIC_TEST|Sampling salivary|Collection of 1 to 2 ml of saliva
223618672|NCT02714192|OTHER|Exercise stress test (BCTT)|Participants are assessed for exercise tolerance using a treadmill with gradually increasing angle to increase workload. Stress test is stopped when there is symptom exacerbation or when participant experiences voluntary exhaustion.
223618673|NCT05083689|DRUG|Injections of 1.25 mg of intravitreal bevacizumab with Timolol and Dorzolamide|31 cases in intervention group receive injections of 1.25 mg of intravitreal bevacizumab monthly for 3 months (months 0, 1 and 2) with topical drops of Timolol twice a day and Dorzolamide twice a day
223618674|NCT05083689|DRUG|Injections of 1.25 mg of intravitreal bevacizumab with artificial tears|31 cases in control group receive intravitreal injection of 1.25 mg bevacizumab monthly for 3 months (months 0, 1 and 2) plus artificial tears (twice a day as a placebo)
224206826|NCT06569017|OTHER|1) Artificial intelligence supported working group|Pregnant women will be a personal information form, breastfeeding diagnosis and evaluation scale, postnatal breastfeeding self-efficacy scale, Lowa infant nutrition attitude scale and Edinburgh postpartum depression scale. Pregnant women in the artificial intelligence-supported study group were aged 32-37. Starting from the first week of pregnancy, a mobile breastfeeding consultancy application supported by IOS and Android will be installed on smart phones. Pregnant women will be expected to use this application actively until birth and submit their questions about breastfeeding to this artificial intelligence-supported mobile application and receive instant answers. After these applications, the breastfeeding diagnosis and evaluation scale, postnatal breastfeeding self-efficacy scale, Lowa baby nutrition attitude scale and Edinburgh postpartum depression scale will be applied again to pregnant women on the first postpartum day, sixth day, third week and third month.
224206827|NCT06569017|OTHER|Online breastfeeding counseling group led by a nurse|The forms that will be applied to pregnant women in all three groups at the first meeting will also be applied to this group. 32-37 in the nurse-led online breastfeeding counseling group. Primiparous pregnant women at the gestational age will be offered 1.5 hours of breastfeeding counseling by one of the researchers, between the 32nd and 37th weeks of pregnancy, with the participation of small groups of five pregnant women in each interactive session. Pregnant women in this group will receive only one session of breastfeeding training. These trainings, which will be given by the nurse, will be carried out online via video call via WhatsApp application. After these applications, the breastfeeding diagnosis and evaluation scale, postnatal breastfeeding self-efficacy scale, Lowa baby nutrition attitude scale and Edinburgh postpartum depression scale will be applied again to pregnant women on the first postpartum day, sixth day, third week and third month.
224314682|NCT02906566|DRUG|Placebo|Placebo of Retinol
224314683|NCT01835054|OTHER|Blood biomarkers|Observational Study using Imaging and Biomarkers
223773659|NCT01062685|DIAGNOSTIC_TEST|Near-infrared spectroscopy assessment|"The InSpectra StO2 Tissue Oxygenation Monitor (model 650; Hutchinson Technology, Hutchinson, MN, USA) with probes spaced at 15 mm will be utilized to obtain StO2 measurements.~Following a minimum initial five-minute stabilization period, the initial StO2 will be measurement and then a Vasoocclusive Testing Procedure (VOT) will be performed using an automated tourniquet (Delfi Tourniquet System; Delfi Medical Innovations, Inc, Vancouver, BC, Canada), insufflated to 50 mmHg over the patient's SBP for a period of three minutes."
224314684|NCT01835054|GENETIC|DNA collection|Observational Study using Imaging and Biomarkers
224314685|NCT01835054|OTHER|Echocardiography|Observational Study using Imaging and Biomarkers
224314686|NCT01835054|OTHER|Cardiopulmonary exercise testing|Observational Study using Imaging and Biomarkers
224314687|NCT01835054|OTHER|Magnetic resonance imaging (MRI)|Observational Study using Imaging and Biomarkers
224314688|NCT01835054|OTHER|Exercise stress doppler echocardiography|Observational Study using Imaging and Biomarkers
224314689|NCT01835054|OTHER|Holter ECG|Observational Study using Imaging and Biomarkers
224314690|NCT02761005|DRUG|Eradication of H. pylori|For the eradication of H. pylori, patients diagnosed to be infected with strain with mutation of 23S rRNA, their H. pylori strains are considered to be resistant to clarithromycin. Then, they are treated with vonoprazan 40 mg, metronidazole 500 mg and amoxicillin 1500 mg for 1 week. Patients diagnosed to be infected with strain without mutation of 23S rRNA, their H. pylori strains are considered to be resistant to clarithromycin. Then, they are treated with vonoprazan 40 mg, clarithromycin 400 mg and amoxicillin 1500 mg for 1 week.
224314691|NCT02868645|BIOLOGICAL|Blood sampling|Patients with bone fibrous dysplasia will have blood sampling to assess periostin rate in serum
223512614|NCT00002011|DRUG|Methoxsalen|
223512615|NCT02431520|PROCEDURE|Self-collection|Women allocated to this arm will be asked to obtain a specimen of vaginal/cervical by self-collection for HCII.
223512616|NCT02431520|PROCEDURE|Gynecologist collection|Women allocated to this arm will be asked to attend to medical office to have their Pap smear obtained by a gynecologist
223512617|NCT00004061|BIOLOGICAL|filgrastim|
223512618|NCT00004061|BIOLOGICAL|palifermin|
223512619|NCT00004061|DRUG|cyclophosphamide|
223512620|NCT00004061|DRUG|etoposide|
223512621|NCT00004061|DRUG|ifosfamide|
223512622|NCT00004061|PROCEDURE|peripheral blood stem cell transplantation|
223512623|NCT00004061|PROCEDURE|quality-of-life assessment|
223512624|NCT00004061|RADIATION|radiation therapy|
223512625|NCT01593111|OTHER|Environmental Intervention|Home-based environmental intervention
223773660|NCT01976845|DRUG|Midazolam|Midazolam (20mg) 2 ml IV, in the pre-op area as a premedication
223773661|NCT01976845|DRUG|Propofol|Propofol (20mg) 2 ml IV, in the pre-op area as a premedication
224206828|NCT06568913|DIAGNOSTIC_TEST|CBC|Platelets counts in pediatric patient with perisistent or chronicITP unresponsive to steroids
224206829|NCT06567756|PROCEDURE|CSPO|The distal rectum is freed to the entrance of the internal and external sphincter space, and then an oblique resection line is designed under direct vision according to the tumor site and shape, ensuring that the distal and lateral margins are not less than 1 cm, and preserving the contralateral dentate line and the intestinal wall as much as possible, and the anastomosis is completed manually or with instruments.
224206830|NCT06567756|PROCEDURE|ISR|Partial, subtotal, or total excision of the internal sphincter and/or a portion of the longitudinal rectal muscle, expansion of the distal rectal excision margin into the anal canal or to the anal verge, and completion of the colo-anal anastomosis manually or instrumentally.
224206831|NCT03533335|OTHER|Oral spray (chlorhexidine spray, chlorine dioxide spray, sterile water spray)|Application of a daily dose of 12 sprays (each delivering a volume of 0.13ml) to the buccal and lingual gingival third of tooth surfaces in each sextant
224206832|NCT04574037|OTHER|Clinical scores such as SAFE score, NIHSS; demographic data such as age and electrophysiological data (such as the absence/presence of Motor evoked potential)|Clinical scores such as SAFE score, NIHSS; demographic data such as age and electrophysiological data (such as the absence/presence of Motor evoked potential) will determine the predictive functional outcome of the upper limb deficit according to the PREP2 algorithm.
224206833|NCT06232707|DRUG|Alnuctamab|Specified dose on specified days
224206834|NCT06232707|DRUG|Pomalidomide|Specified dose on specified days
224206835|NCT06232707|DRUG|Daratumumab|Specified dose on specified days
224206836|NCT06232707|DRUG|Elotuzumab|Specified dose on specified days
224206837|NCT06232707|DRUG|Carfilzomib|Specified dose on specified days
224206838|NCT06232707|DRUG|Dexamethasone|Specified dose on specified days
224206839|NCT01946087|PROCEDURE|Remote ischemic preconditioning at left upper arm|Placement of automated cuff-inflator on the left upper arm after induction of anesthesia RIPCgroup-3 cycles of 5 min ischemia (300 mmHg inflation) \& 5 min reperfusion (deflation)
224206840|NCT01946087|PROCEDURE|Control group|keeping the cuff deflated
224206841|NCT00392717|DRUG|Atorvastatin|
224206842|NCT00392717|DRUG|Fish oils|
224206843|NCT06543251|OTHER|High-intensity interval training group (HIIT)|The participants performed HIIT programs for 12 weeks involving walking/running on a treadmill preceded by a 10-min warm-up at low intensity and exercise with high intensity for 1 min at 85%-90% of the maximum heart rate alternating with low intensity at 50%-55% of the maximum heart rate for 2 min, for 24 minutes, and 10-min cool down.
224206844|NCT06543251|OTHER|Moderate continuous training group (MCT)|Subject participating in 30-min sessions for 12 weeks and Each session consisted of a 10-min warm up, walking/running on a treadmill 30 minutes at 65-70% Maximum Heart rate and 10-min cool down.
224206845|NCT06543251|OTHER|Sedentary control group (CON)|The control group had normal daily life.
224206846|NCT01874015|BIOLOGICAL|mesenchymal cell transplantation|Mesenchymal cell transplantation in patients with Crohn's disease.
224206847|NCT01874015|BIOLOGICAL|mesenchymal cell and fibroblast injection|Transplantation of mesenchymal cell and fibroblast in patients with crohn's disease.
224206848|NCT06541171|OTHER|Magnetic resonance imaging as fpr clinical practice|An abbreviated MR protocol of the abdomen will be used inh association with CT scan; it does not need contrast injection and does not add any risk for patients.
224206849|NCT03254537|DIETARY_SUPPLEMENT|Mediterranean Organic|Traditional Mediterranean diet comprised of organic ingredients
224206850|NCT03254537|DIETARY_SUPPLEMENT|Mediterranean conventional|Traditional Mediterranean diet comprised of conventional ingredients
224206851|NCT00402779|DRUG|Erlotinib|150 mg by mouth daily
224206852|NCT00402779|DRUG|Placebo|Tablet by mouth daily
224206853|NCT04661163|OTHER|Psychotherapy|Virtual Reality Avatar Therapy is a psychotherapeutic intervention targeting auditory hallucinations
224206854|NCT05163249|DRUG|Osimertinib|osimertinib, 80mg, daily, P.O. Until objective disease progression, unacceptable toxicity occurs, consent is withdrawn or another discontinuation criteria is met
224206855|NCT05163249|DRUG|Savolitinib|savolitinib 300mg BID, P.O. Until objective disease progression, unacceptable toxicity occurs, consent is withdrawn or another discontinuation criteria is met
224206856|NCT00871806|DRUG|Commercial tablet with water|40 mg tablet, given once to each subject
224206857|NCT00871806|DRUG|ODT #1 without water|40 mg tablet given once to each subject
224206858|NCT00871806|DRUG|ODT #2 without water|40 mg tablet given once to each subject
224206859|NCT00871806|DRUG|ODT #1 with water|40 mg tablet given once to each subject
224206860|NCT00871806|DRUG|ODT #2 with water|40 mg tablet given once to each subject
224206861|NCT03094923|OTHER|Inspiratory Muscle Training|"The inspiratory muscle training (IMT) will be carried out in the IG with Threshold® IMT (Respironics New Jersey, Inc) consisting of a unidirectional flow control valve which assures the constant resistance (linear load) between 7 and 41cmH20.~The IMT will be carried out in the sitting position with a load of 30% of the MIP during the two weeks preceding the surgery, seven days a week, twice daily in three series of ten repetitions with a 30 second interval between series, under the supervision of a physiotherapist. A load of 15% of the MIP was used only on the first day of training in order for the individual to adapt to the equipment. Subsequently, the 30% MIP load will be applied and readjusted according to the new MIP values determined every four days."
224206862|NCT04014556|DEVICE|micropulse laser|"Micropulse session details:~Mainster focal grid contact lens (×1.05 laser magnification) was used to perform laser. The 577-nm yellow laser (OcuLight SLx, Iridex Corp., Mountain View, California, USA) was used. Fixed treatment parameters were used in all cases: 200-μm spot size, 200-ms exposure duration, 400-mW power, and a 5% duty cycle. Confluent applications with no spacing were administered using 5x5 grid pattern over the entire edematous area including the fovea."
224206863|NCT04014556|DRUG|Aflibercept|Aflibercept
224206864|NCT01982045|DEVICE|AttraX® Putty|Synthetic bone graft comprised of calcium phosphate granules and hydroxyapatite with an advanced biodissolvable polymer carrier that allows for better handling of the granules in putty form.
224206865|NCT01982045|OTHER|Autologous bone graft|Corticocancellous bone harvested from the iliac crest, with our without local bone obtained from decompression and/or preparation for fusion (facetectomy and denudement).
224206866|NCT05967767|DEVICE|Normobaric Hypoxia Exposure|Hypoxia group were exposed to normobaric hypoxia equal to 3420 m (FiO2: 13.5-13.6 %).
224206867|NCT05967767|DEVICE|Normobaric Normoxia Exposure|Placebo group were exposed to normobaric normoxia equal to 162 m (FiO2: 20.9 %) through wearing the altitude generator mask.
224206868|NCT00094900|DRUG|IL-1 Trap|
224206869|NCT00408135|DRUG|telithromycin (HMR3647)|
223618675|NCT04139655|DRUG|Colchicine 0.6 mg|Oral colchicine given at 0.6 mg 1 hour prior to surgery, then 0.6 mg twice daily starting on the night after surgery for 7 days or until discharge from hospital, whichever occurs earlier. For patient under 60kg in body weight, daily dose will be 0.6 mg once daily. Medical and surgical management of the participant will be carried out under each institute's standard clinical practice.
224206870|NCT04708626|OTHER|Description and analysis|Collection of clinical, laboratory and radiological data from medical records.
224206871|NCT04708626|OTHER|Description and analysis|Collection of laboratory data.
224206872|NCT04982718|DIAGNOSTIC_TEST|OraQuick® HCV Self-Test|"Self-testing will be performed using the OraQuick® HCV Self-Test manufactured by OraSure Technologies Inc., USA. Modified IFU developed by the manufacturer will be used to adapt the below professional use kits to a self-test: the OraQuick® HCV Rapid Antibody Test is prequalified by WHO and CE marked for professional use (sensitivity 98.1%, specificity 99.6%).~As it is not approved for self-test use in Malaysia, the OraQuick® HCV Self-Test kits provided to participants in the intervention group will be labelled for Research Use Only (RUO) and test results will not be used for patient management."
224206873|NCT04982718|DIAGNOSTIC_TEST|First Response® HCV Self-Test|"Self-testing will be performed using the First Response® HCV Card Test (Self Test) manufactured by Premier Medical Corporation, India. Modified IFU developed by the manufacturer will be used to adapt the below professional use kits to a self-test: the First Response® HCV Card Test is CE-marked and currently under WHO review for professional use (sensitivity 100%, specificity 100%).~As it is not approved for self-test use in Malaysia, the First Response® HCV Self-Test kits provided to participants in the intervention group will be labelled for Research Use Only (RUO) and test results will not be used for patient management."
224206874|NCT05775536|DRUG|Aspirin 500Mg Tab|Dose: 1 tablet per day starting from visit 2 until visit 3, intake in the evening
224206875|NCT05775536|DIETARY_SUPPLEMENT|Dr. Böhm® Omega 3 complex 870 mg|Dose: 2 tablets per day starting from visit 2 until visit 3, intake in the evening
224206876|NCT02149199|DRUG|budesonide/formoterol 'as needed' + budesonide placebo bid|Symbicort (budesonide/ formoterol) 160/4.5 μg powder for inhalation 'as needed' plus Pulmicort placebo 200 μg powder for inhalation, 1 inhalation twice daily (morning and evening), 52-week treatment
224206877|NCT02149199|DRUG|terbutaline 'as needed' + placebo budesonide bid|Terbutaline 0.4 mg powder for inhalation 'as needed' plus placebo Pulmicort (budesonide) 200 μg powder for inhalation, 1 inhalation twice daily (morning and evening), 52-week treatment
224206878|NCT02149199|DRUG|budesonide bid + terbutaline 'as needed'|Pulmicort (budesonide) 200 μg powder for inhalation, 1 inhalation twice daily (morning and evening) plus terbutaline 0.4 mg powder for inhalation 'as needed', 52-week treatment
224206879|NCT03775382|OTHER|Ascorbic Acid|"Ascorbic acid will be infused into an antecubital vein using a IV infusion pump beginning with a priming bolus of 0.06 g Ascorbic Acid per kg fat-free mass dissolved in 100 ml of saline followed by a drip-infusion of 0.02 g Ascorbic Acid per kg fat-free mass dissolved in 30 ml of saline."
224206880|NCT03775382|OTHER|Normal Saline|Normal saline will be infused by the research nurse into an antecubital vein using an IV infusion pump.
224206881|NCT05840601|DEVICE|Pointdexter|Commercially available prosthetic hand modified with the investigational Pointdexter finger in place of the usual index finger.
224206882|NCT05840601|DEVICE|Comparator|Unmodified commercially available prosthetic hand.
224206883|NCT03252756|OTHER|Placebo|Saline taken by mouth (PO)
224206884|NCT03252756|DRUG|Phytocannabinoid cannabidiol (CBD)|CBD taken by mouth (PO)
224206885|NCT05558007|DRUG|Tadalafil 5mg|Daily oral administration of tadalafil 5mg
224206886|NCT05558007|DRUG|BZ371A|Topical application of 1.5 mL of BZ371A in a concentration of 5mg/mL
224206887|NCT05558007|DRUG|Oral Placebo|Oral administration of a placebo pill
224206888|NCT05558007|DRUG|Topical Placebo|Topical application of 1.5 mL of placebo
223618676|NCT04139655|DRUG|Placebo oral tablet|Placebo oral tablet given at 0.6 mg 1 hour prior to surgery, then 0.6 mg twice daily starting on the night after surgery for 7 days or until discharge from hospital, whichever occurs earlier. For patient under 60kg in body weight, daily dose will be 0.6 mg once daily. Medical and surgical management of the participant will be carried out under each institute's standard clinical practice.
223618677|NCT00521287|OTHER|Immune profiling and DC vaccine|"1. For observational study (immune profiling): blood sampling 3-5 mL~2. For DC vaccine: one dose of DC vaccine(\~10 million cells)/2 week for at least 6 month or until progression."
223618678|NCT06304116|BEHAVIORAL|Rehabilitation therapy|During the treatment, All the participants were provided with the rehabilitation therapy, which included routine rehabilitation, cognitive training, swallowing function training and nutrition support.
223618679|NCT06304116|PROCEDURE|Stellate ganglion block|The percutaneous approach via the paratracheal route was used for Stellate ganglion block . The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
223773662|NCT01976845|DRUG|Saline|Saline 2 ml IV, in the pre-op area as a premedication
223773663|NCT01521611|RADIATION|Targeted radiotherapy|Yttrium-90 labelled anti-CD66 monoclonal antibody.
224206889|NCT02072707|PROCEDURE|Epicardial VT ablation|Combined Epicardial and Endocardial VT Ablation
224206890|NCT02072707|PROCEDURE|Endocardial VT Ablation|Endocardial Only VT ablation
224206891|NCT06649214|DRUG|Olanzapine-samidorphan；|orally once daily, tablet, 10mg/10mg、15mg/10mg or 20mg/10mg，duration of 24 weeks.
224206892|NCT06649214|DRUG|Olanzapine|orally once daily, tablet, 10mg、15mg or 20mg，duration of 24 weeks.
224206893|NCT06650306|OTHER|This study does not involve any interventions|This study does not involve any interventions
224314692|NCT02297698|BIOLOGICAL|NeuVax vaccine|At the time of vaccine administration, a frozen solution of E75 acetate (1.5 mg/mL) is thawed and 1000mcg E75 peptide mixed thoroughly with 250mcg GM-CSF. This constitutes the NeuVax vaccine. Patients randomized to this arm will receive vaccinations of nelipepimut-S/GM-CSF administered intradermally every three weeks for six total vaccinations, 30-120 minutes after completion of trastuzumab infusion. The first vaccination will be given with the third dose of maintenance trastuzumab administered as monotherapy optimally, but may be given with later maintenance doses of trastuzumab, provided there are at least six remaining doses of trastuzumab to overlap with the primary vaccine series.
224314693|NCT02297698|DRUG|Trastuzumab|Herceptin will be administered to patients every three weeks as monotherapy for one year, to be given upon completion of standard of care chemotherapy/radiotherapy. The first trastuzumab infusion will be given no sooner than three weeks and no later than 12 weeks after completion of chemotherapy/radiotherapy. Trastuzumab will be dosed at the recommended initial loading dose of 8 mg/kg and at recommended maintenance doses of 6 mg/kg q3wk.
224314694|NCT02297698|DRUG|GM-CSF|For patients randomized to the GM-CSF alone arm, they will receive inoculations of GM-CSF (250mcg) administered intradermally every three weeks for six total vaccinations, 30-120 minutes after completion of trastuzumab infusion. The first injection will be given with the third dose of maintenance trastuzumab administered as monotherapy optimally, but may be given with later maintenance doses of trastuzumab, provided there are at least six remaining doses of trastuzumab to overlap with the primary vaccine series.
224206894|NCT05397288|BEHAVIORAL|Resistance exercise (R)|"A 6-month program led by trained young-old exercise coaches consisting of structured training with 5 progressive levels of intensity, with protocols for implementation in a home surrounding and community center settings. During the 6-month program, group practice and home visit (individual) sessions (45 mins each) are delivered in a tapering schedule:~* 1st month: group practice (1 time/week), home visits (2 times/week)~* 2nd month: group practice (1 time/week), home visit (1 time/week), phone call (1 time/week)~* 3rd month: group practice (1 time/week), phone calls (2 times/week)~* 4th month: phone calls (2 times/week)~* 5th month: phone calls (1 time/week)~* 6th month: weaning period"
224206895|NCT05397288|BEHAVIORAL|Aerobic exercise (A)|"A 6-month programs led by trained young-old exercise coaches consisting of structured training with 5 progressive levels of intensity, with protocols for implementation in a home surrounding and community center settings. During the 6-month program, group practice and home visit (individual) (45 mins each) are delivered in a tapering schedule:~* 1st month: group practice (1 time/week), home visits (2 times/week)~* 2nd month: group practice (1 time/week), home visit (1 time/week), phone call (1 time/week)~* 3rd month: group practice (1 time/week), phone calls (2 times/week)~* 4th month: phone calls (2 times/week)~* 5th month: phone calls (1 time/week)~* 6th month: weaning period"
224206896|NCT05397288|BEHAVIORAL|Healthy lifestyle education (E)|"A 6-month program led by retired nurses covering topics including nutrition, sleep, medication, cognition, and exercising. During the 6-month program, group talks and individual consultation (45 mins each) are delivered in a tapering schedule:~* 1st month: group talk (1 time/week), individual consultation (2 times/week)~* 2nd month: group talk (1 time/week), individual consultation (1 time/week), phone call (1 time/week)~* 3rd month: group talk (1 time/week), phone calls (2 times/week)~* 4th month: phone calls (2 times/week)~* 5th month: phone calls (1 time/week)~* 6th month: weaning period"
224206897|NCT05146700|DRUG|Restrictive oxygen|Lowest oxygen delivery possible (≥21%) ensuring an SpO2 target = 94%
224206898|NCT05146700|DRUG|Liberal oxygen|15 L O2/min flow for non-intubated trial participants or FiO2 = 1.0 for intubated trial participants in the initial phase; later in the operating room, intensive care unit, post-anesthesia care unit and ward, the flow/FiO2 can be reduced to ≥12 L O2/min or FiO2 ≥0.6 if the arterial oxygen saturation is ≥98%
224206899|NCT06061848|DRUG|SLIT Grazax ALK Nordic 75 000 SQ-T|Daily sublingual grass allergen tablets
224206900|NCT06061848|DRUG|ILIT + Vitamin D|1 mL of Vicotrat D3, Heyl Pharma, 100 000 IU/mL, as intramuscular injection. Followed by 0,1 mL of Alutard SQ timothy, ALK Nordic, 10 000 SQ-U/mL as three intralymphatic injections
223618680|NCT06304116|DRUG|Lidocaine Hydrochloride|Based on the invention above, the patients in the observation group were provided with Stellate ganglion block , using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate ganglion block . The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
223618681|NCT03938935|PROCEDURE|Absorbable polydioxanone suture (PDS)|PDS is a Polydioxanone synthetic monofilament which is absorbable.
223618682|NCT01506271|DRUG|Relebactam 250 mg|Relebactam 250 mg IV every 6 hours for a minimum of 96 hours
224206901|NCT06061848|DRUG|ILIT + placebo|1 ml of Sodium chloride solution 9 mg/mL as intramuscular injection followed by 0,1 mL of Alutard SQ timothy, ALK Nordic, 10 000 SQ-U/mL as three intralymphatic injections
224206902|NCT04580472|DRUG|Cephalexin|If randomized to the antibiotic group, a single dose of cephalexin or clindamycin hydrochloride (if concern for previous allergy to Cephalexin) will be given prior to surgery.
224206903|NCT04580472|OTHER|Placebo capsules|Patients will receive 4 placebo capsules prior to surgery if randomized to placebo group.
224206904|NCT06470737|OTHER|Hypertonic Saline|A bolus injection of hypertonic saline (7% NaCl) will be administered to the FDI muscle using a 1 mL syringe with a disposable needle (27G), and the volume of the bolus will be 0.2 mL
224314695|NCT03252912|BIOLOGICAL|blood samples|Two EDTA tubes (5 mL) and two dried tubes (5mL) will be will be taken the same day as the first lumbar .
224314696|NCT02864810|DRUG|[18F]GP1|\[18F\]GP1 PET/CT imaging for detecting thromboembolism
224314697|NCT00255710|BIOLOGICAL|filgrastim|
224314698|NCT00255710|DRUG|cyclophosphamide|
224314699|NCT00255710|DRUG|fludarabine phosphate|
224314700|NCT00255710|DRUG|mycophenolate mofetil|
224314701|NCT00255710|DRUG|tacrolimus|
224314702|NCT00255710|PROCEDURE|allogeneic bone marrow transplantation|
223618683|NCT01506271|DRUG|Relebactam 125 mg|Relebactam 125 mg IV every 6 hours for a minimum of 96 hours
223618684|NCT01506271|DRUG|Imipenem/cilastatin|A 500 mg dose of imipenem/cilastatin will be administered IV in an open-label fashion once every 6 hours with each dose infused over a 30-minute interval.
224206905|NCT06470737|OTHER|Histamine|A small drop of histamine dihydrochloride will be applied to a previously determined area on the volar forearm, followed by a prick through the drop
224206906|NCT06470737|OTHER|Cowhage|This insertion is conducted by forceps using a stereo-microscope, and 30-35 spicules are gently rubbed into a 1 cm diameter skin area.
224206907|NCT06470737|DEVICE|Transcranial magnetic stimulation (TMS)|Transcranial magnetic stimulation (TMS) will be used to evoke motor-evoked potentials (MEPs) in the muscle of interest and cortical responses (TMS-evoked potentials - TEPs) in the motor cortex with a figure-eight-shaped cone coil.
224206908|NCT06649825|DRUG|Vitamin B1|Vitamin B1 tablets, 100mg bid, taken orally for one year
224206909|NCT06653478|OTHER|No Intervention|No Intervention
224206910|NCT06652087|DRUG|Rifaximin|Rifaximin (Alfa Normix®, Alfa Wassermann S.P.A., Italy, registration number LS-001993, 08/31/2010) in standard doses of 200 mg 3 times a day for 7 days
224206911|NCT06652087|OTHER|Standard HFpEF treatment|diuretic, including an aldosterone antagonist; sodium-glucose cotransporter-2 inhibitor
224206912|NCT06244134|PROCEDURE|ultrasound guided autologous blood injection|guided
224206913|NCT06244134|PROCEDURE|non guided autologous blood injection|non guided
224206914|NCT05802147|BEHAVIORAL|skin-to-skin contact|skin-to-skin contact
224206915|NCT03793309|DRUG|Vitamin D|Oral vitamin D
224206916|NCT01806259|DRUG|Ketorolac 30 mg IV|Active drug
224206917|NCT01806259|DRUG|Placebos|Placebo looking like the Active drug
224206918|NCT01995058|DRUG|cabozantinib|Tablets taken orally
224206919|NCT01995058|DRUG|abiraterone|Tablets taken orally daily
224206920|NCT01995058|DRUG|prednisone|Tablets taken orally twice daily
224206921|NCT03271541|DRUG|Bitopertin|Bitopertin will be administered orally once daily at doses up to 120 milligrams (mg).
224206922|NCT04631185|DRUG|Single pre-operative dose of intravenous antibiotics with intraoperative redosing|Intravenous cefazolin, a cephalosporin antibiotic, will be prescribed to all patients before surgery. In case of allergy to cefazolin, intravenous clindamycin will be prescribed. For allergy to both antibiotics, an appropriate antibiotic should be chosen by the surgeon and documented. All patients will receive one dose of antibiotic within 60 minutes prior to incision, and any intraoperative doses of antibiotics according to current recommendations based on the antibiotic's dosing and on operative time.
224206923|NCT04631185|DRUG|One week of post-operative antibiotics|The patients will be prescribed one week of Cephalosporin Antibiotic (Keflex/Duricef/Other) of their surgeon's choice.
224206924|NCT03001856|PROCEDURE|Oblique Intradermal Suture|
224206925|NCT03001856|PROCEDURE|Intradermal Suture|
224206926|NCT06515496|DIETARY_SUPPLEMENT|Scale HLV Clinical Formula Hair Vitamins|For the first week, participants will take 1 capsule in the morning and 2 capsules in the evening before food. From Week 2 onwards, participants will take 3 capsules daily in the evening before food.
224206927|NCT06515496|OTHER|Placebo|For the first week, participants will take 1 capsule in the morning and 2 capsules in the evening before food. From Week 2 onwards, participants will take 3 capsules daily in the evening before food.
224206928|NCT02957461|DEVICE|BrainScope Ahead 200iD|The BrainScope Battery evaluation will consist of 4 tests to aid in the assessment of concussion: History, Physical, signs and symptoms (SAC, SCAT3), Electrophysiological Function; Neurocognitive Performance Assessment and Ocular Motor assessment. BrainScope Ahead 200iD device will be used to perform EEG.
224206929|NCT01991184|DRUG|GDC-0853|Multiple escalating doses
224206930|NCT02800278|OTHER|observational|describe bone status and outcome of odontoid fracture
224206931|NCT02781688|BEHAVIORAL|Physical Activity|"Self-monitoring: Subjects will be provided with a commercially available activity monitor (i.e., Fitbit) and instructed to wear the device daily.~Active Living counseling: The Active Living counseling program will consists of 12 weekly group educational sessions, facilitated by project interventionists. These sessions will involve discussion of topics related to increasing physical activity, including: identifying and overcoming barriers, setting goals, social support, and time management.~Facility Access: Subjects will have access to the exercise lab in the UT Southwestern Depression Center consisting of equipment for aerobic exercise (treadmills, stationary bikes, etc.)."
224206932|NCT04643054|DIETARY_SUPPLEMENT|Ovotransferrin|Administering 200 mg of ovotransferrin orally in addition to the standard of care therapy for 10 days
224206933|NCT02911610|DEVICE|arthroscopy + volar plate|surgery of wrist fractures with volar plate and added arthroscopy
224206934|NCT02911610|DEVICE|Volar plate|surgery of wrist fractures with volar plate
224206935|NCT01500434|DEVICE|PROMUS Element Coronary Stent System|PROMUS Element is a device/drug combination product composed of two components, a device (coronary stent system including a platinum chromium stent platform) and a drug product (a formulation of everolimus contained in a polymer coating).
224206936|NCT01500434|DRUG|Aspirin|Patients are required to take aspirin indefinitely after stent implant. It is recommended that aspirin 162-325 mg daily be given for at least 6 months after stent placement and that aspirin 75-162 mg daily be given indefinitely thereafter.
224206937|NCT01500434|DRUG|Thienopyridine|Patients must be treated with one of the following thienopyridines for at least 6 months following the index procedure: clopidogrel 75 mg daily; or ticlopidine 250 mg twice daily; or prasugrel (outside the United States and if approved at the time of the procedure). If used, the prescribed dose should be in accordance with approved country-specific labeling. In patients not at high risk of bleeding, thienopyridine treatment should continue for at least 12 months after stent implant.
224206938|NCT03309631|DIAGNOSTIC_TEST|In vitro Diagnostic|
224206939|NCT05043779|PROCEDURE|Awake Airway Nasoendoscopy|Preoperative Awake Airway Nasoendoscopy of upper airway
224206940|NCT06653270|OTHER|Virtual reality simulator|A in-house developed immersive virtual simulation of a normal vaginal delivery developed using a Unity Engine and installed in Oculus® Quest 2 head-mounted device
224206941|NCT06653270|OTHER|Mannequin-based simulator|Legacy PROMPT Flex® mannequin
224206942|NCT06594094|GENETIC|HG302|Once intravenous injection; The duration of the study is about 32 weeks for each subject, including a 6 weeks screening period, enrollment visit, treatment visit, and 26 weeks follow-up period.
224206943|NCT01407107|DRUG|Nitroglycerin 0.2 MG/HR|0.2mg/hr nitroglycerin transdermal patch daily. The first 3 patients will have a low dose patch applied (0.2 mg/hr).
224314703|NCT00255710|PROCEDURE|peripheral blood stem cell transplantation|
224314704|NCT00255710|RADIATION|radiation therapy|
224314705|NCT04844762|BEHAVIORAL|Menthol cigarettes substitutes|In Phase 1, participants will complete 4 smoking sessions using a different product each session to examine each product's abuse liability.
224314706|NCT04844762|BEHAVIORAL|Usual brand menthol cigarettes and substitutes|In Phase 2, to assess uptake, changes in subjective effects, and use over time, participants will select their preferred study product from Phase 1 and be instructed to completely substitute the product for their usual brand menthol cigarette for one week.
223618685|NCT01506271|DRUG|Matching placebo to relebactam|Placebo-matching infusion of IV normal saline (0.9%) once every 6 hours.
223618686|NCT03111238|DRUG|REX-001|REX-001 is administered through an intra-arterial catheter.
223618687|NCT03111238|DRUG|Placebo|Placebo is administered through an intra-arterial catheter.
223618688|NCT01562808|DRUG|Aripiprazole|single oral administration of aripiprazole
224314707|NCT04844762|BEHAVIORAL|Menthol cigarettes substitutes and menthol cigarettes|In Phase 3, participants will complete a final in-lab visit to assess the substitutability of their preferred product from Phases 1 and 2, under simulated ban conditions using a progressive ratio task.
224314708|NCT00007527|DRUG|naloxone|
223618689|NCT02304744|OTHER|Observational study, no intervention.|Observational study, no intervention.
224314709|NCT00007527|DRUG|buprenorphine|
224314710|NCT00399880|BEHAVIORAL|Health literacy intervention|Illustrated medication schedules, pill boxes, pharmacist counseling
223618690|NCT04508946|DRUG|vitamin c - thiamine- hydrocortisone|Triple therapy regimen (vitamin c - thiamine- hydrocortisone)
224314711|NCT02188173|DRUG|dexamethasone 700 ㎍ intravitreal implant|Patients who receive dexamethasone 700 ㎍ (OZURDEX®) intravitreal implant treatment for Diabetic Macular Edema. All decisions regarding treatment are made at the sole discretion of the treating physician in accordance with their usual practices.
223761423|NCT06842875|BEHAVIORAL|Standard self-measured blood pressure program|Participants assigned to the routine care group meet virtually or in-person with a member of WIH's existing SMBP program and enroll in WIH's EPIC MyChart Portal to allow the SMBP program to receive patient-entered BP measurements and respond to messages. Participants will be provided with BP cuffs and taught how to obtain SMBP and report their BP through MyChart. At six weeks postpartum, WIH SMBP staff send a MyChart message to recommend BP ascertainment once per month and to describe the importance of attending a clinical visit with a primary care provider within a year of birth.
224206944|NCT01407107|DRUG|Nitroglycerin 0.4 MG/HR|0.4mg/hr nitroglycerin transdermal patch daily. The first 3 patients will have a low dose patch applied (0.2 mg/hr) if this is well tolerated a higher dose patch (0.4mg/hr) will be used for the next 3 patients.
224314712|NCT04129073|OTHER|Intensive care treatment|Intensive care treatment; Utilization of neuroprognostication tools
224314713|NCT04067986|DRUG|Camrelizumab|"Camrelizumab One course will last 28 days.Intravenous injection at a dose of 200 mg, q2w~One course will last 28 days. Oral administration at a dose of 250 mg/d"
224314714|NCT04067986|DRUG|Apatinib|Apatinib One course will last 28 days.Oral administration at a dose of 250 mg, qd
223618691|NCT05195307|OTHER|Music Group|Pregnant women included in the practice group were given 20 minutes of music every day for ten days. Anxiety and stress levels of pregnant women were measured before and after the intervention.
224206945|NCT01407107|DRUG|Nitroglycerin 0.6 MG/HR|0.6mg/hr nitroglycerin transdermal patch daily. The first 3 patients will have a low dose patch applied (0.2 mg/hr) if this is well tolerated a higher dose patch (0.4mg/hr) will be used for the next 3 patients and if this is well tolerated an even higher dose patch (0.6mg/hr) will be used.
224314715|NCT01399879|OTHER|Faraday cage, movement stabilization|The Faraday cage is a copper-mesh cage that surrounds the device and test site. It helps eliminate surrounding electrical noise. Movement stabilization will be achieved by placing a velcro strap over the arm to minimize random movements.
224314716|NCT01696851|OTHER|tests and questionnaires|lung test, depression and self-efficacy questionnaires and Functional testing.
223618692|NCT04875806|DRUG|NC762|NC762 is an experimental antibody drug that may make the immune response more active against cancer
223618693|NCT04169958|OTHER|safe mood|A tablet application that developed for this study. In addition, sensors are used to examine the possibility of using the system to assess the risk of suicide
224314717|NCT02829151|DRUG|Triple antiplatelet therapy (aspirin (100 mg), clopidogrel (75 mg), and cilostazol (200 mg) )|Combination antiplatelet therapy using aspirin (100 mg), clopidogrel (75 mg), and cilostazol (200 mg) after the index angioplasty
224314718|NCT02829151|DRUG|Dual antiplatelet therapy (aspirin (100 mg) and clopidogrel (75 mg)) using aspirin and clopidogrel|Combination antiplatelet therapy using aspirin (100 mg) and clopidogrel (75 mg) after the index angioplasty
224314719|NCT02829151|DRUG|Dual antiplatelet therapy (aspirin (100 mg) and cilostazol (200 mg)) using aspirin and cilostazol|Combination antiplatelet therapy using aspirin (100 mg) and cilostazol (200 mg) after the index angioplasty
224314720|NCT04257045|OTHER|Interview|Participate in semi-structure, in-depth qualitative interviews
224314721|NCT04257045|OTHER|Questionnaire Administration|Complete questionnaires
224314722|NCT04257045|OTHER|Survey Administration|Complete survey
224314723|NCT04128020|DRUG|Nivolumab|Nivolumab
224314724|NCT04128020|DRUG|Azacitidine|Azacitidine
223618694|NCT01145742|BEHAVIORAL|home health/primary care collaboration|self-management support and telemonitoring of BP and blood glucose
223618695|NCT00111514|BIOLOGICAL|Leish-111f + MPL-SE vaccine|
223618696|NCT00407771|DRUG|Tirofiban|
223618697|NCT01207635|PROCEDURE|Ductal Lavage Fluid Collection|Procedure of inserting a small catheter into the ductal openings in the nipple and washing out cells from inside the duct.
223618698|NCT00292240|BEHAVIORAL|Brief motivational substance use intervention|
223618699|NCT03523884|OTHER|Exercise Program plus Education|Rotator cuff exercises outlined in the American Academy of Orthopedic Surgeons (AAOS) guidelines on management of rotator cuff problems.
223618700|NCT03523884|OTHER|Educational Program (EP).|An information sheet form AAOS, outlining the anatomy, description, causes, symptoms, examination and imaging tests performed on individuals with shoulder conditions
223618701|NCT03291938|DRUG|Oxidative Phosphorylation Inhibitor IACS-010759|Given PO
223618702|NCT03291938|OTHER|Pharmacodynamic Study|Correlative studies
223618703|NCT03291938|OTHER|Pharmacokinetic Study|Correlative studies
223618704|NCT04389359|DRUG|Hydroxychloroquine Sulfate 200 MG|Hydroxychloroquine Sulfate administered orally for a maximum of 6 months. Doses population specific.
223512626|NCT03565588|BEHAVIORAL|Education session with fixed incentive|"All participants will receive an education session on the risk of HIV infection and benefits from medical male circumcision. The sessions will be implemented by trained male healthcare workers who have undergone VMMC.~All participants will receive contributions towards transport costs to access medical male circumcision at participating clinics. On completing VMMC, participants assigned to receive fixed incentives will receive payment through mobile payments. In two sites a community-led intervention will also be implemented to address social obstacles and to increase support from peers, families and social structures."
224206946|NCT06653088|BEHAVIORAL|Physical Education program|"A four-month intervention will be implemented, led by the PE teacher, with three sessions per week. These sessions will last 45 minutes each (Koolwikh et al., 2023), divided into 5 minutes of warm-up, 35 minutes of intervention content, and 5 minutes of return to calm.~The program content of the intervention group will contemplate a warm-up with several activities, such as dancing or games. The intervention part will be composed of circuit-based exercises with several stations and games involving locomotion skills, namely run, gallop, slide, skip, jump, hop, etc.; games that integrate manipulative skills, such as throwing, catching, kicking, punting, striking, rolling and bouncing/dribbling; balance games involving swinging, turning, pulling, etc. Games involving perceptual motor skills, such as body schema, laterality, temporality, and spatiality, and games focused on PA. The return to calm will include activities such as yoga, meditation, and flexibility."
223512627|NCT03565588|BEHAVIORAL|Education session with lottery incentive|"All participants will receive an education session on the risk of HIV infection and benefits from medical male circumcision. The sessions will be implemented by trained male healthcare workers who have undergone VMMC.~All participants will receive contributions towards transport costs to access medical male circumcision at participating clinics. On completing VMMC, participants will participate in a lottery with prizes equivalent in expected value to the fixed incentives. In two sites a community-led intervention will also be implemented to address social obstacles and to increase support from peers, families and social structures."
223512628|NCT06226415|BEHAVIORAL|Rehabilitation therapy|"The study lasted 14d for each patient. During the treatment, All the participants were provided with the rehabilitation therapy, which included routine rehabilitation, cognitive training, swallowing function training and nutrition support.~Particularly, due to dysphagia, the patients enrolled might face difficulty in eating. For patients who were able to finish intake via mouth by compensatory means, the consistency, type, and size of food bolus was arranged. For those who cannot acquire sufficient nutrition through oral intake, the nasogastric tube feeding was provided."
224206947|NCT06652217|DEVICE|Digitally manufactured occlusal splint.|digitally manfactured occlusal splint using intra oral scanner and jaw traccking device for data acqusition and 3d printing for manfacturing of the device
224206948|NCT06652217|DEVICE|conventionally manufactured occlusal splint|the occlusal device will be manufactured conventionally using impression and and anterior deprogramer with bite registeration material for data aquesition and usual construction method using clear acrylic.
224206949|NCT05764434|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|Magnetic Resonance Imaging of the spinal cord using radially acquired Averaged Magnetization Inversion Recovery Acquisitions (rAMIRA)
224206950|NCT01307488|DRUG|Ritonavir boosted Atazanavir + Lamivudine|ATV/RTV 300/100 mg QD + 2 optimized NRTIs for the first 4 weeks and then they will receive ATV/RTV 300/100 mg QD (once daily) and 3TC 300 mg QD for another 92 weeks. Treatment should be taken orally with a light meal at the same time each day.
224206951|NCT01307488|DRUG|Ritonavir boosted Atazanavir + 2 NRTIs|ATV/RTV 300/100 mg QD + 2 optimized NRTIs for 96 weeks. Treatment should be taken orally with a light meal at the same time each day.
223512629|NCT06226415|PROCEDURE|Stellate ganglion block|Based on the invention above, the patients in the observation group were provided with Stellate ganglion block, using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate ganglion block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
223512630|NCT06226415|DRUG|Lidocaine Hydrochloride|Based on the invention above, the patients in the observation group were provided with Stellate ganglion block, using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate ganglion block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
223512631|NCT03997838|DRUG|VVZ-149 Injections|IV infusion of 1000 mg of VVZ-149
223512632|NCT03997838|DRUG|Placebo|IV infusion of 0 mg of VVZ-149
223512633|NCT00483509|DRUG|NGR-hTNF|iv q3W 0.8 mcg/sqm NGR-hTNF
223512634|NCT00483509|DRUG|Doxorubicin|iv q3W 75 mg/sqm doxorubicin 60 minutes after NGR-hTNF infusion
223512635|NCT01347957|OTHER|Nitric Oxide (NO) Gel|Nitric Oxide (NO) Gel is created by premixing of contents from 2 separate gel bottles. The first bottle, NO gel, is a solution of sodium nitrite (14.6mM) in distilled water with hydroxyethylcellulose (molecular weight 50,000-1,250,000) added for gel formation. The second bottle, Releasing-stimulator gel, is a solution of maleic acid (14.6mM) and ascorbic acid (14.6mM) in distilled water with hydroxyethylcellulose added for gel formation.
223618705|NCT03434730|RADIATION|Total Body Irradiation|Participants will receive a total dose of 400 cGy on day -2 and day -1 as 2 fractions (200 cGy x 2). Participants receiving total body irradiation (TBI) are treated in a standing position, and the treatment takes about 20 to 30 minutes.
223618706|NCT03434730|DRUG|Cyclosporine|Dilute in D5W or NS to make a 2.5 mg/ ml solution. Infuse slowly over approximately 1-4 hours (intermittent infusion) or 24 hours for continuous infusion.
224206952|NCT06596382|DIETARY_SUPPLEMENT|Tocotrienol rich-vitamin E|Two dosage are available which are 100 mg for NAFLD patient with underlying metabolic syndrome meanwhile 50mg for NALFD patient without metabolic syndrome
224206953|NCT06596382|DIETARY_SUPPLEMENT|Placebo|Replicate for tocotrienol rich-vitamin E without any active ingredients
224314725|NCT01333891|DRUG|Phenylephrine|Neosynephrine®, Winthrop Breon Laboratories New York, NY, USA 0, 0.5, 1 and 2 μg/kg/min, each infusion step for 5 minutes, total infusion period of 20 minutes
224314726|NCT01333891|DRUG|Sodium-Nitroprusside|Nipruss®, Sanol-Schwarz, Monheim, Germany 0, 0.5, 1 and 2 µg/kg/min, each infusion step for 5 minutes, total infusion period of 20 minutes
223618707|NCT03434730|DRUG|Mycophenolate Mofetil|A 1000 mg dose should be placed in 140 ml of D5W. Administer only with D5W, over at least 2 hours.
224314727|NCT01333891|DEVICE|Suction Cup|experimental stepwise increase of intraocular pressure while measurement of choroidal thickness suction force of 25, 50, 75, and 100 mmH
223618708|NCT03434730|DRUG|Tocilizumab|For participants \< 30kg, dilute with 50mL 0.9% sodium chloride. For participants ≥ 30kg, dilute to 100ml with 0.9% sodium chloride. Administer infusion over 60 minutes with infusion set.
224314728|NCT01333891|DEVICE|Goldmann applanation tonometer|intraocular pressure measurements
224314729|NCT01333891|DEVICE|1060nm Optical coherence tomography|Optical coherence tomography is a widely used non-invasive method to image the retina and choroid. Using a 1060nm light source coupled to a commercially available OCT system (Heidelberg Engineering, Heidelberg, Germany) allows for the measurement of choroidal thickness
224314730|NCT04400682|DRUG|FAVIRA 200 MG Film Tablet|FAVIRA is containing 200 mg favipiravir manufactured by Novelfarma, Turkey.
224314731|NCT04400682|DRUG|AVIGAN 200 MG Film Tablets|AVIGAN is containing 200 mg favipiravir manufactured by Toyama, Japan
224314732|NCT05083130|BEHAVIORAL|a wake prone positioning|The team will give written and verbal advice and if necessary aid patients' positioning themselves in the prone position for at least 8 hours per day. The exact duration of prone sessions will be determined according to ward schedules to take account of nursing procedures, meal times and mitigation strategies. Other methods to encourage the maintenance of prone position includes phone calls to patients, carers or education of carers.
224206954|NCT04145804|DEVICE|Medtronic Minimed 670G insulin pump|It is an insulin pump to deliver insulin to the patient and associated with a sensor to monitor the glucose levels of the patient. The new feature in this device is the automode algorithm which regulates insulin delivery to the patient automatically to keep glucose levels within target.
224314733|NCT04824157|OTHER|Non|Follow up
223618709|NCT03434730|DRUG|Filgrastim|The single use prefilled syringes contain either 300 mcg or 480 mcg Filgrastim at a fill volume of 0.5 mL or 0.8 mL, respectively. For the prevention/treatment of chemotherapy induced neutropenia, the dose of filgrastim is standardized per body weight: ≤ 60 kg = 300 mcg daily subcutaneously; \> 60 kg = 480 mcg subcutaneously daily.
223618710|NCT05646498|PROCEDURE|Closed sinus lift procedure|The closed sinus lift is the elevation of the sinus membrane through the osteotomy
223618711|NCT05646498|DEVICE|Crestal sinus lift|The crestal approach is the elevation of the sinus membrane by osteotomes, piezosurgery, or Densah burs.
224206955|NCT03257800|DRUG|Ketamine|Ketamine 0,5mg.kg-¹was injected intravenously one minute prior propofol 3mg.kg-¹ and one minute before LMA insertion in Ketamine-propofol group
224206956|NCT03257800|DRUG|placebo|The control group which received intravenously the same volume with normal saline one minute prior propofol 3mg.kg-¹ and 1 min before LMA insertion in propofol group
224314734|NCT03664492|OTHER|Educational whiteboard video|Participants will be prompted to complete pre-questionnaire, followed by access to the video, with a prompt to complete the post questionnaire after. If they agree, they will receive 4 to 6 months later, a third questionnaire to complete. For those without access to the internet, we will offer to them view the video at the SickKids at their convenience.
224314735|NCT03812744|DRUG|Whole coffee cherry extract (WCCE)|100mg WCCE
224314736|NCT03812744|DRUG|Placebo Oral Capsule [CEBOCAP]|Silica Oxide
224314737|NCT03393663|OTHER|CKD-related outcomes|the study is observational
224314738|NCT02293863|DRUG|MHAA4549A|Participants will receive a single dose of MHAA4549A by IV infusion on Day 1
224314739|NCT02293863|DRUG|Oseltamivir|Participants will receive oseltamivir capsule either 75 mg or 150 mg BID orally for minimum of 5 days. Dosage and administration should follow local prescribing information for oseltamivir.
224314740|NCT02293863|DRUG|Placebo|Participants will receive a single IV dose of placebo matched to MHAA4549A on Day 1
223618712|NCT00461006|DRUG|Actos|45mg po daily
223618713|NCT00461006|DRUG|aleglitazar|0.6mg po daily
223618714|NCT00139230|DRUG|Taxotere|
224206957|NCT01966107|DRUG|Aclidinium Bromide|400 μg, twice per day, oral administration via a multi-dose dry-powder inhaler (DPI)
224206958|NCT01966107|DRUG|Placebo|Dose matched placebo, twice per day, oral administration via a multi-dose dry-powder inhaler (DPI)
224314741|NCT00566566|OTHER|sample without DNA|family history, anthropometric measurements and blood sampling
224314742|NCT02865421|DRUG|stem cells|adipose tissue derived stromal vascular fraction
224314743|NCT02865421|DRUG|platelet rich plasma|platelet rich plasma transplanted in bald area at a distance
224314744|NCT01975727|DRUG|Placebo|Injection of placebo (saline 0.9%)
224314745|NCT01975727|DRUG|Dexamethasone 3 mg|10 ml Seringue with Dexamethasone
224314746|NCT01975727|DRUG|Dexamethasone 6 mg|10 ml Seringue with Dexamethasone
224314747|NCT01975727|DRUG|Dexamethasone 12 mg|10 ml Seringue with Dexamethasone
224314748|NCT00927797|DRUG|Cyclophosphamide, Pentostatin, Rituximab|
224314749|NCT00361062|BEHAVIORAL|comparative computer simulation|comparative computer simulation assessing the level of aggressiveness before and after the beginning of SSRI treatment.
224314750|NCT00901992|BEHAVIORAL|MEDIAS 2 ICT|MEDIAS 2 ICT is a newly developed education program for the initiation of intensive conventional insulin therapy in type 2 diabetic patients (10 lessons of group sessions for 4-8 participants)
224314751|NCT00901992|BEHAVIORAL|Current ICT program (ACC-ICT)|This program is conducted in 10 lessons in a group setting (4-8 participants)
224314752|NCT02097680|DRUG|Letrozole|One Letrozole 2.5 mg capsule every two days during four months
224314753|NCT02097680|DRUG|Placebo|One placebo capsule every two days during four months
224314754|NCT06017076|OTHER|Oral energy drinks|Patients drank energy drinks (Red Bull®) 250ml about 2-2.5 hours before operation.
224314755|NCT06017076|DEVICE|Warming matress|From the end of anesthesia, warming matriss at 40 ℃ was used to keep warm until the end of surgery.
224314756|NCT04721444|DIAGNOSTIC_TEST|Machine Learning Classification of parenchymal lung change cause|Arms A \& B: Radiomics and deep-learning approaches will be used on patient's imaging to develop a feature vector that can distinguish parenchymal lung changes, e.g. infection from drug-toxicity.
224314757|NCT04721444|DIAGNOSTIC_TEST|Machine Learning Classification of recurrence and non-recurrence|Arm C: Radiomics and deep-learning approaches will be used on patient's imaging to develop a risk-signature for recurrence of malignancy following radical treatment
224206959|NCT00538707|BEHAVIORAL|2-minute Bondet test|2-minute Bondet test
224206960|NCT01465074|DRUG|Nicotine polacrilex|4 mg
224206961|NCT01465074|DRUG|Regular chewing gum; Dentyne Ice, Wrigely´s Mint Gum|30 min chewing, one dose
224206962|NCT00532779|DRUG|Naltrexone SR 16 mg/Bupropion SR 360 mg /day|
224206963|NCT00532779|DRUG|Naltrexone SR 32 mg/Bupropion SR 360 mg /day|
224206964|NCT00532779|DRUG|Placebo|
224206965|NCT00532779|BEHAVIORAL|Ancillary therapy|Ancillary therapy consisting of diet instruction, advice on behavior modification, and exercise counseling
224206966|NCT00958698|OTHER|Communication Intervention|Ancillary studies
224206967|NCT00958698|OTHER|Educational Intervention|Ancillary studies
224206968|NCT00958698|OTHER|Internet-Based Intervention|Ancillary studies
224206969|NCT00958698|PROCEDURE|Psychosocial Assessment and Care|Ancillary studies
224206970|NCT00958698|OTHER|Quality-of-Life Assessment|Ancillary studies
224206971|NCT00958698|OTHER|Questionnaire Administration|Ancillary studies
224206972|NCT02246231|DEVICE|MR imaging|
224206973|NCT02662556|DRUG|sufentanil sublingual tablet 30 mcg|sufentanil sublingual tablet 30 mcg as needed for pain management, but no more frequently than every 60 minutes, for up to 12 hours.
224206974|NCT04382560|OTHER|Deep Breathing training|The intervention will comprise a psychoeducational part on the theorethical background underlying this technique and a pratical session in which partecipant will be instructed to inhale air with his/her nose and exhale with his/her mouth for a period of 3 seconds of inhalation and 7 seconds of exhalation (i.e., 6 cycles of breaths per minute;). During the session, the participant will be encouraged to put one hand over his/her chest and the other over the abdomen in order to see the difference between normal breathing and deep breathing. To help the subjects in the training, an online pacer will give the rhythm of respiration and will be used as visual feedback.
224206975|NCT04382560|OTHER|Compassion focused intervention|"The short compassion focused intervention will begin with a short psychoeducation on the evolved nature and difficulties of the human mind, such as tendencies for negativity bias, negative rumination, and self-criticism. Participants will then be offered insights into how humans can work with their 'tricky brains' using body-based and psychological-based practices aimed at increasing a grounding and soothing compassionate attitude towards ourselves and others. In particular, participants will be instructed to pratice a mindfulness technique designed to help them to become more aware of their present moment-to-moment and more compassionate towards their own emotions. They will then be guided to create an image conveying warmth and compassion to them. Lastly, participants will be guided to bring the image to mind and then write write a brief self-compassionate letter to themselves from that point of view."
224314758|NCT03761563|DEVICE|Fortilink IBF System with TETRAfuse Technology|Cervical and lumbar fusion
223512636|NCT01347957|OTHER|Placebo gel|The placebo gel is created by premixing of contents from 2 separate gel bottles. The first bottle is phosphate-buffered saline. The second bottle is the second gel bottle (Releasing-stimulator gel) as described in experimental arm.
223512637|NCT01935154|DRUG|Vx-001|
223512638|NCT01935154|DRUG|Placebo|
223512639|NCT03486639|OTHER|IPSS questionnaire|IPSS is an 8 question (7 symptom questions + 1 quality of life question) written screening tool used to screen for, rapidly diagnose, track the symptoms of, and suggest management of patients with lower urinary tract symptoms. It was validated for both genders.
223512640|NCT01029197|BEHAVIORAL|CBT and exposure therapy for PTSD|The CBT intervention will be administered twice weekly in group therapy sessions for 7 weeks, and then twice weekly individual sessions for 4 weeks.
223512641|NCT01029197|OTHER|Treatment as Usual|Participants in the treatment as usual condition will receive their usual services at the community clinic where they receive mental health and substance abuse services
223512642|NCT01687205|DRUG|1% Tenofovir Gel|
223512643|NCT00007943|DRUG|gemcitabine hydrochloride|
223512644|NCT03847012|OTHER|exercise|The test order will be random. After at least 12 times of cardiopulmonary rehabilitation training, the test will be performed again.
223512645|NCT03822819|DIETARY_SUPPLEMENT|probiotic cocktail capsules|Daily uptake of probiotic cocktail for three weeks
223512646|NCT03822819|DIETARY_SUPPLEMENT|placebo capsules|Daily uptake of placebo capsule for three weeks
223512647|NCT03469609|OTHER|mucous fistula refeeding|Transfer of infants' own stool
223512648|NCT05938816|BEHAVIORAL|Mindfulness-Based Stress Reduction (MBSR)|MBSR consists of weekly two-hour sessions for eight weeks, and a 7.5 hour retreat between weeks 6 and 7. The MBSR intervention will be facilitated by an experienced and certified MBSR teacher. MBSR curriculum strongly encourages completion of home practice assignments (\~30 minutes daily) to help integration of concepts into daily life. Participants will receive audio CDs and a DVD to help guide home practice.
223618715|NCT00139230|DRUG|Cisplatin|
223618716|NCT00139230|DRUG|5-Fluorouracil|
223618717|NCT00139230|DRUG|Leucovorin|
223618718|NCT00139230|DRUG|G-CSF|
224206976|NCT01556165|DRUG|rasagiline|1 mg/day, tablets, once daily, orally
224206977|NCT01556165|DRUG|placebo|tablets, once daily, orally
224206978|NCT04225416|OTHER|Questionnaire/Structured Interview|No intervention
224206979|NCT02983773|DRUG|THC 7.2%|1 smoked marijuana cigarette with 7.2% THC
224206980|NCT02983773|DRUG|THC 3.0%|1 smoked marijuana cigarette with 3.0% THC
224206981|NCT02983773|DRUG|Placebo|1 smoked placebo marijuana cigarette
224206982|NCT01482442|DRUG|sorafenib|Patients will receive continuous oral treatment with 800 mg of sorafenib daily (Nexavar, Bayer HealthCare Pharmaceuticals-Onyx Pharmaceuticals). Treatment interruptions and dose reductions (to 400 mg once daily) will be permitted for drug-related adverse effects. At the discretion of the investigator, the dose may be re-escalated to after the resolution of the adverse event.
223512649|NCT05938816|BEHAVIORAL|Health and Wellness Education (HWE)|HWE is a didactic-based group intervention designed as an active comparator for randomized-controlled trials of MBSR. HWE provides instruction to participants regarding improving their emotional and physical health. In contrast to MBSR, there are no attempts to train participants' breathing, movement, or meditation habits or practices. HWE is administered in 8 weekly 2.5-hour classes with home practice to be completed between sessions (matched to MBSR for amount and effort). HWE also features one extended 7.5-hour retreat, similar to MBSR.84 Dr. Autumn Gallegos (consultant) has conducted trials of MBSR among veterans with PTSD using a HWE control group, and will provide mentorship to the PI in administering the HWE intervention. Dr. Kaplan and a trained RA will facilitate HWE.
223512650|NCT01642667|DRUG|Prourokinase|a bolus of 1.2 million IU and an infusion of 4.8 million IU in 60 min.
223512651|NCT01642667|DRUG|Placebo|
223618719|NCT00139230|DRUG|Ciprofloxacin|
223618720|NCT04067323|DIETARY_SUPPLEMENT|Soya bean oil|Participants will consume soya bean oil together with yogurt in lunch daily meals and be monitored side effects and diarrhea. Then they will be evaluated anthropometric index, body compositions and blood lipid profile after 2 months (T1) and 4 months (T2) intervention. This product is composed of 12% total energy intake of participants.
224206983|NCT01482442|DRUG|SIR-Sphere|The first step will check patient eligibility and prepare conditioning by performing selective mesenteric and hepatic angiography (to document the arterial tumor supply and to occlude extrahepatic vessels) and 99mTc-macroaggregated albumin scintigraphy. The second step is RADIOEMBOLIZATION therapy. One to two weeks after patient eligibility and conditioning, treatment is performed with SIR-Sphere (SIRTEX Medical Ltd.,Lane Cove,Australia).
223618721|NCT04067323|DIETARY_SUPPLEMENT|MCT oil|Participants will consume MCT oil together with yogurt in lunch daily meals and be monitored side effects and diarrhea. Then they will be evaluated anthropometric index, body compositions and blood lipid profile after 2 months (T1) and 4 months (T2) intervention. This product is composed of 12% total energy intake of participants.
223618722|NCT04362436|RADIATION|TheraSpheres Selective Internal Radiation Therapy (SIRT)|Single-photon emission computed tomography (SPECT) imaging will assess 99mTc-MAA (MAA being macro aggregated albumin) deposition in the tumour bed to estimate the dose of radiation to tumour and healthy tissue, before administration of TheraSpheres to eligible patients
223680754|NCT01275339|DRUG|Tadalafil|Active drug will be encapsulated to look identical to the placebo pill. Subjects will take a single oral dose of tadalafil once daily from the time of randomization until study completion (6 months). Subjects will begin by taking 20 mg (1 pill) daily for 3 days before having the dose increased to 40 mg (2 pills) once daily. If the increase to 40mg daily is not tolerated, then the dose will be decreased back to 20mg daily.
223761424|NCT00945503|DRUG|GSK1018921|GSK1018921 is a GT1 recepor antagonist
224206984|NCT00701558|DRUG|Erlotinib|150 mg po daily
224206985|NCT00701558|DRUG|Gemcitabine|1000 mg/m\^2 iv on days 1, 8, 15 of each 4 week cycle for 6 cycles
224206986|NCT05481554|BIOLOGICAL|Stool sample|Only 1 stool sample will be collected during the patient hospitalisation scheduled within standard care.
224206987|NCT00116376|DRUG|AEE788|
224206988|NCT00395200|PROCEDURE|MSC Treatment|Intravenous administration of up to 2x10\^6 autologous MSCs per kg
224206989|NCT00131937|DRUG|sorafenib tosylate|Given orally
224206990|NCT05531591|DRUG|Aripiprazole Augmentation|Augment current antidepressant treatment with aripiprazole (tablets). Start at 2 mg daily; increase every two weeks (i.e., to 5, 7, 10 mg) to a maximum of 15 mg daily based on symptom severity and side effects.
224206991|NCT05531591|DRUG|Bupropion Augmentation|Augment current antidepressant treatment with bupropion once-daily extended release, starting at 150 mg daily; titrated after four weeks to 300 mg daily based on symptom severity and side effects.
224206992|NCT05531591|DRUG|Switch to bupropion|Taper from current antidepressant therapy. Start bupropion once-daily extended release at 150 mg daily; titrated after four weeks to 300 mg daily based on symptom severity and side effects.
224206993|NCT05531591|DRUG|Lithium Augmentation|Augment current antidepressant treatment with lithium carbonate tablets starting at 300 mg daily, titrated per blood level to 0.4-0.6 meQ/L.
224206994|NCT05531591|DRUG|Switch to nortriptyline|Taper from current antidepressant therapy. Start on nortriptyline tablets starting at 1 mg per kg of body weight daily, titrated per blood level to 80-120 ng/ml
224206995|NCT05925764|DIAGNOSTIC_TEST|Whole Slide Image based Deep Learning|Whole Slide Image Based Deep Learning for Diagnosing the IASLC Grading System of Lung Adenocarcinoma
224206996|NCT06418074|DIETARY_SUPPLEMENT|Ketone Monoester (KE4)|Each subject will receive beta-hydroxybutyrate boned to R 1,3 Butandiol (KE4) 300mg/kg x 3 for five days. After the treatment period effect variables will be examined.
224206997|NCT06418074|OTHER|Placebo|Each subject will receive a placebo drink 3 x day for five days. After the treatment period effect variables will be examined.
224206998|NCT06700681|DRUG|Propofol|TIVA induction and maintain with Propofol.
224206999|NCT06700681|DRUG|Remimazolam|TIVA induction and maintain with Remimazolam.
224207000|NCT06700681|DEVICE|With intubation and controlled ventilation to maintain airway|Patient receives intubation and controlled ventilation to maintain airway.
224207001|NCT06700681|DEVICE|Maintain spontaneous ventilation without intubation|Patient maintains spontaneous ventilation without intubation.
224207002|NCT06701084|GENETIC|Genomic Sequencing|Genomic sequencing data will be comprehensively analyzed for pathogenic variants that explain the participants epilepsy.
224260381|NCT05241639|DIAGNOSTIC_TEST|Pentacam|Pentacam (Oculus GmbH, Wetzlar, Germany) is used to image both the anterior and posterior corneal surfaces, providing a complete pachymetry map. Furthermore, it includes the corneal densitometry program in its software, which detects the amount of backscattered light in different regions of the cornea, providing an objective assessment of corneal transparency, and it is hypothesized that corneal densitometry may be altered in the presence of a systemic inflammatory disease, even in the absence of any corneal haze or scar
224260382|NCT02070458|DRUG|ixazomib|Given PO
224260383|NCT02070458|DRUG|mitoxantrone hydrochloride|Given IV
224260384|NCT02070458|DRUG|etoposide|Given IV
224260385|NCT02070458|DRUG|cytarabine|Given IV
223512652|NCT05875831|BEHAVIORAL|Active Cycle of Breathing|Active Cycle of Breathing Technique to Improve Pulmonary Functions in Post-Surgical Patients
223512653|NCT05875831|DIAGNOSTIC_TEST|Coughing|Coughing to Improve Pulmonary Functions in Post-Surgical Patients
223680755|NCT01275339|DRUG|Placebo|The placebo pill will be encapsulated to look identical to the active drug pill. Subjects will take a single oral dose of placebo once daily from the time of randomization until study completion (6 months). Subjects will begin by taking 1 pill daily for 3 days before having the dose increased to 2 pills once daily. If the increase to 2 pills is not tolerated, then the dose will be decreased back to 1 pill daily.
224314759|NCT03165838|BEHAVIORAL|Postpartum Visit 3-4 Weeks|This visit will be the same as the standard of care postpartum visit, but it will be scheduled earlier.
224314760|NCT03165838|BEHAVIORAL|Postpartum Visit 6-8 Weeks|This standard of care postpartum visit will be scheduled for the standard time interval.
224314761|NCT04277143|DRUG|Daptomycin|"Adult patients are given the recommended dose of daptomycin for injection. Patients with creatinine clearance (CLCR) ≥ 30 mL / min: 6 mg / kg every 24 hours.~Patients with creatinine clearance (CLCR) \<30mL / min (including hemodialysis or peritoneal dialysis): 6mg / kg every 48 hours. Dissolve 6mg / kg of this drug in 0.9% sodium chloride injection and instill it over a 30-minute time course once every 24 or 48 hours."
224314762|NCT00477633|DRUG|Norethindrone/ethinyl estradiol|1 tablet per day
224314763|NCT02553447|DIETARY_SUPPLEMENT|Cholecalciferol|Given PO
224314764|NCT02553447|OTHER|Laboratory Biomarker Analysis|Optional correlative studies
224314765|NCT03323047|DRUG|Acetaminophen|Oral acetaminophen (15 mg/kg) 1 hr pre-operatively
224314766|NCT03323047|DRUG|Low-dose Dexamethasone|Intravenous low-dose dexamethasone (0.15 mg/kg, max. 8 mg) immediately after induction of anesthesia
224314767|NCT03323047|DRUG|Placebo Oral Tablet|Oral placebo 1 hr pre-operatively
224314768|NCT03323047|DRUG|High-Dose Dexamethasone|Intravenous high-dose dexamethasone (0.5 mg/kg, max. 10 mg) immediately after induction of anesthesia
224314769|NCT05888194|DEVICE|Mucogyne® gel|In Mucogyne group, each eligible patient will receive a box of Mucogyne® gel. The patient will apply Mucogyne® gel, 48-hours after delivery, everyday, twice a day, massaging it into the intimate area, for a 10-day period.
224314770|NCT03583684|BEHAVIORAL|Pivotal Response Treatment Program (PRT-P)|The Pivotal Response Treatment Program (PRT-P) will consist of 3 parent-only sessions (60-90 min) and 13 family sessions with the parent and child (60-90 min). These 16 sessions are once per week over a 16 week period.
224314771|NCT00963560|DEVICE|ReSTOR +3|Bilateral implantation of the AcrySof ReSTOR Aspheric +3 Model SN6AD1 Intraocular lens (IOL) for the treatment of cataract.
224314772|NCT00963560|DEVICE|Crystalens HD|Bilateral implantation of the Crystalens HD intraocular lens (IOL) for the treatment of cataract.
224314773|NCT00963560|DEVICE|Crystalens AO|Bilateral implantation of the Crystalens AO intraocular lens (IOL) for the treatment of cataract.
224314774|NCT00095797|DRUG|R(+)XK469|Given IV
224314775|NCT00095797|OTHER|pharmacological study|Correlative studies
224314776|NCT00095797|OTHER|laboratory biomarker analysis|Optional correlative studies
224314777|NCT04494984|DRUG|INM005|The IMP dose to be studied will be 4 mg of protein/kg of subject's weight. The IMP will be added to the 100 mL infusion bag of saline solution. Doses will be administered as an infusion at 2.0 mL/min over 50 min with an interval of 48 h between doses.
224314778|NCT04494984|DRUG|Placebo|Placebo substance will be added to the 100 mL infusion bag of saline solution. Doses will be administered as an infusion at 2.0 mL/min over 50 min with an interval of 48 h between doses.
224314779|NCT03509805|DIAGNOSTIC_TEST|polysomnography|
224314780|NCT02996214|DRUG|Paclitaxel Liposome|Paclitaxel liposome injection 175 mg/m\^2, given on day 1 of a 21-day cycle, for 4-6 cycles.
224314781|NCT02996214|DRUG|Gemcitabine|Gemcitabine 1000 mg/m\^2, given on days 1 and 8 of a 21-day cycle, for 4-6 cycles.
224314782|NCT02996214|DRUG|Cisplatin|Cisplatin 75 mg/m\^2, given on day 1 of a 21-day cycle, for 4-6 cycles.
224314783|NCT05050110|OTHER|Fruits and Vegetable increase|Increase fruits and vegetable consumption in chronic Kidney Patients to maintain Normokalemia
224314784|NCT02242032|DRUG|P-321 Ophthalmic Solution|
224314785|NCT02242032|DRUG|P-321 Ophthalmic Solution placebo|Placebo to match P-321 Ophthalmic Solution
224314786|NCT01852500|OTHER|Sham Osteopathic Manipulative Treatment|Patients from this group received sham osteopathic treatments twice a week for the entire length of stay in the unit.
224314787|NCT01852500|OTHER|Standard care|Patients from control group received standard care plus osteopathic evaluation only, according to the same schedule as the study group.
224314788|NCT02340052|DRUG|Pain treatment|Registration af actual analgesic treatment and outcomes
224314789|NCT00522561|OTHER|energetic and non invasive limb mechanical measurements|Force velocity stiffness running
224314790|NCT05404945|DRUG|Pembrolizumab|Pembrolizumab 400 mg IV
223512654|NCT01080547|PROCEDURE|Laparoscopic Surgery for Colorectal Cancer|Laparoscopic surgery for colorectal cancer using STORZ laparoscope
223512655|NCT01080547|DRUG|XELOX Chemotherapy|XELOX chemotherapy
223512656|NCT01080547|DRUG|mFolfox6 chemotherapy|Conventional (mFolfox6) chemotherapy
223512657|NCT01080547|OTHER|Fast Track Perioperative Treatment|Fast track treatment during perioperation period
223512658|NCT01080547|OTHER|Conventional Perioperative Treatment|Conventional treatment during perioperation period
223512659|NCT01080547|PROCEDURE|Open Surgery for Colorectal Cancer|Open surgery for colorectal cancer using conventional methods
223512660|NCT04562519|DEVICE|TENS|Patients of this group will receive 20 minutes of extra oral TENS over skin of bilateral parotid glands (3 sessions weekly for 3 weeks)
223512661|NCT06571071|OTHER|De-Stress and Chill Gummies-U001|Two gummies in sequence daily after meal for 60 days
223512662|NCT06571071|OTHER|De-Stress and Chill Gummies-I001|Two gummies in sequence daily after meal for 60 days
223512663|NCT06571071|OTHER|Placebo Gummies-001|Two gummies in sequence daily after meal for 60 days
223512664|NCT04801693|DRUG|BI 1819479|BI 1819479
223512665|NCT04801693|DRUG|Placebo|Placebo
223512666|NCT03063164|DEVICE|Intralase IFS150|Intralase flap creation
223512667|NCT03063164|DEVICE|Visumax|Visumax flap creation
223512668|NCT04421001|DEVICE|I-port use|patient will use I-port device fo 2 months
223512669|NCT02005926|PROCEDURE|Wire-localized abnormal node|Before the sentinel lymph node biopsy (SLNB) operation, a hookwire was placed at the suspicious axillary lymph node by ultrasound guidance to localize the abnormal node. In the SLNB operation, radioactive nodes and wire-localized nodes were removed and labeled separately for pathological examination.
224207003|NCT06702267|DEVICE|arterial blood samplers with needles PICO70 and safePICO syringes.|"PICO70 is a self-filling syringe for sample volumes in the range of 0.3-1.5 mL. All syringes are delivered with needle cube for safe needle disposal and a standard tip cap to reduce the risk of blood contact during blood mixing and sample transportation.~safePICO is a more advanced group of syringes based on the PICO70 family. They contain a gold coated magnetic steel ball facilitating automatic mixing of the blood when being used with the Radiometer ABL 90 with mixing module. The safePICO is a self-filling syringe covering a volume range of 0.7-1.5 mL and includes a vented safe tip cap (VTC), which simplifies removal of air bubbles and avoid the operator to get in contact with the blood, after attachment to the syringe. Some variants of safePICO are delivered with a needle shield device (NSD) to ensure safe removal of the needle."
224207004|NCT00850213|DEVICE|Endeavor Resolute Stent|Single implantation
224207005|NCT01640964|DRUG|Terlipressin acetate|IV bolus injection
224207006|NCT01640964|DRUG|Serelaxin (RLX030)|Part A2: IV infusion for 2-3 hours; duration of infusion depends on time required for completion of MRA data acquisition; Part B: IV infusion for approximately 2 hours
224207007|NCT06713954|BEHAVIORAL|Dietary assessment|Dietary intake data will be collected using the Snap-N-Send method, a tool with enhanced validity for assessing athlete total energy intake, where participants will take photographs of their meals and share them via WhatsApp directly with the researcher. Before the study commences, participants will receive standardised instructions on photographing food and adding details in the message such as title, portion sizes and ingredients alongside each photo to enhance data precision. The principal investigator will input these photographs with the added information into Nutritics dietary analysis software, where food weights, portion sizes, and nutritional content will be estimated and calculated. Nutritics will then calculate dependent variables and convert it into a food diary report, aggregating the three days of food diary into average intake.
224207008|NCT06357208|OTHER|Breathing Control and Retention|4 appointments with training of Breathing Control and Retention
224207009|NCT02787746|DRUG|Donepezil|Eligible patients were treated with Aricept® 10 mg/day for 20 weeks of study period. Aricept® should be taken at night, just prior to sleeping. If patient cannot endure 10mg/d，the dose could be reduce to 5mg/d for 4 weeks and then increase back to 10mg/d. Patients who could not endure the 10mg/d titration the 2nd time and were put back to 5mg/d or discontinuance of Aricept® should be considered as withdrawal from the study. There were a visit (visit 1) at week 0, the end of week 4 (visit 2) and the end of week 20 (visit 3), respectively.
224207010|NCT06702514|OTHER|Exercise|After their treatment, both groups will be given a daily exercise program (15 minutes of range of motion, 15 minutes of strengthening exercises) once a day, accompanied by a physiotherapist.
224207011|NCT06702514|OTHER|Paraffin|It was planned to apply paraffin treatment to both hands for 20 minutes, five times a week for 4 weeks, using one session per day for a total of 20 sessions.
224207012|NCT06702514|OTHER|Balneotherapy|The balneotherapy group will receive 20 minutes of paraffin and 20 minutes of balneotherapy on both hands, five times a week for 4 weeks, one session per day for a total of 20 sessions. The spa treatment will be given in the form of a 20-minute full body bath in the pool in each session. The spa water temperature will be 38-40 degrees Celsius.
224207013|NCT06703086|DIETARY_SUPPLEMENT|Berberine Hydrochloride group|The patient will be given a nutritional plan, moderate aerobic exercise with a goal of 10,000 steps or 150 min per week; and the phytopharmaceutical Berberine will be taken 3 tablets ( 500 mg) every 8 hours for 3 months.
224207014|NCT06703086|BEHAVIORAL|nutritional plan|nutritional plan according to your caloric requirements for lifestyle change and you will be scheduled biweekly for 3 months
224207015|NCT06703086|BEHAVIORAL|controlled moderate aerobic exercise|controlled moderate aerobic exercise that will consist of a goal of 10,000 steps or 150 minutes per week.
224260386|NCT03600363|DRUG|Metformin|metformin (1.0g, bid) as a maintenance therapy in patients with complete remission
224260387|NCT03600363|DRUG|Placebos|oral placebos as a maintenance therapy
224260388|NCT05464563|DEVICE|Electroencephalogram|An electroencephalogram is recorded during a task of rest then self-compassion and then empathy.
224260389|NCT06446479|DRUG|Dronabinol Pill|Dronabinol 20 mg
224260390|NCT06446479|DRUG|Placebo|placebo
224260391|NCT01425086|DEVICE|Embrace, PCM, warming blanket|"Infant will be placed on a blanket that encloses the Embrace device, The infant will be wrapped in this blanket to create a snug, comfortable and warm micro-environment."
224260392|NCT00835146|DRUG|Ribavirin 200 mg tablets|1 x 200 mg, single-dose fasting
224260393|NCT00835146|DRUG|COPEGUS™|1 x 200 mg, single-dose fasting
224260394|NCT00468455|PROCEDURE|Laparoscopic or open colorectal surgery|Application of a post-operative diary to be completed by subjects. The intervention is standard of care laparoscopic or open surgery.
224260395|NCT05365308|BEHAVIORAL|Clinical supports|Quality improvement tools for iron deficiency anemia that include computer-assisted identification, an EHR registry, facilitated GI referral, an EHR tool for documentation, and physician education
224260396|NCT06627218|DRUG|Prothrombin Complex Concentrate|Adhere to Recommendations for PCC Management in Major Bleeding Following Trauma
224260397|NCT05086003|COMBINATION_PRODUCT|Combined kidney and bone marrow transplantation|Combined kidney and bone marrow transplantation
224260398|NCT01198964|PROCEDURE|Low-level cortical stimulation|A couple of electrodes will be stimulated (at a lower level than the stimulation used for standard care) over a period of 4-12 hours based on the signals defined by the motor or language task.
224260399|NCT05502679|OTHER|Weight bearing as tolerated|Bearing weight on lower limb extremity
224260400|NCT05502679|OTHER|Pragmatic Exercise protocol|Designed exercise prescriptions according to the patients' needs
224260401|NCT04763733|OTHER|laparoscopic splenectomy|surgical
224260402|NCT03037554|DEVICE|Sleepwear with Lateralized Thermal Characteristics|Subjects will wear sleepwear constructed with insulating fabric on one side and conductive fabric on the other side, arranged bilaterally.
224260403|NCT03037554|DEVICE|Sham-Lateralized Sleepwear|Subjects will wear sleepwear constructed with two insulating fabrics arranged bilaterally.
223680756|NCT03560739|COMBINATION_PRODUCT|ofatumumab with PRF|ofatumumab 20 mg subcutanious injection administered with pre-filled syringe (PRF)
223680757|NCT03560739|COMBINATION_PRODUCT|ofatumumab with AI|ofatumumab 20 mg subcutaneous injection administered with autoinjector (AI)
224314791|NCT05404945|DRUG|Doxorubicin|Doxorubicin 25mg/m2 IV
224314792|NCT05404945|DRUG|Vinblastine|Vinblastine 6mg/m2 IV
224207016|NCT06703515|PROCEDURE|Awake transnasal laser-assisted surgery (TNLS)|For TNLS, patients are admitted to the day center on the same morning or afternoon of the surgery with fasting prior 6 hours. After local anesthesia application, a 445nm blue laser is introduced via a working channel of bronchoscope and laser ablation of vocal cord cyst is performed. During the operation, patient will receive continuous SpO2 monitoring with regular blood pressure monitoring. After the procedure, patients are kept nil-by-mouth for 2 hours until anesthesia wears off, meanwhile with close observation in day ward with continuous SpO2 monitor for 1 hour. Patients will be discharged on the same day of the procedure, with voice rest for 3 days.
224260404|NCT06350240|BEHAVIORAL|Exercise|An exercise program that can be easily applied at home and in the park, which will support the psychomotor, tactile and proprioceptive-rich sensory development specific to children with joint hypermobility. The family will be instructed to do these exercises for 30 minutes a day for 5 days in total, 2 days a week in the playground and 3 days at home for 6 weeks, and the family will be asked to keep a diary to see whether they do the exercises or not.
224314793|NCT05404945|DRUG|Dacarbazine|Dacarbazine 375mg/m2 IV
224314794|NCT05404945|DRUG|Brentuximab vedotin|Brentuximab vedotin 1.8 mg/kg IV
224260405|NCT06350240|BEHAVIORAL|Exercise+texture insoles|In addition to exercise, children in this group will have an individual textured insoles made to suit the child's foot. The child will be asked to place textured insoles inside his shoes and use the textured insoles for 6-8 hours.
224260406|NCT05513677|DEVICE|M4D|Coated catheter
224260407|NCT05513677|DEVICE|Standard of Care|Standard of Care
224260408|NCT06373185|PROCEDURE|Ultrasound-guided sacral erector spinae plane block|Patients were received ultrasound-guided sacral erector spinae plane block, 1ml/kg %0.25 bupivacaine (max 20 ml), for postoperative pain management
224260409|NCT06373185|PROCEDURE|Ultrasound-guided caudal block|Patients were received ultrasound-guided caudal block, 1ml/kg %0.25 bupivacaine (max 20 ml), for postoperative pain management
224260410|NCT03199963|DRUG|4-OH tamoxifen|4-Hydroxytamoxifen (afimoxifene) gel
224260411|NCT03199963|DRUG|Placebo|An absorptive hydroalcoholic gel preparation of the same ingredients as BHR-700, but without 4-OHT.
224260412|NCT03145623|DRUG|Elbasvir and Grazoprevir|Elbasvir 50 mg and grazoprevir 100 mg during the French temporary authorization for use (ATU) program
224260413|NCT01572662|DRUG|Fludarabine monophosphate|40 mg/m2 by vein on Days -6 through -3.
224260414|NCT01572662|DRUG|Busulfan|First two doses of Busulfan, 80 mg/m2 administered as an outpatient or as an inpatient to facilitate for this pharmacokinetically directed therapy. Busulfan is administered at the dose calculated to achieve a total (including first two doses delivered on day -13 and -12) systemic exposure of 20,000 ± 12% µMol-min based on the pharmacokinetic studies.
224260415|NCT01572662|PROCEDURE|Stem Cell Infusion|Fresh or cryopreserved bone marrow or peripheral blood progenitor cells infused on Day 0.
224260416|NCT01572662|DRUG|Tacrolimus|Starting dose of 0.015 mg/kg (ideal body weight) as 24 hour continuous infusion daily adjusted to achieve therapeutic level of 5-15 ng/ml. Tacrolimus changed to oral dosing when tolerated and can be tapered off after day +90 if no graft versus host disease (GVHD) present.
224260417|NCT01572662|DRUG|Methotrexate|5 mg/m2 by vein on Days 1, 3, 6 and 11 post transplant.
223512670|NCT03769948|OTHER|risk factors for diabetic retinopathy|Demographic variables: gender, race, marital status, urban rural status. Co-morbidity variable: neuropathy, nephropathy, peripheral circulatory, ketoacidosis, hyperosmolarity Lab tests variables: alanine aminotransferase (ALT), albumin serum, anion gap, aspartate aminotransferase, blood urea nitrogen, calcium serum, chloride serum, creatinine serum, glucose serum plasma, hematocrit, hemoglobin, mean corpuscular hemoglobin concentration (MCHC), mean platelet volume (MPV), potassium serum, protein total serum, red blood cell (RBC) count, sodium serum, white blood cell (WBC) count
223512671|NCT03030209|PROCEDURE|Distal pancreatectomy|Distal pancreatectomy with or without splenectomy using minimal invasive or open approach
223512672|NCT02443129|DEVICE|DRI-1 Swept source OCT, Atlantis, Topcon|Fundus imaging
223512673|NCT05039385|OTHER|Exercise Program focused on resistance training|"The program will be carried out by a personal trainer. To ensure correct execution, given that the groups will be of a maximum of 5 people. Each session will include:~A) Warm up: movility exercises and coordination games B) Main part: 3 exercises will be included to strengthen different muscle groups (pull , bench press and back squat). Velocity based training (VBT) will be used to control load. 3 sets of 16-30 repetitions mantaining the speed between Light (estimated loss of speed of the series 5-10%).~C) Cool down: feedback with patients based on the work of Stiles-Shields (2015).~Specific training content will focus on safety, while re-educating patients on proper exercise methods, motivation-related attitudes, and transparency on health benefits and potential harms as a result of increased exercise."
223512674|NCT01554852|DRUG|Induction (intensive pathway) - cyclophosphamide, lenalidomide, & dexamethasone (CRD) regimen|Days 1 \& 8 - cyclophosphamide 500 mg PO Days 1-21 - lenalidomide 25 mg daily PO Days 1-4 \& 12-15 - dexamethasone 40 mg daily PO This cycle is repeated every 28 days
223512675|NCT01554852|DRUG|Induction (intensive pathway) - cyclophosphamide, thalidomide, & dexamethasone (CTD) regimen|Days 1,8,15 (i.e. weekly) - cyclophosphamide 500 mg PO Continuously - thalidomide 50 mg hard capsules. Initially 100 mg daily PO for 3 weeks, increasing to 200 mg daily PO Days 1-4 and 12-15 - dexamethasone 40 mg daily PO The cycle is repeated every 21 days
223512676|NCT01554852|DRUG|Induction (intensive pathway) - carfilzomib, cyclophosphamide, lenalidomide, & dexamethasone (CCRD) regimen|Days 1 \& 8 - cyclophosphamide 500 mg PO Days 1 \& 2, 8 \& 9, 15 \& 16 - carfilzomib 20\*/36 mg/m2\*\* IV (\*carfilzomib 20 mg/m2 is only administered on days 1 and 2 of cycle 1; \*\*carfilzomib will be dose capped at a body surface area of 2.2 m2) Days 1-21 - lenalidomide 25 mg daily PO Days 1-4, 8, 9 \& 15, 16 - dexamethasone 40 mg daily PO This cycle is repeated every 28 days
223512677|NCT01554852|DRUG|Induction (non-intensive pathway) - cyclophosphamide, lenalidomide, & dexamethasone attenuated (CRDa) regimen|Days 1 \& 8 - cyclophosphamide 500 mg PO Days 1-21 - lenalidomide 25 mg daily PO Days 1-4 \& 15-18 - dexamethasone 20 mg daily PO This cycle is repeated every 28 days
223680758|NCT02478398|BIOLOGICAL|Short ragweed pollen allergen extract|One sublingual tablet containing 12 units of Amb a 1-U, once daily (QD) for up to 35 weeks.
224260418|NCT01572662|DRUG|G-CSF|5 mcg/kg/day subcutaneously beginning on Day +7, and continuing until absolute neutrophil count (ANC) is \> 500 \* 10/L for 3 consecutive days.
224314795|NCT02777073|DRUG|Victoza|Single dose of Liraglutide
224314796|NCT02777073|DRUG|Placebo|Single dose of generic placebo
224314797|NCT02777073|DRUG|Dapagliflozin 10mg Tab|single dose of 10 mg dapagliflozin
224207017|NCT06703515|PROCEDURE|Microlaryngeal surgery (MLS)|For traditional MLS under general anesthesia, after general anesthesia and intubation with microlaryngeal tube, the patient would be positioned on head-ring support for better alignment and access to glottis. A laryngoscope will be inserted transorally under direct vision and suspended. Vocal cord cysts are visualized with microscope, and removed with microsurgery instruments with microflap technique and sent for routine section. After the surgery, the patient is kept nil-by-mouth until fully awake, and is discharged on same day or the next day depending on the post- operative recovery. Patient will be discharged with voice rest for 3 days.
224207018|NCT06703294|PROCEDURE|Crow's feet injection filling|Patients with crow's feet of different degree were randomly divided into two groups, which were injected with bovine collagen and humanized collagen respectively
224207019|NCT06703294|PROCEDURE|Humanized collagen filling crow's feet|Bovine collagen filling crow's feet
224207020|NCT06713967|PROCEDURE|Metformin (Glucophage)|In this intervention, participants will receive oral metformin (500 mg daily, gradually increasing to 1500 mg daily for non-obese participants and 2000 mg daily for obese participants) starting from the second week of pregnancy and continuing until delivery. Metformin will be administered in combination with a standard diet and exercise plan. The intervention aims to evaluate the impact of metformin on pregnancy outcomes in women with polycystic ovarian syndrome (PCOS), focusing on reducing complications such as early pregnancy loss, preterm delivery, gestational diabetes, and intrauterine growth restriction. Participants will be regularly monitored with follow-up visits, ultrasounds, and glucose tests to assess the effectiveness of the treatment.
224207021|NCT06713967|PROCEDURE|Standard Care (Diet and Exercise Only)|In this intervention, participants will receive a standard diet and exercise plan designed to promote a healthy pregnancy. This intervention does not include any pharmacological treatment, such as metformin. The goal is to evaluate the pregnancy outcomes in women with polycystic ovarian syndrome (PCOS) managed with lifestyle modifications alone, without the added effect of medication. Participants will be monitored through regular follow-up visits, ultrasounds, and glucose tests to track pregnancy progress, including the occurrence of gestational diabetes, preterm delivery, early pregnancy loss, and fetal growth restriction.
224314798|NCT04328961|DRUG|Hydroxychloroquine Sulfate|Eligible participants in a household randomized to this study arm will receive hydrochloroquine therapy
224314799|NCT04328961|DRUG|Ascorbic Acid|Eligible participants in a household randomized to this study arm will receive ascorbic acid therapy.
224314800|NCT02388360|DRUG|topical prostaglandin analogs|
224314801|NCT01296282|DEVICE|Medronics CRT Optivol Impedance Measurement|Pacemaker
223512678|NCT01554852|DRUG|Induction (non-intensive pathway) - cyclophosphamide, thalidomide, & dexamethasone attenuated (CTDa) regimen|Days 1, 8, 15, 22 (weekly) - cyclophosphamide 500 mg PO Continuously - thalidomide 50 mg hard capsules; initially 50 mg daily PO for 4 weeks, increasing every 4 weeks by 50 mg increments to 200 mg daily PO Days 1-4 \& 15-18 - dexamethasone 20 mg daily PO This cycle is repeated every 28 days
223680759|NCT02478398|BIOLOGICAL|Placebo|One placebo sublingual tablet, QD for up to 35 weeks.
224207022|NCT05327517|PROCEDURE|Esophagectomy|Patients receive esophagectomy or definitive chemoradiotherapy according to patient preference
224314802|NCT01296282|DEVICE|External Thoracic Impedance Measurement|
224314803|NCT04229927|DRUG|BPDO-1603|"Arm1 : 1 tablet of the test drug, and 1 tablet of placebo reference drug~Arm2 : 1 tablet of the reference drug, and 1 tablet of placebo test drug"
224314804|NCT03132779|DRUG|Intralipid|Adose of intralipid given and rechecking NKcells activity
224314805|NCT04286451|BEHAVIORAL|Sleep Restriction|Women will be undergo 4 nights of sleep restriction.
224314806|NCT04286451|BEHAVIORAL|Habitual Sleep|Women will be undergo 4 nights of habitual sleep.
224314807|NCT05150847|OTHER|Oxygenation|Oxygenation will be calculated as PaO2/ FiO2 ratio.Static compliance will be calculated as tidal volume divided driving pressure.The potential for lung recruitment will be assessed by means of the R/I ratio (10).
224314808|NCT01374269|OTHER|Exercise program|Standardize the intervention programs Exercise program includes: physical agents, massage of myofascial points, stretching and strengthening exercises, cycloergometer or band aerobic exercises. 12 sessions, 3 per week.
224314809|NCT01374269|DRUG|NSAID (Nonsteroidal anti-inflammatory drugs)|The second group was treated for 10 days with NSAIDs (naproxen 500 mg/d or celecoxib 200 mg/d) according to the indications and contraindications. The patients kept a journal stating whether they had taken the drug and any adverse reactions. If the pain intensity of any participant increased, acetaminophen (1.5 - 2.0 g/d) was proposed as a rescue procedure.
224314810|NCT03961659|DRUG|Liraglutid|Liraglutid will be titrated from 0.6mg/day to 1.8mg/day during the first 2 weeks, if well tolerated. All patients will also continue on their existing dose and regimen of metformin throughout the study.
224314811|NCT03961659|DRUG|Dapagliflozin|Dapagliflozin will be initiated and maintained at 10mg/day every morning until the completion of the study. All patients will also continue on their existing dose and regimen of metformin throughout the study.
224314812|NCT03961659|DRUG|Acarbose|Acarbose will be initiated at 50mg three times daily for the first week, and then titrated to 100mg three times daily if appropriate.All patients will also continue on their existing dose and regimen of metformin throughout the study.
224314813|NCT05154461|OTHER|Alginate|BHB covered in alginate will be realised in stomach-duodenum
224314814|NCT05154461|OTHER|Pea-protein|BHB covered in pea-protein will be released in ileum-colon
224314815|NCT04553874|OTHER||observational study without intervention
224314816|NCT02602444|DRUG|ticagrelor|180 mg loading dose
224314817|NCT05322109|DIAGNOSTIC_TEST|CMR|Clinically indicated cardiac magnetic resonance tomography executed according to international guideline recommendations.
224314818|NCT05537636|OTHER|Rehabiltiation using exercise and manual therapy|"A licensed Physical Therapist will provide manual therapy to help restore spinal and scapular mobility. In association with this patients will be prescribed home exercises using a phased approach.~Phase 1 to gain mobility of the spine and scapular motor control Phase 2 to gain shoulder mobility to strengthen scapular and spine musculature Phase 3 shoulder strengthening with long lever arms."
224314819|NCT05997732|DRUG|Phenylephrine Hydrochloride|Participants will receive three incremental doses via the brachial artery catheter to assess α1-adrenoreceptor mediated vasoconstriction.
224314820|NCT05997732|DRUG|Isoproterenol Hydrochloride|Participants will receive four incremental doses via the brachial artery catheter to assess β-adrenoreceptor mediated vasodilation.
224314821|NCT05997732|DRUG|Norepinephrine Bitartrate|Participants will receive three incremental doses via the brachial artery catheter to assess nonspecific adrenoreceptor activation.
224314822|NCT05997732|DRUG|Propranolol Hydrochloride|Propranolol will be continuously infused through the brachial artery catheter to induce β-adrenergic blockade locally in the forearm.
224314823|NCT05997732|DRUG|Phentolamine Mesylate|Phentolamine will be continuously infused through the brachial artery catheter to induce α-adrenergic blockade locally in the forearm.
224314824|NCT05997732|DRUG|Phenylephrine Hydrochloride|Participants will receive one dose via the brachial artery catheter to evaluate the effectiveness of the α-adrenergic blockade.
224207023|NCT06722573|BEHAVIORAL|Mindfulness Intervention for Emotional Distress(MIED)-normal version|Mindfulness Intervention for Emotional Distress (MIED) program provides standard audio instructions for mindfulness exercises, introduces the nature and law of anxiety, depression, and other emotions, the source of anxiety, depression, and other emotional distress, and the strategies and methods to alleviate emotional distress. These exercises, knowledge and strategies are based on the latest progress in the field of psychological counseling and treatment, and their application in daily life can help alleviate anxiety, depression and other emotional problems.
224207024|NCT06723054|OTHER|regular fluoride 220 ppm F mouthwash without erythritol|The participants will be asked to rinse once daily with a regular fluoride 220 ppm F mouthwash without erythritol.
224207025|NCT06723054|OTHER|regular fluoride 220 ppm F mouthwash with erythritol|The participants will be asked to rinse once daily with a regular fluoride 220 ppm F mouthwash with erythritol.
224207026|NCT06723054|OTHER|high fluoride 500 ppm F mouthwash with erythritol|The participants will be asked to rinse once daily with a high fluoride 500 ppm F mouthwash with erythritol.
224207027|NCT06723782|BIOLOGICAL|AMTRIX-D|Use of a decellularized, viro-inactivated, desiccated, and sterile allogeneic amniotic membrane graft to wrap a tendon after release of its adhesions.
224207028|NCT01095458|BEHAVIORAL|Phone versus Clinic Weight Management Programs|To determine if weight loss is equivalent between individuals that complete weight loss meetings in person versus on the phone.
224207029|NCT05218148|DRUG|sintilimab|Sintilimab 200mg was administered as a 30-60 min intravenous (IV) infusion every 3 weeks.3 cycles before surgery and 5 cycles after surgery.
224207030|NCT05218148|DRUG|Trastuzumab|Trastuzumab was 8mg/kg for the first time, and 6mg/kg for the follow-up. 3 cycles before surgery and 5 cycles after surgery.
224207031|NCT05218148|DRUG|S-1 plus oxaliplatin|"Oxaliplatin 130 mg/m2 was administered IV every 3 weeks. S-1 was given orally twice daily for the first 2 weeks of each 3-week cycle. The S-1 dose was 40 mg for body surface area (BSA) \< 1.25 m2, 50 mg for BSA 1.25 to \<1.5 m2 and 60 mg for BSA ≥1.5 m2.~Body surface area \&lt;1.25m2: Tegio 40mg bid day 1 \~ 14; Body surface area 1.25 \~ \&lt;1.5m2: Tegio 50mg bid day 1 \~ 14; Body surface area ≥1.5m2: Tegio 60mg bid day 1 \~ 14; 3 cycles before surgery and 3 cycles after surgery."
224207032|NCT04796142|OTHER|medication reconciliation|medication reconciliation
224207033|NCT04633187|DRUG|EDP-938|"EDP-938 800mg~Dose adjustments were made for subjects taking azole antifungals."
224207034|NCT04633187|DRUG|Placebo|Subjects took EDP-938 matching placebo tablets once a day orally for 21 days
224314825|NCT05997732|DRUG|Isoproterenol Hydrochloride|Participants will receive one dose via the brachial artery catheter to evaluate the effectiveness of the β-adrenergic blockade.
224314826|NCT05997732|DRUG|Propranolol Hydrochloride|Propranolol will be continuously co-infused with phentolamine to maintain the β-adrenergic blockade.
224314827|NCT05602883|BEHAVIORAL|music therapy|Music is played for 30 minutes to the pregnant woman who is hospitalized due to the threat of premature birth.
224314828|NCT02944305|PROCEDURE|Endotracheal intubation|Endotracheal intubation under direct laryngoscopy using McIntosh blade
224314829|NCT06732895|DRUG|Navepegritide|Once-weekly subcutaneous injection of 100 µg/kg navepegritide for 52 weeks
224314830|NCT06732895|DRUG|Placebo for navepegritide|Once-weekly subcutaneous injection of 100 µg/kg placebo for navepegritide
223680369|NCT01135563|DRUG|Vinblastine and Sirolimus|"Patients will be enrolled to receive vinblastine and sirolimus in 28 day cycles. Using the 3+3 standard Phase1 design, vinblastine will be administered via IV push on Days 1, 8, 15, 22. The starting dose of 4 mg/m2 (Dose Level 1) is 67% of the established MTD (6 mg/m2) for this schedule in pediatrics. Dose escalation will take place in a standard 3+3 design, in which doses will increase by approximately 20 to 25% in successive 3-patient cohorts.~Sirolimus (rapamycin) will be given by mouth (tablet or suspension) once daily throughout the cycle. Ideally patients will remain on the same dose form (tablet or suspension) for the duration of the study. All patients will be assigned a target sirolimus serum trough"
224314831|NCT06632912|BIOLOGICAL|2 doses of vaccine Quadrivalent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha)|Two doses of the experimental vaccine were injected into the deltoid muscle of the upper arm according to the immunization schedule at 0 and 6 months.
224314832|NCT06632912|BIOLOGICAL|3 doses of vaccine Quadrivalent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha)|Three doses of the experimental vaccine were injected into the deltoid muscle of the upper arm according to the immunization schedule at 0, 2, and 6 months.
224314833|NCT00996892|DRUG|Cobimetinib|Repeated oral dosing.
224314834|NCT00996892|DRUG|Pictilisib|Repeated oral dosing.
224314835|NCT06052280|OTHER|Telerehabilitation exercise program|"After the outpatient intensive physical therapy program (common to both study arms), patients in the TrE group will continue with prescribed self-training at home through telerehabilitation, at least 3 times a week for 4 weeks. Each physical exercise session will consist of at least 5 minutes of aerobic warming-up, 35 minutes of specific high-intensity exercises for PD, and 5 minutes of aerobic cool-down.~The TrE arm will be supported by a telerehabilitation device which will be installed and tested at the patients' home immediately after the outpatient intensive program. The device will track any access and exercise duration, so that the physiotherapists will be able to remotely monitor both the actual duration of each session and their weekly frequency. One session per week will be directly and online supervised by a physiotherapist, while the other two will be recorded only."
224207035|NCT01042691|DRUG|Oxaliplatin|The starting dose of oxaliplatin administered via isolated hepatic perfusion will be the safe tolerated dose of intra-arterial infusion and pharmacokinetics from intravenous studies. The dose will be 5 mg/m2 and will be escalated.
224207036|NCT06039293|BEHAVIORAL|Cognitive behavioral therapy and physical activity sessions|The intervention group will receive 10 sessions of cognitive behavioral therapy (CBT) and 6 physical activity sessions over the 12-week period. All Program AACTIVE CBT sessions and exercise sessions will run concurrently and take place virtually using Master of Social Work (MSW) trainees and Movement Science Master of Science students from the University of Michigan.
224207037|NCT06039293|BEHAVIORAL|Enhanced Usual Care + Diabetes Basics Web Series|"Participants will receive the American Diabetes Association Diabetes Basics web series (one video per week for 10 weeks) or Diabetes Basics handouts sent via mail."
224207038|NCT00996008|DRUG|placebo|0.5 g (w/w) placebo cream applied to each target lesion twice daily
224207039|NCT00996008|DRUG|CT 327|0.5 g CT 327 cream will be applied to 2 target lesions twice daily 0.5 g placebo cream will be applied to remaining 2 target lesions twice daily
224207040|NCT01120522|DEVICE|Inferior Vena Cava Filter|Inplant of filter in inferior vena cava.
224207041|NCT05975463|PROCEDURE|HAIC|hepatic artery infusion for 3-4 times.
224207042|NCT05975463|DRUG|Adebrelimab|hepatic artery infusion of Adebrelimab 1200mg, d1, q3w，for 3-4 times.
224207043|NCT05975463|DRUG|Bevacizumab|hepatic artery infusion of Bevacizumab 5mg/kg, d1, q3w, for 3-4 times.
224207044|NCT03186963|PROCEDURE|No immobilization|Conventional wrist dressing
224207045|NCT03186963|PROCEDURE|Volar splint|Volar plaster splint
224207046|NCT02406703|DRUG|Chloroprocaine|
224207047|NCT02406703|DRUG|Mepivacaine|
224207048|NCT05000918|DIETARY_SUPPLEMENT|Okara protein hydrolysate (OPH)|Okara protein hydrolysate (OPH) was a pack of dried beige powder. It can be stored at room temperature, but it must be exposed to direct sunlight.
224207049|NCT01664000|DRUG|thioureidobutyronitrile|Kevetrin (thioureidobutyronitrile)
224207050|NCT04876859|PROCEDURE|CRF of anterior sensitive branches to the hip|Steroid and anesthetic extra articular injection followed by denervation using CRF at 90 celsius degree during a period 90 minutes at the sensitive branches of obturator and femoral nerve, separately.
224207051|NCT04876859|PROCEDURE|Anesthetic block with steroid injection of anterior sensitive branches to the hip|Corticosteroid and anesthetic extra articular injection at the sensitive branches of obturator and femoral nerve, only
224207052|NCT03046537|DIAGNOSTIC_TEST|Breath test|Collecting breath test from participants
224207053|NCT02269007|BIOLOGICAL|inactivated quadrivalent influenza vaccine (split virion)|0.5ml inactivated quadrivalent influenza vaccine (split virion) for each subject, one dose
224207054|NCT04738188|PROCEDURE|DEB-TACE|Drug-eluting beads transcatheter arterial chemoembolization
224207055|NCT04738188|PROCEDURE|cTACE|Transcatheter arterial chemoembolization
224207056|NCT04738188|DEVICE|Drug-eluting Beads|Drug-eluting beads
224207057|NCT04738188|DRUG|Epirubicin|Chemotherapy drug for intra-arterial infusion
223512679|NCT01554852|DRUG|Consolidation (intensive & non-intensive pathways) - bortezomib, cyclophosphamide, & dexamethasone (VCD) regimen|Days 1, 4, 8 \& 11 - bortezomib 1.3 mg/m2 SC or IV Days 1, 8, 15 - cyclophosphamide 500 mg PO Days 1-2, 4-5, 8-9 \& 11-12 - dexamethasone 20 mg daily PO This cycle is repeated every 21 days
223512680|NCT01554852|DRUG|Maintenance (intensive & non-intensive pathways) - lenalidomide maintenance|Days 1-21 - lenalidomide 10 mg daily PO This cycle is repeated every 28 days
223512681|NCT01554852|DRUG|Maintenance (intensive & non-intensive pathways - protocol v5.0 only) - lenalidomide plus vorinostat maintenance|Days 1-21 - lenalidomide 10 mg daily PO Days 1-7 \& 15-21 - vorinostat 300mg PO This cycle is repeated every 28 days
223512682|NCT01554852|DRUG|High dose melphalan therapy and autologous stem cell transplant (intensive pathway only)|High dose melphalan therapy and autologous stem cell transplant to be given as per local practice
223680370|NCT00494767|DRUG|GW869682|GW869682 tablet with a dose strength of 250 mg will be available for subjects
223680371|NCT00494767|DRUG|GSK189075|GSK189075 tablet with a dose strength of 250 mg will be available for subjects
223680372|NCT00494767|DRUG|GSK189075-Placebo|Placebo tablets to match GSK189075 250 mg will be available for subjects
224207058|NCT03117777|BEHAVIORAL|group cognitive behavioral therapy for insomnia|cognitive behavioral therapy for insomnia delivered in group setting for older adults
224207059|NCT04395131|DEVICE|Clearum HF Hemodialyzer|the hemodialyzer will be used 3x week for 3.5-4.5 hours with a Qb of at least 350 ml/min
224207060|NCT06282068|DIAGNOSTIC_TEST|AI computer-aided detection software|non-invasive
224207061|NCT01320826|PROCEDURE|colonoscopy|Data pertaining to all colonoscopies performed by a APC-Endo study physician over a two month period will be collected.
224207062|NCT00872573|DEVICE|C-Stem™ AMT Femoral Component (standard and high off-set variants)|A polished triple tapered cemented femoral component for use in total hip replacement
224207063|NCT01491373|DEVICE|rhBMP-2/ACS/LT-CAGE® Device|rhBMP-2/ACS inserted into Sofamor Danek's LT-CAGE® device.
224207064|NCT01491373|DEVICE|Autograft/LT-CAGE® Device|LT-CAGE® device filled with autogenous bone taken from the patient's iliac crest
224207065|NCT01788163|GENETIC|EGFR mutation test|EGFR mutation being tested in tissue and blood
224207066|NCT04875637|DIAGNOSTIC_TEST|WAI-MEMR|Using wideband acoustic reflectance for middle-ear muscle reflex.
224207067|NCT00265239|DRUG|edaravone|intravenous administration of 30mg Edaravone just before reperfusion therapy
224207068|NCT06700434|OTHER|Bleaching treatment|"After the lip retractor (OptraGate, Ivoclar Vivadent, Schaan, Liechtenstein) was placed, the gingival barrier protection (Biowhiten, Biodent Ltd., İstanbul, Turkey) included in the products was applied to the upper and lower arches from premolar to premolar at the beginning of each session and removed after each treatment. The bleaching gels were applied according to the manufacturer and removed after the recommended period with a disposable surgical saliva ejector, cleaned with gauze and washed with air-water spray. Two bleaching sessions were performed at a 1-week interval. Participants were advised to maintain regular oral hygiene by brushing with toothpaste that does not contain desensitizing or whitening ingredients.~HP18 is applied in 5 applications of 10 minutes per session. HP25 is applied in 3 applications of 15 minutes per session. HP40 is applied in 3 applications of 15 minutes per session."
224207069|NCT06701110|DRUG|[U-14C] WX-081|A single oral dose of approximately 450 mg (100 μCi) of \[U-14C\] WX-081 will be administered to healthy male volunteers. The study will involve pharmacokinetic assessments, including metabolism, mass balance, and excretion pathways, through the collection of biological samples such as blood, plasma, urine, and feces.
224207070|NCT03610646|DRUG|MYL-1701P|"Subjects will receive intravitreal injections of MYL-1701P throughout the 52-week treatment period, with the last dose at 48 weeks.~The additional doses may be administered in accordance with the protocol."
224207071|NCT03610646|DRUG|Eylea|"Subjects will receive intravitreal injections of Eylea throughout the 52-week treatment period, with the last dose at 48 weeks.~The additional doses may be administered in accordance with the protocol."
224207072|NCT02532023|DIETARY_SUPPLEMENT|omega 3 fatty acid|omega 3 fatty acid supplement, 2× 1000 mg softgel daily (1800 mg EPA+DHA per day), 2 times a day, for 2 months
224207073|NCT02532023|DIETARY_SUPPLEMENT|curcumin|curcumin supplement, 2× 500 mg softgel daily (1000 mg curcumin per day), 2 times a day, for 2 months
224207074|NCT02532023|DIETARY_SUPPLEMENT|omega 3 fatty acid placebo|omega 3 fatty acid placebo softgel (Containing 2 g edible paraffin oil), 2× 1000 mg softgel daily (2 g per day), 2 times a day, for 2 months
224207075|NCT02532023|DIETARY_SUPPLEMENT|curcumin placebo|curcumin placebo softgel (Containing 1 g starch powder), 2× 500 mg softgel daily (1 g per day), 2 times a day, for 2 months
224207076|NCT00424515|DRUG|Imatinib|Imatinib was given at a dose of 400 mg orally daily (4 100mg pills). Patients received treatment up to 12 months as long as they were receiving clinical benefit. Dosage may have been increased to twice daily if disease worsened and patient was in otherwise good clinical condition.
224207077|NCT05204628|DRUG|XZP-3621|XZP-3621 tablets will be administered orally at a dose of 500 mg QD until disease progression, unacceptable toxicity withdrawal of consent, or death, whichever occurred first.
224314836|NCT06052280|OTHER|Home self-exercise program|"After the outpatient intensive physical therapy program (common to both study arms), patients in the HSE group will continue with prescribed self-training at home, at least 3 times a week for 4 weeks. Each physical exercise session will consist of at least 5 minutes of aerobic warming-up, 35 minutes of specific high-intensity exercises for PD, and 5 minutes of aerobic cool-down.~The HSE arm will be given a booklet containing detailed explanations and pictures of the assigned exercises, in order to guide them in the correct execution of the requested movements. Subjects in this group will be asked to fill in a training diary to keep track of the training sessions and their duration. Once a week a physiotherapist will contact patients to discuss possible problems encountered in performing the exercises and to help in solving them."
224314837|NCT01987479|DRUG|Non-Biologic DMARDs|Treatment with non-biologic DMARDs, at a stable dose that was initiated at least 4 weeks prior to baseline, is permitted during the study and is at the investigator's discretion.
224314838|NCT01987479|DRUG|Tocilizumab|Tocilizumab 162 mg will be administered once a week by SC injection and as a single fixed dose, irrespective of body weight, for the treatment duration of 24 weeks.
224314839|NCT01987479|DRUG|Methotrexate|Methotrexate will be administered per investigator's discretion.
224314840|NCT02171494|DRUG|IVAX Warfarin|
224314841|NCT02171494|DRUG|BMS Coumadin|
224314842|NCT03705130|DEVICE|Single Vision Contact Lens|Spherical Contact Lens worn on non-dispensing basis
224207078|NCT05204628|DRUG|Crizotinib|Crizotinib capsules will be administered orally at a dose of 250 mg BID until disease progression, unacceptable toxicity withdrawal of consent, or death, whichever occurred first.
224207079|NCT06537908|DRUG|Anti-PD-1/PD-L1 antibodies|Anti-PD-1/PD-L1 Intravenous injection for at least 6 months
224207080|NCT06537908|DRUG|Anti-VEGF|Anti-VEGF Intravenous injection for at least 6 months
224207081|NCT01133444|DRUG|Finasteride|Finasteride tablets 1 mg
224207082|NCT00111774|DRUG|ABX-EGF|
224207083|NCT00267020|DRUG|enzastaurin|1200 milligrams (mg) loading dose then 500 mg, orally, daily, six 28-day cycles
224207084|NCT00267020|DRUG|gemcitabine|1000 milligrams/square meter (mg/m\^2), intravenously on Days 1, 8 and 15 per cycle, six 28-day cycles
224314843|NCT03705130|DEVICE|Multifocal Contact Lens 1|Multifocal Contact Lens worn on non-dispensing basis
224207085|NCT00013182|BEHAVIORAL|social activity|
224207086|NCT01094873|BIOLOGICAL|AdCh3NSmut|Genetic vaccines against Hepatitis C virus infection
224207087|NCT01094873|BIOLOGICAL|Ad6NSmut|Genetic vaccine against Hepatitis C virus infection
224207088|NCT03851731|DRUG|Naltrexone|Intranasal spray
224207089|NCT03851731|DRUG|Naloxone|Intranasal spray
224314844|NCT03705130|DEVICE|Multifocal Contact Lens 2|Multifocal Contact Lens worn on non-dispensing basis
224314845|NCT00278889|DRUG|AZD2171|oral tablet
224314846|NCT00278889|DRUG|5-fluorouracil|intravenous infusion
224314847|NCT00278889|DRUG|Leucovorin|intravenous infusion
224314848|NCT00278889|DRUG|Oxaliplatin|intravenous infusion
224314849|NCT00278889|DRUG|Bevacizumab|intravenous infusion
224314850|NCT03276065|DEVICE|Laser depilation|Fitzpatrick skin type classification will be assessed during the initial visit. The Fitzpatrick skin type classification is based on the level of pigmentation of the skin and its response to ultraviolet light (See Appendix). It will be used to select the best laser to perform hair removal for each patient. The laser treatment group will consist of an 810 nm (for Fitzpatrick skin types I-IV) or Nd:YAG (for Fitzpatrick skin types V-VI) 28 joule application at auto pulse duration for 400 ms. A cooling platform and application of 7% lidocaine/ 7% tetracaine cream, applied 45 minutes prior to treatment, will minimize any discomfort associated with the heat of the laser treatments.
223680373|NCT00494767|DRUG|GW869682-Placebo|Placebo tablets to match GW869682 250 mg will be available for subjects
223680374|NCT02502006|DRUG|Celecoxib|
223680375|NCT02502006|DRUG|Naproxen|
223680376|NCT02502006|DRUG|Placebo|
224207090|NCT03851731|DRUG|Naltrexol|Intranasal spray
224207091|NCT02832882|PROCEDURE|No-touch RFA|No-touch RFA indicates RFA without tumor puncture. In this study, no-touch RFA is performed using Octopus electrodes.
224314851|NCT03276065|OTHER|Standard of care hair depilation|Patients and families in the standard of care group will be taught hair removal techniques and asked to perform either chemical or mechanical depilation as needed to keep the area hair-free. Patients will be given supplies for six months of hair removal.
224314852|NCT06246968|DRUG|Pembrolizumab|Participants will receive Pembrolizumab as part of standard of care treatment.
224314853|NCT06246968|DEVICE|Cryoablation|Cryoablation is a type of thermal ablation that is a minimally invasive alternative technique to surgical resection.
224207092|NCT02832882|PROCEDURE|Conventional tumor puncture RFA|Conventional tumor puncture RFA indicates routine procedure of RFA in our institution. In this study, RFA procedure is performed using Octopus electrodes.
224207093|NCT02902380|DRUG|dexmedetomidine group|dexmedetomidine infusion (0.4 mcg/kg/h) from immediately after anesthetic induction to end of surgery
224207094|NCT02902380|DRUG|control group|0.9% saline infusion
224207095|NCT00006044|DRUG|therapeutic testosterone|
224207096|NCT04282044|BIOLOGICAL|CRX100 suspension for infusion|A fixed dose of CIK cells combined with the specified dose of CDSR.
224314854|NCT04042376|DRUG|Ibrutinib|Ibrutinib will be administered orally, once daily, at a dose of 420 mg (140 mg\*3 capsules taken together at one time).
224207097|NCT04282044|COMBINATION_PRODUCT|Fludarabine|25mg/m IV (five doses given from Day -7 until Day -3)
224207098|NCT04282044|COMBINATION_PRODUCT|Cyclophosphamide|60mg/kg intravenous (IV) (two doses given on Day -7 and -6)
224207099|NCT02602964|OTHER|Deep neuromsucular block|Deep or standard neuromuscular block
224207100|NCT00816517|BIOLOGICAL|injection of botulinum toxin type A.|35 to 100 units injected around a skin lesion (plaque) one time.
224207101|NCT04715386|DRUG|StrataXRT|Patients will be asked to start topical application of their allocated topical preparation on the area of skin that will be irradiated at the onset of radiation therapy, every day until skin symptoms subside (see patient information pamphlet). Apply twice per day and can be reapplied as skin symptoms arise or as needed. The amount of StrataXRT provided to each patient will be recorded throughout treatment.
224207102|NCT01678924|DRUG|AGN-214868|AGN-214868 given as injections into the area of pain on Day 1.
224207103|NCT01678924|DRUG|AGN-214868 Placebo (Vehicle)|AGN-214868 placebo (vehicle) given as injections into the area of pain on Day 1.
224207104|NCT01733186|BIOLOGICAL|CARTISTEM®|
224207105|NCT00757263|GENETIC|polymorphism analysis|
224314855|NCT00254852|PROCEDURE|Posterior Lateral Fusion (PLF)|Posterior lateral fusion (PLF) of the lumbar spine
224314856|NCT00254852|PROCEDURE|Anterior Lumbar Interbody Fusion (ALIF)|Anterior lumbar interbody fusion (ALIF)
224314857|NCT00254852|PROCEDURE|Transforaminal lumbar interbody fusion (TLIF)|Transforaminal lumbar interbody fusion (TLIF)
224314858|NCT00254852|PROCEDURE|Posterior lumbar interbody fusion (PLIF)|Posterior lumbar interbody fusion (PLIF)
223618723|NCT06012682|DRUG|Metformin Hydrochloride|"The investigational medicinal product/placebo will be dispensed to study participants by study staff during randomization visits V1, V2, V3, V4, V5 and V6.~The randomized patient will receive the investigational medicinal product/placebo in tablets of 500 mg. The received tablets will be dispensed in an amount sufficient for the next visit. Patients will be asked to bring unused medicine and all empty ones packaging to the Center for each subsequent visit. The investigational medicinal product/placebo will be administered orally 500 mg three times a day (Table No. 1). The dose of the study product will be gradually increased from 500 mg/day to 1500 mg/day in order to avoid or reduce side effects related to taking the study medicinal product metformin"
223680377|NCT00663247|DEVICE|Mesalazine|3 grams daily for 3 months
223680378|NCT00663247|DRUG|Placebo|3 grams daily for 3 months
224207106|NCT00757263|OTHER|laboratory biomarker analysis|
224207107|NCT00757263|OTHER|questionnaire administration|
224314859|NCT00254852|PROCEDURE|Extreme lateral interbody fusion (XLIF)|Extreme lateral interbody fusion (XLIF)
224314860|NCT06941181|OTHER|neurocognitive tasks|"1. risk-processing: Participants choose between two choices across 72 trials of a forced choice decision-making neurocognitive task (Holt and Laury, 2002). Each trial included a high and low monetary outcome with an associated probability of occurring. Each choice option is shown as a pie with ten slices represented probabilities, in which each piece corresponded to ten percent.~2. cognitive control: A multi-source interference task (MSIT; Bush et al., 2003) is used in which participants are presented with three digits and asked to identify the digit different from the others. In the neutral condition, the target's identity is congruent with its relative position. In the interference condition, the target's identity does not match its relative position. There are a total of 96 neutral trials and 96 interference trials."
224207108|NCT00291512|BEHAVIORAL|Theory-based counseling program|
224207109|NCT00669136|DRUG|AFP + GM-CSF Plasmid Prime and AFP Adenoviral Vector Boost|AFP + GM-CSF Plasmid Prime and AFP Adenoviral Vector Boost
224207110|NCT05675384|DEVICE|TENS Active Treatment|Using a 7-day/week wearable TENS device controlled by a Smart Phone App combined with moderate intensity lifestyle therapy,
224207111|NCT05675384|DEVICE|Sham Device|Using the sham (control) device combined with a moderate intensity lifestyle follow-up
224207112|NCT06540300|OTHER|rTMS stimulation of right IPL|The stimulation site is the right IPL (EEG International 10-20 system, electrode CP4/CP6), with a stimulation frequency of 1-Hz and intensity of 100% RMT. There are 50 pulses each time, 20 seconds each cycle, 5 seconds each, with an interval of 15 seconds, for a total of 60 cycles, a total duration of 20 minutes, and a total of 3000 pulses. Perform treatment once a day, rest for 2 days after 5 consecutive days of treatment, for a total of 2 weeks, and receive 10 treatments.
224207113|NCT01997099|DEVICE|CADD®-Solis VIP Pump|
223680379|NCT01456975|PROCEDURE|Aortic valve reimplantation using Valsalva prosthesis|Aortic valve reimplantation (David procedure)using Valsalva prosthesis
223680380|NCT05207345|OTHER|Interventional programme|"90-minute session divided into:~* 45 minutes of core stability treatment~* 45 minutes of general rehabilitation (active / active, assisted / passive mobilization, stretching, posture maintenance, postural and autonomy training, cycle ergometer, exercise bike and ambulatory training)."
224207114|NCT01997099|DEVICE|CADD™ Solis Medication Safety Software Administrator|
224207115|NCT01973842|DRUG|0.1 mg triptorelin|
224207116|NCT01973842|DRUG|0.2 mg triptorelin|
224207117|NCT01973842|DRUG|0.4 mg triptorelin|
224207118|NCT03711942|PROCEDURE|Intra orifice barrier|After primary root canal treatment, Glass Ionomer Cement (KetacTM Molar, 3M ESPE) applied as intraorifice barrier 3mm inside canal from root canal orifice in first group, as 2mm base on floor of pulp chamber in second group and direct composite restoration in 3rd group without Intraorifice barrier or base.3mm GP in the orifice was removed and intraorifice barrier and 2mm thick base was given of GIC.
224314861|NCT06952361|PROCEDURE|Red blood cell transfusion|Standard red blood cell transfusion performed as part of routine clinical care. All participants received one or more units of RBCs based on a restrictive hemoglobin threshold. The transfusion protocol was not altered for the purpose of the study.
224314862|NCT06282601|OTHER|Audiogram|Tonal and vocal free-field without lip-reading
224314863|NCT06282601|OTHER|Musical priming for the syntax test|Listening to music with a regular or irregular rhythm, then judging the grammaticality of 2x6 blocks of French sentences interrupted by a pause, each block presenting 4 sentences including 2 grammatically correct sentences and 2 grammatically incorrect sentences. The sentences are pronounced by a French female voice at a natural rhythm and comfortable volume.
224314864|NCT06282601|OTHER|Test MMSE|test to assess a person's cognitive functions and memory capacity.
224314865|NCT06282601|OTHER|Barcelona Music Reward Questionnaire|"20 questions exploring 5 main facets of the musical reward experience, with 4 items for each of the 5 facets, for which participants indicate the level of agreement using a 5-level scale, ranging from strongly disagree to strongly agree."
224207119|NCT03711942|PROCEDURE|Base|After primary root canal treatment, Glass Ionomer Cement (KetacTM Molar, 3M ESPE) applied as intraorifice barrier 3mm inside canal from root canal orifice in first group, as 2mm base on floor of pulp chamber in second group and direct composite restoration in 3rd group without Intraorifice barrier or base.2mm thick Base of GIC was applied over the orifice before composite restoration
224207120|NCT03711942|PROCEDURE|Control|After primary root canal treatment, Glass Ionomer Cement (KetacTM Molar, 3M ESPE) applied as intraorifice barrier 3mm inside canal from root canal orifice in first group, as 2mm base on floor of pulp chamber in second group and direct composite restoration in 3rd group without Intraorifice barrier or base.coronal accees upto orifice was restored with composite resin
224207121|NCT02941237|DEVICE|Pulse oximeter|"Time taken to measure oxygen saturation.~Completion of usability questionnaire"
224207122|NCT03373409|DRUG|Albuterol DPI 90mcg|Albuterol unit dose disposable DPI delivers 90mcg of albuterol in the excipient lactose with each inhalation. Albuterol 90mcg will be given on one of the 3 treatment days. One inhalation from the DPI will be used.
224207123|NCT03373409|DRUG|Albuterol DPI 180mcg|Albuterol unit dose disposable DPI delivers 90mcg of albuterol in the excipient lactose with each inhalation. Albuterol 180mcg will be given on one of the 3 treatment days. Two inhalations from the DPI will be used to deliver the 180mcg dose
224207124|NCT03373409|DRUG|Albuterol HFA MDI|Albuterol HFA MDI delivers 90mcg of albuterol with each inhalation. Albuterol 180mcg will be given on one of the 3 treatment days. Two inhalations from the MDI will be used to deliver the 180mcg dose
224207125|NCT02409537|DIETARY_SUPPLEMENT|red wine|the individuals were given red wine to consume for 1 month then a wash out period of 1 month
224207126|NCT02409537|DIETARY_SUPPLEMENT|resveratrol|the individuals were given resveratrol for 1 month and then 1 month wash out period
224207127|NCT02409537|OTHER|placebo|the individuals were given placebo for 1 month
224207128|NCT04498156|OTHER|No intervention|No intervention, observational study
224207129|NCT05048771|OTHER|Questionnaire|Patients will be surveyed through self-administered questionnaires and semidirected interviews with a psychologist
224314866|NCT06953973|OTHER|Tecar Therapy|Tecar Therapy will be applied by a specialist physiotherapist with WINTECARE T-PLUS-Switzerland. Participants in the experimental group included in the Tecar therapy application will be applied to the muscle groups in the neck region at a fixed frequency of 0.448 Mhz for 10 minutes.
224314867|NCT06953973|OTHER|Sham Tecar Therapy|Tecar Therapy will be applied by a specialist physiotherapist with WINTECARE T-PLUS-Switzerland. The patient will be positioned as in the Tecar group, but the heating feature of the device will not be activated.
223618724|NCT06012682|DRUG|Placebo|"The investigational medicinal product/placebo will be dispensed to study participants by study staff during randomization visits V1, V2, V3, V4, V5 and V6.~The randomized patient will receive the investigational medicinal product/placebo in tablets of 500 mg. The received tablets will be dispensed in an amount sufficient for the next visit. Patients will be asked to bring unused medicine and all empty ones packaging to the Center for each subsequent visit. The investigational medicinal product/placebo will be administered orally 500 mg three times a day (Table No. 1). The dose of the study product will be gradually increased from 500 mg/day to 1500 mg/day in order to avoid or reduce side effects related to taking the study medicinal product metformin"
223618725|NCT05640323|DEVICE|Norbert Device|The Norbert Device (ND) is a contactless, noninvasive device that provides measurements of body temperature, oxygen saturation (SpO2), and pulse rate.
223680381|NCT05207345|OTHER|General exercise programme|90 minutes of general rehabilitation (active / active assisted / passive mobilization, stretching, posture maintenance, postural and autonomy training, cycle ergometer, exercise bike and ambulatory training).
223680382|NCT00134420|DRUG|Nutropin AQ|Growth Hormone (Nutropin AQ) treatment given to Group 1 immediately Growth Hormone (Nutropin AQ) treatment given to Group 2 after one year observation
224207130|NCT06542783|BEHAVIORAL|referring to the results of AI model output|determining the ANA pattern type with or without referring to the results of AI model output.
224207131|NCT06348654|BEHAVIORAL|introduction of digital listening may improve the quality of life of patients withe breast cancer|Introduction of a digital listening and communication pathway aimed at improving the quality of life of patients with advanced HER2-negative breast cancer
224207132|NCT00926653|DRUG|Escitalopram|10 to 20 mg daily as part of another study in which participants are enrolled
224207133|NCT00021229|DRUG|imatinib mesylate|"* Phase 1 Stratum I: Starting dose level of 350 mg/m2/day every 28 days X 13 courses (dose escalation)~* Phase I Stratum IIA: Starting dose level of 465 mg/m2/day every 28 days X 13 courses (dose escalation)~* Phase I Stratum IIB: Starting dose level of 465 mg/m2/day every 28 days X 13 courses (dose escalation)~* Phase II: Phase I Stratum I determined dose (Maximum tolerated dose) every 28 days X 13 courses."
224323204|NCT06285032|BEHAVIORAL|Cognitive Behavior Therapy (CBT)|Individuals will participate in a series of eight, 1hour weekly group sessions delivered by a study interventionalist who is a licensed social worker (see personnel list) using a HIPAA-compliant videoconferencing platform (Zoom). Each group will consist of 6-10 participants and participants randomized to this intervention will select between a series of date/time options. The investigators plan to run four groups with staggered start times. All participants will receive digital copies of the workbook for this intervention and each session, they will be given assignments to practice the strategies they learn during the intervention.
223618726|NCT05474352|DEVICE|Allon System|Water garments (Allon system) already pre-filled with warm water will be set up before induction of anesthesia. After the induction of general anesthesia, the water garment will cover the lower and upper extremities, the lateral portion of the chest, and the entire back of the patient, which accounts for 70% of the body surface. The water garment will be opened temporarily on the upper extremities for intravenous access and arterial line placement and will be continued intraoperatively until the patient is transferred from the OR table to the stretcher
223618727|NCT02922530|OTHER|Computerized Plasticity-based Adaptive Cognitive Training|
223618728|NCT02922530|OTHER|Commercially available computerized training|
223618729|NCT04410185|BEHAVIORAL|Meditation|Meditation sessions will take place over 12 weekly sessions of 1.5 hours
223618730|NCT05532644|OTHER|AD drugs|AD drugs
224207134|NCT00021229|RADIATION|local irradiation therapy|"* Phase I Stratum I: Total dose of 5580 cGy using conventional or conformal volume-based delivery techniques once daily, 5 days/week for six weeks prior to receiving imatinib.~* Phase II: Total dose of 5580 cGy using conventional or conformal volume-based delivery techniques once daily, 5 days/week for six weeks prior to receiving imatinib."
224207135|NCT02306473|DRUG|Mannitol|Subjects will be challenged with inhaled mannitol according to already approved protocols.
224207136|NCT06004076|OTHER|Release of upper track of deep front fascial line|I will work on upper track of deep front fascial line, I will make release to diaphragm,mediastinum,scalene muscles, scalene fascia,Fascia endothoracic, transversus thoracis,Infrahyoid muscles, fascia pretracheal and Suprahyoid muscles.
224207137|NCT06004076|OTHER|Corrective exercises for upper crossed syndrome|strength for scapular muscles and deep neck flexor
224207138|NCT02805582|DRUG|10ml ropivacain 0.5%|Ultrasound guided nerve block
224207139|NCT04858074|DRUG|Hypoestoxide|Its active pharmaceutical ingredient (API) is Hypoestoxide, discovered in 1983, which was recently shown to be active against alpha synuclein and was very effective in modifying disease progression in a transgenic mouse model of PD
224207140|NCT02007369|BEHAVIORAL|WhatsApp|Intervention arm with relapse prevention intervention in the social group via the social networking service WhatsApp and the duration of the intervention will be 8 weeks.
224207141|NCT02007369|BEHAVIORAL|Facebook|Another intervention arm with the same intervention content, but the platform for the participants to share and receive quitting advice is Facebook and the duration of the intervention will be 8 weeks.
223618731|NCT04894721|DRUG|Ivermectin|0,6mg/kg of weight orally on days 1 and 7
223618732|NCT04894721|OTHER|Placebo|A substance with similar physical characteristics as ivermectin, without the active drug ingredient
224207142|NCT01380860|PROCEDURE|Colostomy with mesh implantation|Colostomy with mesh implantation
224207143|NCT01380860|PROCEDURE|Simple colostomy|Colostomy with no mesh implantation.
224207144|NCT03569020|OTHER|Subsidy for food purchases and dietitian education|$105/wk of DASH-like foods over 4 weeks purchased with the help of a dietitian in a proportion that reflects the DASH diet.
224207145|NCT05472857|BIOLOGICAL|Claudin 18.2 CAR-T|treatment with anti-claudin18.2 chimeric antigen receptor T-cell infusion
224207146|NCT03774173|DRUG|Aramchol|One Aramchol tablet (300 mg) twice daily and 2 Aramchol tablets (300 mg each) once daily
224207147|NCT02428231|DRUG|dimethyl fumarate|Participants will be dosed twice daily for 12 weeks.
224207148|NCT01014026|OTHER|Screening test|Two Vaginal self sampling devices and HPV test
224207149|NCT05538169|DEVICE|low-level laser diode (Pioon Laser)|"Settings: the spot tip area of this tool is 0.088 cm2, semi-conductor diode, with a wavelength of 980 nm (near infrared), 200 mW output power, 1.97W/cm2 of power density, 3 J energy per point and application time 15 seconds per point\].~* PBM will apply punctually, in continuous emissions.~* Extra-oral points: six points on each parotid gland, three points on each submandibular gland.~* Intra-oral points: two points on each sublingual gland.~* A total of 22 points will be applied in each session."
224260419|NCT03563274|DEVICE|Selective Internal Radiation Therapy with QuiremSpheres®|The main purpose of this study is to further assess treatment efficacy and safety after using QuiremSpheres® for the treatment of patients with unresectable primary liver cancer or unresectable liver metastases suitable for SIRT and allocated to this treatment by a multidisciplinary tumor board.
224260420|NCT01144494|DRUG|Brimonidine|One drop of brimonidine in each eye three times a day for six weeks.
224260421|NCT01144494|DRUG|Artificial tears|Lubricating drops added three times a day for six weeks
224260422|NCT00727480|PROCEDURE|Ultrasound|Ultrasound scanning of fingertips for assessment of possible imaging modes with Gray scale ultrasound, color flow vascularity imaging, and color flow vascularity imaging before and after exercise.
224260423|NCT01836380|BEHAVIORAL|Exercise Training|
224260424|NCT03364192|BEHAVIORAL|Whole Health Coaching|Veterans Health Administration variation of integrative health coaching.
224260425|NCT06429592|OTHER|education|nursing care practice
224260426|NCT04435067|GENETIC|Analysis of genetic mutations and the gene expression profile of lung metastasis and primary neoplasia|The mutational analysis of the main oncogenes and tumor suppressor genes involved in the genesis and tumor progression will be performed on the genomic DNA extracted from each sample using the Ion Torrent TM Oncomine TM Comprehensive Assay version 3 (OCAv3) kit. This panel includes 161 cancer-related genes and allows the identification of all genomic alterations affecting oncogenes and recurrently altered tumor suppressor genes in solid tumors. The study of gene expression will be carried out using Nanostring Technology using the Pancancer IO 360 TM panel which allows simultaneous analysis for each sample of multiple mRNAs associated with crucial pathways in carcinogenesis and the immunological profile of the tumor, defining its up and down conditions gene regulation.
224260427|NCT04435067|OTHER|Radiomics analysis on TAC imaging at diagnosis of lung metastasis and, if possible, of the primary tumor|This study will be performed using the SPAARC IBSI (International Biomarker Standardization Initiative) compliant software implemented in the MatLab environment (MathWorks, Boston, USA) through several steps: (a) CT imaging retrieval, (b) image segmentation and rendering, (c) feature extraction and (d) qualification/quantification. Approximately 200 radiomics characteristics will be extracted, such as: Morphology, Statistical, Intensity Histogram, Gray Level Co-occurrence Matrix 3D\_average, Gray Level Co-occurrence Matrix 3D\_combined, Gray Level Run Length 3D\_average, Gray Level Run Length 3D\_combined, Gray Level Size Zone Matrix 3D, Neighbor Gray Tone Difference Matrix 3D, Gray Level Distance Zone Matrix 3D.
224260428|NCT02341846|OTHER|Qualitative interviews|
224314868|NCT06953973|OTHER|Standard Physiotherapy Program|This study will include routinely applied conventional physiotherapy, heat modalities, electrotherapy (transcutaneous electrical nerve stimulation (TENS) and ultrasound therapy), and exercises. In this study, hot pack will be used to induce vasodilation and reduce muscle spasm. Hot pack will be used for 15 minutes to relax muscle spasms and increase soft tissue flexibility. TENS is a simple noninvasive modality and is widely used in both acute and chronic neck pain. In our study, 50 Hz conventional TENS with a pulse duration of \<150 microseconds will be used. TENS will be applied to the painful area of the neck for 20 minutes. Ultrasound therapy used to warm deep tissues is one of the most frequently used physical therapy methods. An ultrasound device (Chattanooga, USA) will be used in the study. Ultrasound gel will be applied circularly with a thickness of 2-3 mm. Ultrasound will be applied with a 4 cm2 probe for 5 minutes with a frequency of 1 MHz and 1.5 Wt/cm2. Within the scope o
224207150|NCT01826968|PROCEDURE|Alveolar Recruitment maneuver|In this group and during recruitment maneuver the investigators used pressure control ventilation and increased inspiratory time to 50%. The investigators used alveolar recruitment maneuver by increasing inspiratory pressure to 20 cmH20 and progressively increasing Positive Expiratory Pressure (PEEP) up to 45 cmH2O maximal (Ppeak) inspiratory pressure. The recruitment maneuver lasted 2 minutes. After the maneuver PEEP was set to 8 cmH2O and was left until the end of the operation. After the end of the recruitment maneuver volume control ventilation was used until the end of the operation too.
224207151|NCT00470119|BEHAVIORAL|behavioral dietary intervention|A group based modification of the DPP and LookAHEAD lifestyle programs with a goal of 10% weight loss
224207152|NCT00470119|BEHAVIORAL|Exercise intervention|Facility based and home-based exercise designed to increase moderate-to-vigorous aerobic activity in participants to 45 mins/day 5 days/week
224207153|NCT01784419|DRUG|ivacaftor|Eligible subjects were randomized to ivacaftor 150 mg by mouth twice a day for 14 days followed by placebo for 14 days, or vice versa. Randomization was based on a computer-generated schedule produced by the research pharmacy, which was concealed from study personnel until study completion. Ivacaftor was purchased at full retail cost and encapsulated with sucrose to match the sucrose-filled placebo capsules. Prior to beginning study drug, there was a 2-week run-in period to ensure clinical stability, assessed by modified Fuchs criteria and pulmonary function. There was a washout period of a minimum of 14 days between study drug cycles to account for carryover effect. The washout period was extended to 6 weeks for subjects on alternating cycles of inhaled antibiotics to coordinate the study drug cycle with the inhaled antibiotic cycle.
224207154|NCT01784419|DRUG|Placebo|Eligible subjects were randomized to ivacaftor 150 mg by mouth twice a day for 14 days followed by placebo for 14 days, or vice versa. Randomization was based on a computer-generated schedule produced by the research pharmacy, which was concealed from study personnel until study completion. Ivacaftor was purchased at full retail cost and encapsulated with sucrose to match the sucrose-filled placebo capsules. Prior to beginning study drug, there was a 2-week run-in period to ensure clinical stability, assessed by modified Fuchs criteria and pulmonary function. There was a washout period of a minimum of 14 days between study drug cycles to account for carryover effect. The washout period was extended to 6 weeks for subjects on alternating cycles of inhaled antibiotics to coordinate the study drug cycle with the inhaled antibiotic cycle.
224207155|NCT06539455|DRUG|standard anti-TB treatment|standard anti-TB treatment in line with international guidelines (isoniazid , rifampin, ethambutol, and pyrazinamide)
224207156|NCT06286410|OTHER|Bespoke glasses prescription worn during amblyopia treatment.|The investigators aim to use the information they gather about a participant's accommodation response to be used in a bespoke glasses prescription that will be worn during amblyopia treatment. This is to try and improve vision in those with residual amblyopia following standard amblyopia treatment.
224207157|NCT01336608|DRUG|Fluticasone Furoate/Vilanterol|Inhaled corticosteroid/long acting beta-agonist
224207158|NCT01336608|DRUG|Vilanterol|Inhaled long acting beta-agonist
224207159|NCT01336608|DRUG|Placebo|Placebo
224207160|NCT04090684|DRUG|Fixed dose combination Ciprofloxacin/Celecoxib|Fixed dose Ciprofloxacin and Celecoxib capsule to be taken twice daily, total dose 748mg/day
224207161|NCT00944008|DRUG|DepoCyte|
224207162|NCT05134259|DEVICE|Repetitive Transcranial Magnetic Stimulation|TMS device will deliver repetitive trains of magnetic pulses using Magstim Rapid 2 with angulated figure of eight shaped coil. The device comprised two-channel Neuro-EMG-MS digital system for determining the motor threshold of the patients that will be used for establishing the threshold intensity for stimulation. The figure of eight-shaped coil generated a magnetic field of up to 4 Tesla that penetrates the cranium, enters into the soft tissue of the brain and henceforth stimulates the motor neurons.
224207163|NCT00624975|BIOLOGICAL|Peru-15 Vaccine|up to 1 x 10\^9 CFU of Peru-15 given in 5ml single dose vials with 20 ml buffer solution, given once
224207164|NCT00624975|BIOLOGICAL|Placebo|25 mL of buffer solution (2.5 g sodium bicarbonate and 1.65 g ascorbic acid per 100mL potable water)
224314869|NCT06372496|DRUG|Fluticasone furoate/umeclidinium bromide/vilanterol trifenatate|Participants will receive FF/UMEC/VI
224314870|NCT06372496|DRUG|Inhaled corticosteroids/long-acting beta-2 agonists|Participants will receive ICS/LABA
224314871|NCT06229262|DIETARY_SUPPLEMENT|Mango group|Participants will consume 1.5 cups of mangos per day for 12 weeks.
223680383|NCT00134420|PROCEDURE|Arginine and Clonidine Stimulation Testing|This testing was done to determine growth hormone status prior to starting treatment.
224207165|NCT01598415|DRUG|SAR113945|"Pharmaceutical form:Injection~Route of administration: Intra-articular"
224207166|NCT01598415|DRUG|placebo|"Pharmaceutical form:Injection~Route of administration: Intra-articular"
224207167|NCT01298154|OTHER|Dietary intervention|Dietary treatments with beverages
224314872|NCT04759105|DRUG|Autologous BM-MSC|intradiscal injection of autologous bone marrow mesenchymal stromal/stem cells
224314873|NCT04759105|OTHER|Sham Procedure|anaesthesia, no disc injection, no placebo injection
223680384|NCT00134420|PROCEDURE|Growth Factors Laboratory Testing|This involved assessment of growth factors such as IGF#1 before treatment was initiated.
223680385|NCT00134420|PROCEDURE|Neuropsychological Testing|This testing was done prior to treatment and at the end of treatment.
223680386|NCT05179174|GENETIC|blood sample examination|droplet digital PCR in blood sample for research of mutations of GNA11 and GNAQ genes and the following microRNAs: miR - 506-514 cluster, hsamiR - 592 and hsa - miR - 199a - 5p.
224314874|NCT06809114|DRUG|AT03-65|Treatment will continue until disease progression, unacceptable toxicity, subject withdrawal of consent or death.
224314875|NCT03464721|DEVICE|issued with SMART ANGEL device|patients will use the technology at home to record and transmit data for blood pressure and oxygen saturation
224314876|NCT04944979|BIOLOGICAL|Kedrion IVIG 10%|Kedrion intravenous immunoglobulin (IVIg) 10%
224314877|NCT06490939|DRUG|Efepoetin Alfa|Single-intravenous administration
224314878|NCT05897645|OTHER|Registration|collect clinical date, assess the morphologic characteristics of plaque
224314879|NCT05983250|DRUG|TNX-103|oral levosimendan 1 mg
223680387|NCT04944862|BIOLOGICAL|CDX-0159|administered intravenously
223761425|NCT03750903|BEHAVIORAL|Aerobic Exercise|Participants will engage in an aerobic exercise program meeting thrice weekly for a period of 12 weeks.
223761426|NCT03750903|BEHAVIORAL|Stretching and Balance Training|Participants will engage in a balance and stretching comparator condition meeting thrice weekly for 12 weeks.
224207168|NCT02253654|DRUG|Epoetin alfa|Administered intravenously (IV) three times a week (TIW) by appropriately trained healthcare professionals during hemodialysis.
224207169|NCT02751086|PROCEDURE|Robotic Gastrectomy|Minimally invasive surgical approach, related to the availability of a robotic surgical system (eg Da Vinci surgical system), that allows a surgeon to perform surgery through a console and dedicated devices.
224314880|NCT05983250|DRUG|Placebo|Placebo
224207170|NCT02751086|PROCEDURE|Laparoscopic Gastrectomy|Minimally invasive surgical approach performed through traditional laparoscopy.
224207171|NCT01630265|OTHER|Standard written discharge instructions|Group of caregivers who read the standard written discharge instructions prior to answering the questionnaire
224314881|NCT03955978|DRUG|TSR-042|-TSR-042 is administered intravenously via a 30-minute (-5-minute/+15-minute infusion window allowed) infusion
224314882|NCT03955978|RADIATION|Brachytherapy|-This trial will include image-guided brachytherapy with three-dimensional (3-D) treatment planning and in cases where pelvic radiation is deemed appropriate by the treating radiation oncologist, external beam radiation therapy (EBRT) using intensity modulated radiation therapy (IMRT) technique.
224314883|NCT03955978|PROCEDURE|Endometrial biopsy|-Prior to the start of treatment with TSR-042. If this biopsy yields insufficient tumor tissue, an archival sample may be requested, with Fraction 1 of brachytherapy, with Fraction 4 of brachytherapy
224314884|NCT03955978|PROCEDURE|Blood draw for immune response|-Prior to the start of any treatment, at the time of brachytherapy fractions 1 and 4 (corresponding to endometrial biopsy), prior to fourth dose of TSR-042, 6 weeks after the completion of all protocol related therapy
224314885|NCT00602641|OTHER|Laboratory Biomarker Analysis|Optional correlative studies
224314886|NCT00602641|DRUG|Lenalidomide|Given PO
224314887|NCT00602641|DRUG|Melphalan|Given PO
224314888|NCT00602641|DRUG|Prednisone|Given PO
224314889|NCT00602641|OTHER|Quality-of-Life Assessment|Ancillary studies
224314890|NCT00602641|DRUG|Thalidomide|Given PO
224207172|NCT01630265|OTHER|Video Discharge Instructions|Group of caregivers who watched the 3 minute video covering the information in the standard written discharge instructions prior to answering the questionnaire
224207173|NCT01249391|DEVICE|Splinting|Gutter thermoplastic custom-made splint for nominated joint, to be worn at night-time for consecutive nights for 3 months
224207174|NCT03329586|OTHER|High-intensity training|6-month individualized home- and group-based training program with the goal to cycle the Mont Ventoux in France
224314891|NCT06496828|PROCEDURE|Biologically-oriented preparation technique|The preparation will be made according to the new principles of biologically oriented technique to receive monolithic and bi-layered all-ceramic crowns.
224314892|NCT06496828|PROCEDURE|Conventional method of preparation|Teeth prepared with shoulder margins to receive monolithic and bi-layered all-ceramic crowns
224314893|NCT02181855|PROCEDURE|Full-thickness gastroplication (GERD-X)|Endoscopic full-thickness gastroplication wit the GERD-X device
224314894|NCT00003392|BIOLOGICAL|filgrastim|10 mcg/kg/d, day 2 through last day of leukapheresis
224314895|NCT00003392|DRUG|carboplatin|18 AUC IV, approximately days 21, 42
224314896|NCT00003392|DRUG|cyclophosphamide|4 gm/m2 IV, day 1
223680388|NCT04944862|DRUG|Normal saline|administered intravenously
223680389|NCT02206178|DRUG|N-acetylcysteine combination with acetaminophen|
223680390|NCT02206178|DRUG|Placebo|
223680391|NCT00573287|DRUG|clozapine|clozapine--tabs, 450mg. max, daily, 24 weeks
223680392|NCT00573287|DRUG|risperidone|risperidone--tabs, 6mg max, daily, 24 weeks
223680393|NCT01890720|DEVICE|iNPWT|The Incisional Negative Pressure Wound Therapy (iNPWT) will be applied over the clean closed incision immediately following the operation (caesarean section). In the intervention group the therapy will be left in situ for five days.
223680394|NCT01890720|OTHER|Standard postoperative wound dressing|A standard wound dressing will be applied over the clean closed incision immediately following the operation (caesarean section). In the control group the dressing will be left in situ for at least 24 hours as standard procedure.
224314897|NCT00003392|DRUG|melphalan|140 mg/m2 IV , approximately day 63
224314898|NCT00003392|DRUG|paclitaxel|170 mg/m2 IV day 1
224314899|NCT00003392|PROCEDURE|bone marrow ablation with stem cell support|
224314900|NCT00003392|PROCEDURE|peripheral blood stem cell transplantation|
224314901|NCT04488315|DRUG|Dexamethasone lipid microsphere plus ropivacaine|Local scalp infiltration solution will consist of 30ml miscible liquids containing 8 mg dexamethasone lipid microsphere, 150mg ropivacaine and normal saline.
224314902|NCT04488315|DRUG|Ropivacaine alone|Local scalp infiltration solution will consist of 30ml miscible liquids containing 150mg ropivacaine and normal saline
224314903|NCT02168192|BEHAVIORAL|Simulation-Debrief|Subjects underwent a formal debrief, reviewing the BBN skills exhibited in their prior simulation of an obstetrical communication skills scenario.
224314904|NCT02168192|BEHAVIORAL|Traditional lecture|Control group underwent lecture for approximately 10 minutes reviewing BBN skills.
224314905|NCT02145715|DRUG|Velcade|
224314906|NCT02145715|DRUG|Thalidomide|
224314907|NCT02145715|DRUG|Dexamethasone|
224314908|NCT02145715|DRUG|Panobinostat|
224207175|NCT02486471|PROCEDURE|Monsel´s Paste|surgical method to stop bleeding by using the hemostatic Agent monsel´s paste until no more bleeding is visible
224207176|NCT02486471|OTHER|Wait and see|finishing examination without hemostatic intervention, awaiting spontaneous coagulation
223761427|NCT06985901|PROCEDURE|Persistent atrial fibrillation ablation using Pulsed-field ablation|Pulmonary vein isolation with pulsed-field ablation coupled with 3D electroanatomic mapping. Follow-up with insertable cardiac monitor.
224207177|NCT00975273|BEHAVIORAL|Capnometry Assisted Respiration Training|Patients learn to alter their breathing pattern by breathing abdominally, slowly, regularly, and shallowly in order to raise their PCO2 levels with the assistance of a biofeedback device.
224207178|NCT00975273|BEHAVIORAL|Breathing Awareness|Patients learn to alter their breathing pattern by breathing abdominally, slowly, regularly using a biofeedback device.
224207179|NCT00552227|DRUG|ruboxistaurin|oral 32 mg daily
224207180|NCT00552227|OTHER|placebo|placebo
224207181|NCT04693182|OTHER|Shift schedule without quick returns|The intervention entails implementing a shift schedule which abolishes or substantially reduces the number of quick returns (less than 11 hours of rest between two shifts) for a six-month intervention period.
224207182|NCT00069160|DRUG|docetaxel|Patients receive docetaxel intravenous (IV) over 1 hour on days 1 and 8.
224207183|NCT00069160|DRUG|tariquidar|Patients receive tariquidar intravenous (IV) over 30 minutes on days 8 and 22.
224207184|NCT00069160|OTHER|99mTc-sestamibi imaging|Bolus injection of 29 mCi of 99mTc-sestamibi intravenously for each imaging study.
224207185|NCT04675073|PROCEDURE|Ventricular tachycardia substrate-based radiofrequency ablation|The CARTO3 electroanatomic navigation system (Biosense Webster, Diamond Bar, CA, USA) will be used for ablation. An open irrigated 3.5-mm tip ablation catheter (ThermoCool SmartTouch, Biosense Webster, Diamond Bar, CA, USA) will be used for mapping and ablation. The first step of the procedure will be the acquisition of a fast-anatomical map (FAM) of the aorta. This FAM will be then used to integrate the multi-detector cardiac tomography (MDCT) reconstruction and cardiac magnetic resonance (CMR)-derived pixel-signal intensity (PSI) maps within the spatial reference coordinates of the CARTO3 system. RF will be delivered at the entrance of the border zone channels (BZCs) identified in the PSI maps (CMR-guided scar dechanneling technique). Programmed ventricular stimulation (PVS) will be always performed after substrate elimination to test for final inducibility.
224207186|NCT01566669|DRUG|Parecoxib Sodium|Before incision, patients in Group P (n = 120) receive 40mg of parecoxib IV. Thereafter, parecoxib patients receive 40mg of parecoxib IV every 12 h for 48 h. 30 min before the end of surgery, a mixture of 6 mL of ropivacaine 0.25% and 2mg morphine was given epidurally. Epidural patient-controlled analgesia was initiated by using ropivacaine 0.125% (1.25 mg/ml) and morphine 0.005% (0.05 mg/ml) with a basal infusion rate of 2 ml/h, a demand dose of 2 ml, and a 15-min lockout.
224260429|NCT01065857|DRUG|Sodium picosulphate, light magnesium oxide and anhydride citric acid.|2 Single-dose sachets containing sodium picosulphate (0.01g/sachet), light magnesium oxide (3.50g/sachet) and anhydrous citric acid (10.97g/sachet).
224260430|NCT01065857|DRUG|Polyethylene glycol, KCl, NaCl, sodium sulphate anhydrous and sodium bicarbonate.|4 sachets containing Polyethylene glycol 3350 (59 gr), KCl (0.7425 gr), NaCl (1.465 gr), sodium sulphate anhydrous (5.685 gr), sodium bicarbonate (1.685 gr).
224260431|NCT04266340|DRUG|dexmedetomidine|2.5µg/kg intranasal dexmedetomidine group
224260432|NCT04266340|DRUG|midazolam|0.5mg/kg oral midazolam
224260433|NCT04266340|DRUG|midazolam|0.05mg/kg intravenous injection midazolam
224260434|NCT04266340|DRUG|Saline|no premedication
224260435|NCT02919540|OTHER|Kangaroo care approach|skin to skin contact between stable preterm infants and their naked mother's chest
224260436|NCT04452786|PROCEDURE|Endoscopic sleeve gastroplasty|Four-hour solid mixed meal test
224260437|NCT04452786|PROCEDURE|Laparoscopic sleeve gastrectomy|Four-hour solid mixed meal test
224260438|NCT01901263|BEHAVIORAL|patients with alzheimer's disease|the Neuropsychiatric Inventory (NPI), is uded to assess 10 behavioral disturbances occurring in dementia patients: delusions, hallucinations, dysphoria, anxiety, agitation/aggression, euphoria, disinhibition, irritability/lability, apathy, and aberrant motor activity. The NPI uses a screening strategy to minimize administration time, examining and scoring only those behavioral domains with positive responses to screening questions.
224260439|NCT01789463|OTHER|Self rehabilitation|
224260440|NCT01789463|OTHER|Self rehabilitation plus physiotherapy|
224260441|NCT03251755|BEHAVIORAL|Yoga|Exercise promotion using Chinese Yoga
224260442|NCT02528279|DRUG|Coartem|"Patients will receive the study drug combination artemether-lumefantrine (Coartem®) orally as a 6 dose regimen for three consecutive days. Tablets are available as a fixed dose combination of 20mg artemether plus 120mg lumefantrine. The dosing will be based on the body weight and follow the manufacturer's recommendations:~Body weight 5-14kg: 1 tablet; Body weight 15-24kg: 2 tablets; Body weight 25-34kg: 3 tablets; Body weight \> 34kg: 4 tablets; The respective amount of tablets is to be taken at hours 0, 8, 24, 36, 48 and 60 with fatty food."
224260443|NCT04450069|COMBINATION_PRODUCT|CLBR001 and SWI019|Investigational immunotherapy for B cell malignancies
224260444|NCT05984303|BIOLOGICAL|Human Umbilical Cord-derived Mesenchymal Stem Cells|Human Umbilical Cord-derived Mesenchymal Stem Cells will be administered intravenously.
224260445|NCT06308484|DEVICE|Transcutaneous vagus nerve stimulation|Patients that are enrolled in a MBRP program will be subjected to weekly tVNS stimulation during a 30-minute audio guided mindfulness exercise.
224260446|NCT06308484|DEVICE|Closed-loop AM-tACS|Patients that are enrolled in a MBRP program will be subjected to weekly CLAM-tACS stimulation during a 30-minute audio guided mindfulness exercise.
224260447|NCT02939703|OTHER|Diet|Participants will consume either a Control Western Diet or a Microbiome Enhancer Diet.
224260448|NCT03927300|DEVICE|Telemonitoring Software|Recovery of retrospective data in dialysis patients follow or not follow by a telemonitoring application.
224260449|NCT01093833|DEVICE|BD Continuous glucose monitor (BD CGM)|Continuous glucose monitoring for 12-14 hours
224260450|NCT01093833|DEVICE|YSI Glucose Analyzer|Continuous glucose monitoring for 12-14 hours
224260451|NCT01093833|DEVICE|Medtronic Guardian CGM|Continuous glucose monitoring for 12-14 hours
224314909|NCT03301545|PROCEDURE|Fast-Track to Bariatric Surgery|30 participants from the urban Indigenous community who have Type 2 diabetes and are candidates for bariatric surgery at the Centre for Metabolic and Bariatric Surgery will be randomized to the fast-track to bariatric surgery group.
224314910|NCT06582459|DEVICE|HFNC treatment|HFNC treatment HFNC therapy. The initial flow rate of 50-60 L/min was subsequently adjusted to maintain an oxygen saturation (SpO2) ≥92%. The FiO2 was titrated to maintain the PaO2 between 60 and 80 mmHg.
224314911|NCT06582459|DEVICE|NIV treatment|NIV treatment A Mindray SV300 ventilator (Mindray Medical International Limited, Shenzhen, China) was used to deliver NIV via an oronasal mask. The initial inspiratory positive airway pressure (IPAP) was 12-15 cmH2O and adjusted later to achieve a tidal volume of 6-8 mL/kg of predicted body weight and a respiratory rate of \&amp;lt;30 breaths/min. The expiratory positive airway pressure (EPAP) was established at 5-8 cmH2O. Additional-ly, FiO2 was titrated to maintain a PaO2 between 60 and 80 mmHg.
223618733|NCT02021565|BEHAVIORAL|Immediate Intervention Group|Assistive Technology (AT) Specialists, experts on assistive technology devices and how to performing transfer tasks, train Veteran and caregiver dyads to safely, skillfully, and (when appropriate) independently perform three activities of daily living (ADLs): transferring in and out of bed, toileting, and bathing. During the baseline assessments, AT Specialists also recommend assistive technology equipment (grab bars, bed rails, raised toilet seats, etc.), environmental modifications, adaptive methods, and energy conservation techniques. On the first day of the intervention, AT Specialists provide and install recommended equipment and train the dyad to complete the three ADLs using the recommended the modified methods.
224207187|NCT01566669|DRUG|Normal saline|Before incision, patients in Group C (n = 120) receive 2 mL of normal saline IV. Thereafter, they receive 2 mL of normal saline IV every 12 h for 48 h. 30 min before the end of surgery, a mixture of 6 mL of ropivacaine 0.25% and 2mg morphine was given epidurally. Epidural patient-controlled analgesia was initiated by using ropivacaine 0.125% (1.25 mg/ml) and morphine 0.005% (0.05 mg/ml) with a basal infusion rate of 2 ml/h, a demand dose of 2 ml, and a 15-min lockout.
224207188|NCT03091894|DRUG|Propofol|propofol intravenous infusion via syringe pump with loading dose of 0.5 mg/kg over 3 minutes then continuous infusion in a dose of 25-75 ug/kg/minute
224207189|NCT03091894|DRUG|Dexmedetomidine|dexmedetomidine intravenous infusion via syringe pump with loading dose of 0.5ug/kg over 5 minutes the continuous infusion in a dose of 0.2-0.7ug/kg/hour in addition to the propofol infusion as in propofol group
224207190|NCT03044431|PROCEDURE|Cell therapy|Each participant will receive cell therapy with stem cells harvested either from peripheral blood or from bone marrow plus peripheral blood; after harvest, cells are processed and returned to the patient via peripheral circulation on the same day.
224207191|NCT00211666|BEHAVIORAL|Nurse management, home blood pressure monitors, and a chronic disease self management course.|
224207192|NCT02169531|DRUG|ex vivo Activated Immune Cells|The patients who take medication before the enrollment will be required to reduce at least half the amount of the medication before the treatment. The reduction of the medication will continue during and after the therapy until the levels of plasma hemoglobin A1c (HbA1c) increase to equal or above the levels of the baseline measured before the treatment.
224207193|NCT02962531|DRUG|IX-01 caplets 1600 mg (4 x 400 mg), fasted|oral dose under fasted conditions
224207194|NCT02962531|DRUG|IX-01 caplets 1600 mg (4 x 400 mg), fed|oral dose under fed conditions
224207195|NCT02962531|DRUG|IX-01 aqueous dispersion 1600 mg (20 mL), fasted|oral dose under fasted conditions
224207196|NCT05351073|DRUG|NBO|Oxygen inhalation through a mask at a rate of 10 L/min at 1 absolute atmosphere pressure (1 ATA = 101.325 kPa)
224207197|NCT02023320|DIETARY_SUPPLEMENT|Low dose of blueberry dry powder|
224207198|NCT02023320|DIETARY_SUPPLEMENT|High dose of blueberry dry powder|
224207199|NCT03456726|DRUG|Tazemetostat|Tazemetostat will be provided as a 200 mg oral tablet.
224207200|NCT02615873|DRUG|Accordion Pill™ Carbidopa/Levodopa|Accordion Pill™ Carbidopa/Levodopa Capsule 50/400mg , b.i.d or t.i.d or Accordion Pill™ Carbidopa/Levodopa Capsule 50/500mg , b.i.d or t.i.d
224207201|NCT03970668|DRUG|Linagliptin 5 mg Oral Tablet|Patients received linagliptin 5mg once daily orally plus a basal bolus insulin scheme, if they presented hyperglycemia (glucose levels above than 140 mg/dl)
224207202|NCT03970668|DRUG|Insulin|Patients received a basal bolus insulin scheme, if they presented hyperglycemia (glucose levels above than 140 mg/dl)
224207203|NCT03171610|DRUG|Sufentanil group|PCA device containing sufentanil (3 mcg/kg), ramosetron (NaseaTM) 0.3 mg and ketorolac 120 mg in a normal saline with a total volume of 100ml was connected.
224207204|NCT03171610|DRUG|Fentanyl group|PCA device containing fentanyl (20 mcg/kg), ramosetron (NaseaTM) 0.3 mg and ketorolac 120 mg in a normal saline with a total volume of 100ml was connected.
224207205|NCT00002269|DRUG|Ampligen|
224207206|NCT00002269|DRUG|Zidovudine|
224207207|NCT05443217|DIAGNOSTIC_TEST|questionnaire survey|All patients received lifestyle questionnaire, physical performance, and imaging evaluation before treatment.
224314912|NCT06486870|DRUG|Gonadotropin|Human menopausal gonadotrophin (hMG) is given starting on cycle day three in a dose of 75 IU alternate days. The aim of treatment is to achieve mono-ovulation. Monitoring of treatment is achieved by serial transvaginal ultrasound scanning every other day starting from cycle day nine. Size and number of follicles is recorded in patients follow up sheets. The dose of hMG is reviewed around stimulation day 10 and if follicular development is unsatisfactory, the dose is increased to 75 IU daily .If a good response is not achieved day16 ; the cycle is cancelled. A new cycle is commenced with a higher starting dose of hMG (75 IU per day). When one follicle reached a size of \> =18 mm a single dose of 10,000 IU human chorionic gonadotrophin (hCG, Pregnyl, Epifasi, Choriomon) is given.
223618734|NCT02021565|OTHER|Delayed Intervention Control Group|Receives the in-home training intervention six weeks after completing the initial baseline assessment. This allows for a control comparison group while still providing the intervention to all participants.
224207208|NCT02913508|DRUG|Vedolizumab intravenous injection|Vedolizumab intravenous injection
224207209|NCT02913508|DRUG|Vedolizumab subcutaneous injection|Vedolizumab subcutaneous injection
224207210|NCT01938521|DIETARY_SUPPLEMENT|Red Grape Cells (RGC)|Red Grape Cells (RGC) 1000 mg powder once daily by mouth for three month
224207211|NCT01938521|DIETARY_SUPPLEMENT|Placebo (for Red Grape Cells (RGC))|Placebo (for Red Grape Cells (RGC)) powder manufactured to mimic Red Grape Cells (RGC) 1000 mg powder
224314913|NCT06486870|DRUG|Letrozole|5 mg LE oral tablets are administered on the fifth day of menses and then every day for 5 days. Treatment is repeated for up to six cycles
224207212|NCT01440023|BEHAVIORAL|Comprehensive Behavioral Intervention for Tics (CBIT)|CBIT is an 8 session treatment protocol held over 10 weeks. Its core components are implemented across the various therapy sessions. These core components include habit reversal training (HRT), functional assessment/function-based interventions, and a behavioral reward program for the child.
224207213|NCT01440023|BEHAVIORAL|Computerized Response Inhibition Training|Twice-weekly 45 minute computerized sessions for cognitive training focused on enhancing response inhibition capabilities.
224207214|NCT01440023|BEHAVIORAL|Computerized Placebo Cognitive Training|Twice-weekly 45 minute computerized sessions for placebo cognitive training, which has been designed to be irrelevant for response inhibition capabilities.
224207215|NCT02924103|DEVICE|Contamination free bacterial swab|"A comparison of the bacteriology in bacterial swabs (Eswab 481CE, Copan Diagnostics, Italy) from the middle meatus. On the RIGHT side using the Contamination free bacterial swab introduction device that facilitates the introduction of a bacterial swab into the nose without direct or indirect contact with the nasal vestibule."
224207216|NCT00525564|DRUG|Placebo|Placebo diskus inhalation powder
224314914|NCT06486870|PROCEDURE|laparoscopic ovarian drilling|"Laparoscopic ovarian drilling will be done according to the following:~Electrocautery using a mixed current in monopolar electrosurgical needle will be into introduced through the ovarian ipsilateral parts and applied up to 4 point cauterisation of the ovarian capsule, each for 4 second, at 40 W and for a diameter of 3mm and a depth of 4 mm in the antimesentric surface . (Amer et al 2003, Sawant S et al 2019) ,the procedure will be applied for one ovary .~The patient under the study will be followed up to six months of continuous marital life after the procedure"
224314915|NCT04659642|DRUG|Dexmedetomidine Injection [Precedex]|the drug is given 15 minutes before the estimated end of surgery
224314916|NCT04659642|DRUG|Fentanyl Citrate Injection|the drug is given 15 minutes before the estimated end of surgery
223761428|NCT06658041|BEHAVIORAL|Cognitive behavioural therapy (CBT)-based intervention with stepped-care|"After initial clinical assessment, participants will be offered interventions based on their depressive symptom severity (Patient Health Questionnaire-9-item \[PHQ-9\]).~Mild symptoms (PHQ-9=5-9) without major risks (\*see above): 4 weekly CBT-informed intervention sessions led by trained Emotional Support Assistants (Peer Supporters with 80hrs mental health training + 15hrs intensive clinical training).~Mild symptoms (PHQ-9=5-9) with major risk factors or moderate-to-moderately severe symptoms (PHQ-9=10-19): 6 weekly CBT-based intervention sessions led by trained clinical social workers, with 2 booster sessions as necessary. Individual CBT-based intervention will be provided to those unsuitable for group interventions.~In cases of non-remission (PHQ-9≥5): a second intervention trial will be provided. Those needing additional support will be referred to a partnered General Practitioner (if PHQ-9=10-19) or referred to more intensive psychological or psychiatric services as needed."
224207217|NCT00525564|DRUG|Salmeterol diskus inhalation powder|50 micrograms twice a day
224207218|NCT00399490|DRUG|RN624 (PF-04383119)|50 mcg/kg
224207219|NCT02874638|DIETARY_SUPPLEMENT|BASE egg protein|0.8 g/kg/d of protein provided as crystalline amino acid modeled after egg protein
224207220|NCT02874638|DIETARY_SUPPLEMENT|BCAA-enriched egg protein|BCAA-enriched egg protein provided as crystalline amino acid.
224207221|NCT02874638|DIETARY_SUPPLEMENT|small amount of essential amino acids|essential amino acids modeled after egg protein, provided as crystalline amino acid, which is equivalent to the amount of essential amino acid in BASE egg protein
224207222|NCT02874638|DIETARY_SUPPLEMENT|large amount of essential amino acids|essential amino acids modeled after egg protein, provided as crystalline amino acid, which is equivalent to the amount of amino acid in BCAA-enriched egg protein
224207223|NCT00941252|DRUG|Topical imiquimod therapy|therapy consists of treatment with topical vaginal suppositories for 16 weeks, each vaginal suppository contains 6.25mg of imiquimod, frequency (one time a week in treatment week 1+2, two times a week in treatment week 3+4, three times a week in treatment week 5-16)
224314917|NCT04659642|COMBINATION_PRODUCT|dexmedetomidine and fentanyl|the combination of the two drugs with the same used doses is given 15 minutes before the estimated end of surgery
224314918|NCT04343157|RADIATION|Cognitive Sparing Brain Stereotactic Radiosurgery (SRS)|In this proposal, the investigators introduce advanced diffusion and volumetric imaging techniques along with innovative, automated image parcellation methods to identify critical brain regions, incorporate into cognitive-sparing SRS, and analyze biomarkers of radiation response. This work will advance the investigators' understanding of neurocognitive changes after brain SRS and help create interventions that preserve cognitive-function in brain metastases patients.
224314919|NCT01738295|DRUG|Donepezil administration|
224314920|NCT01738295|DRUG|Placebo administration|
224314921|NCT02540005|OTHER|ROTEM analysis|
224314922|NCT03914625|DRUG|Asparaginase Erwinia chrysanthemi|Given IV or IM
224314923|NCT03914625|BIOLOGICAL|Blinatumomab|Given IV
224314924|NCT03914625|DRUG|Cyclophosphamide|Given IV
224314925|NCT03914625|DRUG|Cytarabine|Given IT or IV
224314926|NCT03914625|DRUG|Dexamethasone|Given PO or IV
224314927|NCT03914625|DRUG|Doxorubicin Hydrochloride|Given IV
224314928|NCT03914625|DRUG|Leucovorin Calcium|Given PO or IV
224314929|NCT03914625|DRUG|Mercaptopurine|Given PO
224314930|NCT03914625|DRUG|Mercaptopurine Oral Suspension|Given PO
224314931|NCT03914625|DRUG|Methotrexate|Given IT or IV
224314932|NCT03914625|DRUG|Pegaspargase|Given IV or IM
224314933|NCT03914625|DRUG|Prednisolone|Given PO or IV
224314934|NCT03914625|DRUG|Prednisone|Given PO or IV
224314935|NCT03914625|RADIATION|Radiation Therapy|Undergo cranial radiation therapy
224314936|NCT03914625|RADIATION|Radiation Therapy|Undergo testicular radiation therapy
224314937|NCT03914625|DRUG|Thioguanine|Given PO
224314938|NCT03914625|DRUG|Vincristine Sulfate|Given IV
224314939|NCT05870579|DRUG|[68Ga]Ga-NeoB|"\[68Ga\]Ga-NeoB serves as a radioactive imaging compound to be used for PET imaging for localization of GRPR positive lesions, at screening, potentially at Cycle 2 Day 15 visit, and between 4 and 8 weeks after the last administered dose of \[177Lu\]Lu-NeoB.~\[68Ga\]Ga-NeoB will be administered as a single intravenous (i.v.) dose."
224314940|NCT05870579|DRUG|[177Lu]Lu-NeoB|Study participants will receive \[177Lu\]Lu-NeoB once every cycle
223618735|NCT00258141|DRUG|Rupatadine|
224207224|NCT00149552|DIETARY_SUPPLEMENT|zinc|supplementation with zinc gluconate
224314941|NCT05870579|DRUG|Ribociclib|600 mg once daily (OD) days 1 to 21 every 28 days
224314942|NCT05870579|DRUG|Fulvestrant|500 mg at Cycle 1 Day 1, Cycle 1 Day 15, Cycle 2 Day 1 and every 28 days thereafter
223618736|NCT00258141|DRUG|Placebo|
224314943|NCT05870579|OTHER|Goserelin|For pre/peri-menopausal women and men only.
224314944|NCT06057571|DRUG|TT-00420 (tinengotinib)|TT-00420 (tinengotinib) tablet will be administered orally once daily per protocol defined schedule.
224314945|NCT02633163|DRUG|Low Dose Mesenchymal Stem Cells (MSCs)|Participants will receive a single IV infusion of Mesenchymal Stem Cells (MSCs) 1 x 10\^6 cells/kg in Plasma-Lyte A solution. All participants will receive the infusion at the Baseline (Day 0) visit. All participants will continue on their standard-of-care therapy during the trial.
224314946|NCT02633163|DRUG|High Dose Mesenchymal Stem Cells (MSCs)|Participants will receive a single IV infusion of Mesenchymal Stem Cells MSCs 5 x 10\^6 cells/kg in Plasma-Lyte A solution.
224314947|NCT02633163|DRUG|Placebo Infusion|Participants will receive a placebo infusion that does not contain any mesenchymal stem cells.The placebo infusion will consist of Plasma-Lyte A, which is the same vehicle used to deliver the MSCs in the experimental groups.
224314948|NCT05459935|DEVICE|PBM Tonsil Arm|exposure of hypertrophic tonsils to photobiomodulation
224314949|NCT05459935|DEVICE|Sham PBM Tonsil Arm|non-powered exposure of hypertrophic tonsils to photobiomodulation
224314950|NCT06084117|OTHER|HFNO|Respiratory support with HFNO (as opposed to NIV, as per standard of care)
224314951|NCT06084117|OTHER|NIV|Respiratory support with Non-invasive ventilation, standard of care
224207225|NCT01757236|DRUG|VANCOMYCIN|
224314952|NCT06408298|DRUG|Hydroxychloroquine Sulfate 400Mg Tab|hydroxychloroquine sulfate tablet
224314953|NCT06408298|DRUG|Placebo|Inactive tablet
224314954|NCT03385655|DRUG|Adavosertib|250mg, may dose escalate to 300mg if no drug-related GI tox in cycle 1
224314955|NCT03385655|DRUG|Savolitinib|600mg once daily, orally.
223618737|NCT03040141|DRUG|Low dose of VIS410|Single intravenous infusion of fixed low dose of VIS410 in addition to oseltamivir
223618738|NCT03040141|DRUG|High dose of VIS410|Single intravenous infusion of fixed high dose of VIS410 in addition to oseltamivir
223618739|NCT03040141|DRUG|Placebo|Single intravenous infusion of placebo in addition to oseltamivir
223761429|NCT06658041|OTHER|Care-as-usual|Following an initial interview session with research assessments, participants continue with their usual care at their primary care setting.
224207226|NCT01757236|DRUG|CEFTRIAXONE|
224207227|NCT01757236|DRUG|CLINDAMYCIN|
224314956|NCT03385655|DRUG|Darolutamide|600mg twice daily, orally.
224314957|NCT03385655|DRUG|CFI-400945|Dose level assigned at enrollment, starting at 32mg/day on Days 1-7 and 15-21 or 15-28 depending on toxicity experienced.
224314958|NCT03385655|DRUG|Ipatasertib|400mg daily 3 weeks on, 1 week off
224314959|NCT03385655|DRUG|Durvalumab and Tremelimumab|Durvalumab 1500mg day 1 every 4 weeks; Tremelimumab 225mg day 1 cycle 1
224314960|NCT03385655|DRUG|Carboplatin|AUC 5 IV 60min Day 1 q 21 days
224314961|NCT06425926|DRUG|GIM-531|GIM-531 administered orally daily
224314962|NCT06425926|DRUG|Anti-PD-1 monoclonal antibody|Continued treatment with anti-PD-1 therapy
224314963|NCT05873686|DRUG|NXP900|NXP900 is an orally administered SRC/YES1 kinase inhibitor
224314964|NCT03648814|PROCEDURE|Intracameral injection|A/C injection of 1.25 mg/0.05 mL bevacizumab
224314965|NCT03648814|PROCEDURE|Intravitreal injection|Vitreous injection of 1.25 mg/0.05 mL bevacizumab
224314966|NCT06457256|BEHAVIORAL|CLS-A-FUERTE|CLS-A-FUERTE Intervention Description: The CLS-A-FUERTE program is a school clinician training and psychosocial intervention program designed to improve attention and behavior in Mexican school-aged youth (grades 1-5). Participating school clinicians are supported by a clinical research team of trainers who co-leads weekly training/consultation meetings and observes each intervention component (i.e., 6 weekly parent and student skills groups, as well as classroom management in the form of a Daily Report Card) in-vivo via videoconferencing.
224314967|NCT05557591|DRUG|BNT116|BNT116 is administered by IV injection.
224314968|NCT05557591|DRUG|Cemiplimab|Cemiplimab is administered Q3W by IV infusion
224314969|NCT02185690|DRUG|Binimetinib|"Continuous MEK162 with dose escalation until the Recommended Phase 2 dose (RP2D) one dose level below the Maximum administered dose (MAD) or progression of disease.~MEK162 tablets 15 mg strength will be taken orally on a BID dose schedule."
223618740|NCT04345341|DRUG|TAP block with liposomal bupivacaine and bupivacaine|injecting the mixture of bupivacaine with liposomal bupivacaine in transversus abdominis plane to block the somatic nerves
223618741|NCT01944137|OTHER|Nursing Intervention|Participants will receive 4 planned phone calls from nurse practitioners during their first 2 cycles of chemotherapy, in order to proactively monitor and address chemotherapy-related symptoms.
223618742|NCT04296760|DIAGNOSTIC_TEST|Rectal water-contrast transvaginal ultrasonography|Transvaginal ultrasound scan combined with the introduction of saline solution into the rectum
223618743|NCT04296760|DIAGNOSTIC_TEST|Sonovaginography|Transvaginal ultrasound scan combined with the introduction of saline solution into the vagina
223761430|NCT04633655|OTHER|outcome measures for CIPN testing|questionnaires administration, physician based scales for CIPN data collection
224207228|NCT01757236|DRUG|SULFAMETHOXAZOLE AND TRIMETHOPRIM (CO-TRIMOXAZOLE)|
224207229|NCT01757236|DRUG|FLUOROQUINOLONE|
224207230|NCT01757236|DRUG|LINEZOLID|
224207231|NCT01757236|DRUG|RIFAMPIN|
224207232|NCT00464256|DRUG|rimonabant|
224207233|NCT00188071|DRUG|paracetamol|
224207234|NCT00188071|DRUG|ketoprofen|
224207235|NCT00188071|DRUG|ketoprofen + paracetamol|
224207236|NCT03948737|DRUG|Alpha-Tocopherol|all of the subjects in the alpha-tocopherol group received alpha-tocopherol orally, doses adjusted by age for 4 weeks of treatment.
224207237|NCT03948737|DRUG|Placebo oral tablet|
224207238|NCT03654911|DIAGNOSTIC_TEST|EEG|EEG
224207239|NCT03654911|GENETIC|ApoE|ApoE
224314970|NCT02185690|DRUG|Pemetrexed|4-6 cycles given intravenously in combination with carboplatin as per standard therapy.
224314971|NCT02185690|DRUG|Carboplatin|4-6 cycles of intravenous Carboplatin in combination with Pemetrexed as per standard therapy.
224314972|NCT00478244|DRUG|busulfan|Day -9 through Day -6: 1.1 mg/kg if \< 12 kg IV every 6 hours; 0.8 mg/kg if \> 12 kg.
224314973|NCT00478244|DRUG|cyclophosphamide|Day -5 through Day -2: 50 mg/kg IV over 120 min.
224314974|NCT00478244|DRUG|fludarabine phosphate|Day -5 through Day -3: 25 mg/m2 IV over 60 min.
223618744|NCT01307826|OTHER|massage|"session - 20 minutes.~Before the massage, palpable evaluation of the selected anatomical structures was carried out - to determine which tissues have the greatest sensitivity and which motor organs show increased tension (by pressing the attachment). In all the examined patients, pain of the following muscle attachments were shown:~* latissimus muscle of the back~* major pectoral muscle~* supraspinous and infraspinous muscles~* teres minor muscle~* serratus anterior muscle~* deltoid muscle The decision which muscles and fascias have to be massaged was made on the basis of the performed evaluation. In most cases the above mentioned tissues (together with other motor system organs which are structurally linked to it) were massaged to relax them.~A palpable evaluation of the previously examined points was again performed during the final part, with particular attention paid to painful muscles, in order to analyze the effectiveness of the performed relaxation."
224314975|NCT00478244|PROCEDURE|hematopoietic bone marrow transplantation|allogeneic bone marrow, peripheral stem cell or umbilical cord blood transplantation
224207240|NCT00752154|DRUG|Curcumin (Longvida™)|Curcumin (Longvida™) or matching placebo. They will begin by taking 4 capsules (approximately 2 grams) once a day for 2 weeks and then the dose will be increased to 4 capsules twice a day (4 gram per day) beginning at week 3. Subjects will remain at this dose for an additional 13 weeks for a total 16 weeks. After 16 weeks, the same procedures will be repeated for another 16 weeks
224207241|NCT02328547|DRUG|Fecal microbiota transplantation capsules|Fecal microbiota transplantation capsules contain extensively screened donor stool and are prepared by OpenBiome, Medford, MA.
223618745|NCT01307826|OTHER|massage|classical massage (Swedish massage)
223761431|NCT05364008|DRUG|Green Tea Extract|Green tea extract 1650 mg/day (45% EGCG) along with ovarian stimulation with clomiphene citrate and timed intrauterine insemination for up to 4 cycles.
224207242|NCT02328547|DRUG|Placebo capsules|Placebo capsules prepared by OpenBiome, Medford, MA
224207243|NCT00659854|DIETARY_SUPPLEMENT|Non milk or soy based formula|Babies will be given a non milk or soy base formula for 12 weeks
224207244|NCT00659854|DIETARY_SUPPLEMENT|milk based formula|Babies will be given a milk based formula for 12 weeks
224207245|NCT00044005|DRUG|Lurasidone 20 mg|Lurasidone 20mg oral tablet taken once daily for 6-months
224207246|NCT00044005|DRUG|Lurasidone 40 mg|Lurasidone 40mg oral tablets taken once daily
224207247|NCT00044005|DRUG|Lurasidone 80mg|Lurasidone 80mg oral tablet taken once daily
224207248|NCT02576054|BIOLOGICAL|V501|Quadrivalent HPV \[Type 6, 11, 16 and 18\] L1 VLP vaccine), 0.5 mL intramuscular injection on Day 1, Month 2, and Month 6
224207249|NCT00268554|DRUG|dipyridamole|
224207250|NCT00268554|DRUG|caffeine|
224207251|NCT00344305|BIOLOGICAL|Trivalent influenza virus vaccine live, intranasal|A single, intranasal dose of 0.2 mL (approximately 0.1 mL in each nostril) FluMist trivalent influenza virus vaccine live on Day 0 of the study. Each dose of FluMist vaccine contained 10\^7 FFU of three influenza virus strains.
224207252|NCT01190098|DRUG|Lacosamide|"Subjects randomized to lacosamide according to the following schedule:~Treatment Phase Week Dose Week 1 LCM 50 mg bid Week 2 LCM 100 mg bid Week 3 LCM 150 mg bid Week 4 LCM 200 mg bid"
223761432|NCT05364008|OTHER|Placebo|Placebo 1650 mg/day along with ovarian stimulation with clomiphene citrate and timed intrauterine insemination for up to 4 cycles.
224207253|NCT01190098|DRUG|Placebo|Placebo will be packaged identically to experimental drug and titrated according to the same schedule.
223761433|NCT06636084|PROCEDURE|Guided bone regeneration (GBR)|A composite graft composed of a 50:50 proportion of autogenous bone and a demineralized bone mineral will be positioned around the bony defect or placed in the membrane, depending on the group randomization. The selected membrane will then be secured with screws to ensure a complete and stable coverage of the grafted area.
224207254|NCT01732198|BIOLOGICAL|NU300|
224207255|NCT01732198|BIOLOGICAL|ActHIB|
224207256|NCT01732198|BIOLOGICAL|Prevnar 13|
224207257|NCT01767545|DRUG|Dexamethasone implant|
224207258|NCT01767545|DRUG|Bevacizumab|
224207259|NCT02281071|PROCEDURE|laterally moved coronally advanced flap with microsurgical instruments and x2.5 loupe|The recipient area for the laterally moved flap was prepared. When the flap was moved in the distal-mesial direction another short horizontal incision was performed at the most apical extension of this vertical incision. Once the mucogingival line was reached, flap elevation was continued split-thickness. Flap elevation was terminated when it was possible to passively move the flap laterally above the exposed root. Flap was sutured.
224207260|NCT02957682|DRUG|Praluent (Alirocumab)|
224207261|NCT02957682|DRUG|Placebo|
224207262|NCT01952639|DIETARY_SUPPLEMENT|protein type and amount|Subjects will stay in a supine position and consume a test beverage containing different amounts ans types of protein
224314976|NCT05968417|OTHER|Observational study - sample collection only.|No intervention - blood and/or bone marrow sample collection only
224314977|NCT01870440|DRUG|Ozurdex Intravitreal Injection (0.7 mg)|Intravitreal Injection
224314978|NCT03103841|PROCEDURE|Sleep studies [Polysomnography]|Undertaking of sleep measurements by polysomnography and use of validated sleep questionnaires
224314979|NCT02295540|RADIATION|hypofractionated radiation therapy|Undergo hypofractionated IMRT
224314980|NCT02295540|RADIATION|intensity-modulated radiation therapy|Undergo hypofractionated IMRT
224314981|NCT02295540|PROCEDURE|therapeutic conventional surgery|Undergo surgery
224314982|NCT02295540|OTHER|laboratory biomarker analysis|Correlative studies
224314983|NCT05985772|OTHER|Non-Operative Pain Management|The non-operative treatment arm will receive analgesics, physical therapy and will remain non-weight bearing. This will consist in anti-inflammatory drugs daily for 8-12 weeks and supervised physical therapy at least twice a week over a period of 8 weeks. Subjects in the non-operative arm will be offered the opportunity to crossover to the operative arm (ARM 2) of the study if the subjects do not report symptomatic improvement within 3 months after entry in this study.
223618746|NCT03318549|DIAGNOSTIC_TEST|Visual Performance tests|Participants came to the clinic in person for 2 hours for visual performance tests once every 6 months for up to 5 years. These tests included virtual reality tests and tests on a computer screen to investigate performance during simulated daily life activities, such as driving, situations of low contrast and glare.
224314984|NCT05985772|PROCEDURE|Operative treatment arm will undergo transtibial medial meniscus root repair within 3 weeks of enrollment|The operative treatment group (ARM 2) will be treated acutely with a transtibial medial meniscus root repair and will be non-weight bearing for 6 weeks as well. For ARM 1 subjects if no subjective improvement is seen at 3 months, crossover will be allowed to a transtibial medial meniscal root repair (acute operative pathway (ARM 2)
224314985|NCT01476566|BEHAVIORAL|Educational intervention|Peer continuous medical education (CME) groups in general practice will be recruited to a cluster randomised educational intervention study. Participating groups will be randomised either to an intervention- or a control group. A multifaceted intervention has been tailored where key components are educational outreach visits (EOV) to the CME-groups, audit, and feedback. Trained GPs will conduct the EOVs during which evidence-based recommendations for diagnosis and treatment of HF will be presented. A software will be handed out for installation on participants' practice computers, enabling collection of diagnosis- and prescription-data. The captured data will subsequently be linked to corresponding data from the Norwegian Prescription Database (NorPD).
224314986|NCT01675466|PROCEDURE|early laparoscopy|Laparoscopy under performed by the surgeon on duty or his/her deputy. The aim is to achieve this within 12 hours of randomisation. This will be performed under general anaesthetic and involve the necessary drugs. The procedure will require laparoscopy instruments. There will be a umbilical port which will be 10mm in size and one 5mm port below this. If pathology is found, a further port will be needed to perform treatment.
224314987|NCT01675466|PROCEDURE|General anaesthesia|
223618747|NCT03318549|DEVICE|Brain-computer interface|The brain-computer interface (BCI) consists of a modified virtual reality goggle integrated with wireless no-prep electroencephalogram (EEG). The portable BCI is able to objectively measure multifocal steadystate visual evoked potentials in response to brain stimulation through presentation of visual stimuli in the goggle. The test is done in person and may take up to 30 minutes, once every 6 months for up to 5 years.
223618748|NCT04415372|DIAGNOSTIC_TEST|MRI|The MRI protocol will include conventional testing for MS lesion detection and functional MR imaging to localize associated neurocognitive domains in each subject.
224207263|NCT04622865|DRUG|Masitinib|Masitinib is a small molecule drug that selectively inhibits specific tyrosine kinases such as colony-stimulating factor 1 receptor (CSF1R), c-Kit, LYN, FYN, and platelet-derived growth factor receptor (PDGFR) α and β, in the submicromolar range.
224207264|NCT04622865|DRUG|Isoquercetin|Isoquercetin is a flavonoid, derivative of quercetin. Isoquercetin is rapidly hydrolyzed to quercetin.
224207265|NCT04622865|DRUG|Best Supportive Care|Best Supportive Care is best available therapy at the choice of the investigator, including, but not limited to, oxygenation, analgesics, anti-thrombotics, anti-viral drugs or biologics drugs.
224207266|NCT04500691|OTHER|pain intensity reporting|pain intensity reporting
224207267|NCT06542276|DEVICE|Thermal Vectored Pulsation|The LipiFlow® (Johnson \& Johnson Vision, USA) Thermal Pulsation System, also known as vectored thermal pulsation, is a treatment that applies localized heat and pressure to the meibomian glands lining the eyelids. The device consists of a console connected to single-use, sterile devices applied to each eye known as activators. The activator includes an eye warmer with a large lens that gently sits on the conjunctiva of each eye. The activator cups the upper and lower eyelid and applies regulated, outward heat to the surface of the palpebral conjunctiva with an air bladder that intermittently provides directional, controlled massage of the eyelids to promote expression of the liquified contents.
224207268|NCT02100527|DRUG|PF-05175157|200 mg (as 2x100 mg tablets) twice a day (BID) for 6 weeks
224207269|NCT02100527|DRUG|Placebo|placebo matching 200 mg (as 2x100 mg tablets) BID for 6 weeks
224207270|NCT04507529|OTHER|Peer-mentoring|Patients (mentees) are matched with a peer-mentor. Throughout the intervention period (24 weeks), the mentee and the mentor will have informal telephone contact and meet face-to face approximately 8 times during the intervention period.
224314988|NCT01675466|DEVICE|Laparoscopic instruments|
224314989|NCT01658501|DRUG|50 mg PB1023|
224314990|NCT01658501|DRUG|70 mg PB1023|
224314991|NCT01658501|DRUG|100 mg PB1023|
224314992|NCT01658501|DRUG|Placebo (0.9% Sodium Chloride)|
224314993|NCT01658501|DRUG|Victoza®|
224314994|NCT01658501|OTHER|Diet and Exercise|
224207271|NCT01354262|DIETARY_SUPPLEMENT|Vitamin D|600 IU daily oral supplementation
224207272|NCT01354262|DIETARY_SUPPLEMENT|Vitamin D|50,000 IU supplementation bi-monthly
224314995|NCT01658501|DRUG|Metformin|
223618749|NCT04415372|DIAGNOSTIC_TEST|Neuropsychological Testing|A comprehensive battery of neuropsychological tests will be administered to assess memory, new learning, spatial processing and higher executive function.
223618750|NCT05093439|DIAGNOSTIC_TEST|Heart Rate Variability|Heart rate variability wil be calculated from patients' 10 sec ECG with a dedicated software (Kubios).
223618751|NCT05924945|DEVICE|Bridge™ active device|Bridge is a percutaneous nerve field stimulation device
223618752|NCT05924945|DEVICE|Bridge™ sham device|The sham device has the same appearance and will require the same placement technique as the Bridge (active) device but will not deliver electrical impulses.
223618753|NCT02692937|PROCEDURE|Neurolysis|
224314996|NCT01658501|DRUG|Sulfonylurea|
224314997|NCT01658501|DRUG|Metformin and Sulfonylurea|
224314998|NCT06416046|DEVICE|Gemini laser|Photobiomodulation (810 + 980 nm, 15s/point, 11.8J/cm²) to evaluate healing and pain relief in recurrent aphthous stomatitis. A 0.7mm intraoral tip will be used - spot 0.38cm2 on the extent of the lesion.
224314999|NCT06416046|OTHER|Placebo|Examination and follow-up until the lesion heals spontaneously. The laser will not be activated.
224315000|NCT01861912|DEVICE|Arsenic trioxide TACE|Arsenic trioxide powder 20mg dissolved in lipiodol(the dosage of lipiodol is decided according to the volume of the target lesion)is used for transcatheter arterial chemoembolization(TACE). TACE will be repeated after 4\~6 weeks if it is necessary according to the assessment from imaging modalities
224315001|NCT01861912|DRUG|Arsenic trioxide intravenous infusion|Arsenic trioxide intravenous infusion: arsenic trioxide powder 0.15mg/Kg/d(maxim 10mg/d) dissolved in 250ml 0.9%NaCl solution is used for intravenous infusion.Every course will last for 3 weeks and the next course will be continued after 1 week suspension.Intravenous infusion will be suspended 3 days before and 7\~14 days after TACE.
224315002|NCT01861912|DRUG|lipiodol|Lipiodol is used to dissolve arsenic trioxide for TACE,with the dosage decided according to the volume of the target lesion.
224315003|NCT01861912|DRUG|NaCl solution|250ml NaCl solution is used to dissolve the arsenic trioxide for intravenous infusion.
224315004|NCT02929056|BIOLOGICAL|AmnioExCel dressing and compression therapy|Use of a dehydrated human amnion membrane as a biologic adjunct to the standard of care in patients with venous leg ulcers
223618754|NCT02692937|OTHER|Traditional neck-specific exercise program|
223618755|NCT04320355|OTHER|Soft tissue manual therapy|The intervention is a type of massage.
223618756|NCT06073808|DEVICE|AmnioFix dehydrated Human Amnion/Chorion Membrane Allograft|Dehydrated human amnion/chorion membrane (dHACMs) allografts have recently been identified as an easy-to-use treatment alternative for management of chronic wounds. These commercially available allografts contain concentrated cytokines and growth factors known to promote wound healing. Preclinical studies suggest that dHACM allografts provide a complex, biologically-driven mechanism to promote soft tissue repair and regeneration, including stimulation of mesenchymal stem cell migration and dermal fibroblast proliferation, establishment of a supportive inflammatory environment, and restoration of extracellular matrix integrity with positive tissue architecture remodeling. Clinically, dHACM allografts have been shown to improve healing time and wound closure rates in chronic wound patients. However, no study to date has evaluated the impact of dHACM allografts on nipple necrosis following NSM.
223618757|NCT06073808|DEVICE|Control Device|Control device will be applied to non-experimental breast. Each patient will serve as their own control.
223618758|NCT04138641|DRUG|Cangrelor|Cangrelor intravenous
223618759|NCT00997802|DEVICE|CT colonography and optical colonoscopy|All patients will undergo CT colonography and optical colonoscopy.
223618760|NCT03612778|BEHAVIORAL|Plant-based diet|Prescription of a meal plan based on unrefined plant-based foods supported by peer group meetings and dietary counselling. Change from the standard western-type nutritional pattern to a low-fat, unrefined, plant-based nutritional pattern.
223618761|NCT03612778|BEHAVIORAL|Mediterranean diet|Prescription of a meal plan based on Mediterranean diet pattern supported by peer group meetings and dietary counselling. Change from the standard western-type nutritional pattern to a Mediterranean nutritional pattern.
224315005|NCT02929056|PROCEDURE|SOC alginate dressing and compression therapy|Alginate dressing is an absorbent wound care product that contains sodium and calcium fibers to absorb fluids and promote healing
224315006|NCT00109226|DRUG|Avastin (Bevacizumab)|
224315007|NCT06226181|PROCEDURE|Dacryocystorhinostomy and amniotic membrane|Dacryocystorhinostomy surgery with amniotic membrane placement on the osteotomy site.
224207273|NCT05801640|OTHER|Facilitated Tucking Position|The fetal position was given by the researcher. In the fetal position, the lower and upper extremities of the baby were kept in the flexed position by hand and placed in the side-lying position close to the midline.
224207274|NCT05801640|OTHER|Reiki|Reiki was applied to areas called chakras (forehead, throat, heart, stomach, feet and hands). A total of 15 minutes were applied in the form of 12 minutes touches in each chakra region.
224207275|NCT05617573|PROCEDURE|Total knee arthroplasty due to advanced osteoarthritis.|Postoperative usage of intravenous methylprednisolone
224315008|NCT06226181|PROCEDURE|Conventional dacryocystorhinostomy|Conventional dacryocystorhinostomy surgery without adding amniotic membrane
224315009|NCT04320823|DEVICE|Updated Plasma Collection Feature|Plasma collection using a novel, patented system that supports a more individualized collection approach.
224315010|NCT04320823|DEVICE|Current Plasma Collection Approach|Plasma collection using the current collection approach.
224207276|NCT02828748|OTHER|no intervention in patients treatment, only biopsy taken|
224315011|NCT04365192|DEVICE|I-gel|"The i-gel airway is a supraglottic airway management device made of thermoplastic elastomer, which is soft, gel-like, and transparent.~The i-gel has evolved as a device that accurately positions itself over the laryngeal framework, providing a reliable perilaryngeal seal, and therefore no cuff inflation is necessary."
224315012|NCT04365192|DEVICE|Self-pressurized air-Q|The self-pressured air-Q is a supraglottic airway management device The intracuff pressure of air-Q dynamically equilibrates with the airway pressure and adjusts to the patient's pharyngeal and periglottic anatomy, potentially providing improved airway fit and seal.
224315013|NCT03120325|DEVICE|Vagal Nerve Stimulation|Patients will be giving themselves vagal nerve stimulation for four weeks at interval of two times a day for two minutes on each side for four weeks. The impact of the intervention on gastroparesis symptoms will be measured by upper endoscopy biopsies, blood work, autonomic function tests, survey data, stool samples, urine sample, and saliva samples before after after the four weeks of stimulation treatment.
223618762|NCT03797846|PROCEDURE|combined glaucoma surgery|combined procedure with trabeculectomy and cataract removal
224207277|NCT00079144|BIOLOGICAL|NY-ESO-1 peptide vaccine|
224207278|NCT00079144|BIOLOGICAL|aldesleukin|
224207279|NCT00079144|BIOLOGICAL|filgrastim|
224207280|NCT00079144|BIOLOGICAL|incomplete Freund's adjuvant|
224207281|NCT00079144|BIOLOGICAL|therapeutic autologous lymphocytes|
224207282|NCT00079144|DRUG|cyclophosphamide|
224207283|NCT00079144|DRUG|fludarabine phosphate|
224315014|NCT03685812|DIAGNOSTIC_TEST|Autocad software|The participants will be prepared for image-capture data collection by putting four squared markers on leg and thigh.Each subject will extend his/her leg and make two angles from the resting position (90º) to the full extension, photos will be taken. The tested leg passively moved by the researcher through 20° to 60° of knee extension, the participant will be instructed to actively move that leg to the target angle and hold it in this position another photograph will be taken. The angles will be measured using the AutoCAD software. Knee JPS measurements will also be collected using an IKD by same steps
224207284|NCT05423301|PROCEDURE|Experimental|Respiratory care consists of manual and instrumental bronchial clearance techniques: Expiratory Flow Enhancement (EFE), suctioning, manual cough assist techniques, instrumental clearance techniques (suctioning and Cough Assist) and swallowing disorder management.)
224207285|NCT05423301|PROCEDURE|Control|The control group will receive early respiratory care and rehabilitation by nurses, nurses' aides and doctors until D7. Respiratory care includes aerosol therapy, oral and pharyngeal clearance with aspirations, verbal coughing and sputum removal, and possibly bronchial fibroscopy for clearance if necessary. Early rehabilitation consists of alternating postures in bed, passive chair positioning (patient lift), or active positioning via a bed rail and standing.
224207286|NCT01392586|PROCEDURE|upfront breast surgery|surgery of primary tumor, lumpectomy or mastectomy
224207287|NCT01392586|OTHER|systemic therapy|chemotherapy, immunotherapy or endocrine therapy (possibly followed by local surgery of the breast)
224207288|NCT06538363|BEHAVIORAL|Education|Personalized training advice
224207289|NCT06538363|BEHAVIORAL|Generic Education|Generic training advice
223618763|NCT04236674|DEVICE|Buzzy thermomechanical device|Buzzy thermomechanical device placed near intervention site.
223618764|NCT04236674|BEHAVIORAL|Music Selection|Patient specified procedural music
223618765|NCT01391663|DRUG|Alogliptin|Alogliptin 12.5 mg, tablets, orally, once daily for up to 7 days.
223618766|NCT01391663|DRUG|Alogliptin|Alogliptin 25 mg, tablets, orally, once daily for up to 7 days.
223618767|NCT01391663|DRUG|Alogliptin|Alogliptin 25 mg, tablets, orally, two tablets taken once daily for up to 7 days.
223618768|NCT00462306|PROCEDURE|Survey: Berlin questionnaire|Completion of questionnaire
223618769|NCT02721602|BEHAVIORAL|Families Preventing Diabetes Together|Families in the intervention group will be asked to participate in four in-person sessions at a local Fairview North metropolitan area clinic over the course of two months. Sessions will focus on age-appropriate nutrition and diabetes education, meal planning and cooking skills, healthful eating, and eating meals as a family. All family members will be asked to attend and will be involved in all four, two-hour sessions. The parent with diabetes will also complete one goal setting telephone call based on motivational interviewing techniques during the intervention period.
223618770|NCT01693549|DRUG|Cabazitaxel|
223618771|NCT03515824|BIOLOGICAL|MK-1697|Administered by IV infusion on Day 1 of each 21-day cycle
224207290|NCT01470586|PROCEDURE|Surgery for colorectal cancer|Surgical resection of colorectal cancer
224207291|NCT02490527|DIETARY_SUPPLEMENT|Pure epicatechin capsules (50mg)|Epicatechin is a compound found naturally in dark chocolate.
224207292|NCT02490527|DRUG|Simvastatin (40mg)|A cholesterol-lowering medication that blocks the production of cholesterol.
224207293|NCT02490527|OTHER|Placebo|A substance that has no therapeutic effect and will act as a control.
224207294|NCT02034227|DRUG|SG2000|intravenous doses given on Days 1, 2, and 3 of each 21-day cycle (1 to 6 cycles).
224207295|NCT03347227|PROCEDURE|Catheter ablation|Wide area circumferential catheter ablation for pulmonary vein isolation of persistent atrial fibrillation
224207296|NCT03799094|DRUG|Vitamin C|Participants will receive intravenous vitamin C therapy at the indicated dose.
224207297|NCT03799094|DRUG|Tyrosine kinase inhibitor|Participants will receive Tyrosine kinase inhibitor therapy in cycles: continuous treatment at the indicated dose.
224207298|NCT00176501|BIOLOGICAL|therapeutic allogeneic lymphocytes|If a partially HLA-matched donor is identified and other eligibility criteria are met, the patient will receive irradiated lymphocyte infusion(s).
224207299|NCT01139892|PROCEDURE|Surgical management|
224207300|NCT01139892|PROCEDURE|Endovascular management|
224207301|NCT03371680|DRUG|Injection of 1-13 Carbon Leucine and deuterated water|All patients received a constant intravenous infusion of 1 g 1-13 Carbon Leucine (Cambridge Isotope Laboratories, Andover, MA) dissolved in saline for 24 h. Deuterated water (Cambridge Isotope Laboratories, Andover, MA) was administered as a 25 ml bolus at the study start and then, every 12 hours over the next 36 hours, as intermittent boluses corresponding to 0.0625% of fluid intake, to maintain steady state of deuterium enrichment in body water
224207302|NCT02525146|OTHER|Modified ARTAS (Antiretroviral Treatment and Access to Services) intervention|
223618772|NCT01451489|DRUG|FK506|FK506:0.05-0.1mg/kg/d
223618773|NCT01451489|DRUG|Cyclophosphamide|CTX 750mg/m2 per month in the induction phase,then 750mg/m2 every 2 month for 3 times,then 750mg/m2 every 3 months.
223680760|NCT02478398|DRUG|Self-injectable epinephrine|Intramuscular (IM) injection with suggested doses of 0.15 mg for participants weighing 15-30 kg (33-66 pounds) or 0.3 mg for participants weighing ≥30 kg (≥66 pounds), as needed for severe allergic reactions. Epinephrine was only provided in countries/study sites where it was a regulatory requirement.
223680761|NCT02478398|DRUG|Albuterol/Salbutamol|Inhalation of albuterol 90 mcg/puff or salbutamol 100 mcg/puff metered dose inhaler (MDI), as needed as asthma rescue medication for those participants with asthma
223680762|NCT02478398|DRUG|Loratadine|5 mg (1 mg/mL syrup or 5 mg tablet) for participants 5 years old or 10 mg (1 mg/mL syrup or 10 mg tablet) for participants 6 to 17 years old, as needed for rhinoconjunctivitis symptoms
224207303|NCT05135143|COMBINATION_PRODUCT|Antioxidant formula|Administration of antioxidant formula 3 times a day and once daily.
224207304|NCT02065973|BIOLOGICAL|R-enantiomer of 1,2-dioleoyl-3-trimethylammonium-propane chloride + Peptides from HPV-16 E6 and E7|
223680763|NCT02478398|DRUG|Olopatadine|Opthalmic solution, 1 drop (0.1%) per affected eye twice daily (BID), as needed for rhinoconjunctivitis symptoms
224207305|NCT04190966|BEHAVIORAL|Integrated Behavioural therapy|Integrated smoking cessation behavioural therapy
224207306|NCT04190966|DRUG|Integrated Pharmacotherapy|Integrated smoking cessation pharmacotherapy including choice of combination nicotine replacement therapy, varenicline or electronic cigarettes
224207307|NCT04190966|DEVICE|Integrated Web-based application|Integrated smoking cessation web-based application
224207308|NCT00003673|DRUG|chemotherapy|
224207309|NCT00003673|DRUG|gemtuzumab ozogamicin|
224260452|NCT06361407|BEHAVIORAL|Illusion task|The task is the illusion already described in the arm description. All participants will additionally benefit from a short neuropsychological evaluation exploring attention (CPT-AX) and semantic knowledge (fNART) and a clinical evaluation exploring the sense of self (EASE).
224260453|NCT05105607|DRUG|D-4517.2|Subcutaneous (SC) injection
224315015|NCT03451357|DIAGNOSTIC_TEST|Dependence degree already certificated by Dependence Law.|The European Council defines dependence as the state in which people, due to causes linked to the lack or loss of physical, psychological, or intellectual autonomy, are in need of assistance and/or significant help to carry out common activities of daily life. In primary care, the nurses in charge are trained of data collection. This situation needs of formal care provided by health or/and social workers, private or public.
224315016|NCT00251511|DRUG|Arsenic Trioxide|
224315017|NCT00980447|BIOLOGICAL|UMN-0501|2 doses of recombinant H5N1 A/VN/1203/2004 vaccine 45µg three weeks apart
223618774|NCT00920855|DRUG|bendamustine|"Bendamustine was administered to 3 cohorts of patients at escalating doses of 50 (cohort 1), 70 (cohort 2) and 90 mg/m\^2/dose (cohort 3). Doses were administered by intravenous (iv) infusion once daily on days 1 and 4 of each 28-day cycle. Each iv was administered over 60 minutes and followed the injection of bortezomib.~Bortezomib will be administered to patients at a dose of 1.0 mg/m2/dose as an iv push over 3 to 5 seconds followed by a standard saline flush or through a running iv line. Doses are to be administered to patients on days 1, 4, 8 and 11 of the 28-day cycle."
223618775|NCT00920855|DRUG|bortezomib|Bortezomib was administered at a dose of 1.0 mg/m\^2/dose as an intravenous (iv) push over 3 to 5 seconds followed by a standard saline flush or through a running iv line. Doses are to be administered on days 1, 4, 8 and 11 of each 28-day cycle.
223618776|NCT02650089|OTHER|Resistance Exercise Low intensity|The 40% one maximum repetition resistance exercise session lasted 40 minutes. Three circuits with 7 exercises, 16 repetitions were performed for each exercise, with an interval of 60 seconds between exercises and 120 seconds between circuits. The duration of repetition in the exercises was 3 seconds - 1 second in the concentric phase and 2 seconds in the eccentric phase of the movement.
224315018|NCT00980447|BIOLOGICAL|UMN-0501|2 doses of recombinant H5N1 A/VN/1203/2004 vaccine 90µg three weeks apart
224315019|NCT00980447|BIOLOGICAL|UMN-0501|2 doses of recombinant H5N1 A/VN/1203/2004 vaccine 135µg three weeks apart
224315020|NCT02879903|PROCEDURE|Periodontal treatment|"An experienced periodontist will be performed clinical periodontal parameters, including Plaque Index, Bleeding On Probe, Pocket Probing Depth, Gingival Recession, Clinical Attachment Level using a periodontal probe, at six sites per tooth at all teeth, excluding third molars.~Quadrant scaling and root planning will be weekly performed on each patient under local anesthesia using periodontal curettes and ultrasonic scalers. The maintenance therapy will be included professional plaque control and Scaling and root planing in recurrent periodontal pockets."
224315021|NCT02879903|PROCEDURE|Microbiological collect|Biofilm will be collected with the paper point to analyse presence of Porphyromonas gingivalis fimbrial subunit gene type I, II, III, IV and V.
224315022|NCT02879903|PROCEDURE|Questionnaire|Age will be expressed in years Sex -female and male, will be expressed in percentage. Time of cigarette consumption - will be expressed in years
224315023|NCT02925403|BIOLOGICAL|R21/Matrix-M1|
224315024|NCT02925403|OTHER|Saline|
224315025|NCT02488954|OTHER|Probiotics in the form of cheese portion|
224315026|NCT02401997|BEHAVIORAL|sexual abstinence|The subjects participated in the study are divided into three groups according to the male partners sexual abstinence period during the day of sperm preparation for intrauterine insemination.
224315027|NCT06505798|PROCEDURE|Catheter Ablation|Participants randomised to the catheter ablation arm will undergo Pulmonary Vein Isolation (PVI) which is the essential ablation intervention. The technique used will be at the discretion of the treating physician but may include Cryoballoon (Medtronic/Boston Scientific), Radiofrequency: CARTO (Biosense), pulsed field radiofrequency ablation, or Precision (Abbott Medical) electro-anatomical mapping systems. Additional ablation lesions may be delivered as preferred by the operator and will be documented. Electro-anatomical voltage maps will be collected (in SR/AF) and stored for later analysis.
224315028|NCT04431765|OTHER|Eye Movement Desensitization Reprocessing therapy|The Eye Movement Desensitization Reprocessing therapy uses bi-alternating (right-left) sensory stimulation through eye movements. The patient follows the therapist's fingers from right to left in front of his eyes and also by auditory stimuli. The patient wears a helmet that alternately makes him hear a sound to the right, then to the left or touch the patient holds in his hands buzzers that alternately vibrate from right to left, or alternatively the therapist taps the patient's knees or the back of his hands.
224315029|NCT04431765|BEHAVIORAL|Trauma-Centred Cognitive and Behavioural Therapy|A CBT is a short, scientifically validated therapy that focuses on the interactions between thoughts, emotions and behaviours. These therapies focus on the current problems of the person, while taking into account their historical causes. They help gradually overcome disabling symptoms and aim to strengthen adaptive behaviours. A CBT relies on different techniques that help the patient to identify the mechanisms at the origin of his difficulties, to experiment with new behaviors and thus to gradually come out of vicious circles that perpetuate and aggravate the psychic suffering.
224315030|NCT04173325|DRUG|Nivolumab 10 MG/ML Intravenous Solution [OPDIVO]|PD-1 inhibitor approved by the US FDA for treatment of patients with lung cancer.
224315031|NCT04173325|DRUG|Irinotecan Injection [Camptosar]|Chemotherapy drug currently FDA approved for treatment of multiple tumors, including small cell lung cancer.
224315032|NCT05625074|PROCEDURE|Conventional surgery for great saphenous vein insufficiency|Arch ligation and stripping of great saphenous vein. Prophilatic anticoagulation - Low molecular weight heparin vs DOACs Antibiotics Non-steoridal anti-inflamatory drugs
223618777|NCT02650089|OTHER|Resistance Exercise High intensity|The 80% one maximum repetition resistance exercise session lasted 40 minutes. Three circuits with 7 exercises, 16 repetitions were performed for each exercise, with an interval of 60 seconds between exercises and 120 seconds between circuits. The duration of repetition in the exercises was 3 seconds - 1 second in the concentric phase and 2 seconds in the eccentric phase of the movement.
223618778|NCT02650089|OTHER|Control|In the control session, the participants remained seated in a comfortable chair in the same environment of the resistance exercise sessions.
223618779|NCT03070080|PROCEDURE|restrictive fluid strategy|restrictive lactated ringers as intraoperative fluid therapy in a dose of 6ml/kg/hour
223618780|NCT03070080|PROCEDURE|conservative fluid strategy|conservative lactated ringers as intraoperative fluid therapy in a dose of 12ml/kg/hour
223618781|NCT01484210|DRUG|Elpenhaler active - Diskus placebo|randomized, double-blind, double-dummy, 2-way crossover, single dose study, comparing the efficacy and safety of the Fluticasone/Salmeterol (500/50 μg) combination administered with Elpenhaler® (Rolenium®) versus the innovative one (Seretide Diskus®) in patients with asthma.
223618782|NCT04480268|DRUG|PAXG regimen (cisplatin, nab-paclitaxel, capecitabine, gemcitabine) chemotherapy|"The PAXG regimen includes:~* nab-paclitaxel 150 mg/m2 on day 1 and 15 of each cycle;~* cisplatin 30 mg/m2 on day 1 and 15 of each cycle;~* capecitabine 1250 mg/m2 on 1 day to 28 of each cycle;~* gemcitabine 800 mg/m2 on day 1 and 15 of each cycle. Each cycle lasts 28 days. Patients are treated until maximal response, disease progression or unacceptable toxicity."
223618783|NCT04970875|OTHER|Questionnaire|QoL questionnaire
224207310|NCT01204073|DRUG|TAK-441|"TAK-441 will be administered as an oral tablet as follows:~Patients enrolled in the dose escalation cohorts will receive:~* A single-dose administration on Day 1, followed by a 1-week washout period during which pharmacokinetics is assessed~* Continuous daily dosing on Days 8 through 28 in Cycle 1~* In subsequent cycles, continuous daily dosing over 21 days, repeated continuously~Patients enrolled in the expansion cohorts will receive continuous daily dosing on Days 1 through 21 of each 21-day cycle"
224207311|NCT01274273|DRUG|Interleukin-2|2.4 MIU/m2 s.c. two times daily, 5 days per week, weeks 1 and 2, every 28-day-cycle, for a maximum of 9 cycles (i.e.for a maximum of 9 months).
223618784|NCT00102765|DRUG|fluticasone propionate/salmeterol powder|
223618785|NCT00102765|DRUG|fluticasone propionate powder|
224207312|NCT01274273|DRUG|Interferon Alfa-2b|IFN-alfa given as one priming-week of daily IFN 3.0 MIU, followed by up to 9 treatment cycles (i.e. for a maximum of 9 months) with IFN-alfa 3.0 MIU as a fixed dose s.c. once daily - 5 days per week.
223618786|NCT03309423|DIAGNOSTIC_TEST|venous to arterial conversion (v-TAC)|Venous to arterial conversion (v-TAC) is a software (Obimedical, Denmark), which can convert venous blood gas values to arterial blood gas values. The principle of the method is a mathematical transformation of VBG values to arterialized values (aVBG) by simulating the transport of blood back through the tissue. To facilitate this simulation the following physiologically relevant assumptions were made: 1) The peripheral extremity was well perfused; 2) change in base excess across the tissue sampling site was approximately zero; 3) the respiratory quotient (rate of CO2 production and O2 utilisation over capillaries) could not vary outside the range 0.7 and 1.0, and 4) the haemoglobin concentration was constant from artery to vein.
223618787|NCT00186225|PROCEDURE|ablative allogeneic hematopoietic cell transplantation|
223618788|NCT02202239|DRUG|midazolam|Before induction, midazolam 0.05mg/kg will be injected intravenously.
223618789|NCT02202239|DRUG|Penehyclidine Hydrochloride Injection|Penehyclidine Hydrochloride 0.01mg/kg will be injected intravenously after midazolam is injected.
224207313|NCT01274273|DRUG|Bevacizumab|Bevacizumab doses of 10 mg per kilogram of body weight, given every two weeks i.v. until disease progression, unacceptable toxicity, withdrawal of consent or a maximum of 1 year following obtaining no evidence of disease (NED).
224207314|NCT04024280|OTHER|Physical exercise program|Frequency: 3 weekly sessions. Intensity of aerobic training: reporting 12-17 in the Borg scale. Time of aerobic training: 10 minutes in the first and second weeks and then 2 added minutes at each 2 weeks. Type of aerobic training: walking and stepping. Intensity of resistance training: without load in the first week and, then, 15 submaximal repetitions. Time of resistance training: 30 minutes. Type of resistance training: using free weights; the lower body exercises will be squat, leg extension, leg curl and calf raise; the upper body exercises will be frontal and lateral arm raise, chest press, seated row and bicep curl.
224207315|NCT00209430|DRUG|Iodixanol 320 mgI/mL|
224207316|NCT00003273|BIOLOGICAL|filgrastim|
224207317|NCT00003273|DRUG|carboplatin|
224207318|NCT00003273|DRUG|cisplatin|
224207319|NCT00003273|DRUG|cyclophosphamide|
224207320|NCT00003273|DRUG|etoposide|
224207321|NCT00003273|DRUG|leucovorin calcium|
224207322|NCT00003273|DRUG|methotrexate|
224207323|NCT00003273|DRUG|temozolomide|
224207324|NCT00003273|DRUG|thiotepa|
224207325|NCT00003273|DRUG|vincristine sulfate|
224207326|NCT00003273|PROCEDURE|autologous bone marrow transplantation|
224207327|NCT00003273|PROCEDURE|peripheral blood stem cell transplantation|
224207328|NCT00003273|RADIATION|radiation therapy|
224207329|NCT06362616|RADIATION|Preoperative accelerated partial breast irradiation|Patients will be treated with 5 x 5.2 Gray (Gy) preoperative accelerated partial breast irradiation of the in situ tumor in the breast
224207330|NCT06362616|PROCEDURE|Breast conserving surgery|Patients will be treated with breast conserving surgery.
223618790|NCT02202239|DRUG|Etomidate|Induction dose: 0.3 mg/kg. Maintenance dose: 10 μg•kg-1•min-1.
223618791|NCT02202239|DRUG|Propofol|Induction dose: 2.0 mg/kg. Maintenance dose: 4 to 6 mg/kg/h.
224207331|NCT06362616|PROCEDURE|Sentinel node procedure|Patients will undergo a (repeat) sentinel node procedure.
224207332|NCT06362616|PROCEDURE|Biopsy track removal|The biopsy track will be surgically removed.
224207333|NCT03612713|DRUG|Oxycodone Medication First|Participants will be given 15mg oxycodone one hour before fMRI scan. After at least 1 week wash out participants will be given placebo one hour before fMRI scan.
224207334|NCT03612713|DRUG|Placebo First|Participants will be given placebo one hour before fMRI scan. After at least 1 week wash out participants will be given 15mg oxycodone one hour before fMRI scan.
224207335|NCT02404779|DRUG|cisatracurium besilate|
224207336|NCT02404779|OTHER|Placebo|
224207337|NCT01018342|DRUG|Nitrofurantoin Monohydrate/Macrocrystals Capsules 100 mg|
224207338|NCT01018342|DRUG|Macrobid® Capsules 100 mg|
224207339|NCT04296799|DRUG|SMP-100|SAD/MAD
224207340|NCT04296799|DRUG|Placebo|Placebo
224260454|NCT04972578|DEVICE|Suture Button vs Screw Fixation|Syndesmotic fixation utilizing suture button fixation versus Screw Fixation (placing one or two screws across the syndesmosis)
224260455|NCT06626893|BIOLOGICAL|Functional tests|Functional analyses will be performed on primary sample from each enrolled patient. Isolated blast cells are cultered and incubated with a specific library of drugs (175 drugs) at four different concentrations for 72 hours.
224260456|NCT06626893|GENETIC|Next Generation Sequencing analysis|For each patient, sequencing analyses will be performed on blast cells (for somatic mutations) and on epithelial cells from buccal swab (for germline mutations)
223618792|NCT02202239|DRUG|Fentanyl|During induction, after injection of etomidate, fentanyl 3 μg/kg will be given intravenously.
223618793|NCT02202239|DRUG|Cisatracurium Besilate|"Cisatracurium Besilate 0.14 mg/kg will be used after fentanyl is injected for induction.~During maintenance, intermittent bolus of cisatracurium will be used for maintain muscle relaxation."
223618794|NCT02202239|DRUG|Remifentanil|Remifentanil will be injected continuously during maintenance of anesthesia.
223618795|NCT02202239|DRUG|Sevoflurane|Sevoflurane of 1% to 2% will be administered via inhalation to keep bispectral index（BIS) between 50 to 55.
224207341|NCT05437484|BEHAVIORAL|Peer-led BASICS|"The peer-led BASICS session consisted in a face-to-face 50-minute motivational interview. In this meeting, the peer counsellor oriented the participant using a personalized graphic feedback sheet, with topics including participant's drinking pattern; level of intoxication; perceived and actual descriptive drinking norms, alcohol expectancies; drinking consequences; individual risk factors; financial costs; alcohol caloric consumption, and hours of exercise required to burn those calories, and protective behavioral strategies. Participants received a copy of the personalized feedback, a personalized BAC card, and a tips sheet.~BASICS facilitators were volunteer undergraduate nursing students from who attented a pre-training course and showed being competent to conduct BASICS-based motivational interview and knowledgeable about alcohol."
224207342|NCT00606879|DRUG|SGX523 Capsules|This is a dose escalation study
224207343|NCT04856579|PROCEDURE|Varicocelectomy|Subinguinal varicocelectomy under general anesthesia and complete aseptic condition
224207344|NCT00830388|DRUG|Ketoconazole 2% Foam|Ketoconazole 2% Foam, twice daily application to affected areas for 4 weeks.
224207345|NCT02387788|DRUG|AKB-9778|Phase 2a open-label study to assess the efficacy and safety of subcutaneous 15mg AKB-9778 administered twice daily for 84 days in subjects with macular edema due to RVO.
224207346|NCT02775227|DRUG|Hydrocortisone|
224207347|NCT02775227|DRUG|Pasireotide|
224207348|NCT05640882|OTHER|VRET|10 week prolonged exposure protocol, using Virtual Reality for imaginal exposure
224207349|NCT05640882|OTHER|VRET OLFACTION|10 week prolonged exposure protocol, using Virtual Reality for imaginal exposure with the addition of olfaction
224207350|NCT03778359|DRUG|Leuprorelin|This study was designed to analyze the differences in prognosis and recurrence of patients with endometriosis and adenomyosis after receiving various surgical and medical treatments. This arm intervention is Leuprorelin.
224207351|NCT03778359|DEVICE|Levonorgestrel|This study was designed to analyze the differences in prognosis and recurrence of patients with endometriosis and adenomyosis after receiving various surgical and medical treatments. This arm intervention is Levonorgestrel.
224207352|NCT03778359|DRUG|Dienogest|This study was designed to analyze the differences in prognosis and recurrence of patients with endometriosis and adenomyosis after receiving various surgical and medical treatments. This arm intervention is Dienogest.
224207353|NCT03778359|DRUG|Progestins|This study was designed to analyze the differences in prognosis and recurrence of patients with endometriosis and adenomyosis after receiving various surgical and medical treatments. This arm intervention is Progestins.
224207354|NCT00709475|DRUG|insulin detemir|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
224207355|NCT05190900|OTHER|neural mobilization|neural mobilisation of the posterior tibial, deep peroneal and lateral, intermediate and medial dorsocutaneous nerves.
223618796|NCT02303093|BIOLOGICAL|Octagam IVIG 5% or 10%|Octagam IVIG 5% or 10%
223618797|NCT02303093|BIOLOGICAL|Panzyga|Panzyga
223618798|NCT00346125|BIOLOGICAL|pegfilgrastim|will be given at 6 mg subcutaneously (SC) at the end of the mesna infusion
223618799|NCT00346125|DRUG|doxorubicin hydrochloride|65 mg/m\^2 by continuous intravenous (IV) infusion over 7 days beginning on day 1
223618800|NCT00346125|DRUG|ifosfamide|9 g/m\^2 by continuous intravenous (IV) infusion over 6 days beginning on day 1 with mesna 10.5 g/m\^2 by continuous IV infusion over 7 days beginning on day 1
223618801|NCT00346125|DRUG|pegylated liposomal doxorubicin hydrochloride|45 mg/m2 intravenous (IV) Day 1, repeat every 28 days.
223618802|NCT00346125|PROCEDURE|conventional surgery|The surgical procedure will be decided by the treating physician and independent of study participation
223618803|NCT00346125|RADIATION|fludeoxyglucose F 18|FDG is a radioactive sugar equal to a uniform whole-body exposure of approximately 1.5 rem for each scan. Post-operative radiation therapy may be given according to institutional guidelines in patients felt to have close surgical margins.
223618804|NCT00539994|DRUG|retapamulin|200mg BID retapamulin 3 days
224207356|NCT05741268|BEHAVIORAL|Dialectical behavior therapy|14\) Dialectical behavior therapy will be applied through psychoeducation, discussion, rehrasal and homework assignments. It contains four modules were administered in 14) Dialectical behavior therapy will be applied through psychoeducation, discussion, rehrasal and homework assignments. It contains four modules were administered in the following sequence 1. Mindfulness , 2. Emotion Regulation , 3. Distress Tolerance and 4. Interpersonal effectiveness.
224207357|NCT03724669|BEHAVIORAL|waiting list|After the study ends, they will have access to receive the educational texts and view the online lectures.
224207358|NCT03724669|BEHAVIORAL|benzodiazepines related knowledge intervention|participants receiving 11 articles pushing and 3 online lectures through the electronic interventions App, once a week, last for 3 months
224207359|NCT00149669|BEHAVIORAL|employment-based reinforcement|Work Plus Naltrexone Contingency participants were required to ingest naltrexone to work, and received a brief pay decrease for missing a dose.
224207360|NCT00166374|PROCEDURE|balloon kyphoplasty|
224207361|NCT03793595|DEVICE|Seated Battle Ropes Protocol|Participants will begin swinging the rope as previously described in the seated position using the double arm swing technique for 15 seconds at a cadence of 100 beats/ minutes with a 45 second rest break repeated 10 times.
224207362|NCT03793595|DEVICE|Seated Upper Extremity Arm Bike|A modified Young Men's Christian Association (YMCA) cycle test will be performed.
223618805|NCT00539994|DRUG|Retapamulin|200mg BID retapamulin 5 days
223618806|NCT00539994|DRUG|Placebo|200mg BID placebo 5 days
223618807|NCT04428346|BEHAVIORAL|Incentive payment|Incentive payment to enhance HCV treatment uptake among people with recent injecting drug use attending needle and syringe programs.
223618808|NCT04871659|OTHER|Online Survey completion|Eligible participants will complete surveys electronically via Amazon's mTurk platform
224207363|NCT02458365|BEHAVIORAL|Teen Choices: A Program for Healthy Nonviolent Relationships|A 3-session online, multimedia TTM-based intervention for teen dating violence prevention. For most students, the intervention seeks to reduce risk for dating violence by facilitating progress through the stages of change for using healthy relationship skills; daters are encouraged to use those skills in their dating relationships, and non-daters in their peer relationships, as relationships with peers serve as the foundation for experiences in romantic relationships. For victims of dating violence experiencing fear, the intervention does not focus on healthy relationship skills; instead, it seeks to facilitate progress through the stages of change for keeping oneself safe in relationships.
224207364|NCT02458365|BEHAVIORAL|Health In Motion|A 3-session online, multimedia, TTM-based intervention which targets physical activity, screen time, and healthy eating for obesity prevention. Health In Motion sessions were administered following the baseline, 6-month, and 12-month assessments to increase the benefits of study participation for Comparison schools and students.
224207365|NCT02282007|BEHAVIORAL|Individual NPMP to the participants|The participants in the intervention group will receive NPMP individually adjusted for six months. NPMP is not a standardized treatment approach, but individually adjusted to the individual patient according to their individual problems.
224207366|NCT05991778|DEVICE|Bioelectrical impedance vector analysis (BIVA)|BIVA is a simple, rapid, and noninvasive method, based on the principle that the flow of altering electrical current through a particular tissue differs depending on the content of water and electrolytes, used for monitoring hydratation and nutritional status in critically ill patients.
224207367|NCT05991778|DIAGNOSTIC_TEST|Blood and urine analysis|For regular measurement in 2-3 terms, depending on the length of hospitalization (the first measurement took place within 48 hours of admission, followed one week after admission and the last before transport from the ICU): laboratory indicators of nutritional status will also be taken (albumin, prealbumin, creatinine), inflammation (C-reactive protein, presepsin) and 25-hydroxyvitamin D level.
224207368|NCT05991778|DIAGNOSTIC_TEST|cumulative water balance|Cumulative balance is the sum of daily fluid balances during hospitalization.
224207369|NCT01035593|PROCEDURE|plasmapheresis and IVIG|Plasmapheresis with either 5% human albumin or FFP replacement, plus IVIG 100mg/kg IV after each PP session, every other day x 5 treatments
224207370|NCT01035593|DRUG|recombinant C1 inhibitor|100units/kg IV for seven consecutive days (once daily on PP/IVIG days, twice daily on non-PP/IVIG days).
224207371|NCT05988593|DIETARY_SUPPLEMENT|placebo|consume one bottle (30 mL) per day
224207372|NCT05988593|DIETARY_SUPPLEMENT|MelaGene+|consume one bottle (30 mL) per day
224207373|NCT01226654|DEVICE|Magnetic Resonance Imaging|Magnetic Resonance Imaging EDSS
224207374|NCT00984828|DRUG|velcade|velcade 1.3mg/m2 D1, 4, 8 and 11
224207375|NCT01019278|RADIATION|proton beam radiation therapy|Undergo external proton beam radiation
224207376|NCT01019278|RADIATION|radiation therapy treatment planning/simulation|
224207377|NCT01019278|DRUG|cisplatin|Given IV
224207378|NCT00791154|DRUG|AMG 479|AMG 479 is administered to subjects
224207379|NCT00791154|DRUG|Etoposide|Etoposide is administered to subjects
224207380|NCT00791154|DRUG|Placebo|Placebo is administered with Carboplatin and Etoposide
223618809|NCT02763839|DRUG|BIA 3-202|"The study consisted of 5 treatment periods. Eligible subjects were admitted to the UFH on the morning of the day prior to receive the trial medication (dosing day) and remained in the unit for at least 30 h post-dose.~Subjects were to receive BIA 3-202 50 mg, 100 mg, 200 mg, 400 mg and placebo at 5 separate treatment periods."
223618810|NCT02763839|DRUG|Placebo|Placebo dose consisted of 5 tablets matching BIA 3-202 100 mg tablets; oral route
224207381|NCT00791154|DRUG|AMG 102|AMG 102 is administered to subjects
224207382|NCT00791154|DRUG|Carboplatin|Carboplatin is administered to some subjects in combination
224207383|NCT00791154|DRUG|Cisplatin|Cisplatin is administered to some subjects in combination
224207384|NCT00233376|PROCEDURE|Access to an antibiotic decision support system|
224207385|NCT00233376|BEHAVIORAL|Distribution of local antibiotic guidelines|
224207386|NCT00953927|BIOLOGICAL|MVA85A/AERAS-485|Attenuated virus MVA vector with insertion. Single dose vaccine, 1 x 10\^8 pfu.
224207387|NCT00953927|BIOLOGICAL|Candida Skin Test Antigen|1 test, administered once as a placebo control.
224207388|NCT06568926|DIAGNOSTIC_TEST|Serum Ferritin level|follow up to the ferritin level in beta thalaseemia patients on oral chelation therapy
224207389|NCT00122031|DEVICE|Deep Brain Stimulation with Medtronic Activa Neurostimulator|Deep brain stimulation (DBS) at 130 Hz
224207390|NCT06056531|OTHER|Near infrared light imaging|The participant performing PVC carried out the procedure on the arm vein of another volunteer classmate with the help of vein imaging by NIR. All interventions were conducted under the observation of the researchers.
224207391|NCT06056531|OTHER|Isometric exercise with stress ball|Before the procedure, the students on whom PVC was to be performed were given two stress balls, and they were told how to use them for 15 minutes. The participants were told to squeeze and relax the stress ball in the palm of their hands after counting from one to three, to continue doing this until the procedure began, and to concentrate on squeezing the ball.
224207392|NCT06190873|BEHAVIORAL|post-discharge rehabilitation training|Telephone training will be provided for post-discharge rehabilitation
224207393|NCT02665026|PROCEDURE|stoma closure at different times|Early closure: stoma closure in 12 weeks after surgery for rectal cancer; Late group: stoma closure in 24 weeks after surgery for rectal cancer
224207394|NCT01206946|DRUG|Betamethasone|A single course of betamethasone (two doses of 12 mg/dose given at 24 hourly intervals)
224207395|NCT01206946|OTHER|Normal Saline|Two doses of 2ml of normal saline given at 24 hourly intervals
224207396|NCT00685048|BEHAVIORAL|10 minutes of psycho-education|Patients review with study therapist a brochure about types of gambling people engage in and relationships between gambling, drug use, moods, and legal problems.
224207397|NCT00685048|BEHAVIORAL|10 minutes of brief advice|Patients will review with study therapist a brochure and advice about problem gambling. It will also contain methods for reducing gambling.
224207398|NCT00685048|BEHAVIORAL|four 50-minute individual therapy sessions of MET & CBT|MET \& CBT
224207399|NCT01747239|DRUG|Cabazitaxel|25 mg/m2 IV every three weeks
224315033|NCT01184443|DRUG|Olanzapine|Dosing regimen is in keeping with clinical practice. Patients will typically start oral olanzapine at 2.5mg (rarely 1.25mg) daily for 1 to 2 weeks, and if tolerated and clinically indicated, are increased to 5.0mg daily. The majority of patients will remain on a maintenance dose of 5.0mg, but more agitated patients may take 7.5mg (rarely 10.0mg) daily. Patients will be tapered off as they approach/attain their ideal body weight.
224315034|NCT00459043|DRUG|ZD6474|Taken orally once every morning
224315035|NCT00459043|DRUG|Docetaxel|Given on the first day of every treatment cycle (every 3 weeks)
224315036|NCT00167284|BEHAVIORAL|physician and patient education; physician practice redesign|
224315037|NCT02499484|DRUG|glyceryl trinitrate|Topical GTN will be used daily in combination with a eccentric home exercise program
224315038|NCT02499484|OTHER|Placebo ointment|Topical placebo ointment will be used in combination with a eccentric home exercise program
224315039|NCT02499484|OTHER|Eccentric exercise program|All participants will complete the eccentric exercise program as a home exercise program daily.
224315040|NCT02521805|OTHER|Animal protein|
224315041|NCT02521805|OTHER|Vegetable protein|
224315042|NCT02521805|OTHER|Dietary fiber (cereal food matrice)|
224315043|NCT02521805|OTHER|Dietary fiber (meat food matrice)|
224315044|NCT02521805|OTHER|Dietary fiber (vegetable food matrice)|
224315045|NCT01842997|BIOLOGICAL|split-virion, non-adjuvanted H1N1 vaccine of 15 μg|122 participants (19 at 5-9 weeks pregnant,36 at 10-19 weeks pregnant,13 at 20-29 weeks pregnant,54 at more than 30 weeks pregnant) received split-virion, non-adjuvanted H1N1 vaccine of 15 μg.
224315046|NCT03127111|GENETIC|Gene mutations analysis|Genomic DNA extracted from paired fresh-frozen tumor and normal tissues is used for KRAS mutations, BRAF mutations, PIK3A mutations, and EGFR mutations, etc., by sequencing and for MSI analysis by PCR and capillary electrophoresis.
224315047|NCT03127111|GENETIC|Gene methylation analysis|Genomic DNA extracted from paired fresh-frozen tumor and normal tissues is used for specific gene methylation or CIMP status analysis by MethyLight or bisulfite sequencing. Whole-genome bisulfite sequencing will be used to identify novel candidate set of predictive markers.
224315048|NCT03127111|GENETIC|Gene expression analysis|RNA extracted from paired fresh-frozen tumor and normal tissues or serum is used for specific gene expression analysis by real-time reverse-transcription PCR (RT-qPCR). RNA-seq will be used to identify novel candidate set of predictive markers.
223618811|NCT02763839|DRUG|Sinemet 25/100|Levodopa 100 mg/carbidopa 25 mg (Sinemet 25/100, Merck Sharp \& Dohme) tablets; oral route.
224315049|NCT03127111|GENETIC|SNP analysis|Genomic DNA extracted from serum is used for specific SNP analysis by using sequencing. GWAS with SNPs array will be used to identify novel candidate set of predictive markers.
224315050|NCT03127111|GENETIC|Protein expression analysis|Tissue microarray made from formalin-fixed paraffin-embedded (FFPE) paired tumor and normal tissues is used for specific protein expression analysis by immunohistochemistry staining.
224315051|NCT00004186|DRUG|carboplatin|
224315052|NCT00004186|DRUG|etoposide|
224315053|NCT00004186|DRUG|ifosfamide|
224315054|NCT00004186|DRUG|topotecan hydrochloride|
224315055|NCT00004186|RADIATION|radiation therapy|
223618812|NCT02021942|DRUG|SOM230 LAR|SOM230 LAR in a dosage of 60 mg is administered i.m. once every 4 weeks.
223618813|NCT05549011|OTHER|PENG Block|PENG block for analgesic purposes performed before hip surgery
223618814|NCT05549011|OTHER|SIFI compartment block|SIFI compartment block for analgesic purposes performed before hip surgery
224315056|NCT06387524|PROCEDURE|McConnell Taping|Begin with the patient in supine lying with the knee slightly bent. The knee should be completely relaxed and a foam roller or rolled up towel under the knee. Start the tape in line with the middle of the knee cap at the outer aspect of the knee. Using your thumb on top of the sports tape, gently push the patella towards the inner aspect of the knee whilst simultaneously using your fingers to pull the skin at the inner aspect of the knee towards the patella. Finish this taping technique at the inner aspect of the knee ensuring you have created some wrinkling of the skin at the inner aspect of the knee.
224315057|NCT06387524|PROCEDURE|ECCENTRIC EXERCISES:|"Performed for 6 weeks, in 3 sets of 10-12 repetitions each day. Detailed protocol is as under:~Warm up phase (5 minutes) It will comprise of following components 5 minutes warm up exercise protocol: Marching in place while swinging your arm, rotating toe touching, walking jacks, leg swings, arm circles, shoulder shrugs Eccentric exercises: Each of the following exercise will be performed for 30 seconds, repetitions and hold time will increase with increasing weeks according to patient's stamina.~Straight leg raise, side lying hip abduction, single leg bridging, supported double leg squatting, hip hikes,supported single leg squatting Following is the detailed description of Cool down phase: Hip stretch, cat cow stretch, oblique stretch, lower back stretch, calf stretch, cross body shoulder stretch"
224315058|NCT02618525|OTHER|Supraorbital pressure|Supraorbital pressure is applied by applying pressure over the notch on the inner aspect of eyebrow.
224315059|NCT02618525|OTHER|Jaw thrust maneuver|Jaw thrust is performed by placing the index and middle fingers to physically pull the posterior aspects of the mandible upwards while their thumbs push down on the chin to open the mouth.
224315060|NCT04190758|OTHER|Care as usual|No intervention will be given. The study will follow the effects of care as usual.
224315061|NCT03414216|PROCEDURE|Group 1 early offloading surgery|As above.
224315062|NCT03414216|PROCEDURE|Group 2 - off-loading in fiberglass cast|As above.
224315063|NCT03794050|OTHER|Resistance training exercise|randomized complete crossover for acute resistance training exercise session
224315064|NCT03794050|OTHER|Aerobic training exercise|randomized complete crossover for acute aerobic exercise training exercise session
223618815|NCT05549011|DIAGNOSTIC_TEST|Numeric Rating Scale|Self-reported pain intensity score between 0-10
223618816|NCT05549011|DIAGNOSTIC_TEST|Angle of sitting|Measurement of sitting angle in degrees with a protractor
223680395|NCT01311869|DIETARY_SUPPLEMENT|EGCG ( Green Tea extract)|A randomized double-blind placebo-controlled clinical trial will be conducted with 80 women of reproductive age,the 80 women will be allocated into two groups, 40 each. Each group will be given one of two interventions: The first is 2 capsules of (EGCG which is green tea extract, taken orally with food on daily basis for 6 months, each capsule contain 326.25 mg decaffeinated EGCG,The second group will receive matched (color, taste and texture) placebo for a period of 6 months.
224315065|NCT03523455|DIETARY_SUPPLEMENT|Iron Aid IPS (Iron Protein Succinylate)|Taken orally in capsule form
224315066|NCT03523455|OTHER|Sugar Pill|Taken orally in capsule form
224315067|NCT01689779|DRUG|100,000 IU cholecalciferol|active drug
224315068|NCT01689779|DRUG|Placebo|comparator drug
224315069|NCT02899195|DRUG|Durvalumab|On Day 1 of each 21 day cycle: Durvalumab 1120 mg IV will be administered before pemetrexed and cisplatin chemotherapy over approximately 60 minutes. Approximately 30 minutes after the durvalumab infusion is complete, pemetrexed 500 mg/m² IV will be administered over 10 minutes. Cisplatin 75 mg/m² IV over 2 hours will begin approximately 30 minutes after the end of pemetrexed administration. If carboplatin is substituted for cisplatin, carboplatin Area Under the Concentration-Time Curve (AUC) 5 will be infused over 30 minutes beginning approximately 15-30 minutes after the end of the pemetrexed administration. Maintenance: On Day 1 of each 21 day cycle: Durvalumab 1120 mg IV over approximately 60 minutes.
224315070|NCT00010764|PROCEDURE|Acupuncture|
224315071|NCT00351403|DRUG|Ribavirin|Rebetol 200 mg: applied as hard capsule
223618817|NCT02798250|OTHER|Dual-hormone closed-loop|Interventions will be undertaken 1 to 5 days after sensor insertion. Subjects will be admitted at the research center at 7:00. Subject's pump will be substituted with the study pump and an additional pump containing glucagon will be installed. At 7:00, closed-loop will be initiated. At 9:00, a standardized breakfast (45g CHO) will be served. Study subjects will consume the same meal on the two intervention days. During the intervention, patients will be allowed to do sedentary activities. Patients will be allowed to consume caffeine during the intervention, but will have to replicate their caffeine consumption on both interventions. The intervention day will end at 13:00.
224315072|NCT00351403|DRUG|Peginterferon alfa 2b|PegIntron (50/80/100/120/150 microgram): applied by injection
224315073|NCT04153903|OTHER|OCT, coronary angiography, FFR|Coronary images by OCT and angiography and FFR values will be registered.
224315074|NCT00192803|DRUG|candesartan|
224315075|NCT04561271|OTHER|foot reflexology|Patients will receive one session of foot reflexology with a nurse who received a specific formation. The session lasts 15 to 20 minutes, patients seated, half seated or in supine position. A neutral oil will be used. The technique associates specific movements of foot reflexology. The session is accompanied by relaxing music.
224315076|NCT04561271|OTHER|toucher massage|one session of toucher massage with a nurse (this technique is taught during the formation of every nurse in palliative care units). The session lasts 15 to 20 minutes, patients seated, half seated or in supine position. It consists in a simple massage and effleurage, with fluid and progressive movements. Almond oil will be used. The session is accompanied by relaxing music.
224315077|NCT03838900|DEVICE|Loop|The Loop System consists of an insulin pump (certain versions of Medtronic insulin pumps) and a Dexcom or Medtronic CGM. The system includes an iPhone with the Loop app and a RileyLink to communicate between the pump and iPhone. An Apple Watch may optionally be used with the system.
224315078|NCT03758716|DRUG|FB825, FB825-15D11, Anti-CemX|Pharmaceutical form: 20mg/ml solution Route of administration: IV
224315079|NCT02206360|PROCEDURE|Endoscopic Ultrasound|
224315080|NCT02206360|PROCEDURE|Magnetic Resonance Imaging (MRI)|
224315081|NCT01998763|DIETARY_SUPPLEMENT|Placebo|placebo capsules have similar appearance and smell as 400 IU vitamin D3 capsules,
224315082|NCT01998763|DIETARY_SUPPLEMENT|Vitamin D3|Vitamin D3 2000 IU per day
224315083|NCT04520126|DIETARY_SUPPLEMENT|Olivomed (capsules containing hydroxytyrosol)|patients with stable coronary artery disease will be randomised to Olivomed or placebo for one month and then they will be crossed over to the alternate treatment for one month.
224315084|NCT04520126|DIETARY_SUPPLEMENT|OlivomedSmart - Capsules containing - combination of Oleuropein (OL), Hydroxytyrosol (HT), Oleocanthal (OC) - (OL:HT:OC 2:1:3), (5 mg HT bid).|patients with stable coronary artery disease will be randomised to combination of OL, HT, OC or placebo for one month and then they will be crossed over to the alternate treatment for one month.
224315085|NCT03156504|DRUG|Ketamine Hydrochloride|Subjects will receive three IV ketamine infusions at 0.5 mg/kg, infused over 100 minutes.
224315086|NCT04342455|OTHER|double-low scanning|a CT angiography protocol with low radiation and contrast agent exposure
224315087|NCT00450801|DRUG|Rituximab|Rituximab 375 mg/m2 IV, Days 1 of all cycles
223618818|NCT02798250|DRUG|Insulin|Participant's usual fast-acting insulin analog will be used: Lispro (Humalog), Aspart (NovoRapid) or Glulisine (Apidra).
224207400|NCT02060240|BEHAVIORAL|High Activity|The high activity group will undergo a 12 week ramped exercise protocol.
224207401|NCT06527846|DRUG|JARDIANCE®|JARDIANCE®
224207402|NCT05210998|OTHER|Gradual Aerobic exercise training AND Respiratory muscle training|Combined Exercise Group
224207403|NCT05210998|OTHER|Gradual Aerobic exercise training|Aerobic exercise Group
224315088|NCT00450801|DRUG|Cyclophosphamide|Cyclophosphamide 800 mg/m2 IV, Day 1, Cyclophosphamide 200 mg/m2 IV Days 2 - 5, Cycles 1 and 3. Cyclophosphamide will be given in 100 cc NS IV over 30 minutes.
224315089|NCT00450801|DRUG|Cytarabine|Cytarabine 2 grams/m2 IV every 12 hours x 4 doses, Days 1 and 2, Cycles 2 and 4.
224207404|NCT04127682|OTHER|Antibiotic KAP questionnaire|• Self-administered questionnaire will be used and containing following Physician information (age, sex, place of work, specialty, years of experience, place of work, and post graduate studies and trainings), Practice information (number of days for outpatient's practice/week, average number of patients /day and average percentage of children with ARIs/day), Antibiotic prescription practice (using of guidelines and causes of prescribing antibiotics in acute URIs), Knowledge about antibiotic resistance and attendance of any conference or educational activities concerned with antibiotic use during the last year, Attitude as regard antibiotic prescription.
224315090|NCT00450801|DRUG|Doxorubicin|Doxorubicin 45 mg/m2 IV bolus, Day 1, Cycles 1 and 3
224315091|NCT00450801|DRUG|Etoposide|Etoposide 60 mg/m2 IV daily x 5 days, Cycles 2 and 4
224315092|NCT00450801|DRUG|Ifosfamide|Ifosfamide 1.5 grams/m2 IV once a day (QD) x 5 days, Cycles 2 and 4
224315093|NCT00450801|DRUG|Leucovorin|Leucovorin 180 mg/m2 IV beginning 36 hours after start of methotrexate infusion and then 12 mg/m2 IV every 6 hours until methotrexate level is below 0.01 nM. Day 10, Cycles 1 and 3.
224315094|NCT00450801|DRUG|Methotrexate|Methotrexate 1,200 mg/m2 in 250 cc 5 percent dextrose in water (D5W) IV over 1 hour followed by Methotrexate 5,520 mg/m2 in 1,000 cc D5W by continuous infusion over 23 hours (240 mg/m2 every hour for 23 hours). Day 10, Cycles 1 and 3.
223618819|NCT02798250|DRUG|Glucagon|Glucagon (Eli Lilly) will be used during dual-hormone closed-loop strategy.
224207405|NCT05949931|DRUG|Concurrent penpulimab and AVD|Participants will receive Penpulimab and AVD injection at the same time for a total of 6 cycles. Cycle length = 28 days, Penpulimab and AVD will be administered on D1 and D15 of each cycle.
224207406|NCT05949931|DRUG|Sequential penpulimab and AVD|Participants will receive penpulimab for 3 cycles; follewed by 6 cycles of AVD; finally, penpulimab for 3 cycles. Cycle length = 28 days, Penpulimab and AVD will be administered on D1 and D15 of each cycle.
224207407|NCT02691312|DEVICE|Digital Retinography System|The DRS is a portable non-mydriatic fundus camera in which children place their chin on a chin rest and the camera, after auto-focusing, takes photographs of their retinas. These photographs will be examined by an ophthalmologist (specializing in retinal disease) to assess for evidence of diabetic retinopathy.
224207408|NCT00871065|DRUG|Sildenafil citrate|20 mg tablet orally every 8 hours until Day 14 post-hemorrhage
224207409|NCT00480363|PROCEDURE|Maintenance with lower doses of lenalidomide and dexamethasone|After 9 cycles of lenalidomide and dexamethasone, it follows with lower doses for maintenance
224207410|NCT00854386|DRUG|liberal fluid administration|patients in the liberal group (LG) will receive 8 ml/kg•hr of ringer lactate (RL) solution
224207411|NCT00854386|DRUG|restrictive fluid administration|Patients in the restrictive group (RG) will receive 2 ml/kg•hr of Ringer Lactate (RL) solution throughout the intraoperative period
224207412|NCT05451134|OTHER|Catecholamines|Focus on whether catecholamine exposure is associated with dysglycemia in patients with pheochromocytoma and paraganglioma
224207413|NCT06537024|PROCEDURE|RTSA|
224207414|NCT01226615|DRUG|Chondroitin sulphate (Condrosan®)|800mg (two capsules of 400mg each) taken once a day for four months
224207415|NCT01226615|DRUG|Placebo|Two placebo capsules taken once a day for four months.
224207416|NCT01738009|OTHER|Induction of flow limitation|
223618820|NCT02798250|DEVICE|Dexcom G4 Platinum glucose sensor|
223618821|NCT02798250|DEVICE|Accu Chek Combo insulin pump|
223618822|NCT01490775|BEHAVIORAL|no access to eMedonline|patients will be followed for 3 months but will not use eMedonline
223618823|NCT01490775|BEHAVIORAL|eMedonline access|patients will be given access to eMedonline use for 3 months
223618824|NCT04840446|DEVICE|Dexcom Continuous Glucose Monitoring System|Dexcom Sensor
223618825|NCT01437280|BIOLOGICAL|CGTG-102|"VP=virus particle~Dose Level 1: 3x10\^10 VP/injection~Dose Level 2: 1x10\^11 VP/injection~Dose Level 3: 3x10\^11 VP/injection~Patients will receive 4 administrations of CGTG-102 (on days 1, 4, 8, 15).~Escalation to the next dose level will occur when the safety of all 4 administrations has been evaluated at day 43 on all patients in the preceding dose level.~The total dose will be injected into up to 10 tumors injectable by either direct visualization/palpitation and/or ultrasound. Typically, the largest safely injectable tumors are chosen.~Injections will be performed by a radiologist or other trained physician. Injections will be planned based on the baseline PET-CT: only PET-positive tumors or tumor regions should be injected. Injection needles designed for percutaneous insertion into tissues will be used."
223618826|NCT00510835|PROCEDURE|Early Goal Directed Therapy (EGDT)|Subjects will have a CVC inserted for continuous monitoring of their CVP and Scv02. Early structured treatment will be provided based on subjects' CVP, mean arterial pressure (MAP) and Scv02 measurements.
223618827|NCT00510835|PROCEDURE|Protocolized Standard Care (PSC)|Routine equipment will be used to monitor subjects' blood pressure and oxygen levels. Early structured treatment is based on the subjects' systolic blood pressure and the study doctors' judgment of fluid status and perfusion status.
223618828|NCT00510835|PROCEDURE|Usual Care (UC)|Attending physicians will provide routine care to subjects. Study measurements and treatments will be based on the physicians'/sites' standard practices.
223618829|NCT04163575|BIOLOGICAL|:Anti-CD22-CAR|Cells extracted, followed by induction chemotherapy before CD22-CAR infusion (dose escalation.)
223618830|NCT03084796|DRUG|CHF 5259|Dose Response: Test one of four different doses of CHF 5259
223618831|NCT03084796|DRUG|Placebo|Placebo Control
223618832|NCT03084796|DRUG|Tiotropium Bromide 18 µg Inhalation Capsule|Active Control
224207417|NCT06515340|OTHER|Allulose Dose 1|5 gram consumed orally
224207418|NCT06515340|OTHER|Allulose Dose 2|10 gram consumed orally
224207419|NCT06515340|OTHER|Allulose Dose 3|20 gram consumed orally
224207420|NCT04249063|DRUG|Xylocaine 1 % and Normal Saline|3cc aliquots of local anaesthetic will be injected into the right and left cornual regions and centrally in the fundus. This will be achieved by using a flexible hysteroscopic needle.
224207421|NCT04249063|DRUG|Normal Saline|3cc aliquots of normal saline will be injected into the right and left cornual regions and centrally in the fundus. This will be achieved by using a flexible hysteroscopic needle.
224207422|NCT05492019|DRUG|Doxycycline|Doxycycline 50 mg capsule twice daily for 8 weeks.
224207423|NCT05492019|DRUG|Placebo|Oral placebo identical to Doxycycline
224207424|NCT03638102|BEHAVIORAL|Sleep extension|Sleep extension aims to increase sleep duration for at least 30 minutes using weekly coaching
224207425|NCT03638102|BEHAVIORAL|Healthy living|Participants will receive weekly health education
224207426|NCT05384327|OTHER|Interview|Interviews consist of semi-structured interviews focused on the theoretical knowledge a physician should possess before placing chest tube insertions.
224207427|NCT05384327|OTHER|Multiple Choice Question (MCQ) Test|"The test contains multiple choice questions based on these interviews. Participants will complete this test.~Validity evidence will be collected based on the results of this test."
224207428|NCT04215120|DRUG|Desidustat Oral Tablet|Desidustat tablet
224207429|NCT04215120|DRUG|Epoetin Alfa|Epoetin Injection
224207430|NCT03945760|DRUG|Baricitinib|Baricitinib 2 mg
224207431|NCT03945760|DRUG|Placebo|Placebo
224207432|NCT05027373|DRUG|SSGJ-613|SSGJ-613 injection is 200mg/2mL solution in a single vial.The solution is a clear to slightly opalescent, colorless to a slightly yellow tint.
224207433|NCT05027373|DRUG|Placebo|Placebo injection is 2mL excipient solution in a single vial.The solution is clear and colorless.
224207434|NCT01480882|PROCEDURE|Conventional Chest Physiotherapy (CCPT)|Conventional chest percussion will be applied for a duration of 15 minutes.
224207435|NCT01480882|DEVICE|Mechanical percussion (LEGA)|Mechanical chest percussion will be delivered by a device for 15 minutes.
224315095|NCT00450801|DRUG|Thalidomide|Maintenance therapy.
223618833|NCT00154856|BEHAVIORAL|Detect the variation of limb lengthening|
223618834|NCT05470985|DRUG|Ozanimod|Specific dose on specific days
223618835|NCT02266355|DRUG|Omalizumab|Omalizumab 300 mg SQ every 2 weeks
223618836|NCT03651037|BEHAVIORAL|Thrivors+BH|Digital health platform for breast cancer patients that measures adherence and engagement.
224207436|NCT02252484|OTHER|Weight Loss Program|Program has four main components: diet, physical activity, coaching and diet and exercise monitoring. The program is tailored to each individual in the study.
224207437|NCT02252484|OTHER|Standard of Care|Standard of Care for this patient population.
224315096|NCT00450801|DRUG|Vincristine|Vincristine 1.5 mg/m2 IVP (maximum of 2 mg), Day 1 and 8 , Cycles 1 and 3.
224315097|NCT00450801|DRUG|Mesna|Mesna 360 mg/m2 IV every 3 hours x 5 days, Cycles 2 and 4
224315098|NCT00450801|DRUG|Filgrastim (G-CSF)|G-CSF 480 mcg subcutaneous (SQ) starting Day 13 (Cycles 1 and 3), Day 7 (Cycles 2 and 4)
223618837|NCT02640638|BEHAVIORAL|CenteringPregnancy|8-12 pregnant women whose due dates are in the same month will receive ten 2-hour group prenatal care sessions according to the standard curriculum provided by the Centering Healthcare Institute.
223618838|NCT03487926|RADIATION|[18F]FEPPA|up to 3 PET Scans (\[18F\]FEPPA PET scans done 3 to 6 months apart, and one \[11C\]SL2511.88 PET scan) and 1 MRI
224207438|NCT01131702|DRUG|Ranitidine|Ranitidine Tablets, 300 mg
224207439|NCT01635686|DRUG|DWP422 25mg|
224207440|NCT01635686|DRUG|ENBREL 25MG PFS INJ.|
224207441|NCT01891786|BEHAVIORAL|Self-Management Intervention|The SMI will incorporate a discussion to introduce self-management and why it is important, and about problems associated with reducing CHD risk and managing type 2 diabetes. Specific topics addressed will include health behaviours to reduce CHD risk and manage diabetes including diet and exercise, as well as behaviours specific to managing diabetes, including medication adherence and self-care behaviours (e.g. footcare). Sessions are patient-directed and employ a shared decision-making approach, such that participants work with one another and the practice nurse facilitator to identify specific problems that they wish to address, and to identify solutions and approaches to managing their diabetes and CHD risk
224207442|NCT01891786|BEHAVIORAL|Risk Result|Participants will receive in-person personalised feedback about their combined genetic and lifestyle 10 year risk for developing CHD.
224207443|NCT02093650|DRUG|black cohosh extract|Black cohosh extract 80 mg
224315099|NCT00450801|DRUG|Granisetron|Granisetron 1 mg IV on Day 1, Cycle 1 and 3
224315100|NCT00450801|DRUG|Decadron|Decadron 10 mg IV on Day 1, Cycles 1 and 3
224315101|NCT01966250|DEVICE|electroacupuncture and usual care|"Electroacupuncture: Using 0.25 mm (diameter) X 0.40 mm (length) sized disposable stainless steel needles, electric stimulation will be applied with an electronic stimulator (ES-160, ITO co. LTD, Japan) 2 times/week × 4 weeks. Stimulation will be applied with the current in biphasic wave form. Acupuncture points are Jia-ji (Ex-B2, L3-L5; bilateral) as necessary points and reasonable points (according to decision of practitioner) as accessory points. Each session lasts 15 minutes.~Usual care: Physical therapy and patient education will be performed 2 times per week for 4 weeks. ICT lasts 15 minutes and Hot or Ice pack lasts 10minutes. Doctors will educate patient physiology, pathology, and epidemiology of low back pain. And also suitable postures and exercises for low back pain will be educated."
224315102|NCT01966250|DEVICE|Usual care|Usual care: Physical therapy and patient education will be performed 2 times per week for 4 weeks. ICT lasts 15 minutes and Hot or Ice pack lasts 10minutes. Doctors will educate patient physiology, pathology, and epidemiology of low back pain. And also suitable postures and exercises for low back pain will be educated.
224315103|NCT04677101|DIAGNOSTIC_TEST|Liver Biopsy|Fine-needle liver biopsy
224315104|NCT01423123|DRUG|Paclitaxel|80 mg/m2 IV on days 1, 8, and 15 every 28 days until disease progression.
224315105|NCT01423123|BIOLOGICAL|trastuzumab|4 mg/kg IV loading dose, then 2 mg/kg IV weekly until disease progression.
224315106|NCT01423123|DRUG|Neratinib|Dose level 1: 120 mg/day orally; Dose level 2: 160 mg/day orally; Dose level 3: 240 mg/day orally; Dose level 4: 200 mg/day orally.
224315107|NCT05963815|OTHER|Spine surgery|Patients operated with laminectomy, microscopic discectomy, percutaneous transforaminal endoscopic discectomy, and spondylodesis.
224315108|NCT00004126|DRUG|oxaliplatin|
224315109|NCT00004126|DRUG|paclitaxel|
224315110|NCT05186649|OTHER|WARFARIN|5 mg of daily dosage
224315111|NCT02372279|OTHER|Embryo observation|In EO group, conventional observations will be made.
224315112|NCT02435732|DRUG|Placebo saline solution|saline solution
224315113|NCT02435732|DRUG|Heparin|Added to the one of the arms receiving 200U/kg dose of CINRYZE
224315114|NCT02435732|DRUG|CINRYZE|200U/kg IV dose with or without heparin, or 500U/kg IV dose
224315115|NCT00587860|DRUG|St. John's wort|Dosage form: Tablet (450 mg) Dose: 450 mg twice a day, placebo twice a day
224315116|NCT00587860|DRUG|Placebo|Dosage form: Tablet (450 mg) Dose: 450 mg twice a day, placebo twice a day
223618839|NCT05061511|OTHER|Analysis of inflammasome expression|RNA isolation, spectrophotometric quantification, reverse transcription to cDNA and relative quantification of gene expression using a quantitative reverse transcription polymerase chain reaction (qRT-PCR). Specific inflammasome-related transcripts will be investigated, including ASC, caspase-1, IL-1beta, IL-18, NLRP3, NLRP2, AIM2, POP1, POP2, CARD16, CARD18, TRIM16, and TRIM20. A qRT-PCR System (e.g. StepOne Plus, Applied Biosystems) will be used for the amplification and analysis of the PCR products. Expression data will be reported as the ratio between each investigated target gene and GAPDH (used as housekeeping endogenous control).
223680396|NCT01311869|DIETARY_SUPPLEMENT|Brown rice pills|40 subjects will receive 800 mg EGCG orally daily for 6 months, the other 40 subject will receive brown rice pills for the same duration.
224207444|NCT02093650|DRUG|Placebo|Soy bean oil
224207445|NCT06514118|RADIATION|residual tumor irradiation|lung residual tumor will be given external beam irradiation for 50GY in 25 fractions in total
224207446|NCT06087302|BEHAVIORAL|child-Parent Relationship Therapy (CPRT)|The Child Parent Relationship Therapy (CPRT) is an evidence-based intervention program that trains parents/caretakers to help their children with social, emotional, attachment, and behavioral difficulties
224315117|NCT06582394|COMBINATION_PRODUCT|Exp Group|Balance and coordination were targeted through virtual stepping tasks, where participants practiced stepping in various directions to improve postural control and lower limb function. Additionally, they performed virtual balance exercises by standing on simulated platforms of varying stability. For gait and mobility, participants practiced walking in a virtual environment with real-time feedback to correct gait abnormalities. They also encountered virtual obstacles, which required them to adapt their walking patterns and improve mobility. In this study, both the intervention and control groups underwent a 6-week treatment plan consisting of 5 sessions per week, with each session lasting 45 minutes.
224315118|NCT06582394|OTHER|Control group|For gait training, participants practiced walking on flat surfaces, sometimes with the assistance of parallel bars or walking aids, to improve their walking speed, step length, and rhythm. They also performed sit-to-stand exercises to strengthen the lower limbs and improve mobility for daily activities. Additionally, manual therapy techniques, such as joint mobilizations and stretching, were applied to reduce spasticity and increase range of motion in the affected limbs. Both treatment groups progressed based on individual capabilities, with therapists adjusting exercises accordingly throughout the study. In this study, both the intervention and control groups underwent a 6-week treatment plan consisting of 5 sessions per week, with each session lasting 45 minutes.
224315119|NCT05081986|DEVICE|Transcranial Magnetic Stimulation|Single-pulse transcranial magnetic stimulation and theta-burst stimulation
224315120|NCT05081986|DRUG|Cycloserine|Cycloserine 100mg
224315121|NCT05081986|DRUG|Placebo Oral Tablet|Placebo capsule matched to cycloserine capsule
224315122|NCT04283019|DRUG|CBD|CBD will be orally ingested
224315123|NCT04283019|DRUG|THC|THC will be orally ingested
224207447|NCT05267184|PROCEDURE|Endovascular treatment of the middle meningeal artery|The middle meningeal artery on the same side(s) as the chronic subdural hematoma is embolized with liquid embolic agents.
224315124|NCT03536741|PROCEDURE|TAP block and RS block + General Intravenous Anesthestic|transversus abdominis plane block and rectus sheath block
224315125|NCT03536741|DRUG|General Intravenous Anesthetic|General Intravenous Anesthetic
224315126|NCT04205058|DIETARY_SUPPLEMENT|Standard coffee|One 30 mL espresso cup administered twice a day (08.00 a.m. and 02.00 p.m.).
224315127|NCT04205058|DIETARY_SUPPLEMENT|Caffeine-free coffee|One 30 mL espresso cup administered twice a day (08.00 a.m. and 02.00 p.m.).
224315128|NCT04205058|DIETARY_SUPPLEMENT|Drinking water|One 30 mL espresso cup administered twice a day (08.00 a.m. and 02.00 p.m.).
224315129|NCT00261443|DRUG|Lithium or Valproate with placebo (PBO)|"Tablets, Oral, once daily~lithium 250-2100 mg/day~valproate 250-2500mg/day~Placebo once daily"
224315130|NCT00261443|DRUG|Lithium or Valproate with Aripiprazole|"Tablets, Oral, once daily, 52 weeks post randomization (Pre-Randomization Phases 13-24 weeks)~lithium 250-2100 mg/day~valproate 250-2500mg/day~aripiprazole 15-30 mg/day"
223618840|NCT05061511|OTHER|Histological analysis|"gingival tissue samples will be prepared for paraffin inclusion and different stains will be used to evaluate the histological features of the tissues, distribution of inflammatory cells and alignment of collagen fibers.~Moreover, a trained examiner will assess semi-quantitatively the inflammatory infiltrate under light microscopy.~The expression of inflammatory/immune-related proteins such as NLRP3, ASC-2, IL-1beta and IL-18 protein expressions will be compared among the three groups by immunodetection methods"
223618841|NCT02870283|DRUG|Lithium|
223618842|NCT02870283|DRUG|Valproic Acid|
223618843|NCT02870283|DRUG|Carbamazepine|
223618844|NCT02374151|DEVICE|Electrohysterography|The EHG uses a Graphium electrode patch that is applied to the abdomen and records electrical activity non-invasively
223618845|NCT02741245|DRUG|Ezetimibe 10 mg|
223618846|NCT02741245|DRUG|Rosuvastatin 2.5 mg|
223618847|NCT02741245|DRUG|Placebo for Ezetimibe|
223618848|NCT02741245|DRUG|Placebo for Rosuvastatin|
223618849|NCT01685567|DEVICE|MICHI NPS+f|Cerebral protection with carotid flow reversal
224207448|NCT05267184|PROCEDURE|Standard neurosurgical hematoma evacuation|Standard neurosurgical evacuation of chronic subdural hematoma through burr-hole or mini craniotomy and postoperative subdural or subgaleal drainage.
224207449|NCT00116259|DRUG|Aripiprazole|
224207450|NCT04934332|PROCEDURE|Ultrasound|Ultrasound examination at 1 week and 5 weeks after admission.
224207451|NCT04934332|PROCEDURE|CT scan|CT scan at 5 weeks after admission. CT scan reader will be blinded to clinical data.
224207452|NCT04934332|PROCEDURE|Clinical examination|Weekly clinical examination from week-2 to week-5.
224207453|NCT04300907|DEVICE|Provant Infinity Therapy System|Treatment with the Provant Infinity Therapy System, PEMF device
224207454|NCT05394428|OTHER|No intervention|No intervention
224207455|NCT02172183|DRUG|Psychopharmacological treatment|methylphenidate or atomoxetine
224207456|NCT02172183|BEHAVIORAL|CBT group|
224315131|NCT02373449|OTHER|RS-fMRI|Resting State-functional Magnetic Resonance Imaging. Protocols involving BOLD (blood oxygen level-dependent) and non-BOLD techniques will be used.
224315132|NCT02373449|DRUG|Ketamine|Part of standard care. To be performed over five consecutive days (Monday to Friday) for six hours per day. A therapeutic range of 0.5 to 2.0 mg/kg/hour is targeted.
224315133|NCT00154752|PROCEDURE|CCRT, Pelvic lymphadenoectomy.|
224315134|NCT02711878|BEHAVIORAL|Let's Move Program|Participants will be asked to walk five times per week for twelve weeks for a minimum of 30 minutes while wearing a heart rate monitor and a pedometer. Participants will also receive weekly telephone calls from a member of the research team to monitor walking progress and to change walking duration or intensity level based on their progress.After the twelve week period, participants will enter a maintenance exercise phase for weeks 13-17 in which they will be asked to maintain their exercise regimen.
224315135|NCT02711878|BEHAVIORAL|Let's Flex Program|Participants will be asked to stretch five times per week for twelve weeks for a minimum of 30 minutes. Participants will also receive weekly telephone calls from a member of the research team to monitor progress and to change duration or intensity level based on their progress.After the twelve week period, participants will enter a maintenance exercise phase for weeks 13-17 in which they will be asked to maintain their exercise regimen.
223618850|NCT06483724|PROCEDURE|cervical tourniquet|"After opening the abdominal wall, To reduce bleeding during PAS, make the uterine incision above the placenta's intrauterine borders .~2-investigators extract the uterus from the abdomen 3-An assistant slides a sterile Foley catheter (Ch 16/18 French) down to the lowest point and secures it en bloc around the cervix 4-The bladder peritoneum is isolated from the uterus 5-To remove myometrial tissue, leave a margin of at least 2 cm superior to the cervical internal ostium using electrocautery or scissors ."
223618851|NCT06483724|PROCEDURE|uterine artery ligation|"After opening the abdominal wall, To reduce bleeding during PAS, make the uterine incision above the placenta's intrauterine borders .~2-investigators extract the uterus from the abdomen 3-The bladder peritoneum is isolated from the uterus 4-The uterine vessels were ligated in continuity at the level of the utero-vesical fold on each side 5-To remove myometrial tissue, leave a margin of at least 2 cm superior to the cervical internal ostium using electrocautery or scissors ."
223618852|NCT03123666|DRUG|GMCSF|GM CSF (Sargamostatim-250mcg/M2) over 4 hour and inhalation of same dose by micronebulizer
223618853|NCT03123666|OTHER|Placebo|Placebo identical to GMCSF will be given
224207457|NCT06438354|BIOLOGICAL|subgingival instrumentation plus Perisolv / hyaDent BG|Group A: Perisolv is applied prior to subgingival instrumentation for disinfecting purpose, hyaDent BG seals the site for accelerated blood clot stabilisation and support of cell proliferation.
224207458|NCT06438354|PROCEDURE|subgingival instrumentation|Group B: sites requiring re-treatment are subjected to subgingival scaling
224207459|NCT06540157|OTHER|Binaural Beat Music (BBM) Combined with Rhythmic Photic Stimulation (RPS)|Participants rested on a chair for 10 minutes before the intervention. Participants wore over-ear stereo headphones and RPS glasses, receiving 20 minutes of 10Hz BBM (embedded with classic old songs as mask music) and RPS. The BBM and RPS glasses were purchased from George Szeless's mindLightz.
224207460|NCT06540157|OTHER|Sham group|Participants rested on a chair for 10 minutes before the intervention. Participants wore the same headphones and RPS glasses as the BBM and RPS group but listened to classic Taiwanese old songs without the 10Hz light stimulation from the RPS glasses.
224207461|NCT01048268|DRUG|glucose-dependent insulinotropic polypeptide|"For the first 20 min of the experiment the volunteers will receive GIP at 4 pmol/kg body weight.~For the following 40 minutes the volunteers will receive 2 pmol/kg body weight"
224207462|NCT01048268|DRUG|Placebo|copy GIP infusion rates
224207463|NCT02498899|BEHAVIORAL|Questionnaires|Participants complete questionnaires at baseline, after watching a video, and after reading a story about the patient in the video.
224207464|NCT02498899|BEHAVIORAL|Video|Participants watch a video lasting about 4 minutes.
224207465|NCT03578276|DRUG|Pred-Gati-Brom|The combination drop therapy containing prednisolone acetate 1%, gatifloxacin 0.5%, and bromfenac 0.075%
224207466|NCT03578276|DRUG|Prednisolone acetate 1% ophthalmic suspension|Steroidal anti-inflammatory
224207467|NCT03578276|DRUG|Gatifloxacin Ophthalmic|Antibiotic
224207468|NCT03578276|DRUG|Bromfenac 0.075% Oph Solution|Non-steroidal anti-inflammatory
224207469|NCT00923494|DRUG|20 ml of ropivacaine 0.5%|Patient will receive 20 ml of ropivacaine 0.5% for their ultrasound guided supraclavicular block.
224207470|NCT00923494|DRUG|30 ml of ropivacaine 0.5%|Patient will receive 30 ml of ropivacaine 0.5% for their ultrasound guided supraclavicular block.
224207471|NCT00923494|DRUG|40 ml of ropivacaine 0.5%|Patient will receive 40 ml of ropivacaine 0.5% for their ultrasound guided supraclavicular block.
224207472|NCT00037973|BEHAVIORAL|ventilation feedback|
224207473|NCT00037973|BEHAVIORAL|exercise|
224207474|NCT05774873|DRUG|IBI334 D|Subjects will receive IBI334 D once a week during the first 28-day cycle (QW, 4 weeks), then biweekly (or other dose intervals recommended by the Investigator and Sponsor based on safety, toxicity and PK data), until disease progression, toxicity intolerance, withdrawal of consent, occurrence of other reasons for discontinuing study therapy, or treatment duration reaches 24 months, whichever occurs first.
224207475|NCT05774873|DRUG|IBI334 C|Subjects will receive IBI334 C once a week during the first 28-day cycle (QW, 4 weeks), then biweekly (or other dose intervals recommended by the Investigator and Sponsor based on safety, toxicity and PK data), until disease progression, toxicity intolerance, withdrawal of consent, occurrence of other reasons for discontinuing study therapy, or treatment duration reaches 24 months, whichever occurs first.
224207476|NCT05774873|DRUG|IBI334 A|Subjects will receive IBI334 A once a week during the first 28-day cycle (QW, 4 weeks), then biweekly (or other dose intervals recommended by the Investigator and Sponsor based on safety, toxicity and PK data), until disease progression, toxicity intolerance, withdrawal of consent, occurrence of other reasons for discontinuing study therapy, or treatment duration reaches 24 months, whichever occurs first.
224207477|NCT05774873|DRUG|IBI334 B|Subjects will receive IBI334 B once a week during the first 28-day cycle (QW, 4 weeks), then biweekly (or other dose intervals recommended by the Investigator and Sponsor based on safety, toxicity and PK data), until disease progression, toxicity intolerance, withdrawal of consent, occurrence of other reasons for discontinuing study therapy, or treatment duration reaches 24 months, whichever occurs first.
224207478|NCT05774873|DRUG|IBI334 F|Subjects will receive IBI334 F once a week during the first 28-day cycle (QW, 4 weeks), then biweekly (or other dose intervals recommended by the Investigator and Sponsor based on safety, toxicity and PK data), until disease progression, toxicity intolerance, withdrawal of consent, occurrence of other reasons for discontinuing study therapy, or treatment duration reaches 24 months, whichever occurs first.
223618854|NCT00323141|DEVICE|Ventralex versus Leight Weight Vypro II prothesis|Ventralex and Leight Weight Vypro II prothesis are compared.
223618855|NCT05839171|BEHAVIORAL|music and mandala coloring|Listening to music and coloring mandalas for women who have undergone embryo transfer and are waiting at home
223618856|NCT06028997|BEHAVIORAL|Behavioral and Sleep Hygiene Education with Mindfulness Intervention|Education about good sleep hygiene practices and behavior advice to improve sleep based on current literature for 10-15 minutes/week followed by 50 minutes of yoga Nidra and breathing excersices
223618857|NCT04808817|DIAGNOSTIC_TEST|calorimetry, impedance measurement at baseline and after 3 months of treatment|biobanking (30ml) for cytokines and complement dosages at baseline and after 3 months of treatment calorimetry and impedance measure will be collected at baseline and after 3 months of ICI treatment
223618858|NCT06426472|OTHER|Web-based support program|Web-based support program for infertile women with failed IVF experience
224315136|NCT02711878|BEHAVIORAL|Group Motivational Interviewing|Participants will attend four separate group intervention sessions for 2.5 hours for four consecutive weeks at the beginning of the program. Groups will consist of 6-8 members and will focus on the rationale for aerobic exercise, barriers to exercise, finding time for exercise, how to set short and long term exercise goals, and use of self-monitoring to improve exercise engagement.
223618859|NCT00607087|DRUG|Insulin glulisine|100 U/ml, administration by Continuous Subcutaneous Insulin Infusion with external pump
223618860|NCT00607087|DRUG|Insulin lispro|100 U/ml, administration by Continuous Subcutaneous Insulin Infusion with external pump
223618861|NCT00607087|DRUG|Insulin aspart|100 U/ml, administration by Continuous Subcutaneous Insulin Infusion with external pump
223618862|NCT02173080|OTHER|PLD-Q|polycystic liver disease questionnaire
224315137|NCT05237778|BEHAVIORAL|Imagery Rehearsal Therapy and Targeted memory reactivation during REM sleep|Emerging evidence shows that REM sleep plays a causal role in extinction learning, emotion regulation and consolidation of emotionally positive memories. By using targeted memory reactivation (TMR), a known method where we associate a sound with a waking experience (i.e., a positive outcome of imagery rehearsal therapy in this study) and strengthening it during REM sleep, we want to accelerate the remission of nightmares.
223618863|NCT05455528|DIAGNOSTIC_TEST|estimated GFR calculation|The estimated GFR is computed with Modification of Diet in Renal Disease (MDRD) formula
224207479|NCT05774873|DRUG|IBI334 E|Subjects will receive IBI334 C once a week during the first 28-day cycle (QW, 4 weeks), then biweekly (or other dose intervals recommended by the Investigator and Sponsor based on safety, toxicity and PK data), until disease progression, toxicity intolerance, withdrawal of consent, occurrence of other reasons for discontinuing study therapy, or treatment duration reaches 24 months, whichever occurs first.
224207480|NCT06521034|DRUG|FHND-9041|"In Phase I, using a 3+3 design, dose escalation and expansion studies were conducted at doses of 40, 80, 120 and 180 mg/day. At least 3 patients were enrolled in each dose arm, and no dose-limiting toxicities were observed. With a plateau observed at 120 mg/day, the 80 mg/d and 120mg/d groups were selected for dose expansion. The 80mg/d queue has expanded by 36 patients, and the 120mg/d queue has expanded by 39 patients. In Phase Ⅱ, after comprehensive analysis and consultation, at least 30 patients were enrolled according to the inclusion and exclusion criteria. 37 patients with locally advanced or metastatic EGFR-mutated NSCLC receiving first-line treatment were enrolled."
224207481|NCT04904432|GENETIC|PLIN1 gene sequencing|One supplementary blood sample will be taken (compare to classical ACS treatment and follow up) to realize genetic analyse of PLIN1 gene, looking for mutations
224207482|NCT01986400|BEHAVIORAL|Virtual Peer-to-Peer Support Mentoring|The mentorship program will encourage mentored participants to develop and engage in self-management and transition skills and support their practice of these skills. The mentors will present information to mentored participants in a monitored virtual interaction using Skype for 8 weeks (10 total Skype sessions of 30-60 minutes each) to encourage participation in skill building tailored to their needs. All mentors will complete a paid 2.5 day training course and will be supported throughout the duration of the study (consultations with research staff to deal with unforeseen concerns). Mentored participants will complete online outcome measures prior to randomization (T1) and upon study completion (T2).
224207483|NCT06147609|DEVICE|lower lingual holding arch space maintainer|lower lingual holding arch space maintainer is an orthodontic device which connects two molars lower dental arch. it has an archwire, adapted to the lingual side of the lower anterior teeth, that soldered to the bands on first permanent molar
224207484|NCT06147609|DEVICE|Removable partial denture space maintainer|Removable Partial Denture consists of a pink or gum-colored plastic base to which the new, artificial, replacement teeth are attached to. a metal framework holds the denture in place inside the mouth
224207485|NCT05715788|DRUG|Nitric oxide|Nitric oxide inhalation at 20 ppm
224207486|NCT05715788|BEHAVIORAL|prone positioning|vatilation in prone position
223618864|NCT03499093|OTHER|OES|"The first seven items of OES refer to face, facial profile, mouth, teeth alignment, teeth form, teeth color and gums. They are combined into an OES summary score ranging from 0 to 70. The eight item of OES is an overall impression item and is not included in the summary score.~Internal Consistency was determined using Cronbach's alpha and inter-item correlation for the OES scores (n=140).~Test-Retest Reliability was assessed using Intraclass Correlation Coefficient. Patients with prosthetic needs (n=20 PP-E subjects and n=15 PP-NE subjects) completed twice the OES-F at an interval of two weeks.~Convergent validity was assessed by comparing mean OES summary scores evaluated by participant of the esthetic group (PP-E, n=35) and by an expert group. Expert OES score were based on three photographs of each participant.~Discriminative validity was tested by comparing the OES summary scores using a one-way ANOVA and Scheffe post hoc test."
223618865|NCT04451499|OTHER|Smartphone app|The study specific smartphone app site will be based on current literature plus investigators experience and will include a wide knowledge on types of surgeries, dietary guidelines pre- and post-surgery, fluids type and amount, knowledge on supplementation use pre and post-surgery, general dietary knowledge, psychological information, physical activity, recommendation and tips for long-term surgery success, emphasis will be made on long-term follow-up meetings with the bariatric team and practical information on the preparation to the hospitalization process. The smartphone app site will contain video-based modules and encouraging messages. Patients will be encouraged to use the platform to ask questions and receive answers regarding any aspect of the surgery.
223618866|NCT01597336|PROCEDURE|Tissue plasminogen activator abscess flush|Thirteen ml of 10% tPA in saline at time of drain and twice daily thereafter.
224207487|NCT00981409|DRUG|Fondaparinux sodium|The dose of Fondaparinux will be determined based on a subject's body weight (\<50 kg, 5 mg; 50 to 100 kg, 7.5 mg; \>100 kg, 10 mg) and administered once daily by subcutaneous (SC) injection.
224207488|NCT00981409|DRUG|unfractionated heparin (UFH)|UFH therapy will be started on Day 1 while adjusting activated partial thromboplastin time (aPTT) to maintain aPTT 1.5 to 2.5 times control.
224315138|NCT05237778|BEHAVIORAL|Imagery Rehearsal Therapy|These patients will receive the classic treatment of Imagery Rehearsal Therapy (IRT) for nightmares without any association with a sound.
224315139|NCT01085071|DRUG|Potassium Chloride|KCl is continuously administered and titrated towards a Normal-high Potassium (4.5 mmol/L)
224315140|NCT01085071|DRUG|Potassium Chloride|KCl is continuously administered and titrated towards a Normal-low Potassium (4.0 mmol/L)
223618867|NCT01597336|PROCEDURE|Saline flush of abscess|Thirteen ml of saline is used to flush abscess at time of drain placement and twice daily thereafter.
223618868|NCT02647437|DRUG|Levetiracetam|
223618869|NCT02647437|DRUG|Placebo|
223618870|NCT04423055|DRUG|Etonogestrel contraceptive implant|Place etonogestrel contraceptive implant.
223618871|NCT00700440|DRUG|C225 (cetuximab)|one week before and then weekly during radiotherapy
223618872|NCT01673997|DRUG|Metoprolol Succinate|Metoprolol Succinate ER Tablets 200 mg
223618873|NCT00154297|DRUG|Everolimus (RAD001)|
224207489|NCT02465710|PROCEDURE|Pelvic organ prolapse surgery without mesh|retrospective study
224207490|NCT02465710|PROCEDURE|Pelvic organ prolapse surgery with mesh|
224207491|NCT03153059|OTHER|Stool frequency|This study is just observational study.
224207492|NCT00390949|BEHAVIORAL|Peer education among commercial sex workers and clients|
224207493|NCT00390949|BEHAVIORAL|Condom distribution and promotion|
224207494|NCT00390949|PROCEDURE|Syndromic treatment of sexually transmitted infections|
224207495|NCT00390949|PROCEDURE|Systemic counselling for STI patients|
224207496|NCT04765254|OTHER|no intervention as it is an observational study|both groups will be monitored for the disease progress or deterioration and mortality rate
224207497|NCT02556931|DRUG|Fludarabine|Days -6 through -2: 30 mg/m\^2 IV daily
224207498|NCT02556931|DRUG|Cyclophosphamide|Days -6 and -5: 14.5 mg/kg IV daily Days 3 and 4: 50 mg/kg IV daily
224207499|NCT02556931|RADIATION|Total body irradiation|Day -1: 200 cGy in a single fraction
224207500|NCT02556931|DRUG|Tacrolimus|Start on Day 5 through either Day 60 or Day 90 depending on cohort assignment. May be continued through Day 180 depending on GVHD status.
224207501|NCT02556931|DRUG|Mycophenolate mofetil|Days 5 through 35: 15 mg/kg PO three times daily (max 3 g/day)
224207502|NCT06127004|OTHER|Metacognitive Training for Negative Symptoms (MCT)|See arm/group descriptions
224207503|NCT06127004|OTHER|Supportive Counselling|Se arm/group descriptions
224207504|NCT02987504|DRUG|Samalizumab|Samalizumab is a humanized, anti CD200 monoclonal antibody provided as a sterile 5 mg/milliliters (mL) solution for IV administration.
224207505|NCT03150134|DRUG|Cyclosporine|Patients with advanced AML received early tapering of immunosuppressive drugs(Cyclosporine)
224207506|NCT03150134|DRUG|routine reduction of immunosuppressive drugs(cyclosporine)|patients with AML in CR were given the routine reduction of immunosuppressive drugs(cyclosporine)
224207507|NCT00323635|DRUG|tolterodine|tablet, 4 mg, daily, 1 month
224207508|NCT03361917|DEVICE|Endocuff Vision|Subjects that are randomized to undergo their colonoscopy procedure with the Endocuff Vision device will have the device placed on the colonoscope that will be used during their procedure.
224207509|NCT01558869|DRUG|Capecitabine|1200 mg/m2 BD orally for 1 week of a 2-week cycle (i.e. 1 week on, 1 week off)
224207510|NCT01558869|DRUG|Oxaliplatin|70 mg/m2 IV on day 1 of a 2-week cycle
224207511|NCT01558869|DRUG|Irinotecan|130 mg/m2 IV on day 1 of a 2-week cycle
224207512|NCT03162016|PROCEDURE|transplants|Transplant of palatine tissue and transplant of connective tissue Mucoderm
224207513|NCT06260319|GENETIC|Whole genome sequencing and Genome-Epigenome-Phenome Associations|"* Whole genome sequencing (WGS) and bioinformatics analysis~* Functional validation~* Genome-Epigenome-Phenome Associations"
224207514|NCT01653223|DRUG|simvastatin|"In short statin group: 20 mg per day, start at 5-7 days before surgery and continue for 7 days.~In long statin group: 20 mg per day, start at 5-7 days before surgery and continue for 6 months."
224207515|NCT00774202|DRUG|Rituxan, Cyclophosphamide, Vincristine, Prednisone|'Rituximab, Cyclophosphamide, Vincristine, Prednisone interventions are as follows: Rituximab will be administered as an IV infusion at the standard dose of 375 mg/m2 for 4 doses. However, the schedule of the infusions will be different than the usual one: Rather than administrating the 4 doses once weekly, the first infusion will be given 5 days (± 3 days) prior to the first infusions of C and V and oral P, and the following 3 rituximab infusions will be given on the same day as the 3 cycles of C, V, and P.
224207516|NCT00774202|DRUG|Higher Dose of Rituximab|rituximab 750mg/m2 (twice the standard dose of 375mg/m2) will be given weekly for 4 weeks. Premedication and infusion rate escalation will be exactly the same as for standard dose rituximab. The additional dose will thus run at 400ml/hr.
224207517|NCT05330143|DRUG|ASC22 1mg/kg|ASC22 single-dose of 1mg/kg vials administered subcutaneously once 4 week.
224207518|NCT05330143|DRUG|ASC22 2.5mg/kg|ASC22 single-dose of 2.5mg/kg vials administered subcutaneously once 4 week.
224207519|NCT05330143|DRUG|Antiretroviral Therapy|standard antiretroviral therapy including Integrase inhibitors (INSTIs)
223618874|NCT00650767|DRUG|ARRY-438162, MEK inhibitor; oral|multiple dose, single schedule
223618875|NCT00650767|DRUG|Placebo; oral|matching placebo
224207520|NCT05330143|DRUG|Placebo|0.9% saline vials administered subcutaneously once 4 week.
224207521|NCT05695079|OTHER|No cooling (control)|Participants are exposed to 36°C, 45% relative humidity for 8 hours without cooling intervention (control condition). Drinking water is available ad libitum. Participants are seated throughout exposure, except for during 10 min periods of simulated activities of daily living (light stepping at 2-2.5 METS) performed at hours 1, 3, 5, and 7.
224207522|NCT05695079|OTHER|Electric fan (low airflow)|Participants are exposed to 36°C, 45% relative humidity for 8 hours without cooling interventions (control condition). Drinking water is available ad libitum. Participants are seated throughout exposure, except for during 10 min periods of simulated activities of daily living (light stepping at 2-2.5 METS) performed at hours 1, 3, 5, and 7. While participants are seated, an electric pedestal fan positioned 1 m away will deliver a continuous airflow of 2 m/s to the front of the body.
223618876|NCT01302353|DRUG|Emulsified Isoflurane|
223618877|NCT05396053|OTHER|Physical therapy exercises|Three times a week for 12 weeks.
223618878|NCT05396053|OTHER|Mirror therapy|Three times a week for 12 weeks.
223618879|NCT05396053|OTHER|Constraint Induced Movement Therapy|Three times a week for 12 weeks.
223618880|NCT02273661|DRUG|Liposomal amphotericin B (Ambisome®)|An aerosol of Liposomal Amphotericin B (Ambisome®) at 25 mg x 1/ week will be administered during 6 months
223618881|NCT02273661|DRUG|placebo|An aerosol of isotonic saline x 1/ week will be administered during 6 months
224315141|NCT04175288|OTHER|Ultrasound, manual therapy and exercise|The experimental group will receive ultrasound (US) for 3 sessions a week for 4 weeks, with continuous US (1.8 w/cm2, 1 Mega Hz 8 minutes). Manual therapy will include posterior glides to talocrural joint, subtalar lateral glide, a 1st tarsometatarsal joint dorsal glide and extension mobilization to the 1st metatarsophalangeal joint. All participants in each group will be given specific exercises by the investgators targeting intrinsic and extrinsic muscles of the foot and ankle. Specific stretches for the plantar fascia and Achilles tendon, will be performed. Home exercises will be recorded using a log.
224315142|NCT01049178|DRUG|Oral Silymarin|Dose Level 1: 1 capsules (1 cap at 140mg/cap) given three times per day for a total daily dose of 420 mg 28-days post Dose Level 1 Dose Level 2: 3 capsules (3 caps at 140mg/cap = 420 mg) given three times per day for a total daily dose of 1260 mg Day 56 (28-days post Dose Level 2) Dose Level 3: 5 capsules (5 caps at 140mg/cap = 700 mg) given three times per day for a total daily dose of 2100 mg Day 84 (28-days post Dose Level 3) We will evaluate change from baseline at each dose to determine the minimum effective dose.
224315143|NCT01049178|DRUG|Oral Silymarin, maintenance dose|The maintenance Silymarin dose will be selected based on the dose escalation study and will be dosed PO three times daily as recommended. Silymarin will be provided as a capsule S. marianum (70-80% silymarin), along with an identical appearance placebo capsule created by our investigational pharmacyAt each visit a questionnaire regarding daily symptoms and disease control, the asthma control test (ACT) will be completed, eNO measured, urine collected, spirometry (lung function) measured, venipuncture performed for blood collection (20 mL), as well as assessment of acceptability, toxicity, and masking.
224315144|NCT01049178|DRUG|Placebo|
224315145|NCT03541928|DRUG|HSV-Tk|"Injection of the HSV-tk gene therapy product in four quadrants of prostate to enhance the immune system via bystander effect in which cytotoxicity is conferred to non-transduced neighboring cells. In vivo bystander effects are likely due to a combination of host immunological responses and to gap junction-mediated transport of phosphorylated prodrug metabolites to surrounding cells."
224315146|NCT03541928|DRUG|Valacyclovir|The recommended dose for this trial is 2 g orally t.i.d. for 14 days (day 1 to day 15 and days 31 to 45). This dose has been calculated to give a similar AUC as 10 mg/kg of intravenous acyclovir administered every 8 hours. This is the same dose regimen used in a previous phase I clinical trial of ADV/HSV-tk plus acyclovir and topotecan in patients with recurrent ovarian cancer.
224315147|NCT03541928|DRUG|Bicalutamide|"The recommended dose for Bicalutamide therapy in combination with an LHRH analogue is one 50 mg tablet once daily (morning or evening), with or without food. It is recommended that Bicalutamide be taken at the same time each day.~The use of an oral antiandrogen with medical castration for the treatment of prostate cancer is referred to as combined androgen blockade (CAB). Compared with LHRH-agonist monotherapy, CAB with bicalutamide did not reduce overall QoL but provided an early improvement in QoL related to lower urinary tract symptoms and pain."
224315148|NCT03541928|DRUG|Leuprolide Acetate|Leuprolide acetate 7.5 mg depot injection will be injected monthly for a total of 2 months.
224315149|NCT03541928|RADIATION|Brachytherapy, External beam radiotherapy|On day 60, patient will undergo high dose rate (HDR) Brachytherapy. The patient will have 8-14 needle catheters inserted under ultrasound guidance. CT simulation and radiation treatment planning will be performed. The needle catheters will be connected to an HDR afterloader containing an Iridium 192 source. A single dose of 1250cGy will be delivered.
224315150|NCT03541928|PROCEDURE|Radical prostatectomy|approximately 2-3 weeks after radiotherapy completion, patient will undergo radical retropubic prostatectomy. Use of laparoscopy or robotic assistance will be at the urologist's discretion. Lymph node dissection will be performed.
224207523|NCT05695079|OTHER|Electric fan (high airflow)|Participants are exposed to 36°C, 45% relative humidity for 8 hours without cooling interventions (control condition). Drinking water is available ad libitum. Participants are seated throughout exposure, except for during 10 min periods of simulated activities of daily living (light stepping at 2-2.5 METS) performed at hours 1, 3, 5, and 7. While participants are seated, an electric pedestal fan positioned 1 m away will deliver a continuous airflow of 4 m/s to the front of the body.
224207524|NCT05200806|OTHER|Non-Narcotic ERAS Post-Operative Pain Management|As described previously.
224207525|NCT00646100|PROCEDURE|transcatheter arterial chemoembolization|chemo-lipiodolization with EADM 50mg, Lobaplatin 50mg, and MMC 6mg,plus particleembolization.
224207526|NCT03903952|DIETARY_SUPPLEMENT|Vitamin B12 and folate|Vitamin B12 and folate levels in blood
224207527|NCT00150475|PROCEDURE|Powered Air purifying respirator|
224315151|NCT01289483|DRUG|fospropofol|After the initial bolus dose of study drug is given, a maximum of two supplemental doses of fospropofol at 25% of the initial dose will be permitted. Fospropofol supplements will be administered every 4 min
224315152|NCT01289483|DRUG|fospropofol|After the initial bolus dose of study drug is given, a maximum of two supplemental doses of fospropofol at 25% of the initial dose will be permitted. Fospropofol supplements will be administered every 4 min
223618882|NCT05944679|RADIATION|No Xray|Just one Xray 12 months after the intervention
223618883|NCT05944679|RADIATION|Xray|Xray at 1, 3, 6 and 12 months after intervention
223618884|NCT01774799|BEHAVIORAL|Advance care planning intervention|
223618885|NCT01774799|OTHER|Control group|
224207528|NCT00654888|PROCEDURE|ALK (automated lamellar keratectomy)|ALK is performed with a microkeratome, to make a free cap.
224207529|NCT00654888|DRUG|Mitomycin|mitomycin 0,02%, 30 seconds after ALK
223618886|NCT00387296|DEVICE|functional microarray|functional microarray application
223618887|NCT02548208|DEVICE|Verum focused extracorporeal shockwave|the concentrated shockwave energy per unit area (energy flux density EFD) can vary from 0.06 to 0.09 mJ/mm2. The pulse ratio per point is 200.
223618888|NCT02548208|DEVICE|Sham shock wave|Sham shock wave is performed using the same device as stated above, but using a special applicator that has been isolated with layers of metal and water by the manufacturer, extinguishing the transmitted energy.
223618889|NCT04761133|DRUG|Povidone-Iodine pleural irrigation|Irrigation of the infected pleural cavity with an antiseptic solution to reduce microbial load
223618890|NCT01111617|PROCEDURE|Real-time fMRI feedback|Patients receive real-time fMRI biofeedback to modulate pain
224207530|NCT06170840|DRUG|QY101Placebo/QY101 ointment|External use for BID
223618891|NCT01640782|DRUG|Irinotecan, Leucovorin, 5-Fluorouracil, Docetaxel, Cisplatin|"* Irinotecan (CPT-11) 180 mg/m2, given as 60 min. i.v. infusion on day 1 every 2 weeks followed by~* Leucovorin (LV) 100 mg/m2, given as a 2h i.v. infusion on days 1 and 2 every 2 weeks followed by~* 5-Fluorouracil (5-FU) 400 mg/m2 given as bolus, and then 5-Fluorouracil (5-FU) 600 mg/m2 given as a 22h continuous infusion on days 1 and 2, every 2 weeks for 4 administrations.~After 3 weeks from last infusion:~* Docetaxel (TXT) 75 mg/m2, given as a 1h i.v. infusion on day 1 followed by~* Cisplatin (CDDP) 75 mg/m2, given as a 1h i.v. infusion on.day 1, every 3 weeks, for 3 cycles."
223618892|NCT01640782|DRUG|Leucovorin, 5-Fluorouracil|"* Leucovorin (LV) 100 mg/m2, given as a 2h i.v. infusion on days 1 and 2 every 2 weeks followed by~* 5-Fluorouracil (5-FU) 400 mg/m2 given as bolus, and then 5-Fluorouracil (5-FU) 600 mg/m2 given as a 22h continuous infusion on days 1 and 2, every 2 weeks for 9 administrations."
223618893|NCT00295542|DEVICE|Ambulatory blood pressure monitoring|Sampling at 20-min intervals from 07:00 to 23:00 hours and at 30-min intervals at night for 48 consecutive hours
223618894|NCT00295542|PROCEDURE|Chronotherapy, timing of antihypertensive medication|Comparison of effects of awakening versus bedtime dosing
223618895|NCT00295542|DRUG|ACEI (including spirapril, enalapril, quinapril, lisinopril)|Treatment at awakening versus bedtime
223618896|NCT00295542|DRUG|ARB (including valsartan, telmisartan, olmesartan)|Treatment at awakening versus bedtime
223618897|NCT00295542|DRUG|beta blockers (including nebivolol, atenolol, carvedilol)|Treatment at awakening versus bedtime
223618898|NCT00295542|DRUG|diuretics (torasemide, indapamide, HTCZ) and doxazosin|Treatment at awakening versus bedtime
223618899|NCT00295542|PROCEDURE|Combination therapy in essential hypertension|Treatment at awakening versus bedtime
223618900|NCT02504489|DRUG|Docetaxel + Plinabulin (DP)|Docetaxel 75 mg/m2 IV + Plinabulin 30 mg/m2
223618901|NCT02504489|DRUG|Docetaxel (D)|Docetaxel 75 mg/m2 IV
223618902|NCT04364828|GENETIC|Whole Genome Analysis|Whole Genome Analysis with whole transcriptome analysis and deoxyribonucleic acid (DNA) methylation analysis using Methylation beadchip (EPIC) arrays
223618903|NCT04364828|GENETIC|T-cell receptor (TCR) repertoire|Longitudinal analysis of TCR repertoire of Cluster of Differentiation 4+ (CD4+) and CD8+ T cells from blood samples (Peripheral Blood Mononuclear Cells, PBMCs) from clinically characterized patients
223618904|NCT04364828|GENETIC|SARS-CoV-2 viral composition|Determined by Next Generation sequencing
223680397|NCT03320694|DRUG|Metformin|metformin 500mg twice daily \& increased until 2500mg till normoglycemia was achieved and was continued till delivery
224207531|NCT04114526|OTHER|Nicotine Replacement Therapy|"CHAs meet with all interested residents to discuss taking steps towards quitting. The CHAs follow a four step program with all participant 1) get to know the resident and their smoking, 2) Assess what the resident is ready to do to take steps towards quitting, 3) discuss using nicotine replacement therapy (NRT) in the form of patches, gum or lozenges, 4) set one goal for taking steps towards quitting. CHAs will attempt to follow up with participants after the initial encounter. There is no limit on the number of times the CHA may talk with the participants. Some follow interactions will be brief encounters in the neighborhood, while others will be at scheduled. All contacts with each participant will be tracked.~We will provide up to 6 weeks of NRT patches, gum and lozenges to participants who are interested in using NRT to help them quit."
224207532|NCT05880420|DEVICE|Caregiver operations with medication accessories|After at least an initial outpatient medication (24/72 hours), home medication every 7 days (caregiver) for a total of 10 weeks.
224207533|NCT05880420|DEVICE|Nurse operations with medication accessories|Outpatient medication every week (for a total of 10 weeks). Patients adhering to this arm will be followed at the IGAV nursing clinic of the IFOs.
224207534|NCT02860273|DEVICE|High Flow Nasal Cannula Oxygen|Exercise capacity testing according to High Flow Nasal Cannula Oxygen at 21% in COPD patients involved in a Pulmonary Rehabilitation program.
224207535|NCT02860273|DEVICE|Treadmill|Exercise capacity testing in COPD patients involved in a Pulmonary Rehabilitation Program.
224207536|NCT00078312|DRUG|CEP-10953 (Armodafinil)|Armodafinil (po) 100 to 250 mg/day up to 12 months
224207537|NCT00381446|DEVICE|Marketed contact lens care products|
224207538|NCT05555186|DEVICE|BWL classrooms (Experimental)|Adolescents in the BWL classrooms will be exposed to the circadian stimulating bright light (600-1000lx) to maintain alertness. The programming of the LED lighting system in the intervention group (BWL) will be tuned to provide equal stimuli to the cone and melanopsin-containing photoreceptors measured at the eye height (1.2 m above floor level for sitting position) approximately in the range 4500 -5500 K (cool white light) or between 600 and 1000 lx.
224207539|NCT05555186|DEVICE|DWL classrooms (Comparison)|Participants in DWL classrooms will receive conventional light from the same kind of equipment as used for the intervention group, only not applying high circadian stimulation(300lx). In order to replicate conventional lighting in the classrooms, the programming of the new LED lighting system in the control group (DWL) will meet the minimum requirements according to EN12464-181, or at least 300 lx measured at table height for a light source rated at 3000 K (warm white light).
224207540|NCT03460119|DEVICE|High Flow Nasal Cannula Oxygen|The high flow device that we used was an air oxygen blender (Whisper FlowⓇ), which allows FiO2 adjustment between 0.30 and 1.0 and can deliver a gas flow from 10 to 150 l/min. The gas mixture was routed from a heated humidifier (MR850 with MR 290 chamber) through a one line heated inspiratory circuit (RT241) to the subject at a temperature of 37°C via a nasal cannula (OptiflowⓇ).
224207541|NCT05262933|OTHER|coffee|It will be given to patients brewed coffee to drink and evaluated to hypotension and post spinal puncture headache
224207542|NCT05262933|OTHER|Water|It will be given to patients water to drink and evaluated to hypotension and post spinal puncture headache
224207543|NCT06266975|DEVICE|Biobsy from kidney|using tyrosine kinase inhibitors particulary imatinib in ttt CML patients
224207544|NCT02296788|BEHAVIORAL|Aerobic Exercise|The exercise expenditure goals were calculated by multiplying the participants' body weight by the exercise dose (8 or 20 KKW) divided by the number of sessions (3-5 sessions/wk). The speed and grade were monitored and documented to keep participant heart rate at 65-85% of tested VO2 peak and entered into ACSM equations for energy expenditure.
224207545|NCT01968837|OTHER|Cervical cancer screening|
224207546|NCT01096407|OTHER|laboratory biomarker analysis|Collection of urine samples
224207547|NCT01096407|OTHER|questionnaire administration|Completion of questionnaires
224207548|NCT01096407|PROCEDURE|assessment of therapy complications|An assessment will be completed.
224207549|NCT03424694|RADIATION|HDR brachytherapy as monotherapy|
224207550|NCT05160727|DRUG|Tislelizumab|200mg ivgtt d1 q3w
224207551|NCT05160727|DRUG|Irinotecan|"Concurrent Chemoradiotherapy:~Irinotecan: 80mg/m2/w (UGT1A1\*28 and \*6: 6/6+GG) or 65mg/m2/w (UGT1A1\*28 and \*6: 6/7+GG or 6/6+GA) or 50mg/m2/w (UGT1A1\*28 and \*6: 7/7+GG or 6/6+AA or 6/7+GA) Consolidation therapy: 2 weeks after the completion of chemoradiotherapy. Irinotecan: 200mg/m2 ivgtt d1 q3w."
224207552|NCT05160727|RADIATION|radiotherapy|radiotherapy
224207553|NCT05784727|DEVICE|Earswitch device|The Earswitch™ device consists of an earpiece made from silicon or similar bio-compatible material and incorporates a miniature camera. The earpiece sits within the ear canal and is not in direct contact with the eardrum and the camera is not in contact with the ear-canal. The camera detects voluntary movement from the tensor tympani muscle as presented at the eardrum and the Earswitch system translates this movement to an external virtual keypad or similar to allow the patient to communicate nonverbally.
224315153|NCT01289483|DRUG|fospropofol|After the initial bolus dose of study drug is given, a maximum of two supplemental doses of fospropofol at 25% of the initial dose will be permitted. Fospropofol supplements will be administered every 4 min
223618905|NCT04852939|OTHER|Bowen's technique|"Initially, cup move is performed which requires a vertically rolling Bowen move over the posterior border of the deltoid muscle above the axillary crease.~The subject's arm is held flexed at 90 degrees at mid-chest height. Then, the elbow is slowly and passively moved in the direction of the opposite shoulder.~After maximal adduction of the arm, the therapist firmly taps the lateral aspect of the shoulder with the heel of his/her hand.~The arm is then carried back to the original start position, where the therapist gently moves superiorly and slightly laterally over the anterior fibers of the deltoid. The arm is then carefully lowered.~The therapist strives to undertake a minimum of moves and procedures to trigger the body's own self-healing powers and assess how much pressure to use and where and when to perform a move to release the build-up of stress.~40-minute sessions thrice a week for 6 weeks."
223618906|NCT04852939|OTHER|Conventional physical therapy|"* Hot pack and transcutaneous electrical nerve stimulator (TENS) for 15 minutes.~* Pendulum stretch, 10 revolutions.~* Cross body stretch, 4 repetitions.~* Towel stretch/hand behind the back, 4 repetitions.~* Isometric internal and external rotation exercises. 40-minute sessions thrice a week for 6 weeks."
224207554|NCT02400827|OTHER|malignant cells|
224260457|NCT06626893|BIOLOGICAL|Microvesicles analysis|Analyses on microvesicles isolated from both Bone Marrow samples and Peripheral Blood Samples will be performed to investigate the microenvironment of the disease.
224260458|NCT03069183|DRUG|0.5% Ropivacaine|Ultrasound-guided suprainguinal fascia iliaca compartment block with 40mls 0.5% ropivacaine.
224260459|NCT03069183|DRUG|Normal saline|Ultrasound-guided suprainguinal fascia iliaca compartment block with 40mls normal saline.
224260460|NCT02183311|DRUG|BI 1356 BS - single rising dose|
224260461|NCT02183311|DRUG|BI 1356 BS - multiple rising dose|
224260462|NCT02183311|DRUG|Placebo|
224260463|NCT05834751|DRUG|PEG-rhG-CSF|48-72 hours after chemotherapy,9 mg of PEG-rhG-CSF was injected subcutaneously for mobilization
224260464|NCT05834751|DRUG|RhG-CSF|After clinical evaluation, rhG-CSF was given 10μ g/kg/d for mobilization until the stem cell collection was completed.
224260465|NCT04499677|DRUG|Favipiravir|Dosage and method of administration: Day 1: 1800 mg twice daily; Day 2 to Day 7: 400 mg four (4) times daily.
224260466|NCT04499677|DRUG|Lopinavir/ Ritonavir|Dosage and method of administration: Day 1: 400mg/100 mg twice daily; Day 2 to Day 7: 200mg/50mg four (4) times daily
224260467|NCT04499677|OTHER|Favipiravir Placebo|Dosage and method of administration: Day 1: 1800 mg twice daily; Day 2 to Day 7: 400 mg four (4) times daily.
224260468|NCT04499677|OTHER|Lopinavir/ Ritonavir Placebo|Dosage and method of administration: Day 1: 1800 mg twice daily; Day 2 to Day 7: 400 mg four (4) times daily.
224260469|NCT00918645|DRUG|41 Ca|single oral 1.2 microgram dose of 41Ca; the first two recruited study subjects will also receive an oral dose of stable calcium isotope (46Ca) to compare initial kinetics with prior work.
224260470|NCT02476045|DRUG|5-fluorouracil,leucovorin,panitumumab|Maintenance treatment (ARM A)
224260471|NCT02476045|DRUG|panitumumab|Maintenance treatment (ARM B)
224260472|NCT02476045|DRUG|Oxaliplatin, 5-fluorouracil,leucovorin,panitumumab|Induction treatment
224260473|NCT03388905|DEVICE|Life Vest Wearable defibrilator|The LifeVest is a cardioverter defibrillator worn by a patient at risk for sudden cardiac arrest (SCA). It monitors the patient's heart continuously and, if the patient goes into a life-threatening arrhythmia, can deliver a shock treatment to restore the patient's heart to normal rhythm.
224260474|NCT01747668|DIETARY_SUPPLEMENT|Similac Prenatal Vitamin soft-gel capsule|One capsule per day for Experimental Supplement A Group; Two capsules per day for Experimental Supplement B Group
224260475|NCT01747668|DIETARY_SUPPLEMENT|Placebo (soybean oil and dl-alpha-tocopheryl acetate)|Two capsules per day for the Placebo Group; One capsule per day for the Experimental Group A
224260476|NCT02586935|DRUG|Tideglusib|Administered orally after dispersion in approximately 100 ml of water at dose levels of 400 to 1000 mg
224260477|NCT02586935|OTHER|Placebo|Administered orally after dispersion in approximately 100 ml of water
224260478|NCT00729976|DRUG|Ibuprofen suppository|5-10mg/Kg of ibuprofen
224260479|NCT00729976|DRUG|Ibuprofen Suspension|5-10mg/Kg
224260480|NCT02742194|DIETARY_SUPPLEMENT|Dry extract of ginger|Restrictive diet plus three capsules of 200 mg of dry extract of ginger (5% active ingredient) to be taken three times a day for six months.
224260481|NCT02742194|DIETARY_SUPPLEMENT|Placebo|Restrictive diet plus three capsules of 200 mg of cellulose to be taken three times a day for six months.
224260482|NCT03090880|DRUG|Tinzaparin Sodium|Subcutaneous tinzaparin 4,500 IU once daily for six months.
224260483|NCT00001991|DRUG|Atovaquone|
224260484|NCT02125760|OTHER|Inspiratory Muscle Training (IMT)|Sham IMT at a fixed workload of 10 cmH2O. 5 sets of 10 repetitions, twice a day, 7 days per week, for 4 weeks.
224260485|NCT02125760|OTHER|High-intensity IMT|High Intensity IMT. The training load is the maximum inspiratory load defined according to patient tolerance. This load will be equivalent to 10 maximal repetitions (RM) as 10 consecutive inspirations (x 5 sessions), twice a day.
224315154|NCT01289483|DRUG|fospropofol|After the initial bolus dose of study drug is given, a maximum of two supplemental doses of fospropofol at 25% of the initial dose will be permitted. Fospropofol supplements will be administered every 4 min
224315155|NCT05083897|OTHER|hip adduction isometric contraction|addition of isometric hip adduction contraction to the knee extension for measuring knee extension peak torque by the isokinetic dynamometer
224315156|NCT03926949|OTHER|Parenteral Nutrition|Olimel 7.6% E 1000 ml will be infused over 4-5 hours at outpatient infusion clinic for 5-10 days within 14 days prior to surgery.
224315157|NCT03926949|OTHER|Standard Nutrition Care|Participants will receive nutrition therapy by registered dietitians within 14 days prior to surgery. Patients with SGA B and SGA C will receive advanced nutrition care and specialized nutrition care, respectively.
224315158|NCT02323828|DIETARY_SUPPLEMENT|High RS cookies|High RS cookies ingestion in healthy young adults
223618907|NCT01619371|DEVICE|Simplisse Double Electric Breast Pump|Use of breast pump for 10 minutes.
223618908|NCT05397769|DRUG|Envafolimab Plus Chemoradiotherapy|Envafolimab was administrated with 300mg each time, every three weeks for a total of 22 cycles since the first day of induction chemotherapy.
223618909|NCT04477161|DIETARY_SUPPLEMENT|Ketone Ester Elite endurance Nutrition Drink|Subjects will take one bottle four times daily for four weeks
224207555|NCT05718882|DRUG|Lenvatinib Oral Product Plus VIC1911|"Lenvatinib: 8mg/day (≤ 60Kg), oral. VIC-1911:Groups were divided: 100mg bid（DL1, dose level 1）; 150mg bid（DL2）; 200mg bid(DL3), oral. 50mg bid is defined as DL(-1), 250mg bid is defined as DL(+1). A Bayesian Optimal Interval design schema will be followed to establish the maximum tolerated dose (MTD) of lenvatinib plus VIC-1911 combination and RP2D of VIC-1911 in HCC patients. The study would follow the Bayesian Optimal Interval Design with level size of 2 patients. The R package BOIN is available from CRAN."
224207556|NCT03429374|DEVICE|Liquiband Fix8|LiquiBand® Fix 8™ (Advanced Medical Solutions - Plymouth, UK) is a hernia mesh fixation device providing strong and secure mesh fixation without causing any tissue damage or mechanical trauma. This device is designed to offer precise and controlled delivery of tissue glue (n-butyl-2-cyanoacrylate), resulting in a strong mesh fixation.
223618910|NCT04477161|OTHER|Stool Sample|Subjects will provide a stool sample at 2 timepoints.
223618911|NCT06155422|DRUG|Cadonilimab|recurrent or metastatic cervical cancer in the first, second or third lines Systematic treatment
224207557|NCT03429374|DEVICE|Absorbable tack|Absorbable tack
224207558|NCT04842448|DRUG|Hyperbaric oxygen|Hyperbaric oxygen 240 kPa for 90 minutes (with 10 min compression time, 2 air bakes and 10 minutes decompression time).
224207559|NCT04842448|PROCEDURE|Sham treatment|Sham treatment 134-120 kPa Air (with 5 min compression time, and 5 min decompression to 120 kPa, two air brakes will be reported to the subjects)
223618912|NCT00967317|DRUG|Auris-Sedina|"Drip 2 drops of the medication with the head tilted and protect with a cotton swab. Repeat the process one at a time until the pain relief. Continue the administration of medication every 3 hours until the pain ceases.~The medication should be used for a maximum of 3 days when they should return to the doctor."
223618913|NCT00967317|DRUG|Otosynalar®|Drip 3 drops in the ear 2 times a day. The medication should be used by more than 3 days after which the patient must return to the doctor.
224207560|NCT04840901|DRUG|Lebrikizumab|Administered SC.
224207561|NCT01268683|DRUG|Glyburide for Injection|Administered as specified in the treatment arm.
224315159|NCT02323828|DIETARY_SUPPLEMENT|Placebo|Placebo cookies ingestion in healthy young adults
224315160|NCT01286753|DRUG|Vemurafenib|Vemurafenib 960 mg orally twice daily.
223618914|NCT00798616|DRUG|prednisolone or methylprednisolone|either prednisolone 2mg/kg PO once daily or methylprednisolone 1.6mg/kg IV once daily (if IV access is present) for length of hospitalization, for a maximum of seven days
223618915|NCT00798616|DRUG|placebo|oral or IV placebo
223618916|NCT02356913|DRUG|Nicotine gum|
223618917|NCT02107833|DRUG|OPRX-106|
223618918|NCT05795361|DRUG|Idursulfase-IT|Participants will continue to receive the same dose of idursulfase-IT, once monthly, that was administered during the HGT-HIT-046 \[NCT01506141\] or SHP609-302 \[NCT02412787\] study \[10mg or 30mg\] along with intravenous (IV) infusions of standard-of-care therapy Elaprase via intrathecal drug delivery device (IDDD) or lumbar punctures.
223618919|NCT00012103|OTHER|bronchoalveolar lavage|
224207562|NCT04738552|DEVICE|Nelli|Nelli detects and registers activity that is indicative of seizure events. Nelli captures, stores, and processes video and audio recordings from each patient. Biomarker data is collected during periods of rest for the length of an examination period, which may span several days or months (when used inside and outside of a hospital setting, respectively), as prescribed by a treating physician.
224207563|NCT05446376|DRUG|68Ga-citrate PET/CT|PET/CT Imaging with 68Ga-citrate PET/CT injection
224207564|NCT02216214|DRUG|Mirabegron|oral tablet
224207565|NCT02216214|DRUG|Placebo|oral tablet
224207566|NCT04495296|DRUG|TST001|TST001 will be administered by specified doses on specified day
224207567|NCT04495296|DRUG|Oxaliplatin|Oxaliplatin will be administered by specified doses on specified day
224207568|NCT04495296|DRUG|Capecitabine|Capecitabine will be administered by specified doses on specified day
224207569|NCT04495296|DRUG|Paclitaxel|Paclitaxel will be administered by specified doses on specified day
224207570|NCT04495296|DRUG|Gemcitabine|Gemcitabine will be administered by specified doses on specified day
224315161|NCT00923897|RADIATION|Palliative RT|Prior to receiving radiation treatment, it is recommended that you take medications to reduce the chance of nausea related to therapy. The treatment will take approximately 30 minutes.
224315162|NCT01259271|DEVICE|Selective Nerve Stimulation (SNS) stimulator device|Two hours per study visit separated by a minimum of a 20 hour wash out period between stimulations.
224315163|NCT02625597|DEVICE|Cotton Pellet|
224315164|NCT02625597|DEVICE|Polytetrafluoroethylene Tape|
224315165|NCT02625597|DEVICE|Synthetic Foam|
224315166|NCT02625597|DEVICE|Polyvinylsiloxane|
224315167|NCT02089659|DRUG|Doravirine|Following an overnight fast, a single tablet of 100 mg doravirine was be administered orally
224315168|NCT02240615|DEVICE|Sinopsys Lacrimal Stent|Procedural insertion of the Sinopsys Lacrimal Stent in patients with epiphora
224315169|NCT01609452|BIOLOGICAL|Blisibimod|
224315170|NCT01609452|OTHER|Placebo|
223618920|NCT00012103|OTHER|screening questionnaire administration|
223618921|NCT00012103|OTHER|sputum cytology|
223618922|NCT00012103|PROCEDURE|bronchoscopic and lung imaging studies|
223618923|NCT00012103|PROCEDURE|bronchoscopy|
223618924|NCT00012103|PROCEDURE|computed tomography|
223618925|NCT00012103|PROCEDURE|study of high risk factors|
223618926|NCT02872246|DRUG|BAY 987516|Single dose application of two (2) mg/cm² of test product. Each 50 cm² test site area requires 100 mg of a product to obtain a standard 2 mg/cm² test application.
223618927|NCT02872246|DRUG|SPF 15 Control|Single dose application of two (2) mg/cm² of test product. Each 50 cm² test site area requires 100 mg of a product to obtain a standard 2 mg/cm² test application.
224207571|NCT04495296|DRUG|Cisplatin|Cisplatin will be administered by specified doses on specified days Oxaliplatin will be administered by specified doses on specified day Drug: Capecitabine Capecitabine will be administered by specified doses on specified day
224207572|NCT04495296|DRUG|Nivolumab|Nivolumab will be administered by specified doses on specified day
224207573|NCT06156631|BEHAVIORAL|DASH-ExMAMI|The DASH-ExMAMI consists of ten counseling and health education sessions that each last from 20 to 60 minutes over 10 weeks. The DASH domain will address the following subjects: getting started on DASH, making the move to DASH, tips to reduce salt and sodium, and a week with the DASH eating plan. The Exercise component consists of brisk walking for 30 minutes every day, five days a week. The medication adherence domain is based on the participant's Hill-Bone Compliance to High Blood Pressure Therapy Scale items and their scores. All domains of the intervention are stages and processes of change-matched ones and are provided through 10 motivational interviewing and counseling sessions.
224207574|NCT02645266|DRUG|Aflibercept Injection [Eylea]|Subjects will be administered 2.0mg Aflibercept intraocular injection each month for 5 consecutive months. After the 5th month, the serum cytokine levels in blood work will be assessed as well as patients's visual acuity, and eye pressures. Upon completion of the trial, patients will resume receiving the usual standard of care.
224207575|NCT01410747|DRUG|Tacrolimus|oral
224207576|NCT05864235|BEHAVIORAL|Control|Each week for 6-weeks, control group participants will receive the following weekly text message assessments (without receiving any feedback or support): (1) Thursdays (3pm): weekend plans to drink and desire to get drunk; (2) Sundays (12pm): most drinks consumed on any weekend day and peer pressure to drink.
224207577|NCT05864235|BEHAVIORAL|Goal Support (GS)|Each week for 6-weeks, GS group participants will receive prompts and tailored feedback and support focused on weekly drinking limit goal commitment \& confidence assessments and subsequently receive tailored feedback on goal success to either bolster future goal striving or reframe goal failure.
224207578|NCT05864235|BEHAVIORAL|Coaching for Context-specific Peer Support (CCPS)|Each week for 6-weeks, CCPS group participants will receive weekly motivation and strategies to enlist peer support during drinking episodes.
224207579|NCT05354206|OTHER|Electrophysiology assessment - corticospinal tract|Kinematics and cortical spinal motor excitability
224207580|NCT05354206|OTHER|Electrophysiology assessment - reticulospinal tract|Kinematics and reticular spinal motor excitability
223618928|NCT05054140|DRUG|IMU-838|IMU-838 tablets
223618929|NCT05054140|DRUG|Placebo matching IMU-838|Placebo matching IMU-838 tablets
223618930|NCT01381393|DRUG|Ibandronate|Basically there is no treatment allocation. Subjects who would be administered of ibandronate at their physicians' discretion will be enrolled. Dosage regimen will be recommended according to the prescribing information. Subjects will be enrolled consecutively.
223618931|NCT05662085|OTHER|No intervention|According to clinical practice.
223618932|NCT00116012|DRUG|rNAPc2|
223618933|NCT05990192|DRUG|Niraparib oral capsule|Niraparib used following SBRT treatment until disease progression
223618934|NCT05990192|RADIATION|SBRT|SBRT may be delivered using a specialist SBRT platform, such as CyberKnife or with a linear accelerator with SBRT capabilities.
223618935|NCT04849130|PROCEDURE|Static reconstruction technique according to Schöttle|In static MPFL reconstruction, a graft (harvested autologous gracilis tendon or allogen transplant) is attached to the femoral and patellar bones using tunnels, screws, and/or anchors.
223618936|NCT04849130|PROCEDURE|Dynamic reconstruction technique according to Becher|Dynamic MPFL procedure by detaching and reinserting only the distal part of a hamstring muscle to the patella and leaving the proximal tendon attached to its muscle. This way the patella position can be adjusted dynamically by hamstring contraction.
223618937|NCT04744961|OTHER|SCAR-Q survey|Telephone survey
223618938|NCT05609942|DRUG|BLU-263|BLU-263 Oral Tablets
224207581|NCT05354206|OTHER|Training with some stimulation|Motor task combined with real or sham stimulation
224207582|NCT06320080|DRUG|TQB2223 injection|TQB2223 is an anti- lymphocyte activation gene-3 (LAG-3) antibody.
224207583|NCT06320080|DRUG|Penpulimab Injection|Penpulimab Injection is an anti programmed death-1 (PD-1) antibody.
224207584|NCT04137770|OTHER|Ice pack and ketorolac|Scheduled IV ketorolac will be administered and ice packs will be applied to the surgical site
224207585|NCT00085826|DRUG|Exisulind|
224207586|NCT00826865|DRUG|Levetiracetam|750 mg tablet
224207587|NCT01984619|DEVICE|Cryotherapy for the utilization of wrinkle reduction (iovera)|
224207588|NCT06025500|DIAGNOSTIC_TEST|31P-Magnetic Resonance Spectroscopy (31P-MRS)|31P-Magnetic Resonance Spectroscopy will be performed during exercise testing.
224207589|NCT06520267|DRUG|Antibiotic therapy|Urine culture and antibiotic sensitivity tests were conducted to assess the bacteriological profile. The patients were then prescribed antibiotics based on susceptibility testing for a duration of 1 week.
224207590|NCT04938063|OTHER|Assessing the correlation between Functional Impairment and Parenting Stress|Association Between Functional Impairment and Parenting Stress Among Children Diagnosed With Diplegic Cerebral Palsy
224207591|NCT05585008|DEVICE|two different denture manufacturing technique (heat cure pack and press technique(heat cure acrylic,Acrostone,Egypt)/3d printed dneture(HARZ lab,Russia))|retention for the two groups will be measured at 0,1 and 3months, patient satisfaction will be recorded, and accuracy of the denture base will be measured on the software.
224207592|NCT00713830|DRUG|Lixisenatide (AVE0010)|Self administered by subcutaneous injections once daily within the hour preceding breakfast.
224207593|NCT00713830|DRUG|Placebo|Self administered by subcutaneous injections once daily within the hour preceding breakfast.
224207594|NCT00713830|DEVICE|Pen auto-injector|
224315171|NCT01228799|PROCEDURE|trabeculectomy|trabeculectomy with mitomycin C 0.2mg/ml
224315172|NCT01228799|PROCEDURE|Canaloplasty|Canaloplasty with implant of suture
223618939|NCT05609942|DRUG|Azacitidine|Azacitidine powder for suspension for intravenous infusion / subcutaneous injection
224207595|NCT00713830|DRUG|Sulfonylurea|Sulfonylurea to be continued at maximum effective dose according to local labeling up to end of treatment.
224207596|NCT00713830|DRUG|Metformin|Metformin if given to be continued at stable dose (at least 1.5 gram per day \[except at least 0.75 gram per day in Japan and 1.0 gram per day in South Korea\]) up to the end of treatment.
224207597|NCT03998696|DRUG|Cisplatin 40 mg/m2|Cisplatin 40 mg/m2, weekly, concurrent with Radiotherapy
224207598|NCT03998696|DRUG|Cisplatin 100 mg/m2|Cisplatin 100 mg/m2, three weekly, concurrent with Radiotherapy
224315173|NCT06323447|DIAGNOSTIC_TEST|PointCheck|Binary classification of severe neutropenia
223618940|NCT06542133|DEVICE|AVEIR remote care system|In-clinic or an at-home system designed to support remote follow up in Aveir leadless pacemaker patients
223618941|NCT00990106|DRUG|prazosin hydrochloride|"Subject will be titrated up to the optimum tolerated dose based on the Dosing Algorithm. Males and females will be titrated differently with females titrated slower and to a lower maximum daily dose. The first dose will be taken while the participant is in bed for the night to avoid orthostatic syncope, an uncommon but recognized first dose effect of prazosin or any alpha-1 antagonist if started at a high dose. The first dose effect is avoidable by starting treatment with a low dose (1 mg at bedtime) then titrating the dose upward gradually."
223618942|NCT00990106|DRUG|placebo|placebo
223618943|NCT05152459|DRUG|Tazemetostat|Given PO
223618944|NCT05152459|BIOLOGICAL|Ublituximab|Given IV
223618945|NCT05152459|DRUG|Umbralisib|Given PO
223618946|NCT05577923|DRUG|Trastuzumab|8 mg/kg loading dose IV, then 6 mg/kg IV, every 3 weeks
223618947|NCT05577923|DRUG|pyrotinib|Pyrotinib 320mg, PO daily, continuously
223618948|NCT05577923|DRUG|Dalpiciclib|Dalpiciclib will be given at the dose of 125 mg po q.d. x 21 every 4 weeks
224207599|NCT00357708|DRUG|decitabine|Given IV
224207600|NCT00357708|DRUG|vorinostat|Given orally
224207601|NCT00357708|OTHER|laboratory biomarker analysis|Correlative studies
224207602|NCT00357708|OTHER|pharmacological study|Correlative studies
224207603|NCT00174473|DRUG|Voriconazole|
224207604|NCT06220916|BEHAVIORAL|Dance training in Classical Ballet and Contemporary Dance|Classes, Rehearsals, and Performances of classical ballet and contemporary dance.
224207605|NCT00552682|DRUG|Duloxetine 60 mg, QD|Duloxetine 60 mg, 1 table/day, 1 year
224207606|NCT04650984|DRUG|Onfekafusp alfa|Patients will receive a fixed dose of L19TNF in combination with a fixed dose of doxorubicin.
224207607|NCT04650984|DRUG|Doxorubicin|Patients will receive a fixed dose doxorubicin, administered as a 15 ± 5 minutes i.v. infusion.
224207608|NCT03294382|DRUG|Botulinum toxin type A|5U botulinum toxin in 0.1 mL normal saline, injected in two points at one side, 2.5U per point, local injection
224207609|NCT03294382|DRUG|Placebo|0.1 mL normal saline, injected in two points at one side, 0.05 mL per point, local injection
224207610|NCT00902265|DRUG|desmopressin|desmopressin (Nocturin®) 0.1 mg tablet per day for 12 weeks
224315174|NCT00750685|DEVICE|Mentor Smooth Becker 50 Expander/Breast Implant|The Mentor Becker Expander/Breast Implant is comprised of two components: the Becker implant and the injection dome/fill tube. The breast implant is available in a smooth surface. It has a low bleed, gel-filled outer lumen and an adjustable saline-fillable inner lumen. The silicone elastomer fill tube is pre-inserted into the dual self-sealing valve system at the time of manufacture and is joined to the injection dome by the connector system at the time of surgery. The inner lumen can be gradually filled with saline over an extended period of time via the fill tube by injecting saline through the injection dome. Once expanded to the desired volume, the fill tube and injection dome are removed through a small incision under local anesthetic, and the prosthesis remains in position as a breast implant.
224315175|NCT05703087|BEHAVIORAL|Positive cueing in the information video before a primary TKA|Two weeks before the surgery, in the outpatient clinic (during their preoperative appointment), the pre-surgery information video was shown to the patients. Patients were randomly allocated to either the positive cueing group (intervention) or the standard care group (control) with Castor EDC (14) using a variable block randomization model. Patients did not know whether they watched the adapted video or the standard video.
224315176|NCT06020144|DRUG|TLL-018|Oral tablets administered 2pieces BID for 52 weeks.
224315177|NCT06020144|DRUG|Tofacitinib|Oral tablets administered 1pieces BID for 52 weeks.
224315178|NCT00470392|DRUG|Imiquimod|Each study subject served as his/her own control. For this arm of the study, topical vehicle was applied to one plaque for 5 days. Imiquimod (5% topical cream) was applied to two psoriasis plaques for 5 days. Skin biopsies were taken from half of each of the 3 plaques at specific time points after completion of topical pre-treatment. The other half of the plaques were exposed to UVB light (via Excimer laser). Biopsies were subsequently taken at a specified time point.
223618949|NCT05577923|DRUG|fulvestrant|Fulvestrant will be given intramuscle at the dose of 500 mg every 4 weeks (with an additional 500 mg dose given two weeks after the initial dose.
223618950|NCT02511379|OTHER|Propylene Glycol 0.6% eye drops|
223618951|NCT06067503|DRUG|18F-fluorofuranylnorprogesterone|The dose of the investigational imaging agent, FFNP, is approximately 7 millicurie (mCi) (259 megabecquerels (MBq)), IV slow infusion over approximately two minutes followed by saline flush.
223618952|NCT06067503|DEVICE|Liquid Biopsy|20ml of whole blood will be collected into two Ethylenediaminetetraacetic acid (EDTA) tubes at each timepoint, CTCs are isolated using the microfluidic Versatile Exclusion-based Rare Sample Analysis (VERSA) platform that integrates CTC capture with RNA extraction on a single chip using Exclusion-Based Sample Preparation (ESP) technology
223618953|NCT06067503|DEVICE|Positron Emission Tomography/Computed Tomography|FFNP drug in combination with PET/CT scans to image participant
223618954|NCT06260800|OTHER|Validation CEQ|In initial assessment, EQ-5D-5L and HADS questionnaires were completed. After sessions 1 and 2, CEQ and WAI-S were filled. Finally, EQ-5D-5L was completed before the fourth session.
223618955|NCT00052585|DRUG|irinotecan hydrochloride|Given IV
223618956|NCT00052585|DRUG|gefitinib|Given orally
223618957|NCT00052585|DRUG|leucovorin calcium|Given IV
223618958|NCT00052585|DRUG|fluorouracil|Given IV
223618959|NCT05919953|DEVICE|Virtual reality|Immersive virtual reality neck exercises targeting relaxation, mobility, control, and speed of movement, using the Pico G2 4K headset.
223618960|NCT05919953|BEHAVIORAL|Therapeutic education|"Several brochures will be given to participants. These brochures will cover the general principles of pain, the persistence of pain, tips for managing chronic non-specific pain, and the use of immersive virtual reality in the rehabilitation of chronic non-specific neck pain.~The information provided in the brochures will be discussed with the physiotherapist during the teleconsultations in order to individualize the therapeutic education."
223618961|NCT01194037|DRUG|recombinant variant of interferon-alpha 2b|SC, Weekly
224207611|NCT03323359|DEVICE|Hemopatch|Hemopatch is applied upon the verification made by the surgeon of the presence of an appropriate target bleeding site in the hepatic parenchyma. At the time point of application a stopwatch starts simultaneously. Time to hemostasis is defined as the time required to obtain successful haemostasis in a single bleeding site. At 3 minutes the inspection will be made and, if haemostasis is not achieved, the treatment is considered failed and the Principal Investigator and/or his delegates is allowed to use additional haemostatic measures.The time to haemostasis will be recorded in the patient's medical record and in the electronic Case Report Form. The bleeding site will be observed for 1 additional minute at the end of the haemostatic procedure and, of the surgery to confirm the haemostasis.
224207612|NCT03323359|PROCEDURE|Common Surgical Techniques|Patients undergoing liver resection for any underlying disease and with resectable mass. The list of the underlying diseases is the following (but might not be limited to): Hepatocellular carcinoma, Hilar cholangiocarcinoma, Adrenal cancer metastasis, Breast cancer metastasis, Colorectal cancer metastasis, Ovarian cancer metastasis, Biliary carcinoma, Hemangioma, Hepatic adenoma, Focal nodular hyperplasia, Unilocular hydatid cyst, Multilocular, hydatid cyst.
223618962|NCT01194037|DRUG|Peginterferon alfa-2a|SC Weekly
223618963|NCT01194037|DRUG|Ribavirin|Oral administration (The daily dose of ribavirin(RBV) was 1000mg for subjects weighing \< 75 kg or 1200 mg for subjects weighing ≥ 75 kg)
223618964|NCT04418258|DEVICE|Capillary Endoscopy Aspiration Catheter|Small intestinal fluid will be suctioned with using a capillary endoscopy aspiration catheter\[#CSL2182; Hobbs Medical,Inc. Connecticut, US\] during upper endoscopy
223618965|NCT04418258|DEVICE|Endoscopy Aspiration Catheter|Small intestinal fluid will be suctioned with using an endoscopy aspiration catheter\[#2182; Hobbs Medical,Inc. Connecticut, US\] during upper endoscopy
223618966|NCT06920888|BEHAVIORAL|Cognitive restructuring|CR drawn from classic CBT
224207613|NCT04385719|DRUG|Remdesivir|Remdesivir (GS-5734) is a nucleoside analogue with in vitro activity against filoviruses EBOV, SUDV, BDBV and MARV, in addition to arenaviruses and coronaviruses
224207614|NCT06649656|DRUG|TQB2252 injection|TQB2252 injection is a compound preparation of TQB2223 monoclonal antibody (LAG-3) and penpulimab (PD-1), with a specification of 300mg TQB2223 monoclonal antibody and 100mg (20ml) penpulimab per bottle.
224207615|NCT05559242|DRUG|Anlotinib Hydrochloride Capsule|Anlotinib hydrochloride is a muti-target tyrosine kinase inhibitor
224207616|NCT04701658|DRUG|Bamlanivimab|Administered intravenously.
224207617|NCT04295109|DRUG|the drug of intravenous patient-controlled analgesia|At present, opioids are most widely used in postoperative analgesia. This study aims to use different opioid receptor agonists---fentanyl, oxycodone and butorphanol for analgesia after laparoscopic hysterectomy.Compare the recovery of gastrointestinal function after operation.
224207618|NCT02493023|DEVICE|navigated bronchoscopy|
224207619|NCT02718976|PROCEDURE|Ultrasound/MR image fusion guided lumbar plexus block (Shamrock)|
224207620|NCT02718976|PROCEDURE|Ultrasound guided lumbar plexus block (Shamrock)|
224207621|NCT02718976|DRUG|Lidocaine-epinephrine added gadoterate meglumine|Perineural injection of 20 ml 2% lidocaine with 0.0005% epinephrine added 1 ml of gadoterate meglumine (0.13 ml) and sodium chloride (NaCl, 0.87 ml). The 1 ml of gadoterate meglumine-NaCl is added to the local anesthetic prior to the perineural injection in order to enhance visualization of the local anesthetic on MRI scanning after the intervention.
224207622|NCT04816500|DEVICE|Automatic ischemic conditioning treatment instrument|RIC is a non-invasive therapy that performed by an electric autocontrol device with cuff placed on arm. RIC procedures consist of five cycles of 5-min inflation (200 mmHg) and 5-min deflation of cuff on one arm. The procedure will be performed twice daily for consecutive 1 year after enrollment.
224207623|NCT04816500|DRUG|Regular treatment|Antiplatelet agents and statins administration, vascular risk factors control.
224207624|NCT05016765|DEVICE|Active, self-directed electrical stimulation of the median nerve|Electrical stimulation of the median nerve (12 Hz, pulse width 200µs), initially at the threshold needed to see movement of the right thumb with stimulation. After initial training with the device and education in the rationale for suprathreshold stimulation, participants will choose timing and intensity of stimulation based on their momentary symptom severity and their experience with the treatment since the beginning of the study. Participant can choose right or left median nerve (we will suggest their nondominant hand to minimize interference with daily activities).
224207625|NCT04481399|BEHAVIORAL|Family Strengthening Intervention for Early Childhood Development|The Family Strengthening Intervention for Early Childhood Development (FSI-ECD) is an evidence-based home-visiting behavioral intervention for vulnerable families with children aged 6-36 months. The FSI-ECD targets improving parental emotion regulation and parent-child interactions to improve parental mental health and child development outcomes and reduce family violence. FSI-ECD compromises five core components delivered in 12 modules delivered in weekly sessions via active coaching by community health workers. Core components include coaching on: a) nutrition, health and hygiene; b) early stimulation and playful parenting; c) building resilience and coping skills; d) building problem-solving skills; and d) building emotion regulation and conflict resolution skills.
224315179|NCT00470392|DRUG|Clobetasol|Each study subject served as his/her own control. For this arm of the study, topical vehicle was applied to one plaque for 5 days. Clobetasol propionate 0.05% was applied to two psoriasis plaques for 5 days. Skin biopsies were taken from half of each of the 3 plaques at specific time points after completion of topical pre-treatment. The other half of the plaques were exposed to UVB light (via Excimer laser). Biopsies were subsequently taken at a specified time point.
224315180|NCT05012189|DRUG|Oseltamivir|Nursing home residents and staff 18 years and older are allocated to receive oseltamivir for treatment and chemoprophylaxis for influenza.
224315181|NCT05012189|DRUG|Baloxavir|Nursing home residents and staff 18 years and older are allocated to receive baloxavir for treatment and chemoprophylaxis for influenza.
224315182|NCT04864028|OTHER|physical activity|15min sitting, 15min standing, 15min sitting, 15 min low intensity cycling
224315183|NCT02657928|OTHER|Laboratory Biomarker Analysis|Correlative studies
223618967|NCT06920888|BEHAVIORAL|Attention allocation|AA drawn from contemporary CBTs
223618968|NCT06915207|DIETARY_SUPPLEMENT|Counselling, behavioural, nutrition|integrative medical care delivered by one physician and referral to other health professionals as appropriate
223618969|NCT06613724|DEVICE|Magnet System, DI Biofragmentable|Anastomoses achieved by magnetic compression.
223618970|NCT01347528|BEHAVIORAL|Medication Adherence Support System (MASS)|The intervention consists of the use of an electronic Medication Adherence Monitor for a 6-month period as well as 2 visits to the heart failure outpatient clinic of the TweeSteden hospital (usual care). This monitor (a) dispenses all prescribed medication in the right dosage at the specified time, (b) reminds patients to take their medications through an alarm, sms or voicemail service and records adherence, and (c) sends critical data about non-adherence to the heart failure nurse, via a web application (CarebyWeb). The Medication Adherence Monitor is provided to the patient by the hospital pharmacy, including an instruction how to use the device. After the intervention patients return to usual care only. We expect a training effect, with continued improved adherence in the intervention group.
223618971|NCT02783196|DRUG|Liraglutide|In the LIR arm, the participants will be provided with instructions in using pre-filled single-use plastic syringes ready for once daily subcutaneous injection of LIR. From day 1 to day 10, with LIR daily dose of 0.6 mg (0.1 ml), followed by other 10 day courses (from day 11 to day 20) with LIR 1.2 mg (0.2 ml), then will be up-titrated to high dose 1.8 mg (0.3 ml) of LIR (from day 21 to day 40). At crossover-day 40, the participants will undergo a 14 days wash-out period, day 41 to day 55.
223680398|NCT03320694|DRUG|Insulin|The insulin group was given 3 S/C injections of regular insulin \& one intermediate acting injection at night till normoglycemia was achieved and was continued till delivery
224207626|NCT04481399|OTHER|Community Health Worker Routine|Standard CHW care involves three home visiting sessions delivered to families following childbirth with weekly supervision via phone or face-to-face. Topics of home visiting sessions include: skilled post-natal care for mothers, early initiation of breastfeeding and exclusive breastfeeding practices, adequate nutrition, immunization services and timely use of these services, hand washing and hygiene practices (including waste disposal and food hygiene), building the capacity of family members to appropriately take care of newborns and children under age 5, and building the capacity of family members to recognize and act on postnatal danger signs for newborns, mothers, and children under 5. CHWs also conduct screenings for acute malnutrition and growth monitoring to identify early referrals, and they can provide family planning methods, deworming tablets and other vitamins for acute malnutrition, dehydration, and anti-malaria treatment. Each home-visiting session lasts about 60 minutes.
224207627|NCT04311359|DRUG|Drugs, Generic|All drugs having 19 or more Brain Oedema cases reported to the FAERS database
224207628|NCT03232775|OTHER|Treatment: Physical Exam with Visual Pedagogy and Structure|Routine physical examination participants receive visual pedagogy and reinforcement (preferred food treat).
224207629|NCT03232775|OTHER|Control: Physical Exam without Visual Pedagogy and Structure|Participants engage in routine physical examination without visual pedagogy and reinforcement (preferred food treat).
224207630|NCT05631756|OTHER|Lung Ultrasound|Evaluation of the Lung Ultrasound Score in patients presenting an interstitial syndrom on the lung ultrasound and to compare it with PaO2/FiO2
224207631|NCT00157573|DRUG|GM-CSF, sargramostim|GM-CSF subcutaneous injection
224207632|NCT00850382|DRUG|Dasatinib|"Induction cycle(s):~Dasatinib 100 mg QD on days 8-21.~Consolidation Cycles 1, 2, 3, 4:~Patients will receive dasatinib 100 mg QD on days 6-28.~Maintenance therapy:~Patients completing consolidation therapy will continue to receive single agent dasatinib 100 mg QD for one year (or until relapse)."
224207633|NCT00850382|DRUG|daunorubicin|"Induction cycle(s):~Daunorubicin 60 mg/m2/day administered on days 1 through 3"
224207634|NCT00850382|DRUG|Cytarabine|"Induction cycle(s):~Cytarabine 200 mg/m2/day administered by continuous IV infusion daily for 7 days (days 1 through 7).~Consolidation cycles 1, 2, 3, 4:~Consolidation therapy consists of high-dose cytarabine 3 g/m2 (\>60 years: 1 g/m2) q12h, d 1, 3, 5, administered intravenously over three hours."
224207635|NCT02099331|DRUG|Melatonin|
224207636|NCT02099331|DRUG|Placebo (for Melatonin)|Sugar pill manufactured to mimic Melatonin 20 mg
224207637|NCT03843034|GENETIC|Measure endometrial markers|Endometrial biopsies will be taken from participants in both groups
224207638|NCT00828581|DRUG|lorcaserin|
224207639|NCT00274664|DEVICE|6 hours occlusion by patching|
224207640|NCT00274664|DEVICE|12 hours occlusion by patching|
224315184|NCT02657928|DRUG|Letrozole|Given PO
224315185|NCT02657928|DRUG|Ribociclib|Given PO
224207641|NCT04101721|DRUG|aflibercept|Administered IVT
224207642|NCT04101721|PROCEDURE|laser photocoagulation|Transpupillary conventional laser will be administered according to standard local procedures.
224207643|NCT06701253|DIAGNOSTIC_TEST|point of care ultrasound|Point of care ultrasound for upper airway evaluation.
224207644|NCT06336174|DRUG|Aspirin Tablet, Clopidogrel Bisulfate Tablets and Atorvastatin|All patients received standard medical management, including dual antiplatelet therapy (aspirin and clopidogrel) for three months with aspirin or clopidogrel monotherapy thereafter and high-dose statin, and treatment of hypertension to guideline targets.
224315186|NCT02753361|PROCEDURE|Ultrasound guidance|In the second arm, ultrasound will be used to guide the regional block
224315187|NCT01644383|BEHAVIORAL|logotherapy|Logotherapy is therapy during which the interaction between the therapist and the client centres on the topic of meaning. The problems that the clients experience are presented to the client as inseparable parts of his everyday life. The client is then challenged to discover his/her meaning and to take responsibility in facing up to his/her problem. This approach is aimed at helping the client to deal and understand what his /her existences entail.
224315188|NCT02881697|OTHER|Adipose tissue sampling|
224315189|NCT03228797|PROCEDURE|an ultrasound guided rectus sheath block|
224315190|NCT03228797|PROCEDURE|multiholed catheter|gauge multiholed catheter will be inserted at the end of surgery and after the closure of the peritoneal layer at 3 to 5 cm away from the lower end of the surgical incision
223618972|NCT02783196|DRUG|Placebo|In the PLA arm, the participants will be provided with instructions in using pre-filled single-use plastic syringes ready for once daily subcutaneous injection of PLA. Will start with PLA with matched volume saline injections of 0.1 ml PLA during the first 10 days, followed by 10 days, with 0.2 ml PLA, thereafter PLA will be up-titrated to highest volume 0.3 ml placebo for the rest of the PLA treatment period . At crossover-day 40, the participants will undergo a 14 days wash-out period, day 41 to day 55.
224207645|NCT06336174|PROCEDURE|Endovascular therapy,Aspirin Tablet, Clopidogrel Bisulfate Tablets and Atorvastatin|All patients underwent endovascular therapy and received standard medical management after surgery, including dual antiplatelet therapy (aspirin and clopidogrel) for three months with aspirin or clopidogrel monotherapy thereafter and high-dose statin, and treatment of hypertension to guideline targets.
224207646|NCT03127943|DRUG|Lidocaine|Efficacy for mandibular molar and canine anesthesia
224207647|NCT02368119|BIOLOGICAL|VRC-EBOADC069-00-vp|IM Injection of cAd3-EBO bivalent (Zaire plus Sudan) vaccine (2 x 10(10) vp)
224207648|NCT02368119|BIOLOGICAL|VRC-EBOADC069-00-vp|IM Injection of cAd3-EBO bivalent (Zaire plus Sudan) vaccine (2 x 10(11) vp)
224207649|NCT02368119|BIOLOGICAL|MVA-EbolaZ|IM injection of MVA-EbolaZ vaccine
224207650|NCT02368119|OTHER|Placebo|IM injection injection of Phosphate Buffered Saline
224207651|NCT02280915|OTHER|Savoury food product|
224207652|NCT02977494|DRUG|Daratumumab|Daratumumab (JNJ-54767414) is a novel human IgG1monoclonal Antibody (mAb) that binds with high affinity to a unique epitope on CD38
224207653|NCT02977494|DRUG|Bortezomib|
224207654|NCT02977494|DRUG|Dexamethasone|
224207655|NCT03613194|PROCEDURE|Sampling|"After inclusion in the study, eligible patients having hepatic metastases and/or péritonéales of a colorectal cancer considered as resecables will have biological and tissue samples.~The samples will be carried out at the time of the surgical gesture envisaged under general anaesthesia and will concern:~* Tumoral material: primitive tumour (if available), hepatic metastases and/or peritoneal~* Peritoneal liquid~* none tumoral peritoneum~* Portal blood~* Peripheral blood~* Cellulo-lymphatic material The necessary time to carry out the whole of these samples is estimated at 10-15 minutes maximum.~In the event of complex situations being able to complicate the surgical gesture initially envisaged or to increase by them morbidity, one or more these samples will not be carried out. This decision will be made at the discretion of the investigator."
224207656|NCT02519582|DRUG|Niclosamide|2 g per day orally
224207657|NCT00764244|PROCEDURE|Vitrectomy|Vitrectomy
224207658|NCT00764244|DRUG|Intravitreal triamcinolone injections|Intravitreal triamcinolone injections
224207659|NCT00764244|PROCEDURE|Laser photocoagulation|Laser photocoagulation
224207660|NCT06376773|PROCEDURE|combination chemotherapy with Apatinib or Camrelizumab|Apatinib, chemotherapy alone, Camrelizumab
224207661|NCT00295529|BEHAVIORAL|Multifaceted educational intervention|Educational materials available at end of study
224207662|NCT05875064|COMBINATION_PRODUCT|Restoration with resin composite and polyvinyl crown|Restorative treatment of anterior primary teeth with monochromatic composite resin in single insertion through polyvinyl crowns, after selective removal of carious tissue compared to the effectiveness of conventional restoration.
224207663|NCT05875064|PROCEDURE|Restoration with conventional resin composite|Restorative treatment of anterior primary teeth with conventional composite resin, after selective removal of carious tissue
224207664|NCT01040546|BEHAVIORAL|Individualized education|"We conducted a randomized controlled trial to evaluate the effects of three types of weight control educational intervention programs. Obese subjects were randomly allocated into individualized health education group, group weight control education and mail-delivered health education group.Obese subjects who were randomly allocated into individualized health education group received consulting services provided by a doctor, nutritionist and fitness expert. The interventions were 12 sessions over 6 months."
224207665|NCT01040546|BEHAVIORAL|Grouped education|"We conducted a randomized controlled trial to evaluate the effects of three types of weight control educational intervention programs. Obese subjects were randomly allocated into individualized health education group, group weight control education and mail-delivered health education group.Obese subjects who were randomly allocated into grouped health education group attended 12 sessions of group intervention over 6 months."
224207666|NCT02244086|DRUG|bupivacaine|At the beginning of the work of effective labor maneuver randomly be allocated ( using sealed envelopes) and an outsider to the study prepared the dosage to bupivacaine 0.125% or 0.25% to be administered by epidural catheter for an anesthesiologist to disown the concentration employed. It is measured vital signs, and visual analogue scale dilatation in minutes 0,15,30,60 and 90 after being applied analgesia.
224207667|NCT01339468|DRUG|Advagraf|oral
224207668|NCT01339468|DRUG|Prograf|oral
223680399|NCT06454266|DRUG|ORM regimen|"The subjects received ORM regimen treatment every 21 days for a total of 6 cycles. The specific medication is as follows  Obutinib tablets 150mg qd d1-21 (suspended 2 days before MTX use until MTX drops to safe concentration) Rituximab 375mg/m2, d1 Methotrexate 3g/m2, d2"
224207669|NCT01339468|DRUG|Prograf|intravenous
224207670|NCT02494583|BIOLOGICAL|Pembrolizumab|Pembrolizumab 200 mg IV on Day 1 of each week in 3-week cycles for up to 35 cycles (approximately 2 years).
224207671|NCT02494583|DRUG|Cisplatin|Cisplatin 80 mg/m\^2 IV on Day 1 of each week in 3-week cycles (6 cycle maximum per local country guidelines).
224207672|NCT02494583|DRUG|5-FU|5-FU 800 mg/m\^2/day IV continuous from Day 1-5 of each 3-week cycle.
224207673|NCT02494583|DRUG|Capecitabine|Capecitabine 1000 mg/m\^2 twice daily by oral tablet on Day 1-14 of each 3-week cycle.
224207674|NCT02494583|DRUG|Placebo|Normal saline IV on Day 1 of each week in 3-week cycles for up to 35 cycles (approximately 2 years).
224207675|NCT06567483|DEVICE|ELISIO21HX|Super-high flux dialyzers (ELISIO21HX) will be used. The blood flow rate and dialysate flow rate will be set as 400 and 800 ml/min respectively for 4 hours of dialysis.
224207676|NCT06233058|DRUG|Drospirenone+ Ethinyl Estradiol Tablets-Test product|Drospirenone (3 mg) + Ethinyl Estradiol (0.03 mg) Tablets Manufactured by: Umeda Company Limited, Thailand
224207677|NCT06233058|DRUG|Drospirenone+ Ethinyl Estradiol Tablets-Reference product|Drospirenone (3 mg) + Ethinyl Estradiol (0.03 mg) Tablets Manufactured by: Bayer AG, Berlin, Germany
223618973|NCT06703671|DEVICE|electroacupuncture group|"According to the acupuncture prescription, the acupuncture doctor carried out acupuncture and lifting and twisting, and qi appeared under the needle. Select waist Jiaji point and Shenshu point on the same side to connect a set of electronic needle therapy instrument, the positive pole (red clip) connected to Shenshu point, the negative pole (white clip) connected to waist Jiaji point, after confirming that the electric current intensity of the electric needle instrument returns to zero, open the electronic needle therapy instrument, select continuous wave, 2Hz, current intensity 2mA. During the process of needle retention, the other points were injected every 15 minutes and retained for 30 minutes.The investigators have developed detailed acupoint positioning and operation rules."
223618974|NCT06703671|DEVICE|sham-acupuncture group|The investigators fixed the foam pad with one hand and inserted a comfort needle with the other, making sure the needle only touched the surface of the skin and did not penetrate the point. After the completion of all acupoint operations, the operator selected the simulated needle insertion points of Jiaji point on the waist and Shenshu point on the same side. An electroacupuncture treatment device designed to connect a circuit interrupt treatment is operated with the electroacupuncture group, a process that ensures that the participant does not experience any perceptible stimulation
223618975|NCT06727435|DRUG|non-sedation strategy|Patients eligible for this study will undergo non-sedation strategy, which continuous analgesia without sedation is performed with remifentanil. The remifentanil will be titrated (from 0.1µg/kg/min to 0.2ug/kg/min) every 10-15 minutes to achieve the goal for sedation (RASS score maintaining -2 to + 1). The patients in the non-sedation trial do not receive any sedatives but could receive bolus doses (2.5 or 5mg) of morphine for analgesia.
223618976|NCT06726356|PROCEDURE|Bronchoalveolar Lavage|Bronchoalveolar lavage with saline or saline-acetylcysteine solution on the basis of conventional clinical treatment, with a volume of 90 ml per target lung lobe, up to a maximum of 2 lobes, and a total volume of up to 180 ml.
223618977|NCT06725472|PROCEDURE|Open Heart Surgery|This is a general term for surgical procedures that directly access the heart through an opening in the chest to treat heart problems.
223618978|NCT06725836|PROCEDURE|Implantation of electrodes into the epidural space for spinal cord stimulation|Under X-ray guidance and with neurophysiological supervision, the electrode is implanted. The stimulator is surgically placed in a pocket formed in the iliac crest area on the left side, where it is secured. The generator is connected to an electrode array positioned on the dorsal epidural surface of the spinal cord at the appropriate level (sacral-lumbar/cervical region), as confirmed by intraoperative fluoroscopy.
223618979|NCT06725836|PROCEDURE|Selection of the optimal spinal cord stimulation program for spastic syndrome suppression|During the selection of the optimal stimulation program for spasticity suppression, spinal cord stimulation (SCS) is performed at various sites on the electrode array. Stimulation is initiated at a specific site with a frequency of 60 Hz, and the intensity is gradually increased until the spasticity is alleviated (i.e., the limb can flex and extend without restriction). If there is no effect, the stimulation frequency is increased by 5 Hz, and the intensity is again adjusted from 0 to comfortable values. Stimulation is sequentially applied at different sites, and those sites where muscle spasticity is most effectively suppressed are selected.
223618980|NCT06725836|PROCEDURE|Selection of the optimal spinal cord stimulation program for volitional motor control|Over the course of two weeks, the configuration of the electrodes and the intensity of the stimulation are adjusted to ensure optimal voluntary muscle control. A systematic approach is used to determine the most suitable settings. First, the anodes and cathodes on the electrode array are identified. The desired frequency range is 20-40 Hz. The pulse width is determined empirically. The adjustment begins at 20 Hz, with the stimulation intensity gradually increased. If unpleasant sensations (such as muscle spasms or pain) occur, the intensity is reduced to comfortable values. If there is no effect, the stimulation frequency is increased by 5 Hz, and the intensity is adjusted again from 0 to comfortable levels. Stimulation is sequentially applied at different sites, with the sites that provide the most effective voluntary muscle control being selected.
224207678|NCT06565832|PROCEDURE|One-Minute Sit-to-Stand Test|This test involves sitting down and standing up from a normal height chair (can be a dining room or kitchen chair at home) for one minute. Participants can rest or stop at any time if fatigued. Participants will be asked to record your heart rate and oxygen levels before and after the test and will be given a monitor to do this with if they do not already have one. This test should take a maximum of 5 minutes.
224207679|NCT06565832|PROCEDURE|Chester Step Test|This test involves the participant stepping up and down off of a step (this can be a bottom stair or doorstep at home) keeping up with the beat of a recording. The speed of the beat increases every 2 minutes, and the test continues until the participant cannot keep up with the pace, wish to stop or the test ends which takes 10 minutes. Participants will be asked to record heart rate and oxygen levels before and after the test. This test should take a maximum of 15 minutes.
224315191|NCT03228797|PROCEDURE|an ultrasound guided rectus sheath block &multiholed catheter|a multiholed catheter will be inserted as in Group II and will receive also an ultrasound guided rectus sheath block as described for Group I.
223618981|NCT06725836|DIAGNOSTIC_TEST|Resting electroencephalography for identifying neurocorrelates of spinal cord stimulation.|The procedure utilizes the method of electroencephalography (EEG). Throughout the procedure, EEG signals are recorded. Initially, the participant is recorded in a resting state before the implantation of the stimulator for 20 minutes (5 minutes with eyes open, followed by 5 minutes with eyes closed). After the surgery, the participant is recorded in the same manner before the first activation of the stimulator. After selecting the programs, the participant is recorded without stimulation (eyes open, then closed), followed by recordings with the spinal cord stimulator (SCS) activated (eyes open, then closed). The stimulation is then turned off again, and recording is conducted with eyes open and closed. Before discharge, the participant is recorded in a resting state for 20 minutes with the stimulation program active.
224315192|NCT00311597|PROCEDURE|Radiosurgery|single fractionated radiation therapy
224315193|NCT04786847|BIOLOGICAL|177Lu-DOTA-TLX591|TLX591, a monoclonal antibody HuX591 conjugated with a DOTA chelator and radiolabelled with 177Lu (177Lu-TLX591)
224315194|NCT04050215|PROCEDURE|Computed Tomography|Undergo PET/CT
224315195|NCT04050215|DRUG|Gallium Ga 68-labeled PSMA-11|Given IV
224315196|NCT04050215|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
224315197|NCT04050215|OTHER|Questionnaire Administration|Ancillary studies
224315198|NCT03946852|DEVICE|Abdominal Regional Perfusion|Abdominal Regional Perfusion
223512683|NCT02305615|OTHER|Bevacizumab|Bevacizumab at a dose and schedule according to approved label and SmPC. The recommended dose of bevacizumab, administered as an intravenous infusion, is either 5 milligrams per kilogram (mg/kg) or 10 mg/kg of body weight given once every 2 weeks or 7.5 mg/kg or 15 mg/kg of body weight given once every 3 weeks. Bevacizumab is always used in combination with chemotherapy for the treatment of participants with metastatic CRC. It is recommended that treatment be continued until progression of the underlying disease or until unacceptable toxicity.
223680400|NCT04097782|BEHAVIORAL|Antenat education|Antenatal education group The primiparous pregnant women assigned to the intervention group participated in education classes in groups of 8-10 people. Pregnant women were given structured antenatal education twice a week for two weeks (240 minutes). The total education time was 16 hours. Each session comprised 150 minutes presentation of theoretical knowledge, 45 minutes warm-up and stretching exercises, and 45 minutes relaxation exercises.
224207680|NCT00898742|GENETIC|DNA and tissue microarray analysis|The lab has a candidate gene expression signature for the prediction of the cetuximab response. It may be possible to identify patients who will respond to cetuximab based on the patterns of gene and protein expression.
224207681|NCT00898742|GENETIC|reverse transcriptase-polymerase chain reaction|The lab has a candidate gene expression signature for the prediction of the cetuximab response. It may be possible to identify patients who will respond to cetuximab based on the patterns of gene and protein expression.
224207682|NCT00898742|OTHER|mass spectrometry|The lab has a candidate gene expression signature for the prediction of the cetuximab response. It may be possible to identify patients who will respond to cetuximab based on the patterns of gene and protein expression.
224207683|NCT03008252|OTHER|Lactose breath test|Lactose breath test in NCWS patients with symptoms related to milk and/or milk derivates ingestion.
224207684|NCT03008252|OTHER|DBPC cow's milk protein challenge|DBPC cow's milk protein challenge in NCWS patients with symptoms related to milk and/or milk derivates ingestion.
224207685|NCT01059942|OTHER|mock handoff exposure|Attending and house-staff physicians will analyze six video scenarios using the Hand-off CEX, rating each of the dimensions of hand-off competence for both the senders and receivers of the mock hand-off.
224207686|NCT01059942|OTHER|Introduction of CEX tool in Actual Hand-offs|We will teach hospitalist physicians and house-staff how to utilize the Hand-off CEX in conducting their own hand-offs.
224207687|NCT03666299|DRUG|Lidocaine|Infusion of 2% lidocaine hydrochloride at 4 mL/h, started after tracheal intubation and discontinued until 24 h after surgery.
224207688|NCT03666299|DRUG|Control|Infusion of normal saline at 4 mL/h, started after tracheal intubation and discontinued until 24 h after surgery.
224207689|NCT01844869|DRUG|omacetaxine mepesuccinate|
224207690|NCT02802007|DEVICE|Elipse Intragastric Balloon|
224207691|NCT05443009|DRUG|Lidocaine|A buccal infiltration injection followed by palatal injections and interpapillary injections of 2% lidocaine with 1:100,000 epinephrine will be administered.
224207692|NCT05443009|DRUG|Articaine|A single buccal infiltration injection of 4% articaine with 1:100,000 epinephrine will be administered.
224207693|NCT05988411|DEVICE|Renal Denervation|Renal denervation using the Paradise renal denervation system - a dedicated Renal Denervation (RDN) catheter that delivers a circumferential ring of ablative ultrasound energy
224315199|NCT05099250|DRUG|Bupivacain|local anesthetic agent
223512684|NCT02305615|COMBINATION_PRODUCT|Chemotherapy|Fluoropyrimidine-based doublet chemotherapy (5-Fluorouracil \[5-FU\] or capecitabine plus oxaliplatin or irinotecan) as first-line treatment; and continued fluoropyrimidine treatment with or without treatment modification for oxaliplatin or irinotecan, as per treating physician discretion.
223512685|NCT03722030|OTHER|Baseline Measures|Accelerometer (steps), Biomarkers (finger prick for hemoglobin A1c and c-reactive protein), Anthropometrics (height, weight, waist and hip circumference), Body composition (dual-energy absorptiometry for measuring fat mass, lean mass, % body fat, visceral fat), Functional fitness test.
223512686|NCT03722030|BEHAVIORAL|Strength-Training|2 sessions per week (20-40 min), home-based resistance training
223512687|NCT03722030|OTHER|Mid-point Measures|Accelerometer (steps)
223512688|NCT03722030|OTHER|Post-Study Measures|Accelerometer (steps), Biomarkers (finger prick for hemoglobin A1c and c-reactive protein), Anthropometrics (height, weight, waist and hip circumference), Body composition (dual-energy absorptiometry for measuring fat mass, lean mass, % body fat, visceral fat), Functional fitness test.
224207694|NCT05988411|DEVICE|Catheter Ablation|Catheter ablation - one of the most common procedures performed by Cardiac Electrophysiologists for atrial fibrillation.
224207695|NCT03405701|PROCEDURE|IVM|Patients in IVM group will receive FSH (Menopur, Ferring) for 2 days on day 2/3 of the menstrual cycle (spontaneous/ OCP administration) and the ultrasound scan will be performed subsequently. Oocytes retrieval will be performed 42 hours after the last injection. Pre-maturation will last for 24-30 hours. ICSI will be used for insemination. Freeze-only on day 3 and frozen embryo transfer will be performed on the subsequent cycle using HRT protocol with a maximum of 2 embryos transferred.
224207696|NCT03405701|PROCEDURE|IVF|Patients in IVF arm will undergo controlled ovarian hyperstimulation with recombinant FSH (Menopur, Ferring) in GnRH antagonist protocol, treatment monitoring using ultrasound scans and blood tests. GnRH agonist will be used for final oocytes maturation. ICSI will be used for insemination. Freeze-only on day 3 and frozen embryo transfer will be performed on the subsequent cycle using HRT protocol with a maximum of 2 embryos transferred.
224207697|NCT00004086|BIOLOGICAL|filgrastim|
224207698|NCT00004086|DRUG|cisplatin|
224207699|NCT00004086|DRUG|cytarabine|
224207700|NCT00004086|DRUG|etoposide|
223512689|NCT02816970|DRUG|Vildagliptin|1 tablet contains 50 mg vildagliptin
223512690|NCT02816970|DRUG|Vildagliptin|1 tablet contains 50 mg vildagliptin
223512691|NCT05223712|OTHER|Diagnostic Test: Chronic Kidney Diseases|The development datasets were used to train the deep learning model, which was validated and tested by the other 4 datasets.
224207701|NCT00004086|DRUG|ifosfamide|
224207702|NCT00004086|PROCEDURE|autologous bone marrow transplantation|
224207703|NCT00004086|PROCEDURE|peripheral blood stem cell transplantation|
224207704|NCT00004086|RADIATION|indium In 111 LL2 IgG|
224207705|NCT00004086|RADIATION|yttrium Y 90 epratuzumab|
224315200|NCT05099250|DRUG|magnesium sulfate|In the central nervous system , it has depressant effects, by antagonism at NMDA receptors and through inhibition of release of catecholamines
223618982|NCT06725836|DIAGNOSTIC_TEST|Electroencephalography within the motor imagery paradigm|The procedure utilizes the method of electroencephalography (EEG). Throughout the procedure, EEG signals are recorded. During the experiment, with the stimulator turned off, the participant views a fixation cross on a computer screen. Then, they hear an auditory signal and see a sign indicating a specific movement (complete flexion and extension of the left arm, complete flexion and extension of the right arm, complete flexion and extension of the left leg, complete flexion and extension of the right leg). The participant imagines the movements according to the auditory and visual signals on the screen. Subsequently, the participant performs the same movements in the same order. The motor control stimulation program is then activated, and the entire sequence is repeated (first imagining the movement, then performing the imagined movements). The timing of the command presentations is recorded with marker placements.
224207706|NCT02515461|DEVICE|Low energy shockwave therapy|"Procedure: The patient lies on supine position during treatment. Kidney will be localised in line ultrasound. 3000 shockwaves at a frequency of 4 Hz are applied to each kidney per session. The kidney will be divided into three treatment areas including 1000 shockwaves applied to each treatment area.~Patients will receive 6 sessions over 3 weeks. Treatments are carried out on day 1, day 3, day 7, day 10, day 14, and day 17 after enrollment (average time points).~Treatment is performed using the MODULITH SLX-F2, manufactured by STORZ MEDICAL AG."
224315201|NCT05099250|OTHER|saline|medical solution
224315202|NCT05602324|DIETARY_SUPPLEMENT|Lauric Acid and Berberine|intervention (15 ml lauric acid + 1000 mg berberine) will be provided daily to participants in this arm for the duration of time that they receive enteral nutrition for a period of 14 days maximum
224315203|NCT00590616|PROCEDURE|transthoracic examination|observational transthoracic examination
224315204|NCT00411411|DRUG|Januvia|200 mg t.i.d
224207707|NCT03386071|DRUG|Trametinib 2 mg|The dosage of trametinib for oral administration is 2mg once daily.
224207708|NCT01419873|DRUG|Actrapid Human Insulin|Actrapid Insulin is a drug used in routine neonatal practice to treat hyperglycaemia. The intervention in this study was to base dosing on insulin by a computer based-model approach as opposed to sliding scales, fixed protocols or clinician intuition
224207709|NCT03601923|DRUG|Niraparib|"Niraparib belongs to a class of anti-cancer agents known as PARP (poly ADP ribose polymerase) inhibitors. PARP is a protein in the body that repairs damage to DNA (one of the building blocks of a cell). In cells that are rapidly growing, such as cancer cells, blocking repair of DNA may be of benefit, since it will cause the cell to die.~Niraparib will be given at an initial dose of 200mg or 300 mg by mouth once daily depending on the patient's platelet count and weight at the start of the trial."
224207710|NCT06270160|DIAGNOSTIC_TEST|HIVST|Peer navigators will demonstrate how to use an HIVST kit, including how to 1) open the kit, 2) collect the oral fluid samples, and 3) read the results. In addition to HIVST education, participants will be offered optional pre-test counselling and SMS contact information to connect with their peer navigator. If participants do not want post-test counselling, the PN will follow up within two weeks. If the participants report testing positive, then they will be immediately scheduled for confirmatory testing and enrolled in the support programs at MARPI for young people living with HIV.
224207711|NCT06270160|DEVICE|mHealth|The investigators are collaborating with the WelTel non-profit agency for a supportive SMS intervention. The WelTel system will manage the SMS intervention on their structured mobile phone platform (all SMS interactions are logged). Weekly 2-way supportive messages will automatically be sent on the same weekday with WelTel software to Arm 2+3 participants. The peer navigator will ask Arm 2+3 participants to respond to the SMS within 48 hours to confirm their wellbeing and will follow-up with non-responders. The Arm 2+3 peer navigators and Research Coordinator will access the server every 24-48 hours to triage and respond to participants who express a problem or need.
224207712|NCT06270160|BEHAVIORAL|Creating Futures Livelihoods program|Creating Futures is a group intervention that aims to help young people build their livelihoods, and was designed for use with youth (18-24) in urban informal settlements in South Africa.
224207713|NCT01280305|DRUG|raloxifene|raloxifene 60 mg bid
224207714|NCT01280305|DRUG|placebo|Placebo bid
224207715|NCT00692601|DIETARY_SUPPLEMENT|Acute consumption of Capsiate Natura|10 capsules = 3 mg total capsiate. Consumed ONCE orally as capsules 30 minutes before starting to exercise. 3 active capsules containing 1 mg capsiate each and 7 placebo capsules.
224207716|NCT00692601|DIETARY_SUPPLEMENT|Acute consumption of Capsiate Natura|10 capsules = 10 mg total capsiate. Consumed ONCE orally as capsules 30 minutes before starting to exercise. Each capsule contains 1 mg capsiate.
224315205|NCT00411411|DRUG|Placebo|Placebo
224315206|NCT03886298|PROCEDURE|radiofrequency splanchnic denervation|the authors will denervate the splanchnic nerves via radiofrequency
224315207|NCT03886298|PROCEDURE|retrocrural celiac denervation|the authors will denervate the splanchnic nerves in the retrocrural space via injection of alcohol
224315208|NCT04913558|OTHER|Aerobic exercise|"The exercise will be performed by using the treadmill as the following:~\- The first stage (warming up): It consists of 5 minutes warming up with the treadmill speed set at 1.0 mile per hour.~\- The second stage (active stage): It consists of 20 minutes with the treadmill speed set at 3.0 miles per hour.~\- Third stage (cooling down): It consists of 5 minutes of cooling down with the treadmill speed set at 1.0 miles per hour."
224315209|NCT04913558|OTHER|Traditional Treatment|"1. General advice for reducing fatigue and stress~2. Fluid and diet advice~3. Carrying the Baby~4. While Breastfeeding in a sitting position~5. Selecting Clothing"
224315210|NCT03317418|OTHER|ATR-FTIR Spectrophotometry|Spectrometry imaging
224315211|NCT04559737|OTHER|Case Management|"Population management platforms capable of automatically risk stratifying patients (eg, automatically identifying poor users) may be another cost-effective technology-based tool by enabling a management by exception (MBE) follow-up intervention. This intervention concentrates provider effort on patients most at need by allowing providers to passively observe successful users and actively intervene only in CPAP strugglers. Therefore, in addition to Usual Care we will implement this population management process by identifying CPAP strugglers only and further follow-up encounters will be triggered for these select patients for troubleshooting. Additionally, throughout the 1-year period, Q1 window of \<70% nights \>4 hours will trigger a phone call and at the discretion of the sleep provider convert to video or in-person encounter for troubleshooting. CPAP Follow-Up Questionnaire will also be delivered to patient at 3 months and 1 year."
224315212|NCT02940132|DRUG|SC10914|SC10914 will be administered orally.
224315213|NCT00800007|DRUG|ANZ-521|3x10\^7 cfu or 3x10\^8 cfu ANZ-521 in 250 mL, IV over 2 hours, every 28 days for up to 3 doses.
224315214|NCT00800007|DRUG|Placebo|250 mL normal saline, IV over 2 hours, every 28 days for up to 3 doses.
223618983|NCT06921135|DIETARY_SUPPLEMENT|supplementation, food|Supplementation of fresh foods
223618984|NCT06922578|PROCEDURE|NeoPUTTY MTA pulpotomy|Neoputty MTA pulpotomy performed in vital primary molars with symptomatic irreversible pulpitis
223618985|NCT06922578|PROCEDURE|Endoflas pulpectomy|Endoflas pulpectomy in vital primary molars with symptomatic irreversible pulpitis
223618986|NCT06921811|OTHER|Intact chickpeas|Salad meal containing intact chickpeas
224315215|NCT00923273|DRUG|FDG-PET|PET CT will be performed at baseline and after two cycles of treatment.
224207717|NCT00692601|DIETARY_SUPPLEMENT|Acute ingestion of identical placebo capsules|10 mg placebo = 0 mg total capsiate. Consumed ONCE orally as capsules 30 minutes before starting to exercise. Each capsule contains 1 mg capsiate.
224207718|NCT03452722|DRUG|intraventricual recombinant tissue plasminogen activator application|
224207719|NCT01796769|DEVICE|Continuous Positive Airway Pressure (CPAP) in sleep apnea patients|Usual CPAP treatment in sleep apnea patients
224207720|NCT01796769|DEVICE|Continuous Positive Airway Pressure (CPAP) in sleep apnea patients|CPAP treatment with telemedicine system
224207721|NCT05805293|DEVICE|High-Velocity Nasal Insufflation Therapy|"Parameter settings for the HVNI apparatus are as follows:~1. The flow of HVNI will initially be set at 30-40 L/min, and inspiratory flow rate could be increased to 45-60 L/min.~2. FIO2 will be adjusted to maintain a SaO2 more than 90 % and relative humidity of 30-34%.~3. Temperature range of 35-37°C."
224207722|NCT05805293|DEVICE|Non-Invasive Ventilation|Patients will be put on inspiratory/expiratory pressure 10/5 cmH2O (11). The inspiratory and expiratory pressures will be titrated with increments of 2 cmH2O based on improvement of oxygen saturation by continuous pulse oximetry and arterial blood gases values, alleviation of dyspnea and a decrease of respiratory rate and heart rate. The maximum allowed inspiratory pressure was 20 cm H2O. The maximum allowed expiratory pressure was 10 cm H2O.
224207723|NCT02439593|OTHER|Chemoradiotherapy (CTRT)|CTRT arm: Locoregional radiotherapy along with concurrent weekly gemcitabine
224315216|NCT00923273|DRUG|Pemetrexed|
224315217|NCT00923273|DRUG|Sirolimus|
224315218|NCT00923273|DIETARY_SUPPLEMENT|Vitamin B12|1000 micrograms intramuscularly every 63 days administered the preceding first dose of pemetrexed
223618987|NCT06921811|OTHER|Broken chickpeas|Burger meal containing chickpea flour
223618988|NCT03741088|DEVICE|VORTX Rx treatment|Cavitation-based cellular destruction using focused ultrasound
223618989|NCT06726980|DRUG|dextrose 5%|patients will receive 5 % dextrose infusion
223618990|NCT06726980|DRUG|Dextrose 10%|patients will receive 10 % dextrose infusion (25gm/ 250 mL)
223618991|NCT06726980|DRUG|0.9% saline|patients will receive infused IV 0.9 % saline
223618992|NCT06705075|DRUG|Perfluten|Use of UCA Definity to evaluate uterine fibroids by contrast-enhanced ultrasound (CEUS) and subharmonic-aided pressure estimation (SHAPE) pre and post-uterine artery embolization (UAE).
223618993|NCT05776251|DEVICE|taVNS|"Includes the use of Soterix Medical Device, which consists of a handheld smart-phone size device. There are two electrodes (designed for studies in infants) with small patches that the participant places on the external ear (the cymbals conchae and the tragus). The stimulation intensity is personalized for each participant based on perceptual threshold."
223618994|NCT06890702|DIAGNOSTIC_TEST|biomaker levels|this study will discover and validate novel biomarkers (including urine, feces, cerebrospinal fluid, blood, plaques, emboli, drainage fluid, bone marrow, lymph nodes and brain tissue etc al) of ischemic cerebrovascular disease
223680401|NCT03562767|BEHAVIORAL|Group-based Cognitive Behavioral Intervention|This intervention will include six 1-hour group sessions held biweekly for twelve weeks. Each sixty-minute session will consist of 15 minutes of diabetes education regarding exercise and food planning and approximately 45 minutes of CT-CB presentations/engagement activities. Participants will be encouraged to bring along their family members or friends for support.
224207724|NCT02439593|OTHER|Thermochemoradiotherapy (CTRTHT)|Locoregional hyperthermia with concurrent chemoradiotherapy with weekly gemcitabine
224207725|NCT02848859|BEHAVIORAL|Go! to Sleep|This is an online interactive program that delivers cognitive behavioral therapy for insomnia via the internet.
224207726|NCT02848859|BEHAVIORAL|General Sleep Education|Providing patients information on healthy sleep and habits to promote healthy sleep.
224207727|NCT04250506|DRUG|Daridorexant|Daridorexant (ACT-541468) administered as film-coated tablets for oral use.
224207728|NCT04250506|DRUG|Placebo|Placebo administered as tablets for oral use.
224207729|NCT04250506|DRUG|Moxifloxacin|Moxifloxacin administered as film-coated tablets for oral use.
224207730|NCT03904602|DEVICE|Edema Wear fuzzy wale compression garment|net-like compression structure of Lycra spandex elastic yarn with longitudinal fuzzy wales (similar to corduroy fabric)
224207731|NCT01356290|DRUG|Bevacizumab|10mg/kg, intravenous (iv), biweekly, 1 year
224207732|NCT01356290|DRUG|Thalidomide|3mg/kg, oral, daily, 1 year
224207733|NCT01356290|DRUG|Celecoxib|50-400mg, oral bid, daily, 1 year
224207734|NCT01356290|DRUG|Fenofibric acid|90mg/m2, oral, daily, 1 year
224207735|NCT01356290|DRUG|Etoposide|35-50 mg/m2, oral, alternating 21-day cycles of daily oral etoposide and cyclophosphamide, 1 year
224207736|NCT01356290|DRUG|Cyclophosphamide|2.5mg/kg, oral, alternating 21-day cycles of daily oral etoposide and cyclophosphamide, 1 year
224207737|NCT01356290|DRUG|Etoposide phosphate|0.5mg, intrathecal, day 1-5, every four weeks, alternating with intrathecal liposomal cytarabine, 1 year
224207738|NCT01356290|DRUG|Cytarabine|16-30mg, intrathecal, twice weekly for two weeks out of every four weeks, alternating with intrathecal etoposide phosphate, 1 year
224207739|NCT06538428|GENETIC|DNA methylation profiling|measurement of methylation levels of MGMT, NUPR1,NDRG2,and GLI1 gene
224315219|NCT00923273|DIETARY_SUPPLEMENT|Folic acid tablets|1 mg dose every 63 days administered during the week preceding first dose of pemetrexed and will be continued for 21 days following last dose of pemetrexed.
224315220|NCT00923273|DRUG|Dexamethasone tablets|4 mg dose twice daily the day before, the day of, and the day after pemetrexed.
224207740|NCT05564507|DIAGNOSTIC_TEST|TEE simulation-based training|"All participants of the TEE simulation-based training group received:~1. a traditional didactic training using e-learning with a national free-access online course;~2. two teaching sessions using a TEE simulator for 2 hours per session. The simulation session will involve standardized initial teaching of normal cardiac, including anatomy of mitral valve with some mitral regurgitation cases, aortic valve, tricuspid valve, interatrial septum, and left atrial appendage, and demonstration of image acquisition by the teacher (time duration: 30 min). The duration of each session was 2 h with a 6:1 student to instructor ratio. Each subject had a dedicated 20 min of hands-on to manipulate the probe and undertake a sequential TEE examination under the supervision of the teacher. Other participants could watch their colleagues working on the TEE simulator."
223512692|NCT00388141|BEHAVIORAL|NIDCAP|Systematic care, where the mother and the nurses organize the caring on behalf of the preterm infants' ressources and developmental capacity such as the infant avoid over stimulation and distress
224207741|NCT01158976|DIETARY_SUPPLEMENT|Docosahexanoic Acid|450 mg DHA daily beginning at 16-21 weeks gestation and continuing up to time of delivery
224207742|NCT01158976|OTHER|Placebo|soybean oils with strawberry flavoring
224207743|NCT02959554|DRUG|Nivolumab|240 mg i.v. on D1 of every cycle (Q2W) for 16 weeks. After 16 weeks 480 mg i.v. on D1 of every cycle (Q4W) until disease progress, intolerable toxicity, withdrawal of consent or end of study.
224207744|NCT02959554|DRUG|Sunitinib|According to Standard of Care (SOC). Recommended dose is 50 mg p.o. once daily for 4 consecutive weeks followed by a 2-week rest period (schedule 4/2) to comprise a complete cycle of 6 weeks (until disease progress, intolerable toxicity, withdrawal of consent or end of study).
224207745|NCT02959554|DRUG|Pazopanib|According to Standard of Care (SOC). Recommended dose is 800 mg p.o. daily continuously (until disease progress, intolerable toxicity, withdrawal of consent or end of study).
224207746|NCT00769431|OTHER|educational intervention|
224207747|NCT00769431|OTHER|study of socioeconomic and demographic variables|
224207748|NCT02611531|BEHAVIORAL|Video Module Education (VME)|Participants will complete inhaler education on a tablet device
224207749|NCT02611531|BEHAVIORAL|Teach-To-Goal (TTG)|Participants will complete intensive in-person inhaler education
224207750|NCT06650046|PROCEDURE|Topping-off Group|"Topping-off group Patients who have undergone the Topping-off system insertion surgery for lumbar spondylosis and have complete follow-up data and meet the standards completed at the First Affiliated Hospital of Shandong First Medical University.~Fusion group Patients who have undergone lumbar spine fusion surgery due to lumbar spondylosis and meet the standards and have complete follow-up data completed at the First Affiliated Hospital of Shandong First Medical University."
224207751|NCT06650046|PROCEDURE|Fusion Group|"Topping-off group Patients who have undergone the Topping-off system insertion surgery for lumbar spondylosis and have complete follow-up data and meet the standards completed at the First Affiliated Hospital of Shandong First Medical University.~Fusion group Patients who have undergone lumbar spine fusion surgery due to lumbar spondylosis and meet the standards and have complete follow-up data completed at the First Affiliated Hospital of Shandong First Medical University."
224207752|NCT01884909|DRUG|Metoprolol Succinate ER Tablet 200 mg|1 \* 200 mg tablet per day
224207753|NCT01884909|DRUG|'TOPROL-XL®' ER Tablets 200 mg|1 \* 200 mg tablet per day
224207754|NCT05921370|DRUG|Silodosin 8 mg|"This prospective study will be conducted on patients prepared for Retrograde intrarenal surgery presented to Ain Shams University Hospital. Patients will be randomized with 1:1 ratio into 2 equal groups.~Group A (the study group): Patients will receive silodosin 8 mg one tablet per day for 7 days before their scheduled retrograde intrarenal surgery.~silodosin is an alpha blocker which act to dilate the ureter to facilitate access sheath placement"
224207755|NCT05921370|DRUG|Placebo|"This prospective study will be conducted on patients prepared for Retrograde intrarenal surgery presented to Ain Shams University Hospital. Patients will be randomized with 1:1 ratio into 2 equal groups.~Group A (the study group): Patients will receive silodosin 8 mg one tablet per day for 7 days before their scheduled retrograde intrarenal surgery.~Group B (the control group): Patients will receive Placebo for 7 days before their scheduled retrograde intrarenal surgery."
224207756|NCT03151707|DRUG|Nicotinamide Riboside|Nicotinamide riboside 2g/day for a 2 week duration
224207757|NCT01395693|DEVICE|Salt Lake mask system|Study participants will Salt Lake mask system for 1 week in place of their current mask system.
224207758|NCT03311386|DRUG|Actilyse|thrombolytic therapy
224207759|NCT00740532|GENETIC|Gene mutation analyses and FISH|FISH and mutation analyses of multiple genes
223512693|NCT03258957|OTHER|Fresh Milk|Mothers will be asked to provide at least 1 feed of fresh milk (i.e. within 4 hours of milk expression) per day, other time, feed frozen milk
223512694|NCT06300684|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia (CBT-i)|This intervention involves structured sessions aimed at addressing maladaptive sleep behaviors and promoting healthy sleep habits. Participants in this group will engage in cognitive restructuring, relaxation techniques, and sleep hygiene education to improve sleep quality and duration. The goal of CBTi is to modify behaviors and thoughts that contribute to insomnia, leading to more restful and consolidated sleep patterns.
223512695|NCT01628809|BEHAVIORAL|Mindfulness-Based Stress Reduction|three-day mindfulness-based meditation retreat program
223512696|NCT03272893|BEHAVIORAL|Acceptance and Commitment Therapy|The main component in the treatment is exposure to symptoms and feared situations. The iACT program is adapted from the evidence based face-to-face treatment at the Behavioral Medicine unit at Karolinska University Hospital. The iACT program has a different structure but is equal in content to face-to-face treatment, and is to be completed within ten weeks. Participants receive texts, audio files, movies and exercises and have online contact with their psychologist via an internet platform or a smart phone application. The treatment aims to encourage valued behaviors in the presence of inner discomfort.
223680764|NCT02478398|DRUG|Mometasone furoate monohydrate|Intranasal spray, at doses of 1 spray (50 mcg/ spray) per nostril for participants 5 to 11 years old or 2 sprays (50 mcg/spray) per nostril for participants 12 to 17 years old, as needed for rhinoconjunctivitis symptoms
224207760|NCT06017856|OTHER|Life style intervention program|Life style intervention program for the obese/overweight subjects conducted regardless of this study at the child sport and health center at Meir medical center
223618995|NCT06727461|OTHER|Home-based Feeding EnhancEment in Dementia (Feed@home)|"The FEED@home program is an 8-week initiative led by a speech therapist (ST) and nurse team through teleconsultations and home visits:~* Within 3 days after discharge, a nurse teleconsultation with the family caregiver to assess the patient's mealtime behaviors and provide feeding strategy recommendations and educational materials.~* Two to three home visits by STs during mealtime (depending on the mastery of feeding techniques) to assess swallowing and cognitive feeding issues, providing tailored interventions and proper training of feeding techniques.~* Two teleconsultations by nurses to assess the caregiver's techniques and provide additional training.~* One additional home visit during mealtime by a nurse to assess the caregiver's mastery of the feeding techniques through observation.~* The program lasts 8 weeks, regardless of readmissions, unless the patient converts to tube feeding, moves to a care home, passes away, or withdraws from study."
223618996|NCT06727019|DEVICE|low-level red-light|650-nm low-level red-light
223618997|NCT06727019|DRUG|Atropine (0.01%)|Atropine eye drops at concentration of 0.01%
223618998|NCT06885879|RADIATION|Temporal change of fragmentomics of Circulating tumour DNA undergoing Stereotactic Body Radiation Therapy investigation|"Patients will have blood taking for Circulating tumour DNA (ctDNA) (20cc each) at Week 0 (before radiotherapy), Week 1 (during radiotherapy), Week 2 (after radiotherapy), Week 12 and Week 24.~Radiological assessment will be performed before radiotherapy, Week 12 (approximately 3 months post treatment) and Week 24-26 (approximately 6 months post treatment)."
223618999|NCT06755281|OTHER|Direct Oral challenge|Patients will receive a 1-step or 2-step challenge with the suspected penicillin and will be monitored for any allergic reaction within the first four hours. Patients will be instructed to contact the hospital after the drug provocation test to inquire delayed allergic reactions.
223619000|NCT06755281|OTHER|standard of care|The patient will receive skin prick test and patch test (if a delayed allergy is suspected). Allergen-specific IgE will be measured. If all negative, drug provocation tets will be performed identical to the experimental group.
223761434|NCT06608758|BEHAVIORAL|Electonic health record prompts with education|"1). A baseline audit of diagnostic processes (including data from the Safer DX Checklist and CPT E/M code usage) for patients aged ≥ 3 to 89 years with one or more of 26 diagnoses prone to error to compare cases of PWD with specific disabilities (major mobility impairments,1 mental health concerns,2,3 severe visual impairments/ blindness,4 severe hearing loss/deafness,5 and IDD6,7) versus without the disabilities.~Using analyses of data, chart reviews, staff interviews and mock tracers, a frame of themes underlying increased risk of DE will be co-produced to develop algorithms to identify patients with the specified disabilities at risk. Case studies for education on DE, and EHR prompts, alerts, and decision supports related to the algorithms will be co-produced along with education on the EHR materials. Evaluate for change in use of diagnostic processes among PWD post implementation of algorithms and EHR prompts, alerts and decision supports will be conducted post-intervention."
224207761|NCT01807910|DRUG|methyl-D9-choline|Subjects in both arms will be infused with methyl-D9-choline in order to assess the biosynthesis and kinetics of secretory lipoprotein phospholipids.
224207762|NCT06565910|DRUG|Liposomal bupivacaine plus bupivacaine|Liposomal bupivacaine is a prolonged-release formulation of the local anesthetic bupivacaine. This intervention involves the administration of liposomal bupivacaine plus bupivacaine as a local anesthetic for the pericapsular nerve group (PENG) block under ultrasound guidance. Liposomal bupivacaine is being investigated for its analgesic effect in postoperative pain management following hip replacement surgery. This formulation is designed to provide extended pain relief as compared to conventional bupivacaine formulations.
224207763|NCT06565910|DRUG|Ropivacaine|Ropivacaine is a commonly used local anesthetic in clinical practice, and it serves as the active comparator intervention in this study. Participants in the comparator arm will receive ropivacaine as a local anesthetic for the PENG block under ultrasound guidance.
224207764|NCT01267968|DRUG|GSK2251052|1500 mg (dosing detailed in Arm description)
224207765|NCT06652516|PROCEDURE|plasma exchange|"comparison between the 2 methods of plasma exchange as regards efficacy, performance and adverse events.~Procedure of therapeutic plasma exchange (TPE) :~mTPE will be done by bellco hemodialysis machine (Formula 2000), while cTPE will be done by Nigale Plasma Collector (XJC 2000). The vascular access used for both types of plasma exchange will be central venous catheter inserted into the internal jugular vein, subclavian or femoral vein.~Prescription of TPE The amount of plasma to be treated is usually equivalent to the patient's estimated plasma volume (EPV).~Estimated plasma volume will be calculated using the following formula (Kaplan formula) in litres:~* EPV = 0.07 x wt (kg) x (1 - hematocrit) in males.~* EPV = 0.065 x wt (kg) x (1 - hematocrit) in females."
224207766|NCT01898624|DRUG|mirabegron|oral
224207767|NCT05874518|OTHER|warm needling combined with electroacupuncture|Treatment begins on the 5th day of the menstrual cycle, qd (once a day), usually for 6-8 consecutive days, and continuing to the day of ovulation.
224207768|NCT05874518|DRUG|The treatment with letrozole tablets was started on the fifth day of the menstrual cycle|Letrozole tablets were given at 2.5mg (Jiangsu Hengrui Pharmaceutical Co., Ltd., H19991001, 2.5mg per tablet), po (oral), qd, for 5-7 consecutive days. When the diameter of follicles reaches 18mm, Chorionic gonadotrophin is given at 5000u (Lizhu Group Lizhu Pharmaceutical Factory, Chinese medicine H44020668, 5000u per branch), with intramuscular injection, qd, to promote follicle discharge. Patients were also instructed to have sexual intercourse on the same day and on day 2.
224207769|NCT03058081|DEVICE|High Flow nasal cannula|High intensity Constant Work-Rate exercise test with High Flow Nasal Cannula in COPD patients involved in a Pulmonary Rehabilitation Program after an exacerbation (\< 7 days after hospital discharge). High Flow nasal will be administered through nasal cannula using the Airvo2 (Fisher\&Paykel)
224207770|NCT01875419|DEVICE|Transcranial direct current stimulation (tDCS)|"Patients - tDCS arm: 1 mA current delivered for 20 minutes once a week for 8 weeks, immediately prior to CBT.~Patients - Sham arm: brief current change at the beginning (0 min) and end of each stimulation session (20 min) in order to mimic the effect of an actual stimulation, but no current delivered in between."
224315221|NCT00224419|BEHAVIORAL|Motivational interviewing for smoking cessation|All participants received a tailored CBT (TCBT) intervention that included: a written self-help guide, info about the importance of reducing nicotine exposure to the fetus, 5 face to face and 1 telephone counseling session. Women in the TCBT + NRT arm were guided through a process of deciding on nicotine gum, lozenge or patch. To minimize fetal exposure, the dose of NRT was customized to the woman's current level of smoking. Women who smoked 5-10 cigarettes a day were given the 14 mg patch or instructed to use one 2 mg lozenge or 2 mg piece of gum to replace each cigarette she usually smoked per day. Those who smoked 11 cigarettes or more per day were given the 21 mg patch or instructed to use no more than one lozenge (2 mg) or piece of gum (2 mg) to replace each cigarette she usually smoked per day, not to exceed 15 lozenges or pieces of gum per day.
224315222|NCT00224419|BEHAVIORAL|Cognitive behaviors therapy|6 counseling sessions delivered over the phone or in person
224315223|NCT00224419|DRUG|CBT + NRT|Includes CBT from arm 1 plus choice of NRT (lozenge, gum, or patch) tailored to smoking amount
223619001|NCT03064490|DRUG|Pembrolizumab|Neoadjuvant Pembrolizumab ( 3 cycles) administered concurrently with weekly Carboplatin and Paclitaxel and daily radiation therapy; followed by surgical resection and adjuvant Pembrolizumab ( 3 cycles)
224315224|NCT03040700|OTHER|Myocardial Perfusion Scan|Myocardial perfusion scan will be performed at rest and during pharmacological stress with dipyridamole (99mTc-Sestamibi)
223619002|NCT06777784|OTHER|Product A|Usual Brand (UB) filtered, menthol or non-menthol combustible cigarette
224315225|NCT03040700|OTHER|Coronary CTA|Coronary CTA will be performed using a 320-detector scanner, 0.5 mm slice thickness, with gantry rotation of 350ms. Prior to each scan, the patient's blood pressure and heart rate will be assessed, and if the heart rate is above 70bpm, beta-blockers will be given orally. Following oral beta blocker administration, if the heart rate is still greater than 64bpm, intravenous metoprolol will be administered. A total of 70-100 mL of iodinated contrast will be administered via an automated injector at a rate of 5mL/s. All coronary CTA images will be transferred to a workstation (Vitrea FX-Vital Image) and analyzed by two experienced cardiac imagers who are blinded to all other data using a standard 18-segment coronary tree model.
224315226|NCT03214393|DIAGNOSTIC_TEST|Doppler|Doppler will be done to pregnant women with Pre-Eclampsia
224315227|NCT03214393|DIAGNOSTIC_TEST|serum antibodies|serum antibodies will be measured for pregnant women with Pre-Eclampsia
224315228|NCT03902730|OTHER|Traditional Back Squat|Participants will complete traditional back squat in this four treatment crossover design.
224315229|NCT03902730|OTHER|Barefoot Back Squat|Participants will complete barefoot back squat in this four treatment crossover design.
224315230|NCT03902730|OTHER|Box Squat|Participants will complete box squat in this four treatment crossover design.
224315231|NCT03902730|OTHER|Traditional Back Squat with Chains|Participants will complete traditional back squat with chains in this four treatment crossover design.
224315232|NCT03679182|DRUG|Olanzapine|Olanzapine 5 mg Tab at 0, 12, 24, and 36 hours
223619003|NCT06777784|OTHER|Product B|Modern Nicotine Oral Product Cool Mint 6 mg Nicotine
223619004|NCT06777784|OTHER|Product C|Modern Nicotine Oral Product Cool Mint 12 mg Nicotine
224207771|NCT01875419|BEHAVIORAL|Cognitive Behavioural Therapy|8 sessions of one hour (once weekly) immediately after tDCS or sham stimulation
224207772|NCT00924573|DRUG|Metformin|oral administration
224315233|NCT03795766|PROCEDURE|Surgeries for gynecologic disease|All patients accept surgeries for gynecologic disease.
224315234|NCT01865240|DEVICE|Renal Denervation|Renal Denervation Catheter
224315235|NCT06224465|OTHER|aerobic exercises|"Antiaging diet instruction :Be aware of the amount of calories, Reduce overall fat and sugar intake, Drink at least 10 glasses of water every day in order to remain healthy.~d. Eat a variety of complex carbohydrates and vegetables instead of bread, rice, and corn."
224207773|NCT00924573|DRUG|placebo|oral administration
223619005|NCT06777784|OTHER|Product D|Modern Nicotine Oral Product Cool Mint 15 mg Nicotine
223619006|NCT06777784|OTHER|Product E|Modern Nicotine Oral Product Smooth 6 mg Nicotine
223619007|NCT06777784|OTHER|Product F|Modern Nicotine Oral Product Wintergreen 6 mg Nicotine
223619008|NCT06777784|OTHER|Product G|Modern Nicotine Oral Product Dragon Fruit 6 mg Nicotine
223619009|NCT06777784|OTHER|Product N|Nicorette® White Ice Mint 4 mg nicotine gum
223619010|NCT06188767|DRUG|Testosterone Undecanoate|Following testosterone/placebo injection, participants undergo supervised resistance training for 4 weeks. This period is followed by a washout period with no drug and either continued resistance training or detraining for 16 weeks. Thereafter, another 4-week period with supervised resistance training is commenced, with no drug.
223619011|NCT06607523|DIETARY_SUPPLEMENT|Inulin|Inulin, 4g twice daily for 42 days
224207774|NCT00924573|DRUG|Glimepiride (HOE490)|oral administration
224207775|NCT03264001|BEHAVIORAL|Negative energy balance|20% and 40% reduction of daily energy needs for weight maintenance
224207776|NCT00991146|DRUG|canakinumab|canakinumab
224207777|NCT02504463|DRUG|Samidorphan IV|Single IV administration
224207778|NCT02504463|DRUG|[14c]-Samidorphan sublingual|Single sublingual administration containing radiolabel
224207779|NCT02504463|DRUG|[14c]-Samidorphan oral|Single oral administration containing radiolabel
224207780|NCT05665712|PROCEDURE|enhanced recovery|bundle of factors that have been shown to help with recovery in other surgical services such as good pain control, early ambulation, early nutrition
224207781|NCT06499935|OTHER|Rigid Taping|It is usually light brown or beige and is designed to hold firm, making it ideal for providing support or stability to a joint.
224315236|NCT06380881|DRUG|SHR-2017|SHR-2017
224315237|NCT00509366|DRUG|Cisplatin & Gemcitabine|"Squamous Cell NSCLC:~Gemcitabine 1250 mg/m2 IV over 30 minutes day 1 and 8, followed by Cisplatin 75 mg/m2 IV over 60 minutes day 1; repeat every 21 days for up to 6 cycles"
224315238|NCT00509366|DRUG|Cisplatin & Pemetrexed|"Non-Squamous Cell NSCLC:~Pemetrexed 500 mg/m2 IV over approximately 10 minutes day 1, followed by Cisplatin 75 mg/m2 IV over 60 minutes day 1; repeat every 21 days for up to 6 cycles"
223619012|NCT06770023|DEVICE|Protek Solo Transseptal Cannula|The Protek Solo Transseptal Cannula ECMO cannula will be placed from the right femoral vein and the drainage cannula will be placed from either the left femoral vein or the right internal jugular vein.
223619013|NCT04846387|DIAGNOSTIC_TEST|Magnetic Resonance Imaging (MRI)|"A T1-weighted Anatomical Image, Diffusion Weighted Image, and functional MRI (fMRI) of empty bladder image will be obtained.~Additionally, fMRI image during full bladder state and voiding/holding tasks will be obtained."
223619014|NCT04846387|DIAGNOSTIC_TEST|Post-Void Residual|The patient's post-void residual is determined using a portable ultrasound machine after emptying the bladder just prior to entering the MRI scanner and immediately after the MRI scan.
223761435|NCT06608758|OTHER|Standard of care|Patients without disabilities will receive standard care related to electronic health record prompts, alerts, and decision supports.
223619015|NCT04846387|DIAGNOSTIC_TEST|Uroflowmetry|Patients will urinate into a funnel connected to an electric flow meter to record urine flow rates in mililters per second. This is used as part of the screening process.
223619016|NCT04846387|BEHAVIORAL|Questionaire - AUA Symptom Score|Subjects will fill out questionnaire asking about urinary symptoms. The range is 0-35.
223619017|NCT02647723|DIETARY_SUPPLEMENT|DHA|2 dietary supplement gel capsules providing 450 mg of DHA twice daily by oral intake for 24 weeks
223619018|NCT02647723|DIETARY_SUPPLEMENT|Sugar pill|2 dietary supplement gel capsules providing 450 mg of soybean oil twice daily by oral intake for 24 weeks
224207782|NCT06499935|OTHER|Kinesio-Taping|Kinesio Taping Method is a therapeutic tool utilised by rehabilitation specialists in all programs. Kinesio Taping Method utilises four types of Kinesio Tex Tapes, each with specific properties designed for use on fragile, sensitive skin or applied with higher tensions.
224207783|NCT06499935|OTHER|Sham Taping|Sham taping is the use of any type of tape in a random and ineffective fashion for the purposes of comparison with other taping techniques and types.
224207784|NCT05978817|DEVICE|Damon Ultima bracket|It is metal twin bracket with their recommended arch wire
224207785|NCT06701799|PROCEDURE|CAF+ L-PRF 1 mm|The extent of the depth of the recession will be reported on the anatomical papillae and, after adding 1 mm, 2 horizontal incisions of approximately 3 mm will be made at the base of the surgical papillae laterally to the recession.Two divergent releasing incisions will be made extending approximately 2-3 mm into the alveolar mucosa.The surgical papillae will be detached in partial thickness. A full thickness dissection will be performed from the bottom of the recession to expose approximately 3mm of the crest bone.A partial thickness dissection will be performed in the most apical portion of the flap until complete passivation of the flap is obtained. The L-PRF membrane 1 mm in thickness, will be positioned at the level of the de-epithelialised anatomical papillae.The flap will be repositioned coronally suturing the anatomical papillae on the surgical ones, using a Non-Resorbable 5.0 Polyamide Suture.
224207786|NCT06701799|PROCEDURE|CAF+ L-PRF 2 mm|The extent of the depth of the recession will be reported on the anatomical papillae and, after adding 1 mm, 2 horizontal incisions of approximately 3 mm will be made at the base of the surgical papillae laterally to the recession.Two divergent releasing incisions will be made extending approximately 2-3 mm into the alveolar mucosa.The surgical papillae will be detached in partial thickness. A full thickness dissection will be performed from the bottom of the recession to expose approximately 3mm of the crest bone.A partial thickness dissection will be performed in the most apical portion of the flap until complete passivation of the flap is obtained. The L-PRF membrane 2 mm in thickness, will be positioned at the level of the de-epithelialised anatomical papillae.The flap will be repositioned coronally suturing the anatomical papillae on the surgical ones, using a Non-Resorbable 5.0 Polyamide Suture.
224207787|NCT06650241|OTHER|Behavioral therapy|
224207788|NCT06650241|OTHER|Lip Bumper Therapy|
224207789|NCT06650241|OTHER|Modified Twin-Block Therapy|
223761436|NCT06592586|BIOLOGICAL|GBS-NN/NN2 vaccine|0.5 mL (50 μg GBS-NN +50 μg GBS-NN2 adsorbed to 0.5 mg aluminium as Alhydrogel®)
223619020|NCT06760364|DRUG|CHT102|CHT 102 : MSLN UCAR-T.
224207790|NCT01923961|PROCEDURE|HDF NaCl|
223619021|NCT01806142|OTHER|Medium-chain triglycerides|During Medium-Chain Triglycerides (MCT period), participant will asked to consume two pastries per day that will provide a total of 20 g of MCT/day for 4 weeks.
223619022|NCT01806142|OTHER|Corn oil|During Corn oil period (Control period), participant will asked to consume two pastries per day that will provide a total of 20 g of corn oil/day for 4 weeks.
223619023|NCT03515174|OTHER|Supportive Care Program|This program takes place within one month post-diagnosis of cancer. It will include three info-educational session. After that, recommendations for further consultation with specific healthcare professionals will be made based on the concerns and needs of patients at baseline. Patient will also be given usual care.
224207791|NCT01923961|PROCEDURE|Hemodialysis|
224207792|NCT01923961|PROCEDURE|Standard Predilution Hemodiafiltration|
224207793|NCT06117566|DRUG|WX390|WX390 tablet, once a day
224207794|NCT06117566|DRUG|Toripalimab|240 mg, Day 1, every 3 weeks
224207795|NCT00668369|PROCEDURE|Gradual immunosuppression drug withdrawal.|Ater obtention of biological samples (peripheral blood, liver tissue) enrolled patients undergo gradual decrease in the doses of immunosuppression drugs (tacrolimus, cyclosporine A and/or mofetil mycophenolate) until complete discontinuation or appearance of rejection.
224207796|NCT02362646|BIOLOGICAL|MPC Intramyocardial Injection|Intramyocardial injection of 150 million mesenchymal precursor cells at the time of LVAD implantation
224207797|NCT02362646|DRUG|Control Solution|
224207798|NCT06649643|DIAGNOSTIC_TEST|Inborn errors of immunity|"A. Routine~.1CBC with blood film.~.2Liver Function Test.~.3Kidney Function Test.~4\. Inflamatory marker ESR, CRP~B.Immunology~1. Immunoglobulins IgG, IgM, IgA, IgE~2. Flow cytometric assessment: B Cell (CD19), T cells (CD3,CD4, CD8) anc NK Cells (CD16+56) and other markers whenever needed (e.g. CD40, CD40L for cases of hyper IGM)~3. Chest x-ray to assess thymus and any abnormality~4. DHR123 whenever needed (e.g. chronic granulomatous disease).~5. LAD panel (CD11b CD15-CD18) whenever needed.~6\. Complement assay (CH"
224315239|NCT00509366|DRUG|Docetaxel & Gemcitabine|"Squamous Cell NSCLC:~Docetaxel 75 mg/m2 IV over 60 minutes day 1, followed by Gemcitabine 1250 mg/m2 IV over 30-60 minutes day 1 and alone day 8; repeat every 21 days for up to 6 cycles"
224315240|NCT00509366|DRUG|Pemetrexed & Gemcitabine|"Non-Squamous Cell NSCLC:~Pemetrexed 500 mg/m2 IV over approximately 10 minutes day 1, followed by Gemcitabine 1250 mg/m2 IV over 30-60 minutes day 1 and alone day 8; repeat every 21 days for up to 6 cycles"
224207799|NCT06649643|DIAGNOSTIC_TEST|A. Routine .1CBC with blood film. .2Liver Function Test. .3Kidney Function Test. 4. Inflamatory marker ESR, CRP B.Immunology 1-Immunoglobulins IgG, IgM, IgA, IgE 2-Flow cytometric assessment: B|"A. Routine~.1CBC with blood film.~.2Liver Function Test.~.3Kidney Function Test.~4\. Inflamatory marker ESR, CRP~B.Immunology~1. Immunoglobulins IgG, IgM, IgA, IgE~2. Flow cytometric assessment: B Cell (CD19), T cells (CD3,CD4, CD8) anc NK Cells (CD16+56) and other markers whenever needed (e.g. CD40, CD40L for cases of hyper IGM)~3. Chest x-ray to assess thymus and any abnormality~4. DHR123 whenever needed (e.g. chronic granulomatous disease).~5. LAD panel (CD11b CD15-CD18) whenever needed.~6\. Complement assay (CH"
224207800|NCT06701214|OTHER|Blood collection|Blood will be taken from participants already undergoing blood collection
224207801|NCT06701214|OTHER|Saliva collection|Undergo saliva collection
224207802|NCT06701214|OTHER|Bone marrow collection|Bone marrow will be taken from participants already undergoing bone marrow collection
223619024|NCT03515174|OTHER|Usual Care|Patients will be provided with an information booklet by the study team on self-management of cancer- and treatment-related symptoms, which is routinely provided by the National Cancer Centre of Singapore (NCCS) after cancer diagnosis. Usual general advice is provided by the medical oncologists during the routine consultations.
223619025|NCT06908044|DRUG|Bryophyllum|Bryophyllum Pinnatum - tablets, for 6 Months
223619026|NCT06911216|DRUG|STN1013800 ophthalmic solution|Investigational Product: 0.1% STN1013800 ophthalmic solution once daily (QD) (9AM ± 60 min), one drop for each eye
223619027|NCT06912698|RADIATION|Reduced dose radiation|Reduced dose group would receive 61.48Gy radiation.
224207803|NCT05395702|DRUG|Interferon-Gamma|received by microbiological synthesis; specific antiviral activity on cells is 2x10\*7 Units per mg of protein
223619028|NCT06912698|RADIATION|Standard dose radiation|Standard dose group would receive 69.96Gy radiation.
223619029|NCT06921525|DRUG|Tea Tree Oil Topical Application Oil|Tea tree oil (TTO), derived from the leaves of Melaleuca alternifolia,
224207804|NCT00865306|BEHAVIORAL|"Being Brave: A Program for Coping with Anxiety for Young Children and Their Parents."|"This is a cognitive-behavioral intervention modeled loosely after Kendall's Coping Cat, which includes 7 parent-only sessions and 8-13 child-only sessions. It focuses on helping parents learn strategies for coaching their child in coping with anxiety, and on teaching the child coping skills and carrying out exposure exercises in session and in parent-child homework assignments."
224207805|NCT00397904|BIOLOGICAL|cetuximab|
224207806|NCT00397904|DRUG|cisplatin|
224207807|NCT00397904|DRUG|irinotecan hydrochloride|
224207808|NCT00397904|OTHER|immunohistochemistry staining method|
224207809|NCT00397904|OTHER|laboratory biomarker analysis|
223619030|NCT06921525|DRUG|Azithromycin Ophthalmic Solution|Azithromycin has demonstrated efficacy in improving meibomian gland function and reducing inflammation and improving symptoms of dryness of the eye
223619031|NCT06922396|OTHER|Parameters on admission|"A: Parameters on admission:~* Age.~* Sex.~* Comorbidities (DM, HTN, CKD, IHD, Liver Disease)~* Mode of trauma.~* Laboratory data (RBS, INR, AST, ALT, Urea, Creatinine, WBC ,HB, CK, Myoglobin).~* Ct brain findings.~* Scoring system (GCS, RTS, APACHE II).~B: Parameters after 2 weeks:~* Days on Mechanical Ventilation.~* Medical or surgical management.~* Complications (Pneumonia, DVT, septic shock, Pulmonary embolism, ARDS)."
223619032|NCT06920784|DEVICE|PRISMATIC ADAPTATION|"The experimental treatment includes a session of prismatic adaptation, in which patients, wearing priasmatic lenses, performs pointing exercises using an 11'' tablet. The visual target is represented by a black squares randomly presented in one of three spatial positions of the tablet's screen (in the centre of the screen or at 21° to the right or to the left space). Taking into account the type of lesion resulting from traumatic brain injury, the prismatic deviation induced by the lenses will be changed alternately from right to left. Then patients will wear rightward prism lenses for 5 days and leftward prism lenses for other 5 days. The prismatic deviation will be randomized.~Following these prismatic adaptation, lasting 10 minutes, cognitive training with serious games will be performed, for the remaining 30 minutes."
223619033|NCT06920784|DEVICE|Serious games|patients receiving the same serious games for 10 days over a span of 2 weeks, withouth prismatic adaptation session.
224207810|NCT00397904|PROCEDURE|biopsy|
224207811|NCT02689986|DRUG|Bendamustine, Rituximab|Bendamustine, Rituximab
224207812|NCT02058368|DRUG|Dutasteride 0.5mg capsules|Dutasteride 0.5mg capsules will be supplied as plain, oblong, opaque, dull yellow soft gelatin capsules.
224207813|NCT02058368|DRUG|Dutasteride placebo capsules|Dutasteride placebo will be supplied as plain, oblong, opaque, dull yellow soft gelatin capsules.
224207814|NCT02058368|DRUG|Tamsulosin 0.2mg tablets|Commercially available tamsulosin 0.2mg tablets will be supplied.
224207815|NCT02058368|DRUG|Disintegrating placebo tamsulosin tablet|Disintegrating placebo tamsulosin tablet will be supplied for the run-in period.
224207816|NCT02591316|OTHER|no intervention|
224207817|NCT00359359|DRUG|Sagopilone (BAY86-5302, ZK 219477)|Phase 1: dose escalation/deescalation, starting dose 12mg/m² Sagopilone, Phase 2: MTD or RPIID
224207818|NCT00359359|DRUG|Cisplatin|75 mg/m² as a 1 h infusion after the sagopilone infusion on Day 1
224315241|NCT03936426|DRUG|Cu-64 SARTATE and Cu-67 SARTATE|Cu-64 SARTATE diagnostic drug Cu-67 SARTATE therapy drug
224207819|NCT02292732|DRUG|Trametinib 0.5 mg|Each tablet will contain GSK1120212B equivalent to 0.5 mg of Trametinib. Tablets are yellow, oval, biconvex, film-coated (4.85 x 8.86 millimeter \[mm\]) to be taken orally and once daily
224207820|NCT02292732|DRUG|Trametinib 2 mg|Each tablet will contain GSK1120212B equivalent to 2 mg Trametinib. Tablets are pink, round, biconvex and film-coated tablets (7.5 mm in diameter) to be taken orally and once daily.
224207821|NCT02292732|DRUG|ORTHO-NOVUM® tablet 1/35|Each peach tablet will contain 1 mg of NE and 0.035 mg of EE. Other inactive ingredients will include lactose, magnesium stearate and pregelatinized corn starch
224207822|NCT02292732|DRUG|Placebo|Each green tablet will contain only inert ingredients: D\&C yellow No. 10 Aluminum Lake, FD\&C Blue No. 2 Aluminum Lake, lactose, magnesium stearate, microcrystalline cellulose, and pregelatinized cornstarch. The tablets are to be taken orally and once daily
224207823|NCT05945147|DRUG|Ketamine|An escalating dose of ketamine (0.15 to 0.4 mg/kg/hr) will be administered as 4-hour infusions over 5 consecutive days
224207824|NCT05945147|DRUG|Midazolam|A constant dose of midazolam (0.04 mg/kg/hr) will be administered as 4-hour infusions over 5 consecutive days
224315242|NCT01120509|DEVICE|Inferior Vena Cava Filter|Inplant of filter in inferior vena cava.
224315243|NCT03253055|RADIATION|DEXA|Dual energy X-ray absorptiometry (DEXA): a total of two scans will be performed, one for the assessment of whole body bone mineral density and body composition, and the other scan is performed to specifically assess fracture risk by scanning the hip and femoral head. Effective exposure doses for these scans are \~8uSv and \~4uSv respectively.
224315244|NCT03253055|RADIATION|pQCT|A total of one scan will be performed on the non-dominant Tibia, the effective exposure dose will be between 1.5-1.8uSV.
224315245|NCT03253055|OTHER|Lifestyle Questionnaire|Participants are required to record their lifestyle, diet (5-day self reported), physical activity (IPAQ questionnaire), injury and illness incidence.
224207825|NCT05945147|DRUG|Normal Saline|An escalating dose of normal saline (0.15 to 0.4 mg/kg/hr) will be administered as 4-hour infusions over 5 consecutive days
224207826|NCT05719129|BEHAVIORAL|Date With Destiny (DWD) Seminar|6 days of immersive seminar
224207827|NCT01217567|PROCEDURE|Staples left, subcuticular suture right|Closure of the skin after cesarean section with staples on the left side of the wound and subcuticular suture on the right side.
224207828|NCT01217567|PROCEDURE|Subcuticular suture left side and staples right|Closure of the skin after cesarean section with staples on the right side of the wound and subcuticular suture on the left side.
224207829|NCT00559975|BIOLOGICAL|Subunit influenza vaccine|0.5 mL single dose vaccine
224207830|NCT00559975|BIOLOGICAL|Adjuvanted influenza vaccine|0.5 mL single dose vaccine
224315246|NCT03253055|OTHER|Aerobic Fitness|Aerobic fitness will be tested using a VO2 max exercise protocol using a stationary cycle ergometer, the participants will be expected to perform this to maximal effort or exhaustion.
224315247|NCT03253055|OTHER|Muscular Strength|Muscular strength of the knee extensor and handgrip muscles will be determined using an Isokinetic Dynamometer and a handgrip dynamometer respectively.
224315248|NCT03253055|BIOLOGICAL|Blood draw and finger prick test|15ml of whole blood will be collected for the measurement of fasting serum 25(OH)D levels, parathyroid hormone, C-terminal telopeptide (CTX) and full blood count
224315249|NCT03253055|OTHER|Muscular Power|Muscular power will be determined using an optical measurement system consisting of a transmitting and receiving bar to determine jump height through the interpretation of jump flight of the participant (reported in cm). The equipment used is an Optojump.
224315250|NCT01995305|GENETIC|human whole exome|he exome is the part of the genome formed by exons, coding portions of genes in the genome that are used in the synthesis of proteins, therefore, it is most likely to contribute to the phenotype of an organism. The exome of the human genome, is estimated to comprise 1.5% of the total genome (The human exome is about 30 MB).
224315251|NCT01995305|GENETIC|whole genomic|This study propose to find the genes that are sensitive to DNA crosslink repair, and genes that have key roles in hematopoietic cell development and maturation.
224315252|NCT03275714|DEVICE|Smartphone APP|Participants use the BiP-App for 6 months. The app continuously records data on light and motion sensors, as well as Global Positioning System (GPS) and mood surveys.
223619034|NCT06922721|OTHER|Focus group|"The Well-Being Coffee Group intervention is implemented in two formats: in person and others via videoconference, all facilitated by the same psychologist throughout the study. Across all formats, participation is voluntary and follows an information phase and the signing of an informed consent form. Participants will complete standardized evaluation questionnaires at multiple time points. The discussion groups are designed to create a supportive and open environment that encourages free expression. Their goal is to provide participants with a space to share their thoughts, emotions, and personal experiences, as well as to reflect on those emerging from group discussions. Topics explored include identity, substance use, migratory experiences, and mental health, fostering meaningful dialogue and mutual support."
223619035|NCT06921005|OTHER|Exercise|Recovery with vascular occlusion or active recovery in soccer players.
223619036|NCT06921577|COMBINATION_PRODUCT|antimicrobial agent|Adding nanoparticles to 3Dprinted denture base resin improve the properties of the material
223619037|NCT06913166|OTHER|Online quiz competition|Students in the intervention and control arm will participate in an online quiz game on tobacco or diet related topics respectively. Each day, students could answer a maximum of 10 questions randomly selected from the respective pool of questions by the platform. The students logged onto the online platform and played the quiz competition on weekdays for 5 days.
223761437|NCT01284283|DEVICE|Scandinavian Total Ankle Replacement System (STAR Ankle)|For total ankle replacement
223761438|NCT00665600|DRUG|Levalbuterol HCl|Levalbuterol 0.63 TID
223761439|NCT00665600|DRUG|Levalbuterol HCl|Levabuterol 1.25 mg TID
224207831|NCT00559975|BIOLOGICAL|Adjuvanted influenza vaccine combined with CpG7909|0.5 ml influenza vaccine combined with 10 mcg of CpG7909
224207832|NCT00559975|BIOLOGICAL|Adjuvanted influenza vaccine combine with CpG7909|0.5 mL single dose vaccine combined with 30 mcg of CpG7909
224207833|NCT00559975|BIOLOGICAL|Adjuvanted influenza vaccine combine with CpG7909|0.5 mL single dose vaccine combined with 100 mcg of CpG7909
224315253|NCT06403124|PROCEDURE|Open reduction and internal fixation|Open reduction and internal fixation by reconstruction plate and screws
224315254|NCT02172235|DRUG|Pioglitazone|
224315255|NCT02172235|DRUG|Pioglitazone - low dose|
224315256|NCT02172235|DRUG|BI 10773 - low dose|
224315257|NCT02172235|DRUG|BI 10773 - medium dose|
224315258|NCT02172235|DRUG|BI 10773 - high dose|
224315259|NCT04270318|OTHER|CH Pulpotomy, physiologic saline|Pulp chamber was cleansed with physiologic saline for 30 s.
224315260|NCT04270318|OTHER|CH pulpotomy, NaOCl|Pulp chamber was cleansed with 5 % NaOCl for 30 s.
224315261|NCT04270318|OTHER|MTA Pulpotomy, physiologic saline|Pulp chamber was cleansed with physiologic saline for 30 s.
224315262|NCT04270318|OTHER|MTA pulpotomy, NaOCl|Pulp chamber was cleansed with 5 % NaOCl for 30 s.
224315263|NCT02132858|OTHER|cytology specimen collection procedure|Correlative studies
224315264|NCT02132858|OTHER|laboratory biomarker analysis|Correlative studies
224315265|NCT03269318|DRUG|Montelukast or Salmeterol or Theophylline or Steroid|Medication will be patient specific according to their current medication, clinical symptoms and genotype. It will be from a choice of; leukotriene receptor antagonist (montelukast), long-acting beta2 agonist (salmeterol), theophylline or increase dose of inhaled steroid.
224315266|NCT06028321|DRUG|Part 1 Group 1 Regime A (ACM-001.1)|"Drug: ACM-001.1 immediate release tablets for oral use and matching placebo, and pindolol tablets for oral use.~Subjects randomised to Regimen A received placebo tablets to match the tablet number received by subjects in Regimen B."
224315267|NCT06028321|DRUG|Part 1 Group 2 Regimen C (Pindolol)|Drug: Pindolol tablets for oral use.
224315268|NCT06028321|DRUG|Part 2 Group D (Pindolol)|Drug: Pindolol tablets for oral use. Subjects were dosed over a four day treatment period twice daily. Subjects receiving ACM-001.1 in regimens E, F and G also received placebo tablets to match the tablet number received by subjects receiving pindolol in Regimen D.
224315269|NCT06028321|DRUG|Part 2 Group E (ACM-001.1)|Drug: ACM-001.1 immediate release tablets for oral use and matching placebo. Subjects were dosed over a four day treatment period twice daily. Subjects receiving ACM-001.1 in regimens E, F and G also received placebo tablets to match the tablet number received by subjects receiving pindolol in Regimen D.
224315270|NCT06028321|DRUG|Part 2 Group F (ACM-001.1 )|Drug: ACM-001.1 immediate release tablets for oral use and matching placebo. Subjects were dosed over a four day treatment period twice daily. Subjects receiving ACM-001.1 in regimens E, F and G also received placebo tablets to match the tablet number received by subjects receiving pindolol in Regimen D.
224315271|NCT06028321|DRUG|Part 2 Group G (ACM-001.1)|Drug: ACM-001.1 immediate release tablets for oral use and matching placebo. Subjects were dosed over a four day treatment period twice daily. Subjects receiving ACM-001.1 in regimens E, F and G also received placebo tablets to match the tablet number received by subjects receiving pindolol in Regimen D.
224207834|NCT04824300|PROCEDURE|erector spinae block|Erector spina plane block (ESP) is a technique used in many surgeries for anesthesia and analgesia. It is frequently preferred by anesthesiologists for postoperative analgesia recently because it is easy to apply and no complications are reported in the literature. Erector spina muscle, with arms of iliocostalis, longissimus and spinalis, is located parallel to the spine, from the back of the skull to the pelvis. The injected local anesthetic is distributed in many levels in the cranio-caudal direction and blocks the intercostal spinal nerves, causing sensory block. Providing the necessary perioperative analgesia due to the complex innervation of the breast tissue is a big controversy among anesthesiologists. Multimodal analgesia methods with various regional blocks are more preferred. Erector Spina Plane block is also preferred as another method since it provides both perioperative and postoperative analgesia
224207835|NCT02181842|DRUG|Pioglitazone|Pioglitazone tablets
224207836|NCT01652872|BIOLOGICAL|Darbepoetin alfa|Darbepoetin alfa was presented as single use prefilled syringes (PFS). Investigational product was administered SC Q4W for the duration of the treatment period.
224207837|NCT01652872|OTHER|Placebo|Placebo was presented as single use PFS. Participants received a SC placebo injection in place of darbepoetin alfa therapy when the dose of study drug was withheld per the dosing algorithm for the duration of the treatment period.
224315272|NCT06028321|DRUG|Part 1 Group 1 Regimen B (Pindolol)|Drug: pindolol tablets for oral use. Subjects randomised to Regimen A received placebo tablets to match the tablet number received by subjects in Regimen B.
224315273|NCT06028321|OTHER|Part 1 Group 1 Regimen A (Placebo)|Placebo for oral use. Subjects randomised to Regimen A received placebo tablets to match the tablet number received by subjects in Regimen B.
224315274|NCT06028321|OTHER|Part 2 Group E (Placebo)|"Placebo for oral use. Subjects were dosed over a four day treatment period twice daily.~Subjects receiving ACM-001.1 in regimens E, F and G also received placebo tablets to match the tablet number received by subjects receiving pindolol in Regimen D."
224315275|NCT06028321|OTHER|Part 2 Group F (Placebo)|Placebo for oral use. Subjects were dosed over a four day treatment period twice daily. Subjects receiving ACM-001.1 in regimens E, F and G also received placebo tablets to match the tablet number received by subjects receiving pindolol in Regimen D.
224315276|NCT06028321|OTHER|Part 2 Group G ( Placebo)|Placebo for oral use. Subjects were dosed over a four day treatment period twice daily. Subjects receiving ACM-001.1 in regimens E, F and G also received placebo tablets to match the tablet number received by subjects receiving pindolol in Regimen D.
224315277|NCT03256279|DEVICE|".014 NiTi heat-activated archwire"|".014 NiTi heat-activated archwire In the lower arch during the first three months of the orthodonci treatment"
224207838|NCT06702358|OTHER|Potential Therapeutic Implications of laser Acupoints on Visceral Fat and Hormonal Changes in Post-menopausal Women|Application of laser acupuncture ( E M E ) on 10 acupuncture procedure for each woman which will be detected by therapist according to Acupuncture points Will stimulate St 25 (Tianshu), St 36 (Zusanli), Liv 3 (Taichong); P 6 (Neiguan), H 7 (Shenmen) for the psychical aspect of the therapy and Auriculothera- py: 55 (Shenmen) and 87 (Stomach) Each point stimulating will be Stimulation time, 30 s/point
224315278|NCT03256279|DEVICE|".014 NiTi Superelastic archwire"|".014 NiTi superelastic archwireIn the lower arch during the first three months of the orthodonci treatment"
224315279|NCT04584385|DIAGNOSTIC_TEST|EEG|EEG monitoring
223512697|NCT03733483|BEHAVIORAL|Sleep Deprivation|Participants in this arm will sleep for 8 hours at their habitual time for 1 week outpatient. Food will be provided for the outpatient week by the study. After the outpatient week participants will check into our inpatient Clinical Translational Research Center (CTRC) for a 9 day inpatient stay. During their inpatient stay participants will be sleep restricted to a 5 hour/night sleep opportunity for nights 2-7 of their inpatient stay. Outcome measures include a 24-hour serum draw (urine and blood) which will occur on night 1 (pre) and night 8 (post). Patients will be given a 10 + hour recovery sleep period on night 8 of their inpatient stay.
223512698|NCT03385486|BIOLOGICAL|TBX-3400|Autologous transfusion
223512699|NCT03435315|OTHER|Treadmill Exercise- behavioral approach|12-session, 6-week treadmill exercise program utilizing behavioral techniques while walking
223512700|NCT03435315|OTHER|Treadmill Exercise- traditional approach|12-session, 6-week traditional treadmill exercise program
223512701|NCT04588558|DEVICE|Flywheel exercise|Flywheel training is a strength training modality that offers the possibility of performing exercises with eccentric overload and variable resistance as compared to conventional gravity-based resistance training. Flywheel exercise applied three days a week for 8 weeks
224207839|NCT02790372|OTHER|Case conferencing|Intervention nursing homes carries out regularly case conferencing based on comprehensive geriatric assessments. Case conferencing is carried out each month for nursing home patients included in the study
223619038|NCT06914011|DRUG|Tislelizumab|"* Participants who underwent upfront surgery without prior neoadjuvant therapy:~  * Tislelizumab 200 mg iv D1, Paclitaxel 175 mg/m2 iv D1, and Carboplatin AUC 5 mg/mL/min iv D1, in a 3-week cycle for one cycle~ * Concurrent radiotherapy (25 fractions of 1.8 Gy each, with 5 fractions per week) with Tislelizumab 200 mg iv D1, D22, Paclitaxel 50 mg/m2 iv D1, 8, 15, 22, 29, and Carboplatin AUC 2 mg/mL/min D1, 8, 15, 22, 29~ * Tislelizumab 200 mg iv D1, Paclitaxel 175 mg/m2 iv D1, and Carboplatin AUC 5 mg/mL/min iv D1, in a 3-week cycle for 1 cycle~ * Tislelizumab 400 mg iv D1, in a 6-week cycle for six cycles~* For participants who underwent neoadjuvant chemoradiotherapy followed by surgery will receive adjuvant chemoimmunotherapy in the following sequence:~  * Tislelizumab 200 mg iv D1, Paclitaxel 175 mg/m2 iv D1, and Carboplatin AUC 5 mg/mL/min iv D1, in a 3-week cycle for four cycles~ * Tislelizumab 400 mg iv D1, in a 6-week cycle for six cycles"
223619039|NCT06922370|DIAGNOSTIC_TEST|conventional radiograph or computed tomography|patients with gitelman syndrome evaluated with conventional radiograph or computed tomography
223761440|NCT00665600|DRUG|Albuterol Sulfate|Racemic albuterol 2.5 mg TID
223761441|NCT00665600|DRUG|Placebo|Placebo TID
224207840|NCT04160416|DRUG|Capecitabine-Oxaliplatin-Irinotecan Combination|CAP 1,600 mg/sq.m /day (p.o. day1-10) D1-10; Oxaliplatin (OX): 68 mg/sq.m (d.i.v.) D1; Irinotecan (IRI):135 mg/sq.m (d.i.v.) D1; BEV: 5mg/kg (d.i.v.) D1; CET: 500 mg/sq.m (d.i.v.) D1; Administered every 2 weeks.
224207841|NCT04179123|DEVICE|Customised PAP interfaces|Customised PAP interfaces
224207842|NCT03395574|DRUG|Terlipressin|drug will be given after 30 minutes of induction of anesthesia
224207843|NCT03395574|DRUG|Normal saline|drug will be given after 30 minutes as placebo in control group
224207844|NCT01472315|DRUG|medroxyprogesterone acetate|MPA hormone therapy 30mg two hours before bedtime and 30mg right before going to bed every night for two weeks period
224207845|NCT01472315|DRUG|Placebo|Placebo pills were taken in same way as active comparator
224207846|NCT02703454|PROCEDURE|FIRM-guided RF ablation|
224207847|NCT02703454|PROCEDURE|Conventional RF ablation|
224207848|NCT02913651|DEVICE|Polysomnography|The polysomnography, for both groups, was performed accordance with standard practice
224207849|NCT02284373|OTHER|Flexitouch for 1 month in addition to routine wound care|simultaneous wound care and pneumonic compression
224207850|NCT02284373|OTHER|Routine wound care for venous ulcers and lymphedema|wound care /dressings
224207851|NCT02284373|DEVICE|Flexitouch pneumonic compression|pneumonic compression only
224207852|NCT00447291|DRUG|Supplement: Omega-3 Fish Oil|
224207853|NCT00447291|BEHAVIORAL|Multi-Disciplinary Nutrition & Exercise program|
224207854|NCT04161118|DRUG|CTL019|IV Infusion
224207855|NCT01881217|DRUG|BAY1179470|BAY1179470 will be administered as a 1-hour intravenous infusion.
224207856|NCT02499406|BEHAVIORAL|Dialectical behavior therapy skills group|Skills training in emotion regulation, distress tolerance, interpersonal effectiveness, and mindfulness
224207857|NCT02658500|DIETARY_SUPPLEMENT|Infant Formula|
224207858|NCT02658500|DIETARY_SUPPLEMENT|breast milk|
224207859|NCT03560115|DIAGNOSTIC_TEST|Single-heel rise test|Single heel-rise test is used to assess the strength of plantar-flexors clinically
224207860|NCT01396161|DRUG|PF-05175157 or Placebo|One oral dose of PF-05175157 or placebo is administered as a powder-in-capsule once daily for 14 days immediately before breakfast, in healthy volunteers.
224315280|NCT05875311|DEVICE|telemonitoring|"The system consists of the following elements:~Professional website at the ambulatory centre, which allows:~To set up an individualised care plan To establish the patient's risk profile and targets for improvement. Long-term monitoring of the evolution of cardiovascular risk factors and events that occurred Advise the patient on self-management strategies.~Mobile application software with the following functions:~Scheduled exercise sessions Medication reminder Measurement reminder (weight, blood pressure, heart rate, waist circumference, etc.) Messages: Inbox folder for system messages and messages generated by professionals for a specific patient or video conference.~Training monitor: guides the patient in the performance of their exercise. Access to certified health information for patients"
224207861|NCT01396161|DRUG|PF-05175157 or Placebo|One oral dose of PF-05175157 or placebo is administered as a powder-in-capsule once daily for 14 days immediately before breakfast, in healthy volunteers.
224207862|NCT01396161|DRUG|PF-05175157 or Placebo|One oral dose of PF-05175157 or placebo is administered as a powder-in-capsule once daily for 14 days immediately before breakfast, in healthy volunteers.
224207863|NCT01396161|DRUG|PF-05175157 or Placebo|One oral dose of PF-05175157 or placebo is administered as a powder-in-capsule twice daily for 14 days, immediately before breakfast and dinner, in healthy volunteers.
224207864|NCT01396161|DRUG|PF-05175157 or Placebo|One oral dose of PF-05175157 or placebo is administered as a powder-in-capsule once (or twice) daily for 14 days, immediately before breakfast (and dinner), in patients with type 2 diabetes.
224207865|NCT01493609|BEHAVIORAL|Click-East app|Computer game, delivered as an iPad app, designed to provide an environment to practice basic social skills.
224207866|NCT05171127|PROCEDURE|Diffuse Reflectance Spectroscopy|Measurements of DRS patterns in extirpated tumor and cerebral tissue
224207867|NCT05380882|DRUG|TQB2930 injection|TQB2930 is an anti-HER2 bispecific antibody.
224207868|NCT01551394|DRUG|Meropenem|20 mg/kg every 8 hours (every 12 hours in the youngest age group: \< 32 weeks GA and \< 2 weeks postnatal age). The dose will be given as an infusion over 30 minutes. Treatment duration is 11 ± 3 days.
224207869|NCT01551394|DRUG|Ampicillin + gentamicin or cefotaxime + gentamicin|"Ampicillin:~Neonates below 7 days: 50mg/kg every 12 hours Neonates 7-21 days: 50mg/kg every 8 hours Neonates and Infants from day 22 on: 50mg/kg every 6 hours~Gentamicin:~Neonates less than 32 weeks of corrected age: 5mg/kg every 36 hours Neonates 32 weeks and over of corrected age: 5mg/kg every 24 hours (pre-dose ('trough') concentrations should be less than 2mg/l) Infants over 28 days of postnatal age: once daily dose: initially 5-7mg/kg, then adjust according to serum-gentamicin concentration (pre-dose ('trough') concentrations should be less than 1mg/l)~Cefotaxime:~Neonates below 7 days of PNA: 50mg/kg every 12 hours Neonates and infants from day 7 of PNA: 50mg/kg every 8 hours Treatment duration is 11 ± 3 days."
224207870|NCT05070689|PROCEDURE|ACCSS|A. Chohan Continuous Squeezing Suture (ACCSS)
224315281|NCT05875311|OTHER|control follow-up|Patients are instructed to perform 150 minutes per week of moderate physical activity and follow healthy lifestyles
224315282|NCT02897583|PROCEDURE|YAG vitreolysis|
224315283|NCT02593253|OTHER|Audit and Feedback Bundle|The intervention arm teams will receive the new audit and feedback bundle, which includes access to the electronic dashboard and weekly feedback rounds in which they review their performance on several inpatient quality metrics via the dashboard.
224315284|NCT02593253|OTHER|Bi-weekly audit and feedback emails|The control arm will undergo audit and feedback per the current system, which is biweekly feedback emails with performance on selected quality measures.
224315285|NCT06415877|OTHER|Episio Training|episio repair training
224315286|NCT05262998|PROCEDURE|Plate fixation|"Procedure: plate fixation~Plate fixation was performed by the regular on-call team surgeons and adhered to standard principles of fracture fixation. A standard surgical protocol was used, the approach was moved inferiorly, the fracture was reduced, sometimes with osteosutur and fixed with an antero-superior anatomical plate. 3.5mm Locked and cortical screws were used on both sides of the fracture. Fluoroscopy was used during the procedure. Intradermal suture was used to close the skin~Other: post-intervention All patients were discharged the day after the surgery. Interruption of work was given for 45 days. The same analgesics were administered in both groups for three weeks. Graduated exercises for the shoulder joint with pendular movements in a range of 15°-20° with the protection of a forearm sling were commenced from the postoperative second day. The sling was removed when X-ray films showed growth of callus or an indistinct fracture line."
224315287|NCT05262998|PROCEDURE|Intramedullary Screw|"Procedure: Intramedullary screw fixation~Intramedullary screw fixation was performed by the regular on-call team surgeons and adhered to standard principles of fracture fixation. Intramedullary screw fixation was performed by using a 1.6 or 2.8 mm-diameter threaded guide pin and a 85-100 mm long, 4.5 or 6.5 mm-diameter cannulated screw tapped in along the guide pin. Fluoroscopy was used during the procedure. Intradermal suture was used to close the skin.~Other: post-intervention All patients were discharged the day after the surgery. Interruption of work was given for 45 days. The same analgesics were administered in both groups for three weeks. Graduated exercises for the shoulder joint with pendular movements in a range of 15°-20° with the protection of a forearm sling were commenced from the postoperative second day. The sling was removed when X-ray films showed growth of callus or an indistinct fracture line."
224315288|NCT04987697|BEHAVIORAL|counseling|nine 90-minute weekly psychoeducational group sessions facilitated by a licensed mental health counselor (LMHC).
224207871|NCT06566495|DEVICE|collection of microbiological material from reusable tourniquets|"Microbiological analysis~The material was collected in each group in the same way."
224207872|NCT02833558|DEVICE|PuraStat®|PuraStat® gel is applied through a safe catheter delivery system (via endoscope) over the bleeding point
224315289|NCT04798612|DRUG|Pegasys|45 mikrograms of Pegasys. Two subcutanous doses will be administered with at least 7 days in between
224315290|NCT04798612|DRUG|Saline|0.50 ml of Saline. Two subcutanous doses will be administered with at least 7 days in between
224315291|NCT01158092|DEVICE|Treatment with SInergy™ System|Lateral branch denervation using the SInergy™ System
224315292|NCT01158092|OTHER|Conservative Treatment|Treatment with physical therapy, chiropractic care, and medication
223619040|NCT06920589|BEHAVIORAL|"Safe and Protected Sex intervention targeting HPV"|"This study used the Safe and Protected Sex intervention (Báez et al., 2019), adapted and validated from an HIV prevention program to focus on HPV. The intervention consists of a single module with two stages aimed at increasing HPV knowledge by enhancing personal (self-determination) and social (controlled behavior) motivation.~Module 1: Nursing Consultation on HPV This structured, planned process follows Corona and Kaltmeier's (2012) horizontal methodology, promoting self-care through social support and trust in nurse-patient dialogue. The goal is to provide counseling on HPV prevention and responsible sexual behavior while acknowledging participants' prior knowledge.~Stage 1: A 4.21-minute educational video, HPV Fun Facts, uses persuasive narrative to explain HPV transmission, symptoms, complications, and prevention.~Stage 2: A 45-minute Friendly Educational Guidance session uses open-ended questions to explore participants' experiences."
223619041|NCT06920589|BEHAVIORAL|Diptych of the Secretary of Health in Mexico|a brochure is provided with general information about the human papilloma virus in men, including the form of contagion, diagnosis, treatment and the use of condoms for prevention.
224207873|NCT02833558|PROCEDURE|Electrocautery|Electrocautery (coagulation current) to stop bleeding during ESD
224207874|NCT00843063|DRUG|pantoprazole vs famotidine|pantoprazole 20 mg om and matching placebo nocte vs. famotidine 40 mg om and nocte
224207875|NCT04973839|BEHAVIORAL|Video optimizing expectations before PMR (unguided) + Progressive Muscle Relaxation (PMR)|Participants watch a video aiming to optimize participants' expectations before undergoing a single PMR session without personal support of the experimenter (unguided). The PMR session involves learning to monitor tension in each specific muscle group in the body by deliberately inducing tension in each group. This tension is then released, with attention paid to the contrast between tension and relaxation.
224315293|NCT03850548|OTHER|Prosthetic joint infection with Cutibacterium acnes|patients having a prosthesis infection with C.acnes identified by specific PCR
224315294|NCT04541316|DEVICE|ProFlor inguinal hernia device|Inguinal hernia repair
224315295|NCT00955526|DRUG|Istradefylline|20 mg KW-6002 per day (two 10 mg tablets orally once daily for 12 weeks)
224315296|NCT00955526|DRUG|Istradefylline|40mg KW-6002 per day (two 20 mg tablets orally once daily for 12 weeks)
224315297|NCT00955526|DRUG|Placebo|Two placebo tablets once daily for 12 weeks
224315298|NCT00087620|DRUG|XELODA [capecitabine]|
224315299|NCT04236323|DRUG|Not used remifentanil infusion|Remifentanil is not used during operation
224315300|NCT02249130|DRUG|Tipranavir (TPV)|
224315301|NCT02249130|DRUG|Ritonavir (RTV)|
224315302|NCT02249130|DRUG|Delavirdine (DLV)|
224315303|NCT02249130|DRUG|Zidovudine (ZDV)|
224315304|NCT02249130|DRUG|Lamivudine (3TC)|
224315305|NCT02249130|DRUG|Stavudine (d4T)|
224315306|NCT05160857|DRUG|Herombopag Olamine|The initial dose of hetropapa is recommended to be 7.5mg, once a day, oral on an empty stomach, and can only be eaten after oral administration for 2 hours, so as to avoid taking it with meals.
224207876|NCT04973839|BEHAVIORAL|Video optimizing expectations before PMR (guided) + Progressive Muscle Relaxation (PMR)|Participants watch a video aiming to optimize participants' expectations before undergoing a single PMR session with the personal support of the experimenter (guided). The PMR session involves learning to monitor tension in each specific muscle group in the body by deliberately inducing tension in each group. This tension is then released, with attention paid to the contrast between tension and relaxation.
224207877|NCT04973839|BEHAVIORAL|Neutral video before PMR (unguided) + Progressive Muscle Relaxation (PMR)|Participants watch a neutral video (not aiming to optimize participants' expectations) before undergoing a single PMR session without personal support of the experimenter (unguided). The PMR session involves learning to monitor tension in each specific muscle group in the body by deliberately inducing tension in each group. This tension is then released, with attention paid to the contrast between tension and relaxation.
224315307|NCT03460639|RADIATION|Active laser|Three points on the masseter muscle (upper, middle and lower portions) and one point on the anterior temporal on each side of the face will be irradiated with a wavelength of 780 nm, radiant exposure of 134 J/cm2, power of 50 mW and irradiance of 1.675 W/cm2 for 80 seconds per point, resulting in an energy of 4 J per point and total energy of 32 J per volunteer.20,21 Point application will be performed with a conventional tip in contact with the skin (beam spot: 0.04 cm2).
224315308|NCT03460639|RADIATION|Sham laser|The same procedures will be performed in the sham group, but the device will be switched off and a recording of the emission sounds will be used to give the volunteer the auditory sensation of laser therapy.
224315309|NCT03460639|DIAGNOSTIC_TEST|Control group|In this group, we will only induce fatigue.
224315310|NCT02283008|BEHAVIORAL|Assessment of inhaler technique pre and 6 weeks post training|Assessment of inhaler technique on day one. Education package and training on inhaler use at week 2. Final assessment to establish maintenance of inhaler competence at week 8
224315311|NCT04007653|OTHER|Observation|No intervention
223619042|NCT06922058|DEVICE|Virtual Reality Glasses|Virtual reality glasses haven\&#39;t used in orthodontics in another clinical study.
224315312|NCT03239223|DRUG|ABI-1968|Topical ABI-1968 Cream or Placebo with 4 doses administered up to 4 Cohorts
223619043|NCT01446627|OTHER|There is no intervention for this study|None, no intervention made.
224315313|NCT04437459|OTHER|High-fat shake|Participant consumes a high-fat test shake. Blood is drawn before and 4 hours after this shake to measure triglycerides.
223619044|NCT06939231|BEHAVIORAL|Living Lab approach to improve sustainable and healthy dietary behaviours|Living Lab baseline data collection measures, plus invitations to Study 1-3 and events/ activities (optional), and LL endpoint data collection measures.
223761442|NCT06988332|BEHAVIORAL|Problem Management Plus (PM+)|"Problem Management Plus (PM+) will be delivered according to the Spanish version of the WHO protocol (OMS, 2016).~PM+ is a low-intensity, transdiagnostic psychological intervention based on Cognitive Behavioral Therapy (CBT). The protocol incorporates evidence-based strategies, including problem-solving, stress management, behavioral activation, and accessing social support.~The intervention consists of five individual 90-minute sessions provided by healthcare professionals without previous expertise in mental health care (WHO, 2018). PM+ helpers will be supervised by master trainers specifically trained for Chile.~Two systematic reviews have demonstrated the effectiveness of PM+ in reducing symptoms of common mental disorders, such as depression and anxiety (Schäfer et al., 2023) and specific symptoms of post-traumatic stress (Akhtar et al., 2022)."
223761443|NCT02030860|DRUG|Paricalcitol|Dose: 25 micrograms Route: IV Frequency (within a 28 day cycle):Three times weekly for one cycle beginning day 1 of therapy until the day before surgery (+/- 3 days) (for subjects randomized to receive paricalcitol), then three times weekly for 3 cycles post-operatively (for all subjects).
223761444|NCT02030860|DRUG|Abraxane|Dose: 125mg/m2 Route: IV infusion over 30 minutes Frequency (within a 28 day cycle): Day 1, 8, 15
224207878|NCT04973839|BEHAVIORAL|Neutral video before PMR (guided)+ Progressive Muscle Relaxation (PMR)|Participants watch a neutral video (not aiming to optimize participants' expectations) before undergoing a single PMR session with the personal support of the experimenter (guided).The PMR session involves learning to monitor tension in each specific muscle group in the body by deliberately inducing tension in each group. This tension is then released, with attention paid to the contrast between tension and relaxation.
224207879|NCT00438295|PROCEDURE|temperature control|
224207880|NCT03372395|OTHER|Lactobacillus rhamnosus BMX 54|Given once a day for 10 days, once every 3 days for 20 days and then once every 5 days for other 2 months in all patients (probiotics implementation for 3 months comprehensively).
224207881|NCT04651218|BEHAVIORAL|exericse|participants perform aerobic exercise until they expend 500 kcal
223619045|NCT06939179|OTHER|Class III Malocclusion|Class III malocclusion treatment
223619046|NCT06939179|OTHER|Class III Malocclusion|non treated Class III malocclusion
224315314|NCT04437459|OTHER|Pure glucose solution|Participant consumes 75 grams of pure glucose. Blood is drawn before and 2 hours after this drink to measure glucose.
224315315|NCT04067453|OTHER|Fatiguing contractions|10 sustained external anal sphincter contractions with maximal voluntary contraction of 20 seconds followed by 10 seconds of resting.
223761445|NCT02030860|DRUG|Gemcitabine|Dose: 1000mg/m2 Route: IV infusion over 30-100 minutes Frequency (within a 28 day cycle): Day 1, 8, 15
223761446|NCT04436042|DEVICE|MyHand Device|These subjects may be asked to attend 1-40 sessions (approximately 90 mins) to trial a variety of device controls and/or components.
223761447|NCT06880679|DEVICE|Point of Care Ultrasound|Point of Care Ultrasound during hospitalization
224315316|NCT03385850|OTHER|enteral nutrition|early enteral nutrition group or delayed enteral nutrition group
224315317|NCT00700830|DRUG|insulin detemir|Initial dosage and the following dosages will be prescribed by the physician as a result of a normal clinical evaluation
224315318|NCT00264550|DRUG|Golimumab 100 mg|Participants will receive subcutaneous (SC) injections of golimumab 100 mg every 4 weeks.
224315319|NCT00264550|DRUG|Golimumab 50 mg|Participants will receive subcutaneous (SC) injections of golimumab 50 mg every 4 weeks.
224315320|NCT00264550|DRUG|Methotrexate|Participants will receive methotrexate capsules weekly.
224315321|NCT00264550|DRUG|Placebo injection|Participants will receive subcutaneous (SC) injections of placebo every 4 weeks.
224315322|NCT00264550|DRUG|Placebo capsules|Participants will receive placebo capsules weekly
224315323|NCT01062347|BIOLOGICAL|Zinc|
223761448|NCT06727344|OTHER|Blood Flow Restriction|Exercise with restriction of blood flow supply
224207882|NCT01106118|DRUG|Vardenafil (Levitra, BAY38-9456)|Patients with diagnosis of erectile dysfunction and metabolic syndrome who get vardenafil in routine treatment as prescribed by physician
224207883|NCT03555500|OTHER|Non fasting|Non fasting group is allowed for clear fluids and food up to the time of the procedure.
224207884|NCT04365842|BEHAVIORAL|Digital exercise group|"Hand Rehabilitation Program: Developed hand exercise smartphone app which include: Self-assessment, (b) self-monitoring (c) exercises types/frequency/ diary, (d) patient education, (e) behavioral change and encouragement (f) exercise adherence Sample exercises~1. Hand and finger movements: 6-8 repetitions, according to the diagnosis of the patient~2. Strengthening exercises of hand and finger muscles~3. Exercises to increase grip and pinch strength~4. Exercises to increase tendon swing and pull angle"
224207885|NCT04365842|OTHER|General Home Hand Therapy|"Hand rehabilitation home program will be given to the through the telephone messages with brochures.~1. Hand and finger movements: 6-8 repetitions, according to the diagnosis of the patient~2. Strengthening exercises of hand and finger muscles~3. Exercises to increase grip and pinch strength~4. Exercises to increase tendon swing and pull angle"
224207886|NCT04876807|DRUG|ACP-196|In Parts 1, 2, and 3, participants will receive oral Dose 1 of ACP-196 (reference or acidic formulation as applicable) on Day 1, Day 3, Day 8, and Day 10.
224207887|NCT04876807|DRUG|Omeprazole|Participants will receive omeprazole in all parts as: on Day 8 and Day 10 with water in Part 1; on Day 8 with water and on Day 10 with acidic beverage in Part 2; on Day 8 with water and on Day 10 with grapefruit juice in Part 3.
224207888|NCT00306137|DRUG|Trasylol (Aprotinin, BAYA0128)|"Subjects successfully meeting all screening criteria will be randomized to receive an infusion of aprotinin (a test dose followed by a loading dose of 2 million KIU before skin incision followed by 500,000 KIU/hour until the end of surgery) or matching placebo. The aprotinin was supplied in infusion vials of 200mL solution containing 2,000,000 KIU (10,000 KIU/mL) in 0.9% sodium chloride.~Subjects will be stratified into one of the 4 following strata:~* Stratum 1: complete primary pneumonectomy~* Stratum II: decortication or completion pneumonectomy~* Stratum III: esophagectomy by transhiatal approach~* Stratum IV: esophagectomy by transthoracic approach"
224207889|NCT00306137|DRUG|Placebo|Placebo solution was supplied in identical vials and will consist of 200mL of 0.9% sodium chloride.
224207890|NCT06301737|BEHAVIORAL|Comprehensive rehabilitation|"All the participants are provided with the comprehensive rehabilitation (routine rehabilitation and swallowing function training). The routine rehabilitation included intervention for risk factors (blood pressure, blood lipids, blood glucose, smoking and alcohol restriction, exercise, etc.).~Regrading swallowing function training, both groups are given swallowing function training, including 1) exercises of closure of the vocal folds, pharyngeal, and laryngeal muscles exercises, and respiratory muscle strength training, for 15 min each time and twice per day. 2) isotonic／isometric swallowing exercises, supraglottic swallowing exercises, for 20 min each time and twice per day. 3) effortful swallowing exercises, and cough reflex training, for 10 min each time and twice per day."
224207891|NCT06301737|PROCEDURE|Injection|the patients were provided with Injection. The percutaneous approach via the paratracheal route was used for Stellate ganglion block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
224207892|NCT06301737|DRUG|Lidocaine Hydrochloride|the patients were provided with Stellate ganglion block, using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate ganglion block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
224207893|NCT00875537|OTHER|Capsaicin oral gel 0.025%|Application 3 times daily for 14 days on the tongue, followed by 14 days wash-out
224207894|NCT00875537|OTHER|Capsaicin oral gel 0.01%|Application 3 times daily for 14 days on the tongue, followed by 14 days wash-out
224207895|NCT04726761|DIAGNOSTIC_TEST|Ambulatory Blood Pressure Monitoring, frequent/non-frequent|Patient will have a Spacelabs 90217 attached. This device can automatically measure the blood pressure over 24 hours. Patients will have their blood pressure measured first with a frequent interval, and then a non-frequent interval.
224207896|NCT04726761|DIAGNOSTIC_TEST|Ambulatory Blood Pressure Monitoring, non-frequent/frequent|Patient will have a Spacelabs 90217 attached. This device can automatically measure the blood pressure over 24 hours. Patients will have their blood pressure measured first with a non-frequent interval, and then a frequent interval.
224207897|NCT00668109|DRUG|Levitra (Vardenafil, BAY38-9456)|10 mg one hour prior to sexual intercourse
224207898|NCT00668109|DRUG|Tadalafil|10 mg taken approximately 24 hours prior to sexual intercourse
224207899|NCT04075045|BEHAVIORAL|Wellth Smartphone App|Patients will receive the app that provides reminders to adhere to their self-care regimen and ability to track their daily adherence via photos of the self-care related items (medications, blood pressure cuff, meals).
223761449|NCT06727344|OTHER|Brace|Knee brace to restrict range of motion
223761450|NCT06921512|BEHAVIORAL|TCM Daoyin exercise|"Participants will receive a 12-week, group-based TCM Daoyin intervention consisting of two 90-minute sessions per week (total: 24 sessions), led by qualified physicians. Each session integrates movement regulation, breath regulation, and mind regulation, aiming to alleviate anxiety and depression symptoms. Each session includes a 10-minute warm-up and a 10-minute cool-down.~Compliance and Analysis:~Per-protocol analysis will include participants who attend ≥80% of sessions (≥19/24 sessions). Safety analyses will be conducted on all enrolled participants (n=20) following the intention-to-treat (ITT) principle."
223761451|NCT06893393|DEVICE|Virtual travel-into-nature application Toujours Dimanche|The use of the virtual travel-into-nature application which features real natural environments from the Eastern Canada area.
223761452|NCT05677425|OTHER|Temperature measurement|Temperature measurement in the renal pelvis during ureteroscopic laser activation.
223619047|NCT06937905|DRUG|Standard of Care Chemotherapy|Study treatment in the arm A is left to the investigator appreciations. This may include immune checkpoint inhibitors, docetaxel, topotecan for primary lung tumors, and FOLFOX, FOLFIRI or alkylating-based chemotherapy in primary digestive tumors.
223619048|NCT06937905|DRUG|Tarlatamab|Tarlatamab 10 mg every 2 weeks
223761453|NCT06828419|DEVICE|Domestic single-port laparoscopic surgery system|The minimum distance of the single-port surgical system from the port is 5-7cm to obtain the instrument bending space. The load capacity of surgical tools is increased from 2N to 5N, which greatly improves the structural reliability. At the same time, it can realize 6 degrees of freedom movement。
223619049|NCT07198919|DRUG|Chlorhexidine gel|0.12% Chlorhexidine gel (Consepsis Ultradent)
224315324|NCT06362863|DIETARY_SUPPLEMENT|enteral nutrition biscuits|Addition of enteral nutritional biscuits to existing pharmacological treatment.
224315325|NCT01917214|OTHER|Sutent: Observational Study|Sutent oral therapy
224315326|NCT03416829|BEHAVIORAL|Ambulatory voice biofeedback|Subjects will be provided cues regarding their vocal behavior in daily life. The cues will either be: 100% feedback = a vibrotactile cue on a smartwatch every time the patient voices incorrectly... 25% feedback = a vibrotactile cue on a smartwatch every 4th time the patient voices incorrectly... Summary feedback = the patient's overall compliance (percentage of voiced time within desired limits) will be presented via a smartwatch every 2 minutes of voicing.
223619050|NCT07198919|DRUG|Nitrofurantoin 100 MG|Nitrofurantoin Tablets 100mg
223619051|NCT07200141|RADIATION|GTV 58.75 Gy/25 fractions(Simultaneous Integrated Boost)|"Patients will receive neoadjuvant long course radiotherapy using VMAT or IMAT with daily image guided.~Gross tumor volume (GTV): A total dose of 58.75Gy delivered in 25 fractions using a simultaneous integrated boost approach; CTV: 45Gy/25f; Mesorectum lymph node(GTVnd1):58.75Gy/25f ; Lateral lymph node（GTVnd2）：60Gy/25f;"
223619052|NCT07200141|RADIATION|GTV 50 Gy/25 fractions(Simultaneous Integrated Boost)|"Patients will receive neoadjuvant radiotherapy with GTV 50 Gy in 25 fractions , delivered with IMRT or VMAT technique.~CTV: 45Gy/25f; Mesorectum lymph node(GTVnd1):58.75Gy/25f; Lateral lymph node（GTVnd2）"
223619053|NCT07200141|DRUG|Concurrent Chemotherapy|Concurrent administration of capecitabine (825 mg/m² twice daily, 5 days per week) or XELOX regimen during radiotherapy.
224207900|NCT04075045|BEHAVIORAL|Targeted Incentives|Participants may earn up financial rewards tied to their adherence. The rewards are only usable at pharmacies.
224207901|NCT04075045|BEHAVIORAL|Non-Restricted Incentives|Participants may earn up financial rewards tied to their adherence. The rewards are only usable at most stores, except for prohibited purchases such as alcohol, tobacco, or firearms, and is not redeemable for cash.
224207902|NCT01399125|DRUG|Rivastigmine Patch|Once-daily target patch size 10 cm²
224315327|NCT01439009|DRUG|Tolvaptan|Once-daily oral administration of one tolvaptan 15 mg tablet in the morning
224315328|NCT01439009|DRUG|Placebo of tolvaptan|Once-daily oral administration of one placebo tablet in the morning
224315329|NCT06582992|OTHER|RRBS|Measure of genomic regions with differentially methylated profiles and differentially expressed protein
224315330|NCT01458691|PROCEDURE|Steroid injection into the glenohumeral joint|"* Group: Steroid~* Total volume of injection drugs: 4ml(1ml of triamcinolone acetonide 40mg/ml + 3ml of 2% lidocaine)~* The number of injections : only once during the study period~* Injection site : glenohumeral joint~* Material : 25-gauze spinal needle~* The intra-articular injections were performed using ultrasonographic guidance."
224315331|NCT01458691|PROCEDURE|Allogeneic PRP injection into the glenohumeral joint|"* Group: Allogeneic PRP~* Total volume of injection drugs: 4ml~* The number of injections : only once during the study period~* Injection site : glenohumeral joint~* Material : 25-gauze spinal needle~* The intra-articular injections were performed using ultrasonographic guidance."
224315332|NCT00070551|BIOLOGICAL|GTI-2040|Given IV
224315333|NCT00070551|DRUG|cytarabine|Given IV
224315334|NCT00070551|OTHER|pharmacological study|Optional correlative studies
224315335|NCT00070551|OTHER|laboratory biomarker analysis|Optional correlative studies
223619054|NCT07200141|PROCEDURE|Total mesorectal excision (TME) surgery or non-operative management|"After treatment, patients will undergo restaging and proceed to total mesorectal excision (TME) or non-operative management (watch-and-wait) depending on response and clinical assessment."
223619055|NCT07199049|OTHER|Neuro-Mimic Observation Protocol|Observation of eyelid reflex, eye movements, and pupil responses at three standardized intraoperative time points (after induction, during skin incision, and mid-surgery). Parameters will be recorded alongside BIS values without any intervention, device application, or additional risk to patients.
223619056|NCT07200011|OTHER|Observational: Serum Vitamin D Levels|Participants' serum vitamin D levels will be measured from existing laboratory records, and radiographic images of mandibular implant overdentures will be analyzed to assess marginal bone loss. No active treatment or experimental intervention will be administered
223619057|NCT07199400|BEHAVIORAL|physical activity program|Received eight sessions of technology-assisted exercise courses, covering 26 movements in the shoulders, neck, chest, upper limbs and lower limbs, with demonstrations and real-time feedback on movement performance through high-end monitors
224207903|NCT01399125|DRUG|Rivastigmine Capsules|Twice-daily target dose of 6 mg oral capsule
224207904|NCT01399125|DRUG|Placebo to Rivastigmine patch|Matching placebo to Rivastigmine patch
224207905|NCT01399125|DRUG|Placebo to Rivastigmine capsules|matching Placebo to Rivastigmine capsules
223761454|NCT06769711|PROCEDURE|Surgical procedure using Peroneus Longus for ACL reconstruction.|Surgical procedure using Peroneus Longus for ACL reconstruction.
223761455|NCT06769711|PROCEDURE|Surgical procedure using Hamstring tendons for ACL reconstruction.|Surgical procedure using Hamstring tendons for ACL reconstruction.
224207906|NCT00296829|BIOLOGICAL|Inactivated, split-virion influenza vaccine|
224315336|NCT05810233|DIETARY_SUPPLEMENT|Ascorbic acid 1000mg|Health supplement
224315337|NCT05810233|OTHER|Placebo|Glucose chewable tablet without any ascorbic acid
224315338|NCT04918589|DRUG|Tranexamic acid|3 grams of tranexamic acid (30 mL of 100 mg/mL solution) diluted in 10 mL of normal saline
224315339|NCT04918589|DRUG|Normal Saline|40 mL topical of 0.9% normal saline
223619058|NCT07199153|DEVICE|D Printed Custom Registration Marker for Dynamic Navigation|A patient-specific, 3D printed registration marker designed for use with the Mininavident dynamic navigation system. The marker is fabricated based on CBCT and intraoral scans, enabling accurate registration between virtual planning and clinical implant placement in the esthetic zone. Accuracy of placement is assessed through postoperative CBCT superimposition.
224207907|NCT00647426|DRUG|Sorafenib + Docetaxel/Carboplatin|400 mg po BID Sorafenib + 75 mg/m2 IV Docetaxel on day 1 plus AUC 6 on Carboplatin on day 1 of each 21 day cycle
224315340|NCT03332810|BEHAVIORAL|SME family based physical activity|"* One train-the-trainer workshop: to train the service providers from 8-15 NGO service units on the concept of SME, ways of conducting mental well-being activities and knowledge of adult mental health problem (in particular the mixed anxiety and depressive disorder).~* Two SME family-based physical activities held by each NGO service unit: to organize enjoyable activities according to the needs of individual district as well as to promote positive psychology under the theme of SME. All these activities are organized by the NGO service providers in collaboration with District Healthy City Committee."
224315341|NCT03332810|BEHAVIORAL|Gathering activity|\- Gathering activities will be held for control groups. However, SME concept or techniques will not be introduced during the activity. Physical activity will not be used as the intervention method.
224315342|NCT05516355|BEHAVIORAL|Mindfulness-Based Stress Reduction|"The MBSR is an 8-week standardized program (Kabat-Zinn,1990).~During the retreat, participants will receive intensive training during 3 days (from 4:00pm to 9pm the first day and from 7 am to 10 pm including breaks, the second and third days), including focused attention on the breath, open monitoring of awareness in body-scanning, prosocial meditation (i.e. loving kindness and compassion) and gentle yoga. Training is delivered by certified instructors by the University of Massachusetts Centre for Mindfulness (https://www.umassmed.edu/cfm/)."
224315343|NCT05516355|BEHAVIORAL|Compassion Cultivation Training|"The CCT is an 8-week standardized program (Jinpa, 2010; Jazaieri et al. 2013, 2014) consisting of daily formal and informal practices.~Training will be conducted during 3 days of the retreat (same schedule as the MBSR training). The CCT consists of six sequential steps: 1) Settling the mind and learn how to focus it; 2) Loving kindness and compassion for a loved one practice; 3) Loving kindness and compassion for oneself practice; 4) compassion toward others, embracing shared common humanity and developing appreciation of others; 5) compassion toward others including all beings; and 6) active compassion practices (Tonglen) which involve explicit evocation of the altruistic wish to do something about others' suffering. CCT program is delivered by certified instructors by the University of Stanford Centre for Compassion and Altruism Research and Education (http://ccare.stanford.edu/)."
224315344|NCT01649401|DEVICE|Standard nebulizer|"Nebulizer sessions for the patients will be administerd using our standard nebulizer: Micro Mist, ref 41894, Hudson RCI, distributed by Téléflex Médical."
224315345|NCT01649401|DEVICE|PARI LC Sprint Sp nebulizer|"Nebulizer sessions for the patients will be administerd using the PARI LC Sprint Sp nebulizer.~Manufacturer: PARI GmbH Germany"
224315346|NCT01403220|PROCEDURE|Hemodiafiltration first|Patients will alternate consecutive dialysis sequences between hemodiafiltration and hemofiltration, but starting with hemodiafiltration.
224207908|NCT05709626|DRUG|No aspirin (Prasugurel monotherapy)|12-month prasugrel monotherapy
224207909|NCT05709626|DRUG|12-month DAPT|12-month dual antiplatelet therapy with prasugrel and aspirin
224315347|NCT01403220|PROCEDURE|Hemofiltration first|Patients will alternate consecutive dialysis sequences between hemodiafiltration and hemofiltration, but starting with hemofiltration.
224315348|NCT05015257|DIETARY_SUPPLEMENT|Standard F100|100 kcal and 3 g protein per 100 ml
224315349|NCT05015257|DIETARY_SUPPLEMENT|Standard F75 + Plumpynut|Standard F75 with ready to-use therapeutic food (Plumpynut)
224315350|NCT05015257|DIETARY_SUPPLEMENT|Alternative F75 with CMV + Plumpynut|Alternative F75 containing CMV with ready to-use therapeutic food (Plumpynut)
224315351|NCT05015257|DIETARY_SUPPLEMENT|Alternative F75 without CMV + Plumpynut|Alternative F75 with no CMV with ready to-use therapeutic food (Plumpynut)
224315352|NCT00696787|DRUG|Desvenlafaxine Sustained Release (DVS SR)|
223619059|NCT07199023|DIETARY_SUPPLEMENT|Amino Acid Formula (AAF)|A formula composed of 100% free amino acids with no intact cow's milk protein. Participants will be fed AAF ad libitum according to their nutritional needs. Daily intake and symptoms will be recorded through an electronic diary (eCOA).
224207910|NCT02374931|DRUG|F-18 16 Alpha-Fluoroestradiol|Undergo 18F-FES PET/CT
224315353|NCT00696787|DRUG|Lyrica® (Pregabalin)|
224315354|NCT00696787|DRUG|Placebo|
223619060|NCT07199023|DIETARY_SUPPLEMENT|Extensively Hydrolyzed Formula (eHF)|A formula in which cow's milk proteins are broken down into small peptides through enzymatic hydrolysis, reducing allergenicity. Participants will be fed eHF ad libitum based on their nutritional needs. Intake and symptoms will be tracked through an electronic diary (eCOA).
224207911|NCT02374931|PROCEDURE|Positron Emission Tomography|Undergo 18F-FES PET/CT
224207912|NCT02374931|PROCEDURE|Computed Tomography|Undergo 18F-FES PET/CT
224207913|NCT02374931|OTHER|Laboratory Biomarker Analysis|Correlative studies
224207914|NCT03996382|DIAGNOSTIC_TEST|DPD Scintigraphy|Confirms/Refutes diagnosis of cardiac amyloidosis.
224207915|NCT01410695|DRUG|masitinib 3 mg|
224207916|NCT01410695|DRUG|masitinib 6.0 mg|
224315355|NCT06142474|DRUG|SGLT2 inhibitor|Patients with acute decompensated HF will be open-label randomly assigned to be treated with or without SGLT2 inhibitors (either empagliflozin 10 mg once daily or dapagliflozin 10 mg once daily) 3 days before ventilator weaning in a ratio of 2:1. If the patients are allocated to SGLT2i treatment group, they will be further randomized equally to either empagliflozin- or dapagliflozin-treated group
224315356|NCT00247494|DRUG|mycophenol mofetil (MMF, Cellcept®) 500 mg BID|
224315357|NCT05871723|OTHER|Measurement of multifidus and gastrocnemius muscle thickness with Ultrasound|o measure multifidus and gastrocnemius muscle thickness using ultrasound imaging, the following steps are typically followed. First, the patient is positioned appropriately to allow access to the muscles to be imaged. For example, the patient may lie prone for imaging of the lumbar multifidus or sit with the leg extended for imaging of the gastrocnemius. Next, a trained clinician or technician places an ultrasound probe on the skin over the target muscle and adjusts the settings on the ultrasound machine to optimize the image quality. The probe is then moved around to obtain different views of the muscle, and the images are stored for later analysis. To measure muscle thickness, the clinician or technician identifies the muscle fascia on the ultrasound image and measures the distance between the fascia and the underlying bone or tissue. This measurement provides an estimate of the muscle thickness.
224315358|NCT05871723|OTHER|Berg Balance Scale|The Berg Balance Scale is a clinical assessment tool used to measure an individual's ability to maintain balance during various functional tasks. The test includes 14 items, such as standing unsupported, reaching forward, turning, and standing on one leg. Each item is scored on a 5-point scale, ranging from 0 (unable to perform the task) to 4 (able to perform the task independently and safely). The scores for each item are summed to provide a total score, with a maximum possible score of 56. The Berg Balance Scale is commonly used in clinical and research settings to assess balance impairment and monitor changes in balance over time, particularly in individuals with neurological conditions such as stroke. The test has good reliability and validity and is considered a gold standard for assessing balance in these populations.
223761456|NCT07068308|BEHAVIORAL|web-based FRAIL-SM program|The 8-week web-based FRAIL-SM includes family involvement, self-regulation, autonomy support, information sharing and linkage.
223761457|NCT06775964|BIOLOGICAL|adMSC|IV-infusion of autologous, adipose-derived, Mesenchymal Stem Cells (adMSCs), of approximately 2x10(8) adMSCs in 250mL saline.
223761458|NCT06782295|DEVICE|Constrained Condylar bearing|Patients in this intervention will receive a CCK bearing component
223761459|NCT06782295|DEVICE|posterior stabilized bearing|Patients in this intervention will receive a PS bearing component
223761460|NCT07075354|PROCEDURE|Hydraulic Condensation Root Canal Obturation with BioRoot RCS|Root canal obturation using the hydraulic condensation technique combined with BioRoot RCS, a bioceramic calcium silicate-based sealer. Treatment includes standardized irrigation with sonic activation and drying using a single calibrated paper point without alcohol. The sealer sets hydraulically in the presence of moisture, promotes hard tissue formation, and provides a durable, bioactive seal supporting periapical healing.
224207917|NCT01410695|DRUG|methotrexate|
224207918|NCT01410695|DRUG|Placebo (methotrexate)|
224207919|NCT01410695|DRUG|Placebo (masitinib)|
224207920|NCT05777369|DRUG|Rituximab|375 mg/m2, d0
223512702|NCT04588558|OTHER|Home exercise|The active ROM exercise was performed via knee in extension to full-flexion, then knee in flexion to full-extension exercises, repeated 10 times. The strengthening exercises consisted of quadriceps strengthening by holding maximal isometric contractions for 10 s and performing 10 repetitions. Stretching targeted the gastrocnemius- soleus and hamstring muscle and was performed by asking the patient to stretch the muscle for 30 s and to complete three repetitions for each muscle group.
223512703|NCT04588558|DEVICE|Electrotherapy group|"The participants in the electrotherapy group received TENS (Intellect; Chattanooga Group, Hixson, TN), therapeutic ultrasound (Intellect 340 Combo) and exercise. TENS was applied via four electrodes around the knee joint: two on the medial and two on the lateral aspect on either side of the joint line for approximately 20 min. For pain relief, the devices were set to a continuous mode (110 Hz, 50 μ). Electrical pulses were asymmetric and biphasic.~Therapeutic pulsed ultrasound therapy was administered using a 1-MHz frequency, 0.8 W/cm power ultrasound device with a sound-head area of 5 cm2 and effective radiating area of 3.5-5 cm2 . Ultrasound was applied to the medial and lateral parts of the knee in circular movements for a duration of 5 min with the patient in a supine position.~All participants received the same standardized exercise program. The exercises included aerobic, active ROM, strength, and stretching exercises"
223512704|NCT03666702|OTHER|Upper limb physiotherapy programme|Web-based physio programme
223512705|NCT03666702|OTHER|Usual care|Usual physiotherapy care
223512706|NCT00449800|DRUG|ceftriaxone|
223512707|NCT02813512|DRUG|ADSCs|Autologous ADSCs
223512708|NCT03125356|OTHER|Diet Soda|Subjects will be asked to consume diet soda three times daily for eight weeks.
223512709|NCT01504542|BIOLOGICAL|HS110 vaccine|0.5ml to be administered twice weekly for 18 weeks (36 doses)
223512710|NCT01504542|BIOLOGICAL|Placebo|0.5ml buffered saline placebo to be administered twice weekly for 18 weeks (36 doses)
223512711|NCT01504542|BIOLOGICAL|HS110 vaccine|0.5 mls to be dosed twice weekly for 18 weeks (36 doses)
223512712|NCT02191397|DRUG|Bupropion|Bupropion is an extended-release plain creamy white colored tablet which contains bupropion hydrochloride equivalent to 150 mg of bupropion.
223761461|NCT06898398|PROCEDURE|TACE|TACE procedure was a 2.8-F microcatheter was super-selectively inserted into the tumor feeding artery using the coaxial technique. Then a combination of lipiodol (5-15 ml), lobaplatin (30-50 mg), and Pirarubicin (30-50 mg) was infused into each tumor. We defined technical success as complete embolization of the tumor-feeding artery resulting in no tumor staining observed by angiogram at the end of procedure.
224207921|NCT05777369|DRUG|Mitoxantrone hydrochloride liposome|18 mg/m2, d1
224207922|NCT05777369|DRUG|Cyclophosphamide|750 mg/m2, d1
224207923|NCT05777369|DRUG|Vincristine/Vindesine|Vincristine: 1.4 mg/m2, d1(The maximum dose was 2 mg) Vindesine: 3 mg/m2, d1
224207924|NCT05777369|DRUG|Prednisone|60 mg/m2, d1\~d5
224207925|NCT01818414|DRUG|Misoprostol|400 mcg of buccal misoprostol, 3 hours prior to planned D\&E
224207926|NCT01818414|DRUG|Folic Acid|4 mg of buccal folic acid, 3 hours prior to planned D\&E
224207927|NCT02543164|OTHER|REFERENCE: white bread|"Determination of glycemic response after consumption of white bread:~Capillary glucose will be taken at 0 min (baseline sample), followed by 15, 30, 45, 60, 90 and 120 min after starting to eat the meal to calculate the area under the curve (AUC)."
224207928|NCT02543164|OTHER|TEST: b-glucan enriched bread|"Determination of glycemic response after consumption of bread enriched with barley beta-glucans (Test A) :~Capillary glucose will be taken at 0 min (baseline sample), followed by 15, 30, 45, 60, 90 and 120 min after starting to eat the meal to calculate the area under the curve (AUC)."
224207929|NCT05282355|DIETARY_SUPPLEMENT|Astaxanthin|Our aim was to examine the impact astaxanthin would have, if any, on markers of metabolic flexibility in overweight individuals in comparison to a placebo.
224207930|NCT05282355|DIETARY_SUPPLEMENT|Placebo|To have adequately test the effects of astaxanthin, we provided one group a placebo matched in appearance and taste.
224207931|NCT03543046|DEVICE|Tortle Midliner|The Tortle Midliner will be applied in the treatment group within the first 3 hours of life and maintained until 72 hours of life.
224207932|NCT04477317|DRUG|4% Articaine Hydrochloride with 1:100,000 Adrenaline|new Egyptian articane anesthetic solution.
224207933|NCT04477317|DRUG|2% Mepivacaine Hydrochloride with 1:20,000 Levonordefrin|Mepecaine-L is the brand name of the Egyptian 2% Mepivacaine. It is the most commonly used anesthetic solution in Egypt due to its availability and its lower cost.
224207934|NCT00419900|PROCEDURE|diagnosis of breast cancer by x-ray diffraction of hair|
224207935|NCT01227954|RADIATION|intensity-modulated radiation therapy|30 Gy in 10 fractions to the whole brain using intensity-modulated radiation therapy excluding the hippocampal avoidance area. Bilateral hippocampal contours manually generated on the fused planning MRI CT image set by the treating physician according to protocol-specified contouring instructions. Hippocampal avoidance regions generated by three-dimensionally expanding the hippocampal contours by 5 mm.
224207936|NCT02344459|DEVICE|mechanical pre-induction cervical ripening|The balloon catheters have been used to provide mechanical dilation to the cervix as a method of pre-induction cervical ripening.
224207937|NCT00004375|PROCEDURE|ultraviolet A-1 light treatment|
224207938|NCT01296152|DRUG|depo-medroxyprogesterone acetate|At study entry/ Day 0, participants will receive Depo-medroxyprogesterone (DMPA) 150mg administered intramuscularly (IM) as a single-dose.
224207939|NCT02353299|DRUG|Silenor 6 mg|Silenor 6 mg single nighttime dose.
224207940|NCT02353299|DRUG|zolpidem 10 mg|Zolpidem 10 mg single nighttime dose
224207941|NCT02353299|DRUG|Placebo|placebo single nighttime dose-1.5 hours
224207942|NCT02353299|DRUG|Placebo|placebo single nighttime dose-4 hours
224207943|NCT01096706|DRUG|NO clamp|"After a 20 minute saline washout period, ascending doses of Urocortin 2, Urocortin 3 and substance P (doses as per Protocol 2) will be infused intra-arterially in the presence or the absence of the 'nitric oxide clamp' that will be commenced prior to the infusion of Urocortin 2, Urocortin 3 and substance P, and will be continued throughout the study.~Baseline blood samples will be taken from both forearms at the start of the study for full blood count, cholesterol, glucose, renal function and t-PA and PAI-1 activity and antigen concentrations. Bilateral venous blood samples will be taken at baseline, immediately before the start of Ucn2/Ucn3 infusion and at the end of each dose of Ucn2/Ucn3 for subsequent calculation of net release of t-PA and PAI-1."
224207944|NCT01096706|DRUG|Saline|"After a 20 minute saline washout, incremental doses of Urocortin 2, Urocortin 3 and Substance P (in doses as per Protocol 2) will be infused in the presence of saline placebo.~Baseline blood samples will be taken from both forearms at the start of the study for full blood count, cholesterol, glucose, renal function and t-PA and PAI-1 activity and antigen concentrations. Bilateral venous blood samples will be taken at baseline, immediately before the start of Ucn2/Ucn3 infusion and at the end of each dose of Ucn2/Ucn3 for subsequent calculation of net release of t-PA and PAI-1."
224207945|NCT01096706|DRUG|Fluconazole|"After a 20 minute saline washout period, ascending doses of Urocortin 2, Urocortin 3 and substance P (doses as per Protocol 2) will be infused intra-arterially in the presence of Fluconazole (which serves to inhibit the EDHF pathway) that will be commenced prior to the infusion of Urocortin 2, Urocortin 3 and substance P, and will be continued throughout the study.~Baseline blood samples will be taken from both forearms at the start of the study for full blood count, cholesterol, glucose, renal function, plasma Ucn 2 and 3 and t-PA and PAI-1 activity and antigen concentrations. Bilateral venous blood samples will be taken at after the top dose of Ucn2/Ucn3 infusion and before and after each dose of Substance P for subsequent calculation of plasma Ucn 2/ Ucn 3 and net release of t-PA and PAI-1."
224315359|NCT04257539|BEHAVIORAL|Intervention to Reduce Sedentary Time|Chronic low back pain participants in the intervention group will be provided with a wrist-worn activity device that vibrates after prolonged sedentariness and meet with a health coach trained in motivational interviewing to discuss individual sedentary levels and provide education surrounding sitting habits and strategies for new habit development. Participants will meet with the health coach initially and at 4 weeks during the 8 week intervention period.
223512713|NCT02191397|DRUG|Bupropion Matching Placebo|Bupropion hydrochloride matching placebo tablets will be supplied to maintain blinding
223512714|NCT02191397|DRUG|Escitalopram|Escitalopram is available as a Swedish orange capsule containing escitalopram oxalate equivalent to 10 mg of escitalopram.
223512715|NCT02191397|DRUG|Escitalopram Matching Placebo|Escitalopram oxalate matching placebo tablets will be supplied to maintain blinding
223512716|NCT06237764|OTHER|No intervention|No intervention.
223512717|NCT05472181|DEVICE|rTMS (Repetitive TMS)|TMS stimulation produce electromagnetic pulses that can directly changes the neural firing in the brain. The rTMS applies the magnetic pulses in a repetitive manner, and can induce either an inhibitory or excitatory effect on cortical neurons. In this study we use high frequency rTMS (10 Hz) to provide the excitatory effect.
223512718|NCT05472181|BEHAVIORAL|Speech training|The behavioural training will include reading sentences in which a syllable is spoken in time to a rhythmic beat.
223512719|NCT01113814|DEVICE|FibroScan|
223512720|NCT01113814|DEVICE|Acoustic Radiation Force Impulse (ARFI)- Imaging|
223512721|NCT00549211|DRUG|GSK557296|
223619061|NCT07198061|DEVICE|Cold Atmospheric Plasma (CAP)|CAP-activated gas treatment developed by Xi'an Jiaotong University (Chinese patent No. ZL202110209052.X); administered once daily for 10 days, 25 minutes per session.
223619062|NCT07198061|DEVICE|Sham CAP Therapy|Identical equipment without plasma activation; simulates treatment environment (sound, airflow) for participant blinding.
223619063|NCT07198061|PROCEDURE|Infrapopliteal Endovascular Revascularisation|Balloon angioplasty is performed on infrapopliteal arteries with significant stenosis or occlusion. Technical success is defined as \<30% residual stenosis, confirmed intraoperatively by digital subtraction angiography (DSA). Only patients with successful revascularisation are eligible for randomisation.
223619064|NCT07198061|OTHER|Guideline-Based Standard DFU Care|All participants will receive diabetic foot ulcer (DFU) care according to current international and Chinese clinical guidelines
224315360|NCT04762472|DRUG|Montelukast Oral Tablet|i) Montelukast 10mg daily (tablet) orally x 26 weeks
224315361|NCT04762472|DRUG|Montelukast Placebo Oral Tablet|i) Placebo (Montelukast identical) tablet 1 daily orally x 26weeks
224315362|NCT02666209|DRUG|Ulocuplumab|CXCR4 inhibitor given weekly on a 28 day cycle intravenously
223761462|NCT06898398|PROCEDURE|Surgery|The surgical plan was based on the tumor size, tumor location, and liver function. We applied Pringle's maneuver with cycles of clamping and unclamping times of 1-10 and 5 min, respectively, and maintained the central venous pressure below 4 mmHg during parenchymal dissection to control intraoperative bleeding.
223761463|NCT05321758|BIOLOGICAL|Fecal Microbiota Transplantation|In the induction stage of CD, FMT was given 1-3 courses, 3-6 times per course.
223761464|NCT05321758|DRUG|Immunosuppressive Agents|hormones, azathioprine, thalidomide
224315363|NCT02666209|DRUG|Lenalidomide|immunomodulatory agent given days 1-21 of a 28 day cycle orally in subjects not receiving bortezomib
224315364|NCT02666209|DRUG|Bortezomib|proteasome inhibitor given at physician discretion in subjects not receiving lenalidomide
224315365|NCT02666209|DRUG|Dexamethasone|steroid given at physician discretion on a 28 day cycles
224315366|NCT02656069|DRUG|G-Pen (glucagon injection)|1 mg of pre-mixed liquid Xeris glucagon delivered via auto-injector
224315367|NCT02656069|DRUG|Lilly Glucagon (glucagon injection [rDNA origin])|1 mg of Lilly glucagon reconstituted from lyophilized powder
224315368|NCT05630417|OTHER|Feet and Back Massage|"Foot massage: Feet are the most neglected organs of people and therefore cause many complaints. Foot massage is a massage applied to the back of the foot, toes, soles of the feet, the muscles between the thumb and little fingers, and the heel, where the muscles between the metatarsal bones are located.~Back massage: Back massage is a non-invasive nursing intervention that can be easily applied by nurses. In back massage application; A 10-minute back massage program applied by Çınar and Eşer (2012) will be applied."
224315369|NCT01549405|OTHER|İntercostal nerve block|Nerve block group was administered two levels intercostal block (11 and 12th ribs) with 0.5% bupivacaine with epinephrine before surgery.
224315370|NCT04777149|OTHER|transcranial Random Noise Stimulation (tRNS)|Two electrodes will be placed over the targeted areas on participant's head. A current of random frequency and intensity will be delivered. TRNS will be applied during the first 20 min of functional task practice.
224315371|NCT04777149|OTHER|transcranial Direct Current Stimulation (tDCS)|Two electrodes will be placed over the targeted areas on participant's head. A continuous low intensity current will be delivered. TDCS will be applied during the first 20 min of functional task practice.
224315372|NCT04777149|OTHER|sham-stimulation|Two electrodes will be placed over the targeted areas on participant's head. A continuous low intensity current will be delivered for 1- 2 min.
224315373|NCT05177718|DRUG|Natalizumab 300 MG in 15 ML Injection|Disease modifying agent
224315374|NCT00290550|DRUG|MK0457|IV infusion at 10 mg/m2/hour; 5-day continuous infusion every 21 days
224315375|NCT04737096|DRUG|DAOIB|The DAOIB dose will be adjusted every 8 weeks according to clinical evaluation.
224315376|NCT04737096|DRUG|Placebo|placebo
224315377|NCT04737096|DEVICE|tDCS|tDCS
224315378|NCT02837848|PROCEDURE|Coactivation Strengthening|Coactivation strengthening implies a recruitment of the pectoralis major and the latissimus dorsi while performing regular strengthening.
224315379|NCT02837848|PROCEDURE|Regular Strengthening|Regular strengthening implies external rotation, internal rotation, flexion and abduction of the gleno-humeral joint and scapular protraction and retraction of the scapulothoracic joint strengthening.
224315380|NCT05630690|DEVICE|IPL with smart diagnostic handpiece|treatment with IPL following diagnostic with SMART system
224315381|NCT03558386|BEHAVIORAL|ePRO survey|An electronic patient reported outcomes survey will be completed by the patient.
224315382|NCT03215186|OTHER|observational study|
224315383|NCT00041626|GENETIC|INGN 201|
224315384|NCT06414226|DIETARY_SUPPLEMENT|Krill and Fish Oil vs. Placebo|Participants were prescribed to take a daily dose of 4 capsules (4×500 mg= 2 g/day) stored at an appropriate temperature during the 8-week treatment period. The patients were informed to take 2 of the capsules in the bottle to be taken orally daily in the morning before breakfast and the other 2 capsules before dinner. The capsule bottles contained 500 mg concentrated krill oil, fish oil or placebo (empty capsule) capsules. The daily intake of EPA+DHA from krill and fish oil was determined as 520 mg and 600 mg, respectively. Krill and fish oil were obtained from Aniqnaturals Superba and Orzax Ocean company, respectively.
224315385|NCT01192763|DRUG|gamma-secretase/Notch signalling pathway inhibitor RO4929097|Given orally
223619065|NCT05692544|PROCEDURE|Phototherapy treatment|only patients was proscribe to phototherapy treatment can participate in the study
224315386|NCT01192763|OTHER|laboratory biomarker analysis|Correlative studies
223619066|NCT05929625|DEVICE|BTL-585-2 RF+US|The subjects of RF+US group will receive four simultaneous RF+US treatments of the entire face area including forehead, upper and lower cheeks and area around eyes.
223619067|NCT05929625|DEVICE|BTL-585-2 RF|The subjects of RF only study group will receive four RF treatments of the entire face area including forehead, upper and lower cheeks and area around eyes.
224315387|NCT01192763|OTHER|pharmacological study|Correlative studies
224315388|NCT01192763|PROCEDURE|neoadjuvant therapy|
224315389|NCT01192763|PROCEDURE|therapeutic conventional surgery|
223619068|NCT07198529|DRUG|Short DAPT|Patients receive aspirin and clopidogrel for 1 month after PCI. After 1 month, aspirin is discontinued and clopidogrel monotherapy is continued.
223619069|NCT07198529|DRUG|Standard DAPT|Patients with high bleeding risk will receive aspirin and clopidogrel for 6 months after PCI (unoptimization confirmed in OCT), followed by single antiplatelet therapy thereafter.
223619070|NCT07198529|DRUG|Extended DAPT|Patients (with stet unoptimazation results in OCT imaging) receive aspirin and clopidogrel for 12 months after PCI.
223619071|NCT07198529|DEVICE|OCT-guided PCI|All patients undergo percutaneous coronary intervention with mandatory intravascular imaging using optical coherence tomography to assess stent optimization (expansion, apposition, dissection).
223619072|NCT07199530|OTHER|Blood Product|blood sample for d dimer
223619073|NCT07199114|BEHAVIORAL|Adapted CrossFit Program (12 weeks)|Supervised sessions focused on functional, multi-joint movements adapted for older adults; emphasis on safety and progressive overload.
223761465|NCT07086170|OTHER|Psychological First Aid Training|Structured training based on psychological first aid principles. Delivered in six 60-minute sessions over three weeks. Includes theoretical content, interactive methods, and case-based exercises to build disaster response competencies.
223761466|NCT06923813|OTHER|caloric intake measurement|Detailed daily tracking of the enteral feeding provided to each patient, inclusing the type and amount of nutritional formula administered. Apart from the enteral intake, supplemental calories provided by infusion (e.g. glucose) will be recorded to ensure accurate measurement of caloric intake.
223761467|NCT06923813|PROCEDURE|stool sample collection|"* a nonabsorbable blue dye marker will be administered at the start and end of the stool collection period to precisely indentify the stool produced within a specific time frame.~* stool will be collected for three days. Each sample will be collected, weighted and labeled with the date and time, then stored at -20°C.~* only stool samples from the appearance of the first dye marker to the appearance of the second dye marker will be saved and analyzed.~* bomb calorimetry preparation~  * blending and dilution: each stool sample will be put into a blender and mixed with an equal amount of water~ * freeze dying: the diluted stool will be placed into freeze-dye flasks and frozen at -20°C. The next day, the flasks will be placed into a freeze dryer for 48hours.~ * pellet formation: the freeze-dried samples will be formed into 1-gram pellets and stored until calorimetry~ * calorimetry analysis: the Parr 6200 isoperibol calorimeter will be used to measure the energy content of the stool pellets"
223619074|NCT07198295|DEVICE|TEAVR with false lumen embolization|The procedure involves two key steps: first, deploying a stent-graft in the true lumen to seal the proximal entry tear; second, selectively catheterizing the false lumen to place 1-3 vascular plugs at critical locations-below the distal end of the stent-graft, at the celiac trunk level, and at the distal re-entry tear in the infrarenal aorta-to occlude distal outflow and induce complete false lumen thrombosis.
223619075|NCT07199699|PROCEDURE|Subxiphoid Minimally Invasive Resection of Giant Mediastinal Teratoma Assisted by Double Sternal Elevation|All patients underwent minimally invasive mediastinal tumor resection using a double hook technique via the subxiphoid approach. The procedure was as follows: A 3-4 cm longitudinal incision was made below the xiphoid, and subcutaneous tissue was dissected to reach the anterior rectus sheath. The retroxiphoid space was bluntly dissected, and a thoracoscopic lens was inserted. A double-retractor system was placed in the subxiphoid and suprasternal regions, and retractor height was adjusted to aid in separating tumor adhesions from residual thymic tissue. Blunt dissection was used to separate the tumor from the innominate vein and phrenic nerve. After full tumor mobilization, it was placed into a sterile specimen bag and removed through the incision. The surgical area was rinsed and a mediastinal drainage tube was inserted, and the incision was closed layer by layer.
223761468|NCT06923813|OTHER|energy expenditure measurement|performing indirect calorimetry to measure the REE of each patient
223619076|NCT07199127|DIAGNOSTIC_TEST|DRACO|A novel endoscopic classification to predict the risk of duodenal and ampullary high-grade dysplasia and cancer from baseline esophagogastroduodenoscopy (EGD)
223619077|NCT07199894|DRUG|Mirabegron (beta3-adrenoceptor agonist), Anticholinergics|Anticholinergic and B3 agonist drugs used for treatment of mono-symptomatic nocturnal enuresis
224207946|NCT01096706|DRUG|Aspirin|"Oral Aspirin (600mg stat) will be administered 30 minutes before start of the study. After a 20 minute saline washout period, ascending doses of Urocortin 2, Urocortin 3 and substance P (doses as per Protocol 2) will be infused intra-arterially in the presence of saline.~Baseline blood samples will be taken from both forearms at the start of the study for full blood count, cholesterol, glucose, renal function, plasma Ucn 2 and 3 and t-PA and PAI-1 activity and antigen concentrations. Bilateral venous blood samples will be taken at after the top dose of Ucn2/Ucn3 infusion and before and after each dose of Substance P for subsequent calculation of plasma Ucn 2/ Ucn 3 and net release of t-PA and PAI-1."
224207947|NCT01096706|DRUG|Combined|"Oral Aspirin (600mg stat) is administered 30 minutes before start of the study. After a 20 minute saline washout period, ascending doses of Urocortin 2, Urocortin 3 and substance P (doses as per Protocol 2) will be infused intra-arterially in the presence of the 'nitric oxide clamp' that will be commenced prior to the infusion of Urocortin 2, Urocortin 3 and substance P, and will be continued throughout the study. Intra-arterial Fluconazole is also commenced at the time of the Nitric oxide clamp.~This serves to inhibit the cyclooxygenase, EDHF and NO pathways of endothelial vasodilatation.~Blood samples are taken as per previous arms."
224207948|NCT04064437|DIAGNOSTIC_TEST|Clinical tests|The investigators perform the following clinical tests: vibration threshold test, monofilament test, and height, weight and waist circumference measurement in every participant.
224207949|NCT04064437|DIAGNOSTIC_TEST|Clinical tests|The investigators perform the following clinical tests: height, weight and waist circumference measurement in every participant.
224315390|NCT05127512|OTHER|Education Video|A 6.47-minute education video was created by the research group based on American Urogynecology Society (AUGS) and International Urogynecologic Association (IUGA) patient education pamphlets. Participants in the intervention group will be asked to watch this video after completing a baseline knowledge questionnaire of pelvic floor disorders.
224207950|NCT04064437|DIAGNOSTIC_TEST|Biochemical tests|The investigators perform blood and urine tests in every participant.
224207951|NCT04064437|DIAGNOSTIC_TEST|DXA scan|The investigators perform a dual energy x-ray absorptiometry (DXA scan or osteodensitometry) in every participant.
223619078|NCT07199894|DRUG|Desmopressin (DDAVP)|ADH analogue in treatment of mono-symptomatic nocturnal enuresis
223619079|NCT07199101|RADIATION|Low dose CT|Participants will undergo a low dose CT adopting the pediatric low-dose CT protocol established based on low dose simulation technique.
223619080|NCT07198776|PROCEDURE|Percutaneous Vertebroplasty|Injection of PMMA cement into fractured vertebra under fluoroscopic guidance.
223761469|NCT07086898|OTHER|Integrated Neuromuscular Inhibition Technique|Patients will receive integrated neuromuscular inhibition technique in the form of intermittent ischemic compression, strain counterstrain, and muscle energy technique plus postural correction exercises
224207952|NCT04064437|DIAGNOSTIC_TEST|AGE Reader|The investigators perform a skin advanced glycation end products (AGEs) measurement with the AGE Reader machine in every participant.
224315391|NCT05623618|BEHAVIORAL|PACE labelling|PACE labelling implemented near at least one discretionary food item in secondary school canteens for up to 6 weeks.
224315392|NCT05304247|OTHER|questionnaire and clinical examination|Prevalence and Risk Factors of Black Tooth Stains and Their Relation With Caries Experience in Primary Teeth of A Group of Preschool Children
224207953|NCT03949283|DIAGNOSTIC_TEST|ChemoID Assay|"The ChemoID test is a CLIA-certified and CAP-accredited drug response assay performed by a hospital clinical pathology laboratory that uses patient's live tumor cells to indicate which chemotherapy agent (or combinations) will kill bulk of tumor cells, and cancer stem cells (CSCs) that are known to cause cancer to recur. During the assay, cancer stem cells and bulk tumor cells from an individual patient are exposed to FDA-approved chemotherapy drugs.~The test measures the cytotoxic effect of actual doses of standard-of-care chemotherapies. The ChemoID drug response assay reports a prioritized list of effective and ineffective chemotherapies. The test is designed to target cancer stem cells to mitigate tumor relapse."
223619081|NCT07198438|DEVICE|Deep Prolonged Intermittent Theta Burst Stimulation|This intervention uses a Deymed Repetitive Transcranial Magnetic Stimulator with a double-cone coil (90BFVT-LQC) to target the anterior cingulate cortex (ACC). The resting motor threshold (rMT) is determined from the tibialis anterior muscle. Stimulation is delivered at 90% of the rMT. The protocol consists of 3-pulse 50Hz bursts repeated at a 5Hz frequency, administered in cycles of 2 seconds on and 8 seconds off, for a total of 1800 pulses per session. Treatment consists of 20 sessions administered over four weeks.
223619082|NCT07198438|DEVICE|Standard Prolonged Intermittent Theta Burst Stimulation|This intervention uses a Deymed Repetitive Transcranial Magnetic Stimulator with a planar coil (70BF-LQC) to target the left dorsolateral prefrontal cortex (DLPFC). The resting motor threshold (rMT) is determined from the abductor pollicis brevis muscle. The DLPFC is localized 5.5 cm anterior to the motor hotspot. Stimulation is delivered at 90% of the rMT. The protocol consists of 3-pulse 50Hz bursts repeated at a 5Hz frequency, administered in cycles of 2 seconds on and 8 seconds off, for a total of 1800 pulses per session. Treatment consists of 20 sessions administered over four weeks.
224315393|NCT02916667|OTHER|dietary guidelines|dietary guidelines will include chrono- nutrition diet plan
223619083|NCT07198737|DEVICE|VR and VNS|Participants will have Vagus nerve stimulation at the same time as a relaxing VR experience
223619084|NCT04886713|DIAGNOSTIC_TEST|Adipose and myocardial tissue sampling|After median sternotomy tissue samples will be collected from the epicardial space, the abdominal wall and the myocardium.
223619085|NCT04886713|DIAGNOSTIC_TEST|Cardiac magnetic resonance imaging|"Magnetic resonance imaging will be performed at 1.5 Tesla ('Intera', Philips Medical Systems, Best, The Netherlands). All subjects will be examined in the supine position with initial anatomy scans to cover the thorax to the first sacral vertebrae. The magnetic resonance imaging protocol is summarized in Figure 4.~The following imaging parameters will be acquired:~* Biventricular end-diastolic and end-systolic volume, ejection fraction, stroke volume~* Biventricular mass, wall thickness~* T1 mapping; native and \> 10 minutes post contrast injection as an estimate of left ventricular diffuse fibrosis and extracellular volume~* Late enhancement for detection of regional fibrosis and scar~* Myocardial feature tracking for analysis of deformation/motion~* Epicardial fat volume"
223619086|NCT04886713|DIAGNOSTIC_TEST|Cardiopulmonary exercise testing|After completion of a regular cardiac rehabilitation program patients are scheduled to undergo their discharge examination at 3 to 4 weeks after the operation in order to be functionally characterized. Cardiopulmonary exercise testing will be performed, if possible by patients condition, on a mechanically braked bicycle ergometer and respiratory gas exchange analysis via a mouthpiece or facemask.
223761470|NCT07086898|OTHER|Postural Correction Exercise|The exercise program will be in the form of stretching exercises for the sternocleidomastoids (SCM), the scalenes, and upper fibers of trapezius; strengthening isometric exercises for the neck flexors, extensors, lateral flexors, and neck rotators; and postural correction exercises.
224207954|NCT03949283|DRUG|Standard Chemotherapy|"Control chemotherapy treatment will be chosen from any of the following standard-of-care chemotherapy drugs or combinations:~Liposomal Doxorubicin; Docetaxel; Paclitaxel; Carboplatin; Cisplatin; Gemcitabine; Topotecan; Carboplatin, Gemcitabine; Cisplatin, Gemcitabine; Carboplatin, Liposomal Doxorubicin; Carboplatin, Paclitaxel; Carboplatin, Docetaxel. The treating physician will NOT receive the ChemoID assay results from the ChemoID lab."
224207955|NCT06180577|DEVICE|Nerivio|Nerivio is a prescribed Remote Electrical Neuromodulation (REN) device for treatment of migraine
224207956|NCT06702202|DRUG|Mixture of local anesthetics|Marcaine® (bupivacaine HCl) 0,5% and Xylocaine® (Lidocaine HCL) 2% = 2:1 Given in Femoropopliteal block group (Group F)
224207957|NCT06702202|DRUG|0.5% hyperbaric bupivacaine|Given in Subarachnoid block group (Group S)
224207958|NCT05380830|OTHER|Tied deep-Water Running|4 efforts of tied deep-water running for 5 minutes at 100-110%Vo2max under normoxia with 5 minutes of passive rest under hypoxia (FiO2=13%) or normoxia (FiO2= 20%). Frequency: 3x/week for 8 weeks.
224207959|NCT02826174|PROCEDURE|closed PKP under topical anesthesia|a closed corneal transplantation under topical anesthesia with the anterior chamber maintained
224207960|NCT02826174|PROCEDURE|open-sky PKP under retrobulbar anesthesia|an open-sky corneal transplantation under retrobulbar anesthesia
224207961|NCT02826174|DRUG|Anti-Rejection Agents|Anti-Rejection Agents for both groups
224315394|NCT01796418|DRUG|Beraprost sodium|
224315395|NCT04809051|OTHER|Stratified Transplant Survival Metric|"Both transplant metric conditions display the number of hearts offered to each center, the number of hearts accepted by each center, and the number of transplants performed at each center (in a year), in addition to the condition-specific metrics below. The stratified condition instead features a pair of values corresponding to each center's offers/acceptances/transplant survival rates for donor hearts of optimal or adequate quality."
223619087|NCT00862693|DRUG|Calcitriol|0.5ug/Biw
223619088|NCT07200050|OTHER|Home-based Exercise Program|Participants follow a 12-week home-based exercise program including aerobic, strengthening, and flexibility exercises. Assessments are done at baseline and after 12 weeks.
223619089|NCT00002609|BIOLOGICAL|lintuzumab|
223619090|NCT00002609|DRUG|cytarabine|
223619091|NCT00002609|DRUG|idarubicin|
223619092|NCT00751803|DRUG|BI 44370 TA Low Dose|
223761471|NCT03632187|DRUG|Abatacept|Subcutaneous abatacept every weeks during 3 months
223761472|NCT03632187|DRUG|Placebos|Subcutaneous placebo every week during 3 months
223761473|NCT06889142|DIETARY_SUPPLEMENT|Nicotinamide Mononucleotide|The dietary supplement NMN \[1,000mg\] will be taken orally by participants daily for a total of 12 weeks
224207962|NCT02826174|DRUG|Anti-Inflammatory Agents|Anti-Inflammatory Agents for both groups
224207963|NCT03848000|OTHER|Exercise Programme|Two sessions per week for 12 consecutive weeks. 30 minute education talks covering topics regarding the physical and mental health benefits of exercise and behaviour change. The following 30-60 minute exercise sessions will utilise pad-boxing, football, body-weight training and circuit training.
224207964|NCT03848000|BEHAVIORAL|NHS Standard Care|Weekly one-to-one cognitive-behavioral counselling alcohol addiction support session lasting 1 hour. Drug therapy will be offered if indicated in line with standard therapy.
224207965|NCT06000007|DEVICE|2Morrow Chronic Pain Self-Management Program - digital therapeutic mobile app|2Morrow Chronic Pain Self-Management Program is delivered via a mobile app that engaged patients in evidenced based psychotherapy for chronic pain, including Acceptance and Commitment Therapy and Cognitive Behavioral Therapy based activities, to improve a patient's pain self management. The mobile app also offers the ability to track activities, screen for other problems, support for communicating with medical providers, and access a coach via texting.
224315396|NCT04809051|OTHER|SRTR Information Format|The information format varies based on how the transplant hospital statistics are organized when presented to participants on the choice screen. The SRTR conditions mimic the information format present on the SRTR public reporting website.
223619093|NCT00751803|DRUG|Eletriptan|
223619094|NCT00751803|DRUG|Placebo|
224315397|NCT00299286|DRUG|Lapatinib|"In order for patients to take their study medication for 14 days only, treatment should commence on the 14th day prior to the day before scheduled surgery (i.e. if surgery is scheduled for the 15th of the month, tablets should be taken from the 1st to the 14th of that month).~Lapatinib tablets are dispensed as 250mg tablets. Patients should be advised to take all 6 tablets at once as one dose (total daily dose 1500mg). Tablets should be taken on an empty stomach either one hour before or one hour after a meal at the same time each day and according to the instructions on the bottle."
224315398|NCT00299286|DRUG|Lapatinib-Placebo|"In order for patients to take their study medication for 14 days only, treatment should commence on the 14th day prior to the day before scheduled surgery (i.e. if surgery is scheduled for the 15th of the month, tablets should be taken from the 1st to the 14th of that month).~Lapatinib-placebo tablets will be composed of lactose, cellulose, starch, magnesium stearate, and coated with Opadryl orange and look the same as the active treatment. The patients should take all 6 tablets at once as one dose."
224315399|NCT03430765|BEHAVIORAL|Acceptance and Commitment Therapy|Single 2-hour individual Acceptance and Commitment Therapy coping skills session.
224315400|NCT03880786|DEVICE|pudendal PNE test lead|All patients eligible for release surgery will be implanted a PNE test lead (Medtronic) which will be placed (transforaminal or transgluteally) next to the pudendal nerve, at the level of the ischial spine, after surgical release and connected to an external stimulation device. The PNE lead will be fixed at the ischial-spinal ligament with an absorbable suture to prevent dislocation. If a bilateral dissection is needed, bilateral test leads will be placed. Stimulation will be switched on at the second postoperative day, according to the sensory threshold described by the patient. After three weeks the PNE test lead will be removed at the outpatient clinical visit.
224315401|NCT03924518|DRUG|Granisetron Hydrochloride|Granisetron will be diluted with 0.9% saline to ensure that the therapeutic drug and placebo are identical in appearance, and 50 ml syringes will serve as the containers for all intravenous drugs.
224315402|NCT03924518|DRUG|Placebo（Normal saline）|therapeutic drug and placebo are identical in appearance, and 50 ml syringes will serve as the containers for all intravenous drugs.
224315403|NCT03107221|BEHAVIORAL|"Smart Eating internet-based self-help programme"|An internet-based self-help programme using cognitive behavioural therapy principles to treat individuals receiving input from a specialist eating disorders service. The programme takes 3 months to complete.
224315404|NCT01539018|DRUG|Sorafenib|Sorafenib 400 mg p.o. twice daily until progression or intolerable toxicity alone.
224315405|NCT01539018|DRUG|sorafenib plus tegafur-uracil|Sorafenib 400 mg p.o. twice daily until progression or intolerable toxicity and TEGAFUR-URACIL 125mg/m2 PO BID For 4 weeks and to be repeated on day 36 till progression or intolerance
223619095|NCT00751803|DRUG|BI 44370 TA Medium Dose|
223619096|NCT07200063|OTHER|nano silver mouthwash|nano silver mouthwash will reduce the side effect of chlorhexidine and increase acceptance of the mouthwash to patients
223619097|NCT07200063|OTHER|Chlorhexidine mouthwash (0.12%)|the concentration of chlorhexidine
223619098|NCT07200063|OTHER|Chlorhexidine mouthwash (0.2%)|chlorhexidine mouthwash 0.2% (orovex )
223619099|NCT07198594|OTHER|rTMS|individualized rTMS target the IFC with symptom provocation
224207966|NCT06000007|OTHER|Treatment as usual|Treatment as usual entails continuing with treatment for chronic pain with the patient's primary care provider and any potential specialists they choose to engage with.
224207967|NCT00149773|BEHAVIORAL|Cognitive Therapy|
223619100|NCT07198464|DRUG|Relmacabtagene autoleucel and transplantation|This study enrolled patients with primary central nervous system lymphoma, from whom mononuclear cells and hematopoietic stem cells were collected. Participants receive infusions of hematopoietic stem cells and CAR-T cells, followed by maintenance therapy with orelabrutinib and sintilimab starting on day 15 post-transplantation, for a median duration of up to 6 months and 1 year, respectively.
223619101|NCT02135510|DRUG|metoclopramide|
223619102|NCT02135510|DRUG|dexamethason|
223619103|NCT02135510|DRUG|palonosetron|
223619104|NCT03177928|DEVICE|Transthorathic echocardiogram|In echocardiography lab and using transthoracic echocardiogram to reveal any cardiac changes in patients.
223619105|NCT01332383|DRUG|Naratriptan|
223619106|NCT03186027|DIETARY_SUPPLEMENT|Coenzyme Q10 plus NADH|"Active arm: Coenzyme Q10 plus NADH CFS/ME patients who will be randomized to measure the effect of oral ReConnect supplementation (CoQ10: 200 mg/day plus NADH 20 mg/day; 4 tablets/day) on changes in the fatigue, sleep problems, autonomic function and HRQoL during 8-weeks in term.~Intervention: Reconnect"
224207968|NCT04221100|DEVICE|Radiograph interpretation for pulmonary abnormalities|"The pulmonary abnormalities detected by xrAI and included in the definition of abnormality are as follows: any linear scar or fibrosis, atelectasis, consolidation, abscess or cavity, nodule, pleural effusion, severe cases of emphysema and COPD (mild cases with hyperinflation but not significant emphysema are not flagged), pneumothorax.~Participants in the treatment group will interpret 500 images presented alongside the results of xrAI's processing in a dark room and asked to categorize each image into one of the following categories: lungs are clear, at least one pulmonary abnormality is present, not sure.~Participants in the control group will be asked to interpret the same 500 images as the treatment group but without xrAI's analysis."
224207969|NCT05367934|BEHAVIORAL|Therapeutic Touch|Therapeutic Touch for stress
224207970|NCT05340517|PROCEDURE|video-assisted rib planting|Give the patient intercostal nerve block and laryngeal mask anesthesia, after that, put the patient in lateral position. Make a 4-6cm posterolateral incision along the lower edge of the scapula，sever latissimus dorsi and serratus anterior and reach the rib surface. Lift the scapula with the abdominal retractor (or xiphoid retractor), Free adhesion tissue inside the scapula and put in the thoracoscopic lens. Free the tissue of the upper and lower edges of the ribs carefully, reset ribs and insert rib plate, which is fixed by 90° electric drill and locking screw.
224207971|NCT04911660|DRUG|Empagliflozin 25 MG|1 empagliflozin 25 mg capsule per day for 14 days
224207972|NCT04911660|OTHER|Placebo|1 placebo capsule per day for 14 days
224207973|NCT03984552|BEHAVIORAL|This was an observational study of medical devices (rapid tests) used for the HIV diagnosis in children up to 2 years|"These rapid tests are based on lateral flow immunochromatography technology, in which a nitrocellulose membrane is impregnated with the antigen of interest. The patient sample (blood, serum, plasma, oral fluid, etc.) is applied in this membrane which facilitates the interaction of antibodies in the sample with the antigens on the membrane. This reaction becomes visible to the naked eye thanks to a color developing revelator.~The entire testing process, from sample collection to result reading takes no more than 40 minutes and does not depend on laboratory facilities."
224207974|NCT03378310|DRUG|BMS-986205 reference tablet|Single, 100 mg oral dose.
224207975|NCT03378310|DRUG|BMS-986205 tablet with free base|Single, 100 mg oral dose.
224207976|NCT03375346|DEVICE|Whole body vibration|whole body vibration exercise is a stimulus that uses vibrations generated on a machine with oscillatory movement determined by the amplitude and frequency of the vibration.
224207977|NCT03375346|OTHER|Exercise|maintain a half-squat position (knee joint angle at 160 degrees) on the tilt table with an incline of 60 degrees
224207978|NCT03664388|DRUG|Dual antiplatelet therapy with ticagrelor/prasuglre|Compare bleeding and ischemic events according to the type and duration of dual antiplatelet therapy
224207979|NCT04757675|DRUG|S-ketamine 0.3|0.3 μg/kg intravenous injection s-ketamin
224207980|NCT04757675|DRUG|S-ketamine 0.5|0.5 μg/kg intravenous injection s-ketamin
224207981|NCT04757675|DRUG|S-ketamine 2|2 μg/kg intranasal s-ketamin
224207982|NCT04757675|DRUG|S-ketamine 1+Dexmedetomidine 1|1 μg/kg intranasal s-ketamin + 1 μg/kg intranasal dexmedetomidine
224207983|NCT04757675|DRUG|S-ketamine 0.5 +Dexmedetomidine 2|0.5 μg/kg intranasal s-ketamin + 2 μg/kg intranasal dexmedetomidine
224207984|NCT01396473|BEHAVIORAL|Policy and Environmental Change|Afterschool programs participate in an assessment of physical activity and nutrition practices and policies. Study staff work with teams of afterschool programs in a participatory manner to identify areas in which programs would like to take practice, policy and communication efforts to meet physical activity and nutrition goals. Teams share progress and barriers during ongoing collaborative meetings.
224207985|NCT02209272|DRUG|bacteriostatic saline|
224207986|NCT02209272|DRUG|buffered lidocaine|
224207987|NCT06033963|PROCEDURE|Remote ischemic conditioning|Remote ischemic conditioning (RIC) is induced by 5 cycles of 5 min of bilateral upper limbs ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflations of a blood pressure cuff to 200 mmHg.
224207988|NCT06033963|PROCEDURE|Sham remote ischemic conditioning|Remote ischemic conditioning (RIC) is induced by 5 cycles of 5 min of bilateral upper limbs ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflations of a blood pressure cuff to 60 mmHg.
224207989|NCT05144958|DEVICE|Totally thoracoscopic LAAO - ATRICLIP|The device for surgical totally thoracoscopic left atrial appendage occlusion AtriClip® Gillinov-Cosgrove™ (AtriClip, AtriCure, Dayton, OH, USA) consists of an automatically closing clip placed in a deployment loop on a disposable holder with the head articulation of 60 degrees side-to-side and up/down. The several novel features of the system in comparison to previous ones, such as its length, maneuverability and releasing system, enable it to be used in a totally thoracoscopic fashion. The AtriClip® PRO has parallel titanium crossbars that equalize the force over the tissue trabeculations of the LAA during deployment, ensuring a sealed line at the base of the LAA orifice, as confirmed in preclinical and clinical studies. The clip can be opened and closed repeatedly before final deployment when only the correct placement is confirmed in TEE.
224315406|NCT03887793|OTHER|VACs|The VACs (Vaccinate Adolescents against Cancer) model for HPV vaccine quality improvement is a strategy developed by the American Cancer Society to improve HPV vaccination coverage in large integrated health care delivery systems. It includes the development of a quality improvement (QI) action plan, the formation of a QI team of health care providers, education for the QI team about HPV-related disease burden and vaccine efficacy, HPV vaccine coverage assessments at several time points that are shared with individual clinics within the health are system, and the adoption of specific QI strategies by participating clinics in the health care system.
224315407|NCT02191761|DRUG|SM04755|Escalating Doses
224315408|NCT01422629|DEVICE|Ultrasonic ablation device|High Intensity focused ultrasound treatment
223512722|NCT05085847|OTHER|Mindfulness meditation training|Mindfulness-based intervention encompasses different practices which intend to exercise awareness by using mindfulness meditation training moment by moment. Thus, practices such as mindful breathing, compassionate communication, loving-kindness, self-compassion, mindful listening, dealing with difficulties, the 3 step meditation, walking meditation, body scan with progressive relaxation, thoughts, emotions, gratitude, and sounds and breathing will be teaching to participants. Mindfulness training will be conduct by two instructors with more than 30 years' experience in meditation practices (Zen and Tibetan Buddhist approach to mind-training) and extensive mindfulness teaching and practices (\> 5 years each) experiences.
224315409|NCT05853744|DRUG|lavender essential oil inhaled using cotton balls|cotton balls impregnated with 3 drops of lavender essential oil inhaled from a distance of 10 cm during 20 minutes and pure oxygen administered through a face mask.
223761474|NCT06813235|BEHAVIORAL|iDream2Heal|iDream2Heal (iD2H) is an unsupervised, self-guided web-based version of the cognitive behavioural therapy for insomnia (CBT-I).
224315410|NCT05853744|DRUG|lavender essential oil inhaled using face mask|These three drops were already diluted by five milliliters of distilled water and were sprayed in the area by a nebulizer throughout a face mask. A cotton ball soaked with water was put 10 cm next to the patient.
224315411|NCT05853744|DRUG|Distilled water|inhaled five milliliters of distilled water in the same way as the patients in the experimental group and also cotton balls with 3 drops of water are placed near the patient.
223761475|NCT06813235|BEHAVIORAL|Easy Exercise|Easy Exercise (eEX) is an unsupervised, self-guided web-based exercise intervention.
224315412|NCT00358410|DRUG|GW679769 oral tablets|2x GW679769 60mg tablets
224315413|NCT00358410|DRUG|Placebo|Placebo oral tablets to match experimental intervention
223761476|NCT06813235|BEHAVIORAL|Dream2Heal|Dream2Heal (D2H) is a manualised, multi-component intervention which is grounded with core CBT-I elements of stimulus control, sleep restriction, sleep hygiene, relaxation training, and cognitive restructuring.
223761477|NCT06813235|BEHAVIORAL|iDream2Heal & Easy Exercise|The augmented iDream2Heal \& Easy Exercise (iD2H \& eEX) intervention is a combined, unsupervised, self-guided web-based intervention that covers the content of iD2H and eEX interventions.
223761478|NCT03968822|DRUG|Lidocaine 2%|3 mL of test solution to a skin area on the thigh, 2cm in diameter
224207990|NCT05144958|DEVICE|Percutaneous LAAO - WATCHMAN|Using a modified Seldinger technique a vessel dilator and a guidewire are inserted into the femoral vein. Under trans-esophageal echocardiography and fluoroscopy guidance, an interatrial septum is punctured using typical trans-septal access. The pigtail catheter is placed in the distal portion of the left atrial appendage and then the access sheath is inserted. After choosing the appropriate Watchman size the device is deployed and seals the left atrial appendage.
224207991|NCT05144958|DEVICE|Hybrid- minimally invasive LAAO - LARIAT|LARIAT system consists of: A) endocardial magnet-tipped guidewire. It is placed inside the left atrial appendage through the introduction of a catheter into the femoral vein; B) epicardial magnet-tipped guidewire. It is placed on the outside of the left atrium through the atrial appendage puncture of the pericardium. Each wire has a magnet of opposite polarity enabling end-to-end alignment; C) A compliant occlusion balloon catheter to identify the LAA and allow for a very precise and effective seal of the left atrial appendage; D) The LARIAT suture delivery device. It is introduced by an earlier puncture of the pericardium in the vicinity of the left atrial appendage and guided over magnet wire onto the base of the LAAO. With the LARIAT suture delivery device, the lumen of the left atrial appendage is closed from outside the heart, resulting in the elimination of the thrombus source.
224207992|NCT02231307|DRUG|SUBLIVAC FIX Birch|
224315414|NCT01013558|DRUG|Remifentanil|0.15 microgram/kg/min continuous infusion.
224315415|NCT01013558|DRUG|saline|continuous infusion
224315416|NCT02552303|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|Cognitive Behavioral Therapy for Insomnia.
224315417|NCT02552303|DRUG|Armodafinil|Active medication
224315418|NCT02552303|DRUG|Placebo|Placebo for Nuvigil (armodafinil)
224315419|NCT02814890|PROCEDURE|Video-assisted Pneumonectomy|Video-assisted Pneumonectomy under general anesthesia.
223761479|NCT03968822|DRUG|Lidocaine 1%|3 mL of test solution to a skin area on the thigh, 2cm in diameter
223761480|NCT03968822|DRUG|Bupivacaine 0.25%|3 mL of test solution to a skin area on the thigh, 2cm in diameter
223761481|NCT03968822|DRUG|Bupivacaine 0.5%|3 mL of test solution to a skin area on the thigh, 2cm in diameter
223761482|NCT03968822|DRUG|Intralipid, 20% Intravenous|a 250ml bag administered intravenously
224207993|NCT02787785|DEVICE|Subcutaneous Implantable Cardioverter Defibrillator|The S-ICD is an entirely subcutaneous implantable cardioverter defibrillator.
224207994|NCT02928562|OTHER|exercise|cyclic exercise, aerobic exercise and resistant training exercise
224315420|NCT02814890|PROCEDURE|Thoracic paravertebral block|The procedure is guided by ultrasound combined with nerve stimulator at T3-4, T4-5, T5-6, T6-7 of surgical side.
224315421|NCT01377987|DRUG|Acetazolamide|4 mg/kg, once daily before bed, for 7 days
224315422|NCT01377987|DRUG|Placebo|4 mg/kg, once daily before bed, for 7 days
223761483|NCT03968822|OTHER|Saline intravenously|a 250ml bag administered intravenously
223761484|NCT03968822|OTHER|Saline|3 mL of test solution to a skin area on the thigh, 2cm in diameter
223761485|NCT06904885|BEHAVIORAL|Implementation of a guideline-based model of care for hip and knee osteoarthritis|Guideline-based model of care including GLA:D (Good Life with osteoArthritis from Denmark) -program that includes training for physiotherapists and group based education and exercise for patients with hip and knee OA.
223761486|NCT06908863|OTHER|Tasks learning and MRI scan|"\- 2-week learning and training phase of motor tasks and oral and facial language (OLF) tasks.~Manual fine motor tasks will correspond to activities requiring increasing precision and different types of grip (crushing a ball, modelling clay with the palm of the hand, sorting round coins with thumb/index pliers).~The OLF praxis tasks will correspond to coordinated movements of different parts of the face (cheeks, lips and tongue).~\- MRI (magnetic resonance imaging) exam, During this exam, the investigator will give to the subject instructions for a task to be carried out. These tasks will correspond to the motor tasks previously trained."
223761487|NCT06909344|DEVICE|577 nm Diode laser|All patients will be treated with sessions of the 577 nm Diode laser on one side of the face and on the other side serve as a control
224315423|NCT06149806|DRUG|Sacubitril / Valsartan Oral Tablet [Entresto]|efficacy and tolerability of Sacubitril/Valsartan in the treatment of chronic heart failure on complex congenital cardiopathy
224315424|NCT03905720|PROCEDURE|Acupuncture|A licensed acupuncturist will assess participants' symptoms and administer acupuncture needles in accordance with traditional Chinese medicine principles and the study protocol. Treatments will provided daily for up to four hospital days.
224315425|NCT03905720|BEHAVIORAL|Pain Counseling|Participants will receive sessions with a counselor trained in pain management. The pain counselor will explain, review, and discuss the contents of a Pain Control booklet. Sessions will include pain assessment, pain education, and coping skills, provided daily for up to four hospital days.
224207995|NCT06180174|BIOLOGICAL|MC-1-50|A single infusion of CD19 CAR-T cells will be administered intravenously after lymphodepletion
223761488|NCT06909682|DEVICE|Intervention Group (Device Group - AI-Based Remote Monitoring)|This intervention utilizes a mini-invasive wearable device for continuous remote monitoring of chronic heart failure (CHF) patients. Unlike traditional telemonitoring, it integrates AI-driven predictive analytics to track oxygen saturation (SpO₂), heart rate variability (HRV), electrodermal activity (EDA), temperature, respiratory rate, and sleep quality in real time. The system generates automated alerts for healthcare providers, enabling early detection of CHF exacerbation and proactive intervention through teleconsultations, medication adjustments, or in-person evaluations. Data is securely transmitted to a cloud-based platform, allowing continuous risk assessment and personalized care adjustments. This approach aims to reduce unnecessary hospitalizations, enhance patient monitoring, and optimize heart failure management through advanced AI-based digital health technology.
224207996|NCT01212926|DEVICE|Echographic analysis of myocardial deformation in 2D strain|
224207997|NCT06382766|DIAGNOSTIC_TEST|Skeletal Muscle Ultrasonography|Skeletal Muscle Ultrasonography in Detection of Malnutrition and Prediction of The Outcome among critically ill children
224207998|NCT05764200|DIETARY_SUPPLEMENT|Two day supplementation of a complex fiber mixture|Participants will undergo a two day supplementation of a complex fiber supplement vs. placebo with a two-week washout period between the two interventions in a randomized order
224207999|NCT05764200|DIETARY_SUPPLEMENT|Placebo supplementation|Participants will undergo a two day supplementation of a complex fiber supplement vs. placebo with a two-week washout period between the two interventions in a randomized order
224315426|NCT03624309|DRUG|Anlotinib Plus Docetaxel|Anlotinib (12mg QD PO d1-14, 21 days per cycle) and Docetaxel (75mg/m2 IV d1)
224315427|NCT03624309|DRUG|Docetaxel|Docetaxel (75mg/m2 IV d1)
224208000|NCT06417203|PROCEDURE|spinal anesthesia with hyberbaric bupivacaine|After standard ASA monitoring in the operation room, spinal anaesthesia was induced by injection of 12.5 mg hyperbaric bupivacaine into the subarachnoid space with the help of a spinal needle through the L4-5 intervertebral space.
224208001|NCT06417203|PROCEDURE|spinal anesthesia with hypobaric bupivacaine|After standard ASA monitoring in the operation room, spinal anaesthesia was induced by injection of 12.5 mg hyperbaric bupivacaine into the subarachnoid space with the help of a spinal needle through the L4-5 intervertebral space.
224208002|NCT05283655|BEHAVIORAL|Gut-directed hypnotherapy|hypnotherapy
224208003|NCT05375487|OTHER|Carbonated Natural Mineral Water|750 mL/day of carbonated natural mineral water, with high content of bicarbonate, calcium, and magnesium, in three portions of 250 mL (one portion 30 minutes prior to lunch, one during the afternoon and the last portion minutes before dinner), during 4 weeks.
224208004|NCT05375487|OTHER|Low Mineral Water|750 mL/day of low mineral water (one third prior to lunch, one third during the afternoon and the last third 30 minutes before dinner), during 4 weeks.
224208005|NCT02296671|DRUG|Pemetrexed|
224315428|NCT00535665|BIOLOGICAL|pandemic influenza vaccine (H5N1 strain NIBRG-14)|two-dose regimen with 14 days apart: 5 microgram per dose
224315429|NCT00535665|BIOLOGICAL|pandemic influenza vaccine (H5N1 strain NIBRG-14)|two-dose regimen with 28 days apart: 5 microgram per dose
224315430|NCT00535665|BIOLOGICAL|pandemic influenza vaccine (H5N1 strain NIBRG-14)|two-dose regimen with 28 days apart: 10 microgram per dose
224315431|NCT00535665|BIOLOGICAL|pandemic influenza vaccine (H5N1 strain NIBRG-14)|two-dose regimen with 28 days apart: 15 microgram per dose
224315432|NCT04150263|PROCEDURE|Intraocular lens (IOL) ab externo scleral suture fixation|traditional IOL scleral suture fixation
223619107|NCT03186027|DIETARY_SUPPLEMENT|phosphoserine plus vitamin C|"Placebo arm: phosphoserine plus vitamin C CFS/ME patients who will be randomized to measure the effect of oral Placebo supplementation (phosphoserine and vit C, 4 tablets/day) on changes in the fatigue, sleep problems, autonomic function and HRQoL during 8-weeks in term.~Intervention: placebo"
223619108|NCT02459444|DEVICE|Powerbreathe|Respiratory equipment for physiotherapy, offering to load muscles inspiratory
223619109|NCT02459444|OTHER|Physiotherapy|This was contemplated cinesioterapia unloaded, muscle stretching, coughing technique, sedestração and ambulation if the participant was fit.
223619110|NCT00206843|DEVICE|Triage BNP Test|
223619111|NCT01667653|DIETARY_SUPPLEMENT|Probiotic|Probiotic capsule once daily
223619112|NCT01667653|DIETARY_SUPPLEMENT|Placebo|Placebo capsule once daily
223619113|NCT00519051|OTHER|monitorized pharmacotherapy with antidepressants drugs (Fluoxetine)|Fluoxetine oral,20-60 mg/day for 6 months with telephone monitorization
223619114|NCT03374033|DIETARY_SUPPLEMENT|NUTR +|one extra g/kg/d of protein and lipids starting before 48 hours after birth until 36 weeks postmenstrual age
224208006|NCT02296671|DRUG|Oxaliplatin|
224208007|NCT02296671|DRUG|Leucovorin|
224208008|NCT02296671|DRUG|Fluorouracil|
224208009|NCT02296671|GENETIC|Germline genotyping analyses for TSER|
224208010|NCT06124001|DRUG|Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell))|Intratumoral injection only. Dosing days may be Days 1-2 or Days 1-3.
224208011|NCT06124001|DRUG|camrelizumab for Injection|Administered once at 3 mg/kg intravenously on Days 8 of each cycle.
224208012|NCT01721941|DRUG|Phase I Dose level -1|The dose of TH-302 will be mixed with doxorubicin 50mg to use as the chemoembolization mixture for transarterial chemoembolization (TACE).
224208013|NCT01721941|DRUG|Phase I dose level 1|The dose of TH-302 will be mixed with doxorubicin 50mg to use as the chemoembolization mixture for transarterial chemoembolization (TACE).
224208014|NCT01721941|DRUG|Phase I Dose level 2|The dose of TH-302 will be mixed with doxorubicin 50mg to use as the chemoembolization mixture for transarterial chemoembolization (TACE).
224208015|NCT01721941|DRUG|Phase I Dose level 3|The dose of TH-302 will be mixed with doxorubicin 50mg to use as the chemoembolization mixture for transarterial chemoembolization (TACE).
224315433|NCT04150263|PROCEDURE|Modified IOL ab externo scleral suture fixation|Modified IOL scleral suture fixation
224208016|NCT03890159|BEHAVIORAL|Computer Assited Cognitive rehabilitation|Patients will receive their therapies 1 day a day, 2-3 days a week. The computer-aided cognitive rehabilitation group will perform simulation-based exercises, including exercises related to attention, in a special computer program (Cogniplus TR version) during therapy hours. The total duration of intervention will be 1 month.
223512723|NCT05085847|OTHER|Active control|Participants will receive lectures that provide cognitive and sensorial stimulus which does not specifically involve awareness training (meditation). Lesson topics include science.
223512724|NCT05554224|DIAGNOSTIC_TEST|To propose diagnostic tests for liver diseases before surgical decisions.|Observational although patients are candidates for metabolic surgery.
223619115|NCT03374033|BEHAVIORAL|STIMUL +|Physical activity stimulation consists in flexion/extension of the 4 limbs and other motion exercises of the shoulder girdle and of the hips. This stimulation will take place before the feed for a mean of 30 times a week (minimum 24- maximum 36 times a week, 10 minutes each time) and will start within the 10th day of life until 36 weeks postmenstrual age
223512725|NCT02981160|OTHER|Dietary|The REE testing will be done with the Breezing device, a breath analyzer developed at Arizona State University. The Breezing device is an indirect calorimetry analyzer that measures the rate of oxygen consumption and carbon dioxide production, and determines how much energy the body is burning (REE), and the type of nutrients the body uses to produce energy (energy source). The Breezing device is a cellphone-size, battery-operated, portable technology that syncs with smartphones and electronic pads. The patients will be asked to breathe into a mouthpiece connected to the Breezing device; the data will be then beamed wirelessly to the device. The breath analysis data will displayed on the screen in conjunction with an estimate of total calories burned each day (total energy expenditure, TEE).
223512726|NCT06345703|DRUG|Placebo|NS-136 matching placebo
223512727|NCT06345703|DRUG|NS-136 tablet|Investigational product NS-136
223512728|NCT05264584|DRUG|Isotonic saline|All patients will receive a continuous intravenous infusion of isotonic saline at a rate of 0.5 mL/kg/h for at least 2 to 12 hours before the procedure and continued to receive it 6 to 24 hours afterward.
223512729|NCT05264584|DRUG|N-acetyl cysteine|all the patients will receive 600 mg orally twice daily ,on the day before and the day of exposure to contrast or a single periprocedural dose (within 4 hours of contrast exposure) 1200 mg .
224208017|NCT03890159|BEHAVIORAL|Conventional Cognitive Rehabilitation|Patients will receive their therapies 1 day a day, 2-3 days a week. The home (paper pen) exercise group will take the necessary exercises on paper suitable for their respective levels and the daily tasks suitable for their functional needs and interests. The total duration of intervention will be 1 month.
224208018|NCT02275182|DRUG|Dexmedetomidine|0.5μg/kg Dexmedetomidine as initial loading dose is given for 15 minutes before induction of anesthesia, followed by a maintenance infusion of 0.4μg/kg/min and stopped 30 minutes before the surgery over.
223512730|NCT05264584|DRUG|Febuxostat 80 MG|All patients will receive a continuous intravenous infusion of isotonic saline at a rate of 0.5 mL/kg/h for at least 2 to 12 hours before the procedure and continued to receive it 6 to 24 hours afterward.
224208019|NCT02275182|DRUG|Saline|0.5μg/kg saline as initial loading dose is given for 15 minutes before induction of anesthesia, followed by a maintenance infusion of 0.4μg/kg/min and stopped 30 minutes before the surgery over.
223512731|NCT03844412|DRUG|5% lidocaine/5 mg/ml 0.02% estradiol compound cream|Lidocaine/estradiol cream targets peripheral nerves and tissues affected in VBD. Participants will be provided with a diagram and written instructions, detailing how to apply the cream to the vaginal vestibule daily for weeks 1-16. Treatment with lidocaine/estradiol or placebo cream will be terminated at week 16 (end of month 4).
224208020|NCT04210700|PROCEDURE|Fascia iliaca compartment block|"A linear ultrasound transducer is placed in a sagittal plane to identify the anterior superior iliac spine. By sliding the transducer medially, the fascia iliaca and abdominal internal oblique, sartorius, and iliopsoas muscles are identified. After identifying the bow-tie sign, a 23-gauge needle (7mm, Nipro, Japan) is inserted in plane from caudal to cephalad until the needle tip penetrate the fascia iliaca. After negative aspiration, 0.35% ropivacaine 30mL with 1:400,000 epinephrine will be injected to separate the fascia iliaca and the iliacus muscle."
224208021|NCT04210700|PROCEDURE|Pericapsular nerve group block|A curvilinear ultrasound transducer is initially place on the anterior inferior iliac spine and then aligned to the iliopubic eminence by rotating around 45 degree. In this view, the iliopubic eminence, iliapsoas muscle and tendon, pectineus muscle, femoral artery and vein will be identified. A 23-gauge needle (7mm, Nipro, Japan) is inserted in plane from lateral to medial until the needle tip in the musculofascial plane between the psoas tendon anteriorly and the pubic ramus posteriorly. After negative aspiration, 0.35% ropivacaine 20mL with 1:400,000 epinephrine will be injected.
224208022|NCT03818542|DRUG|ABBV-181|intravenous infusion
224208023|NCT03818542|DRUG|ABBV-368|intravenous infusion
224208024|NCT03818542|DRUG|ABBV-927|intravenous infusion
224208025|NCT03818542|DRUG|ABBV-927|intratumoral injection
224208026|NCT00003166|DRUG|bryostatin 1|Given IV
224208027|NCT00003166|DRUG|vincristine sulfate|Given IV
224208028|NCT00003166|OTHER|laboratory biomarker analysis|Correlative studies
224208029|NCT03250507|DRUG|Bupivacaine|0.25% bupivacaine for TAP block
224208030|NCT03250507|DRUG|Liposomal bupivacaine|Exparel for TAP block
224208031|NCT03250507|DRUG|Saline|Saline for TAP block that will be mixed with liposomal bupivacaine to bring the liposomal bupivacaine group to 60 mL total volume.
224208032|NCT04449588|DRUG|BDB-001 Injection|BDB-001 Injection+Conventional treatment
224208033|NCT04449588|OTHER|Conventional treatment|Conventional treatment only. Local guidelines should be integrated to choose the best supportive care.
224208034|NCT05213507|DRUG|aerosol inhaled Amikacin Sulfate Injection|0.4g Amikacin sulfate injection + 5ml saline, aerosol inhalation, b.i.d., 7-10 days per month, for 3 months.
224208035|NCT05213507|OTHER|conventional therapy|According to the personal characteristics of subjects and guidance of The Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2021, the doctor in charge prescribes appropriate medication, including but not limited to bronchodilators, inhaled corticosteroids and long-term oxygen therapy.
224208036|NCT05388201|OTHER|N95|3M N95 Respirator
224208037|NCT05388201|OTHER|KN95|KN95 Mask (with and without clip)
224208038|NCT05388201|OTHER|KF94|KF94 Mask (with and without clip)
224208039|NCT05388201|OTHER|Surgical|Surgical Mask (with and without clip)
224315434|NCT06633978|DEVICE|MediTrain|Participants will engage with a digital meditation app for 30m/day for 6wks. MediTrain is a tablet-based, meditation-inspired, cognitive training game aimed at improving self-regulation of internal attention and distractions. It was developed in collaboration with meditation thought-leader Jack Kornfield, and Zynga, a world-class video game company. It was created to make benefits of concentrative meditation more easily accessible to anyone, including complete novices. This is achieved by creating a game that yields quantifiable and attainable goals, provides feedback, and includes an adaptive algorithm to gradually increase difficulty as users improve.
223680402|NCT03562767|BEHAVIORAL|Web-based Cognitive Behavioral Intervention|This intervention will include six 1-hour web-based sessions held biweekly for twelve weeks. Subjects in the web-based CT-CB will be asked to reserve a 1 hour period for a web call from the Behavioral Interventionist team. Text reminders will be sent to the participants prior the sessions. During this period, approximately 15 minutes will be reserved for diabetes exercise and food planning education and approximately 45 minutes of CT-CB engagement activities.
223680403|NCT03562767|BEHAVIORAL|Usual Care|Usual care group participants will continue to receive care and follow up from their primary care providers as per the American Diabetes Association guidelines with log books, education regarding self-management strategies and appropriate referrals as needed.
224208040|NCT02902666|DRUG|Paracetamol 1000 mg/codeine phosphate hemihydrate 30 mg tablet|
224208041|NCT02902666|DRUG|Paracetamol 500 mg/codeine phosphate hemihydrate 30 mg tablet|
224315435|NCT06633978|DEVICE|wrist worn multi-sensor watches|Stress and sleep data will be recorded at home throughout the intervention using FDA-approved wrist worn multi-sensor watches.
224315436|NCT06633978|DEVICE|Sleep monitor|Sleep Profiler devices are FDA-cleared reduced-montage EEG recording devices that will be used in accordance with its FDA clearance. They are completely non-invasive and are designed to be comfortable enough to wear all night without interfering with normal sleep. These devices enable quality sleep recordings in the comfort of people's homes, rather than required an overnight stay at a sleep lab at UCSF.
224315437|NCT04981327|DRUG|Apixaban 2.5 MG Oral Tablet [ELIQUIS]|Apixaban 5 MG BID versus Apixaban 2.5 MG BID
224208042|NCT00103259|DRUG|bortezomib|Given IV
224208043|NCT00103259|DRUG|irinotecan hydrochloride|Given IV
224315438|NCT02237391|OTHER|CIPAP Program|The intervention will involve a pain specialist, a clinical health psychologist and a nurse. As needed, it may involve a social worker, an addiction specialist, and other specialists. The pain specialist will conduct an evaluation that includes: history of presenting illness, review of systems, review of pain treatments, medical history, surgical history, addiction history, medications and allergies, insurance for medication, psychosocial history, opioid risk assessment, physical examination, and review of tests and investigations. The psychologist will conduct an evaluation that includes: a structured diagnostic clinical interview, a review of coping strategies, and a review of the questionnaires completed prior to the assessment pertaining to mood, anxiety, trauma and beliefs about pain.
224315439|NCT02237391|OTHER|Treatment as Usual (TAU)|Control group
224315440|NCT00436865|BEHAVIORAL|Weight loss|
224315441|NCT06034782|DIAGNOSTIC_TEST|Fine Needle Aspiration|Fine Needle Aspiration of a salivary gland tumor
224315442|NCT06034782|PROCEDURE|Histologic Examination|Histologic examination of resected salivary tumor
224315443|NCT06523660|BEHAVIORAL|CHUCK CHUCK SKILLS: CHild's Understanding of Cognitive sKills|The intervention will consist of an online EF training that will be delivered across 10 sessions (one 1 hour session per week for ten weeks). It will target core EF components including inhibitory control, attention shifting, and working memory in children with Autism Spectrum Disorder aged 5 to 7 years. It will also provide strategies (e.g., behavioral principles, compliance training) for promoting behavioral regulation and emotion regulation in these children. Accompanied parent coaching will be provided to enhance children's generalization of EF skill attainment.
224315444|NCT06523660|BEHAVIORAL|Parent Psychoeducation|Group-based parent psychoeducation, which consists of 10 sessions, 1-hour weekly program delivered via telehealth, will be provided to the control group.
224315445|NCT00253448|RADIATION|radiation therapy|No more than 2 weeks later, patients undergo conventional radiotherapy once daily, 5 days a week, for 6 weeks.
224208044|NCT00103259|OTHER|laboratory biomarker analysis|Optional correlative studies
224208045|NCT02612415|DEVICE|Treatment strategy: Non-invasive respiratory support delivered via high flow nasal cannula|A heated, humidified, HFNC device will be used to deliver a gas flow rate of 2 L/kg/min for the duration that the patient needs non-invasive respiratory support
224208046|NCT02612415|DEVICE|Treatment strategy: Non-invasive respiratory support delivered via continuous positive airway pressure|CPAP will be provided using a set expiratory pressure of 6-8 cm water (H2O) pressure for the duration that the infant needs non-invasive respiratory support
224315446|NCT00253448|RADIATION|stereotactic radiosurgery|stereotactic radiosurgery to high-risk areas of active tumor determined by MR-spectroscopy
224315447|NCT00599963|DRUG|paricalcitol|paricalcitol 1 mg/day
224315448|NCT01365312|DRUG|Ethanol lock|Placement of 0.5 cc 70% ethanol, every 72 hours, for 15 minutes, into PICC lines randomized to ethanol intervention
224315449|NCT01365312|DRUG|Heparinized saline|0.5 cc heparinized saline to be placed once every 72 hours for 15 minutes, in PICC lines randomized to placebo
224315450|NCT04588025|DEVICE|Point-of-care Portable Perfusion Phantom, P4|P4 is a perfusion phantom developed by Dr. Harrison Kim that can significantly reduce variation in quantitating perfusion of human abdominal tissues across MRI scanners.
224315451|NCT03624907|RADIATION|Daily Stereotactic Body Radiotherapy|After randomization, participants will receive daily standard of care doses of radiotherapy at treating physicians discretion.
224315452|NCT03624907|RADIATION|Non-Daily Stereotactic Body Radiotherapy|After randomization, participants will receive non-daily standard of care doses of radiotherapy at treating physicians discretion.
224208047|NCT05941845|DRUG|Peginterferon Alfa-2A 180 MCG/ML Injectable Solution|"Injections will be carried out on the Nephrology day hospitalization ward. The injections follows a personalized administration schedule: all enrolled patients will receive an injection of Pegasys® at Week 0.~Patients with a persistent Th17 profile (cytokine profile showing IL-17A levels greater than 73 pg/ml) at Week 2 will receive a new dose of Pegasys®, followed by a monthly cytokine profile. In the case of a persistent Th17 profile, 2 injections will be given two weeks apart.~In patients with no Th17 profile at Week 2, no Pegasys® injections will be performed at this time. Cytokine profiles will be performed monthly, and in the case of a persistent Th17 profile, 1 injection will be performed.~In total, patients will receive a minimum of one injection and a maximum of 13 injections of 180 µg (1 injection every two weeks for 24 weeks)."
224208048|NCT01631370|PROCEDURE|Renal denervation|The patients are examined prior to and 6 months after renal denervation. On the day of examination the patients will have blood samples taken and the hyperinsulinemic euglycemic clamp and muscle and adipose tissue biopsies will be performed.
224208049|NCT03845855|OTHER|virtual reality|Virtual reality with a game
224208050|NCT03845855|OTHER|robotic gait|robotic gait therapy
224208051|NCT04416295|DEVICE|LifePod|LifePod consists of a Web-based E-Health platform with two interfaces, one medical for healthcare professionals and one patient interface. LifePod is accessed via a smartphone, tablets and computers via a web application where patients enter symptom parameters and vital parameters such as breathing and mucus status, weight, activity, medication or other disease-specific values. Several different validated questionnaires are sent regularly to the patient to obtain information about the patient's mood and activity. The platform contains a chat function between healthcare professionals and patients. A unique health profile is created in which the patient self-reports their health. The patient receives direct feedback in their web application if they are within the interval given for the individual. The medical interfaces are designed so that patients are automatically placed in a priority order where the person outside the given range is given top priority.
224208052|NCT01572428|PROCEDURE|Inspection with Narrow-Band Imaging(NBI)|Narrow-Band Imaging(NBI)of the colon rather than the standard white light in the inspection of the colon during colonoscopy.
224208053|NCT01572428|PROCEDURE|Standard White Light|Use of Standard White Light on the colon rather than Narrow-Band Imaging(NBI)in the inspection of the colon during a colonoscopy.
224208054|NCT00853931|DRUG|Panitumumab|Panitumumab 6 mg/kg will be administered by intravenous infusion every 2 weeks (Q2W), +/- 3 days, (eg, week 1, 3, 5 \[i.e. Cycles 1, 2, 3, etc.\]) until disease progression or intolerance panitumumab as determined by the investigator.
224208055|NCT01537575|BIOLOGICAL|intravenous immunoglobulins|One course of Intravenous Immunoglobulins 0.4 g/kg/die for 5 consecutive days
224208056|NCT01537575|BIOLOGICAL|Saline solution|Placebo
224208057|NCT03330028|DRUG|Dexamethasone|10 mg by vein approximately 60 minutes before Paclitaxel.
224208058|NCT03330028|DRUG|Diphenhydramine|50 mg by vein approximately 60 minutes before Paclitaxel.
224208059|NCT03330028|DRUG|Famotidine|20 mg by vein approximately 60 minutes before Paclitaxel.
224208060|NCT03330028|DRUG|Mitomycin C|Mitomycin C 30 mg in 3-7 liters of infusate administered using a rolling pump with hyperthermia for approximately 60 minutes through 3 to 4 small incisions in abdomen.
224208061|NCT03330028|DRUG|Cisplatin|Cisplatin 200 mg in 3-7 liters of infusate administered using a rolling pump with hyperthermia for approximately 60 minutes through 3 to 4 small incisions in abdomen.
224208062|NCT03330028|DRUG|Paclitaxel|"Starting dose of Paclitaxel is 20 mg/m2 in 3-7 liters of infusate administered using a rolling pump with hyperthermia for approximately 60 minutes through 3 to 4 small incisions in abdomen.~Dose-escalation scheme of Paclitaxel is in increments of 5 mg/m2."
224208063|NCT02667496|DRUG|Sargramostim GZ402664|Pharmaceutical form:solution Route of administration: subcutaneous
224208064|NCT02667496|DRUG|Placebo|Pharmaceutical form:solution Route of administration: subcutaneous
224208065|NCT02667496|DRUG|Florbetapir F18|Pharmaceutical form:solution Route of administration: intravenous
224208066|NCT01906801|DRUG|Glucosamine sulfate|
224208067|NCT01906801|DRUG|Diacerein|
224208068|NCT01906801|DRUG|Placebo (for Diacerein)|Sugar pill manufactured to mimic Diacerein 50 mg tablet
224208069|NCT00501696|DRUG|4.5 mg Naltrexone|low dose naltrexone 4,5mg on the multiple sclerosis quality of life inventory (MSQLI54)
224208070|NCT00501696|DRUG|Naltrexone|4,5mg low dose naltrexone on the multiple sclerosis quality of life inventory (MSQLI54)
224208071|NCT05512715|PROCEDURE|radioactive iodine|radioactive iodine 15mci
224208072|NCT03880864|RADIATION|Ultrasound|Lung ultrasound
224208073|NCT04230954|DRUG|Cabozantinib 40 MG oral once a day|Cabozantinib 40 mg oral once a day
224208074|NCT04230954|DRUG|Pembrolizumab 200 mg IV every 3 weeks|Pembrolizumab 200 mg IV every 3 weeks
224208075|NCT00663039|DRUG|Oxytocin|24 IU oxytocin (or Placebo) in a total of 6 puffs (3 puffs per nostril)
224208076|NCT00663039|DRUG|Placebo|Single dose (plus a booster dose) drug probe study using intranasal placebo
224208077|NCT02235961|DRUG|NNC9204-0530|Administered as single subcutaneous (s.c., under the skin) injections.
224208078|NCT02235961|DRUG|liraglutide|Administered as subcutaneous (s.c., under the skin) injections of 1.8 or 3.0 mg.
223680404|NCT00509262|DRUG|Sitagliptin|Participants with moderate renal insufficiency will receive two sitagliptin 25 mg tablets orally daily; participants with severe renal insufficiency will receive one sitagliptin 25 mg tablet orally daily
224208079|NCT02235961|DRUG|placebo|Administered as single subcutaneous (s.c., under the skin) injections.
224208080|NCT05643625|OTHER|Pilates exercise and myofascial release|Pilates exercise and myofascial relaxation technique will be applied to the experimental group and pilates exercise will be applied to the control group.
224208081|NCT02866695|DRUG|ingenol mebutate gel 0.015%|ingenol mebutate gel 0.015% to be applied on treatment area
224208082|NCT03224234|DEVICE|Insulclock with feedback|Daily information on a smartphone on insulin administration (time and dosing) as well as reminders in the event of missing doses.
224208083|NCT03224234|DEVICE|Insulclock without feedback|Not feedback on insulin administration.
224208084|NCT02629237|OTHER|Multifaceted education|Subjects will be asked to watch a 5-10 min education film and participate in a 10-15 min counseling session with a trained doctor/nurse before glaucoma surgery,and at 1 week and 2 week after surgery.
223512732|NCT03844412|DRUG|Nortriptyline|Nortriptyline is a centrally-acting tricyclic antidepressant that is FDA-approved for treatment of neuropathic pain. Dosing will begin with one 10 mg pill nightly for week 1, then two 10 mg pills nightly for week 2, three 10 mg pills nightly for week 3, four 10 mg pills nightly for week 4, and five for weeks 5 -16. Treatment with nortriptyline or placebo pill will be tapered off over weeks 16-18, decreasing the dose by 10 mg every 4 days. Participants will be provided with a list of drugs to avoid that are known to interact with nortriptyline.
224208085|NCT03986918|DEVICE|Routine Total Hip Arthroplasty|Patients undergoing routine total hip arthroplasty will receive surveys regarding survivorship and outcomes.
223512733|NCT03844412|DRUG|Placebo cream|The comparison treatment will be an identical-appearing placebo Moisturel™ cream
224208086|NCT02924337|DRUG|Placebo|
224208087|NCT02924337|DRUG|Imeglimin|
224208088|NCT02924337|DRUG|Moxifloxacin|
224208089|NCT02610842|OTHER|Handbook|"The handbook named Hands on - a hand care guide in Systemic Sclerosis contains instructions about the Systemic Sclerosis and hand exercises."
224208090|NCT00756652|DEVICE|Mentor Silicone Gel-Filled Breast Implants|
224208091|NCT00756652|DEVICE|Saline Breast Implants|
224208092|NCT02564952|DRUG|GWP42003-P|GWP42003-P was presented as an oral solution containing 100 mg/milliliter (mL) cannabidiol (CBD) in the excipients sesame oil and anhydrous ethanol (79 mg/mL) with added sweetener (0.5 mg/mL sucralose) and strawberry flavoring (0.2 mg/mL). Participants received up to a maximum of 30 mg/kg/day.
224208093|NCT02564952|DRUG|Clobazam|Participants were taking CLB upon entry into the OLE phase of the trial. CLB was not an investigational medicinal product (IMP) for the OLE phase and was not administered by the Sponsor, but was administered at the physician's discretion, as required for each participant. CLB could be stopped, if clinically indicated, without impact on analysis.
224208094|NCT01972607|OTHER|Exercise Training|12 weeks of aerobic exercise training performed 3x/week at moderate intensity with sessions of 40 min.
224208095|NCT00168766|DRUG|Interferon-beta-1a (Avonex) plus methylprednisolone|oral administration given on 3 consecutive days, monthly as described in protocol.
224208096|NCT05723861|DEVICE|VR|We will use the Pico Headset, a three-dimensional Gear with a connected tablet, and will be positioned on the head with elastic straps. Patients will be instructed about the VR device before their procedure and virtual experiences will initiate just before colonoscope insertion and continuously delivered throughout the procedure for max of 20 minutes. Patients will experience max of 20 minutes of VR and if colonoscopy lasts longer than 20 min, the remaining time of colonoscopy will be performed without using VR. The visualized content of VR will be chosen by the participants among three available contents including beach, nature, or mountain with relaxing music. Participants could opt out and/or request standard medications for pain at any time before or during the procedure.
224208097|NCT05326997|DEVICE|Photobiomodulation group|Participants will have their face sanitized with micellar water (a cosmetic product for cleaning and makeup remover), followed by cleaning with soap. Then, the eyes will be protected with gauze, proper glasses and a black towel on top, a headset with relaxation music will also be placed and then the face will receive the treatment with yellow light. After the session the face will receive sunscreen. A placebo cosmetic will be given to the participant to be applied twice a day and daily sunscreen.
224208098|NCT05326997|OTHER|Group control (Tranexamic acid)|Participants will have their face sanitized with micellar water. Then, the eyes will be protected with gauze, proper glasses and a black towel on top, a headset with relaxation music will also be placed and then the face will receive the treatment with yellow light sham. The person responsible for applying the PBM will simulate the irradiations by positioning the device in the same places described for the PBM group, however, the equipment will be kept off. After the session the face will receive sunscreen. Will be delivered to patients, liposomal tranexamic acid with use 2 x a day home care and daily sunscreen.
224208099|NCT03813394|DRUG|pembrolizumab|-Pembrolizumab in Solution for Injection
223512734|NCT03844412|DRUG|Placebo pill|The comparison treatment will be an identical-appearing placebo pill
224208100|NCT03813394|DRUG|bevacizumab|"* Bevacizumab in Concentrate for Solution~* Bevacizumab in Concentrate for Solution"
224208101|NCT05596227|DRUG|Propofol|Induction of anesthesia will be by IV propofol (2-2.5 mg/kg)
224208102|NCT05596227|DRUG|Fentanyl|Fentanyl will be injected during the induction of anesthesia (1-1.5 mg/kg)
224208103|NCT05596227|DRUG|Rocuronium|Rocuronium will be injected during induction of anesthesia (0.6 mg/ kg)
224208104|NCT05596227|DRUG|Sevoflurane|Sevoflurane inhalationa anesthesia will be used for maintainance of anesthesia
224208105|NCT05596227|OTHER|Erector spinae plane block|In the ESPB group, the probe will be placed in the parasagittal plane at the level of the L3 vertebrae. The spinous process will be visualized, and the probe will move 3 cm laterally from the midline. The erector spinae muscle will be visualized above the transverse process. The needle will be punctured in the craniocaudal direction using the in-plane technique. The needle will be directed superior to the transverse process . Then, 2 mL normal saline solution was injected into the deep fascia of the erector spinae muscle to confirm the proper injection site. After ensuring the location of the needle, 20 mL of 0.25% bupivacaine was administered. The same ESPB procedure will be performed on the other side. In total, 40 mL of 0.25% bupivacaine was administered.
224208106|NCT05596227|OTHER|Thoracolumbar interfascial plane block|In the mTLIP group, the probe will be placed vertically at the L3 vertebrae level. The spinous process and the interspinous muscles (i.e., multifidus, longissimus, and iliocostalis) will be visualized as the anatomic guide points. The probe will move laterally to identify the longissimus and iliocostalis muscles. The needle will be inserted between the longissimus and iliocostalis in the medial-to-lateral direction using the in-plane technique. After confirming the location of the needle, 20 mL of 0.25% bupivacaine was administered. The same mTLIP procedure will be performed on the opposite side. In total, 40 mL of 0.25% bupivacaine will be administered.
224315453|NCT04234971|DRUG|Intervention group (DBM/BMP)|All patients will undergo a standard procedure for exposure of the cleft alveolar defect and closure of all oronasal fistulae. After induction of general anesthesia, the patient will be intubated with an oral ray tube and prepped and draped in sterile fashion. Pre-operative antibiotics will be given to cover oral flora (i.e. Unasyn or clindamycin if penicillin allergy exists). The intra-oral space will be exposed and the nasal floor and palatal mucosa will be primarily closed to create a water-tight space for the graft. The integrity of the nasal floor mucosa will be tested using methylene blue dye. Following closure of the fistula, the alveolar bone graft will be performed. For the treatment group, 10cc of crushed DBM will be mixed with the micro-sized sponge of rh-BMP-2 (Infuse Bone Graft, Medronic, Minneapolis, MN). The sponge and DBM will then be packed into the defect to completely fill the bony space (FIGURE 3). The anterior mucosa will then be closed.
224315454|NCT04234971|DRUG|Control group(autologous ICBG)|The patient will be induced with anesthesia, prepped, and draped. The intra-oral space will be exposed and the nasal floor and palatal mucosa will be primarily closed to create a water-tight space for the graft. The integrity of the nasal floor mucosa will be tested using methylene blue dye. Following closure of the fistula, the alveolar bone graft will be performed.In the control group, the ICBG will be harvested percutaneously using the Accumed bone graft harvesting system. Briefly, an incision will be made in iliac crest and drill bit inserted. Multiple passes of the drill be used to harvest as much autograft bone as possible from the cancellous region of the iliac crest.Following harvest, fibrin glue will be instilled for hemostasis and a Ropivicaine On-Q pain pump inserted for post-operative pain control. The harvest bone graft will be packed into the alveolar defect in a similar fashion and the mucosa closed anteriorly.
223680405|NCT00509262|DRUG|Glipizide|Participants will receive glipizide 2.5 mg (1/2 tablet) orally once daily up to 20 mg orally daily (10 mg twice daily)
224208107|NCT06138678|DEVICE|iTBS (intermittent theta-burst stimulation)|"The iTBS treatment is a type of rTMS (repetitive transcranial magnetic stimulation), delivered with MagPro R30 stimulator and a conventional cool-B65 coil.~The iTBS treatment is applied to over the dorsolateral prefrontal cortex using a standardized measuring of the anatomical landmark F3 from the 10-20 positioning system. The coil is positioned with the handle at in a 45 degree angle from the midline. The centre of the butterfly is placed towards the patient head."
224315455|NCT02052011|DRUG|Ranolazine|Subjects will take the extended-release Ranolazine for a total of 4 weeks. Subjects will take 500 mg twice daily for the first week and then 1000 mg twice daily for remaining period (Dosing will be adjusted with concomitant use of diltiazem, verapamil, erythromycin, simvastatin or metformin).
224315456|NCT02052011|DRUG|Placebo|
224315457|NCT02341898|OTHER|Educational programme for all nurses|
224315458|NCT02341898|OTHER|Training and structured support for nominated key nurses|
224315459|NCT02341898|OTHER|Facultative train-the-trainer module for key nurses|
224315460|NCT02341898|OTHER|Printed study material|
224315461|NCT02341898|OTHER|Supportive material (poster, mugs etc.)|
224315462|NCT02227511|DIETARY_SUPPLEMENT|Fruits|Randomization to extra fruit or nuts as snacks
223680406|NCT00509262|DRUG|Placebo for Sitagliptin|Participants with moderate renal insufficiency will receive 2 placebo for sitagliptin tablets orally daily; participants with severe renal insufficiency will receive 1 placebo for sitagliptin tablet orally daily
224208108|NCT05087576|BEHAVIORAL|Expressive Helping|Expressive helping integrates two distinct areas of research showing that emotional disclosure over writing and support giving improves psychological well-being among healthy and clinical populations. Participants write 4 brief structured writing sessions.
224208109|NCT05087576|BEHAVIORAL|Caregiving Fact writing|Factual Writing has been used with in other writing-based interventions (e.g., expressive writing). It is also completed in 4 brief structured writing sessions.
223680407|NCT00509262|DRUG|Placebo for Glipizide|Participants will receive 1/2 tablet of placebo for glipizide orally once daily up to 2 tablets orally twice daily
223680408|NCT00226629|PROCEDURE|Endovascular vs Open Repair|
223680409|NCT04371302|DIAGNOSTIC_TEST|Questionnaire|Assessment of demographics, burnout, depression and self-perceived medical errors
223680410|NCT01589770|OTHER|cardiac Magnetic Resonance imaging|
223680411|NCT00082472|DRUG|Doxorubicin HCl Inhalation Solution|
223680412|NCT00082472|DRUG|Docetaxel|
224208110|NCT03257774|OTHER|Adhesive strip A|Strip consisting of a newly developed adhesive
224208111|NCT03257774|OTHER|Adhesive strip B|Strip consisting of a newly developed adhesive
224208112|NCT03257774|OTHER|Adhesive strip C|Strip consisting of a newly developed adhesive
224208113|NCT06096181|DRUG|Remifentanil TIVA|Remifentanil is more commonly used in the TIVA combination for pediatric patients having this surgery.
224208114|NCT06096181|DRUG|Dexmedetomidine TIVA|Dexmedetomidine is less commonly used in the TIVA combination for pediatric patients having this surgery.
224315463|NCT02227511|DIETARY_SUPPLEMENT|Nuts|
224315464|NCT06600269|PROCEDURE|Cycling Training|Cycling combined with priming strategies to enhance motor learning tasks. Each session will last for 15 minutes, conducted three times per week, over a period of two weeks.
224315465|NCT00000620|DRUG|Anti-hyperglycemic Agents|Multiple drugs including insulins and oral anti-hyperglycemic agents as needed to reach Glycemia Trial arm-specific goals (intensive control \<6%; standard control 7.0-7.9%).
224315466|NCT00000620|DRUG|Anti-hypertensive Agents|Multiple anti-hypertensive agents as needed to reach Blood Pressure Trial arm-specific goals (intensive control \<120 mm Hg; standard control \<140 mm Hg).
224315467|NCT00000620|DRUG|Blinded fenofibrate or placebo plus simvastatin|Double blind administration of 160 mg/day of fenofibrate in participants with estimated glomerular filtration rate (eGFR) ≥50 mL/min/1.73m2 or 54 mg/day in patients with eGFR \<50 mL/min/1.73m2 or matching placebo in combination with open label simvastatin 20 - 40 mg/day.
224315468|NCT06323148|DRUG|Osimertinib|Adjuvant osimertinib for three years after radical surgery
224315469|NCT06323148|DRUG|No adjuvant therapy|No adjuvant therapy
224315470|NCT02354794|DIETARY_SUPPLEMENT|One form of arginine|3 capsules containing 0.5g of one form of L-arginine (1.5g) 3 times daily (4.5g per day) for 1 month
224315471|NCT02354794|DIETARY_SUPPLEMENT|placebo|3 capsules containing 0.5g cellulose (non active product) 3 times daily (4.5g per day) for 1 month
224315472|NCT04626648|BEHAVIORAL|Pause with a sugar containing drink|Three-minute long intraoperative pause, including a sugar-containing drink
224315473|NCT00134667|DRUG|Photodynamic Therapy (PDT) with Visudyne (verteporfin)|
223619116|NCT05954000|BEHAVIORAL|5 Behavioral Change Techniques|"1. Goal setting: set or agree on a goal defined in terms of behavior to be achieved. Example: Set the goal to take your medication as prescribed tomorrow.~2. Action planning: prompt detailed planning of performance of behavior (must include a setting, frequency, duration, and intensity). Example: Develop a plan for taking your medication.~3. Self-Monitoring of behavior: establish a method for person to monitor and record their behavior. Example: Did you take your statin medication today?~4. Feedback on behavior: Monitor and provide informative or evaluative feedback on performance of the behavior (e.g. form, frequency, duration, intensity). Example: You did not take your statin medication as prescribed yesterday.~5. Prompts/Cues: introduce or define environmental or social stimulus with the purpose of prompting or cueing the behavior. The prompt or cue would normally occur at the time or place of performance. Example: Please remember to take your medication soon."
224208115|NCT06096181|DRUG|Propofol TIVA|Propofol is an anesthetic drug that causes sleep during surgery.
224208116|NCT04886232|DEVICE|VP1 Lido US|Hyaluronic acid dermal filler containing lidocaine
224208117|NCT04886232|DEVICE|Restylane Lyft Lidocaine|Hyaluronic acid dermal filler containing lidocaine
224208118|NCT03236337|BEHAVIORAL|MOVI intervention|MOVI-da Fit! is a multidimensional intervention that consists on: a) 4h/week of a standardized recreative, non-competitive physical activity extracurricular program; and b) informative sessions to parents and teachers about how schoolchildren can became more active. It is aimed to enhance physical fitness, motor skills, physical activity time and active behaviours among 9-to-11 years old children.
224208119|NCT06523309|OTHER|Electroacupuncture treatment|Electroacupuncture treatment consists of conventional acupuncture and electrical stimulation. After acupuncture, the electrical stimulation is continuously stimulated.
224208120|NCT06133907|GENETIC|Serum|Patients who came to the pneumoallergology department of the CHU de Nice since January 2014 for an allergological workup and with tryptasemia was ≥ 8ng/ml (at least once in patient history).
224208121|NCT05905809|DEVICE|UniRelieverTM offloading brace (THUASNE)|The patient will be instructed to wear the brace during walking and physical exercise. The investigator will explain to the patient how to adjust it
224208122|NCT05905809|DEVICE|Unloader One® X brace (Össur)|The patient will be instructed to wear the brace during walking and physical exercise. The investigator will explain to the patient how to adjust it
224208123|NCT00038467|DRUG|Tamoxifen|Tamoxifen 20 mg/day tablets administered p.o. for a period ranging from 2.5 to 3 years.
224208124|NCT00038467|DRUG|Exemestane|Exemestane 25 mg/day tablets administered p.o. for a period ranging from 2.5 to 3 years.
224208125|NCT05531799|PROCEDURE|OPTIMIZATION PHASE|"The goal of the optimization phase of MOST is to identify the most promising combination of experimental components in changing an outcome given a set of environmental constraints. Looking at effectiveness, efficiency, economy, and scalability criteria, we will focus on the proportion of anal HSIL identified (effectiveness), unit cost (efficiency and economy), and accumulating cost to the client over a 12-month period (economy). Meeting these criteria will likely imply scalability. The most appropriate anal HSIL screening algorithm would ideally be one which could~\- identify anal HSIL in at least 20% of HIV-positive MSM and 10% of HIV-negative MSM at baseline and"
224208126|NCT01988493|DRUG|Tepotinib 300 mg|Participants received Tepotinib 300 milligram (mg) orally once daily over a 21-day cycle until disease progression, intolerable toxicity or participant withdrawal.
224208127|NCT01988493|DRUG|Tepotinib 500 mg|Participants received Tepotinib 500 mg orally once daily over a 21-day cycle until disease progression, intolerable toxicity or participant withdrawal.
224208128|NCT01988493|DRUG|Tepotinib 1000 mg|Participants received Tepotinib 1000 mg orally once daily over a 21-day cycle until disease progression, intolerable toxicity or participant withdrawal
224208129|NCT01988493|DRUG|Tepotinib|Participants randomized to receive Tepotinib recommended Phase 2 dose (RP2D) determined from Phase 1b over a 21-day cycle until disease progression, intolerable toxicity or participant withdrawal.
224208130|NCT01988493|DRUG|Sorafenib|Participants randomized to receive Sorafenib 400 mg orally twice daily over a 21-day cycle until disease progression, intolerable toxicity or participant withdrawal.
224208131|NCT00945971|OTHER|Physical activity|The intervention group will engage in exercise program, including aerobic and anaerobic components,twice a week, for 3 months. Exercise testing, blood sampling and cognitive assessment will be used at the start and in the end of this study.
224208132|NCT01544374|OTHER|Tracking & Feedback|Systems based intervention tracking oncology consultations and feeding back information to surgeons
224208133|NCT05472363|DIAGNOSTIC_TEST|Electroencephalogram|A routine test that involves attaching small wires to the head to read the electrical activity of the brain
224208134|NCT05472363|PROCEDURE|Transcranial Magnetic Stimulation|Noninvasive procedure that uses magnetic fields to stimulate nerve cells in the brain. An electromagnetic coil is placed against the scalp near the forehead. The electromagnet painlessly delivers repetitive magnetic pulses to simulate nerve cells in the brain.
224208135|NCT05472363|PROCEDURE|Transcranial Direct Current Stimulation|Noninvasive procedure that uses direct electrical currents to stimulate the brain. A constant, low intensity current is passed through two electrodes that are place on the head.
224208136|NCT05892965|OTHER|iCBT-based EMI|Consists of brief iCBT for psychological support (mandatory), stroke care education (optional), and nurse-led real-time chat-based support messages, delivered according to participants' preferences.
224208137|NCT05548543|DRUG|HCP2202|Take it once per period.
224208138|NCT05548543|DRUG|RLD2202|Take it once per period.
223619117|NCT02458053|BEHAVIORAL|Attends with partner|The index partner will participate in intervention as a couple with their female counterpart.
223619118|NCT02458053|BEHAVIORAL|Couples Skill Training|Participants and their partners will attend a pre session covering topics to assist them in working together to facilitate lifestyle changes.
223619119|NCT02458053|BEHAVIORAL|Face to face group sessions|Group sessions will consists of components in traditional weight management programs.
223619120|NCT02458053|BEHAVIORAL|Self Monitor|Participants will be instructed to monitor their eating and physical activity behaviors online/mobile application.
223680413|NCT00082472|DRUG|Cisplatin|
224208139|NCT05548543|DRUG|RLD2203|Take it once per period.
224208140|NCT00130663|DEVICE|PDA blood pressure screening program and chart reminder|
224208141|NCT00146133|BEHAVIORAL|diet, exercise|
224315474|NCT00134667|DRUG|Macugen (pegaptanib sodium)|
224315475|NCT02480348|DEVICE|Polymer-free DES (Drug Eluting Stent)|
224315476|NCT00348504|DRUG|levosimendan|
223619121|NCT02458053|OTHER|Notebook|The notebook will consist of behavioral lessons, diet and physical activity plans, and additional resources to assist participants in achieving their behavioral goals.
223619122|NCT02458053|BEHAVIORAL|Feedback|Each participant will receive a tailored email providing feedback on their weekly progress.
223619123|NCT00880295|PROCEDURE|endoscopic carpal tunnel release|endoscopic surgery, which is standard of care for carpal tunnel release
223619124|NCT00880295|PROCEDURE|open carpal tunnel release|open surgery, which is standard of care for carpal tunnel release
223619125|NCT06482541|COMBINATION_PRODUCT|5 billion exosomes and saline solution microneedling|Participants will receive 5 billion WJMSC-exosome topical application on one half of the treatment area and an equivalent volume of saline solution on the contralateral half of the treatment area. Microneedling at a depth of .5mm on the entire treatment area will immediately follow the exosome and saline application. Participants will also receive 4 permanent microdot tattoos on the aforementioned locations.
224208142|NCT04425954|PROCEDURE|Endoscopic Endonasal Pituitary Surgery|Surgical treatment consisted of an endoscopic endonasal approach using a rigid 0-degree endoscope, 18 cm in length and 4 mm in diameter.
224208143|NCT06701487|BIOLOGICAL|fMRI imaging (BOLD)|Will be used to investigate neural correlates of Pavlovian-to-instrumental transfer (PIT) effects by measuring the blood oxygenation level dependent (BOLD) response of neural activation in the mesolimbic system.
224208144|NCT06701487|BIOLOGICAL|sMRI (structure)|Will be used to investigate neural correlates of PIT effects by identifying abnormalities in cortical gray and white matter volume.
224208145|NCT06701487|BEHAVIORAL|Pavlovian-to-instrumental transfer (PIT) paradigm|"The paradigm consists of four parts:~In the first part, an instrumental learning task is completed in which subjects must learn which stimuli require a response and which do not. In the second part, a classical (Pavlovian) conditioning task is then completed in which subjects learn by passive viewing which stimuli are associated with certain amounts of money. The third part measures to which instrumental responses (learned in Part 1) are modulated by the presentation of the classically conditioned stimuli (learned in Part 2). At the same time drug-associated stimuli are presented in the background measuring to which extent they conflict with the learned instrumental behavior. In the last part, query trials are implemented in which the participants have to choose between two pictures to assess the relative cue value."
224208146|NCT06701487|DIAGNOSTIC_TEST|Basic psychological assessment (interview)|"* Alcohol, Smoking and Substance Involvement Screening Test (ASSIST)~* Quantity Frequency: Alcohol, Cannabis, (Meth-) Amphetamine, Cocaine)~* SCID: AUD and SUD (Cannabis, Methamphetamine, Amphetamine, Cocaine) criteria and last year \& depressive symptoms \& symptoms for Mania and psychotic disorder (acute and lifetime) MiniDIPS psychotic disorders"
224208147|NCT06701487|DIAGNOSTIC_TEST|Basic psychological assessment (questionnaires)|"* Sociodemographics~* Edinburgh Handedness Inventory (EHI)~* Fagerström Test for Nicotine depend (FTND)~* Barratt Impulsiveness Scale - Kurzversion (BIS-15)~* Allgemeine Depressionsskala (ADS)~* State-Trait-Anxiety Inventory (STAI-T and STAI-S)~* Adult ADHD Self-Report Scale (ASRS)~* Alcohol Use Disorders Identification Test (AUDIT)~* CAS -A (Alkohol)~* Cannabis Use Disorders Identification Test (CUDIT)~* Fragebogen zu Gedanken und Gefühle 14 Items (FGG-14)~* Fragebogen zur Sozialen Unterstützung (F-SozU-K14)~* Trierer Inventar zum chronischen Stress (TICS)~* Oslo 3-Items-Social-Support Scale (Oslo-3)~* Social Readjustment Rating Scale (SRRS)~* International Trauma Questionnaire (ITQ)~* Positive and Negative Affect Schedule (PANAS)"
224208148|NCT06701487|BEHAVIORAL|Neuropsychological tests|"* Digit-Symbol-Test (DST)~* Digit Span Task~* Value-based decision-making task (VBDM)"
224208149|NCT04221217|DRUG|Icosapent|Icosapent (MND-2119) capsules.
224208150|NCT00221052|DRUG|Diclofenac|
224208151|NCT01270607|PROCEDURE|Acupuncture|Treatment given twice per week for 4 weeks
224208152|NCT06700655|BIOLOGICAL|Cornea limbal stem cell transplantation group|The corneal limbal tissue (2mm x 5mm) was harvested from the patient's healthy eye, and ex vivo amplification was performed to obtain an adequate quantity of transplantable corneal limbal stem cells.
224208153|NCT06700655|PROCEDURE|Corneal transplantation|The patient awaited allogeneic corneal donation and underwent corneal transplantation surgery.
224208154|NCT06700655|BIOLOGICAL|Cornea limbal stem cell transplantation combined corneal stromal stem cell group|The corneal limbal tissue (2mm x 5mm) was harvested from the patient's healthy eye, and ex vivo amplification was performed to obtain an adequate quantity of transplantable corneal limbal stem cells and corneal stromal stem cells.
224208155|NCT03537222|DIAGNOSTIC_TEST|Myeloma Patient Outcome Scale (MyPOS)|Patients complete the MyPOS questionnaire on quality of life
224208156|NCT04040907|DRUG|XNW3009|XNW3009 is a small molecule hURAT1 inhibitor
224208157|NCT04040907|DRUG|Placebo|Placebo and active drug will have the same appearance
224208158|NCT04415177|DEVICE|EaseVRx headset with active intervention|VR software developed by AppliedVR informed by evidence-based cognitive behavioral therapy principles, biofeedback and mindfulness strategies for pain management.
224208159|NCT04415177|DEVICE|EaseVRx headset without active intervention|VR software developed by AppliedVR with neutral non-interactive content.
224208160|NCT02618252|DEVICE|Zonare|Patients with difficulty IV access are randomized to receive either intervention with ultrasound machine (Zonare ZS3 machine) or the Veinviewer Flex machine.
224208161|NCT02618252|DEVICE|Veinviewer|Patients with difficulty IV access are randomized to receive either intervention with ultrasound machine (Zonare ZS3 machine) or the Veinviewer Flex machine.
224315477|NCT00348504|DRUG|dobutamine|
224208162|NCT03649256|DIAGNOSTIC_TEST|Thickness of lower uterine segment scar|Ultrasound measurement of thickness of the uterine scar at 3 and 6 months
224208163|NCT03821142|DEVICE|Transvaginal mesh for anterior pelvic organ prolapse repair|synthetic mesh for anterior pelvic organ prolapse with or without apical vaginal wall involvement via the vaginal route in a highly selected patient population
224208164|NCT00627458|BIOLOGICAL|Infanrix Hexa|Vaccine administered as a booster dose at 16-20 months of age
224208165|NCT03411122|DRUG|napabucasin|Napabucasin will be administered at dose of 240 mg twice daily, every 12 hours (BID) on days 1-2 in period 1, and on days 1-11 in period 3.
224315478|NCT00551668|PROCEDURE|proximal patellar surgery|Initial proximal patellar surgery
224315479|NCT00551668|PROCEDURE|Nonoperative|Nonoperative without surgery
224315480|NCT01210872|OTHER|questionnaire administration|
224315481|NCT01210872|PROCEDURE|quality-of-life assessment|
224315482|NCT01210872|PROCEDURE|standard follow-up care|
224208166|NCT03411122|DRUG|cytochrome P450 (CYP450) probe drugs or BCRP transporter substrate|CYP450 probe drugs or BCRP transporter substrate will be administered once every period during days 1-4 in period 2, and days 6-9 in period 3.
224208167|NCT00913861|BEHAVIORAL|hypnosis|Hypnosis: induction of hypnosis by visual fixation and recollection of a pleasant memory, suggestion of relaxation, of self-control and post-hypnotic suggestion for bowel relaxation.
224315483|NCT04554446|PROCEDURE|T-MSAT(Motion style acupuncture treatment using traction)|Motion Style Acupuncture Treatment(MSAT) is a therapeutic technique using acupuncture needle created in Jaseng Hospital. T-MSAT(Motion style acupuncture treatment using traction) is a kind of MSATs, and a treatment that improves musculoskeletal problems by pulling the patient's body through the device and giving instructions for walking while being acupuncture.
224315484|NCT04554446|PROCEDURE|Korean medicine treatment|acupuncture, chuna, pharmacoacupuncture and Korean herbal medicine.
224315485|NCT03529825|DRUG|Rifaximin|Rifaximin will be administered twice a day orally or by nasogastric tube, at a dose of 15 mg/kg divided BID with a maximum dose of 1,650 mg, day -7 to day +28 or discharge (maximum duration 36 days).
223761489|NCT06909682|OTHER|Standard Clinical Follow-Up|Participants in this group will receive standard chronic heart failure (CHF) management according to current clinical guidelines. Their follow-up will consist of scheduled in-person visits every three months, during which they will undergo routine laboratory tests (including BNP, NT-proBNP, renal function, and electrolytes), as well as echocardiography and ECG evaluations. Treatment adjustments will be made based on clinical assessments and reported symptoms. Unlike the intervention group, these participants will not use a wearable device, and their condition will be monitored exclusively through traditional hospital visits and self-reported health status.
224208168|NCT00913861|DRUG|standard sedation|Standard sedation: fentanyl 2x0,5 microg/kg at beginning of procedure and propofol PCS: 20mg bolus than 10mg/bolus, lock-out = 0.
224208169|NCT00913861|BEHAVIORAL|Structured attention|Structured attention: verbal and nonverbal communication; attentive listening; provision of the perception of control; encouragement; use of emotionally neutral descriptors, focus on a sensations.
223761490|NCT06908265|DRUG|Toothpaste including mustard extract|"Intervention: Herbal toothpaste containing 0.5% white mustard (Sinapis alba) extract. To assess its effect on plaque index (PI), approximal plaque index (API), gingival index (GI), bleeding on probing (BoP), and bacterial loads of Streptococcus mutans and Lactobacillus spp.~Dosage and Usage: Participants brush their teeth twice daily for 4 weeks with the assigned toothpaste."
224208170|NCT00637793|DRUG|NGX267|2 capsules in the am of each treatment period
224208171|NCT00637793|DRUG|NGX267|2 capsules in the am of each treatment period
224208172|NCT00637793|DRUG|NGX267|2 capsules in the am of each treatment period
224208173|NCT00637793|DRUG|NGX267|2 capsules in the am of each treatment period
224208174|NCT00168740|DRUG|rituximab|
224208175|NCT02311543|DRUG|TachoSil® patches|TachoSil® is a sterile, ready-to-use, absorbable surgical patch and consists of an equine collagen sponge coated with human fibrinogen and human thrombin.
224208176|NCT03778190|PROCEDURE|Corneal Foreign Body Removal|An eye magnet will be brought close to the foreign body on the surface of the eye in an attempt to remove the foreign body.
224315486|NCT02648932|BIOLOGICAL|Haplo-Cord Transplant|For conditioning regimens, haplo-identical grafts will be selected by the Miltenyi Device
224315487|NCT02648932|PROCEDURE|Matched Unrelated Donor Transplant|
224315488|NCT04683016|OTHER|Questionnaires|"Patients will be asked two sets of questions:~* questionnaire about their perception of periodontal disease (Brief Illness Perception Questionnaire; 9 questions, answers will be registered on a scale of 0 to 10);~* Oral Health Impact Profile 14 (OHIP-14) questionnaire.~All these two sets of questions will be asked before and after non surgical periodontal therapy"
223512735|NCT03721107|BIOLOGICAL|Blautix|Blautix is a live biotherapeutic product consisting of a lyophilised formulation of a proprietary strain of bacterium. The study dosing regimen was two capsules two times per day for the duration of the treatment period.
224208177|NCT05523310|OTHER|Daily questionnaire|All patients will be asked to complete a daily questionnaire regarding their migraine, medications, and prodromal symptoms during that day
224208178|NCT00159081|DRUG|Haloperidol, Risperidone (drug)|targeted dose of 2-4 mg/day over 1 year
224208179|NCT00155259|DRUG|Docetaxel , Cisplatin , Capecitabine|
223512736|NCT03721107|OTHER|Placebo|Placebo control
223512737|NCT03888482|DEVICE|Verofilcon A contact lenses|Investigational daily disposable soft contact lenses
223512738|NCT03888482|DEVICE|Somofilcon A contact lenses|Commercially available daily disposable soft contact lenses
223512739|NCT00558207|DRUG|ARQ 197|120 mg capsule administered twice daily for 240 mg total daily dose
223512740|NCT00558207|DRUG|gemcitabine|1000 mg/m2 administered as an intravenous infusion over 30 minutes once weekly for 4 weeks for the first 28 days (cycle). Each subsequent cycle will consist of 1000 mg/m2 administered as an intravenous infusion over 30 minutes once weekly for 3 weeks with no drug administered in the 4th week.
223512741|NCT02511158|PROCEDURE|Ligament of the knee reconstruction|Reconstruction of ligaments of the knee by autografts
224208180|NCT01979302|OTHER|Depression CAREPATH|Nurses receive training and agency support in depression assessment and depression care management
224208181|NCT01979302|OTHER|Usual Care|Nurses receive training in depression assessment and review of usual care procedures.
224208182|NCT05174078|OTHER|Medically-tailored meals|Medically tailored meals delivered to patients' homes for 15 weeks AND one medical nutrition therapy session with a dietician + viewership of 2 to 4 nutrition education videos.
223512742|NCT06436521|BEHAVIORAL|Positive Cognitive Behavioral Therapy|Positive CBT integrates brief Solution-Focused Brief Therapy with Positive Psychology techniques, within a cognitive-behavioral framework. It is considered a competency and strengths-based model.
224315489|NCT04819763|OTHER|Physical therapy|"Coordination training for lateral movement of the mandible (spatula exercise):~1. A wooden spatula is loosely placed between the teeth of the upper and lower jaw; the head must be aligned with the body axis; the exercise should be performed in front of a mirror.~2. The lower jaw moves to the left and back to the center with little contact to the spatula~3. The lower jaw moves to the right and back to the center under contact with the spatula~Training of the left lateral pterygoid muscle:~1. The left palm is placed on the left temple region~2. Right hand forms a fist and is placed on the tip of the right chin~3. Both arms are aligned parallel to the surface of the floor~4. The lower jaw is moved to the right against a moderate resistance of the fist = concentric muscle work~5. With measured force of the fist, the lower jaw is brought back to the center = eccentric muscle work (Right lateral pterygoid muscle training with opposite hands.)"
223619126|NCT06482541|COMBINATION_PRODUCT|50 billion exosomes and saline solution microneedling|Participants will receive 50 billion WJMSC-exosome topical application on one half of the treatment area and an equivalent volume of saline solution on the contralateral half of the treatment area. Microneedling at a depth of .5mm on the entire treatment area will immediately follow the exosome and saline application. Participants will also receive 4 permanent microdot tattoos on the aforementioned locations.
224208183|NCT05174078|OTHER|Produce box and recipes|Weekly produce box and access to recipes via internet for 15 weeks AND one medical nutrition therapy session with a dietician + viewership of 2 to 4 nutrition education videos.
224208184|NCT06471231|DRUG|vasopressin infusion when the norepinephrine dosage is equal to or greater than 0.25 mcg/kg/min|when the norepinephrine dosage is equal to or greater than 0.25 mcg/kg/min in the absence of adequate MAP (Mean arterial pressure \>65 mmhg), vasopressin infusion will be associated with the standard dosage of 0.3UI/min.
224315490|NCT04819763|OTHER|Appliance therapy|"Upper and lower jaw impressions are registered by using an intraoral scanner. The arbitrary hinge axis position is determined using a face bow.~The stabilization appliance with anterior canine guidance is manufactured in the Lexmann laboratory in Dresden.~The stabilization appliance is incorporated by the dentist and the static and dynamic occlusion is checked. A tension-free fit of the appliance on the lower jaw is necessary. Additionally, equal contacts in the side teeth area and incisors guidance in the case of mandibular protrusion are checked visually and by using occlusion foil. During mandibular lateral movement only the canine guidance takes place and is also registered optically and by using occlusion foil.Interference contacts should be adjusted.~The patient is instructed to wear the stabilization appliance while sleeping. The wearing rhythm is described as intermittent. (three nights - wearing the appliance, one night - not wearing the appliance)."
224208185|NCT06471231|DRUG|vasopressin infusion when the norepinephrine dosage is equal to or greater than 0.5 mcg/kg/min|the infusion of vasopressin at a dosage of 0.3 IU/min will be associated if norepinephrine exceeds the dosage of 0.5 mcg/kg/min in the absence of adequate MAP
224208186|NCT04671160|DIAGNOSTIC_TEST|Assessment the activity of anti-Xa factor.|Assessment the activity of anti-Xa factor in patients treated with CVVHDF and receiving enoxaparin as anticoagulant prophylaxis, patients treated with CVVHDF and receiving fondaparinux as anticoagulant prophylaxis, patients not treated with CVVHDF and receiving enoxaparin as anticoagulant prophylaxis and patients not treated with CVVHDF and receiving fondaparinux as anticoagulant prophylaxis.
224208187|NCT06124326|DIETARY_SUPPLEMENT|Premenstrual Syndrome Supplement|Ginger, Curcumin, Organic Turmeric, Black Pepper, Magnesium, Zinc, Vitamin B6, Vitamin D.
224208188|NCT06404281|BIOLOGICAL|γδ T-PD-1 Ab cells|Cells will be extracted from a healthy donor, followed by ex-vivo expansion, activation and genetic engineering. The ex-vivo expanded γδ T-PD-1 Ab cells will be adoptively transfused to tumor patients.
224208189|NCT03573115|DRUG|Adapalene-Benzoyl Peroxide Gel 0.1-2.5%|Topical gold microparticles (SEB-250) are delivered to two facial areas at baseline, patients are then prescribed a topical Adapalene-Benzoyl Peroxide Gel 0.1-2.5% for 6 weeks followed by a new exposure to gold microparticles (SEB-250)
224208190|NCT06565689|DRUG|YK012|YK012 is a bispecific antibody targeting CD19 on B cells and CD3 on T cells leading to T cell-mediated cytotoxicity of malignant B cells
224208191|NCT01447979|DEVICE|portable artificial pancreas system with Control-To-Range algorithms|The investigators will test the new portable CTR system in CRC conditions for 10h followed by 18h of CTR in a hotel.
224208192|NCT05234242|PROCEDURE|inguinal hernia repair|inguinal hernia repair performed either in stationary/inpatient or ambulatory/outpatient setting
224208193|NCT01538589|DRUG|insulin aspart|Prescribed by the physicians as a result of normal clinical practice
224208194|NCT05795517|DRUG|HSK31679 low dose|HSK31679 low dose and placebo of HSK31679 ，QD，oral，Day1 to week 12
224208195|NCT05795517|DRUG|HSK31679 medium dose|HSK31679 medium dose and placebo of HSK31679 ，QD，oral，Day1 to week 12
224208196|NCT05795517|DRUG|HSK31679 high dose|HSK31679 high dose and placebo of HSK31679 ，QD，oral，Day1 to week 12
224208197|NCT05795517|DRUG|Placebo|placebo ，QD，oral，Day1 to week 12
224315491|NCT03155516|OTHER|Good pain management (GPM) procedure|"In the GPM ward, a close pain assessment will be carried within 1 hour after admission. After the assessment, patient will be given analgesic treatment as needed, by acceptable route, frequency and dosage. A good titration is required in GPM ward. Patient will be close monitor his/her pain level regarding pain score. In opioid use, when patient complains patient level ≥ 4, low dose strong opioids will be introduced in patient suffering with moderate pain.~Compare with current practice, GPM ward will perform pain assessment with higher frequency for adjusting of analgesic medications if required."
224315492|NCT03155516|OTHER|Current practice procedure|Current practice clinical procedure for pain management
224315493|NCT05412355|PROCEDURE|ERAS protocol|ERAS protocol is a series of procedures that enhance the recovery of surgical patients. Patients were grouped according to whether the procedure was attempted.
224315494|NCT06256523|DRUG|GZR18|0.5mg-13mg
223619127|NCT06546046|DEVICE|ECG monitoring by telemetry device and patch-type ECG monitor at the same time|The patient undergoes electrocardiogram monitoring simultaneously through a telemetry device and a patch-type electrocardiograph.
223680414|NCT01230125|DRUG|Mapracorat|Instill study medication into study eye per dosing instructions for 14 days
224208198|NCT05795517|DRUG|Ezetimibe 10mg|Ezetimibe 10mg+placebo of HSK31679 ，QD，oral，Day1 to week 12
224208199|NCT02856451|BIOLOGICAL|Nivolumab|Specified dose on specified days
224208200|NCT03497988|DRUG|Syntocinon|The active substance of Syntocinon is a synthetic nonapeptide identical to the posterior pituitary hormone oxytocin.
224315495|NCT06256523|OTHER|Placebo|administered the same volume as GZR18
224315496|NCT01105624|DRUG|azithromycin ophthalmic solution, 1%|1 drop BID for the first 2 days and then 1 drop QD for the remainder of treatment period (29 ± 1 day)
224315497|NCT01105624|DRUG|Visine® for Contacts®|1-2 drops QID for the treatment period (29 ± 1 day)
223619128|NCT03226925|DIAGNOSTIC_TEST|Non-invasive mechanically-assisted ventilation|Mechanically ventilation will be done through facial masks connected to a respirator. Volunteers/patients are fully conscious during the ventilation.
223761491|NCT06908265|DRUG|Placebo|"lacebo toothpaste, formulated identically to the experimental toothpaste but without white mustard extract. Serves as a control to compare the antibacterial and clinical effects of the herbal toothpaste.~Dosage and Usage: Participants brush their teeth twice daily for 4 weeks with the placebo toothpaste."
224208201|NCT03497988|DRUG|Placebo|The placebo is identical to the Syntocinon formulation with the exception of the active compound, i.e., without oxytocin.
224208202|NCT02617173|DEVICE|Micro 400 Matrix Therapy Products|Positive electrical current with a low amplitude bellow sensation level situated on the scrotum.
224208203|NCT00481273|DRUG|Azacitidine|Physician's discretion
224208204|NCT02268045|BIOLOGICAL|RTXM83|Rituximab biosimilar (RTXM83) will be administered in combination with CHOP chemotherapy regimen (Cyclophosphamide 750 mg/m2, Doxorubicin 50 mg/m2 and Vincristine 1.4 mg/m2 up to a maximum of 2 mg on Day 1 plus Prednisone 40 mg/m2 or 100 mg per day from Day 1 to 5) at a dose of 375 mg/m2 on Day 1 of each 3 week cycle, for 6 cycles, although the administration of 2 additional cycles may be allowed.
224208205|NCT02268045|BIOLOGICAL|Mabthera|Mabthera will be administered in combination with CHOP chemotherapy regimen (Cyclophosphamide 750 mg/m2, Doxorubicin 50 mg/m2 and Vincristine 1.4 mg/m2 up to a maximum of 2 mg on Day 1 plus Prednisone 40 mg/m2 or 100 mg per day from Day 1 to 5) at a dose of 375 mg/m2 on Day 1 of each 3 week cycle, for 6 cycles, although the administration of 2 additional cycles may be allowed.
224208206|NCT01766310|DRUG|Folic Acid|yellow tablet contained 5mg of folic acid, manufactured from the Government Pharmaceutical Organization, Ministry of Public Health, Thailand
224208207|NCT01766310|DRUG|placebo|sugar tablet manufactured to mimic folic acid tablet
224208208|NCT03584035|BEHAVIORAL|sensory motor integration exercises|Sensorimotor integration exercises will be given in study group. The exercises will be performed in standing, sitting and walking. Exercises will be progressively increased from eye open to closed , floor to mat and head turns to right \& left under the supervision of physiotherapist. Sensorimotor integration exercises will take 45 minutes in each session.
224208209|NCT03584035|BEHAVIORAL|conventional physiotherapy|Conventional physiotherapy will take 30 minutes in each session, taking three sessions per weeks for six weeks. The exercises include simple lower extremity exercise and ambulatory training such as sit to stand, stepping, lateral and backward walking, and tandom walking etc.
224208210|NCT03224117|DRUG|DWJ211|inject the Drug into submental fat via subcutaneous
224208211|NCT03224117|DRUG|Normal saline|inject the Drug into submental fat via subcutaneous
224208212|NCT04538768|PROCEDURE|Mesh augmentation|P4HB retromuscular mesh placement for prevention of lateral incisional hernia after stomal closure
224208213|NCT04538768|PROCEDURE|Direct suture|direct fascia suture
224315498|NCT00124124|DRUG|KLH; Peptides; Dendritic Cells|Upon entry into the study, patients randomized to the dendritic cell arm will undergo a complete baseline evaluation and leukapheresis 0.5 to 3 x 106 DCs per peptide antigen (total not to exceed 18 x 106 cells) will be administered intradermally as per injection SOP. They will receive up to 3 booster DC injections (total not to exceed 18 x 10 6 cells per injection) at monthly intervals for a total of 4 injections. The booster injections will not contain KLH, as our volunteer studies have shown that priming occurs following a single injection of DCs
224315499|NCT00124124|DRUG|KLH, peptides plus Montanide|Patients randomized to the Montanide arm will also undergo complete baseline evaluation but not leukapheresis. The peptides will be mixed with the adjuvant, Montanide, and administered subcutaneously at a dose of 100 microgram of each peptide +100 microgram KLH mixed with an equal volume of Montanide. They will receive up to 3 booster injections at monthly intervals for a total of 4 injections. The booster injections will not contain KLH.
224315500|NCT05840679|DRUG|Irrigation Solution|Different concentrations of NaOCl are being used as the endodontic irrigant.
224315501|NCT00561418|DRUG|vorinostat|Vorinostat (SAHA) will be administered orally starting approximately day +60 post HSCT for 21 consecutive days of a 28-day cycle for up to a maximum of 11 cycles.
223619129|NCT03226925|DIAGNOSTIC_TEST|Dynamic MRI acquisition|Dynamic MRI acquisition are specific dynamic sequences intended to visualise the motion of internal structures (anatomical structures or tumour) under non-invasive mechanically-assisted ventilation
223619130|NCT03226925|DIAGNOSTIC_TEST|Planning 4D-CT|In order to perform in-silico planning, 4D-CT will be acquired on patients under non-invasive mechanically-assisted ventilation
224208214|NCT04703465|DRUG|Tenofovir Alafenamide 25 MG|Tenofovir Alafenamide 25mg for 48 weeks will be delivered
224208215|NCT01154673|DRUG|raltegravir|Raltegravir 400 mg BID + Maraviroc 150mg BID in addition to standard HAART
223619131|NCT02360891|OTHER|biomarkers (composite analysis)|biological, imaging, electrophysiological and anatomopathological examinations
223619132|NCT03607955|DRUG|AVB-S6-500|AVB-S6-500 is supplied by Aravive Biologics
223619133|NCT03607955|DRUG|Paclitaxel|Commercially available
223619134|NCT03607955|DRUG|Carboplatin|Commercially available
223619135|NCT03607955|PROCEDURE|Tissue from Diagnostic Laparoscopy|-For patients scheduled to undergo a diagnostic laparoscopy for tissue diagnosis prior to neoadjuvant chemotherapy, a tissue biopsy section from the ovary or an intra-abdominal implant will be performed
223619136|NCT03607955|PROCEDURE|Tissue from Core biopsy|-Standard of care procedure but research specimens will be collected
223619137|NCT03607955|PROCEDURE|Interval Debulking|"* Standard of Care~* Research tissue samples will be collected"
223619138|NCT03607955|PROCEDURE|Peripheral blood|-Before initiation of neoadjuvant chemotherapy and at the time of interval debulking surgery either pre-operatively, intraoperatively, or post-operatively.
223619139|NCT03607955|PROCEDURE|Ascites collection|-A total of 25-100ml of ascites will be collected prior to chemotherapy treatment, if available.
223619140|NCT02756117|DRUG|L-Lysine|
224208216|NCT01154673|DRUG|maraviroc|Raltegravir 400 mg BID + Maraviroc 150mg BID in addition to standard HAART
224208217|NCT01154673|DRUG|emtricitabine 200mg /tenofovir 300mg|emtricitabine 200mg /tenofovir 300mg QD
224208218|NCT01154673|DRUG|lopinavir 400 mg/ritonavir 100mg|lopinavir 400 mg/ritonavir 100mg BID
224208219|NCT05109273|PROCEDURE|Transcatheter ablation|Three-dimensional electroanatomic mapping and radiofrequency ablation with irrigated catheter
224208220|NCT02006810|BEHAVIORAL|Induction of endothelial function variations|
224208221|NCT03768388|DRUG|levoketoconazole|food effect
224208222|NCT05199207|BEHAVIORAL|Physical activity programm|adapted physical activity during 3 month
224208223|NCT03456973|BEHAVIORAL|Nurse AMIE|Supportive care software platform
224208224|NCT00741117|PROCEDURE|Arterial Blood Gas|One blood gas sample will be obtained from an artery in the arm.
224208225|NCT00741117|PROCEDURE|Pulse Oximetry Machine|A pulse oximetry machine will be used at one time point to obtain an oxygen saturation reading. This is done by placing a clip onto the finger. The pulse oximetry value displays on the pulse oximeter machine within seconds.
224208226|NCT00741117|PROCEDURE|Direct and Indirect Serum Bilirubin Measurement|One tube of blood will be drawn from a vein in the arm at one timepoint to measure the direct and indirect serum bilirubin levels.
224208227|NCT01461148|BIOLOGICAL|FSP peptides|100 ug of each FSP (TAF1B(-1), HT001(-1) and AIM2(-1), weekly for 4 consecutive weeks and repeated every four weeks up to a total of 3 cycles.
224315502|NCT00561418|OTHER|Correlative studies|Laboratory as well as quality of life correlative studies will be obtained at days +26 to +38 (at approximately 1 month post HSCT),days +56 to +66 (≈2 mos), and at Cycle 2 Day 1 (≈3 mos.), Cycle 3 Day 1 (≈4 mos.), Cycle 5 Day 1 (≈6 mos.),Cycle 7 Day 1 (≈8 mos.), and off study (ideally at ≈12 mos.)
224315503|NCT04963543|OTHER|FID123238|Lubricant applied to the ocular surface
223761492|NCT06908434|DRUG|GenSci128 tablets|GenSci128 tablets have three specifications, including 50mg, 200mg, 500mg, and are taken in combination with the doctor's advice in different dose levels. GenSci128 will be orally administrated daily (except single dose in Cycle 0) with no interruptions until occurrence of unacceptable toxicity, or progressive disease, or withdrawal of consent, or death, or contact lost, or starting a new anticancer therapy, etc. (whichever occurs first).
224208228|NCT05951231|PROCEDURE|Liver transplantation|Patients who receive an ECD liver after an ex-vivo liver perfusion where the liver has been tested for function and approved according to international functional criteria (Groeningen criteria)
224315504|NCT01090518|BEHAVIORAL|Prolonged Exposure therapy|10 weekly sessions
224315505|NCT01090518|DRUG|Hydrocortisone|30mg 20 minutes prior to each PE session including imaginal exposure (8 total)
224315506|NCT01090518|BEHAVIORAL|Prolonged Exposure therapy|10 weekly sessions
223512743|NCT06436521|BEHAVIORAL|Traditional Cognitive Behavioral Therapy|Traditional cognitive behavioral therapy is a form of psychological treatment that emphasizes that psychological problems are based on faulty or unhelpful ways of thinking and the focus is to change thinking patterns.
223512744|NCT02824549|DEVICE|FreeStyle Libre Flash Glucose Monitoring|
223512745|NCT02554474|BEHAVIORAL|Education, Fitbit/FitViz, physiotherapist counselling.|Participants will receive a brief education session, use a physical activity tracker Fitbit Flex with paired with a FitViz app, and remote counseling by a PT. Intervention will be received immediately.
223512746|NCT02554474|BEHAVIORAL|Same intervention with a 9-week delay|The Delayed Intervention Group will receive the same intervention as the Immediate Intervention Group, but with a 9-week delay.
224208229|NCT01734213|DIETARY_SUPPLEMENT|Eriobotyra Japonica Lindley Extract|Eriobotyra Japonica Lindley Extract (1.5g/day)
224208230|NCT01734213|DIETARY_SUPPLEMENT|Placebo|Placebo (1.5g/day)
223512747|NCT01977976|PROCEDURE|Endometrial aspiration by pipelle|Endometrial aspiration by pipelle is to be performed on LH+7 in the cycle preceding scheduled IVF treatment
223512748|NCT05675293|DEVICE|IONTOPHORESIS|The process of increasing the penetration of drugs into the skin by application of an electric current
223512749|NCT05675293|DRUG|ORAL ANTIBIOTIC|Oral Antibiotic
223512750|NCT06443593|DIETARY_SUPPLEMENT|Tablet VitaBliss vitamin B12 (2.2 mcg)|Oral vitamin B12 supplement 2.2 mcg from BLISS WELNESS, Bliss Lifesciences, LLP to be administered once daily for 24 weeks
223512751|NCT06443593|DIETARY_SUPPLEMENT|Tablet VitaBliss vitamin B12 (2.2 mcg) and Syrup Orofer (5 ml = 50 mg)|Oral vitamin B12 supplement 2.2 mcg from BLISS WELNESS, Bliss Lifesciences, LLP to be administered once daily for 24 weeks and oral iron 25 mg from Emcure Pharmaceuticals Ltd. to be administered once daily for 24 weeks
224208231|NCT05149989|DEVICE|Proning Pillow System|Participants will be asked to lie on the proning pillows in prone position for no more than 5 minutes. Each participant will then be asked to lie on standard hospital pillows for no more than 5 minutes.
224208232|NCT06317766|DEVICE|2910 nm Fiber Laser Treatment; Pre-Clinical Histology Evaluation|Treatment with 2910 nm fiber laser focusing on its diverse energy settings and histological evaluation post abdominoplasty.
224208233|NCT06317766|DEVICE|2910 nm Fiber Laser Treatment; Part 2 Histology Evaluation|Healing Progression: Treatment with 2910 nm fiber laser focusing on its diverse energy settings and histological evaluation post abdominoplasty.
224208234|NCT01909388|RADIATION|MRI-TRUS fusion guided real time HDR|
224208235|NCT03252574|OTHER|A|AIR+ Smart Mask Only
224208236|NCT03252574|OTHER|B|AIR+ Smart Mask with micro-ventilator
224208237|NCT04215107|OTHER|Standard breakfast meal|"The first ultrasound will be preformed during fasting. IUGR group will be served a standard breakfast meal, and perform the second ultrasound after 2 hours from the meal.~The control group will be crossover randomized to meal or prolonged fasting. It will be performed 4 ultrasounds: during fasting and 2 hours after standard breakfast meal. During fasting and during prolonged fasting."
224208238|NCT05813392|BEHAVIORAL|Digital Cognitive Behavioral Therapy for Insomnia|a full self-help digital cognitive behavioral therapy for Insomnia (dCBT-I) through a smartphone APP
224208239|NCT03583840|BEHAVIORAL|ScreenMen website|An educational website that aims to improve evidence-based health screening uptake in men
224208240|NCT00738140|BEHAVIORAL|Diabetes Prevention Program|12-lesson program which will cover diet, exercise, and behavior modification.
224208241|NCT03514173|DEVICE|Remote Patient Monitoring|Use of remote patient monitoring
224208242|NCT00989365|OTHER|Aerobic training|Treadmill training
223619141|NCT02756117|DRUG|Normal (0.9%) Saline|
223619142|NCT02817243|DRUG|SP2086|SP2086 will be administered orally (by mouth) as 100 mg on Days 4, 5, 6, 7, and 8 and Simvastatin will be administered orally as two 20mg tablets on Days 1 and 8. Both SP2086 and Simvastatin tablets will be taken with 8 ounces (240 mL) of water.
224315507|NCT01596738|DRUG|Tranexamic Acid|"1. Tranexamic acid 50mg/ml, 15 mg/kg intravenous after anesthetic induction~2. Tranexamic acid 50mg/ml, 15 mg/kg intravenous after neutralization"
224315508|NCT01596738|DRUG|Saline|"1. Equivalent volume of saline, equal to that of 50mg/ml tranexamic acid at the dosage of 15mg/kg, intravenous after anesthetic induction~2. Equivalent volume of saline, equal to that of 50mg/ml tranexamic acid at the dosage of 15mg/kg, intravenous after neutralization"
224208243|NCT05396326|DRUG|Oxaliplatin|"The first and third cycles : transcatheter arterial infusion of oxaliplatin 85mg/m2, day 1.~The second and fourth cycles: intra-venous oxaliplatin 135mg/m2, day 1."
224208244|NCT05396326|DRUG|Teysuno|Oral S-1, 40mg-60mg bid, day 1-14 for four 21-day cycles.
224315509|NCT02960490|DRUG|E6011|subcutaneous administration
224208245|NCT05396326|PROCEDURE|Transarterial arterial chemoinfusion and embolism (TACiE)|In the first and third cycles : transcatheter arterial infusion of oxaliplatin 85mg/m2, day 1; transcatheter arterial embolism of tumor feeding arteries, day 1, if applicable.
224208246|NCT06341270|DEVICE|transcutaneous electrical acupoint stimulation|transcutaneous electrical acupoint stimulation Transcutaneous electrical acupoint stimulation (TEAS) is a contemporary modification of traditional acupuncture that sends electrical impulses into acupoints through electrodes on the skin surface. In the TEAS group, patients will receive TEAS 30min before anesthesia until be discharged from the postanaesthesia care unit (PACU). The same treatment will be performed on the 1st, 2nd and 3rd days after surgery.The stimulation intensity will be adjusted in accordance with the maximal level tolerated by each patient.
224208247|NCT06341270|DEVICE|sham transcutaneous electrical acupoint stimulation|Patients in the sham group will receive electrode attachment but without stimulation.
224208248|NCT02677337|OTHER|chart abstraction|chart abstraction will be conducted pre and post education intervention to assess efficacy of education at point of care
224208249|NCT02677337|OTHER|Educational Program|
224208250|NCT00514501|DRUG|Iodofiltic acid I 123|
224315510|NCT02960490|DRUG|Placebo|subcutaneous administration
224315511|NCT06354452|OTHER|Person-level linkage of the database looking for relationship with sepsis survival and previous intake of certain drug families and previous dependence on health services.|"A descriptive analysis of the baseline demographics, risk factors, health status, comorbidities, frailty, and previous dependence on health services of all patients admitted to hospitals in the region will be carried out.~Both the overall data of patients admitted to hospitals in any ward and those admitted to ICU will be analysed. The survival data of patients will be compared with their previous individual drug consumption, trying to find out the relationship between chronic consumption of certain families of drugs and inhospital survival to sepsis. In addition, drug dependence and dependence on health services of sepsis survivors will be studied in comparison with their situation prior to sepsis."
224208251|NCT00562874|DIETARY_SUPPLEMENT|Meat Biscuit|75 women and one of their children will receive a biscuit containing dried meat as an ingredient for 5 days each week for 12 months. Women will receive 525 calories and 21 grams of protein per day and children will receive 350 calories and 14 grams of protein per day.
224315512|NCT00437359|DRUG|Toremifene citrate|Toremifene citrate: 40-mg tablets by mouth once daily.
224208252|NCT00562874|DIETARY_SUPPLEMENT|Soy Biscuit|75 women and one of their children will receive a biscuit containing soy four as an ingredient for 5 days each week for 12 months. Women will receive 525 calories and 21 grams of protein per day and children will receive 350 calories and 14 grams of protein per day.
224208253|NCT00562874|DIETARY_SUPPLEMENT|Wheat Biscuit|75 women and one of their children will receive a biscuit containing only wheat lour as a source of protein as an ingredient for 5 days each week for 12 months. Women will receive 525 calories and 8 grams of protein per day and children will receive 350 calories and 5 grams of protein per day.
223512752|NCT06443593|DIETARY_SUPPLEMENT|Tablet VitaBliss vitamin B12 (2.2 mcg) and Tablet Tayo (60000 IU)|Oral vitamin B12 supplement 2.2 mcg from BLISS WELNESS, Bliss Lifesciences, LLP to be administered once daily for 24 weeks and oral vitamin D3 (60000 IU) from Eris Lifesciences Ltd to be administered once in 3 months for 24 weeks
223512753|NCT01766089|DRUG|Remifentanil|Remifentanil (0.1 µg/kg/min) starting 5 min before induction of anaesthesia and continued until peritoneal closure.
223512754|NCT01766089|DRUG|Dexmedetomidine|dexmedetomidine (0.4 µg/kg/h) starting 20 before induction of anaesthesia and continued until peritoneal closure
224208254|NCT03180983|BEHAVIORAL|multimodal intervention|Investigators will propose an online training. In addition, investigators will make phone calls to nursing home interlocutor between two nursing home visits. The tools of this intervention will consist on posters , quiz about bacteriuria and urinary tract infection (UTI) and algorithm to help nurse's reasoning when UTI is suspected.
224208255|NCT05385510|BIOLOGICAL|R21/Matrix-M™|Adjuvanted malaria vaccine
224208256|NCT00329758|DRUG|rosuvastatin|20 mg oral, during 10 days
224208257|NCT00329758|DRUG|Placebo|
224315513|NCT00437359|DRUG|Anastrozole|Anastrozole: 1-mg tablets by mouth once daily.
224315514|NCT00516152|DRUG|Busulfan/Fludarabine phosphate/Tacrolimus/Methotrexate/G-CSF|"Day Preparative Regimen for GVHD Prophylaxis~* 7 Busulfan 0.8 mg/kg IV Q6 hurs, Fludarabine 30 mg/m(2)IV~* 6 Busulfan 0.8 mg/kg IV Q6 hurs, Fludarabine 30 mg/m(2)IV~* 5 Busulfan 0.8 mg/kg IV Q6 hurs, Fludarabine 30 mg/m(2)IV~* 4 Busulfan 0.8 mg/kg IV Q6 hurs, Fludarabine 30 mg/m(2)IV~* 3 Fludarabine 30 mg/m(2)IV~* 2 REST Tacrolimus 0.01 mg/kg CIVI~* 1 REST 0 Unrelated Stem Cell/Bone Marrow Infusion~  * 1 Methotrexate 5mg/m(2)IV~ * 3 Methotrexate 5mg/m(2)IV~ * 6 Methotrexate 5mg/m(2)IV~ * 7 G-CSF 5mcg/kg SQ daily~ * 11 Methotrexate 5mg/m(2)IV~ * 90 Evaluate Response"
224315515|NCT06357806|DRUG|Sintilimab|100mg/10ml/1bottle
224315516|NCT06357806|DRUG|Peg-IFNα-2b|180ug/0.5ml/1bottle
224315517|NCT06357806|DRUG|NAs|tablets
223512755|NCT04171869|OTHER|no intervention|observational study, no intervention
223619143|NCT02817243|DRUG|Simvastatin|SP2086 will be administered orally (by mouth) as 100 mg on Days 4, 5, 6, 7, and 8 and Simvastatin will be administered orally as two 20mg tablets on Days 1 and 8. Both SP2086 and Simvastatin tablets will be taken with 8 ounces (240 mL) of water.
224315518|NCT02667067|DEVICE|Simplify Disc|Simplify Disc at one level in the cervical spine.
224315519|NCT02667067|DEVICE|Anterior Cervical Discectomy & Fusion|"This study will utilize a non-concurrent historical control with subject-level data on a parallel group design. The historical control group will be formed from the randomized ACDF arm (N=133) of the recently completed Kineflex®\|C Disc trial."
223619144|NCT01582399|DRUG|ASKP1240|intravenous(IV) infusion and subcutaneous (SC)
223619145|NCT05842018|DRUG|Toripalimab, Anlotinib and Chemotherapy|"Combination therapy:~Toripalimab 240mg will be intravenously administered on Day 1, Q3W; anlotinib: 12 mg qd d1-d14, d15-d21 discontinued, Q3W; investigator selected chemotherapy regimen (paclitaxel, pemetrexed or gemcitabine and other chemotherapeutic drugs which were not administered in the first-line therapy) for a total of 4 cycles.~Maintenance therapy:~After combination therapy, Patients who achieved complete response（CR）, partial response (PR), or stable disease (SD) were administered with toripalimab plus anlotinib as maintenance therapy. until disease progression or intolerable toxicity, treatment for 2 years, investigator decision, withdrawal of consent, or death."
224315520|NCT03111771|PROCEDURE|carcinological surgery|carcinological surgery for Group K +
223512756|NCT04316650|BEHAVIORAL|Evaluation Scales|"* PATHOS / PEACCE : hypersexuality diagnostic scale~* PDQ-4+: Personality Diagnostic Questionnaire version 4~* AUDIT~* Life trajectory : THQ~* Cognitive function (MoCA, Stroop)~* ISDSS: and self report of sexual activity and desire~* BARS: Brief Adhesion Rating Scale (treatment observance)~* SF-36 scale : quality of life~* BDI-II : Beck Depression Inventory~* BSSI ; Beck suicidal Inventory~* Cognitive functioning evaluation : Molest and Rape Scale~* Empathy: EMPAT~* Evaluation of Cognitive functioning: denial evaluation and Mc Kibben minimization~* Baratt Impulsivity Scale~* CSBI~* Static 99 and Stable 2007"
223512757|NCT04316650|OTHER|osteodensitometry|Osteodensitometry
223619146|NCT01041820|BEHAVIORAL|Exercise|Children will be exposed to a 10-week exercise intervention
223619147|NCT01855360|DRUG|Tauroursodeoxycholic Acid and Doxycycline|
223619148|NCT06449495|DEVICE|NIRVANA|"NIRVANA is a medical device using semi-immersive virtual reality for motor and cognitive neuro-rehabilitation.~NIRVANA creates a sensory room where the patient can have an immersive and stimulating experience by interacting directly with different realistic scenarios. The system creates different scenarios on the wall or floor, and the patient interacts with the stimuli provided. A motion-analysis device detects the patient's behavior and based on the projected environment provides highly stimulating and rehabilitative audiovisual feedback with full whole-body immersion. The system is preconfigured with a series of exercises, which can be customized based on different types of patients, intervening on the level of difficulty, speed of execution and sensitive area of the projection."
223619149|NCT03703089|DRUG|Gemcitabine|Administered by intravenous infusion over 30 minutes.
223619150|NCT03703089|DRUG|nab-paclitaxel|Administered by intravenous infusion over 30-40 minutes.
223619151|NCT04168671|DIAGNOSTIC_TEST|Continuous laryngoscopy during exercise test|Continuous laryngoscopy during exercise test
224208258|NCT05969626|BIOLOGICAL|5-dose group of test vaccine|Subjects will be vaccinated on days 0, 3, 7, 14, and 28
224208259|NCT05969626|BIOLOGICAL|5-dose group of control vaccine|Subjects will be vaccinated on days 0, 3, 7, 14, and 28
224208260|NCT05969626|BIOLOGICAL|4-dose A group of test vaccine|Subjects will be vaccinated on days 0, 3, 7, 14
224208261|NCT05969626|BIOLOGICAL|4-dose B group of test vaccine|Subjects will be vaccinated on days 0, 3, 7, 28
224208262|NCT04672824|BIOLOGICAL|ChAdOx1 RVF|Single dose ChAdOx1 vectored vaccine
224208263|NCT04672824|OTHER|Saline|0.5ml saline placebo
224208264|NCT03868917|PROCEDURE|thoracic paravertebral block using pressure measurement technique|The continuous thoracic paravertebral block using ultrasound machine is combined with pressure measurement during needle advancement.
224208265|NCT01711034|DRUG|OPB-111077|"Dose escalation phase starting with dose of 100mg tablets on Day 1 and 4, and all remaining days of each 28 day cycle until disease progression or toxicity develops.~Dose expansion phase starting with daily dosing of 250mg for 28 day consecutive day cycles."
224208266|NCT02603536|OTHER|WelTel|An evidence-based, text messaging solution for improving patient adherence.
224208267|NCT02788955|BEHAVIORAL|Dietary counselling|
224208268|NCT02788955|OTHER|Dietary Protein|
224208269|NCT01246297|OTHER|Pulmonary Rehabilitation|Twice weekly exercise classes with an education component. For 8 weeks.
224208270|NCT01246297|OTHER|Usual post operative care|Usual post operative care for post lung lobectomy patients for 8 weeks post discharge.
224208271|NCT06000839|DEVICE|(D0) Intradermal injection - micropapula technique|First injection of the product (3ml) in the medium and lower third of the face (whole face excepted forehead)
224208272|NCT06000839|DEVICE|(D14) Intradermal injection - micropapula technique|Second injection of the product (3ml) in the medium and lower third of the face (whole face excepted forehead)
224315521|NCT03111771|PROCEDURE|cervical surgery|cervical surgery for Group K-
224315522|NCT04079465|DEVICE|O2matic|O2matic controls oxygen supply with a closed-loop feedback from a pulse oximeter. The aim is to maintain SpO2 within a predefined target interval according to guidelines for the specific condition causing hypoxemia, with the lowest possible supplementation of oxygen.
224315523|NCT02678078|PROCEDURE|Analyzing biopsy samples|Analyzing biopsy samples that is preformed as part of the patient treatment.
224315524|NCT03068117|OTHER|Regular Early Specialist Symptom Control Treatment (RESSCT)|"Participants will be seen within three weeks of randomisation by the Specialist Palliative Care Team (SPCT), (regardless of, and in addition to, all other treatments being offered). The initial meeting will be an approximately 1 hour consultation with a member of the Specialist Palliative Care team. This may be either a Consultant or Specialist Palliative Care Clinical Nurse Specialist (SPCCNS).~Patients will then continue to be seen regularly on at least a 4 weekly basis (regardless of other treatments, interventions and symptoms) by a member of the SPCT, with consultations lasting approximately 30 minutes. These monthly reviews will continue until end of trial (EOT) or patient death."
224315525|NCT03461731|DEVICE|Control|laser beam only
224315526|NCT03461731|DEVICE|800 nm laser|800 nm laser applied to forearm at 4.4 Joules per square cm during 40 hand grips
224315527|NCT03461731|DEVICE|combination laser|800 nm and 905 nm laser applied to forearm at 4.4 Joules per square cm during 40 hand grips
224315528|NCT03461731|DEVICE|905 nm laser|905 nm laser applied to forearm at 4.4 Joules per square cm during 40 hand grips
224315529|NCT01753557|DRUG|MP-424|MP-424: 750mg every 8 hours (q8h) for 12 weeks
223619152|NCT01252706|BEHAVIORAL|brief intervention|limit time giving information, motivation, empathy, responsibility, self control
223619153|NCT04631848|DEVICE|ULTRASCORE™ Focused Force PTA Balloon|The device will be used for percutaneous transluminal angioplasty (PTA) to dilatate calcified stenoses in below the knee vessels
224315530|NCT01753557|DRUG|RBV|RBV: 600 - 1000 mg/day based on body weight for 24 weeks
223512758|NCT04316650|BIOLOGICAL|blood samples|"* Lipid profile (total cholesterol, triglycerides, HDL cholesterol)~* Liver function (ASAT, ALAT, total bilirubin, transferase gamma-glutamyl et alcalin phosphatases~* Kydney function~* Blood count~* Biological Measurements and Measurement of Systematic Plasma Testosterone and TeBG Levels in Sex Offenders check for pathology of the Gonadotropin Axis~* Biological Measurements of Plasma Prolactin level"
223619154|NCT05354271|OTHER|High-intensity interval training|Patients will cycle or walk/run four intervals of four-min at high intensity with the aim to reach 80-90% of peak oxygen consumption, 90-95% of peak heart rate, 15-17 Borg scale, shortness of breath). Each interval is separated by a three-min active recovery, at 50-60% of peak oxygen consumption or 70-75% of peak heart rate. Total exercise time will be 38 min including the warm-up and cool-down.
223619155|NCT05354271|OTHER|Moderate-intensity continuous training|Patients will cycle or walk/run continuously at moderate intensity (50-60% of peak oxygen consumption, 70-75% of peak heart rate) for 37 min. Total exercise time will be 47 min for the Moderate-intensity continuous training group including warm-up and cool-down (isoenergetic compared to high-intensity interval training).
223512759|NCT04316650|OTHER|ECG|ECG (heart rate, search for cardiac conduction disorders or cardiac arrhythmias)
223619156|NCT00502788|DRUG|Peginterferon Alfa-2a and Ribavirin|"Patients will be treated with alfa-2a and ribavirin as follows:~Peginterferon alfa-2a will be started as a dose of 180 ug subcutaneously once weekly."
223619157|NCT00502788|DRUG|Ribavirin|Ribavirin will be started at a dose of 800mg daily for those weighing less than or equal to 50 kg, 1000 mg daily for those with body weight 51 to 75 kg and 1200 mg daily for those with body weight \> 75 kg. Ribavirin will be given orally in two divided doses. The lower dose has been included because potentially-eligible patients in the TCRN registry have a mean weight of 57 kg.
224208273|NCT06000839|DEVICE|(D28) Intradermal injection - micropapula technique|Third injection of the product (3ml) in the medium and lower third of the face (whole face excepted forehead)
224208274|NCT00646282|DRUG|doxercalciferol|The study drug dosage will be initiated according to baseline iPTH levels. For patients with iPTH\>300 pg/ml, oral Doxercalciferol will be given at 1 mcg/day; for patients with iPTH \<300 pg/ml, oral Doxercalciferol will be initiated at 0.5 mcg/day.
224208275|NCT06566560|OTHER|redispensing oral anticancer drugs|"Participants will receive oral anticancer drugs according to their regular prescriptions, distributed in the original manufacturer's package. Following the guideline, some oral anticancer drug (i.e. requiring temperature storage up to 25C degrees) will be supplemented with a validated temperature indicator (Timestrip Neo, customer configuration), enclosed with a seal bag. Patients are requested to return unused oral anticancer drugs to the outpatient pharmacy that distributed them.~Pharmacy staff will assess the quality of returned oral anticancer drugs, applying the following criteria:~1. the seal bag is unopened~2. the drug package is unopend and undamaged~3. the expiry date is ≥ 3 months~4. the medication has not been stored outside the product label storage claim~Oral anticancer drugs that meet all criteria are restocked, and consecutively redispensed to participants visiting the same outpatient pharmacy."
224315531|NCT01753557|DRUG|PEG-IFN alfa-2a|PEG-IFN alfa-2a: 180mcg/week for 24 weeks
223512760|NCT04316650|GENETIC|Blood and saliva samples|Blood and saliva samples
223512761|NCT02991859|DRUG|Fluticasone furoate (FF) Dry Powder Inhaler|Dry inhalation powder 25 mcg, 100 mcg, and 200 mcg per blister strip will be administered using ELLIPTA for both treatment periods
223512762|NCT02991859|DRUG|Fluticasone propionate (FP) Dry Powder Inhaler|Dry Inhalation powder 50 mcg, 100 mcg, 250 mcg, and 500 mcg per blister strip will be administered using DISKUS for both treatment periods
223512763|NCT02991859|DRUG|Budesonide (BUD) Turbuhaler|Budesonide comprises white to off-white rounded granules, which disintegrate to a fine powder upon slight pressure, will be administered using Turbuhaler for both treatment periods.
223512764|NCT02991859|DRUG|Placebo (ELLIPTA or DISKUS)|Lactose dry powder inhaler will be administered using ELLIPTA or DISKUS for both treatment periods.
223512765|NCT03320083|BEHAVIORAL|Educational care derived from POSSUMS|Intervention group were offered a sleep education session on healthy practices for parent-baby sleep which included information on sleep needs, sleep hygiene, training in strategies to remove obstacles that get in the way of healthy sleep. Information were provided to guide the parent in forming an action plan based on cued care which included aligning the circadian clock with real time, removing the obstacles that get in the way of healthy sleep, physical activity, mindfulness, and relaxation techniques for mothers derived from the POSSUMS approach. However, we could not use Acceptance and Commitment Therapy, because none of the investigators had sufficient training on ACT at the time the study was conducted.
223512766|NCT05259540|DRUG|compound kushen injection combined with pabolizumab|compound kushen injection 20ml/day and pabolizumab 200mg/21 days, both drugs are given intravenously
223512767|NCT06082817|DRUG|Oral Testosterone Undecanoate|50mg oral testosterone undecanoate daily
223512768|NCT03607786|PROCEDURE|Retrograde Inferior Vena Caval Perfusion|Retrograde Inferior Vena Caval Perfusion is achieved by tethering the inferior vena cava with a band around the cannula and by clamping the distal end of the inferior vena cava drainage tube, which allowed a pump to drive oxygenated blood into the inferior vena cava. Pump pressure is maintained at 20-30 mmHg, and blood flow is maintained at 8-12 mL/min/kg. The aim of RIVP is to maintain the lower body perfusion during circulation arrest, and reduce the ischemia-associated vital organ injury.
223512769|NCT03607786|PROCEDURE|Select antegrade cerebral perfusion|Antegrade cerebral perfusion is achieved using a 12 F cannula inserted into the brachiocephalic artery or right axillary artery. The antegrade perfusion flow rate is maintained at 6-12 mL/min/kg
223512770|NCT03825666|OTHER|ProvideXtra® Fresenius Kabi|Improving wellbeeing
223512771|NCT06103799|BEHAVIORAL|IMB model-based continuity of care|The information-motivation-behavioral skills (IMB) model, first proposed by Fisher, is composed of three elements-information, motivation, and behavioral skills-and is aimed at transferring patients' behavior into a positive direction, including self-behavior management ability, medication compliance and so on. For diabetic patients with poor adherence, the IMB model of care can be considered.
223619158|NCT04158583|DRUG|RO7296682|RO7296682 will be administered by the schedules specified in the respective arms.
223619159|NCT05545683|BIOLOGICAL|VLA 2001|VLA2001 is a highly purified whole virus, inactivated, adjuvanted vaccine, using the manufacturing platform of Valneva's encephalitis (JE) vaccine
223619160|NCT05160896|DRUG|Raltitrexed|Raltitrexed 2 mg/m² iv, 15min. day 1
223619161|NCT05160896|DRUG|Irinotecan|Irinotecan 180 mg/m² iv, 30 - 90 min. day 1
223619162|NCT05160896|DRUG|Bevacizumab|Bevacizumab 5 mg/kg, iv, day 1
223619163|NCT05160896|DRUG|Cetuximab|cetuximab 500 mg/ m² , iv, day 1
223619164|NCT01871519|DEVICE|Balloon kyphoplasty|The devices to be used in this study are intended for percutaneous balloon kyphoplasty (BKP) and consist of the Kyphon® bone access needles and cannulae, inflatable bone tamps, curettes, polymethyl methacrylate bone cement (PMMA) bone cements, and bone filler devices.
223619165|NCT00044473|DRUG|levofloxacin|
223619166|NCT03232866|OTHER|Pilates exercise|Pilates methods exercises
223761493|NCT06908772|DRUG|Glumetinib Tablets|An ATP competitive, highly selective MET receptor tyrosine kinase inhibitor
223761494|NCT06908772|DRUG|Osimertinib Mesylate Tablets|3rd EGFR-TKI
224208276|NCT05823194|PROCEDURE|Fertility sparing surgery|Sparing the uterus and/or ovaries of the patients suffering from gynecologic malignancies to keep the patients' fertility
224208277|NCT03506776|DEVICE|Education and Thermometer Group|The education will be provided in video format utilizing the Canadian Association of Wound Care (CAWC) diabetic foot management YouTube video and one-on-one teaching. Participants will be provided with an inspection mirror with an extendable handle to assist with visualizing the bottom of the feet and a pedometer to measure daily activity. One-on-one teaching with the thermometer will be provided. Participants will be given a handout for reference on using the thermometer. The foot model will be marked with a zigzag pattern on the plantar surface to illustrate the path that should be used when measuring temperature. The support person will be included in the teaching if he/she will be assisting the participant to obtain temperature readings.
224208278|NCT03506776|OTHER|Education Only Group|The education will be provided in video format utilizing the Canadian Association of Wound Care (CAWC) diabetic foot management YouTube video and one-on-one teaching. Participants will be provided with an inspection mirror with an extendable handle to assist with visualizing the bottom of the feet and a pedometer to measure daily activity.
224208279|NCT01964391|DRUG|Trastuzumab|Trastuzumab will be administered subcutaneously at a fixed dose of 600 mg (irrespective of body weight) every 3 weeks for 1 year (adjuvant or neo-adjuvant plus adjuvant therapy).
224208280|NCT01964391|DRUG|Doxorubicin|Doxorubicin will be administered in combination with trastuzumab and cyclophosphamide in the adjuvant setting as per local Product Information and the investigator's discretion.
223619167|NCT02779647|BEHAVIORAL|The intervention consisted of physical activity based on play|The intervention consisted of physical activity based on play, with four 90-minute sessions per week for nine months (the school year). The total of sessions was 144, the minimum number of sessions to consider valid that a child has completed the intervention was 115 (80%) in order to perform the minimum level of physical activity recommended for their ages. In parallel, twice-monthly theoretical and practical sessions of nutritional advice were given to the children and their families. The study group performed the physical activity and received the nutritional advice, while the control group received only the theoretical and practical sessions on nutrition.
223619168|NCT06154356|OTHER|Action observation and motor imagery therapy for rehabilitation|"Action observation; Patients will watch some exercises accompanied by music from a previously prepared video for 10 minutes. Exercises include 8-10 repetitions of abduction-adduction, horizontal abduction-adduction, flexion-extension and supination-pronation movements for the upper extremity, and stepping, forward-backward stepping, side stepping and ankle dorsiflexion movements for the lower extremity.~Motor imagery training; Patients will be asked to visualize the actions they watched in their minds for 10 minutes.~Then the patients will watch the video again and will be asked to perform the exercises while watching."
223619169|NCT06154356|OTHER|Sham action observation and motor imagery therapy for rehabilitation|"Sham action observation; Patients will watch a video consisting of static nature photographs for 10 minutes with the same music.~Sham motor imaginary; Patients will think about the video they watched for 10 minutes.~Then, they will watch another video in which the exercises are performed only once, and they will be asked to do the exercises. They will be given enough time to do 8-10 repetitions."
223619170|NCT04221646|DEVICE|BTL-899|Treatment with study device.
223619171|NCT02485704|DRUG|spinosad topical suspension, 0.9%|Topically apply 0.9% suspension up to 120 mL (enough to cover the body from the neck down to the soles of the feet). One application for six hours.
223761495|NCT06908772|DRUG|Glumetinib Tablets Placebo|Placebo
224208281|NCT01964391|DRUG|Cyclophosphamide|Cyclophosphamide will be administered in combination with trastuzumab and doxorubicin in the adjuvant setting as per local Product Information and the investigator's discretion.
224208282|NCT01964391|DRUG|Paclitaxel|Paclitaxel will be administered in combination with trastuzumab in the adjuvant setting as per local Product Information and the investigator's discretion.
224208283|NCT01964391|DRUG|Docetaxel|Docetaxel will be administered in combination with trastuzumab in the adjuvant setting as per local Product Information and the investigator's discretion.
224208284|NCT01964391|DRUG|Carboplatin|Carboplatin will be administered in combination with trastuzumab and docetaxel in the adjuvant setting as per local Product Information and the investigator's discretion.
224208285|NCT01964391|DRUG|Neo-adjuvant chemotherapy|Neo-adjuvant chemotherapy will be administered according to local guidelines in combination with trastuzumab in the neo-adjuvant setting. The study protocol does not mention any specific neo-adjuvant chemotherapy drug names.
224208286|NCT03779282|DRUG|Dexmedetomidine|see descriptions
224208287|NCT02617446|DRUG|Placebo|IV of matching saline solution
224208288|NCT02617446|DRUG|Istaroxime|IV infusion of 0.5 µg/kg/min or 1.0 µg/kg/min istaroxime
224208289|NCT02187939|OTHER|Summer science wellness program emphasizing health education pertaining to nutrition, physical activity, and healthy lifestyle.|The enhanced virtual world education (GROOVE+) will be compared to conventional approach (GROOVE). Each program is Monday-Friday, 9:30-3:30, for 3 weeks in the summer.
224208290|NCT03372772|DRUG|Levocarnitine|Levocarnitine syrup- Oral supplementation about 2000mg/ day for 8 weeks
224208291|NCT03671135|OTHER|TCA Intrastromal Inlay|Anterior surface of Bowmans Layer Corneal Optical Correction Inlay
224208292|NCT03030638|DRUG|Olodaterol|Drug
224208293|NCT03030638|DRUG|Indacaterol|Drug
224208294|NCT00380458|DEVICE|Coblation (radiofrequency-based device)|
224208295|NCT01904084|DEVICE|Volar locked plating|Operative treatment of distal radius fracture with volar locking plate
224208296|NCT01904084|DEVICE|Hoffman external fixator|Patients with distal radius fracture operated with Hoffman external fixator
224208297|NCT05015803|COMBINATION_PRODUCT|CBTi with Application|Participants randomized to this study arm will experience an attempted enhancement of standard video conferencing CBTi, that is facilitated with electronic device-based data and resources to the clinician. Noninvasive ambulatory worn and nearable devices deliver feedback of data to the clinician on an application interface. This information will be used to inform the therapeutic approach and to facilitate a living-space environment that is conducive to effective therapy.
224208298|NCT05015803|BEHAVIORAL|CBTi|Participants randomized to this study arm will experience standard CBTi that is delivered via video conferencing by a clinician, with some application interface use.
224208299|NCT05015803|BEHAVIORAL|Sleep Hygiene Education|Participants randomized to this study arm will experience sleep hygiene education and training, with some application interface use.
224208300|NCT03184376|DIETARY_SUPPLEMENT|Prebiotic oligofructose|Powder format
224208301|NCT03184376|DIETARY_SUPPLEMENT|Placebo maltodextrin|Powder format
224208302|NCT00301925|BIOLOGICAL|pegfilgrastim|
224208303|NCT00301925|DRUG|capecitabine|
224208304|NCT00301925|DRUG|cyclophosphamide|
224208305|NCT00301925|DRUG|epirubicin hydrochloride|
224208306|NCT00301925|DRUG|fluorouracil|
224208307|NCT00301925|DRUG|methotrexate|
224208308|NCT00301925|PROCEDURE|adjuvant therapy|
224208309|NCT04518475|DRUG|eltrombopag combining rituximab|"After enrollment,all subjects receive eltrombopag treatment,the initial dose of eltrombopag administration was an oral 75 mg once daily.Complete blood count including platelet count was done once a week.The dose of eltrombopag was adjusted according to the subject platelet count during the period from week 1 to week 24. If the platelet count \>250×10\^9/L, the eltrombopag will stop until the platelet count \<30×10\^9/L.~All subjects receive single dose infusion of rituximab 375 mg/m(2) within 14 days after enrollment.~Efficacy and safety will be evaluated at Week 4, Week 8, and Week 12."
224208310|NCT04518475|DRUG|eltrombopag|"After enrollment,all subjects receive eltrombopag treatment,the initial dose of eltrombopag administration was an oral 75 mg once daily.Complete blood count including platelet count was done once a week.The dose of eltrombopag was adjusted according to the subject platelet count during the period from week 1 to week 24. If the platelet count \>250×10\^9/L, the eltrombopag will stop until the platelet count \<30×10\^9/L.~Efficacy and safety will be evaluated at Week 4, Week 8, and Week 12."
224208311|NCT01132170|DRUG|Divalproex Sodium|Divalproex Sodium DR Tablets 500 mg
224208312|NCT01556490|DEVICE|TheraSphere|Yttrium 90 microspheres
224315532|NCT01261923|DRUG|Alitretinoin|30 mg capsule of 9-cis-retinoic-acid (9-cis-RA)(Alitretinoin, Toctino®)
224208313|NCT00216424|DRUG|Capecitabine (Xeloda)|
224208314|NCT05228990|DEVICE|warm acupunctrue|"The sterile acupuncture needle (0.3mm×40mm) is taken, and the acupuncture needle is vertically inserted into the corresponding depth of the acupoint. After the needle is transported to get qi, moxibustion will be added at acupoints. The moxibustion distance is about 3cm from the skin, and the local temperature is warm and the patient felt comfortable with the skin. Replace it after burning out. During the acupuncture treatment, in order to avoid burns, it is necessary to strictly control the distance between moxibustion and skin. In the supine position, cardboard should be placed between moxibustion and skin to prevent burns, and ashes should be removed after moxibustion is completely burned. The needle is left for 20 minutes."
224208315|NCT06047249|BEHAVIORAL|KAP Popular Science Research|By conducting a survey questionnaire, investigate the knowledge, attitude, and practice tendencies of patients and their caregivers towards a certain disease, and conduct relevant science popularization；Pre discharge satisfaction survey questionnaire
224208316|NCT06047249|BEHAVIORAL|No KAP Popular Science Research|Pre discharge satisfaction survey questionnaire
224208317|NCT05535842|OTHER|GLOW|GLOW is an app for type 2 diabetes support and education that uses a conversational agent to help users develop self-management skills and learn about diabetes and healthy behaviours. This is achieved through a range of interactive strategies.
224208318|NCT05910450|DRUG|Clascoterone 5% solution|Topical application of 1.5 ml of clascoterone solution 5%, twice a day, to balding areas of the scalp (vertex and temples)
224208319|NCT05910450|DRUG|Vehicle solution|Topical application of 1.5 ml of vehicle, twice a day, to balding areas of the scalp (vertex and temples)
224208320|NCT03253666|OTHER|Nutrient Intake|Dietary nutrient intake (such as folate) and supplemental nutrient intake (such as folic acid)
224208321|NCT00530088|DRUG|porfimer sodium|IV
224208322|NCT00530088|DRUG|Photdynamic Therapy (PDT)|
224208323|NCT00902278|BIOLOGICAL|Flulaval|one 0.5-mL dose via intramuscular injection
224208324|NCT00902278|BIOLOGICAL|Fluvirin|one 0.5-mL dose via intramuscular injection
224208325|NCT00902278|BIOLOGICAL|Fluzone|one 0.5-mL dose via intramuscular injection
224208326|NCT00902278|BIOLOGICAL|Fluarix|one 0.5-mL dose via intramuscular injection
224208327|NCT00902278|BIOLOGICAL|Afluria|one 0.5-mL dose via intramuscular injection
224208328|NCT05954611|BIOLOGICAL|GR2002 injection|one single dose of GR2002 injection
224208329|NCT05954611|BIOLOGICAL|Placebo|one single dose of placebo
224208330|NCT06312761|DRUG|Relugolix 120Mg Tab|Relugolix 120 mg single dose - All subjects
224208331|NCT06312761|DIETARY_SUPPLEMENT|Curcumin|Curcumin 630 mg single dose
224208332|NCT06312761|DRUG|Testosterone Undecanoate 237 MG Oral Capsule|Testosterone Undecanoate 237 MG Oral Capsule
224208333|NCT05810961|BIOLOGICAL|efgartigimod IV|infusion of efgartigimod
224208334|NCT05810961|OTHER|placebo|infusion of placebo
224315533|NCT01027338|OTHER|Tai chi exercise|
223619172|NCT02485704|OTHER|Placebo|Placebo is the same as the drug minus the active ingredient spinosad (vehicle). Topically apply up to 120 mL (enough to cover the body from the neck down to the soles of the feet). One application for six hours.
223619173|NCT02187068|DRUG|Dexmedetomidine|Dexmedetomidine administered intravenously
223619174|NCT01777776|DRUG|LEE011|LEE011 will be administered orally, once daily for 21 consecutive days followed by a 7-day planned break (28-day cycle).
224208335|NCT01741428|BEHAVIORAL|Intervention (INT1)|"The course Program at the Feiring Heart Clinic will:~Clinical examination and ergospirometric testing, optimizing both treatment and prophylactic medication. Promoting physical Activity, changes in lifestyle, dietary changes/weight reduction, smoking cessation. In the follow-up period the participants will be contacted and report regularly through a web-based secure program (MedAxess)(such as: Activity-, dietary- and smoking habits). Each participant will have their own Mentor, helping keeping up the motivation. They will also meet regularly at the local doctors Office which reports relevant parameters to the Project (such as weight, BP, Lipoproteins, blood glucose/HbA1C)"
224208336|NCT05121688|OTHER|Physiotherapy|A Tele-face-to-face multimodal physical therapy program based on health education, respiratory exercises, physical training exercises, aerobic exercises and functional mobility.
224208337|NCT01691261|BIOLOGICAL|PF-05206388|PF-05206388 will be provided as a Retinal Pigment Epithelium living tissue equivalent for intraocular use in the form of a monolayer of Retinal Pigmented Epithelial (RPE) cells immobilized on a polyester membrane. The membrane is approximately 6 mm x 3 mm and will contain a confluent layer of RPE cells, at a nominal dose of 17 mm2. The implant is intended to be life-long.
224208338|NCT04439097|OTHER|Multicomponent physical exercise program associated with a Mediterranean diet|"In this basic structure of each sessions, traditional exercises of mobility, strength, balance and coordination are included with the main objective of improving functional capacities. But, besides, games and some activities are also included with the aim, not only of improving the functional capacity, but also working the cognitive functions to reinforce the global effects.~The Mediterranean diet will based in these main foods: 1) vegetables; 2) fruits; 3) fish or seafood; 4) legumes; 5) nuts; 6) bread or cereals; 7) white meat; 8) eggs; and 9)olive oil."
224208339|NCT04439097|OTHER|Usual care|Usual care and participants continue with their life normally, without participating in a standardized exercise program, and they will be instructed to maintain their current physical activity level.
224208340|NCT04028297|OTHER|Focus cardiac ultrasound (FoCUS)|
224208341|NCT04419428|DEVICE|BiPAP A40 Expiratory Flow Limitation (EFL)|All participants in the observational registry will be using the BiPAP A40 EFL noninvasive ventilator as part of standard of care and will be participating in the same follows up and data collection. The BiPAP A-40 EFL ventilator is intended to provide non-invasive ventilatory support to treat adult patients with Respiratory Insufficiency with the primary cause being COPD. It is intended to be used within the home, institution/hospital, and diagnostic laboratory environments.
224208342|NCT04534387|OTHER|Spanish-Language Hearing Loss Toolkit for Self-Management|The materials include printed information and images designed to increase hearing loss knowledge and focus on self-management topics such as the fundamentals of the ear and hearing, communication strategies, speech understanding in noise, and hearing technology.
224208343|NCT04534387|OTHER|American Speech-Language-Hearing Association (ASHA) Audiology Series Spanish Language Handouts|Standard of care patient education handouts developed by ASHA in the Spanish language.
224208344|NCT00197561|DIETARY_SUPPLEMENT|Placebo|Taken orally once per day from randomization through delivery and through the first 6 months after delivery.
224208345|NCT00197561|DIETARY_SUPPLEMENT|Selenium|200 ug of selenomethionine taken orally once per day from randomization through delivery and for the first 6 months after delivery
224208346|NCT02343497|DIETARY_SUPPLEMENT|Astaxanthin|
224208347|NCT02343497|DIETARY_SUPPLEMENT|Placebo|
224208348|NCT05290805|DIAGNOSTIC_TEST|ECMO flow rate reduction|ECMO flow rate is reduced for the duration of CT image acquisition (max. 1-2 min.), if the hemodynamic and respiratory situation allows it. Feasibility is determined by the accompanying emergency physician right before the CT scan and adapted to the individually tolerable level (max. 50% of initial flow, no less than 1,5 litre/min). After image acquisition, ECMO flow rate is immediately returned to the initial or clinically optimal value at this moment.
224208349|NCT06496711|OTHER|Cancer Patients; Institutions and their employees in the treatment and/or counseling of cancer patients|The study population will be surveyed at 3 yearly measurement time points by means of questionnaires and interviews on attitudes, barrier and support factors for participation in exercise therapy.
224208350|NCT06567990|DIAGNOSTIC_TEST|Non-invasive test for the screening of MASLD-related advanced fibrosis in patients with T2D.|"* Non-invasive blood biological tests = NAFLD Fibrosis Score, FIB-4 score, FNI score, Agile3+ score, FASTscore, ELF, Fibrotest, Fibrometer if performed in clinical care~* Non-invasive imaging = Transient elastography (FibroScan), Questionnaire assessing alcohol consumption"
224208351|NCT04093479|OTHER|blood samples|blood samples will be taken repeatedly
224208352|NCT02542722|BEHAVIORAL|Control|General recommendations about a healthy diet and physical activity and referral to their general physician with a report of the study results in the event of detecting any risk factor or pathological finding
224208353|NCT02542722|BEHAVIORAL|Intensive Intervention|Based on office visits each 3 months during the first year, as well as monthly telephone calls during the first year. Each subject will also attend a group educational meeting each 6 months. At each visit they will be given a series of recommendations and their degree of adherence evaluated and the evolution of their weight checked. The recommendations are designed to re-educate the subjects concerning their dietary and physical activity habits
224208354|NCT03857139|DRUG|Nicotine patch|Participants will receive the transdermal nicotine patch (TNP) to use during the first 2 weeks post-quit. We chose the TNP because of the extensive empirical literature supporting its effectiveness and safety, ease of use, and relatively benign side effect profile. Anxiety and depressive symptoms predict poor smoking cessation outcomes among individuals receiving NRT , suggesting that emotional disturbance influences relapse even in the context of NRT.
224208355|NCT04529096|DRUG|LY3016859|Administered IV
224208356|NCT04529096|DRUG|Placebo|Administered IV
224208357|NCT02615197|BEHAVIORAL|Dialectical Behavior Therapy|Includes all components of standard DBT (individual therapy, group skills training, phone coaching, and therapist consultation team).
223619175|NCT01777776|DRUG|LGX818|LGX818 will be administered orally, once daily on a continuous dosing schedule (28-day cycle).
223619176|NCT06225687|OTHER|Heat Application|The researcher will conduct daily measurements of gastric residual volume (GRV) and abdominal circumference, listen to bowel sounds, and assess distension from the first day of enteral nutrition initiation. Additionally, they will record the frequency of vomiting/defecation. Subsequently, a 15-minute hot application will be applied to the abdominal/lumbar region.
224208358|NCT02615197|BEHAVIORAL|Dialectical Behavior Therapy Prolonged Exposure protocol|Includes an adapted version of Prolonged Exposure therapy for PTSD.
224208359|NCT04663711|BEHAVIORAL|degree of adherence of pre-anesthetic tests at kasr Alaini hospital to the NICE-Uk guidelines|"The anesthesiologist, whom is in charge of preoperative assessment at each unit, will assess patients who are scheduled for elective surgery, and will inform senior anesthesiologists with a minimum 3 years of experience.~preoperative investigations will be divided into: First part will be on patient's gender, ASA classification, medical history and examination.~Second part will be on Grade of surgery - Minor/ Intermediate/ Major or complex.~Third part is requested investigation(s), its rationale, the hierarchy of anesthesiologist requested, and the planned date for surgery.~Fourth part is about whether that investigation(s) is adherent with NICE-UK guidelines or not."
223619177|NCT05065151|OTHER|Stimulation on|Stimulation from Percept DBS will be on while the patient is playing a decision-making game on a computer-based application.
224208360|NCT04769908|DRUG|Systemic Chemotherapy|Systemic Chemotherapy (Oxaliplatin#5-fluorouracil and leucovorin)
224208361|NCT04769908|DRUG|Lenvatinib|Lenvatinib, 8mg or 12mg, po, QD
224208362|NCT04769908|DRUG|Sintilimab|Sintilimab, IV, 200mg, q3w
224208363|NCT00000510|DRUG|aspirin|
224208364|NCT00000510|DRUG|dipyridamole|
224208365|NCT00000510|PROCEDURE|angioplasty, transluminal, percutaneous coronary|
224208366|NCT05174559|OTHER|PreKUnil® LNAA Medical Food for PKU|PreKUnil® LNAA Medical Food for PKU is a commercially available active LNAA treatment product for PKU. PreKUnil® inactive LNAA is a customized placebo for this research.
224208367|NCT00567346|DRUG|Oralgen|Patients will receive drops of grass pollen immunotherapy sublingually
224208368|NCT00567346|DRUG|grass pollen extract|Patients will receive matching placebo sublingually
224208369|NCT04359420|OTHER|BC-Predict|BC-Predict is an automated system for offering an assessment of breast cancer risk to women when they receive their NHS Breast Screening Programme invitation, and generating letters to feedback this risk to women and relevant healthcare professionals. Women at higher risk are offered chemoprevention drugs and additional mammography
224208370|NCT04359420|OTHER|NHS Breast Screening Programme|usual care from NHS Breast Screening Programme, consisting of mammography every three years for most women.
224208371|NCT03087929|OTHER|Follow up|
224208372|NCT05766761|BEHAVIORAL|Intervention condition, the usual prenatal care plus the alcohol intervention|The intervention is theory-driven, based on Motivational Enhancement Theory (MET), and uses motivational strategies to promote alcohol reduction.
224208373|NCT04265456|DRUG|Pregabalin 100mg|Pregabalin is a structural derivative of the inhibitory neurotransmitter gamma aminobutyric acid with anticonvulsant, anxiolytic and sleep-modulating properties.
224208374|NCT04265456|DRUG|Acetaminophen 1300mg|Acetaminophen is a non-salicylate antipyretic and non-opioid analgesic agent.
224208375|NCT04234373|OTHER|Low Carb diet|Low Carb diet (max. 130g carbohydrates/d) for 6 months
224208376|NCT02684669|DRUG|Naloxone|active drug infusion
224208377|NCT02684669|DRUG|Normal saline|placebo comparator
224208378|NCT03178019|OTHER|Laser-Doppler methods|This was a cross-sectional study in which participants were subjected to a screening phase before being eligible to participate in the study. All subjects were submitted to Laser-Doppler methods (assessment of microcirculatory blood flow), bioimpedance analysis (assessment of body composition), venous blood collections (laboratory analysis), and Finometer Pro (assessment of heart rate variability and blood pressure variability).
224208379|NCT02199834|BEHAVIORAL|Peer support|15 patients who have good glycemic control and self-care will be trained as peer supporters to deliver peer support under supervision by a program manager. Peer supporters will call their peers at least 12 times a year to provide both informational and emotional support.
224208380|NCT02199834|BEHAVIORAL|Personalized feedback report|Patients will receive a personalized feedback report displaying trends of metabolic control of A1c, BP, LDL-C, and body weight, with automated decision support based on their own attained values every 4 months through mails.
224208381|NCT02494310|DEVICE|High-Resolution Microendoscopy Imaging|Innovative technique to evaluate epithelial cell morphology in situ. The device is not invasive and does not exchange energy with human body.
224208382|NCT06373419|DEVICE|TFL|Participant undergoing bladder tumour resection that has been randomized to this arm.
224208383|NCT06373419|DEVICE|MOSES holmium laser|Participant undergoing bladder tumour resection that has been randomized to this arm.
224208384|NCT02674074|DEVICE|infrared thermography|measurement of corneal temperature by infrared thermography before and after cold provocation
224208385|NCT06545526|DRUG|celecoxib monotherapy|Patients will be randomly assigned in a 1:1 ratio to receive celecoxib monotherapy or combination of celecoxib and metformin orally for 6 months: celecoxib \[400mg, twice a day\] in arm 1, celecoxib \[400mg, twice a day\] and metformin \[1g, twice a day\] in arm 2.
224208386|NCT06545526|DRUG|celecoxib and metformin combination|Patients will be randomly assigned in a 1:1 ratio to receive celecoxib monotherapy or combination of celecoxib and metformin orally for 6 months: celecoxib \[400mg, twice a day\] in arm 1, celecoxib \[400mg, twice a day\] and metformin \[1g, twice a day\] in arm 2.
224208387|NCT05235737|DRUG|Pembrolizumab|Adding Pembrolizumab as a neoadjuvant and adjuvant therapy to the standard of care protocol
224208388|NCT05235737|DRUG|Pembrolizumab|Adding Pembrolizumab as a neoadjuvant therapy to the standard of care protocol
223619178|NCT05065151|OTHER|Stimulation off|Stimulation from Percept DBS will be off while the patient is playing a decision-making game on a computer-based application.
223619179|NCT05065151|BEHAVIORAL|Decision Making Task|Patients will be playing a decision making task through a computer-based application.
223619180|NCT02806453|DIETARY_SUPPLEMENT|thickened formula|
223619181|NCT02806453|DIETARY_SUPPLEMENT|Mg alginate|
224208389|NCT05085197|DRUG|STSA-1005 injection|Intravenous injection
224208390|NCT05085197|DRUG|Placebo|Intravenous injection
223619182|NCT02806453|BEHAVIORAL|reassurance with lifestyle changes|
224208391|NCT05085197|DRUG|STSA-1005 injection|Intravenous injection
224315534|NCT03071939|OTHER|Assessment of the insight of schizophrenic patients by themselves, their relatives and caregivers|"This study will evaluate the insight of the patient, something carried out in common practice within the Eastern Pole (CH Le Vinatier). This assessment will take place in the specific services where patients are cared for. It will make it possible to evaluate insight more closely by comparing the opinions of the three actors. There is no risk in this study.~The study will be carried out over 2 years with a recruitment of 119 patients responding to the diagnosis of schizophrenia, taken care of within the Eastern Pole (Intra and Extrahospital services)."
224315535|NCT03521843|DEVICE|balloon dilation only|The balloon dilation only will be used to treat the femoropopliteal in-stent restenosis.
224315536|NCT03521843|DEVICE|balloon dilation+local drug delivery|The balloon dilation and local drug delivery will be used to treat the femoropopliteal in-stent restenosis.
224208392|NCT05085197|DRUG|Placebo|Intravenous injection
224208393|NCT05085197|DRUG|STSA-1005 injection|Intravenous injection
224208394|NCT05085197|DRUG|Placebo|Intravenous injection
224208395|NCT05085197|DRUG|STSA-1005 injection|Intravenous injection
224208396|NCT05085197|DRUG|Placebo|Intravenous injection
224208397|NCT04089163|BIOLOGICAL|Toca 511|Toca 511 consists of a purified retroviral replicating vector encoding a modified yeast cytosine deaminase (CD) gene. The CD gene converts the antifungal drug, flucytosine (5-fluorocytosine; 5-FC) to the anticancer drug 5-fluorouracil (5-FU) in cancer cells that have been infected by the Toca 511 vector.
224208398|NCT04089163|DRUG|Toca FC (extended-release formulation of flucytosine)|Toca FC is an extended-release formulation of flucytosine and is supplied as 500 mg tablets
224208399|NCT06272448|OTHER|Telerehabilitation|The subjects will be instructed to login with own credentials to a telerehabilitation platform where a library of videoclips displaying as many different motor activities, grouped by difficulty and function domain (trunk alignment, balance, hand dexterity, speech articulation, ventilation…), will be available. Patients will perform the exercises, according to a pre-determined training protocol, observing and imitating the tasks presented by the videoclips, for a total 45 minutes/day, at least 3 times/week (for no less than 27 sessions in total, equal to 1200 minutes of training). Subjects will be given a smartwatch to be worn 24 hours/ day, for at least 5 days/week. Every 15 +/- 3 days, one physiotherapist will call the patients to check the correct use of the devices, the level of adherence to the exercise program and the need for shaping the training difficulty to the user's skills
224208400|NCT05958238|DEVICE|AR/VR oral care training system|Students simulated the treatment of the elderly with different physical and oral conditions using virtual situations and employed suitable oral care methods depending on each situation through VR. They learned the Bass brushing technique, the interdental brush cleaning method, and the soft tissue cleaning method through AR.
224208401|NCT05958238|OTHER|Traditional classroom teaching|The well-trained oral hygienist provided traditional oral care instruction with the same teaching content in the AR/VR-based training system.
224208402|NCT06290739|PROCEDURE|lymph nodes dissection|Whether lymph nodes dissection should be performed on curative-intent hepatectomy for intrahepatic cholangiocarcinoma is still debated.
224208403|NCT04114578|OTHER|Echocardiography|Echocardiography has become routinely used in the diagnosis, management, and follow-up of patients with any suspected or known heart diseases. It is one of the most widely used diagnostic tests in cardiology. It can provide a wealth of helpful information, including the size and shape of the heart (internal chamber size quantification), pumping capacity, and the location and extent of any tissue damage. An echocardiogram can also give physicians other estimates of heart function, such as a calculation of the cardiac output, ejection fraction, and diastolic function (how well the heart relaxes). The acquisition usually takes about 30 minutes.
224208404|NCT03474640|BIOLOGICAL|Part A|Part A: 80, 240, and 480 mg IV every 14 days.
224208405|NCT03474640|BIOLOGICAL|Part B|Part B: 240 mg IV every 3 weeks
224208406|NCT06389968|DEVICE|Light stimulation|see arm description
224208407|NCT06389968|DEVICE|Sham light stimulation|see arm description
224208408|NCT06110338|DRUG|placebo|placebo iv. once.
224208409|NCT06110338|DRUG|IBI355|IBI355 iv. once.
224208410|NCT05198349|DRUG|M1069|Participants received escalated oral dose of M1069, twice daily (BID) until disease progression, unacceptable toxicity, withdrawal of consent, or any criterion for withdrawal from study intervention.
223619183|NCT01524146|PROCEDURE|Photodynamic Therapy|"PDT is a therapeutic approach that specifically targets neoplastic cells.~• PDT involves three components:~1. Photofrin or a similar Photosensitizing agent that would be injected 3 days prior to laser activation of the agent.~2. Laser System - For laser energy delivery to activate the photosensitizing agent and induce tumor tissue necrosis~3. Optic Fiber - Delivery Fiber used along with the laser system to achieve Photoactivation of the photosensitizing agent.~Technique:~Subjects will be injected with Photofrin or similar drug. 3 days post injection, the subject will receive photodynamic therapy during an Endoscopic Retrograde cholangiopancreatography (ERCP) procedure. Subject will undergo stenting as part of standard of care procedure post photodynamic therapy.~Subject may undergo multiple photodynamic therapy sessions with a gap of at least 3 months."
224208411|NCT05120752|OTHER|FODMAP diet|all participants need to follow a low FODMAP diet, the information will be given by a trained dietitian
224208412|NCT06569680|DRUG|Mosunetuzumab|"Mosunetuzumab will be administered via subcutaneous (SC) injection using a step-up dosing model. Participants will receive Mosunetuzumab on days 1, 8, and 15 of Cycle 1, and on day 1 of Cycles 2 through 8 as follows:~* Cycle 1 Day 1: 5mg~* Cycle 1 Day 8: 45mg~* Cycle 1 Day 15: 45mg~* Cycles 2 through 8, Day 1: 45mg"
224208413|NCT04175691|GENETIC|Sequencing of circRNA/miRNA/lncRNA|Next generation sequencing of circular RNA (circRNA), micro-RNA (miRNA) and long non-coding RNA (lncRNA)
224208414|NCT06289959|DIAGNOSTIC_TEST|cfDNA|After achieving complete metabolic remission (Lugano response assessment criteria) following 6 cycles of R-CHOP-like chemotherapy, patients undergo plasma cfDNA testing upon enrollment，and the follow-up treatment plans are based on cfDNA results.
224208415|NCT04207359|DIETARY_SUPPLEMENT|Creatine|Those randomized to receive creatine (experimental group) will be initially dosed at 20 g/day for 7 days to boost availability of creatine systemically. Thereafter, the dose will be reduced to 5 g/day for maintenance through the duration of the 12-week protocol.
224315537|NCT05336032|OTHER|Food (rice)|Cooked rice with 75 gm carbohydrate
224208416|NCT03669952|OTHER|None intervention|No interventions are realized, only observational study
223619184|NCT06128577|COMBINATION_PRODUCT|3-month intensive intervention|"Intensive nutritional interventions were as follows: i）Estimation of ideal body weight according to height, calculation of calories by giving 30-40kcal/kg/day according to BMI stratification, and calculation of daily protein requirement at 1.5g/kg/day, which was finally converted into daily dietary recommendations according to the results of the calculations. ii）Distribution of additional protein supplementation by whey protein, each sachet containing 15g of whey protein.~The resistance training program included 5 min of warm-up, 20 min of muscle strength training, and 5 min of slow walking and was performed three times a week. Resistance training involved a dumbbell and sandbags as weights for the major muscles of the upper and lower limbs. In the study, aerobic training is brisk walking or jogging for 30 minutes/day, five times a week."
224208417|NCT06542354|BEHAVIORAL|Physical exercise|Physical exercises personally scheduled consisting of daily aerobic exercise(30mins) of fast walking(≥5km) and resisitance training.
224208418|NCT06542354|DIETARY_SUPPLEMENT|Nutrition supplement|Nutritional counselling is given to patients to ensure their daily proteins and energy requirements are met. Oral nutrition supplement (ENSURE) is provided daily seperated in 2 doses
224208419|NCT06542354|BEHAVIORAL|Mental support|Relaxation exercise and psychological counselling delivered by weekly telephone follow-up
224208420|NCT06565533|BEHAVIORAL|Retrogressive imagery (RETI)|"Week 1-2: Participants were asked to imagine a complete version of the FT imagery script included: a) Visualizing the court lines, the basket, and themselves standing at the free-throw line, focusing on their shooting technique. b) Imagining teammates and opponents positioned around the key, noting the main colors in the scene c) Imagining the coach standing on the sideline encouraging them, and paying attention to the sounds of the audience and the cheers from a close friend in the stands. d) Visualizing a high-pressure situation, experiencing the emotions felt during a real game with one second left on the clock, trailing by one point, with the game's outcome depending on their FT shot. Week 3-4: The exception of content dfrom the full script. Week 5-6: The exception of content cdfrom the full script. Week 7-8: The exception of content bcdfrom the full script."
224208421|NCT06565533|BEHAVIORAL|Virtual Reality (VR)|Standing on a lifelike full-sized basketball court, they observe smooth flooring and clear markings. Teammates and opponents don variously colored uniforms, while referees stand ready at the sidelines. Referees position teammates and opponents around the basket as participants feel the texture and weight of the basketball in their hands, as if gripping it for real. The sounds of cheering spectators and encouraging shouts from teammates and coaches further enhance their focus. Participants adjust their stance, noticing beads of sweat trickling down their arms as they prepare for the FT. With bent knees, they ready themselves for the shot, exerting every ounce of their strength as the ball leaves their hands and soars towards the basket. As the ball accurately swishes through the net, the crowd erupts into thunderous applause, and the scoreboard's change in score brings an overwhelming sense of joyous victory.
224208422|NCT00367601|DRUG|Erlotinib|Erlotinib 150 mg qd days 1-21
224208423|NCT00367601|DRUG|Bevacizumab|Bevacizumab 15 mg/kg IV, day 1
224208424|NCT02647632|DRUG|Grazoprevir/Elbasvir|
224208425|NCT02647632|DRUG|Sofosbuvir|
224208426|NCT02647632|DRUG|Ribavirin|
224208427|NCT00618800|BEHAVIORAL|Pharmaceutical Care|Participants receive written information about falls prevention and a personal consultation from a community pharmacist concerning their medication regimen. The pharmacist follows up, as required, with participants' physicians to coordinate any recommended medication changes.
224208428|NCT00618800|OTHER|Written Materials|Participants receive written information about falls prevention.
224208429|NCT06593366|BIOLOGICAL|Fecal Microbiota Transplant|An investigational biologic comprised of 15.0g of dried healthy donor stool contained within a size 00 gelatin capsule, to be taken twice per day, twice per week over an 8-week duration.
224208430|NCT06593366|DRUG|Placebo|Oral placebo capsules (OPC) containing methylcellulose, to be taken twice per day, twice per week over an 8-week duration.
224208431|NCT04980066|PROCEDURE|Sticky bone and EDTA|treatment using Sticky bone after EDTA root surface biomodification
224208432|NCT04980066|PROCEDURE|Sticky bone|treatment using Sticky bone
224208433|NCT03417674|COMBINATION_PRODUCT|Lifestyle intervention|Meal replacement by formula diet, exercise stimulation, and telemedicine coaching.
224208434|NCT06068088|BEHAVIORAL|Self-administered survey at hospital|Self-administered survey on the food practices of the patient Completion before the beginning of chemoradiotherapy
224208435|NCT06068088|BIOLOGICAL|Blood sample for nutritional assessment|15 ml of blood sampled during nutritional examination before the beginning and during the month following the end of chemoradiotherapy
224208436|NCT06068088|OTHER|Consultation with nutritionist doctor and dietician|Before the beginning and during the month following the end of chemoradiotherapy Consultation of approximatively one hour
224208437|NCT03985293|DRUG|Placebo|4 matching placebo tablets taken twice a day (BID)
224208438|NCT03985293|DRUG|PF-06882961|Participants will be randomized to one of 5 active doses (2.5, 10, 40, 80, or 120 mg), taking 4 tablets twice daily for 16 weeks.
224208439|NCT04483570|PROCEDURE|Redo-tethering operation|
224208440|NCT01064869|BEHAVIORAL|Pyscho-behavioural|"A nurse-led programme of intervention will be devised. Patients will attend weekly for a period of 12 weeks. It will have two stages incorporating:~1\. Structured interview to identify demographic information and individual reasons for non-adherence and assessment of readiness to change behaviour~This will be followed by an individualised package incorporating:~1. A structured asthma education programme, to address any gaps in asthma knowledge or requests for information~2. Motivational interviewing based on stages of change model to encourage change and adherence~3. Psychological therapy involving (a) relaxation therapy (b) cognitive behavioural techniques looking at negative and catastrophic thoughts and (c) panic cycle adapted to respiratory patients"
224208441|NCT06651398|BEHAVIORAL|Lenient diet|The interventional goup receives the lenient diet instructions and will eat a light meal until 18h on the day before the colonoscopy. The first dose of Plenvu will be started at 20h. All the other bowel preparation instructions will be the same as in the control group.
224208442|NCT05179434|PROCEDURE|Retrograde renal graft reperfusion|Retrograde venous reperfusion of the renal graft during the kidney transplant procedure with consequent arterial reperfusion
224315538|NCT04009707|OTHER|MoCA (Montreal Cognitive Assessment) test|the MoCA questionnaire is used to assess cognitive disorders
223619185|NCT00902460|DRUG|midazolam; CP-690,550 + midazolam|Period 1 : 2 mg midazolam oral syrup alone Period 2: 2 mg midazolam oral syrup plus 30 mg CP-690,550 after 6 days of CP-690,550 at 30 mg BID
223619186|NCT00902460|DRUG|CP-690,550 + midazolam; midazolam|Period 1: 2 mg midazolam oral syrup plus 30 mg CP-690,550 after 6 days of CP-690,550 at 30 mg BID Period 2: 2 mg midazolam oral syrup alone
223619187|NCT03488277|OTHER|leg elevation|intra operative position that consists in leg elevation with a 30 cm height pillow under the patient's heels
223619188|NCT04936633|OTHER|Intervention by medical staff based on a cloud system|"Remote intervention by medical staff (between Visit 1 and Visit 2; Week 2, 4, 6, 8, 10) : analyzing continuous glucose monitoring data for last two weeks in the cloud system~\- Intervention contents~1. Diet, exercise pattern~2. Causes of hypoglycemia~3. Causes of hyperglycemia~4. Causes of glycemic variability~5. Counseling for improvement plans for the cause~6. Counseling to strengthen lifestyle modification~7. Counseling for insulin administration~8. Counseling for Insulin dose adjustment (adjusted dose)~9. Counseling for how to use a FSGM"
223619189|NCT04776512|PROCEDURE|ESP Block With Bupivacain|bilateral lumbar ESP block using 0.375% Bupivacain
224315539|NCT04009707|OTHER|BEARNI (Brief Evaluation of Alcohol Related Neuropsychological Impairment) Test|This questionnaire is used to assess cognitive disorders
223619190|NCT04776512|PROCEDURE|Epidural Analgesia|Continuous Lumbar Epidural analgesia With 0,125% Bupivacain+0,25 mcg/ml Sufentanil
223619191|NCT05144139|BIOLOGICAL|COVID-19 mRNA vaccine|Intramuscular injection, COVID-19 mRNA vaccine/placebo, 21 days interval
223619192|NCT00727792|PROCEDURE|MRI -Clinical|MRI done is standard of care
223619193|NCT00727792|PROCEDURE|MRI-Research|MRI includes extra sequences
224208443|NCT05179434|PROCEDURE|Conventional antegrade renal graft reperfusion (without retrograde reperfusion)|Conventional arterial antegrade renal graft reperfusion during the kidney transplant procedure
224208444|NCT03790020|DRUG|Bupivacaine|In our study this local anesthetic agent will be applied for postoperative pain relief
224208445|NCT00458016|DRUG|MB07803|Daily oral administration
224208446|NCT00458016|DRUG|Placebo|Daily oral administration
224208447|NCT05410769|BEHAVIORAL|Compassion Focused Therapy|This pilot study aims to propose for the first time a Compassion protocol (Compassion Program for Parkinson) to a group of patients with PD and a group of caregivers and to evaluate its feasibility and effectiveness. The investigators aim to assess whether the program is effective in improving the quality of life and psychiatric symptoms of the patients and caregivers. The Compassion program is a healthy form of self- acceptance, which involves being touched by one's own suffering, along with the desire to alleviate it and treat oneself with understanding and kindness. The duration of the protocol will be 6 weeks (1 meeting/ week of 2 hours). The investigators will recruit 40 patients and 20 caregivers who will be assessed pre and post intervention (Compassionate Mind Training) with interviews, self reports and measurement of the heart rate variability.
224208448|NCT02804191|DRUG|LO2A|eye drop solution.
224208449|NCT02804191|DRUG|Saline|Placebo
224208450|NCT00629668|GENETIC|TNF-alpha and HBV genotype|
224208451|NCT00629668|OTHER|TNF-alpha and HBV genotypes|
224208452|NCT03757741|DIAGNOSTIC_TEST|Cardiac imaging tests|2D transthoracic echocardiography; Late gadolinium-enhancement cardiac magnetic resonance with the evaluation of pulmonary veins anatomy, atrial fibrosis, atrial volumes and the amount of epicardial fat will
224208453|NCT03757741|DIAGNOSTIC_TEST|Venous blood samle collection|Venous blood sample collection 1 day prior to the ablation procedure: Serum levels of high sensitive C Reactive Protein, Matrix metalloproteases, Interleukin-6, and N-Terminal Pro-B-Type Natriuretic Peptide.
224208454|NCT02810496|GENETIC|blood collection for mutation characterization|
224208455|NCT03393312|DEVICE|Transcranial direct current stimulation (tDCS)|Electric current
224208456|NCT05923541|DRUG|RD13-02 cell infusion|Universal CAR-T cells targeting CD7
224208457|NCT04288323|DRUG|Gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid|This study involves an on-label use of Gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid for the ....
224208458|NCT02988310|OTHER|No intervention|
224208459|NCT04269031|DRUG|AZD2373 subcutaneous injection|Randomised subjects will receive a single ascending dose of AZD2373 by SC injection (dose 1, dose 2, dose 3, dose 4, dose 5 and dose 6).
224208460|NCT04269031|DRUG|Placebo|Randomised subjects will receive a single ascending dose of placebo (saline solution) by SC injection.
224208461|NCT00390572|BEHAVIORAL|Sleep Specialty Consultation|The Sleep Specialty Consultation (SSC) consisted of: (1) a thorough sleep disorders evaluation accomplished via a clinician-administered structured interview designed to assess specific symptoms of global sleep disorder categories, review of a sleep history questionnaire, and review of available (CPRS) medical/psychiatric electronic records; (2) education about the specific sleep disorders diagnoses and relevant treatment recommendations provided to the patients; and (3) standardized diagnostic information and treatment recommendations provided to the participants' primary care providers.
224208462|NCT05405478|DRUG|Omalizumab|subcutaneous injection every 2 or 4 weeks, depending on the pretreatment serum total IgE level and body weight
224208463|NCT05405478|DIAGNOSTIC_TEST|SNOT22 score|score will measure at screening; on day 1; and at weeks 4, 8, 16, and 24 (point range, 0-110)
224208464|NCT03534830|DIAGNOSTIC_TEST|MRI|pre-operative MRI to be performed on all patients and then based on the imaging studies, the patient will be divided into the two comparative cohorts
223619194|NCT03522792|OTHER|Neurotensin|Intravenous infusion of neurotensin
223619195|NCT03522792|OTHER|Saline|Intravenous infusion of saline
223619196|NCT03522792|OTHER|Ad libitum meal|Participants will be served a large meal serving. They will be instructed to eat until they do not feel hungry anymore.
223619197|NCT03522792|OTHER|Liquid meal|A standardized mixed liquid meal will be ingested to stimulate endogenous peptide hormone release
223619198|NCT05309148|BEHAVIORAL|Training on eye tracker based device|The intervention is based on the principle of visual biofeedback. The patient sees where his gaze is and can objectively assess and correct his visual error.
224208465|NCT00711165|DRUG|Placebo|2 puffs, qd
224208466|NCT00711165|DRUG|Mometasone Furoate|400 mcg, qd for 8 weeks
224208467|NCT05359341|DRUG|Sitagliptin 50 mg|Adding on sitagliptin to uncontrolled T2D Egyptian patients who are not controlled with diet, exercise and metformin with or without other OADs for 12 weeks.
224208468|NCT05359341|DRUG|Empagliflozin 12.5 MG|Adding on empagliflozin to uncontrolled T2D Egyptian patients who are not controlled with diet, exercise and metformin with or without other OADs for 12 weeks.
224208469|NCT05359341|DRUG|Sitagliptin 50 mg + Empagliflozin 12.5 MG|Adding on another 12 weeks of therapy of empagliflozin to sitagliptin 50mg group not well controlled (HbA1c 7-10%)
224208470|NCT05359341|DRUG|Empagliflozin 12.5 MG + Sitagliptin 50 mg|Adding on another 12 weeks of therapy of sitagliptin 50mg to empagliflozin group not well controlled (HbA1c 7-10%)
224208471|NCT04236635|DRUG|Collagenase Clostridium Histolyticum Single Injection Technique|CCH was injected subcutaneously using a single injection technique. Dose per each administration was 0.07 mg.
224208472|NCT04236635|DRUG|Collagenase Clostridium Histolyticum Multiple Injection Technique|CCH was injected subcutaneously using a multiple injection technique. Dose per each administration was 0.0653 mg.
224208473|NCT05576285|DIAGNOSTIC_TEST|ophthalmoscopy and fundus photography through dilated pupills|ophthalmoscopy and fundus photography through dilated pupills
224208474|NCT01242332|DRUG|Pregabalin|75 mg po 2 hrs before surgery
224208475|NCT02684526|PROCEDURE|Eovist Contrast|Subjects will undergo an MRI (magnetic resonance imaging) scan using the Eovist contrast agent. This MRI scan takes approximately 45minutes to 1 hour to complete.
224208476|NCT02684526|PROCEDURE|Non Eovist Contrast|Subjects will undergo an MRI (magnetic resonance imaging) scan using a contrast agent other than Eovist. This MRI scan takes approximately 45minutes to 1 hour to complete.
224208477|NCT02704299|BIOLOGICAL|Autologous T cells-Based Immunotherapy|TCM cells are the subpopulation of T lymphocytes with key characteristics including high potency and long-term memory of specific immunity.
224208478|NCT02383537|OTHER|Diabetes|the trial is observational with no intervention
224208479|NCT03603925|DIAGNOSTIC_TEST|Positron Emission Test / Magnetic Resonance (PET/MR)|The Philips Ingenuity PET/MR is used for research scanning. Patients receiving a clinically indicated PET/CT, will be approached to be included in this study. There is no special preparation other than that needed for the prerequisite PET/CT scanning. At the completion of the PET/CT scanning, the subject will be taken to the PET/MR scanner, which is in close in proximity, for research scanning. The research scanning would take up to one hour or as tolerated.
224208480|NCT03603925|DIAGNOSTIC_TEST|Positron Emission Test / Computed Tomography (PET/CT)|Patients will receive PET / CT imaging for the detection of cancer or other clinically indicated anomalies. The completed study visit is expected to take approximately 2 hours and not longer than 3 hours.
224208481|NCT00823875|DRUG|Cilostazol group|Cilostazol: At first, 50 mg (1 tablets) Bid, PO after breakfast and dinner. After administration of study drug for 1 week, and if patient has no significant discomfort, the drug dosage will increase to 100mg（2 tablets）Bid.
224208482|NCT00823875|DRUG|Probucol group|Probucol: 250 mg (1 tablet) Bid, PO after breakfast and dinner
224208483|NCT00823875|DRUG|Cilostazol + Probucol group|"Cilostazol: At first, 50 mg (1 tablets) Bid, PO after breakfast and dinner. After administration of study drug for 1 week, and if patient has no significant discomfort, the drug dosage will increase to 100mg（2 tablets）Bid.~Probucol: 250 mg (1 tablet) Bid, PO after breakfast and dinner"
224208484|NCT00823875|DRUG|control group|routine treatment
224208485|NCT06271109|PROCEDURE|Anatomical laparoscopic liver resection for liver neoplasms|resection of liver tumors laparoscopically based on surgical anatomical segmentation of the liver
224208486|NCT06271109|PROCEDURE|Non-Anatomical laparoscopic liver resection for liver neoplasms|resection of liver tumors laparoscopically not based on surgical anatomical segmentation of the liver
224208487|NCT01350609|DRUG|Nifedipine/Candesartan (BAY 98-7106)|Fixed dose combination of 60 mg nifedipine + 32 mg candesartan (1 tablet in one period)
224208488|NCT01350609|DRUG|Nifedipine (Adalat, BAY A1040) and Candesartan (Atacand, BAY 12-9333)|Loose combination of 1 tablet nifedpipine 60mg (Adalat LA) and 2 tablets candesartan 16mg (Atacand) (3 tablets in one period) .
224208489|NCT02317094|OTHER|Blood-flow restricted training|The intervention consists of low-intensity blood-flow restricted training involving 5 lower extremity exercises performed uni lateral in four sets to concentric failure with an intensity of approximately 25 repetition maximum (25RM).
224208490|NCT02317094|DRUG|Care as usual|The intervention consists of various DMARDs, which are given to the patients depending on their physical state and the disease activity.
224208491|NCT00000891|DRUG|Ritonavir|
224208492|NCT00000891|DRUG|Saquinavir|
224208493|NCT00000891|DRUG|Delavirdine mesylate|
224208494|NCT00000891|DRUG|Lamivudine|
224315540|NCT01307111|DRUG|Misoprostol|400 micrograms inserted buccally or vaginally, per the participants desire prior to the IUD insertion.
224315541|NCT01307111|DRUG|Placebo|Pills which are identical to the study drug in appearance, taste, and smell.
223680415|NCT01230125|DRUG|Vehicle|Instill study medication into the study eye per dosing instructions for 14 days
223680416|NCT00936091|DRUG|vitamin A supplements|gelatinous and reddish opaque capsules containing 200 000 IU vitamin A
223680417|NCT00936091|DRUG|Placebo|125 children received placebo capsules
223680418|NCT00736047|BIOLOGICAL|NIC002|
223680419|NCT00736047|BIOLOGICAL|Placebo|
223680420|NCT04388371|DRUG|Glutamine|Glutamine will be administered by IV injection prior to PET imaging.
223680421|NCT04080271|DEVICE|18F-FDG PET/CT|18F-fludeoxyglucose positron emission tomography/computed tomography
223680422|NCT00814216|DRUG|QAV680|
223680423|NCT00814216|DRUG|Matching placebo for QAV680|
224208495|NCT00000891|DRUG|Stavudine|
224208496|NCT00000891|DRUG|Zidovudine|
224208497|NCT00000891|DRUG|Didanosine|
224208498|NCT02026986|BEHAVIORAL|sleep deprivation|sleep deprivation for one night
224208499|NCT02604238|DRUG|Alteplase|Enoxaparin (1mg) 100UI aXa/kg/sc \[LMWH\], 15 -30 minutes prior to administration of intravenous (iv) bolus loading dose of 10 mg in 1 min, followed by iv infusion of 40 mg within two hours (for patients weighing \<50 kg, a loading dose of bolus of 0.5 mg in 1 min, followed by iv infusion of 40 mg in two hours); the infusion will be adjusted to maintain the value of aPTT between 50-70 seconds (1.5 to 2.5 times the reference value).
224315542|NCT02265926|DEVICE|N95 mask|N95 mask material used to cover aperture of Hans Rudolph mask
224315543|NCT02090166|OTHER|Blood test|a blood test will be taken from each patient
224208500|NCT03791515|DRUG|Calcitonin Gene-Related Peptide|"A randomized clinical trial with a double-blinded, randomized, placebo-controlled crossover design. 30 PPTH patients will be included. All participants will receive continuous intravenous infusion of 1.5 µg/min CGRP over 20 min.~The following variables will be recorded before, during and after infusion (every 10 min over 60 min): headache intensity on a verbal rating scale from 0 to 10 and headache characteristics. At 90 min, participants will be discharged and instructed to fill out a headache diary for 24 hours from start of infusion."
224208501|NCT03791515|DRUG|Placebo|"A randomized clinical trial with a double-blinded, randomized, placebo-controlled crossover design. 30 PPTH patients will be included. All participants will receive continuous intravenous infusion of 40 mL placebo (isotonic saline) over 20 min.~The following variables will be recorded before, during and after infusion (every 10 min over 60 min): headache intensity on a verbal rating scale from 0 to 10 and headache characteristics. At 90 min, participants will be discharged and instructed to fill out a headache diary for 24 hours from start of infusion."
224208502|NCT06386471|OTHER|Whole grain rye bread|Single consumption of 4.3 oz of whole grain rye bread
224208503|NCT06386471|OTHER|Refined grain rye bread|Single consumption of 4.3 oz of refined grain rye bread
224208504|NCT06381401|DRUG|bupivacaine 0.25%|superficial cervical plexus block using 10 ml of bupivacaine 0.25%
224208505|NCT06381401|DRUG|bupivacaine 0.125%|superficial cervical plexus block using 10 ml of bupivacaine 0.125%
224208506|NCT04229758|DRUG|Anticoagulants|DOAC for the prevention of thromboembolic events in patients with non-valvular AF or VTE.
224208507|NCT01556464|DEVICE|Auto-adjusting CPAP|A CPAP device that auto-adjusts the pressure setting over the course of the night, depending on how the patient is breathing.
224208508|NCT03376984|COMBINATION_PRODUCT|ND and AMOX modified Gutta Percha|Gutta percha reinforced and modified with 5 nm diameter nanodiamonds and amoxicillin
224208509|NCT03376984|DEVICE|Gutta Percha|Gutta percha is a device made from coagulated sap of certain tropical trees intended to fill the root canal of a tooth. The gutta percha is softened by heat and inserted into the root canal, where it hardens as it cools. Gutta percha is classified as Class I (general controls).
224208510|NCT05661071|OTHER|Modified Mini Mental Test:|To assess the cognitive function of children
224208511|NCT05661071|OTHER|The Controlled Oral Word Association Test|To assess the cognitive function of children
224208512|NCT05661071|OTHER|The Central Nervous System Vital Signs|To assess the cognitive function of children
224208513|NCT05661071|OTHER|Conners' Parent Rating Scale-48 (Parent Report)|To assess attention-deficit/hyperactivity disorder
224208514|NCT05661071|OTHER|Child Behavior Checklist 6-18 ages (Parent Report)|To assesses both child adaptive behaviors and problem behaviors.
224208515|NCT05661071|OTHER|Strengths and Difficulties Questionnaire (Self-Reported)|It is a brief emotional and behavioural screening questionnaire for children and young people.
224208516|NCT05661071|OTHER|Brooke Lower Extremity Functional Classification|To determine the functional status of the lower extremity
224208517|NCT05661071|OTHER|Motor Function Measurement-32 Items|To assessment of motor function and progression of weakness in neuromuscular disorders
223619199|NCT05309148|BEHAVIORAL|Training with a neuropsychologist|The intervention is based on classical neuropsychological techniques aimed at correcting oculomotor disorders and improving visual attention (blank, psychometric, etc.)
223619200|NCT05309148|BEHAVIORAL|Training on eye tracker based device and with a neuropsychologist|This is combination of the first and second interventions
223619201|NCT04382742|BEHAVIORAL|Dynamic Resistance Exercises|Modified Wingate protocol that incorprates 20 minutes of training on a cycle ergometer; included one minute of cycling with resistance to be performed at 85% to 90% of Maximal Heart Rate (MHR) followed by one minute of cycling with no resistance. The protocol will be performed for 10 times for a duration of 20 minute of workout.
223619202|NCT02987270|DRUG|Dihydroartemisinin-piperaquine|Dihydroartemisinin-piperaquine is an antimalarial in the artemisinin-based combination therapy class of drugs. It is the Kenya Ministry of Health second-line treatment for malaria in Kenya.
223619203|NCT02171442|DRUG|BIBR 953 ZW Intravenously|5 mg, 2.8 MBq (76 µCi)
223619204|NCT02171442|DRUG|BIBR 1048 Oral Solution|200 mg free base, 2.8 MBq (76 µCi)
223619205|NCT06009055|DRUG|Remimazolam|0.3mg/kg，injection completed in 30 seconds
224208518|NCT05661071|OTHER|Four Square Step Test|A test of dynamic balance and coordination that clinically assesses the participant's ability to step over objects forward, sideways, and backwards.
224208519|NCT05661071|OTHER|Six Minutes Walk Test|It evaluates the walking function and physical capacity of children at the submaximal level.
224208520|NCT05661071|OTHER|Timed Performance Test|10 meters Walk\& Run Test, Gower's(from a supine to a standing position), Right\& Left Leg Standing, Ascent/Descent of 4 Steps
224208521|NCT05860049|OTHER|Conventional physiotherapy|All participants in both groups (A and B) received conventional physiotherapy program including infrared thermotherapy, transcutaneous electrical nerve stimulation, stretching exercises for for Upper Trapezius, Levator Scapulae, Sternocleidomastoid and Scalenes muscles, and active neck ROM exercises, 3 sessions per week, for 4 weeks.
224208522|NCT05860049|OTHER|Core stability|All participants in both groups (A and B) received core stability exercises in the form of bridging exercise, bridging exercise on a ball, plank, and side plank 3 sessions per week, for 4 weeks.
224208523|NCT05860049|DEVICE|Instrument assisted soft tissue mobilization|Each participant in group (B) was seated in a comfortable position. The participant's forehead rested on his/her forearm on a table in front of him/her. A lubricant (Vaseline) was applied to the skin around the neck area prior to treatment, and the M2T blade (Figure 4) was cleaned with an alcohol pad. First, the M2T blade was used to find the exact areas of restriction in the RT upper trapezius. Then, the M2T blade was used at an angle of 45°, utilizing treatment planes 1, 2, and 3, to apply slow strokes along the muscle, without causing any discomfort or pain, from the muscle origin to its insertion for approximately 3 minutes. This procedure was repeated twice a week, for 4 weeks.
224208524|NCT05161546|DEVICE|EEG and ERG measurements (Retinaute®, BioSerenity)|"The Retinaute® is a portable medical device developed by BioSerenity, France, for performing flash and pattern ERG. It comes in the form of a virtual reality headset, which can be used in outpatient facilities. It is non-invasive and uses skin electrodes for the collection of parameters.~ERG signals will be supplemented with 4 EEG channels, via cup electrodes applied to the skull and allowing the concomitant performance of an EEG."
224208525|NCT05161546|DEVICE|Actigraphy (Motion Watch 8®, CamNtech)|"Actigraphy is an ecological and non-invasive method allowing a reliable characterization of the sleep/wake cycle. It is a portable system for continuously measuring the motor activity of an individual and appreciating the alternation of activity periods (wakefulness) and rest periods (sleep).~An actigraph (MotionWatch8®, CamNtech) looks like a wristwatch that will be worn continuously, by convention on the wrist of the non-dominant hand, over periods ranging from several days to several weeks (here 21 days). Actigraphy does not present a known risk."
224208526|NCT05161546|BEHAVIORAL|Neuropsychological assessments|The purpose of this assessment is to establish a cognitive profile for each participant. It uses a series of tests widely described in the literature and commonly used today.
224208527|NCT05161546|DEVICE|Optical Coherence Tomography (OCT)|The Spectral Domain Optical Coherence Tomography (SD-OCT) is a modern ocular imaging process using infrared radiation and allowing to obtain in a few seconds, and in a non-invasive way, images in section of the eye. The OCT-Angiography (OCT-A) module increments on the OCT. It can detect the movement of the blood elements from sequential SD-OCT slices taken at the same location of the retina and obtain a map of the retinal and choroidal vessels, without injection of fluorescent dye. The device used for both exams will be the OCT spectral RS 3000 Advance 2 + Angioscan (NIDEK, Gamagori, Japan). SD-OCT and OCT-A examinations are fast, painless, non-contact and last less than a minute. There is no particular risk.
224208528|NCT06565754|OTHER|BFR|"Blood flow restriction training is an accessory to a variety of different exercise modes (e.g., resistance exercise, walking, cycling) has recently become a popular research topic. It involves the application of pressurized cuffs to the proximal portion of each lower extremity or upper extremity. It enhance blood pooling in the capillary beds of the limb muscles distal to the tourniquet or cuff.~The 3rd Generation SmartCuffs® pump (SmartCuffs® 3.0 PRO) is Personalized Pressure feature which allows for a fast, hassle-free personalized pressure calculation. With the built-in pressure sensor and on-board computer, it is calculate arterial occlusion pressure and set the optimal pressure for patient's body. There is no need for an external doppler probe or hand pump. This unit will do everything for patient. Smart Cuffs 3rd generation is FDA Approved Listed Class 1 device.~The automatized tourniquet (Smart Tools) contains a ring-shaped single- chamber"
224208529|NCT06565754|OTHER|strengthening exercise|Quadriceps strengthening exercises are part of the treatment of PFPS, but the heavy resistance exercises may aggravate knee pain. Blood flow restriction training (BFRT) provides a low-load quadriceps strengthening method to treat PFPS (Giles et al., 2017).
224208530|NCT04837274|DIETARY_SUPPLEMENT|Placebo|Dextrose (480 mg)
224208531|NCT04837274|DIETARY_SUPPLEMENT|Active|Tary Cherry (480 mg)
224208532|NCT04975113|OTHER|progressive neuromuscular exercise program|The exercises to be performed in the following week at the beginning of each week were explained by the researcher physiotherapist on the brochure and given as a home program and continued for a total of 12 weeks. The researcher physiotherapist saw the patients every week and carried out exercise compliance and control.
224208533|NCT04975113|OTHER|Exercise and Taping|"I taping for accurate positioning of the tissue was applied to the patients to neutralize the patellofemoral joint. During the knee flexion in the supine position, the tape was adhered to the skin with a moderate-to-extreme stretch (50%-75%) . Clinical therapeutic applications of the Kinesio taping methods (Tokyo, Japan: Ken Ikai Co Ltd.). In addition to the patellar taping, correction taping to neutralize the subtalar joint by elevating the midtarsal joint and medial arch was applied. The patients were positioned in prone lying and knee flexion position, the taping was started at the 5th metatarsal level on the dorsal side of the finger and finished extending towards the medial of the tibia . Tapings were renewed at the beginning of each week for 6 weeks."
224208534|NCT05920707|DRUG|Intranasal Oxytocin|Administer oxytocin (24 IU) intranasally, 6 individual 0.1 ml puffs (4 IU/0. 1ml), three puffs per nostril one every 30 seconds.
224208535|NCT05920707|DRUG|Intranasal Arginine Vasopressin|Administer arginine vasopressin (20 IU) intranasally, 6 individual 0.1 ml puffs (3.33 IU/0. 1ml), three puffs per nostril one every 30 seconds.
224208536|NCT05920707|DRUG|Intranasal placebo|Administer placebo intranasally, 6 individual 0.1 ml puffs, three puffs per nostril one every 30 seconds.
224208537|NCT03176511|BEHAVIORAL|A Matter of Balance plus Dual-Task Balance Challenge Group|Participants will receive the standard MOB classes, along with a 15-min DTBC each class, i.e., right and left foot ankle-reaching to three differently colored markers. Three colored dots are placed on the ground in an arc, using different colored stick-on dots. A chair can be placed in front of the color pattern, as needed for safety.
224208538|NCT03176511|BEHAVIORAL|A Matter of Balance Group|Participants will receive the standard MOB class, taught by a certified MOB, using course materials developed by MaineHealth's Partnering for Healthy Aging (http://www.mainehealth.org/pfha).
224208539|NCT04181697|DEVICE|PA measurement with Fitbit Charge 3|Measurement of PA with Fitbit for all participants and controls.
224208540|NCT04181697|DEVICE|PA measurement with Fitbit and ActiGraph GT3X|Measurement of PA with ActiGraph for a subgroup of 20 participants.
223619206|NCT06009055|DRUG|Propofol|2mg/kg，injection completed in 30 seconds
223619207|NCT03603483|PROCEDURE|procedure|"Patients of sever aortic stenosis 1: increase the diameter of aortic anulus by prosthetic patch or pericardial patch.~Patients of sever aortic stenosis 1:only conventional aortic valve prosthesis will be used"
223619208|NCT01743443|OTHER|Cochet-Bonnet esthesiometer central corneal sensitivity|Using the Cochet-Bonnet esthesiometer central corneal sensitivity was measured preoperatively, after 7 days, and once a month after surgery until recovery of the baseline preoperative level. Normal levels of central corneal sensitivity were considered above 40mm.
223619209|NCT00284700|DRUG|Iron|
223619210|NCT03020927|BEHAVIORAL|Reciprocal Imitation Training (Therapist-Delivered)|Naturalistic Developmental Behavioral Intervention aimed at improving social imitation skills.
223680424|NCT00814216|DRUG|Fluticasone Propionate|
223680425|NCT02956902|OTHER|Clinician supported smartphone application intervention|
224208541|NCT01345058|DRUG|lacosamide|"Lacosamide maximum of 200 mg/day, to be titrated as follows:~* Week 1: 50 mg twice a day~* Beginning Week 2: 100 mg twice a day."
224208542|NCT01345058|DRUG|levetiracetam|Low dose ≤1500 mg/day, High dose \>1500 mg/day
224208543|NCT05775237|DIETARY_SUPPLEMENT|Curcumin Gummies|Chew gummies thoroughly and completely before swallowing.
224208544|NCT05775237|DIETARY_SUPPLEMENT|Vitamin C Gummies|Chew gummies thoroughly and completely before swallowing.
223619211|NCT03020927|BEHAVIORAL|Reciprocal Imitation Training (Therapist + Parent Delivered)|Naturalistic Developmental Behavioral Intervention aimed at improving social imitation skills, using a combination of therapist-delivered intervention and parent training to deliver intervention in the home setting.
223619212|NCT02866227|DRUG|TOL-463|TOL-463 vaginal gel
223619213|NCT02866227|DRUG|TOL-463|TOL-463 vaginal insert
223619214|NCT03095729|OTHER|Neuropsychological tests|A battery of tests to evaluate the overall cognitive performance of the subjects (memory, executive, attentional or instrumental functions)
223619215|NCT01209429|DRUG|GH hormone infusion|Norditropin 30 ng/kg/min
223761496|NCT06908213|PROCEDURE|Posterior vertebral fusion surgery with Enhanced Recovery After Surgery (ERAS) procedure|"This will include at least:~* A one-day hospitalization to visit the surgical unit and to provide therapeutic education to patients and their parents.~* A transition to morphine based treatments per os from intravenous morphine on the second day following surgery~* Phone calls from a surgery unit nurse 2 times a day during 5 days~* A teleconsultation with the surgeon between D3 and D5 following surgery"
224208545|NCT05775237|DIETARY_SUPPLEMENT|Multivitamin Gummies|Chew gummies thoroughly and completely before swallowing.
224208546|NCT02820324|DRUG|Oliceridine|
224208547|NCT02820324|DRUG|Placebo|
224208548|NCT02820324|DRUG|Morphine|
224208549|NCT03850262|RADIATION|MRI|"The study will be done on 1.5T MR unit (Siemens) and 1.5T MR unit (Philips) at Assuit University Hospital, or 1.5T MR unit (G.E.) at Eman General Hospital.~* The field of view varied between 14 cm and 16 cm, and slice thickness varied between 3 and 4 mm, with 0.5 mm intersection gap.~* Imaging sequences included sagittal PD proton density, T2 and STIR, axial PD, coronal STIR and coronal oblique."
224208550|NCT00291356|DRUG|GSK189075 oral tablets|
224208551|NCT00291356|DRUG|GW869682 oral tablets|
224208552|NCT04425369|PROCEDURE|two-sided approaches for iliac crest bone graft|Only one side of the ilium was exposed when surgery.
224208553|NCT04980417|PROCEDURE|concomitant cholecystectomy|delayed cholecystectomy
224208554|NCT01892020|DRUG|biphasic insulin aspart 50|Administered subcutaneously (s.c., under the skin) twice daily (BID). Dose individually adjusted. All subjects will receive metformin in combination with trial insulin.
224208555|NCT01892020|DRUG|biphasic human insulin 50|Administered subcutaneously (s.c., under the skin) twice daily (BID). Dose individually adjusted. All subjects will receive metformin in combination with trial insulin.
224208556|NCT05359380|OTHER|ADL performance|"ADL performance~All study groups address the following 10 ADL tasks in 9 different combinations of light temperature and light intensity in order possible differences to be revealed among the study groups and light combinations:~1\. Phone Book Search (PBS), 2. Supermarket receipt (SupRe), 3. Book reading (BR), 4. Cellular message (CM), 5. Cellular entry search (CES), 6. Reading computer screen (RCS), 7. Drops bottle reading (DR), 8. Subtitles reading (SubRe), 9. Open door test (ODT), and, 10. Screwdriver test (ST).~The 9 light combinations are the following:~3000 K - 25 fc, 3000 K - 50 fc, 3000 K - 75 fc / 4000 K - 25 fc, 4000 K - 50 fc, 4000 K - 75 fc / 6000 K - 25 fc, 6000 K - 50 fc, 6000 K - 75 fc"
224208557|NCT06164431|DRUG|ZSP1273 tablet|Participants receive ZSP1273 tablet orally.
224208558|NCT06164431|DRUG|zsp1273 granules|Participants receive ZSP1273 granules orally.
224208559|NCT05093192|OTHER|Exercise trial|Participants will perform a supervised acute bout of aerobic exercise over 20-30 minutes, corresponding to a target power output at an intensity +10 to 15% above ventilatory threshold.
224208560|NCT02251431|DRUG|BYDUREON|Exenatide-extended release, Cohorts A and B
224208561|NCT02251431|DRUG|Placebo|Cohort A only
223619216|NCT01209429|BEHAVIORAL|42 hour fast|The participant will be fasting 42 hours prior to the start of the study day, drinking water is allowed
223619217|NCT01209429|BEHAVIORAL|12 hour fast|12 hour fast will be used as a control scenario to 42 hour fast
223619218|NCT03656991|OTHER|Bicycle intervention|
223619219|NCT06211439|DEVICE|real transcranial alternating current stimulation|The alternating current was non-invasively delivered using an M×N five-channel high-definition transcranial electrical current stimulator (Soterix Medical). A BrainCap (Brain Vision) embedded with high-definition plastic holders consisted of five 12-mm-diameter Ag/AgCl ring electrodes, filled with conductive gel. During real HD-tACS, the current was increased to 2 mA from the onset of stimulation and applied for 20 minutes.
223619220|NCT06211439|DEVICE|sham transcranial alternating current stimulation|For the sham condition(sham HD-tACS), the same electrode placement was used as in the stimulation condition, but the current was only applied during the first and last 30 seconds of the entire 20-minute stimulation period.
223619221|NCT01100866|DIETARY_SUPPLEMENT|POMELLA™ (pomegranate extract)|in a capsule form, 2 x 500mg once daily
223619222|NCT01100866|OTHER|Placebo|placebo capsules
223619223|NCT01279434|DRUG|Vitamin E plus Pentoxiphyllin|Both drugs will be administered daily Vit E (400 mg BD) and pentoxiphyllin (400 mg TDS) for 12 months
223619224|NCT01279434|DRUG|Vitamin E|Vitamin E 400 mg BD daily for 12 months
223619225|NCT05914948|DEVICE|Medtronic 8-contact Vectris subcompact or compact electrode.|Subjects meeting study eligibility criteria will be implanted with a Medtronic 8-contact Vectris subcompact or compact electrode.
223619226|NCT00500617|DIAGNOSTIC_TEST|Corus CAD (ASGES)|Age/Sex/Gene Expression Score - ASGES
223619227|NCT04607486|DIAGNOSTIC_TEST|3DfUS and IPSA of leg muscles|"1. 3DfUS technique enhances a conventional 2D US device into a platform capable of reconstructing 3D anatomical data sets.~2. IPSA for quantification of hyper-resistance and its underlying components. The sensors in the IPSa include gyroscopes and accelerometers to measure joint angle and angular velocity, EMG to measure muscle activity, and a 3 degrees-of freedom force sensor to measure torque applied on the joint.~3. clinical functional capacity = clinical evaluation of degree of independence, mobility and gait"
223619228|NCT00282763|DRUG|MK0686|
224208562|NCT04398888|OTHER|Banxie Xiexin Decoction (BXD)|A modified Banxie Xiexin Decoction based on Chinese medicine syndrome differentiation.
224208563|NCT02752451|OTHER|Non-Anatomic Arthroscopy Simulation|Knee arthroscopy training using Cigar Box Arthroscopy Trainer
224208564|NCT02752451|OTHER|Anatomic Arthroscopy Simulation|Knee arthroscopy training using Anatomic Knee Arthroscopy Trainer
224208565|NCT02752451|OTHER|Pre-assesment education|Reading material and lecture with only still images about performing diagnostic knee arthroscopy
224208566|NCT02493088|OTHER|Antisocial personality recording of behavior and contextual elements|aberrant driving behaviors and upstream contextual elements of individuals diagnosed with antisocial personality disorder will be recorded during the study
224315544|NCT01390532|DEVICE|3D Blood-Pool Gated SPECT (BPGS) with a new designed cardiac imaging camera (DSPECT, Spectrum Dynamics®, Ceasaria, Israel)|"Sequential 5 min Gated blood pool D-SPECT acquisition at rest and during last stage of dobutamine and atropin infusion (\>85% PHR).~Rest and stress left ventricular ejection fraction, phase standard deviation and entropy will be determined using a fully automatic commercial software (QBS, Cedars-Sinai, Los Angeles, CA)."
224315545|NCT05938504|OTHER|ONS_320275|Subjects will consume two packs (165ml/pack) of placebo ONS (ONS\_320275) orally daily at any time of day.
223619229|NCT04931940|DIETARY_SUPPLEMENT|Usual Care|Patients will receive the usual protein dosage at ≤1.2 g/kg/day for up to 28 days in the ICU
223619230|NCT04931940|DIETARY_SUPPLEMENT|Higher Protein/Amino Acid Group|Patients will receive high protein dosage at ≥2.2 g/kg/day for up to 28 days in the ICU
224315546|NCT05938504|OTHER|ONS_211567|Subjects will consume two packs (165ml/pack) of test ONS (ONS\_211567) orally daily at any time of day.
223619231|NCT01218334|DEVICE|12 Lead Glove|Comparison of EKG's derived from the 12 Lead Glove vs. the Gold Standard EKG machine
223619232|NCT03250637|OTHER|Observational|Information on diet, lifestyle, weight, height, medical treatment, environmental exposures, and other socio-economic factors were collected at enrolment using questionnaires and interviews
223619233|NCT04290039|DRUG|Atropine Sulfate Ophthalmic Solution|Atropine sulfate ophthalmic solution, USP 1% is a sterile topical anti-muscarinic indicated for cyclopegia, mydriasis, and penalization of the healthy eye in the treatment of amblyopia. Each mL of Atropine Sulfate Ophthalmic Solution USP, 1% contains active ingredient: atropine sulfate 10 mg equivalent to 8.3 mg of atropine. Inactive ingredients include benzalkonium chloride 0.1 mg (0.01%), dibasic sodium phosphate, edetate disodium, hypromellose (2910), monobasic sodium phosphate, hydrochloric acid and/or sodium hydroxide may be added to adjust pH (3.5 to 6.0), and water for injection, USP.
223619234|NCT04290039|DRUG|Atropine Sulphate Injection|Atropine sulfate injection, USP, 8mg/20mL (0.4 mg per mL) is a sterile, nonpyrogenic, isotonic, clear solution of atropine sulfate in water for injection with sodium chloride sufficient to render the solution isotonic. Each mL contains atropine sulfate, 0.4 mg; benzyl alcohol, 9 mg; sodium chloride 9 mg; and may contain sulfuric acid for pH adjustment, pH 3.5 (3.0 to 3.8).
223619235|NCT02149914|DEVICE|Ryodoraku|Ryodoraku to assess the energy of meridian system for each patient before and after taking the medication
223619236|NCT02149914|DEVICE|ANSWatch|ANSWatch to assess the autonomic nervous system for each patient before and after taking the medication
223619237|NCT02149914|DEVICE|UGI endoscopy|UGI endoscopy to assess the grade of reflux esophagitis for each patient before and after taking the medication
223619238|NCT02149914|OTHER|GerdQ|GerdQ to assess the severity of GERD for each patient before and after taking the medication
223619239|NCT02149914|DRUG|PPI|
223619240|NCT02397577|OTHER|Solid test meal, liquid test meal on two separate occations|13C labeld solid test meal, 13C labeld liquid test meal on two separate occations
223619241|NCT02172430|DRUG|Tiotropium powder inhalation capsules|Powder inhalation via the HandiHaler® once daily
223619242|NCT02172430|DRUG|Tersigan®|2 puffs of oxitropium three times daily via MDI
224208567|NCT01841398|BEHAVIORAL|Multimedia Lifestyle Improvement|"* Goal setting to improve diet, physical activity or smoking behaviours~* Regular health messaging related to the participant's goal, sent by email or text messaging, based on participant preference."
224208568|NCT01841398|BEHAVIORAL|Usual Care|Participant will be refered to SAHARA study website to get information on healthy lifestyle and to get regular update for the course of follow-up.
224208569|NCT00981864|RADIATION|Concurrent Boost RT|Patient will receive radiation to the tumour bed concurrently with whole breast radiation instead of receiving this treatment sequentially, that is, whole breast RT first then followed by RT directly to the tumour bed.
224208570|NCT01838278|BEHAVIORAL|Vojta Physiotherapy Method|Children in the experimental group or Vojta Group, received two weekly sessions of sensory-motor stimulation and two weekly sessions of Vojta Physiotherapy. Sensory motor stimulation and Vojta physiotherapy sessions lasted 50 minutes each. A guidance programme was also given to parents to carry out at home to promote the overall development of the child and teach the necessary Vojta method exercises, these were to be performed four times a day for 20 minutes.
224208571|NCT05133843|PROCEDURE|Assession of complete coronary physiology|Assession of complete coronary physiology in TAVI candidates with intermediate coronary artery stenosis before and 6 months after TAVI.
224315547|NCT04302038|DIETARY_SUPPLEMENT|Protein|Additional daily protein provided by potato protein.
223619243|NCT04032067|DRUG|GV1001 placebo|0.9 % Normal Saline
224208572|NCT03764592|OTHER|radiofrequency ablation|Symptomatic patients whose substrates were identified will undergo catheter ablation; asymptomatic patients will be followed without undergoing catheter ablation.
224315548|NCT04302038|DIETARY_SUPPLEMENT|Placebo control|No additional dietary protein (outside of 0.8 g/kg/day as provided by diet)
223619244|NCT04032067|DRUG|Proscar placebo|PO
223619245|NCT01816217|DEVICE|Intubation with The McGrath Mac videolaryngoscope|
223619246|NCT02861612|PROCEDURE|Nerve Transfer Surgery|Unilateral surgery will be performed under general non-paralytic anesthesia and no-tourniquet conditions to allow for responsive nerve simulation.
223619247|NCT01017484|OTHER|DASH, Control|controlled feeding of either the DASH dietary pattern or a typical American diet at isocaloric level.
223619248|NCT03237793|PROCEDURE|Fluorosed Group|A single episode of laser therapy with without potassium nitrate (RA Thermoseal\*) desensitising agent application was administered to the patients, A group only with desensitising paste and A group with desensitising paste and laser treatment depending on the study group they were assigned
224208573|NCT06427954|BEHAVIORAL|Digital Health App|access to a digital health app
223619249|NCT03237793|PROCEDURE|Non Flourosed Group|A single episode of laser† therapy with or without potassium nitrate (RA Thermoseal\*) desensitising agent application was administered to the patients, depending on the study group they were assignedGROUP 2B: Patients with healthy non fluorosed teeth receiving diode laser treatment$. (n=15)GROUP 2C: Patients with healthy non fluorosed teeth receiving diode laser + desensitising agent (potassium nitrate- RA thermoseal\*\*) treatment.
223619250|NCT02429323|DRUG|Sevoflurane|use of 8% sevoflurane in compared to incremental dose increased each few breaths from 1% to 8%
223761497|NCT06908213|PROCEDURE|Posterior vertebral fusion surgery with standard of care procedure|"Patients in this group will undergo posterior vertebral fusion surgery without the set of procedures for ERAS.~They will have a first consultation with the anesthesist and the surgeon then the surgery will be planned. The discharge from hospital after surgery will not happen early and the standard of care procedures will be followed during and after surgery.~Patients will receive 2 phone calls at D1 and D5 after surgery. The patient will also have 2 appointments at the hospital for post-surgical follow-up at D45 and M12."
223761498|NCT06909604|RADIATION|HER2 expression of PET imaging|Evaluate the diagnostic potential of HER2 imaging using 18F-labelled HER2 affibody , evaluate the predictive and prognostic value of HER2 PET imaging in bladder cancer patients treated with neoadjuvant therapy
223761499|NCT06908642|DRUG|Hemay005 tablet|Hemay005 is a small molecule PDE4 inhibitor.
224208574|NCT06476171|DIAGNOSTIC_TEST|Determination of the level of the studied biomarkers|Determination of the level of hematological indices based on a general blood test; Determination of the levels of the following biomarkers: isolation of neutrophils from the blood using the gradient centrifugation method; assessment using enzyme immunoassay (ELISA) of the content of neutrophil elastase in the supernatant; myeloperoxidase, ELISA; lactoferrin, ELISA; interleukin -1ß,17,10,6, ELISA; presepsin, ELISA; endothelin, ELISA; lipopolysaccharide, LAL test; lipopolysaccharide binding protein, ELISA; NETs release, immunofluorescence method; the number of neutrophils expressing PDL-1, flow cytofluorimetry method; procalcitonin in human plasma and serum, VIDAS B.R.A.H.M.S. PCT; ferritin, reagent for determination (FERRITIN); lactate dehydrogenase, reagent for determination of QSR6128;Endotoxin Activity Assay, chemiluminescent immunodiagnostics.
224208575|NCT04925453|COMBINATION_PRODUCT|active tDCS and cognitive training intervention|Intervention sessions will occur during Visits 2-6. Cognitive training will occur concurrently with tDCS in both the active and sham tDCS groups. Over each 46-minute daily training period, 4 of 5 BrainHQ training tasks will be performed for approximately 11 minutes in a randomly selected order. Order of task presentation will be randomized each session. Stimulation sequences will occur in the first 13 minutes (shut off: Minute 13) of the session and the last 13 minutes of the session (turn on: Minute 33). The Symptom Rating Questionnaire (SRQ) will be asked before and after stimulation to assess for any side-effects. The BrainHQ Task Load Index (TLX) will be administered at the end of each intervention session. At the end of Intervention Session 3, subjects will be given a Blinding Questionnaire which asks whether they thought they received active or sham treatment.
224208576|NCT04925453|COMBINATION_PRODUCT|sham tDCS and cognitive training intervention|Intervention sessions will occur during Visits 2-6. Cognitive training will occur concurrently with tDCS in both the active and sham tDCS groups. Over each 46-minute daily training period, 4 of 5 BrainHQ training tasks will be performed for approximately 11 minutes in a randomly selected order. Order of task presentation will be randomized each session. Stimulation sequences will occur in the first and last 13 minutes of the session. For sham stimulation, the electrodes will be placed at the same positions as for active stimulation, but current will be ramped down immediately after the initial 30s ramp up period. The Symptom Rating Questionnaire (SRQ) will be asked before and after stimulation to assess for any side-effects. The BrainHQ Task Load Index (TLX) will be administered at the end of each intervention session. At the end of Intervention Session 3, subjects will be given a Blinding Questionnaire which asks whether they thought they received active or sham treatment.
224208577|NCT06210516|DEVICE|PowerBreathe|"Primary Outcome Measurement:~1\. Maximal Inspiratory Pressure (MIP)~Secondary Outcome Measurements:~1. Chest circumference measurements~2. Diaphragm movements and thickness (ultrasound)~3. Hand grip strength (with a Jamar hand dynamometer)~4. Motor Activity Log~5. 6 Minute Walk Test (6MWT)~6. Canadian Occupational Performance Measure~7. Charlson Comorbidity Index"
224208578|NCT06210516|OTHER|Conventional Physiotherapy|"Primary Outcome Measurement:~1\. Maximal Inspiratory Pressure (MIP)~Secondary Outcome Measurements:~1. Chest circumference measurements~2. Diaphragm movements and thickness (ultrasound)~3. Hand grip strength (with a Jamar hand dynamometer)~4. Motor Activity Log~5. 6 Minute Walk Test (6MWT)~6. Canadian Occupational Performance Measure~7. Charlson Comorbidity Index"
224208579|NCT02675881|DEVICE|DSM|Monopolar RFA using dual switching mode (DSM)
224208580|NCT02675881|DEVICE|separable clustered electrode|A separable clustered electrode is similar to a clustered electrode, although it differs from a conventional clustered electrode in that each individual electrode is separable.
223619251|NCT05111860|DRUG|Bevacizumab+mFOLFOX6|Bevacizumab 5mg/kg d1 Oxaliplatin 85mg/m2 d1 Calcium Folinate 400mg/m2 d1 5-fluorouridine 400mg/m2 d1 5-fluorouridine 2400mg/m2 46h q2w, 6 cycles
223619252|NCT04617782|COMBINATION_PRODUCT|Donepezil TDS|Transdermal Delivery System
223761500|NCT06908642|DRUG|Placebo|Placebos are the same as drugs, but contain no Hemay005.
223619253|NCT04617782|DRUG|Aricept|Oral
223619254|NCT02152306|DRUG|Fimasartan and Amlodipine|
223619255|NCT02152306|DRUG|Fimasartan|
223619256|NCT05481775|DRUG|Anlotinib|Anlotinib 8mg qd po. Taking anlotinib daily for 2 weeks and stop for 1 week.
223619257|NCT05481775|DRUG|Chemotherapy|Docetaxel 25mg/m2 + Cisplatin 25mg/m2 QW
223619258|NCT05481775|RADIATION|Radiotherapy|Thoracic radiotherapy was delivered using the daily image-guided intensity modulated radiation therapy (IMRT) technique. The total radiation dose was 66-68 Gy to the gross tumor in 17-22 daily fractions.
223619259|NCT05481775|DRUG|Immunotherapy|consolidation Immunotherapy (Tislelizhu 200mg iv. drip, Q3W, up to 12 months.)
224208581|NCT03725358|BEHAVIORAL|Training|Health facilities assigned to this group will receive a two-week training intervention on modern contraceptive methods and counseling techniques - aimed at nurses conducting family planning services. This new curriculum was developed by a large group of experts convened by the Ministry of Health in February 2018. The cascade training that is developed by the national government (cascading down to regions, districts, and finally health facilities) is a 15-day training module that targets family planning nurses, covering theory, practical knowledge (practicing administrations and removals), and counseling of clients.
224208582|NCT03725358|BEHAVIORAL|App|"Health facilities assigned to this group will receive the same programming as the facilities in S1, but they will also be provided with tablets equipped with the job aid, which subsumes the basic data collection software used by the remaining facilities. They will also receive additional training on the use of the tablet-based job aid.~The app is a tablet-based decision-support tool, which is designed for use by the family planning nurse conducting counseling sessions and records the answers to a series of questions that elicit the client's life goals, fertility plans, needs, and preferences regarding contraceptive methods, as well as her medical eligibility (birth history, pregnancy check, breastfeeding status, blood pressure, medications, etc.)."
223619260|NCT04104256|BEHAVIORAL|Nudge #1: Alert highlighting the safety/potential harms to patients of undergoing pre-op tests|"Nudge 1:~* UCLA Ophthalmologists and Anesthesiologists ADVISE AGAINST routine pre-op testing.~* UCLA Pre-op Eval and Planning Center (PEPC) will order any needed labs on the day of surgery.~* Routine pre-op tests are inappropriate.~* Routine pre-op tests do NOT increase patient safety and go AGAINST local and national guidelines Hard stop before allowing the ordering of a pre-op test where physicians must provide accountable justification: EXPLAIN WHY GOING AGAINST GUIDELINES"
223619261|NCT04104256|BEHAVIORAL|Nudge #2: Alert highlighting the financial harms to the patient experiencing pre-op tests|"Nudge #2:~* UCLA Ophthalmologists and Anesthesiologists ADVISE AGAINST routine pre-op testing.~* UCLA Pre-op Eval and Planning Center (PEPC) will order any needed labs on the day of surgery.~* Routine pre-op tests are inappropriate.~* Routine pre-operative tests can increase the patient's out-of-pocket costs without improving the safety or medical outcomes of cataract surgery and go AGAINST local and national guidelines~* Nudge includes hard stop before allowing the ordering of a pre-op test where physicians must provide accountable justification: EXPLAIN WHY GOING AGAINST GUIDELINES"
223619262|NCT04104256|BEHAVIORAL|Nudge #3: Alert highlighting potential psychological harms to the patient of experiencing pre-op tests|"Nudge 3:~* UCLA Ophthalmologists and Anesthesiologists ADVISE AGAINST routine pre-op testing.~* UCLA Pre-op Eval and Planning Center (PEPC) will order any needed labs on the day of surgery.~* Routine pre-op tests are inappropriate.~* Routine pre-operative tests can cause aggravation and psychological stress for the patient without improving the safety or medical outcomes of cataract surgery and go AGAINST local and national guidelines~* Hard stop before allowing the ordering of a pre-op test where physicians must provide accountable justification: EXPLAIN WHY GOING AGAINST GUIDELINES"
224208583|NCT03725358|BEHAVIORAL|Control|The comparison group includes facilities that continue business as usual (no FP training or tablet-based job aid). Each facility in this group will receive a tablet equipped with basic data collection software and a one-day training to use the tablets.
224208584|NCT05925309|DRUG|Basic treatment: sulperazone + ursodeoxycholic acid + compound glycyrrhizin + methylprednisolone + vitamin AD , D , E , K + imipenem or meropenem|Sulperazone 50mg/kg q8h is used intravenously from the first day to the 14th day after KP surgery. Ursodeoxycholic acid 20mg/kg/d p.o, starting from the 5th day after surgery for at least 2 years. Compound glycyrrhizin 20mg/d i.v, 1-4 days after operation, then switch to compound glycyrrhizin tablets 12.5mg b.i.d p.o until 6 months after KP. Methylprednisolone start at 4mg/kg/d i.v on the 8th day after operation, and decrease by 1mg/kg/d every three days. Starting at about the 15th day after operation, methylprednisolone 4mg/kg is given orally every other day, and the dose is gradually reduced at 10-12 weeks. Vitamin AD , D , E , K, are given orally from the 5th day after the KP for at least 2 months. Treatment of cholangitis: sulperazone 50mg/kg q8h i.v., and methylprednisolone could be used. If cholangitis is not controlled, imipenem or meropenem may be used.
224208585|NCT05925309|DRUG|Prophylactic oral antibiotics: compound sulfamethoxazole tablet (SMZ/TMP) + cefaclor|Compound sulfamethoxazole tablet (SMZ/TMP) 25 mg/kg/d p.o. and cefaclor 12.5 mg/kg/d p.o. alternately every 2 weeks, from post-operation day 15 to month 6.
224208586|NCT02452775|BIOLOGICAL|OC-L|
224208587|NCT02452775|OTHER|Montanide|
224208588|NCT02452775|OTHER|poly-ICLC (Hiltonol),|
224208589|NCT02681627|OTHER|Endometrial scratch|If patient randomised to intervention arm, will have speculum examination followed by endometrial scratch with a wallace catheter
224208590|NCT02681627|OTHER|Touching the cervix|If patient is randomised to the control arm, she will have speculum examination followed by cleaning of the cervix with a cotton tip dipped in saline
224208591|NCT02006355|DRUG|Ropivacaine|
224208592|NCT04379102|OTHER|with NT/TLA (NT or also referred to as therapy with local anesthetics (TLA) )|Patients who visited our family planning clinic and opted for IUD application for contraception purposes were also offered NT/TLA treatments simultaneously. 40 patients who matched the inclusion criteria and received IUDs and NT/TLA treatments were included in the study group and 41 patients who only received IUDs were included in the control group. All patients received copper IUDs and none of them were on additional hormonal treatment. Before the insertion of IUD, women in the therapy group received NT treatment with 6ml of 1% procaine injected transvaginal into the cervix at 5 and 7 o'clock localizations.
224208593|NCT02424799|DRUG|GSK2646264 0.5% topical cream|GSK2646264 0.5% topical cream is supplied as white-to-off-white aqueous cream stored in amber glass jars
224208594|NCT02424799|DRUG|GSK2646264 1% topical cream|GSK2646264 1% topical cream is supplied as white-to-off-white aqueous cream stored in amber glass jars
224208595|NCT02424799|DRUG|Placebo|Placebo topical cream is supplied as white-to-off-white aqueous cream stored in amber glass jars
224208596|NCT03582098|DRUG|Idelalisib|Tablets were administered in accordance with the marketing authorization.
224208597|NCT03582098|DRUG|Rituximab|Tablets were administered in accordance with the marketing authorization.
224315549|NCT02437435|OTHER|Reproductive Technique Gimilio|"Patient supine, legs in triple flexion, feet on table, controlling legs left hand and right hand bent on uterine body contact.~Both hands catch utero withdrawal into one on another with arms outstretched. Fixed uterus right hand, left hand, with levers legs combines lateroflexion-rotation parameters of lumbar spine to improve uterine ligaments stretch, repeat technique to tissue relaxation. Then perform massage-cranial caudo zigzag with anteroposterior thrust. (overall hemodynamic maneuver). Finally do anteroposterior pumping about uterine body generating positive and negative pressures.~Hand therapist will keep in touch at all times on the suprapubic region of the patient."
224315550|NCT02437435|OTHER|Placebo Intervention|Patient supine, legs in triple flexion, feet on table. Physical Therapist take contact with his right hand in patient's belly for 5 minutes, without any movement.
224208598|NCT02987114|DRUG|PLT101|PTL 101 (Cannabidiol, CBD) Two piece hard capsules filled with seamless gelatin matrix green beads containing CBD (50 or 100 mg CBD per capsule) The beads should be administered following a meal, mixed with food
224208599|NCT05945368|DRUG|Eribulin mesylate injection、Pertuzumab、Trastuzumab|"* Eribulin mesylate, 1.4 mg /m², day 1 and day 8;~* Trastuzumab, 8 mg/kg load dose in the first cycle and 6 mg/kg in each subsequent cycle on day 1;~* Pertuzumab, 840 mg load dose in the first cycle and 420 mg in each subsequent cycle on day 1; There are four cycles in 21 days"
224208600|NCT01456494|OTHER|Brief Intervention|A brief educational strategy that employs verbal and written instructions, without demonstration or repeated rounds of instruction, to teach patients how to use their inhalers.
224315551|NCT03981913|BEHAVIORAL|Simon Task with high-density EEG recording|"The scalp electrical activity will be collected by a 256-electrodes EEG montage (Electrical Geodesics Inc).~During the task, participants will be asked to answer on a right or left button according to the color of a circle (yellow or blue) presented on the left or right side of a screen. Participants will have to ignore the stimulus position and respond only according to its color. This leads to two experimental conditions When the color of the circle and its position indicate the same answer, the situation is congruent and the answer is facilitated. Conversely, when they indicate two opposite responses, a conflict between the two alternative actions appears and must be resolved to provide a correct answer. This situation is said to be incongruent. At each trial, the stimulus is shown to the left or right of a central fixation cross. The participants then have to answer on a right or left button. At each trial, the reaction time and the accuracy of the response will be collected."
224315552|NCT06632535|OTHER|Chiropractic care|Chiropractic treatment will involve a personalized treatment plan within the context of a general care protocol administered by a chiropractor at the Osher Clinical Center for Integrative Health. The treatment plan will be customized to the patient's clinical needs following the current evidence and clinical practice guidelines.
224315553|NCT06632535|OTHER|Group medical visits|Participants will simultaneously enroll in virtual group medical visits with group discussion, practice based learning, and curricular themes pertaining to chronic pain management, healthy aging, and pillars of lifestyle medicine.
224315554|NCT05354921|DEVICE|Indwelling Catheter|Patients in the experimental group will receive foley catheter upon admission, aseptically. The catheter will be discontinued on the morning following surgery. At TOH most (\>75%) hip fractures are treated within 48 hours of admission and 95% within 72 hours and hence the indwelling catheter is likely to stay in place for 3-4 days.
224315555|NCT05354921|DEVICE|Intermittent Catheterization|"Patients randomized to the intermittent catheterization group will have their PVR monitored every 8 hours pre-operatively. If PVR\>400 mL, an intermittent catheter will be used. If PVR\> 400 mL greater than 3 times pre-operatively, an indwelling catheter will be placed the fourth time. The indwelling catheter will be removed the morning of post-op day 1.~It is expected that a small percentage of patients in either group will not have a PVR\>400 mL preoperatively.~These patients will not be catheterized but will remain in the study. Post-operatively, both treatment groups will have their PVR monitored for 24 hours, or until PVR is less than 200 mL. If PVR\>400 mL and the patient is not able to void further, intermittent catheterization will be done every six hours as needed. If post-operative PVR\>400 mL greater than 3 times post-operatively, an indwelling catheter will be placed the fourth time."
224315556|NCT01192607|DEVICE|Endoscopic treatment during root canal treatment|Endoscopic treatment during root canal treatment
223512772|NCT00712075|BEHAVIORAL|CBSST+PDA|PDA-Assisted Cognitive Behavioral Social Skills Training (CBSST+PDA) includes weekly group therapy sessions, each 90 minutes in length, with 6-8 patients (maximum of 10) were held for 24 weeks. The intervention integrated cognitive behavioral and social skills training interventions modified for use with older patients with psychosis. Participants utilized PDAs to assist with homework completion and compliance.
223512773|NCT00712075|BEHAVIORAL|Cognitive Behavioral Social Skills Training|Cognitive Behavioral Social Skills Training includes weekly group therapy sessions, each 2.5 hours (30 min lunch break) in length, with 6-8 patients (maximum of 10) were held for 24 weeks. The intervention integrated cognitive behavioral and social skills training interventions modified for use with older patients with psychosis.
223512774|NCT00712075|BEHAVIORAL|PDA-only|To control for the effects of having a PDA, a third group was provided PDAs for the same duration as the other two groups. Participants had access to the same basic functions (calendar, contact list, etc.) as the CBSST+PDA group, but did not have any homework or weekly group meetings.
223512775|NCT02268305|DRUG|MSM 1000mg twice a day (6000 mgs)|MSM is believed to have anti-inflammatory properties. MSM is a largely tasteless, odorless, white, crystalline solid which is water soluble. It occurs naturally in the environment and is synthesized in the human body as a byproduct of dietary DMSO.
223512776|NCT02268305|OTHER|Placebo capsules twice a day|Placebo is a capsule filled with rice flour.
223512777|NCT03004677|BEHAVIORAL|Continuous skin-to-skin contact|Infants will rest in skin-to-skin contact on parents' chest 24 hours a day alternating between the parents. The parents will note who provides the SSC and if and for how long they are off SSC for any reason.
223512778|NCT03004677|OTHER|Standard Care|Infants will receive regular care in the NICU. Parents may practice SSC if they like. Parents will note if, with whom, and for how long they provide SSC.
223512779|NCT04223687|OTHER|Sugar-Sweetened Beverage Warning Label|Labels with a pictorial warning will be applied to the front-of-package of all sugar-sweetened beverage containers in the mock store. Investigators developed the text and design of these labels based on previous research.
224208601|NCT01456494|OTHER|Teach-to-Goal Education|Teach-to-goal (TTG) is a method of patient instruction that employs repeated rounds of teaching (demonstration, verbal, written instructions) and assessments (teach-back) of patient comprehension.
224208602|NCT02543515|PROCEDURE|office hysteroscopy|diagnostic procedure
224208603|NCT02941822|DRUG|Ambroxol|Details outlines in the intervention description.
224208604|NCT03485508|DIAGNOSTIC_TEST|Transthoracic echocardiography|Transthoracic echocardiography Blood sample with assessment of biomarkers
224208605|NCT00831038|PROCEDURE|Infant Pulmonary Function Tests|Tests will be performed on study patients within 1 week of study enrollment and again 6 months later.
224208606|NCT06701123|DEVICE|uMAT-R mobile app with coaching component|uMAT-R recovery mobile app with coaching component
224208607|NCT06702488|DRUG|dexmedetomidine|20 mg/kg as a loading dose over 10 minutes before induction then a maintenance dose of 5 mg/kg/hour, which will also be discontinued at the skin closure.
224208608|NCT06703047|DRUG|ATRA+pd-1+chemo|All trans tretinoic acid+tislelizumab+chemotherapy (paclitaxel, cisplatin, or carboplatin)
224208609|NCT06703047|DRUG|placebo+PD-1+chemo|Placebo+tislelizumab+chemotherapy (paclitaxel, cisplatin, or carboplatin)
224208610|NCT06702982|BEHAVIORAL|tele-nursing educational program|The intervention administered in this study was a tele-nursing educational program aimed at improving cancer patients' management of chemotherapy-related symptoms and enhancing their quality of life. The program was delivered via a Telegram group, which provided a platform for regular interaction between the patients and nursing staff. The educational content was designed to address common chemotherapy-related symptoms, such as nausea, fatigue, pain, and loss of appetite, and to provide guidance on managing these symptoms effectively.
224208611|NCT06722690|BEHAVIORAL|eTSF|eTSF is a smartphone app intervention featuring culturally relevant content aimed at supporting Latinx young adults with alcohol use disorder in participating in 12-step groups.
224208612|NCT06722690|BEHAVIORAL|Educational materials|Educational materials on drinking problems and a list of local/online AA meetings.
224208613|NCT01351324|DIETARY_SUPPLEMENT|Absence or presence of fish oil|Oral dose of saturated fat with or without fish oil and a heparin infusion
224208614|NCT06722131|OTHER|Sampling|"Additional biological sampling at the same time as routine-care samples taken in the context of the diagnosis of the infectious disease and if planned at one and 12 months of follow-up~* The considered samples are as follows :~  * Blood sample tubes (5 x 5 mL tubes, i.e. 25 mL)~ * Infection site sample if applicable :~* Urine (10 mL)~* Stool (1 mL)~* CSF (1 mL)~* Sputum (1 mL) or bronchoalveolar lavage fluid (10 mL)~* Nasopharyngeal swab (one swab)~* Genital swab (one swab)~* Skin swab (one swab)~* Biopsy (a fragment of a lung, kidney or brain biopsy, if performed)"
224208615|NCT06722404|DIETARY_SUPPLEMENT|Standard therapeutic foods|All children were initially fed F-75 (75 kcal/ 100mL) therapeutic milk (Phase I) and then progressed to F-100 (100 kcal/ 100mL) (Phase II) and Plumpy'nuts (F-100 in spread form with iron fortification) (Phase III) with follow-up for 48 days
224208616|NCT06722404|COMBINATION_PRODUCT|Therapeutic foods plus Synbiotics|the intervention group received therapeutic foods plus synbiotics containing Oligomate that was fortified in F75 at the rate of 7.5 g/L containing 4.1 g/L GOS for 1 g/100 kcal dose and at the rate of 11.5 g/L containing 6.1 g/L GOS for 1.5 g/100 kcal dose while in F100 and Plumpy'nuts it was fortified at the rate of 10 g/L containing 5.5 g/L GOS for 1 g/100 kcal dose and at the rate of 15 g/L containing 8.25 g/L GOS for 1.5 g/100 kcal dose and Resiton (Lactobacillus paracasei sbsp. paracasei) 3 billion cfu/day and 6 billion cfu/day that were mixed in different combinations.
224208617|NCT03216798|OTHER|questionnaires survey|The questionnaires will be self-administered and anonymous. Information obtained from the questionnaire will not contain identifiable information of patients, CBO staff or health care workers.
224208618|NCT03772548|DIAGNOSTIC_TEST|MRI|We will examine acute (\<4 weeks post SCI) to chronic (\>6 months post SCI) patients using functional, structural, and metabolic MRI in both the brain and the spinal cord.
224208619|NCT03772548|DIAGNOSTIC_TEST|MRI|We will examine healthy control participants using functional, structural, and metabolic MRI in both the brain and the spinal cord.
224208620|NCT04822701|DRUG|BI 767551 intravenous|BI 767551 intravenous
224208621|NCT04822701|DRUG|BI 767551 inhaled|BI 767551 inhaled
224208622|NCT04822701|DRUG|Placebo intravenous|Placebo intravenous
224208623|NCT04822701|DRUG|Placebo inhaled|Placebo inhaled
224208624|NCT05850260|DEVICE|Macintosh laryngoscope|During the pre-implementation period (6 months), the 35 assigned attending anesthetists will perform all tracheal intubations in the operation room according to the standard of care using the standard Macintosh direct laryngoscope as a first intubation option
224208625|NCT05850260|DEVICE|Videolaryngoscope|During the post-implementation period (6 months), the 35 assigned attending anesthetists will perform all tracheal intubations using their personal McGrath Mac videolaryngoscope as a first intubation option.
224208626|NCT04724070|GENETIC|NGS, PDO/PDX establishment|Patients' tumor specimens will be collected for next generation sequencing, PDO/PDX establishment and tissue banking.
224208627|NCT05041179|DIETARY_SUPPLEMENT|Pruvin R|Combination of N-acetylcysteine an glycine
223512780|NCT04223687|OTHER|Neutral label|Neutral labels will be applied to the front-of-package of all sugar-sweetened beverage containers in the mock store. Investigators developed the design of these labels.
223512781|NCT02787174|OTHER|Asthma Medication Adherence Education|
224208628|NCT05041179|OTHER|Isomaltulose|Placebo as comparator to intervention
224208629|NCT02723760|DRUG|99mTc-3PRGD2|"SPECT/CT scanning: single intravenous bolus injection of nearly 11.1 MBq/kg body weight of 99mTc-3PRGD2 on rheumatoid arthritis patients, whole-body planar and lesions section for determination the accumulation of 99mTc-3PRGD2 in the joints and other parts of the body.~For diagnosis study, each patient will be carried out SPECT/CT scanning once. For efficacy evaluation study, each patient will be carried out SPECT/CT scanning three times (before treatment, the midterm treatment and late stage treatment)."
224208630|NCT02959372|OTHER|lung ultrasound|
224208631|NCT02959372|OTHER|placebo|lung ultrasound. The attending physician will not know the result
224208632|NCT05728359|OTHER|Observational study|Blood sampling and clinical data collection
223512782|NCT05522829|BIOLOGICAL|SCTV01E-1 on D0|Day 0; intramuscular injection
223512783|NCT05522829|BIOLOGICAL|SCTV01E-1 on D28|Day 28; intramuscular injection
223512784|NCT05522829|BIOLOGICAL|SCTV01E-1 on D150|Day 150; intramuscular injection
224208633|NCT04909177|OTHER|Smartphone application (app) in combination with headset|The intervention oVRcome is self-help VRET for specific phobia, that is delivered through a smartphone application (app) in combination with headset that holds the smartphone and uses 360º video. oVRcome includes 6 modules of psychoeducation, relaxation, mindfulness, cognitive techniques, exposure through VR, and a relapse prevention module which are aimed to be completed weekly.
224208634|NCT02937285|DRUG|Interferon beta 1a|Subcutaneous injection of 44µg 3 times a week
224208635|NCT02937285|DRUG|Mitoxantrone|10 mg / m² monthly infusion for 6 months
224208636|NCT04338256|BEHAVIORAL|Wellness and Resilience for College and Beyond (Undergraduate College Course)|"The course, Wellness and Resilience for College and Beyond was originally developed by James Mazza, PhD and colleagues at the University of Washington as a 10-week course. The course developers adapted their course materials to fit the needs of a 16-week semester for the purpose of this study. The Wellness Course teaches students evidence-based skills for improving mental health from dialectical behavior therapy, acceptance and commitment therapy, and the field of positive psychology. Classes meet for 2.5 hours weekly with approximately half of class time spent on teaching new content (lecture) and the other half spent with students working in small groups on practice and discussion exercises."
224208637|NCT05900739|BEHAVIORAL|Increase of fruit and vegetable consumption|"Week 1 Presentation of the program. Healthy eating Week 2 Fruit and vegetable: nutritional value, types, seasonality, benefits for health Week 3 Shopping Fruit and vegetable: tips, places, conservation methods Week 4 Healthy menu planning with My Plate Week 5 How to cook Fruit and Vegetable avoiding food waste Week 6 Healthy snacks using Fruit and vegetable Week 7 Batch cooking"
224208638|NCT00736138|PROCEDURE|training and pellots|training and pellots
224208639|NCT02092584|DIETARY_SUPPLEMENT|Omega-3|4 cap 1 g Omega-3 per day for 2 months
224208640|NCT02092584|DIETARY_SUPPLEMENT|Placebo|4 cap 1 g Placebo(paraffin) per day for 2 months
224208641|NCT03969979|DIAGNOSTIC_TEST|Shear wave elastography|shear wave elastogrophy will be performed
224208642|NCT03427788|DRUG|BAY2328065|Doses from 2.25-700 mg once daily in an escalating manner as liquid service formulation (LSF) or tablets
224208643|NCT03427788|DRUG|Placebo|Matching placebo, once daily in an escalating manner as LSF or tablets
224208644|NCT05340842|OTHER|simulation training group|In this study, applied breastfeeding training with Lactation Simulation Model was given to pregnant women in the intervention group (simulation training group, n=64) during antenatal period
224208645|NCT04876482|PROCEDURE|transoral robotic surgery|transoral robotic surgery (TORS) which remove the extra soft tissue of the base of the tongue and soft palate in this study
224208646|NCT04876482|DEVICE|oral appliance|It is a kind of treatment for the participants who refuse surgeries and choose to use other kinds of conservative treatment. The conservative treatments included oral appliance, losing weights and using continuous positive airway pressure. The oral appliance would be wore only at night and it would press the soft palate and protrude the jaw.
224208647|NCT04876482|DEVICE|using continuous positive airway pressure|The participants only used CPAP at night. The device composed of a main machine, pipe and mask. The participants would instruct to wore the mask. The main machine would give positive airway pressure to open the airway and avoid collapsing.
224208648|NCT04876482|BEHAVIORAL|losing weights|The participants would ask to lose weight by changing their diets and exercising, without using drugs and surgeries.
224208649|NCT04876482|COMBINATION_PRODUCT|oropharyngeal rehabilitation|OPR included exercise for soft palate, tongue and oropharynx. There are 13 movements in OPR. The movements would be teach by a physical therapist.
224208650|NCT05183230|BEHAVIORAL|WellPATH-PREVENT|WellPATH-PREVENT is a novel personalized, easy to use, mainly stand-alone mobile intervention which focuses on the exclusive use of the WellPATH tablet app and includes training meetings during hospitalization, and virtual post-discharge coaching meetings. The meetings aim to: a) identify stressors and triggers of negative emotions associated with increased suicidal ideation or with suicidal behavior; b) develop techniques (text or video) to increase cognitive reappraisal ability; c) incorporate the techniques into the WellPATH app and promote the use of WellPATH during stressful incidents, triggers of negative emotions, or scheduled brief training sessions; and d) remotely update the triggers, negative emotions, and techniques in the app.
224208651|NCT05183230|BEHAVIORAL|Optimized WellPATH-PREVENT|The Optimized WellPATH-PREVENT intervention will be as described above, but based on the results of the Proof-of-Concept (R61) Phase, an expert committee will help select the duration (6 or 12 weeks) that shows greater improvement in cognitive reappraisal.
224208652|NCT03877484|DEVICE|ALLEVYN Gentle border|ALLEVYN Gentle border is a triple layer foam dressing consisting of a highly absorbent hydrocellular foam pad held between a perforated wound contact layer (WCL), which is coated with a soft silicone gel adhesive and a highly permeable outer top film.
223619263|NCT04104256|OTHER|Usual Care|Patients will receive usual care from their physicians.
224208653|NCT01755780|OTHER|Left interscalene block|
224208654|NCT01755780|OTHER|Right interscalene block|
224208655|NCT00391092|DRUG|bevacizumab [Avastin]|15mg/kg iv every 3 weeks
224208656|NCT00391092|DRUG|Docetaxel|100mg/m2 iv every 3 weeks
224208657|NCT00391092|DRUG|Herceptin|8mg/kg iv loading dose, followed by 6mg/kg iv every 3 weeks
224208658|NCT04559217|BIOLOGICAL|Radiopharmaceutical 68Ga-DOTATATE|Injection of 68Ga-DOTATATE followed by PET/CT acquisition
224208659|NCT01004900|PROCEDURE|Selective Laser Trabeculoplasty|This is a laser procedure used to treat glaucoma by reducing the pressure in the eye. SLT works by using laser light to stimulate the body's own healing response to lower your eye pressure. Using a special wavelength and energy, the laser affects only pigmented (melanin containing) cells of your eye. SLT improves the flow of fluid in the eye, which in turn lowers your eye pressure.
224208660|NCT01004900|DRUG|Travoprost/ Timolol/ Azopt/ Brimonidine|Travoprost (Topical eye drops) administered once daily before sleep
224208661|NCT04238468|PROCEDURE|Intradermal stromal vascular fraction injection|After flank liposuction, lipoaspirate will be processed by enzymatic digestion, thus stromal vascular fraction will be isolated. Just after the wound is closed the stromal vascular fraction diluted in normal saline (5ml) will be injected intradermally on one site.
223680426|NCT05389852|DRUG|Dexmedetomidine|After completion of supraclavicular brachial plexus block patients will receive intravenous dexmedetomidine 1 mcg/kg
224315557|NCT01228578|DIETARY_SUPPLEMENT|Multivitamin supplements B,C and E|One daily recommended dietary allowance of multivitamins B,C and E or placebo taken daily for 18 months
224315558|NCT00183911|DRUG|floxuridine, 5-Fluorouracil, leucovorin|
224315559|NCT00183911|PROCEDURE|External Beam Radiotherapy|
224315560|NCT00183911|PROCEDURE|Surgery|
224315561|NCT05538078|DRUG|Ozone gel|application of Ozone gel after scaling by ultrasonic scaler in the bottom of periodontal pocket
224315562|NCT00002678|DRUG|dexamethasone|40 mg daily for four days given orally and repeated every 28 days should commence on day 29 of the twelfth cycle of induction therapy.
224315563|NCT00002678|DRUG|melphalan|9 mg/m2 daily for 4 days given orally on an empty stomach every 4 weeks
224315564|NCT00002678|DRUG|prednisone|100 mg daily for 4 days given orally on a full stomach with each cycle of melphalan
224315565|NCT03900897|DEVICE|MED-EL SYNCHRONY PIN Cochlear Implant|Subjects will be implanted with the MED-EL SYNCHRONY PIN Cochlear Implant System with +FLEX24, +FLEX28, +FLEXSOFT electrode arrays. Subjects will be fit with the SONNETEAS (ear-level) and/or RONDO 2 (single-unit) external audio processors.
224315566|NCT03900897|OTHER|Cochlear Implant|Chart review of subjects implanted with a MED-EL cochlear implant under 6 years of age between January 2005 and October 2020.
224208662|NCT06476873|BEHAVIORAL|Online self-questionnaire.|"Descriptive, cross-sectional study This study is aimed at adult chemsex users over the last 12 months (having experimented with chemsex at least once over the last 12 months) and with a good understanding of French.~An online LimeSurvey-type self-questionnaire will be accessible via a URL link to collect and secure the data. A presentation of the study, information on chemsex and help and care services, as well as the information note will be available.~The questionnaire will be distributed via a QR code, giving direct access to the study's web page, or directly via the web link. Posters and flyers will be used in hospitals and/or private clinics, addictology centers, STI prevention and screening centers and associations, as well as via social networks, dating apps and sites, and the online and print press."
224208663|NCT05164848|DRUG|JMT101|JMT101 will be administered intravenously at 6 mg/kg every 2 weeks (q2w) in each 28-week cycle.
224208664|NCT05164848|DRUG|Afatinib|Afatinib will be administered orally at 30 mg or 40 mg per day (qd) in each 28-week cycle.
224208665|NCT01586117|DRUG|Amifostine|intrarectal Amifostine administration 1500mg QD x 5 weeks
224315567|NCT03244683|DIETARY_SUPPLEMENT|Ensure Surgical|Subjects randomized to the intervention arm will consume two Ensure Surgical for 5-7 days.
224315568|NCT03244683|OTHER|Nutrition counseling|All study subjects will be provided with nutrition counseling at the time of study enrollment.
224315569|NCT03244683|OTHER|Low-intensity exercise therapy|Patients randomized to the intervention arm will also be provided with verbal and written instructions for light resistance training. The exercises will be performed at home during the preoperative study period.
224315570|NCT01150812|DRUG|AZD8165|Oral suspension, 2 mg/mL and 20 mg/mL, single doses
224315571|NCT00717379|DRUG|Tacrolimus|oral
224315572|NCT00717379|DRUG|Mycophenolate Mofetil|oral
224208666|NCT00002196|DRUG|CI-1012|
224208667|NCT05202613|DRUG|Doravirine|Doravirine, both as single drug and as fixed combination with lamivudine and tenofovir disoproxil fumarate
224208668|NCT01496690|DRUG|Pregabalin|Subjects are randomized 1:1 to either pregabalin treatment or placebo. The intervention period is 8 weeks. The daily pregabalin dose is 75 mg. during the first week followed by 7 weeks of flexible daily dosing (150, 300, 450 or 600 mg.) depending on tolerability and response. Doses above 150 mg. should be divided in two daily dosages.
224208669|NCT01496690|DRUG|Pregabalin Placebo Capsules|Parallel to Active Comparator
224208670|NCT02314273|DRUG|rhIL-11|patients receive rhIL-11(50 mcg/kg，subcutaneously)after standard chemotherapy，once a day for 10 days or until platelet count ≥80000/mL
224208671|NCT02807324|OTHER|Venapunction|The only invasive procedure is a venapunction where 75 ml blood will be extracted. The only unfavourable side effect can be a small hematoma (rare).
224315573|NCT00717379|DRUG|Methylprednisolone or equivalent|oral
224315574|NCT00717379|DRUG|Prednisone|oral
224315575|NCT05311579|COMBINATION_PRODUCT|Niraparib plus anlotinib|"Niraparib QD D1-21 plus Anlotinib 10mg QD D1-14 until disease progression or intolerable toxicity~21days/cycle"
224315576|NCT03742947|DIAGNOSTIC_TEST|peripartum haemostasis|Three blood samples of 20 ml each at T0 after the anaesthesia for the caesarean section and before the administration of the product (TXA or placebo), T15 fifteen minutes after the administration of the product and T120, 2 hours after the administration of the product.
224315577|NCT01333397|BIOLOGICAL|Botulinum toxin type A|I.M. (in the muscle) injection on day 1 (single treatment cycle)
224315578|NCT01333397|BIOLOGICAL|Botulinum toxin type A|I.M. on day 1 (single treatment cycle)
224315579|NCT01333397|DRUG|Placebo|I.M. on day 1 (single treatment cycle)
224315580|NCT03840187|DIAGNOSTIC_TEST|Digital cervicography|Colposcopist findings and digital cervicography employing Gynescope system
224315581|NCT02068703|BEHAVIORAL|Sleep Education Presentation|Subjects will receive a 10 minute presentation, aimed at educating on the value of sleep WITHOUT a demonstration of tools to improve sleep.
224315582|NCT02068703|BEHAVIORAL|Sleep Tool Demonstration|Subjects will receive a 10 minute presentation, aimed at educating on the value of sleep PLUS a demonstration of tools to improve sleep.
224315583|NCT02939625|DEVICE|muscle training|
224315584|NCT02939625|DEVICE|Continue Positive Airway Pressure|
224315585|NCT02939625|DEVICE|bilevel positive airway pressure|
224315586|NCT03266939|DRUG|Lorcaserin|10 mg acute administration of lorcasein
224315587|NCT03266939|DRUG|Placebo Oral Tablet|Placebo
224315588|NCT00796055|DRUG|MEDI-547|Administered at a dose and schedule as determined by the subject's enrollment cohort as a 60 minute IV infusion as part of a 21-day treatment cycle.
224208672|NCT04778176|COMBINATION_PRODUCT|continuous oral delivery of levodopa/carbidopa|The system consists of a reusable custom dental retainer, its case, and a pre-filled, single-use container which continuously releases levodopa/carbidopa into the back of the mouth.
224208673|NCT00629629|BEHAVIORAL|Dietary Advice|"Step 1 - Provide Exclusive breastfeeding up to 6 mo.~Step 2- After 6 mo, gradually introduce complementary foods and continue breastfeeding up to 2 y or more.~Step 3 - Complementary foods should be given 3 times a day (cereals, beans, fruits, and vegetables) if the child is breastfed, and 5 times a day if not.~Step 4- Mealtimes must be adjusted to the children's cues of hunger and satiety.~Step 5: Foods should gradually get thicker up to the time when the child is able to eat a family meal. Complementary foods should not be liquefied.~Step 6: A large variety of healthy foods should be given daily to guarantee the intake of different nutrients.~Step 7: Different fruits and vegetables should be offered daily. Step 8: Sugar, sweets, soft drinks, salty snacks, cookies, and processed and fried foods must be avoided.~Step 9: Good hygiene practices in food preparation and handling.~Step 10: Adequate feeding during child illness."
224208674|NCT05163431|DEVICE|Hallux Valgus orthosis|Custom designed orthosis and manufactured by 3D printing.
224208675|NCT02766686|RADIATION|Radiotherapy with protons|
224208676|NCT02766686|RADIATION|Radiotherapy with photons|
224208677|NCT06146504|DIETARY_SUPPLEMENT|CanXida Remove (Formula RMV)|Supplement composed of a 12 ingredient anti-fungal, anti-bacterial \& anti-parasite formula.
224208678|NCT06146504|OTHER|Placebo|Placebo product containing Dicalcium Phosphate, Magnesium Stearate, Stearic Acid, Croscarmellose Sodium, and Silica.
224208679|NCT06361316|DRUG|Irinotecan liposome injection|Postoperative adjuvant therapy
224208680|NCT03891979|DRUG|Pembrolizumab|"Pembrolizumab will be given for two doses every 3 weeks starting on day 8 (ie days 8 and 29). Antibiotics will continue throughout the entire four week pre-operative period.~Ciprofloxacin 500mg PO BID days 1-29; Metronidazole 500mg PO TID days 1-29; Pembrolizumab 200mg IV days 8 and 29."
224208681|NCT03891979|DRUG|Ciprofloxacin 500mg PO BID days 1-29|Antibiotics will continue throughout the entire four week pre-operative period.
224208682|NCT03891979|DRUG|Metronidazole 500mg PO TID days 1-29|Antibiotics will continue throughout the entire four week pre-operative period.
224208683|NCT01780688|OTHER|Conventional cigarettes (CC)|Subjects are randomized in a 1:1 fashion to be assigned to one of the 2 sequences, either A) CC and then THS 2.1, or B) THS 2.1 and then CC.
224208684|NCT01780688|OTHER|THS 2.1|Subjects are randomized in a 1:1 fashion to be assigned in one of the sequences, either A) CC and then THS 2.1, or B) THS 2.1 and then CC
224208685|NCT04657237|PROCEDURE|Thoracic Paravertebral block|TPVB will be given using high frequency linear U/S transducer, place the U/S ultrasound probe was placed parallel to the vertebral spine at T4, and, T6 level and shifted 2-3 cm laterally to obtain the appropriate visualization. Following the identification of pleura, transverse process and paravertebral space, the needle was inserted in caudocranial direction using in-plane approach. Confirm negative vessel or pleural breach via aspiration then proceed with local anaesthetic 0.25% bupivacaine (20 ml) delivery slowly divided equally at T4and T6; the pleura will be seen to be pushed downward
224208686|NCT04256005|OTHER|Exercise|Participants will complete one of two exercise conditions (50% Delta GET or 105% VO2peak).
224208687|NCT03783845|COMBINATION_PRODUCT|amoxicillin 500mg and metronidazole 400mg|metronidazole 400mg and amoxicillin 500mg three times daily for two weeks
224208688|NCT06456398|OTHER|Virtual reality|"Through a randomized controlled trial, educational training will be designed, and pre- and post-tests will be conducted to compare the effectiveness of learning advanced anatomy using the Metaverse Virtual 3D Printing System in virtual reality, versus the traditional method of using flat diagrams to correlate with computed tomography scans."
224208689|NCT02698631|PROCEDURE|Conventional AF ablation|"Conventional AF ablation will be carried out according to the standard procedure. Atrial anatomical MRI information will be integrated into the navigation system. Ablation procedure will be carried out with a Smart Touch® catheter (temperature 45 °C, 40W or 30W for anterior or posterior wall, respectively).~Both in first and re-do procedures, procedure endpoint will be electrical isolation of all pulmonary veins."
224208690|NCT02698631|PROCEDURE|LGE-MRI guided AF ablation|"Post-processed LGE-MRI will be used to identify left atrial fibrotic patches and lesions surrounding pulmonary veins (re-do procedures). Both MRI atrial anatomical and fibrosis information will be integrated into the navigation system. Ablation procedures will be carried out with a SmartTouch® catheter (temperature 45°C, 40W or 30W for anterior or posterior wall, respectively).~* Procedural end-point for first ablation procedures will be isolation of all pulmonary veins, and encirclement and isolation of all atrial fibrotic areas.~* In re-do procedures, all left atrial fibrosis patches will be encircled and isolated and, for electrically non-isolated pulmonary veins, all anatomical gaps in lesions surrounding pulmonary veins (as identified in LGE-MRI) will be closed."
224208691|NCT00795782|PROCEDURE|Prophylactic central lymph node dissection|prophylactic ipsilateral versus bilateral central lymph node dissection
224208692|NCT00507182|PROCEDURE|Fluorescence Spectroscopy|1-5 lesions + several normal-looking areas inside the mouth exposed to a beam of light; exposed tissues will emit very small amounts of fluorescence (light) then will be removed.
224208693|NCT02465580|DRUG|hrIL-2 active|active group: placebo group =1:1
224208694|NCT02465580|DRUG|hrIL-2 placebo|active group: placebo group =1:1
223512785|NCT05522829|BIOLOGICAL|SCTV01E on D0|Day 0; intramuscular injection
223512786|NCT05522829|BIOLOGICAL|SCTV01E on D28|Day 28; intramuscular injection
223512787|NCT05522829|BIOLOGICAL|SCTV01E on D150|Day 150; intramuscular injection
223512788|NCT05522829|BIOLOGICAL|SCTV01E-1 on D120|Day 120; intramuscular injection
223512789|NCT05522829|BIOLOGICAL|SCTV01E on D120|Day 120; intramuscular injection
223512790|NCT00490412|DIETARY_SUPPLEMENT|Vitamin D supplement|Vitamin D3 (cholecalciferol), 50,000 IU as a single capsule, will be administered orally to subjects in Groups A and C once every four weeks during study visits.
223512791|NCT00490412|OTHER|Placebo|A placebo will be administered orally to subjects in Groups B and D once every four weeks during study visits.
223512792|NCT00425854|DRUG|BIBW 2992|high dose once daily
223512793|NCT05474716|DRUG|Brimonidine tartrate 0.2% ophthalmic solution|Topical Brimonidine tartrate 0.2% bid ophthalmic solution. A selective alpha 2 adrenergic agonist with ocular hypotensive and neuroprotective properties used in glaucoma and ocular hypertension.
223680427|NCT02535780|PROCEDURE|Transcranial magnetic stimulation|TMS
224315589|NCT05368116|OTHER|Video Assisted Self Management Program|"The main aim of this intervention is to educate the cancer patients receiving chemotherapy regarding the management of chemotherapy related side effects.~It will be one to one teaching session of 10-20 minutes conducted by the principal researcher with the help of a video on self management of chemotherapy related side effects and the video will focus on the self management of selected side effects of chemotherapy including nausea vomiting , Diarrhea , Fever , Mucositis , Skin changes , and Alopecia related distress.~The participants were given video when they comes to the Oncology day care and researcher instructs the participants to watch the video and at the same time the doubts asked by the participants were cleared by the researcher."
223619264|NCT03080857|OTHER|Virtual Platform|The platform will direct patients to review the Canadian Cardiovascular Guidelines and the Heart \& Stroke website for commonly asked questions relating to atrial fibrillation, as well as recommendations regarding nutrition and activity.
223619265|NCT03080857|DEVICE|AliveCor Heart Monitor|A substudy of patients enrolled into the CSAF Tool study who own a compatible smart phone will be randomized to the Alive Cor Heart Monitor plus the virtual platform versus the virtual platform alone. The purpose of this substudy is to assess the feasibility and effect of incorporating Alive COR into a virtual online patient-education platform on patients' quality of life and AF-related emergency room visits and hospitalizations.
223619266|NCT01650298|OTHER|Drug (Direct thrombin or Factor Xa inhibitor)|Patient will stop or restart drug per cardiac device information (AT/AF diagnostics for prespecified AT/AF episode duration per day and total burden).
223619267|NCT00699036|DRUG|avandia|4 mg twice daily
224315590|NCT05368116|OTHER|Standard of care|Standard of care
224315591|NCT00004757|DRUG|acyclovir|
224315592|NCT01085357|PROCEDURE|Cataract Surgery|Cataract Surgery involves the removal of the natural lens, which has become clouded (called a cataract), and insertion of an artificial lens (called an intraocular lens). This procedure is done through a small surgical incision in the eye.
224315593|NCT01085357|DEVICE|CyPass Micro-Stent|The CyPass Micro-Stent is a small tube with a through-lumen designed to redirect aqueous fluid from the front to the back of the eye. The CyPass is implanted in the eye after completion of cataract surgery.
223512794|NCT01378273|DRUG|Epo|Enrollment will occur within 24 hours of birth. Study drug will be administered intravenously for the first 6 doses. Subjects in the Epo arm will then receive 400 U/kg/dose three times a week until they reach 32-6/7 weeks postmenstrual age. Control infants will receive sham injections.
223512795|NCT01378273|OTHER|Control|Subjects will receive 6 doses of vehicle intravenously during the first 2 weeks of life. Doses will be administered at 48 hour intervals from the time of enrollment. Following high dose administration, sham subcutaneous injections will be given three times a week through to 32-6/7 weeks postmenstrual age.
223619268|NCT00699036|DRUG|metformin|500 mg twice daily for 48 weeks
223619269|NCT00699036|DRUG|losartan|losartan 50 mg once daily
223619270|NCT02153593|DRUG|Tranexamic Acid|1g intra-articular before closing the wound surgery
224208695|NCT02515357|BEHAVIORAL|Mediterranean lifestyle|Comprehensive 6-month lifestyle intervention (7 60-min group counselling sessions) aiming at promoting adherence to the Mediterranean lifestyle (food and food group consumption according to the Mediterranean diet, beneficial culinary practices, seasonality and locality of foods consumed, socialization during meals, adequate rest during the day through night sleep and siesta nap, sleep hygiene recommendations and adoption of a physically active lifestyle) and at achieving a 5-10% weight loss.
224208696|NCT02515357|BEHAVIORAL|Standard care|General written instructions regarding the adoption of a healthy lifestyle.
224208697|NCT02515357|BEHAVIORAL|Mediterranean diet|Comprehensive 6-month lifestyle intervention (7 60-min group counselling sessions) aiming at promoting adherence to the Mediterranean dietary pattern (food and food group consumption according to the Mediterranean diet, beneficial culinary practices and seasonality and locality of foods consumed) and at achieving a 5-10% weight loss.
223619271|NCT02153593|DRUG|Fibrin glue|5mL intra-articular before closing the wound surgery
223619272|NCT02153593|PROCEDURE|Electrocauterization|Coagulation blood from vessels by means of a electrocautery
223619273|NCT02321241|DRUG|Aflibercept (EYLEA, BAY-86-5321)|"1. st year: 3 monthly injections followed by 1 injection every two months~2. nd year and following: injection according the visual and anatomical results observed the 1st year"
223619274|NCT02413918|DRUG|iloperidone|Qualifying subjects will take iloperidone starting at 2mg and up to a minimum of 12mg, maximum of 24mg, for 20 weeks in conjunction to the subjects current lithium, and or divalproex, and or lamotrigine.
223512796|NCT05417386|DRUG|FOLFIRINOX|Combination of the drugs 5-Fluorouracil (5-FU), Oxaliplatin, Irinotecan, and Leucovorin given by intravenous infusion
223512797|NCT05417386|DRUG|Oxaliplatin|Part of the FOLFIRINOX drug combination, given by intravenous infusion
223512798|NCT05417386|DRUG|Leucovorin|Part of the FOLFIRINOX drug combination, given by intravenous infusion
223512799|NCT05417386|DRUG|Irinotecan|Part of the FOLFIRINOX drug combination, given by intravenous infusion
223619275|NCT05697783|DRUG|Administration of methadone instead of fentanyl patch|comparison of delirium rates in methadone vs fentanyl patch treated patients
223619276|NCT04985526|OTHER|Octeniderm (octenidine dihydrochloride, 1-propanol, 2- propanol)|Administering Octeniderm (octenidine dihydrochloride, 1-propanol, 2- propanol) or 0,9% sodium chloride (as control agent) to the skin
223619277|NCT04309292|DIETARY_SUPPLEMENT|Prebiotic food supplement|Darmocare Pre = trade name Gut microbiome modulator
223619278|NCT04309292|DIETARY_SUPPLEMENT|Protein supplement|commercially available protein supplementation with high leucine content
223619279|NCT04309292|DIETARY_SUPPLEMENT|Maltrodextrin (placebo)|Starchy substance
223680428|NCT02535780|PROCEDURE|Transcranial direct current stimulation|tDCS
223680429|NCT00997113|DRUG|propofol|1 mg/kg IV followed by 0.5 mg/kg iv prn sedation
224208698|NCT00038129|PROCEDURE|Intramedullary nail implant|Insertion of an intramedullary nail during tibial fracture fixation with or without prior reaming of the intramedullary canal.
223619280|NCT01147042|DRUG|IFN-gamma|Following a washout period subjects have a subcutaneous injection of 50 mcg per meter squared once per week, Monday, for 4 weeks, twice per week, Monday and Thursday, for 4 weeks, then thrice per week, Monday, Wednesday, Friday, for 4 weeks. Total treatment period is 12 weeks.
224208699|NCT00131430|DRUG|taranabant|
224208700|NCT05014425|PROCEDURE|pancreaticoduodenectomy|
224208701|NCT00982774|BIOLOGICAL|LEISH-F2 + MPL-SE vaccine|LEISH-F2 protein (10 ug) + MPL-SE (25ug) Three injections, 14 days apart
224208702|NCT03413969|BEHAVIORAL|CREATION|The physician-oriented intervention will consist of a two-day weekend retreat that focuses on the application of CREATION Health principles in order to reduce burnout and perceived stress and improve well-being and empathy. There will be one four-hour session about each of the following CREATION Health principles: Choice, Trust, Interpersonal Relationships, and Outlook.
224208703|NCT04891367|OTHER|Cognitive behavioral therapy|The G-CBT manual for adolescents has been developed in the OCD-clinic in Aarhus and pilot tested in Aarhus. The G-CBT manual is based on the NordLOTS I-CBT manual in overall content and structure, with a few additional elements added with inspiration from previous individual and group CBT literature as well as the author's ideas. The main therapeutic ingredient is exposure and response prevention. The manual is made up of three individual family sessions, 13 weekly adolescent group sessions, three parent group sessions and two adolescent group booster sessions.The manual contains detailed guiding of therapists for each session and a comprehensive collection of working sheets for the adolescents to be used during sessions.
224208704|NCT05089240|DEVICE|Ophthalmic lens with extra power|
224208705|NCT01284244|DEVICE|Uresta pessary|Participants randomized to the Uresta group will be fitted with device before immediately before performing the pad test. The Uresta pessary is made of medical grade rubber that has been extensively tested for safety. It is bell-shaped, with a narrow tip that allows for easy insertion into the vagina in a similar fashion to a tampon. The device can be easily inserted, and removed by a patient for use when needed. The Uresta comes in 3 sizes. Fitting starts with insertion of the smallest size. If urine leakage continues with valsalva or a cough stress test, it can be replaced by one size larger, until leakage is stopped. If the device prevents the patient from being able to void or is uncomfortable due to its size, the smaller size is replaced. Following the pad test, the participant will be given the opportunity to keep the device for continued use, or remove it if desired.
224208706|NCT01284244|DEVICE|Silastic ring|The silastic ring is a plastic flexible ring similar to that used to administer vaginal estrogen (Estring). It is well tolerated and would not contain any medications. Immediately before performing the pad test, it would be placed high in the vagina, away from the urethra. It would be removed immediately after the pad test. Draping will conceal from the patient which device was inserted.
224208707|NCT01143272|DRUG|Saccharomyces boulardii|Units: 500 mg per day Route of administration : Oral Use Hard-Capsule
224208708|NCT01143272|DRUG|Placebo|Placebo
224208709|NCT02323139|DRUG|Azacitidine and LDE255|Azacitidine at maximum tolerated dose. LDE255 at dose escalation (200, 400 or 800 mg)
224208710|NCT01533272|DRUG|Tenofovir, emtricitabine, maraviroc|experimental drug
224208711|NCT01533272|DRUG|Tenofovir, emtricitabine, lopinavir/r|Lopinavir/r 400mg BID
224208712|NCT00303316|BIOLOGICAL|DTaP-IPV//PRP~T combined vaccine|0.5 mL, Intramuscular
224208713|NCT00303316|BIOLOGICAL|DTaP-IPV//PRP~T combined vaccine|0.5 mL, Intramuscular
224208714|NCT01726335|DRUG|Risperidone prolonged release|Risperidone will be administered as intramuscular injection as 25 milligram (mg) every two weeks, from Week 1 to 50, wherein after Week 3, dose may be adjusted up to 50 mg at physician criterion. For first two weeks, previous oral antipsychotic drug will be maintained and the dose will be gradually decreased and will cease at Week 3.
224208715|NCT01586624|DRUG|Vandetanib, Selumetinib|"Cycle 1: Vandetanib higher (lead in) dose of 300 mg OD (Days 1 to 4) followed by vandetanib steady state dose of 100 mg OD (Days 5 to 14) followed by vandetanib steady state dose of 100 mg OD + 25 mg of selumetinib BD (28 days). Cycle 1 is 42 days long.~Cycle 2 onwards: Vandetanib steady state dose of 100 mg OD + 25 mg of selumetinib BD (28 days). From Cycle 2, cycles are 28 days long.~Patients will be allowed to receive 6 cycles. If the patient is still benefiting clinically with no unacceptable toxicity, then the Investigator can ask the Sponsor for continuation of treatment."
224208716|NCT01586624|DRUG|Vandetanib, Selumetinib|"Cycle 1: Vandetanib higher (lead in) dose of 300 mg OD (Days 1 to 4) followed by vandetanib steady state dose of 100 mg OD (Days 5 to 14) followed by vandetanib steady state dose of 100 mg OD + 50 mg of selumetinib BD (28 days). Cycle 1 is 42 days long.~Cycle 2 onwards: Vandetanib steady state dose of 100 mg OD + 50 mg of selumetinib BD (28 days). From Cycle 2, cycles are 28 days long.~Patients will be allowed to receive 6 cycles. If the patient is still benefiting clinically with no unacceptable toxicity, then the Investigator can ask the Sponsor for continuation of treatment."
224208717|NCT01586624|DRUG|Vandetanib, Selumetinib|"Cycle 1: Vandetanib higher (lead in) dose of 300 mg OD (Days 1 to 4) followed by vandetanib steady state dose of 100 mg OD (Days 5 to 14) followed by vandetanib steady state dose of 100 mg OD + 75 mg of selumetinib BD (28 days). Cycle 1 is 42 days long.~Cycle 2 onwards: Vandetanib steady state dose of 100 mg OD + 75 mg of selumetinib BD (28 days). From Cycle 2, cycles are 28 days long.~Patients will be allowed to receive 6 cycles. If the patient is still benefiting clinically with no unacceptable toxicity, then the Investigator can ask the Sponsor for continuation of treatment."
223619281|NCT03338777|BIOLOGICAL|Suicide plus immunogene therapy|"1. Intra and peritumoral infiltrates with multiple injections of 0.1 ml/cm2 or 0.2 ml/cm3 of lipoplexes bearing the HSVtk suicide gene (1: 1; 1 mg/ml, according to tumor size), co-administered with GCV (12.5 mg/ml). Patients start with a minimum of 0.5 ml and at the 3rd week, the maximum dose is scaled according to the tumor size up to 2 ml maximum.~2. Treated simultaneously with a subcutaneous vaccine produced with:~   * Formolized allogeneic tumor extracts and,~  * Lipoplexes carrying hIL-2 and hGM-CSF genes (0.5 mg each)."
223619282|NCT04233801|DRUG|Empagliflozin|Empagliflozin
224208718|NCT01586624|DRUG|Vandetanib, Selumetinib|"Cycle 1: Vandetanib higher (lead in) dose of 300 mg OD (Days 1 to 4) followed by vandetanib steady state dose of 100 mg OD (Days 5 to 14) followed by vandetanib steady state dose of 100 mg OD + 100 mg of selumetinib OD (28 days). Cycle 1 is 42 days long.~Cycle 2 onwards: Vandetanib steady state dose of 100 mg OD + 100 mg of selumetinib OD (28 days). From Cycle 2, cycles are 28 days long.~Patients will be allowed to receive 6 cycles. If the patient is still benefiting clinically with no unacceptable toxicity, then the Investigator can ask the Sponsor for continuation of treatment."
224315594|NCT01439412|PROCEDURE|Acupuncture and standard treatment|"This group will get standard treatment in general practice in accordance with national guidelines, i.e. general advice about activity, prescription of pain relievers (paracetamol, eventually ibuprofen and eventually tramadol), and eventually sick leave.~In addition they also will receive one treatment of standardized acupuncture procedure during the consultation.~The acupuncture treatment starts with distal points in the right hand: Lumbar Pain Points (Yaotongxue), strong stimulation for one minute. With the needles still positioned, the patient is instructed to make cautious back and hip movements in 2 minutes. Then the patient lies down on a bench to treat the local points Huatuojiaji (Jiaji) bilaterally in the segments of the L2-L4 for 5 minutes."
223619283|NCT04233801|DRUG|Placebo|Placebo
223619284|NCT00761475|PROCEDURE|mesh supported closure|onlay mesh supported closure midline laparotomy
223619285|NCT00761475|PROCEDURE|primary closure|primary closure of the midline
223619286|NCT00761475|PROCEDURE|mesh supported closure|sublay mesh supported closure midline laparotomy
223619287|NCT03441438|DIETARY_SUPPLEMENT|Water|Serum and urine markers will be obtained after drinking 5 oz of water
223619288|NCT03441438|DIETARY_SUPPLEMENT|Red wine|Serum and urine markers will be obtained after drinking 5 oz of water
224315595|NCT01439412|OTHER|Standard treatment in general practice|This group will get standard treatment in general practice in accordance with national guidelines, i.e. general advice about activity, prescription of pain relievers (paracetamol, eventually ibuprofen and eventually tramadol), and eventually sick leave.
223512800|NCT05417386|DRUG|5-Fluorouracil (5-FU)|Part of the FOLFIRINOX drug combination, given by intravenous infusion
223512801|NCT05417386|DRUG|NIS793|Given by intravenous infusion
223512802|NCT05417386|RADIATION|Chemoradiation|Combination of Chemo (Capecitabine) and Radiation Therapy
223512803|NCT05417386|DRUG|Capecitabine|Taken Orally as part of Chemoradiation
223512804|NCT05417386|RADIATION|Radiation Therapy|Radiation Therapy as part of Chemoradiation
223512805|NCT05417386|PROCEDURE|Surgery|Surgical removal of tumor
223512806|NCT06269666|DEVICE|P200TxE|SLO and OCT imaging
223512807|NCT03546257|DEVICE|magnifying endoscopy with narrow band imaging (ME-NBI)|A system consisting of a magnifying endoscope combined with narrow-band imaging (NBI), with the spectral band width narrowed by optical filters, was developed to enhance visualization of mucosal surface structure and vascular architecture. There were some reports that the magnifying endoscopy with narrow band imaging (ME-NBI) is superior to predict the histologic differentiation, depth of invasion and lesion margin than WLE.
223512808|NCT01505803|DIETARY_SUPPLEMENT|Zinc supplements|Participants will receive 40 mg of zinc each day for 12 weeks.
223512809|NCT01505803|DIETARY_SUPPLEMENT|Omega 3 supplements|Participants will receive 2 g of omega 3 fatty acids each day for 12 weeks.
223512810|NCT01505803|DIETARY_SUPPLEMENT|Placebo supplements|Participants will receive placebo supplements each day for 12 weeks.
223512811|NCT03814629|DRUG|Weifuchun|The treatment group（Weifuchun group）was given Weifuchun tablets, 4 tablets each time, 3 times a day, and 1 hour after meals. The control group(vitamin group) was given vitamin tablets (0.2 g), 4 tablets each time, 3 times a day, and 1 hour after a meal.
223512812|NCT02042144|DRUG|Stivarga (Regorafenib, BAY73-4506)|Patients diagnosed with mCRC who have been previously treated with, or are not considered candidates for, other locally approved standard treatment(s) and for whom the decision has been made per investigator's routine treatment practice to prescribe regorafenib
223512813|NCT00195611|DRUG|Prevenar|
223512814|NCT03944876|DRUG|Botulinum toxin type A|Botulinum toxin 25 Allergan units in 0.5 ml Sodium Chloride (NaCl) 0.9 % Braun. One injection in the headache side of the face, targeted at the sphenopalatine ganglion (SPG)
223512815|NCT03944876|DRUG|placebo|0.5 ml Sodium Chloride (NaCl) 0.9% Braun. One injection in the headache side of the face, targeted at the sphenopalatine ganglion (SPG)
223512816|NCT06964230|DRUG|T3D-959|"Experimental:~T3D-959 30 mg dose: T3D-959 is a small molecule dual nuclear receptor agonist that regulates transcription of genes, in particular those involved in glucose energy and lipid metabolism. T3D-959 is 15-times more potent for PPAR delta than for the secondary target of the drug, PPAR gamma. The 15 mg strength capsules contain 15mg T3D-959, pregelatinized starch NF, magnesium stearate NF, and size 0, hard gelatin, white/white, opaque, unmarked capsules. Subjects will ingest two size 0, 15mg capsules once per day in the morning."
223512817|NCT06964230|OTHER|Placebo Comparator|Placebo used to compare to T3D-959 drug
223512818|NCT06964516|PROCEDURE|The group using the whole-breast bandaging method|Use 1 to 2 pieces of sterile loose gauze to knead into a gauze ball, press it on the residual cavity. Then, continue to use 5 to 8 pieces of loose gauze to stack gauze balls within a diameter of 5 cm around the wound for bandaging. Finally, apply compression bandaging with an elastic bra. The time for compression bandaging with the elastic bra is 24 hours.
223512819|NCT06964516|PROCEDURE|The group using the local bandaging method|Knead one or two pieces of loose gauze into a gauze ball to replace multiple gauze balls and place it in the residual cavity. Then, use elastic medical adhesive tape for local compression and sticking. Finally, place a pure cotton clean towel inside the elastic bra and wear the elastic bra for just one day.
223512820|NCT06963892|BEHAVIORAL|Neuromuscular Exercise Programme (GLA:D®-based|Participants underwent supervised neuromuscular exercise sessions based on the Good Life with osteoArthritis in Denmark (GLA:D®) programme. Exercises targeted dynamic joint stability, balance, proprioception, functional movements, and muscle strengthening. Sessions were held once weekly, lasting approximately 60 minutes each, over six consecutive weeks. The intervention was tailored progressively to each participant's capabilities, symptoms, and pain tolerance.
223619289|NCT03441438|DIETARY_SUPPLEMENT|Polyphenolic Compounds|Serum and urine markers will be obtained after consuming 100 mg of provinols powder
223619290|NCT04397510|DRUG|Heparin|Nebulized Heparin
223619291|NCT04397510|DRUG|0.9% Sodium-chloride|Nebulized 0.9% Sodium Chloride
223619292|NCT01860664|DRUG|hydrocortisone ophthalmic ointment 0.5%|"* Patients will be instructed to apply Hydrocortisone Ophthalmic Ointment 0.5% or placebo in the lower cul de sac or lid margin BID~* Patients will be instructed to not use the study medications at least 2 hours prior to their appointment.~* Study medication dosing details:~  * 0.05 grams hydrocortisone per gram of combination product~ * each application equal to 1/20th of a gram~ * total amount of active ingredient applied to each eye per application = 0.0025 grams hydrocortisone~ * total amount hydrocortisone applied per eye per day = 0.005 grams hydrocortisone~ * Total amount of active ingredient applied per eye throughout duration of the two week study = 0.07 grams hydrocortisone"
223619293|NCT01860664|DRUG|placebo|Mineral oil and white petrolatum
223619294|NCT06409806|OTHER|ECOG Array|"The patient will undergo their intracranial neurosurgical procedure as planned, using conventional brain retractors and neurosurgical equipment.~Standard neuromonitoring (EEG, MEP, SSEP) will be placed after the induction of neuroanaesthesia if indicated. Additional to whatever conventional EMBRI neuromonitoring is used, intraoperatively an ECoG array will be positioned under the retractor by the operating surgeon. Further electrode arrays may be placed on the cortical surface remote from the retractor as needed to establish a reference.~Typically we anticipate one ECoG array under the retractor blade with a reference array on an area of unretracted brain."
223619295|NCT04772872|OTHER|Assessment by Brazelton neonatal behavior for group A,Band C|"* Neonatal neurobehavior will be measured by Brazelton neonatal behavior assessment scale.~* Neonatal maturity will be represented by the variance of estimated gestational age that determined by new Ballard score.~* Apgar score will be represented by the variance of degree of scores.~* Birth weight will be measured in grams."
223619296|NCT04848675|OTHER|Inspiratory muscle strength training|Participants will perform inspiratory muscle strength training.
223619297|NCT04848675|OTHER|Brisk walking|Participants will perform brisk walking.
223619298|NCT03118414|OTHER|Physical Exercise|"Participants were trained by exercise program based on their initial muscle strength and balance condition.~They received a 30-minute exercise for 3sessions per week for 8 weeks in this study."
223619299|NCT03118414|OTHER|Virtual Reality|"Participants were trained with the guidance of VR system.The participants will be asked to choose 6 games from the list before each 30-minute session, and were asked to choose the games to include the upper limbs, lower limbs, and also for both strength and balance challenges instead of choosing the games that need to use only upper limbs or lower limbs, and only for strength or balance gain.~They received a 30-minute exercise for 3sessions per week for 8 weeks in this study."
223619300|NCT03118414|OTHER|Brain Exercise|Brain Exercise (BE) BE stimulates the executive function, planning, concentration, visual memory and eye-hand co-ordination of the participants throughout the training.For the brain exercise, participants needed to play cognitive stimulating games; Chinese Checker, Janga and Memory Matched pair game; in the sitting position. The participants needed to paly 10 minutes for each gamed and total duration of all 3 games was about 30 minutes in each session for 3sessions per week for 8 weeks in this study.
224208719|NCT01586624|DRUG|Vandetanib, Selumetinib|"Cycle 1: Vandetanib higher (lead in) dose of 300 mg OD (Days 1 to 4) followed by vandetanib steady state dose of 100 mg OD (Days 5 to 14) followed by vandetanib steady state dose of 100 mg OD + 125 mg of selumetinib OD (28 days). Cycle 1 is 42 days long.~Cycle 2 onwards: Vandetanib steady state dose of 100 mg OD + 125 mg of selumetinib OD (28 days). From Cycle 2, cycles are 28 days long.~Patients will be allowed to receive 6 cycles. If the patient is still benefiting clinically with no unacceptable toxicity, then the Investigator can ask the Sponsor for continuation of treatment."
224208720|NCT01586624|DRUG|Vandetanib, Selumetinib|"Cycle 1: Vandetanib higher (lead in) dose of 300 mg OD (Days 1 to 4) followed by vandetanib steady state dose of 200 mg OD (Days 5 to 14) followed by vandetanib steady state dose of 200 mg OD + 50 mg of selumetinib BD (28 days). Cycle 1 is 42 days long.~Cycle 2 onwards: Vandetanib steady state dose of 200 mg OD + 50 mg of selumetinib BD (28 days). From Cycle 2, cycles are 28 days long.~Patients will be allowed to receive 6 cycles. If the patient is still benefiting clinically with no unacceptable toxicity, then the Investigator can ask the Sponsor for continuation of treatment."
224208721|NCT01586624|DRUG|Vandetanib, Selumetinib|"Cycle 1: Vandetanib higher (lead in) dose of 300 mg OD (Days 1 to 2) followed by vandetanib steady state dose of 300 mg OD (Days 3 to 14) followed by vandetanib steady state dose of 300 mg OD + 50 mg of selumetinib BD (28 days). Cycle 1 is 42 days long.~Cycle 2 onwards: Vandetanib steady state dose of 300 mg OD + 50 mg of selumetinib BD (28 days). From Cycle 2, cycles are 28 days long.~Patients will be allowed to receive 6 cycles. If the patient is still benefiting clinically with no unacceptable toxicity, then the Investigator can ask the Sponsor for continuation of treatment."
224208722|NCT01586624|DRUG|Vandetanib, Selumetinib|"Cycle 1: Vandetanib higher (lead in) dose of 300 mg OD (Days 1 to 4) followed by vandetanib steady state dose of 200 mg OD (Days 5 to 14) followed by vandetanib steady state dose of 200 mg OD + 50 mg of selumetinib BD (28 days). Cycle 1 is 42 days long.~Cycle 2 onwards: Vandetanib steady state dose of 200 mg OD + 50 mg of selumetinib BD (28 days). From Cycle 2, cycles are 28 days long.~Patients will be allowed to receive 6 cycles. If the patient is still benefiting clinically with no unacceptable toxicity, then the Investigator can ask the Sponsor for continuation of treatment."
224208723|NCT00822263|DRUG|N-acetyl-cysteine (NAC)|Anti-oxidant in a pill format
224208724|NCT00822263|DRUG|Placebo|Control for study
224208725|NCT02063386|DRUG|AZD1722|Single oral dose 15 mg of \[14C\]AZD1722
224208726|NCT04393155|OTHER|COVID-19+ observational|This is observational -- there is no intervention
223619301|NCT05959044|DRUG|Folic Acid Tablet|oral 5mg tablet two times daily for 8 weeks
224208727|NCT00545181|DRUG|Vaginal acidifying gel (RepHresh)|"placement of vaginal acidifying gel into vagina to restore normal vaginal pH."
224208728|NCT00545181|DRUG|Metronidazole control|oral metronidazole therapy alone
223619302|NCT05959044|OTHER|Placebo|orally 5mg two times daily for 8weeks
223619303|NCT01026545|DRUG|PF-04287881|500 mg once daily for 10 days
223619304|NCT01026545|DRUG|Placebo|To match 500 mg dose once daily for 10 days
223761501|NCT06909084|PROCEDURE|Myringotomy with ventilation tube|Under microscope tympanic membrane was visualized after cleaning the external auditory canal and myringotomy incision was given with the help of myringotome in anteroinferior quadrant of tympanic membrane. Secretions from middle ear were drained by suction. A tympanostomy tube (Shepard tube) of appropriate size was placed in the incision and canal was packed with bismuth iodoform paraffin paste which was removed after 24 hours.
224208729|NCT06541717|OTHER|Video-Based Fertility Awareness Training|Students will be shown 3 15-minute videos created by researchers on the anatomy and physiology of the male and female reproductive systems, the physiology of pregnancy, fertility awareness development and its importance in terms of infertility.
224208730|NCT04605523|PROCEDURE|blood withdrawal|Additional blood sample will be taken within blood collection as part of standard care
224208731|NCT01456702|PROCEDURE|risk stratification group|goal-directed volume therapy due to svv measurement or volume therapy via standard operated procedures in dependence of cardiac risk factores
224208732|NCT01875133|OTHER|altitude exposure|stay at different altitudes: 490, 1630, 2590 m
224208733|NCT01411670|DRUG|Human protein C concentrate|Continuous infusion of human protein C concentrate at the dose of 3 UI/Kg/Hr to reach a protein C plasma activity of 70-120%
224208734|NCT01411670|DRUG|Activated protein C|Continuous infusion of activated protein C at the dose of 24 micrograms/Kg/Hr for 96 hours
224208735|NCT01411670|DRUG|Placebo comparator|Standard treatment
224208736|NCT01543607|DEVICE|Radiofrequency ablation catheter (Habib EndoHBP)|Catheter placement into bile duct
224208737|NCT02868307|BEHAVIORAL|Answering questionnaire|
224208738|NCT01917578|DEVICE|Ultrasound|"1. Evaluation of the tumor size by sonography is performed before neoadjuvant chemotherapy and prior to surgery.~2. Measurement of tumor size refers to WHO standards."
224208739|NCT01917578|PROCEDURE|CNB|Typically, the pretreatment tumor specimen will be a core needle biopsy. Because 15% to 28% of patients will have no residual tumor after NAT, it is important to have an adequate pretreatment sample in which an unequivocal diagnosis of invasive carcinoma is established and evaluation of hormone receptors and HER2/ neu status is completed before treatment.
224208740|NCT01917578|PROCEDURE|BCS, Modified Radical Mastectomy|All patients after neoadjuvant chemotherapy are performed BCS and modified radical mastectomy.
223619305|NCT01026545|DRUG|PF-04287881|750 mg once daily for 10 days
223619306|NCT01026545|DRUG|Placebo|To match 750 mg dose once daily for 10 days
223619307|NCT01026545|DRUG|PF-04287881|1100 mg once daily for 10 days
223619308|NCT01026545|DRUG|Placebo|To match 1100 mg dose once daily for 10 days
224208741|NCT01917578|DEVICE|Pathologic Large Tissue Selected Table|"1. Pathologic large tissue selected table has obtained Chinese patent.Its license ID is CN101261200.~2. Each piece of breast tissues by cutting with the table has 3mm thickness."
224208742|NCT01917578|DEVICE|Leica TP1020|"Procedure:~1. Alcohol 70 % 1h~2. Alcohol 80 % 1h~3. Alcohol 85 % 1h~4. Alcohol 90 % 1h~5. Alcohol 95 % 1h~6. Alcohol Ⅰ 100 % 1h~7. Alcohol Ⅱ 100 % 1h~8. Xylene Ⅰ 2h~9. Xylene Ⅱ 2h~10. Xylene Ⅲ 2h~11. Paraffin 6h~12. Paraffin 6h"
224208743|NCT01917578|DEVICE|Pathologic Large Tissue Embedded Table|"1. The table is made of brass .It is applying for a chinese patent.~2. The table can simultaneously embed 8 piece of breast tissues."
224208744|NCT01917578|DEVICE|Leica SM2000 R|Each of paraffin section has 4 um thickness.
224208745|NCT01917578|PROCEDURE|HE Stain|"Procedure:~1. Xylene Ⅰ 60℃ 15-20 minutes~2. Xylene Ⅱ 60℃ 15-20 minutes~3. Alcohol 100% Ⅰ 3-5 minutes~4. Alcohol 100% Ⅱ 3-5 minutes~5. Alcohol 95% Ⅱ 3-5 minutes~6. Alcohol 90% Ⅱ 3-5 minutes~7. Wash in running tap water for 3 minutes~8. Hematoxylin 5-10 minutes~9. Wash in running tap water for 3 minutes~10. Differentiate in 1% acid alcohol for 30 seconds~11. Wash in running tap water for 1 minute~12. Bluing in 0.2% ammonia water for 30-60 seconds~13. Wash in running tap water for 3 minutes~14. Counterstain in eosin Y solution for 30-60 seconds~15. Wash in running tap water for 1 minute~16. Alcohol 90% Ⅱ 2-3 minutes~17. Alcohol 95% Ⅱ 2-3 minutes~18. Alcohol 100% Ⅱ 3-5 minutes~19. Alcohol 100% Ⅱ 3-5 minutes~20. Xylene Ⅲ 5-10 minutes~21. Xylene Ⅳ 5-10 minutes~22. Mounting with neutral resin"
224208746|NCT01917578|DEVICE|CX22|The residual tumor areas are microscopically outlined on each slice by pathologist.
224208747|NCT01917578|DEVICE|Epson V600|"1. Each slice that has been microscopically outlined is scanned by Epson V600.~2. Every image by scanning should be saved as JPG."
224208748|NCT01917578|DEVICE|MRI|"1. Evaluation of the tumor size by MRI was performed before neoadjuvant chemotherapy and prior to surgery.~2. Measurement of tumor size refers to WHO standards.~3. The images of patients which were scanned by MRI should be burned onto disc for 3d reconstruction."
223619309|NCT01026545|DRUG|PF-04287881|Optional cohort with dose not greater than 1100 mg
223619310|NCT01026545|DRUG|Placebo|Optional cohort to match dose not greater than 1100 mg
223619311|NCT01026545|DRUG|PF-04287881|750 mg dose once daily for 10 days
223619312|NCT01026545|DRUG|Placebo|To match 750 mg dose once daily for 10 days
223619313|NCT01026545|DRUG|PF-04287881|1100 mg dose once daily for 10 days
223619314|NCT01026545|DRUG|Placebo|To match 1100 mg dose once daily for 10 days
223619315|NCT00008008|BIOLOGICAL|filgrastim|
223619316|NCT00008008|BIOLOGICAL|sargramostim|
223619317|NCT00008008|DRUG|cyclophosphamide|
223619318|NCT00008008|DRUG|thiotepa|
223619319|NCT00008008|PROCEDURE|autologous bone marrow transplantation|
223619320|NCT00008008|PROCEDURE|bone marrow ablation with stem cell support|
223619321|NCT00008008|PROCEDURE|peripheral blood stem cell transplantation|
224208749|NCT01917578|PROCEDURE|Three-Dimensional Reconstruction|"A.Pathological images three-dimensional reconstruction:~1. Pathological images registration is based on skin and shear mark by Photoshop 13.0 software.~2. Residual tumor boundary on Pathological images after registration are outlined and taken three-dimensional reconstruction by 3D-doctor 4.0 software.~3. Observe the shrinkage modes in three-dimensional space.~4. According to WHO standard,the boundaries of all residual tumor images are displayed in one plane and the longest diameter and its longest perpendicular diameter of boundaries are measured in one-dimensional space.~5. According to RECIST standard,the longest diameter of boundaries of residual tumor images in three-dimensional space.~B.MRI images three-dimensional reconstruction:the procedure is similar to Pathological images three-dimensional reconstruction"
224208750|NCT01917578|DEVICE|Mammography|"1. Evaluation of the tumor size by mammography is performed before neoadjuvant chemotherapy and prior to surgery.~2. Measurement of tumor size and calcification extent refers to WHO standards.~3. Calcification extent is not only measured in mammography image but also under microscope."
224208751|NCT01917578|DRUG|TAC,TC,TA,CAF,CEF|"1. TAC:Docetaxel 75 mg/㎡ iv day 1 + Doxorubicin 50 mg/㎡ in day 1 + Cyclophosphamide 500 mg/㎡ iv day 1(Cycled every 21 days for 3 cycles)~2. TC:Docetaxel 75 mg/㎡ iv day 1 + Cyclophosphamide 600 mg/㎡in day 1(Cycled every 21 days for 2 cycles)~3. TA:Docetaxel 75 mg/㎡ iv day 1 + Doxorubicin 50 mg/㎡ in day 1(Cycled every 21 days for 2 cycles)~4. CAF:Cyclophosphamide 100 mg/㎡ po days 1-14 + Doxorubicin 30 mg/㎡ iv days 1,8 +5-fluorouracil 500 mg/㎡ iv days 1,8(cycled every 28 days for 3 cycles)~5. CEF:Cyclophosphamide 75 mg/㎡ po day 1-14 + Epirubicin 60 mg/㎡ iv days 1,8 + 5-fluorouracil 500mg/㎡ iv days 1,8(cycled every 28 days for 3 cycles)"
224208752|NCT01917578|DRUG|AC-P,TEC,AC,TC,TCH,CEF,TAC,CAF|"1. AC-P:Doxorubicin 60 mg/㎡ iv day 1 +Cyclophosphamide 600 mg/㎡ iv day 1(Cycled every 14 days for 4 cycles)→ Paclitaxel 175mg/㎡ by 3h iv infusion day 1(Cycled every 14 days for 4 cycles) or Paclitaxel 80mg/㎡ by 1h iv infusion weekly for 12 wks.~2. TEC:Docetaxel 75 mg/㎡ iv day 1 + Epirubicin 75 mg/㎡ in day 1 + Cyclophosphamide 500 mg/㎡ iv day 1(Cycled every 21 days for 6 cycles)~3. AC:Doxorubicin 60 mg/㎡ in day 1 + Cyclophosphamide 600 mg/㎡ iv day 1(Cycled every 21 days for 4 cycles)~4. TC:Docetaxel 75 mg/㎡ iv day 1 + Cyclophosphamide 600 mg/㎡in day 1(Cycled every 21 days for 4 cycles)~5. TCH:Docetaxel 75 mg/㎡ iv day 1 + Carboplatin AUC 6 iv day1(Cycled every 21 days for 6 cycles) + Trastuzumab 4 mg/kg iv wk 1 → Trastuzumab 2 mg/kg iv for 17 wks → Trastuzumab 6 mg/kg iv every 3 wks to complete 1 year.~6. CEF:Cyclophosphamide 75 mg/㎡ po day 1-14 + Epirubicin 60 mg/㎡ iv days 1,8 + 5-fluorouracil 500mg/㎡ iv days 1,8(cycled every 28 days for 6 cycles)"
224208753|NCT02184507|DIETARY_SUPPLEMENT|Supplement pre CABG|One sachet of the supplement was consumed daily for 7 days before surgery.
224208754|NCT02184507|DIETARY_SUPPLEMENT|Supplement post CABG|One sachet of the supplement was consumed daily for 30 days after surgery
224208755|NCT02184507|DIETARY_SUPPLEMENT|Supplement pre and post CABG|One sachet of the supplement was consumed daily for 7 days before surgery and 30 days after CABG
224208756|NCT02184507|DRUG|Placebo|One sachet of placebo was consumed daily for 7 days before surgery and 30 days after CABG
224208757|NCT02872337|BEHAVIORAL|Preoperative Physical Therapy Session|This was a one-on-one preoperative physical therapy session on preoperative education. These patients were also given access to a surgery specific web-based microsite
224208758|NCT02872337|BEHAVIORAL|Group Preoperative Education Session (per the standard of care)|
224208759|NCT01528878|RADIATION|Stereotactic Radiosurgery using the CyberKnife System.|"Radiation: Stereotactic Radiosurgery using the CyberKnife System. The CyberKnife system has been cleared by the U.S. Food and Drug Administration (FDA) to treat lesions, tumors and conditions, anywhere in the body when radiation treatment is indicated. To address movement of target lesion during the respiratory cycle, the Synchrony™ option will be used.~The Synchrony option precisely tracks tumors in or near the target organ as they move, enabling the highly focused beams of radiation to destroy the tumors with minimal injury to adjacent normal tissue. The Synchrony option records the breathing movements of a patient's chest and combines that information with sequential x-ray pictures of tiny markers inserted inside or in the proximity of the tumor to enable precise delivery of radiation during any point in the respiration cycle. The CyberKnife system with the Synchrony option enables reduced normal tissue exposure by using smaller treatment margins and increased accuracy."
224208760|NCT01335178|BEHAVIORAL|Intervention|The intervention consisted of the following elements: (a) Three motivational interviews, scheduled for baseline, one month, and three months; (b) Feedback on air quality in the home (PM2.5 was measured using a Sidepak and/or a Dylos monitoring device, and air nicotine was measured using passive air nicotine dosimeters); (c) Feedback on child's exposure via hair nicotine; (d) a website designed especially for the project \[parents.org.il\];and (e) various self-help materials, including a booklet, a magnet about TSE, and air fresheners.
224208761|NCT00778271|DRUG|Gabapentin 400mg capsules|
224208762|NCT02036528|DRUG|Gentamicin Topical Gel|
224208763|NCT02036528|DRUG|Ciprofloxacin|
223512821|NCT06963892|BEHAVIORAL|Usual Physiotherapy Care (NHS Standard)|Participants received standard NHS physiotherapy care for hip or knee osteoarthritis. This included routine joint mobility exercises, strengthening activities, general education, and advice. Sessions were delivered in outpatient clinics following standard practice without specific emphasis on neuromuscular control training. Frequency and duration-matched usual clinical care.
223619322|NCT00928486|DRUG|Lenalidomide|Lenalidomide 25mg PO for (days 1 - 21) of a 28-day cycle
223619323|NCT00928486|DRUG|Dexamethasone|Dexamethasone 40 mg by mouth (PO) daily (QD) on days 1-4, 9-12 and 17-20 of each 28 day cycle
223619324|NCT02660177|DRUG|Metamizole|metamizole IV administration
223619325|NCT00173407|PROCEDURE|immunohistochemical, methylation, gene transfection|
223619326|NCT03478540|DRUG|Anti-Retroviral Agents|First line antiretroviral therapy as recommended in China, e.g. tenofovir lamivudine and efavirenz
223619327|NCT01342913|DRUG|Fluticasone Furoate 100mcg/Vilanterol 25mcg|Inhalation Powder
223619328|NCT01342913|DRUG|Fluticaosne Propionate 500mcg/Salmeterol 50mcg|Inhalation Powder
223619329|NCT01447589|DRUG|nelfinavir|Nelfinavir tablets BD 7 days per week from D-7 of starting radiotherapy until completion of radiotherapy on D47. 3 dose levels: 750 mg bd; 1000 mg bd; and 1250 mg bd.
224208764|NCT02036528|DRUG|Doxycycline|
224208765|NCT05786053|PROCEDURE|graded recession of inferior oblique muscle|. Graded recession of IO muscle depends on the amplitude of the V-pattern and degree of IOOA. Eight mm recession for amplitude 7.5 to 10 degree and mild IOOA (10 degree or +1) ,10 mm recession for amplitude 11- 15 degree and moderate IOOA (11 -15 or +2) and maximum recession for amplitude more than 15 degree and marked IOOA (more than15 degree or +3). Simultaneous correction of the horizontal deviation was performed at the same sitting.
224208766|NCT00503854|BEHAVIORAL|Questionnaire|Ancillary studies
224208767|NCT02458898|BEHAVIORAL|Educational Text Message Reminders|45 unique text messages designed by the Stanford Pediatric Gastroenterology physicians and nutritionists
224208768|NCT01000545|DRUG|Sulodexide|SLX 500 LRU, SLX 1000 LRU, SLX 2000 LRU per day to be taken orally for 12 months.
224208769|NCT01000545|DRUG|placebo capsules|8 soft-gel capsules per day to be taken orally for 12 months
224208770|NCT01433198|OTHER|Aquatic training|Aquatic training during a 6 weeks program (15 to 18 sessions of 1 hour)
224208771|NCT01953627|PROCEDURE|Surgical procedure with the system Kymerax|
224208772|NCT01953627|DEVICE|The system Kymerax|
224208773|NCT00448682|DRUG|Docetaxel|
224208774|NCT00448682|DRUG|Floxuridine|
224208775|NCT00448682|DRUG|Leucovorin|
224208776|NCT00448682|DRUG|Oxaliplatin|
224208777|NCT00634582|DRUG|paricalcitol|
224208778|NCT00634582|OTHER|immunoenzyme technique|
224208779|NCT00634582|OTHER|laboratory biomarker analysis|
223619330|NCT01447589|RADIATION|Radical Radiotherapy|Total dose of 66 Gy delivered in 33 fractions (2.0 Gy/fraction) to the primary tumour plus a margin.
223619331|NCT00915954|DIAGNOSTIC_TEST|Oral Glucose Tolerance Test|Participants will have their blood drawn for a baseline value and then will be asked to drink a beverage with 75 grams of sugar. Blood will then be drawn every 30 minutes for 2 hours.
224208780|NCT00634582|PROCEDURE|dual x-ray absorptometry|
224208781|NCT00634582|PROCEDURE|quality-of-life assessment|
224208782|NCT01796860|OTHER|AFO|The purpose of this study is to investigate the impact of a specifically designed ankle foot orthosis (AFO, hinged, with tamarack joint and adjustable check strap) on the spatial and temporal gait parameters, electromyography (EMG), and walking endurance, in select individuals living with MS. Over the 13 week period, the subject will participate in 5 gait training sessions which will be at weeks 1, 2, 3, 7, and 10.
224208783|NCT04496882|DRUG|Vemlidy|25mg Tenofovir Alafenamide
224208784|NCT02903927|DEVICE|Implantation of CT LUCIA IOL|
224208785|NCT02903927|DEVICE|Implantation of Acrysof IQ SN60WF IOL|
224208786|NCT00159666|DRUG|pregabalin|
223619332|NCT00915954|DIAGNOSTIC_TEST|Subcutaneous administration of recombinant human IGF-1|Participants will receive a subcutaneous injection of recombinant human IGF-1 followed by a series of blood draws.
224208787|NCT03565666|DEVICE|iLet Bionic Pancreas insulin-only configuration with Humalog or Novolog|iLet Bionic Pancreas insulin-only configuration with Humalog or Novolog
224208788|NCT03565666|DRUG|iLet Bionic Pancreas insulin-only configuration with Fiasp|iLet Bionic Pancreas insulin-only configuration with Fiasp (faster insulin aspart)
223619333|NCT00915954|DIAGNOSTIC_TEST|Placebo|Participants will receive a subcutaneous injection of saline followed by a series of blood draws.
224208789|NCT03565666|OTHER|Usual care|Usual care
224208790|NCT01425931|PROCEDURE|Heart Lung machine|measurement of microcirculation with O2C device
224208791|NCT04960254|BEHAVIORAL|internet gaming addiction|"The Strengths and Difficulties Questionnaire (SDQ) parent : to asses behavioural change Socioeconomic Scale:It contains four main variables:1-The educational level of the father and mother.2-The occupation of the father and mother. 3-Total family income. 4-life style of the family.~Emotional Avoidance Strategy Inventory for Adolescents (EASI):The EASIA is a 17-item (Kennedy \& Ehrenreich-May 2017) measure assessing the use of emotionally avoidant strategies in adolescents.~The internet gaming addiction scale : t is used to evaluate internet gaming addiction."
224208792|NCT03549845|BEHAVIORAL|Cardiovascular Health Awareness Program|Cardiovascular disease prevention and health promotion
224208793|NCT01830712|DRUG|eptacog alfa (activated)|A review of retrospectively longitudinal data gathered in the routine follow-up from a subset of patients who underwent EOS in studies F7HAEM/USA/3/USA and F7HAEM/USA/4/USA (NCT01561391). Data will be compiled, analysed, and reported in aggregate form.
224208794|NCT05476276|DRUG|ISA specific|ISA specific interventions will be listed in their protocols.
224208795|NCT04428060|OTHER|PERSEUS CPR|Resuscitation based on patient physiology
224208796|NCT04428060|OTHER|Standard CPR|Resuscitation based on current guidelines
224208797|NCT04252326|OTHER|Survey|Doctors, Nurses and Dentists filled survey about adverse drug reractions
224208798|NCT02163031|DEVICE|devices used in the coronary angiography|devices used in coronary angiography by left or right radial route
224208799|NCT06543186|OTHER|Oral health education lecture|Conventional oral health education will be given by trained and calibrated dentists.
223619334|NCT05477615|DRUG|Lazertinib|\- Lazertinib 240mg (3 tablets, 80mg/1tablet) once a day, oral, before disease progression
223619335|NCT05477615|DRUG|Pemetrexed|\- Pemetrexed 500mg/m2 is administered on the 1st day every 3 weeks. One cycle of treatment is defined as continuous administration for 21 days. Pemetrexed and carboplatin can be administered in reduced doses according to the principles of each institution.
223619336|NCT05477615|DRUG|Carboplatin|\- Carboplatin AUC x 5 mg/mL.min is administered on the 1st day every 3 weeks. One cycle of treatment is defined as continuous administration for 21 days. Pemetrexed and carboplatin can be administered in reduced doses according to the principles of each institution.
223619337|NCT05723224|PROCEDURE|elective endoscopic gallbladder treatment|Access to the gallbladder will be performed from the stomach or duodenum using LAMS with electrocautery-enhanced delivery system such as Hot Axios, Boston Scientifics device or Hot Spaxus, Taewoong at the discretion of the endoscopist. A stent of 10 mm in diameter will be used if the largest gallstone will be smaller than 10 mm in size while greater diameter (≥15 mm stent) will be used if the largest gallstone will be larger than 10mm. Colecystoscopy lithotripsy will be performed, when needed, using mechanical lithotripsy and/or laser lithotripsy at the discretion of the endoscopist. First cholecystoscopy will be done 2 weeks after the index procedure
224208800|NCT06543186|OTHER|Oral health education via mHealth on WhatsaApp|For the oral health education intervention via mHealth, WhatsApp medium will be used to disseminate oral health educational material
224208801|NCT06543186|OTHER|Oral health education via Metaverse platform on Meta-OHE|For oral health education intervention via Meta-OHE, it will be done via computer.
224208802|NCT00817258|DRUG|cisplatin|Cisplatin 40mg/m2,weekly
224208803|NCT00817258|RADIATION|3D-CRT (three-dimensional conformal radiation therapy) or IMRT (intensity-modulated radiation therapy)|3D-CRT or IMRT
224208804|NCT02016755|BIOLOGICAL|HGF Plasmid|Intramuscular injection in the affected limb.
224208805|NCT06120179|DEVICE|The Bashir™ Endovascular Catheter (BEC|To demonstrate the efficacy and safety of the Bashir™ Endovascular Catheter for the administration of pharmaco-mechanical catheter directed therapy using pulse spray of r-tPA for the treatment of acute submassive pulmonary embolism.
224208806|NCT01681979|DRUG|Fluticasone propionate (with and without concurrent salmeterol)|"Fluticasone propionate is an inhaled corticosteroid used for the treatment of asthma, often in combination with the long-acting β-agonist salmeterol. For the primary endpoint, exposure status will be determined based on the individual receiving a prescription for the drug of interest (fluticasone propionate or another inhaled corticosteroid) in the 2 weeks immediately before the LMP date or during the first trimester of pregnancy.~Sensitivity analysis will be carried out categorising exposure based on mapping the duration of prescriptions based on the number of inhalers, number of puffs within an inhaler and the prescribed daily dose."
224208807|NCT03179956|DRUG|Ribociclib|Treatment with ribociclib \[600mg\] will be from Days 1-14, with surgical resection on Day 14. Labs (CBC, CMP, coagulation parameters) and an ECG will be checked once in a window defined by days 9-12.
224208808|NCT02399488|DEVICE|Masimo Radical 7|Simultaneous determination of haemoglobin with the continuous haemoglobin monitor, the central lanboratory coulter and a POC:
224208809|NCT01485588|DRUG|hI-con1™ 60µl|Phase 1: 60µl, 150µl, or 300µl per injection (in the eye) on Day 1 only
224208810|NCT01485588|DRUG|hI-con1™ 150µl|Phase 1: 60µl, 150µl, or 300µl per injection (in the eye) on Day 1 only
224208811|NCT01485588|DRUG|hI-con1™ 300µl|Phase 1: 60µl, 150µl, or 300µl per injection (in the eye) on Day 1 only
224208812|NCT02757261|DEVICE|Laser|Low-level laser therapy administrated to acupoints
224208813|NCT02757261|DEVICE|Occlusal splint|Occlusal splint with expander
224208814|NCT02757261|DEVICE|Placebo laser|Placebo laser (Low-level laser therapy administrated to acupoints)
224208815|NCT05020197|DIAGNOSTIC_TEST|self-questionnaires on attachment and PTSD|The questionnaires (attachement type, PTSD symptoms) are administered face to face at the inclusion visit (at D0-D3). Validated self-questionnaires in French will be sent to the patients, either electronically or by post, according to their choice at D30 and D90. To describe the characteristics of the subjects, socio-demographic data, lifestyle, and medical history will be collected. The questionnaires will be administered three times to study the evolution of the parameters over time.
224208816|NCT01582828|PROCEDURE|Epicardial (surgical) ablation|"* Pulmonary vein isolation with bipolar clamps and bipolar box lesion~* Epicardial atrial appendage closure"
224208817|NCT01582828|PROCEDURE|Hybrid|"Epicardial (surgical) ablation~* Pulmonary vein isolation with bipolar clamps and bipolar box lesion~* Epicardial atrial appendage closure~Endocardial assessment after 6-8 weeks, checking for isolation and if necessary touch up by RF ablation"
224208818|NCT00549107|DRUG|Levosimendan|
224208819|NCT00549107|DRUG|Milrinone|
224208820|NCT02085005|DRUG|Capecitabine|Pharmaceutical form:tablet Route of administration: oral
223619338|NCT03872375|DIETARY_SUPPLEMENT|Meal-Replacement Therapy|The meal replacement shake, consumed once per day on two consecutive days, will over a given week lead to negative energy balance and induce weight loss.
223619339|NCT03872375|BEHAVIORAL|Dietary Counseling|A Registered Dietitian of Nutrition will provide consultation on how to induce moderate weight loss.
223619340|NCT02474797|DEVICE|Diaphragmatic ultrasonography|"Daily Measure of Diaphragmatic Thickening Fraction (DTF) will be performed by a trained physiotherapist. Physiotherapist (A. LE NEINDRE). The patient will be then instructed to perform breathing to total lung capacity and then to exhale to residual volume, when it is possible (awaken patient). Awakening status will be recorded. Mechanically ventilated patients will be evaluated in Pressure Support (PS) mode (during daily PS mode research for patients with Controlled Ventilation), with the lower PS level tolerated. PS level will be recorded.~Thickening fraction (TF) measure is performed in B-mode using the following formula: TF (%) = \[(end-inspiration thickness - end-expiration thickness)/(end-expiration thickness) x 100\]. Diaphragmatic dysfunction is defined like a DTF \< 20% (7)."
223619341|NCT00923923|BEHAVIORAL|stress|compare levels of stress
224208821|NCT02085005|DRUG|Aflibercept AVE0005|Pharmaceutical form:concentrate for infusion Route of administration: intravenous
224208822|NCT02085005|DRUG|Oxaliplatin SR96669|Pharmaceutical form:solution for infusion Route of administration: intravenous
224208823|NCT02632227|PROCEDURE|TFU(transfontanel ultrasound)|The respiratory variation of the carotid artery blood flow peak velocity was measured using TFU before and after the fluid administration (10ml/kg for 20 min.)
224208824|NCT01372527|OTHER|TopCare: Use of provider knowledge vs. automated system|We will be evaluating the system in practices where providers are involved in determining to contact a patient, including the most appropriate outreach method, compared with practices where the system is fully automated without provider input.
224208825|NCT02476760|DRUG|DPP-4 inhibitors|Current exposure to DPP-4 inhibitors (ATC A10BH, A10BD07-A10BD13) will be defined as a prescription duration plus a 30-day grace period (to account for non-adherence and the biological half-lives of these drugs) that overlaps with the index day.
224208826|NCT02476760|DRUG|GLP-1 analogs|Current exposure to GLP-1 analogs (ATC A10BX04, A10BX07) will be defined as a prescription duration plus a 30-day grace
223619342|NCT06183580|OTHER|neurofeedback training involving dACC|"Participants are pseudorandomized to the dACC group to undergo neurofeedback (NF). NF training consists of four \~7.33 min NF training runs preceded by a 5 min baseline (no NF) and followed by a 5 min transfer run (no NF). Training entails NF blocks paired to a self-happy face along a bar that indicates changing levels of the dACC. During the control condition, participants will count backward (CB) from 100 cued by an unfamiliar happy face with no NF. During rest conditions, participants see the cue Rest and are asked to relax with their eyes open. During NF, participants will try to increase dACC neural activity by recalling happy memories. The colored bar indicating the neural activity will shift up or down depending on values provided by Turbo-BrainVoyager software. Green = Activity \> baseline and red = Activity \< baseline. Before and after NF training, suicide ideation severity, depression severity, and performance on self-processing behavioral tasks will be assessed."
223619343|NCT06183580|OTHER|neurofeedback training involving amygdala|"Participants are pseudorandomized to the rAMY group to undergo neurofeedback (NF). NF training consists of four \~7.33 min NF training runs preceded by a 5 min baseline (no NF) and followed by a 5 min transfer run (no NF). Training entails NF blocks paired to a self-happy face along a bar that indicates changing levels of the rAMY. During the control condition, participants will count backward (CB) from 100 cued by an unfamiliar happy face with no NF. During rest conditions, participants see the cue Rest and are asked to relax with their eyes open. During NF, participants will try to increase rAMY neural activity by recalling happy memories. The colored bar indicating the neural activity will shift up or down depending on values provided by Turbo-BrainVoyager software. Green = Activity \> baseline and red = Activity \< baseline. Before and after NF training, suicide ideation severity, depression severity, and performance on self-processing behavioral tasks will be assessed."
223619344|NCT02757638|OTHER|Stable isotope infusion|such as glycerol, D2O, tyrosine, phenylalanine, glucose, arginine, and citrulline
223619345|NCT06048302|DRUG|Obicetrapib|1 single dose of obicetrapib
224208827|NCT02476760|DRUG|Insulins|Current exposure to insulin (ATC A10A) will be defined as any use of insulin between base cohort entry and the index day.
224208828|NCT02476760|DRUG|Biguanides|Current exposure to biguanides (ATC A10BA) will be defined as a prescription duration plus a 30-day grace period (to account for non-adherence and the biological half-lives of these drugs) that overlaps with the index day.
224208829|NCT02476760|DRUG|Sulfonylureas|Current exposure to sulfonylureas (ATC A10BB or A10BC) will be defined as a prescription duration plus a 30-day grace period (to account for non-adherence and the biological half-lives of these drugs) that overlaps with the index day.
224208830|NCT02476760|DRUG|Thiazolidinediones|Current exposure to thiazolidinediones (ATC A10BG) will be defined as a prescription duration plus a 30-day grace period (to account for non-adherence and the biological half-lives of these drugs) that overlaps with the index day.
224208831|NCT02476760|DRUG|Alpha-glucosidase inhibitors|Current exposure to alpha-glucosidase inhibitors (ATC A10BF) will be defined as a prescription duration plus a 30-day grace period (to account for non-adherence and the biological half-lives of these drugs) that overlaps with the index day.
224208832|NCT02476760|DRUG|Meglitinides|Current exposure to meglitinides (ATC A10BX02, A10BX03) will be defined as a prescription duration plus a 30-day grace period (to account for non-adherence and the biological half-lives of these drugs) that overlaps with the index (event) day.
224315596|NCT04327323|DEVICE|CCM device implantation|CCM implantation involves the introduction of two active fixation stimulation leads, fixed on the interventricular septum, and connected to the CCM generator (Optimizer Smart IV, Impulse Dynamic, and any subsequent versions of the same device) inserted in the subcutaneous or submuscular pocket. The implantation is ususally performed using vascular access via right or left cephalic or subclavian vein. The CCM signal consists of 2-3 biphasic pulses lasting 10 msec (total duration of about 20 ms) with an amplitude between 4.0 and 7.5 V, delivered during the absolute refractory period of the ventricle, at a distance of 40 msec from ventricular sensing. The CCM device is compatible with other pacing and defibrillation devices already implanted in the patient; at the time of the implantation, the devices are checked in order to confirm the absence of interference between the devices. The patient is instructed to charge the device battery weekly.
224315597|NCT00435812|BIOLOGICAL|HEPLISAV and/or Placebo|Intramuscular (IM) injections on Week 0, Week 4; placebo (saline) injection at Week 24
224208833|NCT04586569|OTHER|Pediatric Interactive Relational Agent (PIRA)|The PIRA is an interactive, online tool used to educate children and families about their child's upcoming surgical and anesthesia experience.
224208834|NCT00179374|BEHAVIORAL|Tailored telephone intervention of education|Tailored telephone intervention to promote metabolic control of diabetes
224208835|NCT00179374|BEHAVIORAL|Print educational intervention|diabetes educational materials by mail
224208836|NCT05151822|OTHER|Training session with the virtual reality mask|Patients will have a training session with the virtual reality mask, the day before surgery. The training consists in the realization, by the patient, of a series of language or neuropsychological tests and evaluation of the acceptability of the device by the patient with Visual Analog Scale (device tolerance from 0 (intolerable) to 10 (completely tolerated)).
224208837|NCT05151822|OTHER|Monitoring of the device|In the operating room : installation and per-operative monitoring of the device. If the device was removed, the list of device side effects or surgery-related adverse events that was required discontinuation of the device will be established.
223619346|NCT04024891|DRUG|Phentolamine Mesylate Ophthalmic Solution 1%|1% phentolamine mesylate ophthalmic solution (Nyxol), a non-selective alpha-1 and alpha-2 adrenergic antagonist
223619347|NCT04024891|OTHER|Phentolamine Mesylate Ophthalmic Solution Vehicle (Placebo)|Topical Sterile Ophthalmic Solution
223619348|NCT02041325|DRUG|Lenalidomide|Subjects will receive oral CC-5013 (lenalidomide) at 25 mg qd for 7 days prior to and 7 days after the vaccine.
223619349|NCT02041325|DRUG|Placebo|Subjects will receive placebo for 7 days prior to and 7 days after the vaccine.
223619350|NCT03832348|DEVICE|PET scan imaging|3 PET scans will be performed after each 3 first infusions of Pembrolizumab
224208838|NCT05151822|OTHER|Acceptability of the device|After the surgery: evaluation of the acceptability of the device by the patient with Visual Analog Scale (device tolerance from 0 (intolerable) to 10 (completely tolerated))
224208839|NCT05151822|OTHER|Patient state of anxiety|Assessing patient's state of anxiety with the State-Trait Anxiety Inventory (STAI) after surgery.
224315598|NCT00435812|BIOLOGICAL|Engerix-B|Intramuscular (IM) injections on Week 0, Week 4, and Week 24
223619351|NCT05295849|BEHAVIORAL|Building Habits Together Online Weight Loss 6-Week Usability Trial|The intervention includes: the Facebook-delivered Diabetes Prevention Program (DPP) Lifestyle Intervention, MyFitnessPal and the Habit app. The DPP will be delivered within a counselor-led private Facebook group. It uses behavioral strategies to help participants 1) achieve a program assigned calorie goal based on amount needed to lose 1-2 pounds per week, 2) develop a healthy diet, and 3) engage in 150-300 minutes per week of moderate intensity exercise. Participants will be instructed to use MyFitnessPal for the first two weeks, the Habit app slip tracker and exercise planner for two weeks, and the Habit app problem solver for two weeks.
223619352|NCT06195709|COMBINATION_PRODUCT|Endocrine therapy|Consist in single agent endocrine therapy or in combination with targeted therapy, per guidelines and label. LH-RH agonist will be used in combination with endocrine therapy whenever appropriate and per label.
223619353|NCT06195709|COMBINATION_PRODUCT|Endocrine therapy combined with the local treatment of FES-negative lesions|Consist in single agent endocrine therapy or in combination with targeted therapy, per guidelines and label. LH-RH agonist will be used in combination with endocrine therapy whenever appropriate and per label. Cases with only 1 or 2 FES-negative lesions that are accessible to local treatment will be reviewed by the Centralized Reading Committee (including a radiation oncologist) to confirm the feasibility of local treatment.
223619354|NCT06195709|COMBINATION_PRODUCT|Chemotherapy|Consist in single agent chemotherapy, poly-chemotherapy, or antibody-drug conjugates, per guidelines and label. Patients who are eligible (per drug label) may receive PARP inhibitor if allocated to Arm B.
223619355|NCT02537613|DRUG|Obinutuzumab|Obinutuzumab given weekly during cycle 1, then monthly during cycles 2-6
223619356|NCT02537613|DRUG|Ibrutinib|Ibrutinib given once daily by mouth
223619357|NCT03397264|BIOLOGICAL|Aflibercept|Intravitreal injection
223619358|NCT03397264|BIOLOGICAL|OPT-302|Intravitreal Injection
224208840|NCT01506817|PROCEDURE|Dynamic contrast-enhanced MRI of the hands|The hand and wrist will be examined in a 3T Siemens Verio® MR scanner with the patients and normal controls supine and the hand along the side of the body (3T Verio) using a semiflex 15 channel body coil. Total imaging time varies between 30-35 minutes.
224208841|NCT04759716|OTHER|Health Literacy-based Weight Control Intervention|intervention arm will be applied to receive health literacy-based mobile Health App, smart sports watch Fitbit versa during the 12 months weight control program
224208842|NCT01382134|DRUG|Aspirin, desmopressin|Aspirin 100mg daily for 3 days Desmopressin 15 microgram subcutaneously once only
224208843|NCT01382134|DRUG|Placebo, desmopressin|Placebo 1 tab daily for 3 days Desmopressin 15 microgram subcutaneously once only
224208844|NCT01803035|DRUG|LTX-109 1 %|
224208845|NCT01803035|DRUG|LTX-109 2 %|
224208846|NCT01803035|DRUG|Placebo gel|
224208847|NCT02677402|OTHER|immersion|
224315599|NCT04637555|DRUG|sacubitril/valsartan|LCZ696 (sacubitril/valsartan) tablet will be available in 24/26 mg, 49/51 mg and 97/103 mg, respectively
223619359|NCT03397264|OTHER|Sham intravitreal injection|Sham (mock) intravitreal injection
223619360|NCT02003235|DEVICE|Daily watching videos using Reviview™, a dichoptic video display device, for 60 min|
223619361|NCT00599872|BIOLOGICAL|Standardized Ragweed Allergenic Extract|Standardized Ragweed Allergenic Extract, sublingual oral
223619362|NCT00599872|BIOLOGICAL|Placebo|Placebo, sublingual oral
223619363|NCT04355234|DIAGNOSTIC_TEST|identify SARS-CoV-2 infection by serology|Blood samples at delivery to identify SARS-CoV-2 infection by serology
224208848|NCT02751255|DRUG|all-trans retinoic acid (ATRA)|Phase 1 and 2: daratumumab 16 mg/kg, first 8 infusions are given weekly, then 8 infusions every 3 weeks, then every 4 weeks until progression Phase 1: ATRA 15, 30, or 45 mg/m2/day for 3 days. Phase 2: ATRA will be administered twice daily as an oral formulation at the MTD dose, or if no MTD is reached, at the dose of 45 mg/m2/day for 3 days. The first administration of ATRA will be given in the morning, two days before the scheduled daratumumab infusion. The last administration of ATRA will be given in the evening of the day that daratumumab was administered (days -2, -1, and 0; day 0 is the day of daratumumab infusion).
224208849|NCT06155149|OTHER|Mobile application|"Mobile application: The content of the mobile application that can be used continuously after the presentation in the education of families will consist of three parts.~In the first section: There will be short information notes and visuals on burn diagnosis and types.~Second part: Frequently seen burns as a result of home accidents will be introduced and the precautions to be taken will be included through visuals.~Third Section: First aid applications specific to each type of burn (scalding, fire-flame, hot contact, electrical, chemical) will be presented with visuals and information notes."
223619364|NCT04355234|BIOLOGICAL|collection of biological samples|Creation of a specific collection of biological samples for new investigations thanks to the collection of several biological samples at the time of maternal SARS-CoV-2 infection, at delivery and in the postpartum period in the parturient and her newborn.
223619365|NCT03388034|PROCEDURE|Nasopharyngeal sampling|A nasopharyngeal sample collected from each nostril by swabbing
223619366|NCT03388034|PROCEDURE|Blood Sampling|Blood sample by the tip of a finger (fingerprick)
223619367|NCT00126035|DEVICE|Migraid|
223619368|NCT01474317|DEVICE|G3 Investigational Blood Glucose Monitoring System|Untrained subjects with diabetes perform self Blood Glucose (BG) tests with capillary fingerstick blood and AST of the palm using the G3 meter and an investigational sensor. Study staff test subject venous blood and all BG results are compared to a reference laboratory glucose method. Untrained subjects utilize some additional features of the meter using the User Guide and provide feedback.
223619369|NCT01105910|OTHER|Systane Ultra Lubricant Eye Drops|1 to 2 drops in each eye 4 times per day for 30 days
223619370|NCT01105910|OTHER|Sensitive Eyes Eye Drops (Bausch & Lomb)|1 to 2 drops in each eye 4 times per day for 30 days
224208850|NCT06155149|OTHER|Family Information Training|Family Information Training: The content of the training to be held for families in the form of a powerpoint presentation is as follows: definition of burns, classification of burns, common causes of burns at home, measures to prevent burns at home, first aid applications in burns.
224315600|NCT00003643|BIOLOGICAL|bleomycin sulfate|
224315601|NCT00003643|BIOLOGICAL|filgrastim|
224315602|NCT00003643|DRUG|cisplatin|
224315603|NCT00003643|DRUG|etoposide|
224315604|NCT00003643|DRUG|paclitaxel|
224315605|NCT03957850|BEHAVIORAL|Cognitive Reappraisal Training|The training procedure is adapted from a study by Denny \& Ochsner (2014). Before the task, participants are instructed that they will be presented pictures and that these pictures will be preceded by a condition specific cue signaling the appropriate strategy during picture viewing. Participants are instructed to indicate their affective response to the image on a rating scale. The task involves 4 conditions: 1) Negative-decrease: participants are asked to view negative pictures and to decrease their affective response by reappraising the negative event. 2) Negative-attend/ 3) Neutral-attend/ 4) Positive-attend: participants are asked to view pictures and to respond naturally to them without trying to alter their affective response. The training task will be repeated over 4 training sessions.
224315606|NCT03957850|BEHAVIORAL|Control Training|The task in the control group is implemented to account for unspecific effects and is as similar as possible to the CR task except that it involves no negative-decrease (i.e., no reappraisal) condition. Instead, the control task only involves the three attend conditions (negative- attend, neutral-attend, positive-attend).
224315607|NCT04082338|BEHAVIORAL|VPN|"The intervention will be delivered through virtual patient navigation (VPN) toolkit system (a web/mobile application). The system includes education modules on HBV management, CHB patient success stories and virtual patient navigation clinical support for overcoming barriers.~In addition to the VPN, each participant will receive 5 text messages; one message once a week for 5 weeks on HBV management for every 6 months in the 18-month study period."
223619371|NCT05621330|DRUG|QL0911|The study in a 2:1 randomization ratio(144 subjects to QL0911). Qilu investigational product (QL0911 or placebo) will be administered in the clinic by a qualified healthcare provider as a subcutaneous injection.
223619372|NCT05621330|DRUG|Placebo comparator|The study in a 2:1 randomization ratio(72 subjects to Placebo ). Qilu investigational product (QL0911 or placebo) will be administered in the clinic by a qualified healthcare provider as a subcutaneous injection.
223619373|NCT03665636|DRUG|Triheptanoin|This is an open-label study. The UX007 (triheptanoin) starting dose will be 0.25 - 0.5 g/kg and titrated to a maximum of 2.5g/kg depending the on the subject's tolerance. The dose may be reduced if not tolerated. The compound will be administered 3-4 times per day, either at the end of a meal or with a snack. It should be given at least 2 hours apart from any cornstarch dose to allow each to act independent of one another, and to prevent the risk of increased gastrointestinal side effects. The doses may be held during episodes of gastroenteritis or diarrhea.
224208851|NCT00188279|PROCEDURE|Minimum Dose Computed Tomography (MnDCT) scan|Minimum Dose Computed Tomography (MnDCT) scan at regular follow up intervals for up to 5 years post-operatively.
224208852|NCT03663959|PROCEDURE|vaginal sacrospinous fixation procedure with dr.Aksakal's desta suture carrier|A right sacrospinous fixation using Dr. Aksakal's Desta suture carrier with two permanent sutures that combined the sacrospinous ligament and vaginal cuff fascia was done. The Desta suture carrier was developed for deep pelvic surgery, and the suture depth can be easily adjusted. After the vaginal hysterectomy, under the vaginal cuff mucosa, we created a tunnel through the spinous process with a straight tool. After passing the rectovaginal pillars, the perirectal space was entered and the ischial spine was palpated. With the help of an index finger placed on the spinous process, we placed two permanent sutures 1.5-2 cm medial to the spinous process on the sacrospinous ligament and iliococcygeus muscle complex using the Desta suture carrier. Next, permanent sutures were combined with the pubocervicovaginal and rectovaginal fascia under the vaginal cuff mucosa.
223619374|NCT00436150|BEHAVIORAL|Interpersonal therapy-based treatment|Participants assigned to receive interpersonal therapy-based treatment will focus on the psychological aspects of pregnancy and factors that may play a role in the development of postpartum depression in teenage mothers, such as poor social support, role transitions, and life stressors. Both groups will attend weekly 1-hour sessions for 5 weeks.
223619375|NCT00436150|BEHAVIORAL|Standard care|Participants assigned to receive standard care will focus more on the health issues associated with pregnancy and postpartum. Both groups will attend weekly 1-hour sessions for 5 weeks.
224315608|NCT04082338|BEHAVIORAL|TM|Receive TM on HBV management respectively once a week for 5 weeks for every 6 months in the 18-month study period.
224315609|NCT00034138|DRUG|oregovomab|
224315610|NCT06070558|DEVICE|MRI with Real Time MRI Rapid Flash sequence|MRI examination of temporomandibular joint with Real Time MRI Rapid Flash sequence
224315611|NCT03776916|OTHER|Simethicone administration 20-30 min before the procedure|Patients intake simethicone 20-30 min before the procedure
224315612|NCT03776916|OTHER|Simethicone administration 31-60 min before the procedure|Patients intake simethicone administration 31-60 min before the procedure.
223619376|NCT04283617|BEHAVIORAL|Intensification of insulin regimen/Nutrition|The intensification of the diabetes regimens will be managed by Dr. Sanchez Rangel, a fully trained attending endocrinologist, The weight goal will be to have no more than 5% weight change. Participants will have regular phone and in-person MD and nutritionist communication over the course of the 12-week study. All individuals will be asked to perform SMBG at least 4 times a day (before breakfast, lunch, dinner, and bedtime). The daily SMBG records will be sent to Dr. Sanchez Rangel weekly for review to guide adjustment of insulin regimens. Target blood glucose levels will be between 80-130 mg/dl before meals and between \< 180 mg/dl at bedtime. Throughout the study, individuals will be contacted via telephone call, email or through additional clinic visits as deemed necessary for maintenance of glycemic control. All individuals will receive education regarding the detection and proper management of hypoglycemia.
223619377|NCT04013386|DRUG|Aprepitant and Dexamethasone|Aprepitant capsule 80 mg and Dexamethasone 8 mg IVI
223619378|NCT04013386|DRUG|Mirtazapine and Dexamethasone|Mirtazapine tablet 30 mg and Dexamethasone 8 mg IVI
223619379|NCT04013386|DRUG|Dexamethasone|Dexamethasone 8 mg IVI
223680430|NCT00997113|DRUG|alfentanil|alfentanil 10 ug/kg immediately prior to propofol dose
223680431|NCT02948218|DEVICE|Acupuncture treatment|Acupuncture treatment will be the Traditional Chinese Medicine type. Acupuncture 3 times per week, 4 weeks is one treatment period. Every patient will be given 3 treatment period.
223680432|NCT01658813|DRUG|5-Fluorouracil and Interferon|5-Fluorouracil Interferon-alfa-2b
223680433|NCT00045721|DRUG|O6-benzylguanine|
223680434|NCT00045721|DRUG|polifeprosan 20 with carmustine implant|
223680435|NCT00045721|PROCEDURE|adjuvant therapy|
223680436|NCT00045721|PROCEDURE|conventional surgery|
223680437|NCT00045721|PROCEDURE|neoadjuvant therapy|
224315613|NCT03776916|OTHER|Simethicone administration > 60 min before the procedure|Patients intake simethicone administration \> 60 min before the procedure.
224315614|NCT03669224|OTHER|Nano Care Gold|Mixture of Gold and Silver nano particles suspended in 70 % Isopropyl alcohol. This group will be compared with no intervention group.
223619380|NCT03481894|DRUG|Kabiven®|"Infusion should start at a low dose (i.e., 12.5 to 25 mL/kg, corresponding to 10.6 to 21.2 kcal/kg/day, 0.49 to 0.98 g lipids/kg/day, 0.41 to 0.83 g amino acids/kg/day and 1.2 to 2.4 g dextrose/kg/day) followed by stepwise increase to the individual target for PN calories.~The daily dose of the study PN should be infused at a constant rate over 20 to 24 hours.~Route of Administration: Infusion into a central vein. Duration of Treatment: Study treatment will last for a minimum of 5 and a maximum of 8 consecutive days. Study treatment will be stopped if oral and/or enteral intake covers 80% or more of caloric requirements. If the indication for PN continues after 8 study days, PN will continue per normal institution policy."
223619381|NCT03481894|DRUG|Compounded standard parenteral nutrition|"Infusion should start at a low dose (i.e., 12.5 to 25 mL/kg, corresponding to 10.6 to 21.2 kcal/kg/day, 0.49 to 0.98 g lipids/kg/day, 0.41 to 0.83 g amino acids/kg/day and 1.2 to 2.4 g dextrose/kg/day) followed by stepwise increase to the individual target for PN calories.~The daily dose of the study PN should be infused at a constant rate over 20 to 24 hours.~Route of Administration: Infusion into a central vein. Duration of Treatment: Study treatment will last for a minimum of 5 and a maximum of 8 consecutive days. Study treatment will be stopped if oral and/or enteral intake covers 80% or more of caloric requirements. If the indication for PN continues after 8 study days, PN will continue per normal institution policy."
223619382|NCT02137863|DRUG|Dexmedetomidine|"Intravenously 1μg/kg/10min administered just before the procedure.~1 μg/kg/h administered during the angiography and was continued 1 hour after the angiography."
223619383|NCT02137863|DRUG|0.9 % NaCl|During 12 hours before the procedure 3 ml/kg/h 0.9 % NaCl infusion and 1 ml/kg/h during the angioplasty and 12 hours after the procedure.
223619384|NCT02137863|DRUG|0.9 % NaCl|"100 ml/10min infusion just before the angiography~1 ml/kg/h infusion during the angiography and was continued 12 hours after the procedure"
223619385|NCT04066439|OTHER|specimen|Immunohistochemistry analysis
223619386|NCT00453154|DRUG|Carboplatin|Given IV
223619387|NCT00453154|DRUG|Cisplatin|Given IV
223619388|NCT00453154|DRUG|Etoposide|Given IV
223619389|NCT00453154|OTHER|Laboratory Biomarker Analysis|Correlative studies
223619390|NCT00453154|OTHER|Placebo Administration|Given PO
223619391|NCT00453154|DRUG|Sunitinib Malate|Given PO
224208853|NCT03663959|PROCEDURE|Laparoscopic Pectocolpopexy procedure|First, the peritoneal layer above and lateral to the bladder was opened parallel to the round ligament toward the pelvic side wall on the right side. Then, with the guidance of the obliterated umbilical artery, lateral to the obliterated umbilical artery and medial to the external iliac vein, the iliopectineal ligament was found . At this point, a segment of approximately 3-4 cm2 was formed, exposing the iliopectineal (Cooper's) ligament. In this area, behind the obliterated umbilical artery, the obturator nerve could be seen, and special care was given not to make contact with the nerve. The same area on the left side was prepared using the same steps. Then, anterior part of the vaginal cuff was prepared for mesh fixation. Bilaterally, the ends of a polypropylene monofilament mesh (1,5x15 cm) were fixed to the iliopectineal ligament with nonabsorbable polypropylene or polyester sutures . The vaginal cuff was elevated to POP-Q level 0-1.
224208854|NCT04826952|PROCEDURE|Orchiectomy|Childhood testicular tumors deserve special diagnostic attention from the therapeutic point of view. A testicular tumor should be considered malignant until proven otherwise. In cases with suspicion of testicular tumors, the inguinal approach is preferred to the scrotal approach for scrotal violation.
224208855|NCT06536699|RADIATION|Radiotherapy - hypofractionated|Hypofractionated Radiotherapy of 55 Gy in 20 fractions in definitive setting and 52.5 Gy in 20 fractions in adjuvant setting. Total duration - 4 Weeks
224315615|NCT03669224|OTHER|No intervention|No intervention will be applied in this group. It will be the negative comparator. In this group only the standard of care will be applied, which means the steps will be cavity preparation followed by adhesive system then resin composite without any surface pre-treatment
223619392|NCT02946437|DRUG|Sevoflurane|Postconditioning with sevoflurane (0.5-1.5vol%) for 4 hours after coiling or clipping of cerebral aneurysm in patients with severe SAH
223619393|NCT02946437|DRUG|Propofol|Before and after postconditioning with sevoflurane the patients will be sedated with intravenous sedatives (midazolam or propofol). The quality of sedation before the postconditioning (propofol or midazolam) will be compared to the sedation one hour after starting the postconditioning (sevoflurane) in the same patient.
223619394|NCT02946437|DRUG|Midazolam|Before and after postconditioning with sevoflurane the patients will be sedated with intravenous sedatives (midazolam or propofol). The quality of sedation before the postconditioning (propofol or midazolam) will be compared to the sedation one hour after starting the postconditioning (sevoflurane) in the same patient.
223619395|NCT02946437|DEVICE|MIRUS™System|The MIRUS™System is the normally used standard equipment for the administration of volatile anaesthetics to patients.
224208856|NCT06536699|RADIATION|Radiotherapy - Conventional|Conventional Radiotherapy of 66 Gy in 30 fractions in definitive setting and 60 Gy in 30 fractions in adjuvant setting. Total duration - 6 Weeks
224315616|NCT03669224|OTHER|Chlorhexidine|2 % chlorhexidine gluconate. This group will be compared with no intervention group.
224315617|NCT06463522|PROCEDURE|Autologous Tumor-infiltrating Lymphocytes|Autologous Tumor-infiltrating Lymphocytes, 2.0\*10\^7/Kg, single intravenous infusion.
224315618|NCT06469502|PROCEDURE|Stretching Exercises|Group 1 will be included in the program consisting of stretching exercises only. Patients will receive a 6-week rehabilitation program consisting of 18 sessions of stretching exercises (3 times a week) under the supervision of a physiotherapist.
224315619|NCT06469502|PROCEDURE|Strengthening Exercises|Group 2 will be included in the program consisting of strengthening exercises only. Patients will receive a 6-week rehabilitation program consisting of 18 sessions of strengthening exercises (3 times a week) under the supervision of a physiotherapist.
223619396|NCT02423850|DEVICE|3D Wound Assessment Monitor (WAM) camera|Three-dimensional wound measurement (2D area, 3D area, perimeter, volume) using 3D-WAM camera
223619397|NCT00282035|RADIATION|APBI utilizing 3D-CRT radiation|Accelerated partial breast irradiation utilizing 3D-CRT
223619398|NCT00282035|RADIATION|Whole breast irradiation|Whole breast irradiation
224208857|NCT00951717|BEHAVIORAL|Behavioral education intervention|One education session with a social worker while at the hospital, provision of an educational pamphlet and summary sheet for partner, a needs assessment by the social worker 2 weeks after hospital discharge, and additional patient education and reinforcement of self-management skills, as needed
224208858|NCT05761015|DRUG|therapeutic program including intermittent drug intake and multimodal rehabilitation program|"The prescribed NSAID molecule shall be chosen according to the patient's risk profile:~* gastric/duodenal risk: age \>65, history of ulcer with remission, history of inflammatory event, current low-dose acetylsalicylic acid treatment ;~* cardiovascular risk (according to Agostino scale \& SCORE);~The molecule with therefore be:~* no risk: niflumic acid, 250 mg per intake;~* gastric/duodenal risk only: diclofenac, 50-100 mg per intake, plus lansoprazole;~* cardiovascular risk only: ketoprofen, 50-100 mg per intake;~* double risk: ibuprofen, 200-400 mg per intake, plus lansoprazole. For the walk test, the highest dose of diclofenac or ketoprofen will be used. Then, the patient will be free to half the dose if pain relief is achieved so.~One gram of acetaminophen will be added to any NSAID intake. The number of intakes will be limited to twice a day (morning and evening) and to 10 times a week."
224208859|NCT06036537|DIAGNOSTIC_TEST|diagnosis of Interstitial lung disease|Serum marker detection，High resolution computed tomography scan
224208860|NCT00414011|DRUG|Moxifloxacin|1 drop 4 times daily for 1 week or until complete re-epithelization (usually 3-4 days) after surgery
224208861|NCT00414011|DRUG|Gatifloxacin|1 drop 4 times daily for 1 week or until complete re-epithelization (usually 3-4 days) after surgery
224208862|NCT00003607|RADIATION|radiation therapy|
224208863|NCT06416007|RADIATION|Lattice therapy (LRT)|5 Fractions LRT
224208864|NCT01532011|DRUG|Erlotinib|"Dose escalation group starting dose: 75 mg by mouth daily for a 28 day cycle.~Dose expansion group starting dose: Maximum tolerated dose (MTD) from dose escalation group."
224208865|NCT01532011|DRUG|Pralatrexate|"Dose escalation group starting dose: 15 mg/m2 by vein on days 1, 8, and 15 of a 28 day cycle.~Dose expansion group starting dose: Maximum tolerated dose (MTD) from dose escalation group."
224208866|NCT02476851|DEVICE|POLFA (Needle Assembly)|Each subject receives the same intervention and blood is drawn into both the INA and CNA. The difference is the order in which the CNA or INA is applied.
224208867|NCT02476851|DEVICE|Kawasumi (Needle Assembly)|Each subject receives the same intervention and blood is drawn into both the INA and CNA. The difference is the order in which the CNA or INA is applied.
224208868|NCT02533505|DRUG|Budesonide 160 mcg and formoterol fumarate dihydrate 4.5 mcg Inhalation aerosol|Subjects will receive a single dose (2 inhalations) of Symbicort pMDI 160/4.5 μg (2 inhalations; total dosage 320/9.0 μg) or placebo (with a spacer) in a cross-over design (a total of 2 doses of Symbicort and 2 doses of placebo over the duration of the study), and assessments will be made before and after dosing at specified timepoints
224208869|NCT02533505|DRUG|Matching Placebo pMDI 160/4.5 μg|Placebo will be given according at the same dose and schedule as the active comparator - cross-over design.
224208870|NCT00040625|DRUG|Pemetrexed|
224208871|NCT00040625|DRUG|Cisplatin|
224208872|NCT06045429|DRUG|Oroxid®|"All patients in experimental arm will receive usual best medical and nursing care with respect to VAP prevention including recently reviewed local ventilator bundle ; standard microbial surveillance (tracheal aspirate) will be performed twice a week (Monday, Thursday) and always ad hoc according to the clinical situation. This reflects current practice. Daily oral care will be provided using Oroxid® mouthwash."
224315620|NCT01044121|OTHER|Mattress Firmness|Current mattress and 6 experimental firmnesses of mattress as defined by a Comfort Support Analysis device.
223512822|NCT05534607|BEHAVIORAL|Ola Mau i ka Hula|"The first 3 months of the hula-based intervention program was designed and standardized as a culturally-based physical activity (PA) that includes 15 minutes of ADRD education and intervention orientation with 12 weeks of hula lessons.~These hula lessons consist of two 60-minute classes per week over 12 weeks. Each hula lesson will consist of 8 participants, providing them with the opportunity to engage-in this social support network.~For the remaining 5 months of the Ola Mau i ka Hula Program, hula lessons led by the kumu hula will be reduced to once a month for 60 min. In addition, the intervention group will meet with a community-peer educator weekly over this 5-month period. Each meeting will be 90 minutes in length with 60 minutes of hula practice following the same format as previous classes, and 30 minutes will cover the PILI Lifestyle Plan curriculum and cultural-based cognitive exercises, alternating weekly."
223512823|NCT05308862|BEHAVIORAL|Care process for assessements of risks|Intervention aiming to reduce the risk of pressure ulcers, malnutrition, poor oral health and falls among older persons in nursing homes, workshops will be conducted in collaboration with nurse aides, registered nurses and managers. Cluster randomization is going to take place via a computerized program prior to the workshops meaning that only those nurse aides, registered nurses and managers working in nursing homes allocated to the intervention group are going to develop an intervention together with the research group and then test it .
223512824|NCT06494371|BIOLOGICAL|LCAR-HL30 cells|Prior to infusion of the LCAR-HL30, subjects will receive a conditioning premedication regimen consisting of cyclophosphamide and fludarabine
223512825|NCT02738697|DRUG|Adjuvant chemotherapy|8\~12 cycles of adjuvant chemotherapy with FOLFOX were performed 4-6 weeks after radical surgery
223512826|NCT02738697|PROCEDURE|Follow-up|Patients received just follow-up instead of adjuvant chemotherapy
223512827|NCT05800002|PROCEDURE|Intravascular ultrasound|Pretreatment strategy, stent size, stent landing zone and post-dilation balloon size are depended on intravascular ultrasound.
223512828|NCT05800002|PROCEDURE|Angiography|Pretreatment strategy, stent size, stent landing zone and post-dilation balloon size are depended on angiography.
223512829|NCT00582452|OTHER|Telephone survey|Telephone survey
223512830|NCT00997815|DRUG|Botulinum toxin A|Concentration at 2 units per 0.1 of normal saline dilution
223512831|NCT00997815|DRUG|Normal saline injection|Using normal saline 2.5 ml injected in control side
223512832|NCT03593447|DRUG|non-cirrhotic subjects. low TG-2349+ low DAG181+Ribavirin|Group1: TG-2349 200 mg + DAG181 100 mg + Ribavirin 1000 mg or 1200 mg
223512833|NCT03593447|DRUG|non-cirrhotic subjects. high TG-2349+ high DAG181+Ribavirin|Group2: TG-2349 400 mg + DAG181 200 mg + Ribavirin 1000 mg or 1200 mg
223512834|NCT03593447|DRUG|non-cirrhotic subjects. low TG-2349+ low DAG181|Group 3: TG-2349 200 mg + DAG181 100 mg
223619399|NCT00060645|DRUG|ridaforolimus|There are sequential dosage cohorts ranging from 3 mg - 225 mg per dose. AP23573 is given intravenously over 30 minutes, administered once daily for 5 days every 2 weeks.
223619400|NCT01314196|OTHER|therapeutic exercises|therapeutic exercises for the shoulder and scapula stabilizers using bat without charge, training and isometric exercises commuting to the cuff muscles, without producing subacromial impaction.
224208873|NCT06045429|DRUG|Chlorhexidine mouthwash|"All patients in experimental arm will receive usual best medical and nursing care with respect to VAP prevention including recently reviewed local ventilator bundle ; standard microbial surveillance (tracheal aspirate) will be performed twice a week (Monday, Thursday) and always ad hoc according to the clinical situation. This reflects current practice. Daily oral care will be provided using 0,2% chlorhexidine"
224208874|NCT05628766|OTHER|complete blood count|Thiol/disulphide levels in the blood will be checked by taking complete blood count
224208875|NCT01027026|OTHER|Early discharge|The patients are discharged the same day as coronary angiography.
224208876|NCT01027026|OTHER|Care as usual. No intervention. (Control group)|The patients are admitted and cared as usual in cardiology ward.
224208877|NCT03235973|DRUG|Fludarabine-Cladribine-Busulfan conditioning regimen|"Conditioning regimen will be performed from day -6 to day -2 and contains:~* Fludarabine 10 mg/m²/d during 5 days (day-6 to day-2).~* Cladribine during 5 days (day-6 to day-2) at one the following define dose level:~  * Dose 1: 10 mg/m²/d~ * Dose 2: 15 mg/m²/d~ * Dose 3: 20 mg/m²/d~ * Dose 4: 25 mg/m²/d~* IV busulfan will be given on day-6 using fixed dose as following:~  * If age ≤ 60 years: starting dose of 130 mg/m²~ * If age \> 60 years: starting dose of 100 mg/m² No busulfan will be administered at day-5, allowing the pharmacokinetic (PK) analyses . Subsequent infusion of IV busulfan will be performed from day-4 to day-2 at the dose recommended by PK analyses"
224208878|NCT05748522|OTHER|Shoulder Mobility|t is one of the seven functional movements studied in FMS. This test requires the participant to simultaneously hold one hand behind the back (internal rotation) and the other hand behind the head (external rotation) with the fisted hands, and bring the hands as close to each other as possible in the back area. The distance measurement in cm is taken with a tape measure between 3 fingers of both hands.
224208879|NCT05748522|PROCEDURE|Diaphragmatic Breathing|"The participant will lie on his back in a comfortable position, diaphragmatic breathing will be taught first in the application group and he will be asked to do diaphragmatic breathing for 90 seconds. At the end of this period, the participant will be referred back to the evaluator physiotherapist, and the physiotherapist will evaluate the shoulder mobility again without knowing which group the participant is in.~In the participant control group, shoulder mobility will be evaluated and the practitioner will be asked to stay in a comfortable position on his back for 90 seconds next to the physiotherapist. At the end of the period, shoulder mobility will be evaluated again by the assessing physiotherapist."
224208880|NCT00804349|DEVICE|Autotitrating Positive Airway Pressure|Patients will be treated with Autotitrating Positive Airway Pressure therapy
224208881|NCT00513565|DRUG|single dose|Subjects will receive single doses of GSK561679, lorazepam, or placebo at each treatment session.
224208882|NCT03306602|DEVICE|Filtek Bulk Fill Posterior Restorative|Filtek™ Bulk Fill Posterior Restorative is a one-step bulk placement solution for fast and easy posterior resin restorations.
224208883|NCT03306602|DEVICE|Filtek Z350 XT|Filtek Z350XT is a material for incremental layered composite resin restorations
224208884|NCT03078803|BIOLOGICAL|Fecal Microbiota Transplant (FMT)|FMT delivered by colonoscopy and oral capsules
224208885|NCT03078803|BIOLOGICAL|Placebo|Transfer of water only
224208886|NCT05745064|DRUG|TL-925|TL-925 is an eye drop.
224208887|NCT05745064|DRUG|Placebo|The composition of the placebo is identical to the active formulation except for the exclusion of the active ingredient.
224315621|NCT01654003|OTHER|CONTROL|In the CONTROL group, the administration of fluid (250-500ml crystalloids or colloids) and cardiovascular supportive drugs will be guided to maintain standard pressure-related parameters within a normal range: MAP \> 65mmHg, HR \< 90/min, CVP \>8-12\< cm H20, urinary output \> 0.5 ml/kg/h. In line with the conventional approach, other physiological parameters will also be targeted: T° \> 35.5°C, Sp02 \> 95%, lactate \< 2.5 mmol/L, normalisation of the BE. The maximal infused volume of hydroxyethyl starch (Voluven®) will be 33 ml/kg.
224315622|NCT01654003|OTHER|OPTIMIZED|In the OPTIMIZED group, the haemodynamic monitor (Pulsiocath)will help to a goal-directed administration of fluid (250-500ml crystalloids or colloids).The cardiovascular supportive drugs will be guided by an algorithm taking into account standard parameters (HR, MAP, lactate, Hb), as well as static and dynamic volumetric parameters (SVI, CI, GEDVI, EVLWI, SVV, PPV, PVI).
223619401|NCT01314196|OTHER|biceps resistance training and therapeutic exercises|The biceps resistance training based on calculations of maximum resistance (MR), being conduct in three series 10 reps with 50% of MR in the first series of training and 75% of MR in the second series, with 2 minutes between each and therapeutic exercises for the shoulder and scapula stabilizers.
223619402|NCT03392103|DRUG|Raltitrexed|concurrent chemotherapy
223619403|NCT03392103|RADIATION|postoperative radiotherapy|concurrent postoperative radiation therapy
223619404|NCT04578275|OTHER|diagnostic strategy using ECGI|"Procedure: Drug treatment, CVE, Pulmonary vein ablation isolation according to treatment guidelines and investigators discretion.~ECGI: customized body surface mapping (57 electrodes) at the inclusion in the study, after treatment assignment and prior to AF ablation procedure."
223761502|NCT06909084|PROCEDURE|Myringotomy alone|Under microscope tympanic membrane was visualized after cleaning the external auditory canal and myringotomy incision was given with the help of myringotome in anteroinferior quadrant of tympanic membrane. Secretions from middle ear were drained by suction. NO FURTHER PROCEDURE WAS DONE and canal was packed with bismuth iodoform paraffin paste which was removed after 24 hours.
223761503|NCT06907979|DEVICE|TMS - Sham|Trains consisting of bursts of three stimuli at 50 hertz (Hz) repeated at 5 Hz frequency delivered at 20% of maximum stimulator output (MSO) in 20 x 2-second trains with 8-second intertrain intervals (192 seconds total)
224315623|NCT02211443|BIOLOGICAL|Recombinant full human Anti-EGFR Monoclonal Antibody|
224315624|NCT04537832|OTHER|No Intervention|No Intervention
224315625|NCT05567770|DRUG|Actinium-J591|Cohort 1 with oligometastatic disease will receive Actinium-J591 and Stereotactic Body Radiation Therapy
224315626|NCT05567770|RADIATION|Stereotactic Body Radiation Therapy|Cohort 1 patients with oligometastatic disease will receive Actinium-J591 and Stereotactic Body Radiation Therapy
224208888|NCT06703463|DRUG|MK-1167|Administered via oral capsule per dosing regimen.
224208889|NCT06703463|DRUG|Diltiazem|Diltiazem hydrochloride administered at a dose of 240 mg QD via oral capsules.
224208890|NCT05799365|OTHER|GMFCS-FR Turkish Adaptation|GMFCS-FR Turkish Adaptation was applied the childrens mother, father and clinical physiotherapist.
224315627|NCT05567770|DRUG|Androgen Deprivation Therapy|Cohort 2 patient with Polymetastatic disease will receive Actinium-J591 and Androgen Deprivation therapy (ADT)
223512835|NCT03593447|DRUG|non-cirrhotic subjects. high TG-2349+ high DAG181|Group 4: TG-2349 400 mg + DAG181 200 mg
224208891|NCT04949984|DEVICE|Bright light therapy|BLT consisted of 30-minute morning sessions with an intensity of 10,000 lux, five days a week (Monday to Friday), for 4 weeks.
224208892|NCT00822679|DRUG|Eszopiclone|Subject receives Eszopiclone for 3 consecutive nights. 3 mg orally at bedtime for patients age 64 and under, and 2 mg QHS for patients age 65 and older.
224208893|NCT00822679|OTHER|Placebo|Subjects are given placebo for 3 consecutive nights
224208894|NCT02377687|OTHER|observational study|
224208895|NCT04015479|DIETARY_SUPPLEMENT|Peanut Protein Powder|Peanut protein powder will be provided to participants who will be instructed to consume 72g daily, mixed with water
224208896|NCT04015479|BEHAVIORAL|Full body resistance training|Participants will undergo supervised resistance training two times per week (5 exercises, 3 sets of 8-12 repetitions per set)
224208897|NCT04189406|OTHER|Venapunction|A blood sample of 3.5 mL (0.2 mL serum for FSH and LH, 0.15 mL serum for E2, 0.15 mL serum for T, 0.15 mL serum for AMH and 0.25 mL serum for Inhibin B) will be collected of all girls with TS at 3 months and 9 months of age. For the girls with TS, this will be collected with an extra venapuncture during a regular outpatient visit within the usual care.
224208898|NCT02741752|PROCEDURE|Decortication|cortical bone perforation
224208899|NCT00306852|PROCEDURE|Baerveldt implant|Patients will be randomized to receive a 350 mm\^2 Baerveldt glaucoma implant or a Trabeculectomy (guarded filtration surgery) with mitomycin C (0.4 mg/ml for 4 minutes)
224315628|NCT03579342|BEHAVIORAL|App-technology and active coaching to improve lifestyles behaviors|Access to the smartphone-app during 12 weeks. A personal health goal related to for example diet, physical activity or stress habits, is set together with a heath coach. Participants receive continuous coaching every 4 weeks during follow-up.
224315629|NCT03579342|BEHAVIORAL|App-technology to improve lifestyle behaviors|Access to the smartphone-app during 12 weeks. A personal health goal related to for example diet, physical activity or stress habits, is set together with a heath coach. Participants receive continuous coaching every 4 weeks during follow-up.
223512836|NCT03593447|DRUG|cirrhotic subjects. high TG-2349+ high DAG181+Ribavirin|Group 5: TG-2349 400 mg + DAG181 200 mg + Ribavirin 1000 mg or 1200 mg\_
223512837|NCT03593447|DRUG|cirrhotic subjects. high TG-2349+ high DAG181|Group6: TG-2349 400 mg + DAG181 200 mg
223512838|NCT00135161|PROCEDURE|FDG-PET-based dose escalation using intensity modulated radiation therapy (IMRT).|FDG-PET-based dose escalation using intensity modulated radiation therapy (IMRT).
223512839|NCT03189433|DRUG|Ryanodex (dantrolene sodium) for injectable suspension|Ryanodex (dantrolene sodium) for injectable suspension, 250 mg/vial to be reconstituted in 5 mL of sterile water for injection to yield a 50 mg/mL suspension that will be administered as a rapid IV push of 2.5 mg/mL.
223512840|NCT06471517|DEVICE|Somatosensory feedback|Performing different mobility tasks in 10 separate sessions while the device is providing or not somatotopic sensations through non-invasive electrical stimulation. Benefits connected to the stimulation of sensory nerves will be assessed.
223512841|NCT05782244|DRUG|Sildenafil Citrate low dose|Sildenafil citrate 20 mg, oral, TID
223512842|NCT05782244|DRUG|Placebo|Placebo, oral, TID
223512843|NCT05782244|DRUG|Sildenafil medium dose|Sildenafil 40 mg, oral, TID
223512844|NCT05782244|DRUG|Sildenafil high dose|Sildenafil 80 mg, oral, TID
223512845|NCT04787042|BIOLOGICAL|ST-067|ST-067 is an engineered variant of human interleukin-18.
223512846|NCT04787042|BIOLOGICAL|Obinutuzumab 25 MG/1 ML Intravenous Solution [GAZYVA]|Obinutuzumab is a humanized anti-CD20 monoclonal antibody of the IgG1 subclass. It recognizes a specific epitope of the CD20 molecule found on B-cells.
223512847|NCT04787042|BIOLOGICAL|pembrolizumab|Pembrolizumab is a potent humanized immunoglobulin G4 monoclonal antibody.
223512848|NCT00068848|BEHAVIORAL|Quick start oral contraceptive initiation|
223512849|NCT01209468|DEVICE|monobloc oral appliance|one piece oral appliance
223512850|NCT01209468|DEVICE|twinblock oral appliance|two-piece oral appliance
223512851|NCT04755062|BEHAVIORAL|Micronutrient-dense plant-rich Intervention|"The mNDPR dietary protocol is designed to be (1) micronutrient rich (i.e., high in plant-derived phytochemicals, antioxidants, vitamins, and minerals); (2) nutritionally adequate and diverse; (3) hormonally favorable, avoiding carbohydrates with a high glycemic index that could elevate levels of serum insulin and minimizing animal protein that may invoke an inflammatory response; and (4) encourage intake of regular meals, limited consumption of snacks, and an overnight fast of at least 12 hours. The calorie breakdown of the diet is derived from approximately: 30-60% vegetables, 10-40% beans/legumes, 10-40% fruit, 10-40% seeds/nuts, 20% whole grains, no more than 10% naturally raised and wild animal products, poultry, eggs, fish, dairy, oil and white potatoes."
223512852|NCT03163264|BEHAVIORAL|Peer Assisted Lifestyle|Patients will use PAL online tool accessing weight management and lifestyle behaviors, and will meet with a health coach regularly to establish SMART goals.
223619405|NCT03636659|DRUG|Amphotericin B Liposome|Manufactured for: Auromedics Pharma LLC, USA
223619406|NCT03636659|DRUG|AmBisome (Amphotericin B) Liposome|Marketed by: Astellas Pharma US, Inc. USA
224208900|NCT00306852|PROCEDURE|Trabeculectomy with mitomycin C|Patients will be randomized to receive either a Trabeculectomy (guarded filtration surgery) with mitomycin C (0.4 mg/ml for 4 minutes) or a 350 mm\^2 Baerveldt glaucoma implant
224208901|NCT04498299|DIAGNOSTIC_TEST|echocardiogram 2D|The patient is accelerating against a workload that gradually increases at a constant rate during the exercise, images will be obtained by echocardiography. The patient begins with 25 Watts with increments of 25 Watts every 3 minutes, continuing the exercise until significant electrocardiographic changes occur or the patient starts with symptoms.
223619407|NCT06305702|DRUG|inetetamab|8mg/kg iv day 1 followed by 6mg/kg iv day 1, cycled every 21 days
223619408|NCT04803383|OTHER|Tele-yoga|Tele-yoga training 3 days a week for 8 weeks
223619409|NCT00617786|PROCEDURE|Current Perception Threshold (CPT) Testing|During the CPT testing a catheter will be placed in the bladder. The catheter has sensors to record the body's sensation of pressure. The sensation felt will be similar to a light touch and is painless. A gel pad will be placed in the general area of the vagina to record the feeling of a light touch.
223619410|NCT04842903|OTHER|Therapeutic Touch|Therapeutic touch is an energy transfer process based on the assumption that every living organism in the universe has an energy field and these energy fields that interact with each other can be changed with the practices made by a conscious and certain intent. TT is an independent nursing practice first applied and developed by nurses Dora Kunz and Dolores Krieger in 1972. TT is also an art of concentration therapy in which the therapist focuses on consciousness as a focus to create balance and coordination in the mutual energy fields of the patient and the environment, and uses their hands to transfer energy. The fact that TT is easy to use, has no known side effects, has low costs, is non-invasive, and its importance among nurses and increasing frequency of its practice in recent years show that it is a powerful alternative to other CAT methods.
223619411|NCT03758781|DRUG|IRX 2|IRX-2 Regimen: 21 day regimen of cyclophosphamide on Day 1 and subcutaneous IRX-2 injections for 10 days between Days 4 and 18. This 21 day regimen will be given every 12 weeks.
223761504|NCT06907979|DEVICE|TMS - Active iTBS|Trains consisting of bursts of three stimuli at 50 Hz repeated at 5 Hz frequency delivered at 110% of measured individual motor threshold in 20 x 2-second trains with 8-second intertrain intervals (192 seconds total)
223761505|NCT06907979|DEVICE|TMS - Active cTBS|Trains consisting of bursts of three stimuli at 50 Hz repeated at 5 Hz frequency delivered at 110% of measured individual motor threshold in 1 x 40-second train (40 seconds total)
223761506|NCT06909721|DRUG|Misoprostol|to compare Misoprostol and Dinoprostone as regarding to cost-effectiveness and safety in induction of normal Labor
224208902|NCT02046499|DRUG|Oxytocin|Oxytocin will be administered intravenously as per standard protocol
224208903|NCT02046499|DRUG|Oxytocin ergometrine|Oxytocin ergometrine will be administered intra-musculalry
224208904|NCT04954209|OTHER|Physical activities in hospital|3 month in a resumption program of physical activity in hospital
224208905|NCT04954209|OTHER|Physical activity outside hospital|3 month in a resumption program of physical activity outside hospital with discovery sessions
224208906|NCT04316598|DRUG|Cannabis Sativa|"Subjects will receive a total of 4 inhaled doses of 20 mg of tetrahydrocannabinol (THC) in 3 days.~Cannabis is provided as a medical grade cannabis flos (Cannabis sativa dried female flower) containing THC 22% and cannabidiol \<1%, supplied by Bedrocan®.~To avoid the respiratory disadvantages of smoking, a vaporization device (Mighty® Medic) will be used to inhale the drug. The prepared capsules will contain 90 mg of Cannabis flos, equivalent to 20 mg of THC."
224208907|NCT04316598|DRUG|Cannabis placebo|"Subjects will receive a total of 4 inhaled doses of cannabis placebo (THC \<0,2%) in 3 days.~Placebo cannabis is provided as a medical grade cannabis flos (Cannabis sativa dried female flower) containing cannabinoids \<0.2%. To avoid the respiratory disadvantages of smoking, a vaporization device (Mighty® Medic) will be used to inhale the drug. The prepared capsules will contain 90 mg of cannabis placebo."
224208908|NCT02425865|DRUG|GOLIMUMAB|Increase/ or Decrease/ Interruption Dose of Golimumab depending on Continuous Clinical Response or Relapse
224208909|NCT00200473|DRUG|Nebivolol|
224208910|NCT05504369|OTHER|Magnetic tape|Tape with magnetic nanoparticles applied to the skin
224208911|NCT05504369|OTHER|Placebo tape|Tape without nano particles applied to the skin
224208912|NCT00883740|DRUG|Pregabalin|Capsule, flexible dosing double-blind. Treatment duration is approximately 4 weeks titrated to 300-450 mg/day
224208913|NCT00883740|DRUG|Placebo|Capsule, flexible dosing double-blind. Treatment duration is approximately 4 weeks
224315630|NCT02685683|DRUG|GED-0301|During Induction period patient will receive mongersen 160 mg daily for 12 weeks. This study also offers subjects the option to continue with maintenance treatment at the discretion of the Investigator, beginning after the Week 12 Visit with alternating no IP for 4 weeks, followed by mongersen (GED-0301) 160 mg QD for 4 weeks, up through the Week 52 Visit during the Maintenance Period. At Week 52, subjects who have achieved an endoscopic improvement of \>50% from baseline based on the SES-CD, as assessed by the central reader, and clinical improvement (HBI \<7), will have the option to continue receiving treatment for an additional year, up through Year 2 (ie, the Week 100 Visit).
224315631|NCT05961917|OTHER|5 cmH2O Positive end-expiratory pressure (PEEP)|PEEP will be set at 5 cmH2O
224315632|NCT05961917|OTHER|10 cmH2O Positive end-expiratory pressure (PEEP)|PEEP will be set at 10 cmH2O
223619412|NCT03758781|DRUG|Nivolumab|Nivolumab 240 mg will be given via IV infusion once every 2 weeks.
223619413|NCT02680522|OTHER|Exercise|exercise training with virtual reality in videogame
223619414|NCT00121563|DRUG|Thalidomide, Ibuprofen or Diazepam|
223619415|NCT02598401|OTHER|observation|Observational study with no intervention
223619416|NCT02107417|DEVICE|active TENS|Experimental Group (EG) who will receive the application of active TENS. The participants of these group will receive TENS within the following parameters: VF mode TENS with a variable frequency between 7 Hz and 65 Hz. It has a pulse width of 200 µs, this is the highest tolerable intensity while still remaining comfortable for the patient. It has an application time of 60 minutes with the highest tolerable intensity, while still remaining comfortable for the patient.
223761507|NCT06908902|PROCEDURE|partial nephrectomy with main or branch renal artery clamping|Robotic-assisted laparoscopic or laparoscopic partial nephrectomy with main or branch renal artery clamping
223761508|NCT06908902|PROCEDURE|partial nephrectomy with zero renal artery clamping|Robotic-assisted laparoscopic partial nephrectomy with zero renal artery clamping
224208914|NCT04144387|PROCEDURE|Myelogram|Two additional myelograms will be performed comparing to standard of care.
224208915|NCT00921219|DRUG|ivermectin|Each subject will receive single doses of (i) 22.5 ml ivermectin oral solution (22.5 mg) and (ii) 10 x 3 mg tablets of ivermectin (30 mg) in 2 separate dosing periods. Doses will be administered 20 minutes after a standard breakfast.
224208916|NCT02696018|DEVICE|Ultrasonography|Ultrasonographic assessment of the diaphragm function
223619417|NCT02107417|DEVICE|placebo TENS|who will be administering the placebo TENS.The participants of these group will receive TENS within the following parameters: VF mode TENS with a variable frequency between 7 Hz and 65 Hz. It has a pulse width of 200 µs, this is the highest tolerable intensity while still remaining comfortable for the patient. It has an application time of 60 minutes The TENS-placebo will be applied where no current will be emitted. Patients in the placebo group will only feel the tingling for 45 seconds and after this period the device will not emit impulses, but it will work for 1 hour.
224208917|NCT05958459|OTHER|Eye Exercise|The individuals in the study group will perform home-based eye exercises for at least 1 session (\~30 min.) every day for a total of 12 weeks, after the patient's condition is stable, starting from the 7th day after the surgery. After the initial assessment, participants will be given illustrated brochures describing the exercises and will be taught how to perform the exercises. Whether individuals comply with the exercise program will be closely monitored (by keeping a diary, online meetings and periodically calling individuals). The control group, on the other hand, will not perform any exercise, but will only be evaluated. Eye exercises include eight steps. These; Covering the eyes with the palm of the hand, blinking, lateral gaze, anterior and lateral gaze, rotational gaze, up-down gaze, nasal tip gaze, and near and far gaze.
224208918|NCT05958459|OTHER|no intervention|no intervention
224208919|NCT06122571|OTHER|ConcenTrace|The product contains concentrated seawater from Utah's inland sea.
224208920|NCT02535247|DRUG|MK-3475|
224208921|NCT02535247|DRUG|Copanlisib|
224208922|NCT01376180|DRUG|Lamotrigine|Administered according to the prescribing information in the locally approved label by the authorities
224315633|NCT03495921|BIOLOGICAL|Vigil|Vigil is composed of autologous tumor cells harvested from the patient at the time of initial de-bulking surgery which are then transfected extracorporeally, with a plasmid encoding for the gene for GM-CSF, an immune-stimulatory cytokine, and a bifunctional, short hairpin RNA which specifically knocks down the expression of furin, the critical convertase responsible for production of the two TGβ isoforms.
224208923|NCT02732886|DEVICE|Medifoam®|Foam Dressing
224208924|NCT02732886|DEVICE|Betafoam®|Foam dressing including Betadine iodine
224208925|NCT05815186|DRUG|Sotorasib|Sotorasib administered at the approved dose of 960mg PO once daily over 21-day treatment cycles
224208926|NCT05815186|DRUG|Ladarixin|Ladarixin administered twice-daily at the recommended phase II dose (RP2D) (determined in the phase I portion of this trial) over 21-day treatment cycles.
224208927|NCT00938418|RADIATION|Dose escalated, accelerated, hypofractionated radiotherapy|Intensity modulated radiotherapy with concurrent chemotherapy
224208928|NCT04083066|DRUG|rituximab in combination with methotrexate, cytarabine and dexamethasone|"Rituximab 375mg/m2D0 is soluble in 0.9% NS concentration 1mg/ml, micro pump is pumped in 4h HD-methotrexate 3.5g/m2 D1 dissolved in 0.9% NS intravenous drip HD-cytarabine 1g/m2 Q12H D2-3 Dissolved in 250ml 5% GS intravenously~Dexamethasone 40mg D1-5 is dissolved in 100ml 5% GS intravenous drip (21 days is a cycle)"
224208929|NCT03869684|DRUG|MT-0814|Randomly assigned dose
224208930|NCT03869684|DRUG|Placebo|Placebo manufactured to mimic MT-0814
223619418|NCT00197314|BEHAVIORAL|circular muscle exercises versus pelvic floor exercises|
223619419|NCT04796714|DRUG|Double antiplatelet therapy|One sachet of aspirin 160 mg and one tablet of clopidogrel 75 mg per day.during 3 months
223619420|NCT04796714|DRUG|Aspirin|One sachet of aspirin 160 mg per day during 3 months
224208931|NCT05084937|OTHER|CeliCAT form|Systematic summary to support transition
224208932|NCT04056299|BIOLOGICAL|AR201 powder|AR201 powder (Hen Egg allergen formulation) provided in capsules
224208933|NCT04056299|BIOLOGICAL|Placebo powder|Placebo powder provided in capsules
224208934|NCT01770678|OTHER|Constraint Induced Movement Therapy|A combination of prolonged restraint of the unaffected upper limb and massed practice of the affected upper limb.
224208935|NCT03895307|OTHER|kinesio tape|two 15 cm I type kinesio tape applied longitudinally
224208936|NCT03895307|OTHER|local anesthetic|local anesthetic: 18-20 cc %0.5 lidocaine subcutaneous injection
224315634|NCT03495921|DRUG|Irinotecan|Injectable formulation of irinotecan was distributed from central supplier. 1 Cycle (5 doses of 50 mg/m2 per syringe) was drawn into provided oral syringes and dispenses to the subject with instructions to refrigerate until administration.
224315635|NCT03495921|DRUG|Temozolomide|Dose: 100 mg/m2 daily, oral Schedule: Days 1-5, every 21 days Administered at least 1 hour before Irinotecan.
224315636|NCT00920790|BIOLOGICAL|KW-0761|KW-0761 is administered weekly for 8 weeks as an intravenous infusion of 2 hours at a dose of 1.0 mg/kg.
224315637|NCT03650530|OTHER|The Family Talk Intervention|The family meets two interventionists at six time points.
224315638|NCT03096158|OTHER|Ventilatory Muscle Training (TREMVEN)|"Early cardiac rehabilitation after coronary artery bypass graft:~The enrolled participants will perform IMT or P-IMT for 20 minutes during the period of hospitalization, using the Power Breathe device (POWERbreathe International LTD). During training, subjects will be instructed to maintain diaphragmatic breathing at a rate at 15 to 20 breaths/min. The inspiratory load will be set at 30% of maximal static inspiratory pressure (PImax). It will be occur once per day until the hospital exit."
223619421|NCT04796714|DEVICE|Brain MRI|Two cerebral Magnetic Resonance Imaging (MRI) examinations will be carried out (D0 and D90).
223619422|NCT04796714|OTHER|Neurological tests|Neurological assessment with the implementation of the modified rankin, National Institute of Health Stroke Score (NIHSS), and Montreal Cognitive Assessment (MoCA) tests (D1 and M3)
223619423|NCT05470140|BIOLOGICAL|WU-NK-101|WU-NK-101 administered on Day 1, Day 8, and Day 15.
224208937|NCT03895307|OTHER|local serum physiologic|serum physiologic : 18-20 cc % 0.09 NaCl subcutaneous injection
224208938|NCT06538545|BEHAVIORAL|Sitting position is used in Experimental Arms 1-2|sitting position Comparison of sitting position and lithotomy position in labor
224208939|NCT02840214|DEVICE|transcranial direct current stimulation|Soterix tDCS RCT device given over left DLPFC for 20 minutes at 2mA.
224208940|NCT02840214|DEVICE|sham tDCS|Soterix tDCS RCT device given over left DLPFC with 30 second ramp on and off of current
224208941|NCT02349009|DRUG|C-82 Topical Gel, 1%|active
224208942|NCT02349009|DRUG|C-82 Topical Gel, Placebo|placebo
223619424|NCT05270668|DRUG|Tulisokibart|Tulisokibart administered at timepoints as directed by the protocol
223619425|NCT05270668|DIAGNOSTIC_TEST|Companion diagnostic ( CDx)|CDx+ or CDx-
223619426|NCT05270668|DRUG|Placebo|Placebo
223619427|NCT05844891|BEHAVIORAL|Telehealth-Enhanced Asthma Care for Home After the Emergency Room (TEACH-ER)|TEACH-ER aims to provide primary care management and educational support for families managing childhood asthma throughout the transition from emergency department to home, and includes several core components: 1) brief, pictorial, and health literacy-informed asthma education in the ED, with color- and shape-coded labels provided for home asthma medications; 2) virtual primary care follow-up within 1 week of discharge using in-home telemedicine (when possible), featuring provider prompts for guideline-based preventive therapy and home delivery of prescribed medications with pictorial action plans; 3) two additional in-home virtual visits to reinforce teaching, review treatment plans, label medications, and support effective management practices. Virtual visits will be completed using the Zoom platform on smartphones or other compatible devices. We anticipate that all three telehealth visits (1 provider visit, 2 educator visits) will be completed within 2 months of enrollment.
224208943|NCT01416298|OTHER|Continuous Renal Replacement Therapy|The investigators will use the NGAL data daily to 1) drive initiation of CRRT in children with elevated NGAL and \> 10-20% fluid overload and 2) drive CRRT discontinuation in patients with decreasing NGAL concentrations. All members of the Critical Care Medicine and Nephrology divisions have agreed that initiation of CRRT within 24-48 hours of a patient reaching \>10% fluid overload is clinically acceptable, and that often the decision to start CRRT has been arbitrary in the past, based on physician bias or preference. All members agree that the current standard of 24-48 hours after \>10% is achieved is acceptable and now will be put into standard clinical practice.
224208944|NCT06336226|PROCEDURE|Brachio basilic arterio venous fistula one stage versus two stage|Comparative study between one stage brachio basilic arterio venous fistula versus two stage
224208945|NCT03081195|BEHAVIORAL|MFG|The MFG is a series of weekly meetings guided by a protocol.Over the course of 16 weeks, groups are held weekly and are facilitated by trained and supervised group leaders (in this case either parent peers or community health outreach workers). Groups can consist of up to 20 families involving adult caregivers and all children over six years of age in the family. The protocols have been designed to provide opportunities during each session to directly apply content to the realities of family life, emergent cultural and values perspectives, as well as tailor messages to age of child. Redundancy for missed appointments and opportunities for reinforcement is built in. We aim for families to attend at least 8 meetings or more (out of 16 sessions in total), as findings suggests this dose is needed to reduce child conduct problems and the majority of families reach this goal.
224208946|NCT06419803|DRUG|Insulin|Insulin will be used in gestational diabetics to control blood glucose levels
224208947|NCT06036901|DIAGNOSTIC_TEST|Coronary CT|Coronary CT evaluation
224208948|NCT01256346|DEVICE|Apparatuses|Each baby will have both pulse oximetry leads (Massimo Radical 7) and electrocardiography leads (3M™ Red Dot™ Neonatal Limb Band Monitoring Electrodes, Pre-wired) applied. The time required for each modality to register a heart rate will be compared.
224208949|NCT04045600|BEHAVIORAL|Trad FCT|This intervention emulates a traditional reinforcement schedule-thinning method during FCT in which clinicians program delays to reinforcement without discriminative stimuli (e.g., the child learns that some FCRs result in reinforcement and some do not). By programming reinforcement approximately every 15 s, the rate of reinforcement will be equivalent to mult FCT. During Period 1 of this project, trad FCT served as an appropriate control condition to which mult FCT could be compared.
224208950|NCT04045600|BEHAVIORAL|Mult FCT|This intervention involves correlating discriminative stimuli (e.g., purple and yellow index cards) with times in which reinforcement for the functional communication response (FCR) is and is not available. During Period 1 of this project, this procedure resulted in rapid reduction of destructive behavior and mitigated resurgence and renewal when the discriminative stimuli were used as programmed.
224208951|NCT04045600|BEHAVIORAL|Mult FCT + Stimulus Fading|This condition is similar to mult FCT except that the experimenters will gradually incorporate natural stimuli (e.g., rugs, tables, lamps) into sessions to approximate target settings that may occasion relapse typically without such gradual stimulus fading.
224208952|NCT04744064|DIETARY_SUPPLEMENT|Protein and carbohydrate|Intake of 2 x 250 ml of either protein (750 KJ, 21.0 g protein (milk protein), 15.0 g carbohydrate, 4.5 g fat ) or carbohydrate ( 750 KJ, 0 g protein, 0 g fat and 49.2 g carbohydrate (2:1 ratio of maltodextrin: fructose))
224315639|NCT03096158|OTHER|Aerobic Training (AERO)|"Early cardiac rehabilitation after coronary artery bypass graft:~It will consist of supervised walking, lasting 20 minutes a day, during the period of hospitalization of the participants. Heart rate (HR) will be constantly monitored through a cardiac monitor (Polar), with the objective of maintaining between 50 and 60% of the maximum HR predicted by age; Similar to 40 to 50% of VO2max. Blood pressure, SpO2 and level of dyspnea (Borg's effort perception scale) will also be monitored constantly. It will be occur once per day until the hospital exit."
223619428|NCT05844891|BEHAVIORAL|Enhanced Care (EC)|Similar to children in the TEACH-ER group, participants in the EC group will receive a symptom assessment using NHLBI guidelines, a recommendation for appropriate preventive medications, and asthma education materials given at the time of the ED visit. After baseline and randomization, we will send the child's PCP a symptom report with guideline-based recommendations for preventive care and recommend a follow-up visit with the PCP. We will also give all providers a summary of the current national guidelines. We will provide systematic feedback to the family and child's PCP at intervals that parallel the TEACH-ER group's telemedicine assessments. This feedback will include prompting caregivers to schedule a recommended follow-up appointment with the PCP, and encouraging providers to adhere to the NHLBI guidelines. While participants will not be blinded to their group allocation, they will be told that they are randomly assigned to two different ways of approaching asthma management.
223619429|NCT05747443|OTHER|Stepped Reminders|Stepped Reminders, which directly reminds providers to order the next LDCT scan and then reminds patients they are due and prompts them to schedule LDCT with Radiology.
224315640|NCT03096158|OTHER|Isometric Handgrip Training (ISO)|"Early cardiac rehabilitation after coronary artery bypass graft:~Study participants will perform 5 x 2 min alternating bilateral contractions of the hand flexor muscles at 30% maximum voluntary contraction with one minute rest between contractions, in a total of 20 minutes training during the period of hospitalization. It will be occur once per day until the hospital exit."
223619430|NCT05747443|OTHER|Patient Education|The Patient Voices Video is an educational video about lung cancer screening.
223619431|NCT05730725|DRUG|BMS-986322|Specified dose on specified days
223619432|NCT05730725|OTHER|Placebo|Specified dose on specified days
223619433|NCT04275323|GENETIC|NL003|Day 0: 8mg of NL003 (32 injections of 0.5ml of NL003) Day 14: 8mg of NL003 (32 injections of 0.5ml of NL003) Day 28: 8mg of NL003 (32 injections of 0.5ml of NL003)
223619434|NCT04275323|OTHER|Normal Saline|Day 0: 16ml of Normal Saline (32 injections ) Day 14: 16ml of Normal Saline (32 injections ) Day 28: 16ml of Normal Saline (32 injections )
223619435|NCT05867979|DIAGNOSTIC_TEST|Identify structural variants by Optical Genome Mapping of DNA extracted from blood leukocytes|The one arm of the study will have a venous blood draw as part of the research. 1 EDTA tube of 5mL will be collected.
223619436|NCT05861466|DRUG|intra-vitreal injection of Ranibizumab|The intravitreal injection will be performed with ranibizumab (0.5 mg/0.05 mL through a 27-gauge needle that will be inserted into the sclera 3.5 mm from the corneal limbus in pseudophakic patients, and 4 mm in phakic patients.
223619437|NCT05861466|PROCEDURE|anterior chamber paracentesis|A 27-gauge needle on a 1-mL syringe will be inserted into the anterior chamber of the eye, and approximately 0.05 mL of aqueous humor will be withdrawn.
224315641|NCT02892149|DRUG|Vadadustat|Oral dose administered once daily for ≥36 weeks. Dose adjustment based on hemoglobin level as defined in the protocol.
223761509|NCT06909513|DEVICE|U-shaped Travel Neck Pillow|Participants in the intervention group will receive a U-shaped travel neck pillow immediately after surgery upon arrival to the ward. The pillow will be used only during rest (supine or semi-Fowler's position) for the first 24 hours postoperatively and removed before mobilization begins. After removal, assessments will include cervical comfort using the Visual Analog Scale (VAS), pain scores during neck movements (flexion, rotation, lateral flexion-excluding extension) via VAS, the McGill Pain Questionnaire for pain localization and severity, and cervical range of motion using a universal goniometer. This intervention aims to evaluate the pillow's effectiveness in reducing neck pain, stiffness, and discomfort, and improving mobility after thyroidectomy.
224208953|NCT01414062|BEHAVIORAL|Cocinar Para Su Salud Program|A series of 9 Cocinar Para Su Salud intervention sessions held over a 12-week period. The 12-week intervention period will be divided into 3 groups: motivation, action, and environment. Each topic will use a nutrition roundtable, food shopping field trip, and a cooking class to teach pertinent points, in order to enable participants to progress from the precontemplation, contemplation, and preparation stages of change to the action and maintenance stages.
224208954|NCT01414062|BEHAVIORAL|Written dietary recommendations|Standard of care: one on one meetings with study staff to receive compiled written information on dietary recommendations for breast cancer survivors produced by the New York City (NYC)-based not-for-profit, God's Love We Deliver
224208955|NCT04558515|DIAGNOSTIC_TEST|Novel malaria diagnostics & tools|Next generation microscopy tools for malaria diagnosis and medical applications
224315642|NCT02892149|DRUG|Darbepoetin alfa|Subcutaneous or intravenous dose administered for ≥36 weeks. Initial dose based on the current package insert for investigational sites in the United States (US), and the Summary of Product Characteristics for all other investigational sites (non-US) for adult participants with chronic kidney disease not on dialysis. For participants already on Darbepoetin alfa, the initial dosing regimen in the study was based on the prior dosing regimen.
224315643|NCT00626808|DRUG|No Intervention|There were no interventions. No subjects were enrolled in this retrospective database study.
224315644|NCT00817518|DRUG|RO4987655|Administered po daily for 28 days, at escalating doses, with a starting dose of 1mg (Part 1) maximum tolerated dose administered po daily until disease progression(Part 2)
223619438|NCT02152631|DRUG|Abemaciclib|Administered orally
224208956|NCT04285983|DRUG|Trelagliptin|Trelagliptin tablets
224208957|NCT04936334|DIAGNOSTIC_TEST|68Ga-PSMA-11 PET Scan|Patients will undergo injection of 68Ga-PSMA-11 at the time of their pre treatment PSMA PET scan and followed until 12 months post surgery.
224208958|NCT00362427|BIOLOGICAL|Hybrid 5 component DTaP, Vero IPV, Hep B and PRP-OMPC|0.5 mL, 4 doses, IM
224208959|NCT00362427|BIOLOGICAL|Hybrid 5 component DTaP, Vero IPV, Hep B and PRP-OMPC|0.5 Ml, 4 doses, IM
224208960|NCT00362427|BIOLOGICAL|Hybrid 5 component DTaP, Vero IPV, Hep B and PRP-OMPC|0.5 mL, 4 doses, IM with concommitant vaccines
224208961|NCT03199846|OTHER|Non-Interventional|Non-Interventional
224315645|NCT00817518|DRUG|RO4987655|Administered po daily for 28 days, at escalating doses , with a starting dose of 1mg (Part 1). Optimal biological dose administered po daily until disease progression (Part 2)
223619439|NCT02152631|DRUG|Erlotinib|Administered orally
223619440|NCT05473026|BEHAVIORAL|Gratitude Intervention|Gratitude journaling and goal setting for exercise readiness over eight weeks.
223619441|NCT05672329|OTHER|0.2 L/kg/min, FiO2 1.0 + continuous jaw thrust|Apnoeic Oxygenation with flow rate 0.2 L/kg/min using OptiFlow system by Fisher\&Paykel and an oxygen inspiration concentration FiO2 of 1.0
223619442|NCT05672329|OTHER|2 L/kg/min, FiO2 1.0 + continuous jaw thrust|Apnoeic Oxygenation with flow rate 2 L/kg/min using OptiFlow system by Fisher\&Paykel and an oxygen inspiration concentration FiO2 of 1.0
223619443|NCT05672329|OTHER|4 L/kg/min, FiO2 1.0 + continuous jaw thrust|Apnoeic Oxygenation with flow rate 4 L/kg/min using OptiFlow system by Fisher\&Paykel and an oxygen inspiration concentration FiO2 of 1.0
223619444|NCT05672329|OTHER|2 L/kg/min using OptiFlow-Switch system, FiO2 1.0 + continuous jaw thrust|Apnoeic Oxygenation with flow rate 2 L/kg/min using OptiFlow-Switch system by Fisher\&Paykel and an oxygen inspiration concentration FiO2 of 1.0
223619445|NCT05624476|DIAGNOSTIC_TEST|mNGS of urine cell-free DNA|Metagenomic sequencing of urine cell-free DNA
223619446|NCT00359463|DRUG|eltrombopag|Subjects will be administered a single oral dose of 50 mg eltrombopag.
223619447|NCT03006380|DRUG|oxytocin|Ecbolic used to reduce blood loss
223619448|NCT03776747|DRUG|Prone hyperpolarized 3 helium gas scan|Hyperpolarized gas used as a contrast agent to test reproducibility of MRI of the lungs/Images done while subject is prone.
223619449|NCT03776747|DRUG|Supine hyperpolarized 3 helium gas scan|Hyperpolarized gas used as a contrast agent to test reproducibility of MRI of the lungs/Images done while subject is supine.
223619450|NCT03776747|DIAGNOSTIC_TEST|Vitals|
223619451|NCT03776747|DIAGNOSTIC_TEST|Pulmonary Function Tests|Pre and post spirometry, diffuse lung carbon monoxide (DLCO), lung volumes
223619452|NCT03776747|DIAGNOSTIC_TEST|Initial protocol MRI scan|Initial scan to determine placement
223619453|NCT02071966|DRUG|Ticagrelor|Comparison of Ticagrelor with another anti-platelet drug (Clopidogrel)
223619454|NCT02071966|DRUG|Clopidogrel|Comparison of Clopidogrel with another anti-platelet drug (Ticagrelor)
223619455|NCT05327179|OTHER|Action Observation Treatment|Action Observation Treatment program will be applied to the group 1 for 3 weeks, 5 days a week, 30 minutes a day. In the videos prepared, activities including daily life activities for the wrist, elbow and shoulder (emptying water from the glass, throwing sugar into the glass, painting, using clothespins, spoons, etc.) will be included.
223619456|NCT05327179|OTHER|Virtual Rehabilitation|Virtual Rehabilitation program will be applied to the group 2 for 3 weeks, 5 days a week, 30 minutes a day. Among the games, games that will improve daily life activities for the wrist, elbow and shoulder (steering wheel, popping balloons, touching the aquarium, etc.) will be selected.
224208962|NCT06540677|OTHER|Musical training|Musical training with Meludia software, an online self-paced music training application
224208963|NCT03121989|DRUG|Hyperpolarized Pyruvate (13C) Injection|The new imaging method being tested in this study is called Metabolic MRI, which provides pictures of the metabolism occurring within cancer cells. It also involves injection of a contrast medicine, Hyperpolarized Pyruvate (13C) Injection, into the arm vein. The Participants in the active comparator arm will be injected with study drug Hyperpolarized Pyruvate (13C) Injection at a dose of 0.43/ml/kg.
224208964|NCT03121989|OTHER|Coil Testing|Participants will receive an MRI with a 1 cm diameter plastic ball that contains 13C-urea that will act as a test object. The test object provides a signal that will be used to ensure that the MRI system is functioning properly for participants in Group 2 . The plastic ball does not come in contact with you and there are no known risks associated with it.
224208965|NCT03121989|DRUG|NAC|Participants will be receiving NAC as part of their clinical treatment.
224208966|NCT00422058|DRUG|liraglutide|Injected s.c. (under the skin) once daily
224208967|NCT00422058|DRUG|orlistat|120 mg capsule. Administered thrice daily
224208968|NCT00422058|DRUG|placebo|Injected s.c. (under the skin) once daily
224208969|NCT04845451|OTHER|Minimal surgical exploration for a neuroma|Orientation marking of the trigger point by injectable sterile methylene blue dye 0.1ml. Marking a 2-3-centimeter long incision line 7 mm from the Neuroma marking on the skin. Local anesthesia using plain 2% lidocaine infiltration of the circumferential exploratory area. Sterile prep and drape in surgical fashion. Meticulous exploratory preparation of the subcutaneous tissue 20 mm at each side of the incision line. Appropriate visibility of the ZT nerve branches embedded in lipomatous and connective tissue over the temporal fascia. Exploratory visualization of the subcutaneous marked tissue by methylene blue using a binocular magnification eases visualization. Using an Adson tissue forceps with side grasping teeth, now an exploratory touch of the above and distal of the marking would deliver the hypersensitive painful Neuroma tissue for sharp excision using surgical scissors. Control of bleeding and skin closure. Sterile pressure dressing. Specimen be sent to pathologic examination.
224208970|NCT04190251|OTHER|Inteprofessional medication adherence support program (IMAP)|In addition to usual care, patients participate in a medication adherence support program combining an Electronic Monitoring system (EM, named MEMS®; Aardex Ltd) and motivational semi-structured interviews. This programm is done by the Unisanté's community pharmacists, in coordination with medical and nurse staff , to support medication adherence and to promote continuity of care. The intervention is held at the Unisanté's community pharmacy. For patients not speaking french, english, or italien, the interviews will be done with a interpreter.
224208971|NCT04349501|OTHER|Restriction Spectrum Imaging Magnetic Resonance Imaging|RSI is a multicompartment model of diffusion MRI that uses data acquired at multiple b-values to distinguish varied diffusion speeds (restricted intracellular, hindered extracellular, and approximately free diffusion).
224208972|NCT05704946|OTHER|THE EFFECT OF LAVENDER INHALATION ON SLEEP QUALITY IN INDIVIDUALS WITH CORONARY HEART DISEASE|The index includes 24 questions that evaluate the quality of sleep and the type and severity of sleep disorders experienced in the last 1 month period. The total score in the index takes a value between 0-21. If the total score is higher than 5, it is interpreted as poor sleep quality.
224208973|NCT00685711|BIOLOGICAL|Cat-PAD|single, escalating dose intradermal and subcutaneous injections of Cat-PAD
224208974|NCT05601193|OTHER|autologous platelet-rich plasma|autologous PRP preparation was done by segregation of PRP following the centrifugation
224208975|NCT03583931|PROCEDURE|VATS Decortication|Surgical procedure to unroof all located collections of the pleural space through a chest wall incision
224208976|NCT03583931|DRUG|Fibrinolytic Therapy|Instillation of DNAse and tPA together through patient's chest tube already in placed to break down complex fluid collection in the pleural space. DNAse and tPA are are administered together only i.e. are not mutually exclusive.
224208977|NCT06566105|GENETIC|precision medicine approach|precision medicine approach to improvement of risk stratification of hepatic and cardiovascular complications in non-alcoholic fatty liver disease in a group of healthy subjects at increased risk of metabolic pathologies
224208978|NCT00848666|DRUG|Topical therapy|One time immersion of the feet in a liquid containing water, alcohol, vinegar, benzoic acid and salicylic acid for a total of 30 minutes.
224208979|NCT01315054|BEHAVIORAL|MMT provider dosage training|Training on methadone dosing provided to health care providers working in methadone maintenance clinics
224208980|NCT01315054|BEHAVIORAL|targeted counseling|targeted counseling provided to methadone maintenance clinic attendees
224208981|NCT01315054|OTHER|national guidelines|Provided a hard copy of the existing national guidelines for methadone dosing
224315646|NCT00643812|OTHER|Installation of gun locker in household|Households were randomized to 'early' and 'late' arms. Each household received a gun locker, which was installed in the household. Early arm received gun lockers at baseline.
224315647|NCT00643812|OTHER|Installation of gun locker in household|"Households were randomized to 'early' and 'late' arms. Each household received a gun locker, which was installed in the household. Late arm received the gun locker 12 months after baseline."
224315648|NCT00047112|DRUG|cisplatin|
224315649|NCT00047112|DRUG|fluorouracil|
224315650|NCT00047112|PROCEDURE|conventional surgery|
224315651|NCT00047112|PROCEDURE|neoadjuvant therapy|
224315652|NCT00047112|RADIATION|radiation therapy|
223619457|NCT03487731|BIOLOGICAL|Allogeneic Human Mesenchymal Stem Cells (hMSCs)|A single administration of 20 million allogeneic mesenchymal stem cell delivered intra-facet via 6 injections of 1.5 mL per injection, total of 9 to 12ml.
223619458|NCT03487731|DRUG|Placebo|A single administration of 1 cc of 1% lidocaine with 1 cc of 2% Ropivicaine and 0.5 cc of betamethasone soluspan (celestone) solution delivered via intra-facet injection.
223619459|NCT05403034|PROCEDURE|Muscle biopsy|Peroperative muscle biopsy will be performed during a planned shoulder surgery (arthrolysis and/or muscle transfer)
224315653|NCT01525017|BIOLOGICAL|Combig-DC (allogeneic dendritic cells) Cancer Vaccine|Cryopreserved dendritic cell suspension of 10 million cells per ml in heat-inactivated plasma, supplemented with 10% dimethyl sulfoxide (DMSO).
223619460|NCT06094608|DEVICE|Morning light treatment|Light therapy via the Re-Timer. Participants will conduct light treatment in the mornings at home for one hour using Re-timer®.
223619461|NCT06094608|BEHAVIORAL|Treatment-as-usual|Participants will not make modifications to their activities or sleep schedule.
223619462|NCT04909489|OTHER|cross-sectional study without intervention|cross-sectional study without intervention
224208982|NCT04424732|RADIATION|Stereotactic Body Radiotherapy|This is a prospective study of breast bone only oligometastases (up to three sites). Following systemic treatment and primary tumor control, patients will receive SBRT to all metastatic sites. Data on toxicities and oncological outcomes will be collected for future analysis. There will be no change in the standard systemic therapy nor the local therapy of the primary tumor.
224208983|NCT04337359|DRUG|Ruxolitinib|5 mg. Tablet
224208984|NCT00326300|DRUG|methylphenidate hydrochloride extended-release tablets|
224208985|NCT01839565|DEVICE|Quadrilateral Surface Plate|Patients with acetabular fracture surgically treated using the Quadrilateral Surface Plate
223619463|NCT05686785|DIAGNOSTIC_TEST|Transient elastography|Transient elastography measures liver stiffness in kPa
223619464|NCT00905450|DRUG|BOL-303242-X|Medication instilled into the study eye, subjects randomized to various drug concentrations and dose schedules.
224208986|NCT03590691|OTHER|Vietnam National Hypertension Program|A training program for health care workers including physicians and nurses and a health educational program for general public regarding hypertension management at community level will be implemented
223619465|NCT00905450|DRUG|Vehicle for BOL-303242-X|Medication instilled into the study eye, subjects randomized to various drug dose schedules.
224208987|NCT03590691|OTHER|Expanded community health worker services|A training program will be implemented for community health workers regarding hypertension management at community level so that they can assist patients better manage their blood pressure at home.
224208988|NCT03590691|BEHAVIORAL|Storytelling intervention|The storytelling intervention consists of interactive, literacy-appropriate, and culturally sensitive multimedia storytelling modules for motivating behavior change through the power of patients speaking in their own voice. Based on preferences that emerged during the researchers' formative work with the partnering rural communities, the storytelling intervention will be delivered by DVD, with serial installments at baseline and at 3, 6, and 12 months after trial enrollment.
224208989|NCT03590691|BEHAVIORAL|Home blood pressure self-monitoring|Patients with hypertension will be provided blood pressure monitors and guided to self-measure their blood pressure and to record their blood pressure daily at home.
224208990|NCT00857493|BIOLOGICAL|IMVAMUNE|Two s.c. vaccinations with 0.5 ml IMVAMUNE® vaccine containing 1 x 10E8 TCID50 / dose
224208991|NCT00857493|BIOLOGICAL|IMVAMUNE|One s.c. vaccination with placebo (0.5 ml saline), followed by a second s.c. vaccination with 0.5 ml IMVAMUNE® vaccine containing 1 x 10E8 TCID50
224208992|NCT00741520|DEVICE|CPAP|Control - no treatment
224208993|NCT00741520|DEVICE|CPAP|CPAP: The airway pressure will be determined by an overnight sleep study titration.
224208994|NCT03289637|DIETARY_SUPPLEMENT|Vitamin D|Vitamin D intervention tested against placebo in a population with heart failure and a 25-OH-vitamin D level\<50nmol/L at screening
224208995|NCT01501071|DEVICE|Esophageal calibration tube|An orogastric calibration tube is inserted during laparoscopic Nissen fundoplication in order to secure a certain esophageal lumen for reducing postoperative dysphagia
224208996|NCT04729634|OTHER|Mobilization|Mobilization and breathing exercises according to clinical care
224208997|NCT03292965|DRUG|Neostigmine|Referring to the randomisation allocation program, participants allocated to group neostigmine, administrate neostigmine as reversal
224208998|NCT03292965|DRUG|Sugammadex|Referring to the randomisation allocation program, participants allocated to group sugammadex, administrate sugammadex as reversal
224208999|NCT05233371|OTHER|Parenting Stress Index (PSI)|"collected by self-questionnaire during the follow-up carried out within the framework of the usual care (at 4, 9, 24 months of corrected age, +/- 18 months according to the neurodevelopmental evolution).~Parental stress will be measured at each visit with the same parent (father or mother)."
224209000|NCT05233371|OTHER|Collection of health care consumption|"Type and number of health professionals consulted between the different visits scheduled as part of the usual follow-up of the Dijon Bourgogne University Hospital,~* Frequency and duration of rehabilitation sessions by type of health professionals,~* Follow-up methods (institutional or private),~Consumption of care will be evaluated by means of self-questionnaires given to parents during follow-up consultations as part of the usual care."
224209001|NCT05233371|OTHER|Assessment of parent satisfaction|"their level of information, their child's follow-up, and the support provided by the professionals.~Satisfaction will be evaluated by means of a self-questionnaire (Likert scale) given to parents during follow-up consultations as part of their usual care."
224209002|NCT01281579|DRUG|Canagliflozin 100 mg|Tablets, oral, 100-mg, once daily on Day 1 and on Days 4 through 9.
224209003|NCT01281579|DRUG|Canagliflozin 50 mg|Tablets, oral, 50-mg, once daily on Day 1 and on Days 4 through 9.
224209004|NCT01281579|DRUG|Canagliflozin 300 mg|Tablets, oral, 300-mg, once daily on Day 1 and on Days 4 through 9.
224209005|NCT00946465|DRUG|Ramipril 10 Capsule (Sandoz)|
224209006|NCT00946465|DRUG|Altace (Ramipril) 10 Capsule (Aventis Pharmaceutical)|
224209007|NCT01884870|PROCEDURE|Surgical Treatment|Surgical Treatment - open, endoscopic or laparoscopic
224209008|NCT05851976|DRUG|Naproxen|Naproxen 500mg twice daily for 16 days
224209009|NCT05851976|DRUG|Duloxetine|Duloxetine 60mg daily for 14 days
224315654|NCT06164262|OTHER|Individuals with CSVD|This does not entail the application of interventions.
223619466|NCT05877755|DEVICE|Cardiac MRI acquisition|All patients will have additional images collected during the magnetic resonance imaging (MRI) examination. These are high-resolution multi-contrast cardiac MRI sequences in gradient echo or in balanced steady state free precession with synchronization on the electrocardiogram. The acquisitions last between 1 minute and 10 minutes. This duration depends on the patient's heart rate and breathing rate. The imaging protocol will last approximately 50 minutes. MRI examinations will be performed on a 1.5 Tesla clinical system with specific cardiac imaging coils.
223619467|NCT01693029|DRUG|HX575 epoetin alfa|Solution for subcutaneous injection. The drug is administered subcutaneously at least once per week over 52 weeks. The dose will be individually titrated to maintain hemoglobin levels between 10 to 11 g/dL.
224209010|NCT02629627|DIETARY_SUPPLEMENT|Conjugated linoleic acid/Leucine|Conjugated linoleic acid/Leucine capsules, 825mg time daily with the first bite of eat meal during 12 weeks.
224209011|NCT02629627|DRUG|Metformin|Metformin in a dosis of 500mg per day (with the first bite of the second meal) during 12 weeks
224209012|NCT02629627|DIETARY_SUPPLEMENT|Placebo of ACL/Leucine|Homologate placebo of ACL/Leucine (linseed oil capsules) in a dosis of 3600 mg each 24 hrs (2 capsules of 2400 mg with the first meal and 1200 mg or 1 capsule with the second meal) during 12 weeks.
224209013|NCT02629627|OTHER|Placebo of Metformin|homologate placebo of metformin (calcinated magnesia) in a dosis of 500 mg per day (with the first bite of the second meal) during 8 weeks
224209014|NCT04188860|DRUG|A combination of anti-PD-1 antibody camrelizumab and albumin-bound paclitaxel|"A combination of anti-PD-1 antibody camrelizumab and albumin-bound paclitaxel would be given for all patients:~* Camrelizumab: 200 mg every time, every 3 weeks, which would be sustained until the appearance of disease progression on intolerable adverse events, and no more than 24 months~* Albumin-bound paclitaxel: 200-300 mg every time, every 3 weeks, no more than 6 courses"
224209015|NCT00886873|DRUG|Mifepristone|
224209016|NCT06702280|DIETARY_SUPPLEMENT|IgY supplement|Ingesting the immune supplement over the experimental period
224209017|NCT05920031|OTHER|Cross-education|Participants will perform resistance exercises at 60% of their 1 repetition maximum (1RM) with the less affected limb. The intervention will be performed three times per week for 8 weeks. Each session will consist of three sets of 15 repetitions of bicep curls, tricep extensions, and wrist flexion/extension exercises with a 1-minute rest period between sets. The exercises will be performed in a seated position, with the participant's forearm resting on a table and the therapist providing manual resistance. The therapist will be positioned in front of the participant.
224209018|NCT05920031|OTHER|Mirror therapy|Participants will perform bilateral upper limb movements while observing the reflection of the less affected limb in a mirror. The intervention will be performed three times per week for 8 weeks. Each session will consist of 10 minutes of mirror therapy, with the participant seated in front of a mirror. The participant will perform various upper limb movements, such as reaching and grasping, while observing the mirror reflection of the less affected limb. The therapist will be positioned beside the participant, providing verbal cues and feedback as necessary.
224209019|NCT05920031|OTHER|Conventional Physical Therapy|articipants will receive conventional rehabilitation for post-stroke upper limb motor impairments, which may include exercises such as range of motion, stretching, and strengthening of the affected limb, as well as other therapies such as electrical stimulation or constraint-induced movement therapy. The intervention will be individualized for each participant and will be performed three times per week for 8 weeks. The frequency, duration, and intensity of the exercises will be gradually increased over the course of the intervention, based on the participant's progress. The exercises may be performed in a seated or standing position, depending on the participant's ability and preference. The therapist will be positioned in front of or beside the participant, providing verbal cues and feedback as necessary.
224209020|NCT02426294|DRUG|Pioglitazone|
224209021|NCT02426294|DRUG|Glimepiride|
224209022|NCT00596973|PROCEDURE|Surgical Treatment|Ileal transposition with sleeve gastrectomy
224209023|NCT05894382|DEVICE|Double Helix Design Defocus Lens Spectacle (RACE)|Double Helix Design Defocus Lens Spectacle wearing more than 10h/day.
224209024|NCT05894382|DEVICE|single-vision spetacle lens|single-vision spetacle lens wearing more than 10h/day.
224209025|NCT02552329|OTHER|Tai Chi exercise|The Tai Chi exercise group will exercise for 50 minutes/session, 3 times /week for 24 consecutive weeks (6 months). Each 50-minute session will include a 10-minute warm up, 30-min exercise, and 10-min cool down, The 10 forms Tai Chi will be used.
224209026|NCT00993629|DRUG|pregnenolone|"Administered adjunctively to treatment as usual"
223619468|NCT01693029|DRUG|US-licensed epoetin alfa|Solution for subcutaneous injection.
223619469|NCT05084313|OTHER|Manual Therapy|This group of patients will receive manual therapy techniques to harmonize vegetative nervous system. PPG and GSR will be recorded during the intervention. The techniques consist of CV-4 technique, suboccipital decompression, lumbo-sacral decompression, release of the transverse diaphragms, frontal lift technique, parietal lift technique, temporal techniques, temporo-mandibular joint myofascial release, deep cervical fasciae technique as described in Upledger's protocol. In addition to the protocol; rib raising technique, larynx and sternocleidomastoid muscle fascial release and occipito-mastoid suture release will be applied. All intervention is planned to take approximately 20 minutes. The group will include forty healthy individuals.
224209027|NCT00993629|DRUG|placebo|adjunctive placebo
224209028|NCT05537246|PROCEDURE|PWV|All cases were evaluated in the service before surgery. Pulse wave velocity measurement was performed with the MOBİL-O-GRAPH device, which is one of the noninvasive methods. Before measuring from patients; It was confirmed that there was no coffee/cigarette consumption within 30 minutes. After resting for 5 minutes in a quiet room, the cuff of the appropriate size was tied to the arm in such a way that it came to the brachial artery. The data recorded by the tonometer was transferred to the computer program. Care was taken that the patient did not move or talk during the measurement.
224315655|NCT01229163|DEVICE|Automated Contingency Management (ACM) software|
223680438|NCT02593136|DIETARY_SUPPLEMENT|Home Fortification Product (HFP)|"The home fortification product (HFP) is a sachet containing multiple vitamins and nutrients as follows:~Iron (Ferrous Fumarate) 12.5 mg Zinc (Zinc Gluconate) 5 mg Folic Acid 0.160 mg Vitamin-A (Vit-A Acetate) 0.30 mg Vitamin-C (Ascorbic Acid) 30 mg Vitamin-B12 0.9 mcg Iodine 90 mcg Maltodextrin (Base)"
223619470|NCT05084313|OTHER|Deep-slow breathing|Patients in this group will do slow paced breathing to increase heart rate variability as it can be partially modulated by respiratory effects. The patients will be able to cease the session in case of feeling uncomfortable. The main purpose will be that the individuals should breathe six breaths per minute to increase respiratory sinus arrhythmia which is also reflected at PPG waveforms and in reduction in GSR. The group will include forty healthy individuals.
224209029|NCT06540040|DEVICE|Aquacel Ag|Aquacel Ag is a Hydrofibre wound dressing composed of non-woven sodium carboxymethylcellulose fibers integrated with ionic silver. It is designed to provide a moist wound environment and has antimicrobial properties to help reduce the risk of infection. The dressing will be applied post-operatively and changed according to a standardized protocol.
223619471|NCT05084313|OTHER|Control|Control group patients will be attached to the sensors, and they will rest in a quiet and controlled indoor environment without any intervention. The aim of including this group is to to understand whether the parasympathetic effects expected in the manual therapy group were due to the intervention. The group will include forty healthy individuals.
223619472|NCT06330740|OTHER|Clinical Decision Support|Upon ordering antibiotics the provider will be prompted to utilize an indication-based order set which guides the clinician to the appropriate empiric antibiotic choice.
223619473|NCT01529073|DRUG|Nitazoxanide|Nitazoxanide 500 mg bid po for 4 weeks, followed by nitazoxanide 500 mg bid plus pegylated interferon alpha 2b 1.5 mg/kg/week sc plus weight-adjusted ribavirin po for 48 weeks.
223619474|NCT01494948|OTHER|allergen challenge|nasal challenges with antigen to which they are sensitive to
223619475|NCT03683173|BEHAVIORAL|Intervention|Participants in the intervention arm may receive community events, partake in walking groups, and receive short messaging service.
223619476|NCT04149249|OTHER|Computer-Assisted Intervention Video Doctor|Complete CONNECT: participants will undergo in-person assessment questions and follow-up assessment questions. They will view and participate in the interactive Video Doctor about Smoking Cessation.
223619477|NCT04149249|OTHER|Computer-Assisted Intervention no Video Doctor|Individuals who are randomized to the control group will undergo the same assessment questions and all follow up assessments like the intervention group. Instead of viewing and participating in the interactive Video Doctor about Smoking Cessation, they receive a handout containing smoking cessation resources.
223619478|NCT04258930|OTHER|Aluminum sulphate and calcium acetate drying soaks|Dilute one envelope of the powder in 500 ml of clean cold water and apply for 10 minutes every 8 hours until completely healed.
223619479|NCT04258930|DEVICE|Topical sterile silicone gel for wounds|Apply a thick layer of silicone gel to all open areas every 8 hours until completely healed.
223619480|NCT04258930|DEVICE|Hydrocolloid dressing|Apply enough hydrocolloid dressings to cover all open areas and change every 2 to 3 days once the dressing becomes saturated (starts to drain around the borders).
224209030|NCT06540040|DEVICE|OPSITE|OPSITE is a transparent waterproof dressing with a high Moisture Vapour Transmission Rate. It is intended to provide a protective barrier while allowing moisture vapor to escape, maintaining an optimal wound healing environment. The dressing will be applied post-operatively and changed according to a standardized protocol.
224209031|NCT06540040|DEVICE|MEPILEX POST OP BORDER|MEPILEX POST OP BORDER is a 4-layer foam dressing designed with flex technology for superior absorption and conformability. It helps manage exudate and protects the wound site. The dressing will be applied post-operatively and changed according to a standardized protocol.
224209032|NCT06540040|DEVICE|Traditional Dressing|Traditional dressing involves the use of gauze pieces, surgical pads, and porous paper adhesive strips. This type of dressing is commonly used in post-operative care to absorb exudate and protect the wound site. The dressing will be applied post-operatively and changed according to a standardized protocol.
224209033|NCT06213389|DEVICE|EzVision® videolaryngoscopy|Patient will be intubated with EzVision® videolaryngoscopy
224209034|NCT06213389|DEVICE|Macintosh Blade|Patient will be intubated with Macintosh Blade
224209035|NCT03131466|DEVICE|High-voltage pulsed radiofrequency|The manual PRF mode of the pain treatment generator will be turned on, the upper temperature limit will be set at 42°C, the PRF output voltage will be gradually increased to the highest voltage the patient can tolerate, and the patient will be treated for 360 s. After the treatment, 1.4 ml of a mixture of 0.4 mL of normal saline and 1 mL of 1% plain lidocaine will be injected through the needle of the cannula, and before the needle being removed, 0.5 mL of normal saline will be injected.
224323205|NCT06285032|BEHAVIORAL|Social Navigation Group|Those in the social navigation intervention, will meet with a navigator weekly through a virtual visit (HIPAA-compliant videoconferencing or phone call based on patient preference) over the course of 8 weeks. Each virtual visit will last approximately 30 minutes with a longer initial intake visit lasting 60 minutes. During the intake visit, the navigator will complete a patient narrative and an inventory of the patient's existing social network, former social network and interests. Using this, the navigator will work with the patient to develop an action plan to promote, establish or re-establish social connections. The action plan will be referenced and refined throughout the course of the 8 weeks. They will suggest specific social activities and connect patients to resources such as, community-based organizations or local social groups matched to individual participant interest to assist with social connection
223619481|NCT05279352|DRUG|FBR-002|Administration on D1 and D3
223619482|NCT05279352|DRUG|Placebo|Administration on D1 and D3
223619483|NCT03567031|PROCEDURE|EtCO2 modification|Controlled modification of EtCO2 through modification of ventilation parameters under general anesthesia without spontaneous breathing
223619484|NCT00363532|DRUG|infusion of calcitonin gene related peptide (CGRP)|
223619485|NCT01934959|DRUG|Bifico|
223619486|NCT06492174|DEVICE|AGENT DCB 40 mm|Drug coated PTCA balloon catheter 40 mm size
223619487|NCT02647281|DRUG|GSK3389404|GSK3389404 is supplied as solution for injection vial. Each vial contains 100 mg/mL of GSK3389404. It's physical appearance is clear colourless to slightly yellow solution.
223619488|NCT02647281|DRUG|Matching Placebo|Placebo is supplied as solution for injection vial. It's physical appearance is clear colourless solution.
223619489|NCT05801991|DEVICE|Neurolens|neurolens® is a type of spectacle lens that uses contoured prism to alleviate vergence demands and fatigue at near and, therefore, encourages comfortable vision.8 This spectacle design uses the neurolens® Measurement Device (nMD) to measure eye alignment and determine the spectacle lenses that are uniquely designed for each wearer.
223619490|NCT05801991|DEVICE|Placebo spectacle lens|Plano (no power) spectacle lenses will be assigned to the placebo group
223619491|NCT00972101|RADIATION|Total Body Irradiation (TBI)|3 Gy of radiation on Days -7,-6, -5 and -4.
223619492|NCT00972101|DRUG|Melphalan|140 mg/m\^2 by vein over 30 minutes as a single dose on Day -8
223619493|NCT00972101|DRUG|Thiotepa|10 mg/kg by vein over 4 hours as a single dose on Day -7
223619494|NCT00972101|DRUG|Fludarabine|40 mg/m\^2 by vein over about 30 minutes 1 time each day on Days -6 through -3.
223619495|NCT00972101|DRUG|Rituximab|"Regimen 1:~375 mg/m\^2 may be given by vein over 4 - 6 hours on Day -9 if needed~Regimen 2:~375 mg/m\^2 may be given by vein over 4 - 6 hours on Day -8 if needed"
223619496|NCT00972101|DRUG|Etoposide|60 mg/m\^2 by vein over 1-2 hours as a single dose on Day -3.
224209036|NCT03131466|DRUG|Nerve block|The radiofrequency generator will be set at the sensory stimulating mode, and the lowest frequency of 0.2 V will be used for 360s-sham PRF treatment, after which 1.4 mL of a mixture of 2 mg of dexamethasone sodium phosphate and 1 mL of 1% plain lidocaine will be slowly injected through the radiofrequency treatment cannula needle. Before the needle being removed, 0.5 mL of normal saline will be injected.
223619497|NCT00972101|DRUG|Anti-thymocyte globulin (ATG)|"Regimen 1:~1.25 and 1.75 mg/kg by vein over 4-6 hours on the Days -4 and -3.~Regimen 2:~0.5, 1.0 and 1.5 mg/kg by vein over 4-6 hours on respective Days -3, -2, and -1."
224209037|NCT02107768|OTHER|Aerobic exercise|"Other: Aerobic exercise The intervention group will conduct a 12 week training period with two training sessions of 60 minutes per week at a local hospital. The start shall be made within 6 weeks after stroke . The training shall be conducted in a group with a maximum of 10 participants and start running as new participants in the intervention group will be added.The intensity during the exercise program should be individualized and based on the initial tests . Patients should be advised to reach a degree of exertion 13-15/20,Rate of Perceived Exertion (Borg 's RPE scale) .~Two fitness goals was to be achieved during the training session~1\. An individual training level corresponded to 50% or more of maximal oxygen uptake for at least 40 min ( Borg 9-11/20 ) . Which corresponds to 70 % of maximum heart rate.~2:nd 80% or more of the estimated maximum oxygen uptake during two periods of 8 minutes( Borg 13-15/20 ) . Which corresponds to 85 % of maximum heart rate."
224209038|NCT06536725|OTHER|Building Organoid-on-chips models|This project obtains surgical or biopsy samples from prostate cancer patients with visceral metastasis for the construction of organoids.
224209039|NCT01850108|DRUG|Thymoglobulin|"Day 9 before BMT: 0.5mg/kg IV; Days 8 \& 7 before BMT: 2mg/kg IV~Days 8 \& 7 - 2mg/kg IV before BMT"
224209040|NCT01850108|DRUG|Fludarabine|Days 6 and 2 before BMT: 30mg/m2/day IV
224209041|NCT01850108|DRUG|Cyclophosphamide (CTX)|Days 6 and 5 before BMT: 14.5mg/kg IV; Days 3 and 4 after BMT: 50mg/kg/day
224209042|NCT01850108|DRUG|Mesna|Days 3 \& 4 after BMT: 40 mg/kg IV
224209043|NCT01850108|DRUG|Sirolimus|Adjusted to maintain a serum trough level of 3-12 ng/mL, taken orally beginning on 5 days after BMT and taken to 1 year after BMT.
223619498|NCT00972101|DRUG|Mycophenolate Mofetil (MMF)|15 mg/kg pills twice a day starting on day -3, and continued until Day 100+ after transplant (1 gram may be given by vein if necessary).
224209044|NCT01850108|DRUG|Mycophenolate mofetil (MMF)|15 mg/kg orally with maximum dose 3 mg/day beginning 5 days after BMT and taken to day 35 after BMT
224209045|NCT01850108|PROCEDURE|Bone marrow transplantation|Day 0 - Transplantation of hematopoietic cells derived from bone marrow of a donor to a recipient as treatment for hematologic disorders
224209046|NCT01850108|RADIATION|Total body irradiation|200 cGy on the day before BMT. Radiation delivered to the entire body of the recipient to eradicate bone marrow cells in the recipient to prepare the recipient to receive the transplanted
224209047|NCT01155258|DRUG|temsirolimus|Given IV
224209048|NCT01155258|DRUG|vinorelbine ditartrate|Given IV
224209049|NCT01418534|DRUG|Torrent's Isosorbide Mononitrate 120 mg ER Tablets|
223619499|NCT00972101|DRUG|Tacrolimus|0.03 mg/kg by vein Day -2 as 24 hour continuous infusion for several weeks. After stem cell transplant, tacrolimus given by mouth 2 times a day for up to 6 months.
223619500|NCT00972101|PROCEDURE|Cord Blood Infusion|Cord blood infusion of larger portion through vein using Central Venous Catheter (CVC) on Day 0.
223619501|NCT00972101|DRUG|G-CSF|5 mcg/kg day subcutaneously (may round up to the next vial) beginning on day +1 and continuing till absolute neutrophil count is \> 2.5 x 10e\^9/L.
223619502|NCT00972101|PROCEDURE|Ex vivo expanded T cell Infusion|Infusion by vein of treated cord blood beginning dose of 1 x 10e\^5 T cells/kg on Day 14+.
224209050|NCT05584839|OTHER|Statistically Analysis|The study was planned as a quantitative research. Socio-demographic information form, anthropometric measurements of hand grip strength, palm length, hand width length, wrist circumference length, Visual Analog Scale scale, EMG findings will be evaluated by hand dynamometer.
223619503|NCT05019690|DRUG|Apatinib Mesylate|Subjects receive Apatinib orally, Dosage form: tablet, Strength: 250 mg/tablet,QD,Q3W
223619504|NCT05019690|DRUG|Albumin-Bound Paclitaxel|Subjects receive Albumin-Bound Paclitaxel,ivgtt, Strength: 125 mg/m\^2,d1、7、15,Q3W
224323206|NCT06285032|BEHAVIORAL|Controlled Group|Those randomized to the control group will receive usual care from their primary care clinician. At the conclusion of the study (after the final outcomes are collected), they will be offered a list of possible community-based organizations for social connection.
224323207|NCT05064553|DEVICE|Study CT/MRI Imaging|Subjects with negative ultrasound will be sent for a study CT/MRI.
223619505|NCT01057953|GENETIC|Blood drawn|Blood drawn for patient
223619506|NCT00547274|DRUG|MK0767|
223619507|NCT03684174|DEVICE|Intraocular pressure measurement|Pressure tip or air puff is applied on eye
223680439|NCT02593136|OTHER|Infant and Young Child Feeding (IYCF) Practices Counseling|Infant and Young Child Feeding (IYCF) Practices Counseling provides direction on breast milk and milk feeding, food variety, and frequency for caregivers of children aged 6 to 18 months. Participants will be visited at least monthly by a field line worker for IYCF counseling and educational materials distribution.
223680440|NCT02937974|DRUG|Xuebijing|Xuebijing injection 50ml in 100ml of Normal Saline IV, in 80mins, per 12 hours. administration of the agent for consecutive 5 days
223680441|NCT02937974|DRUG|Placebo|Normal Saline 150ml IV, in 80mins, per 12 hours. administration of the agent for consecutive 5 days
223680442|NCT00482352|OTHER|laboratory biomarker analysis|Correlative studies
223680443|NCT00938886|DRUG|Naltrexone|Daily 50 mg naltrexone
223619508|NCT04319952|DEVICE|Primary Total Hip Replacement with Metafix™ femoral stem and Trinity™ acetabular cup or TriFit-CF™/TriFit-TS™ femoral stem and Trinity™ acetabular cup implanted by a single surgeon.|The participant will undergo surgery using the hip prostheses and direct anterior surgical approach used by their surgeon-investigator. A patient-specific femoral guide, generated by the OPS™ Plan preoperatively, will be used during the surgical step of the femoral neck resection. These are not study specific procedures as the OPS™ Plan is already in use by the surgeon-investigator in their standard of care practice.
223619509|NCT00276510|DRUG|EGb 761® (Tanakan®)|120 mg, 1 tablet twice a day, oral route, during 5 years.
224209051|NCT05760924|DEVICE|Cardiac Resynchronization Therapy Devices with Defibrillator Function (CRT-D) or CRT-D Leads Replacement|The local anesthesia will be performed on the left/right subclavian area after prepping the skin. The device pocket will be opened, the old CRT-D will be removed and disconnected from the leads. The pacing threshold, intracardiac signal amplitude and impedance (pacing and shock) on the atrial, defibrillation and left ventricular leads will be performed. If there is a lead dysfunction, the new lead will be implanted. The new CRT-D will be connected with leads and placed back into the pocket. The pocket will be closed by separate stitches (2-4 suffice) using the resorbable braided suture.
224209052|NCT05760924|DEVICE|CRT-D or CRT-D Leads Replacement with New Lead Implantation to Left Bundle Branch and Inactivation of Conventional Right and Left Ventricular Pacing|The local anesthesia will be performed on the left/right subclavian area after prepping the skin. The device pocket will be opened, the old CRT-D will be removed and disconnected from the leads. The pacing threshold, intracardiac signal amplitude and impedance (pacing and shock) on the atrial, defibrillation and left ventricular leads will be performed. If there is a lead dysfunction, the new lead will be implanted. The lead implantation to the left bundle branch (LBB) will be performed by transvenous approach and special delivery system. The new CRT-D will be connected with the leads (LBB pacing lead will be connected to defibrillation lead (DL) IS-1 connector of CRT-D and IS-1 tip of DL will be capped) and placed back into pocket. The pocket will be closed by separate stitches (2-4 suffice) using the resorbable braided suture. RV and LV pacing will be inactivated and only LBB pacing will be switched on.
224209053|NCT05760924|DEVICE|CRT-D or CRT-D Leads Replacement with New Lead Implantation to Left Bundle Branch and Inactivation of Conventional Right Ventricular Pacing|The local anesthesia will be performed on the left/right subclavian area after prepping the skin. The device pocket will be opened, the old CRT-D will be removed and disconnected from the leads. The pacing threshold, intracardiac signal amplitude and impedance (pacing and shock) on the atrial, defibrillation and left ventricular leads will be performed. If there is a lead dysfunction, the new lead will be implanted. The lead implantation to the left bundle branch (LBB) will be performed by transvenous approach and special delivery system. The new CRT-D will be connected with the leads (LBB pacing lead will be connected to defibrillation lead (DL) IS-1 connector of CRT-D and IS-1 tip of DL will be capped) and placed back into pocket. The pocket will be closed by separate stitches (2-4 suffice) using the resorbable braided suture. LBB and LV pacing will be switched on.
224209054|NCT05302037|BIOLOGICAL|Allogeneic NKG2DL-targeting Chimeric Antigen Receptor-grafted γδ T Cells (CTM-N2D)|In the production of CTM-N2D, blood cells from healthy donors are used as starting materials. Through a proprietary expansion technology, γδ T cells of high-purity can be obtained. These γδ T cells are further grafted with NKG2DL-targeting CARs using mRNA electroporation to enhance its anticancer potency. The finished product (CTM-N2D) are then infused allogeneically into cancer patients.
224209055|NCT02958774|RADIATION|Hypofractionated Radiation Therapy|Chest/Breast 4005 centigray (cGy)/15 fractions/267 cGy daily Regional nodes 4005 cGy/15 fractions/267 cGy daily 1000 cGy boost to lumpectomy/scar/undissected nodes 200 cGy daily
224209056|NCT06635577|BEHAVIORAL|Verbal Interference Task|"During the second half of the study, participants will undergo an interference task such as repetition of the word the; or shadowing a radio broadcast in order to increase cognitive load and disrupt the use of a mental workspace."
224209057|NCT02866370|DRUG|Nintedanib|Nintedanib (BIBF1120) 200mg twice daily PO, continuously, until progression or withdrawal from the treatment.
224209058|NCT02866370|DRUG|Paclitaxel|"Ovarian Cancer Patients Paclitaxel (80mg/m2) IV Day 1, 8, 15 every 28 days\* Endometrial Cancer Patients Carboplatin (AUC 5) and Paclitaxel (175mg/m2) IV every 21 days\*~\* Patients will usually receive up to 6 cycles of chemotherapy. If in the opinion of the Investigator, a patient would benefit from continuing with chemotherapy beyond 6 cycles, it is acceptable to continue until progression or unacceptable toxicity."
224209059|NCT02866370|DRUG|Pegylated Liposomal Doxorubicin (PLD)|"Ovarian Cancer Patients Pegylated Liposomal Doxorubicin (PLD) (40mg/m2) IV every 28 days\*~\* Patients will usually receive up to 6 cycles of chemotherapy. If in the opinion of the Investigator, a patient would benefit from continuing with chemotherapy beyond 6 cycles, it is acceptable to continue until progression or unacceptable toxicity. The maximal lifetime cumulative dose of doxorubicin or pegylated liposomal doxorubicin allowed is 450 mg/m2."
224209060|NCT02866370|DRUG|Topotecan|"Ovarian Cancer Patients Topotecan 4mg/m2 IV Day 1, 8, 15 every 28 days\*~\* Patients will usually receive up to 6 cycles of chemotherapy. If in the opinion of the Investigator, a patient would benefit from continuing with chemotherapy beyond 6 cycles, it is acceptable to continue until progression or unacceptable toxicity."
224209061|NCT02866370|DRUG|Carboplatin|"Endometrial Cancer Patients Carboplatin (AUC 5) and Paclitaxel (175mg/m2) IV every 21 days\*~\* Patients will usually receive up to 6 cycles of chemotherapy. If in the opinion of the Investigator, a patient would benefit from continuing with chemotherapy beyond 6 cycles, it is acceptable to continue until progression or unacceptable toxicity."
224209062|NCT02866370|DRUG|Doxorubicin|"Endometrial Cancer Patients Doxorubicin IV 60mg/m2 every 21 days\*~\* Patients will usually receive up to 6 cycles of chemotherapy. If in the opinion of the Investigator, a patient would benefit from continuing with chemotherapy beyond 6 cycles, it is acceptable to continue until progression or unacceptable toxicity. The maximal lifetime cumulative dose of doxorubicin or pegylated liposomal doxorubicin allowed is 450 mg/m2."
224209063|NCT00716027|BEHAVIORAL|Standard behavioral treatment for weight loss|A 24-week intervention in which individuals will meet weekly to be instructed on behavioral change associated with weight loss, including modifying dietary intake, self-monitoring weight and eating behaviors, and increasing physical activity.
224323208|NCT05064553|DEVICE|Standard of Care CT/MRI Imaging|Subjects with positive ultrasound are anticipated to have standard of care imaging follow-up as well as other procedures as needed.
223619510|NCT00276510|OTHER|Placebo|1 tablet twice a day, oral route, during 5 years.
223619511|NCT01320475|DRUG|Sufentanil|Epidural infusion of levobupivacaine (1,25 mg/ml) and sufentanil(1 ml = 50 µg diluted in the 200 ml bag of levobupivacaine) IV infusion of saline (placebo for ketamine)
223619512|NCT01320475|DRUG|Ketamine|Epidural infusion of levobupivacaine (1,25 mg/ml) and saline (1 ml = 50 µg diluted in the 200 ml bag of levobupivacaine) IV infusion of ketamine (2 µg/kg/minute) Up to the third postoperative day (6 PM)
223619513|NCT05661786|OTHER|Observation|Monitor every 6 months
223619514|NCT05661786|OTHER|Antiviral treatment|Receive first-line antiviral treatment, including entecavir, tenofovir disoproxil fumarate, tenofovir alafenamide, tenofovir amibufenamide or peginterferon
223619515|NCT05631561|DEVICE|Endovascular denervation System (Generator and Catheter )|All patients receive endovascular denervation (EDN) treatment
223619516|NCT02210000|DRUG|Placebo|Camicinal matching placebo is available as tablet to be taken orally with 100mL of water in the morning
223619517|NCT02210000|DRUG|Camicinal|Camicinal is available as 25 mg tablet to be taken orally with 100mL of water in the morning
224209064|NCT00716027|BEHAVIORAL|Modified behavioral treatment for weight loss|A 24-week intervention in which individuals will meet weekly to be instructed on behavioral change associated with weight loss, including modifying dietary intake, self-monitoring weight and eating behaviors, and increasing physical activity. In this intervention, individuals not meeting weight loss goals will be given one-on-one treatment.
224209065|NCT00535301|DEVICE|grafted anterior prolapse repair|anterior vaginal prolapse repair with graft
224209066|NCT00535301|PROCEDURE|sutured anterior vaginal prolapse repair|anterior vaginal prolapse repair with suture
224323209|NCT05064553|DIAGNOSTIC_TEST|Oncoguard™ Liver Test|Subjects will have a blood sample collected for the Oncoguard™ Liver Test.
223512853|NCT03163264|BEHAVIORAL|Enhanced Usual Care|"Patients will be given information on healthy living messages that were created by the VA, and given more information on specific messages they are interested in from the health coaches, but will not receive official coaching. These messages are the current standard of care at the VA for obesity counseling."
223512854|NCT06329336|BEHAVIORAL|Social Emotional Competence for Children and Parents|This preventive parenting intervention combines behavioral parenting and mindfulness-based well-being practices to support effective parenting.
223512855|NCT04453007|BEHAVIORAL|e-checkup to go|The e-checkup to go alcohol program is designed to motivate individuals to reduce their alcohol consumption using personalized information about their own use and risk factors. The program is a combination of several components including alcohol education, personalized feedback, attitude-focused strategies, and skills training. It is self-guided and requires no face-to-face time with an administrator. It provides tailored feedback regarding quantity and frequency of alcohol use, normative comparisons, physical health information, amount and percent of income spent on alcohol, negative consequences feedback, explanation and advice for how to reach their goals, and resources.
223512856|NCT04453007|BEHAVIORAL|Feedback booster|Booster emails will contain normative feedback indicating average consumption for students at the same institution by sex, their perceptions of student drinkers at the same institution, their own reported consumption, and reminders of strategies they can use to protect themselves from alcohol-related harm.
223512857|NCT05677126|DRUG|Tralement|Tralement with Manganese
223512858|NCT05677126|DRUG|Fixed-dose trace element combination product of zinc, copper, and selenious acid|Tralement without Manganese
223512859|NCT00276003|DRUG|Gemcitabine, Irinotecan, Allopurinol.|Gemcitabine - 1000mg/m2; IV; d1, 8; q 21 days Irinotecan - 100mg/m2; IV; d1, 8; q 21 days Allopurinol - 300 mg; PO; day 1-5; 1st cycle
223512860|NCT03923998|DRUG|Neoadjuvant chemotherapy|Three weekly concurrent chemotherapy with cisplatin 100 mg /m2
223512861|NCT03923998|RADIATION|Neoadjuvant radiotherapy|Preoperative radiotherapy over 5 weeks- Dose 180-200cgys per day/ total 4500 cgys
223512862|NCT03923998|PROCEDURE|Resection and reconstruction|Resection and reconstruction of mandibular/maxillary segment with prefabricated fibular graft
223512863|NCT04968600|PROCEDURE|total knee arthroplasty|Posterior-cruciate-ligament is retained in one arm and sacrificed in another arm during total knee arthroplasty
223512864|NCT05091450|BEHAVIORAL|Couple-based I-BMS intervention for infertility|It is based on the previous I-BMS intervention for women undergoing IVF treatment, and aims to improve fertility quality of life and couple flourishing by (1) increasing awareness of the interconnectedness between physical and psychosocial well-being, (2) practicing body-mind-spirit techniques, (3) facilitating personal growth and partner empathy and compassion, and (3) creating the shared meaning of life, family, children. As a strength-focused and meaning-oriented approach, it utilizes experiential and self-reflective exercises to help participants reconstruct the meaning behind their ordeal and rediscover the strengths that keep them going.
223512865|NCT06163807|DRUG|Antiasthmatic|real-life
223512866|NCT02614066|BIOLOGICAL|brexucabtagene autoleucel|A single infusion of brexucabtagene autoleucel CAR transduced autologous T cells administered intravenously.
223512867|NCT02614066|DRUG|Cyclophosphamide|Administered intravenously.
223512868|NCT02614066|DRUG|Fludarabine|Administered intravenously.
223512869|NCT04933422|DRUG|CM93|oral capsule of CM93 administered once daily
223512870|NCT06029998|DRUG|Bortezomib|sub-cutaneous injection of bortezomib for 6-8 cycles of treatment.
223512871|NCT02096159|DRUG|trimethoprim-sulfamethoxazole|
223512872|NCT02096159|OTHER|placebo|
223512873|NCT03568058|DRUG|personalized vaccine|Vaccine will be constructed for each subject that express multiple candidate tumor-derived neoantigens.
223512874|NCT03568058|DRUG|Pembrolizumab|200 mg pembrolizumab will be administered intravenous (IV) infusion every 3 weeks.
223512875|NCT04274218|OTHER|Perturbation|Participants from both cohorts will experience a simulated trip while walking on the treadmill. The trip is induced through a rapid acceleration and deceleration of the treadmill belt speed.
223512876|NCT04943068|DRUG|Bremelanotide|Subjects will self-administer a fixed dose (1.75 mg) of bremelanotide (BMT) subcutaneously (SC) via auto-injector.
223512877|NCT04943068|DRUG|Placebo|Subjects will self-administer a Placebo subcutaneously (SC) via auto-injector.
224209067|NCT06459401|DEVICE|Propulsion Neuroprosthesis|A neuroprosthesis is a textile-based surface neurostimulation system worn on the waist and paretic lower limb that delivers neurostimulation assistance via electroconductive pads placed on the skin over the target muscles. The neuroprosthesis provides dorsiflexor stimulation during swing phase for foot clearance and plantarflexor stimulation during stance phase for propulsion, delivered synchronously based on integrated sensors detecting the wearer's gait pattern.
224209068|NCT01087801|DRUG|ChiRhoStim|Human Secretin for Injection
224209069|NCT01087801|DRUG|Placebo|Saline for Injection
224209070|NCT05961319|DEVICE|Smart-Home Monitoring|"During the study, various sensors will be employed to capture participant interactions with appliances and furniture. These sensors may include:~Interaction Sensors: These sensors are designed to recognize users' interactions with appliances and furniture within the smart environment.~Smart Biomechanics Devices: Devices such as a Fitbit device an internet of Things grip Dynamometer will be utilized to assess physical balance and strength.~Positioning System using Ultra-Wide Band (UWB) Technology: This positioning system leverages UWB technology, enabling furniture-level accuracies in interpreting self-care activities.~As participants engage with different elements of the smart environment, these sensors will collect data. Additionally, participants will be recorded via video to further enhance the observational data captured during the study."
224209071|NCT00542958|DRUG|NK012|9.0, 12.0, 16.0, 21.0, 28.0 mg/m\^2, and to be determined. Intravenous infusion
224209072|NCT05960708|DRUG|YH35324|Subcutaneous injection of YH35324
224209073|NCT05960708|DRUG|Omalizumab|Subcutaneous injection of Omalizumab
224209074|NCT05960708|DRUG|Placebo|Subcutaneous injection of None of active ingredient
224209075|NCT03146507|RADIATION|Ultrasound|ultrasound assessment of gestational age, amniotic fluid index, and fetal weight
224209076|NCT03146507|RADIATION|Doppler ultrasound|Umbilical artery and Middle cerebral artery Doppler blood flow assesment
224209077|NCT03146507|RADIATION|Fetal echocardiography|The cardiac output (ratio between right side cardiac outputs to left side cardiac output) was calculated
224209078|NCT04330482|BEHAVIORAL|CARE-Well App|Participants randomized into this group will be instructed to use the CARE-Well App at least 4 times per week.
224209079|NCT04330482|BEHAVIORAL|Internet Links|Participants randomized into this group will be instructed to use a computer tablet pre-loaded with a list of internet links relevant to dementia caregiving at least 4 times per week.
224209080|NCT06523465|DRUG|Simvastatin combined with Amlodipine besylate|6-month treatment of Simvastatin combined with Amlodipine besylate
224209081|NCT06523465|DRUG|Simvastatin combined with Spironolactone and Amlodipine besylate.|6-month treatment of Simvastatin combined with Spironolactone and Amlodipine besylate.
224209082|NCT06523465|DRUG|Amlodipine besylate combined Spironolactone|6-month treatment of Amlodipine besylate combined with Spironolactone
224209083|NCT00679094|DRUG|Bowman-Birk inhibitor concentrate|Given orally
224209084|NCT00679094|OTHER|placebo|Given orally
224209085|NCT00679094|OTHER|pharmacological study|Correlative studies
224209086|NCT00679094|OTHER|laboratory biomarker analysis|Correlative studies
224209087|NCT02079389|DEVICE|Lap+Lus|"In the standard arm (Lap) the conditions at the abdomen is only assessed by laparoscopy immediately prior to the resection. In the intervention arm the intra-abdominal conditions are also assessed by laparoscopy, but then supplemented with a laparoscopic ultrasound examination of the primary tumor, liver and retroperitoneum.~All patients are given an CT scan of the abdomen after 3 months."
224209088|NCT04671329|DEVICE|Affirm Contrast Biopsy procedure|Contrast Enhanced Digital Mammography (CEDM) is an extension of the existing indication for diagnostic mammography with the Selenia Dimensions system and 3Dimensions system. Biopsy targeting can be done on captured contrast enhanced images (scout and stereo pair). The CEDM application shall enable contrast enhanced breast imaging using a dual energy technique. This imaging technique can be used as an adjunct following mammography and/or ultrasound exams to localize a known or suspected lesion. Affirm Contrast Biopsy is intended for patients recommended for biopsy who have had a suspicious finding on previous contrast enhanced imaging or have lesions that may be occult under other modalities.
224209089|NCT04592731|DRUG|Gel containing Acetylated Natural Nucleotides|The study drug is a gel containing acetylated natural nucleotides.
224209090|NCT04592731|DRUG|Vehicle Gel|The vehicle gel contains no acetylated natural nucleotides but with the same base as study drug.
224209091|NCT05070169|PROCEDURE|Early Surgical Fixation vs. Delayed Surgical Fixation|Evaluation of the reduction of the peri-operative blood loss in patients undergoing early surgical fixation (within 24 hours) of an intertrochanteric fracture under DOAC therapy compared to a retrospectively enrolled group of patients who underwent delayed surgical fixation (≥48 hours) of an intertrochanteric fracture under DOAC therapy.
224209092|NCT05508321|DIAGNOSTIC_TEST|Nasal brushing|Nasal brushing to harvest nasal cells and perform staining experiments
224209093|NCT05508321|DIAGNOSTIC_TEST|Sniffin' Sticks|Assessment of olfactory function
224209094|NCT05822024|BEHAVIORAL|Promoting Pupils' Physical Literacy Intervention|The physical literacy intervention 3PL is based on activities, games, and modifications of the physical education classes to target and enhance pupils' physical literacy.
224209095|NCT01906034|BEHAVIORAL|Exercise with supervision|
224209096|NCT01906034|BEHAVIORAL|Home-based without supervision|
224209097|NCT05349890|BIOLOGICAL|TCR-transduced T cells|TSA-reactive TCR-engineered T cells
224209098|NCT05349890|DRUG|CDX-1140|Recombinant fully human IgG2κ monoclonal antibody
224209099|NCT05349890|DRUG|Pembrolizumab|Humanized immunoglobulin G4 (IgG4) monoclonal antibody
224209100|NCT00792818|DRUG|Curcuma domestica extracts|1,500 mg per day (oral)divided into 3 times for 28 days
223619518|NCT01378988|DRUG|Dexmedetomidine|For sedation according to protocol
223619519|NCT01329263|OTHER|Menthol to non-menthol|Switch from smoking menthol to non-menthol cigarettes.
223619520|NCT02773186|OTHER|monitoring cerebral oxygen saturation|Children undergoing urological surgery also required of locoregional blockade. Anesthetic induction was achieved with high concentration sevoflurane 6-8% (Sevorane®, Abbvie) and oxygen 50%. Anesthetic maintenance was done with sevoflurane 2-3%, 50% O2/air mixture, fentanyl 1 µg.kg.-1 iv, and rocuronium 0.3 µg.kg.-1 iv if required. Electrocardiogram (ECG), non-invasive arterial pressure, pulse oximetry, end-tidal carbon dioxide and cerebral NIRS oximetry was monitoring by using an INVOSTM5100 (Somanetics Corporation, Troy, MI, USA).
223619521|NCT03959163|DIAGNOSTIC_TEST|Quick MRI|"A quick MRI scan takes about 15 mins or less. No IV or sedation will be necessary. The participant will be required to lie flat and still during the test. A parent will be allowed to be with the participant while they are in the scanner. The machine will produce loud intermittent sounds of banging or knocking so they will have to wear protective headphones. They can listen to music if they would like. If they are less than 1 year old, they will be swaddled and can be held during the test. If a child needs to have a parent in the scanner, it is ideal if the parent can have their head near the participant's legs and arms stretched out to hold the child's hands. If the parent needs to be by the patient's head, it can be accomplished by the parent lying head to head with the child or the parent lying on the child. Ideally they are lying head to head, or just outside of the scanner reaching in."
224209101|NCT00792818|DRUG|Ibuprofen|1,200 mg/days (oral) divided into 3 times for 28 days
224209102|NCT04556877|PROCEDURE|Intraabdominal pressure and optic nerve diameters|Measuring Intraabdominal pressure with a Foley cathater and measuring optic nerve diameters with a USG
224209103|NCT06234605|DRUG|HC-7366|HC-7366 is a novel, orally administered, highly selective and potent general control nonderepressible 2 (GCN2) kinase activator.
224209104|NCT06234605|DRUG|Belzutifan|Belzutifan is a potent and selective HIF-2α inhibitor
224209105|NCT02223598|DRUG|CB-5083|
223619522|NCT05343858|DIETARY_SUPPLEMENT|Experimental: Group 1: Spirulina platensis|16 g/day (two doses of 8g)
223619523|NCT05343858|DIETARY_SUPPLEMENT|Experimental: Group 2: Chlorella vulgaris|16 g/day (two doses of 8g)
223619524|NCT05343858|DIETARY_SUPPLEMENT|Placebo Comparator: Group 3: Control|16 g/day (two doses of 8g)
223619525|NCT02790996|DRUG|Vancomycin|Vancomycin is an antibiotic used to treat a number of bacterial infections.It is recommended intravenously as a treatment for complicated skin infections, bloodstream infections, endocarditis, bone and joint infections, and meningitis caused by methicillin-resistant S. aureus.
223619526|NCT04039126|DRUG|CHEMICAL PLEURODESIS WITH POVIDONE-IODINE-TETRACYCLINE COMBINATION|Pleurodesis is the obliteration of the pleural cavity by inducing adhesions of the visceral and parietal pleural layers, mostly used in patients with pleural effusions, pneumothorax (18). The use of pleurodesis to induce pleural symphysis between the pleural layers dates backs to the beginning of the 20th century by Benthune(19) and has continued to evolve with different Thoracic surgeons and researchers still looking for the ideal pleurodesis agent.
224209106|NCT02223598|DRUG|Dexamethasone|
224209107|NCT05144477|BEHAVIORAL|FAID Fear Intervention|Participants will receive a hard-cover diary, written instructions on diary completion, and a pen. A trained research assistant will meet with the participant face to face or via telephone and explain how to use the diary. Instructions will include recommended frequency for writing (at least twice a week) and tips on how to express themselves. Potential topics will also be addressed, including what to write about in the beginning, during the ICU, and after ICU discharge. The hard copy of the diary will remain with the family member participant, and they will be asked to continue writing in the diary at least until patient discharge from the hospital. Research assistants will check in with participants via weekly telephone calls to provide prompts to remind them to use the diary and support, as needed, if the participant reports difficulty in writing diary entries. These calls will last approximately 1-5 minutes and will continue until patient discharge from the hospital.
224209108|NCT03875300|BEHAVIORAL|Foodwise in Pregnancy|A 7 week programme of nutrition and lifestyle advice, delivered in community venues by trained Healthy Lifestyle Support Workers (HLSWs). Participants must meet study inclusion criteria.
224209109|NCT05643118|GENETIC|OLX10212 is a cell penetrating asymmetric small interference RNA (cp-asiRNA)|Clear colorless solution dissolved in 1X PBS and injected intravitreally
224209110|NCT04903717|BEHAVIORAL|Best Practice Alert|Providers randomized to the intervention arm will have a best practice alert appear for each of their eligible patients upon opening of the order entry screen in the patient's medical record. This alert informs the provider to the presence of HFrEF and absence of MRA prescription, notes the patient's current LVEF, and notes the most recent labs, including NT-ProBNP, potassium, and creatinine. Providers will also have access to a link to best available guideline recommended information regarding use of MRAs and a link to both an order set for prescribing an MRA and an alternate order set with option for potassium monitoring should hyperkalemia be a concern. If a patient is hyperkalemic (i.e. K ≥ 5 mEq/L), a link to an order set for prescribing a potassium binder will be provided instead. If a provider feels that the recommended therapy is not indicated for a particular patient, he/she can select an available reason from the list provided within the alert.
224209111|NCT04632563|OTHER|Questionnaire including MSK-HQ (Musculoskeletal Health Questionnaire)|A questionnaire regarding musculoskeletal past medical history and current symptoms.
223619527|NCT04039126|DRUG|CHEMICAL PLEURODESIS WITH POVIDONE-IODINE ALONE|20mls of 10% povidone-iodine (Wosan Solution Povidone-Iodine Usp 10%, Jawa International Limited) is mixed with 10mls of 1% xylocaine and 30mls of water for injection added to the mixture, making also a total volume of 60mls of the the single pleurodesis agents alone, which will be instilled into the pleural space via the closed thoracotomy tube.
223619528|NCT04369378|BEHAVIORAL|Meditation app usage|Investigators will confirm eligibility of applicants, enroll participants in the study and provide an identification number for de-identification of the data, and provide a list of mental health resources to participants. Participants will then be sent a link to a Google Form for the pre-intervention survey, to be completed prior to first use of the mindfulness app. Participants will also be given access to the mindfulness app (Insight Timer), and instructed to use it for 10 min daily for 30 days. Two days before the end of the 30 day intervention period, participants will be sent a link to a Google Form for the post-intervention survey and will be asked to complete the survey within the next 3 days. Two months after the conclusion of the 30 day intervention period, participants will be sent a link to a Google Form for another post-intervention survey, and asked to complete it within 5 days.
223619529|NCT05655663|OTHER|Vascular investigation|Measure of of carotid stiffness
223619530|NCT02372578|DRUG|ASP3662|oral
223619531|NCT02372578|DRUG|pregabalin|oral
223619532|NCT02372578|DRUG|ASP3662 placebo|oral
223619533|NCT02372578|DRUG|pregabalin placebo|oral
223619534|NCT05626166|DRUG|Placebo|placebo tablets twice daily
223619535|NCT05626166|DRUG|Diosmin|diosmin 600 mg twice daily
223619536|NCT02076607|PROCEDURE|Arthrodesis|Posterior approach to toracolumbar spine fusion.
223619537|NCT02076607|DEVICE|Brace|Toracolumbar imobilization
224209112|NCT01325896|DRUG|PEG-Intron sc injection|"This program is only open to patients with multiple myeloma who have achieved a complete or partial response after a myelosuppressive chemotherapy regimen followed by autologous stem cell infusion of peripheral blood transplant (PBSCT) as treatment intensification. These patients will be treated with PEG-Intron as maintenance therapy, to be permitted during the same concomitant administration of corticosteroids and / or bisphosphonates.~PEG-Intron: 35 mcg per week by subcutaneous injection to progression or recurrence of the disease, or for 5 years maximum.~Patients were administered PEG-Intron to a uniform dose of 15 mg initial week for 2 weeks. If this dose is tolerated, it would be gradually increased to 25 mg and then to 35 mg every 2 weeks, assuming that there is no toxicity of grade 3 or worse."
224315656|NCT06442306|OTHER|Pain Neuroscience Education|Pain Neuroscience Education (PNE) is a cognitive-based education intervention that aims to change pain beliefs in patients experiencing CMP. Researchers have found PNE beneficial in assisting patients to reframe their understanding, attitudes, thoughts, and beliefs regarding their pain experience. PNE directs patients to relate chronic pain to overly sensitive nerves rather than assumed tissue damage. Further, PNE encourages patients to perform daily activities, work, and function in society, all despite pain. This facilitates behavior changes that are key in amending a patient's biopsychosocial state. Multiple sources make a strong case for the incorporation of PNE in having positive effects on reducing physical disability and modulating fear and anxiety in patients with CMP. Researchers have established a positive influence of PNE toward decreased kinesiophobia and have demonstrated a relation between increased self-efficacy and increased functional ability.
224209113|NCT02670993|BEHAVIORAL|Singing sessions.|Patients will be in singing work groups, and will participate to these sessions during 12 weeks, with one session per week of 2 hours.
224209114|NCT02670993|BEHAVIORAL|Painting sessions.|Patients will be in painting groups, they will participate to this work session during 12 weeks, with one session of 2 hours per week.
224315657|NCT06442306|OTHER|General Health Education|General Health Education included: 20 Benefits of Walking 30 Minutes a Day; Why You Should Quit: Smoking Cessation; Heat vs. Cold: How to Use it For Pain Control; Sleep Hygiene.
224209115|NCT04700215|DEVICE|BiPAP|To give bilevel positive airway pressure to the lungs
223619538|NCT05439044|OTHER|Data collection|Anti SARS-CoV-2 Monoclonal Antibodies: casirivimab-imdevimab (Ronapreve) OR bamlanivimab-etesevimab OR tixagevimab-cilgavimab (Evusheld) OR regdanvimab OR sotrovimab (Xevudy) OR adintrevimab
224209116|NCT04700215|DEVICE|Incentive spirometry|IS for 15 minutes after every 4 hours
224209117|NCT00916292|DRUG|FGF-1 141|Each subject will receive two, 3 mm squared punch skin biopsies, one biopsy will receive the study drug, and the second biopsy will remain untreated as a control. Low dose: FGF-1, 0.3 mg per square centimeter.
224209118|NCT00916292|DRUG|FGF-1 141|Each subject will receive two, 3 mm squared punch skin biopsies, one biopsy will receive the study drug, and the second biopsy will remain untreated as a control. High dose: FGF-1, 3.0 mg per square centimeter.
224209119|NCT03883789|DIAGNOSTIC_TEST|FibroScan|FibroScan will be used to assess liver stiffness
224209120|NCT05145660|RADIATION|intensity-modulated radiotherapy (IMRT) with reduced-volume|PGTVnx: 69.9Gy/2.12Gy/33f GTVrpn: 69.9Gy/2.12Gy/33f GTVnd: 69.9Gy/2.12Gy/33f GTVnd-suspicious: 60.06Gy/1.82Gy/33f PTV1: 60.06Gy/1.82Gy/33f PTV2: 50.96Gy/1.82Gy/28f
224209121|NCT05145660|DRUG|Chemotherapy|Concurrent cisplatin (100 mg/m², d1-3, Q3w, maximum to three cycles); The application of induction chemotherapy and consolidation chemotherapy is dependent on the physician's discretion.
224209122|NCT05148455|OTHER|standard-of-care clinical skin examination|inspection of melanocytic nevi by dermatologist
224209123|NCT05148455|DIAGNOSTIC_TEST|skin assessment with the 2D FotoFinder ATBM master system|The FotoFinder® ATBM master device provides the combination of total body mapping with deep learning-driven body scan algorithm which identifies all pigmented skin lesions of the body surface by pattern recognition software and supplies a risk assessment score (0.0-1.0; 0 indicating no suspicion for melanoma, 1 indicating a high suspicion for melanoma).The integrated software analyzer scores regarding malignancy probability of the moles (FotoFinder® score: 0.0-1.0) will be collected.
224209124|NCT05148455|OTHER|data collection by participant questionnaire|At baseline, the participants will complete a questionnaire concerning their previous exposure to sun, their current sun-related protective behaviours, their history of skin check frequency and skin cancer at baseline. Additionally, in each consultation newly-created study-specific questions concerning the participants' examination experience, the sun-related protective behaviours and worries about skin cancer throughout the study will be investigated.
224209125|NCT05092802|DRUG|HLX208|450mg bid po
224209126|NCT04138602|DEVICE|BTL Emsella|Subjects will be asked to sit on the device and the height will be adjusted until the subject's feet are on the floor. The active treatments are individualized, since some subjects will be more sensitive than others. The Emsella Chair will be turned on and the setting gradually increased to the subject's sensory threshold; the maximum sensation the subject can tolerate. The setting will then be decreased slightly and stay unchanged for the remainder of the treatment time. The treatment threshold should be increased with every treatment until the subject reaches 100%.
223619539|NCT01421017|RADIATION|Radiation|
223619540|NCT01421017|DRUG|Imiquimod|
223619541|NCT01421017|DRUG|Cyclophosphamide|
223619542|NCT02152826|DEVICE|Potassium oxalate|Professional application
223619543|NCT04051398|OTHER|transcutaneous nerve electrostimulation (TENS) of acupuncture points|TENS application session over the acupuncture points: Feishu, Zhongfu, Taiyuan and Dingchuan using a frequency of 200Hz and a pulse time of 80 seconds of sufficient intensity to cause a slight sensation of local numbness without muscle fasciculations. The TENS application time will be 30 minutes.
223680444|NCT00938886|DRUG|Placebo|Matched naltrexone placebo
223680445|NCT06119958|DRUG|DWC202313|Experimental Drug 1
223680446|NCT06119958|DRUG|DWC202314|Experimental Drug 2
224315658|NCT00478426|DRUG|Sunitinib Malate|Given PO
224315659|NCT05572671|BEHAVIORAL|Laboratory task modeling smoking lapse behavior|Participants will complete a task (the behavioral intervention) designed to model smoking lapse behavior in the laboratory; during the task, they will be given the option of delaying smoking in exchange for monetary reinforcement.
224315660|NCT03251235|BEHAVIORAL|Cognitive Behaviour Therapy|
223680447|NCT00558571|DRUG|BI 10773 low dose|
223761510|NCT06909370|BEHAVIORAL|peer education|"The training titled The Effect of Peer Education on Human Papillomavirus (HPV) for Students in the Faculty of Health Sciences on Knowledge, Awareness, and Concern Levels includes scientific and up-to-date information about HPV transmission methods, prevention, risk factors, treatment methods, and vaccination. The content of the training aims to provide students with accurate information about HPV, as well as highlight the negative health effects of the virus, particularly its association with serious diseases like cervical cancer. The training seeks to increase students' awareness of HPV and help them manage their levels of concern about the virus. Through the peer education method, students were able to interact with each other, thus providing a more effective learning experience."
224209127|NCT04138602|DEVICE|Sham BTL Emsella|Sham subjects will be seated on the device in the same manner as the active treatment group. The sham treatment will provide some sensation without active HIFEM technology. The programming for the sham treatment will have an amplitude limitation, with the setting below the therapeutic level ( \< 10 % power).
224209128|NCT04333199|BEHAVIORAL|Timely|Email
224209129|NCT04333199|BEHAVIORAL|Transparency|Email
224209130|NCT04333199|BEHAVIORAL|Foot-in-the-door|Email
224209131|NCT03695042|OTHER|Blood Flow Restriction Training with Exercise|The addition of BFR training to an exercise program prescribed for a patient participating in physical therapy for concussion treatment. BFR training partially occludes blood flow to extremities during exercise. This allows one to exercise at lower loads and still gain benefits similar to exercise at higher loads
224209132|NCT03111407|PROCEDURE|total knee arthroplasty|surgical procedure in which damaged parts of the knee joint are replaced with an implant.
224209133|NCT06102707|DRUG|Fluzopril Combined With Apatinib|Fluzopril Capsules 100mg po bid Apatinib Mesylate Tablets 250mg po qd
223761511|NCT06909032|RADIATION|Accelerated partial breast irradiation|Accelerated partial breast irradiation (APBI) will be delivered using Volumetric Modulated Arc Therapy (VMAT). Treatment will be started within 12 weeks of breast conserving surgery and within four weeks of randomisation. Treatment will occur in five (5) once-daily sessions and should be completed within seven (7) days of starting radiotherapy. Two total doses of APBI will be compared: 30 Gy and 26 Gy. The aim is to determine whether quality of life is no worse when a higher dose of APBI is used compared to a slightly lower dose of APBI. The results of this study will help to guide doctors choose the best dose of APBI for patients with early breast cancer in the future.
224209134|NCT05350358|DEVICE|LeMaitre Cardial Dialine II|Surgical treatment for the replacement or bypass with LeMaitre Cardial Dialine II
224209135|NCT06652555|OTHER|Group 1|without Intervention
224209136|NCT03287102|PROCEDURE|Macular hole surgery|Vitrectomy, temporal inverted or complete ILM peeling and gas tamponade
224209137|NCT06267118|DRUG|Hypertonic Saline Solution, 1 Ml|Dilute 0.3 ml hypertonic saline with 3 ml normal saline for nebulization
224315661|NCT00384930|DRUG|tadalafil|2.5 mg tadalafil tablet by mouth once a day for twelve weeks.
224209138|NCT06267118|DRUG|Adrenaline|dilute 0.3 ml adrenaline with 3 ml normal saline for nebulization
224209139|NCT03022019|DEVICE|ReNovaCell|
224209140|NCT01341158|DRUG|human interferon-α|Neoadjuvant treatment: Multiferon is given as flat dosages (3 - 9 - 18 MIU) 5 days per week, subcutaneously for 4 weeks
224315662|NCT00384930|DRUG|tadalafil|5 mg tadalafil tablet by mouth once a day for twelve weeks.
224315663|NCT00384930|DRUG|tadalafil|10 mg tadalafil tablet by mouth once a day for twelve weeks.
224315664|NCT00384930|DRUG|tadalafil|20 mg tadalafil tablet by mouth once a day for twelve weeks.
224209141|NCT00179218|DRUG|nutritional supplementation|oral administration of 2 cans of protein supplement (lactose-free formula that contains a total of 960 kilocalories: 132.8 kilocalories from protein, 412.8 kilocalories from carbohydrates, and 412.8 kilocalories from fat); every other day, 3 days per week, for 6 months
224209142|NCT00179218|BEHAVIORAL|exercise|leg press exercise; every other day, 3 days per week, for 6 months
224209143|NCT01348659|DRUG|7.2% NaCl/hydroxyethylstarch|250 ml of 7.2% NaCl in hydroxyethylstarch (HES 200/0,5) will be given into the venous reservoir of the cardiopulmonary bypass circuit after aortic declamping.
224209144|NCT01348659|DRUG|NaCl 0.9%|250 ml of NaCl 0.9% will be given into the venous reservoir of the CPB circuit after aortic declamping.
224209145|NCT04831931|OTHER|Exercise Program Applied by Telerehabilitation|"Patients will be evaluated 3 times for 4 weeks throughout the study; before the study commences, at the end of 2th and 4th week~Exercises will be planned to last for 15 minutes a day, and will be progressed and changed weekly throughout the study period. To the exercise program; It will be created as a progressive program by including stretching, normal range of motion movements, neck, core and scapular stabilization and strengthening exercises and the same program will be given to both groups."
224209146|NCT03299218|DIETARY_SUPPLEMENT|SNF (Wawamum)|A monthly ration of 30 sachets of SNF (one 50 gram sachet of Wawamum per child per day) will be provided by LHWs. Each recruited child will receive SNF on a monthly basis for the duration of 18 months during his/her age of 6-24 months.
224209147|NCT03299218|BEHAVIORAL|Social and behaviour change communication (SBCC)|SBCC messages will be delivered by LHWs in their monthly routine household visits. Male and female group sessions will be arranged on quarterly basis with the help of health committees.
224209148|NCT03299218|OTHER|Cash|Cash totaling 1600 rupees per month will be transferred by BISP throughout the study period.
224209149|NCT00181831|DEVICE|Proton Magnetic Resonance Spectroscopy|
224209150|NCT05308576|BIOLOGICAL|SCTV01E|D0; intramuscular injection
224209151|NCT05308576|BIOLOGICAL|Placebo|D0; intramuscular injection
224315665|NCT00384930|DRUG|placebo|Placebo tablet taken by mouth one a day for twelve weeks
224315666|NCT06111352|DRUG|Pralidoxime|Inj. Pralidoxime 1 gm I/V will be given as first dose over 10-20 minutes. If no improvement of muscle weakness, then repeat the dose after one hour. Then 1 gram of Inj. Pralidoxime will be given at an 8-hour interval
224315667|NCT06111352|DRUG|Atropine|Inj. Atropine (3 ampule) will be given in intravenous route as a first dose, rapidly. Then the dose will be doubled from the previous dose in every 5 minutes interval until the signs of atropinisation appeared. Then infusion of 10% of the total bolus dose (the dose that was given until the signs of atropinisation appeared) per hour, will be given with intravenous Normal saline/ 5% DNS(Dextrose and Sodium chloride) as a maintenance dose. The dose will be reduced for adjustment, based on clinical features/improvement
224209152|NCT04072744|DEVICE|Heartfelt measurements|"The measurements taken using the Heartfelt device do not require contact with the participant. For the measurements to take place, the participant will simply walk in the field of view of the device. As the device(s) will have been installed at a location allowing the best view of where the participant goes in an out of bed, the participant is not expected to change anything to their routine.~The device can also take measurements in the dark, so if the participant walks in front of the device in the dark, this information will also be captured.~The Heartfelt device is a CE (European Conformity) marked product. Neither the participant, or the medical team will be able to see the data collected by the Heartfelt device during the study. They will be blinded to the data until each participant has completed the study. At that point they can choose to review the data from participant individually or wait until all the data from all participants is available."
224209153|NCT04072744|DEVICE|Connected weighing scales|"The participant will be instructed to use those scales for the period of the study, as often as directed by their healthcare professional. The weighing scales display weight so that the participants can record the weight in their own heart failure records.~The participant will be able to see the weight readings on the weighing scales during the study.~The scales will communicate with the Personal Computer (PC) contained in the Heartfelt device and the data will be sent to the Heartfelt server through an encrypted link."
224209154|NCT01535391|DRUG|Nilotinib|Administered orally at the dose of 300 mg twice daily (total daily dose 600 mg daily) for 24 months (study core), and indefinitely if it is in the interest of the patient (the drug will be given free-of-charge after 24 months to all those patients achieving the CMR4 at 24 months and in absence of safety concerns). Nilotinib dose is increased to 400 mg BID in case of suboptimal response or failure (with the exception of patients who will fail for progression to ABP: in case of progression to ABP, the patient will not be treated with study drug and the choise of the treatment will be up to the physician).
224209155|NCT02198755|DEVICE|Hitachi-Aloka Noblus ultrasound scanner|High resolution ultrasound with the Hitachi-Aloka Noblus Scanner and a 8-15mHz transducer
224209156|NCT02198755|DEVICE|Magnetic Resonance Imaging (MRI)|MRI with or without contrast
224209157|NCT04085263|PROCEDURE|Control group|The patients in this group will receive sham rhomboid intercostal and subserratus plane.
224209158|NCT04085263|PROCEDURE|Rhomboid intercostal and subserratus plane block group|The patients in this group will be receive real ultrasound-guided rhomboid intercostal and subserratus plane.
224315668|NCT04134338|OTHER|To evaluate the effect of wound infection on costs|the degree of costs that is required for trating wound infection
224315669|NCT02474875|OTHER|Educational program|Patients in experimental groups will receive different educational sessions (contents and duration)
224315670|NCT02752087|DRUG|LY900014|Administered SC
224315671|NCT06168630|OTHER|Manual lymph drainage|It consists of patients who will receive manual lymph drainage everyday for 5 days. The subject's position will be supine with their knees bent. Every session will be of 45 minutes. Manual lymph drainage will with abdominal lymph drainage, after which central lymph stimulation will be performed. Then, by stimulating the bilateral axillary lymph nodes, the flow of fluid over the right and left breasts will be directed toward the axillary lymph nodes. While the patients in the prone position, bilateral axillary lymph nodes will be stimulated, and each manual lymph drainage will be performed from the dorsum to the axillary lymph node .
224315672|NCT06168630|OTHER|Control group|The other group will receive massage for 20 minutes every day for 5 days from first day of treatment. Massage will be done using the index and middle fingers in a spiral motion towards the nipples.
224315673|NCT00194701|BEHAVIORAL|Walking exercise|
224315674|NCT04785755|DRUG|Oral standard diuretics therapy|Oral standard diuretics therapy (furosemide 40 mg tablet plus spironolactone 100 mg tablet with a dose increase in 40 mg:100 mg ratio) given once daily in the morning for 38 days (from the first day of the study to the end of the study).
224315675|NCT04785755|DRUG|Hypertonic saline solution|Hypertonic saline solution (150ml, 1.4% - 4.6%) infused slowly over one hour peripherally once daily from the first day of the study for eight days.
224209159|NCT06440486|DIETARY_SUPPLEMENT|Probiotics|Serum and fecal samples were collected at the beginning and end of the study to evaluate the effects of probiotic consumption on immune markers, metabolites, and gut microbiota before and after administration.
224209160|NCT02203188|PROCEDURE|Lid debridgement scaling|
224209161|NCT04840628|OTHER|Resistance of the respiratory system|increase the resistance of the respiratory system of the chronic obstructive pulmonary disease patients
224209162|NCT01093365|DRUG|Varenicline|"* 0.0 mg orally twice per day for three days (placebo)~* 0.5 mg orally twice per day for three days~* 1.0 mg orally twice per day for three days"
224315676|NCT04785755|DRUG|Etilefrine|Etilefrine 5 mg tablet given by mouth three times daily for 38 days (from the first day of the study to the end of the study).
224315677|NCT03047434|OTHER||
224315678|NCT03629756|DRUG|Etrumadenant|Etrumadenant is an A2aR and A2bR antagonist.
224315679|NCT03629756|DRUG|Zimberelimab|Zimberelimab is a fully human anti-PD-1 monoclonal antibody.
224315680|NCT06550752|COMBINATION_PRODUCT|UC-MSCs and PRP|UC-MSCs are progenitor cells that can differentiate into various types of cells in the body and have the ability to regenerate and repair damaged tissue. During repair and regeneration, these cells secrete expedient and powerful bioactive paracrine factors including cytokines, chemokines, collagen, fibronectin, and growth factors promoting tissue repair, angiogenesis, and the regeneration of nerve cells as well as regulating cellular pathways including immunomodulation and inflammatory responses. Additionally, PRP contains numerous growth factors and cytokines, including vascular endothelial growth factor (VEGF), transforming growth factor beta-1 and beta-2 (TGF-β1/2), platelet-derived growth factor (PDGF), insulin-like growth factor (IGF), interleukin 8 and matrix metalloproteinases 2,9. The combined effect of these factors provided by PRP injections is proposed to have anti- inflammatory, reparative, neuroprotective and neurotrophic effects that contribute to the treatment of ED.
224315681|NCT01617252|DEVICE|Optiflow / Facial mask|J0: randomization (Optiflow® or facial mask), lung X-ray, kinesiotherapy H0 : clinical examination, blood gas, respiratory frequency H1 : clinical examination, blood gas, respiratory frequency H6 : clinical examination, blood gas J1: clinical examination, blood gas, respiratory frequency, lung X-ray, diaphragmatic echography, kinesiotherapy J2: clinical examination, blood gas, lung X-ray, kinesiotherapy Follow-up (until withdrawal of Optiflow or facial mask): clinical examination, blood gas, lung X-ray, kinesiotherapy
224315682|NCT05809167|DRUG|VEN+AZA+Modified BUCY|"Venetoclax: 200mg/day\*7days（It should be combined with triazole antifungal drugs).~Azacytidine: 75mg/ m²/day\*7days."
224315683|NCT00000494|DRUG|indomethacin|
224315684|NCT00000494|PROCEDURE|surgery, cardiovascular|
224315685|NCT03832101|BEHAVIORAL|MATB|MATB has two multitasking tasks and two attention tasks. The two multitasking tasks evaluates performance on multiple cognitively demanding assignments in both the auditory and visual domains. The two attention tasks measures performance in sustained and selective attention
224209163|NCT01938742|BIOLOGICAL|Influenza Virus Vaccine, Monovalent A/H7N9 A/Shanghai/2/2013|Monovalent influenza A/H7N9 virus vaccine for intramuscular use is a sterile, clear and slightly opalescent suspension. sanofi A/H7N9 antigen. Group 1 receives 3.75mcg A/H7N9 IM on days 1 and 21, Group 2 receives 7.5 mcg IM on days 1 and 21, Group 3, 4, 5, \& 6 receives 15 mcg IM on days 1 and 21, and Group 7 receives 45 mcg IM on days 1 and 21.
224315686|NCT03471923|DIAGNOSTIC_TEST|Neurological Examination|The family members and healthy volunteers will undergo elements of the neurological examination during which the movement disorders neurologist will look specifically for the presence of cervical dystonia and other sensory abnormalities. If the subject is found to have cervical dystonia or any other sensory abnormalities, the subject will be excluded from the study.
224315687|NCT03471923|DIAGNOSTIC_TEST|Assessment of Non-Motor Features|All subjects will be assessed for four non-motor symptoms, including (1) spatial discrimination threshold, (2) temporal discrimination threshold, (3) vibration-induced illusion of movement, and (4) kinesthesia.
224315688|NCT02955823|DRUG|Rituximab-Dexamethasone-Lenalidomide|"1. st CYCLE: Rituximab 375 mg/m2 i.v. on days 1,8,15; Dexamethasone 5 mg p.o. on days 1,8,15,22; Lenalidomide 15 mg/day p.o. day 2-22~2. nd-4th CYCLE: Rituximab 375 mg/m2 i.v. on day 1; Lenalidomide 20 mg/day p.o. from day 2 to day 22 At the end of 4th CYCLE disease restaging: - if ≥ PR continues with the 5th and 6th cycle: Rituximab 375 mg/m2 i.v. on day 1, Lenalidomide 20 mg /day p.o. day 2-22~   * if \<PR stops the treatment, only follow-up At the end of the 6th CYCLE disease restaging: - if ≥ PR continues with beyond the 6th cycle with Lenalidomide 10mg dd1-21q28 until cycle 12th~  * if \<PR stops the treatment, only follow-up Then, accordingly response rate after the sixth cycle assessment(≥ PR) lenalidomide will be continued at 10 mg dd1-21q28 until 12th cycle or unacceptable toxicity."
224315689|NCT03421795|OTHER|Let's Talk About Pain Training|See arm/group descriptions.
224315690|NCT03421795|OTHER|Family Centered Care Training|See arm/group descriptions.
224315691|NCT04655430|OTHER|3-second SDF application|Dosage: 3-second 38% SDF solution application
224315692|NCT04655430|OTHER|5-second SDF application|Dosage: 5-second 38% SDF solution application
224315693|NCT04655430|OTHER|10-second SDF application|Dosage: 10-second 38% SDF solution application
224315694|NCT04655430|OTHER|15-second SDF application|Dosage: 15-second 38% SDF solution application
224315695|NCT04655430|OTHER|30-second SDF application|Dosage: 30-second 38% SDF solution application
224209164|NCT01938742|DRUG|MF59|MF59 adjuvant is an oil-in-water emulsion composed of a small amount of squalene administered with different dosages. Group 1, 2 \& 3 receives 0.7 ml of MF59 Intramuscularly (IM) on days 0 and 21. Group 4 receives MF59 on day 0, Group 5 receives MF59 on Day 21.
224209165|NCT01468974|DEVICE|ESPRIT BVS|Subjects receiving ESPRIT BVS for the treatment of symptomatic claudication from occlusive vascular disease of the superficial femoral (SFA) or common or external iliac arteries
224315696|NCT04655430|OTHER|45-second SDF application|Dosage: 45-second 38% SDF solution application
224315697|NCT04655430|OTHER|60-second SDF application|Dosage: 60-second 38% SDF solution application
224315698|NCT04655430|OTHER|120-second SDF application|Dosage: 120-second 38% SDF solution application
224315699|NCT04655430|OTHER|180-second SDF application|Dosage: 180-second 38% SDF solution application
224315700|NCT05043441|BEHAVIORAL|Acceptance and commitment therapy (ACT)|Caregivers assigned to this intervention group will receive individual ACT sessions guided by a trained coach for one hour per week over 10 weeks through Zoom videoconferencing with psychoeducation materials provided.
224315701|NCT05043441|BEHAVIORAL|Psychoeducation|The psychoeducation control group will receive care as usual with psychoeducation materials provided.
224315702|NCT06226012|DEVICE|pulsed magnetic field|Children in this group received pulsed magnetic therapy in addition to traditional exercise program
224315703|NCT06226012|DEVICE|Low level laser|Children in this group received low level laser therapy in addition to traditional exercise program
224315704|NCT02029157|DRUG|ARQ197|
224315705|NCT02029157|DRUG|Placebo|
224315706|NCT00270907|DRUG|CT-2103|135 mg/m\^2 IV on Day 1.
224315707|NCT00270907|DRUG|Gemcitabine|1000 mg/m\^2 IV on Day 1 and 8.
224315708|NCT01953978|DRUG|Dexamethasone|Intravenous administration of dexamethasone 16 mg (concentration 4 mg/ml, volume 4 ml) immediately after endotracheal intubation
224315709|NCT01953978|OTHER|Placebo|Intravenous administration of isotonic sodium chloride (concentration 9 mg/ml, volume 4 ml) immediately after endotracheal intubation
224315710|NCT01953978|DRUG|Morphine|Morphine. Patient controlled intravenous morphine (PCA-pump), bolus 2.5 mg, lock-out-time 10 minutes. Concentration : Morphin 1 mg/ml.
224315711|NCT01953978|DRUG|Zofran|Zofran 4 mg iv in case of moderate to severe nausea, supplemented by Zofran 1 mg iv if needed
224315712|NCT01953978|DRUG|Paracetamol|Tablet Paracetamol 1 g orally, 1 hour preoperatively and every 6 hours after extubation time during the first 48 hours.
224315713|NCT01953978|DRUG|Ibuprofen|Tablet Ibuprofen 400 mg orally, 1 hour preoperatively and every 6 hours after extubation time during the first 48 hours.
224315714|NCT00863772|BIOLOGICAL|tanezumab|5 mg dose Intravenously every 8 weeks for duration of study
224315715|NCT00863772|BIOLOGICAL|tanezumab|10 mg dose Intravenously every 8 weeks for duration of study
224315716|NCT00863772|OTHER|Placebo|Placebo, Intravenously, every 8 weeks for duration of study
224323210|NCT06458127|OTHER|Tele-palliative care visit|Participants will meet with a specialty palliative care clinician for a video-consultation once a month, and complete three tele-PC consultations in total over a three-to-four-month period. They will also complete self-report assessments at baseline and immediately after the last PC intervention visit, approximately 3-4 months after enrolment.
224209166|NCT00002126|DRUG|Filgrastim|
224209167|NCT03441958|BIOLOGICAL|ECT-001 (UM171) expanded cord blood|ECT-001 expanded cord-blood will be produced and infused on site
224209168|NCT06566794|DRUG|Caffeine Tablet|0,5 x 100 mg tablet (50 mg caffeine).
224315717|NCT06633770|DIAGNOSTIC_TEST|proclcitonin and presepsin|"All included patients will be subjected to:~* laboratory investigations~  * Complete Blood Count (CBC),~ * Liver Function Test(LFT) ( ALT,AST, Billirubin, total protein and albumin)~ * Kidney function test (KFT) ( Urea and creatinine)~ * Random Blood Glucose (RBG).~ * Erythrocyte Sedimentation Rate(ESR )~ * Urine analysis -A special investigations include (blood culture, C Reactive protein (CRP), proclcitonin and presepsin)."
224315718|NCT06525103|DEVICE|electromagnitic field therapy|"EMSCULPT device (BTL Industries Inc., Boston, MA) based on HIFEM technology.~* Frequency : 50 or 60 Hz.~* Intenisty: 0-100 .Input voltage: 230 V"
224315719|NCT06525103|DEVICE|whole body vibration|"Crazy fit machine.~* Input voltage:220 V.~* Frequency : 30 Hz.~* Maximum power: 1500W.~* Intensity:1 to 50 levels."
223619544|NCT03960216|PROCEDURE|Scaling and root planning|Patients received non-surgical periodontal therapy in the form of full-mouth scaling and root planing (SRP), in two sessions, 1 week apart, with the use of an ultrasonic scaler (Minipiezon Electromedical Systems EMS, Nyon, Switzerland) and hand instruments, under local anaesthesia.
223619545|NCT03960216|PROCEDURE|Supragingival Prophylaxis|Supragingival removal of all deposits (plaque and calculus) with an ultrasonic scaler in two sessions, 1 week apart.
223619546|NCT03071068|DRUG|Anti-PlGF recombinant monoclonal antibody, 4mg dose|3 intravitreal injections of THR-317 4mg approximately 1 month apart
224209169|NCT06566794|DRUG|Bupropion Hydrochloride Capsels|1 x 20 mg tablet.
224209170|NCT06566794|DRUG|Repaglinide Capsels|1 x 0,05 mg tablet.
224209171|NCT06566794|DRUG|Flurbiprofen Capsels|1 x 10 mg tablet.
224209172|NCT06566794|DRUG|Omeprazole 10 MG|1 x 10 mg tablet.
224209173|NCT06566794|DRUG|Dextromethorphan Oral Solution|5,0 ml of 2 mg/ml oral solution (10 mg dextromethorphan).
224209174|NCT06566794|DRUG|Midazolam oral solution|0,5 ml of 2 mg/ml oral solution (1,0 mg midazolam).
224209175|NCT06566794|DRUG|Simvastatin tablets|1 x 10 mg tablet.
224209176|NCT06566794|DRUG|Placebo|2 x placebo tablets in the Placebo Phase/Arm
224209177|NCT06566794|DRUG|Carvedilol|2 x 25 mg tablets
224209178|NCT06566794|DRUG|Diclofenac|1 x 50 mg tablet (three times daily for three days)
223619547|NCT03071068|DRUG|Anti-PlGF recombinant monoclonal antibody, 8mg dose|3 intravitreal injections of THR-317 8mg approximately 1 month apart
224209179|NCT03843268|DEVICE|AMPS Gondola|Gondola is a portable device that runs on batteries and is fitted on both patient's feet when the patient is lying down. The device has been designed for the stimulation of two areas of both feet (first toe and metatarsal) through mechanical impulses set up for pressure, duration and sequence (Automated Mechanical Peripheral Stimulation - AMPS); the treatment requires less than 2 minutes.
224209180|NCT03843268|DEVICE|Sham Gondola|The Sham treatment consist in the stimulation of the same areas through mechanical impulses different for pressure since attached to the steel stick point is positioned a rigid plastic circle with a diameter (12mm); thanks to this the induced pressure ishence lower and the surface contact bigger
224209181|NCT06520995|OTHER|Educational video program|Diabetes education video contents are as follows; Type 2 diabetes definition, symptoms and the effect of diabetes on cognitive functions, Medical nutrition therapy and healthy nutrition recommendations in Type 2 diabetes, The importance of diabetes and exercise, Oral antidiabetic treatments, Insulin treatment, Hypoglycemia symptoms, findings and treatment, Macrovascular complications in diabetes, Microvascular complications in diabetes, Foot Protection and care recommendations, Diabetes self-care skills and problem-solving strategies, Diabetes and stress management.
224209182|NCT06520995|OTHER|A mobile application|This mobile application is a science-based application that patients can access via their smartphone or tablet. It consists of verbal, numerical, visual, logical, memory and attention categories and contains 24 different gamified mind exercises
224209183|NCT00789568|DRUG|sapropterin dihydrochloride|20 mg/kg and 100 mg/kg
224315720|NCT01883349|PROCEDURE|Kidney Transplant|Kidney Transplant Surgery
224315721|NCT01883349|OTHER|No kidney transplant|The control group was made up of subjects without ESRD and were not on the renal transplantation waitlist.
224315722|NCT03864887|PROCEDURE|Oxygen supply of high-low-high procedure|The protocol consisted of 1-hour resting, 3-minute baseline measurement, half-hour measurement at 60% FIO2 (phase I, high oxygen), half-hour measurement at 40% FIO2 (phase II, low oxygen) and half-hour measurement at 60% FIO2 (phase III, high oxygen).
223619548|NCT02093884|OTHER|Text Messaging Intervention|
223619549|NCT02093884|OTHER|Standard Referral|
223619550|NCT00833040|DRUG|Sublingual sufentanil NanoTabs™ and placebo NanoTabs™|During the Titration Phase, patients titrated to the dose of sufentanil that provided adequate pain relief without intolerable side effects. Dosages were 20, 30, 40, 60 and 80 mcg. During the Double Blind Phase, patients were randomized to one of six sequences and took 7 doses of sufentanil (dosage determined in the titration phase, and 3 doses of placebo.
223680448|NCT00558571|DRUG|placebo to BI 10773|
223680449|NCT00558571|DRUG|BI 10773 medium dose|
223680450|NCT00558571|DRUG|BI 10773 high dose|
223680451|NCT02907190|OTHER|Bean Type|1/2 cup of freshly boiled beans will be eaten by participants on separate study visits
223680452|NCT02907190|OTHER|Starchy Foods|1/2 cup serving of one of 4 starchy foods will be eaten by participants on different study visit
223680453|NCT03415386|DRUG|Combination of antiplatelet drugs and anticoagulants for at least one month|Combination of antiplatelet drugs and anticoagulants for at least one month, such as aspirin100mg qd+clopidogrel75mg qd+warfarin (INR1.8-2.2), aspirin100mg qd+clopidogrel75mg qd+dabigatran110mg bid, aspirin100mg qd+ticagrelor60mg bid+warfarin (INR1.8-2.2), and aspirin100mg qd+ticagrelor60mg bid+dabigatran110mg bid. Transthoracic two-dimensional echocardiography will be done at the 1-month, 3-month and 6-month follow-ups to evaluate the left ventricular mural thrombus and determinate whether the antithrombotic therapy regimen could be regulated to double antiplatelet or anticoagulant+clopidogrel75mg qd/ticagrelor60mg bid.
223680454|NCT05324488|OTHER|No intervention|In this registry no intervention is carried out
223680455|NCT01517971|OTHER|laboratory biomarker analysis|Correlative studies
223680456|NCT06046352|PROCEDURE|Electrophysiological study (and ablation when appropriate)|Electrophysiological study (and ablation when appropriate)
223680457|NCT04365101|BIOLOGICAL|CYNK-001|CYNK-001 is an allogeneic off the shelf cell therapy enriched for CD56+/CD3- NK cells expanded from human placental CD34+ cells.
224209184|NCT00789568|DRUG|Moxifloxacin|Moxifloxacin is included as a positive control to demonstrate the assay sensitivity based on the expected increased QTc response.
224209185|NCT00789568|DRUG|Moxifloxacin placebo|Moxifloxacin placebo tablet
224209186|NCT03295968|OTHER|High Intensity Exercise/Ibuprofen|HIEX, with and without the inflammation inhibitor, ibuprofen, on plasma levels of IL-6 and other selective biomarkers of inflammation and appetite on food intake and subjective ratings of appetite in normal-weight boys.
224209187|NCT02139579|DRUG|Bevacizumab|7.5 mg/kg every 3 weeks
224209188|NCT06301256|DRUG|TIRZEPATIDE|Tirzepatide injection contains tirzepatide, a once weekly dual receptor, GIP and GLP-1 receptor agonis t. It is a 39-amino-acid modified peptide with a C20 fatty diacid moiety that enables albumin binding and prolongs the half-life. The molecular weight is 4813.53 Da and the empirical formula is C225H348N48O68.
224315723|NCT03864887|PROCEDURE|Oxygen supply of low-high-low procedure|The protocol consisted of 1-hour resting, 3-minute baseline measurement, half-hour measurement at 40% FIO2 (phase I, low oxygen), half-hour measurement at 60% FIO2 (phase II, high oxygen) and half-hour measurement at 40% FIO2 (phase III, low oxygen).
223619551|NCT02313766|OTHER|PPV : positive pressure ventilation|Inspiratory pressure support ventilation (12 cmH2O) without PEEP
224315724|NCT03864887|DEVICE|Optical monitor for hemodynamic parameter.|Near infrared spectroscopy probes of tow wavelengths were attached on the subjects' foreheat to detect the changes of hemodynamic parameters.
224315725|NCT01226394|PROCEDURE|laparotomy plus HIPEC|Laparotomy + HIPEC
224315726|NCT06164093|OTHER|RNA sequencing is performed on the remaining LPCs|RNA sequencing is performed on the remaining LPCs previously transplanted back into the patients. And the results are analysed combined with the data from the previous clinical trial. (Please note that patients will not receive cell transplantation again as they have already received the treatment in the previous trial \[NCT03655808\])
224315727|NCT06164093|OTHER|Immunofluorescence staining is performed in the surgically resected lung tissue sections|The aim of this intervention is to detect Krt5 protein expression by staining the surgically resected lung tissue sections. This is done to confirm the presence of a small number of LPCs in the lung tissue of patients with bronchiectasis and to investigate their distribution.
224315728|NCT02304133|OTHER|Education|
224315729|NCT02895828|OTHER|Core Stabilization Exercise|the participants asked to performed CSE program, 20 min/session, 2 session/week, 10 weeks
224315730|NCT02895828|OTHER|General Strengthening Exercise|the participants asked to performed GSE program, 20 min/session, 2 session/week, 10 weeks
224315731|NCT05351671|DRUG|RLS-0071 (10 mg/kg intravenously every 8 hours for total of 3 doses)|After challenge with inhaled LPS, subjects will receive IV infusion of RLS-0071 at 10 mg/kg every 8 hours for total of 3 doses.
223619552|NCT02313766|OTHER|PEEP : PPV + PEEP|Inspiratory pressure support ventilation (12 cmH2O) with PEEP (6 cmH2O)
223619553|NCT04739826|DRUG|Flumatinib Mesylate|Flumatinib mesylate tablets 600mg qd
223619554|NCT04739826|DRUG|Nilotinib Pill|Nilotinib Capsules 300mg bid
223619555|NCT03723148|DRUG|Oral Fedratinib|Oral fedratinib administered as directed by treating physician.
223619556|NCT04189367|DRUG|Traditional Chinese Medicine|"One bag of  Qingre Liangkou Ningxin Fang at a time, three times a day for 12 weeks."
223619557|NCT04189367|DRUG|Western medicine|"Western medicine includes:~1. clonazepam 0.5mg every day before sleep or twice a day for 12 weeks~2. Nutritional supplement: vitamin B12, folic acid, iron, zinc, vitamin B complex depending on the hematic deficiency, for 12 weeks"
223619558|NCT06079788|DRUG|Adrenocorticotrophic Hormone|"For patients in complete remission, ACTH is given at a prednisone dose of 1.5-2mg/kg qod or 0.75-1mg/kg qd. ACTH 2 IU/kg/ day, qd,（the maximum dose ≤ 50 IU）, 28 days of continuous use for 5 days， for 24 weeks.~Prednisone: 5mg；Oral tablets; 1.5-2 mg/kg, qod or 0.75-1mg/kg/day,qd, then gradually taper the steroid by 0.25mg/kg qod or 0.125mg/kg qd every 4 weeks.If stable, taper to 5mg qod (body surface area \> 1.0m2) and 2.5mg qod (body surface area \< 1.0m2) and maintain the dose until study completion."
223619559|NCT06079788|DRUG|Steroid|For patients in complete remission, Prednisone: 5mg；Oral tablets; 1.5-2 mg/kg, qod or 0.75-1mg/kg/day,qd, then gradually taper the steroid by 0.25mg/kg qod or 0.125mg/kg qd every 4 weeks. If stable, taper to 5mg qod (body surface area \> 1.0m2) and 2.5mg qod (body surface area \< 1.0m2) and maintain the dose until study completion.
223619560|NCT03573934|OTHER|GLP-2|GLP-2
223761512|NCT04132492|OTHER|no intervention|there is no intervention
224209189|NCT04000373|DEVICE|Ekso GT™ exoskeleton|The rehabilitation treatment will consist of 3 sessions per week for 8 weeks, for a total of 24 sessions. Missed sessions will be made up if possible. Each session will be scheduled for 60 minutes, and will consist of stretching, overground gait training, and gait training with the study device. Rest periods will be provided as necessary during the training visits.
224209190|NCT00998582|DRUG|Tenofovir disoproxil|Participants taking an abacavir-based HIV treatment regimen will be randomized to switch to a tenofovir-based regimen or continue taking abacavir.
224315732|NCT05351671|DRUG|RLS-0071 (loading dose of 120 mg/kg followed by 40 mg/kg every 8 hours for 2 additional doses)|After challenge with inhaled LPS, subjects will receive IV infusion of RLS-0071 at a loading dose of 120 mg/kg followed by 40 mg/kg every 8 hours for 2 additional doses.
224315733|NCT05351671|DRUG|Placebo (saline dosed every 8 hours for a total of 3 doses)|After challenge with inhaled LPS, subjects will receive IV infusion of placebo (saline) dosed every 8 hours for a total of 3 doses.
224315734|NCT05639075|OTHER|Peripheral vision|A gait analysis test will be performed in each patient after cataract surgery to test peripheral vision
224323211|NCT03823534|DRUG|Ketorolac|IV Ketorolac to be given over the course of the first 24 hours after surgery. See arm/group description for further details.
223619561|NCT03573934|OTHER|GIP|GIP
223619562|NCT03573934|OTHER|GLP-2+GIP|GLP-2+GIP
223619563|NCT03573934|OTHER|Placebo|Placebo
223619564|NCT02849379|DEVICE|Cryosurgery|Percutaneous ablation under CT or ultrasound guidance
223761513|NCT06908187|OTHER|Opt-In Early Latinx intervention|Participants will access to the Opt-In Early training program website, but will be able to access the Spanish language version as well. Families will fill out a usage diary to record their experience.
223761514|NCT06908187|OTHER|Opt-In Early Rural Intervention|Participants will access to the Opt-In Early training program website. Parents will be able to interact with the rural community-oriented aspects of the program. Families will fill out a usage diary to record their experience.
224209191|NCT03751527|DEVICE|ZENFLEX peripheral stent system|The ZENFLEX Peripheral Stent System is designed to deliver a self-expanding stent to the iliac artery, superficial femoral arteries and / or proximal popliteal arteries to improve luminal diameter. The self-expanding stent is composed of nickel titanium alloy (nitinol); contains a total of 12 tantalum / gold radiopaque markers and imparts an outward radial force on the luminal surface of the vessel to establish patency.
224209192|NCT00000160|PROCEDURE|Xenon Photocoagulation|
224209193|NCT00000160|PROCEDURE|Argon Photocoagulation|
224209194|NCT00000160|PROCEDURE|Photocoagulation|
224209195|NCT02711579|DRUG|Celecoxib|
224209196|NCT02711579|DRUG|Placebo|
224209197|NCT04959565|BEHAVIORAL|Nutritional behavioral intervention|The participants will get access to an online platform where the FUEL recovery program will be initiated with session 1 immediately after baseline testing and the athletes are requested to follow the lectures lead by highly experienced sports dietitians for the respective weeks. Every other week for 16 weeks (8 sessions in total) participants will be offered individual nutrition counselling (one intervention group) by highly experienced sports nutritionists in each country, based on Motivational Interviewing, the individual's environmental and biological prerequisites, and the Transtheoretical Model, focusing on the individual's readiness to act on a new healthier behavior
224209198|NCT04959565|BEHAVIORAL|Nutritional behavioral intervention|The participants will get access to an online platform where the FUEL recovery program will be initiated with session 1 immediately after baseline testing and the athletes are requested to follow the lectures lead by highly experienced sports dietitians for the respective weeks.
224209199|NCT01032330|DEVICE|occlusion treatment|Patients randomized to the occlusion treatment group will receive occlusion (patching) for 3 hours per day for at least 3 months. Choice of which eye to occlude, or whether to alternate daily, is at investigator's discretion.
224209200|NCT01268319|DEVICE|Embolic Protection Device (EPD)|"The embolic protection device consists of a protection wire, a delivery sheath, a retrieval sheath and various accessories (wire torque device, introducer, dilator tool). The wire of the EPD is used as a standard 0.014 steerable guide wire. The filter is designed for embolic debris capture while maintaining continuous blood flow. At the completion of the procedure, the filter and its contents are removed using the retrieval sheath and then removed from the patient."
224209201|NCT01268319|DEVICE|Intracoronary Spectroscopy and Ultrasonic Evaluation|This intervention requires a near infrared imaging catheter equipped with an intravascular ultrasonic transducer be used to evaluate the coronary artery wall prior to treatment and after treatment. This system detects the lipid containing plaques that may be the source of embolic debris released during standard angioplasty and stent placement.
224209202|NCT01268319|DEVICE|Angioplasty and Stent Implant|The target plaque will be treated with a pre-dilation with a standard angioplasty balloon sized to within 0.5mm of the diameter of the reference vessel diameter. The physician will then implant a coronary artery stent that is appropriately sized for the reference vessel diameter.
224209203|NCT06271135|BEHAVIORAL|CAPILLARY REPAIR SERUM 30ml|Cosmetic procedures were performed on a group of patients after a cosmetic interview containing questions about contraindications to the procedure. The treatment was performed 3-times at 2-week intervals and consisted of cavitation peeling and sonophore-sis with an antioxidant preparation dedicated to vascular skin. The F-808 Skin Scrubber device was used for the treatment. After a month, the procedure was repeated. The stages of a cosmetologist's procedure during a cosmetic intervention were as follows: 1. make-up removal; 2. skin diagnostics, exclusion of contraindications, discussion of the procedure; 3. cavitation peeling - gentle skin cleansing using ultrasound; 4. applying an antioxidant cosmetic mixture (composition: rutin, horse chestnut and arnica extract, acerola, vitamin C, moisturizing complex of algae); 5. performing sonophoresis treatment; 6. applying the cream at the end; 7. discussion of indications for further care.
224209204|NCT06390358|OTHER|Tefillin|Wrapping of arm
224209205|NCT03250013|DRUG|ADHD medications|
224209206|NCT02434796|BEHAVIORAL|Male Peer Groups|In Intervention Arm 1, male partners participate in male peer group workshops on gender norms, IPV and HIV prevention. Men's peer groups address gender inequality and transformation of gender power relations, positive masculinities and accountability of men in the perpetration of violence against women. This intervention aims to improve knowledge and attitudes among men about the harms of IPV on women, men and children; the confidence to internalize positive masculine ideals and to challenge gender stereotypes; and the ability to formulate positive outcome expectations regarding IPV and healthy relationships with their spouses and communities. Male peer group workshops will be conducted as a series of four workshops for a total of 24 hours spread out over a 5-month period.
224209207|NCT02434796|BEHAVIORAL|Male Peer Groups and Community Dialogues|Men participate in male peer group workshops as in Intervention Arm 1. In addition, village level community leaders engage in community mobilization/sensitization activities that include women members of savings groups and their male partners who participate male peer groups. Community dialogues focus on gender norms, IPV and HIV prevention. First, a one-day workshop for community leaders on topics similar to those raised in male peer group sessions. Second, trained community leaders facilitate community dialogues on IPV, HIV prevention, and gender norms with savings groups members and their male partners who participate in male peer groups. Each workshop will be a day-long event.
224323212|NCT03823534|DRUG|Normal saline|An IV normal saline placebo prepared by the hospital pharmacy.
224323213|NCT03823534|DRUG|Acetaminophen|acetaminophen 500 mg PO Q4 hours PRN for mild pain
223680458|NCT01247805|DRUG|sildenafil citrate|Single oral dose of 1 x 20 mg IR oral tablet.
223680459|NCT01247805|DRUG|Sildenafil citrate|single oral dose of 2 x 10 mg sildenafil citrate IR oral tablet.
223680460|NCT01247805|DRUG|sildenafil citrate|single oral dose of 2 mL of the 10 mg/mL sildenafil citrate POS (20 mg dose).
223680461|NCT00353860|DEVICE|SOLEX 300i Stem Cell Selection|
223680462|NCT02461472|OTHER|not intervention|This is a cross-sectional study, no intervention was performed.
223680463|NCT01315821|DRUG|Saccharomyces boulardii|5 million units/day for 3 months
223680464|NCT01315821|DRUG|Placebo|Placebo for 3 months
223680465|NCT03269162|DRUG|Jinfukang Koufuye|30ml per time, tid, po (d6-21, q21)
223680466|NCT03269162|DRUG|Docetaxel|75mg/m2,ivgtt 30mins, d1
223680467|NCT03269162|DRUG|Pemetrexed|500mg/m2, ivgtt 30mins, d1
223680468|NCT03269162|DRUG|Cisplatin|75mg/m2, ivgtt \>2h, d1
223619565|NCT02849379|BIOLOGICAL|NK immunotherapy|Each treatment: 8\~10 billion cells in all, transfuion in 3 times, i.v.
223619566|NCT05572008|BEHAVIORAL|Protein nutrition in paediatric Crohn's disease|"All participants (N = 40) will undergo the same study procedures:~Eating behaviour questionnaire(s) completion Duration: 5 minutes Frequency 2 Dietary intake data via online computerised recall Duration: 60 minutes Frequency: 3 Collection of blood sample via venepuncture Duration: 15 minutes Frequency 1 Strength Tests Duration: 30 minutes Frequency: 1~Half the participants (N = 20) will return for two more visits and will undergo the following procedures:~MRI Scan Duration: 30 minutes Frequency: 1 Consumption of intrinsically labelled protein Duration: 15 minutes Frequency: 1 Insertion of cannulae into hand Duration: 15 minutes Frequency: 1 Collection of blood sample via cannulae (for protein digestion and inflammatory markers and study endpoints outlined below) Duration: 1 minute Frequency: 17"
224209208|NCT01995006|DRUG|metamizole|metamizol tablets (500mg): 1000mg TID during 7 days
224209209|NCT01995006|DRUG|Naproxen|Naproxen tablets (500mg): 500 mg BID during 7 days
224209210|NCT01314222|DRUG|BMS-954561|
224209211|NCT01314222|DRUG|Pregabalin|
224209212|NCT01314222|DRUG|Placebo matching BMS-954561|
224209213|NCT01314222|DRUG|Placebo matching Pregabalin|
224209214|NCT06542744|DEVICE|Training with the Emagina device at home until birth|The subjects will use the device at home according to a series of 3 exercises, 2 sessions per week, followed by a series of 4 exercises, 3 sessions per week starting from D75.
224209215|NCT06542744|OTHER|No intervention|The subjects will follow usual care instructions. Subjects are not trained in the use of Emagina.
224209216|NCT05928273|DEVICE|Corheart 6 Left Ventricular Assist System|Implantation of left ventricular assist device for hemodynamic support
224209217|NCT02253758|DRUG|Propofol|Propofol will be injected as a continuous infusion by TCI intravenously
224209218|NCT04230785|GENETIC|Sequencing of circRNA/lncRNA/miRNA|Next generation sequencing and quantitative real-time polymerase chain reaction of circular RNA (circRNA), long non-coding RNA (lncRNA) and micro-RNA (miRNA)
224209219|NCT04778007|OTHER|Turkish Version of Laryngopharyngeal Measure of Perceived Sensation Questionnaire|The Turkish Version of Laryngopharyngeal Measure of Perceived Sensation Questionnaire consists of 8 questions related with globus pharyngeus symptoms.
224209220|NCT03334526|OTHER|physical training|workout on treadmill requiring the muscles of the lower limbs mostly in concentric (ascent) or eccentric (downhill)
224209221|NCT03334526|OTHER|mental training|The task to imagine for the training group will be an abduction of the thumb
224209222|NCT03334526|OTHER|electrical stimulation|electrical stimulation of the muscles
224209223|NCT02832739|DEVICE|SENACA - ICT based self-management support system|SENACA - ICT based self-management support system is a structured self-management support system with several interacting components, combining tele-monitoring devices and a solution for personalised health plans. ==\> www.senaca.ch
224209224|NCT01677403|DRUG|Tobramycin|Nebulised 80mg twice daily
224209225|NCT01677403|DRUG|Saline|Nebulised 5mls 0.9% Saline twice daily
224209226|NCT06536816|OTHER|Game Profile-based training Group|Game profile-based training is a methodology in sports, including football, where training sessions are designed to simulate the specific conditions and challenges that players face during actual games. Coaches analyze individual and team performance data to identify patterns, positions, and scenarios commonly encountered in matches. The training is then structured to replicate these situations, helping players develop the skills, tactics, and decision-making abilities required in real-game scenarios. This approach aims to make training more targeted and relevant to the dynamics of competitive play.
224209227|NCT06536816|OTHER|Small-sided games Group|"small-sided game in football, often referred to as a SSG, is a practice or training activity where players compete in a reduced playing area with fewer players than a full team."
224209228|NCT06536816|OTHER|Combined training Group with both Game Profile-based training and Small-sided Games|Combined training Group with both Game Profile-based training and Small-sided Games
224209229|NCT03547596|OTHER|questionnaire passation|Questionnaires to evaluate lower urinary tract symptoms and erectile dysfunction.
224209230|NCT01117714|PROCEDURE|Integrated Staging for Early Detection of Metastases in Lung Cancer|To determine the accuracy of EBUS/EUS-guided FNA when compared with surgical mediastinoscopy/thoracoscopy
224209231|NCT00335790|PROCEDURE|Hyperbaric Therapy|
224315735|NCT06983301|OTHER|Brief Cognitive Behavioural Therapy (CBT) for OCD|A brief 5-session CBT face-to-face intervention (therapist supported, involving workbooks) for adolescent Obsessive Compulsive Disorder (OCD). The brief CBT consists of 5 sessions of 60 to 90-minutes, with the option of 2 additional booster sessions (also 60 to 90 minutes), spanning a total of 24 weeks. The intervention includes home tasks, completion of regular routine outcome measures and participants listening to audio-recordings of the therapy sessions. The intervention sessions are delivered by routine child and adolescent mental health services (CAMHS) practitioners and take place in NHS and NHS-commissioned child and adolescent mental health services.
224209232|NCT02690584|BEHAVIORAL|Metacognitive therapy|
224209233|NCT02192216|BEHAVIORAL|Exercise|
224209234|NCT05094986|BEHAVIORAL|Initial Medication Adherence (IMA) Intervention|The IMA intervention promotes health literacy and patient participation in the decision-making process during the recommendation and prescription of a new drug for the management of cardiovascular disease and diabetes. The IMA intervention has four main components: 1. Training for healthcare professionals (GPs, nurses, and community pharmacists) on non-initiation, shared-decision making, health literacy and use of decision aids; 2. Intervention support tools; decision aids (leaflets and website) and implementation tools (dispensing alert in community pharmacies when dispensing insulins and antiplatelet drugs); 3. Shared decision-making process during the GP's consultation; and 4. Information support provided by the nurses and community pharmacists that use the intervention decision aids to explore the patients' doubts and standardise the discourse between primary healthcare professionals.
224209235|NCT05094986|OTHER|Usual Care|Patients received the usual care when being prescribed a new prescription for treatments of cardiovascular disease or diabetes. Nurses and community pharmacists were asked to also provide usual care to those patients. Community pharmacists from the control group had the dispensing alert available when dispensing insulins and antiplatelet drugs.
224209236|NCT01186952|BEHAVIORAL|Caloric restriction|The caloric restriction diet will follow the Canadian Diabetes Association guidelines and be nutritionally balanced with a reduced total fat as well as saturated content.
224315736|NCT02728843|DRUG|Deferiprone|600 mg tablets
224315737|NCT02728843|DRUG|Placebo|Tablets that match the deferiprone tablets in appearance
224315738|NCT01671332|DRUG|Docetaxel|IV over 60 minutes, 75 mg/m2
224315739|NCT01671332|DRUG|Suramin|IV over 30 minutes
224315740|NCT01671332|DRUG|Docetaxel|IV over 60 minutes. 56 mg/m2
224315741|NCT00351533|DRUG|Fish oil (eicosapentaenoic acid and docosahexanoic acid)|Liquid fish oil 7.5cc enterally every 6 hours
224315742|NCT01771471|BIOLOGICAL|NuQu|Allogenic juvenile chondrocytes (NuQu) in fibrin carrier.
224315743|NCT01771471|OTHER|Placebo|0.9% w/v Sodium Chloride for Injection, USP
224315744|NCT01305174|DEVICE|PROTEGE GPS stent vs. VISI-PRO stent|Visi-Pro balloon expandable stent vs. PROTEGE GPS selfexpanding nitinol stent to treat stenosis or occlusion of common and external iliac artery disease
224315745|NCT01293838|DRUG|Cipralex®|"Based on a starting rate of 5 mg/day, increased by 5 mg every 2 weeks to a maximum of 20 mg/day for weeks 7-16, each participant will receive up to:~* 10 mg tablets: 28~* 20 mg tablets: 84~Total for 30 participants:~* 10 mg tablets: 840~* 20 mg tablets: 2520~Continuation study for participants who respond to Cipralex - Across 12 weeks, each participant will receive up to:~\*20 mg tablets: 84~Total for continuation study for all participants (assuming a 60% response rate, N=18):~\*20 mg tablets: 1512"
224315746|NCT04297033|DRUG|Lovastatin|lovastatin 40mg/d 12m
224315747|NCT04297033|DRUG|Placebo|placebo
224315748|NCT05608980|DRUG|0.01% hypochlorous acid|once daily 0.01% hypochlorous acid topical treatment via ultrasonic atomization for 2 weeks
224315749|NCT05608980|DRUG|Placebo|once daily eyelid wipes for 2 weeks
224315750|NCT00088621|DRUG|Lurasidone 80mg tablet|
224315751|NCT03321838|BEHAVIORAL|accommodative/vergence therapy|Accommodative/vergence therapy (60 minutes per visit, one time per week, 12-14 weeks) and home reinforcement (15 minutes each time, five times per week, 12-14 weeks) will be provided to patients of treatment group. These therapy includes accommodative, vergence and anti-suppression technique. No drug is used during the whole therapy process.
224315752|NCT00373698|BEHAVIORAL|Three Component Model of Collaborative Care|Patients randomized to 3CM will receive telephone care management along with usual care by VA clinicians.
224315753|NCT06494345|BIOLOGICAL|Genolair, solution for subcutaneous administration, 150 mg|Genolair (omalizumab), solution for subcutaneous administration, 150 mg for single subcutaneous administration
224315754|NCT06494345|BIOLOGICAL|Genolair, lyophilisate for the preparation of solution for subcutaneous administration|Genolair (omalizumab), lyophilisate for the preparation of solution for subcutaneous administration, 150 mg for single subcutaneous administration
224315755|NCT06494345|BIOLOGICAL|Xolair®, solution for subcutaneous administration, 150 mg|Xolair® (omalizumab), solution for subcutaneous administration, 150 mg for single subcutaneous administration
224315756|NCT05458180|DRUG|Lposomal mitoxantrone hydrochloride,Cyclophosphamide,Vincristine,Etoposide and Prednisone(CMOEP)|"Drug: Liposomal mitoxantrone hydrochloride (15 mg/m2, 18 mg/m2, 20 mg/m2) will be administered by an intravenous infusion on day 1 of each 21-day cycle.~Drug: Cyclophosphamide (750 mg/ m2) will be administered by an intravenous infusion on day 1 of each 21-day cycle.~Drug: Vincristine (1.4mg/ m2，Max dose 2mg) will be administered by an intravenous injection on day 1of each 21-day cycle.~Drug: Etoposide (60 mg/ m2) will be administered by an intravenous infusion on day 1-3 of each 21-day cycle.~Drug: Prednisone (100 mg) will be taken orally from day 1-5 of each 21-day cycle."
224315757|NCT00892996|DRUG|dexamethasone|Metoclopramide 10 mg and dexamethasone 5 mg intravenous
224315758|NCT00892996|DRUG|dexamethasone 5 mg|Ondansetron 8 mg and dexamethasone 5 mg IV
224315759|NCT02841163|DRUG|Herbal medicine|Herbal medicine was administered 2-3 times daily in water-based decoction (120ml) and dried powder (2g) form (Ostericum koreanum, Eucommia ulmoides, Acanthopanax sessiliflorus, Achyranthes japonica, Psoralea corylifolia, Saposhnikovia divaricata, Cibotium barometz, Lycium chinense, Boschniakia rossica, Cuscuta chinensis, Glycine max, Atractylodes japonica).
224315760|NCT02841163|PROCEDURE|Acupuncture|Acupuncture treatment was administered 1-2 times daily using mainly proximal acupuncture points and Ah-shi points.
224315761|NCT02841163|PROCEDURE|Pharmacopuncture|Select herbal ingredients (Eucommia ulmoides cortex, Acanthopanax sessiliflorum cortex, Achyranthis bidentata radix, Saposhnikovia divaricata radix, Cibotium barometz rhizoma, Paeonia albiflora radix alba, Ostericum koreanum radix, Angelica pubescens radix, and Scolopendra subspinipes corpus (Paeonia albiflora twice the proportion of that of other ingredients)) were freeze dried into powder form after decoction, then diluted in water-for-injection and adjusted for acidity and pH. Pharmacopuncture was administered once daily at Hyeopcheok (Huatuo Jiaji, EX B2), Ah-shi points and local acupuncture points using disposable injection needles (CPL, 1 cc, 26G x 1.5 syringe, Shinchang medical co., Korea).
224315762|NCT02841163|PROCEDURE|Bee venom pharmacopuncture|Bee venom pharmacopuncture was administered only after confirming a negative response to hypersensitivity skin tests. Diluted bee venom (saline:bee venom ratio, 10,000:1) filtered for allergens was injected at 4-5 acupoints proximal to the painful site at the physician's discretion. Each acupuncture point was injected to a total of 0.5-1 cc using disposable injection needles (CPL, 1 cc, 26G x 1.5 syringe, Shinchang medical co., Korea).
224315763|NCT02841163|PROCEDURE|Chuna manipulation|Chuna is a Korean version of spinal manipulation that incorporates spinal manipulation techniques for mobilization involving high-velocity, low amplitude thrusts to joints slightly beyond the passive range of motion and gentle force to joints within the passive range of movement. Chuna manipulation was administered 3-5 times a week to pelvic, lumbar, thoracic, and cervical vertebrae at the physician's discretion.
224315764|NCT00769873|DRUG|Enoxaparin|Lovenox 40mg SC daily (30mg SC daily if creatinine clearance \< 30) for 21 days
224315765|NCT00006630|DRUG|Vaccinia Immune Globulin (Human)|
224315766|NCT05756283|BEHAVIORAL|Multimodal Prehabilitation|"EXERCISE~* Supervised exercise~  * High intensity interval training~ * Strength exercise~* Home-based exercise / promotion of physical activity~  * Low-moderate intensity aerobic training~ * Inspiratory muscle training~ * Low-moderate intensity strength training~NUTRITION: nutrition education and optimization. Intake of 0.4g/kg of whey isolate after every supervised training.~PSYCHOSOCIAL: mindfulness, cognitive reframing and coping strategies."
224315767|NCT05097794|DRUG|BR1015-1|\- Administration to the BR1015-1 group: 60 mg of BR1015-1 will be administered one tablet once a day, five-day repeated doses.
224315768|NCT05097794|DRUG|BR1015-2|\- Administration to the BR1015-2 group: 1.5 mg of BR1015-2 will be administered one tablet once a day, five-day repeated doses.
223619567|NCT03932877|OTHER|MMP-14 and s-ENG levels|Venous blood sampled from the antecubital veins for measuring the serum concentration of MMP-14 and s-ENG levels. The serum MMP-14 and s-ENG levels measured using commercially available reagent kits, which is produced to detect human MMP-14 and s-ENG levels (Rel Assay Diagnostics Gaziantep, Turkey). The MMP-14 and s-ENG levels measurements were performed in accordance with the company's protocol.
223761515|NCT06908668|DRUG|Neoadjuvant Chemotherapy Combined with Immunotherapy and Radiotherapy|"1. Recommended Chemotherapy Regimen and Doses:~   Albumin-bound Paclitaxel 260 mg/m² on Day 1, every 3 weeks (Q3W) × 4 cycles, followed by Epirubicin 90 mg/m² on Day 1 + Cyclophosphamide 600 mg/m² on Day 1, every 3 weeks (Q3W) × 4 cycles.~2. Recommended Immunotherapy Dose:~   Adebrelimab 1200 mg, repeated every 3 weeks, starting simultaneously with neoadjuvant chemotherapy and continuing for 1 year (including postoperative administration).~3. Radiotherapy:~Preoperative Radiotherapy:~Positioning: Immobilization with a neck-chest integrated frame, combined CT and MRI positioning with image fusion. Diagnostic MRI images can also be fused simultaneously. CT positioning should be performed with a plain scan, with a slice thickness of 3 mm. MRI positioning should include at least three sequences: T1-enhanced, T2 fat-suppressed, and DWI.~Target and Normal Organ Contouring:~GTVp (Gross Tumor Volume - Primary): Define the breast tumor target area based on MRI, CT, physical examination, and ultrasound"
223619568|NCT01972581|OTHER|Reaction Time Training|
223619569|NCT04674891|OTHER|baseline physical therapy treatment|Group A was control group and the patients received Conventional treatment protocol for 4 weeks which included 3 sessions per week. Patients received hot pack for 15 min and TENS (Transcutaneous Electric Nerve Stimulation) for 10 min. After that Cervical isometric exercises will be performed in sitting (10sec hold,10 to 15 reps)
223761516|NCT06908668|DRUG|Neoadjuvant Chemotherapy Combined with Immunotherapy|"1. Recommended Chemotherapy Regimen and Doses:~   Albumin-bound Paclitaxel 260 mg/m² on Day 1, every 3 weeks (Q3W) × 4 cycles, followed by Epirubicin 90 mg/m² on Day 1 + Cyclophosphamide 600 mg/m² on Day 1, every 3 weeks (Q3W) × 4 cycles.~2. Recommended Immunotherapy Dose:~Adebrelimab 1200 mg, repeated every 3 weeks, starting simultaneously with neoadjuvant chemotherapy and continuing for 1 year (including postoperative administration)."
224209237|NCT01186952|BEHAVIORAL|Diet intervention and structured exercise training program|Participants will follow the diet intervention previously described and a supervised physical activity program. The supervised exercise training sessions will take place three times a week for 4 months. Each session will last 1hour and will include aerobic exercise and resistance training. The aerobic training program will be treadmills intervals exercise at 50-70 % of heart rate reserve(HRR) the first month and 85-90% of HRR from the second to the fourth month. The resistance training programme will consist of two to three sets of 12 repetitions of the following exercises: leg press, chest press, lat pulldown, shoulder press, biceps curl, triceps extension.
224209238|NCT03661294|DIAGNOSTIC_TEST|GE Healthcare Metabolic Oxygenator|
224209239|NCT03351127|RADIATION|Carotid ultrasound examination|Carotid pulse wave velocity of all participants were measured by ultrafast ultrasound imaging technology using SuperSonic Imagine's Aixplorer ultrasound system.
224209240|NCT02791711|OTHER|High Flow Nasal Cannula|Evaluation of the use of High Flow Nasal Cannula by biological markers, questionary of quality of use of HFNC by the physician, questionary of evaluation of adverse events with HFNC
224209241|NCT04307537|PROCEDURE|Post-urethroplasty urethrography|Imaging of the urethra after reconstructive surgery to identify contrast leakage (no, insignificant, signficant).
224209242|NCT06340971|OTHER|Policy|"We will work with stakeholders' policy groups e.g. RCOG, RCM, RCP and policy makers e.g. Department for Health and Social Care, Transport Emissions at the Greater London Authority or Mayor of London's office to disseminate our findings and develop public health messages.~We aim to develop guidance on how pregnant women and their families can reduce their exposure to air pollution by highlighting for example travel routes with less pollution and wear face masks."
224209243|NCT04514328|DEVICE|cerebral 18F-FDG PET-CT|cerebral 18F-FDG PET-CT exam after walking in the garden while 2 weeks (75 minutes/per day from Monday to Friday)
224209244|NCT00418080|DRUG|bicalutamide|
224209245|NCT02221583|DRUG|Astagraf XL|Two PK profiles will be obtained in each subject. Each subject will receive either Astagraf XL 8mg daily or Prograf® 4mg every 12 hours in combination with MMF 1000mg every 12 hours. A full 24 hour PK profile will be constructed. After at least a one week washout period, the patient will be crossed over to the alternative tacrolimus formulation (Astagraf XL or Prograf®) in combination with MMF 1000mg every 12 hours and the PK profile repeated.
224209246|NCT02221583|DRUG|Prograf|Two PK profiles will be obtained in each subject. Each subject will receive either Astagraf XL 8mg daily or Prograf® 4mg every 12 hours in combination with MMF 1000mg every 12 hours. A full 24 hour PK profile will be constructed. After at least a one week washout period, the patient will be crossed over to the alternative tacrolimus formulation (Astagraf XL or Prograf®) in combination with MMF 1000mg every 12 hours and the PK profile repeated.
224209247|NCT02221583|DRUG|Mycophenolate mofetil|Two PK profiles will be obtained in each subject. Each subject will receive either Astagraf XL 8mg daily or Prograf® 4mg every 12 hours in combination with MMF 1000mg every 12 hours. A full 24 hour PK profile will be constructed. After at least a one week washout period, the patient will be crossed over to the alternative tacrolimus formulation (Astagraf XL or Prograf®) in combination with MMF 1000mg every 12 hours and the PK profile repeated.
224209248|NCT04250519|DRUG|Sodium Hypochlorite|Sodium hypochlorite is used as intracanal irrigant to minimize the post operative pain
224209249|NCT04685941|DRUG|Drug-mediated hyperemia|Intracoronary bolus of at least 200 mcg of nitroprussiate or 500 mcg of intracoronary adenosine during 2 minutes. Operators are allowed to combine both drugs.
224209250|NCT04685941|OTHER|Flow-mediated hyperemia|Intracoronary saline infusion at 20 ml/min via dedicated microcatheter (RayFlow; Hexacath, France) during two minutes.
224315769|NCT05097794|DRUG|BR1015-1 + BR1015-2|\- Co-administration to the BR1015-1+BR1015-2 group: 60 mg of BR1015-1 one tablet and 1.5 mg of BR1015-2 one tablet will be co-administered once a day, five-day repeated doses.
224323214|NCT03823534|DRUG|Oxycodone Acetaminophen|oxycodone-acetaminophen 5-325 mg PO Q4 hours PRN for moderate to severe pain
224323215|NCT03823534|DRUG|Morphine|morphine IV PRN (or other opioid) for severe breakthrough pain
224323216|NCT03823534|DRUG|Hydrocodone/Acetaminophen|At discharge, patients will be prescribed 1-2 hydrocodone-acetaminophen 5-325 mg Q4 hours. Those with preexisting liver disease will be prescribed the equivalent in oxycodone.
223761517|NCT06909149|DRUG|Amniotic membrane extract eye drops|Patients received the amniotic membrane extract eye drops once every two hours during waking time as an adjunctive therapy to the specific treatment.
223761518|NCT06909149|DRUG|Specific treatment|Patients received the specific treatment only.
223761519|NCT06909695|OTHER|Blood volume and environmental testing|Testing blood volume measures, iron stores, and physiological responses to acute environmental exposures of heat, cold, and high-altitude (each environment independently)
223761520|NCT06908239|OTHER|thermostatic feeding|In the thermostatic feeding group (intervention arm), milk or formula was delivered directly into the stomach via an infusion pump (Model 8713030CN, Shenzhen Shengnuo Medical Equipment Co., Ltd., Shenzhen, Guangdong, China) located within the incubator. The initial temperature of the milk was set at 38°C, and naturally decreased to match that of the incubator, maintaining a stable, thermostatic environment until the completion of feeding, as well as the setting and adjustment of the temperature of incubator according to the Chinese Medical Association guidelines
223761521|NCT06908239|OTHER|control|In the control arm, standard feeding involved delivering breast milk or formula directly into the stomach using an infusion pump (Model 8713030CN) placed on an infusion stand. The initial temperature of the milk or formula was set at 38°C, and the temperature was allowed to naturally decrease to match the ambient air temperature of the NICU until feeding was completed. For both groups, the feeding volume and speed were managed in accordance with the clinical application guidelines for neonatal nutrition support in China.
224209251|NCT00821522|PROCEDURE|Remote Ischemic Preconditioning|Three 5-minute intervals of leg ischemia induced by tourniquet inflation, prior to initiation of cardiopulmonary bypass.
224209252|NCT01155284|DRUG|Sitagliptin and Lansoprazole|"Sitagliptin (dispensed as 50 mg capsules)and Lansoprazole(dispensed as 30 mg capsules) or matching placebo~* Subjects age 11-17 years at Visit 2 will take 1 capsule once daily~* Subjects age 18-45 years at Visit 2 will take 2 capsules once daily"
224209253|NCT01155284|DRUG|Placebo|Sitagliptin 50mg and Lansoprazole 30 mg or matching placebo will be given daily for 12 months. Subjects age 11-17 at visit 2 will take 1 capsule daily; age 18-45 will take 2 capsules daily.
224209254|NCT06500299|DRUG|HDM1002 100 mg QD|HDM1002 tablets 100mg daily, 12weeks
224209255|NCT06500299|DRUG|HDM1002 200 mg QD 12weeks|HDM1002 tablets 200mg daily, 12weeks
224209256|NCT06500299|DRUG|HDM1002 400 mg QD 12weeks|HDM1002 tablets 400mg daily, 12weeks
224209257|NCT06500299|DRUG|Placebo|Matching placebo will be provided
224209258|NCT06528860|DEVICE|MiSight® 1 day soft contact lenses|Dual-focus contact lenses, daily disposable, material: omafilcon A, water content: 60%.
224209259|NCT06528860|DEVICE|Proclear® 1 day soft contact lenses|Single-vision contact lenses, daily disposable, material: omafilcon A, water content: 60%.
224209260|NCT04775368|OTHER|Administering diagnosis orientation questionnaires for the screening of possible sleep disorders|Several diagnosis orientation self-questionnaires will be conducted by the patient following his or her inclusion in order to detect, among other things, possible sleep disorders.
224209261|NCT02412696|DEVICE|Positive Airway Pressure|Auto-titrating PAP + nasal dilator strips during sleep
224209262|NCT02412696|OTHER|Nasal Dilator Strips|Nasal dilator strips
224209263|NCT03797339|OTHER|risk factors of adverse cardiovascular events|During the follow-up period,general information(age, sex, BMI, blood pressure, the history of drink and smoke, medical history, etc).Blood biochemistry parameters（Lipid, hsCRP levels, etc）and other laboratory examination parameters will be collected
224209264|NCT03797339|OTHER|multi-omics target discovery|Genome-wide genotype , DNA methylation and metabolomes were determined using illumina high-density genotyping chips, high-throughput sequencing, and high-resolution mass spectrometry respectly. Blood exposure of statins and metoprolol and its metabolites was determined by UPLC-MS/MS.
223761522|NCT06909266|OTHER|OT Hope 0 - 5 ans Therapeutic tool|OT Hope 0 - 5 ans Therapeutic tool for self determination of pediatric goals in occupational therapy
223761523|NCT06909266|OTHER|Qualitative interviews with parents|qualitative interviews to understand how vestibular impairments affect their child's daily life activities, challenges encountered, and strategies used to support participation.
224209265|NCT03797339|OTHER|validation|The genome-wide genotype of patients with coronary heart disease was detected using the illumina chip. The methylation level of the functional region was detected by the target region enrichment methylation sequencing method. Intestinal flora differences were detected using 16SrDNA high-throughput sequencing.
224209266|NCT03797339|OTHER|Predictive mathematical models|Machine learning algorithms such as multiple linear regression or Bayesian classification are used to optimize clinical factors and multi-group targets to establish predictive mathematical models.
224209267|NCT04461080|BEHAVIORAL|Community Health Worker|Trained Community Health Worker
224209268|NCT02765542|OTHER|Automated disease assessment & self-care support phone calls|Automated disease assessment \& self-care support phone calls for up to 12 weeks.
224209269|NCT03159000|DRUG|Saline|1ml of 1/3 saline
224209270|NCT03159000|COMBINATION_PRODUCT|lidocaine/bupivacaine|1ml of a 50% 2% lidocaine and 50% 0.5% bupivacaine
224209271|NCT04420000|BEHAVIORAL|Mindfulness|Mindfulness based programme
224209272|NCT04420000|OTHER|Control|Treatment as usual
224209273|NCT02441959|PROCEDURE|Lumbar discectomy Open|Open Discectomy
224209274|NCT02441959|PROCEDURE|Lumbar discectomy Endoscopic|Endoscopic Discectomy
224323217|NCT03823534|DRUG|Oxycodone|Upon discharge, patients will be prescribed the equivalent of 1-2 hydrocodone 5mg Q4 hours upon should they have preexisting liver disease and are unable to consume acetaminophen.
224209275|NCT02578043|DRUG|Clindamycin and Benzoyl Peroxide Gel 1.2%/3.75%|Clindamycin and Benzoyl Peroxide Gel 1.2%/3.75% (Taro Pharmaceuticals Inc.)
224209276|NCT02578043|DRUG|Onexton™ Gel|Onexton™ Gel (Clindamycin and Benzoyl Peroxide Gel 1.2%/3.75%) (Valeant Pharmaceuticals LLC)
224209277|NCT02578043|DRUG|Placebo|Placebo (vehicle of the test product) (Taro Pharmaceuticals Inc.)
224209278|NCT02996461|BIOLOGICAL|VRC-ZKADNA090-00-VP|VRC-ZKADNA090-00-VP is an investigational ZIKV DNA vaccine that is intended to prevent Zika virus infection.
224209279|NCT06222398|DEVICE|Exoskeleton|The study will include one group of patients who are current exoskeleton users.
224209280|NCT03785652|DRUG|LY03005 extended-release tablets 40 mg|LY03005 extended-release tablets 40 mg group :40mg/day，orally once a day, at a regular morning time on an empty stomach or after breakfas
223619570|NCT04674891|OTHER|Cervical Stabilization exercises|"Group B was experimental group and received baseline physiotherapy treatment in addition to Cervical Stabilization exercises. Pillow was placed beneath cervical spine in supine position and guided patients to nod head as though they said 'yes' and asked them to hold for 10 seconds. 10 repetitions were done before progressing to the next target level.~4 weeks (3 sessions per week)~* Hot pack: 10 min~* TENS: 10 min~* Cervical isometric exercises in sitting (10sec hold,10 to 15 reps)~* Cervical Stabilization exercises (10 sec hold, 10 reps)~On eligible participants baseline assessment was taken on day 1, post intervention assessment was taken at the end of 4th week."
224209281|NCT03785652|DRUG|LY03005 extended-release tablets 80 mg group|"LY03005 extended-release tablets 80 mg group :~80mg/day，orally once a day, at a regular morning time on an empty stomach or after breakfast"
224209282|NCT03785652|DRUG|LY03005 extended-release tablets 120 mg group|"LY03005 extended-release tablets 120 mg group :~120mg/day，orally once a day, at a regular morning time on an empty stomach or after breakfast"
224209283|NCT03785652|DRUG|LY03005 extended-release tablets 160 mg group|"LY03005 extended-release tablets 160 mg group :~160mg/day，orally once a day, at a regular morning time on an empty stomach or after breakfast"
224209284|NCT03785652|DRUG|Placebo group|"Placebo group :~Placebo ，orally once a day, at a regular morning time on an empty stomach or after breakfast"
224209285|NCT04089150|RADIATION|Stereotactic Radiotherapy (SBRT)|40 Gray (Gy) in 5 fractions, 2-3 fractions per week over two weeks, 8 Gy per fraction
224209286|NCT04089150|DRUG|mFOLFIRINOX|"* Day 1: oxaliplatin 85mg/m2 + irinotecan 150mg/m2 + leucovorin 50mg~* 5-FU 2400mg/m2 continuous IV infusion, 46 hour continuous infusion~* 14-day cycle, 6 cycles"
224209287|NCT04089150|DRUG|Gemcitabine + Nab-paclitaxel|"* Day 1, Day 8 and Day 15 gemcitabine 1000mg/m2 + nab-paclitaxel 125mg/m2~* 28-day cycle, 3 cycles"
224209288|NCT04089150|DRUG|Gemcitabine + Capecitabine|"* Week 1, 2 and 3, qw: 1000 mg/m2 gemcitabine~* 21 days continuous: 830 mg/m2 oral capecitabine + 7 days rest~* 28-day cycle, 3 cycles"
224209289|NCT04089150|PROCEDURE|Pancreatoduodenectomy (Whipple procedure)|R0 resection. When the tumour is within the head of the pancreas, a standard Whipple's procedure and level 2/3 dissection with modification to obtain margin clearance will be offered. For lesions in the tail, a standard modular resection will be offered.
224209290|NCT02606370|OTHER|Unstable shoe|Wearing Unstable shoes during 1 month
224209291|NCT03466788|OTHER|Self questionnaires of quality of life and living conditions|Patients will complete self-questionnaires of living conditions and quality of life (QLQ-C30; EN24; CIPN20; IPAQ; HADS)
224209292|NCT06704061|BEHAVIORAL|Yoga|A 12-week online yoga course designed to treat pain.
224209293|NCT06704061|BEHAVIORAL|Acceptance and Commitment Therapy (ACT)|A 12-week behavioral therapy course designed to treat pain.
224209294|NCT02553005|PROCEDURE|Acupuncture|
224209295|NCT02618772|DRUG|Midazolam|Intranasal administration of midazolam at dose of 0.4mg/kg (max 10 mg) one time 10 minutes prior to laceration repair
224209296|NCT02618772|DRUG|Saline|Intranasal administration of saline at a dose of 0.08ml/kg (max 2ml) one time prior to laceration repair as a placebo
224209297|NCT02328404|DRUG|50,000 IU vitamin D3|Film-coated tablet Biodal 50,000 IU containing cholecalciferol 50,000 IU
224209298|NCT02328404|DRUG|Placebo|Placebo film-coated tablet of Biodal 50,000 IU
224209299|NCT04348292|DRUG|Durvalumab|Given IV
224209300|NCT04348292|DRUG|Sirolimus|Given PO
224209301|NCT03192566|DRUG|Tylenol|Dosing of Tylenol for post operative pain control
224209302|NCT01417208|DEVICE|SNaP® Wound Care System|Wound dressing applications using customized system. Dressing applications changes per manufacturer recommendation.
224209303|NCT06212375|BEHAVIORAL|Vegetable variety|Either children are offered a variety of three vegetables or a single vegetable.
224209304|NCT06212375|BEHAVIORAL|Vegetable offering strategy|Either children can decide when to eat their vegetables or parents initiate a moment.
224209305|NCT03771768|RADIATION|Diode laser 980nm&100 mWatt|Diode laser 980 nm \&100 milli Watt.
224209306|NCT03771768|DRUG|Triamcinolone Acetonide|0.1 \&5gm paste 4 times/day
224209307|NCT06543134|PROCEDURE|surgery|ENT surgery lasting more than half an hour
224209308|NCT06543134|PROCEDURE|sedation scale|Measurement of postoperative recovery with the Richmond agitation scale and the Riker sedation scale
224209309|NCT06156761|DRUG|Mitoxantrone hydrochloride liposome|Drug: Mitoxantrone hydrochloride liposome (16 mg/m\^2, 18 mg/m\^2, 20 mg/m\^2 and 22 mg/m\^2) will be administered by intravenous infusion on day 1 in a 3-week treatment cycle.
224323218|NCT03779854|RADIATION|Total-Body Irradiation|Undergo TBI
223619571|NCT05917912|DRUG|Amitriptyline Hydrochloride|hydrogel bottle of ATX01 15% , 0,5ml (1pump) per hand, 1ml (2 pumps) per feet during 3 weeks
223619572|NCT05917912|DRUG|Placebo|hydrogel bottle of placebo , 0,5ml (1pump) per hand, 1ml (2 pumps) per feet during 3 weeks
224209310|NCT06156761|DRUG|Capecitabine|Capecitabine (1000 mg/m\^2) will be administered orally in a 3-week treatment cycle, twice a day from day 1 to day 14 of each cycle.
224323219|NCT03779854|DRUG|Thiotepa|Given IV
223619573|NCT03422029|DRUG|177Lu-Dotatate PRRT|"PRRT using 177Lu-Dotatate 100-150mCi will be performed 8-weekly. A maximum of 8 cycles will be administered.~Other: Amino-Acid Solution The Amino-Acid Solution (AAS) to be used in this study, infused over 4-6 h, starting 30 min before PRRT"
223619574|NCT01893801|DRUG|nab-paclitaxel|25 mg/m2 given intravenously (IV) on days 1 and 8 of a 21 day cycle
224209311|NCT06156761|DRUG|Mitoxantrone hydrochloride liposome|Mitoxantrone hydrochloride liposome (16 mg/m\^2, 18 mg/m\^2, 20 mg/m\^2 and 22 mg/m\^2) will be administered by intravenous infusion on day 1 in a 4-week treatment cycle.
224209312|NCT06156761|DRUG|Capecitabine|Capecitabine (825 mg/m\^2) will be administered orally in a 4-week treatment cycle, twice a day from day 1 to day 21 of each cycle.
224209313|NCT00266461|DRUG|Daikenchuto Extract Granules (TU-100)|
224209314|NCT04113564|DRUG|Remimazolam|
224209315|NCT00684216|DRUG|capecitabine|200 mg, BID, PO, QD until progression of disease
224209316|NCT00684216|DRUG|hormonal treatment (tamoxifen, exemestane, anastrozole or letrozole)|either tamoxifen or aromatase inhibitor (exemestane, anastrozole or letrozole), QD, until progression of disease
224209317|NCT01289990|DRUG|BI 10773|BI 10773 tablets once daily
224209318|NCT01289990|DRUG|Placebo|Placebo matching BI 10773 low dose
224323220|NCT03779854|DRUG|Fludarabine|Given IV
224323221|NCT03779854|DRUG|Cyclophosphamide|Given IV
223773664|NCT05540886|BEHAVIORAL|TEACH CLEAN|"The intervention is primary a training facility cleaning champions to educate and supervise other existing facility cleaners with environmental hygiene responsibilities - training of trainers (ToT).~The training content includes as much as possible the seven contextualized modules of TEACH CLEAN training package (CLEAN BOX): i) Introduction to Infection Prevention and Control, ii) Personal hygiene and dress code, iii) Hand hygiene, iv) Personal protective equipment, v) Housekeeping/control of environment, vi) Waste handling, and vii) Linen handling.~Facility training will occur in three selected wards: i) maternity ward, including labour and post-natal rooms, ii) medicine ward, iii) and medicine ward.~There is also supervision stage that refers to ongoing mentorship of cleaning champions by the local partner while they educate and supervise existing facility cleaners with environmental hygiene responsibilities."
224209319|NCT01289990|DRUG|Placebo|Placebo matching BI 10773 high dose
224209320|NCT01289990|DRUG|Placebo|Placebo matching Sitagliptin
224209321|NCT01289990|DRUG|Placebo|Placebo matching BI 10773 high dose
224209322|NCT01289990|DRUG|Placebo|Placebo matching BI 10773 high dose
224209323|NCT01289990|DRUG|BI 10773|BI 10773 tablets once daily
224209324|NCT01289990|DRUG|Placebo|Placebo matching BI 10773 low dose
224209325|NCT01289990|DRUG|Placebo|Placebo matching BI 10773 low dose
224209326|NCT01289990|DRUG|BI 10773|BI 10773 tablets once daily
224209327|NCT01289990|DRUG|Placebo|Placebo matching BI 10773 low dose
224209328|NCT01289990|DRUG|Placebo|Placebo matching BI 10773 high dose
224209329|NCT01289990|DRUG|Placebo|Placebo matching Sitagliptin
224209330|NCT01289990|DRUG|BI 10773|BI 10773 tablets once daily
224209331|NCT01289990|DRUG|BI 10773|BI 10773 tablets once daily
224209332|NCT01289990|DRUG|BI 10773|BI 10773 tablets once daily
224209333|NCT01289990|DRUG|Placebo|Placebo matching BI 10773 high dose
224209334|NCT01289990|DRUG|BI 10773|BI 10773 tablets once daily
224209335|NCT01289990|DRUG|Placebo|Placebo matching BI 10773 low dose
224209336|NCT01289990|DRUG|Placebo|Placebo matching BI 10773 high dose
224209337|NCT01289990|DRUG|Placebo|Placebo matching Sitagliptin
224209338|NCT01289990|DRUG|Sitagliptin 100mg|Sitagliptin once daily
224209339|NCT01289990|DRUG|BI 10773|BI 10773 tablets once daily
224209340|NCT01289990|DRUG|Placebo|Placebo matching BI 10773 low dose
224209341|NCT01289990|DRUG|Placebo|Placebo matching BI 10773 low dose
224209342|NCT01289990|DRUG|Placebo|Placebo matching BI 10773 low dose
224209343|NCT01289990|DRUG|Placebo|Placebo matching BI 10773 high dose
224209344|NCT01289990|DRUG|Placebo|Placebo matching BI 10773 low dose
224209345|NCT01289990|DRUG|Placebo|Placebo matching BI 10773 high dose
224209346|NCT01289990|DRUG|Placebo|Placebo matching BI 10773 high dose
224209347|NCT03023098|DEVICE|Conventional PTA|After passing the stenosis it is dilated with a conventional balloon. The patient is randomized to a second dilatation with a conventional balloon
224209348|NCT03023098|DEVICE|Drug-eluting balloon|After passing the stenosis it is dilated with a conventional balloon. The patient is randomized to a second dilatation with a drug-eluting balloon
224209349|NCT02296047|DRUG|Placebo|physiological saline
224209350|NCT02296047|DRUG|ipratropium bromide|80 µg inhalation once
224209351|NCT02296047|DRUG|salbutamol|400 µg inhalation once
224209352|NCT04529499|DRUG|AVIGAN|Patients will be randomized to the favipiravir + supportive care group in a 1:1 ratio
224209353|NCT04529499|DRUG|Placebo Comparator|Patients will be randomized to the placebo + supportive care group in a 1:1 ratio
224209354|NCT04234152|OTHER|Photo-protection|The MV solution is delivered from producing companies in amber vials. The MV will be sampled by the pharmacy technician in a syringe that is photo-protected with a white label indicating the subject study name, protocol number and the infusion rate. The MV will be transported to the unit in the same photo-protected syringe. In the neonatal unit, this syringe will be installed in the pump and connected to photo-protected extension duration.
224209355|NCT04234152|OTHER|Standard Care|This group will receive the standard practice of PN compounding in the pharmacy followed by infusion in standard infusion kit available in Sainte-Justine's Hospital.
224209356|NCT04068155|DEVICE|DaRT- Diffusing Alpha-emitters Radiation Therapy|Seed(s) loaded with Radium-224 for local intratumoral irradiation with the destructive power of alpha particles
224209357|NCT01854801|OTHER|Individual medical Care|Individual medical care in occupational and environmental diseases centers
224209358|NCT01854801|OTHER|Individual electromagnetic exposures|During 7 days, patient hold a dosimeter measuring their electromagnetic exposures for FM, TV, GSM, DECT, WIFI, TETRA and relay antenna emissions. During this week, patients notify intensity and time of their symptoms on a self-questionary
224209359|NCT00683904|DRUG|Ixabepilone, 32 mg/m^2 + Carboplatin, 5 mg/min/mL|On Day 1 of each 21-day cycle, ixabepilone, 32 mg/m\^2, intravenous (IV) solution administered as a 3-hour infusion; 30 minutes after the end of ixabepilone infusion, carboplatin, 5 mg/min/mL, intravenous IV solution infused over 30 minutes. Repeated once every 3 weeks, for a maximum of 6 cycles.
224209360|NCT00683904|DRUG|Ixabepilone, 32 mg/m^2 + Carboplatin, 6 mg/min/mL|After all participants in Dose Level 1 (ixabepilone, 32 mg/m\^2 + carboplatin, 5 mg/min/mL) have been observed for 1 full 21-day cycle, Dose Level 2(ixabepilone, 32 mg/m\^2 + carboplatin, 6 mg/min/mL) opened. On Day 1 of each 21-day cycle, ixabepilone, 32 mg/m\^2, IV solution administered as a 3-hour infusion; 30 minutes after the end of ixabepilone infusion, carboplatin, 6 mg/min/mL, IV solution infused over 30 minutes. Repeated once every 3 weeks, for a maximum of 6 cycles.
224209361|NCT04639739|BIOLOGICAL|anti-CD19 CAR NK|2×106 /kg、6×106 /kg、2×107/kg Treatment follows a lymphodepletion, the recommended chemotherapy regimen consists of Fludarabine (30 mg/m2 per day) and Cyclophosphamide (500mg/m2 per day) for 3 days prior to cell infusion，the actual regiment is determined by the statue of patients.
224209362|NCT04289467|DRUG|Fenfluramine|Open-label
224209363|NCT01220037|BEHAVIORAL|Adhere to a specific standardized diet for 4 days|24 h before the start of the intervention all subjects will adhere to a standardized diet for 4 days. Young subjects are randomly allocated to either a low protein diet, regular protein diet or high protein diet group. All elderly subjects will adhere to a regular protein diet comparable to the regular protein diet of the young subjects.
224209364|NCT02507115|BEHAVIORAL|TMAP|Text messages for Alcohol Risk Reduction
223619575|NCT01893801|DRUG|Cisplatin|25mg/m2 (or 50mg/m2) given intravenously (IV) on days 1 and 8 of a 21 day cycle
224209365|NCT02507115|BEHAVIORAL|Mojo Texts|Motivational texts not alcohol related
224209366|NCT03874533|DEVICE|Self-adjustment tests|"For patients with an implant Cochlear™, we will be trained during workshop, to use a tablet how to do some tests ; They will do alone, by themselves the tests, just after the workshop and 8 to 30 days later.~Self audiometric test : digit triplet test, consonants discrimination test, Self-fitting of cochlear implant"
224209367|NCT03109860|BEHAVIORAL|Open-hidden|Administration of a treatment openly (in full view of the patient) vs hidden (without the patient's knowledge).
224209368|NCT00758706|DRUG|AZD1236|oral tablet, 75 mg, twice daily during 6 weeks
224209369|NCT00758706|DRUG|Placebo|Dosing to match AZD1236
224209370|NCT04339361|DRUG|lidocaine spray|four puffs (50 ml, 10 mg/puff) of lidocaine spray before tenaculum placement plus vaginal placebo 3 hours before IUD insertion
224209371|NCT04339361|DRUG|vaginal dinoprostone|vaginal dinoprostone 3 mg will be given 3 hours before IUD insertion plus four puffs of saline spray before tenaculum placement
224209372|NCT04339361|DRUG|placebo|vaginal placebo will be given 3 hours before IUD insertion plus four puffs of saline spray before tenaculum placement
224209373|NCT04816162|DRUG|ketofol|prepared in a ratio of (1:4) respectively), where 1ml of ketamine will be added to 20 ml of propofol in a syringe pump
224209374|NCT04816162|DRUG|dexmedetomidine|2 ml (200 µg) of dexmedetomidine added to 0.9% normal saline in a syringe pump
224209375|NCT04816162|OTHER|normal saline|normal saline 0.9% in a syringe pump
224209376|NCT03611751|DRUG|BMS-986165|Specified dose on specified days
224209377|NCT03611751|OTHER|Placebo|Specified dose on specified days
224209378|NCT03611751|DRUG|Apremilast|Specified dose on specified days
224209379|NCT05224518|BEHAVIORAL|elastic band training|elastic band training include stretching exercises
224209380|NCT01460121|DEVICE|SpotOn's corrective elements for dizziness|Eyeglasses with dizziness correction elements (real SpotOn eyeglasses) or eyeglasses with placebo (sham eyeglasses) elements will be worn during the whole four weeks study period.
224209381|NCT01460121|DEVICE|Placebo|
224209382|NCT04239638|DIAGNOSTIC_TEST|Cervical Spinal MRI|Cervical Spinal MRI images of 500 patients will be entered into the system for modeling
224209383|NCT06315725|OTHER|Sweet taste perception with/without sweet taste blockade|In our study, we will use our four different novel flavored beverages, with and without a sweet taste blockade.
224209384|NCT01855100|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Starting dose (3 weeks): 15 mg BID, then 15 mg OD or 20 mg OD.
224209385|NCT03467971|DRUG|Metformin/Gliclazide Fixed Combination|Participants will receive single oral dose of Metformin 1000 mg and Gliclazide 30 mg fixed combination tablet in fasting or fed state.
224209386|NCT06542211|BEHAVIORAL|Intervention plan for improving ankle dorsiflexion limitation group (experimental group)|The experimental group received intervention and rehabilitation training directly for the limited ankle dorsiflexion function, which mainly included subtalar joint loosening (increasing the joint activity space), plantar flexor muscle group relaxation (releasing the tension of antagonist muscles), ankle dorsiflexor muscle strengthening (enhancing the strength of agonist muscles), and integrated exercises (integrating ankle dorsiflexion function into gait training).
224209387|NCT06542211|BEHAVIORAL|Plantar fasciitis routine rehabilitation group|The experimental group received intervention and rehabilitation training directly for the limited ankle dorsiflexion function, which mainly included subtalar joint loosening (increasing the joint activity space), plantar flexor muscle group relaxation (releasing the tension of antagonist muscles), ankle dorsiflexor muscle strengthening (enhancing the strength of agonist muscles), and integrated exercises (integrating ankle dorsiflexion function into gait training).
224209388|NCT03791619|DEVICE|Higher Cylinder Toric IOL|Symfony Toric models ZXT300 and ZXT375 IOL
224209389|NCT03791619|DEVICE|Lower Cylinder Toric IOL|Symfony Toric model ZXT150 IOL
224209390|NCT05413902|DRUG|Toradol|Provide this drug as part of a multimodal pharmacologic regimen for pain management including multiple drugs mentioned in the group description.
224323222|NCT03779854|DRUG|Busulfan|Given IV
223619576|NCT01893801|DRUG|gemcitabine|1000mg/m2 given intravenously (IV) on days 1 and 8 of a 21 day cycle
224209391|NCT05413902|DRUG|Morphine|Provide the standard postoperative morphine dose for pain management as part of the traditional opioid-based pain management regime.
224209392|NCT05413902|DRUG|Orphenadrine|Provide this drug as part of a multimodal pharmacologic regimen for pain management including multiple drugs mentioned in the group description.
224209393|NCT05413902|DRUG|Gabapentin|Provide this drug as part of a multimodal pharmacologic regimen for pain management including multiple drugs mentioned in the group description.
224209394|NCT05413902|DRUG|Acetaminophen|Provide this drug as part of a multimodal pharmacologic regimen for pain management including multiple drugs mentioned in the group description.
224209395|NCT05413902|DRUG|Bupivacaine|Provide this drug as part of a multimodal pharmacologic regimen for pain management including multiple drugs mentioned in the group description.
224209396|NCT05413902|DRUG|Epinephrine|Provide this drug as part of a multimodal pharmacologic regimen for pain management including multiple drugs mentioned in the group description.
224209397|NCT05413902|DRUG|Xylocaine Injectable Solution|Provide this drug as part of a multimodal pharmacologic regimen for pain management including multiple drugs mentioned in the group description.
224323223|NCT03779854|PROCEDURE|Allogeneic Bone Marrow Transplantation|Receive unmanipulated T cell replete BM
224323224|NCT03779854|DRUG|Tacrolimus|Given IV
223619577|NCT03489863|DRUG|Prasugrel|Maintenance dose will be maintained for 10±3 days.
223619578|NCT03489863|DRUG|Ticagrelor|Maintenance dose will be maintained for 10±3 days.
223619579|NCT01045486|DRUG|ATP mixed probiotics|\- Patients in Group A will receive ATP mixed probiotics for 6 weeks. And after 4 weeks wash-out period, they will receive placebo for 6 weeks
223619580|NCT01045486|DRUG|Placebo|\- Patients in Group B will receive placebo for 6 weeks. And after 4 weeks wash-out period, they will receive ATP mixed probiotics for 6 weeks
224323225|NCT03779854|DRUG|Methotrexate|Given IV
224323226|NCT03779854|PROCEDURE|Naive T Cell-Depleted Hematopoietic Stem Cell Transplantation|Receive naive T-cell depleted PBSCs
224323227|NCT03779854|PROCEDURE|Echocardiography|Undergo ECHO
224315770|NCT02777398|PROCEDURE|Trans-Quadrant Channel Surgery|Patients in the experimental group will be general anaesthetized and placed in the prone position. Intra-operational electrophysiological monitoring will be used. Kirschner wire will be used to identify the position of the Quadrant channel with X-ray. After disinfection and draping, an incision of 3cm long and 2-3cm lateral to midline on the tumor side will be made. Soft tissues will be separated. Graded dilators will be used to establish Quadrant channel. Kerrison clamps will be used to expose the very local posterior spinal structures. Vertebral plate will be windowed with power drill to expose dural mater, and tumors will be removed with microsurgical techniques. Hemostasis will be performed after resection. Dural mater will be closed by titanium clips, and close incision by layers.
224315771|NCT02777398|PROCEDURE|Conventional Open Surgery|Patients in the control group will be general anaesthetized during operation and placed in the prone position. Intra-operational electrophysiological monitoring will be used. Surgeons will locate the lesion by X-ray. After disinfection and draping, the midline incision of 7-10 cm and centered by the lesion segment will be made. Soft tissues will be cut and separated to expose posterior structure of spine. The root of spinal process and half of the vertebral plate on tumor side of certain segments will be removed. The dural mater will be opened. Then surgeons will remove tumor with microsurgical techniques. Hemostasis will be precisely performed after resection, and dural mater will be closed by suturing. Incision will be closed by layers. Drainage would be placed if necessary.
224315772|NCT02125721|DRUG|Tiopronin 1g per day|500mg PO BID x 7 days
224315773|NCT02125721|DRUG|Tiopronin 2g per day|1g PO BID x 7 days
224315774|NCT02125721|DRUG|Tiopronin 3g per day|1.5g PO BID x 7 days
224315775|NCT01128608|PROCEDURE|24-Hr Esohpageal pH Monitoring|There will be a 24-hr pH monitoring procedure and two 10-minute infusions each one week apart consisting of high PCO2 solution and 0.1 N HCI solution.
224315776|NCT01128608|PROCEDURE|PCO2 Acid Perfusion and 0.1N HCI Perfusion|A small tube will be inserted through the nostril and into the esophagus. A mild CO2 solution or a mild saline solution will be administered for aprox. 10 minutes during which you will be asked questions regarding any symptoms you may experience.
224315777|NCT00431483|BEHAVIORAL|pharmaceutical consulting|to measure if information and advice by a pharmacist has an impact on quality and quantity of prescribed antibacterials
224315778|NCT01653912|DRUG|GSK2110183 in combination with carboplatin and paclitaxel|Phase I is a dose escalation evaluation of increasing doses of GSK2110183 administered on a continuous daily schedule in combination with carboplatin AUC 5 and paclitaxel 175mg/m2 given every three weeks for a maximum 6 cycles. The dosing regimen identified in Phase I will then be evaluated in Phase II, a single arm study focused on clinical efficacy. Treatment with the three drug regimen will continue for a maximum of 6 x 21 day cycles followed by continuous GSK2110183 at the single agent MTD. Subjects may continue on study drug until progression, death or unacceptable toxicity.
224315779|NCT03309527|BEHAVIORAL|e-aid Cognitive Behavior Therapy|e-aid Cognitive Behavior Therapy
223761524|NCT06908122|DIAGNOSTIC_TEST|laboratory biomarkers in the diagnosis of NAFLD disease|"All included patients will be assessed as follows:~1\. Questionnaire: different questionnaire variables extrapolated from study published by Xin Li, 2024, Bao et al., 2024 (8), (9).The questionnaire will be divided into six parts: First section includes demographic characteristics of patients as (name , age, gender, occupation, educational level and special habits) The second section includes chronic diseases-related questions and drug administration as if a patient were diagnosed with chronic disease, on treatment and drugs used.~The third section for assessment of dietary lifestyle includes:~nutrition adherence to Mediterranean will be assessed by a validated 17-item MedDiet adherence questionnaire, which all participants will answer. A score will be given for each met objective: 1 (compliance) or 0 (non-compliance).~The counseling session will be about the Mediterranean diet program, and a brochure will be given to each patient."
223761525|NCT06908200|DEVICE|Radiofrequency therapy|Radiofrequency or myofascial manual therapy sessions including the abdominal region, the vulva and pelvic floor tissue and Thiele massage done daily by the patient at home
224209398|NCT05413902|DRUG|Methylprednisolone|Provide this drug as part of a multimodal pharmacologic regimen for pain management including multiple drugs mentioned in the group description.
224209399|NCT01966341|BEHAVIORAL|CBT/ Hypnotherapy|The CBT program will consist of 7 sessions that will encompass the following skills of Symptom monitoring, Stress Management, Coping Skills, Relaxation training, Problem solving, and Cognitive Restructuring.The hypnotherapy program will be modeled after the North Carolina Standardized Hypnosis Treatment for Irritable Bowel Syndrome
224209400|NCT01966341|DRUG|Routine Management|Treatment with use of antispasmodics,laxatives, and/or bulking agents (fiber) +/- antibiotics.
224209401|NCT06018246|DIETARY_SUPPLEMENT|Malnutrition five-step treatment model + conventional nutritional intervention|"1. Before operation：Same as arm description.~2. After operation:Same as control group.~3. Out-of-hospital: Same as before operation.~4. Strengthening Health Education and psychological intervention:Dietitians need to strengthen health education and communicate with patients during the implementation of nutrition intervention.For patients who actively cooperate with treatment, dietitians can give encouragement.~5. Exercise Instruction:After the operation, according to the tolerance, the dietitian can instruct the patient to take a certain time walking every day, gradually increase the patient's muscle endurance and improve the body resistance."
224315780|NCT03309527|BEHAVIORAL|e-aid Sleep Hygiene Education|e-aid Sleep Hygiene Education
224315781|NCT03408639|DRUG|CinnaPoietin®|The starting dose of Erythropoietin is 60 (50-100) IU/kg body weight/week for naïve patients. Administration dose for patients who are treated with erythropoietin is similar dose of previously administered amount (IV or SC without any change). After then, dose adjustment will be done based on patients' response.
224315782|NCT03408639|DRUG|Eprex®|The starting dose of Erythropoietin is 60 (50-100) IU/kg body weight/week for naïve patients. Administration dose for patients who are treated with erythropoietin is similar dose of previously administered amount (IV or SC without any change). After then, dose adjustment will be done based on patients' response.
224315783|NCT03408639|DRUG|Nephrovit|Nephrovit tablet is daily administered to all the patients.
224315784|NCT03408639|DRUG|Vitamin B12 Injection|Vitamin B12 is monthly injected to all the patients.
224315785|NCT06179654|BEHAVIORAL|Preoperative pelvic floor physical therapy|Pelvic floor physical therapy to start before prostate surgery rather than after surgery.
224323228|NCT03779854|PROCEDURE|Biospecimen Collection|Undergo CSF and blood sample collection
224323229|NCT03779854|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
224209402|NCT06018246|OTHER|Conventional nutritional intervention|Routine nutrition support in department.Nutritionists will give patients routine parenteral nutrition support via peripheral or central vein 0-48 hours after surgery and then start enteral nutrition support 48-72 hours after surgery.Patients were initially given half of their enteral nutrition and the rest was supplemented with parenteral nutrition.After adaptation, the patient stopped parenteral nutrition and all nutrition came from enteral nutrition.After the patient's gastrointestinal function gradually recovered, the enteral nutrition could gradually decrease.At this time, nutritionists can let the patient eat some light liquid food, but pay attention to eating a small amount of multiple times.After adaptation, patients can gradually transition from liquid diet to semi-liquid diet.We will educate patients and their families about diet and encourage them to eat more high-quality protein-rich foods.
224209403|NCT04711122|DRUG|Third generation cephalosporin antibiotics|Assessment of antibiotic effect
224209404|NCT02253407|BIOLOGICAL|MMR vaccine|
224315786|NCT05877716|DEVICE|Cognitive and Social Cognitive Training|"The Cognitive Training Module is designed to improve the speed and accuracy of auditory information processing while engaging working memory and cognitive control under conditions of close attention and reward. The goal is to increase the effectiveness by which salient stimuli engage and drive plastic changes in brain systems that in individuals with psychosis exhibit relatively poor temporal response.~The Social Cognition Training Module consists of exercises designed to ameliorate core deficits in social cognition expressed in schizophrenia and Autism Spectrum Disorders. The exercises apply principles of implicit learning to restore the brain's capacity to process and utilize socially-relevant information, and include training to improve affect perception, social cue perception, theory of mind, self-referential style, and emotion labeling and working memory."
224315787|NCT05877716|BEHAVIORAL|Personalized Real-Time Intervention for Motivational Enhancement (PRIME) App|The PRIME smartphone-based app is designed to be used for 12 weeks to enhance motivation in people with early psychosis. Participants work towards self-identified goals with the support of the virtual community of age-matched peers, as well as with motivation coaches. Participants discuss their interests and aspirations with each other and with their coach, and the coach sends daily individualized motivational messages. Coaches also provide tailored interventions to enhance motivation, and post daily discussion topics to the PRIME community to encourage interaction between members. Coaches will maintain close communication and feedback on progress with each individual's clinical team.
224315788|NCT05877716|OTHER|Early Psychosis Coordinated Specialty Care|Participants will continue to engage in treatment as usual at their early psychosis coordinated specialty care clinic. These clinics may follow the NAVIGATE model, as an example.
224315789|NCT05041829|OTHER|Dietary sodium|Low sodium diet with sodium of \<2.3 g/day (\<100 mmol/day) and high sodium diet with sodium of ≥4 - \<6 g/day (≥174 - \<261 mmo/day)
224315790|NCT00894829|BIOLOGICAL|heparin sodium - Eurofarma|Heparin sodium 5.000 UI - Eurofarma
224315791|NCT00894829|BIOLOGICAL|heparin sodium - APP|Heparin sodium APP 5.000 USP
224315792|NCT01810510|PROCEDURE|PAV Ventilation|PAV is a mode of ventilation in which the only set parameter is the proportion of work/effort that is provided regardless of the ventilatory pattern the patient chooses- the patient has full control over pressure, volume, flow and time of inspiration as well as respiratory rate. In this mode, the ventilator measures patient respiratory mechanics every 10-15 breaths and delivers a level of pressure proportional to patient effort, thereby maintaining a set proportion of patient effort regardless of the patient's ventilatory pattern. The patients will be on this mode of ventilation for 60 minutes.
224315793|NCT01810510|PROCEDURE|NAVA Ventilation|With NAVA, delivery from the ventilator is triggered, controlled and cycled by the diaphragmatic EMG signal (Edi), which is measured by a specially designed nasogastric or orogastric catheter (NGT or OGT) containing EMG electrodes that cross the diaphragm. In this mode, the ventilator measures the Edi with each breath and instantaneously delivers a level of pressure proportional to Edi magnitude, thereby providing a set proportion of effort on a breath-to-breath basis. The patients will be on this mode of ventilation for 60 minutes.
224315794|NCT02245412|BIOLOGICAL|ALXN1007 10 mg/kg once weekly|ALXN1007 is a recombinant humanized monoclonal antibody that binds to complement component C5a and its metabolite C5a desArg.
224315795|NCT02245412|BIOLOGICAL|ALXN1007 20 mg/kg once weekly|ALXN1007 is a recombinant humanized monoclonal antibody that binds to complement component C5a and its metabolite C5a desArg.
224315796|NCT02245412|BIOLOGICAL|ALXN1007 20 mg/kg twice weekly|ALXN1007 is a recombinant humanized monoclonal antibody that binds to complement component C5a and its metabolite C5a desArg.
224315797|NCT00001526|DRUG|Daclizumab (Zenapax)|
224209405|NCT00005609|BIOLOGICAL|rituximab|
224209406|NCT04717869|DIAGNOSTIC_TEST|Ultrasound|2D ultrasound image collection
224209407|NCT04717869|DIAGNOSTIC_TEST|Biomarker Analysis|Inflammatory and nutritional biomarker analysis
224209408|NCT04717869|OTHER|Frailty Index|A Frailty Index Questionnaire be completed by patients or their surrogates to determine the presence of frailty at ICU admission
224209409|NCT04593589|OTHER|Submandibular Gland Stem Cell Transplantation|Autologous transplantation of salivary stem cells (salisphere derived cells) cultured in vitro as obtained from submandibular glands after postoperative radiotherapy
224209410|NCT06150872|DEVICE|DurVena Photochemical Tissue Passivation|Treatment of a saphenous vein graft with the DurVena Photochemical Tissue Passivation device.
224315798|NCT03293316|DEVICE|Transcranial Random Noise Stimulation|The transcranial random noise stimulation was delivered using a StarStim device (Neuroelectrics®, Barcelona, Spain). The electrodes were encased in a pair of saline-soaked sponges (25 cm2 ), and were secured within a Neurolectrics EEG cap over right DLPFC (F4) and right IPL (P4), according to the 10-20 international EEG system. Other details are stated under the 'intervention arm' descriptions.
224315799|NCT02593643|DRUG|Ketamine|
224315800|NCT02593643|DRUG|Midazolam|
224323230|NCT03779854|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
224323231|NCT01546987|DRUG|GnRH agonist|LHRH agonists are administered with a variety of techniques. The manufacturer's instructions should be followed. Begins within 6 weeks after registration (if not started prior) at same time as anti-androgen and TAK-700 (if applicable).
223761526|NCT06908200|OTHER|myofascial manual therapy|Myofascial manual therapy sessions including the abdominal region, the vulva and pelvic floor tissue and Thiele massage done daily by the patient at home
224209411|NCT05633901|OTHER|Educational Video|Patients will be given the link to the educational video and able to view it as many times as they want
224323232|NCT01546987|DRUG|Anti-androgen|Starts at same time as GnRH agonist, ends at end of radiation therapy. Either flutamide (orally 250 mg three times a day) or bicalutamide (orally 50 mg once a day).
223619581|NCT04907734|OTHER|Caliper|Description of the sample adipose tissue and skinfolds using different calipers.
223619582|NCT02984488|PROCEDURE|single visits|Endodontic treatment is done and completed in a single visit using protaper next rotary system.
224209412|NCT05633901|OTHER|Standard Counseling|Current standard of care verbal counseling from a clinic nurse
224209413|NCT06033703|DRUG|Netarsudil Ophthalmic|Topical administration of Netarsudil
224209414|NCT04974593|OTHER|low fat diet|A trained dietitian will provide instruction of the LFD according to standard practice.
224209415|NCT03145558|DRUG|Tirapazamine|Replacing the standard chemotherapy agent doxorubicin used in TACE with tirapazamine
224209416|NCT03145558|DRUG|Doxorubicin|Standard of care for TACE
224209417|NCT04446117|DRUG|Cabozantinib|Supplied as 20-mg tablets; administered orally daily at 40mg
224209418|NCT04446117|DRUG|Atezolizumab|Supplied as 1200 mg/20 mL vials; administered as an IV infusion once every 3 weeks (q3w)
224209419|NCT04446117|DRUG|Abiraterone Acetate|Supplied as 500 mg tablets; administered orally daily at 1000mg with prednisone 5 mg orally bid
224209420|NCT04446117|DRUG|Enzalutamide|Supplied as 40 mg capsules; administered orally daily at 160mg
224209421|NCT04446117|DRUG|Prednisone|Supplied as 5 mg tablets; administered orally bid at 5 mg with abiraterone 1000mg orally daily
224209422|NCT04166851|BEHAVIORAL|PrEP campaign messages developed via open contest|PrEP campaign messages will be developed via an open contest in Baltimore.
224209423|NCT04166851|BEHAVIORAL|PrEP campaign messages developed via social marketing approach|PrEP campaign messages developed with a traditional social marketing approach.
224209424|NCT03203265|OTHER|Group A: Offline HTC|Offline or online referral to HIV treatment facility HIV-positive participants can choose to receive either an offline or online referral to HIV treatment facilities. An offline referral method usually includes a referral letter and/or a telephone call, followed by a series of calls to participants to ensure successful referral. Those who choose an online referral will be able to register online with an HIV treatment facility which provides ART without cost under the national programs. Participants will receive a registration code which will allow them to access HIV treatment clinics directly without the need to go through the regular registration and appointment system at that facility.
224209425|NCT03203265|OTHER|Group B1: Offline HIV testing and post-test counseling|participants will be guided to access services at the 'Adam's Love Offline Clinic,' a clinic set up specifically to provide private and fast HIV testing and post-test counseling only referred from the Adam's Love Online Clinic.
224209426|NCT03203265|OTHER|Group B2: Online HIV testing and post-test counseling|A trained online counselor will guide the participant through an online HIV testing process which includes quality checking of the test kit,obtaining blood through finger prick,performing the testing steps,reading the test result. A positive result from the first test will trigger the need for referral to confirmatory tests. The provisional nature of the positive result from the single rapid HIV test will be emphasized but the urgency to get immediate confirmatory tests and linkage to HIV treatment facilities will encouraged and supported. HIV positive test result will be confirmed only with three positive tests. Any online testing session with uncertain qualities at any step will be repeated at a later time or the participant will be offered offline HIV testing.
224209427|NCT02300194|DRUG|Topic Morphine|Topical application of a 0.1% morphine gel in patients undergo a procedure. It will be applied 30 minutes before the procedure and the first day every 4 hours. General basic sedation and systemic analgesia will give for all the patients. Efficacy of treatment will be measured with FLACC scale.
224209428|NCT02300194|DRUG|Placebo|Topical application of a placebo hydrogel in patients undergo a procedure. It will be applied 30 minutes before the procedure and the first day every 4 hours. General basic sedation and systemic analgesia will give for all the patients. Efficacy of treatment will be measured with FLACC scale.
224209429|NCT03278483|DRUG|Isoniazid 300 mg Oral Tablet|Isoniazid tablets 300mg daily plus pyridoxine 50mg daily
224209430|NCT03278483|DRUG|Rifampin 600 mg Oral Tablet|Rifampin capsules 600mg daily
224209431|NCT06566755|DRUG|Cadonilimab (AK104) combined with chemotherapy and bevacizumab|"Participants receive Cadonilimab PLUS chemotherapy and bevacizumab of each 21-day cycle.~Treatment period (4-8 cycles)：~* Cadonilimab: 10mg/kg, intravenous infusion, D1, Q3W;~* CapeOx chemotherapy regimen Q3W+ bevacizumab, Q3W:~oxaliplatin: 130 mg/m2 intravenous infusion, D1, Q3W; capecitabine: 850 mg/m2 orally, D1-14, Q3W, twice daily; bevacizumab injection: 7.5mg/kg, IV, D1, Q3W. Maintenance treatment period：~* Cadonilimab: 10mg/kg, administered D1, Q3W;~* capecitabine: 1000 mg/m2 orally, D1-14, Q3W, twice daily;~* bevacizumab injection: 7.5mg/kg, IV, D1, Q3W."
224209432|NCT03311217|BEHAVIORAL|Healthy retail strategies|
224209433|NCT01666067|DRUG|placebo|
224209434|NCT01666067|DRUG|vytorin|
224323233|NCT01546987|DRUG|TAK-700|300 mg twice daily (BID) (600 mg per day) orally, continuously for 2 years starting with ADT.
223619583|NCT02984488|PROCEDURE|two visits|Endodontic treatment is done and completed in two visits using protaper next rotary system.
223619584|NCT01290107|GENETIC|DNA analysis|
223619585|NCT01290107|GENETIC|gene rearrangement analysis|
223619586|NCT01290107|GENETIC|microarray analysis|
223619587|NCT01290107|GENETIC|polymerase chain reaction|
223619588|NCT01290107|OTHER|immunological diagnostic method|
223619589|NCT01290107|OTHER|laboratory biomarker analysis|
223761527|NCT06908915|DEVICE|Nd:YAG laser 1064 nm|The entire face of each patient with rosacea was treated with long-pulse 1064nm Nd:YAG laser. The parameters that been used were spot size: 5mm, fluence: 4.07 J/Cm2, energy: 800 mJ and frequency: 5 Hz. About 2-3 passes performed in each treatment session. Up to four sessions were performed for each patient with 2 weeks interval.
224209435|NCT01666067|DRUG|simvastatin|
224209436|NCT01278446|OTHER|Extensively hydrolyzed, whey protein infant formula|New hydrolyzed formula
224209437|NCT01278446|OTHER|Extensively hydrolyzed, casein protein infant formula|Commercially available hydrolyzed infant formula
224209438|NCT05052879|DRUG|Toronto association|Toronto association coated tablet, 20 mg + 30 mg or 20 mg + 60 mg, oral, 2 hours before the sexual intercourse.
224209439|NCT05052879|DRUG|Tadalafil|Tadalafil coated tablet, 20 mg, oral, 2 hours before the sexual intercourse.
223619590|NCT02718521|PROCEDURE|Hydration Combined With Intravenous Infusion of Isosorbide Dinitrate|Before the coronary procedures, investigators used the same 0.9% sodium chloride for hydration conbined with isosorbide dinitrate in all patients 6 hours before angiography and 12 hours after angiography
223619591|NCT02718521|DRUG|Visipaque|All study participants received intra-arterial (320 mg I/ml; GE Healthcare)
223619592|NCT02718521|DRUG|0.9% sodium chloride ﬂuid administration|
224209440|NCT05052879|OTHER|Tadalafil placebo|Tadalafil placebo coated tablet, oral, 2 hours before the sexual intercourse.
224209441|NCT05052879|OTHER|Toronto association placebo|Toronto association placebo coated tablet, oral, 2 hours before the sexual intercourse.
224209442|NCT06113783|DEVICE|HYALUBRIX 60|1.5% solution of non-modified HA (60mg/4ml) obtained from bacterial fermentation with high molecular weight.
224209443|NCT04923906|DRUG|Aumolertinib|"Aumolertinib 110 mg QD in combination with pemetrexed (500 mg/m2) plus cisplatin (75 mg/m2) or carboplatin (AUC5) on Day 1 of every 21-day cycles up to 4\~6 cycles, followed by Aumolertinib 100mg QD with pemetrexed maintenance (500 mg/m2) on Day 1 of every 21-day cycles.~Dose may be reduced to allow for the management of investigational drug related toxicity."
224209444|NCT04923906|DRUG|Placebo Aumolertinib|Placebo Aumolertinib 110 mg QD Dose may be reduced to allow for the management of investigational drug related toxicity.
224209445|NCT05510856|OTHER|Duloxetine|Duloxetine 30mg / day for 12 cycles (up to 6 months)
224209446|NCT05510856|OTHER|Gabapentin|Gabapentin 300 mg / day for 12 cycles (up to 6 months)
224209447|NCT05510856|OTHER|Lacosamide|Lacosamide 50 mg / day for 12 cycles (up to 6 months)
224209448|NCT04946071|BEHAVIORAL|Arts-based HIV stigma intervention|The intervention will consist of 2-hour weekly sessions offered to students in participating schools. HIV-related stigma will be addressed by providing key information related to HIV and stigma, facilitating the acquisition of coping skills, and utilizing local cultural practices facilitated by Elders using creative methods to shift existing social and cultural norms that produce and perpetuate stigmatization. Specific intervention activities will include three interrelated activities. The core 2-hour weekly session will cover (1) transformative educational activities; (2) arts-based activities; (3) a summative activity consisting of (3) participatory theatre activites.
224209449|NCT00881049|DRUG|Imatinib (Gleevec)|Imatinib will be given for enrolled patients to investigate efficacy and safety
224209450|NCT01488071|DRUG|Vortioxetine (Lu AA21004)|encapsulated tablets, daily, orally
224209451|NCT01488071|DRUG|Agomelatine|encapsulated tablets, daily, orally
224209452|NCT03953911|BIOLOGICAL|Mobile Clinic|This intervention involves the availability of a free mobile clinic operated by Cedar-Sinai Medical Center providing free HPV vaccinations at school campuses.
224209453|NCT03953911|BEHAVIORAL|Educational Sessions for Parents|This intervention involves providing free weekly educational sessions for parents of students at the participant schools pertaining to the HPV Vaccination.
224209454|NCT01361698|BEHAVIORAL|Illness Management and Recovery (IMR)|In this Danish trial IMR will be implemented in group format with 10 patients assigned to each group and two IMR facilitators, and the IMR program will require nine months of weekly sessions to complete.
224209455|NCT05224297|RADIATION|external beam photon therapy|Patients receive external beam photon therapy for different tumor locations (groups).
224209456|NCT05819645|BEHAVIORAL|Fluid intake not as per standard guidlines|The participant will be randomized into two arms. After the randomization one arm will get the per os fluid intake before the standard time frame.
224209457|NCT05789420|OTHER|P1R stick|Regular flavor tobacco stick
224209458|NCT05789420|OTHER|P1M stick|Mentholated flavor tobacco stick
224209459|NCT05789420|OTHER|CIG|Subjects' preferred brand of commercially available, regular or mentholated cigarettes
224209460|NCT04699721|DRUG|nivolumab 4.5mg/kg+Paclitaxel (albumin-bound type) 260mg / m2+ Carboplatin AUC5|3 cycles of nivolumab+Paclitaxel (albumin-bound type)+ Carboplatin AUC5 (21 days/cycle); as well as BiFico (oral taking, 4 capsules/time, 2 times per day)
224209461|NCT04234516|DRUG|Buprenorphine/Naloxone 8/2 milligram (mg) Sublingual Film|3 x 8 mg sublingual buprenorphine/naloxone films wrapped inside one Listerine strip at 8 pm daily + oral placebo pills q.i.d.
224209462|NCT04234516|DRUG|Morphine Sulfate 30 mg|oral morphine sulphate 30 mg immediate release tablets q.i.d. + two sublingual Listerine strips at 8 pm
224209463|NCT02587325|DRUG|nab-sirolimus|nab-sirolimus is an mTOR inhibitor
224209464|NCT06235125|DRUG|Cytalux|Folate analog ligand conjugated with an indole cyanine-like green dye as a solution in vials containing 3 mL at 2 mg/mL
224209465|NCT01029080|OTHER|no interventions|No interventions
224209466|NCT01220128|BIOLOGICAL|GSK Biologicals' recombinant WT1 Antigen-Specific Cancer Immunotherapeutic (ASCI) GSK2302024A|6 or 8 injections at 3 weeks apart, injected intramuscularly in the deltoid or lateral region of the thigh.
224209467|NCT01220128|DRUG|Placebo|6 or 8 doses at 3 weeks apart of sucrose/mannitol-based formulation reconstituted with an oil-in-water emulsion, injected intramuscularly in the deltoid or lateral region of the thigh.
224209468|NCT01220128|DRUG|Aromatase inhibitor|This treatment consisted of any aromatase inhibitor (e.g. letrozole or exemestane), administered intravenously in Cohort A Groups daily for either 18 (if 6 doses of WT1 ASCI/placebo) or 24 weeks (if 8 doses of WT1 ASCI/placebo).
224209469|NCT01220128|DRUG|5-Fluorouracil|Administered intravenously in Cohorts A Placebo, B, C and D/E Groups: for the 6 WT1 ASCI-dose schedule 3 doses at 3 weeks apart, and for the 8 WT1 ASCI-dose schedule 4 doses at 3 weeks apart. For Cohorts A Placebo, B and C Groups, the administration was on the same day as the administration of WT1 ASCI/placebo (Day 1 of each cycle). For Cohort D/E Groups, the administration was on Day 14 of each cycle.
223619593|NCT02718521|DRUG|isosorbide dinitrate|
223619594|NCT03255239|PROCEDURE|Ventral hernia repair|Hernia repair is a surgical procedure to return an organ that protrudes through a weak area of muscle to its original position.
223619595|NCT04273607|DRUG|Subcutaneous Heparin|The intervention group will receive prophylactic heparin instead of standard of care therapeutic intravenous heparin
224209470|NCT01220128|DRUG|Carboplatin AUC|Administered intravenously in Cohort C Groups in 6 doses at 3 weeks apart, on the same day as WT1 ASCI/placebo administration (Day 1 of each cycle).
224209471|NCT01220128|DRUG|Cyclophosphamide|Administered intravenously in Cohorts A Placebo, B, C and D/E Groups: for the 6 WT1 ASCI-dose schedule 3 doses in Cohort C Groups and 6 doses 3 weeks apart in Cohorts A Placebo, B and D Groups, while for the 8 WT1 ASCI-dose schedule 4 doses at 3 weeks apart. For Cohorts A Placebo, B and C Groups, the administration was on the same day as the administration of WT1 ASCI/placebo (Day 1 of each cycle). For Cohort D/E Groups, the administration was on Day 14 of each cycle.
224209472|NCT01220128|DRUG|Docetaxel|Administered intravenously in Cohorts A Placebo, B, C and D/E Groups: for the 6 WT1 ASCI-dose schedule 3 or 6 doses 3 weeks apart, while for the 8 WT1 ASCI-dose schedule 4 doses at 3 weeks apart. For Cohorts A Placebo, B and C Groups, the administration was on the same day as the administration of WT1 ASCI/placebo (Day 1 of each cycle). For Cohort D/E Groups, the administration was on Day 14 of each cycle.
224209473|NCT01220128|DRUG|Doxorubicin|Administered intravenously in Cohorts A Placebo, B, C and D/E Groups: for the 6 WT1 ASCI-dose schedule 6 doses 3 weeks apart (Cohort C patients with this schedule did not receive this treatment), while for the 8 WT1 ASCI-dose schedule 4 doses at 3 weeks apart. For Cohorts A Placebo, B and C Groups, the administration was on the same day as the administration of WT1 ASCI/placebo (Day 1 of each cycle). For Cohort D/E Groups, the administration was on Day 14 of each cycle.
224209474|NCT01220128|DRUG|Epirubicin|Administered intravenously in Cohorts A Placebo, B, C and D/E Groups: for the 6 WT1 ASCI-dose schedule 3 doses 3 weeks apart, while for the 8 WT1 ASCI-dose schedule 4 doses at 3 weeks apart. For Cohorts A Placebo, B and C Groups, the administration was on the same day as the administration of WT1 ASCI/placebo (Day 1 of each cycle). For Cohort D/E Groups, the administration was on Day 14 of each cycle.
224209475|NCT01220128|DRUG|Paclitaxel|Administered intravenously in Cohorts A Placebo, B, C and D/E Groups: only in the 8 WT1 ASCI-dose schedule patients received 4 at 3 weeks apart or 12 weekly doses. For Cohorts A Placebo, B and C Groups, the administration was on the same day as the administration of WT1 ASCI/placebo (Day 1 of each cycle). For Cohort D/E Groups, the administration was on Day 14 of each cycle.
224209476|NCT01220128|DRUG|Trastuzumab|Administered intravenously in Cohort C Groups: for the 6 WT1 ASCI-dose schedule 3 or 6 doses 3 weeks apart, while for the 8 WT1 ASCI-dose schedule 4 doses at 3 weeks apart. For Cohort B and C Groups, the administration was on the same day as the administration of WT1 ASCI/placebo (Day 1 of each cycle). For Cohort D/E Groups, the administration was on Day 14 of each cycle.
224209477|NCT01273584|DRUG|Metformin|Maximum dosage 500 mg 2 tablets 3 times a day (with each meal) start with 1 tablet twice a day and gradually titrate upwards to maximum dose
224209478|NCT01273584|DRUG|Placebo|Placebo maximum dosage 2 tablets 3 times a day ( with meals) start with 1 tablet twice a day and gradually titrate upwards to maximum dose
224209479|NCT03478774|DRUG|Oxygen 70l/min|HFNCT will be provided using OptiFlow by Fisher\&Paykel.
224209480|NCT03478774|DRUG|Oxygen 10 l/min|Medium flow will be applied with a humidifier (Hudson RCI) and a standard nasal cannula.
224209481|NCT03478774|DRUG|Oxygen 2l/min|Low flow will be applied with a humidifier (Hudson RCI) and a standard nasal cannula.
224209482|NCT03478774|PROCEDURE|Jaw thrust|Continuous
224209483|NCT03478774|PROCEDURE|Videolaryngoscopy|Continuous
224209484|NCT03478774|DRUG|oxygen 0.25l/min|0.25l/min of oxygen via an endotracheal tube
224209485|NCT02390466|BIOLOGICAL|VAC-3S|Administered via intra-muscular injection in the arm
224209486|NCT04931758|OTHER|Pain Questionnaire|Subjects will take the FreBAQ questionnaire at Day 0 and a subgroup of 35 controls and 15 patients will take the same questionnaire at Day 7
224209487|NCT00826722|DRUG|Levetiracetam|1000 mg tablet
224209488|NCT06543004|COMBINATION_PRODUCT|AH plus sealer|Root canal sealer will be placed inside the root canals during obturation procedure to seal dentine wall and reinforce the remaining tooth tissue.It will be selected randomly to the study samples.
224209489|NCT06543004|COMBINATION_PRODUCT|Bioceramic sealer|Root canal sealer will be placed inside the root canals during obturation procedure to seal dentine wall and reinforce the remaining tooth tissue.It will be selected randomly to the study samples.
224260486|NCT04154592|OTHER|Humeral Head Depressor Muscle Co-Activation Training- Experimental Group|In addition to the conservative treatment, humeral head depressor muscle co-activation training will be applied for 14 weeks. Participants in the coactivation group will perform the glenohumeral exercises while recruiting the pectoralis major, latissimus dorsi, and teres major muscles. To achieve this, voluntary recruitment of the pectoralis major, latissimus dorsi, and teres major will be taught prior to the demonstration of the glenohumeral exercises using visual feedback provided by EMG Biofeedback. When recruitment is correctly executed (50% of the maximum voluntary contraction signal), it should be maintained while performing the glenohumeral exercises. This will be confirmed by visualizing EMG signals during the exercise training session. During each appointment with the therapist, participants will be evaluated on their capacity to achieve the exercises while performing co-activation.
224260487|NCT04154592|OTHER|Control Group|"The American Society of Shoulder and Elbow Therapists' consensus statement on rehabilitation following arthroscopic rotator cuff repair will be used as guideline for rehabilitation of patients (Thigpen, C. A., Shaffer, M. A., Gaunt, B. W., Leggin, B. G., Williams, G. R., \& Wilcox III, R. B. (2016). The American Society of Shoulder and Elbow Therapists' consensus statement on rehabilitation following arthroscopic rotator cuff repair. Journal of shoulder and elbow surgery, 25(4), 521-535.).~Individuals in the control group will use shoulder straps for 6 weeks after arthroscopic shoulder surgery. These patients will be referred to physiotherapy clinics 6th week. Patients between 6 and 20 weeks (a total of 14 weeks) will be admitted to the rehabilitation program according to the guideline mentioned above."
224260488|NCT03446768|OTHER|Peer support|Access to educational and informational support by a trained peer coach
224260489|NCT03446768|OTHER|Online platform|An online platform that provides educational, informational and access to several therapeutic device metrics
224260490|NCT03446768|OTHER|Respiratory Therapist support|Limited medical support provided by trained Respiratory Therapists.
223619596|NCT04636281|OTHER|Active and passive static stretching exercises|Different group of muscles will be stretched one by one, tricep brachii, bicep brachii, wrist exentsor etc
223619597|NCT03598179|BIOLOGICAL|chimeric antigen receptor T cells|Dose CAR+ cells/kg B-cell lymphoma 4×10\^6 Acute lymphocytic leukemia 2×10\^6 Chronic lymphocytic leukemia 10×10\^6
223619598|NCT02211053|DRUG|Levothyroxine|20 mg IV bolus + 10 mg/h infusion
223619599|NCT02211053|DRUG|placebo|
223619600|NCT03167385|DRUG|Apatinib Mesylate|oral intake of Apatinib Mesylate 500mg once a day until progression of diesase or severe adverse effect
223619601|NCT02193776|DRUG|PA-824|oral
223619602|NCT02193776|DRUG|bedaquiline|oral
224209490|NCT03061773|OTHER|Exercise|Physical training: The combined training program consisted of 12-week aerobic, resistive and flexibility exercises, with 3 sessions per week of aerobic and resistive training in the same session (supervised by physical exercise coaches) and 2 sessions per week of Flexibility training (unsupervised). As stretching sessions were interspersed with sessions of aerobic and weathered training in the daytime period.
224209491|NCT03061773|BEHAVIORAL|Conventional hospital treatment|Conventional hospital treatment: The patients did not perform physical training
224209492|NCT03526796|PROCEDURE|Hyperbaric oxygen therapy|Patients were maintained at 2.4 ATA with 100% oxygen for 90 min and then decompressed back to 1 ATA. The treatment duration is 4 weeks and extends to 6 weeks if necessary.
224209493|NCT03302299|DRUG|Isoniazid 300 Mg ORAL TABLET|The study intervention will include a single arm given (1) 6H: 300 mg INH daily by mouth for 6 months.
224209494|NCT03302299|DRUG|Pyridoxine 25 Mg Oral Tablet|All participants will also receive 25 mg pyridoxine (vitamin B-6) daily by mouth for 6 months for the treatment duration to reduce the risk of INH-induced peripheral neuropathy.
224209495|NCT00850837|DRUG|Acidform Lubricant|5 g application of acid buffered gel (pH = 3.5)
224209496|NCT00850837|DRUG|HEC gel|5 g application of hydroxyethylcellulose gel
224209497|NCT04737915|BEHAVIORAL|Exposure Therapy (In Vivo)|Participant completes a single session of exposure therapy for fear of heights by looking over railings into an atrium at various floor levels in a virtual environment.
224209498|NCT04737915|BEHAVIORAL|Exposure Therapy (Virtual Reality)|Participant completes a single session of exposure therapy for fear of heights by looking over railings into an atrium at various floor levels in a real environment.
224209499|NCT04347031|DRUG|Mefloquine|"1st day: 750 mg of mefloquine per day, inside, in tablets of 250 mg 3 times a day - 1 tablet every 8 hours.~* Day 2: 500 mg of mefloquine, inside, in tablets of 250 mg 2 times a day - 1 tablet every 12 hours.~* 3rd - 7th day: 250 mg of mefloquine, inside, in tablets of 250 mg 1 time a day at the same time."
224209500|NCT04347031|DRUG|Hydroxychloroquine|"1. st day: 800 mg of hydroxychloroquine per day, inside, in 200 mg tablets, 2 tablets 2 times a day;~2. nd - 7th day: 400 mg of hydroxychloroquine per day, inside, in tablets of 200 mg, 1 tablet 2 times a day."
224209501|NCT04347031|COMBINATION_PRODUCT|Mefloquine + azithromycin + / - tocilizumab|"1st day: 750 mg of mefloquine per day, inside, in tablets of 250 mg 3 times a day - 1 tablet every 8 hours.~* Day 2: 500 mg of mefloquine, inside, in tablets of 250 mg 2 times a day - 1 tablet every 12 hours.~* 3rd - 7th day: 250 mg of mefloquine, inside, in tablets of 250 mg 1 time a day at the same time."
224209502|NCT04347031|COMBINATION_PRODUCT|Hydroxychloroquine + azithromycin + / - tocilizumab|"1. st day: 800 mg of hydroxychloroquine per day, inside, in 200 mg tablets, 2 tablets 2 times a day;~2. nd - 7th day: 400 mg of hydroxychloroquine per day, inside, in tablets of 200 mg, 1 tablet 2 times a day."
224209503|NCT06530160|OTHER|ELISA|Enzyme-linked immunosorbent assay
224209504|NCT05404568|PROCEDURE|Total knee arthroplasty|We included patients with knee osteoarthritis who planned to take total knee arthroplasty
224209505|NCT05802342|DRUG|Monosialotetrahexose ganglioside sodium injection|The treatment period was GM1/ placebo with albumin-paclitaxel from cycle 1 to cycle 4/6. The treatment period was GM1/ placebo with albumin-paclitaxel. GM1/ placebo was administered every 2 weeks /3 weeks. GM1 / placebo was administered 1 day before administration (D0), on the day of administration (D1) and on the day after administration (D2), and albumin-paclitaxel-based chemotherapy was administered from day 1, with a total of 4/6 cycles of administration. GM1/ placebo was administered every 2 weeks /3 weeks. GM1 / placebo was administered 1 day before administration (D0), on the day of administration (D1) and on the day after administration (D2), and albumin-paclitaxel-based chemotherapy was administered from day 1, with a total of 4/6 cycles of administration.
224209506|NCT01665573|DRUG|PF-04457845|Acquisition of conditioning Administration of drug Extinction of conditioning
224209507|NCT01665573|DRUG|Placebo|Acquisition of conditioning Administration of placebo Extinction of conditioning
224209508|NCT04682431|DRUG|PY159 Single agent dose level 1|Dose of PY159 as a single agent given in a standard 3+3 design.
224209509|NCT04682431|DRUG|PY159 Single agent dose level 2|Dose of PY159 as a single agent given in a standard 3+3 design.
224209510|NCT04682431|DRUG|PY159 Single agent dose level 3|Dose of PY159 as a single agent given in a standard 3+3 design.
224209511|NCT04682431|DRUG|PY159 Single agent dose level 4|Dose of PY159 as a single agent given in a standard 3+3 design.
224209512|NCT04682431|DRUG|PY159 Single agent dose level 5|Dose of PY159 as a single agent given in a standard 3+3 design.
224209513|NCT04682431|DRUG|PY159 Single agent dose level 6|Dose of PY159 as a single agent given in a standard 3+3 design.
224209514|NCT04682431|DRUG|PY159 Single agent dose level 7|Dose of PY159 as a single agent given in a standard 3+3 design.
224209515|NCT04682431|DRUG|PY159/Pembrolizumab Combination dose level 1|Dose of PY159 and given in combination with pembrolizumab
224209516|NCT04682431|DRUG|PY159/Pembrolizumab Combination dose level 2|Dose of PY159 and given in combination with pembrolizumab
224209517|NCT04682431|DRUG|PY159/Pembrolizumab Combination dose level 3|Dose of PY159 and given in combination with pembrolizumab
223619603|NCT02193776|DRUG|moxifloxacin|oral
223619604|NCT02193776|DRUG|pyrazinamide|oral
223619605|NCT02193776|DRUG|isoniazid, rifampicin, pyrazinamide and ethambutol combination tablet|oral
223619606|NCT05193214|DRUG|Recombinant anti-PD-1 humanized monoclonal antibody injection|Each subject received 609A 200 mg intravenous infusion, once every 3 weeks (Q3W), until disease progression, intolerable toxicity, death, informed withdrawal, early withdrawal from the study, loss to follow-up, or the end of the study, whichever occurs first Whichever prevails.
223619607|NCT02754570|DRUG|Pilocarpine|Pilocarpine will be administered 4 times in addition to latanoprost.
223619608|NCT00182130|PROCEDURE|Quality Initiative in Rectal Cancer (QIRC) strategy|
223619609|NCT00382668|DRUG|Dasatinib|Tablets, Oral, 50 mg, once daily, for one day
223619610|NCT00382668|DRUG|Dasatinib|Tablets, Oral, 20 mg, once daily for one day
223619611|NCT00382668|DRUG|Dasatinib|Tablets, Oral, 70 mg, once daily for one day
223619612|NCT00530413|DRUG|Phenobarbital|Phenobarbital will be given based on weight range
224209518|NCT04682431|DRUG|PY159/Pembrolizumab Combination dose level 4|Dose of PY159 and given in combination with pembrolizumab
224209519|NCT04682431|DRUG|PY159 Single agent dose expansion cohort|Dose of PY159 as a single agent given for predefined tumor histology
224315801|NCT02593643|OTHER|Treatment as usual (TAU)|TAU includes any current treatment a patient is receiving from their primary care practitioner. In the major depressive disorder (MDD) group, TAU may include a newly initiated or longstanding antidepressant. In the bipolar depression (BD) group, TAU may include a mood stabilizer such as lithium or valproate that is a first or second line agent as per Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines (Yatham et al., 2013).
224315802|NCT03677583|OTHER|Duckweed|various meal products such as meal soup, quiche, mashed potato, curry and pasta sauce
224315803|NCT03677583|OTHER|Spinach|various meal products such as meal soup, quiche, mashed potato, curry and pasta sauce
224315804|NCT05146843|DRUG|Mitoquinone|Mitoquinone pill, 20 mg/day
224315805|NCT05146843|OTHER|Placebo|Placebo pill, 20 mg/day
224315806|NCT06013826|OTHER|Telenursing|Patients who were randomly assigned to the intervention group were informed about the method of the study. The patient was informed that he would be called before blood glucose measurement and insulin injection for three days to monitor his fear of self-injection and testing. Insulin injection application training was repeated on the first day. Telephone calls made within the scope of tele-health service were recorded in the Telephone Interview Form. During the phone interviews, the questions that the patients wanted to ask were answered. He was asked to fill in the Insulin Injection Evaluation Form according to his experience during the three-day home treatment process. At the end of the three-day meeting, the tele-health service was terminated.
224315807|NCT05576766|PROCEDURE|Routine care|"1. Routine information provided before surgery.~2. No nutritional therapy.~3. No aerobic exercise.~4. No pelvic floor muscle training.~5. No psychiatrist intervention.~6. Bowel preparation with oral cathartic agent.~7. Fasting for over 8 hours; no oral carbohydrate solution (OCS) loading before surgery.~8. Hypothermia prevention not emphasized.~9. General anesthesia; regional block not emphasized.~10. Routine blood pressure management.~11. Mobilization from postoperative day 1.~12. Start oral feeding from postoperative day 1.~13. Patient-controlled analgesia with opioids.~14. Thromboembolism prophylaxis with low-molecular-weight heparin (LMWH).~15. Routine pelvic drainage tube removal (usually at postoperative day 4).~16. Routine urinary catheterization removal (usually at postoperative day 14)."
224315808|NCT05576766|PROCEDURE|ERAS management pathway|"1. Patient consultation and education before surgery.~2. Nutritional intervention for patients whose BMI\<18.5 or BMI\>24 kg/m2.~3. Aerobic exercise for 2 weeks before surgery.~4. Pelvic floor muscle training for 2 weeks before surgery.~5. Psychiatrist intervention for patients with severe depression and anxiety.~6. No bowel preparation before surgery.~7. Provide oral carbohydrate solution 2 hours before surgery.~8. Hypothermia prevention.~9. General anesthesia combined with regional block.~10. Goal-directed fluid infusion and targeted blood pressure management.~11. Early mobilization.~12. Early oral feeding.~13. Multimodal analgesia, including opioids and non-steroid anti-inflammatory drugs.~14. Thromboembolism prophylaxis with low-molecular-weight heparin; rivaroxaban for high-risk patients.~15. Early pelvic drainage tube removal (at postoperative day 2) unless contraindicated.~16. Early urinary catheterization removal (at postoperative day 7) unless contraindicated."
224315809|NCT04683224|BIOLOGICAL|UB-612|100 µg \[microgram\] of an experimental study vaccine
224209520|NCT04682431|DRUG|PY159/Pembrolizumab Combination dose expansion cohort 1|Dose of PY159 as a single agent and in combination with pembrolizumab for predefined tumor histology
224209521|NCT04682431|DRUG|PY159/Pembrolizumab Combination dose expansion cohort 2|Dose of PY159 as a single agent and in combination with pembrolizumab for predefined tumor histology
224209522|NCT04682431|DRUG|PY159/Pembrolizumab Combination dose expansion cohort 3|Dose of PY159 as a single agent and in combination with pembrolizumab for predefined tumor histology
224209523|NCT04682431|DRUG|PY159/Pembrolizumab Combination dose expansion cohort 4|Dose of PY159 as a single agent and in combination with pembrolizumab for predefined tumor histology
224209524|NCT04682431|DRUG|PY159/Pembrolizumab Combination dose expansion cohort 5|Dose of PY159 as a single agent and in combination with pembrolizumab for predefined tumor histology
224209525|NCT04682431|DRUG|PY159/Pembrolizumab Combination dose expansion cohort 6|Dose of PY159 as a single agent and in combination with pembrolizumab for predefined tumor histology
224209526|NCT01445431|OTHER|Virgin Coconut Oil|Virgin coconut oil applied to the test site twice daily for four weeks
224209527|NCT01445431|OTHER|Mineral Oil|Mineral oil applied to the test site twice daily for four weeks
224315810|NCT04683224|OTHER|Placebo|Placebo is a 0.9% sodium chloride (normal saline) injection
224209528|NCT02239692|DRUG|PICOPREP|Sodium Picosulfate, Magnesium Oxide and Citric Acid as PICOPREP powder for oral solution
224209529|NCT04153201|DRUG|Hydroxychloroquine|Hydroxychloroquine 200 mg daily for patients weighing \< 60 kg, hydroxychloroquine 400 mg daily for patients weighing \>= 60 kg
224209530|NCT00485368|DRUG|Coversyl (perindopril)|
224209531|NCT04466696|BEHAVIORAL|ERAS protocol|items of ERAS protocol applied
224209532|NCT04318535|DRUG|Griseofulvin 500 mg|Griseofulvin 500 mg will be administered as an oral tablet once in each treatment period under fed condition.
224209533|NCT04318535|DRUG|Griseofulvin 250 mg|Griseofulvin 250 mg will be administered as an oral tablet once in each treatment period under fed condition.
224209534|NCT04318535|DRUG|Reference Griseofulvin 500 mg|Reference Griseofulvin 500 mg will be administered as an oral tablet once in each treatment period under fed condition.
224209535|NCT03679312|DRUG|Nitric Oxide|Inhaled nitric oxide, which consists of breathing medical grade air (21% O2) with 40 parts per million of nitric oxide.
223619613|NCT00530413|OTHER|Placebo|Placebo group
223619614|NCT05889182|DRUG|Upadacitinib|Oral Tablets
223619615|NCT05889182|DRUG|Placebo|Oral Tablets
223619616|NCT03467321|OTHER|Physical characteristic assessment|Physical characteristics related to balance, pulmonary function and low back pain were evaluated
223619617|NCT03447002|DIAGNOSTIC_TEST|24 hours urine levels metanephrine and normetanephrine|24 hours rhythm recording and 24 hours urine measurement
223619618|NCT00703456|BEHAVIORAL|Balance Training|balance training three days per week for 4 weeks during single limb standing
223619619|NCT00629226|BIOLOGICAL|cetuximab|Given IV
224315811|NCT01477723|OTHER|Experimental Oral Nutritional Supplement|Experimental ONS orally Two 8 fl oz servings/day
224315812|NCT06334224|DEVICE|Low load resistance training with blood flow restriction|The intervention involves placing a pneumatic tourniquet system over the proximal thigh. The cuff is inflated to 80% of limb occlusion pressure during lower limb strengthening exercises. These exercises include leg press and knee extensor exercises. Four sets (30,15,15,15 repetitions) performed at 20% of one repetition maximum.
224315813|NCT06334224|OTHER|Low load resistance training|Leg press and knee extensor exercises. Four sets (30,15,15,15 repetitions) performed at 20% of one repetition maximum.
224315814|NCT00330317|DRUG|letrozole|2.5mg letrozole once-daily
224315815|NCT03452137|DRUG|Atezolizumab|Atezolizumab intravenous infusion will be administered at a fixed dose on Day 1 of each 21-day cycle for 16 cycles.
224315816|NCT03452137|DRUG|Placebo|Placebo intravenous infusion will be administered a fixed dose on Day 1 of each 21-day cycle for 16 cycles.
224315817|NCT04634279|BEHAVIORAL|Collaborative care Plus|Collaborative care consists of a team of providers that includes a care coordinator, a primary care provider (PCP) and a behavioral health consultant (BHC), who provide evidence- and measurement-based care to a panel of patients using a clinical registry. In this model, the CC team also includes a behavioral health psychotherapist (BHP) who consults on a regular basis but does not deliver direct care. In the Collaborative Care Plus condition, the care coordinator involves family in care, teaches family about naloxone use, and provides Caring Contacts, a suicide prevention method, to patients.
224315818|NCT00109460|BEHAVIORAL|Tobacco Use Disorder|
224315819|NCT04747145|DEVICE|Radiation|60 Gy to be delivered over 30 daily treatments in six weeks. Chemoradiation is to start no sooner than 3 weeks after surgery and not later than 8 weeks.
224315820|NCT04747145|DRUG|Concurrent Chemotherapy (Temozolomide)|75mg/m\^2 x 42 days (concurrent chemotherapy with radiation). Chemoradiation is to start no sooner than 3 weeks after surgery and not later than 8 weeks.
224315821|NCT04747145|DRUG|Adjuvant Chemotherapy (Temozolomide)|Starting no sooner than 4 weeks after completion of chemoradiation, 150-200mg/m\^2, days 1-5 of 28-day cycle, for minimum of six cycles and up to 12 cycles.
223619620|NCT00629226|DRUG|bortezomib|Given IV
223761528|NCT06909656|OTHER|Multimodal electrophysiological recordings|"Intervention(s): Multimodal electrophysiological recordings (Local field potentials, High-Resolution Electroencephalogram, Electromyogram) coupled with video analysis, in experimental condition, in uncontrolled tic and voluntary (tic-like) movement."
224209536|NCT03679312|DRUG|Placebo|Inhaled placebo, which consists of breathing medical grade air (21% O2).
224209537|NCT04923269|DRUG|LY3532226|Administered SC.
224209538|NCT04923269|DRUG|Placebo|Administered SC.
224209539|NCT01480908|PROCEDURE|Echocardiography at rest|Dimensions of all 4 chambers, inspiratory collapse, and gradient over the tricuspid valve is measured. Tricuspid Annulus Plane Systolic Excursion(TAPSE) and Tricuspid Annular peak Systolic Motion(TASM) is measured as well.
224315822|NCT01772875|PROCEDURE|bladder lavage|the bladder is rinced through the urinary catheter with the lavage solution
224315823|NCT04370678|BEHAVIORAL|Change in preference to surgery under COVID-19 pandemic.|Under the COVID-19 pandemic all arthroscopic procedures were cancelled. We wished to describe if patients experienced a change in preference to surgery under this period.
224315824|NCT05985629|DRUG|IPACK|Infiltration between the popliteal artery and capsules of the knee (IPACK) is a novel ultrasound-guided technique that provides additional regional analgesic relief to the posterior aspect of the knee without complications seen in a sciatic nerve block. The intention of the IPACK block is to anesthetize the terminal sensory nerves while sparing the main trucks of the common peroneal and tibial nerves.
224315825|NCT05985629|DRUG|PLACEBO|The control group will receive the normal pre-procedure care including a pre-operative visit, surgery, and post-operative care. The control group will receive a sham block consisting of saline in the same anatomical location and manner that the intervention IPACK block is administered.
224315826|NCT01371747|DRUG|patiromer|Cohorts 1, 2 and 3 - Patiromer starting dose: 8.4 g/day, orally, as a divided dose, twice daily. The dose of patiromer could be titrated based on participant's serum potassium response (Stratum 1)
224315827|NCT01371747|DRUG|patiromer|Cohorts 1, 2 and 3 - Patiromer starting dose: 16.8 g/day, orally, as a divided dose, twice daily. The dose of patiromer could be titrated based on participant's serum potassium response. (Stratum 2)
224315828|NCT01371747|DRUG|patiromer|Cohorts 1, 2 and 3 - Patiromer starting dose: 16.8 g/day, orally, as a divided dose, twice daily. The dose of patiromer could be titrated based on participant's serum potassium response (Stratum 1)
223761529|NCT06908356|DRUG|30mg PRAX-628|Once daily oral
224209540|NCT01480908|PROCEDURE|Echocardiography during exercise|TASM is measured during exercise along with pulse measurements to evaluate the force-frequency-relation.
223619621|NCT00629226|DRUG|cisplatin|Given IV
223619622|NCT00629226|RADIATION|intensity-modulated radiation therapy|Once daily, 5 days a week, for up to 8 weeks
223619623|NCT00737113|DRUG|Genotropin (Recombinant Human Growth Hormone)|Patients will begin daily subcutaneous (SC) therapy at a starting dose of \~0.02mg/kg body weight. The study drug will continue for 90 days post enrollment.
223619624|NCT00454714|DRUG|single dose Sildenafil|Application of a single dose Sildenafil
223619625|NCT00454714|DRUG|Single dose placebo|Application of a single dose placebo
224209541|NCT01480908|PROCEDURE|MRI at rest|Dimensions of all 4 chambers are measured at end-systole and end-diastole. Blood flow measurements through the aortic and the pulmonary valve are made as well. No use of contrast.
224315829|NCT01371747|DRUG|patiromer|Cohorts 1, 2 and 3 - Patiromer starting dose: 25.2 g/day, orally, as a divided dose, twice daily. The dose of patiromer could be titrated based on participant's serum potassium response (Stratum 1)
223619626|NCT02971423|DRUG|ETX2514|
223619627|NCT02971423|DRUG|Placebo|matching placebo infusion
223619628|NCT02971423|DRUG|Sulbactam|
223619629|NCT02971423|DRUG|Imipenem/Cilastatin|
223619630|NCT00962208|DEVICE|orthokeratology lenses|Nightly use of orthokeratology to correct the refractive error for a period of two years
223619631|NCT00962208|DEVICE|single-vision spectacle lenses|Daily use of spectacles to correct the refractive error for a period of two years
223619632|NCT03936114|BEHAVIORAL|SMART|SMART program mindfulness training program
223619633|NCT01139502|BEHAVIORAL|Work rehabilitation based on the cognitive therapeutical model|Work rehabilitation including two weekly meetings in which participant and work consultant discuss problems interfering with work and social interaction. Home work related to these problems is assigned between the meetings.
224209542|NCT01480908|PROCEDURE|Exercise testing|Maximal oxygen consumption is measured during on a bicycle. Prior to the test a spirometry is performed to rull out potential differences in pulmonary function between the cohorts. During the test pulse, blood pressure, saturation, and EKG are monitored. Ventilatory volume, oxygen consumption and carbon dioxide excretion are measured. Anaerobic threshold is calculated at the end of the test.
224209543|NCT03232749|PROCEDURE|intraarticular corticosteroid injections (IACSI)|ultrasound-guided IACSI will be administered
224209544|NCT03232749|DRUG|corticosteroid injections|Corticosteroid will be administered is used to treat pain and swelling that occurs with arthritis and other joint disorder
224209545|NCT03232749|DEVICE|Ultrasound|ultrasound-guided IACSI
223619634|NCT01139502|BEHAVIORAL|Work rehabilitation with the addition of cognitive training|Work rehabilitation with the addition of two hours weekly training of concentration, memory, and executive function
223619635|NCT05668949|DRUG|TTI-101|Given by PO
223619636|NCT05668949|DRUG|Pembrolizumab|Given by IV (vein)
223619637|NCT02867267|DRUG|Thymosin alpha 1|Subcutaneous injections of 1.6 mg thymosin alpha 1 every 12±2 hours for not more than 7 days depending on the change of the subjects' condition, prior to administration, the lyophilized powder is to be reconstituted with 1 ml of the provided diluent.
224209546|NCT06254521|DRUG|Tislelizumab combined with chemotherapy|"Drug: Oxaliplatin Oxaliplatin 130mg/m2 for chemotherapy on Day 1 every 3 weeks and repeat for 2 or 4 cycles. The dose reduction protocol for oxaliplatin-induced toxicity was implemented according to the report in BJC (2018) 118:1322-1328.~Drug: Capecitabine Oral Capecitabine 1000 mg/m2 twice daily combined with oxaliplatin chemotherapy from Day 1 to Day 14 every 3 weeks and repeat for 2 or 4 cycles. The dose reduction protocol for capecitabine-induced toxicity was implemented according to the report in BJC (2018) 118:1322-1328.~Drug: Anti-PD-1 Monoclonal Antibody 200 mg on Day 1 every 3 weeks and repeat for 2 or 4 cycles. The incidence of adverse events with Anti-PD-1 Monoclonal Antibodies is relatively low. The PD-1 monoclonal antibody (Tislelizumab) dose adjustment was implemented according to the prescribing information.~Other Names:~Tislelizumab~Procedure: Colectomy The specific surgical approach, whether it be laparoscopic"
224209547|NCT05224479|OTHER|Traditional workflow triage|Workflow triage is based on order location, STAT designation, and first-in-first-out status.
224209548|NCT05224479|OTHER|Machine learning workflow triage|Workflow triage is based on the machine learning model's confidence of abnormality.
224209549|NCT05224479|OTHER|Random workflow triage|Workflow triage is based on random order.
224209550|NCT04113538|DRUG|Aflibercept|Intraocular injection of 2 ml (40mg/ml)
224209551|NCT03362242|DRUG|ARO-AAT Injection|Single or multiple doses of ARO-AAT by subcutaneous (sc) injections
224209552|NCT03362242|OTHER|Sterile Normal Saline (0.9% NaCl)|Calculated volume to match active comparator
224209553|NCT03967106|OTHER|Ischaemic Preconditioning|IPC to the upper arm using a manual blood pressure machine with cuff. Three cycles of 5 minute cuff inflation to 30mmHg above the systolic blood pressure (BP) followed by 5 minute cuff deflation.
224209554|NCT03967106|OTHER|Sham|Sham intervention to the upper arm using a manual blood pressure machine with cuff. Three cycles of 5 minute cuff inflation to 30mmHg below the diastolic blood pressure (BP) followed by 5 minute cuff deflation.
224209555|NCT03232905|DRUG|PF-06651600|PF-06651600 will be administered as tablet
224209556|NCT03232905|DRUG|Placebo|Matching placebo will be administered as tablet
224209557|NCT01901146|DRUG|ABP 980|ABP 980 was administered at an initial dose of 8 mg/kg over a 90-minute intravenous (IV) infusion, then 6 mg/kg IV infusion Q3W for all subsequent cycles.
224209558|NCT01901146|DRUG|Trastuzumab|Trastuzumab was administered at an initial dose of 8 mg/kg over a 90-minute IV infusion, then 6 mg/kg IV infusion Q3W for all subsequent cycles.
224209559|NCT01901146|DRUG|Paclitaxel|Paclitaxel, 175 mg/m² Q3W for 4 cycles (or 80 mg/m² QW for 12 cycles, if local standard of care).
224209560|NCT01901146|PROCEDURE|Lumpectomy or Mastectomy with Sentinel Node or Axillary Node Dissection|
224209561|NCT01047904|DEVICE|Acclarent Iontophoresis System|Administration of local anesthesia using the Acclarent Iontophoresis System
224209562|NCT04567173|DRUG|Anti-SARS-CoV-2 convalescent plasma|convalescent plasma derived from whole blood donors or standard pheresis from a volunteer who recovered from COVID-19
224209563|NCT01060631|DEVICE|BIS values at return of consciousness in patients + predicted and measured propofol plasma concentrations|Difference between left- and rightsided BIS values in patients with supratentorial brain tumor during course and Comparison between predicted and measured propofol plasma concentrations during course of the study
224209564|NCT01060631|DEVICE|BIS values at return of consciousness in patients + predicted and measured propofol plasma concentrations|Difference between left- and rightsided BIS values in patients with supratentorial brain tumor during course and Comparison between predicted and measured propofol plasma concentrations during course of the study
224209565|NCT01038882|DRUG|Midazolam|Sedation started by injecting a 4 ml drug bolus with midazolam (0.07-0.1 mg/kg dose). Supplemental doses of midazolam (2 mg) were administrated at an interval of \>2 min to maintain conscious sedation
224209566|NCT01038882|OTHER|Physiological serum|We started by injecting a 4 ml drug bolus and we ad supplemental doses (2 ml) to maintain the conscious sedation
224209567|NCT01614925|DEVICE|Emdogain|Periodontal surgery with the additional use of Straumann® Emdogain
224209568|NCT01614925|PROCEDURE|Periodontal surgery|Periodontal surgery alone
224209569|NCT02966522|DRUG|Thalidomide|
224209570|NCT02966522|DRUG|Dexamethasone|
224209571|NCT00968396|PROCEDURE|Apheresis|On Day 5, 3 hour process to separate blood (stem cells from other cells) done 1 time a day for 1-6 days, or until enough stem cells are collected. Stem cells are cultured with donated stem cells from a relative for two weeks before being returned via transplantation.
224209572|NCT00968396|PROCEDURE|Stem Cell Transplantation|Co-culture Stem Cell Infusion on Day 0.
224209573|NCT00968396|DRUG|Melphalan|100 mg/m\^2 IV over 30 minutes daily on Days -2 and -1
224209574|NCT00611741|DRUG|furosemide, Na supplements|furosemide 20 mg, Na supplements 8g in divided doses/day for 5 days
223761530|NCT06904781|PROCEDURE|Pulpotomy|Pulpotomy is a conservative pulp treatment option where only the coronal pulp is removed and a bioactive medicament (MTA) is placed over the remnant radicular pulp after haemostasis is achieved.
223761531|NCT06904781|PROCEDURE|Pulpectomy|Pulpectomy is treatment procedure in primary teeth where the entire coronal and radicular pulp is extirpated and the root canal system filled with a resorbable material (Vitapex/Metapex)
224209575|NCT01672814|DRUG|riboflavin ophthalmic solution|Administration of riboflavin every 2 minutes for 20 minutes
224209576|NCT01672814|DEVICE|Vedera KXS Microwave System|The Vedera KXS dose will be based on the pre-treatment manifest refraction spherical equivalent (MRSE), to be administered one day prior to the CXL procedure.
224209577|NCT03338049|DEVICE|Veran System|Electromagnetic navigation bronchoscopy and electromagnetic navigation transthoracic needle aspiration
224209578|NCT00798824|PROCEDURE|Indwelling nasogastric tube placement|The premature infant is fed with an indwelling nasogastric tube during feeding transition.
224209579|NCT00798824|PROCEDURE|Intermittent orogastric tube placement|The premature infant is fed with an intermittently placed orogastric tube during feeding transition.
224209580|NCT00798824|DEVICE|Nasogastric tube|Premature infants will be fed with a nasogastric tube in place and their feeding behaviors will be noted till discharge.
224209581|NCT00798824|DEVICE|Oral gastric tube|Premature infants will be fed with intermittent orogastric tube placement and their feeding behaviors will be noted till discharge.
224209582|NCT03451227|DRUG|Dexmedetomidine group|The study drug dexmedetomidine (PrecedexTM) will be infused at 0.2-1mcg/kg/hour from the start of the case. The dexmedetomidine infusion will stop at completion of the procedure.
224209583|NCT03451227|DRUG|Remifentanil Group|Remifentanil HCL will be infused at 0.01-0.2 mcg/kg/min titrated to sedation level (SAS less than or equal to 4) and cardiovascular parameters (within 30% of baseline). The infusion will be stopped at the end of the procedure.
224209584|NCT02996448|DRUG|NDV-3A|A vaccine containing recombinant Candida albicans agglutinin-like sequence 3 (rAls3) protein as the antigen, formulated with AlOH adjuvant in phosphate buffered saline. Participants will receive a single 0.5 mL dose containing 300 micrograms of rAls3 and 0.5 mg of aluminum as AlOH, delivered via intramuscular injection.
224209585|NCT02308865|OTHER|multi disciplinary palliative care monthly consultations|multi disciplinary palliative care consultations with a doctor, a nurse, a psychologist and posibility of a physical therapist and a worship person.The primary consultation within 3 weeks inclusion and then every month at the same time that consultations onco-respiratory
224209586|NCT01336218|DRUG|fostamatinib|oral tablets, 150mg (3 X 50mg) single dose per period
224209587|NCT01336218|DRUG|rifampicin|oral tablets, 600mg (2 X 300mg) 8 doses over 8 days
224209588|NCT02083770|BEHAVIORAL|Cancer Clinical Trials Education Program|Hispanic Americans are underrepresented in cancer clinical trials. The purpose of this study is to develop and test programs designed to reduce barriers and increase facilitators associated with cancer clinical trials participation for Hispanic Americans.
224209589|NCT00171119|DRUG|valsartan|
224209590|NCT00688610|OTHER|laboratory value procalcitonin|"A. attending physician includes patient with acute respiratory infection in study, indicates antibiotic prescription and collects procalcitonin-value. Waits for decision from laboratory either change of decision or retention of decision. In case of change decision: antibiotic is not recommended, patient shall not take antibiotic. In case of retention of decision: patient may take the antibiotic.~B. attending physician includes patient with acute respiratory infection in study, indicates NO antibiotic and collects procalcitonin-value. Waits for decision from laboratory either change of decision or retention of decision. In case of change decision: antibiotic is recommended, patient has to be informed about. In case of retention of decision: no change."
224209591|NCT00552526|DIETARY_SUPPLEMENT|Ketogenic diet|Ketogenic diet is a very strict high fat diet
224260491|NCT05133180|DRUG|Oxervate|Oxervate®, an ophthalmic solution containing cenegermin 20 mcg/mL, which is a recombinant human Nerve Growth Factor (rhNGF); one drop of the test product will be instilled in both eyes three times daily (TID).
224260492|NCT05133180|OTHER|Vehicle|Vehicle will be instilled with the same scheme of the test product
224260493|NCT02821676|PROCEDURE|PECI/SPB Block with Active Anesthetic + Placebo Multilevel Intercostal Nerve Block followed by Latissimus Dorsi Flap Breast Reconstruction|30mL of 0.5% Ropivacaine with 1:200,000 epinephrine preoperatively via an ultrasound guided PECI/SPB regional block and 5mL of Normal Saline intraoperatively as an intercostal nerve block to each of the T2-T7 nerve segments
224260494|NCT02821676|PROCEDURE|Placebo PEC/SPB Block + Multilevel Intercostal Nerve Block with Active Anesthetic followed by Latissimus Dorsi Flap Breast Reconstruction|30mL of Normal Saline via an ultrasound guided PECI/SPB block and 5mL of 0.5% Ropivacaine with 1:200,000 epinephrine as an Intercostal nerve block to each of the T2-T7 nerve segments
224260495|NCT03686540|PROCEDURE|ExtraCorporeal Membrane Oxygenation (ECMO)|The objective of this study is to determine the average cost of stay of a patient supported by ExtraCorporeal Membrane Oxygenation from the point of view of the hospital facility, during the hospitalization in which the ECMO was implanted.
224260496|NCT00015691|DRUG|Metformin hydrochloride|
224260497|NCT00015691|DRUG|Rosiglitazone maleate|
224260498|NCT00004148|BIOLOGICAL|recombinant vaccinia-B7.1 vaccine|
224260499|NCT02463786|OTHER|No intervention|No intervention
224260500|NCT04913974|PROCEDURE|Uni-condylar knee arthroplasty|Surgical replacement of medial compartment of arthritic knee with an implant
224260501|NCT02036086|DRUG|Vemurafenib|Drug
224260502|NCT02036086|DRUG|Cobimetinib|Drug
224260503|NCT01535222|DRUG|MDCO-2010|MDCO-2010 solution for infusion. Dosage: Pump priming dose; Loading dose infusion over 6 minutes; Maintenance infusion for duration of surgery
224260504|NCT01535222|DRUG|Placebo|Commercially available NaCl
224260505|NCT01942122|DRUG|DLBS1442 100|Study treatment will be DLBS1442 capsules at a dose of 3x100 mg daily. DLBS1442 will be taken every day for 8 weeks (2 menstrual cycles).
224260506|NCT01942122|DRUG|Mefenamic acid|Control will be mefenamic acid 500 mg tablets, administered 3 times daily for 5 days during the menstrual period, i.e. day 1st to day 5th of the menstrual period. The drug will be given within the 8 weeks of study period (2 menstrual cycles).
224260507|NCT01942122|DRUG|DLBS1442 200|Study treatment will be DLBS1442 capsules at a dose of 3x200 mg daily. DLBS1442 will be taken every day for 8 weeks (2 menstrual cycles).
224315830|NCT01371747|DRUG|patiromer|Cohorts 1, 2 and 3 - Patiromer starting dose: 25.2 g/day, orally, as a divided dose, twice daily. The dose of patiromer could be titrated based on participant's serum potassium response. (Stratum 2)
224315831|NCT01371747|DRUG|patiromer|Cohorts 1, 2 and 3 - Patiromer starting dose: 33.6 g/day, orally, as a divided dose, twice daily. The dose of patiromer could be titrated based on participant's serum potassium response. (Stratum 2)
224315832|NCT01371747|DRUG|losartan|losartan dose: 100 mg/d, oral, once daily (initiated during Run-In Period; Cohort 1)
224315833|NCT01371747|DRUG|spironolactone|Spironolactone dose: 25 mg/d or up to 50 mg/d, oral, once daily (initiated during Run-In Period; Cohort 2)
224315834|NCT01868347|OTHER|treatment|preemptive PEEP before pneumoperitoneum and trendelenburg
224315835|NCT01868347|OTHER|control|PEEP after pneumoperitoneum and trendelenburg
224315836|NCT03261505|DEVICE|Acupuncture|Patients will watch a video of themselves receiving acupuncture or a control video or receive real or sham acupuncture treatment.
224315837|NCT05825443|DRUG|Camrelizumab|Patients received four 21-day cycles of chemotherapy (decided by the researcher) combined with camrelizumab (200 mg in day 1), followed by maintenance with camrelizumab (200 mg in day 1, q3w), until one year or the disease progressed or unacceptable toxicity.
223761532|NCT06909669|BEHAVIORAL|Group brief transdiagnostic cognitive-behavioral therapy|Eight-session treatment based on Barlow's Unified Protocol. These sessions include: improving motivation and commitment to treatment, understanding the functioning of emotions, emotional awareness training, developing more flexible and adaptive thinking patterns, reduction of emotional avoidance and emotion-driven behaviors; awareness and tolerance of physical sensations; interoceptive and situational emotional exposure; achievement, maintenance and relapse prevention.
224315838|NCT06552039|OTHER|Polyherbal Hair Oil|Apply oil with the help of fingertips on your scalp and massage it gently enabling it to penetrate into the roots (follicle) of your hair. Don't apply with your palms and never rub it vigorously as it may uproot weak hair. Let the oil gradually seep into follicle of your hair \& nourish them for the whole night. The oil may be removed in the morning by washing of hair with Ayurvedic Shampoo. Dosage form: liquid frequency: Three times a week Route of Administration: Topical
224315839|NCT06552039|OTHER|Minoxidil Herbal Hair Oil + Minoxidil 5 (%) Hair Serum|"First, apply the herbal hair oil generously to your scalp and hair, ensuring thorough coverage. Gently massage it in with your fingertips to promote circulation and absorption. After the oil application, follow the instructions provided for the application of the minoxidil hair serum. Apply the serum to the areas of your scalp where you desire hair growth, using the dropper provided or as directed. Massage it gently into your scalp to ensure even distribution and absorption. Leave the serum on without rinsing.~Dosage form: liquid Frequency : For Minoxidil - Daily Night Application For Herbal Hair Oil- Thrice a week.~Route of Administration: Topical"
224315840|NCT06552039|OTHER|Minoxidil Hair Serum|Apply the amount prescribed to the area of the scalp being treated, beginning in the center of the area. Dosage form: liquid Frequency : Daily night Application of Minoxidil Route of Administration: Topical
224315841|NCT01744639|BEHAVIORAL|HCC under treatment with radioablation|The evaluation will take place over a period of 30 days.
224315842|NCT05231434|OTHER|water|hydration with mineral water in 10 equal portions, administered at regular intervals from the 15th minute of exercise until the end of the recovery period.
224315843|NCT05231434|OTHER|aerobic activity|aerobic activity
224315844|NCT04852523|DRUG|18F-fluciclovine|18F-Fluciclovine is a synthetic L-leucine amino acid used clinically for PET imaging in patients with biochemical recurrence of prostate cancer following definitive therapy. The pancreas accumulates striking amounts of Axumin, where it is considered a normal finding. Pancreatic beta-cell function may be slow to recover following pancreatic transplantation and may vary as a function of perioperative steroid administration, acute rejection, inadequate islet cell transplantation, allograft pancreatitis or compromised blood supply. Viability of the allograft is a common clinical concern and is difficult to assess based on insulin, C-peptide, and blood sugar levels. Rapid identification of compromised allograft viability is critical in the management of these patients.
224315845|NCT02666443|DRUG|Control intervention (no dexamethasone)|Patients receive a supraclavicular brachial plexus block with 30 mL of solution containing 0.5% bupivacaine, 1:400,000 epinephrine, 0.1 mL normal saline, and an intravenous solution of 50 mL normal saline.
224315846|NCT02666443|DRUG|Peri-neural Dexamethasone 1 mg|Patients receive a supraclavicular brachial plexus block with 30 mL of solution containing 0.5% bupivacaine, 1:400,000 epinephrine, 0.1 mL dexamethasone 1% (1 mg dexamethasone), and an intravenous solution of 50 mL normal saline.
224315847|NCT02666443|DRUG|Intravenous Dexamethasone 1 mg|Patients receive a supraclavicular brachial plexus block with 30 mL of solution containing 0.5% bupivacaine, 1:400,000 epinephrine, 0.1 mL normal saline, and an intravenous solution of 49.9 mL normal saline with 0.1mL dexamethasone 1%
224315848|NCT03209843|PROCEDURE|Percutaneous recanalization of chronic total occlusion|Percutaneous recanalization of chronic total occlusion followed by immediate systematic coronary optical frequency domain imaging (OFDI) at inclusion. Intra-individual post stenting assessment of reendothelialization with a second coronary angiography with OFDI analysis at 3 months.
224315849|NCT03507088|DRUG|Fluoroestradiol (18F)|A FES-PET/(CT) will be performed twice during protocol execution. Patients will be injected with approximately 222 MBq 18F-FES each time.
224315850|NCT06306248|OTHER|Total sleep deprivation|non pharmacologic treatment for depression
224315851|NCT04012788|DIETARY_SUPPLEMENT|Synbiotic mixture|A synbiotic mixture consisting of four probiotic strains and inulin (a prebiotic)
224315852|NCT04012788|OTHER|Placebo comparator|Placebo powder
224315853|NCT05269095|PROCEDURE|Spinal anesthesia only|Patients will receive spinal anesthesia with 2-3 ml 0.5% (10-15 mg) hyperbaric bupivacaine plus 25 ug fentanyl at the L3/4 interspaces.
224315854|NCT05269095|BIOLOGICAL|Spinal anesthesia and ultrasound-guided Genicular nerves block|Patients will receive16 ml bupivacaine 0025% will be administered, and4 ml of this solution will be placed at each of the 4 target nerves.
224315855|NCT05269095|BIOLOGICAL|Ultrasound-guided Adductor Canal block (ACB) technique with infiltration of the interspace between popliteal artery and the capsule of posterior knee block ('PACK)|Adductor Canal block (ACB) technique will be performed using 16 ml bupivacaine 0025% As regarding the Popliteal artery and the capsule of posterior knee block ('PACK), it will be performed Using 16 ml bupivacaine 0.25%
224315856|NCT00725257|OTHER|Mediterranean diet|The recommended composition of the dietary regimen was as follows: Carbohydrate 40 to 50%, protein 15 to 20%; fat 30 to 40%; saturated fat less than 10%.
224315857|NCT00725257|OTHER|Low-fat diet|The recommended composition of the dietary regimen was as follows: Fat less than 30%; carbohydrate 50 to 60%, protein 15 to 20%; saturated fat less than 10%.
224315858|NCT00269139|BEHAVIORAL|Crisis resolution|
224315859|NCT05161910|OTHER|Biomarkers|Kidney biomarkers appear to be useful in differential diagnosis between acute tubular necrosis (ATN) and other types of acute kidney injury (AKI) in cirrhosis, particularly hepatorenal syndrome (HRS-AKI).
223761533|NCT06909669|BEHAVIORAL|Group relaxation|The participants in this group will receive basic training in Jacobson's progressive relaxation with a similar periodicity to the ultra-brief intervention.
223761534|NCT06909669|BEHAVIORAL|Group ultra-brief transdiagnostic cognitive-behavioral therapy|This is a reduction to four sessions of the brief transdiagnostic treatment (Experimental group 1). For this reduction, sessions 1 and 2 of the brief transdiagnostic treatment will be combined, sessions 3 and 6 will be eliminated, and sessions 7 and 8 will be combined. As in experimental group 1, the treatment groups will consist of 8-10 people. Each session will have a duration of 1.5 hours and the intervention will be carried out on a weekly basis, with a maximum duration of four weeks.
223761535|NCT06909669|BEHAVIORAL|Individual ultra-brief transdiagnostic cognitive-behavioral treatment format|Participants of this group, wil receive the same treatment than group 2 (ultra-brief transdiagnostic cognitive-behavioraltreatment in group format) but individual format. Each session will have a duration of 1 hour and the intervention will be carried out on a weekly basis, with a maximum duration of four weeks.
223761536|NCT06909305|DRUG|Ozone|Patients received intraarticular ozone injection.
223761537|NCT06909305|DRUG|Dextrose prolotherapy|Patients received intraarticular dextrose prolotherapy injection.
224209592|NCT00552526|DRUG|Antiepileptic drug (AED)|An AED,not used by the patient before, which we consider to be the most appropriate will be given orally or by gastrostomy. Serum concentration, the body weight, side effects and effects on the epilepsy will be considered when deciding the dose of the AED. Traditions for amount of medicine/kg body weight or optimal serum concentration at our center will be followed. This tradition will be the same as in other major European epilepsy centers but might propose lower, but not higher amounts than recommended by the drug company. Drugs from ACT groups N03A, N05BA, N05CD, H02A or S01EC will be used including prednisolon,levetiracetam, valproate, carbamazepine, oxcarbazepine, topiramate, felbamate, zonisamide, vigabatrin, tiagabil, lamotrigine, pregabalin, rufinamide, clobazam, clonazepam, tiagabine, gabapentin, phenytoin, phenobarbital, ethosuximide, acetazolamide, nitrazepam and other new antiepileptic drugs that might be released during the study period.
224209593|NCT05459545|DEVICE|Use of Eko CORE and Eko CORE 500 electronic stethoscope|Auscultation of heart sounds using electronic stethoscopes
224209594|NCT00309413|DRUG|Placebo/Cannabidiol|600 mg/day, oral, capsules, 2 weeks, than cross-over
224209595|NCT00309413|DRUG|Cannabidiol/Placebo|600 mg/day, oral, capsules, 2 weeks, than cross-over
224209596|NCT03828656|DEVICE|NightWare Therapeutic System|A wearable digital therapeutic system that will measure physiologic data when worn during sleep to deliver a mild vibration via the watch to elicit arousal thereby disrupting nightmares. This detection and stimulation sequence will be performed according to NightWare's proprietary algorithm.
224209597|NCT05839093|DEVICE|Inferior Alveolar Nerve Block Group|A standard IANB injection with a conventional dental injector and a 27-G needle. After determining the injection site and performing aspiration, 1.8 mL of solution was injected at a rate of 1 mL/min to block the inferior alveolar nerve. After achieving lip anesthesia, infiltration was performed at the buccal side of the affected tooth with 0.5 mL using a normal syringe and a 27-G needle. The needle insertion point was the middle of the mesiodistal distance of the crown. Five minutes later, the teeth were isolated and the endodontic procedure was started.
224315860|NCT01782014|PROCEDURE|colonoscopy|colonoscopy using different methods of insufflation
224315861|NCT05349708|DEVICE|THE-FACS|Telehealth home-monitoring tablet and blood pressure cuff
224315862|NCT02928055|DEVICE|Peripheral Nerve Stimulation|The stimulation system includes an external stimulator, percutaneous lead and pad. The stimulator snaps onto the pad. The pad has an embedded power source but also serves as the anode. The 1-channel stimulator outputs a biphasic current waveform with current pulse parameter ranges suitable for PNS. The percutaneous lead is inserted using an introducer (like a hypodermic needle) which is withdrawn and the lead is retained in the muscle by a barb at its tip. After a 1-week stabilization period, stimulation is initiated (daily dose is Group-dependent). Stimulus parameters may be adjusted by the research staff as deemed appropriate. The treatment period is 3 weeks after which the lead will be removed. Total time of electrode implantation is no more than 29 days.
224315863|NCT05088850|OTHER|no intervention|no intervention
224315864|NCT03815214|BEHAVIORAL|Partial meal replacement program|Four meals consist of meal replacements made by OPTAVIA, such as shakes, soups, bars, biscuits, hot drinks, and puddings. Meal replacements will be provided to subjects without charge. For two other daily meals, subjects or their caregivers will be taught how to prepare meals consisting of 5-7 ounces (cooked) of a low-fat protein, 3 servings of non-starchy vegetables, and up to 2 servings of healthy fats.
223761538|NCT06909305|DRUG|Dexmedetomidine|Patients received intraarticular dexmedetomidine injection.
224315865|NCT03815214|BEHAVIORAL|Dietary Counseling|Participants will receive one 45-minute counseling session on a healthy diet
224315866|NCT02094417|DRUG|AMG531|Subcutaneous, weekly injection
224315867|NCT05314803|BEHAVIORAL|Yoga|Participants receive the yoga program, which is delivered by a trained yoga instructor (completed at least a 200-hour yoga teacher training, Yoga Thrive Teacher Training Certification (or similar), and/or practical experience working with individuals affected by cancer). The first class of the week is comprised of 45 minutes of gentle, progressive, hatha-based yoga sequencing and postures with the last 15 minutes focused on guided behaviour change and mindfulness techniques that varies week-to-week, based on the participants in the class. The second class of the week is 60 minutes of gentle, yin-based yoga sequencing and postures with an element of opening and relaxing.
224315868|NCT05858918|DRUG|Clopidogrel|Treatment with dual antiplatelet drug,aspirin 80 mg PO daily with clopidogrel 75 mg PO daily
224315869|NCT05858918|DRUG|Ticagrelor|Treatment with dual antiplatelet drug,aspirin 80 mg PO daily with ticagrelor 90 mg PO twice daily
224315870|NCT02291575|OTHER|Training|(please see Arm Description)
223619638|NCT02867267|OTHER|Placebo|Subcutaneous injections of placebo every 12±2 hours for not more than 7 days depending on the change of the subjects' condition, prior to administration, the lyophilized powder is to be reconstituted with 1 ml of the provided diluent.
223619639|NCT00285896|DRUG|Glucagon-like-peptide-1 (7-36) amide|Continuous, subcutaneous GLP-1 at a dose of 4.8 pmol/kg/min for 51 hours
224209598|NCT05839093|DEVICE|Intraligamentary Injection Group|An infiltration was performed at the buccal side of the affected tooth with 0.5 mL using a normal syringe and a 27-G needle. Then, an intraligamentary injection was performed with a special pressure injection syringe (Sopira Citoject, Kulzer, Hanau, Germany) and a 30-G needle. The needle was placed alongside the tooth and inserted at a 30 angle relative to the longitudinal axis of the crown with the needle between the teeth and the bone. Then, in the mesiobuccal, distobuccal, mesiolingual and distolingual portions of teeth, 0.18 mL of the solution was injected. Five minutes later, the teeth were isolated and the endodontic procedure was started.
224209599|NCT04624061|BEHAVIORAL|Integrated HIV/HTN care model|The intervention is a multi-component intervention of combined HIV and HTN care, based on the PRECEDE framework, to continuously identify barriers and facilitators leads to better health outcomes including dual control of HIV/HTN among adults in HIV care in the intervention compared to control facilities
224209600|NCT01160198|DRUG|ferrous ascorbate|100 mg elemental iron
224209601|NCT01160198|DIETARY_SUPPLEMENT|ferrous bisglycinate chelate 1 OD|60 mg elemental iron
224209602|NCT01160198|DIETARY_SUPPLEMENT|ferrous bisglycinate chelate 2 OD|120 mg elemental iron
224209603|NCT00451269|DEVICE|Rapid diagnosis test for malaria|Rapid diagnosis test for malaria
224209604|NCT04681274|DEVICE|Image features extraction and clustering|"The image processing operations required for local content-based image feature extraction consist of two main tasks: 1) tiling the images in smaller VOIs, typically a small cube, whose size depends on the modality, on the image resolution and on the purpose of the content-based query, and 2) performing feature extraction operations on the VOIs.~The Feature Extraction Engine performs totally unsupervised, automatic and asynchronous extractions of features from the images, organizes and indexes them in a no-SQL database based on unique similarity metric. The results of this phase are a series of clusters of phenotype signatures."
224209605|NCT04681274|DEVICE|Phenotype signature database building|Since the clusters are self-organizing their pathophysiological meaning is not readily apparent and requires further analysis. The characterization of each cluster is performed by analyzing representative samples and their respective correlation with histopathology results. After a series of iterations, the clusters are organized to correlate with distinct tissue subtypes identified by their signature similarity. The final number of clusters is not known a priori and depends on the heterogeneity of the underlying imaging phenotypes.
224209606|NCT02413879|DEVICE|CleanCision|Wound protection during colorectal surgery.
224209607|NCT00128518|DRUG|Indapamide (T2)|1.5 mg/day during 4 weeks
224209608|NCT00128518|DRUG|Perindopril (T1)|4 mg/day during 1 week then 8 mg/day during 3 weeks
224209609|NCT00128518|DRUG|Placebo of Perindopril (P1)|1 pill/day during 1 week then 2 pills/day during 3 weeks
224209610|NCT00128518|DRUG|Placebo of Indapamide (P2)|1 pill/day during 4 weeks
224209611|NCT04766593|OTHER|Oncological functional reeducation program|"It will consist of the following actions:~1. Prescription of multimodal physical exercise.~2. Retraining in activities of daily living."
224209612|NCT06358807|PROCEDURE|Arthroscopic microfracture with intraoperative local PRP gel injection|"Arthroscopic microfracture:~An anteromedial portal and an anterolateral portal are routinely established. A diagnostic arthroscopy is performed. Defects of superficial cartilage, cystic components, and necrotic bone are debrided arthroscopically with curette and shaver to a stable circumferential rim. Microfracture awls are introduced and subchondral channels to 4-6 mm in depth are created, spacing the channels 3 to 5 mm apart across the entire surface of the lesion.~PRP preparation and local injection:~PRP is harvested using a PRP preparation kit via centrifugation. Fifty milliliters of autologous venous blood are drawn from the patient and processed. Platelet count is measured for quality control. On average 4 ml of (range 3-6) PRP is obtained and mixed with thrombin calcium agent in preparation for PRP gel. PRP gel is administered to the injured area using a blunt and long-tip injector, with direct visualization under arthroscope."
224209613|NCT06358807|PROCEDURE|Isolated microfracture|"Arthroscopic microfracture:~An anteromedial portal and an anterolateral portal are routinely established. A diagnostic arthroscopy is performed. Defects of superficial cartilage, cystic components, and necrotic bone are debrided arthroscopically with curette and shaver to a stable circumferential rim. Microfracture awls are introduced and subchondral channels to 4-6 mm in depth are created, spacing the channels 3 to 5 mm apart across the entire surface of the lesion."
224209614|NCT06337968|PROCEDURE|Circum-psoas Block|Ultrasound-guided circum-psoas block with 40 mL of treatment drug (Ropivacaine 0.2% \[local anesthetic\]) 30 minutes prior to induction of anesthesia.
224209615|NCT06337968|PROCEDURE|Sham block|Perform ultrasound scanning without puncture.
224209616|NCT03343054|DRUG|talazoparib|Talazoparib will be administered orally on a continuous basis. Talazoparib may be taken with or without food. Each cycle will consist of 28 days.
223619640|NCT00285896|DRUG|Placebo|continuous subcutaneous placebo infusion at a dose of 4.8 pmol/kg/min for 51 hours
223619641|NCT00935181|BEHAVIORAL|respiratory muscle stretching|stretching exercises for respiratory muscles like diaphragm, pectoral, dorsalis etc
223619642|NCT00888693|DRUG|ABT-288|See Arm Description for details.
223619643|NCT00888693|DRUG|Placebo|See Arm Description for details.
224209617|NCT01467570|DIETARY_SUPPLEMENT|oral rehydration solution Hipp ORS Apple 200|"Volume of the solution calculated by weight:~* fast oral rehydration in 3-4 hours by mouth~* ORS given for ongoing losses until diarrhea stops (maintenance phase)"
224209618|NCT01467570|DIETARY_SUPPLEMENT|ESPGHAN ORS|"Volume of the solution calculated by weight:~* fast oral rehydration in 3-4 hours by mouth~* ORS given for ongoing losses until diarrhea stops (maintenance phase)"
224209619|NCT02626182|DRUG|sildenafil|active sildenafil
224209620|NCT02626182|DRUG|placebo|sugar pill that looks like sildenafil tablets
224209621|NCT04221087|DRUG|Placebos|Sugar water based on same ml dosing of intervention arm drug
224209622|NCT04221087|DRUG|Dexamethasone Oral|0.6mg/kg/dose - single oral dose administration to intervention arm
224209623|NCT01092299|DRUG|AZD1446|ER Fast, 90mg, p.o. capsule
224209624|NCT01092299|DRUG|AZD1446|ER Moderate, 90mg, p.o. capsule
224315871|NCT02291575|OTHER|Control|This group will not receive any training from the Liver Foundation; they will simply be evaluated at baseline and endline.
224209625|NCT01092299|DRUG|AZD1446|ER Slow, 90mg, p.o. capsule
224315872|NCT00580788|DRUG|PTHrP (1-36)|IND # 49,175
224209626|NCT01092299|DRUG|AZD1446|MR
224209627|NCT01092299|DRUG|AZD1446|IR, 90 mg p.o. capsule
224209628|NCT01092299|DRUG|Placebo|IR
224209629|NCT01092299|DRUG|Placebo|ER/MR
224209630|NCT05824299|PROCEDURE|General Anesthesia|Patients will have TURBT under general anesthesia, which is induced with midazolam, propofol, sufentanil and rocuronium. The patients will be mechanically ventilated with laryngeal mask airway (LMA). Anesthesia will be maintained with sevoflurane/desflurane, propofol and remifentanil.
224209631|NCT05824299|PROCEDURE|Spinal Anesthesia|Patients will have TURBT under spinal anesthesia. 10\~15mg of 0.5% ropivacaine will be injected in the subarachnoid cerebrospinal fluid at the levels of L2-L3 or L3-L4 in lumbar space. It will numb the nerve supply of the belly, hips, bottom as well as legs. The patient stays awake and won't feel any pain due to operation.
224209632|NCT03552354|DRUG|Argatroban plus dual antiplatelet|A continuous argatroban infusion of 1.0 ug/kg per minute for 2-5 days adjusted to a target activated partial thromboplastin time of 1.75 X baseline (about 10%). For the first day, clopidogrel with loading dose 300mg, and aspirin 100mg were given, and followed by clopidogrel 75 mg and aspirin 100mg each day
224209633|NCT01381822|DRUG|TH-302|TH-302: administered by IV infusion over 30 or 60 minutes on Days 8, 15 and 22 of a 42 day cycle.
224209634|NCT01207401|DRUG|Lidocaine|1% Lidocaine
224209635|NCT03272867|DIETARY_SUPPLEMENT|ProManna|
224209636|NCT02917616|OTHER|Alkaline drinking-water|
224209637|NCT02917616|OTHER|Neutral drinking-water|
224209638|NCT05880563|DRUG|[18F]-RoSMA-18-d6|\[18F\]-RoSMA-18-d6 will be administered intravenously by a bolus injection followed by a subsequent PET/CT-scan of the brain and the spine
224209639|NCT03555890|DRUG|Levocetirizine IRT 5 mg|Levocetirizine IRT will be available as film-coated tablets. Subjects will receive a single dose of 5 mg levocetirizine IRT. Subjects will receive levocetirizine IRT with 150 mL water in both Part (1 and 2).
224209640|NCT03555890|DRUG|Levocetirizine ODT 5 mg|Levocetirizine ODT will be available as oral disintegrating tablet. Subjects will receive a single dose of 5 mg levocetirizine ODT. In Part 1, subjects will receive levocetirizine ODT with 150 mL water and in Part 2 subjects will receive levocetirizine ODT without water.
224209641|NCT03372369|OTHER|View CDC Poster|The poster designed by the CDC to explain contraceptive effectiveness.
224209642|NCT03372369|OTHER|View Patient-Centered Poster|The poster designed by the research team to explain contraceptive effectiveness. This poster was developed through cognitive interviews with 26 North Carolina women, and the final version of this poster was found to be more useful, acceptable, and attractive than the CDC poster by the majority of women participating.
224209643|NCT00172094|DRUG|NPS 1776 (800 mg)|NPS 1776 (800 mg) powder
224209644|NCT00172094|DRUG|PLACEBO|Placebo in non-carbonated fruit flavored drink (150 ml)
224209645|NCT00172094|DRUG|NPS 1776 (400 mg)|NPS1776 in powdered form to be mixed with a non-carbonated fruit flavored drink
224209646|NCT02218931|BEHAVIORAL|Targeted ESTEEM diet|"The key components of the diet are:~High intake of vegetables, nuts, non-refined grains, legumes and fruits;Moderate to high consumption of fish;Small to moderate intake of poultry and dairy products such as yoghurt and cheese;Low consumption of red meat and processed meat and avoidance of sugary drinks, fast food and high fat food;High fibre;Intake of nuts including walnuts and almonds that are rich sources of monounsaturated and polyunsaturated fatty acids (30 g/day);Olive oil to cook and dress salads as the main source of fat (0.5 l/week)~The intervention will include structured meal plans and grocery lists, recipes for healthy diet and appropriate choices at restaurants"
224209647|NCT02218931|OTHER|Non-randomised cohort|Non-randomised cohort of women with no metabolic risk factors will be followed up to delivery to collect outcome data
224209648|NCT02343822|OTHER|Platelet Rich Plasma Injection|"Plasma component of blood rich in growth factors~-during the injection, 5 needle fenestrations will be done to help stimulate blood flow to the area for healing"
224209649|NCT02343822|OTHER|Saline Injection|"Saline~-during the injection, 5 needle fenestrations will be done to help stimulate blood flow to the area for healing"
224209650|NCT02946502|PROCEDURE|Handheld dynamometry (handgrip strength)|Patients will perform handgrip strength dynamometry through holding the device in their dominant hand with the maximum strength, with standardized arm and body positions, as well as incentives
224209651|NCT01392170|DRUG|PEG-IFNá-2a|45 mcg given subcutaneously as a single weekly dose for 24 months.
224209652|NCT03870737|DEVICE|Active TNS|Participants will receive 4-weeks nightly treatment with active TNS. Positive responders will be invited to participate in 12-month open-extension study.
224209653|NCT04299737|OTHER|Treatment Bundle (as defined below)|Patient decolonization within one hour of incision, improved environmental cleaning (frequency and quality, including but not limited to targeted use of no touch disinfection with UV-C treatment), provider hand hygiene leveraging proximity, improved catheter disinfection, and surveillance optimization.
224209654|NCT02632383|DEVICE|Young with Diabetes - app|"The mHealth app Young with Diabetes containes 8 main functions:~1. Contact your health care provider (ask questions, set the agenda for the next clinical visit)~2. My Department (hotline numbers, videos about the new adult department, pictures of my diabetes team)~3. Chatroom~4. Counting Carbohydrates (information and tips about carbs, introduction to apps to count carbs, quiz)~5. Knowledge-section (Text, links, tips and videos (animations and videoselfies) about What is diabetes?, Alcohol etc.)~6. Tips packages (Receive a tip about alcohol, drivers license etc.)~7. To parents (Text, links, tips and videoselfies to parents about what it is like to be young with diabetes and what they can do to support)~8. Reminder"
224209655|NCT05870826|OTHER|Multiwave locked system laser therapy|High intensity laser therapy
224209656|NCT05870826|OTHER|Sham laser therapy|Sham laser therapy
224209657|NCT04152252|OTHER|Real time feedback|Real-time feedback on chest compression depth, chest compression rate and recoil available to EMS while performing CPR. Feedback is delivered as visual text, numeric and graphical presentations on the defibrillator with audio tones for rate.
223619644|NCT06733467|OTHER|Stimulus properties: remembered feature|The feature used to determine which stimulus feature to remember to will be varied across trials using a letter cue (M = remember-motion; C = remember-color; 0 = remember nothing)
223619645|NCT02904798|DRUG|Polypodium Leucotomos|\- PL 240mg to be taken by the patient for 28 days prior to irradiation with visible light
223619646|NCT01635231|OTHER|hypertonic saline|hypertonic saline 3.0% 7 ml/kg
224209658|NCT04152252|BEHAVIORAL|Post-event debriefing|Structured oral post-event debriefing based on objective performance data from the resuscitation attempt. The debriefing is conducted as hot/immediate self-directed debriefing session with a maximum length of 10 minutes.
224209659|NCT05171699|OTHER|electroacupuncture|The patients in Group EA received electroacupuncture at Zusanli (ST36) (located 5 mm below the head of the inferior fibula and 2 mm lateral to the anterior tibial tuberosity) and Baihui (DU20) (located in the midpoint of the parietal bone) acupoints, the stainless steel acupuncture needles were connected to a Hans acupoint nerve stimulator and inserted into the acupoints.
224209660|NCT05171699|OTHER|shame electroacupuncture|The patients in Group SEA received electroacupuncture at a shallow depth and 1 mm lateral to Zusanli (ST36) (located 5 mm below the head of the inferior fibula and 2 mm lateral to the anterior tibial tuberosity) and Baihui (DU20) (located in the midpoint of the parietal bone) acupoints, the stainless steel acupuncture needles were connected to a Hans acupoint nerve stimulator and inserted into the acupoints.
224209661|NCT05684497|BEHAVIORAL|LBPSP in Pregnancy|LBPSP is a 50-minute interactive presentation as face to face program according to Pender's Health Promotion Model Parameters.
224209662|NCT00802776|PROCEDURE|Femtosecond laser assisted keratoplasty|
224209663|NCT00802776|PROCEDURE|PKP|
224209664|NCT00101894|DRUG|FOLFOX-4|"The FOLFOX-4 regimen will be administered every 2 weeks as follows:~Day 1: oxaliplatin (ELOXATIN™) 85 mg/m2 IV infusion and leucovorin racemate 200 mg/m2 (or 100 mg/m2 l-LV) IV infusion given over 120 ± 10 minutes at the same time in separate bags using a Y-line, followed by 5-FU 400 mg/m2 IV bolus given over 2 to 4 minutes, followed by 5-FU 600 mg/m2 IV infusion as a 22-hour ± 2 hours continuous infusion Day 2: leucovorin racemate 200 mg/m2 (or 100 mg/m2 l-LV) IV infusion over 120 ± 10 minutes, followed by 5-FU 400 mg/m2 IV bolus given over 2 to 4 minutes, followed"
224209665|NCT00101894|DRUG|AMG 706|AMG 706 is a small organic molecule that has been shown in preclinical pharmacology studies to be a potent, oral, multi-kinase inhibitor with anti-angiogenic and anti-tumor activity achieved by selectively inhibiting all known VEGF receptors, PDGF receptor, and Kit.
224209666|NCT00101894|BIOLOGICAL|Panitumumab (Part 1a only)|Panitumumab will be administered by IV infusion at a dose of 6 mg/kg on day 1 of each 2-week cycle.
224209667|NCT00101894|DRUG|FOLFIRI|Irinotecan will be administered over 90 minutes ± 15 minutes on day 1 of each 2-week cycle. Leucovorin will be administered over 2 hours ± 15 minutes during the irinotecan infusion but without mixing, immediately followed by a 5-FU bolus and a 5-FU 46-hour ± 2-hour continuous intravenous infusion.
224209668|NCT01547273|PROCEDURE|bone graft inside socket only|bone graft inside socket only
224209669|NCT01547273|PROCEDURE|bone graft inside and outside socket|bone graft inside and outside socket
224209670|NCT01547273|PROCEDURE|no bone graft|no bone graft
224209671|NCT01266473|OTHER|Physiotherapy|Physiotherapy for Airway Clearance
224209672|NCT00549120|DRUG|Propranolol|40 mg tablets
224209673|NCT00549120|DRUG|Salbutamol|Metered dose inhaler (600 μg)
224209674|NCT00549120|DRUG|Ipratropium|Metered dose inhaler (40 μg)
224209675|NCT00549120|DRUG|Placebo|Placebo for propranolol tablets
224209676|NCT00022126|DRUG|asparaginase|
224209677|NCT00022126|DRUG|cyclophosphamide|
224209678|NCT00022126|DRUG|cyclosporine|
224209679|NCT00022126|DRUG|cytarabine|
224209680|NCT00022126|DRUG|daunorubicin hydrochloride|
224209681|NCT00022126|DRUG|dexamethasone|
224209682|NCT00022126|DRUG|doxorubicin hydrochloride|
224209683|NCT00022126|DRUG|mercaptopurine|
224209684|NCT00022126|DRUG|methotrexate|
224209685|NCT00022126|DRUG|methylprednisolone|
224209686|NCT00022126|DRUG|pegaspargase|
224209687|NCT00022126|DRUG|thioguanine|
224323234|NCT01546987|RADIATION|Radiation therapy|Starts 8-10 weeks after initiation of ADT. Initially 45 Gy (1.8 Gy / fraction) to prostate and pelvic lymph nodes delivered with 3DCRT/IMRT, then a boost using intensity-modulated radiation therapy (IMRT), low dose rate (LDR) brachytherapy, or high dose rate (HDR) brachytherapy.
224323235|NCT06382051|DIAGNOSTIC_TEST|PEST Screening group|PEST Screening group
224209688|NCT00022126|DRUG|vincristine sulfate|
224209689|NCT00022126|PROCEDURE|allogeneic bone marrow transplantation|
224209690|NCT00022126|RADIATION|radiation therapy|
224209691|NCT03966573|RADIATION|Radiographic imaging|Evaluating arthritis in knee and hip bilaterally. Evaluating axis deficiancy and leg length discrepancy.
224323236|NCT06381674|OTHER|Vestibular therapy for mTBI augmented with audio and visual real-time biofeedback|During physical therapy sessions participants will wear sensors on their head, chest, waist, and feet for real-time instrumented audio and visual biofeedback on quality of therapeutic exercise.
223619647|NCT00791388|DRUG|Placebo|oral capsule, 2x/day for 14 days
224209692|NCT03966573|OTHER|Evaluating function|Test function and physical capasity
223619648|NCT00791388|DRUG|PG-760564|oral capsule, 50 mg, 2x/day for 14 days
223619649|NCT00791388|DRUG|PG-760564|oral capsule, 100mg, 2x/day for 14 days
223619650|NCT00791388|DRUG|PG-760564|oral capsule, 200 mg, 2x/day for 14 days
224209693|NCT03966573|OTHER|Forms|Forms for evaluating quality of life, pain, function
224209694|NCT04429373|PROCEDURE|Implant installation with PRF membrane|Platelet-rich fibrin membrane over the buccal aspect of implant site after dental implant installation
224209695|NCT04429373|PROCEDURE|Implant installation without PRF membrane|Implant installation contralateral to the experimental side without PRF membrane
224209696|NCT05049304|OTHER|Functional olive oil|Eleven adolescents will consume OA-enriched functional olive oil. After eating the olive oil, aliquots of cubital blood will be drawn at 2 and 5 hours of the postprandial period. During that time, free access to water intake will be allowed.
224209697|NCT05049304|OTHER|Olive oil|Eleven adolescents will consume olive oil. After eating the olive oil, aliquots of cubital blood will be drawn at 2 and 5 hours of the postprandial period. During that time, free access to water intake will be allowed.
223619651|NCT00791388|DRUG|PG-760564|oral capsule, 400 mg, 2x/day for 14 days
224209698|NCT00425516|DRUG|Taxotere|
224209699|NCT00425516|DRUG|5-Fluorouracil|
224209700|NCT00425516|DRUG|Epirubicin|
224209701|NCT00425516|DRUG|Cyclophosphamide|
224209702|NCT04266119|BEHAVIORAL|Online HOPE intervention|Online HOPE intervention to increase mental health literacy
224209703|NCT02228746|DIETARY_SUPPLEMENT|Alpha-galacto-oligosaccharides|6g of alpha-galacto-oligosaccharides in a 100 mL flavored drink
224209704|NCT06700408|DRUG|Dachaihu Decoction combined Erzhiwan with variation|Chinese medicine granules
224209705|NCT06700408|OTHER|Placebo granules|Placebo granules
224209706|NCT03061279|DEVICE|Fixation by Acutrak headless screw|The fixation provided by the Acutrak headless compression screws provide sufficient fixation to achieve union and a favorable clinical outcome in both horizontal and vertical medial malleolus fractures when compared to bicortical and unicortical screw fixation, tension band wiring, and mini-fragment or buttress plating
224209707|NCT03061279|DEVICE|Fixation by headed screws, plates, and or wires|DePuy-Synthes Cannulated Cancellous Screws, DePuy-Synthes Cancellous Screws, DePuy-Synthes Cortical Screws, DePuy-Synthes 1/3 Tubular Plate, DePuy-Synthes Locking contrast dynamic compression (LC-DCP) Plate, DePuy-Synthes Pre-contoured Plate, and/or 18g Wire are the alternative methods of treatment of medial malleolus fracture.
224209708|NCT02320838|DEVICE|5 KHz|5 KHz transcutaneous electrical stimulation over superficial radial nerve through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft, Netherlands)
224209709|NCT02320838|DEVICE|TENS|TENS transcutaneous electrical stimulation over superficial radial nerve through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft, Netherlands)
224209710|NCT02320838|DEVICE|Sham stimulation|Sham transcutaneous electrical stimulation over superficial radial nerve through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft, Netherlands)
224209711|NCT06701942|OTHER|Multiple family group intervention therapy|"Overview The intervention will be implemented at designated clinics where adolescents living with HIV/AIDS (ALHIV) and their families currently receive care. These sites will provide the MFG intervention alongside standard care services. All eligible adolescents and their family members who consent to participate will be included in the intervention group.~Program Structure The MFG intervention consists of 16 structured sessions, each running for 90 minutes. Sessions will be scheduled to coincide with clinic days over a 14-week period to maximize accessibility and attendance. Parent peers and community health workers, trained by the research team, will facilitate these group sessions.~Session Format Sessions on the MFGT will begin with introducing participants to one another, the facilitators, and the program curriculum. Subsequent sessions will concentrate on areas such as respectful communication, support, resilience building, problem-solving, conflict resolution, stress management"
224209712|NCT02648399|PROCEDURE|surgery：BCND（bilateral central lymph node dissection）|
224209713|NCT02648399|PROCEDURE|surgery：UCND（unilateral central lymph node dissection）|
224209714|NCT06538233|DRUG|Buffered articaine|Injecting buffered articaine in maxillary anterior region and evaluate pain response.
224209715|NCT06538233|DRUG|Non buffered articaine|Injecting non buffered articaine in maxillary anterior region and evaluate pain response.
224323237|NCT06381674|OTHER|Vestibular therapy for mTBI|During physical therapy sessions participants will go through vestibular therapeutic exercise WITHOUT audio and visual real-time biofeedback.
224323238|NCT06568237|DRUG|TEV-56286|TEV-56286 capsules administered orally
223619652|NCT00726947|PROCEDURE|Ultrasound|Ultrasound imaging of Acute DVT
223619653|NCT00726947|PROCEDURE|Ultrasound|Ultrasound imaging of Chronic DVT
223619654|NCT02324946|OTHER|Mass Screening|Preoperative screening with STOP-BANG and DES-OSA scores and postoperative comparison with difficult intubation / ventilation scores.
223619655|NCT05084040|OTHER|90 days interval between catheter maintenance|Length of time between catheter maintenances extended from 60 days to 90 days
224209716|NCT05021588|PROCEDURE|steroid and anticoagulants according to different protocols.|As no standard treatment for COVID-19 was approved; there are many treatment protocols for anti-inflammatory corticosteroids and anti-coagulantsfor severe COVID-19 pneumonia cases, this study aims to assess the most suitable modality in this high-risk group.
224209717|NCT01089985|DRUG|Autologous serum eyedrops|3 times a day for the duration of the study
224209718|NCT05305378|DEVICE|Laser speckle contrast imaging (LSCI)|LSCI videos will be recorded intraoperatively in each patient before, during, and after ICGA in the same surgical field of view to guarantee comparability of the methods.
224209719|NCT05699811|BIOLOGICAL|MSC-IFNα|MSC-IFNα form a dose of 2×10\^6 cells/kg, intravenous infusion every 4-6 weeks
224209720|NCT05699811|DRUG|Nab paclitaxel|125mg/m2, intravenous infusion every 4-6 weeks
224209721|NCT05699811|DRUG|Cyclophosphamide|200mg/m2, intravenous infusion every 4-6 weeks
224209722|NCT05699811|DRUG|Anti-PD-1 monoclonal antibody|200mg, intravenous infusion every 4-6 weeks
224209723|NCT04141137|DEVICE|TricValve® System|The TricValve® Delivery System (catheter) with already pre-mounted biological heart valve is inserted from the femoral vein to access the inferior vena cava (IVC) and superior vena cava (SVC) of the heart under fluoroscopy guidance. The appropriately sized TricValve® is released at the implantation site and positions itself as per the anatomy - self expanding frame.
224209724|NCT01079078|DRUG|Acetaminophen|
224209725|NCT05668715|OTHER|Transcutaneous tibial nerve stimulation (TTNS)|PTNS has some disadvantages such as it is a minimally invasive method applied by needle, and the need to go to the hospital for this. However, the number of studies on transcutaneous tibial nerve stimulation (TTNS) (non-invasive and can be applied at home) tends to increase in recent years
224209726|NCT05597163|DRUG|low concentration atropine (0.01%)|0.01% atropine eye drop
224209727|NCT05597163|DRUG|low concentration atropine (0.025%)|0.025% atropine eye drop
224209728|NCT05597163|DRUG|low concentration atropine (0.05%)|0.05% atropine eye drop
224209729|NCT05597163|DRUG|Placebo|Placebo eye drop
224323239|NCT06568237|DRUG|Placebo|Matching placebo administered orally
224209730|NCT01398982|DRUG|Bupivacaine (study group)|At the conclusion of the surgery, a 0.2 mL/kg bolus of 0.25% Bupivacaine will be injected through each catheter in the OR. At midnight following the OR, 0.2mL/Kg of 0.25% Bupivacaine will be injected through each catheter every 8 hours for the next 2 postoperative days by a MD member of the pain team. At 8am on postoperative day 3, the TAP catheters were removed by the pain team. Our rationale for decreasing the frequency of intermittent boluses from every 12 hours to 8 hours in this study design was based on our finding in the pilot study that patients frequently used more PCA between 8-12 hours following Bupivacaine bolus as the effect of the anaesthetic agent weaned off.
224209731|NCT01398982|DRUG|Isotonic saline (control group)|At the conclusion of the surgery, a 0.2 mL/kg bolus of Saline will be injected through each catheter in the OR. At midnight following the OR, 0.2mL/Kg of Saline will be injected through each catheter every 8 hours for the next 2 postoperative days by a MD member of the pain team. At 8am on postoperative day 3, the TAP catheters were removed by the pain team. Our rationale for decreasing the frequency of intermittent boluses from every 12 hours to 8 hours in this study design was based on our finding in the pilot study that patients frequently used more PCA between 8-12 hours following Bupivacaine bolus as the effect of the anaesthetic agent weaned off.
224209732|NCT03174925|DEVICE|Siemens Acuson S3000 ultrasound system|Shear Wave Elastography
224209733|NCT02235337|DRUG|Riboflavin 400mg daily|
224209734|NCT03840642|BEHAVIORAL|Mirror Me|Mirror Me is a telehealth parent training intervention that teaches parents to promote their child's social imitation during play and daily routines. It uses content from Reciprocal Imitation Training (RIT), an evidence-based NDBI that teaches social imitation within affect-laden playful interactions. Mirror Me presents intervention content in four interactive modules. Program development was guided by the technology acceptance model, media richness theory, and principles of instructional design.
224209735|NCT03840642|BEHAVIORAL|Remote Coaching|Trained therapists will provide feedback to parents as they use the RIT techniques with their child at home. All sessions will follow a similar format including a discussion of accomplishments and challenges, parent practice with feedback, problem solving, and planning for the next week
224209736|NCT01791127|DEVICE|market-released BIOTRONIK pacemaker system including one or two Siello S leads.|
224315873|NCT01937078|DRUG|Famotidine|Each patient will receive 4 randomized treatment phases - three famotidine (one at each of the dose levels) and one placebo. Each treatment phase will last for 14 days. Doses of drug will be titrated upwards, starting at 40mg once daily on day one, 40mg twice daily on day two, and 80mg twice daily (or placebo + drug equivalent) from day three and then continue on this dose for the next 12 days. Regardless of treatment phase, subjects will take 2 tablets twice daily, with varying ratios of active famotidine to placebo. Thus famotidine 80mg/d will consist of 1 tablet of 40 mg famotidine plus 1 tablet of placebo twice a day; 120 mg /d famotidine will be 2 tablets at 40 mg morning and 1 tablet famotidine 40 mg plus 1 tablet placebo evening; famotidine 160 mg/d will be famotidine 40 mg tablets, 2 tablets twice a day. The placebo phase will consist of 2 placebo tablets twice a day.
224315874|NCT02729571|BIOLOGICAL|MTBVAC|Live-attenuated tuberculosis vaccine
224315875|NCT02729571|BIOLOGICAL|BCG|Commercially available live-attenuated tuberculosis vaccine
224315876|NCT00912938|DRUG|zoledronic acid|Intravenous zoledronic acid 4mg over a minimum of 15 minutes in at least 100mls of calcium free infusion solution (0.9% sodium chloride or 5% glucose solution) every 4 weeks.
224315877|NCT00125671|DRUG|Warfarin|
224315878|NCT02861924|OTHER|microcirculatory responses|"The effect of the duration and intensity of the pressure; reproducibility and correlation with ischemic hyperemia post.~measurements are made with the Imager SPECKLE imager (LSCI) give the microvascular perfusion data in arbitrary units called perfusion units (UP)."
224315879|NCT00293111|DRUG|SDX-101 (R-Etodolac)|
224315880|NCT05187728|OTHER|No Intervention|No more intervention will be given.
224315881|NCT01761383|OTHER|Nintendo Wii video console and Nintendo Wii Fit Plus games|The intervention will be provision of Nintendo Wii console and Wii Fit Plus video games to use for the duration of the study with no restrictions or limitations on the games participants are allowed to play or duration of play. There will be 5 home visits over a 6-month period to evaluate Nintendo Wii use and assess patients'health, functioning and quality of life.
224209737|NCT04368182|BIOLOGICAL|Autologous C-TCR055|Autologous C-TCR055 administered by intravenous (IV) infusion
224209738|NCT03380182|OTHER|Acupressure Band|These bands use pressure to stimulate the P6 acupuncture point.
224209739|NCT03380182|OTHER|Sham Band|These sham bands are used to make it seem like the band is using pressure to stimulate the P6 acupuncture point.
224209740|NCT03964220|DRUG|Tiotropium Respimat®|Tiotropium Respimat® 1.25 mcg (on top of baseline Inhaled Corticosteroid/Long-acting beta-agonist )
224209741|NCT03964220|DRUG|Inhaled Corticosteroid/Long-acting beta-agonist|baseline low dose to medium/high dose, baseline medium dose ICS/LABA to high dose ICS/LABA, additional prescription/refill of high-dose-ICS/LABA following the first prescription of baseline high dose ICS/LABA
224209742|NCT02414074|BEHAVIORAL|Youth Behavioral Intervention|Teen Intervene is an early intervention program for 12-19 year olds.
224209743|NCT02414074|BEHAVIORAL|Parent Education|Everyday Parenting is a parent training curriculum.
224209744|NCT03012620|DRUG|Pembrolizumab|Treatment
224209745|NCT06111560|OTHER|We do not have any interventions. This study is based on obseravation.|observational retrospective study without any interventions
224209746|NCT02034994|BEHAVIORAL|Eating behavior and physical activity change|A combination of two prevention school based programs will be addressed to schoolchildren over one year. Primary prevention will be developed monthly in order to reduce cookies and sugar sweetened beverages consumption, reduction of sedentary activities, increase meal consumption frequency and quality etc, in all children from 6th and 7th grades. Overweight and obese children will be invited to participate on a secondary prevention program in which daily physical activity classes will be performed by physical education teachers in school facilities.
224315882|NCT00748761|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|Nondrug psychotherapy administered weekly for 12 weeks
224315883|NCT00748761|BEHAVIORAL|Waitlist|Contact waitlist weekly for 12 weeks
223619656|NCT03930836|BEHAVIORAL|Hand Arm Bimanual Intensive Therapy Including Lower Extremities|Intensive intervention focusing on a constant bimanual coordination with a lower extremities and trunk control stimulation during play and functional activities. 50% of therapeutic time will be performed using the new interactive interface
224209747|NCT03940027|PROCEDURE|EUS-guided celiac plexus neurolysis|EUS-guided celiac plexus neurolysis (EUE-CPN) is an endoscopic ultrasound-guided injection of local anesthetics and neurodegenerative agents into the abdominal ganglion area through the gastric wall, so as to achieve irreversible damage of the abdominal nerve and interrupt the pain pathway of pancreatic cancer.EUS-CPN has the advantages of less trauma, higher technical success rate and lower risk of complications compared with traditional ct-guided CPN in vitro puncture.The data showed that eus-cpn was effective in the treatment of pancreatic cancer related persistent abdominal pain up to about 70%, significantly reducing the dosage of analgesics and improving the quality of life of patients with advanced pancreatic cancer.
224209748|NCT00451594|DRUG|Dexamethasone|"Pulse high dose dexamethasone (Arm 1)~1. Patients will receive 40 mg of oral dexamethasone daily for four consecutive days.~2. Other treatments should be considered if there was a platelet count of 30X109/L or less by day 14~3. If the patient had a platelet count of more than 30X109/L after four days of dexamethasone treatment, no further treatment will be given.~4. If the platelet count drops below 30X109/L within the first 6 months, another four-day course of dexamethasone will be given, followed by 15 mg of prednisone daily, with gradual tapering.~5. Patients whose platelet counts can not be maintained at 30X109/L will be offered other treatments."
224209749|NCT00451594|DRUG|Prednisolone|"Conventional dose prednisone (Arm 2)~1. Prednisone, 1 mg/kg is started at diagnosis. If the platelet count is more than 100X109/L, the dose should be used for 4 weeks minimally and then tapered by 10 mg/1 wk until the dose reaches 0.5 mg/kg of body weight and by 5 mg/1 wk thereafter. (Ann Intern Med 1997, 126, 307-14). If the platelet count is between 30X109/L and 100X109/L, prednisone 1 mg/kg should be used for 8 weeks maximally and then tapered by 10 mg/2 wk until the dose reaches 0.5 mg/kg of body weight and by 5 mg/2 wk thereafter.~2. Guideline of prednisone tapering Duration of prednisone treatment: 3-6 months"
224209750|NCT04247594|DRUG|Voxelotor|synthetic small molecule supplied as 500 mg tablets
224209751|NCT00060489|DRUG|SEROQUEL (quetiapine fumarate) Tablets|
224209752|NCT03082820|DIAGNOSTIC_TEST|Pain-related evoked potentials (PREP)|PREP were performed bilaterally with a concentric surface electrode at twice the individual pain threshold.
224209753|NCT03082820|DIAGNOSTIC_TEST|Quantitative Sensory Testing (QST)|QST was performed bilaterally following the protocol of the German Network on Neuropathic Pain.
224209754|NCT03082820|DIAGNOSTIC_TEST|Nerve conduction studies (NCS)|NCS were performed with patients only.
224209755|NCT03218631|DRUG|Oxandrin|"The primary outcome for this study will be measurements of the pharmacokinetics of a single dose of oxandrolone 0.1 mg/kg both in tablet form and in the MCT oil preparation. Blood samples for pharmacokinetics will be drawn at 9 timepoints.~Safety will be assessed by recording adverse events and assessment of hepatic function at baseline and one week following oxandrolone dosing."
224209756|NCT05212831|DEVICE|Inogen One® G4|Inogen One® G4 will be used for a minimum of 3h per day at Setting 3 during the intervention period.
224209757|NCT04217031|OTHER|No intervention|No intervention
224209758|NCT03183973|BIOLOGICAL|PRF|patients who will receive PRF suspension
224209759|NCT03183973|BIOLOGICAL|placebo group|patients who will receive Placebo
224209760|NCT00666731|OTHER|medical chart review|Demographic information (like address and birth date), the results of physical exams, blood tests, x-rays and other diagnostic and medical procedures and treatments, as well as medical and surgical history.
224209761|NCT00666731|OTHER|questionnaire administration|Collection of personal information, medical history, diet and lifestyle habits, any past or current environmental exposures and to re-create a family tree for any cancers that have occurred in any family members. In accordance with OPRR guidelines, no identifying information such as name, address, or date of birth will be used for relatives, but the affected status (cancer, age of onset, year of birth, age of death) will be recorded.
224209762|NCT00666731|OTHER|study of socioeconomic and demographic variables|Repository
224209763|NCT00666731|PROCEDURE|Excess human biological tissue|Tissue procurement.
224209764|NCT00666731|PROCEDURE|quality-of-life assessment|Cancer care.
224209765|NCT05418257|OTHER|(exposure) telemedicine|medical counseling or treatment only using phone
224209766|NCT02918825|DRUG|Olanzapine|Olanzapine
224209767|NCT02918825|DRUG|Paliperidone|Paliperidone
224209768|NCT06134765|DRUG|Bemalenograstim alfa|Bemalenograstim alfa,20mg, once every treatment
224209769|NCT04951973|DIAGNOSTIC_TEST|Deep Learning Based Early Warning Score (DEWS)|DEWS use 4 vital signs (systolic blood pressure, HR, respiratory rate, and body temperature) to predict in-hospital cardiac arrest. Deep-learning approach facilitates learning the relationship between the vital signs and cardiac arrest to achieve the high sensitivity and low false-alarm rate of the track-and-trigger system (TTS).
224209770|NCT04521439|DIAGNOSTIC_TEST|18F-florbetapir PET+MRSI|PET and MRS quantitative parameters in MS lesions are simultaneously analyzed using hybrid PET/MR for obtaining demyelination and neuronal damage information.
224209771|NCT02706522|DIETARY_SUPPLEMENT|Allocated to Carbohydrated group|Patients received 400 mL of oral isotonic glucose (No NPO®, Daesang, Korea) 12 hours before anesthesia and 400 mL 2 hours before. CHL composition was standard: 12.5 g of carbohydrate per 100 mL, 12% monosaccharide, 12% disaccharide, 76% polysaccharide, 250 mOsm/kg and 50 kcal.
223619657|NCT03930836|BEHAVIORAL|Conventional physical and occupational therapy|Conventional therapy (physical and occupational therapy) is mainly based on neurodevelopmental therapeutic principles. 50% of therapeutic time will be performed using the new interactive interface
224209772|NCT02706522|DIETARY_SUPPLEMENT|Allocated to Placebo group|Patients received 400 mL of oral flavored water (Placebo) 12 hours before anesthesia and 400 mL 2 hours before
224209773|NCT01273922|BIOLOGICAL|NDV-3 investigational vaccine|Two doses of vaccine 6 months apart or placebo(only one dose at Time 0) administered intramuscularly
224209774|NCT00720473|DRUG|Lamotrigine|Lamotrigine with dosage range from 25 mg to 200 mg per day.
224209775|NCT01495169|DRUG|iloperidone (oral tablet)|iloperidone 12 to 24 mg/day followed by 26 weeks of flexible dosing (6 to 24 mg/day)
224209776|NCT03386669|DRUG|F-18|Totally 60 subjects age 20-80 including 20 subjects with a diagnosis of PD,PSP,and CBS. For disease subjects, caregiver should be able to report activities of daily living and their mental status. Patient should be able to give informed consent or have a caregiver give consent with subject assent.
224209777|NCT02846740|DEVICE|Alpha-Stim®.|cranial electrical stimulation
224315884|NCT01443728|DRUG|Experimental: Vitamin D3 100,000 IU|Oral vitamin D3, 100,000 IU \[2.5 mg\] given once a month
224209778|NCT02846740|BEHAVIORAL|Montgomery-Åsberg Depression Rating Scale, Hamilton Anxiety Rating Scale, The Pittsburgh Sleep Quality Index and agitated behavior Scale|A summed global score from rating scales measuring the Modifiable suicide risk factors (MSRF's).
224209779|NCT00884663|DRUG|Candesartan|Candesartan cilexitil tablets, 16 mg once daily
224209780|NCT00884663|DRUG|propranolol|Propranolol hydrochloride capsules 160 mg once daily, slow release formulation
224209781|NCT00884663|DRUG|placebo|placebo tablets and capsules
224315885|NCT01443728|DRUG|Active Comparator: Vitamin D3 12,000 IU|Standard dose oral vitamin D3 12,000 IU \[0.3 mg\] given once a month
224315886|NCT04971187|DRUG|Bintrafusp Alfa|Given IV
224315887|NCT04971187|DRUG|Pemetrexed|Given IV
224315888|NCT04971187|DRUG|Carboplatin|Given IV
224315889|NCT04971187|DRUG|Cisplatin|Given IV
224315890|NCT00229775|DRUG|artemether/lumafantrine vs chloroquine/sulfadoxine-pyrimethamine|
224315891|NCT06361199|DRUG|Proximod|Multiple-dose to establish the safety and PK profile in both healthy subjects and patients with rheumatoid arthritis
224315892|NCT06361199|DRUG|Placebo|Placebo controlled
224315893|NCT05937360|OTHER|cross-sectional community based study|Participants (women between the ages of 18 and 45 years) are selected randomly throughout various regions of Trinidad. Every 10th house from the selected regions would be assessed.
224315894|NCT05780060|BEHAVIORAL|Standard of care, RPM and digital feedback|Standard stroke follow up, RPM and a patient facing smartphone application containing real time BP feedback, educational models, treatment adherence push notification reminders, digital education and digital incentives (n=30). Outcomes will include recruitment, retention and follow up metrics, self-reported adherence to medication regimens and life-style recommendations, patient engagement with RPM data and patient-facing application, cost-effectiveness of the interventions and changes in blood pressure as well as biomarkers like LDL and Hemoglobin A1C.
224315895|NCT05780060|BEHAVIORAL|Standard of care and RPM only|Standard stroke clinic follow up and remote blood pressure monitoring (n=30). Outcomes will include qualitative patient and provider experiences with the TBIs including barriers and facilitators to the use of RPM and patient-facing application in the study population
224315896|NCT01531660|BEHAVIORAL|step-up jogging program|
224315897|NCT01403051|DRUG|EFV/FTC/TDF|FDC efavirenz/emtricitabine/tenofovir disoproxil fumarate (Atripla) 600 mg/200 mg/ 300 mg tablet taken orally once daily at bedtime on an empty stomach.
224315898|NCT01403051|DRUG|Calcium Carbonate|Calcium carbonate 500 mg tablet taken orally twice daily with food for 48 weeks.
224315899|NCT01403051|DRUG|Vitamin D3|One Vitamin D3 4000 IU capsule taken orally once daily with food for 48 weeks.
224315900|NCT01403051|DRUG|Placebo for calcium carbonate|A placebo for calcium carbonate twice daily taken orally as one x 0 mg tablets with food for 48 weeks
224315901|NCT01403051|DRUG|Placebo for vitamin D3|A placebo for vitamin D3 once daily taken orally as one capsule with food for 48 weeks.
224315902|NCT01092858|DRUG|Testosterone Undeconate (Nebido, BAY86-5037)|Testosterone undecanoate 1000 mg (4 ml) i.m. injection at baseline, at week 6, at week 18, at week 30 and at week 42, respectively
224315903|NCT01092858|DRUG|Placebo|Matching placebo i.m. injections at baseline, at week 6, at week 18 at week 30 and at week 42, respectively
224315904|NCT00108134|DRUG|PEP005|
224315905|NCT00674739|DRUG|Imiquimod|daily topical application for up to 8 weeks
224315906|NCT00674739|DRUG|3.75% imiquimod cream|3.75% imiquimod cream applied daily to wart areas for up to 8 weeks.
224315907|NCT00674739|DRUG|placebo cream|placebo cream applied daily to wart areas for up to 8 weeks
224315908|NCT06509113|BEHAVIORAL|The online HIV-related stigma training|The intervention is an online HIV-related stigma training that takes 6 hours in 4 weeks to be completed.
224315909|NCT06509113|BEHAVIORAL|The online HIV epidemiology training with no specific content on stigma|Nursing students will be trained in an online HIV epidemiology training with no specific content on stigma. It will take 6 hours in 4 weeks to complete the training.
224315910|NCT02382042|BEHAVIORAL|Intensive Referral Intervention|
224315911|NCT04653649|BIOLOGICAL|HSP-CAR30|Anti-CD30 CAR T-cells
224315912|NCT00880178|DRUG|Simvastatin and Extended-Release niacin|Participants will be enrolled in this substudy only if they are candidates for the main AIM-HIGH study (NCT00120289). Participants will be randomly assigned to simvastatin or simvastatin plus niacin as a part of the main AIM-HIGH protocol, and adjustments in simvastatin and/or niacin doses will be made as per the protocol for the main AIM-HIGH study.
224315913|NCT00880178|DRUG|Simvastatin|Participants will be enrolled in this substudy only if they are candidates for the main AIM-HIGH study (NCT00120289). Participants will be randomly assigned to simvastatin or simvastatin plus niacin as a part of the main AIM-HIGH protocol, and adjustments in simvastatin and/or niacin doses will be made as per the protocol for the main AIM-HIGH study.
224315914|NCT05411757|COMBINATION_PRODUCT|IBR900 combined with Lenvatinib|IBR900 cell injection: 4.0×10\^9 cells, D1,D3 of each cycle. Lenvatinib: body weight ≥ 60kg, 12mg/qd; body weight \< 60kg, 8mg/qd; administered continuously from D5 of the first cycle
224209782|NCT02428634|BEHAVIORAL|PSIE13|The Program SI! is implemented from 1st to 3rd grade of Elementary. A total of 40 hours of intervention on 1st and 2nd grade and 30 hours on 3rd grade has been established as the minimum intervention per year.
224209783|NCT02428634|BEHAVIORAL|PSIE46|The Program SI! is implemented from 4th to 6th grade of Elementary. A total of 30 hours of intervention has been established as the minimum intervention per year.
224209784|NCT00690924|DRUG|calcitriol|Oral
224209785|NCT00690924|OTHER|laboratory biomarker analysis|Correlative Study
224209786|NCT00690924|OTHER|pharmacological study|Correlative Study
224209787|NCT03202186|DRUG|Progesterone oral capsule|Oral capsule treatment
224209788|NCT03202186|DRUG|Placebo oral capsule|Oral capsule treatment
224209789|NCT01518621|RADIATION|Radiation|Whole brain radiation
224209790|NCT01518621|DRUG|Radiation plus erlotinib|Radiation 3Gy x10 plus erlotinib 150 mg q d, from the day before radiation start, through last day of irradiation
224315915|NCT05411757|COMBINATION_PRODUCT|IBR900 combined with Bevacizumab|IBR900 cell injection: 4.0×10\^9 cells, D1,D3 of each cycle. Bevacizumab:15mg/kg, D1 of each cycle.
224315916|NCT01368653|BEHAVIORAL|Standard treatment|Standard treatment includes a 6-week supply of 21-mg nicotine patches and 4 15-minute individual smoking cessation counseling sessions to help smokers quit smoking
224315917|NCT01368653|BEHAVIORAL|Standard treatment+practice quitting|This intervention includes standard treatment (a 6-week supply of 21-mg nicotine patches and 4 15-minute individual smoking cessation counseling session) and an experimental treatment that involves practice quitting 7 times prior to a target quit date (for 4-12 hours per day) and returning to smoking by puffing smoke without inhaling
224315918|NCT01368653|DRUG|Very low nicotine cigarettes|This intervention will be offered to a subset of smokers from both of the other study arms. To be eligible for this intervention, participants must be smoking at the follow-up interview conducted four weeks after a target quit day in the two arms listed above. Tobacco cigarettes containing very low levels of nicotine (.016-.019 mg in smoke from the cigarettes). These are to be smoked no more often than a smoker normally smokes regular cigarettes and for no longer than 6 weeks.
224315919|NCT00825760|DRUG|Topical PPA904 gel and light|
224315920|NCT00825760|DRUG|Topical placebo gel plus light|
224315921|NCT01849965|DRUG|DSC127|DSC127 0.03%, daily topical application to diabetic foot ulcer for a period of up to 28 days or until ulcer closure, whichever occurs sooner.
224315922|NCT01849965|DRUG|placebo vehicle gel|
223761539|NCT06568211|DEVICE|Virtual Reality|Persons living with dementia (PLwD) will view 360-degree videos using a commercially-available Virtual Reality (VR) head mounted display that has built-in speakers. While wearing the VR headset, PLwD-participant will be able to visually explore the virtual environments by turning their head to face different directions. Care partner-participants will take part in the VR experience concurrently by viewing a tablet that is connected to the VR headset through the \&amp;#34;screen mirroring\&amp;#34; function.
223761540|NCT06568211|DEVICE|Tablet-Only|PLwD and care partner will view 360-degree videos together on a commercially-available tablet that has built-in speakers. They will be able to visually explore the virtual environment using the touch screen (dragging the view around with their fingers).
224209791|NCT02913469|DRUG|Morphine|The patients in group A would be administrated intravenous morphine 5mg
224209792|NCT02913469|DRUG|metoclopramide|the patients in group C would be administrated intravenous metoclopramide 10mg
224209793|NCT02913469|DRUG|saline|the patients in group D would be administrated intravenous 0.9%normal saline 2mland 0.9%normal saline 2ml.
224209794|NCT06460246|DEVICE|Pulse Oximeter|The subjects will have a 22-gauge catheter inserted in the radial artery to measure the oxygen saturation of arterial blood and also wear pulse oximeters.
224209795|NCT02748616|DRUG|Ursodiol|Subjects will begin to take 300 mg Ursodiol 2 (two) weeks after Visit #1 for a total of 8 (eight) weeks.
224209796|NCT00814619|BIOLOGICAL|panitumumab|Given IV
224209797|NCT00814619|DRUG|capecitabine|Given orally
224209798|NCT00814619|PROCEDURE|therapeutic conventional surgery|Patients undergo surgical resection
224209799|NCT00814619|RADIATION|3-dimensional conformal radiation therapy|Patients undergo radiotherapy
224209800|NCT06334250|DEVICE|Catheter ablation of atrial fibrillation using Pulsed Field Ablation|Pulsed Field Ablation of atrial fibrillation at the time of left atrial appendage occlusion
224315923|NCT01849965|DRUG|Standard of Care gel, Aquasite|
224315924|NCT00307398|DRUG|Anecortave Acetate (AL-3789) sterile suspension, 15 mg or 30 mg|One 0.5 mL injection of 30 mg/mL (AA 15 mg) or one 0.5 mL injection of 60 mg/mL (AA 30 mg) into a posterior juxtascleral depot (PJD) at 6-month intervals.
224315925|NCT00307398|OTHER|Anecortave Acetate Vehicle|One 0.5 mL sham injection at 6-month intervals. Syringe containing AA vehicle was not inserted into the eye.
224315926|NCT02135614|DRUG|Presatovir|Presatovir 200 mg (4 x 50 mg tablets) administered orally
224315927|NCT02135614|DRUG|Presatovir placebo|Presatovir placebo tablets administered orally
224209801|NCT06334250|DEVICE|Left atrial appendage occlusion|Left atrial appendage occlusion using the Watchman device
224209802|NCT05137418|BIOLOGICAL|COVID-19 Vaccine,Inactivated|The COVID-19 vaccine,inactivated was manufactured by Sinovac Research\& Development Co., Ltd..600SU Inactivated SARS-COV-2 virus in 0·5 mL of aluminium hydroxide solution per injection
224315928|NCT01358214|BEHAVIORAL|Questionnaire on Quality of Life.|The impact of a disease on patient's Quality of Life has meanwhile gained more influences on the choice of treatment alternatives. The benefit of a method is currently not only defined by the objective outcome but also influenced by the Quality of Life. Two questionnaires with 20 respectively 40 Questions should be filled in by the patients.
224315929|NCT05238610|PROCEDURE|PFO closure|PFO-closure will be performed after 3-6 month of observation and monitoring for paroxysmal atrial fibrillation
224315930|NCT05173181|DEVICE|Flexible intramedullary nail|Fixation of distal ulna fracture with flexible intramedullary nail
224315931|NCT03402061|DIETARY_SUPPLEMENT|nutrient enhanced recipes|normal ingredients will be substituted to promote nutrient density of products
223761541|NCT06915675|BIOLOGICAL|Placental Extract|Participants will receive allografts bone substitutes mixed with flowable human placental derived connective tissue matrix in one extraction socket immediately following tooth extraction.
223761542|NCT06915675|PROCEDURE|Allograft|Participants will receive allografts bone substitutes solely in one extraction socket immediately following tooth extraction.
224209803|NCT03552679|DIAGNOSTIC_TEST|Echocardiography|Echocardiography
224209804|NCT04227652|DRUG|Ibuprofen administration|Administration of ibuprofen, according to treatment recommendations - per orally, into the nasogastric tube, or in the form of a suppository
224209805|NCT04071275|DEVICE|transcranial Direct Current Stimulation (tDCS)|tDCS is a non-invasive technique that allow the administration of low currents directly to the scalp. The currents affect the cortex, and result in changes to the membrane potential of neurons in the stimulated area. This in turn affects the tendency of those neurons to generate action potentials.
224209806|NCT04071275|OTHER|Mirror therapy|Mirror therapy is a behavioral technique that proven useful for the treatment of phantom pain, yet the analgesic effects are unfortunately moderate and not long lasting. The assumed underlying mechanism of mirror therapy treatment is the induction of neuronal plasticity in the opposite direction than the abnormal reorganization of the cortex (due to the amputation), and by that relive pain.
224209807|NCT01268137|PROCEDURE|Deep Brain Stimulation|Surgical electrode implantation in the white matter adjacent to the Cg25 region and implantation of the DBS pulse generating device
224209808|NCT00589693|DRUG|Doripenem|Type=exact number, number=1, unit=g, form=solution for injection, route=intravenously. 1 gram 4-hour infusion of doripenem will be administered every 8 hours for 7 days.
223761543|NCT06919419|BEHAVIORAL|Multicomponent strategy|dentify patients for HIV/STI testing, engage in discussions around PrEP and navigate patients to PrEP after jail incarceration
223761544|NCT06919159|DIAGNOSTIC_TEST|PSMA PET/CT scan|Different developing agents
224315932|NCT05244694|DRUG|Insulin|Priming dose then a constant infusion at 40 mU•m-2•min-1
223761545|NCT06919159|DIAGNOSTIC_TEST|FDG-PET|Different developing agents
224209809|NCT00589693|DRUG|Imipenem-Cilastatin|Type=exact number, number=1, unit=g, form=solution for injection, route=intravenously. 1 gram 1-hour infusion of imipenem-cilastatin will be administered every 8 hours for 10 days.
224315933|NCT01701011|BEHAVIORAL|Coping intervention|Positive reappraisal coping intervention
224315934|NCT03318731|OTHER|Sugar Pill|Taken orally in capsule form
224315935|NCT03318731|DIETARY_SUPPLEMENT|Fenugreek Extract, Low Dose|Taken orally in capsule form
224315936|NCT03318731|DIETARY_SUPPLEMENT|Fenugreek Extract, High Dose|Taken orally in capsule form
224315937|NCT03729817|DEVICE|Submaximal balloon angioplasty|An endovascular procedure involving inflation of a balloon catheter undersized to 50-75% of normal vessel diameter to perform angioplasty of a stenotic blood vessel segment, with the goal of increasing blood flow.
224315938|NCT01229709|BEHAVIORAL|Mindfulness Based Tinnitus Reduction|The Mindfulness Based Tinnitus Reduction (MBTR) program will be held for two-and-a-half hours one evening per week over 8 consecutive weeks. Participants will also complete a day-long Sunday retreat between the 6th and 7th sessions. Each participant will take part in a 30-minute private interview with the course instructor prior to beginning the program.
224315939|NCT02252991|OTHER|physical activity|Patients will realise physical activity either during their treatment, either after their treatment. They will have practise a physical activity three times per week.
224315940|NCT02906358|BEHAVIORAL|Community-based pain self-management|
224315941|NCT02906358|BEHAVIORAL|Clinic-based pain self-management|
224315942|NCT04435535|PROCEDURE|PEP|Positive expiratory pressure 10 cmH2O 15 min
224315943|NCT01171118|DRUG|Physostigmine|Physostigmine is a centrally acting acetylcholinesterase inhibitor that has been proposed as a treatment for sleep disordered breathing. It is currently FDA approved and used commonly by Anesthesiologists in the post anesthetic setting to reverse confusion caused by central anticholinergic medication effects.
223619658|NCT05762796|DEVICE|tDCS in Youth with mild traumatic brain injury|The safety and tolerability of tDCS have been established in children with mTBI (1). A recent study of 13-18 year youths post-mTBI showed that three sessions of 1.5 mA anodal tDCS over the left DLPFC, positively influenced prolonged working memory deficits. (2) Additionally, rodent studies show the effectiveness of tDCS in improving cognitive-motor (motor planning and balance/gait) function in rats with mTBI. (3)
223619659|NCT00498914|DRUG|YM155|Continuous IV infusion
223619660|NCT03090308|OTHER|Noninvasive positive pressure ventilation|All patients were ventilated using NIPPV (Engstrom Carestation), which was delivered to the patient through full-face mask and was started with pressure support of 8-12 cmH2O and PEEP of 3-5 cmH2O and gradually increased in 2 cmH2O steps. When patients tolerate FiO2 ≤ 0.5 with pressure support ≤ 8 cmH2O and PEEP ≤ 5 cmH2O for \> 6 consecutive hours, withdrawal from NIPPV was attempted daily in 30 minutes spontaneous breathing trials.
223761546|NCT06923891|DRUG|Xanomeline/Trospium|Xanomeline/Trospium (titrated dose)
223761547|NCT06923982|OTHER|virtual reality, experimental group|Socio-demographic characteristics form questions were asked to individuals in the intervention group before care. During the care, patients are given virtual reality glasses (VR box 2.0 virtual reality glasses and 6.5 inch) for a total of 15 minutes, ranging from 3 to 10 minutes, and watch videos that the patient wants to watch, such as park, nature and seaside walks, undersea and museum trips, with a music background. and he was shown videos that he could change at any time. After the maintenance, Visual Analog Scale-Pain (VAS-P) scale, General Comfort Level Scale and Satisfaction Evaluation Scale for Virtual Reality Glasses Application questions were applied. 24 hours after the care, VAS-P and General Comfort Level Scale were administered again.
223761548|NCT06923982|OTHER|control group|A socio-demographic questionnaire was administered to the control group before care. During maintenance, no intervention was applied and standard care in routine practice was applied. After the care, Visual Analog Scale-Pain (VAS-P) scale and General Comfort Scale were applied. 24 hours after the treatment, the Visual Analog Scale-Pain (VAS-P) scale and the General Comfort Scale were applied again.
224315944|NCT01171118|DRUG|Oxygen|The administration of nasal cannula-administered oxygen at a flow rate of 2 liters/minute is commonly performed during clinical sedation practice. Thus, this experiment employed its use to compare respiratory effects of oxygen versus room air.
224315945|NCT01171118|DRUG|Placebo|The administration of placebo versus physostigmine was untertaken in the same sedation conditions on the alternate day in each subject (and with both room air and oxygen)
223619661|NCT03902691|DRUG|Pegol-Sihematide|Participants received Pegol-Sihematide by subcutaneous injection once every 4 weeks ; the dose was adjusted throughout the study to maintain a hemoglobin target range of 10.0-12.0 grams per deciliter (g/dL).
223619662|NCT03902691|DRUG|ESPO|Participants received ESPO by subcutaneous injection or subcutaneous injection weekly. The dose was adjusted throughout the study to maintain a hemoglobin target range of 10.0-12.0 g/dL.
223619663|NCT04375917|DEVICE|O2matic|O2matic is a closed-loop-system that controls oxygenadministration according to SpO2. The aim is to maintain SpO2 within a predefined target interval, E.G. 88-92% with the lowest possible supplementation of oxygen by nasal cannula
224209810|NCT00589693|DRUG|Placebo|Form=solution, route=intravenous. Doripenem pacebo will be administered from Days 1 to 7 in imipenem-cilastatin arm and imipenem-cilastatin placebo will be administered in doripenem arm.
224209811|NCT03231709|DRUG|Trelagliptin|Trelagliptin tablets
224209812|NCT03231709|DRUG|Alogliptin|Alogliptin tablets
224209813|NCT01330615|DRUG|EMLA|The cream is applied as a thick layer to the wart and to the surrounding 1 to 2 mm and left on for 60 minutes under occlusion of Tegaderm dressing. The cream is then removed, and liquid cryotherapy applied using cryospray.
224315946|NCT02119819|DRUG|LY2944876|Administered SC
224315947|NCT02119819|DRUG|Exenatide extended-release|Administered SC
224315948|NCT02119819|DRUG|Placebo|Administered SC
224315949|NCT02119819|DRUG|Metformin|Oral
224315950|NCT02699684|DEVICE|Lotrafilcon B contact lenses with EOBO-41|Lotrafilcon B contact lenses packaged with copolymer 845 and EOBO-41
224209814|NCT01330615|DRUG|Placebo|The cream is applied as a thick layer to the wart and to the surrounding 1 to 2 mm and left on for 60 minutes under occlusion of Tegaderm dressing. The cream is then removed, and liquid cryotherapy applied using cryospray.
224209815|NCT04784845|BIOLOGICAL|N. lactamica Y92-1009|Lyophilised N. lactamica reconstituted in phosphate-buffered saline
224209816|NCT01251692|PROCEDURE|Surgery|The corneal epithelium was debrided, and laser ablation was performed to a depth of 5 micron with an ablation zone of 7 to 9 mm, using the Technolas 217C Plano Scan excimer laser.
224209817|NCT00002227|DRUG|Efavirenz|
224209818|NCT00002227|DRUG|Lamivudine|
224209819|NCT00002227|DRUG|Stavudine|
224209820|NCT04188769|DEVICE|constant deep pressure applied by an air splint|inflation of the Johnstone air splint gives a constant local deep pression on the hemiplegic arm
224209821|NCT04188769|DEVICE|intermittent deep pressure applied by an air splint|continuous inflation and deflation of the Johnstone air splint gives an intermittent local deep pression on the hemiplegic arm
224209822|NCT04188769|DEVICE|uninflated air splint|no deep pressure applied by the air splint
224209823|NCT04188769|OTHER|contralateral movement|non-hemiplegic arm is flexed and extended 5 times, with a weight of 5kg in the hand, in order to trigger hypertonia in the hemiplegic arm
224209824|NCT00146003|DRUG|Efalizumab treatment|
224209825|NCT06162117|DIAGNOSTIC_TEST|2- Minute Step Test|2- Minute Step Test will be administered to patients with traumatic meniscus tear
224209826|NCT04057118|DRUG|SKI-O-703|Oral administration, twice per day
224209827|NCT04057118|DRUG|Placebo|Oral administration, twice per day
224209828|NCT05675072|DRUG|FB2001|FB2001 for Inhalation will be reconstituted with normal saline prior to nebulized inhalation. FB2001 will be administered by nebulized inhalation.
224209829|NCT05675072|DRUG|FB2001 placebo|FB2001 placebo will be reconstituted with normal saline prior to nebulized inhalation. FB2001 placebo will be administered by nebulized inhalation.
224209830|NCT05020730|DRUG|PTM-001|PTM-001 (400 mg) every day for 12 weeks
224209831|NCT05020730|DRUG|Placebo|Matching placebo every day for 12 weeks
224209832|NCT04177745|OTHER|Hot application|Before PVC was inserted, the researcher applied a hot application to the catheter insertion site (inner surface of the forearm) using a hot pack for one minute.
224209833|NCT04177745|OTHER|Cold application|Before PVC was inserted, the researcher applied a cold application to the catheter insertion site (inner surface of the forearm) using a cold pack for one minute.
224209834|NCT03273712|RADIATION|90Y-DOTA tyr3-Octreotide|90Y-DOTATOC is a radiopharmaceutical that will be used as a treatment for both children and adults with neuroendrocrine and other somatostatin receptor positive tumors.
224209835|NCT03273712|DIAGNOSTIC_TEST|68Ga-DOTATOC PET Positron Emission Tomography (PET) whole body scan|68Ga-DOTATOC is a radiopharmaceutical used in PET scans to identify tumors as it can adhere to Somatostatin Receptors.
224209836|NCT03273712|DRUG|Amino Acids|This is a solution of amino acids that will decrease the amount of 90Y-DOTATOC that recirculates through the body after injection, therefore decreasing the radiation dose to the kidneys.
224209837|NCT01249690|DRUG|Bortezomib,Pirarubicin,Dexamethasone|Bortezomib:1.3mg/m2,on day 1,4,8 and 11 of each 28 day cycle; Pirarubicin:10mg,on day 1 to 4 of each 28 day cycle; Dexamethasone:20mg,on day 1 to 4 and 8 to 11 of each 28 day cycle; Number of cycles: up to 8 cycles.
224209838|NCT01249690|DRUG|Thalidomide,Pirarubicin,Dexamethasone|Thalidomide:200mg/d, everyday; Pirarubicin:10mg,on day 1 to 4 of each 28 day cycle; Dexamethasone:20mg,on day 1 to 4 and 8 to 11 of each 28 day cycle; Number of cycles: up to 8 cycles.
224209839|NCT02703779|DRUG|Bortezomib|Bortezomib will be given to Group B participants by injection under the skin 11 days and 8 days before stem cell collection.
224209840|NCT02703779|DRUG|Granulocyte colony-stimulating factor (G-CSF)|Granulocyte colony-stimulating factor (G-CSF) will be given to all participants by injection under the skin 4 days and 1 day before stem cell collection, and then continued until the stem cell collection is completed.
224209841|NCT02703779|DRUG|Mozobil|Mozobil will be given to all participants by injection under the skin only if needed per Investigator.
224209842|NCT00677170|DRUG|MLN4924|IV dose escalation for 5 consecutive days followed by a rest period of 16 days for a 21 day cycle. Treated may continue until disease progression or unacceptable toxicity develops.
224209843|NCT05933226|BEHAVIORAL|Khanya|"Khanya is a peer-delivered, behavioral intervention to improve HIV medication adherence and reduce problematic SUD symptoms. Participants will either receive Khanya Step 1 or if they continue to struggle with ART adherence, they will be stepped up to the more intensive intervention, Khanya Step 2."
224209844|NCT03169660|DRUG|Vascular endothelial growth factor trap-eye|Intravitreal injection of vascular endothelial growth factor trap-eye During the first 3 months, 3 monthly injections are performed After 3 serial injections, additional injections are performed once per 2 months until 48 weeks after the initial injection.
224209845|NCT00282425|BIOLOGICAL|Hematopoietic stem cell transplantation|Allogeneic Hematopoietic stem cell transplantation
224209846|NCT01184378|DIETARY_SUPPLEMENT|dairy lipids and soluble milk proteins|one month formula supplementation feces are collected during a 3 days period after 15 and 30 days of formula intake
224209847|NCT01518985|DRUG|Bendavia|Bendavia for infusion Intravenous infusion (0.25mg/kg/hr) for 4 hours
224209848|NCT01518985|DRUG|Sterile saline (0.9%)|Sterile saline for infusion (0.9%) Intravenous infusion for 4 hours
223619664|NCT04133558|OTHER|tracheal aspirate during routine care|tracheal aspirate during routine care
223619665|NCT02995980|DEVICE|Dual-Energy Contrast-Enhanced (DECE) mammography|Contrast mammography
223619666|NCT02995980|DEVICE|digital mammography|routine digital mammography
223619667|NCT05718973|OTHER|short, animated storytelling video (intervention video)|Participants in the Intervention Arm will view a short, animated storytelling video designed to promote psychological capital.
223619668|NCT05718973|OTHER|short, animated storytelling attention placebo video|The Attention Placebo Control Arm will view an attention placebo control video, unrelated to the outcomes measured in this trial.
224209849|NCT01518985|OTHER|Cigarette smoking|One unfiltered cigarette will be smoked at approximately 30 minutes post-study-drug administration start.
224209850|NCT05078801|PROCEDURE|Endoscopic drainage|ERCP and/or EUS-guided biliary drainage
224209851|NCT05078801|PROCEDURE|Percutaneous transhepatic biliary drainage|US or CT-guided percutaneous drainage
224315951|NCT02699684|DEVICE|Lotrafilcon B contact lenses|Lotrafilcon B contact lenses packaged with copolymer 845
224315952|NCT02699684|DEVICE|Hydrogen peroxide-based lens care solution|Commercially-available hydrogen peroxide-based lens care solution for cleaning, disinfecting, and storing silicone hydrogel soft contact lenses
224315953|NCT02699684|DEVICE|Saline solution for rinsing contact lenses|Commercially-available saline solution used as needed
224315954|NCT02699684|DEVICE|Saline solution for rinsing contact lens case|Commercially-available solution used as needed
224315955|NCT01160003|DRUG|GW870086X|5mg and 8.75mg GW870086X once daily for 14 days in separate traetment periods.
224315956|NCT01160003|DRUG|Placebo|placebo will be randomly inserted into one of the treatment periods following the treatment sequences outlined in the protocol.
224315957|NCT01145508|DRUG|Docetaxel|Given IV
224315958|NCT01145508|OTHER|Laboratory Biomarker Analysis|Correlative studies
224315959|NCT01145508|DRUG|Prednisone|Given PO
223619669|NCT01173016|DRUG|Laronidase|Laronidase 0.58 mg/kg intravenously (IV) once a week for a maximum of 2 years
223619670|NCT02719548|DEVICE|Soft edge oval - Hard oval - Modified PF breast shield|"Treatment order:~1. soft-edge oval breast shield~2. Hard oval breast shield~3. modified PersonalFit breast shield"
223619671|NCT02719548|DEVICE|Modified PF breast shield - Soft edge oval - Hard oval|"1. modified PersonalFit breast shield~2. soft-edge oval breast shield~3. Hard oval breast shield"
223619672|NCT02719548|DEVICE|Hard oval - Soft edge oval - Modified PF breast shield|"1. Hard oval breast shield~2. soft-edge oval breast shield~3. modified PersonalFit breast shield"
223619673|NCT03274323|DEVICE|iStent and travoprost or latanoprost|2 iStents will be inserted and patients will be started on travoprost or latanoprost following the procedure
224209852|NCT02424656|PROCEDURE|MRI|EEG-functional MRI, structural MRI, diffusion MRI
224209853|NCT02424656|PROCEDURE|TMS-EEG|Single pulse TMS combined with EEG, resting-state EEG, noise masking (auditory stimulation), electrical stimulation
224209854|NCT02424656|PROCEDURE|FDG-PET|
224209855|NCT02424656|OTHER|Clinical scales|Evaluation of DOC: Coma recovery scale-Revised (CRS-R) and Rancho Los Amigos Scale (RLAS). Evaluation of function: Functional Independent Measure (FIMTM), and Early Functional Assessment (EFA).
224209856|NCT02857296|OTHER|interview and observation|
224209857|NCT03607656|DRUG|Oxaliplatin|Oxaliplatin powder injection
224209858|NCT03607656|DRUG|Capecitabine|Capecitabine tablet
224209859|NCT03607656|OTHER|TCM|TCM decoction orally taken twice a day for at least 3 months
224209860|NCT03607656|DRUG|S-1|S-1 capsule
224209861|NCT03607656|DRUG|Docetaxel|Docetaxel injection
224209862|NCT03607656|DRUG|5-FU|5-FU injection
224209863|NCT05449158|PROCEDURE|left atrial pressure regulation|For patients after atrioventricular node ablation combined with left atrial appendage closure, the regulation of left atrial pressure can be controlled by adjusting the frequency of pacemaker.
224209864|NCT02735226|OTHER|stroke network and policy intervention|Shanghai stroke service and network contributes to update the ability of stroke care of comprehensive and primary stroke center,to improve radiation ability of comprehensive stroke centers and try to form a close relationship between comprehensive stroke centers and its primary stroke centers.
224209865|NCT04976088|DRUG|Diclofenac Sodium 140 mg medicated plaster|Test product: Diclofenac Sodium 140 mg medicated plaster, topical application once a day
224209866|NCT04976088|DRUG|Diclofenac epolamine (DIEP) 180mg medicated plaster, Flector|Reference product: Active-comparator, Diclofenac epolamine (DIEP) 180 mg medicated plaster, Flector®, topical application once a day
224209867|NCT04976088|DRUG|Placebo|Placebo: Placebo plaster, topical application once a day.
224209868|NCT06568120|DEVICE|dragon themed nebulizer masks|This study is an experimental investigation aiming to evaluate the effect of a dragon-themed nebulizer mask (Figure 1), identified during a literature review by the researchers, on the duration of inhaler treatment application, treatment adherence, and children's fear levels. The dragon-designed nebulizer mask, with its colorful and toy-like appearance, is intended to calm children using pediatric aerosol masks. The mask is made of very soft, latex-free plastic, ensuring comfortable use for pediatric patients. It is compatible with all nebulizers and suitable for use in hospital settings. Unlike standard nebulizer masks, its appearance is designed with a dragon character specifically for pediatric patients. The mask is manufactured in China.
224209869|NCT02059369|PROCEDURE|PVI+CFAE+DCC|pulmonary vein Isolation (PVI), CFAE for substrate modification and direct current cardioversion (DCC) if AF persists
224315960|NCT01145508|BIOLOGICAL|Recombinant Fowlpox-PSA(L155)/TRICOM Vaccine|Given SC
224315961|NCT01145508|BIOLOGICAL|Rilimogene Galvacirepvec|Given SC
224315962|NCT06633679|BEHAVIORAL|Se Cuida Intervention|The intervention consist in an internet based cognitive behavioural therapy program delivered through a online platform. Intervention consist of 8 weeks with 8 weekly modules assigned to the participants. The program has been translated and adapted to the Brazilian and is based on CBT techniques focused on managing psychological symptoms of anxiety and depression in young people. Out of a total 14 modules adaptaded, 8 will be delivered in the treatment: 5 will be available to all participants and 3 will be tailored according to the initial assessment and interviews. The intervention is self-guided with support on demand, meaning that when participants need support, they could chat directly through the platform text message channel with a psychoteraphist responsible for them. Also, once a week each participants receive feedbacks regarding their work on the program\&#39;s exercises.
224315963|NCT02844400|DEVICE|Biometric Devices|Patients will wear two devices: HealthPatch Sensor and Phillips Actiwatch. Health data (e.g. average steps per day, resting heart rate) will be collected and monitored over the course of a cycle of cytotoxic chemotherapy.
224315964|NCT02844400|OTHER|Physical Performance Testing|Patients will complete a CPET and 6 minute walk test within one week of starting an upcoming chemotherapy cycle and they will undergo a second CPET upon completion of said chemotherapy cycle.
224315965|NCT00062985|BEHAVIORAL|Mail-based weight loss intervention|
224315966|NCT00062985|BEHAVIORAL|Phone-based weight loss intervention|
224315967|NCT02662283|DRUG|Prednisolone|Oral take prednisolone (0.5 mg/kg, qd) for 8 weeks
224315968|NCT02662283|DRUG|Reh-acteoside|Oral take and reh-acteoside (0.4g bid) for 8 weeks
224315969|NCT02045147|BEHAVIORAL|Grp 1a Low Cognition, Low Activation Intervention|"The intervention is focused on knowledge, skills, confidence and creating a partnership with the health care provider. Education is provided at a 5th grade reading level. The teach back method is used to validate knowledge, skills and confidence. Once knowledge is validated, the interventions focused on motivation."
224315970|NCT02045147|BEHAVIORAL|Grp 2a Low Cognition, High Activation Intervention|"The intervention is focused on knowledge, skills, confidence and creating a partnership with the health care provider. Education is provided at a 5th grade reading level. The teach back method is used to validate knowledge, skills and confidence. Once knowledge is validated, the interventions focused on motivation and handling stressful situations."
224315971|NCT02045147|BEHAVIORAL|Grp 3a Normal Cognition, Low Activation Intervention|"The intervention is focused on knowledge, skills, confidence and creating a partnership with the health care provider. Education is provided for areas of misunderstanding. The teach back method is used to validate knowledge, skills and confidence. Interventions are focused on motivation and developing personal behavioral goals."
224315972|NCT02045147|BEHAVIORAL|Grp 4a Normal Cognition, High Activation Intervention|The intervention is focused on knowledge, skills, confidence and creating a partnership with the health care provider. Focus is on maintaining behaviors during hardship and stress. Empowering, motivating and validating are strategies utilized.
224209870|NCT02059369|PROCEDURE|PVI, CFAE, anterior and roof line, DCC|PVI, CFAE ablation. If AF persists linear lesions (anterior and roof line), cardioversion if AF persists
224209871|NCT00203957|DRUG|Istradefylline|Patients will receive starting dose of 40mg/d. The allowable doses are 20 and 40mg/d
224209872|NCT00203957|DRUG|Istradefylline|Patients will receive starting dose of 40mg/d. The allowable doses are 20 and 40mg/d
224209873|NCT03959137|OTHER|None - Common practice|None - Common practice
224209874|NCT06325176|OTHER|Cryotherapy|During the 1st visit of the patients, they will be assessed for pain and episiotomy wound. The cryotherapy group will include 12 postnatal women. This group will use a bag of ice pack applied to the perineal region. The ice pack will be sealed in plastic bag and wrapped with one layer of a thin cotton tissue so that the skin of the participant would not be in direct contact with ice, which could cause discomfort. During the intervention, the women will be asked to remove their underpants and hygienic pads and remain in the dorsal recumbent position during cryotherapy that lasted 20 minutes. This procedure will be done twice a day for seven consecutive days
224209875|NCT06325176|DEVICE|Infrared light therapy|Infrared group will include 12 postnatal women they will encourage to place an infrared lamp at distance of 45 cm from the perineum and the heat produced with 230 volts for twenty minutes. But the mother is checked after the first five minutes to make sure that she was not being burned. The researcher will demonstrate for each woman how to use infrared lamp, and it will be followed by re demonstrations and discussions. These procedures will carry out in the morning and evening for seven consecutive days. The researcher gives the infrared lamp device for each woman then restore it after completion of the study
224209876|NCT00190684|DRUG|atomoxetine|0.5-1.8 mg/kg/day, by mouth (PO), for up to 5 years
224209877|NCT06540599|DRUG|Analgesic|comparing the effectiveness of analgesics in endometrial biopsy
224209878|NCT03304210|DRUG|PIPAC with Abraxane|Albumin bound nanoparticle paclitaxel (Abraxane) will be administered intraperitoneally using the PIPAC technique. The administered dose will escalate ranging from 35 to 140 mg/m². PIPAC will be performed every 4 weeks for 3 cycles.
224315973|NCT04839692|DRUG|Hyaluronic acid filler|Hyaluronic acid filler treatment of the lips with Restylane Kysse, which is a FDA approved treatment for lip augmentation.
224315974|NCT02556983|RADIATION|CT|Contrast-enhanced CT images of the abdomen and pelvis will be obtained during the portal venous phase using a 256-channel CT system (Philips Healthcare, Cleveland, OH). The target median dose-length product (DLP) is 130 mGy·cm, which corresponded to an effective dose of 2 mSv with a conversion factor of 0.015 mSv·mGy-1·cm-1. The radiation output was automatically adjusted according to the individual patient's body size.
224315975|NCT04924257|DRUG|Esketamine nasal spray|Patients will receive two treatments per week for four weeks (maximum of eight treatment sessions) or until clinical remission (MADRS \<10).
224315976|NCT04924257|PROCEDURE|Electroconvulsive therapy|Patients will receive three treatments per week for four weeks (maximum of 12 ECT treatments) or until clinical remission (MADRS \<10).
224315977|NCT03146962|DRUG|Vitamin C|Vitamin C infusion will be administered intravenously at 1.25 g/kg for 4 days per week for 2-4 consecutive weeks (cohort A) or up to 6 months (cohort B). Cohort C will receive high dose vitamin C for 1-3 weeks. During week 1 vitamin C infusion and Y90 radioembolization of hepatic metastases will occur same day.
224209879|NCT04717999|BIOLOGICAL|NKG2D CAR-T|The NKG2D CAR-T will be administrated via intracerebroventricular injection through an Ommaya catheter. Standard treatments such as temozolomide will be stopped during the infusion of NKG2D CAR-T.
224209880|NCT00136734|DRUG|Methylphenidate|
224315978|NCT00549289|DRUG|cyclosporine A|
224315979|NCT04135326|OTHER|Quality-of-Life Assessment|Ancillary studies
224315980|NCT04135326|OTHER|Questionnaire Administration|Ancillary studies
224315981|NCT04135326|PROCEDURE|Transcranial Direct Current Stimulation|Undergo tDCS
224209881|NCT00136734|OTHER|placebo|placebo
224209882|NCT00085722|PROCEDURE|Dextrose Prolotherapy|Injection procedure: 50% dextrose is diluted with .9% 'normal' saline and 1% lidocaine to achieve 15% dextrose for ligament injections and 25% dextrose for intra-articular injection.
224209883|NCT00085722|PROCEDURE|Saline Prolotherapy|7 mL 9% 'normal' saline and 3mL 1% lidocaine
224209884|NCT00085722|OTHER|At-home physical therapy exercise group|Subjects in the at-home physical therapy exercise group will receive a patient information pamphlet about knee osteoarthritis and conservative care instructions for standard at-home physical therapy exercises
224209885|NCT06500039|OTHER|Positive Psychological Intervention Program|An intervention method consisting of three good things in life and gratitude activities was determined for the intervention group. It will take four weeks. Three good deeds will be held for two weeks, and gratitude activities will be held for the last two weeks. Participants will record the interventions on a prepared booklet.
224209886|NCT06500039|OTHER|Writing Daily Routines|An activity was planned for the control group participants to write their daily routines. They will write down their sleep, nutrition, hygiene and shopping routines, which will be different each week for four weeks. Control group participants will also be given a booklet to write on.
223619674|NCT03274323|PROCEDURE|Trabeculectomy|Standard trabeculectomy
223619675|NCT00379847|DRUG|conivaptan|IV
224209887|NCT04992481|PROCEDURE|PMTC|In patients from the study groups I, II, III, IV a professional mechanical tooth cleaning (PMTC) including air-polishing was proceeded on every visit using a glycine-based prophylaxis powder (Air-Flow Soft, EMS, Switzerland).
224209888|NCT04992481|PROCEDURE|fluoride varnish|In patients from groups I, II, III, IV a fluoride varnish of 5% NaF (Profluorid Varnish, Voco, Germany) was applied with a microbrush. Every patient was instructed to stop from drinking and eating for the next two hours (as recommended by the manufacturer).
224209889|NCT04992481|PROCEDURE|gaseous ozone therapy|Patients from groups II and IV were additionally subjected to in-office ozone therapy using OzonyTron-OZ (Mymed, Germany). Ozone was applied on a silicone double-jaw tray of a proper size (allowing even ozone distribution in the oral cavity) following professional mechanical tooth cleaning. A Full Mouth Desinfection program lasting 5 minutes was used.
224209890|NCT04992481|PROCEDURE|domestic octenidin mouth rinse|Patients from groups III and IV received a domestic mouthrinse (Octenidol MD, Schülke, Germany) and were recommended to use 15 ml of the liquid for 30 seconds after evening toothbrushing.
224209891|NCT06514209|DRUG|cisatracurium|The initial bolus dose of cisatracurium injection is 0.05-0.1mg/kg, followed by a continuous infusion of 1ug/kg/min of cisatracurium, with data on vital signs, respiratory mechanics, TOF response, etc. recorded after a 15-minute wait. The maintenance infusion dose of cisatracurium is then gradually increased in a gradient of 0.5ug/kg/min, with data collection after a 15-minute wait after each increase. If the patient\&#39;s spontaneous breathing completely disappears, the infusion dose of cisatracurium will no longer be increased, and the titration will end.
224209892|NCT03115060|DRUG|intravenous fluid administration WITH NORMAL SALINE, PLASMALYTE A, OR RINGER LACTATE|intravenous fluid to be used for maintainance and replacement during renal transplant surgery will be normal saline, ringer lactate or plasmalyte A depending on the arm of intervention
224209893|NCT00966082|PROCEDURE|endoscopic band ligation|Perform EBL until esophageal varices are eradicated, and then follow-up endoscopy with 3-6 months interval
224209894|NCT00966082|PROCEDURE|endoscopic band ligation+Propranolol|Perform EBL same as EBL group. In addition, take propranolol to reduce 25% in HR or HR ≤55/min
224209895|NCT04212182|DEVICE|HFNC|HFNC provides warmed and humidified gas administered through slightly enlarged nasal prongs.
224209896|NCT04212182|DEVICE|NPPV|NPPV is the standard therapy for ventilatory failure in AECOPD.
224209897|NCT02998372|PROCEDURE|patellar stabilization|surgery to either alter soft tissues around the patella or reorient the patellar tendon to restore patellar stability
224209898|NCT02265640|DRUG|BIIL 284 BS boli|
224209899|NCT02265640|DRUG|BIIL 284 BS tablet C|
224209900|NCT02265640|OTHER|standard breakfast|
224209901|NCT01188642|BEHAVIORAL|obesity lifestyle intervention|physical activity 5 times per week + nutrition education
224209902|NCT01785043|DRUG|Liraglutide|Liraglutide is available if pre-filled pens (6 mg/ml) as a solution for injection (Victoza®). One ml of solution contains 6 mg of Liraglutide (human glucagon-like peptide-1 analogue produced by recombinant DNA technology in Saccharomyces cerevisiae). One pre-filled pen contains 18 mg Liraglutide in 3 ml.
224209903|NCT01785043|DRUG|Sitagliptin|Sitagliptin is available in 100 mg film-coated tablets (Januvia®). Each tablet contains sitagliptin phosphate monohydrate, equivalent to 100 mg sitagliptin.
224209904|NCT06566625|DIAGNOSTIC_TEST|Cardiac MRI (CMR) examination|"An MRI examination of the heart (CMR) is presently performed as a follow-up examination in patients where an invasive coronary angiography (ICA) shows no obstructive findings. The intervention in this study is characterized by having the CMR performed before, rather than after, the ICA.~In addition, this study will implement some novel CMR sequences which have not been previously tested in this patient cohort:~* CMR Angiography (imaging the coronary arteries using MRI)~* CMR Fingerprinting (sequences which perform T1 and T2 mapping simultaneously)"
224209905|NCT00995488|DRUG|ABI-007 (Abraxane®)|ABI-007 is a novel albumin-bound paclitaxel combining a protein with a chemotherapeutic agent in the particle form.
224209906|NCT03345953|DRUG|BP 1.4979|Double blind versus placebo
224209907|NCT03345953|DRUG|Placebo|Double blind versus placebo
224209908|NCT00438035|PROCEDURE|ECG spectral|
224209909|NCT06701396|DRUG|Tasimelteon|Oral capsule
224209910|NCT06701396|DRUG|Placebo|Oral capsule
224209911|NCT04501341|BIOLOGICAL|Bone-marrow aspiration, Intra-pancreatic Catheterisation of BM-MNC|Autologous bone-marrow mononuclear cells infused to the main blood vessels that supply the pancreas according to the results of previous pancreatic CT-scan, performed by interventional radiologist. The target is to distribute the BM-MNCs equally in all part of the pancreas. Dosage: 1 x 10\^5 - 1 x 10\^6 CD34 cells/kgBW
224209912|NCT04501341|BIOLOGICAL|Intravenous Infusion of UC-MSC|Allogeneic umbilical cord tissue-derived mesenchymal stem cells will be given via intravenous infusion. Dosage: 2 x 10\^6 cells/kgBW, twice, with three months interval
224209913|NCT01781689|PROCEDURE|Functional Electric Stimulation|apply to the hemiplegia affected limbs, helping movement
224209914|NCT01781689|OTHER|Rehabilitation programs|include occupational therapy and physical therapy
224209915|NCT06479746|BEHAVIORAL|Emotional support|Emotional support helps the woman giving birth effectively, meets her emotional needs and expectations, ensures her comfort, improves birth outcomes, increases her self-esteem, ensures a positive birth experience and facilitates her transition into the role of motherhood.
224315982|NCT05438914|DEVICE|Repair of the subscapularis|"The subscapularis will be repaired using the suture through bone and prosthesis holes surgical technique."
223619676|NCT04277728|DIAGNOSTIC_TEST|hypoperfusion-hypodensity mismatch|hypoperfusion-hypodensity mismatch on computed tomography
223619677|NCT03290443|DRUG|Enasidenib|100 mg enasidenib (CC-90007)
223619678|NCT00657540|DRUG|Analatro|30 mL of lyophilized antivenom, reconstituted in 50 mL saline infused over 10 minutes, up to 2 doses
223619679|NCT00657540|DRUG|Saline|50 mL of saline infused over 10 minutes
223619680|NCT03714178|DEVICE|FARAPULSE Endocardial Ablation System|Endocardial ablation using the FARAPULSE Endocardial Ablation System.
223619681|NCT03296917|DRUG|PrEP-001|A spray dried powder for intranasal administration formulated from an aqueous mixture of pre-gelatinized waxy maize starch and the drug substance delivered using a single dose nasal powder device.
224315983|NCT06255158|BEHAVIORAL|INSIGHT Program|"INSIGHT Program:~the program targets the reduction of EMSs' interference in social information processing, which may otherwise lead to the use of deviant behavior to fulfill emotional and sexual needs. Furthermore, the program has specific goals: (1) developing insight about the offense cycle; (2) fostering empathy for victims; (3) enhancing intimate and social/ interpersonal skills; (4) increasing emotional regulation skills."
224209916|NCT02604186|OTHER|Botulinum Toxin Injections|Each patient in the treatment group will receive 400 units of botulinum toxin. 100 units will be injected at adductors at each leg and 100 units will be applied in each triceps surae bilaterally.
224209917|NCT02604186|OTHER|Placebo Injections|Each patient in the placebo group will receive sterile sodium chloride injections at adductors and triceps surae muscles bilaterally.
224315984|NCT06255158|OTHER|Treatment As Usual (TAU)|TAU in Portuguese prisons is primarily aimed to increase educational and professional qualifications
224315985|NCT03899441|OTHER|Video|Two short animated videos - one that reviews minimally-invasive surgery and sentinel lymph node mapping and biopsy for endometrial cancer treatment. This video as reviews possible complications. The second video reviews peri-operative instructions.
224315986|NCT00183560|BEHAVIORAL|Mindfulness based cognitive therapy (MBCT)|Following antidepressant discontinuation, participants receive MBCT, an 8-week group program that integrates aspects of cognitive therapy and mindfulness meditation.
224315987|NCT00183560|DRUG|Antidepressants|Participants continue on dosage of the antidepressant that was used to achieve clinical remission.
224315988|NCT00183560|DRUG|Placebo plus clinical management|Following discontinuation of active antidepressant, participants are placed onto the placebo and clinical management regimen.
224315989|NCT00071279|DRUG|SR34006 (idraparinux sodium) Injection|
224315990|NCT03112642|PROCEDURE|Local anesthetic block [0.35% marcaine]|In the absence of paresthesia and after negative aspiration, the 40 ml of local anesthetic block \[0.35% marcaine\] will be administered.
224315991|NCT03112642|DEVICE|Braun DIG-R-C Stimuplex Blockade Monitor System|The blockade system will be initially set at 1 milliamp. As the proximity of the tip of the needle to the components of the brachial plexus becomes evident by ultrasound approximation and the stimulation pattern of the hand and wrist, the output of the system will be reduced to .3-.5 milliamps. With use of the Braun DIG-R-C Stimuplex Blockade Monitor System.
224315992|NCT04261101|OTHER|Test-enhanced learning|Test-enhanced learning with short answers of questions regarding diabetes and adrenal
224315993|NCT04497948|DRUG|Acalabrutinib|Acalabrutinib (CALQUENCE®) is a covalent BTK inhibitor
224315994|NCT02740114|DRUG|Bupivacaine|150 mg (0.25%) injected on each side of the wound at the end of surgery before wound closure.
224209918|NCT03756207|PROCEDURE|multidisciplinary bladder-preservation therapy|Maximal transurethral resection followed by radiotherapy with concomitant radio-sensitizing chemotherapy
224209919|NCT03406832|DRUG|Nitroprusside Sodium|Intracoronary infusion 50\~100μg each time (repeated)
224209920|NCT03406832|DRUG|Tirofiban Hydrochloride|Intracoronary infusion 10μg/kg for single time
224209921|NCT03406832|DRUG|Heparinized saline|Intracoronary infusion 2ml for single time
224315995|NCT02740114|DRUG|Liposomal Bupivacaine|266 mg injected on each side of the wound at the end of surgery before wound closure.
224315996|NCT02740114|DRUG|Oxycodone|1-2 tabs (5 mg) by mouth every 4 hours as needed for pain.
224315997|NCT02740114|BEHAVIORAL|Pill Diary|Participants complete a pill diary every day for 30 days after hospital discharge.
224315998|NCT02740114|BEHAVIORAL|Symptom Questionnaire|Participants called or emailed and asked questions about symptoms three (3) and 7 days after hospital discharge, and then 1 time every week after that for a total of 8 weeks.
224315999|NCT00000542|DRUG|Inhibitors, ACE|
224316000|NCT00000542|DRUG|amlodipine|
224316001|NCT00000542|DRUG|lisinopril|
224316002|NCT00000542|DRUG|doxazosin|
224316003|NCT00000542|DRUG|chlorthalidone|
224316004|NCT00000542|DRUG|pravastatin|
224316005|NCT00000542|BEHAVIORAL|diet, fat-restricted|
224316006|NCT04455321|PROCEDURE|Suture materials effect on istmocel|Effect of suture materials with different absorption times on istmocel
224316007|NCT02246114|DEVICE|piCO+ Smokerlyzer® monitor|
224316008|NCT02246114|OTHER|Text messages|
224316009|NCT04353895|DEVICE|Guidance for pedicle screw insertion (Mazor Stealth)|Using imaging devices and navigation for guidance, we perform a posterior vertebral fusion with pedicle screw insertion
224316010|NCT04353895|DEVICE|Guidance for pedicle screw insertion (O-arm Navigation)|Using imaging devices and navigation for guidance, we perform a posterior vertebral fusion with pedicle screw insertion
224316011|NCT00171665|DRUG|Diclofenac topical sodium gel 1%|
224316012|NCT04348695|DRUG|Ruxolitinib plus simvastatin|"Ruxolitinib 5 mg orally every 12 hours for 7 days, which will be increased to 10 mg every 12 hours for a total of 14 days.~Simvastatin 40 mg orally every 24 hours for 14 days"
224316013|NCT04348695|OTHER|Standard of Care|Patients will receive treatment according to usual clinical practice in the participant site.
223512878|NCT06017128|OTHER|sexual counseling based on the PLISSIT model|In the initial follow-up, the experimental group will receive information about total hip replacement surgery and its impact on sexual life based on the PLISSIT model. An educational booklet containing information about total hip replacement surgery, the rehabilitation process, and post-operative sexual life will also be prepared and distributed. In the second follow-up (5-7 days after surgery), the experimental group will be provided with information about home care before discharge and returning to sexual life.
223512879|NCT01331330|DEVICE|Deep Brain Stimulation|Normal DBS Programming
223512880|NCT01331330|DEVICE|Deep Brain Stimulation|Low Programming
224209922|NCT04493554|DRUG|Vasopressin|Administration of vasopressin (20 IU) intranasally
224209923|NCT04493554|DRUG|Placebo|Administration of placebo intranasally
224209924|NCT02865642|DRUG|Serotonin Uptake Inhibitors|
224316014|NCT06582862|OTHER|Exercise|Subjects will do aerobic and anaerobic exercise
224316015|NCT02091024|DIETARY_SUPPLEMENT|ECE (Ecklonia cava extract)|ECE 200mg, twice a day
224316016|NCT02091024|DIETARY_SUPPLEMENT|Placebo|Placebo 200mg, twice a day
224316017|NCT02125864|PROCEDURE|intravitreal injection|collecting blood samples
223619682|NCT03296917|DRUG|G-004|A spray dried pre-gelatinized waxy maize starch powder (G-001) in the single dose nasal powder device
223619683|NCT05979740|DRUG|Disitamab Vedotin and Toripalimab|Each patient received RC48 injection \[2.0 mg/kg, Q2W, iv\] and Toripalimab injection \[3mg/kg, Q2W, iv\] for 1\~2 cycles, and Radiotherapy radiotherapy at the second or third cycle. The total dose of bladder irradiation field was greater than 50Gy (about 30 times), and the safety monitoring of the subjects was conducted within 28 days after receiving the study drug treatment for the first time.
223619684|NCT04781010|DEVICE|MRI|MRI pattern in children with Leukodystrophy
223619685|NCT03852602|DRUG|Preemptive Analgesics|Analgesic application15 minutes before the treatment
223619686|NCT03852602|DRUG|Control|Analgesic application15 minutes before the end of the treatment
223619687|NCT06028919|DEVICE|Temperature controlled DiamondTemp (DT) ablation catheter|The DiamondTemp catheter is a new ablation catheter that uses 6 industrial grade diamonds to actually measure the temperature of the surface tissue being cauterised. This enables the DiamondTemp catheter to control the amount of power being delivered from the ablation catheter into the tissue being ablated by maintaining a constant temperature at the surface of the heart.
223619688|NCT06028919|DEVICE|Tacticath/Tactiflex (TF) ablation catheter|The Tactiflex ablation catheter is currently the market leader and routinely used for VT ablation.
224209925|NCT02865642|DRUG|Placebo|
224209926|NCT02816749|PROCEDURE|Maggot debridement therapy|Participant will receive bio-bags treatment every 3 days until the wound heal completely, when wounds assessed.
224209927|NCT02816749|PROCEDURE|Conventional Dressing Therapy|Participant will be disinfected by iodophor and dressed by gauze 3 days until the wound heal completely, when wounds assessed.
224209928|NCT04828629|DIAGNOSTIC_TEST|Diagnostic tests|Selected prognostic factors will be analyzed, among others: demographic data of the patient, physical examination, symptoms, co-morbidities, results of selected laboratory tests, lung imaging (X-ray or computed tomography) selected electrocardiographic and echocardiographic data, patient's cooperation with the doctor, treatment applied, parameters in the spiroergometric study, body mass analysis.
224209929|NCT04641273|DRUG|BAY1817080|Tablet, intake orally.
224209930|NCT04641273|DRUG|Placebo for BAY1817080|Tablet, intake orally.
224209931|NCT04641273|DRUG|Placebo for Pregabalin|Capsule, intake orally.
224209932|NCT04641273|DRUG|Pregabalin|Capsule, intake orally. Starting dose 75 mg BID first week, increase to 150 mg BID in second week.
224209933|NCT02876705|OTHER|Exercise|Completion of this study will took a total of three sessions, separated by one-week intervals. At week one, participants will complete a baseline incremental cycling and running tests to determine the workload and velocity values corresponding to their RPE (6-20 Borg's scale) = 15 (i.e., heavy). Participants also will be familiarized with the use of body maps and reporting procedures. At week two and three, participants will complete the constant-power cycling and constant velocity running tasks. The constant-power cycling and running will last up to volitional exhaustion. The end will be set when participants won't be able to cycle longer at the fixed cadence.
224209934|NCT03529318|PROCEDURE|Biopsies from endoscopy|"1\) Patients scheduled for endoscopy (EGD or colonoscopy) for IBD will be consented to allow physicians who are performing endoscopies to take additional biopsies and blood samples for research purposes."
224209935|NCT04183218|PROCEDURE|Biospecimen Collection|Undergo biospecimen collection
224209936|NCT04183218|DEVICE|Cardiac Event Monitor|Receive cardiac monitor
224209937|NCT04183218|OTHER|Chemoradiotherapy|Undergo CRT
224209938|NCT04183218|RADIATION|Radiation Therapy|Undergo RT
224209939|NCT02702271|DEVICE|WATCHMAN FLX|Left atrial appendage closure with WATCHMAN FLX
224209940|NCT01494649|DRUG|Test Toothpaste|0.454% stannous fluoride toothpaste
224209941|NCT01494649|DRUG|Negative Control Toothpaste|0.76% sodium monofluorophosphate toothpaste
224209942|NCT00247130|DRUG|Omeprazole|
223512881|NCT05572216|PROCEDURE|Robot assisted partial nephrectomy with 3D image guidance|patient have a partial nephrectomy for renal complex tumor
223512882|NCT05259722|DRUG|Delgocitinib|Cream for topical application 20 mg/g
223512883|NCT05259722|DRUG|Toctino|1 capsule toctino 30 mg per day; optional reduction to 10 mg per day in case unacceptable adverse reactions to the higher dose occur
223512886|NCT02370862|DRUG|Neostigmine and Glycopyrrolate|
223512887|NCT00962650|DEVICE|Transgastric diagnostic peritoneoscopy with laparoscopic assistance|Device: Natural Orifice Transgastric Endoscopic (NOTES GEN 1 Toolbox): Articulating Hook Knife(IN2505), Articulating Snare (IN2503), Articulating Needle Knife(IN2504), Articulating Graspers(IN2501 or IN2506), Articulating Biopsy Forceps(IN2502), Steerable Flexible Trocar (IN0501) with Rotary Access Needle (IN0502), Flexible Bipolar Hemostasis Forceps (IN0301), and/or Flexible Maryland Dissector(IN1601)
223512888|NCT02624089|DRUG|Ropivacaine|Ropivicaine will be administered via in-line nebulization using the Aeroneb Pro™ system
223512889|NCT02624089|DRUG|Normal saline|Normal saline will be administered via in-line nebulization using the Aeroneb Pro™ system
223512890|NCT02402036|DRUG|Regorafenib|Regorafenib orally for 21 days every 28 day cycle
223512891|NCT03026725|OTHER|Tri-calcium Phosphate|A paste contains Tri Calcium Phosphate \& Fluoride
223512892|NCT03026725|OTHER|Placebo|paste manufactured to mimic Clinpro, without Tri Calcium Phosphate
223512893|NCT03811873|DIAGNOSTIC_TEST|Dual x-ray absorptiometry|DEXA is a means of measuring bone mineral density (BMD) using spectral imaging. Two X-ray beams, with different energy levels, are aimed at the bones. Soft tissue absorption is subtracted out, then the bone mineral density (BMD) can be determined from the absorption of each beam by bone.
223512894|NCT03811873|OTHER|Vertebral Fracture Assessment|Lumbar/thoracic spine x-ray and labs assessed for bone turnover markers.
224209943|NCT00247130|DRUG|Ranitidine|
224209944|NCT01174368|BIOLOGICAL|Cancer Macrobead placement in abdominal cavity|8 macrobeads per kilogram
224209945|NCT02580201|BIOLOGICAL|Oral Polio Vaccine|"Opvero™ (oral) is a trivalent, live attenuated poliomyelitis virus vaccine containing at least 6.0 log 50% cell culture infective dose (CCID50) of LS c2ab strain of live attenuated polio virus type 1, 5.0 log CCID50 of P712, Ch, 2ab strain of live attenuated polio virus type 2, 5.8 log CCID50 Leon I2aIb strain of polio virus type 3. Excipients: human albumin, HEPES buffer solution, magnesium chloride solution (containing polysorbate 80 and phenol red), hydrochloric acid or sodium hydroxide for pH adjustment.~The vaccine is presented as a suspension for oral administration. One dose of vaccine (0.1 ml) is contained in two drops which are delivered from the dropper supplied with the multidose container."
224209946|NCT03757052|DIAGNOSTIC_TEST|Penicillin Skin Testing|Skin test protocol: prick skin tests (penicilloyl-polylysine 0.000012 mol/0.05 mL, penicillin G 10,000 U/mL, penoate 10,000 U/mL, ampicillin 100 mg/mL, amoxicillin 71 mg/mL, histamine/positive control, diluent/negative control), then intradermal skin tests (penicilloyl-polylysine 0.000012 mol/0.05 mL, penicillin G 10,000 U/mL, penoate 10,000 U/mL, ampicillin 1 mg/mL, diluent/negative control), administered as an intradermal injection of a standardized volume of 0.02 mL. Graded oral challenge with amoxicillin : a first dose of 50 mg of amoxicillin; 20-minute observation period; in the absence of any objective symptom of an allergic reaction, a second dose of amoxicillin of 450 mg; final observation period of 60 minutes, under nurse and medical supervision.
224209947|NCT02747251|OTHER|Strengthen your Shoulder|A simple home-based elastic band strengthening exercise intervention. This program consists of progressive high volume resistance training exercises with an elastic band.
224209948|NCT02747251|OTHER|Usual Care|"Usual care, consisting of a referral to general rehabilitation in the municipal under the Danish Health Act § 140, most often with the alternative option to choose a private physiotherapeutic clinic, partly at their own expense. Also includes any additional treatment the patient receives between baseline and follow-up, except that included in Strengthen your Shoulder."
224316018|NCT03392350|BEHAVIORAL|Physician Body Scan Consultation with Behavioral Intervention|The RENEW™ program consisted of 7 bi-monthly face-to-face web sessions over 16-18 weeks followed by an average of 15 monthly check-in sessions (maintenance) over 80 weeks.This included modules on responding to stress, enhancing effects of relaxation, nourishing theimmune system, physical activity, and social support.
223619689|NCT02064946|DIETARY_SUPPLEMENT|vitamin D|50,000IU/week of vitamin D3
223619690|NCT02064946|DIETARY_SUPPLEMENT|Placebo|
223619691|NCT05495932|DIAGNOSTIC_TEST|blood sample|blood sample taken to measure serum mepolizumab concentration at baseline, 1 month and 6 months during study follow-up
223619692|NCT02602769|DIAGNOSTIC_TEST|Transcriptome profiling|The investigators will obtain blood to extract peripheral mononuclear cells. These cells will be used to generate patient specific hypothalamic cells that will be used for transcriptome profiling.
224316019|NCT06581913|OTHER|Behavioral assessment|Eating Awareness, Acceptance of Food Cravings, Healthy Life Awareness Health Perception
223619693|NCT01458639|DRUG|Technegas V SPECT imaging|Technegas V SPECT imaging and Technetium 99m MAA Perfusion imaging for the diagnosis pf pulmonary embolism.
223619694|NCT01458639|DRUG|Xenon-133 Ventilation Planar imaging|Xenon-133 Ventilation Planar imaging and Technetium 99m MAA Perfusion imaging for the diagnosis pf pulmonary embolism.
223619695|NCT01169129|OTHER|surgery|resection of brain metastases
223619696|NCT01169129|RADIATION|radiosurgery|radiosurgery to brain metastases
223619697|NCT02870998|OTHER|Active learning|1-day continuing education activity consisting of a lecture on patient education.
224209949|NCT00179153|DIETARY_SUPPLEMENT|Nepro nutritional supplement|oral nutritional supplement (Nepro); every other day, 3 days per week, for 6 months
224316020|NCT03936712|DIETARY_SUPPLEMENT|Energy Drink|Each participant visited the laboratory for two formal test sessions, drinking a caffeine-containing ED (RB) and a caffeine and taurine free beverage drink (PL). All sessions were arranged in the early evening hours to avoid any time of day effects. The two definitive test sessions were separated by an interval of seven days to allow sufficient recovery between tests and to ensure caffeine washout. To avoid identification, two opaque and unmarked cans of RB or PL were ingested by each participant (i.e., 500 mL) in the presence of a researcher. The two drinks were similar in volume, texture, and appearance. One can of RB drink (i.e., 250ml) contained 80 mg of caffeine, 1 g of taurine, 27 g of carbohydrates, 0.6 g of protein, 5 mg vitamin B6 and 487 kJ of energy.
223619698|NCT02870998|OTHER|Passive learning|1-day continuing education activity consisting of a brief lecture on patient education and workshops.
223619699|NCT03900507|PROCEDURE|endometriosis surgery|"Medical treatment was initiated in patients with abdominal incision due to endometriotic focus in the incision line.~however, patients with surgical excision indications were the study group."
223619700|NCT00317993|DRUG|ezetimibe|
223619701|NCT00317993|DRUG|simvastatin|
223619702|NCT00317993|DRUG|ezetimibe plus simvastatin|
223619703|NCT04458506|PROCEDURE|Maxillary expansion|Correction of the unilateral posterior cross bite in children
223619704|NCT02946281|BEHAVIORAL|Do CHANGE|The intervention aims to increase behavioral flexibility and change patients' (unhealthy) lifestyle. At the same time the intervention should increase patient self-management and improve the patient reported outcomes (e.g. quality of life, anxiety, depression).
223619705|NCT01262807|OTHER|Exercises|A specific set of standardized exercises will be taught to patients who are randomized to the intervention group. They will be instructed to do these exercises daily while in-cast. They will have an exercise log to track adherence.
223619706|NCT06381804|OTHER|shotblocker|shotblocker device
223619707|NCT06381804|OTHER|palm stimulator|palm stimulator
223619708|NCT04622111|DRUG|CPL207280|IMP is a tablet with CPL207280 as an Active Pharmaceutical Ingredient (API).
223619709|NCT04622111|DRUG|Placebo|matching placebo tablet
223761549|NCT06923176|DRUG|Biejia-Ruangan compound|Biejia-Ruangan compound have the functions of softening hardness, dispersing lumps, removing blood stasis and detoxifying, and nourishing qi and blood. Used for chronic hepatitis B liver fibrosis, as well as early liver cirrhosis characterized by blood stasis obstructing collaterals, qi and blood deficiency with incomplete heat toxicity.
223761550|NCT06923176|OTHER|Routine medical care|Routine medical care
224209950|NCT06146686|DEVICE|Fanta AF blue rotary files 20 taper 4|single rotary file Fanta AF blue rotary files 20 taper 4
223619710|NCT04622111|DRUG|Metformin hydrochloride 750 mg|IMP is a tablet with Metformin hydrochloride as an Active Pharmaceutical Ingredient (API).
223619711|NCT04072926|DRUG|BioRoot|Influence of biomaterial BioRoot on periapical healing
223619712|NCT04634578|DRUG|Bevacizumab|"All participants will receive a single intravitreal injection of bevacizumab in one or both eyes following enrollment into the study. The injection/s should be given as soon as possible but no later than 2 days after the diagnosis of type 1 ROP meeting all of the inclusion criteria and none of the exclusion criteria.~Eyes meeting eligibility criteria will receive a single dose of 0.063 mg or 0.25mg bevacizumab provided by the pharmacy at the investigator's institution."
223619713|NCT05101447|DRUG|Mycophenolate Mofetil|At baseline, subjects will be randomized 1:1 to one of two treatment arms: the current standard of clinical care \[MMFBSA: 600 mg/m2/dose; max: 3 gram/day\] or pharmacokinetically-driven precision dosing \[MMFPK: 12-hour target area under the exposure curve of MPA (MPA-AUC0-12) at 60 mg\*h/L\].
223619714|NCT03092583|OTHER|Blood sample|35 mL, 7 tubes
223619715|NCT01793428|OTHER|Capillary lactate level|Use of capillary sample to determine lactate level upon arrival at vital emergency unit and at 2 hours
223619716|NCT02656017|DRUG|Metformin|Monitoring of tolerability and symptoms.
223619717|NCT02656017|OTHER|Placebo|Monitoring of tolerability and symptoms.
223619718|NCT06269224|OTHER|Participants were recreational runners who run between 20 to 50 km weekly; each one has 35 runners.|The Myoton device was used over the Latissimus Dorsi (LD) muscle on both dominant and nondominant sides to measure muscle tone (Hz), elasticity, and stiffness (N/m) values. Trunk flexibility and flexibility of lumbar extensor muscles were measured with tape measurement (cm). The trunk range of motion (ROM, ˚) was measured using goniometer. Thoracolumbar Fascia Length Test and Modified Schober Test were used for thoracolumbar (TLF) fascia flexibility. The weekly training distance (km), duration (h) and daily water consumption (lt) rates were recorded. The percentage of individuals experiencing lower extremity injuries and lower back pain within the RSM group was calculated.
223619719|NCT00400777|DRUG|Valsartan, hydrochlorothiazide and amlodipine|
223619720|NCT05400135|BEHAVIORAL|Qungasvik (Tools for Life)|The Qungasvik (toolbox) intervention is designed to build protection against alcohol use disorder (AUD) and suicide in Yup'ik Alaska Native youth 12-18 years old. The intervention is a community-driven and culturally-based process that develops and delivers 18-24 prevention activities leading to the two primary prevention variables, Reasons for Life and Reflective Processes about the Consequences of Alcohol Use and secondary prevention variables of multi-level protective factors and social networks.
223619721|NCT05241262|DRUG|N-Acetylcysteine|1800, 3600 or 5400 mg NAC per day (divided into 3 daily doses) depending on dose toxicity plan
223761551|NCT06924762|DRUG|Placebo intramuscular injection|On the basis of background treatment, intramuscular injection of placebo was added.
223761552|NCT06924762|DRUG|Human interleukin-2 (I) intramuscular injection|On the basis of background treatment, intramuscular injection of human interleukin-2 (I) will be added.
223761553|NCT06924086|DEVICE|Deep Brain Stimulation|Picostim DBS Device
224209951|NCT06146686|DEVICE|Fanta AF baby rotary files 20 , 25 , 30 taper 4|multiple rotary files system Fanta AF baby rotary files 20 , 25 , 30 taper 4
223761554|NCT06924268|BEHAVIORAL|Single Art Therapy Session|Each participant will engage in a 30-60 minute structured art therapy session using pre-drawn coloring sheets featuring themes such as mandalas, nature scenes, and inspirational designs. A variety of coloring tools will be provided, including crayons, colored pencils, markers, gel pens, and watercolor paints. Sessions will be facilitated by the primary investigator, who will provide non-directive prompts and engage in casual conversation to foster comfort and engagement.
223619724|NCT06255782|GENETIC|ECUR-506|ECUR-506 is a gene editing treatment delivering a gene encoding the editing enzyme and an OTC gene.
223619725|NCT03760523|DRUG|Minnelide|Patients will take Minnelide orally once daily on Days 1-21 of 28 day Cycle. Dose Escalation Schedule: Dose Level -1: .5 mg, Dose Level 1: .75 mg, Dose Level 2: 1 mg, Dose Level 3: 1.25 mg.
223619726|NCT05515523|GENETIC|Adipose Derived (AD) Stromal Vascular Fraction (SVF)|autologous stromal vascular fraction cells from adipose tissue for reintroduction to the same patient during a single surgical procedure for treatment of pain and function associated with OA of the knee joint
223619727|NCT05416138|DEVICE|Transcranial magnetic stimulation (TMS)|TMS will be performed at either peaks or troughs of ongoing prefrontal theta oscillations (3-7 Hz) concurrently with the cognitive test at the beginning of every test trial. Theta oscillations will be monitored in real-time at the left dorsolateral prefrontal cortex using electroencephalography (EEG).
223619728|NCT06202144|DEVICE|Noninvasive support|Noninvasive respiratory support delivered through a helmet
223619729|NCT05952349|DRUG|OLIVE OIL 5ML/5MG (BD) NUTRITIONAL SACHET 2100MG (BD)|44 Patients with PCOS receiving olive oil 5ML/5MG (BD) nutritional sachet 2100MG (BD
223761555|NCT06924229|DRUG|Hormonal treatment|hormonal treatment for breast cancer
223761556|NCT06923904|OTHER|Trial group, treated with a 980 nm diode laser and desensitizing topical gel|The study aims to evaluate the actual efficacy of diode lasers in laser desensitization by comparing the topical gel Emoform Actisens, containing 5% potassium nitrate, alone and in combination with a diode laser.
224209952|NCT04895228|PROCEDURE|injection|triamcinilone 40 mg injection (Kenacort) + 4 ml of .5 % lidocaine hydrochloride (Xylocaine) under ultrasound guidance
224209953|NCT05906498|DRUG|Acetyl cysteine|N-acetyl cysteine (NAC) is synthetic cysteine amino acid, which in turn elevate the glutathione level in the body, which have important direct antioxidant activity.
224209954|NCT05906498|DRUG|Vitamin E|vitamin E possessing an anti-inflammatory action
224209955|NCT02533388|DEVICE|Hwato Electronic Acupuncture Treatment Instrument|Thirty minutes prior to the induction of anaesthesia, the patients in the TEAS group started to receive TEAS by a stimulator (Hwato Electronic Acupuncture Treatment Instrument, model No.: SDZ-II, Suzhou Medical Appliances Co., Ltd., Suzhou, China) to the right hand, forearm and neck by an experienced acupuncturist at the Hegu (LI4), Neiguan (PC6), Lieque (LU7), Chize (LU5), Futu (LI18) and Renying (ST9) acupoints. TEAS was peformed with an alternate dense-disperse frequency of 2 and10 Hz ( 2 Hz for 10 s and 10 Hz for 5 s). The optimal intensity ranged from 6-15 mA, The stimulus continued until 5 min before the end of surgery.
224209956|NCT02533388|DEVICE|Placebo|The patients in the Sham group were also connected to the apparatus, but electronic stimulation was not applied.
224209957|NCT05166512|BEHAVIORAL|DPP Cooks|6 'food agency' based cooking skills classes during the first 4 months of the DPP
224209958|NCT05166512|BEHAVIORAL|DPP|Standard DPP
224209959|NCT05044832|BEHAVIORAL|Personalized Music|Personalized music delivered during the perioperative and post-operative periods. Those assigned to the music group will receive music in the preoperative holding area as well as in the post-operative care unit.
224209960|NCT05425277|BEHAVIORAL|Reciprocal Intervention Teaching (RIT)|RIT is a relatively straightforward, brief NDBI. It employs four simple strategies to target motor imitation and initiating joint attention during play: (1) contingent imitation of the child's verbal and nonverbal behavior, (2) linguistic mapping, (3) direct elicitation of object and gesture imitation following the child's interest, and (4) contingent reinforcement. It has been used at low intensities (e.g., 1-3 hours per week) over short periods of time (e.g., 10-12 weeks) to produce robust changes in pivotal social-communicative skills. RIT is easy to learn and can be implemented with fidelity by undergraduate-level therapists with limited backgrounds in ASD, as well as by caregivers and siblings.
224209961|NCT05425277|BEHAVIORAL|Daily Routines|The Routines webinar was adapted from a web-based tutorial developed by PI Stone and colleagues (Ibanez et al., 2018). The webinar covers topics such as why everyday routines are important, especially for children with ASD, specific steps for increasing children's participation in routines, and how to use strategies such as visual supports to clarify expectations, and provides numerous video examples of caregivers using different strategies. Providers are also given access to a video library of caregivers using the Daily Routines strategies with their children, as well as a workbook to use with families during treatment.
224209962|NCT06539208|DRUG|YOLT-201|Infusion of YOLT-201 at Day 1
224209963|NCT06564337|DEVICE|Surveyed zirconia crown|Patient recruitment will be from the patient population that presents to the undergraduate dental clinic requiring removable dental prosthesis (RPD) to replace missing teeth. Selection of abutment teeth for zirconia surveyed crowns will be similar to that currently utilized when selecting RPD abutments to be restored with either porcelain fused to metal or full metal surveyed crowns for tissue and tooth supported RPD's.
223619730|NCT05952349|DRUG|Metformin (1000 mg Twice a day)|44 Patients with PCOS receiving Metformin 1000mg (BD)
223619731|NCT05406414|BEHAVIORAL|Transdiagnostic sleep and circadian treatment|"The intervention group receives sleep treatment consisting of 6 sessions of 60 minutes each over 6 weeks. The sessions are delivered individually and have the following content:~1. Assessment and introduction to the sleep diary~2. Review of sleep diary - agreements on behavior changes and goals.~3. Information on normal sleep, sleep problems and circadian rhythm~4. Cognitive techniques~5. Introduction to relaxation training~6. Follow-up on goals and plan for prevention relapse of sleep problems"
223619732|NCT05406414|BEHAVIORAL|Active waitlist control group|The control group receives sleep hygiene education consisting of a single session in which 10 points of sleep advice are presented. They receive a booklet on how to promote good sleep practice and must work on their own for the next 6 weeks to implement this while waiting for the intervention.
223619733|NCT06840002|DRUG|SHR-A1811|SHR-A1811.
223619734|NCT06840002|DRUG|Carboplatin|Carboplatin.
223619735|NCT06840002|DRUG|Bevacizumab|Bevacizumab.
223619736|NCT06840002|DRUG|Oxaliplatin for Injection|Oxaliplatin for injection.
223619737|NCT06840002|DRUG|Paclitaxel injection|Paclitaxel injection.
223619738|NCT06840002|DRUG|Doxorubicin hydrochloride liposome injection|Doxorubicin hydrochloride liposome injetction.
223619739|NCT06840002|DRUG|Adebrelimab Injection|Adebrelimab injection.
224209964|NCT04744077|BEHAVIORAL|Influencer Instagram account|Participants randomized to this group will follow a public Instagram account. This account was chosen because they have a strong following (over 600,000 followers) and it is a public account that anyone can follow. The content shared on this page is motivational and community driven. There is a focus of healthy living with an emphasis on exercise. Additionally, there are no paid sponsorships or radical exercise advice, which is common on other influencer pages. The Co-PIs determined that this page accurately represents the exercise-related content that is readily available on Instagram. The research team will not have control over the content of this account, but the account holder will be notified about the study.
224209965|NCT04744077|BEHAVIORAL|Research study Instagram account|Intervention arms will deliver the same exercise-related content on the same schedule on the intervention Instagram accounts. The arms will deliver 13-weeks worth of content which goes through the last possible day of the intervention. The structure was based on feedback from stakeholders in a formative focus group. All of the content delivered through the accounts is evidence-based and referenced from reputation organizations/agencies such as the American College of Sports Medicine, American Heart Association, Center for Disease Control, and World Health Organization. Each Co-PI will post videos to answer participant questions. To ensure that the content between both groups is the same, the Co-PIs will meet to determine which questions to answer and draft the response.
223619740|NCT02362438|GENETIC|scAAv9/JeT-GAN|scAAV9/JeT-GAN is a biological gene transfer reagent
223619741|NCT04232033|OTHER|Fibroblast growth factor 21 infusion|Infusion of Fibroblast growth factor 21
223619742|NCT04232033|OTHER|Placebo infusion (saline)|Infusion of Saline
223619743|NCT05382494|DRUG|Mometasone Furoate 50mcg Nasal Spray|Intranasal steroid (Mometasone Furoate 50mcg) one spray each nostril daily for 6 weeks
223619744|NCT05382494|DRUG|Sodium Chloride 0.9 % Nasal Spray|Intranasal saline spray (Sodium Chloride 0.9%) one spray each nostril daily for 6 weeks
223619745|NCT04125563|DRUG|Capsicum Oleoresin|The soft gel capsules used in the study are easily digested in the stomach and contain standardised doses of 0,4 mg Capsicum oleoresin with the main component capsaicin (8-methyl-N-vanillyl-6-nonenamide) (from chili extract).
223619746|NCT04125563|DRUG|Placebos|Soft gel capsules filled with placebo - sorbitol and colorant.
223619747|NCT03093922|DRUG|Atezolizumab|1200 mg/m\^2
223619748|NCT03093922|DRUG|Gemcitabine|1000 mg/m\^2
223619749|NCT03093922|DRUG|Cisplatin|70 mg/m\^2
223619750|NCT06846541|DRUG|Open-Label ESK-001|Open-Label ESK-001
223619751|NCT06846541|DRUG|Blinded ESK-001|Blinded ESK-001 during Randomized Treatment Withdrawal Period
223619752|NCT06846541|DRUG|Placebo|Placebo during Randomized Treatment Withdrawal Period
224209966|NCT02450409|PROCEDURE|Implantation of TKA using the gap technique|Implantation of total knee arthroplasty using a specific operative technique (GT) serving as control.
224209967|NCT02450409|PROCEDURE|Implantation of TKA using anatomical alignment|Implantation of total knee arthroplasty using a specific operative technique (AA) being experimental.
223619753|NCT04467073|BEHAVIORAL|Online RIT|"Online RIT presents RIT techniques in four sequential learning modules: (1) Setting Up For Success (2) Imitating your Child (3) Describing Play (4) Teaching Object Imitation. Each learning module includes an instructional video, quiz, interactive exercises, and at-home planning and reflection. The website also includes a video library, Frequently Asked Questions, downloadable visual aids, links to relevant external resources, and a customizable dashboard that allows users to track their individualized goals and the amount of time they have spent working on their goals (e.g., practice log)."
223619754|NCT04148534|DRUG|Rocroniom, Non Depolarizing Muscle Relaxant|compare the operating condition of two different levels of muscle relaxation on facial nerve monitoring using transcranial motor evocked potential in CPA surgery
224209968|NCT03999346|OTHER|retrospective analysis of the Swiss Trauma Registry data|retrospective analysis of protectively documented registry data based on data completeness, patient outcomes, patient characteristics
224209969|NCT02139306|DRUG|Ataluren (PTC124®)|Oral Ataluren TID
224209970|NCT02139306|DRUG|Placebo|Oral Placebo TID
224209971|NCT05255783|DEVICE|subcutaneous continuous glucose sensor|Dexcom G6 continuous glucose monitoring system
224209972|NCT06498557|OTHER|Peripheral nerve block methods|We apply different nerve blocks to patients for analgesic purposes after knee replacement surgery. These blocks are a combination of SFIP block and adductor channel block and iPACK block.
224209973|NCT04449354|DEVICE|HidraWear Ax|An adhesive free wound dressing fixation device for people living with Hidradenitis Suppurativa (HS), Hidrawear AX, designed to make dressing changes quick and easy for subjects. The unique features of the product completely remove the use of adhesives on the skin.The body conforming garment acts as a second skin and incorporates largely perforated panels over wound affected areas, minimising skin contact and aerating the area. The main function of the perforated is to act as a retaining device for the wound pads. The garment facilitates easy insertion, removal, precise positioning and adjustment of a non- adhesive wound dressing onto the effected wound space. The perforated section of the garment sits on the outer surface of the dressing providing provisional fixation. Next, an outer patch is placed on the outside of the garment on the footprint of the dressing. Through a hook and loop mechanism the dressing is now fully secured in place.
224209974|NCT04237259|OTHER|Parent-administered TCM pediatric massage training|"Massage therapy is a kind of complementary and alternative therapy, which involves a number of techniques such as friction, pressing, rubbing, grasping, pinching, and kneading. TCM pediatric massage, also called pediatric tuina and pediatric anmo, is a special part of TCM massage system that usually use lines or surfaces rather than points as acupoints and the manipulations are different from those of TCM adult massage. From TCM perspective, the pathogenesis of ADHD is the abnormal exuberance of yang, which can be relieved by specific approaches of massage.~Participants in this group will receive two TCM pediatric massage training sessions (5 hours in total, one is 3 hours, and the other is 2 hours). The protocol will be tested for feasibility at the first feasibility stage (the first 8 subjects)."
224209975|NCT04237259|OTHER|Progressive Muscle Relaxation Exercise|The principle of progressive muscle relaxation exercise is to achieve a relaxation state through relaxing our muscles. With training, we become more familiarized with the sense of relaxation so that we can voluntarily induce this sensation in the face of a stressor.
223619755|NCT04736888|OTHER|extended-reality CPR training|extended-reality technologies based CPR training module
223619756|NCT04736888|OTHER|conventional CPR training|conventional CPR training with video
223619757|NCT04306614|PROCEDURE|Endobronchial Ultrasound guided Transbronchial Fine Needle Aspiration|Bronchoscopic procedure to allow for sampling mediastinal lymphadenopathy or proximal lung tumours under real-time ultrasound guidance.
223619758|NCT03604211|RADIATION|Cyberknife Radiation Therapy|Stereotactic Radiotherapy of lymphnode recurrence after prostatectomy +/- salvage radiotherapy
223619759|NCT03895333|OTHER|Audiological profiling and bone mineral densitometry measurement|bone mineral densitometry measurements and hearing test patients, osteoporosis according to whether the hearing test will be analyzed.
223619760|NCT02792231|DRUG|Ofatumumab subcutaneous injection|Ofatumumab 20 mg prefilled syringes for subcutaneous injection on days 1, 7, 14, week 4 and every 4 weeks thereafter
223761557|NCT06924242|PROCEDURE|total or partial thyroidectomy|Total thyroidectomy is a surgical procedure that involves the complete removal of the thyroid gland. It is performed to treat conditions such as thyroid cancer, large goiters, or severe hyperthyroidism. The surgery is typically conducted under general anesthesia through an incision in the lower neck. Postoperative management may include hormone replacement therapy with levothyroxine to compensate for the loss of thyroid function. Potential complications include hypocalcemia due to parathyroid gland injury and vocal cord dysfunction from recurrent laryngeal nerve damage.
224209976|NCT05060952|DIAGNOSTIC_TEST|Calprotectin Lateral Flow Test|Semiquantitative point of care photometric assay for the calprotectin level in joint fluid aspirate
224209977|NCT03438305|OTHER|sonar assessment of gastric volume in Diabetic patients|assessment of gastric volume in Diabetic Patients
224209978|NCT03438305|OTHER|sonar assessment of gastric volume in Non Diabetic patients|assessment of gastric volume in Non- Diabetic Patients
224209979|NCT00160446|DRUG|Asoprisnil|5mg Tablet, oral Daily for 12 weeks
224209980|NCT00160446|DRUG|Asoprisnil|10 mg Tablet, oral Daily for 12 weeks
223619761|NCT02792231|DRUG|Teriflunomide-matching placebo capsules|Placebo capsule, matching in appearance to teriflunomide, taken orally once daily
223619762|NCT02792231|DRUG|Teriflunomide capsule|Teriflunomide 14 mg oral capsule taken once daily
223619763|NCT02792231|DRUG|Matching placebo of ofatumumab subcutaneous injections|Matching placebo of ofatumumab subcutaneous injections on days 1, 7, 14, week 4 and every 4 weeks thereafter
223761558|NCT06924749|DRUG|EGCG|"EGCG (high pressure liquid chromatographic purity~≥ 95%; from Ningbo Hepu Biotechnology Co., Ltd.) is dissolved in 0.9% normal saline; 10ml is inhaled by atomization three times a day."
224209981|NCT00160446|DRUG|Asoprisnil|25 mg Tablet, oral Daily for 12 weeks
224209982|NCT00160446|DRUG|Placebo|Tablet, oral Daily for 12 weeks
224209983|NCT06090500|PROCEDURE|Cryotherapy|preoperative submucosal infiltration injection of cold saline solution (2-5 degrees Celsius)
224209984|NCT06090500|PROCEDURE|Diclofenac sodium|preoperative submucosal infiltration injection of Diclofenac sodium (25mg/ml)
224209985|NCT06090500|PROCEDURE|Dexamethasone sodium phosphate|preoperative submucosal infiltration injection of dexamethasone sodium phosphate (4mg/ml)
224209986|NCT02913261|DRUG|Ruxolitinib (RUX)|Ruxolitinib was provided as 5 mg tablets for oral use.
224209987|NCT02913261|DRUG|Best Available Therapy (BAT)|BAT was based on the investigator's best judgment, taking into account the manufacturer's instructions, labeling, patient's medical condition, and institutional guidelines for any dose adjustment. The BAT in this study was identified by the investigator prior to patient randomization among the following treatments currently used in this setting: anti-thymocyte globulin (ATG), extracorporeal photopheresis (ECP), mesenchymal stromal cells (MSC), low-dose methotrexate (MTX), mycophenolate mofetil (MMF), mTOR inhibitors (everolimus or sirolimus), etanercept, or infliximab. No other types or combinations of BAT were permitted.
224209988|NCT00285350|DRUG|mycophenolate mofetil|
224209989|NCT03166306|DIAGNOSTIC_TEST|PET-CT Imaging with [89Zr]-bevacizumab|Subjects will receive 1 millicurie of 89Zr and less than 5 mg of bevacizumab, followed by PET-CT imaging.
224209990|NCT01236053|DRUG|Gabapentin prescriptions|The exposure of interest is gabapentin use as defined by prescriptions recorded by the GPRD general practitioner (British National Formulry codes). Data on prescriptions for gabapentin will be extracted for each case and control from entry into the study cohort up to two years prior to the index date (the exposure window). A two year lagged exposure is incorporated to account for latency between cancer onset and GPRD diagnosis, and for protopathic bias (gabapentin prescription for initial pain symptoms of undiagnosed cancer). Gabapentin exposure will be parameterized as follows: (1) Ever versus never exposed; (2) Number of prescriptions; (3) Duration of exposure; and (4) Cumulative dose.
224209991|NCT03286595|OTHER|Mobi mHealth app|"Mobile application (i.e. the app) that patients interact with via their smartphone to collect daily and weekly survey information. Data is visualized on a clinician-facing Dashboard, which can be used to inform treatment."
224209992|NCT02271100|DEVICE|ultrasound guidance|use of ultrasound for entry position estimation
224209993|NCT02271100|DEVICE|palpation guidance|use of palpation for position estimation
224209994|NCT02460315|PROCEDURE|early cholecystectomy|Those patients are primarily managed by endoscopic sphincterotomy and stone extraction for management of CBD stones. Then, the study population will be divided into 2 groups; group 1 will be managed by early laparoscopic cholecystectomy (LC) within 3 days after ERCP
224209995|NCT02460315|PROCEDURE|late cholecystectomy|Those patients are primarily managed by endoscopic sphincterotomy and stone extraction for management of CBD stones. Then, the study population will be divided into 2 groups; group 2 will be managed by late LC one month after ERCP.
224209996|NCT04164394|OTHER|Placebo|Placebo treatment (maltodextrin), once daily (u.i.d)
224209997|NCT04164394|DIETARY_SUPPLEMENT|I31 Probiotic|I31 probiotic formula (dietary supplement), consisting of 3 billion cfus of strains P. acidilactici CECT7483, L.plantarum CECT7484 and L.plantarum CECT7485, once daily (u.i.d)
224209998|NCT06567977|OTHER|Trimbow|Trimbow® is a fixed triple therapy containing a long-acting muscarinic antago-nist (LAMA, Glycopyrronium), a long-acting beta-adrenergic agonist (LABA, Formoterol) and an inhaled corticosteroid (ICS, beclomethasone). Trimbow® has an extra-fine formulation delivered as a controlled dosage aerosol. Trim-bow® is to be applied in accordance with its current marketing authorisation and the guidance specified in the summary of product characteristics (SmPC) in each country.
223619764|NCT05196828|DEVICE|NTX100 Neuromodulation System|Active Noninvasive peripheral nerve stimulation device programmed to active mode
223619765|NCT01270178|DRUG|Entecavir|film coated tablets / 0.5mg / once daily / 3 years
223761559|NCT06924736|DEVICE|Intravascular Shockwave Therapy Device / Disposable Coronary Shockwave Catheter|Randomly assign subjects to the experimental group to treat the lesions with an intravascular shockwave therapy device/disposable coronary artery shockwave catheter.
224209999|NCT06569004|DEVICE|randomised study, two group (experimental and control)|Use of IR beam before peripheral intravenous catheter application
224210000|NCT03010475|DRUG|Furosemide|Oral administration A total of three single doses.
224210001|NCT03010475|DRUG|Rosuvastatin|Oral administration. A total of three single doses.
224210002|NCT03010475|DRUG|SNAC|Oral administration. A total of five single doses.
224210003|NCT03010475|DRUG|Semaglutide|Oral administration. Once daily.
224210004|NCT04803773|DEVICE|"UFOGUIDE patient transducer"|The transducer is maintained by a flexible/rigid structure, consisting of a support base, and three to four feet forming an arch around the area to be treated. These feet exist in several lengths (10, 20, 30, 40 cm) depending on the area to be treated and can be easily mounted on the base by fast attachment. The structure is based on the principle of granular jamming: it is flexible in its normal state, and can be stiffened by the application of depression within the feet.
224210005|NCT01067989|DRUG|Cyclophosphamide, Capecitabine, Methotrexate, Celecoxib, Pamidronate (or Zoledronate)|"1. Cyclophosphamide Tab. 50mg, 1x1/day, continuously.~2. Capecitabine Tab. 500mg, 1+2/day, continuously.~3. Methotrexate Tab. 2.5mg, 1x2/day, 2 days every week.~4. Celecoxib Tab. 200mg, 1x2/day, continuously.~5. Pamidronate I.V. 90mg, every 4 weeks; or Zoledronate I.V. 4mg, every 4 weeks)"
224210006|NCT03305783|PROCEDURE|cholecystectomy|elective cholecystectomy performed due to gallstones, cholecystitis or other non-malignant conditions and therefore done regardless of the protocol of this study.
224210007|NCT01734421|OTHER|Control group|6-month implementation of recommendations of a Clinical Practice Guideline smoking cessation
224210008|NCT01734421|DEVICE|Cell phone Aplication for Smarth Phone|
224210009|NCT03658356|OTHER|Video instructions|Pregnant patient will watch her video explaining how to collect a urine sample for asymptomatic bacteriuria determination.
223619766|NCT03309878|BIOLOGICAL|Mogamulizumab|Given IV
223619767|NCT03309878|BIOLOGICAL|Pembrolizumab|Given IV
223619768|NCT05510063|DRUG|Humira (Adalimumab)|Subcutaneous (SC) injection
223619769|NCT05510063|DRUG|SB5 (Adalimumab Biosimilar)|Subcutaneous (SC) injection
223619770|NCT02520817|DIETARY_SUPPLEMENT|175 mg zinc gluconate, 50000 IU vitamin A, 500 mg vitamin C and 100 mg vitamin E once daily plus lactulose; dose 30-60 ml/day for 3 months|
223619771|NCT02520817|DIETARY_SUPPLEMENT|Lactulose|
223619772|NCT01096316|BEHAVIORAL|Depression Care Management|The intervention is conducted by a social worker who has the role of a Depression Care Manager (DCM). First, a unique engagement session develops rapport with the DCM, providing education and identifying health concerns. DCM meets in-person and/or by phone every 1-2 weeks for 12 weeks, then monthly for the rest of the 12-month intervention. Patients choose either medication or Problem-Solving Treatment-Primary Care therapy. Depressive symptoms are assessed at each visit with the PHQ-9, as well as response to medications or to PST, with a total of 8 PST-PC sessions. Patients with inadequate response after 8 weeks to the first choice will switch or combine treatments. Providers are given extensive feedback about the patient's health care concerns.
223619773|NCT02461667|DRUG|SRP plus Placebo Gel|After SRP, placebo gel was delivered subgingivally into the pocket
223619774|NCT02461667|DRUG|SRP plus Alendronate gel|Alendronate (ALN) After SRP, ALN gel was delivered subgingivally into the pocket
223619775|NCT02461667|DRUG|SRP plus Metformin gel|Metformin (MF) After SRP, MF gel was delivered subgingivally into the pocket
223619776|NCT04078802|PROCEDURE|VNOTES/VH|same as above
223619777|NCT01772628|BEHAVIORAL|Classroom-based component|Selected topics about sex, communication, and relationships were integrated in 8 English classroom lessons and 8 Christian Religious Education classroom lessons. The component was implemented in a period of 14 weeks in Senior One classrooms of all the 11 intervention schools.
223619778|NCT01772628|BEHAVIORAL|STI/HIV prevention education|"For this component, the project partnered with Naguru Teenage information and Health Centre a local NGO providing youth friendly Sexual Reproductive Health services. The STI/HIV prevention education was implemented once in each school on a day that had been agreed upon with the school administration."
223761560|NCT06924736|DEVICE|Non - compliant balloon dilatation catheter|Randomly assign subjects to the control group to treat the lesions with a non - compliant balloon catheter.
224210010|NCT00405483|PROCEDURE|Standard exposure|Minimal invasive vs standard exposure of the joint is the difference between a small incision, smaller equipment for less tissue damage vs large incision (standard is greater than 10cm)and subsequent more tissue damage.
224210011|NCT00405483|PROCEDURE|Minimally Invasive|Minimally invasive surgical technique (minimal incision)
224210012|NCT06568887|COMBINATION_PRODUCT|Dextrose Water|Individuals in this group will receive three injections of 5% dextrose water per week for six weeks period to treat their pain in sacroiliac joint and then their responce will b documented.
224210013|NCT06568887|COMBINATION_PRODUCT|Corticosteroid Injection|Individuals in this group will receive three corticosteroid injections per week for a period of six weeks to treat their pain in Sacroiliac joint and then their responce will also be documented.
224210014|NCT05576597|DRUG|Sodium Butyrate|2 capsules butyrate supplement once a day for 12 weeks
224210015|NCT06568991|DIETARY_SUPPLEMENT|Low Protein Rice MATSUBUMAI|"Investigators will recruit 100 subjects participating in thePRE-ESRD education plan at KMUH. Subjects will receive dietary education of low protein diet (providing energy 25 to 35 Kcal/Kg/day, protein 0.6 to 0.8 g/Kg/day) by dietitians. Subjects will be randomly assigned to a observational group or rue low protein rice group."
223619779|NCT01772628|BEHAVIORAL|Homework assignment component|This component was to facilitate open parent-child interactions and encourage interpersonal learning in a friendly home environment about selected Sexual Reproductive Health issues. Homework assignments were developed on the basis of the topics covered in the learners' component. Students were asked to discuss each assignment with their parents/guardians and recorded answers in 32 paged exercise books provided by the project which were eventually handed over to the researchers at the end of the intervention. Students were given 8 English homework assignments and 7 Christian Religious Education homework assignments.
223761561|NCT06923449|OTHER|Multidisciplinary Tumor Board|Institution of Multidisciplinary Tumor Board for Gastric Cancer at Fondazione Policlinico Gemelli in november 2019
223761562|NCT06924775|OTHER|Weighted jump rope training|Unlike isolated jump rope studies, this intervention was embedded within the participants' habitual CrossFit routine, enhancing ecological validity. Performing the jump rope protocol immediately prior to regular training-rather than as a stand-alone session-was intended to promote warm-up and neuromuscular priming benefits. The use of a weighted rope introduced a resistance stimulus that is rarely incorporated in jump rope interventions.
223761563|NCT06923059|OTHER|AI-assisted endoscopy recovery assessment|The intervention group will be assessed by the AI model regularly, which will be installed in a smartphone attached to the head of the stretcher once the patient in this group arrives at the recovery room. After the recovery nurse starts the AI application following the standard-of-care baseline assessment of vital signs, the AI application will prompt an automatic voice alarm to wake up the patient by asking if he/she is awake every 10 minutes.
223761564|NCT06924645|PROCEDURE|Fecal Microbiota Transplant (FMT)|Fecal Microbiota Transplantation (FMT) is delivered as a single dose of oral microbiota capsules within 72 hours before starting standard therapy.
224210016|NCT03089931|PROCEDURE|Cervical spinal surgery|Cervical laminoplasty or anterior discectomy and fusion
224210017|NCT02418559|DRUG|JNJ-63623872 (300 mg)|Participants will receive JNJ-63623872 300 mg tablet orally once on Day 1 under fasted conditions.
224210018|NCT02418559|DRUG|JNJ-63623872 (600 mg)|Participants will receive JNJ-63623872 600 mg (2\*300 mg) tablet orally once on Day 1 under fasted conditions.
224210019|NCT02418559|DRUG|JNJ-63623872 (1200 mg)|Participants will receive JNJ-63623872 1200 mg (4\*300 mg) tablet orally once on Day 1 under fasted conditions.
224210020|NCT02418559|DRUG|Placebo|Participants will receive placebo tablet orally once on Day 1 under fasted conditions.
224210021|NCT04559776|OTHER|gait analysis|gait analysis with 3D optoelectronic system and surface EMG
224210022|NCT01016158|DRUG|Umbilical cord serum eyedrops|20% umbilical cord serum eye drops 3 to 4 times a day
224210023|NCT01175161|DEVICE|Copper T380A Intrauterine Device|the Copper T380A IUD will be placed either 10 minutes to 48 hours postpartum, or 4-6 weeks postpartum.
224210024|NCT01111994|DRUG|Clindamycin Phosphate 1.2% and Tretinoin 0.025% Gel|Clindamycin Phosphate 1.2% and Tretinoin 0.025% Gel QD for 3 months
224316021|NCT03936712|DIETARY_SUPPLEMENT|Placebo Drink|The PL drink was prepared by an agri-food engineer; it did not contain any caffeine or taurine, but comprised carbonated water, carbohydrates, citric acid lemon juice reconstituted from concentrate (1 %), supplemented by flavorings, of sodium citrate, acesulfame K, sucralose, potassium sorbate and RB (a flavoring that contains propylene glycol E1520 (0.23 mL).
223619780|NCT01772628|BEHAVIORAL|Parenting component|Three one day parenting workshops were conducted in each of the 11 schools for parents/guardians during the period in which the lessons were being implemented. First workshop was conducted at the beginning of the intervention, the second in the middle of the intervention and the third at the end of the intervention. Each workshop in a school was facilitated by one selected teacher and one selected parent in the school. In the first workshop a brochure about the intervention was distributed to all the parents/guardians in attendance.
224210025|NCT02515552|BEHAVIORAL|The Fibromyalgia Wellness Project|Web-based symptom and behavior self-monitoring program with automated feedback derived from the user's personal data. A personal informatics approach is used involving proprietary within-subject statistical analysis procedures to determine user feedback that provides behavioral guidance based on statistically significant change in symptom levels associated with specific user behavior and self-management strategies.
223619781|NCT02836652|DEVICE|HeartMate II (HMII)|Left Ventricular Assist Device
223619782|NCT02836652|DRUG|Warfarin|(INR Target 2.0-2.5, median 2.25, per standard of patient care)
223619783|NCT02836652|DRUG|acetylsalicylic acid (ASA) therapy|(81mg/day)
223619784|NCT01474525|DEVICE|Home Blood Glucose Telemonitoring System|"The system is designed to send the measured blood glucose values directly to a hospital server. Values recorded by the glucometer are sent to the Blackberry® cell phone. A special removable Bluetooth® adapter unit is required for data transmission from the glucometer to the Blackberry®. The patient must then select on the Blackberry® the meal period the last measurement corresponds. The cellular phone serves as the platform for data-transmission to the central server. The threshold number of readings can be set for each patient individually through the web-interface. The system can be accessed by both the patients and the care providers through a secure web-interface.~Apart from collecting values the system generates automated adherence reminders to patients and high/low blood glucose alert messages to both patients and their care providers."
223619785|NCT03679975|DRUG|Riluzole Oral Soluble film (ROSF) 50 mg|Enrolled subjects underwent an instrumental evaluation of swallowing safety before and after administration of a single dose of the ROSF formulation containing 50 mg of riluzole.
223619786|NCT02349633|DRUG|PF-06747775|
223619787|NCT02349633|DRUG|Palbociclib|
223619788|NCT02349633|DRUG|Avelumab|
223619789|NCT06474624|OTHER|Cardio Rehabilitation program|A total of 24 30 (8-10 weeks) sessions of an exercise-based Cardio Rehabilitation program 3 days a week.
223619790|NCT06474624|OTHER|Cycling for 20-30 minutes|Cycling for 20-30 minutes at 50-70% of Wmax between warm-up and cool-down periods.
223761565|NCT06924645|OTHER|Standard Therapy|Standard Therapy Alone
223761566|NCT06923787|DRUG|Lidocaine|intravenous infusion of lidocaine
223761567|NCT06923787|DRUG|Dexamethasone|intravenous infusion of dexamethasone
223761568|NCT06923787|DRUG|Placebo|saline solution intravenous infusion
223761569|NCT06923397|BEHAVIORAL|Interrupted Sedentary Time Intervention|A 12-week, semi-supervised exercise intervention comprised of reminder prompts, counseling, and activities of walking, cycling, and resistance band exercise for at-home and in-clinic settings. Supervision will be under an exercise trainer. Resistance bands, Libre Pro continuous blood sugar monitor, and Fitbit and ActivPAL trackers will be provided to participants.
223761570|NCT06923865|BEHAVIORAL|training group|"Participants in training group are invited to take part in two structured training sessions per week, each lasting 90 minutes:~One session takes place in a larger group setting, where participants engage in physical activities and games together.~The second session is held in a small group format with 1-2 peers-either friends the participant already knows or peers they meet during the larger group session.~Each training session is supervised by a qualified instructor and includes:~Fun, game-based activities~Short workouts aimed at improving fitness~A focus on social interaction, enjoyment, and participation~The sessions are designed to be supportive, engaging, and motivating, with the goal of increasing physical activity in a positive group environment."
223619791|NCT06474624|OTHER|Cycling a total of 4 cycles|Cycling a total of 4 cycles consisting of 4 minutes at 85-100% of Wmax followed by 3 minutes of active recovery periods at 50-70% of Wmax between warm-up and cool-down periods.
223619792|NCT03647930|DEVICE|Microporous Polysaccharide Hemospheres (MPH)|Microporous Polysaccharide Hemospheres (MPH)
223619793|NCT00558246|DEVICE|Dermabond Protape (Prineo)|cyanoacrylate and pressure sensitive adhesive mesh - topical skin adhesive
223619794|NCT00558246|DEVICE|Suture|Topical Suturing
223619795|NCT05478421|PROCEDURE|Collagen sponge|The bone cavity will be filled with collagen sponge.
223619796|NCT05478421|PROCEDURE|GBR|The bone cavity will be applied with guided bone regeneration with deproteinized bovine substitute (DBBM, Bio-Oss®, granulometry 0.25-1 mm; Geistlich Pharma AG) and absorbable collagen membrane (Bio-Gide®, Geistlich Pharma AG) .
223619797|NCT05478421|PROCEDURE|CS/GBR|The bone cavity will be applied with guided bone regeneration with collagen sponge and deproteinized bovine substitute (DBBM, Bio-Oss®, granulometry 0.25-1 mm; Geistlich Pharma AG) and absorbable collagen membrane (Bio-Gide®, Geistlich Pharma AG) .
223619798|NCT04722900|OTHER|intrauterine exposure to elevated glucose levels|intrauterine exposure to elevated glucose levels
223619799|NCT05233865|BEHAVIORAL|Water exercise|Participants will be asked to sit and stand multiple times (before, immediately after, and 2 hours after a 15-minute walking session). The walking session will consist of 3 minutes of walking at a light intensity followed by 9 min of walking at a moderate intensity and a 3-minute cool down walking at a light intensity. This walking session will occur in a pool.
223619800|NCT05233865|BEHAVIORAL|Land exercise|Participants will be asked to sit and stand multiple times (before, immediately after, and 2 hours after a 15-minute walking session). The walking session will consist of 3 minutes of walking at a light intensity followed by 9 min of walking at a moderate intensity and a 3-minute cool down walking at a light intensity. This walking session will occur on land.
223619801|NCT01492790|PROCEDURE|Emergency cholecystectomy first|The intervention is an emergency cholecystectomy without prior common bile duct imaging
223619802|NCT01492790|PROCEDURE|Sequential common bile duct imaging/cholecystectomy|This intervention is a common bile duct imaging modality and, if needed, ERCP first followed in the same hospital stay by a cholecystectomy
224210026|NCT03951181|BEHAVIORAL|LEAP-MS|The LEAP-MS intervention is a co-produced, digital interactive education and activity tool, specifically developed for PwPMS. The tool includes multimedia education about being active with PMS, tailored physical activity ideas and interactive functions enabling the development of personalised activity programmes, goal setting and activity logs. The digital tool works in conjunction with support from trained physiotherapists. The feasibility study will evaluate how the LEAP-MS intervention can be used in practice.
224210027|NCT04568642|DEVICE|Activate FiO2 controller|Closed-loop FiO2 controller will be activated in the experimental arm
224210028|NCT04568642|DEVICE|Deactivate FiO2 controller|Closed-loop FiO2 controller will be deactivated in the experimental arm
224210029|NCT00000135|DRUG|MSL-109|60 mg, IV (in vein) every two weeks, treatment continued until death or common closeout.
224210030|NCT00000135|OTHER|Placebo|60 mg, IV (in vein) every two weeks, treatment continued until death or common closeout.
224210031|NCT05685693|PROCEDURE|Robotic-assisted total knee arthroplasty (raTKA)|Robotic-assisted total knee arthroplasty is an orthopaedic surgery that involves replacing the articular surfaces (femoral condyles and tibial plateau) of the knee joint with smooth metal and highly cross-linked polyethylene plastic. The robot (ROSA Knee System, Zimmer Biomet, US) assists in planning and placement of the implants and resection sites.
224210032|NCT05685693|PROCEDURE|conventional total knee arthroplasty|total knee arthroplasty is an orthopaedic surgery that involves replacing the articular surfaces (femoral condyles and tibial plateau) of the knee joint with smooth metal and highly cross-linked polyethylene plastic. In conventional TKAs, no patient-specific instrumentation or robotic assistance is provided.
223619803|NCT06034210|DEVICE|Customised 3D-printed insoles|Based on measurements from the 3D scanning procedure, and factoring in individual data such as age, weight, and activity preferences, custom insoles are designed using the ZOLA software. The insoles are then 3D-printed by Zoles ApS in Espergærde (Denmark), using BCN3D printers (Barcelona, Spain) and a TPU (Thermoplastic Polyurethane) filament material from Recreus (Alicante, Spain). The printed insoles are tailored for optimal support, performance, and comfort, with varying densities for areas like the arch and heel. They are finished with an OnSteam® microfiber cover for added durability and comfort. The insoles are intended for regular insertion into participants' shoes to align with their unique biomechanical needs. (Information translated and adapted from: https://www.zoles.eu/da/processen-bag-saalerne/)
223619804|NCT01008943|BIOLOGICAL|Autologous Muscle Derived Cells|Urethral injection of autologous muscle-derived cells
223619805|NCT02249936|DRUG|AZD1722|
223619806|NCT02249936|DRUG|Omeprazole|
223619807|NCT06007534|OTHER|Samples|Blood samples, urine samples and oropharyngeal swabs before taking 200mg of doxycycline and then 2h, 24h, 48h, 7 days, 14 days, 60 days and 90 days after the single dose of doxycycline Hair samples: at the time of doxycycline administration, 1 month and 3 months after the single dose of doxycycline
223619808|NCT05590481|DEVICE|TIBIAL TRANSCUTANEOUS ELECTROSTIMULATION|The electrodes will be surface (silicone rubber and carbonate), brand Quark®, with dimensions of 5 cm by 3 cm, coupled with conductive gel and fixed to the volunteer's skin with micropore tape. For the placement of the electrodes, the volunteer will be positioned in the horizontal supine position on the stretcher, with the knee in semiflexion and the head supported on a pillow. The electrodes will be positioned one immediately posterior to the medial malleolus of the ankle and the other approximately 10 cm above it, both fixed with micropore tape, on both legs of the patient. To ensure that the electrodes stimulate the tibial nerve, a transcutaneous electrical nerve stimulation (TENS) current with a frequency of 1 Hz will first be applied, with a gradual increase in intensity, to verify a rhythmic movement of flexion of the hallux. The following parameters will be used for TTNS: frequency 10Hz (Hertz), pulse duration 200 μs (microseconds), for 30 minutes.
224210033|NCT05288374|DRUG|Celecoxib 100 mg|Administering Celecoxib 100 mg (Celebrex) regularly every 12 hours for 3 days starting at 6 in the morning on the day of surgery
224210034|NCT05288374|DRUG|Placebo|Administering placebo regularly every 12 hours for 3 days starting at 6 in the morning on the day of surgery
224210035|NCT04599673|DRUG|AMNIOGEN|"AmnioGen® amnion matrix allograft is a bioactive tissue matrix processed from 100% human amniotic tissue. The allograft is processed with advanced technology so the graft can be suspended in liquids and applied through needles and syringes.~Amniotic tissue is composed of structural extracellular matrix, which is rich in various types of collagen, growth factors, cytokines, and specialized proteins. Thus, the application of amniotic tissue is known to modulate localized tissue inflammation, reduce scar tissue formation and promote the healing of soft tissue."
224210036|NCT04599673|OTHER|normal saline|10 ml normal saline
224210037|NCT02865473|DRUG|Pilocarpine|topical instillation into the study eye
224210038|NCT05627388|OTHER|Dreem 3 System At-Home Monitoring|Patients will be asked to wear the Dreem 3 System and actigraphy devices at home. Research support staff will teach patients how set up the device beforehand. Patients will wear Dreem and actigraph for 5 nights, while keeping the actigraph on during the day, to monitor sleep/wake cycle. Then, for an additional continuous 48hr measurement, patients will wear the Dreem and actigraph. The patient will be given 2 devices, as one device can record up to 24h of data continuously. Patients are not required to stay home during the 48hr testing period. However, patients will be instructed to refrain from participating in activities which may shift or require removal of Dreem. Patients who wish to remain home for the 48hr testing period should have adequate sustenance (i.e., groceries). Any caffeine and sleep medication intake will be logged by the patient in a sleep diary. If needed, patients will be given an off work order from work/school for the 48hr assessment.
224210039|NCT05139901|DRUG|Dornase Alfa|inhalations twice daily
224210040|NCT05139901|DRUG|Saline|inhalations twice daily
224210041|NCT01550068|DIAGNOSTIC_TEST|Echocardiography|
224210042|NCT06503523|OTHER|Hypertonic Saline|A bolus injection of hypertonic saline (7% NaCl) will be administered to the FDI muscle using a 1 mL syringe with a disposable needle (27G), and the volume of the bolus will be 0.1 mL
224210043|NCT06503523|OTHER|Histamine|A small drop of histamine dihydrochloride will be applied to a previously determined area on the volar forearm, followed by a prick through the drop
224210044|NCT06503523|OTHER|Cowhage|This insertion is conducted by forceps using a stereomicroscope, and 30-35 spicules are gently rubbed into a 1 cm diameter skin area.
223619809|NCT05590481|BEHAVIORAL|behavioral therapy protocol|submitted to a behavioral therapy protocol, which involves bladder training, pelvic floor muscle training and modification of liquid intake. The orientation will be based on the initial evaluation of the patient, in which the responsible researcher will give verbal orientations and deliver booklets on the pathology, behavioral therapy and sleep hygiene.
223619810|NCT06518824|DEVICE|DBS On|The DBS device will be turned on while the patient undergoes the working memory task.
223619811|NCT06518824|DEVICE|DBS Off|The DBS device will be turned off while the patient undergoes the working memory task.
223619812|NCT04471961|GENETIC|Exome sequencing in pediatrics cancers|This pediatric oncology study proposing a global approach integrating trio-based whole exome sequencing, somatic DNA and RNA analysis will improve the recognition of genetic predisposition and the characterization of target therapies in children with cancer.
223619813|NCT05423977|DRUG|ZV0203|Participants will be allocated to one of the following dose groups: 0.3, 0.6, 1.2, 1.8, 2.7 and 3.6 mg/kg, and receive a treatment of ZV0203-ADC followed by 21 days of dose limited toxicity (DLT) observation period.
223619814|NCT05685043|DEVICE|perfusion CT|Patients are selected for thrombectomy based on perfusion CT criteria. When the results from the perfusion CT scan (analyzed by RAPID software) indicate a core infarct volume exceeding 70 ml in patients \< 80 years or 55 ml in patients \> 80 years, then treatment is limited to best medical treatment (intravenous fibrinolysis if applicable) and no mechanical thrombectomy will be performed. This is the current standard of care for patients treated more than 6 hour after onset.
223619815|NCT05428332|DEVICE|Tri-Compartment Unloader Brace|Knee brace that is designed to reduce compressive forces on all three compartments of the knee.
223619816|NCT06532643|GENETIC|anti-CD20/CD30-CAR-T cells|"Each subject will be infused with single dose of anti-CD20/CD30-CAR-T cells. A classic 3+3 dose escalation will be employed."
223619817|NCT06532643|DRUG|Fludarabine|Fludarabine will be given at a dose of 25 mg/m2/day intravenously (IV) for 3 days prior to the infusion of anti-CD20/CD30-CAR-T cells.
224210045|NCT06503523|DEVICE|Transcranial magnetic stimulation (TMS)|Transcranial magnetic stimulation (TMS) will be used to evoke motor-evoked potentials (MEPs) in the muscle of interest and cortical responses (TMSevoked potentials - TEPs) in the motor cortex with a figure-eight-shaped cone coil.
224210046|NCT04099082|OTHER|samples|blood sample nasal swab
223619818|NCT06532643|DRUG|Cyclophosphamide|Cyclophosphamide will be given at a dose of 250 mg/m2/day intravenously (IV) for 3 days prior to the infusion of anti-CD20/CD30-CAR-T cells.
223619819|NCT05533385|OTHER|Allergenic extract|In each subject a drop of each of the 3 concentrations of both allergenic extracts will be applied in addition to the positive control (histamine) and the negative control. The application will be made in duplicate on the anterior face of the subject's arm. The distance between each application should be approximately 4 cm.
223619820|NCT01725906|DRUG|empirical therapy|"1. Nexium (esomeprazole), 40mg, bid, 14 days, plus~2. Amoxicillin (Amoxicillin Trihydrate), 1gm, bid, 7 days, plus~3. Flagyl (metronidazole), 500mg, bid, 7 days, plus either one of the following drugs~4. Select either one of the drugs according to medication history Cravit (levofloxacin) , 250 mg, bid, D8-14 Klaricid (clarithromycin), 500 mg, bid , D8-14 Tetracycline, 500 mg, bid, D8-14"
223619821|NCT01725906|DRUG|Genotypic resistance guided therapy|"1. Nexium (esomeprazole), 40mg, bid, 14 days, plus~2. Amoxicillin (Amoxicillin Trihydrate), 1gm, bid, 7 days, plus~3. Flagyl (metronidazole), 500mg, bid, 7 days, plus either one of the following drugs~4. Select either one of the drugs according to genotypic resistance results Cravit (levofloxacin) , 250 mg, bid, D8-14 Klaricid (clarithromycin), 500 mg, bid , D8-14 Tetracycline, 500 mg, bid, D8-14"
223619822|NCT06509659|DIAGNOSTIC_TEST|Methacholine Challenge Test|MCT with IOS alone versus MCT IOS and FEV1 combined
224210047|NCT05863182|BEHAVIORAL|Juntos Familia Family based intervention|Students and parents will participate in weekly 2.5 hour sessions around topics related to managing experiences with prejudice, discrimination and racism.
223619823|NCT02370329|OTHER|Laboratory Biomarker Analysis|Correlative studies
223619824|NCT02370329|OTHER|Quality-of-Life Assessment|Ancillary studies
223619825|NCT02370329|BIOLOGICAL|Ropeginterferon Alfa-2B|Given SC
223619826|NCT06580587|DRUG|MK-8527|Oral administration
224210048|NCT02340078|DEVICE|HA IDF II plus|
224210049|NCT02340078|DEVICE|HA IDF II|
224210050|NCT00004328|DRUG|enalapril|
224210051|NCT00004328|DRUG|polystyrene sulfonate|
224210052|NCT05096026|BEHAVIORAL|Standard PCP Outreach|These patients were sent two study outreach messages. Study Outreach 1 was an electronic secure message sent on behalf of the PCP, encouraging COVID-19 vaccination and designed based on behavioral science principles. Letters were sent to patients who had not signed up for the electronic health record portal. Study Outreach 2 was a postcard sent to all patients who had not been vaccinated or made an appointment by four weeks after Study Outreach 1.
224316022|NCT06550544|PROCEDURE|Office hysteroscopy|"A rigid 2.9 mm hysteroscope with 30° forward oblique lens and outer sheath diameter of 5 mm will be used in the procedure. Vaginoscopic approach will be used. A 5 F grasper will be used to grasp and extract the IUD.~Pain intensity will be assessed by visual analogue scale immediately after the procedure."
223619827|NCT04244253|DRUG|OPC-64005 20 mg , Once-daily|Active, High Dose
223619828|NCT04244253|DRUG|OPC-64005 10 mg , Once-daily|Active, Low Dose
223619829|NCT04244253|DRUG|Placebo, Once-daily|Placebo
223619830|NCT05222958|DEVICE|Gestob App|Gestop App is a mobile app that aims to help pregnant women quit smoking through gamification. It also allows you to obtain information about tobacco and pregnancy.
223619831|NCT04663321|DRUG|MK-1942|MK-1942 (5 mg or 10 mg capsules) titrated from 5 mg to 20 mg dose BID or 10 mg BIW over 4 weeks.
224210053|NCT05096026|BEHAVIORAL|Culturally Tailored PCP Outreach|These patients were sent messages similar to those in Standard PCP Outreach, but with additional culturally tailored content and photos.
224210054|NCT00935896|PROCEDURE|Low tidal volume|twenty patients were randomly (opaque sealed envelopes) assigned to receive mechanical ventilation in volume-controlled mode either with VT of 10-12 ml/kg predicted body weight (high VT group, n=10) or with VT of 5-7 ml/kg predicted body weight (low VT group, n=10) with an inspiratory fraction of oxygen (FIO2) set at the minimal level at which an arterial oxygen saturation of \> 90% and minimal PEEP (4-5cmH2O). The predicted body weight of male patients was calculated as equal to 50+0.91(centimeters of height-152.4); that of female patients was calculated as equal to 45.5+0.91(centimeters of height-152.4).
224316023|NCT06550544|PROCEDURE|Ultrasound guided|"An alligator forceps will be introduced into the uterine cavity under ultrasound sound guidance. The IUD will be grasped and extracted outside the uterus.~Pain intensity will be assessed by visual analogue scale immediately after the procedure."
223619832|NCT04663321|DRUG|Placebo|Dose matched placebo capsules BID orally over 4 weeks.
223619833|NCT05046834|OTHER|cold application|Oral paracetamol 10 mg/kg, which is administered as standard 60 minutes before the procedure, will be given to patients who have decided to remove the chest tube by the physician and comply with the limitations of the study. After that, initial pain severity and vital signs of the patient will be recorded using FLACC 15 minutes before the start of the chest tube removal process (1.MEASURE). After this measurement, the cold gel package will be wrapped in gauze and placed directly on the skin, covering the area around the chest tube with a radius of about 5 cm. The cold gel package will remain on the skin surface for about 20 minutes. After 15 minutes, the cold package will be removed and the chest tube will be removed by the doctor.
223619834|NCT05046834|OTHER|cold application until 13.6 C|After measurements, the cold gel package, which rotates with one end open and forms a circle, will be wrapped in gauze and placed directly on the skin in a radius of about 5 cm, covering around the chest tube. 10 of the app. After the minute, the skin temperature will be measured with an infrared thermometer if the heat falls below 13.6 o C, the process will be terminated. If the skin temperature does not fall below 13.6 0 C, the application will continue, the application will be terminated when the heat falls below the specified temperature. After the cold package is removed, the chest tube will be removed by the doctor.
223619835|NCT04327206|DRUG|BCG Vaccine|"Freeze-dried powder: Live attenuated strain of Mycobacterium bovis (BCG), Danish strain 1331.~Each 0.1 ml vaccine contains between 200000 to 800000 colony forming units. Adult dose is 0.1 ml given by intradermal injection"
223619836|NCT04327206|DRUG|0.9%NaCl|0.9% Sodium Chloride Injection
223619837|NCT04665843|DRUG|Atezolizumab|Atezolizumab at a fixed dose of 1200 mg will be administered by intravenous (IV) infusion Q3W on Day 1 of each 21-day cycle.
223619838|NCT04665843|DRUG|Tiragolumab|Tiragolumab at a fixed dose of 600 mg will be administered by IV infusion Q3W on Day 1 of each 21-day cycle.
223619839|NCT04665843|DRUG|Placebo|Placebo will be administered by IV infusion Q3W on Day 1 of each 21-day cycle.
223619840|NCT06798402|DRUG|Ciprofloxacin (BAYO9867)|Intralesional ciprofloxacin (2 mg/ml, 100 ml, Ciproxin®, Bayer Schering pharma AG, Germany), each lesion was injected based on lesion size (2 mg/cm2).
223619841|NCT06798402|DRUG|sodium stibogluconate (Pentostam)|Intralesional sodium stibogluconate (100 mg/ml, 100 ml vial, Pentostam®, GlaxoSmithKline, UK), each lesion was injected based on lesion size (1 mg/cm2)
223619842|NCT05727878|DRUG|KPI-012|KPI-012 is a secretome product composed of biologically active components secreted from human bone marrow-derived mesenchymal stem cells
223619843|NCT05727878|DRUG|KPI-012 Vehicle|KPI-012 formulation with no active drug
223619844|NCT04198792|OTHER|No intervention|No intervention, but ECPR patients will be compared to ECMO-patients that have not had cardiac arrest
223619845|NCT02181309|DRUG|Meloxicam, low dose|
223619846|NCT02181309|DRUG|Meloxicam, medium dose|
223619847|NCT02181309|DRUG|Meloxicam, high dose|
223619848|NCT00571155|DRUG|levetiracetam|oral and intravenous dosing 2000-3000 mg per day
223619849|NCT05513339|DEVICE|WHOOP strap 4.0|Subjects will wear the WHOOP strap 4.0 for continuous physiologic monitoring.
223619850|NCT05734599|DEVICE|NMR-based metabolic profiling|Clinical parameters and VCTE results of each patient will be collected. Patients will be grouped into two groups according to VCTE, FIB-4 and NFS, and undergo NMR-based metabolic profiling
223619851|NCT05788055|DIAGNOSTIC_TEST|Stool Analysis|Stool Analysis to detect H.Pylori Antigen in Stool
223619852|NCT06403462|PROCEDURE|transversalis fascial plane block|ultrasound guidance transversalis fascial plane block after iliac bone graft
223619853|NCT06403462|PROCEDURE|transversus abdominis plane block|ultrasound guidance lateral transversus abdominis plane block after iliac bone graft
223619854|NCT00005992|BIOLOGICAL|PSA prostate cancer vaccine|
223619855|NCT00005992|BIOLOGICAL|therapeutic autologous dendritic cells|
223619856|NCT03936608|DEVICE|Programming individualized RV-LV pacing offset to optimize ECG|After CRT device implant, participants will undergo physiologic evaluations at various (up to 10 or more) RV-LV offset settings including ECGs. The RV-LV offset that optimizes the paced QRS morphology on ECG will be programmed.
224316024|NCT01439256|BEHAVIORAL|Computer Controlled Telephone Counseling|The subjects in the intervention arm receive medication adherence counseling through a computer controlled telephone counseling program
224316025|NCT01439256|OTHER|Physician information and management recommendations|Treating physicians for those subjects in the intervention arm receive through the medical record system a summary of blood pressure values and adherence data and recommendations.
223619857|NCT03936608|DEVICE|Nominally programming CRT device without RV-LV offset|After CRT device implant, participants will undergo physiologic evaluations at various (up to 10 or more) RV-LV offset settings including ECGs. Nominal standard-of-care CRT programming with no RV-LV offset will be programmed.
223619858|NCT03214861|OTHER|Carbohydrate quality|This is an observational study examining the association between carbohydrate quality and coronary heart disease. The investigators used a variety of carbohydrate quality metrics to evaluate carbohydrate quality including carbohydrate, starch, total fiber, cereal fiber, fruit fiber, and vegetable fiber intakes, and the ratios of carbohydrate to total fiber, carbohydrate to cereal fiber, starch to total fiber, and starch to cereal fiber intakes.
223619859|NCT04379063|OTHER|COVID-19 pandemic|Currently practicing during the COVID-19 pandemic
223619860|NCT01332123|DEVICE|Alignment perturbations|Increased foot plantar flexion, increased foot dorsal flexion, increased foot supination, increased foot pronation (always 2 degrees from the neutral position)
223619861|NCT05850949|DIETARY_SUPPLEMENT|Konjac Grain|Without supplementation, followed by Supplementation with Dietary Fibre the Konjac-Grain week 1, repeated until week 6, blood collected with a fine needle 10ml citrate-Tube Glucose was measured with disposable 'test-strip', which is then inserted into an electronic blood glucose meter (device: Accu-Check Instant S Glucose from Roche) . Normal value:70 to 99 mg/dL (3.9 to 5.5 mmol/L). Further HbA1c (glycated Hemoglobin A1c) concentration was checked with disposable 'test-strip', which is then inserted into an electronic HbA1c meter (device: Accu-Check Instant S HbA1c from Roche). Unit value fir HbA1c = mg/dl
224210055|NCT00935896|PROCEDURE|Low tidal volume|Immediately after ICU admission, once all inclusion and exclusion criteria were met and consent obtained, twenty patients (16 men, 4 women, median age of 49 yrs) were randomly (opaque sealed envelopes) assigned to receive mechanical ventilation in volume-controlled mode either with VT of 10-12 ml/kg predicted body weight (high VT group, n=10) or with VT of 5-7 ml/kg predicted body weight (low VT group, n=10) with an inspiratory fraction of oxygen (FIO2) set at the minimal level at which an arterial oxygen saturation of \> 90% and minimal PEEP (4-5cmH2O). The predicted body weight of male patients was calculated as equal to 50+0.91(centimeters of height-152.4); that of female patients was calculated as equal to 45.5+0.91(centimeters of height-152.4)
224210056|NCT00935896|OTHER|low tidal volume|tidal volume of 5-7 ml/kg predicted body weight
224210057|NCT01831596|DEVICE|ciSNaP|SNaP disposable, mechanically powered Negative Pressure Wound Therapy System
223619862|NCT00423657|DRUG|ceftaroline|600 mg parenteral infused over 60 minutes, every 12 hours for 5 to 14 days
223619863|NCT00423657|DRUG|vancomycin plus aztreonam|vancomycin at 1 g parenteral infused over 60 minutes followed by aztreonam 1 g infused over 60 minutes, every 12 hours, for 5 to 14 days.
223619864|NCT00423657|DRUG|Placebo|Ceftaroline fosamil 600 mg administered intravenously over 60 minutes every 12 hours, followed by placebo administered over 60 minutes every 12 hours.
223619865|NCT05289843|OTHER|Rosmarinus Officinallis|Root canal Irrigants
224210058|NCT05619809|DIETARY_SUPPLEMENT|Thermogenic dietary supplement|Daily ingestion of OxyShred thermogenic dietary supplement.
224210059|NCT05619809|DIETARY_SUPPLEMENT|Protein supplement|Daily ingestion of protein supplement.
224210060|NCT05619809|DIETARY_SUPPLEMENT|Placebo supplement|Daily ingestion of a placebo dietary supplement.
223619866|NCT04538937|OTHER|no intervention|no intervention
223619867|NCT02748863|DRUG|Placebo|2 mL + 2 x 1 mL Placebo s.c. at randomization, weeks 1, 3, and 4, thereafter 4-weekly until week 48
223619868|NCT02748863|DRUG|Secukinumab 2 mL form|Secukinumab 300 mg/2mL + 2 x 1 mL placebo s.c. at randomization, week 1 , 3, 4, thereafter 4-weekly until Week 48
223619869|NCT02748863|DRUG|Secukinumab 1 mL form|Secukinumab 150 mg/1mL x 2 + 2 mL placebo s.c. at randomization, week 1 , 3, 4, thereafter 4-weekly until Week 48
223619870|NCT04087980|DEVICE|Poseidon System|Multicenter Pilot Study of the Poseidon System for the Ablation of Prostate Tissue Utilizing Sterile Water Vapor in Patients with Intermediate Risk Localized Prostate Cancer
223619871|NCT02795117|DRUG|Ivermectin|
223619872|NCT02795117|DRUG|Ivermectin (reference)|
223619873|NCT02795117|DRUG|Placebo|
223619874|NCT04258878|PROCEDURE|Sternotomy|Procedure: Sternotomy for coronary artery bypass graft, valvuloplasty, aortic surgery or combined procedures, under extracorporeal circulation or not, in emergency or scheduled.
223761571|NCT06924372|OTHER|Taking saliva samples of unstimulated saliva will be collected in sterile containers, salivets.|Subjects will sit in a filiological position in a dental chair. Samples of unstimulated saliva will be collected in sterile containers, salivets. A prerequisite for taking saliva samples will be that subjects do not take water and food until two hours before the examination, according to the manufacturer's instructions. SARSTED Salivette will be used. In a sterile manner, the swab will be removed from the salivette with sterile tweezers and applied to the patient's mouth on the buccal mucosa. The tampon will be held for a minimum of 2 minutes in the patient's mouth (with buccal mucosa). After the elapsed time, the tampon will be removed from the mouth, using sterile tweezers and sterile gloves and will be inserted into the saliva and closed. After sampling, the salivates will be transported to the Department of Microbiological Diagnostics of the Institute for Pulmonary Diseases of Vojvodina. Transport should be done in the shortest possible time.
224210061|NCT06033183|BIOLOGICAL|Blood sample|Blood sample collection : 2 X 5 ml
224210062|NCT06328543|OTHER|Histamine|Histaminergic itch will be evoked by a 1% histamine solution. A droplet of histamine solution will be placed on the predetermined area on the forearm, and the SPT lancet will be pierced through the histamine.
224210063|NCT06328543|OTHER|Cowhage|25 spicules will be inserted in the center of the predefined skin area on the mandibular area. The spicules will be gently rubbed for 15-20 seconds in circular motion to facilitate epidermal penetration.
223619875|NCT02422498|RADIATION|external beam radiation therapy|Radiation therapy to the target tumor will be delivered with external beam radiation therapy. In metastatic cases where the intent is palliative, the dose of radiation will be 3750 cGy delivered in 15 daily fractions, 4-5 days a week. In locoregionally recurrent cases where the intent is to enhance locoregional control, the dose of radiation will be 5000 cGy delivered in 25 fractions, 4-5 days a week plus an optional 10-14 Gy boost to areas of gross tumor.
223619876|NCT02422498|DRUG|cisplatin|Cisplatin treatment should be initiated following study registration. The dose of cisplatin is established as 25 mg/m\^2 ivpb once a week (+ 3 days) for 1-2 weeks prior to radiation. The length of one cycle of Cisplatin is 21 days.
223619877|NCT02422498|PROCEDURE|Biopsy of Target Tumor|Biopsy of the tumor to be irradiated will be performed. Fresh tissue specimens will be sent to the laboratory for performance of the MSK-HRR Assay.
223619878|NCT01059409|PROCEDURE|Meniscal Allograft|Meniscal Allograft
223619879|NCT05507307|BEHAVIORAL|mindfulness-based pregnancy education program.|Pregnant education program based on mindfulness is planned as 2 sessions per week for 4 weeks, in total 8 sessions. Each session is planned to last 40-60 minutes on average. Sessions will continue as individu
224210064|NCT05093374|DRUG|anti-VEGF agent|"All patients will be treated at baseline. A loading dose of 2 additionally monthly treatments will be performed at months 1 and 2. Patients showing no intra- and/or subretinal fluid in the central 1mm subfield at month 1, no treatment will be given till any disease activity is documented.~Presence/change of sub- and intraretinal fluid will be assessed objectively by AI software and the results will be provided during the visit to the investigator. The final decision for/against retreatment is always made by the discretion of the clinical investigator. Should the Investigators decision differ from the study protocol, the reason will be indicated in the CRF."
223619880|NCT02305030|DRUG|BIA 9-1067|
223619881|NCT02305030|DRUG|Warfarin|
223619882|NCT03206216|DIAGNOSTIC_TEST|Diode Laser fiber type Selective Stimulator (DLss)|A laser device to assess pain sensitivity to stimulation
223619883|NCT04958824|DIAGNOSTIC_TEST|Pharmacogenetic test|Pharmacogenetic test results for Cytochrome P450 genes are examined for markers of variant metabolism.
223619884|NCT05711043|DEVICE|Endoscopic sutured gastroplasty with endomina|"Subjects in the intervention group will be treated with an ESG with the endomina ® and TAPES devices (Endo Tools Therapeutics S.A.), both CE-marked for endoscopic gastroplasty. The endomina is a device that can be attached to an endoscope and allows remote actuation of the device during a peroral intervention. Thanks to a therapeutic channel that can be angled perpendicularly to the axis of vision of the endoscope, it allows the possibilities of making transoral full thickness tissue apposition and performing, via a transoral route, large plications with tight serosa to serosa apposition in the stomach. This suturing will be done from the incisura to the upper body of the stomach, along the great curvature with TAPES, a single use needle preloaded with suture.~In addition to the endomina device, any other required endoscopic accessories can be used during the procedure (e.g., grasping forceps, loop cutter)."
223619885|NCT04236102|DIAGNOSTIC_TEST|Biocartis Idylla platform - real time PCR detecting EGFR, KRAS and BRAF mutations in liquid based cytology and blood plasma samples|Automated real time PCR mutation analysis - 1. Can the Idylla platform provide a standardised and effective method for detecting EGFR, KRAS and BRAF mutations in blood and liquid based cytology samples for patients with lung and pancreatic cancer. Mutation detection increases the treatment options for patients.
223619886|NCT01960140|DRUG|Baricitinib|Administered orally
223619887|NCT01960140|DRUG|Simvastatin|Administered orally
223619888|NCT03438617|BEHAVIORAL|Peer Support|The intervention involves monthly education/support groups co-led by a CHC doctor / nurse and peer leaders. These meetings will begin with a general discussion about participants' previous month, what they had been doing, any special events etc. Meetings will devote time to identifying goals and specific plans for reaching them, rehearsal and/or discussion of specific behaviors to execute plans and ways in which the group members can be helpful to each other. This will be organized around a Diabetes Action Plan. Peer leaders will also organize activities to promote healthy lifestyles, such as walking groups, to promote informal contacts among peer leaders and participants.
223619889|NCT00732823|DEVICE|Placebo - No device worn|
223619890|NCT00732823|DEVICE|Prototype device(unnamed)-A battery operated inflatable pneumatic cuffs|
223619891|NCT00732823|DEVICE|Prototype device(unnamed)-A battery operated inflatable pneumatic cuffs|
223619892|NCT00732823|DEVICE|Prototype device(unnamed)-A battery operated inflatable pneumatic cuffs|
223619893|NCT06279858|DIETARY_SUPPLEMENT|Probiotics|Patients will be recruited and included in the study. At baseline, a detailed medical history, and physical and neurological examination will be carried out, with all medications and medical problems documented for all participants. In the first 4 weeks, each patient will receive a weekly call to evaluate tolerability of the probiotic and any adverse events (AEs). Visit 2 will be organized after 6 weeks and final visit 3 after 12 weeks of study period. Any change in medications will also be documented during visits. The examination and documentation of AEs, will be repeated at each visit, while CGI-I will be scoring at visit 2 and final visit 3. Outcome measures will be repeated at the final followup visit at 3 months/end of treatment. Stool samples will be collected twice, at the baseline and final visits. Analyses of microbiome will be performed once, at the end of the study, when all samples are collected and sent to the selected laboratory.
223619894|NCT01353404|DRUG|Sequence 1|fenofibrate 65mg, fed condition, per oral → fenofibrate 65mg, fasting condition, per oral → fenofibrate 160mg, fed condition, per oral
223619895|NCT01353404|DRUG|Sequence 2|fenofibrate 65mg, fed condition, per oral → fenofibrate 160mg, fed condition, per oral → fenofibrate 65mg, fasting condition, per oral
223619896|NCT01353404|DRUG|Seqeunce 3|fenofibrate 65mg, fasting condition, per oral → fenofibrate 160mg, fed condition, per oral → fenofibrate 65mg, fed condition, per oral
223619897|NCT01353404|DRUG|Sequence 4|fenofibrate 65mg, fasting condition, per oral → fenofibrate 65mg, fed condition, per oral → fenofibrate 160mg, fed condition, per oral
223619898|NCT01353404|DRUG|Sequence 5|fenofibrate 160mg, fed condition, per oral → fenofibrate 65mg, fed condition, per oral → fenofibrate 65mg, fasting condition, per oral
223619899|NCT01353404|DRUG|Sequence 6|fenofibrate 160mg, fed condition, per oral → fenofibrate 65mg, fasting condition, per oral → fenofibrate 65mg, fed condition, per oral
223619900|NCT04394923|PROCEDURE|Modification of the pulmonary vein ablation line|The ablation line previously drawn will be modified regarding the esophageal print position in order to avoid RF application within the red layer of the esophageal print.
223619901|NCT04394923|PROCEDURE|Regular PVI ablation|Blinded to the esophageal position based on the type of AF, closer to the ostium for paroxysmal AF and wider for persistent AF
223619902|NCT03571139|DEVICE|Phacoemulsification|Cataract surgery and in the bag posterior chamber lens implantation
223619903|NCT03780920|PROCEDURE|manual therapy/osteopathy|"In this group, children will benefit from early osteopathic treatment over a period ranging from the third day to 4 months. The number of sessions will not be fixed, on average, 3 sessions will be carried out during this period at the University Hospital of Montpellier.~The duration of the session will be between 20 minutes to 30 or even 40 minutes"
224210065|NCT05093374|DRUG|anti-VEGF agent|"All patients will be treated at baseline. A loading dose of 2 additionally monthly treatments will be performed at months 1 and 2. Patients showing no intra- and/or subretinal fluid in the central 1mm subfield at month 1, no treatment will be given till any disease activity is documented.~In this cohort the amount of retinal fluid will not be assessed by AI software at the time of retreatment."
224210066|NCT00682097|DRUG|RO4998452|Escalating oral doses
224210067|NCT00682097|DRUG|placebo|Oral doses
223619904|NCT04826172|DRUG|IMB-1018972|Modified release (MR) oral tablet
223619905|NCT04826172|DRUG|Placebo|Matching oral tablet
223761572|NCT06924372|OTHER|Dental status|Dental status in both groups of subjects will be assessed by clinical visual examination by determining the prevalence of caries of deciduous and permanent teeth using the KEP and KEPS indexes. The clinical examination will be carried out in a dental chair using artificial light-reflectors, using a dental mirror and a dental probe on all surfaces of the tooth, which are dried with air from the puster. On the basis of a dental examination, the prevalence of caries of deciduous and permanent teeth will be determined.
224210068|NCT01311505|DRUG|Myrin© 2 (Rifampicin + Isoniazid)|Two (2) fixed-dose combination tablets each containing Rifampicin 150 mg and Isoniazid 75 mg
224210069|NCT01311505|DRUG|Rimactane® (Rifampicin)|One (1) capsule of Rifampicin 300 mg
223619906|NCT05655884|OTHER|Music Listening Application|"15 minutes before going to the surgery, the child's favorite and chosen music piece will be loaded onto the mp3 player and played by the researcher via the creatone music pillow for 15 minutes. After the child returns to the service from the recovery room (the room where the patient is observed in the operating room for a certain period of time until he recovers from the surgery and his general condition is stable), and after he regains consciousness, music will be played by the music group again for 15 minutes."
224210070|NCT04330677|DRUG|Oxytocin nasal spray|Intranasal administration of 24 International Units, Oxytocin will be given 30 minutes before the fear extinction task (Study 1) or fMRI measurement (Study 2).
224210071|NCT04330677|DRUG|Placebo nasal spray|The placebo spray contains the identical ingredients, except for the peptide itself. It will be given 30 minutes before the fear extinction task (Study 1) or fMRI measurement (Study 2).
224210072|NCT04330677|DRUG|Estrogen Gel|Participants received a single dose of estradiol gel (Estramon 2 mg estradiol, Hexal AG, Holzkirchen, Germany), applied to their shoulder, 3 hours prior to the fear extinction task (Study 1) or fMRI measurement (Study 2).
224210073|NCT04330677|DRUG|Placebo Gel|Participants received a single dose of the placebo gel (ultrasonic gel, 2 mg), applied to their shoulder, 3 hours prior to the fear extinction task (Study 1) or fMRI measurement (Study 2).
224210074|NCT00444665|DRUG|Travatan-Z|
224210075|NCT04285892|DEVICE|CAPA-IVM|"CAPA medium keeps oocytes in meiotic arrest for 22-24 hours. IVM medium allows oocytes to resume meiosis.~CAPA medium: 10% human serum albumin (HSA) + 10nM estradiol (E2) + 25nM CNP + 5ng/ml Insulin + 1mIU/ml follicle stimulating hormone (FSH) IVM medium: 10% HSA + 10nM E2 + 5ng/ml Insulin + 101mIU/ml FSH + 100ng/ml AREG CNP: peptide naturally occurring in follicles to maintain meiotic arrest, E2: estrogen, enhances effects of CNP, Insulin: basic growth factor used in cell cultures and component of commercially available LAG medium of the standard IVM system, AREG: downstream effector of the LHCG receptor which helps meiotic resumption. HSA, FSH and hCG are CE labeled. CAPA IVM medium is currently not yet available as CE marked commercially available medium and needs to be prepared in house."
224210076|NCT04657458|BIOLOGICAL|ExoFlo|Intravenous administration of bone marrow mesenchymal stem cell derived extracellular vesicles
224210077|NCT00002066|DRUG|Thymopentin|
224210078|NCT06255730|PROCEDURE|Stellate Ganglion Block|the patients in the observation group were provided with Stellate Ganglion Block, using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate Ganglion Block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
223619907|NCT05655884|OTHER|Foot Reflexology Practice:|Children in this group; Before going to the surgery, foot reflexology will be applied by the researcher, only to the left foot, for 10 minutes. After the child returns to the service from the recovery room (the room where the patient is observed in the operating room for a certain period of time until he recovers from the surgery and his general condition is stable), and after he regains consciousness, foot reflexology will be applied again, only on the left foot, for 10 minutes.
223619908|NCT00543257|OTHER|Use of paper forms to write down information|Parents will be asked to write down information specific to their child's ADHD using paper forms.
224316026|NCT06632886|DIAGNOSTIC_TEST|AI-Assisted Non-Contrast CT for Multi-Cancer Screening|Participants identified by the AI model as having potential cancerous lesions, including those suspected of lung, liver, gastric, colorectal, esophageal, pancreatic, and breast cancer, will be required to undergo blood tests (for tumor markers) and additional imaging studies (such as contrast-enhanced CT, MRI, Endoscopy, etc.) to confirm the diagnosis of cancerous lesions.
224316027|NCT05153993|OTHER|Fascia stretch|"Stretch of the fascia plantaris during 3x30, 5x/week, 6 weeks"
224316028|NCT05723939|DIETARY_SUPPLEMENT|Carnosine supplementation|Intake of carnosine supplement in form of capsules or functionally enriched chicken meet for three weeks
223619909|NCT00543257|OTHER|Computer|Parents will use a computer to complete data entry on information specific to their child's ADHD care
223761573|NCT06924372|OTHER|Periodontal status|The assessment of the presence of dental plaque will be determined visually using the Silness and Loe plaque index, while the condition of the gingiva will be determined using the gingival index Loe and Silness . Before the examination, the subject will be advised to rinse his mouth with water to remove food residues and dental plaque. Performed in the dental chair using artificial light-reflectors, by gently pulling the dental probe over the vestibular, oral, mesial and distal surfaces of all crowns of the present teeth. Four values will be entered for each tooth. The result will be obtained by adding up all the values.
223761574|NCT06923644|OTHER|Optimal Metabotype-specific diet|Following screening, baseline measurements, and determination of Metabotype, participants will be randomly assigned, using minimisation, to either the Precision Nutrition (PN) group or the Control (CN) group. The PN group will receive a diet hypothesised to be optimal for their specific Metabotype. All participants will adhere to their assigned diets for 12 months. Each Metabotype-specific diet will align with the Dutch Healthy Dietary Guidelines, while varying in macronutrient composition and quality.
224316029|NCT05723939|DIETARY_SUPPLEMENT|Controls|Intake of placebo capsules or regular chicken meet for three weeks
224316030|NCT00142025|DRUG|Oxcarbazepine|
224316031|NCT04578405|PROCEDURE|Intracorporeal anastomosis|Anastomosis performed totally laparoscopically
224316032|NCT04578405|PROCEDURE|Extracorporeal anastomosis|Anastomosis performed through a minilaparotomy
224316033|NCT00129389|DRUG|Fluorouracil|Arm A: FAC Arm B: FAC-wP
224316034|NCT00129389|DRUG|Doxorubicin|Arm A: FAC Arm B: FAC-wP
224316035|NCT00129389|DRUG|Cyclophosphamide|Arm A: FAC Arm B: FAC-wP
224316036|NCT00129389|DRUG|Paclitaxel|Arm B: FAC-wP
223619910|NCT06313983|DRUG|Hemay022+AI|hemay022：orally once daily，A 21-day cycle
223619911|NCT06313983|DRUG|Lapatinib+Capecitabine|Take the pills according to the instructions
223619912|NCT00971802|DRUG|PF-03882845 or Placebo|PF-03882845 20 mg or Placebo, daily for 10 days.
224210079|NCT06255730|DRUG|Lidocaine Hydrochloride|the patients in the observation group were provided with Stellate Ganglion Block, using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate Ganglion Block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
224210080|NCT02737072|DRUG|LY2510924|Administered SQ
224210081|NCT02737072|DRUG|Durvalumab|Administered IV
224210082|NCT03930056|DEVICE|C-Brace II|"Participant will complete 3-6 orthoses sessions to complete clinical evaluations and fittings conducted by certified orthotists.~Participant will receive 10-20, one hour training sessions over 1-2 months in the lab. These sessions include tuning the device and system tweaks in accordance to needs/preferences of participant, vitals signs, skin checks, pain, and exertion levels. Sessions involve training with the device, which includes putting on / taking off the device, transfer training, gait training, and balance and fall prevention.~Up to 20 sessions will be conducted until minimum safety guidelines are reached during a minimum of at least 3 training sessions in a row.~Participant will take the assigned device home to use for a 3-month period. Participant will be given an activity monitor to wear at all times except showering and instructed how to charge the device and use it. Participant will return for testing at 3, 6 and 12 months after receiving the brace for testing."
224210083|NCT03930056|DEVICE|Traditional Care KAFO intervention|Participant will continue with use of their own KAFO. Participant will receive 10-20, one hour training sessions over 1-2 months in the lab, if Patient is not already receiving care in a therapy setting. These sessions include tuning the device and system tweaks in accordance to needs/preferences of participant, vitals signs, skin checks, pain, and exertion levels. Sessions involve training with the device, which includes putting on / taking off the device, transfer training, gait training, and balance and fall prevention. Up to 20 sessions will be conducted until minimum safety guidelines are reached during a minimum of at least 3 training sessions in a row. Participant will continue with the assigned device home to use for a 3-month period. Participant will be given an activity monitor to wear at all times except showering and instructed how to charge the device and use it. Participant will return for testing at 3, 6 and 12 months after receiving the brace for testing.
224210084|NCT02827188|OTHER|Mega Team-videogame|Subjects randomly assigned to the treatment group will be instructed to practice Mega Team for 30-35 minutes a day, approximately 5 days a week for a minimum of 21 days and a maximum of 25 days.
224210085|NCT06568354|OTHER|Yoga|The yoga program was applied to all patients in this group, accompanied by a physiotherapist. Sessions included selected breathing, warm-up, and relaxation exercises.
224210086|NCT06568354|OTHER|Motor control exercises|Motor control exercises with three different progressive phases were applied to all patients in this group accompanied by a physiotherapist.
224316037|NCT04420845|BEHAVIORAL|Diabetes Self-Management and Support (DSMES) and Sleep Hygiene Education and Support (SHES)|SHES outlines the importance of sleep for people with type 2 diabetes mellitus and provide practical information and guidance about sleep habits. Specifically, the focus will be on: avoiding consumption of caffeine, nicotine, alcohol; avoiding use of light emitting devices before bedtime; avoiding excessive intake of fluids or heavy meals before bedtime; promoting regulation of light, noise, and temperature in the bedroom; timing of and importance of exercise; maintaining consistent sleep and wake times; establishing a pre-bedtime routine; and managing stress.
223619913|NCT00971802|DRUG|PF-03882845 or Placebo|PF-03882845 60 mg or Placebo, daily for 10 days.
223619914|NCT00971802|DRUG|PF-03882845 or Placebo|PF-03882845 120 mg or Placebo, daily for 10 days.
223619915|NCT00971802|DRUG|PF-03882845 or Placebo|PF-03882845 185 mg or Placebo, daily for 10 days.
223619916|NCT01994642|DRUG|Ciprofloxacin 0.3%/dexamethasone 0.1% sterile otic suspension|
223619917|NCT01994642|DRUG|CIPRODEX® (ciprofloxacin 0.3%/dexamethasone 0.1%)|
223619918|NCT01994642|DRUG|Placebo Sterile Otic Suspension|
223619919|NCT00363844|DRUG|Sitagliptin phosphate|50 mg QD or 100 mg QD for 12 months
223619920|NCT01387217|DRUG|GSK2018682|GSK2018682
223619921|NCT01387217|DRUG|Placebo|Matched Placebo
223619922|NCT00217958|BEHAVIORAL|SHS reduction intervention based on social cognitive learning theory|
223619923|NCT00574808|OTHER|Outreach Facilitation implementing elements of the Chronic Care Model|"An outreach facilitator helps the practice identify areas for improvement, set goals and targets, and agree on the processes needed to reach them in order to improve the care delivery within the practices. Each facilitator will be assigned up to 12 practice sites. The first year of program implementation will involve frequent (once every 3-4 weeks) visits to the practices. Afterwards, the intervention will move into a sustainability mode, during which the frequency of visits will decrease to one every 6-8 weeks during the second year, and one every 12-15 weeks during the third year and thereafter. After the first year of program implementation, each facilitator will be able to take on 12 new practices during the second year, while still being able to sustain contact with the previous 12 practices. Similarly, in the third year, another set of 12 practices will begin the intense phase of program implementation."
223619924|NCT03831477|DEVICE|Venus Viva|The Venus Viva™ is a non-invasive medical aesthetic device, intended for use in dermatologic and general surgical procedures, requiring ablation and resurfacing of the skin, using the Viva applicator.
223619925|NCT00690729|BEHAVIORAL|Cognitive Behavioral Bibliotherapy|Minimal therapist direction for self-guided bibliotherapy involving exposure and response prevention
223619926|NCT00690729|BEHAVIORAL|Cognitive Behavioral Therapy|Therapist-directed exposure and response prevention
223619927|NCT00429559|DRUG|Hycamptin|1.75mg/m2 IV on day 1 every week for 3 weeks in cycles of 4 weeks Number of cycles: until progression
223619928|NCT00429559|DRUG|Gemcitabine|"Gemcitabine at starting dose of 700 mg/m 2 with increments of 100 mg/m2 IV on day 1 every week for 3 weeks in cycles of four weeks.~Number of cycles: until progression"
224210087|NCT06567236|OTHER|3D software|Participants in the experimental arm will receive extra training on Planmeca Romexis Compare Software adapted to evaluate endodontic access preparation.
224210088|NCT00567996|DRUG|Indacaterol 150 μg|Indacaterol 150 μg once daily (o.d) inhaled
224210089|NCT00567996|DRUG|Salmeterol 50 μg|Salmeterol 50 μg twice daily (b.i.d) delivered via a proprietary dry powder inhaler
224210090|NCT00567996|DRUG|Placebo to Indacaterol|Placebo to Indacaterol inhaled via SDDPI.
224210091|NCT00567996|DRUG|Placebo to Salmeterol|Placebo to salmeterol delivered via a proprietary dry powder inhaler
224210092|NCT00937599|DIETARY_SUPPLEMENT|Brazil Nut|During 16 weeks the adolescents consumed 3-5 nuts/day
224210093|NCT02170142|DEVICE|MRI|non-invasive MRI techniques (DTI) and (ASL) will be used to assess normal brain development. DTI is capable of invasively delineating macroscopic anatomic components with high contrast and revealing structures at the microscopic level. ASL is capable of measuring cerebral blood flow and cerebral metabolic rate of oxygen.
224210094|NCT03430557|PROCEDURE|PRP|platelet rich plasma
224210095|NCT03430557|PROCEDURE|periapical surgery without PRP|retrograde MTA filling will be done after apicectomy and flap will be closed without filling anything in the bony lesion.
224210096|NCT02956005|DRUG|ENVARSUS®|ENVARSUS XR is a form of the anti-rejection drug, tacrolimus, for people who have had a kidney transplant
224210097|NCT04562298|BIOLOGICAL|LCAR-M23 cells|Prior to infusion of LCAR-M23, subjects will receive a premedication regimen (intravenous infusion of cyclophosphamide 300 mg/m2 and fludarabine 30 mg/m2 once daily for 3 days; fludarabine dose reduction to 25 mg/m2 and cyclophosphamide to 250 mg/m2 are allowed if the subject' s creatinine clearance is 50-70 mL/min/1.73 m2). A single dose, single Infusion of LCAR-M23 is scheduled 5 to 7 days after the initiation of the premedication regimen.
224210098|NCT05898009|GENETIC|blood sample for BRCA2 mutation detection|blood sample
224210099|NCT04245397|DRUG|SX-682|SX-682 is an oral small molecule selective inhibitor of C-X-C Motif Chemokine Receptor 1 (CXCR1) and CX-C Motif Chemokine Receptor 2 (CXCR2)
224316038|NCT01602718|OTHER|exercise training|Pilot study of independent home exercise training (walking or cycling exercise plus low level resistance exercise) for 3 months. Patients will be given specific recommendations for type, frequency, duration and progression of their program and will be contacted weekly by study staff to assess progress and evaluation for any problems. This is a 3 month exercise training intervention in 15 subjects (and 15 no-exercise controls).
224316039|NCT06633315|OTHER|low dos dexmedetomidine|received dexmedetomidine 2.5 μ g/kg nasal drops
223761575|NCT06923644|OTHER|Sub-optimal diet|Participants randomised to the Control Group (CN), will be randomly assigned one of the two diets optimised for a different Metabotype of the same sex. The assigned CN Group diet will always have a macronutrient content and quality that is different than their hypothesised optimal diet. All diets will align with the Dutch Healthy Dietary Guidelines.
223761576|NCT06923566|PROCEDURE|Targeted muscle reinnervation|"In 1ry TMR ,after the amputation is performed by the standard method , transected nerves will be replanted micro surgically to motor entry points (MEPS)in the hand as predetermined by Daugherty et al , Motor branches in the recipient muscles could be determined by a nerve stimulator intraoperatively.~In 2ry TMR , neuroma site will be explored and it will be excised ,the distal end of the transected nerve will be connected micro surgically to the nearest MEPS"
223761577|NCT06924580|OTHER|ECG screening|Each subject is subjected to ECG assessment.
223761578|NCT06923540|DRUG|IV Acetaminophen|This intervention will be administered to patients undergoing abdominal surgery who are nil per os (NPO) directly after surgery. This patient group has not been properly studied in other clinical studies using IV Acetaminophen. The study aim is to determine if patients who have an altered enteral route may benefit from IV Acetaminophen.
223761579|NCT06924411|DEVICE|Direct Intubation|Direct laryngoscopy intubation
224210100|NCT04245397|DRUG|Decitabine|Decitabine is a hypomethylating agent.
224210101|NCT03784612|BEHAVIORAL|App-technology for healthy eating habits|Access to smartphone-app, including a 12 week healthy eating program. A new theme on healthy dietary habits is presented each week.
224210102|NCT05357742|BEHAVIORAL|Individualized basic need navigation and lifestyle coaching and skills training|During each session participants will receive the manualized study intervention which includes 1) DKD education, 2) Individualized basic needs navigation, and 3) Lifestyle coaching and skills training. Participants will be provided a FORA 2-in-1 device with glucose test strips to allow testing at least once a day. The device automatically uploads blood pressure and glucose readings to a secure server in real time and the health educator will have access to this secure server. Readings will be used to guide lifestyle coaching and skills training.
224210103|NCT05357742|BEHAVIORAL|Enhanced usual care|During each session participants will receive DKD education only.
224210104|NCT05461248|PROCEDURE|stoma drainage reinfusion|1 month after radical rectal surgery, the stoma drainage fluid was reinfused once a week for 2 months. For each reinfusion, eat liquid food the day before, collect 400-600mL of stoma discharge on the same day (if the stoma fluid is too small, it can be mixed with warm water), and use an enema bag to reinfuse from the patient's anus. Generally, the flow rate is controlled at about 100mL/min.
224210105|NCT05461248|PROCEDURE|Standard of Care - No Return of Stoma Drain|No Return of Stoma Drain
224210106|NCT05439291|PROCEDURE|Regular Epilation Regimen|Epilation using laser device
224210107|NCT05439291|PROCEDURE|Surgical excision|Excision of pilonidal pit with trephine
224210108|NCT00323687|DRUG|Truvada|300mg / 200 mg QD tenofovir DF and Emtricitabine Fixed Dose Combination (FDC) Tablet (oral)
224210109|NCT05887518|DEVICE|Socks Developed with Wearable Technology|This new material will have the ability to prevent hypothermia by rewarming the patient when the body temperature drops below 360C and will reduce the risk of DVT that may develop in patients due to hypothermia. Thus, a single material will be used for two important complications of the surgical process, such as hypothermia and DVT, which negatively affect patient outcomes. This situation suggests that this material developed with an innovative approach will be more cost effective.
224210110|NCT06381375|OTHER|Anti Tuberculosis Drug|"1. Estimate the prevalence of prescribing drugs known to have major drug-drug interaction(s) with anti-tuberculous drugs among Kasr Alainy tuberculous patients.~2. Assess the outcome of prescribing drugs known to have major drug-drug interaction(s) with anti-tuberculous drugs among Kasr Alainy tuberculous patients (response to treatment and the prevalence of life-threatening events)."
224210111|NCT05808699|DEVICE|handheld fundus camera|Fundus camera
223619929|NCT03243695|OTHER|Angled Abutment|virtual implants will be placed on a planning software allowing abutments to be placed at an angle to the implant. Teeth will be extracted at the surgery using periotome and implants will be placed using computer aided surgical guide. The angled abutment will be placed and a temporary crown material will be fabricated.
223619930|NCT03243695|OTHER|straight abutment|virtual implants will be placed on a planning software allowing abutments to be placed at straight to the implant. Teeth will be extracted at the surgery using periotome and implants will be placed using computer aided surgical guide. The straight abutment will be placed and a temporary crown material will be fabricated.
223619931|NCT03642977|DIAGNOSTIC_TEST|Real time PCR and RT-PCR for DNA and RNA viral species|Qualitative and quantitative real time PCR and RT-PCR assays will be performed on hematopoietic stem cell transplant recipients' plasma samples collected at five specific time points over a one-year period after transplantation (the day of transplantation (D0), 30 days (D30), 3 months (M3), 6 months (M6) and one year (Y1) after transplantation), for the screening of a selection of at least 21 DNA and RNA viruses (belonging to the Herpesviridae, Polyomaviridae, Adenoviridae, Parvoviridae, Anelloviridae, Picornaviridae and Flaviviridae families).
223619932|NCT02163525|PROCEDURE|Global Fibroid Ablation (GFA)|GFA is radiofrequency ablation of fibroids. This is a laparoscopic procedure whereby a radiofrequency probe is inserted into the fibroid under laparoscopic and ultrasound guidance. Each fibroid is heated to temperatures averaging 95 deg C. The fibroid undergoes coagulative necrosis and shrinks and/or disappears.
223619933|NCT02163525|PROCEDURE|Abdominal or Laparoscopic Myomectomy|Myomectomy is a procedure in which an incision is made into the uterus and the fibroids are surgically removed from the uterus. The uterine incision is closed with sutures. This procedure can be performed through an abdominal incision or via laparoscopy.
223619934|NCT02163525|PROCEDURE|Uterine Artery Embolization (UAE)|UAE is a minimally invasive surgical procedure used to treat uterine fibroids. An embolic material is injected into the uterine artery(ies) to block blood flow to one or more fibroids. This procedure is performed by an interventional radiologist.
223761580|NCT06924112|OTHER|Isometric exercises|The three isometric exercises were performed without the addition of BFR following the best evidence recommendations. Each exercise was performed for 10 repetitions, with isometric contraction of 15 seconds followed by a rest period of 15 seconds, intensity with a load at 20-25% of the maximal voluntary isometric contraction (MVIC), rest period after each exercise of 2 minutes, and pain level below 5 on the verbal Numeric Pain Rating Scale (NPRS).
223761581|NCT06924112|DEVICE|Isometric exercises with BFR|Participants will perform three isometric exercises with BFR. An auto-regulated portable BFRT SmartCuffs® 3.0 Pro system with a 17-inch long and 5-inch-wide cuff (Smart Tools Plus, United States), placed on the most proximal part of the arm, will be used. The session will begin with a maximal occlusion test to personalize the occlusion pressure to the participant. The limb occlusion pressure (LOP) will be set at 60% of the maximum occlusion pressure. Each exercise was performed for 10 repetitions, with isometric contraction of 15 seconds followed by a rest period of 15 seconds, intensity with a load at 20-25% of the MVIC, rest period after each exercise of 2 minutes with cuff deflated (reperfusion), and pain level below 5 on the NPRS.
224316040|NCT06633315|OTHER|high dos dexmedetomidine|received dexmedetomidine 3 μ g/kg nasal drops
224316041|NCT06633315|OTHER|dexmedetomidine and esketamine|received dexmedetomidine 2 μ g/kg nasal drops plus ketamine 0.5 mg/kg nasal drops
223512895|NCT05486286|DEVICE|NCKU-NG system|A live-video system (NCKU-NG system) was developed to assist in the placement of enteral feeding tubes. This system consists of a camera and light source that can be inserted into the commercial NG tube to view live video during feeding tube placement. Manual air insufflation may aid feeding tube placement and improve visualization of anatomic landmarks. After the procedure, an abdominal X-ray is done to confirm the position of the feeding tube.
223512896|NCT02466581|DRUG|Sulphasalazine + Hydroxychloroquine OR Prednisolone|Methotrexate: 25mg/week. SSZ: 2 g/day. HCQ: 35 mg/kg/week (Finland and Denmark) Methotrexate: 25mg/week. Prednisolone 20 mg/day tapered in 9 weeks to 5 mg/day, discontinued after 9 months. (Sweden, Norway, and Iceland)
223512897|NCT02466581|BIOLOGICAL|Cimzia|Certolizumab-pegol: 200 mg s.c. every other week. Methotrexate: 25mg/week
223512898|NCT02466581|BIOLOGICAL|Orencia|Abatacept: 125 mg s.c. every week. Methotrexate: 25mg/week
223512899|NCT02466581|BIOLOGICAL|RoActemra|Tocilizumab is given as 4-weekly infusions at dosage 8 mg/kg or 162 mg in solution s.c. every week. Methotrexate: 25mg/week
223512900|NCT02381327|DEVICE|Mandometer|Mandometer is an eating disorder conditioning tool, class 2 device cleared by the FDA for the treatment of eating disorders. Mandometer offers on-line, real-time feedback on how much food to eat and how quickly to eat during a meal.
223512901|NCT02744547|DIETARY_SUPPLEMENT|Spirulina|Spirulina in a dose of 250 mg/kg/day will be given orally for 3 months.
223512902|NCT04871945|DIAGNOSTIC_TEST|Elecsys Anti-SARS-CoV-2 S (Roche Diagnostics GmbH, Mannheim, Germany), 2) ACCESS SARS-CoV-2 IgG II (Beckman Coulter, Inc. USA)|The antibody level will be measured by the above mentioned methods. The trial drugs are not used but the vaccine that included in National Immunization Program for COVID-19 in Korea will be used for the study.
223512903|NCT02233088|BEHAVIORAL|ELM Group|"ELM participants are trained to portion their meals according to the Perfect Plate method, a modified version of the USDA's ChooseMyPlate.gov. The stress management focuses on mindful living, cognitive restructuring; the enhancement of positive emotions. The physical activity component focuses on reduction of sedentary activity (by increasing daily step counts) and moderate-to-vigorous physical activity."
223512904|NCT02233088|OTHER|ELM Classes|ELM classes will be administered through Rush Generations program and focus on health education.
223512905|NCT02233088|OTHER|ELM Individual|ELM Individual arm participants will receive education materials on metabolic syndrome and diet, exercise, stress reduction recommendations. The participants will be recommended to follow these guidelines and discuss/seek support from their health care provider (visits at baseline, 3 and 6 months will be recommended.
223512906|NCT02667834|BEHAVIORAL|Social Cognition and Interaction Training (SCIT)|A randomized, controled trial of social cognition and interaction training ( SCIT) for patients with schizophrenia Spectrum disorders
223512907|NCT02667834|BEHAVIORAL|therapeutic education program (ETP)|usual treatment ,30 hours with therapist, only discussion between patients
224210112|NCT04475731|DRUG|Ponatinib|"Ponatinib 45 mg/day x 4 weeks x 3 courses.~+/- chemotherapy:~* vincristine or~* L-VAMP (leucovorin, vincristine, aracytin, methotrexate, prednisone)"
224210113|NCT06582888|DRUG|Varenicline Tartrate|varenicline (target dose 1mg twice daily)
224210114|NCT06582888|DRUG|Placebo|matched placebo
224210115|NCT06652009|OTHER|Radical nephroureterectomy|Radical nephroureterectomy
224210116|NCT06652009|RADIATION|Radical radiotherapy|Radical radiotherapy with stereotactic body radiation therapy (SBRT) or moderately segmented radiotherapy
224210117|NCT05924555|OTHER|Intermittent cardiopulmonary exercise test|Exercise test with step-change from rest to a relatively low constant workload.
224210118|NCT05924555|OTHER|Incremental cardiopulmonary exercise test|Exercise test with incremental workload until maximal workload.
224210119|NCT05924555|OTHER|Echography of upper leg|Determine upper leg muscle size
224210120|NCT05924555|OTHER|Hand grip strength with hand dynamometer|Determine muscle strength
224210121|NCT05924555|OTHER|Fill in questionnaires regarding physical activity|SQUASH, mMRC, questionnaire designed to report myopathic symptoms in LcFAOD patients.
224210122|NCT06567964|PROCEDURE|Erector Spinae Plane Block(ESPB)|"ESPB was administered preoperatively under ultrasound guidance via a high-frequency linear probe (Sonosite M-Turbo, Fujifilm Sonosite Inc., USA) (Figure 1). The procedure was as follows:~1. Patient Positioning: The patient was positioned in the lateral decubitus position, with the side to be blocked uppermost.~2. Ultrasound Setup: A high-frequency linear ultrasound probe was placed in a parasagittal orientation over the transverse process of the lumbar vertebra at the level of surgery.~3. Needle Insertion: After skin disinfection with chlorhexidine, a 22-gauge, 100-mm needle (Stimuplex A, B. Braun Melsungen AG, Germany) was inserted in-plane to the ultrasound probe. The needle was advanced until the tip contacted the transverse process.~4. Injection: Following negative aspiration to ensure no vascular puncture, 20 mL of 0.5% bupivacaine was injected incrementally, with real-time ultrasound visualization to confirm the correct spread of the anesthetic solution."
224210123|NCT06567964|PROCEDURE|Wound infiltration|"Wound infiltration was performed by the surgeon at the end of the surgery via the following procedure:~1. Preparation: After hemostasis was achieved and before skin closure, 20 mL of 0.5% bupivacaine was prepared in a sterile syringe.~2. For infiltration, the anesthetic mixture was infiltrated into multiple layers of the surgical wound. This included the subcutaneous tissue and muscle layers, ensuring the even distribution of the anesthetic solution to cover the entire surgical area."
223512908|NCT00362323|DRUG|fenofibrate (F) + metformin (M) hydrochloride fixed combination|F80mg/M500mg - per os - twice a day during 24 weeks / or / F80mg/M850mg - per os - twice a day during 24 weeks /or / F54mg/M850mg - per os - three times a day during 24 weeks
223512909|NCT00362323|DRUG|Metformin|500mg - per os - twice a day during 24 weeks /or / 850mg - per os - twice a day during 24 weeks /or / 850mg - per os - three times a day during 24 weeks
223512910|NCT00642265|PROCEDURE|osteosynthesis|operative treatment
223512911|NCT00642265|OTHER|sling|conservative treatment
223512912|NCT00231465|DRUG|docetaxel (Taxotere®)|Taxotere® will be administered to patients a maximum of 2 cycles, after a maximal response is achieved, and then discontinued.
223512913|NCT00231465|DRUG|ZD1839|ZD1839 will be continued until progression, or until trial closure, whichever comes first.
223512914|NCT03727581|DIAGNOSTIC_TEST|Ultrasound guidance|Jugular vein is punctured with ultrasound guidance and guidewire is advanced. Right atrium and inferior vena cava junction is visualized by ultrasound using substernal view. Presence of guidewire in inferior vena cava or right atrium is confirmed. The procedure of catheter insertion is continued.
223512915|NCT03003897|OTHER|Soluble Fiber|Participants receiving soluble fiber.
223512916|NCT03003897|OTHER|Placebo|Participants receiving placebo.
223512917|NCT01463345|OTHER|Blood transfusion|Conservative transfusion arm: Subjects randomized to the conservative transfusion arm will receive transfusions of PRBCs post-surgery only when their Hgb level measures \< 7.5 g/dl. Blood products should be given to maintain Hgb levels \>7.5 g/dl.
223512918|NCT01463345|OTHER|Blood transfusion|Liberal transfusion arm: Subjects randomized to the liberal transfusion arm will receive transfusions of PRBCs post-surgery only when their Hgb level measures \< 9.0 g/dl. Blood products should be given to maintain Hgb levels \> 9.0 g/dl.
223512919|NCT06150443|OTHER|Osteopathic manipulative treatment (OMT)|Two osteopathic primary care physicians will performing osteopathic manipulative techniques with a minimum of three direct techniques focused on carpal tunnel. These techniques will include the interosseous membrane technique, the flexor retinaculum soft tissue technique, and the radiocarpal somatic dysfunction technique. They will also evaluate and treat the cervical spine, with particular attention to the C5-7 levels, all the way to the wrist and hand as they see fit based on the findings of their osteopathic structural exam.
223512920|NCT06150443|OTHER|Conservative treatment|Conservative therapy will be defined as including the use of splints, NSAIDs, opioids, and therapeutic injection of the carpal tunnel with steroids. Physical therapy will be excluded from the conservative therapy regimen.
223512921|NCT06516848|OTHER|High Intensity Inspiratory Muscle Training Group (H-IMT)|Respiratory muscle strengthening training will be given with a resistive threshold inspiratory muscle strengthening device. Initially, it will be worked out vigorously at 80% of the maximum inspiratory pressure determined by mouth pressure measurement. The load will be increased weekly.
223512922|NCT06516848|OTHER|Low Intensity Inspiratory Muscle Training Group (L-IMT)|Respiratory muscle strengthening training will be given with a resistive threshold inspiratory muscle strengthening device. Initially, it will be worked out vigorously at 30% of the maximum inspiratory pressure determined by mouth pressure measurement. The load will be increased weekly.
223512923|NCT00313898|DRUG|sildenafil (viagra)|
223512924|NCT00622063|DRUG|ARQ 501|Treatment with ARQ 501 or ARQ 501 as combination therapy at the dose and regimen previously received
223512925|NCT06034275|DRUG|VIP943 (QW)|VIP943 will be administered by IV Infusion weekly
223512926|NCT06034275|DRUG|VIP943 (BIW)|VIP943 will be administered by IV Infusion bi-weekly
223512927|NCT01848808|DIETARY_SUPPLEMENT|Wobenzym PS|
223512928|NCT01848808|DIETARY_SUPPLEMENT|Placebo|
223512929|NCT00494156|DRUG|heparin|
223512930|NCT00494156|DRUG|aspirin and clopidogrel|
223512931|NCT01185366|DRUG|Everolimus|10 mg by mouth once a day.
223512932|NCT01185366|DRUG|Sunitinib|50 mg by mouth daily for 4 weeks on / 2 weeks off
223619935|NCT05948241|OTHER|Online psychological support group|"1. st Session: Presentation of the participants and the objectives of the group, which are the management of depression and the promotion of self-care. Discussion on heart failure and its clinical management. Arrangements will be made with these patients about confidentiality between the participants, as it is a group intervention where each participant can expose their personal issues.~2. nd Session: Discussion on depression and its clinical management. From the 3rd to the 11th Session: They will aim to offer support for the emotional demands of the participants, related to the daily and future challenges inherent in the care provided with HF, seeking to promote self-care. As it is a homogeneous group, it is expected to enable enriching exchanges within the group about changes in habits or adaptations to HF, since psychological support groups have this function.~12th Session: Closing and evaluation of participants. Scheduling for reassessment of instruments"
224210124|NCT02524665|OTHER|MAXCLARITY II (2.5% BPO) Foam Cleanser|Available over the counter.
224210125|NCT02524665|OTHER|MAXCLARITY II (2.5% BPO) Foam Treatment|Available over the counter.
224210126|NCT02524665|OTHER|MAXCLARITY II (0.5% Salicylic Acid) Toner Foam|Available over the counter.
224210127|NCT02524665|OTHER|MURAD Clarifying Cleanser (1.5% SA)|Available over the counter.
224210128|NCT02524665|OTHER|Exfoliating Acne Treatment Gel (1% SA)|Available over the counter.
224210129|NCT02524665|OTHER|Skin Perfecting Lotion|Available over the counter.
224210130|NCT05940688|BEHAVIORAL|Digital Health intervention|Health care information delivered via a link in a text message that is then opened in a secure browser.
224210131|NCT05940688|BEHAVIORAL|Community Health Worker|Health care information delivered via CHW.
224210132|NCT05940688|BEHAVIORAL|Digital Health Intervention plus Community Health Worker|Health care information delivered via DHI plus CHW
223512933|NCT03466164|BEHAVIORAL|Mindfulness Based Stress Reduction Program|8 week, 10-session course of mindfulness training
223512934|NCT02668419|DEVICE|Neuromuscular Electrical Stimulator|"Quadriceps and calf muscles of both legs were simultaneously stimulated using self adhesive surface rectangular electrodes. During all session period, the patients were maintained in the supine Fowler 45º position. Stimulation parameters were set up as follows: biphasic current of 40 Hz, 400-µs pulse duration, mode on-time 10s and off-time 20s and maximal amplitude of 60 mA. The stimulation intensity was progressively increased according to the patient tolerance until a muscular contraction was observed. Stimulation was performed twice a day; the session duration was 60 min."
223512935|NCT02668419|OTHER|Physical Therapy Session|each session consisted of breathing exercises and global active exercises of the upper and lower limbs in bed. The treatment was applied twice a day during the hospitalization period. The protocol was interrupted if the patient had signs or symptoms suggestive of poor tolerance to exercise: 1) cyanosis, pallor, dizziness, nausea or pre-syncope; 2) chest pain; 3) bradycardia; 4) a drop in systolic blood pressure \>15 mmHg in comparison to baseline; 5) an excessive rise in systolic blood pressure defined as \>200 mmHg; 6) a rise in diastolic blood pressure during exercise \>110 mmHg; 7) fatigue rated ≥6/10 on the perceived exertion Borg scale (PEB); and/or 8) electrocardiographic signs of cardiac ischemia or ventricular arrhythmias.
223512936|NCT02708706|DRUG|hyaluronic acid (hyruan)|2cc hyaluronic acid
224210133|NCT04181216|DEVICE|Anatomically aligned total knee arthroplasty implant|In same patient, one total knee arthroplasty using anatomically aligned total knee arthroplasty implant Other total knee arthroplasty using conventional total knee arthroplasty implant
224210134|NCT04196270|DRUG|Ropivacaine injection|In a dose finding study the total volume of ropivacaine changes according to the biased coin up-and-down sequential design
224210135|NCT03128073|DEVICE|Carry life system, ultrafiltration (CLS UF)|The addition of Glucose-salt intermittently to a volume of the intraperitoneal fluid in the device which is then returned to the subject.
223512937|NCT02708706|OTHER|physical therapy|patient received traditional physical therapy, including therapeutic exercise and stretch exercise
223512938|NCT04078399|DRUG|Azacitidine combined with interferon preemptive treatment|Azacitidine combined with interferon preemptive therapy for prevention and treatment of recurrence of allogeneic transplantation of myeloid tumors (AML/MDS/MPN) in the blood system
223512939|NCT05125432|DEVICE|Acupuncture group|Acupuncture group Patients with breast cancer who experienced AIA were assessed by the Brief Pain Inventory (BPI)scale and McMasters College Osteoarthritis Index Score (WOMAC). Patients who met the criteria for inclusion would receive regular acupuncture treatment. The location of acupuncture is based on the principles of acupuncture treatment in Traditional Chinese medicine. Patients with high scores and obvious pain received standardized acupuncture treatment, and standard acupuncture points and most painful joint (up to 3) specific point. Meanwhile, blood samples of patients were collected, and SNP related to AIA was screened through SNP typing technology.
223512940|NCT02544724|BIOLOGICAL|NM-IL-12|Single SC administration of NM-IL-12 will be administered at least 48 hours after completion of the last chemotherapy dose of each cycle
224210136|NCT00157729|DRUG|pyridoxal-5'-phosphate with and without ACE inhibitor|
224210137|NCT05297149|BEHAVIORAL|Hippotherapy|The hippotherapy program consisted of 6 weekly sessions that varied in duration between 20 and 30 minutes depending on the weekly program and the participant's condition. Each session started with brief greetings and contact with the horse.
224210138|NCT05297149|BEHAVIORAL|Home exrecises|The home exercise program consisted of the following balance training exercises: one leg standing on foam with eyes open and closed, double leg standing on foam with eyes open and closed, walking in tandem with eyes open and closed, balance exercises on an inclined surface, balance exercises in squat, and jumping over an obstacle on the ground. All participants performed the exercises under parental supervision, 3 times per week for 6 weeks. The physiotherapist made video calls to the children and parents to ensure their adherence to the home exercise program.
223512941|NCT01514175|DRUG|IV Ibuprofen|Patients will be randomized to receive 800 mg intravenous ibuprofen or 30 mg ketorolac; each of the two treatment groups will consist of 25 patients.
223512942|NCT01514175|DRUG|IV Ketorolac|Patients will be randomized to receive 800 mg intravenous ibuprofen or 30 mg ketorolac; each of the two treatment groups will consist of 25 patients.
223512943|NCT04049565|DIAGNOSTIC_TEST|Procalcitonin biomarker and CRP biomarker|collecting blood samples to measure serum CRP and Procalcitonin
223512944|NCT03799120|DRUG|Tamsulosin BID|comparison of once daily versus twice daily tamsulosin
223512945|NCT03799120|OTHER|Placebo|Placebo
223512946|NCT01691313|DRUG|Vanoxerine|single oral dose
223512947|NCT01691313|DRUG|Placebo|single oral dose
223512948|NCT02774278|DRUG|Erlotinib|Erlotinib will be administered at 150 milligrams (mg) orally daily until disease progression, unacceptable toxicity or death.
223619936|NCT05948241|OTHER|Standard multidisciplinary care|The control group will undergo 1 consultation with the multidisciplinary team, offered as standard treatment at the Heart Failure outpatient clinic of the Institute of Cardiology, with the areas: medicine, nutritionist and psychology. Monitoring with a multidisciplinary team is the gold standard for monitoring patients with HF and its multiple comorbidities. These patients are followed up on average every 3 months in this outpatient clinic.
224210139|NCT06594289|PROCEDURE|In laparoscopic hepatectomy, the subhepatic inferior vena cava was restricted and the patient was given non-restricted intraoperative fluid intake|"The specific steps of IVC blocking were performed by the principal physician under laparoscopic operation: slightly incision of the posterior peritoneum on both sides of the inferior vena cava above the level of the renal vein. The blood vessel blocking band is passed behind the inferior vena cava on the left or right side of the inferior vena cava. According to the intraoperative situation, the blocking band (flow limiting blocking/incomplete blocking of subhepatic inferior vena cava) was tightened to control the bleeding from hepatic vein on the liver section. Patients in this group did not use vasoactive drugs/underuse means to control CVP, so they need to strictly communicate with the anesthesiologist, and take the fluid intake based on the physiological requirements and fluid loss of individual patients (cancel the restriction of fluid intake)."
224210140|NCT04395885|OTHER|Electronic questionnaire|Assess the current sexuality according to the gender using sexual questionnaires for men and women were adapted from the Arabic validated version of the five-item International Index of Erectile Function which is a validated, multidimensional, self-administered questionnaire used for the clinical assessment of erectile dysfunction.and for female Arabic validated version of the Female Sexual Function Index
224210141|NCT03022799|DRUG|KM-819|
224210142|NCT03022799|DRUG|Placebo|
224210143|NCT02642991|DEVICE|Phenacite|contact lens
224210144|NCT02642991|DEVICE|comfilcon A|contact lens
224210145|NCT03036540|DEVICE|application in midline catheter|The routine insertion of midline catheter for the patients admitted in hospital who needs peripheral venous approach for the period more than 5 days or with the insufficient peripheral veins system
224210146|NCT03403010|OTHER|Rehabilitation-specific gaming platform|The rehabilitation specific gaming software was developed as part of the ICT4rehab project with partners from the Vrije Universiteit Brussel and the University Libre de Bruxelles. The ICT4Rehab puts several ICT tools supporting 2/3D user interaction into place. The games can be controlled using a Kinect camera system (Microsoft(®) (Redmond, WA) Kinect™) or a Wii balance board (® NintendoTM, Japan), depending on the choice of the therapist and the needs of the child.
224210147|NCT05215509|BEHAVIORAL|Exercise|Supervised high-intensity interval training for 12 weeks three times per week. The supervision may be physical or online supervision
224210148|NCT05215509|BEHAVIORAL|No exercise|Control group, therefore no supervised exercise regime
224210149|NCT00683046|DRUG|Fludarabine|Fludarabine 30 mg/m2 intravenously daily at the same time over 30 minutes on days -7,-6,-5,4,-3,.
224210150|NCT00683046|DRUG|Melphalan|Melphalan 140 mg/m2 IV on day -2.
224210151|NCT00683046|DRUG|Stem cells|Stem cell infusion on day 0.
223512949|NCT05644509|BIOLOGICAL|Oncolytic Virus Injection（Revottack）+PD-1|Intravenous injection of Revottack injection combined with PD-1(Toripalimab） inhibitor
223512950|NCT06277726|OTHER|Emotional freedom technique group|Emotional freedom technique will be applied to women in this group before intrauterine device application.
223512951|NCT06277726|OTHER|Music group|Women in this group will wear headphones and listen to music throughout the intrauterine device application.
223512952|NCT06277726|OTHER|Control group|No intervention will be applied to women in the control group.
223512953|NCT05662943|DRUG|Intravitreal aflibercept injection|Intravitreal injection of aflibercept (0.2 mg / 0,05 ml; Bayer Co. Ltd.,)
223512954|NCT05673850|DRUG|NET or NCT|In this study, we included 518 ER-positive BC patients who received either neoadjuvant endo-crine therapy (NET) or neoadjuvant chemotherapy (NCT).
223512955|NCT00408447|DRUG|Busulfan|Busulfan 4 mg/kg/d x 4d
223512956|NCT00408447|DRUG|Fludarabine|Fludarabine 30 mg/m2/d x 6d
223512957|NCT00408447|DRUG|Alemtuzumab|Alemtuzumab 2mg/m2 x 1d, 6mg/m2 x 2 d, 20mg/m2 x 2d
223512958|NCT00408447|PROCEDURE|Allogeneic stem cell transplant|Allogeneic stem cells will be given on day 0 (after chemotherapy conditioning)obtained either from a family donor (first degree relative) or sibling cord blood donor.
223512959|NCT02122523|PROCEDURE|Near-Infrared (NIR) dye Indocyanin Green (ICG)|
223512960|NCT00065546|OTHER|Estrogen plus choline depletion diet|Post-menopausal subjects receive estrogen and are then challenged with a low choline diet to determine if estrogen protects them from induction of choline deficiency.
223512961|NCT00065546|OTHER|Placebo plus choline depletion diet|Post-menopausal women are randomized to receive a placebo and are then subjected to a low choline diet to determine if clinical signs of choline deficiency can be induced.
223512962|NCT00065546|OTHER|Pre-menopausal women with SNPs given a low choline diet|Pre-menopausal women with specific genetic polymorphisms in genes related to choline metabolism are placed on a choline depletion diet to determine if the SNPs increase or decrease the risk of diet-induced choline deficiency.
223512963|NCT01312675|DEVICE|S.A.F.E.BT|Five (5) S.A.F.E.BT treatments within a 7 day treatment period.
223512964|NCT02449577|OTHER|Beverage sequence ABCD|Participants receive test beverages in the randomised order ABCD
223512965|NCT02449577|OTHER|Beverage sequence CADB|Participants receive test beverages in the randomised order CADB
223512966|NCT02449577|OTHER|Beverage sequence DACB|Participants receive test beverages in the randomised order DACB
223512967|NCT02449577|OTHER|Beverage sequence CBAD|Participants receive test beverages in the randomised order CBAD
223619937|NCT03407898|OTHER|intubation time|intubation attempt number and intubation time
223619938|NCT00657046|DRUG|Droxidopa|Capsules containing 200 mg droxidopa
223619939|NCT00657046|DRUG|Placebo|Capsules with mannitol substituted for droxidopa
223619940|NCT00388986|DRUG|GK Activator (2)|100mg po bid
223619941|NCT00388986|DRUG|Glyburide|10-20mg po daily
223619942|NCT05353595|DIETARY_SUPPLEMENT|Insect protein|Insect protein concentrate retrieved from lesser mealworms.
224210152|NCT00683046|DRUG|Campath|Campath, 20 mg IV on day -7, 6, -5, -4, and -3.
223619943|NCT05353595|BEHAVIORAL|Running exercise|40 minutes of running on a treadmill at 70% heart rate corresponding Vo2peak
223619944|NCT01415271|OTHER|Internet Communication|bi-weekly communication of blood sugars using an internet platform between patients with type 2 diabetes and an endocrinologist
223619945|NCT05537220|DRUG|N-acetylcysteine|After randomization, participants will be given about 10-months supply of study drug (intervention), with instructions to take 3 effervescent tablets in water twice a day. They will return to the clinic at M4.5 for evaluation and then at M9, M18, M27, M36, M40.5 and M45. At each in-clinic visit, drug reconciliation will occur. At each visit at Baseline, M9, M18, M27, M36, that is, every 9 months, participants will be given another 10-month supply of study drug.
223619946|NCT05537220|DRUG|Placebo|After randomization, participants will be given about 10-months supply of placebo, with instructions to take 3 effervescent tablets in water twice a day. They will return to the clinic at M4.5 for evaluation and then at M9, M18, M27, M36, M40.5 and M45. At each in-clinic visit, efficacy and safety assessments will be done and drug reconciliation will occur. At baseline, M9, M18, M27, and M36 participants will be given another 10-month supply of placebo.
223619947|NCT04534205|BIOLOGICAL|BNT113|IV injection
223619948|NCT04534205|BIOLOGICAL|Pembrolizumab|IV infusion
223619949|NCT04210674|OTHER|The traditional medicinal product of Argan spinosa oil|All children were randomly divided into two groups to receive either the traditional medicinal product of Argan spinosa oil or The conventional topical steroid ointment.
223619950|NCT05775068|RADIATION|Radiotherapy|Radiotherapy
223619951|NCT04727307|DRUG|Atezolizumab (neoadjuvant)|Atezolizumab 1200mg will be delivered as an IV infusion on Day 1 of each cycle (every 3 weeks) in neoadjuvant, for 2 cycles. The initial dose will be delivered over 60 (± 15) minutes and if tolerated subsequent infusions may be given over 30 (± 10) minutes.
223619952|NCT04727307|PROCEDURE|Percutaneous Radiofrequency|Any RFA system (uni/multi-needle, monopolar or multi-bi-polar) is allowed. Microwave ablation or irreversible electroporation is not allowed.
223619953|NCT04727307|DRUG|Bevacizumab (adjuvant)|Bevacizumab 15 mg/kg will be delivered as an IV infusion on Day 1 of each 3 week cycle in adjuvant, for 15 cycles maximum. The initial dose will be delivered over 90 minutes (±15 minutes) and if tolerated subsequent infusions may be given over 60 (± 10) minutes then over 30 (± 10) minutes.
223619954|NCT04727307|DRUG|Atezolizumab (adjuvant)|Atezolizumab 1200 mg will be delivered as an IV infusion on Day 1 of each cycle (every 3 weeks) in adjuvant, for 15 cycles maximum. The dose will be delivered over 30 (± 10) minutes.
223619955|NCT06952816|DEVICE|Emily.AI|EMILY.AI is composed of an O2 regulating valve together with an intelligent system, EDGE computing, which allows the automation in the regulation of O2 and its customization.
223619956|NCT06961084|DRUG|Iodine-124|Given Orally
223619957|NCT06961084|PROCEDURE|Positron Emission Tomography (PET)/Computerized tomography (CT)|Combination of PET and CT imaging
223619958|NCT05528809|OTHER|Blood sampling|A blood sampling will be performed during the inclusion visit (day 0).
224210153|NCT00883129|DRUG|Mycophenolate mofetil|24 months of oral mycophenolate mofetil, up to a maximal dose of 1.5 grams twice daily as tolerated
224210154|NCT00883129|DRUG|Cyclophosphamide|12 months of oral cyclophosphamide, up to a maximal dose of 2 mg/kg daily as tolerated
224210155|NCT00883129|DRUG|Placebo|12 months of placebo will be delivered to participants in the Cyclophosphamide arm during the second year in order to maintain the blind with the Mycophenolate arm, which receives drug for the entire 2 years.
223619959|NCT00060541|PROCEDURE|Laboratory tests|
223619960|NCT00060541|PROCEDURE|Radiological exams|
223619961|NCT02278926|OTHER|Ultrasound|Ultrasound measurements
223619962|NCT02278926|OTHER|Tapping and body inspection to define the area of insulin injection|Obese patients with a thickening fat subcutaneous tissue that could have interfered with the interpreting and analyzing of the data are left out of this first study. In the control group we manage to define the lypo-hypertrophic area by tapping and body inspection
224210156|NCT00997269|DIETARY_SUPPLEMENT|Co-enzyme Q-10|Patients will be supplemented with 300 mg of CoQ-10 1 time daily for one month
224210157|NCT00997269|DIETARY_SUPPLEMENT|Placebo|Patients will be supplemented with CoQ-10 placebo 1 time daily for one month
224210158|NCT03273257|DRUG|Riociguat|"Riociguat will be initiated at 1 mg tid. The dosage will be increased by 0.5 mg at 2 week intervals based on tolerability as assessed by systolic blood pressure up to a maximum dose of 2.5 mg tid.~Downtitration to 0.5 mg tid is foreseen for patients with low optimal tolerability."
224210159|NCT03273257|DRUG|Placebo|Placebo will be given analogue to riociguat with matching tablets.
224316042|NCT02187692|BEHAVIORAL|MCT|The meta-cognitive training (the MCT) consists of eight structurized psychological therapy modules that provides basic knowledge about cognitive biases that are associated with schizophrenia and it provides the sklills how to overcome negative consequences of the biases. The MCT includes: Module 1 manages self-serving bias (i.e. external-personal attribution for failure, internal attribution for positive events); Module 2 and 7 target the jumping to conclusion; Module 3 and 7 concern beliefs flexibility and bias against disconfirmatory evidence; Module 4 and 6 target deficits in theory of mind; Module 5 is devote to ameliorate the cognitive over-confidence in false memories; Module 8 deals with depressive thinking style.
223619963|NCT06588556|BEHAVIORAL|ICUconnect|ICUconnect is essentially digital infrastructure for facilitating consistent person-centered communication. It is a web app platform that works on any digital device (smartphone, computer, tablet) and uses a series of automated and timed text messages and emails to direct family members and clinicians to perform timeline-driven tasks (e.g., surveys, content review, coaching features, family meetings) across the 7- to 10-day intervention period.
223619964|NCT06588556|OTHER|Usual care|Control family participants will receive standard ICU care that includes the study team's suggestion to clinicians to conduct regular family meetings. While control participants will also report needs, all family meetings that occur, and other outcomes via texted or emailed links to surveys within the app platform, control group needs will not be visible to clinicians and ICUconnect content will not be visible to family members. However, basic study information and staff contacts will be available on a control group-specific website accessible via links sent by the platform at the time of each data collection.
223619965|NCT05594719|DEVICE|Shorter-wavelength dominant light|Shorter-wavelength dominant light
224316043|NCT03195335|OTHER|Assessment via questionnaire|All the children will be assessed via assessment questionnaires.
224316044|NCT02329535|DRUG|Micronized progesterone|vaginal caps 400 mg daily up to 36 weeks of gestation
224316045|NCT03760185|DRUG|Brimonidine Tartrate|All subjects will apply brimonidine tartrate to one eye (right eye) only for the duration of study participation.
224316046|NCT00170664|DRUG|Paclitaxel|
223512968|NCT02449577|OTHER|Beverage sequence ABDC|Participants receive test beverages in the randomised order ABDC
223512969|NCT02449577|OTHER|Beverage sequence DABC|Participants receive test beverages in the randomised order DABC
223512970|NCT02449577|OTHER|Beverage sequence DCAB|Participants receive test beverages in the randomised order DCAB
223512971|NCT02449577|OTHER|Beverage sequence DBCA|Participants receive test beverages in the randomised order BDCA
223512972|NCT02449577|OTHER|Beverage sequence ADCB|Participants receive test beverages in the randomised order ADCB
223512973|NCT02449577|OTHER|Beverage sequence BADC|Participants receive test beverages in the randomised order BADC
223512974|NCT02449577|OTHER|Beverage sequence ACDB|Participants receive test beverages in the randomised order ACDB
223512975|NCT01538407|OTHER|Strength Training|The exercises will be performed in standard strength training equipment. Prior to each of the strengthening exercise sessions, a warm up phase is performed by 5-10 minutes of ergometer cycling at a moderate intensity. Muscle strengthening exercises will be performed according to the standard progressive resistance and overload principle. The exercise programme consists of three exercises performed with three sets of 10 repetitions at 60%-85% of patient's 10RM. Training load will be progressed by means of bi-weekly estimates of muscle strength to ensure a constant load of 60%-85% RM. Exercises are: 1. Leg extension, 2. Leg press, and 3. Forward lunges.
223512976|NCT00127933|DRUG|capecitabine [Xeloda]|825mg/m2 po bid on days 1-14 of each 3 week cycle
223512977|NCT00127933|DRUG|Taxotere|75mg/m2 iv on day 1 of each 3 week cycle
223512978|NCT00127933|DRUG|Herceptin (HER2-neu positive patients only)|4mg/kg iv (loading dose) followed by 2mg/kg iv weekly
223512979|NCT00127933|DRUG|capecitabine [Xeloda]|825mg/m2 po bid on days 1-14 of each 3 week cycle
223512980|NCT00127933|DRUG|Taxotere|75mg/m2 iv on day 1 of each 3 week cycle
223512981|NCT03580187|DRUG|Morphine (+)|"We performed a first nebulization of 10 mg (1mL) of morphine diluted in 4 mL of normal saline using a nebulizer with an oxygen flow rate of 8 L / min. The quality of analgesia was assessed by VAS at rest and cough after 10 minutes. If ≤ 4, we concluded to a success. If VAS was still\> 4, a second nebulization was performed. After 20 minutes, if VAS still higher than 4 we performed a third nebulization. If pain level was ≤ 4, we concluded to a success. After 30 minutes, if VAS still\> 4, we concluded to a failure of morphine nebulization.~The patients were divided into two groups:~morphine (+) group: good response to morphine in nebulization morphine (-) group: failure of morphine in nebulization"
223512982|NCT01101555|DRUG|subcutanious administration|drug will be administered subcutaneously in varying amounts over a verying time period according to details stated in the 'arms' section
223512983|NCT01101555|OTHER|Placebo|Placebo will be given to one member of each cohort.
223512984|NCT02422901|DRUG|vitamin C|According to the character of an observational study no intervention other than the administration of Pascorbin® 7.5g (which is administered routinely in these cases) is provided.
223512985|NCT00881244|DRUG|AS1411|I.v. 4-7 days, 1-40 mg/kg/day
223512986|NCT01339013|DEVICE|Anesthetic Conserving Device (AnaConDa )|Standard HME was replaced by AnaConDa. AnaConDa has charcoal filter, HME does not.
223512987|NCT01783938|BIOLOGICAL|Nivolumab|
223512988|NCT01783938|BIOLOGICAL|Ipilimumab|
223512989|NCT01872936|DRUG|Miravirsen|
223512990|NCT01872936|DRUG|Telaprevir|
223512991|NCT01872936|DRUG|Ribavirin|
223512992|NCT03753477|DRUG|DWJ1351(FDC Amlodipine/Olmesartan/Rosuvastatin)|DWJ1351(FDC Amlodipine/Olmesartan/Rosuvastatin) X 1 tablet followed by Sevikar(Amlodipine/Olmesartan) X 1 tablet and Crestor(Rosuvastatin) X 1 tablet (after washout period)
223512993|NCT03753477|DRUG|Sevikar and Crestor|Sevikar(Amlodipine/Olmesartan) X 1 tablet and Crestor(Rosuvastatin) X 1 tablet followed by FDC Amlodipine/Olmesartan/Rosuvastatin X 1 tablet (after washout period)
223619966|NCT05594719|DEVICE|Light similar to the solar spectrum proportion|Light similar to the solar spectrum proportion with no specific wavelength dominant
223619967|NCT05594719|DEVICE|Longer-wavelength dominant light|Longer-wavelength dominant light
223619968|NCT03181867|DRUG|18F-DCFPyL|Subjects will receive IV dose of 18F-DCFPyL by bolus injection. The maximum amount of injected active drug will be less than 4.02 mcg. The target administered activity will be 8 mCi.
223619969|NCT03181867|DRUG|18F-FDG|Cohort 2 may receive a one-time 18F-FDG PET/CT after a positive 18F-DCPyL PET/CT. 18F FDG PET/CT imaging may be performed per clinical standard of care. FDG is administered at a dose of 10mCi intravenously. A whole-body PET/CT will be performed beginning post 18F FDG injection.
223619970|NCT03181867|DRUG|PSMA-11|For up to 10 eligible patients from either cohort 1 or 2, an optional salivary gland blocking study may be performed in which a salivary gland is cannulated and injected with unlabeled DCFPyL or PSMA-11.
223619971|NCT01212562|PROCEDURE|Immunocryosurgery|Assessing the efficacy of cryosurgery during continued imiquimod application (immunocrysurgery) in the treatment of basal cell carcinoma of the skin
223619972|NCT06248606|DRUG|Adagrasib|Adagrasib 600mg orally
223619973|NCT06248606|RADIATION|Stereotactic Radiosurgery|Delivered as per standard of care
223619974|NCT06237335|DRUG|RCT2100|RCT2100 supplied as varying dose strengths administered via oral inhalation using nebulizer
223619975|NCT06237335|OTHER|Placebo|Placebo of similar volumes to experimental dose strengths administered via oral inhalation using nebulizer
223619976|NCT06237335|DRUG|RCT2100|RCT2100 supplied as varying dose strengths administered via oral inhalation using nebulizer for 4 weeks
223619977|NCT06237335|DRUG|RCT2100|RCT2100 supplied at a single dose strength administered via oral inhalation using nebulizer for 12 weeks
223619978|NCT01619839|DRUG|NKTR-181|
223619979|NCT01619839|DRUG|Placebo|Placebo dosing will be only in the double-blind randomization arm and will be identical in form to the Experimental NKTR-181
223619980|NCT01936675|OTHER|Genetic Risk Score|Patients in this arm will receive their genetic-informed risk for having a heart attack.
223619981|NCT04772703|DIAGNOSTIC_TEST|COMET ASSAY|The description in the detailed description of the study
224316047|NCT00170664|DRUG|Carboplatin|
223512994|NCT06265805|BEHAVIORAL|comprehensive rehabilitation therapy|"Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training.~Pulmonary function training, including standing training, cough training, and diaphragm muscle training."
223512995|NCT06265805|DEVICE|Intermittent Oro-esophageal Tube Feeding|The observation group was given enteral nutritional support with Intermittent Oro-esophageal Tube according to the following procedure: Before each feeding, inside and outside of the tube was cleaned with water. During feeding, the patient should maintain a semi-reclining or sitting position with mouth opened, and the tube was inserted slowly and smoothly into the upper part of the esophagus by medical staffs while the appropriate depth of intubation was checked with the calibration markings on the tube wall. The distance from the incisors to the head part of the tube should be between 22-25 cm. However, the specific depth should be evaluated based on patients' feedback and adjusted accordingly. After insertion, the tail part of the tube should be put into a container full of water and the absence of continuous bubbles indicated a successful intubation. Then, the feeding was to be conducted three times per day with 50 ml per minute and 400-600ml for each feeding.
223619982|NCT02251015|PROCEDURE|occlusal plate|"In the plate group arm, the patients used the occlusal splints for all night plus 4 hours during the day and they made therapeutic exercises 15 repetitions 3 times a day.~The orientation for therapeutic exercises seek to correctly position the jaw in the resting position (maxillary teeth approximately 2mm away from the mandibular teeth and the tip of the tongue accommodated on top of the incisive papilla on the hard palate, beyond an exercise that consisted of repeated opening and closing movements paying close attention to the position of the tongue, the point of which being accommodated on the incisive papilla during the exercises. The patient was instructed to perform 15 repetitions 3 times a day."
223619983|NCT02251015|PROCEDURE|therapeutic exercises|The orientation for therapeutic exercises seek to correctly position the jaw in the resting position (maxillary teeth approximately 2mm away from the mandibular teeth and the tip of the tongue accommodated on top of the incisive papilla on the hard palate, beyond an exercise that consisted of repeated opening and closing movements paying close attention to the position of the tongue, the point of which being accommodated on the incisive papilla during the exercises. The patient was instructed to perform 15 repetitions 3 times a day.
223619984|NCT01467544|OTHER|Tai Chi class|The 8-week tai chi group intervention will be lead by Project PI. A focused short form of tai chi involving 12 movements will be used in this project. Each of 8 weekly 60-minute sessions will begin with a 10-minute guided meditation session. Movements learned the previous week will be reviewed prior to introducing new movements. Training DVDs will be produced and provided to participants for weekly and ongoing practice of the techniques.
223619985|NCT06561295|OTHER|Later Morning Timing of Spontaneous Breathing Trials|Later Morning Group: Patients in this group will have their SBTs scheduled between 8:00 AM and 9:00 AM, closer to the time of day shift rounds.
223619986|NCT02110563|DRUG|DCR-MYC|"Dosing: 2 hour IV infusion on Day 1 and 8 of each 21 day cycle.~Starting dose: 0.1mg/kg/dose~Dose escalation: 100%, 50%, or 25% increase in subsequent cohorts depending upon toxicity.~Number of cycles: until progression or unacceptable toxicity develops."
223619987|NCT00348439|DRUG|Plasmin|27 mg of human-derived plasmin to be reconstituted with 0.9% Sterile Sodium Chloride for a single intravitreal injection.
223619988|NCT00348439|DRUG|Vehicle|Plasmin formulation, without active ingredient to be reconstituted in 0.9% Sterile Sodium Chloride and administered in a single intravitreal injection.
223619989|NCT00343265|DRUG|Vaginal progesterone gel|Vaginal gel once daily
223619990|NCT00343265|DRUG|Placebo gel|once daily
223619991|NCT03298802|DRUG|Hydrochlorothiazide 50mg Tablet|Hydrochlorothiazide 50 mg per os once daily as soon as the subjects can tolerate sips of water after delivery and for a total of fourteen days postpartum.
223619992|NCT03298802|DRUG|Placebo Tablet|Placebo per os once daily as soon as the subjects can tolerate sips of water after delivery and for a total of fourteen days postpartum
223761582|NCT06923085|OTHER|Observational Assessment Only|This is an observational study examining bilateral sensorimotor function in patients with cervical radiculopathy. No interventional procedures were applied. Participants underwent comprehensive assessments including pain evaluation (VAS), neck disability (NDI), upper extremity functionality (DASH), muscle strength measurements, sensory function testing, hand performance evaluation, kinesiophobia (TAMPA), and emotional status assessment (Beck Inventory). The study compared findings between different cervical radiculopathy groups and a control group with non-specific neck pain.
223761583|NCT06924671|BEHAVIORAL|GLA:D Back|GLA:D Back is a 10-week program based on first-line recommendations of patient education and structured exercise taught in a group format.
224210160|NCT03273257|PROCEDURE|Pulmonary endarterectomy|PEA will be performed at the end of medical treatment (Day 90)
224210161|NCT01301378|PROCEDURE|Molteno 3 glaucoma drainage shunt|Patients needing glaucoma drainage surgery
224210162|NCT05696457|BEHAVIORAL|Passive music therapy|Patients included in the experimental group receive a 25 min passive music therapy session on a daily basis, which changes depending on their emotion.
224210163|NCT02469558|DIETARY_SUPPLEMENT|Winclove 851 and 110|prebiotic and probiotic mixture
224210164|NCT02469558|DIETARY_SUPPLEMENT|Placebo|white powder without pro/probiotic
224210165|NCT01400607|BIOLOGICAL|Neocartilage Implant/DeNovo® ET (Engineered Tissue Graft)|The Neocartilage Implant is a cartilage repair technology cultured from juvenile human cartilage cells.
224210166|NCT01400607|OTHER|Microfracture|Marrow stimulation using the microfracture technique; performed arthroscopically
224210167|NCT04985877|DIETARY_SUPPLEMENT|Yakult light 300|2 bottles of fermented Milk containing Lactobacillus casei Strain Shirota per day, Intervention for 12 weeks.
224210168|NCT02564172|DEVICE|CMS group|"Conus medullaris stimulation with pentapolar surgical lead includes:~* Pentapolar surgical lead implant ((TM)Penta lead from St Judes Medical ANS which is the medical device under study)~* Test phase of 10 days according to HAS(Haute Autorité de Santé) recommendation~* If test phase positive, the lead is kept and subcutaneous rechargeable generator is implanted.~* If test phase negative, the lead is removed.~Optimal medical management : Similarly to patients randomized in active comparator group, patients randomized in experimental group will also be prescribed optimized medical management (treatment for pain relief) under algologist control.~(A decrease of the consumption of pain treatment should be observed if conus medullaris stimulation has a positive effect)."
224210169|NCT02564172|OTHER|OMM group|"Optimal Medical Management (treatment for pain relief) includes analgesics and/or antidepressant and/or antiepileptics.Usually, drugs for neuropathic pain are prescribed as follows:~* at effective dose, and minimal effective dose on the basis of adverse events and contraindications~* as alone treatment in first and second line, then combination treatment. All this depends on the patient, on her/his pain, on her/his previous treatment.~Medical treatment prescription will reviewed by algologist at each clinical visit. It is not possible in this indication to establish a standardized treatment.~Non drugs therapies (physiotherapy, psychobehavioral approaches…) will not be forbidden or contra-indicated."
223619993|NCT05355103|OTHER|Educational tool about epidural analgesia|See arm description
223619994|NCT02313701|OTHER|Standardized visual presentation|Visual presentations will address what type of procedure they will undergo, the risks and benefits of the procedure (i.e. injury to nearby organs, risks of infection and bleeding, risk of re-operation), alternative treatments to the procedure, what to expect during the pre-operative period, and what to expect in the post-operative period (i.e. urinary catheter, constipation, pain management, hospital stay).
223619995|NCT00646646|DRUG|propofol|sedative
223619996|NCT00646646|DRUG|dexmedetomidine|Sedative
223619997|NCT00646646|DRUG|Midazolam|sedative
223619998|NCT00646646|DRUG|saline placebo|saline placebo
223619999|NCT04907981|DIAGNOSTIC_TEST|Novel coronavirus infection|Using eye examination to judge whether novel coronavirus is infected or not.
223620000|NCT00128739|DRUG|Budesonide|
223620001|NCT00377520|DRUG|pemetrexed|900 mg/m2, intravenous (IV), every 21 days, until disease progression
223620002|NCT03901495|OTHER|Diaana|"Diaana, the AMHTD used, functions as follows: on the basis of an interactive questionnaire completed by the patient before the consultation, it performs an exhaustive anamnesis focused on the problem and proposes a panel of DDs with a high sensitivity. The artificial reasoning system of Diaana mimics how a specialist physician would reason to establish a DD. The information transmitted is in an easy-to-use form for the physician that includes a summary of the anamnesis centered on relevant elements from the questionnaire and a list of possible diagnoses with their emergency level, potential contributing factors, and first-line management proposals."
223620003|NCT01944007|DRUG|Cross-Linked Polyelectrolyte (CLP)|CLP was administered orally, in capsules, for 9 consecutive days.
223620004|NCT02111447|DRUG|Propofol|Propofol infusion with nasal oxygen
223620005|NCT02111447|DRUG|Propofol|Propofol infusion with an LMA
223620006|NCT02111447|DRUG|Sevoflurane|Sevoflurane with an LMA
223620007|NCT02111447|DRUG|Isoflurane|Isoflurane with an LMA
224210170|NCT00407966|DRUG|alvocidib|Given IV
224210171|NCT00407966|DRUG|cytarabine|Given IV
224210172|NCT00407966|DRUG|mitoxantrone hydrochloride|Given IV
224210173|NCT05582655|BEHAVIORAL|ONLINE|The ONLINE intervention applies the JASPER (Joint Attention, Symbolic Play, Engagement, and Regulation: Kasari et al., 2021) social communication intervention for young children with autism. The JASPER approach has been tested in a caregiver-mediated format where caregivers are taught to use the JASPER strategies with their children during play and home routine (e.g., Kasari et al., 2010; Kasari et al., 2014). The JASPER intervention is being adapted in this study to include online web based materials.
223620008|NCT03476200|BEHAVIORAL|Cognitive Behavioral Therapy|The intervention consist of 14 weekly group meetings lasting 1.5 or 2 h. Groups are made up of 10 patients. Each group session follow a structured format and consisted of the following elements: introduction to the session, discussion of homework, group discussion and the development of new coping skills. The sessions deal with the following: concept of stress, cognitive restructuring, alternative thought control strategies, relaxation techniques, training in social skills, training in social skills and humour and optimism as coping strategies.
223620009|NCT06953960|DRUG|ABBV-453|Oral Tablet
223620010|NCT06953960|DRUG|Daratumumab|Subcutaneous (SC) Injection
223620011|NCT06953960|DRUG|Dexamethasone|Oral Tablet
223620012|NCT06953960|DRUG|Pomalidomide|Oral Capsule
223620013|NCT07149376|DEVICE|TOMs of Maine Sensitive SLS Free Xtra Fresh|"Cover the entire length of bristled head with toothpaste. Brush your teeth twice daily (morning and evening) for one (1) minute each time.~For investigational use only by the study participant. Not for Sale."
223620014|NCT07149376|DRUG|Colgate Cavity protection toothpaste|"Cover the entire length of bristled head with toothpaste. Brush your teeth twice daily (morning and evening) for (2) two minutes each time.~For investigational use only by the study participant."
223620015|NCT07157254|OTHER|No intervention|During the no treatment period participants do not receive any study drug
223620016|NCT07157254|DRUG|GTX-102|antisense oligonucleotide
223620017|NCT07153887|DRUG|Vebreltinib|"Vebreltinib： Oral capsule formulation, specification: 100 mg/capsule. Subjects will start medication after enrollment, 200 mg bid po, until disease progression, intolerable toxicity, or death.~If disease progression is observed in the first evaluation (2 months after the first administration), if the investigator deems it possible to continue benefiting from targeted therapy, targeted therapy combined with best supportive care can be continued until the second evaluation (4 months)."
223620018|NCT07153887|OTHER|Standard medical treatment|standard treatment like chemotherapy, PD1, Anlotinib……
223620019|NCT07160829|OTHER|No treatment given|No treatment given
223620020|NCT07171164|BEHAVIORAL|Motivate Aim: CHW text message reminders and counseling|Participants receive both text message reminders and a counseling session, along with information about RSV and the vaccine, to encourage RSV vaccine uptake.
223620021|NCT07171164|BEHAVIORAL|Motivate Aim: CHW text message reminders only|Participants receive text message reminders along with information about RSV and the RSV vaccine to encourage vaccine uptake, but do not receive the counseling intervention
223620022|NCT07171164|BEHAVIORAL|Activate Aim: CHW text message reminders and counseling|Participants receive both text message reminders and a counseling session, along with information about RSV and the vaccine, to encourage discussion of RSV vaccine uptake among older adults in their social networks
224210174|NCT05582655|BEHAVIORAL|COACH|COACH includes live synchronous caregiver coaching in the JASPER intervention model. Coaching follows prior published JASPER caregiver coaching protocols (e.g., Shire, Shih, Barriault, \& Kasari, 2022). This implementation strategy has been tested in a pilot study when applied by community early intervention providers (Shire, Baker Worthman, \& Arbuckle, 2021).
224316048|NCT01191944|DRUG|pramipexole immediate release tablet|0.375mg-4.5mg(daily dose), three times a day
224210175|NCT06286813|OTHER|Plant (natural) oils|Using 10 ml of plant(natural) oil once a day for daily skin care of newborns
223620023|NCT07171164|BEHAVIORAL|Activate Aim: CHW text message reminders only|Participants receive text message reminders along with information about RSV and the vaccine to encourage discussion of RSV vaccine uptake among older adults in their social networks, but do not receive the counseling intervention
223620024|NCT07170878|DIETARY_SUPPLEMENT|Blueberry Supplementation|The research group (Control Group (CG) (n:12): soccer training group; Supplementation Group (EG) (n:12): group given blueberry supplement in addition to soccer training; Reinforcement+Exercise (SEG) (n:12): the group who was given additional blueberry supplement in soccer training and 20 minutes of resistance band exercise) consisted of 36 male athletes in the football branch and regularly participating.
223620025|NCT07170878|DIETARY_SUPPLEMENT|Supplementation Group|Supplementation + Exercise
223620026|NCT07186049|BEHAVIORAL|Thesis Sessions|Thesis Sessions
223620027|NCT07186049|BEHAVIORAL|General Health Guidelines|General Health Guidelines
223620028|NCT07186049|BEHAVIORAL|Thesis and Exercises|Thesis and Exercises
223620029|NCT07192341|DRUG|Sacubitril/Valsartan|Patients will be treated with conventional anti-heart failure therapy plus sacubitril/valsartan (oral administration of an initial dose of 24/26 mg twice daily, gradually increasing to 97/103 mg, depending on follow-up blood pressure) \[Entresto, 100 mg (sacubitril 49 mg/valsartan 51 mg)\].
223620030|NCT07192341|DRUG|Conventional anti-heart failure therapy|Patients will be treated only with conventional anti-heart failure therapy as a control group.
223620031|NCT07194837|DEVICE|diode laser|810 nm diode laser (Elexxion clarosdental laser, Singen Deutschland, Germany) in a continuous wave mode with a power of 1.5 Watts in 4 cycles of 5 seconds with 20 seconds intervals in between each.
223620032|NCT07194837|OTHER|Calcium Hydroxide (Ca(OH)2)|Calcium hydroxide paste (MetaBiomed, Chungcheongbuk-do, Korea) will be placed inside the root canal and left for 1 week.
223620033|NCT07193199|DEVICE|Revanesse Sculpt+|Revanesse Sculpt+ is approved and commercially available for use in Canada and is manufactured by Prollenium Technologies Inc. All study participants will receive Revanesse Sculpt+ for the treatment of mild to severe chin retrusion.
223620034|NCT07190339|PROCEDURE|ultrasound-guided femoral and obturator nerve articular branches pulsed radiofrequency|"Hemodynamic monitoring is provided. The hip joint where the procedure will be performed is cleaned with povidone-iodine. Sterile draping is performed. For PRF application to the articular branches of the femoral nerve, a convex ultrasound probe is first used to locate the articular branches of the femoral nerve in the groin area, followed by the articular branches of the obturator nerve. The radiofrequency cannula is inserted sequentially into the target points and sensory feedback is obtained. Then, a pulsed radiofrequency current, which has therapeutic properties for chronic pain and does not damage tissues by exceeding a temperature of 42 degrees, is applied to the relevant nerve root for 240 seconds. Subsequently, an injectate consisting of 2 cc of 5% bupivacaine, 4 mg of dexamethasone, and 2 cc of physiological saline is administered to the same nerve.~Translated with DeepL.com (free version)"
223680469|NCT04774458|PROCEDURE|Fluoroscopic-guided cervical epidural access|After identifying the target level of the cervical spine under a fluoroscopy-guided anteroposterior image, an 18-Tuohy needle is inserted through a paramedian approach after local infiltration with 1% lidocaine. When feeling a strong resistance through the needle by a ligamentum flavum, the image intensifier is rotated to 50 degrees contralateral oblique (CLO) direction. After then, the needle is advanced to just before the ventral interlaminar line in CLO view. It is subsequently advanced further until it is in the epidural space using a LOR-to-air technique. Correct epidural access is confirmed by the injection of contrast medium. After identifying epidural space in AP and CLO view without abnormal dispersion of contrast,(vascular uptake, intrathecal spreads, etc.), a 3-4ml mixture of 0.5% lidocaine with dexamethasone 5mg is injected.
223761584|NCT06923579|PROCEDURE|Titanium Mesh Cage|"the Harms cage was adapted for long bone reconstruction due to its structural stability and biocompatibility. The cage provides immediate mechanical support while allowing for bone ingrowth, addressing the limitations of traditional methods.~Advantages of the titanium mesh cage include its ability to maintain bone length, provide immediate stability, and allow for earlier weight-bearing. The porous structure facilitates vascularization and bone integration, potentially leading to improved healing outcomes"
223761585|NCT06923852|BEHAVIORAL|Smoking cessation support that World Health Organization (WHO) 5A model (Ask, Advise, Assess, Assist, Arrange).|Smoking cessation support that World Health Organization (WHO) 5A model (Ask, Advise, Assess, Assist, Arrange).
224210176|NCT04355767|BIOLOGICAL|Convalescent Plasma|SARS-CoV-2 convalescent plasma with neutralizing SARS-CoV2 antibodies titers of ≥1:160 administered via intravenous (IV) infusion.
224210177|NCT04355767|BIOLOGICAL|Saline|Saline with multivitamin administered via intravenous (IV) infusion..
224210178|NCT02341976|OTHER|Vibratory platform exercises|Different positions on vibratory platform with different frequencies
224210179|NCT05503914|RADIATION|low-dose radiotherapy|On the first and second days of induction chemotherapy, local tumor were irradiated with 0.5Gy bid for 4 times.
224210180|NCT01185639|RADIATION|stereotactic body radiation therapy|For lung, liver, axial skeleton, and adrenal tumors a dose of either 54 Gy in 3 fxs or 5000 cGy in 5 fx using SBRT techniques
224210181|NCT01999322|DRUG|Faster-acting insulin aspart|Administered subcutaneously (s.c., under the skin). Dose individually adjusted.
224210182|NCT01999322|DRUG|insulin aspart|Administered subcutaneously (s.c., under the skin). Dose individually adjusted.
224210183|NCT00897507|OTHER|Laboratory Biomarker Analysis|Correlative studies
224210184|NCT05990608|OTHER|Peabody Developmental Motor Scales-2, PDMS|"The Peabody Developmental Engine Scales-2, PDMS, is a standardized norm-referenced test used to determine the motor skill level of children aged 0 to 6, identify delays in engine development, and determine individual needs and challenges. The 2 scalar, which allows children to evaluate rough and thin motor skills, consists of 6 sub-tests and 249 articles. The rough motor scale contains 4 sub-tests and 151 items, including reflex, equilibrium, locomotion and object manipulation. The slim motor scale consists of 2 sub-tests and 98 items, including cognition and visual-motor integration. Using the age-appropriate normal value ranges in the test manual to determine developmental stress risk and level, the coarse motor skills, slim motor skills, and general motor development are categorized as very low, low, below average, above average, high, very high."
224316049|NCT01191944|DRUG|pramipexole extended release tablet|0.375mg-4.5mg, once a day
224210185|NCT02272972|OTHER|Application of knowledge|Educational Intervention has been performed at the treating surgeon (video and poster). The surgeons applies the achieved knowledge when performing the intraoperative fluoroscopy in patients with pertrochanteric fractures.
224210186|NCT05991492|DEVICE|Web-based Cognitive Behavioral Therapy for Insomnia (wCBT-I|Digital insomnia treatment
224210187|NCT04187469|DRUG|Moxifloxacin, Isoniazid, Rifampicin|"Moxifloxacin 400 mg/day, Rifampicin ≤50 kg 450 mg/day \> 50 kg 600 mg/day, Isoniazid 300 mg/day.~All treatment is taken daily, for a duration of up to 6 months depending on treatment arm."
224210188|NCT04187469|DRUG|Rifampicin,Isoniazid,Pyrazinamide,Ethambutol|"Rifampicin ≤50 kg 450 mg/day, \>50 kg 600 mg/day, Isoniazid 300 mg/day, Pyrazinamide 1500mg/day, Ethambutol ≤50 kg or the elderly 750mg/day, \>50 kg 1000mg/day.~All treatment is taken daily, for a duration of up to 26 weeks depending on treatment arm."
224210189|NCT02200614|DRUG|Darolutamide (Nubeqa, BAY1841788)|Darolutamide 600 mg (2 tablets of 300 mg) twice daily with food, equivalent to a total daily dose of 1200 mg.
223620035|NCT07193004|BEHAVIORAL|Quality of Life|"Measures - We will use the Kansas City Cardiomyopathy Questionnaire (KCCQ-12) to assess QoL, Mini-Montreal Cognitive Assessment (Mini-MoCA) to assess cognitive function, the Clinical Frailty Scale (CFS) to assess frailty status, and life expectancy estimation by the heart team to categorize patients as having: 1-2 years expected survival or more than 2 years expected survival (This will allow for an analysis of how life expectancy correlates with QoL improvements after TAVI).~Assessment Timeline - Patients will be assessed at four key time points: at time of referral (baseline assessment), pre-procedure (to assess impact of delay on the patient), 30 days post-TAVI (early follow-up to assess recovery and improvement in QoL), and 3 months post-TAVI (longer-term follow-up to evaluate sustained QoL changes). At each time point, the KCCQ-12, Mini-MoCA, and Clinical Frailty Scale (CFS) will be administered."
223620036|NCT07199036|DEVICE|TEDS (Transcutaneous Diaphragmatic/Phrenic Nerve Stimulation)|Per session 20 min, twice daily; 5 days/week; up to 28 days or until successful weaning.
223620037|NCT07199036|DEVICE|abFES (Functional Electrical Stimulation of Abdominal Muscles)|Per session 20 min, twice daily
223620038|NCT07199036|DEVICE|Sham TEDS|Position/time matched; 2 Hz low-intensity sensation only; no visible contraction.
223620039|NCT07199036|DEVICE|Sham abFES|Position/time matched; sensation only; no visible contraction.
223620040|NCT07199192|DRUG|Corticosteroid|systemic corticosteroids at a dose equivalent to 40 mg of prednisolone per day for 7 days or until discharge
223620041|NCT07200102|DRUG|Selinexor|Selinexor will be provided by Karyopharm Therapeutics, Inc.
223620042|NCT07198763|OTHER|Conventional pulmonary rehabilitation|After completing the assessments, participants will be randomly divided into two groups: Group 1, which will perform PR exercises and the Group 2, which will perform PR through dance. Both groups will have the interventions of pulmonary rehabilitation during approximately 50 minutes, for 8 weeks. The group 1 will perform five different exercises with resistance bands, with 3 sets of 1 minute each. Exercises will always begin with the lightest resistance band, and if more than 30 repetitions are observed in 1 minute, the resistance band will be replaced with one of the next highest resistance. The Group 2 will perform rehabilitation through dance using 2 different playlists. The music will be from nationally and internationally known artists. The steps will be based on the exercises performed in group 1 and will be incremented throughout each song and playlist. At the end of 8 weeks of intervention, the evaluative tests will be applied again.
223620043|NCT07198048|BEHAVIORAL|Music-Based Therapy for Post Stroke Aphasia|Participants will be instructed to maintain their usual activities each day, except we will ask them to select a time of day, a comfortable and distraction free environment, and an apparatus for regular music listening (earbuds, headphones, speakers). Participants will listen mindfully to randomized selections from the playlist that meets their needs that day (i.e., energizing or relaxing). Participants will listen to their music selections on shuffle for 30 minutes per day for 8 weeks using the strategies provided by the music therapist. The target listening duration is 30 minutes as it is a common target for time spent on task before taking a break. Participants will complete their daily journal entry immediately after music listening. The music therapist will make a weekly telephone call to each participant in the experimental arm. The telephone call will last \~30 minutes. During this telephone call, the music therapist will update the music playlists and help submit their logs.
223680470|NCT00537901|RADIATION|First-Line Bevacizumab and Chemotherapy|Chemotherapy
223680471|NCT00537901|DRUG|Bevacizumab|Chemotherapy
223680472|NCT02094768|DIETARY_SUPPLEMENT|Reduced Fat Milk|Subjects will be provided with and instructed to consume the equivalent of 20oz. reduced fat milk per day for 3 weeks
224210190|NCT02200614|DRUG|Placebo|Matching placebo 2 tablets twice daily with food.
224210191|NCT00866528|DRUG|pazopanib|oral pazopanib once daily (Phase I starting dose 800 mg)
224210192|NCT00866528|DRUG|paclitaxel|paclitaxel IV once every 3 weeks (Phase I starting dose 135 mg/m2).
224210193|NCT01898884|DRUG|VP 20629|
224210194|NCT01898884|DRUG|Placebo|
224210195|NCT04471792|DRUG|Creatine monohydrate|Creatine monohydrate will be used in combination with muscle stretching.
223680473|NCT02094768|DIETARY_SUPPLEMENT|Sugar Sweetened Soda|Subjects will be provided with and instructed to consume 2 cans (24oz) of sugar sweetened soda per day for 3 weeks
223680474|NCT02972476|DRUG|Budesonide & formoterol fumarate and Aclidinium bromide|
223680475|NCT02972476|DRUG|Fluticasone 500 & salmeterol and Aclidinium bromide|
224210196|NCT04471792|DIETARY_SUPPLEMENT|Cellulose|Cellulose will be used in combination with muscle stretching.
224210197|NCT00759759|DRUG|morphine sulfate sustained-release capsules|1 x 200 mg, single-dose capsule
224210198|NCT00759759|DRUG|KADIAN (morphine sulfate sustained-release) capsules|2 x 100 mg, single-dose capsule
224210199|NCT01592227|DRUG|Marketed paracetamol|Marketed paracetamol
224210200|NCT01592227|DRUG|Experimental paracetamol formulation|Experimental paracetamol formulation
224210201|NCT03137758|DRUG|PCUR - 101|PCUR-101 Capsules 25 mg are solid dosage forms for oral administration
224210202|NCT05524207|PROCEDURE|carotid artery stenting|Implantation of stents at the site of carotid artery stenosis for the treatment of carotid plaque with severe stenosis
224210203|NCT04503707|DRUG|Follitropin Delta|The Intervention (solution for injection) is delivered with a pre-filled injection pen. The REKOVELLE dose will be based on a recent determination (within the last 12 months) of AMH (anti- müllerian hormone) measured by the ELECSYS AMH Plus Immunoassay.
223761586|NCT06924463|OTHER|None AHT|This study does not involve any interventions. It analyzes pre-existing biological samples (FFPE tumor tissue) and clinical data from patients with rhabdomyosarcoma.
223620044|NCT07198048|BEHAVIORAL|Audiobook Intervention for Post Stroke Aphasia|Participants will be instructed to maintain their usual activities each day, except we will ask them to select a time of day, a comfortable and distraction free environment, and an apparatus for regular music listening (earbuds, headphones, speakers). Participants will listen mindfully to an audiobook selected with a speech-language pathologist (SLP). Participants will listen to their audiobook for 30 minutes per day for 8 weeks using the strategies provided by the SLP. The target listening duration is 30 minutes as it is a common target for time spent on task before taking a break. Participants will complete their daily journal entry immediately after audiobook listening. The SLP will make a weekly telephone call to each participant in the experimental arm. The telephone call will last \~30 minutes. During this telephone call, the SLP will update the audiobook library and help submit their logs.
223620045|NCT07200154|DRUG|Adebrelimab with concurrent chemoradiotherapy|Adebrelimab combined with chemotherapy and concurrent radiotherapy, followed by maintenance therapy with Adebrelimab until disease progression or intolerable toxicity, for up to 2 years.
223620046|NCT04480658|DRUG|Bryophyllum pinnatum 50 %, tablets into capsules (verum: 2x2capsules/day)|"Bryophyllum is administered for 3 weeks. Bryophyllum is given in form of capsules, 350mg per capsule, 0-0-2-2/d: 2 capsules 30min. before supper,2 capsules before going to bed.~Other Names:~Bryophyllum pinnatum/Kalanchoe"
223620047|NCT04384055|DIAGNOSTIC_TEST|Lung Ultrasound|Lung ultrasound will be performed on patients undergoing investigation for covid-19 based on a nasopharyngeal PCR.
223620048|NCT02947737|OTHER|Amniotic membrane dressing|We will place an amniotic membrane dressing on the donor site
223620049|NCT02947737|OTHER|Gentamicin and xeroform dressing|We will place xeroform, gentamicin and telfa on the donor site
223620050|NCT00955396|DRUG|GSK1014802|Tablets
223620051|NCT00955396|DRUG|Placebo|Tablets
223620052|NCT00320515|DRUG|pemetrexed|"Phase 1 - dose escalating: 600 mg/m2 level 1, 700 mg/m2 level 2, 800 mg/m2 level 3, 900 mg/m2 level 4, intravenous (IV), every 21 days, until disease progression~Phase 2 - 700 mg/m2, intravenous (IV), every 21 days, until disease progression"
223620053|NCT00320515|DRUG|cisplatin|75 mg/m2, intravenous (IV), every 21 days, until disease progression
223620054|NCT00851786|BIOLOGICAL|ZOSTAVAX|Subcutaneous injection of 0.65 mL of ZOSTAVAX at Day 0 and Week 6
223620055|NCT00851786|BIOLOGICAL|Placebo|Subcutaneous injection of 0.65 mL of placebo at Day 0 and Week 6
223620056|NCT03698123|OTHER|Dietary Modification|Participants will be provided with meals, snacks and drinks with specific macronutrient compositions and encouraged to only eat and drink study meals, snacks and drinks and to avoid eating after 10:00 hours.
223761587|NCT06924125|DIAGNOSTIC_TEST|Motor function scales|Evaluation of patients motor function using motor scales (MFM32, CHOP)
224210204|NCT00013273|PROCEDURE|Physical Conditioning|
224210205|NCT05677984|PROCEDURE|Awaken prone positioning ventilation|patients were mandated to keep a prone position for at least 12 hours.
223620059|NCT04446468|BEHAVIORAL|PEACE|The intervention consists of three synergistic components that work to support the patient after inpatient psychiatric discharge: 1) Brief educational component, where the patient receives a one-hour, one-on-one, personalized educational session on suicide prevention; 2) Seven regular contacts after discharge, where the study psychologist who delivered the brief educational visit will contact the patient to monitor the patient's symptoms, assess treatment adherence, review their safety plan, and assist the patient with engaging in care, if needed; and 3) Mobile app, which aims to improve the patient's social connectedness and provide additional educational materials on suicide.
223620060|NCT04446468|OTHER|Standard Psychiatric Hospital Discharge Care|Current VA standard discharge care includes five core elements. First, patients and their outpatient providers are required to be involved in discharge planning. Second, patients should be offered evidence-based treatments to address their mental health symptoms. Third, the inpatient team should work with the patient to complete a safety plan prior to discharge. Fourth, the inpatient team should arrange two follow-up care visits within 30 days of discharge. Fifth, the inpatient team in conjunction with the SPC assess whether patients are appropriate to be placed on the High Risk for Suicide List. Patients who are placed on the High Risk for Suicide List receive enhanced oversight as outlined in VA policy.
223620061|NCT02707627|DEVICE|Laser Therapy|Laser therapy is a technology that can be used to treat hypertrophic burn scars.
223620062|NCT01102686|DRUG|Pyrimethamine|Pyrimethamine will be taken orally as a single daily dose of 25 mg/day for 4 weeks, then increasing by 25 mg per dose in three four-week steps, to a final dose of 100 mg/day
223620063|NCT01102686|DRUG|Leucovorin|To eliminate or minimize potential hematologic effects of Pyrimethamine, Leucovorin is to be co-administered with Pyrimethamine at a dose level of 5 mg per day, given when Pyrimethamine is administered.
223620064|NCT00445549|DRUG|Vandetanib|300 mg daily dose, 28 day cycle
223761588|NCT06924125|DIAGNOSTIC_TEST|MUSCLE ULTRASOUND|Ultrasound guided evaluation of 28 muscles evaluated accross different body regions, assessed using the Heckmatt gradinf system (semiquantitative scale).
223761589|NCT06924125|DIAGNOSTIC_TEST|Muscle Elastography|Assess the mechanical properties of muscles, such as stiffness and elasticity.
223761590|NCT06924125|OTHER|Complete physical examination|Complete physical evaluations including muscle power and goniometry measurements
223761591|NCT06924125|OTHER|Ventilatory/ respiratory and other support assessment|Assessment of ventilatory, respiratory, and other support needs to evaluate the necessity of assistive devices
223761592|NCT06924125|OTHER|Oromotor function and nutrition|Assessment of bulbar funcionality: feeding devices, nutritional status.
223761593|NCT06924125|OTHER|Motor Milestone Assessments|Motor milestones age of acquisition and loss
224210206|NCT02432456|DRUG|Ketamine|All individuals randomized to the experimental arm of the trial will receive early ketamine therapy (within 6 hours of admission) at a rate of 0.15 mg/kg/hr dosed based on ideal body weight. Individuals in the control arm will receive our standard of care for thoracic trauma patients, however, they will receive an additional placebo infusion of normal saline.
224316050|NCT02709291|BEHAVIORAL|behavioral parent training|Parents receive up to 6 sessions of the Family Check-Up program
224210207|NCT02432456|DRUG|Placebo|Individuals enrolled into the control arm of the trial will receive a normal saline placebo infusion at a rate equivalent to the dosage of ketamine in the experimental arm.
224210208|NCT02432456|PROCEDURE|Intercostal Nerve Block|All individuals enrolled into the trial will undergo an Intercostal Nerve Blockade as a part of the institutional standard of care for rib fractures. This procedure will be performed according to current standard protocols in the Emergency Department or on admission.
223620065|NCT01411826|BEHAVIORAL|Information + Narratives + Support Group|Information from CDC website Narratives about CRCS written by others Peer social support among study participants
223620066|NCT01411826|BEHAVIORAL|Information Only|Information from CDC website on colon cancer screening.
223761594|NCT06923722|DIETARY_SUPPLEMENT|High-flavonoid grape intervention|High-flavonoid grape powder: 60 g, equivalent to 300 g fresh grapes. Total polyphenols: 437 mg/100g).
224210209|NCT02432456|DRUG|Acetaminophen|All patients admitted to the hospital will be placed on scheduled acetaminophen 1000mg PO q 6 hours unless signs of liver disease/impairment or creatinine clearance \< 35ml/min at which point dosage would be reduced to 650mg q 8 hours. Individuals unable to take oral medications would be placed on intravenous acetaminophen.
224210210|NCT02432456|DRUG|Ibuprofen|All patients will be placed on scheduled Ibuprofen or an equivalent NSAID at dosage of 600mg every 6 hours. Patients must have a Glomerular Filtration Rate \> 60 ml/min with no contraindications to NSAID therapy (e.g. Aspirin use, allergy/sensitivity, concurrent ACE inhibitor use, other nephrotoxins, etc)
224210211|NCT02432456|DRUG|Pantoprazole|All individuals on scheduled Non-Steroidal Anti-Inflammatory Drug (NSAID) therapy will receive scheduled pantoprazole at 40mg daily. Individuals unable to take medications orally will be placed on intravenous therapy. Individuals with previous reaction or intolerance to pantoprazole will be placed on an equivalent proton pump inhibitor.
224210212|NCT02432456|DRUG|Methocarbamol|All individuals enrolled in the trial will be placed on scheduled methocarbamol 500 mg orally every 6 hours while admitted. Individuals with previous intolerance to methocarbamol will be placed on a pharmacy directed equivalent.
224210213|NCT02432456|DRUG|Opioid|"All individuals will receive as needed opiate therapy as an adjunct to the scheduled medications and ketamine/placebo solution. Choice in opiate therapy will be at the discretion of the attending trauma faculty. Dosage and adjustments will be in accordance with the institutional policy on appropriate opiate dosage adjustment."
224210214|NCT00301873|DRUG|IV Zometa|Zometa will be given at 4 mg intravenously over 15 minutes every 3 months for 1 year.
223620067|NCT05354661|DEVICE|Hypotension Prediction Index|treatment of hypotension before the appearance following HPI algorithm
223620068|NCT03439280|DRUG|Mezagitamab|Mezagitamab subcutaneously.
223620069|NCT03439280|DRUG|Pomalidomide|Pomalidomide orally.
223620070|NCT03439280|DRUG|Dexamethasone|Dexamethasone orally.
223761595|NCT06923722|DIETARY_SUPPLEMENT|Low-flavonoid grape intervention|60 g powder isocaloric-matched control (Total polyphenols: \< 60 mg)
224210215|NCT04814888|OTHER|intubation with a cuffed ETT by a printed 3D airway model|Two anaesthesiologists unaware of patient's demographic data such as patient's height, weight, and age predicted and recorded ETT size by inserting various sized cuffed-ETTs (MallinckrodtTM Hi-Lo tracheal tube, Covidien, Ireland) to a printed 3D airway model. If the diameter of trachea undersized, air leak around ETT can occur. In that case, we can use that ETT after inflating the pilot balloon with small amount of air. Standard monitoring (non-invasive blood pressure measurement, electrocardiogram, and pulse oximetry) was applied to pediatric patients in the operating room and general anesthesia was induced with ketamine 1 mg/kg and rocuronium 0.6 mg/kg and maintained with sevoflurane. After intubation with a cuffed ETT by a printed 3D airway model was finished, an air leak test was performed by one of three anaesthesiologists dedicated to pediatric cardiac anesthesia.
223620071|NCT04986670|BEHAVIORAL|Nutritional Counseling|Medical oncology providers will refer participants to oncology RDs for remotely delivered medical nutrition therapy counseling. For cohort 1, participants will receive nutrition counseling for 8 months. The counseling will be provided on a weekly basis during the first 6 months and every other week during the last 2 months (for cohort 1 only). For cohort 2, participants will receive nutrition counseling for 6 months. The ultimate frequency of nutrition counseling being provided to each participant will also be adjusted according to the participant's preference and needs.
223620072|NCT04986670|OTHER|Medically Tailored Meals (MTMs)|Medically tailored meals will be provided to participants in the intervention group for a total of 24 weeks for both cohorts. During the first 8 weeks of the intervention, 3 meals/day will be provided each week for a total of 168 meals per participant. It will be followed by less frequent meal provision during the subsequent 16 weeks following this schedule: 3 meals/day will be provided every other week for the next 8 weeks (a total of 84 meals per participant); and 3 meals/day will be provided every four weeks during the last 8 weeks (a total of 42 meals per participant). The number of meals provided to each participant may be adjusted according to participant's preference and needs.
223620073|NCT04986670|BEHAVIORAL|Nutrition Prescription|Oncology providers will advise participants with lung cancer to follow evidence-based nutrition recommendations using a Nutrition Prescription. The Nutrition Prescription aims to enhance providers' role in communicating basic nutrition advice to participants with lung cancer. It contains seven recommendations, adapted from the newly released Cancer Prevention Recommendations by WCRF/AICR with strong evidence-base.
223761596|NCT06923930|DEVICE|External Cueing Device|A portable product that provides movement pattern constraints to ensure improved exercise form, and provides a target zone for exercise effort
223761597|NCT06923930|OTHER|Exercise|"Shoulder stabilization exercise protocol contains 8 exercises (I, Y, T, i, w, alternating arm I/i, n, and supine serratus punch) completed for 8 repetitions each for 3 weeks, and in weeks 4-6 completed at 2 sets of 8 repetitions each."
223761598|NCT06923696|BEHAVIORAL|Diet therapy|One of the groups will follow a gluten-free diet therapy, while the other will follow a LOW FODMAP diet.
223761599|NCT06922838|OTHER|Virtual Reality intervention|The head-mounted virtual reality device is used to provide patients with relaxing videos of nature scenes accompanied by calming music and guided meditations.
223761600|NCT06922838|OTHER|Aromatherapy|The cotton ball soaked in lavender essential oil is placed near the patient's pillow.
223761601|NCT06924424|DRUG|Aponermin, pomalidomide, dexamethasone|Three drugs combination for R/R MM. Aponermin, 10mg/kg d1-5 Pomalidomide 4mg d1-21 Dexamethasone 20mg d1,d8,d15 Each treatment cycle is 28 days.
224210216|NCT02618707|OTHER|Lactate|Lactate samples will drawn at specific time points within 5 time intervals: before CPB after induction, during cooling on CPB, during rewarming on CPB, immediately after CPB in the operating room, and after admission to the post-operative intensive care unit.
224210217|NCT03970252|DRUG|Fluorouracil|Given IV
224210218|NCT03970252|DRUG|Irinotecan|Given IV
224210219|NCT03970252|DRUG|Irinotecan Hydrochloride|Given IV
224210220|NCT03970252|DRUG|Leucovorin|Given IV
224210221|NCT03970252|DRUG|Leucovorin Calcium|Given IV
224210222|NCT03970252|BIOLOGICAL|Nivolumab|Given IV
223620074|NCT04986670|OTHER|Nutrition Assessment|Oncology care providers will assess the nutritional status of patients with lung cancer using PG-SGA Short Form (the Scored Patient-Generated Subjective Global Assessment). PG-SGA is an interdisciplinary patient assessment in oncology and other chronic catabolic conditions. The short form contains four patient generated historical components (weight history, food intake symptoms, and activities and function).
223620075|NCT04986670|BEHAVIORAL|Nutrition Toolkit|Patients will receive a printed copy of a Nutrition Toolkit from providers. Evidence-based nutrition recommendations have been compiled for cancer survivors from 4 sources into a Nutrition Toolkit. The sources include: (1) AmericanCancer Society (ACS) Nutrition and Physical Activity Guidelines for Cancer Survivors; (2)World Cancer Research Fund / American Institute for Cancer Research (WFRF/AICR) Cancer Nutrition Guide; (3) National Cancer Institute (NCI) Eating Hints; and (4) National Comprehensive Cancer Network (NCCN) Guidelines for Cancer Survivors. The Nutrition Toolkit outlines topics about the impact of cancer treatment on dietary intake patterns and quality, strategies to manage treatment-related eating issues, maintaining a healthy weight post treatment, and evidence-based recommendations and practical. Nutrition Toolkit strategies for improving diet quality and maintaining an optimal weight for cancer survivors.
224210223|NCT03970252|DRUG|Oxaliplatin|Given IV
223620076|NCT04986670|BEHAVIORAL|Monthly Emails|Monthly emails will be sent to participants to encourage the use of the toolkit with healthy recipes and general nutrition information.
224210224|NCT03970252|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
224210225|NCT04567160|DRUG|Propofol|"In the propofol group, general anesthesia will be induced using target-controlled infusion (TCI) of propofol and remifentanil. Marsh pharmacokinetic model will be used to set the initial target predicted effect-site concentration of propofol at 3.0 mcg/ml in flash mode. Simultaneously, target-controlled infusion of remifentanil will be started to reach an initial target predicted effect-site concentration of 3 ng/mL using the Minto pharmacokinetic model.~After tracheal intubation, TCI of remifentanil is paused."
224210226|NCT04567160|DRUG|Sevoflurane|In the sevoflurane group, induction of general anesthesia will be carried out by spontaneous breathing through a mask while progressively opening up the dial of the sevoflurane vaporizer up to 8%. Like in the propofol group, target-controlled infusion of remifentanil is simultaneously started to reach an initial target predicted effect-site concentration of 3 ng/mL. Vaporizer is adjusted when gas equilibration reaches the patient-specific concentration 1.0 MAC of sevoflurane. After tracheal intubation, TCI of remifentanil is paused.
223620077|NCT01925560|OTHER|Agave Inulin|3x3 Latin square with 3 periods
223620078|NCT01925560|OTHER|Placebo|control- 0 (zero) grams/day inulin
223620079|NCT02598726|DRUG|Curcumin|Given PO
223620080|NCT02598726|OTHER|Laboratory Biomarker Analysis|Correlative studies
223620081|NCT02598726|DIETARY_SUPPLEMENT|Piperine Extract (Standardized)|Given PO
223620082|NCT02598726|OTHER|Quality-of-Life Assessment|Ancillary studies
223620083|NCT01043068|DRUG|Cancer pain management|Interventions based on published pain guideline. The interventions consisted of the following: (1) nursing pain assessment of current pain, worst pain, pain relief, and acceptability of pain; (2) feedback to guide analgesic prescribing by physician.
224210227|NCT00739622|DRUG|TMC278|
223620084|NCT04890860|OTHER|cardiac surgery involving mitral or tricuspid valve repair procedure, with cardiopulmonary bypass|cardiac surgery involving mitral or tricuspid valve repair procedure, with cardiopulmonary bypass
223620085|NCT05691517|PROCEDURE|Biopsy Procedure|Undergo tumor biopsy
223620086|NCT05691517|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
224210228|NCT02440074|OTHER|Autologous bone marrow mesenchymal stem cells|Bone marrow collection from patient, mesenchymal cells isolation and expansion under Good Manufacturing Practice (GMP) conditions following the IBGM-Valladolid protocol (MSV). Autologous MSV implantation by intradiscal injection.
224210229|NCT00927979|DRUG|10 mLRopivacaine 1%|Intraperitoneal nebulization of 10 mL Ropivacaine 1%
223620087|NCT05691517|PROCEDURE|Computed Tomography|Undergo CT scan
224210230|NCT00927979|DRUG|Water for injection|Intraperitoneal nebulization of 10 mL water for injection
224210231|NCT00927979|DRUG|10 mL Ropivacaine 1%|Intraperitoneal nebulization of 10 mL Ropivacaine 1%
223620088|NCT05691517|DRUG|pH Low Insertion Peptide-exatecan Conjugate CBX-12|Given IV
223680476|NCT02972476|DRUG|Fluticasone 250 & salmeterol and Aclidinium bromide|
223680477|NCT02972476|DRUG|Aclidinium bromide & formoterol fumarate|
223680478|NCT05245448|DRUG|Tetrandrine|Administered orally
223680479|NCT05245448|DRUG|Placebo|Administered orally
224210232|NCT04443231|DEVICE|Optical Coherence Tomography Angiography|AngioVue (Optovue, Fremont, CA, USA) was used to capture the OCTA images before ICL surgery and at 3 months follow-up.
224210233|NCT04923607|DRUG|TQC2731|TQC2731 injection
224210234|NCT04923607|DRUG|Placebo|Matching placebo with no active ingredients
224210235|NCT01508572|DRUG|bevacizumab-IRDye800CW|In this two stage, non-randomized, non-blinded, prospective, multicenter feasibility study, bevacizumab-IRDye800CW will be administered to a total of 20 patients with proven breast cancer.
224210236|NCT06392321|DRUG|Fentanyl|comparison between bupivacaine, bupivacaine and fentanyl.
224210237|NCT06392321|DRUG|Dexmedetomidine|comparison between bupivacaine, bupivacaine and dexmedetomidine..
224210238|NCT06309121|DIETARY_SUPPLEMENT|Postbiotic ABB C3|A daily dose of 550 mg of the postbiotic blend ABB C3 in individual sachets for the first 3 months of the study.
224210239|NCT06309121|DIETARY_SUPPLEMENT|Placebo|A daily dose of 550 mg of the placebo in individual sachets for the first 3 months of the study.
224210240|NCT06309121|DIETARY_SUPPLEMENT|Follow-up Postbiotic ABB C3 (Optional)|Option given to all participants: a daily dose of 550 mg of the postbiotic blend ABB C3 in individual sachets for months 4 to 6 of the study.
224210241|NCT05166369|BEHAVIORAL|Communication skills training|"This intervention consists of a course on communication skills for healthcare professionals.~It will be done remotely via the internet and will include: communication skills training and optimal management of acute non-complicated RTI and delayed antibiotic prescription. Training modules will be delivered via a specific website password protected. Healthcare professionals will also receive a by-monthly feedback about the rate of antibiotic prescription and consumption for RTI."
224210242|NCT05166369|BEHAVIORAL|Mobile phone application on RTI|"This intervention involves the use of a mobile phone application by parents and caregivers.~The mobile app will provide information, education and interactive tools about acute noncomplicated respiratory tract infections.~PC centres allocated to this group will display posters and flyers to inform parents and caregivers about the mobile app. Healthcare staff will also promote the use of this app by parents and caregivers.~The app information will be useful before the consultation, and will also allow the patient to interact with the physician during the consultation, potentially improving share decision-making.~Importantly, the app will allow tailoring the guidance provided according to the type of infection or the number of days with symptoms.~Healthcare professionals in the primary care centres allocated to this group will also receive a by-monthly feedback about the rate of antibiotic prescription and consumption for RTI."
224210243|NCT03101215|DIETARY_SUPPLEMENT|phosphorus|adding of phosphorus to high carbohydrate meal
224210244|NCT01479556|DRUG|Pregabalin|Pregabalin Alpha2-delta calcium channel blocker. 150mg BID p.o.
224210245|NCT01479556|DRUG|Placebo|150mg BID p.o.
224210246|NCT02066688|DRUG|folic acid|Patients receive oral folic acid 1mg daily for 36 months in the absence of unacceptable toxicity or any other adverse effects.
224210247|NCT02066688|DRUG|folic acid calcium vitamin D3|Patients receive oral folic acid 1mg + calcium 1200mg +vitamin D3 250 IU daily for 36 months in the absence of unacceptable toxicity or any other adverse effects .
224210248|NCT02066688|DRUG|calcium|calcium 1200mg/d + vitamin D3 250 IU/d daily supplements
224210249|NCT05774769|PROCEDURE|Commissural edge to edge mitral valve repair|Edge to edge is the suture of mitral valve leaflets tissue in the regurgitant spot. If the regurgitant jet is near a mitral commissure, it is called a commissural edge to edge.
224210250|NCT00975338|OTHER|LIFEspan|Rehabilitation services provided by an inter-disciplinary team of health professionals addressing the transfer of care to adult services and emerging needs related to transition to adulthood. LIFEspan staff are cross-appointed to both a pediatric and an adult hospital through a formally linked model of care.
224210251|NCT00975338|OTHER|Non-LIFEspan|Standard of care in the absence of a formal partnership between a pediatric and an adult hospital.
224210252|NCT05128331|DIETARY_SUPPLEMENT|spermidineLife|dietary supplement that is made of natural wheat germ extract with high spermidine content
224210253|NCT05128331|DIETARY_SUPPLEMENT|Placebo|dietary supplement that is made of cellulose.
224210254|NCT06125873|DRUG|Metformin|Moringa + Metformin - Moringa 1 gm and Metformin 500 mg
224210255|NCT01445236|OTHER|Immunosuppresion withdrawal|Gradual discontinuation of all immunosuppressive drugs.
224210256|NCT04497571|PROCEDURE|Piezoelectric osteotomy.|Implants placed using the ultrasonic technique.
224210257|NCT04497571|PROCEDURE|Conventional drilling|Implants placed using drilling technique
224210258|NCT04992169|BEHAVIORAL|Smartphone-App Parent Training in Pivotal Response Treatment|Parents are trained in Pivotal Response Treatment, Pivotal Response Treatment is a well-known, scientifically supported treatment that focuses on using child motivation, play-based lessons, and parent involvement to target the language skills and social engagement of children with autism. The core smartphone app will offer eight interactive lessons in PRT, consisting of video examples, slides, and brief quizzes.
224210259|NCT04793165|DEVICE|Non-hybrid closed-loop system with ARG algorithm|To assess efficacy and safety of non-Hybrid Closed-loop System, without CHO counting
224210260|NCT02130895|OTHER|STOPP Criteria Decision Support Content|"55 previously developed clinical decision support suggestions based on the STOPP criteria will be activated in the physician EMR. Each suggestion provides a patient specific rule that, if triggered will display its title in an existing Clinical Decision Alerts box on the bottom right hand column in the patient's EMR chart. For example, in a patient with diabetes and on a beta blocker then the suggestion Consider: avoiding b-blockers in elderly diabetics with \>=1 hypoglycaemic episodes / month will be presented to the physician in the side bar (not a popup). The physician then can decide to review, consider, or ignore the recommendation."
224210261|NCT01987258|BEHAVIORAL|Interval Walking|
224210262|NCT01987258|BEHAVIORAL|Continuous walking|
224210263|NCT00770354|DRUG|AS1402|A complete treatment cycle spans 28 days. Patients randomised to AS1402 will receive a 1-hour infusion of 9 mg/kg on day 1, 8, 15 and 22 of each cycle. Patients will receive letrozole (2.5 mg daily tablet).
224210264|NCT00770354|DRUG|Letrozole|Daily 2.5 mg oral letrozole tablet
224210265|NCT06602037|DIAGNOSTIC_TEST|[89Zr]Zr-DFO-SHR1920|Enrolled pancreatic cancer patients will receive a single dose (1-3mCi) of \[89Zr\]Zr-DFO-SHR1920 (total 1-2mg antibody mass). Multiple immunoPET/CT imaging sessions will be performed on day 0, day 1(24 h), day 3 (72 h), day 5 (120 h) or day 7 (168 h).
224210266|NCT06602037|DIAGNOSTIC_TEST|[18F]F-RESCA-3A12|Enrolled pancreatic cancer patients will receive 0.05-0.1mCi/kg of \[18F\]F-RESCA-3A12. ImmunoPET/CT imaging will be acquired 1h after \[18F\]F-RESCA-3A12 injection.
223512996|NCT06265805|DEVICE|Nasogastric Tube Feeding|The control group was given enteral nutritional support with Nasogastric Tube Feeding according to the relevant guidelines. Within 4 hours after admission, the placement of the feeding tube was conducted by professional medical staffs and after intubation, the tube was secured to the patient\&#39;s cheek with medical tape. The feeding was conducted once every 3-4 hours, with 200-300ml each time. The total feeding volume was determined based on daily requirements. The feeding content was formulated by the nutritionists based on the patient\&#39;s condition and relevant guidelines to reach the energy demand as 20-25 kcal/kg/day and protein supplementation of 1.2-2.0 g/kg/day for both two groups. For patients with limited tube feeding compliance, we made appropriate adjustments to ensure that they were not at risk of severe malnutrition as much as possible.
223512997|NCT04400955|DIAGNOSTIC_TEST|Audiometry tablet diagnostic tool and web-based test|as above
223512998|NCT04324489|DRUG|DAS181|Patient receives nebulized DAS181 (4.5 mg BID/day, a total 9 mg/day) for 10 days.
224210267|NCT06602037|DIAGNOSTIC_TEST|[68Ga]Ga-NOTA-3A12|Enrolled pancreatic cancer patients will receive 0.05-0.1mCi/kg of \[68Ga\]Ga-NOTA-3A12. ImmunoPET/CT imaging will be acquired 1h after \[68Ga\]Ga-NOTA-3A12 injection.
224210268|NCT02972151|DRUG|Comprehensive treatment of TCM|Subjects were treated with comprehensive treatment of TCM including Oral medicine: 1 dose daily by our hospital pharmacy medicine room Decoction decoction, each agent 200ml, and the 2 ton service. 10 days for a course of treatment, continuous treatment of 3 courses; retention enema with traditional Chinese medicine oral drugs according to different types of concentrated decoction enema, each dose of medicine decocting 2 times, 2 days of external application of Chinese medicine: Chinese medicine enema; break into powder, into the bag, steam for 45 minutes, and so the temperature dropped to appropriate, will be installed a Chinese medicine bag used on patients with lower abdomen for 20 minutes. Above method, a course of treatment for 10 days, continuous treatment of 3 courses.
224210269|NCT02972151|OTHER|Expectant treatment|Expectant treatment group patients were not treated during the observation period.（3 months after the start of the trial and 1 months after the end of the trial.）From the point of view of medical ethics, the expectant treatment group of patients at the end of the observation period, given the treatment of traditional Chinese medicine treatment group.
224316051|NCT02709291|BEHAVIORAL|interventionist training|Interventionists are trained in the delivery of the Family Check-Up program and deliver sessions to families in their community
224316052|NCT01404130|DRUG|Isotretinoin|0.5-1mg/kg daily for 4-6 months
224316053|NCT01830790|DRUG|Sildenafil citrate|Single dose of 100mg Sildenafil citrate
223512999|NCT05372900|OTHER|Test Product|Whey Protein Isolate with Mulberry leaf extract
223513000|NCT05372900|OTHER|Control Product|Wheat Protein Hydrolysate
223513001|NCT01713140|OTHER|1 strength training set performed until contraction failure|Electromyographic (EMG) activity of the vastus medialis (VM), vastus lateralis (VL), semitendinosus (ST) and biceps femoris (BF) muscles will be recorded during knee extensions performed in a knee extension machine in a single set performed until contraction failure. The relative loading will be 10 repetition maximum (RM). The absolute load (kilograms) corresponding to 10 RM is defined a minimum of 3 days before the day where the EMG-data are recorded. Range of motion and time under tension for each repetition will be controlled for.
223513002|NCT05538468|OTHER|Assessment|Thirty stroke patients were included in the study. After the demographic information was obtained from all patients who accepted to participate in the study by complying with the inclusion criteria; The kinesiophobia scores of the patients were evaluated, depression severity, postural control and pain severity.
223513003|NCT00498485|DRUG|Placebo|Subjects will be randomly assigned to either placebo or drug. The medication and the placebo come as a liquid and patients will start taking an initial dose about 30 min before they expect to sleep. If subjects awaken after less than 5 hrs of sleep, they will take a second dose. If they sleep more than 5 hrs, they will skip the second dose. We will call patients weekly to see how they are doing . If they have tolerable side effects or report significant improvement, we will maintain the dose. But if patients report no effect, the dosage will be incremented by 1 ml per week until good sleep is achieved or a predetermined maximum is reached.
223513004|NCT00498485|DRUG|Sodium Oxybate|Subjects will be randomly assigned to either placebo or drug. The medication and the placebo come as a liquid and patients will start taking an initial dose about 30 min before they expect to sleep. If subjects awaken after less than 5 hrs of sleep, they will take a second dose. If they sleep more than 5 hrs, they will skip the second dose. We will call patients weekly to see how they are doing . If they have tolerable side effects or report significant improvement, we will maintain the dose. But if patients report no effect, the dosage will be incremented by 1 ml per week until good sleep is achieved or a predetermined maximum is reached.
223513005|NCT03306381|OTHER|Dietary intervention|Elimination of certain products.
223513006|NCT04607382|DRUG|LEP|LEP dosage up to the discretion of the treating gynecologists.
223513007|NCT04607382|DRUG|NSAIDs and/or Chinese medicine (CM)|Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Chinese medicine (CM) dosage up to the discretion of the treating gynecologists.
223513008|NCT00440570|DEVICE|Low levels of amplitude-modulated electromagnetic fields|
223513009|NCT00440570|DEVICE|Emitter of low levels of amplitude-modulated electromagnetic fields|
223513010|NCT03087357|OTHER|SmartNIPT|A novel, non-next generation sequencing (NGS) test that is designed to perform as well as conventional NGS screening while being simpler and less expensive.
223513011|NCT03072875|DEVICE|CAMS-RAS|
223513012|NCT03478787|DRUG|risankizumab|Subcutaneous (SC) injection
223513013|NCT03478787|DRUG|secukinumab|Subcutaneous (SC) injection
223513014|NCT05396781|DRUG|Proflavine|5-10 ml of proflavine hemisulfate (0.01%) will be sprayed on the esophageal mucosa.
223513015|NCT05396781|DEVICE|Mobile, Augmented High Resolution Microendoscope|The marHRME will then be inserted through the endoscope and gently placed against the mucosa. Imaging of abnormal tissues will be performed.
223513016|NCT05142085|DIETARY_SUPPLEMENT|nano-PSO|This active treatment will be delivered to 3 out of 5 patients
223513017|NCT05142085|OTHER|placebo|This treatment will be assigned to 2 out of 5 patients
223513018|NCT04221152|DRUG|Empagliflozin Tablets|The administration is oral administration with water before or after breakfast.
223513019|NCT03832088|DIAGNOSTIC_TEST|Berg Balance Scale|Berg Balance Scale performed for balance disorder
223513020|NCT03832088|DIAGNOSTIC_TEST|Timed Up and Go Test|Timed Up and Go Test for walking speed
223513021|NCT03832088|DIAGNOSTIC_TEST|Jamar hand dynamometer|Jamar hand dynamometer for grip strength which correlates with muscle strength of patient
223513022|NCT03832088|DIAGNOSTIC_TEST|Calf circumference|Calf circumference for muscle mass evaluation. Calf circumference is an anthropometric measurement which correlates with muscle mass.
223513023|NCT04411407|DEVICE|PROM registration via the DANBIO WebApp and the outpatient touchscreen in a randomised order|PROM registration via the DANBIO WebApp and the outpatient touchscreen in a randomised order
223513024|NCT02016508|DRUG|autologous bone marrow derived stem cells|intravitreal injection of autologous bone marrow stem cells in 0.1 ml volume
223513025|NCT01539525|BEHAVIORAL|Motivational Interview|Motivational Interview provided by either a Nurse or Computer
223620089|NCT02372604|DRUG|Levocetirizine (as levocetirizine dihydrochloride), 5mg ( then 20 mg) per day . Oral administration.|"Week 1 to week 5, every day : - the morning : 5 mg of levocetirizine (capsule)~* the evening : placebo capsule~Week 6 to week 10, every day : - the morning : 10 mg of levocetirizine (capsule)~* the evening : 10 mg of levocetirizine (capsule))"
223620090|NCT02372604|DRUG|Levocetirizine, (as levocetirizine dihydrochloride) 20 mg ( then 5 mg) per day. Oral administration.|"Week 1 to week 5, every day : - the morning : 10 mg of levocetirizine (tablet)~* the evening : 10 mg of levocetirizine(tablet)~Week 6 to week 10, every day : - the morning : 5 mg of levocetirizine (tablet)~* the evening : placebo tablet"
224210270|NCT00517257|DRUG|Atorvastatin|80 mg orally once daily for 24 weeks
224210271|NCT00517257|DRUG|Placebo|Placebo tablet orally once daily for 24 weeks
224210272|NCT04101084|OTHER|Therapy|Rocking sessions in a safe rocking chair for 2 hours daily for six weeks
224210273|NCT01713478|OTHER|echocardiography|The patients and controls will be investigated by echocardiography, biomarkers, and ECG. After 1 year investigators will assess 1year mortality.
224210274|NCT05862714|DRUG|Fluconazole|400 mg stat. Follow up at 4 weeks
224210275|NCT05862714|DRUG|Itraconazole|1000 mg stat. Follow up at 4 weeks
224210276|NCT06620016|DIAGNOSTIC_TEST|Circulating microRNAs.|Pre and post-surgery evaluation of peripheral blood circulating microRNAs levels.
223513026|NCT01539525|OTHER|Treatment as Usual|Subjects given a brochure listing relevant recovery resources in the local area.
223513027|NCT01506375|BIOLOGICAL|gpASIT+TM|1 subcutaneous injection every 7 days during 29 days
223513028|NCT01506375|BIOLOGICAL|gpASIT+TM + adjuvant|1 subcutaneous injection every 7 days during 29 days
223513029|NCT04086667|OTHER|Spinal manipulation|Spinal manipulation: The patient is placed in the side-position and a standard manipulation lumbar-roll technique will be applied at the indicated segment dependent on the subgroup indication.
223513030|NCT05838040|OTHER|General exercises|General exercise is a structured exercise program designed to help individuals with back pain improve their fitness levels. The program comprises of a series of exercise classes that are led by a physiotherapist. The classes involve a combination of aerobic, strength, and flexibility exercises, and aim to improve overall physical fitness, reduce pain, and improve function. The program is specifically designed for individuals with back pain, and the exercises are tailored to meet the needs of each participant. The Back to Fitness Program is based on the principles of exercise prescription and is intended to be a safe and effective way to manage back pain through exercise.
223513031|NCT05838040|OTHER|General exercises with tranversus abdmoinis contraction|General exercise is a structured exercise program designed to help individuals with back pain improve their fitness levels. The program comprises a series of exercise classes that are led by a physiotherapist. The classes involve a combination of aerobic, strength, and flexibility exercises, and aim to improve overall physical fitness, reduce pain, and improve function. The program is specifically designed for individuals with back pain, and the exercises are tailored to meet the needs of each participant. In addition to these exercises, the Back to Fitness Program includes the activation of the transverse abdominis muscle, which is an important stabilizing muscle in the core. The activation of this muscle is done through specific exercises and techniques, and is intended to improve core stability and reduce the risk of further back injuries.
223513032|NCT02410174|RADIATION|Stereotactic Body Radiotherapy (SBRT)|
223513033|NCT05415111|PROCEDURE|Subepithelial connective tissue|Study specific intervention is the placement of a soft tissue autogenous graft (SCTG) in addition to bone grafting of periimplantitis-affected implants.
223513034|NCT05415111|PROCEDURE|Volume stable Collagen Matrix|Study specific intervention is the placement of a soft tissue substitute (VCMX) in addition to bone grafting of periimplantitis-affected implants.
223513035|NCT05415111|PROCEDURE|No soft tissue augmentation|Study specific control intervention is the placement of a bone graft at periimplantitis-affected implants. No soft tissue grafts will be placed.
223513036|NCT06255587|OTHER|Screening|cross sectional
223513037|NCT00190892|DRUG|olanzapine|
223513038|NCT00190892|DRUG|carbamazepine|
223513039|NCT01712074|DRUG|PF-05212377 (SAM-760)|30 mg QD of PF-05212377 (SAM-760)
223513040|NCT01712074|OTHER|Placebo|Placebo QD
223513041|NCT06419309|OTHER|Dietary intervention|"Four different dietary interventions are planned.~* Gluten-free, lactose-free diet,~* Diet enriched with Aronia Melanocarpa,~* Gluten-free, lactose-free and enriched with Aronia Melanocarpa diet,~* Healthy diet"
223513042|NCT05150288|OTHER|HMO-supplemented infant formula|Starter Infant Formula supplemented with 1.5g/L of Human Milk Oligosaccharides
223620091|NCT02374697|DEVICE|During tele-expertise|
223620092|NCT04892498|RADIATION|Hypofractionated radiotherapy|10-24Gy/5-8Gy/2-3f
223620093|NCT04892498|DRUG|PD-1 inhibitor|q3w, until PD
223620094|NCT04892498|DRUG|GM-CSF|200μg, D1-D7, ≥8 cycles
223620095|NCT04892498|DRUG|IL-2|at a dose of 2 million IU, D8-D14, ≥8 cycles
224210277|NCT06346197|DRUG|Balstilimab|Balstilimab: 240mg, IV, Q2W, until disease progression, unacceptable toxicity, patient or investigator decision or up to 2 years.
224210278|NCT06346197|DRUG|Botensilimab|Botensilimab: 75mg, IV for up to 4 doses, Q6W until disease progression, unacceptable toxicity, patient or investigator decision or up to 2 years.
224210279|NCT06346197|DRUG|Folfox Protocol|oxaliplatin 85 mg/m2 , leucovorin 400 mg/m2 , and fluorouracil 400 mg/m2 administered IV on Day 1 of each treatment cycle, and fluorouracil 1200 mg/m2 IV continuous infusion over 24 hours daily or per local standard on Days 1 and 2 of each treatment cycle, every 2 weeks.Treatment is recommended until disease progression, unacceptable toxicity, or up to 24 months in patients without disease progression.
224210280|NCT06346197|DRUG|XELOX|Oxaliplatin 130mg/m² IV on Day 1 of each treatment cycle + capecitabine 1000mg/m² orally twice daily on Days 1 to 14 of each treatment cycle, every 3 weeks. Treatment is recommended until disease progression, unacceptable toxicity, or up to 24 months in patients without disease progression.
224210281|NCT06346197|DRUG|Nivolumab|240mg, IV, Q2. Treatment is recommended until disease progression, unacceptable toxicity, or up to 24 months in patients without disease progression.
224210282|NCT03761121|OTHER|Wave-CAIPI|"wave-CAIPI technology, a data acquisition / reconstruction scheme designed to optimally exploit available information in modern multi-channel receivers and in multi-contrast/time-series data for improved image encoding"
223620096|NCT03858049|DRUG|Crinone|Participants received Crinone 8% (90 milligrams \[mg\] an intravaginal progesterone gel contained in a single use, one piece applicator) once daily in morning from the day of endometrial transformation (Day -5) until ongoing pregnancy was confirmed up to Day 63.
223620097|NCT03858049|DRUG|Duphaston|Participants received 10 mg of Duphaston tablet orally twice a day from the day of endometrial transformation (Day -5) until ongoign pregnancy was confirmed up to Day 63.
223620098|NCT06459427|PROCEDURE|Robot-Assisted Stereotactic Brainstem Hematoma Puncture|Positioning and surgical procedures are carried out based on the use of robotic navigation equipment. Precise preoperative design is conducted using preoperative imaging data to create a preoperative three-dimensional visualization model. During surgery, robot-assisted stereotactic puncture is performed. First day, urokinase may be used as needed to assist in dissolving residual hematoma and adjusting the depth of the drainage tube. For every 10 mL of hematoma, 1 mL of 10,000 IU urokinase in 0.9% sodium chloride solution is injected, followed by flushing with 2 mL of 0.9% sodium chloride solution through the tube after closing it for 2 hours, and then reopening it. Urokinase injections into the drainage tube are used 1-2 times daily to facilitate hematoma drainage. Third day, if the residual hematoma volume is \<3 mL or if the drainage tube has been in place for \>5 days, the drainage tube is removed.
223620099|NCT06459427|DRUG|Conservative non-surgical treatment|Oxygen therapy, intensive care, maintaining stable blood pressure (targeting 140/90 mmHg), sedation, intracranial pressure control, arousal promotion, gastric protection, maintaining homeostasis, infection control, neurological nutrition, brain function improvement, nutritional support, general condition improvement, and other treatments are provided. For comatose patients, ensuring airway patency, administering nebulized expectorants, preventing respiratory depression, improving respiratory function, and performing tracheostomy if necessary are part of the care plan. Close monitoring of patients' conditions and proactive symptomatic treatment are prioritized. Regular follow-up cranial CT scans are scheduled to monitor intracranial conditions. Ventricular puncture drainage is considered if there is concomitant intraventricular hemorrhage or obstructive hydrocephalus (with patient consent).
223620100|NCT02079740|PROCEDURE|Biopsy Procedure|Undergo biopsy
223620101|NCT02079740|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
223620102|NCT02079740|PROCEDURE|Computed Tomography|Undergo conventional CT or PET/CT
223620103|NCT02079740|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223620104|NCT02079740|BIOLOGICAL|Navitoclax|Given PO
223620105|NCT02079740|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
223620106|NCT02079740|DRUG|Trametinib|Given PO
223620107|NCT01734473|DIETARY_SUPPLEMENT|Hydrolyzed casein protein|Amount provided is based on the fat-free mass of subject
223620108|NCT01734473|DIETARY_SUPPLEMENT|Hydrolyzed casein protein + carbohydrates|Amount provided is based on the fat-free mass of subject
224210283|NCT06701097|BEHAVIORAL|Emotion regulation training|Man is a social being and therefore interacts with his environment. In the process of interaction, they can transfer their feelings, thoughts, and information. However, the interaction process may not always continue smoothly. People's inability to express their emotions appropriately today negatively affects communication. The reason why people cannot express their emotions may be the high level of alexithymia. The concept of alexithymia means having difficulty in recognizing, expressing, and naming emotions. High levels of alexithymia in students, who are future healthcare professionals, can negatively affect themselves, other healthcare professionals and the patients they care for; it can cause burnout in healthcare professionals, decrease the quality of care they provide and cause them to experience interpersonal communication conflicts.
224210284|NCT06703866|OTHER|Non Small Cell Lung Cancer (NSCLC)|"Application of value based medicine predictive model"
224210285|NCT06702397|DEVICE|Microscope|The microscope provides a direct examination of the testicular parenchyma at 20-25x magnification.
223620109|NCT01734473|DIETARY_SUPPLEMENT|Hydrolyzed casein protein + leucine|Amount provided is based on the fat-free mass of subject. Leucine (40% of essential amino acid content)
224210286|NCT06702397|DEVICE|Surgical loupes|Surgical loupes offer magnification of 3.5-5x.
224210287|NCT06703788|DRUG|A fiixed combination of Chinese herbal medicine|a fixed combination of Chinese herbal medicine with Ma-Xing-Gang-Shi-Tang (initiate at 2 grams, with increments of 0.5 grams every 2-4 weeks, up to a maximum dose of 4 grams once daily) and Coptis chinensis (initiate at 0.5 grams, with increments of 0.5 grams every 2-4 weeks, up to a maximum dose of 1 gram once daily), twice a day
223513043|NCT00754286|OTHER|Aromatherapy Scented Wand|"The aromatherapy used in this will be Quease Ease™, manufactured by Soothing Scents, Inc. Quease Ease is a blend of lavender, spearmint, ginger, and peppermint soaked into a pad placed within a wand dispenser that emits a fragrance when placed within a few inches of the nares. Participants will be given aromatherapy wand at the onset of their chemotherapy treatment. Participants will be instructed how to self-administer the aromatherapy treatment. Specifically, they can hold the wand under their nose and breathe in deeply five times when they feel symptoms of nausea or anxiety."
223513044|NCT00754286|OTHER|Placebo wand|Placebo wands will look identical to the scented wands but will not contain a scent. Participants will be given the placebo wand at the onset of their chemotherapy treatment. Participants will be instructed how to self-administer the placebo treatment. Specifically, they can hold the wand under their nose and breathe in deeply five times when they feel symptoms of nausea or anxiety.
223513045|NCT00797901|OTHER|Collaborative Care|
223513046|NCT02268851|DRUG|TGR-1202|Capsules taken whole daily with water and with food
223513047|NCT02268851|DRUG|Ibrutinib|Capsules taken whole with water- Do not consume fish oil, vitamin E, grapefruit, or Seville oranges
223513048|NCT03123107|DRUG|Ascorbic Acid|Ascorbic acid doses will be mixed in 100 mL normal saline and infused over 60 minutes. The postoperative dose will be given on postoperative day #1.
223513049|NCT02474901|BIOLOGICAL|Quadrivalent Live Attenuated Influenza Vaccine|
223513050|NCT02539394|DRUG|Methylprednisolone Acetate|Methylprednisolone Acetate is a corticosteroid known to reduce swelling and inflammation.
224210288|NCT06703788|DEVICE|Laser acupuncture|Laser acupuncture could be used based on medication therapy at following acupoints: CV9, ST25, SP15, ST28, ST40, and two auricular points (stomach and hunger points)
224210289|NCT06702917|DEVICE|GSI Cardiac Scan|"The investigational GSI Cardiac scan will take place immediately (back-to-back acquisition) following the single energy, non-GSI CCTA. The GSI Cardiac scan takes around 1 minute.~A subset of Cohort B's participants who are eligible due to a history of heart attack will have the investigational GSI Cardiac scan 10-15 minutes after the end of the CCTA scan."
224210290|NCT06702917|OTHER|Standard of Care CCTA|The standard of care scan will be a single-energy, non-GSI CCTA. Any pre-contrast screening (such as kidney function or pregnancy testing) will follow the site's standard operating procedures. The administration of contrast media (either IV or oral) and any cardiac medications used to control heart rate will be prescribed per the site's standard operating procedures. All contrast and cardiac medications will be FDA approved and used in accordance with its approval.
223620110|NCT01734473|DIETARY_SUPPLEMENT|Hydrolyzed casein protein + carbohydrates + leucine|Amount provided is based on the fat-free mass of subject. Leucine (40% of essential amino acid content)
223620111|NCT01734473|DIETARY_SUPPLEMENT|4 levels of hydrolyzed casein protein + carbohydrates|Amount provided is based on the fat-free mass of subject. The 4 levels are: 0, 0.02, 0.05, 0.15 g casein protein/kg fat free mass/hr. The ratio between protein and carbohydrates is fixed.
223620112|NCT03493945|BIOLOGICAL|M7824|1,200 mg intravenous (IV) once every 2 weeks.
223620113|NCT03493945|DRUG|N-803|8-15 mcg/kg subcutaneous every 2 weeks.
223620114|NCT03493945|BIOLOGICAL|MVA-BN-Brachyury|MVA-BN-Brachyury will be administered subcutaneously (2 doses 2 weeks apart).
223620115|NCT03493945|BIOLOGICAL|FPV-Brachyury|FPV-Brachyury will be given 2 weeks after second dose of modified vaccinia Ankara (MVA)-Bavarian Nordic (BN)-Brachyury, then every 4 weeks until 6 months, then every 3 months for 2 years, then every 6 months.
223620116|NCT03493945|DRUG|Epacadostat|600 mg orally twice daily (1200 MG total).
224210291|NCT06702917|OTHER|Research CCTA|The research scan will be a single-energy, non-GSI CCTA. Any pre-contrast screening (such as kidney function or pregnancy testing) will follow the site's standard operating procedures. The administration of contrast media (either IV or oral) and any cardiac medications used to control heart rate will be prescribed per the site's standard operating procedures. All contrast and cardiac medications will be FDA approved and used in accordance with its approval.
224210292|NCT06702709|OTHER|Instrument Assisted Soft Tissue Mobilization|The IASTM method will be applied bilaterally to each target muscle, duration 25 minutes. During treatment, three repetitions are performed on each target muscle, with each repetition lasting 50 seconds. The IASTM technique will be applied at a 60-degree angle. The application sequence follows a specific pattern: For the first 10 seconds, light pressure will be applied during the sweeping stroke, and for the next 20 seconds, moderate pressure will apply during the fanning and brushing strokes. Finally, 10 seconds of deep pressure will administer utilizing oblique sweeping strokes. To help the tissues relax, the treatment will finish with mild sweeping and broad strokes on the hamstring region for 10 seconds
224210293|NCT06702709|OTHER|Neurodevelopmental Therapy|The neurodevelopment therapy for spastic diplegic cerebral palsy includes tone-inhibitory postures. This study will use five-tone inhibitory postures that will be appropriate for the reduction of muscle tone, elongation of lower extremities muscles, and improve gross motor function by enhancing balance and stability. The following posture will be repeated 3 times on the bilateral lower limb in one session and maintained for 50 seconds with 60 seconds rest between each posture. The total duration of NDT will be 25 minutes.
224210294|NCT06702605|DRUG|XNW5004 tablets|XNW5004 will be administered orally as tablets.
224316054|NCT03219190|BEHAVIORAL|LST High School Online|The proposed preventive intervention for high school PDA will (1) utilize both online e-learning modules and interactive classroom sessions to address PDA and concurrent alcohol/drug abuse; (2) positively change social norms surrounding PDA and alcohol/drug abuse; (3) challenge positive expectancies about the benefits of PDA; (4) discourage diversion of prescription medication; (5) enhance protective factors by building social, self-regulation, and relationship skills through interactive learning and behavioral rehearsal scenarios; and (6) include online booster sessions.
224316055|NCT00754715|DRUG|AZD2516|Solution administered once orally
224316056|NCT00754715|DRUG|Placebo|Solution administered only once
224316057|NCT01226407|DRUG|CG200745|Multiple administration (IV) over the cycles untile MTD/LTD
224316058|NCT00706862|DRUG|Talactoferrin|Oral, 1.5 grams twice per day
224316059|NCT00706862|DRUG|Placebo|Oral, twice per day
224316060|NCT00601562|DRUG|Zidovudine|
224316061|NCT04735926|DRUG|Calcifediol 75mcg|Soft gelatin capsule. Oral administration once per week
224316062|NCT04735926|DRUG|Calcifediol 100mcg|Soft gelatin capsule. Oral administration once per week
223513051|NCT02539394|OTHER|Hemostatic Matrix Kit|Hemostatic Matrix Kits help prevent uncontrollable bleeding in a operative site during a procedure.
223513052|NCT01472835|DRUG|Midazolam|Used for anxiolysis
223513053|NCT01472835|DRUG|Fentanyl|Used for analgesia and as a sedative
223513054|NCT03614988|OTHER|Evening Levothyroxine Administration|Bedtime levothyroxine intake, with 60-minute meal-free interval
223513055|NCT03614988|OTHER|Morning Levothyroxine Administration|Morning levothyroxine intake, 60 minutes before breakfast.
223513056|NCT04995926|PROCEDURE|Labial mucosal epithelium grafting for corneal limbus substitution|Labial mucosa epithelium grafting for corneal limbus substitution will be used to treat limbal stem cell deficiency by way of corneal surface re-epithelization
223513057|NCT02595554|RADIATION|Concurrent chemoirradiation|External beam radiation therapy (EBRT) with concurrent weekly platinum chemotherapy followed by brachytherapy
223513058|NCT02595554|DRUG|Paclitaxel|New adjuvant chemotherapy 3 cycles with Paclitaxel 150mg/m2 over 3 hours and Cisplatin
223513059|NCT02595554|PROCEDURE|Radical Surgery|Radical hysterectomy (Type III or Type IV hysterectomy) plus bilateral pelvic lymph node dissection and para-aortic lymph node dissection or sampling
223513060|NCT02595554|DRUG|Cisplatin|New adjuvant chemotherapy 3 cycles with Paclitaxel and Cisplatin 70mg/m2
223513061|NCT01044693|DRUG|Placebo|Placebo capsule
223513062|NCT01044693|DRUG|Nebivolol 5 mg|Nebivolol 5mg single oral dose
223513063|NCT01044693|DRUG|metoprolol tartrate 50 mg|metoprolol tartrate 50 mg single oral dose
223513064|NCT01044693|DRUG|Sildenafil25 mg|Sildenafil 25 mg single oral dose
223513065|NCT04180878|BEHAVIORAL|Intervention|Participants received a interactive physical activity monitoring system that allowed study personnel to monitor their activity level.
223620117|NCT03493945|DRUG|Acetaminophen|Antipyretic medication, orally, prior to infusion, up to 650mg.
223620118|NCT03493945|DRUG|Ibuprofen|Antipyretic medication, orally, prior to infusion, up to 600mg.
223620119|NCT03493945|DRUG|Naproxen|Antipyretic medication, orally, prior to infusion, up to 500mg.
223620120|NCT03493945|OTHER|Benadryl|50mg orally prior to infusion.
223620121|NCT03493945|DIAGNOSTIC_TEST|EKG|Baseline and principal investigator discretion.
223620122|NCT03493945|DIAGNOSTIC_TEST|Bone scan|Restaging every 12 weeks.
223620123|NCT03493945|DIAGNOSTIC_TEST|CT chest, abdomen and pelvis|Every 12 weeks after start of therapy.
223620124|NCT03493945|DIAGNOSTIC_TEST|MRI|If clinically indicated.
223620125|NCT03477942|BIOLOGICAL|Autologous Mesenchymal Stem Cells|Bone marrow will be harvested from each individual patient's iliac crest, followed by stem cell isolation, expansion and preparation. Stem cell will be injected approximately 3-4 weeks after bone marrow harvest, injecting 50x10\^6 MSCs in the knee via a medial parapatellar approach under sterile technique in 8 patients with generalized knee OA or focal chondral defects.
223620126|NCT05152823|BIOLOGICAL|Gene Therapy|AAV9 carrying the IGHMBP2 gene.
223620127|NCT04752267|PROCEDURE|Computed Tomography|Undergo PET/CT
223620128|NCT04752267|DRUG|18F-FMAU|Given IV
223620129|NCT04752267|PROCEDURE|Multiparametric Magnetic Resonance Imaging|Undergo mpMRI
224210295|NCT06702566|DRUG|PD-1 and PD-L1 inhibitor|"PD-1 inhibitor includes pembrolizumab，Nivolumab，Sintilimab，tislelizumab，Triplimab，Camrelizumab, Serplulimab.~PD-L1 inhibitor includes durvalumab,Atezolizumab,Adebrelimab,Envafolimab."
223620130|NCT04752267|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
223620131|NCT06785272|DRUG|magnesium sulfate|After initial therapy with the systemic CSs routinely used for acute asthma management at a given site, 3 treatments with inhaled salbutamol and ipratropium, eligible patients with PRAM ≥5 will, under the care of the research nurse, receive a 30-minute IV infusion of 75 mg/kg of Mg sulfate(maximum 2.0 g) \[experimental group\]
223761602|NCT06924307|DEVICE|Executive Function Intervention|The intervention is an in-home cognition training system that provides parents with a modular series of short, easy-to-follow, collaborative cognitive training activities they will share with their child to address the needs of families with young children identified with deficits in executive function (EF), a critical cognitive process associated with self-control. The system employs a novel two-generational training model that views parental involvement as a critical component of the intervention process. In this model, an engaging, parent-facing smartphone application will deliver personalized daily training activities consisting of both traditional hands-on activities as well as collaborative, parent-controlled, child-facing video games. This approach supports multiple pathways for learning and building strong personal relationships between parent and child.
223761603|NCT05686642|DRUG|LT3001 Drug:high dose|Administered by intravenous infusion.
223761604|NCT05686642|DRUG|Placebo|Administered by intravenous infusion.
224210296|NCT06702566|DRUG|Targeted drugs|Targeted drugs includes EGFR-TKIs,ALK-TKIs,Multitargeted Tyrosine Kinase Inhibitors, VEGF antibody, EGFR antibody, antibody-drug conjugates drugs
223620132|NCT06785272|DRUG|Normal Saline|After initial therapy with the systemic CSs routinely used for acute asthma management at a given site, 3 treatments with inhaled salbutamol and ipratropium, eligible patients with PRAM ≥5 will, under the care of the research nurse, receive a 30-minute IV infusion of 0.9% saline \[control group\].
223761605|NCT05686642|DRUG|LT3001 Drug:low dose|Administered by intravenous infusion.
223761606|NCT00004733|DRUG|levodopa|
223620135|NCT06528093|DRUG|BI 765883|BI 765883
224210297|NCT06702566|DRUG|chemotherapy drugs|Chemotherapy drugs are determined based on the investigator's decision.
224316063|NCT04735926|DRUG|Calcifediol 125mcg|Soft gelatin capsule. Oral administration once per week.
223620136|NCT06528093|DRUG|gemcitabine|gemcitabine
223620137|NCT06528093|DRUG|nab-paclitaxel|nab-paclitaxel
223620138|NCT02217163|DRUG|Carfilzomib, , Cyclophosphamide, Dexamethasone|Carfilzomib is administered intraveneously over 30 minutes. For cycle 1 only, Carfilzomib is administered at 20mg/m2 on Day 1 and 2, dose will be escalated to 36mg/m2 on Day 8,9,15 and 16 of the 28-days cycle. Patients who tolerate the 36mg/m2 dose are kept at this dose for the subsequent cycles on Day 1,2,8,9,15,16 on a 28 days cycle. Cyclophosphamide is given at a fixed dose of 500mg once per week orally, along with dexamethasone which is given on the days of Carfilzomib administration, 30 minutes to 4 hours prior to Carfilzomib infusion.
223620139|NCT03622008|DRUG|FEP-TAZ 4 g|FEP-TAZ 4 g (2 g cefepime + 2 g tazobactam) IV treatments as a q8h infusion (90 min) regimen for 10 days
223620140|NCT03622008|OTHER|Placebo|Placebo IV
223620141|NCT00434538|DEVICE|BST-DermOn|
223620142|NCT06032065|BEHAVIORAL|Supervised Treadmill Exercise|This is a 12 week intervention where participants will walk for exercise 3 times a week on a treadmill at a center while being supervised by healthcare personnel.
223620143|NCT06032065|BEHAVIORAL|Home-Based Exercise|This is a 12 week intervention where participants will walk at home for exercise with guidance from a study coach. They will have 4 in person visits in the first four weeks and then have weekly phone calls in the last 8 weeks of the intervention with their coach.
223620144|NCT06032065|DIETARY_SUPPLEMENT|Nitrate-rich beetroot Juice|Participants will drink one shot of nitrate rich beet-root juice twice daily for 12 weeks.
223620145|NCT04889846|PROCEDURE|SAFE early intervention approach|SAFE approach is a national early intervention approach which is based on sensory strategies, activity based motor training, family collaboration and environmental enrichment.
223620146|NCT03415321|DEVICE|Postpartum Mobile Support Application|"Women in the experimental group will use the Postpartum Mobile Support Application during six weeks after birth.~Women will be evaluated three times in total, one for the first day after birth, second for the seventh day after birth and the last for the sixth week after birth.~Short messages and calls will be remind of women's Postpartum Mobile Support Application use"
223620147|NCT04175249|OTHER|Pizza meal challenge|Vegetarian pizza containing 10 grams of salt
223620148|NCT06428110|OTHER||
223620149|NCT06240026|DEVICE|taVNS|transauricular vagal nerve stimulation electrodes (NEMOS, CerboMed GmbH, Erlangen, Germany), attached to a digitimer.
223620150|NCT06240026|DEVICE|Earlobe Stimulation|Standard electrodes (Ambu, Neuroline, Bordeaux, France) cut into 0.6cm circles, attached to a digitimer.
224316064|NCT04735926|OTHER|Placebo|Soft gelatin capsule. Oral administration once per week.
224210298|NCT06703775|OTHER|Low level laser therapy (LLLT)|The first experimental will receive LLLT using the Fisioline Lumix 2 (Italy). Participants will be placed in a comfortable, supported sitting position and will wear protective eyeglasses to prevent retinal damage. The LLLT (GaAs type, 1-10 mW, 904 nm) will be applied to the most painful points on the deltoid and/or upper trapezius muscles. Treatment will target a minimum of two and a maximum of four painful points, with each point irradiated for 3-4 minutes, for a total session duration of up to 15 minutes.
224210299|NCT06703775|OTHER|Neural mobilization techniques|The second experimental will receive Neural Mobilization Therapy (NMT). The procedure will begin by positioning the patient in a sitting position. The initial positioning will involve placing the patient's arm at their side with the elbow bent at 90 degrees. The therapist will gently extend the patient's shoulder (moving the arm backward) while keeping the elbow bent, creating tension on the axillary nerve. This tension will be held for a few seconds, ensuring it remains within the patient's tolerance and does not cause discomfort or pain. The shoulder will then be slowly returned to the initial position, releasing the tension on the nerve. This sequence of tension and release will be repeated, gradually increasing the range of motion as tolerated. The treatment will consist of three sets of 10 repetitions, with a one-minute rest between sets, performed three times per week for a total of 12 sessions over four weeks.
223620151|NCT06343831|PROCEDURE|2-Dimensional (2-D) Photographs (Visit 1/ Follow up Visit 3-6)|The study participant will be requested to stand upright with hands comfortably behind their back and turn 45 degrees and 90 degrees in either direction for standard anteroposterior (AP), oblique and lateral photos. Standardized photographic poses will be utilized so that only the participant's neck and torso will be visible and all jewelry on the neck and arms will be removed to eliminate potential identifiers. The photographs will be acquired using a commercially available camera or study iPad device.
223620152|NCT06343831|PROCEDURE|3-Dimensional (3-D) Photographs (Visit 1- 6)|3-Dimensional surface scans of the participant's torso will be acquired using a commercially available handheld camera scanning device that offers texture, geometry, and color acquisition from any complex surface using white light technology, which is safe for exposure to skin and eyes. Prior to imaging, a pattern of lines and dots will be marked on the patient's breasts using a washable marker. The study participant will be requested to sit upright on the exam room table with hands comfortably behind their back while the research staff member moves around their torso with the handheld scanner. The exam room table will then be reclined to a lay-flat position such that the patient is laying supine, and breast imaging will be repeated. Standardized photographic poses will be utilized so that only the participant's neck and torso will be visible and all jewelry on the neck and arms will be removed to eliminate potential identifiers.
223620153|NCT06343831|PROCEDURE|Ultrasound Soft Tissue Assessment (Visit 1/ Follow up Visit 4-6)|The images will be acquired using a commercially available handheld ultrasound scanning device. The study participant will be requested to sit upright on the exam room table with hands comfortably behind their back while the research staff member obtains images of the specific area of the breast of chest wall to be grafted (V1) and that which was grafted (V4-6). Images usually take 5-10 minutes to acquire depending on the number of areas grafted.
223620154|NCT06343831|PROCEDURE|Magnetic Resonance Imaging Volume Assessment (Visit 1/ Follow up Visit 4-6)|An MRI of the breast will be obtained around visit 1 and visits 4-6 timepoints. The images will be acquired in collaboration with the Breast Imaging Core and the Magnetic Resonance Research Imaging Center. Dr. Abe (co-investigator, radiology) will review the images to assess volume of the overall breast, the specific areas of the breasts that were grafted.
223620155|NCT06343831|PROCEDURE|BREAST-QTM questionnaire (Visit 1/ Follow up Visit 4-6)|"The BREAST-QTM measures three satisfaction domains and three quality of life (QoL) domains.6 For BREAST-QTM, each domain has a score range from 0 - 100. A difference in score, either positive or negative, of 10 points is considered clinically important; a difference of 20 points is considered clinically very important. This survey will be administered to participants via iPad during visit 1 and visits 4-6 and takes approximately 10-20 minutes to complete."
224210300|NCT06703775|OTHER|Conventional physical therapy program|The following exercises will be performed by the patients of three groups. Pendulum exercise, Isometric Scapular Retraction, Rotator cuff exercise, Wall creeping exercise, Active assisted ROM exercises, Codman exercises. Each exercise will be performed for all movements namely flexion extension and abduction-adduction, one sets of each 10-15 repetitions within pain-free range and instructed to carry out their activities of daily living.
224210301|NCT06702813|DEVICE|High-Frequency Oscillatory Ventilation|Administer 10 minutes of high-frequency oscillatory ventilation in awake ICU patients.
223620156|NCT05016882|DRUG|NNC0194 0499 50 mg/mL|Patients will receive subcutaneous (s.c., under the skin) injections of NNC0194-0499 once weekly The study will last for about 19 months
223620157|NCT05016882|DRUG|Placebo (NNC0194-0499)|Patients will receive subcutaneous (s.c., under the skin) injections of placebo once weekly The study will last for about 19 months
223620158|NCT05016882|DRUG|Semaglutide 3 mg/mL|Patients will receive subcutaneous (s.c., under the skin) injections of semaglutide once weekly The study will last for about 19 months
223620159|NCT05016882|DRUG|Semaglutide placebo|Patients will receive subcutaneous (s.c., under the skin) injections of semaglutide placebo once weekly The study will last for about 19 months
223620160|NCT05016882|DRUG|NNC0174 0833 10 mg/mL|Patients will receive subcutaneous (s.c., under the skin) injections of NNC0174-0833 once weekly The study will last for about 19 months
223620161|NCT05016882|DRUG|NNC0174 0833 placebo|Patients will receive subcutaneous (s.c., under the skin) injections of NNC0174-0833 placebo once weekly The study will last for about 19 months
223620162|NCT05607810|GENETIC|ADVM-022|Long term follow-up of subjects who previously received ADVM-022
223620163|NCT01419795|DRUG|lenalidomide|Given PO
224210302|NCT06703528|DEVICE|cryoablation|The therapeutic cryoablation agent used in this trial was liquid nitrogen with an evaporation temperature of -196°C, which was transported to the ablation pen through a vacuum line to exchange energy at the heart site to perform cryoablation.
224210303|NCT06519266|DEVICE|PHP|Patients will be treated with 2 cycles of PHP (CHEMOSAT® Hepatic Delivery System for Melphalan) six weeks apart
224210304|NCT06519266|DRUG|IPI1/NIVO3|Patients will be treated with 2 cycles of i.v. ipilimumab 1mg/kg and nivolumab 3mg/kg q3w, followed by continued i.v. nivolumab 480mg q4w up to 1 year.
223620164|NCT01419795|BIOLOGICAL|rituximab|Given IV
223620165|NCT01419795|OTHER|pharmacological study|Correlative studies
224210305|NCT06519266|DRUG|IPI3/NIVO1|Patients will be treated with 4 cycles of intravenous (i.v.) infusion with ipilimumab 3mg/kg and nivolumab 1mg/kg q3w followed by continued i.v. nivolumab 480mg q4w up to 1 year.
224316065|NCT04735926|OTHER|Placebo|Soft gelatin capsule. Oral administration once per week.
223620166|NCT01419795|OTHER|laboratory biomarker analysis|Correlative studies
223620167|NCT00367250|DRUG|Cetuximab|weekly i.v.
223620168|NCT00367250|DRUG|Trastuzumab|weekly i.v.
223620169|NCT01391364|DEVICE|SofLens in investigational solution|SofLens in investigational solution, worn on a daily disposable basis for 7 days.
223620170|NCT01391364|DEVICE|SofLens in currently marketed solution|SofLens packaged in currently marketed solution, worn on a daily disposable basis for 7 days.
223620171|NCT01690052|DRUG|Cevimeline|"Cevimlenine Vs Pilocarpine, cross over design. Two sequences were evaluated cevimeline first, then pilocarpine and pilocarpine first, then cevimeline. Each sequence was evaluated for 4 weeks with one week washout period in between both sequences. 15 patients were randomly assigned to a specific sequence by a research pharmacist independent from the study authors. The patients received 30mg of cevimeline three times a day and pilocarpine 5mg three times a day."
223620172|NCT01690052|DRUG|Pilocarpine|Cevimlenine Vs Pilocarpine, cross over design, 4 weeks, one week wash out
224316066|NCT04185623|PROCEDURE|denudation time lag|The time between ovum pickup and denudation of oocyte
224316067|NCT00603837|DEVICE|NeoWrap|This is a polyethylene wrap that will be placed around the ELGAN from the neck down to prevent heat loss.
224316068|NCT00603837|DEVICE|InfaTherm|A gel blanket containing a sodium acetate-based medium that, when activated, becomes exothermic and provides heat.
223620173|NCT01866332|OTHER|Conventional Physical Therapy|Combination of manual therapy techniques, general exercises and specific exercises for spinal segmental stabilization. Patients will receive 10 sessions of treatment over a period of five weeks (two sessions/week). The treatment will be tailored to the patient presentation (i.e. pragmatic treatment).
223620174|NCT01866332|DEVICE|Kinesio Tex Gold ( Kinesiotaping )|Kinesiotaping intervention is based upon the use of specific elastic tapes (known as Kinesio Tex Gold) that are applied with a certain amount of tension fixed to the skin of patients with the target muscles in a stretched position. The tapes will be placed over the superficial back muscles (erector spinae muscles).
223620175|NCT02421172|BIOLOGICAL|CJM112|CJM112 Fully human IgG1 monoclonal antibody
223620176|NCT02421172|DRUG|Placebo|
223620177|NCT04128137|DRUG|Fludrocortisone|50 µg/day during one week then augmentation of 50 µg each weeks until a maximum dose of 200 µg/day. And a maintenance phase of 4 weeks at a stable dose
223620178|NCT04128137|OTHER|Placebo|50 µg/day during one week then augmentation of 50 µg each weeks until a maximum dose of 200 µg/day. And a maintenance phase of 4 weeks at a stable dose
223620179|NCT04715620|DRUG|Niraparib|Niraparib 300mg/day (body weight ≥77Kg and baseline platelet count ≥150,000/µL) or 200mg/day (body weight \<77Kg or baseline platelet count \<150,000/µL)
223620180|NCT02426333|OTHER|Abiraterone Acetate|Exclusively determine pharmacokinetics and pharmacodynamics of abiraterone for the indication according to the drug label (CRPC)
223620181|NCT02122835|BEHAVIORAL|aerobic exercise training|12 weeks of supervised aerobic exercise training
223620182|NCT00683878|DRUG|Dapagliflozin|Tablets, Oral, 5.0 mg, once daily, up to 48 weeks
223620183|NCT00683878|DRUG|Dapagliflozin|Tablets, Oral, 10.0 mg, once daily, up to 48 weeks
223620184|NCT00683878|DRUG|Placebo matching Dapagliflozin|Tablets, Oral, 0 mg, once daily, up to 48 weeks
223620185|NCT00683878|DRUG|Thiazolidinedione (Pioglitazone)|Tablets, ≥ 30 mg, Once daily, up to 48 weeks
223620186|NCT00132743|DEVICE|Stent|Stent
223620187|NCT00132743|BEHAVIORAL|Supervised Exercise Therapy|Supervised exercise therapy, three times per week
224210306|NCT02771340|BIOLOGICAL|ICON-1|Intravitreal injection of ICON-1
224210307|NCT02548117|DRUG|Finasteride|Subjects will take 5 mg finasteride orally every day for about 2 years.
224210308|NCT04479943|OTHER|MOVIN|MOVIN is a multi-component unit-based intervention comprised of five components that are implemented simultaneously in a hospital unit. The five components are: 1) psychomotor skills training, 2) unit ambulation culture, 3) communication, 4) resources, 5) ambulation environment.
224316069|NCT04611529|DRUG|Ibuprofen 400 mg|Ibuprofen 400mg
223620188|NCT00132743|DRUG|Cilostazol|Cilostazol, 100 mg twice a day
223620189|NCT04319198|DRUG|Sacituzumab Govitecan-hiy|Administered intravenously
223620190|NCT06333665|OTHER|Whether there is type 2 diabetes mellitus before surgery|Patients were grouped according to whether they had type 2 diabetes mellitus before surgery
223620191|NCT00555412|DRUG|A - 10 mg loxapine q 4 h x 3 (30 mg total)|loxapine aerosol inhalation high dose regimen (30 mg total)
223620192|NCT00555412|DRUG|B - 10 mg x 1, 5 mg x 2 loxapine q 4 h (20 mg total)|loxapine aerosol inhalation middle dose regimen (20 mg total)
223620193|NCT00555412|DRUG|C - 5 mg loxapine q 4 h x 3 (15 mg total)|loxapine aerosol inhalation low dose regimen (15 mg total)
223620194|NCT00555412|DRUG|D - inhaled placebo q 4 h x 3|placebo aerosol inhalation (0 mg total)
223620195|NCT05440877|BEHAVIORAL|VR materials|In the lecture room for the intervention group, participants in the intervention group will be given QR codes for viewing these online videos and VR cardboards, a web including photo hunt sections that allow viewers to find cues for smoking cessation treatment. They are asked to view these videos and photos with their own mobile phones.
223620196|NCT05440877|BEHAVIORAL|Tutorial guide|A tutorial guide including description of the smokers' cases
223620197|NCT05506540|DRUG|ENN0403 1mg|ENN0403 capsules for oral use
224316070|NCT04611529|DRUG|Topical diclofenac|Diclofenac 1% gel 4gm
224316071|NCT04762849|PROCEDURE|Laparoscopic one anastomosis gastric bypass|Laparoscopic one anastomosis gastric bypass include the creation of gastric pouch; a jejunal loop measure about 200 cm from the ligament of Treitz and anastomosed to the gastric pouch. For the creation of a gastric pouch and gastroenterostomy use a linear stapler.
224316072|NCT04762849|DEVICE|A shape-memory ring for adjustable gastric banding|A shape-memory ring (SMR) use for adjustable gastric banding. SMR is placed around the gastric pouch above the gastro-entero-anastomosis.
223620198|NCT05506540|DRUG|ENN0403 4mg|ENN0403 capsules for oral use
223620199|NCT05506540|DRUG|ENN0403 10mg|ENN0403 capsules for oral use
223620200|NCT05506540|DRUG|ENN0403 20mg|ENN0403 capsules for oral use
223620201|NCT05506540|DRUG|ENN0403 30mg|ENN0403 capsules for oral use
223620202|NCT05506540|DRUG|ENN0403 20mg (Fed)|ENN0403 capsules for oral use
223620203|NCT05506540|DRUG|ENN0403 6mg QD X 14 Days|ENN0403 capsules for oral use
223620204|NCT05506540|DRUG|ENN0403 12mg QD X 14 Days|ENN0403 capsules for oral use
223620205|NCT05506540|DRUG|ENN0403 20mg QD X 14 Days|ENN0403 capsules for oral use
223620206|NCT05506540|DRUG|Placebo|Placebo capsules for oral use
223620207|NCT03824223|DIAGNOSTIC_TEST|Hypoxic challenge test|Physiological response to 15% ambient oxygen monitored.
223620208|NCT00184834|BEHAVIORAL|quality of life|
223620209|NCT06169319|BIOLOGICAL|Collagenase Clostridium Histolyticum (CCH)|Biologic: Intrafascial injection
223620210|NCT06169319|BIOLOGICAL|Placebo|Intrafascial injection
223620211|NCT06363383|BIOLOGICAL|MB-001|Oral, delayed release formulation of a biologic drug
223620212|NCT04552522|OTHER|shrimp allergy with intend to eat shrimp|shrimp allergy with intend to eat shrimp and treat with oral immunotherapy
223620213|NCT05181592|DRUG|Luspatercept|Once 1.75 mg/kg on Day 1 of each 21-day cycle for 24 weeks (9 cycles)
223620214|NCT04554277|BIOLOGICAL|Biomarker guided therapy|Guided therapy using sST-2 monitoring at the discharge from initial hospitalisation, 6, 12, 18 and 24 months of following.
223620215|NCT02843165|DRUG|Checkpoint blockade immunotherapy|Approved Checkpoint blockade immunotherapy (including anti-CTLA-4 and anti-PD-1/PD-L1 antibodies)
223620216|NCT02843165|RADIATION|Checkpoint blockade immunotherapy plus SBRT|SBRT at 28.5 Gy (9.5 Gy x3 fractions) will be delivered within 1 - 21 days of the start of Cycle 1 of the CBI plus CBI (approved CBIs including anti-CTLA-4 and anti-PD-1/PD-L1 antibodies)
223761607|NCT03420885|BEHAVIORAL|Ba Duan Jin|Ba Duan Jin, a traditional Chinese health-preserving technique, combines the traditional Chinese medicine and traditional Chinese philosophy and embrace the body, breath and spirit. Ba Duan Jin consists of eight main movements. According to traditional theory, every movement has unique effect to different Zang-fu organs.
223620217|NCT05262855|DRUG|[68Ga]FAPI-46|\[68Ga\]-FAPI-46 is a radioactive diagnostic agent indicated for use with Positron Emission Tomography (PET) imaging for the detection of Fibroblast Activation Protein (FAP) positive cancer cells and cancer-associated fibroblasts (CAF) in patients with pancreatic ductal adenocarcinoma (PDAC).
223620218|NCT06800261|BIOLOGICAL|Sinovac PCV24|Sinovac PCV24 (0.5 mL) is administered intramuscularly according to different immunization schedules.
223620219|NCT06800261|BIOLOGICAL|Prevnar®|Prevnar® (0.5 mL) is administered intramuscularly according to different immunization schedules.
223620220|NCT03650621|DEVICE|Magnetic acupuncture|5 magnetic acupuncture stickers will be placed on the infants ear
223620221|NCT03650621|DEVICE|stickers (magnets removed)|in this group 5 stickers (magnets removed) will be placed on the infants ear
223620222|NCT04984356|BIOLOGICAL|WU-CART-007|A single IV infusion of WU-CART-007 Cells on Day 1
224210309|NCT04479943|OTHER|Surveys and Focus groups|Nurses will answer surveys about nurse behavior, changes in self-efficacy, frequency and distance of patient ambulation, documentation of ambulation, qualitative data collected to determine barriers to implementation
224210310|NCT04032522|OTHER|point-of care (PoC) neonatal HIV early infant diagnosis (EID)|clinical impact of a PoC-EID for infants and neonates at birth and week 4-8 weeks, linked with nurse-supported immediate ART initiation in HIV-infected neonates, versus standard-of-care (SoC)
223620223|NCT04926818|DRUG|Fingolimod|Fingolimod capsule administered orally once daily at a dose of either 0.5 mg or 0.25 mg (depending on patient's body weight).
223620224|NCT04926818|DRUG|Ofatumumab|Ofatumumab as a solution for injection in an autoinjector containing 20 mg ofatumumab (50 mg/mL, 0.4 mL content) for subcutaneous administration. A loading dose at Day1, Day 7 and Day 14 and then injections every 4 weeks/ 6 weeks (depending on patient's body weight).
223620225|NCT04926818|DRUG|Siponimod|Siponimod tablet administered orally once daily. Titration period, Day 1 to Day 6, first dose is either 0.1 mg or 0.25 mg up to daily dose of either 0.5 mg, 1 mg or 2 mg (depending on CYP2C9 genotype and body weight).
223620226|NCT04926818|OTHER|Fingolimod placebo|Fingolimod matching placebo capsule
224210311|NCT01098058|OTHER|CBT plus treatment as usual|16 one-hour therapy sessions taking place over 42 weeks in addition to usual medical follow-up appointments
224210312|NCT01098058|OTHER|Treatment as usual|Treatment as usual appointments at the Adult ADHD Service - typically one 30-minute appointment every three to six months
223620227|NCT04926818|OTHER|Siponimod placebo|Siponimod matching placebo tablet
223620228|NCT04926818|OTHER|Ofatumumab placebo|Ofatumumab matching placebo autoinjector
223620229|NCT06065488|DEVICE|ankle kinesio tap|Kinesio Tape is popular among athletes and non-athletes for its ability to protect, support, and promote activity in overworked muscles. Few people are aware, however, that its healing benefits don't end there. Research studies show that taping ankle with Kinesio Tape actually improves ankle range of motion.
223620230|NCT06958835|DRUG|Linezolid 600 mg|linezolid 600 mg tablets (twice a day for 5 days)
223620231|NCT06958835|DRUG|Placebo|Placebo tablets (twice a day for 5 days)
223620232|NCT06287463|DRUG|DCC-3084|Administered orally
223620233|NCT04699890|OTHER|Blood sampling, questionnaires and specific exams|Patients will have additionnal blood samples, answer to self-questionnaires and will performed an electrocardiogram and an echocardiography if not performed in routine care.
223761608|NCT03420885|BEHAVIORAL|Health Education|Health education includes work, rest, diet and other basic programs according to the different conditions of participants.
223761609|NCT03163368|RADIATION|Neoadjuvant stereotactic radiosurgery|Dose escalation of neoadjuvant stereotactic radiosurgery
223620236|NCT04663997|DRUG|177Lu-PSMA-617|IA of 7.4GBq (± 10%) IV every 6 weeks; maximum 6 cycles
223620237|NCT04663997|DRUG|Docetaxel|75mg/m2 IV every 3 weeks maximum 12 cycles
223620238|NCT06102902|DRUG|BET Bromodomain Inhibitor ZEN-3694|Given PO
223761610|NCT03163368|PROCEDURE|Neurosurgical resection|Surgical resection of newly diagnosed brain metastases
223620239|NCT06102902|PROCEDURE|Biopsy Procedure|Undergo biopsy
223620240|NCT06102902|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
223620241|NCT06102902|BIOLOGICAL|Cetuximab|Given IV
223620242|NCT06102902|PROCEDURE|Computed Tomography|Undergo CT
223620243|NCT06102902|PROCEDURE|Echocardiography Test|Undergo ECHO
223620244|NCT06102902|DRUG|Encorafenib|Given PO
223620245|NCT06102902|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223620246|NCT06102902|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
223620247|NCT05304351|BIOLOGICAL|Amezosvatein Antigen High Dose Arm A|Suspension for injection administered intramuscularly (IM) in the deltoid region of the non-dominant arm in Month 0 and Month 2 per study schedule
223620248|NCT05304351|BIOLOGICAL|Amezosvatein Antigen Low Dose Arm B|Suspension for injection administered intramuscularly (IM) in the deltoid region of the non-dominant arm in Month 0 and Month 2 per study schedule
223620249|NCT05304351|BIOLOGICAL|Shingrix|Suspension for injection administered intramuscularly (IM) in the deltoid region of the non-dominant arm in Month 0 and Month 2 per study schedule
223620250|NCT05304351|BIOLOGICAL|Amezosvatein Adjuvant Dose Arm D|Suspension for injection administered intramuscularly (IM) in the deltoid region of the non-dominant arm in Month 0 and Month 2 per study schedule
223620251|NCT05304351|BIOLOGICAL|Amezosvatein Adjuvant Dose Arm F|Suspension for injection administered intramuscularly (IM) in the deltoid region of the non-dominant arm in Month 0 and Month 2 per study schedule
223620252|NCT05304351|BIOLOGICAL|Amezosvatein Adjuvant Dose Arm H|Suspension for injection administered intramuscularly (IM) in the deltoid region of the non-dominant arm in Month 0 and Month 2 per study schedule
223620253|NCT05304351|BIOLOGICAL|Amezosvatein Adjuvant Dose Arm J|Suspension for injection administered intramuscularly (IM) in the deltoid region of the non-dominant arm in Month 0 and Month 2 per study schedule
223761611|NCT04743661|DRUG|Irinotecan|"Irinotecan is a semisynthetic water-soluble analog of camptothecin (a plant alkaloid isolated from Camptotheca acuminata). Irinotecan is available in single-dose amber glass vials in 40 mg (2 mL) and 100 mg (5 mL), 300 mg (15 mL), and 500 mg (25 mL).~Patients on Stratum 1 will be given irinotecan at 50 mg/m2/day IV on Days 1 through 5 of each chemotherapy course."
223761612|NCT04743661|DRUG|Temozolomide|"An orally administered alkylating agent, a second generation imidazotetrazine. A prodrug of MTIC, temozolomide spontaneously decomposes to MTIC at physiologic pH. Exerts its effect by cross-linking DNA. Temozolomide capsules are available in six different strengths (5, 20, 100, 140, 180, 250 mg). The capsules vary in size, color, and imprint according to strength. In the US, capsules are packaged in 5-count and 14-count bottles.~Patients on Stratum 1 will be given temozolomide at 150 mg/m2/dose PO on Days 1-5 of each chemotherapy course."
223761613|NCT04743661|DRUG|Bevacizumab|"Bevacizumab is a recombinant humanized anti-vascular endothelial growth factor (anti-VEGF) monoclonal antibody. Bevacizumab is supplied as a clear to slightly opalescent, sterile liquid ready for parenteral administration. Each 400 mg (25 mg/mL, 16 mL fill) glass vial contains bevacizumab with phosphate, trehalose, polysorbate 20, and Sterile Water for Injection.~Patients on Stratum 1 will be given bevacizumab at 10 mg/kg/day IV on Days 1 and 15 of each chemotherapy course, with the exception of the last course of Induction Chemotherapy (i.e., Course 2 or 4) where it will be administered on Day 1 only."
223620254|NCT05304351|BIOLOGICAL|Amezosvatein Adjuvant Dose Arm L|Suspension for injection administered intramuscularly (IM) in the deltoid region of the non-dominant arm in Month 0 and Month 2 per study schedule
223620255|NCT01273168|DRUG|Z-Endoxifen|Genetic polymorphisms in CYP2D6 and concomitant medications alter tamoxifen metabolism, limiting exposure to the active metabolite endoxifen. These factors are associated with a higher rate of recurrence and shorter disease-free survival in breast cancer patients receiving tamoxifen. Administration of endoxifen directly to patients is anticipated to bypass the effects of CYP2D6 polymorphisms and concomitant medications and provide adequate active drug levels in all treated patients, resulting in clinical benefit.
223620256|NCT01631617|DRUG|Trimethoprim/sulfamethoxazole (TMP/SMZ)|800/160 orally every 12 hours for 14 days
223620257|NCT01631617|DRUG|Cephalexin|500 mg orally every 8 hours for 14 days
223620258|NCT01631617|DRUG|Doxycycline|20 mg orally every 12 hours for 56 days or 100 mg orally every 12 hours for 56 days
223620259|NCT01631617|OTHER|Sodium hypochlorite|6 % dilute bleach
223620260|NCT01631617|OTHER|Placebo capsules|Capsule orally every 8 hours daily for 14 days
223620261|NCT01631617|OTHER|Placebo Sodium hypochlorite|Three times a week for 14 days
223620262|NCT04543396|OTHER|Resistance exercise|A training program designed to enhance core strength, stability, and function will be performed on the Tonal device. Training sessions will occur twice weekly for eight weeks. Performance of this program will be supervised by a designated and clinically trained research team member who will not conduct the statistical analysis and subsequently not be blinded to Group assignment. The program will last approximately 20 minutes in length and incorporate the a series of progressive exercises.
223620263|NCT05518643|PROCEDURE|ERAS protocol|ERAS protocol as described above
223620264|NCT04705662|DIAGNOSTIC_TEST|Lactulose breath test|Participants will complete a 3 hour breath test pre and post iron supplementation. This will include taking 4 exploratory samples for volatile organic compound (VOC) analysis.
223620265|NCT04705662|OTHER|Stool sample|Participants will provide a stool sample pre and post iron supplementation
223620266|NCT04705662|OTHER|Daily Diary|Monitoring stool form, consistency and frequency on a daily basis
223620267|NCT04705662|OTHER|Irritable Bowel syndrome severity scoring system (IBS-SSS) questionnaire|Participants will complete the questionnaire pre and post iron supplementation
223620268|NCT04705662|DIETARY_SUPPLEMENT|Ferrous Sulphate|Participants will take Ferrous sulphate 200mg (65mg elemental iron) for 4 weeks (+/- 2 days). Participants will be required to take 2 tablets per day.
223620269|NCT02443077|PROCEDURE|Autologous Bone Marrow Transplantation|Undergo autologous hematopoietic progenitor cells or bone marrow transplant
223620270|NCT02443077|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous hematopoietic progenitor cells or bone marrow transplant
223620271|NCT02443077|DRUG|Carmustine|Given IV
223620272|NCT02443077|DRUG|Cyclophosphamide|Given IV
223620273|NCT02443077|DRUG|Cytarabine|Given IV
223620274|NCT02443077|DRUG|Etoposide|Given IV
223620275|NCT02443077|DRUG|Ibrutinib|Given PO
223620276|NCT02443077|OTHER|Laboratory Biomarker Analysis|Correlative studies
223620277|NCT02443077|DRUG|Melphalan|Given IV
223620278|NCT02443077|OTHER|Pharmacogenomic Study|Correlative studies
223620279|NCT02443077|OTHER|Placebo Administration|Given PO
223620280|NCT06846320|DRUG|ABBV-932|Oral Capsule
223620281|NCT06846320|DRUG|Placebo for ABBV-932|Oral Capsule
223620282|NCT06846320|DRUG|Antidepressant Therapy (ADT)|Standard of care
223620283|NCT06553456|DRUG|Recombinant Human Serum Albumin|The experimental drug was administered at a dose of 20 g/ day for 7 days.
223620284|NCT06553456|DRUG|Human Serum Albumin|The positive control drug was administered at a dose of 20 g/ day for 7 days.
223620285|NCT05726396|DRUG|RMT|A single loading dose of RMT capsules containing \~5 x 10 11 bacteria on day 1 followed by 2 x 10 11 bacteria daily for 6 days. The RMT capsule preparation (\~2-5 capsules, size 00) is self-administered on an empty stomach with at least one glass of water. Clear liquids are allowed, and food can be resumed 2 hours after administration.
223620286|NCT05726396|DRUG|Placebo|Participants will receive an identical looking placebo capsules daily for 7 days (i.e 5 placebo capsules on day 1), followed by 2 placebo capsules daily from Day 2-7. The placebo capsule preparation is self-administered on an empty stomach with at least one glass of water. Clear liquids are allowed, and food can be resumed 2 hours after administration.
223620287|NCT05072418|BEHAVIORAL|Eye-opened and Eye-closed|The participants were instructed to perform six 60-second trials (2 conditions × 3 trials) of maintaining an upright stance on a force plate (Kistler Type 9260A, Switzerland) under the eyes open (EO) and eyes closed (EC) conditions. The order of EO and EC was alternated for each participant, and half of the subjects began with the EO (or EC) condition. For both conditions, the participants stood with their feet 1 cm apart on a force plate and their arms relaxed comfortably at their sides.
223620288|NCT03049761|DEVICE|Water Flosser|Power interdental cleaner
223620289|NCT03049761|DEVICE|String Floss|Mechanical interdental cleaner
223620290|NCT03049761|DEVICE|Manual Toothbrush|ADA standard soft bristle toothbrush
223620291|NCT02005367|BEHAVIORAL|Natural Recovery-Horticulture|"Participants in Natural Recovery-Horticulture received a one-hour small group therapy session during the week using Horticulture modules with a staff facilitator while DAP-CP participants attended a large psychoeducational group at that time.~Natural Recovery participants also pursued four hours of gardening on each weekend day while DAP-CP attended large-group lectures."
223620292|NCT02005367|BEHAVIORAL|Natural Recovery-Art/Music|Participants in Natural Recovery-Art/Music received a one-hour small group therapy session during the week using Art/Music modules with a staff facilitator while DAP-CP participants attended a large psychoeducational group at that time. Natural Recovery participants also pursued four hours of art or music on each weekend day while DAP-CP attended large-group lectures.
223620293|NCT04073186|DEVICE|ACUVUE® OASYS with Transitions™|JJVC Marketed Contact Lens
223620294|NCT00473434|DRUG|Paliperidone|3mg or 6mg or 9mg or 12mg once daily for 52 weeks
223620295|NCT03820609|BEHAVIORAL|Digital Intervention|This digital application for sexual assault prevention can be completed on a tablet computer.
223620296|NCT05552027|DEVICE|CCS System- Prototype|Participants will be exposed to each of the 3 scenarios with the sensor system enabled (with feedback)
223620297|NCT05552027|DEVICE|CCS System- Control|The participants will be exposed to each of the 3 scenarios with the system disabled (no feedback).
223620298|NCT05512377|DRUG|brigimadlin|brigimadlin
223620299|NCT04218968|DRUG|Carvedilol|Primary procedures in this study are MIBG scan, DAT scan, NM-MRI, and carvedilol titration. Subjects will return for research visits and imaging every six months for three years. The investigators hypothesize that the rate of decline in DAT scan123I-Ioflupane uptake will be slower in subjects who have received the adrenergic blocker carvedilol, resulting in a decreased clinical phenoconversion rate to parkinsonism.
223620300|NCT02781922|GENETIC|Autologous cardiac stem cells (JRM-001)|3x 10\^5 cells/kg, single treatment
223620301|NCT05894434|BEHAVIORAL|Multisensory Training|The procedure involves repeatedly presenting identical visual-auditory stimuli at a single location in the hemianopic field (initially at 45° of eccentricity along the azimuth) while the patient maintains central fixation (0°, 0°). The visual (a 500 ms flash) and auditory (500 ms broadband noise burst) stimuli are in spatial and temporal congruence.
223620302|NCT05894434|BEHAVIORAL|Unisensory Training|The procedure involves repeatedly presenting identical auditory stimuli (500 ms broadband noise burst) at a single location in the hemianopic field (initially at 45° of eccentricity along the azimuth) while the patient maintains central fixation (0°, 0°).
223620303|NCT04014920|DEVICE|Oxygen group|The control group will receive oxygen (first randomization), HFNO oxygen or standard oxygen (second randomization)
223620304|NCT04014920|DEVICE|NIV Group|The experimental group will receive NIV (first randomization) alternated with HFNO or standard oxygen (second randomization)
223620305|NCT03785249|DRUG|MRTX849|MRTX849 will be administered orally once or twice daily in a continuous regimen
223620306|NCT03785249|DRUG|Pembrolizumab|Pembrolizumab is administered as an intravenous infusion once every 3 weeks
223620307|NCT03785249|DRUG|Cetuximab|Cetuximab will be administered as an intravenous infusion once per week or once every 2 weeks
223620308|NCT03785249|DRUG|Afatinib|Afatinib will be administered orally once a day in a continuous regimen
223620309|NCT02508012|OTHER|Immuno monitoring|treatment optimization
223620310|NCT06388941|DRUG|Iptacopan|LNP023 administered orally
223620311|NCT06388941|DRUG|Placebo|Matching placebo administered orally
223620312|NCT06388941|DRUG|Rituximab|Standard of care
223620313|NCT04599088|OTHER|Brain functional MRI with simplified urodynamics|"Structural:~MPRAGE provides a structural image, which is used for coregistration of subjects. Structural scans are then performed including Diffusion Spectrum Imaging (DSI; microstructural), and Fluid-attenuated inversion recovery (FLAIR; white matter specific) scans.~Functional:~With about 50 ml in the bladder, resting state functional BOLD measurements are made, followed by functional whole-brain images while a small amount of saline is infused and withdrawn from the bladder, in 2 blocks of 4 repetitions each. Each repetition starts with a 12-scan pause, followed by infusion (6 scans = 12 s), pause (6 scans), and withdrawal (6 scans). Each block of 4 repetitions is completed by a 6 scan pause during which scanning continues. 24 ml is infused at 120 ml/min, and slightly less is withdrawn to avoid accommodation.This is repeated on an empty and full bladder along with a resting state image."
223620314|NCT04824469|OTHER|intervention group|web based training: By establishing a website, training on drug use, symptom management and quality of life will be provided.
224210313|NCT04148508|BEHAVIORAL|Tailored Emotional Competence Self-help|The active interventions are all entirely self-help and provide psycho-education, tips, advice and strategies for well-being promotion. Interventions are personalised to the individual based on emotional competence skills. Intervention is in addition to self-monitoring in the app. Intervention components include selection of 2 from 4 of : targeting worry and rumination; increasing emotional knowledge and perception skills; improving achievement appraisals including attribution retraining and growth mindset; improving social appraisals including positive interpretations of ambiguous social events
224210314|NCT04148508|BEHAVIORAL|Cognitive-behavioural Approach|The active interventions are all entirely self-help and provide psycho-education, tips, advice and strategies for well-being promotion, based on cognitive-behavioural principles such as increased activity and challenging negative thinking. Interventions are generic and common to all participants. Intervention is in addition to self-monitoring in the app.
224210315|NCT04148508|BEHAVIORAL|Self-monitoring|Self-monitoring app that involves monitoring emotions and emotional events over time within the app and being able to review emotion over time
223620315|NCT01453140|DRUG|Cyclophosphamide and Sirolimus|"On the first day of treatment, cyclophosphamide will be administered at a dose of 4g/m2 IV x 1 dose. Patients who are \>40% above ideal weight will be dosed based on adjusted weight and adjusted BSA.~One day after the administration of cyclophosphamide, patients will receive sirolimus 6 mg PO x 1 and on the following day will start sirolimus at a dose of 2 mg PO daily."
223620316|NCT01453140|DRUG|Low dose IL-2 with Cytoxan + Sirolimus|"Patients in treatment arm B will be receiving low-dose IL-2 in conjunction with the cyclophosphamide and sirolimus.~IL-2 will be administered at a dose of 0.5E6 IU/m2 SQ daily x 8 weeks followed by 4 weeks off, starting 14 days after the cyclophosphamide."
223620317|NCT01453140|DRUG|Low dose IL-2, low dose Vidaza, cyclophosphamide & Sirolimus|"Patients in treatment arm C will be receiving low-dose azacitidine (Vidaza). The Vidaza will be initiated between day 27 and 32 following the cyclophosphamide.~The dose administered will be 10 mg SQ daily for 5 days followed by 3 weeks off."
223620318|NCT01453140|DRUG|Cyclophosphamide and Sirolimus|Day 1: Cyclophosphamide Day 2: Sirolimus
223620319|NCT01453140|DRUG|Low dose IL-2 with Cytoxan + Sirolimus|treatment arm B will be receiving low-dose IL-2 in conjunction with the cyclophosphamide and sirolimus
223620320|NCT01453140|DRUG|Low dose IL-2, Vidaza, Cytoxan & Sirolimus|Vidaza will be initiated between day 27 and 32 following the cyclophosphamide.
223620321|NCT05223270|OTHER|wound dressing under the NIMV mask|wound dressing under the NIMV mask
223620322|NCT00641004|DRUG|Rebamipide and Esomeprazole|"1. Rebamipide 100mg TID for 12 weeks~2. Esomeprazole 40mg OD + Esomeprazole-matching placebo BID for 12 weeks"
223620323|NCT00925262|BEHAVIORAL|Cognitive Processing Therapy|an adaptation of cognitive behavioral therapy used to address mental health effects of trauma exposure
224210316|NCT05720793|COMBINATION_PRODUCT|FMT Capsule + SIMBA Capsule|Participants in this arm will receive FMT capsules in addition to their usual treatment. participants will also be administered SIMBA sample collection capsules.
224210317|NCT06463756|OTHER|AI|"Radiomics extracts quantitative information from medical images to generate high-dimensional feature vectors for analysis. It aims to provide insights into disease processes and improve diagnosis.~Deep learning utilizes neural networks with multiple layers to learn complex patterns from data. In medical imaging, it enables accurate and efficient analysis for disease detection and diagnosis."
224210318|NCT06495268|OTHER|Individualised data-driven hearing rehabilitation|"HA fittings will be conducted with the Real-Ear Measurements (REM) method that is recommended by the latest ISO-standard (21388:2020) and by the preliminary results of the BREM study at KUH. After the fitting of the HAs, participants' auditory-related outcomes will be immediately assessed using DigiKuulo and re-fitting is performed if needed based on the following criteria:~1. The absolute improvement in the DIN test is less than 1,5dB (SNR), OR~2. The absolute result of the DIN test is more than -8,5 dB (SNR) OR~3. The participant is unsatisfied with the HA fitting~Participants are invited to intervention-related monitoring appointments at 3, 6 and 12 months after the primary HA fitting. At these visits, auditory outcomes of the rehabilitation are assessed via DigiKuulo and re-fittings are performed as needed."
224210319|NCT06495268|OTHER|Standard care hearing rehabilitation|HA will be fitted with automatic algorithms by HA manufacturers and REM-fitting is only applied in complex cases based on the hearing rehabilitator's clinical judgement. Three months after the HA fitting, participants will be contacted via phone call to inquire about the status of the rehabilitation. Additional monitoring visits may be offered based on the participant's feedback. After the 3-month monitoring phone call participants will be advised to further contact the study team if they are dissatisfied with the amplification or for any other problem with their device.
224210320|NCT00206037|DEVICE|COLLOSS E|
224210321|NCT00206037|DEVICE|TomoFix Plate|
224210322|NCT06507059|DRUG|cabotegravir/rilpivirine (600mg/ 900mg)|Immediate switch from oral antiretroviral to long-acting injectables
224210323|NCT06507059|DRUG|Antiretroviral Combinations|Standard all-oral antiretroviral combinations
224210324|NCT02908607|DEVICE|Thermal imaging|Examination of the cervix by thermal imaging camera
224210325|NCT02549885|OTHER|PNF contract-relax|Proprioceptive neuromuscular facilitation, using the technique of contract-relax on neck diagonal.
224210326|NCT02549885|OTHER|Static stretching|Static stretching of neck muscles.
224210327|NCT00834288|DRUG|Tramadol HCl|1x200 mg Tramadol HCl OAD tablet daily
224210328|NCT00834288|DRUG|Tramadol HCl|1x50 mg Tramadol HCl IR (Ultram®) tablet 6-hourly
223620324|NCT00925262|BEHAVIORAL|Behavioral Activation|form of counseling intervention to promote positive behaviors and reduce negative behaviors as a means of reducing depression symptomatology and severity
223620325|NCT00925262|BEHAVIORAL|nonspecific counseling|nonspecific counseling interventions useful for a broad range of mental health and psychosocial problems.
223620326|NCT00557921|DRUG|CGT-2168 (clopidogrel 75 mg/omeprazole 20 mg) and aspirin|(CGT-2168 active and Comparator placebo, one capsule each daily; and enteric coated aspirin at daily dose level assigned by study physician)
223620327|NCT00557921|DRUG|Plavix (clopidogrel 75 mg) and aspirin|(CGT-2168 placebo and Comparator active, one capsule each daily; and enteric coated aspirin at daily dose level assigned by study physician)
223620328|NCT05268640|PROCEDURE|Double-level cervical cerclage|two cervical sutures + regimen of antibiotics + indomethacin + progesterone
223620329|NCT05268640|PROCEDURE|Single-level cervical cerclage|single cervical suture + regimen of antibiotics + indomethacin + progesterone
223620330|NCT01003158|DRUG|AZD8931|Tablet Oral bid
223620331|NCT01003158|DRUG|Paclitaxel|IV once weekly for 3 weeks followed by a week off
224210329|NCT05645562|BEHAVIORAL|Pain neuroscience education program|"1. Types of pain (peripherical and central pain)~2. Pain as information.~3. Benign and harmful pain~4. Psychological factors and pain in sport (Injuries, catastrophizing and pain)"
224210330|NCT05645562|BEHAVIORAL|Self-care education program|"1. The importance of resting~2. Nutritional habits~3. Recovery techniques for athletes~4. Principles of stretching, strengthening and endurance training"
224210331|NCT00572468|DRUG|Simvastatin|40 mg of simvastatin
224210332|NCT00572468|OTHER|Placebo|placebo
224210333|NCT03770481|BEHAVIORAL|nurse-led communication strategy|Nurse-led communication strategy (NLCS) applies 'COMFORT' framework that research nurses use the framework to engage one communication session per day with surrogates and two discussions with bedside nurses or attending physician during the ICU stay.
224210334|NCT06354972|PROCEDURE|Minimally invasive surgical procedure|All the experimental sites underwent a minimally-invasive surgical technique (MIST) procedure under magnification (Cortellini and Tonetti 2007). The full-thickness flap was minimally raised both on the buccal and oral side, avoiding vertical releasing incisions. Granulation tissue was scraped from the bony surfaces of the defect, and the root was debrided using minicurettes/ultrasonic device and chemically treated by EDTA. Regenerative procedure was carried out using a combination of enamel matrix derivatives and bone xenograft. The flaps were then repositioned and sutured in order to obtain passive primary closure.
223513066|NCT04180878|BEHAVIORAL|Intervention 2|Participants received an interactive physical activity monitoring system, an electronic scale to report weekly body weight, weekly hour long conference calls with structured interactive educational lessons led by Health Educator, dietary recalls were completed at three different time points during their participation, and study personnel monitored physical activity levels weekly.
223513067|NCT00747071|DRUG|Colostrum|Daily administration of Colostrum derived antibodies against C. difficile.
223513068|NCT03450135|BEHAVIORAL|Trier Social Stress Test|Participants will perform an acute psychosocial stress manipulation (Trier Social Stress Test) involving a speech task and challenging mental arithmetic.
223513069|NCT03450135|BEHAVIORAL|Emotional go/no-go task|Participants will perform an emotional go/no-go paradigm to examine electrophysiological (EEG) correlates of cognitive and affective processing.
223513070|NCT05431907|DRUG|Allocetra-OTS|Allocetra-OTS is a cell-based therapy consisting of non-HLA matched allogeneic peripheral blood mononuclear cells, derived from a healthy human donor following a leukapheresis procedure, induced to an apoptotic stable state.
223513071|NCT03372915|BEHAVIORAL|Standard Exposure|Exposure therapy conducted according to standard clinical care practices
223513072|NCT03372915|BEHAVIORAL|Exposure + Inhibitory Learning|Exposure therapy conducted according to practice recommendations based derived from research on inhibitory learning theories of fear extinction
223513073|NCT01248390|BEHAVIORAL|Interactive metronome|A randomized, controlled investigation into the effects of IM training on a sample of boys with attention deficit disorder showed positive results. Compared to an active control treatment, IM training improved performance on a host of measures, including attention, motor control, language processing, reading, and parental reports of improvements in the regulation of aggressive behavior.16 It should be noted that these cognitive and behavioral functions are common symptom areas in individuals surviving TBI and are likely to be especially affected in cases of blast injury
223513074|NCT01250314|OTHER|Radiology|Spine radiography, densitometry, evaluation of bone architecture and micro-architecture (computed tomography of lumbar spine and hip and peripheral micro-scanner (XREME SCANCO) at tibia and wrist).
223513075|NCT01250314|OTHER|Biological, biochemical and genetic samples|"\*Serum calcium and phosphore evaluation, bone remodeling markers, 25-hydroxyvitamin D level assessment: Blood samples plasma (5 ml):Creatin, calcemia, phosphoremia, alkaline phosphatase, bone alkaline phosphatase, osteocalcin, CTX, 25 hydroxyvitamin D and parathormone~Urinary samples :~Deoxy-pyridinoline, creatinuria Fasting morning urine on a sample Calciuria, creatinuria, cortisoluria Day urine on a sample~\*Assessment of possible determinants of fractures in man~Blood samples plasma (5 ml):~* Sexual Hormones: Estradiol, Testosterone, SHBG, LH, FSH~* Homocysteine~* IGF1~  * Extraction of DNA for a genetic polymorphism study:~Sample of 10 ml of blood on EDTA for DNA extraction.~Tested polymorphisms will be: LRP5, CYP19 (Aromatase), COL1A1 (Collagen I),MHTFR, IGF-1,VDR vitamin D receptor~Globally 20 ml of blood will be taken for each subject. Every biological sample for biochemical dosages and for genetic analysis will be preserved in an anonymous way."
223513076|NCT04455295|DEVICE|Transdermal Vagus Nerve Stimulation (tVNS)|Mild non-invasive transdermal electrical stimulation at the ear (0.0-1.0 mA, 0.0-30.0 Hz). Used in previous studies with no unexpected adverse events. Stimulator not considered a FDA regulated device in previous studies.
223513077|NCT00620802|DRUG|CGT-2168|(CGT-2168, one capsule each daily)
223513078|NCT00620802|DRUG|Plavix|(clopidogrel, 75 mg)
223513079|NCT02495935|DEVICE|OkuStim®|Transcorneal Electrical Stimulation delivered by the Okuvision Stimulation Set manufactured by Okuvision GmbH, Reutlingen, Germany
223513080|NCT02495935|DEVICE|Sham-OkuStim®|Transcorneal Electrical Stimulation delivered by the Okuvision Stimulation Set manufactured by Okuvision GmbH, Reutlingen, Germany
223513081|NCT01968408|DIETARY_SUPPLEMENT|Lactobacillus reuteri DSM 17938|10(9) CFU/daily
223513082|NCT01968408|DIETARY_SUPPLEMENT|Placebo|
224210335|NCT04654286|PROCEDURE|Nerve transfer procedure|"1. Identification of potential donor nerves: phrenic nerve, accessory nerve, intercostal nerve, motor branch nerve innervating long head of triceps muscle, motor branch of ulnar nerve innervating flexor carpi ulnaris (FCU) muscle, and motor branch of median nerve innervating flexor carpi radialis (FCR) muscle.~2. Donor nerve is checked for its viability with an electric stimulator during surgery~3. Viable donor nerve is dissected, transferred to the recipient area, and sutured with end-to-end anastomosis."
224210336|NCT04654286|PROCEDURE|Nerve transfer with HAM-AdMSC composite wrapping|When the nerve transfer procedure is finished, the end-to-end anastomosis is wrapped by a composite consisted of human amniotic membrane and allogeneic adipose-derived mesenchymal stem cells (HAM-AdMSC)
224210337|NCT06425419|DRUG|Topotecan|20 micrograms of intravitreal topotecan given in a 1 cc tuberculin syringe at a concentration of 20 mcg/20mcL.
224210338|NCT01211613|PROCEDURE|Manual Manipulation|Doctor of chiropractic will apply manual high-velocity low-amplitude thrust to lumbar spine of research participants.
224210339|NCT01211613|DEVICE|Mechanically-assisted manipulation|Doctor of chiropractic will use the Activator Instrument to apply a mechanically-assisted thrust to the lumbar spine of research participants.
224210340|NCT01211613|OTHER|Standard Medical Care|Patients will receive an examination with a physician who is board certified in physical medicine and rehabilitation. Treatment will consist of medical monitoring of the patient's condition over 4 weeks (baseline and 2 follow up exams) and a prescription for over-the-counter anti-inflammatory medications if indicated.
224210341|NCT01810393|DRUG|Trastuzumab|Trastuzumab will be administered at a dose of 6 milligrams per kilogram (mg/kg) IV or 600 milligrams per 5 milliliter (mg/5mL) SC in 21-day cycles as per schedule described in respective arm.
224210342|NCT04379973|DRUG|Lipiodol Ultra Fluide®|Tubal flush with 5-10mL oil-soluble contrast medium (OSCM) (Lipiodol Ultra Fluide®, Guerbet, France) immediately after Hyfosy. The use will be off-label.
223620332|NCT00743249|DEVICE|MINI MONOKA canalicular stent, 10 mm|40 mm hollow intubation stent composed of a silicon tube and an oval collarette head (plug), cut to 10 mm length
223620333|NCT00743249|DEVICE|MINI MONOKA canalicular stent, 20 mm|40 mm hollow intubation stent composed of a silicon tube and an oval collarette head (plug), cut to 20 mm length
223620334|NCT02653326|DEVICE|Telerehabilitation Monitors|After completing a 12-session physical therapy programme and the aforementioned co-interventions, patients will receive a telerehabilitation strategy comprised by electrocardiographic monitoring and a smartphone application aimed at detecting adverse events during exercise activities. These devices will also inform patients and healthcare providers regarding the adequacy of their physical activities in terms of cardiovascular outcomes and the observed changes during treatment.
223761614|NCT04743661|DRUG|Omburtamab I-131|"Omburtamab is a murine IgG1 monoclonal antibody (mAb) against B7-H3 (CD276) manufactured by in vivo growth of the hybridoma cell line without the use of animal-derived components. Omburtamab will be radiolabeled with iodine-131 at a designated radiolabeling facility. 131I-omburtamab is supplied as a sterile, injectable, radioactive product in a vial. Each supplied vial will contain enough radioactivity to prepare 50 mCi of 131I-omburtamab, formulated in 3.5-4 mL of solution. 131I-omburtamab should be administered via an intraventricular access device (i.e., Ommaya catheter or programmable VP shunt). Radioimmunotherapy consists of 56 days.~Patients on Stratum 1 will receive a therapeutic dose of 50 mCi cRIT 131I-omburtamab on Days 8 and 36 of Radioimmunotherapy.~Patients on Stratum 2 will receive a therapeutic dose of 50 mCi cRIT 131I-omburtamab on Days 1 and 29 of Radioimmunotherapy."
224210343|NCT05886673|OTHER|experimental cream|experimental cream
224210344|NCT05886673|OTHER|standard of care|standard of care
224210345|NCT00443131|BIOLOGICAL|GSK Malaria vaccine 257049|Three-dose vaccination by slow intramuscular injection. Three different formulations of this vaccine are tested (without adjuvant, with adjuvant AS01B, with adjuvant AS02A).
224210346|NCT01241812|BEHAVIORAL|Lower limb muscle strengthening|Participants in the exercise group will receive a lower limb strengthening program consisting of 6 exercises targeting the quadriceps, hamstrings, and hip abductor groups. They will perform these exercises at home 4 times per week (3 sets of 10 repetitions per exercise). Over the course of the intervention, each participant will consult with the physiotherapist a total of 5 times (once per week in weeks: 1,2,3,5, and 8) to ensure proper performance of exercises and safe progression of resistance.
224316073|NCT04879680|PROCEDURE|sentinel node detection|Under general anesthesia 5 ml at 2.5mg/ml of Infracyanine ® (Laboratoire SERB; France) were injected circumferentially around the areola. Two ml of patent blue-V dye (Laboratoire Guerbet, Aulney-Sous-Bois, France) were injected in combination in the cohort of patients undergoing the procedure after primary chemotherapy. This was followed by a breast massage to facilitate absorption into the lymph vessels, then the surgical lights were turned off and image were obtained under near-infrared light using a first generation Near Infra Red (NIR) device \[K\]. Course of subcutaneous lymphatic drainage pathway fluorescence was followed up to where it disappeared to enter to deeper axilla and an incision was performed at that place. Lymphatic duct identification using the NIR camera allowed localization and removal of the sentinel lymph node(s).
224316074|NCT06430931|PROCEDURE|Minimal invasive abdominal prolapse surgery using Polypropylene mesh|All procedures will be performed with robotic assistance of the da Vinci Si-HD (intuitive Surgical, Inc, Sunnyvale, CA).
223620335|NCT02653326|PROCEDURE|Physical Therapy|Physical therapy will be provided in form of twelve 90-minute sessions. Exercises will be tailored to patient needs, but a common goal of reaching an oxygen consumption of 80-90% will be used for every participant.
224210347|NCT00365469|DIETARY_SUPPLEMENT|Probiotic|Bifidobacterium longum \[BL999\] and Lactobacillus rhamnosus \[LPR\]
224210348|NCT00365469|OTHER|Placebo|Commercially available cow's milk based infant formula without probiotic supplementation
224210349|NCT03853213|BEHAVIORAL|Cognitive Bias Modification Training|"In task 1, participants view a pair of threat-neutral words and then a single letter (E or F). Participants' task is to tap a button as quickly and accurately as possible to indicate whether they see E or F. The letter appears in the neutral location on 90.6% of trials, thereby reinforcing participants' attending away from threat. In task 2, participants view a word or phrase corresponding to a threatening (e.g., dying) or benign (e.g., sleep) interpretation of a sentence (e.g., You have been waking up tired recently). They are asked to tap a button to indicate whether the word or phrase was related to the sentence. Positive feedback (Correct) is given for rejected threat interpretations and for benign interpretations. Otherwise, negative feedback (Incorrect) is given."
223620336|NCT02653326|BEHAVIORAL|Nutritional Counseling|Nutritional counseling will be provided in 60-minute group sessions for included participants. A nutritionist will provide education in terms of healthy eating and risk factor modification.
223620337|NCT02653326|OTHER|Depression Screening|Participants will be screened for depression using the Hospital Anxiety and Depression scale, which has been validated for Spanish-speaking countries. If depression is confirmed, pharmacologic treatment and/or psychotherapy will be prescribed at the discretion of the attending physician.
223620338|NCT02653326|DRUG|Treatment of Comorbidities|Whenever needed, treatment of comorbid conditions, such as hypertension, diabetes or dyslipidemia, will be provided for study participants.
223761615|NCT04743661|DRUG|Liothyronine|Liothyronine (or equivalent) will be given as premedication for 131I-omburtamab to prevent thyroid accumulation. Liothyronine (or equivalent) will be administered at 25 µg PO, NG, or G-tube (if weight \< 25 kg) or 50 µg PO, NG, or G-tube (if weight ≥ 25 kg) daily starting on Day 1 of Radioimmunotherapy (for Stratum 1 patients) or Day 1 of Dosimetry (for Stratum 2 patients), with a mandated minimum of 7 days before each 131I-omburtamab injection and 14 days after each 131I-omburtamab injection. On the day of the 131I-omburtamab injection, administer any time before the injection.
223761616|NCT04743661|DRUG|SSKI|SSKI (potassium iodide) will be given as premedication for 131I-omburtamab to prevent thyroid accumulation. SSKI (potassium iodide) will be administered as 7 drops (\~0.35 mL) PO, NG, or G-tube daily starting on Day 1 of Radioimmunotherapy (for Stratum 1 patients) or Day 1 of Dosimetry (for Stratum 2 patients), with a mandated minimum of 7 days before each 131I-omburtamab injection and 14 days after each 131I-omburtamab injection. On the day of the 131I-omburtamab injection, administer any time before the injection.
223620339|NCT05109936|DRUG|Adenuric|Immediate prescription (at randomization) of ADENURIC 80 mg / day (febuxostat), hypo-uricemic treatment, for a period of 2 x 6 weeks
223620340|NCT04177706|DRUG|Ketamine Hydrochloride|Participants receiving the active study medication will receive 60 mg ketamine twice per week for four weeks under clinical supervision.
223620341|NCT04177706|DRUG|Placebo|Participants receiving the placebo study medication will receive saline twice per week for four weeks under clinical supervision.
223761617|NCT04743661|DRUG|Dexamethasone|Dexamethasone will be given as premedication for 131I-omburtamab to prevent possible meningeal inflammatory reaction. Starting within 24 hours prior to each 131I-omburtamab injection, dexamethasone will be administered orally at 0.5 mg (if weight \< 15 kg) or 1 mg (if weight ≥ 15 kg) twice-daily doses for a total of 6 doses to alleviate infusion-related AEs: Two doses starting 24 hours pre-131I-omburtamab injection, two doses on the day of the injection (can be given before or after), and two doses 24 hours post-131I-omburtamab injection.
223761618|NCT04743661|DRUG|Antipyretic|An antipyretic (e.g., oral acetaminophen \[15 mg/kg, 650 mg maximum\] or equivalent) will be given as premedication for 131I-omburtamab within 1 to 3 hours before each 131I-omburtamab injection.
223761619|NCT04743661|DRUG|Antihistamine|An antihistamine (e.g., IV diphenhydramine \[1 mg/kg, 50 mg maximum\] or equivalent) will be given as premedication for 131I-omburtamab within 1 to 3 hours before each 131I-omburtamab injection.
223620347|NCT05767021|DRUG|Mirikizumab|Administered IV
223620348|NCT05767021|DRUG|Mirikizumab|Administered Subcutaneously (SC)
223620349|NCT02423057|DRUG|TdCyd|Methylation-mediated silencing of genes is an epigenetic mechanism implicated in carcinogenesis; agents that inhibit this mechanism are of clinical interest because of their potential to re-activate silenced tumor suppressor genes. The nucleoside analog 4'-thio-2'-deoxycytidine (TdCyd) is incorporated into DNA where it engages the active site of DNA methyltransferase I (DNMT1), a maintenance methyltransferase that contributes to the hypermethylation and silencing of tumor suppressor genes. TdCyd offers an improvement over current DNMT inhibitors by virtue of a higher incorporation rate into DNA at lower levels of cytotoxicity; treatment with TdCyd is anticipated to result in the inhibition of tumor growth due to DNMT1 depletion at oral doses that are well tolerated in extended dosing schedules.
223761620|NCT04743661|DRUG|anti-emetics|An anti-emetic (e.g., IV ondansetron \[0.25 mg/kg, 16 mg maximum\] or equivalent) will be given as premedication for 131I-omburtamab within 1 to 3 hours before each 131I-omburtamab injection.
223761621|NCT03395769|BIOLOGICAL|AB-SA01|AB-SA01 is an investigational bacteriophage therapeutic for treatment of Staphylococcus aureus infections
224316075|NCT06430931|PROCEDURE|Minimal invasive abdominal prolapse surgery using OviTex 1S permanent mesh|All procedures will be performed with robotic assistance of the da Vinci Si-HD (intuitive Surgical, Inc, Sunnyvale, CA).
224316076|NCT04867174|BEHAVIORAL|Financial incentives|Each of the study arms, including the no message/control arm, will be interacted with different financial incentives (N=5,000)
224316077|NCT04867174|BEHAVIORAL|Convenient scheduling link|In addition, study arms will be randomly assigned a convenient link to the county public vaccine appointment scheduling system highlighted for participants (N=5,000).
223620350|NCT06072131|DRUG|Belinostat Injection|Belinostat 600 mg/m2 or 1000 mg/m2 along with CHOP is given in each cycle
223620351|NCT06072131|DRUG|Pralatrexate Injection|Pralatrexate 20 mg/m2 or 30 mg/m2 along with COP is given in each cycle
223620352|NCT06072131|DRUG|CHOP|CHOP is the comparator arm
223620353|NCT06072131|DRUG|COP|COP is given in combination with Pralatrexate
223620354|NCT06412510|OTHER|Prehabilitation|"Exercise Intervention: SmartGyms, band or smartphone used to scan into the TechnoGym MyWellness kiosk, which controls the TechnoGym Excite Live and Biostrength equipment. The exercise session will consist of a program that adheres to the FITT (Frequency, Intensity, Timing, and Type) exercise prescription in accordance with ACSM 2018 ACSM Roundtable recommendations for Physical Function for combined Aerobic and Resistance training.~Nutrition Intervention: 30 gm protein supplement~Supportive care/Mind-body intervention: Yoga, mindfulness practices, art therapy, and music therapy"
223620355|NCT03822897|RADIATION|Radiation|"35 fractions, 5/wk, 7 wks 70Gy/56Gy, or~35 fractions, 6/wk, 6 wks, 70Gy/56Gy, or~35 fractions, 5/wk, 7 wks OR 6/wk, 6 wks 70Gy/56Gy"
224210350|NCT03853213|BEHAVIORAL|Attention Control Training|In task 1, participants view a pair of threat-neutral words and then a single letter (E or F). Participants' task is to tap a button as quickly and accurately as possible to indicate whether they see E or F. The target letter is equally likely to appear in the threat location as the neutral location. Thus, participants' patterns of attention are not trained toward or away from threat. In task 2, participants view a word or short phrase corresponding to either a threatening or benign interpretation of a sentence that follows it. They are asked to tap a button to indicate whether the word or phrase was related to the sentence. Positive feedback and negative feedback are equally likely to be given regardless of whether participants endorse the threatening or benign interpretations.
223620356|NCT03822897|DRUG|Cisplatin|100 mg/m2 on day 1, 22, and 43 or 40 mg/m2 /wk for 7 wks
223620357|NCT04325425|DRUG|FOLFOXIRI Protocol|Platinum-Etoposide regimen will be administered once every 21 days. Treatment will be continued for 6 to 8 cycles or 24 weeks maximum. One cycle consists of 21 days (3 weeks) with injection on D1 of each cycle (D1=D22). Patients are eligible for repeated treatment cycles in the absence of disease progression and undue adverse events.
223620358|NCT04325425|DRUG|Cisplatin injection|"Cisplatin 100 mg/m2, IV infusion over 3 hours or Carboplatin AUC 5, IV infusion over 30 minutes on day 1 \[the dose of carboplatin will be determined for each cycle using the Calvert's formula (carboplatin dose (mg) = target AUC 5 x estimated glomerular filtration rate (eGFR, mL/min) + 25)\];~• Etoposide 100 mg/m² IV infusion over 1 hour on day 1,2 and 3"
223620359|NCT00875849|BIOLOGICAL|cetuximab|
223620360|NCT00875849|DRUG|cisplatin|
223620361|NCT00875849|RADIATION|radiation therapy|
223620362|NCT05220722|DRUG|SD-101|SD-101 doses will be delivered via HAI using the PEDD method of administration.
223620363|NCT05220722|BIOLOGICAL|Pembrolizumab|During Phase 1b, Cohort B, pembrolizumab will be administered together with SD-101.
223620364|NCT05220722|BIOLOGICAL|Nivolumab|During Phase 1b, Cohort C, nivolumab will be administered together with ipilimumab and SD-101.
223620365|NCT05220722|BIOLOGICAL|Ipilimumab|During Phase 1b, Cohort C, ipilimumab will be administered together with nivolumab and SD-101.
223620366|NCT06146257|DRUG|GLB-001|Administered orally according to the assigned treatment schedule
223620367|NCT06850415|DEVICE|Siriraj gastrointestinal transit capsule|The Siriraj gastrointestinal transit capsule is a local made colonic transit capsule. Each capsule contains 6 circular-shaped radiopaque markers.
223620368|NCT06850415|DEVICE|Sitz-Markers|The standard Sitzmark colonic capsule containing 24 ring-shaped radiopaque markers.
224210351|NCT02898064|DEVICE|thoracolumbosacral orthosis or cervicothoracolumbar orthosis|"An off the shelf spinal brace which will be applied to the patients trunk. They will have straps and harnesses which the patient can fasten and remove if needed. The brace will need to be worn by the intervention group all the time for 3 months except when lying in bed. In the presence of lower thoracic (T8 downwards), thoraco-lumbar and lumbar (L1- L3) fractures, a thoracolumbosacral orthosis will be applied. For upper thoracic fractures (T1-T7) a cervico-thoracic or cervico-thoraco-lumbar orthosis will be used."
224210352|NCT02898064|OTHER|Standard care|Standard surgery, radiotherapy, chemotherapy, drug therapy as applicable and decided by the participants consultant as part of standard care
224210353|NCT00350337|BIOLOGICAL|Pre-transfection F17|Dengue tetravalent Vaccine F17 Pre transfection: 0.5 mL volume per dose, administered at 0 and 6 months via subcutaneous injection
224210354|NCT00350337|BIOLOGICAL|Post-transfection F17|Dengue tetravalent Vaccine F17 Post transfection: 0.5 mL volume per dose, administered at 0 and 6 months via subcutaneous injection. For the booster phase of the study, a booster dose was administered at five months to one year following the second dose.
224210355|NCT00350337|BIOLOGICAL|Post-transfection F19|Dengue tetravalent Vaccine F19 Post transfection: 0.5 mL volume per dose, administered at 0 and 6 months via subcutaneous injection. For the booster phase of the study, a booster dose was administered at five months to one year following the second dose.
224210356|NCT00350337|OTHER|Placebo|Sterile solution of buffered water (0.9% NaCl), U.S. FDA accepted vaccine excipient, phenol red dye(phenolsulfonphthalein, used in vaccines as a pH indicator); 0.5 mL volume per dose, administered at 0 and 6 months via subcutaneous injection
223620369|NCT06272812|BIOLOGICAL|MTBVAC|Vaccine Dose: MTBVAC 5x10\^5 Formulation (approximately, per standard dose): 3 - 17x10\^5 CFU Sucrose Sodium glutamate Presentation: Lyophilized pellet in vials (10 doses) Volume: 0.1 mL/dose Intradermal
223620370|NCT06272812|BIOLOGICAL|Placebo|0.9% saline Volume: 0.1 mL/dose Intradermal
223620371|NCT04211818|BEHAVIORAL|Eating Behavior|A dietary book will be given to the patient and will be filled by this one during 14 days
223620372|NCT04211818|BIOLOGICAL|Blood glucose records|A glycemic sensor will be placed at the back of the patient's arm
223620373|NCT03496805|DRUG|MGE|The patients will take 4 capsules by mouth BID (twice daily).
223620374|NCT03496805|OTHER|Placebo|The patients will take 4 capsules by mouth BID (twice daily).
223620375|NCT03496805|OTHER|ADT|Androgen deprivation therapy (ADT) is to be started within 60 days prior to initiation of MGE.
224316078|NCT04867174|BEHAVIORAL|Race concordant|Randomized to a messenger who is race concordant with the participant
224316079|NCT04867174|BEHAVIORAL|Gender concordant|Randomized to a messenger who is gender concordant with the participant
224316080|NCT02121873|DEVICE|Nipple aspirator|The subject will undergo nipple aspiration with a suction device designed to elicit fluid from the nipple.
223620376|NCT04347603|PROCEDURE|TAVR|Femoral percutaneous aortic prosthesis (TAVR)
223620377|NCT04058431|OTHER|Osteopathic Manipulative Treatment|Osteopathic manipulative treatment (OMT) is defined as the therapeutic application of manually guided forces by an osteopathic physician to improve physiologic function and/or support homeostasis that has been altered by somatic dysfunction. Somatic (body framework) dysfunction or altered function of related components is observed in the skeletal, arthrodial and myofascial structures, and their related vascular, lymphatic, and neural elements. Techniques can use a direct method where the restrictive barrier is engaged and a final activating force is applied to correct the somatic dysfunction, or an indirect method where the restrictive barrier is disengaged and the dysfunctional body part is moved away from the restrictive barrier until tissue tension is equal in one or all planes and directions
223620378|NCT04058431|OTHER|Control- No Intervention|This group will refrain from getting OMT while in the study.
223620379|NCT05852509|BEHAVIORAL|TPA4You|TPA4You integrates technology components in the form of video-conferencing (e.g., Zoom) with a health coach, wearable sensor (e.g., Fitbit), and personalized text messaging into a package to (a) tailor physical activity (PA) prescriptions based on the family care partners of persons with heart failure (HF-FCP)'s feedback and individual wearable sensor data, (b) provide tailored PA coaching sessions using video-conferencing, and (c) motivate daily exercise using text messages.
223620380|NCT05852509|BEHAVIORAL|Attention control group|Participants will be given booklets, provided by the NIA, AHA, and National Alliance for Caregiving, that include content about self-care for FCPs' health and well-being, but not specific to PA or exercise. Participants will receive text messages every other day to encourage them to wear the Fitbit device, and to provide friendly greetings and reminders of upcoming survey data collection.
223620381|NCT06108219|DRUG|Miricorilant (Cohort A)|Miricorilant 100 mg for oral dosing
223620382|NCT06108219|DRUG|Placebo (Cohort A)|Matching placebo for oral dosing for 48 Weeks
223620383|NCT06108219|DRUG|Miricorilant (Cohort B)|Miricorilant 100 mg for oral dosing Miricorilant 200 mg for oral dosing
223620384|NCT06108219|DRUG|Placebo (Cohort B)|Matching placebo for oral dosing for 24 Weeks
223620385|NCT00876200|DRUG|Minoxidil|"Normotension: 0.2mg/kg/day for children under 12 and 5mg/day for children aged 12 or more.~Hypertension: 0.2mg/kg/day, increasing up to a maximal dosage of 1 mg/kg) for children under 12. 5mg/day, increasing as needed of 0.1 mg/kg/day (up to a maximal dosage of 40 mg/day) for children aged 12 or more."
223620386|NCT00876200|DRUG|Placebo|"Normotension: 0.2mg/kg/day for children under 12 and 5mg/day for children aged 12 or more.~Hypertension: 0.2mg/kg/day, increasing up to a maximal dosage of 1 mg/kg) for children under 12. 5mg/day, increasing as needed of 0.1 mg/kg/day (up to a maximal dosage of 40 mg/day) for children aged 12 or more."
223620387|NCT01368588|RADIATION|radiation therapy|Undergo RT using IMRT or 3D-CRT
223620388|NCT01368588|RADIATION|Whole-pelvic radiotherapy (WPRT)|Undergo whole-pelvic radiotherapy (WPRT)
223620389|NCT04154943|DRUG|Cemiplimab|Intravenous (IV) infusion every 3 weeks (Q3W)
223620390|NCT00872625|DRUG|cyclophosphamide|
223620391|NCT00872625|DRUG|docetaxel|
223620392|NCT00872625|DRUG|epirubicin hydrochloride|
223620393|NCT00872625|DRUG|fluorouracil|
223620394|NCT00872625|PROCEDURE|neoadjuvant therapy|
224260508|NCT05119504|BEHAVIORAL|Acceptance and Commitment|"During the 90-minute, one-on-one interventionist led session, participants will learn three inter-related acceptance-based techniques tailored for coping with physical discomfort and negative affect during physical activity. (1) cognitive defusion (i.e., disentangling physical sensations and thoughts from behavior), (2) acceptance (i.e., increasing willingness to experience unpleasant physical sensations/negative affect without trying to change or control them), and (3) valued action (i.e., evaluating the role of physical activity as a valued behavior). Participants will be taught these techniques via didactic instruction, metaphors, and experiential activities.~All participants will receive a two-week physical activity prescription based on national guidelines recommending 150 minutes of at least moderate intensity physical activity per week."
223620395|NCT00872625|PROCEDURE|therapeutic conventional surgery|
223620396|NCT00872625|RADIATION|hypofractionated radiation therapy|
223620397|NCT00872625|RADIATION|image-guided radiation therapy|
223620398|NCT00872625|RADIATION|radiation therapy|
223620399|NCT00872625|RADIATION|stereotactic radiosurgery|
223620400|NCT06960577|DRUG|Durvalumab|Anti- PD-L1 Antibody.
223620401|NCT06960577|DRUG|Methotrexate|Chemotherapy agent.
223620402|NCT06960577|DRUG|Vinblastine|Chemotherapy agent
223620403|NCT06960577|DRUG|Doxorubicin|Chemotherapy agent
223620404|NCT06960577|DRUG|Cisplatin|Chemotherapy agent
223620405|NCT06960577|DRUG|Durvalumab|Anti- PD-L1 Antibody
223620406|NCT06960577|DRUG|Gemcitabine|Chemotherapy agent
223620407|NCT06960577|DRUG|Cisplatin|Chemotherapy agent
223620408|NCT05800665|DRUG|RO7656594|RO7656594 will be administered orally at specified dose on specified days.
223620409|NCT04021485|OTHER|neurodevelopmental assessment|"As part of the usual follow-up of premature children, a follow-up consultation is planned around the age of 5 years. During this visit, a neurodevelopmental assessment will be carried out for the Betanino study. The duration of this evaluation is evaluated around 3h in total.~Interventions will include:~* Standardized neurological exam~* Morphometric measurements including height, weight, head circumference~* Blood pressure measurement~* Multiple aspects of cognition using ancillary indexes of WPPSI-IV subtests, NEPSY-II subtests,~* Social Relativeness, using Social Relativeness Scale parental questionnaire,~* Parental stress using PSI questionnaire"
223620410|NCT05717647|OTHER|Observational study: neuromonitoring|collection of multimodality neuromonitoring data including ICP, brain tissue oxygen tension, cerebral microdialysis data
223620411|NCT06518798|BEHAVIORAL|Fasting Mimicking Diet|Participants will be instructed to follow their usual diet except for 5 days when they eat the foods in the FMD kit. The FMD consists of a blend of 100% plant based nutrients generally regarded as safe. One FMD kit provides for the replacement of the normal diet with plant products for five consecutive days. The formulation of these products was based on studies carried out at the Longevity Institute of the University of Southern California, led by Dr. Valter Longo and his collaborators over several decades of research.
223620412|NCT06240780|OTHER|Activated Incrediwear Products|Activated Incrediwear products incorporates semiconductor elements within the fabric that releases negative ions when stimulated by body heat. The negative ions activate cellular vibrations that increase blood flow and circulation.
223620413|NCT06240780|OTHER|Sham Incrediwear Products|Simple fabric Incrediwear products that do not include the semiconductor elements within the fabric.
223620414|NCT05570851|BEHAVIORAL|Alcohol Cessation Text Messages|Intervention condition will consist of a text message program designed to promote alcohol cessation tailored to HNC patients and targeted to VA or Civilian populations in addition to usual-care-advice.
223620415|NCT05570851|BEHAVIORAL|Usual Care|Control condition will consist of a provider-delivered alcohol cessation intervention with usual-care-advice.
223620416|NCT06337188|DEVICE|Experimental AAC|Participant receives an AAC system comprising 2 wearable sensors for movement-mediated cursor control and muscle activity mediated cursor selection that is integrated with an adaptive and individualized keyboard to test communication performance.
223620417|NCT06337188|DEVICE|Generic AAC|Participant receives an AAC system that is similar to that used to satisfy their normal daily communication needs such as an eye-tracking device with a generic AAC keyboard to test communication.
223620418|NCT01239381|RADIATION|Stereotactic body radiotherapy-proton|Dose will be determined by the size and location of the tumor(s); 2-3 treatments per week for two weeks
223620419|NCT06237049|BIOLOGICAL|BNT162b2 (Omi XBB.1.5)/RIV|Combination of BNT162b2 (Omi XBB.1.5) and RIV
223620420|NCT06237049|BIOLOGICAL|BNT162b2 (Omi XBB.1.5)|Licensed COVID-19 vaccine
223620421|NCT06237049|BIOLOGICAL|RIV|Licensed recombinant influenza vaccine
223620422|NCT06237049|OTHER|Normal saline placebo|Normal saline (solution for injection)
223620423|NCT04941573|COMBINATION_PRODUCT|Hyperpolarized 129-Xenon (MagniXene) MRI of the lung|Hyperpolarized xenon is a contrast imaging agent for lung MR imaging. Inert noble gas xenon is hyperpolarized using Xemed developed technology. The gas is administered to the human subjects as a short seconds-long breath-hold while inside the MRI scanner. Once the gas is inhaled, lung images of HP Xenon distributed within the lung spaces can be acquired. Additionally, xenon follows a similar path to oxygen, dissolving in lung tissue and further in bloodstream.
223620424|NCT03005925|DEVICE|Smartphone|Smartphone application coupled with a hand dynamometer
223620425|NCT03005925|OTHER|physical follow up|regular visits with the specialist
223620426|NCT04782063|OTHER|Calibration of infant breast milk and formula milk intake|We will calibrate (reduce) the pumped breast milk or formula intake of infants of overweight and obese mothers who exceed 75%ile of WHO BMI, in order to prevent infant obesity and subsequent childhood obesity.
223620427|NCT04069091|BEHAVIORAL|'Enjoy your Bump' (iloodottaa.fi) online self-help intervention|"The intervention employs elements of cognitive behavioral therapy: empathic, clear and sensitive communication with women and their families, problem self-formulation of solutions to problems, behavioral activation, identification and changing negative automated negative thoughts, addressing low confidence, and promoting problem- solving and relapse prevention.~The Enjoy your Bump intervention has been adapted to the Finnish culture and healthcare setting (ilodottaa.fi)."
224210357|NCT04779385|PROCEDURE|PIPAC|"under general anaesthesia, a laparoscopy was performed using an open laparoscopic technique to prevent intestinal wounds, which would contraindicate the procedure. A 12 mmHg pneumoperitoneum was created, and to ensure the safety of the procedure the pressure of the pneumoperitoneum was maintained constant throughout the procedure. Two laparoscopic balloon trocars (of 11 and 12 mm) were used. A thorough exploration of the abdomen, Peritoneal Cancer Index assessment, images, peritoneal biopsies, and ascites cytology (in the case of ascites) were performed prior to administration of the chemotherapy aerosol.~For carcinomas of gastric origin, Doxurubicin at a dose of 1.5 mg/m2 was administered in combination with Cisplatin 7.5 mg/m2 diluted in 40 and 150 mL of 0.9% sodium chloride, respectively. In the case of contraindication, Oxaliplatine at a dose of 92 mg/m2 in a 5% dextrose solution was recommended."
224210358|NCT06568185|DRUG|Alpha-Lipoic Acid/Vitamin/Mineral Supplement PolyMVA|BIONERV® s the first combination of alpha lipoic acid 300mg and vitamin B complex. Bionerv® is in oral film-coated, orange colour, oblong shape and no marking and embossing on the tablet. Each tablet contains 4 active ingredients as follows: Alpha lipoic acid 300mg, Vitamin B12 (methylcobalamin) 500mcg, Vitamin B6 (pyridoxine) 8mg, Vitamin B1 (thiamine) 39mg. To be taken after meal 1 tablet once daily.
224210359|NCT00000478|DRUG|atenolol|
224210360|NCT00000478|DRUG|nifedipine|
224210361|NCT00000478|DRUG|diltiazem|
224210362|NCT00000478|DRUG|isosorbide dinitrate|
224210363|NCT00000478|PROCEDURE|coronary artery bypass coronary artery bypass|
224210364|NCT00000478|PROCEDURE|angioplasty, transluminal, percutaneous coronary|
223620428|NCT03281928|DIETARY_SUPPLEMENT|Sodium and Potassium Citrate|Sodium and potassium citrate levels will be altered in diet and renal mineral handling will be measured as compared to placebo.
223620429|NCT03281928|DIETARY_SUPPLEMENT|Placebo|Sodium without Potassium Citrate
223620430|NCT06085833|DIAGNOSTIC_TEST|Nanomechanical Phenotype Test|The ARTIDIS ART-1 device is an in-vitro diagnostic device based on Atomic Force Microscope (AFM) technology. The ART-1 device uses a probe to measure the nanomechanical phenotype of tissue components. ARTIDIS nanomechanical phenotype measurements are performed on fresh tissue after it is collected via biopsy or resection.
223620431|NCT02008123|DRUG|Primidone|Primidone is an antiepileptic used for the management of generalized tonic-clonic seizures and for the management of complex partial seizures. One of primidone's active metabolite is phenobarbital, which is a potent cytochrome P450 inducer. In this study, primidone will be used to induce CYP 1A2 in order to provide more efficient metabolism of clopidogrel to its active form
223620432|NCT02659930|DRUG|liposomal doxorubicin|liposomal doxorubicin IV day 1 of a 28-day cycle
223620433|NCT02659930|DRUG|pomalidomide|pomalidomide once a day, days 1-21 of a 28-day cycle, at the dose levels described in dose escalation plan
223620434|NCT06823141|DEVICE|Virtual reality immersion|The study intervention, defined by the use of a virtual reality, exclusively takes place during the pre-oxygenation period where the patient is exposed to a virtual reality immersion scenario.
223620435|NCT05578092|DRUG|MRTX0902|SOS1 inhibitor
223620436|NCT05578092|DRUG|MRTX849|KRAS G12C inhibitor
223620437|NCT00391482|BEHAVIORAL|Peer Mentoring Intervention for HCV-Infected IDUs|
223620438|NCT02351765|DRUG|Acelarin|First-in-class nucleotide analogue
223620439|NCT02351765|DRUG|Cisplatin|Platinum-compound chemotherapy drug
223620440|NCT02243592|OTHER|Laboratory Biomarker Analysis|Undergo sequencing and SNP analysis
224210365|NCT04462133|DIAGNOSTIC_TEST|Dual-priming oligonucleotide-based multiplex polymerase chain reaction (DPO-PCR)|Empirical H. pylori eradication treatment versus tailored therapy based on DPO-PCR results
223620441|NCT05246774|BIOLOGICAL|Biological sample collection|"The following biological samples will be collected on 4 occasions (at enrollment, 4 weeks after, 12 weeks after and 52 weeks after) :~* fecal sample~* urinary sample~* blood sample (22 ml at each occasion)"
224210366|NCT02858518|OTHER|questionnaires|scales : HEMORR2HAGES (hepatics diseases, alcoholism, cancer, thrombocytopenia, anemia and antecedent...), HAS-Bled (arterial hypertension, renal function, liver function, cerebrovascular accident...), ATRIA (anemia, serious kidney diseases, hypertension, antecedent...), Shireman (gender, age, hemorrhage, diabetes, anemia...), Charlson (age, cardiovascular disease, lung disease, neurological disease, endocrinal disease, nephrology, liver disease, gastroenterology, cancer) and standardised geriatric assessment (comorbidities, cognition, mobility, pain, nutrition, living environment...)
224210367|NCT02535676|DEVICE|Transcranial Direct Current Stimulation|The device will produce a direct current of 2 mA from one electrode to the other. In active stimulation, the device will be turned on for 20 min and in sham stimulation the device will be turned in 2 mA for one minute and will be automatically turned off the remaining 19 minutes. The sham or active mode is chosen by a numeric code.
224210368|NCT00244660|PROCEDURE|Frequent blood pressure measurements|
224210369|NCT00244660|BEHAVIORAL|Education|
224210370|NCT01040676|BEHAVIORAL|Automated Telephone Nutrition Support|See Intervention Group description.
224210371|NCT02854189|DEVICE|Oxford unicompartmental knee arthroplasty|The Oxford unicompartmental knee arthroplasty was applied in all patients with medial osteoarthritis knee.The Oxford unicompartmental knee arthroplasty is mobile bearing unicompartmental knee arthroplasty.
223620442|NCT05246774|OTHER|Questionnaires|"The following questionnaires will be filled by the patients on 4 occasions (at enrollment, 4 weeks after, 12 weeks after and 52 weeks after) :~* CTCAE Radiation Adverse Event Questionnaire~* Lower Urinary Tract Disorders Questionnaire (IPSS Score)~* Quality of Life Questionnaire (FACT-P)~* Physical Activity Questionnaire (IPAQ)"
223620443|NCT03273335|DEVICE|Millipore biomarker assay plate|Millipore biomarker assay plate CSF cytokine assays as well as CSF flow cytometry
223620444|NCT04428736|BEHAVIORAL|Disclosure Toolkit|"Participants will receive a Disclosure Toolkit consisting of a family letter, gene information chatbot, and informational website to aid in communicating their genetic test results with at-risk relatives."
223620445|NCT06158334|DRUG|Describe the respective haemostatic efficacy of Elocta® for haemopilia A during surgical procedures|All surgical data will be collected: surgery, biology, administration of Elocta®, bleeding and transfusion, hemostatic efficacity, surgery complication and bleeding
223620446|NCT06158334|DRUG|Describe the respective haemostatic efficacy of Alprolix® for haemopilia B during surgical procedures|All surgical data will be collected: surgery, biology, administration of Alprolix®, bleeding and transfusion, hemostatic efficacity, surgery complication and bleeding…
223620447|NCT04354376|DRUG|Loop diuretics, thiazides, dihydropyridines|Loop diuretics, thiazides, or dihydropyridines dispensing claim is used as the reference
223620448|NCT04354376|DRUG|Telmisartan|Telmisartan dispensing claim is used as the exposure
223620449|NCT05120414|OTHER|balanace exercises|Balance exercises included standing with feet together (narrow base of support), Standing in Tandem position, Standing eye open to eye closed, multidirectional functional reach during standing, March in place and walk sideways. Time period was of 4 weeks (10 repetitions in each set, 3 sets per session, 1 session daily, 3 days weekly).
223620450|NCT05120414|OTHER|Balance Exercises plus Ankle strategy|ankle strategy exercises included raising and lowering heels and forefeet, heel to toe walking, stepping up and down and right and left and diagonal inclination of body during standing.While balance exercises included standing with feet together (narrow base of support), Standing in Tandem position, Standing eye open to eye closed, multidirectional functional reach during standing, March in place and walk sideways. Time period was of 4 weeks (10 repetitions in each set, 3 sets per session, 1 session daily, 3 days weekly).
223620451|NCT06802406|OTHER|Food Bags|Participants will receive bags of shelf-stable food for 2-3 days for one individual twice a week in clinic. They will also receive recipes, handouts, and videos to help with education and food preparation.
223761622|NCT07172503|DRUG|68Ga-NOTA-GPA33 nanobody|To perform integrated PET/MR or PET/CT visualization of patients with clinically suspected or confirmed colorectal cancer, gastric cancer, pancreatic cancer and other malignant tumors with high GPA33 expression and healthy volunteers, using specific positron imaging agents target GPA33(in the case of \[68Ga\]Ga-NOTA-GPA33 nanobody) , to achieve the following purposes: Patients with malignant tumors: for diagnosis and staging of diseases, comparing with the gold standard pathological diagnosis, evaluating diagnostic efficacy, clarifying the presence or absence of lesions, and determining the location and nature of lesions; comparing with \[18F\]FDG PET for accurate staging, evaluating the tumor load, and helping to determine the therapeutic plan. Healthy volunteers: Pharmacokinetic analysis will be performed to clarify the distribution and metabolism of the drug in the body and its safety.
224210372|NCT01169831|OTHER|Exercise Training|2 weeks of daily aerobic exercise training
224210373|NCT01169831|OTHER|Exercise Cessation|Stopping all exercise for 2 weeks
224210374|NCT06567366|BIOLOGICAL|CAR T-cell therapy|Participants will receive CAR T-cell therapy via infusion on Day 0 (given as per treatment guidelines). Prior to CAR T-cell Therapy, participants will begin receiving lymphodepleting chemotherapy on Days -5 through -3 (given as per treatment guidelines).
224210375|NCT06567366|DRUG|Glofitamab|"Glofitamab is given intravenously at a dose of 2.5mg over 4 hours on Cycle 1 Day 8.~Glofitamab is given intravenously at a dose of 10mg over 2 hours on Cycle 1 Day 15.~Glofitamab is given intravenously at a dose of 30mg over 2 hours on Day 1 of Cycles 2-6 (as relevant)."
224210376|NCT06567366|DRUG|Obinutuzumab|Obinutuzumab pre-treatment is given intravenously at a dose of 1g on Cycle 1 Day 1.
224210377|NCT05722340|PROCEDURE|Non-intubated video-assisted thoracic surgery (NIVATS) for lung biopsy|An epidural anaesthesia associated with mild sedation requiring no ventilation is used.
224210378|NCT05722340|PROCEDURE|Intubated general anaesthesia video-assisted thoracic surgery (IGAVATS) for lung biopsy|Uses a traditional deep anaesthesia and one-lung ventilation
224210379|NCT04218344|OTHER|60mls of blood donated for research analysis|All patients presenting with a possible Acute Coronary Syndrome will be invited to donate 60 mls of blood at the time of their angiogram.
224210380|NCT06650683|BEHAVIORAL|Pediatric HAH|Pediatric HAH nursing support for home nursery care provided by parents as part of their child's disease.
223620452|NCT05852080|BEHAVIORAL|multilevel system intervention based on information platform|"1. Standardized templates of medical record~2. Continuous medical quality control and feedback system: the hospital included in the study upload the medical records of all AIS patients by medical records scanning system. Quality control platform of Cerebral apoplexy in Zhejiang province extracts and analyze the data through the computer and calculates the percentage of stroke of undetermined cause.~3. Team collaboration based on video conferencing: hospitals will receive corresponding suggestions for their improvement from experts online.~4. Enhanced feedback incentives"
223620453|NCT00003239|BIOLOGICAL|Recombinant Interferon Alfa|Daily by subcutaneous injection.
224210381|NCT00047554|DRUG|Travoprost, 0.004% ophthalmic solution|
224210382|NCT01892605|BEHAVIORAL|music listening|The treatment group listened to Mozart K.448 for eight minutes once daily before bedtime for at least six months.
223620454|NCT00003239|DRUG|Cytarabine|Daily by subcutaneous injection.
223620455|NCT00003239|DRUG|Omacetaxine Mepesuccinate|Homoharringtonine is administered by continuous infusion on days 1-5.
224210383|NCT04721327|OTHER|remote CI programming|provision of CI programming provided remotely via Zoom in a 2 hour session
224210384|NCT00833976|DRUG|Lovaza|4 grams per day
224210385|NCT06702176|DEVICE|EXOPULSE MOLLII SUIT active|Exopulse Mollii suit is a new assistive device that has been developed by Exoneural Network (initially Inerventions AB), a Swedish med-tech company. Exopulse Mollii suit is a full-body garment with integrated 58 electrodes that can transcutaneously stimulate several groups of muscles. The device is CE labelled and is intended to use for reducing spasticity and improving blood circulation. The outfit is very easy to put on, it can be used for one hour every day and the analgesic effects last 24 hours or more. EXOPULSE Mollii suit consists of transcutaneous stimulation of several muscles by means of a feeble electric current (i.e., low frequency \~20 Hz, low-intensity 2mA), aiming to reduce pain. This treatment method theoretical background primarily refers to the theory of gate control. Based on this theory, the stimulation of large proprioceptive fibers would inhibit the nociceptive information transmitted by small fibers.
224210386|NCT06702176|DEVICE|EXOPULSE MOLLII SUIT (sham)|It consists of applying the same parameters used for the active session (low frequency: 20 Hz; current intensity: 2 mA; pulse width ranging from 25 to 175 µs) but for a shorter duration of time (1 minute).
224210387|NCT03911960|BEHAVIORAL|Acceptance and Commitment Therapy|2 in person and 5 telephone sessions of acceptance and commitment therapy for tobacco cessation plus up to 8 weeks of nicotine patch
224210388|NCT03911960|BEHAVIORAL|Enhanced Usual Care|2 in person sessions of tobacco cessation counseling, up to 8 weeks of nicotine patch, referral to state quitline.
224210389|NCT03515889|BEHAVIORAL|Ideal Protein Weight Loss Method|"An initial visit will take place in which each participant assigned to the experimental group will complete a health profile questionnaire.The Ideal Protein method will be explained and the participant will be weighed, measured and given diet related informational materials. A staff member will assist the participant with the selection of foods and snacks to ensure adequate quantity for the week. Weekly follow-up visits of 15 minutes duration will be implemented with a telephone follow-up occurring during the first 4 days after the initial appointment.~For 12 weeks Ideal Protein foods that are of the appropriate composition and quantity will be provided at weekly or twice monthly intervals as included in the diet. Dietary supplements will be provided (multivitamin, calcium/magnesium, potassium, omega-3, and Ideal Salt substitute)."
224210390|NCT03515889|BEHAVIORAL|Standard Weight Loss|"This arm utilizes evidence-based strategies that have been shown to be effective for long-term weight loss and weight loss maintenance (including behavioral techniques, diet modification, and social support) consistent with the 2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults. Participants in this arm will have an initial one hour consultation with a trained interventionist, where the fat goal and calorie restriction goal are explained.~For 12 weeks low-fat reduced calorie foods that are of appropriate composition and quantity will be provided at weekly or twice monthly intervals as included in the diet. Dietary supplements will be provided (multivitamin, calcium/magnesium, potassium, omega-3, and Ideal Salt substitute)."
224210391|NCT06700746|PROCEDURE|Prolotherapy|Prolotherapy is an injection of a relatively small volume of an irritant or sclerosing solution at sites of painful ligament and/or tendon insertions, and in adjacent joint space over the course of several treatment sessions
224210392|NCT06700746|DEVICE|Extracorporeal shock wave therapy (ESWT)|Extracorporeal shock wave therapy (ESWT), a kind of physical modalities, generating acoustic pulses, that are high positive pressure amplitudes, subsequently transferring concentrated energy to small focal distant areas of 2-8 mm in diameter
224210393|NCT06540482|DIAGNOSTIC_TEST|Reliability test|The test was administered two days apart to evaluate the reliability of the retest test.
224210394|NCT02670980|DEVICE|Intelligent Retinal Implant System|
224210395|NCT01518465|DRUG|dalteparin|Given SC
223620456|NCT03212118|BEHAVIORAL|Treatment as usual (TAU-0)|"The standard NAV procedure, which consists of a telephone call within 8 weeks to an employer who have employees on 100% sick leave, in addition to regular NAV conversations on-demand (not fixed intervals) between the NAV caseworkers and the employees."
223620457|NCT03212118|BEHAVIORAL|Structured talks (TAU-2)|Two structured talks (not including elements from motivational interviewing)
223620458|NCT03212118|BEHAVIORAL|motivational interviewing (MI)|Two structured talks (must have a valid motivational interviewing content).
223620459|NCT00290173|DRUG|efficacy of oral ritodrine in maintaining uterine quiescence|
224210396|NCT01518465|DRUG|lenalidomide|Given PO
223620460|NCT05513352|DEVICE|tACS - transcranial alternating current stimulation|"TACS is a non-invasive brain stimulation (NIBS) techniques that belong to the class of low current transcranial electric stimulation. In contrast to the better known transcranial direct current stimulation (tDCS), the tACS current is not constant, but alternates with a certain frequency.~The stimulation will be applied over the left temporo-parietal cortex at participants' individual alpha frequency. The stimulation intensity will be 2 milliampere (mA, peak-to-peak value, corresponding to a sine wave of ±1 mA amplitude). Stimulation will be delivered through conductive rubber electrodes."
223620461|NCT05513352|DEVICE|sham - transcranial alternating current stimulation|"During sham stimulation (placebo), tACS will be ramped up and down for 12 seconds , that is, no electric stimulation wil be applied during the actual experiment. The up and down ramping will be repeated at the end of the experiment.~The sham condition serves to evoke sensations associated with tACS stimulation, but without stimulating during the actual experiment."
224210397|NCT01518465|DRUG|dexamethasone|Given PO
223620462|NCT05513352|DEVICE|NF - Neurofeedback|"Neurofeedback (NF) is a non-invasive approach that combines neurophysiological recordings with real-time sensory feedback (most studies use visual feedback). Through real-time NF, individuals thus can learn to regulate their brain activity.~In this study, NF will be based on concurrent EEG recordings. During NF, participants will observe a space ship automatically navigating through a narrow tunnel. The modulation of their neural alpha power lateralization into the trained direction will be rewarded by the acceleration of the space ship, a modulation in the opposite direction will reduce speed and autopilot accuracy."
224210398|NCT01518465|OTHER|laboratory biomarker analysis|Correlative studies
224210399|NCT03872622|OTHER|Blood tests, intestinal biopsies, stool samples, environmental exposure questionnaire and FFQ questionnaire|Blood tests, intestinal biopsies, stool samples, environmental exposure questionnaire and FFQ questionnaire.
224210400|NCT05762120|OTHER|Weight Management Programme|"Weight Management Programme which consists of 4 phases:~1. Very low calorie diet~2. Low calorie diet~3. Maintenance phase~4. Continuance phase"
224210401|NCT06256731|DEVICE|Eye-Tracking|Eye-tracking technology and algorithms used to successfully capture and track eye movements using an electronic tablet and the embedded camera of the device.
224210402|NCT06539039|PROCEDURE|non surgical periodontal therapy|participants received full mouth one stage debridement using hand instruments and use of universal curette for sub gingival debridement and ultrasonic scalers through use of supragingival and subgingival ultrasonic tips
223620463|NCT04438694|BIOLOGICAL|Convalescent Plasma|Convalescent Plasma
223620464|NCT04438694|DRUG|Standard of Care|Standard of Care drugs administered as per Cairo University ICU protocol
224210403|NCT02433535|DRUG|Simvastatin|Simvastatin is used to lower cholesterol, however, it also possess anti-inflammatory and immunomodulatory properties that may also alleviate allergic airway inflammation in asthma.
224210404|NCT02433535|OTHER|Placebo|A placebo pill will be given to the placebo group. There will be no detectible differences between study drug pill and placebo pill.
224210405|NCT05898490|BEHAVIORAL|Animation Therapy|The process of shooting a stop-motion animation film, is designed according to the interests and leading of the participant.
224210406|NCT03461315|OTHER|Functional assistance model|Preventive home visits carried out by a Team Dedicated Exclusively to the Home Patient.
224210407|NCT01788137|DRUG|chemotherapy (CHOP)|Treatment Arm A (CHOP): cyclophosphamide(C), 750mg/m2 for injection on day1; doxorubicin(H), 50 mg/m 2 for injection on day1; and Vincristine(O), 1.4 mg/ m2 for injection on day1, prednisone(P) 60 mg/m2 orally on days 1 to 5. The therapy was repeated every 21 days for a total of 6 cycles
223620465|NCT00507169|DRUG|SVT-40776|
223620466|NCT05555875|BEHAVIORAL|IntelliCare Plus|Mobile-app-based digital mental health intervention for individuals struggling with depression and/or anxiety. The app reflects components of evidence-based psychological treatments such as cognitive-behavioral therapy.
224210408|NCT01788137|DRUG|chemotherapy(c-ATT)|Treatment Arm B (c-ATT):Alternative 3 regimen to be used sequentially(CHOPB→IMVP-16→DHAP).The therapy was repeated every 21 days for a total of 6 cycles.
224210409|NCT03414307|PROCEDURE|Intracerebral catheter placement|Image guided stereotactic placement of intra-hemorrhage catheters to evacuate intra-cerebral hemorrhage
224210410|NCT03414307|DEVICE|Robot-assisted intracerebral catheter|ROSA is a robotic device with trajectory planning software that can be used to aid in planning multiple trajectories to large, irregular clots, and aids in navigating into and out of the cerebral hematoma with minimum human error.
224210411|NCT00923728|DRUG|AVN944|
224210412|NCT00297492|BEHAVIORAL|Reduction Phone Counseling|Counseling of smokers to undergo gradual reduction in cigarettes per day prior to quit date. This includes 5 counseling calls: 3 calls focused on reduction prior to the quit date, 1 call two days prior to the quit date to discuss common strategies for preparing to quit, and 1 call two days after the quit date to discuss relapse prevention. Telephone counseling also discusses the proper use of nicotine lozenges during reduction and after the quit date.
224210413|NCT00297492|BEHAVIORAL|Abrupt Phone Counseling|Counseling of smokers to set a quit date and not change cigarettes per day prior to quit date. This includes 5 counseling calls: 1 to set a quit date, 1 two days prior to the quit date to discuss common strategies for preparing to quit, and 3 after the quit date to discuss relapse prevention. Telephone counseling also discusses the proper use of nicotine lozenges after the quit date.
224210414|NCT00297492|BEHAVIORAL|Minimal Abrupt Phone Counseling|Minimal counseling to mimic intervention at a primary care office. This includes 2 counseling calls: 1 to set a quit date and 1 two days after the quit date to discuss relapse prevention. Telephone counseling also discusses the proper use of nicotine lozenges after the quit date.
223620467|NCT04951830|DIAGNOSTIC_TEST|MRI|MRI of TMJ
223620468|NCT02738008|DRUG|ARC-520 Injection|IV injection
223620469|NCT02738008|DRUG|entecavir|All participants will take entecavir or tenofovir throughout the study. Participants will be instructed to take their medication daily.
223620470|NCT02738008|DRUG|tenofovir|All participants will take entecavir or tenofovir throughout the study. Participants will be instructed to take their medication daily.
223620471|NCT02738008|DRUG|antihistamine|All participants will be pretreated with an oral antihistamine. The antihistamine used should in general be an H1\>H2 receptor blocker and would include diphenhydramine 50 mg, cetirizine 10 mg, chlorpheniramine 8 mg or hydroxyzine 50 mg. The Investigator is free to choose any of these antihistamines available locally and consistent with their country's Marketing Authorisation.
223761623|NCT07171814|DRUG|Honghua Xiaoyao tablets|The non-exposed group (patients who did not receive Honghua Xiaoyao Tablets or other targeted drug treatments) only received routine clinical observation, and no drug intervention was applied after obtaining informed consent. If patients need to withdraw from the study due to their condition during the study period, on the premise that the patients have given full informed consent, doctors shall recommend other treatment regimens in accordance with clinical standards (when necessary, first-line drugs such as selective serotonin reuptake inhibitors (SSRIs) may be selected for intervention).
223761624|NCT04036500|DRUG|Estradiol|Patients will be given estradiol: 1 mg oral and 1 mg sublingual.
223761625|NCT02283788|DRUG|BIA 2-093|
223620472|NCT04621448|BEHAVIORAL|Moving Together|"Two-way livestreaming virtual group classes will be offered for 1 hour, 2 days/week for 12 weeks to all participants. Classes will be led by a trained instructor who will demonstrate all movements and will provide brief explanations for the goals of movements. Consistent with the in-person program, classes will focus on the 7 guiding principles of Moving Together:~1. repetition with variation (to promote procedural learning);~2. progressive, functional movements (to improve daily function);~3. slow pace and step-by-step instruction (to minimize cognitive demands);~4. participant-centered goal orientation (to enhance personal meaningfulness of movements);~5. body awareness, mindfulness and breathing (to encourage present-centeredness);~6. social interaction (to promote meaningful connection); and~7. positive emotions (to promote feelings of well-being."
223620473|NCT00004925|BIOLOGICAL|trastuzumab|
223620474|NCT00004925|DRUG|pegylated liposomal doxorubicin hydrochloride|
223620475|NCT03143530|PROCEDURE|Pectoralis block|Pectoralis block involving injection near the coracoid process in the fascial planes between both the pectoralis major and minor muscles (pecs I), and the fascial plane between the pectoralis minor and serratus anterior muscles (pecs II).
223620476|NCT03143530|DRUG|Normal saline injection|Pectoralis block involving injection of normal saline 30ml near the coracoid process in the fascial planes between both the pectoralis major and minor muscles (pecs I), and the fascial plane between the pectoralis minor and serratus anterior
223620477|NCT03143530|DRUG|Ropivacaine Injection|Pectoralis block involving injection of ropivacaine injection 30ml of 0,25% (75 mg) near the coracoid process in the fascial planes between both the pectoralis major and minor muscles (pecs I), and the fascial plane between the pectoralis minor and serratus anterior
223620478|NCT01735448|OTHER|Focus group|"Initially, ten focus groups with an average sample size of 5-7 participants each will be performed in two communities within South Australia, one being Adelaide and the other Murray Bridge, this includes focus groups held with healthcare workers.~The proposed focus groups will be conducted by experienced mediators who have undertaken Aboriginal cultural awareness training and have experience in qualitative research methods. Both mediators have also been involved in all aspects of project development and consultation with Aboriginal Elders and key stakeholders since its conception.~We will be using topic guides (reviewed by Aboriginal Elders and researchers) that will be semi-structured with open-ended questions designed to encourage group discussion around smoking cessation and the use of pharmacotherapies in particular, in addition to other objectives identified during the consultation phase of this research."
223620479|NCT01735448|OTHER|One-on-one interviews|One-on- one interviews will be held with both medical clinicians and key stakeholders and will be conducted by existing TQEH (The Queen Elizabeth Hospital), Clinical Practice Unit employees, experienced in qualitative research. Informed consent will be required and the interview will be audio taped to allow analysis of the qualitative data. All interviews will remain anonymous, unless the interviewee prefers to be named. In this case, they will be named in the acknowledgement section of all publications and presentations. Moderator guides have been developed and reviewed in the same process undergone by the focus group moderator guides
223620480|NCT01735448|OTHER|Survey|A four page survey will be administered to all focus group and interview participants in addition to select cohorts including tobacco related special interest groups of the Thoracic Society of Australia and New Zealand (TSANZ). The survey will include demographic data, smoking history and current smoking status (questions related to smoking for current tobacco users include the Fagerstrom test for nicotine dependence, multiple Likert scales for cravings, motivation to quit, confidence etc.) and Likert scales examining perceptions, attitudes and knowledge about tobacco use, cessation, prevention, health and research in the Aboriginal setting.
223620481|NCT04912778|OTHER|Filling in an online survey|Patients are asked to fill in an online survey regarding functional status, quality of life and symptoms of central sensitisation.
223620482|NCT03145311|PROCEDURE|Repetitive transcranial magnetic stimulation (rTMS)|
223620483|NCT03550378|DRUG|MEDI0382|Participants will receive subcutaneous MEDI0382 titrated from 50 μg upto 300 μg (50 μg once daily for 4 days, followed by 100 μg daily for 7 days, 200 μg daily for 7 days, and 300 μg daily for 14 days) for 32 days.
223620484|NCT03550378|DRUG|Placebo|Participants will receive SC placebo matched to MEDI0382 once daily for 32 days.
223620485|NCT04129502|DRUG|TAK-788|TAK-788 capsule
224210415|NCT00297492|DRUG|Pre-Quit Nicotine Lozenges|"2 mg lozenges for participants usually smoke their first cigarette more than 30 minutes after awaking.~4 mg lozenge for participants who usually smoke their first cigarette less than 30 minutes after awaking.~Replace each forgone cigarette during reduction with one lozenge. Use additional lozenges to combat cravings to smoke."
223620486|NCT04129502|DRUG|Pemetrexed|Pemetrexed IV infusion
223620487|NCT04129502|DRUG|Cisplatin|Cisplatin IV infusion
223620488|NCT04129502|DRUG|Carboplatin|Carboplatin IV infusion
223620489|NCT02519023|DRUG|Liposomal Bupivacaine|In one arm the TAP infiltration will contain 10 mL of 0.25 % bupivacaine with epinephrine injected followed by 20 mL of a 50:50 mixture of liposomal bupivacaine and normal saline. This will then be repeated on the contralateral side.
223620490|NCT02519023|DRUG|Bupivacaine|Surgical Infiltration of the study solution will be performed both prior to incision and at the end of surgery just prior to closure of incisions. At each time, the surgeon will inject 5 mL of 0.25% bupivacaine into each of the port site incisions.
223620491|NCT02519023|DEVICE|Ultrasound|An ultrasound, which is a beam of high frequency sound that allows one to visualize images in the body, will be used to aid investigators to observe the local anesthetic being infiltrated into the plane
223620492|NCT02519023|DRUG|Epinephrine|TAP infiltration will contain 10 mL of 0.25 % bupivacaine with epinephrine.
223620493|NCT02519023|DRUG|acetaminophen|all individuals will receive scheduled acetaminophen (1 gram every 6 hours),
224210416|NCT00297492|DRUG|Post-Quit Nicotine Lozenges|"2 mg lozenges for participants usually smoke their first cigarette more than 30 minutes after awaking.~4 mg lozenge for participants who usually smoke their first cigarette less than 30 minutes after awaking.~Replace each forgone cigarette while abstinent with one lozenge. Use additional lozenges to combat cravings to smoke."
224210417|NCT03367273|OTHER|skin biopsy|Lesional skin biopsy was taken from every patient. Also a skin biopsy was taken from every control subject
223620494|NCT02519023|DRUG|ibuprofen|all individuals will receive scheduled ibuprofen (800 mg every 8 hours)
223761626|NCT02283788|DRUG|Moxifloxacin|
223761627|NCT02283788|DRUG|Placebo|
223620495|NCT02519023|DRUG|Oxycodone|all individuals will receive PRN oxycodone 5-10mg q4h if pain is rated at more than 5 out of 10 on a numerical pain scale.
223620496|NCT05196607|OTHER|Survey|A dedicated survey on the use of mobile applications to all patients who were to be operated on a scheduled basis in our Surgery Service
223761628|NCT03787992|DRUG|Alflutinib Mesylate (AST2818) 80mg//40 mg+ placebo|"The initial dose of AST2818 80 mg once daily can be reduced to 40 mg once daily under specific circumstances. A cycle of treatment is defined as 21 days of once daily treatment.~Number of Cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria."
223761629|NCT03787992|DRUG|Placebo Gefitinib 250 mg|The initial dose of Placebo Gefitinib 250 mg once daily cannot be reduced. A cycle of treatment is defined as 21 days of once daily treatment. Number of cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.
223620497|NCT04916574|OTHER|Nasal Spray Containing Anti-SARS-CoV-2 Antibodies Derived from Bovine Colostrum|Concentration of active substance on nasal mucosal surface in time
223620498|NCT04590014|DEVICE|Conventional Precision Flow|Patients will be placed on HVNI therapy using Vapotherm's conventional HVNI device design (Precision Flow). Patients will receive HVNI therapy through an appropriately-fitted Prosoft dual-pronged nasal cannula. Physiologic and ventilation parameters will be recorded.
223620499|NCT04590014|DEVICE|HVNI HVT2.0 Device|Patients will be placed on HVNI therapy using Vapotherm's new HVNI device design (V2.0). Patients will receive HVNI therapy through an appropriately-fitted Prosoft dual-pronged nasal cannula. Physiologic and ventilation parameters will be recorded.
223620500|NCT00468299|DRUG|Misoprostol and placebo|Women in this group receive 800 mcg misoprostol plus a placebo
223620501|NCT00468299|DRUG|Mifepristone and misoprostol|This group receives mifepristone 200 mg orally; followed by 800 mcg misoprostol bucally
223620502|NCT01667289|RADIATION|Radiotherapy alone|Radiotherapy alone Technique: IMRT Total Dose: 50 Gy Per fraction: 2 Gy
223620503|NCT01667289|DRUG|Concurrent chemoradiation|"Concurrent chemoradiation~Chemotherapy:~Methotrexate 40 mg/m2 weekly X 5 Radiotherapy Technique: IMRT Total dose: 50 Gy Per Fraction: 2 Gy"
223620504|NCT05931757|DRUG|Olverembatinib|Olverembatinib will be taken 40mg qod from the time of diagnosis, and Blinatumomab will be given intravenously up to five cycles.
223620505|NCT05841368|DIAGNOSTIC_TEST|CAM-ICU|Delirium in adult patients will be screened according to CAM-ICU
223620506|NCT05841368|DIAGNOSTIC_TEST|pCAM-ICU|Delirium in adult patients will be screened according to pCAM-ICU
223620507|NCT03731832|DRUG|MLN9708|Study drug will be given as a single, oral dose of 4.0 mg weekly (day 1, 8 and 15) for 3 weeks, followed by 1 week without study drug in a 28-day cycle
223620508|NCT03731832|DRUG|Pomalidomide 4 MG Oral Capsule|Study drug will be given as an oral dose of 4.0 mg on day 1 until day 21, followed by 1 week without study drug in a 28-day cycle.
223761630|NCT03787992|DRUG|Gefitinib 250 mg|"The initial dose of Gefitinib 250mg once daily cannot be reduced. A cycle of treatment is defined as 21 days of once daily treatment.~Number of Cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria."
223620509|NCT03731832|DRUG|Dexamethasone|Dexamethasone will be administered as a single, oral dose of 40 mg/day weekly on day 1, 8, 15 and 22 in patients from 18 to 74 years old. For patients ≥ 75 years old dose has to be reduced to 20 mg/day with the same treatment schedule.
223761631|NCT03787992|DRUG|Placebo AST2818 80mg//40 mg|The initial dose of Placebo AST2818 80 mg once daily can be reduced to Placebo AST2818 40 mg once daily under specific circumstances. A cycle of treatment is defined as 21 days of once daily treatment. Number of cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.
223761632|NCT01275183|DRUG|raltegravir and cisplatin|"Cisplatin, intravenous, 30 mg/m2, days 2 and 16, 1 to 2 hours~Raltegravir, oral,400 mg, twice per day, days 1 through 5 or days 15 to 19~Part 2 (optional): Docetaxel, intravenous, 75 mg/M2, day 2, every 21 days, 3 to 6 cycles~Part 2 (optional): Cisplatin, intravenous, 75 mg/M2, day 2, every 21 days, 3 to 6 cycles~Part 2: (optional): Raltegavir, oral, 400 mg, twice per day, days 1 through 5, 3 to 6 cycles"
223761633|NCT01602276|PROCEDURE|Transcranial Direct Current Stimulation (tDCS)|Anodal, Cathodal or Sham tDCS
223761634|NCT00008346|DIAGNOSTIC_TEST|Full Field Digital Mammography|Radiologic test to screen women for Breast cancer using digital detectors
223620510|NCT03731832|DRUG|Cyclophosphamide|Cyclophosphamide will be administered once daily as an oral dose of 50 mg on cycle days 1 to 21, followed by one week without drug in a 28-day cycle.
223620511|NCT01746303|DIETARY_SUPPLEMENT|Omega-3 fatty acid|A fixed dose of 2.4 g/day (EPA: 1.6 g, DHA: 0.8 g; 4 capsules/d).
223620512|NCT01746303|DIETARY_SUPPLEMENT|Blueberry powder|Whole, freeze-dried blueberry powder made of 50%:50% mixture of Tifblue and Rubel blueberries.
223620513|NCT01746303|OTHER|Placebo oil|Corn oil capsules that are identical in size, shape, and color to omega-3 capsules.
223761635|NCT00008346|DIAGNOSTIC_TEST|Screen Film Mammography|Radiologic test to screen women for Breast cancer using plain film detectors a resolution screen
223761636|NCT02929576|DRUG|Enzalutamide|Enzalutamide will be administered as four 40-mg capsules once daily (160 mg/day).
223761637|NCT02929576|DRUG|Placebo|
223761638|NCT02929576|DRUG|Paclitaxel|Paclitaxel (90 mg/m2) will be administered by constant-rate intravenous infusion of ≤ 1 hour once weekly for 16 weeks. Dose reductions or alterations to the schedule are allowed to maintain patient safety.
223761639|NCT04641923|OTHER|Adhesion barrier|Adhesion barrier application at the time of first surgery
224210418|NCT05891873|DIAGNOSTIC_TEST|CAM-ICU|Patients who meet the inclusion criteria will be screened daily for delirium using the screening test mentioned above.
224210419|NCT05891873|DIAGNOSTIC_TEST|ICDSC|Patients who meet the inclusion criteria will be screened daily for delirium using the screening test mentioned above.
224210420|NCT05891873|DIAGNOSTIC_TEST|4AT|Patients who meet the inclusion criteria will be screened daily for delirium using the screening test mentioned above.
224210421|NCT05891873|DIAGNOSTIC_TEST|p(s)CAM-ICU|Patients who meet the inclusion criteria will be screened daily for delirium using the screening test mentioned above.
223620514|NCT01746303|OTHER|Placebo powder|Placebo powder matched for color, taste, and sugar content as closely as possible and milled similarly to the blueberry powder.
224210422|NCT05891873|DIAGNOSTIC_TEST|CAPD|Patients who meet the inclusion criteria will be screened daily for delirium using the screening test mentioned above.
223620515|NCT00799201|DRUG|Naloxone and Docusate|Naloxone 6mg (15 mL) every 6 hours plus docusate sodium liquid 10 mL (100mg) every 12 hours
223761640|NCT01083433|BEHAVIORAL|Diabetes related psychological counseling and education|The psychology intervention is based in part on an intervention to maintain parental support for diabetes care in adolescence which was developed by Anderson and colleagues (1999). The first session will include education to parents and children regarding the importance of sharing responsibility for treatment related tasks. The second session will include a discussion of the treatment sharing plan developed at the first visit and problems that may have occurred will be discussed. The third session will include a discussion of planning for possible future problems. Visits 1, 2, and 3 will include 30 minutes of diabetes education.
223761641|NCT01083433|DEVICE|Continuous Glucose Monitor|Patients in the intensive diabetes clinic plus CGM group will wear the iPro after the baseline visit followed by every month for 4 months.
223761642|NCT02242877|DRUG|Telmisartan|
223761643|NCT02242877|DRUG|Telmisartan combined with hydrochlorothiazide|
223761644|NCT04722640|DRUG|SKYRIZI|SKYRIZI
224210423|NCT05891873|DIAGNOSTIC_TEST|MASTcz (The Mississippi Aphasia Screening Test)|People with aphasia will be examined by a skilled speech therapist.
224210424|NCT05891873|DIAGNOSTIC_TEST|EEG|Patients with positive delirium will undergo EEG examination. 10-min native EEG.
224316081|NCT02121873|DEVICE|Ductal lavage microcatheter|Upon completion of the nipple aspiration procedure, subjects will undergo a nipple block with local anesthesia. The duct will be lavaged with the ductal lavage microcatheter. Samples will be immediately processed for shipping to Covance for WGS. Subjects will be contacted 24 hours and again 2 weeks after the procedure to collect any untoward effects of participating in the study.
224316082|NCT02121873|DEVICE|Blood draw|Blood will be drawn and immediately processed for shipping to Covance for WGS.
224210425|NCT02664766|BEHAVIORAL|Exercise training program|Supervised 8-week exercise training program. Aerobic exercise (walking, jogging) of increasing duration at 50-60% HRR, at least two sessions per week. Participants will be recording their daily alcohol consumption. Participants will also undergo three trials of acute exercise (before, at the 4th week and at the 8th week of exercise training) in order to investigate whether exercise training can lead to changes in acute responses to exercise. Each trial involves 30 min of exercise on a cycle ergometer at 50-60% HRR.
224210426|NCT05233774|DRUG|Allogeneic MSC|An allogeneic bone marrow-derived medicinal signaling cell (MSC) formulation
224316083|NCT04851392|DRUG|Cannabis with delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD)|Cannabis with delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) - inhaled and vaporised cannabis flower
224210427|NCT05233774|OTHER|Placebo|Placebo
224316084|NCT04851392|DRUG|Cannabis with THC without CBD|Cannabis with THC without CBD - inhaled and vaporised cannabis flower
224316085|NCT04851392|DRUG|Placebo cannabis|Placebo cannabis, without THC and without CBD - inhaled and vaporised
224316086|NCT00451048|DRUG|sunitinib malate|Given orally
224316087|NCT03988686|PROCEDURE|Radical prostatectomy plus standard care|To add radical prostatectomy on the basis of current standard of care for those with oligometastatic prostate cancer
224316088|NCT03988686|DRUG|Standard of care for metastatic prostate cancer|androgen deprivation therapy with or without other systemic therapies based on current guidelines for metastatic prostate cancer
223620516|NCT04002076|BEHAVIORAL|Robot-assisted hand combined with occupational therapy|Robot-assisted hand group contains 15 minutes of grasp and release motion, 15 minutes of visual feedback training and 30 minutes traditions occupational therapy. Traditional occupational therapy includes cognition training, sensory-motor function therapy, passive ROM exercise, functional hand training, activity of daily living skill training, instruction of using assistive devices,and so on.
224316089|NCT02974712|DRUG|Fentanyl|
224316090|NCT02974712|DRUG|Saline|
224316091|NCT03571412|DEVICE|repetitive Transcranial Magnetic Stimulation|Subject will receive 5Hz LDLPFC or 5Hz DMPFC rTMS
224316092|NCT03079635|DIETARY_SUPPLEMENT|Control|Beverage provided and a four hour postprandial assessment of energy metabolism using a metabolic cart and appetite using a visual analog scale follows.
224316093|NCT03079635|DIETARY_SUPPLEMENT|Omega 3 fatty acids|Beverage provided and a four hour postprandial assessment of energy metabolism using a metabolic cart and appetite using a visual analog scale follows.
224316094|NCT05913505|BEHAVIORAL|OSC+|The first session of the HRVB intervention will focus on introducing the client to HRVB and calculating the participant's resonance frequency which typically range from 4.5-7 breaths per minute. Participants will first complete a five-minute baseline breathing condition. Following the breathing condition, the participants will complete five conditions for five minutes each. Specifically, each condition will have the person breath at 6, 6.5, 5.5, 5, and 4.5 breaths per minute with a minute break between. Session two will focus on practicing resonance frequency breathing and solidifying the correct resonance frequency for the participant. Additionally, this session will introduce the technique of breathing through pursed lips and abdominal breathing. For sessions three through five, participants will practice resonance frequency breathing and review previous strategies.
223620517|NCT04002076|BEHAVIORAL|Traditional occupational therapy|Occupational therapy contains 60 minutes of traditional occupational therapy, which includes cognition training, sensory-motor function therapy, passive ROM exercise, functional hand training, activity of daily living skill training, instruction of using assistive devices,and so on.
223761645|NCT01895894|DRUG|Mycophenolate mofetil|Mycophenolate mofetil 20\~30mg/kg/day PO until nephrotic syndrome relapse (max. 1 year)
223761646|NCT04982029|DRUG|Cannabidiol 100 MG/ML [Epidiolex]|600mg
223761647|NCT04982029|DRUG|Placebo|Matching placebo
223761648|NCT05458856|DRUG|Triptorelin embonate 22.5 mg|A prolonged release formulation of triptorelin pamoate 22.5 mg 6-month formulation in D, L-lactide-co-glycolide polymers for single subcutaneous injection on Day 1 and Day 169
224210428|NCT05833373|DEVICE|Vagal stimulation with the device tVNS from tVNS Technologies GmbH|The tVNS device is used to stimulate the Ramus auricularis of the Nervus vagus with a dedicated ear electrode for at least one hour per day on a daily basis. Stimulation frequency is 20Hz, pulsewidth is 200µs and amplitude is determined individually.
224210429|NCT05833373|DEVICE|Sham stimulation with the device tVNS from tVNS Technologies GmbH|The tVNS device is used to stimulate the Ramus auricularis of the Nervus vagus with a dedicated ear electrode for at least one hour per day on a daily basis. In this case to perform a sham stimulation a non conducting ear electrode is used. The device is set to the same settings with a frequency of 20Hz, a pulsewidth of 200µs and an amplitude that is determined individually.
224210430|NCT06522230|OTHER|Fascial Stretch Therapy|Fascial Stretch Protocol uses a combination of circumduction, traction, proprioceptive neuromuscular facilitation (PNF) and specific FST maneuvers. Stretch is applied in both active \& passive methods taking into consideration: (1) Oscillatory - slow passive joint oscillations (back and forth movement in a regular rhythm). Small controlled oscillations help with proprioceptors around the joints, acilitates blood flow, gently stretches the ligaments, tendons, nerves, \& muscles and slows the nervous system down; (2) Traction - allows for assessment of the joint capsule movement and to decompress the joint. (3) Movement - designed to enhance the reflexes and are intentionally gentle to maximize benefits; (4) PNF - helps improve flexibility by alternating muscle contractions and relaxations. This stimulates the neuromuscular system, allowing muscles to relax deeper and increase range of motion. (5) Breath - allows the body to increase oxygen consumption to facilitate recovery.
224210431|NCT03519022|DRUG|Cocaine|The pharmacodynamic effects of cocaine will be determined during maintenance on placebo and duloxetine.
223761649|NCT05099328|BEHAVIORAL|Recast Therapy|Recast therapy is when a interventionist uses the child's own productions as a platform for restating or recasting the child's speech with corrections or alterations to focus on a particular syntax target.
223761650|NCT05099328|BEHAVIORAL|Syntax Stories|Syntax stories are specially constructed stories read verbatim designed to teach a syntax target.
224210432|NCT03519022|DRUG|Placebo oral capsule|The pharmacodynamic effects of placebo will be determined during maintenance on placebo and duloxetine.
223761651|NCT03882606|DEVICE|Scharioth Macula Lens (SML, Medicontur)|magnifying intraocular lens for pseudophakic patients implanted in the ciliary sulcus in one eye of each patient
223761652|NCT02882282|OTHER|Laboratory Biomarker Analysis|Correlative studies
223761653|NCT02882282|OTHER|Patient Observation|Undergo observation
223761654|NCT02882282|BIOLOGICAL|Pembrolizumab|Given IV
223761655|NCT05836597|DEVICE|Virtual reality|Virtual reality
224210433|NCT03519022|DRUG|Methylphenidate|The pharmacodynamic effects of methylphenidate maintenance will be determined during maintenance on placebo and duloxetine.
224210434|NCT02359734|OTHER|Smart pump safety Intervention bundle for improving IV medication administration process with smart pump|Smart pump safety intervention bundle includes three components--1) eliminating unauthorized medications; implement standardized discontinuation policy of medications, implement standardized keep vein open rates and keep vein open rate order sets, and implement standardized verbal order practice. 2) Implement standardized intravenous(IV) labeling and IV tubing labels. 3) Implement standardized drug library lists and drug library use policies
224210435|NCT06209424|BEHAVIORAL|Habitual Activity|Participants will maintain habitual levels of physical activity (inclusive of structured physical activity).
224210436|NCT06209424|BEHAVIORAL|Step-Reduction|Participants will be required to reduce their daily step-counts to \<2,000 steps/day. Further, they will be required to refrain from structured physical activity.
224210437|NCT06209424|BEHAVIORAL|Resistance Exercise|Participants will undergo a 50-minute resistance exercise protocol, which includes multiple sets of different exercises using weights. Each set will consist of 10 repetitions at 75% of their 1 repetition maximum (1RM). The exercises include bench press superset with lat pulldowns, overhead press superset with seated cable rows, leg press, and leg extensions with 90s rest in between sets. Before the exercise protocol, there will be a standardized 10-minute warm-up that involves cycling, leg swings, arm circles, bodyweight squats, and bench push-ups
224210438|NCT00137358|PROCEDURE|Radiation Therapy|
224210439|NCT00137358|DRUG|Cisplatin|
224210440|NCT00137358|DRUG|Amifostine|
224210441|NCT03633019|DRUG|rhTPO|high dose rhTPO ih
223761656|NCT03057626|OTHER|Cytology Specimen Collection Procedure|Undergo collection of blood and urine
223761657|NCT03057626|OTHER|Laboratory Biomarker Analysis|Correlative studies
223761658|NCT03057626|OTHER|Quality-of-Life Assessment|Ancillary studies
223761659|NCT06484153|DRUG|Pirfenidone|Two doses of pirfenidone (200 mg,tid,po;500 mg,tid,po) were set up. Using the 3+3 design, the DLT observation period is 28 days.
223761660|NCT06484153|DRUG|Fruquintinib|3mg, orally, qd
223761661|NCT06484153|DRUG|Pembrolizumab|200mg iv every 3 weeks
223761662|NCT02252887|DRUG|Gemcitabine|
223761663|NCT02252887|DRUG|Trastuzumab|
223761664|NCT02252887|DRUG|Pertuzumab|
223761665|NCT04626518|BIOLOGICAL|Pembrolizumab|Administered via IV infusion at a dose of 200 mg Q3W or 400 mg Q6W
223761666|NCT04626518|BIOLOGICAL|MK-4830|Administered via IV infusion at a dose of 800 mg Q3W
223761667|NCT04626518|DRUG|Belzutifan|Administered via oral tablet at a dose of 120 mg QD
223761668|NCT04626518|DRUG|Lenvatinib|Administered via oral capsule at a dose of 20 mg QD
223761669|NCT04626518|BIOLOGICAL|Pembrolizumab/Quavonlimab|Administered via IV infusion at a dose of 400 mg/25 mg Q6W
223761670|NCT04626518|BIOLOGICAL|Favezelimab/Pembrolizumab|Administered via IV infusion at a dose of 800 mg/200 mg Q3W
223761671|NCT05593653|DRUG|Suvorexant|20mg taken at bedtime for 4 weeks
223761672|NCT05593653|DRUG|Placebo|placebo taken at bedtime for 4 weeks
223620518|NCT06185465|DEVICE|Prontosan Wound Irrigation Solution|After debridement surgery, the test group is selected according to the randomization number of enrollment. For experimental group, Prontosan Wound Irrigation Solution is extracted with syringe (Dosage 1-2ml/cm2), and the wound is rinsed 1 cm from the wound. Then, Prontosan wound irrigation solution is used to saturate the gauze, and the gauze is applied to the wound for 15 minutes. After removing the gauze, cover it with oil gauze, then cover it with 8 layers of gauze and wrap it with a bandage.
223620519|NCT06185465|DEVICE|Normal Saline|After debridement surgery, the test group is selected according to the randomization number of enrollment. For control group, normal saline is extracted with syringe (Dosage 1-2ml/cm2), and the wound is rinsed 1 cm from the wound. Then, normal saline is used to saturate the gauze, and the gauze is applied to the wound for 15 minutes. After removing the gauze, cover it with oil gauze, then cover it with 8 layers of gauze and wrap it with a bandage.
223620520|NCT05081895|DEVICE|Electrical Impedance tomography|Patients will be monitored with electrical impedance tomography during routine care with special attention to effects of neuromuscular blockade and postural changes.
223620521|NCT05081895|OTHER|Lung mechanics and gas exchange|Patient lung mechanics and gas exchange will be monitored during routine clinical care, with specific attention to postural changes and use of neuromuscular blockade.
223620522|NCT04802330|OTHER|Questionnaire|Assessment of causes of FGM Beni Suef localities. 3. Explore the relationship between some of the social and demographic variables such as age, education, place of residence, marital status, religion and economic level and practice of FGM.
223620523|NCT05444556|DRUG|Imlunestrant|Administered orally.
223620524|NCT05444556|DRUG|Repaglinide|Administered orally.
223620525|NCT05444556|DRUG|Omeprazole|Administered orally.
223620526|NCT05444556|DRUG|Dextromethorphan|Administered orally.
223620527|NCT05444556|DRUG|Quinidine|Administered orally.
223620528|NCT05444556|DRUG|Rosuvastatin|Administered orally.
223620529|NCT05444556|DRUG|Digoxin|Administered orally.
223620530|NCT06110663|DRUG|HS-10241+ Almonertinib|HS-10241 300mg twice daily (BID) combined with Almonertinib 110mg once daily (QD) orally, for every cycle of 21 days until disease progression or other criteria for treatment discontinuation will be met.
223620531|NCT06110663|DRUG|Pemetrexed + Cisplatin /Carboplatin|"The standard chemotherapy treatment of cisplatin/carboplatin combined with pemetrexed for 4\~6 cycles (every 3 weeks).~Participants will continue receive pemetrexed monotherapy until disease progression or other criteria for treatment discontinuation will be met."
223620532|NCT01847352|DRUG|Intravenous administration of ferric carboxymaltose|Intravenous administration of ferric carboxymaltose 15mg/kg up to a maximum dose of 1000mg
223761673|NCT04389216|DEVICE|Cool-tip electrode for Radiofrequency Ablation|Radiofrequency ablation of the tumour in the surgery group, associated whith axillary surgery when applicable
223761674|NCT06259409|DEVICE|Regenn® Negative Pressure Therapy System|Controlled application of negative pressure (i.e., reduced atmospheric pressure or mild vacuum) to manage the wound environment.
224210442|NCT04446819|DEVICE|Compression gloves|Patients wear small-size compression gloves (one or two size smaller than suitable size) for dominant hands and suitable-size compression gloves for non-dominant hands for 90 minutes during the administration of albumin-binding paclitaxel (start from 30 minutes before albumin-binding paclitaxel infusion).
224210443|NCT03096717|DIAGNOSTIC_TEST|colonoscopy and histology|colonic biopsies for detection of dysplasia
224210444|NCT03365219|DEVICE|Alexis O-Ring Wound Retractor|A flexible self-retaining plastic Alexis retractor was used in place of standard surgical retractors.
224210445|NCT03365219|OTHER|Standard Surgical Retractors|Routine hand-held metal retractors as needed by the surgical team
224210446|NCT01291719|DEVICE|glucose and insulin infusions|combined algorithm directed glucose and insulin infusion with 5 minute blood glucose measurements to direct glucose control; regular insulin and glucose are infused intravenously as adjusted by the algorithm without manual intervention in the group of diabetic individuals under study to adjust the glucose level to a target range of 80-180 mg/dl
224210447|NCT05578417|OTHER|No Intervention|As this is an observational study, no intervention will be administered.
223620533|NCT01847352|OTHER|Subacute hypoxic exposures|Exposure to six hours of isocapnic hypoxia with end-tidal partial pressure of oxygen clamped at 55 Torr, with and without prior iron infusion
223620534|NCT01071681|DRUG|Telmisartan (Kinzal/Pritor, BAY68-9291)|Patients under daily life treatment receiving Pritor according to local drug information.
223620535|NCT04771832|PROCEDURE|ERAS|Enhanced Recovery After Surgery (ERAS) protocol is an evidence-based multimodal perioperative protocol focused on stress reduction and the promotion of a return to function
223620536|NCT01043172|DRUG|Gemcitabine|Gemcitabine : 1000 mg/m2/day D1,8,15 Repeated every 4 weeks 6 cycles
223620537|NCT02570503|DRUG|Ropivacaine|Ropivacaine (5mg/ml)-50ml
223620538|NCT02570503|DRUG|Ketorolac|ketorolac (30mg/ml)- 1 ml
223620539|NCT02570503|DRUG|Clonidine|clonidine (0.1mg/ml)- 0.8ml
223620540|NCT02570503|DRUG|Epinephrine|epinephrine (1mg/ml)-1ml
223620541|NCT02570503|DRUG|0.9% sodium chloride|Sodium chloride 0.9%- 47.7 ml
223620542|NCT01464086|OTHER|whole body MRI|whole body MRI at inclusion, one and two years
223761675|NCT06259409|DEVICE|Prevena™ Incision Management System|Controlled application of negative pressure (i.e., reduced atmospheric pressure or mild vacuum) to manage the wound environment.
223761676|NCT02227524|OTHER|No device|Compare walking function and ability in a sample of persons with MS under four different assistive device conditions: no device, single-point cane (SPC), four-point cane (FPC) and trekking pole (TP).
223761677|NCT02227524|DEVICE|Single-point cane (SPC)|Compare walking function and ability in a sample of persons with MS under four different assistive device conditions: no device, single-point cane (SPC), four-point cane (FPC) and trekking pole (TP).
224210448|NCT02359084|BEHAVIORAL|Family Navigation|
224210449|NCT02359084|BEHAVIORAL|Conventional Care Management|
223620543|NCT02823769|DEVICE|SI-R21204 resin composite|Primary caries of posterior teeth will be restored using SI-R21204 resin composite. Procedures will be done under local anesthesia if necessary. The preperation and restoration of the tooth will be done according to to the guidelines for ordinary restorative techniques.
223620544|NCT02823769|DEVICE|Nanohybrid resin composite|One of the cavities will be restored with a nanohybrid resin composite (Clearfil Majesty) as a control restoration wth ordinary restorative techniques.
223620545|NCT05534217|BIOLOGICAL|corneal debridement of corneal abrasion|Surgical debridement for traumatic corneal epithelial abrasions
223620546|NCT04264442|DRUG|Losmapimod|Patients will receive Losmapimod 15 mg by mouth twice daily for a total of 30 mg daily until 90 days after commercial drug is available post regulatory approval or until the study is discontinued by the Sponsor. The study drug should be taken with food and the date and time of each dose taken should be recorded in the subject diary.
223620547|NCT03826940|DRUG|Lovastatin 60 MG|60 MG Lovastatin per day for 3 consecutive days
223620548|NCT03826940|DRUG|Placebos|60 MG Placebo per day for 3 consecutive days
223620549|NCT06141707|OTHER|Arabic pediatric sleep questionnaire|Pediatric Sleep Questionnaire (PSQ) developed and validated by chervil et al. (2000) is a 22 item questionnaire which had been shown to have a sensitivity of 81% and specificity of 87% for SRBD.These scales for childhood SRBDs, snoring, sleepiness, and behavior are valid and reliable instruments that can be used to identify SRBDs or associated symptom-constructs in clinical research when polysomnography is not feasible.
223620550|NCT05348486|RADIATION|Dose escalation|Dose escalation 75,9 - 79,2 Gy in 33 fractions for GTV hypoxic or any hypoxic LN \> 2cm
223620551|NCT06114186|DEVICE|FAM intervention consisting of a Follower of glucose data, Action Plan, and Remote Monitoring of glucose data|using remote monitoring and real-time glucose data sharing with a Follower.
223620552|NCT06114186|OTHER|standard of care|self reported HbA1C or GMI
223620553|NCT01623479|DRUG|bimatoprost 0.03%|Subjects with hypotrichosis of the eyelashes using bimatoprost 0.03% (Latisse®) as prescribed by physician for at least 12 months
223620554|NCT01384734|DRUG|BMS-663068 400 mg|Tablets, Oral, 400 mg, twice daily (BID), 24+ weeks until optimal dose is selected, or 96 weeks if optimal dose
223620555|NCT01384734|DRUG|BMS-663068 800 mg|Tablets, Oral, 800 mg, twice daily (BID), 24+ weeks until optimal dose is selected, or 96 weeks if optimal dose
224210450|NCT01774695|BEHAVIORAL|Increased physical activity|"The subjects were encouraged to increase their level of physical activity for 12 weeks in the previous study.~The advice was individual but was based on the recommendations of the Swedish National Institute of health. The recommendation for increasing cardiorespiratory fitness is 20-60 minutes of moderate to vigorous intensive physical activity 3 to 5 days per week."
224260509|NCT05119504|BEHAVIORAL|Multi-Health Behavior|The multi health behavior condition will include didactic material focused broadly on healthy lifestyle recommendations including physical activity. It will also emphasize that physical activity is one of several interconnected health behaviors including balanced diet, sleep, stress management. All participants will receive a two-week physical activity prescription based on national guidelines recommending 150 minutes of at least moderate intensity physical activity per week.
224260510|NCT04942496|DRUG|Chlorhexidine Gluconate|Antimicrobial Skin Wash
223620556|NCT01384734|DRUG|BMS-663068 600 mg|Tablets, Oral, 600 mg, once daily (QD), 24+ weeks until optimal dose is selected, or 96 weeks if optimal dose
223761678|NCT02227524|DEVICE|Four-point cane (FPC)|Compare walking function and ability in a sample of persons with MS under four different assistive device conditions: no device, single-point cane (SPC), four-point cane (FPC) and trekking pole (TP).
223620557|NCT01384734|DRUG|BMS-663068 1200 mg|Tablets, Oral, 1200 mg, once daily (QD), 24+ weeks until optimal dose is selected, or 96 weeks if optimal dose
223620558|NCT01384734|DRUG|Raltegravir 400 mg|Tablets, Oral, 400 mg, twice daily (BID), 24+ weeks until optimal dose is selected, or 96 weeks if optimal dose
223620559|NCT01384734|DRUG|Tenofovir 300 mg|Tablets, Oral, 300 mg, Once daily (QD), 24+ weeks until optimal dose is selected, or 96 weeks if optimal dose
223620560|NCT01384734|DRUG|Ritonavir 100 mg|Tablets, Oral, 100 mg, Once daily, 96 weeks
223620561|NCT01384734|DRUG|Atazanavir 300 mg|Capsules, Oral, 300 mg, Once daily, 96 weeks
223620562|NCT01528930|DRUG|Amikacin|500 mg, once daily for 2 years
223620563|NCT02634385|PROCEDURE|Renal Artery Embolization|Patients will be receiving embolization prior to planned partial nephrectomy.
223761679|NCT02227524|DEVICE|Trekking pole (TP).|Compare walking function and ability in a sample of persons with MS under four different assistive device conditions: no device, single-point cane (SPC), four-point cane (FPC) and trekking pole (TP).
223761680|NCT05436470|DEVICE|PK Papyrus|The PK Papyrus is a balloon mounted stent that will be administered during standard of care treatment of pseudoaneurysms.
223620564|NCT02634385|PROCEDURE|Partial Nephrectomy (Surgical Resection)|Patients will be undergoing planned partial nephrectomy post embolization.
223620565|NCT02991638|DRUG|Ibrutinib|Relapsed / refractory chronic lymphocytic leukemia and Waldenstrom macroglobulinaemia (lymphoplasmacytic lymphoma): 420 mg daily Relapsed / refractory mantle cell lymphoma: 560 mg daily Relapsed / refractory indolent B-cell non-Hodgkin lymphoma: 560 mg daily Treatment is continued until disease progression
223620566|NCT01290523|DEVICE|Selective internal radiation therapy of the liver with Yttrium-90 glass microspheres (TheraSphere)|Administration of Yttrium-90 TheraSphere glass microspheres into the hepatic artery
223620567|NCT03071263|DRUG|Patiromer|2 packets/day starting dose, administered orally
223761681|NCT01253616|DEVICE|vagus nerve stimulation (VNS)|Daily stimulation synchronized with tones at the study assigned dose (amplitude, frequency, on/off cycle and treatment period).
223761682|NCT00196950|BIOLOGICAL|Meningococcal (vaccine)|
223761683|NCT00222469|DRUG|bevacizumab|10mg/kg IV on Day 1 Q 2 weeks
223620568|NCT03071263|DRUG|Placebo|2 packets/day starting dose, administered orally
223620569|NCT03071263|DRUG|Spironolactone|25 mg tablet/day starting dose, administered orally
223761684|NCT00222469|DRUG|gemcitabine|1000mg/m2 as fixed-rate infusion at 10mg/m2/min on Day 1 and Q 2 weeks.
224260511|NCT04942496|DEVICE|Hibi Universal Bathing System|Cloths used for patient bathing
224260512|NCT04942496|OTHER|0.1% SLS|Positive control
224260513|NCT04942496|OTHER|Distilled Water|Negative Control
224260514|NCT00370539|DRUG|verteporfin, bevacizumab, triamcinolone acetonide|
223620570|NCT05569902|DEVICE|active tACS|transcranial alternating current stimulation is a non-invasive method of entraining specific frequency bands in the brain by applying weak intensities of electric current in a desired shape and phase to the desired brain regions.
223620571|NCT05569902|DEVICE|sham tACS|transcranial alternating current stimulation is a non-invasive method of entraining specific frequency bands in the brain by applying weak intensities of electric current in a desired shape and phase to the desired brain regions.
223620572|NCT00002781|DRUG|boronophenylalanine-fructose complex|
223620573|NCT05839574|DRUG|MTX monotherapy|MTX in a single dose of 100 mg intravenously and 50 mg in intra-amniotic injection (day 0), along with 30 mg potassium chloride in case of positive fetal heartbeat (FH), and subsequent hysteroscopic evacuation of products of conception (POC)
223620574|NCT05839574|DRUG|MTX + letrozole add-on|MTX in a single dose of 100 mg intravenously and 50 mg in intra-amniotic injection (day 0), along with 30 mg potassium chloride in case of positive fetal heartbeat (FH) + Letrozole in a daily dose of 5 mg (2 x 2.5 mg) orally for 10 days from day 0, and subsequent hysteroscopic evacuation of products of conception (POC)
223620575|NCT05101434|DIAGNOSTIC_TEST|Periodontal Probing|with the help Michigan probe, periodontal pocket measurement was done.
223620576|NCT01665469|DIETARY_SUPPLEMENT|Tomato extracted lycopene|
223620577|NCT01665469|DIETARY_SUPPLEMENT|Placebo|
223620578|NCT02854046|OTHER|Calcific Uremic Arteriolopathy|
223620579|NCT01917747|BEHAVIORAL|Patient Navigator|The patient navigator group will involve regular phone contact with the patient navigator. The patient navigator will contact the participant by phone to conduct an interview and provide education on infant hearing and diagnostic hearing services. The timing of the subject child's appointment and the instructions of the outpatient auditory brainstem response test are discussed. In the second part of the study, further educational tools are given to parent(s) and discussion of additional follow up mechanisms, including community hearing services and types of interventions for pediatric hearing loss is imparted.
223761685|NCT00222469|DRUG|oxaliplatin|100mg/m2 on Day 2 and Q 2 weeks.
223620580|NCT01917747|BEHAVIORAL|Standard scheduling and follow-up|The subjects will have access to discuss any questions or concerns with our office or audiology staff, as is the standard of care practice. They will not be contacted by study personnel or the patient navigator after discharge from the hospital and before the initial diagnostic test or before any subsequent auditory brainstem response test. The patients may contact and be contacted by our clinic staff regarding scheduling or rescheduling of the hearing test, as is standard practice.
223620581|NCT05370976|DRUG|Cytotect®CP|"Cytotect®CP in two phases:~Induction phase: 1 ml/kg/week for 4 weeks Maintenance phase: 1 ml/kg/2 weeks for 12 weeks or corticosteroid dose \< 0.5 mg/kg, according to which condition occurs first.~Patients developing CMV infection under Cytotect®CP must be given standard anti-CMV treatment (Gancyclovir or Foscarnet) according to their center procedure. Cytotect®CP will be maintained"
223620582|NCT05710315|DEVICE|RELiZORB™|RELiZORB cartridges will be used with routine enteral feedings for 5 days for randomized participants
223620583|NCT05710315|OTHER|Placebo|Placebo cartridges will be used with routine enteral feedings for 5 days for randomized participants
223620584|NCT04492410|OTHER|rapid serological test|screening using a rapid serological test with a drop of blood from a finger prick
223620585|NCT00603330|BIOLOGICAL|Mesenchymal stem cells|Mesenchymal Stem Cell infusion
223620586|NCT03692559|OTHER|full aseptic dressing|Replacement of the central venous catheters in the dressing process
223620587|NCT02976714|OTHER|spontaneous sputum|"CF patients carry a spontaneous sputum that is made in the context of bronchial drainage sessions conducted as part of usual care (inclusion, 6 months, 12 months, 18 months).~The collection of spontaneous sputum is carried out within the bronchial drainage sessions, which are routinely performed at each visit. The spontaneous sputum is collected in a sterile container. In order not to contaminate the sputum with buccal epithelial cells will be asked patients to rinse the mouth before expectorate."
223620588|NCT00093210|DRUG|rFIX|
223761686|NCT05168475|BIOLOGICAL|Rituximab|Hospital stock of rituximab used as intervention; biosimilars are allowed
224210451|NCT04372212|DEVICE|Hernia sac inversion and Snaring|"Vertical trans umbilical 5-mm incision \[Point A\] is made and 5-mm trocar passed under vision using open technique. Pneumoperitoneum is then established with CO2 flow of 1.5-2.5 L/min.~Both SGDs were used to invert the hernia sac. Then, modified polypectomy snare (SN) was introduced via the trocar at point B and opened inside the abdomen. SGD-C passed inside the loop of SN and re-catches the hernial sac, which was then twisted around its neck several times. SN was closed tightly at the proper neck and coagulation diathermy current was applied to it leading to separation of the hernia sac. Detached sac (grasped by SGD-C) is then pushed antegradely out through the umbilical port."
224210452|NCT04313023|DRUG|PUL-042 Inhalation Solution|20.3 µg Pam2 : 29.8 µg ODN/mL (50 µg PUL-042) PUL-042 Inhalation Solution
223620589|NCT00093210|DRUG|rFIX-R|
223620590|NCT02997501|PROCEDURE|T790M+ Testing|The patient will need to have T790M+ testing
223620591|NCT02997501|PROCEDURE|Baseline Visit Blood & Urine Testing|Blood count and standard chemistry testing to ensure patient meets inclusion/exclusion criteria
224210453|NCT04313023|DRUG|Placebo|Sterile saline for inhalation
223761687|NCT05168475|BIOLOGICAL|Infliximab|Hospital stock of infliximab is used in the trial; biosimilars are allowed
223761688|NCT05168475|BIOLOGICAL|Tocilizumab|Hospital-supplied stock.
223761689|NCT01589822|BIOLOGICAL|EVICEL Fibrin Sealant|Intraoperative
223761690|NCT01140477|DEVICE|Toric Accommodating Lens|Toric accommodating lens implanted after cataract extraction
224210454|NCT01980316|DRUG|Argatroban|Argatroban in patients undergoing load 250μg/kg, followed by 15μg/kg/min continuous intravenous infusion.5 days after surgery, take 10mg intravenous infusion of speed 2/day
224210455|NCT01980316|DRUG|non-argatroban treated group|Patients in control group will receive Unfractionated heparin treatment
224210456|NCT04953208|DEVICE|active tDCS|Treatment will be applied daily 5 days/week for a period of 6 weeks, which equals a tDCS stimulation for a total of 30 treatment sessions. Every treatment session consists of 30 minutes of intervention.
224210457|NCT04953208|DEVICE|sham tDCS|sham stimulation for a total of 30 treatment sessions. Every treatment session consists of 30 minutes of intervention.
224210458|NCT04953208|BEHAVIORAL|cognitive and emotional control video game|a video game targeting cognitive and emotional control. total of 30 treatment sessions. Every treatment session consists of 30 minutes of intervention.
224210459|NCT04953208|BEHAVIORAL|sham video game|a video game which does not target cognitive control, played for total of 30 treatment sessions. Every treatment session consists of 30 minutes of intervention.
223620592|NCT02997501|PROCEDURE|Baseline ECG|ECG to ensure absence of any cardiac abnormality
223620593|NCT02997501|PROCEDURE|Visual Slit-Lamp Testing|Slit-lamp testing performed to ensure patients do not have any eye abnormalities or symptoms
223620594|NCT02997501|DRUG|AZD9291 Dosing|Patients to be provided with AZD9291 every 6 weeks (+/- 7 days)
223620595|NCT02997501|PROCEDURE|Plasma AZD9291 testing|The patient will need to have plasma AZD9291 testing before treatment
223620596|NCT05057481|DRUG|Mycophenolate Mofetil 500mg|MMF 2gram/day orally for 12 weeks
223620597|NCT05057481|DRUG|Rituximab|375 mg/m2 of rituximab given intravenously weekly for 4 weeks.
223620598|NCT00415285|DRUG|Docetaxel|
223620599|NCT00415285|DRUG|Capecitabine|
223620600|NCT00415285|DRUG|Docetaxel/Capecitabine|
223620601|NCT03712514|OTHER|Destabilization of the upper cervical spine by Cervistab|Simulate a situation of destabilization of the cervical spine with Cervistab
224210460|NCT03256708|DIETARY_SUPPLEMENT|Prolardii|Prolardii: 2 capsules per day for 12 to 15 days
224210461|NCT03256708|DIETARY_SUPPLEMENT|Placebo|Inactive ingredients
224210462|NCT00786019|BEHAVIORAL|Exercise program|Three month exercise program located at the Anschutz Medical Campus at I-225 and Colfax. The program runs three times per week for about an hour each session. Gym is open Monday - Saturday during specific hours (morning, noon, evening).
224210463|NCT00786019|DRUG|Ascorbic Acid (Vitamin C)|"During one exercise study visit, 0.06 grams of Vitamin C per kilogram fat-free mass per 100 milliliters (mL) of normal saline administered; Subjects will receive a bolus of 100mL Vitamin C solution given at 5ml/minute over 20 minutes followed by a drip-infusion given at 1.7ml/minute."
224210464|NCT00303264|DRUG|dexloxiglumide|
224210465|NCT00303264|DRUG|Nexium (esomeprazole)|
224210466|NCT02437890|BIOLOGICAL|ALX-0061|
224210467|NCT02437890|BIOLOGICAL|Placebo|
224210468|NCT04268784|DRUG|DNL343|Single and repeating oral dose(s)
224210469|NCT04268784|DRUG|Placebo|Single and repeating oral dose(s)
224210470|NCT02479932|OTHER|Transperitoneal cesarean technique|Pfannenstiel-Kerr technique for laparatomy and uterine entry
224210471|NCT02479932|OTHER|Extraperitoneal cesarean technique|Pfannenstiel incision, paravesical approach to lower uterine segment extraperitoneally and Kerr incision for uterine entry
224210472|NCT00005588|RADIATION|radiation therapy|
224210473|NCT04554407|DEVICE|SOMAVAC® 100 Sustained Vacuum System|The SOMAVAC® 100 is a battery operated device that delivers 100mm/Hg of continuous suction.
224210474|NCT02414854|DRUG|Dupilumab|Solution for injection, Subcutaneous injection in the abdomen, upper thigh or upper arm.
224210475|NCT02414854|DRUG|Placebo|Solution for injection, Subcutaneous injection in the abdomen, upper thigh or upper arm.
224210476|NCT02414854|DRUG|Inhaled corticosteroid (ICS) therapy|Oral inhalation, stable dose (medium or high dose) of ICS in combination with up to 2 other controller medicines (second or third controller therapy)
224210477|NCT02414854|DRUG|Albuterol/Salbutamol|Oral inhalation as needed
224210478|NCT02414854|DRUG|Levalbuterol/Levosalbutamol|Oral inhalation as needed
223620602|NCT03195283|OTHER|Meal service|The type of meal service in the hospital (usual care)
223620603|NCT02023307|DEVICE|V-Loc Suture|
223620604|NCT06341712|DRUG|Cabozantinib|Participants will receive cabozantinib orally Once daily (QD) on a continuous dosing schedule for cycles of 28 days.
223620605|NCT06341712|OTHER|Best Supportive Care (BSC)|Participants will receive BSC. BSC includes antibiotics, nutritional support, correction of metabolic disorders, optimal symptom control and pain management (including palliative radiotherapy), etc. but does not include tumor specific therapy.
223620606|NCT06341712|OTHER|Best Supportive Care (BSC)|Participants will receive BSC alone. BSC includes antibiotics, nutritional support, correction of metabolic disorders, optimal symptom control and pain management (including palliative radiotherapy), etc. but does not include tumor specific therapy.
223620607|NCT00415948|DEVICE|Biomarkers|
223620608|NCT02429635|BEHAVIORAL|My exercise|"Health Screening I and II Questionnaires on health and lifestyle, physiological test of fitness, physiological health tests and blood profile - compiled in a health profile report. Individual guidance and advice from professional health advisor.~Team-workshop I and II A 2 hours' workshop lead and facilitated by a trained and professional health advisor. It consists of short talks on exercise and health, and on health behavior change and motivation in addition to work with self-reflection and discussion tasks. Competence, support and advice during 2. workshop.~Exercise groups Small groups with similar exercise level and ambitions who support each other in their efforts to establish new exercise habits according to their individual exercise plan"
224210479|NCT04146454|OTHER|Smartphone-based balance exercises|A smartphone-based wearable telerehabilitation system will provide video and audio instructions on how to perform in-home dynamic weight-shifting balance exercises (i.e., physical therapists' recommended dynamic balance exercises).
224210480|NCT00553748|DRUG|F-18 FLT|One - 10 mci dose of F-18 FLT is administered IV over about 5 seconds prior to PET imaging. Each imaging dose contains no more than 6.1 micrograms of FLT.
224210481|NCT00673322|BIOLOGICAL|Gene Modified T Cells|One time infusion Modified T-Cells given through a vein in the arm or a catheter over a 30-60 minute period.
224210482|NCT05380622|DIAGNOSTIC_TEST|Coronary CT angiography|"Coronary CT angiography (CCTA) will be performed according to standard protocol and measurement of fractional flow reserve (FFR) or other physiological indices will be at the at the discretion of the physicians in charge.~Stenosis and plaque features, disease patterns, hemodynamic parameters, and fat metrics on CCTA will be analyzed blindly in the core lab."
224210483|NCT01357031|DRUG|Amitriptyline|It will be administered Amitriptyline (25mg) once a day at bed time. Patients may keep their abortive treatment that they usually used. The drug will be encapsulated in a bottle of 30 capsules will be given to patients at every visit.
224210484|NCT01357031|DRUG|Melatonin|It will be administered Melatonin (3mg) at bed time, half an hour before the usual time of sleep of the patient.
224210485|NCT01357031|DRUG|Placebo|It will be administered placebo capsules, identical to Melatonin (3mg) and Amitriptyline (25 mg) patients will take the study medication at bed time
223620609|NCT04632888|OTHER|Telephone support for breastfeeding follow-up|The researcher, after the mother is discharged, by making a video call by phone every day for the first week, providing counseling to the mother on matters that she needs and recording it in the Baby Monitoring Form The researcher gives the mother a video
223620610|NCT00152503|DRUG|Seletracetam (UCB44212)|"* Pharmaceutical form: oral capsules~* Concentration: 2, 10 and 50 mg~* Route of administration: oral administration"
223620611|NCT01173354|DIETARY_SUPPLEMENT|Free balanced amino acid mixture|7 g free amino acids provided as a one time bolus, including 15 g carbohydrates. As part of the total amount of essential amino acids 24% is leucine.
223761691|NCT01140477|DEVICE|Accommodating Lens|Accommodating lens implanted after cataract extraction
223761692|NCT04256616|OTHER|This is an observational study that does not concern a direct intervention on patients and control subjects and does not interfere with the clinical management of patients.|"urine collection: DNA is isolated from urine samples (catheterized, washout, midstream) and the 16S rRNA gene is sequenced.~Specimen collection: Specimens collected during TURBT are selected by a pathologist and trasferred to the laboratory. The tissues are treated ex vivo with MMC."
223620612|NCT01173354|DIETARY_SUPPLEMENT|Free essential amino acid mixture|7 g free essential amino acids provided as a one time bolus, including 15 g carbohydrates. As part of the total amount of essential amino acids 40% is leucine.
224210486|NCT06515444|BEHAVIORAL|10 minutes program|The curriculum component offers 10-minute daily doses of activities targeting the development of eight socioemotional competences in children: (i) emotional knowledge and management, (ii) developing a healthy identity, (iii) establishing and maintaining positive relationships, (iv) feeling and showing empathy, (v) establishing and reaching goals, (vi) responsible decision-making, (vii) contributing to the community and (viii) developing spirituality. The activities do not require the teacher to plan or to prepare material for the students.
224210487|NCT06515444|BEHAVIORAL|1 hour PD program|The professional development (PD) component is a 1-hour dose of activities targeting each of the eight SECs on which the curriculum focuses. The focus of PD is not to teach about SEC development in children but to develop SEC in teachers. Thus, this is an 8-hour PD program distributed throughout the academic year.
224210488|NCT05976217|DRUG|Venetoclax|100 mg daily by mouth for 3 weeks This drug inhibits a protein (Bcl-2) that protects cells from undergoing programmed cell death.
224210489|NCT02701816|DEVICE|innova stent (Boston scientific)|
224210490|NCT06036173|OTHER|diagnosis of lymphedema|being diagnosed with secondary lymphedema in the upper extremity according to the International Lymphedema Association
224210491|NCT06036173|OTHER|breast cancer surgery|be diagnosed and undergo surgery
224210492|NCT03888092|DRUG|Z650|receive oral Z650 once daily until disease progression or unacceptable toxicity occurs, each cycle is defined as 28 days
224210493|NCT06146543|OTHER|Stress ball|Before the procedure begins, the patient's free hand will be given an elastic ball that is large enough to hold in the palm of the hand and squeeze easily. He/she will be asked to squeeze this ball slowly throughout the process. At the end of the procedure, the ball will be removed from his hand and the patient will be relieved.
223620613|NCT03375034|DRUG|NDMC 20mg|Oral administration of one NDMC 20mg capsule and two Placebo capsules
223620614|NCT03375034|DRUG|NDMC60mg|Oral administration of three NDMC 20mg capsules
223620615|NCT03375034|DRUG|Clonazepam 1.5mg|Oral administration of three clonazepam 0.5mg capsules
223620616|NCT03375034|DRUG|Placebo|Oral administration of three Placebo capsules
223761693|NCT05444309|PROCEDURE|Quadratus lumborum (QL) block group|patient will receive 0.5 mg/kg of bupivacaine 0.25% through the quadratus lumborum block approach
224210494|NCT05810974|DIETARY_SUPPLEMENT|Concentrated beetroot juice|Subjects will consume 70ml shot (Beet-it Sport nitrate 400 shot, James White Drinks) and this drink contains 0.4g inorganic nitrate
224210495|NCT05810974|DIETARY_SUPPLEMENT|Nitrate depleted beetroot juice + potassium nitrate (KNO3)|Nitrate-depleted beetroot juice (70ml) and 0.4g KNO3- will be mixed. (Same appearance and taste with Beet-it sport shot)
224210496|NCT05810974|DIETARY_SUPPLEMENT|Nitrate depleted beetroot juice|Subjects will consume 70ml of (Beet-it Placebo shot, James White Drinks). This drink is the same as the Beet-it Sport nitrate shot but has the nitrate removed.
224210497|NCT04723173|DEVICE|Feature for noise reduction (on)|The noise reduction feature shall support the hearing aid user in noisy situations and shall reduce the listening effort.
224210498|NCT04723173|DEVICE|Feature for noise reduction (off)|To show the advantage of the noise reduction feature there is a comparison without the feature necessary.
224210499|NCT06354439|DRUG|Letrozole tablets|10 mg of letrozole PO for 7 days
223761694|NCT05444309|PROCEDURE|Pericapsular Nerve Group (PENG) block group|patient will receive 0.5 mg/kg of bupivacaine 0.25% through the Pericapsular Nerve Group (PENG) block
224210500|NCT06354439|DRUG|Methotrexate Sodium|100 mg of methotrexate IM, single dose
224210501|NCT05430308|PROCEDURE|Chlorhexidine scrub|Surgical site selected for performing the thoracoscopy will be cleaned with 4%w/v chlorhexidine gluconate solution for 3 minutes
224260515|NCT00345696|DRUG|Bevacizumab|5 mg/Kg intravenous, 90-60-30 minutes, every 2 weeks.
224260516|NCT00345696|DRUG|Capecitabine|600 mg/m2, orally, every 12 hours, continuous.
224260517|NCT00345696|DRUG|Oxaliplatine|85 mg/m2, intravenous, 2 hours infusion, every 2 weeks
224260518|NCT00433719|DRUG|Combivir and efavirenz|Arm 1: Combivir and efavirenz for 12 months Arm 2: Placebo for 2 months then Combivir and efavirenz for 10 months
224260519|NCT01970566|OTHER|Behavioral and Drug|Topiramate-Phentermine plus cognitive behavioral therapy
224260520|NCT01970566|OTHER|Behavioral|Intense Exercise/Moderate Calorie Restriction
224260521|NCT01970566|OTHER|Behavioral and Drug|Topiramate-Phentermine plus cognitive behavioral therapy
224260522|NCT01970566|OTHER|Behavioral|Intense Exercise/Moderate Calorie Restriction
224260523|NCT00120887|DRUG|Atorvastatin|
223620617|NCT04361435|PROCEDURE|Chest physiotherapy using a non-invasive oscillating device|NIOD will be implemented on four different parts of the chest walls, 3 minutes for each part and 12 minutes in total per each session. Left and right front and posterior chest walls will be stimulated, particularly, on the anterior chest, intercostal spaces 1-2 above nipple line and lateral side of the mid-clavicular line 1-2 below intercostal spaces. The intensity of the NIOD can be selected between 80-100%, which is pre-specified on the machine.
223620618|NCT00874146|GENETIC|Fluorescent in-situ hybridization (FISH)|Dual color FISH test to assess ratio of HER2/neu amplification
223620619|NCT02922725|DRUG|5-hydroxytryptophan and Creatine|
223620620|NCT02922725|OTHER|Placebo control|
223620621|NCT01300234|DRUG|Tenofovir disoproxil fumarate (TDF) tablets|white, almond-shaped, film-coated tablets containing 300mg of TDF
223620622|NCT01300234|DRUG|Adefovir dipivoxil (ADV) tablets|white to off-white, round, biconvex tablets containing 10mg of ADV
223620623|NCT04140968|DRUG|Utrogestan|300mg Utrogestan (1 tablet 100mg + 1 tablet 200mg) in the second and third menstrual cycle daily from cycle day 15 to 26.
223620624|NCT03994510|OTHER|Clinical and biological assessments - a 5 Years follow-up|During each visit, a clinical evaluation will be carried out, as well as the filling of hetero-questionnaires and self-questionnaires. Two biological collections will be made: one during the inclusion visit, and the other during the last visit, 5 years after inclusion.
223620625|NCT03253679|DRUG|Adavosertib|Given PO
223620626|NCT02944409|DEVICE|total knee prothesis VEGA System|total knee replacement
223620627|NCT06622161|DEVICE|automated oxygen vs manual oxygen|Patient characteristics, ventilator, and blood gas parameters at the time of study will be shown in Tabular form. At the start of the study, half of the babies will be randomly assigned to a manual 12-hour period where a bedside nurse will adjust the FiO2 of the baby according to SpO2 levels, and half of the babies to an automated 12-hour period where Oxygenie will adjust FiO2 according to target SpO2 levels. After 12 hours, they will be shifted to contralateral intervention. The ventilator parameters (peak inspiratory pressure, positive end expiratory pressure, and rate) will be compared between the automated and manual 12-hour periods. The amount of time spent within different ranges of SpO2 will also be measured and shown in tabular form.
223620628|NCT00895635|BEHAVIORAL|Treadmill Exercise Training|60-minute sessions of supervised treadmill exercise training three times a week for 12 weeks
223620629|NCT00895635|BEHAVIORAL|Arm Ergometry Exercise Training|60-minute sessions of supervised aerobic arm exercise training using an arm ergometer three times a week for 12 weeks
223620630|NCT00895635|BEHAVIORAL|Usual Care|Usual care for PAD
223620631|NCT02584179|DEVICE|Biparametric MRI before biopsy|All included men with suspicious lesions on bpMRI will have bpMRI targeted biopsies in addition to standard TRUS-bx.
223620632|NCT03737461|DRUG|Allogenic BM-MSCs Injection|Cell dose will be 20±5 million cells suspended in 2 ml of HypoThermosol isotonic transport solution
223620633|NCT03737461|OTHER|Sham Procedure|sham-maneuver as in the cell-treated patients are added, consisting in anesthetic infiltration with 2 ml of 1% xylocaine in the paravertebral muscles close to the affected segment.
223620634|NCT06038331|BIOLOGICAL|SclerFIX-IP|Decellularized, viro-inactivated, freeze-dried and sterile allogeneic graft of amniotic membrane of umbilical cord used as an interposition implant in the STT joint
223620635|NCT03269422|RADIATION|MR-based image-guided, intensity-modulated radiotherapy|Patients will receive a standard dose of 8 Gy/fraction for five fractions for a total dose of 40 Gy to the prostate with a simultaneously delivered boost of 9 Gy for five fractions (clinically non-standard dose of 45 Gy total) to a single dominant lesion with a maximum dimension of at least 0.5 cm as determined on pre-treatment diagnostic T2 MRI imaging.
223620636|NCT03190057|DEVICE|BIOFREEDOM™ FAMILY stent|Percutaneous coronary intervention with BIOFREEDOM™ FAMILY stent
223620637|NCT05660772|DEVICE|Microfragmented Adipose Tissue|Microfragmented Adipose Tissue derived using Lipogems® Kit
223620638|NCT05660772|DRUG|Corticosteroid|intra-articular knee injection of corticosteroid
223620639|NCT05693571|BEHAVIORAL|Valera Smart Phone Application and Care Manager Dashboard|Valera mobile health application will provide educational materials around mental health and Systemic Lupus Erythematosus (SLE) and the ability to connect to a SLE care team via a care manager.
223620640|NCT06027099|DRUG|Tizanidine|Tizanidine 2mg three times a day for 5 weeks after surgery
223761695|NCT03938116|OTHER|Healing Hearts Together|Participants in the HHT group will be assembled in groups and attend 8 weekly 2-hr sessions at UOHI led by 2 facilitators with psychology training. Sessions: 1) focus on understanding love, attachment, and their relationship to heart health; 2) provide an opportunity to share experiences related to cardiovascular disease with partners and peers; and 3) assist in identifying and improving communication patterns that may inhibit positive interactions and healthy behaviours. Participants are introduced to concepts through didactic presentations, videos, group and couple discussion and homework exercises. Participants will receive a folder containing copies of in-session and take-home exercises as well as the Hold Me Tight book to review between sessions.
224210502|NCT05430308|PROCEDURE|Povidone-iodine|The surgical site selected for performing the thoracoscopy will be just cleaned with normal saline followed by 10% w/v povidone-iodine solution
223620641|NCT06027099|BEHAVIORAL|MI-Opioid Taper|Motivational Interviewing (MI) and guided Opioid Tapering support adapting MI principles for enhancing motivation to change in pain treatment and tailoring key MI tools to postoperative opioid use delivered through weekly phone calls from weeks 2 to 7, and at week 11. The guided opioid tapering protocol will be a 25% total daily opioid dose reduction every 7 days with opioid discontinuation 7 days after reaching 1 opioid pill per day.
223620642|NCT06027099|DRUG|Placebo|1 tablet three times a day for 5 weeks after surgery
223620643|NCT06027099|BEHAVIORAL|Enhanced Usual Care|Participants will receive weekly phone calls from weeks 2 to 7, and at week 11. 1 topic per call will be reviewed in this sequence:1) standardized instructions on taking opioid medications after surgery, 2) safe opioid use, 3) avoiding medication errors, 4) local mental health resources and 988 Suicide \& Crisis lifeline, 5) disposal of unused medications, 6) prescription drug abuse, and 7) complementary health approaches for chronic pain. Education materials will be reviewed in a didactic style without a tailored discussion.
223620644|NCT03863119|DRUG|Vamorolone|2.0 mg/kg/day, 4.0 mg/kg/day, or 6.0 mg/kg/day at physician discretion
223620645|NCT06544174|OTHER|Percutaneous Coronary Intervention of CTO|CTO-PCI is a procedure of interventional cardiology attempting revascularisation of the CTO
223620646|NCT03692702|BEHAVIORAL|WE PLAY|WE PLAY is an online preschool teacher training that is based in theory and implementation science. It contains six components: (1) online training; (2) video library; (3) game sheets; (4) teacher self-assessment; (5) supervisor support; and (6) activity packs containing low cost physical activity equipment
223620647|NCT03902314|DRUG|Lidocaine Iv|Intravenous infusion
223620648|NCT03902314|DRUG|Saline Solution|Intravenous infusion
223620649|NCT06098937|DEVICE|Kalifilcon Toric Lens|Kalifilcon A Daily Disposable Toric for Ametropia
223620650|NCT06098937|DEVICE|Total1 for Astigmatism|Total1 for Astigmatism
223620651|NCT06098937|DEVICE|Precision1 for Astigmatism|Precision1 for Astigmatism
223620652|NCT06098937|DEVICE|MyDay Toric|MyDay Toric
223620653|NCT04816214|DRUG|Capmatinib|Capmatinib was available as a film-coated tablet for oral use, with a strength of either 150 mg or 200 mg. The initial dose of the combination therapy consisted of capmatinib 400 mg administered orally twice daily (b.i.d).
223620654|NCT04816214|DRUG|Osimertinib|Osimertinib was available as a tablet for oral use, with a strength of either 80 mg or 40 mg. The initial dose of the combination therapy consisted of osimertinib 80 mg administered orally once per day (q.d)
224210503|NCT00088023|DRUG|PT-523 for Injection|
223620655|NCT04816214|DRUG|Pemetrexed|Pemetrexed concentrate for solution for intravenous use was to be administered intravenously. The procurement of pemetrexed was to be done locally, following local practices and regulations.
223620656|NCT04816214|DRUG|Cisplatin|Cisplatin concentrate for solution for intravenous use was to beadministered intravenously during the study. The procurement of cisplatin was to be done locally, following local practices and regulations.
223620657|NCT04816214|DRUG|Carboplatin|Carboplatin concentrate for solution for intravenous use was to be administered intravenously during the study. The procurement of carboplatin was to be done locally, following local practices and regulations.
223620658|NCT00625079|DRUG|sildenafil|the dose of sildenafil will be 20mg three times per day (orally)
223620659|NCT00550407|DRUG|lamotrigine|lamotrigine 100mg/day or 200mg/day
223620660|NCT00550407|DRUG|Placebo|placebo once daily
223620661|NCT00930085|OTHER|SELDI-TOF MS for plasmatic proteic profile|An extra blood sample is required to determine the plasmatic proteic profile used to identify one or several signatures which are correlated to the clinical evolution (mortality at D30).
223620662|NCT05546775|DIAGNOSTIC_TEST|DHR|"To describe the clinical characteristics and pattern of presentation of patients diagnosed as CGD in Assiut, and to find the most common presenting symptoms.~* To mention the immunological profile of patients diagnosed with CGD (Immunogloulins level - B, T, natural killer cells enumeration with flow cytometry- DHR123)~* To assess the growth parameters in patients with CGD."
223620663|NCT06296485|BEHAVIORAL|SAGE Group Sessions|Participants enroll in 3 educational group sessions and receive CGMs
223620664|NCT06296485|OTHER|Usual Care|Participants continue to receive usual care (Control Arm)
223761696|NCT01931267|BEHAVIORAL|Tablet Computer Motivated Instruction|Using tablet computer to motivate patient learning breath skill and maintain practive. Research nurse will give 3 times instruction to patients during hospitalization. This arm estimated including 77 subjects
224210504|NCT04624750|DRUG|Mexiletine|"Patients will be enrolled sequentially into 2 cohorts. Cohort 1 - (patients aged 12 to \< 18 years): approximately 8 weeks - 4 weeks of dose titration period + 4 weeks of maintenance period.~Cohort 2 - (patients aged 6 to \< 12 years,): approximately 8 weeks - 4 weeks of dose titration period + 4 weeks of maintenance period.~Enrolment for Cohort 2 will begin after initial safety assessment of patients in Cohort 1 by the DSMB and no safety concerns are observed. The dose level for cohort 2 will be confirmed by PK modelling study."
224210505|NCT04843800|PROCEDURE|Manual therapy|Acupuncture, Chiropractic are recognized complementary medicines and Therapeutic Massage is an alternative healing practice.
223620665|NCT02151669|BEHAVIORAL|Mediterranean Diet|Nutritional intervention conducted by a dietitian who designs a nutrition program to enhance the traditional Mediterranean diet pattern using new technology as an educational tool in primary care: DIET blog. Participants will be referred to a single annual visit and one group session per year for two years.
223620666|NCT00584415|DEVICE|GP ablation + PV isolation|All patients underwent GP ablation and PV isolation using the NaviStar ThermoCool ablation catheter
223620667|NCT03741686|DIETARY_SUPPLEMENT|konjac glucomannan|Konjac-mannan fiber-enriched biscuits (0.5 g/412KJ \[100kcal\] of glucommanan)
223620668|NCT03741686|DIETARY_SUPPLEMENT|wheat bran|Wheat bran (hard red wheat bran) fiber enriched biscuits
223620669|NCT02935647|DRUG|Diprivan|
223620670|NCT02650180|DEVICE|Soberlink Cellular Device|Alcohol Breath Analyzer
223620671|NCT06383403|DRUG|Elafibranor|Round and orange film coated tablet of 80 mg.
223620672|NCT06383403|OTHER|Placebo|Round and orange film coated tablet of placebo
223761697|NCT01931267|BEHAVIORAL|Systematic Instruction|Research nurse give 3 times systematic instruction during hospitalization This arm estimated including 77 subjects.
223620673|NCT01174121|DRUG|Pembrolizumab (Keytruda)|"Arm 3 or 5: Pembrolizumab 2mg/kg IV over approximately 30 minutes on Days -2, 21, 42, and 63 Arm 4: Pembrolizumab 2mg/kg IV over approximately 30 minutes (for patients who meet progressive disease per RECIST criteria and have resolved major toxicities after cell infusion or anytime during the post-treatment~evaluation period; starting within 4 weeks of progression; may receive up to 8 doses every 3 weeks)."
223761698|NCT05120219|DRUG|FDC tablet|single HR20033 FDC tablet fed, take orally on an empty stomach and then after meals
223761699|NCT05120219|DRUG|FDC tablet|single HR20033 FDC tablet fasted, take orally after meals and then on an empty stomach
223620674|NCT01174121|DRUG|Fludarabine|Days -7 to -3: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days.
223620675|NCT01174121|DRUG|Cyclophosphamide|Days -7 and -6: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with Mesna 15 mg/kg/day X2 days over 1 hr.
223620676|NCT01174121|DRUG|Aldesleukin|Aldesleukin 720,000 IU/kg IV (based on total body weight) over 15 minutes every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 4 days (maximum 12 doses.)
223620677|NCT01174121|BIOLOGICAL|Young TIL|Day 0: Cells will be infused intravenously (IV) on the Patient Care Unit over 20-30 minutes (one to four days after the last dose of fludarabine).
224210506|NCT01876199|BEHAVIORAL|intense follow up|
223620678|NCT06330064|DRUG|Ifinatamab deruxtecan|Intravenous administration
223620679|NCT03937830|DRUG|durvalumab|1,150 mg flat dose every 21 days, starting on day 1 of cycle 1
223620680|NCT03937830|DRUG|Doxorubicin-Eluting Beads|used for TACE (only in patients with HCC BCLC stage B)
223620681|NCT03937830|PROCEDURE|TACE|TACE with Doxorubicin-Eluting Beads (only in patients with HCC BCLC stage B) on Cycle 2. More TACE can be done if clinically necessary.
223620682|NCT03937830|DRUG|bevacizumab|7.5 mg/kg dose every 21 days, starting on day 1 of cycle 2
223620683|NCT03937830|DRUG|Tremelimumab|300, 150 or 75 mg once on day 1 of cycle 1
223620684|NCT03642197|BEHAVIORAL|Attendance|The SFA and PA arms will be instructed to attend pre-surgery classes and clinical visits with the patients.
223620685|NCT04604730|PROCEDURE|Primary anastomosis without protective stoma|Primary anastomosis without protective stoma
223620686|NCT04604730|PROCEDURE|Anastomosis with protective stoma|Anastomosis with protective stoma
223620687|NCT00187863|BEHAVIORAL|pain perception|pain perception
223620688|NCT06374953|DIAGNOSTIC_TEST|Ultrasound-based viscoelastic hemostasis analysis|Adding recombinant tissue plasminogen activator (rtPA) and/or Tranexamic acid （TXA）to blood in vitro, and fibrinolysis capacity is assessed using ultrasound-guided viscoelastic coagulation testing.
223620689|NCT05089370|COMBINATION_PRODUCT|Oral Decitabine/Cedazuridine (DEC-C) in Combination with Nivolumab|Activation of the RIG-I innate immune pathway and increased expression of tumor antigens and pro-immune genes during Nivolumab treatment may enhance the frequency and activity of anti-tumor immune cells (CD4+ and CD8+ T-cells, NK cells) and reduce the frequency and activity of immunosuppressive cells (MDSCs, Tregs) (1-4), increasing the overall effectiveness and success of Nivolumab treatment. This pilot clinical trial will demonstrate whether combinatorial immunotherapeutic approaches that target epigenetic immune repression and RIG-I activity can favorably alter the tumor immune cell microenvironment and benefit mucosal melanoma patients.
224210507|NCT04821570|BIOLOGICAL|COVID-19 Vaccine|Per recommended dosing schedule
223620690|NCT06392074|DRUG|MB04|Subcutaneous injection
223620691|NCT06392074|DRUG|US License Enbrel|Subcutaneous injection
223620692|NCT06392074|DRUG|EU Source Enbrel|Subcutaneous injection
223620693|NCT05051579|DRUG|LY3502970|Administered orally
223620694|NCT05051579|DRUG|Placebo|Administered orally
223620695|NCT02447614|PROCEDURE|Adenotonsillectomy|Adenotonsillectomy
224210508|NCT05285332|PROCEDURE|surgical treatment 1|Mastectomy OR Breast conserving surgery
224210509|NCT05285332|PROCEDURE|surgical treatment 2|Resection of metastasis
223620696|NCT02447614|OTHER|Conservative treatment|Mometasone Furoate Aqueous Nasal Spray or uticasone propionate (1/once qd) and（or）Leukotriene antagonists(4 or 5mg/once qn) or H1 receptor antagonists
223620697|NCT02447614|OTHER|no treatment|just regular follow-up
223620698|NCT01271556|DRUG|Salmeterol|50 mcg MDI (inhalatory), once on days A and C at t=0,
223620699|NCT01271556|PROCEDURE|saline infusion (0.9 per cent sodium chloride)|rapid 50-minute 750-ml 0.9% saline infusion 240 minutes after inhalatory treatment on day A and B
223620700|NCT01271556|OTHER|Placebo|placebo, inhalatory (MDI) once
223620701|NCT05055024|DRUG|Mazindol|Drug: NLS-2
223620702|NCT06262893|PROCEDURE|Shoulder arthroscopy blocks|Effect of dexamethasone adjuvant in combined supraclavicular block and suprascapular block versus Interscalene block in patients undergoing shoulder arthroscopy.
224210510|NCT05285332|DRUG|Systemic therapy|Endocrine therapy or chemotherapy or targeted therapy
224210511|NCT00750009|OTHER|educational intervention|Patients receive a tailored intervention or generic information
223620703|NCT03329313|DRUG|Lowering sodium concentration dialysate|Concentration of sodium in dialysate at 140 mmol/l
223620704|NCT03329313|DRUG|Highing sodium concentration dialysate|Concentration of sodium in dialysate at 145 mmol/l
223620705|NCT03333707|BEHAVIORAL|Pacifica App|The app contains several activities which are digital implementations of standard psychotherapy practices. Users may select which app elements they would like to use, and when. These app elements include relaxation and meditation activities, tools to examine your thoughts or self-talk, goal setting lists, and mood and health ratings. The app also has a peer support community where users can communicate with others who are having similar experiences. There is no minimum requirement for amount of time spent on any given activity, or in the app in total. The commercially available app has a feature to connect users to their existing healthcare providers, but this feature will not be available to study participants. Study participants may continue to see their existing providers.
223620706|NCT06389578|DRUG|Teprotumumab|SC administration and IV infusion
223620707|NCT00717249|DEVICE|galyifilcon A control lens|Marketed daily wear contact lens
223620708|NCT00717249|DEVICE|galyfilcon A with a silver additive|Investigational daily wear contact lens
223620709|NCT00876616|DRUG|Tacrolimus+Mycophenolate mofetil|FK506 4mg/d,MMF 1.0g/d
223620710|NCT00876616|DRUG|Cyclophosphamide|CTX 0.75g/m2 BSA
223620711|NCT00360412|DRUG|E2007|
223620712|NCT03318588|PROCEDURE|Vitrectomy|Pars plana vitrectomy
224210512|NCT05731388|DIAGNOSTIC_TEST|Push enteroscopy|A push enteroscopy using a pediatric colonoscope will be performed along with capsule endoscopy. These are part of the standard of care.
224210513|NCT01644578|PROCEDURE|Real-time imaging for MRI-guided procedures|Real-time imaging for improvement of workflow in MRI-guided procedures
224210514|NCT03614871|OTHER|Epidemiological study|
224210515|NCT06253754|OTHER|MRI examination|All included subjects will be examined with MRI
224210516|NCT02033577|PROCEDURE|Distal gastrojejunal bypass|RYGB with 200 cm BP limb and 150 cm common limb, effect on EWL, QoL and complications
224210517|NCT02033577|PROCEDURE|RYGB|RYGB with 60 cm BP limb and 150 cm alimentary limb, effect on
224210518|NCT05131997|DRUG|AD-221|PO, Once daily(QD), 8 weeks
223620713|NCT01205100|BEHAVIORAL|Bio-feedback|By providing on-line electromyography information of muscle activity, patients will be able to control and actively correct their muscle activity during the 15 min treatment session. Each patients will attend 3 treatment sessions.
223620714|NCT01205100|DRUG|Placebo|
223620715|NCT00043043|DRUG|celecoxib|
223620716|NCT05430958|DRUG|INO-4800|INO-4800 will be given at 0.8 or 1.6 mg for at least 6 months but no more than 12 months following the completion of a primary vaccination.
223620717|NCT05430958|DRUG|INO-9112|INO-9112 will be given in at various doses (dose of 0, 0.05, 0.10, 0.20 or 0.40 mg) in combination with INO-4800.
223620718|NCT05430958|DEVICE|CELLECTRA® 2000|Electroporation (EP) using the CELLECTRA® 2000 device will be administered following ID delivery of INO-4800.
223620719|NCT05094726|RADIATION|photobiomodulation|Photobiomodulation (PBM) describes the use of red or near-infrared light to stimulate, heal, regenerate, and protect tissue that has either been injured, is degenerating, or else is at risk of dying.
224210519|NCT05131997|DRUG|AD-221A|PO, Once daily(QD), 8 weeks
223620720|NCT05094726|OTHER|placebo intervention by photobiomodulation device|placebo intervention while the photobiomodulation device is on the off mode
223620721|NCT04874935|DRUG|Lansoprazole|administration of lansoprazole 60 mg twice daily 4 days before starting neoadjuvant chemotherapy regimen and continue till end of chemotherapy cycles
223620722|NCT04874935|DRUG|Placebo|administration of Placebo capsule twice daily 4 days before starting neoadjuvant chemotherapy regimen and continue till end of chemotherapy cycles
223620723|NCT03082248|OTHER|Physical Therapy|Patients allocated to the conservative treatment group will receive physical therapy according to the treatment-based classification approach and also educational leaflets and folders.
223620724|NCT03082248|PROCEDURE|Spinal Surgery|Patients allocated to the surgical procedure group will undergo spinal surgery procedures and techniques specific for the low back region.
224210520|NCT05131997|DRUG|AD-221B|PO, Once daily(QD), 8 weeks
223620725|NCT03388606|BEHAVIORAL|Growth Mindset|30 Minute interactive video
223620726|NCT04065139|DRUG|Pressurized intraperitoneal aerosol chemotherapy (PIPAC)|After insufflation of a 12 mmHg of capnoperitoneum at 37°C, two balloons safety trocars (10 and 12mm) are inserted into the abdominal wall. Injection of Doxorubicin (2.1 mg/m2 in 50 ml NaCl 0.9%) and Cisplatin (10.5 mg/m2 body surface in 150 ml NaCl 0.9%) with a flow rate of 0.7ml/s, the therapeutic capnoperitoneum is maintained for 30 min at body temperature.
223620727|NCT04065139|DRUG|Standard chemotherapy|Patient will receive standard poly chemotherapy proposed by the oncologist or any new standard validated during the study, until progression or toxicity.
223620728|NCT01568489|DRUG|HL-009 Liposomal Gel|Topical adenosylcobalamin gel
223620729|NCT01568489|DRUG|Placebo|Placebo gel
223620730|NCT01041313|DRUG|Memantine|7 days prior to surgery, start taking 5mg memantine daily; 4 days prior to surgery, increase dose to 5mg twice daily; 2 days prior to surgery, increase dose to 10mg in the morning, and 5 mg in the evening; on the day of surgery, increase dose to 10mg twice daily, and continue on this dose until 14 days after surgery.
223620731|NCT01041313|DRUG|Placebo|7 days prior to surgery, start taking one placebo tablet daily; 4 days prior to surgery, increase dose to one placebo tablet twice daily; 2 days prior to surgery, increase dose to 2 placebo tablets in the morning, and one placebo tablet in the evening; on the day of surgery, increase dose to 2 placebo tablets in the morning and 1 placebo tablet in the evening. On the first day after surgery through 14 days after surgery, take 1 placebo tablet twice daily.
223620732|NCT00001114|DRUG|Interferon alfa-2b|
223620733|NCT00001114|DRUG|Didanosine|
223620734|NCT03075917|OTHER|Self Questionnaire|self questionnaire for allergic rhinitis control
223620735|NCT06974201|DEVICE|Diabetes M bolus calculator|"Diabetes:M Bolus Calculator is an application for precise bolus insulin dose. Full guide for using the Diabetes:M mobile app, can be accessed at~* In English https://www.manula.com/manuals/sirma-medical-systems/diabetes-m-user- guide/mobile/en/topic/introduction~* In Bulgarian https://www.manula.com/manuals/sirma-medical-systems/diabetes-m-user- guide/mobile/bg/topic/introduction Instructions for the subject Trial participants must use the Diabetes:M Bolus Calculator before every insulin application and must record the insulin units applied.~Step-by-step instructions for bolus calculation via Diabetes:M app:~1. Open Diabetes:M app~2. Go to Bolus Advisor~3. Enter blood sugar, carbohydrates~4. Tap Calculate~5. Tap Save button~6. Confirm transferring the bolus to log entry screen~7. Enter note and some feedback if needed~8. Tap Save button to save the record"
224210521|NCT05131997|DRUG|AD-221C|PO, Once daily(QD), 8 weeks
224210522|NCT00388479|DRUG|Alvimopan|
224210523|NCT00897273|GENETIC|comparative genomic hybridization|
224210524|NCT00897273|GENETIC|gene expression analysis|
224210525|NCT00897273|OTHER|study of socioeconomic and demographic variables|
224210526|NCT00897273|PROCEDURE|evaluation of cancer risk factors|
224210527|NCT00897273|PROCEDURE|study of high risk factors|
224210528|NCT04349176|DRUG|Dose|Randomized to either 100U or 155U
224210529|NCT03745027|DIAGNOSTIC_TEST|in vitro fertilization|All patients underwent gonadotropin-releasing hormone agonist (GnRHa) treatment for in vitro fertilization and Follicular fluid sialic acid levels are measured.
224210530|NCT01422720|DRUG|Eslicarbazepine Acetate|ESL tablets (800 mg) QD
224210531|NCT00606801|DRUG|Galantamine|Galantamine 8 mg/day
224210532|NCT00606801|DRUG|placebo|sugar pill
224210533|NCT03508362|DEVICE|Functional Magnetic Resonance Imaging (fRMI)|Acquisition of a functional MRI on the sub thalamic nucleus
224210534|NCT03152227|OTHER|ACGG|50 high-producing chicks to households along with provision of technical input on production
223620736|NCT06974201|DEVICE|Diabetes M app|"Diabetes:M Bolus Calculator is an application for precise bolus insulin dose. Full guide for using the Diabetes:M mobile app, can be accessed at~* In English https://www.manula.com/manuals/sirma-medical-systems/diabetes-m-user- guide/mobile/en/topic/introduction~* In Bulgarian https://www.manula.com/manuals/sirma-medical-systems/diabetes-m-user- guide/mobile/bg/topic/introduction Instructions for the subject Trial participants must use the Diabetes:M Bolus Calculator before every insulin application and must record the insulin units applied.~Step-by-step instructions for bolus calculation via Diabetes:M app:~1. Open Diabetes:M app~2. Go to Bolus Advisor~3. Enter blood sugar, carbohydrates~4. Tap Calculate~5. Tap Save button~6. Confirm transferring the bolus to log entry screen~7. Enter note and some feedback if needed~8. Tap Save button to save the record"
223620737|NCT06973395|BEHAVIORAL|Nursing interventions, education, and follow-up will be provided to Type 2 diabetes patients for blood glucose variability.|Implementation of individual nursing interventions and provision of trainingIndividual nursing interventions will be applied to individuals with Type 2 diabetes regarding the risk of variability in blood glucose, and education and follow-up will be provided.
223620738|NCT06972381|BEHAVIORAL|Navigator|Participants in the navigator condition will meet with their counselor for sessions twice in month 1, once in month 2, once in month 4, and once in month 8. Three additional sessions may scheduled if desired by the participant. Navigators will assess treatment preferences, provide information about evidence-based treatment options for weight loss, aid in decision making, and facilitate action during the intervention initiation process. Following initiation of a weight loss treatment, navigators will also assess adherence to and acceptability of the selected weight loss intervention, and engage in problem solving and motivational enhancement to facilitate persistence with the original intervention or provide the support necessary for switching to an alternative intervention option. Additional intervention contact will include monthly emails over the 12 month period. Navigators will receive resource guides to help them tailor sessions to the individual participant.
223620739|NCT06366464|DRUG|Pitolisant tablet|Pitolisant tablet
223620740|NCT06366464|OTHER|Placebo tablet|Placebo tablet
223620741|NCT05809908|DRUG|Tricaprilin|"Each dose of IMP will be administered orally 30 minutes after completing a full meal.~There is 1 g of tricaprilin per 2 ml of AC-OLE-01-VA.~Participants will titrate from 5 g twice a day to 20 g twice a day, up to 40 g total daily dose of tricaprilin; 80 ml total daily dose of AC-OLE-01-VA, over the course of 2-4 weeks."
223620742|NCT05809908|DRUG|Placebo|"Each dose of IMP will be administered orally 30 minutes after completing a full meal.~Participants will titrate from 5 g twice a day to 20 g twice a day, up to 40 g total daily dose of placebo; 80 ml total daily dose of placebo, over the course of 2-4 weeks."
223620743|NCT04550741|OTHER|telerehabilitation|After obtaining consent, the volunteers will be included in the study at the start of the 4th week and randomized into two arms: Experimental and Control group
223620744|NCT03604198|DRUG|relacorilant|CORT125134 is supplied as capsules for oral dosing.
223620745|NCT05746520|OTHER|Antibiotic|Type of antibiotic is per clinical judgement with the duration being the experimental aspect of this study.
223620746|NCT05148234|DRUG|Deoxyribonucleic acid (DNA) methyltransferase inhibitors (DNMTi) Decitabine|For Higher Risk (HR) Myelodysplastic Syndromes (MDS) cohort, the study drug of BMS-986253 will be given in combination with standard of care (SOC) Food and Drug Administration (FDA)-approved DNMTi by mouth (PO) decitabine and cedazuridine according to guidelines outlined in FDA product label. Standard of care (SOC) DNMTi will be administered via oral route once daily starting Day (D)2 of each treatment cycle through D6.
223620747|NCT05148234|DRUG|Deoxyribonucleic acid (DNA) methyltransferase inhibitors (DNMTi) Cedazuridine|For Higher Risk (HR) Myelodysplastic Syndromes (MDS) cohort, the study drug of BMS-986253 will be given in combination with standard of care (SOC) Food and Drug Administration (FDA)-approved DNMTi by mouth (PO) decitabine and cedazuridine according to guidelines outlined in FDA product label. Standard of care (SOC) DNMTi will be administered via oral route once daily starting Day (D)2 of each treatment cycle through D6.
223620748|NCT05148234|DRUG|BMS-986253|Intravenous (IV) infusion, 200 mg/Vial (20 mg/mL) or 1000 mg/vial (100mg/mL). Abbreviated Title: Human Humax (HuMax)-interleukin 8 (IL-8) (BMS-986253) in Myelodysplastic Syndromes 34 Version Date: 9/08/2021 outlined in Food and Drug Administration (FDA) product label.
223620749|NCT05148234|PROCEDURE|Bone Marrow Biopsy|"Bone marrow biopsy: required at screening/baseline, Phase I post cycle (C)~1(C1Day(D)28 +/- 3 days) and Phase II post cycle 2 (C2D28 +/- 3 days) and post cycle 6 (C6D28 +/- 3days); and if needed clinically in the setting of aplasia or concern for disease progression."
223620750|NCT05148234|PROCEDURE|Bone Marrow Aspiration|"Bone marrow aspiration: required at screening/baseline, Phase I post cycle (C)~1(C1Day(D)28 +/- 3 days) and Phase II post cycle 2 (C2D28 +/- 3 days) and post cycle 6 (C6D28 +/- 3days); and if needed clinically in the setting of aplasia or concern for disease progression."
223620751|NCT05148234|PROCEDURE|ECG|12-lead electrocardiogram (ECGs) will be performed at baseline only for safety.
223620752|NCT03061201|BIOLOGICAL|SB-525 (PF-07055480)|Single dose of investigational product SB-525 (PF-07055480)
223620753|NCT05797441|BEHAVIORAL|EMPOWER|The goals of EMPOWER are to increase patients' self-efficacy for managing their PTSD, enable the maintenance or building upon gains made in TFT through the continued application of TFT skills, and encourage engagement in meaningful life activities. The program includes a Veteran workbook and four planned therapist contacts over the twelve weeks following TFT completion. The intervention includes: self-monitoring of symptoms, continued practice of TFT skills, engagement in meaningful activities, goal setting, and therapist support.
223620754|NCT05797441|OTHER|Treatment As Usual|The comparison condition will be TAU following completion of TFT. In the spirit of TAU, providers will not be restricted in the type or intensity of services offered. Depending on local clinic policy or norms, providers randomized to TFT may provide post-TFT treatment themselves or Veterans may be referred to other providers and/or back to the clinician who referred the Veteran to TFT. If providers would have typically discharged Veterans following TFT, that is also allowable.
223620755|NCT06373458|DRUG|Ritlecitinib|Ritlecitinib 50mg QD for 36 weeks starting at Day 1
223761700|NCT05120219|DRUG|FDC tablet|single and multiple doses of HR20033 FDC tablet
223761701|NCT00888303|DRUG|Dexamethasone|20 minutes before total or partial thyroidectomy for benign disease a single dose of intravenous 8 mg/2mL of dexamethasone is administered
224210535|NCT03152227|BEHAVIORAL|BCC|Nutrition sensitive BCC on poultry-specific aspects of nutrition, WASH, women's empowerment, and use of income combined with home gardening.
223620756|NCT06432985|BEHAVIORAL|Focus Group|In 60-minute focus groups, participants will be categorized based on their survey responses and engaged in semi-structured discussions using open-ended questions and probes to gather detailed information. The moderators will follow best practices in qualitative research, introducing the topic of smoking cessation in the context of cancer screening and treatment and guiding the discussions from broader issues to participant-generated examples.
224210536|NCT04189289|PROCEDURE|ESP block group|USG probe will be placed in a longitudinal parasagittal orientation 3 cm lateral to T7 spinous process. The erector spinae muscles will be identified hyperechoic transverse process. The patient's skin will be anesthetized with 2% lidocaine. A 21-gauge 10-cm needle was inserted using an in-plane superior-to-inferior approach or an out-plane approach. Following confirmation of the correct position of the needle with 5 ml normal saline, a dose of 20 ml %0.25 bupivacaine will be administered. The same procedure will be performed at the other site (totally 40 ml %0.25 bupivacaine). Standard pain follow up and monitorization will be performed.
223620757|NCT06432985|BEHAVIORAL|Contingency Management|Participants will provide baseline data on their recent substance use and smoking habits and severity. They will receive a CO monitor and iCO app and will upload videos verifying smoking abstinence a minimum of once per day, 5 times per week. Financial incentives will be provided at weekly visits contingent on tobacco abstinence verified through Remote (mobile) CO monitoring. They will receive clinician feedback at the time of each CO reading, following established VA protocols for CM.
223620758|NCT06432985|BEHAVIORAL|Behavioral Counseling (Cognitive Behavioral Therapy, CBT)|Participants will receive a 5-session smoking cessation behavioral counseling for approximately 15-20 minutes weekly. Sessions may be held by secure video conference or by telephone, per participant preference. Sessions will use CBT principles with MI incorporated for resolving reluctance to quit.
223620759|NCT06432985|BEHAVIORAL|TUD Treatment as Usual (TAU)|Participants assigned to TAU will receive referral to VA Tobacco Cessation Clinic and provision of the VA Telequit quitline. The VA Tobacco Cessation Clinic is modeled after VA Tobacco Cessation Clinics across all VA facilities and involves delivery of brief counseling and pharmacotherapy for TUD if desired. VA Telequit is a national toll-free number available to Veterans that allows them to speak with a smoking cessation counselor for a recommended minimum of five sessions to develop a quit plan and receive counseling, strategies to prevent relapse, and weekly proactive follow-up calls based on National Cancer Institute guidelines.
223620760|NCT03412877|DRUG|Cyclophosphamide|Days -7 and -6: Cyclophosphamide 60 mg/kg/day x 2 days IV in 250 mL D5W infused simultaneously with mesna 15 mg/kg/day over 1 hour x 2 days.
223620761|NCT03412877|DRUG|Fludarabine|Days -7 to -3: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days.
223620762|NCT03412877|DRUG|Aldesleukin|Aldesleukin 720,000 IU/kg IV (based on total body weight) over 15 minutes approximately every 8 hours beginning within 24 hours of cell infusion and continuing for up to 4 days (maximum 10 doses). Patients in Cohort 3 may receive 72,000 IU/kg IV.
223620763|NCT03412877|BIOLOGICAL|Individual Patient TCR-Transduced PBL|Day 0: Cells will be infused intravenously on the Patient Care Unit over 20-30 minutes (2-4 days after the last dose of fludarabine).
223620764|NCT03412877|DRUG|Pembrolizumab (KEYTRUDA(R))|Arm 2: Pembrolizumab 2 mg/kg IV over approximately 30 minutes on Days -2, 21, 42, and 63.
223620765|NCT05698316|DIAGNOSTIC_TEST|Collection of both retrospective and prospective data collection in 3 visits.|3 clinic visits with multimodal imaging done at least at 6 months interval between 2 visits and meet the inclusion and exclusion criteria. Those with one visit remaining to complete 2 years, images will be acquired prospectively. In addition to the images, routine demographic data (age and sex) and available visual acuity (VA) (BCVA if possible, VA with Pinhole or VA with patient's glasses) will be collected. Multimodal imaging includes mandated macular OCT with or without enhanced depth imaging and infrared imaging. Fundus autofluorescence (AF) and multicolor imaging are optional. All imaging must be done on Heidelberg Spectralis system.
223620766|NCT03062358|BIOLOGICAL|pembrolizumab|Administered as an intravenous (IV) infusion every 3 weeks (Q3W)
223620767|NCT03062358|DRUG|placebo|Normal saline solution administered as an IV infusion Q3W
223620768|NCT03062358|OTHER|best supportive care (BSC)|BSC will include pain management and management of other potential complications including ascites per local standards of care.
223620769|NCT04628663|DRUG|Dexmedetomidine|Administration
223620770|NCT04628663|OTHER|Normal Saline|Administration
223620771|NCT05051527|DRUG|Legalon® 140 mg|Legalon® 140 mg as per the Summary of Product Characteristics (SPC) and as per treating Investigator's decision
223620772|NCT05358808|DRUG|TCB008|TCB008 is derived from the peripheral blood mononuclear cells (PBMCs) of unrelated, healthy donors and consists of expanded cluster designation (CD)3+ T cells expressing the γ chain variable region 9 δ-chain variable region 2 (Vγ9Vδ2) T cell receptor (TCR); it is infused into patients to boost their immune system. It is currently developed for treatment of cancers and infectious diseases.
223620773|NCT06444867|DRUG|LEO 158968|SC injection
223761702|NCT00888303|DRUG|saline solution|20 minutes before total or partial thyroidectomy for benign disease 100 mg of saline solutions are administered intravenous
224210537|NCT04189289|PROCEDURE|Control group|The patients in this group will be performed no block. Standard pain follow up and monitorization will be performed.
224210538|NCT02082262|DRUG|AGN-229666|One to two drops of AGN-229666 twice daily in each eye for 10 weeks.
224210539|NCT01241162|BIOLOGICAL|Autologous dendritic cell vaccine with adjuvant|"Week 1:~Decitabine (DAC): 10 mg/m2/day IV (Mon-Fri)~Weeks 2 and 3:~Vaccine: 3-5 E6 peptide pulsed DC (Mon)~Hiltonol applied topically to vaccine site before and after vaccination"
223620774|NCT05831111|BIOLOGICAL|mRNA-1195.1|Sterile liquid for injection
223620775|NCT05831111|BIOLOGICAL|mRNA-1195.2|Sterile liquid for injection
223620776|NCT05831111|BIOLOGICAL|mRNA-1189|Sterile liquid for injection
223620777|NCT05831111|BIOLOGICAL|Placebo|0.9% sodium chloride (normal saline) injection
223620778|NCT05831111|BIOLOGICAL|mRNA-1195|Sterile liquid for injection
223620779|NCT03861273|BIOLOGICAL|PF-06838435/ fidanacogene elaparvovec|Gene Therapy
223620780|NCT05012410|BEHAVIORAL|Immediate treatment group with High-Intensity Prompts|Caregivers in the immediate treatment group with high-intensity prompts will use the WeCareAdvisor tool for 6 months. Caregivers will receive telephone and email prompts to use the tool.
223761703|NCT00888303|PROCEDURE|Thyroidectomy, total or partial|Surgical standard intervention
224210540|NCT05303831|OTHER|Mechanical ventilator|patients on a mechanical ventilators in ICU will be followed for 28-days for clinical outcomes
224210541|NCT01559831|BIOLOGICAL|IXIARO|Vero-cell derived Japanese encephalitis (JE) vaccine IXIARO, 0.5 ml intramuscular
224210542|NCT01852773|PROCEDURE|Open repair of thoracic aorta injury|open surgical management of aortic injury
224210543|NCT01852773|PROCEDURE|TEVAR|Use of endovascular (minimally invasive) techniques for repair of aortic injury
224210544|NCT01287780|DEVICE|Collagen-gentamicin sponge|A 10 by 10 cm sponge consisting of 280 mg collagen and 130 mg gentamicin.Two sponges are inserted during hemiarthroplasty surgery, one in the joint and one underneath the fascia at the time of surgical closure.
224210545|NCT02232139|DRUG|Midazolam|The participants receive the pharmacological premedication before the surgery anyway
224210546|NCT02068404|DRUG|Nifedipine|
224210547|NCT02104401|DEVICE|tDCS|tDCS will be applied with a Soterix CT tDCS Device with a HD-tDCS 4x1 Multi-Channel Stimulation Interface. During stimulation, a low level of constant DC electrical current (1-2 mA) will be applied via the electrodes. Current will be ramped up over 10-60 seconds, and typically causes very mild tingling and itching sensations. The current will be applied for no more than 20 minutes per session, at which time the current is ramped down over 10-60 seconds. Subjects will be seated in a chair throughout tDCS administration. Subjects will receive tDCS 5 days/week for 4 weeks.
224210548|NCT04812704|DIETARY_SUPPLEMENT|Whey protein|Patient receive protein supplement in liquid form after each exercice session
224210549|NCT01586767|RADIATION|Proton radiation therapy|Daily proton radiation therapy
224210550|NCT01586767|RADIATION|Intensity-modulated radiotherapy|Daily intensity-modulated radiotherapy
224210551|NCT02837367|DIETARY_SUPPLEMENT|Administration of supplements containing methyl-donors|Administration of supplements containing methyl-donors: betaine, 5-MTHF (L-5-methyltetrahydrofolate), Vitamin B12, choline bitartrate, ALA (alfa-linolenic acid), EPA (eicosapentaenoic acid), DHA(docosahexaenoic acid)
224210552|NCT05041244|DEVICE|Negative pressure wound therapy delivered through VAC|Initial cycle: Continuous first 48 hours Subsequent cycle: Consider intermittent DPC (5 min ON/2 mins OFF) for rest of the therapy Target Target Pressure: 50-175mmHg, to be titrated for more drainage Dressing change interval: every week; need for more frequent dressing need to be evaluated. More frequent change of adaptic can be considered. (Adaptic is a layer of thin dressing that will be in direct contact with the wound to reduce the risk of maceration and adherence to the dressing)
224210553|NCT05041244|DEVICE|Standard of care|"Participants in the control arm will have their dressings changed as per the current standard of care.~Effective management of DFU will depend on accurate diagnosis and assessment and appropriate debridement of non-viable tissues in patients from both arms Patients will be advised to continue off loading and any evidence of early infection should be promptly treated."
224210554|NCT01318941|DRUG|Ranibizumab|
224316095|NCT05913505|BEHAVIORAL|OSC-|During the first week, the baseline will be assessed and resonance frequency. Specifically, during their first intervention session the participants will be told that the goal of the sessions includes decreasing heart rate variability and avoiding slow and steady breathing. The participants will then be asked to choose five strategies to lower their heart rate oscillations. Participants will be told to avoid slow breathing as it causes large heart rate oscillations. For the second session, the therapist will check in with the participant and discuss how the practice went. Participants will then select three strategies that they will practice for three five-minute conditions following a five-minute baseline. Sessions three, four, and five will include three conditions: a five-minute baseline and two strategies of their choice. For each session, the best strategy will be calculated and written on the assignment sheets to be used during the week for their four homework sessions.
224316096|NCT03926520|DEVICE|Electroconvulsive Therapy (ECT)|Stimulus method of delivery will be RUL electrode placement, and ultra-brief (UB) pulse width (0.25-0.37ms). At the first ECT session, seizure threshold (ST) will be determined by titration with the empirical dose titration method and subsequent treatments will be approximately 6 times the ST. Following other NIMH sponsored multicenter ECT studies (PRIDE, U01 MH055495), stimulus settings will be adjusted as needed during the ECT course based on seizure quality and treatment efficacy. Participants will be administered anesthesia.
224316097|NCT05184543|OTHER|Routine Exercise Program|8 weeks of routine basketball training will be done. Dynamic stretching exercises, in which large muscle groups are exercised, can be applied for 20 minutes.
223620781|NCT05012410|BEHAVIORAL|Immediate treatment group with Low-Intensity Prompts|Caregivers in the immediate treatment group with low-intensity prompts will use the WeCareAdvisor tool for 6 months. Caregivers will receive email prompts to use the tool.
223620782|NCT05012410|BEHAVIORAL|Waitlist Control after three months with High-Intensity Prompts|After 3 months, caregivers will use the WeCareAdvisor tool for 3 months. Caregivers will receive telephone and email prompts. Once the caregiver receives the WeCareAdvisor tool, they will receive a weekly automated email as well as a weekly telephone call from study staff to prompt them to use the tool.
224210555|NCT01318941|OTHER|Ranibizumab|
224210556|NCT05294614|BEHAVIORAL|"Sonreír es diveritdo - Smiling is fun"|Smiling is Fun is an online program with the most effective psychological procedures for depression and other techniques to promote coping ability, emotional regulation and resilience along 8 modules. The modules and their aims are: 1) Motivation for change; advantages and disadvantages of changing and importance of motivation; 2) Understanding emotional problems; psychoeducational information, maintaining factors and management of medication and sleep hygiene; 3) Learning to get going; behavioural activation strategies; 4) Learning to be flexible; how interpret negative thoughts and situations in a more flexible way; 5) Learning to enjoy; importance of positive emotions and strategies to promote them; 6) Learning to live; how to identify the psychological strengths and importance of doing activities based on values and vital goals; 7) Living and learning; putting into practice the strengths identified in previous module; 8) From now on… what?; a relapse prevention module.
223620783|NCT05012410|BEHAVIORAL|Waitlist Control after three months with Low-Intensity Prompts|After 3 months, caregivers will use the WeCareAdvisor tool for 3 months. Caregivers will receive email prompts.
223620784|NCT06304168|OTHER|Non-Interventional Study|Non-interventional study
224210557|NCT03239795|OTHER|Advertisement|Advertisement by means of a poster and pamphlets in FP waiting rooms, removing all the other posters and pamphlets (except mandatory information, like opening hours, fees, etc.)
223620785|NCT00001987|DEVICE|HR-pQCT scan|HR-pQCT is a non-invasive, low-dose three-dimensional imaging method used to evaluate volumetric bone mineral density and bone microarchitecture of peripheral skeletal sites, including distal radius and distal tibia. HR-pQCT has an ability to differentiate between cortical and trabecular bone compartments providing density and structure parameters.
223620786|NCT06827795|DEVICE|A burr used in spine surgery|A burr used in spine surgery
223620787|NCT04038138|DIAGNOSTIC_TEST|Validation of new COA for FSHD patients|Monitoring of commonly used and news COA in patients with facioscapulohumeral muscular dystrophy
223620788|NCT06528769|DRUG|all-trans retinoic acid|Given orally
223620789|NCT06528769|DRUG|Cemiplimab|Given intravenously (IV)
223620790|NCT06528769|PROCEDURE|Computed Tomography|Undergo CT
223620791|NCT06528769|PROCEDURE|Magnetic resonance imaging|Undergo MRI
223620792|NCT06528769|PROCEDURE|Biospecimen Collection|Undergo blood and urine sample collection
223620793|NCT06284317|DRUG|Adjuvant durvalumab|Durvalumab is given at a fixed dose of 1500 mg i.v. every 4 weeks (±1 week) until relapse or unacceptable toxicity, for a maximum of 12 cycles after surgery.
224210558|NCT00773981|PROCEDURE|Transrectal vacuum assisted drainage|Treatment with vacuum drainage (VD) is a new method primarily developed for wound therapy. The principle of the method is application of negative pressure on the wound surface with the help of a sponge that is connected to a pump. Sponge dressings should be changed 3 times pr week as long as vacuum therapy is used. If there has been no development of granulation tissue or no shrinking of the cavity in 3 weeks Vacuum therapy can be stopped. Maximum vacuum therapy is 8 weeks.
224210559|NCT01375569|DRUG|TRC105|
223620794|NCT03799341|BEHAVIORAL|Prize-Based Contingency Management|"Participants assigned to Prize-based Contingency~Management (PBCM) conditions will receive PBCM as an adjunct to TAU. PBCM will involve twice weekly one-on-one sessions with a provider for 12-weeks. During each session, a urine specimen provided by the patient will be tested for cocaine using a point-of-care dip-test. Results of point-of-care testing will be shared with the patient and negative results will be reinforced with draws from a fish bowl containing 500 paper slips, 250 of which award small, large, or jumbo prizes (remaining slips deliver words of encouragement). Patients will be reinforced with a single prize draw for their first negative specimen; an additional prize draw will be added for each consecutive negative result (up to 8~prize draws per session). Abstinence-contingent prize draws will be reset to one upon either a positive test result or unexcused, missed appointment."
223620795|NCT03799341|BEHAVIORAL|Treatment As Usual Outpatient Substance Use Treatment|All participants will receive treatment as usual outpatient substance use services during the 12-week treatment interval. TAU will specifically entail recommended participation in at least two outpatient group and/or individual psychotherapy encounters per week within the Center for Treatment of Addictive Disorders (CTAD) at VA Pittsburgh Healthcare System. Participants will additionally continue any previously prescribed pharmacotherapy for substance use and/or other mental health conditions, if applicable.
223620796|NCT05353530|BIOLOGICAL|Ex-Vivo expanded autologous IL-8 receptor (CXCR2) modified CD70 CAR (8R-70CAR) T cells|Single dose of 8R-70CAR T cells administered IV
224210560|NCT01159119|DRUG|EUR-1066-A|Eur-1066 capsules taken daily for 28 days either during treatment period 1 or treatment period 3.
224316098|NCT05184543|OTHER|Core Stability Exercise Program|In addition to the 8-week routine basketball training, 20 min core stability exercises will be given to the Core Group. Core stability exercises will be performed on the stable surface for the first 4 weeks, and core stability exercises will be performed on unstable surfaces for the next 4 weeks.
223620797|NCT05357443|PROCEDURE|Gastric bypass with transection of vagal nerves|Vagal nerve interruption above the level of the stomach is a known treatment for complicated peptic ulcer disease. It is not commonly performed during routine gastric bypass. The vagi are, however, interrupted part-way down the stomach to create the gastric pouch. This is the pars flaccida technique.
223620798|NCT05357443|PROCEDURE|Gastric bypass without transection of vagal nerves|Dissection between the neurovascular bundle and the stomach, spareing the vagus nerves. This is the perigastric technique.
223620799|NCT05889117|DEVICE|Intermittent theta-burst treatment (iTBS) using MagPro Transcranial Magnetic Stimulator (manufacturer: Magventure)|3-10 minute sessions of brain stimulation applied to the left dorsolateral prefrontal cortex, up to 10 sessions a day, 30 sessions in total, planned within 2 weeks.
223620800|NCT06227091|DIETARY_SUPPLEMENT|Beetroot juice|acute dose of beetroot juice
223620801|NCT06227091|DIETARY_SUPPLEMENT|Placebo|depleted nitrate beetroot juice
223620802|NCT02873533|OTHER|geriatric care and longitudinal follow up|geriatric care and longitudinal follow up
223620803|NCT04216472|DRUG|Alpelisib|Given PO
223620804|NCT04216472|DRUG|Nab-paclitaxel|Given IV
223620805|NCT06576856|OTHER|This is an observational study, no intervention is anticipated.|There is no intervention. This is an observational study.
223620806|NCT05695599|DEVICE|Whole body vibration training|3 times per week of 20 to 30 minute sessions during 16 weeks of training
223620807|NCT01800097|DRUG|modafinil|Tablet, 400 mg once daily, morning (200 mg if age 65 or above) for 3 months
223620808|NCT01800097|DRUG|placebo|Tablets, 400 mg once daily ( 200 mg if age 65 or above)morning for 3 months.
223620809|NCT04440826|OTHER|Whole Food Meal|Whole foods meal
223620810|NCT04440826|OTHER|Processed Food Meal|Processed food meal
223620811|NCT04440826|OTHER|Gluten-free and lactose-free|Gluten-free and lactose-free food meal
224210561|NCT01159119|DRUG|Zenpep|Capsules taken for daily for 28 days during treatment period 2
224210562|NCT01159119|DRUG|EUR-1066-B|Eur-1066 capsules taken daily for 28 days either during treatment period 1 or treatment period 3.
224316099|NCT05184543|OTHER|Body Weight Neuromuscular Warm-Up Program|Each 20-minute program consists of 5 different parts. The beginning of the program consists of low-speed running exercises with the ball. The running track for each exercise will include 4 basketball court areas. The second part consists of active stretching exercises. The third part consists of exercises focusing on general strength. The fourth part consists of plyometric, balance, and jump exercises. The final section consists of a sprint with sudden changes of direction and basketball movements.
223620812|NCT05311956|DEVICE|Active tDCS|The study intervention will be participants self-applying 40 tDCS active stimulations with in-person supervision provided by trained study personnel. The self-applied intervention will continue 5 times per week over eight consecutive weeks. Treatment will occur in the home.
223620813|NCT05311956|DEVICE|Sham tDCS|In this arm of the study participants will self-apply 40 sham tDCS stimulations with in-person supervision provided by trained study personnel. The self-applied intervention will continue 5 times per week over eight consecutive weeks. Treatment will occur in the home.
223620814|NCT06307054|DRUG|anti-CLL-1 CAR NK cells|Eligible patients enrolled in the study after screening will receive lymphocyte collection(from the patient or a donor ) and receive single dose CLL-1 CAR NK cells infusion after a successful cell production. There are a total of four cell dose level:5×10\^6 CAR-NK cells/kg,1×10\^7CAR-NK cells/kg,2×10\^7CAR-NK cells/kg,4×10\^7CAR-NK cells/kg
223620815|NCT02960022|DRUG|enzalutamide|Subjects will receive enzalutamide orally once daily at the same time each day.
223620816|NCT02960022|DRUG|abiraterone acetate|Subjects enrolling from study 9785-CL-0011 or MDV3100-10 (PLATO) study may receive abiraterone acetate once daily and prednisone twice daily, in addition to enzalutamide
223620817|NCT02960022|DRUG|prednisone|Subjects enrolling from study 9785-CL-0011 or MDV3100-10 (PLATO) study may receive abiraterone acetate once daily and prednisone twice daily, in addition to enzalutamide
223620818|NCT02960022|DRUG|Leuprolide acetate|Subjects enrolling from study MDV3100-13 (EMBARK) study may receive leuprolide acetate once every 12 weeks in addition to enzalutamide once daily
223620819|NCT06192576|DRUG|Olipudase alfa|This study will not administer any treatment, only observe the treatment as prescribed in real-world clinical practice.
223620820|NCT04927416|DRUG|68-Gallium-DOTATATE-PET/CT|68Ga-DOTATATE is administered one-time via intravenous injection of 5 mCi in a volume of 3-5 ml containing up to 50 mcg \[68Ga\] DOTATATE.
223620821|NCT01116648|PROCEDURE|Biopsy Procedure|Undergo optional tissue biopsy
223620822|NCT01116648|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223620823|NCT01116648|DRUG|Cediranib Maleate|Given PO
223620824|NCT01116648|PROCEDURE|Computed Tomography|Undergo CT
223620825|NCT01116648|PROCEDURE|Echocardiography Test|Undergo ECHO
223620826|NCT01116648|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223620827|NCT01116648|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
223620828|NCT01116648|DRUG|Olaparib|Given PO
223620829|NCT01172314|DIETARY_SUPPLEMENT|EAA+LEU vs total AA|15 g as a bolus
223620830|NCT01172314|DIETARY_SUPPLEMENT|Total AA vs EAA+LEU|15 g as a bolus
224210563|NCT05578755|BEHAVIORAL|FutureU|"FutureU is based on the assumption that future orientation can be strengthened by increasing the extent to which people identify with their future self. People who identify more with their future self appear to be more inclined to make more altruistic choices favoring their future self and foregoing immediate gratification. The intervention provides psychoeducation and exposure to and interaction with the future self. Participants interact with a digitally aged version of themselves, i.e., their 'future self', using a smartphone application (app) or through immersive virtual reality (VR).~The app consists of three week-long modules. Participants interact with the app on a daily basis for about 5 minutes a day for 21 consecutive days.~The VR consists of three sessions, each lasting about 30 minutes. Each VR session is guided by a trained researcher."
223620831|NCT04133506|DRUG|Aspirin 300mg|see earlier (only half of healthy volunteers receive aspirin)
223620832|NCT04539938|DRUG|tucatinib|300 mg orally twice daily
223620833|NCT04539938|DRUG|trastuzumab deruxtecan|5.4 mg/kg via intravenous (into the vein; IV) infusion on Day 1 of each of 21-day cycle
223620834|NCT05049928|OTHER|Telerehabilitation solution (m-Rehab)|"The telerehabilitation program consists of the following elements:~* Mobile applications and website usable on smartphone and tablet for the patient.~* Teleconsultation solution for the patient and the doctors.~* Video conferencing solution for professionals involved in patient follow-up: educators in adapted physical activity, physiotherapists, psychologists, dieticians, etc.~* Web interface for health professionals allowing the collection and monitoring of various parameters in physical activity and nutrition as well as progress in therapeutic education activities.~* Withings® connected objects"
223620835|NCT06980376|OTHER|a2 UHT milk|Pregnant women in this arm will drink a2 UHT Milk twice a day, 200ml each time, until study completion. Their infants will be fed with the mother's breastmilk exclusively.
223620836|NCT06980376|OTHER|Conventional UHT Milk|Pregnant women in this arm will drink conventional UHT Milk twice a day, 200ml each time, until study completion. Their infants will be fed with the mother's breastmilk exclusively.
223620837|NCT04201470|OTHER|Blood withdrawal|Measurement of serum neurofilaments light chain and GFAP
223620838|NCT04201470|OTHER|MRI|Cervical and cerebral MRI without contrast injection
223620839|NCT04201470|OTHER|Neurologic / neuropsychologic tests - Patients|EDSS (Expanded Disability Status Scale), NHPT (Nine Hole Peg Test), T25FW (Timed 25-Foot Walk Test), 6MWT (Six-Minute Walk Test), CSCT (Computerized version of the Symbol Digit Modalities Test)
223620840|NCT04201470|OTHER|Neurologic / neuropsychologic tests - Controls|NHPT, T25FW, CSCT
223620841|NCT00285909|BEHAVIORAL|Alcohol: 25 gday (white wine)|
223620842|NCT06604130|DIAGNOSTIC_TEST|Prostate cancer screening decision|The subjects would receive serum PSA test.
223620843|NCT06763055|DRUG|Colchicine 0.5 mg|The intervention group will receive 0.5mg of oral colchicine daily as soon as possible after randomization, to continue for 30 days.
223620844|NCT06763055|DRUG|Deferoxamine Mesylate|The intervention group will receive deferoxamine mesylate at a dose of 32mg/kg/day via intravenous infusion immediately (within 1 hour) and continued for 2 consecutive days
223620845|NCT06763055|OTHER|Control (Standard treatment)|The group will not receive deferoxamine mesylate or colchicine
223620846|NCT00410956|BIOLOGICAL|bevacizumab|
223620847|NCT00410956|DRUG|dexamethasone|
223620848|NCT00410956|DRUG|floxuridine|
223620849|NCT00410956|GENETIC|protein expression analysis|
223620850|NCT00410956|OTHER|flow cytometry|
223620851|NCT00410956|OTHER|immunoenzyme technique|
223620852|NCT00410956|OTHER|immunohistochemistry staining method|
223620853|NCT00410956|OTHER|immunologic technique|
223620854|NCT00410956|OTHER|laboratory biomarker analysis|
223620855|NCT00410956|PROCEDURE|dynamic contrast-enhanced magnetic resonance imaging|
223620856|NCT06618118|DRUG|Fosigotifator|Oral Use
223620857|NCT06618118|DRUG|Placebo|Oral Use
223620858|NCT07008586|DIETARY_SUPPLEMENT|OliPhenolia®|Olive derived hydroxytyrosol will be ingested via a commercially available olive fruit wastewater (OliPhenolia®) in a dose relative to participant body mass.
224210564|NCT05578755|BEHAVIORAL|Goal-setting|In the control condition participants set goals (as in the intervention conditions), but receive no further guidance.
223620859|NCT07008586|DIETARY_SUPPLEMENT|Taste and appearance matched placebo|Equal parts prune juice (Sunsweet California Prune Juice, Yuba City, CA, USA), diet cola (Tesco Cola, Tesco, UK) and tonic water (Tesco low calorie Indian tonic water, Tesco, UK).
223620860|NCT05872295|DRUG|IKS014|IKS014 is a human monoclonal antibody (Ab) targeting HER2 linked to monomethyl auristatin F (MMAF) cytotoxic agent.
223620861|NCT00765440|DIETARY_SUPPLEMENT|therapeutic nutritional supplementation|Given orally
223620862|NCT00765440|OTHER|placebo|Given orally
223620863|NCT06327685|DRUG|Avapritinib|Avapritinib is an oral tyrosine kinase inhibitor.
224210565|NCT01614613|DEVICE|Bayer G3 / Tatsu System|Study staff performed Blood Glucose (BG) tests with capillary fingerstick blood collected from subjects with diabetes. All meter BG results were compared with plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).
224210566|NCT01614613|DEVICE|Accu-Chek® Aviva Nano Meter/Accu-Chek® Aviva Test Strips|Study staff performed Blood Glucose (BG) tests with capillary fingerstick blood collected from subjects with diabetes. All meter BG results were compared with plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).
223761704|NCT04275128|DEVICE|Cooled radiofrequency ablation|Cooled radiofrequency thermal treatment uses the electrical current produced by radio waves to destroy a part of nerve tissue and relieve pain.
224210567|NCT01614613|DEVICE|Freestyle Lite® Meter and Test Strips with ZipwikTM tabs|Study staff performed Blood Glucose (BG) tests with capillary fingerstick blood collected from subjects with diabetes. All meter BG results were compared with plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).
224210568|NCT01614613|DEVICE|OneTouch® Ultra®2 / OneTouch® Ultra® Blue Test Strips|Study staff performed Blood Glucose (BG) tested with capillary fingerstick blood collected from subjects with diabetes. All meter BG results were compared with plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).
224316100|NCT02548390|DRUG|RXDX-107|Subjects in this study will receive RXDX-107 intravenously at dose levels specified for their respective dose cohorts. Dosing will begin at 25 mg/m2 on Day 1 and Day 2 of a 28-day cycle and will escalate until the maximum tolerated dose (MTD) or (RP2D) is determined. An additional schedule of administration of RXDX-107 on Day 1 of a 28 day cycle may be assessed. Cycles will be repeated in four-week (28 day) intervals for up to 6 cycles or until progression of disease, unacceptable toxicity, or another discontinuation criterion is met.
223761705|NCT04275128|DEVICE|Conventional radiofrequency ablation|Genicular nerve ablation involves using radiofrequency to heat up the genicular nerve until it dies, causing relief of pain. This is a minimally invasive treatment that does not require any medication.
224210569|NCT01614613|DEVICE|One Touch® VerioTM Pro/One Touch® VerioTM Test Strips|Study staff performed Blood Glucose (BG) tests with capillary fingerstick blood collected from subjects with diabetes. All meter BG results were compared with plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).
224210570|NCT01614613|DEVICE|Truetrack® Meter/Truetrack® Test Strips|Study staff performed Blood Glucose (BG) tests with capillary fingerstick blood collected from subjects with diabetes. All meter BG results were compared with plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).
224316101|NCT03267901|OTHER|food|45 g of walnut / iso-caloric white bread
224316102|NCT04207463|DRUG|AK105|AK105 is a humanized monoclonal antibody that specifically binds to PD-1. AK105 has a typical antibody structure and is composed of two lgG1 subtype heavy chains and two kappa subtypes light chains covalently linked by disulfide bonds.
224316103|NCT04207463|DRUG|Anlotinib|a multi-target receptor tyrosine kinase inhibitor
224316104|NCT02603991|PROCEDURE|PINS Vagus Nerve Stimulator|The stimulators are implanted in the body,with the stimulation of the IPG
223620864|NCT06327685|DRUG|Decitabine|Decitabine is a nucleoside metabolic inhibitor given intravenously.
223620865|NCT06327685|COMBINATION_PRODUCT|Decitabine/Cedazuridine|Decitabine/Cedazuridine is a combination medicine given orally.
223620866|NCT06868511|PROCEDURE|Neuronavigation-assisted Stereotactic Minimally Invasive Puncture Combined with Tenecteplase|Neuronavigation-assisted stereotactic minimally invasive puncture will enhances catheter placement precision, reducing complications and improving hematoma evacuation and neurological outcomes. TNK, a third-generation thrombolytic will offers advantages over alteplase (rt-PA), including a longer half-life for rapid bolus administration and effective thrombolytic effects to dissolve clots and promote hematoma clearance.
223620867|NCT06868511|DRUG|Standard medical treatment|The standard medical treatment for this group of patients will be provided according to the optimal care standards defined by the American Heart Association (AHA) guidelines for intracerebral hemorrhage management
223620868|NCT06625411|DRUG|VRDN-003|VRDN-003 is an investigational, subcutaneously administered, humanized monoclonal antibody directed against the Insulin-like Growth Factor-1 receptor (IGF-1R).
223620869|NCT06625411|DRUG|Placebo|All participants will receive the same number of injections to maintain masking. Masking will be maintained by the use of placebo injections that appear identical to VRDN-003 injections.
223620870|NCT06625060|BIOLOGICAL|IPN10200|Lyophilised powder
223620871|NCT06625060|OTHER|Placebo|Excipients without active substance, Lyophilised powder
223620872|NCT06625060|BIOLOGICAL|IPN10200 dose A|Lyophilised powder
223620873|NCT06625060|BIOLOGICAL|IPN10200 dose B|Lyophilised powder
223620874|NCT01650194|DRUG|enzalutamide|Participants received 160 mg of enzalutamide orally once daily (4 capsules, 40 mg each).
223620875|NCT01650194|DRUG|abiraterone acetate|Participants received 1000 mg of abiraterone acetate orally once daily (4 tablets, 250 mg each).
223620876|NCT01650194|DRUG|prednisone|Participants received 5 mg of prednisone orally twice daily (2 tablets, 5 mg each).
223761706|NCT05593224|DEVICE|Intracranial Stent (Tonbridge)|The intracranial stent consists of a self-expanding, laser-carved nickel-titanium stent and its delivery system.
223620877|NCT05937399|BEHAVIORAL|Intervention video|This intervention is an integrated health video provides individual (smoking) and environmental risk communication on intention to obtain lung cancer screening.
223620878|NCT05937399|BEHAVIORAL|Control video|This intervention is an integrated health video provides individual (smoking) risk communication on intention to obtain lung cancer screening.
223620879|NCT05741528|DRUG|SEP-363856|SEP-363856 tablet
223620880|NCT06703567|BEHAVIORAL|Standard Policy|Patients will receive information about the GEP test by clinical teams
223620881|NCT06703567|BEHAVIORAL|Standard Policy + GEP Information Film|Patients will receive information about the GEP test by clinical teams and, after consultation with physician, they will be sent a link to view the film regarding OncotypeDX
224210571|NCT05580549|DIAGNOSTIC_TEST|Alcohol biomarker Phosphatidylethanol (PEth)|The prevalence of hazardous alcohol use will be mapped through the biomarker PEth and the questionnaire AUDIT.
224210572|NCT01259518|DRUG|TRIN2755|In treatment schedule A (Group A), the planned starting dose to be investigated is 25 mg TriN 2755 given once followed by a recovery period of 4 weeks. Subsequent patients can only be included on a new dose level when the safety review from all patients included at the preceding dose level(s) at Day 28 after infusion (end of Cycle 1) does not indicate relevant toxicity.
224210573|NCT01259518|DRUG|TRIN2755|In treatment schedule B (Group B), the starting dose to be investigated is 800mg, given once every 7 days in a 4 week cycle. Subsequent patients can only be included on a new dose level when the safety review from all patients included at the preceding dose level(s) at Day 28 after the start of the first infusion (end of Cycle 1) does not indicate relevant toxicity.
223620882|NCT06712784|BEHAVIORAL|Treatment Package (for both simulation and procedure sessions|Treatment Package for both simulation and procedure sessions will include visit priming (contingency specifying stimuli in the form of social stories and YouTube videos) and differential reinforcement of alternative behavior (DRA).
224210574|NCT03541213|PROCEDURE|myocardial biopsy|Myocardial biopsy (after opening cardiac cavities under general anesthesia for valvular surgery) for mitochondrial metabolism analyses.
224210575|NCT03541213|PROCEDURE|sternal bone marrow biopsy|Sternal bone marrow biopsy (after sternal opening under general anesthesia for valvular surgery) for the quantification of iron stores
223620883|NCT07037277|DRUG|Bemnifosbuvir-Ruzasvir|BEM/RZR Fixed-dose Combination (FDC) tablets administered orally once daily for a total of 8 weeks (in those without cirrhosis) or 12 weeks (in those with compensated cirrhosis)
223620884|NCT07037277|DRUG|Sofosbuvir-Velpatasvir|SOF/VEL Fixed-dose Combination (FDC) tablets administered orally once daily for a total of 12 weeks
223620885|NCT06726226|OTHER|Standard care for preterm infants|Standard care for preterm infants according to the institutional protocol
223620886|NCT06726382|DRUG|Esketamine Nasal Spray|1 x 28 mg dose
223620887|NCT06726382|DRUG|Esketamine 28 mg|1 x 5,6 ml p.o.
224210576|NCT03541213|BIOLOGICAL|blood sample|blood sample (under general anesthesia for valvular surgery, using the arterial catheter already in place) for hepcidin quantification (hormone not dosed in the usual martial assessment)
224316105|NCT02603991|DRUG|Levetiracetam|The best anti-epileptic drugs to patients who participate in this study，Levetiracetam，
223620888|NCT06726382|DRUG|Cobicistat 150 MG|1 x 150 mg tablet
223620889|NCT06725875|OTHER|White Noise Group|During the procedure, a mobile white noise (WN) application called Noise: White, Pink, Brown will be played via over-the-ear headphones to provide the individual with a sense of comfort. The intensity of the white noise will be determined using sound samples for patient comfort. The mobile WN application will be played to the patient by selecting white from among the color options. The sound level will be adjusted below 50 dB using a measuring device to prevent possible hearing damage (12). At the end of the procedure, the listening process will be terminated and the headphones will be removed. At the end of the procedure, the outer and inner surfaces of the headphones will be cleaned with disposable disinfectant wipes to prevent decontamination when used by another patient.
223620890|NCT06725875|OTHER|Earplug group|2\. Earplug group: An earplug that prevents patients from hearing outside sounds will be used during the procedure. Features: Smooth, dirt-resistant surface provides better hygiene. Earplugs are easy to roll for quick and easy insertion. Conical design fits comfortably in ear canals. Soft polyurethane foam is hypoallergenic. Similar earplugs were used in a previous study
223620891|NCT04388683|DRUG|Nitric Oxide|"Subjects will receive iNO using the INO pulse device at a dose of 125 mcg/kg IBW/hr (equivalent to approximately 20 ppm). The clinical disease severity will be assessed pre-randomization as the worse of 2 scores measured 2 hours apart. Patients eligible for randomization will be those with scores of 1 or 2 (below), and randomization will be stratified according to score (1 or 2). Study drug will begin within 1 hour of randomization. Beginning on the day following randomization (day 1), we will be calculate clinical score, daily, as the average of 3 measurements taken within 2 hour windows centered at 6AM, 2PM, and 10PM."
223620892|NCT06730061|DRUG|Elafibranor|Tablet of 80 mg
223620893|NCT06725771|DRUG|Bupleurum Plus Dragon Bone and Oyster Shell Decoction Combined with Sertraline|Bupleurum Plus Dragon Bone and Oyster Shell Decoction and Sertraline are given to patients simultaneously
223620894|NCT06725771|DRUG|Sertraline Hydrochloride Tablets|Sertraline are given to patients simultaneously
223620895|NCT03288571|BIOLOGICAL|Wharton Jelly Mesenchymal stem cells|Wharton Jelly Mesenchymal stem cells will be injected in the renal parenchyma
223620896|NCT06726642|DIAGNOSTIC_TEST|Cell-free DNA analysis|Analysis of cell-free DNA in blood plasma will involve targeted sequencing of key cancer-related genes, cell-free methylated DNA immunoprecipitation and high-throughput sequencing (cfMeDIP-seq), and shallow whole genome sequencing (sWGS).
223761707|NCT00773175|DRUG|recombinant human hyaluronidase|150 Units in 1 mL
223620897|NCT00880698|BIOLOGICAL|RotaTeq|2 mL solution of live reassortant rotaviruses, containing G1, G2, G3, G4 and P1A which contains a minimum of 2.0 - 2.8 x 10\^6 infectious units (IU) per individual reassortant dose, depending on the serotype, and not greater than 116 x 10\^6 IUs per aggregate dose
223620898|NCT00880698|BIOLOGICAL|Placebo|2 mL solution
224210577|NCT00046384|DRUG|aripiprazole|
224210578|NCT03275779|BEHAVIORAL|Low Frequency Condition|Young, untrained participants complete 7 days of habitual physical activity followed by a 7 day period where participants complete a single bout of unilateral resistance exercise.
224316106|NCT00002926|DRUG|cytarabine|
224316107|NCT00002926|DRUG|etoposide|
224316108|NCT00002926|DRUG|idarubicin|
223620899|NCT06727162|PROCEDURE|Contrast-Enhanced Ultrasound|"Participants are scanned in a supine position with the neck fully exposed. A routine ultrasound examination is first performed to assess the cervical lymph nodes. Assessment includes: number, size, location (zones I-VII), structure, echogenicity, margin, shape, hilum, calcification, and vascular distribution.~After the routine ultrasound scan, the ultrasound system is switched to dual contrast-enhanced ultrasound mode. Sonazoid (GE Healthcare) is then administered intravenously through the antecubital vein at a dose of 0.015 mL/kg, followed by an injection of 5 mL of physiological saline. A timer is started after the injection, and video recording is made during the vascular phase from 5 to 60 seconds."
223620900|NCT06727188|DIAGNOSTIC_TEST|Laboratory as cbc crp|Using laboratory and imaging investigations to help in diagnosis and follow up the cases
223620901|NCT01810770|DRUG|Radium-223 dichloride (Xofigo, BAY88-8223)|Radium-223 dichloride, 55 kBq/kg body weight, will be administered as a slow bolus IV injection at 4 week intervals for up to 6 doses.
223620902|NCT07049640|OTHER|Acupressure Group|Effects of Acupressure Interventions
223620903|NCT07049640|OTHER|Cold Application to Acupressure Points Group|Effects of Cold Application to Acupressure Points Interventions
223620904|NCT06705634|OTHER|Dry Needling|A sterile, disposable, solid filament needle (Seirin Corp., Shizuoka, Japan) will be inserted manually into the multifidus of the C5-C6 cervical muscles. Once the needle has been inserted, the needle will be pistoned in an up and down motion within the multifidus muscle at approximately 1Hz for 10 seconds and then left in-situ for 5 minutes.
223620905|NCT06726291|DRUG|NEPA (300mg netupitant/0.5mg palonosetron)|a single dose (capsule) of NEPA (300mg netupitant/0.5 palonosetron) at day 1 for a maximum of 4 cycles
223620906|NCT06880510|DEVICE|t-VNS transcutaneous auricular vagus nerve stimulator|An investigator will clip the the transcutaneous auricular vagus nerve stimulator (taVNS) to the outer ear, and apply electrical current to modulate the activity of the vagus nerve. During this process, the investigator will monitor pupil size and heart rate to determine whether either of these variables is affected by vagus nerve stimulation.
223620907|NCT06785415|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
223620908|NCT06785415|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
223620909|NCT06785415|PROCEDURE|Bone Scan|Undergo bone scan
223620910|NCT06785415|PROCEDURE|Chest Radiography|Undergo chest x-ray
223620911|NCT06785415|PROCEDURE|Computed Tomography|Undergo CT and/or PET/CT
223620912|NCT06785415|BIOLOGICAL|Daratumumab|Given SC
223620913|NCT06785415|DRUG|Dexamethasone|Given PO
223620914|NCT06785415|BIOLOGICAL|Elotuzumab|Given IV
223620915|NCT06785415|DRUG|Iberdomide|Given PO
223620916|NCT06785415|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
224316109|NCT00002926|PROCEDURE|allogeneic bone marrow transplantation|
224316110|NCT00002926|PROCEDURE|peripheral blood stem cell transplantation|
223620917|NCT06785415|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
223620918|NCT04111718|BIOLOGICAL|Platelet-rich plasma (PRP)|Autologous platelet-rich plasma which will be derived from blood drawn from the patient.
223620919|NCT04111718|BEHAVIORAL|Viewing of preparation|The patient will receive a description of the preparation process and will view the preparation in the centrifuge.
223620920|NCT06576934|PROCEDURE|Transjugular intrahepatic portosystemic shunt (TIPS)|TIPS implantation is performed by creating a shunt between the liver vein and the portal vein to enable portal pressure reduction.
223620921|NCT06743347|OTHER|MRI Contrast|Pass a Phase Contrast MRI. No injection required.
223620922|NCT06895057|OTHER|Exercise|Individuals who voluntarily accept to participate in the study will be divided into two groups as telerehabilitation and clinical practice groups by randomization. Exercises will be applied face to face to the clinical practice group and online to the telerehabilitation group via tablet. Individuals who will participate in the study will be applied twice a week for 8 weeks, each session lasting 50 minutes. Pain, quality of life, endurance, functionality, and flexibility assessments will be taken face to face for both groups before and after the application. Treatment satisfaction scale (PGIC) will be taken from both groups in the 4th and 8th weeks. All assessments will be evaluated twice before and after the training by the same therapist in the clinic, face to face.
223620923|NCT06785207|DEVICE|3D-printed scoliosis brace|"Scoliosis brace will be 3D printed using a Filament Innovations Icarus printer and the material CPX. There will be corrugations where extra strength is needed. The brace will be made using the same shape as the participant's current brace to minimize variables at play.~According to Sec. 890.3490 of the Code of Federal Regulations Title 21, scoliosis braces are Class I devices, requiring only general controls. This device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter, subject to the limitations in § 890.9. The device is also exempt from the current good manufacturing practice requirements of the quality system regulation in part 820 of this chapter, with the exception of § 820.180, regarding general requirements concerning records and § 820.198, regarding complaint files."
223620924|NCT05107908|BEHAVIORAL|Active Implicit Priming|Approximately 10-minute behavioral intervention
223620925|NCT05107908|BEHAVIORAL|Control Implicit Priming|Approximately 10-minute behavioral intervention
223620926|NCT05107908|BEHAVIORAL|Food Exposure Task|Approximately 10-30 minute behavioral intervention
223620927|NCT06922331|DRUG|Upadacitinib|A selective Janus kinase (JAK) 1 inhibitor used for the treatment of refractory inflammatory bowel disease.
223620928|NCT06932861|BIOLOGICAL|mRNA Tumor Vaccine Therapy|personalized mRNA vaccines
224316111|NCT05727826|DEVICE|Thrive MD-01 .|The experimental group received a 60 Hz vibration stimulation treatment using the SMV method three times per week for two weeks (EG).
224316112|NCT00682357|DRUG|Methylprednisolone and Lidocaine|Methylprednisolone 80 mg, intra-articular and lidocaine 20 mg
223620929|NCT06938165|OTHER|Fecal Microbiota Transplant (FMT)|FMT in patients with refractory GVHD
223620930|NCT06938919|DEVICE|routine care without electronic respiratory sound monitoring system|Maintain heart rate between 50-100 bpm; maintain systolic blood pressure between 90-160 mmHg; maintain SpO2 above 94%.
224316113|NCT00682357|DRUG|Methylprednisolone and Lidocaine|Methylprednisolone 16 mg intra-articular and lidocaine 20 mg
224316114|NCT00682357|DRUG|Placebo and Lidocaine|Placebo and lidocaine 20 mg
224316115|NCT04682522|DRUG|Metronidazole Oral|250 mg Three times a day
223620931|NCT06938919|DEVICE|routine care with electronic respiratory sound monitoring system|Maintain heart rate between 50-100 bpm; maintain systolic blood pressure between 90-160 mmHg; maintain SpO2 above 94%; and refer to the following electronic breath sound abnormalities to maintain sedation depth: Maintain respiratory rate (RR) at 12-20 bpm; avoid partial airway obstruction
223620932|NCT06937450|DEVICE|CLR Irrigator|All enrolled patients will have their hemothorax treated with a CLR device that allows for easy suction and irrigation through indwelling catheters,
223620933|NCT06937450|PROCEDURE|Serial Lavage and Drainage|The current protocol is to do a singular lavage and drainage, this study will investigate the benefits of daily lavage.
223620934|NCT06937450|DEVICE|28 Fr Open Chest Tube|Patients will have a standard 28 Fr open chest tube or a percutaneous 14Fr chest tube placed.
223620935|NCT06937450|DEVICE|Percutaneous 14Fr Chest Tube|Patients will have a standard 28 Fr open chest tube, or a percutaneous 14Fr chest tube placed.
223620936|NCT06938126|DIETARY_SUPPLEMENT|L-Arginine and Citrulline-Malate Supplementation|L-Arginine and Citrulline Malate supplementation was consumed as a liquid one single time to examine the acute effects on sport performance
223620937|NCT06938126|DIETARY_SUPPLEMENT|Placebo consumption|Consumption of placebo as a liquid
223620938|NCT06938490|PROCEDURE|Anterior rectal resection with D3-lymphatic dissection|"This study aims to determine the incidence of anastomosis failure in the group with first SA and LCA preservation in order to identify the feasibility of manipulation.~The study is unique in that there is only one study in the world that evaluates the incidence of anastomosis failure with preservation of the first sigmoid and there is no study comparing the groups described in this study."
223620939|NCT06938256|OTHER|Suboccipital Muscle Inhibition|With the patient in the supine position and the eyes closed, the therapist sits behind the subject's head and place the palms of his/her hands beneath it, resting the pads of his/her fingers on the projection of the posterior arch of the atlas. Pressure is exerted upward and toward the therapist. The pressure is maintained for 2 minutes until tissue relaxation had been achieved. The physiotherapist progressively increased the pressure exerted during the 10 minutes of treatment.
223620940|NCT06938256|OTHER|Rocabado 6x6 Exercises|"Rocabado created 6X6 program for the management of CGH which includes 6 fundamental components, one session under supervision and remaining five sessions by the subject at home.~These components are:~* Rest position of the tongue~* Control of TMJ rotation~* Rhythmic stabilization technique~* Stabilized head flexion~* Axial extension of the neck~* Shoulder posture"
223620941|NCT06937411|DRUG|LY4100511|Administered orally
223761708|NCT06097234|DEVICE|Pelex Upp|Biofeedback-mediated pelvic floor trainer. It captures contraction and relaxation of the pelvic floor muscles during use by the subject, and represents these contractions and relaxations back to the subject to improve conscious control of the muscle groups.
224210579|NCT03275779|BEHAVIORAL|High Frequency Condition|Young, untrained participants complete 7 days of habitual physical activity followed by a 7 day period where participants complete the same total volume of resistance exercise as the low frequency condition as five smaller bouts of unilateral resistance exercise.
224210580|NCT02891564|BEHAVIORAL|Band Together|a mobile 3D video game that has been shown to reduce older adults' susceptibility to interference by augmenting sustained attention and working memory abilities (e.g. cognitive control) through targeted adaptive algorithms. This game is analogous to Project: EVO.
224210581|NCT02891564|OTHER|Control Mobile 3D video game|expectancy-matched control game
224210582|NCT01557452|DRUG|Givinostat|ready-to-use oral suspension, administered in fed condition and on a outpatient basis, especially intended for paediatric patients
224210583|NCT00440375|DRUG|Rosiglitazone|
224210584|NCT04765852|OTHER|High dose probiotic supplement|One probiotic stick pack will be dissolved in 10 mL lukewarm formula milk or breastmilk at body temperature. The dissolved supplement will be fed orally, preferably in the morning, starting on Day 1 until Day 56.
224210585|NCT04765852|OTHER|Low dose probiotic supplement|One probiotic stick pack will be dissolved in 10 mL lukewarm formula milk or breastmilk at body temperature. The dissolved supplement will be fed orally, preferably in the morning, starting on Day 1 until Day 56.
224210586|NCT04765852|OTHER|Placebo|One placebo stick pack will be dissolved in 10 mL lukewarm formula milk or breastmilk at body temperature. The dissolved supplement will be fed orally, preferably in the morning, starting on Day 1 until Day 56.
224210587|NCT00124475|DRUG|alitretinoin|
224210588|NCT05368233|OTHER|ERAS protocol|ERAS protocol whch helps to optimise the length of hospital stay.
224210589|NCT03827785|DEVICE|rTMS treatment group|For rTMS treatment, we will stimulate the dorsal lateral prefrontal cortex of each patients using the iTBS pattern everyday. Treatment will lasted for 30 days.
224210590|NCT03827785|DEVICE|sham rTMS treatment group|For sham rTMS treatment, we will stimulate the dorsal lateral prefrontal cortex of each patients using the sham iTBS pattern and sham coil everyday for 30 minutes. Treatment will lasted for 30 days.
224210591|NCT03251209|OTHER|Physical practice|Physical Practice: reproduce through the motor execution (4 distinct tasks: stacking cubes, opposition of fingers with precision gripping, passing water from one glass to another, sequencing of bottles), the activities assisted in the video (5 minutes / task).
224210592|NCT03251209|OTHER|Mental practice|Mental practice: think about the tasks watched in the videotherapy (4 distinct tasks: stacking cubes, opposition of fingers with precision gripping, passing water from one glass to another, sequencing of bottles) for 5 minutes / task.
224210593|NCT03251209|OTHER|Videotherapy|Videotherapy, being 2 minutes per task (4 distinct tasks: stacking cubes, opposition of fingers with precision gripping, passing water from one glass to another, sequencing of bottles)
224210594|NCT00490737|DRUG|daptomycin|6mg/kg, i.v. infusion over 30 minutes; every 48 hours for a total of 3 doses
224210595|NCT02067988|DEVICE|Holmium-166 microspheres hepatic radioembolization.|Holmium-166 microspheres hepatic radioembolization.
224210596|NCT01074307|DRUG|Low Dose Bisoprolol|Bisoprolol tablet (Concor) will be administered orally at a starting dose of 1.25 milligram (mg) once daily for 2 weeks. The dose will be further escalated from 1.25 mg to 2.5 mg once daily after 2 weeks and will be administered up to 26 weeks, only if the previous administered dose is well tolerated. If the subject could not tolerate the increased dose, then the last tolerated dose will be maintained up to 26 weeks.
223620942|NCT07145996|OTHER|AI Based Exercises|This intervention combines structured exercise therapy with artificial intelligence-powered movement analysis using Google MediaPipe Pose technology. Participants perform prescribed exercises (flexibility, core stability, functional strength) while a computer vision system analyzes their movements through standard webcam or smartphone cameras. The AI provides real-time feedback on exercise form, automatically counts repetitions, measures hold times, and flags technique errors. Physiotherapists review AI-generated performance data and provide personalized corrective guidance through scheduled video consultations. The platform delivers 8-week progressive exercise programs specifically designed for chronic non-specific low back pain, integrating objective movement monitoring with human therapeutic oversight to optimize adherence and clinical outcomes.
223620943|NCT07145996|OTHER|Standard Telerehabilitation|This intervention delivers structured exercise therapy through pre-recorded video instructions without AI monitoring or automated feedback. Participants receive the same exercise components as the AI-enhanced group (flexibility, core stability, functional strength) but rely on video demonstrations and written instructions for proper technique. Physiotherapists conduct periodic consultations via video conferencing to monitor progress, provide guidance, and adjust exercise programs based on visual observation and participant self-reports. The 8-week progressive program represents current standard telerehabilitation practice for chronic non-specific low back pain, serving as an active comparator to isolate the specific effects of AI-enhanced movement analysis and real-time feedback systems.
223620944|NCT07147634|BEHAVIORAL|Outdoor science education|Following Québec's mandatory curriculum, primary school teachers will provide life science lessons 2h/week for a total of 5 weeks in an outdoor setting
223620945|NCT07147634|BEHAVIORAL|Indoor classroom-based science education|Following Québec's mandatory curriculum, primary school teachers will provide life science lessons 2h/week for a total of 5 weeks inside the classroom
223620946|NCT06954909|BEHAVIORAL|Hydration education and self-assessment|Hydration education is a 25-minute session based on the theory of planned behavior, including the instructions how to use a worksheet for hydration self-assessment and materials.
223620947|NCT01800591|BEHAVIORAL|Financial incentive|
223620948|NCT07198269|DEVICE|Intelligent emergency ventilator for transport|In this study, eligible patients are first evaluated by research staff to confirm that they meet the inclusion criteria. Once eligibility is established, the research team accesses the electronic data capture (EDC) system via a WeChat QR code, where patients are randomly assigned in a 1:1 ratio to either the domestic ventilator group (TV80) or the imported ventilator group (HAMILTON-T1). After randomization, both patient and ventilator preparation procedures are conducted according to a standardized protocol.
223620949|NCT07198269|DEVICE|high-performance emergency ventilator for transport|In this study, eligible patients are first evaluated by research staff to confirm that they meet the inclusion criteria. Once eligibility is established, the research team accesses the electronic data capture (EDC) system via a WeChat QR code, where patients are randomly assigned in a 1:1 ratio to either the domestic ventilator group (TV80) or the imported ventilator group (HAMILTON-T1). After randomization, both patient and ventilator preparation procedures are conducted according to a standardized protocol.
223620950|NCT07200180|DRUG|Аrgon-oxygen breathing mixture|Patients receive a course of inhalations with an argon-oxygen mixture according to the following protocol: 60 minutes on day 1 prior to surgery, 60 minutes one hour before being transferred to the operating room, and 60 minutes on the first postoperative day
223620951|NCT07200180|DRUG|Nitrogen-oxygen breathing mixture|Patients receive a course of inhalations with an nitrogen-oxygen mixture according to the following protocol: 60 minutes on day 1 prior to surgery, 60 minutes one hour before being transferred to the operating room, and 60 minutes on the first postoperative day
223620952|NCT07199712|OTHER|Ozone Therapy (In-Office and Home-Based Treatment)|The intervention consists of professional in-office ozone therapy delivered with the Ozono DTA device (Sweden-Martina) applied to oral mucosal lesions. The first treatment is administered at baseline and additional sessions are performed at 48 hours, day 5, day 8, day 12, and day 15, if clinically required. Alongside in-office therapy, participants perform a 15-day domiciliary regimen with ozonated oral care products, including toothpaste with 2% ozonated sunflower oil, a mouthrinse with 4% ozonated sunflower oil solution, and a topical gel with 15% ozonated sunflower oil, each used twice daily. Clinical outcomes are assessed at each visit from baseline to day 15 with the WHO oral mucositis scale and the Visual Analogue Scale for pain.
223620953|NCT07200128|DRUG|Ritlecitinib|As provided in real world practice
223620954|NCT07198789|OTHER|Altograno® Bakery Foods|Altograno® Pasta, Pizza and Flatbrad, in substitution of the same amount of carbohydrates usually eaten in a stabilized diet
223620955|NCT07198789|OTHER|Standard Whole-Grain Bakery Foods|Industrial standard whole-grain Pasta, Pizza and Flatbrad, in substitution of the same amount of carbohydrates usually eaten in a stabilized diet
223761709|NCT06097234|BEHAVIORAL|Pelvic Floor Physical Therapy|A form of physical therapy whereby the subject is given instructions on how to identify the pelvic floor, how to coordinate the pelvic floor contractions and relaxations, as well as counseling on dietary changes that affect pelvic floor and pelvic organ function
223761710|NCT05357391|DEVICE|The Pressure Injury Prediction and Education model using a mobile application system|Data from the medical records will be used to analyze the probability and risk of wound healing for creating a Pressure Injury Prediction and Education Model using a mobile application system.
223761711|NCT06139913|OTHER|aerobic exercise|moderate intensity aerobic exercise using treadmill
224210597|NCT01074307|DRUG|High Dose Bisoprolol|Bisoprolol tablet (Concor) will be administered orally at a starting dose of 3.75 mg once daily for 2 weeks. The dose will be subsequently increased to 5 mg, 7.5 mg, or 10 mg once daily every two weeks and will be administered up to 26 weeks, only if the previous administered dose is well tolerated. If the subject could not tolerate the increased dose, then the last tolerated dose will be maintained up to 26 weeks.
224210598|NCT02023788|BIOLOGICAL|PNEUMOSTEM|"A single intratracheal administration~Low Dose Group (3 patients): 1.0 x 10\^7 cells/kg High Dose Group (6 patients): 2.0 x 10\^7 cells/kg~\* The subjects were administered with Pneumostem in the earlier part of the Phase I study. No drug/biologics will be administered to any subject during this part of the study."
224210599|NCT01134588|OTHER|Paper questionnaire|
224210600|NCT01134588|OTHER|Touch screen questionnaire|
224210601|NCT01293409|OTHER|Transcranial Brain-Targeted Bright Light Treatment|Transcranial Brain-Targeted Bright Light Treatment via Ear Canals
224210602|NCT05661656|PROCEDURE|Intra-arterial chemoinfusion of breast cancer|Patients will be cannulated via the femoral artery. Then, a 4F fixed-curve catheter (Cobra catheter, Cook Corporation, Bloomington) was advanced to the ipsilateral subclavian artery. Digital subtraction angiography (DSA) was performed to determine tumor arterial blood supply. Super selection of the internal mammary artery done by micro-catheter. Chemo-infusion was decided by the major feeding artery. The intra-arterial chemoinfusion regimen consisted of docetaxel 75 mg/m2 and epirubicin 50 mg/m2 in 200 mL of normal saline and 5% glucose; the drugs were slowly infused via the catheter over at least 15 minutes. Intraarterial infusion was performed once every 3 weeks on average.
224210603|NCT04422015|OTHER|No intervention|No intervention
224210604|NCT02798237|OTHER|Aerobic treadmill training|"Participants will receive three sessions per week over 12 weeks, in groups of 2-4 participants, by a trained physiotherapist. The duration of the sessions will be 40 minutes (5-10 minutes of warm-up/cool-down and 30 minutes of aerobic treadmill training at 60-80% of heart rate reserve). The training intensity progression will be individualized.~Before and after the training, participants will remain at rest for 10-15 minutes to measure heart rate, blood pressure and peripheral oxygen saturation (SpO2). The heart rate will be measured continuously during training. Participants will be asked to report any discomfort and to not volunteer to participate in other exercise program. Device: treadmill."
224210605|NCT02798237|OTHER|Control (overground walking)|Participants will receive three sessions per week over 12 weeks, in groups of 2-4 participants, by a trained physiotherapist. The duration of the sessions will be 40 minutes (5-10 minutes of warm-up/cool-down and 30 minutes of comfortable walking below 40% of heart rate reserve). Before and after the exercise, participants will remain at rest for 10-15 minutes to measure heart rate, blood pressure and peripheral oxygen saturation (SpO2). The heart rate will be measured continuously. Participants will be asked to report any discomfort and to not volunteer to participate in other exercise program
224210606|NCT00460252|PROCEDURE|insulin titration applying a computer algorithm|
224210607|NCT03325452|BIOLOGICAL|venous lactate|value of venous lactate
224210608|NCT06540378|DRUG|Stiripentol|
224210609|NCT06218888|DRUG|Tislelizumab|Tislelizumab 200mg，D1, Q3W
224210610|NCT06218888|DRUG|Fruquintinib|Fruquintinib 3mg ,D1-D14, Q3W
224210611|NCT06218888|DRUG|Chidamide|Chidamide 30mg
224210612|NCT05769088|DIETARY_SUPPLEMENT|Ingestion of a Pre-Workout Supplement|"The Multi-Ingredient Pre-Workout Supplement is administered 15 minutes before the beginning of training sessions. No supplementation is administered in non-training days.~The Resistance Training is performed in alternate days. The training Protocol is: 10 minutes of standardized warm-up, Strength Circuit training using free weights (Alternate Box Step-Ups, Bench Press; Parallel Squat; Up-right Row; Deadlift; Alternate Lunges; Shoulder Press; Leg Extension). The participants perform 16 repetitions of each exercise, with 30 seconds rest and 3 minutes rest after every set. If they can complete 16 repetitions easily, 2.5 to 5 kg are added for the next set. Also, whole-body Perceptual Response is assessed using the 0-10 OMNI-RES Scale, after every set and 15 minutes after finishing."
224210613|NCT05769088|DIETARY_SUPPLEMENT|Ingestion of a Maltodextrin Supplement|"The Maltodextrin Supplement is administered 15 minutes before the beginning of training sessions. No supplementation is administered in non-training days.~The Resistance Training is performed in alternate days. The training Protocol is: 10 minutes of standardized warm-up, Strength Circuit training using free weights (Alternate Box Step-Ups, Bench Press; Parallel Squat; Up-right Row; Deadlift; Alternate Lunges; Shoulder Press; Leg Extension). The participants perform 16 repetitions of each exercise, with 30 seconds rest and 3 minutes rest after every set. If they can complete 16 repetitions easily, 2.5 to 5 kg are added for the next set. Also, whole-body Perceptual Response is assessed using the 0-10 OMNI-RES Scale, after every set and 15 minutes after finishing."
224210614|NCT06130709|PROCEDURE|Atrial fibrillation catheter ablation in a population of BTKi-induced atrial fibrillation|Atrial fibrillation catheter ablation in a population of BTKi-induced atrial fibrillation
224210615|NCT02625207|DRUG|Maraviroc (Part 1)|300 mg twice daily x 5 days
223513083|NCT05830643|BEHAVIORAL|Social skills group psychotherapy|"Groups are 1.5-hours and facilitated by a psychiatrist and social worker. The groups follow Cognitive Behavioral Therapy (CBT) and the Good Lives Model (GLM). Groups involve a check-in to receive advice from group members and then revolve around 1-2 topics. The facilitators are responsible for asking probing questions about the topic to facilitate group discussion and learning.~CBT treatment involves efforts to change thinking patterns which might include: Learning to recognize one's distortions in thinking that are creating problems, and then to re-evaluate them. Gaining a better understanding of the behavior and motivation of others. Using problem-solving skills to cope with difficult situations.~GLM conceptualized healthy sexuality as the natural outcome of success in achieving life goals. Some patients have difficulty changing their self-identity from that of sex offender to that of former sex-offender. The GLM principles are helpful in achieving this aim."
223761712|NCT03285373|DRUG|NOAC|New Oral Anticoagulant
224210616|NCT02625207|DRUG|Maraviroc (Part 2)|150 mg once daily x 10 days
224210617|NCT02625207|DRUG|Darunavir/cobicistat (Part 2)|800/150 mg once daily x 10 days
224210618|NCT01480271|DRUG|2 ng GSK2445053|2ng GSK2445053 administered intranasally
224210619|NCT01480271|DRUG|20ng GSK2445053|20ng GSK2445053 administered intranasally
224210620|NCT01480271|DRUG|100ng GSK2445053|100ng GSK2445053 administered intranasally
224210621|NCT01480271|DRUG|200ng GSK2445053|200ng GSK2445053 administered intranasally
224210622|NCT01480271|DRUG|400ng GSK2445053|400ng GSK2445053 administered intranasally
224316116|NCT06137625|BEHAVIORAL|With regular rhythm|All children learn one dance choreographie with regular rhythm music.The pre-recorded choreography is displayed on a large screen in front of the child. The child practices the choreography by imitating the models in order to learn the sequence movements.
224210623|NCT01480271|DRUG|1000ng GSK2445053|1000ng GSK2445053 administered intranasally
224210624|NCT01480271|DRUG|2000ng GSK2445053|2000ng GSK2445053 administered intranasally
224210625|NCT01480271|DRUG|4000ng GSK2445053|4000ng GSK2445053 administered intranasally
224210626|NCT01480271|DRUG|Placebo|Placebo administered intranasally
224210627|NCT04365088|DRUG|Deflazacort 30 MG Oral Tablet|After the taken a deflazacort pill once preoperatively (one hour ago), local anesthesia was obtained using 2 ml articaine hydrochloride 40 mg/ml with epinephrine 0.01 mg/ml . The horizontal incision was made with no. 15 scalpel blade and a full thickness mucoperiosteal flap was raised. In all surgical procedures, bone removal and/or tooth sectioning were performed under sterile saline irrigation. Following the extraction, granulation tissues were removed, and bleeding was controlled. Finally, the mucoperiosteal flap was repositioned by 3.0 silk sutures.
223513084|NCT05830643|BEHAVIORAL|Adult interest group psychotherapy|"Groups are 1.5-hours and facilitated by a psychiatrist and social worker. The groups follow Cognitive Behavioral Therapy (CBT) and the Good Lives Model (GLM). Groups involve a check-in to receive advice from group members and then revolve around 1-2 topics. The facilitators are responsible for asking probing questions about the topic to facilitate group discussion and learning.~CBT treatment involves efforts to change thinking patterns which might include: Learning to recognize one's distortions in thinking that are creating problems, and then to re-evaluate them. Gaining a better understanding of the behavior and motivation of others. Using problem-solving skills to cope with difficult situations.~GLM conceptualized healthy sexuality as the natural outcome of success in achieving life goals. Some patients have difficulty changing their self-identity from that of sex offender to that of former sex-offender. The GLM principles are helpful in achieving this aim."
224316117|NCT06137625|BEHAVIORAL|Without regular rhythm|All children learn one dance choreographie without regular rhythm music.The pre-recorded choreography is displayed on a large screen in front of the child. The child practices the choreography by imitating the models in order to learn the sequence movements.
223513085|NCT03158779|COMBINATION_PRODUCT|SBRT and chemotherapy|Patients affected by locally unresectable pancreatic cancer receive integrated treatment of FOLFIRINOX or Gemcitabine-Abraxane and a Stereotactic Body Radiation Therapy with a total dose of 54 Gy in 6 fractions of 9 Gy /fractions.
223513086|NCT01084486|DRUG|Metformin|
223513087|NCT00991003|PROCEDURE|Colon capsule endoscopy|The PillCam® Colon Capsule is 11mm x 31mm in size (Figure 1), is equipped with two cameras acquiring pictures from both ends of the capsule at a rate of 4 frames per second (2 pictures per second and camera). The PillCam® Colon Capsule is automatically activated when it is removed from the package. It enters sleeping mode after approximately 10 minutes and starts transmitting again 1 h 45 min later. It has a total operating time of 8 - 10 hours. During the examination the patient wears a sensor array which is attached to the abdominal skin and a data recorder for storage of the information generated by the ingested capsule. After the examination the data are downloaded into the Given Imaging workstation and a video is generated.
223513088|NCT00991003|PROCEDURE|Conventional Colonoscopy|
223513089|NCT02820103|BEHAVIORAL|Text+Visual BCT-based intervention|Participants in the visual intervention group will receive usual care specified below plus a specifically developed Text + Visual BCT-based intervention, comprising 12 BCTs identified from SR and expert consensus study. An animated video, just under 8 minutes in length is hosted online in the Intervention Modelling Experiment. The animation contains 9 of the 12 BCTs and tells the 'delay stories' of three different characters. It was not possible to deliver all of the 12 BCTs comprehensively in the relatively passive media of the animation as some techniques require active participation from participants (e.g. action planning). Thus, n=7 BCTs (1 2 Problem-solving; 1 4 Action planning; 5 2 Salience of consequences; 7 1 Prompts/cues; 9 3 Comparative imagining of future outcomes; 15 2 Mental rehearsal of successful performance) are also delivered via short web-based exercises which follow the animation.
223513090|NCT02820103|BEHAVIORAL|Text-only BCT intervention|Participants in the text-only BCT-based intervention group will receive the usual care specified above plus a text-only BCT-based intervention. This was developed in the same way as the text + visual BCT-based intervention but does not include the visual elements (i.e. animation). Instead, the voiceover from the animated film is displayed in text on screen and narrated in audio. The BCTs which require active engagement are delivered via identical web-based exercises as the text + visual BCT-based intervention.
223513091|NCT02820103|BEHAVIORAL|Leaflet information (control)|Participants in the control group will receive information that is currently used routinely in the NHS site to inform patients with ACS what to do if they experience symptoms after discharge.
223513092|NCT02205359|DEVICE|aCRT ON|CRT device with AdaptivCRT enabled (AdaptivBiV and LV)
223513093|NCT02205359|DEVICE|aCRT OFF|CRT device with AdaptivCRT disabled
223513094|NCT04303403|DRUG|Trametinib|Taken orally once daily
223513095|NCT04303403|DRUG|Ruxolitinib|Taken orally twice daily
223513096|NCT04113980|OTHER|music group|The children in the groups were distracted by music 2 minutes before venipuncture, until the process was over
223513097|NCT04113980|OTHER|kaleidoscope group|The children in the groups were distracted by kaleidoscope 2 minutes before venipuncture, until the process was over
223513098|NCT04113980|OTHER|video group|The children in the groups were distracted by watching video 2 minutes before venipuncture, until the process was over
223513099|NCT00573820|RADIATION|Far Infrared Radiation|Far Infrared Radiation (5μm to 20μm wavelength) for 30 to 40 minutes each treatment session.
223513100|NCT02112227|OTHER|PACT-HF Model|PACT-HF Model includes the following 1) comprehensive patient assessment 2) self-care education 3) patient-centered discharge summary 4) early follow up with FP 5) referral of high-risk patients to regional multidisciplinary HF clinic and to nurse-led home care
223513101|NCT02427672|DEVICE|Transcranial direct current stimulation|
223513102|NCT02427672|DEVICE|Sham transcranial direct current stimulation|
223513103|NCT00067873|BEHAVIORAL|Diet|
223513104|NCT00067873|BEHAVIORAL|Aerobic exercise|
223513105|NCT00067873|BEHAVIORAL|Resistance exercise|
223513106|NCT04595812|DRUG|Misoprostol 200mcg Tab vaginal|2 tablets vaginally 1 hour before surgery
223513107|NCT04595812|DRUG|Oxytocin|30 IU oxytocin in 500 ml normal saline at a rate of 120 ml/h
223513108|NCT04595812|DRUG|Carbetocin|100 μg IV Carbetocin (1ml) in 5 ml saline over 1 minute
224210628|NCT04365088|DRUG|Sugar pill|Sugar pill
224210629|NCT00192088|DRUG|pemetrexed|
224210630|NCT00192088|DRUG|oxaliplatin|
224210631|NCT00362856|DRUG|larazotide acetate|capsule
224210632|NCT00362856|DRUG|Placebo|capsule
224210633|NCT02162511|DEVICE|CliniMACS CD34+ cell enrichment and T-cell depletion|
224210634|NCT00003061|DRUG|cytarabine|
224210635|NCT00003061|DRUG|methotrexate|
224210636|NCT00003061|RADIATION|radiation therapy|
223513109|NCT04595812|PROCEDURE|pericervical hemostatic tourniquet|a Foley catheter size 18, which will be firmly tied at the level of the cervico-isthmic junction of the uterus before the uterine incision,The time of tourniquet administration will be recorded, and will be released not later than 45 minutes after its application. For those requiring multiple applications, the tourniquet will be reapplied after a period of at least 15 minutes.
223513110|NCT01570907|DRUG|Quetiapine Fumarate|25 mg tablet
223513111|NCT05900310|DIAGNOSTIC_TEST|Core Cognitive Evaluation (CCE)|The Linus Health Core Cognitive Evaluation (CCE) is an easy-to-use but powerful tool to augment and facilitate cognitive health assessment during a patient's visit to their PCP. As a digital assessment solution, the CCE combines objective insights into cognitive ability with patient-reported insights to detect early signs of cognitive impairment and reveal specific modifiable risk factors earlier than the existing status quo assessments. The CCE is an FDA-listed Class II 510k exempt software as a medical device. The CCE has two components: The Digital Clock and Recall (DCR™) test and the Life and Health Questionnaire (LHQ).
223513112|NCT05535088|DEVICE|Virtual reality|Virtual reality consists for about a minute and a half 6 times per session. During the first and the second session, subjects will experiment virtual reality while sited. Moreover, during the third and the fourth session subjects will be standing with a side by side stand. During the last two experimental sessions subjetcts will be standing with a semi tandem stand.
223513113|NCT02405065|DRUG|HM95573|BID or QD, PO X 21 day cycle Number of cycles: until progression or unacceptable toxicity develops
223513114|NCT06539663|COMBINATION_PRODUCT|OmniLenz®|OmniLenz® applied for 1 week in all patients after development of corneal perforation
223513115|NCT02815254|OTHER|High intensity functional exercise|
223513116|NCT02815254|OTHER|Low intensity functional exercise|
223513117|NCT06549920|RADIATION|Internal mammary node irradiation|Irradiation of the internal mammary nodes in intercostal space 1-4.
223513118|NCT00667589|DRUG|urea 40% cream|urea 40% cream applied twice per day to affected areas
223513119|NCT00667589|DRUG|fluocinonide 0.05% cream|fluocinonide 0.05% cream applied twice per day to affected areas
223513120|NCT00667589|DRUG|tazarotene 0.1% cream|tazarotene 0.1% cream applied twice per day to affected areas
223513121|NCT00667589|DRUG|bland emollient cream (Udderly smooth® Udder Cream)|bland emollient cream applied twice per day to affected areas
223513122|NCT02792257|DRUG|Dronabinol (Marinol®)|5mg - 10mg daily dose
223513123|NCT02792257|DRUG|Placebo|Daily dose
223620956|NCT07198750|DEVICE|HI-PEMF - Knee (Chronic Pain Protocol)|"High-intensity pulsed electromagnetic field (HI-PEMF) therapy applied to the symptomatic knee using the Chronic Pain protocol of the BTL-6000 Super Inductive System, 10-minute duration per session, applied twice per week over 5 weeks (total of 9 sessions). The applicator is positioned 2-3 cm above the patella, without skin contact, with the patient seated or in supine position."
223761713|NCT05822869|PROCEDURE|EIT-guided mechanical ventilation strategy|During prone ventilation, the PEEP level is adjusted based on EIT monitoring. The optimal PEEP is the lowest sum of collapse and overdistension percentages
223513124|NCT01528852|DRUG|Chlorhexidine 4%|4% liquid solution used for cord cleaning once daily for 10 days
223513125|NCT01528852|DRUG|Chlorhexidine 4%|Chlorhexidine 4% liquid solution used for cord cleaning once daily for 10 days
223513126|NCT01528852|OTHER|Control cord cleaning solution|Mild soapy solution used to clean cord once daily for 10 days
223513127|NCT00553475|DRUG|placebo|Dosage: placebo, oral administration, Treatment duration: 13 weeks (1-week titration and 12-week fixed dose)
223513128|NCT00553475|DRUG|pregabalin|Dosage: 300 mg/day (150 mg bid), oral administration, Treatment duration: 13 weeks (1-week titration and 12-week fixed dose)
223513129|NCT00553475|DRUG|pregabalin|Dosage: 600 mg/day (300 mg bid), oral administration, Treatment duration: 13 weeks (1-week titration and 12-week fixed dose)
223513130|NCT05975125|DRUG|Vitamin C 500 MG Oral Tablet|compare between Vitamin C with iron supplement and iron supplement alone in prevention of anemia in pregnancy.
223513131|NCT03072342|PROCEDURE|Intensive Periodontal Treatment|
223513132|NCT03072342|PROCEDURE|Control Periodontal Treatment|
223513133|NCT03286075|DEVICE|tDCS Anode session|"The aim of this unique anode tDCS session is to study the possibility of enhancing emotional processing, attentional resources and physiological responses in healthy subjects.~The arm will be compared to the other 2, enabling us to compare different tDCS stimulation modes.~Stimulation will be performed using a tDCS stimulator (Neuroconn or Neuroelectric tDCS stimulator) with two 7×5 cm (35 cm2) sponge electrodes soaked in a saline solution (0.9% NaCl) Anode will be placed over the left dorsolateral prefrontal cortex (F3 according to the international EEG system) and cathode over the right dorsolateral prefrontal cortex (F4 according to the international EEG system)."
223513134|NCT03286075|DEVICE|tDCS Cathode session|"The aim of this unique cathode tDCS session is to study the possibility of inhibiting or altering emotional processing, attentional resources and physiological responses in healthy subjects.~This arm will be compared to the other 2, enabling us to compare different tDCS stimulation modes.~Stimulation will be performed using a tDCS stimulator (Neuroconn or Neuroelectric tDCS stimulator) with two 7×5 cm (35 cm2) sponge electrodes soaked in a saline solution (0.9% NaCl) Cathode will be placed over the left dorsolateral prefrontal cortex (F3 according to the international EEG system) and anode over the right dorsolateral prefrontal cortex (F4 according to the international EEG system)."
223513135|NCT03286075|DEVICE|tDCS Placebo session|"This arm will help compare the effects of stimulation versus no stimulation on emotional processing, attentional resources and physiological responses.~Stimulation will be performed using a tDCS stimulator (Neuroconn or Neuroelectric tDCS stimulator) with two 7×5 cm (35 cm2) sponge electrodes soaked in a saline solution (0.9% NaCl) Anode will be placed over the left dorsolateral prefrontal cortex (F3 according to the international EEG system) and cathode over the right dorsolateral prefrontal cortex (F4 according to the international EEG system)"
223513136|NCT02713841|DRUG|inhaled human insulin (INH)|recombinant human insulin administered with Adagio-01 inhaler device
223513137|NCT02713841|DRUG|sc insulin lispro (LIS)|insulin lispro administered subcutaneously
223761714|NCT05822869|PROCEDURE|Lung protective ventilation group|Lung-protective ventilation strategy during prone positioning that continues the supine position.
223761715|NCT01823029|DRUG|erythropoietin|
223761716|NCT01823029|DRUG|enteral nutrition.|
223761717|NCT01823029|DRUG|injection of iron|
224210637|NCT05640583|DEVICE|Hygieacare System|The device is an FDA cleared colon irrigation device, it will be used according to clearance. The sampling of the colon effluent sampled is the are of study.
223620957|NCT07198750|DEVICE|HI-PEMF - Quadriceps (Muscle Strengthening Protocol)|"HI-PEMF therapy will be applied to both the symptomatic knee and the quadriceps muscle (rectus femoris). The knee application will follow the same procedure as in Group A, using the Chronic Pain protocol of the BTL-6000 Super Inductive System. In addition, the quadriceps will be treated using the Muscle Strengthening protocol. Each site will receive 10 minutes of therapy per session, twice per week over 5 weeks (total of 9 sessions). The applicator for the quadriceps will be positioned perpendicular to the muscle belly, without skin contact, with the patient lying supine and a cushion under the knee for slight flexion."
223620958|NCT07198750|BEHAVIORAL|Home-Based Exercise Program|Standardized home-based exercise program prescribed to both groups. It includes five exercises: isometric quadriceps contractions, straight leg raises, seated knee extensions, sit-to-stand from chair, and stationary marching. Participants are instructed to perform the exercises three times per week during the 5-week intervention. Printed instructions and a video guide are provided. Adherence is reinforced via weekly follow-up.
223620959|NCT07197931|PROCEDURE|Additional extra-pulmonary vein trigger ablation group|"1. Circumferential PVI is performed in all patients.~2. After PVI, isoproterenol is infused starting at 5 μg/min, increased every 3-5 min to 10 and 20 μg/min (max 30 μg/min) to reach 85% of predicted heart rate for ≥10 min.~   2-1) If AF persists, internal cardioversion (5-30 J) is performed using catheters in the right atrium and coronary sinus.~   2-2) If sinus rhythm is present, a 15-beat drive train (10 mA, 2 ms) is delivered at 250 ms, shortened by 10 ms to 180 ms or until capture fails, up to three times, to induce AF or AT. Isoproterenol continues for 2 min. If arrhythmia occurs, cardioversion is repeated.~3. After cardioversion, isoproterenol is stopped and the patient is observed for 10 min.~4. Sustained or reproducible arrhythmias are defined as non-PV triggers.~5. These are localized with activation mapping, P-wave analysis, and high-density mapping.~6. Ablation is performed with the same catheter.~7. Reassessment is done with the same protocol."
223620960|NCT07197931|PROCEDURE|Empirical pulmonary vein isolation group|"1. Circumferential pulmonary vein isolation (PVI) is performed in all patients.~2. After PVI, a waiting period of at least 20 minutes is observed, followed by reassessment of pulmonary vein isolation before concluding the procedure.~3. Additional linear ablation or CFAE ablation not specified in the study protocol should be avoided whenever possible.~4. In cases where typical atrial flutter has been documented prior to the procedure or is induced during the procedure, cavo-tricuspid isthmus (CTI) ablation is performed. At the operator's discretion, CTI ablation may also be permitted even in patients without a prior history or inducibility.~5. If atypical atrial flutter involving these pathways is induced during the procedure, additional linear ablation (e.g., roof line, posterior-inferior line, left lateral isthmus, or anterior line) may be performed."
223620961|NCT07198880|DEVICE|BiPAP device (non invasive ventilation)|"BiPAP initiated 2-4 weeks post-discharge; IPAP 16 cmH₂O (titrate), EPAP 4 cmH₂O; supplemental O₂ as needed monitor SpO₂, ABG, vitals; target ≥20% PaCO₂ reduction, improved pH, reduced work of breathing; adherence ≥4 hrs/nigh~Scheduled monitoring of SpO₂, symptoms, and adherence; outpatient follow-up at 2-4 weeks and after 1, 3, 6 ,12 month intervals"
223620962|NCT07198880|DRUG|Optimal Medical Management ( long acting beta agonist , long acting muscarinic antagonist and inhaled corticosteroids)|Patients will continue on standard COPD management: inhaled bronchodilators, inhaled corticosteroids, LTOT when required, but without NIV
223620963|NCT02907684|DIETARY_SUPPLEMENT|Almonds|Participants to consume almonds as snacks to contribute to 20% of their energy requirements daily for 4 weeks
223620964|NCT02907684|DIETARY_SUPPLEMENT|Muffins/Crackers|"Participants to consume muffins/crackers as snacks to contribute to 20% of their energy requirements daily for 4 weeks~NB all participants will have a run in period for 2 weeks whereby muffins are consumed, this is prior to randomisation."
223761718|NCT02401568|DEVICE|Dynamic CT|Various low dose CT acquisitions will be successively performed on the wrist to allow a four dimensional evaluation. The same type of acquisition will be performed during various manoeuvers (radio-ulnar deviation, clenching fist, and dart-throwing motion).
223761719|NCT02401568|PROCEDURE|Arthrography|percutaneous intra-articular injection of contrast media in the medio-carpal and radio-carpal joints
224316118|NCT06501430|OTHER|Heating Therapy|Heating Therapy will be performed on subjects along with PNF Exercises.
224316119|NCT06501430|OTHER|Manual Soft tissue Release|Manual Soft tissue Release will be performed on subjects along with PNF Exercises.
223761720|NCT04718870|DRUG|Dupilumab SAR231893|Pharmaceutical form: solution for injection Route of administration: subcutaneous (SC)
224210638|NCT02777853|DIETARY_SUPPLEMENT|Green tea|The intervention product is regular green tea brewed with hot water in a large quantity. The tea obtained is dried and the powder, with added sugar, is distributed over sealed aluminium sachets (1 gram of powder per sachet). The product has been cleared for consumption by Unilever's Microbiology Department and the independent Safety and Environmental Assurance Centre of Unilever.
224210639|NCT02777853|DIETARY_SUPPLEMENT|Placebo tea|A product of similar colour and taste, but not the presumed actives of tea (polyphenols), is used as placebo. The product has been cleared for consumption by Unilever's Microbiology Department and the independent Safety and Environmental Assurance Centre of Unilever.
224210640|NCT01604954|BEHAVIORAL|Nutrient-label|A label indicating that the lunch they will eat is low in saturated fat and free from trans fat will be posted on the containers.
224210641|NCT01604954|BEHAVIORAL|Calorie-label|"A label indicating the amount of calories for a fixed serving plus information about daily caloric requirement (The recommended daily caloric intake for an average adult is 2000 calories) will be posted on the containers."
224316120|NCT04738695|DIAGNOSTIC_TEST|Point-of-care rapid anti-SARS-CoV-2 antibody test (Orient Gene Biotech) and Dry Blood Spot collection (Euroimmun)|Bimonthly finger pricks with collection of 1-10 drops of capillary blood for detection of anti-SARS-CoV-2 immune markers
224316121|NCT02931981|PROCEDURE|surgery or biopsy|Do radical surgery or biopsy to obtain a pathological result
223620965|NCT01456065|BIOLOGICAL|Procure|The IMP (Investigational Medical Product) consists of 1.3\*107 autologous, fully mature DCs, double loaded with TERT-mRNA and Survivin-peptide, diluted in 0.5 mL of a standard freezing solution, made up of 10% DMSO (Dimethyl sulfoxide), solved in a physiologic water solution of 5% glucose; provided in a 2 mL cryovial. 8 vial will be injected on weekly administration basis to the patient.
223620966|NCT01456065|BIOLOGICAL|Procure|The IMP consists of 1.3\*107 autologous, fully mature DCs, double loaded with TERT-mRNA and Survivin-peptide, diluted in 0.5 mL of a standard freezing solution, made up of 10% DMSO, solved in a physiologic water solution of 5% glucose; provided in a 2 mL cryovial, 8 vials will be injected into the patient on biweekly basis.
223620967|NCT00932581|OTHER|Bradykinesia UPDRS Motor Full Examination|The first group will receive the full motor examination section in its original order.
223620968|NCT00932581|OTHER|Bradykinesia subscale of UPDRS Motor Examination|The second group will receive the bradykinesia subscale first followed by the remainder of the motor examination section.
223620969|NCT04561440|DIAGNOSTIC_TEST|molecular karyotyping|performed by NGS or CMA chip
223620970|NCT00006133|DRUG|estradiol|
223620971|NCT00006133|DRUG|ethinyl estradiol|
223620972|NCT00006133|DRUG|medroxyprogesterone|
223620973|NCT00006133|DRUG|norethindrone|
223620974|NCT01344083|DRUG|T1210|2 drops T1210 once a day
223620975|NCT01344083|DRUG|Olopatadine hydrochloride|2 drops once a day Olopatadine
223620976|NCT01060696|DRUG|Mefenamic acid or Hyoscine or placebo|Mefenamic acid 500 mg. single oral use 30 minutes before SIS Hyoscine 10 mg. single oral use 30 minutes before SIS Placebo single oral use 30 minutes before SIS
223620977|NCT00056953|BEHAVIORAL|Peer mentoring program|
223620978|NCT00794950|DRUG|Sunitinib|"Patients are treated with a 6-week induction course of intravesical bacillus Calmette-Guerin (BCG) followed by a 2 week rest period and 4 week course of oral Sunitinib.~Patients will receive intravesical BCG (81 mg Theracys BCG in 50 ml normal saline) once weekly for 6 weeks within 6 weeks of bladder biopsy confirming high risk non-muscle invasive urothelial carcinoma. Two weeks after completion of BCG, patients will receive Sunitinib (50 mg daily) continuously for 28 days followed by a two week rest period. Patients will be reassessed with transurethral resection and urine cytology. Those with residual/recurrent disease will receive a second course identical to the initial protocol. Those with a complete response following initial or second treatment will be placed on maintenance BCG (3 week course every 6 months for 2 years). Those failing (progression, intolerance) initial/secondary treatments will be offered alternative therapy."
223620979|NCT02717052|DRUG|(S)-ketamine (Main study)|"Ketanest® S (Esketaminhydrochlorid) 5mg/ml and 25mg/ml ampoules; Actavis Italy S.P.A./Pfizer Corporation Austria GmbH~Dosis: 0.25mg/kg bodyweight i.v. over 40 Minutes (ending 10 minutes before PET measurement)"
224210642|NCT01604954|BEHAVIORAL|No label|Lunches will be free from labels, so that no nutritional information will be provided to the participants(control group).
224210643|NCT04168047|PROCEDURE|Barostat procedure|Pressure threshold will be measured during the barostat procedure
224210644|NCT04168047|OTHER|Anxiety and Depression Evaluation|Anxiety and Depression will be measured using HAD anxiety and depression scale
223620980|NCT02717052|DRUG|(S)-ketamine (Pilot II)|"Ketanest® S (Esketaminhydrochlorid) 5mg/ml and 25mg/ml ampoules; Actavis Italy S.P.A./Pfizer Corporation Austria GmbH~Dosis: 0.10mg/kg bodyweight i.v. bolus applied over 5 minutes (starting 15 minutes before PET measurement) and continuous infusion of 0.30mg/kg bodyweight i.v. applied over the course of 130 minutes."
223620981|NCT02717052|DRUG|(R,S)-ketamine (Pilot II)|"Ketamin-hameln (Ketaminhydrochlorid) 50mg/ml Ampullen; Hameln Pharma Plus GmbH; Sanova Pharma~Dosis: 0.20mg/kg bodyweight i.v. bolus applied over 5 minutes (starting 15 minutes before PET measurement) and continuous infusion of 0.60mg/kg bodyweight applied i.v. over the course of 130 minutes."
223620982|NCT02717052|DRUG|Placebo|0.9% saline solution i.v. over 40 Minutes (ending 10 minutes before PET measurement)
223620983|NCT02717052|OTHER|PILOT Study II: PET1|\[11C\]DASB PET
223620984|NCT02717052|OTHER|PILOT Study II: PET2|\[11C\]DASB PET
223620985|NCT02717052|OTHER|Main Study: PET1|\[11C\]DASB PET
223620986|NCT02717052|OTHER|Main Study: PET2|\[11C\]DASB PET
224210645|NCT04168047|OTHER|Assessment of sleep quality|Sleep quality will be measured using Pittsburg sleep quality index
223620987|NCT02717052|OTHER|PILOT Study I: PET1|\[11C\]DASB PET
223620988|NCT02717052|OTHER|PILOT Study I: PET2|\[11C\]DASB PET
223620989|NCT02717052|DRUG|(R,S)-ketamine (Pilot I)|"Ketamin-hameln (Ketaminhydrochlorid) 50mg/ml Ampullen; Hameln Pharma Plus GmbH; Sanova Pharma~Dosis: 0.50mg/kg bodyweight i.v. over 40 Minutes (ending 10 minutes before PET measurement)"
223620990|NCT02717052|DRUG|(R,S)-ketamine (Pilot III)|"Ketamin-hameln (Ketaminhydrochlorid) 50mg/ml Ampullen; Hameln Pharma Plus GmbH; Sanova Pharma~Dosis: 0.80mg/kg bodyweight i.v. over 50"
223620991|NCT02717052|OTHER|PILOT Study III: PET1|\[11C\]DASB PET
223620992|NCT02717052|OTHER|PILOT Study III: PET2|\[11C\]DASB PET
223620993|NCT04737018|OTHER|Fugl-Meyer Assessment (FMA)|assessment of motor skills : measurement of the intensity of reflexes, as well as an assessment of voluntary movements and motor coordination Score from 0 to 34
223620994|NCT04737018|OTHER|Medical Research Concil (MRC)|evaluation of muscular strength score from 0 to 5
223620995|NCT04737018|OTHER|2 Minute Walk Test (2MWT)|Assess functional walking and aerobic abilities
223620996|NCT04737018|OTHER|Timed Up & Go Test|measures the time it takes to get up from a chair, walk 10 feet, turn around, return to the seat and sit down
223620997|NCT04737018|OTHER|Modified Ashworth Scale|score from 0 to 4 evaluation of spasticity
223620998|NCT04737018|OTHER|Postural Assessment Scale for Stroke|score from 0 to 36 measures the patient's ability to maintain stable postures and balance in changes of position
224210646|NCT06304545|DRUG|Camrelizumab|Camrelizumab IV 200mg
224210647|NCT06304545|DRUG|Chemotherapy|Capecitabine PO oxaliplatin IV
224210648|NCT06304545|RADIATION|Radiotherapy|Radiotherapy 50Gy /45Gy /25 fractions
223620999|NCT04737018|DEVICE|posturographic recording|analysis of static equilibrium parameters and positional measurement of the center of gravity on the Winposturo platform
223621000|NCT04737018|OTHER|vibration program|a 4-week program of muscular focal vibrations, at the rate of 5 sessions of 30 minutes per week, in addition to conventional rehabilitation. The program will apply a frequency of 100 Hz, with an amplitude of 1 mm
223621001|NCT04737018|OTHER|sham program|a 4-week program of muscular focal vibrations, at the rate of 5 sessions of 30 minutes per week, in addition to conventional rehabilitation.
223621002|NCT01706523|DRUG|STX209 (arbaclofen)|Long-term, daily, orally-administered STX209
223621003|NCT02649556|OTHER|THS 2.2|Ad libitum use of THS 2.2 in an ambulatory setting for 26 weeks.
223621004|NCT02649556|OTHER|CC|"Ad libitum use of CC in an ambulatory setting for 26 weeks.~The subject's own preferred brands of CC (no brand restriction) continue to be used as the reference product."
223621005|NCT04291573|DEVICE|HD-tDCS|Real stimulation (2mA, 20min) with anode on C3/C4 of the lesioned hemisphere and 4 return electrodes \~4cm away
223621006|NCT04291573|DEVICE|Sham HD-tDCS|Sham stimulation (2mA, ramp up and down phases of 30s) with anode on C3/C4 of the lesioned hemisphere and 4 return electrodes \~4cm away
223621007|NCT04810052|BEHAVIORAL|Behavioral Intervention|Perform 1 nice thing
223621008|NCT04810052|BEHAVIORAL|Behavioral Intervention|Write a letter or note of gratitude
223621009|NCT04810052|BEHAVIORAL|Behavioral Intervention|Track daily activities
223621010|NCT04810052|OTHER|Interview|Ancillary studies
223761721|NCT05149742|BEHAVIORAL|Cognitive and audiometry evaluation|"For both Patients and controls:~* Cognitive functions evaluation~* Tonal and vocal audiometry~* Self questionnaires"
224210649|NCT02836197|BEHAVIORAL|Communication skills training|The general aim of the communication skills training program is to help physicians learn effective communication skills in contexts of high uncertainty. The training will last 30 hours, will be spread over 4 months. The training will be conducted by group of 3 subjects. The training will include mainly role-plays, theoretical information and modeling techniques. A training manual has been developed to increase content standardization and reduce potential group or trainee biases. The role-plays will be based on clinical cases brought up by the participants.
224210650|NCT00436527|DRUG|Metronidazole gel 1%|Applied once to a test site on the right or left cheek (as determined by a randomization design)
224210651|NCT06047782|OTHER|Cardiac MRI (with contrast agent)|Cardiac MRI with contrast agent
224316122|NCT00588458|PROCEDURE|CT cholangiography|Cholografin 20ml will be diluted in 100 ml of normal saline and infused over 30 minute time interval. Following the infusion of the cholografin, morphine (0.04 mg/kg) will be administered to contract the sphincter of Oddi and improve bile duct distension and visualization. Thirty minutes following the administration of morphine a test scan (CT cholangiography) will be performed through the liver to determine if there is adequate biliary excretion. The test scan will consist of 10 mm thick image obtained through the mid liver. If there is evidence of biliary excretion, high-resolution images will be performed through the liver and bile ducts. The axial images will be reconstructed into maximum intensity projection models and volume rendered models that can be viewed in 3-dimension.
224316123|NCT03474458|DRUG|Doxycycline|Doxycycline
224316124|NCT03474458|DRUG|Standard of care therapy|Standard of care therapy
223621011|NCT04810052|OTHER|Quality-of-Life Assessment|Ancillary studies
223761722|NCT01613781|OTHER|TOF count-guided partial NMB|TOF count-guided partial NMB Using partial neuromuscular blockade to maintain train-of-four response of two, TOF response measured by the neuromuscular transmission module (NMT module)
223621012|NCT04810052|OTHER|Questionnaire Administration|Ancillary studies
223621013|NCT05914090|PROCEDURE|ERAS|Among adults, patients undergoing elective extracorporeal circulation for cardiac surgery are included in the ERAS strategy intervention plan, which mainly includes preoperative education, preoperative oral intake of multidimensional carbohydrate beverages, multimodal analgesia, blood protection strategies, correction of perioperative hypoalbuminemia, early removal of tracheal intubation, maintenance of blood sugar at reasonable levels, and targeted liquid therapy.
223761723|NCT01613781|OTHER|T1/Tc guided partial NMB|Using partial neuromuscular blockade to maintain T1/Tc amplitude of 50%, T1/Tc amplitude measured by the neuromuscular transmission module (NMT)
223761724|NCT01904604|BIOLOGICAL|Placebo Viaskin® Patch|Placebo (e.g., no peanut) patch in an epicutaneous application for 24 hours every 24 hours.
224210652|NCT00036582|DRUG|Clozapine|
224210653|NCT06306794|OTHER|crochet octopus|During the endotracheal aspiration procedure, the octopus will be given to experimental group 10 minutes before the procedure.
224210654|NCT01408576|DRUG|Epratuzumab|600 mg infusions delivered weekly for a total of 4 consecutive weeks (cumulative dose 2400 mg) over eight 12-week treatment cycles
224316125|NCT04577664|PROCEDURE|total thyroidectomy|a total thyroidectomy (TT) in which the entire gland is removed
223513138|NCT00859274|DRUG|budesonide|Budesonide is given via inhalation utilising a dry powder inhaler called Easyhaler. The dosage is 400 ug twice daily. The duration of the study is 12 weeks but very probably the patients continue the usage of this drug as a part of their routine clinical management.
223513139|NCT03842800|OTHER|MRI|Patients and volunteers will receive an MRI.
223513140|NCT03842800|DRUG|Ketamine|Ketamine will be administered to a subset of healthy controls that agree to receive the drug as part of receiving an MRI.
223513141|NCT06687629|PROCEDURE|Concha bullosa crushing|Concha bullosa crushing
223513142|NCT06687629|PROCEDURE|Concha bullosa resection|Concha bullosa resection
223513143|NCT06164730|DRUG|VERVE-102|Intravenous (IV) infusion
223513144|NCT06695078|OTHER|No Intervention: Observational Cohort|No Intervention: Observational Cohort
223513145|NCT06694961|OTHER|Online Educational Material|Online educational material will be an easy way to reach large number of physicians
223761725|NCT01904604|BIOLOGICAL|Low-dose DBV712 Viaskin® Patch|100 microgram (µg) dose of peanut proteins in an epicutaneous application for 24 hours every 24 hours.
223761726|NCT01904604|BIOLOGICAL|High-dose DBV712 Viaskin® Patch|250 microgram (µg) dose of peanut proteins in an epicutaneous application for 24 hours every 24 hours.
224210655|NCT01408576|DRUG|Epratuzumab|1200 mg infusions delivered every other week for a total of 4 weeks (cumulative dose 2400 mg) over eight 12 week treatment cycles
224210656|NCT02328001|BEHAVIORAL|Debriefing endoscopists of the procedure accessory costs|Informing endoscopists of the number of accessories used and the dollar value of the accessories
224210657|NCT05474560|DRUG|Allopurinol (100 mg/day) plus lifestyle intervention|participants accept allopurinol treatment (100 mg, once a day, orally). Behavioral: lifestyle intervention According to NAFLD guidelines, participants receive lifestyle intervention (diet and exercise).
224210658|NCT05474560|DRUG|Febuxostat 40 mg plus lifestyle intervention|participants accept Febuxostat treatment (100 mg, once a day, orally). Behavioral: lifestyle intervention According to NAFLD guidelines, participants receive lifestyle intervention (diet and exercise).
224210659|NCT05474560|BEHAVIORAL|Life style intervention|According to NAFLD guidelines, participants receive lifestyle intervention (diet and exercise).
224210660|NCT06542094|PROCEDURE|Deep Brain stimulation|All subjects will receive bilateral surgical implantation of DBS system.
224210661|NCT00802529|DRUG|Methylprednisolone|2 transtympanic injections at interval of two weeks.
224210662|NCT00802529|DRUG|Gentamicin|2 transtympanic injections at an interval of two weeks. If there is significant hearing loss before second injection, it will be replaced by normal saline in double blinded fashion.
224210663|NCT01944189|DIETARY_SUPPLEMENT|Food|"Nested comparative bioavailability study: 48 out of 70 children randomized to 2 food arms under 2 dose groups of artemether lumefantrine (20mg /120 mg) treatment according to standard care weight based dose groups (\> 5 to \>15 kg receive 1 tablet and 15 to \> 25 kg receive 2 tablets)~Food arms:~Standard arm = Milk~Experimental arm = maize porridge plus oil~Groups include Single dose group= 1 tablet of artemether lumefantrine (20/120 mg) and Double dose group= 2 tablet of artemether lumefantrine (20/120 mg)~Standard arm children receiving milk and single dose(12) Standard arm children receiving milk and double dose(12) Experimental arm children receiving maize porridge plus oil and single dose(12) Experimental arm children receiving maize porridge plus oil and double dose (12)"
224210664|NCT01869712|OTHER|Cupping therapy|
224210665|NCT01869712|OTHER|Acupuncture|
224210666|NCT01757366|DRUG|Ginsenoside Rg3 plus First-line Chemotherapy|"Ginsenoside Rg3 20mg 2/day po,patients will receive Ginsenoside Rg3 until progression~XELOX(oxaliplatin 130mg/m2 iv d1;capecitabine 1000mg/m2 po bid d1-14)every 3 weeks for 4 cycles followed by capecitabine until progression"
224210667|NCT01757366|DRUG|First-line Chemotherapy|XELOX(oxaliplatin 130mg/m2 iv d1;capecitabine 1000mg/m2 po bid d1-14)every 3 weeks for 4 cycles followed by capecitabine until progression
224210668|NCT01041937|PROCEDURE|Cemented Tibia|Total knee arthroplasty with cemented or cemented tibia, and post operative clinical outcome tracking
224210669|NCT01041937|PROCEDURE|Cementless Tibia|Assessing the clinical outcomes of the different type of fixation
224210670|NCT03850561|DIETARY_SUPPLEMENT|Coenzyme Q10 200|Coenzyme Q10 200 mg/day
224210671|NCT03850561|DIETARY_SUPPLEMENT|Coenzyme Q10 400|Coenzyme Q10 400 mg/day
224210672|NCT00444873|DRUG|lanreotide (Autogel formulation), duration of treatment 24-56 weeks, depending on dose interval|Six deep subcutaneous injections of Lanreotide Autogel, 24-56 week intervals.
224210673|NCT06119373|OTHER|Single daily icodextrin exchange|PD initiation with single daily exchange of 2-liter icodextrin-based dialysis solution.
224210674|NCT06119373|OTHER|Conventional PD group|PD is initiated with 2 to 3 exchanges of 2-liter glucose-based dialysis solution.
224210675|NCT00803673|DRUG|100mcg|100mcg '719
223513146|NCT06694298|DRUG|SYS6020|BCMA Chimeric Antigen Receptor T Cell（SYS6020）Injection Intravenous infusion
223513147|NCT06688838|DRUG|Tofacitinib|If a patient does not respond well to DMARDs treatment, then Tofacitinib or TNFi treatment may be used instead.
223513148|NCT06687759|DRUG|[14C]MK-1084|Oral administration
223513149|NCT06695260|DIAGNOSTIC_TEST|CT scan|CT will be performed when the wrist is under loading compared to normal conditions. scapholunate kinematics will be examines
223513150|NCT06690749|DEVICE|Negative pressure therapy, NPT|"We designed the experiment based on current clinical cases involving negative pressure therapy (NPT) for wounds and related animal studies. In this study, we applied three levels of negative pressure: -105 mmHg, -125 mmHg, and -145 mmHg, each for 10 minutes.~The -125 mmHg dosage was chosen based on findings from a previous study. Similar studies that utilized increments and decrements of 20 mmHg informed our research.~Moreover, to prevent any damage to new capillaries, we established a base dosage of -125 mmHg and refrained from using negative pressure levels exceeding -150 mmHg."
223513151|NCT06689228|OTHER|Rational Drug Use Training|Rational Drug Use Training and Tele-monitoring will include information on drugs and their importance, rational drug use, rational drug use in haemodialysis patients, harms of irrational drug use, benefits of rational drug use, obstacles encountered in rational drug use, ways to overcome obstacles encountered in rational drug use, and increasing self-efficacy. The first training is planned to last approximately 30-35 minutes for each patient and the second training (summary training) is planned to last approximately 15-20 minutes. With telemonitoring, reminder messages will be sent to patients' phones at intervals.
223513152|NCT02318979|DEVICE|Otto Bock prosthesis|Participants will run using the Otto Bock prosthesis at a recommended stiffness and height, one category stiffer than recommended at the recommended height, one category softter than recommended at the recommended height, at the optimal stiffness and 2 cm taller, and at the optimal stiffness and 2 cm shorter.
223513153|NCT02318979|DEVICE|Ossur prosthesis|Participants will run using the Ossur prosthesis at a recommended stiffness and height, one category stiffer than recommended at the recommended height, one category softter than recommended at the recommended height, at the optimal stiffness and 2 cm taller, and at the optimal stiffness and 2 cm shorter.
223513154|NCT02318979|DEVICE|Freedom Innovations prosthesis|Participants will run using the Freedom Innovations prosthesis at a recommended stiffness and height, one category stiffer than recommended at the recommended height, one category softter than recommended at the recommended height, at the optimal stiffness and 2 cm taller, and at the optimal stiffness and 2 cm shorter.
223513155|NCT02369692|DEVICE|Magellan Robotic 6 Fr Catheter|The Hansen Medical Magellan™ Robotic Catheter 6 Fr (Magellan™)
223513156|NCT05683626|DRUG|Humira|subcutaneous injection
223513157|NCT00383851|DRUG|ATN-224|
223513158|NCT00383851|DRUG|Temozolomide|
223513159|NCT02148627|DRUG|LY3041658 (SC)|Administered SC
223513160|NCT02148627|DRUG|LY3041658 (IV)|Administered as slow IV infusion
223513161|NCT02148627|DRUG|Placebo|Administered as slow IV infusion
224210676|NCT00803673|DRUG|500mcg|500mcg '719
224210677|NCT00803673|DRUG|1000mcg|1000mcg '719
224210678|NCT00803673|DRUG|Placebo|Placebo '719
224210679|NCT00710086|DRUG|Hydromorphone|Intravenous administration of hydromorphone 1mg at the patient's request if they felt uterine contraction pain
224210680|NCT00710086|DRUG|Remifentanil|Remifentanil intravenous PCA: 0.2μg/kg, lockout time interval 2 minutes, continuous infusion rate 0.2-0.8μg/kg/min.
224210681|NCT05040035|DIAGNOSTIC_TEST|ACT measurement|Measurement of active clotting time (ACT)
224210682|NCT03928613|BEHAVIORAL|tablet based Cognitive Training based on location information|Participants perform Tablet based Cognitive training using interactive voice services and tags three times (minimum 30 minutes per time) a week for 6 weeks
224210683|NCT03067506|OTHER|No intervention|No intervention
224210684|NCT05658107|DRUG|BI 765423|BI 765423
224210685|NCT05658107|DRUG|Placebo|Placebo
224316126|NCT04577664|PROCEDURE|subtotal thyroidectomy|subtotal thyroidectomy (STT) , in which most of the gland is removed leaving a small unilateral or bilateral remnant in situ about 4-5 grams.
223513162|NCT05399342|OTHER|No Intervention|Patients in the LAAOS III trial either had or did not have their left atrial appendage occluded at the time of surgery in that trial. No further intervention is required in this cohort, it is observational follow-up only.
223513163|NCT01905683|DRUG|IncobotulinumtoxinA (16-20 Units per kg body weight)|Active ingredient: Clostridium Botulinum neurotoxin type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl); Total dose per injection cycle: up to 500 units; Mode of administration: intramuscular injection into spastic muscles.
223513164|NCT03555045|PROCEDURE|conducting the slanted recession technique on the superior and inferior poles|conducting the slanted recession technique on the superior and inferior poles of the muscle based on far and near deviations.
223513165|NCT03555045|PROCEDURE|conducting the augmented recession technique on the muscle|conducting the augmented recession technique on the muscle for 1 to 1.50 mm more compared with the standard method.
223513166|NCT05877612|DEVICE|Implantable spinal cord stimulator|Spinal cord stimulation is possible thanks to implantable spinal cord neurostimulators. These are medical devices, which include a stimulation electrode and an implantable box, designed to deliver electrical stimulation for pain relief. The electrode is implanted in the epidural space in order to stimulate the posterior cords of the spinal cord through the dura mater, at the dorsal or cervical level.
223513167|NCT01932580|DRUG|FLOT (5-fluorouracil, oxaliplatin, docetaxel)|Administration of FLOT chemotherapy before and after surgery
223513168|NCT00246207|DRUG|CONCERTA (OROS methylphenidate hydrochloride)|
223513169|NCT06138080|DIAGNOSTIC_TEST|Contrast-enhanced voiding ultrasonography (CEVUS), Direct isotope cystography|We have no specific intervention. We investigate different diagnostic modalities of VUR.
223513170|NCT01435915|DRUG|Ropinirole|"Ropinirole 2 milligrams once daily prolonged release tablet will be given at 24-hour intervals in the morning.~Single and repeat dose treatment periods will be separated by 7 days of washout period."
223513171|NCT01395537|DRUG|Carboplatin AUC|Carboplatin AUC 6 IV over 30 minutes on day one of a three week cycle. This will be continued for 6 cycles or until progression of disease or intolerable side effects.
223513172|NCT01395537|DRUG|Paclitaxel|Paclitaxel 175 mg/m2 IV over 3 hours day one of a three week cycle. This will be continued for 6 cycles or until progression of disease or intolerable side effects.
223513173|NCT01395537|DRUG|lapatinib|Lapatinib should be taken once daily, at the same time daily, on an empty stomach, either 1 hour before, or 1 hour after meals.
223513174|NCT00537082|DRUG|FTY720|Administered orally once daily for 6 months
223513175|NCT00537082|DRUG|Placebo|Administered orally once daily for 6 months
223513176|NCT03396458|DIAGNOSTIC_TEST|Hepatitis B serology|A serum specimen will be taken and assessed for hepatitis B serology (HBsAg, anti-HBs and anti-HBc).
223513177|NCT03396458|OTHER|Questionnaire|Participants will be asked to fill in a questionnaire regarding sociodemographic factors, migration history, risk factors for HBV infection (e.g. sharing toothbrushes, HBV infected family member) and HBV vaccination status.
223513178|NCT03586232|DIETARY_SUPPLEMENT|Arnica Montana|Arnica Montana is from the Asteraceae plant family and is native to the mountain areas in Europe and western North America. It is reported to have anti-inflammatory, antiseptic, and vasodilatory properties and is often used in plastic surgery to help reduce pain, edema, and ecchymosis postoperatively.
223513179|NCT03586232|DIETARY_SUPPLEMENT|Bromelain|Bromelain is a protease enzyme derived from the pineapple plant, Ananas comosus, which has been used to reduce swelling, inflammation, and pain and may help to reduce wound healing time.
223513180|NCT03586232|OTHER|Placebo|A pharmacologically inert preparation
223513181|NCT02568254|DEVICE|Lens 1 (etafilcon A)|Each lens type will be worn for approximately 2 weeks (12 +/- 2 days).
223513182|NCT02568254|DEVICE|Lens 2 (nelfilcon A)|Each lens type will be worn for approximately 2 weeks (12 +/- 2 days).
223513183|NCT02568254|DEVICE|Lens 3 (nesofilcon A)|Each lens type will be worn for approximately 2 weeks (12 +/- 2 days).
223513184|NCT01580722|PROCEDURE|early reconstruction|patients underwent \< 8 weeks reconstruction after injury
223513185|NCT01580722|PROCEDURE|delay reconstruction|patients underwent \> 8 weeks reconstruction after injury
223513186|NCT03325257|OTHER|Routine care|This study is an observational one - there is no change to the routine care. Patients received the Nivolumab independently of the study. Only data will be collected during this project.
224210686|NCT05779488|DIETARY_SUPPLEMENT|maca|2.25 g of Maca extract, twice per day for 12 weeks
224210687|NCT05779488|DIETARY_SUPPLEMENT|placebo|2.25 g of starch, twice per day for 12 weeks
224316127|NCT05516979|DRUG|100 mg AP1189|AP1189 tablets for oral use
224316128|NCT05516979|DRUG|Placebo|Matching placebo for oral use
224316129|NCT04482387|DEVICE|DigiVis visual acuity app|Self-testing of visual acuity app on two occasions
224316130|NCT04011670|OTHER|200 mg caffeine tablet|"* Transcranial alternating current stimulation (140 Hz tACS) at 1 mA and active vigilance condition~* Transcranial alternating current stimulation (140 Hz tACS) at 1 mA and passive vigilance condition~* Transcranial alternating current stimulation (140 Hz tACS) sham and active vigilance condition~* Transcranial alternating current stimulation (140 Hz tACS) sham and passive vigilance condition"
224210688|NCT06132412|DEVICE|transcranial direct current stimulation|Transcranial direct current stimulation (tDCS) is a form of noninvasive brain stimulation that can have neuromodulatory effects on central nervous system structures, specifically the primary motor cortex (M1), and can potentially target maladaptive plasticity and nociplastic sources of pain. There is both anodal and cathodal tDCS, anodal stimulation increases excitability of the cortex whereas cathodal stimulation decreases excitability. At the synaptic level, anodal tDCS induces effects that mimic long term potentiation (LTP), while cathodal tDCS results in long term depression.
224210689|NCT06132412|OTHER|physical therapy|Participants will receive individualized and impairment-based physical therapy treatment for their knee pain. This treatment can involve manual therapy, exercise or balance training depending on their particular needs.
223621014|NCT00432484|DRUG|Lingzhi and Sen Miao San|G lucidum and SMS were supplied as capsules, containing 4.0 gm of G lucidum extract, 2.4 gm of Rhizoma atractylodis (Cangzhu), 2.4 gm of Cotex phellodendri(Huangbai), and 2.4 gm of Radix achyranthes Bidentatae(Niuxi). Each patient took either 3 capsules twice daily as recommended by the TCM experts or identical-looking placebo.
224210690|NCT05218317|DIAGNOSTIC_TEST|in-vivo Corneal Confocal Microscopy|All study subjects underwent IVCM (Rostock Cornea Module, Heidelberg Retinal Tomograph III; Heidelberg Engineering, Germany). Before the examination, two drops of topical anesthetic with proparacaine hydrochloride (Alcaine 0.5%, Alcon-Couvreur, Belgium) were applied to both eyes. A carbomer-based gel (Viscotears 0.2%; Dr. Gerhard Mann, Chem.- Pharm. Fabrik, Germany) was used as the coupling agent between the cornea and the applanating cap of IVCM. For correctly positioning the central cornea, all subjects were asked to fixate a determined fixation point and controlled with the device camera. All scans were performed in approximately 5 minutes for each eye by a single experienced ophthalmologist, masked from the subject's disease status.
224210691|NCT04656574|BEHAVIORAL|Simulation-based training|The simulation training included the activities that midwives should do during the birth and management of vaginal delivery with episiotomy. The students received theoretical training, and to reinforce it, they were asked to mold a fetal head from a potato, make a cardboard cervix showing dilatation measurements during vaginal delivery, and make a fetal position identification model taking the occiput as a reference point.
224210692|NCT02733458|DRUG|GELAD|Gemcitabine, 1.0g/m2/d IV, day 1 Etoposide, 60mg/m2 IV, day 1 to day 3 Dexamethasone, 40mg/d IV, day 1 to day 4 Pegaspargase, 2000IU/m2/d IM, day 4
224210693|NCT02733458|RADIATION|Radiotherapy|Radiotherapy: 50-56Gy
224210694|NCT00221572|PROCEDURE|Determination of bot density of Cystic Fibrosis patients|Determination of bot density of Cystic Fibrosis patients.
224210695|NCT00552617|DRUG|Sugammadex|"After induction of anesthesia an intubation dose of (Neuromuscular blocking agent) NMBA was administered IV: either 0.9 mg/kg rocuronium or 0.1 mg/kg vecuronium.~Maintenance doses of 0.1-0.2 mg/kg rocuronium IV or 0.02-0.03 mg/kg vecuronium IV could be administered if necessary.~At reappearance of T2 the randomized single dose of sugammadex 0.5 to 4 mg/kg IV was administered"
224210696|NCT00552617|DRUG|Placebo|"After induction of anesthesia an intubation dose of NMBA was administered IV: either 0.9 mg/kg rocuronium (arm 1) or 0.1 mg/kg vecuronium (arm 6).~Maintenance doses of 0.1-0.2 mg/kg rocuronium IV or 0.02-0.03 mg/kg vecuronium IV could be administered if necessary.~At reappearance of T2 the randomized single dose of Placebo IV was administered"
224210697|NCT00552617|DRUG|Rocuronium|"After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV.~Maintenance doses of 0.1-0.2 mg/kg rocuronium IV could be administered if necessary."
224210698|NCT00552617|DRUG|Vecuronium|After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV. Maintenance doses of 0.02-0.03 mg/kg vecuronium IV could be administered if necessary.
224210699|NCT03800186|OTHER|Proximal type A|Patients with fracture of proximal type A
224210700|NCT03800186|OTHER|Proximal type B|Patients with fracture of proximal type B
224210701|NCT03800186|OTHER|Proximal type C|Patients with fracture of proximal type C
224210702|NCT03800186|OTHER|femoral shaft|Patients with fracture of femoral shaft
224316131|NCT04011670|OTHER|Non-active tablet|"* Transcranial alternating current stimulation (140 Hz tACS) at 1 mA and active vigilance condition~* Transcranial alternating current stimulation (140 Hz tACS) at 1 mA and passive vigilance condition~* Transcranial alternating current stimulation (140 Hz tACS) sham and active vigilance condition~* Transcranial alternating current stimulation (140 Hz tACS) sham and passive vigilance condition"
223621015|NCT06411717|DEVICE|Microstructure lens A|Subjects randomized to Trial Group A will be required to wear microstructural lens A (microstructural design type with low defocus ratio) for 12 months
223621016|NCT06411717|DEVICE|Microstructure lens B|Subjects randomized to Trial B will be required to wear microstructural lens B (high defocus ratio microstructural design type) for 12 months
223621017|NCT06411717|OTHER|Control group|Subjects randomized to the control group will be required to wear aspherical single-light lenses for 12 months
223621018|NCT04325971|OTHER|Neuroimaging|MR, EEG recordings
223621019|NCT05498610|DRUG|NNC0480 0389|"Participants will get 1 injections of NNC04800389. It will be injected with a needle into a skin fold on the abdomen.~The study will last for a maximum of 72 days"
224210703|NCT03800186|OTHER|distal femur|Patients with fracture of distal femur
224210704|NCT06673550|PROCEDURE|Intragastric balloon|Randomized trial comparing fluide-filled intragastric balloon at different filling volumes.
224316132|NCT05096832|BIOLOGICAL|Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01)|"Appearance: Creamy white suspension Dosage form: Suspension for injection Strength: 10 μg (0.5 mL) /vial Vaccination route: Intramuscular injection into the lateral deltoid of the upper arm Vaccination dosage: 10 μg (0.5 mL) Immunization schedule: 1 dose on Day 0, which should be 3-6 months after the second dose of 2-dose regimen of inactive vaccine (BBIBP-CorV or CoronaVac).~Storage condition: Store at 2-8 °C protected from light Expiry date: 24 months temporarily"
224316133|NCT05096832|BIOLOGICAL|Blank Preparation of Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01)|The dosage, appearance, administration method, and other aspects are consistent with that of investigational vaccine, except that no vaccine antigen is contained.
224210705|NCT04688814|PROCEDURE|Single puncture combined lumbar erector spinae plane block and quadrates lumborum block|"Patients will lay laterally with the fracture side independent, a curvilinear transducer will be placed in a parasagittal plane 3-4 cm lateral to the lumbar spinous process of L4.The probe is shifted slowly to the lateral side till the transverse processes disappear. After subcutaneous local infiltration with lidocaine 1% at the cephalic end of the probe, the block needle is advanced through the erector spinae and QL muscles, until it pierces the epimysium of the QL muscle. LA is injected anterior to the QL, between the QL and psoas muscles.~Then the caudal end of the probe is rotated slowly medially towards lumbar spine till the transverse process of L4 appears in the ultrasound image. The needle is withdrawn to subcutaneous tissue, then advanced in plane towards transverse process of L4. After contacting it, LA is deposited between transverse process and overlying ESM."
224210706|NCT04688814|DRUG|Morphine Sulfate|Patients will receive GA and analgesia will be based on opioids mainly intravenous morphine
224210707|NCT04323449|DEVICE|Compare two control methods for a wheelchair-mounted robotic manipulator|Participants will pay one visit to the lab where they will be asked to complete a set of manipulation tasks using a wheelchair-mounted robotic manipulator using the new custom vision-guided control and default joystick or switch control. The sequence of the two control methods will be counterbalanced.
224210708|NCT01111084|DRUG|Follitropin alpha (r-FSH)|The dosage and administration of follitropin alpha was according to each centre's protocol and within technical specification recommendations.
224210709|NCT03307902|BIOLOGICAL|Imiquimod + ID HBVv|Imiquimod ointment + intradermal 10μg Sci-B-Vac vaccine
224210710|NCT03307902|BIOLOGICAL|Aqueous + ID HBVv|Aqueous ointment + intradermal 10μg Sci-B-Vac vaccine
224210711|NCT03307902|BIOLOGICAL|Imiquimod + IM HBVv|Imiquimod ointment + intramuscular 10μg Sci-B-Vac vaccine
224210712|NCT02399059|PROCEDURE|Antibiotic lavage|Peritoneal irrigation with gentamycin-clindamycin solution
224210713|NCT02399059|PROCEDURE|Normal saline lavage|Peritoneal irrigation with normal saline
224210714|NCT00267579|BEHAVIORAL|Strongest Families (formerly Family Help Program): Behaviour Disorder Program|Evidence-based psychological and behavioural Distance Intervention
224210715|NCT06232759|DRUG|Transarterial chemoembolization combined with Tyrosine Kinase Inhibitors and Tislelizumab|Patients with unresectable hepatocellular carcinoma were received transarterial chemoembolization combined with Tyrosine Kinase Inhibitors and Tislelizumab
224210716|NCT04947059|DRUG|Gemcitabine Hydrochloride combined with continuous saline irrigation|Immediate single intravesical instillation with gemcitabine combined with continuous saline irrigation in bladder cancer patients who are treated with a transurethral resection of the tumor
223621020|NCT05498610|DRUG|Semaglutide|"Participants will get 1 injections of semaglutide. It will be injected with a needle into a skin fold on the abdomen.~The study will last for a maximum of 72 days"
223621021|NCT00825292|PROCEDURE|Polp removal and identification|Identify polyp during colonoscopy then remove polyp
224210717|NCT04947059|DRUG|Epirubicin Hydrochloride combined with continuous saline irrigation|Immediate single intravesical instillation with epirubicin combined with continuous saline irrigation in bladder cancer patients who are treated with a transurethral resection of the tumor
224210718|NCT02120859|DEVICE|FFR - guided DEB angioplasty|DEB-only angioplasty is attempted in all patients. At baseline, quantitative coronary angiography (QCA) and fractional flow reserve (FFR) using an intracoronary standard bolus of adenosine are performed. If FFR at baseline is greater than 0.8, PCI is deferred, otherwise predilation with a non-coated balloon is performed. In case of severe recoil (\> 50% residual stenosis) or flow-limiting dissection the procedure is deemed not suitable for DEB-only angioplasty and stent implantation is performed at the discretion of the operator. In all other cases, the lesion is treated using a Sequent Please® paclitaxel-eluting balloon (DEB). QCA and FFR measurements are repeated and the result is considered satisfactory if there is no flow-limiting dissection, residual stenosis \< 40% and FFR \> 0.8.
224210719|NCT02120859|DEVICE|Provisional bare metal stenting|In case of suboptimal results after the FFR-guided DEB angioplasty described above, a bare metal stent is implanted inside the segment previously treated by DEB.
224210720|NCT02793375|DRUG|Montelukast|Age appropriate dose of Montelukast given to patients prior to undergoing adenotonsillectomy, and the day after surgery, with pain scores and amount of opioid pain medication required measured postoperatively.
224210721|NCT02793375|DRUG|Placebo|Age appropriate dose of placebo given to patients prior to undergoing adenotonsillectomy, and the day after surgery, with pain scores and amount of opioid pain medication required measured postoperatively.
224210722|NCT05931952|OTHER|Buteyko breathing technique|"Group A: Buteyko breathing technique and conventional (chest physiotherapy) treatment for 5 times a week for about 20 minutes in one session for a period of 4 weeks. There are three steps involved in buteyko breathing technique.~Step 1; control pause breathing test (patient is asked to sit in an upright position and take normal breath. After this, asked the patient to take small breath-in for 2s and out for 3s. Control pause phase should not exceed for \>30 seconds).~Step 2; maximum pause or shallow breathing (patient is asked to place fingers under the nose to monitor inflow of air. 2 or 3 flickers of air is taken in and exhale as slowly as possible).~Step 3; combine step 1 and 2. Bronchial drainage will be performed as a conventional treatment for 2 to 3 minutes in each segment. During that time, patient is asked to take deep and slow breaths followed by cough to help in clearing mucus."
223621022|NCT00825292|PROCEDURE|colon polyp removal|identify and remove polyp
223621023|NCT00825292|PROCEDURE|ETMI colonoscope (ETMI scope is a FDA approved device)|ETMI colonoscope used to identify colon polyps as compared to HD white light colonoscope identifying colon polyps.
223621024|NCT01590030|PROCEDURE|Laparoscopic dermoid cystectomy|Laparoscopy will be performed by pneumoperitoneum with CO2. A complete pelvic examination will be performed to exclude malignant disease. Ovarian capsule will be incised by scissors on mesial side in study group and antimesial side in control group. After cleavage plane identification the cyst enucleation will be completed by atraumatic dissection.
223621025|NCT00055302|DRUG|Arimidex 1 mg|Arimidex (anastrozole) 1mg once daily by mouth
223621026|NCT00002328|DRUG|Azithromycin|
223621027|NCT05738135|DRUG|Aminophylline group|Patients will receive 4 mg/kg aminophylline diluted in 50 ml normal saline over 30 minutes.
224210723|NCT05931952|OTHER|Papworth method|"Papworth method and conventional chest physiotherapy (bronchial drainage) treatment. Intervention will be given for a period of 5 sessions per week for 1 month. Duration of each session will be 20 minutes. This technique is performed particularly during remission period that make it feasible for respiratory physiotherapist to integrate this method into activities of daily living. Papworth method has five components including Papworth method ameliorates asthmatic symptoms breathing, education, relaxation, combination of breathing and relaxation exercise and home exercises and also improves quality of life.~Bronchial drainage will be performed as a conventional treatment for 2 to 3 minutes in each segment. During that time, patient is asked to take deep and slow breaths followed by cough to help in clearing mucus."
224210724|NCT05558852|PROCEDURE|Laparoscopic Meshless Sacrocolpopexy Technique|Meshless sacrocolpopexy: laparoscopic approach to central and anterior compartment prolapse
224210725|NCT00593099|DRUG|Bupropion|BUP \[as the intermediate-release (IR) formulation\] was inducted on Day 1 of the trial at 75 mg po qd x 3 days, then increased to 150 mg \[as BUP SR formulation\] qd x 4 days, and then increased to a final dose of up to 150 mg po bid (300 mg/day) by Day 15 (target quit date; TQD) as tolerated. This dose was continued for an additional eight (8) weeks at up to 150 mg po bid. Flexible dosing was permitted to allow for adjustments needed if a bipolar subject did not tolerate the full dose of BUP at 300 mg/day. BUP was discontinued at the end of Week 10.
223621028|NCT05738135|DRUG|normal saline|Patients will receive 50 ml normal saline over 30 minutes.
223621029|NCT06007846|DRUG|Namenda|Memantine 5 mg by mouth once daily, to be titrated up to 20 mg daily
224210726|NCT00593099|DRUG|Placebo|matching placebo capsules (PLA) containing only a dextrose matrix.
224316134|NCT04462887|BEHAVIORAL|Nursing intervention program|The intervention consisted of structured information (SI) provided in a booklet, nursing telephone support (NTS) and access to a nurse pager 24h/day. The SI booklet, Sudden Cardiac Arrest: A Survivor's Experience, contains 2 components: a descriptive component including individual verbatim statements about experiences of others during the first year of recovery and a management component outlining successful strategies used by others in dealing with issues in recovery. The NTS telephone calls included: check-in about current concerns, assessment of the topic for the week, review of common recovery experiences, discussion of behavioral strategies for dealing with the topic for the week, provision of positive feedback for strategies already working well, anxiety reduction statements, practice of new behaviors using role-playing and problem solving techniques, summarization, setting specific goals for the upcoming week, and collaborating on a learning assignment for the subsequent week.
223621030|NCT00242268|DRUG|Simvastatin|
224316135|NCT05532709|OTHER|Plyometric training|m level one (weeks one and two; 1-2 sets of 10 repetitions) to level two (weeks three and four; 1-2 sets of 8 repetitions) and finally level three (weeks five and six; 1-2 sets of 6 repetitions). Plyometric training programs included both leg jumps, single-leg jumps, hurdle jumps, drop jumps, box jumps or lunge jumps
223621031|NCT00966654|DRUG|Placebo|1.5 pmol/kg/min (5 ng/kg/min) saline infused continuously over 72 hours.
223621032|NCT00966654|DRUG|GLP-1 (7-36) amide|1.5 pmol/kg/min (5 ng/kg/min) GLP-1 infused continuously over 72 hours.
223621033|NCT06290115|OTHER|Questionnaires set 1|Participants of case group will be asked to respond to the demographic information，the Family Emotional Expressivity Questionnaire（FEEQ）、the Parent-Adolescent Communication Scale（PACS）、the Childhood Trauma Questionnaire（CTQ）、the Parental Bongding Instrument（PBI）、the Adolescent parent-child relationship intimacy questionnaire and the Ottawa Self-injury Inventory（OSI）.
223621034|NCT06290115|OTHER|Questionnaires set 2|Participants of control group 1 will be asked to respond to the demographic information，the Family Emotional Expressivity Questionnaire（FEEQ）、the Parent-Adolescent Communication Scale（PACS）、the Childhood Trauma Questionnaire（CTQ）、the Parental Bongding Instrument（PBI） and the Adolescent parent-child relationship intimacy questionnaire.
224316136|NCT05532709|OTHER|Circuit training|"The circuit training consists of 6 exercises, divided in 2 blocks (1st block contains~½ squats, bench press and pushups and 2nd block contains burpees, squat thrust and lunges) of 3 minutes."
224316137|NCT01146756|DRUG|AZD6244|MEK inhibitor AZD6244 (Selumentinib) in combination with thoracic radiotherapy
224316138|NCT03938285|OTHER|Theranova 400 membrane|Patients will receive 4 different dialysis treatment, HD with a high flux membrane, extended HD, On Line Hemodiafiltration, and the novel On Line Hemodiafiltration with an MCO membrane.
224316139|NCT03938285|OTHER|FxCordiax 120 membrane|Patients will receive 4 different dialysis treatment, HD with a high flux membrane, extended HD, On Line Hemodiafiltration, and the novel On Line Hemodiafiltration with an MCO membrane.
223621035|NCT06290115|OTHER|Questionnaires set 3|Participants of control group 2 will be asked to respond to the demographic information，the Family Emotional Expressivity Questionnaire（FEEQ）、the Parent-Adolescent Communication Scale（PACS）、the Childhood Trauma Questionnaire（CTQ）、the Parental Bongding Instrument（PBI） and the Adolescent parent-child relationship intimacy questionnaire.
223621036|NCT00575185|DRUG|Valomaciclovir|4 grams orally of valomaciclovir (2 grams BID) for 21 days.
223621037|NCT00575185|DRUG|placebo|Placebo tablets orally twice daily for 21 days.
223621038|NCT04634097|OTHER|Experimental group|"Clusters will be proposed LE DECLIC EPRI intervention, which is a complex intervention, associating 3 components,:~A. DECLIC program set up in the centers, open to concerned patients.~B. 3 training sessions :~* one public of primary care physicians in order to give them the opportunity to be involved in the medical care in charge of the patient suffering from cancer pain.~* one public of cancer physicians, leaders of opinions in each cancer centers participating to the study and one public of health professionals in order to train them to be educators (team building).~* for healthcare professionals in order to train them as educators in this program.~C. The collaboration of one primary care network, specialized in pain management, in order to reinforce the patient care pathway."
223621039|NCT04634097|OTHER|standrad group|Standard follow-up patient related to pain. Specific to each center : with or without existing local ETP program (standard care).
223621040|NCT04046328|DRUG|Enteric-Coated Cholestyramine (ECC) Capsule|Enteric-Coated Delayed Release Cholestyramine Capsules
223621041|NCT04046328|DRUG|Placebo|Enteric-Coated Delayed Release Placebo Capsules
223513187|NCT02931539|DRUG|Maribavir|Maribavir 400 milligrams (mg) (2x200 mg tablets) will be administered twice daily for 8 weeks.
223513188|NCT02931539|DRUG|Ganciclovir|Ganciclovir as per the investigator's prescribed dosing regimen will be administered for 8 weeks.
223513189|NCT02931539|DRUG|Valganciclovir|Valganciclovir as per the investigator's prescribed dosing regimen will be administered for 8 weeks.
223513190|NCT02931539|DRUG|Foscarnet|Foscarnet as per the investigator's prescribed dosing regimen will be administered for 8 weeks.
223513191|NCT02931539|DRUG|Cidofovir|Cidofovir as per the investigator's prescribed dosing regimen will be administered for 8 weeks.
223513192|NCT02059642|DRUG|MG01CI (1400 mg)|MG01CI (Metadoxine Immediate-release/Slow-release, Bilayer Caplet) 1400 mg administered orally once daily
223513193|NCT02059642|DRUG|placebo|Placebo 1400 mg administered orally once daily
223513194|NCT03178942|DRUG|Permethrin Cream, 5%|Permethrin Cream 5%
223513195|NCT03178942|DRUG|Elimite™ Cream (permethrin) 5%|Permethrin Cream 5%
223513196|NCT00490997|DRUG|Ketamine only|"Ketamine 1.0 mg/kg IV and placebo intralipid as initial sedation agents (double blinded).~Ketamine .25 mg/kg IV and placebo intralipid q2 minutes prn for additional sedation"
223513197|NCT00490997|DRUG|Ketamine - Propofol|"Ketamine .5 mg/kg and Propofol 1 mg/kg as initial sedation agents (double-blinded).~Saline Placebo and Propofol .5 mg/kg q 2minutes for additional sedation"
223513198|NCT06929975|BEHAVIORAL|podcast training|In accordance with the established training program for participants, a four-phase podcast listening process aimed at reducing birth fear will be implemented. The first podcast will be launched at the 33rd week of pregnancy, with the goal of helping participants gain information about the childbirth process and reduce their anxiety. Following that, a second podcast will be played at the 34th week of pregnancy, focusing on supporting psychological preparation for childbirth. The third podcast, to be implemented at the 35th week, will address topics such as relaxation techniques and breathing exercises that can be used during labor. Finally, the fourth podcast, played at the 36th week, will emphasize the importance of positive thinking and partner support during labor. To evaluate the effectiveness of the podcast sessions, psychological status and partner support scales will be applied at specific weeks.
223513199|NCT03023696|PROCEDURE|Bilateral Cervical Keyhole Foraminotomy|Under microscopic or loop magnification, a high-speed burr is used to perform the foraminotomy. The keyhole foraminotomy begins at the lamina-facet junction, with careful consideration of the amount of facet resection. Typically, only the medial one third is drilled. Then a 1- or 2-mm Kerrison punch can be carefully placed over the nerve root and then used to undercut the facet, ensuring that the spine is not destabilized by the foraminotomy. The amount of facet resection must not exceed 50% in order to preserve spine stability.
223513200|NCT03023696|PROCEDURE|Cervical Decompression|Cervical decompression for myelopathy, including the following procedures: laminoplasty, laminectomy, discectomy and fusion
223513201|NCT04755725|DEVICE|Epidural catheter|epidural catheter inserted pre induction
223513202|NCT04755725|DEVICE|rectus sheath catheter|The surgeon will place one hand inside the abdomen and with the other hand inserted the Tuohy needle through the skin and fascia. The surgeon will feel when the needle tip is just superfacial to interface between the peritoneum and muscle layer and avoid penetration of inferior epigastric artery. The procedure will be repeated on the contralateral
223513203|NCT06933875|BEHAVIORAL|Clinical Decision Support Tool|Deliver prognostic information and evidence-based decision support at the point of care
223513204|NCT03645681|DEVICE|InnAVasc arteriovenous graft surgical implant|An InnAVasc AVG will be surgically implanted into the upper arm or forearm of enrolled participants
223513205|NCT03755154|DRUG|S65487- initial scheme|S65487 is administered as single agent via i.v. infusion once a week on a 3-week cycle.
223513206|NCT03755154|DRUG|S65487 - alternative scheme|S65487 is administered in 3 to 5 i.v. infusions the first week of each cycle then once a week on the rest of the 3-week cycle.
223513207|NCT02958072|OTHER|LeucoPatch|LeucoPatch is an fully autologous growth factor-containing dressing
223513208|NCT06027398|DIAGNOSTIC_TEST|SARS-CoV-2 RNA detection|SARS-CoV-2 RNA detection in used mask filters
223513209|NCT03527979|PROCEDURE|IVF/ICSI|IVF/ICSI
223513210|NCT00839579|OTHER|1x4 min interval|Aerobic interval training
223513211|NCT01926509|DRUG|MK-8892|
223513212|NCT01926509|DRUG|Placebo for MK-8892|
223513213|NCT03681093|DRUG|Fevipiprant 150 mg|Fevipiprant (QAW039) 150 mg once daily administered orally as tablet
223513214|NCT03681093|DRUG|Fevipiprant 450 mg|Fevipiprant (QAW039) 450 mg once daily administered orally as tablet
223513215|NCT03681093|DRUG|Placebo|Placebo once daily administered orally as tablet
223513216|NCT06633549|OTHER|Home Accidents Prevention Training|Mothers in the education group who participated in the study were informed about the research and their written consent was obtained. Mothers filled out the 'Information Form' then completed the 'Diagnostic Scale of the Mother's Safety Measures for Home Accidents in Children Aged 0-6 Years'. Mothers were helped when filling out the form and their questions were answered. The training program was organized so that there would be a maximum of 5 mothers in each group. The trainings were conducted face-to-face with a PowerPoint presentation and lasted about 40-45 minutes. Question-answer and discussion methods were used during the training. After the training, the mothers were asked to fill out the same scale again one month later. One month after the training, the mothers were interviewed face-to-face and the scale was filled in again and the changes they made at home were recorded.
223621042|NCT02082418|DIETARY_SUPPLEMENT|Alpha-lactalbumin|Subjects will ingest the liquid meal containing alpha-lactalbumin and carbohydrates (0.6 g/kg FFM protein + 0.3 g/kg FFM carbohydrates).
223621043|NCT02082418|DIETARY_SUPPLEMENT|Whey|commercially available whey protein
223621044|NCT02082418|DIETARY_SUPPLEMENT|Casein|commercially available casein protein
223621045|NCT06501586|DRUG|SGB-3908|SGB-3908 for sc injection
224210727|NCT06045832|DEVICE|MAXPOWER Biological Antibacterial Liquid|MAXPOWER Biological Antibacterial Liquid is a mouthwash product self-developed in China, which contains betaine, antibacterial peptide and other antimicrobial substances, which have been proved by experiments to have a good biological safety and at the same time have a killing effect on bacteria. Mouthwash belongs to the category of medical devices, not drugs.
224210728|NCT06045832|DEVICE|Water|Water
224210729|NCT03220152|DRUG|emtricitabine / tenofovir 200/300 mg|Fixed dose combination of emtricitabine / tenofovir 200/300 mg once daily orally during one year
224210730|NCT02149537|DRUG|hydroxyurea|
224210731|NCT03719261|DRUG|chitosan nanoparticles|Chitosan is a bioactive polymer obtained from deacetylation of chitin and is used in biomedical application due to its antimicrobial properties and biocompatibility and ability to resist aging for longer periods provide antibacterial effect in root canal disinfection.10ml of cs-np will be used during instrumentation in intervention group
224210732|NCT03719261|DRUG|Sodium Hypochlorite|Sodium hypochlorite (NaOCL) is the most recommended irrigant due to its broad antibacterial effect, necrotic tissues and dentin collagen dissolving capability and inactivation of endotoxins.10ml of 2.5%NaOCL will be used during instrumentation in control group
224210733|NCT02878811|OTHER|Observational study|This is a non-interventional study, patients receive their usual treatment as determined by the physician.
224210734|NCT00423228|DRUG|ZT-1|Patients in the ZT-1 treatment group will receive ZT 1-1 mg capsules administered p.o. daily during the first month of treatment, followed by ZT-1 implants (9 mg) administered s.c. during the second month of treatment, followed by ZT-1 implants (12 mg) administered s.c. every 4 weeks during months 3 to 6 of treatment. Patients in the ZT-1 treatment group will receive dummy donepezil capsules during months 2 to 6 of the treatment period.
224210735|NCT00423228|DRUG|Donepezil|Patients in the donepezil treatment group will receive donepezil 5 mg capsules administered p.o. during the first month of treatment, followed by donepezil 10 mg/day during months 2 to 6 of the treatment period. Patients in the donepezil treatment group will also receive s.c. injections of dummy ZT 1 implants every 4 weeks during months 2 to 6 of the treatment period.
224210736|NCT06398561|BEHAVIORAL|Active Patient Program|"The Active Patient Program is a peer-leader intervention that consist of training patients with a chronic disease or mental health illness for improve the symptoms of that pathology.~Training is carried out in groups of about 12-15 patients and usually has 2 patient trainers. These patients lead the sessions through the theoretical content they have integrated, motivation, group leadership, exchange of experiences and promotion of communication. In this way they favor problem-solving by the patients who attend the sessions, thus improving their self-management and self-efficacy.~In the group formed by patients who are trainers and patients who benefit from the sessions, a climate of trust is created that favors the expression of emotions on both sides, empathy and assertiveness. In addition to fostering socio-affective bonds between the participants and increasing perceived social and emotional support."
224210737|NCT05384197|DRUG|Enhanced regimen|"Sulfamethoxazole-Trimethoprim (TMP-SMX) twice daily will be utilized as the first choice AP for 2 days with the last day of AP course being one day prior to intervention.~In patients with allergy or resistance to TMP-SMX, the following antibiotics will be considered in the following order: 100 mg Nitrofurantoin twice daily, 500 mg Ciprofloxacin twice daily or 200 mg Cefpodoxime twice daily.~Patients with positive culture which is sensitive only to parenteral antibiotics will receive culture-based intramuscular/intravenous antibiotics following the same schedule (2 days with the last day of AP course being one day prior to intervention)"
223513217|NCT06633549|OTHER|Control Group|Mothers in the control group were informed about the research and the 'Informed Consent Form' was signed. The mothers filled out the 'Information Form' and this process took about 15-20 minutes. Mothers were helped when filling out the form and their questions were answered. In addition, mothers were asked to complete the 'Diagnostic Scale of the Mother's Safety Measures for Home Accidents in Children Aged 0-6' by introducing. A month later, they were informed that they had to fill out this scale again. A month later, the mothers were interviewed face-to-face and allowed to fill out the scale again. After the last test, the mothers in the control group were given 'Home Accidents and Prevention Training for Children in the 0-6 Age Group' and the output of the training presentation was distributed.
223513218|NCT01704573|DRUG|2-[18F]-fluro-3-[2(S)-2-azethidinylmethoxy]-pyridine|"The study will be performed using an Investigational New Drug (IND) Application for the 2-\[18F\]FA radioligand. The 2-\[18F\]FA radiotracer allows us to measure nicotine receptors. The PET imaging technique used at these sessions allows us to measure the amount of light that 2-\[18F\]FA gives off in different regions of the brain, we can estimate how many nicotine receptors are in that region.~2-\[18F\]FA (radiotracer) is investigational, which means it is not approved by the United States Food and Drug Administration (FDA) for the way that it is being used in this research study. For this reason, we have received approval for all procedures in the current study including the use of 2-\[18F\]FA from the FDA."
223513219|NCT05175378|OTHER|Lifestyle intervention|We investigated the potential cardiovascular health effects of the Mediterranean dietary pattern on adult women with relapsing-remitting multiple sclerosis, in regards to body weight, body composition, cardiovascular blood biomarkers (fasting glucose, lipids, C-reactive protein), as well as depression and anxiety levels.
223513220|NCT05686486|OTHER|Tai Chi inspired gymnastics|"The intervention programme will address the themes of relax and seek flexibility and contact and follow. The programme will be divided into four parts with six sessions per part. A typical session will be as follows:~* Joint warm-up~* A body session focused on relaxation and flexibility in different planes: sagittal/sagittal and frontal/sagittal, frontal and transversal/sagittal, frontal and transversal.~* A more playful session in pairs on the theme of contact and follow. Example: put the back of your hand against the back of your partner's hand and initiate movements and the other must follow without resistance."
223513221|NCT05033561|BIOLOGICAL|nOPV2|Novel Oral Poliomyelitis Type 2 Vaccine
223513222|NCT02445365|DEVICE|AutoRIC device|
224210738|NCT05384197|DRUG|Extended regimen|"Sulfamethoxazole-Trimethoprim (TMP-SMX) twice daily will be utilized as the first choice AP for 7 days with the last day of AP course being one day prior to intervention.~In patients with allergy or resistance to TMP-SMX, the following antibiotics will be considered in the following order: 100 mg Nitrofurantoin twice daily, 500 mg Ciprofloxacin twice daily or 200 mg Cefpodoxime twice daily.~Patients with positive culture which is sensitive only to parenteral antibiotics will receive culture-based intramuscular/intravenous antibiotics following the same schedule (7 days with the last day of AP course being one day prior to intervention)"
224210739|NCT02105597|OTHER|Mobile application|The intervention in this study is a mobile application which will be downloaded into the participant's smartphone.
224210740|NCT03076528|OTHER|Sensor-based interactive exercise (game-based exercise)|This intervention includes interactive game-based lower extremity training including repetitive ankle movements in multiple directions. Wearable sensors will provide real-time feedback from foot and ankle position and allow perception of motor-errors during each motor-action
223621046|NCT06501586|OTHER|SGB-3908-Matching placebo|Normal saline (0.9% NaCl) matching volume of SGB-3908 doses will be administered
223621047|NCT05718947|DIAGNOSTIC_TEST|Brain MRI (3T, 7T, 9.4T)|All patients will undergo anatomical brain imaging on a 3T, 7T and 9.4T MRI scanner within the same day at baseline and again 6 months later. An optimized protocol for every separate field strength will be run. Sequences will include at least T1-weighted, T2\*-weighted and a T2 SPACE or FLAIR sequence. No intravenous contrast will be used.
223621048|NCT02167308|DEVICE|Laser acupuncture|a GaAlAs semiconductor diode Laser Phototherapy Device with a wavelength of 808nm. Maximum power output is 150 milliwatt in continuous wave mode.
224210741|NCT03076528|OTHER|Non-technology foot and ankle exercise program|Subjects are asked to perform non-technology based foot and ankle exercises, which include plantar flexion and extension.
224210742|NCT05348707|OTHER|epidemiology|To review medical records to describe diagnosis and severity of the disease.
224210743|NCT05348707|OTHER|epidemiology|To compare pre and per Covid-19 epidemics in terms of numbers of admissions and proportion of severe disease.
224210744|NCT00554177|DRUG|Medicane (mifepristone)|2 doses of 1200mg, Administered 2-3 days apart
224210745|NCT00554177|DRUG|Placebo|2 doses of 1200mg, administered 2-3 days apart
223621049|NCT03723551|DRUG|Afabicin|Administered intravenously and orally.
223621050|NCT03723551|DRUG|Standard of Care|Administered with SOC in accordance with local practice and applicable treatment guidelines.
223621051|NCT04017221|DRUG|Sodium-glucose cotransporter 2 (SGLT2) inhibitors|Current exposure to SGLT2 will be defined as a prescription for a SGLT2 inhibitor (canagliflozin, dapagliflozin, empagliflozin) alone or in combination with other antidiabetic drugs, excluding DPP-4 inhibitors and insulin.
223621052|NCT04017221|DRUG|Dipeptidyl peptidase-4 (DPP-4) inhibitors|Current exposure to DPP-4 will be defined as a prescription for a DPP-4 inhibitor (alogliptin, linagliptin, saxagliptin, sitagliptin, vildagliptin) alone or in combination with other antidiabetic drugs, excluding SGLT2 inhibitors and insulin.
223621053|NCT04017221|DRUG|Other treatment combinations|Current exposure to other treatment combinations will be defined as a prescription of other antidiabetic drugs (metformin, sulfonylureas, thiazolidinediones, GLP-1 receptor agonists, alpha-glucosidase inhibitors, meglitinides, insulin, or combinations of these drugs), current use of insulin (alone or combination with other antidiabetic drugs), and non-current use of antidiabetic drugs.
223621054|NCT03472625|DIAGNOSTIC_TEST|Screening and diagnosis of aphasia, dysarthria, dysphagia|"Screening (day 2 +/- 1; day 7 +/-1): NIHSS (National Health Institute Scale) 9 and 10 scores, dysphagia screening (nurse), speech-, and language screening (speech therapist)~Diagnostic assessment (day 2 +/-1-):~Dysphagia: MASA (Mann Assessment of Swallowing Abilities), FOIS (Functional Oral Intake Scale) Dysarthria: perceptual assessment, NSVO-Z (Nederlands spraakverstaanbaarheidsonderzoek - zinnen) Aphasia: ScreeLing, BNT (Boston Naming Test)"
223621055|NCT00490087|DEVICE|Levonorgestrel intrauterine device (IUD)|
223621056|NCT00579774|OTHER|Low AGE Diet|Diet
223621057|NCT00579774|OTHER|Regular Diet|Diet
223621058|NCT00251524|DRUG|Bevacizumab, Oxaliplatin, Pemetrexed|Avastin 15 mg/kg IV, Alimta 500 mg/m2 IV given over 10 minutes, Eloxatin 120 mg/m2 IV given over 2 hours
223621059|NCT01405768|DRUG|sodium bicarbonate buffered lidocaine|8.4% sodium bicarbonate will be mixed with lidocaine in a 1:10 ratio prior to mixing with epinephrine and injecting into the cervix.
223621060|NCT01405768|DRUG|Non-buffered lidocaine|
223761727|NCT05124665|BEHAVIORAL|Social Support|"The intervention to be evaluated in this study is a multidimensional, socio-behavioral Norming intervention. The various components of this intervention are designed to harness household dynamics and prosocial inclinations to encourage individuals to accept the HIV testing invitation. Each component is briefly described in the arm description."
223761728|NCT02978287|DRUG|BAVU Solution|Tissue preservation solution for transplantation
223761729|NCT02526069|BEHAVIORAL|Acceptance and Commitment Therapy|An application based on Acceptance and Commitment Therapy
224210746|NCT05706454|DRUG|Ramatroban|"Route of Administration: Oral Dose: 75 mg; Frequency: Twice daily; Total duration of intervention: 28 days.~Subjects will be evaluated over a study period of approximately 365 days."
224210747|NCT05706454|DRUG|Placebo|Matching placebo will be administered orally twice a day
224210748|NCT00386854|BEHAVIORAL|physical training|
224210749|NCT02770053|PROCEDURE|Foraminal enlargement|After determining the working length, a flexible size 30 K-file will be inserted 1 mm beyond the WL and the apical foramen will be enlarged.
224210750|NCT04281654|OTHER|Active Social Conversation|Active Social Conversation
224210751|NCT06141954|DEVICE|Ultrasound waves therapy|Therapeutic ultrasound is proposed to deliver energy to deep tissue sites through ultrasonic waves, to produce increases in tissue temperature or non- thermal physiologic changes. Low level laser therapy penetrates particularly light waves that increase cellular metabolism.
224210752|NCT06141954|DEVICE|Low level laser therapy|Low-level laser (light) therapy (LLLT) is a fast-growing technology used to treat a multitude of conditions that require stimulation of healing, relief of pain and inflammation, and restoration of function.
224210753|NCT04184154|OTHER|Questionnaires|The self-questionnaire of 104 questions collected personal and socio-demographics data, global and sexual quality of life characteristics (European Organisation for Research and Treatment of Cancer \[EORTC\] quality of life questionnaires: QLQ-C30 and gynecologic and cervical cancer specific-questionnaire QLQ-CX24), vaginal dilatators and moisturizers use, and barriers and facilitators of their use. Clinical data were extracted from the patients' medical files. Vaginal stenosis was evaluated at 6 weeks after the end of brachytherapy and after 1-year follow-up by in-town gynecologists or in our Institute, and censored in case of complete vaginal obliteration
224210754|NCT04064528|DIETARY_SUPPLEMENT|Amino Acids|10 g bolus of essential amino acids
223513223|NCT05440565|DIAGNOSTIC_TEST|Fecal immunochemical test|Fecal immunochemical test can concentrate the high-risk population.
223621061|NCT05041049|DEVICE|Comparing Visual Reality to High-fidelity mannequin Stimulation|"This is a prospective, randomized, non-inferiority study. VR will be compared to HFS, which will be considered the a priori gold standard for residents simulation training.~The study will be divided into two phases. In the pre-test phase, participants will be randomly allocated to receive either a VR or HFS scenario (scenario 1, see below). In the post-test phase, all participants (regardless the initial grouping) will undergo a HFS scenario (scenario 2, see below).~All scenarios have been chosen from critical events published by the Society of Pediatric Anesthesia48 and adult sources49.~The study will be conducted at the McGill University Health Center - Research Institute (MUHC-RI)."
223513224|NCT05440565|DIAGNOSTIC_TEST|APCS score|APCS score can concentrate the high-risk population.
224210755|NCT05558605|DIAGNOSTIC_TEST|AI-guided echo|AI-guided echocardiography
224210756|NCT05558605|DIAGNOSTIC_TEST|Standard echo|Standard echocardiography
223513225|NCT03008473|DEVICE|video laryngoscope and chest CT iminge|
223513226|NCT03008473|DEVICE|Conventional intubation of uniblocker|
223513227|NCT01100580|DIETARY_SUPPLEMENT|low salt diet|Daily salt intake less than 4 g/day
223513228|NCT01100580|DIETARY_SUPPLEMENT|water therapy|abundant intake of water with a low mineral and low sodium content (at least 2 litres in winter and 3 in summer).
223513229|NCT01882829|DRUG|dextromethorphan/quinidine|up to 45/10 mg every 12 hours in patients with TRD with a short 7 day tapering period in which subjects are tapered off 45/10 mg dose from twice a day to once daily for an additional 7 days at post 8-week treatment period to minimize the potential for discontinuation effects
223513230|NCT00800345|DRUG|Oral Topotecan|Starting on Cycle 1 Day 1, each subject will receive the assigned dose of topotecan administered by mouth.
223513231|NCT00800345|DRUG|Pazopanib|Starting on Cycle 1 Day 1, each subject will receive the assigned dose of pazopanib administered by mouth.
223513232|NCT05280860|PROCEDURE|ultrasound-guided bilateral rectus sheath block|Bilateral RSB was guided by ultrasound before surgery after the completion of general anesthesia, First, the probe is placed transversely and perpendicular to reveal the anterior, hypoechoic, and posterior rectus sheath of the hyperechoic rectus abdominis. Moving the probe outward to reveal the sound images of the lateral margin of the rectus abdominis, external oblique, internal oblique, and transverse abdominis muscles. After the scanning, the needle was inserted from any segment of the probe under the guidance of real-time ultrasound; the tip reached between the rectus abdominis muscle and the posterior sheath of the rectus abdominis muscle. After no blood was extracted, 1 \~ 2 ml of normal saline was firstly injected to determine whether the tip position was correct, If the needle tip was correctly positioned, 0.5 % ropivacaine 10 mL of local anesthetic was injected on each side. The same anesthesiologist was performed bilateral RSB under ultrasound guidance.
223513233|NCT05901207|DIAGNOSTIC_TEST|blood test|blood test
223513234|NCT06794359|PROCEDURE|Minimally Invasive Coronary Artery Bypass Grafting|Minimally Invasive Coronary Artery Bypass Grafting will be accomplished by complete revascularization of all previous defined coronary targets through left anterior thoracotomy. On or off pump approach will be determined by the surgeon. For on pump cases, femoral canulation will be performed and aortic cross clamp will be used. Off Pump cases will be performed using Medtronic Octopus and Starfish NS. Intra operative Transit time flow measurement will be performed in all cases.
223513235|NCT06794359|PROCEDURE|Coronary artery bypass surgery|Procedure: Conventional Coronary Artery Bypass Grafting will be accomplished by complete revascularization of all previous defined coronary targets through classical total sternotomy. On or off pump approach will be determined by the surgeon. Intra operative Transit time flow measurement will be performed in all cases.
223513240|NCT04878757|BEHAVIORAL|CFI - Classwide Fraction Intervention|40 sessions (2 sessions per week; 25-31 minutes per session) of explicit fraction intervention designed to improve students understanding of fraction magnitude and fraction operations.
223513241|NCT05626777|DRUG|Pre-filled syringe, mepolizumab 100 mg/month|Pre-filled syringe, mepolizumab, 100 mg/month, 6 first months of treatment administered by nurse, 6 last months of treatment administered by patient
223513242|NCT05626777|DRUG|Auto-injector pen, mepolizumab 100 mg/month|Auto-injector pen, mepolizumab, 100 mg/month 12 months of treatment administered by patient
223513243|NCT05119335|DRUG|Oral NKT2152|Oral HIF2α inhibitor
223513244|NCT06634862|OTHER|Normatec Air Compression|Intermittent pneumatic pressure has been used in other studies, usually for deep vein thrombosis and vascular disorders. In this way, it has not been compared with other recovery interventions for post-exercise recovery applications.
223513245|NCT06634862|OTHER|Soft Tissue Mobilization|The soft tissue mobilisation technique has been investigated in other studies in terms of its effect on soft tissue and its role recovery. In this way, there is no comparison with other recovery interventions for post-exercise recovery applications.
223513246|NCT06634862|OTHER|Percussive therapy|Percussive therapy has been investigated in device research and athlete health. In this way, it has not been compared with other recovery interventions for post-exercise recovery applications.
223621062|NCT05664321|OTHER|Observational, case-control study|obese \[(BMI ≥30 kg/m2), (n=44)\], and non-obese \[(BMI= 18.50-24.99 kg/m2), (n=48)\].
223621063|NCT03424564|DRUG|Perampanel|Oral Tablet
223621064|NCT01589796|PROCEDURE|TAP block|injection of 20ml of Ropivacaine 0.5% in the proper place once it is identified
223621065|NCT01722305|DRUG|Dexamethasone|Given PO
224210757|NCT06538805|OTHER|Minimal invasive management of dental caries|Minimal invasive management of dental caries among dentists
224210758|NCT00788723|DEVICE|Transcranial Magnetic Stimulation|Transcranial magnetic stimulation (TMS) using paired-pulse technique at different interstimulus intervals (ISIs) allows the study of the excitatory and inhibitory system of human motor cortex non-invasively. Motor evoked potentials (MEP) will be recorded, and stored on a VikingSelect (Viasys Healthcare, USA). Two magnetic stimulators (Magstim 200, The Magstim Company Ltd, U.K.) connected through a Bistim and a Magstim figure-of-eight coil will be used for TMS.
224210759|NCT01042002|BEHAVIORAL|High intensity exercise|High intensity exercise 3xweek for minimum 6 weeks
224210760|NCT01254994|DRUG|entecavir|Patients in the ETV Group were prescribed 0.5 mg entecavir following oral fasting one time per day.
224210761|NCT01254994|DRUG|Traditional comprehensive medical treatment|bed rest, sufficient energy and vitamins, reduced glutathione, prostaglandin E1, hepatocyte growth factor (HGF), plasma and albumin, maintenance of water and electrolyte balance, and prevention and treatment of complications, such as infections, hepatic encephalopathy, hemorrhage, hepatorenal syndrome and ascites.
224210762|NCT01289431|DRUG|Mapracorat|administered daily to each eye for 2 weeks following allergen challenge using a CAC model
224210763|NCT01289431|DRUG|Vehicle|administered daily to each eye for 2 weeks following allergen challenge using a CAC model
224210764|NCT04175873|OTHER|music|Patients will listen to music with MP3 headphones for 1 hour preoperatively and throughout the operation.
224210765|NCT03367286|OTHER|inspection mode|different inspection modes：Computed Tomography Perfusion (CTP) or Magnetic Resonance Perfusion (MRP)
224210766|NCT02069834|DRUG|Arm 1 (intervention)|Dolutegravir 50 mg/j + Rilpivirine 25 mg/j qd orally (intake during meal)
224210767|NCT02069834|DRUG|Arm 2 (control)|Continuation of existing HAART at the time of randomization
224210768|NCT03125824|DEVICE|Soliton Acoustic Wave Device|Treatment of tattoos with Soliton Acoustic Wave Device as an accessory to laser
224210769|NCT03682627|PROCEDURE|Fenestration|A standardized fenestration of the peritoneum will be performed. A 2 cm incision will be made in the peritoneum that is parallel to the skin incision after the transplant procedure. The peritoneal will not be sutured at the edges to keep the fenestration open. No interpositioning of the omentum will be performed.
224210770|NCT03682627|PROCEDURE|Fenestration and clipping|A standardized fenestration of the peritoneum will be performed. A 2 cm incision will be made in the peritoneum that is parallel to the skin incision after the transplant procedure. The window edges will be clipped after fenestration using 8 metal clips.
224210771|NCT01432782|DRUG|Placebo|Saline 4 ml
224210772|NCT01432782|DRUG|Botulinum Toxin Type A|per-endoscopic injection of 100 U of botulinum toxin dissolved in 4 ml of saline
224210773|NCT05244174|DEVICE|Pancreatic stent|Insertion of a pancreatic stent during ERCP to improve pancreatic secretion
224210774|NCT03665480|DRUG|G-SCF|In G-CSF treatment group, all patients are treated with G-CSF at the dose of 5ug/kg pre day until neutrophil higher than 0.5 g/L or 14 days from day three after induction therapy. MRD is monitored at day 14 and 28, respectively, with flow cytometry and quantity PCR if a fusion gene is available.
223621066|NCT01722305|OTHER|Laboratory Biomarker Analysis|Optional correlative studies
224210775|NCT06568640|PROCEDURE|Superselective adrenal arterial embolization|Superselective adrenal arterial embolization is an operation to inject embolic agent into adrenal artery through catheter to embolize part of adrenal gland, so as to reduce the secretion of adrenal hormone and reduce blood pressure.
224210776|NCT06418360|DEVICE|TECAR|Transfer Energy Capacitative and Resistive Therapy
224210777|NCT06418360|DEVICE|conventional physical therapy; Transcutaneous Electrical Nerve Stimulation, hotpack|10 sessions of HP and TENS for two weeks, five times a week. HP was applied to the painful knee area for 20 minutes using a heating pad for superficial heating purposes. TENS was applied to the painful knee area for 20 minutes at 80 Hz frequency
224210778|NCT05194280|PROCEDURE|Robotic surgery|Robotic-assisted donornephrectomy
223621067|NCT01722305|OTHER|Pharmacological Study|Optional correlative studies
224210779|NCT00337129|DRUG|eribulin mesylate|1.4 mg/m2 by IV bolus on Days 1 and 8 of an every 21-day cycle.
224210780|NCT06332365|COMBINATION_PRODUCT|Acetonide triamcinolone 0.2% +hyaluronicacid 1%|topical application cream form twice a day for 4 weeks
224210781|NCT06332365|DRUG|Corticoid Acetonide triamcinolone 0.2%|topical application cream form twice a day for 4 weeks
223621068|NCT01722305|DRUG|Pomalidomide|Given PO
223621069|NCT00005984|DRUG|cyclophosphamide|intravenously over 2 hours on day 1 and on days -7 and -6
224210782|NCT06332365|DRUG|Hyaluronic acid 1%|topical application cream form twice a day for 4 weeks
224210783|NCT05232565|PROCEDURE|Percutaneous Transluminal Coronary Angioplasty|Angioplasty intervention of coronary vessels or coronary bypass graft stenosis
224210784|NCT03434626|BEHAVIORAL|ACP Education|Decision aid and Goals of Care Designation form information administered by Navigator
224210785|NCT03434626|OTHER|Usual care|Usual care includes reviewing Goals of Care Designation form and Greensleeve with physician
224210786|NCT03141931|DIETARY_SUPPLEMENT|Supplement|Concentrated Omega-3 Triglycerides-fish 332 mg Equiv. Eicosapentaenoic Acid (EPA) 134 mg Equiv. Docosahexaenoic Acid (DHA) 66.8 mg Flax Seed Oil (Linseed Oil) 334 mg Equiv. Oleic acid 58.5 mg Equiv. Linoleic acid 58.5 mg Equiv. Linolenic acid 192 mg Borago officinalis seed oil fixed (Borage) 434 mg Equiv. gamma-Linolenic acid 95.5 mg
224210787|NCT03141931|DIETARY_SUPPLEMENT|Placebo|polyethylene glycol (500mg), oleic acid (659mg) and propylene glycol (115mg)
223621070|NCT00005984|DRUG|filgrastim|filgrastim (G-CSF) daily subcutaneously (SQ) starting on day 5 and continuing until completion of leukapheresis. Patients also receive G-CSF IV starting on day 0 and continuing until blood counts recover
223621071|NCT00005984|DRUG|recombinant interferon alfa|Beginning on Day 1, subcutaneous (SQ) daily administration in the absence of unacceptable toxicity or disease progression
223621072|NCT00005984|PROCEDURE|peripheral blood stem cell transplantation|Patients receive the PBSC transplantation on day 0.
223621073|NCT00005984|PROCEDURE|radiation therapy|total body irradiation twice a day on days -4 through -1
223761730|NCT02203812|DRUG|Probiotic Arm|Each Inersan lozenge contains at least 1 billion colony forming unit of Lactobacillus brevis CD2
223761731|NCT02203812|DRUG|Placebo Arm|Placebo lozenges contain all ingredients except the active constituent (probiotic, Lactobacillus brevis CD2)
223621074|NCT05821985|PROCEDURE|The study group|The patients within the study group will receive intraarticular TMJ and masseteric Trigger point injection of a solution that contains (0.75 ml. 12.5% Dextrose solution, 0.75 ml. Saline solution, and 1.5 ml. Lidocaine). Each patient will receive four injections at two-week intervals, aided by a 25 gauge needle connected to a 3 ml. plastic syringe.
223621075|NCT05821985|PROCEDURE|The Control group|"The Control group:~Patients in the control group will receive intraarticular TMJ and masseteric Trigger point dry needle insertion without injecting any solution. Each patient will receive four dry needle insertions at two-week intervals, aided by a 25-gauge and 3.8 cm length needle.~i.e., All the patients will be subjected to intraarticular needle insertion. However, only the patients within the study group will be injected with the Dextrose Prolotherapy solution."
223621076|NCT04355754|DEVICE|Ventil - a gas flow divider|Checking ventilation parameters set and obtained and clinical parameters while ventilating the patient and an artificial lung simultaneously, using inspiratory flow divider.
223621077|NCT06391099|OTHER|Best Practice|Undergo standard of care diet
223621078|NCT06391099|PROCEDURE|Biospecimen Collection|Undergo blood and stool sample collection
223761732|NCT04147442|DEVICE|Hearing aid with fine-tuned and standard programs|A digital, wireless hearing aid is programmed specifically to each subject's hearing loss and fitted with both a program that is fine-tuned for their specific music playing as well as the standard music program that uses pre-determined settings.
223761733|NCT04216862|OTHER|Exercise|Different type of exercises for treatment of Forward Head Posture
224210788|NCT02559531|DEVICE|Mobile triage system|A mobile triage system used by EMS providers will be evaluated using standardized clinical vignettes
223621079|NCT06391099|PROCEDURE|Computed Tomography|Under CT
223621080|NCT06391099|OTHER|Dietary Intervention|Undergo ketogenic diet
224210789|NCT03801395|OTHER|There is no intervention|No intervention
224210790|NCT06191510|PROCEDURE|Bio-Oss Exposed|Molar extraction with a flapless approach and immediate implant installation, filling the gap with deproteinized bovine bone mineral (Geistlich Bio-Oss) and left exposed to the oral environment.
223621081|NCT06391099|OTHER|Educational Activity|Receive coaching support
223621082|NCT06391099|OTHER|Glucose Measurement|Undergo blood glucose testing
223621083|NCT06391099|OTHER|Ketone Measurement|Undergo ketone measurement
223621084|NCT06391099|OTHER|Questionnaire Administration|Ancillary studies
223621085|NCT06218914|BIOLOGICAL|NT-112: Autologous, engineered T Cells targeting KRAS G12D|NT-112 targets KRAS G12D in the context of HLA-C\*08:02
223621086|NCT06218914|BIOLOGICAL|AZD0240: Autologous, engineered T Cells targeting KRAS G12D|AZD0240 targets KRAS G12D in the context of HLA-A\*11:01 or HLA-A\*11:02
223621087|NCT06196385|DEVICE|intensive Cervical Traction|A 30-minute cervical traction protocol, twice a day, for five consecutive days per week for 6 weeks. The main objective will be the evaluation of depression, insomnia, and quality of life. We evaluate at prior to the treatment and, at the end of the protocol, for depression, insomnia, and quality of life.
223621088|NCT02249806|OTHER|PH target therapy according to physician|Patients receiving PH target therapy
223621089|NCT06043024|DEVICE|Stabilization occlusal splint|Patients will be treated with a stabilizing occlusal splint made of hard acrylate resin, about 1.5 mm thick in the posterior teeth area with an incisal plateau for canine guidance. OS will be made by the same dental technician in the dental laboratory.
223621090|NCT02869633|DRUG|Ibrutinib|Given by mouth
223621091|NCT02869633|OTHER|Laboratory Biomarker Analysis|Correlative studies
223621092|NCT05787340|OTHER|Bilişsel Egzersiz Terapi Yaklaşımı (BETY, Cognitive Exercise Therapy Approach)|Bilişsel Egzersiz Terapi Yaklaşımı (BETY, Cognitive Exercise Therapy Approach) is a group exercise method that conforms to the biopsychosocial model via telerehabilitation.
223621093|NCT01381016|DRUG|Estradiol|Subjects were instructed to apply 0.1 mg/d transdermal estrogen for one month.
223621094|NCT01381016|DRUG|Gonadotropin-releasing hormone (GnRH)|Pituitary response was assessed to determine how estradiol administration alters pituitary sensitivity to GnRH.
223761734|NCT02686346|DRUG|Brentuximab Vedotin|"Phase I:~Cohort K: BV on Day 1: 1.2 mg/kg (cycle 1-3) and 1.8 mg/kg (cycle 4) Cohort K+1: BV on Day 1: 1.8 mg/kg (cycle 1-3) and 1.8 mg/kg (cycle 4) Cohort K-1: BV on Day 1: 0.8 mg/kg (cycle 1-3) and 1.8 mg/kg (cycle 4)~Phase II:~BV on Day 1: at the Maximal Tolerated Dose (MTD) defined at Phase I"
223761735|NCT02686346|DRUG|Etoposide|100 mg/m² Days 1-2-3 of Cycles 1-2-3
223761736|NCT02686346|DRUG|Carboplatine|max 800mg Day 2 of Cycles 1-2-3
223761737|NCT02686346|DRUG|Ifosfamide|5 g/m² Day 2 of Cycles 1-2-3
223761738|NCT04054037|OTHER|No intervention|This is an observation study, no intervention will be indicated during diagnosis and treatment.
223761739|NCT01267396|DRUG|Sertraline|Sertraline Hydrochloride Tablets 100 mg
223761740|NCT01395940|DRUG|KLH-2109|
223761741|NCT01395940|DRUG|KLH-2109|
223761742|NCT01076985|DRUG|Lopinavir/ritonavir (Kaletra)|Lopinavir/ritonavir (LPV/r) evaluated separately in patients who were naive to previous antiretroviral treatment and those who were not.
223761743|NCT02376192|DEVICE|Initial MicroScan® (Microvision Medical) SDF Measurement|Initial SDF measurements are recorded in the obstetric preoperative area within two hours prior to administration of spinal anesthesia.
224210791|NCT06191510|PROCEDURE|Mucograft Exposed|Molar extraction with a flapless approach and immediate implant installation, filling the gap with deproteinized bovine bone mineral (Bio-Oss; Geistlich) and covered by a collagen matrix (Mucograft; Geistlich).
224210792|NCT00802269|PROCEDURE|Retinal laser photocoagulation|Retinal laser photocoagulation using a 532 nm laser
224210793|NCT01327638|DRUG|etoricoxib|Patients with SpA/AS who took etoricoxib
224210794|NCT01327638|DRUG|Other COX-2 inhibitor|Patients with SpA/AS who took other COX-2 inhibitors
224210795|NCT01327638|DRUG|nsNSAIDs|Patients with SpA/AS who took nsNSAIDs
224210796|NCT05828433|OTHER|Epley-Canalith Repositioning|Epley-Canalith Repositioning The intervention was given for approximately 15min, for 2 times in a week, for 4 weeks.
224210797|NCT05828433|OTHER|Vestibular Rehabilitation Therapy|"Vestibular Rehabilitation Therapy Habituation exercises: The patients were asked to repeat the exercises 5 -10 times for 5 to 10 min, for 2 days in a week, for 4 weeks.~Gaze stability exercises and balance training: The exercises were performed in 3 sets or 5 repetitions, for 2 days in a week, for 4 weeks."
224210798|NCT02557568|OTHER|Staphylococcus aureus carriage|Staphylococcus aureus carriage is measured in the nose. Nasal samples were taken by the nursing staff of the ward using nylon flocked swab. Prior taking the sample, swabs were wetted using an additional tube containing a sponge impregnated with normal saline solution.
224210799|NCT03990246|OTHER|Acid stable emulsion with solid droplets|This will be a 250 mL acid stable beverage emulsion in which the droplets are crystalline. It will have identical similar to the other intervention, i.e. in a set of samples the emulsion lipid droplets are in the liquid state and are either acid stable or unstable and, in the other set of samples they are solid (i.e. crystallized) and are also either acid stable or unstable in the acidic environment of the stomach, and will be introduced at least 7 days apart. The emulsion will contain 20% of the lipid palm stearin with 2.2% of the emulsifier sorbitan monooleate (Tween80)
224210800|NCT03990246|OTHER|Acid stable emulsion with liquid droplets|This will be a 250 mL acid stable beverage emulsion in which the droplets are liquid. It will have identical similar to the other intervention, i.e. in a set of samples the emulsion lipid droplets are in the liquid state and are either acid stable or unstable and, in the other set of samples they are solid (i.e. crystallized) and are also either acid stable or unstable in the acidic environment of the stomach, and will be introduced at least 7 days apart. The emulsion will contain 20 % of the lipid palm olein with 2.2% of the emulsifier sorbitan monooleate (Tween80)
224210801|NCT03990246|OTHER|Acid unstable emulsion with solid droplets|This will be a 250 mL acid unstable beverage emulsion in which the droplets are solid. It will have identical similar to the other intervention, i.e. in a set of samples the emulsion lipid droplets are in the liquid state and are either acid stable or unstable and, in the other set of samples they are solid (i.e. crystallized) and are also either acid stable or unstable in the acidic environment of the stomach, and will be introduced at least 7 days apart. The emulsion will contain 20% of the lipid palm stearin with 2.5% of the emulsifier sorbitan monostearate (Span60)
224210802|NCT03990246|OTHER|Acid unstable emulsion with liquid droplets|This will be a 250 mL acid unstable beverage emulsion in which the droplets are liquid. It will have identical similar to the other intervention, i.e. in a set of samples the emulsion lipid droplets are in the liquid state and are either acid stable or unstable and, in the other set of samples they are solid (i.e. crystallized) and are also either acid stable or unstable in the acidic environment of the stomach, and will be introduced at least 7 days apart. The emulsion will contain 20 % of the lipid palm olein with 2.5% of the emulsifier sorbitan monostearate (Span60)
224210803|NCT03904667|OTHER|Watson on oncology surgery decision evaluation|Watson on oncology surgery decision evaluation. The system acquires and evaluates a large amount of structured and unstructured data from previous medical records through machine learning and natural language processing, and USES algorithms to select treatment options as the best choice for a particular patient.
224210804|NCT00893867|DRUG|DP-b99|1mg/kg/day over 4 consecutive days given intravenously and initiated up to 9 hours following acute stroke onset.
224210805|NCT00893867|DRUG|Placebo|1mg/kg/day over 4 consecutive days given intravenously and initiated up to 9 hours following acute stroke onset.
224210806|NCT00563524|DRUG|ILV-094|SC and IV administration on days 1, 14, 28, and 42
223761744|NCT02376192|DRUG|Spinal Anesthesia- Bupivacaine|The spinal anesthetic technique is standardized. In the operating room spinal anesthesia will be administered with the L2-L5 interspaces in the sitting position using 12 mg of hyperbaric bupivacaine with 15 mcg of fentanyl and 150 mcg of preservative free morphine.
223513247|NCT06636422|DRUG|Motherwort injection|Patients will be given motherwort injection according to their disease condition in the real world. The investigator only can record the information on the usage of the drug and the relevant medications without any interventions.
223513248|NCT02469961|DRUG|Dexmedetomidine|Participants will receive an interscalene block and will be sedated with Dexmedetomidine and compared to sedation with propofol
223513249|NCT02469961|DRUG|Propofol|Participants will receive an interscalene block and be sedated with Propofol and compared to sedation with Dexmedetomidine
223513250|NCT02469961|OTHER|Interscalene block|Interscalene block is used for the main anesthetic for the case
223513251|NCT02935036|DRUG|ADPS topical product|topical product
223513252|NCT02935036|DRUG|Placebo Control|topical product
223513253|NCT05298046|DRUG|Experimental: TAVO101|TAVO101 single ascending dose IV infusion.
223513254|NCT05298046|OTHER|Other: Placebo|Placebo single ascending dose IV infusion.
223513255|NCT03629717|PROCEDURE|Ultrasound-guided core needle biopsy|Tissue collection for this research proposal will be used for research purposes only and will not inform participant care
223513256|NCT03629717|DRUG|Denosumab|Denosumab is a human IgG2 monoclonal antibody with affinity and specificity for human RANKL
223513257|NCT03629717|PROCEDURE|Blood draw|20 mL of fasting whole blood will be collected before denosumab (Day 1) and one month after denosumab administration (day 60 +/- 10 days)
223513258|NCT03629717|DRUG|Calcium|1200mg daily
223513259|NCT03629717|DRUG|Vitamin D|800 IU daily
223513260|NCT06363981|DEVICE|Active rTMS over the left DLPFC and over the left DMPFC|Active rTMS over the left DLPFC and over the left DMPFC to induce the long term potentiation of stimulated areas.
223513261|NCT06363981|DEVICE|Active rTMS over the left DLPFC|Active rTMS over the left DLPFC to induce the long term potentiation of stimulated area.
223513262|NCT06363981|DEVICE|Sham rTMS|Sham rTMS over the left DLPFC or over the left DLPFC and over the left DMPFC for placebo.
223513263|NCT03435107|DRUG|Durvalumab|"Study treatment consists of durvalumab 1500 mg Q4W for patients \> 30 kg, and will be repeated every 4 weeks. For patients ≤ 30 kg, weight based dosing of 20 mg/kg durvalumab Q4W will be used.~Response evaluation will be performed every 8 weeks (± 1-week window period). Treatment will be continued until disease progression, unacceptable adverse events or the patient's refusal.~Treatment through progression is at the investigator's discretion, and the investigator should ensure that patients do not have any significant, unacceptable, or irreversible toxicity that indicate that continuing treatment will not further benefit the patient. The Investigator should ensure that patients still meet all of the inclusion criteria and none of the exclusion criteria for this study."
224210807|NCT05478486|DRUG|MSP008-22|"It is single group assignment interventional model in this clinical trial, consisting of 5 cohorts of 3 patients in each, to be enrolled such that there exists an overall gender balance for the entire trial and to also ensure including minimum five (5) patients of TNBC and minimum five (5) male patients.~The trial will be initiated with dosing of a cohort of 03 patient with the Safe starting dose for MSP008-22. Dosing of the patients for the next higher dose cohort will initiate only after: (i) All 03 patients have been recruited in the lower dose Cohort and if a repeat Cohort at this dose level is recommended, another 03 patients have been recruited at same dose level (ii) all dosed patients have completed the allocated study cohort duration, (iii) safety and pharmacokinetic results have been reviewed by the Independent Dose Escalation Committee (DEC) and approved for dose escalation to next cohort."
224210808|NCT01866995|DRUG|"Raylis"|"Raylis (1 kapsule contains: ginseng root powder 50 mg, false ginseng root powder 50 mg, codonopsis root powder 50 mg, astragalus membranaceus root powder 50 mg, epimedium alpinum herbal extract 100 mg)"
224210809|NCT01866995|OTHER|standard prostatostasis therapy|
224210810|NCT01230502|DRUG|Group 1 Donor Specific Regulation (DSR) +, Mycophenolic acid (MPA) monotherapy|"Group 1 Donor Specific Regulation (DSR) +, MPA monotherapy~Mycophenolate sodium : Myfortic therapy will be maintained at a target dose of 720mg BID.~Tacrolimus doses will be lowered to achieve levels of 3-5 ng/ml. 6 months later, immunological monitoring will be repeated and tacrolimus will be completely discontinued if the subject remains DSR + without development of donor specific antibodies (DSA). Those who become DSR- or develop DSA will remain on a tacrolimus dose achieving levels of 3-5 ng/ml, and will not undergone any additional reduction.~Subjects will be followed for 24 months at 6 month intervals, and will provide health information and blood samples."
224210811|NCT01230502|OTHER|data and sample collection|"Group 2 : Donor specific regulation (DSR) + standard of care:~These subjects will be maintained on standard of care immunosuppression consisting of Tacrolimus and Mycophenolate sodium (MPS) with no reduction in tacrolimus dose during the 24 months of study enrollment.~Subjects will be followed for 24 months at 6 month intervals, and will provide health information and blood samples"
224210812|NCT01230502|OTHER|data and sample collection|"Group 3 : Donor specific regulation (DSR) - standard of care:~These subjects are those who were DSR negative and/or DSA positive at enrollment and therefore are not eligible for the withdrawal aspect of the study. These subjects will be maintained on standard of care immunosuppression consisting of Tacrolimus and Mycophenolate sodium (MPS) with no reduction in tacrolimus dose during the 24 months of study enrollment. These subjects will be asked to provide heath information and donate blood, exclusively for research testing, at the same 6 month intervals as those in the other two arms of the study, and will be followed for 24 months."
224210813|NCT05614479|OTHER|GATEKEEPER intervention|"Agents will identify candidates in their areas of work (e.g., associations of elderly people).~Training sessions will be held for healthcare professionals and community agents.~Dissemination of materials, resources, and channels to contact and inform candidates to invite them to participate in the study. Recruitment procedures posters, leaflets, videos, newsletters, or appointments will be used.~Candidates interested and accepted will download the application on their mobile devices and will surf on the app which pretends to promote healthy aging. Users will provide some data and complete questionnaires (available in the application) for the baseline and final assessment.~Professionals will visualize how and how much participants are interacting by using the MAHA dashboard."
224210814|NCT01154400|DIETARY_SUPPLEMENT|Casein protein hydrolysates|15 g casein protein hydrolysates + 15 g maltodextrin
224210815|NCT01154400|DIETARY_SUPPLEMENT|Whey protein hydrolysates|15 g whey protein isolate + 15 g maltodextrin
224210816|NCT01154400|DIETARY_SUPPLEMENT|Casein protein hydrolysates + LEU|15 g casein protein hydrolysate + 2.1 g LEU (40% of EAA content) + 15 g maltodextrin
224210817|NCT01154400|DIETARY_SUPPLEMENT|Whey protein hydrolysates + LEU|15 g whey protein isolate + 1.5 g LEU (40% of EAA content) + 15 g maltodextrion
224210818|NCT04767542|DRUG|Intravenous Infusion|analgesic
224210819|NCT04767542|PROCEDURE|Local anesthesia|Local anesthetic agent (Bupivacaine 0.5%) will be injected bilaterally to transverses abdominis muscle
224210820|NCT02307188|DEVICE|Constellation Full Contact Mapping Catheter|64-electrode intracardiac mapping catheter.
224210821|NCT02583607|DEVICE|Brava|"The purpose of the study is to examine the efficacy of Brava with fat grafting in woman undergoing mastectomy in the institution.~woman who will agree to participate in the study will be instructed how to wear the Brava, and after 200 hours of using the device they will be operated for fat transfer to the breast in order to reconstruct it."
224210822|NCT00102388|DRUG|vildagliptin|
224210823|NCT00102388|DRUG|Gliclazide|
224210824|NCT02156349|DEVICE|Accu-Chek Smart Pix Software|Software with adherence evaluation software used according to Integrated Personalized Diabetes Management (PDM)
223513264|NCT05130281|BEHAVIORAL|Maya mobile app|The Maya app teaches cognitive behavioral therapy (CBT) techniques including emotion monitoring, cognitive restructuring, mindfulness, and exposure to help individuals with anxiety.
223513265|NCT05130281|BEHAVIORAL|Social Support|Participants earn points and badges for completing sessions, homework, and skills on time and receive post session feedback via text message. Participants can identify a person they know to receive updates about their progress and support them throughout their time in the program. Participants will not be required to choose a person they know to receive updates about their use of the program; instead, they can choose to have a member of the study team serve as their social support if they are assigned to this condition.
223513266|NCT05130281|BEHAVIORAL|Gain Framed|Participants earn points and badges for completing sessions, homework, and skills on time and receive post session feedback via text message.
223513267|NCT05130281|BEHAVIORAL|Loss Framed|Participants lost points and badges for not completing sessions, homework, and skills on time and receive post session feedback via text message.
223513268|NCT06249672|OTHER|Local excision|Organ preservation after RCT (radiochemotherapy) of rectal cancer
223513269|NCT04481659|PROCEDURE|Lap partial ISR|A direct laparoscopic surgery with completely abdominal approach laparoscopic partial intersphincteric resection
223621095|NCT01381016|DRUG|Progesterone|Subjects who failed to initiate a menstrual period following 40 days on the patch were instructed to take 200 mg daily of progesterone for 10 days or as long as deemed necessary.
223761745|NCT02376192|DEVICE|Comparative MicroScan® (Microvision Medical) SDF Measurement|A second comparative SDF measurement be recorded within 10 minutes after induction of spinal anesthesia.
224210825|NCT02156349|DEVICE|Accu-Chek Smart Pix readout Device|Smartpix device for data upload out of blood glucose meter devices
224210826|NCT05424107|OTHER|KIDMED|Pre-and post-intervention evaluation of the adherence to the Mediterranean diet and its effect on prediabetic state, as well as, other anthropometric values.
224210827|NCT04780659|BIOLOGICAL|Comirnaty (COVID-19, mRNA vaccine)|Comirnaty will be administered two times, one at Day 0 and the second dose at Day 21.
224210828|NCT03530033|DRUG|Lidocaine|Local injection of lidocaine reduces muscle tremor
224210829|NCT06542328|DEVICE|ERI CVX-air portable X-ray system|investigational device
223621096|NCT06295159|DRUG|Nivolumab|Nivolumab is a fully human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1 (PD-1, PCD-1) with immune checkpoint inhibitory and antineoplastic activities. Upon administration, nivolumab binds to and blocks the activation of PD-1, an immunoglobulin superfamily (IgSF) transmembrane protein, by its ligands programmed cell death ligand 1 (PD-L1), which is overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on antigen-presenting cells (APCs). This results in the activation of T cells and cell-mediated immune responses against tumor cells. Activated PD-1 negatively regulates T-cell activation and plays a key role in tumor evasion from host immunity.
223621097|NCT06295159|DRUG|Nivolumab + Relatlimab|Opdualag (Nivolumab and Relatlimab-rmbw) is a combination formulation composed of nivolumab, a human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1 (PD-1, PCD-1), and relatlimab-rmbw, a human IgG4 monoclonal antibody directed against the inhibitor receptor lymphocyte activation gene-3 (LAG-3). Nivolumab binds to and blocks the activation of PD-1 by its ligands programmed cell death ligand 1 (PD-L1), which is overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on antigen-presenting cells (APCs). This prevents PD-1-mediated signaling and PD-1-mediated inhibition of the immune response. Relatlimab binds to LAG-3 on tumor infiltrating lymphocytes (TILs) and prevents LAG-3 binding to major histocompatibility complex (MHC) class II. This prevents LAG-3-mediated signaling and LAG-3-mediated inhibition of the immune response.
224210830|NCT06542328|DEVICE|Samsung GM85 (K180543) or MobileDaRt Evolution (K080701)|The commercially available comparator equipment used for pulmonology.
224210831|NCT06542328|DEVICE|Samsung GC85A (K160997) or Fujifilm FDR Smart X (K212956)|The commercially available comparator equipment used for Orthopaedic.
224210832|NCT00253461|PROCEDURE|computed tomography|Within 4 weeks after initial imaging, patients also undergo a CT scan.
224210833|NCT00253461|PROCEDURE|positron emission tomography|"Phase I: IV over 10 minutes followed immediately by a 1-2 hour positron emission tomography (PET) scan.~Phase II: fludeoxyglucose F 18 IV and, 1 hour later, undergo a PET scan."
224210834|NCT00253461|RADIATION|11C topotecan|Phase I and II: IV over 10 minutes
224210835|NCT00253461|RADIATION|fludeoxyglucose F 18|Phase II: fludeoxyglucose F 18 IV
224210836|NCT05842577|DEVICE|VRRS Tablet (Khymeia s.r.l., Noventa Padovana, Italy)|The motor exercises were performed using inertial sensors for the acquisition and processing of the movement performed by the patient. The patient was trained to perform these exercises using visual and auditory feedback in a serious game environment. The exercises were aimed at the rehabilitation of balance and at the improvement of motor performance in lower limbs (e.g., maintaining balance on one leg, marching in place, standing on tiptoe, squatting, etc.). The therapists involved in the study customized the protocol of exercises in TR mode according to the characteristics and needs of the subject.
224210837|NCT05842577|OTHER|At-home conventional rehabilitation|The CG rehabilitation was an active comparator treatment and consisted of a written home-based self-administered booklet with conventional motor activities tailored for each subject. The motor activities were chosen and adapted from a specialized manual. The motor exercises were aimed at the rehabilitation of balance and at the improvement of motor performance in lower limbs (e.g., maintaining balance on one leg, marching in place, standing on tiptoe, squatting, etc).
224210838|NCT01669044|DRUG|dexmedetomidine|dexmedetomidine: IV (in the vein)at 1μg/kg in 10 minutes as a loading dose, followed by a continuous infusion at 0.3μg/kg/h.then adjust the infusion dose to maintain the ramsay scale at 3-4 scores.
224210839|NCT01669044|DRUG|propofol|propofol: IV (in the vein)at 0.5mg/kg as a loading dose, followed by a continuous infusion at 0.5mg/kg/h.then adjust the infusion dose to maintain the ramsay scale at 3-4 scores.
224210840|NCT04262869|DRUG|Carboplatin|Given IV
223621098|NCT06295159|DRUG|Ipilimumab|Ipilimumab is a type of monoclonal antibody and a type of immune checkpoint inhibitor that may block CTLA-4 and help the immune system kill cancer cells. Ipilimumab binds to the protein CTLA-4 to help immune cells kill cancer cells better and is used to treat many different types of cancer. These include cancers that have certain mutations (changes) in genes involved in DNA repair.
223761746|NCT02376192|DRUG|Bolus Phenylephrine/Ephedrine Treatment|Participants who experience hypotension following induction of spinal anesthesia will be treated with a bolus of phenylephrine and/or ephedrine as needed.
223761747|NCT02376192|DRUG|Phenylephrine Infusion|Participants will have an infusion of phenylephrine started immediately following the induction of spinal anesthesia for prevention of hypotension.
224210841|NCT04262869|BIOLOGICAL|Durvalumab|Given IV
224210842|NCT04262869|DRUG|Paclitaxel|Given IV
224210843|NCT04262869|DRUG|Pemetrexed|Given IV
224210844|NCT00123331|DRUG|Cyclosporine discontinuation|
224210845|NCT00123331|DRUG|Rapamycin medication|
224210846|NCT00325429|DRUG|Vildagliptin|
224210847|NCT01098734|DRUG|WBI-1001|A 12-week study to assess the efficacy, safety and tolerability of topically applied WBI-1001 creams. First 6 weeks will be double-blinded, placebo-controlled and the following 6 weeks will be double-blinded, non-placebo- controlled. After 6 weeks patients in Groups 2 and 3 will continue double-blinded treatment for a further 6 weeks, but patients in Group 1 will enter a 6-week double-blinded phase with one of the two active creams (half treated with 0.5% and half with 1.0% WBI-1001 cream). All patients treated twice daily (BID).
224210848|NCT00619086|DRUG|Dexamethason Helvepharm ®|8 mg Dexamethason i.v. 45 minutes prior to surgery
224210849|NCT00619086|DRUG|Placebo|100 ml sodium chloride i.v. 45 minutes prior to surgery
223621099|NCT04428398|DIAGNOSTIC_TEST|Analysis of urine samples with flow cytometry|"Urine samples will be conserved and frozen upon arrival. All samples will be stained according to T cell and TEC (tubular epithelial cells) panel with fluorochromes.~T cell panel: CD3, CD4, CD8, CCR7, CD45RO, CD28, CD279; TEC panel: vimentin, cytokeratine, CD10, CD13, CD227, CD326"
223621100|NCT05883969|BEHAVIORAL|GO-PLAY|The intervention is family-centered, individualized, goal-directed, intensive, and carried out within the home environment. The GO-PLAY intervention will last for six months and consists of a home visit once a month and a virtual meeting by telephone or video once a month. The intervention will be family centered. Experienced physiotherapists and occupational therapists will be the primary therapists providing the intervention to ensure uniformity. The motor learning element of the intervention is based on the principles of motor learning and dynamic systems theory. Emphasis is on children's self-initiated actions, which are stimulated by meaningful and motivating activities and toys. The child's play preferences to elicit self-generated motor activity will be the underlying basis of the training. Minimal manual guidance is provided when needed and withdrawn when the child demonstrates self-generated ability to complete part of the task.
224210850|NCT02866019|DEVICE|CLS2702C/CLS2702D|CLS2702C (cell sheet) will be transplanted to the wound site using CLS2702D (transplantation device) (screening period, 1 month \[4 weeks\]; cell sheet culture period, 0.5 month \[16 days\]; transplantation period, assessment/follow-up period, 6 months \[24 weeks\])
224210851|NCT01512784|BIOLOGICAL|Quadrivalent Human Papillomavirus (6, 11, 16 and 18) vaccine (Gardasil ®)|"Human Papillomavirus vaccine (types 6, 11, 16 and 18) (Recombinant, adsorbed).~Each dose of Gardasil suspension for injection contains 0,5 ml. The shot is usually given in the arm muscle, 3 shots are given on the following schedule:~First dose: at chosen date. Second dose: 2 months after dose 1. Third dose: 6 months after dose 1.~Ingredients: highly purified non-infectious protein for each of the Human Papillomavirus types (6, 11, 16 and 18). Each dose (0,5ml) contains approximately:~Human Papillomavirus type 6 L1 protein 20 micrograms. Human Papillomavirus type 11 L1 protein 40 micrograms. Human Papillomavirus type 16 L1 protein 40 micrograms. Human Papillomavirus type 18 L1 protein 20 micrograms."
224210852|NCT01512784|BIOLOGICAL|Quadrivalent Human Papillomavirus (6, 11, 16 and 18) vaccine (Gardasil ®)|"Human Papillomavirus vaccine (types 6, 11, 16 and 18) (Recombinant, adsorbed).~Each dose of Gardasil suspension for injection contains 0,5 ml. The shot is usually given in the arm muscle, 3 shots are given on the following schedule:~first dose: at chosen date. Second dose: 2 months after dose 1. Third dose: 6 months after dose 1.~Ingredients: highly purified non-infectious protein for each of the Human Papillomavirus types (6, 11, 16 and 18). Each dose (0,5ml) contains approximately:~Human Papillomavirus type 6 L1 protein 20 micrograms. Human Papillomavirus type 11 L1 protein 40 micrograms. Human Papillomavirus type 16 L1 protein 40 micrograms. Human Papillomavirus type 18 L1 protein 20 micrograms."
224210853|NCT05131490|BEHAVIORAL|A mobile application intervention developed for gynecological cancer patients receiving chemotherapy|"The mobile application will consist of modules. It is planned to include four education modules and consultancy modules in the application.~1. Module 1: It will consist of sub-categories with information to be prepared in line with the current literature on gynecological cancer types and treatments applied. There will be information and short videos that will strengthen coping with physical symptoms, especially from chemotherapy.~2. Module 2: In this area, there will be meditation and relaxation/breathing exercises, information on relaxing complementary therapies, anxiety reduction and stress management techniques videos and audio recordings.~3. Module 3: Current developments on gynecological cancers will be included.~4. Module 4: Encouraging recovery stories and videos of cancer survivors will be included.~5. Module 5: Counseling module. This is the area where patients who cannot find answers in the frequently asked questions section can ask questions to the research team."
224210854|NCT01450579|BIOLOGICAL|ASP7373|Intermuscular administration
224210855|NCT01450579|BIOLOGICAL|Placebo|Intramuscular administration
224210856|NCT00002484|RADIATION|radiation therapy|
224210857|NCT02530632|DRUG|Propofol|General anesthesia maintained with intravenous propofol infusion
224210858|NCT02530632|DRUG|Sevoflurane|General anesthesia maintained with inhalational sevoflurane
224210859|NCT02530632|PROCEDURE|General anesthesia induction|Induce routine of general anesthesia, including propofol 1-3mg/kg, fentanyl 1-3mcg/kg, cisatracurium 0.2-0.3mg/kg.
224210860|NCT02855632|DRUG|G-CSF|7 days after first hysteroscopic adhesiolysis, G-CSF will be injected into the uterine cavity after balloon removing.
224210861|NCT02855632|DRUG|Normal saline|7 days after first hysteroscopic adhesiolysis, normal saline will be injected into the uterine cavity after balloon removing.
224316140|NCT06361121|PROCEDURE|mid-point transverse process to pleura (MTP) block|"the T1-T12 thoracic spinal levels will be sonographically identified using a high frequency linear US probe (HFL\_50, 15\_6MHz). Then the probe will be placed vertically and nearly 3 cm lateral to the spinous process at the thoracic level T4/T5. The paraspinal muscles (erector spinae, trapezius, rhomboid), transverse processes , superior costo-transverse ligament (SCTL) and parietal pleura will be all identified under parasagittal scanning.~In MTP block group, A 22G, 50mm block needle (SONOTAP,Pajunk, -Geisingen,Germany) will be inserted in the cranial to caudal direction via an in-plane approach between the 2 transverse processes and advanced till it reaches the mid-point between the transverse process and pleura. After negative aspiration of blood or air, a total volume of 20 ml of bupivacaine 0.25% ( not exceeding a maximum dose of 2 mg/kg) will be injected superficial to the SCTL."
224316141|NCT06361121|PROCEDURE|Thoracic Paravertebral Block|In the TPV block group , the transverse process and the pleura will be identified and the needle will be inserted in the cranial to caudal direction till it pierces the SCTL and reaches the paravertebral space. After negative aspiration of blood or air a total volume of 20 ml of bupivacaine 0.25% will be injected displacing the pleura downwards
223621101|NCT05883969|BEHAVIORAL|Usual care|Children will receive referral for rehabilitation in the municipality as usual. Standard care consists of the additional follow up assessments in CP-EDIT as well as rehabilitation offered by their local hospital/community or other private initiatives when diagnosed with CP or high risk of CP. The approach, frequency, and location (at home or rehabilitation centers) is varied according to the center's protocol and not possible to standardize.
224316142|NCT04566289|DEVICE|PiCSO|Percutaneous coronary intervention
224316143|NCT01517958|OTHER|Respiratory Distress Group|Diagnostic lung ultrasound.
224316144|NCT01517958|OTHER|Control Group|Lung ultrasound
223621102|NCT04206319|DRUG|Radium-223|an alpha particle-emitting drug, dose consists of 55 kBq/kg (1.49 microcurie/kg); administered every 4 days
224210862|NCT02855632|DRUG|hormone therapy|In all cases hormone therapy was commenced shortly after the operation, consisting of oestradiol valerate at a dose of 6 mg per day for 21-28 days with the addition of medroxyprogesterone acetate at a dose of 6 mg per day for the last 7-10 days of the oestrogen therapy. Following the withdrawal bleed, the hormone therapy was repeated for another cycle.
224210863|NCT02855632|OTHER|Cook balloon|At the end of the procedure, the Cook balloon were placed in the uterine cavity of each patient.the device was removed after 7 days.
224210864|NCT05064488|DRUG|Evobrutinib|Participants will receive evobrutinib film-coated tablet, twice daily under fed conditions from Days 4 to 12 in Part 1 and from Days 2 to 8 in Part 2 of the study.
224210865|NCT05064488|DRUG|Digoxin|Participants will receive digoxin tablet under fed conditions, once a day on Day 1 and Day 10 in Part 1.
224210866|NCT05064488|DRUG|Metformin|Participants will receive metformin oral solution under fed conditions, once a day on Day 1 and Day 10 in Part 1.
224210867|NCT05064488|DRUG|Rosuvastatin|Participants will receive rosuvastatin tablet under fed conditions, once a day on Day 1 and Day 10 in Part 1.
224210868|NCT05064488|DRUG|Sumatriptan|Participants will receive sumatriptan tablet under fed conditions, once a day on Day 1 and Day 8 in Part 2.
224210869|NCT02766088|PROCEDURE|Blood sample collection|All participants will have an enrolment visit with collection of a blood sample and a termination contact/visit. Participants or their parents/guardians will be contacted weekly or every two weeks to monitor the occurrence of febrile episodes. Additional visits will be made if febrile episodes occur. In case of dengue suspicion, a blood sample will be collected.
224210870|NCT01222715|BIOLOGICAL|Bevacizumab|Given IV
224210871|NCT01222715|DRUG|Cyclophosphamide|Given IV
224316145|NCT04322058|OTHER|The Dads' Club|The core intervention is Core 24/7 workshop attendance
223513270|NCT04481659|COMBINATION_PRODUCT|NCRT+Lap partial ISR|Preoperative radiation and chemotherapy + laparoscopic completely abdominal approach laparoscopic partial intersphincteric resection
223513271|NCT06497088|DEVICE|Nasotrak System|"Device: The Nasotrak System~The Nasotrak Medical System is intended to aid, in conjunction with institutional protocols, qualified operators in the placement of the Nasotrak's 12 Fr feeding tube into the stomach of patients requiring enteral feeding after insertion and before every feed. The Nasotrak nasogastric tube(NGT) is designed for use with Nasotrak's handheld device (HHD) which is able to detect the tip of the NGT via piezoelectric sensor, which converts ultrasound waves to electronic signals, thus assisting to track its location as an indicator of placement in the stomach. Nasotrak's NGT is intended only to be used with Nasotrak's HHD.~The Nasotrak NGT is intended for the administration of nutrition, fluids and medications by the nasoenteric route for patients who have an intact gastrointestinal tract but are physically unable to manage nutritional intake through normal mastication and deglutition."
223513272|NCT06268717|OTHER|Ground pork containing alpha-gal|150 grams of cooked, ground pork meat containing alpha-gal sugar eaten once
224210872|NCT01222715|OTHER|Laboratory Biomarker Analysis|Correlative studies
224210873|NCT01222715|DRUG|Temsirolimus|Given IV
224210874|NCT01222715|DRUG|Vinorelbine Tartrate|Given IV
224210875|NCT02360397|DRUG|ranolazine|Ranolazine 1000 mg tablet twice daily for 30 days
224210876|NCT05415982|OTHER|Ketogenic Diet|The intervention is a ketogenic diet based on high-fat ketogenic meals prepared by the study participants, complemented with ketogenic food products from Natural Ketosis and Vitaflo. Exogenous ketones are provided by Audacious Nutrition. The macronutrient composition of the ketogenic diet given approx.: Fat 87 E%, Carbohydrate 3 E%, Protein 10 E%,
224210877|NCT05344066|OTHER|Best NHS Care|Personalised advice and support from a diabetes dietician to follow NICE healthy eating diet and physical activity recommendations for GDM.
224210878|NCT05344066|OTHER|Intermittent Low Energy Diet|Two non-consecutive days of a food based 1000 kcal diet and five days of the NICE healthy eating diet and physical activity recommendations for the best NHS care group.
224210879|NCT01499927|OTHER|electronic reminders|Behavioral: Early switching from intravenous to oral antiinfective agents due to electronic reminders
224210880|NCT06141382|OTHER|English Langugae-Sensory based narrative intervention|Sensory based narrative intervention (auditory, visual and tactile stimulations) in English language will be administered on children with autism spectrum disorder (ASD). Intervention will be administered thrice a week in 45-minute-long session for 6 weeks.
224210881|NCT06141382|OTHER|English Language-Narrative intervention|Narrative intervention with the help of only pictures in English language will be administered on children with autism spectrum disorder (ASD). Intervention will be administred thrice a week in 45-minute long session for 6 weeks.
224210882|NCT06141382|OTHER|Urdu Langusge-Sensory based narrative intervention|Sensory based narrative intervention (auditory, visual and tactile stimulations) in Urdu language will be administered on children with autism spectrum disorder (ASD). Intervention will be administered thrice a week in 45-minute-long session for 6 weeks.
223513273|NCT06268717|OTHER|Pork meat not containing alpha-gal|150 grams of cooked, ground pork meat not containing alpha-gal sugar
223513274|NCT06844812|OTHER|This is not an interventional study. Patients who are planned to start methylphenidate treatment have been invited to participate in the study.|This is not an interventional study. Patients diagnosed with Attention Deficit Hyperactivity Disorder (ADHD), for whom methylphenidate treatment is planned, have been invited to participate in the study. The patients have been enrolled in follow-up, and our contact information has been provided to them. As part of routine care, patients have been called in once a month. Necessary dosage adjustments have been made in accordance with medical guidelines, without any intervention for the study. Patients with complaints or those who needed to be seen earlier have been seen in between. As a result, the patients were followed for a total of 3 months for this study. Serum samples for oxidative stress markers were collected at baseline (before treatment started) and at the 3rd month (after treatment began).
223513275|NCT05018507|OTHER|Data collection only|No intervention, just data collection from system machines
223513276|NCT01446588|BEHAVIORAL|Yoga Intervention|Three yoga classes per week for 8 weeks.
224210883|NCT06141382|OTHER|Urdu Language-Narrative intervention|Narrative intervention with the help of only pictures in Urdu language will be administered on children with autism spectrum disorder (ASD). Intervention will be administered thrice a week in 45-minute long session for 6 weeks.
223621103|NCT04206319|DRUG|18F Sodium Fluoride|18F-NaF (Sodium Fluoride) is a radio-pharmaceutical used to image skeletal pathology with positron emission tomography (PET) imaging
223621104|NCT06373159|OTHER|No study intervention|Retrospective observational study using Real World Data (RWD) in Japan without study intervention
223621105|NCT05005403|DRUG|Azirkitug|Intravenous (IV) Infusion
223621106|NCT05005403|DRUG|Budigalimab|Intravenous (IV) Infusion
223621107|NCT05005403|DRUG|Bevacizumab|Intravenous (IV) Infusion
223621108|NCT04897217|DRUG|Megestrol Acetate|The control arm will consist of oral progesterone therapy (megestrol acetate 160mg po daily). The intervention will be administered on an outpatient basis.
223621109|NCT04897217|DRUG|Levonorgestrel Drug Implant|Participants in the comparison arm will have a levonorgestrel intrauterine device placed in the office or in the operating room if the office procedure not tolerated or if they have not had a prior dilation and curettage.
223621110|NCT01631435|OTHER|Pillcam colon capsule and PillCam™ Prep Procedure|PillCam® Crhon capsule preparation will include a clear liquid diet and administration of a purgative sulfate-free polyethylene glycol electrolyte lavage (SF-ELS) solution (e.g. Nulytely) divided into two doses: the first dose on the evening before the exam and the 2nd dose on the morning of the exam day.
223621111|NCT01631435|DEVICE|Ileocolonoscopy|"Conventional ileocolonoscopy Examination (same day or within 24 hours)of CE procedure~• Ileocolonoscopy with intubation of terminal ileum"
223621112|NCT02542046|DRUG|Barium|Administration of barium oral contrast agent prior to CT scan
223621113|NCT02542046|DRUG|Diatrizoate|Administration of diatrizoate oral contrast agent prior to CT scan
223621114|NCT02542046|DRUG|Iohexol|Administration of iohexol oral contrast agent prior to CT scan
223621115|NCT01179321|OTHER|Early referral to Dietitian for assessment and nutrition support|
223621116|NCT03443141|DRUG|Vitamin E|The applied dressing will be embebbed in Vitamin E
223621117|NCT03443141|DRUG|Standard dressing|The applied dressing is a normal one without adding any product to it.
223621118|NCT03867214|DRUG|Glutamine|1 g of tranexamic acid in 100 mL of normal saline intravenously approximately 15 minutes before incision
223621119|NCT03867214|DRUG|Normal saline|100 mL of normal saline intravenously approximately 15 minutes before incision
223621120|NCT01005251|DRUG|lesogaberan (AZD3355)|60 mg, oral, capsules, bid for 4 w
223621121|NCT01005251|DRUG|lesogaberan (AZD3355)|120 mg, oral, capsules, bid for 4 w
223621122|NCT01005251|DRUG|lesogaberan (AZD3355)|180 mg, oral, capsules, bid for 4 w
223621123|NCT01005251|DRUG|lesogaberan (AZD3355)|240 mg, oral, capsules, bid for 4 w
223621124|NCT01005251|DRUG|Placebo|oral,capsules, bid for 4 w
223761748|NCT03606525|PROCEDURE|subarachnoid block|Vertebral column length and abdominal girth will be measured before routine subarachnoid block is given to recruited patients
224210884|NCT06141382|OTHER|Bilingual-Sensory based narrative intervention|Sensory based narrative intervention (auditory, visual and tactile stimulations) in both English and Urdu language will be administered on children with autism spectrum disorder (ASD). Intervention will be administered thrice a week in 45-minute-long session for 6 weeks.
224210885|NCT06141382|OTHER|Bilingual-Narrative intervention|Narrative intervention with the help of only pictures in both English and Urdu language will be administered on children with autism spectrum disorder (ASD). Intervention will be administered thrice a week in 45-minute long session for 6 weeks.
223621125|NCT03777358|DEVICE|3D-TVS|The 3D-TVS will be done by an experienced gynecological sonographer. The uterine cavity will be assessed by obtaining a mid-coronal view. Then hysteroscopy will be performed
223621126|NCT03675503|OTHER|Fall Prevention Decision Support|Decision support used by nurses to appropriately provide ambulatory aids to hospitalized patients in order to reduce hospital falls
223621127|NCT02837900|DRUG|TPX-100 200 mg 4 times weekly for 4 weeks|Ea. subject will received active TPX-100 200mg in the Left knee
223621128|NCT02837900|DRUG|TPX-100 200 mg 4 times weekly for 4 weeks|TPX-100 100mg Right
223621129|NCT01898455|DEVICE|RhinoChill intranasal cooling|The RhinoChill device will be used to locally cool the posterior nasopharynx, surrounding tissues and vasculature using a variable cooling flow rate based on patient comfort and tolerance, for a maximum of 20 minutes. Local anaesthetic spray will be administered to patients if the nasal catheters or cooling is poorly tolerated.
223621130|NCT06558552|OTHER|transcutaneous pulsed radiofrequency|Instead of invasive application of PRF directly to the lesion area or nerve, transcutaneous pulsed radiofrequency (TCPRF) is applied noninvasively.
223621131|NCT06558552|OTHER|extracorporeal shock wave therapy (ESWT)'|A shock wave is created together with sound and pressure waves. Changes at the cellular level with the shock wave include increased collagen production, increased blood flow in the applied area, acceleration of wound healing and cellular proliferation.
223621132|NCT03416855|DRUG|Insulin degludec /insulin aspart|Commercially available Insulin degludec /insulin aspart (Ryzodeg® FlexTouch®) according to routine clinical practice at the discretion of the treating physician.
223621133|NCT02690181|BIOLOGICAL|GBS Trivalent Vaccine|Administration of lyophilized formulation of a GBS trivalent vaccine containing 5 µg of each polysaccharide capsules from serotypes Ia, Ib, and III of Group B Streptococcus conjugated to CRM-197 .
223621134|NCT03976479|OTHER|Body composition, questionnaires, biochemistry and blood pressure results|Body composition status, nutritional status, cardiovasculat status, health status, lifestyle factors
223621135|NCT02326038|DRUG|Methylphenidate|single oral administration of 20 mg tablet
223621136|NCT01776658|DRUG|SYL1001|Ocular topical administration of SYL1001 for 10 consecutive days
223621137|NCT01776658|DRUG|Placebo|Ocular topical administration of placebo for 10 consecutive days
223621138|NCT01909440|BEHAVIORAL|exercise intervention|Receive whole body RT
223621139|NCT01909440|DIETARY_SUPPLEMENT|nutritional supplementation|Given whey protein supplementation PO
223621140|NCT01909440|PROCEDURE|quality-of-life assessment|Ancillary studies
224210886|NCT04692220|OTHER|Detection of Adverse Drug Events or Drug-Related Problems|Detection of Adverse Drug Events or Drug-Related Problems
224210887|NCT04229316|DEVICE|zLOCK Facet Stabilization System|zLOCK Facet Stabilization System is a device intended to provide posterior stability in lumbar spine in order to reduce lumbar back pains
224210888|NCT05415319|BEHAVIORAL|Laboratory tasks in middle childhood/pre-adolescence|Children will watch a 2-minute clip from a live-action movie and complete Storytelling and Mask tasks from the Laboratory Temperament Assessment Battery.
224210889|NCT03250910|DRUG|Sofosbuvir and Velpatasvir|All patients received a generic version of VEL/SOF fixed-dose combination (Sofosvel®, VEL/SOF 100/400 mg film coated tablet, Beacon Pharmaceuticals Ltd. Mymensingh, Bangladesh) 1 tablet per day for 12 weeks.
224210890|NCT03250910|DRUG|Ribavirin|Patients with decompensated cirrhosis (Child-Pugh B or C), received weight-based ribavirin (RBV)(Robatrol®, 200 mg capsule, Genovate Biotechnology Co. Ltd., Hsinchu, Taiwan; 1,200 mg per day if the body weight ≥ 75 kg; 1,000 mg per day if the body weight \< 75 mg) for 12 weeks.
224210891|NCT01676584|DRUG|RO6811135|single ascending doses sc
224210892|NCT01676584|DRUG|placebo|single doses sc
224210893|NCT01824459|DRUG|S-1|S-1：40\~60mg bid，d1\~14 q3W
224210894|NCT01824459|DRUG|Oxaliplatin|oxaliplatin：130mg/m2，iv drip for 2h，d1,q3W
224210895|NCT01824459|DRUG|Cisplatin|cisplatin：60mg/m2，iv drip ，d1,q3W
224210896|NCT00130000|DRUG|Eculizumab|
224210897|NCT01537549|DRUG|alpha-lipoic acid and L-acetyl carnitine|alpha-lipoic acid and L-acetyl carnitine capsules, 600mg/1.5g daily for 6 months
224210898|NCT05806333|DIAGNOSTIC_TEST|FAPI PET|Drug: 18F-FAPI 18F-FAPI were injected into the patients before the PET/CT scans
224210899|NCT00192751|BEHAVIORAL|Psychoeducational group sessions|
224210900|NCT01331083|DRUG|PX-866|PX-866: 8mg orally taken daily
223621141|NCT01909440|OTHER|questionnaire administration|Ancillary studies
223621142|NCT01909440|OTHER|pharmacological study|Correlative studies
224210901|NCT04396483|PROCEDURE|Pomeroy's tubal sterilization|Both Fallopian tubes will be grasped by allis forceps and a kokher forceps will be applied below the allis forceps then excision of tubal part above kokher and transfixation of both ends away from each other during cesarean section
224210902|NCT04396483|PROCEDURE|Salpingectomy|Both fallopian tubes will be completely removed during cesarean section
223621143|NCT01909440|OTHER|laboratory biomarker analysis|Correlative studies
223761749|NCT01481116|DRUG|TAK-875|TAK-875 25 mg, tablets, orally, once daily and metformin ≥1500 mg or Maximum Tolerated Dose (MTD) for up to 104 weeks.
223761750|NCT01481116|DRUG|TAK-875|TAK-875 50 mg, tablets, orally, once daily and metformin ≥1500 mg or MTD for up to 104 weeks.
224210903|NCT06092645|DRUG|surufatinib plus cadonilimab|Surufatinib: 250mg , po,qd, d1-d21, every 3 weeks for a treatment cycle. Cadonilimab: 10mg/kg, iv, d1, every 3 weeks for a treatment cycle
223621144|NCT02291146|BEHAVIORAL|LA Sprouts intervention|see arm 1 description
223621145|NCT02870777|COMBINATION_PRODUCT|MRD-directed therapy|The purpose of this study is to establish risk stratification based on cytogenetics at diagnosis and MRD analysis after induction chemotherapy and before consolidation chemotherapy to determine whether a MRD directed therapy for low and intermediate AML patients has positive results in terms of overall survival.
223761751|NCT01481116|DRUG|Glimepiride|Glimepiride 1 mg, tablets, orally, once daily (up-titrated to 2 mg after 1 week of treatment. Up-titrated to a maximum of 6 mg in 2 mg increments/down titrated if recurrent (or severe) hypoglycemia occurs) and metformin ≥1500 mg or MTD for up to 104 weeks.
224210904|NCT01063725|DIETARY_SUPPLEMENT|Femarelle|A soy based food supplement containing 322 mg of soy extract and 108 mg of flaxseed, to be taken twice daily
224210905|NCT01063725|OTHER|Placebo|Capsules containing 430 mg of microcrystalline cellulose, as a placebo, to be taken twice daily
224210906|NCT01208922|DRUG|Rifamycin SV-MMX®|2 Rifamycin SV-MMX® 200 mg tablets and 1 placebo to ciprofloxacin capsule, b.i.d.
224210907|NCT01208922|DRUG|Ciprofloxacin|1 ciprofloxacin 500 mg capsule and 2 placebos to Rifamycin SV-MMX® 200 mg tablets, b.i.d.
224210908|NCT01400672|BIOLOGICAL|Tumor Lysate Vaccine|Vaccination is injected intradermally every 2 weeks for 4 doses, then every 4 weeks for up to 1 year. Patients will receive 1 mg protein divided into 2 doses at two separate subinguinal sites.
224210909|NCT01400672|DRUG|Imiquimod|Marketed as 5% Aldara cream topically applied; total of 12.5 mg divided between the two vaccination sites and reapplied at the vaccination sites 24 hours later.
224210910|NCT01400672|RADIATION|Radiation therapy|"Initial course of radiation therapy is given over 6-7 weeks, 5580 cGy. At the time of the 3rd vaccination, an additional 180 cGy fractions will be delivered in single doses in a novel effort to induce NKG2D ligand upregulation (thereby sensitizing residual tumor to lymphocyte attack). The total radiation dose for each patient will be 5760 cGy."
224210911|NCT06058468|PROCEDURE|Cardioneuroablation of right anterior ganglionated plexus|Right anterior ganglionated plexus will be localized using anatomical approach. Radiofrequency energy will be delivered until heart rate acceleration \>30% is achieved or if radiofrequency time exceeds 120 seconds.
224210912|NCT06058468|PROCEDURE|Pulmonary vein isolation|Application sites near the ostia of pulmonary veins will be determined. Radiofrequency energy will be delivered using point-by-point technique. After applications, the acute PVI endpoint will be confirmed by the elimination of PV potentials and lack of capture during pacing from the ablation lines.
224210913|NCT02880163|DEVICE|ResQFoam|Hemostatic device for the treatment of emergent, exsanguinating, Class III or IV intraabdominal hemorrhagic shock in subjects due to trauma
224210914|NCT01498419|DRUG|Moxifloxacin (M)|
224210915|NCT01498419|DRUG|Pretomid (Pa)|
223621146|NCT04441359|OTHER|Supplemented formula|standard infant formula supplemented with 8 g/L prebiotic inulin-type fructans
223621147|NCT04441359|OTHER|Standard formula|standard infant formula not supplemented with prebiotic inulin-type fructans
223621148|NCT01905098|OTHER|Sauna Detoxification Protocol|"All study participants will actively undergo sauna intervention sessions.~The sauna will be pre-warmed to 160 degrees Fahrenheit and humidity set to 25% +/- 5%. Participants will have a scheduled 10-min break every 30 minutes of sauna, during which time vital signs, symptoms, and fluid intake will be assessed and recorded.~On a weekly basis, lab assessments will be performed to compare participants' baseline lab values with those during the sauna intervention, and to monitor for safety. In addition, weekly serum samples will be taken for PCB assessment."
224210916|NCT01498419|DRUG|Pyrazinamide (Z)|
224210917|NCT01498419|DRUG|Rifafour|Rifafour e-275 once daily for 8 weeks. Daily dose dependent on weight as follows: 30-37kg: 2 tablets, 38-54 kg: 3 tablets, 55-70 kg: 4 tablets: 71 kg and over: 5 tablets
224210918|NCT04078919|DIETARY_SUPPLEMENT|Nut consumption|daily consumption of 20 percent of daily calories intake from nuts (pistachio, almond and peanuts)
224210919|NCT04078919|OTHER|Low calorie diet|Low calorie diet
224210920|NCT05397600|DRUG|Bimatoprost Ophthalmic|Eyedrops
224210921|NCT03183271|RADIATION|external beam proton radiation therapy.|Treatment of irradiation with protons beam The patients will be enrolled either at the Centro Nazionale di Adroterapia Oncologica (CNAO), Pavia, Italy, or at referral Hospitals enrolling head and neck patients for treatment with photon IMRT.
224210922|NCT00439751|DRUG|Goserelin Acetate|Continuous goserelin, 12 week (10.8 mg) depot, will be used as ADT for both study arms. It is supplied as a sterile syringe for subcutaneous use.
224210923|NCT04519203|DEVICE|SPI|Either standard monitoring alone or added with SPI
224210924|NCT04519203|DEVICE|Standard|Standard monitoring alone
224210925|NCT05526274|DIAGNOSTIC_TEST|Vibration-Controlled Transient Elastography (VCTE) with Controlled Attenuation Parameter (CAP)|VCTE with associated CAP is an effective, non-invasive and safe diagnostic method to estimate the degree of fibrosis and steatosis in the liver.
224210926|NCT05739227|OTHER|allogenic CD19-CAR-NK cells|The relapsed/refractory B-cell hematologic malignancies patients will receive allogenic CD19-Targeted CAR-NK cells infusion up to 3 dose levels (1x10\^6/kg, 5x10\^6/kg, 2x10\^7/kg) after FCE chemotherapy
224210927|NCT00955760|DRUG|Neramexane|Drug-Drug Interaction Study
224210928|NCT02239601|OTHER|Physical Therapy|Physical therapy assessment and treatment for any positive signs of nerve entrapment prior to chemotherapy including nerve gliding exercises, education and splinting. A home program was provided and continued throughout chemotherapy treatment
224210929|NCT06544473|DRUG|17-beta estradiol|Treatment with orally administered estrogen for 14 days
224210930|NCT06544473|DRUG|17-beta estradiol|Treatment with transdermally administered estrogen for 14 days
224210931|NCT00006225|BIOLOGICAL|filgrastim|
224210932|NCT00006225|BIOLOGICAL|recombinant flt3 ligand|
224210933|NCT00006225|BIOLOGICAL|recombinant human thrombopoietin|
224210934|NCT00006225|BIOLOGICAL|recombinant interleukin-3|
224210935|NCT00006225|PROCEDURE|in vitro-treated peripheral blood stem cell transplantation|
224210936|NCT06155825|BEHAVIORAL|no intervention|Group 4 will receive no intervention
224210937|NCT06155825|DRUG|nonnutritive suckling|Group 1 will receive nonnutritive suckling
224210938|NCT06155825|DRUG|oral glucose 25%|Group 2 will receive oral glucose 25%
224210939|NCT06155825|BEHAVIORAL|facilitated tuckling|Group 3 will undergo facilitated tuckling
224210940|NCT01508325|DRUG|Bisoprolol|Subjects will receive bisoprolol fumarate (Concor®) at a dose of 5 milligram (mg) once daily orally as sustained release (SR) tablets for a period of 4 weeks. The dose of bisoprolol will be escalated to 7.5 mg orally once daily for next 4 weeks (Weeks 4 to 8) and to 10 mg orally once daily for the next 4 weeks (Weeks 8 to 12), if clinic systolic blood pressure (SBP) was greater than or equal to (\>=) 140 millimeters of mercury (mmHg) and/or diastolic blood pressure (DBP) was \>=90 mmHg measured every 4 weeks.
224210941|NCT01508325|DRUG|Metoprolol|Subjects will receive metoprolol succinate (Betaloc SR) at a dose of 47.5 mg once daily orally as SR tablets for a period of 4 weeks. The dose of metoprolol will be escalated to 71.25 mg orally once daily for next 4 weeks (Weeks 4 to 8) and to 95 mg orally once daily for the next 4 weeks (Weeks 8 to 12) if clinic SBP was \>=140 mmHg and/or DBP was \>=90 mmHg measured every 4 weeks.
224210942|NCT04682639|DRUG|Etrasimod|Participants will receive etrasimod tablet by mouth, once daily during the 24-week Double-Blind and 28-week Extension Treatment Periods.
224210943|NCT04682639|DRUG|Placebo|Participants will receive etrasimod matching placebo tablet by mouth, once daily during the 24-week Double-Blind Treatment Period.
224210944|NCT04682639|DRUG|Etrasimod|Participants will receive etrasimod tablet by mouth, once daily during the 28-week Extension Treatment Period.
224210945|NCT01743768|DRUG|SB010|Treatment group (n=19), receiving the active drug substance.
223761752|NCT02808286|BEHAVIORAL|Hybrid|The hybrid emotion-focused treatment integrates procedures from exposure and dialectical behavior therapy (DBT) with a clear uniting conceptualization focused on targeting underlying processes that maintain co-occurring chronic pain and emotional problems.
224210946|NCT01743768|DRUG|Placebo|Treatment group (n=19), receiving placebo.
224210947|NCT00769158|DRUG|Topiramate and Naltrexone|Topiramate 200 mg and Naltrexone 50 mg
224210948|NCT00769158|OTHER|Placebo|Placebo Comparator
224210949|NCT00523887|DRUG|Fentanyl transdermal therapeutic system|
224210950|NCT01286207|DRUG|Rizatriptan 5 mg|Rizatriptan 5 mg orally once for treatment of index migraine attack, followed by two additional doses within 24 hours of the initial dose for migraine recurrence(s)
224210951|NCT01286207|DRUG|Rizatriptan 10 mg|Rizatriptan 10 mg orally once for treatment of index migraine attack, followed by two additional doses within 24 hours of the initial dose for migraine recurrence(s)
223513277|NCT04566510|OTHER|long lasting insecticidal nets with alpha-cypermethrin + pyriproxyfen (PPF LLIN, Royal Guard))|Next-generation bed net combining insecticides with different modes of action
224210952|NCT01286207|DRUG|Standard Care|Active standard care
224210953|NCT01383954|DRUG|Diclofenac Gel|Diclofenac gel 4 grams (g) applied topically 4 times daily (QID) to the affected knee(s) for up to 4 weeks. Participants took a maximum dosage of 32 g/day.
224210954|NCT05980351|OTHER|exercise|The children will receive exercise program(stretching exercise,range of motion exercise and isometric exercise)
224210955|NCT00450177|DRUG|Ferrous Sulfate|Iron group
224210956|NCT00450177|DRUG|Placebo Oral Tablet|Placebo group
224210957|NCT05974865|BEHAVIORAL|Healthy Babies and Healthy Moms|
224210958|NCT05974865|BEHAVIORAL|Baby Basics Prenatal Guide|
224210959|NCT01185730|PROCEDURE|Right Heart Catheterization|all patients of the all centers will have Right Heart Catheterization at the diagnosis
224210960|NCT01752322|DRUG|Lidocaine 5% medicated plaster|
224210961|NCT01752322|DRUG|Placebo plaster|
224210962|NCT00716586|DRUG|2% dorzolamide|Carbonic anhydrase inhibitor, Trusopt (2% dorzolamide)
224210963|NCT02613416|DRUG|Denosumab|monthly subcutaneous injections
224210964|NCT02287506|OTHER|Optimised Diagnostic Strategy|(ODS) based on integrating Clinical information (a validated clinical probability model), Biomarkers (GAD, IA2 and ZnT8 autoantibodies) and Genetic testing for MODY
224210965|NCT04182984|DRUG|Symptomatic Treatment, Steroids, Immunosuppressive Agents( azathioprine, tacrolimus, Mycophenolate Mofetil)|Treatment regimens are determined according to the physician's judgment and preferences of the patients.
223621149|NCT01905098|OTHER|Observation Sessions|All enrolled participants will undergo observation protocol consisting of one (1) hour visit weekly consistent with Sauna Visits lab assessment time points, to be completed in 3 weeks (4 total sessions within 21 days). At each Observation Visit a blood draw for CBC/D, CMP, and PCBs analysis will be performed, as well as query for symptoms and MOSES questionnaire will be assessed.
223621150|NCT06208553|OTHER|QI toolkit implementation|Patients and clinicians will have access to online toolkits of resources (e.g., video, checklist, rehabilitation tracker, quick guides) reflecting quality indicators for rehabilitation care after total hip and knee replacement surgery.
224210966|NCT01542684|DRUG|Azacytidine|Starting dose: 40 mg/m\^2 intravenously (IV) or subcutaneously (SQ) daily for 4 days.
224210967|NCT01542684|DRUG|GM-CSF|250 mcg/m\^2 IV or SQ one day (the next day) after completion of azacytidine treatment, for 3 consecutive days.
224210968|NCT05620459|PROCEDURE|Ridge augmentation using chin bone ring with simultaneous implant placement|surgical guides are to be used to harvest chin bone ring, the rings are to be used for bone augmentation in extraction sockets (salama and salama classsification type II),simultaneously implant placement.
224210969|NCT02706600|BEHAVIORAL|myCOPD|"myCOPD is a system that can be accessed by patients using any device that can connect to the internet and can operate in any internet browser. It contains: Educational information, Inhaler technique videos explaining the correct technique required to use different inhaler devices licensed for use in people with COPD.~Medication and symptom diaries. Appointment diary Bitesize pulmonary rehabilitation videos designed to promote and support exercises that can be done in a home setting.~Oxygen Alert Card - Users can create their own oxygen alert card online A 5 Day local weather and pollution reports - Feed for reports come from the met office and DEFRA.~A Self management plan, which consists of a traffic light system to direct patients to the most appropriate action to take should their symptoms deteriorate. The action plan is populated automatically with the information input by the patients."
224210970|NCT02706600|BEHAVIORAL|Written Self management plan|The HealthQuest written self management plan was produced in 2013. It is a one page document which contains a written self management plan which can be individualised for the patient. It consists of a traffic light system to direct patients to the most appropriate action to take should their symptoms deteriorate.
224210971|NCT04790409|DRUG|sintilimab and anlotinib|This study was a one-arm, open-label, phase II study of PD-1 monoclonal antibody combined with ilotinib in the treatment of advanced EGFR rare-mutant non-small cell lung cancer (NSCLC). 21 patients enrolled in the study who underwent platinum-containing systemic chemotherapy and EGFR-TKI failure were enrolled in the study.
224210972|NCT01173588|OTHER|yogurt added with bifidobacteria and soluble fiber (YBF)|Yogurt in YBF was added with 1.5 g inulin/100 g and ≥5 x 107 CFU of bifidobacterium/mL
224210973|NCT00303433|DRUG|Namenda|
224210974|NCT01329705|DEVICE|Ankle Dorsiflexion Dynasplint|"Dynamic splinting utilizes the protocols of Low-Load Prolonged Stretch (LLPS) with calibrated adjustable tension to increase Total End Range Time (TERT)to reduce contracture. The Dynasplint or Experimental group will add this therapy to their standard of care regimen"
224210975|NCT01329705|OTHER|Standard of care|"Patients will begin a 12 week course of physical therapy with once-weekly therapy appointment, focusing on:~* range of motion stretching of the Achilles tendon, hamstrings, hip flexors and any other tight musculature~* strengthening of tibialis anterior to allow dorsiflexion in swing phase of gait as well as strengthening of other weak musculature~* gait training to improve heel strike and toe off, stride length, and gait progression~* sensory, proprioceptive training in foot position and degree of plantarflexion or dorsiflexion~* no electric stimulation (e-stim) will be utilized"
224210976|NCT03086083|BEHAVIORAL|EMDR standard protocol|Patient have only one standard EMDR session about a traumatic situation remembered by him.
224210977|NCT03086083|BEHAVIORAL|protocol without brain stimulation|Patient have only one standard EMDR session about a traumatic situation remembered by him, however, without the bilateral brain stimulation.
224210978|NCT00763269|DRUG|Triclosan, Silicon dioxide, fluoride|Brush twice daily
224210979|NCT00763269|DRUG|Triclosan, fluoride|Brush twice daily
223621151|NCT01077635|DRUG|Exposure to licensed dose of FPV (+/- 20% of 18mg/kg BID + RTV)|HIV-1 infected children currently or having ever been exposed to FPV (+/- 20% of 18mg/kg BID + RTV)
223621152|NCT00003714|DRUG|Pyrazoloacridine|IV (by vein) over 3 hours every 3 weeks
223621153|NCT04426929|OTHER|Conventional exercise therapy|Coldpack, TENS, Ultrasound agents and conventional exercise therapy (codman, wand, isometric exercise) will be applied.
223621154|NCT04426929|OTHER|Closed Chain Exercise Group|An exercise program consisting of 3 phases that runs from simple to difficult and includes closed kinetic chain exercises and proprioceptive exercises will be implemented in this group.
223621155|NCT04426929|OTHER|Video Based Exercise Group|Closed chain exercises based on video games will be applied. These exercises also include proprioceptive exercises.
223761753|NCT02808286|BEHAVIORAL|internet Cognitive Behavior Therapy (iCBT)|A state-of-the-art CBT pain treatment, delivered via the internet.
224210980|NCT02279576|DRUG|Pazopanib|Pazopanib 800mg/day continuously administered.
224210981|NCT02279576|DRUG|Paclitaxel|Paclitaxel 65 mg/m2 in weekly administration 3 administrations (D1, D8 and D15) every 4 weeks period.
224210982|NCT02832076|PROCEDURE|Subcutaneous negative suction drain for 10 days|
224210983|NCT02832076|PROCEDURE|No subcutaneous drain|
224210984|NCT00133094|DRUG|Simvastin|
224210985|NCT00133094|PROCEDURE|Computer-based decision support technology|
224210986|NCT05932927|BIOLOGICAL|Proteomic sequencing|Proteomic sequencing, bioinformatics analysis，find abnormal indicators between two groups
223621156|NCT00937352|DRUG|Bapineuzumab|"0.5 mg/kg, administered via IV (in the vein) infusion every 13 weeks for 4 years.~1.0 mg/kg, administered via IV (in the vein) infusion every 13 weeks for 4 years."
224210987|NCT00732394|OTHER|MSDR|"The MSDR® questionnaire establishes an individual's musculoskeletal functional status using information gathered from 1) a questionnaire the patient fills out regarding medical history, chronic medical conditions, and health risk factors; 2) anatomic pain survey completed by the patient; and 3) evaluation by a trained researcher of various patient biometric parameters related to range of motion. Stratifying an individual into a risk category with this evidence-based assessment tool then permits an assessment of which patients respond long term to therapy.~MSDR® demonstrates the ability to benchmark specific musculoskeletal findings (both clinical and sub-clinical) to ICD-9 Diagnoses supported by diagnostic, radiographic and/or MRI findings where clinically indicated."
224210988|NCT01971229|OTHER|Carbohydrate based drink|After consumption of the test drink to record the insulin response and gastric emptying.
224210989|NCT01971229|OTHER|Whey protein based drink|After consumption of the test drink to record the insulin response and gastric emptying.
224210990|NCT06700629|PROCEDURE|Distal Penile Hypospadias (Disorder)|"Three operations which are Tubularized incised plate urethroplasty (TIP), Mathieu and meatal advancement and glanuplasty (MAGPI).~A three experienced operators with number of operations done by each one more than one hundred operation in the last year.~The operators will be fixed for each surgical technique as follows:~1. Doctor (A) for Matheiu. ( 35 operations)~2. Doctor (M) for MAGPI. ( 35 operations)~3. Doctor (S) for TIP ( 35 operations). Tubularized incised plate urethroplasty:(3,6) Indication: for distal penile hypospadias with or without penile curvature with any width of the uretheral plate and also for any type of distal hypospadias associated with curvature.~Key steps for this operation are as follows:~Glans retraction using stay suture 4-0 or 5-0 silk. Uretheral catheter pass through hypospadic meatus to bladder. Parallel longitudenal incision is done 1-2mm proximal to hypospadic meatus. A circumferential incision is made 2-3 mm below coronal sulcus dorsally"
224210991|NCT06038266|PROCEDURE|cardiac surgeries|predict perioperative risk factors for readmission after cardiac surgeries
224210992|NCT04155957|OTHER|Rapid Recovery Rehabilitation Programme|"Usual intervention at Hospital Clínic de Barcelona for post-operative rehabilitation of TKA patients. Participants, already at home after hospital discharge, must perform 5 different exercises 4 times a day (twice in the morning, twice in the afternoon).~Participants are also encouraged to walk and stretch their legs. Domiciliary visits by a physiotherapist start at approximately 2 weeks after the surgery to help participants do the exercises."
224210993|NCT04155957|DEVICE|ReHub|"Participants use a telerehabilitation platform, ReHub, as a guide to perform the TKA rehabilitation exercises of the Rapid Recovery Rehabilitation Programme intervention.~The exercise plan in ReHub is carried out by a site physiotherapist on the first day after discharge by using ReHub to acquire the participant's movement pattern with a wearable inertial sensor that transmits data to the platform.~The wearable inertial sensor participants must wear tracks movement while they do the TKA rehabilitation exercises. Movement is analysed and feedback is given in real time. At the end of each exercise, participants can select if they have felt pain in a scale from 1 to 10. A physiotherapist monitors the participants' progress remotely."
224210994|NCT06701266|DEVICE|Point of Care Test|PoCT as a chairside test, ELISA as a gold standard
224210995|NCT05532046|DRUG|BAY2413555 Dose 1|BAY2413555 Dose 1
223621157|NCT01169103|DRUG|recombinant human growth hormone (rhGH)|Initial rhGH dose 0.4mg administered by subcutaneous injection daily. Dose will be increased to 0.6 mg after one week and then increased to 0.8mg after two weeks.
223621158|NCT01169103|DRUG|Placebo|Placebo will be administered by daily subcutaneous injections. Sham increases will be used.
223621159|NCT05805631|DRUG|Pemetrexed|Intrathecal Pemetrexed
223761754|NCT05159843|BEHAVIORAL|Therapeutic education|"Participants randomized to this arm receive therapeutic education during four sessions of four consecutive days. An advanced practice nurse who specializes in diabetes will teach these sessions. The sessions will have small groups of five patients and it will last of one hour each day. The outline of the session is as follow (Figure 1):~First session: Insulin administration and blood glucose self-analysis Second session: Management of hypoglycemia and hyperglycemia Third session: Healthy diet adapted to the diabetic patient Four session: Physical exercise"
224210996|NCT05532046|DRUG|BAY2413555 Dose 2|BAY2413555 Dose 2
224210997|NCT05532046|DRUG|Placebo to BAY2413555|Placebo to BAY2413555
224210998|NCT04638725|OTHER|Blood sample for genetic analysis|Blood samples will be collected in two 6 ml EDTA tubes after informed consent and inclusion in the study
224210999|NCT00727896|BEHAVIORAL|Pre-coded messages|Earlier life style modification and existing drug therapy was used and now SMS is added as a tool for reminder
224211000|NCT00727896|DRUG|Diabetes Treatment|Life style modification and drug therapy
224211001|NCT00675701|DRUG|placebo|capsules
224211002|NCT00675701|DRUG|lixivaptan|capsules
224211003|NCT00675701|DRUG|moxifloxacin|tablets
224211004|NCT05017376|PROCEDURE|small incision lenticular extraction|In patients with the same degree of myopia, different optical zones were designed for operation
224211005|NCT04259879|OTHER|Fasting|Food intake restriction
223621160|NCT03977792|DRUG|BOR15001L7|BOR15001L7 topically applied to infected area, 5 times a day, until complete healing of the infection.
223621161|NCT03977792|DRUG|Docosanol Cream 10%|Comparator product topically applied to infected area, 5 times a day, until complete healing of the infection.
223621162|NCT00000266|DRUG|Flupenthixol|
223621163|NCT00141453|DRUG|olmesartan medoxomil|Tablets 10, 20, or 40 mg
223621164|NCT00141453|DRUG|Placebo Tablets|Matching placebo tablets
223621165|NCT06705647|OTHER|Chronic Obstructive Pulmonary Disease (COPD)|The base line acoustic and mel frequency ceprtum coefficients will be analysed statistically between COPD voices and healthy control groups to highlight the correlation between COPD and its effects on voice production.
223761755|NCT04242108|DIAGNOSTIC_TEST|Deep learning algorithm based on AS-OCT scans|The OCT scans of study subjects would be imported into the algorithm. Automated classfication of angle width and detection of synechia would be performed by the algorithm. The diagnostic performance of the algorithm would be compared with gonioscopy records.
223761756|NCT05691426|DIAGNOSTIC_TEST|Assessment of pulse wave amplitude (PWA)|Assessment of pulse wave amplitude (PWA) through peripheral arterial tonometry (PAT) using the device EndoPAT (Itamar Medical)
224211006|NCT02821117|DEVICE|FreeStyle Libre Flash Glucose Monitoring System|"Subjects will wear the FreeStyle Libre Flash Glucose Monitoring System masked for 14 days followed by 8 weeks unmasked wear.~During the 2 weeks of masked device wear participants will use the BG strip port for self-monitoring of blood glucose (SMBG). Scanning the sensor at least every 8 hours during this phase.~Followed by 8 weeks of unmasked device wear when participants will use the device (Sensor glucose and SMBG) according to labelling for their day to day management."
224211007|NCT06698614|DIAGNOSTIC_TEST|MRI|MRI imaging of the kidney and heart with an intravenous infusion of manganese dipyridoxl diphosphate (Mangafodipir, MnDPDP).
224211008|NCT06698614|DIAGNOSTIC_TEST|Blood tests|full blood count, urea and electrolytes, liver function test, CRP, biomarkers for endothelial function, storage of serum and plasma for future analyses.
224211009|NCT06698614|DIAGNOSTIC_TEST|Urine tests|Urine protein, Urine creatinine
224211010|NCT06698614|DIAGNOSTIC_TEST|Cardiovascular analysis|24 hour blood pressure, arterial stiffness
224211011|NCT05920018|DIETARY_SUPPLEMENT|Vivomixx®|Daily application of four sachets, i.e. 1.800 bio bacteria/day for 48 weeks
224211012|NCT05920018|DIETARY_SUPPLEMENT|Conjugated linoleic acid (CLA/Tonalin® FFA 80)|Daily application of two capsules p.o., i.e. 2g/day for 48 weeks
224211013|NCT05920018|OTHER|Maltose placebo|Daily application of four sachets for 48 weeks
224211014|NCT05920018|OTHER|Sunflower oil placebo|Daily application of two capsules p.o for 48 weeks
224211015|NCT03943121|PROCEDURE|Steroid-eluting stent implant|After endoscopic bilateral sinus surgery, the Steroid-eluting stents were randomly implanted in one side of the sinus.
224211016|NCT03943121|PROCEDURE|Without Steroid-eluting stent implant|After endoscopic bilateral sinus surgery, the Steroid-eluting stents were randomly implanted in one side of the sinus. And the side without the stent is defined as the control side.
224211017|NCT00287352|DRUG|Olanzapine, Amantadine|Olanzapine continuing as clinically indicated, Amantadine 100 mg tid
224211018|NCT00287352|DRUG|Olanzapine and placebo|Olanzapine continuing as clinically indicated
224316146|NCT01708967|PROCEDURE|pretreatment method for transnasal endoscopy|"Catheter-free method : The patient then takes simethicone (10cc). After that, the nasal cavity is sprayed with epinephrine (1cc) and lidocaine HCL (4%, 4cc).~Catheter inesertion method: After preparation steps the same as in the 'catheter-free' method, a 14 Fr. flexible catheter is coated with 2% lidocaine HCL gel and 8% lidocaine HCL spray. After that, the catheter is inserted into the patient's nasal cavity, and maintained about 1 minute for anesthesia. A 16 Fr. catheter is prepared by the same method with as the 14Fr. catheter. After the 14 Fr. cathter has been removed from the patient's nasal cavity, the 16 Fr. catheter is inserted into the patient's nasal cavity."
223513278|NCT04566510|OTHER|long lasting insecticidal nets with deltamethrin + piperonyl butoxide (PBO LLIN, PermaNet 3.0))|Next-generation bed net combining an insecticide with a synergist
223513279|NCT04566510|BEHAVIORAL|Social behaviour change communication|SBCC activities will use digital and other platforms, similar to those used for the COVID-19 response, including the following: (1) LLIN launch on television and radio; (2) regional advocacy meetings on Zoom; (3) mass media platforms (for advertisements, mini skits, DJ mentions, radio spots, interactive talks); (4) social media platforms; (5) VHTs; (6) operation hotlines and toll-free call centres; (7) community mobilisation (megaphones); and (8) use of appropriate information, education, and communication materials. Communication will include messages about COVID-19, malaria, and use, care, repair and repurposing of LLINs.
223513280|NCT01442285|BEHAVIORAL|personalized, motivational messages|A Healthcare Provider Report will be printed after each assessment and reviewed by the subject's oncologist. If any mental health functioning scale scores fall in the elevated or high range, a treatment plan will be constructed. Subjects will receive a personalized Patient Feedback Report after each assessment which will include motivationally tailored messages and suggestions for action.
223513281|NCT02347865|DRUG|AMG 162 - Prolia|500 patients
223513282|NCT02347865|DRUG|AMG 162 - Prolia|250 patients, one year later
223513283|NCT01558414|PROCEDURE|SILS Cholecystectomy|Cholecystectomy performed by Single Incision Laparoscopic Surgery with the SILS TM device
223513284|NCT01558414|PROCEDURE|FSIS cholecystectomy|Cholecystectomy performed by Flexible Single Incision Surgery with the flexible endoscope through a single incision at the umbilicus
223513285|NCT01558414|PROCEDURE|Conventional laparoscopy|Minimally invasive cholecystectomy through the conventional laparoscopic approach using 3 ports (one 11-cm umbilical port and two accessory 5-mm ports).
223513286|NCT00464529|DEVICE|Real-Time Continuous Glucose monitoring System (RT-CGMS)|
223513287|NCT00368849|DRUG|atomoxetine|This study utilizes a crossover design. Accordingly, half of the participants receive 40 milligram twice a day atomoxetine at arm one while the remaining half receive this intervention at arm two.
223513288|NCT00368849|DRUG|Matching Placebo|This study utilizes a crossover design. Accordingly, half of the participants receive twice a day matching placebo at arm one while the remaining half receive this intervention at arm two.
223513289|NCT03167710|OTHER|Dry Needling, manipulation, stretching|HVLA thrust manipulation to elbow, wrist and spine (C5-C6). Dry needling to wrist extensor muscles on the dorsal forearm, proximal and distal of the lateral epicondyle. Up to 8 treatment sessions over 4 weeks.
223513290|NCT03167710|OTHER|manual therapy, exercise, ultrasound|Impairment-based manual therapy, exercise and ultrasound targeting the wrist extensors on the dorsal forearm, proximal and distal of the lateral epicondyle. Up to 8 treatment sessions over 4 weeks.
223513291|NCT05462496|PROCEDURE|Biopsy|Pre-treatment tumor biopsy
223513292|NCT05462496|DRUG|FOLFIRINOX|"Patients will receive FOLFIRINOX chemotherapy every 2 weeks for 5 cycles. One cycle of mFOLFIRINOX = 14 days.~Cycles of mFOLFIRINOX are delivered as follows\*:~* Oxaliplatin: 85 mg/m2 IV over 2 hours on Day 1, followed by,~* Irinotecan: 150 mg/m2 IV over 90 minutes on Day 1, followed by,~* Leucovorin\*\*: 400 mg/m2 IV over 2 hours on Day 1, followed by,~* 5FU: 2400 mg/m2 IV over 46-48 hours on Days 1-3"
223513293|NCT05462496|DRUG|Ciprofloxacin|Ciprofloxacin and metronidazole will be initiated 7 days following 5th dose of FOLFIRINOX. Subjects will self-administer ciprofloxacin 500mg PO BID on days 1-21. Participants will be instructed to take the antibiotics with food to minimize stomach upset and to administer at the same time each day. Treatment with antibiotics will continue for 21 days unless there is unacceptable toxicity or disease progression. Subjects will record date, time and number of tablets they take on provided drug diaries.
224211019|NCT02971332|PROCEDURE|Stapled Transanal Rectal Resection|"The prolapsed tissue is pulled out through the CAD using e gauze pad and Allis forceps; this allows us to identify the extent of the prolapse to be resected. Four to five parachute stitches are then apposed circumferentially, like parachute cords, at the apex of the prolapse, in order to control the tissue during resection. The prolapse is then opened longitudinally at 3 o'clock with the electric scalpel between two Kocher clamps. Two traction stitches are applied at the deep vertex of the prolapse, one for each Kocher apex.~The longitudinal opening then allows the surgeon to begin circumferential resection of the rectum by pulling on the parachute stitches. This maneuver is performed counterclockwise using an average of 4-6 recharges, with care to always place the stapler at the base of the prolapse. The resected specimen was always inspected before the end of the procedure."
224211020|NCT05588375|BEHAVIORAL|home-based physical activity telemonitoring program|The home telehealth physical activity training program is a telemedicine physical activity training that uses Google Meet software to communicate and supervise through webcams.
224211021|NCT03355807|DRUG|Magnesium|The magnesium group (group Mg, n \_ 40) received an additional infusion of MgSO4
223621166|NCT02838069|BIOLOGICAL|Injection (2x106 ASC/5ml).|Injection of Autologous adipose derived stem cells (2x106 ASC/5ml). The patient of this group will receive one single administration of the cells and will be followed for 12 months. A final follow up visit will occur at Month 24.
224211022|NCT01219088|DRUG|Bupivacaine, morphine|1.8-2.5 mL of 0.5% heavy bupivacaine for spinal anesthesia 20 mL of 0.25% bupivacaine for femoral nerve block 0.1 mg of intrathecal morphine 20 mL of 0.25% bupivacaine for periarticular infiltration
224211023|NCT05152407|OTHER|Topical application of MRB 0.3% serum and placebo serum (hemi face or skull)|Serums will be topically applied twice a day (mornings and evenings).
224211024|NCT01514409|DIETARY_SUPPLEMENT|5-Hydroxytryptophan|"Thirty-three participants were randomly allocated in a double-blind manner to receive either 3x50mg capsules of 5-HTP or placebo (silica) for 14 days.~5-HTP is produced commercially by extraction from the seeds of the African plant griffonia simplicifolia."
224211025|NCT01514409|DIETARY_SUPPLEMENT|Pharmaceutical grade silica|Pharmaceutical grade silica was utilized as placebo
224211026|NCT00305071|DRUG|compound cranberry extract tablet|
224211027|NCT04325061|DRUG|Dexamethasone|Dexamethasone (20 mg/iv/daily/from Day 1 of randomization during 5 days, followed by 10 mg/iv/daily from Day 6 to 10 of randomization
224211028|NCT03405909|DIAGNOSTIC_TEST|contrast enhanced ultrasound (CEUS)|CEUS with SonoVue following standardized protocol
224211029|NCT03405909|DIAGNOSTIC_TEST|MRI|CE-MRI following standardized protocol
224211030|NCT03405909|DIAGNOSTIC_TEST|Histology|diagnostic liver biopsy
224211031|NCT00876811|DIETARY_SUPPLEMENT|individually quick frozen red raspberries|Consumption of one-cup frozen red raspberries daily for four weeks, followed by a four week period of non-treatment.
224211032|NCT00876811|DIETARY_SUPPLEMENT|individually quick frozen red raspberries|Consumption of one-cup frozen red raspberries for two weeks, then consumption of two-cups frozen red raspberries for an additional two weeks, followed by four weeks of non-treatment.
224211033|NCT00876811|DIETARY_SUPPLEMENT|individually quick frozen red raspberries|Consumption of one-cup frozen red raspberries for two weeks, then consumption of four-cups frozen red raspberries for an addition two weeks, followed by four weeks of non-treatment.
224211034|NCT06700954|OTHER|legume-rich Planetary Health Diet|legume-rich diet based on the Planetary Health Diet, with a focus on vegetable protein
223621167|NCT02838069|BIOLOGICAL|Injection (10x106 ASC/5ml).|Injection of Autologous adipose derived stem cells (10x106 ASC/5ml). The patient of this group will receive one single administration of the cells and will be followed for 12 months. A final follow up visit will occur at Month 24.
223621168|NCT02838069|OTHER|Placebo|Injection of placebo 0.5% glucose in saline with 4.5% alb/5ml The patient of this group will receive one single administration and will be followed for 12 months. A final follow up visit will occur at Month 24.
223621169|NCT02639273|DRUG|Nalmefene|Active Drug
223621170|NCT02639273|OTHER|Placebo|Single Dose Placebo
223621171|NCT05236725|DEVICE|Remote Blood Pressure Cuff|specialized, Bluetooth enabled BP monitoring cuff
224211035|NCT06700954|OTHER|control diet based on Western Diet low in legumes|diet based on the Western dietary pattern including animal protein sources (= control diet)
224211036|NCT05605184|OTHER|Survey|Survey
224211037|NCT02845973|BIOLOGICAL|gut microbiota|
224211038|NCT03970382|BIOLOGICAL|NeoTCR-P1 adoptive cell therapy|The investigational agent in this protocol is NeoTCR P1, an autologous adoptive T cell therapy (ACT) for patients with solid cancer. NeoTCR P1 is composed of apheresis derived CD8 and CD4 T cells that are precision genome engineered to express one autologous TCR of native sequence that targets a neoepitope (neoE) presented by human leukocyte antigen (HLA) receptors exclusively on the surface of that patient's tumor cells and not on other cells in the body.
224211039|NCT03970382|BIOLOGICAL|nivolumab|Nivolumab is a human IgG4 anti-PD-1 monoclonal antibody
224211040|NCT03970382|BIOLOGICAL|IL-2|IL-2 is a biologic response modifier. It is a type of protein called a cytokine.
224211041|NCT00422773|DRUG|Cetuximab|Dose level Infusion time (h) Dose level unit 1 2 3 4 Cetuximab 2.0 mg/m² 500 500 500 500 Irinotecan, before oxaliplatin 1.0 mg/m² 95 125 165 180 Oxaliplatin, with folinic acid 2.0 mg/m² 85 85 85 85 Folinic acid, with folinic acid 2.0 mg/m² 400 400 400 400 5-FU Infusion 46.0 mg/m² 3200 3200 3200 3200
223621172|NCT05236725|DEVICE|Blood Pressure (BP) monitoring smart phone app, BabyScripts™|app that works with the monitoring cuff
223621173|NCT05236725|BEHAVIORAL|Instructions|Verbal and written instructions to conduct BP checks at home
223621174|NCT02153957|BEHAVIORAL|Physical Activity|12 weeks of enhanced physical activity with Zamzee monitor.
223621175|NCT06768671|DRUG|Sonelokimab|Open label
223621176|NCT04210648|DEVICE|Mobile app|Mobile app for self-managing emotional dysregulation
223621177|NCT04512144|BEHAVIORAL|Headspace Smartphone Application|Headspace is a smartphone application used for mindfulness, meditation, and stress reduction. It has been utilized in other behavioral and quality of life studies.
224211042|NCT00127348|DEVICE|CPAP (Continuous Positive Airway Pressure)|
224211043|NCT04878250|DRUG|Bintrafusp alfa|4 doses of bintrafusp alfa (1200mg flat dose) administered intravenously at 14 day intervals before undergoing radical cystectomy.
224316147|NCT05652595|DRUG|GP40141|Once, at a dose of 3 mcg/kg, Subcutaneously in the shoulder area
224211044|NCT06279936|OTHER|Neuropsychological battery|COVID-19 patients with persistent complaints of cognitive disabilities (more than 4 weeks post-infection) in daily life are examined with an extensive neuropsychological test battery (see below) at the outpatient clinic of the University Psychiatric Centre in Duffel and at the University Hospital Antwerp. This battery covers a broad range of reliable and valid tests divided into six cognitive domains: attention, memory, visuospatial functions, language, executive functions and psychomotor speed/coordination. The neuropsychological examination lasts an average of 2 hours per participant. The tests are carried out by the same experienced neuropsychologist and also follow a standardized sequence. In addition to the neuropsychological assessment, two self-report scales are filled out by each patient. These scales are used to detect possible complaints of fatigue and possible cognitive problems which are experienced by the patient during daily life activities.
224211045|NCT06279936|OTHER|Surveys and symptom severity questionnaires|Both self-rated surveys and clinician administered questionnaires
224211046|NCT06279936|OTHER|Blood withdrawal|"Blood samples will be collected in a standardized manner by venipuncture. Two blood vials will be collected and processed to perform the following analyses:~* serum collection tube(s) allowing for HERV-W ENV and serological assays~* plasma collection tubes for the assessment of other immune-related biomarkers (including but not limited to CRP, IL-6, IL-1b, TNF-a, IFN-g, tryptophan, kynurenine, 3-OH-kynurenine, quinolinic acid, kynurenic acid, enzymes of the kynurenine pathway)."
224211047|NCT06279936|OTHER|Saliva swabs|Salivary cortisol measures will be used as functional measure of the HPA axis activity, as the unbound cortisol fraction in saliva is highly correlated to plasma cortisol. Baseline diurnal cortisol and CAR levels will be measured using saliva, collected at home with Salivette® (Sarstedt) synthetic swabs. The rationale behind the choice of home sampling, is to maximize normal circumstances and to minimize stress related to the measuring procedure.
224211048|NCT01716507|PROCEDURE|Retinal Detachment repair|Comparing 23 gauge vs 20 gauge pars plana vitrectomy.
224211049|NCT05578885|PROCEDURE|Bier block|patients in group a (n = 25) received 2% lidocaine3 mg/kg (maximum, 200 mg) for IVRA and 2 mL NaCl 0.9% IV , patients in group b (n = 25) received 2% lidocaine 3 mg/kg (maximum, 200 mg) plus 8 mg dexamethasone for IVRA and 2 mL NaCl 0.9% IV , and those in group c (n = 25) received 2% lidocaine 3 mg/kg (maximum, 200 mg) plus fentanyl IV
224211050|NCT00047437|BEHAVIORAL|Supervised Exercise Training Program|Exercise 30 minutes minimum three times per week.
224211051|NCT02609178|PROCEDURE|FGP|To execute FGP technique, the occlusal surface of the interim should be back cut to leave at least 1mm occlusal space. Then apply the recording resin. Ask the subjects to close the mouth to maximum intercuspal position then perform right lateral, left lateral and protrusive movements in succession ending in maximum intercuspation position. Excessive resin then should be trimmed off and Bausch articulating paper would be used to mark the intercuspal contacts. Zinc oxide is then applied to check eccentric occlusion, trimmed off resin if there're interferences. Then the interim would be used as a copy to design the occlusal surface of the crown. (CAD/CAM)
224211052|NCT02609178|PROCEDURE|AVR|the crowns in this group would be designed by setting virtual articulator to average mode (CAD/CAM)
224211053|NCT06013761|OTHER|IF 16:8 as active comparator vs. IF MCT 16:8 as experimental arm|12 weeks intermittent fasting according to the 16:8 method (IF 16:8) are compared with 12 weeks intermittent fasting with additional intake of exogenous MCTs (IF MCT 16:8) in a within-subject-crossover design in 28 patients with drug-resistant epilepsy. In order to enable the highest possible adherence, there are no restrictions on the composition of the food.
224211054|NCT01128153|DRUG|Saxagliptin|5 mg tablet once daily for 24 weeks to be taken orally
223621178|NCT06145373|DRUG|Fitusiran (SAR439774)|Pharmaceutical form:Solution for injection-Route of administration:Subcutaneous (SC) injection
224211055|NCT01128153|DRUG|Placebo|tablet once daily for 24 weeks to be taken orally
224316148|NCT05652595|DRUG|Nplate|Once, at a dose of 3 mcg/kg, Subcutaneously in the shoulder area
223621179|NCT06145373|BIOLOGICAL|Clotting factor concentrates (CFC) or bypassing agents (BPA)|Pharmaceutical form: Solution for injection-Route of administration: Intravenous (IV) injection
223621180|NCT06145373|BIOLOGICAL|Antithrombin concentrate (ATIIIC)|Pharmaceutical form:Solution for injection-Route of administration:Intravenous (IV) injection
223621181|NCT06145373|BIOLOGICAL|Emicizumab|Pharmaceutical form:Solution for injection-Route of administration:SC injection
223621182|NCT03770390|PROCEDURE|Surgical correction of pectus excavatum|Surgical correction of pectus excavatum
224211056|NCT03746886|OTHER|Breast-milk|A single breast-milk sample will be collected from 20 women. Milk samples will be pooled for analysis.
224211057|NCT02933827|DRUG|ELIXCYTE|Adipose-derived stem cells (ADSCs)
224316149|NCT00789243|PROCEDURE|Forearm vascular study|Forearm blood flow measured by venous occlusion plethysmography during interarterial infusion of substance P (2,4,8 pmol/min). Venous blood sampling via cannula in antecubital fossa.
224316150|NCT00046241|DRUG|Extended-release bupropion hydrochloride|
224316151|NCT05424458|PROCEDURE|Anterior Implant Treatment|Patients received routine examinations before surgery. The surgical procedures were performed by experienced experts. Immediate loading protocol was delivered if the insertion torque was over 35 N·cm; otherwise, removable restorations with submerged implants were applied. After a healing period of 3 to 6 months, a definitive screw-retained porcelain-fused-to-metal (PFM) or a CAD/CAM zirconia restoration were performed.
224316152|NCT03731442|RADIATION|Involved field irradiation|Involved field irradiation; intensity-modulated radiation therapy
224316153|NCT03731442|RADIATION|Elective field irradiation|Elective field irradiation; intensity-modulated radiation therapy
223621183|NCT06797089|DEVICE|Oral appliance therapy plus scaling and root planing on left or right of mouth|This device opens the upper airway by bringing the mandible forward to improve breathing during sleep. The mouth shield minimizes mouth breathing to optimize salivary function. Scaling and root planing (deep cleaning of all teeth requiring it).
223621184|NCT06840171|OTHER|Mandala coloring|Mandala group will participate in 8 sessions of mandala application. Mandala Coloring Application will be applied to the Intervention group 2-3 times a week for 3 weeks. Mandala application will be done by the researcher and feedback about the mandala will be received from the patients at the end of each session. Data collection forms will be applied before the mandala painting application starts and after the mandala painting application ends (after the 8th session).
223621185|NCT06039579|DRUG|VH4004280|VH4004280 was administered as tablets orally at Day 1.
223621186|NCT06039579|DRUG|VH4011499|VH4011499 was administered as tablets orally at Day 1 and Day 6.
223621187|NCT06039579|DRUG|VH4004280 Matching Placebo|VH4004280 Matching Placebo was administered as tablets orally at Day 1.
223621188|NCT06039579|DRUG|VH4011499 Matching Placebo|VH4011499 Matching Placebo was administered as tablets orally at Day 1 and Day 6.
223621189|NCT06039579|DRUG|Antiretroviral therapy|Antiretroviral therapy was administered as available and as per investigator's recommendation.
223621190|NCT05968274|DEVICE|Rebox-Physio 4 (real stimulation)|Rebox-Physio 4 is a CE-certified medical device class IIa. The device is a voltage-controlled generator of specific DC electric pulses with voltage amplitude 0-21 V, current intensity up to 200 uA, rectangular pulse shape, pulse frequency 3000 Hz and pulse duration 0.25 ms. Rebox currents are applied locally at the site of pain non-invasively transcutaneously with a touch of a flexible pin active treatment electrode (cathode) while the patient holds a cylindrical electrode (anode) to close electric circuit. Stimulation time in one point is 3-5 seconds until the current intensity reaches stable target values of 140-160 uA. During one session, total 20-50 points are systematically treated at a mutual distance of approx. 2 cm over the target region.
223621191|NCT05968274|DEVICE|Rebox-Physio 4 (sham stimulation)|"In the sham stimulation, the comparator will be a visually identical sham version of the real Rebox-Physio 4.The sham device has a resistor installed at the output generating current of negligible intensity (maximum 1 uA) assuming no relevant physiological effect. The application procedure will be identical to the real device. When applied to the patient, the sham device displays false voltage and current intensity values and responds to the operator´s actions in real time mimicking the real stimulation. The operator is therefore blinded."
223621192|NCT06014684|BEHAVIORAL|Timing of exercise|High Intensity Interval Training (HIIT) program for 12 weeks (3 per week/36 sessions in total)
223621193|NCT06548087|DEVICE|Gigstride Ambulatory Device|"For patients who are scheduled to be seen by the investigator in clinic with one of the above diagnoses, and recommended to use some type of ambulatory aid, the investigator will offer the Gigstride ambulatory device as an alternative and inquire about the patient's interest in participating in the study. After choosing to be a part of the study, the participant will use Gigstride device to perform the following tasks:~* Walk a different distances to assess speed and fatigue~* Perform functional mobility tasks (sit-to-stand, stand-to sit, stand-pivots, etc.)~The participant will then be asked to fill out a questionnaire, Gigstride Clinical Trial Questionnaire that will be used for qualitative data, such as ease of use and comfortability with using the device.~The overall amount of time for the evaluation and questionnaire will take approximately 30 minutes to 1 hour."
223621194|NCT04493372|DIAGNOSTIC_TEST|Tests of sympathetic inhibition|Bolus phenylephrine infusion using the Oxford technique will generate the need to inhibit sympathetic activity. Similarly, resting state Mayer waves will be assessed with regard to heart rate and blood pressure responses.
223621195|NCT04493372|DIAGNOSTIC_TEST|Tests of sympathetic activation|Cold pressor test of the hand will be used to cause sympathetic activation. Valsalva's maneuver will assess the ability to buffer against blood pressure fall (phase II).
223621196|NCT04493372|DIAGNOSTIC_TEST|Testing of autonomic dysreflexia|Cold pressor test of the foot and bladder pressor response (in individuals with SCI) will be tested.
223621197|NCT05412927|DEVICE|PMA P150009 AngelMed Guardian® System|"The AngelMed Guardian® System is an implantable cardiac monitor with patient alerting capability and an additional external alarm device. The Guardian® System is indicated for use in patients who have had prior ACS events and who remain at high risk for recurrent ACS events. The Guardian® System is indicated as an adjunct to patient recognized symptoms. The Guardian® System detects potential ongoing ACS events, characterized by sustained ST segment changes, and alerts the patient to seek medical attention for those potential ACS events.~A Guardian® System alert is a more accurate predictor of ACS events when compared to patient recognized symptoms alone and demonstrates a reduced rate over time of patient presentations without ACS events (false positives) when compared to patient recognized symptoms alone. In the absence of symptoms, the Guardian® System may identify asymptomatic ACS events and prompt the patient to seek medical attention."
223761757|NCT05691426|DIAGNOSTIC_TEST|Salivary Nitric Oxide|assessment the levels of salivary Nitric Oxide using a Nitric Oxide colorimetric detection kit,
223761758|NCT04508569|BEHAVIORAL|Big Decisions|Big Decisions is a promising teen pregnancy prevention intervention that consists primarily of abstinence-plus sexual health education curriculum. The intended dosage for students is 10 classroom-based sexual health lessons.
224211058|NCT05610982|BEHAVIORAL|Yoga Program|The yoga program involves two weekly 60-minute group-based classes. Participants can attend in-person or online (via Zoom). In total, 24 classes will be offered across 12 weeks. The program structure has been developed and approved by certified yoga instructors (n=12) and adults diagnosed with gynecologic cancer (n=6). The classes will follow a flexible base class that the instructor can then adapt as they see fit to promote participants' comfort, safety, and engagement. The program will also include group discussions and journaling that participants may participate in, if they choose. Finally, participants will be encouraged to access an online database of pre-recorded short-duration yoga practices to support their at-home practice.
224211059|NCT02419469|DRUG|Cytarabine|"Participants initially receive intrathecal treatment using Cytarabine 100 mg on Day 1. Induction chemotherapy must begin within 3 days of the intrathecal Cytarabine dose.~Consolidation Therapy 1: Cytarabine 75 mg/m2 subcutaneously Days 1 - 4 and 8 - 11.~Consolidation Therapy 3B: Cytarabine 75 mg/m2 subcutaneously Days 1 - 4 and Days 8 - 11."
224211060|NCT02419469|DRUG|Daunorubicin|Induction Therapy: Daunorubicin 25 mg/m2 by vein weekly for 4 doses.
224211061|NCT02419469|DRUG|Vincristine|"Induction Therapy: Vincristine 1.5 mg/m2 by vein weekly for 4 doses.~Consolidation Therapy 1: Vincristine 1.5 mg/m2 by vein Week 3 and Week 4.~Consolidation Therapy 2: Vincristine 1.5 mg/m2 by vein every 10 days for 5 doses.~Consolidation Therapy 3A: Vincristine 1.5 mg/m2 by vein weekly for 3 doses.~Consolidation Therapy 3B: Vincristine 1.5 mg/m2 by vein Weeks 3 and 4.~Maintenance Therapy (24 months): Vincristine 1.5 mg/m2 by vein every 28 days."
224211062|NCT02419469|DRUG|Prednisone|Induction Therapy: Prednisone 60 mg/m2/day by mouth for 28 days.
224211063|NCT02419469|DRUG|PEG asparaginase|"Induction Therapy: PEG asparaginase 2000 IU/m2 by vein on Day 4 of induction.~Consolidation Therapy 1: PEG-asparaginase 2000 IU/m2 by vein Week 3 and Week 7.~Consolidation Therapy 2: PEG-asparaginase 2000 IU/m2 by vein Weeks 1 and 4.~Consolidation Therapy 3A: PEG-asparaginase 2000 IU/m2 by vein in Week 1.~Consolidation Therapy 3B: PEG-asparaginase 2000 IU/m2 by vein Week 3."
223621198|NCT04608617|DEVICE|Viz LVO (De Novo Number DEN170073)|"Viz LVO is a notification-only, parallel workflow tool for use by hospital networks and trained clinicians to identify and communicate images of specific patients to a specialist, independent of standard of care workflow.~Viz LVO uses an artificial intelligence algorithm to analyze images for findings suggestive of a pre-specified clinical condition and to notify an appropriate medical specialist of these findings in parallel to standard of care image interpretation. Identification of suspected findings is not for diagnostic use beyond notification. Specifically, the device analyzes CT angiogram images of the brain acquired in the acute setting and sends notifications to a neurovascular specialist that a suspected large vessel occlusion has been identified and recommends review of those images. Images can be previewed through a mobile application."
223621199|NCT04608617|OTHER|Baseline Effectiveness Cohort|No Intervention was performed for the pre-Viz group. Record review to establish operational metrics only occurred.
223621200|NCT05963672|DEVICE|EEG-guided sleep protection|"The tablet will display a specific picture prioritize sleep or prioritize care depending on the patient status determined by the algorithm. When the picture favor/prioritize sleep is displayed, all caregivers and visiting family are asked to follow the sleep protection rules: refrain to enter the room for not urgent reasons, switch off television, reduced light in the room/corridor, reduce noise in front of the door, close curtain (if any), and delay non urgent care…etc; if caregivers have to enter the room, headlight and/or additional light will be favored. All these rules will be established collegially by nurses and doctors. Obviously, urgent care and reactions to alarms are maintained.~When the picture favor/prioritize care is displayed, all caregivers and visiting family are invited to perform non urgent care, cleaning, restocking perfusion needles, comfort care, visiting."
224211064|NCT02419469|DRUG|Ofatumumab|"Induction Therapy: Ofatumumab 300 mg by injection or vein on Day 2 and Ofatumumab 2000 mg by injection or vein on Day 15.~Consolidation Therapy 1: Ofatumumab 2000 mg by injection or vein Week 1 and Week 5.~Consolidation Therapy 2: Ofatumumab 2000 mg by injection or vein Week 1 and Week 5.~Consolidation Therapy 3A: Ofatumumab 2000 mg by injection or vein Week 1 and Week 3."
224211065|NCT02419469|DRUG|Rituximab|"Induction Therapy: If Ofatumumab not available, Rituximab 375 mg/m2 by vein on Day 1 and on Day 15.~Consolidation Therapy 1: If Ofatumumab not available, Rituximab 375 mg/m2 by vein Week 1 and Week 5.~Consolidation Therapy 2: If Ofatumumab not available, Rituximab 375 mg/m2 by vein Week 1 and Week 5.~Consolidation Therapy 3A: If Ofatumumab not available, Rituximab 375 mg/m2 by vein Week 1 and Week 3."
223621201|NCT05963672|OTHER|Control condition|the recording device will be placed on the patient to record sleep but the tablet will be masked and placed face down on the bench in the room, invisible from the door.
223621202|NCT04755816|BEHAVIORAL|Sodium intervention|The sodium dietary intervention provides the user with a tailored message to assist with making dietary choices based on sodium content when they arrive at a grocery store or restaurant.
223621203|NCT04755816|BEHAVIORAL|Clinical worsening intervention|The intervention adapts to the participant's reported symptoms and provides feedback with a global health status indicator (HSI). Users will receive tailored push notification based on their HSI status.
223621204|NCT04755816|BEHAVIORAL|Educational content|Standard heart failure educational information and a daily symptom survey.
223621205|NCT03866655|DEVICE|OWise|OWise Breast Cancer is a supportive care digital tool for breast cancer patients. The tool can be accessed as a mobile phone application or as a website. The tool has various tools for self-managing and self-monitoring treatment and symptoms such as an appointment calendar, a symptom-tracker, a modifiable question list and a recording device for consultations.
223621206|NCT02469623|DEVICE|Dipole Density Mapping with AcQMap followed by ablation|
223621207|NCT02763644|DRUG|LFG316 active drug|LFG316
224211066|NCT02419469|DRUG|Methotrexate|"Induction Therapy: Intrathecal methotrexate 12 mg on Day 8 and Day 29.~Consolidation Therapy 1: Intrathecal methotrexate 12 mg Weekly, Weeks 1 - 4.~Consolidation Therapy 2: Methotrexate by vein every 10 days starting at 100 mg/m2 and increasing by 50 mg/m2 as tolerated. and Intrathecal methotrexate 12 mg Week 1.~Consolidation Therapy 3A: Intrathecal methotrexate 12 mg in Week 1.~Consolidation Therapy 3B: Intrathecal methotrexate 12 mg Week 1 and 2.~Maintenance Therapy (24 months): Methotrexate 20 mg/m2 by mouth weekly, hold on days of intrathecal methotrexate.~Maintenance Therapy (24 months): Intrathecal methotrexate 12 mg every 3 months for 4 doses."
224211067|NCT02419469|DRUG|Cyclophosphamide|"Consolidation Therapy 1: Cyclophosphamide 1 gram/m2 by vein Week 1 and Week 5.~Consolidation Therapy 3B: Cyclophosphamide 1 gram/m2 by vein Week 1."
224211068|NCT02419469|DRUG|Mercaptopurine|"Consolidation Therapy 1: Mercaptopurine 60 mg/m2/day by mouth Days 1 - 14.~Maintenance Therapy (24 months): Mercaptopurine 75 mg/m2 by mouth nightly."
224211069|NCT02419469|DRUG|Doxorubicin|Consolidation Therapy 3A: Doxorubicin 25 mg/m2 by vein weekly for 3 doses.
224211070|NCT02419469|DRUG|Dexamethasone acetate|"Consolidation Therapy 3A: Dexamethasone 10 mg/m2 by mouth on Days 1 - 7 and Days 15 - 21.~Maintenance Therapy (24 months): Dexamethasone 6 mg/m2/day by mouth Days 1 - 5 every 28 days."
223621208|NCT02763644|OTHER|Standard of care treatment|SoC (site specific)
223621209|NCT01028989|DIETARY_SUPPLEMENT|Reduced Glycemic Load Diet|"36-40% fat; 40-42% carbohydrate; 18-22% protein~Glycemic Load \<=46 per 1000 calories"
223621210|NCT01028989|DIETARY_SUPPLEMENT|Standard Diet|"25-27% fat; 55-57% carbohydrate; 18-22% protein~Glycemic Load \>=77 per 1000 calories"
223621211|NCT01719796|PROCEDURE|Regional analgesia infusion|
223621212|NCT03536013|OTHER|Other: Full-thickness placental allograft|A full-thickness placental allograft will be applied to the annulus of the index lumbar level prior to site closure.
223621213|NCT00038753|PROCEDURE|Vision Screening|
224211071|NCT02419469|DRUG|Thioguanine|Consolidation Therapy 3B: Thioguanine 60 mg/m2/day by mouth for 14 days.
224211072|NCT02670512|DEVICE|Telehome Monitoring|
224211073|NCT01682512|DRUG|BI 695500|
223513294|NCT05462496|DRUG|Metronidazole|Ciprofloxacin and metronidazole will be initiated 7 days following 5th dose of FOLFIRINOX. Subjects will self-administer metronidazole 500mg PO every 8 hours on days 1-21. Participants will be instructed to take the antibiotics with food to minimize stomach upset and to administer at the same time each day. Treatment with antibiotics will continue for 21 days unless there is unacceptable toxicity or disease progression. Subjects will record date, time and number of tablets they take on provided drug diaries.
223513295|NCT05462496|DRUG|Pembrolizumab|Pembrolizumab will be initiated 7 days post initiation of antibiotics. Subjects will receive a flat dose of pembrolizumab 200mg IV over 30 minutes.
224211074|NCT01682512|DRUG|BI 695500|
224211075|NCT01682512|DRUG|Rituxan®|
224211076|NCT01682512|DRUG|Rituxan®|
223621214|NCT06366178|DEVICE|BONFIX system|"The device corresponds to a customized, single-use surgical guide (Class IIa medical device), with a set of different sizes, adapted to the fronto-zygomatic distance (FDZ) measurement, in order to enable better conformation of the orbito-naso-frontal bandeau during surgery for anterior craniostenosis, an ideal conformation that could lead to optimal symmetry and adapted to the morphology of the upper third of infants.~The surgeon conforms the orbito-naso-frontal bandeau by adapting the advancement between the device supports according to the FDZ and then positioning it directly on the surgical guide."
223621215|NCT03992053|OTHER|sacroiliac joint injection|Image-guided sacroiliac joint injection under fluoroscopy or CT guidance and the success of intraarticular access was demonstrated by inter-articular contrast spread (the standard of care, not part of study intervention).
223621216|NCT01160276|DRUG|cyclosporine+colchicine|the 14 patients of the 1st group are under cyclosporine and One pill of colchimax 1mg will be taken by all the patients at Day 3.
223621217|NCT01160276|DRUG|tacrolimus|the 14 patients of the second group are under tacrolimus and One pill of colchimax 1mg will be taken by all the patients at Day 3.
223621218|NCT04870658|PROCEDURE|Dental implant treatment|Patients who receive one o more dental implant treatment to restore oral function.
223621219|NCT02760940|DRUG|oral liposomal iron|After screening, anemic patients will be treated during 8 weeks with 28mg of oral liposomal iron per day and then the investigators will report data assessing the tolerability and efficacy of oral liposomal iron treatment in these patients.
223621220|NCT00010400|DRUG|Cyclophosphamide|
223621221|NCT00010400|DRUG|filgrastim|
223621222|NCT06359158|DEVICE|Digital stethoscope use|In this interventional study, 84 medical students were randomly allocated to an intervention group utilizing a novel digital stethoscope curriculum or a control group receiving traditional instruction. The intervention leveraged digital stethoscopes, enabling visualization and analysis of recorded breath sounds. Pre- and post-assessments evaluated respiratory
223621223|NCT05548517|BEHAVIORAL|Time Restricted Eating (TRE)|9-hour eating window
223621224|NCT05548517|BEHAVIORAL|Calorie Restriction|daily calorie restriction
223621225|NCT05013736|DEVICE|Magnetic Resonance Imaging|3 Tesla Discovery MR750 MRI scanner (GE Healthcare, Waukesha, WI) will be used to perform structural imaging, diffusion MRI, relaxometry and microstructural imaging. The exact scan length and parameters of each scan type (T1, T2, DWI) will be set for this study to optimize the quality of data and decrease the length of scanning session for each type of scan. All of the imaging methods have been previously implemented at UW-Madison. Each sequence will take approximately 5-10 minutes.
223621226|NCT05013736|BEHAVIORAL|Behavioral Assessments|The behavioral assessments (GMA: General Movements Assessment; HINE: Hammersmith Infant Neurological Examination; Baby Observation of Selective Control AppRaisal (BabyOSCAR); Bayley-4 / Bayley Scales of Infant and Toddler Development 4th ed; Pediatric Evaluation of Disability Inventory -Computer Adaptive Test (PEDI-CAT)) are infant and age-specific and will be administered by trained pediatric occupational and physical therapists.
223621227|NCT05013736|DEVICE|Non invasive Transcranial Magnetic Stimulation|TMS will be used to assess cortical excitability and circuitry (not as a neuromodulation intervention). Single-pulse TMS (Magstim 200², Magstim, UK) with a scalp surface coil will be used to assess how the brain is developing and how connected the tract is, between the brain and a target muscle on the arm. 10-20 TMS stimulation pulses will be delivered at a range of stimulation intensities (50-100%) increasing by 5% maximal stimulator output (MSO) at each stage. In sum, around 150 stimulation pulses per hemisphere are expected for TMS assessment for each infant.
224211077|NCT01682512|DRUG|MabThera®|
224211078|NCT00127257|BEHAVIORAL|Biofeedback|
223621228|NCT03315520|DRUG|Bendamustine|"BeEAC conditioning regimen:~bendamustine 200 mg/м2 D-6 - D-5; cytarabine 400 mg/м2 D-4 - D-1; etoposide 400 mg/м2 D-4 - D-1; cyclophosphamide 140 mg/м2 totally, divided in 4 days (D-4 - D-1)"
223621229|NCT06085599|BEHAVIORAL|Progressive relaxation exercises|The progressive muscle relaxation technique involves suggestive stretching and relaxation in sixteen different muscle groups of the body. This technique is based on tensing each muscle group for approximately 10 seconds and then abruptly releasing this tension.
223621230|NCT02356159|BIOLOGICAL|Rituximab|Rituximab: 375 mg/m\^2 intravenous (IV) day 1 for patients with cluster of differentiation 20 (CD20)-positive disease.
223621231|NCT02356159|DRUG|Conditioning chemotherapy|Fludarabine:30 mg/m\^2 per day intravenous (IV) infusion over 30 minutes, daily on days -6, -5, -4, and -3; Cyclophosphamide:1200 mg/m\^2 per day IV infusion over 2 hours on Days 6, -5, -4, -3. Mesna: 1200 mg/m\^2 per day IV infusion, daily on days 6, -5, -4, and -3 Furosemide: 20 mg IV flat dose on days -6, -5, -4, -3; Furosemide: 20 mg IV flat dose on days -6, -5, -4, -3.
223621232|NCT02356159|DRUG|TMS|Tacrolimus: 0.02 mg/kg, start day 3. Continue intravenous (IV) or by mouth (PO). Taper will begin at day +60 if no acute graft-versus-host disease (GVHD) then at day +100 and discontinue at day +180 as tolerated. Methotrexate: 5 mg/m\^2 IV over 15 minutes on days 1, 3, 6, and 11. Sirolimus: 12 mg PO on days -3 to 60, followed by a taper if GVHD does not develop.
224211079|NCT00127257|DRUG|Diazepam|
224211080|NCT00127257|BEHAVIORAL|Pelvic floor retraining|
224211081|NCT03397563|DEVICE|Continuous Positive Airway Pressure|standard automatic CPAP machine set on optimal automatic pressure
224211082|NCT03397563|DEVICE|sham Continuous Positive Airway Pressure|CPAP machine with pressure set below effective impact, i.e. low pressure of 4 cm H2O and adjustment of the ventilation mask
224211083|NCT04132739|BEHAVIORAL|Diet|The Nutrition Intervention will consider the participants' food preferences and concerns for managing glycemic control and maintaining muscle-mass. Each topic will be presented interactively and the participants will be encouraged to attend 2 times/week (attendance will be logged). The topics will be presented as a combination of evidenced-based materials for older adults with type 2 diabetes. We anticipate 3 sessions/topic during the 6-month intervention and will modify the topics and time to fit the needs of our audience. The lessons and materials will be offered in English and Spanish. The food quality change will be measured using a Food Frequency Questionnaire validated in Hispanic populations. The goals are to increase the participants' self-efficacy (belief and self-confidence) that they have the tools necessary to manage diabetes and reduce mobility impairments.
224316154|NCT03731442|DRUG|Paclitaxel|Paclitaxel 135-150mg/m2, d1, every 3 weeks
224211084|NCT04132739|BEHAVIORAL|Exercise|The Exercise Intervention will involve 30-minute exercise sessions based on the Otago Exercise Program. The exercises involve lower and upper limb strengthening, balance training and a walking plan. The participants will receive illustrations of the exercises to do. Each participant will exercise for 30 minutes, 2x/week during supervised sessions in the facilities and be encouraged to do the exercises by themselves on days the group sessions are not offered. We will also teach self-monitoring for signs of low-blood glucose to ensure safety. Progression will be done every two weeks during the first 2 months, once at month 3, and once at month 6 by increasing intensity and/or difficulty and the walks by increasing continuous walking time and walking speed without compromising safety.
223621233|NCT02356159|DRUG|FLAG|Fludarabine: 25 mg/m\^2 per day intravenous (IV) over 30 minutes, daily on days 1-5 Cytarabine: 2,000 mg/m\^2 IV over 4 hours, on Days 1, 2, 3, 4, 5. Filgrastim: 5 mcg/kg per day subcutaneous (SC) beginning 24 hours PRIOR to initiation of chemotherapy.
224211085|NCT04132739|BEHAVIORAL|Diet and exercise|A combination of the diet and exercise interventions following the same procedures previously described.
224211086|NCT06478446|OTHER|observation|HD patients were observed and evaluated with three scales.
223513296|NCT05462496|PROCEDURE|Surgical Resection|Following completion of 21 days of antibiotics, participant will undergo repeat imaging studies. If there is no progressive disease which renders participant surgically unresectable (based on NCCN guidelines 2.2021), subject will undergo definitive surgical resection.
223513297|NCT02006836|DIETARY_SUPPLEMENT|Pomelo|The sugar content of the pomelo was 5.86% of full weight, and we use 922g Majia pomelos which contained about 50g sugar equal to 50g glucose for GI measurement.
223513298|NCT02006836|DIETARY_SUPPLEMENT|Glucose|We dissolved 50 g of glucose in 200 ml water.
223513299|NCT02006836|OTHER|Blank|For the self-control period the diabetic patients underwent 3-day CSII treatment without change of insulin dose and we did not applied any intervention.
223513300|NCT02006836|DRUG|Insulin|Patients who were included in the test of glycemic responses to postprandial pomelo consumption were hospitalized with the treatment of Continuous Subcutaneous Insulin Infusion(CSII), and the insulin for CSII was insulin aspart(NovoRapid).
223513301|NCT02006836|DRUG|met or diet|In diabetic group, 20 diabetic patients were included for GI measurement , 18 of whom were on metformin treatment. Only 2 patients were on diet control due to the early stage of this disease.
223513302|NCT06500897|DEVICE|VEST|External MEsh Support for safein vein
223513303|NCT06309797|DEVICE|Interdental brush+HA|interdental brushes (TePe Munhygienprodukter AB, Malmö; TePe 0.4 mm and TePe 0.6 mm) +20 mL of 0.2% HA gel (Gengigel; Ricerfarma, Milan, Italy)
223513304|NCT06309797|DEVICE|Interdental brush|interdental brushes (TePe Munhygienprodukter AB, Malmö; TePe 0.4 mm and TePe 0.6 mm)
223513305|NCT02571543|DRUG|Ibuprofen|Beginning with 400mg Ibuprofen, 5 times. Depending on the outcome of stage 1 the treatment dose will increase to 800mg, 5 times.
223513306|NCT05280314|DRUG|IO102-IO103|IO102-IO103 is a combination of an indoleamine 2,3-dioxygenase 1 (IDO1) peptide (IO102) and a programmed death-ligand 1 (PD-L1) peptide (IO103), emulsified with an adjuvant (Montanide ISA 51 VG).
223513307|NCT05280314|DRUG|Pembrolizumab KEYTRUDA®|Pembrolizumab KEYTRUDA® administered intravenously
223513308|NCT04950907|DIAGNOSTIC_TEST|vats|Use uniportal tubeless VATS to obtain the biopsy
223513309|NCT04950907|DIAGNOSTIC_TEST|CT-guided fine needle biopsy|Use CT-guided fine needle to obtain the biopsy
223513310|NCT01699685|DRUG|QAB149|Capsule form in blister packs inhaled with the Novartis Concept 1 SDDPI
223513311|NCT01699685|DRUG|Placebo|Capsule form in blister packs inhaled with the Novartis Concept 1 SDDPI
223513312|NCT01699685|DRUG|NVA237|Capsule form in blister packs inhaled with the Novartis Concept 1 SDDPI
223513313|NCT04202211|BIOLOGICAL|FMT oral|lyophilized FMT given orally (10 capsules) twice weekly for total of 8 weeks
223513314|NCT04202211|BIOLOGICAL|FMT enema|lyophilized FMT given via enema (1) twice weekly for total of 8 weeks
223513315|NCT04202211|OTHER|Placebo oral|placebo given orally (10 capsules) twice weekly for total of 8 weeks
223513316|NCT04202211|OTHER|Placebo enema|placebo given via enema (1) twice weekly for total of 8 weeks
223513317|NCT02885922|DRUG|anti-diabetic drug|Add-on anti-diabetic drug in type 2 diabetic patients
223513318|NCT03635996|DRUG|Etripamil NS 70 mg|All patients will receive a total of 200 micro-liters of etripamil NS 70 mg via the Aptar Pharma Nasal Spray Bidose System each time they self-administer study drug.
223513319|NCT03635996|DEVICE|Aptar Pharma Nasal Spray Bidose System|Patients will self-administer the study drug using the Aptar Pharma Nasal Spray Bidose System. The devices will be prefilled and packaged into child-resistant boxes.Instructions for its use will be provided in the study drug box.
223513320|NCT02797548|DRUG|Aspirin only|Aspirin only during surgery
223513321|NCT02797548|DRUG|No antiplatelet therapy|No antiplatelet therapy will be during surgery
223513322|NCT04482803|DRUG|Carbon nanoparticles suspension injection will be injected into or around the cortex of the clinically assessed positive lymph nodes|Before NST, one of the clinically assesed positive lymph nodes will be subjected to ultrasound-guided CNB or FNA, and a locating clip (Ultraclip, BARD) will be placed. Meanwhile, a small amount of Kanarine (carbon nanoparticles suspension injection, 0.5ml:25mg, H20073246) will be injected into or around the cortex of the locating lymph node and other clinically assessed positive lymph nodes. Preoperative FNA will be performed again for locating clip labelled node.
223513323|NCT06377748|OTHER|Facilitated tucking position|Neonates in this group will be given facilitated tucking position (lower and upper extremities will be held in right lateral flexion position and midline) by a volunteer nurse one minute before the vaccination procedure. The nurse will administer intramuscular vaccine injection into the vastus lateralis region of the left leg of the infant in the facilitated tucking position according to routine practice.
223513324|NCT06377748|DEVICE|ShotBlocker|Immediately prior to the vaccination procedure, the nurse will place the protruding surface of the ShotBlocker on the neonate's vaccination procedure site (left leg vastus lateralis muscle). The nurse will continue to hold the ShotBlocker at the injection site by pressing against the skin for 20 seconds. At the end of the time, she will grasp the tissue with the ShotBlocker and inject the vaccine through the opening in the center. After the procedure is completed and the needle is withdrawn, the ShotBlocker will be removed from the skin.
224211087|NCT00229541|PROCEDURE|Counselling and 3-week medical in-patient rehabilitation|Counselling and 3-week medical in-patient rehabilitation in IG
224211088|NCT05695235|DEVICE|CGM|Wearable continuous glucose monitoring systems (CGMS) provide a minimally invasive means of passively tracking ambulant interstitial fluid glucose levels in real time.
224211089|NCT05695235|DEVICE|Oura ring|Wearable sleep tracking device
224211090|NCT05695235|BEHAVIORAL|Cognitive tasks and questionnaires|Participants will be prompted daily to fill out a short set of wellbeing questions and perform a short alertness test on their mobile phones and laptop.
224211091|NCT03720184|PROCEDURE|HAR|"HAR, the 6 steps procedure that results in 300ml of haemodilution. Step 0: Circuit is primed with 1000ml of crystalloid solution. Step 1: Venous line content is drained to the reservoir. Step 2: arterial srystalloid priming is displaced to the reservoir retrogradely by autologous blood. Step 3: Crystalloid priming is discarded to the collector bag. Step 4: An amount of 300ml of arterial blood is sequestered to the reservoir avoiding the mixture. Step 5: The centrifugal pump and the oxygenator are reprimed with autologous blood displacing the priming and GME to the collector bag. Step 6: CPB is initiated with a low haemodilution of 300ml.~Available at: https://zenodo.org/record/4276132#.X7K8AchKgRk"
224211092|NCT04057755|DRUG|botulinum toxin A|
224211093|NCT04057755|DRUG|NaCl|
224211094|NCT02887612|OTHER|ctDNA test|
224211095|NCT04074213|DRUG|Clozapine|Clozapine treatment
224211096|NCT01826318|BEHAVIORAL|Stress coping|"Students in the intervention group received a 10 minute instruction to cope with stress. They were informed that an emergency situation is a stressful experience for health care workers and that perceived stress may interfere with their decision-making abilities and performance. Particularly, feeling overwhelmed by stress may cause cognitive impairment potentially leading to loss of concept how to deal with an emergency situation, which in turn further increases stress (vicious cycle). However, it is possible to overcome this situation by focusing on the basic conditions of the situation and the immediate actions that are needed. They were instructed that they should ask two task-focusing questions aloud (what is the patient's condition?, what immediate action is needed?) to overcome the negative consequences of feeling overwhelmed by stress."
224211097|NCT00416403|DRUG|fluvastatin sodium|Given orally
224211098|NCT00416403|PROCEDURE|Breast Cancer Surgery Only - Arm III|Breast Cancer Surgery
224211099|NCT06030271|DEVICE|Microcatheter|Support and facilitate the placement of the guidewire in the coronary artery with a CTO.
223621234|NCT02356159|DRUG|EPOCH-F|"Fludarabine: 25 mg/m\^2 per day intravenous (IV) infusion over 30 minutes, daily on days 1-4. Etoposide: 50 mg/m\^2 per day continuous IV infusion over 24 hours on days 1-4. Doxorubicin: 10 mg/m\^2/day continuous intravenous (CIV), days 1-4. Vincristine: 0.4 mg/m\^2 per day continuous IV infusion over 24 hours daily on days 1-4.~Cyclophosphamide: 750 mg/m\^2 IV infusion over 30 minutes on day 5. Prednisone: 60 mg/m\^2 per day by mouth (PO) daily on days 1-5. Filgrastim: 5 mcg/kg per day SC or IV."
224211100|NCT01728935|DRUG|Tenofovir disoproxil|Tenofovir disoproxil 300mg daily
224211101|NCT04822467|DEVICE|SQ53 Wipe|SQ53-based wipe to be used by the participant daily or upon dressing change
223621235|NCT02356159|PROCEDURE|Hematopoietic stem cell transplant|Hematopoietic stem cell transplant
224211102|NCT04822467|DEVICE|Ethanol Wipe|Ethanol-based wipe to be used by the participant daily or upon dressing change
224211103|NCT04736576|DEVICE|Wearable device|As a low-interventional procedure, enrolled patients will be provided with wearable device and requested to wear the device at all-times, except of while bathing and sleeping, for 6 cycles (24 weeks).
224211104|NCT01819701|DIETARY_SUPPLEMENT|LC-1000|L-carnitine 1000 mg /d
224211105|NCT01819701|DIETARY_SUPPLEMENT|LC-2000|L-carnitine: 2000 mg/d
224211106|NCT01819701|DIETARY_SUPPLEMENT|Q10-150|Coenzyme Q10: 150 mg/d
224211107|NCT01819701|DIETARY_SUPPLEMENT|Q10-300|Coenzyme Q10: 300 mg/d
224211108|NCT01819701|OTHER|Placebo|
224211109|NCT06700421|DRUG|Adebrelimab + Apatinib|Adebrelimab combined with apatinib
224211110|NCT04432818|BEHAVIORAL|Pack Health's digital life coaching (DLC)|Pack Health smartphone-based DLC platform will be provided for 16-week subscription which allows unlimited bidirectional communication between enrolled participants and their life coach
224211111|NCT04275388|DRUG|Xiyanping injection|Xiyanping injection, 10-20ml daily, Qd, the maximum daily does not exceed 500mg (20mL) + Lopinavir tablet /Ritonavir tablet or Alpha-interferon nebulization or Abidor Hydrochloride,
224211112|NCT04275388|DRUG|Lopinavir / ritonavir, alpha-interferon nebulization,Abidor Hydrochloride|Lopinavir / ritonavir tablets, 2 times a day, 2 tablets at a time; alpha-interferon nebulization;Abidor Hydrochloride
223621236|NCT02356159|DRUG|Palifermin|Escalating doses of palifermin given during transplant phase.
223621237|NCT02356159|DRUG|Acetaminophen|Before each infusion of rituximab as indicated.
223621238|NCT02356159|DRUG|Diphenhydramine|Before each infusion of rituximab as indicated.
223621239|NCT02356159|DRUG|Prednisone|For engraftment syndrome.
223621240|NCT02356159|DRUG|Epinephrine|Emergency medication as indicated.
224211113|NCT00294931|DRUG|irinotecan|
224211114|NCT00294931|DRUG|carboplatin|
224211115|NCT00294931|DRUG|bevacizumab|
224211116|NCT02394353|DEVICE|Transient hepatic elastography|
224211117|NCT04390035|DEVICE|Blood Flow Restriction using Delfi Personalized Tourniquet System|Participants assigned to the test group will undergo blood flow restriction training 2 days per week beginning at week 1-2 post-surgery and continuing through week 16 post-surgery using the FDA-approved Delfi Personalized Tourniquet System (PTS) with personalized pressure of 80% of the limb occlusion pressure (LOP). The LOP is the amount of pressure required to fully occlude arterial and venous blood flow to the limb. Otherwise, both the test group and control group will follow a standard 6-month post-surgery rehabilitation protocol which is standard of care for ACLR recovery.
224211118|NCT01651494|DRUG|DAS181|DAS181-F04 is a recombinant neuraminidase that is delivered onto the cell surface of the upper and central airway topically and locally through an inhaler as an encapsulated dry powder. DAS181-F04; 20 mg single-dose each day via oral inhalation for 3 days; 6 subjects
224211119|NCT01651494|OTHER|Placebo|Placebo: White to off-white powder with Lactose Monohydrate and 5 % moisture; 20 mg single-dose each day via oral inhalation for 3 days; 3 subjects
224211120|NCT02872155|OTHER|Oral hydratation|500 mL of water two hours before computed tomography and 2000 milliliters 24 hours after performing computed tomography
224211121|NCT02872155|DRUG|Bicarbonate endovenous hydratation|Intravenous hydration: sodium (1.6 molar) Bicarbonate 3 mL / kg / h starting one hour before the computed tomography and sodium bicarbonate (1/6 M) 1 mL / kg / h during the hour after computed tomography.
223513325|NCT06377748|COMBINATION_PRODUCT|Combined facilitated tucking and ShotBlocker|Neonates in this group will be given facilitated tucking position (lower and upper extremities will be held in right lateral flexion position and midline) by a volunteer nurse one minute before the vaccination procedure. The nurse will place the ShotBlocker on the procedure site and apply pressure to the skin for 20 seconds. At the end of the time, the nurse will grasp the tissue with the ShotBlocker and inject the vaccine through the central opening. After the injection is completed and the needle is withdrawn, the ShotBlocker will be removed from the skin. The newborn will continue to take facilitated tucking position until 1 minute after the ShotBlocker is removed.
223513326|NCT00582829|OTHER|Generic Print Intervention|"Generic Print Intervention: The generic print intervention will consist of the pamphlet, Colorectal Cancer Screening Saves Lives published by the Center for Disease Control that will be mailed to the participant."
223513327|NCT00582829|OTHER|Tailored Print Intervention|Tailored Print Intervention: The tailored print intervention will consist of a cover letter detailing the participant's stage of readiness along with a color pamphlet with information personally tailored for the individual participant.
223513328|NCT00582829|OTHER|Tailored print plus tailored phone intervention|Tailored print plus tailored phone intervention: The tailored print plus tailored telephone intervention will consist of a phone counseling session and the tailored print information described above. The tailored print material will serve as a guide during the telephone counseling contact and a reinforcement of the information.
223513329|NCT02834442|DRUG|MT-7117|
223513330|NCT02834442|DRUG|Placebo|
223513331|NCT03612414|DIETARY_SUPPLEMENT|Aqualief|Three tablets/day
223513332|NCT03612414|DIETARY_SUPPLEMENT|Placebo|Three tablets/day
223513333|NCT06507644|PROCEDURE|light curettage|Before the treatment, the treated area will be degreased with 0.2% aqueous chlorhexidine. Next, a light curettage will be performed on the face with a sterile curette.
223513334|NCT06507644|OTHER|Pre irradiation of 1 hour|A thin layer of the photosensitizing medication, approximately 1 mm thick, will be applied to the participant's facial lesion sites. Then an occlusive dressing will be used to enhance MAL penetration, which will be covered with aluminum foil to prevent ambient light from influencing the protoporphyrin production process. For the PDT technique, the dressing will remain on the face for 1 hour.
223513335|NCT06507644|OTHER|Pre irradiation of 3 hour|A thin layer of the photosensitizing medication, approximately 1 mm thick, will be applied to the participant's facial lesion sites. Then an occlusive dressing will be used to enhance MAL penetration, which will be covered with aluminum foil to prevent ambient light from influencing the protoporphyrin production process. For the PDT technique, the dressing will remain on the face for 3 hour.
223513336|NCT06507644|OTHER|topical application of 8% methyl aminolevulinate photosensitizer MAL|Participants will be treated with 8% topical MAL photosensitizer
223513337|NCT06507644|OTHER|topical application of 16% methyl aminolevulinate photosensitizer (MAL)|Participants will be treated with 16% topical MAL photosensitizer
223513338|NCT06507644|DEVICE|Visible light source|Skin illumination will be performed using a visible light source (LED) with a wavelength of 643 nm
223513339|NCT04885712|DRUG|Metformin≥1000mg|Subjects take the investigational products once a day for 24 weeks.
223513340|NCT04885712|DRUG|Pioglitazone 15mg|Subjects take the investigational products once a day for 24 weeks.
223513341|NCT04885712|DRUG|Pioglitazone 30 mg|Subjects take the investigational products once a day for 24 weeks.
223513342|NCT04885712|DRUG|Pioglitazone 15mg Placebo|Subjects take the investigational products once a day for 24 weeks.
223513343|NCT04885712|DRUG|Pioglitazone 30mg Placebo|Subjects take the investigational products once a day for 24 weeks.
223513344|NCT04885712|DRUG|Dapagliflozin 10mg|Subjects take the investigational products once a day for 24 weeks.
223513345|NCT03876548|DEVICE|Cadexomer Iodine Gel|Subjects will apply gel product to keloid scar site every other day for 28 days following keloid scar revision surgery.
223513346|NCT02916914|OTHER|Q2 feeding|Infants are going to be fed every 2 hours
223513347|NCT03607136|OTHER|exercise training|Aerobic exercises, strengthening exercises, flexibility training for 60min, twice a week for 12 weeks
223513348|NCT02402231|DRUG|Omalizumab|Omalizumab is the treatment during oral immunotherapy with peanuts as protection
223513349|NCT05058456|DEVICE|Shockwave Medical Mini S Peripheral IVL Catheter|The Shockwave Medical Mini S Peripheral IVL Catheter is intended for lithotripsy-enhanced catheter dilatation of lesions, including calcified lesions found in the peripheral vasculature, such as the iliac, femoral, ilio-femoral, popliteal, infra-popliteal, and renal arteries. The Mini S IVL Catheter is not for use in the coronary or cerebral vasculature.
223513350|NCT03849235|DIETARY_SUPPLEMENT|Standardised meal or glucagon|Standardised meal (Nutridrink, Nutricia, 300 kcal, 18.4 g carbohydrates, 5.8 g fat, 12 g protein) or 1mg glucagon
223513351|NCT04534725|DRUG|Interferon alfa|intranasal spray
223513352|NCT04534725|DRUG|Selinexor|oral tablet
223513353|NCT04534725|DRUG|Lenzilumab|intravenous infusion
223513354|NCT04250389|OTHER|Hemodynamic assessment (micro and macrocirculatory)|"Each of the variable related to macro- and microcirculatory will be evaluated before and one hour after start of MB infusion.~Macrocirculatory parameters will include :~* Mean, systolic, diastolic arterial, heart rate (HR)~* Cardiac output (CO), sequential vascular response (SVR) and stroke volume (obtained with transthoracic echocardiography or transpulmonary thermodilution catheter if available).~* A passive leg raising (PLR) test will be performed before and one hour after MB infusion. Patients will be classified as fluid responder if they had a CO of at least 10% after PLR.~Microcirculatory parameters will include :~* Cutaneous and gingival refill time~* Tissue oxygen saturation combined with vascular occlusion test (VOT)~* Video microscopy measurements of the sublingual microcirculation~* Metabolic variables: Arterial blood gases including arterial lactate and central venous blood gases."
223513355|NCT00374985|DRUG|Docetaxel, Oxaliplatin|weekly doses
223513356|NCT00374985|PROCEDURE|Radiotherapy|regular fractions
223513357|NCT05227014|PROCEDURE|Colorectal resection|All patients undergoing elective colorectal surgery with anastomosis will be included in a prospective database after written informed consent.
223513358|NCT03015948|DRUG|SHR4640|a single dose of SHR4640 (n=8) for each dose cohort
223513359|NCT03015948|DRUG|Placebo|a single dose of placebo (n=2) for each dose cohort .
223513360|NCT01449994|DEVICE|Activator IV (Activator Methods Int. Phoenix, Arizona)|Instruments gives a defined impulse on specified areas of the body
223513361|NCT02202265|DIETARY_SUPPLEMENT|Olive oil|30ml a day of olive oil
223513362|NCT02202265|DIETARY_SUPPLEMENT|Nuts|30g a day of nuts
223513363|NCT02202265|DIETARY_SUPPLEMENT|Control diet|Diet based on standard guidelines
223513364|NCT00001789|DRUG|BG9588|
223513365|NCT01744366|DRUG|Degarelix|
223513366|NCT01744366|DRUG|Goserelin|
223513367|NCT01395602|DRUG|Cabergoline|cabergoline 0.5 mg twice weekly
223513368|NCT01395602|OTHER|placebo|1 pill twice weekly
223513369|NCT02376855|OTHER|eConsult|"An electronic consultation or eConsult is a secure message consult that allows specialists to provide advice on cases without seeing a patient face to face. They contain a reason for consult, any relevant tests, procedures or reports. The responsibility lies with the primary care provider to act, or not act on the advice as they deem fit."
223513370|NCT00165308|DRUG|Tamoxifen|Given orally, daily for one year.
223513371|NCT05527314|DRUG|Remimazolam|Anesthesia was induced with Remimazolam 0.4-0.8 mg/kg (about 1 minute) by intravenous injection until the loss of consciousness (LoC), followed by remimazolam 1-2 mg/kg/h until the end of surgery.
223513372|NCT05527314|DRUG|Sevoflurane|Anesthesia was induced with 8 % Sevoflorane by sevoflurane volatilization tank until the loss of consciousness (LoC), followed by 2 %-3 % Sevoflorane until the end of surgery.
223513373|NCT05527314|DRUG|Fentanyl|Anesthesia was induced with fentanyl 3-4 ug/kg by intravenous injection after the LoC.
223513374|NCT05527314|DRUG|Cisatracurium Besylate|Anesthesia was induced with cisatracurium besilate 0.1 mg/kg by intravenous injection after the LoC. And the cisatracurium besilate 0.02 mg/kg is allowed to add as appropriate during the operation.
223513375|NCT05527314|DRUG|Remifentanil|After the LoC, remifentanil 0.1\~0.3 ug/kg/min inject intravenously until the end of surgery.
223513376|NCT05624957|DRUG|Lidocaine epinephrine|Under aseptic condition every one litre of fluid irrigation will be mixture with 10 ml of lidocaine 2% and 0.25mg epinephrine and the last one use before end of surgery dexamethasone 8 mg will be added.
223513377|NCT05624957|DRUG|Epinephrin|0.25 mg epinephrine mixed with one litre of fluid irrigation
223513378|NCT00000726|DRUG|Foscarnet sodium|
223513379|NCT02267525|DRUG|Velusetrag|
223513380|NCT02267525|DRUG|Placebo|
223513381|NCT01729429|BEHAVIORAL|HPV brochure, recall, reminders|"* HPV-vaccine specific brochure mailed before clinic visit~* Telephone recalls after visit for those who complete pre-clinic survey and decline the vaccine~* Telephone reminders for those who complete the pre-clinic survey and are late for receiving the 2nd and/or 3 doses"
223513382|NCT01729429|BEHAVIORAL|General Adolescent Vaccine Brochure|Participants were mailed a brochure describing the 4 recommended adolescent vaccines (HPV, meningococcal, tetanus diptheria acellular pertussis (TDAP), and influenza) 1-2 weeks before a clinic visit
223513383|NCT02012777|DRUG|propranolol|Propranolol hydrochloride is a synthetic beta-adrenergic receptor-blocking agent. This will be administered in an open-label single administration to 3 cohorts (10mg, 20mg, and 40mg) of children with sickle cell disease. Patient blood will be evaluated for red cell adhesion and patient data evaluated for safety monitoring.
223513384|NCT01404065|PROCEDURE|Transcranial Direct Current Stimulation (tDCS)|Subjects will undergo tDCS stimulation. For both active and sham stimulation, we will use electrodes of 35cm\^2, at an intensity of 2mA. For active tDCS, the subject will undergo stimulation for 20 minutes. For sham stimulation, the current will be ramped up and then down again (for 30 seconds total) to simulate the feeling of active stimulation.
223513385|NCT04882605|GENETIC|MHC typing|Allelic genotyping resolution of MHC genes (HLA-A, -B, -C, -DRB1, -DQA1, -DQB1, -DPA1, -DPB1 and -DRB3/4/5) using Illumina technology.
223513386|NCT04882605|GENETIC|KIR typing|Allelic genotyping resolution of all 13 KIR genes (KIR2DL1, KIR2DL2/2DL3, KIR2DL4, KIR2DL5A, KIR2DL5B, KIR2DS1, KIR2DS2, KIR2DS3, KIR2DS3/2DS5, KIR2DS4, KIR3DL1/3DS1, KIR3DL2, KIR3DL3), 2 KIR pseudogenes (KIR2DP1 and -3DP1) using Illumina technology.
223513387|NCT04882605|GENETIC|Assessment of KIR-based prediction scores|Compiling donor/recipient MHC and KIR typings into 28 major KIR-based prediction scores
223513388|NCT01407133|DEVICE|transcranial magnetic stimulator (class 2b) Medtronic © MagPro X100 (with MagOption) stimulator and Butterfly Coil MCF-B65 (figure-8 coil with fluid cooling)|"The study is based on a dual procedure consisting of comparisons between active and sham rTMS on the one hand and between four increasing levels of magnetic pseudo-dose on the other hand. Each level comprises 16 patients randomly assigned to active rTMS group (12 patients) or sham rTMS group (4 patients). The transition from one level to another is authorized by an independent oversight committee charged with checking the tolerability of rTMS sessions for the tested level. The neuronavigated rTMS use either active or sham figure-eight coil and is centered over the primary auditory cortex contralateral to the perceived predominant side of tinnitus. This target is located through anatomical brain MRI and neuronavigated brain system. According to the stimulation parameters, each rTMS session can last from 5 to 112 minutes and the whole rTMS intervention from 1 to 20 weeks. The follow-up is spread over twelve months."
223513389|NCT01407133|DEVICE|Sham transcranial magnetic stimulator Medtronic © MagPro X100 (shielded figure-8 coil with fluid cooling)|Same sound level as active rTMS, but magnetic field strongly attenuated
223513390|NCT00251654|PROCEDURE|perineural block (anesthesia)|continuous peripheral regional anesthesia ropivacaine 0.33% for 3 to 5 days
223513391|NCT01832038|DRUG|Lacosamide|"Strength: Lacosamide (LCM) 50 mg, LCM 100 mg~Formulation: Tablet~Frequency: twice daily during the study period (until the date of approval)~At the completion of EP0008 \[NCT01710657\], all subjects who choose to enroll in EP0009 will be taking a dose of Lacosamide 200 mg/day. At the beginning of EP0009, the investigator may maintain the LCM dose or increase or decrease the dose. During the Treatment Period, the investigator will be allowed to increase or decrease the dose of LCM to optimize tolerability and seizure reduction. The LCM dose may be decreased to 100 mg/day or increased, no faster than 100 mg/day per week, up to 400 mg/day."
223513392|NCT04241432|DEVICE|vibrating platform|Use of two different types of vibrating platform
224211122|NCT02872155|DRUG|Saline endovenous hydratation|If there is contraindication for administration of bicarbonate the pattern of intravenous hydration is performed with saline solution: 3 ml / kg / h for 1 hour before the procedure and normal saline 1 mL / kg / hour for hour after computed tomography.
223621241|NCT02356159|OTHER|IV Saline|Before each infusion of rituximab as indicated.
223621242|NCT02356159|DIAGNOSTIC_TEST|ECG|As indicated.
223621243|NCT02356159|DIAGNOSTIC_TEST|ECHO|As indicated.
223621244|NCT02356159|DIAGNOSTIC_TEST|MUGA|As indicated.
223621245|NCT02356159|DIAGNOSTIC_TEST|DEXA|As indicated.
223621246|NCT02356159|DIAGNOSTIC_TEST|CT chest|As indicated.
223621247|NCT02356159|DIAGNOSTIC_TEST|PET|As indicated.
223621248|NCT02356159|DIAGNOSTIC_TEST|MRI|As indicated.
223621249|NCT02356159|PROCEDURE|BM aspirate|As indicated.
223621250|NCT02356159|PROCEDURE|BM biopsy|As indicated.
223621251|NCT02356159|PROCEDURE|Lumbar puncture|As indicated.
223621252|NCT06525220|DRUG|Petosemtamab|MCLA-158
223621253|NCT06525220|DRUG|Pembrolizumab|Humanized Antibody
224211123|NCT03732729|DEVICE|massage chair|Patient should use massage chair, twice per day, for 30minutes
223621255|NCT00861705|BIOLOGICAL|Bevacizumab|Given IV
223621256|NCT00861705|DRUG|Carboplatin|Given IV
223621257|NCT00861705|DRUG|Cyclophosphamide|Given IV
223621258|NCT00861705|DRUG|Doxorubicin Hydrochloride|Given IV
224211124|NCT00429468|DRUG|Vicodin® CR (extended-release hydrocodone/acetaminophen)|
224211125|NCT00829439|DRUG|Levodopa/Carbidopa (4:1)|"Dosages are based on levodopa.~Each cohort of 3 subjects will be placed on an increasing dose of levodopa (2, 5, 10, and 15 mg/kg/day) for 1 week, provided subjects in the preceding cohort tolerated the lower dose.~Levodopa/Carbidopa is a combined formulation that will be dispensed as capsules. It should be taken 3 times a day."
224211126|NCT01935531|DRUG|3% diclofenac in 2.5% hyaluronic acid gel|
223513393|NCT05281653|BEHAVIORAL|Neuromuscular exercise Training|Progressive neuromuscular exercise training
223513394|NCT05281653|BEHAVIORAL|Routine training sessions|Routine training sessions
223513395|NCT04484662|OTHER|Potted Mint Plants|We will measure 2 indoor environments (living room and bedroom) for placing potted plants.
223513396|NCT04205825|OTHER|The New Safety Checklist|Patients randomized in the New Safety Checklist intervention, nurses will use the New Safety Checklist, which we have named: INCARDIO-PASS (Interventional CARDIOlogy-Patient Safety System) checklist.
223513397|NCT04759404|OTHER|Deep Oscillation Treatment|Deep oscillation to the lumbar region and stretching and strengthening exercise for waist, back and abdominal
223513398|NCT04759404|OTHER|Myofascial Release Treatment|Myofascial release to the lumbar region and stretching and strengthening exercise for waist, back and abdominal
223513399|NCT05517785|OTHER|Motor performance tests|Performance of 5 motor tests: plank, single leg stance test, standing long jump test (broad jump), 4 x 10 agility test and 20 m shuttle run tests (beeps), after taking ADHD drug or not taking the drug before motor tests performance
223513400|NCT04501705|DRUG|Apatinib Mesylate|"Apatinib mesylate tablets: Orally, 500 mg, once a day, with warm water for half an hour after a meal (the time of taking the medicine every day should be the same as possible).~Continue to use 28 days as a cycle, medication until disease progression (PD), intolerable toxicity occurs or the patient withdraws informed consent. However, the longest period does not exceed 24 cycles, and the treatment after 24 cycles is determined by the investigator."
223513401|NCT03492294|DIAGNOSTIC_TEST|functional magnetic resonance imaging|Patients with disorders of consciousness were assessed by functional magnetic resonance imaging while they were exposed under the condition of music.
223513402|NCT02072057|DRUG|Ruxolitinib|
223513403|NCT01125644|DRUG|SPK-843|SPK-843 is a semi-synthetic substance derived from Partricin A. 05 mg/Kg solution of SPK-843 in 10% intralipid will be administered i.v. in a hour for a treatment of 14 days
223513404|NCT04985110|DRUG|Cotrimoxazole|The treatment group will receive Cotrimoxazole Forte 960 mg PO q.d. 4 hours before the biopsy procedure.
223513405|NCT04985110|DRUG|Placebo|The placebo group will receive placebo q.d. 4 hours before the biopsy procedure.
223513406|NCT03137407|BIOLOGICAL|Botulinum Toxins, Type A|Intramuscular injection
223513407|NCT03137407|BIOLOGICAL|Placebo|Intramuscular injection
223513408|NCT00998959|BEHAVIORAL|Mindfulness Based Stress Reduction and Psychoeducation|Participants will receive six individual weekly 50-minute sessions of mindfulness based stress reduction (MBSR) as well as problem solving therapy (PST. PST is a type of therapy that focuses on psychosocial problems and using your skills and resources to function better. MBSR uses exercises in mindfulness to reduce stress.
223513409|NCT00998959|BEHAVIORAL|Psychoeducation|Participants will receive six individual weekly 50-minute sessions of psychoeducation. Psychoeducation consists of education on depression, its symptoms, its treatment, and recovery.
223513410|NCT02913573|DEVICE|Ultrasound|Pectoral nerve block is a regional block administered under ultrasound guidance which blocks the nerves of the thorax and chest areas.
223513411|NCT02913573|DRUG|0.25% bupivacaine|Pectoral nerve block is a regional block administered under ultrasound guidance where 15 mL of 0.25% bupivacaine is instilled between the pectoral major and pectoral minor muscles where the lateral and medial pectoralis nerves lie. In a similar manner, 20 mL of 0.25% bupivacaine will be deposited under ultrasound-guidance at the level of the third rib above the serratus anterior muscle.
223513412|NCT02976844|PROCEDURE|Positive end-expiratory Pressure|Positive end-expiratory pressure will be used during mechanical ventilation.
223513413|NCT03629002|BIOLOGICAL|Study of the gene expression profile|qPCR analysis
223513414|NCT00555373|DRUG|Sirolimus|"1. Tacrolimus (Prograf®) At 6 months post-transplantation, patients will have Prograf® tapered by 25% per week such that they will be off of this medication by 7 months post-transplantation.~2. Sirolimus (Rapamune®):~At 6 months post-transplantation, all patients will be administered Sirolimus at a dose of 1.65-2.79 mg/m2/day as a tablet or liquid (administered q 12 hours)."
223513415|NCT01509404|DRUG|Valganciclovir|Valcyte per package insert guidelines for 200 days post transplant
223513416|NCT01509404|BIOLOGICAL|CMV hyperimmune globulin|100 mg/kg administered at 90 days, 120 days, and 180 days post-transplant
223513417|NCT01509404|DRUG|Valganciclovir|valganciclovir per package insert guidelines for prophylaxis against CMV infection for 200 days post-transplant
223513418|NCT02079285|PROCEDURE|EUS-FNA|
224211127|NCT03512626|DEVICE|OptiVis, Aaren Scientific|All the surgeries were performed under topical anesthesia using a standard phacoemulsification procedure with Infiniti Vision System (all from Alcon Laboratories, Inc, Fort Worth, TX).
223621259|NCT00861705|OTHER|Laboratory Biomarker Analysis|Correlative studies
223621260|NCT00861705|DRUG|Paclitaxel|Given IV
223621261|NCT06418152|BEHAVIORAL|Multi-modal treatment|Multi-modal treatment was designed to target PD-specific declines in the areas of cognitive function and gait and posture impairments. MMT consists of simultaneously training a motor and cognitive task.
223621262|NCT03190941|DRUG|Cyclophosphamide|Days -7 and -6: Cyclophosphamide 60 mg/kg/day x 2 days IV in 250 mL D5W infused simultaneously with mesna 15 mg/kg/day over 1 hour x 2 days.
223621263|NCT03190941|DRUG|Fludarabine|Days -7 to -3: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days.
224211128|NCT03512626|DEVICE|Monofocal IOL|All the surgeries were performed under topical anesthesia using a standard phacoemulsification procedure with Infiniti Vision System (all from Alcon Laboratories, Inc, Fort Worth, TX).
223621264|NCT03190941|BIOLOGICAL|Anti-KRAS G12V mTCR PBL|Day 0: Cells will be infused intravenously on the Patient Care Unit over 20-30 minutes (2-4 days after the last dose of fludarabine).
223621265|NCT03190941|DRUG|Aldesleukin|Aldesleukin 720,000 IU/kg IV (based on total body weight) over 15 minutes approximately every 8 hours beginning within 24 hours of cell infusion and continuing for up to 3 days (maximum 9 doses).
223621266|NCT02729519|PROCEDURE|TAVI|standard procedure TAVI performed with systematic pre dilatation (With prior balloon dilatation) (ARM A) ou without pre dilatation (ARM B)
223621267|NCT05840302|DEVICE|Activity monitor|Measure of number of steps and physical activity during one week using the activity monitor (connected watch) named the ActiGraph-wGT3X-BT medical device, Pre-test before intervention, post-test 3-months and 1-year after intervention
223621268|NCT05840302|OTHER|Questionnaire|Self and hetero assessments measuring pain, different determinants of chronic pain and physical activity
224211129|NCT04040959|DRUG|Nicotinamide riboside|Nicotinamide riboside is a naturally occurring vitamin B3 derivative found in yeast, bacteria, and mammalian tissues, and also has been detected in cows' milk.
224211130|NCT04989621|DRUG|Orelabrutinib and Rituximab|Orelabrutinib 150mg po qd d1-28; Rituximab 375mg/m2 iv.drip d1.
224211131|NCT04989621|DRUG|Orelabrutinib|Orelabrutinib 150mg po qd
223621269|NCT02455245|DRUG|Carboplatin and Vincristine|Carboplatin 175 mg/m2 IV infusion Vincristine 1.5mg/m2 IV
223621270|NCT02455245|DRUG|Carboplatin|Carboplatin 560 mg/m2 (or 19 mg/kg for children weighing less than 12 kg) IV
223621271|NCT04498221|PROCEDURE|Imaging procedure|During routine examination under anaesthetic 4 x peritumoural injection of investigator's choice of 99mTc-human albumin colloidal particles or Lymphoseek (lymphatic mapping tracer) followed by freehand SPECT scan
223621272|NCT04498221|PROCEDURE|Surgical procedure|Excision of contralateral nodes identified on imaging \*(fhSPECT or SPECT/CT\*) during routine examination under anaesthetic. Serial sectioning of excised (sentinel) nodes to identify micrometastasis.
223621273|NCT00497380|DIETARY_SUPPLEMENT|Arginine|Oral nutritional supplement
223621274|NCT06413108|DRUG|TB31F|transmission-blocking monoclonal antibody TB31F
223621275|NCT06413108|OTHER|Normal saline|normal saline as control (placebo)
223621276|NCT04765371|DRUG|DEXAMETHASONE|Patients will take 60 mg per day of Prednisolone (40 mg morning and 20 md evening) between D1 to D10
223621277|NCT04765371|DRUG|PREDNISOLONE|Patients will take 60 mg per day of Prednisolone (40 mg morning and 20 md evening) between D1 to D10
223621278|NCT06183359|OTHER|SIP|compare the SIP group versus the ACT group
223621279|NCT02839551|PROCEDURE|simplified drug provocation test|Assessment of the Hypersensitivity to betalactams by simplified drug provocation test
223621280|NCT05050643|OTHER|EBQI-IC|Individual (ongoing) consultation (IC), often described as coaching or supervision, is endorsed by implementation experts as an effective implementation strategy
223621281|NCT05050643|OTHER|EBQI-LC|A Learning Collaborative is a systematic approach to process improvement based on the Institute for Healthcare Improvement Breakthrough Series Collaborative model. During the Collaborative, organizations will test and implement system changes and measure their impact. They will share their experiences to accelerate learning and broader implementation of best practices.
223621282|NCT04643457|DRUG|UCB9741|\- Pharmaceutical form: Solution Participants will receive UCB9741 during the Treatment Period.
223621283|NCT04643457|DRUG|Intravenous Placebo|\- Pharmaceutical form: Solution Participants will receive Placebo to maintain the blinding during the Treatment Period.
223621284|NCT04643457|DRUG|Subcutaneous Placebo|Pharmaceutical form: Solution Participants will receive subcutaneous Placebo to maintain the blinding during the Treatment Period.
223621285|NCT00667628|DRUG|TAC-101|Participants received TAC-101 20 mg (2 x 10-mg formulated tablets) administered orally every day with approximately 8 oz. water within 1 hour following a morning meal for 14 days followed by a 7-day recovery period, repeated every 21 days.
223621286|NCT00667628|DRUG|Placebo|Participants received placebo (two matching tablets) at same frequency and duration of active treatment.
224211132|NCT03974581|OTHER|Primary percutaneous coronary intervention|Patient receives primary percutaneous coronary intervention as part of his treatment; decision to allocate by treating physician.
224211133|NCT03974581|OTHER|Pharmacoinvasive strategy|Patient receives primary fibrinolysis and subsequent coronary angiography (pharmacoinvasive strategy) as part of his treatment; cases with failed fibrinolysis are scheduled for immediate rescue PCI. Decision to allocate by treating physician.
224211134|NCT05377333|DRUG|LY3457263|Administered SC.
224211135|NCT05377333|DRUG|Placebo|Administered SC.
224211136|NCT05377333|DRUG|Dulaglutide|Administered SC.
224211137|NCT01148680|BIOLOGICAL|Islet Graft|Iterative injection of pancreatic islets (minimum: 250,000 IEQ / injection or 3500 IEQ / kg / injection) with a threshold required total of 11,000 IEQ / kg in 2 or 3 injections per patient)
224211138|NCT03054961|DEVICE|Near-infrared spectroscopy|Measurement of CCO redox state and cerebral oxygenation during epileptic seizures.
224211139|NCT00176852|DRUG|Busulfan, Fludarabine, ATG, TLI|Busulfan 0.8 mg/kg/dose intravenous (IV) Days -8 and -7 Fludarabine 35 mg/m2 IV Days -6 through -2 Antithymocyte globulin (ATG) 30 mg/kg IV Days -2 and -1 Total lymphoid radiation 300 cGy
224316155|NCT03731442|DRUG|Platinum|for lobaplatin, 30mg/m2, d1-2, total dose should not exceed 50mg,every 3 weeks; for nedaplatin 50mg/m2, d1-2, every 3 weeks;
224211140|NCT00176852|DRUG|Busulfan, Cyclophosphamide, ATG, GCSF|Busulfan 0.8 mg/kg/dose intravenous (IV) Days -9 through -6 Cyclophosphamide 50 mg/kg IV Days -5 through -2 ATG 30 mg/kg IV Day -1 GCSF 5 mcg/kg/day IV until ANC \>2500 x 2 days.
224211141|NCT00176852|DRUG|Campath, Fludarabine, Cyclophosphamide|Receives Campath-1H 0.2 mg/kg Days -10 through -6, Fludarabine 35 mg/m2 intravenous (IV) Days -6 through -2, total body irradiation (TBI) 300 cGy Day -1.
224211142|NCT00176852|RADIATION|Total Body Irradiation|300 cGY Day -1
224211143|NCT00176852|PROCEDURE|Stem cell infusion|Given Day 0
224211144|NCT03744988|DIAGNOSTIC_TEST|serum androgen levels|measurement of serum free and total testosterone
224211145|NCT04543305|DRUG|PRT1419|PRT1419 will be administered orally
224211146|NCT03751319|OTHER|CGA|Comprehensive Geriatric Assessment
224211147|NCT02026102|BEHAVIORAL|ICD Decision Aid Toolkit|Research assistants will provide patients with a toolkit of decision aids. Participants will have the option of using all of the decision aids or just some of the decision aids.
224211148|NCT04809038|OTHER|dry needling|Patient will be placed in a comfortable prone position and encouraged to maintain complete relaxation. The selected active MTrPs was prepared by wiping the area with alcohol pad, and a gauge needle with its plastic guide tube in place will be palced over the active MTrPs .a tapping motion will be used to advance the needle to a depth of 5 to 10 mm for 30 seconds
223621287|NCT03327974|OTHER|DEPASSE Apllication|"Application DEPASSE in depressed patients. This application was developed by the laboratory SERVIER, by a scientific committee of psychologists and psychiatrists: Pr. Courtet, Dr Rimlinger and Pr. Swendsen.~Depasse is available for all on the App store and on Googleplay.~This application has several interests:~\- The first is the daily monitoring of the symptoms allowing a regular evaluation throught smileys simulating a scale from 1 to 5. The 10 parameters evaluated are: mood, dark ideas, sleep, stress, concentration, social activities, energy, pleasure, motivation and libido.~There is the possibility to generate a graph representing the evolution of these parameters.~Tips adapted to the actual mood are provided related to the dysfunctional parameters."
223621288|NCT06580496|BEHAVIORAL|Mightier|Mightier is a pediatric at-home intervention program that includes an app-based biofeedback video game that utilizes heart rate (HR) monitoring during game play to teach and facilitate practice of emotional regulation skills in children ages 6-14. The program also uses physical materials including printed workbooks and conversation cards that focus on teaching additional Cognitive Behavioral Therapy (CBT)-based skills and concepts.
223621289|NCT03838562|OTHER|Vestibular rehabilitation with virtual reality|"Both group follow three or four weeks of vestibular rehabilitation program with 2 sessions of physical therapy per day and one collective session of balance exercices per day, five day per week. More orthoptist care and muscle strengthening.~The exercises performed include rotating exercises, static balance exercises with eyes open and closed, head fixed and with head oscillation. Exercises on unstable planes and on dynamic force platforms. Different walking and eye stabilization exercises.~Only visual misinformation is distinct in both groups. Optokinetic application with three-dimensional head-mounted is used in the experimental group."
223621290|NCT03838562|OTHER|Standard optokinetic stimulator or dynamic visual surround|"Both group follow three or four weeks of vestibular rehabilitation program with 2 sessions of physical therapy per day and one collective session of balance exercices per day, five day per week. More orthoptist care and muscle strengthening.~The exercises performed include rotating exercises, static balance exercises with eyes open and closed, head fixed and with head oscillation. Exercises on unstable planes and on dynamic force platforms. Different walking and eye stabilization exercises.~Only visual misinformation is distinct in both groups. Standard optokinetic stimulator (stimulopt) or dynamic visual surround (smart equitest) are used in the control group."
224211149|NCT04809038|OTHER|magnesium sulphate iontophoresis|The subjects in the iontophoresis group received MgSO4 iontophoresis using an iontophoretic drug delivery system (Phoresor\_IIAuto,ModelPM850,IOMED. MTrPs were examined using pincer palpation and marked by pin. MgSO4 was applied to the active positive electrode using a syringe with a concentration of 100 mg/cm2. The active electrode was placed directly over the marked area where the sensitive MTrPs were located. The dispersive electrode was applied to the skin 6 inches distal from the active electrode.
224211150|NCT04809038|OTHER|stretching exercise|The patient will be placed in a comfortable and relaxed sitting position with his back supported ; one hand was placed on the side of the head applying the stretching force, while the other hand was placed on the patients shoulder applying shoulder stablization . The direction of stretched force was in flexion , side bending to the opposite side and rotation to the same side . The stretched position will be sustained for 30 seconds , then a relaxation period of 30 seconds . This procedure was repeated 3 times .
224211151|NCT03608696|DRUG|Buprenorphine|buprenorphine 0.075 mg/ml solution
224211152|NCT02476500|PROCEDURE|LLETZ on a training model|LLETZ is performed on a sausage-based training model using all surgical devices used in the original procedure
224211153|NCT00817778|DRUG|AZD1656|Subjects will be treated with tolerable dose twice daily for another 24 days.
224211154|NCT00817778|DRUG|Placebo|Subjects will be treated with tolerable dose twice daily for another 24 days.
224211155|NCT00783978|OTHER|whole blood sample|2 ml of whole blood for children 5 ml of whole blood for parents that will be used only if 1 mutation is found in children
224211156|NCT03039582|DIAGNOSTIC_TEST|Bidigital palpation|palpation of the anovaginal distance with two fingers
224211157|NCT03039582|DIAGNOSTIC_TEST|Perineal ultrasound|ultrasound measurement of the anovaginal distance
224211158|NCT00039416|DRUG|imatinib mesylate|Given orally
224211159|NCT00039416|OTHER|laboratory biomarker analysis|Correlative studies
224211160|NCT06079086|DEVICE|Breast Implants Lifesil|The surgery is performed through an incision (4 cm) in the inframammary fold and displacement in the supra-muscular plane, creation of a pocket for the inclusion of the prosthesis, followed by strict hemostasis and washing with an antibiotic solution. Placement of the prosthesis by digital maneuver and closure in layers using absorbable synthetic 4-0 polycaprolactone suture. Afterwards, an occlusive dressing is applied to the surgical wound. IV antibiotics (cephalosporin) 1g are administered at the beginning of surgery, followed by repeat/booster doses every 6 hours in the first 24 hours. Analgesic and anti-inflammatory medications are administered, varying according to each patient's restrictions.
224211161|NCT00823459|DRUG|Everolimus|Given PO
224211162|NCT00823459|OTHER|Archival Tissue Analysis|Correlative studies
224316156|NCT03731442|DRUG|PEG-rhG-CSF|PEG-rhG-CSF 3-6mg, 48 hours after chemotherapy
223621291|NCT04079387|DEVICE|ENDOTRACHEAL TUBE + STYLET|"The experimental group consists in intubating the trachea with an endotracheal tube + stylet with a straight-to-cuff shape and a bend angle of 25° to 35°"
223621292|NCT04079387|DEVICE|ENDOTRACHEAL TUBE ALONE|intubating the trachea with an endotracheal tube alone
223761759|NCT04182035|OTHER|patient-tailored therapy|The subjects in the PTT group will receive the individual tailored treatment program combining best evidence active and passive treatment strategies (manual therapy, individual exercises) in combination with education tailored to the individual situation of the patient and selected home exercises. 9 individual therapy sessions will be performed, in combination with 9 additional home exercise sessions.. NRS and NDI-scores will be monitored before every treatment. The therapist will register when the cut-off score of 30% NDI reduction is present in order to determine the evolution in pain/disability reduction. The importance of self-efficacy will be emphasized and tailored home-exercises will be monitored and adjusted every week.
223621293|NCT02946346|OTHER|vaginal sampling|
223621294|NCT06634901|OTHER|Health Literacy Educational Session- Comparator|During the pre-to-post-test interval for the Knowledge, Attitudes, and Practices (KAP) measure, participants in this arm will take a break and have lunch.
223621295|NCT06634901|BEHAVIORAL|Health Literacy Educational Session|The Intervention is a 90 minute small group (n=6-10) session with an expert epilepsy provider reviewing fundamental information about epilepsy being a treatable neurologic condition, with topics including epidemiology, causation facts and myths, treatment and the importance of consistent medication, stigma, barriers to care and well-being. These topics will be covered in the first 45 minutes, leaving the second 45 minutes for Q\&A with the expert. This session provides the basic health information relevant to people with epilepsy, communication of which is often sacrificed in overcrowded clinics found in low resource settings.
223621296|NCT06247215|OTHER|Religious leaders|Religious leaders who have experience providing pastoral or spiritual care to Chinese Americans living in Chicago
223621297|NCT06247215|OTHER|Chinese Americans|Chinese Americans living in Chicago.
223621298|NCT06247215|OTHER|Chinese Americans with end-of-life care discussions|Chinese Americans who have experience discussing end-of-life care decisions with others.
223621299|NCT06247215|OTHER|Chinese Americans with chronic diseases|Chinese Americans who are diagnosed with cancer, hypertension, or heart disease and their family caregivers
223621300|NCT06353256|BEHAVIORAL|usual postpartum care|Usual clinical and educational postpartum care
223761760|NCT04182035|OTHER|Non-patient tailored therapy: generalized exercise program|The NPTT will receive an individual (hands-off) treatment, which includes an active neck exercise program, non-tailored education and non-tailored home exercises, according to a previously published program with good results.53 The sessions will be performed once a week under supervision (9 therapy sessions, standard exercise program) and once a week by the patient at home (9 home exercise sessions, standard exercise program).
223761761|NCT04182035|OTHER|Education|Education considering neck pain information
224211163|NCT05801354|DRUG|Turmeric Gel|Turmeric gel will be used as non-vital pulpotomy medicament compared with Formocresol (which is gold standard)
224211164|NCT05801354|DRUG|Formocresol|Formocresol will be used as non-vital pulpotomy medicament (which is gold standard)
224211165|NCT00505128|PROCEDURE|Endoscopic sphincterotomy|procedure
224211166|NCT01261416|DRUG|levetiracetam|Patients will receive levetiracetam as needed for clinical and/or electrographic seizures. Need for levetiracetam will be determined by the clinical team and will NOT determined by the study protocol.
223621301|NCT06353256|BEHAVIORAL|usual postpartum care + community health worker intervention|participants will receive routine care and also community health worker support and visits.
223621302|NCT03360682|DRUG|Lamivudine 300 MG|Lamivudine 300 MG/day (48 weeks)
223621303|NCT03360682|DRUG|Abacavir 600 MG|Abacavir 600 MG/day (48 weeks)
223621304|NCT03360682|DRUG|Dolutegravir 50 mg|Dolutegravir 50 MG/day (48 weeks)
223621305|NCT03360682|DRUG|Tenofovir Disoproxil 245Mg Tablet|Tenofovir 245 MG/day (48 weeks)
223621306|NCT03360682|DRUG|Emtricitabine 200 MG|Emtricitabine 200 MG/day (48 weeks)
223621307|NCT06275815|OTHER|Sit Together and Read (STAR)|Sit Together and Read (STAR) features an explicit, systematic sequence of 15 objectives that target four dimensions of print knowledge: print organization, print meaning, letters, and words. These objectives are explicitly targeted in the context of repeated adult-child shared reading sessions and are systematically cycled over an intervention period so the child has repeated opportunities for acquiring the targeted print objectives. STAR is a manualized 15-week intervention.
223621308|NCT06275815|BEHAVIORAL|Monetary Reward|Caregiver receives a monetary reward of $0.50 for each session logged (up to 60 sessions) and audio-recording completed (up to 15 audio recordings).
223621309|NCT06275815|BEHAVIORAL|Text Encouragement|Caregiver receives three tailored encouraging text messages specific to each week of the Sit Together and Read intervention.
223621310|NCT03774238|OTHER|FMD analysis|Blood sample and vascular exploration.
223621311|NCT05641896|DRUG|[18F]FAPI-74 PET/CT|\[18F\]FAPI-74 is a radioactive diagnostic agent indicated for use with Positron Emission Tomography (PET) imaging for the detection of Fibroblast Activation Protein (FAP) positive cancer cells and cancer-associated fibroblasts (CAF) in patients with gastrointestinal cancers.
223761762|NCT00129233|DRUG|Valsartan|valsartan 80 to 160 mg daily
223761763|NCT00129233|DRUG|Amlodipine|Amlodipine 5 to 10 mg daily.
223761764|NCT02170584|DRUG|BIBR 953 ZW IV|
223761765|NCT02170584|DRUG|BIBR 1048 MS tablet|
223761766|NCT02170584|DRUG|BIBR 1048 MS oral solution|
223761767|NCT02170584|DRUG|BIBR 953 ZW IV Placebo|
223761768|NCT06355869|OTHER|repeated 3D gait-analysis|An observational 3D gait-analysis was performed with a period of 1-14 days is foreseen between the two measurements.
224211167|NCT00566618|DRUG|Dasatinib|"Phase I: First Cohort = 100 mg PO Daily x 28 days; Next Cohort = Dose Expansion or Reduction Based on Dose Limiting Toxicity (DLT) in Initial Cohort.~Phase II: Recommended Phase II Dose (RP2D) as determined with Phase I."
224211168|NCT00566618|DRUG|Zoledronic Acid|"Phase I: First Cohort = 4 mg IV Over 15 min. every 4 Weeks; Next Cohort = Dose Expansion or Reduction Based on Dose Limiting Toxicity (DLT) in Initial Cohort.~Phase II: Recommended Phase II Dose (RP2D) as determined with Phase I."
224211169|NCT02923115|DRUG|DS-1040b|Single, continuous intravenous infusion over 12 to 24 hours (depending on cohort)
224316157|NCT04311671|DRUG|Moxidectin|2 mg tablets, encapsulated for blinding
224211170|NCT02923115|DRUG|Placebo|Single, continuous intravenous infusion of 0.9% sodium chloride over 12 to 24 hours
224211171|NCT02923115|DRUG|Enoxaparin|Subcutaneous injection 1 mg/kg twice daily
224211172|NCT06542861|OTHER|High-frequency simulation-based team training|"The intervention is a standardized high-frequency training program as described in intervention arm. It is supported by four preliminary initiatives:~1. 15 extra pediatric simulation facilitators were educated, bringing the total number up to 40.~2. A two-day pre-intervention workshop for all pediatric simulation facilitators.~3. A scenario bank containing standardized scenarios on common pediatric and neonatal emergencies was created and made accessible for simulation facilitators to support consistency in the intervention.~4. Purchase of equipment. Eight Leardal manikins. Four SimPads. Four monitors. During the intervention year, these will rotate between the pediatric departments."
223621312|NCT02867423|DEVICE|CK Boost radiation|single dose of 8 Grays is issued by the CK to the 6th week after conventional radiation
223621313|NCT06256666|DEVICE|BIS Quantitative EEG|Pain assessment will be conducted before and in the postoperative period using the objective PANAID scale and, when possible, the NRS. Simultaneously, EEG recordings using the BIS (Bispectral Index) will be performed. Cognitive status will be assessed before surgery using the Pfeiffer scale
223621314|NCT06016686|OTHER|VNS stimulation and intraneural recordings|A minimum of three stimulation frequencies (1, 10 and 30 Hz), each up to 60s in duration, will be delivered via the VNS device. Intraneural recordings proximal or distal to the VNS electrodes during delivery of VNS will be performed. Approximately two to five fascicles will be explored in each nerve.
223621315|NCT06016686|OTHER|Record multi-unit activity from intraneural sites|Perform a more detailed vagal nerve mapping study by recording from single nerve fibers, including those fibers supplying the heart, lungs, airways and other end-organs. The investigators shall perform functional mapping of the left and right vagus nerves, such as those with cardiac-related and/or respiratory-related neural activity. The research team will also record activity from other nearby fibers to map the differences in neurological behavior in fascicles that control the heart, lungs, airways and other systems.
223621316|NCT02879604|OTHER|Compensatory cognitive training|In addition to the usual care, method of compensatory cognitive remediation
223621317|NCT02879604|OTHER|Usual|Usual care
223621318|NCT05256901|DRUG|Sugammadex|Participants will receive 4mg/kg for a TOF 0-1 and 2mg/kg for a train of four (TOF) 2 or more.
223621319|NCT05256901|DRUG|Neostigmine/Glycopyrrolate|Participants will receive 0.07mg/kg of Neostigmine and 0.01mg/kg of Glycopyrrolate, administered by anesthesia once at least two twitches are present.
223621320|NCT02908425|OTHER|Statin user|Subjects will be studied on 2 occasions with both being identical. One will be after 7 days or more of cholesterol lowering statin administration and the other occasion will be after at least 4 weeks of cholesterol lowering statin discontinuation. All study visits include (but are not limited to) blood draws, urine collection, and stable isotope infusions.
223621321|NCT06461897|DRUG|Upadacitinib|Oral Tablet or Oral Solution
223621322|NCT06461897|DRUG|Dupilumab|Subcutaneous Injection
223621323|NCT00781612|DRUG|Docetaxel|Docetaxel will be administered as per local prescribing information.
223621324|NCT00781612|DRUG|Paclitaxel|Paclitaxel will be administered as per local prescribing information.
223621325|NCT00781612|DRUG|Pertuzumab|Pertuzumab will be administered intravenously at a dose of 420 milligrams (mg) no more frequently than every 3 weeks (Q3W) (or as directed in the parent study protocol if less than Q3W).
224211173|NCT00520494|DRUG|Vivaglobin|Human normal immunoglobulin G (IgG) for subcutaneous (SC) use.
223621326|NCT00781612|DRUG|Trastuzumab|Trastuzumab will be administered as per local prescribing information.
223621327|NCT00781612|DRUG|Trastuzumab Emtansine|Trastuzumab emtansine will be administered as intravenous (IV) infusion. Participants on weekly dosing schedule of trastuzumab emtansine in parent study, may switch to Q3W schedule as per the clinical judgment of the investigator. The starting dose of Q3W schedule must not exceed 3.6 milligrams per kilograms (mg/kg).
223621328|NCT00781612|DRUG|Atezolizumab|Atezolizumab will be administered at a dose of 1200 mg by IV infusion every three weeks (Q3W)
223621329|NCT02674347|DRUG|3 g or 6 g Zidebactam|IV for over a duration of 60 minutes
223621330|NCT02674347|DRUG|Placebo|IV matching the Investigational drug
223621331|NCT02982902|BIOLOGICAL|CMV specific adoptive t-cells|It is expected that the cell dose will be in the range of 10\^3 - 10\^5 virus - specific, antigen selected T cells per kg of recipient weight.
223621332|NCT03121508|BEHAVIORAL|Taking on Diabetes to Advance You (TODAY) Project|This is an individualized educational intervention with activity components designed to assist in modifying habits, roles, and routines to promote healthy lifestyle patterns for individuals with type 2 diabetes.
223621333|NCT06229691|BEHAVIORAL|30 minute treadmill walk|"Participants will walk on a treadmill at their preferred speed for 30 minutes. One minute challenge periods will occur at minutes 7, 17, and 27, when the treadmill speed will increase by 50%. This walk will induce a magnitude of muscle fatigue corresponding to an individual participant's fatigability."
223621334|NCT01962441|DRUG|SOF|400 mg tablet administered orally once daily
223621335|NCT01962441|DRUG|RBV|Tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
223621336|NCT01962441|DRUG|Peg-IFN|180 µg administered via subcutaneous injection once weekly
223621337|NCT04960969|OTHER|Time-restricted feeding for 4 weeks|Participants in this group will follow a time-restricted diet for 28 days. Consumption of only non-energy drinks will be allowed for 16 hours. During the 8-hour eating period, there will be no restriction on the content of the diets.
224211174|NCT01257529|DRUG|Pregabalin controlled release, 330 mg, low-fat|A single oral dose of 330 mg controlled release tablet administered following a low-fat evening meal
224211175|NCT01257529|DRUG|Pregabalin controlled release, 330 mg, medium-fat|A single oral dose of 330 mg controlled release tablet administered following a medium-fat evening meal
224211176|NCT01257529|DRUG|Pregabalin controlled release, 330 mg, high-fat|A single oral dose of 330 mg controlled release tablet administered following a high-fat evening meal
224211177|NCT01257529|DRUG|Pregabalin immediate release, 300 mg|A single oral dose of 300 mg immediate release capsule administered following a medium-fat evening meal
224211178|NCT01307631|DRUG|Akt Inhibitor MK2206|Given PO
224211179|NCT01307631|OTHER|Laboratory Biomarker Analysis|Correlative studies
224211180|NCT05218031|BEHAVIORAL|Acceptance and Commitment Therapy|A 90-120 minute 5-week group intervention for unaccompanied minors. Each week there will be a different focus. Week 1: Grounding, Week 2: Unhooking, Week 3: Values, Week 4: Self-compassion, Week 5: Making room for unwanted thoughts and feelings.
224211181|NCT05182931|DRUG|Dabrafenib 75 MG|Refer arm description
224211182|NCT05182931|DRUG|Trametinib 2 MG|Refer arm description
224211183|NCT03471182|BEHAVIORAL|Psychiatric and Cognitive Testing|Interviews, questionnaires, and computer testing.
224211184|NCT03471182|DRUG|Cocaine Self-adminstration|The intervention will include a training and safety session that consists of physician/nurse-administered cocaine followed by a self-regulated cocaine administration period under carefully controlled and closely monitored conditions.
224211185|NCT03471182|RADIATION|Positron Emission Tomography|PET scans will be performed on a High Resolution Research Tomograph (HRRT), the highest resolution human brain scanner available. Antecubital venous catheters will be used for IV administration of the radiotracer and for venous blood sampling. A radial artery catheter may also be inserted by an experienced physician before the PET scan. At the beginning of each scan, the participants's head will be immobilized and a 6-minute transmission scan, using an orbiting 137Cs point-source, is obtained and used for attenuation correction. PET scans will be acquired using bolus or bolus plus constant infusion administration of \[18F\]FPEB.
224211186|NCT03471182|OTHER|Magnetic Resonance Imaging|Structural and functional MRI data will be acquired using a Siemens Trio TIM 3.0T system at the Yale Magnetic Resonance Research Center. High-resolution structural MRI data will be acquired to facilitate analysis of PET data and may be used in additional analysis of tissue volume and brain structure. Resting-state and task-based functional MRI data will be acquired using state-of-the-art multiband echo-planar imaging (EPI) gradient-echo sequences. Diffusion-weighted MRI data will also be acquired using multiband imaging sequences to investigate anatomical connectivity.
224211187|NCT04167280|DRUG|Ipratropium Metered Dose Inhaler|MDI to deliver 20mcg per puff ipratropium bromide
223621338|NCT02147743|BEHAVIORAL|CCP+MDFT|Multidimensional Family Therapy (MDFT; Liddle, 2002) is one of a new generation of multi-systems oriented family-based intervention for adolescent substance abuse and delinquency. It has demonstrated considerable success with juvenile justice youth at various stages of their involvement in the justice system. The model has demonstrated efficacy in reducing substance use and delinquency, increasing the prosocial behaviors (e.g., family functioning, school outcomes) of substance abusing and court involved adolescents.
223621339|NCT02147743|BEHAVIORAL|CCP+SAU|Services As Usual community partners will provide individualized mental health counseling and psychiatric services, psychoeducational groups and substance abuse counseling.
223621340|NCT06356402|BEHAVIORAL|Oral Health Educational Module for Mothers (OHEM) lecture|OHEM via lecture will be delivered to the mothers by an oral health professional who will be instructed to teach their children.
223621341|NCT06356402|BEHAVIORAL|Oral Health Educational Module for Mothers (OHEM) exhibition|OHEM via exhibition will be delivered to the mothers who will be instructed to teach their children.
223621342|NCT06356402|BEHAVIORAL|Oral Health Educational Module for Mothers (OHEM) demonstration|OHEM via demonstration will be delivered to the mothers by an oral health professional who will be instructed to teach their children.
223621343|NCT01441843|DRUG|Lorazepam|Once 1mg \<75kg body weight, 1.5mg 75kg and \>75kg body weight, IV, before surgery
224211188|NCT04167280|DRUG|placebo metered dose inhaler|matched MDI to deliver inactive drug
224211189|NCT00161330|DRUG|oral amoxicilline/clavulanic acid|
223621344|NCT01441843|DRUG|NaCl 0.9% (Sodium Chloride)|Once 1ml \<75kg body weight, 1.5ml 75kg or \>75kg body weight, IV, before surgery
223621345|NCT02750189|OTHER|Direct cost|Money spent to treat COPD in medical institute based on HIRA
223621346|NCT02750189|OTHER|Indirect cost|extra-expanses excluding hospital fees
223621347|NCT00325715|DRUG|AGN 201904|
223621348|NCT00325715|DRUG|esomeprazole|
223621349|NCT02383875|BEHAVIORAL|Opticourses|An intervention session consisted of five two-hour educative workshops which aimed to help people to improve the nutritional quality of food purchases under budgetary constraints.
223621350|NCT03003052|PROCEDURE|Dental implants|Data collection from pre-implant assessment, implant surgery, and hygiene recall appointments, to assess implant survival and success.
223621351|NCT00466232|DRUG|Topotecan|4 mg/m2 IV on day 1, 8, 15. Repeat every 28 days.
223621352|NCT00466232|DRUG|Sorafenib|Dose escalation study at 3 dose levels: 200 mg po daily, 200 mg po bid, 400 mg po bid.
224211190|NCT00161330|DRUG|iv ceftriaxone|
224211191|NCT00068406|RADIATION|3-Dimensional Conformal Radiation Therapy|
224211192|NCT00068406|DRUG|Cisplatin|Given IV
223621353|NCT06149494|DRUG|Vapendavir|Participants randomized to the experimental cohort will be administered Vapendavir.
223621354|NCT06149494|DRUG|Placebo|Participants randomized to the placebo cohort will be administered placebo.
223621355|NCT03700801|DRUG|Triple combination therapy group|Triple oral hypoglycemic therapy based on metformin, dapagliflozin plus saxagliptin.
223621356|NCT03700801|DRUG|Premixed insulin therapy group|Subcutaneous injection therapy with insulin aspart 30 in patients with T2DM
223621357|NCT01028105|OTHER|Preoperative MRSA screening|MRSA preoperative screening and post operative infection rate, 30 days post operative
223621358|NCT03544905|DRUG|CYH33 for tablet|1mg; 5mg; 10mg; 20mg; 30mg; 50mg; 75mg; 100mg; 130mg; 160mg; 200mg; 240mgBID or QD(Decided by SMC accroding to the safty and PK data)
223621359|NCT00956735|OTHER|Pistachio|3.0 oz (2 servings) of roasted and salted or unsalted pistachios
223621360|NCT03972865|OTHER|EmbrunMan race|The EmbrunMan is a long-duration triathlon including 3.8 km of swimming, 188 km of cycling and 42.2 km of running, with a cumulative vertical drop of 4000 metres. Duration of the race varies between 10 hours and 16hours depending on the athletes' performance.
223621361|NCT01402401|DRUG|AUY922|
223621362|NCT01402401|DRUG|Trastuzumab|
223621363|NCT03016572|BEHAVIORAL|Standard of Care|Follow-Up Calls, Questionnaires
223621364|NCT03016572|BEHAVIORAL|Crisis Intervention|Frontline Services will be administering follow up phone calls for participants of the study, recently discharged from the emergency room.
223621365|NCT03016572|BEHAVIORAL|Wraparound Services|Tapestry will be assigning case management services for participants randomized into the third arm of the study.
224211193|NCT00068406|PROCEDURE|Conventional Surgery|
223621366|NCT04918186|DRUG|Durvalumab|1500mg IV, 60 min day 1 every 4 weeks
223621367|NCT04918186|DRUG|BA3011|IV
223621368|NCT04918186|DRUG|BA3021|IV
223621369|NCT04918186|DRUG|ENB003|IV
223621370|NCT04918186|DRUG|Toripalimab|IV
223621371|NCT04522453|OTHER|paper-based version of mental health Gap Action Program-Intervention Guide|A paper-based guide for diagnosis and management of mental disorders in primary care.
223621372|NCT04522453|OTHER|digital version of the mental health Gap Action Program-Intervention Guide|A digital guide and client data entry tool for diagnosis and management of mental disorders in primary care.
223621373|NCT01361022|DRUG|Lendormin tablet|Lendormin tablet 250mc is administrated and compared
223621374|NCT01361022|DRUG|Brotizolam tablet|Brotizolam tablet 250mc is administrated and compared
224211194|NCT02656615|DRUG|abiraterone acetate|Abiraterone acetate 1000 mg once daily and Prednisone 2x5 mg daily (continuously as per prescription label).
224211195|NCT05251415|BIOLOGICAL|Blood sampling|Blood will be taken in larger quantity.
224211196|NCT06102837|BIOLOGICAL|tumor vaccine|tumor vaccine produced by our team
224211197|NCT06102837|RADIATION|Radiotherapy|conventional treatment in clincial
223621375|NCT05218369|DRUG|IL6 Antagonist|Patients will receive IL-6 antagonist therapy at the consultant's discretion.
223621376|NCT06209619|PROCEDURE|Biopsy|Undergo biopsy
223621377|NCT06209619|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223621378|NCT06209619|PROCEDURE|Computed Tomography|Undergo PET/CT
224211198|NCT06102837|DRUG|Chemotherapy|conventional treatment in clinical
224211199|NCT06102837|PROCEDURE|Surgery|conventional treatment in clinical
224211200|NCT02052037|DIETARY_SUPPLEMENT|Egg inclusion|Participants will meet with a registered dietitian and receive instructions for including 2 eggs per day (10 to 14 eggs/week)in their meal plan, while preserving an isocaloric condition relative to the egg exclusion phase. The study dietitian will provide individualized guidance to participants on how to make room for eggs in their diet, while giving them latitude in determining how to adjust for the extra calories from the eggs, to better approximate real-world conditions. Treatment phase will last for 12 weeks.
223621379|NCT06209619|DRUG|Golcadomide|Given PO
223621380|NCT06209619|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
223621381|NCT06209619|BIOLOGICAL|Rituximab|Given IV
223621382|NCT01792310|DRUG|LAM561|"Patients will receive treatment cycles of 21 days, until any criterion for discontinuation (clinical or radiological progression of disease, clinically unacceptable toxicity, or another general discontinuation criterion) is met.~Patients are expected to receive between one and 6 cycles of treatment. The treatment period may be extended if clinical benefit is shown.~In the event of significant GI toxicity, the treatment schedule may be modified from continuous dosing to an intermittent regime In the case of toxicity, the dose of LAM561 may be reduced or delayed by up to 14 days at the discretion of the Investigator. A maximum of two dose reductions will be permitted per patient. Treatment holidays of no more than 14 days are also permitted for reasons other than toxicity. Intra-patient dose escalation may be permitted in certain specific circumstances."
223621383|NCT05976516|DIAGNOSTIC_TEST|CXCL2/CXCL8|Detecte CXCL2/8 content in nucleus pulposus and peripheral blood of patients in each group
223621384|NCT03153774|DIAGNOSTIC_TEST|Assessment of sarcopenia prevalence|Handgrip test, Bioimpedance analysis (Bodystat), 6-min walking test, Short physical performance battery (balance test, 4-min walking test, 5 times getting-up test), Biological markers test, Trans-thoracic echography, Electrocardiogram 12 leads, Palm gripping test
223621385|NCT00354016|BIOLOGICAL|preservative free inactivated split influenza vaccine using the strain composition 2006/2007|
223621386|NCT05425602|DRUG|MAX-40279-01: 50mg/70mg|\[Stage 1\]The starting dose of MAX-40279 was 35 mg BID, and three dose levels were initially set: 35 mg, 50 mg, and 70 mg administered twice daily (BID) continuously, and the dose of KN046 was 5 mg/kg as a fixed dose administered every 3 weeks. \[Stage 2\]When the RP2D dose is obtained in the dose-finding phase, the trial will enter the dose expansion phase.
223621387|NCT04504422|DEVICE|transcranial Direct Current Stimulation (tDCS)|tDCS was applied for 20 minutes through two saline-soaked sponge electrodes (diameter 6cm) using the YMS-201B (Ybrain Inc, South Korea).
223621388|NCT05308875|BIOLOGICAL|PD1-BCMA-CART|Single infusion of PD1-BCMA-CART administered intravenously (i.v.)
223621389|NCT05671835|DRUG|TTI-101|Orally via a tablet.
223621390|NCT05671835|DRUG|Placebo|Orally via a tablet.
223621391|NCT02928068|BEHAVIORAL|Occupational Performance Coaching (OPC)|OPC focuses on increasing positive child-caregiver interactions and child learning opportunities in everyday routines and contexts, which positions families for improved trajectories over time. OPC capitalizes on families' strengths, while supporting caregivers in using their own resources and ideas to advance child function. Caregivers identify goals, while therapists ask reflective questions and make reflective comments, affording caregivers an opportunity to gain a deeper understanding of their own current knowledge and the impact of their strategies on their children's adaptive behavior. Thus, families generate their own solutions and are ultimately responsible for carrying out the intervention and evaluating its effectiveness.
223621392|NCT03961334|DRUG|Dabigatran|150mg 2x/d
223621393|NCT03961334|DRUG|Apixaban|5mg 2x/d
223621394|NCT03961334|DRUG|Edoxaban|60mg 1x/d
223621395|NCT03961334|DRUG|Aspirin|100mg 1x/d
223621396|NCT03961334|DRUG|Clopidogrel|75mg 1x/d
223621397|NCT03668795|PROCEDURE|Bakrey balloon insertion within the uterus and caesarean hysterectomy|Creating an intrauterine tamponade to stop the uterine bleeding by inflating an intrauterine balloon with 600 cc of saline versus undergoing hysterectomy if conservative management failed
223621398|NCT04785222|DRUG|dexmedetomidine 5 mcg mixed with 0.5% plain bupivacaine|Bilateral infraorbital nerve block with dexmedetomidine 5 mcg mixed with 0.5% plain bupivacaine, in total volume of 2 ml per side
224211201|NCT02052037|DIETARY_SUPPLEMENT|Egg exclusion|"Participants will meet with the dietitian and receive relevant meal planning guidance and instructions to avoid eggs and specific egg-containing products.~During both intervention phases, study participants will be advised to eat to their usual state of fullness, and dietary monitoring and weighing will be conducted to ensure that an isocaloric condition is maintained. Treatment phase will last for 12 weeks."
224211202|NCT03860571|DRUG|Placebo|Oral tablet
224211203|NCT03860571|DRUG|BT-11|Oral tablet
224211204|NCT02212561|DRUG|Selinexor|Given orally on days 1,3,8,10,22 and 24 of each cycle
224211205|NCT02212561|DRUG|Fludarabine|Will be given intravenously (IV) over 30 minutes daily on days 16 through 20. Fludarabine may be given prior to day 16 if it is determined to be in the participant's best interest based on disease progression. Chemotherapy may be delayed by 1-3 days if clinically indicated.
224211206|NCT02212561|DRUG|Cytarabine|Will be given IV over 4 hours daily on days 16 through 20. Cytarabine may be given prior to day 16 if it is determined to be in the participant's best interest based on disease progression. Chemotherapy may be delayed by 1-3 days if clinically indicated.
224211207|NCT02212561|DRUG|methotrexate/hydrocortisone/cytarabine|Intrathecal (IT) triples will be given prior to cycle 1: IT cytarabine, IT methotrexate, and IT methotrexate/hydrocortisone/cytarabine (MHA) are acceptable. Patients without evidence of central nervous system (CNS) leukemia will receive no further IT therapy during cycle 1. Patients with CNS disease will receive weekly ITMHA until the cerebrospinal fluid becomes free of leukemia (minimum of 4 doses).
224211208|NCT01098383|DRUG|Acetyl-Choline Esterase Inhibitors and Choline supplements|"Donepezil will be used at initial dose of 2.5 mg/day (during the first two weeks), and an increased dose of 5 mg/day (from the 3rd week and on), according to the treatment protocol listed below. The tablets will be taken during breakfast.~AChE inhibitors are considered as potent agents for clinical use in Alzheimer's and Parkinson's dementias (Wevers \& Schroder, 1999) and treatment with these agents was proven to be well-tolerated, safe and effective in these populations. Cholinergic side effects are generally transient, mild and dose-related, and primarily include diarrhea, nausea, and vomiting.~Choline tablets will be taken at daily doses of 250 mg (in children with up to 40 kg body weight) and 500 mg (in children with more than 40 kg body weight), based on half of the adult daily dose."
224211209|NCT01098383|DRUG|Indistinguishable placebo tablets, matching both donepezil and choline|Indistinguishable placebo tablets, matching both donepezil and choline, will be given in the same amounts and schedules
224211210|NCT05525637|DRUG|YZJ-1139 20mg|YZJ-1139 20mg tablets, once daily in the evening
224211211|NCT05525637|DRUG|YZJ-1139 40mg|YZJ-1139 40mg tablets, once daily in the evening
224211212|NCT05525637|DRUG|Placebo|Match placebo tablets, once daily in the evening
224211213|NCT06330077|DRUG|Ifenprodil|Treatment administration
224211214|NCT06330077|DRUG|Placebo|Treatment administration
224211215|NCT03451331|DRUG|Nivolumab|Nivolumab 360mg (and/or) Maintenance Single Agent Nivolumab 480mg (starting \~ 2-4 weeks after completing combination chemotherapy plus nivolumab)
223621399|NCT01140308|DRUG|CoEnzyme Q10|Randomization to Treatment: Simvastatin 20mg + 600 mg CoQ10 (pill) Load Subjects for 2 weeks on Treatment (CoQ10) Eight weeks of Treatment
223621400|NCT01140308|DRUG|Placebo|Randomization to Treatment: Simvastatin 20mg + Placebo 600mg Load Subjects for 2 weeks on Treatment Eight weeks of treatment
223621401|NCT05868603|OTHER|Remineralization gel|Remineralization gel
223621402|NCT02262585|DRUG|BIBR 277 tablet|
223621403|NCT02262585|DRUG|BIBR 277 capsule|
224211216|NCT03451331|DRUG|Gemcitabine|1000 mg/m\^2
224211217|NCT03451331|DRUG|Carboplatin|AUC 4.5 (based on the Calvert formula)
224211218|NCT03451331|DRUG|Oxaliplatin|130 mg/m\^2
224211219|NCT04405674|DRUG|Tislelizumab|Tislelizumab 200mg administered intravenously (IV) on Day 1 of each 21-day cycle
224211220|NCT04405674|DRUG|Carboplatin|Carboplatin AUC 5 administered intravenously (IV) on Day 1 of each 21-day cycle, 4 cycles
224211221|NCT04405674|DRUG|Pemetrexed|Pemetrexed 500mg/m2 administered intravenously (IV) on Day 1 of each 21-day cycle
224211222|NCT04405674|DRUG|Bevacizumab|Bevacizumab 7.5mg/kg administered intravenously (IV) on Day 1 of each 21-day cycle
223621404|NCT00655265|DRUG|Colesevelam hydrochloride film-coated tablets|tablets
224211223|NCT04405674|DRUG|Nab paclitaxel|Nab-paclitaxel 260mg/m2 administered intravenously (IV) on Day 1 of each 21-day cycle, 4 cycles
224211224|NCT01491282|OTHER|Enabling and disabling VNS|No intervention
224211225|NCT02719782|BIOLOGICAL|Biological: TCR-T|Autologous T cells transfected with mRNA encoding HBV antigen-specific TCR
224211226|NCT01875991|DRUG|Etanercept via Autoinjector A|Autoinjector A is a hand-held, reusable, electromechanical device used with a single-use disposable cassette preassembled with an etanercept 50-mg prefilled syringe.
224211227|NCT01875991|DRUG|Etanercept via Autoinjector B|Autoinjector B is a single-use, spring-loaded, self-contained autoinjector preassembled with an etanercept 50-mg prefilled syringe.
224211228|NCT05585268|OTHER|Medication reconciliation supplemented with MedSafer and deprescribing brochures|This unit will act as an intervention unit for the MedRec where MedSafer deprescribing reports will be handed to the treating team and deprescribing brochures from the Canadian Deprescribing Network will be given to patients.
224211229|NCT02873481|BEHAVIORAL|Centering Pregnancy Care plus Yoga (CPC+Y)|Gentle prenatal yoga for 30 minutes at the end of the Centering Pregnancy Care session
224211230|NCT02552381|OTHER|Fibrin Structure|Modifications of Fibrin Structure in patients who have developed VTE in comparison with patients without VTE.
224211231|NCT05998733|DIAGNOSTIC_TEST|Early general coagulation function (5 items of coagulation) and thromboelastogram monitoring|"* Correlation analysis of sepsis severity with FDP and D-Dimer~* Discussion on the critical value and area under the curve of FDP and D-Dimer in diagnosis of sepsis~* Differences in age and sex of FDP and D-Dimer in diagnosis of sepsis~* Effect of FDP and D-Dimer diagnosis of sepsis on severe conversion rate and all-cause mortality of patients~* The difference of thromboelastogram in patients with sepsis of different severity~* Thromboelastogram items (R time α Correlation between angle, k time, maximum blood clot strength and comprehensive coagulation index) and sepsis"
224211232|NCT06059742|OTHER|Action Observation Therapy with Rhythmic acoustic stimulation|Action observation therapy is observing some action and the performing Rhythmic acoustic stimulation is performing movement on the rhythm of beats
224316158|NCT04311671|DRUG|Ivermectin|3 mg tablets, encapsulated for blinding
223621405|NCT00655265|DRUG|Placebo|Tablets
223621406|NCT01893996|DRUG|Adalimumab|Patients will be randomized 1:1 to receive either adalimumab or placebo for the first 26 weeks of the trial, and then after a 26 week washout period, will be crossed over into the other arm (either placebo or adalimumab) for weeks 52-78.
223621407|NCT01893996|DRUG|Placebo|
223621408|NCT04892641|DRUG|Epetraborole|Epetraborole hydrochloride 250 mg tablets for oral administration
223621409|NCT04892641|DRUG|Placebo|Matching placebo for 250 mg epetraborole hydrochloride tablets for oral administration
224211233|NCT06059742|OTHER|Action Observation Therapy without Rhythmic acoustic stimulation|Action observation therapy is observing some action and the performing Rhythmic acoustic stimulation is performing movement on the rhythm of beats
224211234|NCT03817632|DEVICE|Computer assisted primary total knee replacement with OrthoPilot FS101 navigation system and Software 5.1|Computer Assisted Total Knee Replacement with the OrthoPilot FS101 and the software TKA 5.1
224211235|NCT03817632|DEVICE|Computer assisted primary total knee replacement with OrthoPilot Elite navigation system and Software 6.0|Computer Assisted Total Knee Replacement with the with the OrthoPilot Elite and the software TKA 6.0
224211236|NCT01785875|DRUG|Etelcalcetide|Administered by bolus injection into the venous line of the dialysis circuit at the end of hemodialysis treatment, and prior to or during rinse-back with each hemodialysis session (ie, 3 times per week).
224211237|NCT03112993|DRUG|sugammadex|once at the end of the surgery
224211238|NCT03112993|DRUG|Neostigmine|once at the end of the surgery
223621410|NCT06643611|BEHAVIORAL|Continuous Glucose Monitor|Patient will be provided a continuous glucose monitor. Pharmacist will provide information regarding how to best manage type 2 diabetes.
223621411|NCT06643611|BEHAVIORAL|Usual Care|Routine physician office visits and hemoglobinA1c every 3 for those with HbA1c outside goal and every 6 months for those with HbA1c within goal. Medication regimens managed by physicians, nurse practitioners, and physician assistants. Patients are sent reminders on the phone prior to their visits or when they are due for a visit or any physical examination.
223621412|NCT03755297|OTHER|Blood sample analysis of patients treated as standard care|Blood sample to analyse percentage of blood cells (regulatory B cells et T cells)
223621413|NCT04517799|DRUG|Epidiolex|"While in the intervention arm subjects will receive EPIDIOLEX, an oral purified CBD solution developed by GW Pharmaceuticals. The formulation is a 100 mg/mL solution, which allows for easy dose titration and administration even to young children. EPIDIOLEX is naturally-derived CBD, and has been found to have a purity of over 98%. The solution includes a sweetener to make it palatable. Dosing is dependent upon each subject's weight.~The dosage will be titrated over time as follows:~Week 1: 5 mg/kg/day, divided into 2 doses Week 2: 10 mg/kg/day, divided into 2 doses Weeks 3-8: 20 mg/kg/day, divided into 2 doses If a child's weight changes by greater than 2 kg during the study, the dose will be adjusted to reflect the weight change."
223621414|NCT04517799|DRUG|placebo oral solution|"GW has developed a placebo that is identical in color and taste, and will be administered in the same volume as the CBD, so that parents and investigators should not be able to detect differences between the 2 treatments. Dosing is dependent upon each subject's weight.~The dosage will be titrated as follows:~Week 1: 5 mg/kg/day, divided into 2 doses Week 2: 10 mg/kg/day, divided into 2 doses Weeks 3-8: 20 mg/kg/day, divided into 2 doses If a child's weight changes by greater than 2 kg during the study, the dose will be adjusted to reflect the weight change."
223621415|NCT06801899|PROCEDURE|Total pancreatectomy (TP)|The investigators perform TP in patients who undergo surgical resection of a malignant tumor in the pancreatic head.
223621416|NCT06801899|PROCEDURE|Partial pancreaticoduodenectomy (PD)|The investigators perform partial PD with anastomosis of the pancreas in patients who undergo surgical resection of a malignant tumor in the pancreatic head. This is the current standard procedure.
223621417|NCT06009926|DRUG|Acetaminophen|Given PO
223621418|NCT06009926|PROCEDURE|Biospecimen Collection|Undergo blood and urine sample collection
223621419|NCT06009926|DIETARY_SUPPLEMENT|Broccoli Sprout/Broccoli Seed Extract Supplement|Given PO
223621420|NCT06009926|DRUG|Placebo Administration|Given PO
223621421|NCT06009926|OTHER|Questionnaire Administration|Ancillary studies
223621422|NCT06009926|OTHER|Training|Undergo flashover training
223621423|NCT06229353|BIOLOGICAL|Gardasil 9|Prevent HPV-associated diseases and cancers
223621424|NCT03826043|DIAGNOSTIC_TEST|Blood sample analysis|Thrombophilia, blood count and coagulation count
223621425|NCT05054790|BIOLOGICAL|"Neo-Bladder Construct"|Subjects will undergo an open full thickness bladder biopsy from which autologous urinary bladder smooth muscle and urothelial cells will be procured and expanded ex vivo. After approximately 5 - 7 weeks, expanded cells will be seeded on a biodegradable scaffold to produce the neo-bladder construct that will be surgically implanted onto an opened native bladder during an augmentation cystoplasty.
223621426|NCT04835805|DRUG|Belvarafenib|Twice daily (BID), continuous dosing
223621427|NCT04835805|DRUG|Cobimetinib|Once daily (QD) or three times weekly (TIW) for 21 days, 7 days off
223621428|NCT04835805|DRUG|Nivolumab|Once every 4 weeks (Q4W)
224211239|NCT01131728|DRUG|Naproxen Sodium & Pseudoephedrine HCl|Naproxen Sodium 220 mg and Pseudoephedrine Hydrochloride 120 mg Extended Release Tablets
224211240|NCT04363411|OTHER|finger prick screening for BBV infections and questionnaires by outreaching methodology|Screening by fingerprick for HCV Ab, HBsAg and HIV Ab and a questionnaire will be performed at sites outside of the regular treatment facilities.
224211241|NCT00417027|PROCEDURE|Programmed Intermittent Epidural Bolus (PIEB)|A commercial pump that can be programmed to administer intermittent boluses and patient controlled boluses does not exist. Two pumps were prepared for each subject with the same epidural solution. One pump was programmed to administer the programmed intermittent epidural bolus(PIEB). The second pump was programmed to administer patient controlled epidural analgesia (PCEA)with a dose of 5 mL delivered with a lockout of every 10 minutes.
224211242|NCT00707174|DRUG|Imiquimod Cream|Our current standard-of-care is to use imiquimod daily for 12 weeks followed by a staged-excision with 2mm margins per stage. These margins are justified because the standard-of care for lentigo maligna is continuing to evolve
224211243|NCT00707174|DRUG|Tazarotene Cream 0.1%|Tazarotene is a topical retinoid cream that is commonly used to treat psoriasis and acne. It is known to help keratinocyte maturation and thinning of the stratum corneum (top layer of the epidermis). The stratum corneum functions as the primary barrier to the penetration of topical medications. The penetration of topical medications can be enhanced if the stratum corneum is thinned. We believe that the treatment of lentigo maligna with imiquimod, and staged-excision, will be improved by the addition of tazarotene cream.
224211244|NCT00489931|DRUG|VRC-AVIDNA036-00-VP|
224211245|NCT01779947|DRUG|Estradiol Vaginal Tablets 10 mcg|
224211246|NCT01779947|DRUG|placebo|
224211247|NCT04342403|DIAGNOSTIC_TEST|Quality of Life|Quality of life instruments including King's Sarcoidosis Questionnaire (KSQ) and Sarcoidosis Assessment Tool (SAT)
224316159|NCT04311671|DRUG|Albendazole|400 mg tablets
223621429|NCT04459156|DIETARY_SUPPLEMENT|Fiber Inulin|Commercially available inulin is provided as powder. The following doses will be administered twice daily (with breakfast and dinner): Day 1-2: 5-g; Day 3: 7.5-g; Day 4: 10-g; Day 5: 12.5-g; Day 6-7: 15-g. All supplements are commercially available.
224211248|NCT06374121|DEVICE|PerSorb cartridge (CytoSorbents Europe GmbH, Germany)|This is a highly bio-/hemo-compatible, low-flow resistance polymer cartridge able to remove cytokines and other inflammatory mediators via adsorption.
224211249|NCT06374121|DEVICE|PerLife PerKidney|The system for ex vivo kidney reconditioning (Aferetica, Italy), which allows hypothermic oxygenated pulsatile perfusion of the organ.
224211250|NCT03143205|BEHAVIORAL|AWARENESS for Sexual Minorities|9 session, individually delivered, cognitive behavioral intervention focused on modifying sexual minority stress responses to reduce the impact of sexual minority stress experiences.
224211251|NCT03143205|BEHAVIORAL|Writing tasks|Writing sessions to explore daily activities.
224211252|NCT04400253|BEHAVIORAL|SAATH Intervention|SAATH intervention is a physical activity intervention for South Asian mothers and daughters with group exercise classes and discussion groups.
224211253|NCT00695981|PROCEDURE|Rotator cuff repair|Rotator cuff repair + physical therapy according to a standardized protocol
224211254|NCT00695981|PROCEDURE|Conservative treatment|Physiotherapy according to a standardized protocol
224211255|NCT04991311|DRUG|Glepaglutide|Glepaglutide will be delivered in a single-use autoinjector.
224211256|NCT04238494|DIAGNOSTIC_TEST|Nuclear magnetic resonance (NMR)|Muscle architecture, lipid and active tissue muscle content should be measured. Proton NMR imaging (MRI)
223761769|NCT03138668|DRUG|Ropivacaine Injection|"All 20 study participants will receive both treatment Low dose Ropivacaine and High dose Ropivacaine in form of a nerve block injection around the lateral femoral cutaneous nerve. Treatment Low dose Ropivacaine and High dose Ropivacaine will be randomized to be given in either right or left lower extremity. If the participant is randomized to receive treatment Low dose Ropivacaine in the right lower extremity, treatment High dose Ropivacaine will be given in the left lower extremity, and vice versa. Each participant will thus constitute as their own control."
223761770|NCT03138668|DRUG|Ropivacaine Injection|"All 20 study participants will receive both treatment Low dose Ropivacaine and High dose Ropivacaine in form of a nerve block injection around the lateral femoral cutaneous nerve. Treatment Low dose Ropivacaine and High dose Ropivacaine will be randomized to be given in either right or left lower extremity. If the participant is randomized to receive treatment Low dose Ropivacaine in the right lower extremity, treatment High dose Ropivacaine will be given in the left lower extremity, and vice versa. Each participant will thus constitute as their own control."
224211257|NCT00054275|DRUG|docetaxel|Docetaxel IV infusion weekly for 3 weeks with a one-week break. One cycle is 4 weeks (28 days). Patients' actual weight will be used to calculate dose.
224211258|NCT00054275|DRUG|erlotinib hydrochloride|OSI-774 will be taken 1 hour before or 2 hours after meals. Cycle 1 will be administered at dose level -1.If no grade 3 or 4 toxicity occurs during cycle 1, then the patient may proceed to be treated at dose level 0 for the remaining chemotherapy cycles.
224211259|NCT00152659|PROCEDURE|Tissue sample (procedure/screening)|Tissue sampling
223621430|NCT04459156|DIETARY_SUPPLEMENT|Placebo Maltodextrin|Commercially available maltodextrin is provided as powder. The following doses will be administered twice daily (with breakfast and dinner): Day 1-2: 5-g; Day 3: 7.5-g; Day 4: 10-g; Day 5: 12.5-g; Day 6-7: 15-g. All supplements are commercially available.
223621431|NCT04551469|BEHAVIORAL|music|Music intervention for 30 minutes
223761771|NCT02661438|DRUG|Placebo to Ciprofloxacin DPI (BAYQ3939)|Placebo to Ciprofloxacin DPI, 3 doses during test session, 1 additional dose for patients during device training
223761772|NCT05850156|PROCEDURE|basal blood collection|blood collection is performed in the context of routine care for hemoglobin analysis. An additional volume of 300µL of blood is taken for the purposes of the study
224211260|NCT03794999|DRUG|Benralizumab-exposure|Exposure is defined as any dose of benralizumab for any length of time from 8 weeks prior to Last Mentrual Period (LMP) through the end of pregnancy, as reported by the mother and validated through medical record review. The 8-week cut-off prior to LMP is based upon the terminal half-life of benralizumab of approximately 15 days (clearance of benralizumab is based on five half-lives).
224211261|NCT03794999|DRUG|Exposure to other asthma medications|Exposure to asthma medications for any number of days, at any dose, and at any time from LMP up to the date of enrollment, but no exposure to benralizumab during pregnancy or within 8 weeks prior to LMP.
224211262|NCT00129532|DRUG|1.0% C31G SAVVY vaginal gel|
224211263|NCT06348173|DRUG|Mepolizumab|Compare the response to mepolizumab and benralizumab before and after treatment
224211264|NCT03669874|DEVICE|Endoscopic fundoplication|"Endoscopic fundoplication is a less invasive alternative to the traditional surgical fundoplication.~The MUSE device is similar to an endoscope, so the whole procedure can be done by a single operator. The device is composed of a shaft with a distal rigid part which is placed in the esophagus 3 cm proximal to the esophago-gastric junction containing a cartridge holding five B-shaped titanium surgical Staples and a tip which is retroflexed and contains an ultrasonic transducer which defines the correct tissue thickness for stapling the fundus against the esophagus. The device must be extracted to be reloaded with 5 more staples at a time for creation of a 180° anterior fundoplication."
223621432|NCT03650673|DIAGNOSTIC_TEST|Identification of subgroups of patients with early AD with risk of progression|Clinical examination with questionnaires, Biological collection, Imaging (radiography, densitometry, ultrasound, and MRI)
223621433|NCT04678115|DEVICE|Magnetic Levator Prosthesis (MLP)|Neodymium magnet embedded in a glasses frame and a polymer embedded (PDMS) micro-magnet array fitted externally to the upper lid with IV 3000 securement film. The IV 3000 is FDA approved for extended wear on the skin.
224211265|NCT03545360|DEVICE|BTL-703 (Treatment group)|Treatment with BTL-703 device
224211266|NCT00561184|BIOLOGICAL|H5N1 influenza vaccine|One 0.5 ml booster injection 12 months after the second injection, of influenza vaccine containing 7.5 micrograms of H5N1 influenza antigen
224211267|NCT00561184|BIOLOGICAL|H5N1 influenza vaccine|One 0.5 ml booster injection 12 months after the second injection, of influenza vaccine containing 15.0 micrograms of H5N1 influenza antigen
224211268|NCT01676311|DRUG|Huperzine A|Huperzine A will be administered for 12 weeks as outlined in the Arm Description
224211269|NCT01676311|DRUG|Placebo|Placebo Arm (blinded randomization) for Huperzine A Intervention
223621434|NCT04678115|DEVICE|Kinesiotape Frontalis Sling (KTFS)|Kineso Tape is FDA registered as a 510K exempt class 1 device, typically used by physical and occupational therapist to support muscular healing and movement. It is sometimes used on the face in cases of facial palsy or on the eye lid to support the lid in cases of severe blepharoptosis. In such cases it may be attached near the lid margin above the lashes extending up to the forehead skin overlying the frontalis muscle. Alternatively it may be a very short piece attached only along the lid skin. The tape is easily removed.
223621435|NCT06804057|OTHER|Blood Collection|Blood will be collected for the subjects who are willing to participate in the optional biorepository
223621436|NCT03396666|OTHER|Telemouv|Telemouv telerehabilitation solution Patients will receive telerehabilitation solution during three months
223621437|NCT06565390|DEVICE|Babies in the Owlet monitor group|The Owlet group will be given an Owlet OSS 3.0 monitor to wear when sleeping. The Owlet alarms if the baby has a very low heart rate or very low oxygen levels. In addition, caregivers in the Owlet group with a smart phone and Wi-Fi access will be able to use an application to monitor the baby's vital signs and sleep state.
223621438|NCT05707962|DRUG|Magnesium sulfate|"All babies with moderate or severe Hypoxic Ischemic Encephalopathy fulfilling the inclusion criteria will be randomized to receive either the standard treatment (oxygen and fluid therapy along with anticonvulsants if required) plus 3.0 ml/kg of 10% dextrose water given over 30 minutes, three dose given 24 hours apart or to receive standard treatment PLUS three doses of Magnesium Sulphate infusion given over 30 minutes at 250 mg/kg per dose given 24 hours apart. The volume of infusion shall be adjusted with 10% dextrose water to make it~up to 3.0 ml. The resulting reconstituted solution for intravenous infusion shall be 8.3% Magnesium Sulphate delivered over 30 minutes at a rate of 0.1 ml/kg/minute i.e. 8.3 mg/kg/minute. The treatment should be started as soon after birth as possible and not later than 24 hours of life. The babies who meet the exclusion criteria will not be continued into the study."
223621439|NCT03025386|OTHER|logatoms test|A forced choice test will evaluate the discrimination of the most confusing logatoms in the cochlear implant users, and representative of the French language.
223621440|NCT03025386|OTHER|Electroencephalography|Mesure of the mismatch negativity wave
223621441|NCT00409071|DRUG|Cocculine®|12 tablets in 3 days at each of the CT courses: 2 on the day before evening of the CT courses; 2 on the morning, noon and evening of the CT courses; 2 on morning and noon of the day after the CT courses.
223621442|NCT00409071|DRUG|placebo|12 tablets in 3 days at each of the CT courses: 2 on the day before evening of the CT courses; 2 on the morning, noon and evening of the CT courses; 2 on morning and noon of the day after the CT courses.
223621443|NCT03477734|DEVICE|CS1 & heart monitor|Daily activities while wearing the investigational device as well as the control device
223621444|NCT05831098|DEVICE|Reveal TP (Syphilis) Antibody Test|All subjects tested with both investigational devices and conventional syphilis serology tests.
223621445|NCT02266316|DEVICE|Air warming mask|Mask that warms air at the mouth
223621446|NCT00690560|BIOLOGICAL|rituximab|
223621447|NCT00690560|DRUG|cyclophosphamide|
223621448|NCT00690560|DRUG|doxorubicin hydrochloride|
223621449|NCT00690560|DRUG|prednisone|
223621450|NCT00690560|DRUG|vincristine sulfate|
223621451|NCT00690560|RADIATION|yttrium Y 90 ibritumomab tiuxetan|
223621452|NCT06340958|DRUG|CLE-100|1 tablet of CLE-100 administered once daily
223621453|NCT06340958|DRUG|Placebo|1 tablet of placebo administered once daily
223621454|NCT03290846|DRUG|Secretin Human|Randomized, single-blinded secretin hydrochloride infusion.
223621455|NCT03290846|DRUG|Saline Solution|Randomized, single-blinded saline infusion.
223621456|NCT03290846|OTHER|Cold exposure|All subjects will undergo a cold exposure PET scan.
223621457|NCT04908397|DIETARY_SUPPLEMENT|L-carnitine|supplement provided twice a day for 2 weeks
223621458|NCT00713492|DRUG|Alcohol|human laboratory alcohol consumption.
223621459|NCT06049654|DEVICE|NVT ALLEGRA TAVI System TF|Transcatheter aortic valve implantation of a NVT ALLEGRA TAVI System TF in patients with severe haemodynamical valve deterioration of a biological aortic valve implanted surgically
223621460|NCT06049654|DEVICE|EDWARDS SAPIEN 3 or SAPIEN ULTRA SYSTEM|Transcatheter aortic valve implantation of an EDWARDS SAPIEN 3 SYSTEM in patients with severe haemodynamical valve deterioration of a biological aortic valve implanted surgically
224316160|NCT03000478|BEHAVIORAL|Prolonged Exposure|
224316161|NCT03000478|BEHAVIORAL|Virtual Reality Exposure Therapy|
224316162|NCT03349983|BIOLOGICAL|MVA-BN-Brachyury/ FPV-Brachyury|Two priming doses of MVA-BN-Brachyury followed by boost doses of FPV-Brachyury monthly for 6 months
223621461|NCT03650114|BIOLOGICAL|Ofatumumab|subcutaneous injection of 20 mg ofatumumab every 4 weeks
223621462|NCT03650114|BIOLOGICAL|Tetanus toxoid (TT) containing vaccine (Td, Tdap)|0.5mL Vial/Syringe Containing 5 limit of flocculation (LF) tetanus toxoid
223621463|NCT03650114|BIOLOGICAL|13-valent pneumococcal conjugate vaccine (13-PCV)|0.5mL Vial/Syringe
223621464|NCT03650114|BIOLOGICAL|23-valent pneumococcal polysaccharide vaccine (23-PPV)|0.5mL Vial/Syringe
223621465|NCT03650114|BIOLOGICAL|Seasonal Quadrivalent influenza vaccine|Seasonal 2020-2021 0.5mL Vial/Syringe (trivalent may be used where quadrivalent is not available)
223761773|NCT05850156|PROCEDURE|blood collection M6|6 months +/- 2 months after inclusion, a blood collection is performed in the context of routine care for hemoglobin analysis. An additional volume of 300µL of blood is taken for the purposes of the study
223621466|NCT03650114|BIOLOGICAL|Keyhole limpet hemocyanin (KLH) neo-antigen|1mg Vial
223621467|NCT06584513|OTHER|Specific tapering plan for sleep medication, educational and cognitive behavioural therapy elements|The intervention consists of a patient-centred intervention to help patients in deprescribing BSHs and better managing their sleep problems. The material used consists of training modules, brochures, and self-monitoring tools. There are materials for physicians and for patients.
223621468|NCT03997669|OTHER|Collection of pleural effusion|Detection of pleural effusion
223761774|NCT05850156|PROCEDURE|blood collection M12|12 months +/- 2 months after inclusion, a blood collection is performed in the context of routine care for hemoglobin analysis. An additional volume of 300µL of blood is taken for the purposes of the study
223761775|NCT03270046|PROCEDURE|Water enema|Addition of water enema in standard PEG preparation in participants scheduled for CRC screening.
223761776|NCT00859170|DEVICE|Accordion device|an antiretropulsion device
224211270|NCT05992207|OTHER|motor imaginary training|Each child shown a video of 5 minutes of illustrating normal movements while the child resting in semi#reclined sitting in quiet room in front the screen. Children then asked to close their eyes and imagine practicing the task like the illustrative video. Repetition of the exercises depend on the children ranging from 5 to 10 repetitions per exercise.
224211271|NCT05992207|OTHER|physical therapy training|facilitation of balance and protective reactions from standing position, standing on one leg, weight shifting from standing, squat to standing, strengthening exercises for trunk muscles and for upper and lower extremities musculatures, gait training activities for correction of gait pattern
223621469|NCT06451965|OTHER|Timeline Intervention|"The proposed intervention consists of six sessions. In Session One, the focus is on building rapport, assessing individual difficulties, setting client-focused goals, and introducing the timeline. Participants complete timeline examples during the session and as homework.~In Session Two, psychoeducation is provided regarding the impact of stroke, addressing changes in identity and associated feelings of grievance.~Session Three onwards introduces active change methods, encouraging reflection on complex life events. The aim is to promote resilience, meaning, self-compassion, and self-acceptance by exploring past coping strategies and finding significance in events of regret. This framework aims to enhance research on complex interventions, considering efficacy, effectiveness, theory-based approaches, and systems perspectives."
223621470|NCT03858153|BEHAVIORAL|EXCAP Exercise|12 weeks of at-home walking and resistance exercise.
223621471|NCT03858153|BEHAVIORAL|Nutrition Education|12 weeks of implementing eating tips and tracking food.
223621472|NCT06481670|OTHER|Carbohydrate drink|The \>50 g carbohydrate drink will be consumed up to 2 hours prior to surgery.
223621473|NCT06800066|BEHAVIORAL|Purchase Behavior - (Non-CBD ads)|Participants will complete 1 shopping visit and will be randomly assigned to one of 2 conditions: 1) non-CBD advertising (control condition) or 2) CBD advertising (experimental condition). Each condition will have approximately 20 advertisements. In each condition, the Participant will be asked to purchase 3 products.
223621474|NCT06800066|BEHAVIORAL|Purchase Behavior - (CBD ads)|Participants will complete 1 shopping visit and will be randomly assigned to one of 2 conditions: 1) non-CBD advertising (control condition) or 2) CBD advertising (experimental condition). Each condition will have approximately 20 advertisements. In each condition, the Participant will be asked to purchase 3 products.
223621475|NCT06058650|PROCEDURE|Biopsy of Breast|Undergo biopsy of breast
223621476|NCT06058650|OTHER|Medical Device Usage and Evaluation|Utilization of the Stereo Navigator accessory
223621477|NCT06058650|RADIATION|Scintimammography|Undergo MBI
223621478|NCT06058650|OTHER|Technetium Tc-99m Sestamibi|Given IV
223621479|NCT05851586|PROCEDURE|Supervised exercise + home exercise program|The supervised exercise + home exercise program group will receive a written home exercise program with general stretching and strengthening exercises for the neck, thoracic spine, lumbar spine, shoulder and hand/wrist. They will also be provided with two supervised exercise sessions per month delivered in a group setting in order to ensure proper performance of the home exercise programs.
223621480|NCT05851586|PROCEDURE|Home exercise program only|The home exercise program only group will receive a written home exercise program with general stretching and strengthening exercises for the neck, thoracic spine, lumbar spine, shoulder and hand/wrist, without any supervised guidance on exercise performance.
223621481|NCT03836079|DEVICE|preCARDIA system|Intermittent occlusion of the SVC
223621482|NCT01419561|DRUG|Zidovudine|Zidovudine 600 mg will be administered orally 4 times a day or i.v. at 300 mg every 6 hours for 14 days for cycle 1 and for 7 days (up to additional 7 days if ongoing symptoms) for following cycles.
223621483|NCT01419561|DRUG|Liposomal Doxorubicin|Liposomal doxorubicin (20 mg/m2) will be administered i.v. over 1 hour at day 1 of each cycle
223621484|NCT01419561|DRUG|Valganiclovir|Valganciclovir (900mg) will be administered orally twice/day or Ganciclovir (5 mg/kg) will be administered i.v. over 1 hour for 14 days for cycle 1 and for 7 days (up to additional 7 days if ongoing symptoms) for following cycles.
224211272|NCT05570058|DRUG|RXC007|RXC007 will be administered in the form of oral capsules at 3 potential dose levels: 20 mg, 50mg and 70 mg in 5 cohorts. 12 patients of cohorts 1, 2 and the Expansion cohort will receive RXC007. The Dosage regimen is BID or QD.
224211273|NCT05570058|DRUG|Placebo|The placebo will be administered in the form of oral capsules at each dose level to 4 of the 16 participants within cohorts 1, 2 and the Expansion cohort. The Dosage regimen is BID or QD
223621485|NCT01419561|DRUG|Rituximab|"Rituximab (375 mg/m2) will be admnistered i.v. at 50 mg/hr up to 100 mg/hr at day 1 of the first cycle and at 100mg/hr up to 400 mg~/hr at day 1 of following cycles."
224211274|NCT01080209|DRUG|Brimo PS DDS®|Patients who received Brimo PS DDS® intravitreal implant in a previous study.
223621486|NCT01419561|OTHER|Standard Therapies|Standard of Care drugs
223621487|NCT01419561|OTHER|Cohort 1|Participants who are infected with KSHV who meet criteria for inflammatory cytokine syndrome (KICS)
223621488|NCT06489873|DIETARY_SUPPLEMENT|Active Comparator (Lutein, zeaxanthin, and fish oil supplement (LZF)|Each participant will be assigned to t a LZF supplement daily for six months
223621489|NCT06489873|DIETARY_SUPPLEMENT|Placebo Comparator|Each participant will be assigned to take a placebo supplement daily for six months
223621490|NCT06319807|BEHAVIORAL|Digital Health Intervention|Participants will receive: 1) behavior change goals, 2) self-monitoring with tailored feedback, and 3) skills training. We will use text messaging to administer the intervention pieces. At baseline, each participant will complete a series of surveys to gain background information. Throughout the study participants will report their goal adherence in response to a text messaging prompt and immediately receive tailored feedback. Text messages will be deployed daily with 2 check in messages per week; participants will receive tailored feedback based on their response.
223761777|NCT02922452|DRUG|BMS-986141|Single dose BMS-986141 and Multiple doses of Dilitazem
223761778|NCT02922452|DRUG|Dilitazem|Single dose BMS-986141 and Multiple doses of Dilitazem
224211275|NCT01080209|OTHER|Sham|Patients who recieved sham in a previous study.
224211276|NCT02572180|BEHAVIORAL|EMG-based biofeedback training|
224211277|NCT02572180|BEHAVIORAL|NIRS-based neurofeedback training|
224211278|NCT03986645|DEVICE|MR data acquisition|MR data acquisition using CE and non-CE marked pulse sequences.
224211279|NCT03676959|DRUG|ZKAB001 5mg/kg|5mg/kg/times bi-week IV administration of ZKAB001
224211280|NCT03676959|DRUG|ZKAB001 10mg/kg|10mg/kg/times bi-week IV administration of ZKAB001
224211281|NCT03676959|DRUG|ZKAB001 15mg/kg|15mg/kg/times bi-week IV administration of ZKAB001
223621491|NCT06319807|BEHAVIORAL|Safety Control|Participants will receive: 1) behavior change goals, 2) self-monitoring with tailored feedback, and 3) skills training. We will use text messaging to administer the intervention pieces. At baseline, each participant will complete a series of surveys to gain background information. Throughout the study participants will report their goal adherence in response to a text messaging prompt and immediately receive tailored feedback. Text messages will be deployed daily with 2 check in messages per week; participants will receive tailored feedback based on their response.
223621492|NCT01259180|PROCEDURE|acupuncture treatment|twice a week, 6 weeks, 12sessions penetrating skin with stailess steel acupuncture device(diameter: 0.25-0.3mm,legth: 30-70mm) points: BL 23,BL31,BL32, BL40, BL53, GB30, SP 6 bilaterally plus Ashi. with
224211282|NCT00109629|DRUG|VRC-HIVDNA016-00-VP|
223621493|NCT01259180|PROCEDURE|Sham acupunture|twice a week, 6 weeks, 12 sessions not penetrating skin with dull acupuncture device(Park Sham device :Acuprime Co. Ltd, UK) point: 1\~2inches away from real acupuncture point
223621494|NCT06752694|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223621495|NCT06752694|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow biopsy and aspiration
224211283|NCT00109629|DRUG|VRC-HIVADV014-00|
224211284|NCT02030834|BIOLOGICAL|CART-19|Single infusion of CART-19 cells administered by i.v. injection (total dose of 1 - 5 x108 CART-19 cells, calculated as a range of 2-50% transduced cells in total cells).
224211285|NCT00561405|BEHAVIORAL|Motor Learning Walking Program|Motor Learning principles based Walking Program (MLWP) Participants practice variety of real life over ground walking related activities. Order of practice, instructions, guidance and feedback are provided in a manner that facilitates cognitive engagement of learner. Sessions 45 minutes, 3x per week over 5 weeks for a total of 15 sessions
223621496|NCT06752694|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy and aspiration
223621497|NCT06752694|PROCEDURE|Bone Marrow Transplantation|Undergo bone marrow transplant
223621498|NCT06752694|PROCEDURE|Computed Tomography|Undergo CT
224211286|NCT00561405|BEHAVIORAL|Body Weight Supported Treadmill Training|Participants practice walking on a treadmill while supported with an overhead harness system. Up to 40% body weight support. Target Treadmill speed 2.0 mph. 1 or 2 Trainers (at least one Physical Therapist plus another Physical Therapist or Physiotherapy Assistant) will help guide participants leg, foot and trunk during treatment. Aim is to practice high numbers of repetition of the normal gait cycle on treadmill. Duration of sessions - 20 minutes of treadmill training within a 45 minute session ( 4 sets of 5 minutes of training with 5 minute rests). 3 sessions per week for 5 weeks. Total of 15 sessions.
224211287|NCT01132235|BIOLOGICAL|etanercept|50mgs subcutaneous injections twice a week for 12 weeks
224211288|NCT06260384|OTHER|electrocardiogram|it is a non-invasive study to diagnose criteria of Wolf-Parkinson-Wall syndrome and detect any arrhythmias
224211289|NCT05187663|PROCEDURE|Photodynamic (PDT) group|Mucoperiostal buccal and lingual incisions were made using a surgical blade under local anaesthesia. Full-thickness mucoperiosteal flaps were elevated buccally and lingually. In the photodynamic (PDT) group, after careful removal of granulation tissue and mechanical debridement of the implant surface, decontamination of implant surfaces and peri-implant tissues was performed using the photodynamic therapy, PDT (HELBO, Photodynamic Systems GmbH, Wels, Austria). The implant surface and the surrounding tissue were exposed to the laser light by means of fibres (HELBO ® TheraLite Laser HELBO ® 2D Spot Probe; bredent medical GmbH \& Co KG) for the 30s/spot, which operates on the wavelength of 660 nm and irradiance of 100 Mw. Bone augmentation and bio-resorbable membrane were applied in peri-implant defects using the bovine bone substitute and collagen membrane (Bio -Oss and Bio Guide, GeistlichPharma; Dembone). The mucoperiosteal flaps were repositioned and sutured.
223621499|NCT06752694|DRUG|Cyclosporine|Given PO
224211290|NCT05187663|PROCEDURE|Chlorhexidine (CHX) group|Mucoperiostal buccal and lingual incisions were made using a surgical blade under local anaesthesia. Full-thickness mucoperiosteal flaps were elevated buccally and lingually. In the chlorhexidine (CHX) group, after careful removal of granulation tissue and mechanical debridement of the implant surface 1% gel of chlorhexidine (Chlorhexamed® - Direkt) was applied on the implant surface for one minute and irrigated for 1 min by saline. Bone augmentation and bio-resorbable membrane were applied in peri-implant defects using the bovine bone substitute and collagen membrane (Bio -Oss and Bio Guide, GeistlichPharma; Dembone). The mucoperiosteal flaps were repositioned and sutured.
224211291|NCT03368547|PROCEDURE|Computed Tomography|Undergo PET/CT scan
224211292|NCT03368547|RADIATION|Gallium Ga 68 Gozetotide|Given IV
224211293|NCT03368547|PROCEDURE|Positron Emission Tomography|Undergo PET/CT scan
224211294|NCT01440595|DRUG|Grazoprevir|Grazoprevir 100 mg tablets once daily for 12 weeks.
224211295|NCT01440595|DRUG|Placebo to Grazoprevir|Placebo to Grazoprevir once daily for 12 weeks
223621500|NCT06752694|DRUG|Fludarabine|Given IV
223621501|NCT06752694|DRUG|Granulocyte Colony-Stimulating Factor|Given SC
223621502|NCT06752694|DRUG|Mycophenolate Mofetil|Given PO
223621503|NCT06752694|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo PBSC transplantation
223621504|NCT06752694|DRUG|Ruxolitinib|Given PO
223621505|NCT06752694|DRUG|Sirolimus|Given PO
223621506|NCT06752694|RADIATION|Total-Body Irradiation|Undergo TBI
223621507|NCT06752694|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
224211296|NCT01440595|DRUG|Peginterferon alfa-2b (Peg-IFN)|Peg-IFN weekly subcutaneous injection at 1.5 mcg/kg/week for 12 or 24 weeks
224211297|NCT01440595|DRUG|Ribavirin (RBV)|Ribavirin 200 mg capsules twice daily at a dose of 600 mg to 1400 mg based on weight for 12 or 24 weeks
223621508|NCT06752694|PROCEDURE|Echocardiography|Undergo ECHO
223621509|NCT05626673|BEHAVIORAL|Prayer app|Participants will be given the Pray.com app and directed to use it daily.
223621510|NCT04074746|BIOLOGICAL|Anti-CD30/CD16A Monoclonal Antibody AFM13|Given IV
223621511|NCT04074746|DRUG|Cyclophosphamide|Given IV
223621512|NCT04074746|DRUG|Fludarabine|Given IV
223621513|NCT04074746|DRUG|Fludarabine Phosphate|Given IV
223621514|NCT04074746|BIOLOGICAL|Genetically Engineered Lymphocyte Therapy|Given AFM13-NK cells IV
223621515|NCT05719441|BIOLOGICAL|VRC07-523LS|10 mg/kg intravenous infusion over approximately 15 to 30 minutes once at entry
224211298|NCT05099783|DIAGNOSTIC_TEST|late gadolinium enhanced magnetic resonance imaging|Candidate inpatients or outpatients will be identified if pharmacological or electrical cardioversion has be performed and MRI were performed after cardioversion at least twice.
224211299|NCT05474261|PROCEDURE|Valsalva maneuver|Valsalva maneuver: increase intrabdominal pressure
224211300|NCT05765929|OTHER|Non-operative treatment|Patients will be treated with a walker-orthosis for 6 weeks. Weightbearing as tolerated
224316163|NCT04664946|DRUG|Intra-arterial administration of neuroprotective agents|Intra-arterial administration of 3-n-butylphthalide for 24 hours via microcatheter at 17.36 ug/min.
224316164|NCT02655705|DRUG|Cyclosporine A|Male 200 mg/day, Female 150 mg/day for 16 weeks
224316165|NCT02655705|DRUG|Methotrexate|Initial dose with 10 mg/week, increasing 2.5 mg every 2 weeks up to 15 mg/week maintenance dose
223621516|NCT05719441|BIOLOGICAL|PGT121.414.LS|5 mg/kg intravenous infusion over approximately 30 to 60 minutes once at entry
223621517|NCT05719441|OTHER|Placebo|Sodium Chloride for Injection USP, 0.9%
223621518|NCT05719441|DRUG|ART|Bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablet orally once daily with or without food
223621519|NCT06098690|BEHAVIORAL|Culturally Tailored Multimedia Psychoeducational HPV Intervention|The culturally tailored multimedia psychoeducational intervention will involve audio and visual content and will be delivered in a bilingual fashion (English and Spanish) among adults 18-45 years-old.
223621520|NCT06098690|BEHAVIORAL|General HPV Multimedia Psychoeducational Control Group|The general/publicly available multimedia intervention will involve audio and visual content and will be delivered in a bilingual fashion (English and Spanish) among adults 18-45 years-old.
223621521|NCT01673828|DRUG|Allopregnanolone injection|Allopregnanolone intravenous solution in 0.9% sodium chloride injection with 6% sulfobutyl ether β-cyclodextrin sodium
223621522|NCT01673828|DRUG|Placebo injection|Placebo intravenous solution, 0.9% sodium chloride injection with 6% sulfobutyl ether β-cyclodextrin sodium
223621523|NCT05395390|BEHAVIORAL|Exercise (Resistance Training|Resistance Training done both at home and on site using either dumbells or keiser pneumatic exercise machines respectively
223621524|NCT06587386|DRUG|First patient Bupivacaine liposome and next patient Bupivacaine liposome|This study was conducted using the biased coin method, where each patient's use of bupivacaine liposome dose depended on the previous patient's response. Based on previous research and our past experience, the first recruited patient used a dose of 66.5mg (15ml). Subsequently, if motor function was preserved, the next patient received a higher dose (increased by 6.65mg) with a probability of b=0.11; or the same dose with a probability of 1-b=0.89. If motor function was blocked, the next patient received a lower dose (decreased by 6.65mg).
223621525|NCT03840447|BEHAVIORAL|Chronic Disease Self-Management programme|"The primary aim of the intervention is to achieve greater self-management of the chronic condition by changing the role of the passive citizen to empowerment in self-confidence and self-reliance. The intervention consists of a series of 6 workshops (with 7 to 8 activities), 2.5 hours each, which are held once a week for 6 weeks. One professional and one peer will volunteer together to lead a series of workshops. To this end, professionals and peers will be recruited and trained in the CDSMP principles.~Over 6 workshops, citizens set realistic health goals, learn to self-manage pain and discomfort, to self-manage their diet, self-manage physical activity, mood and the way the disease influences their personal relationships. The intervention is designed to actively involve citizens."
224316166|NCT01275729|DRUG|Furosemide|dose: 1 mg / kg (iv) if the patient is furosemide naive or 1.5 mg/kg (iv) if the patient is not furosemide naive
224316167|NCT06582940|RADIATION|MRI-guided adaptive SRT|MRI-guided online adaptive SRT (without PTV expansion margin). The total dose will be 30Gy/5 fractions, administered once daily. MRI will be acquired.
224316168|NCT06582940|RADIATION|Conventional SRT|Conventional SRT (with PTV expansion margin). The total dose will be 30Gy/5 fractions, administered once daily. CBCT will be acquired.
224316169|NCT01366625|DEVICE|Renal denervation with a catheter-based procedure (Symplicity® Catheter System)|Disruption of the renal nerves with a catheter-based procedure.
224316170|NCT00131495|DRUG|Testosterone (transdermal patches)|Testosterone patch (300mcg/day, changed twice a week for one year
223621526|NCT04012073|DEVICE|Invasive Mechanical ventilation|"Volume-control ventilation with tidal volume will be set at 6 mL/Kg of predicted body weight, respiratory rate to maintain pH\>7.30 and PaCO2\<50 mmHg and FiO2 will be set to achieve a SpO2\>88-95%.~In case of hypercapnia with Ph\<7.30 despite a respiratory rate=30-35, an increase in tidal volume up to 8 ml/kg will be allowed.~In both groups, the assigned ventilation protocol will be followed for a minimum of 72 hours from randomization and any time fully controlled ventilation is deemed necessary by the attending physician up to 14 days from randomization. After 14 days from randomization, PEEP will be set according to the clinical practice of each institution.~After 72 hours from the study protocol, the PEEP setting protocol according to the assigned treatment will be resumed at any time within 14 days from enrolment if fully controlled ventilation is established, according to the decision of the attending physician in charge."
224316171|NCT00131495|DRUG|Placebo patch|placebo patch changed twice a week for one year
224316172|NCT00022334|BIOLOGICAL|AFP|Increasing doses of AFP will be given to groups of 3 intradermally. Subjects will receive 3 biweekly vaccinations. At least 2 patients at a given dose must have received their complete 3 vaccination schedule with a 30 day observation period after the last vaccination before a higher dose is initiated.
224316173|NCT03031418|DIAGNOSTIC_TEST|ExoDx Prostate Intelliscore|ExoDx Prostate (IntelliScore) is a non-invasive, urinary 3-gene expression validated test in which the results of the assay are adjunctive to the ordering physician's clinical judgment and work-up of the patient in the determination of whether a prostate needle biopsy is necessary. The ExoDx Prostate (IntelliScore) was clinically validated to discriminate patients with higher grade prostate cancer from those with more indolent lower grade cancer and benign disease.
224316174|NCT04976413|BEHAVIORAL|Eye Movement Desensitization and Reprocessing (EMDR) psychotherapy|Experimental arm will receive eight phase EMDR treatment using manualized standard protocol. Selection of targets for reprocessing through EMDR will be made according to adaptive information processing model's postulations, that links traumatic events with the symptoms of depression and anxiety. Time period allocated to EMDR treatment is 12-14 weeks.
224316175|NCT04976413|BEHAVIORAL|Counselling as usual|Control arm will receive counseling as usual for 12-14 weeks
223621527|NCT04012073|DRUG|Neuromuscular Blocking Agents|All patients will receive NMBA for 48 hours after the enrolment. The decision to stop NMBA administration after 48 hours will be left to the attending physician, but muscle paralysis will be strongly encouraged if PaO2/FiO2 ratio remains lower than 80-100 mmHg. NMBA administration will be resumed anytime deemed necessary by the attending physician.
224211301|NCT04912635|OTHER|Neo App|Neo is a smartphone-based dashboard application that utilizes concepts from behavioral science and health psychology to support patients to improve their adherence to therapy. This is done through behavior change techniques and intervention functions (Michie, Atkins \& West, 2014). This app is designed to prompt participants' self-regulation of lifestyle and health behaviors, to support adherence to therapy. Such self-regulation of lifestyle behaviors is informed by presenting health metric data (through wearables, myAir (biofeedback) and self-report), in an easy to understand dashboard platform on the app. Participants will be asked to use their PAP device (as normal), use a Withings blood pressure cuff and activity monitor. This data is brought into the Neo app through an API Exchange gateway. This data will be presented to the participant and communicated in an easy to understand way.
224211302|NCT00896883|DEVICE|Middle Turbinate Implant|Middle Turbinate Implant placement at time of surgery and follow ups.
223621528|NCT04012073|PROCEDURE|Prone positioning|Prone positioning will be used in all enrolled patients as a standard of care: the decision about the timing and the duration of prone position sessions will be left to the attending physician and the time spent by the patient in the prone and in the supine position will be recorded: PEEP will be re-set according to the protocol of the allocated treatment anytime patient's position is changed.
223621529|NCT04012073|PROCEDURE|Resume of spontaneous breathing|"Assist/control and assist ventilation will be allowed after 72 hours from the enrolment if deemed appropriate by the attending physician.~During spontaneous breathing, PEEP will be set according to the decision of the attending physician and the practice of each institution: however, in order to standardize the treatments, moderate PEEP (10-15 cmH2O) will be encouraged in case of moderate hypoxemia (PaO2/FiO2\<150 mmHg) in control group, while PEEP close to the value set during controlled ventilation according to the treatment protocol but \<15 cmH2O will be suggested in the intervention group.~During assist/control and assisted ventilation, PEEP will never be higher than the last PEEP set according to the assigned protocol during controlled ventilation.~Fully controlled mechanical ventilation will be resumed any time during the study period if the patient meets the criteria described above or any time deemed necessary by the physicians in charge"
223621530|NCT04012073|PROCEDURE|Rescue treatments|Recruitment maneuvers, extracorporeal membrane oxygenation (ECMO), extracorporeal CO2 removal (ECCO2-R) after randomization will be allowed in both groups as rescue therapies and according to the decision of attending physicians: any of these procedures will be accurately recorded on the case report form.
223621531|NCT04012073|PROCEDURE|Weaning from PEEP|"In order not to delay weaning from mechanical ventilation, when a patient is managed with assist/control or assist ventilation with PEEP higher than 8 cmH2O, a daily PEEP weaning trial will be performed whether PaO2/FIO2 ratio\>150 mm Hg and FIO2\<0.5: PEEP will be decreased to 8-5 cm H2O and arterial blood gas will be sampled after 20 -0 minutes. Previous ventilatory settings will be resumed if during the procedure transcutaneous oxyhemoglobin saturation decreases below 88%, PaO2/FIO2 falls below 150 mm Hg or if the patient experiences abnormal changes in respiratory rate or other clinical signs suggestive of respiratory distress.~When PaO2/FIO2 is no lower than 200 mm Hg at PEEP≤8 cmH2O, the patient will be considered to have acceptable gas exchange on 8-5 cmH2O of PEEP and will be deemed capable to tolerate this setting"
223621532|NCT04012073|PROCEDURE|Weaning from mechanical ventilation|"A 30-120-minute spontaneous breathing trial will be initiated as the following criteria are met and whether the patient tolerates fully assist ventilation with PEEP≤8 cmH2O for at least 4 hours without experiencing hypoxemia (SpO2\<88% or PaO2/FiO2\<150mmHg):~* improvement or resolution of the underlying cause of acute respiratory failure~* normal sensorium~* correction of arterial hypoxemia (PaO2 ≥ 60 mmHg at a FiO2 ≤ 0.4 with PEEP ≤ 8 cmH2O);~* absence of fever (≥ 38 °C) or sepsis;~* blood hemoglobin concentration of 7 g/dL or more;~* hemodynamic stability~For the purpose of the study, success of the spontaneous breathing trial will be defined as presence of the following criteria:~* respiratory rate \< 35/min,~* arterial oxygen saturation ≥ 90%,~* heart rate \< 120/min,~* systolic blood pressure \> 90 and \< 160 mmHg~* adequate cough. If the spontaneous breathing trial is successful, the patient will be extubated."
224316176|NCT02252406|DRUG|Ranolazine|Ranolazine 500 mg from baseline to week 3 and 1000 mg thereafter until week 24
224316177|NCT02252406|OTHER|Placebo|Matching placebo tablets daily for 24 weeks.
223621533|NCT04012073|PROCEDURE|Extubation|"Each extubated patient will undergo oxygen therapy via high flow nasal cannula (maximum flows tolerated and FiO2 titrated to obtain 96%\>SpO2\>92%). Pre-emptive noninvasive ventilation (NIV) after extubation will be allowed in prolonged to wean patients (i.e. more than 3 SBT failure or more than 7 days from the first spontaneous breathing trial to being extubated) if deemed necessary by the physician in charge.~In case of respiratory failure during oxygen therapy via high flow nasal cannula after extubation and, a rescue NIV trial will be allowed before intubation in both groups at the discretion of the attending physician."
224211303|NCT01347879|DRUG|Visonac PDT|cream application prior to illumination with red light
224211304|NCT01347879|DRUG|Vehicle cream with PDT|placebo/vehicle cream application prior to illumination with red light
224211305|NCT06539819|PROCEDURE|Electrical Posterior Box Isolation and Rotor Modulation Ablation group (R&B group)|the intervention is conducting electrical posterior box isolation plus rotor modulation ablation
224211306|NCT06539819|PROCEDURE|Electrical Posterior Box Isolation group (BO group)|the intervention is conducting electrical posterior box isolation alone
224211307|NCT00447707|BEHAVIORAL|Positive Choice|
224316178|NCT04034407|PROCEDURE|Damage control surgery|"All patients with clinical and radiological suspicion of colonic perforation and generalized Peritonitis with indication for emergency surgery were included in the study.~Randomisation was performed intraoperatively in all patients after the performing surgeon confirmed a colonic perforation with generalized peritonitis."
224316179|NCT03545893|DRUG|Ibuprofen 600 mg|Ibuprofen 600mg prescription, to be taken 1 tablet as needed every 6 hours for pain.
224316180|NCT03545893|DRUG|OxyCODONE 5 Mg Oral Tablet|Oxycodone 5mg Oral Tablet prescription, to be taken 1-2 tablets as needed every 6 hours for pain.
224316181|NCT02964572|DRUG|Glimepiride|In accordance with the standard treatment guidelines of diabetes, glimepiride as a drug of active comparator will be administered to improve blood sugar in patients with poorly controlled blood sugar.
223621534|NCT06811727|DRUG|Continuos ceftazidime/avibactam infusion|Continuous infusion will include a loading dose of 2 g/0.5 g administered over 2 hours, followed by continuous infusion of 6 g/1.5 g over 24 hours, equivalent to 0.25 g of ceftazidime per hour. The drug reconstitution and dilution process are shown in Figure 2. The final volume of solution of CZA will be 50 mL, which gives concentration of ceftazidime of 40 mg/mL, with 4:1 concentration ratio for avibactam (10 mg/mL). The solution will be administered via an infusion syringe, with an infusion rate of 6.25 mL/h. Dose adjustments will be applied according to renal function, calculated using Cockroft-Gault formula
223621535|NCT06811727|DRUG|Intermitent dosing as per SMPC|Intermittent dosing, as outlined in the SmPC, consists of 2 g/0.5 g administered by prolonged infusion over 2 hours every 8 hours. Dose adjustments will be applied according to renal function, calculated using Cockroft-Gault formula.
223621536|NCT03932370|PROCEDURE|Flexible ureteroscopy|The procedure will be performed in an endourology room where a radiolucent operative table together with a C-arm, a video-camera unit and a Laser device are available. Irrigation fluids include normal saline and/or sterile water.
223621537|NCT03932370|PROCEDURE|mini-Percutaneus nephrolithotomy|The procedure is done in the prone position under fluoroscopy guidance with a semi-rigid 12Fr. Nephroscope
223621538|NCT01730560|OTHER|Treatment A|"The computer-based training task consists of a novel ramp-step search paradigm with a stimulus traversing the screen from left to right or right to left. Subjects are asked to pursue the stimulus (ramp phase) and then saccade to find its location when it suddenly jumps (step phase). The stimulus is an open spinning circle. At the end of each movement, the gap can be located at the top or at the bottom, and patients are asked to indicate this location by pushing the response button as quickly as possible.~The starting point will alternate between left and right. The training task includes 3 sessions with 100 movements each. Reaction Times and errors will be monitored online to ensure that the patient performs the task correctly.~Each treatment phase has the same pattern:~* two visits in pre-tests evaluation (V1 and V2),~* one visit to perform treatment (A or B) and to assess immediate and 2h post-effects (V3),~* two visits after treatment (V4 at one week and V5 at one month)."
223621539|NCT01730560|OTHER|Treatment B|"Placebo treatment using the same computer-based training task, but including only the ramp phase.~Each treatment phase has the same pattern:~* two visits in pre-tests evaluation (V1 and V2),~* one visit to perform treatment (A or B) and to assess immediate and 2h post-effects (V3),~* two visits after treatment (V4 at one week and V5 at one month)."
223621540|NCT06784349|DRUG|ALN-APOC3|Administered as per the protocol
223621541|NCT06784349|DRUG|Matching Placebo|Administered as per the protocol
223621542|NCT06806332|DEVICE|Nanodropper|The Nanodropper is the only FDA-listed, volume-reducing adaptor for eyedrop bottles. By twisting the Nanodropper onto a compatible bottle, the drop-size can be reduced by over 60%. Smaller drops have been shown to reduce waste, cost, and side effects.
223621543|NCT04420624|DRUG|Colchicine|1 mg (or 0.5mg) tablet of colchicine taken once a day for 1 month
223621544|NCT06672978|DRUG|Meropenem-Vaborbactam|Administered as specified in the treatment arm
223621545|NCT06672978|DRUG|Antibiotics|Administered as prescribed by the study physician in accordance with the local marketing authorizations
223621546|NCT06600711|DRUG|Nitazoxanide|5 mL suspension (100 mg), 2x/day for 3 days
223621547|NCT06600711|DRUG|Placebo|identical in consistency, appearance, and taste to nitazoxanide suspension. 5 mL suspension given 2x/day for 3 days
223621548|NCT06595953|BEHAVIORAL|Gaze-Contingent Music Reward Therapy|All subjects will receive CBT and will be randomized to either active or control forms of GCMRT. This involves the monitoring of a patient s eye-movements during the free-viewing of computer-displayed matrices of faces expressing various emotions in tandem with the playing of pleasant music. In the active form of the therapy, music stops when subjects view negative valence faces, whereas in the control condition, music plays continuously. Subjects undergo 12 weeks of CBT, where GCMRT is delivered in the last eight weeks of therapy.
223621549|NCT06596005|DRUG|TJ0113|200 mg or 400 mg Capsule, Once Daily
223621550|NCT06596005|DRUG|Placebo|Capsule, Once Daily
223621551|NCT06588777|PROCEDURE|Modified thoracoabdominal nerve block through perichondrial approach (M-TAPA)|transversus abdominis, internal oblique, and external oblique muscles will be identified with a high-frequency (10 MHz) linear probe on the costochondral angle in the sagittal plane under ultrasound guidance at the 10th costal margin. A deep angle was given to the costochondral angle at the edge of the 10th costal margin with the probe in the sagittal direction to view the lower surface of the costal cartilage in the midline. A 22-G, 100-mm block needle will be inserted in the cranial direction using the in-plane technique and the needle tip will be moved to the posterior aspect of the 10th costal cartilage. It is noted that the needle tip never crossed the cranial edge of the 10th costal cartilage
223621552|NCT06588777|PROCEDURE|Quadratus lumborum block|"using ultrasound guidance (Sonosite turbo M, Bothell, Washington, USA) and a curved ultrasound probe (2.5-7.5 MHz). The probe will be placed in the mid-axillary line between the lower costal margin and the iliac crest in a transverse plane to view all abdominal layers. The probe will be moved towards the posterior axillary line, to reach a point where all three abdominal muscle layers merge to form aponeurosis.~The aponeurosis will then be followed dorsally until the quadratus lumborum muscle is seen deep to transversalis fascia with its attachment to the transverse process of the L4 vertebral body. A 22 G, 100 mm, blunt, insulated nerve block needle will be inserted 1 cm medial to the probe and advanced using the in-plane technique with ultrasound real-time assessment. The injection site will be the junction of transversalis fascia and the anterolateral border of quadratus lumborum muscle"
224211308|NCT00323271|BEHAVIORAL|Cognitive-behavior therapy|CBT: The components of CBT include (1) identification of idiosyncratic beliefs about pain and pain treatment, as well as reconceptualization of the pain experience as subject to personal control (sessions 1-2), (2) instruction in specific cognitive (e.g., distraction) and behavioral (e.g., change in activity patterns such as alternating activity with periods of rest) skills (sessions 3-8), and (3) consolidation of cognitive/behavioral skills through activities such as role playing (sessions 9-11).
224211309|NCT00323271|OTHER|Interventional|Educational intervention: Session topics will include information on the etiology of MS, MS subtypes and disease progression, common symptoms of MS, medical management of MS, rehabilitation approaches to management of MS-related symptoms, exercise, sick day management, stress management, psychosocial adjustment, family involvement, and appropriate use of the health care system.
224211310|NCT05112263|DRUG|Tofacitinib|For the tofacitinib the dose of 10 mg BD will be administered for 8 weeks (10 mg TDS for initial three days) and then reduced to 5 mg BD for the period of study
223621553|NCT06654310|BEHAVIORAL|Delivery of FCS Skills Curriculum|"The UW study team will conduct two 2-hour train-the-trainer sessions with all surgical attendings who have committed to participation as a trainer in the FCS curriculum. The designated trainer will deliver each 2-hour session during the existing formal educational time for residents. If existing protected educational time will not allow for a 2-hour training session, the sessions can be delivered in two 1-hour sessions. These sessions will be incorporated into the curriculum similar to all other formal training provided to residents with the same expectations to attend.~Each 2-hour FCS session starts with a 30-minute exercise in empathic communication. The remaining 90 minutes are devoted to skills that support decision making about surgery."
223621554|NCT06668870|BEHAVIORAL|Supplemental Text Messaging|Will receive education about the collection of patient-generated data, training in using the data collection tools, and guidance on the standard frequency for collection and sharing of information. Supplemental text messages will be sent to engage patients and deliver personalized reminders to complete monitoring tasks.
223621555|NCT06668870|BEHAVIORAL|Education and Training for Patient-Generated Data|Will receive education about the collection of patient-generated data, training in using the data collection tools, and guidance on the standard frequency for collection and sharing of information.
223621556|NCT06673017|DRUG|PTM-101|PTM-101, an absorbable drug product containing paclitaxel
223621557|NCT03100149|DRUG|RO7046015|RO7046015 will be administered at dose of 4500 milligrams (mg) for participants with body-weight greater than or equal to (\>/=) 65 kilograms (kg) or 3500 mg for participants with body-weight less than (\<) 65 kg.
223621558|NCT03100149|DRUG|RO7046015|RO7046015 will be administered at dose of 1500 mg to all participants in the indicated arm.
223621559|NCT03100149|DRUG|Placebo|RO7046015 placebo will be administered to all participants in the indicated arm.
223621560|NCT06666348|DRUG|Mirdametinib|Participants will receive orally administered mirdametinib in combination with intravenous vinblastine chemotherapy
223621561|NCT06611748|DEVICE|Key Grip|KeyGrip is an implantable peripheral nerve stimulator that is being studied for its ability to provide coordinated activation of innervated paralyzed muscles. KeyGrip will be configured to activate nerves of the upper extremity (arm and hand) in order to facilitate movements such as hand opening and/or closing
223621562|NCT06611748|DEVICE|Implanted Key Grip Electrodes|"The KeyGrip System uses modified implanted wires (called electrodes) that deliver stimulation to the muscles. These electrodes are also investigational."
223621563|NCT06674642|OTHER|Traditional Indigenous Foods diet|A diet composed of traditional indigenous foods will be given to participants.
223621564|NCT06859346|DIETARY_SUPPLEMENT|Arm 1: TisinaTM complex|Route of administration: Oral. Dose: 500 mg (2 caplets) at a single time. Regimen: Take 2 caplets, three times a day (total of 6 caplets daily) with meals.
223621565|NCT06859346|DIETARY_SUPPLEMENT|Arm 2: Placebo (Microcrystalline Cellulose)|Route of administration: Oral. Dose: 500 mg (2 caplets) at a single time. Regimen: Take 2 caplets, three times a day (total of 6 caplets daily) with meals.
223621566|NCT07002203|BIOLOGICAL|Personalized Neoantigen Peptide Vaccine|This is a personalized cancer vaccine made of 10-20 synthetic long peptides derived from the unique mutations (neoantigens) found in a patient's tumor. Each vaccine is custom-formulated based on whole exome and RNA sequencing of tumor and normal tissue. The peptides are administered intramuscularly in combination with poly-ICLC (Hiltonol) as an adjuvant to enhance immune response. The intervention aims to induce T-cell responses against tumor-specific neoantigens. Vaccinations are given during priming and booster phases, with long-term follow-up and immune monitoring.
223621567|NCT04737720|DRUG|Recombinant LCAT|iv infusion
223621568|NCT07007637|DRUG|Sonelokimab|Sonelokimab
223621569|NCT07006480|DEVICE|Real time CGM data monitoring|CGM data will be monitored in real time during daytime in the hospital. Alerts about high and low glucose levels will be communicated to patient's nurse and treating providers.
223621570|NCT07006480|DEVICE|Insulin dose adjustment based on glucometer and CGM glucose data trends|Insulin dose will be modulate based on glucometer values and previous day glucose trends as recorded on CGM.
223621571|NCT07006480|DEVICE|Share CGM data on admission and on discharge from the hospital|Record 14 days' worth of CGM data prior to admission and all CGM data recorded during the hospitalization at the time of discharge from the hospital
223621572|NCT06604663|BEHAVIORAL|Activation of the CDSS system|Activation of the CDSS system, whereby outreach workers and clinicians have access to and ability to act upon lists of patients who are at highest risk of missing their upcoming clinical appointment.
223621573|NCT06625398|DRUG|VRDN-003|VRDN-003 is an investigational, subcutaneously administered, humanized monoclonal antibody directed against the Insulin-like Growth Factor-1 receptor (IGF-1R).
223621574|NCT06625398|DRUG|Placebo|All participants will receive the same number of injections to maintain masking. Masking will be maintained by the use of placebo injections that appear identical to VRDN-003 injections.
223621575|NCT07011147|DEVICE|Bionic Pancreas|The intervention group will use the iLet Bionic Pancreas (BP) for 13-weeks. They will be trained on the iLet BP system and its components by a Certified iLet Trainer. They will also be trained on how to use the study continuous glucose monitor (CGM) system, blood glucose meter, and ketone meter. Participants will have four mid-period follow up phone calls to review medications, ongoing eligibility, and solicit any occurrences of adverse events and device issues. At the end of 13-weeks, they will complete final visit tasks and will be transitioned back to their pre-study insulin delivery method with guidance provided by a study investigator.
224211311|NCT05112263|DRUG|Cyclosporine|: Intravenous Cyclosporine 2 mg/kg continuous infusion for 5-7 days and then shifted to oral cyclosporine 4 mg/kg/day in two divided doses for 12 weeks.Those who respond with intravenous cyclosporine will be shifted to oral cyclosporine 4 mg/kg for 12 weeks while the thiopurine dose is adjusted to the patient's weight
224211312|NCT00068770|RADIATION|radiation therapy|Radiation is standard treatment 6000cGy in 30 fractions. Patients will receive celecoxib 400 mg bid during RT treatment
224211313|NCT00068770|DRUG|Celecoxib|Celecoxib will begin 1 week prior to RT at 400mg bid orally. One day 1 only 1 dose will be administered. Starting on day 2 and throughout treatment until progression, 2 doses will be administered at least 12 hours apart. Celecoxib will continue throughout the 6 week course of RT.
223621576|NCT07011147|OTHER|Routine Care|Participants will continue with their current diabetes treatment. Participants will be trained on the use of the study blood glucose meter. They will have four mid-period follow up phone calls to review medications, ongoing eligibility, and solicit any occurrences of adverse events. At the end of 13-weeks, they will complete final visit tasks and will be asked if they would like to participate in the observational extension phase where they will use the iLet Bionic Pancreas for 13 weeks.
224211314|NCT05418387|BEHAVIORAL|Social Support Network Intervention|The navigator will provide basic patient navigation services and Supportive Health Education to the patient/caregiver dyads in the patient's preferred language using the Support Network Workbook. The intervention will consist of 7 telephone sessions. There will be 2 sessions in the first month and one session per month after the first month (6 months total). Coaching and guiding techniques rather than lectures will be used applying dyads' specific social support network information. Each session will be about 30 minutes long.
223621577|NCT03712527|OTHER|Injection of Platelet rich plasma|The blood of the PRP patients group will be centrifuged by the nurse using the dedicated device. A single centrifugation is required to separate the red and white blood platelets and plasma. This method of centrifugation is carried out using specific kits (Mini-GPS System III, Zimmer Biomet Company). The PRP is then collected by the nurse into a syringe that will be provided to the injector physician. Duration of preparation: 20 to 25 minutes. After a standardized sterile preparation, a local anaesthesia will be performed. Then, the injector will inject a volume of 2 mL of PRP into the median portion of the suspected disc under radiographic guidance.
223621578|NCT03712527|OTHER|Injection of NaCl|The placebo will be a single-dose of saline solution which corresponds to NaCl 0,9% ProAmp 10 ml (Laboratoire Aguettant). The vials will be kept at room temperature (≤ 25°C) within the local pharmacy of each centre. 2 mL of this solution will be intra-discal injected.
223621579|NCT05446194|DEVICE|Non invasive neuromodulation device pattern 1|The study device consists of a headset, which looks like a music earphone headset, and a base station that powers the headset. The headset has metallic earpieces that fit into the ear canals. When activated, the study device will deliver a prescribed stimulation pattern for approximately 20 minutes.
223621580|NCT05446194|DEVICE|Non invasive neuromodulation device pattern 2|The study device consists of a headset, which looks like a music earphone headset, and a base station that powers the headset. The headset has metallic earpieces that fit into the ear canals. When activated, the study device will deliver a prescribed stimulation pattern for approximately 20 minutes.
223621581|NCT06689241|DRUG|Enoxaparin|40mg
223621582|NCT06689241|DRUG|rivaroxaban|10mg
223621583|NCT07019727|PROCEDURE|ESSKA/ESMA 'ACL Prevention for All' methodology|A workshop led by a trained physiotherapist/strength and conditioning coach and conducted under medical supervision. Based on the ESSKA/ESMA 'ACL Prevention for All' methodology, a total of 12 exercise units lasting 5 minutes each will be included.
223621584|NCT06312644|DRUG|Ultomiris|Participants exposed to Ultomiris at any point during the 40 weeks prior to conception (LMP+14 days) or at any point during pregnancy or breastfeeding up to 52 weeks after birth.
223621585|NCT06625242|DRUG|Filgotinib Maleate|Administered as oral tablets.
223621586|NCT06626074|DEVICE|Quantitative MRI sequences|additional sequences during MRI
223621587|NCT06686849|BEHAVIORAL|Low-touch: texting|Text message: The patients' primary caregiver will be sent up to three text messages spaced one week apart, starting at one week post no-show. The message will identify the child by the first name and give information about the missed visit (date, time, clinic location) and how to reschedule (by clinic-specific phone number, and/or directing the patient to myatriumhealth.org). If a patient has a newly scheduled well-child visit on file prior to all three text messages being sent, messages will be stopped.
223621588|NCT06686849|BEHAVIORAL|High-touch: Community health worker outreach|Community health worker (CHW) outreach: Within approximately one week of patient enrollment and randomization to the high-touch intervention arm, the community health worker will call the primary phone number in the patient's record. Up to three phone call attempts will be made and logged for this number, then a fourth and final attempt will be made to reach the secondary contact phone number in the patient's health record. If the caregiver is successfully reached, the CHW intervention will be limited to one phone call in which the CHW will assess reason(s) why the patient missed the appointment, will screen for social and other needs, and will assist in rescheduling the missed appointment and addressing potential barriers to attendance.
223621589|NCT07024745|BEHAVIORAL|Intervention Group|The Intervention is 1) interact with the Us\*Now mHealth app for 1 month; 2) participate in 4 weekly sessions with other group members and led by a Female Facilitator. Each week will cover a different topic - Week 1: Intersectional Stigma, Week 2: Sexual Health, Week 3: HIV Prevention, Week 4: Engagement in PrEP Care.
223621590|NCT07024745|BEHAVIORAL|Control (Standard treatment)|The Control group will be asked to interact with the Us\*Now mHealth app for 1 month.
223621591|NCT05561634|RADIATION|Radiotherapy|Irradiation of the tumoral bed.
223621592|NCT05561634|OTHER|Observation|Patients will be followed up in consultation every 3 months.
223621593|NCT05561634|DRUG|Vismodegib|Sonic Hedgehog inhibitors (SHHi) = Vismodegib et Sonidegib,
223621594|NCT06347718|DRUG|anti-CD19 CAR T cell therapy|Single-dose
223621595|NCT06462053|RADIATION|Short-course radiotherapy|Short-course radiotherapy: 25Gy/5Fx
223621596|NCT06462053|DRUG|PD-1 antibody (Toripalimab)|Toripalimab 240mg d1 q3w
223621597|NCT06462053|RADIATION|Long-course radiotherapy|Long-course radiation: 50Gy/25Fx
223621598|NCT06462053|DRUG|Oxaliplatin|Oxaliplatin: 130mg/m2 d1 q3w
223621599|NCT06462053|DRUG|Capecitabine|Xeloda
224316182|NCT02964572|DRUG|Empagliflozin|Empagliflozin as a drug of experimental will be administered to improve blood sugar in patients with poorly controlled blood sugar.
224316183|NCT01535092|DRUG|Silibinin|20mg/Kg daily by intravenous infusion, for 14-21 days pre-OLT and for 7 days post-OLT
223621600|NCT06110091|BEHAVIORAL|Integrated Behavioral Therapy Program|Integrated Behavioral Therapy is a behavioral program that includes education, lifestyle habits management, cognitive, relaxation, and behavioral conditioning for nocturia and insomnia
223621601|NCT06110091|BEHAVIORAL|Health Education Program|Health Education Program modules focus on brain health and includes topics such physical activity, social engagement, sleep topics (e.g., changes in sleep that occur with aging, effects of poor sleep on health), medications/medical conditions, vision and hearing impairment.
224316184|NCT01535092|DRUG|Placebo|Saline, daily infused for 14-21 days pre-OLT and for 7 days post-OLT
224211315|NCT05418387|BEHAVIORAL|Control (Patient Navigation Service)|The patient navigator will provide basic patient navigation services consisting of health care barriers/social needs assessment, referral to social workers (if eligible) and support groups for patients and caregivers, and transportation assistance without Supportive Health Education. Patient/caregiver dyads in the control group will be contacted at 3- and 6-months post-enrollment and asked about their experience receiving treatment, any challenges they encountered or are currently facing, and the care support they received from family members, friends, CHWs, and health care providers.
224211316|NCT03187288|DRUG|CFI-400945 Fumarate|CFI-400945 is an investigational drug that is being look at for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). CFI-400945 is an oral (taken by mouth) drug that blocks Polo-like kinase 4 (PLK4) activity. PLK4 is a protein that is important in regulating cell growth and division and cell death. Many tumors are shown to make too much PLK4. When there is too much PLK4 produced, it is believed to contribute to uncontrolled cancer cell growth and division. Therefore, by blocking this protein from working, it is believed to stop tumors from growing or shrink them.
224211317|NCT01125007|DEVICE|Two kind toothbrushes|a randomization was performed in which the participants were allocated to the following experimental procedures: Two quadrants (1 and 3 or 2 and 4) with medium toothbrush Two quadrants with soft toothbrush. All procedures were performed using the same dentifrice. Each quadrant was brushed for 30 seconds by the participant without specific instructions on the technique, under supervision of the person in charge of the randomization.
224211318|NCT03974607|BEHAVIORAL|Physical Activity Program (PAP)|A Physical Activity Program (PAP) will be carried out. Previously an initial measure will be made to know the little active adolescents. At the end of the PAF a retention measure will be carried out to know the scope and persistence of the variables analyzed. The PAF will be developed with a frequency of three weekly sessions, of 60 minutes, in the period of the intervention, with the exception of weeks in which there is a public holiday, where we will take measures to recover the class. A schedule for the sessions will be set according to the interests of the participants and will be the same for all. During the sessions, basic physical abilities and motor skills will be worked on with playful proposals focused on the improvement of physical and psychosocial parameters. They will always have the same monitor Graduate in Physical Activity and Sports Sciences, which will be responsible for developing the PAF.
224211319|NCT06568809|OTHER|Time interval between recovery of body temperature and operation|The time between body temperature recovery and surgery was collected as categorical factor and was scheduled to be analyzed in the following categories: 0-2 weeks; 3-4 weeks; 5-6 weeks; 7-8 weeks; And ≥ 3 months (control group).
224211320|NCT01238822|DRUG|Methylphenidate|18 mg methylphenidate
224211321|NCT01238822|DRUG|placebo|Placebo
224211322|NCT01238822|DRUG|Methylphenidate|36 mg methylphenidate
224211323|NCT01238822|DRUG|Methylphenidate|54 mg methylphenidate
223621602|NCT02867475|OTHER|Physical activity motivation|Physical activity motivation
223621603|NCT05673057|DRUG|MP0533 (multispecific DARPin CD3 Engager Targeting CD33, CD123 and CD70) monotherapy, Part 1|MP0533 is administered by intravenous infusion
223621604|NCT05673057|DRUG|MP0533 (multispecific DARPin CD3 Engager Targeting CD33, CD123 and CD70) monotherapy, Part 2-Arm A|"* MP0533 is administered by intravenous infusion~* Obinutuzumab pretreatment administered"
223621605|NCT05673057|DRUG|MP0533 (multispecific DARPin CD3 Engager Targeting CD33, CD123 and CD70) + azacitidine + venetoclax|"* MP0533 is administered by intravenous infusion~* Azacitidine is administered by subcutaneous injection for 7 days per cycle~* Venetoclax is administered orally for 14 days per cycle~* Optional obinutuzumab pretreatment administered"
223621606|NCT05673057|DRUG|MP0533 with Obinutuzumab pretreatment|"* MP0533 is administered by intravenous infusion at densified dosing schedule~* Obinutuzumab pretreatment administered"
223621607|NCT05673057|DRUG|MP0533 + azacitidine + venetoclax with optional Obinutuzumab pretreatment, Arm B relapsed/refractory AML|"* MP0533 is administered by intravenous infusion~* Azacitidine is administered by subcutaneous injection for 7 days per cycle~* Venetoclax is administered orally for 14 days per cycle~* Optional obinutuzumab pretreatment administered"
223621608|NCT05673057|DRUG|MP0533 + azacitidine + venetoclax with optional Obinutuzumab pretreatment, Arm B in treatment naïve patients|"* MP0533 is administered by intravenous infusion~* Azacitidine is administered by subcutaneous injection for 7 days per cycle~* Venetoclax is administered orally for 14 days per cycle~* Optional obinutuzumab pretreatment administered"
224211324|NCT02529800|DRUG|HIP1402|Tamsulosin HCl 0.4mg
224211325|NCT02529800|DRUG|HGP0412|Tamsulosin HCl 0.2mg
224211326|NCT02572427|OTHER|Education for intubation skills|Routine training in neonatal resuscitation, intensive cognitive and hands on training for intubating neonates using manikins in a simulation lab.
224211327|NCT02572427|OTHER|No added education for intubation skills|Routine training in neonatal resuscitation but no added experience in simulation lab.
224211328|NCT01261429|DRUG|Tasigna|"The study drug is nilotinib (Tasigna®). All patients will be administered with nilotinib 400 mg twice a day for one year. The patient will begin the treatment the day of inclusion.~The prescribed dose should be swallowed whole with a glass of water. Doses of 400 mg should be administered twice daily approximately 12 hours apart. Patients should not eat within two hours before and one hour after taking nilotinib and need to avoid foods such as grapefruit juice which may inhibit CYP3A4 enzymes."
223621609|NCT07030972|OTHER|Exercise|Individuals in the control and intervention groups will be included in a routine exercise program. For this exercise program; shoulder joint range of motion exercises, finger ladder, Codman and stick exercises will be given to protect functional range of motion in the early stages and to increase it in the later stages. Isometric exercises will be performed on the scapular muscles in the early stages to preserve muscle strength. In the later stages, rotator cuff, scapula stabilizers and deltoid strengthening exercises will be shown and applied, initially with low-resistance therabants for strengthening. In addition, neuromuscular control exercises and proprioceptive exercises will be included in the treatment to increase joint stabilization and coordination. Exercises will be performed for 6 weeks, 3 days a week, with 10-30 repetitions.
223761779|NCT02178033|DRUG|Split dose low-volume PEG solution|"All participants will receive low-volume (2L) PEG plus ascorbic acid solution (MOVIPREP®, Norgine, Harefield, United Kingdom); in the control arm the whole colonoscopy preparation is administered the day before colonoscopy; in the  active comparator  arm one liter of the bowel preparation is administered on the evening before the colonoscopy and the remaining liter on the day of the procedure."
223621610|NCT07030972|OTHER|Deep friction massage|Individuals in the intervention group will receive a deep friction massage to the biceps tendon after the exercise program. The individual will be placed in a long sitting position with their back supported. While the patient's shoulder is next to the body and the elbow is flexed at 90 degrees, the therapist's thumb will be placed on the painful area on the extension of the biceps tendon fibers and a deep friction massage will be applied to the point where the tendonitis occurs in a transverse direction for 3-10 minutes.
223621611|NCT07030998|DEVICE|Wearable Device|"Wearable device to collect the following health metrics directly from participants for the duration of the study (4 weeks). Health metrics are collected every 15 minutes, except for the ECG which will be collected once per week.~Data points:~* ECG data (Once per week)~* Exercise time~* Body Temperature~* Heart Rate~* Irregular Heart Rhythm~* Blood Oxygen Saturation~* Respiratory Rate"
223621612|NCT06710483|BEHAVIORAL|Pre-Dental Telehealth (PDT)|The PDT will be a scripted telehealth interview 3-7 days before the scheduled dental visit to review medical and dental history, to evaluate the participants' needs for the dental visit, and to set an agreed goal for the dental visit using shared decision making. The goal wlll be one of the following: Goal 1: exam cleaning only, Goal 2: exam and cleaning, Goal 3: exam, radiographs, and cleaning.
223621613|NCT06714591|DRUG|BL-M11D1|"The study includes 2 parts:~Part 1 Dose escalation and Dose Finding"
223621614|NCT06713239|DEVICE|Cleerly Labs and Cleerly ISCHEMIA|Participants in the coronary plaque-based care arm will have CCTA at baseline. CCTA images will be redacted and uploaded to Cleerly, interpreted using Cleerly Labs and Cleerly ISCHEMIA, and archived.
223621615|NCT07122687|DRUG|Pemetrexed|500 mg/m2 D1 IV Q3W
223621616|NCT07122687|DRUG|Cisplatin|75 mg/m2 D1 IV Q3W
223621617|NCT07122687|DRUG|IBI363|1.5 mg/kg D1 IV Q3W
223621618|NCT07122687|DRUG|Carboplatin|AUC 5 mg/ml/min D1 IV Q3W
223621619|NCT07122687|DRUG|Keytruda|200mg D1 IV Q3W
223621620|NCT06880744|DRUG|Risankizumab|Intravenous (IV) Infusion
223621621|NCT06880744|DRUG|Risankizumab|Subcutaneous (SC) injection
223621622|NCT06880744|DRUG|Vedolizumab|Intravenous (IV) infusion
223621623|NCT05148546|DRUG|Neoadjuvant nivolumab|Patients will receive 2 cycles of nivolumab 360mg (arm A and C) or 3mg/kg (arm B) every 3 weeks followed by a nephrectomy.
223761780|NCT05466578|DRUG|abrocitinib|
223761781|NCT02310191|PROCEDURE|Carotid stenting|Procedures will be carried out via the femoral approach following a Seldinger technique. All patients will be on long-term aspirin (100 mg/day) and a 525-mg loading dose of clopidogrel. A dose of 10 000 units unfractionated heparin will be administered at the beginning of the intervention. A cerebral protection device (FilterWire EZ™; Boston Scientific, Natick, Massachusetts, USA) will be use in all patients if possible. The type of covered stent and other specific intervention strategies will be left to the discretion of the interventional radiologists. After predilatation of the stenosis (if needed), an appropriate stent for each stenosis will be implanted and then dilated using a balloon catheter.
224211329|NCT00123110|DRUG|metformin|Initiated on 500 mg daily and titrated up to 1000 mg twice a day during the first four weeks, remaining at that dose until 12 weeks
224211330|NCT00123110|DRUG|leuprolide injection|3.75 mg injection every 4 weeks (e.g. at baseline, 4, and 8 weeks)
224211331|NCT00123110|DRUG|placebo pill|matching pill twice a day for 12 weeks
224316185|NCT03458299|BEHAVIORAL|Motivational Interviewing|2 hours of motivational interviewing
223761782|NCT04921930|DRUG|Artesunate Oral Product|Dose escalation intake of artesunate
224316186|NCT03458299|BEHAVIORAL|Psychoeducation|2 hours of DVD viewing and discussion
223621624|NCT05148546|DRUG|Neoadjuvant ipilimumab|Patients will receive 2 cycles of ipilimumab 1mg/kg every 3 weeks followed by a nephrectomy.
223621625|NCT05148546|DRUG|Neoadjuvant relatlimab|Patients will receive 2 cycles of relatlimab 360mg every 3 weeks followed by a nephrectomy.
223621626|NCT06686446|BEHAVIORAL|Enhanced Education Package|"Participants randomised to the intervention arm will receive an advanced patient education toolkit and reminders delivered by email/SMS in addition to the standard education provided by their treating clinician.~Weekly repeat reminders - these reminders will be sent via either SMS or email over a period of 3 months. They will instruct and remind the participant to take their INCS/INAH as per their treating clinician recommendation and why it is important to take it as instructed.~Education Toolkit - contains links to websites of key organisations including the National Allergy Council (NAC), Allergy \& Anaphylaxis Australia (A\&AA), Australasian Society of Clinical Immunology and Allergy (ASCIA), National Asthma Council Australia (NACA) and AusPollen which include educational videos and other resources."
223621627|NCT07042165|DRUG|Atorvastatin|Participants will be orally administering one tablet daily of 40 mg Atorvastatin for two weeks followed by two tablets daily for two weeks (totalling 80 mg daily).
223621628|NCT07042165|DRUG|Placebo|Placebo tablets are manufactored by the Central Pharmacy of the Capital Region of Denmark and are identical to the IMP except with the active ingredient (atorvastatin) omitted. Participants will be orally administering one tablet daily for two weeks followed by two tablets daily for two weeks.
223761783|NCT00993096|DRUG|insulin degludec/insulin aspart|Single dose of 0.4 U/kg body weight injected subcutaneously (under the skin)
223761784|NCT00993096|DRUG|insulin degludec/insulin aspart|Single dose of 0.6 U/kg body weight injected subcutaneously (under the skin)
223761785|NCT00993096|DRUG|insulin degludec/insulin aspart|Single dose of 0.8 U/kg body weight injected subcutaneously (under the skin)
224211332|NCT00123110|DRUG|placebo injection|matching injection every 4 weeks (e.g. baseline, 4, and 8 weeks)
224211333|NCT03375996|DRUG|cyclopentolate 0.5% eye drops|cyclopentolate 0.5% eye drops and measurement of the pupillary mydriasis (dilatation)
224211334|NCT00004009|DRUG|tipifarnib|
224211335|NCT04741945|DRUG|Metformin|2000 mg/day metformin for 12 months (1000 mg b.i.d.) with a slow up-titration six weeks prior to full dose treatment.
224211336|NCT03801278|DRUG|FPA144|Bemarituzumab administration every two weeks
224211337|NCT00876109|DRUG|GDC-0941|GDC-0941 will be administered in escalating oral doses QD or BID in Groups A and B, respectively. In Group C, the dose/regimen will be determined on the basis of data from Groups A and B. The overall starting dose will be 15 mg administered in the first cohort enrolled in Group A.
224211338|NCT04989231|BIOLOGICAL|Investigational sIPV|Three intramuscular injections of the investigational vaccine (0.5 ml) at 0 month ,1 month and 2 months respectively; Single intramuscular injection of the investigational vaccine (0.5 ml) at 18 months
224211339|NCT04989231|BIOLOGICAL|Control IPV|Three intramuscular injections of the control vaccine (0.5 ml) at 0 month ,1 month and 2 months respectively;Single intramuscular injection of the control vaccine (0.5ml) at 18 months
223621629|NCT07046143|DEVICE|tSCS|The experimental group received noninvasive spinal cord electrical stimulation treatment, requiring patients to take the prone position or sitting position, the anode was placed in the patient's bilateral anterior superior iliac spines, the cathode was placed in the nerve root outlets corresponding to the upper and lower spinal segments of the spinous processes, the stimulation frequency was adjusted to 10,000 Hz, the treatment frequency was 30Hz, the pulse width was 1ms, the waveform was a square wave, and the length of a single session of the treatment was 20min, and the amplitude of current was adjusted to the sensory threshold below the threshold value for 20min twice a day for 2 weeks.The duration of a single treatment was 20 min, and the amplitude of the current was adjusted to below the sensory threshold, each time 20 min, twice a day for 2 weeks of noninvasive spinal cord electrical stimulation.
223621630|NCT07046078|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic HCT
223621631|NCT07046078|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223621632|NCT07046078|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow biopsy and/or aspiration
223621633|NCT07046078|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy and/or aspiration
223621634|NCT07046078|DRUG|Cytarabine|Given IV
223621635|NCT07046078|PROCEDURE|Echocardiography Test|Undergo ECHO
223621636|NCT07046078|DRUG|Fludarabine|Given IV
223621637|NCT07046078|DRUG|Idarubicin|Given IV
223621638|NCT07046078|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
223621639|NCT07046078|BIOLOGICAL|Peripheral Blood Stem Cell|Given IV
223621640|NCT07046078|OTHER|Questionnaire Administration|Ancillary studies
223621641|NCT07046078|BIOLOGICAL|Recombinant Granulocyte Colony-Stimulating Factor|Given SC
223621642|NCT07046078|RADIATION|Total-Body Irradiation|Undergo TBI
223621643|NCT07044336|DRUG|Puxitatug Samrotecan|2.4 mg/kg on Day 1 Q3W Route of administration: IV infusion
223621644|NCT07044336|DRUG|Doxorubicin|60 mg/m2 on Day 1 Q3W Route of administration: IV
223621645|NCT07044336|DRUG|Paclitaxel|80 mg/m2 on Days 1, 8, and 15 in 28-day cycles Route of Administration: IV
223621646|NCT07042594|DRUG|RBD1119|Subcutaneously Administered RBD1119 in Healthy Subjects.
224211340|NCT01839227|OTHER|Neurologic and neuropsychologic tests|"Cognitive functioning was assessed with the following test: Korean Mini-Mental State Examination (K-MMSE) and visuomotor test of D-LOTCA battery.~Regional cerebral oxygen saturation was continuously monitored using the INVOS 5100 (somatics,Troy, MI) with bifrontal placement of two sensors before the induction of the anesthesia until the end of operation.~Baseline rSO2 was defined as the average saturation value over a 1 min period before induction of general anesthesia, beginning approximately 3 min after the sensors were applied in supine position. After the induction, baseline prone rSO2 was defined over a 5min period after the change of position.~There is no intervention were made according to rSO2 values. Physiologic variables including BIS, PaCO2,PaO2, glucose, electrolyte, hematocrit, HR, MAP, and nasopharyngeal temperature were measured every 1 hours during the surgery."
223621647|NCT07042594|DRUG|Placebo|Subcutaneously Administered Placebo in Healthy Subject.
223621648|NCT06723795|OTHER|Cardiologist evaluation|The cardiology consultation will include the following: a structured interview (see Appendix A), physical examination, review of laboratory tests including HbA1c, lipid profile, BNP, ECG, and POCUS (point-of-care ultrasound) to assess heart contraction and valve function.
223621649|NCT06723795|OTHER|Pulmonologist evaluation|optimize basic treatment, and recommend continued follow-up as needed.
223621650|NCT07045181|DIAGNOSTIC_TEST|XGBoost machine learning|XGBoost is a powerful machine learning algorithm known for its efficiency and performance. It is an optimized gradient boosting library designed to be highly efficient, flexible, and portable. XGBoost works by combining multiple weak prediction models, typically decision trees, to produce a strong predictive model. It supports various objective functions and evaluation metrics, making it suitable for a wide range of tasks, including classification and regression. XGBoost also includes features like regularization to prevent overfitting and can handle missing data effectively.
223621651|NCT06727071|PROCEDURE|Hyperglycemic clamp|A continuous infusion of 20% dextrose will be maintained throughout the procedure, while a variable rate of insulin infusion will be used to control participants blood glucose level.
223761786|NCT00993096|DRUG|biphasic insulin aspart 30|Single dose of 0.4 U/kg body weight injected subcutaneously (under the skin)
223761787|NCT00993096|DRUG|biphasic insulin aspart 30|Single dose of 0.6 U/kg body weight injected subcutaneously (under the skin)
224211341|NCT04911127|DRUG|200mg Cannabidiol by capsules twice daily|200mg twice daily via 50mg capsules
223621655|NCT06925503|BEHAVIORAL|Mind-Body Conditioning Course|Evidence-based mindfulness intervention curated to the physical and emotional needs of University Dance students
223621656|NCT06732427|DRUG|fospropofol Disodium for injection|Group L received slow intravenous sufentanyl 0. 1 ug / kg +fospropofol Disodium for injection 8mg / kg (completed within 60 seconds)
223621657|NCT06732427|DRUG|Propofol|Group B received slow intravenous sufentanyl 0. 1 ug / kg +propofol 2mg / kg (completed within 60 seconds)
223621658|NCT06592261|DRUG|Insulin regular, 2.0-3.2 mU/m2/min (euinsulinemia)|Insulin infusion to recapitulate euinsulinemia (normal basal insulin)
223621659|NCT06592261|DRUG|Insulin regular, 32 mU/m2/min (hyperinsulinemia)|Insulin infusion to induce hyperinsulinemia for assessment of insulin sensitivity
223621660|NCT06592261|DRUG|Octreotide Acetate, 6-45 ng/kg/min|Suppression of endogenous insulin secretion
223621661|NCT06592261|DRUG|Dextrose 20 % in Water|Production of steady-state plasma glucose (SSPG) reflective of insulin sensitivity at hyperinsulinemia
223621662|NCT06592261|DRUG|Glucagon, 0-0.5 ng/kg/min|Replacement of endogenous glucagon suppressed by octreotide. (Use is optional at the PI's discretion.)
223621663|NCT01624792|DIETARY_SUPPLEMENT|Olive oil|Dose: 7.0 g/day (= 7 capsules/day).
224211342|NCT04911127|DRUG|400mg Cannabidiol by capsules twice daily|400mg twice daily via 50mg capsules
224211343|NCT04911127|DRUG|Placebo capsules|MCT oil capsules as placebo for CBD
224211344|NCT05190640|DIETARY_SUPPLEMENT|De-Stress Gummies|one gummy a day for De-Stress Gummies and one gummy a day for Sleep Gummies
223621664|NCT01624792|DIETARY_SUPPLEMENT|Fish oil|Dose: 7.0 g/day (= 7 capsules/day = 3.5g EPA+DHA/day).
223621665|NCT01624792|DIETARY_SUPPLEMENT|Fish oil and placebo|Dose: 7.0 g/day (= 4 capsules/day fish oil = 2.0g EPA+DHA/day and 3 capsules/day olive oil).
223621666|NCT06727097|DIAGNOSTIC_TEST|Posturography|"Successful completion of all four indices of the mCTSIB, without severe imbalance (i.e., near fall with safety harness and urgent knee to grab emergency handlebars) constitutes PSR +, non-completing on any of the index is noted as PSR -. Exploratorily, the average sway velocity index will be captured for each condition, to characterize sensory reweighting patterns."
223621667|NCT06727097|DIAGNOSTIC_TEST|Walking Speed|The 10-meter walk test (10MWT) is the gold standard measure of post-stroke walking function that reflects overall mobility and health status. Method: Two 10MWT trials (using a stopwatch) are averaged and documented in meters/second. The functional ambulatory category (FAC) will be collected as supplement. Exploratorily: Participants will also perform the 10mWT (fast paced-FP) with two attempts. Both SS and FP will be performed over the Zeno Walkway Gait Analysis Mat, to capture supplementary spatiotemporal data.
223621668|NCT06727097|DIAGNOSTIC_TEST|Instrumented 7M Timed UP and GO|This sub-aim will use iTUG to determine the effects of BLT on dynamic balance. In contrast to the traditional TUG, inclusion of wearable triaxial accelerometers and gyroscopes-placement test increases the sensitivity (87%) and specificity (87%) for identifying individuals prone to falls. Two trials are averaged and documented in seconds. Secondary analysis will be performed on data obtained from the sensors to determine (stride length, stride velocity, cadence, peak arm swing velocity, and turning velocity, during the task), to correlate with the TUG time/speed. Time points: Same as Posturography and 10 MWT.
223621669|NCT06727097|OTHER|Fall Event Records|A robust fall incident journal elucidating the date, time, nature, and management of the fall event will be provided to all study participants for documentation. The study research coordinator will contact the patient/caregiver/facility to collect the data q2 weeks. A tally of the total number of fall events between visits will be recorded.
223621670|NCT06727097|DIAGNOSTIC_TEST|MRI (3T)|Structural neuroimaging biomarkers:. The fractional anisotropy map from the primary fiber population in each voxel will be resampled to MNI space (using the warp derived from structural preprocessing) and projected onto a template white matter skeleton using local maxima to further optimize registration accuracy. Small vessel disease parameters, including white matter hyperintensities using the Fazekas scale and number/site of microhemorrhages, will be recorded for exploratory analyses.
223621671|NCT06732596|OTHER|Embodied conversational agent (ECA)|The app with the ECA will be provided.
223621672|NCT06732596|OTHER|Technical support|Technical support will include assistance downloading and setting up the app on the participant's phone, walking them through a brief demonstration, and answering any questions the participant has about how to use the app.
224211345|NCT03855462|DEVICE|MCT oil injection|"The patient treatment is the classical surgical procedure which is used for retinal detachment with MCT oil :~* Vitrectomy, then flattened retina, and finally MCT injection in place of the vitreous.~* MCT ablation after 4 to 6 weeks (after effective retinopexy)~* after MCT ablation, total follow-up duration by patient is 6 months."
224211346|NCT01772394|BEHAVIORAL|Cognitive Remediation Therapy|Cognitive remediation therapy (CRT) is an intensive training cognitive therapy that encourages people to reflect on and try to modify the way they think, with a particular focus on improving cognitive flexibility. It is a manualised therapist-led intervention consisting of multiple versions of a variety of tasks and mental exercises that address the difficulties in flexibility and holistic processing. CRT is an individual 10-sessions long program (2 sessions per week).
224211347|NCT01772394|BEHAVIORAL|Sham Therapy|The Sham therapy (ST) has been designed to match the CRT format: an individual manualised therapist-led 10-sessions long program (2 sessions per week). ST sessions have been designed so as to avoid set-shifting and central coherence training. Rather, ST is a manualised sham intervention consisting of multiple exercises on 3 domains: soft physical activity, emotional expression recognition and interpersonal functioning.
224211348|NCT03348501|OTHER|survey for long-term follow-up of the disease|patients will be regularly asked about their state of health (occurrence of a major health event that required hospitalization, for example ...), and about their living conditions (alcohol and tobacco consumption, socio-economic environment). Questionnaires of quality of life and satisfaction related to care will also be offered at regular intervals to better know the impact of their disease on their daily lives and their perception of their care.
224211349|NCT02783508|DRUG|IV Meperidine|"Intravenous meperidine 50mg in 100cc NaCl 0.9% . Repeated doses (if needed): intervals of 2 hours minimum until a maximum of 4 doses.~In cases of nausea or vomiting intravenous metoclopramide 10mg will be offered to the parturient.~If pain intensity (according to visual analogue scale), 20 to 30 minutes from administration, will not decline or the parturient will ask for a different type of analgesia, inhaled nitrous oxide or epidural analgesia will be offered."
224316187|NCT02460406|OTHER|traditional physiotherapy|We are applying routine traditional physiotherapy consisted of neurodevelopmental treatment (stretching, weight bearing, functional reaching \& walking so on).
224316188|NCT02460406|OTHER|progressive functional strength training|"Participants allocated to the experimental group completed three times a week, 12-week progressive resistance training protocol. This protocol consisted of functional squat system with virtual reality in leg press, plyometric exercises, exercises with Bosu ball \& heel-rise exercises. This intensity of training is approximately equal to training at an intensity of 60% to 80% of one-repetition maximum according to National Strength and Conditioning Association (NSCA) protocols. Intensity of exercise is gradually increased 10% bi-weekly."
223761788|NCT00993096|DRUG|biphasic insulin aspart 30|Single dose of 0.8 U/kg body weight injected subcutaneously (under the skin)
223621673|NCT06732596|OTHER|Additional ECA messages|Weekly text messages will be provided reminding participants to use the app on behalf of OBAT clinical staff.
223621674|NCT06732596|OTHER|Additional incentives|Additional incentives will be provided after logging into the app for 20 days followed by monthly lotteries for those who log in 15 days per month
223621675|NCT03273023|DEVICE|Promus PREMIERTM Everolimus-Eluting Platinum Chromium Coronary Stent System|Promus PREMIERTM Stent System
223621676|NCT06745284|DRUG|Survodutide|Survodutide
223621677|NCT06745284|DRUG|Semaglutide|Semaglutide
223621678|NCT06892275|BEHAVIORAL|Enhanced Usual Care|Risk assessment and notification, referral to nurse practitioner (NP) at the Ralph Lauren Center (RLC)
224211350|NCT02783508|DRUG|Nitrous Oxide|"Nitrous oxide in a 50/50 mix with oxygen given via self-administered face mask. The parturient will be advised to place the mask tightly on her face and to breathe through it at the first sign of forthcoming uterine contraction. Between contractions, she will be advised not to breathe through the mask.~In cases of nausea or vomiting intravenous metoclopramide 10mg will be offered to the parturient.~If pain intensity (according to visual analogue scale), 20 to 30 minutes from administration, will not decline or the parturient will ask for a different type of analgesia, intravenous meperidine or epidural analgesia will be offered."
224211351|NCT01922635|OTHER|Valadation of the metrological properties of questionnaire of quality of life|
224211352|NCT01818219|PROCEDURE|Records of EADI derived parameters|
224211353|NCT05606913|DRUG|dulaglutide|Dulaglutide administered subcutaneously (SC) once a week.
223621679|NCT06892275|BEHAVIORAL|Decision Support|The decision aid describes two different breast cancer screening plans: (1) annual mammography only; and (2) annual mammography plus annual breast MRI. The decision aid provides balanced information about breast MRI, including its risks, limitations, and benefits.
224211354|NCT05606913|DRUG|IBI362|IBI362 administered subcutaneously (SC) once a week.
224211355|NCT05873075|OTHER|Intravascular laser irradiation of blood|Intravascular laser irradiation of blood via an intravenous catheter for irradiation of the blood under a period of 60 minutes daily for 20 days
224211356|NCT02539979|DRUG|Paracetamol|
224211357|NCT02539979|DRUG|Placebo - Normal Saline|Normal Saline 100cc
223621680|NCT05371964|DRUG|Imetelstat sodium|Imetelstat sodium will be administered as intravenous (IV) every 28 days.
224211358|NCT04734431|BIOLOGICAL|Eosinophil count|Evaluation of the eosinophil count from admission to day 7
224211359|NCT06299631|PROCEDURE|Ileocolic resection|Ileocolic resection by open or laparoscopic approach
224211360|NCT02390973|PROCEDURE|Sleeve Gastrectomy|
224211361|NCT02390973|PROCEDURE|Roux-en-Y Gastric Bypass|
224211362|NCT02390973|PROCEDURE|Biliopancreatic Diversion with Duodenal Switch|
223621681|NCT05371964|DRUG|Ruxolitinib|Ruxolitinib will be administered, orally (PO), twice daily (BID) in cohort B as the standard of care per local prescribing guidelines.
223621682|NCT05371964|DRUG|Pacritinib|Pacritinib will be administered once daily (QD) or BID in cohort B as the standard of care per local prescribing guidelines.
223761789|NCT03112161|OTHER|Eucaloric Feeding Period|
223761790|NCT03112161|OTHER|Overfeeding Feeding Period|
224211363|NCT02390973|OTHER|Medical management|
224211364|NCT01262729|PROCEDURE|therapeutical hypothermia|Patients after successful cardiopulmonary resuscitation will be treated in accordance to international guidelines (Guidelines 2005 on cardiopulmonary resuscitation. Resuscitation 2005; 67: S7-S23)
224211365|NCT01262729|DRUG|Xenon Inhalation|Patients after successful cardiopulmonary resuscitation will be inhalated with 65-70% Xenon within 2 hours additional to therapeutical hypothermia
224211366|NCT06542731|DRUG|ONO-4578|Specified dose on specified days
224211367|NCT06542731|DRUG|ONO-4538|Specified dose on specified days
224211368|NCT06542731|DRUG|Docetaxel|Specified dose on specified days
224211369|NCT06542731|DRUG|Ramucirumab|Specified dose on specified days
224316189|NCT01873183|OTHER|Goal directed fluid therapy|
224316190|NCT01285297|BIOLOGICAL|Bone Marrow Aspirate Concentrate|Injection of up to 18 mL BMAC
223621683|NCT05371964|DRUG|Momelotinib|Momelotinib will be administered once daily QD in cohort B as the standard of care per local prescribing guidelines.
223621684|NCT05371964|DRUG|Fedratinib|Fedratinib will be administered QD in cohort B as the standard of care per local prescribing guidelines.
223621685|NCT06727214|DRUG|Chemotherapy with platine|medical records that patients received neoadjuvant systemic chemotherapy platine based
223761791|NCT03112161|OTHER|Underfeeding Feeding Period|
223761792|NCT00077168|DRUG|anastrozole|
223761793|NCT00077168|DRUG|tamoxifen citrate|
224211370|NCT04506346|DIAGNOSTIC_TEST|difficult tracheal intubation|Grade Ⅲ or Ⅳ according to Cormach-Lehane Grading of laryngoscopic view
224211371|NCT02093468|DRUG|MST-188|
224211372|NCT02093468|DRUG|Saline|
224211373|NCT00142324|DRUG|Donepezil|
224211374|NCT00996918|DRUG|Bapineuzumab 0.5 mg/kg|Bapineuzumab I.V., 0.5 mg/kg, infusion every 13 weeks for a total of 16 infusions.
224211375|NCT00996918|DRUG|Bapineuzumab 1.0 m/kg|I.V., 1.0 mg/kg, infusion every 13 weeks for a total of 16 infusions.
224211376|NCT06406231|DEVICE|comparing efficacy of TENS and PEMF in knee osteoarthritis|"Sessions will be conducted by a physiotherapist from the center, trained in the technique.Three sessions per week for three weeks. We used an Automatic Program (approximately 20 minutes).~For each group, the physical therapy was given as below:~G2: Patients treated with magnetotherapy:~-Device used: a prototype of a Health magnetic therapy (H.M.T) generator developed by a group of engineering researchers at the University of Tunis El Manar, employing low-frequency electromagnetic waves. The chosen program is Analgesia. An applicator containing magnets will be placed on the affected knees. The patient will sit on a chair bending knees.~G1 : Patients treated with TENS~-Device used: TENS from ECO2 from Schwa Medico, 2016, France. We chose the Gate control program (high frequency). The patient will sit with bent knees on a chair and adhesive patches will be placed on the affected knee. The intensity will be adapted to the patient's tolerance in both groups."
224211377|NCT01754480|BIOLOGICAL|Fibrin Sealant Grifols|Combination of 3 mL fibrinogen and 3 mL thrombin, in separate syringes assembled on a syringe holder (6 mL of solution in total), applied topically to the target bleeding site.
224211378|NCT01754480|DEVICE|Surgicel®|Up to four Surgicel® sheets applied to the target bleeding site according to Package Insert instructions and the surgeon's usual clinical practice.
224211379|NCT02714140|BEHAVIORAL|PB-HCT +|Participants will be offered 3 HIV testing options. The investigators will rank the predicted utility of all EXISTING HIV testing options for each participant and select those 3 PB-HCT options that jointly maximize the share of participants predicted to prefer at least one of the three options over the common option.
224316191|NCT03059797|DRUG|Anlotinib|Anlotinib Day 1 to day 14 followed by 7 days off treatment in a 21-day cycle
224316192|NCT03059797|DRUG|Placebo|Placebo Day 1 to day 14 followed by 7 days off treatment in a 21-day cycle
224316193|NCT03817541|DEVICE|Edmon (reg), BBraun|exhaled propofol will be compared With plasma propofol values
224211380|NCT02714140|BEHAVIORAL|PB-HCT -|Participants will be offered 3 HIV testing options. The investigators will rank the predicted utility of all feasible HIV testing options for each participant and select 3 PB-HCT options that are less preferred than the common option
223621686|NCT06727305|DRUG|Sirolimus 0.5 Mg Oral Tablet|Sirolimus 0.5 mg oral tablets daily for 2 weeks and complete PK/PD testing. After the first 2 weeks, dose increase, or dose reduction will be made to obtain a stable blood level of 5-7 ng/ml.
223621687|NCT06727305|DRUG|Sirolimus 1Mg Oral Tablet|Sirolimus 1 mg oral tablets daily for 2 weeks and complete PK/PD testing. After the first 2 weeks, dose increase, or dose reduction will be made to obtain a stable blood level of 5-7 ng/ml.
223621688|NCT06727305|DRUG|Sirolimus 2 MG Oral Tablet|Sirolimus 2 mg oral tablets daily for 2 weeks and complete PK/PD testing. After the first 2 weeks, dose increase, or dose reduction will be made to obtain a stable blood level of 5-7 ng/ml.
223621689|NCT06727305|DRUG|Everolimus 0.5 MG Oral Tablet|Everolimus 0.5 mg oral tablets daily for 2 weeks and complete PK/PD testing. After the first 2 weeks, dose increase, or dose reduction will be made to obtain a stable blood level of 5-7 ng/ml.
223621690|NCT06727305|DRUG|Everolimus 1 MG Oral Tablet|Everolimus 1 mg oral tablets daily for 2 weeks and complete PK/PD testing. After the first 2 weeks, dose increase, or dose reduction will be made to obtain a stable blood level of 5-7 ng/ml.
223621691|NCT06727305|DRUG|Everolimus 2 MG Oral Tablet|Everolimus 2 mg oral tablets for daily for 2 weeks and complete PK/PD testing. After the first 2 weeks, dose increase, or dose reduction will be made to obtain a stable blood level of 5-7 ng/ml.
223621692|NCT06742853|DRUG|AZD0780|AZD0780 tablet will be administered orally.
223621693|NCT06742853|DRUG|Ezetimibe|Ezetimibe tablet will be administered orally.
223621694|NCT06742853|DRUG|Rosuvastatin|Rosuvastatin tablet will be administered orally.
223621695|NCT06742853|DRUG|Bempedoic Acid|Bempedoic Acid tablet will be administered orally.
223621696|NCT06742853|DRUG|Placebo|Placebo will be administered orally.
223621697|NCT04782258|DRUG|Tolvaptan Suspension|Syrup
224316194|NCT05696379|OTHER|Angiography derived index of micro-circulatory resistance (Angio-IMR)|Angiography derived index of micro-circulatory resistance (Angio-IMR) post percutaneous coronary intervention.
223621698|NCT04782258|DRUG|Tolvaptan Tablets|Tolvaptan (OPC-41061) Tolvaptan tablets will be administered orally as split-dose regimens (15/7.5 mg, 30/15 mg, and 45/15 mg) upon awakening and 8 hours later (twice daily) based on weight if able to swallow tablets.
223621699|NCT06861855|OTHER|Observation|observation of METTL-14 prognosis
223621700|NCT06861855|BEHAVIORAL|IHC|IHC of METTL-14
223621701|NCT06747351|BIOLOGICAL|TAK-881|Participants will receive SC infusion of TAK-881.
223621702|NCT06747351|BIOLOGICAL|HYQVIA|Participants will receive SC infusion of HYQVIA.
223621703|NCT06747351|DEVICE|SC Investigational Needle Sets|The single-use only SC needle set will be used to administer TAK-881/HYQVIA to the target depth below the skin surface. One needle set (single or bifurcated) will be used per infusion.
223621704|NCT07059429|DRUG|Ketamine|Ketamine administered intravenously at 0.15 mg/kg/h via PCA with 1 mg boluses, 5-minute lockout, maximum 500 mg per 24 hours after knee arthroplasty.
223621705|NCT07059429|DRUG|Standard Analgesia|Standard analgesia includes ketoprofen 100 mg twice daily and paracetamol 1000 mg every 8 hours for 24 hours after knee arthroplasty; morphine 10 mg IM as needed for rescue therapy.
223621706|NCT07060963|BEHAVIORAL|Motivational interviews within the context of a health promotion-based diabetes self-management program|The researcher provided counseling services to pregnant women to provide Diabetes Self-Management Group training based on Pender's Health Promotion Model. A group was formed consisting of at least 10 people. The training was completed face-to-face and practically, in 1 day (160 minutes), in 4 sessions, each session being 40 minutes. Motivational interviews were conducted by the researcher within the scope of the health promotion-based diabetes self-management program. A second motivational interview was planned according to the determined need and the interviews were provided. Each interview lasted approximately 40 minutes. In order to ensure continuity for the pregnant women who obtained positive behavioral outcomes, reinforcement was provided by telephone interviews and the counseling process was completed.
223621707|NCT05616338|OTHER|Blood sample|"A blood sample and a nasal brush for each participant. The nasal brushing will allow the isolation of epithelial cells that will serve as a comparison for the bronchial tissue produced from blood-derived iPS.~A blood sample of approximately 14 ml will be taken for isolation and freezing of the blood mononuclear cells allowing the generation of iPS."
223621708|NCT06685718|DRUG|BG-60366|Administered orally
223621709|NCT06750562|BEHAVIORAL|interactive game|Interactive game supported sleep hygiene will be prepared by researchers. The game will be shared after each sleep hygiene training. The intervention is planned as 4 trainings and 4 games in total.
223621710|NCT06424522|DIETARY_SUPPLEMENT|Dietary Fiber|Receive dietary fiber
223621711|NCT06424522|PROCEDURE|Enema Administration|Undergo RRE
223621712|NCT06424522|DRUG|Loperamide Hydrochloride|Receive loperamide hydrochloride
223621713|NCT06424522|PROCEDURE|Physical Therapy|Undergo pelvic floor physical therapy
223621714|NCT06424522|OTHER|Questionnaire Administration|Ancillary studies
223621715|NCT06424522|PROCEDURE|X-Ray Imaging|Undergo abdominal film x-ray
223621716|NCT06428409|BIOLOGICAL|Sacituzumab tirumotecan|Given by IV infusion.
223621717|NCT06428409|DRUG|Fluorouracil (5-FU)|5-FU is administered by IV infusion over 46 to 48 hours every 2 weeks.
223621718|NCT06428409|DRUG|Leucovorin (LV) or levoleucovorin|LV or levoleucovorin is administered by IV infusion every 2 weeks.
223761794|NCT00077168|PROCEDURE|adjuvant therapy|
223761795|NCT00077168|RADIATION|radiation therapy|
224211381|NCT02714140|BEHAVIORAL|Economic incentive|Participants will be re-contacted three months after being offered PB-HCT options. Participants will be reminded of the options, and offered an incentive to present for testing using any of the PB-HCT options or the common option.
224316195|NCT02498041|PROCEDURE|Transnasal Endoscopy|Experimental procedure with transnasal endoscopy for the first 80% of the patients (n=90). The examination is limited to the esophagus and the proximal stomach.
224316196|NCT02498041|DEVICE|Office-based disposable transnasal endoscopy Endosheath|Experimental procedure with portable, disposable transnasal endoscopy for the last 20% of patients only (n=25). The examination is limited to the esophagus and the proximal stomach.
224211382|NCT02714140|BEHAVIORAL|PB-HCT ++|Participants will be offered 3 HIV testing options. The investigators will rank the predicted utility of all feasible ENHANCED HIV testing options for each participant and select those 3 PB-HCT options that jointly maximize the share of participants predicted to prefer at least one of the three options over the common option.
224211383|NCT02714140|BEHAVIORAL|SMS Reminder|Participants will receive an SMS reminder to test.
224211384|NCT02566967|DRUG|tofacitinib|oral tofacitinib will be taken 2 times daily
224211385|NCT00391040|BEHAVIORAL|SGS education|
224211386|NCT00568100|PROCEDURE|PSV and NAVA|evaluated the effect of PSV and NAVA on breathing pattern, respiratory effort, gas exchange and level of breathing comfort in COPD patients
224211387|NCT04250896|OTHER|Control group|Standard child care in health unit plus exposure to EsIAN
224211388|NCT04250896|BEHAVIORAL|SMS´s sending by cell phone for behavior change|SMS messages sent through a cell pone through the RapidPro platform on practices related to the prevention of infant malnutrition to primary caregivers and the strengthening of counseling for the prevention of infant malnutrition with health providers.
224211389|NCT00279149|PROCEDURE|Visio conference system connected to the Tele-stroke network|Visio conference system connected to the Tele-stroke network
224211390|NCT03384407|DEVICE|Red cell survival in INTERCEPT treated red cells|Red cell recovery/survival analysis of untreated and INTERCEPT treated RBC concomitantly
224211391|NCT02341209|DRUG|Doxycycline monohydrate|Doxycycline will be administered in either tablets or capsules for either five months or a year depending on response.
224211392|NCT01029769|DRUG|Olanzapine or amisulpride|Oral olanzapine 5mg to 20mg/d OR oral amisulpride 200mg to 800mg/d; both preferably once daily, both encapsulated for blinding
223621719|NCT06428409|DRUG|Rescue medication|Participants are allowed to take rescue medication to prevent hypersensitivity and/or infusion reactions as a premedication to study treatment. At the discretion of the investigator, participants are provided with a prescription for rescue medications. Recommended rescue medications are antihistamine, histamine-2 (H2) receptor antagonist, acetaminophen or equivalent, dexamethasone or equivalent infusion. A steroid mouthwash (dexamethasone or equivalent) may be given as prophylaxis for stomatitis/oral mucositis.
224211393|NCT05152004|DRUG|Pariet|Rabeprazole 20 mg and amoxicillin 750 mg qid for 14 days
224211394|NCT05152004|DRUG|Amolin|Rabeprazole 20 mg and amoxicillin 750 mg qid for 14 days
224211395|NCT05152004|DRUG|Klaricid|Rabeprazole 20 mg and amoxicillin 1 g bid. for 7 days, followed by rabeprazole 20 mg, amoxicillin 1 g, clarithromycin 500 mg, and metronidazole 500 mg bid. for 7 days
224211396|NCT05152004|DRUG|Flagyl|Rabeprazole 20 mg and amoxicillin 1 g bid. for 7 days, followed by rabeprazole 20 mg, amoxicillin 1 g, clarithromycin 500 mg, and metronidazole 500 mg bid. for 7 days
224211397|NCT06520241|OTHER|Pregnant|Data were collected using the Personal Information Form, Depression-Anxiety-Stress Scale (DASS-21), and Oral Health Impact Scale (OHIP-14-TR).
223621720|NCT06428409|DRUG|Supportive care measures|Participants are allowed to take supportive care measures for the management of adverse events associated with study intervention at the discretion of the investigator. Supportive care measures may include but are not limited to antidiarrheal agents and antiemetic agents. Artificial tear drops or gel may be given as a supportive care for Ocular Surface Toxicity.
223621721|NCT06428409|DRUG|Cisplatin|Given by IV infusion.
223621722|NCT06428409|BIOLOGICAL|Pembrolizumab|Given by IV infusion.
223621723|NCT06458062|DEVICE|Pocket Colposcope|Each patient will receive treatment in order to prevent cervical cancer
223621724|NCT06570889|DIETARY_SUPPLEMENT|Cholecalciferol D3|Oral intake of 1 capsule per day from week 22-26 in pregnancy to 1 week after delivery
223621725|NCT06570889|OTHER|Olive oil|Oral intake of 1 capsule per day from week 22-26 in pregnancy to 1 week after delivery
223621726|NCT02483429|DEVICE|VRT Care|The VOG report includes direct device output (physiologic traces, quantitative measures) plus most likely diagnosis, category, and clinical trial care pathway (peripheral, equivocal, central) instructions. The VOG report becomes part of the patient's emergency department clinical record.
223621727|NCT06826105|DRUG|Zenpep|two capsules (each containing 15000 USP units of lipase) together with nutritional supplements
223621728|NCT06826105|DRUG|Placebo|two capsules (containing placebo) together with nutritional supplements
224211398|NCT06433986|PROCEDURE|Modified Coronally Advanced Tunnel (MCAT)Technique|Scaling and root planing will be performed and after resolution of gingival inflammation, root coverage procedure will be done with Volume Stable Collagen Matrix(VCMX) using MCAT.
224211399|NCT06433986|PROCEDURE|Vestibular Incision Subperiosteal Tunnel Access (VISTA)Technique|Scaling and root planing will be performed and after resolution of periodontal inflammation, root coverage procedure will be done with Volume Stable Collagen Matrix(VCMX) using VISTA.
224211400|NCT01294605|BIOLOGICAL|Boostrix™ (dTpa)|Intramuscular, 3 doses
224211401|NCT01294605|BIOLOGICAL|GSK Biologicals' reduced-antigen-content combined diphtheria, tetanus, acellular pertussis and inactivated polio vaccine (dTpa-IPV; BoostrixTM)|Intramuscular, single dose
223621729|NCT06740305|OTHER|Altitude|"Subjects will be exposed to simulated altitude (30,000 ft, 4.3 psia) in a hypobaric chamber. This is the same ambient pressure to which astronauts are exposed during EVA (space walks)."
224211402|NCT01294605|BIOLOGICAL|Ditanrix™ Adult, TedivaxTM (Td)|Intramuscular, 2 doses
224211403|NCT01294605|BIOLOGICAL|Ditanrix™ Adult, TedivaxTM (Td)|Intramuscular, 3 doses
224211404|NCT00187057|DRUG|vinblastine, vincristine, prednisone, daunorubicin|See Detailed Description section for details of treatment interventions.
224211405|NCT00187057|DRUG|doxorubicin, methotrexate, cyclophosphamide, L-asparaginase|See Detailed Description section for details of treatment interventions.
224211406|NCT00187057|DRUG|etoposide, cytarabine, mercaptopurine|See Detailed Description section for details of treatment interventions.
224211407|NCT00187057|DRUG|dexamethasone, procarbazine|See Detailed Description section for details of treatment interventions.
224211408|NCT00187057|PROCEDURE|chemotherapy, intrathecal chemotherapy, steroid therapy|See Detailed Description section for details of treatment interventions.
224211409|NCT05606159|DIETARY_SUPPLEMENT|Bacillus velezensis DSM 33864|1 probiotic capsule to be taken orally once a day, with breakfast, once a day for 8 weeks.
224211410|NCT05606159|DIETARY_SUPPLEMENT|Placebo|1 microcrystalline cellulose-containing placebo capsule to be taken orally once a day with breakfast, for 8 weeks.
224211411|NCT06476743|OTHER|Sensory Integration Therapy|This group will receive sensory integration therapy for 30 minutes along with routine physical therapy treatment (warm up exercises and Stretching exercises (hamstrings, quadriceps, and calf muscles) for 15 minutes per session for 3 days a week for 8 week.
224211412|NCT06476743|OTHER|Balance Board Training|This group will receive balance board training for 30 minutes along with routine physical therapy treatment (warm up exercises and Stretching exercises (hamstrings, quadriceps, and calf muscles) for 15 minutes per session for 3 days a week.
224211413|NCT04440007|DRUG|Abivertinib|Abivertinib maleate is a third-generation EGFR tyrosine kinase inhibitor and BTK Inhibitor. The starting dose is 200 mg p.o. QD for up to 28 days.
223621730|NCT06740305|DRUG|100% Oxygen|Oxygen pre-breathing prior to altitude or simulated high altitude exposure is routinely used by the Air Force, NASA and organizations such as Duke Medical Center to prevent and treat decompression sickness as well as for treatment of patients. Oxygen used for this study is medical grade.
223621731|NCT06896916|DRUG|Etentamig|Intravenous (IV) Infusion
223621732|NCT06896916|DRUG|Iberdomide|Oral Capsule
223621733|NCT07058519|DRUG|Osimertinib-based adaptive treatment|Participants in Cohort 1 will receive Osimertinib-based adaptive treatment (either Osimertinib monotherapy or Osimertinib plus chemotherapy) depending on ctDNA EGFRm clearance or relapse by ctDNA EGFRm dynamic monitoring, until radiological disease progression (PD) as per RECIST v1.1 or other withdrawal criteria are met.
223621734|NCT07058519|DRUG|Osimertinib 80 MG|Participants in Cohort 2 will receive Osimertinib 80 mg once daily (QD) plus pemetrexed maintenance every 3 weeks (Q3W) until radiological PD as per RECIST v1.1 or other withdrawal criteria are met.
223621735|NCT07055451|DRUG|B/F/TAF|Tablet for oral suspension administered
223621736|NCT06827990|DEVICE|GORE® Ascending Stent Graft (ASG device)|Endovascular aortic repair of the ascending aorta
223761796|NCT03219060|BEHAVIORAL|Motivational interviewing for smoking cessation in nurses|Intervention, four one-to-one sessions on an approximately weekly basis, with 3 components: MI context, toolkit, and relapse prevention. The sessions were embedded in a MI context and followed two phases: exploratory and resolutive. The former explored the potential ambivalence that nurses experienced and constructed motivation for change; the latter reinforced the decision to quit and developed a change plan. Participants could choose over a range of tools: some more helpful in the exploratory phase (i.e. decisional balance sheet) and others in the resolutive phase (i.e. problem solving skills). The third component was directed at maintenance strategies. The therapy stayed with the nurses in terms of where they were in relation to they readiness for change.
224316197|NCT02498041|DEVICE|Standard upper GI endoscopy|Upper GI endoscopy with standard gastroscope.
223621737|NCT07065929|DIETARY_SUPPLEMENT|Early nutritional management|"The food ingested by patients is collected until the day 7 of the stroke so that dieticians can calculate their needs and provide a suitable diet. If this is not sufficient, a reinforced nutrition strategy (meal enrichment) is implemented.~On day 5 of the stroke, if energy intake is less than 2/3 of the energy objectives, the strategy is switched to level 2, unless it is possible to increase intake within 48 hours."
223621738|NCT07063498|BEHAVIORAL|Coughing Maneuver|1\. Voluntary Coughing Maneuver (Hileli Öksürük): Patients in this group were instructed to perform a voluntary coughing maneuver immediately prior to the percutaneous biopsy procedure. The maneuver was demonstrated by the clinician, and patients were asked to perform 2-3 forceful coughs while in the biopsy position, 30 seconds before needle insertion, to reduce anxiety and procedural pain perception.
223621739|NCT07063498|BEHAVIORAL|Stress ball|2\. Stress Ball Intervention: Patients were given a standard-sized rubber stress ball to hold and repeatedly squeeze during the entire percutaneous biopsy procedure. The intervention began 1 minute before needle insertion and continued until the procedure was completed. The aim was to provide a behavioral distraction to alleviate anxiety and pain.
223621740|NCT06292637|BEHAVIORAL|Cognitive Behavioral Faith Fellowship to Improve Thy Health (CB-FAITH)|CB-FAITH is a behavioral depression intervention set inside a cognitive behavioral framework, and Afrocentric paradigm and informed by faith-based principles, designed to treat major depressive disorder among African American adults. The 13-treatment modules focus on increasing knowledge of depression and healthy coping behaviors. It is designed to be co-delivered by licensed mental health clinicians and pastors at churches.
223621741|NCT05417594|DRUG|AZD9574|Participants will receive AZD9574 orally.
223761797|NCT03219060|BEHAVIORAL|Brief advice|Brief advice based on 5As
224211414|NCT04440007|OTHER|Standard of Care|Standard of Care as determined by the Investigator
224211415|NCT01466673|DRUG|Ethinyl estradiol/Norgestimate (EE/NGM)|Ethinyl estradiol/Norgestimate encapsulated oral tablet will be administered once daily at bed time as 0.035/0.18 milligram (mg) for Days 1-7, 0.035/0.215 mg for Days 8-14, and 0.035/0.250 mg for Days 15-21 of EE/NGM, respectively up to 6 consecutive menstrual cycles consisting of 21 days each.
224211416|NCT01466673|DRUG|Ethinyl estradiol/Desogestrel (EE/DSG)|Ethinyl estradiol/Desogestrel oral formulation will be administered once daily at bed time as 0.040/0.025 mg for Days 1-7, 0.030/0.125 mg for Days 8-22 of EE/DSG, respectively up to 6 consecutive menstrual cycles consisting of 22 days each.
224211417|NCT01248611|DRUG|fentanyl|nasally, dose titrated to effect
224211418|NCT00854607|OTHER|No Intervention|Blood samples will be collected for 12 weeks to evaluate levels of fungal biomarkers.
224211419|NCT05430009|RADIATION|Liver SBRT|24-45 Gy delivered in 3-5 fractions to 1-4 lesions.
224211420|NCT05430009|DRUG|Pembrolizumab|200 mg every 3 weeks or 400 mg every 6 weeks
224316198|NCT02498041|PROCEDURE|Esophageal biopsies|2 research biopsies taken if endoscopic evidence of columnar-lined esophagus
223621742|NCT05417594|DRUG|Temozolomide (TMZ)|Participants will receive temozolomide orally.
223621743|NCT05417594|DRUG|[11C]AZ1419 3391|Participants will receive \[11C\]AZ1419 3391 intravenously.
223621744|NCT05417594|DRUG|Trastuzumab Deruxtecan (T-DXd)|Participants will receive T-DXd intravenously.
223621745|NCT05417594|DRUG|Datopotamab Deruxtecan (Dato-DXd)|Participants will receive Dato-DXd intravenously.
223621746|NCT07065227|BEHAVIORAL|Augmented Theme|The music is augmented by embedding the natural rhythms of bodily functions (e.g. breathing, heart rate variability, vascular tone, etc) that signal the body to calm.
224211421|NCT04324307|DRUG|PD-L1/CTLA4 BsAb|PD-L1/CTLA4 BsAb 5mg/kg, iv，Q2W
224211422|NCT04324307|COMBINATION_PRODUCT|GP|Gemcitabine 1000mg/m2, iv, D1,8,15, 28days/cycle; nab-Paclitaxel 125mg/m2，iv，D1,8,15, 28days/cycle;
224211423|NCT04324307|COMBINATION_PRODUCT|FOLFIRINOX|Fluorouracil 2400mg/m2，iv，D1, 14days/cycle; Oxaliplatin 68-85mg/m2，iv, D1,14days/cycle;Irinotecan135-180mg/m2，iv, D1, 14days/cycle;Calcium Folate 400mg/m2，iv, D1, 14days/cycle;
224211424|NCT02009982|PROCEDURE|Cardioneuroablation|Catheter Ablation of Vagal Inputs in Left Atrium
224211425|NCT02009982|DEVICE|Biosense Webster Navistar ThermoCool Diagnostic/Ablation Deflectable Tip Catheter|This is the device that will be used to perform the Cardioneuroablation procedure
224211426|NCT00597727|DRUG|Peanut SLIT|Liquid peanut protein drops diluted in glycerin which are dosed under the tongue.
223621747|NCT07065227|BEHAVIORAL|Mozart Theme|The selected Mozart composition consists of: Composition Eine kleine Nachtmusik, K. 525 (5 minutes 30 seconds), Andante from Piano Concerto No. 21, K. 467 (6 minutes 30 seconds), and Ave verum corpus, K. 618 (3 minutes).
223621748|NCT03948529|DRUG|eltrombopag|eltrombopag at the starting dose of 50mg/day. After 2 weeks of eltrombopag initiation and in the absence of platelet response, eltrombopag will be increased every two weeks (50mg increase) up to a maximum dose of 150mg/day (2 maximum escalation from D1, with maximum dose escalation phase of 4 weeks).
223621749|NCT06559891|DEVICE|TIVUS™ Renal Denervation System|Renal artery catheterization procedure used to denervate the renal sympathetic nerves in the perivascular space using ultrasound energy.
223621750|NCT06559891|OTHER|Sham|For those subjects randomized to the sham control, the angiogram will serve as the sham procedure.
224211427|NCT00597727|DRUG|Placebo SLIT|Liquid glycerin without peanut which are dosed under the tongue.
224211428|NCT02007746|OTHER|Liver transient elastography (Fibroscan)|Fibroscan will be performed as a measure of liver stiffness. The study will be obtained free of charge in this study.
224211429|NCT02007746|OTHER|Ferriscan|Ferriscan will be done to assess the quantity of liver iron in iron overloaded subjects.
224211430|NCT02007746|PROCEDURE|Liver biopsy in iron overloaded subjects.|Liver biopsy will be done and the results will be compared to Fibroscan results.
224211431|NCT00311571|DRUG|Ethidronate|
224211432|NCT00311571|BEHAVIORAL|Physical training|
224211433|NCT00965263|BIOLOGICAL|Cocaine vaccine (TA-CD)|TA-CD (82,360 μg; IM) were administered at weeks 1, 3, 5 and 9.
223621751|NCT06056024|DRUG|BI 3706674|BI 3706674
223621752|NCT04972162|DEVICE|Web App Strategy Fitting|Web App Strategy fitting of hearing aids
223621753|NCT04972162|DEVICE|Standard-of-care Fitting|Standard-of-care fitting of hearing aids
223621754|NCT07071519|DRUG|Risankizumab|Risankizumab intravenous (IV) infusion
223621755|NCT07071519|DRUG|Risankizumab|Risankizumab subcutaneous (SC) injection
223621756|NCT06335979|DRUG|PIT565|In each cohort, there will be 3 sentinel participants. Additional participants might be added depending on safety and observed biological activity.
223621757|NCT00044304|DRUG|Imatinib|The dosing regimen to be used initially (400 mg po qd in adults and 260 mg/m2/day in children with food and a glass of water) is identical to that recommended by the FDA for the treatment of the chronic phase of chronic myelogenous leukemia (CML) (Prod Info Gleevec ). In patients with ANC \<1500/mm3, platelet counts \< 75,000mm3 or abnormal liver function tests (ALT or AST \> 2.5 or bilirubin \> 3 times the upper limit of normal), the starting dose will be reduced to 300 mg po qD.
224211434|NCT02682433|DEVICE|diagnostic hysteroscopy|Women who were routinely referred to perform diagnostic hysteroscopy. As part of the procedure, clear liquid is inserted into the uterine cavity. After the hysteroscopy, abdominal and vaginal sonar will be performed, and the findings will be recorded and will be compared. Immediately after completion of the office hysteroscopy, two-dimensional and three-dimensional sonar to demonstrate the uterine cavity and its walls will be performed while using the liquid which is left in the uterine cavity. It is important to note that no additional invasive operation will be performed beyond what is necessary to perform hysteroscopy. It should be emphasized that the sonar test will be performed immediately and in the same position as the hysteroscopy test. All procedures will be performed in women clinics or day hospitalization. It should be noted that the medical examinations will not be performed unless there are medical reasons.
224211435|NCT02682433|DEVICE|diagnostic sonar test|Women who were routinely referred to perform diagnostic hysteroscopy. As part of the procedure, clear liquid is inserted into the uterine cavity. After the hysteroscopy, abdominal and vaginal sonar will be performed, and the findings will be recorded and will be compared. Immediately after completion of the office hysteroscopy, two-dimensional and three-dimensional sonar to demonstrate the uterine cavity and its walls will be performed while using the liquid which is left in the uterine cavity. It is important to note that no additional invasive operation will be performed beyond what is necessary to perform hysteroscopy. It should be emphasized that the sonar test will be performed immediately and in the same position as the hysteroscopy test. All procedures will be performed in women clinics or day hospitalization. It should be noted that the medical examinations will not be performed unless there are medical reasons.
224211436|NCT03054935|OTHER|Indirect Calorimetry|Measurement of resting energy expenditure
223621758|NCT00044304|DRUG|Ruxolitinib|The dosing regimen to be used initially (15 mg po bid) is identical to that recommended by the FDA for the treatment of myelofibrosis with platelet counts of 100-200,000/mm3 (Prod Info ruxolitinib). In patients with platelet counts \<100,000/mm3, moderate renal impairment (CrCl \<60 mL/min) or abnormal liver function tests (ALT or AST \> 2.5 or bilirubin \> 3 times the upper limit of normal), the starting dose will be reduced to 10 mg bid. The recommended guidelines for dose adjustment during therapy and discontinuation of therapy in myelofibrosis will be followed.
223761798|NCT03097653|OTHER|Decision-aid|Web platform with a multilevel information and an aid for the decision to be taken. The content is splitted in 16-20 screens; each screen contains the answer to a common question (i.e. What is mammography screening? What are its benefits and harms? What results can be expected from the participation to mammography screening? What is breast cancer?). The information covers also controversial topics as overdiagnosis, overtreatment and the disagreement among scientists about harms and benefits' quantification.
224211437|NCT00233350|DEVICE|use of navigated 3D ultrasound during surgery|
224211438|NCT00148694|DRUG|Cisplatin|Intravenously once every three weeks for a total of 12 weeks
224316199|NCT03957525|OTHER|Pre-Operative Preparatory Virtual Reality Program|The Influence of a Pre-Operative Preparatory Virtual Reality Program on the Self-Assessed Anxiety of Children Undergoing Elective Surgery
223621759|NCT05189925|BIOLOGICAL|gp91 Grans|Adults with gp91phox-deficient CGD without systemic infection will participate in a dose escalation trial to identify the MTD (the most effective yet safe dose) of gp91 Grans IV infusion.
223621760|NCT07134231|DRUG|Fluoride free toothpaste in a chalk base|Fluoride free toothpaste in a chalk base with herbal ingredients
223621761|NCT07134231|DRUG|Fluoride Toothpaste|Fluoride toothpaste containing 1000 ppm MFP and 1.5% arginine in a PCC/RNCC base
223621762|NCT07134231|DRUG|Fluoride free toothpaste in a PCC/RNCC base|Fluoride free toothpaste in a PCC/RNCC base
223621763|NCT07134231|DEVICE|Toothbrush|A commercially available adult soft bristle toothbrush
223761799|NCT03097653|OTHER|Standard information|Web platform with a standard brochure. This standard brochure represents a combination of the best information available from the three participate centre' brochures.
223621765|NCT06935890|OTHER|Jack Jumper Ant Venom Immunotherapy|Jack Jumper Ant Venom Immunotherapy involves injections, under the skin, of gradually increasing doses of insect venom. The treatment is usually between 3-\<6 years duration. Participants will have completed this treatment at least 18 months prior to their enrolment in this trial.
223621766|NCT05121324|DRUG|Standardized seizure protocol|The intervention is a standardized seizure protocol for paramedics that prioritizes administration of only intramuscular (IM) or intranasal (IN) midazolam, up to 2 doses given 5 minutes apart, with age-based dosing as follows: 6-16 months (1.25 mg); 17 months-5 years (2.5 mg); 6-11 years (5 mg); 12-13 years (10 mg).
223621767|NCT05121324|DRUG|Conventional seizure protocol|"The control is the EMS agency's current seizure protocol, based on conventional calculation-based dosing. These vary from one EMS agency to the other with respect to recommended midazolam doses ranging from 0.05-0.3 mg/kg and with multiple route choices listed, including intravenous, intraosseous, intramuscular, intranasal, and rectal.~for paramedics that prioritizes administration of only intramuscular (IM) or intranasal (IN) midazolam, up to 2 doses given 5 minutes apart, with age-based dosing as follows: 6-16 months (1.25 mg); 17 months-5 years (2.5 mg); 6-11 years (5 mg); 12-13 years (10 mg)."
223761800|NCT01818804|DIETARY_SUPPLEMENT|n-3PUFA|
223761801|NCT01818804|DIETARY_SUPPLEMENT|olive oil|
223761802|NCT05114356|DEVICE|TIDAL Cervical Interbody Fusion implant|Cervical interbody fusion device
224211439|NCT06529458|OTHER|Intervention 1 Group|The researcher will apply pressure to the P6 acupressure point on both wrists for approximately 5 minutes at the same time as chemotherapy. He will also have the patient or a relative repeat the method and do it at home three times a day before meals for 5 days.
224211440|NCT06529458|OTHER|Intervention 2 Group|The researcher will apply drops of ginger oil to the P6 acupressure point on both wrists for approximately 5 minutes at the same time as chemotherapy, using circular motions. At the same time, the researcher will have the patient or a relative repeat the method and apply it at home three times a day before meals for 5 days.
224211441|NCT06529458|OTHER|Control Group|No interference will be made
223621775|NCT07190066|OTHER|Data Collection campaign|Participants will be asked to download the MELIROA app, compatible with iOS and Android, to their smartphones and test it for 14 days. The app will prompt the user to set a weekly goal on physical activity and support daily self-monitoring and step count tracking. Τhe app will also offer culturally adapted educational material through mini-courses, motivational and practical tips and an embedded library of materials relevant to physical activity, healthy diet and alcohol consumption. To boost motivation, it will also include reminders and gamification features like badges and points.
223621776|NCT07185776|DRUG|HRS-5632 Injection|HRS-5632 injection.
223621777|NCT07185776|DRUG|HRS-5632 Injection Placebo|HRS-5632 injection placebo.
223621778|NCT07185256|GENETIC|OPGx-BEST1|Experimental Genetic Therapy
223621779|NCT07200024|OTHER|Virtual functional- based treadmill training|rehabilitation technique that combines virtual reality (VR) with treadmill training to improve gait, balance, and functional mobility for individuals with conditions like stroke
223621780|NCT07200024|OTHER|gait training|a specialized form of physical therapy focused on improving a person's walking ability, balance, and coordination after an injury, stroke, neurological condition, or other illness.
223621781|NCT07199725|COMBINATION_PRODUCT|immediate dental implant|control group: 8 teeth were extracted then 8 immediate implants were placed without bone grafting
223621782|NCT07199725|COMBINATION_PRODUCT|immediate dental implant, natural bovine bone substitute material|study group: 8 teeth were extracted then received 8 immediate implants followed by grafting with natural bovine bone substitute material with hyaluronic acid
223621783|NCT07199816|PROCEDURE|Fluoroscopy-Guided Caudal Epidural Block|Under fluoroscopic guidance, the patient in the prone position will receive a caudal epidural injection through the sacral hiatus. A 22-gauge, 3.5-inch spinal needle (Spinocan®, BRAUN) is used to inject 1 mL of contrast media (Omnipaque 300) to confirm correct needle placement. Then, 10 mL of treatment solution (8 mL of 0.5% lidocaine and 2 mL of 8 mg dexamethasone) is administered.
223761803|NCT02633956|DRUG|Obeticholic Acid|Once a day (QD) by mouth (PO)
223761804|NCT02633956|DRUG|Atorvastatin|"Initiate treatment with Atorvastatin at Week 4 visit with a dose of 10 mg once daily (QD) by mouth (PO).~Increase Atorvastatin to 20 mg once daily (QD) by mouth (PO) at Week 8 visit if 10 mg daily is tolerated.~Atorvastatin may be titrated up or down at Week 12 visit as clinically indicated."
223761805|NCT02633956|DRUG|Placebo|Once a day (QD) by mouth (PO)
223761806|NCT00065884|DRUG|Valproate|
223761807|NCT02224872|PROCEDURE|Bone marrow transplant|Day 0
223761808|NCT02224872|DRUG|Thymoglobulin|0.5 mg/kg IV on Day -9 2 mg/kg IV on Days -8, -7
223761809|NCT02224872|DRUG|Fludarabine|30 mg/M2 IV on days -6 to -2
223761810|NCT02224872|DRUG|Cyclophosphamide|14.5 mg/kg IV on days -6, -5, 3, 4
223761811|NCT02224872|RADIATION|TBI|200 cGy on day -1
224211442|NCT02634567|BEHAVIORAL|Cogmed Working Memory Training (CWMT)|The CWMT (Cogmed) method consists of 25 training sessions done online. Each participant assigned to the training group will complete eight exercises for five weeks with five sessions every week. Each session consists of a selection of various tasks that target the different aspects of attention/working memory. Participants will engage in weekly discussions over the phone for about 1 hour with an assigned Cogmed coach who will provide support and encouragement over the 5 weeks.
224211443|NCT02549274|OTHER|self-rehabilitation + physiotherapy|2 training sessions in self-rehabilitation at the hospital and then a self-rehabilitation / day session + 14 physiotherapy sessions (2 by week)
224211444|NCT02549274|OTHER|physiotherapy|14 physiotherapy sessions (2 by week)
224211445|NCT02022410|OTHER|CAS after primary and revision TKA|CAS and RAPT
224211446|NCT05700110|OTHER|Non-Interventional|Non-interventional
224211447|NCT00839007|DRUG|CD-NP|Infusion of CD-NP at one of up to 6 doses or placebo
224211448|NCT02034617|BEHAVIORAL|LiMoNid|One LiMoNid observation will be performed on day 1-3 post birth, one in time of discharge, and one in the home when the infant has reached 40 weeks (+/- 2 week). All observations are performed in presence of and in collaboration with the parents with the outspoken aim to guide the parents to learn how to read and respond to their infant' signals
224211449|NCT01498900|DRUG|repaglinide|Prescription according to the product labelling at the physicians' discretion
224211450|NCT04626765|DRUG|CD19 CAR-T|CD19 CAR-T infusion for pediatric patients with CD19 positive tumor cells
224211451|NCT04626765|DRUG|CD22 CAR-T|CD22 CAR-T infusion for pediatric patients with CD22 positive tumor cells
224211452|NCT04626765|DRUG|CD 19+22|CD19+22 CAR-T infusion for pediatric patients with CD19 positive and CD22 positive tumor cells
224211453|NCT04626765|DRUG|Fludarabine|25mg/㎡ for D-4、D-3 and D-2
223621784|NCT07199816|PROCEDURE|Combined Lumbar Sympathetic Ganglion Block and Caudal Epidural Block|Patients will receive both a caudal epidural block and a lumbar sympathetic ganglion block (LSGB) under fluoroscopic guidance. The LSGB is performed at the L2 or L3 vertebral body on the affected side using a 21-gauge Chiba needle. After confirming needle position with contrast imaging, 10 mL of solution (2 mL of 8 mg dexamethasone + 8 mL of 1% lidocaine) is injected. A caudal block is then performed as described above.
224211454|NCT04626765|DRUG|Cyclophosphamide|500mg/㎡ for D-3 and D-2
224211455|NCT06540612|OTHER|Aerobic exercise|Aerobic exercise is a set of physical activities that work large muscle groups continuously and rhythmically.
223621785|NCT07199426|OTHER|Physical-Cognitive Training|Participants will receive an 8-week physical-cognitive training program using the Blazepod device, consisting of exercises targeting both balance and cognitive skills. Sessions will be conducted three times per week, each lasting one hour.
223621786|NCT07199426|OTHER|Conventional Balance Training|Participants will receive an 8-week conventional balance training program. Sessions will be conducted three times per week, each lasting one hour.
223621787|NCT07199140|BEHAVIORAL|Haptonomy|Pregnant participants will receive a four-session haptonomy intervention, each lasting approximately 45 minutes. The sessions aim to enhance body awareness, reduce childbirth-related anxiety, and support birth self-efficacy. The intervention includes breathing exercises, relaxation techniques, and activities promoting maternal-fetal interaction.
224211456|NCT06540612|BEHAVIORAL|Physical activity counseling|Physical activity counselling is a service that provides personalized guidance and support to help individuals adopt a healthy lifestyle.
224211457|NCT02567266|BEHAVIORAL|Unified Protocol for Adolescents (UP-A)|The UP-A is an emotion-focused, transdiagnostic approach for adolescents (ages 12-18) with a primary emotional disorder. It is a developmental adaptation of the Unified Protocol, a transdiagnostic treatment for adults with emotional disorders. Clinicians present all skills in the context of the emotions most salient to presenting concerns and adolescent/caregiver conceptualizations of treatment needs, thereby personalizing treatment. The UP-A is delivered in 8-21 weekly sessions, with clinician flexibility regarding the sequencing and depth with which various sections are presented to clients and caregivers, as well as the emotions targeted during the course of the intervention.
224211458|NCT02567266|BEHAVIORAL|Youth Outcomes Questionnaire|"The YOQ consists of parent- and youth-report measures of symptoms and alliance administered weekly on a tablet computer. The YOQ online system then generates reports to provide clinicians with systematic feedback about client progress, flagging critical items that have been endorsed (e.g., suicidality, hallucinations), presenting graphs of ratings over time, and providing empirically-derived alerts when clients are failing to progress or showing deterioration. Clinicians will be trained to use this feedback to modify treatment as needed, share it with families as appropriate, and use it to enhance use of supervision."
224211459|NCT02567266|BEHAVIORAL|Treatment as Usual|Clinicians assigned to the TAU condition will be instructed to use whatever treatment methods and outcome monitoring strategies they typically use with adolescents with internalizing disorders.
224211460|NCT01002131|DEVICE|CBCT|Cone Beam Computer Tomography. 3D-imaging Digital Volume Tomography, compared with gold standard intraoperative findings.
224211461|NCT00104117|DRUG|XL999|XL999 was to be given biweekly to an initial cohort of subjects at 0.20 mg/kg and to successive cohorts at doses that escalated by cohort according to a design for safely determining an MTD. After determination of the MTD, one or more additional cohorts were to receive XL999 weekly at the MTD or a lower dose, as determined by the CRC on the basis of interim safety and PK data. By a protocol amendment after initiation of the study, subjects were to be enrolled in an additional cohort to receive a weekly XL999 dose of 200 mg.
224211462|NCT05037942|OTHER|Blood flow restriction at 40% limb occlusion pressure|A 13-cm-wide pneumatic cuff will be applied to the most proximal portion of the chosen thigh (as determined by randomisation), immediately distal to the inguinal fold, prior to a bout of lower-body resistance exercise. The cuff will be inflated to 40% of limb occlusion pressure pressure and will remain inflated throughout the exercise (total occlusion time: \~5 mins).
224316200|NCT02786225|BEHAVIORAL|Collaborative Care|Intervention Group: Women (n=118) will be seen one time, simultaneously by a VUMC perinatologist and a VUSN nurse-midwife (the CARE visit). During the CARE visit, the nurse-midwife and perinatologist will complete the CARE checklist The checklist will be signed by the woman and providers and scanned into the medical record. Following the CARE visit, women will return to midwifery care or be referred to perinatology depending on their needs, remaining in the study. Women returning to the midwifery practice will see a primary midwife for the remainder of care.
224211463|NCT05037942|OTHER|Blood flow restriction at 80% limb occlusion pressure|A 13-cm-wide pneumatic cuff will be applied to the most proximal portion of the chosen thigh (as determined by randomisation), immediately distal to the inguinal fold, prior to a bout of lower-body resistance exercise. The cuff will be inflated to 80% of limb occlusion pressure pressure and will remain inflated throughout the exercise (total occlusion time: \~5 mins).
224211464|NCT01545752|OTHER|teaching by non-interactive CD|teaching book with non-interactive CD
224211465|NCT01545752|OTHER|Interactive CD|Teaching book with interactive CD
224211466|NCT04501549|PROCEDURE|percutaneous coronary intervention|PCI will be performed according to local practice.The bifurcation lesion will be imaged by OCT on at least two time-points for each patient. Plaque morphology will be characterized by OCT. Off-line quantitative coronary angiography (QCA) will be performed before and after PCI and the following QCA parameters will be computed: reference vessel diameter (RVD), lesion length and diameter stenosis (DS) of Main Vessel (MV) and side branch (SB). Blood samples will be taken prior to PCI and 8-12 hours later to determine peri-procedural myocardial injury and infarction following PCI by measuring serum Troponin.
224211467|NCT00243815|DRUG|ibuprofen|
224211468|NCT01255696|BIOLOGICAL|ALV003|
224211469|NCT01255696|BIOLOGICAL|ALV003 placebo|
224211470|NCT02813707|OTHER|QoL questionnaire regarding the long term complication|Micronutrients evaluation
224211471|NCT03027973|DRUG|UPA|Experimental drug
224211472|NCT03027973|DRUG|TEA|Active comparator
224211473|NCT03027973|DRUG|Placebo (for UPA)|Sugar pill manufactured to mimic UPA 5 mg
224211474|NCT03027973|DRUG|Placebo (for TEA)|Sugar pill manufactured to mimic TEA 500mg
224211475|NCT03963999|DIAGNOSTIC_TEST|Ultrasound Elastography|Ultrasound shear wave elastography
224211476|NCT03963999|DRUG|Contrast Enhanced Ultrasound (CEUS)|Contrast-enhanced ultrasound (CEUS) uses an intravenous injection of microbubble contrast agent.
224211477|NCT00123487|DRUG|dasatinib|Tablets, Oral, 70 mg BID, indefinitely, survival study
223621788|NCT07199348|DEVICE|Embobio|Embolization with the device Embobio
223621789|NCT07198555|DRUG|BBM-A101|"Single-dose intra-articular （IA）injection （2ml）(phase Ia)~Low dose group， Middle dose group； High dose group； Control group ：Placebo"
224211478|NCT00123487|DRUG|dasatinib|Tablets, Oral, 140 mg QD, indefinitely, survival study
224211479|NCT04024085|OTHER|completion of the test created Time to be Ready to Void|completion of the test created (Time to be Ready to Void) The participants have to stand up from a chair with armrests, walk 6 meters to the toilet, open the door and turn on the light, close the door, undress and position themselves to urinate
224211480|NCT02343562|DIETARY_SUPPLEMENT|Probiotics|Probiotics in the form of sachet will be given twice daily for a period of at least 6 months during the trial period.
224211481|NCT02343562|DIETARY_SUPPLEMENT|Placebo|Multivitamin off-the-counter.
224211482|NCT06410040|DRUG|Lorlatinib|lolatinib 100mg qd po
224211483|NCT02345863|DRUG|Bendamustine|"Debulking:~2 cycles of Bendamustine (70 mg/m² iv) will be administered before induction unless a contraindication is existing or it is not clinically indicated."
224211484|NCT02345863|DRUG|GA101|"Induction~GA101 iv infusion:~Cycle 1: Day 1 100 mg Day 1 (or 2) 900 mg Day 8 1000 mg Day 15 1000 mg Cycle 2-6: Day 1 1000 mg~Maintenance After the induction ibrutinib po 420 mg daily and GA101 iv 1000 mg every three months will be continued.~GA101: Cycle 1-8 Day 1 1000 mg"
224211485|NCT02345863|DRUG|Ibrutinib|"Ibrutinib will be administered as a daily oral dosage of 420 mg starting on cycle 2 day 1.~Cycle 2-6: Day 1 420 mg daily~Maintenance After the induction ibrutinib po 420 mg daily and GA101 iv 1000 mg every three months will be continued.~Ibrutinib: Cycle 1-8 420 mg daily"
223621790|NCT07198555|DRUG|Placebo|Placebo(phase Ia)
223761812|NCT02224872|DRUG|Mesna|40 mg/kg IV on days 3, 4
224211486|NCT01987024|DEVICE|Actim Partus® test|
224211487|NCT01987024|OTHER|usual procedure|
224211488|NCT04676919|DEVICE|phonophoresis therapy with pulsed mode ultrasound|phonophoresis therapy with pulsed mode ultrasound, five days a week for three weeks
224211489|NCT04676919|DEVICE|phonophoresis therapy with continuous mode ultrasound|phonophoresis therapy with pulsed mode ultrasound, five days a week for three weeks
223621791|NCT07198555|DRUG|BBM-A101|"Single-dose intra-articular （IA）injection （2ml）(phase Ib) Low dose group， High dose group~Control group ：Placebo"
223621792|NCT07198555|DRUG|Placebo|Placebo（phase Ib）
223761813|NCT02224872|DRUG|Tacrolimus|For patients 18 years or older, tacrolimus will be given per institutional standards; may be increased or later changed to a PO BID schedule. Treatment to continue until Day 365 or longer if GVHD present
223761814|NCT02224872|DRUG|Mycophenolic acid mofetil|15 mg/kg PO/IV TID beginning on day 5 through day 35
223761815|NCT04400721|DRUG|Erector spinae plane block with ropivacaine 3.75mg/ml|Single shot erector spinae block
223761816|NCT01057043|DEVICE|Pulsatile cupping|8 sessions cupping in 4 weeks, administered by a cupping machine. Cupping is administered in each session for 15 minutes with silicon cupping glasses to the knee (osteoarthritis) and the lower back.
224211490|NCT04676919|DEVICE|sham ultrasound|sham ultrasound therapy, five days a week for three weeks
224211491|NCT03090919|BIOLOGICAL|Platelet transfusion|
224211492|NCT03090919|OTHER|Saline|
224211493|NCT02197754|OTHER|Controlled diet|"Volunteers will be provided a controlled diet during the entirety of the 10 week treatment period. Meals will be prepared using traditional American foods.~The controlled diet will include polyphenol-rich foods, including apples, berries, and green tea. A blend of multiple polyphenol-rich foods was chosen to investigate whole foods, multiple commodities, and multiple bioactives."
224211494|NCT03896919|DIAGNOSTIC_TEST|HLA-DQ by luminex technology in kidney transplantation|HLA typing (DQ) for donor and recipient using Luminex microbead method from EDTA blood sample
224211495|NCT05191225|DRUG|RiTUXimab Injection [Truxima]|375 (mg/m2) / 60 minutes
224211496|NCT05191225|DRUG|RiTUXimab Injection [Truxima]|375 (mg/m2) / 30 minutes
224211497|NCT00213213|DRUG|Sucrose|
224211498|NCT01904552|DEVICE|Electronic Root Canal Length Measurement Device|Electronic Apex Locator is used to find the apical foramen of the root canal. It uses a weak electrical current passed through the canal by endodontic file
224211499|NCT01406275|DRUG|Amoxicillin and clavulanate|
224211500|NCT03835975|BIOLOGICAL|13vPnC|Pneumococcal conjugate vaccine
223621793|NCT07199491|BEHAVIORAL|Healthy Liver/Hígado Sano program|Participants will attend weekly classes over the 6-month period. This consists of 16 core sessions delivered in the first 6 months (weekly, but with flexibility to skip weeks as necessary due to holidays, etc). The sessions are 30-60 minutes long, conducted in a group setting, with a CDC-certified Lifestyle Coach facilitating the sessions.
223621794|NCT07199491|BEHAVIORAL|Usual Care|participants will first complete a 30- to 45-minute questionnaire that will cover topics such as physical activity, diet, alcohol use, and stress.Participants will then be asked to wear an accelerometer for 7 days and complete a log to identify when it was worn and removed each day.Height and weight will also be measured and a Fibroscan® assessment (to measure amount of fat and scar tissue in the liver), as well as blood work to monitor the liver enzymes will be done
223621795|NCT07198854|OTHER|Not applicable- observational study|This is a retrospective cohort study and intervention is not applicable.
223621796|NCT07199075|BEHAVIORAL|Questionnaires|"Questionnaires~* Oswestry Disability Index (ODI)~* Pain NRS lower back and (wors side) leg~* EQ-5D-3L"
223621797|NCT07199075|RADIATION|Computer Tomography|One additional CT scan is performed for some patients
223621798|NCT07199010|DRUG|Taletrectinib|Taletrectinib, 600mg, QD
223621799|NCT07198841|DRUG|IBI351 combined with cetuximab β|Subjects will receive treatment with IBI351 plus cetuximab β, consisting of oral IBI351 administered at 600 mg twice daily (BID) either in a fasting or fed state, combined with intravenous infusion of cetuximab β injection dosed at 500 mg/m² (body surface area) every two weeks. Each treatment cycle spans two weeks. Therapy will continue until disease progression, unacceptable toxicity, or meeting other protocol-defined criteria for treatment discontinuation-whichever occurs first. Dose adjustments may be implemented throughout the study based on drug-related toxicities.
224211501|NCT03835975|BIOLOGICAL|PPSV23|Pneumococcal polysaccharide vaccine
224211502|NCT03835975|BIOLOGICAL|20vPnC|Pneumococcal conjugate vaccine
224211503|NCT02267252|OTHER|Antibody-sperm binding|
223621800|NCT07199543|DRUG|benzydamine HCl|The investigational medicinal products were tasted during two study ambulatory visits, separated by a wash-out of at least 3 days
223621801|NCT07198581|BEHAVIORAL|LLM-assisted chemotherapy side effect management|Healthcare providers collect patient symptoms during clinic visits, anonymize the information, and input it into the LLM system via temporary chat sessions. The LLM generates management recommendations which physicians review and consider when adjusting treatment plans. Healthcare providers anonymize patient information and input into LLM using temporary chat sessions. LLM recommendations serve as reference only, with physicians making all final clinical decisions.
224211504|NCT04608084|BIOLOGICAL|Autologous platelet rich plasma eye drops|Participant own blood is used for the preparation of Autologous platelet rich plasma eye drops
224316201|NCT02786225|BEHAVIORAL|Comparison Care- Usual Care + primary midwife|Comparison Group: Usual care enhanced with primary midwife. Women in the comparison group (n=118) will receive the standard individual consult visit with a perinatologist and then, if they return to midwifery care, have one consistent midwife (primary midwife) for the majority of remaining prenatal care.
224316202|NCT05489614|DRUG|Olpasiran|Participants will receive olpasiran by subcutaneous (SC) injection.
223621802|NCT07198932|DRUG|Cofrogliptin add to insulin|Patients will be treated with commercially available cofrogliptin according to routine clinical practice at the discretion of the treating physician.
224316203|NCT05301595|PROCEDURE|TAP block|Please see description of TAP block group.
224316204|NCT05301595|PROCEDURE|QL Block|Please see description of QL block group.
224316205|NCT02029196|OTHER|E-vapour product|Smokers of conventional cigarettes who switch to use an e-vapour product.
223621803|NCT07198932|DRUG|Linagliptin add to insulin|Patients will be treated with commercially available linagliptin according to routine clinical practice at the discretion of the treating physician.
223621804|NCT07199270|BIOLOGICAL|GR2303 injection|single dose
223621805|NCT07199270|BIOLOGICAL|Placebo|single dose
223621806|NCT07199270|BIOLOGICAL|GR2303 injection|multiple dose
223621807|NCT07199270|BIOLOGICAL|Placebo|multiple dose
223621808|NCT07199868|PROCEDURE|During early-mid follicular phase, using TV-US guidance and conscious sedation, 1.5 ml of PRP was injected into each ovary's subcortical layer using a 17-gauge ovum pick-up needle.|During early-mid follicular phase, using TV-US guidance and conscious sedation, 1.5 ml of PRP was injected into each ovary's subcortical layer using a 17-gauge ovum pick-up needle.
224211505|NCT04466774|DIAGNOSTIC_TEST|Dip Home-Based Dipstick Analyzer|The Dip Home-Based Dipstick Analyzer is a prescription, in-vitro diagnostic, home use device, which qualitatively and semi-quantitatively measures six urine analytes. The device combines a urine stick kit with an easy to use smartphone application using an image recognition algorithm.
224211506|NCT04466774|DEVICE|Urine analysis predicate device for professional user|Results of the experimental HBDA device will be compared to the results of the predicate device tested by a professional user.
224316206|NCT02029196|OTHER|Conventional cigarette|Smokers of conventional cigarettes who continue smoking conventional cigarettes.
224316207|NCT02847871|BEHAVIORAL|PRISME-3P program|"PRISM-3P program will consist on a visit in the geriatric centre:~* Consultation with the geriatrician to rule a condition associated with loss of mobility and not known until now.~* Perform a nutritional assessment by a dietician followed by appropriate care management.~* Educational activity based on exercises and physical activity and balance: MAPA teaches exercises to develop strength and balance; gives tips to increase time spent on non-sedentary activities and enhance endurance followed by a monthly phone coaching.~* At 3 months, in case of no improvement of the SPPB score of 1 point, a training of 10 weeks with two sessions per week will be perform by the MAPA individually or in small patients groups;~* Implementation of a information exchange processing (mail, phone and book binding) between the various stakeholders."
224316208|NCT04999891|OTHER|Neurocognitive tests|Battery of neurocognitive tests and questionnaires including MoCA, PHQ-9, Falls History, FIFE, STOPBANG, Nutritional Survey, Global Physical Activity Questionnaire, Brief Pain Index, NuDESC, 3D-CAM.
224316209|NCT01121081|DRUG|Alga Dunaliella Bardawil|4 capsules per day, 2 in the morning 2 in the evening for 3 month
224316210|NCT01121081|DRUG|Placebo|"Drug: Alga Dunaliella Bardawil~4 capsules per day, 2 in the morning 2 in the evening for 3 month"
224316211|NCT06633601|DEVICE|MR-Guided Focused Ultrasound Technology|MRI Guidance for use with High-intensity-focused ultrasound (HIFUS)
223621809|NCT07199569|BIOLOGICAL|Jynneos|MVA-BN manufactured in primary CEF cells. MVA-BN (CEF) vaccine contains 0.5 × 10E8 to 3.95 × 10E8 Inf.U and is an LF suspension to be administered subcutaneously into the deltoid muscle of the upper arm (preferably the nondominant arm). Participant will receive 2 doses 4 weeks apart (Day 1 and Day 29).
223621810|NCT07199569|BIOLOGICAL|MVA-BN (Quail)|MVA-BN manufactured in CCX.E10 quail cell line. Vaccine contains 0.5 × 10E8 to 3.95 × 10E8 Inf.U. and is a LF suspension to be administered subcutaneously into the deltoid muscle of the upper arm (preferably the nondominant arm). Participant will receive 2 doses 4 weeks apart (Day 1 and Day 29).
223621811|NCT07199881|PROCEDURE|Stepwise PSV adjustment protocol|Patients will undergo standardized stepwise PSV changes (baseline, ±3 cmH₂O, ±6 cmH₂O, return to baseline), with 2-minute stabilization and repeated measurements of ventilatory parameters.
223621812|NCT07198243|DRUG|STW 5-II|"STW 5-II is an herbal medicinal product for the symptomatic treatment of functional dyspepsia with main symptoms such as epigastric pain, epigastric burning, postprandial fullness and early satiation, but often also loss of appetite, excessive belching and heartburn. STW5-II consists of six herbal extracts: bitter candy tuft, camomile flower, caraway fruit, melissa leaf, peppermint leaf, and licorice root.~STW 5-II will be a solution for oral intake, for the treatment of FD, administered as 20 droplets in liquids, three times daily during 8 weeks. Recommended time of ingestion is just before or with meals. Patients and study staff are blinded for the intervention"
223621813|NCT07198243|DRUG|Placebo|Matching placebo will be a solution for oral intake, administered as 20 droplets in liquids, three times daily during 8 weeks. Recommended time of ingestion is just before or with meals. Patients and study staff are blinded for the intervention.
223621814|NCT07198178|OTHER|Peer Training|"Peer Selection Fourth-year nursing students who have completed the Clinical Practice-I course and are currently attending the Clinical Practice-II course and are in clinical practice four days a week will be invited to volunteer to become peer tutors after being informed about the purpose of the study. These volunteer peer tutors will be selected from among students with strong academic achievement (grade point average of 3.50 or above) and good communication skills, taking into account their clinical experience.~Peer Training Fourth-year students selected as peers will receive a training program consisting of four 40-minute sections, each lasting 160 minutes, prepared by the faculty members and aligned with the Fundamentals of Nursing course curriculum. This training aims to equip peers with the knowledge and skills to guide, provide feedback, and support to first-year students during clinical practice. The training will utilize active learning methods such as role-playing and case st"
223621815|NCT04833114|DRUG|Polatuzumab Vedotin|Polatuzumab vedotin 1.8 mg/kg will be administered intravenously on Day 1 of each 21-day cycle for up to 3 cycles.
223621816|NCT04833114|DRUG|Mabthera|Rituximab (Mabthera/Rituxan®) will be administered as per local practice at a dose of 375 mg/m2 intravenously on Day 1 of each 21-day cycle for up to 3 cycles.
223621817|NCT04833114|DRUG|Ifosfamide|Ifosfamide 5000 mg/m² will be administered i.v. over a 24 hr period starting on cycle Day 2.
223621818|NCT04833114|DRUG|Carboplatin|Carboplatin AUC 5 max 800 mg will be administered i.v. on cycle Day 2.
223621819|NCT04833114|DRUG|Etoposide|Etoposide 100 mg/m² will be administered i.v. on cycle Days 1, 2 and 3.
223621820|NCT07198087|DRUG|Tirabrutinib|Administered orally
223621821|NCT07199907|BEHAVIORAL|Associative Inference|Objects, faces, and scenes will be arranged into 12 ABC triads presented as overlapping AB and BC pairs. AB pairs will comprise objects; BC pairs will consist of the same B object paired with a face or scene (C). Twelve non-overlapping (NO) pairs will serve as controls. Participants will study overlapping (AB, BC) and NO pairs (4s) across two 5-minute fMRI runs. Each pair will be presented three times within a run. Following learning, participants will complete a self-paced 3-alternative forced choice (AFC) inference task during which they will select the C item that shares a common relationship with an A cue. Foils for inference trials will be C items from other ABC triads, of the same face/scene subcategory. Participants will then complete a final, self-paced 3-AFC memory test of premise associations (AB, BC) and NO pairs. To quantify memory retrieval and how overlapping events are organized, before and after learning, participants will view the A and C items during fMRI scanning.
223621822|NCT07199907|BEHAVIORAL|Probabilistic Inference|"Participants will visit a virtual zoo, which is divided into three zones, each containing the same five monsters, but with different likelihoods of occurrence. Participants learn the underlying likelihood distributions by virtually navigating each zone. On each trial, two monsters appear; participants select the monster that they predict will next appear (6s). After making their choice, the correct monster appears and feedback is provided (2s). Participants tour each zone four times across 9 runs. Following learning, participants are tested on probabilistic inference. Here, participants see a series of monster photographs and are asked to infer in which zone they were taken. On each trial, a sequence of individual monster images (3.5s each) will then appear (1-6 monsters) prior to a decision screen, in which participants choose which of the two zones most likely produced the photos (4s) and are given feedback (1.5s). Participants will perform nine fMRI runs of the inference task."
223761817|NCT04301167|BEHAVIORAL|befriending|Participants are new users of the ALONE befriending intervention, which matches participants to volunteer befrienders who visit once weekly for a minimum of 12 months. It is a criterion of study involvement that participants commit to completing at least two data collection timepoints before being matched to a befriender.
223761818|NCT04608266|DRUG|Camostat Mesylate|Camostat mesylate, oral administration 600mg/day (2 x 100mg tablets every 8 hours) for 14 days
223761819|NCT04608266|DRUG|Placebo|Placebo tablets, oral administration 2 tablets every 8 hours for 14 days
223761820|NCT02111252|DRUG|TAK-850|TAK-850 injection
223761821|NCT05028374|DRUG|"A single booster dose of the Moderna mRNA COVID-19 vaccine"|All participants will receive a single dose of the Moderna mRNA COVID-19 vaccine administered intramuscularly. This is an open label, non-randomized trial.
223761822|NCT04750122|DRUG|neoadjuvant chemotherapy upon in vitro PTC drug sensitivity screenning|The choice of chemotherapy is based on the PTC drug sensitivity results.
223761823|NCT03706235|OTHER|Blood draw (venipuncture)|Draw 40 mls of blood from eligible subjects. Process and ship samples to sponsor.
223761824|NCT00148603|DRUG|montelukast|
223761825|NCT00072865|DRUG|Pemetrexed|
223761826|NCT00072865|DRUG|Carboplatin|
223761827|NCT04355962|DRUG|Sevoflurane|Sedation with sevoflurane (etSevo 0.5-1.5 Vol %) for 48 hours in patients with COVID-19 ARDS
224316212|NCT06633601|DRUG|Definity Suspension for Injection|Microbubble contrast agents for ultrasound
224211507|NCT01725074|BEHAVIORAL|"Case Management CM CHD"|"Patients, who are randomized to the intervention group, will receive case management from a trained and experienced physician assistant. The case manager will carry out following tasks:~* Biweekly/monthly telephone consultations or home visits~* Identification of health or personal problems of the patient~* Monitoring of medical parameters~* Coordination of contact with health care providers if necessary~* Support to the patient related to health status and environmental changes~* Promote disease-self management through coaching~* Counseling, that is focused on emotional support and active listening"
223621823|NCT07199322|DEVICE|Robotic upper limb rehabilitation in patients with Stroke with AI support|"Participants will receive upper limb robotic treatment using MOTORE (Mobile robot for upper limb neurOrtho Rehabilitation), a medical device indicated for post-stroke and post-traumatic rehabilitation. MOTORE is a portable, autonomous, omnidirectional, haptic robot that provides force feedback to the user and supports active, passive, and assistive movements.~The device includes software with assessment and rehabilitation exercises presented as interactive games (serious games), enabling personalized therapy and measurement of patient performance. MOTORE follows the assist as needed paradigm, actively assisting or resisting movements based on the patient's intentions. Parameters are set by the AI-based decision support system (CO-AIDER). Treatment will be delivered daily for 45 minutes, five days per week, for a total of 30 sessions."
223621824|NCT07199322|DEVICE|Robotic upper limb rehabilitation in patients with Stroke without AI support|"Participants will receive upper limb robotic treatment using MOTORE (Mobile robot for upper limb neurOrtho Rehabilitation), a medical device indicated for post-stroke and post-traumatic rehabilitation. MOTORE is a portable, autonomous, omnidirectional, haptic robot that provides force feedback to the user and supports active, passive, and assistive movements.~The device includes software with assessment and rehabilitation exercises presented as interactive games (serious games), enabling personalized therapy and measurement of patient performance. MOTORE follows the assist as needed paradigm, actively assisting or resisting movements based on the patient's intentions. Parameters are set by the clinical team based on their expertise. Treatment will be delivered daily for 45 minutes, five days per week, for a total of 30 sessions."
223621825|NCT07198360|OTHER|No intervention|Not found
223621826|NCT07199738|DEVICE|Cemented CoCr|Primary TKA performed using the LEGION MS with Cemented Tibia (JII) with LEGION CR non-porous (CoCr) Femoral component
223621827|NCT07199738|DEVICE|Cemented Oxinium|Primary TKA performed using the LEGION MS with Cemented Tibia (JII) with LEGION CR non-porous (Ox) Femoral component
223621828|NCT07199738|DEVICE|Cementless|Primary TKA performed using the LEGION MS with CONCELOC Tibia with LEGION CR porous (without HA) Femoral component
223621829|NCT07198035|DRUG|PF-07248144|Participants will receive a single dose of PF-07248144 by mouth in Period 1 on Day 1 and Period 2 on Day 14, with a washout period of at least 14 days between two doses of PF-07248144
223621830|NCT07198035|DRUG|Carbamazepine|Participants will receive Carbamazepine by mouth once a day for Day 1 through 3, then twice a day for Day 4 through 7, and then three times daily for Day 8 through 20 in Period 2.
223621831|NCT07198672|DRUG|Herombopag|Each T-DM1 treatment cycle typically lasts 3 weeks, with prophylactic administration of eltrombopag continuing until 21 days after the end of that T-DM1 treatment cycle. Oral administration of eltrombopag ethanolamine tablets begins on the evening of the first day of each T-DM1 treatment cycle, starting at a dose of 7.5 mg once daily.
223621832|NCT07197970|DEVICE|NxiDIME™ Intracranial Drug-Eluting Stent System|The experimental group will receive the NxiDIME™ Intracranial Drug-Eluting self-expanding Stent System (RICOTON Technology Co., Ltd.)
223621833|NCT07197970|DEVICE|NOVA DES Intracranial Drug-Eluting Stent|The experimental group will receive the NOVA DES Intracranial Drug-Eluting balloon-expandable stent System
223621834|NCT07198412|PROCEDURE|Ultrasound-guided spinal anesthesia|Spinal anesthesia performed under real-time ultrasound guidance using a curvilinear ultrasound probe and 25-27G pencil-point spinal needle. Intrathecal injection of bupivacaine 0.5% hyperbaric (12-15 mg) following local infiltration with lidocaine 1% (2-3 mL).
223761828|NCT04355962|DRUG|Intravenous drug|Intravenous sedation in control group will be continued as initiated at the ICU e.g. propofol, fentanyl, midazolam, dexmedetomidine
223761829|NCT01857258|DIETARY_SUPPLEMENT|Green Tea Concentrate|Green tea concentrate is being examined as a dietary supplement that can regulate postprandial excursions in blood glucose
223761830|NCT03755024|DEVICE|ultrasound|"The compulsory ultrasound measurements to be obtained at all visits include the following biometrical parameters:~* Biparietal diameter~* Head circumference~* Abdominal circumference~* Femur length~* Humerus length"
224211508|NCT01725074|BEHAVIORAL|Social Interaction|Identical as the CM CHD group, but with exclusion of medical control measures and the medical aspects.
224211509|NCT04039165|BEHAVIORAL|PP-MI Intervention|The positive psychology exercises include gratitude-based activities, strengths-based activities, and meaning-based activities. The physical activity goal setting exercises include the following topics: health benefits, social resources, and neighborhood walkability.
224211510|NCT02619331|PROCEDURE|Allergy test reading|Reading of allergy skin tests (in response to allergen extracts or histamine or negative control) by HSL-DI versus direct observer evaluation (CWFM)
224211511|NCT01511900|DRUG|CAT 1004|Multiple dose oral administration once daily for 14 days of CAT 1004 at dose level 1-9 subjects will be treated with CAT-1004
224211512|NCT01511900|DRUG|Placebo|Multiple dose oral administration of placebo daily for 14 days-3 subjects will be treated with placebo per cohort
224211513|NCT01511900|DRUG|CAT 1004|Multiple dose oral administration once daily for 14 days of CAT 1004 at dose level 2 -9 subjects will be treated with CAT-1004
224211514|NCT01511900|DRUG|CAT 1004|Multiple dose oral administration BID for 14 days of CAT 1004 at dose level 3-9 subjects will be treated with CAT-1004
224211515|NCT01511900|DRUG|CAT 1004|Multiple dose oral administration BID for 14 days of CAT 1004 at dose level 4-9 subjects will be treated with CAT-1004
224211516|NCT01511900|DRUG|CAT 1004|Multiple dose oral administration daily for 14 days of CAT 1004 at dose level TBD-9 subjects will be treated with CAT-1004
224211517|NCT05692466|DIAGNOSTIC_TEST|Comprehensive molecular panel test|Lab test
224211518|NCT05692466|OTHER|EORTC QLQ-30|Quality of life questionnaire
224211519|NCT01264328|DRUG|Panitumumab + paclitaxel|Paclitaxel 80 mg/m2 may be infused, intravenously, over one hour every week. Panitumumab will be administered every 2 weeks at a dose of 6 mg/kg, using a non pyrogenic low protein binding filter with a 0.20-0.22-μm pore size intravenously over 1 hour ± 15 minutes. Panitumumab will be administered prior to paclitaxel.
224211520|NCT06567535|PROCEDURE|Navigation and endoscopy|The model was reconstructed using patient CT data, and intraoperative surgery was performed using endoscopy and navigation.
224211521|NCT05365022|DEVICE|ROSA® System Robotic Assisted Knee Prosthetic Surgery|Robotic Assisted Knee Prosthetic Surgery using ROSA® (Zimmer-Biomet) System
224211522|NCT02314949|PROCEDURE|intestinal transplantation|
224211523|NCT06541743|DEVICE|Regular Toothbrush|Participants and their guardians will be instructed in the horizontal scrub technique and asked to adhere to a brushing regimen of two minutes, twice daily, for 45 days. Standard fluoride toothpaste and a diary for recording brushing experiences will also provided. Guardians will be supervised brushing to ensure compliance and prevent the use of other oral hygiene measures.
224211524|NCT06541743|DEVICE|Musical toothbrush|Participants and their guardians will be instructed in the horizontal scrub technique and asked to adhere to a brushing regimen of two minutes, twice daily, for 45 days. Standard fluoride toothpaste and a diary for recording brushing experiences will also provided. Guardians will be supervised brushing to ensure compliance and prevent the use of other oral hygiene measures.
224211525|NCT06541743|DEVICE|Electric toothbrush|Participants and their guardians will be instructed in the horizontal scrub technique and asked to adhere to a brushing regimen of two minutes, twice daily, for 45 days. Standard fluoride toothpaste and a diary for recording brushing experiences will also provided. Guardians will be supervised brushing to ensure compliance and prevent the use of other oral hygiene measures.
224211526|NCT02339428|DRUG|diclophenac sodium|Patients will be given 100mg p.o. diclophenac sodium tablets
224211527|NCT02339428|DRUG|Placebo|Inactive pill manufactured to mimic diclofenac tablet
224211528|NCT03248778|BEHAVIORAL|disclosure-support counseling intervention|The intervention will include three components: (a) assessment; (b) decision-making and support; and (c) disclosure, planning, and action. The individualized assessment comprehensively will consider the family's history, experiences with disclosure, communication skills, coping resources, and factors likely to affect disclosure (e.g., familial, psychological, social, cultural, and medical issues). The second component of decision-making and support focused on developing communication skills and strategies, with role-play and practice outside of the sessions as necessary. Costs and benefits of disclosure were considered along with the range of disclosure options. Materials, including a pros and cons chart of disclosure and a disclosure continuum worksheet, were used to stimulate discussions of possible plans and consequences. In the third component, parents were encouraged to formulate and practice a disclosure plan for later use.
224211529|NCT03343145|BIOLOGICAL|Leucostim 5µg/kg/day|5µg/kg/day (based on actual body weight) Leucostim®, subcutaneously, once a day, for up to 14 days or until the target ANC of 10,000/mm3 following the expected chemotherapy-induced ANC nadir
224211530|NCT03343145|BIOLOGICAL|Neupogen 5µg/kg/day|5µg/kg/day (based on actual body weight) Neupogen®, subcutaneously, once a day, for up to 14 days or until the target ANC of 10,000/mm3 following the expected chemotherapy-induced ANC nadir
224211531|NCT00677677|BIOLOGICAL|Human papillomavirus quadrivalent vaccine|Patients meeting the inclusion / exclusion criteria will be enrolled from outpatient transplant clinics. Upon enrolment, baseline serum will be obtained and patients will be given the first dose of vaccine. Two months later, serum will again be obtained and the second dose of vaccine will be administered. Finally, at month 6, serum will be obtained and the third dose of vaccine will be given. The final serum samples will be collected at months 7, 12 and 36. At 48 hours and 7 days after each vaccination, patients will be contacted by telephone for local and systemic adverse effect reporting.
224211532|NCT04580173|DIAGNOSTIC_TEST|metabolomics analysis|Targeted and untargeted metabolomics-based analysis will be performed using Gas Chromatography tandem Mass Spectometry and Liquid Chromatography tandem Mass Spectrometry, in order to quantify serum biomarkers.
224211533|NCT02238470|DRUG|oral anticoagulants|Comparison of patients receiving oral anticoagulants with or without microbleeds in magnetic resonance imaging
224211534|NCT01832688|OTHER|Programmatic prenatal care optimization|To further integrate and improve nutrition-related services and messages in the prenatal care package.
224211535|NCT00081835|DRUG|NP-016 Vaccine Immune Globulin (IV-VIG)|
224211536|NCT03923816|DRUG|Conservative fluid strategy: 12 mL/kg/h of Lactated Ringer (LR).&Restrictive fluid strategy:6 mL/kg/h of Lactated Ringer (LR).|comparison of two intraoperative fluid strategies upon hepatic outcome in hepatobiliary surgery
224211537|NCT00061945|DRUG|allopurinol|Given PO
224316213|NCT04521101|OTHER|VAST Course|Educational course to teach non-technical skills
224316214|NCT03717012|DRUG|Nintedanib|stable dose
224211538|NCT00061945|DRUG|cyclophosphamide|Given IV
224211539|NCT00061945|DRUG|daunorubicin hydrochloride|Given IV
224211540|NCT00061945|DRUG|vincristine sulfate|Given IV
224211541|NCT00061945|DRUG|dexamethasone|Given PO and as eye drops
224211542|NCT00061945|DRUG|asparaginase|Given SC
224211543|NCT00061945|BIOLOGICAL|filgrastim|Given SC
224211544|NCT00061945|DRUG|imatinib mesylate|Given PO
224211545|NCT00061945|DRUG|methotrexate|Given IT, IV, and PO
224211546|NCT00061945|DRUG|cytarabine|Given IV
224211547|NCT00061945|DRUG|trimethoprim-sulfamethoxazole|Given PO
224211548|NCT00061945|DRUG|mercaptopurine|Given PO
224211549|NCT00061945|DRUG|leucovorin calcium|Given IV and PO
224211550|NCT00061945|BIOLOGICAL|alemtuzumab|Given SC
224211551|NCT00061945|DRUG|acyclovir|Given PO
224316215|NCT03717012|OTHER|Pulmonary rehabilitation program|12 weeks
224316216|NCT06526624|DRUG|HS-20093|Subjects in experimental arm will be given HS-20093 intravenously at a dose of 8.0 mg/kg every 3 weeks, until disease progression or until other criteria for treatment discontinuation are met.
224316217|NCT01425658|DRUG|distilled water|The placebo group (group P) received bupivacaine 10mg combined with 0.5ml distilled water intrathecally .
224316218|NCT01425658|DRUG|Clonidine|The clonidine group (group C) received bupivacaine 10mg combined with 75 microgram clonidine intrathecally .
224316219|NCT01425658|DRUG|Fentanyl|The Fentanyl group (group F) received bupivacaine 10mg combined with 25 microgram fentanyl intrathecally .
224316220|NCT00789035|DRUG|BI 10773|
224316221|NCT00789035|DRUG|placebo|
224316222|NCT00789035|DRUG|metformin|
224211552|NCT00061945|OTHER|laboratory biomarker analysis|Correlative studies
223621835|NCT07198412|DRUG|Midazolam plus ultrasound-guided spinal anesthesia|Patients will receive midazolam (0.02-0.05 mg/kg IV; max 5 mg) 5-10 minutes prior to spinal anesthesia. Ultrasound guidance used for spinal needle placement. Intrathecal bupivacaine 0.5% hyperbaric (12-15 mg) after lidocaine 1% (2-3 mL) infiltration. Oxygen supplementation at 2 L/min and standard monitoring.
223621836|NCT07198412|PROCEDURE|Landmark-guided spinal anesthesia|Spinal anesthesia performed using the traditional landmark palpation technique without ultrasound guidance or sedation. Intrathecal bupivacaine 0.5% hyperbaric (12-15 mg) after lidocaine 1% (2-3 mL) infiltration, using a 25-27G pencil-point spinal needle.
223621837|NCT07198516|DRUG|Addition of Hengge Liejing treatment for 48 weeks|Treatment with Hengge Liejing for 48 weeks, drug formulation: tablets. Dosage: 10mg qd, taken orally in the morning, before or after breakfast, for 48 consecutive weeks
224211553|NCT00061945|OTHER|pharmacological study|Correlative studies
224211554|NCT04326569|OTHER|Blood sample|Blood sample to quantify copeptin
224316223|NCT05029219|DEVICE|Arm I (Virtual reality group)|"In the preparatory session, the participant is given a survey. It is about demographic information such as gender, age, and age, as well as prior experience with the procedure. The primary test is performed with a fluoroscopy guided lumbar transforaminal epidural block with a human-shaped phantom.~After that, the test group and the control group receive the same audiovisual education for about 5 minutes. The test group receives about 60 minutes of training using a virtual reality program."
224316224|NCT05029219|DEVICE|Arm II (Self study group)|"In the preparatory session, the participant is given a survey. It is about demographic information such as gender, age, and age, as well as prior experience with the procedure. The primary test is performed with a fluoroscopy guided lumbar transforaminal epidural block with a human-shaped phantom.~After that, the test group and the control group receive the same audiovisual education for about 5 minutes. The control group have provided with video materials and books provided during audiovisual education and have given time for self-study for 60 minutes. Subsequently, a second test is performed with a fluroscopy-guided lumbar transforaminal epidural block with a human-shaped phantom."
223621838|NCT07199413|BIOLOGICAL|SV-BR-1-GM Vaccine|\~20 X 10\^6 cells across 4 injection sites
223621839|NCT07199413|DRUG|Cyclophosphamide|300 mg/m\^2 Intravenous
223621840|NCT07199413|DRUG|Pembrolizumab|200 mg/m\^2 Intravenous
223621841|NCT07199413|DRUG|Interferon|0.18 mcg subcutaneous
223621842|NCT07199361|DEVICE|Peripheral Transcutaneous Magnetic Stimulation from MagVenture|"MagVenture Pain Therapy System: It is an FDA-cleared magnetic stimulator system that provides brief and focused magnetic pulses to non-invasively stimulate peripheral nerves and provide relief of chronic intractable, post-traumatic, and post-surgical pain for patients 18 years or older. It is a relatively new technique in the US for pain relief in the clinical setting and thus not very widespread yet. Evidence shows Magnetic Peripheral Nerve Stimulation to have a promising average pain relief of up to 87%\*. Using magnetic pulses, MagVenture Pain Therapy engages sensory, pain, and motor fibers mechanistically to recondition the central nervous system by eliminating noxious pain signals to the brain, reducing chronic neuropathic pain for responsive patients.~\*Bedder M, Parker L.: Magnetic Peripheral Nerve Stimulation (mPNS) for Chronic Pain, 2023"
223621843|NCT07199790|OTHER|Action observation videos|The participant will see videos of balance exercises performed by the assigned reference, depending on their group, without performing any physical movement.
223621844|NCT07199790|OTHER|Therapeutic exercise|The therapeutic exercise program aimed at improving balance and preventing falls will be carried out three times per week (Monday, Wednesday, and Friday), with each session lasting 30-45 minutes. Each session will be structured into three blocks: a warm-up of 5-10 minutes, a main block focused on balance and strength lasting 20-25 minutes, and a cool-down of 5-10 minutes.
223621845|NCT07198971|OTHER|Music therapy|"Music therapy sessions in addition to nursing consultations:~creation of a soundtrack to listen to in order to help quit smoking"
223621846|NCT07197996|DEVICE|Intermittent Pneumatic Compression|The IPC arm will use the Kendall SCD™ 700 Sequential Compression System, a routinely employed device for VTE prophylaxis in stroke patients. In this study, IPC sleeves will be applied bilaterally to the legs within 36 hours of stroke onset and operated according to the manufacturer's instructions. The intervention is distinguished by its cyclical external leg compression to enhance venous return, and it serves as the comparator to the geko® device for evaluating effects on cerebral blood flow and haemodynamics.
223761831|NCT05118841|DRUG|ZX-4081|Twice daily (BID), oral dosing of ZX-4081 at the assigned dose level in a 28-day cycle
223761832|NCT01163604|DRUG|Argatroban|Intravenous Infusion, 20mg/day for 2 days before and 3 days after stenting, (10mg/3h, twice a day), with accompanied aspirin and clopidogrel treatment
223761833|NCT01163604|DRUG|non-argatroban treated group|Patients who underwent intracranial and extracranial artery stenting were randomly chosen to receive only aspirin and clopidogrel treatment.
224211555|NCT06338800|BEHAVIORAL|One session exposure with Virtual Reality|Participants will receive one session exposure with virtual reality from their therapists.
224316225|NCT01335035|DRUG|deferasirox|
224316226|NCT02386124|OTHER|frailty evaluation|assessment of mental and physical frailty before discharge from cardiac departement
224211556|NCT01578252|DRUG|Ondansetron Tablets USP 8 mg|8 mg tablet once a day
224316227|NCT05640258|DIAGNOSTIC_TEST|rotatory chair testing in a velocity step protocol.|Tc was evaluated by the rotational velocity step test using the OtoaccessTM interface (Interacoustics Nydiag 200, Middlefart, Denmark). Subjects were seated on the rotatory chair wearing videonystagmography goggles with their heads supported and tilted 30° forward, thus bringing the horizontal semicircular canals plane perpendicular to the axis of rotation. Standard videonystagmography techniques were employed to record eye-movements. Subsequent to eye movements' calibration, the chair was accelerated about the yaw axis at 30°/sec2 to a maximal velocity of 90°/sec, followed by rotation at a constant velocity. After 57 seconds of constant velocity rotation, the chair was decelerated to zero velocity at 30°/sec2. The described velocity step was conducted both clockwise and counter-clockwise, giving a total run time of 4 minutes.
224316228|NCT00157924|DRUG|simvastatin (+) ezetimibe|simvastatin (+) ezetimibe 10/20mg.
224211557|NCT01578252|DRUG|Ondansetron Hydrochloride|8 mg tablet once a day
224211558|NCT04698278|DEVICE|PanOptix Trifocal Intraocular Lens|This is a FDA approved trifocal lens that will be placed in patients who have had previous myopic LASIK or PRK.
224211559|NCT06390111|DRUG|nadofaragene firadenovec|The investigational medicinal product dose, concentration, and assessments are aligned with nadofaragene firadenovec US prescribing information.
224316229|NCT00157924|DRUG|atorvastatin|atorvastatin 10mg
223621847|NCT07197996|DEVICE|geko® T3|The geko® T3 device is a small, disposable, battery-powered neuromuscular electrostimulation device manufactured by Firstkind Ltd. In this study, the geko® will be applied bilaterally to the common peroneal nerve at the knee within 36 hours of stroke onset. It delivers transcutaneous electrical stimulation at 1 Hz, producing involuntary rhythmic foot dorsiflexion to activate the calf and foot muscle pumps. The intervention is distinguished from IPC by its mechanism of action (neuromuscular stimulation vs. external compression) and will be evaluated for its impact on cerebral haemodynamics, neurovascular coupling, and dynamic cerebral autoregulation during VTE prophylaxis.
223621848|NCT07198191|DRUG|SGLT2 inhibitors (e.g., dapagliflozin, empagliflozin)|Exposure to SGLT2 inhibitors following AMI in patients with T2DM
223621849|NCT07198191|DRUG|DPP4 inhibitors|Exposure to DPP4 inhibitors following AMI in patients with T2DM
223621850|NCT07198347|DRUG|AG2001|Oral administration, three times daily for 7 days.
223621851|NCT07198347|DRUG|AG20011|Oral administration, three times daily for 7 days.
223621852|NCT07198347|DRUG|AG20012|Oral administration, three times daily for 7 days.
223621853|NCT07199478|PROCEDURE|Integrated mHealth and ERAS Digital Rehabilitation via WeChat Mini-Program|"This intervention arm is distinguished by the following key features:~Theory-Driven Design: Uniquely integrates three established behavioral theories into its core functionality: Bandura's Self-Efficacy Theory, the Health Belief Model, and Illeris's Learning Model. This theoretical foundation directly informs the app's features to target psychological and behavioral barriers to recovery.~Multi-Functional Platform: Combines several evidence-based components into a single, cohesive platform within the ubiquitous WeChat ecosystem. Key features include:~Visual Goal and Progress Tracking: Provides patients with mastery experiences.~Peer Community (Modeling Community): Features patient stories and videos to provide vicarious experiences and social support.~AI-Powered Persuasion System: Delivers automated, personalized feedback and remote encouragement from healthcare providers.~Built-in Emotional Management Tools: Includes an emotion diary"
223621854|NCT07199478|PROCEDURE|Standardized ERAS Protocol|Participants received only the standardized Enhanced Recovery After Surgery (ERAS) protocol, representing the conventional care model.
223621855|NCT07198802|OTHER|No Intervention|This project involves no therapeutic intervention for the subjects.
223621856|NCT07199764|DRUG|Odetiglucan|Odetiglucan 4 mg/kg IV every 3 weeks
223621857|NCT07199764|DRUG|Mitazalimab|Mitazalimab 0.9 mg/kg IV every 3 weeks
223621858|NCT07198659|COMBINATION_PRODUCT|Monomethyl Auristatin E (MMAE) / autologous neutrophil biological agents|Isolate the patients' autologous neutriphil cells, induce and culture them with Monomethyl Auristatin E (MMAE) in a GMP-compliant laboratory. Prior to the reinfusion of neutrophil biological agents into patients, stereotactic radiotherapy with a dose of 2-6 Gy is administered to pancreatic cancer lesions. The number of neutrophils that were reinfused was 2.0-8.0x10\^8.
223621859|NCT07199777|DRUG|SNP318|Once daily, oral administration
223621860|NCT07199777|DRUG|Placebo|Once daily, oral administration
223621861|NCT07199855|DRUG|blinatumomab combined with venetoclax as maintenance therapy|blinatumomab combined with venetoclax as maintenance therapy for high-risk Philadelphia chromosome-negative acute B-cell lymphoblastic leukemia (B-ALL) after allogeneic hematopoietic stem cell transplantation
223621862|NCT07199283|OTHER|Bundle Intervention|Bundle intervention
223621863|NCT07199998|OTHER|Samples collection (whole blood, urine, vaginal and cervical cells)|During the clinical visit, samples will be collected from participants, including blood, urine, and vaginal and cervical cells. These samples will be used for a range of analyses, including determination of the vaginal microbiota composition and sequencing, cytokine profiling, and assessment of local immunity through flow cytometry using CyTOF technology. Urine samples will be analyzed for pollutants such as phthalates and bisphenol, while blood samples will be used for blood cell counts.
223621864|NCT07198399|DIETARY_SUPPLEMENT|Auri Super Mushroom Daily Gummies|Each gummy contains a blend of 12 functional mushroom extracts (300 mg equivalent each).
223621865|NCT07198451|DRUG|Gemcitabine Submucosal Injection|A chemotherapeutic agent. Administered via submucosal injection into the bladder wall using a specialized injection gun. Dosage: 1000mg per injection. Regimen: One injection immediately post-TURBT, followed by one injection every three months for a total of four injections.
223621866|NCT07198451|DRUG|Gemcitabine Intravesical Instillation|Standard therapy. Administered by instilling a solution into the bladder via a catheter. Dosage: 2000mg dissolved in 50mL normal saline per instillation. Regimen: One instillation immediately post-TURBT, followed by an induction phase (once weekly for 8 weeks) and a maintenance phase (once monthly for 10 months). The solution is retained for 30-60 minutes.
223761834|NCT04613180|DRUG|Montelukast Sodium|Montelukast is used to prevent wheezing, difficulty breathing, chest tightness, and coughing caused by asthma in adults and children 12 months of age and older. Montelukast is also used to prevent bronchospasm (breathing difficulties) during exercise in adults and children 6 years of age and older.
223761835|NCT04613180|DRUG|Placebo|placebo containing no active substance
223761836|NCT00860652|RADIATION|Adjuvant Radiotherapy|Adjuvant RT (ART) commenced within 4 months of Radical Prostatectomy. 64Gy in 32 fractions to the prostate bed.
224211560|NCT01039584|DRUG|Butoconazole Nitrate Vaginal Cream|vaginal cream
224211561|NCT01039584|DRUG|Placebo|vaginal cream
224211562|NCT01039584|DRUG|Gynazole 1 vaginal cream|vaginal cream
224211563|NCT03341715|DRUG|Mavoglurant (AFQ056)|2-100mg tablets of Mavoglurant will be administered on the morning of 1 of the 2 experimental days by an RN or the physician investigator.
224211564|NCT03341715|OTHER|Placebo|Two matching tablets of placebo will be administered on the morning of 1 of the 2 experimental days by an RN or the physician investigator.
224316230|NCT06361719|OTHER|Experimental Group (EG)|Starter infant formula will be administered to the participants orally, ad libtium to 6 months, after which they will transfer to a classical follow-up formula (non-trial formula) until the end of the trial (12 months of age).
224211565|NCT06267677|DIETARY_SUPPLEMENT|High protein liquid formula|liquid and high amount of protein
224211566|NCT03443219|DEVICE|Spritztube®|After preoxygenation, anaesthesia was induced with midazolam, propofol, and fentanyl,Spritztube® was inserted and both cuffs inflated
224211567|NCT03443219|DEVICE|LMA Supreme™|After preoxygenation, anaesthesia was induced with midazolam, propofol, and fentanyl,LMA Supreme™ was inserted and both cuffs inflated
224211568|NCT03672396|BEHAVIORAL|Home-based exercise|The intervention consists of aerobic and strength training \~3 times per week for 12 weeks with each session lasting 1 hour. The progressive aerobic exercise will involve walking that varies from from 15 to 30 minutes done 2-4 times per week at an intensity from 40% to 65% of heart rate reserve. Therabands elastic bands will be used to perform 12 to 15 repetitions per exercise. Once a participant can comfortably complete 15 repetitions for all prescribed sets, they will increase resistance by moving up to the next band. The training volume increased from 1 set per exercise on week 1 to 3 sets by week 12.
224211569|NCT03408236|DRUG|Botulinum toxin type A|Experimental
224211570|NCT03408236|DRUG|Botulinum toxin type A|Active Comparator
224211571|NCT04270552|DRUG|Ismigen|Sublingual tablets containing 7 mg of bacterial lysate from the following bacteria: Staphylococcus aureus, Haemophilus influenzae serotype B, Klebsiella pneumoniae, Klebsiella ozaenae, Neiserria catarrhalis, Streptococcus viridans, Streptococcus pyogenes, Streptococcus pneumoniae (6 strains: TY1/EQ11, TY2/EQ22, TY3/EQ14, TY5/EQ15, TY8/EQ23, TY47/EQ24) - sublingual use 1 tablet per day over 10 days for 3 successive months.
224211572|NCT04270552|DRUG|Placebo|Matched tablets without any active substance.
224211573|NCT01297634|DRUG|Botulinum Toxin Type-A (day 0)|"* Botulinum Toxin Type-A 1 unit. Dilution:1U/0,01ml (with saline solution). will be injected in the left and right belly to the Frontal Muscle.~* Botulinum Toxin Type-A 1 unit. Dilution: 0,5U/0,01ml (with saline solution). will be injected in the left and right belly to the Frontal Muscle.~* Botulinum Toxin Type-A 1 unit. Dilution: 0,25U/0,01ml (with saline solution). will be injected in the left and right belly to the Frontal Muscle."
223621868|NCT07198828|BEHAVIORAL|mHealth Smoking Cessation Application|"Participants receive the mHealth smoking cessation application with:~* Educational content about smoking risks and cessation benefits~* Motivational messages and progress tracking~* Social support features~* Interactive elements and quizzes~* Monthly monitoring and support"
223621869|NCT07198828|BEHAVIORAL|Paper-based Control Materials|"Participants receive paper-based smoking cessation module containing equivalent content:~* Motivational content and cessation benefits~* Ex-smoker success stories~* Trigger identification and coping strategies~* Weekly quizzes with prizes (online access)~* Monthly check-ins"
223621870|NCT07198711|DRUG|Propofol - Emergence-from-LOR Protocol|Intravenous propofol infusion that meets the criteria: (1) maintenance of spontaneous ventilation, (2) sedation level corresponding to a Patient State Index (PSI) no lower than 25; and (3) loss of responsiveness (LOR) defined by the Richmond Agitation Sedation Scale (RASS) = -5 \[unarousable\]. Anesthesia is then maintained at that level for 30 minutes, followed by spontaneous emergence.
223621871|NCT07198711|DRUG|Propofol - Light Sedation Protocol|Intravenous propofol infusion titrated stepwise to reach a state where participants are sedated but have behavioral responsiveness. Sedation is maintained at this level for 30 minutes.
224211574|NCT01297634|DRUG|Botulinum Toxin Type-A (day 0)|"* Botulinum Toxin Type-A 2 Units. Dilution:1U/0,01ml (with saline solution). will be injected in the left and right belly to the Frontal Muscle.~* Botulinum Toxin Type-A 2 units. Dilution: 0,5U/0,01ml (with saline solution). will be injected in the left and right belly to the Frontal Muscle.~* Botulinum Toxin Type-A 2 units. Dilution: 0,25U/0,01ml (with saline solution). will be injected in the left and right belly to the Frontal Muscle."
224211575|NCT01297634|DRUG|Botulinum Toxin Type-A (day 0)|"Botulinum Toxin Type-A 3 units. Dilution:1U/0,01ml (with saline solution). will be injected in the left and right belly to the Frontal Muscle.~* Botulinum Toxin Type-A 3 units. Dilution: 0,5U/0,01ml (with saline solution). will be injected in the left and right belly to the Frontal Muscle.~* Botulinum Toxin Type-A 3 units. Dilution: 0,25U/0,01ml (with saline solution). will be injected in the left and right belly to the Frontal Muscle."
223621872|NCT07199296|DRUG|Orelabrutinib|orelabrutinib 150mg/day PO once daily
224211576|NCT04902261|DRUG|Tislelizumab|Tislelizumab 200 mg every three weeks
224211577|NCT04902261|DRUG|Nab paclitaxel|Nab-paclitaxel 125mg/m2 on d1 and d8 every three weeks
224211578|NCT04902261|DRUG|Gemcitabine|Gemcitabine 1000mg/m2 on d1 and d8 every three weeks
224211579|NCT02306434|BEHAVIORAL|Therapy by iCBT|Internet Cognitive behavioral therapy (iCBT) is given by a psychologist in the U-CARE platform. The intervention will focus on management of childbirth related fear. This means that the participants read texts and do homework assignments instructed from an internet page. Additional resources such as pictures, animations, videos and sounds will be a part of the treatment program. A psychologist will communicate with the participants through internal text-messages and will give feed back on their home work assignments. The content of the intervention will be standard components from CBT, for example relaxation training, behavioral activation, exposure for fear related stimuli, cognitive restructuring, behavioral sleep treatment.
224211580|NCT02306434|OTHER|Standard care-counselling|Standard care (Counselling by midwives)
224211581|NCT04628221|DEVICE|OsteoProbe System|"The OsteoProbe® System (OsteoProbe) is a bone microindentation measurement tool. The device is a measurement tool that is not intended to make a diagnosis or provide a treatment decision. There are no other available measurement tools for clinical assessment of bone's resistance to microindentation."
224211582|NCT02462239|OTHER|Whole-body FDG PET-CT|
224211583|NCT00099320|DRUG|exenatide|After a 2-week placebo lead-in period (twice daily, given subcutaneously) in addition to their current therapy regimen, subjects will administer 20 mcg of exenatide (2 units \[5 μg\] ), twice daily by subcutaneous injection, for the first 4 weeks of therapy, and then 40 μL of study drug (4 units \[10 μg\] of exenatide) twice daily by subcutaneous injection, for the remaining 12 weeks of therapy.
224211584|NCT00099320|DRUG|Placebo|After a 2-week placebo lead-in period (twice daily, given subcutaneously) in addition to their current therapy regimen, subjects will administer placebo (in equivalent amounts to exenatide) for 16 weeks of therapy.
224211585|NCT05955235|OTHER|Not Applicable(Observation Study)|Not Applicable(Observation Study)
224211586|NCT00064935|PROCEDURE|Endometrial biopsy|
224211587|NCT03744806|DRUG|Bevacizumab Injection|
224211588|NCT01257828|DRUG|riluzole|50mg BID orally for 14 days prior to surgery and 28 days after the surgery
223621873|NCT07199296|DRUG|Rituximab (R)|rituximab 375 mg/m² IV on day 1, 8, 15, 22 in Cycle 1, then day 1/cycle
224211589|NCT01257828|DRUG|Placebo medication|50mg BID orally for 14 days prior to surgery and 28 days after the surgery
224211590|NCT04690387|BIOLOGICAL|AV-COVID-19|Autologous dendritic cells previously incubated with SARS-CoV-2 spike protein
224211591|NCT04690387|OTHER|GM-CSF|GM-CSF as an adjuvant
224211592|NCT06416761|GENETIC|genetic polymorphisms|
224211593|NCT04416672|OTHER|PRO-CTCAE items|"Enrolled patients will be asked to complete a subset of the PRO-CTCAE items based on cancer type, and the following instruments used as anchors to measure psychometric properties:~* the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life disease-specific module, if a linguistically validated Italian version exists, or the General QLQ-C30, if the Italian version is not available.~* the Hospital Anxiety and Depression Scale (HADS)~* The Patients' Global Impression of Change (PGIC) Scale."
224211594|NCT02044965|OTHER|Antibiotic|2 mg/kg per day via oral ingestion.
224211595|NCT02044965|DRUG|Probiotic|2 capsules; 5 billion total organisms of L. rhamnosus GR-1 and L. reuteri RC-14 per capsule
224211596|NCT00958685|DIETARY_SUPPLEMENT|ginger|Study group received 1200 mg of ginger extract and control group 2 gram of coconut oil as placebo
224211597|NCT00958685|DIETARY_SUPPLEMENT|placebo|Study group received 1200 mg of ginger extract and control group 2 gram of coconut oil as placebo
224316231|NCT06361719|OTHER|Control Group (CG)|Starter infant formula will be administered to the participants orally, ad libtium to 6 months, after which they will transfer to a classical follow-up formula (non-trial formula) until the end of the trial (12 months of age).
224316232|NCT02640690|BEHAVIORAL|Trauma Center Trauma Sensitive Yoga Intervention (TCTSY)|(10) 1-hour sessions of trauma sensitive yoga
224316233|NCT02640690|BEHAVIORAL|Cognitive Processing Therapy|(12) 1.5 hour sessions of cognitive processing therapy
223621874|NCT07199296|DRUG|BEAM (carmustine (BCNU), etoposide, cytarabine, melphalan)|the reference doses are as follows (each center may adjust them as appropriate based on actual conditions): carmustine 300mg/m² IV d-1; etoposide 200mg/m² IV d-6-(-3); cytarabine 200mg/m² IV d-6-(-3); melphalan 140mg/m² IV d-2.
223621875|NCT07199296|DRUG|orelabrutinib maintenance|orelabrutinib 150mg/day PO once daily
223621876|NCT07198906|OTHER|Determination of VEXUS score and onset of chronic renal failure|The aim is to prospectively evaluate the association between the ultrasound score (VEXUS) and the occurrence of acute renal failure post-operatively following cardiac surgery. The VEXUS (Venous Excess UltraSound) score is an ultrasound tool used in medicine to assess systemic venous congestion, i.e. excess pressure in the venous system linked to volume overload or right heart failure. The VEXUS score relies on ultrasound of the inferior vena cava (IVC) to assess the extent of congestion in this vein. score 0 : Normal IVC + Normal Dopplers; score 1 : Dilated IVC + altered hepatic venous Doppler, but normal portal vein; score 2 : Portal vein shows significant pulsatility; score 3 : Severe pulsatility + marked alteration of hepatic and portal flow
223621877|NCT07199829|DIETARY_SUPPLEMENT|Vitamin Arm 1|Subject receives dietary supplement for 90 days
223621878|NCT07199829|DIETARY_SUPPLEMENT|Vitamin Arm 2|Subject receives dietary supplement for 90 days
223761837|NCT00860652|RADIATION|Early Salvage Radiotherapy|Active surveillance with early Salvage RT (SRT). SRT - 64Gy in 32 fractions to the prostate bed. RT should commence no later than 4 months following the first PSA measurement ≥ 0.2ng/mL.
224211598|NCT00995540|DRUG|INGAP Peptide|100 mg INGAP Peptide tid subcutaneous injection for 12 weeks
223621879|NCT07199829|DIETARY_SUPPLEMENT|Vitamin Arm 3|Subject receives dietary supplement for 90 days
223621880|NCT07199829|OTHER|Placebo|Subject receives placebo for 90 days
223621881|NCT07198373|DRUG|Maintenance Therapy Group|Patients achieving remission (complete or partial) at the 3-month post-CAR-T infusion assessment receive oral zanubrutinib capsules for maintenance therapy for 2 years.
224211599|NCT00995540|DRUG|INGAP Peptide|200 mg INGAP Peptide tid subcutaneous injection for 12 weeks
224211600|NCT00995540|DRUG|Placebo|Placebo tid subcutaneous injection for 12 weeks
224211601|NCT01003548|DEVICE|SMART dynamic system of embryo culture|Embryos will be cultured in a dynamic system of microfluidics.
224211602|NCT01003548|DEVICE|Static culture|Embryos cultured in 40 microliters microdrops of G-IVF plus series V
224211603|NCT02780921|PROCEDURE|prehabilitation|
224211604|NCT02780921|OTHER|nutritional support|
224211605|NCT05473858|DRUG|OraVerse Injectable Product|injection of oraverse,
224211606|NCT05473858|DEVICE|diode laser|patient exposed to diode laser
224211607|NCT04517981|BEHAVIORAL|Psychological intervention|Choose according to the wishes of the enrolled subjects and the results of the evaluation
224211608|NCT04517981|OTHER|Comprehensive intervention|Choose according to the wishes of the enrolled subjects and the results of the evaluation
224211609|NCT03319381|BEHAVIORAL|Following new SOPs|The new SOPs comprised early whole-body CT, damage control surgery, and the use of goal-directed coagulation management and are based on the ATLS® concept, which was the strictly followed protocol before implementation of the new SOPs
224211610|NCT02313519|DIETARY_SUPPLEMENT|Probiotics|Probiotics are prepared in capsule form
224211611|NCT02313519|DIETARY_SUPPLEMENT|Placebo|Glucose powder
224211612|NCT00975884|BIOLOGICAL|GSK investigational vaccine GSK2340272A|Two intramuscular injections
224211613|NCT01656967|DEVICE|AMBU Aura-I/aScope 2|Once ventilation is achieved, the patients in group A will be intubated through the shaft of Aura-I via the the Ambu aScope.
224211614|NCT01656967|DEVICE|LMA Fastrach Single Use|The patients in group B will be intubated by ETT via the Intubating LMA as is standard procedure.
224316234|NCT00176618|DRUG|sulindac|Sulindac 150 mg po BID
224316235|NCT00176618|DRUG|curcumin|Curcumin 250 mg po BID
224316236|NCT04648800|DRUG|BCG-10 vaccine|"The BCG-10 anti-tuberculosis vaccine~* powder and solvent for preparing a suspension for intradermal injections of Vaccinum tuberculosis (BCG) cryodesiccatum;~* lyophilised BCG vaccine~* one dose (0.1 ml) contains 50 micrograms of half-dried mass of BCG mycobacteria, which corresponds to 150,000 - 600,000 of live BCG bacilli- the Brazilian Moreau sub-strain."
224316237|NCT04648800|DRUG|0.9% saline|0.9% saline
224316238|NCT01118975|DRUG|Vorinostat|"300 mg 4 days on then 3 days off~As defined in the protocol, the dose of vorinostat was increased to 400 mg 4 days on then 3 days off in the pilot phase because the adverse event threshold was not met. In the Phase II cohort, the dose of vorinistat was 400 mg 4 days on and 3 days off."
224316239|NCT01118975|DRUG|Lapatinib|1,250 mg once daily
223621882|NCT02843841|OTHER|Blood and fecal sample.|Blood (28 ml) and fecal sample at day 0, 4 days, 3 months and one year after transplantation
224211615|NCT01426321|OTHER|Imaging guided LV lead positioning|"LV lead positioning guided by echocardiography (mechanical strain evaluation by speckle tracking) in combination with cardiac CT. A viable segment with the latest mechanical activation is targeted, and an appropriate optimal cardiac vein segment is then chosen using the CT images."
224211616|NCT02364219|OTHER|Prewarming|Patients are treated according to standard operating procedures plus prewarming period of at least 30 minutes during induction of combined general and epidural anesthesia.
224211617|NCT02364219|DEVICE|Microdialysis|71 High Cut-Off Brain MD Catheter Membrane cut-off: 100 kDa Membrane length 30 mm Shaft length: 60 mm Dialysis AB, Stockholm, Sweden
224211618|NCT06282666|PROCEDURE|Spinal anesthesia|Before the beginning of surgery, all patients will be anesthetized with 0.5 % hyperbaric bupivacaine (Marcaine Heavy), 1.5 - 2.5 mL solution. A pencil point spinal needle will be used.
224211619|NCT06282666|PROCEDURE|lumbar erector spinae plane block|Investigators will perform the lumbar ESPB under ultrasound control at the L3 level on the ipsilateral site of the surgery. After dissection with 0.9 NaCl, we will leave a catheter in the ESP. Then, we used 0.25% bupivacaine with epinephrine (5mcg/mL), 0.4 mL per kg, up to 40 mL.
224211620|NCT06282666|PROCEDURE|Epidural analgesia|After identifying the epidural space and spinal anesthesia (combined technique), a catheter will be placed in the epidural space. Investigators will give an epidural catheter a test dose of 2% lidocaine (2 mL). At the end of the surgery, the patient will receive 5 mL of a mixture containing 0.1% bupivacaine with fentanyl (2 mcg/mL).
224211621|NCT06282666|PROCEDURE|patient-controlled analgesia|Each participant will receive a pump with oxycodone (1mg/ml) using a patient-controlled analgesia (PCA) technique, a bolus of 1 mL, and a lockout of 5 minutes for the first postoperative day.
224211622|NCT06282666|DIAGNOSTIC_TEST|Timed Up and Go test|Investigators will measure the time the patient took to rise from a chair, walk three meters, turn around 180 degrees, walk back to the chair, and sit down while rotating 180 degrees. We will assess the patient before the surgery and 24 and 48 hours after hip replacement.
223621883|NCT01928927|DRUG|Telmisartan|Participants received Telmisartan 40 mg daily during weeks 0-4 followed by telmisartan 80 mg daily during weeks 5-48.
224211623|NCT06282666|DIAGNOSTIC_TEST|neuropathic pain symptom inventory|The Neuropathic Pain Symptom Inventory (0-100; 0 denotes no pain, 100 the most severe pain) will be evaluated before the surgery and three and six months following the procedure.
224211624|NCT06282666|DIAGNOSTIC_TEST|Lovett test|A physiotherapist will use the six-grade Lovett scale to measure muscle strength, in which 0 denotes no muscle contractility, and 5 denotes the complete range of motion against gravity, with full resistance. We will test this before the surgery, 24 and 48 hours after the operation.
224211625|NCT06282666|DIAGNOSTIC_TEST|Visual analog scale|Investigators will measure pain intensity with VAS (0-10; 0 denotes no pain, 10 maximal pain) before and after the surgery. Pain will be evaluated at rest and upon the activity.
224211626|NCT06282666|DIAGNOSTIC_TEST|Quality of Recovery 40|Investigators will assess the quality of recovery with QoR-40 a day after the surgery, a month, and three months following the procedure. The minimal score is 40, and the maximal is 200. The higher the result, the better the quality of recovery is.
224211627|NCT06282666|DIAGNOSTIC_TEST|Ability to sit, stand upright, and walk|A physiotherapist will evaluate the patient's ability to sit, stand upright, and walk at planned times.
224211628|NCT05186922|BIOLOGICAL|CM326|CM326 injection
223621884|NCT06284083|DIAGNOSTIC_TEST|taking a blood sample|Blood samples collected from patienst, only 7 mL
223621885|NCT03369977|DEVICE|BioGlue Surgical Adhesive|BioGlue (produced by CryoLife in Kennesaw, GA) is a surgical adhesive with two components respectively purified bovine serum albumin (BSA) and Glutaraldehyde (their proportions are 4:1). Crosslinked bonds (covalent bonds) of Glutaraldehyde cross-link the protein on the surface of the tissue and the amino residue of the bovine serum albumin. BioGlue also adheres to the synthetic matrix material by a mechanical interlocking mechanism in the space of graft matrix.
223621886|NCT03369977|OTHER|Traditional Surgical Repair|Traditional surgical repair as determined by the surgeon
224211629|NCT05186922|OTHER|Placebo|Placebo
224211630|NCT05417126|BIOLOGICAL|Gene Therapy-vMCO-010|The vMCO-010 is an adeno-associated virus serotype 2-based vector carried multi-characteristic opsin (MCO) gene expression cassette
224211631|NCT02015468|OTHER|Early mobilization|Early weightbearing and physiotherapy
224211632|NCT02015468|OTHER|Late mobilization|Late mobilization, none-weightbearing and home exercises
224211633|NCT01669668|PROCEDURE|radiofrequency ablation|Undergo RFA
224211634|NCT01669668|PROCEDURE|laparoscopy|Undergo laparoscopic ultrasound
224316240|NCT01520870|DRUG|PF-299804 (Dacomitinib)|Dacomitinib will be administered orally at a dose of 45 mg/day, until disease progression, unacceptable adverse side effects or study end.
224316241|NCT05978752|PROCEDURE|Endoscopic gel embolization of gastric fundus varices and ligation of esophageal varices|For patients with GOV1 esophagogastric varices, gastric varices will be treated with endoscopic gelatinous embolization, esophageal varices will be treated with ligation.
223621887|NCT01756196|DRUG|Spinal Steroid Injection|Steroid Injection
223621888|NCT02557737|DRUG|Botulinum Toxin Type A|To inject Botulinum toxin type A on the spasticity lower extremity for stroke patients by Ultrasonography direct-guidance, Ultrasonography direct-guidance, Electric stimulation and Surface anatomy landmark.
223621889|NCT03043885|DEVICE|FDBA|Graft material used to graft extraction socket
223621890|NCT03043885|DEVICE|PRF|Autologous blood product used to graft extraction socket
223621891|NCT03043885|PROCEDURE|Blood Clot|Surgical treatment of extraction socket without addition of graft material
223621892|NCT01063647|DRUG|Treosulfan|10 g/m² i.v. infusion, day -6, -5, -4
223621893|NCT01063647|DRUG|Treosulfan|12 g/m² i.v. infusion, day -6, -5, -4
223621894|NCT01063647|DRUG|Treosulfan|14 g/m² i.v. infusion, day -6, -5, -4
223621895|NCT04875052|DEVICE|Experimental: Whole Body Vibration|Whole body vibration will be delivered using a commercially available device at a frequency of 30Hz and acceleration of 2g for 1 minute a total of 6 times with 2 minutes of rest between exposures.
223621896|NCT04875052|DEVICE|Experimental: Local Muscle Vibration|Local muscle vibration will be delivered using a prototype device at a frequency of 30Hz and acceleration of 2g for 1 minute a total of 6 times with 2 minutes of rest between exposures.
224211635|NCT04367922|BEHAVIORAL|Positive Emotion Skills Course|The skills will be delivered over approximately 6 weeks, and individuals can participate from any device and location with internet access. A week will consist of 1-2 days of didactic material and 5-6 days of real-life skills practice and reporting. Participants cannot skip ahead, and can only progress to the next lesson if they have completed the current one, but they can return to old lessons or exercises if they wish to. Skills include: positive events, capitalizing, gratitude, mindfulness, positive reappraisal, personal strengths, achievable goals, self-compassion.
224211636|NCT00730288|BIOLOGICAL|Chimeric dengue serotype (1, 2, 3, 4)|0.5 mL, Subcutaneous, 1 dose
224211637|NCT00730288|BIOLOGICAL|Chimeric dengue serotype (1, 2, 3, 4)|0.5 mL, Subcutaneous, 1 dose
224211638|NCT00730288|BIOLOGICAL|Chimeric dengue serotype (1, 2, 3, 4)|0.5mL, Subcutaneous, 1 dose
224211639|NCT00862888|DRUG|PF-00446687|Single 200mg dose as an oral solution
224211640|NCT00862888|DRUG|Placebo|Placebo for oral solution
224211641|NCT00862888|DRUG|Placebo|Placebo for tablet
223621897|NCT04875052|OTHER|Standard ACL Rehabilitation|Patients will complete a standard of care rehabilitation emphasizing restoration of early weight bearing, range of motion, quadriceps function, balance, and neuromuscular control.
224211642|NCT00862888|DRUG|Sildenafil|Single oral dose 100 mg tablet
224211643|NCT00862888|DRUG|PF-00446687|Single 125 mg dose as an oral solution
224211644|NCT00862888|DRUG|PF-00446687|Single 175 mg dose as an oral solution
224211645|NCT00862888|DRUG|PF-00446687|Single 20 mg dose as an oral solution
224211646|NCT00862888|DRUG|Placebo|Placebo for oral solution
224211647|NCT00862888|DRUG|Placebo|Placebo for tablet
224211648|NCT00862888|DRUG|Sildenafil|Single oral dose 100 mg tablet
224211649|NCT04810507|DRUG|Anagliptin BID Treatment|Continuous Glucose Monitoring with Anagliptin 100mg BID or Sitagliptin 100mg QD treatment for 12 weeks
224211650|NCT03604601|PROCEDURE|salvage surgery|Salvage surgery hopes to control the recurrence of larynx, pharynx, fistula and neck tumor and improve the quality of life and survival rate
224211651|NCT02105831|OTHER|Contrast ultrasound skeletal muscle perfusion imaging|1\. Contrast ultrasound perfusion imaging will be performed in patients in whom LVAD will be placed for clinical indications of severe heart failure.
224211652|NCT00479765|DRUG|OncoGel (ReGel/Paclitaxel)|OncoGel administered into cavity after surgical resection of recurrent glioma. Each subject will receive one dose of OncoGel on the day of surgical resection.
224211653|NCT00348569|DEVICE|64 Channel VCT|
224211654|NCT05525299|BEHAVIORAL|Reminiscence-Based Life Review|"The reminiscence chatting activities covering 6 themes include:~Week 1: Instruction of the 'Life Story Narrative Journal' and My 'Childhood' memories Week 2: My 'Adolesces' memories and Memorable moments spent with my family Week 3: My 'Adulthood' memories and My very first full time job Week 4: My thoughts when I received my cancer diagnosis Week 5: My favourite activities before and after receiving a cancer diagnosis Week 6: When COVID-19 hits, \_\_\_\_\_ changes and The story goes on! The future pages are more to come!~A 'Life Story Narrative Journal' with six themes to recall subjects' memory through the life review reminiscence activities will be given. The Life Story Narrative Journal is a diary booklet that enables the participant to write down and express their thoughts in a narrative."
223621898|NCT00379015|BIOLOGICAL|trastuzumab|
224211655|NCT05241899|DRUG|Fruquintinib + RC48|Fruquintinib (4mg orally, once daily for 3 wks on/1 wk off) combined with of RC48( 2.5mg/kg by intravenous infusion during 30-90 min every 2 weeks)
224211656|NCT04064333|DEVICE|Slow-Stream Expiratory Muscle Strength Training|All participants will receive an initial visit for training on the therapy protocol, use of a weekly therapy log to track breaths, and use and maintenance of the EMST device. This will constitute the first EMST session and will be included in the therapy log as Week 1, Day 1. Each participant will have a minimum of seven weekly check-in visits from the research assistant and/or a member of the research team, where the EMST150 resistance will be recorded and adjusted to maintain training at 75% of their maximum load, as measured using the EMST150 device instruction manual. During these check-in visits, participants will provide their completed weekly therapy log and receive a new log.
224211657|NCT02726737|DRUG|sodium bicarbonate|
223621899|NCT00379015|DRUG|cyclophosphamide|
224211658|NCT02726737|DRUG|Lidocaine|
224211659|NCT02726737|DRUG|sterile distilled water|
224211660|NCT00420849|DRUG|Lenalidomide|Oral lenalidomide at a dose of 25 mg daily for 21 days every 28 days. Treatment as tolerated until disease progression, drug became commercially available or limited to 6 treatment cycles.
224211661|NCT00420849|DRUG|Dexamethasone|Oral pulse dexamethasone at a dose of 40 mg daily on days 1-4, 9-12, and 17-20 for each 28-day-cycle for cycles 1 through 4. Beginning cycle 5, a maintenance dose of dexamethasone (40 mg QD) was administered on Days 1 to 4 of each 28-day cycle.
224211662|NCT05106998|DEVICE|nailfold capillaroscopy|Nailfold capillaroscopy (NFC) is a non-invasive easily repeatable technique and the best method for morphological analysis of nutritional capillaries in the nailfold area
224211663|NCT06472050|DRUG|Romosozumab|osteoporosis treatment
224211664|NCT06472050|DRUG|Denosumab|osteoporosis treatment
224211665|NCT03360526|DEVICE|PICSI|Semen processing is done by double layer density gradient method followed by adding Sperm to the dot of hyaluronan on the PICSI dish, within minutes the bound sperm are attached by their acrosome to the surface of the dot. (Selecting an individual bound sperm with enhanced genetic and developmental integrity ensures that the sperm selected is the optimal sperm from the sample for oocyte injection.
224211666|NCT03360526|PROCEDURE|TESA|"Patients will undergo TESA which is performed by sticking a needle in the testis and aspirating fluid and tissue with negative pressure then examine the sample for presence of motile~sperms followed by sample processing and oocyte injection."
223621900|NCT00379015|DRUG|docetaxel|
223621901|NCT00379015|DRUG|epirubicin hydrochloride|
223621902|NCT00379015|PROCEDURE|conventional surgery|
223621903|NCT00379015|PROCEDURE|neoadjuvant therapy|
223621904|NCT05164393|DRUG|AVX001|Topical gel treatment for once daily application
223621905|NCT06173830|OTHER|radiofrequency ablation|34 patients with chronic knee osteoarthritis meeting the criteria will undergo ultrasound-guided radiofrequency ablation of the genicular nerve.
224211667|NCT05854277|OTHER|educational video|To explain the novel score, a six-minute instructional video was compiled and available to watch, as well as an online tool on the GIEQs website that could be used to grade the image-sets using the score.
224211668|NCT01284816|PROCEDURE|bariatric surgery|The bariatric surgery is a relevant treatment for severely obese patients those with metabolic complications, as it significantly reduces weight, hypertension and ameliorates glycemic control.
224211669|NCT04078659|DRUG|Propofol infusion|Following induction of anaesthesia, propofol infusion will be started 75 mcg/kg/min for the first 10-15 minutes, then a maintenance infusion of propofol (50 mcg/kg /min)
224211670|NCT04078659|DRUG|Magnesium Sulfate infusion|Before induction of anaesthesia, Magnesium Sulfate infusion will be started at 40 mg/kg in 100 ml saline over 10 minutes as the loading dose then Magnesium sulfate infusion 10-15 mg/kg/hr started immediately after induction of anaesthesia
224211671|NCT04078659|DRUG|Lidocaine|Patients will receive iv lidocaine 1.5 mg/kg before induction of anaesthesia
224211672|NCT04078659|DRUG|Fentanyl|Patients will receive fentanyl 1-2 mcg/kg before induction of anaesthesia
224211673|NCT04078659|DRUG|Propofol|Patients will receive propofol in a dose of 1-2 mg /kg
224211674|NCT04078659|DRUG|Atracurium|Patients will receive 0.6 mg /kg iv atracurium over 60 sec, to facilitate tracheal intubation
224211675|NCT04078659|PROCEDURE|Mechanical Ventilation|Patients lungs will be ventilated using the volume controlled mechanically ventilated with 40% oxygen in the air with positive end-expiratory pressure (PEEP) of 5 cmH2O, tidal volume 500 ml and Respiratory Rate of 12 per minute
224211676|NCT02754505|OTHER|Early rehabilitation|The early rehabilitation program consisted of a coordinated exercise therapy and neuromuscular electrical stimulation, for two hours and five days a week until discharge from the acute hospital. Exercise therapy included strength training (three days/week, one to three sets of 12-15 repetitions, 8-10 exercises involving the major muscle groups: thighs, calves, buttocks, trunk, shoulder girdle), aerobic exercise (large muscle activities five days/week, 10-30 min/session, 50-80% maximal heart rate) and active breathing techniques. For neuromuscular electrical stimulation we applied Compex-P© devices producing biphasic symmetric impulses with a frequency of 50 Hz and a pulse width of 0.35 ms (stimulus regime: 8 s on/24 s off) five days/week, 30 min/session involving the anterior thighs and buttocks.
224211677|NCT02754505|OTHER|Usual care|exercise therapy, respiratory therapy, neuromuscular electrical stimulation (as described above).
224211678|NCT00709020|DRUG|white button mushroom extract|Dose escalation with six evaluable subjects per dose level. Doses begin at 5 g/day, then 8 g/day, then 10 g/day then 13 g/day.
224211679|NCT00709020|OTHER|flow cytometry|Performed on blood samples taken day -14 and -7 prior to treatment and days 1, 8, 15, 29, 57 and 85 of treatment.
224211680|NCT00709020|OTHER|high performance liquid chromatography|Performed on blood samples taken day -14 and -7 prior to treatment and days 1, 8, 15, 29, 57 and 85 of treatment.
224211681|NCT00709020|OTHER|laboratory biomarker analysis|Performed on blood samples taken pre-treatment on day 1 and on day 85 after treatment.
224211682|NCT00709020|OTHER|mass spectrometry|Performed on blood samples taken day -14 and -7 prior to treatment and days 1, 8, 15, 29, 57 and 85 of treatment.
224211683|NCT00709020|OTHER|pharmacogenomic studies|Performed on blood samples taken on days 1, 8, 15, 29, 57 and 85 of treatment.
224211684|NCT00709020|OTHER|pharmacological study|Performed on blood samples taken pre-dose and at 0.25, 0.5, 0.75, 1, 2, 4 and 6 hours after White Button Mushroon extract on day 1 of treatment and pre-dose on days 8, 15, 29, 57 and 85 after start of treatment.
224211685|NCT01702766|DIETARY_SUPPLEMENT|Bifidobacterium animalis subsp. lactis|
224211686|NCT04318249|BEHAVIORAL|Assisted Relaxation Therapy|This intervention includes using a smartphone application that helps with breathing techniques and sleep.
224211687|NCT04318249|BEHAVIORAL|Modified Assisted Relaxation Therapy|This intervention includes using a smartphone application that is modified to help with breathing techniques and additional sleep instructions.
224211688|NCT00944125|DEVICE|Dual Site LV Pacing|Dual Site LV Pacing vs. BiV Pacing for a total of six months which includes two three crossover periods.
224211689|NCT00944125|DEVICE|BiV Pacing|Dual Site LV Pacing vs. BiV Pacing for a total of six months which includes two three crossover periods.
224211690|NCT06314074|OTHER|Oscillometric blood pressure monitoring at 2.5-minute intervals|Oscillometric blood pressure will be measured at 2.5-minute intervals during surgery.
224211691|NCT06314074|OTHER|Oscillometric blood pressure monitoring at 5-minute intervals|Oscillometric blood pressure will be measured at 5-minute intervals during surgery.
224211692|NCT00446134|DRUG|Taribavirin|Oral (200 mg) Tablet: 20mg/kg/day BID, patients will be treated for a total of 48 weeks. in addition, all patients will receive peginterferon alfa-2b (PEG-Intron) by weekly subcutaneous injection. Patients who complete treatment with study drug or discontinue treatment prematurely will enter a 24-week follow-up period.
224211693|NCT00446134|DRUG|Taribavirin|Oral (200 mg) Tablet: 25mg/kg/day BID, patients will be treated for a total of 48 weeks. in addition, all patients will receive peginterferon alfa-2b (PEG-Intron) by weekly subcutaneous injection. Patients who complete treatment with study drug or discontinue treatment prematurely will enter a 24-week follow-up period.
224211694|NCT00446134|DRUG|Taribavirin|Oral (200mg)Tablet: 30mg/kg/day BID, patients will be treated for a total of 48 weeks. in addition, all patients will receive peginterferon alfa-2b (PEG-Intron) by weekly subcutaneous injection. Patients who complete treatment with study drug or discontinue treatment prematurely will enter a 24-week follow-up period.
224211695|NCT00446134|DRUG|Ribavirin|Oral (200mg)Tablet: 800 mg/day, 1000 mg/day, 1200 mg/day, or 1400 mg/day BID, patients will be treated for a total of 48 weeks. in addition, all patients will receive peginterferon alfa-2b (PEG-Intron) by weekly subcutaneous injection. Patients who complete treatment with study drug or discontinue treatment prematurely will enter a 24-week follow-up period.
224211696|NCT05388526|OTHER|No intervention|There was no intervention to be administered, only collection of data through various tests and questionnaires.
224211697|NCT04280939|PROCEDURE|spinal anesthesia|prospective randomized double-blind study of patients undergoing total hip or knee replacement, as well as partial knee replacements (medial, lateral, patellafemoral, or bilateral). All groups will be matched for age, sex, American Society of Anesthesiologists class, and type of surgery. An attempt will be made to achieve a similar proportion of THA, TKA, and partial knee replacements in each group. We will randomize patients to one group of spinal anesthesia protocole.
223621906|NCT06173830|OTHER|physical therapy|34 patients with chronic knee osteoarthritis meeting the criteria will undergo 10 sessions of physical therapy.
223621907|NCT00383552|DRUG|Mometasone Furoate/Formoterol Fumarate Combination MDI 100/10 mcg BID|MF/F 100/10 mcg via a metered dose inhaler (MDI) twice daily for 26 weeks
223621908|NCT00383552|DRUG|Mometasone Furoate MDI (MF MDI)|MF 100 mcg via metered dose inhaler twice daily for 26 weeks
223621909|NCT00383552|DRUG|Formoterol Fumarate 10 mcg|F via metered dose inhaler 10 mcg twice a day for 26 weeks
223621910|NCT00383552|DRUG|Placebo|Placebo metered dose inhaler twice a day for 26 weeks
223621911|NCT00489996|DRUG|gemcitabine|
223621912|NCT00489996|DRUG|cisplatin|
223621913|NCT02156843|DRUG|Pyridorin|300 mg BID (twice daily, every 12 hours), oral capsule taken until end stage renal disease or death occurs, or the study is terminated by the sponsor.
223621914|NCT02156843|DRUG|Placebo|Placebo excipients without the active drug, oral capsule taken BID (twice daily, every 12 hours), until end stage renal disease or death occurs, or the study is terminated by the sponsor.
223621915|NCT00972413|RADIATION|Computed Tomography|In Group I, twelve CBCT studies will be performed. The objectives will be to illustrate the capacity of CBCT to image the breast in its entirety as compared with the gold standard mammographic exam.
223621916|NCT00972413|RADIATION|Computed Tomography|In Group II , at least fifty (50) study participants, who are categorized as BI-RADS® 4, 5 based on prior diagnostic work-up and are also scheduled for breast biopsy of a lesion, will undergo a breast CBCT specifically designed to image the breast.
223621917|NCT00972413|RADIATION|Computed Tomography|In Group III, at least 30 study subjects, who are categorized as BI-RADS® 4, 5 based on prior diagnostic work-up and are also scheduled for breast biopsy of a lesion, will undergo a unilateral intravenous (IV) CE CBCT of the involved breast.
223621918|NCT05383469|OTHER|Exercise Training|Endurance training with a resistance-free bicycle ergometer Strength training with bodyweight Non-resistance ankle pumping exercises
223621919|NCT05383469|OTHER|Massage|Classical massage including superficial and deep stroking and friction methods for the lower extremity.
223621920|NCT05383469|OTHER|Neuromuscular Electrical Stimulation|Symmetrical biphasic current at a frequency of 30-85 Hz
223621921|NCT05383469|OTHER|Compression Therapy|Compression therapy is a treatment applied to patients in the form of Four Layer Compression Bandage and Compression Stocking. Four Layer Compression Bandage is a treatment that requires four different types of bandages. The compression stocking is an elastic stock with various tension and length.
224211698|NCT06566924|OTHER|Control|Students in the control group were taken to the laboratory practice within one week after the training presentation. Students were expected to act in accordance with the skills of isolation precautions in line with the 'Sample Scenario'.
224211699|NCT06566924|OTHER|Training Group for Standardised Patient Simulation|One week after the training presentation, the experimental group was invited to the simulation training. Simulation training was carried out in a hospital environment. Materials to be used in standardised patient and isolated patient care were made availa
224211700|NCT00105352|PROCEDURE|Mixed Meal Tolerance Test|
223621922|NCT03177863|PROCEDURE|Expectancy|Clinical monitoring. See arm description
223621923|NCT03692208|BEHAVIORAL|My Diabetes Goal Survey and Optional Care Management|The intervention is already described in the intervention arm description.
223621924|NCT03694405|BIOLOGICAL|MenACWY-CRM|Booster vaccination with MenACWY-CRM
223621925|NCT03694405|BIOLOGICAL|MenACWY-DT|Booster vaccination with MenACWY-DT
223621926|NCT03694405|BIOLOGICAL|MenACWY-TT|Booster vaccination with MenACWY-TT
223621927|NCT01393158|DRUG|Apremilast|20mg of Apremilast taken orally BID for 3 months or 30 mg of Apremilast taken orally BID for 6 months.
223621928|NCT00924521|DIETARY_SUPPLEMENT|Whole grain diet|Participants in this group will receive 6-9 servings of whole grain daily to replace the refined grains typically included in the average American diet. Number of servings will depend upon calorie assignment.
223621929|NCT00924521|DIETARY_SUPPLEMENT|Refined grain|Participants in this group will receive only refined grains as typically consumed in the average American diet.
223621930|NCT01869608|PROCEDURE|oral glucose tolerance test 2 days post-partum|Screening for type 2 diabetes after gestational diabetes mellitus.
223621931|NCT06377176|OTHER|Massage therapy|the intervention group underwent ten sessions of twice-weekly mother and infant massage therapy for five weeks.
224211701|NCT00105352|PROCEDURE|Glucagon Stimulation Test|
224211702|NCT03998215|BIOLOGICAL|Diphtheria booster vaccination|Participants received intramuscularly in the deltoid muscle one dose of the trivalent vaccine against diphtheria, tetanus and acellular pertussis
224211703|NCT03933839|BEHAVIORAL|PainCOACH|PainCOACH is an eight-week, automated, internet-based training in specific pain coping skills (such as progressive muscle relaxation, pleasant imagery and activity pacing), and guided practice with each skill.
224211704|NCT03334916|DRUG|YMC026|YMC026 20mL TID
224211705|NCT03334916|DRUG|Placebo|Placebo 20mL TID
224211706|NCT04384926|PROCEDURE|Elective Cancer Surgery|Planned, curative cancer surgery
224316242|NCT05978752|PROCEDURE|Endoscopic gel embolization of gastric fundus varices and sclerotherapy of esophageal varices|For patients with GOV1 esophagogastric varices, gastric varices will be treated with endoscopic gelatinous embolization, esophageal varices will be treated with sclerotherapy.
223621932|NCT04935996|DEVICE|Pleuropulmonary echography|Pleuropulmonary echography is performed, in addition of the chest X-ray already performed in routine care
223621933|NCT00582439|DEVICE|Reamer-Irrigator-Aspirator (RIA)|Patients must already be scheduled for bone grafting of a fracture or nonunion with harvest of autologous graft material from their femur using the RIA system. The reaming procedure will be conducted using the trochanteric entry portal through the tip of the greater trochanter.
223621934|NCT01992796|DRUG|Irbesartan|75 mg/per os/for 15 days
223621935|NCT00747903|DRUG|aminolevulinic acid hydrochloride|
223621936|NCT02125396|OTHER|Transarterial chemoembolization|Adjuvant transarterial chemoembolization \[5-15 ml lipiodol 5-fluorouracil (500 mg/m2) and adriamycin (30 mg/m2)\]
223621937|NCT02125396|OTHER|Radiotherapy|Adjuvant radiotherapy is used for postoperative curative HCC
224211707|NCT04335292|DRUG|Osimertinib First-Line|Osimertinib, 80 mg, oral, daily
224211708|NCT04335292|DRUG|Platinum + Pemetrexed Chemotherapy Second-Line|Platinum-based chemotherapy (carboplatin or cisplatin) and pemetrexed are prescribed as per institutional standards.
224211709|NCT04335292|DRUG|Osimertinib Third-Line|Rechallenge with osimertinib, 80 mg, oral, daily
224211710|NCT02001870|PROCEDURE|In Vitro Fecundation (IVF)|In vivo fertilization will be performed according to the usual procedure of each Assisted Reproductive Technology (ART) center.
224211711|NCT02001870|PROCEDURE|Intra Uterine Insemination (IUI)|Intra-uterine insemination will be performed according to the usual procedure of each ART center
224211712|NCT05123040|DRUG|Ruxolitinib 10 MG Oral Tablet|By mouth twice daily through day 56, then tapered
224211713|NCT05123040|DRUG|hCG|2,000 units/m2 SQ every other day x 3 doses, followed by twice weekly x 14 doses
224211714|NCT05123040|DRUG|Corticosteroids|"Dose level 1 (starting dose) = 1 mg/kg~* Dose level 2 = 0.5 mg/kg~* Dose level 3 = 0.25 mg/kg~* Dose level 4 = 0.1 mg/kg~* Dose level 5 = 0 mg/kg~  • If dose level 1 is determined to be below the Recommended Phase 2 Dose (RP2D), the dose will be escalated:~* Dose level -1 = 1.5 mg/kg~* Dose level -2 = 2 mg/kg"
224211715|NCT04241185|DRUG|Pembrolizumab|400 mg of IV (intravenous) pembrolizumab once every 6 weeks.
224211716|NCT04241185|RADIATION|Conventional Radiotherapy (Bladder only)|64 Gy of radiation administered to participant's bladder only. Thirty-two fractions will be administered over 6.5 weeks.
224211717|NCT04241185|RADIATION|Conventional Radiotherapy (Bladder and pelvic nodes)|64 Gy of radiation administered to participant's bladder and pelvic nodes. Thirty-two fractions will be administered over 6.5 weeks.
224316243|NCT05978752|PROCEDURE|Endoscopic gelatinous embolization of gastric varices (esophageal varices not treated)|For patients with GOV1 esophagogastric varices, only gastric varices will be treated with endoscopic gelatinous embolization, esophageal varices will not be treated.
224316244|NCT00905671|DEVICE|LipiScan Coronary Imaging Catheter|Intravascular near infrared spectroscopic imaging of the coronary artery with a fiberoptic catheter.
224316245|NCT06329609|DEVICE|Airvo 3 with respiratory rate algorithm|Airvo 3 with respiratory rate algorithm is an active humidification system used to deliver high flow respiratory gases (air and/or oxygen) and monitor respiratory rate
224316246|NCT01679509|PROCEDURE|Single-port laparoscopic adnexal surgery|
224316247|NCT01679509|PROCEDURE|Three-port laparoscopic adnexal surgery|
224316248|NCT03300583|BEHAVIORAL|Focus groups|Focus group discussion led by the PI and facilitated by another researcher.
224316249|NCT03300583|BEHAVIORAL|Semi-structured interviews|1:1 semi-structured interviews led by the PI
224316250|NCT00435760|DRUG|Aclidinium bromide|200 micrograms, once daily, 1 day treatment
224316251|NCT00435760|DRUG|Placebo Tiotropium|1 puff once daily, 1 day treatment
224316252|NCT00435760|DRUG|Tiotropium|1 puff of 18 µg (22.5 µg tiotropium bromide monohydrate) in the morning between 8:00 and 10:00
223621938|NCT01412177|DRUG|OTO-104|Single intratympanic injection of 12 mg OTO-104
223621939|NCT01412177|DRUG|Placebo|Single intratympanic injection of placebo
224211718|NCT04241185|RADIATION|Hypofractionated Radiotherapy (Bladder only)|55 Gy of radiation administered to participant's bladder only. Twenty fractions will be administered over 4 weeks.
224211719|NCT04241185|DRUG|Cisplatin|35 mg of cisplatin per cubic meter of body volume, administered once weekly via IV infusion.
224211720|NCT04241185|DRUG|Fluorouracil (5-FU)|5-FU administered via IV infusion at a dose of 500 mg per cubic meter of body volume on Days 1-5 and 22-26.
224211721|NCT04241185|DRUG|Mitomycin C (MMC)|MMC administered via IV infusion at a dose of 12 mg per cubic meter of body volume on Day 1.
224211722|NCT04241185|DRUG|Gemcitabine|Gemcitabine administered via IV infusion at a dose of 27 mg per cubic meter of body volume twice weekly.
224211723|NCT04241185|DRUG|Placebo to Pembrolizumab|Placebo to intravenous (IV) pembrolizumab administered once every 6 weeks.
224211724|NCT06465706|DEVICE|LAmbre investigational device|Randomized 1:1 to either experimental group or control group.
224211725|NCT04106947|OTHER|Questionnaires|Questionnaires
224211726|NCT05851612|PROCEDURE|constant PEEP|Constant PEEP of 5 cm H2O will be applied and maintained throughout one-lung ventilation.
224211727|NCT05851612|PROCEDURE|Driving pressure guided PEEP|PEEP titration will be started at 5 cmH2O and then increased in 1 cmH2O interval to 10 cmH2O. After 10 breath cycles will maintained, Driving pressure (ΔP) will be measured at each PEEP level at the last cycle. The PEEP indicating the lowest ΔP will be selected if multiple levels of PEEP showed the same lowest ΔP, the lowest PEEP will be selected. Driving pressure will be calculated as plateau pressure minus PEEP. Titration will stopped if peak inspiratory pressure of 50 cm H2O, or plateau pressure of 40 cm H2O reached, or hypotension will be observed.
224211728|NCT05851612|PROCEDURE|oxygenation method guided PEEP|PEEP titration will be started from 5 cmH2O and increase of 1 cmH2O every 4 min with fixed driving pressure that will result in delivery of a fixed tidal volume (TV) of 6ml/kg ideal body weight (IBW). Optimal PEEP will be defined as the PEEP below which PaO2 /FIO2 falls by at least 20%. If at least 20% PaO2 /FIO2 decrement is not obtained, then PEEP that will result in the highest PaO2 will be selected.
224211729|NCT06153667|DEVICE|Bearing nsPVA|Bearing nsPVA Embolization Particles are irregularly-shaped, biocompatible, hydrophilic, nonresorbable particles produced from polyvinyl alcohol. These embolization particles are intended to provide vascular occlusion or reduction of blood flow within target vessels upon selective placement through a variety of catheters. Bearing nsPVA Embolization Particles are used for the embolization of symptomatic (leiomyoma uteri) uterine fibroids.
224211730|NCT06536582|BIOLOGICAL|Platelet rich growth factor injection (autologous product)|All patients will undergo two PRGF injections, one at recruitment and one 14 days after the first injection. The injection site will be the shoulder with tendinopathy.
224211731|NCT00103415|BEHAVIORAL|Endurance training|
224211732|NCT00103415|BEHAVIORAL|Weight-lifting training|
224316253|NCT00435760|DRUG|Placebo LAS34273|1 puff, 1 dat treatment
224316254|NCT04936165|PROCEDURE|Low-Level Laser Therapy|Use 810-nm-photosource to irradiate the participants' brain and forearm for 10 minutes with a water-cooling radiator to keep it at 25 ± 0.5 ℃.
224316255|NCT02463357|DIETARY_SUPPLEMENT|Quercetin|
224316256|NCT02463357|DRUG|Nifedipine extended release|
224316257|NCT02463357|DRUG|Methazolamide|
224316258|NCT02463357|DRUG|Metformin|
224316259|NCT02463357|DRUG|Placebo|
224316260|NCT02463357|DRUG|Nitrite|
224316261|NCT00019240|DRUG|cidofovir|
224316262|NCT01328522|DRUG|SAR153191 (REGN88)|"Pharmaceutical form:solution~Route of administration: subcutaneous"
223621940|NCT03272802|DRUG|Edaravone|Edaravone is a free radical scavenger. this drug showed desirable effects like slowing decline of physical function by 33 percent in previous studies.
223621941|NCT03272802|DRUG|Riluzole|Riluzole is a treatment option for amyotrophic lateral sclerosis. The occurrence of ventilator-dependence or tracheostomy is delayed in selected patients who treated with this drug.
224211733|NCT05151172|DEVICE|endovascular thrombectomy (EVT)|minimally invasive endovascular surgery for mechanical removal of occluding intracranial thrombus
224211734|NCT05151172|OTHER|Standarad medical care|Stanadard medical care wil involve use of thrombolytic drugs, Blood pressure management, use of antiplatelet or anti coagulant drugs
224211735|NCT02970175|DRUG|Terlipressin administration|Patients undergoing a bronchoscopy under local anesthesia for biopsy sampling of endobronchial lesions. Bronchoscopy will be done with terlipressin administration
224211736|NCT02970175|PROCEDURE|bronchoscopy under local anesthesia|Patients undergoing a bronchoscopy under local anesthesia for biopsy sampling of endobronchial lesions. Bronchoscopy will be done with terlipressin administration
223621942|NCT01777035|OTHER|early PT OT|"1. Passive range of motion (ROM) in pts who remain unresponsive despite sedative interruption.~2. active assisted ROM in supine position.~3. treatment is advanced to bed mobility activities~4. sitting balance activities followed by participation in activities of daily living (ADLs) and exercises that encourage increased independence with functional tasks.~5. progression to transfer training, and finally pre-gait training and ambulation.~6. progression of activities dependent on patient tolerance and stability~7. therapy sessions continue on a daily basis throughout hospital stay until return to prior level of function or is discharged."
223621943|NCT03298360|OTHER|Blood sample|167mL of blood in EDTA tube will be obtained on a research visit, after signature of written informed consent
223621944|NCT02539004|OTHER|Ultrasound study|Ultrasound study using real-time image fusion with a previous NCCT
224211737|NCT02970175|PROCEDURE|Biopsy sampling|Patients undergoing a bronchoscopy under local anesthesia for biopsy sampling of endobronchial lesions. Bronchoscopy will be done with terlipressin administration
224211738|NCT04068571|BEHAVIORAL|I-PUSH|Innovative partnership for universal and sustainable healthcare
224211739|NCT02955992|BEHAVIORAL|Improving communication during the end-of-life process|
224211740|NCT01814995|BEHAVIORAL|Nutrition/Physical Activity Intervention|Please see Arm description.
224211741|NCT04816877|DRUG|Opioid|Patients with acute pancreatitis will be divided into two groups - patient controlled analgesia (PCA) and physician-directed analgesia (PDA). Opioids are routinely administered as standard of care for treating pain associated with acute pancreatitis. Patients in the PCA group will be receiving opioids via a PCA pump, that the patient can use to self-regulate the dose and timing of drug administration. We will follow a specific protocol that has been designed by our pain physician for the PCA pump. Patients in the PDA arm will receive PRN opioids as directed by the physician, which will be administered by the nurse.
224211742|NCT04677894|DEVICE|Laryngoscopy|During the intubation, the head of the patient was kept in a neutral position, patients were nasotracheally intubated
224211743|NCT00381186|BEHAVIORAL|diet- and exercise intervention|
224211744|NCT00199095|DRUG|Adriamycin|
224211745|NCT00199095|DRUG|Cyclophosphamide|
224211746|NCT00199095|DRUG|Cytarabine|
223621945|NCT04507022|DRUG|Estradiol Valerate|2mg three times daily
224211747|NCT00199095|DRUG|Dexamethasone|
224211748|NCT00199095|DRUG|Idarubicin|
224211749|NCT00199095|DRUG|Ifosfamide|
224211750|NCT00199095|DRUG|Methotrexate|
224211751|NCT00199095|DRUG|Mercaptopurine|
224211752|NCT00199095|DRUG|VM26|
224211753|NCT00199095|DRUG|Vincristine|
224211754|NCT00928135|DRUG|Xylitol|15% xylitol solution for aerosol; Dosage: 5 ml twice a day (BID)
223621946|NCT04507022|DRUG|Progesterone|100 mg daily intramuscular
223621947|NCT04507022|DRUG|Aromatase inhibitor|2.5 mg twice daily for 5 days
223621948|NCT05682755|DRUG|Chidamide|initial time：platelet count ≥50×10\^9/L after allo-HSCT initial dose: 5 mg oral twice weekly initial adjustment: according to the platelet count tested weekly platelet count ≥50×10\^9/L-increased by 5 mg 20×10\^9/L≤ platelet count \<50×10\^9/L-remains unchanged platelet count \<50×10\^9/L- reduced by 5 mg maximum dose: 20 mg oral twice weekly terminal time: 180 days after allo-HSCT
223680480|NCT03786627|OTHER|Combined NMES and motor control|This group will receive the neuromuscular electrical stimulation using interferential mode (6000 Hz, beat frequency 20-50 Hz, scanning effect) on bilateral lumbar multifidus muscles. The intensity will be set at the subject's maximum tolerance. Stimulation will be set at 10 seconds on and 60 seconds off to minimize muscle fatigue. The total stimulation time is 15 minutes. After that, this group will receive 30 minutes motor control training. This motor control training will focus on the control of the lumbar multifidus muscle in various functional tasks. It is believed to restore the motor units in individuals with arthrogenic muscle inhibition. This motor control training will take approximately 30 minutes. This group will receive intervention twice a week for 8 weeks.
224211755|NCT00928135|DRUG|Hypertonic saline|7% hypertonic saline solution for aerosol; Dosage: 5 ml twice a day (BID)
224211756|NCT04718272|PROCEDURE|thoracic drainage management|After uniportal VATS pulmonary lobectomy, the traditional silicone tube which placed through the surgical incision was removed in the operating room in the experimental group.
224211757|NCT01033175|PROCEDURE|maximal cardiopulmonary exercise testing|Cardiopulmonary exercise testing (CPET) will be performed on a cyclic ergometer with continuous monitoring of a 12-lead electrocardiogram, heart rate and blood pressure. While breathing with a mask, the patients will perform a ramp protocol which includes 2-minutes free pedaling and progressive increase of power by 10, 15 or 20 watts/minute; power size will be selected after considering the patient' s daily activity and parameters of pulmonary function. CPET will be performed until exhaustion, unless the subjects reveal symptoms or signs indicating the exercise should stop (e.g. severe breathlessness).
224211758|NCT01033175|PROCEDURE|peripheral blood samples|Peripheral venous blood samples will be collected again in the morning after a fasting period of ≥12 hours. After immediate centrifugation, aliquots will be stored at -75˚C until analysis. Inflammatory markers and erythropoietin will be analyzed by flow cytometry and by enzyme-linked immunosorbent assay, using commercially available kits.
223621949|NCT02136966|OTHER|MNP + IYCN counseling + cooking demonstrations|Growth monitoring and promotion sessions will take place every month at village level for all children 0-23 months of age and will serve as an entry point for all the interventions. During these sessions children under 24 months will be weighed monthly and screened for MAM and uncomplicated SAM for treatment in the community as well as complicated SAM for referral to health facility During the monthly sessions cooking demonstrations will take place in which the community Health workers will instruct the mother how to prepare a good complementary food for 6-23 months olds adding the MNP. These meals will be given to the child during the session. Mothers will be encouraged to prepare the same meal at home During the monthly sessions enhanced IYCN counseling will be given to the mothers of 6-23 months olds, using improved BCI messages developed based on the rapid assessment of practices and foods available in the community and adaptation of the WHO manual.
223621950|NCT02208102|PROCEDURE|Radio-frequency catheter ablation|
223621951|NCT03546985|DEVICE|episil®|Firmly press the pump and apply the stream of liquid to the oral cavity 3 times (a total volume of 0.45 mL approximately). Distribute to affected areas in the mouth, for example by using the tongue. Wait for 5 minutes for the protective film to form.
223621952|NCT03546985|DEVICE|Kang Su|Gently pour 5 mL of rinse into the mouth, keep the rinse staying in the oral cavity for at least 1 minute, and spilt out the liquid.
223621953|NCT01311817|BIOLOGICAL|BMB72 (actA/plcB-deleted Listeria monocytogenes expressing influenza A nucleoprotein)|1mL liquid contained in an adhesive skin patch
224211759|NCT03199898|DIAGNOSTIC_TEST|Silverman-Andersen Retraction Score|The Silverman-Andersen Retraction Score (SAs) is used to assess severity of respiratory distress in newborn and preterm infants without respiratory support.The score comprises 4 inspiratory categories of movements (thoraco-abdominal, intercostal, xiphoid, and chin movements) and one expiratory category (grunting).
224211760|NCT03749525|DRUG|shenfu injection|we hypothesis that shenfu injection could improve patients' arterial vascular reactivity with septic shock
224211761|NCT03013517|DRUG|Viaskin Peanut 250µg|DBV712 250 µg, once daily
224211762|NCT03338673|DEVICE|tDCS|tDCS is a non-invasive procedure in which electrodes are attached to the scalp and send a small direct current to stimulate brain function
224211763|NCT03338673|OTHER|BrainHQ|BrainHQ is a web-based, commercially available cognitive training program that includes exercises to enhance working memory
223621954|NCT01687361|DIETARY_SUPPLEMENT|branched-chain amino acids (BCAA) supplementation|
223621955|NCT01687361|DRUG|PLACEBO|
223621956|NCT04579991|OTHER|Visnadin, ethyl ximeninate, coleus barbatus and millet in emulgel|Topical product, apply small amount on mucosal surface of vulva included clitoris once daily
223621957|NCT04579991|OTHER|Emulgel-only|Topical placebo product, apply small amount on mucosal surface of vulva included clitoris once daily
223621958|NCT02855008|BEHAVIORAL|STEPS|Agencies providing residential services to individuals with ID gave us letters of agreement (N=9) when we submitted for funding. We randomized these agencies and followed the specific order. Over the past year, recruitment issues have resulted in our only being able to recruit at six of the original nine agencies. To address the issues, we compiled a list of 15 additional local agencies within a 50 mile radius. We are recruiting from an additional six agencies and are in contact with another four. We also changed our recruitment criteria to include co-ed homes. Within each agency we then, (1) determine homes that that meet criteria and, by gender (male, female, co-ed), randomize to STEPS or attention-control condition. Residential staff are consented first. Individuals with ID (or guardians if they have one) are then consented. 18 homes will participate in STEPS.
223621959|NCT02855008|BEHAVIORAL|Food for Life|Agencies providing residential services to individuals with ID gave us letters of agreement (N=9) when we submitted for funding. We randomized these agencies and followed the specific order. Over the past year, recruitment issues have resulted in our only being able to recruit at six of the original nine agencies. To address the issues, we compiled a list of 15 additional local agencies within a 50 mile radius We are recruiting from an additional six agencies and are in contact with another four. We also changed our recruitment criteria to include co-ed homes. Within each agency we then, (1) determine homes that that meet criteria and, by gender (male, female, co-ed), randomize to STEPS or attention-control condition. Individuals with ID and staff are recruited after randomization. Residential staff are consented first. Individuals with ID (or guardians if they have one) are then consented. 18 homes will participate in Food for Life.
223621960|NCT04773392|DRUG|Twice-daily Tacrolimus|Within 48 hours of transplantation, immediate release tacrolimus (IRT) (0.1 mg/kg /day) will be administered twice a day.
223621961|NCT04773392|DRUG|Once-daily envarsus XR|Within 48 hours of transplantation, Envarsus XR (0.13mg/kg/day) will be administered once a day.
224211764|NCT00140738|BIOLOGICAL|GSK Biologicals' 719125|Patients receive six vaccinations at two-week intervals
224211765|NCT00327652|DRUG|CRS-100|Live-attenuated Listeria monocytogenes
224211766|NCT06320093|OTHER|SOUND Intervention|The intervention involved active (vocal and rhythmic production) and passive (listening to musical pieces) musical activities accompanied by motor coordination exercises. It consisted of 12 meetings (2 per week for 6 weeks) of 45 minutes each.
224211767|NCT03354923|BEHAVIORAL|PEERS intervention|PEERS is a 14-week manualized social skills treatment program that targets the friendship skills of adolescents with ASD. In the Israeli adaptation of PEERS, two meeting were extended. An adolescents group will be held concurrently with the parents group in different rooms. Both groups will begin the session with homework review, followed by a didactic social skills lesson, utilizing the teaching methods of modeling and role-playing. In order to practice the newly learned social skills,a behavioral rehearsal interaction will be assigned in the adolescents group. Finally,Socialization homework assignments designed to address further mastery and generalization of newly learned skills within the natural social environment will be assigned too.
224211768|NCT01005407|BIOLOGICAL|HEPLISAV and/or Placebo|Intramuscular (IM) injections on Week 0 and Week 4; placebo (saline) injection at Week 24
224211769|NCT01005407|BIOLOGICAL|Engerix-B|Intramuscular (IM) injections on Week 0, Week 4 and Week 24
224211770|NCT00434148|DRUG|Pasireotide|
224211771|NCT05278949|OTHER|The surgical intervention|The participant's primary IOL is re-fixed without utilizing any new material.
223621962|NCT04773392|DRUG|Induction Immunosuppression with Basiliximab or Rabbit Anti Thymoglobulin (rATG)|Induction immunosuppression with Basiliximab or Rabbit Anti Thymoglobulin (rATG) per protocol. The dose of Basiliximab will be a standard of two 20 mg doses and total rATG will not exceed 6 mg/kg.
223621963|NCT04773392|DRUG|Methylprednisolone, prednisone|Methylprednisolone intraoperatively (500mg) and immediately post transplantation (200mg on post operative day (POD) #1, 150mg on POD#2, 100mg on POD#3) then oral prednisone (50mg on POD #4, 20mg on POD #5). Oral prednisone will be tapered down to a minimal dose of 5mg within 6 weeks post transplantation.
223621964|NCT04773392|DRUG|Mycophenolate mofetil (MMF) or Mycophenolic acid (MPA)|Mycophenolate mofetil (MMF) (up to 1000mg) or Mycophenolic acid (MPA) (up to 720mg) will be administered twice a day.
223621965|NCT04773392|DRUG|Azathioprine|Azathioprine (1-3 mg/kg) will be administered once a day.
223621966|NCT02568969|DEVICE|Eirus continuous lactate monitor|a triple-lumen central venous catheter (Eirus TLC) functioning as a regular central venous catheter (CVC) with an integrated microdialysis function will be inserted via the left jugular vein for continuous monitoring of lactate and glucose using Eirus intravascular microdialysis system (Maquet Critical Care, Solna, Sweden) after calibration with arterial sample. Eirus TLC will be used for both drug administration and blood sampling and will be removed postoperatively when a central line will no longer be necessary.
223621967|NCT05750251|PROCEDURE|levator muscle resection surgery|conventional ptosis surgery
223621968|NCT05750251|PROCEDURE|Müller's muscle-conjuctival resection surgery|conventional ptosis surgery
223621969|NCT05750251|PROCEDURE|full-thickness anterior blepharotomy surgery|conventional eyelid retraction surgery
223621970|NCT06473064|OTHER|Benelli technique for nipple sparing mastectomy in surgical treatment of grade 3 and 4 gynecomastia|".The Nipple areola complex (NAC )margins on both sides are marked as circular. -Around the initial circle, a second circle (external) was drawn 1 cm broader than the boundary.~* The skin was resected, with deepithelialization between the two circles.~* A transdermal incision was made through the border of the external circle.~  -. The breast tissue around the pedicle was lifted over the pectoral fascia and excised by preserving the NAC and the underlying breast pedicle~* The base of the mammary pedicle under the NAC was infixed at the farthest end of the mastectomy area by using 3/0 absorbable multifilament suture material~  * Hence, the space formed after mastectomy was filled with a breast pedicle located posterior to the NAC.~ * The closure of the circular deepithelialized area around the NAC with a diameter of 1 cm accomplished by using 4/0 absorbable monofilament suture material and the surgery was completed"
223621971|NCT04522895|DRUG|Enasidenib|Participants receive up to 12 cycles of Enasidenib.
223621972|NCT02197312|DEVICE|NobelProcera Bridge Shaded Zirconia|
223621973|NCT03087396|DEVICE|Treatment of insufficiency fractures|Filling of micro fractures or insufficiency fractures with a bone substitute material
223621974|NCT00269178|BEHAVIORAL|Peer Health Education Programme|
223621975|NCT02314663|DEVICE|"COMBINED STRATEGY"|"Participants in the intervention group will be supplied with: a) printed matter containing information on the disease and its management (this will be handed out at each of the follow-up visits); b) mobile-telephone text messages containing guideline summaries, reminders of forthcoming appointments and/or arrangements for making new appointments in the event of non-attendance (in the periods between visits); and, c) self-report cards to check compliance with recommendations (across the entire follow-up)."
223621976|NCT05471544|DRUG|Sulfadoxine pyrimethamine|"Sulphadoxine is a slowly eliminated sulphonamide. It is used in a fixed dose combination of 20 parts sulphadoxine with 1 part pyrimethamine given orally or intramuscularly.~The medicine is no longer recommended for the treatment of malaria. However, it is being used for Intermittent Preventive Treatment during pregnancy (IPTp) and as a co-packaged combination with amodiaquine for seasonal malaria chemoprevention.~Sulphadoxine is readily absorbed from the GIT. It is widely distributed in body tissues and fluids and crosses the placenta into foetal circulation. It is also readily detectable in breast milk. It is excreted predominantly as the unchanged drug."
223621977|NCT05471544|DRUG|Amodiaquine|"Amodiaquine is a Mannich base 4 amino-quinoline that interferes with parasite haem detoxification. It is more effective than chloroquine in both chloroquine sensitive and resistant P. falciparum infections. However, there is cross-resistance between chloroquine and amodiaquine.~It is readily absorbed in the GIT and rapidly converted in the liver to the active metabolite, desethylamodiaquine. Desethylamodiaquine is responsible for all the antimalarial effect."
223621978|NCT01874197|DEVICE|B-TEVAR device|Implantation of the Branched Thorcoabdominal aortic anerysm device
223621979|NCT02055898|DRUG|Sodium Oxybate|
223621980|NCT02055898|OTHER|placebo (fresh potable water)|
223621981|NCT03802578|BEHAVIORAL|HAND EXERCISE|
223621982|NCT05072392|DEVICE|Foley catheter|"Using a 16G Foley catheter to cover the tip of the endotracheal tube as it passes through the nose. This is done in comparison to the standard practice of directly passing an endotracheal tube through the nose without a cover.~Both groups use warmed endotracheal tubes and the use of topical vasoconstrictor (4 sprays of 0.1% xylometazoline to each nare)."
223621983|NCT06468098|DRUG|IBI363 + chemotherapy|In this group, patients will receive IBI363 and chemotherapy
223621984|NCT06468098|DRUG|IBI363 + Investigator's Choice SOC|In this group, patients will receive IBI363 and Investigator's Choice SOC
224211772|NCT01845701|DRUG|Artesunate-Amodiaquine|"Pharmacology: Amodiaquine is effective against the erythrocytic stages of all four species of P. falciparum. Amodiaquine accumulates in the parasite's lysosomes and prevents breakdown of haemoglobin on which the parasite depends for its survival.~Artesunate is a water-soluble hemisuccinate derivative of artemisinin. Artesunate and its active metabolite dihydroartemisinin are potent blood schizonticides, active against the ring stage of the parasite.~The fixed-dose combination dihydroartemisinin-piperaquine has a cost advantage over other ACTs that brings it within reach of many, making it a potential best candidate for deployment in Africa and other poor countries. The drug is currently produced in China (Duo-cotecxin®)."
223621985|NCT00730977|DRUG|dry powder inhaled mannitol|single doses of 40 mg, 70 mg and 100 mg
223621986|NCT01620060|DRUG|Lurasidone|Lurasidone 20, 40,80, 120 or 160 mg/day oral single and multiple does of lurasidone for 12 days
223621987|NCT02180581|DIETARY_SUPPLEMENT|Probiotic (2 * 10^9 cfu/day)|Combination of two probiotics (2 \* 10\^9 cfu/day) or probiotics for 6 months
223621988|NCT02180581|DIETARY_SUPPLEMENT|Placebo|Placebo for 6 months
223621989|NCT06378034|DIETARY_SUPPLEMENT|Lactium|300 mg per day, taken 30 min to 60 min before bedtime
223621990|NCT06378034|DIETARY_SUPPLEMENT|Placebo|300 mg per day, taken 30 min to 60 min before bedtime
223621991|NCT06349694|OTHER|Transcutaneous MPN stimulation (T-MPNS)|Transcutaneous MPN stimulation (T-MPNS) is the electrostimulation of the lumbosacral roots that produce an activation of the lumbosacral plexus that controls the visceral organs and the pelvic floor muscles, thereby improving bladder control.
223621992|NCT06349694|OTHER|Transcutaneous tibial nerve stimulation (TTNS)|Transcutaneous tibial nerve stimulation (TTNS) is the electrostimulation of the lumbosacral roots that produce an activation of the lumbosacral plexus that controls the visceral organs and the pelvic floor muscles, thereby improving bladder control.
223621993|NCT06349694|OTHER|BT (Control group)|Conventional bladder training
223621994|NCT00743002|DRUG|TT223 with Metformin and/or TZD|Daily subcutaneous injection: 1 mg for 1 week; followed by 2 mg for 1 week; followed by 3 mg for 10 weeks
223621995|NCT00743002|DRUG|Placebo with Metformin and/or TZD|Daily subcutaneous injection: 1 mg for 1 week; followed by 2 mg for 1 week; followed by 3 mg for 10 weeks
223621996|NCT00367575|PROCEDURE|Internet personalized alcohol feedback (PAF)|
223621997|NCT04985721|DRUG|Pamiparib|40 mg orally twice a day
223621998|NCT04985721|DRUG|Tislelizumab|200 mg IV every 21 days
223621999|NCT00231777|DRUG|Comparator: MK0517|a single administration of 40 mg MK0517 by IV immediately prior to surgery
223622000|NCT00231777|DRUG|Comparator: ondansetron|a single administration of 4 mg ondansetron by IV immediately prior to surgery
223622001|NCT05440812|BEHAVIORAL|Storytelling and Training to Advance Individual Recovery Skills (STAIRS)|STAIRS is a 8-week program, in which 8 different themes are addressed. Coverage of each theme starts with a group meeting guided by a professional and expert by experience. In these meetings different exercises are done (e.g., filling out an actual and desired week-schedule, role-playing a difficult situation), information is given and experiences are shared. Between meetings, participants can choose from a range of homework exercises to practice their desired skills in a tailored way. In addition, participants can share experiences with the other group members and exchange reactions using a private online community.
223622002|NCT02787928|DRUG|Intrathecal hydromorphone|Intrathecal hydromorphone will be administered in an up/down dosage fashion. A successful dose will be defined as a patient not requiring additional narcotic pain medication outside of the standard VCU order set, which includes PRN oxycodone 5 and 10 mg every 4 hours and a one time PRN 1 mg hydromorphone IV. Failure of a dose will be if patient requires additional narcotic pain medication outside of these parameters
223622003|NCT00297219|DRUG|Low dialysate calcium|1.25 mmol/L dialysate calcium
223622004|NCT00297219|DRUG|high dialysate calcium|1.75 mmol/L dialysate calcium
223622005|NCT00702468|DRUG|Sativex|containing delta-9-tetrahydrocannabinol (THC)(27 mg/ml):cannabidiol (CBD)(25 mg/ml), in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring. Dose: 100 µl oromucosal spray, as required for symptom relief
223622006|NCT00702468|DRUG|Placebo|Contains no active drug and is delivered in 100 microlitre actuations by a pump action oromucosal spray
223622007|NCT05650008|DRUG|Intrathecal local anesthesia|Administration of local anesthetic into intrathecal space to achieve surgical anesthesia
223622008|NCT04458636|DRUG|Prednisolone|Oral
223622009|NCT02190136|OTHER|Protein whole foods|Protein-rich whole foods consumed at 20-30 grams of protein at each of 4-6 meals per day
223622010|NCT02190136|OTHER|Protein Resistance Exercise Training|Protein rich whole foods diet and resistance training 3 times per week for 11 weeks
223622011|NCT02190136|OTHER|Protein Stretching/Yoga Training|Protein-rich whole foods diet of 20-30 grams of protein at each of 4-6 meals per day with stretching/yoga training 3 times per week for 11 weeks
223622012|NCT05691881|DRUG|68Ga-NY105|Patients will receive a tracer (20-40mcg, IV) dose of 68Ga (2-5mCi) labelled NY105
223622013|NCT02053012|DEVICE|PVT-192|PVT-192 Psychomotor Vigilance Task Monitor is a hand-held, self-contained system used for repetitive reaction time measurement.
223622014|NCT02579668|OTHER|Language Therapy|
223622015|NCT03308344|BEHAVIORAL|Mindfulness training|The present MT program includes topics related to mindfulness, emotion regulation, and connection. It will be delivered in short, weekly sessions.
223622016|NCT05089006|PROCEDURE|Partial nephrectomy with robot-assisted and open surgery|Robot-assisted partial nephrectomy (RAPN) is considered as a feasible minimally invasive alternative to open partial nephrectomy (OPN) for the surgical treatment of renal tumors. The main advantages of this technique include a three-dimensional magnified view of the surgical field, enhanced dexterity, and greater precision in both dissection and reconstruction.
223622017|NCT04822181|DRUG|Semaglutide|Semaglutide administrated subcutaneously (under the skin) once weekly there will be a period of dose escalation before reaching the target dose.
223622018|NCT04822181|DRUG|Placebo|Placebo administrated subcutaneously (under the skin) once weekly.
223622019|NCT02190526|DRUG|Mesalazine(asacol 800 mg)|
223622020|NCT02190526|DRUG|Amitriptyline|
224211773|NCT01845701|DRUG|Dihydroartemisinine-Piperaquine|It is a bisquinoline antimalarial drug (1,3-bis\[1-(7-chloro-4 quinolyl)-4- piperazinyl\]-propane) that was first synthesised in the 1960s, and used extensively in China and Indochina as prophylaxis and treatment during the next 20 years. A number of Chinese research groups documented that it was at least as effective as, and better tolerated than, chloroquine against falciparum and vivax malaria. With the development of piperaquine-resistant strains of P. falciparum and the emergence of the artemisinin derivatives, its use declined during the 1980s. However, during the next decade, piperaquine was rediscovered by Chinese scientists as one of a number of compounds suitable for combination with an artemisinin derivative.
223622021|NCT02190526|DRUG|placebo like asacol|
223622022|NCT02190526|DRUG|placebo like amitriptyline|
223622023|NCT02780843|OTHER|Computerized Tomography|Standard Operational Plan at admission: CT and CT-angiography
223622024|NCT02780843|OTHER|Magnetic Resonance Imaging|Standard Operational Plan at admission: Diffusion Weighted Imaging (DWI), T2-FLAIR, Gradient and arterial Time-of Flight (TOF)
223622025|NCT05225038|OTHER|Exercise|Participants will meet with an exercise physiologist to undergo evaluation and develop individualized regimens for prehabilitation.
223622026|NCT05225038|DIETARY_SUPPLEMENT|Nutritional|Participants will meet with a nutritionist to undergo evaluation and develop individualized regimens for prehabilitation.
223622027|NCT05225038|BEHAVIORAL|Behavioral Medicine|"Participants will have 1 appointment with behavioral medicine - all participants will meet with the same behavioral medicine specialist to ensure consistency. Participants will receive education regarding factors that affect postoperative recovery and relaxation techniques.~Participants will also have the option to request faith support."
223622028|NCT05225038|BEHAVIORAL|Smoking Cessation|Participants who are actively smoking will be counseled regarding smoking cessation during their preoperative appointment with a member of the surgical team. They will also be offered a referral to smoking cessation resources.
223622029|NCT05975255|DRUG|Remimazolam besylate|Intravenous administration of predetermined dose of Byfavo for 30 seconds
223622030|NCT05961267|BEHAVIORAL|Questionnaire|A gynecological follow-up questionnaire will be proposed to patients with one of the above mentioned pathologies. This is a standardized questionnaire specifically designed for this study.
224211774|NCT01845701|DRUG|Artemether-lumefantrine combination|CoArtem® is an oral, fixed combination of artemether- a derivative of artemisinin and lumefantrine- a novel molecule developed by the Academy of Military Medical Sciences (AMMS) in Beijing. It is the only co-formulated ACT approved by WHO and is currently available through WHO at a negotiated public sector price. Both compounds are effective as single agents. However, recrudescence is common with artemether and lumefantrine has a slow onset of action. A fixed combination tablet (20 mg artemether/120 mg lumefantrine) has therefore been developed. Fixed combination therapy improves compliance and has the advantage of carrying a lower risk of selecting drug resistant strains. No resistance to either component has been observed to date.
224211775|NCT04117048|DEVICE|LabPad® point-of-care|All at home INR measurements will be performed by the nurse using the LabPad® point-of-care
224211776|NCT03747094|DRUG|Fentanyl|0.5 mic/kg fentanyl will be given immediately before the procedure
224211777|NCT03747094|DRUG|Ketamine|0.25 mg ketamine will be administered immediately before the procedure
224211778|NCT04369079|OTHER|manual myofascial techniques|Fascial techniques were used together with the following techniques: deep massage of neck and shoulder girdle muscles; trigger point therapy; tissue scar treatment in the vicinity of the scar and directly on the scar, by stretching, breaking, pulling, as well as static and dynamic rolling; post-isometric relaxation (stretching) of shoulder and neck muscles; active release technique of the chest and shoulder; selected fascial distortion model techniques; and fascial manipulation techniques consisting of developing specific CC-center of coordination and CF-center of fusion points in the operated area and the shoulder on the same side.
224211779|NCT04369079|OTHER|conventional therapy consisting of exercise and massage.|Underwent kinesiotherapeutic procedures that included various floor gymnastic exercises with gymnastic stick, balls, and/or elastic tapes, conventional massage of neck and shoulder girdle muscles and therapeutic exercises to increase ROM in the upper limb and in the chest area.
224211780|NCT05567094|DRUG|Dexamethasone|Patients will receive 0.2 mg/kg dexamethasone, administered as an intravenous bolus within 5 minutes after induction of anesthesia
224211781|NCT05567094|DRUG|Saline placebo|Patients will receive 2ml saline placebo, administered as an intravenous bolus within 5 minutes after induction of anesthesia
224211782|NCT04561934|DRUG|Silver diamine fluoride|Application of 38% SDF (Riva Star, SDI, Bayswater, Australia), and Resin modified glass ionomer cement (RMGIC) (Fuji Lining LC; GC, Tokyo, Japan) prior resin composite restoration (Filtek Z350 XT,3MESPE).
223622031|NCT03839368|PROCEDURE|fixation of angle fracture|open reduction and internal fixation of angle fracture
223622032|NCT04698343|DEVICE|Noninvasive Peripheral Nerve Stimulation (NPNS)|NPNS device programmed to deliver active stimulation.
224211783|NCT04561934|OTHER|resin modified glassionomer cement|resin modified glassionomer cement
224211784|NCT01624155|BEHAVIORAL|Education|EMR referral to teratogen and contraception counseling
224211785|NCT00864084|OTHER|Pulmonary rehabilitation|Pulmonary rehabilitation involves the prescription of customized exercise programs and education on disease management.
224211786|NCT04169425|PROCEDURE|elective diverting ileostomy|
224211787|NCT00275236|DRUG|Rotigotine|
224211788|NCT03461029|DEVICE|BIS monitor|The investigators placed on the forehead of all patients the sensor BIS quatroTM, that connects with the monitor, and they registered sedation and recorded the values obtained.
223622033|NCT02931019|PROCEDURE|Intubation|
224211789|NCT04185701|OTHER|SiVIEW software|Eye examination by a technician with the SiVIEW software
224211790|NCT04185701|OTHER|Expert|Eye examination by an expert including optimal correction in distance and near vision
224211791|NCT04399850|OTHER|Hypnosis group|Patients who receive hypnosis
224211792|NCT06420401|DIETARY_SUPPLEMENT|araboxylan|During the study period, subjects are instructed to take one pocket of arabosylan per day during the first week, followed by two pockets of araboxylan per day during the remianing 11 weeks. Aside from the dietary supplement provided, all participants are instructed to continue their normal routine and not make any changes to their dietary habits or physical activity.
224211793|NCT06420401|DIETARY_SUPPLEMENT|inulin|During the study period, subjects are instructed to take one pocket of inulin per day during the first week, followed by two pockets of inulin per day during the remianing 11 weeks. Aside from the dietary supplement provided, all participants are instructed to continue their normal routine and not make any changes to their dietary habits or physical activity.
224211794|NCT06420401|DIETARY_SUPPLEMENT|inulin and araboxylan|During the study period, subjects are instructed to take one pocket of inulin and araboxylan per day during the first week, followed by two pockets of inulin and araboxylan per day during the remianing 11 weeks. Aside from the dietary supplement provided, all participants are instructed to continue their normal routine and not make any changes to their dietary habits or physical activity.
224211795|NCT06420401|DIETARY_SUPPLEMENT|placebo control|During the study period, subjects are instructed to take one pocket of placebo control per day during the first week, followed by two pockets of placebo control per day during the remianing 11 weeks. Aside from the dietary supplement provided, all participants are instructed to continue their normal routine and not make any changes to their dietary habits or physical activity.
223622034|NCT05256680|OTHER|Gardening Activities|"In the research, the elderly in the experimental group will have gardening activities once a week for 3 months.~No intervention will be applied to the elderly in the control group during the research. They will participate in routine activities in the nursing home."
223622035|NCT06094920|DRUG|Empagliflozin 10 MG|Oral administration
224211796|NCT04501263|BEHAVIORAL|DEMCoN Educational Intervention|Educational programme on constipation for Health care professionals in this clinical specialist palliative care
224211797|NCT02414490|DRUG|Intravenous Immunoglobulin|The decision to treat with IVIg will be entirely at the discretion of the patient's treating physician.
223622036|NCT06094920|DRUG|Finerenone|"Oral administration.~Finerenone treatment may be initiated if serum potassium levels are ≤5.0 mmol/L. Conversely, if serum potassium levels are \>5.0 mmol/L, the initiation of finerenone treatment should be avoided. In such cases, a second serum potassium measurement will be performed two days later. If serum potassium levels are ≤5.0 mmol/L, these patients can still be considered for inclusion. However, if serum potassium levels are \>5.0 mmol/L again, these patients will be excluded, and an assessment of the underlying cause(s) of hyperkalaemia will be conducted.~The recommended initial dose of finerenone is determined based on eGFR, which will be assessed prior to the commencement of the trial. If eGFR is ≥60 mL/min/1.73m2, the dose will be set at 20 mg once daily. If eGFR is ≥25 to \<60, the dose will be set at 10 mg once daily. Participants with an eGFR \<25 are not advised to undergo finerenone treatment and will be excluded from the study."
223622037|NCT06094920|DEVICE|Withings BPM Connect|"CE marked and clinically validated blood pressure monitor. Clinical trial results are within the margin of acceptance defined by the internationally recognized evaluation standard of blood pressure monitors ANSI/AAMI/ISO 81060-2:2013, EN ISO 81060-2:2014, developed by the European Society of Hypertension, British Hypertension Society and Association for the Advancement of Medical Instrumentation/American Heart Association.~Blood pressure will be measured by the participants once daily on 40 days. Three consecutive measurements are taken."
223622038|NCT06094920|DEVICE|Withings Body|"CE marked and clinically validated advanced Wi-Fi smart scale.~Body weight will be measured by the participants once daily on 49 days."
223622039|NCT06094920|DIAGNOSTIC_TEST|PeeSpot Urine Collection Device|Biochemical urine data will be collected using first-morning void urine samples. Participants will obtain urine samples with the PeeSpot device, a validated tool designed for the collection and preservation of small urine volumes. This device comprises a urine absorption pad, a holder, a tube, and a lid. Patients can void directly onto the absorption pad while it is placed in the holder. Following voiding, the pad and holder are inserted into the tube, sealed with the lid, and stored in a refrigerator until they are sent to the laboratory using a biological materials envelope (PolyMed, DaklaPack, Europe). Through the incorporation of an inert hygroscopic polymer, the pad efficiently absorbs 1.2 mL of urine, and with the addition of various preservatives, the urine remains stable for up to four days. The investigators will employ the PeeSpot to determine the first-morning void levels of albumin, creatinine, sodium, potassium, glucose, urea, and osmolality once daily on 28 days.
224211798|NCT06303882|BEHAVIORAL|routine rehabilitation treatment|The routine rehabilitation treatment included intervention for risk factors (such as blood pressure, blood lipids, and blood glucose control, restriction of smoking and alcohol, exercise, etc.) Besides, the patients with stable vital signs were scheduled for specialized rehabilitation training upon enrollment, and targeted rehabilitation programs were selected, conducted by experienced rehabilitation therapists.
224211799|NCT06303882|BEHAVIORAL|Computer-assisted Cognitive Function Training|Based on the patient's cognitive impairment assessment results, the training content includes Attention game training, Executive function program training, Logical reasoning training, Agility training, Memory training. The training is conducted seven days a week, once a day, for a duration of 30-45 minutes per session
224211800|NCT06303882|BEHAVIORAL|conventional cognitive training|including Memory training, attention training, and executive function training were conducted 2-5 times per week, lasting for 30-60 minutes each session, based on the patient's condition.
224211801|NCT01155635|DRUG|Carvedilol|Use of Carvedilol with any dose
224211802|NCT01155635|DRUG|No Carvedilol|No use of Carvedilol
224211803|NCT06541912|PROCEDURE|conventional implant|"A full thickness mucoperiosteal flap was elevated under local anesthesia, osteotomy sites were prepared according to manufacturer's instructions and parallel pin was used to confirm position and angulation of osteotomy site. Conventional implant placement was done on one side.~Resonance frequency analysis instrument was used to measure Implant Stability Quotient (ISQ) and check the primary stability of the implant. The surgical wound closure was done with mattress and single interrupted sutures, using 4-0 vicryl sutures."
224211804|NCT06541912|PROCEDURE|UV implant|"A full thickness mucoperiosteal flap was elevated under local anesthesia and osteotomy sites were prepared according to manufacturer's instructions. Parallel pin was used to confirm position and angulation of osteotomy site. UV implant was activated using UV Activator2 and placed in another site.~Resonance frequency analysis instrument was used to measure Implant Stability Quotient (ISQ) and primary stability of the implant was measured. The surgical wound closure was done with mattress and single interrupted sutures, using 4-0 vicryl sutures."
224211805|NCT06537284|BEHAVIORAL|ImRs-DSR|Imagery Rescripting with Memory Reconsolidation Disruption
224211806|NCT06537284|BEHAVIORAL|ImRs|Imagery Rescripting regular
224211807|NCT04056091|PROCEDURE|Back rub stimulation|Immediately after birth, all infants with an expected birthweight \>1500 g who have been dried and remain apneic (not crying) will receive physical stimulation (back rubs). Stimulation can be repeated at maximum two or three times for about 3-5 seconds.
224211808|NCT04056091|PROCEDURE|Foot flicks stimulation|Immediately after birth, all infants with an expected birthweight \>1500 g who have been dried and remain apneic (not crying) will receive physical stimulation (foot flicks). Stimulation can be repeated at maximum two or three times for about 3-5 seconds.
224211809|NCT00731601|DRUG|pantoprazole|pantoprazole 40 mg/q6h IV infusion for three days
224211810|NCT00731601|DRUG|pantoprazole|pantoprazole 8 mg/h IV infusion for three days
224211811|NCT06540274|PROCEDURE|lumbar surgery|Discectomy, lumbar fusion or laminectomy
224211812|NCT04696627|OTHER|Questionnaire|Participants from all 3 groups will be interviewed
224211813|NCT06536920|DIAGNOSTIC_TEST|Migraine screening questionnaire|Screening test
224211814|NCT02980562|DRUG|Polyethylene Glycols|(Split dose 2L PEG-Asc)
224211815|NCT02980562|DRUG|Bisacodyl|(1L PEG-Asc plus bisacodyl)
224211816|NCT03862937|DIETARY_SUPPLEMENT|Exercise training + whey protein|Whey protein (2x / day - 20g for breakfast and 20g for dinner).
224211817|NCT03862937|OTHER|Exercise training + placebo (maltodextrin)|Maltodextrin (2x / day - 20g for breakfast and 20g for dinner).
224211818|NCT00593931|OTHER|fMRI|Functional Magnetic Resonance Imaging without contrast
224211819|NCT02215239|BEHAVIORAL|Workplace intervention|WHO Healthy Workplace Framework and Model. The intervention plan is to implement a cyclic or iterative process recommended by WHO. The process includes eight steps: (1) Mobilize; (2) Assemble; (3) Assess; (4) Prioritize; (5) Plan; (6) Do; (7) Evaluate; (8) Improve. We focus on different phases of exercise and prescribe individualized physical activity program.
224211820|NCT05602974|RADIATION|stereotactic body radiation therapy|adjuvant stereotactic body radiation therapy
224211821|NCT05602974|OTHER|regular follow-up|regular follow-up
224211822|NCT06542471|DEVICE|Dual intramedullary nailing|\- Elastic nailing for radius under image guidance through distal entry point and physeal sparing technique.
224211823|NCT06542471|DEVICE|Dual plating|\- ORIF for radius done first through volar approach.
224211824|NCT01531062|DRUG|Nigella sative|Nigella sativa seed extracts, 300 mg capsule bid, for 56 days
224211825|NCT01531062|DIETARY_SUPPLEMENT|black sticky rice|300 mg capsule bid, 56 days
224211826|NCT04808960|DIAGNOSTIC_TEST|clinical Computed Tomography|Clinical CT was acquired (scanned at 1.25mm x 1.25mm on a standard algorithm and then reformatted into an axial, coronal and sagittal series at 3mm x 2mm) on all fully intact cadavers prior to the onset of this study by the Schulich School of Medicine \& Dentistry at the University of Western Ontario, in accordance with the Anatomy Act of Ontario and guidelines of Western's Committee for Cadaveric Use in Research.
224211827|NCT02350322|OTHER|Schoolmeal with fatty fish|Schoolmeal with fatty fish three times a week for 12 weeks
224211828|NCT02350322|OTHER|Schoolmeal without fish|Schoolmeal with meat/cheese three times a week for 12 weeks
224211829|NCT02350322|DIETARY_SUPPLEMENT|Supplement|Omega-3 capsules three times a week for 12 weeks
224211830|NCT02936479|DRUG|C1-INH (Berinert)|
224211831|NCT06289335|DRUG|saline solution|20 mL of saline
224211832|NCT06541821|OTHER|survey evaluation|assessment of physical activity, fear of movement, and ostomy compliance
224211833|NCT00300573|DRUG|Dexelvucitabine|nucleoside inhibitor of HIV Reverse Transcriptase
224211834|NCT03633773|BIOLOGICAL|MUC-1 CART cell immunotherapy|After fludarabine and cyclophosphamide pre-chemotherapy，MUC-1 CART immunotherapy is given. A decent interval later, levels of specific antibodies, CART cells and serum cytokines will be assessed.
224211835|NCT02118207|OTHER|Aerobic running exercise|60 min of aerobic intervals completed prior to SCUBA diving
224211836|NCT03574818|DRUG|Necitumumab-Gemcitabine-Cisplatin|"* Gemcitabine 1250mg/m2 IV on D1, D8~* Cisplatin 75mg / m2 IV on D1~* Necitumumab 800mg IV on D1, D8 (peripheral blood for effector cells and cytokine measurements prior to each cycle) Repeat cycle every 21 days up to 3 cycles."
224211837|NCT03574818|DIAGNOSTIC_TEST|Evaluation to determine if patient is a candidate to proceeed with surgical resection or not|Patients will be evaluated with repeat imaging studies (PET/CT or CT Chest, Abdomen, Pelvis) and will be re-evaluated for surgical resection. Patients who had progressive disease or are NOT a surgical candidate will come off the study and will be treated according to standard therapies. All patients will be followed up for 2-year disease-free survival and overall survival
224211838|NCT01552629|DRUG|QGE031|
224211839|NCT01552629|DRUG|Placebo|
224211840|NCT01552629|DRUG|Cyclosporine A|
224211841|NCT04886869|DIETARY_SUPPLEMENT|caffeine|oral consumption
224211842|NCT00046020|DRUG|Venlafaxine ER|
224211843|NCT01353794|DRUG|Sorafenib (Nexavar, BAY43-9006)|The treatment with Sorafenib 200mg tablets should comply with the recommendations written in the local product information. The decision about the duration of treatment is solely at the discretion of the attending physician
224211844|NCT05801107|DRUG|WX-0593|WX-0593 Tablets 60 mg QD，once daily for 7 days, followed by 180 mg of WX-0593 tablets,once daily in a 21-days cycle.
224211845|NCT02095210|OTHER|Radiolabeled [68Ga]ABY-025|Single dose of 100 μg ABY-025 labeled with 500 MBq gallium-68, administrated as a slow intravenous injection. All patients will receive the same dose.
224211846|NCT02379676|DRUG|Ticagrelor|Ticagrelor 90mg twice daily for 30 days
224211847|NCT02379676|DRUG|Clopidogrel|Clopidogrel 75mg once daily for 30 days
224211848|NCT03881722|DIETARY_SUPPLEMENT|Mg alginate|Mg alginate after feedings
224211849|NCT05065242|BEHAVIORAL|Cognitive Behavioural Therapy|Sleep restriction, Stimulus control, sleep hygiene and cognitive techniques to handle sleep disturbing thoughts.
224211850|NCT01658215|DRUG|V0116 transdermal patch (Test treatment )|
224211851|NCT01658215|DRUG|Nicotine transdermal patch (Reference treatment )|
224211852|NCT00393978|DRUG|Quetiapine and placebo|placebo (titrated to 150-300 mg/day) in combination with quetiapine (titrated to 400-800 mg/day).
224211853|NCT00393978|DRUG|Quetiapine and Topiramate|topiramate (titrated to 150-300 mg/day) in combination with Quetiapine (titrated to 400-800 mg/day).
224211854|NCT05287802|OTHER|Balance and proprioception exercises|Balance and proprioception exercises using two different methods (classical balance training and Biodex) in addition to strengthening exercises
224211855|NCT05287802|OTHER|Home exercises program|Isometric exercises for the quadriceps and hamstrings at home
224211856|NCT02437539|DRUG|Injection of 68Ga-NOTA-AE105|One injection of 68Ga-NOTA-AE 105
224211857|NCT02437539|DEVICE|Positron Emission Tomography scans|Following injection of 68Ga-NOTA-AE105 the patients will be PET scanned at 10 minutes, 1 hour and 2 hours post injection
224211858|NCT00156286|DRUG|Gleevec|
224211859|NCT02428491|BIOLOGICAL|Hexaxim®|DTaP-IPV-Hep B-PRP-T combined vaccine, 0.5 mL, Intramuscular
224211860|NCT04583592|DRUG|Camostat Mesilate|Camostat mesilate administered as oral 100 mg round tablets. Study dose: Two 100 mg tablets (200 mg total) taken orally 4 times daily for 14 days.
224211861|NCT04583592|DRUG|Placebo|Placebo administered as oral round tablets. Study dose: Two placebo tablets taken orally 4 times daily for 14 days.
224211862|NCT01861717|DRUG|lanreotide|Somatuline Depot 90 mg deep subcutaneous injection every 4 weeks X 3 doses
223622040|NCT06094920|DIAGNOSTIC_TEST|Hem-Col Capillary Blood Collection Device|Capillary blood samples will be obtained using a BD Microtainer® Contact-Activated Lancet (Franklin Lakes, New Jersey, USA) once daily on 17 days. These blood samples will be collected into Hem-Col® tubes (Hem-Col, Labonovum, Limmen, the Netherlands), specifically designed for collection of capillary blood acquired through a finger prick. The Hem-Col microtube is equipped with an anticoagulant and a preservation buffer, enhancing the stability of analytes in whole blood. These Hem-Col tubes have the dimensions of standard blood collection tubes and are constructed from polyethylene, featuring a pierceable cap made of thermoplastic elastomers. Each tube incorporates a liquid barrier, with the inner part preventing the loss of Hem-Col preservation fluid and the outer part serving as a scoop for collecting blood from a finger prick. The Hem-Col lithium heparin tubes will be utilized for the analysis of creatinine, potassium, hsCRP, haematocrit, cystatin C, and fasting plasma glucose.
223622041|NCT06094920|BEHAVIORAL|Questionnaire: participants' perspectives toward the feasibility of participation in a trial at home with digital technologies|Participant perspectives regarding the feasibility of participating in a home-based trial will be evaluated using a digital questionnaire. This questionnaire includes inquiries adapted from the validated Telehealth Usability Questionnaire, supplemented with additional questions employed in prior studies that assessed the feasibility of decentralized clinical trials. The web application Research Electronic Data Capture 10.0.23 (REDCap - www.projectredcap.org) will facilitate the administration of these digital questionnaires. Participants will receive a link to access the digital questionnaires via email. Weekly telephone calls will be conducted to evaluate adherence to study procedures and monitor the occurrence of adverse events.
223622042|NCT02181465|BIOLOGICAL|G17DT|
223622043|NCT00088530|DRUG|pixantrone, cyclophosphamide, vincristine, rituximab, prednisone|Day 1: pixantrone (150 mg/m2), cyclophosphamide (750 mg/m2), vincristine (1.4 mg/m2), rituximab (375 mg/m2) Days 1-5: prednisone (100 mg/day)
223622044|NCT00088530|DRUG|Vinorelbine, Oxalplatin, Ifosfasmide, Etoposide, Mitoxatrone, Gemcitabine or Rituximab|Day 1: cyclophosphamide (750 mg/m2), vincristine (1.4 mg/m2), rituximab (375 mg/m2) Days 1-5: prednisone (100 mg/day)
223622045|NCT04127721|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo ASCT
223622046|NCT04127721|DRUG|Busulfan|Given IV
223622047|NCT04127721|DRUG|Fludarabine|Given IV
223622048|NCT04127721|DRUG|Itacitinib|Given PO
223622049|NCT04127721|DRUG|Methotrexate|Given IV
223622050|NCT04127721|DRUG|Tacrolimus|Given IV and PO
223622051|NCT03792659|OTHER|Blood Sample Draw|Approximately 100 cc (less than 1/2 cup) of blood will be drawn from both groups.
223622052|NCT01286675|DRUG|Eltrombopag|oral eltrombopag, 50 mg, 100 mg, 150 mg, days 2-15
223622053|NCT00739401|DEVICE|Suprarenal Proximal Cuff Extension|Powerlink 25 and 28mm Suprarenal Proximal Extensions augmenting the 25 and 28mm Powerlink bifurcated stent graft
223622054|NCT01723241|DRUG|XAF5, concentration A|
223622055|NCT01723241|DRUG|XAF5, concentration B|
223622056|NCT01723241|DRUG|XAF5, concentration C|
223622057|NCT01723241|DRUG|Placebo|
223622058|NCT04986163|DEVICE|Non-invasive analgesia monitoring with ANSPEC-PRO monitor and MEDSTORM monitor|The patients are monitored with two monitors under anesthesia: one monitor attached to the left hand and one monitor to the right hand. When one monitor is connected to the patient, the other monitor will be disconnected. The first monitor is ANSPEC and the second monitor used is MEDSTORM.
223622059|NCT04986163|DEVICE|Non-invasive analgesia monitoring with ANSPEC-PRO monitor and MEDASENSE monitor|The patients are monitored with two monitors under anesthesia: one monitor attached to the left hand and one monitor to the right hand. When one monitor is connected to the patient, the other monitor will be disconnected. The first monitor is ANSPEC-PRO and the second monitor used is MEDASENSE.
223622060|NCT04986163|DEVICE|Non-invasive analgesia monitoring with MEDSTORM monitor and MEDASENSE monitor|The patients are monitored with two monitors under anesthesia: one monitor attached to the left hand and one monitor to the right hand. When one monitor is connected to the patient, the other monitor will be disconnected. The first monitor is MEDSTORM and the second monitor used is MEDASENSE.
223622061|NCT03796273|OTHER|Best Practice|Undergo standard surgery
223622062|NCT03796273|DRUG|Ketoconazole|Given PO
223622063|NCT05648253|DEVICE|Hyivy Intravaginal Device|Intravaginal use of Hyivy device three times per week for 12 weeks, with each session consisting of 10 minutes of heat (37-39ºC) and 10 minutes of dilation.
223622064|NCT04575155|BEHAVIORAL|TEAM Strategy|"1. Pharmacists will have read/write EHR access with established Epic security points~2. Pharmacists will initiate medication reconciliation activities by calling the patient for a Comprehensive Medication Review. Pharmacists will add notes in their medication list for the prescriber, requesting the removal or discontinuation of prescribed drugs that patients report they are not taking and adding medications omitted from the provider's list. The pharmacist will provide notifications via secured Epic messaging direct to prescribers of any patient concerns.~3. At 6 month if poor adherence is determined, the pharmacist will initiate Therapy Management Review which is a call from the pharmacist to the patient specifically about the medication(s) for which they have poor adherence. If necessary, the pharmacist will create notes and send an in-basket message to the prescriber.~4. The prescriber will make changes to the patient's EHR and/or contact the patient as they see fit."
223622065|NCT06329765|BEHAVIORAL|Exercise with CUped - a motor-assisted, split crank pedaling device and undergo 50 m of gait training.|Exercise with CUped - a motor-assisted, split crank pedaling device and undergo 50 m of gait training.
223622066|NCT04046536|DEVICE|Transcranial Magnetic Stimulation|A non-invasive treatment that emits magnetic pulses to stimulate the brain.
223622067|NCT04046536|DEVICE|Sham Transcranial Magnetic Stimulation|Sham rTMS will consist of the same parameters as active, however, the subject will not receive the actual magnetic stimulation due to the use of a double sided Active/Sham coil used specifically for research studies.
223761838|NCT04917094|DEVICE|Compression stocking|"A below-the-knee compression stock will be worn daily for 2 weeks from waking up to before sleep.~Bioelectrical impedance will be performed before and 2 weeks after wearing the stocking to assess the total body water content.~Measuring the calf and neck circumference will be done before and after wearing the compression stocking. After 2 weeks, the patient will return back to the clinic for calf and neck circumference measurement.~Sleep test will be done the night before and 2 weeks after wearing the compression stocking. Oxygen Desaturation Index(ODI) will be assessed through a level 4 home sleep apnea testing device.~Patients recruited will have mild excessive to severe excessive daytime sleepiness and/or STOP-Bang score of 3 or more, with underlying conditions such as type II diabetes and hypertensive patients using the Epworth sleepiness scale. Epworth sleepiness scale will be assessed again 2 weeks after to assess for increase sleep efficiency."
224211863|NCT02256319|DRUG|Dexmedetomidine|Patients will receive a loading dose of 1 µg/kg in 10 min before starting the surgery. The maintenance dose will be 0.2-1 µg/kg/h for a Ramsey Sedation Score of 3-4 during the surgery´s preparation. It will be reduced to 0.2 µg/kg/h 15 min before starting the microelectrode recording for a Ramsey Sedation Score of 2. After the placement of the deep brain stimulator we will record the local field potentials activity. In addition, the subscales of rigidity, tremor and bradykinesia of the Unified Parkinson's Disease Rating Scale (UPDRS-III) score will be evaluated. Once the deep brain stimulator recording and neurologic exploration will be over patients will receive a maintenance dose 0.2-1 µg/kg/h until the end of the surgery. It will be stopped to transfer the patient to the ICU.
224211864|NCT02256319|DRUG|Propofol|The target doses are 0.5, 1, 1.5, 2 and 2.5 µg/kg. For its administration we will use the TCI (target controlled infusion) system. After programming each dose we will wait until the plasma and brain concentration of propofol are stabilized in this target and then we will record the local field potentials activity through the DBS. In addition, the subscales of rigidity, tremor and bradykinesia of the UPDRS-III score will be evaluated.
224211865|NCT06039098|DEVICE|DCS|DCS monitoring of brain
223622072|NCT03886506|BIOLOGICAL|PLX-PAD|PLX-PAD 300×106 cells in a mixture containing 10% DMSO, 5% human serum albumin and Plasma-Lyte, will be administered via 30 IM injections (0.5 mL each) delivered into the leg twice,at 8 weeks interval.
223622073|NCT03874468|DEVICE|X-ray|standing anteroposterior radiographs of the full-length lower limb with patients in the standing position. ( HKA Long Film Radiographs ).
223622074|NCT05346575|BEHAVIORAL|Teaching Obesity Treatments to Adult Learners (TOTAL)|TOTAL includes both video component and motivational telemedicine calls delivered via VA Video Connect (VVC) by a study interventionist. We will invite study participants to watch the 18-minute video at least once. The motivational component of TOTAL will consist of three telemedicine-based (VVC), one-on-one, 30-minute calls at 1 week, 6 months, and 12 months after randomization. This timing was selected so Veterans would have regular interactions with the interventionist within one year of initiating the intervention. Each motivational session will be tailored to where Veterans are in the treatment initiation process. Electronic outcome assessment surveys will be sent to the participants at baseline, at each motivational telemedicine visit, and for the 18 month assessment.
223622075|NCT05346575|BEHAVIORAL|Usual care|The usual care group will be electronically sent the 1-week, 6-month, 12-month, 18-month assessments. All usual care participants will be offered the opportunity to watch the educational video component of TOTAL after the final outcome assessment is performed (18 months post-randomization). Veterans in the usual care arm will also have access to the MOVE! program via referrals from the PCP or self-referral to MOVE!. If they initiate treatment in MOVE!, they may progress through MOVE! and receive obesity medications or be referred for bariatric surgery if they choose to do so.
223622076|NCT06547437|DRUG|Papaverine|papaverine a smooth muscle relaxant
223622077|NCT06547437|DRUG|normal saline|normal saline 0.9% 100 cc
223622078|NCT05159427|DRUG|Glucotrol XL 5Mg Extended-Release Tablet|Participants are randomized to take one tablet of this study drug by mouth.
223622079|NCT05159427|DRUG|Glipizide ER 5 MG 24 HR Extended Release Oral Tablet|Participants are randomized to take one tablet of this study drug by mouth.
223622080|NCT05159427|DRUG|Rifaximin 200Mg Tab|Participants will take one tablet of this study drug by mouth.
223622081|NCT05159427|DRUG|13C6-Glipizide|Participants will take 1 mg of this study drug dissolved in 40 ml glucose solution by mouth.
224211866|NCT00399919|DRUG|Propionyl-L-Carnitine|2 grams per day for six months
224211867|NCT00399919|DRUG|PLC|2 grams/day for six months
224211868|NCT02670200|BEHAVIORAL|cognitive behavior therapy|treatment technique to help people to overcome psychological distress and mental diseases
223622082|NCT06297187|DEVICE|CUSA (Cavitronic Ultrasonic Surgical Aspirator)|CUSA® Excel and CUSA® Clarity Ultrasonic Surgical Aspirator Systems are indicated for use in the surgical procedures where fragmentation, emulsification and aspiration of soft and hard tissue is desirable.
223622083|NCT06063161|BEHAVIORAL|Music therapy intervention|Music therapy intervention administered for 30 minutes 3x/week by certified music therapist.
223622084|NCT06063161|OTHER|Non-guided music listening|Participants will listen to generic music playlists.
223622085|NCT06063161|OTHER|Standard of care|placebo arm, routine standard of care
223622086|NCT04133883|PROCEDURE|Ultrasound, Haemophilia Joint Health Score|Systematic joint examinations of ankles, knees and elbows
223622087|NCT06054607|DIETARY_SUPPLEMENT|High-amylose maize starch+acetate/butyrate|High-amylose maize starch (HAMS), commercially available as Hylon VII (Ingredion, Inc.), to which the SCFA acetate or butyrate has been chemically added. Hylon VII is a HAMS containing \~70% amylose and used in a variety of food products. To produce SCFA-enriched HAMS, Hylon VII is chemically modified through esterification with the SCFA acetate or butyrate.
223622088|NCT06054607|OTHER|Low-amylose maize starch|Rapidly digestible low-amylose maize starch (0% amylose, 100% amylopectin) sold commercially as AMIOCA (Ingredion, Inc).
223622089|NCT01745926|DEVICE|MECHANICAL CHEST COMPRESSION|
223622090|NCT03693521|DEVICE|Handgrip strength measurement|Measurement of handgrip strength with Jamar hand-held dynamometer as a complement to standard care of patients with diabetes type 2 by diabetes-nurses.
223622091|NCT03693521|OTHER|Standard care|Standard care of patients with diabetes type 2 by diabetes-nurses.
223622092|NCT02428101|GENETIC|polymorphism analysis|
223622093|NCT06085534|DRUG|LNK01001|Capsules for oral use
223622094|NCT06085534|DRUG|Placebo|Capsules for oral use
223622095|NCT02083471|DIETARY_SUPPLEMENT|Specific Oral Tolerance Induction with Egg or Cow's milk|
223622096|NCT04484558|DRUG|Actilyse|Infusion
223622097|NCT00467740|DRUG|BI 1744 CL|
223622098|NCT02903160|DRUG|Abiraterone acetate|Abiraterone acetate 1000 mg PO daily
223622099|NCT02903160|DRUG|Prednisone|5 mg PO twice a day
223622100|NCT02903160|DRUG|Radium-223 dichloride|50 kBq/kg IV monthly
223622101|NCT02903160|DRUG|cabazitaxel|25 mg/m2 IV every 3 weeks
223622102|NCT02903160|DRUG|Carboplatin|Carboplatin AUC 4 IV every 3 weeks
223622103|NCT02903160|DRUG|Enzalutamide|160 mg PO daily
223622104|NCT01838317|DRUG|Pioglitazone|
223622105|NCT02737007|DRUG|[14C]-GSK3191607|\[14C\]-GSK3191607 is a solution to be administered intravenously as a single dose infusion over 15 minutes. It is a radio-labeled product; 100 mcg of \[14C\]-GSK3191607 contains approximately 7.4 kilobecquerel (kBq) of \[14C\] radioactivity.
223622106|NCT02203877|DIETARY_SUPPLEMENT|Lactobacillus fermentum CECT5716|Intervention with a probiotic strain in form of a daily capsule containing 3x109cfu/capsule.
223622107|NCT02203877|DIETARY_SUPPLEMENT|Maltodextrin|Intervention with a daily capsule containing maltodextrin as placebo
223622108|NCT00274248|DRUG|MLN518|
223622109|NCT02149381|BEHAVIORAL|CBASP|Cognitive behavioral group intervention for individuals suffering from chronic depression
223622110|NCT02149381|BEHAVIORAL|Befriending|Social support intervention, sessions once per week
223622111|NCT02149381|OTHER|Treatment as usual|Conventional psychiatric outpatient treatment (individual counseling)
223622112|NCT01892670|OTHER|Donation of 1 whole blood unit|Donation of 450-500 mL of whole blood according to local blood bank procedures and national guidelines.
223622113|NCT01009541|DRUG|Pregabalin controlled release, 82.5 mg|82.5 mg controlled release tablet administered once daily for three days.
223622114|NCT01009541|DRUG|Pregabalin controlled release, 165 mg|165 mg controlled release tablet administered once daily for three days.
223622115|NCT01009541|DRUG|Pregabalin controlled release, 330 mg|330 mg controlled release tablet administered once daily for three days.
223622116|NCT01009541|DRUG|Pregabalin immediate release, 150 mg|150 mg immediate release capsules administered every 12 hours for three days
224211869|NCT03033069|DRUG|Brexpiprazole|Brexpiprazole oral tablets.
224211870|NCT03033069|DRUG|Sertraline|Sertraline oral capsules.
223622117|NCT02527681|DRUG|Ceftobiprole medocaril|Ceftobiprole medocaril was administered as a single intravenous infusion, with a bodyweight-adjusted volume, at a constant rate over 4 hours. The ceftobiprole dose was 7.5 mg/kg, which corresponds to 10.0 mg ceftobiprole medocaril.
223622118|NCT03272750|DIETARY_SUPPLEMENT|Bioscalin® new formulation with Galeopsis Segetum|Total duration of the study was 4 months; each subject, took by mouth two capsules/die of placebo at breakfast and one tablet/die of study product at lunch for the first 3 months of the trial.
223622119|NCT03272750|DIETARY_SUPPLEMENT|Reference product|Total duration of the study was 4 months; each subject, took by mouth two capsules/die of reference product at breakfast and one tablet/die of placebo at lunch for the first 3 months of the trial.
223622120|NCT03272750|DIETARY_SUPPLEMENT|Placebo|Total duration of the study was 4 months; each subject, took by mouth two capsules/die of placebo at breakfast and one tablet/die of placebo at lunch for the first 3 months of the trial.
223622121|NCT03236896|BEHAVIORAL|Exercise|Strength training exercises for older adults. All subjects will complete questionnaire (MENQOL Scale),hot flash diary and wear the fitbit flex for duration of study.
223622122|NCT03236896|BEHAVIORAL|No exercise|All subjects will complete questionnaire (MENQOL Scale),hot flash diary and wear the fitbit flex for duration of study.
223622123|NCT02006316|PROCEDURE|Microsurgical subinguinal varicocelectomy|
223622124|NCT05244512|OTHER|Evidence-based leadership training|7-modules online training over six months mentored by tutors. Independent familiarisation of reading material, peer-group discussions, self-reflection, assignments, tutor's feedback.
223622125|NCT05244512|OTHER|Conventional training|7-modules online training over six months. Independent reading only.
223622126|NCT06112483|BEHAVIORAL|SWELE Programme|"This 16-week programme focuses on Supporting Wellness in E-Child Learning Environments (SWELE) programme by combining unstructured outdoor play with mindfulness-based interventions to promote mental health in SEN students, in the context of the COVID-19 pandemic. There is no such SWELE programme to promote mental health for SEN students in Hong Kong, especially in the context of COVID-19 pandemic.~A playful approach of unstructured play has also been found effective on promoting positive emotions and emotional competence among early adolescents (Harn \& Bo, 2019). Unstructured Outdoor Play coupled with Mindfulness-based Interventions via SWELE programme to Promote Mental Health for children and adolescents with SEN during COVID-19 pandemic. Very limited unstructured outdoor play-based programme integrated into the extra-curricular activities in the special schools in Hong Kong."
223622127|NCT00885066|DRUG|capecitabine|
223622128|NCT00885066|DRUG|erlotinib hydrochloride|
223622129|NCT00885066|DRUG|gemcitabine hydrochloride|
223622130|NCT01127243|PROCEDURE|day-case laparoscopic supracervical hysterectomy|patients discharged home the same day of the operation
223622131|NCT01127243|PROCEDURE|inpatient LSH|patients discharged home the day after the operation
224211871|NCT03033069|DRUG|Brexpiprazole Matching Placebo|Brexpiprazole matching placebo oral tablets.
223622132|NCT01082250|DRUG|Lurasidone HCl|120mg dose. 3-way cross-over for 21 days
223622133|NCT00730158|DRUG|KD018|Traditional Chinese Medicine formulation administered orally twice a day for 4 days on days 1-4 every 2 weeks from the second cycle, at a dose of 1,800 mg, twice a day.
223622134|NCT00730158|DRUG|Irinotecan|Irinotecan will be administered intravenously once every 2 weeks from the first cycle, at a dose of 215 mg/m².
223622135|NCT00730158|DRUG|Placebo|Placebo capsules will be administered orally twice a day for 4 days on days 1-4 every 2 weeks.
223622136|NCT01051674|OTHER|High fiber vs. low-carbohydrate diets|High fiber diet involves at least 40 grams of dietary fiber or more per day for women and at least 50 grams of dietary fiber per day for men. Low-carbohydrate diet involves less than 120 grams of carbohydrate per day for both men and women.
224211872|NCT03033069|DRUG|Sertraline Matching Placebo|Sertraline matching placebo oral capsules.
224211873|NCT05517863|DEVICE|laser therapy|"All patients received 2 sessions of laser therapy / week in two consecutive months of treatment aiming complete wound closure , patients received \& infrared laser therapy plus traditional wound care:~(I) Use red \& infrared laser therapy device with 4 different wavelengths in a synchronized mode:~1. 980 nm for wound decontamination, improve circulation, lymphatic drainage~2. 915 nm enhances O2 delivery~3. 810 nm increases ATP production~4. 650 nm accelerate surface healing, tissue regeneration plus traditional wound treatment mentioned before"
224211874|NCT02146235|BEHAVIORAL|Psycho-Music Therapy|
224211875|NCT01189071|DRUG|Darifenacin|an M3 selective anticholinergic medication. M3 muscarinic receptors are felt to be related to bladder and ureteral contractility. The ureteral and bladder spasms related to ureteral stents are felt to be due to inappropriate contractions. By using a selective M3 receptor, it is felt that there will be fewer side effects. Participants will be placed on the standard 15 mg oral daily dosage for 3 days prior to the stent being placed, day 3 being the am of the surgery.
224211876|NCT00062036|BIOLOGICAL|aldesleukin|
224211877|NCT00062036|BIOLOGICAL|filgrastim|
224211878|NCT00062036|BIOLOGICAL|incomplete Freund's adjuvant|
224211879|NCT00062036|BIOLOGICAL|interleukin-2 gene|
224211880|NCT00062036|BIOLOGICAL|therapeutic tumor infiltrating lymphocytes|
223622137|NCT01012986|OTHER|Assessment of reading skills|
224211881|NCT00062036|DRUG|cyclophosphamide|
224211882|NCT00062036|DRUG|fludarabine phosphate|
224211883|NCT05048745|PROCEDURE|interval appendectomy|interval appendectomy
224316263|NCT04682925|OTHER|skin care arm of where evidence-based practices in the implementation guide|"1. The nasal mucosa and nasal skin under the nasogastric tube will be cleaned and dried twice a day with a pH-compatible cleanser.~2. A water-based moisturizing cream will be applied to the nasal skin under the nasogastric tube twice a day, after care with a pH-compatible cleanser.~3. Spray skin barrier will be applied twice a day after applying water-based moisturizing cream to the nasal skin under the nasogastric tube.~4. The nasal mucosa and nasal skin under the nasogastric tube will be evaluated twice daily for signs of pressure-related injury. All these care interventions applied to the skin care arm will be applied together with the doctor and nurse responsible for the treatment and care of the patient."
224316264|NCT04682925|DEVICE|hydrocolloid (Convatec Granuflex-extra thin) dressing|The nasal skin of the patients and the surrounding skin will be cleaned with a pH-compatible cleaner, dried and a new hydrocolloid cover will be applied once a day. All these care interventions applied to the hydrocolloid dressing arm will be applied together with the physician and nurse responsible for the treatment and care of the patient.
223622138|NCT01459484|DRUG|Mifamurtide arm|"PRE SUGERY TREATMENT:~Methotrexate: 12g/m2 (3 cycles) Cisplatinum: 120mg/m2 (3 cycles) Doxorubicin: ADM 75mg/m2 (3 cycles)~POST SURGERY TREATMENT for good responder patients with positive P-GLYCOPROTEIN~Methotrexate 12g/m2 (10 Cycles) Cisplatinum 120mg/m2; Doxorubicin 90mg/m2 MEPACT 2 mg/m2 twice a week for the first 3 months the weekly for the next 6 months (total lenght treatment 44 weeks)~POST SURGERY TREATMENT for poor responder patients with positive P-GLYCOPROTEIN~Methotrexate 12g/m2; Cisplatinum 120mg/m2; Doxorubicin 90mg/m2 ifosfamide 15g/m2 MEPACT 2 mg/m2 twice a week for the first 3 months the weekly for the next 6 months (total lenght treatment 44 weeks)~All the product are used as commercial formulation"
223761839|NCT04125108|OTHER|pulmonary rehabilitation|Pulmonary rehabilitation programs were designed to include both 30 minutes resistance and 30 minutes aerobic exercises. Eight basic resistnace exercises were used incorporating, bench press, leg press, leg curl, leg extension, toe raises, biceps curl, triceps curl, shoulder press. Additionally each exercise training session also included aerobic conditioning exercises ona treadmill or cycle ergometer. Aerobic exercise training was carried out 5 days per week, with each session lasting 30 minutes. All exercise sessions were preceded by a 5-minutes warm up period on a treadmill set.
223761840|NCT00165971|PROCEDURE|BIS monitoring|
224211884|NCT01488799|BEHAVIORAL|Motivational Interviewing and Cognitive Behavioural Therapy|Participants with a diagnosis of severe Generalized Anxiety Disorder will be randomly assigned to receive either 4 weekly sessions of MI followed by 11 weekly sessions of CBT (MI-CBT arm) or 15 weekly sessions of CBT (CBT alone arm). Both groups will also receive 2 follow-up CBT treatment sessions at 1 and 3 months post-treatment. In order to increase generalizability to clinical practice, in the CBT phase for the MI-CBT arm, therapists will shift to MI in the presence of empirically derived markers of resistance and shift back to CBT when resistance has diminished. In the CBT alone arm therapists will respond to resistance using manualized recommendations derived from leading CBT theorists for the management of resistance.
224211885|NCT02843347|PROCEDURE|Blood draw|Three tubes of blood (28.5 mL in total) will be obtained at the Baseline Visit. The sample will be stored for future research.
224211886|NCT00583245|OTHER|Gait Training|Gait training with physical therapist 2/week for 3 months
224211887|NCT04156867|DEVICE|Dynesys|discectomy with Dynesys
224211888|NCT05302284|DRUG|RC48-ADC|2.0 mg/kg IV every 2 weeks
224211889|NCT05302284|DRUG|Toripalimab|3.0 mg/kg IV every 2 weeks
224211890|NCT05302284|DRUG|Gemcitabine|1000mg/m2 IV infusion on Days 1 and 8 of every 3 week cycle
223761841|NCT00393055|DIETARY_SUPPLEMENT|xylitol|1g xylitol lozenges to be dissolved in mouth. Five lozenges daily for three years
224211891|NCT05302284|DRUG|Cisplatin|70mg/m2 IV infusion on Day 1 of every 3 week cycle
224211892|NCT05302284|DRUG|Carboplatin|AUC=4.5, IV infusion on Day 1 of every 3 week cycle
224211893|NCT01972542|DIETARY_SUPPLEMENT|Oral fat tolerance test|
224211894|NCT03291678|PROCEDURE|new laparoscopic orchiopexy|closure of the internal ring of the inguinal canal after descending of the testis to scrotum using needle percutaneous
224211895|NCT03291678|PROCEDURE|classic laparoscopic orchiopexy|delivery of abdominal testis into scrotum without closure of the internal ring of the inguinal canal
224211896|NCT02623426|DRUG|Dexamethasone intravitreal implant 0.7 mg|Standard preparation as described for intravitreal injections.
224211897|NCT02623426|DRUG|Intravitreal Methotrexate 400 µg|Intravitreal Methotrexate 400 µg injection procedures should be carried out under controlled aseptic conditions which include the use of sterile gloves and a sterile eyelid speculum (or equivalent). Adequate anesthesia and a broad-spectrum microbicide such as betadine, applied to the periocular skin, eyelid and ocular surface are required prior to the injection.
223622139|NCT01459484|OTHER|3 drugs arm|"High grade osteosarcoma who do not over express ABCB1/P-glycoprotein will be treated with a standard 3-drugs regimen~PRE-SUGERY TREATMENT:~Methotrexate: 12g/m2 (3 cycles) Cisplatinum: 120mg/m2 (3 cycles) Doxorubicin: ADM 75mg/m2 (3 cycles)~POST SURGERY TREATMENT:~Methotrexate 12g/m2 (10 cycles) Cisplatinum 120mg/m2; Doxorubicin 90mg/m2~Total lenght 34 weeks~All the product are used as commercial formulation"
223622140|NCT03535350|DRUG|Ibrutinib|"Dose response of Ibrutinib. Level 1 starting dose is 420mg daily. Level 2 starting dose is 560mg daily. Level -1 starting dose is 280mg daily.~November 2020:~420 mg of ibrutinib plus temozolomide and radiation was found to be safe - up to 36 participants can betreated at the expansion cohort in both arm 1 and arm 2."
223622141|NCT03535350|RADIATION|Radiation|2Gy x 30minutes for 6 weeks.
223622142|NCT03535350|DRUG|Temozolomide (TMZ)|Cycle 1 150mg/m2 and cycle 2-6 will be up to 200mg/m2.
223622143|NCT00844376|DRUG|Atorvastatin suspension|A single dose of 80 mg Atorvastatin suspension
223622144|NCT00844376|DRUG|Lipitor|A single dose of 80 mg Lipitor tablet
223622145|NCT03195816|BEHAVIORAL|Computerized Cognitive training|Experimental group will receive 1 year of a computer-based cognitive stimulation program, first 6 months, 60-minutes twice a week and next 6 months once a week training in group-setting, using a tablet with a software with specific training focused on attention, executive and speed processing functions.
223622146|NCT03806621|PROCEDURE|Rotational Atherectomy|Patients with severe calcified lesions will receive rotational atherectomy during index PCI
223622147|NCT03630835|OTHER|99mTc-Annexin-V-128 uptake on scintigraphy|"An intravenous catheter will be placed in the forearm and a dose of 370 Mega-Becquerels of 99mTc-Annexin-V-128 (1-2 ml) over 10 seconds will be injected through the catheter. The patient will wait for 90 minutes in semi-supine position for the clearance of the radiotracer from blood. At 90 minutes p.i., the patient will be placed in a supine position on the bed of a SPECT-CT gamma-camera. A SPECT acquisition including the heart and the brain will be performed over 20 minutes. At the end of the SPECT acquisition, the bed will move to the CT of the imaging system. A CT angiography will be acquired during the intravenous injection of 30-40 ml of iodinated CT contrast agent from the heart to the brain to localize the signal on the SPECT images. The iodinated contrast agent that is currently available at Bichat Hospital for CTA is Iomeron 400 provided by Bracco Imaging.~The total duration of the imaging study will be 2 hours."
223622148|NCT05714267|DEVICE|Active noise cancelling|During the operation, active noise canceling device (Sony wh100xm3) will be applied to the patients in Group-1 after spinal anesthesia is applied and will not be removed until the operation is completed. At the end of the surgery, the trait anxiety scale will be administered to the patients and the VAS pain scale will be administered at the 1st Hour, 8th Hour and 24th Hour. The obtained data will be recorded.
223622149|NCT05714267|DEVICE|Passive noice cancelling|During the operation, passive noise canceling device (3M Peltor X5a) will be applied to the patients in Group-2 after spinal anesthesia is applied and will not be removed until the operation is completed. At the end of the surgery, the trait anxiety scale will be administered to the patients and the VAS pain scale will be administered at the 1st Hour, 8th Hour and 24th Hour. The obtained data will be recorded.
223622150|NCT05714267|DEVICE|Active noise cancelling with music therapy|The patients in Group-3 will be given music therapy with an active noise canceling tool (Sony wh100xm3) during the surgery. The music that the patient will listen to will be left to the patient's preference. Music therapy with an active noise canceling device will be applied after spinal anesthesia is applied and will not be removed until the surgery is completed. At the end of the surgery, the trait anxiety scale will be administered to the patients and the VAS pain scale will be administered at the 1st Hour, 8th Hour and 24th Hour. The obtained data will be recorded.
223622151|NCT03326388|DRUG|Selumetinib|Selumetinib Intermittent Dosing
223622152|NCT06020898|DRUG|Sodium valproate|Patients with acute ischemic stroke included in the study are randomly assigned to low-dose sodium valproate group, high-dose sodium valproate group and placebo group. Besides receiving conventional treatment for stroke, 10mg/kg sodium valproate, 20mg/kg sodium valproate or normal saline were given intravenously for 3 consecutive days, respectively.
223622153|NCT06020898|DRUG|Normal saline|Patients with acute ischemic stroke included in the study are randomly assigned to low-dose sodium valproate group, high-dose sodium valproate group and placebo group. Besides receiving conventional treatment for stroke, 10mg/kg sodium valproate, 20mg/kg sodium valproate or normal saline were given intravenously for 3 consecutive days, respectively.
223622154|NCT06451302|DRUG|cyclophosphamide, adriamycin, vincristine，Ifosfamide，etoposide|The doses and intensity of chemotherapy vary according to risk stratification. Mainenance therapy is added to high-risk patients.
223622155|NCT01747512|DRUG|C-PERT|Patients with thyroid and Head and Neck cancer
223622156|NCT01747512|DRUG|G-PERT|Patients with thyroid and Head and Neck cancer
223622157|NCT02967146|DEVICE|adhesive barrier|After having axillary dissection, investigator has to inject the mediclore on op site directly and suture the site.
223761842|NCT00393055|DIETARY_SUPPLEMENT|inactive lozenge|1g inactive lozenge, dissolved in mouth. Five/day for three years
224316265|NCT04682925|OTHER|control|In routine care, the skin under the nasogastric tube is evaluated once a day for redness and wound formation by the nurse responsible for the patient's care and is cleaned and dried with appropriate cleaners.
224316266|NCT00899522|OTHER|biologic sample preservation procedure|Once the pathologist has taken the material needed to establish diagnosis of cancer, the anonymized snap-frozen and fresh samples will be either shipped to our laboratory for analysis or will be picked up by a member of the principal investigator's lab team. Samples will be stored indefinitely.
224316267|NCT00899522|PROCEDURE|biopsy|Once the pathologist has taken the material needed to establish diagnosis of cancer, 1-10 grams of the remaining tissue should be placed in phosphate buffered saline and shipped to the Bagby Lab.
223761843|NCT05349448|DRUG|Hylase plus Triamcinolone plus sterile isotonic saline|transforaminal fluroscopic epidural injection
223761844|NCT05349448|DRUG|Hylase plus Dexmedetomidine plus Triamcinolone|transforaminal fluroscopic epidural injection
223761845|NCT05187416|DIAGNOSTIC_TEST|two-dimensional shear wave elastography|Preoperative ultrasound elastography examination
223761846|NCT01441193|BIOLOGICAL|HIV-1 Tat/delta-V2 Env combined vaccine|
223761847|NCT01441193|BIOLOGICAL|HIV-1 delta-V2 Env vaccine|
223761848|NCT01441193|BIOLOGICAL|HIV-1 Tat vaccine 7.5 microg|
223761849|NCT01441193|BIOLOGICAL|HIV-1 Tat vaccine 30 microg|
224316268|NCT06582186|DRUG|Individualization of first voriconazole maintenance doses|Individualization of first voriconazole maintenance doses
224211898|NCT02623426|DRUG|Intravitreal Ranibizumab 0.5 mg|Intravitreal Ranibizumab 0.5 mg injection procedures should be carried out under controlled aseptic conditions which include the use of sterile gloves and a sterile eyelid speculum (or equivalent). Adequate anesthesia and a broad-spectrum microbicide such as betadine, applied to the periocular skin, eyelid and ocular surface are required prior to the injection.
223622158|NCT03168477|OTHER|dry needling|Dry needling to the supraspinatus (proximal/distal teno-osseus junction and musculotendinous junction under acromion process), deltoid muscle, upper trapezius muscle and levator scapulae muscle on the painful side. Clinicians may also needle the terres major, infraspinatous, rhomboids and thoracic paraspinals, as needed. Up to 12 treatment sessions over 6 weeks.
223622159|NCT03168477|OTHER|spinal manipulation|HVLA thrust manipulation to cervical, thoracic and/or upper rib articulation (R1-R3).
223622160|NCT03168477|OTHER|mobilization|Impairment-based mobilization targeting the muscles, scapulae and joint capsule of the painful shoulder. Up to 12 treatment sessions over 6 weeks.
223622161|NCT03168477|OTHER|exercise|Impairment-based exercise targeting the muscles, scapulae and joint capsule of the painful shoulder. Up to 12 treatment sessions over 6 weeks.
223622162|NCT03168477|OTHER|modalities|Interferential electrotherapy targeting the muscles, scapulae and joint capsule of the painful shoulder. Up to 12 treatment sessions over 6 weeks.
223622163|NCT00660192|DRUG|Botox|subjects randomized to receive Botox with have a series of injections of onobotulinumtoxinA totalling 200 to 300 units. Botox is prepared b adding 1cc of preservative free saline in 100 unit vial. Final dose is determined by bod and neck size.
223622164|NCT00660192|OTHER|Placebo|subjects randomized to receive Placebo will have a series of injections of saline solution totalling 2cc's to 3cc's injected into the scalp in a halo pattern; and into affected neck muscles.
224211899|NCT00279799|BEHAVIORAL|Afiya HIV Prevention Intervention|Group-based session plus individually tailored HIV prevention phone sessions
224211900|NCT00279799|BEHAVIORAL|Afiya HIV prevention intervention|Afiya group-based intervention + nutrition phone sessions (attention control)
223622165|NCT02866058|PROCEDURE|Cesarean Section|
223622166|NCT06163963|DIAGNOSTIC_TEST|Sentinel Lymph Node Mapping With Double Tracer and Double Injection Sites in Early-Stage Endometrium Cancer|This is a single arm interventional prospective study. Sentinel lymph node detection rate of the tracer injected in cervix (ICG- indocyanine green) before operation and the second tracer injected in uterine fundal subserosa (sterile charcoal black) at the start of operation are investigated. It is anticipated that additional tracer used in the uterine serosa may overcome the insufficiency (or increase the detection rate) of the standard single tracer injected in cervix for detection rate of sentinel lymph nodes, especially in paraaortic sentinel lymph nodes.
224316269|NCT01619566|DRUG|Duloxetine|oral tablet, 30mg daily for 1 week (titration up) oral tablet, 60mg daily for 8 weeks (treatment) oral tablet, 30mg daily for 1 week (titration down, if needed)
224316270|NCT01767324|DEVICE|Injection to deltoid|Deliver 0.5 milliliters of saline intradermally
224316271|NCT01767324|DEVICE|Injection to forearm|Deliver 0.5 milliliters of saline intradermally
224316272|NCT01767324|DEVICE|Injection to thigh|Deliver 0.5 milliliters of saline intradermally
224316273|NCT02106234|OTHER|No prophylactic iv hydration|Control group: Patients having been referred for an elective procedure involving intravascular iodinated contrast material administration and for intravenous prophylactic hydration according to current guidelines (but only those patients with an eGFR ≥30ml/min/1.73m2) will NOT receive the standard intravenous prophylactic hydration treatment with normal saline prescribed.
224316274|NCT03743155|BIOLOGICAL|mesenchymal cells|Autologous bone marrow aspiration is used as a cellular source to obtain MSVs and is subjected to the protocolized anticoagulant procedure. After checking the perfect condition of the shipment and the correct completion of the documentation that accompanies it, the processing of the bone marrow will be carried out. The processing of the bone marrow will be done in the Cell Therapy Unit of the IBGM under NCF, within 24 hours of the completion of the aspiration
224316275|NCT02796638|DEVICE|Adaptive Servo-Ventilation|A positive pressure airway device that increases and decreases inspiration pressure in concordance with the patient's natural breathing cycles.
224316276|NCT04594824|OTHER|No Intervention|no intervention
224316277|NCT00030225|BIOLOGICAL|ELAD|
223622167|NCT06163963|DIAGNOSTIC_TEST|charcoal injection to uterus to map sentinel lymph nodes|During surgery for endometrial cancer, charcoal injection to uterus to map sentinel lymph nodes in para aortic area besides the classic ınjection of indocyanine green for pelvic sentinel lymph node mapping.
223761850|NCT01782313|DRUG|tivozanib|Given PO
223761851|NCT01782313|OTHER|laboratory biomarker analysis|Correlative studies
224211901|NCT04675528|DRUG|DHP107(Oral paclitaxel)|DHP107 200 mg/m\^2 orally twice daily on Day 1, 8, and 15 in every 28 days (On food effect study day, DHP107 200 mg/m\^2 orally once daily on Day 1, 8 of Cycle 1 with fasted or fed condition according to the assigned sequence)
224211902|NCT05886283|PROCEDURE|phacoemulsification|"we started with a clear corneal incision of 2.2 mm at 9 o'clock and a port incision of 1 at 2 o'clock. Continuous Circular Capsulorhexis of 6 mm was performed under the same ophthalmic viscosurgical device. A hydro dissection was performed, then followed by phacoemulsification.~the Nucleus has been treated using 2 different techniques After bimanual infusion/aspiration cortex removal and Visco expansion of the capsular bag, a hydrophobic single-piece: AcrySof acrylic IOL was implanted."
224211903|NCT05886283|PROCEDURE|utrasound phacoemulsification|US group:The nucleus was held with the phaco tip at a high vacuum. The phaco choppe was drawn towards the phaco tip to cleave it by a manual separation between the two instruments. The fragments were then aspirated with phaco power. The standard parameters used during phacoemulsification were a vacuum level of 500 mmHg, pressurized irrigation of 90 mmHg, and 40% of phaco power
224316278|NCT00030225|OTHER|Standard of care (Control)|
224316279|NCT01399658|PROCEDURE|Image-guided brachytherapy|MRI-guided application of brachytherapy
224316280|NCT01399658|DRUG|3'-Deoxy-3'-18f-Fluorothymidine|Assessing tumor proliferation in Gynecologic cancer
224316281|NCT00851435|BIOLOGICAL|KBPA-101|1.2 mg/kg KBPA-101 i.v. infusion, 3 single doses, every third day
224316282|NCT02890784|DRUG|dasatinib (SPRYCEL®)|Treatment optimization for patients with chronic myeloid leukemia (CML)
224211904|NCT05886283|PROCEDURE|nanolaser phacoemulsification|Laser group: The nucleus was fragmented using the shockwaves emanating from the phaco tip and then aspirated. The phaco chopper was used to accelerate the mechanical fragmentation of the nucleus and minimize the dissipated energy.
224211905|NCT02431481|DRUG|LEE011|400 mg
224211906|NCT06678191|DRUG|BDP/FF/G (Beclomethasone diprprionate, formoterol fumarate, glycopyrronium bromide) 172/5/9 μg|In accordance with the requirements of non-interventional studies, the assignment of patients to Trimbow 172/5/9 μg pMDI therapy should be made independently of the study, and patients should only be considered for inclusion in the study after a prior therapeutic decision has been made by a pulmonologist.
224211907|NCT04247646|DIETARY_SUPPLEMENT|Melatonin|Participants will take sublingual melatonin (or placebo) nightly for 29 doses after undergoing total knee replacement surgery.
224211908|NCT04247646|DIETARY_SUPPLEMENT|Placebo|Participants will take sublingual melatonin (or placebo) nightly for 29 doses after undergoing total knee replacement surgery.
224211909|NCT05900531|DRUG|K-757|administered orally
224211910|NCT05900531|DRUG|K-757 and open-label sitagliptin|both administered orally
224211911|NCT05900531|DRUG|Matching placebo to K-757|administered orally
223622168|NCT02730481|DRUG|Oraxol|Oraxol will be supplied as paclitaxel capsules and HM30181AK-US tablets.
223622169|NCT05970172|DRUG|Roxadustat|Oral
223622170|NCT03190954|DRUG|[11C]raclopride plus placebo|Placebo (po) will be given 60 minutes prior to \[11C\]raclopride scan to measure baseline dopamine D2 receptors. MRI scan to follow end of PET scan. Subject blind as to drug administration.
223622171|NCT03190954|DRUG|[11C]raclopride plus drug|Methylphenidate 60 mg. po will be given 60 minutes prior to \[11C\]raclopride scan to measure striatal dopamine release. MRI scan to follow end of PET scan. Subject blind as to drug administration.
223622172|NCT03190954|DRUG|[11C]NNC-112|\[11C\]NNC-112 PET scan obtained without any drug intervention to measure dopamine D1 receptors. Blind N/A
223622173|NCT05779423|DRUG|Ipilimumab|Monoclonal antibody administered through intravenous infusion
224211912|NCT05900531|DRUG|Matching placebo to K-757 and matching placebo to K-833|both administered orally
224316283|NCT02460679|DRUG|EPI-589|An immediate release film-coated table at a 250 mg dosage strength will be administered per dose and schedule specified in arm.
224316284|NCT01277159|DRUG|A. Control Nerve Block. IV Dexamethasone (4 mg).|A. Control Nerve Block. IV Dexamethasone (4 mg).
224316285|NCT01277159|DRUG|B. Nerve Block with Dexamethasone (4 mg). IV saline.|B. Nerve Block with Dexamethasone (4 mg). IV saline.
223622174|NCT05779423|DRUG|Nivolumab|Monoclonal antibody administered through intravenous infusion
223622175|NCT05779423|PROCEDURE|Cryoablation|Procedure of freezing a tumor performed via CT-guidance by interventional radiologist.
223622176|NCT05159960|PROCEDURE|SLT|A drop of Pilocarpine 4% is administered to the eye 20 minutes before SLT. Immediately before SLT a drop of Tetracaine hydrochloride 1% is administered. Selective laser trabeculoplasty is conducted through a Latina lens, in a fashion determined by randomization to a study arm (see description).
224316286|NCT01277159|DRUG|C. Control Nerve Block. IV Dexamethasone (4 mg). IV Buprenorphine (0.3 mg)|C. Control Nerve Block. IV Dexamethasone (4 mg). IV Buprenorphine (0.3 mg)
223622177|NCT04614129|DIAGNOSTIC_TEST|Low Dose CT|All participants will have a low dose chest CT either within one year of enrollment or after enrollment
223622178|NCT05984979|OTHER|Standardized meal|The participants will receive a standardized meal for breakfast
223622179|NCT03644615|OTHER|Mindfluness and usual care|Intervention based on a mindfulness training program as a therapeutic alternative in osteoarthritis of the knee or hip. Mindfulness is a technique of attention training, which is to focus one's attention on the present moment and to examine the sensations that come to mind, how they appear, how they last time, and how they disappear.
224316287|NCT01277159|DRUG|D. Nerve Block with Buprenorphine (0.3 mg). IV Dexamethasone (4 mg).|D. Nerve Block with Buprenorphine (0.3 mg). IV Dexamethasone (4 mg).
224316288|NCT01277159|DRUG|E. Nerve Block with Dexamethasone (4 mg) / block Buprenorphine (0.3 mg).|E. Nerve Block with Dexamethasone (4 mg) / block Buprenorphine (0.3 mg). IV saline.
223622180|NCT03644615|OTHER|Usual care|No intervention on the patients
223622181|NCT03744429|OTHER|Mediterranean Diet|Participants will be provided with meals that follow a Mediterranean meal plan.
223622182|NCT06028022|DIETARY_SUPPLEMENT|Mushroom Extract|Given Reishi mushroom extract PO
223622183|NCT06028022|DRUG|Placebo Administration|Given PO
223622184|NCT06028022|OTHER|Quality-of-Life Assessment|Ancillary studies
223622185|NCT06028022|OTHER|Questionnaire Administration|Ancillary studies
223622186|NCT05756751|DEVICE|Device: Impella 5.5 with SmartAssist|Patients who are deemed high-risk due to low preoperative ejection fraction undergoing cardiac surgery with cardiopulmonary bypass (CPB) which will be supported by the Impella 5.5 System.
223622187|NCT04979806|DRUG|Cefepime-zidebactam (FEP-ZID)|3 g (2 g FEP + 1 g ZID) IV q8h
223622188|NCT04979806|DRUG|Meropenem|1 g IV q8h
223761852|NCT04708197|DEVICE|rTMS (repetitive transcranial magnetic stimulation )|applying high frequency TMS over the damaged hemisphere in chronic post stroke aphasic patients
224211913|NCT05900531|DRUG|K-757 and K-833|both administered orally
224211914|NCT05900531|DRUG|Matching placebo to K-757, open-label sitagliptin|both administered orally
224211915|NCT05063149|DRUG|Broncho-Vaxom|Broncho-Vaxom is a bacterial extract comprising lyophilised fractions of 21 different inactivated bacterial strains, which are frequently causing RTI.
224211916|NCT05063149|OTHER|Placebo|Placebo powder from a capsule will be given, which will be indistinguishable from the active study drug.
224211917|NCT00272623|PROCEDURE|Seldinger technique or venous cut-down for port placement|
224211918|NCT06697756|BEHAVIORAL|High-effort resistance exercise training|Six sets per exercise, 8 repetitions per set.
224211919|NCT06697756|BEHAVIORAL|Low-effort resistance exercise training|Three sets per exercise, 4 repetitions per set.
224316289|NCT02620579|DRUG|Propranolol LA (60 mg)|Long-acting propranolol (Propranolol LA) 60 mg to be administered orally daily for Days 1 (before exercise induced muscle injury) and Days 2-4 following exercise induced muscle injury.
224211920|NCT06701344|DRUG|Go-CHOP (Golidocitinib plus Cyclophosphamide, vincristine, doxorubicin and prednisone)|"Induction Treatment:~Golidocitinib:150mg QD Cyclophosphamide:750mg/m2，d1 vincristine:1.4mg/m2，d1(max 2mg) doxorubicin:50mg/m2，d1 Prednisone:60mg/m2 (max 100mg)，d1-d5 Every 21 days"
223622189|NCT04061720|BEHAVIORAL|Enhanced Chronic Care|Enhanced Chronic Care involves four chronic care calls per year. Enhanced Chronic Care is designed to help participants explore their goals and concerns with regard to smoking, engage in a nondirective, supportive, motivational interventions, and provide information about evidence-based smoking treatment available to them and ways to initiate treatment (i.e., warm hand-off from a clinical provider).
223622190|NCT04061720|BEHAVIORAL|Standard Care|Standard Care involves one call per year. During the Standard Care call, participants will be encouraged to quit smoking, reminded of the cessation treatment available to them, and provided with a number to call should they become interested in treatment.
223622191|NCT06243939|BEHAVIORAL|Motivational Interview to Increase Health Management Self-Efficacy and Quality of Life in Pregnant Women Diagnosed with Gestational Diabetes Mellitus|Motivational interviewing is a client-centered approach used to elicit behavioral change by helping clients explore and resolve their ambivalence.
223622192|NCT05237401|PROCEDURE|Non-Surgical Periodontal treatment (NSPT)|participants will receive local anaesthesia, then thorough debridement of the root surface will be completed to the depth of the periodontal pocket and of the furcation lesion, by using sonic scaler (KaVo Sonicflex, KaVo, Germany), piezo-electric/ultrasonic devices with specific thin and delicate tips (such as Cavitron, Dentsply Sirona, US) and/or curettes.
223622193|NCT05237401|PROCEDURE|Surgical Periodontal treatment/ Open Flap Debridement (OFD)|Patients will receive local anaesthesia and intrasulcular incisions will be made on the buccal and lingual/palatal aspects in order to reflect full-thickness flaps. After reflection of the flaps, the granulation tissue around the tooth will be removed with the non-cutting edge of a suitable scaling instrument such as a curette, taking care not to damage the root surfaces. Thorough debridement of the furcation area will be carried out by using diamond coated inserts, sonic scaler (KaVo Sonicflex, KaVo, Germany), piezo-electric/ultrasonic devices with specific thin and delicate tips (such as Cavitron, Dentsply Sirona, US) and/or curettes. Osteoplasty (removal of non-supporting bone) may be carried out, as judged by the operator. The surgical site will be closed with resorbable or non-resorbable sutures.
223622194|NCT05920122|DRUG|2% Chlorhexidine gluconate with 70% alcohol|Patients will be prepared similarly using the appropriate number of 26mL Chloraprep sticks for their body surface area. The lever will be pinched to activate the ampoule and release the antiseptic. The solution will be given time to partially load in the sponge. The sponge will be pressed against the skin area where the incision is intended moving back and forth for 30 sec , then working up towards the upper edge of the surgical field and then working from below the incision sight to the upper thighs. The antiseptic will be given time to dry (3 min)
223622195|NCT05920122|DRUG|4% Chlorhexidine Gluconate aqueous solution|Patients will be scrubbed preoperative with an applicator that contain 4% chlorohexidine aqueous solution (3 consecutive applications) liberally over 2 minutes followed by drying with sterile towel. The area scrubbed will be the same as the chloraprep group.
223622196|NCT05180448|BEHAVIORAL|Coach Share On|If an index participant is randomized to have Coach Share ON, the coach will have continuous access to objective, real-time, detailed device data, and address data directly in all individual interactions with index participants (groups, individual weigh-ins, phone calls, texts), conveying that they are closely monitoring progress.
223622197|NCT05180448|BEHAVIORAL|Group Share On|If Group Share is ON, participants in a given LM group will view and respond to aspects of each other's self-monitoring device data in their small-group text messages. Each small group participant's data will be highlighted one day of the month, and content from the Group Share Off message library also will be sent.
223622198|NCT05180448|BEHAVIORAL|Friend/Family Share On|Index participants who are randomized to have Friend/Family Share ON will give their friend or family member access to their self-monitoring data. Text messages sent by the program bot, which includes the index participant and friend/family member, will use a similar format as described in Group Share ON. The friend or family member will be trained to respond to data in ways that enhance the participant's motivation and self-regulation.
223622199|NCT05180448|BEHAVIORAL|Coach Share Off|Among index participants who are randomized to have Coach Share OFF, the coach will have no access to their device data. Index participants will be explicitly told their coach does not have data access. During groups and phone calls, the participant will self-report progress, and goal setting will be based on that self-report. Text messages from the coach will be personalized in the OFF condition, as they are when coach data sharing is ON, though these messages will not be informed by device data. Instead, text messages will provide a reminder of key goals and strategies discussed in the previous phone call and provide encouragement for participant efforts.
223761853|NCT04894617|DRUG|Amantadine|200 mg Amantadine daily for a total of 5 days.
223761854|NCT04894617|DRUG|Lactose monohydrate|Lactose monohydrate two tablet daily for a total of 5 days.
224211921|NCT06701344|DRUG|Golidocitinib|"Maintenance Treatment:~Complete remission patients will further divide into two groups. Unfit, frail old patients will receieve Golidocitinib 150mg QD for two years. Fit, young patients will receive ASCT."
224211922|NCT06700863|RADIATION|Radiation Therapy|Radiotherapy for Head and Neck Cancer Patients
224211923|NCT06700785|DIETARY_SUPPLEMENT|Lysine butyrate|Lysine butyrate supplement. This study will compare plasma pharmacokinetic profiles of three commercially available butyrate supplements.
224211924|NCT06700785|DIETARY_SUPPLEMENT|Sodium Butyrate|Oral sodium butyrate supplement.
224211925|NCT06700785|DIETARY_SUPPLEMENT|Tributyrin|Oral tributyrin supplement.
224316290|NCT02620579|DRUG|Placebo|Placebo capsules will be prepared by the University of Florida Investigational Drug Service to be visually indistinguishable from the active medication and delivered orally. Placebo administration will be done in the same fashion as propranolol - administered on Days 1 (before exercise induced muscle injury) and the Days 2-4 after the exercise induced muscle injury.
223622200|NCT05180448|BEHAVIORAL|Group Share Off|Among index participants randomized to have Group Share OFF, supportive accountability will not be the target of participant interactions and no data will be shared with LM program peers. Instead, once weekly prompts for small group text exchanges will encourage index participants to provide social support (primarily of the informational type) to each other. Index participants will be explicitly told that they should not include information on goal progress such as weight change or minutes of PA.
223622201|NCT05180448|BEHAVIORAL|Friend/Family Share Off|If an index participant is randomized to Friend/Family Share OFF, the text messages from the bot will prompt the participant and friend/family member to communicate about the LM program; those messages will be standardized, except for names, and will not be tailored to index participant progress. Index participants will be instructed to refrain from sharing any device data with friends or family members.
223622202|NCT05180448|BEHAVIORAL|Behavioral Weight Loss Treatment|Standard Behavioral Weight Loss Treatment (remotely delivered)
223622203|NCT01871350|DIETARY_SUPPLEMENT|Daily intake for 10 weeks (+/- 2 weeks)|
223622204|NCT03173924|DRUG|18F-NaF|Baseline IV followed by PET/CT IMAGING
223622205|NCT03173924|DRUG|18F-DCFPyL|Baseline IV followed by PET/CT IMAGING. Additional 18F-DCFPyL PET/CTs might be performed during the subject s follow up period if, in the opinion of the referring clinician, there has been a considerable change in patient status (progression or response) based on clinical grounds/PSA value or to help assess changes of standard of care therapy.
223622206|NCT03173924|DRUG|18F-FDG|Baseline IV followed by PET/CT IMAGING. Additional 18F-FDG PET/CTs may be obtained per PI discretion within a 21-day window relative to each 18F-DCFPyL PET/CTs.
223622207|NCT05797168|DRUG|AZD5335|IV Antibody-drug conjugate
223622208|NCT05797168|DRUG|Saruparib (AZD5305)|Oral PARP inhibitor
223622209|NCT05797168|DRUG|Bevacizumab|IV Monoclonal antibody
223622210|NCT05797168|DRUG|Carboplatin|IV Alkylating agent
223622211|NCT05797168|DRUG|AZD9574|Oral PARP inhibitor
223622212|NCT04215536|DRUG|Empagliflozin|Empagliflozin dispensing claim is exposure
223622213|NCT04215536|DRUG|DPP-4 inhibitor|DPP4 inhibitor dispensing claim is reference
223622214|NCT00811525|DEVICE|Mentor Siltex® Contour Profile Gel Mammary Prosthesis|"The CPG mammary prosthesis is a silicone elastomer mammary device with a textured surface. The Siltex® (textured) shell consists of a smooth shell bonded to an additional layer of silicone that has a textured pattern imprinted into its surface. The Siltex® shell is textured to provide a disruptive surface for collagen interface. The CPG implant contains a gel that is a more cohesive silicone gel than that used in other Mentor gel implants. The gel is made from the same materials as Mentor's standard gel. The contour shape of the CPG is designed to provide inferior projection with reduced superior fullness. The CPG mammary prosthesis contains raised orientation marks on the anterior and posterior of the implant which may help the physician ensure proper placement. CPG was available in sizes 120 cc-775 cc and 5 styles with various projection and height options.~With approval of MemoryShape™ (CPG 321) Breast Implants, the study converted to a post approval study for this style."
223622215|NCT02371824|OTHER|MRI sequence|One supplementary MRI sequence Dynamic Contrast Enhancement (DCE) was added to the clinical protocol.
223622216|NCT00567853|DEVICE|Implantation of the MEMO 3D Annuloplasty Ring|Implantation of the MEMO 3D Annulopalsty Ring for mitral valve repair.
223622217|NCT02764463|DEVICE|Fiber Reinforced Composite Fixed Partial Dentures|All restorations were made indirectly on a plaster model using unidirectional E-glass fibers (Vectris- Ivoclar Vivadent, , liechtenstein) in combination with a laboratory resin composite (Signum, Heraeus-Kulzer)
223622218|NCT00002998|DRUG|cisplatin|
223622219|NCT00002998|DRUG|gemcitabine hydrochloride|
223622220|NCT00649844|DRUG|Clozapine|Clozapine 25 or 100 mg tablets. Patients were initially titrated over the first 10 days to 300 mg/day and remained at this dose for 1 week. Thereafter, the dose could be varied between 250 and 600 mg/day based on response and tolerability for a total treatment duration of 18 weeks
223622221|NCT00649844|DRUG|Ziprasidone|Ziprasidone 40, 60, or 80 mg capsules. Patients were initially titrated over the first 3 days to 80 mg/day, which could subsequently be increased to between 80 and 160 mg/day based on response and tolerability for a total treatment duration of 18 weeks
223622222|NCT01601535|DRUG|MLN8237|Every course will be 21 days. MLN8237 will be administered orally daily starting on day 1 through day 7.
223622223|NCT01601535|DRUG|Irinotecan|Irinotecan will be administered intravenously during each course on study day 1 through day 5.
223622224|NCT01601535|DRUG|Temozolomide|Temozolomide will be administered orally during each course on study day 1 through day 5.
223622225|NCT05753839|PROCEDURE|Cytoreductive nephrectomy±metastasectomy|Partial or complete nephrectomy by open, laparoscopic, or robotic approach and/or metastasectomy Tumor tissue, blood, urine and stool specimens for translational biomarker research will be sample at baseline, surgery, after induction therapy, and after 3 months of maintenance therapy.
223622226|NCT05753839|PROCEDURE|Cytoreductive nephrectomy±metastasectomy|Partial or complete nephrectomy by open, laparoscopic, or robotic approach and/or metastasectomy Tumor tissue, blood, urine and stool specimens for translational biomarker research will be sample at baseline, surgery, after induction therapy, and after 3 months of maintenance therapy.
223622227|NCT05753839|OTHER|Human-derived materials sampling|Tumor tissue, blood, urine and stool specimens for translational biomarker research will be sample at baseline, after induction therapy, and after 3 months of maintenance therapy.
223622228|NCT06205537|OTHER|Control Liquid Supplement|Ready to drink supplement.
223622229|NCT06205537|OTHER|Experimental Liquid Supplement|Ready to drink supplement.
223622230|NCT05388214|BEHAVIORAL|E-Co|The E-Co intervention will integrate active components of a mobile health exercise intervention (GO-EXCAP) into a cognitive rehabilitation intervention (MAAT-G).
223622231|NCT04257448|DRUG|Romidepsin|Powder and solvent for solution for infusion; Intravenous use
223622232|NCT04257448|DRUG|Azacitidine|Powder for suspension for injection; Subcutaneous use
223622233|NCT04257448|DRUG|nab-Paclitaxel|Powder for suspension for injection; Intravenous use
223622234|NCT04257448|DRUG|Gemcitabine|Powder for solution for infusion; Intravenous use
223622235|NCT04257448|DRUG|Durvalumab|Concentrate for solution for infusion; Intravenous use
223622236|NCT04257448|DRUG|Lenalidomide capsule|Hard capsule for oral use
223622237|NCT03545256|PROCEDURE|outpatient surgery for T1-N0 or T2-N0 cancers of the oral cavity or oropharynx with lymph node search|"The surgical procedure associated with the sentinel lymph node technique is carried out in two stages:~\- Lymphoscintigraphy at Day-1 : This is the identification of the lymphatic network of the patient by a prior injection of radioactive tracer, nanocolloids labeled with technetium99, around the primary tumor. A planar CT image acquisition is performed to identify the sentinel lymph nodes (Gs(s)) which are then marked on the skin with an indelible marker.~Surgery on D0:~The patient is admitted to the hospital at 7:00 am in outpatient unit. He is reviewed by the anesthetist before the intervention and is transferred to the operating room for the intervention under AG.~The main tumor is operated by mouth."
223622238|NCT05626478|DRUG|Dextenza 0.4Mg Ophthalmic Insert|DEXTENZA 0.4Mg Ophthalmic Insert is a corticosteroid (to decrease inflammation) intracanalicular insert placed in the punctum, a natural opening in the eye lid, and into the canaliculus and is designed to deliver dexamethasone to the ocular surface for up to 30 days without preservatives.
223622239|NCT05626478|DRUG|Prednisolone Acetate 1% Oph Susp|Prednisolone Acetate 1% is a corticosteroid (to decrease inflammation) and being used as a topical drop after cataract surgery per Standard Of Care.
223622240|NCT05626478|DRUG|Prolensa 0.07% Ophthalmic Solution|Prolensa 0.07% is a NSAID (to decrease inflammation, swelling and pain) and is being used as a topical drop after cataract surgery per Standard Of Care.
223622241|NCT05654532|DRUG|AC699|Participants will receive AC699 orally daily in 28-day cycles.
223622242|NCT04168203|DRUG|Apixaban 2.5 MG|apixaban 2.5 mg orally twice daily for a duration of 12 months
223622243|NCT04168203|DRUG|Placebo oral tablet|placebo oral tables twice daily for a duration of 12 months
223622244|NCT03743935|OTHER|Gadolinium-enhanced cardiac MRI|Gadolinium-enhanced cardiac MRI during the 1st days post-STEMI with specific sequences including extra-cellular volume measurement
223622245|NCT05668988|DRUG|sunvozertinib|orally, 300 mg, once daily until a treatment discontinuation criterion is met.
223622246|NCT05668988|DRUG|Pemetrexed+carboplatin|Participants randomized into chemotherapy arm can receive up to 6 cycles of pemetrexed + carboplatin (pemetrexed 500 mg/m2 + carboplatin area under the plasma concentration-time curve 5 mg/ml per minute (AUC5), IV infusion, every 3 weeks) as the initial treatment. Participants whose disease has not progressed after 4 cycles of first-line platinum-based doublet chemotherapy may receive pemetrexed maintenance monotherapy until a treatment discontinuation criterion is met.
223622247|NCT05665101|PROCEDURE|Coil embolization of aneurysm sac|Patients are treated with standard EVAR with additional coiling of the aneurysm sac. The distinct type of coils used is not predefined.
223622248|NCT05858034|OTHER|Customized activity plan|Clients with identified challenges to successful aging (pre-frail or frail on screening) will be invited to develop an individualized activity plan to increase mobility, strength, and stamina. Plans will combine activities to improve strength (resistance training), balance (balance exercises), and stamina, and establish weekly goals. Resistance bands and pedometers will be provided. Progress will be measured by self-reported adherence to the activity plan at week 2, 4, 8, 12 and 24 (assessed by telephone at weeks 2, 4, 8 and in person at week 12 and 24). Depression questionnaire (PHQ-9), fatigue screen, exhaustion questions, and SF-12, a measure of health-related quality of life, will be administered at baseline, week 12 and 24.
223622249|NCT05858034|OTHER|Customized nutrition plan|Participants with nutritional needs will have the option of meeting with a nutritionist to develop a personalized nutritional plan with a goal of improving diet quality and optimizing caloric intake. Progress will be measured as above.
223622250|NCT04981821|BEHAVIORAL|GO-EXCAP Mobile App|A mobile app delivery platform to deliver an exercise program \[Exercise for Cancer Patients (EXCAP©®)\]. EXCAP©®) is a progressive walking and resistance exercise program
223622251|NCT04981821|BEHAVIORAL|Behavioral Placebo Control|Participants will meet with an oncology nurse (for approximately 60 min) to review the NCI booklet Chemotherapy and You: Support for People With Cancer, which includes facts about chemotherapy and its side effects. They will be provided with NCI online resources to review at home.
223622252|NCT03327597|OTHER|Clinical follow-up 1|Participants receive routine care outside the bounds of the trial. No further work-up.
223622253|NCT03327597|OTHER|Mental Health and Quality of Life questionnaire|Participants receive a Mental Health and Quality of Life questionnaire that will be answered electronically on the study website (www.blodskimun.is)
223622254|NCT03327597|OTHER|Standard follow-up or treatment.|Participants previously diagnosed as having MGUS or participants that have multiple myeloma or other lymphoproliferative diseases will receive standard clinical follow-up and treatment.
223622255|NCT03327597|OTHER|Clinical follow-up 2|Standard clinical follow-up according to International Myeloma Working Group (IMWG) guidelines.
223622256|NCT03327597|OTHER|Clinical follow-up 3|Intensive clinical follow-up with regular clinical assessment, laboratory testing and radiology imaging.
223622257|NCT03327597|OTHER|Clinical follow-up control|Control clinical visit
223622258|NCT01787461|DIETARY_SUPPLEMENT|Imedeen|Two tablets per day for 6 months
223622259|NCT01787461|DIETARY_SUPPLEMENT|Placebo|Two tablets per day for 6 months
223622260|NCT04582786|DRUG|Morphine|Repeated bolus according to pain score
224211926|NCT06702670|DRUG|Treatment with Diphenhydramine|Diphenhydramine 50mg IV will be administered within 1 hour of the cervical exam which diagnosed prolonged active phase of labor
224211927|NCT06702670|COMBINATION_PRODUCT|Usual Care|Participants will receive cervical exams every 2 hours in active labor, placement of intrauterine pressure catheter, up titration of Pitocin if contractions are inadequate, maternal repositioning, and use of adjunct devices such as a peanut ball.
223622261|NCT04582786|DRUG|Morphine HCl|Infusion of morphine HCl solution for intravenous administration
223622262|NCT04582786|DRUG|STR-324|Infusion of solution for intravenous administration
223622264|NCT05009498|DIETARY_SUPPLEMENT|Vitamin D3 supplementation|Vitamin D3 in 50,000 IU capsules Loading dose of 150,000 IUs (3 capsules) Interval dosing of 50,000 IUs (1 capsule) every 2 weeks for 1 year
223622265|NCT05009498|OTHER|Placebo|Placebo capsule, identical in appearance to the Vitamin D3 supplement capsule Dosing intervals identical in duration and quantity as Vitamin D3 supplement group
223622266|NCT06204549|OTHER|Screening and management of cormobidities|"During the routine care assessment and as part of the research, patients will :~* Fill in cardiovascular risk assessment score: Life's simple 7~* Provide an additional blood sample (1 dry tube of 7 mL and 1 heparin tube of 7 mL) during their biological testing. These samples will be used for lipoprotein (a) testing and biological collection.~After hospital discharge, patients will be contacted by telephone at 3 and 12 months for re-evaluation and will fill in the Life's simple 7 score. Prior to this contact, patients will have biological tests as prescribed just before hospital discharge (including blood ionogram, creatinine, liver assessment, lipid assessment (LDL, HDL, triglycerides), fasting blood sugar test, A1C test, urinary albumin/creatinine ratio, protein/ urinary creatinine ratio). They will weigh themselves and take blood pressure self-measurements over 3 days."
223622267|NCT05168046|BEHAVIORAL|Mindfulness based stress reduction|program of weekly mindfulness based stress reduction intervention during 2 months and practice during 3 months
223622268|NCT02923206|DEVICE|TheraSorb sFlt-1 adsorber|Removal of excessive sFlt-1 from the plasma of subjects/ patients with therapeutic apheresis.
223622269|NCT05686070|DRUG|Asundexian (BAY2433334)|Once daily, oral
223622270|NCT05686070|DRUG|Placebo|Placebo to asundexian, once daily, oral
223622271|NCT06168669|DIAGNOSTIC_TEST|xBar system|xBar system is surgical drain with embedded sensors. Collected data will be evaluated for an ability to identify anastomotic leaks. The xBar system does not have therapeutic indication.
223622272|NCT00720590|DRUG|Atazanavir|400 mg of atazanavir (two 200-mg capsules) per day for 4 weeks
223622273|NCT00720590|DRUG|Lopinavir/ritonavir|400 mg/100 mg of lopinavir/ritonavir (three soft-gel capsules, each containing 133.3 mg lopinavir and 33.3 mg ritonavir) twice per day with food for 4 weeks
223622274|NCT00720590|DRUG|Placebo|Daily dose of placebo for 4 weeks
223622275|NCT05743803|OTHER|Sensititization campaign on preoperative fasting rules|"* Planned and repeated mandatory on site lecture about pre-operative guidelines for surgeons, anesthetists and paramedics.~* Reminder display in surgical wards and consults.~* Individualized fasting cards for patients.~* Short message service reminder on pre-operative fasting rules for patients.~* Medical fasting prescription with clear fasting times."
223622276|NCT04879628|DRUG|SAR441344 IV|Pharmaceutical form: Solution Route of administration: IV infusion
223622277|NCT04879628|DRUG|placebo IV|Pharmaceutical form: Solution Route of administration: IV infusion
223622278|NCT04879628|DRUG|SAR441344 SC|Pharmaceutical form: Solution Route of administration: SC injection
223622279|NCT04879628|DRUG|placebo SC|Pharmaceutical form: Solution Route of administration: SC injection
223622280|NCT04879628|DRUG|MRI contrast-enhancing preparations|gadolinium compound, including but not limited to Magnevist, Multihance, Prohance, or Elucirem
223622281|NCT04899063|DEVICE|ELIOS Procedure|Treatment with the ELIOS System
223622282|NCT05046782|DEVICE|restriction spectrum imaging (RSI)|detect prostate cancer better than a standard-of-care MRI
223622283|NCT03167437|DRUG|Vorinostat|It is a histone deacetylase (HDAC) inhibitor indicated for the treatment of cutaneous manifestations in patient with cutaneous T-cell lymphoma (CTCL) who have progress, persistent or recurrent disease on or following two systemic therapies. We are using this drug off label for the purpose of this study
223622284|NCT03167437|DRUG|Ustekinumab|Ustekinumab inhibits the bioactivity of human IL-12 and IL- 23 by preventing these cytokines from binding to the IL- 12Rbeta1 receptor protein expressed on the surface of immune cells. It is FDA approved for the treatment of adult patients with active psoriatic arthritis and more recently, in September 2016, ustekinumab has been approved for the treatment of patients with Crohn s disease.
223622285|NCT06014762|BIOLOGICAL|P-CD19CD20-ALLO1|Single weight-based IV administration
223622286|NCT06014762|DRUG|Rimiducid|Single weight-based IV administration
223622287|NCT02911974|DEVICE|Acquire EUS Biopsy Device|1\. At EUS, once the pancreatic mass is identified, patients will be randomized to undergo sampling using the 22G Acquire EUS Biopsy Device or Expect EUS Aspiration Needle.
223622288|NCT02911974|DEVICE|Expect EUS Aspiration Needle|1\. At EUS, once the pancreatic mass is identified, patients will be randomized to undergo sampling using the 22G Acquire EUS Biopsy Device or Expect EUS Aspiration Needle.
223622289|NCT02928575|DRUG|Sunitinib|Before concurrent treatment, patients will receive sunitinib orally at a dose of 12.5 mg once daily for one week prior to radiation. Patients will then receive a concomitant treatment of sunitinib at a dose of 12.5 mg once daily along with temozolomide (75 mg/m2 daily) along with radiotherapy (60 Gy in 30 fractions) over a period of 6 weeks.
223622290|NCT02928575|DRUG|Temozolomide|Temozolomide (75 mg/m2 daily) will be administered along with sunitinib (12.5 mg once daily) and radiotherapy (60 Gy in 30 fractions) over a period of 6 weeks. This concurrent treatment of sunitinib, temozolomide and radiotherapy is followed by a 1 month break after which the adjuvant temozolomide treatment is administered at a dose of 150/200mg/m2 daily, for 5 of 28 days over a period of 6 months.
223622291|NCT02928575|RADIATION|Radiation Therapy|Patients will receive a concomitant treatment of radiotherapy (60 Gy in 30 fractions), sunitinib (12.5 mg once daily) and temozolomide (75 mg/m2 daily) over a period of 6 weeks.
223622292|NCT05120362|DRUG|Cream containing JAK Inhibitor|The study drug is a cream containing JAK Inhibitor.
223622293|NCT03649074|DEVICE|AKL-T01|"AKL-T01 multitasking digital treatment. AKL-T01 multitasking treatment employs perceptual discrimination attention/memory task as well as a continuous motor driving task."
223622294|NCT01943812|DRUG|Estradiol and progeterone|Estradiol and progesterone
223622295|NCT03292380|OTHER|No intervention was included|
223680481|NCT03786627|OTHER|Motor control and placebo NMES|This group will the neuromuscular electrical stimulation without turning the electrical current for 15 minutes. After that, this group will receive 30 minutes motor control training. This motor control training will focus on the control of the lumbar multifidus muscle in various functional tasks. This motor control training will take approximately 30 minutes. This group will receive intervention twice a week for 8 weeks.
224211928|NCT06410859|DRUG|"Botulinum Toxin Type A for Injection,also known as HengLi®"|This study plans to enroll 240 subjects, and the efficacy measures \[VAS score, DSIS score, daily pain duration (if applicable), and number of daily pain episodes\] will be collected from subjects using the electronic Patient-Reported Outcomes (ePRO) throughout the study. The study period mainly consists of a screening period (14 days before the first dose), a double-blind treatment period (from the first dose to Week 12), and an extension period (from Week 13 to Week 52), including a maximum of 4 treatment cycles (each cycle lasts 12 week)
224211929|NCT04942964|DRUG|Bocidelpar|Oral
224211930|NCT03030482|PROCEDURE|touch massage|Patients will have a touch massage session during 30 minutes the intervention will take place remotely (1 h) of all events that can generate anxiety
224211931|NCT00500656|DRUG|Icatibant|Icatibant: a stable, synthetic decapeptide and specific BK B2 receptor antagonist.
224211932|NCT00500656|DRUG|Tranexamic Acid|over encapsulated film tablet an anti-fibrinolytic agent,is used in some European countries for the treatment of acute oedema episodes and the continuous prophylaxis of HAE.
224211933|NCT00500656|DRUG|Oral Placebo|hard capsule matched to tranexamic acid
224316291|NCT02620579|BEHAVIORAL|Shoulder Anatomy Education|Shoulder anatomy education modules will be administered Days 2-4 (after exercised induced muscle injury) following exercise enhance injury with the goal of participant understanding shoulder anatomy and injury while reviewing: a) structure and arthrokinematics of the shoulder joint; b) muscle anatomy of the shoulder with emphasis on the rotator cuff; and c) potential shoulder pain generators from the exercise-induced injury. This education component will be devoid of information related to pain signaling and cognitive restructuring that characterizes Pain Processing Education modules. These education modules will be scripted and structured so they are provided in a standardized manner for all subjects.
224316292|NCT02620579|BEHAVIORAL|Pain Processing Education|Pain processing education modules will be administered Days 2-4 (after exercised induced muscle injury) following exercise enhance injury with the goal of better understanding of pain processing and psycho-education. This information will encourage shoulder activation by: a) reducing the threat of muscle injury; b) encouraging normal use of the shoulder and arm; and c) addressing specific concerns expressed by the subject (e.g. pain with shoulder motion is a sign of re-injury). This education component will be devoid of detailed information on shoulder anatomy, movement, and injury that characterizes the Shoulder Anatomy Education modules. These education modules will be scripted and structured so they are provided in a standardized manner for all subjects.
224316293|NCT00796107|DRUG|RG1507|R1507 was administered at a dose 16 mg/kg every 3 weeks.
223622296|NCT04036331|BEHAVIORAL|Brenner FIT Standard|After referral, families attend an orientation, in which they are then scheduled for an initial introductory 2-hour intake group session and cooking class; these occur within 2-4 weeks of the orientation. Monthly 1-hour long visits with the dietitian, counselor, and physical activity specialist are held for 6 months, in which the child and caregiver see the pediatrician. During the 6 months of treatment, they attend 4 group classes, choosing from topics such as meal planning, physical activity, and parenting. Specialized visits with the physical activity specialist or dietician are scheduled as pertinent issues arise. Clinic visits include individualized goal setting (for behaviors family/clinician have agreed to address), healthy eating and physical activity education, and behavioral counseling to implement changes at home.
223622297|NCT04036331|BEHAVIORAL|By Design Essentials|A dietitian provides each participant with a detailed program manual that describes the prescribed diet. The dietitian utilizes standard behavioral techniques to promote lifestyle behavior changes that enable participants to implement and maintain behaviors necessary to adhere to the dietary prescription. Participants also receive a standard exercise program designed to promote exercise energy expenditure of approximately 600 kilocalories\*/week. The exercise prescription includes resistance training for 2 days per week and aerobic training for 3 days per week, to meet a 600 kilocalories\*/week expenditure goal. Behaviorists meet with participants to provide individual and group-based counseling to learn the skills necessary to adopt the prescribed dietary pattern and exercise plans. Group sessions will be delivered consecutively over 6 months (20 total; 1.5 hours each).
223622298|NCT04036331|BEHAVIORAL|Dyad Plus|"This will include all components of the standard Brenner FIT program and By Design Essentials.~In addition, group sessions, one-on-one parent/child communication sessions, joint goal setting/tracking, and home environment assessment. Dyads will attend 6 meetings that will last approximately 1 hour each."
224211934|NCT00500656|DRUG|S.C. Placebo|solution for injection, matched to icatibant for injection
224211935|NCT01903213|DRUG|bixalomer|Oral
224211936|NCT03548454|DRUG|Duloxetine|Open label prescription
224211937|NCT03548454|DRUG|Desipramine|Open label prescription
224211938|NCT05458895|OTHER|ECIG lab session 1|vaping session with e-liquid including a standardized, 5-minute, 10-puff vaping bout (30 seconds between each puff) followed by 30 minutes of ad libitum (as desired) vaping.
224211939|NCT05458895|OTHER|ECIG lab session 2|vaping session with e-liquid including a standardized, 5-minute, 10-puff vaping bout (30 seconds between each puff) followed by 30 minutes of ad libitum (as desired) vaping.
224211940|NCT05458895|OTHER|ECIG lab session 3|vaping session with e-liquid including a standardized, 5-minute, 10-puff vaping bout (30 seconds between each puff) followed by 30 minutes of ad libitum (as desired) vaping.
224211941|NCT05458895|OTHER|ECIG lab session 4|vaping session with e-liquid including a standardized, 5-minute, 10-puff vaping bout (30 seconds between each puff) followed by 30 minutes of ad libitum (as desired) vaping.
224211942|NCT05458895|OTHER|ECIG lab session 5|vaping session with e-liquid including a standardized, 5-minute, 10-puff vaping bout (30 seconds between each puff) followed by 30 minutes of ad libitum (as desired) vaping.
224211943|NCT05458895|OTHER|ECIG lab session 6|vaping session with e-liquid including a standardized, 5-minute, 10-puff vaping bout (30 seconds between each puff) followed by 30 minutes of ad libitum (as desired) vaping.
224211944|NCT05458895|OTHER|ECIG lab session 7|vaping session with e-liquid including a standardized, 5-minute, 10-puff vaping bout (30 seconds between each puff) followed by 30 minutes of ad libitum (as desired) vaping.
224211945|NCT05458895|OTHER|ECIG lab session 8|vaping session with e-liquid including a standardized, 5-minute, 10-puff vaping bout (30 seconds between each puff) followed by 30 minutes of ad libitum (as desired) vaping.
224211946|NCT04639310|DRUG|XEN496|XEN496 sprinkle capsules. Parents / caregivers will be instructed to sprinkle and mix the contents of the capsules into soft foods or liquids and feed it to the child TID.
223622299|NCT05322460|OTHER|CUMACA-M Program|The CUMACA-M Program will focus on a web-based tailored intervention, using artificial intelligence, for Long-Term Survivors of Breast Cancer. It will be structured into modules related to the specific needs of LS-BS, including physical, psychological, and social needs
224211947|NCT04639310|DRUG|Placebo|Placebo sprinkle capsules. Parents / caregivers will be instructed to sprinkle and mix the contents of the capsules into soft foods or liquids and feed it to the child TID.
224211948|NCT01400373|DEVICE|Prehospital intra-nasal cooling with RhinoChill|Patients in the intervention group will receive prehospital intra-nasal cooling with RhinoChill as soon as possible during the resuscitation (i.e. intra-arrest). Intra-nasal cooling will be ongoing until systemic hypothermia is started at the intensive care unit.
224211949|NCT04590417|DRUG|Estradiol valerate 2 mg, cyproterone acetate 25 mg|The entire study period will be approximately 1 year, which will include around 2 months of document preparation, 5 months of recruitment, 3 months of follow-up, and 2 months of data analysis.
224211950|NCT04648774|PROCEDURE|Serratus anterior plane (SAP) block|With the patient in supine position, an ultrasound transducer will be used to find the 4th rib in the mid-axillary line. A 17g touhy needle will be introduced in-plane in an inferior to superior direction until its tip rests between the serratus anterior muscle and the 4th rib or the 3rd external intercostal muscle. A bolus of study drug 10ml (either ropivacaine 0.2% or normal saline) will be delivered though the needle. A 18g multiholed catheter will be inserted and secured to the patients' skin with adhesive dressings. A further 10ml of study drug will be administered through the catheter. The same procedure will be followed on the contralateral side. The study drug will be administered by programmed intermittent bolus (PIB) 10ml every 2 hours to each side in a staggered, alternating fashion. The PIB study drug will to be continued for 72 hours post-insertion.
224211951|NCT04648774|PROCEDURE|Normal saline placebo|Patients in both groups will receive the standard of care analgesic medications in the cardiovascular intensive care unit and the ward.
224211952|NCT06236334|BEHAVIORAL|ELFI lifestyle intervention|A (digital) lifestyle support intervention. Based on anthropometrics, food intake and lifestyle preferences, subjects will receive behavioral lifestyle support, especially with the focus on healthy food intake.
224211953|NCT04528992|OTHER|Blood Flow Restriction Therapy|BFR is a rehabilitation method that involves wearing a tight band around the exercising extremity to briefly limit blood flow while doing light weight exercises. The response is similar to heavy weight training or lifting but without the stress on the extremity that is still healing from surgery. Will be given after 2 weeks standard postoperative physical therapy per surgeon's ACL reconstruction protocol following surgery.
224211954|NCT04528992|OTHER|Standard Postoperative Physical Therapy|This is the surgeon's standard postoperative physical therapy protocol after ACL reconstruction.
223622300|NCT00775099|PROCEDURE|Forearm Vascular Study|Forearm venous occlusion plethysmography to measure forearm blood flow during intra-arterial infusion of the vasodilators Verapamil (10-100 µg/min), bradykinin (100-1000 pmol/min), sodium nitroprusside (2-8 µg/min) and Acetylcholine (5-20 mg/min).
223622301|NCT00775099|PROCEDURE|Badimon Chamber|Ex-vivo assessment of thrombus formation using Badimon Chamber
223622302|NCT05864417|OTHER|Sunscreen Color tone 2.0|Participants will topically apply sunscreen color tone 2.0.
223622303|NCT05864417|OTHER|Sunscreen Color tone 3.0|Participants will topically apply sunscreen color tone 3.0.
223622304|NCT00556894|DRUG|CF101|orally q12h
223622305|NCT00556894|DRUG|Placebo|orally q12h
224211955|NCT03342326|OTHER|Exposure to familiar songs|3 conditions : a) Words and Music (sing condition), b) Words only (spoken condition) and c) Music only (instrumental condition) After each song : rate the popularity of the song on a scale of 1 to 5.
224211956|NCT03342326|OTHER|Music Experience Questionnaire|questions about the past music training
224211957|NCT03342326|OTHER|Implicit tasks memory|"2 tests : a) Completion of trigrams : freely complete the first 3 letters of a word.~b) lexical decision : judge whether an audibly presented sound sequence is a word existing in the French language or not."
224211958|NCT03342326|OTHER|Questionnaires|Mini Mental State Examination, 5 words by Dubois and fluence verbal test
224211959|NCT03871569|OTHER|bucco-dental teleexpertise|A bucco-dental consultation remotely using telemedicine system
224211960|NCT05407337|BEHAVIORAL|Psychotherapy using Narrative Exposure Therapy (NET)|"There are four NET sessions, each lasting thirty minutes and defined in advance on a weekly basis. The first session is the one where the person concerned will establish his/her Life Line and start his/her life story with the peer mediator.~The second and third session will be the one where the person will continue his life story. Each session will begin with the mediator reading the story from the previous session, with the person concerned modifying the story if they wish.~The fourth session will also start with the reading of the story from the previous session and will finish the story if necessary. It will also be the occasion to give the printed story to the person concerned at the end of the session and have it signed by the mediator and the patient.~To prevent a possible risk of decompensation of the subject during the session, there will be a psychiatrist on site at the time of the NET to be available if the patient needs it."
224211961|NCT06497361|BIOLOGICAL|PRG-2311|PRG-2311 (CD19/BCMA-targeting CAR-T Cells)
224211962|NCT00454311|PROCEDURE|Biopsy of Day 3 Embryo|
224211963|NCT00454311|PROCEDURE|· day embryo biopsy|
224211964|NCT06116448|OTHER|high-fidelity simulation|The high-fidelity simulation involved a student and a computer-based mannikin. Prior to the start of the scenario, a pre-briefing session was provided. The scenario was executed with the help of the researcher from the control room. The student's performance during the simulation was recorded with video. Each simulation lasted around 30 minutes. Following the simulation, a debriefing session was held with the student, and feedback was provided. Scales were used to assess the implementation of the practices.
224316294|NCT00796107|DRUG|Letrozole|Letrozole was administered orally at a dose 2.5 mg daily.
223622306|NCT02331186|PROCEDURE|bariatric surgery|bariatric surgery for obese women
223622307|NCT01189474|DEVICE|Blephasteam|Eye lid warming goggles
223622308|NCT06070792|OTHER|NEURO LINGUISTIC PROGRAM|NEURO LINGUISTIC PROGRAM
223622309|NCT06070792|OTHER|PROGRESSIVE MUSCLE RELAXATION EXERCISES|PROGRESSIVE MUSCLE RELAXATION EXERCISES
223622310|NCT00361881|DRUG|ME-609|Cream, dose 5 times daily during 5 days.
223622311|NCT00361881|DRUG|acyclovir in ME-609 vehicle|Dose 5 times daily for 5 days
224211965|NCT06116448|OTHER|hybrid simulation|The hybrid simulation involved a student and a standardized patient. The patient wore a wearable breast model and held a model baby. Prior to the start of the scenario, a pre-briefing session was provided. The student's performance during the simulation was recorded with video. Each simulation lasted around 30 minutes. Following the simulation, a debriefing session was held with the student, and feedback was provided. Scales were used to assess the implementation of the practices.
224211966|NCT06116448|OTHER|telesimulation|The telesimulation involved a student and a standardized patient. The patient wore a wearable breast model and held a model baby. Students and patients communicated via video conferencing. Prior to the start of the scenario, a pre-briefing session was provided. The student's performance during the simulation was recorded with video. Each simulation lasted around 30 minutes. Following the simulation, a debriefing session was held with the student, and feedback was provided. Scales were used to assess the implementation of the practices.
224211967|NCT04725565|BEHAVIORAL|Genetics ADvISER Decision Aid Plus Standard Genetic Counselling|The decision aid will educate patients about the types of incidental finding they can learn from genomic sequencing and will give them opportunity select what types of results they would like to receive.
224211968|NCT04725565|BEHAVIORAL|Standard Genetic Counseling|Standard Genetic counseling to learn about and select incidental results from genomic sequencing.
224211969|NCT02551302|DEVICE|Solera™ Medtronic|The control group will receive a monosegmental posterior lumbar spine fusion with an intervertebral cage (PLIF). Solera™ Medtronic
223622312|NCT00361881|DRUG|Vehicle|Dose 5 times daily for 5 days
223622313|NCT01603303|BEHAVIORAL|Questionnaires|Completion of 8 or 9 brief questionnaires at start of study and 6 and 12 months afterwards. Questionnaires should take about 45 to 50 minutes to fill out each time.
224211970|NCT02551302|DEVICE|CD HORIZON BalanC™ Medtronic|"The intervention group will receive a hybrid system with a PLIF and a flexible pedicle screw system above the fusion. Surgery will be performed with the following devices:~CD HORIZON BalanC™ Medtronic"
224211971|NCT02056574|DRUG|NA-1|
224211972|NCT02056574|DRUG|Placebo|
224211973|NCT05449327|DRUG|Rivaroxaban 10 MG|Patients are randomly divided into two groups. One group receives no prophylaxis with an anticoagulant, the other one receives Rivaroxaban. The dosage of Rivaroxaban is 10 mg given orally once daily starting on the day of the surgery and continuing the following 13 days.
224316295|NCT01148615|DRUG|Aflibercept (AVE0005)|"Pharmaceutical form: solution for infusion~Route of administration: intravenous"
224316296|NCT01148615|DRUG|Docetaxel (XRP6976)|"Pharmaceutical form: solution for infusion~Route of administration: intravenous"
224316297|NCT00143871|DRUG|Rituximab|
224316298|NCT02567877|PROCEDURE|thyroidectomy|Patients enrolled in the study will undergo a clinically-indicated thyroidectomy performed as standard of care.
224316299|NCT02567877|DRUG|levothyroxine in thyroidectomy patients|Patients will initiate levothyroxine treatment after surgery consistent with standard of care. The drug dosage will be titrated to TSH goal that matches the pre-surgery TSH (+/- 1 mIU/L)
223622314|NCT01603303|OTHER|Education Materials|Participants receive written handout about ways to keep bones stronger during treatment with Aromatase Inhibitors (AIs) and ways to prevent AI side effects such as muscle aches, stiffness, sexual problems, and hot flashes.
224211974|NCT06542627|DEVICE|Freestyle Libre|Glycemic control was monitored using CGM data for two weeks, followed by individualized dietary education.
224211975|NCT05347082|DRUG|Cholecalciferol|Tablets of 4000 IU
224211976|NCT01253889|DRUG|Glucose 25% oral solution|0.5ml of 25% glucose (26-31 weeks gestational age group) or 1.0 ml of 25% glucose (32-42 weeks gestational age group). This application can be repeated if necessary to a maximum of four times, adding up to max 2ml of 25% glucose in the 26-31 weeks gestational age group or 4ml of 25% glucose in the 32-42 weeks gestational age group.
224316300|NCT03637387|DRUG|BIIB074|Administered as specified in the treatment arm
224316301|NCT03637387|DRUG|Placebo|Administered as specified in the treatment arm.
224316302|NCT03375177|OTHER|Natural history of disease|registry plan
224316303|NCT00055367|DRUG|natalizumab|
224316304|NCT02997748|PROCEDURE|Remote ischemic preconditioning (RIPC)|3 cycles or more cycles of 5 to 10-min inflation of a blood-pressure cuff to 200 mm HG (or at least to a pressure 50 mmHG higher than the systolic arterial pressure) to one upper arm followed by 5 min reperfusion with the cuff deflated. In Non-Responder two additional cycles of 10 min cuff inflation will be performed in arm 6.
224316305|NCT00824343|DRUG|P276-00|For patients to be recruited in amended protocol, P276-00 will be administered to all subjects at a dose of 144 mg/m2/day as i.v infusion in 200 ml of 5% dextrose over 30 minutes from day 1 to day 5 and from day 8 to day 12 in each 21 day cycle. Subjects will receive treatment till progression of disease or till unacceptable toxicity. All subjects will be followed up for survival status till one year of initiation of protocol treatment.
224316306|NCT04411914|DRUG|Clavulanic Acid|Drug will be given in 250mg capsules.
223622315|NCT01603303|OTHER|Luvena|Use vaginally 2 or 3 times a week.
223622316|NCT01603303|OTHER|Hyalo-Gyn|Use vaginally 2 - 3 times a week.
223622317|NCT01603303|OTHER|Vaginal Lubricant|Water-based vaginal lubricant used during sexual activity.
223622318|NCT01603303|BEHAVIORAL|Interactive Internet-Based Website|Participants use an interactive, internet-based website called Tendrils: Sexual Renewal after Cancer before, during and after treatment with AIs.
223622319|NCT01603303|BEHAVIORAL|Telephone Counseling.|Telephone counseling for up to 30 minutes in weeks 2, 4, 6, 8, 10, 12, 16, 20, and 24. The counselor will follow a manualized program and some sessions will be recorded.
223622320|NCT02341352|DRUG|fluoride varnish|Sodium fluoride 50mg/ml
223622321|NCT02341352|BIOLOGICAL|Immunoglobulin Yolk|anti-Streptococcus mutans IgY
223622322|NCT02341352|DIETARY_SUPPLEMENT|Probiotics|2g/day，Lactobacillus rhamnosus HN001, Bifidobacterium lactis Bi-07, Bifidobacterium lactis HN019, maltodextrin, fructose, skimmed milk powder
223622323|NCT03477045|DIETARY_SUPPLEMENT|Single dose fish oil|Fish oil consumed within a single high fat test meal
223622324|NCT03477045|DIETARY_SUPPLEMENT|Repeated dose fish oil|Fish oil consumed daily for 8 weeks
223622325|NCT03477045|DIETARY_SUPPLEMENT|single dose Camelina seed oil|camelina seed oil consumed within a single high fat test meal
223622326|NCT03477045|DIETARY_SUPPLEMENT|repeated dose camelina seed oil|camelina seed oil consumed daily for 8 weeks
223622327|NCT00569140|DRUG|E10030|Intravitreal injection
224211977|NCT01253889|OTHER|Oral water|0.5ml of oral water (26-31 weeks gestational age group) or 1.0 ml of oral water (32-42 weeks gestational age group). This application can be repeated if necessary to a maximum of four times, adding up to max 2ml of oral water in the 26-31 weeks gestational age group or 4ml of oral water in the 32-42 weeks gestational age group.
224211978|NCT04154566|OTHER|Aerobic Exercises|Aerobic exercise refers to exercise that involves or improves oxygen consumption by the body. It is the type of activity that uses large muscle groups. Its performance is in a continuous and rhythmic way with a main goal to make the heart and lungs work harder than they do when the person at rest
223622328|NCT02537717|DEVICE|Sapphire Lens|Each subject randomized to wear either the test or control in either the left of right eye.
223622329|NCT02537717|DEVICE|enfilcon A|Each subject randomized to wear either the test or control in either the left of right eye.
223622330|NCT06352242|OTHER|Flow cytometry analysis to determine the level of trogocytosis by effector immune cells in patients|"For each patient, a blood sample will be taken at D0 before the CAR-T cells are injected then at D3, D7, D10, D30 after the injection. Flow cytometry analysis will be performed on each sample on the day of collection to determine the level of trogocytosis by effector immune cells (T lymphocytes, NK cells, CAR-T cells) and to define the phenotypic signature of trogocytosis."
224211979|NCT02585531|DRUG|Hypertonic Saline 3%|"The treatment will be administered in the following order :~First day: 3 treatments of nebulized HS 3% 3ml of treatment with interval 20 minutes Second to fourth day: One treatment of nebulized HS 3% 3ml every 24 hours ."
223622331|NCT06352242|OTHER|Flow cytometry analysis to determine the level of trogocytosis by effector immune cells in volunteers|For each healthy volunteer, a single blood sample will be taken at enrollment. Flow cytometry analysis will be performed on each sample on the day of collection to determine the level of trogocytosis of normal lymphocytes and NK cells.
223622332|NCT05675046|DEVICE|Carpal Tunnel Release with Ultrasound Guidance using the UltraGuideCTR device|Participants who were treated with the Carpal Tunnel Release with Ultrasound Guidance procedure using the UltraGuideCTR device in the ROBUST Study.
223622333|NCT00005617|BIOLOGICAL|dendritic cell-MART-1 peptide vaccine|Number DC: dependent on the group route of immunization: dependent on the group subjects will receive 3 biweekly vaccinations. In case of grade III-IV toxicity in 1/3 subjects at any dose group or route, up to 6 subjects will be included in that group.
223622334|NCT00005617|PROCEDURE|leukapheresis|Patients require a single leukapheresis to obtain 2x10\^9 PBL, which are cryopreserved in RPMI 1640, 20% autologous serum, 10% DMSO. Aliquots are thawed at days -7, 7 and 21 for the first, second, and third immunizations respectively. Blood is drawn at the time of leukapheresis and on the day of the first vaccination for autologous serum, which is sufficient for the cell cultures of all patient groups.
223622335|NCT01014130|RADIATION|Hypofractionated radiotherapy (HypoRT)|Highly conformal hypofractionated radiotherapy to a total dose of 54 Gy given in 3 fractions of 18 Gy each, delivered weekly on days 0, 7 and 14 with a maximum deviation of +/- 2 days from the specified time allowed.
223622336|NCT01014130|RADIATION|Conventionally Fractionated Radiotherapy (ConRT)|Standard radiotherapy to a total dose of 60-66 Gy prescribed to an isodose covering the PTV. It will be delivered as 30-33 fractions over a period of six to six and a half weeks. If the use of chemotherapy is the institutional practice for this group of patients, concurrent carboplatin and paclitaxel will be given weekly (paclitaxel (45mg/m2/wk) and carboplatin (AUC=2/wk) for 6 weeks.
223622337|NCT03133247|DRUG|SHR-1316|PD-L1
223622338|NCT00064363|DRUG|talampanel|
223622339|NCT05195567|DIAGNOSTIC_TEST|Glucometer Test|measurement of the blood glucose concentration using the blood glucose monitor for personal use
223622340|NCT05195567|DIAGNOSTIC_TEST|blood glucose measurement, laboratory reference device|measurement of the blood glucose concentration using a laboratory reference device
224211980|NCT02585531|DRUG|Epinephrine and Dexamethasone|"The treatment will be administered in the following order :~First day: One treatment of nebulized dexamethasone 4mg (1ml of dexamethasone 8mg/2ml) + 3ml NS, followed by two treatments of nebulized epinephrine (3 ml of epinephrine in a 1:1000 solution per treatment) with interval 20 minutes Second to fourth day: One treatment of nebulized dexamethasone 4 mg (1ml of dexamethasone 8mg/2ml) + 3ml Normal saline 0.9%, every 24 hours."
224316307|NCT04411914|OTHER|Placebo|Placebo
224316308|NCT05697523|OTHER|Expanded Disability Status Scale, pulmonary function test, International Physical Activity Questionnaire - Short Form, 6 minute walk test|Expanded Disability Status Scale, pulmonary function test, International Physical Activity Questionnaire - Short Form, 6 minute walk test
223622341|NCT00251459|DRUG|rhuFab V2 (ranibizumab)|
223622342|NCT02624271|OTHER|blood samples analysis|Analyze blood samples with GastroPanel test to detect gastric precancerous lesions.
223622343|NCT04612725|BIOLOGICAL|Benralizumab|2 induction doses of benralizumab (dose A and B) compared to placebo, and a comparison of maintenance dosing regimens (B vs A) in the 28-week extension period.
223622344|NCT04612725|BIOLOGICAL|Placebo and Benralizumab|2 induction doses of benralizumab (dose A and B) compared to placebo, and a comparison of maintenance dosing regimens (B vs A) in the 28-week extension period.
223622345|NCT03293667|OTHER|Exploratory synovial fluid analysis|An additional blood sample (3 10 ml tubes) and an additional specific analysis to characterize subpopulations of regulating T lymphocytes infiltrating the synovium of RA patients and comparing them with those of peripheral blood.
224211981|NCT01566474|DRUG|Omeprazole|Omeprazole 40 mg/day alone. Patients will take the capsule once in the morning before breakfast. This is the standard therapy for patients suffering from Barrett's esophagus.
224211982|NCT01566474|DRUG|Melatonin|Omeprazole 40 mg/day + Circadin 6 mg/12 hours. Patients will take the Omeprazole capsule once in the morning before breakfast together with 3 tables of 2 mgs of Circadin (melatonin). In the evening, before dinner, patients will take 3 tablets of 2 mg of Circadin.
224316309|NCT04174612|DRUG|Cytarabine|100 mg/m2/bid day 1-3 100 mg/m2/die day 4-7
224316310|NCT04174612|DRUG|Daunorubicin|60 mg/m2/die day 1-3
224316311|NCT04174612|DRUG|Midostaurin|50 mg/bid day 8-21
224316312|NCT04174612|DRUG|Cytarabine HD|100 mg/m2/bid day 1-3 100 mg/m2/die day 4 1.500 mg bid day 5-7
224316313|NCT01375179|DRUG|KRP203|
224316314|NCT01375179|DRUG|Placebo matching KRP203|
224316315|NCT04284059|DRUG|Placebos|Placebo, vitamin AD and vitamin D are identical in the appearance to guarantee blind. The patients need to administrate 3 capsules once a day for 8 weeks.
224211983|NCT01858558|BIOLOGICAL|aMIL|On day 0, patients will receive auto transplant followed by Tadalafil and aMIL. At day 60, patients will receive Lenalidomide.
224211984|NCT01858558|DRUG|No aMIL|On day 0, patients will receive auto transplant followed by Tadalafil. At day 60, patients will receive Lenalidomide.
224211985|NCT03190018|DEVICE|lCarry Life System Peritoneal Dialysis (CLS PD)|The assigned intervention is with the CLS PD device in patients currently receiving peritoneal dialysis for the duration of one study session. A temporary Pigtail catheter is inserted on the same morning as the study session and removed after the session on the same day.
224211986|NCT01142466|DRUG|Interferon beta-1a (Rebif)|The dosage of IFN-beta-1a , following initial dose titration, was 44 mcg injected subcutaneously (s.c.) tiw. An auto-injector device, Rebiject, was available as an optional aid for the administration of IFN-beta-1a . IFN-beta-1a was administered, if possible, at the same time (preferably in the late afternoon or evening) on the same three days at least 48 hours apart each week.
223622346|NCT03659318|PROCEDURE|Robotic-assisted TKA|Total knee arthroplasty is carried out with help of robotic surgery system, using a Robodoc system. CT-based preoperative planning using ORTHODOC (Integrated Surgical Technology Corp) performed in the first step before the day of surgery, and the robotic-assisted surgery using the ROBODOC surgical assistance in the second step. The bone markers are registered to the computer, and the computer arm does all the cutting and preparation of bones. This is in contrast to conventional jigs and cutting blocks. Actual implantation of the implants is done by a surgeon. A Duracon posterior cruciate-substituting total knee prosthesis (Stryker Orthopedics, Mahawh, NJ, USA) are used in all knees.
223622347|NCT03659318|PROCEDURE|Conventional TKA|Total knee arthroplasty is carried out with classical, conventional, manual method. A surgeon measures the angle, length of the cuts with bone landmarks and specialized surgical instruments. After all the cuts actual implantation is done. A Duracon posterior cruciate-substituting total knee prosthesis (Stryker Orthopedics, Mahawh, NJ, USA) are used in all knees.
224211987|NCT05079152|BIOLOGICAL|COVAX+PPV23;COVAX+IIV4|1st dose : combined vaccination of COVAX+PPV23; 2nd dose: combined vaccination of COVAX+IIV4
224211988|NCT05079152|BIOLOGICAL|COVAX only (1st and 2nd dose)|1st dose: COVAX only; 2nd dose: COVAX only
224211989|NCT05079152|BIOLOGICAL|PPV23 for the 1st dose and IIV4 for the 2nd dose|1st dose: PPV23 only; 2nd dose: IIV4 only
224211990|NCT03546699|DIAGNOSTIC_TEST|Estimation of hospital-wide incidence of ARDS|"Estimation of hospital-wide incidence of ARDS defined according to both the Berlin definition and the Kigali modification.~* To describe clinical characteristics and outcomes for these patients.~* To analyze the prognosis and time course of patients who initially meet criteria for Kigali-defined ARDS and subsequently progress to Berlin-defined ARDS.~For the subset of patients who have chest CT, to determine the sensitivity and specificity for bilateral opacities of both chest radiographs and chest ultrasound done within 12 hours as compared to the reference standard CT scans."
223622348|NCT04712955|OTHER|Bloodflow restricted exercise|Low-intensity bloodflow restricted resistance exercise is conducted as traditional knee extension exercise with a load corresponding to 30% of 1 repetition maximum (RM), with concurrent partial occlusion of the circulation by means of inflatable pneumatic cuffs wrapped around the proximal part of the thighs. Cuffs are inflated to a pressure corresponding to 50% of the arterial occlusion pressure, which only compromises venous but not arterial blood flow.
224211991|NCT04515511|OTHER|4% gelatin|Pulmonary artery catheter insertion is prepared before fluid challenge. Baseline hemodynamic value and each time after 5 sequential intravenous boluses of 100 mL colloid are recorded.
224316316|NCT04284059|DIETARY_SUPPLEMENT|vitamin AD|A vitamin AD capsule contains vitamin A 2000 IU and vitamin D 700 IU. The patients need to administrate 3 capsules once a day for 8 weeks.
223622349|NCT02867462|OTHER|Standard care|standard care
223622350|NCT02867462|OTHER|manipulator consultation radiotherapy added to standard care|
224211992|NCT04244994|DEVICE|Aptima-Combo2 and Aptima Mgen|Self-taken penile meatal swabs versus first-catch urine samples for the detection of Chlamydia trachomatis, Neisseria gonorrhoeae and Mycoplasma genitalium using Aptima-Combo2 and Aptima Mgen
223761855|NCT05599035|DEVICE|repititive transcranial magnetic stimulation|a figure-of-8 coil (7-cm diameter loop) positioned over the parietal area for ten sessions (10 trains, with frequency of stimulation 20-Hz, each lasting for 10 seconds with an inter-train interval of 30 seconds. The intensity of stimulation was set at 80% of the RMT for the first dorsal interosseous (FDI) of the contralateral hand with a total 2000 pulses for each parietal area.)
223622352|NCT04875195|BIOLOGICAL|Pembrolizumab|Pembrolizumab, 400 mg, Q6W, intravenous (IV) infusion.
224211993|NCT01140620|DRUG|ketamine|ketamine infusion to achieve plasma concentrations of 100 ng/mL. Duration approximately 3 hours
224211994|NCT01140620|DRUG|risperidone|risperidone (2 mg) capsule. One dosing of 2 mg.
224211995|NCT01140620|DRUG|saline|saline infusion. Duration approximately 3 hours
224211996|NCT01140620|DRUG|placebo risperidone|placebo capsule to match risperidone 2 mg capsule
224211997|NCT00569231|DRUG|Candida Antigen|Intralesional injection of 0.3ml candida antigen into largest wart at baseline visit and then every 3 weeks +/- 3 days for a maximum of 10 treatments.
224211998|NCT01914822|DRUG|methylphenidate hydrochloride|
223622353|NCT06191640|DRUG|Ivacaftor or elexacaftor/tezacaftor/ivacaftor|HEMT's are prescribed at the discretion of the treating physician and is not dictated by the principal investigator of this study.
223622354|NCT05190120|PROCEDURE|Femoral Nerve Block|Patients having ACL reconstruction, meniscus surgery and knee arthroscopy
223622355|NCT05190120|PROCEDURE|Adductor Canal Nerve Block|Patients having ACL reconstruction, meniscus surgery and knee arthroscopy
223622356|NCT05190120|DRUG|preoperative Femoral Nerve Block using 20ml of 0.5% ropivacaine|
223622357|NCT05190120|DRUG|Preoperative Adductor canal block with 0.75%% ropivacaine 13.3ml.|
224211999|NCT01914822|DRUG|Sugar pill (placebo)|
224316317|NCT04284059|DIETARY_SUPPLEMENT|vitamin D|A vitamin D capsule contains vitamin D 400 IU. The patients need to asministrate 6 capsules/time, once a day for 2 weeks, then change to 5 capsules/time, once a day for 6 weeks.
224212000|NCT00004739|DRUG|Antiretroviral therapy|
223622358|NCT06305247|DRUG|IPN01194|"IPN01194 will be taken orally over a period of 28 days (a Cycle) at the assigned dose level. The dose limiting toxicity (DLT) observation period consists of the first 28 days of treatment with IPN01194 (Cycle 1).~Participants will receive IPN01194 treatment beyond Cycle 1 until treatment is precluded by toxicity, disease progression, or upon participant's request or investigator decision."
223622359|NCT06305247|DRUG|IPN01194|"All participants will receive IPN01194 orally for 28-day cycles at one of the two dose levels determined at the end of Phase I.~Participants will receive IPN01194 treatment until treatment is precluded by toxicity, disease progression, or upon participant's request or investigator decision"
224212001|NCT02789124|OTHER|Carotid Doppler Measurement in response to passive leg raise|The investigators will measure Carotid Flow time in the semi-recumbent position, then lay the patient flat and do a passive leg raise. The investigators will then meausre Carotid Flow Time at 1 minute, 2 minutes, and 3 minutes. Patients who have 10 % increase in stroke volume on the Flotrac / Vigileo monitor will be considered fluid responders. The investigators will try to identify an optimum % increase of Carotid Flow Time that can predict fluid responsiveness.
224212002|NCT00821041|BEHAVIORAL|Cognitive Behavioral Therapy|6 weeks of relaxation training, cognitive therapy, sleep restriction, stimulus control, sleep hygiene, psychoeducation, hypnotic tapering and mindfulness training
224212003|NCT00700310|DRUG|perampanel|2 mg perampanel or placebo in a 1:1:1:1 ratio, 170 subjects/arm, a total of 680 subjects. All subjects will take a maximum of 6 tablets daily and will be up-titrated weekly in 2-mg increments to their randomized dose.
224212004|NCT00700310|DRUG|perampanel|4 mg perampanel or placebo in a 1:1:1:1 ratio, 170 subjects/arm, a total of 680 subjects. All subjects will take a maximum of 6 tablets daily and will be up-titrated weekly in 2-mg increments to their randomized dose.
224212005|NCT00700310|DRUG|perampanel|8 mg perampanel or placebo in a 1:1:1:1 ratio, 170 subjects/arm, a total of 680 subjects. All subjects will take a maximum of 6 tablets daily and will be up-titrated weekly in 2-mg increments to their randomized dose.
224212006|NCT00700310|DRUG|Placebo|Placebo in a 1:1:1:1 ratio, 170 subjects/arm, a total of 680 subjects. All subjects will take a maximum of 6 tablets daily.
224212007|NCT02739802|DRUG|Coppertone(BAY987517)|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.Formulation number - SR16-02.
224212008|NCT04331652|PROCEDURE|Polypectomy without anesthesia or analgo-sedation|"Premedication: paracetamol 1g oral. Patient will undergo polypectomy without anesthesia. During the procedure, pain will be monitored using a pain assessment scale from 0 to 10 (0 meaning no pain and 10 meaning maximum pain imaginable). At any time, if the patient express a pain strictly superior to 4 an analgo-sedation will be proposed and/or general anesthesia.~Pulse and blood pressure will be monitored. Assessment of patient satisfaction after the intervention."
224212009|NCT05659706|OTHER|cognitive evaluations and non cognitive evaluations|Mini Mental State Examination Charlson Comorbidity Index Katz Index ICOPE step 1 The 15-item geriatric depression scale (GDS-15) Medical Outcomes Study Short Form 36 (SF-36) Short Physical Performance Battery ( SPPB)
224212010|NCT05189483|DRUG|Albumin-Bound Paclitaxel|Enrolled patients will receive 300 mg/m2 of nab-paclitaxel (Hengrui Pharmaceutical, Lianyungang, China) via a 30-min intravenous infusion on day 1. The treatment was repeated every three weeks until progressive disease occurrence or unacceptable adverse events.
224212011|NCT05189483|DRUG|Camrelizumab|Enrolled patients will receive the following treatment: 200 mg of PD-1 inhibitor (camrelizumab; Hengrui Pharmaceutical, Lianyungang, China) via a 30-min intravenous infusion on day 1. The treatment was repeated every three weeks until progressive disease occurrence or unacceptable adverse events.
224212012|NCT06540092|DIAGNOSTIC_TEST|ultrasound|ultrasound measurements during first trimester
224212013|NCT01913873|OTHER|serum concentration changes cardiac biomarkers|Serum concentration determination for cardiac biomarkers (CK-MB and Hs-cTn) preoperatively, at induction of anesthesia (after placement of the arterial line), upon arrival at the intensive care unit (ICU), as well as every 3 hours for 12 hours, then every 6 hours the following 12 hours and a last sample is taken 48 hours after surgery.
224212014|NCT01837420|DRUG|VB-201 80mg|
224212015|NCT01837420|DRUG|VB-201 160mg|
224212016|NCT01837420|DRUG|Placebo|
224212017|NCT00818831|DRUG|QBI-139|QBI-139 is being administered once a week over a two hour infusion in escalating doses.
224212018|NCT01999231|BIOLOGICAL|ESAT6-CFP10|32 healthy subjects who meet the standard of protocol are allocated four different groups according to dosages of ESAT6-CFP10 :1μg/ml ESAT6-CFP10、5μg/ml ESAT6-CFP10、10μg/ml ESAT6-CFP10、20μg/ml ESAT6-CFP10.Each dose group have six healthy subjects(three male and three female) , at the same time set up two people for substitute (one male and one female) . ESAT6-CFP10 administered intradermally by the mantoux injection technique. Each receives only one dosage in right or left arm .
224212019|NCT05066074|PROCEDURE|Distal Radial Vascular Access|Distal Radial Vascular Access
224316318|NCT03028116|BIOLOGICAL|influenza vaccine|"A allantoic split inactivated seasonal influenza vaccine has been prepared on eggs and is made from inactivated parts of the following influenza virus strains:~NIBRG-121xp (A/California/7/2009 (H1N1)v and А/PR/8/34 (H1N1)), NYMC X-217 (A/Victoria/361/2011(H3N2) and А/PR/8/34 (H1N1)), NYMC BX-49 (B/Texas/06/2011 (Yamagata lineage) - like High Yield Reassortant (1:1:6) With B/Lee/40 NP, B/Panama/45/90 NS genes)."
223622360|NCT05300724|OTHER|No intervention|No intervention will be administered in this study.
223622361|NCT02664129|OTHER|Video self-observation|Patients will watch the video of them in acute decompensation phase then they will be asked about their emotions, their understanding and awareness of mental illness
223622362|NCT02664129|OTHER|Non Self video observation|Patients will not watch the video of them in acute decompensation phase.
223622363|NCT03471312|DRUG|Magnesium|magnesium therapy
224212020|NCT01127386|DRUG|Lenalidomide|25mg od, dose reduction according to toxicity
224212021|NCT01127386|DRUG|Lenalidomide|start with 5mg od and increase of dosage to 10mg, 15mg or 25mg until CRP response (50% decrease)
224316319|NCT03028116|BIOLOGICAL|Placebo|water for injection
223680482|NCT05125185|OTHER|The Effectiveness of USM-Insulin Adherence Module (U-IAM) for Type 2 Diabetes in Improving Insulin Adherence, Glycemic Control and Inflammation|To study the effect of counseling using USM-Insulin Adherence Module (U-IAM) for Type 2 Diabetes in improving Insulin Adherence, Glycemic Control and Inflammation
223680483|NCT00061282|DRUG|Clotrimazole|One retention enema, administered nightly
223622364|NCT06001801|BEHAVIORAL|Diabetes Prevention Program|"The DPP group is led by the Community Health and Social Services Center (CHASS) community health workers (CHWs). For this study, the workers will deliver 16 weekly sessions (core phase) followed by two monthly sessions (maintenance phase). Each session lasts one hour plus the time required to weigh each participant and review food and activity logs.~This program will help participants make healthy lifestyle changes. Examples are improvements in eating and physical activity. The goal is that participants lose some weight and eat healthier food.~Sessions will be offered in-person in a room with video capacity to allow attendance of participants that cannot attend in person. For those participating virtually, the CHWs will briefly review with them what participants logged.~Participation in this project should last approximately 6-months."
223622365|NCT06001801|BEHAVIORAL|INSPIRA|"This intervention will include the DPP plus additional interventions. The additional interventions include: participants to stay for an extra 30 minutes following the regular DPP sessions. In these INSPIRA sessions, participants will be trained in providing mutual peer support, be matched with a peer partner and asked to talk at least once a week, receive vouchers or gift cards, discuss participants action plans with the peer partner, and share challenges, successes, and tips from the CHW and others in the session.~CHWs will provide brief trainings on autonomy-supportive peer support approaches over the first three weeks of sessions.~Participation in this project should last approximately 6-months."
223622366|NCT02515734|DRUG|fluorouracil|
223622367|NCT02515734|DRUG|Leucovorin|
223622368|NCT02515734|DRUG|irinotecan|
223622369|NCT02515734|DRUG|oxaliplatin|
223622370|NCT02515734|BIOLOGICAL|bevacizumab|
223622371|NCT02515734|BIOLOGICAL|cetuximab|
223622372|NCT04000529|DRUG|TNO155|Capsule
223622373|NCT04000529|DRUG|Spartalizumab|Concentrate for solution for infusion
223622374|NCT04000529|DRUG|Ribociclib|Capsule and tablet
223622375|NCT05036252|DIAGNOSTIC_TEST|Cardiopulmonary Exercise Test|All enrolled participants will undergo a cardiopulmonary exercise test (CPET). The CPET will be conducted using an electronic motorized treadmill with 12-lead ECG monitoring performed by ACSM-certified exercise physiologists.
223622376|NCT05036252|DIAGNOSTIC_TEST|Echocardiogram|Resting assessment of LVEF and GLS will be evaluated through Conventional 2D and Doppler echocardiograms will be performed per protocol using a commercially available ultrasound scanner, according to the American Society of Echocardiography (ASE) recommendations for a comprehensive examination.
223622377|NCT05036252|DIAGNOSTIC_TEST|Echocardiography|As soon as possible following completion of the CPET, subjects will be placed in the supine position and 2D echocardiographic images will be obtained in the apical 4-/ 3-/2-chamber views.
223622378|NCT00951366|OTHER|Patient Registry|The CHILD Clinic Patient Registry is an observational study designed to identify epidemiologic and genetic factors associated with chronic lung disease in former preterm infants or those with lung disease in the neonatal period.
223622379|NCT02354235|DRUG|Teneligliptin|
223622380|NCT02354235|DRUG|Canagliflozin|
223622381|NCT02354235|DRUG|Placebo|
224212022|NCT01127386|OTHER|basic cachexia management (prokinetics, physical activity counselling, nutritional counselling)|twice during study
224212023|NCT03406039|BEHAVIORAL|Integrated Online CBT and MI|The treatment condition will have access to 12 treatment modules and have 8-weeks to complete them. The content of all modules is derived from Cognitive Behavioural Therapy and Motivational Interviewing. Through module engagement, young adults will identify goals related to alcohol use and mood, learn strategies to cope with alcohol cravings, triggers, and social pressures, and learn how to prevent relapse. There will also be several modules to target anxiety and depression, focusing on strategies designed to help reduce negative thinking and worry, increase behavioural activation, and increase self-care (e.g., sleep hygiene).Participants will have immediate access to all modules, and it will be recommended that they work through the modules sequentially.
224212024|NCT02881463|OTHER|therapeutical exercises|Participants of experimental group performs daily an 8-week home therapeutical exercise program. Exercises are periodized by weeks (1-8 weeks). The aim of program is the leg muscle strengthening using an elastic band (Thera-Band, System of Progressive Exercise, USA), body balance training, and leg muscle stretching.
223622382|NCT03416140|OTHER|Therapeutic Exercise|30 minutes per day of therapeutic exercise
223622383|NCT06458075|BEHAVIORAL|CO-LEAD|The investigators will provide clinicians with a program to teach them to use effective communication strategies with patients to review real-time pharmacy refill data and the DOSE-Nonadherence-SLE survey, and engage and formulate solutions to adherence barriers together. The study team will provide the clinician intervention training in-person or virtually and will include didactics, demonstration, and practice that include two one-hour sessions one month apart. After training, CO-LEAD clinicians will be encouraged to incorporate the intervention in regular clinic visits with all patients.
223622384|NCT03923270|DRUG|Durvalumab|Participants in all arms will be administered 1500 mg of Durvalumab intravenously every 4 weeks.
223622385|NCT03923270|DRUG|Tremelimumab|Participants in arm B will be administered 75 mg of Tremelimumab intravenously every 4 weeks for up to 4 doses.
223622386|NCT03923270|DRUG|Olaparib Pill|Participants in arm C will be self-administer 300 mg of Olaparib orally.
223622387|NCT03923270|RADIATION|Thoracic Radiotherapy|Thoracic Radiotherapy will be administered at 3 Gray units X 10 fractions
223622388|NCT03923270|DRUG|Tremelimumab|Participants in arm D will be administered 300 mg of Tremelimumab intravenously in 1 single dose
224212025|NCT03608410|OTHER|Weekly Internet based PRO questionnaires|If core symptoms worsen and exceeds a predefined threshold, a PRO-notification is sent to the hospital.
224212026|NCT00681824|BIOLOGICAL|Fibrin Sealant, Vapor Heated, Solvent/Detergent-treated with 500 IU/mL thrombin and synthetic aprotinin (FS VH S/D 500 s-apr)|Application of a thin layer of FS VH S/D 500 s-apr to the entire length of the suture loop and the adjacent area to at least 5 mm away from the suture line, including all suture holes. After application, the product is to be allowed to polymerize for 3 minutes.
223622389|NCT06087276|DRUG|60 mg ulixacaltamide|Once daily oral treatment with titration
223622390|NCT06087276|DRUG|Placebo|Once daily oral treatment
223622391|NCT03069352|DRUG|Placebo|tablet
223622392|NCT03069352|DRUG|Venetoclax|tablet
223622393|NCT03069352|DRUG|Cytarabine|Subcutaneous injection
224212027|NCT00681824|PROCEDURE|Standard of care|Standard care: defined as the closure of a dura defect by suturing in a patch of autologous fascia, pericranium or suturable collagen-based dura substitute.
224212028|NCT02272881|PROCEDURE|surgical reconstruction|Patients randomized to surgical flap closure will undergo reconstructive plastic surgery to close an intended pressure ulcer at the earliest date after selection. Our group's co-investigator and staff plastic and reconstructive surgeon will decide on the optimal technical repair. Given the lack of retrospective evidence to support a superior surgical repair (myocutaneous, fasciocutaneous, local flap arrangement versus free microvascular tissue transfer) we will defer to our physician staff preference on a per patient basis. The time from enrollment to surgical intervention will be tracked, and no patient will be dropped from the study should this time exceed the two-week ideal.
224212029|NCT02272881|PROCEDURE|wound management|Patients selected to the supportive wound care arm will be managed by the Center for Wound Care at Cottage Health System, a certified wound care center. They will receive standard of care conservative wound care including: debridement, dressing changes, wound checks, physical therapy, occupational therapy, antibiotic treatment, nutritional support and close follow-up over the study period.
224212030|NCT03724916|DRUG|TAK-079|TAK-079 subcutaneous injection.
224212031|NCT03724916|DRUG|TAK-079 Placebo|TAK-079 placebo-matching subcutaneous injection.
224212032|NCT00077402|DRUG|fenretinide|
224212033|NCT04575038|DRUG|Brequinar|Dihydroorotate dehydrogenase inhibitor (DHODHi)
224212034|NCT04575038|DRUG|Placebo|Placebo capsules
224212035|NCT04315831|DRUG|Transdermal Buprenorphine|Intervention will be applied for patients with moderate to severe cancer pain
224212036|NCT03191019|BEHAVIORAL|Mobile-phone app for smoking cessation|Android App for smoking cessation
224212037|NCT03455335|DRUG|20 million hMSCs|
224212038|NCT03455335|DRUG|40 million hMSCs|
224212039|NCT03455335|DRUG|80 million hMSCs|
224212040|NCT01897558|DEVICE|Pacemaker implantation|
224212041|NCT02615379|DEVICE|EPIFLO|Transdermal continuous oxygen therapy is oxygen delivery to the wound site directly. Ogenix makes a small portable oxygen concentrator (Trade Name: EPIFLO) that makes continuous transdermal delivery of oxygen possible. It is a 3 ounce oxygen generator that continuously delivers 3 ml of pure oxygen to the wound site.
223622394|NCT02621424|DEVICE|RTMS|stimulation of the brain with magnetic pulses
223622395|NCT02621424|DEVICE|sham|sham noise to block the sound of stimulation
224212042|NCT05934552|DRUG|Lactulose|lactulose and lactobacillus acidophilus on ckd patients
224212043|NCT00683332|DRUG|Tigecycline (Tygacil)|This is a non-interventional study; patients are administered Tygacil as prescribed by their doctor as per registered indications stated in product label/insert (50 mg by Intravenous Injection).
224212044|NCT00631800|DRUG|Pagibaximab (formerly BSYX-A110)|Pagibaximab at 60, 90 mg/kg intravenously at Days 0, 7, 14
224212045|NCT00665197|RADIATION|Protracted Course Radiotherapy|External Beam Radiation 30 Gy in 10 fractions
224212046|NCT00665197|RADIATION|Short Course Radiotherapy|External Beam Radiation 20 Gy in 5 fractions
224212047|NCT04322227|DRUG|Foliglurax 10 mg (treatment A)|Foliglurax 10 mg, (BID) capsules, orally
224212048|NCT04322227|DRUG|Foliglurax 30 mg (treatment B)|Foliglurax 30 mg, BID capsules, orally
223622396|NCT06659640|DRUG|ALN-6400|ALN-6400 will be administered subcutaneously (SC)
224212049|NCT04322227|DRUG|Placebo (treatment C)|Placebo, BID capsules, orally
224212050|NCT01001676|DEVICE|Percutaneous Transluminal Angioplasty (PTA)|Angioplasty with the use of Conventional balloon
224212051|NCT01001676|DEVICE|Paclitaxel Eluting Balloon Angioplasty|Angioplasty with the use of paclitaxel eluting balloon
224212052|NCT02037373|BIOLOGICAL|Octaplas™|Octaplas™ infusion solution for IV administration as prescribed by the treating physician.
224212053|NCT02037373|BIOLOGICAL|Plasma|Plasma as prescribed by the treating physician.
224212054|NCT04562025|DRUG|UC-MSCs|3 times of UC-MSCs (1\*10E6 UC-MSCs/kg body weight/100mL saline containing 1% human albumin intravenously at week 1,week 2, week 3).
224212055|NCT04562025|DRUG|Placebo|3 times of cell-free stem cell suspension (saline containing 1% human albumin/100mL intravenously at week 1, week 2, week 3).
224212056|NCT01501201|PROCEDURE|Gastric By-Pass|Bariatric surgery laparoscopic Roux-en-Y Gastric Bypass (RYGBP)
224212057|NCT01501201|DRUG|optimized medical management|group receiving an optimized medical management, among patients with obesity and poorly controlled type 2 diabetes
224212058|NCT02841540|DRUG|H3B-8800 (RVT-2001)|H3B-8800 (RVT-2001) orally at specified doses and schedules.
224212059|NCT01358019|DRUG|LY2523355|Days 1, 2, and 3 in a cycle that consists of 21-days
224212060|NCT06160479|DRUG|Calcium supplement|Different amount of calcium supplement in pregnancy
224212061|NCT01318733|DRUG|CD07805/47 gel 0.5%|In this open-label study, all subjects will receive treatment with CD07805/47 gel 0.5% applied once daily, for up to 12 months.
224212062|NCT03038282|DIETARY_SUPPLEMENT|Chromium Chloride|Transdermal chromium chloride 50 to 600 mcg/day.
224212063|NCT03038282|OTHER|Individual Exercise|Participants will engage in 150 minutes of exercise over 3-5 days per week for 12 weeks
224212064|NCT05436691|OTHER|Information and Coping with Anxiety Training|Informing and Coping with Anxiety Training was given to the experimental group before the operation through a prepared booklet.The information booklet about the training was created by the researchers by reviewing the current literature. The booklet provides information for patients scheduled for hysterectomy about how to cope with surgery-related anxiety. The booklet provides information on what the hysterectomy is, why it is performed, what risks it has, what should be done before, during and after the hysterectomy, what rules the patient should comply with after hysterectomy, in which cases she should present to the health institution, what changes she might experience in her social, physical, sexual and emotional life after the surgery. The booklet also provides information about discharge training and coping with anxiety.
223622397|NCT06659640|DRUG|Placebo|Placebo will be administered subcutaneously (SC)
223622398|NCT06560255|DIETARY_SUPPLEMENT|n-3 fatty acid|Oral intake of 4 capsules per day from week 22-26 in pregnancy to 1 week after delivery
223622399|NCT06560255|OTHER|Rape seed oil|Oral intake of 4 capsules per day from week 22-26 in pregnancy to 1 week after delivery
224212065|NCT01292460|DRUG|Timolol/ FDC/ Placebo/ Tafluprost|"Prior timolol users: Timolol (administered at 08:00 and 20:00) or FDC of tafluprost and timolol (at 08:00) and Placebo eye drops (at 20:00).~Prior prostaglandin users: Tafluprost (administered at 08:00) or FDC of tafluprost and timolol (administered at 08:00)."
224212066|NCT05552092|DEVICE|Esophageal temperature monitoring according to the depth|"Core temperatures will be measured with a tympanic thermometer as a reference. When the tympanic membrane (TM) temperature is constant after measuring three consecutive times at 10 seconds intervals, the temperature will be assumed as the core body temperature.~Initially, the esophageal stethoscope (ES) will be inserted to a depth of 45 cm from the incisor. After 30 minutes of monitoring, when the changes in the body temperatures stabilized, initial temperatures of the TM and ES thermistor will be assessed.~After 5 minutes, ES will be taken out 2 cm back, and the temperatures of each site will be measured when the temperature change of the ES thermistor stabilized below 0.1°C. Eventually, the depth of ES will be changed from 45 to 27 cm with a 2 cm interval, and the temperature at each position will be measured."
224212067|NCT05552092|OTHER|Anatomical landmark|For the further evaluation of the optimal insertion depth of GDT, anatomical landmarks such as distance from the cricoid cartilage to the carina (CCD) and distance from the carina to the intervertebral disc between T8 and T9 (CDD) will be measured using an electronic caliper on a preoperative chest X-ray.
224212068|NCT02795949|DRUG|Antipseudomonal beta-lactam antibiotic|Pharmaceutical form: solution for infusion
224212069|NCT02795949|DRUG|De-escalation(short-spectrum antibiotic)|Pharmaceutical form: solution for infusion
223622400|NCT06118255|DRUG|fenfluramine|The study drug, fenfluramine HCl, is an oral solution to be administered in equal doses twice daily (BID). It will be based on the current dose and participant's weight (kg).
223622401|NCT05766488|DEVICE|Continuous Glucose Monitor (CGM)|A Freestyle Libre 2 continuous glucose monitor (CGM) will be provided in the experimental arm of this study for 6 months.
224212070|NCT00488046|BIOLOGICAL|H5N1 (6-2) AA ca Recombinant (A/Hong Kong/213/2003 x A/AnnArbor/6/60 ca)|Intranasal vaccine
224212071|NCT03095963|OTHER|a mixture of highly charged Lactobacilli and Bifidobacteria (VSL#3®)|Patients assigned to the study group took the probiotic supplement VSL#3® for two months, in addition to levothyroxine
224212072|NCT03095963|DRUG|levothyroxin|replacement therapy for hypothyroidism
224316320|NCT02569918|DEVICE|Surface electrical stimulation|"Surface electrical stimulation using the following experimental devices. 1) The CE-approved HASOMED electrical isolated stimulator (Rehastim). 2) Two hand prosthesis: the robotic hand Azzurra (Prensilia, Italy) and the robotic hand Multi-sensory Prosthetic Hand (Wessling robotics, Germany) 3) The EPIONE Psychophysical Testing Platform software for stimulator control. Surface stimulation therapy is provided while providing visual guidance to the subject."
223622402|NCT05766488|DEVICE|Self-monitoring Blood Glucose (SMBG)|A traditional glucometer device will be assigned in the active comparitor arm of this study for 6 months.
224316321|NCT04468451|BEHAVIORAL|A 48-hour ROC training program with a standing posture|The 2-hour training session is composed of two 30-minute driving sessions and two 25-minute natural play sessions, with a 10-minute break. Every week's treatment program will be before planned and adjusted by the therapist and the caregivers through discussion and clinical observation of participant's performance in the previous session. Training will concentrate on building the concept of casual-effect on the switch and car motion, goal-oriented driving in a hospital, and upper limb use in functional tasks with driving and hand use in functional tasks for exploration in natural play session.
224316322|NCT04468451|BEHAVIORAL|A 24-hour ROC training program with a standing posture|The 1-hour training session is composed of a 30-to-35-minute car play and a 25-minute natural play. Every week's treatment program will be before planned and adjusted by the therapist and the caregivers through discussion and clinical observation of participant's performance in the previous session. Training will concentrate on building the concept of casual-effect on the switch and car motion, goal-oriented driving in a hospital, and upper limb use in functional tasks with driving and hand use in functional tasks for exploration in natural play session.
223622403|NCT03663725|DRUG|Intensified protocol|Early Temozolomide (TMZ) 1 cycle (150 mg/m²/ day X 5 days, per os) Started between day 2 and 15 after surgery/ biopsy RT (60 Gy, 2 Gy/fraction) + concomitant TMZ (75 mg/m2/day X 42 days, per os) Started between W4 and W6 after surgery/ biopsy Adjuvant TMZ 6 cycles (150-200 mg/m2 X 5 days /month, per os) Started 1 month after the end of the concomitant TMZ Prolonged TMZ Until progression, intolerance, patient's or physician's decision (150-200 mg/m2 every 4 weeks, per os)
223622404|NCT03663725|DRUG|Stupp protocol|RT (60 Gy, 2 Gy/fraction) + concomitant Temozolomide (75 mg/m2/day X 42 days, per os) Started between W4 and W6 after surgery/ biopsy Adjuvant TMZ 6 cycles (150-200 mg/m2 X 5 days /month, per os) Started 1 month after the end of the concomitant TMZ
223622405|NCT05433961|DRUG|MagniXene Hyperpolarized Xenon MRI|Magnetic Resonance Imaging of lung function using Hyperpolarized Xenon as a contrast agent.
223622406|NCT03327181|DIETARY_SUPPLEMENT|short chain fatty acid tracers|stable tracer infusion of acetate, propionate, and butyrate
223622407|NCT05009277|DEVICE|Device|LINDA thermal device
223761856|NCT06460727|OTHER|task oriented exercise training on dynamic surface|Following exercises will be performed in this group: Make the child bounce on swiss ball, reaching the toy with both hand kept over the head on platform swing, high sitting on swiss ball throwing ball with both hands, reaching the toy with one hand shifting the wait towards reaching side.
223761857|NCT06460727|OTHER|task oriented exercise training on static surface|The children in this group will receive following TOET: Sit to stand from various cjair heights , standing and reaching indifferent directions for an object, Stepping forwards, backwards, and sideways onto blocks of various heights, walking forward , backward and sideways, Walking up and down stairs
223761858|NCT02548988|OTHER|Neuromuscular Electrical Stimulation|Selective Neuromuscular Electrical Stimulation on VMO
223761859|NCT02900820|OTHER|Discontinuing antibiotic therapy|Patients assigned to this group will be asked to discontinue antibiotic therapy.
223761860|NCT02900820|OTHER|Continuing antibiotic therapy|Patients assigned to this group will be asked to complete antibiotic therapy.
223761861|NCT02616224|OTHER|No intervention|No intervention was administered in this study.
223761862|NCT00115596|OTHER|Formal Curriculum; Low-Fidelity Simulation|The intervention was a formal procedural skills training curriculum consisting of didactic lectures and simulation training.
223761863|NCT01369875|DRUG|Cyclophosphamide|60 mg/kg/day X 2 days intravenous (IV) over 1 hour on days -7 and -6
223622408|NCT03835429|DEVICE|MyTAP oral appliance plus mouth shield|The midline traction oral appliance (MyTAP, Airway Management Inc.(AMI), Dallas Texas) is currently marketed as a medical device to treat snoring and obstructive sleep apnea and is FDA cleared.
223622409|NCT00968500|BEHAVIORAL|Questionnaires/Interviews|"Prior to the interview, the measure of prolonged grief disorder symptoms, the PG-13, will be re-administered to participants as a quality assurance check. We will administer 7 self-report measures, which participants can complete in our office, at home, or via telephone, depending on their preferences. These questionnaires should take approximately 75 to 80 minutes to complete. If you are asked to take part in the in-depth interview and you choose to take part, the interview that will take approximately 60 to 90 minutes to complete, depending on the length of the responses to the questions asked.~The participant may also be asked if they would be willing to fill out an additional questionnaire about parents' thoughts on the most appropriate timing for raising the topic of a postmortem examination and factors that are important to include in discussions. Despite its importance, autopsy is often not discussed with parents whose child is dying from cancer."
223622410|NCT03396081|BEHAVIORAL|PRADO-IC|"1. Help of administrative employees to schedule the first medical visits after an hospitalization for heart failure.~2. Home nurse's visiting program, during 2 to 6 months after the hospitalization for heart failure."
223622411|NCT03396081|BEHAVIORAL|No intervervention Usual Care|Advices about the care pathway, provided by care givers. Prescription of home nurse's visits if needed.
223622412|NCT05931367|DRUG|Retatrutide|Administered SC
223622413|NCT05931367|DRUG|Placebo|Administered SC
223622414|NCT06210386|DEVICE|Noninvasive ventilation|noninvasive ventilation
223622415|NCT06051578|OTHER|Abdominal wall tension measurement|"All patients will have the tension of their abdominal wall measured during surgery using a tension scale or tensiometer."
223622416|NCT06366282|BEHAVIORAL|Caregiver Counseling for Childhood Traumatic Injury|Caregiver intervention will be provided by the counseling team that includes components of trauma narrative, psychoeducation, coping strategies, and resilience-building using, for burn patients.
223622417|NCT06366282|BEHAVIORAL|Standard of Care for Childhood Traumatic Injury|Control group receives the current standard of care provided by the counseling team
223622418|NCT02963272|OTHER|Conventional strategy|Conventional strategy to manage the patients with HF, following the international guidelines.
223622419|NCT02963272|OTHER|ST2-guided strategy|patients wit ST2 over the median are targeted with higher doses of drugs with putative effects on fibrosis and anti HF pathophysiology
223622420|NCT05790460|OTHER|Telehealth|Enhanced synchronous telehealth nurse navigation, compared to usual care nurse navigation, to increase timely molecularly-informed treatment recommendations through early integration of concurrent molecular testing.
223622421|NCT04750642|DEVICE|CI632D|CI632 cochlear implant with Slim Modiolar electrode including dexamethasone in the electrode within wells (CI632D)
223622422|NCT04750642|DEVICE|CI632|CI632 cochlear implant with Slim Modiolar electrode with market approval and does not include dexamethasone
223622423|NCT06532084|DRUG|Sorafenib|Sorafenib 200 mg bid for 168 days starting in the time fram between engraftment with neutrophils \> 1.0 x 10\^9/L, white blood cells\> 1.5 x 10\^9/L, platelets\> 1.5 x 10\^9/L and day+100 after allogeneic hematopoietic cell trnaplantation
223622424|NCT05147792|DEVICE|CLAAS|CLAAS
223622425|NCT05147792|DEVICE|WATCHMAN left atrial appendage closure device / Amulet left atrial appendage occluder|WATCHMAN left atrial appendage closure device / Amulet left atrial appendage occluder
223622426|NCT06483984|DEVICE|Noninvasive ventilation|Respiratory support with a facemask connected to a ventilator through a heated humidifier. Ventilator will be set in the pressure support mode.
223622427|NCT00092222|DRUG|Etoposide|Etoposide 50 mg/m2 /day continuous intravenous infusion (CIVI) over 24 hours x 4 days (days 1-4) of 21 day cycle. A maximum of 6 cycles of R-EPOCH-R will be administered except in exceptional circumstances.
223622428|NCT00092222|DRUG|Interferon-alpha|Ages 18 and over: Initial dose of 7.5 million units subcutaneous, three times weekly x 14 days; subsequent dosesincrease dose as tolerated each 14 days to a maximum of 45 million units subcutaneous three times weekly; Ages 12-17: Initial dose of 5 million units/m2 subcutaneous, three times weekly x 14 days Subsequent doses: Increase dose as tolerated each 14 days to a maximum of 30 million units/m2 subcutaneous, three times weekly
223622429|NCT00092222|DRUG|Rituximab|Rituximab 375 mg/m2 IV day 1, shall be administered prior to Doxil injection. When combined with EPOCH chemotherapy, Rituximab will be given on days 1 and 5.
223622430|NCT00092222|DRUG|Zidovudine|Cycle 1: Zidovudine 600 mg PO QID x 7-21 days in outpatient setting;600 mg PO q6hours x 7-21 (Intravenous zidovudine 300 mg q 6 hours may be substituted) days for inpatients; Cycle 2 and beyond: 600 mg PO QID x 7 days in outpatient setting; 600 mg PO q 6 hours x 7 days (300 mg q 6 hours may be substituted)
223622431|NCT00092222|DRUG|Liposomal Doxorubicin|21 day cycle; 20 mg/m2 Liposomal Doxorubicin given on day 1 and shall be administered after completion of Rituximab infusion from 2 to 6 cycles.
223622432|NCT00092222|DRUG|Bortezomib|1.3 mg/m2 IV days 1, 4, 8, and 11. Cycle length is 21 days.
223622433|NCT00092222|DRUG|Valganciclovir|Cycle 1: Valganciclovir 900 mg PO BID x 7-21 days in outpatient setting; 900 mg PO q 12 hours x 7-21 days for inpatients; Cycle 2 and beyond: 900 mg PO BID x 7 days for outpatients; 900 mg PO q 12 hours x 7 days (Intravenous ganciclovir 5 mg/kg may be substituted) for inpatients
223622434|NCT00092222|DRUG|Doxorubicin|10 mg/m2 /day CIVI over 24 hours x 4 days (days 1-4) of 21 day cycle.
223622435|NCT00092222|DRUG|Vincristine|0.4 mg/m2 /day CIVI over 24 hours x 4 days (days 1-4) of 21 day cycle.
223622436|NCT00092222|DRUG|Cyclophosphamide|Cyclophosphamide: if CD4 \< 100 cells/mm3, 187 mg/m2 IV (Day 5) if CD4 greater than or equal to 100 cells/mm3, 375 mg/m2 IV (Day 5) of 21 day cycle.
223761864|NCT01369875|DRUG|Fludarabine|25 mg/m\^2/day intravenous piggyback (IVPB) daily over 30 minutes for 5 days (days -5 to -1)
223622437|NCT00092222|DRUG|Filgrastim (G-CSF)|Filgrastim 300 micrograms subcutaneous daily beginning day 6 until absolute neutrophil count recovery 5000 cells/mm3 (Pegfilgrastim may be substituted with PI approval, at the recommended dose of one 6mg syringe)
223622438|NCT00092222|DRUG|Prednisone|Prednisone 60 mg/m2/day PO x 5 days (days 1-5)of 21 day cycle.
223622439|NCT00092222|DRUG|Sirolimus|Maximum daily dose of 40 mg given as a single agent on 21 day cycle.
223622440|NCT00092222|OTHER|Observation Only|Observation of symptoms
224212073|NCT05674266|DEVICE|AN Active tDCS|"The tDCS active stimulations will be directed to PFC regions for six weeks delivered for three times a week.~tDCS will be delivered by a battery driven, constant current stimulator through a pair of saline-soaked sponge electrodes kept firm by elastic bands.~The anode will be placed on the left PFC, F3 position according to the 10-20 international EEG system for electrode placement, while the cathode will be placed on the right PFC, F4 position according to the 10-20 international EEG system for electrode placement.~Stimulation intensity will be set at 1 milliampere (mA), the duration of stimulation will be 20 min."
224212074|NCT05674266|DEVICE|AN Sham tDCS|The same electrode placement will be used as in the stimulation conditions (left anodal/right cathodal), but the current will be applied for 30 s and will be ramped down without the participants awareness, and will be held three times a week for six weeks.
224212075|NCT03772184|PROCEDURE|Cervical inversion|inverting the cervical lip after delivery
224212076|NCT04216537|DIAGNOSTIC_TEST|Glioma groups based on molecular pathology or genetic variation|Patients with newly diagnosed glioma that receive tumor resection
223622441|NCT02733120|OTHER|stable isotope infusion|stable isotopes such as 15N2, TRP, 2H3-Leucine, L-\[2H3\]-3-Methylhistidine, 2H2-Glycine, 2-D-hydroxyproline, 1-13C-ketoisocaproic acid (KIC), L-\[Guanido-15N2\]-Arginine, L-\[ureido-13C-2H2\]-Citrulline), L-Glutamine-amide-15N, 1,2-13C2-L-Glutamic acid, 1,2-13C2Taurine, and 13C-Urea is given IV simultaneously
223622442|NCT06657365|DEVICE|Radiofrequency (RF) Treatment with Volnewmer|Non-invasive radiofrequency-based skin tightening using the Volnewmer device.
223622443|NCT06657365|DEVICE|Radiofrequency (RF) Treatment with Thermage CPT|Non-invasive radiofrequency-based skin tightening using the Thermage CPT device.
223622444|NCT00663364|DRUG|Physiogel AI Lotion, Physiogel Lotion|Physiogel AI Lotion and Physiogel Lotion is a cosmetic, applied twice daily to dry skin
223761865|NCT01369875|BIOLOGICAL|Aldesleukin|720,000 IU/kg intravenous (IV) over 15 min every 8 hours (+/- 1hr) beginning within 24 hours of cell infusion and continuing for up to 5 days (max. 15 doses.)
223761866|NCT01369875|BIOLOGICAL|Tumor Infiltrating Lymphocytes|Intravenous (IV) over 30 minutes on day 0
223761867|NCT01518075|OTHER|Spontaneous Breathing|"Evaluation of breathing - swallowing interaction without non invasive mechanical ventilation. Patient breath spontaneously.~Measurements of respiratory and swallowing parameters were monitored using respiratory inductive plethysmography. Swallowing was monitored noninvasively. Two bolus sizes were used, (5, 10 ml), in random order. Five sets of two boluses were studied, taking care not to use the same bolus size twice consecutively. The study participants were blinded to bolus size."
223761868|NCT01518075|OTHER|Non Invasive Mechanical Ventilation|Evaluation of breathing - swallowing interaction with non invasive mechanical ventilation. Patient breath under non invasive mechanical ventilation. Measurements of respiratory and swallowing parameters were monitored using respiratory inductive plethysmography. Swallowing was monitored noninvasively. Two bolus sizes were used, (5, 10 ml), in random order. Five sets of two boluses were studied, taking care not to use the same bolus size twice consecutively. The study participants were blinded to bolus size.
223761869|NCT02611167|BIOLOGICAL|Allogeneic bone marrow-derived MSCs (1 x 10 6 MSC/kg)|Bone marrow-derived allogeneic MSCs will be delivered intravenously in escalating doses of 1 x 10 6 MSC/kg, 3 x 10 6 MSC/kg, 6 x 10 6 MSC/kg, or 10 x 10 6 MSC/kg of body weight to a population of patients with idiopathic Parkinson's disease (iPD).
223761870|NCT02611167|BIOLOGICAL|Allogeneic bone marrow-derived MSCs (3 x 10 6 MSC/kg)|Bone marrow-derived allogeneic MSCs will be delivered intravenously in escalating doses of 1 x 10 6 MSC/kg, 3 x 10 6 MSC/kg, 6 x 10 6 MSC/kg, or 10 x 10 6 MSC/kg of body weight to a population of patients with idiopathic Parkinson's disease (iPD).
224212077|NCT00467337|PROCEDURE|Medial-Wedge Insole intervention|
224212078|NCT03940326|DRUG|Levetiracetam|Levetiracetam with initial dose of 500 mg per 12 hours which will be increased 500 mg/week to target dose of 2000 mg/day and the dose could be increased to 3000 mg/day if seizures recurred
224212079|NCT03940326|DRUG|Valproate|Sodium valproate with initial dose of 500 mg/day which will be increased 500 mg/week to target dose of 1500 mg/day and the dose could be increased to 2000 mg/d if seizures recurred.
224212080|NCT02330250|OTHER|Pharmaceutical Care|"The patients assigned for the intervention group will receive guidance from a pharmacist (pharmaceutical consultation) in addition to the medical care habitually delivered by the hospital.~The pharmacist will review the drug therapy, identifying current and potential problems related to the drug prescription, making a systematic assessment of the need, effectiveness and safety of all medications and their adequacy to the patient's life routine. A care plan will then be designed along with the patient that may include interventions and/or referral to other practitioners."
223622448|NCT06605079|BEHAVIORAL|Complex intervention|"A complex intervention is carried out in the intensive care unit. This includes:~* telemedical consultations by specialized palliative care experts from external institutions for the respective hospital staff~* the training of hospital staff in the intensive care unit in basic palliative care and~* the use of checklists for the early identification of eligible patients and the structured recording of palliative care needs.~The efficacy and cost-effectiveness of the complex intervention will be investigated using a controlled clinical trial in a cluster-randomized controlled design. In addition, as part of the multicenter clinical study in WP 2 staff, patients and relatives will also be surveyed."
223622449|NCT06605079|OTHER|Routine treatment|No complex intervention is established, just routine procedures.
223622450|NCT03672474|DEVICE|Photobiomodulation REGEnLIFE RGn530 device|For the photobiomodulation group the device is set up and activated. REGEnLIFE RGn530 medical device will follow EC labelling if proven to be safe and effective
223622451|NCT03672474|DEVICE|SHAM REGEnLIFE RGn530 device|For the photobiomodulation group the device is set up and not activated. REGEnLIFE RGn530 medical device will follow EC labelling if proven to be safe and effective
223622452|NCT06819865|DEVICE|EkoSonicTM Endovascular System|EkoSonicTM Endovascular System and its upgraded versions if applicable The EkoSonicTM Endovascular System is a non-implanted system comprising a sterile, single-use EkoSonic Endovascular Device (Infusion Catheter and Ultrasonic Core) and reusable EKOSTM Control System 4.0(Control Unit, Connector Interface Cable and power cord).
223622453|NCT06986863|OTHER|Always Uniquely Me mobile phone application|The app will allow the user to organize their healthcare information and personal needs which can help improve communication with doctors, clinicians and first responders.
223622454|NCT06987968|DRUG|VS-01 on top of SOC (Active Treatment Group)|Patients will received VS-01 intraperitoneally up to four consecutive days on top of SOC
223622455|NCT06987968|DRUG|SOC|Patients will received SOC
223622456|NCT06658821|DIETARY_SUPPLEMENT|LDL557-HK capsule|Subjects will take once a day during the experimental period. one LDL557-HK capsule(Heat-killed Lactobacillus delbrueckii subsp. lactis LDL557 1x10\^10cell) within 30 minutes before lunch.
223622457|NCT06658821|DIETARY_SUPPLEMENT|Placebo Capsule|Subjects will take once a day during the experimental period. one placebo capsule within 30 minutes before lunch.
223622458|NCT06661187|PROCEDURE|Cryoanalgesia|Patients who received cryoanalgesia: patients subjects underwent arterial puncture. patients in the intervention group had a small plastic bag filled with 12 oz of crushed ice applied to the radial artery puncture site for 3 min (timed with a stopwatch) without external compression or massage.
223622459|NCT06661187|PROCEDURE|Psychological instructions|Psychological interventions using verbal signals of the impending procedure, music distraction, visual distraction, and breathing interventions be used during arterial puncture in adults
223622460|NCT06661187|PROCEDURE|Routine care|No intervention deliver routine care
223622461|NCT05202353|DRUG|BI 456906|BI 456906
223622462|NCT05202353|DRUG|Semaglutide|Semaglutide
223622464|NCT06854549|BEHAVIORAL|Parental Reading Picture-book|"In addition to receiving routine care, the experimental group will be given the Reading Picture Books from Scratch educational booklet once the preterm infant is removed from the incubator, the group assignment is confirmed, and participation in the study is verified. They will then undergo the Picture Book Reading Intervention. This intervention targets the preterm infant and one of the parents. It involves reading picture books from the second to the fourth day after the infant is removed from the incubator, during the visiting period from 14:10 to 14:20."
223622465|NCT04716231|BIOLOGICAL|Atacicept|Once weekly subcutaneous (SC) injections by prefilled syringe
223761871|NCT02611167|BIOLOGICAL|Allogeneic bone marrow-derived MSCs (6 x 10 6 MSC/kg)|Bone marrow-derived allogeneic MSCs will be delivered intravenously in escalating doses of 1 x 10 6 MSC/kg, 3 x 10 6 MSC/kg, 6 x 10 6 MSC/kg, or 10 x 10 6 MSC/kg of body weight to a population of patients with idiopathic Parkinson's disease (iPD).
224212081|NCT02330250|OTHER|Control|The patients assigned to the control group will receive the medical care habitually provided by the hospital and will be attended by a non-pharmacist professional, who will provide hygiene/nutritional counseling and risk reduction, such as smoking cessation advice; use of estrogen-based contraceptive drugs; exposure to sunlight, proper use of sunscreen and clothes; nutritional guidance on the intake of low saturated-fat food. As usual, information about the use of medication will be provided by the attending physician.
224212082|NCT06353035|OTHER|Rewilding|Private yards of the intervention study subjects will be modified with vegetation and deadwood.
224212083|NCT05693181|BIOLOGICAL|Multiple systemic (i.v.) administration of allogenic non-related group- and rhesus-compatible mononuclear cord blood cells|Each HUCBCs sample contain 500 +/- 50 x 10\*6 allogenic non-related group- and rhesus-compatible mononuclear cord blood cells
224212084|NCT05693181|OTHER|Control vehicle (sterile saline)|Sterile saline infusion in control patients
223622466|NCT04716231|OTHER|Placebo to match Atacicept|Once weekly subcutaneous (SC) injections by prefilled syringe
223622467|NCT04039464|DRUG|Mono-Therapy with Sildenafil|The subjects will be randomized to receive sildenafil alone and will undergo study procedures as outlined in section 1.3. There will not be a placebo group.
223622468|NCT04039464|DRUG|Duo-Therapy with Sildenafil + Bosentan|The subjects will be randomized to receive combination up-front therapy sildenafil and bosentan and will undergo study procedures as outlined in section 1.3. There will not be a placebo group.
223622469|NCT05975905|BIOLOGICAL|Dose A KER-012|Dose A KER-012 (Q4W);
223622470|NCT05975905|BIOLOGICAL|Dose B KER-012|Dose B KER-012 (Q4W);
223622471|NCT05975905|BIOLOGICAL|Dose C KER-012|Dose C KER-012 (Q4W);
223622472|NCT05975905|BIOLOGICAL|Placebo for 24 Weeks followed by Dose B KER-012 for 72 weeks|Treatment Period (24 weeks): Placebo SC (Q4W) Extension Period (72 weeks after Placebo treatment): KER-012 (Dose B) SC (Q4W)
223622473|NCT04012411|PROCEDURE|Brain MRI|Multimodal brain MRI: volumetry, diffusion tensor, functional rest MRI
223622474|NCT04012411|PROCEDURE|Lumbar Punction|Analysis of BDNF, Tau, NFL and TrkB in cerebrospinal fluid
223622475|NCT04012411|GENETIC|Blood sample|Analysis of BDNF, Tau, NFL, and Val66Met polymorphism
223622476|NCT04012411|OTHER|Cognitive evaluation|Symbol Digit Modality Test (SDMT), Stroop test, Trail Making Test, Empan
223622477|NCT05089695|DEVICE|Noninvasive respiratory support|Treatment of acute hypoxemic respiratory failure
223761872|NCT02611167|BIOLOGICAL|Allogeneic bone marrow-derived MSCs (10 x 10 6 MSC/kg)|Bone marrow-derived allogeneic MSCs will be delivered intravenously in escalating doses of 1 x 10 6 MSC/kg, 3 x 10 6 MSC/kg, 6 x 10 6 MSC/kg, or 10 x 10 6 MSC/kg of body weight to a population of patients with idiopathic Parkinson's disease (iPD).
223622478|NCT06592001|DEVICE|Atala™ lead|Subjects will receive the Atala™ lead being evaluated in the study.
223622482|NCT06409130|DRUG|NNC0194-0499|Administered subcutaneously.
223622483|NCT06409130|DRUG|Semaglutide|Administered subcutaneously.
223622484|NCT06409130|DRUG|NNC0194-0499 placebo|Administered subcutaneously.
223622485|NCT06409130|DRUG|Semaglutide placebo (Group A)|Administered subcutaneously.
223622486|NCT06409130|DRUG|Cagrilintide + semaglutide|Administered subcutaneously.
223622487|NCT06409130|DRUG|Cagrilintide|Administered subcutaneously.
223622488|NCT06409130|DRUG|Cagrilintide placebo|Administered subcutaneously.
223622489|NCT06409130|DRUG|Semaglutide placebo (Group B)|Administered subcutaneously.
223622490|NCT00874458|PROCEDURE|magnetic resonance imaging|
224212085|NCT02755233|OTHER|Pulmonary Function|Spirometry and DLCO were measured according to performance standards based on the statements from the American Thoracic Society (ATS) and the European Respiratory Society (ERS). Values of DLCO were adjusted for the patient's current hemoglobin value, and the patients were asked to withhold cigarette smoking at least four hours before pulmonary function testing. Lung volumes and DLCO were measured with a commercial ZAN300 CO Diffusion system (nSpire Health GmbH, Oberthulba, Germany)
223622491|NCT00874458|PROCEDURE|radiomammography|
223622492|NCT00874458|PROCEDURE|ultrasound imaging|
223622493|NCT03771144|PROCEDURE|arthrolysis|Surgery is performed under general anesthesia. The usual duration of this surgery is on average 1h30. This surgery requires an anterior approach and a posterior approach. The patient is placed in lateral decubitus. The arthroscope of 2.7 is introduced by a posterior route. An anterior instrumental track is made from inside out through the rotator interval.
223622494|NCT06865105|DRUG|Lutikizumab|Subcutaneous (SC) Injection
223622495|NCT06865105|DRUG|Risankizumab|Subcutaneous (SC) Injection
223622496|NCT06671782|OTHER|Kegel exercises|Kegel exercises without any formal training
223622497|NCT06671782|OTHER|Pelvic Floor Muscle Exercise Program with biofeedback|Patients in the intervention arm will undergo PFME training with a physical therapist 2 times before surgery (4-6 weeks \[in person\] and 3-4 weeks \[in person\], before surgery) (within ±1 week is considered acceptable to avoid protocol violations). Patients in the intervention group will also undergo 2 PFME training sessions after surgery (3 weeks and 1.5 months after surgery).
223622498|NCT06671782|OTHER|Questionnaires|All patients will complete the Prostate Quality of Life Survey at baseline and at 1.5, 3, and 6 months after radical prostatectomy (within ±2 weeks is considered acceptable to avoid protocol violations). This is part of the standard of care for patients undergoing prostatectomy.
223622499|NCT06671782|OTHER|Interviews|A qualitative interview with each of the 15 patients in the intervention group to obtain information about the patient's experience. The interview will last for 30-60 min and will be conducted at 3-6 months after prostatectomy, when the patient has completed all 4 physical therapy sessions. It will cover topics related to patient involvement, satisfaction, and activation.
223761873|NCT06410872|DIAGNOSTIC_TEST|BART Task|The Zuckerman's Sensation Seeking Scale version-V (SSS-V) - Four-factor score, The Barret Impulsiveness Scale (BIS), Gormally's Binge Eating Scale (BES), The World Health Organization-developed AUDIT (Alcohol Use Disorders Identification Test) screen, The CAGE questionnaire for substance abuse-adapted to include drugs, Gamblers Anonymous's 20 Questions (GA20), Hospital Anxiety and Depression Scale (HADS)
223761874|NCT04515004|DRUG|leucoselect phytosome|A standardized grape seed procyanidin extract complexed with soy phospholipid.
223622502|NCT04902339|BEHAVIORAL|Mindfulness-Oriented Recovery Enhancement|8 weeks of therapy integrating mindfulness, reappraisal, and savoring skills.
223622503|NCT04902339|OTHER|Neurofeedback|Near-infrared spectroscopy neurofeedback during savoring practice.
223622504|NCT04902339|BEHAVIORAL|Supportive Psychotherapy|8 weeks of supportive, process-oriented psychotherapy.
223622507|NCT01697397|DEVICE|Recording of Myoelectric Signals|Obtain recordings of the electrical signals of the gut.
223622508|NCT06678984|PROCEDURE|with treated umbilical vein allograft|Surgical treatment of female stress urinary incontinence using a treated allogeneic umbilical vein sling
223622509|NCT06678984|PROCEDURE|with autologous fascial pubovaginal sling|Surgical treatment of female stress urinary incontinence using a autologous fascial pubovaginal sling
223761875|NCT04314089|DRUG|GT103|intravenously (dose depending)
224212086|NCT06311539|OTHER|Theraband Strengthening Exercise Program|"Resisted knee flexion in prone position and resisted knee extension in seated position (for dominant leg) and bilateral squats were practiced in 3 sets of 12 repetitions. Participants rested for 30 seconds between sets. The program, which lasted approximately 30 minutes in total, continued for a total of 6 weeks, the first 3 weeks with the red theraband and the last 3 weeks with the black theraband.~15 morning type participants will be included in the morning exercise program (08:00) and 15 morning type participants will be included in the evening exercise program (18:00).~15 evening type participants will be included in the morning exercise program (08:00) and 15 evening type participants will be included in the evening exercise program (18:00)."
224316323|NCT04468451|BEHAVIORAL|A regular therapy program without receiving any ROC training|The regular therapy group will be an active control group without receiving any additional training. The training dosage will be their own therapy, including occupational, physical and speech therapy. They will continue their regular therapy, including physical, occupational and speech therapy. The general propose of the training is to improve the developmental scales, mobility, socialization and upper limb use in functional tasks.
223622510|NCT05863702|BEHAVIORAL|Penny|The chatbot will assist patients who have not been see for cancer follow-up care, with scheduling follow-up appointments, labs, scans, specialty appointments, and monitor compliance with the appointments made.
223761876|NCT04321876|BEHAVIORAL|Collaborative Behavioral Health Program|Collaborative care is the delivery of mental health care through a proactive collaboration of primary care providers, behavioral care managers based in primary care practices, and psychiatrists who provide supervision to the behavioral care managers and consultation to the primary care providers.
223622514|NCT06886126|DRUG|HDM1005 injection or placebo|HDM1005 injection subcutaneous injection QW for 22weeks
223622515|NCT06928571|BEHAVIORAL|Connect4Health Engage|Intervention focused on motivating and guiding patients to use empirically supported, freely available online tools for weight loss.
223622516|NCT06928571|BEHAVIORAL|Connect4Health Discover|Educational control - information about healthy eating and physical activity
223622517|NCT07077070|DEVICE|Standard Electrical Categorical Loudness Scaling task (Standard-ELS)|The Standard-ELS task is conducted using the Mobile Research Application within the Nexus Research system. It is completed in two phases: the first phase identifies the lower and upper bounds of the loudness range based on participant ratings, while the second phase collects data from stimulations delivered within the established range.
223622518|NCT07077070|DEVICE|Fast Electrical Categorical Loudness Scaling task (Fast-ELS)|The Fast-ELS task employs an algorithm to estimate the lower and upper bounds of the loudness range using a limited number of samples. This range is then refined by collecting additional samples across various loudness categories for comprehensive coverage.
223622519|NCT07080320|DEVICE|MoCap|"For each subject, the displacement of markers, the deformation of regions between markers, and the evolution of angles formed by the markers during facial expressions and vertical movements will be analyzed with MoCap. These will be compared between the two age groups (18-33 years vs. 50-65 years) using a MANOVA model. The reference values for marker displacement will be defined by the interval between the 2.5% and 97.5% percentiles of the values for each marker. If the distribution is Gaussian, the percentiles will be derived from the standard normal distribution; otherwise, the non-parametric method will be used.~The intervention will be Interventions :~* Recruitment of healthy and pathological subjects.~* Full-face and macro images of the periorbital region~* Measurement of periorbital skin properties using MoCap and standard reference tools.~* Application of a tightening product (aloe vera) and periorbital massage.~* Measurement of skin response to a vertical jump."
223622520|NCT06801587|DRUG|Triamcinolone acetonide plus ropivacaine|The local infiltration solution in the triamcinolone acetonide plus ropivacaine group will consist of ropivacaine and triamcinolone acetonide. For local infiltration, a total of 30mL solution will be prepared for each group, 1 ml of triamcinolone acetonide (40mg per 1ml) plus 15 ml of 1% ropivacaine diluted to 30 ml with saline as the test drug in the triamcinolone acetonide group. The surgeon will perform incision infiltration before the skin incision. A total of 10 mL of solution will be injected into each level. The study solution will be injected into the entire thickness of the planned incision site. The epidural space and intrathecal space will not be infiltrated.
223622521|NCT06801587|DRUG|Ropivacaine alone|The local infiltration solution in the ropivacaine alone group will consist of ropivacaine alone. For local infiltration, a total of 30mL solution will be prepared for each group, which will include 15ml of ropivacaine added to 15mL of saline for ropivacaine group . The surgeon will perform incision infiltration before the skin incision. A total of 10 mL of solution will be injected into each level. The study solution will be injected into the entire thickness of the planned incision site. The epidural space and intrathecal space will not be infiltrated.
223622522|NCT06097728|DRUG|Volrustomig|MEDI5752: Administered as IV infusion
223622523|NCT06097728|DRUG|Pemetrexed|Alimta: Administered as IV infusion
223622524|NCT06097728|DRUG|Carboplatin|Paraplatin: Administered as IV infusion
223622525|NCT06097728|DRUG|Cisplatin|Platinol: Administered as IV infusion
223622526|NCT06097728|DRUG|Nivolumab|Opdivo: Administered as IV infusion
223622527|NCT06097728|DRUG|Ipilimumab|Yervoy: Administered as IV infusion
223622528|NCT06139328|DRUG|BI 765845|BI 765845
224212087|NCT00058617|BIOLOGICAL|Injection of EBV Specific CTLs|"Each patient will receive two injections, 14 days apart, according to the following dosing schedules:~Group One Day 0 2x10\^7 cells/m2 Day 14 2x10\^7 cells/m2~Group Two Day 0 2x10\^7 cells/m2 Day 14 1x10\^8 cells/m2~Group Three Day 0 1x10\^8 cells/m2 Day 14 2x 10\^8 cells/m2~If patients with active disease have stable disease or a partial response by the RECIST criteria at their 8 week or subsequent evaluations they are eligible to receive up to 6 additional doses of CTLs at monthly intervals-each of which will consist of the same cell number as their second injection. Patients will not be able to receive additional doses until the initial safety profile is completed at 6 weeks following the second infusion."
224212088|NCT03028883|OTHER|Dose adjustments|Do higher doses of buprenorphine result in a higher rate of neonatal abstinence syndrome as compared to lower doses of buprenorphine
224212089|NCT05068206|DRUG|AK105 injection|AK105 is programmed death 1（PD-1） monoclonal antibody
223622529|NCT06139328|DRUG|Placebo matching BI 765845|Placebo matching BI 765845
223622530|NCT05800964|DRUG|AMG 305|Short-term intravenous (IV) infusion
223622531|NCT07087054|DRUG|Paltusotine|Experimental Drug: Randomized
223622532|NCT07087054|DRUG|Placebo|Matching Placebo Drug: Randomized
223622533|NCT06270875|BEHAVIORAL|ADAPT HF|ADAPT is a multicomponent, lay palliative care coach-led or self-led supportive care intervention designed to improve pain of life in individuals with advanced heart failure. Participants will complete weekly sessions of the educational programs. This program includes the following modules: pain psychoeducation, self-care and relaxation tips, social support and communication, and spirituality and meaning coping. The sessions will either be self-guided or completed with a lay coach navigator.
223622534|NCT02893865|DEVICE|Continuous positive airway pressure|Continuous positive airway pressure treatment during three months with adherence recording
224212090|NCT05068206|DRUG|Anlotinib hydrochloride capsule|Anlotinib is small molecule multi-target tyrosine kinase inhibitor.
223622535|NCT02893865|DEVICE|Sham-continuous positive airway pressure|Sham-continuous positive airway pressure during three months with adherence recording
223622536|NCT06930157|DRUG|Shenling Baizhu granules (TCM patent medicine)|Shenling Baizhu granules is a traditional Chinese medicine preparation in granular form. Participants in the experimental group will take 6 grams orally three times daily, before or with meals, for 6 months each year over a 2-year period. The granules contain multiple Chinese herbs including Ginseng, Poria, Atractylodes macrocephala, and other traditional ingredients. This formulation is standardized according to Chinese pharmacopoeia standards and is manufactured under GMP conditions. This intervention is being tested for its ability to prevent the recurrence of low-risk colorectal adenomas after endoscopic resection.
223622537|NCT06928051|DRUG|S-892216|S-892216 will be administered orally as a tablet.
223622538|NCT06928051|DRUG|Placebo|Placebo will be administered orally as a tablet.
223622539|NCT07083960|DRUG|OM336|OM336 is an engineered bispecific antibody directed against BCMA and CD3
223622540|NCT06788002|OTHER|Low-dose radiotherapy combine with chemoimmunotherapy|Radiation: 1.4Gy for 5 days to the liver metastasis before chemoimmunotherapy. Chemoimmunotherapy: gemcitabine(1000mg per square meter on days 1,8) , cisplatin (80mg per square meter on day 1), penpulimab (200mg, day1)
223622553|NCT07088406|BEHAVIORAL|Physical Activity Promotion|The Conmigo Physical Activity intervention involves the delivery of ten weekly sessions led by YMCA Facilitators supported by Drs. Arredondo and Ayala, Project Manager and student research assistants. Mothers and daughters (8-11 years old) will be invited to participate in ten in-person 2-hour sessions on topics such as PA parenting, communication, goal setting, etc. Mothers and daughters participate together in most activities, with small group breakouts where just mothers or just daughters have separate activities during some sessions. Each session includes didactic teaching, skill building (e.g. role plays), interactive discussions, 30 minutes of group PA, and goal-setting/review of previous goals. Overall, the activities are designed to promote increased physical activity and mediators to PA (family communication, parenting strategies, etc.). Each cohort will include 12-15 mother-daughter dyads.
223622554|NCT07088406|BEHAVIORAL|Healthy Eating|The Healthy Eating intervention involves the delivery of 10 sessions by YMCA facilitators supported by Drs. Arredondo and Ayala, the Project Manager, and student research assistants. Mothers and daughters (8-11 years old) will be invited to participate in 10 2-hour in-person sessions that include both large and small group activities. Overall, the activities are designed to promote engagement in dietary behavioral strategies and parenting strategies across contexts and settings to promote fruit, vegetable and fiber consumption. Large and small groups activities include goal setting, implementation planning, homework activities, and focused discussion on mediators (e.g., family communication, parenting strategies) and moderators (e.g. acculturation). Each cohort will include 12-15 mother-daughter dyads.
223622555|NCT06907199|PROCEDURE|Electrofulguration (EF)|Nitrofurantoin (NF) daily antibiotic prophylaxis for 6 months plus Electrofulguration.
223622556|NCT06907199|DRUG|Nitrofurantoin (NF)|Nitrofurantoin (NF) daily antibiotic prophylaxis given daily for 6 months.
223622557|NCT06318273|DRUG|ABBV-969|Intravenous (IV) Infusion
223622558|NCT07090226|OTHER|Spatial-frequency domain imaging (SFDI)|SFDI is a method using near-infrared (NIR) light to generate wide field images (\>10 x 10 cm) of tissue optical properties (absorption and scattering coefficients) at sub-surface depths of 1-10 mm. With SFDI the tissue surface (skin) is illuminated by a rapid sequence of sinusoidal light patterns of varying spatial frequency and at different optical wavelengths. Collected camera images are then processed to yield maps of sub-surface optical properties.
223622559|NCT06797544|DRUG|Levofloxacin 0.5%|"Intralesional levofloxacin (5 mg/ml, 100 ml, Tavanic®, Sanofi, France) will be injected into each lesion based on its size (5 mg/cm2). The infiltration of intralesional dose will be given once weekly for up to 6 weeks. Treatment will be stopped in patients cured before 6 weeks of treatment, and patients were only asked to come for lesion assessment. A fine insulin needle will be used to infiltrate the lesion.~The lesion will be thoroughly infiltrated with the drug solution until the base will be completely blanched. Depending on the lesion size, the amount of solution required ranged from 0.2 to 4.0 ml per lesion. No local anesthesia was added. The solutions were injected intralesionally and not subcutaneously."
223622560|NCT06648460|OTHER|Effort-based Decision-Making Task|"Virtual Reality-based multi-stage task in which individuals must explore distinct rooms in a virtual environment that vary in the amount of effort (walking) and reward (points) they receive."
223622561|NCT07093814|DRUG|VRT106|VRT106,intravenous
223622562|NCT06904833|DEVICE|locomotion formats|two different types of popular locomotion methods in golf (i.e., walking 18 holes and using a buggy)
223622563|NCT05606419|DIETARY_SUPPLEMENT|CDED+PEN|Dietary intervention (Liquid food replacement intervention and specific exclusion diet). Focus on 24 hour diet recalls to asses adherence.
223622564|NCT05606419|DIETARY_SUPPLEMENT|CDED+dairy|Dietary intervention (Specific exclusion diet plus early dairy introduction). Focus on 24 hour diet recalls to asses adherence.
223622565|NCT06908824|PROCEDURE|Conventional surgery|Pars plana vitrectomy (PPV) with temporal internal limiting membrane (ILM) flap would be performed. Perfluorocarbon liquid (PFCL) or viscoelastic may be used as an adjunct. Air/Fluid exchange would be performed at the end of surgery, further exchange of air with 8-14% octafluoropropane (C3F8) would be performed based on operating surgeon's discretion. In cases a temporal ILM flap could not be created, an ILM flap would be created from other quadrants, for example, a nasal ILM would be created instead. Patients with visually significant cataract may undergo concomitant phacoemulsification and intraocular lens implantation or deferred to post-operative month 6-12. Patients would be instructed to adopt a face-down posturing in the first 5 days following operation.
223622566|NCT06908824|PROCEDURE|ILM flap with no gas tamponade|Pars plana vitrectomy with temporal internal limiting membrane (ILM) flap would be performed. The ILM flap would be stabilised over the macular hole using perfluorocarbon liquid (PFCL) followed by sub-PFCL dispersive viscoelastic injection. The PFCL would be removed towards the end of surgery. In cases a temporal ILM flap could not be created, an ILM flap would be created from other quadrants, for example, a nasal ILM would be created instead. Concomitant phacoemulsification and intraocular lens implantation would be performed in patients with visually significant cataract or deferred to post-operative month 6-12. Patients will be instructed to avoid excessive movement and adopt a face forward/ supine position for first 24 hours. Afterwards, there would be no restriction on post-operative posturing.
223622567|NCT07092566|DRUG|Ropivacaine HCL|123 mg, intramuscular
223622568|NCT07092566|DRUG|Exparel|100 mL total dose - Intramuscular (IM), intraoperatively
224212091|NCT05068206|DRUG|CapeOX|CapeOX is Capecitabine+Oxaliplatin. Capecitabine is a kind of fluorouracil drug, and Oxaliplatin is a kind of platinum anticancer drug.
224212092|NCT05068206|DRUG|Bevacizumab|Bevacizumab is a recombinant human monoclonal antibody.
223622569|NCT07092566|DRUG|Epinephrine|0.25 mg, intramuscular
223622570|NCT07092566|DRUG|Clonidine HCL|0.04 mg, intramuscular
223622571|NCT07092566|DRUG|Ketorolac|15 mg, intramuscular
223761877|NCT06050564|OTHER|Treatment recommendations will be based on video documented PBS-Score|Therapeutic recommendations from orthopedic surgeons, will be summarized and described
224316324|NCT06346925|DRUG|Herombopag Olamine Tablets|Three Herombopag Olamine Tablets is administered to healthy subjects.
224316325|NCT00366366|BIOLOGICAL|Infanrix-Hexa|
223622572|NCT06905158|DEVICE|White noise device|"* Product name: TinniSoothe white noise-non-invasive tinnitus device~* Usage: Worn around the neck during the daytime and docked to a stand at night~* Duration: At least one-month of use"
223622573|NCT07098338|DRUG|Rilvegostomig|Rilvegostomig will be administered as IV infusion.
223622574|NCT07098338|DRUG|Ramucirumab|Ramucirumab will be administered as IV infusion.
223622575|NCT07098338|DRUG|Dato-DXd|Dato-DXd will be administered as IV infusion.
223622576|NCT07095140|OTHER|Ecological Momentary Assessment|Complete EMAs
223622577|NCT07095140|OTHER|Monitoring|Wear alcohol monitoring wristband
223761878|NCT06274398|DRUG|TAF/EVG rectal insert|Phase 1: rectal inserts applied daily for 3 consecutive days Phase 2: rectal inserts applied every other day for 14 days
223761879|NCT06274398|DRUG|Matching placebo rectal insert|Phase 1: rectal inserts applied daily for 3 consecutive days Phase 2: rectal inserts applied every other day for 14 days
223761880|NCT00645333|DRUG|MK-0752, Docetaxel, Pegfilgrastim|MK-0752 in escalating doses of 300, 450, 600, and 800 mg given orally on days 1-3, followed by docetaxel 80 mg/m2 day 8 and pegfilgrastim 6 mg SQ on day 9
223761881|NCT05365581|DRUG|ASP2138|Intravenously or Subcutaneously
223622578|NCT07095140|DRUG|Nicotine Oral Pouch|Receive ONPs
223622579|NCT07095140|OTHER|Survey Administration|Ancillary studies
223622580|NCT04479683|OTHER|FTH then DH support|"FTH output and DH relay one day a week until the minimum healthy weight. This treatment combines over one day a medical evaluation by a senior psychiatrist, family work (parents group and multi-family therapy session), a therapeutic education group, a cognitive remediation group and a dietary follow-up with therapeutic meals.~During this phase, all children are evaluated once a week on a somatic level."
223622581|NCT04479683|OTHER|standard care|continuation of full-time hospitalization until the minimum healthy weight is reached, defined as the weight corresponding to the return to the previous BMI corridor (previous BMI +/- 1 BMI corridor, e.g. change from 25th to 10th percentile). This management combines bi-weekly medical follow-up by a senior psychiatrist, weekly family work, weekly therapeutic education group, weekly cognitive remediation group and bi-weekly dietary follow-up with therapeutic meals.
223622582|NCT06911320|DRUG|Bemnifosbuvir (BEM)/Ruzasvir (RZR) as a fixed-dose combination|A single dose of BEM/RZR will be administered
223622583|NCT05826223|OTHER|Implementation and evaluation of a sepsis sub-phenotyping algorithm|The algorithm will run silently in the background and continuously compute the subphenotypes of patients who are presenting to the emergency department (ED) with suspected infection.
223622584|NCT06118333|DRUG|BL-B01D1|Administration by intravenous infusion
223622585|NCT06118333|DRUG|capecitabine|Oral administration
223761882|NCT05365581|DRUG|Pembrolizumab|Intravenously
223761883|NCT05365581|DRUG|Oxaliplatin|Intravenously
223761884|NCT05365581|DRUG|Leucovorin|Intravenously
223761885|NCT05365581|DRUG|Fluorouracil|Intravenously
223761886|NCT05365581|DRUG|Ramucirumab|Intravenously
223761887|NCT05365581|DRUG|Paclitaxel|Intravenously
223622586|NCT06118333|DRUG|gemcitabine|Administration by intravenous infusion
223622587|NCT06118333|DRUG|docetaxel|Administration by intravenous infusion
223622588|NCT06821022|OTHER|Pain Neuroscience Education|The intervention group will receive a lecture of 70min duration on pain neuroscience. The objective of this educational session is to educate students that pain can be overprotective, and that nociceptive transmission can be heavily influenced by central sensitisation (sensitivity of the central nervous system) as well as the thoughts and beliefs of the individual. The session used drawings, stories and metaphors to depict the underlying neuroscience of pain, and current pain theory.
223622589|NCT06821022|OTHER|Red Flags Education|The control group received an education session of red flags. Red flags form part of routine subjective practice for therapists as a process of screening serious or potentially sinister pathologies. Sign and symptoms for such pathologies include history of cancer, systemic symptoms such as fever or unexplained weight loss, and saddle analgesia. The red flag session will not include the neuroscience of pain.
223622590|NCT05296070|DRUG|Loncastuximab tesirine 150 µg/Kg|Participants will be treated with loncastuximab tesirine at a dose of 150 µg/Kg given as an intravenous infusion (given as per treatment guidelines for 30 minutes or longer) on Day 1 (+/- 3 days) of each 21 day cycle for Cycle 1 - 2.
223622591|NCT05296070|DRUG|Loncastuximab tesirine 75µg/Kg|Participants will be treated with loncastuximab tesirine at a dose of 75 µg/Kg given as an intravenous infusion (given as per treatment guidelines for 30 minutes or longer) on Day 1 (+/- 3 days) of each 21 day cycle for Cycle 3 - 6.
223761888|NCT05365581|DRUG|Irinotecan|Intravenously
223761889|NCT06058598|OTHER|Exercise Training|6-months supervised exercise training + 6 months unsupervised exercise training
223761890|NCT06058598|OTHER|Lifestyle Counselling|12-months of lifestyle counselling
223761891|NCT00643838|DRUG|Kalinox 170 bar|Flow of gas administrated to the patient between 4 and 15 litre/min and less than 1 hour
223761892|NCT04965792|OTHER|Screening|Blood test
223761893|NCT06700798|DRUG|Orelabrutinib|150mg po
223761894|NCT06700798|DRUG|rituximab|375mg/m\^2, intravenous
223761895|NCT06700798|DRUG|Cyclophosphamide|750mg/m\^2
223761896|NCT06700798|DRUG|Vincristine|1.4mg/m\^2
223761897|NCT06700798|DRUG|Prednisone tablet|60mg/m\^2
223761898|NCT05657470|DRUG|Tenecteplase|intra-arterial tenecteplase
223761899|NCT06846866|DRUG|BMS-986419|Specified dose on specified days
223761900|NCT06846866|DRUG|BMS-986419 Matching Placebo|Specified dose on specified days
223761901|NCT06846866|DRUG|Moxifloxacin|Specified dose on specified days
223761902|NCT06846866|DRUG|Moxifloxacin Matching Placebo|Specified dose on specified days
223761903|NCT06846268|DRUG|ADG126|Administered via intravenous infusion on Day 1 only (Q6W) or Day 1 and Day 22 (Q3W).
223761904|NCT06846268|DRUG|Pembrolizumab|Administered via intravenous infusion on Day 1 and Day 22.
223761905|NCT05100745|DEVICE|Therapeutic Device|This device delivers ultrasound energy to the targeted area of the lower limb.
223761906|NCT04476017|DRUG|SAGE-718|Oral tablets.
223761907|NCT02704364|BIOLOGICAL|NGM282|
223761908|NCT02704364|OTHER|Placebo|
223761909|NCT02975934|DRUG|Rucaparib|Rucaparib will be administered daily.
223622592|NCT06914908|DRUG|lunsekimig|Pharmaceutical form: solution for injection Route of administration: subcutaneous
223622593|NCT06914908|DRUG|Mometasone furoate nasal spray (MFNS)|Pharmaceutical form: Intranasal spray Route of administration: intranasal
223622594|NCT06914596|DEVICE|Emanate Perio PODS|Emanate Perio PODS used overnight for 14 days post-SRP
223622595|NCT06914596|DEVICE|Emanate Perio PODS|Emanate Perio PODS used 2x/day for 30 minutes use
223622596|NCT06806592|DRUG|Nerandomilast|Nerandomilast
223622597|NCT06806592|DRUG|Placebo matching nerandomilast|Placebo matching nerandomilast
223622598|NCT07107256|DRUG|TQC2731 injection|TQC2731 injection is a humanized monoclonal antibody that targets TSLP, blocks the TSLP signaling pathway, inhibits the production of downstream cytokines, and exerts anti-inflammatory effects.
223622599|NCT07107256|DRUG|Placebo of TQC2731|TQC2731 injection is a humanized monoclonal antibody that targets TSLP, blocks the TSLP signaling pathway, inhibits the production of downstream cytokines, and exerts anti-inflammatory effects.
223622600|NCT07020936|DEVICE|Normal Glycemia Goal|Participants will use the normal AIDANET system aggressivity adjustment to achieve target glucose for both the hotel and AIDANET at home periods.
223622601|NCT07020936|DEVICE|Tight Glycemia Goal|Participants will have the AIDANET system controller target set to have higher aggressivity adjustment to maintain target glucose for both the hotel and AIDANET at home periods.
223622602|NCT05603104|DRUG|Clozapine|See arm description
223622603|NCT05603104|DRUG|Esketamine Nasal Product|See arm description
223622604|NCT05603104|DRUG|Escitalopram|See arm description
223622605|NCT05603104|DRUG|Sertraline|See arm description
223622606|NCT05603104|DRUG|Venlafaxine|See arm description
223622607|NCT05603104|DRUG|Lithium|See arm description
223622608|NCT05603104|DRUG|Valproate acid|See arm description
223622609|NCT05603104|DRUG|Quetiapine|See arm description
223622610|NCT05603104|DRUG|Second-line Antidepressants|See arm description
223622611|NCT05603104|DRUG|Second-line Antipsychotics|See arm description
223622612|NCT05603104|DRUG|Ketamine Hydrochloride|See arm description
223622613|NCT05603104|DRUG|Esketamine hydrochloride|See arm description
223622614|NCT05603104|DRUG|Bupropion|See arm description
223622615|NCT06638307|DRUG|MEN2312|MEN2312 administered as oral tablets.
223622616|NCT06638307|DRUG|Elacestrant|Elacestrant administered as oral tablets.
223622621|NCT06920199|BIOLOGICAL|Donor-derived Treg cell injection combined with interleukin 2|Subjects received Treg cell infusion at day D0, and interleukin 2 was administered subcutaneously daily from 1 week before to 12 weeks after infusion.
223622622|NCT01403623|PROCEDURE|Resuscitation and post resuscitation care with plastic bag|Infant will be resuscitated and placed in a plastic bag up to his/her neck and around the back of his head (not covering the face) in the delivery room and taken to the nursery. The infant will remain in the plastic bag until first axillary temperature remains stable at 36.5-37.5 degrees Celsius. Expected length of time approximately one hour.
223622623|NCT01403623|PROCEDURE|Resuscitation- no plastic bag for temperature regulation|Infant will be resuscitated in the delivery room and taken to the nursery. The infant will be observed per unit standard until first axillary temperature remains stable at 36.5-37.5 degrees Celsius. Expected length of time approximately one hour.
223622624|NCT05063565|DEVICE|TheraSphere Y-90 glass microsphere therapy|TheraSphere Y-90 glass microsphere therapy administered through the hepatic artery at index procedure.
223622625|NCT05063565|DRUG|Durvalumab (Imfinzi) immunotherapy|"1500 mg, every 4 weeks that continues for a maximum duration of 18 months or until confirmed progression (by site assessment), unacceptable toxicity, study withdrawal, or study early termination by the sponsor. Treatment beyond confirmed radiographic progression is permitted per patient consent if the following criteria are met:~* Absence of clinical symptoms or signs indicating clinically significant disease progression~* No decline in performance status~* Absence of rapid disease progression or threat to vital organs or critical anatomical sites (i.e. new CNS metastasis, respiratory failure due to tumor compression, spinal cord compression) requiring urgent alternative medical intervention~* No other treatment discontinuation criteria are met"
223622626|NCT05063565|DRUG|Tremelimumab immunotherapy|300 mg, single administration
223622627|NCT07115875|OTHER|Digital Outreach|Digital outreach interventions through focus groups. The study is based on narrative interventions that highlights culturally sensitive and values among Native American communities.
223622628|NCT07115875|OTHER|In Person consultation|In-Person Consultation will receive standard of care at IHS Lawton Hospital. Consultation includes a colonoscopy risk assessment (i.e., current medication use, risk of perforation and bleeding, ability to complete bowel prep).
223622629|NCT06062238|BIOLOGICAL|M72/AS01E-4 Mycobacterium tuberculosis investigational vaccine|Participants will receive an intramuscular dose of M72 (recombinant fusion protein) reconstituted with AS01E-4 (an adjuvant system), on Day 1 and Day 29.
223622630|NCT06062238|BIOLOGICAL|Placebo|Participants will receive an intramuscular dose of normal saline (0.9 percent \[%\] sodium chloride \[NaCl\]), on Day 1 and Day 29.
223622631|NCT06924606|DRUG|JS207 injection +docetaxel|Patients receive JS207 10mg/kg or other dosage and docetaxel 75mg/m2, q3w.
223622632|NCT06924606|DRUG|JS207 injection +JS004 injection|Patients receive JS207 10mg/kg or other dosage and JS004 200mg, q3w.
223622633|NCT06924606|DRUG|JS207 injection|Patients receive JS207 10mg/kg or other dosage.
223622634|NCT06918067|DEVICE|Coloplast Micro Zone Luja Female Catheter|clean self-catheterization with 14 Fr Coloplast micro zone Luja female urinary catheter
223622635|NCT06918067|DEVICE|Coloplast SpeediCath Female Catheter|clean self-catheterization with 14 Fr two eyelet Coloplast SpeediCath female urinary catheter
223622636|NCT07114614|OTHER|Specimen #1|Specimen 1 will be collected in a 10 ml SST (serum separator tube).
223622637|NCT07114614|OTHER|Specimen #2|Specimen #2 will be collected in a 10 ml SST (serum separator tube)
223761910|NCT02975934|DRUG|Abiraterone acetate or Enzalutamide or Docetaxel|Abiraterone acetate and enzalutamide will be administered daily. Docetaxel will be administered every 3 weeks.
224212093|NCT04406883|DRUG|Extraction + filled with Simvastatin solution impregnated gelatin sponge|All two first premolars were extracted carefully, have used periotome as a means of atraumatic extraction that facilitated the removal of teeth with minimum damage to the surrounding alveolar bone, teeth to be extracted should have minimum periapical changes radiographically; with decreasing soft tissue reflection; the socket was tan gently irrigated with normal saline and hemostasis was achieved. It must be noted that A group (Extraction + filled with Simvastatin (Poursina Pharmaceutical Co. Tehran-Iran) solution impregnated gelatin sponge (Maquira Industry Dental Products S.A. Brazil) and B group (Extraction + without Simvastatin solution impregnated gelatin sponge), was placed in one of the sockets.
224212094|NCT02851953|DEVICE|Aqueduct-100|
224212095|NCT04388527|BIOLOGICAL|COVID-19 Convalescent Plasma|Participants will receive 2 units of convalescent plasma collected from ABO-compatible donors who have recovered from COVID-19.
224212096|NCT03980860|OTHER|Exercise Type|The implementation of 2 types of exercise programs to reduce body fat
224212097|NCT02966574|DEVICE|whole body MRI|The examination will be conducted in the pretreatment assessment of breast cancers with a high metastasis risk and in the monitoring of metastatic breast cancers. The examination is performed without intravenous injection of contrast medium, from the top of the skull to mid-thigh using diffusion weighted sequences in the axial plane, T1-weighted sequences in the coronal plane, STIR T2 weighted sequences in the coronal plane and T1-weighted sequences in the sagittal plane on the spine. Total examination duration is one hour. The interpretation of the results is made by two independent reporters with a complementary expertise, according to a systematic lecture grid.
224212098|NCT01153022|OTHER|joint mobilization techniques|In the experimental group, ankle joint mobilization was applied for five minutes, using grade II joint traction rhythmic oscillation (Mailland Scale) with the knee in 15° of flexion, subtalar in neutral and ankle in resting position (10º plantarflexion). During the control study, participants were placed under the same conditions as those of the experimental group but only the hands of the evaluator were placed in the foot, in the position of joint traction simulation.
224212099|NCT01692431|DIETARY_SUPPLEMENT|EPA|High fat meal containing EPA
224212100|NCT01692431|DIETARY_SUPPLEMENT|DHA|High fat meal containing DHA
224212101|NCT01692431|DIETARY_SUPPLEMENT|Placebo|High fat meal containing negligible EPA/DHA content
223622638|NCT07118371|OTHER|Clamshell exercise|The clamshell starts with lying on the side, with legs stacked and knees bent at a 45-degree angle. Rest the head on the lower arm and use the top arm to steady the frame. Hipbones are stacked on top of one another, as there is a tendency for the top hip to rock backward. Engage the abdominals by pulling your belly button in, as this will help to stabilize the spine and pelvis. Keeping the feet touching, raise the upper knee as high as they can without shifting the hips or pelvis. They don't move their lower leg off the floor. Pause, and then return the upper leg to the starting position on the ground. 20 reps will be done on each side. Each exercise will be performed in 3 sets of 10 repetitions with 1 minute of rest after every exercise set.
223622639|NCT07118371|OTHER|Frog pump exercises|"The Frog pump exercise will start with lying on your back, arms by sides, palms facing down. Alternatively, make fists with your hands, rest the elbows on the floor, and lift the fists so that your forearms are perpendicular to the floor. Then bend the knees and press the soles of the feet together so that the legs create a frog legs or butterfly shape. Pressing the outer edges of the feet against the floor, engage the core, and use the glutes to lift the hips. Make sure the shoulders and upper back remain anchored to the floor. Pause, then slowly lower the hips to the floor. . 20 reps will be done on each side. Each exercise will be performed in 3 sets of 10 repetitions with 1 minute of rest after every exercise set."
223622640|NCT06925555|DRUG|BV+R-CHP|Brentuximab Vedotin, 1.8mg/kg/dose, d0、Rituximab, 375 mg/m2, d0、Cyclophosphamide, 750 mg/m2, d1、Doxorubicin, 50 mg/m2, d1、Prednisone, 60mg/m2, d1-5
223622641|NCT07123298|BEHAVIORAL|CAPABLE Care + Connect - Open Label Pilot|As in CAPABLE, the delivery characteristics of CAPABLE Care + Connect consist of an assessment-driven, individually tailored package of interventions delivered over the course of 4 months by an occupational therapist (OT) (\~6 home visits for ≤ 1hour), a registered nurse (RN) (\~4 home visits for ≤ 1hour) and a handy worker (HW). Adaptations targeting those in JHOME will be made on a per-client basis as part of the open-label pilot. The investigators will further refine and develop the intervention by receiving feedback from the open label pilot participants and CAPABLE clinicians who implemented the pilot to gain those perspectives of the acceptability and feasibility of implementing the CAPABLE Care + Connect intervention. Based on this feedback, the study team will have developed an adapted iteration of the prototype.
223622642|NCT07123298|BEHAVIORAL|CAPABLE Care + Connect - Pilot|As in CAPABLE, the delivery characteristics of CAPABLE Care + Connect consist of an assessment-driven, individually tailored package of interventions delivered over the course of 4 months by an occupational therapist (OT) (\~6 home visits for ≤ 1hour), a registered nurse (RN) (\~4 home visits for ≤ 1hour) and a handy worker (HW). Refinements based on the open label pilot results will be included.
223761911|NCT02684292|BIOLOGICAL|pembrolizumab|IV infusion
223761912|NCT02684292|BIOLOGICAL|brentuximab vedotin|IV infusion
223761913|NCT03770156|BEHAVIORAL|Questionnaires|Overall Impression of the current state and evolution since the attacks
223761914|NCT03362502|GENETIC|PF-06939926|"Recombinant adeno-associated virus, serotype 9 (AAV9) carrying a truncated human dystrophin gene (mini-dystrophin) under the control of a muscle-specific promoter.~Subjects will receive a single intravenous infusion of one of 2 dose levels."
224212102|NCT02827422|OTHER|not provided|
224212103|NCT04977817|DIETARY_SUPPLEMENT|Similac Probiotic Tri-Blend|Probiotic dietary supplement, Similac Probiotic Tri-Blend
224212104|NCT02820935|DRUG|CC-220|
224212105|NCT02820935|DRUG|Rifampin|
224212106|NCT02820935|DRUG|Itraconazole|
224212107|NCT05764902|BEHAVIORAL|Patient-tailored intervention|The intervention group will receive various tailored interventions designed to address multiple patient preferences, including sleeping, eating, and resting habits, hobbies, visitation preferences, religious and spiritual needs, preferences for independence and privacy, and any other specific requests or requirements.
224212108|NCT06232369|DEVICE|Active repetitive deep transcranial magnetic stimulation (dTMS)|"Before the intervention, the brain structure of each participant will be captured using an MRI scanner, and individualized spatial coordinates of the hypothesized target will be determined based on these 3D structural images. Then the resting motor threshold will be tested using the method of thumb twitching observation.~The intervention will employ the H7 coil that is accurately delivered to the intended target by an optic navigation and a deep pulse protocol at 90% of the tested threshold for 15-minute stimulation duration."
223622643|NCT07125209|OTHER|Patient Reported Outcomes Assessment|Functional Assessment of Cancer Therapy - Ovarian (FACT-O) and Functional Assessment of Cancer Therapy-Cognitive Function (FACT-Cog) will be used to assess patient reported outcomes.
223622644|NCT07125209|OTHER|Cognitive and General Health Assessments|"* Rey Verbal Learning Test~* Trail Making Test~* Patient Health Questionnaire (PHQ-2)~* Mini Mental State Exam (MMSE)~* Controlled Oral Word Association Test of the Multilingual Aphasia Examination"
223622645|NCT07129694|DEVICE|Anterior cruciate ligament reconstruction|Single-bundle anterior cruciate ligament reconstruction will be performed using the test device. In addition, single-bundle anterior cruciate ligament reconstruction will also be performed in the control group using autologous knee flexor tendons.
223622646|NCT07129694|PROCEDURE|Anterior cruciate ligament reconstruction|Single-bundle anterior cruciate ligament reconstruction will be performed using the test device. In addition, single-bundle anterior cruciate ligament reconstruction will also be performed in the control group using autologous knee flexor tendons.
223622647|NCT07137247|PROCEDURE|Venipuncture|"For adults (including those who are 18 years old): During the routine follow-up visits, an extra 30 milliliters of peripheral blood will be drawn.~For minors (under 18 years old): During the routine follow-up visits, an extra 6 milliliters of peripheral blood will be drawn.~Follow-ups will be conducted every six months, with a minimum of six visit points."
223622648|NCT06938620|OTHER|Bottle with a flow restrictor|Flow restrictors added to liquid medicine bottles to determine whether they limit accessibility of liquid bottle contents to young children compared with control bottles without flow restrictors.
223761915|NCT06283446|BEHAVIORAL|High-Intensity Cue|Participants in the high-intensity group will receive high-intensity image cues that represent self-reported events they did on the previous day and self-reported events they look forward to in the future.
224212109|NCT06232369|DEVICE|Sham repetitive deep transcranial magnetic stimulation (dTMS)|"Before the intervention, the brain structure of each participant will be captured using an MRI scanner, and individualized spatial coordinates of the hypothesized target will be determined based on these 3D structural images. Then the resting motor threshold will be tested using the method of thumb twitching observation.~The intervention will employ the H7 coil that is placed on the scalp to mimic the sensation and sounds of the actual treatment but without letting the magnetic field reach the brain tissue for 15-minute duration."
224212110|NCT02344914|DEVICE|receive Laboraide|"After giving consent, randomization will be carried out using sealed envelopes. After randomization women will be offered to withdraw consent. Women assigned to the study group will receive a sealed Laboraide™ package.~Labor follow up will be documented regularly including outcome. The use of the DSD will not affect the regular management of labor according to the routine standards of the delivery suite. Following delivery, patients will be asked to complete a satisfaction questionnaire."
224212111|NCT01046721|DRUG|Exenatide|single dose of 5 microg Exenatide. Subcutaneous administration
224212112|NCT01046721|DRUG|Saline|subcutaneous administration of 0.9% saline solution (0.02 ml)
224212113|NCT01368679|PROCEDURE|Endoprothesis Implantation|stent implantation in the abdominal artery using endovascular
224212114|NCT00106379|DRUG|Truvada (tenofovir DF + emtricitabine)|
224212115|NCT00106379|DRUG|Emtriva (emtricitabine)|
224212116|NCT00106379|DRUG|Viread (tenofovir DF)|
224212117|NCT02229487|OTHER|Oral glucose tolerance|
224212118|NCT00858559|DEVICE|Implantable cardioverter defibrillator with Home Monitoring function|Implantable cardioverter defibrillators can send data from its diagnostic and therapy memory via wireless Home Monitoring on a daily basis to an internet based platform, securely accessed by the attending physician
224212119|NCT00858559|DEVICE|Standard implantable cardioverter defibrillator|Implantable cardioverter defibrillators used as standard devices without Home Monitoring
224212120|NCT02018042|DRUG|Abatacept|"After the screening period, subjects will begin weekly self-administered subcutaneous abatacept and will continue treatment for 6 months. Patients will be instructed in self-administration of study medication at baseline (week zero) and will be observed self-administering medication at each visit. Instructions regarding study drug administration will be reinforced as needed.~The 6-month treatment period is expected to provide adequate time to assess the short-term efficacy and safety of abatacept in patients with moderate to severe AAP. Responders will then be followed for 6 months off drug."
224212121|NCT06237699|OTHER|Digital ICU diary|A digital ICU diary is an electronic platform or application designed to facilitate the documentation and communication of the experiences, progress, and medical journey of patients in the Intensive Care Unit (ICU).
224212122|NCT02258607|DRUG|Momelotinib (MMB)|Momelotinib (MMB) tablet(s) administered orally once or twice daily
224212123|NCT02258607|DRUG|Trametinib|Trametinib tablet administered orally once daily
224212124|NCT03151785|OTHER|Face-to-face BLS training|Pupils will receive CPR training by standardised face-to-face BLS training only
224212125|NCT03151785|OTHER|Lifesaver training|Pupils will receive CPR training by Lifesaver programme only
224212126|NCT03151785|OTHER|Lifesaver and Face-to-Face BLS training|Pupils will receive CPR training by Lifesaver and standardised face-to-face BLS training
224212127|NCT04456985|DIETARY_SUPPLEMENT|Folic acid and vitamin B12|Take folic acid and VitB12 for 3 consecutive days before surgery
223622649|NCT06938620|OTHER|Control bottle|Traditional bottle either no cap or an incompletely-closed child-resistant cap
223622650|NCT06937424|OTHER|Dry cotton pellet group|The contaminated dentine surface was scrubbed with a dry cotton pellet until no visible sealer remnants were observed
223622651|NCT06937424|OTHER|Ethanol-saturated cotton pellet 7 seconds group|The contaminated dentine surface was scrubbed with a 70% ethanol-saturated cotton pellet for 7 seconds
223622652|NCT06937424|OTHER|Ethanol-saturated cotton pellet visibly clean group|The contaminated dentine surface was scrubbed with a 70% ethanol-saturated cotton pellet until no visible sealer remnants were observed.
223622653|NCT06937424|DEVICE|Ethanol-saturated cotton Pellet + air polishing group|After the contaminated dentine surface scrubbing with an 70% ethanol-saturated cotton pellet until no visible sealer remnants were observed, air polishing was performed for 10 seconds using the AquaCare Twin device (Velopex, UK). Sodium bicarbonate powder (Velopex) was applied at a pressure of 2 bar, with a medium media flow and 17.5% ethanol-saturated solution (AquaSol, Velopex). The standard tip was positioned approximately 5 mm from the dentin surface and moved in a vertical (up-and-down) direction during the procedure. The application time and parameters were determined in consultation with the manufacturer due to the lack of previous clinical studies using the AquaCare device for this purpose.
223622654|NCT06937424|OTHER|Microbrush 7 sec group|The contaminated dentine surface was scrubbed with a 70% ethanol-saturated microbrush for 7 seconds
223622655|NCT06937424|OTHER|Microbrush visibly clean group|The contaminated dentine surface was scrubbed with a 70% ethanol-saturated microbrush until no visible sealer remnants were observed.
223622656|NCT06937424|DEVICE|Air abrasion group|Air abrasion was performed for 10 seconds using the AquaCare Twin device (Velopex, UK). Aluminium oxide particles (53 µm, Velopex) were applied at a pressure of 2 bar, with a medium media flow and 17.5% ethanol-saturated solution (AquaSol, Velopex). The standard tip was positioned approximately 5 mm from the dentin surface and moved in a vertical (up-and-down) direction during the procedure. The application time and parameters were determined in consultation with the manufacturer due to the lack of previous clinical studies using the AquaCare device for this purpose.
223622657|NCT06938217|DEVICE|Low-flow ECMO|low-flow ECMO, defined as 1-2.5 L of blood flow/min.
223622658|NCT06937112|OTHER|PET-CT examination|Intravenous injection of 18F-FAPI-YQ104 for PET-CT examination
223622659|NCT06938737|BEHAVIORAL|laughter yoga|Laughter yoga sessions begin with gentle warm-up techniques that include stretching and flexing movements, songs, applause and body movements. These techniques aim to break down any inhibitions against laughter and develop childlike playfulness. Breathing exercises prepare the lungs for laughter and are combined with a series of laughter exercises that follow.
223622660|NCT06938659|DRUG|Emicizumab Injection|Emicizumab 0.8-1.5mg/kg weekly for 4 weeks as loading dose. Then 0.8-1.5mg/kg 4-weekly for 24 weeks will be used in Emicizumab group-I and Emicizumab Group- WI
223622661|NCT06938659|DRUG|Factor VIII (FVIII)|10-15 unit/Kg thrice weekly (for conventional half-life products) or twice weekly (for extended half-life products) for 28 weeks. Inj. Factor VIII is available in 250U, 500U, 750U \& 1,000 IU vail sizes. Dose will be round up to full nearest full vail strength.
223622662|NCT06937632|BEHAVIORAL|sleep hygiene intervention|sleep program was done three times a week for 2 weeks for the study group (6 sessions in total). It took roughly 30 minutes for each session. sessions were demonstrated during the first 3 sessions, re-demonstration of all the 3 of other sessions. Over a course of two sessions, the older adults in the intervention group were taught how to perform sleep program. The telephone number of each subject was taken to check their consistency with the proposed nursing interventions.
223622663|NCT06938243|DEVICE|Vagus Nerve Stimulation in early stage|Device implantation was done under general anaesthesia. A horizontal neck crease incision was created left of the midline at the level of the cricoid cartilage. After the vagus nerve was identified, the stimulation lead was wrapped around the vagus nerve. The lead was then tunnelled subcutaneously to the pulse generator device which was contained in a subcutaneous pocket in the pectoral region.
223622664|NCT06938243|DEVICE|Vagus Nerve Stimulation in late stage|Device implantation was done under general anaesthesia. A horizontal neck crease incision was created left of the midline at the level of the cricoid cartilage. After the vagus nerve was identified, the stimulation lead was wrapped around the vagus nerve. The lead was then tunnelled subcutaneously to the pulse generator device which was contained in a subcutaneous pocket in the pectoral region
223622665|NCT06938893|OTHER|Exercise|Cardiac output (CO) was measured after exercise intervention in patients with normal cardiac function
223622666|NCT06937268|DIAGNOSTIC_TEST|DOTATATE-PET scan|DOTATATE tracer PET scan for meningioma
223622667|NCT06937606|BEHAVIORAL|Self-compassion training|Online group intervention: led by a certified mindfulness teacher for mindful self-compassion and additional qualification in self-compassion in healthcare communities (duration: 6 weekly appointments of 90 min each);
223622668|NCT06938750|DEVICE|SECHOLD DEVICE|PLACEMENT OF A MULTIPLE THERAPY GRIPPING DEVICE TO FIX THE DRIPPER SYSTEMS ALONG ITS PATH TO SOME SURFACE OR SPACE, AVOIDING IT TO REMAIN IN THE AIR, WITHOUT MARKING OR LABELING AND FAVORING ITS ORGANIZATION. SECHOLD is a vascular access fixation device designed for critical clinical environments such as ICU and operating rooms. It allows the simultaneous connection of 3-6 parenteral therapies to the same vascular access, ensuring clear and protocolized identification of each drug by means of labels with name, concentration and infusion range, in addition to a universal color code. This reduces the risk of drug administration errors and facilitates optimal visualization of essential information. SECHOLD also organizes infusion systems connected to the same vascular access, preventing knots and pulls that can compromise catheter integrity in case of accidental infusion bag drops.
223622669|NCT06938880|BIOLOGICAL|ZGGS18 for Injection|Intravenous infusion
223622670|NCT06938880|BIOLOGICAL|ZG005 for Injection|Intravenous infusion
223622671|NCT06939218|BEHAVIORAL|Countermovement Jump (CMJ)|Participants perform a vertical jump starting from a standing position, bending their knees to 90 degrees, and then jumping as high as possible. The height of the jump is measured using a laser measurement tool (OptoJump-Microgate, Optojump, Bolzano, Italy).
223622672|NCT06939218|BEHAVIORAL|Repeated Jump Test|Participants perform repeated vertical jumps for 20 seconds, with the height of each jump measured using a laser measurement tool (OptoJump-Microgate, Optojump, Bolzano, Italy).
223622673|NCT06939218|BEHAVIORAL|Repeated Sprint Ability (RSA) Test|articipants perform six 30-meter sprints with 20 seconds of rest between each sprint. Sprint times are measured using photocell timing gates (RaceTime, Microgate, Bolzano, Italy).
223761916|NCT06283446|BEHAVIORAL|Low-Intensity Cue|Participants in the low-intensity group will receive low-intensity image cues that represent self-reported events they did on the previous day and self-reported events they look forward to in the future.
223761917|NCT02075840|DRUG|Alectinib|Participants will receive alectinib 600 mg orally (four 150 mg capsules) BID from Visit 0 (baseline) until disease progression, unacceptable toxicity, withdrawal of consent or death.
223761918|NCT02075840|DRUG|Crizotinib|Participants will receive crizotinib 250 mg capsules orally BID from Visit 0 (baseline) until disease progression, unacceptable toxicity, withdrawal of consent or death.
224212128|NCT04456985|DIETARY_SUPPLEMENT|brown sugar aqueous|take 20 ml of brown sugar aqueous solution with the same concentration as the intervention group 3 days before the operation
224212129|NCT04276285|PROCEDURE|Laparoscopic TAP|Subcostal TAP block will be performed after surgery under laparoscopic guidance
224212130|NCT04276285|PROCEDURE|US TAP|Subcostal TAP block will be performed after surgery under US guidance
224212131|NCT04835415|PROCEDURE|Bilateral retrolaminar block|in lateral position and after skin sterilization. The spine is palpated from cervical (C7) downward toT7 and point marked to identify the spinous process. The linear high frequency transducer (6-13 MHz) will be placed parasagittal plane 1 cm lateral to the midline. The needle (18 gauge) is inserted in the plane view of the ultrasound probe to target the T7 and needle is advanced from downward to upward until the needle tip contacted the lamina. After negative aspiration, a 20 ml of bupivacaine 0.25 % plus 5ug/ml adrenaline (1:200000) will be injected. The procedure will be repeated following the same steps on the other side.
224212132|NCT04835415|PROCEDURE|Thoracic epidural analgesia|In the lateral position, after skin sterilization, Ultrasound with high frequency linear probe (5-13 MHz). Thoracic intervertebral space (T7-8) will be identified by counting from the C7 to prominent thoracic spine (T7). The probe will be used in parasagittal plane 2 cm from midline. The probe will be directed medially to identify the dura matter at the T7-8 intervertebral space . the needle 18 gauage will be inserted in plane to target T7-8 intervertebral space ., after needle tip reached target space, loss of resistance technique then 20 ml bupivacaine 0.25% plus 5ug/ml adrenaline (1:200000) was injected after aspiration
223622674|NCT06939218|BEHAVIORAL|Maximum Sprint Test|Participants perform three maximum effort sprints over 40 meters. Sprint times and speeds are measured using 1080 motion analysis
223622675|NCT06939218|BEHAVIORAL|Change of Direction (COD) Test|Participants perform a sprint with a change of direction, running 5 meters in one direction and then 5 meters at a 90-degree angle. The time to complete the test is measured.
223622676|NCT06939218|BEHAVIORAL|Shooting Test|Participants perform a shooting test, aiming to hit a target with maximum speed. The speed of the shot is measured using radar.
223622677|NCT06939218|BEHAVIORAL|Small side game test|Participants engage in a 5v5 small-sided game on a 600 m² field to simulate match conditions and assess performance in a game-like scenario.
224212133|NCT05107154|BEHAVIORAL|Dialectical Behavioural Therapy|DBT skills training is organized into 5 specific modules designed to support skills needed to control emotional reactivity, including: Mindfulness, Distress Tolerance, Walking the Middle Path (a family-based module developed by our co-investigators specifically for teens), Emotion Regulation, and Interpersonal Effectiveness.
224212134|NCT03412461|OTHER|Thought Spot|Thought Spot is a mobile app and website. This digital platform was designed and produced in partnership with transition aged youth in post-secondary education. The platform maps out wellness and mental health services across the Greater Toronto Area.
224316326|NCT06198166|OTHER|Cuevas Medek|Group A: will receive Cuevas Medek (CME) In a following procedure: supporting the patient in balance at the leg level and with slight posterior support. Then, once kept in the air for few seconds, slight up and down oscillations will make. The materials that will be used consists of three wooden boxes with the same dimensions (20cm x 40cm x 60cm), a bigger box, a wooden plate and two planks with the same dimensions (17cm x 80cm). Boxes
224316327|NCT06198166|OTHER|Standard kinetic programs|Group B: will receive standard kinetic programs consisting of stretching (2 sets 15 repetitions with 5 seconds hold) , passive mobilizations (2 sets of 20 repetitions), orthosis( for 6 hours). These techniques and orthotics devices typically focus on tight muscles, maintain proper foot alignment and to address sensory processing difficulties and promote relaxation. Stretching will focus on the hamstrings and calf muscles tightness.
224316328|NCT00900822|DEVICE|Straumann Bone Ceramic|Granules applied once during surgery
224316329|NCT00900822|DEVICE|BioOss|Granules that are applied once during surgery
224316330|NCT01721317|DRUG|Ezogabine/Retigabine IR|Subjects received drug (dose strength 300 mg to 1200 mg) orally with or without food. The 3 daily doses are to be administered with approximately an 8-hour interval between them.
223622678|NCT06939218|BEHAVIORAL|Performance and Comfort Perception Questionnaire|Participants complete a questionnaire to assess their perception of performance and comfort on the surface, using a Visual Analogue Scale (VAS).
223622679|NCT06939218|BEHAVIORAL|Perceived Exertion Questionnaire|Participants complete a questionnaire to assess their perceived exertion during the tests, using the Borg scale
223622680|NCT06943833|BIOLOGICAL|Volrustomig|IV infusion
223622681|NCT07141238|OTHER|Environmental microplastic exposure|Exposure to environmental microplastics measured by their presence in intestinal tissue, blood, urine, and stool using Raman spectroscopy. This study does not assign any exposure or treatment; it investigates the existing presence of microplastics as an environmental factor of interest.
223622682|NCT06954675|DIETARY_SUPPLEMENT|Exogenous ketone ester|25g Bis-octanoyl-(R)-1,3-butanediol (C8)
223622683|NCT06954402|BEHAVIORAL|Acute Stress Intervention (MAST-based)|This intervention uses the Maastricht Acute Stress Test (MAST) to induce an acute stress response. Participants are exposed to standardized stress tasks while performing laboratory-based assessments of cognitive, emotional, and control aspects of resilience.
224316331|NCT01721317|DRUG|Placebo|Matching placebo will be available
223622684|NCT06954402|BEHAVIORAL|Non-Stress Intervention (NST-based)|In this control intervention, participants complete the same battery of laboratory tasks without exposure to the acute stressor.
223622685|NCT06951217|COMBINATION_PRODUCT|AP01|AP01 will be administered open-label via the eFlow Nebulizer System
224316332|NCT03391414|DRUG|hypertonic bicarbonate|8.4% sodium bicarbonate inhaled
223761919|NCT02178163|OTHER|cytology specimen collection procedure|Correlative studies
223761920|NCT02178163|OTHER|laboratory biomarker analysis|Correlative studies
224316333|NCT03391414|DRUG|sodium chloride|7% sodium chloride inhaled
224316334|NCT01581125|BEHAVIORAL|Sleep:wake 1|Sleep and Wake durations for arm 1
224316335|NCT01581125|BEHAVIORAL|Sleep:wake 2|Sleep and Wake durations for arm2
224316336|NCT05300750|OTHER|Oral fluids|Starting amount of oral fluid after 2 hours post C/s should be 5cm and then increase gradually to be 45-50 cm of oral fluid at 4 hours post C/s and 100 cm each hours later.
224316337|NCT05300750|OTHER|Chewing gum|Chewed free sugar gum for 15 minutes
224316338|NCT03168334|DRUG|IDP-123 Lotion|Tazarotene 0.045% Lotion
224316339|NCT03168334|DRUG|IDP-123 Vehicle Lotion|Vehicle Lotion
224212135|NCT03412461|OTHER|Resource Pamphlet|The resource pamphlet that participants will be given will include information on the mental health and wellness services available at their respective post-secondary institution.
224212136|NCT05741983|PROCEDURE|Microfracture (MFx)|The ankle arthroscopy will be a standard procedure. The lesion will be identified, measured and prepared with curettage and soft tissue shaver. Preparation includes debridement of the unstable cartilage and in case of a chondral defect associated with a bone defect, the subchondral cyst is debrided. After debridement, the defect is classified and the lesion size is measured again.The microfracture will be performed with a microfracture awl. In cases of a chondral defect associated with a bone defect (osteochondral defect) the bone lesion must be treated concomitantly. Portal closure will be with steri-strips. All patients will follow the standard postoperative rehabilitation protocol including post op non-weight bearing and range of motion exercises for 6 weeks.
224212137|NCT05741983|DEVICE|Chondro-Gide®|After the microfracture is performed and before the concomitant treatment of a bony lesion (if present), the defect size will be templated, and the membrane cut into its correct size. The joint is then drained and the membrane will be applied over the defect and stabilised with Fibrin glue. In cases of a osteochondral defect the bone lesion must be treated concomitantly. Once the bone defect has been treated, the Chondro-Gide® membrane is used to cover the site, and to support new cartilage tissue formation at the joint interface. Fluid will be reintroduced, and the stability of the membrane will be confirmed arthroscopically.
223622686|NCT06954597|DRUG|TOP-N53|TOP-N53 solution (IMP) containing 80 µg/ml TOP-N53 is applied topically directly to the digital ulcer of patients with systemic sclerosis. The dose if defined by volume and exposure time of the IMP.
223622687|NCT06954597|DRUG|Sildenafil|Parallel treatment with Sildenafil 20 mg 3-times per day is permitted if patient has been on a stable dose for 2 weeks prior to screening.
223622688|NCT06954597|DRUG|TOP-N53 vehicle|TOP-N53 vehicle solution will be topically applied to digital ulcers of systemic sclerosis patients.
223622689|NCT07150494|DEVICE|Phototherapy|Phototherapy used to decrease high billirubin level in neonatal jaundice
223622690|NCT07156201|DRUG|ABS-1230|ABS-1230
223622691|NCT07156201|DRUG|Placebo|Placebo
224212138|NCT01954082|DRUG|myo-Inositol 5% Injection|"Abbott Nutrition Division, Abbott Laboratories is supplying myo-Inositol 5% Injection to the clinical centers for the duration of the trial.~Inositol: myo-Inositol 5% Injection is an isotonic, preservative-free, sterile 5% solution of myo-inositol in water containing 0.5 gm sodium chloride per liter (8.55mM), pH 6.5-7.5. It is administered via IV infusion using syringe pump over 15-30 minutes twice per day at 12-hour intervals at a dose of 80 mg inositol/kg/day (40 mg inositol/kg/dose), which is equivalent to 1.6 mL/kg/day (0.80 mL/kg/dose)."
224212139|NCT01954082|DRUG|Placebo|% glucose(dextrose)
224212140|NCT03804931|PROCEDURE|Fecal microbiota transplantation|200 mL of prepared fecal microbiota suspension from healthy donors' fresh feces was injected into the intestine
224212141|NCT03804931|PROCEDURE|Infusion of Saline|Infusion of Saline
224212142|NCT03804931|DRUG|5-Aminosalicylic acid(5-ASA) and/or Prednisone|Mesalazine and/or Prednisone
223622692|NCT07156188|OTHER|Permanent Suture|In both control and intervention groups, an open umbilical hernia repair will be performed based on a standardized surgical technique. Dissection and identification of the fascial defect will be performed in a standardized manner. In the control group, a permanent 0-0 polypropylene suture will be used to close the hernia defect in a transverse or vertical interrupted fashion using either the simple interrupted or the figure-of-eight technique. If the surgeon creates an opening in the umbilical skin or extends the skin incision beyond the paraumbilical incision during the procedure, the participant will be excluded from the study.
223622693|NCT07156188|OTHER|Absorbable|In both control and intervention groups, an open umbilical hernia repair will be performed based on a standardized surgical technique. Dissection and identification of the fascial defect will be performed. An 0-0 polydioxanone suture (PDS) will be used to close the hernia defect in either a transverse or vertical interrupted fashion using either simple interrupted or figure-of-eight technique. If the surgeon creates an opening in the umbilical skin or extends the skin incision beyond the paraumbilical incision during the procedure, the participant will be excluded from the study.
223622694|NCT02797158|PROCEDURE|TAVI procedure|Targeted and selected revascularization guided on myocardial ischemia detection after the TAVI procedure by using single photon emission computed tomography (SPECT) myocardial perfusion imaging.
224212143|NCT04629131|BIOLOGICAL|TNM002 Dosage 1 (10 μg/kg)|TNM002 (human monoclonal antibody against tetanus toxin), 10 μg/kg, Intramuscular injection, given once.
224212144|NCT04629131|BIOLOGICAL|Placebo|placebo to match TNM002 Dosage 1, given once
224212145|NCT04629131|BIOLOGICAL|TNM002 Dosage 2 (35 μg/kg)|TNM002 (human monoclonal antibody against tetanus toxin), 35 μg/kg, Intramuscular injection, given once
224212146|NCT04629131|BIOLOGICAL|Placebo|placebo to match TNM002 Dosage 2, given once
224212147|NCT04629131|BIOLOGICAL|TNM002 Dosage 3 (100 μg/kg)|TNM002 (human monoclonal antibody against tetanus toxin), 100 μg/kg, Intramuscular injection, given once
224212148|NCT04629131|BIOLOGICAL|Placebo|placebo to match TNM002 Dosage 3, given once
224212149|NCT04629131|BIOLOGICAL|TNM002 Dosage 4 (250 μg/kg)|TNM002 (human monoclonal antibody against tetanus toxin), 250 μg/kg, Intramuscular injection, given once
224212150|NCT04629131|BIOLOGICAL|Placebo|placebo to match TNM002 Dosage 4, given once
223622695|NCT07160972|OTHER|Lifestyle Management|Participants will use the X Life model via AR glasses or mobile terminal (smartphone/tablet) for 7 days. The system provides personalized dietary and exercise recommendations at dynamic trigger points (before/after meals, before/after exercise, before bedtime) using baseline clinical data, real-time CGM readings, dietary images, activity data, and wearable monitoring (activity, sleep, heart rate). Standard care guidance will also be provided in accordance with national dietary and physical activity guidelines.
223761921|NCT05452993|DEVICE|Analysed Retinophotography|taking 2 retinophotographs per eye, and then analysed by AI software to detect Diabetic retinopathy
223761922|NCT05523765|DRUG|Brepocitinib|Oral Brepocitinib
224212151|NCT05265169|DEVICE|Microwave ablation|Microwave ablation of colorectal liver metastases (CLM)
224212152|NCT03213080|DEVICE|Targeted Lung Denervation (TLD)|Targeted Lung Denervation (TLD) procedure.
224212153|NCT02190344|DEVICE|8-channel paddle coil|MRI Coil
224316340|NCT01778634|DRUG|Azithromycin|Azithromycin intravenous 20 mg/kg every 24 h x 3 days
224316341|NCT01778634|DRUG|Placebo|D5W
223622696|NCT07164053|DEVICE|MyVeo is an all-in-one surgical visualization headset used with compatible surgical microscopes and other medical imaging systems in the area of neurosurgery, ENT, spine, plastic and reconstructive su|"MyVeo is an all-in-one surgical visualization headset used with compatible surgical microscopes (ARveo 8/ARveo 8x) and other medical imaging systems. It is a digital accessory to an operating surgical microscope that enables the visualization of the surgical field through a visualization headset including:~* Display of surgical field illuminated and magnified by the surgical microscope (White Light).~* Display of fluorescence of fluorophores within the indicated excitation and emission ranges, as defined by the respective filters (accessories to the compatible surgical microscopes ARveo 8x such as GLOW400 and GLOW800)."
223622697|NCT07166380|DRUG|RK-4 injection|patients with LHI will take drug RK-4 (1 mg or 2 mg or 4 mg) by transcranial bone marrow injection once daily for consecutive 3 days.
224212154|NCT03077594|DEVICE|Mucosal Impedance|Aim 1: Mucosal impedance will be measured by an endoscopic probe 1 cm above the gastroesophageal junction, 5 cm above the gastroesophageal junction and in the proximal esophagus in an area not exposed to the index therapeutic radiofrequency ablation. Aim 2: Mucosal impedance will be measured 1 cm above gastroesophageal junction, 1 cm below previous squamous columnar junction, 1 cm above previous squamocolumnar junction.
224212155|NCT03077594|OTHER|Research Biopsies|Aim 1: Research biopsies will be obtained at 1 cm above the gastroesophageal junction, 5 cm above the gastroesophageal junction, and in the proximal esophagus in an area not exposed to the index therapeutic radiofrequency ablation. Aim 2: Aim 2: Research biopsies will be taken 1 cm above gastroesophageal junction, 1 cm below previous squamous columnar junction, 1 cm above previous squamocolumnar junction.
224212156|NCT03077594|DEVICE|Volumetric Laser Endomicroscopy|Aim 2: Volumetric laser endomicroscopy will be done and marked at 1 cm above gastroesophageal junction, 1 cm below previous squamous columnar junction, 1 cm above previous squamocolumnar junction.
224212157|NCT06204276|DEVICE|Experimental: Asymmetrical high-flow nasal cannula|Asymmetrical high-flow nasal cannula will be set at 40 and 60 L/min in a random order. Temperature will be set at 37 degree celsius and inspired oxygen fraction (FiO2) will be adjusted to maintain oxygen saturation by pulse oximetry (SpO2) \>/= 94% in acute hypoxemic patients and between 92-94% in acute hypercapnic COPD patients
224212158|NCT06204276|DEVICE|Active comparator: Conventional high-flow nasal cannula|Conventional high-flow nasal cannula will be set at 40 and 60 L/min in a random order. Temperature will be set at 37 degree celsius and FiO2 will be adjusted to maintain SpO2 \>/= 94% in acute hypoxemic patients and between 92-94% in acute hypercapnic COPD patients
224212159|NCT04670029|OTHER|Adapted physical activity|APA sessions during chemotherapy with aerobic and anaerobic sessions on site and at home (+ home exercises book if the patient so wishes)
224212160|NCT05114265|DRUG|KUR-101|Single oral dose of KUR-101
224212161|NCT05114265|DRUG|OxyNorm|Single oral dose of OxyNorm
224212162|NCT05114265|DRUG|Placebo|Single oral dose of placebo
224212163|NCT02299674|OTHER|Level overground ambulation|
224212164|NCT03244397|OTHER|Physical therapy + educational strategy|See arm/group descriptions
224212165|NCT03244397|BEHAVIORAL|Educational strategy|See arm/group descriptions
224212166|NCT03520621|OTHER|No intervention|no intervention
224212167|NCT02454972|DRUG|lurbinectedin (PM01183)|
224212168|NCT00077779|DRUG|Adalimumab|
224212169|NCT01145703|DIETARY_SUPPLEMENT|RDA Vitamin D3 only|800 IU of Vitamin D3 daily for 6 months
224212170|NCT01145703|DIETARY_SUPPLEMENT|Vitamin D2/3 Repletion only|Vitamin D repletion with 50,000 IU of Vitamin D2/3 up to 3 x week(until levels are \>75 nmol/l; 6-12wks) followed by 6 months maintenance supplementation with 2000 IU Vitamin D3 and up to 1000mg Calcium daily
224212171|NCT01145703|OTHER|Vitamin D2/3 Repletion + AEX|Vitamin D repletion with 50,000 IU of Vitamin D2/3 up to 3 x week(until levels are \>75 nmol/l; 6-12wks) followed by 6 months maintenance supplementation with 2000 IU Vitamin D3 and up to 1000mg Calcium daily plus aerobic exercise training
224212172|NCT01145703|OTHER|Vitamin D2/3 Repletion + RT|Vitamin D repletion with 50,000 IU of Vitamin D2/3 up to 3 x week(until levels are \>75 nmol/l; 6-12wks) followed by 6 months maintenance supplementation with 2000 IU Vitamin D3 and up to 1000mg Calcium daily plus resistance training
224212173|NCT02910310|OTHER|Uterine balloon tamponade|An intervention consisting of inserting a condom attached to a urinary catheter into the uterus and inflating it with fluid to stop postpartum bleeding
224212174|NCT01787214|DIETARY_SUPPLEMENT|Full dose|20% of daily energy needs supplied by walnuts
224212175|NCT01787214|DIETARY_SUPPLEMENT|Half dose|10% of daily energy needs supplied by walnuts
224212176|NCT01787214|DIETARY_SUPPLEMENT|Control|Walnut free meals
224212177|NCT02346981|BEHAVIORAL|Resistance training|Supervised resistance training program was performed on three nonconsecutive days per week at morning period for 12 weeks. The resistance training program included eight exercises in two consecutive sets of 10-15 repetitions until moderate fatigue, except for crunch exercise which was performed on 20 to 30 repetitions without overload. The participants were instructed to perform repetitions at a ratio of 1:2 (concentric and eccentric phases, respectively). Subjects rested for 60- to 90-s between each set and for 2- to 3-min between each exercise. Each subject was individually supervised. Increases of 2-5 % for the upper limb exercises and 5-10 % for the lower limb exercises every time that subjects were able to complete 15 repetitions in both sets.
224212178|NCT02154113|DEVICE|Ultrashape|All subjects receive 3 successive Ultrashape treatments every two weeks in the anterior abdomen.
224212179|NCT02154113|DEVICE|Velashape II|All subjects receive 3 successive Velashape treatments every two weeks in the anterior abdomen.
224212180|NCT01795703|DRUG|Abiraterone|Abiraterone will be administered orally as 1000 milligram (mg) per day for 28-daily dosing cycles which will be continued until disease progression or unacceptable toxicity.
224212181|NCT01795703|DRUG|Prednisolone|Prednisolone will be administered orally as 5 mg tablets twice daily for 28-daily dosing cycle which will be continued until disease progression or unacceptable toxicity.
223622698|NCT07161037|DRUG|VX-407|Tablets for oral administration.
223622699|NCT07168161|DRUG|BDB-001 injection|Intravenously administered
224212182|NCT03165890|DRUG|ACETAZOLAMIDE oral capsule|Administration of 125mg acetazolamide in the morning, 250mg in the evening, starting 24 hours before departure to 3200m
223622700|NCT07168161|DRUG|Cyclophosphamide|Intravenously administered
223622701|NCT07168161|BIOLOGICAL|Rituximab|Intravenously administered
223622702|NCT07168161|DRUG|Azathioprine|Intravenously administered
223761923|NCT03606759|PROCEDURE|Weekly assessment|"Weekly assessment during 3 months :~Severity of addiction (Addiction Severity Index, ASI) Mini International Neuropsychiatric Interview, MINI Craving intensity (BILAN-7 jours) Individual cues of each participant (QSA) Substance use and gambling (BILAN-7 jours)"
224212183|NCT03165890|DRUG|Placebo oral capsule|Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3200m
224212184|NCT03189264|PROCEDURE|percutaneous nephrolithotomy for kidney stones|Use of various methods of access to the renal collecting system (pneumatic balloon dilatation vs. traditional technique with coaxial dilators) during percutaneous nephrolithotomy for treatment of kidney stones greater than 2 cm.
224212185|NCT01377233|DRUG|Zicronapine open-label lead-in 10 mg daily|Encapsulated tablet ,10 mg, once daily, open-label
224212186|NCT01377233|DRUG|Zicronapine 10 mg daily|Encapsulated tablet, 10 mg, once daily, double-blind
224212187|NCT01377233|DRUG|Zicronapine 20 mg once weekly|Encapsulated tablet, 20 mg, once weekly (on day 1 of each 7 day cycle), double-blind
224212188|NCT01377233|DRUG|Zicronapine 30 mg once weekly|Encapsulated tablet, 30 mg, once weekly (on day 1 of each 7 day cycle), double-blind
224316342|NCT01072617|DEVICE|Transcranial magnetic stimulation via MagPro x100 device|"Participants will receive 10 repetitive transcranial magnetic stimulation sessions to the vermis of cerebellum using the MagPro x100 TMS device. These 10 rTMS sessions will be administered from Monday to Friday in five days, twice a day with a minimum of 4-hour gap between the sessions. Repetitive TMS will be applied with the intermittent theta burst pattern (iTBS). These parameters are known to cause excitation in brain activity.~Anatomically precise localization of rTMS will be achieved using a frameless stereotactic system."
223622703|NCT07168161|DRUG|Prednisone|Intravenously administered
223622704|NCT07172412|DRUG|Selinexor|Selinexor 60 mg biw q21d
223622705|NCT07172412|DRUG|Anlotinib|Anlotinib 12mg d1-14 qd PO
223622706|NCT07172412|BIOLOGICAL|DLL3 CAR-NK cells|1.0×10\^9 DLL3-CAR-NK+ cells d5 q6w
223622707|NCT07172412|DRUG|Etoposide + Cisplatin/Carboplatin|Etoposide 100mg/m\^2 d1-3+ cisplatin 75mg/m\^2 d1-3 or Carboplatin AUC5
223622708|NCT07172412|DRUG|Tislelizumab/Atezolizumab/ Durvalumab/Benmelstobart/Toripalimab/Serplulimab|Use immunotherapy according to the standard immunotherapy-combined-chemotherapy protocol.
223622709|NCT07160985|OTHER|AI-based Lifestyle Management|Participants will use the X Life model via smartphone/tablet for 28 days, receiving real-time, personalized dietary and exercise recommendations triggered by CGM and activity tracker data. Participants can interact with the system by uploading meal images, physical activity data, and wearable-derived metrics.
223622710|NCT07160985|OTHER|Lifestyle Management|Participants will receive guideline-based lifestyle counseling according to national prediabetes prevention guidelines, delivered via mobile terminal, without AI-generated recommendations.
223622711|NCT07175987|OTHER|RDTH002581|Participants assigned to this Study Intervention will use the product only in the CLT portion of the study.
223622712|NCT07175987|OTHER|RDTH002580|Participants assigned to this Study Intervention will use the product in the CLT and HUT portions of the study.
223622713|NCT07175987|OTHER|RDTH002582|Participants assigned to this Study Intervention will use the product in the CLT and HUT portions of the study.
223622714|NCT07175987|OTHER|RDTH002578|Participants assigned to this Study Intervention will use the product only in the CLT portion of the study.
223622715|NCT07175987|OTHER|RDTH002577|Participants assigned to this Study Intervention will use the product in the CLT and HUT portions of the study.
223622716|NCT07175987|OTHER|RDTH002579|Participants assigned to this Study Intervention will use the product in the CLT and HUT portions of the study.
223761924|NCT03606759|PROCEDURE|Weekly assessment ajusted|"Weekly assessment during 3 months :~Severity of addiction (Addiction Severity Index, ASI) Mini International Neuropsychiatric Interview, MINI Craving intensity (BILAN-7 jours) Individual cues of each participant (QSA) Substance use and gambling (BILAN-7 jours) Individually Adjusted Therapy scale (ATI)"
224212189|NCT01377233|DRUG|Zicronapine 45 mg once weekly|Encapsulated tablet, 45 mg, once weekly (on day 1 of each 7 day cycle), double-blind
224212190|NCT01774006|OTHER|individual embryo culture or group culture|Embryos cultured in a 25 microliter droplet of culture media individually in a conventional petridish or in groups of 2-10 embryos in a Well-of-the-Well petridish
224212191|NCT02408406|OTHER|Communication Intervention|Use PatientCareAnywhere system
224212192|NCT02408406|OTHER|Educational Intervention|Use PatientCareAnywhere system
224212193|NCT02408406|OTHER|Internet-Based Intervention|Use PatientCareAnywhere system
224212194|NCT02408406|OTHER|Quality-of-Life Assessment|Ancillary studies
224212195|NCT02408406|OTHER|Questionnaire Administration|Ancillary studies
224212196|NCT01843907|BEHAVIORAL|Empowerment|To give patients the necessary resources to take care of their own health
224212197|NCT01843907|OTHER|Conversation with nurse|To find out, if the nurse, using her ....
224212198|NCT03899337|DRUG|Acalabrutinib|100mg capsule, PO, BD
224212199|NCT03899337|DRUG|Cyclophosphamide|750mg/m\^2, IV bolus
224212200|NCT03899337|DRUG|Doxorubicin|50mg/m\^2, IV bolus
224212201|NCT03899337|DRUG|Vincristine|1.4mg/m\^2, IV infusion
224212202|NCT03899337|DRUG|Prednisolone|40mg/m\^2, PO, OD
224212203|NCT03899337|DRUG|Rituximab|375mg/m\^2, IV infusion
224212204|NCT01997528|DEVICE|Change of blood flow or sweep gas flow ( ILA Activve)|
224212205|NCT04597554|DIETARY_SUPPLEMENT|Cranberry|Cranberry beverage and gummies supplement
224212206|NCT04597554|DIETARY_SUPPLEMENT|Placebo|Placebo beverages and gummies supplement
224212207|NCT04905654|DRUG|Levcromakalim|To investigate the role of levcromakalim compared with placebo in migraine with aura patients
224212208|NCT04905654|DRUG|Saline|To investigate the role of levcromakalim compared with placebo in migraine with aura patients
224316343|NCT03944824|OTHER|Exercise Plan using resistance bands|Exercise under the guidance of an exercise physiologist using elastic resistance bands and weekly meeting with an exercise physiologist for 12 weeks
223622717|NCT07179276|PROCEDURE|CO2gap-guided resuscitation strategy|"For patients assigned to the interventional arm, adherence to the algorithm will complement clinical practices in the following areas:~* Blood sampling for venous blood gas analysis. Blood samples will be taken from an existing central venous catheter; central venous access is common clinical practice in critically ill patients.~* The use of dobutamine and blood transfusions in patients showing signs of oxygen deficiency (both will be carried out in accordance with the intended use and conditions of current practice)."
223622718|NCT07167121|DIAGNOSTIC_TEST|CPAx|"Evaluation of :~Respiratory function Cough Moving within the bed Supine to sitting on the edge of the bed Dynamic sitting Standing balance Sit to stand (starting position ≥ 90°) Transfering from bed to chair Stepping Grip strength (predicted mean for age and gender on the strongest hand)"
223622719|NCT07183657|OTHER|Education in inhalation technique|Education in inhalation technique
223622720|NCT07181902|PROCEDURE|Erector Spinae Plane Block (ESP)|Ultrasound-guided ESP block performed immediately after cesarean section at T9 level using 20 mL of 0.25% bupivacaine. Standard perioperative care and analgesia protocols are applied.
223622721|NCT07181902|PROCEDURE|Retrolaminar Block (RLB)|Ultrasound-guided Retrolaminar Block performed immediately after cesarean section at T9 level using 20 mL of 0.25% bupivacaine. Standard perioperative care and analgesia protocols are applied.
223622722|NCT07176104|DIETARY_SUPPLEMENT|Functional Bovine Milk|Functional milk product enriched with standardised bioactive peptides, provided daily for 12 months.
223622723|NCT07176104|DIETARY_SUPPLEMENT|Non-Functional Bovine Milk|Standard bovine milk with identical caloric and macronutrient profile to the functionalized milk, without enrichment, provided daily for 12 months.
223622724|NCT07177287|BEHAVIORAL|IMB navigator app|Mobile application developed based on the IMB model, supported by a navigator nurse. Includes educational content, reminders and behavioral support. Patients will be followed for 6 months.
224212209|NCT06171997|OTHER|Swaddling after bath group|"The babies were bathed in the bathtub. Then swaddling was done. The baby was taken into the incubator and waited for 15 minutes. At the end of 15 minutes, the swaddle was opened quietly and slowly, without disturbing the body posture. Stress and comfort scores were given by two observers by video recording the babies before bathing, before swaddling and after swaddling.~Newborns' stress will be assessed with the Newborn Stress Scale and their comfort with the Newborn Comfort Behavior Scale."
224212210|NCT03310203|DIAGNOSTIC_TEST|Iron|Labelled iron
224212211|NCT01182714|PROCEDURE|immediate removal of in-dwelling catheter|
224212212|NCT01182714|PROCEDURE|24 hours delayed removal of catheter|
223622725|NCT07181499|DRUG|Befotertinib|Befotertinib was administered orally at a starting dose of 75 mg per day for 21 days, which could be increased to 100 mg per day if grade 2 or higher thrombocytopenia or headache did not occur within 21 days, or maintained at the original dose (75 mg per day) if grade 2 or higher thrombocytopenia or headache occurred within 21 days.
223622726|NCT07181499|DRUG|Pemetrexed + Carboplatin|pemetrexed (500 mg/m²) and carboplatin (AUC 5), administered every 3 weeks, for a total of 2\~4 cycles.
223622727|NCT07181837|GENETIC|MVX-220|AAVhu68 viral vector
223622728|NCT07187310|PROCEDURE|EXORA block|in a supine position, a linear Ultrasound probe (L6-12 RS linear array transducer (6-12 MHz) on GE Healthcare Logiq P7, made in Korea) will be sagittally applied at the parasternal line, lateral to the sternum and xiphoid process. The probe will be manipulated craniocaudally to identify the 6th, 7th, and 8th costal cartilages. At the level of the 8th costal cartilage, a transverse orientation will be used to visualize the rectus abdominis muscle and the costal cartilage beneath. An 88-mm, 22-gauge needle will be directed in-plane from medial to lateral. After confirming the needle position below the rectus abdominis muscle using 4 ml isotonic saline as a hydro-dissection, 25 ml of plain bupivacaine 0.25% concentration will be injected. the spread of the local anesthetic is to be observed to advance laterally under the external oblique muscle and medially under the rectus muscle. The same procedure will be repeated on the other side.
223622729|NCT07187310|PROCEDURE|Erector Spinae Plane block|in a right lateral position, the linear Ultrasound probe will be placed vertically 3 cm lateral to the midline at the level of the 7th thoracic spinal process, identifying the T7 transverse process, and the overlying erector spinae (ES) muscle. An 88-mm, 22-gauge needle will be advanced craniocaudally in-plane until hitting the T7 transverse process. After using hydro-dissection with 4 ml of isotonic saline to confirm the correct needle position, 25 ml of 0.25% bupivacaine will be administered below the erector spinae muscle. The same procedure will be repeated on the other side.
224212213|NCT01700920|PROCEDURE|bone marrow aspirate|
223622731|NCT07189130|OTHER|Exercise: 80% 1 RM with 2 minutes break|Participant will do resistance exercise at 80% 1RM with 2 minutes break, 4 sets of each exercise. Included exercises are lat pull, bench press and leg press.
224212214|NCT00301431|DRUG|DVS-233|
224212215|NCT06527820|BEHAVIORAL|Talk About It (conversation aid)|"Talk About It is a conversation aid aimed to increase awareness of options and prompt discussion."
224212216|NCT05245773|OTHER|Automated SMS program to support post-discharge transitions of care|The intervention will consist of automated text messages on a tapering schedule over the course of 30 days post-discharge, with responses escalated back to the practice care management team. After initial enrollment messages, patients will receive check-in messages on a tapering schedule over the course of 30 days. For the first week they will receive 3 total messages; the second week they will receive a total of 2 messages. For the last 2 weeks they will receive weekly messages. If a patient need is identified, the request will be escalated to the practice (triaged by the care management RN) for a follow up phone call. Patients will be able to reach out at any time by sending a message to the same number, and they will be entered into the same pathway. For any escalated need, patients will receive a follow up phone call from the practice staff.
224212217|NCT05785520|DEVICE|ST500 SINGLE-DOSE GEL|ST500 SINGLE-DOSE GEL is a hydrogel to be applied to intact skin, useful to limit the physiological degeneration of the joints and tissues, improving their functionality. The presence of a peptide mixture and sodium hyaluronate facilitates the movement of joints and tendons for greater mobility and flexibility.
224212218|NCT00595426|DRUG|YM150|Oral
224212219|NCT00595426|DRUG|Warfarin|Oral
224212220|NCT05716191|OTHER|Naturally different iodine levels exposure|A cross-sectional survey of thyroid disease in elderly people in areas with different iodine nutrition backgrounds
224212221|NCT05694429|OTHER|Product K cleanser and moisturizer|Product K cleanser and moisturizer contain ingredients that may improve skin hydration and elasticity
224212222|NCT01398592|DRUG|Vildagliptin|50mg vildagliptin bid
223622732|NCT07189130|OTHER|Exercise: 80% 1RM with1 minute break|Participant will do resistance exercise at 80% 1RM with 1 minutes break, 4 sets of each exercise. Included exercises are lat pull, bench press and leg press.
223622733|NCT07189130|OTHER|Exercise: accenuated eccentric exercise|Participant will do accenuated eccentric resistance exercise at 80% 1RM in concetric part of movement and 110% 1RM in eccentric part of movement with 2 minutes break, 4 sets of each exercise. Included exercises are lat pull, bench press and leg press.
223622734|NCT07189130|OTHER|Control|Timeline of events will be same as in exercise protocol (blood withdrawal and Stroop test), except participants will not do any kind of exercise protocol, instead they will be seating.
223622735|NCT07187518|DEVICE|Measurements with the POROUS R4C ultrasound device at the midshaft tibia|The POROUS R4C ultrasound device measures the cortical bone of the midshaft tibia. Ultrasound gel is first applied onto the skin surface, covering the region of interest, followed by placing the ultrasound transducer with a medical ultrasound gel pad placed in front of it. At the marked position on the leg, four technical measurement readings are performed: 2x CortBS and 2x Multifocus, with repositioning the probe between individual measurements, the chronological order of which is not crucial. Scanning time for each measurement takes 1-2 minutes. Out of the four measurements, the two optimal measurements (one for CortBS and one for Multifocus) are selected by the device, based on pre-defined quality criteria.
223622736|NCT07187518|DEVICE|DXA measurement of the hip and lumbar spine|The following DXA measurements are to be performed: • Spine L1-4 • Hip left • Hip right (alternatively, if a valid measurement of the left hip is not possible) Scanning takes approximately 15 minutes. A maximum number of one repeat measurement is planned (e.g., hip or spine). Note: The DXA scan of the hip is performed on the same side of the body as the POROUS R4C ultrasound scan.
223622737|NCT07191288|DEVICE|VR (VR-Breathing+Mystical)|The VR-based slow-paced breathing application is designed to provide rewarding biofeedback for a specific breathing pattern characterized by prolonged exhales. As users extend their exhales, a veil of fog gradually lifts, introducing a mystical type experience. Over time, users are rewarded with a full 360-degree panoramic view of the beautiful nature scene, accompanied by relaxing music. After approximately 5 minutes of prolonged exhales, the nature scene responds to the user's breathing by slowing down, with falling snowflakes moving more slowly, further enhancing the mystical atmosphere. This intervention was designed to be visually captivating, mystically evocative, and emotionally engaging. Duration: 10 minutes.
223622738|NCT07191288|DEVICE|VR (VR-Mystical)|Users will experience the gradual unveiling of a beautiful natural landscape as the fog lifts, and eventually, the scene slows down similar to the VR Breathing+Mystical condition. However, this application does not provide any biofeedback or breathing instructions. Users are invited to passively observe the unfolding experience, immersing themselves in the environment for 10 minutes. Relaxing music accompanies the scene. This condition relies solely on the immersive and aesthetic qualities of the virtual environment to potentially induce relaxation.
223622739|NCT07191288|DEVICE|Computer (Non-VR-Breathing)|In this conventional breathing intervention, participants will be instructed to follow a slow-paced breathing pattern guided by a simple visual cue (an expanding and contracting circle) displayed on a computer screen for 10 minutes. This condition is designed to guide slow-paced breathing without incorporating any rewarding elements.
223622740|NCT07191288|DRUG|VR (VR-Control)|In the control condition, participants will watch a neutral documentary for 10 minutes in VR. This condition is used to control for the effects of the immersive VR experience. It does not include any components related to guided breathing or mystical-type content, or any form of rewarding elements.
223622741|NCT07184281|BEHAVIORAL|12-hour time-restricted eating|Based on the current health education model, the subjects in the experimental group were administered for 12 hours of TRE. Carry out the propaganda and education of the 12-hour TRE feeding mode, the core content is that the eating time window is limited to 12 hours/day, the last meal is no later than 19:00, the study subjects can freely choose the eating time window, do not restrict energy intake during eating, and during the fasting period, they are allowed to drink non-calorie, sugar-free drinks (water, tea, coffee). Record the time of eating every day.
223622742|NCT07184281|BEHAVIORAL|health education|"The current health education model is adopted, that is, health education is carried out in accordance with the Guiding Outline for Health Education in Primary and Secondary Schools."
223622743|NCT07187466|DRUG|mirabegron|Mirabegron is a beta-3-agonist, which acts upon the noradrenergic system and avoids the cognitive and gastrointestinal side effects of anticholinergic bladder relaxants.
223622744|NCT07187466|BEHAVIORAL|Exercise-based behavioral therapy|The exercise-based behavioral therapy is a comprehensive training program administered individually by a trained nurse practitioner interventionist to address urinary incontinence and other lower urinary tract symptoms.
224212223|NCT01398592|DRUG|Sitagliptin|100mg sitagliptin po qd
224212224|NCT00139386|DRUG|Candesartan|Candesartan Cilexetil (4-12 mg per day)
224212225|NCT00689663|PROCEDURE|Laparoscopic cholecystectomy|Randomized to three arm.
224212226|NCT00939705|DRUG|topiramate|Topiramate (brand name Topamax) is an anticonvulsant (antiepilepsy) drug. IUPAC name 2,3:4,5-Bis-O-(1-methylethylidene)-beta-D-fructopyranose sulfamate
224212227|NCT04063566|PROCEDURE|Magnetic Resonance Imaging (MRI)|Prostate cancer screening MRI
224212228|NCT04063566|PROCEDURE|Prostate-specific antigen (PSA) test|Blood test for PSA levels
224212229|NCT04314427|PROCEDURE|Roux-en-Y gastric bypass|
224212230|NCT04314427|PROCEDURE|Sleeve gastrectomy|
224212231|NCT04156191|DRUG|ARQ-151 cream 0.15%|ARQ-151 cream 0.15% applied to atopic dermatitis lesions once a day for 28 days
224212232|NCT04156191|DRUG|ARQ-151 cream 0.05%|ARQ-151 cream 0.05% applied to atopic dermatitis lesions once a day for 28 days
224316344|NCT03944824|DIAGNOSTIC_TEST|Modified Fried Frailty Scale|Patients will be screened for frailty pre and post with sit-to-stand test, timed up and go test, handgrip strength test and administered the low physical activity questionnaire. These components together consist of the Modified Fried Frailty Index.
224316345|NCT05440318|DEVICE|Wireless wearable digital devices|Wireless wearable digital devices (including a small patch, modified watch, and datahub smartphone with electronic Patient Reported Outcomes \[ePRO\] capability) will be provided to each participant enrolled in the study.
224316346|NCT00979641|DRUG|Docetaxel|
223622745|NCT07199595|DRUG|Dexamedomedine|"Group A (the Dexmedetomidine group):~Dexmedetomidine: loading dose 1 µg/kg IV over 10 min after induction and then maintenance dose 0.2- 0.7 µg/kg/hr based on hemodynamic response."
223622746|NCT07199595|DRUG|MgSO4|Magnesium Sulfate: Used as an IV loading dose at 20 mg/kg IV over 17 minutes as an induction agent, followed by maintenance of 10 mg/kg/h
223622747|NCT07198022|DRUG|Cryotherapy|Using crytotherapy as topical anesthetic
223622748|NCT07198022|DRUG|topical anesthetic|Comparing the two versions (the room temperature and + 4°C) of the gold standard of local anesthetics, the solution, which contains lidocaine.
223622749|NCT07198022|DRUG|Topical anesthetic gel|Tolerable taste, containing benzocaine at gel formula.
223622750|NCT07198022|DRUG|Placebo|The placebo participants will be informed to have the standard topical anesthetic spray.
223622751|NCT07199257|BIOLOGICAL|GR1802 injection|Recombinant fully human anti-IL4Rα monoclonal antibody drug.
223622752|NCT07199257|BIOLOGICAL|Placebo|Placebo
223622753|NCT07198217|DRUG|SBRT combined with Tislelizumab followed by Tislelizumab|The enrolled population consists of patients with stage IIIB/C-IV non-small cell lung cancer who are driver gene negative or unknown, as well as those with driver gene positive targeted drug resistance. The patients reaching SD, PR, or CR after 4 cycles of platinum based dual drug chemotherapy. The patient will receive SBRT radiotherapy combined with Tislelizumab treatment, followed by Tislelizumab maintenance therapy.
223622754|NCT07199842|OTHER|Dynamic Neuromuscular Stabilization Exercises in Addition to Conventional Treatment|Dynamic Neuromuscular Stabilization Exercises in Addition to Conventional Treatment
223622755|NCT07199933|DRUG|Diacerein 50 mg Capsule|Drug:Diacerein 50 mg Capsule. Weeks 1-4: 50 mg/day; Weeks 5-24: 100 mg/day.
223622756|NCT07199933|DRUG|Placebo 50 mg|Drug:Placebo 50 mg Capsule. Weeks 1-4: 50 mg/day; Weeks 5-24: 100 mg/day.
223622757|NCT07200115|DEVICE|Cervical Ripening Double Balloon (CRDB) Catheter|The physician will place a CRDB catheter for overnight cervical preparation. The CRDB catheter is comprised of two balloons that can be inflated with up to 80 mL of sterile water.
223622758|NCT07200115|DEVICE|Osmotic Dilators|Osmotic dilators (e.g., laminaria and Dilapan-S) are mechanical dilators that are placed in the cervix prior to gynecologic procedures and facilitate dilation through the slow absorption of moisture. The physician will place osmotic dilators in the standard fashion.
223622759|NCT07198867|BIOLOGICAL|A-CAR028|A-CAR028 is a novel 2nd generation 4-1BB bispecific chimeric antigen receptor T-cell (CAR-T) targeting both CD33 and CLL-1 antigens
224212233|NCT06529224|OTHER|Online questionnaire|An online questionnaire will be distributed in electronic format to all the healthcare professionals concerned.
223622760|NCT07199244|DIETARY_SUPPLEMENT|marine-based heme iron|Participants will consume 9mg of SalmoFer on day 1, followed by 6mg each day for 56 days.
223622761|NCT07198698|OTHER|Paloma Sahid Method, a patented technique (PCT/CL2023/050061)|The participants will receive treatment that integrates manual and mechanical lymphatic drainage through linear sliding movements directed toward relevant lymph nodes. Each session lasts approximately one hour. This intervention was complemented by compression therapy, applying 30-40 mmHg at the ankle, 70% compression at the calf, and 30% compression at the thigh.
223622762|NCT07198165|DRUG|PD-1 inhibitor based immunotherapy|Short-course radiotherapy (25Gy/5Fx) followed by 4 cycles of CAPOX regimen (Oxaliplatin 130mg/m² IV infusion, Capecitabine 1000mg/m² orally for 14 days, Q3w) combined with Bevacizumab (7.5mg/kg IV infusion, D1, Q3w) + PD-1 inhibitor (Toripalimab 240mg IV infusion, D1, Q3w).
223622763|NCT00286858|DEVICE|Insignia Ultra and Insignia AVT|Regular AV-Delay increase to allow for intrinsic AV conduction, if present.
223622764|NCT02772601|DRUG|Caffeine|
223622765|NCT02772601|DRUG|Warfarin|
223622766|NCT02772601|DRUG|Omeprazole|
223622767|NCT02772601|DRUG|Metoprolol|
223622768|NCT02772601|DRUG|Midazolam|
223622769|NCT02772601|DRUG|Risankizumab|
223622770|NCT03306914|OTHER|Albumin resuscitation|Albumin 5% is used as the intra-operative colloid
223622771|NCT03306914|OTHER|Hydroxyethylstarch resuscitation|Hydroxyethyl starch 6% is used as the intra-operative colloid
223622772|NCT03306914|DRUG|Albumin 5%|Infusion of Albumin 5% intra-operatively
223622773|NCT03306914|DRUG|Hydroxyethylstarch 6%|Infusion of Hydroxyethylstarch 6% intra-operatively
223622774|NCT04187118|OTHER|Quality of life|Quality of life one year post chemo-therapy
223622775|NCT01733420|DRUG|Biodentine pulpotomy|
223622776|NCT01733420|DRUG|White MTA pulpotomy|
223622777|NCT01733420|DRUG|Tempophore pulpotomy|
223622778|NCT04864522|DRUG|SLAMF7 FPBMC|Participants will receive 8 weekly infusions of SLAMF7 FPBMC, then 8 additional infusions every 2 weeks.
223622779|NCT02254811|BIOLOGICAL|Fecal Microbiota Transplant|transfer of healthy human gut bacteria to restore the microbiome
223622780|NCT05461859|PROCEDURE|Cardioneuroablation (CNA) of the right anterior ganglionated plexus (RAGP)|CNA of RAGP
223622781|NCT02649413|DRUG|Prednisone|Children with Idiopathic Nephrotic syndrome will start 60 mg/m2 prednisone.children that response in 8 days will receive an adjusted dose while the rest of the group will receive the 4 weeks usually dose.
223622782|NCT00675714|PROCEDURE|Stable Isotope Infusion Study|1-8 hour stable isotope infusion study to be done following each surgery. Tagged isotopes to assess uptake into blood and tissues.
224212234|NCT01671384|DRUG|Valproate, Levocarnitine|"All patients with diagnosis of SMA aged 2-15 years already registered in Myopathy Clinic of AIIMS will be recalled. Information will be sent to all Government Hospitals in Delhi that such a study is currently in progress and all the referrals will also be recruited. These patients and all those newly diagnosed at Myopathy Clinic, AIIMS will be randomized into two groups:~Group I (Physiotherapy + Placebos) Group II (Physiotherapy + Valproate and Levocarnitine)~The investigators will be blinded to the code of the medicine. It will be broken only at the end of the study or if there are any significant side effects. So one group will receive Valproate and levocarnitine and other group will receive Placebo and placebo."
224316347|NCT02876718|DRUG|Rivaroxaban (Xarelto, BAY 59-7939)|No specified dosing or dosage in the study. The treatment decision falls within current practice and the prescription of the medicines is clearly separated from the decision to include the patient in the study.
224316348|NCT01034956|DEVICE|hyaluronic acid or calcium hydroxylapatite filler|Intradermal and subdermal injection of facial soft tissue filler within the past 24 months; survey of patients to assess satisfaction and determine the presence of treatment related adverse events.
224212235|NCT01671384|DRUG|Placebo|"All patients with diagnosis of SMA aged 2-15 years already registered in Myopathy Clinic of AIIMS will be recalled. Information will be sent to all Government Hospitals in Delhi that such a study is currently in progress and all the referrals will also be recruited. These patients and all those newly diagnosed at Myopathy Clinic, AIIMS will be randomized into two groups:~Group I (Physiotherapy + Placebos) Group II (Physiotherapy + Valproate and Levocarnitine)~The investigators will be blinded to the code of the medicine. It will be broken only at the end of the study or if there are any significant side effects. So one group will receive Valproate and levocarnitine and other group will receive Placebo and placebo."
224212236|NCT00618774|DRUG|telmisartan40/amlodipine5|
224212237|NCT00618774|DRUG|telmisartan80/amlodipine5|
224212238|NCT00092079|DRUG|MK0217A, alendronate sodium (+) cholecalciferol / Duration of Treatment: 24 weeks|
224212239|NCT04116346|OTHER|Oral intake allowed|Oral intake (food and fluids) allowed up to the time of the procedure
224212240|NCT03716999|OTHER|Starlight Therapy|Starlight Projector will be placed in patients' rooms and project starlight on the ceilings and walls in an effort to reduce unpleasant symptoms
224212241|NCT04283487|DIETARY_SUPPLEMENT|Fructans|500ml 0.9% normal saline containing 40g fructans
224212242|NCT04283487|DIETARY_SUPPLEMENT|Glucose|500ml 0.9% normal saline containing 40g glucose
224212243|NCT04283487|DIETARY_SUPPLEMENT|Saline|500ml 0.9% normal saline
224212244|NCT02149862|OTHER|Urine infrared analysis|Collected urine sample will be stored at -80°C for further infrared analysis. Spectra will be analyzed by visual inspection, and statistical method such as Principal Components Analysis and logistic regressions methods.
224212245|NCT02046785|OTHER|0.9% saline solution|comparing values obtained before and after administration of 500 ml of 0.9% salin
224212246|NCT06580782|DRUG|Calcium Carbonate 500 MG|Calcium Carbonate 500mg, orally, every 4 hours.
224212247|NCT06580782|DRUG|Standard Dose Synthetic Pitocin|The participant will receive thestandard-dose synthetic oxytocin for labor induction or augmentation.
224212248|NCT02915588|OTHER|early isometric loading after rotator cuff surgery|
224212249|NCT02915588|OTHER|passive motion after rotator cuff surgery|
224212250|NCT00755937|OTHER|Data collection post infusion|
224212251|NCT00755573|DRUG|Pregabalin|Pregabalin 300 mg - 600 mg BID
224212252|NCT00755573|DRUG|placebo|Regime as described for pregabalin
224212253|NCT00991042|OTHER|blood collect|Five milliliters of venous blood was drawn in the morning from subjects and immediately centrifuged.
223622783|NCT00675714|PROCEDURE|Collection of blood and tissues|Blood draw with each stable isotope infusion study and weekly Tissue biopsy: skin, fat, muscle at stable isotope infusion study
223622784|NCT00675714|PROCEDURE|Radiology testing: Dual-energy X-ray absorptiometry (DEXA), ultrasound, MRI|Testing to be done following every stable isotope infusion study to measure muscle, fat and bone tissues.
223622785|NCT00675714|DRUG|Humatrope|Humatrope (Growth Hormone) dose:0.05mg - 0.2mg/kg/day SQ daily for up to 2 years post burn injury.
223622786|NCT00675714|DRUG|Ketoconazole|Ketoconazole administration (or other glucocorticoid blocker--itraconazole or fluconazole) PO daily for up to 2 years post burn injury
224212254|NCT05110625|BEHAVIORAL|preDIABE-TEXT|Participants will receive text messages (three per week) in their mobile phones during six months.
224212255|NCT05110625|OTHER|Online Education|Primary healthcare workers will receive an online educacion about prediabetes. This intervention will aim at: 1) raising awareness about the importance of T2DM prevention; 2) increasing knowledge about effective strategies for diabetes prevention; 3) improving knowledge about brief counselling techniques; and, 4) enhancing communication skills.
224212256|NCT05177237|DRUG|Endostar|Endostar: 210 mg (14 PCS) continuous infusion for 168h, Q3W, 4 cycles. Methylprednisolone: 80mg intravenously, once daily, for 3-5 days, gradually reduced to 10mg/ day oral maintenance dose.
223622787|NCT00675714|DRUG|Oxandrolone|oxandrolone (or other anabolic steroid-testosterone or nandrolone) daily for up to 2 years post burn injury
223622788|NCT00675714|DRUG|Propranolol|Propranolol (or other beta adrenergic blocker--metoprolol, inderol), PO administration daily for up to 2 years post burn injury.
223622789|NCT00675714|DRUG|Oxandrolone and propranolol combined|Daily administration of oxandrolone and propranolol to be given for up to 2 years post burn injury.
224212257|NCT01447316|OTHER|Subject outcomes following bariatric surgery|Subject outcomes (body composition, gait analysis, lower extremity joint pain and perceived quality of life) measured at per-op, 2, 4 weeks and 3 months.
224212258|NCT00572156|DRUG|NutropinAq® (Somatropin [rDNA origin])|rhGH (Somatropin) 45µg/kg once daily injection
224212259|NCT00572156|DRUG|Increlex® (Mecasermin [rDNA origin] injection) + NutropinAq® (Somatropin [rDNA origin])|rhGH 45µg/kg and rhIGF-1 150µg/kg once daily injection
224212260|NCT00572156|DRUG|Increlex® (Mecasermin [rDNA origin] injection) + NutropinAq® (Somatropin [rDNA origin])|rhGH (Somatropin) 45µg/kg and rhIGF-1 (Mecasermin) 50µg/kg once daily injections
224212261|NCT00572156|DRUG|Increlex® (Mecasermin [rDNA origin] injection) + NutropinAq® (Somatropin [rDNA origin])|rhGH 45µg/kg and rhIGF-1 100µg/kg once daily injections
224212262|NCT03008031|PROCEDURE|CESM with a reduced dose of contrast agent|
224212263|NCT02261974|DEVICE|Active Treatment Viveve|Subject will receive 90 Joules/cm2 radiofrequency energy to the vaginal introitus
224212264|NCT02261974|DEVICE|Sham Treatment Viveve|Subject will receive ≤ one (1) Joule of radiofrequency energy to the vaginal introitus
224212265|NCT03523013|DEVICE|CPAP|CPAP treatment with different pressure for OSA patients
224212266|NCT01669278|DEVICE|Endosheath|Flexible sheathed nasopharyngolaryngoscopy
224212267|NCT06531265|PROCEDURE|Endobronchial cryobiopsy and cryotherapy using flexible bronchoscopy|Bronchoscopic evaluation of endobronchial lesion with biopsy and cryotherapy for recanalisation
224212268|NCT01680289|PROCEDURE|Three adhesive coats|After caries removal, enamel margins will be conditioned with phosphoric acid gel 37% by 15 seconds and dentin walls by 8 seconds. The etchant will be removed with use of water spray by 30 seconds. The water excess will be removed with a cotton pellet. The first layer of Prime \& Bond 2.1 adhesive will be applied with a microbrush. After 20 seconds a second layer will be applied and after a similar period a third layer will be applied over cavity walls. Again, after 20 seconds, the layers will be gently air-dried and photopolymerized by 10 seconds with a LED photoactivation unit.
224316349|NCT00006509|BIOLOGICAL|ALVAC(2)120(B,MN)GNP (vCP1452)|
224316350|NCT00006509|BIOLOGICAL|gp160 MN/LAI-2|
224212269|NCT01680289|PROCEDURE|Two adhesive coats|After caries removal, enamel margins will be conditioned with phosphoric acid gel 37% by 15 seconds and dentin walls by 8 seconds. The etchant will be removed with use of water spray by 30 seconds. The water excess will be removed with a cotton pellet. The first layer of Prime \& Bond 2.1 adhesive will be applied with a microbrush. After 20 seconds a second layer will be applied and after 20 seconds, the layers will be gently air-dried by 5 seconds. The two layers will be photopolymerized by 10 seconds with a LED photoactivation unit.
224212270|NCT02227537|DEVICE|Providence Nighttime Bracing System|Providence Nighttime Bracing System
224212271|NCT02227537|DEVICE|Providence Nighttime Bracing System|The Providence brace is a polypropylene plastic, acrylic framed, system designed to apply corrective forces to scoliatic curves achieving correction or reduction of scoliosis.
224212272|NCT04097119|DIETARY_SUPPLEMENT|Dietary supplementation|Subjects receive a specific dietary supplementation designed to support HDL function daily for 12 weeks
224212273|NCT04768764|PROCEDURE|Ultrasound Guided Middle Adductor Canal Block|"Middle adductor canal block will be applied post-operatively with guidance of USG.~Drug:Bupivacaine 0.25% Injectable Solution"
224212274|NCT04768764|PROCEDURE|Ultrasound Guided Femoral Nerve Block.|Femoral nerve block will be applied post-operatively with guidance of USG. Drug:Bupivacaine 0.25% Injectable Solution
224212275|NCT04768764|DRUG|Bupivacain|10 ml %0,5 Bupivacaine will be diluted with 10 ml saline solution. Bupivacaine 0.25% Injectable Solution
224212276|NCT04768764|PROCEDURE|Spinal Anesthesia|Patients will be placed in the lateral decubitus position.Subarachnoid space will be entered through the most suitable intervertebral space.Bupivacaine 0.5% Heavy will be given in the appropriate dose.
224212277|NCT04208191|BEHAVIORAL|Quality Improvement Collaborative|Facilities that participated in a QI collaborative to improve PCC for MH and FP services
224212278|NCT01950806|OTHER|Pecan-containing diet|
223622790|NCT00675714|DRUG|Humatrope and propranolol combined|Humatrope (growth hormone) and propranolol administration daily for up to 2 years post burn injury.
223622791|NCT00675714|DRUG|Placebo|placebo to be given once a day for up to two years post burn injury.
223622792|NCT00675714|BEHAVIORAL|Exercise--Hospital supervised intensive exercise program|intensive exercise program supervised by trained personnel in the hospital environment for six up to twelve week program.
224212279|NCT01950806|OTHER|Nut-free diet|
223622793|NCT00675714|BEHAVIORAL|Home exercise program|Home intensive exercise program: training occurs in hospital then patient sent home to continue exercise program for six weeks and up to 12 weeks at home.
223622794|NCT03496493|DEVICE|All patients|Peripheral arterial oxygen saturation recording with both study devices
224212280|NCT01062022|BEHAVIORAL|Standard of Care|Families randomized to this arm will receive the standard of care. They will be compared to the families in the FOCUS-CI arm of the study.
224212281|NCT01062022|BEHAVIORAL|FOCUS-CI|Families randomized to this arm of the study will be part of a family skill-building/resiliency training program designed to provide information and skills training
223622795|NCT01704027|RADIATION|Simultaneous integrated boost intensity-modulated arctherapy|"Three dose levels will be delivered at each fraction, 5 days a week, 30 fractions :~* Pelvis : 55,5 Gy (1,85 Gy/fr)~* Seminal vesicles : 66 Gy (2,2 Gy/fr)~* Prostate : 72 Gy (2,4 Gy/fr)"
223622796|NCT01704027|DRUG|Androgen deprivation|Patients will received androgen deprivation for a maximum of three years. This treatment can start six months before radiotherapy and at least the day one of radiotherapy.
223622797|NCT00101231|DRUG|alvocidib|Given IV
224212282|NCT01223196|DRUG|Pioglitazone|This study will examine the effect of Pioglitazone on tissue inhibitor of metalloproteinases (TIMP-3) and on TNF-alfa converting enzyme in the skeletal muscle of type 2 diabetic subjects.
224212283|NCT01223196|DRUG|Placebo|Inactive placebo for comparison to Pioglitazone on tissue inhibitor of metalloproteinases (TIMP-3) and on TNF-alfa converting enzyme in the skeletal muscle of type 2 diabetic subjects.
223622798|NCT06525285|PROCEDURE|Connective tissue graft wall technique|Harvested connective tissue graft will be placed over the exposed root surface like a wall to cover the gingival recession
224212284|NCT02071381|DRUG|DW330SR 45mg|
224212285|NCT02071381|DRUG|DW1030 75mg|
223622799|NCT03293602|DEVICE|F-MISO PET imaging|F-MISO PET imaging will be added to the preoperative staging explorations of a patient with high risk prostate cancer candidate to radical prostatectomy. Patient will be selected during multidisciplinary meeting and urology consultation of Bordeaux and Toulouse university hospitals. Functional MRI imaging should be available before surgery. If patient consent to participate in the study, F-MISO PET imaging will be planed before prostatectomy. Results of this exam will not be considered for patient therapeutic management.
223622800|NCT04590274|DRUG|Hydroxychloroquine|Hydroxychloroquine
223622801|NCT04590274|DIETARY_SUPPLEMENT|Vitamins and Minerals|elemental Zinc Vitamin C Vitamin D3 N-acetylcysteine Elderberry Quercetin
223622802|NCT04590274|DRUG|Azithromycin|Azithromycin
223622803|NCT01319708|PROCEDURE|mild ovarian stimulation|100-150 mg of clomiphene citrate from day 2 till day 6 of the cycle and 150 mg of gonadotrophins as soon as 1 follicle is more than 14mm together with 1 fixed dose of GnRH antagonist until egg recovery
223622804|NCT01319708|PROCEDURE|conventional ovarian stimulation|300-450 IU of FSH starting by day 2 of menstrual cycle together with a fixed dose of GnRH antagonist starting by day 6 till egg recovery, or same doses with GnRH agonist long protocol
223622805|NCT00644423|DRUG|Omega-3 Fatty Acid|One capsule three times per day x 1 day (325mg EPA/225mg docosahexaenoic acid (DHA) tid) Two capsules three times per day x 1 day (650mg EPA/450mg DHA tid) Three capsules three times per day thereafter (975mg EPA/675mg DHA tid)
223622806|NCT00644423|DRUG|Placebo|Matching Placebo
223622807|NCT00002327|DRUG|Cidofovir|
223622808|NCT01769742|BEHAVIORAL|Early mobility bundle|
223622809|NCT00100035|PROCEDURE|Polarity therapy|
223622810|NCT03011320|DRUG|EC1456|intravenous (IV) bolus dose
223622811|NCT03011320|DRUG|99mTc-Etarfolatide|Injection of unlabeled etarfolatide followed by etarfolatide labeled with 740 to 925 megabecquerels (MBq) \[20 to 25 millicuries (mCi)\] of sodium pertechnetate Tc-99m injection, followed by a single-photon emission tomography (SPECT) or single-photon emission tomography with in-line x-ray computed tomography (SPECT/CT) scan.
224212286|NCT05804201|PROCEDURE|EUS-guided hepatico-gastrostomy would be performed with Niti-S HOT Giob|(2) The EUS procedure will be performed with a therapeutic echoendoscope with a large working channel under guidance of ultrasound, endoscopy, and fluoroscopy. The echoendoscope will be positioned in the stomach or duodenum. Liver segment III, or sometimes segment II, will be punctured with an 19G needle. After puncture, a guidewire will be introduced in the dilated bile duct, and a Hot Giobor will be placed. All procedures will be performed with the patient and in the supine or prone position under monitored anesthesia.
224212287|NCT04657978|PROCEDURE|Substrate guided left atrial ablation|Ablation therapy targeting areas of low voltage, which may include encirclement, homogenization or targeting of abnormal electrograms and anchored to a non-conducting structure if the region is in close proximity or likely to create an isthmus for arrhythmias.
224212288|NCT03296215|OTHER|Observational|To determine different patterns of admission and their Outcome
224212289|NCT02591784|DRUG|Nimotuzumab|the nimotuzumab treatment; 200mg/w,weekly,5-6 weeks.
224212290|NCT02591784|RADIATION|Radiotherapy|the Radiotherapy treatment;95%PTV A dose of 50-60Gy will be administered in 25-30 fractions ( 2 Gy /fraction)
223622812|NCT03240601|DEVICE|Transcutaneous spinal stimulation|For TSS, a transcutaneous electrical nerve stimulation (TENS) unit is used. A 2 inch diameter round electrode is placed on the skin over T11/T12 (cathode), and a large butterfly electrode is placed on the skin over the umbilicus (anode). Pulse width is set to 400 microseconds at 50 Hz.
223622813|NCT01782898|DRUG|Esmolol administered at a rate of 0.5 mg/kg followed by an infusion of 5-15 mcg/kg/min|Esmolol administered at a rate of 0.5 mg/kg followed by an infusion of 5-15 mcg/kg/min
223622814|NCT01782898|DRUG|Placebo Comparator: .9 normal saline|Placebo Comparator: Placebo .9 normal saline infused at the same rate (/mg/kg bolus followed by 5-15 mcg/kg/mn) as the Esmolol would be administered,
224212291|NCT02248337|DRUG|Colon preparation for colonoscopy|Colon cleansing prior to perform colonoscopy
224212292|NCT06543511|OTHER|Genetic Blood Test|Germline genetic testing using skin fibroblasts
223622815|NCT01519323|DRUG|vemurafenib|Cohort 1 (participants \>=45 kg): starting dose level 720mg; next dose level 960 mg Cohort 2 (participants \<45 kg): starting dose 480 mg
223622816|NCT04406298|PROCEDURE|small quantity paracentesis|Intermittent small quantity paracentesis (upto 3L/day) for upto 5 days
223622817|NCT04406298|PROCEDURE|Large Volume Paracentesis|Large Volume Paracentesis \> 5litres
224212293|NCT04537585|COMBINATION_PRODUCT|Tomeka®|Tomeka® is a farine mixte made by soy, sorghum, maze and mushrooms
224212294|NCT04537585|DRUG|"Vernonia amygdalina"|"Vernonia amygdalina is the Intervention that was pre-specified to be administered as part of the protocol as a particular intervention of not of interest because the World Health Organization doesn't support its use due to two reports case of toxicity in Kinshasa in a child and Mbandaka in an adult in the Democratic Republic of the Congo that why investigators would like review its usage in a large community and update that intervention of not of interest as appropriate (using randomisation on the follow up of participants who will take by themselves those herbs called Congo Bololo to compare, as necessary, to the ones who are afraid to take them because of reported cases of toxicity)."
224316351|NCT05637736|BEHAVIORAL|Mindfulness-based Stress Reduction by Therapeutic VR|Therapeutic VR+MBT was provided using a head-mounted display which designed to enclose eyes and block external stimuli almost entirely. Patients can see immersive natural scenes through VR devices and hear stereo sounds through headphones. We uploaded a programme, which was designed to induce recordings of guided meditations (The same as the MBT), musics for meditation and consists of meditation-videos of 40 minutes. We will guide patients to choose their favorite meditation videos, such as forest, seaside, lake, snow mountain, field and so on.
224316352|NCT05637736|BEHAVIORAL|Mindfulness-based Stress Reduction|39 participates randomized and allocated to this group. MBT was conducted as an 8-week group intervention. Sessions typically began with formal mindfulness meditations that include breathing exercises, prolonged expiratory relaxation, body scan, and meditation. MBT was delivered by the first author, who has specialized training in mindfulness meditation.
224212295|NCT04078087|DRUG|Non obese|After standard anesthesia monitoring, Administration of oxygen was performed for 3 minutes with 10 L/min fresh gas flow of 100% oxygen. After oxygen administration, 25% of (2 mg/kg) total propofol dose was injected over 3-5 seconds (Propofol Lipuro 1%, B. Braun Melsungen AG, Germany). The patients were observed and asked immediately whether they had pain in the arm, its VAS score, type of pain (burning, parathesia or other) and its onset was documented (to differentiate early or late type of pain).
224316353|NCT02587078|DRUG|Volulyte|Patients who meet the inclusion criteria (at Screening, see below for definition) will be randomized immediately in a ratio of 1:1 to either intravenous Volulyte® or Jonosteril® for fluid resuscitation (on RAND). Fluid resuscitation with study drug will be started immediately in order to reach initial hemodynamic stabilization.
223622818|NCT03189368|DEVICE|Activation of multi-site pacing capability on CRT devices|"Instead of administering a single LV pulse at the most (electrically) delayed segment of the ventricle, multi-site pacing allows for a more detailed sculpting of the LV activation sequence. Based on the MPP-IDE study results, activation of the antero-lateral wall, or at least its most delayed segments, closely followed by a pulse to the apex and then by a right ventricular one will yield favorable results in terms of hemodynamics and clinical parameters.~Programming features:~* Interpolar distance for the first left ventricular pulse \>30mm (i.e. non-sequential poles used)~* Nearly simultaneous (Δt=5msec) second left ventricular pulse and~* Threshold of ≤3.5V@0.5msec"
223622819|NCT00034307|DRUG|sitaxsentan sodium|
223622820|NCT06077721|DRUG|Milrinone|giving intravenous milrinone: 50 mcg/kg loading dose by IV push over 10 minutes, then 0.375-0.75 mcg/kg/ min infusion
223622821|NCT02493439|BEHAVIORAL|Best Possible Self|
223622822|NCT02493439|BEHAVIORAL|Daily Activities|
223622823|NCT01414634|BIOLOGICAL|ETIMS|injection of peptide-coupled PBMC by i.v. infusion
223622824|NCT05378685|PROCEDURE|Endotracheal intubation|The patient is intubated using a laryngoscope and cuffed endotracheal tube. The selection and size of the equipment is at the discretion of the pediatric cardiac anesthesiologist.
224316354|NCT02587078|DRUG|Jonosteril|Patients who meet the inclusion criteria (at Screening, see below for definition) will be randomized immediately in a ratio of 1:1 to either intravenous Volulyte® or Jonosteril® for fluid resuscitation (on RAND). Fluid resuscitation with study drug will be started immediately in order to reach initial hemodynamic stabilization.
224212296|NCT04078087|DRUG|Obese.|After standard anesthesia monitoring, Administration of oxygen was performed for 3 minutes with 10 L/min fresh gas flow of 100% oxygen. After oxygen administration, 25% of (2 mg/kg) total propofol dose was injected over 3-5 seconds (Propofol Lipuro 1%, B. Braun Melsungen AG, Germany). The patients were observed and asked immediately whether they had pain in the arm, its VAS score, type of pain (burning, parathesia or other) and its onset was documented (to differentiate early or late type of pain).
224212297|NCT00864487|DRUG|Neratinib|HKI-272
224212298|NCT01150513|DRUG|EC-T|four cycles of EC (epirubicin: 90 mg/m2; cyclophosphamide :600 mg/m2, day 1) followed by four cycles of T (docetaxel : 75 mg/m2 or paclitaxel 175 mg/m2, day 1)
224212299|NCT01150513|DRUG|TP|six cycles of TP (docetaxel: 75 mg/m2 or paclitaxel 175 mg/m2 d1; carboplatin AUC=5, day 1)
224212300|NCT03283865|DIAGNOSTIC_TEST|Ultrasound guidance for caudal block|The attending anesthesiologist will perform or instruct the placement of a caudal block according to their standard of practice. At the time of administration of local anesthetic into the caudal space, the study collaborator (SC) will ultrasound the caudal space keeping the provider placing the block blinded to the imaging. The provider placing the block will inject 0.5mL of preservative free saline. The provider will then be asked to state if they are correctly in the caudal space or not. If the provider feels they are not in the caudal space, they will re-do the procedure. If the provider fails to identify incorrect location and this is noted by ultrasound, the SC will inform the provider to re-do the procedure
224212301|NCT05755724|OTHER|3-D Teaching|Telesimulation using immersive VR technology. Briefly, students will have a 360° camera mounted to their head, which will broadcast their first-person perspective to their teachers. Teachers will be able to immerse themselves in the perspective of the trainee using a virtual reality HMD (Oculus Quest 2), which allows them to look around freely and view equipment, hand movements, etc. and offer instruction accordingly.
224212302|NCT05755724|OTHER|2-D Teaching|Telesimulation using standard teleconferencing software and equipment including 2D computer monitors, webcams, and an ultrasound machine linked to a computer (enabling ultrasound images to be transmitted).
224316355|NCT03366207|DRUG|Ciprofloxacin|Ciprofloxacin 250 mg PO twice daily (BID) x 3 days for women with uUTI.
223622825|NCT03908801|BEHAVIORAL|Specialized water dance intervention|Group activity in a warm pool (32-34 °C) led by two SWAN leaders. During each session, nine songs are played and the participants, assisted by a support person, perform dance movements rhythmically to the mood of the music. The songs are chosen to stimulate different movement patterns and to emphasize different emotions.
223622826|NCT00379535|DRUG|potassium iodide|per os
224212303|NCT06236126|PROCEDURE|1% Lidocaine Injection|Prior to insertion of the Tuohy epidural needle, each patient will receive an injection of 3 mL 1% lidocaine either intradermally (Group Intradermal) or subcutaneously (Group Subcutaneous).
224316356|NCT00706485|DEVICE|Yttrium-90 Plaque Applicator|Placed on the dura during surgery for 10-17 1/2 minutes
224316357|NCT01504997|DEVICE|Robot assisted distal gastrectomy (DaVinci)|patients who received robot assisted distal gastrectomy
223622827|NCT00379535|DRUG|placebo|per os
223622828|NCT01572207|BEHAVIORAL|Immediate exercise|Subjects in the immediate exercise group will be prescribed a home exercise program during the first meeting and will begin the 12 week training period immediately following the first meeting.
223622829|NCT01572207|BEHAVIORAL|Delayed exercise|Subjects in the delayed exercise group will begin the home exercise program 12 weeks following the initial meeting.
224212304|NCT03598673|DRUG|The Efficacy and Tolerability of Nebivolol in Nigerians|To determine the effect of Nevibolol on office blood pressure of Blacks residing in Nigeria
224316358|NCT01495078|PROCEDURE|Telemonitoring|"Is a computer system designed jointly by engineers and clinical personal of Parc Salut Mar) to be able daily automated selfreported symptom and weight, blood pressure and heart rate monitoring . The system allow weekly follow up throught videoconferences.~Information from the telemonitoring system is automatically downloaded to a secure Internet site for review by clinicians and nurses."
224316359|NCT01651793|OTHER|Caffeinated cocoa|70 mg caffeine, 179 mg theobromine, 499 mg flavanols, and 1 packet of Truvia sweetener
224316360|NCT01651793|OTHER|Cocoa|21 mg caffeine, 179 mg theobromine, 499 mg flavanols, and 1 packet of Truvia sweetener
223622830|NCT03658421|DRUG|Dexmedetomidine|Dexmedetomidine added to lower concentration of ropivacaine for postoperative analgesia in FNB
223622831|NCT03658421|PROCEDURE|ultrasound-guided femoral nerve block|ultrasound-guided femoral nerve block, a single bolous of 20 ml ropivacaine (concentration 0.2% for H group or 0.1% for L group) before surgery followed by continuous femoral nerve block using an infusion rate of ropivacaine 0.2% 5 ml/h for postoperative analgesia started right after surgery
223622832|NCT03658421|DEVICE|intravenous patient-controlled analgesia pump with morphine|All subjects received intravenous patient-controlled analgesia (IV-PCA) pumps to measure additional morphine consumption, which included 50 mg morphine in 50 ml saline: bolus 2 mg; lock out time, 15 minutes.
223622833|NCT03658421|PROCEDURE|Continuous femoral nerve block|All the continuous femoral nerve block infusion regimes in the pump were connected to CFNB catheter, which contained only ropivacaine with different concentrations (ropivacaine 0.1% for L group and LD group; ropivacaine 0.2% for H group, 5 ml/h).
223622834|NCT00232765|DEVICE|CYPHER Sirolimus-Eluting Stent|CYPHER Sirolimus-Eluting Stent
223622835|NCT00232765|DEVICE|Uncoated BX VELOCITY Balloon-Expandable Stent|Uncoated BX VELOCITY Balloon-Expandable Stent
223622836|NCT04070781|DRUG|Itacitinib|"Itacitinib is a novel, potent, and selective inhibitor of the Janus Kinase (JAK) family of protein tyrosine kinases (TYKs) with selectivity for Janus Kinase 1 (JAK1). Itacitinib is an investigational product.~Itacitinib 200 mg daily in 28-day long cycles"
223622837|NCT04070781|DRUG|Tocilizumab|"Tocilizumab is a biologic medication currently approved to treat adults with moderately to severely active rheumatoid arthritis (RA), adults with giant cell arteritis (GCA), and children ages two and above with Polyarticular Juvenile Idiopathic Arthritis (PJIA) or Systemic Juvenile Idiopathic Arthritis (SJIA). Tocilizumab blocks the inflammatory protein interleukin 6 (IL-6). This improves joint pain and swelling from arthritis and other symptoms caused by inflammation.~Tocilizumab 4 or 8mg/kg cycle 1 day 1 every 4 weeks in 28-day cycles"
224212305|NCT00075465|DRUG|docetaxel|
224212306|NCT00075465|DRUG|epirubicin hydrochloride|
224212307|NCT00289939|BEHAVIORAL|Motivational interviewing to reduce risk for HIV and DV|
224316361|NCT01651793|OTHER|Caffeine|473 ml brewed water containing 66 mg caffeine, caramel coloring and one packet Truvia sweetener
224212308|NCT03932838|OTHER|Clinical and radiologic evaluation|Follow up post surgery: clinical and radiologic evaluation
224212309|NCT01364246|BIOLOGICAL|human umbilical cord mesenchymal stem cells|Participants will be given hUC-MSCs transplantation.
224212310|NCT04483427|COMBINATION_PRODUCT|Nalbuphine, ketorolac, accufuser|multimodal analgesic regimen consisting of nalbuphine combined with ketorolac using IV continuous infusion silicon device (Accufuser)
224212311|NCT05134727|DRUG|AZD5055|Healthy participants will receive AZD5055
224212312|NCT05134727|DRUG|Placebo|Healthy participants will receive placebo
224212313|NCT04384731|DRUG|poractant alfa|Patient receiving surfactant (3 mL/kg of a poractant alpha solution diluted to 16 mg/mL, resulting in a total dose of 48mg/kg) administred by bronchial fibroscopy. The total volume will be divided in each of the five lobar bronchi.
224212314|NCT02554344|DRUG|Curcumin|Patients will receive 500mg of curcumin administered orally, twice a day for 12 weeks.
224212315|NCT02552394|DRUG|huJ591|HuJ591 will be administered as an intravenous infusion at a concentration of 5 mg/mL and rate of \<5 mg/minute. Pre-medications prior to J591 infusion with diphenhydramine 25 - 50 mg p.o. or IV and acetaminophen 500 - 650 mg p.o.
224212316|NCT03635060|PROCEDURE|Dorsal Bridge Plating|This study will be a pilot randomized control trial that will focus on treating patients with the described fracture pattern either with dorsal distraction plating with or without any additional fragment specific fixation or standard open reduction internal fixation.
224212317|NCT03635060|PROCEDURE|Volar locking plating|This study will be a pilot randomized control trial that will focus on treating patients with the described fracture pattern either with dorsal distraction plating with or without any additional fragment specific fixation or standard open reduction internal fixation.
224212318|NCT05435872|DEVICE|The Artificial intelligence Cloud Platform|The Artificial intelligence Cloud Platform would be used as the auxiliary device for endoscopists during the whole endoscopic examination to help endoscopists complete the quality control, indicate potential lesions, and aid in diagnosis.
224212319|NCT02145000|BIOLOGICAL|Rotavirus vaccine (BRV-PV)|Three doses of BRV-PV containing ≥ Log10 5.6 FFU/Dose of each serotype G1, G2, G3, G4 and G9, or placebo, will be administered at 4 week intervals between doses (with a window of -1 to +4 weeks). The first administration will occur at 6-8 weeks of age.
224212320|NCT02145000|BIOLOGICAL|Placebo|
224212321|NCT05180630|DEVICE|Audeo P90 hearing aid with custom earmolds using dynamic venting|Audeo P90 hearing aids coupled to custom earmolds that use dynamic venting.
224212322|NCT05180630|DEVICE|Audeo P90 hearing aid with Open domes|Audeo P90 hearing aid coupled with non-custom, manufacturer open domes
223622838|NCT05574686|BEHAVIORAL|Telehealth Blood Pressure Monitoring and Food Insecurity|Telehealth Blood Pressure Monitoring and Food Insecurity
224212323|NCT05180630|DEVICE|Audeo P90 hearing aid with Vented domes|Audeo P90 hearing aid coupled with non-custom, manufacturer vented domes
224212324|NCT05482438|DEVICE|Polyethylene|Wear measurement
224212325|NCT05942131|OTHER|Group-based laughter yoga|"A total of 8 sessions of laughter yoga will be applied to the students in the intervention group, 2 sessions per week. Each session will last 45 minutes on average. Each session will consist of groups of 7 people. An information meeting about the sessions will be held with the midwifery students who volunteered to participate in the study and assigned to the intervention group before starting laughter yoga. Midwifery students will be administered Secondary Traumatic Stress Scale for Social Media Users and Beck Depression Inventory before and after 4-6 weeks."
224212326|NCT02163629|BEHAVIORAL|Stress management|
224212327|NCT04774809|DRUG|Low Dose SHR0302 Ointment BID|Low Dose SHR0302 Ointment BID
223622839|NCT03096834|BIOLOGICAL|AMG334 (70 mg) Pre-Filled Syringe (PFS)|Two injections of AMG 334 70 mg (equaling 140 mg total dose) will be administered via subcutaneous injection
223622840|NCT03096834|BIOLOGICAL|Placebo Pre-Filled Syringe (PFS)|Subcutaneous injection of matching placebo
223622841|NCT00836368|DIETARY_SUPPLEMENT|gamma-tocopherol|oral doses 1,200 mg of gamma tocopherol (2 capsules of the gamma tocopherol enriched vitamin E preparation)
223622842|NCT02669953|DRUG|Aflibercept|
223622843|NCT00433173|PROCEDURE|intravenous glucose tolerance test|The IVGTT (70) is a 4 hour study with baseline sampling for insulin and glucose, followed by the administration of 0.3 mg/kg infusion of glucose, and subsequent frequent samples through 180 minutes. At 20 minutes, subjects will receive a 0.03 U/kg infusion of regular human insulin over 45 seconds to enhance the insulin level to better help us assess the impact of insulin on glucose uptake and to facilitate minimal model analysis. The IVGTT will be administered at baseline and after 3 months.
223622844|NCT00433173|DRUG|testosterone|transdermal 7.5 g/per day for 3 months
223622845|NCT00433173|DRUG|anastrozole|tablet (per oral) 10.0 mg/ daily 3 months
223622846|NCT00433173|DRUG|goserelin acetate implant|single depot injection 10.8 mg 3 months
223622847|NCT00433173|PROCEDURE|aerobic capacity (VO2 Max)|This test is employed to assess VO2max in all subjects. O2 and CO2 will be collected and measured from the expired air during the exercise stress test and used to calculate VO2max. This test will be administered at baseline and after 3 months.
224212328|NCT04774809|DRUG|High Dose SHR0302 Ointment BID|High Dose SHR0302 Ointment BID
224212329|NCT04774809|OTHER|Placebo Comparator: Vehicle|Placebo
223622848|NCT00433173|PROCEDURE|MRI|1H-MR spectroscopy will be performed to measure IMCL at baseline and after 3 months.
223622849|NCT00433173|PROCEDURE|muscle biopsy|Biopsies (20-50mg) will be obtained from the vastus lateralis muscle under local anesthesia (1% lidocaine) using a 5 mm Bergström needle (65) with suction applied. The muscle biopsy will be performed at baseline and after 3 months.
224212330|NCT04676607|DRUG|SHR7390|SHR7390
224212331|NCT00989807|DRUG|Aztreonam lysine|Open-label, expanded access for Aztreonam lysine for inhalation 75 mg three times daily
224212332|NCT03922815|DRUG|rescue fentanyl|a rescue dose of fentanyl 0,5 mcg per kilogram of body
224212333|NCT03922815|DRUG|rescue propofol|propofol in a single dose of 0,5 mg/kg of body weight
224212334|NCT02011516|DRUG|Baclofen|
224212335|NCT02011516|BEHAVIORAL|Psychosocial|
224212336|NCT02011516|DRUG|Placebo|
224316362|NCT01651793|OTHER|Placebo|473 ml of brewed water, caramel coloring and one packet Truvia sweetener
224212337|NCT03715660|DIAGNOSTIC_TEST|Xpert bladder cancer monitor|Xpert Bladder Cancer Monitor, is a qualitative in vitro diagnostic test designed to monitor for the recurrence of bladder cancer in patients previously diagnosed with bladder cancer.The test utilizes a voided urine specimen and measures the levels of five targetmRNAs (ABL1, CRH, IGF2, UPK1B, ANXA10) by means of real-time, reverse transcription-polymerase chain reaction (RT-PCR). The Xpert Bladder Cancer Monitor is indicated as an aid to standard clinical evaluation in monitoring for bladder cancer recurrence in patients previously diagnosed with bladder cancer and should be used in conjunction with other clinical measures to assess disease recurrence.
224212338|NCT00705796|DRUG|MPP10, testosterone|Testosterone intranasal, 7.6 mg, twice daily to be taken immediately after waking up and washing/showering (approx. 7:00-8:00 AM) and at lunch time (approx. 12:00 AM).
224212339|NCT00705796|DRUG|Testosterone|AndroGel® 50 mg, once daily in the morning after washing/showering.
224212340|NCT01825616|DIETARY_SUPPLEMENT|Vitamin D2 mushroom powder|Subjects will be given Portobello mushroom powder with or without vitamin D mixed in soymilk powder in six plastic containers (one for each week of the study). Subjects will ingest one level teaspoon of the product each day (with or without 4,000 IU vitamin D2) and consume during breakfast in one of the following ways: mixed in water, juice, yogurt, or milk.
224316363|NCT01737073|BEHAVIORAL|IVR self-management|A course of self-management training that includes 12 education and self-management skill modules presented over 12 consecutive weeks. Participants will be asked to practice each skill daily and report via IVR on their completion of the daily skill practice. They will receive a 10 minute call each week from a nurse care manager to discuss their weekly progress.
224316364|NCT01737073|BEHAVIORAL|Opioid monitoring|Monthly automated monitoring of prescription opioid use including pain relief, physical activity, pain-related interference, mood, adverse effects, adherence and satisfaction with treatment.
223622850|NCT00433173|PROCEDURE|measurement of resting metabolic rate (energy expenditure)|Energy expenditure in the form of resting metabolic rate (RMR) will be measured via a metabolic monitor at baseline and after 3 months.
223622851|NCT00433173|PROCEDURE|Dual energy x-ray absorptiometry|Total and regional percent body fat, fat mass, lean tissue mass and bone mineral content will be determined by DEXA (Lunar Prodigy version 8.50). DEXA provides an in vivo assessment of body composition with minimal requirements for subject cooperation and will be employed at baseline and after 3 months.
223622852|NCT00433173|PROCEDURE|Fasting oral glucose tolerance test|To examine glucose and insulin metabolism a standard 75g OGTT will be conducted at baseline and after 3 months.
223622853|NCT04085575|DRUG|Acide Tranexamique|Recruited patients were randomly before the operation by generating random numbers with Microsoft Excel 2007. They were assigned in two groups: 1 g of intra-articular tranexamic acid (TXA) and 2 g of intra-articular tranexamic acid.
223622854|NCT04416204|OTHER|glycogen loading|Subjects will consume an isocaloric diet \[60% carbs, 20% protein, 20% fat (33 kcal/kg/day)\] for 3 days prior to the overnight study.
223622855|NCT04416204|OTHER|No Glycogen Loading|Subjects will consume an isocaloric diet \[40% carbs, 20% protein, 40% fat (33 kcal/kg/day)\] for 3 days prior to the overnight study.
223622856|NCT02516280|DEVICE|Cryoton ™|In the intervention group, participants received hyperbaric gaseous cryotherapy delivered with a Cryoton ™ device (Cryonic Médical, Salins-les-Bains, France) within an hour after the surgery and two times per day the next postoperative days. The tip of the nozzle was kept 10-15 cm above the dry skin as the gaseous CO2 was sprayed on three zones of 5 cm by 10 cm (medial, lateral and posterior, respectively) using a slow and regular sweeping movement for approximately 30 seconds after a skin temperature of 2°C is reached.
223622857|NCT02516280|DEVICE|Control ice bag|In the control group, participants received two 20-minute treatments of cryotherapy within an hour after the surgery and two times per day the next postoperative days. Cryotherapy was performed using an ice bag that was applied directly on the anterior aspect of the knee. The ice bag is a square latex bag of 30 cm by 30 cm filled with crushed ice and wrapped in a thin pillow case. The treatment assessor applied the intervention in a standardized manner by ensuring that the knee was fully extended while covering the surgical incision and both lateral and medial aspects of the knee with the iced bag.
224316365|NCT01737073|OTHER|Enhanced usual care|Weekly automated wellness tip and usual clinical care
224316366|NCT05198180|DRUG|Topical 30%Potassium hydroxide solution|Patients will apply the solution every day under occlusion for 3 months
223622858|NCT04456504|BIOLOGICAL|Recombinant hepatitis B vaccine with CpG adjuvant|Each participant will receive two doses of hepB-CpG separated by one month and blood draw to measure antibody to the hepatitis B surface antigen prior to dose 2 and one month after dose 2.
223622859|NCT03998306|DIETARY_SUPPLEMENT|Experimental: Probiotics|"the participants will receive probiotic lozenge before falling asleep for 12 weeks.~the participants will receive dietetic and hygienic instructions"
223622860|NCT03998306|OTHER|No intervention|No intervention
223622861|NCT04912258|DRUG|Trans arterial chemoembolization with Irinotecan Drug-eluting Beads|preoperative chemoembolization with Irinotecan Drug-eluting Beads
224212341|NCT01825616|OTHER|Placebo|Mushroom powder without vitamin D2
224212342|NCT06567938|PROCEDURE|Percutaneous coronary intervention|PCI with DES implantation
224212343|NCT00709735|DRUG|Propranolol|0.67 mg/kg short-acting propranolol combined with 1 mg/kg long-acting propranolol
224212344|NCT00709735|DRUG|Placebo|Placebo (matching propranolol) short-acting and long-acting capsules
224212345|NCT04547478|DIAGNOSTIC_TEST|low dose chest CT(LDCT)|cross sectioned muscle area of the 1st vertebrae level obtained by LDCT
224316367|NCT05198180|DRUG|Topical 45% hydrogen peroxide solution|Patients will apply the solution every day under occlusion
224316368|NCT06063057|BIOLOGICAL|low dose Bivalent Enterovirus Vaccine (Vero Cell), Inactivated|Bivalent Enterovirus Vaccine (Vero Cell), Inactivated antigen content: EV71 480 U-CA16 600 SU/0.5 ml
224316369|NCT06063057|BIOLOGICAL|medium dose Bivalent Enterovirus Vaccine (Vero Cell), Inactivated|Bivalent Enterovirus Vaccine (Vero Cell), Inactivated antigen content: EV71 960 U-CA16 600 SU/0.5 ml
224316370|NCT06063057|BIOLOGICAL|high dose Bivalent Enterovirus Vaccine (Vero Cell), Inactivated|Bivalent Enterovirus Vaccine (Vero Cell), Inactivated antigen content: EV71 1920U-CA16 1200SU/0.5ml
224316371|NCT06063057|BIOLOGICAL|Enterovirus type EV71 vaccine (Vero cell), Inactivated|Enterovirus type EV71 vaccine (Vero cell), Inactivated (Sinovac)
223622862|NCT06378229|DRUG|Psilocybin|A psychedelic drug found in certain mushrooms. It will be in a capsule of 25mg psilocybin (PEX010).
223622863|NCT03901170|DRUG|Letrozole 2.5mg|oral administration of letrozole 2.5mg/tab, 1tab once per day from stimulation Day 7 to hCG Day.
223622864|NCT01131507|DRUG|EUR-1008 (APT-1008)|EUR-1008 (APT-1008) (Zenpep® \[pancrelipase\] 3,000 lipase units delayed release capsules) from open capsules mixed with a small amount of apple juice or apple sauce will be administered orally starting at the same dose as administered at the end of study PR-011 (NCT01100606), with dose increments of 3,000 lipase units. The dose will be adjusted based on participants' age and body weight. Total dose will not exceed 10,000 lipase units per kilogram (kg) of body weight per day unless clinically indicated. Total duration of study treatment will be up to 12 months.
223622865|NCT00591682|DRUG|MSX-122|"Dosage form = capsule~Starting Dose (First Patient Cohort - Dose Level 1) = 50 mg taken orally once daily, 7 days per week for 4 weeks (total of 28 days), followed immediately by a second course of 28 days with identical dosage form and schedule. (Each patient in each cohort treated for a minimum of 56 days, unless obviated by toxicity.)~* If there is no evidence of toxicity at the current dose level, then the dose of MSX-122 will be increased by 100% for the next patient cohort.~* If a grade 1-2 toxicity is observed, then the dose will be increased by 50% for the next patient cohort.~* If a grade 3 toxicity (non-dose limiting toxicity) is observed then the dose will be increased by 25% for the next patient cohort."
223622866|NCT03571230|DRUG|two sensitive antibiotics(amoxicillin, clarithromycin, metronidazole, tinidazole, levofloxacin, furazolidone and tetracycline)|Patients will receive a 10-day triple therapy for the H.pylori eradication. The regimen contains one PPI and two sensitive antibiotics determined by AST. The susceptibility of amoxicillin, clarithromycin, metronidazole, tinidazole, levofloxacin, furazolidone and tetracycline will be evaluated.
223622867|NCT03571230|DRUG|two antibiotics based on personal medication history(amoxicillin,clarithromycin,furazolidone)|Patients will receive a 14-day bismuth-based quadruple therapy for the H.pylori eradication. The regimen contains one PPI, Colloidal Bismuth Pectin and two antibiotics based on personal medication history. If the patient has taken clarithromycin, roxithromycin and azithromycin for less than 2 weeks before, he will be treated with amoxicillin and clarithromycin. Otherwise, he will be treated with amoxicillin and furazolidone.
223622868|NCT03571230|DRUG|one proton pump inhibitor(PPI)|All the patients need this drug.
223622869|NCT03571230|DRUG|Colloidal Bismuth Pectin|All the patients treated with 14-day bismuth-based quadruple therapy need this drug.
223622870|NCT03571230|DRUG|two antibiotics for failed eradication(tetracyclin,furazolidone)|If the patients failed with AST guided eradication therapy or empirical therapy, patients will be treated with another 14-day bismuth-based quadruple therapy. The regimen contains one PPI, Colloidal Bismuth Pectin, tetracycline and furazolidone.
223622871|NCT02849418|DRUG|GSK1358820|GSK1358820 injection contains botulinum toxin type A (100 U), sodium chloride (0.9 milligrams \[mg\]), and human serum albumin (0.5 mg). The 30 mL of study drug will be administered as 30 injections each of 1.0 mL, evenly distributed at 30 sites in the detrusor muscle, spaced approximately 1 centimeter (cm) apart. The injection will be administered using cystoscopy and under local anesthesia. General anesthesia may be used excluding neuromuscular blocking agents.
224212346|NCT05066347|DEVICE|Cardiophone Plus|Cardiophone Plus (Bittium Faros 360 Mobile event recorder, Bittium Biosignals Ltd., Finland., an external loop recorder with 3 leads for 2 channels. Cardiophone Plus evaluates all cardiac beats and rhythm abnormalities that are detected as per the algorithm programmed into the device. These abnormalities are then automatically and immediately transmitted to a central monitoring station without the need for any patient intervention (device-triggered transmission). This transmission occurs through the cell phone that comes with the device. The central monitoring station is in Windsor, Ontario (Canadian Cardiac Care) and is staffed round the clock by certified electrocardiographic technicians and a cardiologist on-call.
224212347|NCT02998515|DEVICE|Companion (Liquid oxygen device)|
224212348|NCT02998515|DEVICE|Activox (concentrator)|
224212349|NCT02043093|BEHAVIORAL|Sources of Strength|"Sources of Strength (http://www.sourcesofstrength.com/) has three phases:~1. Introduction to school and community partners. Staff advisors for the program are identified and trained.~2. A standard process is used for nominating student peer leaders, who are trained through a 4-hour interactive workshop. A major focus is on increasing knowledge of 'sources of strength' and skills for increasing use of those resources for themselves and other students.~3. Peer Leaders plan and conduct messaging with Adult Advisor mentoring. A school-wide messaging phase involves presentations; media campaigns through posters, public service announcements, videos."
224212350|NCT02725671|DEVICE|Explorer|ECG device which records comprehensive voltage potential data in the myocardium
224212351|NCT05965622|BEHAVIORAL|Attachment Based Family Therapy (ABFT) + Treatment As Usual (TAU)|"Attachment Based Family Therapy (ABFT): ABFT is a manualized treatment, that emerges from interpersonal theories that suggest suicide can be precipitated, exacerbated, or buffered against by the quality of family relationships. Therefore, ABFT focuses on strengthening parent-child attachment bonds to create a protective and secure base for young adult development. Sessions are scheduled weekly, and the intervention lasts on average 16 weeks.~The participants in the ABFT condition will also receive treatment as usual (TAU)."
224212352|NCT05965622|BEHAVIORAL|Treatment As Usual (TAU)|The participants in the treatment as usual (TAU) condition will only receive regular existing care to treat suicidality in young adults.
224212353|NCT05652816|PROCEDURE|Split-thickness skin graft|Transplantation of autologous skin to burn area
224212354|NCT05652816|BIOLOGICAL|Artificial skin graft|Decellularized amnion membrane formed into 3-D matrix
224212355|NCT05652816|BIOLOGICAL|Artificial skin graft co-culture|Decellularized amnion membrane formed into 3-D matrix seeded with autologous keratinocyte co-cultured with amnion epithelial stem cells
223622872|NCT02849418|DRUG|Placebo|Placebo injection contains sodium chloride (0.9 milligrams \[mg\]); 30 mL of the injection will be injected at 30 sites in the detrusor muscle, spaced approximately 1 centimeter (cm) apart. The injection will be administered using cystoscopy and under local anesthesia. General anesthesia may be used excluding neuromuscular blocking agents
223622873|NCT02534376|DRUG|ezetimibe 10mg-simvastatin 40mg|Vytorin (ezetimibe 10mg-simvastatin 40mg) will be given on an outpatient basis. The drug will be taken orally each day until the subject undergoes radical prostatectomy. The start of Vytorin is timed so that patients get the last dose the day before surgery. Subjects receive a two to four weeks of Vytorin.
223622874|NCT03245203|PROCEDURE|FOLFIRI+beacizumab|Eligible patients received bevacizumab 5.0 mg/kg followed by irinotecan 125mg/m2 combined with LV 200mg/m2 followed by 5-FU bolus 400mg/m2,then 5-FU infusion 2.4\~3.0g/m2 over a 46-h period.Those agents were given for a 2-week cycle.Treatment was administered for six cycles. LARC was reevaluated and operated after 4\~8 weeks.
223622875|NCT03245203|PROCEDURE|CRT|total dose of radiotherapy was 40\~50Gy, a subdose of 1.8\~2Gy for continuous 5 weeks, 5 times/week.Then,5-FU infusion 400mg/m2 combined with LV 200mg/m2 over 24 h for 4 days/week during the first and fifth weeks of radiotherapy.Whereas,Capecitabine was administered orally at a dose of 825mg/m2 twice a day for 5 days of a week. Second staging and operation were performed in the sixth week after chemoradiotherapy.
223622876|NCT01254253|DEVICE|Percutaneous coronary intervention, PCI|PCI was performed using standard techniques for CTO.
223622877|NCT00762359|DRUG|Lansoprazole|Lansoprazole 15 mg, capsules, orally, once daily and gefarnate placebo-matching capsules, orally, twice daily for up to 12 to 30 months.
223622878|NCT00762359|DRUG|Gefarnate|Gefarnate 50 mg, capsules, orally, twice daily and lansoprazole placebo-matching capsules, orally, once daily for up to 12 to 30 months.
223622879|NCT06077656|BIOLOGICAL|IVT PCV-25 Formulation A|25 valent pneumococcal conjugate vaccine containing low dose polysaccharide and low dose adjuvant
223622880|NCT06077656|BIOLOGICAL|IVT PCV-25 Formulation B|25 valent pneumococcal conjugate vaccine containing low dose polysaccharide and high dose adjuvant
223622881|NCT06077656|BIOLOGICAL|IVT PCV-25 Formulation C|25 valent pneumococcal conjugate vaccine containing high dose polysaccharide and high dose adjuvant
223622882|NCT06077656|BIOLOGICAL|PCV 20|20 valent pneumococcal conjugate vaccine
223761925|NCT03471338|BEHAVIORAL|Cognitive rehabilitation|"At-site inclusion visit: assessment of patient's eligibility by cognitive complaint questionnaire and BCcogSEP, VAPS and multiple errands test conducted by neuropsychologist.~At-site baseline visit: assessment of quality of life (MUSIQOL), self-esteem (SEI), depression (MADRS), anxiety (HAMA), BICAMS: SDMT, CVLT-II, BVMTR, metacognition (MCQ-30), fatigue (EMIF-SEP), subjective sleep quality (PSQI) conducted by a neuropsychologist.~At-home neuropsychological management (9 weeks): The patient performs the program (PRESCO software) on his computer autonomously at home at a rate of 3 sessions per week. A neuropsychologist performs at-home visits and weekly phone meetings to train the patient to the software, to encourage him to do exercises and to answer any software use-related questions.~At-site follow-up visits: short and long-term retest of assessments performed in inclusion visit."
224212356|NCT00666718|DRUG|Insulin Glargine|patient glucose-level dependent, injection, once daily in the evening, 24 weeks
224212357|NCT00666718|DRUG|Insulin Lispro Protamine Suspension (ILPS)|patient glucose-level dependent, injection, once daily in the evening, 24 weeks
224212358|NCT00666718|DRUG|Insulin Lispro|subcutaneous injections prior to meals, 24 weeks
223622883|NCT01453049|DRUG|rosiglitazone/glimepiride fix dose combination|oral, once daily, dosage is titrated according to FPG and hypoglycemia events
223622884|NCT01453049|DRUG|glimepiride|oral, once daily, dosage is titrated according to FPG and hypoglycemia
223622885|NCT01366768|OTHER|Oral amino acid mixture|Amino acid mixture 2,93 ml/kg
223622886|NCT01366768|OTHER|Intravenous amino acid administration|Amino acid mixture 2,93 ml/kg
223622887|NCT00668421|DRUG|CEP-701 (Lestaurtinib)|Lestaurtinib (CEP-701), oral formulation. Phase 1: 80 BID - 160 BID; phase 2: 140 mg
223622888|NCT00882440|DRUG|losartan potassium|losartan oral capsule (10, 25, 50, 100 or 150 mg) once daily for 8 weeks
224212359|NCT00963599|DRUG|Comparator: montelukast/loratadine|montelukast 10 mg/loratadine 10 mg tablet taken once daily at bed time for 2 weeks
224212360|NCT00963599|DRUG|Comparator: montelukast|montelukast 10 mg tablet taken once daily at bed time for 2 weeks
224212361|NCT00963599|DRUG|Comparator: loratadine|loratadine 10 mg tablet taken once daily at bed time for 2 weeks
223622889|NCT00882440|DRUG|Placebo|Placebo capsule to losartan
223622890|NCT00882440|DRUG|Enalapril|Enalapril 20 mg oral tablet taken once daily for 8 weeks
223622891|NCT04803318|DRUG|Combination of three inhibitors Trametinib, Everolimus and Lenvatinib|Oral administration of three inhibitors including Trametinib, Everolimus and Lenvatinib.
223622892|NCT00213616|PROCEDURE|surgical reinnervation|laryngeal reinnervation with a phrenic nerve root
223622893|NCT06453148|OTHER|Non-interventions|Usual care evaluations
223622894|NCT00210535|DRUG|Topiramate; Placebo|
223622895|NCT03177902|DRUG|Chemotherapy|Newly diagnosed breast cancer patients undergoing at least four cycles of chemotherapy.
224212362|NCT00963599|DRUG|Comparator: placebo|placebo tablet taken once daily at bed time for 2 weeks
224212363|NCT02135094|DEVICE|Active ultrasound therapy device|low intensity continuous therapeutic ultrasound at 3 megahertz (MHz) frequency and 0.132 Watts/cm2 for treatment duration of 4 hours per day
224212364|NCT02135094|DEVICE|Placebo ultrasound therapy device|The placebo device appears and operates identically to the active device except that it does not emit ultrasound.
223622896|NCT03629964|DEVICE|Wiersma Head Stabilizer|Experimental device attached to treatment table.
223622897|NCT03629964|DEVICE|AlignRT system|The AlignRT system (an FDA approved medical device that automatically turns off the radiation beam if the head moves beyond a set distance) will be used to track real-time motions of the head. This system is used with radiation therapy as standard of care.
223622898|NCT05951114|DIAGNOSTIC_TEST|Maximum inspiratory/Expiratory manoeuvre for patients can follow the order|Bedside ultrasound will be performed for each patient at the time before, after surgery, before and after extubation, and at the time of ICU discharge, under the end-expiratory occlusion, maximum inspiratory, and/or expiratory manoeuvre
224212365|NCT00243282|BEHAVIORAL|Relaxation Response (instruction, pocket practice card prov)|
224212366|NCT00243282|BEHAVIORAL|Mindfulness training using model developed from UMass|
224212367|NCT00654446|DRUG|Rosuvastatin|
224212368|NCT00654446|DRUG|Simvastatin|
224212369|NCT05467449|DEVICE|DxFLEX 10C|A device combining flow cytometry and reagents for immunophenotyping analysis
224212370|NCT05176301|RADIATION|computed tomography, Magnetic resonance image|Investigators measured the cervical cord and canal diameter by using CT and MRI that were previously taken.
224212371|NCT00867126|DRUG|pioglitazone hydrochloride|
224212372|NCT00867126|OTHER|laboratory biomarker analysis|
224212373|NCT00867126|OTHER|questionnaire administration|
224212374|NCT00867126|PROCEDURE|quality-of-life assessment|
224212375|NCT04583631|PROCEDURE|Adenoidectomy surgery|All patients underwent adenoidectomy under general anesthesia by routine curettage method and adenoid tissues were put in formaldehyde and sent to the genetics department for the exploration of ER stress and apoptosis markers.
224212376|NCT04496778|DEVICE|low level laser therapy ( laser acupuncture combined with nasal laser irradiation)|"Cold Laser Therapy Watch (Laser Watch- 650 nm) combines acupuncture and nasal cavity for external blood irradiation. Laser watch with 10 laser beams - is applied to the left wrist.~Nasal Probe with 2 laser beams - is applied to the nose cavity"
224212377|NCT04496778|OTHER|aerobic exercise|3 d/week for 45 to 60 minutes per session for 3 months. started by 40%-50% Heart Rate Reserve (determined by using a walking treadmill exercise test) during the first 6 weeks increasing gradually up to 50%-70% Heart Rate Reserve
224212378|NCT03496207|DRUG|Placebo|Placebo
224212379|NCT03496207|DRUG|Sotatercept|Sotatercept (ACE-011) is a recombinant fusion protein consisting of the extracellular domain of the human activin receptor type IIA linked to the Fc piece of human IgG1.
223622899|NCT01048879|PROCEDURE|pharmacokinetic blood sampling|blood samples collected to assess oseltamivir concentrations
223622900|NCT01048879|PROCEDURE|pharmacokinetic blood and dialysate sampling|blood and dialysate samples collected and assayed for oseltamivir concentrations
223622901|NCT05482308|DRUG|Tafamidis free acid tablet (Test)|Variant 12.2 mg tafamidis free acid tablet (Test)
223622902|NCT05482308|DRUG|Tafamidis free acid tablet (Reference)|Proposed commercial 12.2 mg tafamidis free acid tablet (Reference)
223622903|NCT05433246|BEHAVIORAL|Massage therapy group|Massage therapy was performed with a classical massage technique using effleurage, petrissage, and superficial friction techniques for a total of 40 minutes on the areas below the elbow-forearm-hand (20 minutes), and below the knee-lower leg-foot (20 minutes). The patients in the massage group received 16 sessions of classical massage performed by the research nurse, who had classical massage training and certification.
223622904|NCT05397327|OTHER|3D virtual planning software|3D virtual planning software developed by Sectra AB (Linköping, Sweden)
223622905|NCT05822934|DRUG|Carboplatin-Gemcitabine Cisplatin-Gemcitabine|Carboplatin-gemcitabine versus cisplatin-gemcitabine as neoadjuvant chemotherapy for treatment of muscle invasive urinary bladder cancer
224212380|NCT03496207|OTHER|SOC|SOC therapy refers to approved PAH-specific medications and may consist of monotherapy or combination therapy with endothelin-receptor antagonists, phosphodiesterase 5 (PDE5) inhibitors, soluble guanylate cyclase stimulators, and/or prostacyclin analogues or receptor agonists.
224212381|NCT00569335|DRUG|S-1, Irinotecan, Bevacizumab|"S-1 is administered orally on days 1 to 14 of a 21-day cycle. Patients are assigned on the basis of body surface area (BSA) to receive one of the following oral doses twice daily: 40 mg (BSA \<1.25m2), 50 mg (BSA \>1.25 to \<1.50 m2), or 60 mg (BSA \>1.50 m2).~Irinotecan 150 mg/m2 is administered by intravenous infusion on day 1. Bevacizumab 7.5 mg/kg (body weight) is administered by intravenous infusion on day 1."
224212382|NCT01235858|PROCEDURE|wearing of sterile gowns|Anesthesiologists wearing sterile gown for epidural insertion
224212383|NCT01235858|PROCEDURE|No gown|Anesthesiologists not wearing sterile gown for epidural insertion
224212384|NCT04382690|BEHAVIORAL|All participants will be asked to respond to the same survey questions|All participants will be asked to respond to the same survey questions
224212385|NCT03923114|RADIATION|Ga-68-NODAGA-exendin-4 PET/CT|PET/CT imaging after injection with Ga-68-NODAGA-exendin-4
224212386|NCT00657917|DRUG|Paromomycin +Gentamicin topical cream|WR297,396 for treatment of patients with parasitologically confirmed, primarily ulcerative, Old World CL, who had either failed pentavalent antimony treatment, or who where ineligible for pentavalent antimony therapy.
224212387|NCT00689208|DRUG|Atropine|10 ug/kg bolus, 4 ug/kg/h infusion
224212388|NCT00689208|DRUG|Physostigmine|0,12ug/kg/min
224212389|NCT00689208|DRUG|Placebo Sodium|
224212390|NCT03454100|BEHAVIORAL|multisectoral package of activities|A multi-sectoral package of village level activities, including having a well dug, a shared latrine installed, training on handwashing and hygiene across the water chain, training on conservation agriculture techniques, care groups for pregnant and breastfeeding mothers, and training on market gardens.
224212391|NCT02709122|DEVICE|ThoraQuik atraumatic set for pneumothorax decompression|pneumothorax decompression in case it is found in accordance with the actually recommendations
224212392|NCT05762510|GENETIC|GMCN-508B (LentiRed)|LentiRed Drug Product is administered by intravenous infusion following myeloablative conditioning with busulfan.
224212393|NCT02492295|DRUG|Propofol|"Propofol will be administered as a 0.5mg/kg (at a concentration of 10mg/mL, rounded to the nearest 0.5mL) initial bolus, followed by repeat 0.25mg/kg boluses (same rounding) every three to five minutes as needed to maintain RASS target -2 (light sedation - awakens to voice \<10 seconds) to RASS target of -3 (moderate sedation - movement or eye opening without eye contact) for 15 minutes. No more than 1.5mg/kg of propofol will be administered over this time period. After the sedation session is complete, patients will be allowed to wake up and will be monitored in the ED for at least another hour prior to discharge."
224212394|NCT03015909|DRUG|Somatropin|
224212395|NCT00810615|OTHER|Hyperbaric oxygen @ 2.4 ATA|Subject will breath 100% oxygen at 2.4 Atmospheres Absolute (ATA) in three 30 minute periods separated by 10 minutes of breathing air at 2.4 ATA. Hyperbaric exposures will be done up to 5 times per week with a total number of 30 exposures.
224212396|NCT00810615|OTHER|Sham treatment|
224212397|NCT02525562|DEVICE|Triathlon Total Knee System with X3 insert|Total knee replacement
224212398|NCT02525562|DEVICE|Scorpio NRG Total Knee System with X3 insert|Total knee replacement
223622906|NCT00414856|DRUG|AFQ056|
223622907|NCT03450863|DRUG|Fast-acting insulin aspart|Patients will be treated with commercially available fast-acting insulin aspart as bolus insulin (multiple daily injection \[MDI\]) or as insulin used in the insulin pumps (continuous subcutaneous insulin infusion \[CSII\]). Dosing of fast-acting insulin aspart is individual and determined by the treating physician in accordance with the needs of the patient.
224212399|NCT02525562|DEVICE|Triathlon PKR System with X3 insert|Partial Knee Resurfacing
224212400|NCT02525562|PROCEDURE|Total Knee Replacement|Total Knee Replacement
224212401|NCT02525562|PROCEDURE|Partial Knee Resurfacing|Partial Knee Resurfacing
224212402|NCT01731860|DEVICE|Additional PET Scan|Additional PET Scan with no additional radiopharmaceutical administration.
224212403|NCT03235531|DRUG|Valproate|Valproate is an anti-epileptic medication that can influence the chemical changes in the brain that result from alcohol withdrawal syndrome (AWS) via three mechanisms of action: (1) an increase in GABA activity, (2) inhibition of glutamate binding to NMDA, and (3) restoration of the balance between dopamine and acetylcholine activity. VPA may be effective in the prevention of AWS, and could serve as efficacious adjuvant to traditional benzodiazepine (BZD) therapy for AWS, both decreasing symptoms of AWS and decreasing the use of BZDs.
224212404|NCT03235531|DRUG|Lorazepam|Lorazepam is a benzodiazepine used to treat symptoms of AWS. Standard of care at CAMC is monitoring by CIWA tool and administration of lorazepam according to CIWA score.
224212405|NCT05036239|OTHER|Eccentric biceps curls|10 x 5 repetitions of eccentric biceps curls, interspaced by 30 seconds of rest.
224212406|NCT05181761|OTHER|Gel Polish|One hand of a subject with receive nail polish to compare bacterial growth between hands with gel nail polish to those without.
224212407|NCT03179501|DRUG|NP001|NP001
223622908|NCT00467077|BIOLOGICAL|PEG-interferon alfa-2b|PEG-Interferon will be administered subcutaneously (sq) once weekly for 6 weeks
224212408|NCT03179501|DRUG|Placebo|Normal saline
224212409|NCT00343122|PROCEDURE|echocardiography for intrapulmonary vasodilatation|
224212410|NCT06541418|BEHAVIORAL|Transtheoretic Model Based Behavior Change Program|The Behavior Change Program was implemented in 7 sessions of 50 minutes, once a week. Each session in the Behavior Change Program; The warm-up exercise consisted of giving general information about the purpose and the main theme of the session, discussion and feedback on the subject, and the planning of the next week, and a closing process. The Transtheoretic Model Based Behavior Change Program was prepared by the researcher with reference to the behavior change programs in the literature and the elements of the Transtheoretic model.
223622909|NCT00467077|DRUG|gefitinib|ZD1839 will be administered at a dose of 250 mg orally once daily,
223622910|NCT05183061|DRUG|Ehedrine Norepineprine|No interventions required considering that this was a retrospective study.
223622911|NCT01274481|DRUG|Iloprost|patients inhale 20 mcg of Iloprost via nebulizer and, if oxygenation and blood pressure is maintained receive a second dose of 20 mcg of Iloprost 30 minutes later.
223622912|NCT02454738|RADIATION|Ultralow dose chest CT scan|Ultralow-dose chest CT scan is performed using a 64-row multidetector CT system (Discovery CT750HD; GE Healthcare, Waukesha, WI) with 1.25-mm-thick axial slices at less than 1 mSv (volume computed tomography dose index: 0.39 milligray).
223622913|NCT03671941|DRUG|D578|D578 Tab.1T single oral administration under fasting condition
223622914|NCT03671941|DRUG|CKD-357|CKD-357 Tab.1T single oral administration under fasting condition
223622915|NCT03242486|DEVICE|toric intraocular lens|
224212411|NCT00732342|BEHAVIORAL|Contingency Management|Prizes given for targeted behavior of abstinence
224212412|NCT01225315|DRUG|Placebo|Matching placebo administered orally twice daily
224212413|NCT01225315|DRUG|Setipiprant|ACT-129968 (Dose 1, Dose 2, or Dose 3) administered orally twice daily
224212414|NCT03402620|DRUG|Gonadotropins|Human menopausal gonadotropin 75 IU ampoules start at cycle day 2
224212415|NCT03644459|BIOLOGICAL|LYN00101|"Concentrate for intravenous infusions (10 mg / ml) with Molecular Weight 150 - 151 kDa.~Each cycle of treatment consists of 24 weeks. Patients who enroll into this study will receive an infusion of assigned dose of LYN00101 biweekly. No intra-patient dose escalation is allowed. The proposed dose escalation sequence is 10mg/kg, starting from 8 mg/kg."
224212416|NCT02822807|BIOLOGICAL|Blood sampling|
224212417|NCT02572973|OTHER|Acoustic Neuromodulation (ANM)|The purpose of this study is test the safety of the Acoustic Neuromodulation (ANM) treatment and see what effects it has on your child's anxiety symptoms. Observation and anecdotal evidence suggest that this is an effective intervention for anxiety disorders. This is the first research study to test this theory, and could lead to more robust studies in the future. This study intends to assess the efficacy of this type of intervention for children with an anxiety disorder. As this is only a pilot study, the results will also inform the design and execution of future research on this treatment. We hope to add to the growing literature supporting novel treatment approaches for affected individuals.
224212418|NCT05771116|PROCEDURE|ERECTOR SPINAE PLANE BLOCK and PARAVERTEBRAL BLOCK:|catheter will be placed for ERECTOR SPINAE PLANE BLOCK
224212419|NCT05771116|PROCEDURE|PARAVERTEBRAL BLOCK:|catheter will be placed for PARAVERTEBRAL BLOCK
224212420|NCT04067024|PROCEDURE|Local anesthesia made by surgeon|infiltration with local anesthetics
223622916|NCT05635656|DEVICE|Digital symptom mapping and biofeedback treatment|Digital symptom mapping and biofeedback treatment
223622917|NCT02761226|PROCEDURE|Platform Matched Design (Group A)|10 patients with missing upper posterior teeth will receive dental implant with platform matched design (the patients will receive implant 4.2mm with same abutment diameter 4.2mm)
223622918|NCT02761226|PROCEDURE|Platform Switching Design (Group B)|10 patients with missing upper posterior teeth will receive dental implant with platform switching design(the patients will receive implant 4.2mm with smaller abutment diameter 3.5 mm
223622919|NCT03498807|DEVICE|Ventiltor P/V Loop|determine the Optimal PEEP and keep 48hr on ARDS patients
223622920|NCT03498807|DEVICE|Electrical Impedance Tomography|determine Optimal PEEP and keep 48hr on ARDS patients
223622921|NCT01316523|DRUG|Rituximab|Rituximab 375 mg/m2/wk x 4 weeks, to begin Day 15 of cycle 1. After 4 cycles of therapy if patient does not respond to treatment, the patient will receive a second course of Rituximab.
224212421|NCT04067024|PROCEDURE|Regional anesthesia group|Pecs block I and Supraclavicular nerf block
224212422|NCT03313479|DRUG|Dexmedetomidine|Dexmedetomidine will be given with GS
224212423|NCT01797952|DRUG|Lactobacillus CD 2|2x109 (2 billion) viable cells of Lactobacillus CD2 as active ingredient
224212424|NCT01797952|OTHER|Placebo|The placebo is a mix of sugars and salts used as excipients in the active formulation
224212425|NCT01418261|DEVICE|Renal denervation (Symplicity Catheter System)|
224212426|NCT01418261|DIAGNOSTIC_TEST|Renal angiogram|
224212427|NCT02883387|OTHER|Preoperative CT angiography|Patients will receive a CT scan to map the blood vessels to be used during surgery for breast reconstruction
224212428|NCT02883387|OTHER|No Preoperative Imaging|No imaging will be done to map blood vessels prior to surgery
224212429|NCT05529628|DIAGNOSTIC_TEST|Cytokine levels|Preoperative cytokine levels of the patients
223622922|NCT01316523|DRUG|Lenalidomide|Lenalidomide will be taken at 20 mg daily, days 1-21 of a 28 day cycle, to be continued until the disease progresses, there are too many side effects, or after twelve cycles if the patient responds to treatment.
223622923|NCT05937763|OTHER|Staffing model|Staffing the hospitals emergency department offload zone with a PCP or RN or current workflow.
223622924|NCT01451723|DRUG|Polyphenon E|Polyphenon E is a standardized green tea extract. For this study we will use capsules of Polyphenon E containing 200 mg of EGCG per capsule. Subjects will take two capsules twice a day with food.
223622925|NCT01451723|OTHER|Placebo|Matching placebo capsules
223622926|NCT05041231|DEVICE|Photobiomodulation therapy (PBT)|"Any invasive procedures will be done. The treatment in question will be done by a device that looks like a bracelet, which is placed on the hand/fingers to emit light/laser and does not cause pain or temperature change. There will be 8 photobiomodulation sessions, 2 per week, 10 minutes each session.~The dosimetric parameters of the therapy will be carried out in a standardized and personalized way, with programming of the light and all the necessary information so that the device can carry out the application of the treatment application of electromagnetic waves in the red and infrared spectral range 660-1000 nm)."
224212430|NCT05589428|DIETARY_SUPPLEMENT|Low sodium bread|Bread low in sodium
224212431|NCT05589428|OTHER|Placebo|Normal bread from bakery
224212432|NCT01077531|DRUG|Otelixizumab|Otelixizumab injection for intravenous infusion. Otelixizumab (GSK2136525) is a humanised, aglycosyl, non-mitogenic, anti CD3 monoclonal antibody (MAb).
224212433|NCT01077531|DRUG|Matching placebo|Matching placebo for intravenous infusion
224212434|NCT06129331|DRUG|Amyloid-specific treatment|Amyloid-specific treatment
224212435|NCT06129331|OTHER|No amyloid-specific treatment|No amyloid-specific treatment
223622927|NCT05041231|DEVICE|Sham Photobiomodulation therapy (Sham PBT)|Similar to active PBT, however, the device will not provide the active electromagnetic waves)
223622928|NCT06447558|BEHAVIORAL|palatal stimulation with a finger in premature infants|Oral administration of breast milk droplets, palatal stimulation with a finger in premature infants
224212436|NCT00765466|DRUG|AVR118|daily doses of 4.0 mL AVR118 subcutaneously
224212437|NCT04832165|OTHER|Inspiratory muscle strength training|Inspiratory muscle training during 8 weeks, 30 inspirations at 60% of the PIM (maximum inspiratory pressure), 2 times a day for 5 days per week.
224212438|NCT00921804|DRUG|AZD 8529|40mg oral daily capsule administered as a single dose in the morning for 28 days
224212439|NCT00921804|DRUG|Risperidone|4mg (2mg on Day 1) oral daily capsule administered as a single dose in the evening for 28 days
224212440|NCT00921804|DRUG|Placebo to match AZD8529|Placebo to match AZD8529 administered as a daily capsule in the morning for 28 days during the treatment period and also during the 3-7 day washout or run-in period
224212441|NCT00921804|DRUG|Placebo to match risperidone|Placebo to match risperidone administered as a daily capsule in the evening for 28 days during the treatment period and also during the 3-7 day washout or run-in period
224212442|NCT01448265|PROCEDURE|Cryoballoon ablation.|Cryoballoon ablation using a novel circular mapping catheter.
224212443|NCT01255722|DRUG|iobitridol|single IV injection
224212444|NCT01255722|DRUG|iopromide|Single IV injection
224212445|NCT01255722|DRUG|iomeprol|Single IV injection
224212446|NCT02164539|DRUG|FF|Fluticasone furoate is available as fluticasone furoate inhalation powder (100 mcg per blister), combination of fluticasone furoate/umeclidinium bromide inhalation powder (fluticasone furoate: 100 mcg per blister, umeclidinium bromide: 15.6, 62.5, 125, or 250 mcg per blister) and combination of fluticasone furoate/vilanterol inhalation powder (fluticasone furoate: 100 mcg per blister, vilanterol: 25 mcg per blister)
223622929|NCT04750291|DRUG|Botulinum toxin type A|1 infiltration in the biceps muscle with botulinum toxin (100 IU)
223622930|NCT04750291|OTHER|Placebo|1 infiltration in the biceps muscle with placebo or sterile saline
223622931|NCT00793988|PROCEDURE|Vibration-assisted anaesthesia|"All anaesthetic injections will consist of xylocaine 1% with 1:100,000 adrenaline and will be administered through a short 30 Gauge needle at a constant slow speed at multiple (6-7) sites along the upper lid by a single oculoplastic consultant.~The vibration device and placebo will be operated by a single oculoplastics fellow. The vibrating device / placebo will be placed on the middle of the forehead 1 cm above the mid-brow point 1 second before the anaesthetic injection is commenced. It will be lifted off the skin every time the injection needle exits the skin and it will be replaced on the same point 1 second before the needle reenters the skin at a new injection site."
223622932|NCT00793988|PROCEDURE|Switched-off vibrating device|The placebo consists of a switched-off vibrating device applied to the test site and a second identical switched-on vibrating device held close (but not touching) the first, which will therefore make the same sound. Care will be taken to ensure that the devices are out of the participants' view. The test and placebo will be randomly assigned to either the first or second eyelid; the right eyelid will be injected first in all patients, as is our routine practice.
223622933|NCT01373463|DRUG|Pemetrexed|Pemetrexed by vein every 21 days for 3 cycles
224212447|NCT02164539|DRUG|UMEC|Umeclidinium bromide is available as combination of fluticasone furoate/umeclidinium bromide inhalation powder (fluticasone furoate: 100 mcg per blister, umeclidinium bromide: 15.6, 62.5, 125, or 250 mcg per blister)
224212448|NCT02164539|DRUG|VI|Vilanterol is available as vilanterol inhalation powder (25 mcg per blister) and combination of fluticasone furoate/vilanterol inhalation powder (fluticasone furoate: 100 mcg per blister, vilanterol: 25 mcg per blister)
224212449|NCT03113825|DEVICE|Investigational Imaging device|Fluorescence imaging of the of the primary tumor specimen, any secondary breast specimens, and lymph nodes will be performed.
224212450|NCT03113825|DRUG|AVB-620|AVB-620 will be administered IV before the surgical procedure.
224212451|NCT01833221|DRUG|injection of 1% lidocaine, 2mL for facial nerve block|injection with a fine needle of 2mL lidocaine in close contact of the facial nerve trunk
223622934|NCT01373463|DRUG|Carboplatin|Carboplatin by vein Every 21 days for 3 cycles
224212452|NCT02139605|PROCEDURE|D3 Lymphadenectomy|D3 Lymphadenectomy involves surgical removal of lymph nodes from echelon or compartments 1 to 3 in gastric cancer patients
224212453|NCT05301166|BEHAVIORAL|Technology Based Motivation Education Program|Technology-Based Motivation Education Program consists of web-based education, motivation program and individual motivation interviews. This program will be prepared according to the Health Belief Model (HBM). It will be applied for 4 months. Participants will take a pre-test before starting the program and a post-test at the end of the program. Individual motivation interviews will be 6 sessions in total. A website will be prepared for the Technology Based Motivation Education Program. This website consists of two parts, a web-based education and motivation program for obesity. The motivation program will enable the participant to follow the program and receive motivational messages.
224212454|NCT05301166|OTHER|Web Based Education|Students in the control group will participate in web-based educations on obesity prepared only according to the Health Belief Model in the Technology-Based Motivation Education Program. Individual interviews supporting web-based education will be held with the control group once a month.
224212455|NCT02643966|DEVICE|Whole breast ultrasound|Breast cancer screening with whole breast ultrasound
224212456|NCT01866982|PROCEDURE|Umbilical Cord Milking|Umbilical cord milked toward the neonate four times at a speed of 20cm/2seconds, prior to clamping and cutting umbilical cord. Procedure takes about 10-20 seconds.
224212457|NCT01866982|PROCEDURE|Delayed Cord Clamping|Performed by positioning the baby 20 cm below the placenta for 45-60 seconds prior to umbilical cord clamping and cutting.
224212458|NCT02245360|DRUG|Phleum pratense grass pollen allergen extract|Allergy Immunotherapy grass tablet 75,000 SQ-T given once daily over 60 days
224212459|NCT02245360|DRUG|placebo|placebo tablet given once daily over 60 days
224212460|NCT04368325|DIAGNOSTIC_TEST|Serum creatinine levels|Comparison of treatment length using mechanical ventilaton, length of stay in ICU, survival between two groups
223622935|NCT01373463|RADIATION|Radiation Therapy|Radiation treatment 5 days a week for 5-6 weeks.
223622936|NCT01373463|DRUG|Pemetrexed|Pemetrexed by vein every 21 days for 3 cycles
223622937|NCT01373463|DRUG|Cisplatin|Cisplatin by vein every 21 days for 3 cycles
223622938|NCT01373463|RADIATION|Radiation Therapy|Radiation treatment 5 days a week for 5-6 weeks.
223622939|NCT01373463|PROCEDURE|Lobectomy|Surgery
224212461|NCT02533323|DRUG|gemcitabine|gemcitabine :1250mg/m2 (ivdrip) on days 1
224212462|NCT02533323|DRUG|oxaliplatin|oxaliplatin :85 mg/m2 (ivdrip) on day 1
223761926|NCT03471338|BEHAVIORAL|Standard Psychological care|"At-site inclusion visit: assessment of patient's eligibility by cognitive complaint questionnaire and BCcogSEP, VAPS and multiple errands test conducted by neuropsychologist.~At-site baseline visit: assessment of quality of life (MUSIQOL), self-esteem (SEI), depression (MADRS), anxiety (HAMA), BICAMS: SDMT, CVLT-II, BVMTR, metacognition (MCQ-30), fatigue (EMIF-SEP), subjective sleep quality (PSQI) conducted by a neuropsychologist.~At-home neuropsychological management (9 weeks): A neuropsychologist performs at-home visits and weekly phone meetings consisting in discussion of the patient's cognitive disorders.~At-site follow-up visits: short and long-term retest of assessments performed in inclusion visit."
224212463|NCT02533323|DRUG|pegaspargase|pegaspargase : 2500 IU/m2 (intramuscular injection)
224212464|NCT00764049|DEVICE|Single pass albumin dialysis|6 hours sessions of albumin dialysis.
223622940|NCT01373463|PROCEDURE|Lobectomy|Surgery to remove a portion of the lung where the tumor is located.
223622941|NCT04687657|DRUG|umbilical cord blood|During the consolidation chemotherapy stage, the umbilical cord blood transfusion is given twice (interval of 1 month) to support treatment. On the first day after umbilical cord blood transfusion, the proportion of NK cells in peripheral blood is detected. If it is less than 20%, the NK cells sre activated by subcutaneous injection of recombinant human interleukin-2 (rhIL-2) on the second day after infusion.
223622942|NCT05987358|DRUG|TQB3454 tablets|TQB3454 is a selective IDH1 mutant enzyme inhibitor.
223622943|NCT05987358|DRUG|TQB3454 tablets matching placebo|Placebo tablets without active substance.
223622944|NCT04463472|BIOLOGICAL|AG0301-COVID19|1.0 mg of AG0301-COVID19 twice at 2-week intervals
223622945|NCT04463472|BIOLOGICAL|AG0301-COVID19|2.0 mg of AG0301-COVID19 twice at 2-week intervals
223622946|NCT05357625|BEHAVIORAL|Feedback Informed Treatment|FIT is based on two simple questionnaires and aims to assess and improve the effectiveness of therapeutic treatment. Treatment outcomes are assessed with the Outcome Rating Scale (ORS), a four-item self-report instrument measuring client functioning in the area of quality of life. Therapeutic alliance is assessed using the four-item Session Rating Scale (SRS). In FIT the feedback from the client is used to continuous adjustment and improvement of therapy
223622947|NCT04375150|DRUG|Tyrosine kinase inhibitor (TKI)|TKIs
223622948|NCT04375150|DRUG|Immuno-oncology (IO)|IOs
223622949|NCT05297877|OTHER|Experimental AI Echo Machine|Participants will go through the training programme using an AI machine for learning.
223622950|NCT05297877|OTHER|Conventional Echo Machine|Participants will go through the training programme using a conventional machine for learning.
223622951|NCT01393275|OTHER|rehabilitation exercise intervention|"exercise intervention: 15 minutes warm up, 30 minutes strength endurance training, 60 minutes rehabilitation exercise training - once a week~15 minutes warm up, 30 minutes strength endurance training - once a week"
223761927|NCT03057639|OTHER|Quality-of-Life Assessment|Ancillary studies
224212465|NCT01788059|OTHER|injection the mesenchymal stem cell in non union site|
224212466|NCT05312255|BEHAVIORAL|Behavioral Intervention|Wear a FitBit device and receive prompts for 6 months
224212467|NCT05312255|DRUG|Beta-Adrenergic Antagonist|Receive beta-blocker regimen as per SOC
224212468|NCT05312255|DRUG|Propranolol|Given PO
224212469|NCT05312255|OTHER|Quality-of-Life Assessment|Ancillary studies
224212470|NCT05312255|OTHER|Questionnaire Administration|Ancillary studies
224212471|NCT05312255|OTHER|Resistance Training|Undergo strength training for 6 months
224212472|NCT05312255|OTHER|Short-Term Fasting|Participate in intermittent fasting
224212473|NCT02197169|DRUG|Single intratumoral injection of DNX-2401|"In the randomized group, following brain tumor biopsy and histological confirmation of recurrent glioblastoma/gliosarcoma, a single injection of DNX-2401 was administered directly into the brain tumor with or without subsequent interferon gamma (IFN-γ)~No additional subjects will be randomized. A single intratumoral dose of DNX-2401 will be delivered by cannula."
224212474|NCT02197169|DRUG|Interferon-gamma|In the randomized group, a single injection of DNX-2401 was followed by interferon gamma (IFN-γ). No additional subjects will be randomized or receive IFN-γ following DNX-2401
224212475|NCT01612702|DRUG|Dexamethasone|Dexamethasone 10 mg intravenous administration
224212476|NCT05033015|PROCEDURE|Mouth rinse|To test a novel mouth rinse containing enzymes to prevent development of WSL with a control
224212477|NCT02331030|PROCEDURE|Supraclavicular|Ultrasound-guided supraclavicular brachial plexus block
224212478|NCT02331030|PROCEDURE|Pecs II block|Ultrasound guided interfascial plane block between pectoralis minor and serratus anterior
224212479|NCT02331030|PROCEDURE|Sham block (Grade 1)|Sham block -- with skin preparation, ultrasound scanning of pecs II block area, but no actual needle injection
224212480|NCT02331030|DRUG|Ropivacaine 0.5% 20ml|Local anaesthetic solution administered for supraclavicular block
224212481|NCT02331030|DRUG|Ropivacaine 0.5% 10ml|Local anaesthetic solution administered for pecs II block
223622952|NCT01393275|OTHER|placebo control group|"exercise intervention: 15 minutes warm up, 30 minutes strength endurance training, 5 minutes walking 55 minutes conversation in the group- once a week~15 minutes warm up, 30 minutes strength endurance training - once a week"
223622953|NCT00443040|DRUG|Asimadoline|Asimadoline was provided in coated tablets of 1.0 mg strength. Subjects were given 3 tablets of study drug 90 minutes prior to their operation and then 3 tablets b.i.d. for up to 10 post-operative doses. Subjects randomized to receive 3.0 mg of asimadoline received three 1.0 mg asimadoline tablets at each scheduled dose, while those randomized to receive 1.0 mg of asimadoline received two placebo tablets and one 1.0 mg asimadoline tablet at each scheduled dose.
223622954|NCT00443040|DRUG|Placebo|Placebo was provided in coated tablets identical in appearance to asimadoline tablets. Subjects were given 3 tablets of placebo 90 minutes prior to their operation and then 3 placebo tablets b.i.d. for up to 10 post-operative doses.
223622955|NCT01149317|PROCEDURE|Acupuncture|Weekly acupuncture treatment for up to 14 weeks to augment usual care
223622956|NCT03357107|PROCEDURE|Transoral robotic surgery (TORS)|All patients underwent primary tumour resection with transoral robotic surgery (TORS) using the daVinci robot (Intuitive Surgical, Sunnyvale CA)
223622957|NCT01222013|DRUG|Imatinib Mesylate|patient will receive Imatinib (Glivec®), 300 mg/m²/day, per oral, in conjunction with chemotherapy, maximum dose allowed 400 mg/dia.
224212482|NCT04905719|DIAGNOSTIC_TEST|Ultrasound|Each patient included to the study will undergo Point-of-Care ultrasound testing specific for the area defined in the Groups section.
224212483|NCT01542736|DRUG|Carboplatin|Administered concurrently with craniospinal radiation.
224212484|NCT01542736|DRUG|Vincristine|Administered concurrently with craniospinal radiation.
223622958|NCT01582815|DRUG|JNJ-40411813|Type= range, unit= mg, number= 25 to 150, form= capsules, route= oral administration. JNJ-40411813 will be administered twice daily during 8 weeks, following fixed and flexible schedules in which the dose can range from 25 mg to 150 mg.
224212485|NCT01542736|RADIATION|24 Gy|Craniospinal radiation.
224212486|NCT04102228|DEVICE|1Hz inhibitory rTMS|20 minutes of 1Hz (1200 pulses) repetitive transcranial magnetic stimulation (rTMS) applied by Magstim Rapid 2 stimulator equipped with an airfilm figure-8 coil
223622959|NCT01582815|DRUG|Placebo|Form= capsule, route= oral administration. Matching placebo will be administered twice daily during 8 weeks.
223622960|NCT02222571|BEHAVIORAL|Parents and Tots Together Program|Group-based parenting program, 9 weeks delivered in a community setting
223622961|NCT02222571|BEHAVIORAL|Supervision for Safety|group-based safety intervention for parents
223622962|NCT02316028|DRUG|Decitabine|"administration of decitabine by hepatic arterial infusion~* Accrual of patients and dosing of decitabine will be guided by a traditional 3+3 design using an accelerated titration for the first three dose levels.~* Proposed dose levels:~  1. 10 mg/m2 per course~ 2. 15 mg/m2 per course~ 3. 20 mg/m2 per course"
223622963|NCT01778790|DEVICE|Deep Brain Stimulation with Activa PC Multi-program Neurostimulator|"Device: DBS 130 Hertz (Hz) frequency, 90us pulsewidth, 4 Volt (V) currency Amplitude~Device: DBS - No Stimulation (Sham) 130 Hertz (Hz)frequency, 90us pulsewidth, 0 Volt (V) currency Amplitude"
223622964|NCT01323023|BEHAVIORAL|varies by project|
223622965|NCT01157702|BIOLOGICAL|Inactivated influenza vaccine (split virus, Vero cell-derived)|One 0.5 mL dose of inactivated influenza vaccine in a pre-filled syringe, administered by intramuscular injection into the musculus deltoideus in the upper arm
223622966|NCT03070288|OTHER|Red-green-blue measurements of nasal mucosa image|Adobe Photoshop Elements 7.0 program automatically measures the numerical values of the RGB color components in the selected area
224212487|NCT04102228|DEVICE|1Hz sham rTMS|20 minutes of 1Hz (1200 pulses) repetitive transcranial magnetic stimulation (rTMS) applied by Magstim Rapid 2 stimulator equipped with an airfilm figure-8 sham coil.
224212488|NCT04102228|BEHAVIORAL|Multi-Modality Aphasia Therapy (M-MAT)|Participants receive 3.5 hours of intensive speech therapy in small groups delivered by a blinded speech language pathologist and therapy assistant. The objective of M-MAT is to improve word production through shaping of responses (ie. Gradually increasing complexity of spoken targets towards eventual mastery) and social-mediated repetitive practice. Therapists use game-based interactive tasks and rich multi-modal cueing (gestures, written words, drawing, reading words) to improve spoken production and oral communication.
224212489|NCT01682473|DRUG|ZSTK474|Two arms, each with serial cohorts receiving escalating doses.
224212490|NCT00251771|PROCEDURE|catheter-directed venous thrombolysis|catheter-directed continuous intravenous infusion of alteplase 0.01mg/kg/h and low-dose heparin. Max dose 20mg/24 h and up to 96 hrs.
224212491|NCT02400905|DEVICE|BioMimics 3D Vascular Stent System|Femoropopliteal stenting
224212492|NCT02854566|DEVICE|osteosynthesis|Fracture reduction and fixation with screws/plates/cables (standard of care)
224212493|NCT06254391|DRUG|Low-dose aspirin|Implementation of low-dose aspirin (30 mg)
224212494|NCT00908531|DRUG|letrozole (Femara)|tablet 2.5 mg daily
224212495|NCT01190202|PROCEDURE|Blood sampling|Capillary blood samples collected by finger/heel prick
224212496|NCT01190202|PROCEDURE|Assessment of body temperature|Assessment of axial body temperature with a digital thermometer
224212497|NCT04853888|BEHAVIORAL|ATTACH™ Parenting Program|"ATTACH™ parenting program offers an innovative, novel approach to early intervention, focusing on improving parent-child relationship quality by targeting parents' underlying reflective function (RF)-the ability to better understand one's own and one's child's thoughts and feelings. RF is essential for high quality parent-child relationships and secure parent-child attachment, both tied to child development and health, especially cognition, communication and inflammation.~."
224212498|NCT02470442|DRUG|Sevoflurane/Desflurane|Anesthesia induced with sevoflurane and anesthetic maintenance with desflurane
224212499|NCT02470442|DRUG|Sevoflurane|Anesthesia induced with sevoflurane and anesthetic maintenance with sevoflurane
224212500|NCT01350531|BEHAVIORAL|Skills training|This component includes skills most proximal to adhering to the eating and weight loss plan (e.g., calorie counting, making healthy food choices, measuring food portions, scheduling snacks and meals, meal planning, completing food logs daily, following an exercise plan).
224212501|NCT01350531|BEHAVIORAL|Contingency Management|Contingency management uses behavioral principles to counteract the reinforcing mechanisms of food and inactivity.
224212502|NCT04640909|OTHER|Peripheral blood samples withdrawal|Peripheral blood samples evaluation
224212503|NCT06611033|BIOLOGICAL|V118C|Intramuscular Administration
224212504|NCT06611033|BIOLOGICAL|V118|Intramuscular Administration
224212505|NCT06611033|BIOLOGICAL|PREVNAR 20™|Intramuscular Administration
224212506|NCT06611033|BIOLOGICAL|Saline|Intramuscular Administration
224212507|NCT05354336|DRUG|SHR6390(100mg)|SHR6390 at a single oral dose of 100 mg.
224212508|NCT05354336|DRUG|SHR6390(125mg)|SHR6390 at a single oral dose of 125 mg.
224212509|NCT05354336|DRUG|SHR6390(150mg)|SHR6390 at a single oral dose of 150 mg.
224212510|NCT02493985|OTHER|0.5% CO2|The subjects will be randomized to breath 0.5% carbon dioxide during one of the -12 degree head down tilt body position periods in crossover design
223622967|NCT03065816|DRUG|Z0063|Pharmaceutical form: chewable tablets Route of administration: oral
223622968|NCT03065816|DRUG|Gaviscon|Pharmaceutical form: chewable tablets Route of administration: oral
223622969|NCT06325059|OTHER|Study of renal progenitors|Evaluation of the role of renal progenitors in pathogenesis and mechanisms of disease progression in kidney biopsies performed for diagnostic purposes
223622970|NCT00965601|BEHAVIORAL|Cognitive Behavioral Therapy|Subjects randomized to the Active Arm will receive workbook assignments a series of six phone intervention interviews of Cognitive Behavioral Therapy (CBT)
223622971|NCT04479397|PROCEDURE|Latarjet Surgery for anterior shoulder instability|Bone block procedure for anterior shoulder instability
223622972|NCT04479397|PROCEDURE|No sling in postoperative care|No sling will be used in postoperative care.
223622973|NCT02681809|DRUG|ocriplasmin 0.0625mg|Up to 3 intravitreal injections of ocriplasmin 0.0625mg approximately 1 month apart
224212511|NCT02493985|OTHER|ambient air|The subjects will be randomized to breath ambient air during one of the -12 degree head down tilt body position periods in crossover design
224212512|NCT00086931|DRUG|capecitabine|oral dose escalating, twice daily.
224212513|NCT00086931|DRUG|oxaliplatin|IV over 2 hours on days 1, 8, 15, 22, and 29.
224212514|NCT00086931|PROCEDURE|conventional surgery|curative-intent surgery 6-8 weeks after the completion of chemoradiotherapy
224212515|NCT00086931|PROCEDURE|neoadjuvant therapy|chemotherapy and radiation prior to surgery
224212516|NCT00086931|RADIATION|radiation therapy|once daily 5 days a week for 5.5 weeks
224212517|NCT00701168|DEVICE|yttrium Y 90 microspheres (Therasphere®)|This is a local therapy for unresectable liver tumors with limited treatment options. It may be repeated under special circumstances.
224212518|NCT01819389|DRUG|Imatinib and Nilotinib|
224212519|NCT02740660|DRUG|Caffeine 100mg / Albuterol 4mg|
224212520|NCT02740660|DRUG|Placebo|
224212521|NCT02740660|BEHAVIORAL|Family weight management counseling|
224212522|NCT03874585|BEHAVIORAL|Group counseling and nicotine replacement|Participants will receive a 30-minute group smoking cessation counseling session and a supply of nicotine replacement.
224212523|NCT03874585|BEHAVIORAL|Group counseling, nicotine replacement, and text messaging support|Participants will receive a 30-minute group smoking cessation counseling session, a supply of nicotine replacement, and the 6-week text messaging intervention to provide ongoing support for quitting
224212524|NCT05303480|DRUG|Chlormethine|Chlormethine gel 0.016%
224212525|NCT02441179|OTHER|Acute Intermittent Hypoxia|Patients will breath 9% oxigen for 1.5 minutes interspersed with 1.5 minutes of 21% oxigen (normoxia), 15 times for a total of 45 minutes.
224212526|NCT02441179|OTHER|Body weight-assisted treadmill training|Patient´s gait will be trained through a weight-assisted treadmill (BWSTT). All recruited patients will start BWSTT at a speed of 0.6 km/hr. The physical therapist will manually correct posture to assure an adequate gait, increasing the speed of treadmill progressively depending upon the patient progress and tolerance. This training will be done immediately after the protocol of AIH or Sham and it will last 45 minutes.
224212527|NCT02441179|OTHER|Sham Protocol|It consists of continuous normoxia (FiO2=0.21) for 45 minutes for 5 consecutive days and then 3 times per week for 3 weeks. Total time: 4 weeks.
224212528|NCT02593084|BEHAVIORAL|Higher Intensity Resistance Training|Bi-weekly resistance training for 12 weeks using multi-joint movements involving both upper and lower extremities (e.g squats). Participants will perform 3-5 sets of 3-6 repetitions at Rating of Perceived Exertion 8/10. The intervention will be administered by a Physical Therapist or trained fitness professional.
224212529|NCT02593084|BEHAVIORAL|Lower Intensity Resistance Training|Bi-weekly resistance training for 12 weeks using single-joint movements involving both upper and lower extremities (e.g leg extension). Participants will perform 3-5 sets of 8-10 repetitions at Rating of Perceived Exertion 5/10. The intervention will be administered by a Physical Therapist or trained fitness professional.
224212530|NCT03091400|DRUG|Atomoxetine|Atomoxetine (40 mg qd titration dose for first seven days, followed by 80 mg qd target dose for remaining five weeks)
224212531|NCT03091400|DRUG|Placebo|Identically encapsulated placebo, with dose matched to experimental agent (40 mg qd titration dose for first seven days, followed by 80 mg qd target dose for remaining five weeks)
224212532|NCT02588742|DIETARY_SUPPLEMENT|Melatonin|Patients in the melatonin group are given 5mg of melatonin at 8 pm the day before surgery, POD#0, POD#1, POD#2, POD#3, POD#4, and POD#5.
224212533|NCT02588742|DIETARY_SUPPLEMENT|Placebo|Patients in the control group are given placebo at 8 pm the day before surgery, POD#0, POD#1, POD#2, POD#3, POD#4, and POD#5.
224212534|NCT04622618|DRUG|Gabapentin|Anticonvulsant, Antiemetic, Analgesic
224212535|NCT04991896|DRUG|Flecainide Injectable Product|Flecainide is given as an IV infusion of 1.5 mg/kg (max 150 mg) in DW 5% over 10 min under continuous monitoring. Concomitant administration of a b-blocker is also applied in all patients. The dose and type of b-blocker are selected according to heart rate during the AF and patient's medical history.
223622974|NCT02681809|DRUG|ocriplasmin 0.125mg|Up to 3 intravitreal injections of ocriplasmin 0.125mg approximately 1 month apart
223622975|NCT02681809|DRUG|Sham injection|3 sham injections approximately 1 month apart. No actual injections. No medication is used.
223622976|NCT01308541|DRUG|arm 1|"Bolus Dose: two bolus doses of 15.0 mg/kg (first dose) and 8.0 mg/kg (second dose), 40 minutes apart.~Continuous Infusion Dose: Total dose of 42.0 mg/kg administered over 3 hours at an infusion rate of 0.40 mg/kg/min for 1 hour, followed by 0.20 mg/kg/min for 1 hour, followed by 0.10 mg/kg/min for 1 hour."
223622977|NCT01308541|DRUG|LUSEDRA|Mode of administration: intravenous (IV).Continuous Infusion Dose: Total dose of 42.0 mg/kg administered over 3 hours at an infusion rate of 0.40 mg/kg/min for 1 hour, followed by 0.20 mg/kg/min for 1 hour, followed by 0.10 mg/kg/min for 1 hour.
223622978|NCT01308541|DRUG|Propofol (arm 3)|Mode of administration: intravenous (IV). A loading dose administered at a constant infusion rate of 0.20 mg/kg/min (0.50 mL/kg/min) for 10 minutes, followed by a constant-rate 2-hour infusion at 0.10 mg/kg/min; total dose infused over 130 minutes is 14.0 mg/kg.
223622979|NCT04245111|OTHER|Immunofluorescence Imaging|Patients will be administered FDA approved ICG through intravenous injection and imaged by a FDA approved surgical microscope (Pentero or Spy Elite) which is 0.5 meter away from the subject. Both ICG fluorescence and the two imaging systems have been used for routine clinical practice for many years. Figure (a) shows the Schematic sketch of the imaging systems. ICG fluorescence imaging utilizes intravenously injected ICG, which is a fluorescent dye that is FDA-approved for clinical use, illuminated with near-infrared light. The ICG dye is indirectly activated and the dynamic fluorescence due to bone perfusion can be captured by a video rate imaging system.
223622980|NCT02547311|BEHAVIORAL|Team Clinic|
223622981|NCT05767008|OTHER|Sunscreen -R43|Long wear metal oxide particles
223622982|NCT02039115|DRUG|prednisone|6 weeks of prednisone and placebo therapy will be given over 6 weeks after both the first and second stage complete Barretts Excision.
223622983|NCT02039115|DRUG|placebo|6 weeks of placebo therapy will be given in the same manner as the prednisone arm after the first and second stage complete Barretts excision.
223622984|NCT04084158|DRUG|Toripalimab injection (JS001)|Toripalimab injection (JS001) is a humanized IgG4 monoclonal antibody against the programmed death-1 (PD-1) receptor, blocks the interaction of PD-1 with its ligands and promotes T cell activation in preclinical studies.
223622985|NCT04084158|DRUG|Paclitaxel, Albumin-Bound|Paclitaxel
223622986|NCT04084158|RADIATION|Radiotherapy|PTV 50.4Gy/28 fractions, PGTV 61.6Gy/28 fractions, once a day, 5 days a week.
223622987|NCT04084158|DRUG|Platinum-Based Drug|carboplatin
223622988|NCT01442246|DRUG|Leuprorelin Acetate|Leuprorelin Acetate 45 mg, one injection every 6 months for 24 months
223622989|NCT05356377|DRUG|Pegvaliase-Pqpz|Participants will have been prescribed pegvaliase-pqpz (Palynziq) by their primary metabolic care providers as part of their standard care. \[Note that prescription and standard care are independent of the present study.\]
223622990|NCT04392739|DRUG|Tpoxx|oral antiviral
223761928|NCT03057639|OTHER|Questionnaire Administration|Ancillary studies
224212536|NCT00393770|DRUG|L-acetylcarnitine|250-500 mg/kg/die.
224212537|NCT04916288|DEVICE|central venous cathterization|central venous catheterization through the right internal jugular vein
224212538|NCT05969028|DEVICE|igel|First responder ventilation strategy. First responders in King County routinely use the BVM as part of core treatment of SCA. As part of EMS training, we have introduced a training module for use of the igel in simulated resuscitation, which has been enthusiastically accepted by EMS leadership and providers. The i-gel is already successfully practiced by BLS providers in a number of other communities and challenges in training and clinical application will be monitored, but not anticipated.
224212539|NCT05969028|PROCEDURE|Compression Rate|Compression rates. The EMS system routinely measures EMS CPR performance and specifically the chest compression rate using information derived and electronically recorded from defibrillator patches. As detailed in the Background section, this CPR surveillance activity highlights the variability of compression rates across the guideline-directed range of 100-120 compressions per minute. In addition our CPR surveillance indicates that a metronome can be used to obtain and maintain a specific compression rate within the parameters specified by this trial. This will be the tool used to guide compliance with the assigned chest compression rate by on-scene providers.
224212540|NCT00667498|DRUG|Metformin|"The subject will receive either metformin or placebo drug, given as 500mg tablets (or corresponding placebos) necessary to increase the dose incrementally over a three week period.~The time it takes to incrementally increase the dose to the desired dose of 500mg in am and 1000mg in pm will count as intervention time. Both the metformin and placebo group will also be given a multivitamin with vitamin B12 to avoid potential anemia."
224212541|NCT00667498|DRUG|Placebo|"The subject will receive either metformin or placebo drug, given as 500mg tablets (or corresponding placebos) necessary to increase the dose incrementally over a three week period.~The time it takes to incrementally increase the dose to the desired dose of 500mg in am and 1000mg in pm will count as intervention time. Both the metformin and placebo group will also be given a multivitamin with vitamin B12 to avoid potential anemia."
223622991|NCT03316196|BEHAVIORAL|COGENT COGNITIVE TRAINING|Computer-administered cognitive training program. COGENT is a modified working memory capacity task designed to train cognitive functioning. COGENT was designed to contain high interference across trials. By requiring repeated practice with utilization of interference control across trials, COGENT is thought to enhance plasticity of cognitive systems and improve performance. That is, training is based on the premise that learning-based neural changes will occur via repeated exposure to a task demanding cognitive control resources
224212542|NCT04529161|DIETARY_SUPPLEMENT|Fasting Mimicking Diet (FMD)|The treatment consists in the self-administration of FMD at home - closely followed by the neuropsychologist by phone and by a properly trained nutritionist in the FMD sector - for 5 days a month for 6 consecutive months.
224212543|NCT04529161|DIETARY_SUPPLEMENT|Routinary diet habits|Subjects will follow their routinary eating habits for 6 consecutive months
224212544|NCT01359072|OTHER|Self administered coping intervention|The self administered coping intervention (i.e. NUCARE workbook) aims to teach individuals how to cope with their cancer. The intervention embraces two major areas: (i) the enhancement of a sense of personal control; and (ii) the learning of emotional and instrumental coping responses. The approach emphasizes training in problem-solving, relaxation techniques, cognitive coping skills, goal setting, communication, social support and lifestyle factors. The didactic material of the Nucare program is comprised of a workbook containing 12 chapters addressing the above mentioned aspects.
224212545|NCT03887819|DIAGNOSTIC_TEST|Hystological evaluation|The original tissues samples will be fixed in 10% neutral buffered formalin and embedded in paraffin blocks. Sections (4 μm thick) will be stained with hematoxylin and eosin stain (H\&E) for diagnosis. The immunohistochemistry for anti-LCA, anti-CD68, and anti-CD3 will be performed to identify the inflammatory infiltrate.
224212546|NCT06567795|DEVICE|Hemotag|Hemotag non-invasive medical device is used to see cardiac function for DM2 patients at-home for 30 days
224212547|NCT02620319|DEVICE|SX-ELLA Stent DV Tracheal (DV Stent)|The trachea is intubated with a rigid bronchoscope while participants are placed under total intravenous anesthesia and jet ventilation. The delivery apparatus containing the stent is introduced through a rigid tube to the desired depth under visual control. Then the stent is deployed and its position is determined and, if necessary, stent is repositioned using rigid forceps. In-stent balloon dilation is carried out. If needed, thoracic surgeon can secure the stent in place via external (percutaneous) fixation: one suture is passed through the stent, the tracheal wall, soft tissues, and skin; the suture is then knotted on the skin of the neck. The suture is removed two to three weeks after implantation.
224212548|NCT00051636|DRUG|Zoledronic Acid|Zoledronic acid 5 mg in 5 mL of sterile water intravenous infusion.
224212549|NCT00051636|DRUG|Risedronate|Oral risedronate 30 mg capsules.
224212550|NCT00051636|DRUG|Placebo to Risedronate|Oral placebo of risedronate capsules.
223622992|NCT03316196|BEHAVIORAL|Non training computer condition|The non-training condition requires participants to complete a similar computer task for the same length of time. The non-training is a modified working memory capacity task designed to be inert. The non-training condition was designed to contain relatively less interference demands across trials. Participants are required to remember the same total number of items as in COGENT (i.e., storage requirements were equivalent), but the task contains relatively less interference inherent in the task.
223622993|NCT03405883|OTHER|Vaginal swab + endometrial biopsy|In the midluteal phase of the cycle, a vaginal swab (E swab) and endometrial biopsy (TAO brush) will be obtained.
223622994|NCT03856060|OTHER|Questionnaire Administration|Complete questionnaires
223622995|NCT03856060|OTHER|Video|Watch videos of doctor and patient interaction in different settings
223622996|NCT04587947|DRUG|sacubitril/ valsartan|Heart rate variability measurement is carried out by means of a 12-channel ECG for 30 minutes in supine position followed by 10 minutes in standing position. All parameters, including blood values and echocardiographic parameters are assessed before beginning of sacubitril/ valsartan therapy and 3 months after starting treatment
223622997|NCT02159586|DEVICE|gastric electrical stimulator|
223622998|NCT06400069|OTHER|Evaluation of serum NLRP6 levels|intervention: Evaluation of serum NLRP6 levels control: Evaluation of serum NLRP6 levels
223622999|NCT05272683|DRUG|GLPG3667|On day 1 and day 8, participants will receive a single dose
224212551|NCT00051636|DRUG|Placebo to Zoledronic Acid|5 mL of sterile water one dose intravenous infusion.
224212552|NCT00051636|DIETARY_SUPPLEMENT|Calcium and Vitamin D|Calcium and vitamin D supplements were supplied.
224212553|NCT04495192|GENETIC|Genetic analysis of different single nucleotide polymorphisms on ApoE, BDNF and DRD2 genes assessment|Genomic DNA will be obtained from EDTA-whole venous blood sample by Automated Systems QiaCube (Qiagen). The genetic analysis of 5 different single nucleotide polymorphisms on ApoE, BDNF and DRD2 genes will be performed by HRM analyses and direct sequencing on Automatic Genetic Analyzer. All the aliquots will be amplified by a real-time PCR. The genetic polymorphism data will be compared to sex- and age-matched control of the DNA banking of the neurogenetic Laboratory of Florence Hospital.
224212554|NCT02528422|DRUG|Acyl-Ghrelin|
224212555|NCT06063954|OTHER|electroacupuncture|Electroacupuncture (EA) is a form of acupuncture in which a weak electric current is passed through the acupuncture needles into acupoints in the skin.
224212556|NCT01890694|DRUG|Tolvaptan|15 mg once daily
224212557|NCT01890694|DRUG|Placebo|15 mg once daily
223623000|NCT05272683|DRUG|Itraconazole|On days 5 to 11, participants will receive itraconazole once daily
223623001|NCT05083273|OTHER|Cohorte|Completion of a socio-demographic, professional, medical and personal questionnaire
223623002|NCT06785467|OTHER|eDoula App|eDoula is an app that will give patients reading material and videos to watch based on their due date. It also provides helpful postpartum device.
223623003|NCT04371783|PROCEDURE|Immediate FET|FET is performed in the first menstrual cycle following the stimulated IVF cycle
223623004|NCT04371783|PROCEDURE|Delayed FET|FET is performed in the second menstrual cycle following the stimulated IVF cycle
223623005|NCT06445348|DEVICE|Cervical pedicle screw|cervical pedicle screw
223623006|NCT06112665|DRUG|Tofacitinib 5 MG|Patients receive Tofacitinib and Naproxene
224212558|NCT01890694|BEHAVIORAL|Hepatic Encephalopathy Assessment|The Number connection test, Digit symbol test, Constructional apraxia, Inhibitory control test, Repeatable Battery for the Assessment of Neuropsychological Status will be administered on Days 1, 2, 4, 6, and 8; discharge day; Weeks 1-4 post-discharge; and Months 2-6 post-discharge.
224212559|NCT01890694|BEHAVIORAL|Quality of Life Assessment|The SF-36 and Liver Disease Questionnaire will be administered on Day 1, Discharge day, Weeks 1-4 post-discharge, and months 2-6 post-discharge
224212560|NCT01890694|BIOLOGICAL|Vital signs|Vital signs (blood pressure, heart rate, respiration, temperature, weight, height) will be recorded at every visit.
224212561|NCT01890694|BIOLOGICAL|Blood laboratory tests|Blood laboratory tests (chemistry, hematology, liver function, urine electrolytes, renin, and copeptin) will be recorded at every visit.
224212562|NCT01890694|PROCEDURE|Ascites Evaluation|Ascites will be assessed at every visit.
224212563|NCT01890694|PROCEDURE|Edema|Edema will be assessed at every visit.
224212564|NCT03983746|DEVICE|core stability exercises and treadmill training exercises|Forty-five children with Down syndrome included in the study. The children aged 4-6 years, and they were equally divided randomly into three groups (A), (B) and (C). Group A received traditional physical therapy intervention strategies to facilitate the balance of participated children. Group (B) received same as the group (A), with additional core stability exercises training. Group (C) received same intervention strategies as group (A) in conjunction with a treadmill exercise program. The children's balance was evaluated using the Berg Balance Scale and the Biodex Balance System. Treatment sessions were for 60 min, thrice a week, for eight consecutive weeks.
224212565|NCT04536467|DRUG|Goserelin|chemotherapy+goserelin
224212566|NCT04536467|DRUG|Chemotherapy|standard chemotherapy
224212567|NCT02869828|DEVICE|Monitoring by arterial catheter and Spot-on|
224212568|NCT02869828|DEVICE|Monitoring by oesophagal probe and Spot-on|
224212569|NCT06221683|DRUG|Homoharringtonine|3mg/m2/day for weighing \>10kg, 0.1mg/kg/day for weighing ≤10kg, d1-7, ivgtt, qd, more than 6 hours
224212570|NCT06221683|DRUG|Cytarabine|100mg/m2/q12h for weighing \>10kg, 3.3mg/kg/q12h for weighing ≤10kg, d1-7, ivgtt, q12h, more than 30 minutes in SDC group; 10mg/m2/q12h for weighing \>10kg, 0.33mg/kg/q12h for weighing ≤10kg, d1-10, s.c.,q12h (the first dose at 8 am) in the LDC group;
224212571|NCT06221683|DRUG|Etoposide|100mg/m2/d for weighing \>10kg, 3.3mg/kg/d for weighing ≤ 10kg, d1-5, ivgtt, qd, more than 4 hours
224212572|NCT06221683|DRUG|Venetoclax|100mg/m2/d for weighing \>10kg, 3.33mg/kg/d for weighing ≤10kg, d12-25, po, qd
224212573|NCT06221683|DRUG|Mitoxantrone hydrochloride liposome|5mg/m2/d for weighing \>10kg, 0.17mg/kg/d for weighing ≤ 10kg, d1, 3, 5, ivgtt, qod, more than 2 hours at 10 am.
224212574|NCT06221683|DRUG|Recombinant Human Granulocyte Colony-Stimulating Factor|5ug/kg/d, d1-10, s.c., qd, at 1pm
224212575|NCT06221683|DRUG|Idarubicin Hydrochloride|3mg/m2/day for weighing \>10kg, 0.1mg/kg/day for weighing ≤ 10kg, d1-7, ivgtt, qd, more than 6 hours.
224212576|NCT06221683|DRUG|Sorafenib|100mg/m2/day for weighing \>10kg, 3.3mg/kg/day for weighing ≤10kg, from identification, po, qd
224212577|NCT06221683|DRUG|Gilteritinib|20mg/m2/day for weighing \>10kg, 0.7mg/kg/day for weighing ≤ 10kg, from identification, po, qd
224212578|NCT06221683|DRUG|Avapritinib|50mg/m2/day for weighing bodyweight \>10kg, 1.65mg/kg/day for weighing ≤ 10kg, po, qd
224212579|NCT01745484|OTHER|SPECT-based treatment plan|"SPECT will be performed on all patients at baseline. Two treatment plans will be made- functional SPECT-based plan and conventional CT-based plan. Randomization will take place if both plans are satisfying established criteria for tumour coverage and normal tissue sparing. Randomization between Arm 1 and Arm 2 will be done, where the patients will be treated either by SPECT-plan or by CT-plan respectively.~The SPECT data are viewed as a multicoloured image in the spectrum colour setting to allow accurate volume contouring around a predefined colour. The threshold level is adjusted individually for each patient in order to match the size of the SPECT image within the lung volumes defined on CT. A new contour of functional lung is created from the SPECT images using a threshold of 30% of the maximum uptake for each patient. A treatment plan is generated. The principal objective for each plan is to minimize the volume of lungirradiated"
224212580|NCT06157489|OTHER|Kinesio tape|Kinesiotape is applied on masseter muscle, orbi and infrahyoid muscles for facilitating suprahyoid muscle
223623007|NCT06384066|OTHER|GetWell Mobile Application|GetWell utilizes an interactive health care application to allow patients to participate in their care. We plan to work with GetWell to develop a custom built plan for urethroplasty patients and provide patient education.
223623008|NCT06384066|OTHER|Standard of Care|Office Based Pathway
223623009|NCT05979064|PROCEDURE|Laparoscopically harvested omental tissue autograft|"1. Standard neurosurgical removal of recurrent GBM,~2. removal of fat from abdomen called omentum using a thin tube with a camera (laparoscopically),~3. the omental fat will be transferred and implanted into brain tumor cavity,~4. standard closure of surgical resection cavity."
224212581|NCT02416089|DEVICE|Tampostat|
224212582|NCT02416089|DEVICE|Condom catheter tamponade|
224212583|NCT00431574|PROCEDURE|dosing|
223623010|NCT06304103|DRUG|AND017|Administer AND017 once per day (QD)
223761929|NCT02711423|DRUG|Gantenerumab|Gantenerumab will be supplied as a high-concentration liquid formulation for SC injection into the abdomen. The single dose will be administered on Day 1.
224212584|NCT03810742|DRUG|Nanoliposomal Irinotecan|Nanoliposomal Irinotecan (nal-IRI, ONIVYDE®) in Combination with TAS-102 (LONSURF®)
224212585|NCT02946619|BEHAVIORAL|Self-Regulation Condition|
224212586|NCT02946619|BEHAVIORAL|Enhanced self-Regulation Condition|
224212587|NCT03162354|OTHER|Application of a validated Clinical Decision Rule (CDR) as an AHT screening tool|"The Clinical Decision Rule (CDR) for AHT reads as follows:~Every acutely head-injured infant or young child hospitalized for intensive care presenting with any one or more of these four variables should be considered high risk and thoroughly evaluated for abuse: (1) any clinically significant respiratory compromise at the scene of injury, during transport, in the Emergency Department, or prior to admission; (2) Any bruising involving the child's ear(s), neck, or torso; (3) Any subdural hemorrhage(s) or fluid collection(s) that are bilateral OR involve the interhemispheric space; (4) Any skull fracture(s) other than an isolated, nondiastatic, linear, parietal, skull fracture."
224212588|NCT03394274|OTHER|restrictive and liberal transfusion|hemoglobin threshold value was accepted 8g/dl. restrictive blood transfusion group was defined that if perioperative transfusion was started equal or under hemoglobin level 8 g / dL. Liberal blood transfusion group was defined as perioperative transfusion was started over hemoglobin level 8 g / dL .
224212589|NCT02595541|DRUG|milrinone|IV milrinone (0.75 mcg/kg) loading dose over one hour started during re-warming of the patient (before weaning from CPB) and followed by a maintenance dose of 0.75 mcg/kg/minutes till the end of the study.
224212590|NCT02595541|DRUG|Sildenafil|IV milrinone (0.75 mcg/kg) loading dose over one hour started during re-warming of the patient (before weaning from CPB) and followed by a maintenance dose of 0.75 mcg/kg/minutes till the end of the study. After baseline measurements, sildenafil (1mg/kg) administered in ICU via a nasogastric tube, to be repeated every 4 hours via a nasogastric tube or orally. Sildnafil is presented in tablet form which was dissolved in water to make a concentration of 1 mg/ml.
224212591|NCT00881452|DRUG|CM-AT|Single unit dose powder of active substance (CM-AT) administered 3 times per day for 90 days
224212592|NCT00881452|DRUG|Placebo|Single unit dose powder of non-active substance administered 3 times per day for 90 days
224212593|NCT00743119|DRUG|Placebo capsules|Placebo capsules
224212594|NCT00743119|DRUG|Inactive marijuana (0% THC)|Inactive marijuana cigarettes (0% THC) provided by NIDA
224212595|NCT00743119|DRUG|Low dose Dronabinol|Dronabinol 10mg
224212596|NCT00743119|DRUG|High dose Dronabinol|Dronabinol 20mg
224212597|NCT00743119|DRUG|Low THC marijuana|marijuana cigarettes (1.98% THC) provided by NIDA
224212598|NCT00743119|DRUG|High THC marijuana|Marijuana cigarettes (3.56% THC) provided by NIDA
224212599|NCT05887674|BEHAVIORAL|Diet intervention|Low inflammatory-index diet
224212600|NCT05887674|BEHAVIORAL|Exercise|Guided muscle strength training and stretching exercises
224212601|NCT05887674|BEHAVIORAL|Cognitive training|Cognitive training will be implemented in person
224212602|NCT05927207|OTHER|TRIP|TRIP is a mobile app-based intervention for supporting and empowering parents of children with autism spectrum disorder (ASD), comprises of a 6-week structured training on mindfulness and educational modules on ASD parenting skills.
224212603|NCT05632757|BEHAVIORAL|Psychological assessments|The visit will take place during a multidisciplinary assessment in the ALS Center at the Timone Hospital, Neuromuscular Disease and ALS Department. The patient will be accompanied by his/her caregiver. During this multidisciplinary assessment, the patient is present at the hospital between 8am and 4pm. The various scales and self-questionnaires can be completed during this time. The time required to complete these scales and self-questionnaires is estimated to be about 90 minutes.
224212604|NCT03113175|BEHAVIORAL|Collaborative care|Collaborative care provided by the general practitioner and the care manager. Treatment modalities: Cognitive-behavior Therapy, psychoeducation, medication according to a stepped care model
224212605|NCT03113175|BEHAVIORAL|Consultations-Liaison|Consultation-Liaison provided by general practitioner involving a educational relationship with the Collabri Flex team (care manager and psychiatrist).
224212606|NCT03984136|BEHAVIORAL|COHIV with exchange mechanism|A WeChat-based mini program has been developed to send and receive Center for Disease Control and Prevention certified online HIV results (COHIV). WeChat is the ubiquitous communication and social networking tool in China. Participants in the intervention group will receive his friend's COHIV only when the participants share their own in exchange. If the participant already has the COHIV, the system will lead the user to send his COHIV to the friend. If the participant does not have the COHIV, the system will guide him to make online appointment at the testing clinic.
223761930|NCT02711423|DRUG|Placebo|Placebo will be supplied as a matching liquid formulation for SC injection into the abdomen. The single dose will be administered on Day 1.
224212607|NCT03984136|BEHAVIORAL|COHIV without exchange mechanism|The participants in the control group will be able to receive the friend's Center for Disease Control and Prevention certified online HIV results (COHIV) entirely at the friend's discretion without the mandatory exchange requirement. The system will also guide users on how to get an HIV test by making appointments with the MSM friendly clinics in the mini program.
224212608|NCT02856620|OTHER|Observational only|Observational only
224212609|NCT06653790|BEHAVIORAL|Psychosocial stimulations|The psychosocial stimulation will be offered in two phases: in-patient (at stabilization unit) and after discharge patient will be referred to out-patient (at outpatient therapeutic centre) and developmental out-patient. The sessions with development paediatrician and team will be held every week lasting for about 20-40 min in the presence of the caregiver. The intervention includes auditory, tactile and visual stimulation, hand-eye coordination, and different types of sensory-motor training that included fine and gross motor activities. The guiding principle will be to enhance a child's holistic development-cognitive, language, physical, and social-in an integrated manner by using age-appropriate play materials, cultural tools, and resources.
224212610|NCT06652997|DRUG|SPH3348|Single oral administration of SPH3348 tablets（480mg） under fasting and fed conditions
224212611|NCT05103410|DRUG|ARIPiprazole 30 MG|Patients will receive Aripiprazole 30 mg tablet orally 3 h before surgery
224212612|NCT05103410|DRUG|Placebo|Patients will receive placebo tablet which is identical in appearance, size, shape, and color to aripiprazole 3 h before surgery
224212613|NCT01965015|DEVICE|Implantation of the V-Wave inter-atrial shunt|Percutaneous implantation of the V-Wave shunt by right heart catheterization (RHC) approach
224212614|NCT05480488|DRUG|Midazolam|Subjects will receive a single oral dose of 2 mg midazolam (Treatment A, B, and C).
223761931|NCT05703022|OTHER|Aerobic interval training|The intervention will start between 7 and 21 days after heart valve surgery. While hospitalized the participants will perform supervised aerobic interval training comprised 4x4 minute, 3 times per week. Intensity will start at 60% of maximum heart rate in the first week, around 13-14 in Borg RPE-Scale. The workload will be gradually increased as the participant tolerance improves, but not above 85% of maximum heart rate or 16-17 in Borg RPE Scale.
223761932|NCT06075524|PROCEDURE|Biospecimen Collection|Undergo blood and optional stool/tissue sample collection
223761933|NCT06075524|OTHER|Electronic Health Record Review|Medical records are reviewed
224212615|NCT05480488|DRUG|Warfarin|Subjects will receive a single oral dose of 25 mg warfarin (Treatment A and B).
223761934|NCT04664998|DRUG|Daily oral PrEP|All participants will be offered daily oral PrEP at each visit
224212616|NCT05480488|DRUG|Daridorexant|Subjects will receive an o.d. oral dose of 50 mg daridorexant from Day 1 to Day 7 of Treatment B and a single oral dose of 50 mg daridorexant on Day 1 of Treatment C.
224212617|NCT03510013|PROCEDURE|1-1-8 wash-in|wash-in phase during start of low flow anesthesia
224212618|NCT03510013|DRUG|Sevoflurane|Drug used for wash-in protocol
224212619|NCT02176642|DRUG|Oxybutynin extended release|5mg tablet taken by mouth daily for 6 weeks
224212620|NCT02176642|DEVICE|Posterior Tibial Nerve Stimulation|In office therapy administered for 30 minutes once every week for a total of 6 weeks
224212621|NCT02176642|DRUG|Placebo|Tablet taken by mouth daily for 6 weeks
224212622|NCT06541613|DRUG|local anesthetic injection (bupivacaine)|The in-plane technique with a 22G, 80 mm block needle is used to inject 30 ml of 0.25% bupivacaine into the external oblique intercostal plane on both sides.
224212623|NCT06541613|OTHER|normal saline injection|the control group will receive 30ml of normal saline bilaterally into the external oblique intercostal plane on both sides
224212624|NCT00727298|BIOLOGICAL|Infliximab|Infliximab administered at a dose of 3-10 mg/kg at Week 0, Week 2, and Week 6, and every 4-8 weeks thereafter for 24 months for the treatment of chronic inflammatory disease.
224212625|NCT00653887|OTHER|Biofeedback|4 sessions of biofeedback one session each week
224212626|NCT00653887|OTHER|Placebo|4 sessions, one each week, of discussion about anorectal disease
224316372|NCT03907657|DRUG|Perflutren lipid microsphere|Baseline B-mode US will be performed to confirm the lesions being imaged (unless it is a subject with no lesions, then a basic B-mode US will be performed. Perflutren is a diagnostic drug that is intended to be used for contrast enhancement. The vial contains a clear, colorless, sterile, non-pyrogenic, hypertonic solution which is activated by mechanical agitation with Vialmix®.It will be dispensed in inactivated form to a study team member. The contrast agent will be activated just prior to administration (ideally to be used within 5 minutes of activation). Contrast agent Definity (or Lumason) will be activated according to package insert instructions, including use of VialMix®, the device used to activate Definity. Administration will occur IV in coordination with sonography staff trained specifically in contrast ultrasound imaging.The total imaging time is anticipated to be less than 30 minutes.
224212627|NCT00508235|BEHAVIORAL|Questionnaire|Questionnaire about the patient's relationship with their best friend.
224212628|NCT03717974|OTHER|Telemedecine follow-up after an intervention at home of the mobile team|"After a first visit of the mobile team at home, patients are followed by telemedicine. Moreover, in case of pain, a specialized consultation by an algologist of La Sagesse will be realized."
223623011|NCT04580238|DRUG|Botox 200 UNT Injection|"Treatment Protocol:~Botox 200 IU vials for 40 patients for the duration of study (4 treatment cycles); Treatment will be based on the PREEMPT study full treatment (standard of care) and follow the pain protocol to a total of 195 IU in standard injection sites"
224212629|NCT03717974|OTHER|Mobile team follow-up after an intervention at home of the mobile team|"After a first visit of the mobile team at home, patients are followed by mobile team. Moreover, in case of pain, a specialized consultation by an algologist of La Sagesse will be realized."
224212630|NCT04419077|BEHAVIORAL|Virtual reality exposure|"Patients will be exposed to a 10-20 min virtual reality session just before an oncological procedure (invasive act or chemotherapy).~Patients will be able to choose between 4 virtual universes (beach, underwater, forest, space) and seven musical content."
224212631|NCT00295620|DRUG|Anastrozole|1mg tablet daily
224212632|NCT01309828|DRUG|Azilsartan medoxomil and chlorthalidone|Fixed-dose combination tablets.
224212633|NCT01309828|DRUG|Olmesartan medoxomil and hydrochlorothiazide|Fixed-dose combination tablets.
224212634|NCT00217971|DRUG|Dronabinol|Dronabinol
224212635|NCT00217971|DRUG|Placebo|placebo
224212636|NCT02809534|DRUG|Anlotinib|Anlotinib p.o. qd
224212637|NCT02989610|DEVICE|Omnidirectional stimulation|At the 3-month follow-up, therapeutic window, symptom relief and side effect thresholds are evaluated at the best level for omnidirectional stimulation with the Infinity DBS lead.
223623012|NCT04580238|COMBINATION_PRODUCT|Non Botox based Standard of Care Treatments for Headache/Migraine|Control Group will receive normal standard of care Non-Botox based interventions.
224212638|NCT02989610|DEVICE|Directional stimulation|At the 3-month follow-up, therapeutic window, symptom relief and side effect thresholds are evaluated using directional contacts at the best segmented level of the Infinity DBS lead.
224212639|NCT00068653|DRUG|Celecoxib|Celecoxib 400mg orally two times a day, taken with meals.
224212640|NCT00068653|DRUG|ZD1839|ZD1839 250 mg po every day, taken with or without food.
224212641|NCT04179474|DRUG|Ubrogepant|Oral administration of 100 mg ubrogepant tablet once daily \[Intervention A=single dose and Intervention D=repeated daily dose\].
224212642|NCT04179474|DRUG|Erenumab|Single dose subcutaneous (SC) injection of erenumab 140 mg \[Intervention B\].
224212643|NCT04179474|DRUG|Galcanezumab|2 SC injections of galcanezumab 120 mg \[Intervention C\].
223623013|NCT06510933|DEVICE|Heel cups in different BMI index and its correlation to physical activity in children|Procedure: Group with muscle retraction will use a 5 millimeter heel cups in 3 and 6 months
223623014|NCT05318131|OTHER|Sleep and Lifestyle Advice Website|Participants will be asked to view a website at least once a week for 3 months (remotely). The website includes information about exercise, nutrition and sleep. Participants will also have a check-in call with a health coach at 6 weeks, and will be sent email newsletters at approximately 1 and 2 months with additional information about sleep, nutrition, and exercise.
223623015|NCT05318131|OTHER|Surveys and Sleep Monitors|At baseline and at 3 months, participants will be asked to complete online surveys and to wear an ActiGraph sleep monitor for one week. ActiGraph sleep monitors are wristbands that measure continuous sleep/wake activity information. The recorded ActiGraph data is deidentified and no individual personally identifiable information is collected. A unique serial number identifies each wrist monitor. At the end of the study, participants will also have a telephone exit interview with the study team to provide feedback on their progress during the study and about the website.
223623016|NCT05288647|PROCEDURE|TMJ injection|four sodium hyaluronate injections in superior TMJ space
223623017|NCT03608319|DRUG|A4250|9.6 mg
224212644|NCT02643810|OTHER|Exercise training|Patients to be randomized to the 'interval training group' or 'continuous training group' will undergo exercise training sessions 3 times per week for a period of 12 weeks.
224212645|NCT01532349|DRUG|Cholecalciferol|Children will be randomly allocated to receive either cholecalciferol supplementation 4000 IU per day 400 IU/day. We are proposing a supplementation dose of 4000 IU/day in children with CKD, which is considered a safe dose by KDOQI standards; vitamin D2 doses as high as 10,000 IU/day have been given to French patients with CKD for \> 1 year with no evidence of vitamin D toxicity. Cholecalciferol will be provided in both tablet and liquid form, based on the ability to tolerate and preference of the subject. Participants will be monitored for signs of 25D toxicity (hypercalcemia, hyperphosphatemia, hypercalciuria) during the follow up period of 1 month and 3 months from baseline.
224212646|NCT04609865|DRUG|Lidocaine 2%|the lidocaine infusion protocol is a bolus of 1 mg/kg (ideal weight), followed by 3mg/kg/h for the first hour, 1.5 mg/kg/h for the second hour, 0.72 mg/kg/h for the next 22 hours, and then 0.6mg/kg/h for 14 days or until extubation.
224316373|NCT03907657|DRUG|Sulfur hexafluoride lipid microspheres|Baseline B-mode US will be performed to confirm the lesions being imaged (unless it is a subject with no lesions, then a basic B-mode US will be performed. Lumason will be used as a secondary contrast agent only if Definity(perflutren) is unavailable.This drug will be administered using the dosing range and administration type within the Lumason prescribing information. The contrast agent will be activated just prior to administration (ideally to be used within 5 minutes of activation). Contrast agent Definity (or Lumason) will be activated according to package insert instructions, including use of VialMix®, the device used to activate Definity. Administration will occur IV in coordination with sonography staff trained specifically in contrast ultrasound imaging.The total imaging time is anticipated to be less than 30 minutes.
223623018|NCT05323695|BEHAVIORAL|Depression Screening Intervention|All participants will be screened for depression using PHQ-2 and PHQ-9. Those screened positive for PHQ-2 but decline further screening with PHQ-9 will be assisted for further assessment or care. Those with mild to severe symptoms (score of 7 or higher on PHQ-9) will be assisted for further assessment or care with a psychiatrist.
223623019|NCT03192176|DRUG|Fezolinetant|Oral Capsule
223623020|NCT03192176|DRUG|Placebo|Oral Capsule
223623021|NCT05671692|DRUG|Pregnenolone|Pregnenolone 250 mg BID x 14 DAYS, followed by Pregnenolone 500 mg BID x 14 DAYS, followed by Pregnenolone 1000 mg BID x thereafter for the remainder of the 8-week trial
223623022|NCT05671692|DRUG|Placebo|Same as active comparator, except placebo dispensed.
223623023|NCT06362850|OTHER|Tele-support|via real-time audio-video connection through an experienced physician
223623024|NCT05188586|OTHER|MRI/Imaging|Blood collection and pancreatic cancer early detection testing with return of results.
223623025|NCT05108246|BEHAVIORAL|Dual-Task Exercise Training|Simultaneous cognitive-motor training
223623026|NCT05983458|PROCEDURE|Transaortic valve replacement|"TAVI procedure will be performed under conscious sedation. Foley urinary catheters and jugular lines will be avoided.~For femoral access, closure devices will be Prostar or ProGlide, which are similar and carry low rates of major vascular complications . Single femoral access and a radial access as the secondary arterial access will be used to reduce the rate of vascular complications.~All procedures will be performed with cerebral protection using the Sentinel device. During valve implantation, commissural alignment will be checked for all patients. As a practical rule, commissural alignment will be checked in co-planar view and in cusp-overlap view."
223623027|NCT05833958|DRUG|GMRx-4 IR polypill - sitagliptin, dapagliflozin, metformin|As described previously
223623028|NCT05833958|DRUG|Metformin|As described previously - Experimental Arm, 175mg at night
223623029|NCT05833958|DRUG|Metformin|As described previously - Active Comparator Arm, 500mg in the morning and 500mg at night
223623030|NCT03532542|DRUG|Casimersen|Casimersen solution for IV infusion
223623031|NCT03532542|DRUG|Golodirsen|Golodirsen solution for IV infusion
223623032|NCT05097820|DEVICE|Placement of testicular prosthesis|The surgical implantation of one or two testicular prostheses on request of the patient
223623033|NCT04787224|OTHER|immediate implant with vestibular socket therapy|A 1-cm long vestibular access incision was cut, 3-4 mm apical to the mucogingival junction of the involved tooth. The socket orifice and the vestibular access incision were connected by a subperiosteal tunnel that was created using a periotome and a micro-periosteal elevator. Implants were installed using a CADLCAM surgical guide. A flexible cortical membrane shield of heterologous origin, 0.6 mm in thickness was prepared by hydrating and trimming it. It was then tucked through the vestibular access incision, till it extended 1 mm below the socket orifice, and stabilized using a membrane tack ( to the apical bone. The gap between the implant and the shield/the labial plate was then filled with particulate bone graft \[75% autogenous bone chips harvested form local surgical sites and 25% inorganic bovine bone mineral matrix.
223623034|NCT05294315|PROCEDURE|Bi-level erector spinae block|erector spinae block at 4th and 6th transverse process
223623035|NCT05294315|PROCEDURE|Single level erector spinae block|erector spinae block at 4th transverse process
223623036|NCT03166514|DIETARY_SUPPLEMENT|Commercially Available Food Bar|
223623037|NCT03166514|DIETARY_SUPPLEMENT|Placebo|
223623038|NCT06139341|DRUG|BI 765845|BI 765845
223623039|NCT06139341|DRUG|Placebo|Placebo
223623040|NCT06389526|BIOLOGICAL|CHS-1000|Specified dose on specified days
223623041|NCT06389526|BIOLOGICAL|Toripalimab|Specified dose on specified days
223761935|NCT04664998|DRUG|Daily oral PrEP|All participants will be offered daily oral PrEP at each visit.
224212647|NCT04609865|DRUG|Control|The NaCl 0,9% infusion protocol is a bolus of 0.05 ml/kg (ideal weight), followed by 0.15 ml/kg/h for the first hour, 0.075 ml/kg/h for the second hour, 0.36 ml/kg/h for the next 22 hours, and then 0.03 ml/kg/h for 14 days or until extubation.
223623042|NCT03604367|DEVICE|GAITRite assessment|The fMRI Bipedal Paradigm will allow investigators to study the effects treadmill-assisted gait training have on cortical control of bipedal movement in chronic stroke patients.
223623043|NCT01349517|PROCEDURE|MIE|The patients in this group would perform minimal invasive three-incision subtotal esophagectomy (thoracoscopic and/or laparoscopic)
223761936|NCT00676299|DRUG|JNJ-26483327|
224212648|NCT04175652|BEHAVIORAL|Laughter yoga|The laughter yoga practice was initiated through clapping and warm-up exercises: hands were clapped keeping hands in parallel with each other and ensuring that the fingertips touched each other. To increase the energy level of the group, a rhythmic beat was added to the clapping in the form of 1-2, 1-2-3. While this was being sung a rhythm was tapped out on the floor by moving the feet up and down. Eye contact was constantly maintained with the participants. In the second phase, deep breathing exercises were performed. Participants were encouraged to inhale from the diaphragm. Individuals were asked to put their hands on their belly and inhale through the nose and then slowly exhale through the mouth. After the deep breathing exercise, the participants were encouraged to laugh through playing children's games in the third phase.
224316374|NCT01917292|PROCEDURE|One-Stage Full-Mouth Disinfection|"1. Basic oral hygiene instructions~2. Dental extractions will be performed (only in cases of teeth that could not be saved)~3. Standard cycle of supragingival ultrasonic scaling and polishing~4. Scaling and root planning after the administration of local anesthesia, four quadrants in one session~5. Minocycline Hydrochloride Ointment (Periocline, OraPharma) were delivered locally into the periodontal pockets"
223623044|NCT01349517|PROCEDURE|Three-incision thoracotomy|The patients in this group would perform three-incision subtotal esophagectomy (thoracotomy and laparotomy)
223623045|NCT01349517|PROCEDURE|Ivor-Lewis esophagectomy|The patients in this group would underwent Ivor-Lewis esophagectomy
223623046|NCT01349517|PROCEDURE|Sweet esophagectomy|The patients in this group would underwent Sweet esophagectomy.
223623047|NCT03847766|BEHAVIORAL|PRO-based follow-up|Diagnose specific questionnaires are used to screen patients in need of contact to the outpatient clinic
223623048|NCT03847766|BEHAVIORAL|PRO-based telephone consultation|diagnose-specific questionnaires are used to support communication between clinician and patient during a phone consultation
223623049|NCT00103168|DRUG|imatinib mesylate|400 mg/day for 2 years
223623050|NCT02302768|DIETARY_SUPPLEMENT|Selenomethionine|
223623051|NCT02302768|OTHER|Placebo|
223623052|NCT01500772|DRUG|Alisporivir|ALV 200 mg soft gel capsules administered orally
223623053|NCT01500772|DRUG|Peginterferon alfa-2a|PEG 180 μg administered via subcutaneous (s.c.) injection once weekly
223623054|NCT01500772|DRUG|Ribavirin|RBV 200 mg tablets (weight-based dose: \< 75 mg = 1000 mg/day; ≥ 75 kg = 1200 mg/day) administered orally in a divided daily dose
223623055|NCT01733875|DRUG|CC-220 0.03 mg|A single dose of CC-220 0.03 mg will be administered orally once a day.
223623056|NCT01733875|DRUG|CC-220 0.1 mg|A single dose of CC-220 0.1 mg will be administered orally once a day.
223623057|NCT01733875|DRUG|CC-220 0.3 mg|A single dose of CC-220 0.3 mg will be administered orally once a day.
223623058|NCT01733875|DRUG|CC-220 1 mg|A single dose of CC-220 1 mg will be administered orally once a day.
223623059|NCT01733875|DRUG|CC-220 2 mg|A single dose of CC-220 2 mg will be administered orally once a day.
223623060|NCT01733875|DRUG|Placebo|A single dose of placebo will be administered orally once a day.
223623061|NCT01733875|DRUG|CC-220|CC-220 4 mg will be administered orally once a day
223623062|NCT01733875|DRUG|CC-220|CC-220 6 mg will be administered orally once a day
223623063|NCT01733875|DRUG|CC-220|CC-220 1 mg will be administered orally once a day in each of 2 study periods - once with food and once without food
223761937|NCT03804359|DRUG|Rituximab|"In the personalized arm, the patient will be treated in function of the CysR activity result during the inclusion visit."
223761938|NCT04339400|DRUG|TQ05105|TQ05105 is a JAK2 inhibitor.
223761939|NCT00952107|DEVICE|FLARE imaging system|Testing of operation of imaging system
224212649|NCT00116285|BIOLOGICAL|Ragweed MATA MPL|
224212650|NCT01357785|PROCEDURE|Cell therapy|The use of periodontal ligament stem cells for periodontal regeneration
224212651|NCT02073188|DEVICE|iBGStar|
223623064|NCT02040649|OTHER|Non-sedation|Patients are awake or have natural sleep during mechanical ventilation. Pain is treated with morphine iv.
223623065|NCT02040649|OTHER|Control, sedation (propofol, midazolam)|Continuous iv-sedation (propofol first 48 hours, from then midazolam) to Ramsey 3-4 with a daily wake up attempt, where sedation is stopped until patient is awake.
223623066|NCT00718510|DRUG|L-Arginine|3 grams, twice daily, oral administration
223623067|NCT02418871|DEVICE|FluidVision AIOL|Investigational implantable medical device intended for long-term use over the lifetime of the cataract subject. An improved injector system was used.
223623068|NCT02418871|PROCEDURE|Cataract surgery|Performed using standard microsurgical techniques
223623069|NCT00153036|DRUG|rt-PA 0.9 mg/kg verum or placebo Intravenous|
223623070|NCT02338635|DRUG|Ursodeoxycholic Acid|Inhibition of ER stress (Ursodeoxycholic Acid)
223623071|NCT04926649|PROCEDURE|Differential ventilation to the non-dependent lung|When the hypoxemia occurs during sing lung ventilation in robot-assisted cardiac surgery, the non-dependent lung will be ventilated with normal tidal volume in conventional ways and the surgery procedure have to be ceased. In this trial, the non-dependent lung will be ventilated with the continuous positive airway pressure (CPAP) or the high-frequency low-volume ventilation (HFLVV) to prevent the hypoxemia.
223623072|NCT00127634|DRUG|Human Insulin Inhalation Powder|patient specific dose, inhaled, before meals, 24 months, up to 36 months
223623073|NCT00127634|DRUG|Injectable Insulin|patient specific dose, injectable, before meals, 24 months, up to 36 months.
223623074|NCT00127634|DRUG|Insulin Glargine|patient specific dose, injectable, as needed, 24 months up to 36 months
223623075|NCT02314052|DRUG|DCR-MYC|"Dosing: 2 hour IV infusion on Day 1 and 8 of each 21 day cycle.~Starting dose: 0.125mg/kg/dose~Number of cycles: until progression or unacceptable toxicity develops.~PHASE 1b Dose escalation: 50% or 25% increase in subsequent cohorts depending upon toxicity until maximum tolerated dose (MTD) is identified.~PHASE 2 Cohort expansion at the MTD: Additional patients to be treated at the highest dose tolerated to assess efficacy and further assess safety"
224212652|NCT02073188|DEVICE|Traditional Glucometer|
224316375|NCT01917292|PROCEDURE|Periodontal care|"1. Basic oral hygiene instructions~2. Standard cycle of supragingival ultrasonic scaling and polishing"
224316376|NCT02130622|DRUG|Promethazine|
224316377|NCT02130622|DRUG|Sugar pill|
224316378|NCT02304666|PROCEDURE|Colonoscopy for biopsies samples|
224316379|NCT03138408|DRUG|SC-004|Intravenous
224316380|NCT03138408|DRUG|ABBV-181|Intravenous
223623076|NCT03701139|PROCEDURE|posterior capsulotomy|After phacoemulsification with intraocular lens implantation, primary posterior capsulotomy will be performed to remove the primary posterior capsule opacification after posterior capsule polishing. A limited anterior vitrectomy will be performed if the anterior hyaloid surface is broken.
223623077|NCT03701139|PROCEDURE|laser capsulotomy|A routine phacoemulsification with intraocular lens implantation is performed. Then the Nd:YAG laser capsulotomy will be performed 1 month postoperative to remove the primary posterior capsule opacification.
223623078|NCT04315155|DRUG|Belinostat|"Doublet Regimen Dose levels for Part 1:~Belinostat Dose Level 1 (starting dose) 500 mg/m2 Dose Level 2 750 mg/m2 Dose Level 3 1000 mg/m2"
223623079|NCT04315155|DRUG|nivolumab|Doublet Regimen Dose levels for Part 1 Nivolumab Dose Level 1 (starting dose) 360 mg Dose Level 2 360 mg Dose Level 3 360 mg
223623080|NCT04315155|DRUG|ipilimumab|Triplet and Doublet Regimen Dose Levels for Phase 2 Ipilimumab Doublet Dose n/a Triplet Dose 1 mg/kg
223623081|NCT04315155|DRUG|nivolumab|Triplet and Doublet Regimen Dose Levels for Phase 2 Nivolumab Doublet Dose 360 mg IV Triplet Dose 3 mg/kg
223623082|NCT04315155|DRUG|Belinostat|Triplet and Doublet Regimen Dose Levels for Phase 2 Belinostat Doublet Dose RP2D Triplet Dose RP2D
223623083|NCT00965666|DRUG|Etanercept|All qualified subjects receive 24 weekly subcutaneous injections of Etanercept.
223623084|NCT02558517|DRUG|prednisone discontinuation|randomization
223623085|NCT00117637|DRUG|Sorafenib (Nexavar, BAY43-9006)|Multi kinase inhibitor
223623086|NCT00117637|DRUG|Interferon|Interferon
223623087|NCT01618032|OTHER|HVLA|High velocity and low amplitude manipulation in traction of subtalar jonit
223623088|NCT01618032|OTHER|MWM|Mobilization with movement as Mulligan for increase dorsiflexion of the ankle in weight bearing
224212653|NCT02556632|DRUG|Curcumin-based Gel|Applied topically
223623089|NCT01618032|OTHER|placebo|Manual contact during a period of time similar of teh other interventions
223623090|NCT01654926|PROCEDURE|blood ultrafiltration|
223623091|NCT02417883|DRUG|Furosemide|Evaluate urinary excretion rate fo furosemide
223623092|NCT02432326|DRUG|BBI608|The BBI608 starting dose is 240 mg twice daily (480 mg total daily). Dose will be decreased to 160 mg twice daily (320 mg total daily) at modification level 2 and 80 mg twice daily (160 mg total daily) at modification level 3. For BBI608 once daily dosing, doses at starting level and modification level 1 are 240 mg once daily, and 480 mg once daily at escalated levels. Dose will be decreased to 160 mg once daily at modification level 2 and 80 mg once daily at modification level 3.
223623093|NCT02432326|DRUG|BBI503|The BBI503 starting dose is 200 mg once daily. Dose at modification level 1 to 3 will be 100 mg once daily.
223623094|NCT04215926|OTHER|No intervention; cross-sectional study|No intervention; cross-sectional study
223623095|NCT01476007|DRUG|oral Cobalamin (vitamin B12)|Intervention group: oral Optovite® B12 1000 gammas.
223623096|NCT01476007|DRUG|intramuscular Cobalamin (vitamin B12)|Control group: intramuscular Optovite® B12 1000 gammas.
223623097|NCT03431298|BEHAVIORAL|Aerobic exercise & movement control|"The aerobic exercise content is no different between the experimental group and the active comparator group.~The movement control is individual training which divided into fourths progressing sessions.~* First, lumbo-pelvic and hip dynamic direction control.~* Second, trunk muscle groups, hip muscle groups and thigh muscle groups extensibility control.~* Third, trunk muscle groups and hip muscle groups through range control.~* Fourth, functional movement control training"
223623098|NCT03431298|BEHAVIORAL|Aerobic exercise|"The aerobic exercise will organized in groups. Each group has 6-8 persons. The exercise form is fixed at each time.~The description of exercise form is as below:~* 10 min Warm up~* 40 min Aerobic exercise (which focus on lower extremity muscle strengthening and increasing muscle endurance)~* 10 min Cool down"
223761940|NCT02493738|DRUG|Lozanoc 50mg|Lozanoc 50mg single dose under fed and fasted condition
223761941|NCT02493738|DRUG|Sporanox 100mg|Sporanox 100mg single dose under fed condition
224212654|NCT02556632|PROCEDURE|Dermatologic Complications Management|Apply HPR Plus topically
224212655|NCT02556632|OTHER|Laboratory Biomarker Analysis|Correlative studies
224212656|NCT02556632|OTHER|Placebo|Apply placebo gel topically
224316381|NCT02444910|DRUG|KDT501|600mg twice daily, Oral, for 10days; then 800mg twice daily, Oral, for 10 days; then 1,000mg twice daily, Oral, for 8 days.
223623099|NCT04688658|DRUG|Nivolumab|Nivolumab is a human IgG4 monoclonal antibody that blocks PD-1. It is a type of immunotherapy and works as a checkpoint inhibitor, blocking a signal that prevents activation of T cells from attacking the cancer.
223623100|NCT04688658|DRUG|Duvelisib|Duvelisib is a potent inhibitor of both γ and δ isoforms. Duvelisib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
223623101|NCT03881839|OTHER|emergency|The objective of this research will be to assess, in patients presenting in an emergency department, the prior consultation of medical information on a website, the impact on the emergency consultation decision and the relevance of this consultation.
223623102|NCT05740488|DRUG|Apalutamide|240mg, po, qd
223623103|NCT05740488|DRUG|89Sr|100\~150MBq(based on weight), iv, q90d
223623104|NCT05740488|DRUG|Luteinizing Hormone-Releasing Hormone Analog|sc, 3.6mg, q30d or 10.8mg, q90d
223623105|NCT00537602|DRUG|miglustat|
223623106|NCT00537602|DRUG|placebo|
223623107|NCT01582061|DRUG|Pasireotide sub-cutaneous|Pasireotide sub-cutaneous was supplied in 1 ml ampoules containing 900 μg, 600 μg, or 300 μg pasireotide per 1 ml of solution and was administered BID. Starting dose was 900 μg and 600 μg for glucose impaired metabolism patients
223761942|NCT01407913|PROCEDURE|caudal epidural steroid injection|injecting steroids in the epidural space via caudal route
223761943|NCT02559869|DRUG|[18F] GE-180|PET Tracer Ligand
223761944|NCT05409027|DRUG|SPI-62|SPI-62 is supplied as 1 mg tablets for oral dosing.
223761945|NCT05409027|DRUG|Cortisone-d8|Cortisone-d8 is supplied as a 1 mcg/mL solution for infusion
224212657|NCT02556632|OTHER|Questionnaire Administration|Ancillary studies
224212658|NCT03934437|BEHAVIORAL|mLTCR|mHealth-enhanced Linkage to Care and Retention
224212659|NCT03934437|BEHAVIORAL|LTCR|Linkage and Retention Services (Standard-of-Care)
224212660|NCT04508621|DRUG|TNX-102 SL|Patients will take 1 tablet of randomly assigned study drug sublingually starting on Day 1 for 2 weeks. At the Week 2 visit, all patient will have the dose increased to 2 tablets for 12 weeks.
224316382|NCT02468050|BEHAVIORAL|Moderate intensity exercise training|6 weeks of moderate intensity exercise training (50 - 75% of heart rate reserve). Sessions are facility and home based and include cardiovascular warm-up, cardiovascular training, muscular conditioning, and flexibility exercises.
224212661|NCT04508621|DRUG|Placebo SL Tablet|Patients will take 1 tablet of randomly assigned study drug sublingually starting on Day 1 for 2 weeks. At the Week 2 visit, all patient will have the dose increased to 2 tablets for 12 weeks.
223623108|NCT05924061|OTHER|Cathepsin B and pentraxin 3 levels in preeclampsia with pregnant women|The effect of cathepsin b and pentraxin 3 levels on maternal/fetal outcomes in pregnant women diagnosed with preeclampsia
223623109|NCT03573414|OTHER|raspberry powder, milled flaxseed and soy milk|"* The participants will consume a breakfast consisting of 30 g of milled flaxseed, 40 g of raspberry powder and 250 ml of soy milk for 3 days~* The participants will provide blood and urine samples"
223623110|NCT01895075|DRUG|Inhaled budesonide|Inhaled budesonide 1 mg tid until 36 weeks' corrected gestational age or fully weaned from supplemental oxygen and respiratory support (CPAP or high flow nasal canula)
223623111|NCT01895075|DRUG|Normal saline|2 ml normal saline by inhalation
223623112|NCT05858086|OTHER|Novel same-day discharge protocol after total joint arthroplasty|Preoperative gait/stair training with physical therapy, then postoperative ambulation with nursing after total joint arthroplasty
223623113|NCT05858086|OTHER|Conventional postoperative physical therapy clearance|Physical therapy evaluation and clearance after total joint arthroplasty
223623114|NCT01615250|BIOLOGICAL|Intramyocardial implantation of stem cells|Intramyocardial implantation of autologous peripheral mononuclear cells with CD34+ stem cells by NOGA.XP navigation system. Сell concentration is 200 million cells in 1 ml.
223623115|NCT05583916|PROCEDURE|Same Day Discharge - Video-Assisted Thoracoscopic Surgery (VATS) Lung|All patients will be scheduled to surgery at the start of the day and will be discharged within the same day as the procedure.
224212662|NCT03168269|DIAGNOSTIC_TEST|Coronary Computed Tomographic Angiography (CCTA)|CCTA of coronary arteries
224212663|NCT00808015|DRUG|varenicline|Champix will be prescribed as per usual practice and at the sole discretion of the physician
223623116|NCT06512064|DIAGNOSTIC_TEST|AWARE|AWARE testing to estimate lung function and aid in disease diagnosis
223623117|NCT03488836|PROCEDURE|reciproc|rotary reciprocating protocol
223623118|NCT03488836|PROCEDURE|race rotary|race rotary group protocol
223761946|NCT02656641|BEHAVIORAL|Continuous Client Feedback|Clients complete rating scales before each therapy session. The therapist then views these results and discusses treatment progress with the client during the session.
224212664|NCT01066039|DRUG|Bisoprolol|Bisoprolol tablet will be administered orally at dose of 5 milligram (mg) once daily for 24 weeks. If the blood pressure is not less than 130/80 millimeter of mercury (mmHg) during the first 8 weeks of treatment (up-titration), then the dose will be adjusted to 10 mg daily. In cases of hypotensive effect, symptomatic bradycardia or arrhythmia, the daily dose will be reduced to 2.5 mg.
223623119|NCT02756338|DEVICE|BioMonitor 2 Insertable Cardiac Monitor|
223623120|NCT00961155|DRUG|cyklezonid|160 mcg once daily
223623121|NCT00961155|DRUG|montelukast sodium|5 or 10 mg according to age once daily
224212665|NCT00057785|DRUG|cisplatin|100 mg/m\^2 intravenously on days 1, 22, and 43 and 80 mg/m\^2 intravenously on days 71, 99, and 127
224212666|NCT00057785|DRUG|fluorouracil|1000 mg/m\^2/day as 96-hour continuous infusion on days 71-74, 99-102, and 127-130
224212667|NCT00057785|RADIATION|Intensity modulated radiation therapy|The gross tumor and lymph node metastasis, Planning Target Volume (PTV) 70 (Clinical Target Volume \[CTV\] 70 with a 5 mm margin) will receive 70 Gy in 33 fractions at 2.12 Gy per fraction. Treatment will be delivered once daily, 5 fractions per week, over 6 weeks and 3 days.
223761947|NCT02656641|BEHAVIORAL|Continuous Self Feedback|Clients complete rating scales before each therapy session. Progress is not reviewed with the therapist.
223623122|NCT00961155|DRUG|placebo|fluticasone placebo twice daily, montelukast placebo once daily
223623123|NCT00961155|DRUG|formoterol 12 mcg twice daily|formoterol 12 mcg twice daily will be given to children for 3 months
223623124|NCT06160232|DRUG|Psilocybin (high dose)|Psilocybin-assisted therapy
223761948|NCT02845752|DRUG|Stiolto Respimat|Oral inhalation spray
223761949|NCT02845752|DRUG|Placebo Respimat|Oral inhalation spray
224212668|NCT02574260|BIOLOGICAL|Talimogene Laherparepvec|Administered by intratumoral injection.
224316383|NCT02468050|BEHAVIORAL|Self Management of exercise|In addition to the 6 week exercise program (refer to Exercise Treatment Group), participants randomly assigned to the Self Management Group will learn strategies for the self management of exercise.
224316384|NCT00693095|BIOLOGICAL|CMV-ALT + CMV-DCs|CMV-ALT (3 X 10e7) with CMV-DCs (2 X 10e7)
224316385|NCT00693095|BIOLOGICAL|CMV-ALT + Saline|CMV-ALT (3 X 10e7) with Saline
223623125|NCT06160232|DRUG|Active placebo (low dose of psilocybin)|Placebo-assisted therapy
223623126|NCT00483613|BEHAVIORAL|Cognitive-behavioral therapy of Meichenbaum|
223623127|NCT00219063|DRUG|aliskiren|
223623128|NCT03395899|DRUG|Atezolizumab|PD-L1 antibody
223623129|NCT03395899|DRUG|Cobimetinib|Highly selective small-molecule inhibitor of MEK1 and MEK2
223623130|NCT03395899|DRUG|Ipatasertib|Selective, ATP-competitive small molecule inhibitor of all three isoforms of the serine/threonine kinase Akt
223623131|NCT03395899|DRUG|Bevacizumab|Highly specific humanized monoclonal antibody that targets VEGF
223623132|NCT03688815|DIAGNOSTIC_TEST|myocardial perfusion scintigraphy|Myocardial perfusion scintigraphy as it is described in the international literature.
223761950|NCT05912699|OTHER|Slimbiotics Postbiotic|"SlimBiotics postbiotic formula contains the following ingredients:~* Heat-inactivated L. fermentum K8 Postbiotic.~* Microcrystalline cellulose."
224212669|NCT01083901|BEHAVIORAL|Resistance training|high intensity progressive resistance exercise training
224212670|NCT01397656|PROCEDURE|CPR using 30:2 ratio|Participants will begin performing CPR using a ratio of 30 compressions to 2 ventilations. Participants will then cross over to the other intervention and use continuous compressions.
223623133|NCT04309110|DEVICE|or geko™ X-T3|The geko™ X-T3 is a next generation self adhesive medical device incorporating a new formulation skin adhesive. It is about the size of a wrist watch which attaches to the side of the knee and when switched on, gentle painless electrical pulses are produced which contract the calf muscles and increase blood flow to the lower leg. The only difference between the currently used geko™ T3 device and the new geko™ XT-3 device is the adhesive used to attach each device to the skin.
223623134|NCT02334930|OTHER|Biopsy|
223623135|NCT03654794|BIOLOGICAL|Cell pharmacokinetics of tacrolimus|"Three levels of tacrolimus will be tested. Each aliquot will be supplemented with an amount of tacrolimus to achieve one of these three levels of concentration.~At 0, 5, 15, 30, 60, 120, 240mn, the samples will be separated into 2 aliquots : one dedicated to the determination of tacrolimus in mononuclear cells, the other dedicated to the determination of calcineurin activity. in mononuclear cells."
223623136|NCT01416402|DRUG|Arhalofenate|400 mg once daily orally for two weeks then up-titrated to 600 mg once daily orally for an additional two weeks
223623137|NCT01416402|DRUG|Febuxostat|80 mg once daily orally for 5 weeks
223623138|NCT01416402|DRUG|Colchicine|Colchicine 0.6 mg daily as prophylaxis to prevent gout flares
223623139|NCT05684458|PROCEDURE|Reiki|Reiki, a non-invasive, free and safe complementary therapy method, is practiced with a series of hand positions held on the patient's body to help balance the life force energy.
223623140|NCT04864249|DEVICE|SNOO|The SNOO is a commercially available device which is a responsive bassinet for neonates. The bassinet is designed to respond to the infant's cries and automatically respond by emitting engineered white noise sounds and providing a rhythmic rocking motion. The infant is also swaddled to remain securely back-down. The SNOO automatically increases the emitted sound and motion if the infant is still crying. However, if the infant does not settle within 3 minutes, the SNOO will shut off and alert the adults for additional assistance. Parents can also modify the SNOO settings to meet the baby's need for sound and/or motion.
224212671|NCT01397656|PROCEDURE|CPR using continuous compressions|Participants will begin performing CPR using continuous chest compressions. Participants will then cross-over to the other intervention arm and perform CPR using a ratio of 30 compressions to 2 ventilations.
224212672|NCT03567200|BEHAVIORAL|Single-Arm Feasibility|Participants in each of the 8 participating groups (N=10-12 per group) are exposed to an integrated intervention program (integration of physical activity and psychosocial components). Each session is co-facilitated by a trained research staff member and a registered social worker, providing participants with the opportunity to engage in physical activity behaviours as well as discuss various psychosocial topics that are applicable to the participants interests. Physical activities include participating in group activities such as rock climbing, self-defence, yoga, etc. Psychosocial topics addressed include group discussions around cyber-bullying, sexual abuse and exploitation, gender issues, etc.
224212673|NCT06610279|DRUG|TAK-951|TAK-951 SC injection
224212674|NCT06610279|DRUG|Placebo|TAK-951 matching placebo SC injection
224212675|NCT06081946|OTHER|Histamine|Histaminergic itch will be evoked by a 1% histamine solution. A droplet of histamine solution will be placed on the predetermined area on the forearm, and the SPT lancet will be pierced through the histamine with 120 g of pressure for 1-2 seconds
224212676|NCT06081946|OTHER|Cowhage|25 spicules will be inserted in the centre of the predefined skin area on the mandibular area. The spicules will be gently rubbed for 15-20 seconds in circular motion to facilitate epidermal penetration
223623141|NCT04864249|OTHER|Safe sleep education in the postpartum period|Comprised of education from the postpartum clinical nurse with a corresponding educational handout to take home
223623142|NCT02724332|DRUG|Rapamycin|2mg,po,bid
223623143|NCT01858792|DRUG|Belimumab 1 mg/kg|Belimumab 1 mg/kg IV plus standard therapy; belimumab 1 mg/kg administered on Days 0, 14, 28, and every 28 days thereafter through 72 weeks.
223623144|NCT01858792|DRUG|Belimumab 10 mg/kg|Belimumab 10 mg/kg IV plus standard therapy; belimumab 10 mg/kg administered on Days 0, 14, 28, and every 28 days thereafter through 72 weeks.
223623145|NCT01858792|OTHER|Placebo|Placebo IV plus standard therapy; placebo administered on Days 0, 14, 28, and every 28 days thereafter through 72 weeks.
224212677|NCT03528967|DRUG|Enoxaparin 40 mg / 0.4 mL Prefilled Syringe|
224212678|NCT03528967|DRUG|Aspirin 100 mg Oral Tablet, Enteric Coated|
224212679|NCT04212741|DIETARY_SUPPLEMENT|A+ HA(tm)|oral solution of hyaluronic acid mixture
224212680|NCT04212741|DIETARY_SUPPLEMENT|Placebo|oral solution with no-active ingredients
223761951|NCT05912699|OTHER|Placebo|The placebo capsules contain microcrystalline cellulose only.
224212681|NCT06540365|BEHAVIORAL|Pathways and Resources for Engagement and Participation (PREP)|Each participant will work individually with an occupational therapist (OT) to pursue one leisure-oriented, community-based activity chosen by the young person. The participant will choose the community program using the PREP 5 steps (Make goals; Map out a plan; Make it happen; Measure the process and outcomes; Move forward). The OT will then search for the appropriate program, identify and remove potential environmental barriers to participation in that activity (e.g., accessibility, equipment), and educate program instructors regarding the person's specific needs. This process will include an expected 8 sessions lasting 12 to 18 weeks (depending on the assigned baseline length).
224212682|NCT03717298|DIETARY_SUPPLEMENT|Ocoxin-Viusid®|"An oral solution of Ocoxin-Viusid® (30 ml vials) will be used at a rate of 60 ml daily (1 vial every 12 hours), preferably administered after breakfast and lunch. It will be prescribed for a period of 2 weeks before starting the QT.~The treatment with Ocoxin-Viusid® will continue in the possible periods of time of suspension of the chemotherapy treatment due to toxicities attributable to the oncospecific treatment.~The treatment will be administered continuously from the inclusion of the patient in the study, up to one year."
224212683|NCT01725737|DRUG|GlyTI-M|
224212684|NCT01725737|DRUG|Placebo|Placebo Comparator: starch
224212685|NCT00084617|DRUG|oxaliplatin|Given IV
224212686|NCT00084617|DRUG|irinotecan hydrochloride|Given IV
224212687|NCT00084617|DRUG|capecitabine|Given orally
223761952|NCT00403000|DRUG|dutasteride|Oral
223761953|NCT00240370|DRUG|Muraglitazar|
223761954|NCT01507285|DRUG|liraglutide|Initial single dose followed by subsequent multiple s.c. (under the skin) doses on several dose levels (1.25, 5, 7.5, 10 and 12.5 mcg/kg). Each subject will be allocated to one dose level only
223761955|NCT01507285|DRUG|placebo|Initial single dose followed by subsequent multiple s.c. (under the skin) doses
224212688|NCT00377715|DRUG|Dimebon|
223623146|NCT05107544|OTHER|HIGH INTENSITY INTERVAL TRAINING|Will be prescribed HIIT through online modality to a group of adolescents with type 1 diabetes 3 times a week for 3 months. The training is going to have 2 phases, the initial phase and improvement phase, which are going to be differentiated according to work intensity following the recommendations of the American College of Sports Medicine. During the initial phase (first 4 weeks) the intensity is going to be 60-75% of the VO2 max. During the improvement phase the intensity is going to increase to a 75-85% of the VO2 max for 8 week.
223623147|NCT00300755|DRUG|pantoprazole sodium enteric-coated spheroid|pediatric spheroids taken daily x 8 weeks
223623148|NCT00276263|DRUG|Sarcosine (N-methylglycine)|Randomization to two treatment groups. One group treated with sarcosine 2 g/day for 16 weeks, the other group treated with placebo 2 g/day for 16 weeks.
223623149|NCT00006053|DRUG|imatinib mesylate|
224212689|NCT00377715|DRUG|Placebo|
224212690|NCT01625286|DRUG|AZD5363 when combined with weekly paclitaxel.|AZD5363: oral capsule, twice daily in a weekly 2 days on-treatment, 5 days-off, schedule. Treatment to begin the day following the first dose of paclitaxel and to continue until treatment withdrawal. Paclitaxel: intravenously once a week. AZD5363 and paclitaxel will be received for 3 consecutive weeks, followed by one week off-therapy in 4-week cycles.
224212691|NCT01625286|DRUG|AZD5363 when combined with weekly paclitaxel.|AZD5363: oral capsule, twice daily in a weekly 4 days on-treatment, 3 days-off, schedule. Treatment to begin the day following the first dose of paclitaxel and to continue until treatment withdrawal. Paclitaxel: intravenously once a week. AZD5363 and paclitaxel will be received for 3 consecutive weeks, followed by one week off-therapy in 4-week cycles.
224212692|NCT01625286|DRUG|AZD5363when combined with weekly paclitaxel.|Either a 2/5 or 3/4 intermittent dosing schedule of AZD5363 based on the outcome of Part A. Dosage: oral formulation, twice daily. Treatment to begin the day following the first dose of paclitaxel and to continue until treatment withdrawal. Paclitaxel: intravenously once a week. AZD5363 and paclitaxel will be received for 3 consecutive weeks, followed by one week off-therapy in 4-week cycles.
224212693|NCT01625286|DRUG|A placebo in combination with weekly paclitaxel.|Either a 2/5 or 3/4 intermittent dosing schedule of placebo matched to AZD5363 based on the outcome of Part A. Dosage: oral formulation, twice daily. Treatment to begin the day following the first dose of paclitaxel and to continue until treatment withdrawal. Paclitaxel: intravenously once a week. placebo and paclitaxel will be received for 3 consecutive weeks, followed by one week off-therapy in 4-week cycles.
224212694|NCT05649423|OTHER|POSTURAL DRAINAGE WITH PERCUSSION|"Each position should be held for a minimum of five minutes. In each position, your chest should be lower than your hips to allow mucus to drain. On your back: Patient's chest should be lower than his hips, which you can achieve by lying on a slanted surface up about 18 to 20 inches. On your sides: With pillows under your hips, lie on one side. To clear congestion from the right and left lobes. On your stomach: Drape patient's body over a stack of pillows, this is best in clearance of mucus from the lower back area of the lungs.~Percussion The equipment required here is cupped hands of caregiver to deliver the force required to drain the thick secretions. Patient should be in a comfortable position to enhance the effect. This loosens the thick, sticky secretions from the walls of the lung allowing them to into the larger airways, The sound heard must be hollow. The force applied must be equal."
224212695|NCT05649423|OTHER|Postural drainage|"* Each position should be held for a minimum of five minutes.~* In each position, your chest should be lower than your hips to allow mucus to drain On your back: Patient's chest should be lower than your hips, which you can achieve by lying on a slanted surface or propping patient's hips up about 18 to 20 inches~* This position is best for draining the bottom front parts of your lungs. On your sides: With pillows under your hips, lie on one side so that your chest is lower than your hips. To clear congestion from the bottom part of the right lung, lie on your left side. To clear congestion from the bottom part of your left lung, lie on your right side.~On your stomach: Drape patient's body over a stack of pillows or other object, and rest his arms by his head, with his chest lower than his hips. This position is best for clearing mucus in the lower back area of the lungs."
224212696|NCT04364542|PROCEDURE|Suprascapular nerve block|The patient lies supine in beach chair position with surgical drapes on. The anatomical landmarks are outlined and the infiltration spot is identified. The block is performed with 10 ml ropivacaine 0.75%.
224212697|NCT04364542|PROCEDURE|Interscalene Nerve Block|The patient lies supine position with the head turned to the contralateral side to the block. A linear high-frequency ultrasound probe is used for identifying the roots of supraclavicular brachial plexus using the traceback technique. The block is performed with 15 ml ropivacaine 0.5%.
223623150|NCT05532826|OTHER|donor EBV-specific T lymphocytes|"EBV-DNA reactive after transplantation, or did not turn negative after +30 days, peripheral blood lymphocytes of the donor were collected to prepare EBV-CTL, and the first transfusion of EBV-CTL 6.0x105 was given at 48h to rapidly culture EBV-CTL, then EBV-CTL 6.0x105/kg was injected once a week untile EBV-DNA negative for 2 consecutive times or GVHD happened. After the second infusion, EBV-DNA did not decrease and there was no aGVHD patients, EBV-CTL infusion volume was increased to 1.2x106/kg, once a week. After 2 cycle infusion, EBV-DNA still did not decrease, and the reinfusion was terminated.~Peripheral blood lymphocytes were collected from donors of high-risk patients at +14 days after allogeneic hematopoietic stem cell transplantation to prepare EBV-CTL, and EBV-CTL 6.0x105/kg was infused at +21d, +28d, +35d and + 42D for prevention. During treatment, if the patient develops GVHD, the infusion should be stopped."
223680484|NCT05694143|OTHER|Education Intervention|"This intervention is based on the Health Belief Model Theory, which examines the attitudes and beliefs of adolescents with enhanced knowledge and perceived disease risk. As a result, It aims to build on adolescents' skills and behaviours rather than increase their knowledge, beliefs, and relative skills. In order to develop the education program, health promotion experts with a special interest in changing obesity-related behaviours will assist the researcher.~The intervention is specifically designed to help adolescents:~* To know facts, statistics and harmful effects of obesity and overweight.~* To know facts about physical activity and its importance.~* To know facts about a healthy diet and its importance.~* Definition of BMI and calculating the BMI.~* To read the Nutrition Facts label.~* To develop decision-making and self-care education."
223761956|NCT00654069|DRUG|Placebo|2 tablets every 6 hours for 48 hours
223761957|NCT00654069|DRUG|Acurox 5/30 mg|2 tablets every 6 hours for 48 hours
223761958|NCT00654069|DRUG|Acurox 7.5/30|2 tablets every 6 hours for 48 hours
224212698|NCT04364542|PROCEDURE|Arthroscopic rotator cuff repair|Conventional arthroscopic rotator cuff repair.
224212699|NCT00402207|DRUG|extrafine HFA-beclomethasone|
223623151|NCT04442542|OTHER|Respiratory muscle training 1 (Experimental Group)|"The participant must perform a series of exercises that will be the same for the two groups in this investigation. In addition to the exercises, this group will use the incentive inspirometer device with a new method created by the main author called the Method JaPer.~For the method JaPer, the participant sits and holds the device. Then put the mouthpiece of the inspirometer in the mouth. Be sure to make a good seal on the mouthpiece with your lips. And exhale normally until you run out of air. And after that, inhale slowly as much as possible. This maximum value will be taken as an indicative parameter of its maximum inspiratory capacity and 50 and 80% for 1 set of 10 repetitions at 50% of their maximum value, 2 sets of 10 repetitions at 60% of its maximum capacity and ends with 1 series at 80% of its maximum capacity. It is highlighted that in each series before finishing and without stopping to rest, the participant must do 5 repetitions at 100% maximum capacity"
223623152|NCT04442542|OTHER|Respiratory muscle training 2 (Control Group)|Training of respiratory muscles under the protocol of conventional use. Which is that the participant sits and holds the device. Then put the mouthpiece of the inspirometer in the mouth. Be sure to make a good seal on the mouthpiece with your lips. And exhale (exhale) normally until you run out of air. And after that, inhale (inspire) slowly as much as possible. Repeat 10 times and use these indications for 3 sets. In addition, participants must perform the same breathing exercises that are identical for experimental group.
223623153|NCT03284606|DEVICE|TAPING|Taping in conjunction with common rehabilitation for hemiplegic patients
223623154|NCT03284606|PROCEDURE|Common rehabilitation|Common rehabilitation for hemiplegic patients
223623155|NCT02333461|DIETARY_SUPPLEMENT|Placebo|Participants were randomly assigned to receive one of four botanical interventions or placebo.
223623156|NCT02333461|DIETARY_SUPPLEMENT|Apple|Participants were randomly assigned to receive one of four botanical interventions or placebo.
223623157|NCT02333461|DIETARY_SUPPLEMENT|Grape|Participants were randomly assigned to receive one of four botanical interventions or placebo.
223761959|NCT00737516|BIOLOGICAL|HPC, Cord Blood|Search for HLA compatible cord blood units using the NMDP registry
223761960|NCT06442501|OTHER|routine care|routine care
224212700|NCT00402207|DRUG|HFA-fluticasone|
224212701|NCT04801030|BEHAVIORAL|YourCoViDVaxFacts|The intervention will be delivered via multiple strategies- social media (YouTube, Facebook), radio, newspaper, tv ads, community partner networks. Participants receive culturally-tailored message on COVID-19 and the vaccine. The strategies will have a link that will open to a website that is optimized for viewing on a computer or mobile phone which has the look and feel of an app, but without requiring the user to download anything to the phone. On the website, participants will be prompted to select their top concerns from a list. Based on the responses, the top barriers or need will each be mapped to a corresponding educational message, which will be displayed to the user with appropriate images or graphics.
224212702|NCT01832545|OTHER|Aquatic Exercise|
224212703|NCT01832545|BEHAVIORAL|Educational Program|Control Group
224212704|NCT04709029|DRUG|Dexamethasone intravenous|Evaluation of intravenous dexamethazone in prevention of postdural puncture headache
224316386|NCT00711035|BIOLOGICAL|Trivirus Specific CTLs for EBV, CMV and Adenovirus Infection|"Follow-up Assessments: The timing of follow-up visits is based on the date of CTL infusion. If a patient has multiple CTL doses the schedule resets again at the beginning so follow up relates to the last CTL dose.~Follow up will occur at 7 days, 14 days, 21 days, 28 days, 42 days, 90 days, 180 days, and 365 days post enrollment."
224212705|NCT04709029|DRUG|Dexamethasone intrathecal|Evaluation of intrathecal dexamethazone in prevention of postdural puncture headache
224212706|NCT02630004|DRUG|Melatonin oral gel 3%|
224212707|NCT02630004|DRUG|Placebo oral gel|
224316387|NCT01837134|DEVICE|telemedical (TM) group|telemedical devices (weighing machine and step counter)
224316388|NCT01837134|BEHAVIORAL|telemedical coaching (TMC) group|care calls once per week for 12 weeks
224316389|NCT04236934|OTHER|Assesment of diaphragm shape and diaphragm movement (by M-mode and the AREA-method) by ultrasound before and after thoracentesis|Questionnaire is about symptoms measured by Edmonton Symptom Assessment Score (ESAS) and dyspnea also by modified Borg Scale (MBS)
224316390|NCT05382234|DIAGNOSTIC_TEST|CBC, ESR ,CRP,Liver Function ,renal function ,ABG,Na,K,D-dimmer ,cardiac enzyme,ferritin ,blood and urine culture in negative cases|cllinical and laboratory evaluation of MIS-C,Effectivness of different therapeutic modalities,Outcome of cases (morbidity,mortality)
224316391|NCT03399708|DRUG|Apremilast 30mg|Apremilast will used in line with its license. This includes the standard dose titration scheme (see section 6) and then the usual maintenance dose of 30 mg twice daily orally.
224316392|NCT04462432|OTHER|no intervention|This is an observation study, with no intervention.
223623158|NCT02333461|DIETARY_SUPPLEMENT|Raspberry|Participants were randomly assigned to receive one of four botanical interventions or placebo.
223623159|NCT02333461|DIETARY_SUPPLEMENT|Apricot/Nectarine|Participants were randomly assigned to receive one of four botanical interventions or placebo.
223623160|NCT02503592|OTHER|Vestibular testing|Patients who have received a cochlear implant within 90 days, and had vestibular testing pre-operatively, will undergo post-op vestibular testing
223623161|NCT03547778|DRUG|Misoprostol 50 mcg pesssary|Participants in the study arm will receive vaginal misoprostol (50 mcg) to be inserted the night before the procedure. Whereas the control group will get a placebo.
223761961|NCT01416883|DRUG|ICI176,334-1|Subject will receive single dose of ICI176,334-1
223761962|NCT03417661|DRUG|HEXI-PREP By Clinell Wipes|Sterile single sachet wipe containing 3ml solution.
223761963|NCT03417661|DRUG|Chloraprep|Sterile applicator containing 3ml solution.
223761964|NCT03417661|DRUG|Placebos|Sterile saline (0.9% w/v) wipe, containing 3ml of solution.
223623162|NCT03547778|DRUG|Placebos|The control group will receive placebo pessaries to be inserted vaginally the night before the procedure.
223623163|NCT03192826|DRUG|Brinzolamide/Brimonidine FC|1 drop of Brinzolamide/Brimonidine FC 1 hour before capsulotomy
223623164|NCT03192826|DRUG|Brimonidine 0.2%|1 drop of Brimonidine 0.2% 1 hour before Nd-YAG capsulotomy
223623165|NCT03192826|DRUG|Artificial tears|1 drop of artificial tears 1 hour before Nd-YAG capsulotomy
223623166|NCT02694744|DRUG|patiromer|8.4 g/day starting dose, administered orally
223623167|NCT01379417|DIETARY_SUPPLEMENT|Probiotic supplementation|1 capsule per day, from inclusion to 4 or 6 weeks after inclusion
223623168|NCT05224115|OTHER|[11C]CHDI-00485180-R|Mutant huntingtin aggregate binding PET radioligand.
223623169|NCT05224115|OTHER|[11C]CHDI-00485626|Mutant huntingtin aggregate binding PET radioligand.
223623170|NCT01842802|DEVICE|Diode Laser|Diode Laser for treatment of subcutaneous fat
223623171|NCT01842802|DEVICE|YAG laser|YAG laser for treatment of subcutaneous fat
223623172|NCT00686777|BIOLOGICAL|Pegylated Interferon alfa-2b|Pegylated Interferon alfa-2b 1.5 ug/kg SC once weekly for 48 weeks
223623173|NCT00686777|DRUG|Ribavirin|Ribavirin 400 mg/day orally
223623174|NCT04297865|DRUG|A dose as CJ-15314|A dose as CJ-15314, 1 capsule
223761965|NCT01178892|DIETARY_SUPPLEMENT|Placebo|Three placebo gel capsules filled with vegetable oil are taken daily for a total of approximately 2 grams of vegetable oil. Each gel capsule also contains 15 IU of vitamin E, natural lemon flavoring, rosemary extract, and a small amount of non-omega-3 fish oil.
224212708|NCT06537102|OTHER|Unilateral laparoscopic ovarian drilling|"Laparoscopic drilling was performed under general anesthesia as follows: 10-mm subumbilical entry and two 5-mm secondary ports in the lower part of the abdomen just above the anterior superior iliac spine. The laparoscope is introduced through the subumbilical port, and secondary ports was used for introduction of the instruments, the type of needle was an insulated unipolar needle electrode with a non-insulated distal end. We are planning to use the least thermal effective dose which is 60 J/cm3 of ovarian tissue.~The number of punctures (Np) per ovary was calculated according to the following formula: N p = 60 J/cm3/40 W × 4 s, with 3 mm diameter and 4 mm depth for each puncture using power setting of 300 W for 2-4 s. Unilateral: was done on the larger ovary."
224212709|NCT06537102|OTHER|Bilateral laparoscopic ovarian drilling|"Laparoscopic drilling was performed under general anesthesia as follows: 10-mm subumbilical entry and two 5-mm secondary ports in the lower part of the abdomen just above the anterior superior iliac spine. The laparoscope is introduced through the subumbilical port, and secondary ports was used for introduction of the instruments, the type of needle was an insulated unipolar needle electrode with a non-insulated distal end. We are planning to use the least thermal effective dose which is 60 J/cm3 of ovarian tissue.~The number of punctures (Np) per ovary was calculated according to the following formula: N p = 60 J/cm3/40 W × 4 s, with 3 mm diameter and 4 mm depth for each puncture using power setting of 300 W for 2-4 s. Bilateral: Using dose adjusted according to ovarian volume."
224212710|NCT00828516|OTHER|Acupuncture and moxibustion|Acupuncture is a form of traditional east Asian medicine that uses needles inserted superficially under the skin to stimulate sites on the body known as acupuncture points. Traditional practice encompasses moxibustion, the application of heat (usually from the smouldering herb artemisia vulgaris or mugwort) to stimulate the points by warming them.
224212711|NCT01051973|BEHAVIORAL|Cognitive behavior therapy|A 10-week treatment based on exposure to symptoms and related feelings.
224212712|NCT01051973|BEHAVIORAL|Stress management|A 10-week stress management treatment including applied relaxation and dietary advice.
224212713|NCT06536946|BIOLOGICAL|Immunohistochemical staining|Staining of cutanous squamous cell carcinoma and its mimickers by monoclonal antibodies against human B-catenin by immunohistochemical procedures
224212714|NCT06539689|DEVICE|Sperstent® peripheral spot stent system|Sperstent® peripheral spot stent system, Percutaneous Transluminal Angioplasty (PTA), Digital Subtraction Angiography（DSA）
223623175|NCT04297865|DRUG|B dose as CJ-15314|B dose as CJ-15314, 1 capsule
223623176|NCT04297865|DRUG|C dose as CJ-15314|C dose as CJ-15314, 1 capsule
223623177|NCT04297865|DRUG|D dose as CJ-15314|D dose as CJ-15314, 2 capsules
223623178|NCT04297865|DRUG|E dose as CJ-15314|E dose as CJ-15314, 1 capsule
223623179|NCT04297865|DRUG|F dose as CJ-15314|F dose as CJ-15314, 2 capsules
223623180|NCT04297865|DRUG|Placebo|Placebo, 1 capsule
223623181|NCT04297865|DRUG|Placebo|Placebo, 1 capsule
223623182|NCT04297865|DRUG|Placebo|Placebo, 1 capsule
223623183|NCT04297865|DRUG|Placebo|Placebo, 2 capsules
223623184|NCT04297865|DRUG|Placebo|Placebo, 1 capsule
223623185|NCT04297865|DRUG|Placebo|Placebo, 2 capsules
223623186|NCT01370902|DRUG|NNC 0141-0000-0100|Single dose administered subcutaneously (under the skin), up to six dose levels. Progression to next dose will be based on safety evaluation. Initiation of the MD s.c. phase will depend on the results from the SD i.v. cohorts as well as the first two dose cohorts of the SD s.c. part
223623187|NCT01370902|DRUG|placebo|Single dose administered subcutaneously (under the skin) as a comparator at all dose levels
223623188|NCT01370902|DRUG|NNC 0141-0000-0100|Multiple doses administered subcutaneously (under the skin) at 4 different occasions with a dosing interval of two weeks, at five different dose levels.
223623189|NCT01370902|DRUG|placebo|Multiple doses administered subcutaneously (under the skin) as a comparator at all dose levels
223623190|NCT01370902|DRUG|NNC 0141-0000-0100|Single dose administered intravenously (into a vein), up to nine dose levels. Progression to next dose will be based on safety evaluation. Initiation of the SD s.c. phase will depend on the results from the first three dose cohorts of the SD i.v. part
223623191|NCT01370902|DRUG|placebo|Single dose administered intravenously (into a vein), as a comparator at all dose levels
223623192|NCT06012123|PROCEDURE|Aortoiliac angioplasty and stenting|Covered endovascular reconstruction of aortic bifurcation (CERAB) in patient with aorto-iliac occlusive disease
223623193|NCT00516113|DRUG|paroxetine|Capsules containing either placebo or paroxetine 20 mg. The treatment start after ovulation and when the subject has experienced premenstrual irritability for 2 days. The dosage is one capsule daily at 8 AM
223623194|NCT03803306|COMBINATION_PRODUCT|Vedic Medical Astrology|Individualised astrological based interventions were given including vedic counselling, diet, colors, gems, mantras and the worship deities as an adjuvent to ongoing conventional treatments
223623195|NCT03803306|OTHER|Placebo vedic medical astrology (PMA)|Conventional treatments were followed with counselling and diet suggestions. astrological interventions were not incorporated during the study phase.
223623196|NCT03707353|BIOLOGICAL|ChAd63 ME-TRAP and MVA ME-TRAP vaccination|vaccination with ChAd63 ME-TRAP 5x10\^10 vp (intramuscularly and intravenously) vaccination with MVA METRAP 2x10\^8 pfu (intramuscularly) and MVA METRAP 2x10\^7 pfu (intravenously) Group 5 will be challenged with malaria by mosquito bite.
223623197|NCT01945021|DRUG|Crizotinib|
223623198|NCT01808859|DEVICE|Tourniquet|hyperbaric bupivacaine 12.5-15 mg Celecoxib 400 mg and paracetamol 1 g will be given preoperatively. Postoperatively celecoxib 200 mg x 2 and paracetamol 1 g/6 h is given is given for 2 weeks.
223623199|NCT01320358|DRUG|ECMPS-IEM|ECMPS-IEM
223623200|NCT01911715|DRUG|MDV3100|Oral
223623201|NCT03582215|DRUG|Part 1: Cream|Approximately 2 mg per cm2 of body surface will be applied topically 4 times per day for 4 days to approximately 75% of the body surface area
223623202|NCT03582215|DRUG|Part 1: Lotion|Approximately 2 mg per cm2 of body surface will be applied topically 4 times per day for 4 days to approximately 75% of the body surface area
223623203|NCT03582215|DRUG|Part 1: Spray 1|Approximately 2 mg per cm2 of body surface will be applied topically 4 times per day for 4 days to approximately 75% of the body surface area
223623204|NCT03582215|DRUG|Part 1: Spray 2|Approximately 2 mg per cm2 of body surface will be applied topically 4 times per day for 4 days to approximately 75% of the body surface area
223623205|NCT03582215|DRUG|Part 2: Lotion|Approximately 2 mg per cm2 of body surface will be applied topically 1 time on day 1 and 4 times per day on following 3 days to approximately 75% of the body surface area
223623206|NCT03582215|DRUG|Part 2: Aerosol Spray|Approximately 2 mg per cm2 of body surface will be applied topically 1 time on day 1 and 4 times per day on following 3 days to approximately 75% of the body surface area
223623207|NCT03582215|DRUG|Part 2: Nonaerosol Spray|Approximately 2 mg per cm2 of body surface will be applied topically 1 time on day 1 and 4 times per day on following 3 days to approximately 75% of the body surface area
223623208|NCT03582215|DRUG|Part 2: Pump Spray|Approximately 2 mg per cm2 of body surface will be applied topically 1 time on day 1 and 4 times per day on following 3 days to approximately 75% of the body surface area
223623209|NCT03796507|DRUG|Temozolomide|oral temozolomide at 75 mg per square meter of body surface area daily for 21 days
223623210|NCT04978883|OTHER|No intervention|No intervention
224212715|NCT06539689|DEVICE|Everflex® self-expanding peripheral stent system|Everflex® self-expanding peripheral stent system, Percutaneous Transluminal Angioplasty (PTA), Digital Subtraction Angiography（DSA）
223623211|NCT02163902|DRUG|ATX-101|Clinical evaluation, patient reported outcome questionnaires, photographs, caliper measurements, recording of adverse events
223623212|NCT02163902|DRUG|Placebo|Clinical evaluation, patient reported outcome questionnaires, photographs, caliper measurements, recording of adverse events
223623213|NCT05238077|PROCEDURE|Visible Light-Ultraviolet A Light or Narrowband-Ultraviolet B phototherapy|Patients will have different kinds of light shined on different areas
223623214|NCT02319330|BEHAVIORAL|Nurse-delivered mobile phone counseling intervention|Multi-dimensional, patient-centered counseling approach used to build patient-provider rapport, establish sources of support, and enable and empower problem solving to address inter-related, multi-tiered barriers to care.
223623215|NCT02319330|BEHAVIORAL|Treatment as Usual|Routine HIV clinic-based counseling
223623216|NCT03636581|BEHAVIORAL|Lifestyle counseling|This group will receive online education modules to educate them on exercise prescription, nutrition and behavioral changes.
223623217|NCT02793726|PROCEDURE|NMR|NMR
223623218|NCT04942587|BEHAVIORAL|LISTENING TO THE RECORDINGS SAYING BY PARENTS|The baby was made listen to the lullaby recorded in the voice of parents starting with, during and after the care for 10 minutes.
223623219|NCT00380237|BIOLOGICAL|H9N2 (6-2) AA ca Reassortant (A/Chicken/Hong Kong/G9/97 x A/Ann Arbor/6/60 ca)|Live attenuated H9N2 (6-2) AA ca Reassortant (A/Chicken/Hong Kong/G9/97 x A/Ann Arbor/6/60 ca) vaccine
224212716|NCT03841903|DIAGNOSTIC_TEST|spinal cord MRI|high-resolution spinal cord MRI sequences on a 3Tesla magnet (Siemens Prisma) with high contrast between SC and CSF as well as high contrast within the SC (grey-white matter contrast)
224212717|NCT05445037|DEVICE|hemodynamic continuous monitoring|Continuous monitoring will be done with clearsight continuously assessing blood pressure, cardiac output and heart rate; NIRS electrode to assess cerebral O2 saturation, peripheral O2 saturation, BIS value and axillary temperature.
224212718|NCT05445037|DEVICE|Standard Monitoring|Standard monitoring will be done with non-invasive blood pressure, heart rate, NIRS electrode to access cerebral O2 saturation, peripheral O2 saturation, axillary temperature, BIS value. In addition, patients will use Clearsight, but the device will be blind to the anesthesiologist. Pressure monitoring will be every 5 min.
223623220|NCT03186612|BEHAVIORAL|OT+VR intervention with videogames for the upper limb (dexterity)|Patients will performe exercises with video capture of the upper limb movements via the performance of functional and manual dexterity activities based on the following games: Flip Out, Air Hockey, Particlesículas, Dunkit, Cuenta PecesCounting fishes and Robo Maro.
223623221|NCT02832648|DIETARY_SUPPLEMENT|selenase (selenium)|Selenase (Biosyn, Germany) Sodium selenite pentahydrate
223623222|NCT00572377|DRUG|FemLife Gel|the gel or placebo (240 mcg)applied to the vagina; 20 doses to be used over the 30 day period and to complete the Female Sexual Encounter Profile (FSEP).
223623223|NCT00572377|DRUG|Placebo|the gel or placebo (240 mcg) applied to the vagina; 20 doses to be used over the 30 day period and to complete the Female Sexual Encounter Profile (FSEP).
223623224|NCT05665036|COMBINATION_PRODUCT|SIG-005 (hIDUA Producing Spheres)|Laparoscopic administration of SIG-005 spheres, an encapsulated allogeneic cell therapy genetically modified with a non-viral vector to produce hIDUA
223680485|NCT05694143|OTHER|No Intervention|They will have their regular curriculums and normal physical activity routine
223680486|NCT03557996|DRUG|Silver Diamine Fluoride|SDF will be applied with a brush
223680487|NCT03557996|DRUG|Sodium Fluoride Varnish|NaF will be applied with a brush
223680488|NCT03320876|DRUG|filgotinib|one filgotinib oral tablet once daily.
223680489|NCT01962168|DEVICE|Evolution® Biliary Stent - Uncovered|Commercially available device
223623225|NCT01983475|DRUG|Denosumab|In clinical trials, denosumab (Amgen Inc., Thousand Oaks, CA), has been shown to be more potent in reducing osteoclastosis and function than bisphosphonates.39,40 The rate of bone loss in the lower extremity at sites of interest in patients with acute SCI has been reported to be several-fold greater than the rate of bone loss in postmenopausal women not prescribed antiresorptive medications, which is about 3-5% per year.11,50,51 The dose of denosumab chosen for our protocol in patients after acute SCI will be the same dose that has been shown to be efficacious to treat postmenopausal osteoporosis (60 mg SQ q 6 months).
223623226|NCT01983475|DRUG|Placebo (identical Denosumab volume of normal saline)|The placebo group will receive the identical volume of normal saline at parallel time points.
223623227|NCT02174731|DRUG|Roxadustat|Roxadustat will be administered orally three times a week (TIW) to achieve an Hb level of 11 g/dL and maintain a Hb level of 11±1 g/dL.
224212719|NCT03368872|OTHER|Astaxanthin formulation|Astaxanthin formulation containing AstaReal® astaxanthin (Haematococcus pluvialis algae extract), tocotrienol, and zinc will be orally administered starting on Day 1 until Day 120
224212720|NCT03368872|OTHER|Placebo|Placebo will be orally administered starting on Day 1 until Day 120.
224212721|NCT03368872|OTHER|Exercise training|The subjects will undergo interval treadmill incline protocol (target 85% HR max, 3 times a week for 40 to 60 minutes) starting on Day 31 until Day 120.
224212722|NCT06701877|BEHAVIORAL|Circle of security Parenting (COS-P)|The Circle of Security Parenting® (COS-P) program is an attachment-based intervention designed to enhance caregiver sensitivity, parental reflective functioning, and the quality of the child's attachment to their caregiver. This manualized intervention, with both educational and therapeutic components, empowers caregivers to better understand and respond to their child's needs, fostering secure attachment (22).
224212723|NCT06701877|BEHAVIORAL|Traitement as usual (TAU)|TAU typically involves home visits, educational and psychological support for foster carers and/or children in placement, and efforts to support and monitor contact between children and their birth families.
224212724|NCT02926053|PROCEDURE|Surgical removal of tumor tissue for T cell production|Surgical removal of \> 1 cm3 tumor tissue chosen with regards to high rate of success and to minimize the general risks involved in a surgical procedure.
224212725|NCT02926053|DRUG|Cyclophosphamide|Cyclophosphamide 60 mg/kg is administered i.v. on day -7 and day -6.
224212726|NCT02926053|DRUG|Fludarabine|Fludarabine 25 mg/m2 is administered on day -5 to day -1. Maximum dose of 50 mg per administration.
224212727|NCT02926053|BIOLOGICAL|TIL infusion|The maximum number of expanded TILs are infused over 30-45 minutes on day 0.
224212728|NCT02926053|DRUG|Interleukin-2|Interleukin-2 is administered as high-dose bolus infusions (600.000 IU/kg) over a 15 minute period every 8 hours and continuing for up to 5 days (maximum of 15 doses).
224212729|NCT01814917|DRUG|colestilan|body surface area equivalent (BSAeq) 3 g/day, 6 g/day, 9 g/day, 12 g/day or 15 g/day
224212730|NCT01814917|DRUG|CBPB|
224212731|NCT06233175|OTHER|combined kinetic chain exercises|combined kinetic chain exercises in form of wall slide ,terminal knee extension ,forward step up and down ,side step up and down ,straight leg raise ,seated knee extension ,stretching exercises , hot back and trans cutaneous electrical stimulation,
224212732|NCT06233175|OTHER|conventional|stretching exercises and hot back and trans cutaneous electrical stimulation,with out combined kinetic chain exercises
224212733|NCT05052320|DEVICE|Audiological assessment|TO assess audiological profile in recovered covid19 subjects
224212734|NCT04581031|DEVICE|Continuous vital sign monitoring - Isansys Patient Status Engine|CE marked wearable continuous vital signs monitors
224212735|NCT04581031|OTHER|Machine Learning/AI Algorithm|Patient data will be subjected to machine learning/AI algorithms to determine whether algorithms may be beneficial as an early indication of patient's condition worsening.
224212736|NCT00226902|PROCEDURE|Changing hemoglobin concentration|
224212737|NCT02280642|BIOLOGICAL|Both 2nd and 3rd doses on time|
224212738|NCT02280642|BIOLOGICAL|2nd dose late and 3rd dose on time|
224212739|NCT02280642|BIOLOGICAL|2nd dose on time and 3rd dose late|
224212740|NCT02280642|BIOLOGICAL|Both doses late|
224212741|NCT05087199|DIAGNOSTIC_TEST|Rt-PCR.|Nasopharyngeal swab for Rt-PCR for COVID-19
224212742|NCT06292806|DRUG|FSH-R|controlled ovarian stimulation for IVF
224212743|NCT05027009|PROCEDURE|Physical Examination|Undergo total body exam
224212744|NCT05027009|OTHER|Solar Simulated Light|Undergo exposures to simulated sunlight
224212745|NCT02588352|DIETARY_SUPPLEMENT|Salt tablet|Subjects will be given salt tablets and instructed to take 4 grams of sale three times a day (total of 12 grams of salt/day) for one week
224212746|NCT03586037|DRUG|AD-2011 10/20 mg|AD-2011 10/20 mg tablet
224212747|NCT03586037|DRUG|AD-2012 80mg|AD-2012 80mg tablet
224212748|NCT03586037|DRUG|AD-2011 10/20 mg + AD-2012 80mg|AD-2011 10/20 mg + AD-2012 80mg tablet
224212749|NCT01758315|OTHER|Training and in-office coaching|Participating practices will be coached to perform rapid, small-scale tests of change and to iteratively improve performance of problem-prone care systems, as well as to imbed simple measurement in routine daily work streams to guide improvement efforts. The sixteen intervention practices will serve as realistic research laboratories to help advance malpractice risk prevention and patient safety in specific areas by refining tools and strategies for smaller practices.
224212750|NCT03958071|DRUG|Nintedanib|Nintedanib initiators
224212751|NCT03958071|DRUG|Pirfenidone|Pirfenidone initiators
224316393|NCT05873933|OTHER|Hemptress Oil|Full ingredient list of the test product: Rubus occidentalis (Black raspberry) seed oil\*, Carica papaya (Papaya) seed oil\*, Bixa orellana (Annatto) seed oil\*, Orbignya oleifera (Babassu) seed oil\*, Borago officinalis (Bourrache) seed oil\*, Daucus carota (Carrot) seed oil\*, Hibiscus sabdariffa (Hibiscus) seed oil\*, Aronia melanocarpa (Chokeberry) seed oil\*, Vaccinium macrocarpon (Cranberry) seed oil\*, Moringa oleifera (Moringa) seed oil\*\*, Persea americana (Avocado) oil\*, Ribes nigrum (Black currant) seed oil\*, Copaifera officinalis (Copaiba) resin\*, Canabis sativa (Hemp) seed oil\*, Moringa peregrina seed oil extract \& Caprylic/Capric Triglyceride\*\* (Moringa peregrina extract), Ascorbyl tetraisopalmitate (Vitamin C), Proprietary full-spectrum blend of Cannabis sativa (Hemp) extract, Silica (Algica), Ergocalciferol (Vitamin D2), Menaquinone (Vitamin K2), Tocopherol (Vitamin E)\* Organic Ingredient\* Wild Crafted/Regenerative\*\*
223623228|NCT02174731|DRUG|Epoetin alfa|Epoetin alfa will be administered TIW consistent with approved prescribing information for epoetin alfa to achieve an Hb level of 11 g/dL and maintain a Hb level of 11±1 g/dL.
223623229|NCT03119259|BEHAVIORAL|ABC Clinical Program|"The goal of the ABC Clinical Program is to help primary care physicians achieve the standard of care in the diagnosis, evaluation and management of patients with ADRD. The ABC Clinical Program is delivered by an interdisciplinary team led by a care coordinator. The informal caregiver is also enrolled in the program and caregiver burden is assessed and managed. The ABC team collects all relevant data and formulates an individualized care plan in collaboration with the informal caregiver. The care coordinator communicates the team's recommendations to the primary care physician and finalizes a collaborative plan of action. During the next year, the ABC team uses face-to-face and telephone interactions with the patient and caregiver to monitor and modify implementation of the care plan.~The goal of IUHP Usual Care is to provide preventive care services to their patients. Older adults are assessed for ADRD during clinic visits and refered to brain care specialty as necessary."
223623230|NCT03119259|BEHAVIORAL|BCN|"BCN is a mobile application (app) for informal caregivers of patients with Alzheimer's Disease and related dementias (ADRD). The BCN app delivers the following behavioral support:~1. 24/7 psychoeducation and caregiver support on a variety of ADRD related topics, presented as a browse-able library of stories and advice cards or Notes;~2. Assessment of informal caregiver status and patients behavioral and psychological symptoms of dementia (BPSD), in the form of the selfadministered HABC Monitor, along with reporting and historical tracking of HABC Monitor scores;~3. Engagement tools, in particular, (i) a toolkit for saving, sorting, creating/editing, and sharing Notes and (ii) a bi-directional messaging tool for communicating with clinicians or trusted others."
223623231|NCT00983346|DRUG|Bortezomib|"Bortezomib will be administered as a 3-5 second bolus IV injection at the dose of 0.7 mg/m2 on days 1, 8, 15, and 22 of each 42 day cycle.~Patients will undergo nine 42-day cycles. At the end of this (day 378), patients will be assessed for bone remodeling changes. Evaluation for toxicities will be evaluated at the beginning of each cycle."
223623232|NCT02640274|BEHAVIORAL|Nurse-led counselling programme|The intervention is an individual nurse-led counselling programme in addition to usual care. The intervention includes 3 outpatient clinic visits (at weeks 2, 14 and 26) and two telephone calls (at weeks 4 and 16) by a cardiovascular nurse during the first 6 months early discharged. The counselling focuses on cardiac risk reduction behaviour based on guidelines issued by European Society of Cardiology and self-management support.
223623233|NCT02640274|OTHER|Usual care|
223623234|NCT01032616|OTHER|Threonine Experimental: Study Period 1|Enteral and parenteral infusion of threonine isotope
223623235|NCT01032616|OTHER|Lysine Experimental: Study Period 2|Both intravenous (iv) and intragastric (ig) Lysine isotopes.
223623236|NCT03267368|BEHAVIORAL|Comprehensive Care Program|Pulmonary rehabilitation and smoking cessation
223623237|NCT02345135|PROCEDURE|Blood collection|In all patients with Ataxia telangiectasia blood was collected at each visit date to determine blood count, lymphocyte subpopulation count and immunoglobulin levels in serum (IgA, IgG, IgM, IgE), as well as alpha feto protein (AFP).
223623238|NCT02345135|PROCEDURE|Lung function measurement|In all patients - Ataxia telangiectasia and healthy controls - a lung function measurement was done to determine vital capacity (VC), forced expiratory volume in 1 second (FEV1), peak expiratory flow (PEF) and Tiffenau index.
223623239|NCT02345135|BEHAVIORAL|Symptom diary|All patients - Ataxia telangiectasia and healthy controls - were requested to keep a symptom diary for the months September to March of the years 2012/2013 and 2013/2014 to determine days with symptoms as coughing during day and night, cold and fever, as well missing days at kindergarten/school/work, intake of medication (especially antibiotic treatment) and hospitalisations.
224212752|NCT03958071|OTHER|Untreated Cohort|Untreated
224212753|NCT02035683|PROCEDURE|PET/CT|PET/CT scan at baseline and 3 weeks after first cycle chemotherapy
224212754|NCT03829033|RADIATION|Radiotherapy|Radiotherapy with either photons or protons.
224212755|NCT00294320|DRUG|Aldara (Imiquimod)|250mg of Imiquimod cream for application once daily 3 times per week.
223623240|NCT02050438|PROCEDURE|Total Knee Arthroplasty|
223761966|NCT01178892|DIETARY_SUPPLEMENT|Omega-3|The study supplement, omega-3-fish oils, is taken as 3 gel capsules daily that together contain approximately 2 grams of fish oil. Each gel capsule (1/3 of the daily dose) has a total omega-3 dosage of 615 mg with two major omega-3 components of ethyl eicosapentaenoic acid (EPA; 425 mg) and docosahexaenoic acid (DHA; 100 mg). Vitamin E (15 IU), an antioxidant, is added to each gel capsule to prevent oxidation and preserve freshness. Each gel capsule also contains natural lemon oil and rosemary extract to enhance taste and freshness.
224212756|NCT00294320|OTHER|Vehicle cream|250mg vehicle cream for application once daily 3 times per week.
224212757|NCT04946422|PROCEDURE|Arthroscopy|Discharge diagnosis of patients with sports injury-related injuries
224212758|NCT05861440|DRUG|Prednisolone|adjunct steroid per study protocol
224212759|NCT05861440|DRUG|standard anti-tuberculosis agents|standard anti-tuberculosis agents
224212760|NCT03250065|DEVICE|Application of prototype sensor to a standard endotracheal tube|During anaesthesia the device under study, a prototype saturation sensor will be applied to a standard endotracheal tube that ventilates the patient as normal.
224212761|NCT01528631|OTHER|D-Fagomine|30 mg (initial dose), with 50 grams of sucrose in 200 ml of water.
224212762|NCT01528631|OTHER|D-Fagomine|0 mg (control) blended with 50 grams of sucrose in 200 ml of water.
224212763|NCT04150926|OTHER|Black currant|"The effect of black currant puree will be compared with black currant-quinoa product, quinoa base and with liquid with glucose, fructose and sucrose~Experimental: Black currant and quinoa product~Active Comparator: Quinoa base Meal study comparing the effect of black currant puree with liquid with glucose, fructose and sucrose, black currant and quinoa product and quinoa base"
224212764|NCT04150926|OTHER|Black currant-quinoa product|The effect of black currant puree will be compared with black currant-quinoa product
224212765|NCT04150926|OTHER|Quinoa base|The effect of black currant puree will be compared with quinoa base
224212766|NCT03724968|DRUG|Nivolumab|Nivolumab will be given by vein on day 1 of each cycle.
224212767|NCT03724968|DRUG|Relatlimab|Relatlimab will be given by vein on day 1 of each 28-day cycle
224212768|NCT03724968|DRUG|Ipilimumab|Ipilimumab will be given by vein on day 1 during cycles 1-4 (cycles are 21 days).
224212769|NCT05140863|DRUG|HSK16149 20mg BID|HSK16149 20mg, orally twice a day, treatment period; 12-weeks fixed dose
224212770|NCT05140863|DRUG|HSK16149 40mg BID|HSK16149 40mg, orally twice a day, treatment period; 12-weeks fixed dose
223623241|NCT05371769|OTHER|chronic pain management education program|The chronic pain management training program will be applied for 2 weeks. The training consists of 15 videos about theory and practice topics in chronic pain management. There are evaluation questions at the end of each video.
223623242|NCT05371769|OTHER|No intervention|No intervention will be made.
223623243|NCT03293615|OTHER|exploration|Difference of the following parameters in patients i) with DM, ii) with another inflammatory myopathy iii) without neuromuscular disease.
223623244|NCT02715739|OTHER|No intervention|
223623245|NCT06560203|PROCEDURE|Mechanical thrombectomy|Neurointerventionist determine whether to proceed with interventional therapy after assessing the location and degree of occlusion, the tortuosity of the access vessel, and the presence of stenosis or occlusion in the proximal artery. In cases where there is no proximal stenosis or occlusion, mechanical thrombectomy is performed, and the specific thrombectomy strategy is tailored by the researcher based on the patient's condition. For lesions associated with proximal vascular stenosis or occlusion, it is necessary to navigate the catheter through the proximal stenosis or occlusion to access the intracranial occlusion. Researchers have the discretion to treat the stenotic or occluded vessels, which may include options such as no treatment, stent thrombectomy, thrombus aspiration, balloon angioplasty, stent replacement, intra-arterial thrombolysis or various combinations of these methods.
223623246|NCT00003468|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|Children with a low grade astrocytoma that have not responded to standard therapy will receive Antineoplaston therapy (Atengenal + Astugenal).
223623247|NCT04694222|DEVICE|Nd:YAG laser|For LANAP, the fiber optic tip of the Nd:YAG laser (1064 nm) (Fotona Fidelis AT, USA) was used. For LLLT R24 biostimulation handpiece tip (950-μm) Nd:YAG laser (1064 nm) was used.
223623248|NCT02341560|DRUG|QPI-1007 Injection - 1.5 mg|
223623249|NCT02341560|DRUG|QPI-1007 Injection - 3.0 mg|
223623250|NCT02341560|OTHER|Sham Injection Procedure|Sham Procedure
223623251|NCT01663870|BEHAVIORAL|Audio Recorded Interviews|Audio recorded interview at beginning of visit and after using HealthATM website.
223623252|NCT01663870|BEHAVIORAL|Focus Group Session|Focus group session taking 60-90 minutes.
223623253|NCT01663870|OTHER|Website Session|10-15 minute session with the HealthATM website.
223623254|NCT01663870|BEHAVIORAL|Questionnaire|Questionnaire completion at end of audio recorded interview taking about 5 minutes.
223623255|NCT05356416|OTHER|Ischemic compression|"Ischemic compression technique is a massage technique that consists of moderate compression, typically applied with the fingers, to the MTrP. Application of this technique to an MTrP results in a positive effect on pain-pressure threshold.~Patients in Group B will receive a single session of ischemic compression technique for ischemic compression technique sustained pressure on the trigger points will be maintained for 30 seconds."
223623256|NCT05356416|OTHER|Dry needling|"Trigger-point dry needling is an invasive procedure where a fine needle or acupuncture needle is inserted into the skin and muscle.~Patients in dry needling (DN) group will receive a single session of DN of 10 minutes with sterile needles insert on trigger points in scalene muscles as first twitch response will obtained needles will be manipulated in and out of the muscles to get 2 or 3 more local responses."
223623257|NCT04056416|DEVICE|MedBIKE|A MedBIKE will be installed into a participants home and connected to clinicians via telehealth for monitoring during exercise sessions. Sessions will be based on standardized guidelines for aerobic exercise. Heart rate, ECG, oxygen saturation and rating of perceived exertion will be monitored throughout the session.
223623258|NCT05478642|OTHER|The Hospital Anxiety and Depression Scale.|"The study was carried out on the basis of the National Military Medical Clinical Center Main Military Clinical Hospital. All patients participated in Operation Joint Forces and received gunshot wounds during combat operations.~A retrospective analysis of disease histories for the period from 2014 to 2021 was carried out. Data collection was carried out at all stages of treatment: medical and nursing brigade, military mobile hospital, military medical clinical center, during rehabilitation, within 12 months of the injury.~Recruitment of patients for the prospective study was carried out in the period from 02.24.2022 to 05.24.2022. Data collection was carried out during the Russian invasion of Ukraine and the offensive on Kyiv."
223623259|NCT06493760|DRUG|SSGJ-707|bispecific antibody
223623260|NCT06493760|DRUG|Bevacizumab|VEGF antibody
223623261|NCT06493760|DRUG|Oxaliplatin|chemotherapy
223623262|NCT06493760|DRUG|Capecitabine|chemotherapy
224212771|NCT05140863|DRUG|Placebo BID|Placebo, orally twice a day, treatment period; 12-weeks fixed dose
224212772|NCT06540313|OTHER|Stellate Ganglion Block|Stellate ganglion block refers to the injection of local anesthetic drugs into tissues around and near SG to regulate the tension of the sympathetic nervous system, inhibit the outflow of the sympathetic nerve in the innervation area of the stellate ganglion to the ipsilateral head, neck, chest and upper limb, and finally achieve the role of regulating the autonomic nervous system, circulatory system, endocrine system and immune system of the human body to maintain dynamic balance. It is used to treat a variety of pain and non-pain diseases.
224212773|NCT02268188|OTHER|education|Attend classes as part of Harvesting Health program
224212774|NCT02268188|OTHER|nutrition intervention|Learn how to incorporate nutrition guidelines into daily meal plans as part of Harvesting Health program
223623263|NCT06493760|DRUG|Calcium Folinate|chemotherapy
223623264|NCT06493760|DRUG|5-fluorouracil|chemotherapy
223680490|NCT02463552|DRUG|Naproxen|The patient will receive a single-dose of Naproxen (500 mg) one hour before the bleaching procedure.
223680491|NCT03377140|DIETARY_SUPPLEMENT|Hesperidin|2 capsuls
223680492|NCT03377140|OTHER|control|2 capsuls
223680493|NCT02674854|DRUG|PG324 Ophthalmic Solution 0.02%/0.005%|1 drop daily in the evening (PM) in both eyes (OU)
223680494|NCT02674854|DRUG|Netarsudil (AR-13324) ophthalmic solution 0.02%|1 drop daily in the evening (PM) in both eyes (OU)
223680495|NCT02674854|DRUG|Latanoprost ophthalmic solution 0.005%|1 drop daily in the evening (PM) in both eyes (OU)
224212775|NCT02268188|BEHAVIORAL|exercise intervention|Use FitBit to log daily steps as part of Harvesting Health program
223623265|NCT00580619|OTHER|Autonomic Function Testing|The autonomic function tests include asking the subject to breathe deeply for two minutes and breathing as fast and as hard as they can for 30 seconds, maintaining a handgrip for 3 minutes, breathing against pressure for 15 seconds, placing one hand in ice water for 1 minute and an orthostatic test. All these tests are meant to stimulate the autonomic nervous system to produce changes in blood pressure and heart rate of short duration that reflect how well the involuntary nervous system is working. In addition, a 24-hour blood pressure monitoring and exercise test may be also performed in some subjects.
223623266|NCT00580619|OTHER|Saline infusions|The effects of continuous IV infusion or pulse IV administration of saline in increasing total blood volume and fatigue score will be evaluated
223623267|NCT00580619|DRUG|L-NMMA trimethaphan|Trimethaphan IV infusion for approximately 60 minutes at a dose of 4-6 mg/min L-NMMA IV infusion for approximately 45 minutes at 125, 250, and 500 mg/kg/min for 15 minutes each
223623268|NCT00580619|DRUG|methyldopa|Aldomet oral twice a day for 12 weeks
223623269|NCT04430920|OTHER|Intensive intraoperative blood pressure management|Targeting intraoperative mean arterial pressure ≥ 80 mmHg.
223623270|NCT04430920|OTHER|Conventional intraoperative blood pressure management|Targeting intraoperative mean arterial pressure ≥ 65 mmHg or 60% of the baseline level (use the higher target).
223623271|NCT00302809|DIETARY_SUPPLEMENT|Concord Grape Juice|Approximately 16 oz of grape juice or placebo
223623272|NCT02374164|DRUG|Febuxostat XR|Febuxostat XR capsules
223623273|NCT04376216|DRUG|Prednisone|60 mg with dose tapering over 2 months
224212776|NCT02268188|OTHER|questionnaire administration|Ancillary studies
224316394|NCT04669561|DRUG|Lifitegrast 5% Ophthalmic Solution|Open label, self-controlled, single group study of the efficacy of Lifitegrast 5% in improving higher order aberrations, ocular scatter index, and best corrected visual acuity in patients with dry eye. All patients will receive lifitegrast 5% for 4 weeks and will be evaluated at baseline (before treatment) and at 7, 14, and 28 days.
223623274|NCT04969029|DRUG|Tirelizumab|In the immunotherapy group, the treatment regimen was Tirelizumab 200mg, intravenously infused once every 3 weeks until the end of 12 months of treatment, with a total of 17 infused times.
223623275|NCT01055561|OTHER|Acupuncture|Participators will be stimulated at specific acupuncture points as determined for the disease by the professional acupuncturists, and acupuncture once a day,last for one week.
223623276|NCT04220346|OTHER|Tablet group|Children in the Tablet group started to play the game with Tablet about 5-10 minutes before circumcision, and continued to play the game during the whole procedure.
223623277|NCT04034303|GENETIC|analysis of genetic and epigenetic risk factors|analysis of gene, methylation and expression, microbiome
223623278|NCT05757986|OTHER|The presence of nausea and vomiting within 24 hours after surgery|This is a prospective risk prediction model building, thus there is no traditional definition of intervention.
223623279|NCT04249856|DIAGNOSTIC_TEST|Dynamic Spectral Imaging (DYSIS)|Women who have a colposcopy exam performed at Randers Regional Hospital were examined by Dynamic Spectral Imaging colposcopy (DYSIS)
224316395|NCT06578871|RADIATION|Intensity Modulated Radiotherapy (IMRT) to Mucosa at Risk|Patients in Arm 1, after the surgical procedure, will receive radiotherapy to the at-risk mucosa.
223623280|NCT02314325|DRUG|ADVATE [Antihemophilic Factor (Recombinant)]|In Arm 1 prior patients will be dosed as per body weight 20-40 IU/kg 5-7 infusions per fortnight
223623281|NCT02314325|DRUG|ADVATE [Antihemophilic Factor (Recombinant)]|In Arm 2 patients who have completed arm 1 will cross over onto an individualised PK tailored alternate day dosing regimen
223623282|NCT01168349|DRUG|epoetin beta [NeoRecormon]|As prescribed by physician
223623283|NCT01757106|DRUG|Xenon|general anaesthesia with xenon 50-60% in oxygen (FiO2=0.4-0.5)
223623284|NCT01757106|DRUG|sevoflurane|general anesthesia with sevoflurane 1.4% in 50% oxygen/medical air
224212777|NCT02268188|OTHER|laboratory biomarker analysis|Correlative studies
224212778|NCT02268188|OTHER|quality-of-life assessment|Ancillary studies
224212779|NCT04084028|BEHAVIORAL|Active Cooking Classes|6 cooking classes will be held every week for 6 consecutive weeks. The lessons are patterned after Dr. Amy Trubek's cooking pedagogy and will be tailored for those cooking for themselves for the first time. Classes begin with a brief lecture on the day's topic. Students will work in teams of 2 in the foods lab to actively practice skills and cook a meal. Students receive recipes and information sheets that cover pantry supplies, grocery lists, knife skills and cooking equipment. All students attend a 2 hour kitchen intensive demonstration as an orientation.
224212780|NCT04084028|BEHAVIORAL|Meal Kits|Students receive 6 weeks of home delivered meal kits. Meal kits include ingredients and detailed instructions for 3 meals, which each serve two people. Students may select meals from a list of 18 options that include vegan, vegetarian, and gluten free options.
224212781|NCT04084028|BEHAVIORAL|Recipes|Students are emailed a set of recipes once a week for 6 weeks. Recipes include options for breakfast, lunch, dinner, and snacks. Recipe sets include vegan, vegetarian, and gluten-free options. This intervention was cancelled by COVID-related disruptions and did not take place.
224212782|NCT05974345|DRUG|Inclisiran sodium|Drug: Inclisiran sodium 300 mg virtually subcutaneously administered on Day 1, Month 3 (Day 90) and every 6 months thereafter until end of simulation.
224212783|NCT05974345|DRUG|Placebo|Drug: Placebo virtually subcutaneously administered on Day 1, Month 3 (Day 90) and every 6 months thereafter until end of simulation.
224316396|NCT06578871|PROCEDURE|Surgical Intervention|These patients will undergo Neck dissection, TORS tonsillectomy (unilateral vs bilateral tonsillectomy at the discretion of the treating physician) + ipsilateral tongue base mucosectomy.
224316397|NCT06578871|RADIATION|Intensity Modulated Radiotherapy (IMRT) to Ipsilateral Neck|For Arm1, after the surgical procedure, the patients will receive radiotherapy to the ipsilateral neck. For Arm2, the patients will only receive IMRT to neck, if multiple ipsilateral nodes or single ipsilateral node \>3 cm is observed
223623285|NCT01475591|BEHAVIORAL|Web-based multimodal rehabilitation based on cognitive based principles|The patient will be randomized to either the interventions group (multimodal pain rehabilitation with an added web-based multimodal rehabilitation with CBT-influences) or a control group (multimodal pain rehabilitation).
224212784|NCT05974345|DRUG|Ezetimibe|Drug: Ezetimibe 10 mg virtually orally once a day until end of simulation.
224212785|NCT05974345|DRUG|Evolocumab|Drug: Evolocumab 140 mg virtually subcutaneously administered every two weeks until end of simulation.
224212786|NCT03521544|OTHER|Self-myofascial release|The subjects roll a foam roller under a determinated part of the body to self-massage that area.
224212787|NCT00779844|PROCEDURE|bariatric coelioscopic surgical procedure|total intra-venous anesthesia (propofol and remifentanil) being delivered using a close-loop system with the Bispectral Index as the single input for the controller
224212788|NCT00779844|PROCEDURE|supra-umbilical coelioscopic surgical procedure|total intra-venous anesthesia (propofol and remifentanil) being delivered using a closed-loop system with the Bispectral Index as the single input for the controller
224212789|NCT03989180|DEVICE|C-Scan System|"* Subjects will receive detailed instructions (verbally and written) about the normal operation of the recorder and how to handle it during normal daily routine. They will be asked to document all their daily activity in a personal diary (attached)~* The recorder will be secured to their lower back to test its functionality"
224212790|NCT03880929|OTHER|no intervention|no intervention
224212791|NCT02380066|DRUG|Anyu Peibo|Placebo
224212792|NCT02768220|DRUG|empagliflozin|Test to see how 30 days of jardiance changes serum and urinary advanced glycation end product levels
224212793|NCT02768220|DRUG|linagliptin|Test to see how 30 days of tradjenta changes serum and urinary advanced glycation end product levels
224212794|NCT00299273|BEHAVIORAL|Low calorie high fat/protein diet|6 weeks of caloric restriction (50%) on a high fat/protein diet
224212795|NCT00002273|DRUG|Ganciclovir|
224212796|NCT02071758|BIOLOGICAL|LEISH-F3 + SLA-SE|
224212797|NCT02071758|BIOLOGICAL|LEISH-F3 + GLA-SE|
224212798|NCT02100241|PROCEDURE|Active stretching|The participants performed three specific exercises of static active stretching of the hamstring muscles, maintaining the maximum tightness that was tolerable without pain for 15 seconds. Each exercise were performed twice, with a total of six repetitions.
224212799|NCT02076932|BEHAVIORAL|Spinning|After the baseline studies, the women will perform Spinning three times a week. Two of the sessions are performed on our location by trained instructors and the third training is self-training in a local fitness center where we provide free membership. All trainings are heart rate monitored.
224212800|NCT00822861|DRUG|TPI ASM8|4 mg/mL, 1 mg BID for 4 days
224212801|NCT00822861|DRUG|TPI ASM8|4 mg/mL, 2 mg BID for 4 days
224316398|NCT04077944|DIAGNOSTIC_TEST|maternal serum concentration of trace elements and heavy metals levels|The maternal serum levels of trace elements and heavy metals in both groups were measured using an inductively coupled plasma-mass spectrometry (ICP-MS)
224316399|NCT02255968|DRUG|EDP-788|EDP-788 Capsules. All interventions are given as multiple doses.
224316400|NCT02255968|DRUG|Placebo|Matching placebo capsules. All interventions are given as multiple doses
223761967|NCT01178892|BEHAVIORAL|Yoga|Yoga instruction is provided during 12 weekly 90-minute classes, designed for women without prior yoga experience. Each class includes an introductory breathing exercise, 11 to 13 gentle postures followed by deep relaxation with a visualization exercise. Study participants are expected to attend each of the 12 weekly yoga classes plus do daily 20-minute at-home practices. Classes are offered at 2 different times during the week.
223761968|NCT01178892|BEHAVIORAL|Exercise|The exercise intervention is facility-based aerobic exercise training on a treadmill, stationary bicycle or elliptical trainer performed 3 times a week for 12 weeks. The duration of each training session is determined for each woman based on the weekly total energy expenditure goal and workload required to achieve her prescribed exercise heart rate. Women train at 50-60% heart rate reserve (HRR) for the first month and then increase intensity to 60-70% HRR. To ensure that women train at their prescribed exercise heart rates, women wear Polar Heart Rate Monitors while exercising. The exercise counselor overseeing each exercise session records each participant's exercise heart rate every 5-10 minutes to document that she is in her target heart rate range.
224212802|NCT00822861|DRUG|TPI ASM8|4 mg/mL, 4 mg BID for 4 days
224316401|NCT02184767|DRUG|ADASUVE®|ADASUVE® 2.5, 5, or 10 mg
224316402|NCT05468801|OTHER|Individualized Homeopathic Remedy|An individualized homeopathic remedy selected for each subject according clinical homeopathic parameters will be administered daily in the form of oral globules as an add on to conventional treatment.
224212803|NCT00822861|DRUG|TPI ASM8|4 mg/mL, 8 mg OD for 4 days
224212804|NCT04397354|DRUG|Intracochlear Dexamethasone|intracochlear injection of dexamethasone with cochlear implantation
224212805|NCT04397354|DRUG|Intratympanic Dexamethasone|intratympanic injection of dexamethasone with cochlear implantation
224212806|NCT04397354|DRUG|No additional drugs(control Group)|Control group: No drugs will be injected middle ear with cochlear implantation
224212807|NCT04806477|OTHER|Telemedicine Consultation|Brief telemedicine consultation, blinded to subsequent face-to-face evaluation.
224212808|NCT04806477|OTHER|Face-to-face Consultation|Direct face-to-face evaluation (without telemedicine consultation before).
224212809|NCT06190782|COMBINATION_PRODUCT|PD-1 inhibitor+/- chemotherapy combined with local therapy|"1. PD-1 inhibitor +/- Chemotherapy PD-1 inhibitor: all FDA approved PD-1 inhibitor producter is suitable~   First line:~   i. TP: paclitaxel 135-175mg/m2,d1+ DDP25mg/m2, d1-3 or 75mg/m2,d1;q21d (albumin-bound paclitaxel or paclitaxel liposomes as alternative of paclitaxel permitted as alternative) or ii. PF: DDP Second line (other platinum-based agents permitted as alternative such as carboplatin, nedaplatin, oxaliplatin, lobaplatin, etc.) i. Docetaxel or ii. Irinotecan or iii. Paclitaxel (albumin-bound paclitaxel or paclitaxel liposomes as alternative of paclitaxel permitted as alternatives)~2. Local therapy i. Radiotherapy GTV=all suspected lesions. SBRT: for lung, liver, adrenal gland, celiac lymphnode metatstases 48Gy/6fx; for spine metastatic disease 30Gy/10Fx; for brain metastases 24Gy/30fx; IMRT: for bone metastatic disease 30Gy/10fx; for esophageal lesion or lesion unsuitable of SBRT 50.4Gy/28fx; ii. Surgery iii. Radiofrequency/microwave ablation"
224316403|NCT05468801|OTHER|Placebo|Placebo plus Standard Pharmacologic Treatment
224316404|NCT03338725|OTHER|Clinical pharmacy model|Patients who are being monitored by a clinical pharmacy model
224316405|NCT02806024|DRUG|Tranexamic Acid|
224316406|NCT02806024|DRUG|Placebo Drug|50 cc Normal Saline IV
224316407|NCT00051935|DRUG|Alglucosidase alfa|20 mg/kg (qow); intravenous
224316408|NCT03456141|PROCEDURE|third molar surgery|The patient is asked to complete the diary each post-surgery day for 14 days. Recovery is organized into three QOL domains: lifestyle, oral function, and pain.
224316409|NCT03203122|OTHER|IPL laser|IPL laser monthly. Vertical and horizontal treatment, one pass over. Settings according to fitzpatrick skin type
224316410|NCT03203122|OTHER|No sham treatment|The treatment is slightly painful, and noisy. Sham treatment impossible
224316411|NCT03555123|DRUG|Simdax|Levosimendan2.5mg/ml
224316412|NCT02166658|DRUG|Cabazitaxel|Cabazitaxel 25 mg/m2 i.v. infusion (infusion time about 1h) on D1 of each 21-day cycle. Continuation of treatment until progression of brain metastases or unacceptable toxicity.
223623286|NCT01368250|PROCEDURE|Transcatheter Aortic Valve Implantation|Minimal Invasive Implantation of a biological prosthesis in Aortic Position
223623287|NCT02257034|OTHER|Taichi|
223623288|NCT02257034|OTHER|Dance|
223623289|NCT04538638|PROCEDURE|Mesenteric sparing ileocolic resection|Mesentery left in situ
223623290|NCT04538638|PROCEDURE|Central mesenterectomy ileocolic resection|Mesentery is taken up to the level of the ileocolic trunk
223623291|NCT03535974|DIETARY_SUPPLEMENT|Preparation with Spirulina|Preparation with Spirulina to ameliorate the size of benign thyroid nodules
223623292|NCT03535974|DIETARY_SUPPLEMENT|Placebo|Placebo administration for 6 weeks bid
223623293|NCT06466694|BEHAVIORAL|Modified Dialectical Behavioural Therapy|The therapy will be co-delivered by the Elder, a perinatal psychiatrist and social worker trained in DBT. To evaluate through a patient lens content of the Dialectical Behavior Therapy (DBT) through the lens of an Indigenous Knowledge Carrier (Elder)
223623294|NCT04485897|DEVICE|icare HOME device (Icare Oy, Vanda, Finland)|icare HOME device versus hospital based measurements
223623295|NCT02185703|DEVICE|Chordate System S020 in treatment mode|
223623296|NCT02185703|DEVICE|Chordate System S020 in placebo mode|
223623297|NCT02068326|BEHAVIORAL|Mentalization Based Treatment|
224212810|NCT06190782|DRUG|systemic therapy alone|"1.PD-1 inhibitor +/- Chemotherapy PD-1 inhibitor: all FDA approved PD-1 inhibitor producter is suitable~First line:~i. TP: paclitaxel 135-175mg/m2,d1+ DDP25mg/m2, d1-3 or 75mg/m2,d1;q21d (albumin-bound paclitaxel or paclitaxel liposomes as alternative of paclitaxel permitted as alternative) or ii. PF: DDP Second line (other platinum-based agents permitted as alternative such as carboplatin, nedaplatin, oxaliplatin, lobaplatin, etc.) i. Docetaxel or ii. Irinotecan or iii. Paclitaxel (albumin-bound paclitaxel or paclitaxel liposomes as alternative of paclitaxel permitted as alternatives)"
224316413|NCT03226535|DEVICE|Ultrasound-CT Fusion|The Clear Guide SCENERGY is an Ultrasound-CT fusion device which supplements existing ultrasound and CT capabilities. The participants randomly selected (out of 20 patients) for use of the Clear Guide SCENERGY (test group) will receive ultrasound-CT fusion guidance from the MDs performing the procedure.
224316414|NCT02929888|DRUG|Lysine Acetilsalicilate|
224316415|NCT02929888|DRUG|Aspirin|
224316416|NCT02208830|OTHER|pulmonary rehabilitation|Pulmonary rehabilitation: 8 week, twice weekly exercise program with aerobic treadmill training and lower limb strength training.
224316417|NCT02208830|OTHER|conventional program|The conventional program is conducted with duration of 8 week, twice weekly. The techniques used will be: expiration with the glottis open in lateral posture (Eltgol), autogenous drainage (AD) and shaker. Each technique will last for 30 minutes.
224316418|NCT03953326|BEHAVIORAL|HeartPhone app|Evaluative conditioning (temporally distributed micro-doses presented upon activation of smartphone screen)
224316419|NCT03953326|DRUG|Acetylcholine|Endothelium-dependent vasodilation is tested with the localized delivery of the neurotransmitter
224316420|NCT03953326|DRUG|Sodium Nitroprusside|Endothelium-independent vasodilation is tested with the localized delivery of the nitric oxide donor
224316421|NCT03953326|DRUG|L-Arginine, N2-((4-Methylphenyl)Sulfonyl)-, Methyl Ester|This nitric oxide inhibitor is continuously given during the localized delivery of the endothelium-dependent agonist acetycholine.
223623298|NCT02068326|BEHAVIORAL|Treatment As Usual|Treatment As Usual
223623299|NCT04059549|BEHAVIORAL|PartnerCHESS|"Patients randomized to the PartnerCHESS group will receive all A-CHESS services plus the following services from ABCT:~Urge discussion. Daily EMAs will track preconditions for relapse (urges), review urge reduction options on PartnerCHESS, and encourage discussions between partners on the causes of and ways to reduce urges.~Homework checklist. Tracks which interventions the couple is using/practicing, along with resources to help.~Relapse plan. Monitoring and reminders of steps planned for relapse prevention. Reminders. Reminders to notice something positive in partner, of reasons to stay sober, to take meds, etc.~Trigger identification and removal. During set-up, patient and partner enter triggers. PartnerCHESS will quiz couples on upcoming trigger events and remind them of ways to address each."
223623300|NCT04059549|BEHAVIORAL|A-CHESS|A-CHESS control group
223623301|NCT05011227|DRUG|Camrelizumab|2 cycles Camrelizumab before endoscopic surgery and one year after
223623302|NCT05011227|DRUG|Chemotherapy|2 cycles Gemcitabine based chemotherapy before endoscopic surgery, with or without after surgery
223623303|NCT05011227|PROCEDURE|endoscopic surgery|standard endoscopic surgery for recurrent nasopharyngeal carcinoma
223623304|NCT04676295|BEHAVIORAL|Face-to-face and web-based lifestyle intervention|Families are provided at baseline with one 60 min face-to-face dietary counseling session with nutritionist using family-oriented motivational interviewing and solution focusing techniques. The intervention continues in an interactive web-based portal where different modules include assignments, activities, and tests and related videos targeting five cardiovascular health-linked behaviors: 1) improving quality of fat in the diet, 2) increasing the consumption of foods rich in fiber, 3) decreasing the use of salt, 4) increasing physical activity and 5) reducing smoking.
223623305|NCT04581226|DIAGNOSTIC_TEST|Lung ultrasound|All children will be studied in the supine position. LUS will be performed with the portable device MicroMax (Sonosite, Bothell, Washington, USA) using a linear probe of 6 to 12 MHz. All ultrasound scans will be performed by the same anesthetist, who has experience of more than 30 lung ultrasound scans in pediatric patients. Each hemithorax will be divided into six regions, using three longitudinal lines (parasternal, anterior and posterior axillary) and two axial lines (one above the diaphragm and the other 1 cm above the nipples)
223623306|NCT02639494|DEVICE|Self-Centering Guide Catheter|
223680496|NCT02901756|DIETARY_SUPPLEMENT|Antemig|Participants were instructed to take one tablet every morning for three months.
224212811|NCT01664273|DRUG|Plasmid AMEP|"Cohorts of 3 patients will received increasing doses of plasmid AMEP:~50 μg, 100 μg, 250 μg and 500 μg. Starting dose will be the lowest dose.~Injection volume will remain constant at 200 μL.~Once-only treatment and intra-individual dose escalation will therefore not occur."
224212812|NCT01882231|OTHER|DCE-MRI, DW-MRI, MT-MRI, and CEST-MRI|Imaging techniques using high-field MRI to make quantitative assessments in patients with osteosarcoma or Ewing sarcoma
224212813|NCT03666546|DRUG|Lactulose crystals 20 g|White or almost white crystalline powder. The product will be provided in sachets to be dissolved in 250 mL water.
224212814|NCT03666546|DRUG|Lactulose crystals 30 g|White or almost white crystalline powder. The products will be provided in sachets to be dissolved in 250 mL water.
224212815|NCT03666546|DRUG|Lactulose liquid 20 g|Clear, viscous liquid, colourless or pale brownish-yellow liquid syrup (solution). The products will be provided in sachets to be dissolved in 250 mL water.
224212816|NCT03666546|DRUG|Lactulose liquid 30 g|Clear, viscous liquid, colourless or pale brownish-yellow liquid syrup (solution). The products will be provided in sachets to be dissolved in 250 mL water.
224212817|NCT03666546|DRUG|Glucose|White crystalline powder. To standardise for 30 g glucose, 33 g glucose monohydrate will be used. The products will be provided in sachets to be dissolved in 250 mL water.
224212818|NCT03666546|DRUG|Still water|250 mL still water will be used. Water from the same source will be also used to dissolve investigational and control products
223623307|NCT02663011|OTHER|Language Evaluation-Preschool Language Scale Corrected edition(PLS-C), Lin|"To assess age and gender effect in the language error type (semantics, syntax and pragmatics)of developmental delay preschool aged children, a standardize tool Preschool Language Scale Corrected edition(PLS-C), Lin was adopted for evaluation."
224316422|NCT01994850|DRUG|brentuximab vedotin|Trade name: Adcetris
224316423|NCT00621270|DRUG|BCI-540|BCI-540 80 mg once (q.d.) or three times (t.i.d.) a day versus placebo
224316424|NCT05051514|DIAGNOSTIC_TEST|Evaluation|To examine the differences in postural stability, anxiety/depression, and quality of life of the patients according to the severity of Obstructive Sleep Apnea Syndrome.
223623308|NCT02678351|DRUG|68Ga-PSMA-11|Undergo 68Ga-PSMA-11 PET/MRI
223623309|NCT02678351|PROCEDURE|Magnetic resonance imaging (MRI)|Undergo 68Ga-PSMA-11 PET/MRI
223623310|NCT02678351|PROCEDURE|Positron Emission Tomography (PET)|Undergo 68Ga-PSMA-11 PET/MRI
223623311|NCT00741052|DRUG|Ciprofloxacin|12 hourly oral dose of ciprofloxacin for 3 days
223623312|NCT00741052|DRUG|Azithromycin|1 gm Azithromycin single dose
223623313|NCT00988884|BIOLOGICAL|V503|V503 (Multivalent HPV L1 VLP vaccine) given as a 0.5 mL intramuscular injection in the deltoid muscle of the non-dominant arm at Day 1, Month 2, and Month 6
223623314|NCT00988884|BIOLOGICAL|Comparator: Menactra™ (Concomitant)|Menactra™ given as a single 0.5 mL intramuscular injection in the deltoid muscle of the dominant arm on Day 1.
223623315|NCT00988884|BIOLOGICAL|Comparator: Adacel™ (Concomitant)|Adacel™ given as a single 0.5 mL intramuscular injection in the deltoid muscle of the dominant arm on Day 1.
223623316|NCT00988884|BIOLOGICAL|Comparator: Menactra™ (Non-Concomitant)|Menactra™ given as a single 0.5 mL intramuscular injection in the deltoid muscle of the dominant arm at Month 1.
223623317|NCT00988884|BIOLOGICAL|Comparator: Adacel™ (Non-concomitant)|Adacel™ given as a single 0.5 mL intramuscular injection in the deltoid muscle of the dominant arm at Month 1.
223623318|NCT01919229|DRUG|LEE011 (ribociclib)|Ribociclib was supplied in 200 mg hard gelatin capsules for oral use.
223623319|NCT01919229|DRUG|letrozole|Letrozole was supplied in 2.5mg tablets for oral use.
223623320|NCT06473415|DIAGNOSTIC_TEST|Electroencephalography|Electroencephalography using the Sleep-Profiler device
223623321|NCT00700596|DRUG|Salvinorin A|Low dose: Active SA 250μg Medium Dose: Active SA 500μg High Dose: Active SA 750μg
223623322|NCT00700596|DRUG|Placebo|Control or Placebo SA (30 % ethanolic solution)
223623323|NCT00763113|DEVICE|Vanguard PS Knee|Vanguard PS Knee
223623324|NCT00763113|DEVICE|Vanguard CR Knee|Vanguard CR Knee
223623325|NCT00184223|BEHAVIORAL|Motivational Interviewing|2 sessions of 45 minutes each with manual guided motivational interviewing delivered individually by a trained therapist.
223623326|NCT00184223|OTHER|Treatment as usual|Treatment as usual is individualized according to the clinical condition of the patients during the stay and in accordance with general national and international medical standards. It includes detoxification, pharmacotherapy, and general psychotherapy. Also, treatment is given for any coexisting non-substance-related disorder, including psychiatric disorders.
223623327|NCT01655758|DRUG|0.5% timolol|
223623328|NCT01655758|DRUG|timolol-dorzolamide fixed combination|
223623329|NCT01655758|DRUG|Latanoprost|
223623330|NCT01655758|DRUG|Travoprost|
223623331|NCT01655758|DRUG|Bimatoprost|
223623332|NCT05311735|PROCEDURE|Freeze-Dried Bone Allograft control|Bone grafting to prevent alveolar ridge collapse after tooth removal
223623333|NCT05311735|PROCEDURE|Mineralized Dentin Graft|Mineralized tooth graft used as a bone graft substitute to prevent alveolar ridge collapse after tooth removal
223623334|NCT05311735|PROCEDURE|Partial-Demineralized Dentin Graft|Partially mineralized tooth graft used as a bone graft substitute to prevent alveolar ridge collapse after tooth removal
224212819|NCT01572831|OTHER|PCT and clinical algorithm for stopping abx|In the experimental arm, antibiotics will be stopped based upon the PCT-guided algorithm. This PCT algorithm also incorporates clinical parameters to ensure utmost safety for the patients. These clinical parameters are; resolution of fever (temperature less than 38.3 and greater than 36.0), shock (on no vasopressors), and leukocytosis (\<12,000 and \>4,000).
224212820|NCT06016101|OTHER|100 Patients|"For patients and professionals: retrieval of socio-demographic data~For patients :~* Pill counting~* Morisky questionnaire"
224212821|NCT06016101|OTHER|Healthcare professionals (20 doctors, 20 pharmacists and 20 nurses)|"For patients and professionals: retrieval of socio-demographic data~For healthcare professionals :~* Evaluation of user experience~* Evaluation of the report produced by the application"
224316425|NCT00820781|PROCEDURE|Portacaval shunt|Subject taken to the operating room and undergoes portacaval shunt surgery
224316426|NCT00820781|PROCEDURE|Sclerotherapy|Subject taken to Endoscopy Suite and undergoes endoscopic sclerotherapy
224316427|NCT01586507|DRUG|ULTRAM ER|One dose of ULTRAM ER that is closest to 2 mg/kg, based on the participant's body weight and adjusting the dose in 25 mg increments.
224212822|NCT01804192|OTHER|Acu-TENS|Systolic and diastolic blood pressures will be taken on the left arm by a digital blood pressure monitor (Mindray PM-8000 Express Patient Monitor, Bio-Medical Electricity, Hamburg, Germany). The mean arterial pressure (MAP) will be recorded from the machine. Three ECG electrodes will be applied over left and right clavicles and left upper quadrant of abdomen respectively and then connect to a digital patient monitor device (Mindray PM-8000 Express Patient Monitor, Bio-Medical Electricity, Hamburg, Germany). The heart rate (HR) will be measured. The ECG signals will be transferred to the PowerLab 16/30 (ADInstruments Pty Ltd. NSW, Australia) for data acquisition and analysis of the HRV.
224212823|NCT01561118|OTHER|Bicycle-Ergometer Training|"Performance adapted, hence individualised three times weekly bicycle-ergometer training during hemodialysis. Each training will last 30 to 50 minutes with 70-80% of the patient specific maximum workload over 12 weeks (36 training sessions - first part of the study compared to no intervention).~In the second part of the study both groups get the opportunity for another 12 weeks of individualised three times weekly bicycle-ergometer training during hemodialysis."
224212824|NCT00158795|BIOLOGICAL|Haemophilus Influenza type b vaccine|
224212825|NCT04972136|DEVICE|Active Bilateral Theta Burst Stimulation|A total of 30 active BL-TBS sessions. Stimulation will begin with right DLPFC (cTBS) followed by left DLPFC (iTBS)
223623335|NCT00626275|DRUG|ADL5859|
223623336|NCT00626275|DRUG|Naproxen|
223623337|NCT00626275|DRUG|Placebo|
224212826|NCT04972136|DEVICE|Sham Bilateral Theta Burst Stimulation|A total of 30 sham BL-TBS sessions. Stimulation will begin with right DLPFC (cTBS) followed by left DLPFC (iTBS)
223623338|NCT00626275|DRUG|ADL5859|
223623339|NCT00626275|DRUG|Placebo|
223623340|NCT02760615|DRUG|Caffeine|Caffeine tablets
223623341|NCT02760615|DRUG|Losartan|Losartan tablets
223623342|NCT02760615|DRUG|Omeprazole|Omeprazole capsules
223623343|NCT02760615|DRUG|Dextromethorphan|Dextromethorphan capsules
223623344|NCT02760615|DRUG|Midazolam|Midazolam syrup
223623345|NCT02760615|DRUG|Vedolizumab|Vedolizumab solution for IV infusion
224212827|NCT05321121|DRUG|Dexmedetomidine|Dexmedotomidine for Acute Pain Control in Patients with Multiple Rib Fractures
224212828|NCT05321121|OTHER|Placebo|The control arm will receive an infusion of normal saline
224212829|NCT02760784|BEHAVIORAL|Early weight bearing|The intervention implies that the selected patients, will be allowed to bear weight on the injured leg form day 1 while wearing the orthosis, in contrast to the control group, who must wait 6 weaks.
224212830|NCT03728699|DIAGNOSTIC_TEST|Sample Collection Blood|Collected from each patient twice weekly.
224212831|NCT03728699|DIAGNOSTIC_TEST|Stool Sample|Collected from each patient twice weekly.
224212832|NCT05037552|PROCEDURE|Bipolar coagulation|"Cystectomy will be done via laparoendoscopic surgery After identifying the correct plane of cleavage, the stripping technique will be used. The cyst wall will be gently pulled down from the remaining ovary with two pairs of atraumatic forceps.~Once the whole cyst wall will be separated from the ovary cortex, bleeding of the remaining ovarian stromal tissue will be controlled by bipolar coagulation. Then, the remnant tissue will be examined using irrigation and coagulated with minimal bipolar power (20-W current) on any sites that are bleeding."
224212833|NCT05037552|PROCEDURE|Coagulation by FLOSEAL haemostatic agent|"Cystectomy will be done via laparoendoscopic surgery After identifying the correct plane of cleavage, the stripping technique will be used. The cyst wall will be gently pulled down from the remaining ovary with two pairs of atraumatic forceps.~Once the whole cyst wall will be separated from the ovary cortex, bleeding of the remaining ovarian stromal tissue will be controlled by either hemostatic sealants (FloSeal). Using a laparoscopic applicator, FloSeal will be applied to the surface of bleeding sites under direct vision and the ovarian cortex was gently pressed for 2 min with small gauze."
224212834|NCT01339078|PROCEDURE|Plastic stenting|The patients receive plastic stenting after ortothopic liver transplantation with a choledocho-choledochal anastomosis, presenting with an anastomotic stricture. These patients will receive change of the stent every 3 months, for a total duration of 1 year.
223623346|NCT04736914|DRUG|R-CHOP/R-DHAOx； Zanubrutib（induction）； ASCT conditioning ； Zanubrutinib（Maintenance）|"Alternating 3× R-CHOP/ 3× R-DHAOx, every 21 days plus oral Zanubrutinib in cycle 1, 3, 5 in combination with R-CHOP:~R-CHOP (cycle 1,3,5):~Rituximab 375 mg/m2 D1, I.V. Cyclophosphamide 750 mg/m2 D1, I.V. Doxorubicine 50 mg/m2 D1, I.V. Vincristine 1.4mg/m2(max 2mg)D1, I.V. Prednisone 100mg D1-5, oral Zanubrutinib 160mg BID D1-21, oral~R-DHAOx (cycle 2,4,6):~Dexamethasone 40mg D1-4 oral/I.V. Rituximab 375mg/m2 D1, I.V. Ara-C 2×2g/m2 q12h D2, I.V. Cisplatin 100mg/m2 D1, I.V.~Maintenance:~* Zanubrutinib, 160mg PO BID, continuously for 2 year or until progressive disease。~* Zanubrutinib maintenance will start after regeneration of peripheral blood count after the end of the last cycle of induction therapy or ASCT"
223623347|NCT04886323|DEVICE|Cold atmospheric plasma treatment device|Treat with cold atmospheric plasma treatment device.
223623348|NCT04886323|DRUG|Itraconazole Capsules|Treat with Itraconazole capsules
223623349|NCT03502837|OTHER|emotional sound and neutral sound|"Neutral voice is a meaningless sound (namely the interjection ah) and the emotional stimuli were the same voice pronouncing the same word with an emotional prosody of happiness or sadness.The stimulus material consisted of positive and negative sound selected from the International Affective Digitalized Sounds (IADS) database.In order to identify experimental stimuli sets that were matched for ratings of arousal and valence between the two valence types,investigators used an algorithm to equate normative valence and arousal ratings for the selection of auditory stimuli."
223623350|NCT04999839|DRUG|NDI-034858 study drug|NDI-034858 2 mg oral capsules.
223623351|NCT04999839|DRUG|NDI-034858 study drug|NDI-034858 5 mg oral capsules.
223623352|NCT04999839|DRUG|NDI-034858 study drug|NDI-034858 15 mg oral capsules.
223623353|NCT04999839|DRUG|NDI-034858 study drug|NDI-034858 30 mg (2\*15 mg) oral capsules.
223623354|NCT04999839|OTHER|Placebo|Placebo matched to NDI-034858 oral capsules.
223623355|NCT01362348|DRUG|pazopanib eye drops|10 mg/mL (1 drop) four times daily
223623356|NCT01021735|DRUG|etanercept or adalimumab|etanercept 50mg/week by s/c injection adalimumab 40mg eow by s/c/ injection
223623357|NCT01021735|DRUG|Rituximab|1g x2 by IV infusion repeated every 5 months or more
223623358|NCT02388581|DRUG|Lansoprazole, Amoxicillin, Clarithromycin, Metronidazole|Anti-H. pylori Therapy
224316428|NCT01586507|DRUG|ULTRAM ER|The target dose for Group 2 will be the one that achieves a level of exposure similar to that seen with a single 200 mg ULTRAM ER dose in adults.
224316429|NCT05842993|DEVICE|Hydrogen generator|Patient inhales hydrogen gas for 2 hours per day in the flow rate of 2L/min via nasal cannula by applying hydrogen generator (HZS-2700A, Qingdao Haizhisheng Corp.,LTD, Qingdao, China) for 12 weeks.
223623359|NCT06011408|OTHER|TDtect|Collecting video data on abnormal movement
223623360|NCT02851303|DRUG|Morphine|Morphine wean protocol as described in arm description
223623361|NCT02851303|DRUG|Methadone|Methadone wean protocol as described in arm description
223623362|NCT02572323|DRUG|Tesamorelin|Tesamorelin is an injectable medication already approved by the U.S. FDA to treat abdominal fat accumulation in HIV
223623363|NCT06262789|OTHER|"Return-to-work after cancer consultation"|"The return-to-work after cancer consultation is carried out by a specialist in occupational pathology, who may be assisted by a psychologist and/or a nurse and/or a social worker, depending on the patient's personal situation. During this consultation, the team assesses the patient's medical situation, social situation and psychological situation. This consultation lasts approximatively 1 hour and aims to guide the patient in the different stages of return to work, to identify obstacles and apprehensions about return to work, to assess the patient's functional capacities and motivations, to provide information on the legislation, actors and tools for employment maintenance and to discuss possible adjustments of the work situation. The consultation provides a response to potential or encountered problems, directs the patient towards the actors and tools adapted to his/her situation."
223623364|NCT05887986|OTHER|hand-held fan airflow stimulation|"Outcome dyspnea measures:~After the fan training application given to the hand-held fan airflow stimulation group by the researchers, the hand fan application will be made for 5 days. On the baseline, day 3, and day 5 of the study, the dyspnea level will be evaluated.~Outcome comfort measures:~After the fan training application given to the hand-held fan airflow stimulation group by the researchers, the hand fan application will be made for 5 days. On the baseline, day 3, and day 5 of the study, the comfort level of the patients will be evaluated."
223623365|NCT02734693|DRUG|dasotraline 4mg|dasotraline 4mg/day
223623366|NCT02734693|OTHER|Placebo|placebo/day
223623367|NCT04954508|DIAGNOSTIC_TEST|The hug-up test|It is a new physical test used to detect supraspinatus tear
224212835|NCT01339078|PROCEDURE|Kaffes stenting|The patients receive Kaffes stenting after ortothopic liver transplantation with a choledocho-choledochal anastomosis, presenting with an anastomotic stricture. These patients will receive change of the stent every 6 months, for a total duration of 1 year.
224212836|NCT02579785|BEHAVIORAL|Mhealth intervention|A series of ten automated interactive voice messages will be delivered to the participant's mobile phone over a period of 4 months. Messages will be targeted to the method of contraception the participant is using (no-method, condoms, pills, injectable, implant, copper coil). Messages will support uptake of contraception among no-method users. Messages will support existing users to continue their method and to use it correctly and will also encourage participants who are not happy with their method to switch to a different method. All messages will end with five options: Press 1 to repeat the message, press 2 to listen to recorded information about methods of contraception, press 3 to speak to a counsellor, press 4 to tell me you're fine, press 5 to stop receiving these messages.
224212837|NCT04345731|OTHER|Over the counter drug labels|A control condition based on the current standard OTC label and 3 experimental labels will be compared to identify OTC labels that more effectively communicate critical information for the reduction of adverse drug events to the consumer
224212838|NCT02123069|DEVICE|Brachial artery catheter|A catheter will be placed in the brachial artery by a physician on the study day.
224212839|NCT02123069|DRUG|Acetylcholine|Acetylcholine will be infused into the brachial catheter while blood flow levels in the forearm are measured. Acetylcholine will be infused at the following doses: 1.0, 2.0, 4.0, and 8.0 ug/100 ml tissue/min for 2 minutes each.
224316430|NCT05842993|DEVICE|Analogue machine|Patient inhales normal air for 2 hours per day in the flow rate of 2L/min via nasal cannula with analogue machine for 12 weeks. This machine has the same appearance as the hydrogen generator.
224316431|NCT02548169|BIOLOGICAL|DC Vaccine + Standard of Care Chemotherapy|"4 doses of DC vaccine at 2 weeks interval, combined with either:~* Standard of care neoadjuvant folinic acid, oxaliplatin, irinotecan and 5- Fluorouracil (5FU) (FOLFIRINOX) regimen alone (6 cycles)~* FOLRIRINOX regimen followed by 5-FU chemoradiation or Gemcitabine Chemoradiation~* Gemcitabine + nab-paclitaxel~The first vaccination will include one intradermal injection of 100 μL at 15 x106 cells/mL in the upper thigh and one subcutaneous injection of 1 mL (15 x 106 cells/mL) .~The participants will receive 3 additional subcutaneous vaccinations, each injection of 1 mL at 15 x 106 cells/mL, at 2 weeks interval, on Day 2 of study weeks 3, 5 and 7.~Participants will receive 2 booster DC vaccinations subcutaneously of 1 mL at 15x106 cells/mL."
224316432|NCT05235516|DRUG|AK104|q3w iv
224316433|NCT05235516|RADIATION|EBRT|45-50.4Gy
224316434|NCT05235516|RADIATION|BT|≥80Gy
224316435|NCT05235516|DRUG|cisplatin|qw iv
224316436|NCT05235516|DRUG|Placebo|q3w iv
224316437|NCT01515917|DRUG|Citicoline|Participants randomly assigned to the experimental group, who, in addition to the research staff will be blind to such assignment, will be instructed to orally administer 1000 mg daily citicoline. These participants will receive a 14-day supply of citicoline at visit 1 and again at visit 2, making for a 28-day administration period.
224316438|NCT01515917|DRUG|Omega-3|Participants randomly assigned to the experimental group, who, in addition to the research staff will be blind to such assignment, will be instructed to orally administer 2000 mg daily omega-3. These participants will receive a 14-day supply of omega-3 at visit 1 and again at visit 2, making for a 28-day administration period.
223623368|NCT04954508|DIAGNOSTIC_TEST|EC test|It is a traditional physical test used to detect supraspinatus tear
223623369|NCT04954508|DIAGNOSTIC_TEST|FC test|It is a traditional physical test used to detect supraspinatus tear
223623370|NCT04954508|DIAGNOSTIC_TEST|Neer impingement sign|It is a traditional physical test used to detect supraspinatus tear
223623371|NCT04954508|DIAGNOSTIC_TEST|Hawkins-Kennedy impingement sign|It is a traditional physical test used to detect supraspinatus tear
223680497|NCT04919447|PROCEDURE|pacemaker implantation|cardiac pacing has been widely used in the treatment of bradyarrhythmias and heart failure, which can effectively improve the survival rate of patients.
223623372|NCT04954508|DIAGNOSTIC_TEST|diagnostic arthroscopy|The arthroscopic operation involved complete inspection of the supraspinatus. Supraspinatus tears were categorized as fullthickness tears (FTTs), which were classified as small (≤1 cm), moderate (≤3 cm), large (≤5 cm), and massive (\>5 cm), on the basis of the largest dimension, and partial-thickness tears (PTTs), which were classified as bursal-sided, articular-sided,and intra-tendinous. Other combined diseases including acromioclavicular joint derangement, infraspinatus lesions, subscapularis lesions, superior labrum anterior and posterior (SLAP) lesions, biceps disorders, and Bankart lesions were recorded as well to assess the specificity of the tests.
223623373|NCT01067677|DRUG|Metaclopramide|0.5 mg/kg for rescue after PONV
223623374|NCT01067677|DRUG|Ondansetron|0.1 mg/kg (max 4 mg0
223623375|NCT01067677|DRUG|diphenhydramine|0.25 mg/kg (max 25 mg)
223623376|NCT01067677|DRUG|Saline|equal volume (5 ml)as experimental rescue medications
223623377|NCT05239481|DEVICE|colonoscopy position identification sheet|According to the body position requirements of the left lying position during colonoscopy, the research group used ink to add the body position prompt sign on the disposable bed sheet .Through the position identification, patients can intuitively understand the position that should be used in the operation and the position that should be placed in each part of the body.
224316439|NCT01515917|OTHER|Rice bran oil|Rice bran oil will be one of two placebos administered to participants randomly assigned to the placebo arm. Rice bran oil will serve as the placebo for omega-3 fatty acids and will be orally administered daily in 500 mg doses.
223623378|NCT05239481|DEVICE|Traditional disposable cleaning sheet|Traditional disposable cleaning sheets were used during control colonoscopy.Before the examination, the nursing staff took a unified and simple language to guide the patient.
223623379|NCT05670522|DEVICE|Transcranial direct current stimulation|"Transcranial direct-current stimulation (tDCS), over the motor cortex, is a potential therapy option for motor control deficits in children with CP. The application of tDCS involves positioning 2 rubber electrodes sheathed in saline-soaked pads onto the scalp, held in place by a rubber strap. Low-intensity, direct-current, of 1 to 2 mA, is delivered to cortical areas from the device.~The standard-of-care gait training included various gait training and balance tasks as well as resistive exercises and passive stretching as necessary. Task-specific gait exercises included: walking in a closed indoor environment, walking in an open indoor environment, walking on various floor surfaces, and climbing stairs up and down without assistance. The children also performed dynamic balance exercises by walking on a balance board."
223623380|NCT05670522|DEVICE|Virtual reality|"Virtual reality rehabilitation is an emerging therapy for motor rehabilitation of children with CP. The therapy is provided through a computer-simulated environment where they interact with real-world-like objects and events through sight, sound, and touch. The Wii Remote was used as the interactive interface, and standard computer/television screens were used as the display hardware. Therefore, VR therapy was of the non-immersive type.~The standard-of-care gait training included various gait training and balance tasks as well as resistive exercises and passive stretching as necessary. Task-specific gait exercises included: walking in a closed indoor environment, walking in an open indoor environment, walking on various floor surfaces, and climbing stairs up and down without assistance. The children also performed dynamic balance exercises by walking on a balance board."
223623381|NCT03121859|OTHER|Neck stabilization exercise|Exercise
223623382|NCT03121859|OTHER|TENS|Transcutaneous electrical nerve stimulation (TENS)
223623383|NCT03121859|OTHER|IFC|Interferential current therapy(IFC)
223623384|NCT02787395|PROCEDURE|shoulder dislocation self reduction|shoulder dislocation self reduction using one of three methods in the study
223623385|NCT03626259|DRUG|Losartan and Amlodipine|Losartan and amlodipine in fixed combination capsules, 100mg/5mg. One time daily with the first bite of eat meal per 8 weeks
223623386|NCT03626259|DRUG|Losartan|Losartan capsules, 100mg. One time daily with the first bite of eat meal per 8 weeks
223623387|NCT03389022|DRUG|Ketamine|0,15 mg/kg pre-incisional single bolus dose of ketamine in the operating room.
223623388|NCT03389022|DRUG|Saline|Intravenous injection given pre-incisional in the operating room.
223623389|NCT03389022|DRUG|Ketamine|0,3 mg/kg pre-incisional single bolus dose of ketamine in the operating room.
223623390|NCT03389022|DRUG|Ketamine|0,15 mg/kg pre-incisional single bolus dose of ketamine, followed by continuous infusion of 1 mg/kg in the operating room.
223623391|NCT03389022|DRUG|Ketamine|0,3 mg/kg (LBM) of intravenous pre-incisional single bolus injection, followed by continuous infusion of 1mg/kg ketamine given for bariatric patients in the operating room.
223623392|NCT00934453|BIOLOGICAL|Lactobacillus rhamnosus GG ATCC 53103|Study drug capsules (1x10\^10 LGG/capsule) are to be taken orally twice a day every day dissolved in cow's milk or soy milk on an outpatient basis for six months.
223623393|NCT00934453|BIOLOGICAL|Placebo|Placebo capsules composed of microcrystalline cellulose are to be taken orally twice a day dissolved in cow's milk or soy milk on an outpatient basis for six months.
223623394|NCT02050477|PROCEDURE|Laparoscopic Vertical Gastroplasty|The Magenstrasse and Mill procedure is a conservative vertical gastroplasty described in 1987 through a laparotomy. A tubular gastric pouch is created by a vertical stapling extending from the antrum to the angle of Hiss. In this study, we evaluate the laparoscopic technique of the procedure.
223623395|NCT00526292|BIOLOGICAL|natural killer cell therapy|The patient must be admitted by Day -8 to the Bone Marrow Transplant Service. On Day 0, patients will receive a single dose of allogeneic NK cells isolated from a HLA-haploidentical related donor and will be monitored for hematopoietic recovery.
223623396|NCT00526292|DRUG|cyclophosphamide|Day -6 cyclophosphamide 60mg/kg infused over 1 hour (dose adjusted for body weight) for 2 days
223623397|NCT00526292|DRUG|fludarabine|Day -5 fludarabine 25mg/m2 CIV for 5 days
223623398|NCT03899714|OTHER|Cryotherapy|Crushed ice in a plastic bag will be used, as it is a widely accessible and financially convenient method of cryotherapy. One half of a kilogram of ice will be placed in a plastic bag. The plastic bags will be 17 cm wide and 22 cm long. The air will be squeezed out of the bag and it will be sealed. The bag will be wrapped in a wet towel and applied to the tested area. Every five bags of crushed ice will be kept in an insulated foam container containing one kilogram of dry ice. Dry ice has a temperature of negative 80 degrees Celsius, and is used to keep the bags of crushed ice in a frozen state till the participants are briefed and the testing began.
224212840|NCT02123069|DRUG|Nitroprusside|Nitroprusside will be infused into the brachial catheter while blood flow levels in the forearm are measured. Nitroprusside will be infused at the following doses: 0.25, 0.5, 1.0, and 2.0 ug/100 ml tissue/min for 2 minutes each.
224212841|NCT02123069|DRUG|Norepinephrine|Norepinephrine will be infused into the brachial catheter while blood flow levels in the forearm are measured. Norepinephrine will be infused at the following doses: 1.0, 2.0, 4.0, and 8.0 ug/100 ml tissue/min for 2 minutes each.
224212842|NCT02123069|DRUG|Nitroprusside and phenylephrine|A single dose of nitroprusside (100 ug) will be infused through an IV; one minute later, a single dose of phenylephrine (150 ug) will be infused.
224212843|NCT03398655|DRUG|VB-111 + Paclitaxel|VB-111 will be administered intravenously at a dose of 1x10e13 VPs every 2 months Paclitaxel will be administered intravenously at a dose of 80mg/m2 every week
224212844|NCT03398655|DRUG|Placebo + Paclitaxel|Placebo will be administered intravenously every 2 months Paclitaxel will be administered intravenously at a dose of 80mg/m2 every week
224212845|NCT06542510|BEHAVIORAL|working night shift|working night shift
224212846|NCT03171506|OTHER|Ketogenic diet|Participants in the usual care plus ketogenic diet group will receive usual care plus dietary counseling in accordance with a ketogenic diet such that \~5% energy comes from carbohydrate, 25% energy from protein, and 70% energy from fat for the duration of the 12 week study.
224212847|NCT03171506|OTHER|AND diet|Participants in the usual care plus AND diet group will receive usual care plus dietary counseling in accordance with the Academy of Nutrition and Dietetics guidelines in 2013 for the duration of the 12 week study.
224212848|NCT04377178|DEVICE|Dentin grinder|After atraumatic extraction of the tooth, autogenous dentin particles are made with the help of a device - dentin grinder from the separated root and these particles are incorporated into the extraction socket
224212849|NCT04377178|DEVICE|Bone mill|After atraumatic extraction of the tooth, autogenous dentin particles are made with the help of a device - Bone mill from the separated root and these particles are incorporated into the extraction socket
224212850|NCT02270905|DEVICE|dCELL® Meniscus|decellularised porcine xenograft
224212851|NCT00871598|DRUG|BTT1023|intravenous, three infusions over three weeks
224212852|NCT00871598|DRUG|Placebo|intravenous, three infusions over three weeks
224212853|NCT00871598|DRUG|BTT1023|Test challenge
224212854|NCT06352398|PROCEDURE|erector spina plan block|erector spina plan block
224212855|NCT06352398|PROCEDURE|Serratus posterior superior intercostal plan block (SPSIPB)|Serratus posterior superior intercostal plan block (SPSIPB)
224212856|NCT06352398|DRUG|0.25% bupivacaine|Before the operation, 0.25% bupivacaine 30 ml was administered to both groups.
224212857|NCT05530642|BEHAVIORAL|Emotional Resilience Skills Training (ERST)|"The ERST training is designed as a train the trainer model. Sauer-Zavala, a co-developer of the UP, personally trained a group of PSP trainers from each of the PSP pilot sectors (i.e., CanOps, Regina Fire \& Protective Services, Regina Police Service, Saskatoon Police Service, Regina Emergency Medical Services, Ottawa Emergency Medical Services) during a week-long interactive workshop. The trainers continue to have access to Sauer-Zavala for optional follow-up consultation and support related to delivery of the ERST training for questions or to address any issues that arise during training. Having consultation and support available for the trainers should help to offset concerns raised about ensuring training fidelity subsequent to other mental health programs. Participants have ongoing access to ERST to support skill retention after training is completed, which should help to offset previous indications of problems with skill development for mental health programs."
224212858|NCT02621827|OTHER|Oral dose of stable isotope labeled 25(OH)D3|At each measurement, women are given an oral dose of stable isotope labelled 25(OH)D3. Blood and urine samples are collected at baseline and on day 21 post-dose. Additional blood samples are collected post-dose on days 6,9,24,27 and 30.
224316440|NCT01515917|OTHER|Microcrystalline Cellulose|Microcrystalline Cellulose will be one of two placebos administered to participants randomly assigned to the placebo arm. Microcrystalline Cellulose will serve as the placebo for Citicoline and will be orally administered daily in 470 mg doses.
223623399|NCT02278406|OTHER|Deep brain stimulator|We will measure brain oxygen levels with a non-invasive near infrared spectroscopy device.
223623400|NCT03418155|DRUG|Treatment of TongBi Capsule|TongBi Capsule:0.31g,3times a day, oral, for 4 weeks.
223623401|NCT03418155|DRUG|Treatment of TongBi placebo|TongBi placebo:0.31g,3times a day, oral, for 4 weeks.
223623402|NCT01718379|DRUG|Lenalidomide|Lenalidomide:10 mg per day during 21 days
223623403|NCT01718379|DRUG|Epoetin beta|Epoetin beta: 60,000 Units/week.
223623404|NCT02263469|BIOLOGICAL|Replenine®-VF (High Purity Factor IX)|
224212859|NCT03584204|DIAGNOSTIC_TEST|imaging|computed tomography, magnetic resosnance imaging, ultrasound
224212860|NCT00813501|BIOLOGICAL|immunosuppressive therapy|
224212861|NCT00813501|OTHER|immunological diagnostic method|
224212862|NCT00813501|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
224212863|NCT00796289|DRUG|GnRH iontophoretic transdermal Lutrepatch|10 mg GnRH iontopheretic transdermal patch. A new patch is applied two times each day (every 12 hours). Delivery current and membrane thickness adjusted to deliver the 'high target' study dose, which is estimated to be 800 picograms/ml
224316441|NCT04349943|OTHER|nutrition therapy|With enteral nutrition as the preferred solution, the gradual transition from slow to fast, from lean to dense, from essential to whole protein type is conducted.
224316442|NCT02808416|BIOLOGICAL|Personalized cellular vaccine|"Cancer patients with brain metastases will undergo tumor resection or biopsy, and receive tumor antigen mRNA pulsed cellular vaccines.~Other Names:~• Tumor antigen pulsed DC and PBMC, autologous tumor vaccine"
224316443|NCT06399861|DEVICE|Incubator ambient relative humidity (RH) of 70%|The incubator will be set to an ambient relative humidity (RH) of 70%.
224316444|NCT06399861|DEVICE|Incubator ambient relative humidity (RH) of 90%|The incubator will be set to an ambient relative humidity (RH) of 90%.
223623405|NCT04069559|OTHER|To develop nursing students' attitudes towards refugees program which based on contact hypothesis.|In the first three weeks, education were given to the intervention group about refugees. Students watched a film on the theme of migration. After than the students contacted refugees in three different centers ( an immigrant health center, a school and a civil Society Organization) each of them for a total of nine weeks and two days a week.
224316445|NCT00345943|OTHER|MRI|Magnetic Resonance Imaging scans
223623406|NCT04077021|DRUG|CCW702|Investigational immunotherapy for prostate cancer
223623407|NCT00837902|DRUG|Atenolol (β-blocker)|25 mg tablet
223623408|NCT03072446|DEVICE|Gel-Beads embolic material|Patients will receive embolization of their uterine fibroids using Gel-Beads.
223623409|NCT04888624|DEVICE|DrySee® dressing with moisture detection|DrySee® is a waterproof bandage designed to protect surgical incisions. It contains an indicator at the perimeter of the dressing, and at the wound site that turns blue when it comes into contact with liquid (figure 1). The indicator identifies a break in the integrity of the postoperative dressing. Changing the dressing at this point prevents bacteria from reaching the incision reducing the risk of infection. In addition, the waterproof dressing allows patients to shower or bath following surgery.
223623410|NCT04888624|DEVICE|Tegaderm® + Pad transparent film dressing|Tegaderm® is a transparent adhesive dressing commonly used as a postoperative dressing. The dressing has been shown to be superior to gauze in reducing SSIs. Tegaderm®, like DrySee,® is waterproof; however, it lacks technology that identifies a breach in dressing integrity.
224212864|NCT00796289|DRUG|GnRH iontophoretic transdermal Lutrepatch|10 mg GnRH iontopheretic transdermal patch. A new patch is applied two times each day(every 12 hours). Delivery current and membrane thickness adjusted to deliver the 'medium target' study dose, which is estimated to be 400-600 picograms/ml
224212865|NCT00796289|DRUG|GnRH iontophoretic transdermal Lutrepatch|10 mg GnRH iontopheretic transdermal patch. A new patch is applied two times each day (every 12 hours). Delivery current and membrane thickness adjusted to deliver the 'low target' study dose, which is estimated to be 200 picograms/ml
224212866|NCT00796289|DRUG|clomiphene citrate|Oral, 50 mg daily for 5 days
224212867|NCT00796289|DRUG|placebo clomiphene citrate|oral, taken for 5 days
223623411|NCT04013308|PROCEDURE|Iontophoresis with 2% potassium iodide|10 iontophoresis treatments with 2% potassium iodide on the area of thyroid gland; electrodes with tin foil (Amperage:2mA, duration: 30min)
223623412|NCT03180385|DEVICE|Neurally-Adusted Ventilatory Assist (NAVA)|Delivery of positive pressure is based on the electrical activity of the diaphragm (Edi) via a nasogastric (NG) catheter that is placed on the phrenic nerve, which runs along the esophagus. This results in synchronous ventilation for the patient.
223623413|NCT03180385|DEVICE|Biphasic Positive Airway Pressure Support (BiPAP)|Conventional form of non-invasive respiratory support that does not deliver positive airway pressure in a synchronous fashion.
223623414|NCT04338282|DRUG|toripalimab|240mg/d, every 3 weeks, for up to one year or until disease progression, whichever comes first
224212868|NCT00796289|DRUG|placebo GnRH patch|Placebo transdermal patch with a high target delivery of placebo(every 90 minutes). New patch to be applied every 12 hours.
224316446|NCT00345943|BEHAVIORAL|Neuropsychological Testing|Neuropsychological tests
224316447|NCT01035983|DRUG|Frovatriptan 2.5 mg|
224316448|NCT00895414|DRUG|doxorubicin hydrochloride|Given IV 5-10 minutes on day 1. Treatment repeats every 14 days for 2 courses in the absence of disease progression or unacceptable toxicity.
223623415|NCT05403996|BEHAVIORAL|Activa-Mente|Active break program
223623416|NCT03289793|OTHER|Neurofeedback training|"Children in group A will receive BCI-based training implemented through original P300-based controlled games.~They will attend 30 1-hour long training sessions at a pace of 2 sessions per week.~Each session includes: installation of the child, the EEG system and an eye-tracking system, a 5-minutes relaxation phase, a short EEG recording at rest, a brief reminder of the instructions, 30 minutes of training by playing video games and finally a time for the child to wash her/his hair.~Moreover, 4 neuropsychological sessions will complement the 30 training sessions. During these sessions neuropsychological tests and quality of life questionnaires will be answered."
223623417|NCT03289793|OTHER|Active Sham control|"Children in group B will receive a training that is not based on brain activity, but in a blind fashion. They will attend 30 1-hour long training sessions at a pace of 2 sessions per week.~Each session includes: installation of the child, setting up the EEG and eye-tracking systems, a 5-minutes relaxation phase, short EEG recording at rest, a brief reminder of the instructions, 30 minutes of video game based training and finally a time for the child to wash her/his hair.~Besides, 4 neuropsychological sessions will complement the 30 training sessions. During these sessions neuropsychological tests and quality of life questionnaires will be performed."
224212869|NCT05875766|OTHER|Osteopathy|4 sessions of osteopathy after DIDT surgery
223623418|NCT03289793|OTHER|Baseline control group|The children included in this group will not receive any training. They only take part to the 4 neuropsychological sessions. Like others, they will attend 1 neuropsychological session every two months over six months.
223623419|NCT05096624|OTHER|DD-TENS system|Use of DD-TENS system
223623420|NCT05096624|OTHER|Gold Standard|Gold standard
223623421|NCT05096624|OTHER|Digital Denture system|Use of Digital Denture system
224212870|NCT05875766|OTHER|Physiotherapy|Physiotherapy after DIDT surgery (reference treatment)
224212871|NCT02574507|BEHAVIORAL|Couples-Based Behavioral Weight and Symptom Management|Investigators anticipate that the intervention developed in phase I will consist of a total of 12 sessions 90 minutes in length (18 therapy hours) spaced across approximately 5 months. Sessions are spaced to provide participants sufficient time to complete home practice exercises and adequately examine change in weight and maintenance of weight loss. Sessions will be conducted individually for each day. The first 6 sessions will occur weekly and the final 6 sessions will occur biweekly.
224212872|NCT05216328|DRUG|Macrogol Only Product in Oral Dose Form|Information already included in arm/group description.
224212873|NCT05216328|DRUG|Magnesium hydroxide 724mg|Information already included in arm/group description.
224316449|NCT00895414|DRUG|enalapril maleate|Given orally - Beginning 1 week before course 2, patients also receive oral enalapril maleate once daily until day 8 of course 2. OR Beginning 1 week before course 1, patients receive oral enalapril maleate once daily until day 8 of course 1.
224316450|NCT00252239|DRUG|tenecteplase|This study will compare 3 different doses of tenecteplase to tPA.
224316451|NCT00252239|DRUG|tissue plasminogen activator, tPA|To date, tissue plasminogen activator (tPA) is the only scientifically-proven and FDA-approved treatment for acute stroke.
224316452|NCT06008366|DRUG|7MW3711 for injection|IV administration of 7MW3711, Q3W, 3 weeks a cycle
224316453|NCT06008366|DRUG|7MW3711 for injection|IV administration of 7MW3711, the dosage regimen including dosage and dosing frequency for cohort expansion is conformed on basis of the data in part 1
224212874|NCT02088294|BEHAVIORAL|Lifestyle Education (LS)|See arm description
224212875|NCT02088294|BEHAVIORAL|LS + Stress Reduction Guided Imagery|See Arm Description
224212876|NCT02088294|BEHAVIORAL|LS + Activity/Eating Guided Imagery|See arm description
224212877|NCT05001373|BIOLOGICAL|Core-g28v2 60mer mRNA Vaccine|100µg, Intramuscularly
224212878|NCT05001373|BIOLOGICAL|eOD-GT8 60mer mRNA Vaccine|100µg, Intramuscularly
223623422|NCT01301807|DRUG|Carfilzomib|Given IV
223623423|NCT01301807|DRUG|Panobinostat|Given PO
223623424|NCT00627588|BIOLOGICAL|ProSavin|ProSavin is a gene therapy designed to delivery three key enzymes involved in the synthesis of dopamine
223623425|NCT00627588|BIOLOGICAL|ProSavin|ProSavin is a gene therapy designed to delivery three key enzymes involved in the synthesis of dopamine
223623426|NCT00896714|DEVICE|Closed loop anesthesia|Propofol and Remifentanil are administered automatically using a closed-loop system
223623427|NCT05724732|BIOLOGICAL|GT201|Autologous tumor infiltrating lymphocyte injection
223623428|NCT02693808|PROCEDURE|Autologous fat injection|Injection in one side with autologous fat and the other side with hyaluronic acid.
223623429|NCT02693808|PROCEDURE|Hyaluronic acid injection|Injection in one side with autologous fat and the other side with hyaluronic acid.
224212879|NCT00639587|DRUG|Ketotifen|Ketotifen dry syrup 0.1%; 1 mg b.i.d.; for 2 weeks
224316454|NCT04235361|DIAGNOSTIC_TEST|Differential RPA tests|The mobile diagnostic suitcases will be deployed at Ebola Treatment centres in DRC. Samples of patients refered for diagnostic testing will be tested by PCR by existing diagnostic teams, and will be additionally tested by the mobile suitcase laboratory using differential RPA tests for 6 parameters.
224316455|NCT03052868|OTHER|Cognitive Assessment|Cognitive testing session
224212880|NCT00639587|DRUG|Cetirizine|Cetirizine tablet; 10 mg o.d.; for 2 weeks and 5 mg b.i.d.; for 2 weeks
224212881|NCT02627885|BEHAVIORAL|Internet-based CBT|Through the use of CBT material at an Internet-platform, we aim for behavioral changes in the subjects to improve everyday level of functioning and quality of life.
224316456|NCT01216787|DRUG|gamma-secretase/Notch signalling pathway inhibitor RO4929097|
223623430|NCT04931264|DIAGNOSTIC_TEST|YuWell YE660D Electronic Sphygmomanometer|Measurement blood pressure by YuWell YE660D Electronic Sphygmomanometer and Desk Mercury Sphygmomanometer
223623431|NCT01222845|DRUG|Test meal|Porridge made from rolled, or pinhead oats providing 50 g of carbohydrate
223623432|NCT02898454|DRUG|Dupilumab SAR231893 (REGN668)|"Pharmaceutical form: Solution~Route of administration: Subcutaneous"
223623433|NCT02898454|DRUG|Placebo|"Pharmaceutical form: Solution~Route of administration: Subcutaneous"
223623434|NCT02898454|DRUG|Mometasone furoate nasal spray|"Pharmaceutical form: Suspension~Route of administration: Intranasal"
223623435|NCT00148902|DRUG|lapatinib|lapatinib
223623436|NCT00148902|DRUG|docetaxel|docetaxel
223623437|NCT03144739|OTHER|Training in management of children's mental health problems|"General practitioners will be trained using internationally-developed materials, including the World Health Organization's mental health need/service gap (mhGAP) materials and others, adapted for the trial setting (based on formative work that is part of the project). They will be assisted and monitored as part of the ongoing collaborative care program in which they are participating."
223623438|NCT03144739|OTHER|Current collaborative care protocol|General practitioners have been trained to recognize children's mental health problems and to refer them to a partner community mental health center. They receive feedback about the referral but are not encouraged to take on care for the child themselves.
223623439|NCT01476423|DRUG|activated recombinant human factor VII|A prospective, observational multi-national registry collecting data and evaluating the efficacy and safety of rFVIIa in patients with GT with past or present refractoriness to platelet transfusions. The registry will also collect data from a broader range of GT patients treated with systemic haemostatic treatment (with or without antifibrinolytic drugs or other agents) used in the clinics. Data collection will continue for a maximum of six years. Baseline data as well as data obtained during either bleeding episodes or invasive procedures/surgeries will be recorded in the registry.
223623440|NCT05823402|DIAGNOSTIC_TEST|SPECT/CT|SPECT/CT imaging can generate 3-dimensional images of the location where the PSMA radioligand therapy has accumulated in the body. SPECT/CT imaging can also measure doses of radiation delivered to those locations.
223623441|NCT00106847|DRUG|Infliximab|
224212882|NCT02627885|OTHER|SMT|Standard Medical Treatment includes pharmacological management and other typical medical interventions for the patient group but no behavioural interventions
224212883|NCT00063700|PROCEDURE|reducing exposure to marketing pressures|
224212884|NCT03591107|OTHER|PTSD Care Management (PCM)|Collaborative care for PTSD facilitated by a trained CM who will engage the patient into care, monitor progress over 6 months, coordinate care with primary care and behavioral healthcare providers and social services, and receive monthly supervision by the study psychiatrist in addition to education and feedback
224212885|NCT03591107|OTHER|Minimally Enhanced Usual Care (MEU)|Education and feedback alone
224316457|NCT01216787|OTHER|pharmacological study|
224316458|NCT01216787|PROCEDURE|therapeutic conventional surgery|
224316459|NCT01216787|OTHER|laboratory biomarker analysis|Correlative studies
224316460|NCT00789737|DRUG|Welchol|Welchol 625mg tablets
224316461|NCT00789737|DRUG|Placebo|placebo
224316462|NCT02288156|DRUG|Capsaicin|via nasal spray
224316463|NCT02288156|DRUG|placebo|via nasal spray
224316464|NCT00891917|DIETARY_SUPPLEMENT|Ubiquinol-10 Syrup|10 mg/kg/day in 2 divided doses for 3 months or Placebo Syrup for 3 months
224316465|NCT00891917|DIETARY_SUPPLEMENT|syrup (placebo)|syrup looks exactly like the Ubiquinol-10 Syrup but has no active ingredients or supplementation
224316466|NCT02950818|BEHAVIORAL|Take Heart|Participants receive an evidence-based heart disease self management program consisting of a combination of five two and a half hour group sessions and telephone counseling offered by a trained facilitator employed by the Detroit Area Agency on Aging. The program is designed so that participants select an area to work on (e.g., diet, exercise, medication taking, communication with health care professionals) and receive support, information, and encouragement from group members and program facilitators, to help them reach their goals.
224316467|NCT05354635|OTHER|Antibiotics Dosing|Dosing concerns the main antibiotics used in the unit: b-lactams, linezolid, vancomycin and aminosides
224212886|NCT06538454|BEHAVIORAL|Resistance training|"The exercises will be the same in both stages: squat, bench press, stiff, rowing, hip thrust and shoulder press. Futhermore, the rest interval (2 minutes) and the exercise order (alterning upper and lower limbs) also will be the same in the stages.~In the chronic experiment, the resistance training will be carried for 10 weeks with 2 weekly sessions in alternate days. The sets in both groups will be carried close to muscle failure.~The difference between groups is the intensity, who reflects the repetition zone. The 80%1RM group will be perform 8-10 repetitions per set, while the 60%1RM group will be perform 18-20 repetitions."
224212887|NCT02464527|BEHAVIORAL|Stimulus-stimulus pairing|The participants will attend clinic-based treatment sessions for one hour per day, five days per week, for 6-weeks.The stimulus-stimulus pairing procedure will consist of sounds and words being systematically paired with delivery of a preferred item.
224212888|NCT02464527|OTHER|Vocal recorder|The vocal recorder is a voice recording device that enhances vocalization data. The parent/ guardian will be instructed on how to use the vocal recorder. The vocal recorder will then be deployed at the participant's homes via parent/guardian. The parent/guardian will record vocalizations for approximately 1 hour while in the home or community setting pre, mid, and post treatment. The parent/guardian will return the vocal recorder to the study team for analysis of the recordings.
224212889|NCT04596930|PROCEDURE|Laser ablation thermal therapy|The Visualase Thermal Therapy System is used to necrotize or coagulate soft tissue through interstitial irradiation under MRI guidance
224212890|NCT06008639|DEVICE|treatment group-Device: NirsCure - Active NirsCure - Active settings|Treatment was performed once a day,5-6 times a week for 16 weeks.
224212891|NCT06008639|DEVICE|placebo group-Device: NirsCure - Sham NirsCure - Sham settings|Treatment was performed once a day,5-6 times a week for 16 weeks.
224212892|NCT02113969|DEVICE|Vaginal Pessary|Pessary fitting session at recruitment, follow up at 1 week, then monthly to complete 1 year follow up. QoL, symptoms and sexual function Surveys will be conducted at recruitment, 6 and 12 month. The absence of bacterial vaginosis (through study of vaginal discharge and pH) will be checked prior to positioning pessary and then each control. At the end of follow up period the success related variables will be determine with a statistical model. This information will be analyzed by an expert panel aiming to identify relevant clinical variables not included. This panel will generate a Standardized Management Protocol for symptomatic pelvic organ prolapse using vaginal pessaries.
224212893|NCT02631044|BIOLOGICAL|JCAR017 (lisocabtagene maraleucel) single-dose schedule|Participants will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of JCAR017. During JCAR017 production, participants may receive low-dose chemotherapy for disease control. Upon successful generation of JCAR017 product, participants will receive treatment with JCAR017 therapy. Treatment will include lymphodepleting chemotherapy followed by one dose of JCAR017 administered by intravenous (IV) injection.
224212894|NCT02631044|BIOLOGICAL|JCAR017 (lisocabtagene maraleucel) 2-dose schedule|Participants will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of JCAR017. During JCAR017 production, participants may receive low-dose chemotherapy for disease control. Upon product availability, participants will receive study treatment consisting of lymphodepleting chemotherapy followed by two IV doses of JCAR017.
224212895|NCT05613335|PROCEDURE|Maxillary sinus augmentation using autologous fibrin glue with simultaneous implant placement|Maxillary sinus augmentation using autologous fibrin glue with simultaneous implant placement
224212896|NCT05613335|PROCEDURE|Maxillary sinus augmentation using mixture of autologous fibrin glue with bone graft with simultaneous implant placement|Maxillary sinus augmentation using mixture of autologous fibrin glue with bone graft with simultaneous implant placement
224212897|NCT01902134|DRUG|Placebo|Placebo single oral dose (first 8 hours)
224212898|NCT01902134|DRUG|Tramadol-single dose|Tramadol single oral dose (first 8 hours)
224212899|NCT01902134|DRUG|Dexketoprofen-single dose|Dexketoprofen single oral dose (first 8 hours)
223623442|NCT02953600|DIETARY_SUPPLEMENT|Standard Dose Spirulina Platensis|As previous small scale of clinical trial results in HBV patients provided by Far East Bio-Tec Company, lamivudine combined with oral Spirulina platensis would also improve the sero-conversion rates of HBeAg.
224212900|NCT01902134|DRUG|Dexketoprofen/Tramadol-single dose|Dexketoprofen/Tramadol oral single dose (first 8 hours)
224212901|NCT01902134|DRUG|Tramadol-multiple doses|Tramadol multiple oral doses t.i.d. for 5 days (total 12 doses)
223623443|NCT02953600|OTHER|Zero Spirulina Platensis|the zero pill-taken group is a comparison for two other groups.
224212902|NCT01902134|DRUG|Dexketoprofen-multiple doses|Dexketoprofen multiple oral doses t.i.d. for 5 days (total 12 doses)
224316468|NCT02870218|DRUG|Smoking research cigarettes with e-cigarette|Smoking research cigarettes with varying levels of nicotine with unlimited access to 15 mg/ml nicotine-containing e-cigarettes.
224212903|NCT01902134|DRUG|Dexketoprofen/Tramadol-multiple doses|Dexketoprofen/Tramadol multiple oral doses t.i.d. for 5 days (total 12 doses)
224316469|NCT02870218|DRUG|Nicotine discrimination thresholds|Measure of nicotine thresholds for detecting and recognizing the addictive, rewarding effects of smoking.
224316470|NCT03489109|BEHAVIORAL|Intermittent fasting|Subject will consume approximately 25% of their daily calories for 2 days per week. The other 5 days they will eat their normal diet
224316471|NCT03489109|OTHER|Standard of Care|Subject will receive standard of care recommendations for healthy diet and lifestyle
223623444|NCT02953600|DIETARY_SUPPLEMENT|Double Dose Spirulina Platensis|As previous small scale of clinical trial results in HBV patients provided by Far East Bio-Tec Company, lamivudine combined with oral Spirulina platensis would also improve the sero-conversion rates of HBeAg. Hence, the investigators would like to see if the investigators could improve sero-conversion rates much faster by taking double dose of Spirulina platensis.
223623445|NCT05993663|BEHAVIORAL|Arts in health group intervention|12 sessions using the Arts in Health methodology with the aim of having a better understanding of the disease, developing healthy lifestyle habits and greater emotional intelligence. Visual thinking strategies, game based activities, mindfulness and dance will be used
223680498|NCT04121624|DEVICE|novel mobile phone application for blood pressure monitoring.|Comparative blood pressure measurement with the smartphone application and the non-invasive reference method (upper arm cuff).
223680499|NCT01030601|DRUG|Dexamethasone sodium phosphate|0.5mg in 0.05cc of Dexamethasone from a 10mg/ml vial
223623446|NCT01622959|PROCEDURE|Acupuncture|"-Group Acupuncture: Receiving protocol of acupuncture. Acupuncture is performed by a trained certificied resident.~The protocols, which allow acupuncture points to be selected from a pool of pre-determined points for each condition, provide sufficient standardization to assist replication, yet are flexible enough to allow individualized treatments. These protocols also allow for additional points, such as 'ashi points', to be used at the discretion of the acupuncturist. The location of the points, angle of insertion and depth of insertion were sourced from a popular text 'A Manual of Acupuncture'.~-Group Morphine: Receiving 5mg of morphine followed by intravenous administration of 2,5 mg morphine each 5 min, until VAPS becomes \<30%. Treatment failure is defined as VAPS\>30 %, 30min after beginning of the protocol. In this case, analgesic treatment was administered according to the treating physician discretion."
224212904|NCT00305110|DRUG|2 mg IV hydromorphone|
224212905|NCT03518710|OTHER|Neuropsychological evaluation|"Neuropsychological evaluation (about 60 min) the same day realized by a student in Science Thesis under the responsibility of Prof. Yves Chaix and including:~* Process evaluation:~* Oculomotors: DEM test (5min)~* Visuo-attention: computerized STROOP (15min)~* Visuo-Perceptive: DTVP3 (30min)~* Phonological \& lexical: Exalang (10min)"
224212906|NCT03518710|OTHER|Evaluation of the reading assistance technique|"Evaluation of the reading assistance technique (about 30 min) and comprising:~\- Reading evaluation:Test lark (3min) Experimental task: 3-way help with reading (without help, color help and highlight help (25 min)"
224212907|NCT01824069|OTHER|Intramuscular injection of a suspension of adult mesenchymal stem cells derived|Intramuscular injection of a suspension of adult mesenchymal stem cells derived from adipose tissue at doses of 1 million per kilo of weight. Only one dosis by patients
224212908|NCT00678379|DRUG|lidocaine (1%) + bupivacaine (0.5%)|"Submucosal injection of 1.5 mL into each tonsillar fossa prior to performing tonsillectomy.~B - lidocaine (1%) + bupivacaine (0.5%)"
223623447|NCT00647296|DRUG|Placebo|Placebo: 2 tablets taken orally twice daily
223623448|NCT00647296|DRUG|Dexpramipexole 50 mg/day|Dexpramipexole: 2 x 12.5 mg tablets taken orally twice daily
223623449|NCT00647296|DRUG|Dexpramipexole 150 mg/day|Dexpramipexole: 2 x 37.5 mg tablets taken orally twice daily
223623450|NCT00647296|DRUG|Dexpramipexole 300 mg/day|Dexpramipexole: 2 x 75 mg tablets taken orally twice daily
223623452|NCT01917383|DRUG|Trabodenoson|Ophthalmic eye drop
223623453|NCT01917383|DRUG|Latanoprost|Ophthalmic eye drop
223623454|NCT01917383|DRUG|Timolol|Ophthalmic eye drop
223623455|NCT01736111|BEHAVIORAL|one way text|
223623456|NCT01736111|BEHAVIORAL|Personal feedback|
223623457|NCT00352677|DRUG|INNO-406|Oral, twice daily self-administration of 10 mg and/or 50 mg tablets
223623458|NCT06124963|DRUG|WX390|WX390 tablet, 0.9 mg once a day
223623459|NCT06124963|DRUG|Toripalimab|240 mg, Day 1, every 3 weeks
224212909|NCT00678379|DRUG|Normal saline|"Submucosal injection of 1.5 mL into each tonsillar fossa prior to performing tonsillectomy.~A - normal saline"
224212910|NCT00678379|DRUG|Lidocaine (1%) + Bupivacaine (0.5%) + Clonidine (25mcg)|"Submucosal injection of 1.5 mL into each tonsillar fossa prior to performing tonsillectomy.~C - lidocaine (1%) + bupivacaine (0.5%) + clonidine (25mcg)"
224212911|NCT01407575|DRUG|Buprenorphine|low-dose buprenorphine (range 0.2 mg/day -- 1.6 mg/day)
224212912|NCT01407575|DRUG|Placebo|matched placebo
224212913|NCT04030884|DIETARY_SUPPLEMENT|Honey and water mixture|"60 gr of organic Turkish BlackSea Region Chestnut Honey and 100 ml Spring water mixture both mixed in room temperature and ingested up to two hours before the surgery by participants who were nill by mouth from midnight prior to the operation day."
223623460|NCT05092672|BEHAVIORAL|Exercise|Participants will engage in moderate-intensity (40-59% HRR) exercise for 30 min
223623461|NCT03159390|OTHER|phenylacetate salt of ornithine|
223623462|NCT03883581|DRUG|dextromethorphan HBr and quinidine sulfate|All eligible and enrolled study participants will be administered the study drug, Nuedexta, as recommended by their treating neurologists.The drug will be administered per the efficacy and safety protocol, with no changes in administration method or recommended dose for individuals with ALS. Prior to commencing treatment with Nuedexta, participants will undergo a comprehensive bulbar evaluation of swallowing, airway protection, speech functions, and complete validated patient-reported surveys. Following 30 days of Nuedexta treatment, participants will be e-evaluated using the same battery of assessments.
223623463|NCT03584334|RADIATION|18FDG PET|Diagnostic performance of 18FDG PET for identification of early tumor escape to immunotherapy in patients with unresectable melanoma or Broncho-Pulmonary Carcinoma No to Advanced or Metastatic Small Cells
223623464|NCT05692596|OTHER|Data collection|Investigators will compile data typically collected clinically. This data will include demographics, cancer screening procedures, cancer diagnosis and staging, chemotherapy, immunotherapy, radiation therapy, surgery, comorbidities, medication use, lifestyle and other cancer risk factors, quality of life, vital status, and molecular data generated from specimens collected clinically.
223623465|NCT06848881|PROCEDURE|Cryoablation|The eligible patient will be randomized to cryoablation group to receive cryoablation.
223623466|NCT06848881|PROCEDURE|Thoracoscopic Surgery|The eligible patient will be randomized to thoracoscopic surgery group to receive surgery.
223623467|NCT06128278|DRUG|S-equol|Oral supplementation of S-equol
223623468|NCT06128278|OTHER|Placebo|Oral supplementation of placebo
223623469|NCT00456404|DRUG|peppermint water|
223623470|NCT06560398|BEHAVIORAL|Continuing Medical Education Events (CME)|An engaging 1-hour informational session focusing on topic areas such as implicit bias and emerging evidence from recent cancer clinical trials with CME credit or American Board of Internal Medicine (ABIM) Maintenance of Certification (MOC) points available.
224212914|NCT05488652|OTHER|Time restricted eating|not more than 10 hrs. eating window daily goal for 6 months
224212915|NCT03712137|DEVICE|VOLUX XC|Participants will be treated with VOLUX XC hyaluronic acid (HA) injectable gel on day 1 with optional touch-up at day 30 and optional maintenance treatment at Month 12.
224212916|NCT03712137|OTHER|No-treatment control|No-treatment during the control period. Optional delayed-treatment with VOLUX XC (initial with optional touch-up) at the beginning of the Post-Control period.
224212917|NCT04800900|OTHER|Pharmaceutical intervention|A pharmacist will analyse patient's prescription, identify if there is prescribing omission and inappropriated drug prescribed and when necessary will require to doctors deprescribe or introduce or remove prescribed drugs
224212918|NCT05537337|BEHAVIORAL|Multicomponent Intervention|"The multicomponent intervention consists of the following components (already described in the detailed description section):~1. Food labels (with the summary of healthiness of shopping baskets \& targets)~2. Ordering~3. Within Group Healthier Substitution"
224212919|NCT00989040|DRUG|usual treatment: Versatis|"* To explore if the cognition is failed in treated patients suffering of neuropathic postzosteria pain.~* To see if treated patients with patch (Versatis®) have better cognition than treated patients without patch."
224316472|NCT04147923|DIETARY_SUPPLEMENT|Floradapt Mature Immune Defense + Multivitamin|The product consists of two L. plantarum strains, KABP XXXX and KABP XXXX with a combined strength of \>1 x 10\^9 CFU. Participants will also consume a multivitamin.
223623471|NCT06560398|BEHAVIORAL|Trial Connect Portal|A digital tool to help facilitate rapid referral of patients to clinical trial opportunities at Moffitt.
223623472|NCT06560398|BEHAVIORAL|Clinical Trial Newsletters|Electronic/paper newsletters to highlight open trials at Moffitt that will be distributed by email/mail.
223623473|NCT06560398|BEHAVIORAL|Implicit Bias Training|A one-hour educational module will cover information on implicit bias to support the recruitment of diverse patients.
223623474|NCT06560398|BEHAVIORAL|Recruitment Dashboard|A dynamic dashboard depicting the number of patients recruited to clinical trials by gender, race, ethnicity, age, cancer type, residence in the catchment area, and other key clinical characteristics.
223623475|NCT06560398|BEHAVIORAL|Portfolio Profiler|An interactive dashboard to allow cancer center physicians easily identify gaps in the current clinical trial portfolio that may be contributing to racial/ethnic disparities in trial enrollment.
223623476|NCT06560398|BEHAVIORAL|Eligibility Calculator|A digital calculator that will allow for assessment of the potential impact of clinical trial eligibility criteria (e.g., comorbidities, age, lab values) that may disproportionately exclude patients who are Black and Hispanic prior to submission of clinical trial protocols to the Scientific Review Committee.
223623477|NCT06560398|BEHAVIORAL|Clinical Trial Education Sessions (Community Residents Only)|An engaging 1-hour educational session delivered by a community health educator that includes basic information about clinical trials, their importance, myths, need for diversity in the trials process, and resources for finding more information about clinical trials.
223623478|NCT06560398|BEHAVIORAL|ACT WONDER²S Phone-line/Email (Community Residents and Moffitt Patients)|A study team member will be available for questions via a dedicated phone-line and email for community residents and Moffitt patients with a return contact within 24-hours.
223623479|NCT06560398|BEHAVIORAL|New Patient Information (Moffitt Patients Only)|Including CHOICES DA, a web-based tool to improve multiple aspects of decision-making related to participation in cancer clinical trials.
223623480|NCT06560398|OTHER|No Intervention|Control group with no intervention.
223623481|NCT05986370|PROCEDURE|lumbar spinal manipulative therapy|Spinal manipulative therapy involves the application of spinal manipulation over several sessions. Spinal manipulation is defined as a high-velocity, low-amplitude thrust performed by a clinician to move a segment of the spine in a specific direction. This type of intervention often generates cavitation sounds (audible pops).
223623482|NCT05986370|PROCEDURE|sham spinal manipulative therapy|Sham spinal manipulative therapy (sham SMT), was designed to be structurally equivalent to SMT, i.e., to attend to the same body regions with the same amount of contact as well as to have the same number, frequency and length of sessions. SMT and sham SMT will be provided by the same treatment provider and will appear to be similarly tailored to the participants' condition. Sham SMT does not share the component of interest of SMT, i.e., the activation of deep high-threshold mechanoreceptors via high-velocity, low-amplitude thrusts applied to the spine. Yet, it shares all the other components not of interest in this study that may contribute to the placebo response, such as therapeutic alliance, contextual factors, physical touch, and expectations. Furthermore, deception will be used to balance expectations and enhance blinding.
223623483|NCT05986370|PROCEDURE|full spine spinal manipulative therapy|Spinal manipulative therapy involves the application of spinal manipulation over several sessions. Spinal manipulation is defined as a high-velocity, low-amplitude thrust performed by a clinician to move a segment of the spine in a specific direction. This type of intervention often generates cavitation sounds (audible pops).
223623484|NCT04334889|OTHER|Visual cues|Participants will be asked to move following cues displayed on a screen in front of them.
223623485|NCT04959396|DEVICE|IUB SEAD|The investigative device, the IUB SEAD™, is a novel spherical endometrial ablation device developed to allow for simple, office-based chemical EA to treat benign causes of the symptom of HMB
223623486|NCT06654778|OTHER|PEEP|Patients will be ventilated with PEEP of 8 cm H2O and fluid management: 500 ml of Ringer's lactate in the recovery room before surgery and Ringer's lactate at a rate of 4 mL/kg/hour from the beginning to the end of the surgery.
223623487|NCT06654778|OTHER|PEEP/RM|Patients will be ventilated with PEEP of 8 cm H2O, and then RM (30 cm H2O for 30 s) will be applied immediately after the second LUS examination and repeated every 30 minutes till emergence and fluid management: 500 ml of Ringer's lactate in recovery room before surgery and Ringer's lactate at a rate of 4 mL/kg/hour from the beginning to the end of the surgery
223623488|NCT06654778|OTHER|PEEP/RM/RF|Patients will be ventilated with PEEP of 8 cm H2O, and then RM (30 cm H2O for 30 s) will be applied immediately after the second LUS examination and repeated every 30 minutes till emergence and restrictive fluid management (RF). Ringer's lactate at a rate of 3 mL/kg/hour from the beginning to the end of the surgery
223623490|NCT06987643|DRUG|Neflamapimod|Neflamapimod is a highly specific inhibitor of the intra-cellular enzyme mitogen-activated protein kinase14 (p38α) provided in 40mg capsules
224212920|NCT01084603|DRUG|Oral Nicotine|A new l mg oral nicotine product
224316473|NCT04147923|DIETARY_SUPPLEMENT|Placebo + Multivitamin|No active ingredients + a multivitamin supplement
223623491|NCT06987643|DRUG|Placebo|Placebo is a capsule that looks just like neflamapimod but without the active ingredients
223623492|NCT05592990|DRUG|NGI226|NGI226 MP
223623493|NCT05592990|DRUG|Placebo|Placebo MP
223623494|NCT06998329|OTHER|There will be no intervention|There will be no intervention
223623495|NCT06938139|OTHER|None-placebo|None, observational study
223623496|NCT06939374|DEVICE|Intracoronary Cryotherapy|Intracoronary cryotherapy for stabilization of High-risk coronary plaque
223623497|NCT06938503|DRUG|AG regimen|Patients will receive 4 cycles of AG (gemcitabine 1000 mg/m\^2 and nab-paclitaxel 125 mg/m\^2 on days 1 and 8 of a 21-day cycle), followed by Irreversible Electroporation Ablation and 3 cycles of adjuvant AG (gemcitabine 1000 mg/m\^2 and nab-paclitaxel 125 mg/m\^2 on days 1 and 8 of a 21-day cycle).
223623498|NCT06938503|DRUG|Nimotuzumab|Patients will receive 4 cycles of Nimotuzumab (400 mg on days 1, 8, and 15 of a 21-day cycle), followed by Irreversible Electroporation Ablation and 3 cycles of adjuvant Nimotuzumab (400 mg on days 1, 8, and 15 of a 21-day cycle).
223623499|NCT06937190|DIETARY_SUPPLEMENT|Creatine Monohydrate|Participants will receive 5 grams of creatine monohydrate powder dissolved in water, flavored with a sugar-free agent, 30 minutes before sleep each night for 7 days.
223623500|NCT06937190|DIETARY_SUPPLEMENT|Placebo (Maltodextrin)|Visually identical placebo (maltodextrin powder, 5 g/day), flavored with a sugar-free agent, dissolved in water and consumed 30 minutes before sleep for 7 consecutive days.
223623501|NCT06939400|PROCEDURE|Photodynamic therapy (PDT)|GBM patients recevied surgical combination photodynamic therapy
223623502|NCT06939400|PROCEDURE|GBM patients recevied traditional treatment options|GBM patients recevied traditional treatment options (including surgery combined with radiotherapy and chemotherapy)
223623503|NCT06937645|DRUG|Hyaluronic Acid (HA)|hyaluronic acid PRP preparation used to wash the endometrium on the day of oocytes retrieval
223623504|NCT06937645|DRUG|platlet rich plasma (PRP)|PRP preparation used to wash the uterine cavity on the day of oocytes retrieval
223623505|NCT06938451|OTHER||This is an observational study and does not involve an intervention
223623506|NCT04590690|OTHER|Special diet|The research clinic will provide subjects with a special diet for six days. After six days of isocaloric sodium, calcium and fluid intake, the study team will analyze three sequential 24-hour urine compositions including supersaturation of calcium oxalate, calcium, and urine volume, as well as stool collections. We will also evaluate components of 24-hour urine composition, specifically supersaturation, and the microbial contributions to urinary composition in 72-hour stool samples simultaneously collected using shot-gun metagenomic sequencing in men and women 1 year after surgery.
224316474|NCT06201429|DEVICE|Mechanical Tissue Resuscitation (MTR™)|Mechanical Tissue Resuscitation (MTR™) to externally drain excess fluid volume from the site of surgery in patients who have undergone a surgical procedure (craniotomy/craniectomy) for which a portion of the skull has been removed resulting in exposure of the dura/brain and require drainage of fluid.
224212921|NCT01084603|DRUG|NiQuitinTM Nicotine Lozenge|A marketed 4 mg Nicotine lozenge
224212922|NCT01084603|DRUG|Nicorette® Nicotine Gum|A marketed 4 mg Nicotine Gum
224212923|NCT04959110|DIAGNOSTIC_TEST|Pharmacokinetic study|"* Start CVVH session with isotonic citrate solution (13.3 mmol/L) as predilution, targeting citrate dose at 3 mmol/L~* Blood samples collection at pre-filter for citrate concentration, blood gas, electrolyte and ionized calcium and magnesium~* In addition, 10 minutes after the end of citrate infusion, blood samples were taken simultaneously from both pre-filter and post-filter to calculate citrate clearance by filter"
224212924|NCT02483481|DIAGNOSTIC_TEST|shear wave ultrasound elastography|shear wave ultrasound elastography
224212925|NCT02886481|DEVICE|perioperative monitoring|
224212926|NCT05826106|PROCEDURE|R anastomosis|Modifying the surgical technique of totally laparoscopic Billroth-II reconstruction with Braun anastomosis and to name it as the R anastomosis.
224316475|NCT03471000|OTHER|Short implants Treatment|Short implants are placed in the alveolar bone and a clinical Ostell and Periotest evaluation of the implants after a period of time is done. Analysis of periapical radiographs and CBCT images after a period of time. Bone around the implant was measured, marginal bone level loss is determined.
223623507|NCT00187252|DEVICE|Atrial Overdrive Pacing|Pacemaker/ ICD implant
223623508|NCT02926638|DRUG|Erlotinib Hydrochloride|Given PO
223623509|NCT02926638|OTHER|Laboratory Biomarker Analysis|Correlative studies
223623510|NCT02926638|BIOLOGICAL|Rilotumumab|Given IV
223623511|NCT01308697|PROCEDURE|Operative fixation of flail chest|Plate fixation
223623512|NCT01308697|OTHER|Non Operative management|Non Operative treatment of Flail Chest
223623513|NCT05542654|OTHER|Foot Massage|Pregnant women in the intervention group were given a foot massage for 15 minutes each, for a total of 30 minutes for three days, while the control group did not receive foot massage.
223680500|NCT00913692|DRUG|Glutamine|Subjects were randomized to take one of the study agents, 15 gm by mouth twice daily for 5 months. After a 2 week washout period, subjects began the other agent at 15 gm by mouth twice daily for 5 months.
223680501|NCT00913692|DRUG|Glycine|Subjects were randomized to take one of the study agents, 15 gm by mouth twice daily for 5 months. After a 2 week washout period, subjects began the other agent at 15 gm by mouth twice daily for 5 months.
223680502|NCT02102503|BEHAVIORAL|Standard Treatment|
223680503|NCT02102503|BEHAVIORAL|MI and Medication review|
223680504|NCT01552733|DEVICE|'Inmotion Arm Robot'|To improve limb function in those with limb impairment
223680505|NCT01552733|OTHER|Standard of care|Rehabilitation Therapy
223680506|NCT00000931|BEHAVIORAL|Behavioral intervention|
223680507|NCT00000931|BEHAVIORAL|Risk-reduction counseling|
223680508|NCT04738318|DRUG|Glucocorticoids|Patients will receive a single intraoperative dose of 10mg of intravenous dexamethasone intraoperatively. Following surgery, the participant will be provided with a six-day oral methylprednisolone taper course.
223680509|NCT04738318|DRUG|Saline|Patients will receive a single intraoperative dose of 10 mg of saline. Following surgery, the participant will be provided with a six-day placebo course.
223680510|NCT00374205|DRUG|Artesunate plus Amodiaquine|Artesunate 50 mg and Amodiaquine 153 mg co-blister tablets: 3 days once daily weight-adjusted dosing according to manufacturer
223623514|NCT07198815|DRUG|Investigational Eye Drops (NPDR-01)|NPDR-01 is an investigational ophthalmic solution administered as one drop (50 μL) to the affected eye(s) once daily for a period of 6 months. It is designed to reduce retinal microaneurysms and slow the progression of non-proliferative diabetic retinopathy.
223623515|NCT07199673|DRUG|Injection Sclerotherapy|identifying the hemorrhoidal pedicle, 3-5 ml of 5% phenol in almond oil is injected into the submucosal plane of the hemorrhoid pedicle
223623516|NCT07199673|DEVICE|Rubber Band Ligation|knee-elbow position is used. After identifying the hemorrhoids with a proctoscope, a rubber band is applied at the base of each hemorrhoid using Barron's Gun and Elise's tissue forceps.
223623517|NCT07199920|DEVICE|Achieva 3.0T dStream Philips|Classic and MRF sequences will be carried out on the clinical machine (Achieva 3.0T dStream Philips) of the IRMaGe platform (CHUGA, Université Grenoble Alpes, Inserm, CNRS).
223623518|NCT07200193|GENETIC|CRMA-1001|Epigenetic gene silencing therapy delivered by intravenous (IV) infusion
223623519|NCT07198321|DRUG|GFH276|GFH276 will be administered at the assigned dose level, orally, until disease progression or intolerable toxicity.
223623520|NCT06526338|DRUG|1.0% IP-001 for injection|Participants will receive a single injection of 1.0% IP-001 following local ablation or surgical resection and local ablation
223623521|NCT06526338|PROCEDURE|Surgical Resection and Local Ablation|Participants will undergo surgical resection of the tumor and local ablation by either radiofrequency ablation (RFA ) or microwave ablation (MWA)
223623522|NCT06526338|PROCEDURE|Local Ablation Alone|Participants will have local ablation of the tumor by either radiofrequency ablation (RFA) or microwave ablation (MWA) alone
223623523|NCT07200037|BEHAVIORAL|inspiratory muscle training|This intervention will include a long term program of 8 weeks IMT in PMV patients who these patients who have required at least 6h of mechanical ventilation for 21 consecutive days.
223623524|NCT07198425|OTHER|Successful decannulation group|Patients who successfully completed the decannulation process and had their tubes removed, with no reinsertion of the tracheostomy tube or endotracheal intubation within 48 hours after decannulbation.
223623525|NCT07198425|OTHER|Successful decannulation group|Patients who did not pass the decannulation process, and the multidisciplinary team advised against removal of the tracheostomy tube; or patients who passed the decannulation process and had the tracheostomy tube removed but required reinsertion of the tracheostomy tube or endotracheal intubation within 48 hours due to medical conditions.
223623526|NCT07199517|OTHER|HRP Sampling period|During a 28-day sampling period, participants randomized to HRP are instructed to try their selected HRP (ECIGS, IQOS, or ONPs) and will complete daily e-diaries of cigarette smoking behavior and product uptake.
223623527|NCT07199517|OTHER|NPL Sampling period|During a 28-day sampling period, participants randomized to NPL are instructed to try nicotine patches and nicotine lozenges and will complete daily e-diaries of cigarette smoking behavior and product uptake.
223623528|NCT07198607|OTHER|Pistacia lentiscus Oil Nasal Drops (Bactorinol®)|Bactorinol® nasal drops (medical device containing ultra-fractioned and winterized Pistacia lentiscus oil). Participants will receive isotonic saline nasal wash plus 5 drops per nostril twice daily for 30 days, followed by 5 drops per nostril twice daily for 15 days per month for the subsequent 11 months.
223623529|NCT07198607|OTHER|Placebo Nasal Drops (matched to Bactorinol®)|Placebo nasal drops identical in appearance and administration to Bactorinol®. Participants will receive isotonic saline nasal wash plus placebo drops, 5 drops per nostril twice daily for 30 days, followed by 5 drops per nostril twice daily for 15 days per month for the subsequent 11 months.
223761969|NCT01178892|BEHAVIORAL|Usual Activity|"Women randomly assigned to the Usual Activity group will be asked to continue with their usual physical activities during the study and not make changes. At completion of the intervention, women will have the opportunity to attend a yoga class and receive the yoga booklet, CD, and DVD for home use; or receive a one-month gym membership."
223623531|NCT07197944|DRUG|Glepaglutide|Subcutaneous (SC) injections twice weekly
223761970|NCT01103934|DRUG|Vitamin D3|4000 IU once daily
223761971|NCT01103934|DRUG|Placebo|Placebo taken once daily
223761972|NCT01103934|DRUG|Fluticasone Propionate|200 mcg daily, intranasal
224316476|NCT03471000|OTHER|Regular implants Treatment|Sinus lift procedure is done and regular implants are placed in the alveolar bone and a clinical Ostell and Periotest evaluation of the implants after a period of time is done. Analysis of periapical radiographs and CBCT images after a period of time. Bone around the implant was measured, marginal bone level loss is determined.
224316477|NCT02181790|DEVICE|Excimer laser|twice weekly treatments with the excimer laser for a total of 8 weeks.
224316478|NCT02181790|DRUG|Acitretin|17.5mg/d
223623532|NCT07197944|OTHER|Placebo|SC injections twice weekly
223623533|NCT07198204|OTHER|isometric exercises|Isometric quadriceps exercise: Patients lie in a supine position. A rolled-up towel was put beneath the knee. They were instructed to maximally activate their thigh muscles to straighten their knee and hold the contraction for 5 seconds (Group A), 10 seconds (Group B), or 20 seconds (Group C).
223623534|NCT07198204|OTHER|therapeutic ultrasound|all patients will reciece ultrasound for 5 minutes using 1MHz frequency, 0.8 wc2, 5cm2 head with adequate gel as a coupling medium
223623535|NCT07198204|OTHER|Transcutanous electrical nerve stimulation|all participants will recieve TENS for 30 minutes per session. the parameters will be Burst TENS, with main frequency of 100Hz, burst frequency of 4 Hz, intensity to the comfortable muscle twitch, electrodes size according to the size of the patients knee.
223623536|NCT07198009|DIETARY_SUPPLEMENT|2-HOBA (Hobamine)|Participants will take oral 2-hydroxybenzylamine (2-HOBA, Hobamine), a dietary supplement with Generally Recognized as Safe (GRAS) status. The study dose is 400 mg three times daily with meals for 6 weeks.
223623537|NCT07200089|DRUG|NT-I7|NT-I7 will be supplied by NeoImmuneTech Inc
223623538|NCT07200089|DRUG|Placebo|Placebo will be supplied by NeoImmuneTech Inc
223623539|NCT07200089|BIOLOGICAL|B-cell Maturation Antigen (BCMA) CART-T therapy|Standard of care
223761973|NCT02639364|DEVICE|Nellcor Puritan Bennett 840 ventilator system|Puritan Bennett 840 ventilator can provide the VCV,PCV,Bi-level Airway Pressure Ventilation-airway Pressure Release Ventilation(BILEVER-APRV) mode.
224316479|NCT01005277|OTHER|Laboratory Biomarker Analysis|Correlative studies
224316480|NCT01942889|DIETARY_SUPPLEMENT|Antioxidant Supplementation associated to Comprehensive respiratory Rehabilitation Program|Vit E, Vit C, Selenomethionine, Zinc gluconate
223623540|NCT07199634|OTHER|"Undetectable & You HIV treatment literacy app"|The app delivers information on the transmission prevention benefits of HIV treatment through the Undetectable Equals Untransmutable (U=U) message, alongside real-life video testimonials of patients living with HIV (PLHIV) and their partners. It underscores the key behavioral skills required for U=U, namely, ART adherence and viral load monitoring.
224212927|NCT02197221|DRUG|Bortezomib-Melphalan|Bortezomib will be administered on days: -6, -3, +1, +4. Melphalan will be administered on day -2. The PBSC will be injected on day 0.
223623541|NCT07198685|DRUG|bedaquiline|Administer 400 mg orally once daily for 2 weeks, followed by 200 mg orally three times a week for 22 weeks
223623542|NCT07198685|DRUG|Delamanid (DLM)|Administer 100 mg orally, twice daily for 24 weeks.
223761974|NCT02662387|DEVICE|External nasal dilator (END)|Applying External nasal dilator as adjuvant to high flow oxygen
223623543|NCT07198685|DRUG|Linezolid (LZD)|Administer 600 mg orally, once daily for 24 weeks.
223623544|NCT07198685|DRUG|Levofloxacin|test group:Administer 800 mg orally, once daily for 24 weeks;control group:Administer 800 mg orally, once daily for 72 weeks
223623545|NCT07198685|DRUG|Cycloserine|Administer 250mg orally, twice daily for 72 weeks.
223623546|NCT07198685|DRUG|Clofazimine|Administer 100 mg orally, once daily for 72 weeks
223623547|NCT07198997|OTHER|digital anesthesia|mandibular anestezi ile digital intrsosseoz anesteziyi kıyasslayan calısma yok.
223623548|NCT07199803|OTHER|Obstetric Quality of Recovery-10 (ObsQoR-10©) Scoring Tool|The ObsQoR-10 tool aims to quantitatively measure functional recovery at 24 hours postpartum. It includes 10 questions on a 0 to 10 scale, aimed at pain management, the adverse effects of narcotics and the perception of recovery by the patient.
223761975|NCT02662387|OTHER|High flow nasal cannula (HFNC)|Non-invasive positive pressure ventilation
224212928|NCT02197221|DRUG|Melphalan|Melphalan will be administered on day -2. The PBSC will be injected on day 0.
224212929|NCT05103059|DIAGNOSTIC_TEST|BMI|Patients with cancer cachexia will be enrolled in the study, and the following data will be collected: age, sex, total protein, albumin, hemoglobin (Hb), white blood cell (WBC) count, neutrophil count, lymphocyte count, red blood cell (RBC) count, platelet (PLT) count, body mass index (BMI), mid-arm circumference (MAC), thickness of triceps skinfold (TSF), handgrip strength (HGS), and calf circumference (CC)
224212930|NCT05720728|DIAGNOSTIC_TEST|collection of blood samples|For each patient, a serum sample collected at the time when candidemia is suspected (time of execution of blood cultures) will be examined. For patients with candidemia, all serum samples taken during infection follow-up will also be examined.
224316481|NCT00927732|DRUG|hydroquinidine|capsules of 300 mg LP, 1 or 2 or 3 times per day : frequency will be determined by tests after patient inclusion before her/his randomization
224316482|NCT00927732|DRUG|placebo (sugar)|capsules of placebo have same design and color than capsules of hydroquinidine except for their content as they contain sugar and not hydroquinidine
224316483|NCT05255796|PROCEDURE|one-piece|Patients underwent phacoemulsification cataract surgery with one-piece IOL implantation.
224316484|NCT05255796|PROCEDURE|plate-haptic|Patients underwent phacoemulsification cataract surgery with plate-haptic IOL implantation.
224316485|NCT00482807|DRUG|bicalutamide|
224316486|NCT00482807|DRUG|docetaxel|
224316487|NCT00482807|DRUG|goserelin|
224316488|NCT00482807|RADIATION|intensity-modulated radiation therapy|
223623549|NCT07198152|OTHER|None intervention|this study is retrospective based on the CT images, which dose include any intervention.
223623550|NCT07199309|DRUG|MAR001|Subcutaneous Injection
223623551|NCT07199309|DRUG|Placebo|Subcutaneous Injection
223623552|NCT07198386|DRUG|CS060380|Oral QD
223623553|NCT07198386|DRUG|Placebo|Oral QD
223623554|NCT07198633|DRUG|QLC5508|B7H3 ADC; QLC5508 will be administered by injection at the dose and dosing frequency specified in the protocol.
223623555|NCT07198633|DRUG|abiraterone acetate|An oral CYP17 inhibitor; abiraterone acetate will be administered orally at the dose and dosing frequency specified in the protocol
223623556|NCT07198633|DRUG|enzalutamide|An oral androgen receptor inhibitor; enzalutamide will be administered orally at the dose and dosing frequency specified in the protocol.
223623557|NCT07198633|DRUG|QLH12016|An oral androgen receptor PROTAC; QLH12016 will be administered orally at the dose and dosing frequency specified in the protocol
223623558|NCT07198945|PROCEDURE|6-month follow-up|Eligible patients randomized to the 6-month follow-up arm will undergo their first surveillance procedure 6 months after the removal of their large polyp to check for recurrent polyp tissue.
223623559|NCT07198945|PROCEDURE|12-month follow-up|Eligible patients randomized to the 12-month follow-up arm will undergo their first surveillance procedure 12 months after the removal of their large polyp to check for recurrent polyp tissue.
223680511|NCT00374205|DRUG|Artemether-Lumefantrine|Artemether 20 mg/Lumefantrine 120mg fixe-dose-combination tablets: 3 days twice daily weight-adjusted dosing according to manufacturer
223680512|NCT00899080|GENETIC|gene expression analysis|
223680513|NCT00899080|GENETIC|reverse transcriptase-polymerase chain reaction|
223680514|NCT00899080|OTHER|immunoenzyme technique|
223680515|NCT00899080|OTHER|laboratory biomarker analysis|
223680516|NCT00899080|OTHER|platelet aggregation test|
223680517|NCT00573729|OTHER|Pulsed Dye Laser 577 nm|Comparison of 577 nm Versus 595 nm Wavelengths of Pulsed Dye Laser Treatment of Port Wine Stain Birthmarks
223680518|NCT00573729|OTHER|Pulsed Dye Laser 595 nm|Comparison of 577 nm Versus 595 nm Wavelengths of Pulsed Dye Laser Treatment of Port Wine Stain Birthmarks
223680519|NCT04456231|DRUG|Plenvu|Patients will receive Plenvu for preparation of endoscopy
223680520|NCT04903821|DRUG|BAY3427080|Orally administered, single dose on Day 1 and single does once daily on Day 3 to 8
223680521|NCT06171633|BEHAVIORAL|E-STOP online educational program (treatment condition)|Participants access online video modules through an online learning platform. Program includes modules on civility and upstander interventions and education about sexual harassment, microaggressions, and implicit bias.
223680522|NCT06171633|BEHAVIORAL|E-STOP online educational program (control condition)|Participants access online video modules through an online learning platform. Program includes authorship ethics only.
223680523|NCT01718912|DRUG|metronidazole-nystatin oral rinse|
224212931|NCT03775148|BEHAVIORAL|Transdiagnostic Intervention for Sleep and Circadian Dysfunction (TranS-C)|TranS-C integrates elements of evidence-based interventions, namely cognitive-behavioural therapy for insomnia, delayed sleep phase type, and interpersonal and social rhythm therapy.
224212932|NCT03906149|COMBINATION_PRODUCT|Whole-body hyperthermia + standard medical care|Whole-body hyperthermia will be applied two times during 4 weeks (week 0 and 2 after randomization) in addition to standard medical care. The hyperthermia will be applied using Heckel-HT3000 MPIIb. During the 6 weeks of primary observation, the current medication should be maintained. The dose may be optimized with respect to clinical effectiveness and the reduction of side effects. The type of medication should not be changed during the 6 weeks. The use of additional somatic therapies such as sleep deprivation, light therapy, electroconvulsive therapy, or transcranial magnetic stimulation is not allowed.
224212933|NCT03906149|COMBINATION_PRODUCT|Standard medical care|Standard medical care included guideline-based anti-depressive drug treatment in combination with psychotherapy. During the 6 weeks of primary observation, the current medication should be maintained. The dose may be optimized with respect to clinical effectiveness and the reduction of side effects. The type of medication should not be changed during the 6 weeks. The use of additional somatic therapies such as sleep deprivation, light therapy, electroconvulsive therapy, or transcranial magnetic stimulation is not allowed.
224212934|NCT06176859|OTHER|HIV PrEP Delivery|To test an end-to-end decentralized delivery service for pre-exposure prophylaxis (PrEP) to safely increase PrEP access and use among priority populations in South Africa.
224212935|NCT03447483|OTHER|Patients starting a treatment by ICI|"Completion of the Quality of Life Questionnaire Core 30 (QLQ-C30) before treatment administration and during the 12 months of treatment period, at the following time points:~* every 6 weeks for treatment regimen administered every 2 or 3 weeks~* at Weeks 6, 12, 20, 24 for treatment regimen administered every 4 weeks"
224212936|NCT06182007|PROCEDURE|Cardiopulmonary Resuscitation|Cardiopulmonary Resuscitation (Advanced Life Support) according to current guidelines
224212937|NCT06091774|DEVICE|CHD therapy through iATROS medical device|The intervention to be carried out in the treatment group is the use of the therapy control for the treatment of CHD played out via the iATROS medicine product. Patients will receive a suitable and medical device certified measuring device for recording vital parameters. The iATROS app is downloaded to the patient's smartphone and the app is activated by entering a code that identifies the user as a participant in the study. When using the app for the first time, the patient is guided through the first steps of using the app and asked to transfer his or her health data to the app. The therapy control by means of the medication product takes place over the entire duration of the study.
224212938|NCT03815357|OTHER|Referral to Immunology|Screening for primary immunodeficiency including splenic dysfunction
224212939|NCT01091376|DRUG|Erlotinib|Erlotinib 150mg/day
223623560|NCT07199166|BEHAVIORAL|Autobiographical Rewriting Workshops|10 two-hour autobiographical rewriting workshop sessions, held weekly. This program encourages participants to explore their own history in a way that fosters narrative resilience, highlighting their ability to overcome challenges, transform failures into learning opportunities, express themselves creatively, reexamine their memories, and rebuild a more positive sense of identity that better aligns with the needs of accurate self-recognition of their potential. This program is particularly inspired by the concepts of resilience (Boris Cyrulnik), identification (Karine Gros), the Hero's Journey (Joseph Campbell), narrative therapy (David Denborough), and works on various types of story structures (Blake Snyder).
223623561|NCT07199166|BEHAVIORAL|Non-specific writing workshops|10 sessions of 2 hours of non-specific writing, held weekly. To increase the active role of the participants, they will be encouraged to write on the theme of the session during the time between sessions. The writing themes are non-specific, unlike the intervention group, and include topics such as poetry, historical events, nature reports, imaginary interviews, children's stories, etc.
223623562|NCT07198126|PROCEDURE|Pterygium Excision with Conjunctival Autograft|Excision of primary Grade II or Grade III pterygium Conjunctival autograft harvested and transplanted at the excision site Graft secured with sutures
223623563|NCT07199946|DRUG|Verapamil (Part A)|Verapamil 3-6mg/kg body weight and 24 hrs
223623564|NCT07199946|DRUG|Placebo|Placebo given in part B, the comparator arm of the double blind randomized trial
223623565|NCT07199621|PROCEDURE|uterine incision by scissors versus scalpel|procedure in uterotomy in cs
223623566|NCT07198724|DRUG|Elacestrant|Selective estrogen receptor degrader (SERD), film-coated tablet, taken orally per protocol.
224212940|NCT01091376|RADIATION|Thoracic radiotherapy|60-70Gy/30-35f
224212941|NCT03533530|DIAGNOSTIC_TEST|Low-density ESI (LD ESI)|Electrical source imaging using low density EEG
224212942|NCT03533530|DIAGNOSTIC_TEST|High-density ESI (HD ESI)|Electrical source imaging using high density EEG
224212943|NCT03533530|DIAGNOSTIC_TEST|No electrical source imaging (ESI)|For all patients: MRI, semiology, visual interpretation of EEG. When needed: PET, SPECT.
224212944|NCT06270030|DRUG|LNZ101 (Aceclidine /Brimonidine) ophthalmic solution|Once daily from day 1 to day 8; Everyday, subject will be administered with 1 drop in each eye followed by another drop in each eye 2 minutes later
224212945|NCT06270030|DRUG|LNZ100 (Aceclidine) ophthalmic solution|Once daily from day 1 to day 8; Everyday, subject will be administered with 1 drop in each eye followed by another drop in each eye 2 minutes later
224316489|NCT02798432|PROCEDURE|Total knee arthroplasty|Use of an uncemented femoral component or a cemented femoral component randomly assigned.
224316490|NCT02798432|DEVICE|NEXGEN LPS total knee arthroplasty|Hybrid (non cemented femoral component, cemented tibial component) NEXGEN LPS total knee arthroplasty versus Cemented NEXGEN LPS total knee arthroplasty (both components are cemented).
223761976|NCT02462577|DRUG|local instillation of morphine to surgical wound|comparison between different drug doses effects on pain
223761977|NCT05651464|DRUG|Vancomycine|Application of 15-20 mg per kgKG Vancomycine I.V. prior to ECMO liberation
223761978|NCT05445765|BIOLOGICAL|anti-CD33 CAR T cells|Anti-CD33 CAR T cells are used to treat patients. Patient will be administered either fresh or thawed CAR T cells by IV injection after receiving lymphodepleting chemotherapy.
223761979|NCT03852797|DRUG|Oxytocin|Oxytocin solution, 20nM concentration
223761980|NCT03852797|DRUG|Ketamine|Ketamine in solution, 10-4M to 10-7M
223761981|NCT03852797|DRUG|Propofol|Propofol in solution, 10-4M to 10-7M
224212946|NCT06270030|DRUG|Placebo (Vehicle) ophthalmic solution|Once daily from day 1 to day 8; Everyday, subject will be administered with 1 drop in each eye followed by another drop in each eye 2 minutes later
224316491|NCT03107247|DRUG|Imaging Time|Participants will be asked to be imaged at an additional time point.
224316492|NCT01819610|DRUG|SPRIX|
223623567|NCT07198724|DRUG|Trastuzumab Deruxtecan|HER2-directed antibody-drug conjugate, vial, via intravenous (into the vein) infusion per standard of care
223623568|NCT07198568|DIAGNOSTIC_TEST|Surface electromyography|A previous other study has examined the suprahyoid muscle activity patterns in sarcopenic dysphagia patients using surface electromyography (sEMG). However, there was a lack of research analyzing the swallowing dynamics of sarcopenic dysphagia alongside Videofluoroscopic Swallowing Study (VFSS). VFSS enables the observation of swallowing in phases, offering a crucial method for assessing the presence of dysphagia and identifying the specific phases where dysphagia occurs. Therefore, the present study aims to investigate the characteristics of sarcopenic dysphagia across phases using sEMG and VFSS. Additionally, the investigators aim to analyze the relationship between suprahyoid muscle activity patterns and swallowing dynamics utilizing these modalities.
223623569|NCT07198568|DIAGNOSTIC_TEST|Videofluoroscopic swallowing study (VFSS)|VFSS enables the observation of swallowing in phases, offering a crucial method for assessing the presence of dysphagia and identifying the specific phases where dysphagia occurs. The investigators will utilize Videofluoroscopic Dysphagia Scale (VDS), that composed of fourteen categories, which can be divided into oral and pharyngeal phases to assess scores based on VFSS results. The oral phase composed of 7 items (lip closure, bolus formation, mastication, apraxia, tongue-to-palate contact, premature bolus loss, and oral transit time). The pharyngeal phase also included 7 items (triggering of pharyngeal swallowing, vallecular residues, pyriform sinus residues, laryngeal elevation, coating of pharyngeal wall, pharyngeal transit time, and aspiration). VDS can assess the components of dysphagia in such detail. Therefore, investigators can evaluate the etiology of dysphagia more precisely.
223623570|NCT07199452|DRUG|MK-4646|Oral Capsule
223623571|NCT07199452|DRUG|Rifabutin|Oral Capsule
223623572|NCT07199374|BEHAVIORAL|PARCA|PARCA is an s an app to facilitate goal management, resource allocation, and managing progress.
223623573|NCT07199959|PROCEDURE|venipuncyure|venipuncture as clinical practical setting
223623574|NCT07199959|DRUG|Entrectinib|600mg, oral, once daily
223623575|NCT05319587|DRUG|Liposomal Annamycin|2-hour intravenous infusion liposomal annamycin daily for 3 consecutive days followed by 18 days off study drug (i.e., one treatment cycle = 21 days).
223623576|NCT05319587|DRUG|Cytarabine|Administered during cycle 1 at a dose of 2.0 g/m2/day by 4 hours IV infusion for 5 consecutive days and this dose will remain constant for all cohorts, including the expansion phase.
223623577|NCT00361556|BEHAVIORAL|The Back Book|A book on how to prevent back pain
223623578|NCT00361556|BEHAVIORAL|The Back Guide|A guide for the prevention of back pain.
223623579|NCT00361556|BEHAVIORAL|General health book|A book on general health
223623580|NCT04373928|PROCEDURE|Drug guided by Mini-PDX/PDX|Chemotherapeutic agents guided by Mini-PDX/PDX will be applied to PC patients and the efficiency will be studied.
223623581|NCT03049462|DRUG|Mirabegron|Women will take 100mg daily for 4 weeks. Men will take 200mg daily for 4 weeks. The medication is available in 50 mg tablets.
223623582|NCT03049462|OTHER|B Complex Plus Vitamin C Tablets|Males will be randomized to take placebo versus active drug (mirabegron). Those taking placebo will take 4 tablets each day to mirror to active group (taking 4 tablets of 50 mg each).
223623583|NCT06348628|BEHAVIORAL|Motivational Interview|4 Motivational interviews within first 6 months
223623584|NCT06348628|BEHAVIORAL|Placebo|Advices on standard of care treatment of NAFLD within first 6 months
223623585|NCT02965430|DEVICE|AL-SENSE|A diagnostic pantyliner for detection of amniotic fluid leaks compared with standard clinical diagnosis
223623586|NCT05389033|DIETARY_SUPPLEMENT|Probiotic bacteria|28 days daily supplementation with active probiotic
223623587|NCT05389033|OTHER|Placebo Capsule|28 days daily supplementation with placebo
223680524|NCT05255185|PROCEDURE|domino therapy|The investigators evaluated routine blood test results, C-reactive protein level, the erythrocyte sedimentation rate, and other indicators. X-rays and CT scans of the surgical site were obtained and the Musculoskeletal Tumor Society (MSTS) score was calculated. Treatment involved debridement and lavage of the prosthesis, and systemic and local antibiotics.
223680525|NCT04231981|DRUG|Retifanlimab|INCMGA00012 500 mg will be administered on Day1 of each cycle (once every four weeks), for up to 2 years.
223761982|NCT03852797|DRUG|Etomidate|Etomidate in solution, 10-4M to 10-7M
223761983|NCT00792610|BIOLOGICAL|hepatitis B vaccine|Recombinant HBsAg, 20mcg/ml/vial (GSK) one vial IM at Day 0, Month 1, month 6 during follow-up, respectively.
223761984|NCT04889625|DEVICE|senofilcon A C3|Test Lens
224212947|NCT00370669|DRUG|bevacizumab|
224212948|NCT00370669|DRUG|triamcinolone acetonide|
224212949|NCT00838669|DRUG|Extended release OROS paliperidone|
224212950|NCT05088824|PROCEDURE|hernia repair by desarda technique|It involves use of undetached strip of external oblique aponeurosis to strengthen the posterior wall of the inguinal canal which is based on the physiological principles. This is a physiological repair and is tension free, can be used in strangulated hernia
224212951|NCT01270841|DRUG|Placebo|Placebo capsule 1x daily for 3 months
224212952|NCT01270841|DRUG|topical testosterone|testosterone gel applied 1x daily for 3 months
224212953|NCT01270841|DRUG|Androxal|Capsule of either 12.5 mg or 25 mg Androxal, 1x daily for 3 months
224316493|NCT05039138|OTHER|NEUROMUSCULAR TRAINING EXERCISE|patients will receive neuromuscular training exercises in group II
224316494|NCT05039138|OTHER|traditional training exerises|traditional strength training exercises in group I
224316495|NCT03696238|DIETARY_SUPPLEMENT|500mg of Aronox® >40% polyphenol aronia extract|Name: Aronia PE 40% polyphenols Description: Powdered extract obtained from aronia berries (Aronia melanocarpa) Dosage form: Capsule (opaque, beige, size 00) Strength: 500 mg aronia extract Regimen 1 capsule, once a day with breakfast (except on days when attending the laboratory) Batch number: As per label Expiry Date: As per label Manufacturer: NATUREX / Virage sante
224212954|NCT02082912|DRUG|D-cycloserine|D-cycloserine 100mg PO twice weekly (Monday and Wednesday) for three weeks
224212955|NCT02082912|OTHER|Placebo|Placebo pill PO twice weekly (Monday and Wednesday) for three weeks
224212956|NCT02082912|DEVICE|HandMentor Pro|The HandMentor Pro (Kinetic Muscles Inc.) is a robotic device that has recording electrodes. The device gives feedback during various activities requiring varying levels of wrist control. The main goal of the hand robot is to improve active range of motion about the wrist and fingers and wrist control. The robotic therapy will be done over 3 consecutive weeks for 2 hours each session (days 1, 3, 5, 8, 10, 12, 15, 17 and 19, for 18 hours total).
224212957|NCT06520436|PROCEDURE|Arthroscopic-Assisted Reduction|The arthroscopic-assisted reduction was used as a one-stage operative treatment for all hips. In addition to that, Dega pelvic osteotomy and/or femoral shortening and varus derotation osteotomies were performed when necessary.
224212958|NCT02122159|BIOLOGICAL|MA09-hRPE Cellular Therapy|A suspension of either 50,000 MA09-hRPE cells (first cohort), 100,000 MA09-hRPE cells (second cohort), 150,000 MA09-hRPE cells (third cohort) or 200,000 MA09-hRPE cells (fourth cohort) in 150 uL of BSS plus will be implanted over 1 minute in the space created.
224212959|NCT06450600|BEHAVIORAL|Multiple Sclerosis Therapeutic Education Program|"The MS Self-Management Education Workshop is designed as an integral part of our therapeutic education program targeting individuals diagnosed with multiple sclerosis (MS). This intervention focuses on empowering participants with knowledge and skills necessary for effective self-management of their condition. The workshop includes interactive sessions that cover a range of topics critical for MS patients, such as:~Understanding the nature and progression of MS, highlighting the importance of early symptom recognition and management strategies.~Techniques for managing common MS symptoms, including fatigue, mobility issues, and cognitive challenges, with practical advice on daily living adaptations.~Guidance on medication management, including the use of disease-modifying therapies and managing side effects.~Strategies for emotional well-being, including coping mechanisms for dealing with the psychological impact of MS, stress management, and fostering resilience."
224212960|NCT00769899|DRUG|AZD7325|Capsule for oral, single dose
224212961|NCT00769899|DRUG|Placebo|Placebo capsule for oral, single dose
224212962|NCT02858856|DRUG|Sipjeondaebo-tang|Herbal medicine which is a compound of 10 herbs.
224212963|NCT02986152|BEHAVIORAL|Cancer Distress Coach Mobile App|"Cancer Distress Coach is a stand-alone symptom management tool with three basic components. The Learn about Distress module provides psycho-education. The Insights module includes an inspiring Quote of the Day, daily activity planning tips, a graph displaying the user's distress level plotted over time, and assessment feedback. The main action of the application is in the Activities module that provides patients with skills to manage their stress in the moment they experience it. Depending on the severity, the patient is routed to any of a number of helpful skills based on cognitive-behavioral principles. The stress management tools include positive imageries, soothing songs and pictures, and the Relax-Identify-Decide tool. Also included is find support and get support now to connect the user to his/her support network and locate informal cancer and non-cancer related support or (immediate) professional care."
224212964|NCT02412956|BEHAVIORAL|SmokefreeMOM Text|
223623588|NCT06085508|BEHAVIORAL|Digital patient education to reduce kinesiophobia after MI and/or AF|Group-meetings 7 times via Zoom® video with a tutor (nurse, physiotherapist) and learn about PA, kinesiophobia, AF and/or MI. Scenarios start the problem-based learning process involving recorded lectures, behavioral activation, and exposure to PA. Week1: Programme intro. Formulation of individual goals. Home assignment (HA): Lecture PA after MI/AF. Week 2. Discuss HA. Scenario 1: Why PA after MI/AF? (PBL) Formulate questions\*. HA: Answer the questions. Week 3. Follow-up HA. Scenario 2. What is MI/AF.\* Week 4. Discuss HA. Scenario 3. Living with MI/AF and kinesiophobia - How to make a change?\* HA: Map weekly activities, rate as frightening/non-frightening. List PA and choose one to implement. Use SMART GOALS. Lecture: Kinesiophobia. Week 5. Discuss HA. Scenario 4. How can I reduce my fear for PA.\* SMART, the activity. Week 6. Discuss HA. Week 7. Own individual work. HA: Evaluate, revise, and perform activities. Week 8. Follow-up of the activity plan. Summarize the program.
223623589|NCT04124640|OTHER|Patients' data (baseline characteristics, clinical and outcomes) from routine care visits|Use of a standardized scale to collect clinical and patient-centered data, to assess the effectiveness of Libicare in real life in female 45-65 years old. Patients' data (baseline characteristics, clinical and outcomes) will be collected according to sites routine care.
223623590|NCT02607059|OTHER|Registry|
223623591|NCT05246917|PROCEDURE|Handsewn anastomosis|To perform hand sewn anastomosis (either end to end or Kono-s) during the reconstruction face of ileocolic resection
223623592|NCT01456637|BEHAVIORAL|CBT for insomnia|The techniques used throughout the self-help manual are all effective in reducing insomnia: 1) Stimulus control: patients should only go to bed when sleepy, use the bed and bedroom for sleep (and sex) only, maintain a regular rising time, avoid daytime naps and get out of bed and go into another room when unable to fall asleep within 15-20 minutes (return only when sleepy). 2) progressive muscle relaxation. 3) sleep hygiene education (improving health and environmental factors that affect sleep). 3). Sleep restriction, whereby participants will stay only the time in bed that they sleep. 4) cognitive therapy to challenge and dispute incorrect and unhelpful thoughts about sleep (e.g. I must sleep at least 8 hours, otherwise I'll be a wreck tomorrow).
224316496|NCT03696238|OTHER|Placebo|Name: Placebo Description: Identical formulation as the treatment consisting of colored maltodextrin using artificial colors Dosage form: Capsule (opaque, beige, size 00) Strength: 500 mg placebo Regimen 1 capsule, once a day with breakfast (except on days when attending the laboratory) Batch number: As per label Expiry Date: As per label Manufacturer: NATUREX (Advance nutraceutical) / Virage sante
223623593|NCT03363737|BEHAVIORAL|Transtheoretical Model|Exposure to content on Facebook, either daily (dynamic) or just at one time period (static).
224212965|NCT03604354|DRUG|Tapentadol 100 MG Oral Tablet|This arm will receive drugs one hour before undergoing unilateral total knee arthroplasty. Interventions tapentadol 100mg oral tablets.
224212966|NCT03604354|DRUG|Pregabalin 150mg|This arm will receive drugs one hour before undergoing unilateral total knee arthroplasty. Interventions pregabalin 150mg oral tablets.
224316497|NCT02845193|DEVICE|Modified Nasoalveolar molding|Infants will receive this appliance which is a maxillary plate with nasal stent in addition to taping on the upper lip (taping is routine step in Grayson's nasoalveolar molding technique).
224316498|NCT02845193|DEVICE|Taping|Infants will receive a tape only on the upper lip segments to mold it to touch each other.
224212967|NCT02881073|OTHER|Maternal plasma PlGF quantification|A point of care test performed on maternal plasma, to quantify the level of the protein PlGF (placental growth factor) in the serum of the pregnant woman with suspected pre eclampsia to help the clinician in stratifying the level of further care for her in her pregnancy
224212968|NCT00420888|DRUG|ABR-217620/naptumomab estafenatox|10 mcg/kg or 15 mcg/kg, 5 minute bolus intravenous injection on 4 consecutive days / 8 week cycle repeated 3 times
224212969|NCT00420888|DRUG|IFN-alpha|3 MIU, 6 MIU, and 9 MIU, subcutaneous or intramuscular injection 3 times / week
224212970|NCT04668118|DRUG|Diquafosol|As a P2Y2 receptor agonist, diquafosol can be used to stabilize the tear film by stimulating P2Y2 receptors on the corneal epithelial cells and conjunctival goblet cell, which increase the secretion of tear fluid and mucin on the ocular surface, thereby repairing the ocular surface and stabilizing the tear film.
224212971|NCT01929148|PROCEDURE|Prophylactic bilateral salpingectomy|Salpingectomy will be performed by coagulation and section of the tube, beginning from the very distal fimbrial end, carefully preserving the ovarian vascularization, and proceeding toward the uterine cornu
224212972|NCT01929148|PROCEDURE|Laparoscopic myomectomy without PBS|Standard laparoscopic myomectomy without salpingectomy
223623594|NCT05036096|DEVICE|CBBCT Imaging|Both breasts will be scanned by CBBCT. Only one breast will be scanned if the patient had mastectomy.
223623595|NCT05036096|DEVICE|Digital Mammography|Both breasts will take digital mammography standard views (CC, MLO) Only one breast will take digital mammography standard views if the patient had mastectomy.
223623596|NCT06223334|OTHER|No intervention|observational study to evaluate the different clinical and etiological patterns of epileptic syndromes in infants and early childhood.
223623597|NCT01908426|DRUG|Cabozantinib tablets|
223623598|NCT01908426|DRUG|Placebo tablets|
223623599|NCT04936906|BEHAVIORAL|Extra Care (EC) Intervention|The EC intervention includes pre- and post- procedure calls from the surgeon, written educational material, personalized music during the operation, post-procedure skin cancer protection education, and are allowed to bring a guest into the procedure room.
223623600|NCT04936906|OTHER|Usual Care (UC)|Standard of care pre and post surgery management provided to patients undergoing Mohs Surgery.
223623601|NCT00007592|DRUG|Chlorthalidone|
223623602|NCT00007592|DRUG|Furosemide|
223623603|NCT03335384|DIAGNOSTIC_TEST|Esophageal Balloon|Small flexible catheter with deflated balloon at distal end to be inserted into the esophagus through the nose
223623604|NCT03335384|DIAGNOSTIC_TEST|Gastric Balloon|Small flexible catheter with deflated balloon at distal end to be inserted into the stomach through the nose
224212973|NCT04383080|PROCEDURE|Acupuncture|acupuncture at specific acupuncture points
224212974|NCT04383080|DEVICE|Low-level laser therapy|low level laser emission on specific acupuncture points
224212975|NCT01454882|BEHAVIORAL|Effects of Clothing|There will be two temperature conditions; warm temperature \[WT, 75°F (24°C)\] and cool temperature \[CT, 60°F (16°C)\]. During each condition, subjects will vary the amount of clothing they are wearing at specified times
224212976|NCT01454882|BEHAVIORAL|Effects of Temperature|There will be two temperature conditions; warm temperature \[WT, 75°F (24°C)\] and cool temperature \[CT, 60°F (16°C)\]. During each condition, subjects will vary the amount of clothing they are wearing at specified times
224212977|NCT01454882|BEHAVIORAL|Low Physical Activity|This will be a randomized study with two within subject conditions (high and low physical activity levels)
224212978|NCT01454882|BEHAVIORAL|High Physical Activity|This will be a randomized study with two within subject conditions (high and low physical activity levels)
224316499|NCT02845193|DEVICE|CAD/NAM|computer aided design NAM
224316500|NCT02458287|BIOLOGICAL|Bococizumab 150mg|Bococizumab autoinjector (pre-filled pen) combination Product. 150mg every 2 weeks for 10 weeks, subcutaneous injection.
224316501|NCT02458287|BIOLOGICAL|Bococizumab 75mg|Bococizumab autoinjector (pre-filled pen) combination Product. 75mg every 2 weeks for 10 weeks, subcutaneous injection.
223623605|NCT03335384|DIAGNOSTIC_TEST|Nasal Pressure Transducer|Pressure transducer inserted into nasal plug
223623606|NCT00182026|BEHAVIORAL|personal feedback report|A computer-generated feedback report that provides personalized diabetes self-management recommendations to participants based on their responses to a self-administered questionnaire.
223623607|NCT05974241|DRUG|Methylphenidate, aripiprazole, and combination|Methylphenidate (4 weeks), aripiprazole (4 weeks), and the combination (2weeks). The primary outcome was improvement of irritability as measured by Aberrant Behavior Checklist-irritability subscale (ABC-I). During the first step, the subjects received pharmacological treatment of methylphenidate with flexible dosage for 4 weeks. Those subjects who had suboptimal response to methylphenidate (reduction of ABC-I score \< 25%) entered the second step and the medication was switched to aripiprazole. After 4 weeks of treatment, those whose ABC-I scores reduced \< 25% entered the third step and received the treatment of combination of methylphenidate and aripiprazole for two weeks (3rd step).
223623608|NCT02657096|PROCEDURE|Hybenx treatment (device)|In the maxillary quadrant assigned to SRP + hybenx treatment, hybenx was applied, after SRP, on the gingiva with a 30-second incubation period and then thoroughly rinsed away through abundant irrigation with a sterile saline solution.
223623609|NCT02657096|PROCEDURE|Scaling and Root Planing (SRP)|The contra-lateral quadrants were treated as conventional Scaling and Root Planing (SRP) alone.
223623610|NCT01647789|DRUG|CFG920|
223623611|NCT01893463|DEVICE|iTClamp50|
223623612|NCT02426580|BEHAVIORAL|wechat|The wechat model of dietary education every 1 month by cellphone
223623613|NCT02686372|BIOLOGICAL|TCR-T|Autologous T cells transfected with mRNA encoding HBV antigen-specific TCR
223623614|NCT02686372|BIOLOGICAL|No intervention and TCR-T (at crossover)|Autologous T cells transfected with mRNA encoding HBV antigen-specific TCR
223623615|NCT03046186|DIAGNOSTIC_TEST|Mixed meal test with double tracer technique|
223623616|NCT05515965|OTHER|Kinesiotaping|The mechanical correction method of taping to the Kinesiotape group was used. In rheumatoid hand patients, due to the presence of a deformity called hitchhiker's finger, the thumb is taped with 50-75% tension to create a pulling force in the direction of flexion and abduction. The application was performed with the patient in a sitting position with his arm supported by a pillow from the elbow. Evaluation parameters were evaluated before and 1 hour after the application, and the acute effect was examined. Both the dominant and nondominant hands of the patients were taped and the differences between the two hands were also examined.
223623617|NCT05515965|OTHER|Sham|Sham application was applied to both dominant and nondominant hands in Control Group patients. Sham taping is the bonding of I tape to the 1st finger without tension and does not contain any features. Evaluation parameters were evaluated before and 1 hour after the application, and the acute effect was examined. Both the dominant and nondominant hands of the patients were taped and the differences between the two hands were also examined.
223623618|NCT02202421|BEHAVIORAL|Targeted Applied Behavior Analysis (T-ABA)|Participants will be enrolled in a five week Targeted Applied Behavior Analysis (T-ABA) parent therapy group. T-ABA parent groups will be 1.5 hours in length. Following the five weeks of parent group sessions, parents will participate in five weekly one-hour parent-therapist sessions in which a therapist will work one-on-one with the parent and their child. One treatment group (T-ABA Parent Group plus Individual Therapy) will also receive eight one-hour individual therapist-child applied behavior analysis therapy sessions concurrent with the parent group and parent-therapist sessions. The second treatment group (T-ABA Parent Training Only) will be offered eight one hour individual therapist-child applied behavior analysis sessions at the conclusion of the study if desired.
224212979|NCT01454882|BEHAVIORAL|Direct calorimetry and doubly labeled water|TDEE will be measured simultaneously for 14 days using direct calorimetry and doubly labeled water. A heterogeneous sample of adult men and women in stable health will be studied.
223623619|NCT06499298|DRUG|Nivolumab|As per product label, as prescribed by treating physician
223623620|NCT02649582|BIOLOGICAL|Dendritic cell vaccine plus temozolomide chemotherapy|"When eligible after total or subtotal resection (as assessed by neurosurgeon and post-operative brain MRI):~1. Leukocyte apheresis (before chemoradiation): for DC vaccine production~2. Chemoradiation (standard treatment: initiated as soon as the patient's hematological blood values are adequate after apheresis): 2 Gy once daily 5 days/week for 6 weeks with 75 mg/m² temozolomide daily from the first until the last day of radiotherapy (no longer than 49 days in total)~3. Induction immunotherapy: intradermal vaccination with autologous WT1 mRNA-loaded DCs weekly (+/-1 day) for 3 weeks, starting ≥ 1 week after radiotherapy~4. Chemo-immunotherapy: 150-200 mg/m²/d temozolomide days 1-5 every 28 days +/- 2 days (max. 12 months) starting ≥3 days after the third vaccine of the induction immunotherapy + DC vaccination on day 21±3 days of every 28-day cycle"
223623621|NCT04149912|DIAGNOSTIC_TEST|Online questionnaire|Online questionnaire via SoSciSurvey
223623622|NCT02061787|DEVICE|balloon pulmonary angioplasty|patients with chronic thromboembolic pulmonary hypertension who underwent balloon pulmonary angioplasty
223623623|NCT04901793|BEHAVIORAL|Virtual Reality Headset and handheld remote control.|Brand name: Oculus Quest
223623624|NCT01964651|DRUG|JNJ-42165279 50 mg|JNJ-42165279 50 mg orally administered once daily for 10 days.
223623625|NCT01964651|DRUG|JNJ-42165279 100 mg|JNJ-42165279 100 mg orally administered once daily for 10 days.
223623626|NCT01964651|DRUG|JNJ-42165279 30 mg|JNJ-42165279 30 mg orally administered once daily for 10 days.
223623627|NCT01964651|DRUG|Placebo|Matching placebo orally administered once daily for 10 days.
223623628|NCT04142203|OTHER|23 h surgery|Patients were treated in 23 surgical unit
223623629|NCT01517399|DRUG|tivantinib|three oral 120 mg tablets administered twice a day
223623630|NCT01517399|DRUG|omeprazole|One 40 mg oral capsule once alone and once again with tivantinib
223623631|NCT01517399|DRUG|s-warfarin|One 10 mg oral tablet once alone and once again with tivantinib
223623632|NCT01517399|DRUG|caffeine|One 200 mg oral tablet once alone and once again with tivantinib
223623633|NCT01517399|DIETARY_SUPPLEMENT|vitamin K|One oral 5 mg tablet on multiple days when and around warfarin administration
223623634|NCT01517399|DRUG|digoxin|One oral 0.25 mg tablet once alone and once again with tivantinib
223623635|NCT01517399|DRUG|midazolam|Intravenous 1.5 mg dose once alone and once again with tivantinib
223623636|NCT04874025|DRUG|Ibrance|Observational study of Ibrance 75 mg, 100 mg and 125 mg.
223623637|NCT03413007|DIAGNOSTIC_TEST|Immune compleX Predictive Index|iXip is an algorithm thant integrates PSA, PSA-IgM, prostate volume and age of the patient in order to provide the probability of prostate cancer
223623638|NCT04734639|BEHAVIORAL|CON . control condition without exercise / rest condition|Control condition without exercise / rest condition. The adolescents will be asked to remain quiet and at rest during the morning and will receive an ad libitum meal at dinner time. Their food reward will be assessed before dinner. Their appetite feelings will be assessed at regular intervals.
223623639|NCT04734639|BEHAVIORAL|Def-Mixed. Condition with a mixed energy deficit induced by exercise + dietary restriction.|Def-Mixed. Condition with an exercise-induced energy deficit The adolescents will received a calibrated lundh meal with a deduction of 250 kcal compared with the lunch meal of Con; and will be asked to realise an acute exercise set at 65% of their capacities (cycling) during the afternoon, inducing an energy expenditure of 250 kcal. Dinner will be served ad libitum. Their food reward will be assessed before dinner. Their appetite feelings will be assessed at regular intervals.
223623640|NCT04734639|BEHAVIORAL|Def-EI. Condition with an energy-restriction energy deficit|Condition with an energy-restriction energy deficit The adolescents will receive a calibrated breakfast reduced from 500 kcal compare to their CON and Def-mixed conditions. Dinner will be served ad libitum. Their food reward will be assessed before dinner. Their appetite feelings will be assessed at regular intervals.
223623641|NCT06301958|DRUG|Dextrose prolotherapy|A 25% dextrose solution is used to relieve arthritis of the knee joint like osteoarthritis and rheumatoid arthritis.
223623642|NCT02685319|PROCEDURE|muscle biopsy|a muscle sample will be taken from the mid-thigh (Vastus Lateralis) and analyzed
223623643|NCT02773381|DRUG|semaglutide|Oral administration once-daily.
224316502|NCT02458287|BIOLOGICAL|Bococizumab 150mg placebo|Bococizumab placebo autoinjector (pre-filled pen) combination Product. 150mg placebo every 2 weeks for 10 weeks, subcutaneous injection.
224316503|NCT02458287|BIOLOGICAL|Bococizumab 75mg placebo|Bococizumab placebo autoinjector (pre-filled pen) combination product. 75mg placebo every 2 weeks for 10 weeks, subcutaneous injection.
224316504|NCT01323751|DRUG|ACY-1215|Liquid oral dose on Days 1-5 and 8-12 of 21-day treatment cycle
224316505|NCT02613182|DRUG|NEOD001|NEOD001
224212980|NCT06541782|BEHAVIORAL|Dyadic CAT-based Intervention|The experimental dyadic CAT-based intervention will promote mutual sensorimotor play, pretend play, songs, and games among the mother-child dyads while encouraging flexibility, creativity, and enjoyment. This intervention will involve eight weekly 45-minute sessions in the families' homes and will be conducted by trained creative art therapists. The dyadic CAT-based intervention will follow a manualized protocol presenting the goals, principles, and proposed activities for the intervention sessions. It will provide instructions for maintaining intervention fidelity, while allowing flexibility to tailor the meetings to each dyad's strengths and needs. The dyadic CAT-based intervention meetings will be recorded using video camera.
224212981|NCT06541782|BEHAVIORAL|Psycho-Educational Parent Counseling|This intervention will involve only mothers and will be conducted by trained parent counselors with experience in working with IDD. This intervention will involve eight weekly 45-minute sessions performed online via Zoom. The psycho-educational parent counseling will follow a protocol presenting the goals, principles, and central issues in parenting a child with IDD to improve the parent-child relationship and address concerns and difficulties related to the child's diagnosis, development, and behavior. It will provide general instructions for maintaining study validity and replication, while allowing flexibility to tailor the intervention to each family's needs.
224212982|NCT03914144|OTHER|Catheter insertion|A data collection sheet will be assigned for every patient who is recruited for the study. The clinician caring for the patient will be asked to fill in this form after the delivery has occurred. The form essentially will describe if the patient received any catheter during the delivery and if so, an indwelling catheter or an intermittent (in/out) catheter and how many episodes this occurred.
223623644|NCT02773381|DRUG|placebo|Oral administration once-daily.
223623645|NCT02760459|DRUG|Dexamethasone|
223623646|NCT02760459|DRUG|Normal saline solution|
223623647|NCT03893396|DEVICE|Coronary angioplasty|Procedure used to open clogged heart arteries. Involves the insertion of a tiny balloon and/or a stent to widen the artery.
224212983|NCT04737668|OTHER|Intrathecal pump refill with Virtual Reality|VR game
223623648|NCT04156061|OTHER|Delivery of CT scan results|Method of results delivery - verbal or visual.
224212984|NCT04737668|OTHER|Intrathecal pump refill with distraction|Video
224212985|NCT04737668|OTHER|Intrathecal pump refill|daily routine care for pump refill
224212986|NCT02288689|DEVICE|Acuuvix SonoAce UGEO|Ultrasonographic vaginal examination
223623649|NCT05195164|OTHER|No intervention|There was no intervention
223623650|NCT05835765|DEVICE|Dynamic Elastometric Body in Preterm Newborns|The study group made up of 12 newborns will use Flexa bodysuits made to the measurements of newborns.The bodysuit will be worn for a minimum of 4 hours and a maximum of 6 hours each day for a week (depending on any signs of discomfort). After 6 hours, the body will be removed and reapplied the next day for 4-6 hours. The child will use the same leotard for the entire study period (1 week) and changed only if dirty.
223623651|NCT00268918|DRUG|Docetaxel|Participants may continue receiving study drug as long as their disease does not worsen
223623652|NCT00268918|DRUG|PTK787|Participants may continue receiving study drug as long as their disease does not worsen
223623653|NCT00367328|DEVICE|1320nm Nd: YAG nonablative laser|a 4 mm piece of skin tissue (about the size of a pencil-head eraser) from the affected area. This procedure is called a punch biopsy and will be done to confirm your diagnosis. A culture swab similar to a Q-Tip will be used to wipe the affected areas during the first visit to determine any bacteria that may be present. A survey with questions will be given at the first visit, again after 3 months and at the last visit to measure the success of the treatment. Photographs will be taken prior to each treatment and one month following your last treatment. A laser, which is a very powerful light, will be used to treat half of the skin that is affected by your condition.
223623654|NCT04443634|PROCEDURE|Ultrasound Guided Adductor Canal Block|It will be performed at the midthigh level, approximately halfway between the superior anterior iliac spine and the patella, a high-frequency linear ultrasound (US) transducer 5-12 MHz probe. Underneath the sartorius muscle the femoral artery was identified, with the vein just inferior and the saphenous nerve just lateral to the artery. From the lateral side of the transducer a 10-cm, 18-gauge Tuohy needle (Braun Medical, Melsungen, Germany) was inserted in plane, through the Sartorius muscle. With the tip of the Tuohy needle placed just underneath the vasto-adductor membrane and lateral to the artery and the saphenous nerve, 20 ml local anesthetic mixture will be injected to expand the adductor canal. the volume of local anesthetic will be selected according to the studied group
223623655|NCT04443634|PROCEDURE|Ultrasound Guided Saphenous Nerve Block|"It will be performed at the intermuscular plane between the sartorius and the vasus medialis muscles at the lower third of the thigh.~The US probe will be positioned on the front of the lower part of the thigh immediately above the patella to see both the patella (hyperechoic curved line) and vastus medialis infront of it (closer to skin). The probe is then moved medially over the vastus medialis till we see the end of the muscle and we see an intermuscular plane between it and Sartorius muscle. A 20 guage spinal needle will be then passed in an in plane direction within the substance of vastus medialis muscle and then pass within the vastus medialis until it faces the intermuscular plane between VM muscle and Sartorius. Once the needle tip is located in close proximity to the target structures, gentle aspiration will be performed followed by 20 ml local anesthetic will be injected."
223761985|NCT04889625|DEVICE|Dailies Total 1® Multifocal Contact Lenses|Control Lens
224212987|NCT04156074|DIETARY_SUPPLEMENT|Vitamin D enriched (20 mcg/day) olive oil emulsion drink|Vitamin D enriched (20 mcg/day) olive oil emulsion drink. 30 mL drink daily
224212988|NCT04156074|DIETARY_SUPPLEMENT|Vitamin D enriched (20 mcg/day) coconut oil emulsion drink|Vitamin D enriched (20 mcg/day) coconut oil emulsion drink 30 mL drink daily
224212989|NCT04156074|DIETARY_SUPPLEMENT|Placebo coconut oil emulsion drink|Placebo coconut oil emulsion drink 30 mL drink daily
224212990|NCT04156074|DIETARY_SUPPLEMENT|Vitamin D supplement (20 mcg/day)|Vitamin D supplement (20 mcg/day) Pill consumed daily
224212991|NCT00443950|DRUG|Etanercept|
224316506|NCT01686230|OTHER|acupuncture|In each session, we treat bilaterally, 3 times a week and 2 days off a week, each patient in the acupuncture treatment groups will receive 12 sessions of acupuncture treatment over 4 weeks. The whole study period is 20 weeks including 4-week baseline period,4-week treatment period, and 12-week follow-up period. we will investigate at 0 day,4week,8week,12week,16week after randomization。
224212992|NCT03638752|OTHER|Comprehensive education group|"The details of Comprehensive education are as follows:~1. introduce the purpose, method and function of breathing training and the whole process of gastroscopy;~2. instruct patients to take deep breath training, inhaling with his/her nose and exhaling with his/her mouth,~3. provide patients with a disposable dental biting device and repeat exercising deep breathing again until he/she is fully mastered,~4. inform patients to cooperate with the instructions issued by endoscopist and endoscopy nurse during the whole process of gastroscopy,~5. inform patients to inhale with nose and exhale with mouth when the gastroscope passes through the throat, then he/she should perform inhaling and exhaling with his/her nose until the end of the gastroscopy when the endoscopist ask to adjust the breathing method,~6. inform patients that there would be some normal physiological reaction when gastroscopy, such as throat discomfort and nausea/vomiting."
224212993|NCT04442373|DIAGNOSTIC_TEST|Rotational thromboelastometry|1.8 ml blood sample
223623656|NCT04443634|PROCEDURE|General anesthesia|"General anesthesia was induced by propofol 1-2 mg/kg fentanyle 100micg and laryngeal mask was inserted. Maintanace of anesthesia was performed by sevoflurane 2-3%.~Then the surgical procedure started. All patients had arthroscopic knee surgery( ACL repair) surgery under tourniquet control.~Immediately after end the surgical procedure, either ACB or combined ACB and saphenous nerve block distal to adductor canal were performed according to randomization."
223623657|NCT04443634|DRUG|Bupivacaine 20 ml|20ml bupivacaine 0.5%
223623658|NCT04443634|DRUG|Bupivacaine 30ml|30ml bupivacaine 0.5%
223623659|NCT04443634|DRUG|Bupivacaine 10ml|10ml bupivacaine 0.5%
223623660|NCT01638663|DRUG|Tolvaptan|15 mg pr day for 1 day
223623661|NCT01638663|DRUG|Placebo|1 tablet Unikalk 1 pr day for 1 day
223623662|NCT04085419|DRUG|Denosumab 60 MG/ML Prefilled Syringe [Prolia]|denosumab 60 mg subcutaneously every 6 months
223761986|NCT02135575|BEHAVIORAL|Spinning|After the baseline studies the pre and postmenopausal women will be randomized to spinning training groups and the intervention will last for 3 months. The spinning group will spin three times per week under guidance of a trained instructor. The training is heart rate monitored.
224212994|NCT00002774|DRUG|Tirapazamine|"Tirapazamine is a benzotriazine with selective cytotoxicity for hypoxic cells. Under hypoxic conditions, it undergoes a 1-electron reduction to form a cytotoxic free radical that poisons topoisomerase II and causes DNA breaks, chromosomal aberrations, and cell death.~Tirapazamine was administered on Days 1 and 22 prior to the administration of neoadjuvant cisplatin and on Days 43, 45, 47, 71, 73, and 75 within 1 or 2 hours prior to each simultaneous cisplatin dose.~Tirapazamine dose was as follows:~Level 1 - 300 mg/m2 during the induction phase and 160 mg/m2 during the simultaneous phase (n = 4)~Level 2 - 330 mg/m2 during the induction phase and 260 mg/m2 during the simultaneous phase (n = 4)~Level 3 - 300 mg/m2 during the induction phase and 220 mg/m2 during the simultaneous phase (n = 25)"
223761987|NCT06803680|DRUG|BGB-B455|Planned doses administered on specified days per protocol.
223761988|NCT06803680|DRUG|Chemotherapy|Administered in accordance with relevant local guidelines and/or prescribing information.
223761989|NCT03578510|DEVICE|Hemocontrol hemodialysis|Each participating patient underwent one standard hemodialysis and one hemodialysis with Hemocontrol in random order, both 4 hours in total duration. The Hemocontrol system guides the patients' blood volume along a predefined ideal relative blood volume trajectory, by continuously adjusting ultrafiltration volume and dialysate sodium concentration.
223761990|NCT03578510|DEVICE|Standard hemodialysis|Each participating patient underwent one standard hemodialysis and one hemodialysis with Hemocontrol in random order, both 4 hours in total duration. During standard hemodialysis, a constant ultrafiltration rate and dialysate conductivity was used.
223761991|NCT06086301|OTHER|PICTURE-THIS|Discharge plans include scheduling post-discharge appointments, community support referrals, transportation arrangements, and addressing identified gaps. Transition care includes 8 check-ins over 3 months post-discharge, focusing on assessing, troubleshooting, and celebrating transition successes, using phone or video. Telehealth-assisted 'warm hand-offs' will connect interventionists with home health and primary care teams during initial visits. '1st touch daytime troubleshooting' offers extra support between check-ins. Problem-solving rehabilitation will be continued from hospital to home, with 7-10 sessions over 3 months, including a home safety survey. A Post-ICU Caregiver Toolkit provides workbooks, training videos, and resources. Lastly, referrals for patient and caregiver social/mental health support are provided.
224212995|NCT00002774|DRUG|Cisplatin|The simultaneous chemoradiotherapy (CRT) regimen included cisplatin 20 mg/m2 administered 3 times per week.
224212996|NCT00002774|DRUG|5-fluorouracil|"100 mg/m2 per day on Days 1 and 22, and continuous infusion (CI) 5-FU at a dose of 1000 mg/m2 per day for 120 hours per cycle starting on Days 1 and 22.~The simultaneous chemoradiotherapy (CRT) regimen included continuous infusion (CI) 5-FU 600 mg/m2 per day for 96 hours per cycle in Weeks 1 and 5 of RT."
223761992|NCT06086301|OTHER|Enhanced Usual Care|Enhanced Usual Care (EUC) control group will receive: (1) Patient and Family Re-sources published by the SCCM for PICS prior to hospital discharge; (2) ongoing assessments on the same schedule as the PICTURE-THIS intervention; (3) referral for urgent or emergent issues identified during assessments. The investigators will not provide the URL for the Post-ICU Caregiving Toolkit but the investigators will not restrict its access either. This control design balances 3 goals: 1) masking participants to group allocation; 2) responding ethically to harm/distress; 3) maintaining group separation to optimize efficacy testing of PICTURE-THIS.
223623663|NCT04085419|DRUG|Zoledronic Acid|zoledronic acid 5 mg intravenously once a year
223623664|NCT02780401|OTHER|Laboratory Biomarker Analysis|Correlative studies
223623665|NCT02780401|BIOLOGICAL|pUMVC3-IGFBP2-HER2-IGF1R Plasmid DNA Vaccine|Given ID
223623666|NCT02780401|BIOLOGICAL|Sargramostim|Given ID
223623667|NCT00621374|BEHAVIORAL|Cognitive Behavioral Therapy (CBT) +Hypnosis (HYP)|There is also the possibility that the two treatments together may be even more helpful than either one alone. Because some of the patients in this study will get both CBT and self-hypnosis, we will be able to determine if each one facilitates the efficacy of the other. If the patients treated in this study report benefits, as we expect they will, then this will encourage us to design and complete a larger study to better understand how patients with MS would benefit from these treatments.
224212997|NCT00002774|RADIATION|Radiotherapy (RT)|"During the CRT regimen, RT was given within 3 hrs of the tirapazamine infusion. The dose for the parallel opposed fields was 2 Gy/fraction/day given 5 dys/week up to a total dose of 66-70 Gy at the target lesion. The dose to the supraclavicular region was 50 Gy at a depth of 3 cm, delivered in 25 fractions. Supervoltage photons (≥4 megavolts) were used to treat both locations.~After 50 Gy were delivered to the primary site and regional lymph nodes, all sites were reassessed for clinical response by physical exam, direct fiber optic evaluation, and radiographic imaging (CT or MRI).~Subjects with a CR at both the primary site and the neck completed RT treatment to a total dose ≥66 Gy to the primary site and the involved lymph node(s). Subjects with a CR at the primary site but a partial response (PR) at the neck completed RT treatment to the primary site followed by neck dissection. Subjects with a PR at the primary site stopped radiation at 50 Gy and underwent salvage surgery."
224212998|NCT02746029|OTHER|Clinical examination|
224212999|NCT03568526|OTHER|Educational Intervention|Attend a therapy session
224213000|NCT03568526|BEHAVIORAL|Exercise Intervention|Complete exercise
223623668|NCT00621374|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|"One treatment module is we will study is called cognitive restructuring or cognitive-behavior therapy (CBT). In this treatment, people learn to identify negative thoughts that make them feel bad or anxious. Such negative thoughts lead to feelings of frustration and anxiety, and can even increase the experience of pain, because they cause a person to focus more on pain. With CBT, people learn to identify and stop these thoughts, and then replace them with more reassuring ones. When they do this, they feel more relaxed and focus less on their pain. As a result, they often say that they feel much better and are less aware of pain."
223623669|NCT00621374|BEHAVIORAL|Self-Hypnosis Training (HYP)|Self-hypnosis (HYP) is another strategy that people can learn to manage pain. With this treatment, people learn to enter a state of focused attention, and then change how they experience pain. Although we do not yet know how hypnosis works, research has repeatedly shown that the effects are real; when people report decreases in pain with hypnosis, scans and images of the brain's activity show decreases in the parts of the brain that process pain information. With hypnosis, people are not just pretending to feel less pain, they actually do feel less pain.
223623670|NCT00621374|BEHAVIORAL|Education Control (CONT)|The CONT condition for this study will include lectures that are interactive and are compelling and informative enough to be both (1) credible as an attentional control condition and (2) perceived as helpful to subjects. The CONT condition will not, however, include instructions in making specific cognitive or behavioral changes related to pain management. Thus, it could control for non-specific factors related to behavioral treatment, but will not impact the primary outcome measure (pain).
223623671|NCT01103167|BEHAVIORAL|control of ultrafiltration|During the interventional period, dry weight of patients will be adjusted according to the results of body composition.
223623672|NCT04233008|DEVICE|Foley catheter length|see arm description
223623673|NCT03707795|DRUG|Betamethasone sodium phosphate/betamethasone acetate (Celestone® Soluspan®), 30 mg IM once a day for four days|Participants will be given four IM injections throughout the study
223623674|NCT01479101|OTHER|MammaPrint 70-gene expression profile|
223623675|NCT01479101|OTHER|BluePrint 80 gene expression profile|
224213001|NCT03568526|OTHER|Quality-of-Life Assessment|Ancillary studies
224213002|NCT03568526|OTHER|Questionnaire Administration|Ancillary studies
223623676|NCT01991392|DEVICE|Nasogastric tube|For nasogastric decompression.
223623677|NCT01991392|DEVICE|No nasogastric tube|For nasogastric decompression.
223623678|NCT01235091|BEHAVIORAL|NIDA Cooperative Agreement Standard Intervention plus HIV/STD testing|At the end of Baseline Session I, HIV pre-test counseling, per the NIDA Cooperative Agreement, was delivered, along with education about STD prevention, and biological samples were collected to test for HIV, Hepatitis C, syphilis, chlamydia and gonorrhea. At Baseline Session II, HIV post-test counseling was conducted and women were given their random group assignment.
223623679|NCT01235091|BEHAVIORAL|Standard Intervention plus Well-Woman Exam|At the end of Baseline Session I, HIV pre-test counseling, per the NIDA Cooperative Agreement, was delivered, along with education about STD prevention, and biological samples were collected to test for HIV, Hepatitis C, syphilis, chlamydia and gonorrhea. At Baseline Session II, HIV post-test counseling was conducted and women were given their random group assignment. This group was assigned to additionally receive a well-woman examination within seven days.
223761993|NCT06086301|BEHAVIORAL|Run-In Phase|All participants receive a Run-In Phase during the acute critical illness hospitalization. It consists of 3 inpatient study visits: (1) health and social screening; (2) planning for rehabilitation; (3) discharge education and training.
223761994|NCT04671810|BIOLOGICAL|Elizaria®|Elizaria® will be prescribed by the Physician according to the actual SMPC.
223761995|NCT02459977|DRUG|Basiliximab|Basiliximab induction therapy
224213003|NCT03568526|OTHER|Survey Administration|Ancillary studies
224213004|NCT04870931|PROCEDURE|TEM / TEM-ESD|Transanal local excision of a rectal tumour as a conventional, full-thickness TEM or submucosal dissection as TEM-ESD
224213005|NCT01305265|DEVICE|cuff manometer|endotracheal tube cuff will be inflated to 22-26 cm H20 using cuff manometer
224213006|NCT00063596|DRUG|Vitamin A supplementation|
224213007|NCT04440163|BIOLOGICAL|MenABCWY|N meningitidis groups A, B, C, W, and Y vaccine
224213008|NCT04440163|BIOLOGICAL|Saline|Placebo
224213009|NCT04440163|BIOLOGICAL|Trumenba|Bivalent recombinant lipoprotein 2086 vaccine
224213010|NCT04440163|BIOLOGICAL|MenACWY-CRM|Meningococcal group A, C, W-135, and Y conjugate vaccine
224213011|NCT04742816|DIAGNOSTIC_TEST|IHX-CL measurements|The distribution of measured IHX-CL values and other continuous variables will be assessed to ensure a parametric distribution.
224213012|NCT04742816|DRUG|Iohexol|Iohexol clearance measurement
224213013|NCT05990647|DIAGNOSTIC_TEST|Dynamometric tension assessment|"Tension dynamometry was carried out using the Back-Check 600 diagnostic complex by Dr.WOLFF® (GmbH, Germany). The dynamometric stress assessment included tasks for flexion and extension of the body. The functional assessment of the abdominal wall muscles was assessed when preparing the patient for surgery (1-10 days before AWR-abdominal wall reconstruction) and 6 months after AWR."
224213014|NCT05990647|DIAGNOSTIC_TEST|Postural balance|"Postural balance was assessed using raster photostereography and baropodometry on the DIERS diagnostic complex by Formetric-4D (GmbH, Germany). When analyzing the topography of the optical field, muscle imbalance is revealed in the form of lateral deviation and inclination of the trunk and pelvis, as well as the values of the angle of kyphosis and lordosis. When conducting baropodometry, the level of displacement of the pressure area on the feet of patients in a static and dynamic position was assessed. Diagnosis of postural balance in patients with incisional ventral hernia was performed a few days before surgical treatment and 6 months after AWR."
224213015|NCT05990647|DIAGNOSTIC_TEST|Assessment of the hernia defect size|"Parameters of the hernial defect, including the volume of the hernial sac, the diameter of the hernial orifice, the ratio of hernia volume to the abdominal cavity volume, were performed using preoperative (1-10 days before AWR) multispiral computed tomography on a GE BrightSpeed 16 tomograph (General Electric©, USA)"
224213016|NCT05990647|DIAGNOSTIC_TEST|Physical activity of patients|"To analyze the physical activity of patients, the measurement of the number of steps was used. The measurements of steps and the amount of distance traveled were carried out using a physical activity monitor - a fitness bracelet MiBAND (China). Measurements were taken 10 days before AWR and within 6 months after AWR."
224213017|NCT01430182|DRUG|Methadone|0.2 mg\*kg-1 by actual body weight, administered over 10 minutes, once induction of anesthesia and endotracheal intubation are complete.
224213018|NCT01430182|DRUG|Morphine|0.2 mg\*kg-1 by actual body weight, administered over 10 minutes, once induction of anesthesia and endotracheal intubation are complete.
223623680|NCT01235091|BEHAVIORAL|Standard Intervention plus Well-Woman Exam and Peer-Delivered Intervention|At the end of Baseline Session I, HIV pre-test counseling, per the NIDA Cooperative Agreement, was delivered, along with education about STD prevention, and biological samples were collected to test for HIV, Hepatitis C, syphilis, chlamydia and gonorrhea. At Baseline Session II, HIV post-test counseling was conducted and women were given their random group assignment. This group was assigned to receive a well-woman exam within seven days along with four two-hour peer-delivered educational sessions, covering health and nutrition, stress and coping, substance abuse, and HIV/AIDS.
223623681|NCT04863170|PROCEDURE|orthognathic surgery|surgical intervention of the maxilla and / or mandible that includes orthodontic treatment before and after surgery
223623682|NCT05448495|OTHER|Posterior TAP block|Using high-frequency linear ultrasound probe, a total volume of 24 ml (20 ml isobaric bupivacaine 0.5% + 2 ml dexmedetomidine \[0.5 mcg\\kg\] + 2ml dexamethasone \[0.1mg\\kg)\] will be injected at the plane between internal oblique and transversus abdominis near the aponeurosis at the posterior axillary line.
223623683|NCT05448495|OTHER|ESPB|Using high-frequency linear ultrasound probe, a total volume of 24 ml (20 ml isobaric bupivacaine 0.5% + 2 ml dexmedetomidine \[0.5 mcg\\kg\] + 2ml dexamethasone \[0.1mg\\kg)\] will be injected at T9 erector spinae plane
223623684|NCT00416624|DRUG|darbepoetin alfa|
223623685|NCT00416624|DRUG|epoetin alfa|
223623686|NCT00416624|PROCEDURE|fatigue assessment and management|
223623687|NCT00416624|PROCEDURE|quality-of-life assessment|
223623688|NCT04190602|DEVICE|NeoChord Artificial Chordae Delivery System, Model DS1000|The intended use of the device is for the placement of artificial chordae when the natural chordae tendinae have become elongated or ruptured due to degenerative valve disease.
224213019|NCT01074021|DRUG|Nimotuzumab|"Nimotuzumab:(200mg/w,weekly, 7-8 weeks, one week before radiotherapy)~Radiotherapy:~IMRT: Nasopharynx: GTV 66-78. 2Gy,CTV1 60-64Gy,CTV2 54-60Gy.30-34 times, 2.20-2.30Gy/time,once a day, 5 days/w, 6-7 weeks. Neck: lymph node positive, GTVn 60-70Gy, once a day, 5 days/w, 6-7weeks; lymph node negative, CTVn50-55Gy, once a day, 5 days/w, 6-7 weeks.~CRT: Nasopharynx, 70-(76-80)Gy, 35-(38-40)times, 2Gy/time, once a day, 5 days/w, 6-8weeks. If disease residual when radiotherapy finished could increase the dose appropriate. Neck: lymph node positive, 64-70 Gy, 32-35 times, 2 Gy/time, once a day, 5 days/w, 6-7 weeks; lymph node negative, 50-56 Gy, 25-28 times,2 Gy/time, once a day, 5 days/w, 5-6weeks cisplatin~Chemotherapy:~Cisplatin (100 mg/m2,1 time/21d, 3 times，on days 2, 23, 44 during the radiotherapy)"
224316507|NCT01686230|DRUG|Basic treatment|"Each group in the basic treatment，Foundation treatment including health education and basic drug therapy.~We recommend lifestyle modification for all patients. Modifications include increasing exercise; limiting alcohol consumption; and weight loss; quit smorking etc.~Basic medication： Aspirin: 100mg qd; Metoprolol：25mg bid; Ramipril:5mg qd; Atorvastatin:20mg qn."
224316508|NCT02493192|DRUG|pethidine and haloperidol injection|
223623689|NCT03147846|PROCEDURE|delayed cord clamping|delay of cord clamping for 60 seconds
223623690|NCT03147846|PROCEDURE|cord milking|active cord milking 5 times
223623691|NCT06260566|DRUG|N-Acetylcysteine|"This is a phase 1 study of tolerance of a novel delivery method of oral NAC medication in infants with biliary atresia. The study consists of two parts:~* Administering applesauce alone (lead-in): In study days 1-2, infants will receive one infant spoon (approximately ½ teaspoon) of plain applesauce by mouth twice a day. If the infant tolerates 3-4 of 4 total doses without emesis, the infant will progress to the final two days of the study.~* Administering applesauce plus NAC (for infants who tolerate applesauce in study days 1-2): In study days 3-4, infants will receive an individualized dose of powdered oral NAC mixed into one infant spoon of applesauce by mouth twice a day for a maximum of four doses of NAC medication. 4 doses will be trialed: 150 mg/kg/day, 240 mg/kg/day, 330 mg/kg/day, and 420 mg/kg/day using BOIN study design for dose escalation."
223623692|NCT01095640|DRUG|adapalene 0.3% topical gel|once a day, 84 days
223623693|NCT03876717|DRUG|Colesevelam Hydrochloride|Colesevelam is a sequestrant that binds bile acids in the intestinal lumen, the bile acids are then excreted with the feces. Colesevelam is registered for treating hypercholesterolemia but it is as other sequestrants (e.g. cholestyramine and colestipol) effective against bile acid diarrhoea.
223623694|NCT03876717|DRUG|Placebo oral capsule|Inactive placebo tablets over-encapsulated with DB caps AAA
223623695|NCT01019187|PROCEDURE|Quality-of-Life Assessment|Ancillary Studies
223623696|NCT01019187|OTHER|Questionnaire Administration|Ancillary Studies
223623697|NCT01019187|OTHER|Placebo|Given orally
223623698|NCT01019187|PROCEDURE|Fatigue Assessment and Management|
223623699|NCT01019187|PROCEDURE|Sleep Disorder Therapy|
223623700|NCT01019187|DRUG|Armodafinil|Given orally
223623701|NCT01019187|PROCEDURE|Quality-of-life assessment|Ancillary studies
223623702|NCT01019187|OTHER|Questionnaire Administration|Ancillary Studies
224213020|NCT01074021|DRUG|placebo plus chemoradiotherapy|"Placebo treatment:4 bottles/w,weekly, 7-8 weeks, one week before radiotherapy~Radiotherapy:~IMRT: Nasopharynx: GTV 66-78. 2Gy,CTV1 60-64Gy,CTV2 54-60Gy.30-34 times, 2.20-2.30Gy/time,once a day, 5 days/w, 6-7 weeks. Neck: lymph node positive, GTVn 60-70Gy, once a day, 5 days/w, 6-7weeks; lymph node negative, CTVn50-55Gy, once a day, 5 days/w, 6-7 weeks.~CRT: Nasopharynx, 70-(76-80)Gy, 35-(38-40)times, 2Gy/time, once a day, 5 days/w, 6-8weeks. If disease residual when radiotherapy finished could increase the dose appropriate. Neck: lymph node positive, 64-70 Gy, 32-35 times, 2 Gy/time, once a day, 5 days/w, 6-7 weeks; lymph node negative, 50-56 Gy, 25-28 times,2 Gy/time, once a day, 5 days/w, 5-6weeks cisplatin~Chemotherapy: Cisplatin (100 mg/m2,1 time/21d, 3 times，on days 2, 23, 44 during the radiotherapy)"
224213021|NCT03137082|DRUG|Guanfacine XR 3mgs/daily|Guanfacine 3mg tablet
224213022|NCT03137082|DRUG|Placebo (for guanfacine)|Sugar pill manufactured to mimic guanfacine tablets
224213023|NCT03047382|OTHER|AKI Care Bundle|Patients identified as high risk of AKI by the electronic clinical prediction model will be managed with a care bundle of best practice.
224213024|NCT00206466|DRUG|Taxotere|Docetaxel (Taxotere) 100 mg/m2 is to be administered on day 1. A core biopsy is to be performed one day after chemotherapy (day 2) and on days 8, 15 and 22. On day 22, after repeat core biopsy, a second cycle of docetaxel (Taxotere) chemotherapy (100 mg/m2) will be given. Docetaxel (Taxotere) will be given three-weekly for a total of four cycles. Primary surgery will then be conducted, if operable, following completion of neoadjuvant treatment. Adjuvant AC (doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2, every three weeks) for four cycles will then be administered. Adjuvant radiotherapy will be considered following completion of AC chemotherapy. Patients whose tumors were ER and/or PgR positive would be commenced on tamoxifen for five years after completion of AC chemotherapy.
224213025|NCT00206466|DRUG|Adriamycin/cytoxan|Adjuvant AC (doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2, every three weeks) for four cycles will then be administered. Adjuvant radiotherapy will be considered following completion of AC chemotherapy. Patients whose tumors were ER and/or PgR positive would be commenced on tamoxifen for five years after completion of AC chemotherapy.
224213026|NCT02768740|DRUG|Hydrocortisone hemisuccinate|In the 200-mg group, patients received an intravenous bolus of 50 mg of hydrocortisone every six hours for seven days associated with a continuous infusion of placebo for five days. In the 300-mg group, patients received an initial bolus of 100 mg of hydrocortisone followed by a continuous infusion of 300 mg per day for five days associated with a bolus of placebo every six hours for seven days.
224213027|NCT00544557|DRUG|Etanercept|The patients will be treated in accordance with the requirements of the labeling of etanercept in Germany. The dosage and duration of therapy is to be determined by the physician to meet the patients' individual needs for treatment.
224213028|NCT00214630|DRUG|rosuvastatin calcium|
224213029|NCT00214630|DRUG|atorvastatin|
224213030|NCT01535248|OTHER|Transthoracic Echocardiography|Patients undergoing ERCP will have surveillance with transthoracic echocardiography with exams occurring every 10 mins or more often if needed to evaluate for the presence of intra-cardiac air associated with ERCP insufflation.
224213031|NCT03782857|BEHAVIORAL|Intervention|Prevention of recurrent stroke, myocardial infarction and death Stepwise escalation of preventive medication Life style counselling including adherence to preventive treatment
223623703|NCT01019187|PROCEDURE|Fatigue Assessment and Management|
223623704|NCT01019187|PROCEDURE|Management of Therapy|
223623705|NCT01019187|PROCEDURE|Sleep disorder therapy|
223623706|NCT01019187|PROCEDURE|cognitive assessment|
223623707|NCT01019187|PROCEDURE|Quality of Life assessment|Ancillary Studies
223623708|NCT01019187|OTHER|Questionnaire Administration|Ancillary studies
223623709|NCT01019187|OTHER|Placebo|Given orally
223623710|NCT01019187|PROCEDURE|Fatigue assessment and management|
223623711|NCT01019187|PROCEDURE|Management of therapy and complications|
223761996|NCT02459977|DRUG|No basiliximab|No basiliximab induction therapy
223761997|NCT02459977|PROCEDURE|Kidney transplantation|kidney transplantation
223761998|NCT03000582|DIETARY_SUPPLEMENT|Creatine monohydrate|Creatine monohydrate (5.0 g creatine monohydrate, 1.5 g dextrose)
223761999|NCT03000582|DIETARY_SUPPLEMENT|Creatine nitrate-1|Creatine nitrate-1 (1.0 g creatine monohydrate, 0.5 g nitrate, 5.0 g dextrose)
224213032|NCT04091269|DEVICE|automatic adjustmen of inspiratory triger and cycling-off based on waveform and PSV with fixed Esence|The ventilators have a compunter drived funcation of automatic adjustmen of inspiratory triger and cycling-off based on waveform, IntelliCycleTM 2.0.
224213033|NCT06185712|BEHAVIORAL|Nurse-led disease management education|Nurse-led disease management education was applied to the intervention group
224213034|NCT02002117|OTHER|DNA mass|DNA mass spectrometry
224213035|NCT06502041|PROCEDURE|MARPE with MOP|mini-screw assisted rapid palatal expansion with micro-osteoperforation
224316509|NCT02493192|OTHER|birth ball|
223762000|NCT03000582|DIETARY_SUPPLEMENT|Creatine nitrate-2|Creatine nitrate-2 (2.0 g creatine monohydrate, 1.0 g nitrate, 3.5 g dextrose)
223623712|NCT01019187|PROCEDURE|Sleep disorder therapy|
223623713|NCT01019187|DRUG|Armodafinil|Given orally
223623714|NCT01019187|PROCEDURE|Cognitive Assessment|
223623715|NCT01019187|PROCEDURE|Quality of Life Assessment|Quality of Life Assessment
223623716|NCT01019187|OTHER|Questionnaire Administration|Ancillary Studies
223623717|NCT01019187|PROCEDURE|Fatifue assessment and management|
223623718|NCT01608711|BIOLOGICAL|AGS-1C4D4|Intravenous Infusion
223762001|NCT03000582|DIETARY_SUPPLEMENT|Placebo|Placebo (6.5 g dextrose)
223623719|NCT01608711|BIOLOGICAL|gemcitabine|Intravenous Infusion
223623720|NCT02660788|OTHER|Standard Reminder Postcard|
223623721|NCT02660788|OTHER|Family Physician Reminder Letter|
223623722|NCT00768989|DRUG|Atazanavir|Capsules, Oral, 300 mg, twice daily, 96 weeks
223623723|NCT00768989|DRUG|Raltegravir|Tablet, Oral, 400 mg, twice daily, 96 weeks
223623724|NCT00768989|DRUG|Atazanavir|Capsules, Oral, 300 mg, once daily, 96 weeks
223623725|NCT00768989|DRUG|Ritonavir|Capsules, Oral, 100 mg, once daily, 96 weeks
223762002|NCT03716934|DEVICE|Arctic Front Advance® balloon catheter|Cryoablation of bidirectional block of all pulmonary veins
224213036|NCT06502041|PROCEDURE|MARPE without MOP|mini-screw assisted rapid palatal expansion without micro-osteoperforation
224213037|NCT03205384|PROCEDURE|surgery|
224213038|NCT01362114|DRUG|SIHOGAYONGGOLMORYU TANG EXTRACT GRAN|three times a day, AC 30 min., 4 capsules taken each time (4capsules=2.5g), 8 weeks
223623726|NCT00768989|DRUG|Tenofovir/Emtricitabine|Tablet, Oral, 300-mg Tenofovir/200-mg Emtricitabine, once daily, 96 weeks
224213039|NCT01362114|OTHER|Placebo|three times a day, AC 30 min., 4 capsules taken each time (4capsules=2.5g), 8 weeks.
224213040|NCT03567915|OTHER|Evaluation of gastric volume and content|The gastric volume and gastric content are assessed at 4, 5, 6, 7, and 8 hours after eating a meal.
224213041|NCT00272337|DRUG|Aspirin|Dosage
224213042|NCT03105115|DRUG|fentanyl|intrathecal fentanyl will be added as adjuvant for spinal anesthesia using heavy bupivacaine, while dexmedetomidine will be infused intravenously during operation
224213043|NCT03105115|DRUG|bupivacaine only|heavy bupivacaine will be injected intrathecally during spinal anesthesia, without fentanyl, while dexmedetomidine will be infused intravenously during operation
224213044|NCT02651896|RADIATION|HypoIGRT|"Hypofractionated intensity modulated and image guided radiotherapy 60 Gy in 20 fractions over four weeks for the prostate gland to all groups.~For intermediate and high risk group: seminal vesicle will be included: 48 Gy in 20 fractions over 4 weeks (proximal third to half on physicians description).~Image guidance with cone beam CT will be mandatory before every treatment fraction."
223623727|NCT01753622|BEHAVIORAL|Exercise group|"Supervised physical conditioning program of three 55-60 minute sessions per week during whole pregnancy (from week 9 to 38). Each session consists of 25-30 minutes of cardiovascular exercise, 10 minutes of specific exercises (strength and balance exercises), and 10 minutes of pelvic floor muscles training.~Aerobic activity was prescribed at light to moderate intensity, aiming for 55-60 of maximal heart rate. All subjects wore a heart rate (HR) monitor (Polar FT7) during the training sessions to ensure that exercise intensity was light to moderate."
223623728|NCT02021201|DRUG|risperidone|Patients with schizophrenia will be treated for 10 weeks treatment with risperidone
223623729|NCT02021201|DRUG|Sertindole|Patients with schizophrenia will be treated for 10 weeks treatment with serindole
223623730|NCT06425861|DRUG|THB335 single dose|Single dose as oral capsule
223623731|NCT06425861|DRUG|Single dose placebo|Single dose as oral capsule
223623732|NCT06425861|DRUG|THB335 fasted/fed|Single dose fasted and fed as oral capsule
223623733|NCT06425861|DRUG|Placebo fasted/fed|Single dose fasted and fed as oral capsule
223623734|NCT06425861|DRUG|THB335 multiple dose|Multiple ascending doses oral capsule
223762003|NCT03716934|DRUG|Antiarrhythmic drug|The drug will be chosen based on the preference of the researcher / responsible physician and current clinical practice guidelines.
223762004|NCT03716934|DEVICE|Confirm RX heart monitor® (Abbott)|Is a subcutaneous implantable device that provides continuous monitoring of the heart rate for more than 3 years without any effect on cardiac function
223762005|NCT04135703|BEHAVIORAL|Risk Prevention Services + Housing|opioid and related prevention services in addition to 6 months of rental assistance
223762006|NCT04135703|BEHAVIORAL|Risk Prevention Services Only|opioid and related prevention services for 6 months
223762007|NCT05806216|DEVICE|EarliPoint Diagnosis|Diagnosis by the EarliPoint System: Evaluation for Autism Spectrum Disorder
223762008|NCT05806216|BEHAVIORAL|Clinically Certain Expert Clinician Diagnosis (CC-ECD)|Diagnosis by an expert clinician using gold standard developmental assessment tools.
224213045|NCT01020305|DRUG|Temsirolimus|"Temsirolimus is an inhibitor of the mammalian target of rapamycin (MTOR, aka HGNC:3942)~IUPAC name: (1R,2R,4S)-4-{(2R)-2-\[(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,27-dihydroxy-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-1,5,11,28,29-pentaoxo-1,4,5,6,9,10,11,12,13,14,21,22,23,24,25,26,27,28,29,31,32,33,34,34a-tetracosahydro-3H-23,27-epoxypyrido\[2,1-c\]\[1,4\]oxazacyclohentriacontin-3-yl\]propyl}-2-methoxycyclohexyl 3-hydroxy-2-(hydroxymethyl)-2-methylpropanoate"
224213046|NCT01020305|DRUG|Casodex (bicalutamide)|Casodex (bicalutamide) 50 mg/day PO
224213047|NCT00140998|DRUG|17 beta estradiol|
224213048|NCT00467818|DRUG|Omega 3 fatty acids|The study will start with low doses and based on the weight of the individual the dosage will be increased biweekly.
224213049|NCT00467818|OTHER|Placebo|Same dosage as that of omega 3 fatty acids
224213050|NCT01653483|DRUG|GSK573719|Novel Dry-Powder Inhaler
224213051|NCT01653483|DRUG|GSK573719matched-placebo|Novel Dry-Powder Inhaler
224213052|NCT04843176|DIAGNOSTIC_TEST|Prototype artificial intelligence algorithm|Developed by the University of Hong Kong
224213053|NCT04843176|DIAGNOSTIC_TEST|LI-RADS|The Liver Imaging Reporting and Data System (LI-RADS) was established to standardize the lexicon, interpretation and communication of radiological findings related to HCC
224213054|NCT02184494|DEVICE|pro5 AIRdaptive Power Plate (Badhoevedorp, The Netherlands)|"Subjects will be exposed to vertical vibration with a frequency and peak-to-peak displacement of 30 Hz and 1 mm, respectively, which provides a peak-to-peak acceleration of about 4.16 G.~Whole Body Vibration"
224213055|NCT01017029|DRUG|Everolimus|
224213056|NCT01017029|DRUG|Mycophenolate mofetil + Everolimus|
223623735|NCT06425861|DRUG|Multiple dose placebo|Multiple doses oral capsule
223623736|NCT03387670|DRUG|Simvastatin|"* One (1 = 40mg) simvastatin tablet once daily at night for 1 month~* Two (2 = 80mg) simvastatin tablets once daily at night, for the next 35 to 53 months"
223623737|NCT03387670|DRUG|Placebo|"* One (1) placebo tablet once daily at night for 1 month~* Two (2) placebo tablets once daily at night, for the next 35 to 53 months"
223623738|NCT02724358|PROCEDURE|TACE|iodized oil (5ml) + Pirarubicin (20mg)
223623739|NCT02724358|DRUG|Rg3|20mg, BID, maintained though Month 12.
223623740|NCT02724358|OTHER|TACE + Rg3|
223623741|NCT02724358|PROCEDURE|protective therapy|standard liver protective therapy
223623742|NCT04706715|OTHER|89Zr-DFO-REGN3767|Anti-LAG-3 PET imaging tracer
223623743|NCT04706715|DRUG|Cemiplimab|Cemiplimab 350 mg every 3 weeks with or without platinum-based chemotherapy.
223762009|NCT04811274|BIOLOGICAL|Blood collection|2 to 5 ml
223762010|NCT04811274|BIOLOGICAL|Bronchoalveolar lavage fluid collection|5 to 25 ml
223762011|NCT03757182|OTHER|Wearable activity monitor|Continuous monitoring of physical activity including step counts, sleep, heart rate, with consumer-based wearable activity monitor (Fitbit Charge HR)
224213057|NCT04426526|DEVICE|BTL 799-2|High power magnet system
224213058|NCT04934514|BIOLOGICAL|IAH0968|IAH0968 is an investigational product.
224213059|NCT04934514|DRUG|Gemcitabine|Gemcitabine 1000 mg/m\^2 intravenous infusion
224213060|NCT04934514|DRUG|Cisplatin|Cisplatin 75 mg/m\^2 intravenous infusion
224213061|NCT01702350|DRUG|GSK2251052|Oral formulation of an an antibacterial
224213062|NCT05934032|OTHER|observational, non-interventional|observational, non-interventional
224213063|NCT00718965|DRUG|AVE5530|one tablet in the evening with dinner
224213064|NCT00718965|DRUG|Placebo|one tablet in the evening with dinner
224213065|NCT02974374|DRUG|PF-06835919|Single or repeated, escalating dose
224213066|NCT02974374|OTHER|Placebo|Single or repeated, escalating dose
223623744|NCT04477408|OTHER|plantar sensory exercise group|"plantar sensitive exercises~Plantar sensitive exercises:~30 minutes / 3 days per week / 8 weeks Walking on different 4 different textured floors and hot floor (15 minute) Trying to recognize small objects with the soles of the feet (5min) Seated work with barbed ball and balance pad (5min) Massage to the sole of the foot with different textured fabrics (5min)"
224213067|NCT00136019|DRUG|SPM 927|
223623745|NCT06181526|DRUG|Aleeto|According to the groups, patients would be treated with Aleeto via intrathecal injection or intravenous injection, and the specific dosage and administration method of Aleeto will depend on the grouping.
224213068|NCT02350010|DEVICE|CT Angiography|"CTA Scan with the specified sequences below:~120 kVp, 360 mAs, 0.5 second/rotation, 0.75 mm thick with a pitch of 0.65. Coronal and sagittal multiplanar reconstructed images with 10.0-mm-thick images spaced by 3 mm.~Axial reformed images were 4 mm thick with 2-mm spacing. 90 mL of nonionic iodinated contrast (OPTIRAY 350) at 5 mL/s."
224213069|NCT00446264|PROCEDURE|islet transplantation|Islet transplantation consisted of up to three sequential fresh islet infusions within three months. Access to the portal vein was gained under general anesthesia by percutaneous catheterisation of a peripheral portal branch under ultrasound guidance or by surgical catheterisation of a small mesenteric vein.
224213070|NCT00446264|DRUG|daclizumab - sirolimus - tacrolimus|Immunosuppressive consisted of Tacrolimus, target through level at 3-6 ng/ml, Sirolimus, target through level at 12-15 ng/ml for three months and at 7-10 ng/ml thereafter. A five-dose induction course of Daclizumab 1mg/Kg was administered biweekly beginning one hour prior to the first infusion
224213071|NCT02056275|OTHER|Nutrition supplement + dietary counseling|Nutritionally balanced nutritional supplement providing 1.0 kcal/ml.
223623746|NCT06181526|DEVICE|intravenous injection|According to the groups, patients would be treated with Aleeto or placebo +100ml sodium chloride injection via intravenous injection, depend on the grouping
223513419|NCT05612295|BEHAVIORAL|MBPP|"MBPP program consist of three fundamental principles (i.e., attention monitoring, acceptance, sport-specific rationale) and six performance-related core mental attributes including three behavioral and three neurocognitive components.~Each session will start with a brief homework discussion and recap of the preceding session, and instructors will deliver a topic-related brief story or group activity to participants, followed by a theoretical introduction and practice of mindfulness. Finally, at the end of each session, instructors will guide participant to discuss mindfulness applications related to specific sports performances. At the end of the session, participants will be assigned homework to increase the effectiveness of MBPP, and participants will be encouraged to practice daily for at least 10-15 min between the sessions."
223623747|NCT06181526|DEVICE|intrathecal injection|According to the groups, patients would be treated with Aleeto or placebo + 8ml sodium chloride injection via intrathecal injection, depend on the grouping.
223623748|NCT04051359|OTHER|Low carbohydrate (130 g) diet|Isocaloric moderately reduced carbohydrate diet (RCD, reduced carbohydrate diet) (\~130 grams of carbohydrates)
223623749|NCT03798106|DRUG|Durvalumab, pazopanib|Durvalumab 1500mg IV 1hr q3weeks Pazopanib 800mg QD PO q3wwks
223623750|NCT04678583|PROCEDURE|Resection of colorectal liver metastases|Comparison of two liver surgery methods
223623751|NCT04532307|BEHAVIORAL|Standard of Care SOC|Research assistants refer the consenting participants to Isisekelo Sempilo adolescent and youth friendly services with HIV testing, treatment if positive and PrEP eligibility screening and offer if negative and family planning
224213072|NCT02056275|OTHER|Dietary Counseling|Dietary counseling provided at each study visit by study dietitian.
224213073|NCT04801979|DIAGNOSTIC_TEST|Incremental Step Test|"Performance of the incremental step test (number of steps) for the assessment of exercise capacity. The step test will be designed according to the characteristics of other validated field tests - the walking tests (6-minute walk test and the incremental shuttle walking test) The step test will be performed on a 20 cm tall, single-step device with no handles. The criteria for stopping the test will be the same as described in standard operating procedures for the walking field tests, with the addition of the inability to follow the work rate for a period of 10 seconds.~The main outcome of the test will be the highest number of steps and work rate achieved."
224213074|NCT00398359|BEHAVIORAL|Motivational Interviewing (physicians)|Identifying and referring children with BMI \>93%.
224213075|NCT00398359|BEHAVIORAL|Behavior Modification (families)|Group meetings and individual family meetings based on behavior modification for healthy lifestyle changes.
224213076|NCT03619499|DEVICE|non invasive ventilation|patients who will fulfill the criteria of severe bronchiolitis will be connected to non invasive ventilation including continuous positive airway pressure via nasal prongs or nasal mask. Mode of ventilation, inspired oxygen levels, oxygen saturation, respiratory rate, and blood gas values from arterial samples prior to and after 2 and 4 hrs of ventilation or nearest time, will be documented.
224213077|NCT04025970|GENETIC|Circulating tumor cell and circulating tumor DNA test|Patient stratification based on presence or absence of suspicious findings of cells and DNA
224213078|NCT03372499|DIETARY_SUPPLEMENT|diet management strategy for encephalopathy|diet management strategy for encephalopathy means diet management strategy from the nutritional management consensus of hepatic encephalopathy.
224213079|NCT02753400|DRUG|emixustat hydrochloride|Tablet for oral administration
224213080|NCT02753400|OTHER|Placebo|Placebo tablets for oral administration contain only inactive ingredients
224213081|NCT01824771|OTHER|Plasma lactate were measured|Three different doses (20 ml/kg/h, 35 ml/kg/h and 45 ml/kg/h) of CVVH were applied to critically ill patients who experiencing CVVH. Each dose of CVVH was sequentially gave to each patient and lasted for 30 minutes separately
224213082|NCT02796196|OTHER|Medical Chart Review|Review of medical chart
224213083|NCT02796196|DEVICE|Monitoring Device|Wearable physical activity monitoring device
224213084|NCT02796196|PROCEDURE|Physical Therapy|Undergo primarily self-directed physical therapy
224213085|NCT01415921|DRUG|Pyridostigmine Bromide|15, 30, and 60 mg tabs, 1 tab every 8 hours for 10 weeks. Forced titration protocol increases dose at 2 week intervals from 15 to 30 to 60 mg as tolerated. Continue maximally tolerated dose for 4 weeks and then downtitrate at weekly intervals (60 to 30 to 15) and then discontinue.
224213086|NCT01815021|DIETARY_SUPPLEMENT|amorphous calcium carbonate|
224213087|NCT01815021|DIETARY_SUPPLEMENT|crystalline calcium supplements|
224213088|NCT00600288|DRUG|diquafosol tetrasodium Ophthalmic Solution, 2%|1-2 drops administered in each eye 4 times a day for 6 weeks
224213089|NCT00600288|DRUG|Non-preserved saline solution (Placebo)|1-2 drops administered in each eye 4 times a day for 6 weeks
224213090|NCT00377728|DRUG|GSK256066|
224213091|NCT04980521|OTHER|The radon app|Participants will be asked to use the radon app.
224213092|NCT04980521|OTHER|Print brochure|Participants will receive print brochures.
224213093|NCT03440203|OTHER|difficult activities of daily living in each group|Compare the severity of pain by the severity of diabetic peripheral neuropathy. Compare the difficulties in ADLs in three group of diabetic patients
224213094|NCT02660385|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|This behavioral intervention includes strategies for modifying thoughts, cognitions and behaviors regarding sleep provided by a therapist in a group format.
223513420|NCT05612295|BEHAVIORAL|Self-talk|self-talk sessions include: Session 1 \& 2. The concepts, types, and the importance of self-talk will be introduced; Session 3. Researchers, coaches and the athletes will work together to design syntactically recognizable, concise, and clear sport-specific instructional scripts for specific sports performance (e.g., running); Session 4. practice of sport-specific instructional self-talk; Session 5. researchers, coaches and the athletes will work together to design syntactically recognizable, concise, and clear sport-specific motivational self-talk scripts for specific sports performances; Session 6. practice of sport-specific motivational self-talk; and Session 7 \& 8. general practice for learned self-talk techniques.
223513421|NCT00506311|DRUG|Fibrin Sealant|Tisseel applied externally to the dissected groin area.
223513422|NCT04038008|DRUG|Fluconazole|Fluconazole is manufactured by Pharmtechnology LLC, Republic of Belarus. Each tablet contains 200 mg of fluconazole.
223513423|NCT04038008|DRUG|Diflucan®|Diflucan® is manufactured by Fareva Amboise, France (MAH: PFIZER PHARMA PFE GmbH, Germany). Each hard capsule contains 200 mg of fluconazole.
223513424|NCT06300632|OTHER|geriatric locomotive syndrome|Elderly individuals will be included in the study. Before each elderly person starts the study, they will be informed about the content of the study and they will read and sign the consent form stating that they participate in the study voluntarily. Socio-demographic data (age, body mass index, and family history, fall history, ) of all individuals participating in the study will be recorded.Within the scope of the evaluation, locomotive syndrome evaluation will be made through a survey. Fear of movement will be evaluated with the Tampa kinesiophobia scale, your physical activity level with the physical activity scale for the elderly, your physical performance with the short physical performance battery, your fatigue level with the fatigue severity scale, and your cognitive functions with the Montreal Cognitive Assessment Scale.
223513425|NCT01978015|DRUG|travoprost and timolol maleate fixed combination|travoprost 0.004% and timolol maleate 0,5%, 1 eye drop at 8p.m. for 6 months
223513426|NCT01978015|DRUG|latanoprost and maleate timolol fixed combination|Latanoprost 0.005% and timolol maleate 0,5%, 1 eye drop at 8 p.m for 6 months
223513427|NCT01978015|DRUG|bimatoprost and timolol maleate fixed combination|bimatoprost0.03% and timolol maleate 0,5%, 1 eye drop at 8 p.m for 6 months
223513428|NCT01978015|DRUG|dextran and hypromellose|Dextran 70 and hypromellose, lubricant eye drop at 8 a.m and 8 p.m for 6 months
223623752|NCT04532307|BEHAVIORAL|SRH enhanced Isisekelo Sempilo|Self-collected vaginal and urine samples are collected at enrolment. Research assistants then provide an Isisekelo Sempilo clinic referral appointment for results, treatment, HIV testing, sexual health, fertility, and family planning counselling, including the personal benefits of ART and Undetectable=Uninfectious among those infected, and PrEP for those eligible and who are negative.
224213095|NCT02660385|BEHAVIORAL|Self-Management Education for Heart Failure|This is an educational education designed to teach patients about self-management their heart failure. It includes information on medications, lifestyle, cardiac devices, diet, and when to seek assistance from a health care provider.
224213096|NCT02287337|PROCEDURE|Manipulation|High velocity low amplitude thrust joint manipulation to cervical spine facet joints
224213097|NCT02287337|PROCEDURE|Exercise|Therapeutic exercises to the cervical, thoracic and scapular musculature
224213098|NCT01132456|DEVICE|Drug eluting stent treatment|Endeavor RESOLUTE Zotarolimus-Eluting Coronary Stent Implantation
224213099|NCT00154037|DRUG|Pioglitazone (drug) and/or candesartan (drug)|
224213100|NCT02883309|OTHER|intradialytic physical training program|Nine patients participated in the experimental group in a combined training program, which lasted 12 weeks with a frequency of 3 times a week, the training sessions were carried out within each dialysis session during the first 2 hours of the dialysis treatment, the working session involved a warm up period, aerobic exercise with pedals, or strength exercises based on free weight depending on the training stage. The Borg scale and the heart rate reserve were used to control the training intensity. The disability level was evaluated at the beginning and the end of the study through the World Health Organization Disability Assessment Schedule II, the aerobic capacity was evaluated through the six minute walk and the limbs strength was evaluated through a dynamometer.
224213101|NCT01527825|BIOLOGICAL|Trivalent influenza vaccine (seasonal)|"Single 0.5ml dose of Southern hemisphere 2012 TIV, formulation containing:~* An A/California/7/2009 (H1N1)pdm-like virus~* An A/Perth/16/2009 (H3N2)-like virus\*~* A B/Brisbane/60/2008-like virus \* A/Wisconsin/15/2009 and A/Victoria/210/2009 are A/Perth/16/2009-like viruses for use in the 2012 Southern Hemisphere winter. This vaccine is the same as the vaccine used for the 2011 Southern hemisphere influenza season."
224213102|NCT01527825|BIOLOGICAL|Normal saline|0.5ml normal saline will be used as 'placebo' vaccine to maintain blinding
224213103|NCT01830920|DRUG|THR-184|THR-184 is a synthetic oligopeptide administered intravenously.
224213104|NCT01830920|DRUG|Placebo|A normal saline solution identical in appearance to the active drug solution
224213105|NCT01313728|DRUG|Dapsone plus Tretinoin Gel|Dapsone gel, followed by tretinoin gel one hour later, applied once daily to the assigned side of the face for 2 weeks
223623753|NCT04532307|BEHAVIORAL|Peer-support (Thetha-Nami)|The research assistants refer the participant to a Thetha Nami peer-navigator in their community. Peer navigators will assess their health, social and educational needs, provide mentorship, and help them access the services they need. The peer navigator will facilitate attendance, adherence and retention at the Isisekelo Sempilo clinic.
223623754|NCT04532307|BEHAVIORAL|SOC + SRH + peer-support|A combination of interventions 2 and 3, to include both self-collected STI testing, nurse led testing and counseling, and referral to a Thetha Nami peer navigator to encourage clinic attendance and sexual health promotion.
223623755|NCT03549975|DRUG|Botulinum Toxin Type A 100 unit/Vial (Product)|Botulinum toxin type A injection followed by functional electrical stimulation
223623756|NCT02745197|DIETARY_SUPPLEMENT|Nutritional Supplement|Participants will take 2 capsules, containing the nutritional supplement, 3 times per day.
223623757|NCT02745197|DIETARY_SUPPLEMENT|Placebo|Participants will take 2 capsules, containing a placebo, 3 times per day.
223623758|NCT05267080|DEVICE|CLINIPORATOR|The CLINIPORATOR is used to perform percutaneous electrochemotherapy on liver tumours.
223623759|NCT04346095|DRUG|Oral Sedatives with or Without Analgesia|The participants will receive oral triazolam with topical proparacaine and sub-tenon's mixture of lidocaine and marcaine.
223623760|NCT04346095|DRUG|Intravenous Sedatives with or Without Analgesia|The participants will receive intravenous midazolam, propofol or fentanyl with topical proparacaine and sub-tenon's mixture of lidocaine and marcaine.
223623761|NCT00228280|PROCEDURE|Mineral Trioxide Aggregate (MTA)|retrograde rootfilling with MTA or smoothening of the orthograde root-filling, gutta-percha
223623762|NCT04271852|DEVICE|bio-feedback treatment|50 patients will treated with phenix u2 and phenix u4 treating equipment。
223623763|NCT04247139|OTHER|Kefir|commercial versus traditional kefir
223623764|NCT05677282|DRUG|Rifaximin 550 MG|Rifaximin 550 mg as a single dose administered orally.
223762012|NCT03653936|DEVICE|HITT device|Rebion has developed a noninvasive, handheld device that uses retinal polarization scanning (RPS) to rapidly assess eye fixation and retinal integrity in adults and children. RPS can automatically detect the fixation of the human eye with proprietary technology that uses a scanned annulus of polarized laser light to create a signature that confirms central fixation within seconds. RPS requires no calibration or imaging, and eye movement recordings are not required. The HITT device is a repurposed Pediatric Vision Scanner (PVS), Rebion's first commercial product which has passed all applicable safety and performance standards.
223762013|NCT04917146|OTHER|Self-administered questionnaires for relatives (caregivers=CG)|"Sociodemographic and medical information for the patient and the CG. SF36 questionnaire for the quality of life (physical, mental) of family CGs This assessment will be supplemented by specific questions relating to: physical health, emotional state, personal and leisure activities of the caregiver.~The CG's knowledge and representations of the disease : questions adapted from the Brief-IPQ disease representation questionnaire.~Questions will also focus on the caregiver's reactions to the patient's illness.~We have constructed a questionnaire to assess the main areas of aid in the context of SSc: emotional, domestic help, administrative, medical, for trave (16 items and an open question).~The CG Reaction Assessment-CRA questionnaire to assess the positive and negative dimensions of helping (24 items). It assesses five dimensions: self-esteem, financial impact, impact on health, impact on time and lack of family support.~The reason for the assistance provided."
223762014|NCT06301854|DRUG|TPN171H|10 mg/ time, as needed, it is recommended to take warm water within 0.5 to 4 hours before sexual activity.
223762015|NCT01968642|BEHAVIORAL|Educational Intervention|
224213106|NCT01313728|DRUG|Tretinoin Gel|Tretinoin gel applied once daily to the assigned side of the face for 2 weeks
224213107|NCT05789303|DRUG|Belantamab mafodotin|Cycles 1, 3, 5, 7, etc. (odd numbered cycles): 1.9 mg/kg IV on Day 1 (28-day cycles)
224213108|NCT05789303|DRUG|Carfilzomib|"Cycle 1: 20 mg/m2 on Day 1, then 56 mg/m2 on Days 8/15~Cycles 2-8: 56 mg/m2 on Days 1/8/15~Cycles 9+: 56 mg/m2 on Days 1/15"
224213109|NCT05789303|DRUG|Pomalidomide|3 mg Day 1-21 of 28-day Cycle
223623765|NCT05677282|DRUG|Azithromycin 500 MG|Azithromycin 500 mg as a single dose administered orally.
223623766|NCT05677282|DRUG|Loperamide|4 mg loperamide administered orally with study antibiotic (rifaximin or azithromycin). Additional loperamide to use as needed, but not to exceed 16 mg/day for 2 days as per licensed use (one 2 mg capsule after each looses stool).
223623767|NCT06147843|OTHER|Blood sample|Blood sample will be taken to identify Genomic, metabolomic, metabolic, neurofilaments, and inflammation markers associated to weight loss
223623768|NCT04218721|OTHER|InvolveMe|An eHealth application that allows participants to report symptoms and needs prior to out-patient visits at the hospital. The application creates a summary that allows patients to prioritize what is important to talk with their health care providers about. Health care providers can use the summary to prepare the consultation.
223623769|NCT06790420|DRUG|Rituximab Pfizer|For the acute therapy, Rituximab is administrated once a week up to 8 times and for maintenance therapy, it is administrated every 8 weeks up to 12 times
224213110|NCT05789303|DRUG|Dexamethasone|"Cycles 1-4: 40 mg Days 1/8/15/22~Cycles 5+: 20 mg Days 1/8/15/22"
224213111|NCT03726086|DIAGNOSTIC_TEST|laryngoscopy|A flexible camera (fiberoptic endoscope) is placed in the patient's nose to view the nose, throat, and airway.
224213112|NCT05795062|DRUG|apixaban|patients treated with apixaban
224213113|NCT05795062|DRUG|warfarin|patients treated with warfarin
224213114|NCT02558660|BEHAVIORAL|Education|Educational intervention about an existing SNAP healthy food incentive program
224213115|NCT02558660|BEHAVIORAL|voucher|$10 voucher to spend on produce at farmers markets
224213116|NCT00896701|OTHER|flow cytometry|
224213117|NCT00896701|OTHER|immunologic technique|
223623770|NCT06790420|DRUG|Rituxan|For the acute therapy, Rituximab is administrated once a week up to 8 times and for maintenance therapy, it is administrated every 8 weeks up to 12 times
223623771|NCT06366737|DEVICE|KILBON Appliance|palatal TAD assissted lingual appliance for en-mass retraction
223623772|NCT06366737|DEVICE|CAT appliance|palatal TAD assissted clear aligner
223623773|NCT03661723|DRUG|Pembrolizumab|Pembrolizumab is a drug (an antibody) that may treat cancer by working with the immune system
224213118|NCT00896701|OTHER|laboratory biomarker analysis|
224213119|NCT00002084|DRUG|Valacyclovir hydrochloride|
224213120|NCT00002084|DRUG|Acyclovir|
224213121|NCT00333073|DEVICE|Bulkamid|initial injection with option for second (if required)
224213122|NCT04310748|DRUG|Total Intravenous Anesthesia(TIVA)|"Ventilation of the patients was provided with a mixture of 40% oxygen and 60% air. Along with induction, propofol at a dose of 6-10 mg/kg/hour and remifentanil infusion at a dose of 0.3-0.4 mcg/kg/min were started for the maintenance of anesthesia. Drug concentrations were adjusted to maintain BIS values between 40-60 in the maintenance of anesthesia.~The MAP target was determined to be in the range of 50-65 mmHg. Blood was collected and stored to measure TAS, TOS, Catalase, Myeloperoxidase, Total Thiol, Native Thiol and Disulfide parameters before and after induction at 5,30,60 and 120 minutes. Hemodynamic data (HR, SBP, DBP, MAP, SpO2) and BIS values of the patients were recorded at 5-minute intervals. The extubation time was recorded. The surgical field opinion and satisfaction assessment were made by Boezaart Scoring and the survey presented to the surgeon, respectively. The patients were followed up for 30 minutes; numerical pain scores and nausea-vomiting scores were recorded"
224213123|NCT04310748|DRUG|Inhalation Anesthesia|"Ventilation of the patients was provided with a mixture of 40% oxygen and 60% N2O. As soon as mechanical ventilation started, sevoflurane was opened at a concentration of 2-3% with a MAK value of 1.1-1.3. Drug concentrations were adjusted to maintain BIS values between 40-60 in the maintenance of anesthesia.~The MAP target was determined to be in the range of 50-65 mmHg. Blood was collected and stored to measure TAS, TOS, Catalase, Myeloperoxidase, Total Thiol, Native Thiol and Disulfide parameters before and after induction at 5,30,60 and 120 minutes. Hemodynamic data (HR, SBP, DBP, MAP, SpO2) and BIS values of the patients were recorded at 5-minute intervals. The extubation time was recorded. At the end of the surgery, the surgical field opinion and satisfaction assessment were made by Boezaart Scoring and the survey presented to the surgeon, respectively. The patients were followed up for 30 minutes; numerical pain scores and nausea-vomiting scores were recorded."
224213124|NCT03456362|DEVICE|REPETITIVE TRANSCRANIAL MAGNETIC STIMULATION|theta burst stimulation (TBS) is a novel form of repetitive transcranial magnetic stimulation that mimics protocols inducing long-term potentiation (LTP) or long-term depression (LTD) in animal models. Whereas continuous TBS (cTBS) induces long-lasting inhibition of cortical areas, iTBS exerts the opposite effect, increasing cerebellar excitability
224213125|NCT00318266|DEVICE|Nuclear Matrix Protein 22 Urine sample kit|Urine sample obtained from patient will be tested with the NMP22 sample kit to see if it can detect bladder cancer.
224213126|NCT03628222|DEVICE|ENB-TBLB|"ENB Guidance: The iLungTM SuperNavigator system will be used, it comprises of iLungTM ENB system, location catheter and guide catheter. The guide catheter can supply a 1.9 mm working channel for biopsy tools.~The location catheter is inserted into the guide catheter beforehand, then both are introduced via the working channel of the bronchoscope. Under guidance of ENB system, the location catheter reaches the lesion, and actual distance is confirmed by the X-ray.~TBLB: Location catheter is retracted, then the biopsy forceps and brush was introduced, and pathologic specimens are obtained."
224213127|NCT03628222|DEVICE|X-ray-TBLB|Based on chest CT, the physician determines the lesion location. Under X-ray guidance, via the bronchoscope's working channel, the biopsy forceps and brush are introduced and pathologic specimens are obtained.
224213128|NCT05331846|BEHAVIORAL|the smell of breast milk|Smell of breast milk during endotracheal aspiration will reduce pain and stress
224213129|NCT05393765|BEHAVIORAL|Yönetebilirim|"Yönetebilirim is an interactive web-based program developed to improve the self-management skills of individuals with MS by supporting self-regulation under the leadership of nurses."
224213130|NCT03494205|DRUG|Urtica comp. gel|"Urtica comp. gel is a Swissmedic registered medication. The scope of application of Urtica comp. is an imbalanced, affected process of skin-regeneration, in particular when stemming from an overdose of heat or light.~It is applied in first and second-degree burn and scalding, sunburn, allergic and hyperergic (excessive) skin conditions (dermatoses), insect bites, abrasions and ulcers."
224213131|NCT03494205|DRUG|"institutional standard skin care Excipial-Hydrolotion"|"The institutional standard skin care Excipial-Hydrolotion is available to all patients"
224213132|NCT03876873|PROCEDURE|Head Rotation During Face Mask Ventilation|Participants will receive face mask ventilation in either a neutral head position (practice standard position) or a head rotation position (45 degree angle).
224213133|NCT03876873|DEVICE|Medline Top Valve Anesthesia Mask|Face mask used per standard of care to provide oxygen to subjects before surgical procedures.
224213134|NCT03358732|DEVICE|endometrial navigation one day before the embyo transfer using IUI catheter ,|one day before the actual ET, the participants, in the study group, were taken into the operating room with a moderately full bladder at 10 am. The patient was placed in the lithotomy position and a sterile speculum was inserted into the vagina. The cervix was cleaned with sterile swabs and sterile water, and a mock transfer was performed using a soft catheter (Wallace Intrauterine Insemination Catheter; Sims Portex Ltd., Hythe, Kent, UK). The catheter has an outer sheet with memory , to aid insertion, and a soft inner catheter with atraumatic tip. Under ultrasound guidance, only the soft inner catheter was introduced beyond the internal cervical os till it was 0.5 cm from the fundus. It was, then, gently withdrawn out of the uterus, and the speculum was removed.
223513429|NCT02167126|DEVICE|Kinesio Taping|"using the V technique, the knee was positioned at 45º of flexion, the origin of both tapes was located 10 cm below the anterior-superior iliac spine with one tape going laterally and one medially to the rectus femoris muscle belly, passing around the patella and finishing on the tibial tuberosity."
223513430|NCT02167126|DEVICE|Placebo Tape|"Micropore tape was applied using the V technique, the knee was positioned at 45º of flexion, the origin of both tapes was located 10 cm below the anterior-superior iliac spine with one tape going laterally and one medially to the rectus femoris muscle belly, but because it is not elastic, the knee joint was not crossed and the end points were the medial and lateral aspects of the patella."
223513431|NCT04854499|DRUG|Magrolimab|Administered intravenously
223513432|NCT04854499|DRUG|Pembrolizumab|Administered intravenously
223513433|NCT04854499|DRUG|Docetaxel|Administered intravenously
223513434|NCT04854499|DRUG|5-FU|Administered intravenously
223513435|NCT04854499|DRUG|Cisplatin|Administered intravenously
223513436|NCT04854499|DRUG|Carboplatin|Administered intravenously
223513437|NCT04854499|DRUG|Zimberelimab|Administered intravenously
223513438|NCT06272929|DEVICE|doppler ultrasound|doppler US
224213135|NCT03547531|OTHER|Natural Tooth Brushing Method|Natural tooth brushing method is the method that is naturally used by the people with horizontal, rotary, or simple up and down motions and any position of the brush without any instruction of particular tooth brushing method.
224213136|NCT03547531|OTHER|Modified Circular Tooth Brushing Method|Modified Circular tooth brushing method is a combination of small circular motion of brushing with the position of the brush slightly reach underneath the gingival that are applied for each jaw in all facial surfaces and posterior lingual of tooth arches.
224213137|NCT01878500|DEVICE|Intraoperative stereotactic imaging with VectorVision|Surgeon will use intraoperative stereotactic imaging with VectorVision® Cranial Guided Image System by Brainlab Inc. to assist in bladder exstrophy closure. Prior to the operation a team consisting of pediatric urologist, pediatric radiologists, and a VectorVision rep will use pre-operative MRI to map out specific bony and muscular structures of the pelvic floor. Doing so will allow the pediatric urologist to use these markers intraoperatively to help guide his closure and also allow for future surgeons who use this technology to understand the correct planes to develop for the same surgery.
224213138|NCT02007187|DRUG|Danhong injection|A kind of injection made from two kind of Chinese herbs: salvia miltiorrhiza and safflower
224213139|NCT02007187|OTHER|Standard medical care|Standard medical care is in accordance with China Guideline for the diagnosis and treatment of unstable angina (UA) and non-ST-elevation myocardial infarction (NSTEMI) (2007) issued by Chinese Society of Cardiology of Chinese Medical Association
224213140|NCT02007187|DRUG|Placebo|0.9% saline added into 250ml 0.9% saline by an independent research nurse, sealed with brown bag in order to make the investigators and patients blinded, using brown infusion tube for infusion.
224213141|NCT02103634|DEVICE|NaF PET/MRI|
224213142|NCT02103634|DEVICE|NaF PET/CT|NaF PET/CT images will be obtained through fusion software. Researchers will fuse the Non AC and AC NaF images with the low dose CT obtained in the FDG PET/CT study.
224213143|NCT02103634|DEVICE|FDG PET/CT|
224213144|NCT03402126|OTHER|TPD RAMWare|TPD RAMWare injected into enrolled subject's Implantable cardioverter-defibrillator (ICD) device for use
223623774|NCT03661723|DRUG|Bevacizumab|"Bevacizumab (also known as Avastin) is designed to prevent or slow down the growth of cancer cells by blocking the growth of blood vessels."
223623775|NCT03661723|RADIATION|Re-irradiation|Radiotherapy destroys cancer cells using radiation aimed at a cancer from a machine
223623776|NCT05765682|OTHER|Mepivacaine Spinal|spinal block using 60mg of mepivacaine
223623777|NCT05765682|OTHER|Bupivacaine Spinal|spinal block using 10mg of bupivacaine
224213145|NCT02442752|DRUG|Dexlansoprazole|Dexlansoprazole capsules
224213146|NCT02117479|DRUG|Ruxolitinib|5 mg tablets to be administered by mouth twice daily (BID)
224213147|NCT02117479|DRUG|Placebo|5 mg tablets to be administered by mouth twice daily (BID)
224213148|NCT02117479|DRUG|Capecitabine|150 and 500 mg tablets to be administered by mouth twice daily (BID)
223623778|NCT06025916|DRUG|Tranexamic acid|20 ml of oral solution TA (100mg/ml)
223623779|NCT04237467|OTHER|No intervention|There was no intervention.
223623780|NCT05757843|DIAGNOSTIC_TEST|Signatera ctDNA test|The first mandatory ctDNA test will be done at screening for the bespoke ctDNA profiling. The next mandatory ctDNA test will be completed prior to the 5th cycle of consolidation Durvalumab. ctDNA testing will be repeated approximately every 4 weeks until two consecutive negative analyses occur. ctDNA testing will be otherwise discontinued after progressive disease or after up to 1 year of consolidation treatment per standard medical practice is considered complete, whichever occurs first.
223623781|NCT05757843|DRUG|Durvalumab|All subjects will receive consolidation Durvalumab approximately every 4 weeks. Durvalumab will be stopped after two consecutive negative ctDNA analyses occur.
223762016|NCT00885833|DRUG|Fludarabine, Busulfan, Thymoglobulin|fludarabine (40 mg/m2 once daily i.v. on days -8, -7, -6, -5, -4 \& -3) busulfan (0.8 mg/kg every 6 hours i.v. on days -6, -5, -4, \& -3) thymoglobulin (2.5 mg/kg once daily i.v. on days -8, -7, -6 for cord blood and on days -4, -3, -2 for bone marrow or mobilized peripheral blood)
223762017|NCT04893954|DIAGNOSTIC_TEST|Full Spine Radiography|Full Spine Radiography
223762018|NCT04893954|DIAGNOSTIC_TEST|Lumbar spine MRI|Lumbar spine MRI
223762019|NCT04374877|DRUG|CHS-388|CHS-388 is a fully human IgG1 antibody against IL-27. Inhibition of IL-27 with CHS-388 reduces STAT1 phosphorylation leading to increased pro-inflammatory (anti-tumor) cytokine secretion (e.g., IFN-g, TNF-a) and decreased expression of inhibitory immune checkpoint receptors (e.g., PD-L1, TIGIT, LAG3) on immune cells that may result in anticancer therapeutic activity.
223762020|NCT04374877|DRUG|Pembrolizumab|Pembrolizumab by intravenous (IV) infusion
224213149|NCT01283607|BEHAVIORAL|Digicoach|Digicoach is an e-health cognitive behavioral therapy with 4-12 weekly sessions especially developed for IVF women. Digicoach is facilitated by an e-therapist. The investment for the weekly home work assignments is about one and a half hour. Digicoach consist of different modules (e.g. stress reduction, acceptance). Digicoach starts before the hormonal down regulation as the start of the IVF procedure and ends three weeks after the pregnancy test.
224213150|NCT03354962|COMBINATION_PRODUCT|Nivolumab + Ipilimumab|Nivolumab + Ipilimumab alone (standard dosage regimen)
224213151|NCT03354962|COMBINATION_PRODUCT|Combined treatment schema|SBRT (recommended optimal dose) with Nivolumab + Ipilimumab (standard dosage regimen)
224213152|NCT03859570|DRUG|Pentoxifylline|Pentoxifylline (PTX) is a methylxanthine derivative that is a nonselective inhibitor of cyclic nucleotide phosphodiesterase (PDE). This enzyme, which has at least 5 subtypes, is responsible for inactivation of the important second messengers, Cyclic adenosine monophosphate (AMP) and cyclic guanosine monophosphate (GMP)
223623782|NCT05791253|OTHER|Pain management|Check whether pain management was carried out according to the recommendations of the French Society of Anaesthesia and Intensive Care (SFAR) and the French Society of Emergency Medicine (SFMU)
223762021|NCT04374877|DRUG|Toripalimab|Toripalimab by IV infusion
223762022|NCT03681457|DRUG|LJN452|Dose A single dose
223762023|NCT03473743|DRUG|Erdafitinib|Participants will receive erdafitinib orally.
224213153|NCT03859570|DRUG|Placebos|Placebo
224213154|NCT01333631|DRUG|Valproic acid|Valproic acid given concurrent with chemoradiotherapy for patients with pancreatic cancer
224213155|NCT01485705|OTHER|Retrospective examination by experts whether care given fo child admitted at the ICU for suspicion of bacterial infection (not nosocomial) was optimal or not|"When child is admitted at Intensive Care Unit (ICU) for suspicion of bacterial infection that is not nosocomial, data on child's infection and cares received, is completed on an electronic Case Report Form (e-CRF) by Doctor of ICU. Characteristic optimal or not of initial medical care is then determined by the independent experts blinded from issue of the care."
224213156|NCT00390169|BEHAVIORAL|Mindfulness Meditation-Based Stress Reduction|
224213157|NCT00390169|BEHAVIORAL|Supportive-Expressive Group Therapy|
224213158|NCT02846467|OTHER|Informed consent trough a portable video media|Information provided to patients using the mobile application (iURO app)
224213159|NCT02846467|OTHER|Written informed consent|Information provided to patient trough the traditional informed consent (written IC) for transurethral resection of bladder or prostate.
224213160|NCT01959230|DRUG|Brimonidine Tartrate|Ophthalmic solution to be applied as directed.
224213161|NCT01959230|DRUG|Vehicle|Ophthalmic solution to be applied as directed.
223623783|NCT06797024|DRUG|JY231 Injection|JY231 injection is administered intravenously and produces autologous CAR-T cells in the patient's body some time after infusion. A total of 3 dose groups were established to conduct a 3+3 dose-escalation study. The doses were divided into two categories: non-lymphodepletion and lymphodepletion pretreatment. The three dose groups for lymphodepletion included: 2×10\^8 TU, 4×10\^8 TU, and 8×10\^8 TU. The three dose groups for non-lymphodepletion included: 2×10\^9 TU, 4×10\^9 TU, and 8×10\^9 TU. The decision to perform lymphodepletion was based on the lymphocyte count and function during the patient screening period.
223623784|NCT04909710|OTHER|Mobile Game System for Potential Treatment of Developmental Delays|Mobile game system meant to generate valuable data for measuring progress and building novel artificial intelligence models while delivering impactful education for and treatment of children with developmental delays such as autism.
223623785|NCT06479343|DEVICE|Liquid Embolic System (Tonbridge)|Endovascular treatment with Liquid Embolic System (Tonbridge).
223623786|NCT06479343|DEVICE|Onyx Liquid Embolic System (Medtronic)|Endovascular treatment with Onyx Liquid Embolic System (Medtronic).
223623787|NCT04175730|DEVICE|Ultrasound and MRI|A single subsequent ultrasound guided prostate biopsy with MRI fusion
223623788|NCT04175730|DEVICE|Ultrasound|A single subsequent ultrasound guided prostate biopsy
223623789|NCT02519608|DRUG|Aspirin 100 mg|Patients with COPD and SCAD undergoing PCI and stent implantation will receive aspirin
223762024|NCT03473743|DRUG|Cetrelimab|Participants will receive cetrelimab by intravenous infusion.
223762025|NCT03473743|DRUG|Cisplatin|Participants will receive cisplatin by intravenous infusion as a part of platinum chemotherapy.
224213162|NCT01959230|DRUG|Sodium Fluorescein|For use as needed during the study for evaluating corneal damage.
223623790|NCT02519608|DRUG|Ticagrelor|Patients with COPD and SCAD undergoing PCI and stent implantation will receive according randomization aspirin + ticagrelor (loading dose 180 mg + maintenance 90 mg x2)
223623791|NCT02519608|DRUG|Clopidogrel|Patients with COPD and SCAD undergoing PCI and stent implantation will receive according randomization aspirin + clopidogrel (loading dose 600 mg + maintenance 75 mg)
224213163|NCT01959230|DRUG|Fluorescein Sodium and Benoximate Hydrocholoride Ophthalmic Solution USP|For use as needed during the study for intraocular pressure and dilated ophthalmoscopy.
224213164|NCT05284474|DIAGNOSTIC_TEST|soluble fms-like tyrosine kinase to placental growth factor ratio (sFlt-1/PlGF)|soluble fms-like tyrosine kinase to placental growth factor ratio (sFlt-1/PlGF) will be incorporated to the management of early-onset small fetuses (estimated fetal weight ≤10th percentile)
224213165|NCT00391937|DEVICE|Articular Surface Replacement (ASR) hip prosthesis|a DePuy ASR™ primary resurfacing femoral and acetabular component (DePuy International Ltd, Leeds, UK). The cement that will be used is one dose of DePuy SmartSet® GHV 40 gram, a high-viscosity cement with gentamycin (DePuy CMW, Blackpool, UK). Instrumentation includes standard ASR™ instruments and Ci™ Software for DePuy ASR™ System1.0.
223623792|NCT02760966|OTHER|Alcohol 70º|
223623793|NCT02760966|OTHER|Soap|
224213166|NCT05547100|DRUG|LYBALVI|5 mg Olanzapine/10 mg Samidorphan dose approved for use in treatment for schizophrenia and bipolar I disorder
224213167|NCT01444274|DEVICE|Obalon Gastric Balloon(s)|One or two balloons administered per patient
224213168|NCT00101205|DRUG|oxaliplatin|Given IV
224213169|NCT00101205|DRUG|etoposide|Given IV
224213170|NCT01453374|DRUG|VIVITROL 380mg|380 mg IM injection given once monthly
223623794|NCT01207700|BEHAVIORAL|CHW based intervention post ACS|CHW is trained and supervised to provide interventions that could improved adherence to post ACS care
223623795|NCT04149834|PROCEDURE|Group A (Test): Patients will receive NIPSA|patients received Non- incised papilla surgical approache
223623796|NCT04149834|PROCEDURE|Group B (Control): Patients will receive M-MIST|patients received Modified Minimally Invasive Surgical Technique
223623797|NCT03776864|BIOLOGICAL|Pembrolizumab|Given IV
223762026|NCT03473743|DRUG|Carboplatin|Participants will receive carboplatin by intravenous infusion as a part of platinum chemotherapy.
223762027|NCT04087122|DEVICE|Esophageal warming device (Attune Medical, Chicago, IL|Prospective, single center pilot stud
223762028|NCT05521204|DRUG|Olverembatinib|Given PO
223762029|NCT02433314|DRUG|SAGE-547|
223762030|NCT03628911|DEVICE|Tetanizing Burst Therapy|Tetanizing Burst Therapy tetanizes skeletal muscle with a brief burst of stimulation prior to ICD shock, thereby reducing muscular contraction due to the shock
224213171|NCT00195585|DRUG|Isovorin|
224213172|NCT00195585|DRUG|UFT|
224213173|NCT06452433|DRUG|gumarontinib|300 mg , qd ,po, expect 6 months.
224213174|NCT06452433|DRUG|third-generation EGFR-TKI (Osimertinib, Almonertinib or Furmonertinib)|According to the actual situation of patients. Take as recommended, expect 6 months.
224213175|NCT02744625|DRUG|Higher doses of vasopressor therapy for a MAP of 75 mmHg|
224213176|NCT02744625|DRUG|Lower doses of vasopressor therapy for a MAP of 65 mmHg|
224213177|NCT02744625|DRUG|Propofol for light sedation|Propofol for light sedation
224213178|NCT03631459|DRUG|Kanglaite Injection/Capsules|Kanglaite injection 200 mL, iv. gtt qd×7d or more, followed by Kanglaite capsule 0.45g×6 tablets qid po×14d as one cycle for at least 4 cycles
224213179|NCT00103103|DRUG|bortezomib|
224213180|NCT00103103|DRUG|fluorouracil|
224213181|NCT00103103|DRUG|leucovorin calcium|
224213182|NCT01201954|DRUG|sucrose|oral sucrose solution, 24%, 0,5 ml/kg, 2 minutes before start the suctioning sterile water, 0,5 ml/kg, 2 minutes before start the suctioning
223513439|NCT00107614|DRUG|DT PACE + Rituxan|INDUCTION PHASE DT PACE + Rituxan DT PACE + Rituxan + PBSC Collection Response Assessment TRANSPLANT PHASE Transplant 1 (MEL 200 (patients with \< 50% response to induction) OR MEL-DT PACE (Patients with \> 50% response to Induction) Transplant 2 (identical to the first, except patients with progressive or proliferative disease, will receive BEAM) MAINTENANCE PHASE Rituxan every 3 months x 1 year
223513440|NCT01267136|DRUG|Codeine with acetaminophen|Liquid codeine/acetaminophen (Capital® 5mL= 120mg acetaminophen/12 mg codeine) 0.72 mg/kg \[=0.3 mL/kg\] (max. 36 mg) PO Q6h, plus 0.72 mg/kg (max. 36 mg) PO Q3h pro re nata (PRN) (max. of 3 PRN doses/day)
223623798|NCT03776864|DRUG|Umbralisib|Given PO
223623799|NCT03074708|OTHER|3D visualization and 3D printing|From January 2016 to December 2018,the clinical data of 200 patients with the hepatobiliary and pancreatic diseases will be collected.All the patients received abdominal CT scanning and 3D reconstruction. Then we used the 3D reconstruction model and the 3D printed model based on the 3D reconstruction model in the operation planning and the operation.The clinical data include operative time, intraoperative blood loss,and postoperative complications after surgery.
223623800|NCT06524609|DRUG|Epigallocatechin-3-Gallate|After determining the optimal dose, the efficacy of EGCG was compared with that of a control group (75% alcohol).
224213183|NCT03155828|DEVICE|CPAP|Women with diagnosed obstructive sleep apnea will be treated using continuous positive airway pressure as per standard of care.
224213184|NCT00146237|DRUG|phenytoin|
224213185|NCT00309127|BEHAVIORAL|Multidisciplinary team care|
224213186|NCT01243866|OTHER|comprehensive dental treatment|Early treatment children were scheduled for comprehensive dental treatment over a 2-month period (from May to June 2007). All test children had their last dental treatment visit within the last 2 weeks of the second treatment month. The follow-up survey was scheduled for each child to be approximately 6-month after their dental last visit. This step was very important to make sure that all children were examined at exactly the same interval between end of treatment and when re-examined at the follow-up examination.
223513441|NCT01267136|DRUG|Tramadol suspension|Liquid tramadol 1.05 mg/kg \[=0.3 mL/kg\] (max. 52.5 mg) PO Q6h, plus 1.05 mg/kg (max. 52.5 mg) PO Q3h PRN (max. of 3 PRN doses/day).
223513442|NCT03823482|DRUG|Lidocaine|Administration of lidocaine 2% 4 mg/kg administered as regional anesthesia of the scalp prior to Mayfield frame placement and lidocaine 1% 40 mg topically to the throat prior to direct laryngoscopy and endotracheal intubation.
223513443|NCT01893814|DIETARY_SUPPLEMENT|Probiotics|
223513444|NCT01893814|DIETARY_SUPPLEMENT|Control|
223513445|NCT02755883|BEHAVIORAL|Physical activity plus positive affect|Subjects will be randomized to a physical activity goal and will receive the positive affect component.
223513446|NCT02755883|BEHAVIORAL|Physical activity plus education|Subjects will be randomized to a physical activity goal and will receive the educational component.
223513447|NCT02722330|DEVICE|Baha 5 SuperPower on Baha Attract System|The Investigational device involves the following parts: the sound processor unit, an actuator unit and a cable that connects the sound processor and actuator units. The actuator unit is attached to the Sound Processor Magnet (SP Magnet) of the Baha Attract System which is pulled towards the BIM400 Baha Implant Magnet that is fixated to the BI300 Implant. The actuator unit can also be connected to the Baha Softband via a snap coupling.
223513448|NCT00456911|BEHAVIORAL|Fat and carbohydrate controlled diet|
223513449|NCT05178654|DRUG|[14C]PF-07321332|Single oral dose of 300 mg \[14C\]PF-07321332 containing approximately 100 µCi \[14C\]PF-07321332 coadministered with 100 mg ritonavir.
223513450|NCT05426681|DRUG|GlyBURIDE Oral Tablet|"Enrolled patients will receive 12 doses of Glyburide starting within 8 hours of spinal cord injury. The dosing regimen involves an initial dose of 1.25mg followed by 11 consecutive doses of 0.625 mg every 6 hours. The total daily dose of Glyburide on Day 1, Day 2, and Day 3 will be 3.125 mg, 2.5 mg, and 2.5 mg respectively.~Intervention: Drug: Glyburide"
223513451|NCT02096380|DRUG|One cycle TPF induction chemotherapy for NPC|"One cycle TPF induction chemotherapy for NPC~Patients receive docetaxel (60mg/m2 on day 1), cisplatin (20mg/m2 on day 1-4) and fluorouracil (800mg/m2/d, continuous infusion, d1-4) every three weeks for single one cycle before the radiotherapy, then receive radical radiotherapy with IMRT and cisplatin (30mg/m2) every week for six cycles during radiotherapy.~A total dose of 70Gy in 30 fraction to PTV-P, 60Gy in 30 fraction to PTV-1 and 54Gy in 30 fraction to PTV-2."
223623801|NCT06524609|DRUG|Alcohol|After determining the optimal dose, the efficacy of EGCG was compared with that of a placebo control group (75% alcohol).
223623802|NCT00192881|DEVICE|Bx Sonic & Cypher stent from Cordis|
223623803|NCT04344808|DEVICE|Dynamic navigation system|The navigation system allows clinicians, using a specific software, to visualize the position of the surgical drill (tip location and shaft axis direction) on the reconstructed 3D image of the pre-acquired CBCT. The software guides the surgeon, in real-time, to the preoperative planned position.
223623804|NCT04344808|DEVICE|Freehand implant placement|Dental implants will be placed without any guidance once a virtually planning of the ideal position on the CBCT is done
224213187|NCT01243866|OTHER|Only emergency dental treatment|Regular treatment did not receive any dental treatment in the period when the early children were treated unless they had toothache or dental infection. In that case they were treated for the pain but did not have comprehensive dental treatment
224213188|NCT00720304|DRUG|docetaxel|Beginning on week 3, patients receive docetaxel IV over 1 hour once a week
224213189|NCT00720304|DRUG|erlotinib hydrochloride|oral erlotinib hydrochloride once daily for up to 2 years in the absence of disease progression or unacceptable toxicity
224213190|NCT00720304|GENETIC|fluorescence in situ hybridization|Patients undergo blood sample, tissue biopsy, mucosal scraping, and saliva collection at baseline and periodically during study. Samples are analyzed for markers of angiogenic activity (VEGF, sVEGFR-2, sKIT, ICAM, and PDGF), pharmacokinetic studies, gene expression profile, and human papilloma virus DNA by enzyme linked immunosorbent assay (ELISA), immunohistochemistry, fluorescence in situ hybridization (FISH), and PCR.
224213191|NCT00720304|GENETIC|polymerase chain reaction|Patients undergo blood sample, tissue biopsy, mucosal scraping, and saliva collection at baseline and periodically during study. Samples are analyzed for markers of angiogenic activity (VEGF, sVEGFR-2, sKIT, ICAM, and PDGF), pharmacokinetic studies, gene expression profile, and human papilloma virus DNA by enzyme linked immunosorbent assay (ELISA), immunohistochemistry, fluorescence in situ hybridization (FISH), and PCR.
224213192|NCT00720304|OTHER|immunoenzyme technique|Patients undergo blood sample, tissue biopsy, mucosal scraping, and saliva collection at baseline and periodically during study. Samples are analyzed for markers of angiogenic activity (VEGF, sVEGFR-2, sKIT, ICAM, and PDGF), pharmacokinetic studies, gene expression profile, and human papilloma virus DNA by enzyme linked immunosorbent assay (ELISA), immunohistochemistry, fluorescence in situ hybridization (FISH), and PCR.
224213193|NCT00720304|OTHER|immunohistochemistry staining method|Patients undergo blood sample, tissue biopsy, mucosal scraping, and saliva collection at baseline and periodically during study. Samples are analyzed for markers of angiogenic activity (VEGF, sVEGFR-2, sKIT, ICAM, and PDGF), pharmacokinetic studies, gene expression profile, and human papilloma virus DNA by enzyme linked immunosorbent assay (ELISA), immunohistochemistry, fluorescence in situ hybridization (FISH), and PCR.
224213194|NCT00720304|OTHER|laboratory biomarker analysis|Patients undergo blood sample, tissue biopsy, mucosal scraping, and saliva collection at baseline and periodically during study. Samples are analyzed for markers of angiogenic activity (VEGF, sVEGFR-2, sKIT, ICAM, and PDGF), pharmacokinetic studies, gene expression profile, and human papilloma virus DNA by enzyme linked immunosorbent assay (ELISA), immunohistochemistry, fluorescence in situ hybridization (FISH), and PCR.
223513452|NCT02096380|DRUG|Three cycles TPF induction chemotherapy for NPC|"Three cycles TPF induction chemotherapy for NPC~Patients receive docetaxel (60mg/m2 on day 1), cisplatin (20mg/m2 on day 1-4) and fluorouracil (800mg/m2/d, continuous infusion, d1-4) every three weeks for three cycles before the radiotherapy, then receive radical radiotherapy with IMRT and cisplatin (30mg/m2) every week for six cycles during radiotherapy.~A total dose of 70Gy in 30 fraction to PTV-P, 60Gy in 30 fraction to PTV-1 and 54Gy in 30 fraction to PTV-2."
224213195|NCT00720304|OTHER|pharmacological study|Patients undergo blood sample, tissue biopsy, mucosal scraping, and saliva collection at baseline and periodically during study. Samples are analyzed for markers of angiogenic activity (VEGF, sVEGFR-2, sKIT, ICAM, and PDGF), pharmacokinetic studies, gene expression profile, and human papilloma virus DNA by enzyme linked immunosorbent assay (ELISA), immunohistochemistry, fluorescence in situ hybridization (FISH), and PCR.
223513453|NCT04392362|DRUG|Adenosine|A vial of adenosine with 6mg
223513454|NCT05781750|DRUG|zetomipzomib|Subcutaneous injection of zetomipzomib
223513455|NCT05781750|DRUG|placebo|Subcutaneous injection of placebo
223513456|NCT00365820|DRUG|Tegaserod|
223513457|NCT05552573|BIOLOGICAL|low-dose LYB001|This vaccine is prepared through gene recombination and 3 doses of low-dose(30µg/0.5ml) LYB001 at the schedule of 0, 28, 56 days.
223513458|NCT05552573|BIOLOGICAL|Recombinant COVID-19 Vaccine (CHO Cell)|This vaccine is Positive-controlled vaccine and 3 doses (0.5ml) at the schedule of 0, 28, 56 days.
223513459|NCT05552573|BIOLOGICAL|high-dose LYB001|This vaccine is prepared through gene recombination and 3 doses of high-dose(60µg/0.5ml) LYB001 at the schedule of 0, 28, 56 days.
223513460|NCT04919473|BIOLOGICAL|Gene Therapy product:vMCO-I|The vMCO-I is an adeno-associated virus serotype 2-based vector carried multi-characteristic opsin (MCO) gene expression cassette
223513461|NCT02224079|DRUG|BIIB 722 CL|
223513462|NCT02224079|DRUG|Placebo|Hydroxypropyl-beta-cyclodextrin (HPβCD)
223513463|NCT03752073|DEVICE|Trans-cervical cervical balloon|Insertion of Foley Catheter
223513464|NCT03752073|DEVICE|Hygroscopic cervical dilator|Insertion of Dilapan-s
223513465|NCT03635866|DIAGNOSTIC_TEST|Fluciclovine PET/MRI|It is unknown how many negative MRFTBs of PI-RADS 4 lesions are false negative biopsies or false positive tests.
223513466|NCT01934231|DRUG|Amoxicillin-Potassium Clavulanate Combination|The drug is available in two sachets (CVA/AMPC Dry Syrup 0.505 g and CVA/AMPC Dry Syrup 1.01 g). CVA/AMPC Dry Syrup 1.01 g sachet contains 42.9 mg of Potassium Clavulanate and 600 mg of Amoxicillin Hydrate. It is a white to yellowish white powder and has strawberry flavor and it is white to yellowish white suspension when it is suspended before use.
223513467|NCT00534586|DRUG|Propofol|TCI 0.5 mcg/ml 1.0 mcg/ml
223513468|NCT00534586|DRUG|Remifentanil|continuous infusion 0.05 mcg/kg/min 0.15 mcg/kg/min
223513469|NCT00534586|DRUG|S-Ketamine|continuous infusion 0.25 mg/kg/h 0.50 mg/kg/h
223513470|NCT00534586|DRUG|Sevoflurane|via face mask 0.40 Vol% 0.80 Vol%
223513471|NCT06424119|BEHAVIORAL|Traditional Cardiac Rehabilitation|Patient must have a qualifying cardiovascular event and eligible for ICR. Once patient is randomized to TCR arm, they will attend 36 sessions of the program at one of three locations.
223513472|NCT06424119|BEHAVIORAL|Intensive Cardiac Rehabilitation|Patient must have a qualifying cardiovascular event and eligible for ICR. Once patient is randomized to ICR arm, they will attend 72 sessions of the program at one of three locations.
223513473|NCT06424119|OTHER|C2life® Food|Patient must have a qualifying cardiovascular event and eligible for ICR. Once patient is randomized to ICR arm with food, they will receive the food at the beginning of the second week of their respective program. Food will be delivered by mail weekly for a total of 11 weeks to the patient's home address.
223513474|NCT04733482|BEHAVIORAL|Cosmetic care|
223623805|NCT01950858|BIOLOGICAL|Weight reduction|
223623806|NCT03196908|DIETARY_SUPPLEMENT|Energy Drink Brand 1|Two 16-oz containers of Energy Drink Brand 1 consumed in 60 minutes
223623807|NCT03196908|DIETARY_SUPPLEMENT|Energy Drink Brand 2|Two 16-oz containers of Energy Drink Brand 2 consumed in 60 minutes
223623808|NCT03196908|OTHER|Placebo|Lime juice, water, and cherry flavoring
223623809|NCT01881191|OTHER|MRI|
223623810|NCT03452540|DRUG|1000mg DS102 (BID)|Participants assigned to the open label pilot phase received 1000mg DS102 (BID)for 28 days.
223623811|NCT00648336|DRUG|Mercaptopurine 50 mg|50mg, single dose fasting
223623812|NCT00648336|DRUG|Purinethol® Tablets 50 mg|50mg, single dose fasting
223623813|NCT02348476|OTHER|No Intervention|No study drug is administered in this study.
223623814|NCT00839189|BIOLOGICAL|Clinical Center Reference Endotoxin (CCRE)|Inhalation of 10,000 EU CCRE
223623815|NCT05075746|DEVICE|enVista Toric|enVista Toric IOL
224213196|NCT00720304|PROCEDURE|therapeutic conventional surgery|At 6-8 weeks after completion of chemoradiotherapy, patients with N2 or greater cervical lymph node involvement at baseline or with residual disease may undergo surgery.Patients with persistent disease during study therapy undergo salvage surgery 6-12 weeks after completion of chemoradiotherapy.
224213197|NCT00720304|RADIATION|intensity-modulated radiation therapy|radiotherapy (may be intensity-modulated) once daily for 8 weeks in the absence of disease progression or unacceptable toxicity.
224213198|NCT00720304|RADIATION|radiation therapy|radiotherapy (may be intensity-modulated) once daily for 8 weeks in the absence of disease progression or unacceptable toxicity.
224213199|NCT04820335|BEHAVIORAL|Structured External Memory Aid Treatment (SEMAT)|"During the 7 weeks of treatment, the interventionist will teach 3 categories of external memory aids (calendars, timers, notes) following an already-developed detailed treatment manual (described here briefly).~Week 1: Introduction of External Memory Aid Treatment and Person-Centered Goal Setting. Weeks 2-7. In the next six weeks, three categories of external memory aids will be taught: calendars, timers, and notes. The focus of the first session will be how to use the strategies, and the second session will build awareness of when to use these strategies during everyday tasks. Within each category, three types of strategies will be taught to participants. Within each session, learning phases will follow training stages from compensatory learning theory: 1) acquisition phase, 2) application phase, and 3) an adaptation phase."
224213200|NCT03875131|OTHER|Biomarkers of Dementia and Cognitive Decline|"Biomarkers will be obtained at baseline, 6, 12, 18, and 24 months.~The six questionnaires listed below will be administered at the baseline visit, and repeated at the 24-month visit to evaluate cognitive decline.~* Mini-Mental Status Evaluation~* Hachinski Ischemic Scale~* Cognitive Subscale of Alzheimer's Disease Assessment Scale~* Disability Assessment for dementia~* Quality of life improvement as assessed by:~  * Minnesota Living with Heart Failure Scale~ * Anti-Clot Treatment Scale (ACTS) Quality of Life Survey"
224213201|NCT04441203|DEVICE|CardioMems|novel implantable sensor inserted into the right pulmonary artery that measures pulmonary artery pressures (PAP) in patients with HF, the CardioMEMS™ HF System
224213202|NCT06702254|BEHAVIORAL|Experimental: Psychological manualized treatment with CBT and ACT|The intervention is brief and centered around four therapeutic sessions that can be extended or shortened depending on how long patients are hospitalized. Core techniques from CBT and ACT are included in the manual and consists of behavioral activation and values and unhelpful thoughts. Nursing staff on these wards have received training in the manual parallel with supervision which is not given in the treatment as usual wards. The wards that have not received the intervention will be offered this at the end of their TAU period.
224213203|NCT06702254|OTHER|Treatment as usual|This treatment as usual can consist of medication, brief talks, leisure activity on the wards.
224213204|NCT06424704|DIAGNOSTIC_TEST|Microbiological culture|Samples taken from chronic suppurative otitis media patients in the Medical Microbiology Laboratory of Selçuk University Faculty of Medicine will be planted in 5% sheep blood Columbia agar, eosin methylene blue agar and saboraud dextrose agar, and the media will be incubated at 37oC for 24-48 hours. Growing bacteria and fungi were examined using traditional methods \[Gram staining, catalase test, coagulase test, bacitracin disk, PYR test (L-pyrrolidonyl-β-naphthylamide), oxidase test, IMViC test, lactophenol cotton blue, etc.\] and VITEK 2 (bioMerieux, France).
224213205|NCT03660514|BEHAVIORAL|Jovenes Sanos|FP counselors in intervention clinics will a) provide counseling and education regarding risk of partner detection of FP methods, and women's and girls' strategies to use FP methods to minimize partner detection risk integrated into standard FP counseling, b) make brief inquiries to allow clients the opportunity to disclose experiences of RC and IPC (i.e., screening), c) provide method-specific counseling based on this information and the method chosen by the client, d) provide supported linkage of IPV survivors to local IPV support services (i.e. warm referral), and e) distribute palm-sized educational materials on RC and IPV, as well as IPV services.
224213206|NCT01933412|BIOLOGICAL|Sci-B-Vac Hepatitis B Vaccine|Sci-B-Vac Hepatitis B Vaccine
224213207|NCT01933412|BIOLOGICAL|Engerix B Hepatitis B Vaccine|
224213208|NCT05645055|OTHER|treat these patients with biologics|treat these patients with biologics
224213209|NCT01822964|DEVICE|targeted brain cooling (33°C) by RhinoChill device|targeted brain cooling by Rhinochill device to 33°C tympanic temperature during TAVI procedure. After valve implantation, slow rewarming until 35.5°C
224213210|NCT01822964|DEVICE|Placebo - current clinical practice, no cooling|
224213211|NCT04833452|PROCEDURE|Endoscopic dacryocystorhinostomy|Endoscopic DCR
224213212|NCT05614466|OTHER|The Simply B Study|"This study will be conducted in three parts:~Part A: A prospective open label pilot intervention study, comparing the proportion of people with hepatitis B who are managed by their GP in primary care clinics before, 12 months and 24 months after implementation of the Simply B electronic hepatitis B support package.~Part B: A nested qualitative health services feasibility study using semi -structured interviews and thematic analysis Part C: A mathematical modelling study using a Markov model to determine cost effectiveness of Simply B for increasing hepatitis B treatment uptake compared to status quo of hospital care."
224213213|NCT02236390|BEHAVIORAL|Exposure, Relaxation, and Rescripting Therapy|5 sessions that last approximately one hour addressing nightmares and sleep problems. Participants will log sleep events and associated symptoms
224213214|NCT02236390|BEHAVIORAL|Cognitive Processing Therapy - Cognitive|12 sessions cognitive behavioral treatment targeting posttraumatic stress symptoms.
223513475|NCT04921306|DRUG|Clenbuterol Hydrochloride|Daily ingestion of clenbuterol hydrochloride capsules (40 microgram/day) for a total period of 28 days with a wash-out period of at least 6-8 weeks.
223623816|NCT05075746|DEVICE|enVista non-Toric (spherical)|enVista non-Toric (spherical) IOL
223513476|NCT04921306|DRUG|Placebo|Daily ingestion of placebo capsules for a total period of 28 days with a wash-out period of at least 6-8 weeks.
223513477|NCT01314248|DEVICE|each child will receive both the LMA and ILA|each child will receive both the size 2 LMA and size 1.5 ILA
223513478|NCT05679934|OTHER|Exercise Program|Stretching and strengthening exercises will be applied to the participants
223513479|NCT00101400|DRUG|Sorafenib (Nexavar, BAY43-9006)|Sorafenib 400 mg administered twice daily (b.i.d.)
223513480|NCT04297735|OTHER|Standard of care group|Visits every 6 months is standard of care.
223513481|NCT04297735|BEHAVIORAL|Telemedicine group|Conduct monthly telemedicine 'skype' visit
223623817|NCT04136808|DRUG|enfortumab vedotin (EV)|Participants will receive an intravenously (IV) administered dose once weekly for the first 3 weeks of every 4-week cycle (i.e., on days 1, 8, and 15)
223623818|NCT01045460|BIOLOGICAL|Activated marrow infiltrating lymphocytes|Administered on Days 3 and 4.
223623819|NCT01045460|BIOLOGICAL|Allogeneic Myeloma Vaccine|Allogeneic granulocyte macrophage colony-stimulating factor (GM-CSF)-based myeloma cellular vaccine. Administered on Days 21, 60, 180, and 300.
223623820|NCT01045460|DRUG|Cyclophosphamide|Administered at 2.5 g/m\^2.
224213215|NCT03899506|DRUG|Olanzapine|Patients receiving Olanzapine per the ED protocol
224213216|NCT03899506|DRUG|Midazolam|Patients receiving Midazolam per the ED protocol
223623821|NCT01045460|BIOLOGICAL|Filgrastim|Administered post cyclophosphamide daily until leukapheresis.
223623822|NCT01045460|PROCEDURE|Leukapheresis|Performed approximately 12 days post cyclophosphamide. Exact date depends on peripheral blood CD34+ cell counts.
224213217|NCT03939403|DRUG|Time of administration of Corifollitropin Alfa|"The used treatment will be identical in both arms. The difference between the groups will be the moment of beginning of the stimulation as well as the later administration of more FSH activity.~The control grup will receive the treatment on the 5th day after the cessation of hormonal contraceptive use. The used treatment will be identical in both arms. The difference between the groups will be the moment of beginning of the stimulation as well as the later administration of more FSH activity.~The intervention grup will receive the treatment on the 7th day after the cessation of hormonal contraceptive use."
224213218|NCT01333475|DRUG|MK-2206 + AZD6244|MK-2206 and AZD6244 hydrogen sulfate are selective inhibitors of human AKT and MEK, respectively, with preclinical and clinical anti-tumor activity as single agents and in combination with a variety of drugs. Combination treatment in mouse cancer models harboring mutations in both the PI3K and RAS pathways was more potent compared to either agent used alone, and resulted in substantial tumor inhibition, including tumor regression.
224213219|NCT06422156|RADIATION|Stereotactic body radiation|Patients will receive SBRT with doses ranging from 35-40 Gy in five fractions.
223623823|NCT01045460|DRUG|Melphalan|100 mg/m\^2/day given on Days -2 and -1.
223623824|NCT01045460|BIOLOGICAL|Autologous stem cell transplant|Infused on Day 0.
223623825|NCT04356222|DRUG|Durvalumab|Intravenous infusion once every two weeks ,once 10mg/kg.
223623826|NCT04356222|DRUG|methotrexate|Intrathecal chemotherapy specified dose on specified days
223623827|NCT04103216|OTHER|Nitazoxanide with Lactobacillus Reuteri DSM 17938|Nitazoxanide with probiotics
223623828|NCT04103216|OTHER|Nitazoxanide|Nitazoxanide with placebo
224213220|NCT06422156|DRUG|Nimotuzumab|Patients will receive Nimotuzumab 400 mg weekly or Nimotuzumab 600mg on day 1 and 8 of a 21-day cycle until disease progression.
224213221|NCT06422156|DRUG|mono-chemotherapy|Patients will receive mono-chemotherapy (Gemcitabine, S-1 or capecitabine) until disease progression.
224213222|NCT00003692|PROCEDURE|therapeutic thoracoscopy|
223623829|NCT05030181|OTHER|kinesiotaping and exercise|kinesiotaping group, ''I'' strip kinesiotape will be applied with the space correction technique for the upper trapezius muscle, for a total of 4 sessions, 2 days a week, and the patients will be included in the 1-month home exercise program.
224213223|NCT00003692|PROCEDURE|video-assisted surgery|
223623830|NCT05030181|OTHER|exercise|exercise
224213224|NCT00547807|OTHER|Non-nutritive sucking|Non-nutritive sucking is applied by using a gloved finger
224213225|NCT00547807|OTHER|Swaddling|Swaddling is an age-old practice of wrapping infants snugly in swaddling cloths, blankets or similar cloth so that movement of the limbs is tightly restricted
223623831|NCT03964103|DIETARY_SUPPLEMENT|gQ-lab daily|probiotics
224213226|NCT04811911|RADIATION|Narrowband ultraviolet B|Patients will receive 8 sessions of NB-UVB per month for 3 successive months
224213227|NCT04811911|DRUG|Methotrexate|Patients will receive 25 mg/1ml of methotrexate vial per week for 3 successive months
224213228|NCT03526185|DRUG|Tumor Infiltrating Lymphocytes|The regimen consists of treatment with cyclophosphamide and fludarabine,followed by infusion of up to 3x1011 lymphocytes (minimum of 1x109) expanded in vitro from subjects own resected tumor followed by the administration of aldesleukin (IL-2).
223623832|NCT03964103|DIETARY_SUPPLEMENT|Placebo|powdered skim milk, lactose
223623833|NCT00524485|DRUG|aminolevulinic acid|
223623834|NCT00524485|PROCEDURE|laser therapy|
223623835|NCT02319200|DRUG|Metformin|"1000 mg (2x500 mg) at morning and 1000 mg (2x500 mg) at afternoon (2000 mg per day)~Metformin daily during 36 months"
224213229|NCT03526185|DRUG|Nivolumab and Ipilimumab|• Within 1 week post discharge subjects will be treated with Nivolumab 1 mg/kg and Ipilimumab 3 mg/kg every 3 weeks for 4 doses. Following this, patients will receive Nivolumab 480 mg every 4 weeks. Adjuvant Nivolumab will continue until evidence of disease progression or inability to tolerate treatment.
224213230|NCT04948385|DRUG|Propofol|deep sedation with propofol +/- adjuvants such as midazolam, sufentanil, lidocaine and/or dehydrobenperidol
224213231|NCT04948385|PROCEDURE|No sedation|No sedation
224213232|NCT04688983|DRUG|Ponatinib|30 mg QD starting day 1, given continuously unless interruption required for toxicity
223623836|NCT02319200|DRUG|placebo tablet|4 tablets per day for 36 months
223623837|NCT00436332|BIOLOGICAL|bevacizumab|
223623838|NCT00436332|DRUG|erlotinib hydrochloride|
223623839|NCT00456053|DRUG|FG2216|
223623840|NCT02268149|DRUG|BIIL 284 BS|
223623841|NCT02268149|DRUG|Prednisone|
223623842|NCT02268149|DRUG|Placebo|
223623843|NCT00472108|RADIATION|Photodynamic Therapy (PDT)|
223623844|NCT00472108|DRUG|Metvix cream|
223623845|NCT00472108|DRUG|Placebo Cream|
223623846|NCT02538744|DRUG|Doxazosin|Participants will be randomized into two groups: placebo and doxazosin 8 mg/d. The doxazosin dose will be increased every 4 days over 11 days, starting with 1mg on the first study day and and ending with 8mg 11 days later. Participants will receive one capsule daily that will contain either placebo or doxazosin.
223623847|NCT02538744|DRUG|Modafinil|After titrating doxazosin to the target dose, study procedures will be completed three times, once during treatment with each dose of modafinil (0 \[placebo\], 200, and 300 mg/d), in pseudo-random order such that 200 mg precedes 300 mg).
223623848|NCT02538744|DRUG|cocaine|On the 5th day of study medication treatment participants will receive non-contingent doses of cocaine (placebo, 20, 40 mg, IV) and participate in cocaine self-administration sessions.
224213233|NCT04688983|DRUG|Blinatumomab|A single cycle of blinatumomab treatment is 6 weeks in duration, which includes 4 weeks of blinatumomab CIVI followed by a 2-week treatment-free interval.
224213234|NCT04688983|DRUG|Imatinib|starting day 1, given orally at 400mg BID continuously for 8 weeks
224213235|NCT02981602|DRUG|IONIS-HBVRx|Ascending multiple doses of IONIS-HBVRx by subcutaneous (SC) injection
224213236|NCT02981602|DRUG|Placebo|Placebo
224213237|NCT04740112|OTHER|Foods with beta-glucan from oats and barley|Breakfast bars made with varying levels of total dietary fiber and beta-glucan, with or without claims on package image
224213238|NCT01489696|DRUG|mirabegron|oral
224213239|NCT01489696|DRUG|tamsulosin|oral
223623849|NCT02538744|DRUG|Placebo|
223623850|NCT02767271|DRUG|Luliconazole Cream 1%|Luliconazole cream will be applied topically per schedule specified in the arms.
223623851|NCT01394055|DRUG|RM-131|100 μg subcutaneously once
224213240|NCT04839588|OTHER|Usability study|"Participants will first be screened for propensity to simulation sickness and for cognitive state using the MoCA evaluation test. Those who passed the screening will perform 4 usability sessions rating the ease of use and perceived benefit of the experimental system and of a caregiver interface laptop. The 2 healthy volunteers will evaluate first, such that issues may be resolved before testing is done on the impaired participants. Each session will be compensated with a $35 payment. During each session participants will play a series of increasing difficulty simulated tasks, aimed to train primarily the executive functions domain. At the end of each session participants will rate their experience using custom subjective evaluation forms with multiple items. Each item will be scored using a 5-point Likert scale. At the end of the 4th session, participants will also fill the USE standardized usability form.~This usability evaluation will be conducted at the NJ Bioscience Center."
223762031|NCT06404203|DIETARY_SUPPLEMENT|Balparmak Apitera Royal Jelly Herbal Capsule Food Supplement 500 mg/day|Volunteers will receive Balparmak Apitera Royal Jelly Herbal Capsule Food Supplement in a dose of 500 mg/day for 4 weeks.
223762032|NCT06404203|DIETARY_SUPPLEMENT|Balparmak Apitera Royal Jelly Herbal Capsule Food Supplement 1000 mg/day|Volunteers will receive Balparmak Apitera Royal Jelly Herbal Capsule Food Supplement in a dose of 10000 mg/day for 4 weeks.
224213241|NCT00238056|DRUG|domperidone Drug|
224213242|NCT00612079|DRUG|Sertindole|oral 3 x 4mg
224316510|NCT01741883|BEHAVIORAL|Side effect prevention training (SEPT)|SEPT is aimed to optimize patients' response expectations before the start of pharmacotherapy to prevent nocebo side effects during adjuvant endocrine treatment. SEPT is a three session cognitive-behavioural training. It includes psychoeducation about AET to provide a realistic view on AET, reduction of concerns about side effects and strengthening of necessity beliefs. Further contents are side effect management training and problem solving to enhance self-efficacy expectations about coping as well as imagination training to integrate positive aspects of medication into daily life.
224316511|NCT01741883|BEHAVIORAL|Attention Control group (ACG)|Supportive therapy includes common or unspecific factors such as elicitation of affect, a treatment context, empathy, reflective listening, and feeling understood. Supportive therapy thus provides a control condition for common factors and therapist attention, while lacking the specific intervention part. It will be delivered in the same frequency and at the same time points as the side effect prevention training (three individual sessions and three booster telephone calls).
224316512|NCT03968978|BIOLOGICAL|Tezepelumab (APFS)|Tezepelumab subcutaneous injection, administered by Accessorized pre-filled syringe (APFS).
223623852|NCT01394055|DRUG|Placebo|Matching placebo volume subcutaneously once
223623853|NCT04642625|OTHER|Visual Analog Score|"The VAS is a widely used tool in research and clinical practice, and its reliability and validity in pain assessment has been clearly demonstrated. It consists of a 100 mm line. 0 cm no pain, 10 cm is associated with 'worst possible pain'. The patient is asked to mark the line to 'score' the pain. VAS values of 1cm - 3cm weak, 4cm - 6cm moderate, and \>7cm are the indicators of severe pain."
223623854|NCT04642625|OTHER|patient satisfaction|The patient's satisfaction with postoperative pain treatment will be recorded. 4 options; excellent, good, medium and bad.
223623855|NCT01274949|DEVICE|LI-ESWT|Low intensity shock wave treatment - 12 sessions
223623856|NCT00272493|BIOLOGICAL|Hepatitis B virus vaccine with GM-CSF adjuvant|Arm B participants will receive 40 mcg of HBV vaccine and 250 mcg of GM-CSF at study entry, Week 4, and Week 12.
223623857|NCT00272493|BIOLOGICAL|Hepatitis B virus vaccine|Arm A participants will receive 40 mcg of HBV vaccine at study entry, Week 4, and Week 12.
224213243|NCT00612079|DRUG|Placebo|3 x 4mg Placebo
224213244|NCT00386100|DRUG|Avandamet 6 mg/1500 mg (ttd)|One 2 mg/ 500 mg capsule will be taken in the AM with the morning meal Two 2 mg/ 500 mg capsules will be taken in the PM with the evening meal
223623858|NCT02084485|DRUG|PH-797804|30 MG Single dose
223623859|NCT02084485|DRUG|Placebo|matching placebo
223623860|NCT03439306|DEVICE|Pulse Oximeter|The Pulse Oximeter are placed on the left and right Index fingers of each subject of the healthy adult volunteer group to evaluate the SpO2 accuracy performance.
223762033|NCT06404203|DIETARY_SUPPLEMENT|Balparmak Apitera Royal Jelly Herbal Capsule Food Supplement 1500 mg/day|Volunteers will receive Balparmak Apitera Royal Jelly Herbal Capsule Food Supplement in a dose of 1500 mg/day for 4 weeks.
224213245|NCT00386100|DRUG|Avandamet 4 mg/1000 mg (ttd)|One 2 mg/500 mg capsule will be taken in the AM with the morning meal. One 2 mg/500 mg capsule will be taken in the PM with the evening meal.
224213246|NCT00386100|DRUG|Avandamet 2 mg/500 mg (ttd)|one placebo capsule will be taken in the AM with the morning meal one 2 mg/ 500 mg capsule will be taken in the PM with the evening meal.
224316513|NCT03968978|BIOLOGICAL|Tezepelumab (AI)|Tezepelumab subcutaneous injection, administered by Autoinjector (AI) device.
224316514|NCT01178216|BIOLOGICAL|Rituxan|Rituximab (1gm) given on day# 15. Transplanted patients will receive an additional dose of Rituximab at 3M if DSA remains or 6M if denovo DSA present.
223623861|NCT05323136|DRUG|MT1002 for Injection|single dose: 0.90 mg/kg initial loading dose (bolus intravenous injection) over 5 minutes + 1.8 mg/kg/hour (infusion) for 4 hours.
223623862|NCT01258543|OTHER|General Osteopathic Evaluation|2 general osteopathic evaluations of approximately 1 hour in duration done consecutively on the same day with a 15 minute break between evaluations
223623863|NCT06013735|DRUG|sodium fluoride solution|sodium fluoride solution mouth rinse (0.2%).
223623864|NCT06013735|DRUG|guava leaves aqueous extract|guava leaves aqueous extract mouth rinse (0.5%)
223623865|NCT06013735|DRUG|pomegranate peel aqueous extrac|pomegranate peel aqueous extract mouth rinse (0.5%).
223623866|NCT06013735|OTHER|Distilled water|placebo distilled water
223623867|NCT00576355|BEHAVIORAL|Interpersonal and Social Rhythm Therapy for Adolescents (IPSRT-A)|IPSRT-A involves 20 weeks of individual therapy, incorporating informed psychological, behavioral, and practical strategies adapted to the developmental needs of adolescents.
223623868|NCT00576355|BEHAVIORAL|Treatment As Usual (TAU)|TAU includes the offering of educational information about bipolar disorder and referral to a mental health provider.
223623869|NCT00174577|DRUG|Risperidone|
223623870|NCT03028233|BEHAVIORAL|Healthy Lifestyle|A Community Health Worker coaches families regarding healthy eating, physical activity, and obesity prevention, and promotes the use of existing built environment resources.
223623871|NCT03028233|BEHAVIORAL|Positive Parenting|A Community Health Worker coaches parents on improving positive parenting skills and promotes the use of relevant community resources.
223623872|NCT02800538|DIETARY_SUPPLEMENT|intragastric infusion of nutrient|Intragastric infusion of nutrient that can be widely found in daily food or placebo.
223623873|NCT01841879|BEHAVIORAL|Intervention Program|"Receives an integrated tobacco control and occupational health (OH) intervention (The Healthy, Safe, and Tobacco-Free Worksites program) aimed at promoting tobacco cessation among workers and supporting the adoption, implementation, and enforcement of tobacco control policies.~Through six health education events at the worksites, blue-collar workers (who face dual health risks through their exposures to occupational hazards and their high rates of tobacco use) will gain the knowledge, skills, and social support needed to quit tobacco use.~Simultaneously, management will receive OH and tobacco policy consultations to help build a healthy and safe work environment, where workers' hazardous exposures are reduced."
223623874|NCT01841879|BEHAVIORAL|Delayed Intervention|Receives abbreviated 2-month delayed intervention designed to provide employees with knowledge and skills to quit tobacco after final data collection time point, as well as one non-tobacco event in between data collection points.
223623875|NCT02986126|BEHAVIORAL|Resiliency Class|See Arm Description
223623876|NCT02986126|OTHER|Resource for Services (RS)|See Resource for Services (RS) Description
223623877|NCT02441023|BEHAVIORAL|Nutritional therapy and education|"1. Nutritional therapy guidance according to sex, age, weight and comorbidity present. The recommendations of calories and macronutrients intake were indicated according to the Official Mexican Standards for Diabetes treatment and the American Diabetes Association standards for medical care in diabetes.~2. Education with multimedia application: Patients were exposed to the multimedia application previous to the nutritional counseling. Multimedia application comprises the following modules: 1) Introduction, 2) Nutrition, 3) Physical Exercise, 4) Diabetes myths 5) Metabolic control indicators 6) Knowing diabetes, 7) Diabetes complications including testimonials."
224213247|NCT00386100|DRUG|Avandamet 8 mg/ 2000 mg (ttd)|Two 2 mg/ 500 mg capsules will be taken in the AM with the morning meal. Two 2 mg/ 500 mg capsules will be taken in the PM with the evening meal.
223623878|NCT02441023|BEHAVIORAL|Nutritional therapy|Nutritional therapy guidance according to sex, age, weight and comorbidity present. The recommendations of calories and macronutrients intake were indicated according to the Official Mexican Standards for Diabetes treatment and the American Diabetes Association Standards for medical care in diabetes.
223623879|NCT05206721|OTHER|Open tracheal suction system flushing with chlorhexidine|After suctioning the patient's secretions, the responsible nurse inserted the SC into the CHX filled container and flushed the entire suction system with CHX.
223623880|NCT05259735|COMBINATION_PRODUCT|Clinical Guideline based Management|Clinical guidline based management will be done for Type 2 diabetes Mellitus
224213248|NCT00386100|DRUG|Metformin 500 mg (ttd)|One placebo capsule will be taken in the AM with the morning meal. One 500 mg capsule will be taken in the PM with the evening meal.
224213249|NCT00386100|DRUG|Metformin 1000 mg (ttd)|One 500 mg capsule will be taken in the AM with the morning meal. One 500 mg capsule will be taken in the PM with the evening meal.
224213250|NCT00386100|DRUG|Metformin 1500 mg (ttd)|One 500 mg capsule will be taken in the AM with the morning meal. Two 500 mg capsules will be taken in the PM with the evening meal.
224213251|NCT00386100|DRUG|Metformin 2000 mg (ttd)|Two 500 mg capsule will be taken in the AM with the morning meal. Two 500 mg capsule will be taken in the PM with the evening meal.
223623881|NCT05259735|OTHER|Comparator|In this arm usual management of T2DM without any clinical guideline
223623882|NCT04189705|DRUG|MCT-SR|Rebamipide 150mg
223623883|NCT04189705|DRUG|Mucosta Tab.|Rebamipide 100mg
223623884|NCT01339689|DRUG|Ganaxolone|200-600 mg bid, capsules, up to 12 weeks
223623885|NCT01339689|DRUG|Placebo|capsules, bid, up to 12 weeks
223623886|NCT02350517|DRUG|Paclitaxel+Nedaplatin+Endostar|Patients will receive chemotherapy every 3 weeks: Paclitaxel 175mg/m2 IV over 3 hours on Day 4; Nedaplatin 80mg/m2 IV over 1 hours on Day 4; Endostar 3mg/day for 14 days continuous infusion from Day 1 to Day 14
223623887|NCT05062174|DRUG|Mifepristone 200 MG|Orally, one time dosage of 200 mg
223623888|NCT05062174|PROCEDURE|Prophylactic mastectomy|Planned prophylactic mastectomy (having one or both breasts removed).
223623889|NCT00325455|DRUG|MK0859|
223623890|NCT00947375|DRUG|Lamictal TM|First group patients received either haloperidol deaconate 50 mg in weekly intramuscular and Lamictal TM 150-200 mg in day per so for 12 weeks.
223623891|NCT00947375|DRUG|Haloperidol Decanoate|Second group patients were given haloperidol deaconate 50 mg in weekly intramuscular and placebo per os for 12 weeks.
223623892|NCT04481412|DRUG|Topical cetirizine|Topical cetirizine 1% spray that will be prepared at Faculty of Pharmacy, Cairo University and will be applied once daily.
223623893|NCT04481412|DRUG|Placebo|96% ethanol that will be applied once daily.
223623894|NCT04481412|DRUG|Topical minoxidil|Topical Minoxidil 5% that will be applied once daily.
223623895|NCT00287898|BEHAVIORAL|Telephone Genetic Counseling|Participants will receive all genetic counseling via telephone
223623896|NCT00287898|BEHAVIORAL|Usual Care|subjects will receive standard in-person genetic counseling
223623897|NCT00667888|RADIATION|Conventional Fractionated Intensity Modulated Radiotherapy|A total dose of 75.6 Gy will be delivered in 42 fractions to the planning target volume (PTV).
223623898|NCT00667888|RADIATION|Hypofractionated Intensity Modulated Radiotherapy|A total dose of 72 Gy will be delivered in 30 fractions to the PTV.
223623899|NCT04859322|DRUG|Glucagon|Pancreatic clamp
223623900|NCT02684773|PROCEDURE|Conventional Hemodialysis|The intervention involves 3 hemodialysis sessions/week that consists of 4 hours/session
223623901|NCT02684773|PROCEDURE|In-centre Nocturnal Hemodialysis|The intervention involves 3 hemodialysis sessions/week administered overnight (8 hours/session) in-hospital
223623902|NCT03604952|DIAGNOSTIC_TEST|COPD patients|Tests performed one week before Ramadan (C), and during the second (R-2) and the fourth weeks of Ramadan (R-4)
223623903|NCT04730908|OTHER|DENTIFRICE|GEL -DENTIFRICE FOR BRUSHING TEETH
223623904|NCT05932277|DRUG|BMS-986419|Specified dose on specified days
223623905|NCT05932277|DRUG|Caffeine|Specified dose on specified days
223623906|NCT05932277|DRUG|Bupropion|Specified dose on specified days
223623907|NCT05932277|DRUG|Flurbiprofen|Specified dose on specified days
223623908|NCT05932277|DRUG|Omeprazole|Specified dose on specified days
224213252|NCT02222285|OTHER|Medical Food : Vayarin_005|
224213253|NCT02222285|OTHER|Placebo|
224213254|NCT04167488|DEVICE|Actigraphic measurement|Physical activity assessed with actigraphic device worn during 7 days
223623909|NCT05932277|DRUG|Midazolam|Specified dose on specified days
223623910|NCT05932277|DRUG|Fexofenadine|Specified dose on specified days
223623911|NCT06403007|BEHAVIORAL|Phonics plus morphology|This intervention trains teachers to teach phonics plus morphology to at-risk poor readers
223623912|NCT06403007|BEHAVIORAL|Phonics plus set-for-variability|This intervention trains teachers to deliver phonics plus set-for variability to at-risk poor readers.
223623913|NCT05854108|DIAGNOSTIC_TEST|Cervical Traction|Cervical Traction to Improve Pain and Quality of Life in Cervical Radiculopathy
223623914|NCT05854108|DIAGNOSTIC_TEST|Snag|Snag to Improve Pain and Quality of Life in Cervical Radiculopathy
223623915|NCT00499681|DRUG|lapatinib ditosylate|Given once daily, 1500mg, for 2 weeks; Given once daily, 1500mg, for 14 weeks in Arm II
223623916|NCT00499681|DRUG|letrozole|Given once daily, 2.5mg, for 2 weeks; Given once daily, 2.5mg, for 14 weeks
223623917|NCT00499681|OTHER|placebo|Given once daily for 2 weeks
223762034|NCT06404203|OTHER|Plasebo|Volunteers will receive a soft vegan gelatin capsule containing lactose in a dose of 1500 mg/day for 4 weeks.
223762035|NCT03129516|BEHAVIORAL|Determining Imaginary levels|Determining the motor imaginary: internal visual, external visual and kinesthetic imagery
224213255|NCT00491673|PROCEDURE|Uncemented primary bipolar hemiarthroplasty of the hip|Uncemented primary bipolar hemiarthroplasty of the hip
224213256|NCT00491673|PROCEDURE|Cemented primary bipolar hemiarthroplasty of the hip|Cemented primary bipolar hemiarthroplasty of the hip
224213257|NCT00970931|DRUG|Chlorthalidone plus amiloride|Oral Chlorthalidone 12.5 mg plus amiloride 2.5 mg, once a day for 18 months
224213258|NCT00970931|DRUG|placebo|Oral placebo once a day, for 18 months
224213259|NCT04816422|OTHER|Proprioceptive neuromuscular facilitation|"rocedure~1. Bilateral upper extremity pattern for trunk by Chopping, Lifting~2. Bilateral lower extremity pattern for trunk.~3. Trunk lateral flexion.~4. Combination patterns for the trunk by Upper and lower trunk flexion, Upper trunk flexion with lower trunk extension, Upper and lower trunk extension, Upper trunk extension with lower trunk flexion."
223623918|NCT00883779|DRUG|Placebo|po on days 15-28 of each 4 week cycle until disease progression
223623919|NCT00883779|DRUG|Platinum chemotherapy (cisplatin or carboplatin)|cisplatin --75mg/m2 oon day 1 of each 4 week cycle for 6 cycles or carboplatin--5xAUC on day 1 of each 4 week cycle for 6 cycles
223623920|NCT00883779|DRUG|erlotinib [Tarceva]|150mg po on days 15-28 of each 4 week cycle until disease progression
223623921|NCT00883779|DRUG|gemcitabine|1250mg/m2 iv on days 1 and 8 of each 4 week cycle for 6 cycles
223623922|NCT02140047|BIOLOGICAL|Haemophilus b conjugate vaccine diphteria CRM197 protein conjugate)-Low + DPT-IPV|0.25mL, subcutaneous injection
223623923|NCT02140047|BIOLOGICAL|Haemophilus b conjugate vaccine diphteria CRM197 protein conjugate)-High + DPT-IPV|0.5mL, subcutaneous injection
223623924|NCT02140047|BIOLOGICAL|Haemophilus influenza type b conjugate vaccine + DPT-IPV|0.5mL, subcutaneous injection
223623925|NCT03397979|BEHAVIORAL|Infrequent versus Frequent Soaking Baths|Submersion of skin, affected by atopic dermatitis, in a bathtub filled with luke-warm water, where the frequency and duration of these baths are varied, to look for any differential effect.
223762036|NCT02552316|DEVICE|NB-UVB Phototherapy|
223623926|NCT03159416|DRUG|Inclisiran|Inclisiran is a synthetic, chemically modified small interfering ribonucleic acid (siRNA) targeting proprotein convertase subtilisin kexin type 9 (PCSK9) messenger ribonucleic acid (mRNA) with a covalently attached triantennary N-acetylgalactosamine (GalNAc) ligand.
223623927|NCT05842317|DRUG|Lenvatinib Plus Tislelizumab|Lenvatinib is 12mg/d for body weight \>= 60kg, 8mg/d for body weight \<60kg, once daily orally, once a day, after meals (take at the same time every day as much as possible); Tislelizumab is administered intravenously at a dose of 200mg/q3w.
223623928|NCT05842317|DEVICE|Transarterial Chemoembolization(TACE)|A catheter is inserted through a small incision in the groin and guided to the hepatic artery, which supplies blood to the liver;A contrast dye is injected through the catheter to help visualize the blood vessels in the liver; A mixture of chemotherapy drugs and an embolic agent (such as small beads or gel foam) is injected through the catheter and into the artery that feeds the tumor;The embolic agent helps to block the blood flow to the tumor, which starves it of oxygen and nutrients; The chemotherapy drugs are then trapped in the tumor.
224213260|NCT04816422|OTHER|Conventional treatment|"Group 2 has received conventional trunk exercise program for 45 min/day, 4 days~/ week for the period of 4 weeks the intervention includes static and dynamic functional trunk movement and strengthening exercise to the trunk muscles which includes motor developmental patterns, basic trunk movement, trunk-arm linked movements, trunk-leg linked patterns in sitting, transfer activities, with 2 minutes rest in between the repetition of each set, Progression will be made by increasing the repetition and resistance According to individual ability."
224213261|NCT02464085|OTHER|Longitudinal evaluation of recovery|Stroke survivors will be assessed at four time frames post stroke to evaluate neuroplastic and clinical changes in arm recovery over the first 12-months post stroke.
223762037|NCT02659020|DRUG|Olaratumab|Administered IV
224213262|NCT03467828|GENETIC|polymorphism analyzing|Blood samples will be taken to EDTA containing tubes and then will be analyzed for genetic polymorphisms.
224213263|NCT03695406|BEHAVIORAL|Mind-Body Program for Fear of Recurrence|An adapted protocol of the Relaxation Response Resiliency Program, a manualized, group-based, multimodal mind body program. Protocol adaptation includes refinement of content and study procedures to target fear of cancer recurrence (FCR) among adult cancer survivors.
224213264|NCT01706770|DEVICE|enfilcon A|
224213265|NCT01706770|DEVICE|galyfilcon A|
224213266|NCT06462209|OTHER|ladder training|"Players practiced Ladder training for 60 minutes thrice a week for 8 weeks. There are 3 different types of drills. The first types of drills are steady state drills. These drills focus on quickness Endurance and utilize a constant rhythm throughout the ladder. The second types of drills are burst drills. These drills focus on the ability to turn on rapid burst of foot movement.~The third types of drills are elastic response drills. These drills focus on improving the reactive speed components of the lower leg. A standard agility ladder is 15 feet long and 20 inches wide Step."
224213267|NCT06462209|OTHER|plyometric training|In plyometric training players practiced for 60 minutes thrice a week for 8 weeks. warm up for 15 minutes , plyometric training for 30 minutes and cool down for 15 minutes
224213268|NCT02020785|OTHER|Higher phosphorus period|"Commercially-available unaltered food/beverage products containing phosphorus additives (\~1gm/d of phosphorus) will be given for 3 weeks.~All participants at the beginning of the study will receive dietary education to reduce their baseline consumption of phosphorus to a goal of \~1gm/d by receiving education on avoiding phosphorus-based additives."
224213269|NCT02020785|OTHER|Lower phosphorus period|"Commercially-available unaltered food/beverage products without phosphorus additives (\<10mg/d of phosphorus) will be given for 3 weeks.~All participants at the beginning of the study will receive dietary education to reduce their baseline consumption of phosphorus to a goal of \~1gm/d by receiving education on avoiding phosphorus-based additives."
224213270|NCT04494282|PROCEDURE|Endoscopic retrograde pancreatography|Endoscopic cannulation of main pancreatic duct
224213271|NCT05840666|OTHER|Mulligan Sustained Natural Apophyseal Glide (SNAG)|Application of the MWM technique developed by Brian R. Mulligan. The clinical researcher will perform and holds sustained passive segmental glide at the target joint maintaining the slack whereas the patient will actively move in the direction of pain or stiffness. These MWM techniques when applied to spinal segments or joint is called sustained natural apophyseal glide (SNAG).
224213272|NCT05840666|OTHER|McKenzie Method|An active therapy technique involving repeated movements or sustained positions along with an educational component prescribed to the patient for of minimizing the pain and disability and increase the spinal range of motion. The method will involve the assessment of symptomatic and mechanical responses to repeated movements and sustained positions in the direction of preference. The method will be used for assessment and treatment of patients and with derangement syndrome.
224213273|NCT05840666|OTHER|Conventional Physical Therapy|It includes usual physical therapy care such as Therapeutic Ultrasound, Moist Heat-pack, TENS and standard exercises.
224213274|NCT00108758|DRUG|activated recombinant human factor VII|
224213275|NCT06098222|BEHAVIORAL|Slow breathing exercise training|Slow breathing exercise training will be given by the researcher in a single one-hour session in the meeting room of the unit 24 hours after the PCI and/or the next day. After a 20-minute silent rest in the training, patients will be asked to breathe slowly through the nostrils for 4 seconds and slowly exhale through the mouth for 6 seconds to reach 6-8 breaths/min. The patient will rest for 5 seconds after every 6 slow breaths. During the training period, a stopwatch will be used by observing the patient's chest and abdominal movements in order to determine whether the patients have reached the required respiratory rate.
223623929|NCT05566535|DRUG|Ruxolitinib|Ruxo will be administered to patients with PV in a real-world setting. Treatment with Ruxo is according to local approved label. Ruxo treatment should be administered according to drug official instruction and in compliance with clinical practice at the certain medical center.
223623930|NCT04757207|OTHER|survey|International Physical Activity Questionnaire (short form)
223623931|NCT05101590|DEVICE|Monitored by HDA|Participants undergoing elective major surgery with an arterial line as part of their standard care and additional monitoring with HDA as part of their care.
223623932|NCT03313869|DIETARY_SUPPLEMENT|XXS-2A + Omega-3 + Vitamin E + Selenium|Micronutrient cocktail supplementation with 560,7 mg/ day of polyphenols (3 pills/day), 2,1 g/day of omega-3 fatty-acids (3 pills/day), 168 mg/day of vitamin E and 80µg/day of selenium (1 pill/day)
223623933|NCT03313869|DIETARY_SUPPLEMENT|control diet|habitual diet to be followed
223623934|NCT00003464|DRUG|temozolomide|
223762038|NCT02659020|DRUG|Gemcitabine|Administered IV
223623935|NCT00003464|RADIATION|radiation therapy|
223623936|NCT01904409|DRUG|Placebo|
223623937|NCT01904409|DRUG|Rifaximin SSD 40 mg IR tablet|
223623938|NCT01904409|DRUG|Rifaximin SSD 80 mg IR tablet|
223623939|NCT01904409|DRUG|Rifaximin SSD 40 mg SER tablet|
223623940|NCT01904409|DRUG|Rifaximin SSD 80 mg SER tablet|
223623941|NCT01904409|DRUG|Rifaximin SSD 80mgIR/80mgSER tablet|
223623942|NCT00605852|DRUG|GSK835726|GSK835726 will be available in single dose and repeat dose formulations.
223623943|NCT00605852|DRUG|Placebo|Placebo will be given to subjects.
223623944|NCT00079040|DRUG|cisplatin|Given IV
223762039|NCT02659020|DRUG|Docetaxel|Administered IV
223762040|NCT02659020|DRUG|Placebo|Administered IV
223762041|NCT00222547|DRUG|Vitamin A|
223762042|NCT00222547|DRUG|Albendazole|
224213276|NCT03810664|DRUG|Somatrogon|A single dose of 12 mg of somatrogon will be injected as one sc injection to the arm on each dosing day (Day 0 and Day 14).
224213277|NCT04895319|DEVICE|Computer-assisted surgery|The reconstruction was performed with the help of virtual surgical plan and 3D printed models.
224213278|NCT00724074|DEVICE|On-Q PainBuster with Bupivacaine|On-Q PainBuster continuous wound infusion analgesia system, using bupivacaine as the local anaesthetic
224213279|NCT00724074|DEVICE|Usual Care|Usual Care
224213280|NCT02234258|BEHAVIORAL|Cognitive behavioral social skills|
224213281|NCT02234258|BEHAVIORAL|Psychoeducation|
224213282|NCT00459589|BEHAVIORAL|nutritional intervention with dietician plus usual nutritional care|nutritional intervention with dietician at each cycle of chemotherapy in 6 first cycles to maintain 30 kcal/kg/d and 1.2 protein/kg/d
223623945|NCT00079040|DRUG|etoposide|Given IV
224213283|NCT00459589|BEHAVIORAL|usual nutritional care|usual nutritional care
224213284|NCT03284073|PROCEDURE|Uterus transplantation|Transplantation of the uterus from a live donor and IVF treatment
224213285|NCT06290869|BEHAVIORAL|Phone-based Tobacco Treatment, Nicotine Replacement, and Stepped Care Intervention|In the MedStar Health System (MHS) arm, we offer 5 phone sessions with a tobacco treatment specialist (TTS) during the first 3 months of treatment plus combination nicotine replacement (patches and lozenges). For those who have not quit at 3 months, 50% will be randomly assigned to stepped care (3 phone sessions with RN/NP + prescription medications as needed) vs. the continued TTS + NRT intervention. Those who have quit at 3 months will be offered 3 relapse prevention phone sessions with the TTS. Thus, all are offered 8 sessions. The TTS will use motivational interviewing to address ambivalence about quitting, education about the risks of continued smoking, encouragement to use and adhere to NRT, and the impact of the screening result (the teachable moment) by framing it as a potential motivator or opportunity to reduce future health risks and to maximize quality of life.
224213286|NCT06290869|BEHAVIORAL|E-Referral to the Tobacco Quitline|In the Quitline E-Referral arm, an e-referral will be generated from the EHR by our staff, will be signed by the LCS ordering provider and sent to the quitline through the closed-looped quitline's success.58-61,123 The quitline is an important comparator, given that it is an evidence-based and low-cost intervention already employed by many LCS sites system and the standard quitline protocol will then occur: 5 proactive contact attempts, up to 5 sessions, and up to 8 weeks of free NRT (depending on supplies). Quitline counselors are highly trained to conduct cessation treatment and extensive research has validated the quitline's success. The quitline is an important comparator, given that it is an evidence-based and low-cost intervention already employed by many LCS sites.
224213287|NCT03160365|PROCEDURE|ACQUISITION OF IMAGES|In addition to the conventional clinical protocol, 4 MRIs qere performed at Day 0, day 1,day 15 and day 30 and a preoperative CT scan without injection of a contrast agent.
224213288|NCT01016821|DRUG|Oxycodone|Intravenous, 1 mg, 5 times, in every 5 minutes, duration of drug administration 25 minutes
224213289|NCT00755508|DRUG|Ramelteon and gabapentin|Ramelteon 4 mg, tablets, orally, once daily and gabapentin 400 mg, capsules, orally, once daily for up to one week.
223513482|NCT04297735|BEHAVIORAL|Telemedicine|Review details of medication indication and use, activity recommendations and changes, and knowledge of arrhythmia changes and activities which are helpful with arrhythmia changes.
223513483|NCT05678127|PROCEDURE|Skin biopsy|"Two 3mm skin biopsies from the abdominal wall will be taken. One at the triggerpoint of the pain, the second one at the contralateral, non-affected side of the abdominal wall.~Lidocaine will be used for local anaesthesia of the skin, before the biopsies will be taken."
223513484|NCT00032331|PROCEDURE|PET Imaging|
223513485|NCT00032331|PROCEDURE|CT scan|
223513486|NCT03906955|BEHAVIORAL|Efficacy for Lifestyle PA|The intervention group is asked to participate in three (10-minute) video chats during the first three weeks of six weeks of engaging in lifestyle physical activity. Participants in this group will receive information that addresses outcome expectations in week one (e.g. physical, social, and self-evaluative outcomes and intrinsic and extrinsic motives), self-efficacy in week two (e.g. the four efficacy sources: vicarious experiences, mastery experiences, social persuasion, and perceptions of physiological and affective responses to behavior), and self-regulatory strategies in week three (e.g. goal-setting, self-monitoring, and planning) for engaging in lifestyle physical activity.
223513487|NCT03906955|BEHAVIORAL|Efficacy for Work-life Balance|The time-matched control group is asked to participate in three (10-minute) video chats during the first three weeks of six weeks of engaging in lifestyle physical activity. Participants in this group will receive information that addresses outcome expectations in week one (e.g. physical, social, and self-evaluative outcomes and intrinsic and extrinsic motives), self-efficacy in week two (e.g. the four efficacy sources: vicarious experiences, mastery experiences, social persuasion, and perceptions of physiological and affective responses to behavior), and self-regulatory strategies in week three (e.g. goal-setting, self-monitoring, and planning) for work-life balance.
223513488|NCT06088914|DEVICE|Anodal transcranial direct current stimulation|Anodal tDCS will be delivered for 5 consecutive days. Participants will receive 2 mA of stimulation for 20 minutes with the anodal electrode placed on the ipsilesional primary motor cortex (M1) and the cathodal electrode placed over the contralateral supraorbital area.
223513489|NCT06088914|DEVICE|Sham transcranial direct current stimulation|Sham tDCS will be delivered for 5 consecutive days. Participants will receive sham stimulation for 20 minutes with the current intensity ramping down after 30 seconds of stimulation. The anodal electrode placed on the ipsilesional primary motor cortex (M1) and the cathodal electrode placed over the contralateral supraorbital area.
223513490|NCT01807741|DRUG|Asenapine|Available in 5 and 10 mg.
223513491|NCT01807741|DRUG|Placebo|
223513492|NCT05546372|DEVICE|Endobiliary radiofrequency ablation (eRFA)|Intraductal radiofrequency ablation of tumor prior to stent placement
223513493|NCT05546372|DEVICE|uncovered self-expanding metal stent (uSEMS)|Intraductal placement of uncovered metal stent
223513494|NCT02082782|PROCEDURE|Irreversible electroporation (IRE)|Percutaneous (CT-guided) or open (US-guided) irreversible electroporation of central colorectal liver metastasis.
223513495|NCT06199830|DIAGNOSTIC_TEST|positive bronchial provocation test|Patients were asked to inhale gradually increasing doses of methacholine (0.9% saline, 0.078, 0.312, 1.125 and 2.504 mg), and FEV1 was measured after each inhalation. This test was stopped until a reducing in baseline FEV1 of 20%.
223623946|NCT00079040|BIOLOGICAL|bevacizumab|Given IV
223623947|NCT00079040|OTHER|laboratory biomarker analysis|Correlative studies
223762043|NCT03950518|DRUG|Anlotinib Hydrochloride Capsules|Anlotinib Hydrochloride Capsules, 12mg/d
223762044|NCT03950518|DRUG|Arginine hydrochloride|AHC,12mg/d AH,40g/d
223623948|NCT03688269|DRUG|Intravenous dexamethasone|Intravenous injection of 8mg/2ml dexamethasone
223623949|NCT03688269|DRUG|Intravenous saline|Intravenous injection of 2ml Saline 0.9%
223623950|NCT03688269|DRUG|Perineural ropivacaine|Perineural injection of 20ml ropivacaine with adjustment of the concentration determined by sequential up and down method
223762045|NCT03950518|DRUG|levamisole|AHC,12mg/d AH,40mg/d LM,150mg/d
223762046|NCT03962803|BIOLOGICAL|20 µg recombinant hepatitis B vaccine at months 0, 1, and 6|three-dose, 20 µg per dose
223623951|NCT05511181|DEVICE|BioWave|The BioWave device is called BioWaveGO. It is a FDA 510(k) cleared high frequency sinusoidal neurostimulator
223623952|NCT05511181|DEVICE|TENS|The TENS device is called Intensity 5000. It is a FDA 510(k) cleared TENS device
223623953|NCT06329908|DRUG|LG002|Neo-DCVac combined with ICIs in the treatment of advanced lung cancer resistant to ICIs.
223623954|NCT04506840|OTHER|Physical activity|Patients will participate in a program of physical exercise. Resistance training, endurance training, balance and flexibility will be trained with the objective to reduce the side effects of chemotherapy and, in order to improve their quality of life
223623955|NCT04056819|BIOLOGICAL|Allogeneic umbilical cord mesenchymal stem cells|UMSC01 cells will be one single IC infusion followed by one single IV infusion with 12 months of follow up after treatment.
223623956|NCT00325897|DRUG|Macrolide Antibiotic (Azithromycin)|Azithromycin (daily capsule, 250 mg for 12 months)
223623957|NCT00325897|DRUG|Placebo|Placebo taken on a daily basis
223623958|NCT04418791|BEHAVIORAL|Modified Intermittent Fasting followed by Regular Diet|Modified intermittent fasting (MIF) means fasting for 2 non-consecutive days/week. Fasting is defined as consuming less than 500 kcalories in 1 day (in the course of max. 6 hours). After 12 weeks of fasting, a period of 12 weeks with a regular diet follows.
223623959|NCT04418791|BEHAVIORAL|Regular Diet followed by Modified Intermittent Fasting|Regular diet means subject can eat as usual for 12 weeks. Next, a period of 12 weeks fasting follows: modified intermittent fasting (MIF) means fasting for 2 non-consecutive days/week. Fasting is defined as consuming less than 500 kcalories in 1 day (in the course of max. 6 hours).
223623960|NCT03380728|DRUG|Ibogaine Hydrochloride|The first 3 patients will receive oral doses of 20 to 400 mg of ibogaine in an open-label design. If the 3 higher doses (240, 320 and 400 mg) are well tolerated, the next 9 volunteers will receive these doses or placebo randomly in 3 different groups.
224213290|NCT00755508|DRUG|Ramelteon and gabapentin|Ramelteon 8 mg, tablets, orally, once daily and gabapentin 800 mg, capsules, orally, once daily for up to one week.
223623961|NCT05781178|DIETARY_SUPPLEMENT|Oral nutritional supplement rich in omega-3 and olive oil polyphenols|Nutritional intervention with an oral nutrition supplement with anti-inflammatory effect and a programme of physical exercise
223623962|NCT02366494|DRUG|Bicalutamide|ANDROGEN BLOCKADE
223623963|NCT02366494|DRUG|Leuprolide|ANDROGEN BLOCKADE
223623964|NCT02366494|DRUG|Goserelin|ANDROGEN BLOCKADE
223623965|NCT02366494|DRUG|Triptorelin|ANDROGEN BLOCKADE
223623966|NCT02366494|DRUG|Docetaxel|Chemo hormonal therapy
223623967|NCT02366494|DRUG|Abiraterone|Chemo hormonal therapy
223623968|NCT02366494|DRUG|Apalutamide|Nonsteroidal antiandrogen medication
223623969|NCT02366494|DRUG|Enzalutamide|Nonsteroidal antiandrogen medication
223623970|NCT04701008|DRUG|Ketamine|IV ketamine - 10mg bolus may be repeated repeated 2-3 times depending on clinical judgement
223623971|NCT04991649|BEHAVIORAL|Acceptance and Commitment Therapy-based Asthma Management Training Program|In addition to the routine pediatric asthma outpatient service as received with the TAU group, participants in the ACT group will additionally receive a two-weekly 2-hour Positive Parenting Program (Triple-P) and a four-weekly 2-hour ACT program (a total of six weekly sessions, 6-8 parents per group). The Triple-P aims to increase parental self-regulation and positive parenting practices to promote child cooperation, lead to consistent discipline and promote routines in childhood asthma management. On the other hand, The ACT sessions foster parents' psychological flexibility to cultivate non-judgmental acceptance of difficult parenting experiences, be mindful in daily parenting, develop an observer-self, and promote commitment to one's values.
223762047|NCT03962803|BIOLOGICAL|20 µg recombinant hepatitis B vaccine at months 0, 1, 2, and 6|four-dose, 20 µg per dose
223762048|NCT03962803|BIOLOGICAL|60 µg recombinant hepatitis B vaccine at months 0, 1, 2, and 6|four-dose, 60 µg per dose
223762049|NCT03164967|BIOLOGICAL|Bivigam|
223762050|NCT06406530|PROCEDURE|PRF|Patients blood is standardized centrifuged and split in to a red-phase (erythrocytes) and white-phase (PRF). The gained PRF is processed to a clot-fort and is inserted into the alveolus.
223762051|NCT06406530|PROCEDURE|Natural Healing|After the tooth extraction, natural healing is aimed by allowing a blood clot formation without any further intervention.
223762052|NCT04382911|DRUG|18F-fluoroestradiol|Patients will receive the FES tracer during a PET/MRI scan
223762053|NCT04126512|OTHER|PDA ligation|PDA ligation was performed at bedside, if a local cardiac surgery team was available, or in the case this service was not available, infants were referred to off-site specialist paediatric cardiac surgical services, where PDA ligation was performed.
223762054|NCT05996120|PROCEDURE|Hypothermic Cardiopulmonary Bypass|Mild hypothermia (between 32 - 35 °C) during cardiopulmonary bypass
223762055|NCT05996120|PROCEDURE|Normothermic Cardiopulmonary Bypass|Normothermia (active maintenance of temperature between 36.5 °C to 37.5°C; no active cooling below 36.5 °C) during cardiopulmonary bypass
223762056|NCT05950568|PROCEDURE|Quadratus lumborum block typen II|A 22 gauge needle was positioned between the quadratus lumborum muscle posterior border and the erector spinae muscle in the thoracolumbar fascia's middle layer
223762057|NCT05950568|PROCEDURE|Quadratus lumborum block III|A 22 gauge needle was positioned between the psoas and quadratus lumborum muscles at the anterior fascia lumbosacral
224213291|NCT00755508|DRUG|Ramelteon|Ramelteon 8 mg, tablets, orally, once daily and gabapentin placebo-matching capsules, orally, once daily for up to one week.
224213292|NCT00755508|DRUG|Gabapentin|Ramelteon placebo-matching tablets, orally, once daily and gabapentin 800 mg, capsules, orally, once daily for up to one week.
224213293|NCT00755508|DRUG|Placebo|Ramelteon placebo-matching tablets, orally, once daily and gabapentin placebo-matching capsules, orally, once daily for up to one week.
224213294|NCT03577652|DRUG|Ticagrelor|Ticagrelor, 90mg, 90mg twice daily
224213295|NCT06061718|DRUG|iDose TR|anchored intracameral implant containing travoprost
224213296|NCT03636542|DRUG|liposomal bupivacaine|Experimental
224213297|NCT03636542|DRUG|bupivacaine|Active comparator
224213298|NCT03791918|DRUG|Lenvatinib|12 mg (or 8 mg) once daily (QD) oral dosing.
224213299|NCT03791918|DRUG|PD-1 antibody|3mg/kg intravenously every 2 weeks
224213300|NCT03791918|PROCEDURE|TACE|A standard hepatic artery catheter was introduced via the femoral artery percutaneously. Selective catheterization of the proper hepatic artery was performed using standard diagnostic catheters and fluoroscopic guidance. TACE Drug Protocol were injected.
223623972|NCT04991649|BEHAVIORAL|Treatment-as-usual Group|Participants in the treatment-as-usual (TAU) group will receive routine pediatric asthma outpatient services. These services include regular follow-up appointments once every 3-6 months for reviewing the child's health conditions by pediatricians, refilling medications and asthma education (1.5-2 hours every 3-4 weeks) by Advanced Practice Nurse specialized in pediatric respiratory care, and referrals to community care/welfare services by psychiatrist/medical social worker for parental training in ADHD care.
223623973|NCT03870919|DRUG|Palbociclib|"The included patients will first receive the following systemic treatment according standard of care:~* Non-steroidal aromatase inhibitor (letrozole)~* Palbociclib~* Monthly Luteinizing hormone-releasing hormone (LHRH) analogue for non-menopausal patients only. Surgical bilateral oophorectomy is an acceptable option."
223623974|NCT03870919|OTHER|locoregional treatment|After normally 6 courses of systemic treatment initiation, the loco-regional treatment of the primary tumour will be performed: surgery (conservative or mastectomy) with or without radiotherapy, or radiotherapy
223623975|NCT05954858|PROCEDURE|Tissue autograft of pedicled temporoparietal fascial (TPF) or pericranial flap to bypass the blood brain barrier (BBB)|Surgical tissue autograft of pedicled temporoparietal fascial (TPF) or pericranial flap into the resection cavity of newly diagnosed glioblastoma multiforme (GBM) patients.
223623976|NCT03740022|PROCEDURE|ACL plasty|standard ligamentoplasty by Kenneth Jones
223623977|NCT03740022|PROCEDURE|ACL + ALL plasty|standard ligamentoplasty and anterolateral plasty
223623978|NCT05748275|DIAGNOSTIC_TEST|Argos|Biometry measurements first with the Argos device, then the IOLMaster 700 device.
223623979|NCT05748275|DIAGNOSTIC_TEST|IOLMaster 700|Biometry measurements first with the IOLMaster 700 device, then the Argos device.
223623980|NCT06172452|BEHAVIORAL|Project Body Neutrality SSI|Online, 30-minute self-guided intervention for youth ages 13-17
223623981|NCT06172452|BEHAVIORAL|Supportive Therapy SSI|Online, 30-minute self-guided activity for youth ages 13-17
224213301|NCT03791918|DRUG|TACE Drug Protocol|lipiodol mixed with chemotherapy drugs(EADM , lobaplatin, and MMC) followed by polyvinyl alcohol particles (PVA)
223623982|NCT03915717|DEVICE|EchoMark|EchoMark is implanted during surgery to mark the at-risk blood vessels to enable EchoSure ultrasound-based monitoring
223623983|NCT03915717|DEVICE|EchoSure|EchoSure ultrasound scans are performed to monitor the free flap
223623984|NCT03093909|DRUG|Gemcitabine|Nebulized dose of aerosol GCB twice a week continuously (escalating treatment dose schema, starting at 0.75 mg/kg to 3.0 mg/kg). Participants receive a pre-determined volume of nebulized solution, according to the dose level and weight of the participant, with each aerosol GCB administration. One cycle is 4 weeks in duration.
223623985|NCT05837390|DEVICE|Cervical stiffness assessment|The cervical stiffness is assessed by using the licensed, CE-marked Pregnolia System, during a sterile speculum examination. The single-use, sterile Pregnolia Probe is placed on the anterior lip of the cervix at 12 o'clock position and a recording of cervical stiffness is generated over maximum 60 seconds (typically ̴15 seconds) and displayed as Cervical Stiffness Index (CSI) in mbar. The measurement is repeated 3 consecutive times without any time lag.
223623986|NCT05837390|OTHER|Cervical length measurement|Cervical length measurement will be obtained via transvaginal ultrasound using a GE Voluson E10 ultrasound machine and 7.5MHz transvaginal probe. All measurements will be performed with the woman in a supine position with an empty bladder in the sagittal plane measuring from the internal to external cervical OS. The full length of the cervical canal will be visualized with the closed portion of cervix remaining being measured. Three measurements are taken with the shortest being documented as the final assessment.
223623987|NCT05837390|OTHER|Fetal fibronectin|Vaginal swab collection. The specimen will be obtained from the posterior fornix over 10 seconds using the polyester tipped swab provided in the Hologic specimen collection kit. This sample will be then be stored frozen and processed using the Rapid fFN 10Q System (HOLOGIC, Marlborough, MA, USA) within 3 months.
223762058|NCT05950568|PROCEDURE|Transversus abdominis plane block|A 22 gauge needle was positioned between the internal oblique and transversus abdominis muscles
224213302|NCT05634018|DIAGNOSTIC_TEST|aneurysmectomy with sampling of a segment of the aneurysm wall|"Patients with aneurysms of the abdominal aorta undergo an ultrasound examination of the abdominal aorta to assess the elastic properties of the aortic wall. The accessible wall of the abdominal aortic aneurysm is taken intraoperatively.~In in vitro studies, the strength properties of the aneurysm wall are measured during uniaxial tension on a tensile testing machine, which makes it possible to evaluate the elastic properties of the test sample.~The assessment of the boundaries of the linearity of the surface under study, as well as the yield strength of the vascular wall and thrombotic masses, is evaluated under shear stresses using a rheometer. To correlate the mechanical properties with the structural composition of the aneurysm tissue, spectral analysis of the studied tissues by laser-induced fluorescence and histological examination with staining of the obtained sections for the presence of elastic fibers, fibrous tissues and calcification will be used."
224213303|NCT02156518|PROCEDURE|Vocal Function Exercises|Vocal Function Exercises
224213304|NCT02156518|PROCEDURE|Vocal Hygiene|Vocal Hygiene
224213305|NCT02773888|DEVICE|HS-1000|
224213306|NCT02947373|DRUG|Hyperpolarized Pyruvate|Hyperpolarized Pyruvate
224213307|NCT03910582|PROCEDURE|personalized frozen-thawed embryo transfer|The blastocysts were delayed or advanced transferred after ovulation depending on the endometrium dating in RIF group
224213308|NCT03910582|PROCEDURE|routine frozen-thawed embryo transfer|The blastocysts were transferred 5 days after ovulation regardless of endometrium dating in control group.
224213309|NCT05698420|DEVICE|Dialysis using the Theranova-400 device.|Patients receive hemodialysis treatment using the Theranova-400 dialyzer.
224213310|NCT05698420|DEVICE|Dialysis using the FX80 device.|Patients receive hemodialysis treatment using the FX80 dialyzer.
224213311|NCT06013020|DRUG|NOAC+DAPT|Century Clot-guided rivaroxaban plus DAPT.
224213312|NCT06013020|DRUG|DAPT|Standard DAPT for 1 month, following lower-dose ticagrelor or clopidogrel plus aspirin for 11 months.
223623988|NCT05954468|OTHER|standardized and validated surveys|To evaluate the cognitive and psycho-social long term impact of a NMDAR encephalitis, we will collect the data using specific interview assessments such as the PROMS (Patient-reported Outcome Measures Information System) and PREMS (Patient-reported experiences measures) as well as we will check the cognitive performance in order to combine the expertise from clinical neurology, social \& health psychology
224213313|NCT02677610|DRUG|MSRD-100|MSRD-100 is a topical gel.
223623989|NCT06542029|BEHAVIORAL|Groups 4 Health (G4H)|"Groups 4 Health, G4H, (Ryhmät kuntoon) at the University of Helsinki is a manualized group intervention for the students that focuses on social connectedness and aims at improving general health and life satisfaction. G4H groups are facilitated by two psychology MA students (or licensed psychologists) carefully trained for the intervention and mentored by experienced clinical psychologists. G4H consists of five 90 minutes sessions that aim to give participants the knowledge and skills they need to effectively manage their social group memberships and identities. Each session contains exercises and discussions described in the G4H workbook that target different aspects of group life identified within the social identity model of identity change and put the Social Identity Approach to Health -model to practice. Students earn 2 ECTS (European Credit Transfer and Accumulation System) credits for completing the intervention."
224213314|NCT02677610|DRUG|Vehicle|Vehicle is a topical gel without the active ingredient in MSRD-100
223623990|NCT06542029|BEHAVIORAL|The study psychologists' group intervention|University of Helsinki study psychology team organizes group interventions for various challenges of studying for bachelor's and master's students. These groups offer client-centered peer support facilitated by one to two study psychologists. Recurring themes in the groups include: challenges in attentiveness, independent studying, and scientific writing, as well as support for re-entering the studies after a break. The approach in the different thematic groups is largely similar: short presentations, group discussions and practices. These groups have been implemented as both face-to-face and remote meetings. One group typically lasts for a study period and comprises five to six 90 minutes sessions. Typical group size is six to 12 students.
224316515|NCT02335918|DRUG|Combination of varlilumab and nivolumab|"Phase I: Varlilumab dosing will be dependent on the cohort assigned in combination with 3 mg/kg of nivolumab every two weeks.~Phase II: Patients with CRC, RCC or GBM enrolled in Phase ll will receive 3.0 mg/kg of varlilumab in combination with 240 mg of nivolumab every 2 weeks. Patients with SCCHN or ovarian cancer will receive varlilumab at a dose of either 3 mg/kg every 2 weeks, 3 mg/kg every 12 weeks, or 0.3 mg/kg every 4 weeks, in combination with 240 mg of nivolumab every 2 weeks.~Patients may be discontinued from receiving study treatment based on the results of disease assessments or if experiencing intolerable side effects."
223623991|NCT06542029|BEHAVIORAL|Towards better well-being and studying -online course|"Towards better well-being and studying -online course (Kohti parempaa opiskelua) is an optional, seven-week online course that aims to foster university students' well-being and study skills. It is available for all University of Helsinki students. The course is based on principles of Acceptance and Commitment therapy and aims to support the development of psychological flexibility. The course takes place in Moodle platform and the students earn 3 ECTS credits for completing it. This course progresses week by week and has six central themes which include individual work in practicing psychological flexibility skills as well as study skills on a weekly basis and weekly group discussion."
223623992|NCT05655598|DRUG|Palbociclib Oral Product|125 mg/day (FDA approved dose) or the last tolerated dose before progression for 21 days of a 28-day cycle
223623993|NCT05655598|DRUG|TAS-116|120 mg/day, 5 days on 2 days off, for days 1-28 of a 28 day cycle
223623994|NCT05655598|DRUG|TAS-116|80 mg/day, 5 days on 2 days off, for days 1-28 of a 28 day cycle
223623995|NCT05655598|DRUG|TAS-116|40 mg/day, 5 days on 2 days off, for days 1-28 of a 28 day cycle
224213315|NCT00559884|DRUG|GSK189075 (Modified and immediate release formulations)|
224213316|NCT03101579|DRUG|Pemetrexed|Pemetrexed,10-15 mg, intrathecal injection via lumbar puncture, twice per week for 2 weeks, followed by once per week for 2-4 weeks.
224213317|NCT03101579|DRUG|Dexamethasone|Dexamethasone, 5 mg, intrathecal injection via lumbar puncture, simultaneously with pemetrexed, twice per week for 2 weeks, followed by once per week for 2-4 weeks.
224213318|NCT03101579|DRUG|Folic Acid|Folic acid, 400 μg, oral, once per day, prior to the first intrathecal pemetrexed, until 21 days after the last intrathecal pemetrexed.
224213319|NCT03101579|DRUG|Vitamin B12|A single dose of vitamin B12 1000 μg, intramuscular injection, before the first intrathecal pemetrexed.
224213320|NCT00701935|DRUG|placebo|subcutaneous injection, twice a day
224213321|NCT00701935|DRUG|exenatide|subcutaneous injection, twice a day, 10mcg
224213322|NCT02478593|BEHAVIORAL|Educational booklet|Participants in the intervention group will receive an 8-page booklet that includes a list of generic and brand benzodiazepine names, benzodiazepine medication knowledge test, information about the associated risks of benzodiazepine use, and a list of safe alternative to their potentially inappropriate medication, as well as a stepwise tapering method. Recommendations to discuss decreasing use of benzodiazepines with physicians as well as to consult physicians before stopping any medication are also advised in the booklet. Participants in the control group will receive a booklet, produced by the Centers for Disease Control and Prevention, containing information regarding the important of exercise for seniors.
224213323|NCT03912688|DEVICE|acupoint stimulation|
224213324|NCT03912688|DEVICE|single acupoint|
224213325|NCT03912688|DEVICE|dual acupoints|
224213326|NCT00703378|DRUG|Docetaxel (Taxotere®)|Phase 1 Cycle 1 and 2 Patients in group 1 receive 40mg/m2/week of docetaxel in a 1-hour infusion. Patients in group 2 receive 30mg/m2/week of docetaxel in a 1-hour infusion. Patients in group 3 receive 20mg/m2/week of docetaxel in a 1-hour infusion.
223623996|NCT03023202|OTHER|PMMTB (Precision Medicine Molecular Tumor Board)|PMMTB is a clinical intervention, NOT a research intervention. The research component of this study is to observe the outcomes of the PMMTB.
223623997|NCT05668234|OTHER|interview|semi-directive interview
223623998|NCT05553509|OTHER|PER CUTANEOUS TRANSLUMINAL ANGIOPLASTY|SURGICAL DEBRIDEMNT
224213327|NCT04373161|DEVICE|Home Pulse Oximetry Monitoring|Patients to check their home oxygen saturation three times daily and return to the ED for sustain oxygen \<92% or for worsening symptoms.
224213328|NCT00469534|PROCEDURE|IMRT|
224213329|NCT02344134|BIOLOGICAL|NBP607|0.5 mL, intramuscular, a single dose
224213330|NCT02344134|BIOLOGICAL|Agrippal S1|0.5 mL, intramuscular, a single dose
224213331|NCT04952441|BEHAVIORAL|RISE Program|Psychoeducational sessions designed to impact Resilience, Insight, Self-Compassion, and Empowerment
223623999|NCT03808090|DIETARY_SUPPLEMENT|Normal Individuals|"Controlled Dietary phase: Low oxalate fixed diet~4 days of fixed normal calorie diet with low oxalate (\< 60 mg/day), normal calcium (800-1200 mg/day)"
223624000|NCT04737512|BEHAVIORAL|Mindfulness-Based ADHD Treatment for Children|MBAT-C is derived from Mindfulness-Based Stress Reduction (MBSR), a well-known and extensively-studied mindfulness intervention. Unlike all other mindfulness-based interventions, however, MBAT-C is tailored to the needs, abilities, and vulnerabilities of children with ADHD through the use of age-appropriate class length, homework assignments, contemplative practices, and discussion topics.
224213332|NCT06120452|OTHER|Rael Miracle Clear Complete Acne Serum|"This acne serum contains the following ingredients:~1.5% Salicylic acid. 2% Niacinamide. 0.5% Zinc Pyrrolidone Carboxylic Acid (PCA). Hyaluronic Acid."
224213333|NCT03674827|BIOLOGICAL|PF-06936308|PF-06936308 components will be administered 4 times per cycle. A cycle is 4 months.
224213334|NCT04379661|BEHAVIORAL|Online support Group|12 one-hour, once-weekly online support groups for people with Multiple Sclerosis to address anxiety related to the COVID-19 outbreak and its effects on them.
224213335|NCT00527397|DRUG|CP-464,005|Taken for 1 year (52 weeks) immediately before each meal (breakfast, lunch, and supper). Dose: adjusted based on the results of self-monitoring of blood glucose before each meal.
223624001|NCT04737512|BIOLOGICAL|Goal-Standard Medication (Treatment as Usual)|"Participants will receive gold-standard, non-experimental medication. This treatment arm relies on a step-by-step approach that is designed to mimic pharmacologic treatment-as-usual in the community. The treatment algorithm is as follows:~1. All participants will start with Concerta; Ritalin may be started if the effect of Concerta wears off mid-day;~2. If Concerta +/- Ritalin is ineffective or not tolerated, participants will progress to Vyvanse; Adderall may be started if the effect of Vyvanse wears off mid-day;~3. If Vyvanse +/- Adderall is also ineffective or not tolerated, participants will progress to Kapvay;~4. If Kapvay is ineffective or not tolerated, participants will progress to Intuniv.~5. Alternative combinations of the above medications will be considered if the above combinations are ineffective or otherwise not tolerated."
223762059|NCT04521166|DEVICE|Hearing aid|Settings in a wearable hearing aid will be adjusted within a clinically-relevant range for two features. The features include wide dynamic range compression and microphone directionality.
223762060|NCT04059848|COMBINATION_PRODUCT|tDCS(Intelect Mobile Stimulation and Combination, DJO, France)|
224213336|NCT00527397|DRUG|CP-464,005|Taken for 1 year (52 weeks) immediately before each meal (breakfast, lunch, and supper). Dose: adjusted based on the results of self-monitoring of blood glucose before each meal.
224213337|NCT00527397|DRUG|CP-464,005|Taken for 1 year (52 weeks) immediately before each meal (breakfast, lunch, and supper). Dose:adjusted based on the results of self-monitoring of blood glucose before each meal.
224213338|NCT05990205|DRUG|Life Style Intervention + Metformin|hypocaloric diet, 25 kcal/kg of ideal weight, 45% of the total intake of carbohydrates, 30% lipids, and 25% protein sources + physical activity (\>150 min medium intensity per week) + Metformin extended release 750mg each 12 hours
224213339|NCT05990205|BEHAVIORAL|Life Style Intervention|hypocaloric diet, 25 kcal/kg of ideal weight, 45% of the total intake of carbohydrates, 30% lipids, and 25% protein sources + physical activity (\>150 min medium intensity per week)
224213340|NCT01559961|DRUG|TTI-1612|Single intravesical 30-minute treatments with escalating doses of TTI-1612.
224213341|NCT01783483|DEVICE|SternaLock Blue closure system|SternaLock Blue closure system is a primary closure system plate-based
224213342|NCT01783483|DEVICE|Suture Wire|Closure system wire-based used to approximate the two halfs of the sternum following a median sternotomy.
224213343|NCT05751083|OTHER|brisk walk+ low intensity aerobic exercises|"Brisk Walking Protocol General flexibility Exercises Protocol Chair Sitting~1. Extending leg up then down~2. Raising up then down on toes later heels~3. Marching in place~4. Bringing leg to sideway then back towards middle~5. Bringing leg towards chair then forward~6. Bend arms up towards shoulders then back down again.~7. Pushing arms away from chest then back~8. Pushing arm up from shoulders then back down~9. Raising shoulders towards ears then back down~10. Rolling shoulders forward and backward~11. Raising arm at shoulder levels and extend forearm upward towards ceiling then back down~12. Bringing elbows inwards and outwards from chest Standing Balance Exercises"
224213344|NCT05751083|OTHER|Brisk walk|"Brisk Walking Protocol~The brisk walking protocol will consist of :~1. 10 min: warming up of the knees, hips and back by flexibility exercises~2. 30 min of walking~3. 5 min of cool down."
223762061|NCT04059848|COMBINATION_PRODUCT|NMES(Enraf Nonius, Endomed-182, Netherlands)|
223762062|NCT00006012|BIOLOGICAL|filgrastim|
223762063|NCT00006012|DRUG|amifostine trihydrate|
223762064|NCT00006012|DRUG|cisplatin|
223762065|NCT00006012|DRUG|etoposide|
224213345|NCT00158327|BEHAVIORAL|Telephone-based collaborative care|Participants assigned to the telephone-based program will have a choice of what type of treatment they will receive. The choices will include pharmacotherapy, workbook training designed to help participants improve their coping skills, referral to a community mental health specialist, or some combination of these treatments. Participants will receive telephone calls one to two times every month for 12 months. During the calls, participants will be asked about their attitude toward and adherence to their treatment regimen. They will also be asked about recent episodes of anxiety they have experienced and what coping techniques they have used.
223762066|NCT00006012|DRUG|paclitaxel|
223762067|NCT00006012|DRUG|topotecan hydrochloride|
223762068|NCT00006012|RADIATION|radiation therapy|
223762069|NCT06431061|DEVICE|Lens A (omafilcon B)|15 minutes of daily wear.
223624002|NCT05405920|BEHAVIORAL|Team-based Care Strategy for Hypertension Control|The core component of the intervention is a stepped-care protocol, based on the 2017 American College of Cardiology (ACC)/American Heart Association (AHA) Clinical Practice Guideline for High Blood Pressure and the 2021 World Health Organization (WHO) Hypertension Guideline. Using a team-based care model, a physician-nurse-CHW team will work with patients to implement clinical guideline-based treatment in all intervention clinics. Team-based care components will include task sharing and shifting, health care team training, home BP monitoring, BP audit and feedback, and CHW-led health coaching on lifestyle modification and medication adherence.
223624003|NCT05405920|BEHAVIORAL|Enhanced Usual Care|We will train the primary care physicians, nurses, and other clinic staff in performing standardized BP measurements. We will offer physician education on clinical guidelines for hypertension management and issue continuing medical education credits. Patient educational materials will be distributed. We will not conduct any other interventions in the enhanced usual care clinics.
223624004|NCT03748823|COMBINATION_PRODUCT|Ravulizumab OBDS|The ravulizumab OBDS is a biological-device combination product consisting of a prefilled cartridge containing ravulizumab SC and an on-body injector.
223624005|NCT03748823|BIOLOGICAL|Ravulizumab|Administered by IV infusion. Ravulizumab IV doses will be based on participant body weight.
223624006|NCT06120712|BIOLOGICAL|GC101 TIL|"Patients with advanced, recurrent or metastatic melanoma (excluding uveal melanoma) who have failed standard treatment such as PD-1 antibodies (if BRAF mutation is present, BRAF and MEK inhibitors have failed) and are ineligible for resection."
223624007|NCT00590187|DRUG|Sapacitabine, Arm A|200 mg b.i.d. x 7 days every 3-4 weeks
223624008|NCT00590187|DRUG|Sapacitabine, Arm B|300 mg b.i.d. x 7 days every 3 - 4 weeks
223624009|NCT00590187|DRUG|Sapacitabine, Arm C|400 mg b.i.d. x 3 days/week x 2 weeks every 3 - 4 weeks
223624010|NCT00590187|DRUG|Sapacitabine, Arm D|200 mg b.i.d. x 7 consecutive days every 4 weeks
223624011|NCT00590187|DRUG|sapacitabine, Arm E|300 mg q.d. x 7 consecutive days every 4 weeks
223624012|NCT00590187|DRUG|sapacitabine, Arm F|300 mg b.i.d. x 3 consecutive days per week for 2 weeks every 4 weeks
224213346|NCT00158327|BEHAVIORAL|Usual care|Usual care may include one or more of several different treatments such as pharmacotherapy and cognitive behavioral therapy; the treatments will be chosen by participants' physicians and will be delivered for 12 months.
223624013|NCT00590187|DRUG|Sapacitabine, Arm G|200 mg b.i.d. x 7 consecutive days every 4 weeks
223624014|NCT00590187|DRUG|Sapacitabine, Arm H|300 mg q.d. x 7 consecutive days every 4 weeks
223624015|NCT00590187|DRUG|Sapacitabine, Arm I|100 mg q.d. x 5 consecutive days per week for 2 weeks every 4 weeks
223624016|NCT05003479|BIOLOGICAL|SARS-CoV-2 Vaccine (Vero Cells), Inactivated|2 doses of SARS-CoV-2 Vaccine (Vero Cells), Inactivated should be administered as an intramuscular injection into the lateral deltoid of the upper arm with a 28-day interval.
224213347|NCT06567093|OTHER|Baby Foot and Leg Massage|"Baby Foot Massage stages~* The baby is placed on his back, either on the bed or on the couch.~* One of the baby's feet is lifted into the air by grasping the back of the ankle.~* Start stroking with circular movements, starting from the heel and moving up to the toes. Stroking should be done with the thumb.~* Here, it might be good to get between the toes.~* The same procedure is applied to the other foot.~* Massage is continued until it is noticed that the baby calms down.~Baby Leg Massage stages~* Start by lifting the leg to be massaged.~* Here, the palms of both hands are used. The baby's leg is placed between both hands and the leg is stroked by moving the palms in opposite directions. This movement is continued from above the ankle to the hip.~* The same procedure is applied to the other leg.~* Massage is continued until the baby calms down."
223624017|NCT05003479|BIOLOGICAL|Placebo|2 doses of Placebo should be administered as an intramuscular injection into the lateral deltoid of the upper arm with a 28-day interval.
223624018|NCT03345251|DEVICE|Hydrotubation|
223624019|NCT01664910|PROCEDURE|Allogeneic Bone Marrow Transplantation|Undergo allogeneic BM transplant
223624020|NCT01664910|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic PBSC or BM transplant
223624021|NCT01664910|BIOLOGICAL|Anti-Thymocyte Globulin|Given IV
223624022|NCT01664910|DRUG|Bendamustine Hydrochloride|Given IV
223624023|NCT01664910|DRUG|Fludarabine Phosphate|Given IV
223624024|NCT01664910|BIOLOGICAL|Inotuzumab Ozogamicin|Given IV
223624025|NCT01664910|DRUG|Methotrexate|Given IV
223762070|NCT06431061|DEVICE|Lens B (comfilcon A)|15 minutes of daily wear.
223624026|NCT01664910|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo allogeneic PBSC transplant
223624027|NCT01664910|BIOLOGICAL|Rituximab|Given IV
223624028|NCT01664910|DRUG|Tacrolimus|Given IV or PO
223624029|NCT03929185|DIAGNOSTIC_TEST|blood analysis with SCENT B1|analyze blood samples with chemoresistive sensors
223624030|NCT03929185|DIAGNOSTIC_TEST|tissue analysis with SCENT B1|analyze tumor biopsies collected during surgery with chemoresistive sensors
223624031|NCT04479085|OTHER|nursing intervention|"It includes individual trainings for the regulation of the home environment,~give a booklet~to reinforce education and to give anti-allergic bedding sets."
223624032|NCT00984477|DRUG|AZD5122|A single dose of oral suspension
223624033|NCT00984477|DRUG|Placebo|A single dose of oral suspension
223624034|NCT00984477|DRUG|AZD5122|A single intravenous infusion
223624035|NCT05675319|DRUG|Allogeneic Stem Cells|Allogeneic Stem Cell Transplantation
223624036|NCT05675319|DRUG|carfilzomib/lenalidomide/dexamethasone (KRD)|triple regimen for first relapse should be applied according to latest Summary of Product Characteristics (SmPC) version
223624037|NCT05675319|DRUG|elotuzumab/lenalidomide/dexamethasone (ERD)|triple regimen for first relapse should be applied according to latest SmPC version
223624038|NCT05675319|DRUG|daratumumab/bortezomib/dexamethasone (DVD)|triple regimen for first relapse should be applied according to latest SmPC version
223762071|NCT02614547|DRUG|SAGE-547|Administered as intravenous infusion.
224213348|NCT02832791|PROCEDURE|QUADRICEPS TENDON|Once the limb is prepped and draped,it is exsanguinated, and the tourniquet is raised to 250 mm Hg. We will make an arthroscopic examination through an anterolateral viewing portal to corroborate the ACL injury as well as the determination of possible associated lesions. The accessory medial portal is stablished slightly above the joint line (about 2 cm of the medial edge of the patel) that is used as an instrumentation portal. Then,, a high anteromedial portal, is made higher than the previous to see the femoral footprint. Once the associated meniscal or cartilaginous lesions are addressed attention turns to the harvesting of the graft. A 4 cm vertical incision is made starting at the proximal pole of the patella and directed proximally and centered in line with the quadriceps tendon. The subcutaneous tissue is dissected and a 70-80 mm long ,10 mm wide and 7mm depth graft is obtained with the use of a n21 scalpel 2cm of both limbs of the graft are sutured
224213349|NCT02832791|PROCEDURE|HAMSTRING TENDON|"Once the limb is prepped and draped,it is exsanguinated, and the tourniquet is raised to 250 mm Hg. The procedure begins with an arthroscopic examination through an anterolateral viewing portal to corroborate the ACL injury as well as the determination of possible associated lesions. The accessory medial portal is stablished slightly above the joint line, at about 2 cm of the medial edge of the patellar tendon. This portal is used as an instrumentation portal. A third portal, a high anteromedial portal, is made higher than the previous, this portal will allow visualization of the femoral footprint.~Once the associated meniscal or cartilaginous lesions are addressed attention turns to the harvesting of the graft.~A 4cm oblique incision is made starting 2 cm medial to the tibial tubercle and directed proximally and medially. After dissecting the subcutaneous tissue the Sartorius fascia is incised and both tendons are identified and harvested with the use of a tendon stripper"
224213350|NCT02934269|DRUG|Placebo|
224213351|NCT02934269|DRUG|CC-90006|
224213352|NCT00828490|BEHAVIORAL|provider feedback|The provider-level intervention includes a targeted review of trigger-flagged beneficiaries' drug utilization history and an information packet sent to providers which includes patient-specific pharmacy and medical claims history, patient specific recommendations, and provider comparative profiling.
224213353|NCT00828490|BEHAVIORAL|patient intervention|The patient intervention arm includes the provider-level intervention mentioned above in addition to Medication Therapy Management Services (MTMS), a program that provides patients one-on-one therapy counseling administered by community pharmacists who have completed an MTMS certificate program.
224213354|NCT00828490|BEHAVIORAL|Process-level|The process-level intervention includes the provider-level intervention plus in-clinic evidence-based quality improvement workshops with opportunity for CME credit
224213355|NCT02761265|PROCEDURE|Surgical intervention|Surgery to correct spinal deformity
224213356|NCT02761265|OTHER|None (Asymptomatic group)|Gait and balance testing performed, no treatment in this asymptomatic group
224213357|NCT02888132|PROCEDURE|Echocardiography-guided transthoracic radio frequency ablation for HOCM ventricular septum|
224213358|NCT02888132|PROCEDURE|Echocardiography-guided transthoracic laser ablation for HOCM ventricular septum|
224213359|NCT00442715|PROCEDURE|Exercise chalenge test|
224213360|NCT05229315|DRUG|Toripalimab|PD-1 Immune Checkpoint Inhibitor Combined With IMRT,used at 2 weeks before radiotherapy, once every 2 weeks, 10 cycles in total
223624039|NCT05675319|DRUG|daratumumab/lenalidomide/dexamethasone (DRD)|triple regimen for first relapse should be applied according to latest SmPC version
223624040|NCT05675319|DRUG|ixazomib/lenalidomide/dexamethasone (IRD)|triple regimen for first relapse should be applied according to latest SmPC version
224213361|NCT05229315|PROCEDURE|Intensity modulated radiotherapy|Intensity modulated radiotherapy
224213362|NCT03398928|OTHER|Acupuncture|Acupuncture added to usual care
224213363|NCT05616611|RADIATION|High-Intensity laser|intervention that lasted 3 sessions/week for 12 weeks).
223624041|NCT05675319|DRUG|pomalidomide/bortezomib/dexamethasone (PVD)|triple regimen for first relapse should be applied according to latest SmPC version
223624042|NCT05675319|DRUG|carfilzomib/daratumumab/dexamethasone (KDD)|triple regimen for first relapse should be applied according to latest SmPC version
223624043|NCT05675319|DRUG|Autologous Stem Cells|Autologous Stem Cell Transplantation
224213364|NCT05616611|OTHER|Traditional physiotherapy exercises|intervention that lasted 3 sessions/week for 12 weeks).
224213365|NCT05616611|RADIATION|Shock Wave therapy|intervention that lasted 3 sessions/week for 12 weeks).
224213366|NCT06204172|DEVICE|Intensive Neurowave Emotional Stimulation (INES)|Patients will undergo Neurowave-assisted multisensory stimulation five days a week for four weeks, featuring emotionally significant audio-visual content tied to personal history. Control group participants will experience primary auditory stimulation through familiar sounds, following a traditional rehabilitation approach mimicking the experimental group's frequency and intensity but without Neurowave use. This allows for a meaningful comparison of the two groups' experiences.
224213367|NCT06204172|OTHER|Intensive Sensorial Emotional Stimulation (ISES)|The Intensive Sensorial Emotional Stimulation (ISES) in the control group involves primary auditory stimulation with emotionally rich everyday sounds, including familiar voices, favorite songs, and sounds related to daily life and past activities. It mimics the experimental group's frequency and intensity, lasting 45 minutes per session, five days a week, for four weeks. Unlike the experimental group using Neurowave, the control group follows a traditional rehabilitation approach with paper materials, live photos, face-to-face interaction, and classic music tapes, facilitating a meaningful comparison between the two groups' experiences.
224213368|NCT01140269|OTHER|PCR test|PCR samples will test for Staphylococcus aureus (including MRSA) from wound swab and positive blood culture samples to augment treatment decisions. Serial PCR testing will follow after positive results to catalog pathogen loads over the course of treatment in a blinded fashion.
224213369|NCT04681222|PROCEDURE|LFCN|LFCN block was performed in combination with PENG block
223624044|NCT05675319|DRUG|daratumumab/pomalidomide/dexamethasone (DPD)|triple regimen for first relapse should be applied according to latest SmPC version
223624045|NCT05675319|DRUG|isatuximab/carfilzomib/dexamethasone (Isa-KD)|triple regimen for first relapse should be applied according to latest SmPC version
223624046|NCT05675319|DRUG|selinexor/bortezomib/dexamethasone (SVD)|triple regimen for first relapse should be applied according to latest SmPC version
223762072|NCT02614547|DRUG|Placebo|Administered as intravenous infusion.
223624047|NCT04730765|PROCEDURE|left elective colectomy (Surgical Experimental Group)|Conventional laparoscopic resection of the sigmoid colon is performed using four ports. The left colon is mobilised from the lateral side along Gerota's fascia. The splenic flexure is mobilised at the discretion of surgeons. The mesentery of the sigmoid colon is then medially fenestrated at the promontory level. The superior rectal artery as well as the inferior mesenteric artery and vein are identified and are cut using tissue-sealing devices. A linear stapler device is applied for division of the large intestine. The sigmoid is retracted through a Pfannenstiel incision or enlargement of the left lower abdominal incision. Colorectal anastomosis is performed using a double stapling technique following open resection of the affected colon.
223624048|NCT04730765|DRUG|antibiotic therapy (medical Control Group)|Antibiotic treatement for 10 days by oral or intravenous administration
224213370|NCT04681222|PROCEDURE|Wound infiltration|Wound infiltration was performed in combination with PENG block
224213371|NCT06370195|BEHAVIORAL|Comprehensive rehabilitation|The study lasted 10d for each patient. During the treatment, All the participants were provided with the rehabilitation therapy, which included routine rehabilitation, cognitive training, swallowing function training.
223624049|NCT04421170|BEHAVIORAL|smartphone app for smoking cessation|Paticipants will receive 12-week app-based smoking cessation intervention with follow-up to 26 weeks.
223624050|NCT02742961|OTHER|Peripheral nerve block|A physician billing code for deposition of a local anesthetic solution around an anatomically defined nerve or nerve plexus
223624051|NCT00143910|OTHER|observation|
223624052|NCT05241379|DEVICE|Amber UI System|The implantable components of the Amber UI system consist of an implantable pulse generator (Picostim Amber IPG), 2 electrode leads with anchoring system
223624053|NCT01754974|BIOLOGICAL|Peginterferon Lambda-1a|
223624054|NCT01754974|DRUG|Ribavirin|
223624055|NCT01754974|BIOLOGICAL|Peginterferon alfa-2a|
223624056|NCT05354908|OTHER|scientific and academic productivity|Number and quartile of scientific products generated by the group
223624057|NCT01011673|DRUG|Metoclopramide|metoclopramide 20mg IVSS + diphenhydramine 25mg IVSS
224213372|NCT06370195|PROCEDURE|Stellate ganglion block|Based on the invention above, the patients in the observation group were provided with Stellate ganglion block , using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate ganglion block . The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
224213373|NCT06370195|DRUG|Lidocaine hydrochloride|Based on the invention above, the patients in the observation group were provided with Stellate ganglion block , using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate ganglion block . The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
223624058|NCT01011673|DRUG|Ketorolac|ketorolac 30mg IVSS
223624059|NCT03242629|DRUG|oral chloral hydrate|Chloral hydrate syrup was available in a concentration of 100 mg×ml-1.The children assigned to receive 0.8 ml×kg-1 of chloral hydrate (80 mg×kg-1) by oral.
223624060|NCT03242629|DRUG|enema chloral hydrate|Chloral hydrate syrup was available in a concentration of 100 mg×ml-1 at our hospital.The children assigned to receive 0.8 ml×kg-1 of chloral hydrate (80 mg×kg-1) by enema.
223624061|NCT04199507|OTHER|physical fitness assessment|assessment
223624062|NCT01632020|DRUG|Placebo|2 capsules by mouth twice daily; minimum of 10 days, maximum of 21 days
223624063|NCT01632020|DRUG|Metformin|850 mg (2 capsules) by mouth twice daily; minimum of 10 days, maximum of 21 days
223624064|NCT00752050|DRUG|Mentor Purified Toxin Botulinum Toxin Type A|For Part II, subjects in this arm will receive five 0.1 mL intramuscular injections at the Day 0 Treatment Visit: two in each corrugator and one in the procerus muscle. The total treatment dose (sum of the five injections) to be administered will be 30 U of the Active Comparator Mentor Purified Toxin.
223624065|NCT00752050|DRUG|Preservative-free Saline|For Part II, subjects in this arm will receive five 0.1 mL intramuscular injections at the Day 0 Treatment Visit: two in each corrugator and one in the procerus muscle. The total treatment dose (sum of the five injections) to be administered will be 0.5 mL of the placebo (preservative-free saline).
223624066|NCT04368260|DEVICE|Control swab|FDA-cleared nasopharyngeal swab
223624067|NCT04368260|DEVICE|Prototype swab|Injection molded polypropylene flocked nylon nasopharyngeal swab
223624068|NCT03550612|DIAGNOSTIC_TEST|magnetic resonant imaging,cranial ultrasound.|Magnetic resonant image performed at term gestation neonate suffer of hypoxic ischemic encephalopathy and its results will be analysed in details and classified according to global score of magnetic resonant image injury.Cranial ultrasound results will be analysed regards (periventricular - interventricular haemorrhage-Ventricular size-basal ganglia, thalamus and cerebellum affection) and Doppler (peak systolic flow velocity-end diastolic peak flow velocity-mean velocity and resistance index).Cerebral bleeding will be diagnosed be cranial ultrasound and confirmed be standard magnetic resonant image in term equivalent age.
223624069|NCT03550612|DIAGNOSTIC_TEST|Amplitude integrated electroencephalogram|"Amplitude integrated electroencephalogram before and during cooling will be assessed and classified according to Hellstrom Westas et al 2006 and it will be compared with the results of cranial ultrasound and magnetic resonant imaging.~Neurodevelopment study at 12 and 14 month age using Bayley ɪɪɪ score will be compared with the results of cranial ultrasound,magnetic resonant imaging and Amplitude integrated electroencephalogram."
223624070|NCT05553795|PROCEDURE|Early removal of chest drain|Chest drains are removed 3 hours after the end of surgery in absence of contraindications in arm A.
223624071|NCT05553795|PROCEDURE|Chest drain|The chest drains in arm B are removed during the further postoperative course according to standard algorithm.
223624072|NCT02906423|OTHER|PROMIS-10 questionnaire|Patient completed a PROMIS-10 questionnaire
223624073|NCT02828761|DEVICE|Coronary Calcium Scoring|Scan with 64-detector row or better CT scanners with quantification by the Agatston method.
223624074|NCT02828761|PROCEDURE|Standard Care|Routine clinical monitoring of chest pain patients. Any of a number of non-invasive cardiac tests such as coronary CT angiography, stress echocardiography and stress radionuclide myocardial perfusion imaging may be performed.
223624075|NCT00420576|DRUG|DBT-Danggui Buxue Tang|Herbal Combination of Danggui (Radix Angelicae Sinensis) and Huangqi (Radix Astragali)in granules form, in 3 different dosage 6g/3g/1.5g, once time per day for 3 Months treatment
223624076|NCT03225235|RADIATION|SBRT|hypofractionated stereotactic radiotherapy (SBRT) using CyberKnife for Patients With Low and Intermediate Risk of Progression Prostate Cancer
223624077|NCT01239966|DEVICE|Combined ECCOR and RRT|Insertion of a membrane oxygenator (Hilite 2400 LT, Medos, Germany) within an hemofilter circuit (M150,PrismaFlex, Hospal); either upstream or downstream of the hemofilter.
223762073|NCT01072695|DRUG|GS-9256|75 mg BID x 28 days
223624078|NCT03651635|DIAGNOSTIC_TEST|Blood sampling for MR-proADM & CT-proET-1|Collection of at most 8 blood samples (3ml each) per Patient admitted to the study and sampling for MR-proADM \& CT-proET-1
223624079|NCT01929590|DRUG|PEG-3350 group 2|split-dose (PEG-3350; 2 L the day before 17:00-19:00 h and 2 L same day of the procedure 06:00-08:00 am)
224213374|NCT06370195|PROCEDURE|Placebo injection|1 milliliter of normal saline will be used for injection. The percutaneous approach via the paratracheal route was used for Stellate ganglion block . The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
224213375|NCT02095119|DRUG|Nimotuzumab|Monoclonal antibody Nimotuzumab will be administered alone at a 200mg dose weekly during the first 4 weeks. Posteriorly it will be administered with a maintenance dose of 200 mg every 2 weeks in combination with chemotherapeutic agents Cisplatin in patients with good renal function or Gemcitabine in patients with kidney failure data until exclusion or death occurs. The administration will be intravenously in 250 ml of saline solution in a time period of 30 minutes.
224213376|NCT02095119|DRUG|Cisplatin|Cisplatin will be administered at a calculated dose of 50mg/m2/BSA every 21 days as concomitant therapy to Nimotuzumab, until 6 cycles are completed, exclusion or death occurs, only in patients whose creatinine clearance as defined by the Cockcroft-Gault equation is \>/= 60. The administration form will be intravenously.
224213377|NCT02095119|DRUG|Gemcitabine|Gemcitabine will be administered at a calculated dose of 800 mg/m2/BSA every 21 days as concomitant therapy to Nimotuzumab, until 6 cycles are completed, exclusion or death occurs, in patients with kidney failure data(Creatinine clearance as defined by the Cockcroft -Gault equation \< 60). The administration form will be intravenously.
223624080|NCT01929590|DRUG|PEG-3350 group 1|PEG-3350; PEG-4 L the day previous of the study, starting at 17:00 and finishing at 21:00 h
223624081|NCT01929590|DRUG|PEG-3350 group 3|low-volume 2 L PEG-solution (same day of the procedure 06:00-08:00 am)
223624082|NCT00549640|DRUG|Methylphenidate|54 mg Methylphenidate per day for 8 weeks. Allowing for a ramp up in the first two weeks (starting dose is 18 mg/day).
223624083|NCT00549640|DRUG|Placebo|non-active (sugar pill)designed to be a look-alike to the methylphenidate. Given at the same frequency and dosage look-alike to the active comparator (methylphenidate 54 mg)
223624084|NCT04272346|BEHAVIORAL|Writing for others|Participants will receive general instructions for completing the writing sessions and will be asked to write for at least 20 minutes per session. Topics covered in each session will vary and are related to common cancer-related themes (e.g., receiving a diagnosis, undergoing treatment, etc.). Participants will be instructed not to worry about grammar, spelling, or sentence structure and reminded that their responses will remain anonymous. Writing sessions (four in total) will be spaced 1 week apart, and participants will be instructed to write about their experience for the benefit of a newly-diagnosed cancer patient.
223624085|NCT04272346|BEHAVIORAL|Processing + writing for others|Participants will receive general instructions for completing the writing sessions and will be asked to write for at least 20 minutes per session. Topics covered in each session will vary and are related to common cancer-related themes (e.g., receiving a diagnosis, undergoing treatment, etc.). Participants will be instructed not to worry about grammar, spelling, or sentence structure and reminded that their responses will remain anonymous. Writing sessions (four in total) will be spaced 1 week apart. For the first three writing sessions, participants will write their deepest thoughts and feelings regarding cancer diagnosis and treatment. In the final writing session, participants will be instructed to write about their experience for the benefit of a newly-diagnosed cancer patient.
223762074|NCT01072695|DRUG|GS-9190|40 mg BID x 28 days
223762075|NCT01072695|DRUG|Ribavirin|1000-1200 mg/day given BID
224213378|NCT02095119|PROCEDURE|CT Scan|A CT Scan will be performed in all patients prior to the beginning of treatment to assess any measurable tumor found by this method. The CT Scan will be repeated once the patient completes the induction phase with Nimotuzumab (4 once a week doses), when the patient has completed 3 full cycles of combination therapy with Nimotuzumab (every 2 weeks)and Gemcitabine or Cisplatin (every 21 days)and once more when the patient has completed 6 full cycles of the aforementioned therapy.
223762076|NCT01072695|DRUG|Peginterferon alfa-2a|180 ug q week
223762077|NCT01067404|BIOLOGICAL|Trivalent inactivated influenza vaccine|0.25mL dose of 2009-10 trivalent inactivated influenza vaccine (TIV)
223762078|NCT01585766|DRUG|MEDI-551 30 MG-IV|Participants received a fixed IV dose of 30 milligram (mg) MEDI-551 infused on Days 1 and 15.
223762079|NCT01585766|DRUG|MEDI-551 60 MG-SC|Participants received SC injection of 60 mg MEDI-551 on Day 1.
223762080|NCT01585766|DRUG|PLACEBO-IV-SC|Participants received either a fixed IV dose of placebo matching with MEDI- 551 on Days 1 and 15 or SC injection on Day 1
224213379|NCT01633749|BIOLOGICAL|Trivalent influenza subunit vaccine Influvac|3x 15mcg HA per 0.5 ml,trivalent one injection at Day 1
224213380|NCT00947518|DRUG|Chlorhexidine|Baby wipes containing 0.25% free chlorhexidine (equivalent to 0.44% chlorhexidine digluconate)
224213381|NCT00947518|DRUG|Normal saline|Cleansing the skin (except the face)with baby wipes containing normal saline
224213382|NCT00458718|DRUG|rimonabant (SR141716)|
223624086|NCT04272346|BEHAVIORAL|Facts-only writing|Participants will receive general instructions for completing the writing sessions and will be asked to write for at least 20 minutes per session. Topics covered in each session will vary and are related to common cancer-related themes (e.g., receiving a diagnosis, undergoing treatment, etc.). Participants will be instructed not to worry about grammar, spelling, or sentence structure and reminded that their responses will remain anonymous. Writing sessions (four in total) will be spaced 1 week apart. Unlike the previous conditions, participants will not be instructed to write about their experience for the benefit of a newly-diagnosed cancer patient.
223624087|NCT01682408|DRUG|Fostamatinib - 1 x 150mg mannitol-based 38% drug-loaded tablet(orange reference)|1 x 150mg mannitol-based 38% drug-loaded tablet(orange reference)
223624088|NCT01682408|DRUG|Fostamatinib - 3 x 50mg microcrystalline cellulose-based 13% drug loaded tablets,(blue) fed|3 x 50mg microcrystalline cellulose-based 13% drug loaded tablets,(blue) fed
223624089|NCT01682408|DRUG|Fostamatinib - 1 x 150mg mannitol based 38% drug-loaded tablet (batch variant A)|1 x 150mg mannitol based 38% drug-loaded tablet (batch variant A)
223624090|NCT01682408|DRUG|Fostamatinib - 1 x 150mg mannitol based 38% drug loaded tablet (batch variant B)|1 x 150mg mannitol based 38% drug loaded tablet(batch variant B)
223624091|NCT01682408|DRUG|Ranitidine|150 mg ranitidine
223624092|NCT05406011|DIETARY_SUPPLEMENT|Pelleted sour cherry (anthocyanin) containing chewing gum usage.|Dietary Supplement usage (daily 3 times for 2 weeks) with salivary sampling on fixed days (1., 4. and 7.) and daytime (between 12:00 and 14:00) of the week. Procedure: Scaling after a control period without sour cherry chewing gum usage (1 week).
223624093|NCT05406011|DIETARY_SUPPLEMENT|Pelleted chewing gum for stimulated saliva sampling.|Stimulated saliva sampling after chewing a pelleted gum without active ingredient (used only before stimulated saliva sampling), during the whole experimental period (control and parallel with sour cherry chewing gum usage) with sampling on fixed days (1., 4. and 7.) and daytime (between 12:00 and 14:00) of the week.
223624094|NCT05406011|PROCEDURE|Scaling|Scaling after a 1-week control period without chewing the sour cherry gum.
224213383|NCT04130919|DRUG|Tilpisertib|Tablets administered orally once daily
223624095|NCT04958499|BEHAVIORAL|Bio-healthy Park|Experimental group will receive the exercise program on bio-healthy machinery with a frequency of 2 sessions per week of 55 minutes for 8 weeks. Experimental group 1 will perform the intervention program using machinery designed for self-loading use. The machines used will be rider, low gemini, high gemini, walk, bottoms, flywheels circles, flywheels rotation, twin swing, surf, swing press and rowing. Intensity will be controlled by subjective perception of effort and heart rate (Polar 420). There will be a warm-up 8-10 minutes, a main part 40-45 minutes and a return to calm 5-10 minutes. The intervention programs will be developed by a graduate in Physical Activity and Sport Sciences. The load will be progressed every 2 weeks.
223624096|NCT03022396|BIOLOGICAL|High Dose Fluzone® (intramuscular)|Licensed seasonal High dose trivalent inactivated influenza
223624097|NCT03022396|BIOLOGICAL|Fluzone® (intramuscular)|Licensed seasonal trivalent inactivated influenza
223624098|NCT00064285|DRUG|alvocidib|
223624099|NCT00064285|DRUG|imatinib mesylate|
223624100|NCT02232035|DRUG|normal saline/diazepam at the active phase of labor|A single dose intravenous injection of normal saline (2ml)/diazepam (10mg, 2ml) at the beginning of active phase of labor.
223624101|NCT02028481|PROCEDURE|Postoperative air tamponade|Pars plana vitrectomy, ILM peeling and air tamponade. No postoperative face down positioning. All patients need to be pseudophakic prior to intervention.
223624102|NCT00803283|DRUG|Hydromprphone Hydrochloride (HCl) OROS|Participants will receive hydromorphone HCl OROS 8 milligram (mg) every 24 hours, for 3 to 14 days of titration phase. Hydromorphone HCl OROS will be continued as per Investigator's discretion for next 14 days of maintenance phase.
223624103|NCT00803283|DRUG|Morphine Sustain Release (SR)|Participants will receive morphine SR 8 mg every24 hours, for 3 to14 days of titration phase. Morphine SR will be continued as per Investigator's discretion for next 14 days of maintenance phase.
223624104|NCT01861626|DRUG|V0057 - A mg|Single oral administration
223624105|NCT01861626|DRUG|Isotretinoin|Single oral administration
224213384|NCT04130919|DRUG|Placebo|Tablets administered orally once daily
224213385|NCT04699643|DRUG|EVER4010001|Please refer to information in arm/group descriptions.
224213386|NCT06314984|OTHER|Group I A (Conventional needle syringe)|The injection site was isolated using cotton roll and the topical anesthesia (Benzocaine 4%) was applied to the injection site and left for 3-5 minutes then the injection was done in the mandible by the conventional needle syringe \[Inferior Alveolar Nerve Block\].
224213387|NCT06314984|OTHER|Group I B (Conventional needle syringe)|The injection site was isolated using cotton roll and the topical anesthesia (Benzocaine 4%) was applied to the injection site and left for 3-5 minutes then the injection was done in the maxilla by the conventional needle syringe \[Infiltration\].
224213388|NCT06314984|DEVICE|Group II A (Comfort-in Jet Injector)|The injection site was isolated using a cotton roll and the topical anesthesia (Benzocaine 4%) was applied to the injection site and left for 3-5 minutes then the injection was done in the mandible by the needleless Comfort-in jet injector \[Inferior Alveolar Nerve Block\].
223513496|NCT04427111|DEVICE|Non-titratable-customized mandibular advancement device|The most comfortable protruded mandibular position situated between 60-75% of MMPV was determined according to patient response with 6mm of the vertical interocclusal dimension between maxillary and mandibular central incisors and registered. The upper and lower acrylic resin splints were secured to each other in the posterior region with auto polymerizing acrylic resin and NTC-MADs were obtained. The patients were instructed to wear their non-titratable-customized mandibular advancement device every night.
223513497|NCT04787016|OTHER|Pilate training|Pilates is an exercise training program used to build core strength and flexibility.
223513498|NCT04565353|BEHAVIORAL|Flu shot text messages|Participants will receive text messages per descriptions listed in the arms.
223513499|NCT03239054|BEHAVIORAL|Physical activity|pregnancy prescription for physical activity as part of prenatal care can increase healthy exercise behaviors during pregnancy
223513500|NCT03239054|BEHAVIORAL|Control group|Information will be given as part of standard care
223624106|NCT03833492|BEHAVIORAL|Underwater EMR|Polypectomy is performed under full water emersion without the use of submucosal injection.
223624107|NCT02028533|DRUG|Oxytocin|
223624108|NCT02028533|DRUG|Placebo|
223624109|NCT02774980|BEHAVIORAL|Recurrent depression|
224213389|NCT06314984|DEVICE|Group II B (Comfort-in Jet Injector)|The injection site was isolated using cotton roll and the topical anesthesia (Benzocaine 4%) was applied to the injection site and left for 3-5 minutes then the injection was done in the maxilla by the needleless Comfort-in jet injector \[Infiltration\].
224213390|NCT00737321|PROCEDURE|Samples will be collected|wound tissue biopsy, blood samples, saliva collection and wound VAC sponge (if applicable).
224213391|NCT02624518|DRUG|68Ga-RM2|Imaging with PET/MRI
224213392|NCT02624518|PROCEDURE|Magnetic Resonance Imaging|Imaging with 68Ga-RM2 PET/MRI
224213393|NCT02624518|PROCEDURE|Positron Emission Tomography|Imaging with 68Ga-RM2 PET/MRI
224213394|NCT01168882|DRUG|RGB-286638|The starting dose is a flat-fixed dose of 40 mg given i.v. over 60 min, weekly x3, of a 28-days cycle (q4 weeks)
224213395|NCT02947282|OTHER|Educational Workshop|They will attend a 2 hour class on pelvic floor health
224213396|NCT05573373|DRUG|Parimparib|The dosage and protocol of the drug were carried out according to the description.
224213397|NCT05573373|DRUG|Chemotherapy drug|The dosage and protocol of the drug were carried out according to the description.
224213398|NCT05573373|DRUG|Targeted Therapy Agent|The dosage and protocol of the drug were carried out according to the description.
224213399|NCT00004582|DRUG|Lopinavir/Ritonavir|
224316516|NCT03616717|DRUG|Modafinil|"Drug: modafinil Each participant receives a single pill of placebo or active drug (modafinil 100 mg or 200 mg) 30 minutes after arriving at the lab. The participant then completes approximately 6 hours of testing in the laboratory. The participant stays at the lab for 7.5 hours in order to monitor physical condition in case the participant received the active pill. One week later, that participant receives a single pill of an alternate comparator and is again tested in the laboratory. Thus, in total, each participant receives one placebo pill and two active pills, each time separated by one week.~Other Names:~Provigil Alertec Modavigil"
224316517|NCT03616717|DRUG|placebo|Drug: Placebo Each participant receives a single pill of placebo or active drug (modafinil 100 mg or 200 mg) 30 minutes after arriving at the lab. The participant then completes approximately 6 hours of testing in the laboratory. The participant stays at the lab for 7.5 hours in order to monitor physical condition in case the participant received the active pill. One week later, that participant receives a single pill of an alternate comparator and is again tested in the laboratory. Thus, in total, each participant receives one placebo pill and two active pills, each time separated by one week.
224213400|NCT00004582|DRUG|Efavirenz|
224316518|NCT02254434|DRUG|Eltrombopag|Eltrombopag 50 mg per tablet for oral route of administration will be sourced locally
224316519|NCT05189834|DIETARY_SUPPLEMENT|Gelsectan|Xyloglucan, vegetable protein and xylooligosaccharides
224316520|NCT02722915|PROCEDURE|fMRI|collection of functional brain data for 1 hour per day
224316521|NCT02722915|BEHAVIORAL|Neurofeedback|Task of the participants is to increase or decrease the connectivity between selected brain regions in double-blind, randomized order. After the regulation they will get a feedback about the regulation success. (Patients and controls with AVH: days 3 \& 4; controls without AVH: Days 2 \& 3)
223513501|NCT00684294|BIOLOGICAL|TGFβ2 Antisense-GMCSF Gene Modified Autologous Tumor Cell (TAG) Vaccine|Patients with solid tumors will receive TAG Vaccine 1 x 10\^7 cells/ injection or TAG Vaccine 2.5 X 10\^7 cells/injection once a month for up to 12 doses via intradermal injection as long as sufficient material is available. Selection of cohort is dependent on the amount of tumor cell yield following harvest and processing.
223513502|NCT05428670|DRUG|Zanubrutinib+Rituximab+Lenalidomide|Zanubrutinib is a bruton' s tyrosine kinase inhibitor independently developed in China.
224213401|NCT03720522|PROCEDURE|Short cardiovascular MRI (CMR)|A short CMR without additional contrast administration will be performed immediately after the routine brain MRI (at admission or after 24h).
223624110|NCT00371592|DRUG|Acyclovir|800 mg tablet taken orally twice daily
223513503|NCT05428670|DRUG|RCHOP/RCDOP|RCHOP/RCDOP is the classic treatment of diffuse large B cell lymphoma.
223513504|NCT01829763|DRUG|injection botox|
224213402|NCT03720522|PROCEDURE|Adenosine-perfusion cardiovascular MRI (CMR)|An adenosine-perfusion CMR using contrast medium (gadolinium) will be performed in all patients (except group 1) between 48h and 6 days after admission.
224213403|NCT03720522|PROCEDURE|Blood draw|"The following study-specific parameters will be tested: neuropeptide Y 1-36, neuropeptide Y 3-36, total plasma metanephrines, metabolomics analysis~Time points for blood draw: at admission (routine), 3h (routine), 24h (routine), 48h, 72h and 3 months."
224213404|NCT03720522|PROCEDURE|Urine (collection over 24h)|"The following study-specific parameters will be tested: catecholamines.~Time points for collection: at 24h, 72h, and 3 months"
224213405|NCT00717873|DEVICE|Airway clearance Device|Provided by the Vest Airway clearance system
224213406|NCT00370396|BIOLOGICAL|Synflorix|1 dose injected IM in the right thigh or deltoid.
224213407|NCT00370396|BIOLOGICAL|Prevenar|1 dose injected IM in the right thigh or deltoid.
224213408|NCT00370396|BIOLOGICAL|Infanrix hexa|1 dose injected IM in the right thigh or deltoid.
224213409|NCT00637442|DRUG|Reminyl retard|retard tablets once a day WEEK1-4: 8mg; WEEK 5-8: 16mg, WEEK 9-24: 24mg
224213410|NCT04454970|DEVICE|Urethrotech Urethral catheterisation device (UCD)|Urethral indwelling catheter
224213411|NCT04454970|DEVICE|Bardia Aquafil long term catheter|Urethral indwelling catheter
224316522|NCT02722915|OTHER|PANAS|to assess the mood before and after the fMRI and after 1 week during a telephone interview
224316523|NCT02722915|OTHER|AVHRS|to assess the intensity and quality of the hallucinations before and after the fMRI and after 1 week during a telephone interview
224316524|NCT02722915|OTHER|SF36|questionnaire about life quality after 1 week during a telephone interview
223513505|NCT04613089|OTHER|Natural History|Natural History and Clinical Follow Up.
223513506|NCT00216931|DRUG|iloprost|
224213412|NCT00615771|PROCEDURE|Day 3 embryo transfer|Standard of care
223762081|NCT01585766|DRUG|MEDI-551 100 MG-IV|Participants received a fixed IV dose of 100 mg MEDI-551 infused on Days 1 and 15.
223762082|NCT01585766|DRUG|MEDI-551 300 MG-SC|Participants received SC injection of 300 mg MEDI-551 on Day 1.
223762083|NCT01585766|DRUG|MEDI-551 600 MG-IV|Participants received a fixed IV dose of 600 mg MEDI-551 infused on Days 1 and 15.
223513507|NCT06421441|OTHER|Self Management Skills Training|Nursing students will be given self-management skills training for a total of 12 hours, two days a week, two hours a day (60 min. + 60 min.) for three weeks.
223513508|NCT06202989|DRUG|Multiprofen-CC™ plus standard treatment|Multiprofen-CC™ \[ketoprofen (10%), baclofen (5%), amitriptyline (2%), and lidocaine (5%)\] Dose: 1.0g, 3 times per day for 6 weeks after surgery
223513509|NCT06202989|OTHER|Placebo plus standard treatment|The placebo is the base cream with no medicinal ingredients to be applied 3 times per day for 6 weeks after surgery
223513510|NCT06057103|DRUG|ZX-7101A|ZX-7101A Tablets single dose tablet, 80 mg, Oral
223513511|NCT06057103|DRUG|Oseltamivir|Oseltamivir phosphate capsule was administered as a single drug, 75 mg twice daily, for 5 days,Oral
223513512|NCT06057103|DRUG|ZX-7101A and Oseltamivir|ZX-7101A tablet (80mg, single dose) was combined with oseltamivir phosphate capsule (75 mg twice daily),Oral
223513513|NCT06057103|DRUG|ZX-7101A|ZX-7101A Tablets single dose tablet, 80 mg, Oral
223513514|NCT06057103|DRUG|Oseltamivir|Oseltamivir phosphate capsule was administered as a single drug, 75 mg twice daily, for 5 days,Oral
223513515|NCT06057103|DRUG|ZX-7101A and Oseltamivir|ZX-7101A tablet (80mg, single dose) was combined with oseltamivir phosphate capsule (75 mg twice daily),Oral
223513516|NCT06057103|DRUG|ZX-7101A|ZX-7101A Tablets single dose tablet, 80 mg, Oral
223513517|NCT04555733|DRUG|Lemborexant|Lemborexant oral tablets.
223513518|NCT05670340|DEVICE|Switched Prosthetic Profile|The implant will be rehabilitated with a switched emergence profile
223513519|NCT05670340|DEVICE|Matched Prosthetic Profile|The implant will be rehabilitated with a matched emergence profile
223513520|NCT05333965|DEVICE|Lens A (lehfilcon A lens)|Daily wear for 1 month.
223513521|NCT05333965|DEVICE|Lens B (comfilcon A lens)|Daily wear for 1 month.
223513522|NCT05855278|DIAGNOSTIC_TEST|PET/MRI|The participants receive 18F-FDG PET/MRI before and during definitive chemoradiotherapy.
223513523|NCT02320552|OTHER|No intervention|no intervention
223513524|NCT01975480|DRUG|Desvenlafaxine|
223513525|NCT00382863|DEVICE|HeartNet Ventricular Support System|The HeartNet Implant is placed on the epicardial surface of the heart surrounding both the left and right ventricles.
223513526|NCT00382863|DRUG|Optimal Medical/Device Therapy|Optimal Medical/Device Therapy - For the purpose of the PEERLESS-HF study, optimal medical therapy is defined as the use of ACE inhibitors and Beta blockers in the highest tolerable doses for three months prior to study enrollment, and Optimal device therapy is defined as CRT or CRT-D for at least three months prior to study enrollment, when indicated.
223513527|NCT02168439|DRUG|Dexmedetomidine|
223513528|NCT02168439|DRUG|Midazolam|
223513529|NCT01067911|DIETARY_SUPPLEMENT|Butter and Vegetable oils from soy, flaxseed, high oleic safflower and canola|Test meals prepared with different common fats and oils and consumed by test subjects. Postprandial lipids will be assessed for 6 hours after the consumption of the test meal.
223513530|NCT01067911|DIETARY_SUPPLEMENT|In this study subjects will consume test meals containing vegetable oils (soy, flaxseed, high oleic safflower and canola) and butter|Test meals prepared with different common fats and oils and consumed by test subjects. Postprandial lipids will be assessed for 6 hours after the consumption of the test meal.
223513531|NCT01067911|DIETARY_SUPPLEMENT|In this study subjects will consume test meals containing vegetable oils (soy, flaxseed, high oleic safflower and canola) and butter|Test meals prepared with different common fats and oils and consumed by test subjects. Postprandial lipids will be assessed for 6 hours after the consumption of the test meal.
223513532|NCT01067911|DIETARY_SUPPLEMENT|In this study subjects will consume test meals containing vegetable oils (soy, flaxseed, high oleic safflower and canola) and butter|Test meals prepared with different common fats and oils and consumed by test subjects. Postprandial lipids will be assessed for 6 hours after the consumption of the test meal.
223513533|NCT06569927|PROCEDURE|Utilization of a perioperative position management protocol for congenital microtia patients based on the ADDIE model.|Key elements included formation of a multidisciplinary team，perioperative postural management, preoperative sleeping posture adaptability training, neck movement training, standardization of head position angles and head suspension time during surgery, use of protective headrests, attention to transfer and handover procedures, and specially designed pillows.
223513534|NCT06571916|BEHAVIORAL|Brief-SfSL|"Brief-SfSL is a single 90-minute intervention that that:~1. helps clients understand their suicide narrative, which explores the origin and meaning of their suicidal thoughts~2. builds specific skills to keep oneself safe from suicide even if suicidal thoughts are present~3. includes enhanced safety planning by identifying the barriers to enacting a safety plan and solutions to overcome them"
223513535|NCT06570590|PROCEDURE|Minimally invasive lapidus procedure with no arthroscopy|The two procedures, with and without arthroscopy, only differ by the method of assessing cartilage removal. Cartilage removal will be assessed arthroscopically in the procedure with arthroscopy. In the procedure without arthroscopy, cartilage removal will be assessed via direct visualization through a mini arthrotomy procedure. After use of the cartilage burr the surgeon will make a small dorsal portal and use this opening to ensure that the cartilage is removed and all debris removed. The incision will be 2 cm long and centered over the dorsal medial aspect of the joint.
223762084|NCT06418256|OTHER|Spleen, blood and plasma collection|Adult patients for whom a splenic intervention (spleno-pancreectomy, or a total or partial splenectomy) is planned as part of their care. One or more tubes of venous blood collected for the care will be recovered following the pre- or intra-operative assessment. Immediately following surgery, after careful examination by the pathologist in charge, the whole spleen or spleen fragments will be collected for further analysis. Whenever possible a catheter will be introduced in the splenic artery, the spleen will be flushed/rinsed with 0.1 - 2 L of cold perfusion medium then transferred to the laboratory for ex-vivo perfusion. Before and at the end of the ex-vivo perfusion, splenic blood and spleen fragments will be collected and processed for further analyses.
223762085|NCT01312584|DIETARY_SUPPLEMENT|Processed High-flavanol|
223762086|NCT02827058|DEVICE|G25 pencil point needle|
223762087|NCT02827058|DEVICE|G27 pencil point needle|
224213413|NCT00615771|PROCEDURE|Day 2 embryo transfer|Embryos are transferred 1 day prior to standard of care
224213414|NCT01462695|OTHER|Diagnostic Laboratory Biomarker Analysis|Correlative studies
224213415|NCT01462695|OTHER|Pharmacological Study|Correlative studies
224213416|NCT01462695|DRUG|Sunitinib Malate|Given PO
224213417|NCT03251183|DIAGNOSTIC_TEST|Comprehensive Cardiovascular magnetic resonance (CMR)|Cardiovascular magnetic resonance (CMR) provides non-invasive, radiation-free and in-depth evaluation of myocardial structure and function. In addition to established tools for assessment of cardiac volume, mass, function and regional myocardial scar with late Gadolinium enhancement (LGE), several novel quantitative CMR parameters will be assessed including T1-mapping or fully quantitative perfusion Imaging.
224213418|NCT03251183|DIAGNOSTIC_TEST|Blood sampling|Blood samples will eventually be analysed for markers related to heart failure (BNP/NT)-pro-BNP, myocardial inflammation and fibrosis (cytokine profiling, Galectin-3, Procollagen Type I and III, hsCRP). Whole blood will be frozen for DNA isolation and genome analysis. Peripheral blood mononuclear cells will be isolated by Ficoll in a subset of patients and will be used for RNA isolation allowing RNA-seq or reverse transcription (RT) - polymerase chain reaction (PCR) analysis.
223624111|NCT00371592|DRUG|Acyclovir placebo|800 mg placebo tablet taken orally twice daily
223624112|NCT03963765|PROCEDURE|Group I (Standard DL-PDT)|Daylight photodynamic therapy with photosensitizer (MAL - Metvix, Galderma ®)
223624113|NCT03963765|PROCEDURE|Group II (DL-PDT with microneedles)|Daylight photodynamic therapy with photosensitizer (MAL - Metvix, Galderma ®) and Microneedles - motorized pen with a tip of 17 grouped needles with 0,5mm (Dermapen Beauty®- Korea) as a techniques of transepidermal drug delivery (TED)
223624114|NCT03963765|PROCEDURE|Group III (DL-PDT with CO2 laser)|Daylight photodynamic therapy with photosensitizer (MAL - Metvix, Galderma ®) and Ablative Fractional Laser (AFXL), CO2 laser, roller-type ferrule, composed of one row with seven fractionating pins (7x1), 60 W, 15 mJ/pixel, 125μm/pixel, 2 mm spacing between ablation zones, density \<1% (Pixel Alma Lasers ®) was applied, single-pass
223762088|NCT00186667|PROCEDURE|high dose chemotherapy and autologous hematopoietic cell transplant|
224213419|NCT03251183|DIAGNOSTIC_TEST|TTE (EchoErgo)|Measurements will include cavity dimensions, flow velocities, myocardial motion velocity and strain as well as for change of parameters during ergometric stress.
224213420|NCT03251183|DIAGNOSTIC_TEST|Invasive pressure-volume (PV) Loops|Multiple parameters (including EDPVR, ESPVR, dp/dt min, Tau, Ea) will be derived from the various PV loop assessments and additional relevant parameters will be calculated. Right ventricular and pulmonary pressures including pulmonary vascular resistance will be measured with Swan-Ganz catheters using right venous femoral approach.
224213421|NCT03251183|DIAGNOSTIC_TEST|Left ventricular (LV) biopsy|"A set of myocardial biopsies for each patient will be stained with Masson Trichrome for qualitative and quantitative assessment of the collagen volume fraction; fat droplets will be identified by red oil staining, Congo Red for amyloid immunohistology will be used to determine total leukocytes (CD45), T-cells (CD3) and monocytes/macrophages (CD68).~A second set of biopsies will be frozen immediately and stored at -80°. Western blot analysis will be performed to determine alterations at the myofilament level including titin isoform composition and phosphorylation status."
223624115|NCT03963765|PROCEDURE|Group IV (DL-PDT with microdermabrasion)|Daylight photodynamic therapy with photosensitizer (MAL - Metvix, Galderma ®) and Microdermabrasion - aluminum oxide crystal (Pan Eletronic®) as a techniques of transepidermal drug delivery (TED)
223624116|NCT04320004|BEHAVIORAL|Education|Subject receives education
223624117|NCT04320004|BEHAVIORAL|Education with Reminder|Subject receives education with reminder
223624118|NCT04320004|BEHAVIORAL|Education + Disposal Bag|Subject receives education and disposal bag
223624119|NCT04320004|BEHAVIORAL|Education + Disposal Bag with Reminder|Subject receives education + disposal bag with reminder
223624120|NCT01651481|DRUG|HCP1102|
223624121|NCT01651481|DRUG|Singulair and Xyzal|
223624122|NCT02579460|OTHER|Cessation of Acid Suppressing Medications|Acid suppressing medications are stopped for all participants the day after baseline assessment. Subsequent evaluations are performed while the participant is not on acid-suppressing medications. Endoscopy with biopsies will be performed in all patients on day 0, 7, and 14.
223624123|NCT00332072|DRUG|bimatoprost/timolol fixed combination|
223624124|NCT00399516|DEVICE|Precision|
223624125|NCT02644759|BIOLOGICAL|Stem Cell Transplantation|Interventional radiology-mediated transplantation of purified, autologous stem cells into pancreatic artery and capillaries, and intravenous injection of autologous, immunomodulated mononuclear cells.
223624126|NCT05157295|DRUG|OnabotulinumtoxinA|100 U of Onabotulinumtoxin A diluted in 10 mL of saline injected into the wall of the detrusor muscle at various sites
223624127|NCT06140602|OTHER|Intervention shake|The pecan shake contains 69g of pecans
223624128|NCT00120016|BEHAVIORAL|dietary counseling|telephone counseling
223762089|NCT02273648|DEVICE|Drug Eluting Stent (DES)|Percutaneous Coronary Intervention
223762090|NCT06484075|DRUG|Placebo|The placebo will be a tablet, but only containing inert inactive ingredients.
223762091|NCT06484075|DRUG|Suvorexant|Drug approved for improving sleep
223762092|NCT05892510|DRUG|Intra-arterial tenecteplase injection at the completion of thrombectomy|Intra-arterial tenecteplase (0.062mg/kg, maximum 6.25mg) administered as a bolus at the completion of thrombectomy through a microcatheter at the site of the initial-but-now-retrieved intracranial occlusion, or in direct contact with the residual thrombus
223762093|NCT05892510|DRUG|Placebo|intra-arterial bolus of 0.9% Sodium Chloride solution
223624129|NCT04932928|DEVICE|FreeStyle Libre|Flash glucose monitoring + Education on lifestyle modification
223624130|NCT04932928|DEVICE|Blood glucose meter|Self monitoring of blood glucose + Education on lifestyle modification
223624131|NCT02631096|DRUG|ARB-001467|An IV infusion of ARB-001467
223624132|NCT02631096|OTHER|Placebo|An IV infusion of placebo
223624133|NCT04361071|DEVICE|stent|stent
223624134|NCT04361071|DEVICE|plaque excision system|plaque excision system
223762094|NCT04569500|OTHER|PETAL program|patients and their close relations will benefit from the therapeutic education program PETAL in order to accompany them throughout their experience of laryngectomy and to reduce its impact on social and professional aspects of life.
223762095|NCT00203749|BEHAVIORAL|Community-Based HIV VCT|"COMMUNITY MOBILIZATION. This component of the intervention uses community outreach to enhance the uptake of VCT, thus increasing the rate of HIV testing and frequency of discussions about HIV and reducing stigma through community education and mobilization.~EASY ACCESS TO VCT. This component is designed to remove practical barriers and increase safety of VCT. Mobile vans or temporary units set up at local community sites will provide free, anonymous VCT in specific, chosen sites where people gather, such as market areas, shopping centers, and community centers.~POST-TEST SUPPORT SERVICES. This component is designed to build psychosocial support to improve the quality of life for individuals diagnosed with HIV. The expected outcomes include a reduction in social harm, an increase in social support through disclosure to those most likely to provide support, and a reduction in internalized stigma. Social support should also decrease the behavioral risk of further transmission."
223762096|NCT00203749|BEHAVIORAL|Standard clinic-based VCT|Control communities will receive Standard Clinic-Based VCT (SVCT) instead of the community-based VCT (CBVCT) intervention. Each of these communities will have access to SVCT that reflects local access to health care. The training for VCT counselors will be the same in the CBVCT and SVCT communities; however, no active recruitment for participation in the SVCT services will be made beyond the standard procedures of each clinic for informing patients of services (e.g., telling individual patients that VCT is available, posting of a flyer in the clinic announcing VCT availability, etc). As such, no active outreach or community mobilization will be conducted by the study staff in the SVCT settings (although it is possible that such activities will occur due to local initiative).
223624135|NCT04482517|OTHER|Density Gradient Centrifugation|Semen processing is done by double layer density gradient method.
223762097|NCT03065556|DRUG|188-0551 Solution|Topical solution containing active drug
223762098|NCT03065556|DRUG|Vehicle Solution|Topical solution containing no active drug
223762099|NCT03187405|DRUG|EVD + IVF with Alteplase|Intraventricular fibrinolysis: Injection through the EVD of 1mg in 1 mL of Alteplase every eight hours during 3 days (9 doses).
223762100|NCT01120210|DRUG|JNJ-39588146 5 ng/kg/min|1-hour infusion of JNJ-39588146 5 ng/kg/min on Day 1
223762101|NCT01120210|DRUG|JNJ-39588146 15 ng/kg/min|1-hour infusion of JNJ-39588146 15 ng/kg/min on Day 1
223762102|NCT01120210|DRUG|JNJ-39588146 30 ng/kg/min|1-hour infusion of JNJ-39588146 30 ng/kg/min on Day 1
223762103|NCT01120210|DRUG|Placebo|1-hour infusion of matching placebo on Day 1
223762104|NCT01120210|DRUG|JNJ-39588146 5, 15, or 30 ng/kg/min|18-hour infusion of JNJ-39588146 or matching placebo on Day 1 immediately folllowing the 3-hour infusion at a dose equal to the maximum dose tolerated by that patient during the 3-hour infusion in Part 1 of the study.
223762105|NCT02995291|DRUG|OraVerse|1.7ml OraVerse (0.4 mg phentolamine mesylate) will be injected once after the participants are found to be well anesthetized following an injection of 1.8ml Bupivacaine 0.5% (inferior alveolar nerve block). Oraverse will be injected at the same site Bupivacaine was injected.
223762106|NCT02995291|DRUG|Saline Water (Control)|1.7ml saline water will be injected once after the participants are found to be well anesthetized following an injection of 1.8ml Bupivacaine 0.5% (inferior alveolar nerve block). The water will be injected at the same site Bupivacaine was injected.
223762107|NCT02052739|DRUG|SAGE-547|Solution for injection for IV infusion
223762108|NCT04818359|BEHAVIORAL|MoviS Training|Patients will undergo a supervised exercise program consisting of 3 months of aerobic exercise training (2 d/week of directly supervised exercise and 1 d/week of remotely supervised exercise) with a progressive increase in exercise intensity (40-70% of heart rate reserve) and duration (20-60 min).
223762109|NCT06219915|DRUG|Carbidopa 25 mg|Participants will take one 25mg Carbidopa tablet 3 times a day for 10 days.
224213422|NCT03355222|BEHAVIORAL|Promotion of chicken eggs|Community is provided with chickens and young children are to receive one egg a day; selected mothers will consume eggshell.
224213423|NCT05494775|DRUG|Anti-vascular endothelial growth factors (Anti-VEGFs)|Intravitreal injection of anti-vascular endothelial growth factors (Anti-VEGFs).
223624136|NCT04482517|OTHER|Physiological ICSI|Sperm selection by PICSI dishes depending on hyaluronan binding of sperm head
223762110|NCT06219915|DRUG|Carbidopa-Levodopa 25/100 mg|Participants will take one 25/100mg carbidopa-levodopa tablet 3 times a day on days 4-6, then increase to 1.5 tablets 3 times a day on days 7-10.
223762111|NCT06219915|DRUG|Placebo 1|Participants will take one 25mg placebo tablet 3 times a day for 10 days.
223762112|NCT06219915|DRUG|Placebo 2|Participants will take one 100mg placebo tablet 3 times a day on days 4-6, then increase to 1.5 tablets 3 times a day on days 7-10.
223762113|NCT05703061|BEHAVIORAL|10-hour Time in Bed|Participants will be asked to increase their time in bed to 10-hours per night for 7 consecutive days.
223762114|NCT05320029|DEVICE|Disposable Powered Articulating Endoscopic Linear Cutter Stapler|Using the Disposable Powered Articulating Endoscopic Linear Cutter Stapler according to routine treatment
224213424|NCT02647554|DRUG|ulinastatin|ulinastatin 400,000 IU every 8 hours for 10 days
224213425|NCT02647554|DRUG|Placebo|matching placebo every 8 hours for 10 days
224213426|NCT04516694|BEHAVIORAL|Financial incentive (gain)|Participants will receive a daily financial incentive framed as a gain with money allocated each day of adherence to a self-care coal. Participants will receive an additional weekly incentive for meeting a clinical outcome goal.
223624137|NCT04482517|OTHER|Magnetic activated cell sorting|Sperm selection by using Annexin V micro-beads and separation columns
223624138|NCT04482517|OTHER|Testicular sperm|Using testicular sperm retrieved by TESA or TESE
223624139|NCT05966649|OTHER|Synbiotics|Oral synbiotic (food supplement) containing 8 probiotic Lactobacillus strains, the prebiotics inulin, fructooligosaccharides (FOS) and D-mannose.
223624140|NCT05966649|OTHER|Placebo|Matching placebo
223624141|NCT05837338|DRUG|BXP154|BXP154 will be self-administered topically following wound induction
223624142|NCT05837338|DRUG|Placebo|Placebo will be self-administered topically following wound induction
224213427|NCT04516694|BEHAVIORAL|Financial incentive (loss)|Participants will receive a daily financial incentive framed as a loss with money allocated up front and taken away each day of non-adherence to a self-care coal. An additional weekly incentive will be deducted for failure to meet a clinical outcome goal.
224213428|NCT00665717|DRUG|Pravastatin|40 mg tablet; QD; 4 days
223624143|NCT03957148|BEHAVIORAL|Sugar-sweetened beverage reduction education for preschool children|Participants in the SSB-IMB program will receive 10 weeks of SSB related nutrition education at their child's preschool. Each week a different lesson pertaining to parental information, motivation, or behavioral skills related to SSBs will be presented via an interactive display board. Twice a week, two student educators will stand by display boards for two hours and deliver the lessons that will last 5-10 minutes with each parent. These displays will include an activity for parents to apply knowledge and skills learned during the short lesson. Educators will also provide parents with informational handouts pertaining to each lesson to reinforce concepts learned. Display board education is flexible, so that if a parent arrives while another parent is receiving education, the second educator can begin the lesson with the new parent. Multiple parents can participate in a lesson at the same time. Groups of 2-3 parents can review the lesson together, learning from each other.
223624144|NCT00000214|DRUG|Buprenorphine|
224213429|NCT00665717|DRUG|Raltegravir|400mg tablet; BD 4 days
224213430|NCT00665717|DRUG|Pravastatin and raltegravir|pravastatin 40mg tablet QD for 4 days; raltegravir 400mg tablet BD for 4 days
224213431|NCT05742061|DRUG|Corticosteroid|The injection will be given at a site near the superolateral pole of patella in the suprapatellar pouch under aseptic conditions and the patient will be advised to take one day of rest after injection and apply ice to the area if there are any signs of inflammation.
224213432|NCT05742061|OTHER|Platelet Rich Plasma|PRP preparation :- 20 ml of venous blood will be drawn from the antecubital vein using an 18G needle to avoid traumatizing platelets and will be collected in a sterile tube containing 2 ml of Sodium Citrate anticoagulant. Approximately 2 ml of whole blood will be separated for a complete blood count.The blood with anticoagulant will centrifuged at 4000 rpm for 6-10 minutes to separate erythrocytes and then at 4000 rpm for 6-10 min to concentrate platelets.The final product was 4-5 ml of PRP containing leukocytes with platelet concentration of 3-5 times the average normal value.
223624145|NCT00348712|DRUG|rosiglitazone|Tablets, 4 mg once or twice daily.
223624146|NCT00348712|DRUG|inhaled human insulin|Treat-to-target dose titration scheme, inhalation.
223624147|NCT00348712|DRUG|metformin|Tablets, 2000 mg/day.
223624148|NCT05095961|DRUG|Prednisone|5 day course of oral prednisone pre-operatively. 30mg per day.
223624149|NCT05901701|RADIATION|Low Level LASER therapy|using semiconductor InGaAsp diode LASER type 940 nm with continuous mode of operation, with time of application 180 sec per session for 12 sessions.
223624150|NCT05901701|DEVICE|Hard occlusal splint|2 mm thickness occlusal splint constructed over the maxillary arch using CAD/CAM technology.
223762115|NCT05320029|DEVICE|ECHELON Flex Powered Articulating Endoscopic Linear Cutters|Using the ECHELON Flex Powered Articulating Endoscopic Linear Cutters according to routine treatment
223762116|NCT02694419|DEVICE|Doppler evaluation|Endometrial volume, endometrial and subendometrial vascularity indices are measured by 3D power Doppler
224213433|NCT05059717|PROCEDURE|Magnetic Resonance Imaging|Undergo standard of care MRI
224213434|NCT05059717|PROCEDURE|Magnetic Resonance Imaging|Undergo MR DENSE imaging
224213435|NCT01547637|PROCEDURE|Obturator nerve block|Peripheral obturator nerve block using 10 ml of 2% lidocaine
223624151|NCT00756106|DRUG|temozolomide|Temozolomide is administered according to standard of care practice guidelines. Dosing may be modified at the discretion of the treating investigator.
223624152|NCT00756106|OTHER|Imaging biomarker analysis|MRI
224213436|NCT01547637|PROCEDURE|Obturator nerve block|Ultrasound guided peripheral obturator nerve block
224213437|NCT05165017|BIOLOGICAL|AlloRx Stem Cells®|Umbilical cord-derived allogeneic mesenchymal stem cells
224213438|NCT05165017|OTHER|Placebo control|Placebo infusion without mesenchymal stem cells
224213439|NCT01872468|BEHAVIORAL|Structured intervention|Initial training session based on patient personal experiences and reflexion (30 minutes). CKD learning session (30 minutes). Personal plan of actions to cope with own disease (30 minutes. Discussion of doubts (30 minutes). Follow up visits every four months at physicians and nurses´ offices over a two-year period
223624153|NCT00756106|RADIATION|Photon Radiation Therapy|Radiation is administered to the tumor plus edema with a 1-2 centimeter margin for a total dose of 60 Gy in 30 fractions.
223762117|NCT06348719|PROCEDURE|Robot-assisted laparoscopy|The experimental procedure corresponds to robot-assisted laparoscopy.
223762118|NCT06348719|PROCEDURE|conventional laparoscopy|"The control procedure corresponds to conventional laparoscopy."
224213440|NCT04912973|PROCEDURE|Robotically Assisted Total Knee Arthroplasty - Knee Replacement|Robotically Assisted Total Knee Arthroplasty with a particular alignment strategy
224213441|NCT00127764|DRUG|dexamethasone (50mg 1dd6, 3 consecutive days/month)|
224213442|NCT00148928|BIOLOGICAL|P501-AS15 vaccine|
224213443|NCT05552430|DEVICE|RelieveVRx|Participants will complete daily skills-based Virtual Reality (VR) sessions for 8 weeks (an average of 6 minutes per day) to determine the feasibility of at-home VR technology to aid the recovery of acute orthopedic musculoskeletal injuries. The VR device software is equipped with pain-specific treatment modules (e.g., Pain Education, Relaxation/Interoception, Mindful Escapes, and Pain Distraction Games) derived from evidence-based principles of cognitive behavioral therapy (CBT), mindfulness, and pain neuroscience education.
223624154|NCT05918796|DRUG|Bupivacaine|18 ml of bupivacaine of 0.25% injected bilaterally in quadratus lumborum block
223624155|NCT05918796|DRUG|Dexamethasone|dexamethasone
223624156|NCT04816448|OTHER|cervical mobilization (Headache SNAG)|For cervical mobilization the patient's position is sitting on a chair in the erect posture. The therapist handled C2 spinous process with the middle phalanx of one hand. With the other hand, he performed ventral glide asked the patient to move neck in all directions (Flexion, Extension, Side bending and rotation) one by one and then slowly move the neck back to its starting position while the therapist maintained the ventral glide.
224213444|NCT05128487|DRUG|NDI-101150|NDI-101150 capsules
224213445|NCT05128487|DRUG|Pembrolizumab|Pembrolizumab IV infusion
224213446|NCT00297206|DRUG|Valaciclovir|Valaciclovir will be administered as an extemporaneously prepared suspension formulation. Valaciclovir oral suspension will be prepared by crushing marketed Valtrex Caplets 500 milligram (mg) and suspending the resultant powder in Suspension Structured Vehicle USNF with dose strength of 25 milligram per milliliter (mg/mL) or 50 mg/mL.
223624157|NCT04816448|OTHER|Sub-occipital myofascial release|"For the application of the technique , the patient position is supine lying with the head fully supported on therapist's hands and therapist places 3 middle fingers just inferior to the nuchal line, lifts the fingers tips towards the ceiling while resting the head on the table and then therapist will apply a gentle upward pull. This procedure done for 2 to 3 minutes and 5 to 7 repetitions, 3 sessions per week on alternate days were given for 6 weeks.~Evaluation was done before treatment, during treatment at 4th week and after treatment at 6th week. Outcomes will be measured by NDI, PNRS and Universal Goniometer."
223624158|NCT00171379|DRUG|Enteric-Coated Mycophenolate Sodium|
223624159|NCT04980534|DIETARY_SUPPLEMENT|Viusid and Asbrip|Patients will be assigned to receive daily oral doses of 4.5gr of Viusid and 10 ml of Asbrip every 8 hours and standard care.
223624160|NCT04980534|DRUG|COVID-19 Standard Therapy|Patients will be assigned to receive the standard therapy for COVID-19 disease: Antibiotic, Antivirals, Analgaesic, Anti-inflammatory drugs.
223624161|NCT00900978|BIOLOGICAL|7 valent pneumococcal conjugate vaccine (7v-PCV) - Prevenar|The 7v-PCV will be given to children below 2 years of age. Nasopharyngeal swabs will be taken from the children before vaccination and after finishing the vaccination. The vaccine will be given in a 2+1 scheme.
223624162|NCT03806192|BEHAVIORAL|Telephone-Based Intervention|Attend psychoeducational counseling sessions via telephone
223624163|NCT03806192|OTHER|Behavioral, Psychological or Informational Intervention|Attend psychoeducational counseling sessions via video teleconference
223624164|NCT03806192|OTHER|Questionnaire Administration|Ancillary studies
223624165|NCT00441623|BEHAVIORAL|observational|effect of protein-bound uremic retention solutes
223762119|NCT06348719|OTHER|Prospective cohort study|A prospective cohort of patients will be set up to support the randomized controlled trial. Patients will be offered participation in this cohort if the center is unable to participate in the randomized trial (i.e., does not have a robot, or does not have a laparoscopic column with fluorescence), if the patient refuses randomization in the randomized controlled trial, if the surgeon refuses to randomize the patient, or if the surgeon does not meet the learning curve criteria required for robotic surgery. These patients will be followed in exactly the same way as patients included in the randomized controlled trial, once their consent has been obtained.
224213447|NCT00902252|DEVICE|Usual|All subjects will wear their usual pouching system for the first 21 days of the study.
224213448|NCT00902252|DEVICE|Natura®|All subjects will wear the Natura® Flexible Skin Barrier with Flange (Stomahesive® or Durahesive®) in the US and Natura® Stomahesive® Flexible Skin Barrier with Flange in Europe for 14 days.
223624166|NCT03324776|DRUG|Afrezza Inhalant Product|Mealtime Ultra-Rapid Acting Insulin
223624167|NCT03139760|BEHAVIORAL|POWERSforID|Feasibility and outcomes associated with use of the POWERSforID system and coaching phone calls over the course of 24 weeks
223624168|NCT03630796|DRUG|Sevoflurane|Use of sevoflurane (compared to total intravenous anesthesia) in congenital heart deffects surgeries.
223624169|NCT03630796|DRUG|TIVA|Total intravenous anesthesia
224213449|NCT00902252|DEVICE|Vitala™|"After the successful completion of Stages 1 and 2, subjects will enter the ramp up schedule to allow the subject to adjust to the device. This consists of weekly increases in wear time of the Vitala™ device beginning with 4 hours of daily wear per week (Days 36 to 42), followed by 6 hours of daily wear time per week (Day 43 to 49), followed by 8 hours of daily wear time (Days 50 to 56) and progressing to 12 hours of daily wear per week (Day 57 to 215)."
224213450|NCT01319305|DEVICE|FinESS Sinus Treatment|balloon sinuplasty
224213451|NCT05889026|DEVICE|Extracorporeal shock wave therapy|Stimulation was given to the brachial muscle, 1000 times, 4Hz, and energy flux density was 0.030mJ/mm2.
223624170|NCT04274816|DRUG|Tremelimumab|Intradermal injection of tremelimumab 7 days prior to sentinel node biopsy, with escalating doses of 2, 5, 10 or 20 mg tremelimumab (3 patients per dose level with an expansion at the optimal dose level with an additional 5 patients).
223624171|NCT02859922|DEVICE|Laryngeal Tube Suction Disposable|Laryngeal Tube Suction Disposable
223624172|NCT02859922|DEVICE|Supreme Laryngeal Mask Airway|Supreme Laryngeal Mask Airway
224213452|NCT05889026|PROCEDURE|Botulinum toxin treatment|The toxin dose was established for each patient: it ranged between 80 unit and 300 unit.
224213453|NCT00177099|DRUG|FK506, GP11046, GP11511|
223624173|NCT01406301|DRUG|fondaparinux|fondaparinux
223624174|NCT01672645|BIOLOGICAL|NIC7-001|Intramuscular, multiple dose
223762120|NCT06348719|OTHER|Retrospective cohort study|Retrospective data collection from the medical records of all patients who underwent hysterectomy for low- or intermediate-risk endometrial cancer during the inclusion period at a participating center and who were not included in the randomized controlled trial or prospective cohort; up to a limit of 1000 inclusions. For this retrospective cohort, only data concerning initial age, BMI, histological type of cancer and surgical approach used will be collected.
223624175|NCT01672645|BIOLOGICAL|NIC7-003|Intramuscular, multiple dose
223624176|NCT01672645|BIOLOGICAL|Saline|Saline (0.9% sodium chloride)
223624177|NCT03944928|OTHER|Lung ultrasound|"For each usual consultation every 3 months, the patient will have clinical examination and pulmonary function tests (CPI score). Thoracic ultrasound will be made during the consultation (M0, M3, M6, M9 and M12). The presence, gravity and localisation of each ultrasound sign will be described. CT-scan data will be collected in the 3 months before the start of the study and during the study. To be enrolled in the study does not change to the usual follow-up.~For the thoracic ultrasound, a convex probe will be used (1 to 5 MHz). Patient will be layed down in a right lateral prone position then left. Thoracic ultrasound will be timed, saved and anonymized. 14 intercostal spaces will be explored by experimented operator.~The records will be seen a second time by same operator then a second operator. this will measured interoperator and intraoperator variability."
223624178|NCT03735836|OTHER|MAG-EPA/MAG-DHA omega-3 oils|The monoglyceride (MAG) eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) are chemically modified fish oils that fall into the Natural Health products category in Canada.
223624179|NCT04102397|PROCEDURE|Vojta therapy after standard therapy|Vojta Therapy \~20 minutes/session: Application of the Reflex Creeping complex, activating several stimulus points on the facial and the nuchal sides (Figure 3a), and then the activation of the Reflex Rolling complex in both the supine position and with the patient lying on his or her side, alternating between nuchal and facial stimulation and guiding from the head.
223624180|NCT04102397|PROCEDURE|Standard therapy|"\~50 minutes/session:~* TENS Current (20 minutes, phase duration=0.10 microseconds, frequency=50 Hz). The intensity applied depended on the patient's tolerance for the treatment (Figure 2a).~* Pulsating ultrasound (5 minutes around the shoulder, frequency=1MHz, intensity=1 W/cm2) (Figure 2b).~* Kinesiotherapy. In stages: at first assisted (with isometric exercises), then free, and finally, with resistance, usually with elastic bands (Figure 2c).~* Cryotherapy (5 minutes)."
223624181|NCT00871767|DRUG|AZD5672|40 mg tablet (Test formulation)
223624182|NCT00871767|DRUG|AZD5672|40 mg tablet (Reference formulation)
223624183|NCT00871767|DRUG|AZD5672|100 mg tablet (Test formulation)
223624184|NCT00871767|DRUG|AZD5672|100 mg (2 x 50 mg tablet (Reference Formulation)
223624185|NCT05604846|DIETARY_SUPPLEMENT|ProPrems|The intervention product, commercially known as ProPrems®, is a combination of (one billion freeze-dried bacteria per 0.5 g in a maltodextrin base powder: Bifidobacterium infantis Bb-02 (DSM 33361) 300 million, Bifidobacterium lactis (BB-12®) 350 million, and Streptococcus thermophilus (TH-4®) 350 million will be given daily once to eligable infants born extremly preterm (\<28weeks of gestation) once they tolerate 3ml of enterla feeds until the age of 34 weeks of gestation.
223624186|NCT03297957|DEVICE|Hands-free goggle system|-Manufactured at Washington University
223624187|NCT00539981|BIOLOGICAL|FluBlok®|Dose: 0.5 mL, single dose; Route of administration: intramuscular. Recombinant Trivalent Hemagglutinin Influenza Vaccine containing 45 microgram (mcg) of each hemagglutinin derived from A/Solomon Islands/3/2006 (H1N1), A/Wisconsin/67/2005 (H3N2), and B/Malaysia/2506/2004
223624188|NCT00539981|BIOLOGICAL|Placebo|Dose: 0.5 mL normal saline for injection, single dose; Route of administration: intramuscular
223624189|NCT02675907|DRUG|N1539|
223762121|NCT06348719|OTHER|information and consent|information and consent
223762122|NCT06348719|OTHER|randomization|Randomization
223762123|NCT06348719|OTHER|Collection of socio-demographic, clinical, biological, imaging and histopathological data, treatment decision, recurrence|Collection of socio-demographic, clinical, biological, imaging and histopathological data, treatment decision, recurrence
223762124|NCT06348719|OTHER|Surgical data collection|Surgical data collection at Day 0
223762125|NCT06348719|OTHER|Biological data collection|Biological data collection at Day 1
223762126|NCT06348719|OTHER|Collection of histological data from the surgical specimen|Collection of histological data from the surgical specimen et Day 42
224213454|NCT01364298|DRUG|Gabapentin/B-complex|Gabapentin/B-complex (Gavindo®) tablet will be administered orally at an initial dose of 300 milligram per day (mg/day) on Day 1, followed by 600 mg/day (one 300 milligram \[mg\] tablet every 12-hour) on Day 2, then 900 mg/day (one 300 mg tablet every 8-hour) on Day 7, then 1800 mg/day (two 300 mg tablets every 8-hour) on Day 21, then 2700 mg/day (three 300 mg tablets every 8-hour) on Day 35, and finally 3600 mg/day (four 300 mg tablets every 8-hour) on Days 56 and 84. Maximum dose allowed will be 3600 mg/day. The total duration of treatment will be 84 days (12 weeks).
224213455|NCT01364298|DRUG|Pregabalin|Pregabalin (Lyrica®) capsule will be administered orally at an initial dose of 150 mg/day (one 75 mg capsule every 12-hour) from Day 1 to 7, followed by 300 mg/day (one 150 mg capsule every 12-hour) on Day 7, then 600 mg/day (two 150 mg capsule every 12-hour) on Days 21, 35, 56 and 84. Maximum dose allowed will be 600 mg/day. The total duration of treatment will be 84 days (12 weeks).
223624190|NCT02675907|DRUG|Intravenous Placebo|
223624191|NCT05298488|BEHAVIORAL|Home office|Working from home
223624192|NCT05298488|BEHAVIORAL|Office|Working at the office
223624193|NCT01611792|OTHER|Stabilization exercise protocol|The stabilization exercise protocol consists of exercises focused on improving the ability of trunk muscles to stabilize the spine, beginning with training to isolate the deeper abdominal muscles as well as deep dorsal trunk muscles. Then patients were progressed to exercises that added leverage of the limbs while maintaining the co-contraction of the deeper abdominal muscles and deep dorsal trunk muscles while breathing normally. Various positions (e.g., supine and quadruped positions) were used to challenge the patients based on their tolerance. Finally, patients were progressed to exercises in more functional positions that included tasks/activities that were reported as challenging and/or painful; patients performed the tasks at the speed demanded by the particular task. Maintenance of the co-contraction of deep trunk muscles was emphasized during these functional activities.
223624194|NCT01611792|OTHER|Strength and conditioning exercise protocol|This protocol contained trunk strengthening and endurance exercises. It consisted of 3 phases: 1) initial strengthening of trunk flexors/extensors in single plane movements, 2) trunk and lower-extremity stretching as well as progression of trunk-strengthening exercises to include multi-planar trunk movements. Aerobic exercises were progressed as tolerated and patient education about body biomechanics were reinforced, and 3) trunk-strengthening exercises under dynamic conditions (e.g., unstable support surface and in multi-planar trunk movements). During the 10 week protocol, exercises became more challenging, and each subject had to complete at least the first phase before moving onto the next phase in order to be included in post-testing analyses. There was no specific focus on the deep abdominal or deep dorsal trunk muscles during any of these exercises.
223624195|NCT05252546|DRUG|pyrotinib tablet|single oral dose of pyrotinib or co-administered with Montmorillonite Power or Loperamide
223624196|NCT05252546|DRUG|Montmorillonite Power|3 g or one pouch of montmorillonite power 2 hours after pyrotinib administration
223624197|NCT05252546|DRUG|Loperamide|4 mg of loperamide with pyrotinib followed by 2mg every 2 hours for 2 times for a total of 8mg/day
223762127|NCT06348719|OTHER|Phone calls|Phone calls at Day 1, Day 3,Day 7,Day14,Day 21 , Month 3
223762128|NCT06348719|OTHER|Pain assessment|Pain assessment at day 1 , Day 3,Day 7,Day14,Day 21 , Month 3
223762129|NCT06348719|OTHER|Collect of data on non-reimbursed transport|Collect of data on non-reimbursed transport at Day 3,Day 7,Day14,Day 21 , day 42, Month 3, month 6
224213456|NCT00294632|DRUG|Lenalidomide|Starting Dose 10 mg By Mouth Daily on Days 1-21
223624198|NCT05294926|DRUG|Rocuronium|After applying standard monitoring of pulse oximetry, ECG, noninvasive blood pressure, general anesthesia will be induced with fentanyl 1 µg/kg and propofol 2-3 mg/kg and Rocuronium 0.6 mg/kg will be administered for muscle relaxation after loss of consciousness, under the guidance of neuromuscular blockade monitoring. Tracheal intubation will be performed at a train-of-four count of 0. After that end-tidal carbon dioxide and temperature will be continuously monitored during the procedure. Mechanical ventilation will be instituted with o2:air of 4 L/min, tidal volume of 6-8 ml/kg and respiratory rate appropriate to achieving end-tidal carbon dioxide of 30-35 mmHg. no positive end-expiratory pressure; and inspiratory/expiratory ratio 1: 2. The patient's position will then be changed from supine to prone. Ephedrine 4 mg (if mean arterial pressure \< 60 mmHg and heart rate \< 40 bpm), or atropine 0.5 to 1.0 mg (if heart rate \< 40 bpm) are used to prevent hypotension or bradycardia
223624199|NCT05294926|DEVICE|nerve stimulator|Neuromuscular blockade monitoring will be established and continuously monitored after induction using the Train Of Four (TOF) at the adductor pollicis muscle on the opposite hand and wrist to radial artery cannulation. Two surface electrocardiography electrodes will be placed on cleaned skin overlying the ulnar nerve, with one electrode positioned on the ulnar side of the flexor carpi radialis tendon and the other positioned 3cm proximal to the first. The transducer is then positioned with the flat side against the thumb. Supramaximal stimuli will be applied after autonomic calibration of acceleromyograph after an initial tetanic stimulus. After confirming a train-of-four ratio of 95 to 105%, neuromuscular blockade monitoring will start. The train-of-four mode of supramaximal stimulation (0.2 ms duration, frequency 2 Hz, two s duration) will be applied at 15 s intervals, which last until the end of anaesthesia.
223624200|NCT05389098|OTHER|Hand-Eating|eat-hands type food mode
223624201|NCT05389098|OTHER|Control|Usual eating mode
223624202|NCT00166218|DEVICE|near-infrared spectroscopy|
223624203|NCT02313220|DRUG|Dapagliflozin|Oral use
223624204|NCT02313220|DRUG|Exenatide|Powder and solvent for suspension for injection, prolonged release suspension. Subcutaneous use.
223624205|NCT02313220|DRUG|Placebo|Oral and Subcutaneous use.
223624206|NCT01129622|DRUG|letrozole|Letrozole (12.5 mg/day ) which is higher than the dose routinely used for therapeutic indications is given for a brief duration (3 successive days) aiming to promote acute aromatase inhibition suitable for pre-diagnostic regimens.
223624207|NCT00004838|DRUG|succimer|
223624208|NCT02900794|DEVICE|Gold Laser|Under endoscopic visualization, the Gold Laser will be utilized to perform 1) excision of the concha bullosa, 2) maxillary antrostomy, and 3) submucosal cauterization of the turbinates. Suction/irrigation will be utilized as necessary.
223624209|NCT02900794|PROCEDURE|Microdebridement|Under endoscopic visualization, the microdebrider will be utilized to perform 1) excision of the concha bullosa, 2) maxillary antrostomy, and 3) submucosal cauterization of the turbinates.
223624210|NCT05046223|PROCEDURE|The responses to bronchoscopic insertion for bronchoscopic interventions such asTBNA, Cryotherapy, etc.|cough response, the changes of BP, HR, SpO2, Trans dermal CO2 during bronchoscopic interventions
223624211|NCT05046223|PROCEDURE|postoperative recovery|anesthetic recovery in postoperative care unit recovery of swallowing by questionnaire in POD1
223624212|NCT02733263|DIETARY_SUPPLEMENT|15 g RMD|15 grams of resistant maltodextrin
223624213|NCT02733263|DIETARY_SUPPLEMENT|25 g RMD|25 grams of resistant maltodextrin
223624214|NCT02733263|DIETARY_SUPPLEMENT|0 g RMD|0 grams of resistant maltodextrin
223624215|NCT02949349|DRUG|Mycophenolate mofetil|Provided as 250mg/capsule, dose specific for each arm, orally twice a day, for 24 weeks.
223624216|NCT02949349|DRUG|Azathioprine|Provided as 50mg/tablet, 1mg/kg, orally twice a day, for 24 weeks.
223624217|NCT02949349|DRUG|Prednisolone|Daily dose not more than 10mg, orally, for 24 weeks.
223624218|NCT04256694|DIAGNOSTIC_TEST|Rapid Antigen Test for Group A Streptococcus|Rapid strep tests will be performed by throat swab of healthy adult volunteers.
223624219|NCT00002814|BIOLOGICAL|filgrastim|
223624220|NCT00002814|DRUG|paclitaxel|
224213457|NCT00294632|DRUG|Rituximab|375 mg/m\^2 By Vein Weekly for 4 Weeks
224213458|NCT06439264|OTHER|bentonite clay gel with hydroxyapatite|bentonite clay gel presents great potential for bone healing and it leads to the formation of interconnected microporous structure, which can promote native cell infiltration, proliferation,
224213459|NCT01162018|PROCEDURE|acupuncture|The eligible women would be randomized and stratified by sleep problems to two arms: (Acupuncture Arm vs. Sham Acupuncture) with a goal of having 48 patients complete the study (we anticipate about 20% attrition rate). The study interventions will begin after patients completed their treatment. The placebo control for acupuncture will be a validated sham acupuncture control Assessments will be made with daily diaries and with weekly questionnaires. There are ten sessions each lasting approximately 20 minutes. All participants will have PSG data collected.
224213460|NCT01162018|OTHER|placebo|
223624221|NCT00002814|DRUG|topotecan hydrochloride|
223624222|NCT03585478|DRUG|Latiglutenase|Latiglutenase administered orally (daily)
223624223|NCT03585478|OTHER|Placebo|Placebo administered orally (daily)
223624224|NCT04364477|PROCEDURE|transversus abdominis plane (TAP) block|The transversus abdominis plane (TAP) block is a regional anesthesia technique described in recent years that provides analgesia for the anterior portion of the abdominal wall after abdominal surgery.
223624225|NCT03101280|DRUG|Atezolizumab|Atezolizumab 1200 mg (equivalent to an average body weight-based dose of 15 milligrams per kilogram \[mg/kg\]) will be administered by IV infusion once every 3 weeks, corresponding to a 21-day treatment cycle. Participants will receive atezolizumab starting on Cycle 1, Day 1. Participants deriving clinical benefit will be allowed to continue on study treatment until the absence of unacceptable toxicity or compelling evidence of disease progression.
223680526|NCT04781660|DEVICE|Implantable Alginate Hydrogel|"Implantable Alginate Hydrogel is a single use, multiple component device. It is expected to be used as a space-occupying material implanted into the myocardium to affect the shape of the left ventricle and reduce the clinical symptoms of patients with left ventricular ischemia and non-ischemic cardiomyopathy.~The hydrogel serves as an artificial myocardial filler to stop the continuous expansion of the ventricle and restore it to a more favorable shape and size. The expected clinical effect of the Implanted Alginate Hydrogel is to reduce the clinical symptoms of patients and improve the quality of life by improving the structure and function of the failing heart."
224213461|NCT00492466|DRUG|Interferon-beta-1a|dosage and frequency as per label
224213462|NCT00492466|DRUG|methylprednisolone|dosage and frequency as per Biogen Idec protocol
224213463|NCT00344526|DRUG|Melphalan|
224213464|NCT00344526|DRUG|Dexamethasone|
224213465|NCT00344526|PROCEDURE|Autologous stem cell transplantation|
224213466|NCT05584774|PROCEDURE|PELDAN|percutaneous endoscopic lumbar dissectomy and annuloplasty and nucleoplasty
224213467|NCT06362304|DIAGNOSTIC_TEST|99mTc-CNDG SPECT/CT|FDG-PET and 99mTc-CNDG will be performed within 2 weeks before surgery.
224213468|NCT02020655|OTHER|Shear- force model|Shear- force model
224213469|NCT01528046|DRUG|Vincristine|Vincristine (VCR) = 1.5 mg/m\^2/day (maximum dose 2 mg), days 1 and 8, administered as intravenous (IV) bolus over 1-5 minutes
224213470|NCT01528046|DRUG|Irinotecan|Irinotecan (IRN) = 50 mg/m\^2/day, days 1-5, IV over 60 minutes
224213471|NCT01528046|DRUG|Temozolomide|Temozolomide (TEM) = 50 mg/m\^2/day by mouth (PO) Days 1-5
224316525|NCT03149757|BEHAVIORAL|YouTHrive|"The YT website is a mobile-enhanced private social networking website. Participants on the site are anonymous and choose alternate usernames and personalized profile features for a new online identity within YT. The investigators designed YouTHrive to encourage social support, reduce isolation, improve HIV medication adherence, and promote general well being. The study involves rolling recruitment so that new members are continuously entering the intervention. Participants use YT for five months before graduating from the program. The core components of YT are: 1) peer-to-peer interaction in a shared feed; 2) daily monitoring of HIV medication adherence and real-time mood; 3) daily mixed-media content with strategies to improve medication adherence' and 4) goal setting and monitoring."
223624226|NCT03101280|DRUG|Rucaparib|The starting dosage level of rucaparib for Part 1 is 400 mg PO BID during a 21-day treatment cycle. During Part 1, the rucaparib doses were increased up to a maximum of 600 mg PO BID using a standard 3 + 3 dose escalation. RP2D was identified as 600 mg BID. During Part 2 of the study, rucaparib will be dosed at the RP2D determined in Part 1. Participants in Part 1 of the study will receive rucaparib starting on Cycle 1, Day 1. During Part 2, participants will receive rucaparib monotherapy during a 21-day run-in period. After completion of the rucaparib run-in period and the first on-treatment biopsy between Days 15 and 21 of the run-in period, participants will begin Cycle 1, Day 1 of the rucaparib. Participants deriving clinical benefit will be allowed to continue on study treatment until the absence of unacceptable toxicity or compelling evidence of disease progression.
223624227|NCT05329844|DRUG|Vildagliptin 50 MG|50 mg Vildagliptin as single-dose per study period
223624228|NCT00591006|DRUG|Phenytoin (brand name Dilantin)|Three days prior to imaging, participants will take two capsules containing phenytoin tablets (100 mg) by mouth at 0900 hours and 2100 hours (400 mg/day) for a total of three days with the last dose at 0900 hours on the day of the imaging (7 doses total).
223680527|NCT01701518|DRUG|Ozurdex|biodegradable 0.7mg dexamethasone implant
223680528|NCT06200025|OTHER|Cue-based speech therapy in virtual reality|Treatment applied with virtual reality headsets to provide 3d visual and auditory cues to individuals in a virtual environment. A treatment environment where the provision of cues can be controlled by the therapist, interacting with 3d clues and receiving feedback on the accuracy of the named objects.
223680529|NCT06200025|OTHER|Cue-based speech therapy|Treatment involving the assessment of language skills and the presentation of communication strategies to the individual, including the use of personalized phonological cues.
223762130|NCT06348719|OTHER|Collect of everyday help|Collect of everyday help at inclusion, Day 3,Day 7,Day14,Day 21 , day 42, Month 3, month 6
224213472|NCT01528046|DRUG|Metformin|Metformin (MET) = dose as per dose escalation, divided twice a day (BID), PO continuously for the 21 day cycle.
224213473|NCT06110221|OTHER|Periodontal clinical measurements, GCF and saliva sampling|"Clinical periodontal indices included probing depth (PD), clinical attachment loss (CAL), the dichotomous scoring of bleeding on probing (BOP +/-), gingival index (GI), and plaque index (PI). Clinical recordings were performed at six points (mesiobuccal, buccal, distobuccal, mesiopalatal, palatal, and distopalatal) of all teeth, except the 3rd molars.~GCF and saliva samples were obtained 1 day following the clinical measurements. Unstimulated whole saliva was collected from all participants. GCF was sampled with paper strips from two deepest pockets in periodontitis group; the most inflamed sites with clinical signs of redness or edema in gingivitis group; and the sites without visible inflammation in periodontally healthy group. GCF and saliva samples were stored at -80 °C until further analysis."
224213474|NCT03797222|DIETARY_SUPPLEMENT|Vitamin E|Subjects will take an oral Vitamin E (alpha-tocopherol) supplement once daily with a fat-containing meal for 2 weeks. The dose will be based on subject age (150 IU if 1-3 years old, 300 IU if 4-8 years old, 450 IU if 9-17 years old, 600 IU if \>17 years old). Formulations include 50 IU/mL liquid and 200 IU capsules. The liquid formulation will be used for subjects who will receive \<600 IU daily, or for any subjects who prefer liquid medication to capsules.
224213475|NCT05448768|DEVICE|TBS for Amyloid-positive MCI|The investigators will perform standard intermittent TBS (iTBS) parameters to left DLPFC of every patient in the study. The frequency parameters of TBS are 3-pulse 50-Hz bursts, every 200 ms at 5 Hz, and the intensity is 90% of active motor threshold. A single session of iTBS contains 2 s of TBS repeated every 10 s for 20 times. In this study, The investigators will give two sessions of iTBS separated by 15 min.
224213476|NCT05448768|DEVICE|TBS for Amyloid-negative MCI|The investigators will perform standard intermittent TBS (iTBS) parameters to left DLPFC of every patient in the study. The frequency parameters of TBS are 3-pulse 50-Hz bursts, every 200 ms at 5 Hz, and the intensity is 90% of active motor threshold. A single session of iTBS contains 2 s of TBS repeated every 10 s for 20 times. In this study, The investigators will give two sessions of iTBS separated by 15 min.
224213477|NCT05590325|DRUG|Dolutegravir|"Single dose of the DTG-DT in two sequential cohorts and multiple-doses of the DTG-DT or DTG-ODF in a two cohorts.~Qualitative Acceptability will be collected from mothers and health workers in structured discussion guides."
224213478|NCT01548183|BEHAVIORAL|Lifestyle counseling|Weekly SMS assessments of risky sexual encounters with feedback
224213479|NCT06324214|DIETARY_SUPPLEMENT|Urolithin A (Mitopure)|Compound belonging to the 'urolithin' class. First discovered over 40 years ago as a gut-derived metabolite in rats and subsequently in humans. A food and dietary ingredient, and more specifically, a post-biotic compound. Derived from ellagitannins, which are present in foods such as pomegranate, berries, and walnuts. An 'inducer' of mitophagy.
223624229|NCT00591006|DRUG|Hydrocortisone|Beginning two days prior to the imaging (the day after initiating the phenytoin or placebo), participants will begin taking 4 tablets containing hydrocortisone (20 mg) or placebo also at 0900 hours and 2100 hours (160 mg/day) with the last dose at 0900 hours on the day of the imaging (5 doses total). The doses were selected to achieve a low therapeutic blood level of phenytoin and stress level of cortisol. Newcomer et al. (1999) used this dose of hydrocortisone in healthy controls. The imaging will be performed at approximately 1300 hours.
223624230|NCT00591006|DRUG|Placebo|Participants take two capsules of placebo 100 mg at 0900 hours and 2100 hours for a total of 3 days with the last dose at 0900 hours on the day of imaging (7 doses total). Beginning two days prior to the imaging (the day after initiating placebo), participants will being taking 4 tablets containing placebo (20 mg) also at 0900 hours and 2100 hours with the last dose at 0900 hours on the day of the imaging (5 doses total).
223624231|NCT01204099|DRUG|Docetaxel|
223762131|NCT06348719|OTHER|Collection of the business resumption date|Collection of the business resumption date at Day 3,Day 7,Day14,Day 21 , day 42, Month 3, month 6
223762132|NCT06348719|OTHER|SF36 questionnaire|SF36 questionnaire at inclusion, Day 3,Day 7,Day14,Day 21 , day 42, month 6
223624232|NCT01204099|DRUG|PX-866|
223624233|NCT04368026|OTHER|No intervention (survey study for medical doctors).|No intervention
223624234|NCT00054392|DRUG|carboplatin|
223624235|NCT00054392|DRUG|gemcitabine hydrochloride|
223624236|NCT00054392|DRUG|paclitaxel|
223624237|NCT04207034|PROCEDURE|flap surgery with diode laser|"Patient will be asked to rinse with 0.2% chlorhexidine mouthwash. Following the administration of local anaesthesia 2% lignocaine hydrochloride ( with 1: 80,000 epinephrine) , Laser application will be carried out , with the help of 810 nm (A.R.C LASER FoxTM) diode laser with a flexible optic tip of 300µm . The sulci will be lased with a repeated beam ( 0.2 sec on 0.3 sec off) at an output power of 1.0 W.~Intracrevicular incision will be placed with the help of 15c Bard Parker surgical blade , full thickness mucoperiosteal flap will be elevated .~Debridement of granulation tissue will be done and flap will be suture back in position using 3-0 black breaded silk suture, the site will be covered with non eugenol periodontal dressing for protection.~Postoperative instructions will be given to the patient. 2 ml blood will be collected at baseline(sample 1) , at 5 minutes (sample 2) and within 20-30 minutes (sample 3) of starting the procedure."
223624238|NCT04207034|PROCEDURE|flap surgery|"Patient will be asked to rinse with 0.2% chlorhexidine mouthwash. Following the administration of local anaesthesia 2% lignocaine hydrochloride ( with 1:80,000 epinephrine) ,intracrevicular incision will be placed with the help of 15c Bard Parker surgical blade , full thickness mucoperiosteal flap will be elevated .~Debridement of granulation tissue will be done and flap will be suture back in position using 3-0 black breaded silk suture, the site will be covered with non eugenol periodontal dressing for protection.~Postoperative instructions will be given to the patient. 2 ml blood will be collected at baseline(sample 1) , at 5 minutes (sample 2) and within 20-30 minutes (sample 3) of starting the procedure"
223624239|NCT03576508|DRUG|CNTX-4975-05|1 mg (2mL) IA injection
223624240|NCT03576508|DRUG|Qutenza|8% topical patch
223624241|NCT03576508|DRUG|Lidocaine (without epinephrine)|15 mL IA injection of 2% lidocaine (without epinephrine)
223624242|NCT05213832|DRUG|Isoflurane Inhal Soln|Administration of isofluorane in patients with severe SAH
223762133|NCT06348719|OTHER|Questionnaire EQ5D-5L|Questionnaire EQ5D-5L at day 1, Day 3,Day 7,Day14,Day 21 , day 42, month 3, month 6
223762134|NCT06348719|OTHER|FIGO Stadium|FIGO Stadium at inclusion and Day 42
223762135|NCT06348719|OTHER|Collection of treatments (analgesics and anticoagulants up to J42, complication-related treatments, etc.)|Collection of treatments (analgesics and anticoagulants up to J42, complication-related treatments, etc.) at day 1, Day 3,Day 7,Day14,Day 21 , day 42, month 3, month 6
224213480|NCT06324214|OTHER|Placebo|Placebo.
224213481|NCT04287452|OTHER|Control|Control
224213482|NCT04287452|OTHER|Dog Therapy|Exposure to certified therapy dogs and their handler.
224213483|NCT02889536|OTHER|Focus group interviews|Focus group interviews. Two groups with patients referred to repair of parastomal bulging and three groups with patients attending the outpatient stoma clinics
223624243|NCT01064063|DEVICE|Vanguard CR|The Vanguard CR is a metal and polyethylene total condylar knee system. The system contains three primary components: femoral, tibial, and bearing components, and a peripheral component: the patella button.
223624244|NCT01064063|DEVICE|AGC knee|The AGC knee is a metal and polyethylene total condylar knee system offering complete component interchangeability.
223624245|NCT01334060|BIOLOGICAL|p.DOM-WT1-37 DNA Vaccine and p.DOM-WT1-126 DNA Vaccine|p.DOM-WT1-37: 1mg/dose/vaccine p.DOM-WT1-126: 1mg/dose/vaccine The DNA vaccine will be administered 6 times at 4 weekly intervals. Responders (Immunological but without molecular progression) may continue vaccination 3 monthly to maximum of 24 months. The vaccines will be injected intramuscularly (im) followed by electroporation (EP) into separate locations.
223624246|NCT06091696|OTHER|inspiratory muscle training|inspiratory muscle training will be done by using a pressure threshold loading device (Threshold Inspiratory Muscle Training, Respironics, Pittsburg, PA, USA). By using a spring-loaded one-way valve, this device provides air flow-independent resistance to inspiration at a detectable intensity.
223624247|NCT06091696|OTHER|Aerobic exercises|Exercise training sessions under the supervision of an experienced physiotherapist were conducted for 30 minutes, 3 times per week, with intensity ranging between 13 and 15 on the rated perceived exertion scale (RPE).
223624248|NCT03009786|OTHER|Measurement of salivary flow|A compress of about 0.95 g which is weighed and then placed under the tongue of the subject for 5 minutes. Once the time has elapsed, the compress is weighed, a simple subtraction determines the weight of saliva produced in 5 minutes
223624249|NCT03400618|OTHER|Moderate carbohydrate diet|30 E % carbohydrates included in the diet
223624250|NCT03400618|OTHER|Higher carbohydrate diet|50 E % carbohydrates included in the diet
223624251|NCT05594459|PROCEDURE|Mini invasive analgesic technique|patients will be treated with early interventional neuromodulatory techniques, before high opioids dosages.
223624252|NCT05594459|DRUG|high opioids dosages|patients will be treated with high opioids dosages
224213484|NCT04354402|OTHER|No intervention|No intervention
224213485|NCT00261937|DRUG|Inhaled Furosemide vs Placebo (Normal Saline)|
224213486|NCT00712491|DRUG|Sirolimus|Three subconjunctival injections of 1320 micrograms sirolimus each.
224213487|NCT00712491|DRUG|Sirolimus|Three intravitreal injections of 352 micrograms sirolimus each.
224213488|NCT04084912|DRUG|Dexamethasone Sodium Phosphate|intravenous injection of one ampoule dexamethasone Sodium phosphate 2 ml 8 mg
223624253|NCT00689390|BIOLOGICAL|Boceprevir|In previous treatment studies, boceprevir was administered as specified by the protocol. No treatment was administered on the current follow-up study (P05063, NCT00689390).
223624254|NCT00689390|BIOLOGICAL|Narlaprevir|In previous treatment studies, narlaprevir was administered as specified by the protocol. No treatment was administered on the current follow-up study (P05063, NCT00689390).
223762136|NCT06348719|OTHER|Collection of adjuvant treatments|Collection of adjuvant treatments at month 6
223624255|NCT00689390|BIOLOGICAL|Peginterferon alfa-2b|In previous treatment studies, peginterferon alfa-2b was administered as specified by the protocol. No treatment was administered on the current follow-up study (P05063, NCT00689390).
223762137|NCT06348719|OTHER|Recording of any complications, emergency room visits/unscheduled consultations, additional work stoppages to the initial one|Recording of any complications, emergency room visits/unscheduled consultations, additional work stoppages to the initial one at Day 3,Day 7,Day14,Day 21 , day 42, month 3, month 6
223624256|NCT00689390|DRUG|Ribavirin|In previous treatment studies, ribavirin was administered as specified by the protocol. No treatment was administered on the current follow-up study (P05063, NCT00689390).
223624257|NCT00689390|OTHER|Blood/Plasma Collection|Blood samples were collected at all visits during the LTFU for blood chemistry and hematology. Plasma samples were collected at all visits as appropriate from participants who were sustained responders at the end of FU in the previous treatment protocol for HCV-RNA PCR and HCV sequence analysis.
223624258|NCT01434277|OTHER|Eye Drops with Experimental Preservative|Glycerin, Hypromellose, Polyethylene glycol 400 with experimental preservative PQ-42
223762138|NCT06348719|OTHER|Collection of data|Collection of data on age, baseline, BMI, histological type of cancer and surgical approach used
224213489|NCT04084912|DRUG|Saline Solution|intravenous injection of one ampoule saline
224213490|NCT03567239|DEVICE|Using adaptive device.|Participant uses the specially designed device for a specified length of time (no less than two days) and feedback is then gathered from the participant through questionnaires. These questionnaires include NASA-TLX, PIADS, QUEST, and a single question asking if the device improved their ability to address their specific need.
223624259|NCT02343263|DRUG|Bupivacaine|1 milliliter (mL) of 0.75% Bupivacaine Hydrochloride will be infused into 4mL of fibrin sealant (diluting the Bupivacaine HCl to 0.15%). The bupivacaine-infused fibrin sealant will then be applied to the tonsillectomy (or adenotonsillectomy) wound bed.
223624260|NCT02343263|BIOLOGICAL|Fibrin Sealant|Fibrin sealant will be applied to the wound bed topically as per product instructions.
223624261|NCT04068402|DEVICE|Vivio System|The Vivio System is an electronic auscultatory device and optical sensor, plus software application intended to provide support to the physician in the evaluation of heart sounds in patients. The product will analyze the acoustic signals of the heart and signals from a captured arterial (carotid) waveform. The analysis procedure will identify and analyze specific heart sounds and arterial waveform features captured by the Vivio device, to devise a scoring system for severe aortic stenosis.
223624262|NCT00701285|DRUG|pitavastatin|pitavastatin 4mg once daily
223624263|NCT00701285|DRUG|pravastatin|pravastatin 10mg once daily
224213491|NCT06009432|OTHER|Rehabilitation|The control group will receive the usual post-operative care of stretching, lower extremity strengthening, balance exercises, activities of daily living recommendations. The study group will be given proprioceptive neuromuscular facilitation exercise in addition to the program given to the control group.
224213492|NCT06129487|BEHAVIORAL|Narrative pictorial warning labels for alcoholic beverages|Pictorial warning labels consisting of text and narrative imagery (e.g., photos of cancer patients) conveying the risk of alcohol for oral cancer, esophageal cancer, and larynx cancer.
223624264|NCT03174184|DRUG|Rifampin|Oral administration of rifampin at a dosage of 20 mg/kg daily
223624265|NCT03174184|DRUG|MEROPENEM 2 grams TID|Intravenous administration at a dosage of 2 grams thrice daily
223624266|NCT03174184|DRUG|MEROPENEM 1 gram TID|Intravenous administration at a dosage of 1 gram thrice daily
224213493|NCT06129487|BEHAVIORAL|Non-narrative pictorial warning labels for alcoholic beverages|Pictorial warning labels consisting of text and non-narrative imagery (e.g., images of diseased organs) conveying the risk of alcohol for oral cancer, esophageal cancer, and larynx cancer.
224213494|NCT02512991|OTHER|Helicopter Emergency Medical Service|May 1st 2010, the first Danish Helicopter Emergency Medical System (HEMS) was implemented in Region Zealand and the Capital Region of Denmark.
224213495|NCT00659581|DRUG|Telmisartan|Oral administration
224213496|NCT03223285|BEHAVIORAL|Real Treatment Group|"Real Diaphragm manoeuvres The experimental manoeuvres include the Doming The Diaphragm Technique as described by Digiovanna (2004), Chila (2011) and Yao (2014) and the Manual Diaphragm Release Technique as described by Ricard (2009), De Coster (2005) and Roha (2015). Both manoeuvres are performed in two sets of 10 repetitions, within a 1-minute interval.~Multifaced physiotherapy/osteopathic treatment includes: vertebral mobilisations (C0-D1), high-velocity low-amplitude (HVLA) thrusts of the cervical spine, soft tissue techniques"
223624267|NCT03174184|DRUG|MEROPENEM 3 grams QD|Intravenous administration at a dosage of 3 grams once daily
223624268|NCT03174184|DRUG|Amoxicillin/Clavulanate Potassium 500 MG-125 MG Oral Tablet|Amx/Clv will be administered orally at a dose of 500 mg/125 mg thrice daily
223624269|NCT03174184|DRUG|Amoxicillin/Clavulanate Potassium 875 MG-125 MG Oral Tablet|Amx/Clv will be administered orally at a dose of 875 mg/125 mg once daily
223624270|NCT00973752|DRUG|Prednisone|Orally during Induction, Consolidation 1, CNS, Consolidation 2, and Continuation therapy.
223762139|NCT06105528|DRUG|PMN310|60-minute intravenous infusion
223762140|NCT06105528|DRUG|Placebo|60-minute intravenous infusion
223762141|NCT04114435|OTHER|Echocardiography|Diagnostic test which uses ultrasound waves to make images of the heart chambers, valves and surrounding structures
223762142|NCT02043015|BEHAVIORAL|Condom choices|Men will receive the condom package that includes an assortment of styles, sizes, features and colors at their baseline visit, and will be able to get more condoms for free at any time after that visit by coming to a study clinic during clinic hours, or during a scheduled study visit.
223624271|NCT00973752|DRUG|Vincristine|Intravenously during Induction, CNS, Consolidation 2 and Continuation Therapy
223624272|NCT00973752|DRUG|Doxorubicin|Intravenously during Induction, CNS, and Consolidation 2 therapy
223624273|NCT00973752|DRUG|PEG-asparaginase|Intravenously during Induction, Consolidation 1, CNS, and Consolidation 2 therapy
223624274|NCT00973752|DRUG|Cytarabine|Intrathecally during Induction and CNS therapy
223762143|NCT02043015|BEHAVIORAL|Condom-compatible lubricant choices|Men will receive condom-compatible lubricant that will include different types of lubricant (e.g., silicone-based) and different packaging (individual sachets or flat, discreet packages) at their baseline study visit, and participants will be able to access enhanced condom-compatible lubricant at any time after that visit by coming to a study clinic during clinic hours, or during a scheduled study visit.
223762144|NCT02043015|BEHAVIORAL|Couples HIV counseling and testing (CVCT)|Participants will be invited to schedule couples voluntary HIV counseling and testing (CVCT) appointments with a clinic counselor at any point after they complete their baseline study visit.
224213497|NCT03223285|BEHAVIORAL|Sham Treatment Group|"Sham Diaphragm manoeuvre: the physiotherapist will simply lie hands on the rib cage, and rest along the anterolateral costal margin below rib 7, during normal breathing of the patient for 40 breathes.~Multifaced physiotherapy/osteopathic treatment includes: vertebral mobilisations (C0-D1), high-velocity low-amplitude (HVLA) thrusts of the cervical spine, soft tissue techniques"
224213498|NCT01649245|DRUG|Reiferon retard|Eligible subjects will be treated with Reiferon Retard® 160 µg weekly by subcutaneous injection for 48 weeks, together with weight-based oral ribavirin (1200 mg/day if body weight is \>75 kg and 1000 mg/day if body weight is ≤ 75 kg) in divided doses.
224213499|NCT01337609|DRUG|Ganeden BC30|2 billion CFU per capsule; One pill daily for 60 days
224213500|NCT01337609|OTHER|Placebo (sugar pill)|1 pill daily for 60 days
224316526|NCT03149757|BEHAVIORAL|Information-only Control|Participants will receive 21 emails, once per week, for five months. The emails will include static informational content relatable to YLWH, but informational content will not be focused on ART medication adherence.
224316527|NCT00769938|DEVICE|PCI (percutaneous coronary intervention)|only patients scheduled for PCI can be included tough this intervention would also take place without this study. What we want to study is the difference in outcome after a little change in the antithrombotic treatment
224316528|NCT00908310|DRUG|Omniscan|OMNISCAN will be administered intravenously at the medical discretion of the prescribing physician.
224316529|NCT02607267|OTHER|LSG and LRYGB|The role of the Edmonton Obesity Staging System in predicting post-operative outcome and 30-day mortality after metabolic surgery (LSG and LRYGB)
224316530|NCT04854889|DRUG|Decitabine|Demethylating agents
223513536|NCT06570590|PROCEDURE|Minimally invasive lapidus procedure with arthroscopy|After removal of the cartilage with the cartilage burr, a 3.0 arthroscope will be inserted to inspect the joint for all cartilage removal. Any residual cartilage pieces will be removed to ensure complete cartilage debridement from the subchondral bone and fragments removed from the joint.
223513537|NCT03408808|PROCEDURE|Platelet rich plasma|Aspiration of ganglion and injection with platelet rich plasma.
223513538|NCT03408808|PROCEDURE|Aspiration alone|Aspiration of the ganglion
223513539|NCT00237627|DRUG|PS-341|PS-341 will be administered as an intravenous push into a side arm of either a peripheral or central intravenous line infusing normal saline at 100 ml/hr. Patients will be treated twice weekly for two weeks, followed by a one week rest period, such that the typical days of treatment will be days 1, 4, 8, 11 of each three-week cycle. The initial dose level for PS-341 will be 0.9 mg/m2/dose intravenously, while subsequent dose levels will be determined according to a modified Fibonacci schema
223513540|NCT00237627|DRUG|Doxil|Doxil will be administered at a dose of 30 mg/m2 as a 1 hour infusion through either a peripheral or central intravenous line every 3 weeks (on day 4 of each 21 day cycle)
223513541|NCT00237627|DRUG|Velcade|Velcade will be adminstered intravenously at 1.3 mg/m2 days 1, 4, 8, 11 every 3 weeks
223513542|NCT02543385|DRUG|S Ketamine|S+ketamine will be given in group I only in the doses of 0.25mg/kg (iv bolus) before induction along with midazolam and 0. 25 mg/kg (iv bolus) 20 minutes prior to extubation
223513543|NCT01019174|DRUG|Cyclophosphamide|comparison of lenalidomide/low-dose dexamethasone in combination with continuous oral cyclophosphamide to lenalidomide/low-dose dexamethasone combined with single cyclophosphamide doses intravenous
223513544|NCT01019174|DRUG|Cyclophosphamide|comparison of lenalidomide/low-dose dexamethasone in combination with continuous oral cyclophosphamide to lenalidomide/low-dose dexamethasone combined with single cyclophosphamide doses intravenous
223513545|NCT02040012|DRUG|AZP-531|
223513546|NCT02040012|DRUG|Placebo|
223513547|NCT00130390|DRUG|Nitazoxanide|One nitazoxanide 500 mg tablet twice daily for 28 days
223513548|NCT00130390|OTHER|Placebo|One placebo tablet twice daily for 28 days
223513549|NCT00658073|PROCEDURE|Kidney transplantation with MSCs infusion|Patients in Group A will receive the first MSCs infusion intravenously within 24 hours after kidney transplant operation , and the second infusion of MSCs will be performed two weeks later.
223513550|NCT00658073|PROCEDURE|kidney transplantation without MSC infusion|kidney transplantation with standard immunosuppressive treatment regime
223513551|NCT02180672|DRUG|Nasal Fluticasone|One spray per nostril, per day.
223513552|NCT02180672|DRUG|Placebo|One spray per nostril, per day.
223513553|NCT06192797|PROCEDURE|HAIC|administration of gemcitabine and oxaliplatin via the tumor feeding arteries every 3 weeks.
223513554|NCT06192797|DRUG|Lenvatinib plus pucotenlimab|lenvatinib (8mg, qd) plus pucotenlimab (200mg, q3w)
223513555|NCT01963832|DRUG|Fluoxetine|
223513556|NCT01963832|DRUG|Placebo|
223624275|NCT00973752|DRUG|Methotrexate|Intrathecally during Induction, CNS, and Continuation Therapy
223624276|NCT00973752|DRUG|Imatinib|Orally during Induction, Consolidation 1, CNS, Consolidation 2 and Continuation Therapy
223624277|NCT00973752|DRUG|Clofarabine|Intravenously during Consolidation 1 Therapy
223624278|NCT00973752|DRUG|6 Mercaptopurine|Orally during CNS, Consolidation 2 and Continuation Therapy
223624279|NCT02023424|DRUG|Glatiramer Acetate (Copaxone®)|GA is a potent inducer of Th2-cells and modulates these immune cells to secrete high levels of neurotrophic factors, particularly BDNF. The induced cells cross the blood brain barrier (BBB), accumulate in the CNS and express BDNF and other regulatory substances in situ.
224213501|NCT01337609|OTHER|Ganeden BC30, Placebo (sugar pill)|Ganeden BC30 (2 billion CFU per capsule), One capsule daily for 30 days Sugar Pill (placebo), One capsule daily for 30 days
224213502|NCT00725725|BEHAVIORAL|Cognitive-behavioral therapy|Participants underwent 5 weekly CBT session (sessions were 60-90 minutes in duration).
224213503|NCT00725725|DRUG|Org 25935|4 mg Org 25935 is given in tablet form, a single dose 2 hours prior to 3 CBT sessions. A total of 3 doses of trial medication is given over a 2-week period.
224213504|NCT00725725|DRUG|Org 25935|12 mg Org 25935 is given in tablet form, a single dose two hours prior to 3 CBT sessions. A total of 3 doses of trial medication is given over a two-week period.
224213505|NCT00725725|DRUG|Placebo|Placebo is given in tablet form, a single dose 2 hours prior to 3 CBT sessions. A total of 3 doses of trial medication is given over a 2-week period.
224213506|NCT01010321|DEVICE|confocal microscopy|non-invasive imaging
224213507|NCT02614885|DEVICE|RFA|Radiofrequency ablation of the cavity walls of a simulated lumpectomy in the excised prophylactic mastectomy tissue.
224213508|NCT01824108|PROCEDURE|Lumbar discectomy|All the patients were in prone positions on the operation table and received general anesthesia. A midline incision was made and paravertebral muscles were dissected unilaterally. Disc excision and nerve root decompression were initially accomplished through a unilateral transflaval approach. Then the wound was closed with a suction drain.
223513557|NCT01963832|PROCEDURE|eCMIT|
223513558|NCT01963832|PROCEDURE|Usual Care|
224213509|NCT01824108|PROCEDURE|Lumbar discectomy combined with Wallis interspinous dynamic stability system|The Wallis interspinous implant is placed after a lumbar discectomy. Interspinal ligaments of operated segment were removed and supraspinal ligament were retained. And then the proper size of Wallis implant was mounted underneath the supraspinous ligament and secured to the spine with the attached Dacron bands,above and below the corresponding spinous processes.
224213510|NCT01619085|DRUG|Nintedanib|Nintedanib twice a day
223513559|NCT05653011|OTHER|Endoscopic biopsy|"When patients have colonoscopy or sigmoidoscopy for evaluation of their disease course, biopsied samples are collected.~In the IBD group, samples are obtained at endoscopically active and/or inactive lesions. In the control group, samples are obtained at endoscopically normal lesions."
223513560|NCT02837952|DRUG|FDC IBU/APAP 250 mg/500 mg|FDC IBU/APAP 250 mg/500 mg
223513561|NCT02837952|DRUG|Placebo|Placebo
224213511|NCT01672307|DRUG|Minoxidil lotion 2%|Minoxidil lotion 2% is applied twice daily to one eyebrow.
223513562|NCT01362530|DRUG|Aprepitant 125 mg|On the morning of Day 1: one 125 mg capsule PO 60 minutes prior to chemotherapy for participants 12 to 17 years of age
223513563|NCT01362530|DRUG|Aprepitant 80 mg|On the morning of Days 2 and 3: one 80 mg capsule PO for participants 12 to 17 years of age
223513564|NCT01362530|DRUG|Aprepitant powder for suspension (PFS)|On the morning of Day 1: 3.0 mg/kg (up to 125 mg) PO 60 minutes prior to chemotherapy for participants 6 months to \<12 years of age. On the morning of Days 2 and 3: 2.0 mg/kg (up to 80 mg) PO 60 minutes prior to chemotherapy (if applicable) for participants 6 months to \<12 years of age
223513565|NCT01362530|DRUG|Ondansetron|Day 1: Administered according to product label for pediatric usage or local standard of care
223513566|NCT01362530|DRUG|Placebo for Aprepitant 125 mg|On the morning of Day 1: one 125 mg capsule PO 60 minutes prior to chemotherapy for participants 12 to 17 years of age
223513567|NCT01362530|DRUG|Placebo for Aprepitant 80 mg|On the morning of Days 2 and 3: one 80 mg capsule PO for participants 12 to 17 years of age
224213512|NCT01672307|DRUG|Placebo|Placebo is applied twice daily to the other eyebrow.
224213513|NCT06159686|DRUG|Hemp|The application of the hemp-containing cream occurred in the morning and evening on the itching areas, excluding the face for 4 weeks.
224213514|NCT06159686|DRUG|Placebo|The application of the placebo cream occurred in the morning and evening on the itching areas, excluding the face for 4 weeks.
224213515|NCT01887860|OTHER|Cetaphil Daily Facial Moisturizer SPF 50|Other: Cetaphil Daily Advance Ultra Hydrating Lotion 0.2ml or 0.2g of Cetaphil on occlusive, hypoallergenic patch applied to skin for 24 hrs 9 times on Monday, Wednesday, and Friday for 3 weeks
224213516|NCT05100394|RADIATION|Laser Therapy|Therapeutic laser therapy was applied.
224213517|NCT05100394|OTHER|Ultrasound + Moist Heat pack + Exercises|Ultrasound therapy, a moist heat pack, and a home exercise program were given.
224213518|NCT03233373|DEVICE|Seek CompactPro thermal imager|A device with image/video recording capability, it is non-invasive and only relies on infrared emissions from heat sources (the patient).
224213519|NCT03994419|PROCEDURE|Anaesthesia for surgery|Observational study observing proportion of obese and overweight children attending for surgery. Observing adverse events following general anaesthesia for surgery in obese versus healthy weight children.
224213520|NCT01963221|RADIATION|fludeoxyglucose(18f)|
224213521|NCT01963221|OTHER|blood sample|
223624280|NCT01723735|DRUG|Alirocumab|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
223624281|NCT01723735|DRUG|Ezetimibe|"Pharmaceutical form: overencapsulated tablet~Route of administration: oral"
223624282|NCT01723735|DRUG|Ezetimibe Placebo|"Pharmaceutical form: capsule~Route of administration: oral"
223624283|NCT01723735|DRUG|Fenofibrate|"Pharmaceutical form: tablet~Route of administration: oral"
223624284|NCT04872361|PROCEDURE|Low PEEP|Patients will be ventilated with a PEEP of 4 cm H2O and no RMs throughout the study
223624285|NCT04872361|PROCEDURE|High PEEP|PEEP of 10 cm H2O will be applied
223624286|NCT04872361|PROCEDURE|High PEEP/RM|PEEP of 10 cm H2O and RM (30 cm H2O for 30 s) immediately after the second lung ultrasonographic examination and repeated every 30 minutes till emergence
223624287|NCT04872361|DEVICE|Lung ultrasonogrphy assessment|"The thorax will divided into 12 quadrants, each of them will be assigned a score of 0-3 as 0, normal lung sliding with fewer than three single B lines~1. three or more B lines~2. coalescent B lines~3. consolidated lung. The LUS (0-36) will be calculated with higher scores indicating more aeration loss"
223624288|NCT00392392|DRUG|nab-paclitaxel|ABI-007
223624289|NCT00392392|DRUG|Bevacizumab|Bevacizumab
223624290|NCT00392392|DRUG|Trastuzumab|Trastuzumab
223624291|NCT05334368|DRUG|Depemokimab|Depemokimab will be administered.
223624292|NCT05334368|OTHER|Placebo|Matching placebo will be administered.
223624293|NCT00490464|DRUG|Nicardipine and Nipride|
224213522|NCT01963221|OTHER|cardiac and aortic magnetic resonance imaging|
224213523|NCT01963221|OTHER|carotid femoral pulse wave velocity|
224213524|NCT01963221|RADIATION|positron emission tomography|
224213525|NCT01963221|RADIATION|computed tomography|
224213526|NCT02009111|BEHAVIORAL|Couple CARE for Parents|Couple CARE for Parents is a skill-based relationship enhancement program based on a self-regulatory model. It consists of seven sessions and two follow-up booster sessions that occur over the baby's first eight months of life. The first home visit is scheduled 7 - 14 days following recruitment. The next two sessions are scheduled in two week intervals. Sessions 4 through 7 are scheduled in three week intervals. Home visits are expected to last 1.5 to 2 hrs. Out-of-session viewing of the video and completing the exercises typically requires 45 min to 1 hr. The typical phone consultation lasts 15- to 30- min per person. Thus, the program lasts a minimum of 8 to 12 hours. The program will also include two booster sessions (beyond the 8 - 12 hrs).
224213527|NCT03125629|DRUG|F-18 FDG|Radiolabel for positron emission tomography / computed tomography (PET/CT) and computed tomography (PET/CT) imaging
224213528|NCT03125629|DRUG|Ga-68-DOTA-TATE|Radiolabel for positron emission tomography / computed tomography (PET/CT) and computed tomography (PET/CT) imaging
224213529|NCT03125629|DEVICE|Positron Emission Tomography / Computed Tomography (PET/CT) Scan|Scan using a regular medical care (IDE-exempt) Discovery 600 / 690 PET/CT scanner.
224213530|NCT03125629|DEVICE|Positron Emission Tomography / Magnetic Resonance Imaging (PET/MRI) Scan|Scan using a NOVEL GE PET/MRI scanner.
224213531|NCT03909971|DRUG|Lorlatinib|ALK inhibitor-treated ALK-positive NSCL treatment
224213532|NCT00241319|DRUG|R89674 (generic name not yet established)|
224213533|NCT03339531|RADIATION|2D radiotherapy|
224213534|NCT02322242|DRUG|Systemic Dexamethasone|Intravenous infusion of dexamethasone (4mg)
224213535|NCT02322242|DRUG|Perineural dexamethasone|Perinerual administration of dexamethasone (4mg)
224213536|NCT06696170|DEVICE|CellFX nano-pFA 360 Endocardial Ablation Catheter System|The CellFX nano-PFA 360 Endocardial Ablation Catheter System includes the nano-pFA 360 Endocardial Ablation Catheter, CellFX Console, switcher box/adapter, and sensing cable. The System is a proprietary endocardial catheter system designed for use in cardiac electrophysiology procedures for the treatment of arrhythmias, including atrial fibrillation. The nano-PFA 360 Catheter ablates cardiac tissue using nonthermal nano-second pulses of electrical energy. Nanosecond Pulsed Field Ablation (nsPFA or nano-PFA) is a cell-specific, nonthermal ablation technology that delivers nanosecond-duration pulses of high-amplitude electrical energy to tissue via bipolar electrodes. The pulses disrupt the ability of the cell and internal organelles to maintain cellular homeostasis by creating nanopores in lipid membranes, ultimately leading to regulated cell death (RCD).
224213537|NCT01909752|DRUG|Cyclophosphamide|Cyclophosphamide (300 mg/m2) will be administered as a single dose three days prior to beginning vaccine therapy.
224213538|NCT01909752|BIOLOGICAL|DRibble vaccine|DRibble vaccine will be administered at Weeks 1, 4, 7, 10, 13, 16, 19, 25, 31, 37, and 43.
224213539|NCT01909752|DRUG|Imiquimod|Imiquimod cream (5%, 250 mg containing 12.5 mg imiquimod - one packet/day) will be self applied once per day starting with the second vaccine (week 4). Immediately following vaccination and for four days following each vaccine cycle (total 5 days) imiquimod will be applied to a 4 x 5-cm outlined area of healthy extremity skin that includes the vaccine site.
224213540|NCT01909752|DRUG|GM-CSF|GM-CSF will be administered at 50 mcg/day starting with the second vaccine (week 4) and continuing with each subsequent vaccine. A volume of 0.2 cc will be delivered by the CADD-MSTM 3 Ambulatory infusion pump at a rate of 0.008 cc/hr. The pump will be refilled after three days for a total of six days of infusion.
223513568|NCT01362530|DRUG|Placebo for Aprepitant PFS|On the morning of Day 1: 3.0 mg/kg (up to 125 mg) PO 60 minutes prior to chemotherapy for participants 6 months to \<12 years of age. On the morning of Days 2 and 3: 2.0 mg/kg (up to 80 mg) PO 60 minutes prior to chemotherapy (if applicable) for participants 6 months to \<12 years of age
223513569|NCT01362530|DRUG|Emetogenic chemotherapy|"Any moderately or highly emetic chemotherapeutic agent such as cyclophosphamide, doxorubicin, methotrexate, carboplatin, cisplatin, irinotecan, carmustine, ifosfamide, and streptozocin, or chemotherapeutics of a lower emetogenicity that were not previously tolerated. No chemotherapeutic agents were specified by the protocol, and many could potentially have been used."
223513570|NCT06427642|BIOLOGICAL|Mononuclear cells|UCB-MNCs are obtained from umbilical cord blood by density gradient centrifugation
223513571|NCT06427642|DEVICE|Mild hypothermia therapy|Mild hypothermia therapy via hypothermia therapy apparatus
223513572|NCT06427642|DEVICE|Breathing support technique|Breathing support via ventilator
223513573|NCT06427642|PROCEDURE|Total parenteral nutrition|Liquid nutrition injected directly into the bloodstream
223513574|NCT03471286|DRUG|Epacadostat|Drug is taken orally two times per day for 14 days, prior to surgical resection of tumor.
223513575|NCT02674256|DRUG|CRH|100µg CRH powder for injection (CRH ferring®, Ferring, Aalst, Belgium) and 1 mL of NaCl 0.9% will be put together, then the solution will be injected intravenously over the course of 1 minute
223513576|NCT02674256|OTHER|Placebo|1 mL of NaCl 0.9% will be injected intravenously over the course of one minute
223513577|NCT06014723|PROCEDURE|Submaximal balloon angioplasty|The goal of submaximal balloon angioplasty is to use the balloon to improve the stenosis of the criminal artery by more than 20%.
223513578|NCT03291236|OTHER|Follow-up for death and recurrence of patients|All patients are follow-up to determine specific date of diagnosis, recurrence and death.
223513579|NCT04315961|DRUG|Blinded drug dose conditions|Capsules will contain commonly prescribed or over-the-counter drugs or placebo. Capsules in this study may contain sedatives, muscle relaxants, or anti-anxiety medications, stimulant drugs/weight loss medications, or antihistamines which must remain blinded for the purposes of this study.
223513580|NCT01485198|PROCEDURE|Bone Marrow Autologous Stem Cells Infusion|Extraction and knee infusion of Bone Marrow Autologous Stem Cells
223513581|NCT01485198|DRUG|Acetaminophen|Acetaminophen (750mg orally TID) administration
223624294|NCT00931034|BEHAVIORAL|South Beach Diet with South Beach Diet Products|
223624295|NCT00931034|BEHAVIORAL|American Diabetes Association Diabetes Meal Plan|
223624296|NCT05701293|PROCEDURE|Endovascular implantation of Renzan Stent|Endovascular treatment of LEAD patients with Renzan Stent
224316531|NCT06611280|OTHER|No Interventions|No delivered intervention.
224316532|NCT03423186|DRUG|SOBI003|Weekly i.v.infusion
224213541|NCT01909752|BIOLOGICAL|HPV vaccine|Immunization with HPV vaccine will consist of two 0.5-mL intramuscular injection at the time of the first and third vaccinations. The preferred site of administration is the deltoid region of the upper arm.
224213542|NCT04920565|DEVICE|hemoperfusion with polymyxin B|polymyxin B is covalently immobilized on polystyrene strands, selectively removes endotoxin and at the same time there is no leaching of the ligand, immobilization is carried out by electrostatic interaction and Vanderwals force
224213543|NCT02516878|PROCEDURE|Acupuncture|"Eight body acupuncture points will be chosen as Tianshu(ST-25), Daheng(SP-15), Daimai(GB-26), Qihai(CV-6), Zhongwan(CV-12), Zusanli(ST-36), Fenlong(ST-40), Sanyinjiao(SP-6). The needles will be retained for 30 minutes.~Participants of the treatment group will additionally receive unilateral auricular acupressure at four auricular points as Hunger, Shen men, Spleen and Stomach with Semen Vaccariae embedded within adhesive tape in each treatment session. Acupressure will be applied by the subjects with repeat pressing of the tape with fingertips for 3 minutes per point, 3 times per day. The embedded tape will be retained in-situ until the next visit and then the alternate side of ear will be treated."
224316533|NCT02785952|BIOLOGICAL|Ipilimumab|Given IV
224316534|NCT02785952|OTHER|Laboratory Biomarker Analysis|Correlative studies
224316535|NCT02785952|BIOLOGICAL|Nivolumab|Given IV
224316536|NCT02785952|OTHER|Quality-of-Life Assessment|Ancillary studies
223513582|NCT05518981|DEVICE|Respiratory Remote Patient Monitor (Spire Health Tag)|"The RPM service, tailored to chronic respiratory disease patients, utilizes a system that includes three components: undergarment-adhered cardiorespiratory sensors, in-home data transmission hub, and web-based clinical dashboard. The sensors are a set of six proprietary, skin-safe devices that include sensors for intermittent photoplethysmography, continuous respiratory force, and tri-axis accelerometers for activity. Clinical liaisons monitor deviations from patient-specific baselines and contact subjects for a risk assessment call, including questions about symptoms. If a subject fails the risk assessment, they are escalated to the site to be seen, and potentially treated, by their pulmonologist."
223513583|NCT03351959|RADIATION|neo-adjuvant treatment|long-course radio-chemoradiation; short-course radiation with immediate/delayed surgery
223513584|NCT01408108|PROCEDURE|Laparoscopic hiatal repair with sub-lay partially absorbable lightweight mesh|"A fashioned according to the dimensions of hernia defect partially absorbable lightweight mesh Ultrapro™ (Ethicon, Inc.) will be sutured to both crura with 3 to 5 interrupted non-absorbable (Ethibond™ 3-0 by Ethicon, Inc.) sutures (as tension-free repair). Subsequent 2 to 3 interrupted non-absorbable sutures will approximate crura to completely cover a mesh to preclude its contact with the esophagus (original sandwich sub-lay technique)."
223513585|NCT01408108|PROCEDURE|Laparoscopic primary posterior crural repair|"Posterior cruroraphy will be performed with 3 to 4 interrupted non-absorbable (Ethibond™ 3-0 by Ethicon, Inc.) sutures.~In the both arms laparoscopic procedure will be done in a standard fashion: reduction of hernia with excision of hernia sac and mobilization of distal esophagus, exposure of borders of hiatal opening including crura posteriorly to esophagus, repair if hiatal hernia defect (30 Fr esophageal bougie is used), a short (2,5 - 3,5 cm) 360° fundoplication wrap (floppy-Nissen procedure) (30 Fr esophageal bougie is used)."
223513586|NCT05601063|BEHAVIORAL|Winterlight Speech Assessment|Digital assessment of speech and language abilities
223513587|NCT03021005|BEHAVIORAL|HIV Self-testing|
223513588|NCT04498273|DRUG|Apixaban 2.5 MG|Subjects will be contacted either electronically or by telephone within 24 hours of randomization to confirm receipt of the study treatment. Study drug will be shipped to subjects home. Subjects will take Apixaban 2.5 MG twice a day; once in the morning and once in the evening for 45 days. Subjects will be contacted (electronic or telephone) minimally weekly after initial start of study medication and contact will continue up to day 75 after starting study treatment. Follow up electronic contact will be dependent on initial patient response, compliance with response, and medication adherence, for the trial duration using electronic contacts and through telephone contacts. Participants will be queried for any clinically relevant endpoints, especially major bleeding, or need to seek healthcare attention for any reason. Follow-up will occur from the time of study drug receipt and through the 30 day safety period.
223513589|NCT04498273|DRUG|Apixaban 5MG|Subjects will be contacted either electronically or by telephone within 24 hours of randomization to confirm receipt of the study treatment. Study drug will be shipped to subjects home. Subjects will take Apixaban 5 MG twice a day; once in the morning and once in the evening for 45 days. Subjects will be contacted (electronic or telephone) minimally weekly after initial start of study medication and contact will continue up to day 75 after starting study treatment. Follow up electronic contact will be dependent on initial patient response, compliance with response, and medication adherence, for the trial duration using electronic contacts and through telephone contacts. Participants will be queried for any clinically relevant endpoints, especially major bleeding, or need to seek healthcare attention for any reason. Follow-up will occur from the time of study drug receipt and through the 30 day safety period.
223513590|NCT04498273|DRUG|Aspirin|Subjects will be contacted either electronically or by telephone within 24 hours of randomization to confirm receipt of the study treatment. Study drug will be shipped to subjects home. Subjects will take Aspirin twice a day; once in the morning and once in the evening for 45 days. Subjects will be contacted (electronic or telephone) minimally weekly after initial start of study medication and contact will continue up to day 75 after starting study treatment. Follow up electronic contact will be dependent on initial patient response, compliance with response, and medication adherence, for the trial duration using electronic contacts and through telephone contacts. Participants will be queried for any clinically relevant endpoints, especially major bleeding, or need to seek healthcare attention for any reason. Follow-up will occur from the time of study drug receipt and through the 30 day safety period.
223513591|NCT04498273|DRUG|Placebo|Subjects will be contacted either electronically or by telephone within 24 hours of randomization to confirm receipt of the study treatment. Study placebo will be shipped to subjects home. Subjects will take placebo twice a day; once in the morning and once in the evening for 45 days. Subjects will be contacted (electronic or telephone) minimally weekly after initial start of study medication and contact will continue up to day 75 after starting study treatment. Follow up electronic contact will be dependent on initial patient response, compliance with response, and medication adherence, for the trial duration using electronic contacts and through telephone contacts. Participants will be queried for any clinically relevant endpoints, especially major bleeding, or need to seek healthcare attention for any reason. Follow-up will occur from the time of study drug receipt and through the 30 day safety period.
223624297|NCT03153696|BEHAVIORAL|Cellie Coping Kit Intervention|The Cellie Coping Kit intervention is grounded in empirical evidence regarding injury recovery. By utilizing parents as coaches, the Cellie Coping intervention can be initiated in the hospital and continued as the child recovers at home. The intervention's portable, engaging design and active partnership with parents as consistently available coaches, allows families to use the intervention anywhere (i.e., home, hospital, during procedures) ensuring the child is supported at the time the injury-related stressor arises. The Cellie Coping Intervention consists of 1) a stuffed toy to promote engagement, 2) caregiver book, and 3) coping cards. Skills are presented in a way usable by most parents and children without medical team support.
223624298|NCT01682733|DRUG|Botulinum toxin|In this study, Botulinum toxin will be injected in half of the subjects not as a primary treatment modality for obesity, but to retard the muscular grinding gastric activity arount the suture insertion sites to see if it improves the durability of the gastroplasty.
224213544|NCT05633537|PROCEDURE|pulpectomy procedure and the clinical evaluation|in this study, pulpectomy procedure was performed in a single visit and the root canals were filled with different obturating materials. The clinical follow up evaluation was carried out after three, six and twelve months after pulpectomy procedures. The teeth were clinically evaluated each follow up visit for the following clinical features: absence of spontaneous pain, no tenderness with percussion, no abnormal mobility and absence of swelling \& sinus or fistula. If the tooth exhibited any one of above clinical features, the pulpectomy was considered to be a failure (F); otherwise, it was regarded as clinical success (S).
224213545|NCT05633537|RADIATION|radiographic evaluation|Radiographic evaluation was performed immediately after teeth restoration (base line radiograph), then after three, six and twelve months. The parallel periapical technique was performed using the rinn (XCP) periapical film holder and a long cone which was mounted to the x-ray tube. The criteria for radiographic success were no evidence of extensive pathologic root resorption, reduction or no change in pre-operative pathologic inter-radicular radiolucency and no evidence of new postoperative pathologic radiolucency.
224213546|NCT02546037|DEVICE|FX100 dialyzer|comparison of dialyzers
224213547|NCT02546037|DEVICE|SOLACEA 21H|comparison of dialyzers
223513592|NCT02124421|PROCEDURE|Cytoreductive Surgery (CRS)|Cytoreductive surgery
223513593|NCT02124421|DRUG|Adjuvant Chemotherapy|Six weeks post-surgery (CRS or CRS/HIPEC) standard combination chemotherapy will be administered every 21 days for 6 cycles
223513594|NCT02124421|OTHER|Questionnaire|Questionnaires designed to assess quality of life in ovarian cancer patients will be administered to study participants
223513595|NCT02124421|PROCEDURE|Hyperthermic intraperitoneal chemotherapy|Hyperthermic intraperitoneal chemotherapy with carboplatin, AUC=6
223513596|NCT02124421|DRUG|Carboplatin|AUC=6 mg/mL/min IV (in the vein), on day 1. Repeat every 21 days for 6 cycles.
223513597|NCT02124421|DRUG|Paclitaxel|175 mg/m2 IV (in the vein), day 1. Repeat every 21 days for 6 cycles
223513598|NCT02124421|DRUG|Paclitaxel|Day 1: paclitaxel 135 mg/m2 IV (in the vein). Repeat every 21 days for 6 cycles Day 8: paclitaxel 60 mg/m2 IP (intraperitoneal). Repeat every 21 days for 6 cycles
223513599|NCT02124421|DRUG|Cisplatin|Day 2: cisplatin 75 mg/m2 IP (intraperitoneal). Repeat every 21 days for 6 cycles
223513600|NCT01950494|OTHER|fiteBac Hand Sanitizer|Skin gel created for health care workers that is currently on the market. This sanitizer has an additive layer to protect the skin that is also thought to helpo hand dermatitis.
223513601|NCT05199038|DRUG|Octreotide|Octreotide infusion for 2 days in patients with bleeding esophageal varices.
223513602|NCT04228653|DEVICE|Renishaw Drug Delivery System|Device that allows pharmaceuticals to be delivered into the brain is to be assessed over a period of time to inform of the long term safety of the implanted device.
223513603|NCT04046952|DEVICE|Statseal with TR Band|Patients will have a Statseal Advance RAD (SS) disc applied after withdrawing the radial sheath 2-4 cm. A Tegaderm dressing will be applied to secure the disc position. The TR band will be applied over the SS disc with the center of the balloon (the green dot) over the center of the SS disc. The TR band will be inflated with 8cc of air (which is typically occlusive pressure), and the sheath removed. No deflation will occur immediately. After 20 minutes of pressure, 3 cc of air will be removed from the TR band. After an additional 40 minutes (60 minutes after procedure), the TR band will be completely deflated.
223513604|NCT04046952|DEVICE|TR band only|Patients will have a TR band applied over the arteriotomy site and inflated with 15-18ml of air. After aspirating and clearing the contents of the sheath, the radial sheath will be removed. The TR band will be deflated until bleeding occurs, and 2 ml of air will be reintroduced to provide hemostasis. Patent hemostasis will be documented with plethysmography and oximetry as described below within 5 minutes after band application and removal, and within 30 min of discharge or after 24 hours. The TR band will be left inflated and in place for 60 minutes following the procedure for all patients (regardless of diagnostic or PCI procedure), after which full deflation attempts will commence.
223513605|NCT05598307|DRUG|magnesium bolus followed by normal saline infusion|a bolus dose of magnesium will be followed by normal saline infusion
223513606|NCT05598307|DRUG|magnesium bolus followed by magnesium infusion|a bolus dose of magnesium will be followed by a magnesium infusion
223513607|NCT05598307|DRUG|normal saline bolus followed by normal saline infusion|a bolus of normal saline will be followed by normal saline infusion
223513608|NCT00215553|DRUG|A.1 Lucinactant|3 30 mL aliquots at concentrations of 5, 5, and 10 mg/mL
223513609|NCT00215553|OTHER|B.3 SoC|Standard ARDS management and ICU care
223513610|NCT00215553|DRUG|A.2 Lucinactant|3 30 mL aliquots at a concentration of 10 mg/mL each
223513611|NCT00215553|DRUG|A.3 Lucinactant|2 50 mL aliquots at concentrations of 10 and 20 mg/mL
223513612|NCT00215553|DRUG|A.4 Lucinactant|2 50 mL aliquots at concentrations of 10 and 20 mg/mL, with bolus re-treatment allowed
223513613|NCT00215553|DRUG|B.1 Lucinactant|2 50 mL aliquots at concentrations of 10 and 20 mg/mL
223624299|NCT01682733|DEVICE|Overstitch Endoscopic Suturing System|The gastroplasty will be accomplished by a series of intralumenally placed full thickness interrupted sutures through the gastric wall, using the FDA-approved (510K) endoscopic suturing device, the Overstitch Endoscopic Suturing System.
224213548|NCT00000737|DRUG|Dronabinol|
224213549|NCT00000737|DRUG|Megestrol acetate|
224213550|NCT00127569|DRUG|Rituximab|
224213551|NCT05151094|OTHER|Observation|Observation of clinical outcomes and comparison to non-treated patients
224316537|NCT02785952|OTHER|Questionnaire Administration|Ancillary studies
223624300|NCT06306209|OTHER|Treatment as usual (TAU), i.e., pharmacotherapy plus clinical management|All participants enrolled in the study will receive Treatment as usual (TAU), i.e., pharmacotherapy plus clinical management. Clinicians will be free to choose antidepressant medication, doses and drug combinations, including augmentations strategies and non-pharmacological treatments, which will follow standard clinical treatment guidelines for MDD.
223624301|NCT00394199|DRUG|Fluticasone propionate/Formoterol Fumarate 100/10|FlutiForm 100/10ug is a HFA pMDI that delivers 50ug of Fluticasone propionate per actuation and 5ug of Formoterol fumarate per actuation. Patients will take 2 actuations BID for 12 weeks.
223624302|NCT00394199|DRUG|Fluticasone propionate 100|Fluticasone 100 is a HFA pMDI that delivers 50ug of Fluticasone propionate per actuation. Patients will take 2 actuations BID for 12 weeks.
223624303|NCT00394199|DRUG|Formoterol fumarate 10|Formoterol 10ug is a HFA pMDI that delivers 5ug of Formoterol fumarate per actuation. Patients will take 2 actuations BID for 12 weeks.
223624304|NCT04604041|DIAGNOSTIC_TEST|1. Clinical testing; 2. Neurophysiological examination (TMS, EMNG); 3. Psychomotor examination; 4. Neuropsychological evaluation; 5. Flow cytometry; 6. ELISA|All groups will not have the same intervention. Interventions are listed and numbered for each group.
223624305|NCT00085163|DRUG|celecoxib|
223624306|NCT00085163|DRUG|fluorouracil|
223624307|NCT00085163|DRUG|leucovorin calcium|
223624308|NCT00085163|PROCEDURE|adjuvant therapy|
223624309|NCT02066766|OTHER|No treatment given|Patients will fill out a questionnaire by interview.
224213552|NCT05355831|DEVICE|Active Transcranial Direct Current Stimulation|See arm/group description
223624310|NCT05869435|DEVICE|FastWire System Device - Peripheral|The Investigator can use the FastWire System during the procedure to cross CTO Caps and/or to cross multiple lesions.
223624311|NCT00409539|DRUG|Placebo|Placebo, 2 week duration.
223624312|NCT00409539|DRUG|Placebo|Taken for the 8 week duration, in parallel with alternative arms (doses of 20, 40, 80 or 120mg SMP-986).
223624313|NCT00409539|DRUG|SMP-986|Comparison of varying dosages (20, 40, 80 or 120mg) of SMP-986 against placebo. Dosing is to occur once daily, in the morning, for a duration of 8 weeks
223624314|NCT01112137|DRUG|Clopidogrel|
223624315|NCT01112137|DRUG|Clopidogrel|
223624316|NCT01112137|DRUG|Clopidogrel|
223624317|NCT01112137|DRUG|Clopidogrel|
223624318|NCT03324490|PROCEDURE|Thoracic Spinal Anesthesia|"Spinal anesthesia will be performed for patients of the TSA group at the T7-T8 intervertebral space, using a 27 G pencil point needle with an introducer (Braun Melsungen, Melsungen, Germany).~When correct placement is confirmed by the free flow of clear CSF, 1.5 ml of hyperbaric Bupivacaine 0.5% (7.5 mg) in addition to 0.5 ml Fentanyl (25 μg) \& 5 μg dexmedetomidine will be injected."
223624319|NCT03324490|PROCEDURE|Thoracic Epidural Anesthesia|"Epidural anesthesia will be performed for patients of the TEA group at the T7-T8 intervertebral space, using the Prefix Custom Epidural Anesthesia Tray with an 18 G Tuohy epidural needle \& a 20 G epidural catheter.~Patients will initially receive 5-10 ml of a mixed preparation of 0.5% isobaric Bupivacaine with 2 μg Fentanyl per ml volume as a bolus dose via the epidural catheter, this will be followed by a continuous infusion of 5-10 ml/hr started 1 hour after the bolus dose \& continued throughout the procedure."
224213553|NCT05355831|DEVICE|Sham stimulation|See arm/group description
224213554|NCT00359840|DRUG|darbepoetin alfa|
223624320|NCT03324490|DRUG|Bupivacaine 0.5% (hyperbaric)|Neuro-axially injected
223624321|NCT03324490|DRUG|Bupivacaine 0.5% (isobaric)|Neuro-axially injected
223624322|NCT03324490|DRUG|Fentanyl|Neuro-axially injected
223624323|NCT03324490|DRUG|Dexmedetomidine|Neuro-axially injected
224213555|NCT04901130|DEVICE|Computer-aided Real-time Automatic Quality Control System (AQCS)|Automatic quality-control system(AQCS), developed based on deep convolutional neural network (DCNN) models, could improve the colonoscopists' performance during withdrawal phase and significantly increase polyp and adenoma detection.
223624324|NCT00689312|DRUG|Enfalyte|Each patient will receive one 250 ml dose.
223624325|NCT00689312|DRUG|Pediatric Electrolyte|Each patient will receive one 250 ml dose.
224213556|NCT01215682|DIETARY_SUPPLEMENT|vitamin D|2000 IU/day of vitamin D3 as a once-daily dose
224213557|NCT01215682|DIETARY_SUPPLEMENT|placebo|sweetened water
224213558|NCT04635904|BEHAVIORAL|Imaginal exposure one-session|Participants in this arm will be asked to decide alongside with the intervention provider (a clinical PhD student or M.A student under the supervision of the principal investigator) to imagine a script based on a future distressing anxiety provoking scenarios multiple times while honing in on the most negative aspects.
224316538|NCT05734014|BEHAVIORAL|Connectedness Activities|Indigenous Connectedness: Promoting respect, listening to elders, understanding Crow cultural values.
224316539|NCT06981650|BEHAVIORAL|video|use of a video
224316540|NCT06981650|BEHAVIORAL|education|standard talk and paper handout
223624326|NCT00689312|DRUG|Pedialyte|Each patient will receive one 250 ml dose.
223624327|NCT06293521|PROCEDURE|Pulpotomy|After the chamber is deroofed and coronal pulp is amputated using a round-end fissure bur in a high-speed handpiece with adequate water spray and light pressure until canal orifices were reached, The access cavity is flushed with sterile normal saline solution. Saline-wetted cotton pellets were placed for about 5 minutes over amputation sites applying moderate pressure to control pulpal hemorrhage. After discarding the pellets, blood oozing was present, MTA+ Cerkamed will be manipulated in the ratio of 3:1 (powder: liquid) to obtain a putty mix. This mix will be placed over the radicular pulp with the help of a suitable sterile amalgam carrier. Gentle condensation of the mix will be done in the pulp chamber with a moistened cotton pellet, followed by application of glass ionomer cement.
223624328|NCT06293521|PROCEDURE|Partial Pulpectomy|"Pulp tissue extirpation is done. Biomechanical preparation is done using rotary files with frequent irrigation with Chlorhexidine. The canals are dried using sterile absorbent paper points followed by obturation by the paste of Zinc oxide and eugenol.~The tooth with then be restored with stainless steel crown"
223624329|NCT00073658|DRUG|Citalopram|
223624330|NCT00073658|DRUG|Risperidone|
223624331|NCT00466063|DRUG|Deferasirox|
223624332|NCT03034486|DRUG|D930, D565|Period 1: D565 administered 1 time for one day/ Period 2: D930 administered 3 time per day for 9 days/ Period 3: D565(1 time per day) with D930(3 time per day) administered for 9days
223624333|NCT00629044|BIOLOGICAL|Assessing the blood level of cholesterol 24 S Hydroxylase|Comparison of venous blood level of Cholesterol 24 S hydroxylase and 24 hydroxycholesterol in patients with Glaucoma and AMD and in healthy subjects.
224213559|NCT04635904|BEHAVIORAL|Imagery rescriptinf one-session|Participants in this arm will be asked to decide alongside with the intervention provider (a clinical PhD student or M.A student under the supervision of the principal investigator) o imagine a script based on a future distressing anxiety provoking scenarios one time while honing in on the most negative aspects. Afterwards they will insert changes into the script that try to help them cope in the imagery.
224213560|NCT02507258|DEVICE|PROFEMUR® Am Femoral Stem w/ PROCOTYL® O Shell|PROFEMUR® Am cementless stems with PROCOTYL® O HA Coated Acetabular Component
224213561|NCT05775263|PROCEDURE|CT angiogram|CT angiography of the brain 30 minutes from establishment of NRP
224213562|NCT04147052|BEHAVIORAL|iSLEEPms|Participants randomized to iSLEEPms complete daily online sleep diary forms and weekly online educational modules. Modules focus on typical elements of CBT-I, adapted for individuals with MS: education about sleep in MS, sleep restriction, and stimulus control; sleep hygiene and relaxation; and cognitive restructuring around sleep and coping with MS. Sleep diaries are scored each week, and feedback is provided to participants to guide adjustments to their recommended bedtimes and wake times. Telephone support is available to provide clarification around module content.
224213563|NCT01051999|DIETARY_SUPPLEMENT|Glutamine|Oral glutamine powder
224213564|NCT01051999|DIETARY_SUPPLEMENT|L-alanine|L-alanine oral powder
224213565|NCT00546832|DRUG|TDS-943 (topical diclofenac sodium 4% spray)|
224213566|NCT00546832|DRUG|celecoxib|
224213567|NCT00546832|OTHER|placebo|
224213568|NCT02917356|OTHER|Spiritual laying on of hands (SP)|"The SP will be applied after physical therapy (kinesiotherapy). Spiritual healers from Spiritism will perform the SP. In order to produce a culturally acceptable environment, the Spiritist therapists will 'prepare' the environment by praying for 5 minutes. The Spiritist therapists will hold both hands 10-15 cm above the patients' head. Then, they will longitudinally lower their hands starting from the patients' head towards their legs, for four times. Subsequently, the therapists shall lay their hands on patients' head and on their knees. The therapists will remain silent during these procedures and try to 'heal' the patients. The subjects will remain in a seated position, blindfolded with dark-blinded goggles, and will receive the following verbal command: Relax and calm your mind."
224213569|NCT02917356|OTHER|Non-spiritual Laying on of Hands|"The non-spiritual laying on of hands will be applied after physical therapy (kinesiotherapy), for 5 minutes, without touching the patients and without 'preparing' the environment. They will hold their hands 10-15 cm above patient's head and will focus on healing the patients. They will visualize the following sentence: I want you to heal; without saying prayers or invocations. The subjects will remain in a seated position, blindfolded with dark-blinded goggles, and will receive the following verbal command: Relax and calm your mind."
224213570|NCT02917356|OTHER|Control group|"The patients will be subjected to physical therapy (kinesiotherapy), only. However, they will be accompanied by people who will stay in the room and move slowly and randomly in order to sham the presence of someone performing the laying on of hands. However, they will not perform the laying on of hands. These people will not focus on healing the patients and they will be asked to mentally count 5 minutes while they are with the patients. The subjects will remain in a seated position, blindfolded with dark-blinded goggles, and will receive the following verbal command: Relax and calm your mind."
224213571|NCT03470909|PROCEDURE|Skin-Sparing Mastectomy (SSM)|"For patients undergoing SSM, 10 points of interest in radial localization have been selected for investigation of the presence of residual breast tissue.~The points are located under the remaining skin envelope and will be investigated by performing small biopsies with a cervical biopsy forceps.~Additionally, the distance between the surface of the specimen and the glandular tissue will be explored at five points at the base of the removed breast.~These histological sections will be radially oriented."
224213572|NCT03470909|PROCEDURE|Nipple-Sparing Mastectomy (NSM)|"For patients undergoing NSM, 14 points of interest in radial localization have been selected for investigation of the presence of residual breast tissue, i.e. comparing to SSM, 4 additional biopsies will be taken behind the peripheral part of the areola.~The points are located under the remaining skin envelope and will be investigated by performing small biopsies with a cervical biopsy forceps.~Additionally, the distance between the surface of the specimen and the glandular tissue will be explored at five points at the base of the removed breast.~These histological sections will be radially oriented."
224213573|NCT00256100|DRUG|Fondaparinux Sodium|The active group of the study will be given fondaparinux 10mg/24 hours for haemofiltration anticoagulation
224213574|NCT00515385|DRUG|MGAWN1|"Eight subjects per cohort, each receives a single IV infusion of MGAWN1 of saline control on study day 0 (6 MGAWN1, 2 saline control.~Cohort 1 - 0.3 mg/kg Cohort 2 - 1 mg/kg Cohort 3 - 3 mg/kg Cohort 4 - 10 mg/kg Cohort 5 - 30 mg/kg"
224213575|NCT00515385|DRUG|MGAWN1|Single IV dose
224213576|NCT00515385|OTHER|Placebo|Single IV dose
224213577|NCT02316678|OTHER|No intervention|There is no intervention
224213578|NCT02043561|OTHER|induction of urge by rectal distension|
223624334|NCT00629044|BIOLOGICAL|Assessing the blood level of cholesterol 24 S hydroxylase|Comparison of venous blood level of cholesterol 24 S hydroxylase and 24 hydroxycholesterol in patients with Glaucoma, AMD end in healthy subjects
224213579|NCT06017011|OTHER|Total contact cast|Total contact cast will be put on the patient at the diagnosis of Acute charcot neuroarthropathy and the patient will be followed till clinical remission and after that till 6months post clinical remission. F18 Fluoride PET scan and MRI of the foot with DWI and ADC sequence to be done at baseline, Clinical remission, 3months post clinical remission and 6months post clinical remission to quantitate the process of remission.
224316541|NCT06292403|OTHER|Strength Training|training time will be 30 minutes therapy, once a day, 3 days a week for 8 weeks. were allowed to rest for 3-5 min during each training.
224316542|NCT06292403|OTHER|Mirror therapy|Participants in the (trial group) mirror and strength training group observed the reflection of the exercising arm and leg in the mirror. Participants in the (control group) strength training only group will exercise without a mirror entirely.
223624335|NCT00629044|BIOLOGICAL|assessing the blood level of cholesterol 24 S hydroxylase|Comparison of venous blood level of cholesterol 24 S hydroxylase and 24 hydroxycholesterol in patients with glaucoma, AMD and in healthy subjects
223762145|NCT02043015|DRUG|Pre-exposure prophylaxis with FTC/TDF|For men who meet eligibility criteria, PrEP with Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) will be made available beginning one month into the study. Men who express interest and meet eligibility criteria at their baseline visit can initiate PrEP at 1 month if they test negative for HIV. For men with extenuating circumstances, whose risk profile changes, of those who become more comfortable with the PrEP intervention through enrollment in the study, PrEP will be available to initiate at the 4 month visit. Men who accept PrEP will be required to have clinic visits, in addition to the regularly scheduled study visits, one month after starting PrEP and at least every 3 months afterward to monitor blood creatinine, AST/ALT and phosphorus levels.
224213580|NCT04149054|BEHAVIORAL|"Mobile health app called Hola Bebe"|For the pilot, all participants received a mobile app that contained 6 interactive audio/written modules in Spanish and English on the following topics: healthy eating; physical activity; portion control; eating healthy while eating out; eating out in Chinese, Italian, Mexican restaurants; and eating out in fast food restaurants. As noted above, the mobile app was customizable to include personalized activity reminders/notifications, and tailored action plans, along with videos for easy at-home exercises and user-friendly, easy-to-follow recipes.
224213581|NCT02488902|DRUG|Placebo|Placebo
223762146|NCT02043015|OTHER|Staff and provider MSM and LGBT sensitization training|The training for clinicians will focus on specific sexual health issues for MSM, including taking sexual histories in a non-judgmental way, physical examination techniques including anal examinations, and collection of rectal swabs for STI testing. Trainings will include topics about stigma, sexual identity and coming out, anal sex, STIs, and mental health. Training on LGBT sensitization will be provided for medical providers and staff in target clinics.
223762147|NCT02043015|BEHAVIORAL|HIV Testing and Risk-reduction counseling|Risk-reduction counseling will be provided to all men at baseline and additionally at 3, 6, and 12 month visits, with an additional counseling session for men on PrEP at their initiation visit (either month 1 or 4), their 1-month follow-up visit (either month 2 or 5) and at their 9 month visit. Risk reduction counseling will be client-centered counseling, according to CDC's Fundamentals of HIV Prevention Counseling protocol.
224213582|NCT02488902|DRUG|Tafenoquine 25mg|Tafenoquine 25mg
224213583|NCT02488902|DRUG|Tafenoquine 50mg|Tafenoquine 50mg
224213584|NCT02488902|DRUG|Tafenoquine 100 mg|Tafenoquine 100 mg
224213585|NCT02488902|DRUG|Tafenoquine 200 mg|Tafenoquine 200 mg
224213586|NCT02488902|DRUG|Mefloquine 250 mg|Mefloquine 250 mg
224213587|NCT04087382|DEVICE|thrombectomy|Transfemoral a microcatheter with its distal end was positioned a few millimeters beyond the distal aspect of the clot, the guide wire was exchanged by Solitaire stent device. The device was held in place when 3 mm was out of the microcatheter. The microcatheter was slowly pulled back to deploy the TR or ST device over the clot.
224213588|NCT04087382|OTHER|non intervention group|medical treatment (Asprin, statin, nootropic drug)
224213589|NCT03880331|PROCEDURE|Debridement|Aggressive vs Minimal Debridement
224213590|NCT05897762|BEHAVIORAL|Tele rehabilitation Group|It has been determined that the telerehabilitation method applied in chronic hemiplegic patients increases daily living activities, upper extremity functionality, and spasticity levels decrease.
224213591|NCT01113294|PROCEDURE|catheter ablation|circumferential pulmonary vein isolation complex fractionated atrial electrograms ablation circumferential pulmonary vein isolation combined left atrial roof ablation circumferential pulmonary vein isolation combined left atrial isthmus ablation circumferential pulmonary vein isolation combined left atrial roof and isthmus ablation circumferential pulmonary vein isolation combined complex fractionated atrial electrograms ablation
224213592|NCT03978169|DIAGNOSTIC_TEST|pleuropulmonary ultrasound|three pleuro-pulmonary ultrasound scans will be performed, preoperatively on the day of surgery, post-operatively in the recovery room and the day after surgery
224213593|NCT02450760|OTHER|Social incentive|Quantify adherence to 90 days of home blood pressure monitoring and to determine if a social incentive improves adherence
224213594|NCT05620680|BIOLOGICAL|CD7 CAR-T cells|patient was subjected to 0.5-2×10\^6 cells/kg of CD7 CAR- T
224213595|NCT01589029|DRUG|CANAKINUMAB (ILARIS®)|subcutaneous injection every 8 weeks
224213596|NCT02824991|PROCEDURE|detection of local twitch response intensities during dry needling|
224213597|NCT03786874|OTHER|Identify work interruptions|estimate baseline characteristics of the collaborative working model (proportion expressed as a percentage)
224213598|NCT03786874|OTHER|Understand work interruptions|Team-review of the results of the task interruption and professional representations, identify activities to protect from task interruption
224213599|NCT03786874|OTHER|Act to limited work interruptions|Adaptation of organizations; Awareness raising and Coaching for change
224213600|NCT04071392|PROCEDURE|Hysterosalpingogram (HSG)|An infusion pump delivered saline via balloon catheter under continuous pressure monitoring. After one minute, investigators withdraw the fluid and recorded volumes in and out. Subjects then undergo hysterosalpingogram (HSG) for evaluation of tubal patency.
224316543|NCT01741051|DEVICE|HEPA Filter|
224316544|NCT00062400|PROCEDURE|psychosocial assessment and care|
224316545|NCT05700370|DIAGNOSTIC_TEST|MyProstateScore|MyProstateScore is a urine-based biomarker test used to predict the risk of clinically significant prostate cancer
223513614|NCT00215553|DRUG|B.2 Lucinactant|2 50 mL aliquots at concentrations of 10 and 20 mg/mL, with bolus re-treatment allowed
223513615|NCT05960123|PROCEDURE|Tubularized Incised Plate (TIP) urethroplasty|tubularization of urethral plate with or without spongioplasty
223513616|NCT02944461|DRUG|Dapsone 7.5 % gel|Dapsone gel 7.5% applied once daily to truncal acne
223513617|NCT02193347|BIOLOGICAL|PEPIDH1M vaccine|PEPIDH1M vaccine is made up of 500 µg of 25 amino acid peptide administered with 150 µg of GM-CSF mixed 1:1 with Montanide ISA 51 administered intradermally. The peptide vaccine is administered in the groin area approximately 10 cm below the inguinal ligament.
223513618|NCT02193347|BIOLOGICAL|Tetanus-Diphtheria Toxoid (Td)|After consent has been signed, all subjects will undergo standard of care vaccination with 0.5 mL of Td (tetanus and diphtheria toxoids adsorbed) intramuscularly (I.M.) into the deltoid muscle to ensure adequate immunity to the tetanus antigen. Within 48 hours of leukapheresis, subjects will receive a vaccine site pre-conditioning as a single dose of Td toxoid (1 flocculation unit, Lf, in a total volume of 0.4 mLs saline) administered intradermally to the right side of the groin one day prior to receiving the first PEPIDH1M vaccine.
224213601|NCT01957631|DRUG|Corticosteroid injection (Bupivacaine and Depo Medrol)|The use of corticosteroid injections to treat heel pain has been a relatively common practice. They are mainly used in conjunction with other modes of conservative therapies. With a 10cc syringe, 3 mL of 0.5% Bupivacaine and 2 mL of 80mg Depo Medrol are injected into the medial calcaneal tubercle using an aseptic technique.
223624336|NCT03179566|BEHAVIORAL|Information Sheet|Patients will receive an informational sheet about how to dispose of leftover opioid medication during discharge. Nurses will provide this information sheet and a brief, scripted description of its use and importance of safe disposal at the time of discharge following surgery.
223624337|NCT03179566|BEHAVIORAL|Deterra Drug Deactivation System|This system is a pouch that deactivates prescription drugs, rendering them ineffective for misuse and safe for regular garbage disposal. It uses a patented activated carbon technology to deactivate drugs, including pills, liquids, and patches, and has been found to be 99% percent effective in studies funded by the National Institute of Drug Abuse (NIDA). Additionally, the pouches are made from environmentally friendly materials and contain active ingredients that are considered non-toxic and pose minimal risk, according to their MSDS. Nurses will provide the Deterra bag and a brief, scripted description of its use and importance of safe disposal at the time of discharge following surgery.
224213602|NCT01957631|BIOLOGICAL|Platelet rich plasma injection|10-15cc of patient's blood is drawn and centrifuged in a Rotofix 32A at 1500 cycles/minute for 5 minutes to separate the platelets from the other components of blood. 4-6cc of concentrated platelets are then re-injected into the medial calcaneal tuberosity using an aseptic technique. Sterile techniques are very important in this procedure to decrease the risk of infection.
223624338|NCT00877136|DEVICE|TheraSphere®|TheraSphere® consists of insoluble glass microspheres where yttrium-90 is an integral constituent of the glass. TheraSphere® is delivered into the liver tumor through a catheter placed into the hepatic artery. This artery provides the main blood supply to the tumor in the liver. TheraSphere® being unable to traverse the tumor vasculature is embolized within the tumor and exerts a local beta radiation radiotherapeutic effect with relatively limited concurrent injury to surrounding normal tissue.
223624339|NCT02662972|DRUG|Botulinum Toxin Type A|
223624340|NCT01130753|DRUG|Erlotinib|Erlotinib 150mg per day for 8 weeks
223624341|NCT05093816|BEHAVIORAL|Common Elements Toolbox|The Common Elements Toolbox (COMET) is an online single-session intervention. It is entirely self-guided and lasts about 60 minutes. Participants complete a series of reading and writing exercises focused on four modules: cognitive restructuring, behavioral activation, gratitude, and self-compassion. The intervention is entirely unguided and completed in a single sitting.
223624342|NCT02600481|PROCEDURE|low-pressure pneumoperitoneum|Using low-pressure(between 7-10 mm Hg ) pneumoperitoneum to complete robot-assisted surgeries,such as radical prostatectomy or cystectomy.
223624343|NCT02600481|PROCEDURE|standard-pressure pneumoperitoneum|Using standard-pressure (between 12-16 mm Hg )pneumoperitoneum to complete robot-assisted surgeries,such as radical prostatectomy or cystectomy.
223624344|NCT05118191|OTHER|OOLER|Following the baseline block (first four weeks), participants will use the OOLER device to power a cooling mattress pad each night during sleep for four weeks.
223624345|NCT05118191|OTHER|EmbrWave|Following the baseline block (first four weeks), participants will use the Embr Wave 2 device to provide pulsed warm sensations to the inner wrist each night during sleep for four weeks.
223624346|NCT00356681|DRUG|AMG 706 placebo|Blinded placebo
223624347|NCT00356681|DRUG|Bevacizumab|Bevacizumab is a recombinant, humanized anti-VEGF monoclonal antibody.
223624348|NCT00356681|DRUG|AMG 706|AMG 706 is a small organic molecule that has been shown in preclinical pharmacology and PK studies to be a potent, oral, multi-kinase inhibitor with anti-angiogenic and anti-tumor activity achieved by selectively targeting all known VEGF, PDGF and Kit receptors.
223624349|NCT00356681|DRUG|Paclitaxel|Paclitaxel is an antineoplastic agent that acts by promoting and stabilizing the polymerization of microtubules.
223624350|NCT01863459|DRUG|Lisdexamfetamine Dimesylate|
223624351|NCT01863459|DRUG|placebo|
223624352|NCT01239511|DRUG|green tea polyphenols (STA-2)|2 capsules t.i.d., after meal
223624353|NCT00525512|DRUG|tiotropium 18 mcg|Oral inhalation once daily of 18mcg tiotropium via handihaler
223624354|NCT00525512|DRUG|Placebo|Oral inhalation of once-daily placebo matching tiotropium via handihaler
223624355|NCT03841110|DRUG|FT500|FT500 is an allogeneic, iPSC-derived Natural Killer (NK) cell cancer immunotherapy
223624356|NCT03841110|DRUG|Nivolumab|Immune Checkpoint Inhibitor
223624357|NCT03841110|DRUG|Pembrolizumab|Immune Checkpoint Inhibitor
223624358|NCT03841110|DRUG|Atezolizumab|Immune Checkpoint Inhibitor
223624359|NCT03841110|DRUG|Cyclophosphamide|Lympho-conditioning agent
223624360|NCT03841110|DRUG|Fludarabine|Lympho-conditioning agent
223624361|NCT03841110|DRUG|IL-2|Biologic response modifier
223624362|NCT04905550|DRUG|Almonertinib|Almonertinib 110mg p.o qd. Treatment with Almonertinib will continue until progression or unacceptable toxicity.
223624363|NCT04905550|RADIATION|Stereotactic Radiotherapy(SRT) or Stereotactic Radiosurgery(SRS) or Whole-Brain Radiotherapy(WBRT)|Image guided, 24-15 Gy\*1F was recommended if use SRS. 9-12 Gy\*3F/1W or 6Gy×5F/1W was recommended if use SRT. 30Gy/10F/2W for WBRT, large residual lesions will be treated with a local dose (≤DT 45Gy/15F).
223624364|NCT01383603|BIOLOGICAL|Cat-PAD|Intradermal injection 1 x 4 administrations 4 weeks apart
224213603|NCT02373735|OTHER|crystalloid|Group A (SVV \<10%): infuse crystalloid 6-10 ml/kg/hr during surgery. Group B (SVV 10-20%): infuse crystalloid 2-4 ml/kg/hr until cystectomy, 6-10 ml/kg/hr after cystectomy
224213604|NCT02373735|OTHER|colloid|Group A (SVV \<10%): infuse colloid 200 ml if SVV is ≥ 10%. Group B (SVV 10-20%): infuse colloid 200 ml if SVV is \> 20%
224213605|NCT02373735|OTHER|mannitol|Group B (SVV 10-20%): infuse mannitol 0.5 g/kg if SVV is \< 10%
223624365|NCT01596803|PROCEDURE|Taking of blood|Taking venous blood samples to analyse oxidant stress
224213606|NCT02373735|OTHER|lasix|Group B (SVV 10-20%): infuse lasix 5 mg if SVV is \< 10%
224213607|NCT05053919|DEVICE|Schumann resonance sleep device|"A Schumann resonance sleep device would stably output the composite frequency of a the Schumann resonance frequency (7.83 Hz) wave, theta wave, and delta wave.~The subjects were asked to use the device (place it next to the bed facing the subject's head, turn it on about one hour before going to bed every night, and turn it off after getting up the next day) every night for four weeks."
224213608|NCT05053919|DEVICE|Placebo sleep device|"A Placebo sleep device is an instrument with the same appearance and operation as the Schumann resonance sleep device, but does not output any frequency wave.~The subjects were asked to use the device (place it next to the bed facing the subject's head, turn it on about one hour before going to bed every night, and turn it off after getting up the next day) every night for four weeks."
224213609|NCT01255579|DRUG|Salmeterol Fluticasone|salmeterol 50 mcg and fluticasone 250 mcg (diskus) b.i.d.
224213610|NCT01255579|DRUG|formoterol - beclometasone|formoterol 12 mcg and beclometasone 200 mcg HFA (by MDI) b.i.d.
224213611|NCT01776450|DEVICE|Endovascular AAA repair|
224213612|NCT02387307|DRUG|rSIFN-co|rSIFN-co is a drug developed by Sichuan Huiyang Life Science and Technology Corporation for the treatment of solid tumors especially in non-small cell lung cancer and other tumor types. The study comprises of 2 stages: the dose-escalation stage and dose expansion stage.
224213613|NCT06112405|OTHER|App-based CCAAP|App-based CCAAP, could remind patients take controller and reliever when asthma symptoms get worse through mobile.
224213614|NCT06112405|OTHER|Written CCAAP|Written CCAAP, conventional management for patients with asthma, remind them take controller and reliever when asthma symptoms get worse.
224213615|NCT00681577|BIOLOGICAL|URLC10, KOC1, VEGFR1 and VEGFR2|Patients will be vaccinated twice a week for 8 weeks. On each vaccination day, the URLC10 peptide (1mg), KOC1 peptide (1mg), VEGFR1 peptide (1mg) and VEGFR2 peptide (1mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection in combination with S-1 chemotherapy.
224213616|NCT01523522|OTHER|Myoblast injection|Autologous myoblast injection in the anal sphincter
224213617|NCT01523522|PROCEDURE|saline solution injection|saline solution injection in anal sphincter
224213618|NCT05059782|DRUG|chemotherapy, targeted therapeutics, immunotherapy|Chemotherapy drugs ,targeted drugs or Immune checkpoint inhibitors are taken throughout the body or a combination of these drugs according to clinical needs is performed when necessary.
224213619|NCT05059782|RADIATION|IFRT, IMRT or SBRT|IFRT（involving field radiotherapy） IMRT （ intensity modulated radiation therapy） SBRT （stereotactic body radiation therapy）
224213620|NCT02369627|DEVICE|Rapid HIV Self-Test (OraQuick® In-home HIV Test)|The participant will utilize materials and directions contained within the OraQuick In-Home HIV Test kit to properly perform a rapid HIV self-test. The participant will first swab his upper and lower gums using an Oral Swab Test Stick. The participant will then place this device in a test tube, and the results will be displayed in the Test Window within 20 minutes. Test results expire after 40 minutes.
224213621|NCT02369627|DEVICE|Conventional Home-Based HIV Test (Home Access Express)|The participant will utilize materials and directions contained within the Home Access Express HIV-1 Test System to properly perform a conventional home-based HIV test. The participant is required to gather a blood sample by lancing his finger. Blood samples are collected by placing drops of blood on a packaged specimen card. The participant will then mail his blood sample to the Home Access laboratory using a self-addressed, pre-paid shipping envelope. The Home Access laboratory will process the blood sample, and the participant is required to call the facility to learn his HIV test result.
224213622|NCT02369627|OTHER|Community/Medical-Based HIV Test|The participant will receive a link to a CDC website (https://gettested.cdc.gov) to search for HIV testing locations in his surroudning community. This resource website will provide the participant with places that offer HIV testing for free or at a low cost. The participant also has the option of going to places that can use his insurance or charge for testing. The pariticant is responsible to pay for any testing costs.
224213623|NCT04472182|DRUG|Fluoride varnish with xylitol coated calcium and phosphate|Fluoride varnish with xylitol coated calcium and phosphate
223624366|NCT01596803|DIETARY_SUPPLEMENT|needle biopsy of the vastus lateralis muscle|T0 needle biopsy of the vastus lateralis muscle (analysis of oxidative stress and inflammatory markers)During 17 weeks supplementation by Vit E, C , Zn Se After 17 weeks: veinous blood samples and needle biopsy
224213624|NCT04431531|OTHER|10 Sessions of yogatherapy associate with EMDR|The first group will have Yogatherapy plus EMDR treatment
224213625|NCT04431531|OTHER|The second group will have EMDR without yogatherapy|the second one will have EMDR treatment
224213626|NCT02268331|OTHER|Active Surveillance|
224213627|NCT02268331|OTHER|Passive Surveillance|
224213628|NCT00872391|RADIATION|Hypofractionated linear accelerator radiotherapy|10 fractions of stereotactic linear accelerator radiotherapy with 6 Gy per fraction at the 80% isodose for the planning target volume.
224316546|NCT02566356|DRUG|Oxytocin|40 IU of the oxytocin will be administered intranasally for a one time dose at the beginning of the visit.
223624367|NCT01596803|DIETARY_SUPPLEMENT|Vit C Vit E Zn Se|T0 venous blood samples and needle biopsy of the vastus lateralis muscle During 17 weeks vit E 400mg/d, Se 200µg/d, Vit C 500mg/day, Zn 25 mg/d After the supplementation of 17 weeks:venous blood samples and needle biopsy of the vastus lateralis muscle
223624368|NCT01596803|DIETARY_SUPPLEMENT|Placebo Vit E Placebo Vit C Zn Se|venous blood samples and needle biopsy
223624369|NCT04268186|DEVICE|Direct tDCS|Transcranial direct current stimulation (tDCS) will be applied. Stimulation amplitude is 2 mA. Stimulation duration is 20 minutes. The configuration used is two electrodes at AFz and CPz of the 10-10 electrode system.
223624370|NCT04268186|DEVICE|Indirect tDCS|Transcranial direct current stimulation (tDCS) will be applied. Stimulation amplitude is 2 mA. Stimulation duration is 20 minutes. The configuration used is two electrodes at AF3 and AF4 of the 10-10 electrode system.
224213629|NCT01373476|DRUG|Qideng Mingmu capsule|High dosage group (4 Qideng Mingmu capsules each time): 4#, po, tid,24 weeks; Middle dosage group (2 Qideng Mingmu capsules plus 2 placebos each time):4#, po, tid,24 weeks;Low dosage group (1 Qideng Mingmu capsule plus 2 placebos each time):3#, po, tid,24 weeks.
224213630|NCT01373476|DRUG|Placebo Comparator|Placebo group (4 placebos each time):4#, po, tid,24 weeks.
224316547|NCT02566356|DRUG|Saline Nasal Spray|40 IU of the saline nasal spray will be administered once at the beginning of the visit.
224316548|NCT05148390|DEVICE|Cutimed® Gelling Fiber|application of dressing
224316549|NCT01806506|PROCEDURE|Laparoscopic sleeve gastrectomy|Laparoscopic sleeve gastrectomy (LSG) is a restrictive bariatric procedure. LSG involves resection of a large part of the body and fundus of the stomach starting from the antrum up to the angle of His. The remaining part of the stomach (the gastric sleeve) is calibrated with a 36 French bougie.
224213631|NCT00918229|DEVICE|balloon implant|Absorbable perirectal spacer implantation
224213632|NCT00918229|PROCEDURE|Balloon implantation|Implantation of the balloon between the prostate and the anterior rectal wall
224213633|NCT01864720|BEHAVIORAL|Professionally-administered cognitive-behavioral therapy for insomnia (CBT-I)|The treatment content will be the same whether it is administered by a professional or self-administered. This multimodal approach combines behavioural (i.e., stimulus control therapy, sleep restriction), cognitive (i.e., cognitive restructuring), and educational (i.e., sleep hygiene) strategies that are administered over a 6-week period.
223624371|NCT04268186|DEVICE|Personalized tDCS|Transcranial direct current stimulation (tDCS) will be applied. Stimulation amplitude is 2 mA. Stimulation duration is 20 minutes. The configuration used will be optimized to stimulate key nodes connected to MCC, including anterior insula, MFG and supramarginal gyrus, and designed using an individual head model that will be combined with each subject's measured connectivity map. The number of electrodes will be minimally 2 and maximally 32.
223624372|NCT04268186|DEVICE|Sham tDCS|Transcranial direct current stimulation (tDCS) will be applied. Stimulation amplitude is 2 mA. Stimulation duration is 20 minutes. Placebo stimulation will be applied by ramping the current up and immediately down over 30 seconds. The configuration used is two electrodes at AF3 and AF4 of the 10-10 electrode system.
223624373|NCT02609958|DRUG|Varlitinib|"varlitinib tablets with:~1. starting dose: 300mg BID~2. target dose: 400mg BID~3. dose modification by investigator allowed between 200mg BID to 500mg BID"
223624374|NCT03133611|OTHER|Speech assessment|Each subject will undergo short non-invasive speech assessment lasting approximately 15 minutes that will be recorded using microphone.
223624375|NCT03133611|OTHER|Routine clinical assessment|Volunteers who enroll in the study will undergo various assessments lasting about 2 hours, including neurological examination of both motor and non-motor skills, autonomic testing and cognitive testing.
223624376|NCT04809012|BIOLOGICAL|STI-3031|STI-3031 is an anti-PD-L1 antibody
223624377|NCT01439516|BEHAVIORAL|Information|Receipt of PREPARED educational book and video about treatments for end stage renal disease (ESRD)
223624378|NCT04608981|DRUG|Prednisolone 30 mg|Steroidal anti-inflammatory drug as a preoperative medication
223624379|NCT04608981|DRUG|Diclofenac Potassium 50mg Tab|Non-steroidal anti-inflammatory drug as a preoperative medication
223624380|NCT04608981|DRUG|Placebo|Starch
223624381|NCT00809016|RADIATION|3-dimensional conformal radiation therapy|
223624382|NCT00809016|RADIATION|fludeoxyglucose F 18|
223624383|NCT00809016|RADIATION|intensity-modulated radiation therapy|
223624384|NCT04228263|DRUG|Hydroxychloroquine|400mg
223624385|NCT04228263|DRUG|Folic Acid|5 mg
223624386|NCT04228263|DRUG|Low-dose aspirin|75 mg
223624387|NCT03289208|DRUG|MCI-186|30 mg of edaravone will be administered intravenously over 60 minutes.
223624388|NCT05110638|DRUG|SKX-16 (Luliconazole 10% Solution)|SKX-16 (Luliconazole 10% Solution) will be applied to each toenail and periungual areas once daily for 29 days such that there is sufficient quantity of solution to treat all toenails. All ten toes will be treated regardless of whether affected. The applications will occur in the clinic and be applied by study personnel. The nails will remain exposed until the applied solution dries.
223624389|NCT01784991|DRUG|Hydromorphone|1mg of Hydromorphone at timepoint 0 and 1 mg of hydromorphone at 15 min timepoint.
223624390|NCT01784991|DRUG|Usual care group|Patient will have pain treated at timepoint 0 as per usual care based on physician discretion. At 15 min timepoint, patients will be asked for pain level, and then subsequently treated as per physician discretion.
223624391|NCT00662207|DEVICE|Vibrator|A vibrator will be applied to the patient's bottom to determine if it will induce a bladder contraction
223624392|NCT00662207|PROCEDURE|Anal dilator|A balloon will be used for anal dilation to determine if it will result in relaxation of the pelvic floor and urethral sphincter. An anal dilator is being conduced with the balloon
223624393|NCT02361359|OTHER|Psychological questionnaires|
223624394|NCT02584946|OTHER|Avenanthramides|AVAs are a group of diphenolic acids that are found only in oats (Avena sativa).
223624395|NCT00632216|DRUG|Risedronate Sodium|
223624396|NCT04264858|DRUG|Immunoglobulin of cured patients|0.2g/kg, ivdrip, once a day, for 3 days
223624397|NCT04264858|DRUG|γ-Globulin|0.2g/kg, ivdrip, once a day, for 3 days
223624398|NCT02372643|OTHER|clitoral, transvaginal and transrectal ultrasound|Doppler Ultrasound assessment of clitoral hemodynamics will be performed in all subjects. Transvaginal and transrectal ultrasound will be performed in subjects giving their consent to these procedures.
223624399|NCT05256485|BEHAVIORAL|cognitive behavioral therapy,mindfulness based relapse prevention,twelve-step therapy|"In cognitive-behavioral therapy, participants learned that thoughts and emotions contribute to behavior, and responses to thoughts and emotions can be controlled.~in mindfulness-based relapse prevention, participants learned to focus on the present moment experience including craving with an attitude of acceptance and non-judging.~In twelve-step therapy, participants learned principles of acceptance, gratitude, forgiveness, tolerance, patience, humility, and honesty together with participation in different healthy ways to enrich life."
224213634|NCT01864720|BEHAVIORAL|Web-based cognitive-behavioral therapy for insomnia (CBT-I)|The treatment content will be the same whether it is administered by a professional or self-administered. Each week, the patients will first have to read written information on the website, and then watch a video capsule (duration between 5 and 20 min each). The treatment material will be identical to the video (DVD)-based CBT-I that we previously developed. Patients will complete their daily sleep diary electronically on the website and the content will be interactive. It will include the sending of automated emails to remind participants to complete the treatment tasks and encourage adherence, provision of tailored feedback (e.g., texts, charts) based on the information that they provide in their sleep diary, as well as quizzes with automated correction to reinforce patients' understanding of the content.
224213635|NCT05025982|PROCEDURE|combination of lymphaticovenular anastomosis and liposuction|Surgeries were carried out under local anesthesia and light sedation.LVA was performed adopting supramicrosurgical technique.Liposuction was performed following completion of the LVA
224213636|NCT00003682|DRUG|doxorubicin hydrochloride|
224213637|NCT00003682|DRUG|methylprednisolone|
224213638|NCT00888030|OTHER|there are no interventions currently listed for this study|
223624400|NCT06435208|OTHER|Subgingival instrumentation|All the participants will undergo scaling and root planning with hand scalers, curettes and ultrasonic scaler.
223624401|NCT00798200|OTHER|Exercise program|All exercise programs will include endurance and strength exercises.
223624402|NCT01169025|DRUG|Ketamine|Subjects receive 0.3 mg/kg IV ketamine over 5 minutes and are evaluated every 10 minutes. Residual or recurring pain will be treated as needed with adjunctive open-label bolus dosing of IV fentanyl (1 mcg/kg) followed by repeat boluses as needed every 10 minutes during the flight. For this open-label portion of the flight, subjects are asked if they need additional pain medication every 10 minutes, unless an earlier, spontaneous request is made by the subject or the provider determines that more is needed. For the potential of rare ketamine side effects (dysphoria, anxiety, or agitation), 2 mg IV midazolam is given every 5 minutes as needed for any of these symptoms. Vital signs are measured continuously throughout the protocol. Blood pressure is measured at 5 minute intervals.
223624403|NCT01169025|DRUG|Fentanyl|Subjects receive 1 mcg/kg IV fentanyl over 5 minutes. After first dose administration, subjects are evaluated every 10 minutes. Residual or recurring pain is treated as needed with adjunctive open-label bolus dosing of IV fentanyl (1 mcg/kg) followed by repeat boluses as needed every 10 minutes during the flight. For this open-label portion of the flight, flight nurses will query participants regarding their desire for additional pain medication every 10 minutes unless an earlier, spontaneous request is made by the participant or the provider determines that more is needed. Vital signs are measured continuously throughout the protocol. Blood pressure is measured at 5 minute intervals.
223624404|NCT06021925|OTHER|Obstetrical history|Selection of donors by EFS retrospectively on the basis of inclusion criteria. Information note sent by e-mail, non-opposition as well as a questionnaire to be completed online to obtain data on obstetrical history.
223624405|NCT06021925|OTHER|Anti-HLA Antibody tests|Analyze responses in relation to the results of the anti-HLA Antibody tests performed at the time of donation.
223624406|NCT02249416|DRUG|Tipranavir (TPV) low|
223624407|NCT02249416|DRUG|Ritonavir (RTV) low|Norvir®
223624408|NCT02249416|DRUG|Tipranavir (TPV) high|Retrovir®
223624409|NCT02249416|DRUG|Ritonavir (RTV) high|
223624410|NCT02249416|DRUG|Zidovudine|
223624411|NCT02588599|DEVICE|Erchonia LUNULA|Active low level laser light therapy
224213639|NCT03060148|DEVICE|Medtronic neurostimulation system|Dual leads for spinal cord stimulation will be performed at 90% of the motor threshold for 24 hours/day at 50 Hz and pulse width 0.2 ms
224316550|NCT01806506|PROCEDURE|Roux-en-Y Gastric Bypass|Roux-en-Y gastric bypass (RYGB) is an intermediate (restrictive and malabsorptive) operation. RYGB involves creation of a 15-20 mL gastric pouch that is anastomosed to a 100cm Roux limb created at 100cm from the ligament of Treitz.
223624412|NCT02530346|DRUG|No Mechanical Bowel Preparation|no enemas or oral laxatives will be given in this group
223624413|NCT02530346|DRUG|Mechanical Bowel Preparation|oral laxatives (polyethylenglycol at 100 ml/kg/dose for up to 3 times) and stoma enemas (20mlkgdo of normal saline 3 times a day) will be prescribed
223624414|NCT01259141|DRUG|Moxifloxacin|0.4 Qd for 7days
223624415|NCT01259141|DRUG|Cephalosporins and azithromycin|cefuroxime 1.5 bid for 7 days plus azithromycin 0.5 qd for 7 days
223624416|NCT06296186|BEHAVIORAL|Prolonged Exposure Therapy|Exposure therapy for PTSD
223624417|NCT02507765|OTHER|Laboratory Biomarker Analysis|Correlative studies
223624418|NCT02507765|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
223624419|NCT02507765|PROCEDURE|Transarterial Chemoembolization|Undergo TACE
223624420|NCT00457717|DRUG|0.25 % atropine|
223624421|NCT00457717|DRUG|0.5 % atropine|
223624422|NCT00457717|PROCEDURE|0.25 % atropine+auricular acupoints|
223624423|NCT03353675|BIOLOGICAL|TG4010|1 dose (1x1E+08) Subcutaneous injection/week over 6 weeks then 1 dose/3 weeks
223624424|NCT03353675|DRUG|Chemotherapy|"Pemetrexed/Cisplatin or Carboplatin~Pemetrexed maintenance"
223624425|NCT03353675|DRUG|Nivolumab|360 mg IV administration every 3 weeks
223624426|NCT05539066|DEVICE|AI health assistant|To study the advantages of AI health assistant management group compared with conventional management group in terms of comprehensive compliance rate, metabolic index level, hypoglycemia incidence rate, and mastery of diabetes related knowledge.
223624427|NCT04670341|OTHER|chewing tapioca pearls in bubble tea drinks|Saliva was collected on the first day before bubble tea consumption (pretest) and on the third day after bubble tea consumption (posttest); collection was conducted in the morning (09:00 a.m.-12.00 p.m.).
223624428|NCT04670341|OTHER|drink tea without chewing tapioca pearls|Saliva was collected on the first day before drink tea without tapioca pearl (pretest) and on the third day after tea consumption (posttest); collection was conducted in the morning (09:00 a.m.-12.00 p.m.).
223624429|NCT01938079|DRUG|Ketamine|Ketamine will be initiated as a one-time 40 mg bolus of ketamine followed by a continuous intravenous infusion of 5 micrograms/kg/min at the start of ECMO.
223624430|NCT01938079|OTHER|Sedative drug regimen|(Standard of Care) Fentanyl or hydromorphone and midazolam infusions will be administered to all patients and titrated at the discretion of the attending physician to maintain the desired level of sedation.
223624431|NCT05354817|DRUG|mFOLFIRINOX|mFOLFIRINOX: - Oxaliplatin; Leucovorin; Irinotecan and 5-FU
223624432|NCT03649542|OTHER|Fluidotherapy plus exercise|The Fluidotherapy® unit (ULTRA 115: Henley International, Sugar Land, Texas) is a high intensity heat modality consisting of a dry whirlpool of finely divided solid particles suspended in a heated air stream. A certified technician The cleaned the Fluidotherapy® unit per the user manual.
224213640|NCT03053622|BIOLOGICAL|Mirikizumab Test|Administered SC
224213641|NCT03053622|BIOLOGICAL|Mirikizumab Test|Administered IV
224213642|NCT03053622|BIOLOGICAL|Mirikizumab Reference|Administered SC
224213643|NCT03648086|OTHER|intestinal microbiota transplantation|Participants in Exprerimental group take 6 times IMT with 2-week intervals
224213644|NCT02598622|DRUG|Acetylcarnitine|Acetylcarnitine is taken 2 times a day for days 1 through 21.
224213645|NCT02598622|DRUG|Placebo|Placebo is taken 2 times a day for days 1 through 21.
224316551|NCT05644600|DRUG|Nintedanib|The subjects will be administered Nintedanib soft capsules single oral dose in the morning of Day 1 in fasted state.
224316552|NCT05644600|DRUG|AZD5055|The subjects will be administered AZD5055 as single oral dose on Day 1 in the fasted state.
224316553|NCT04614246|DRUG|BAY1817080|Tablet, oral administration
223624433|NCT05075330|BEHAVIORAL|Opioid Use Disorder Stigma Reduction|Billboards with destigmatizing language regarding opioid use disorder placed in the community.
223624434|NCT05449821|DIAGNOSTIC_TEST|Serum and salivary samples will be collected. Asprosin levels will be determined by biochemical analysis|Serum and saliva samples will be collected from both groups for biochemical analysis.
223762148|NCT02043015|BEHAVIORAL|Linkage to care|Men will be linked to needed services including HIV care and treatment for positives identified at baseline or during the study, including antiretroviral medications, and mental health services. At the end of their baseline visit, participants will receive service referral handouts for HIV care and treatment, mental health services, and other resources, as appropriate. Men who test positive for STIs will be treated at the clinic site.
223624436|NCT03243136|OTHER|Exposure of interest is food insecurity|Households were considered food insecure if any of the following conditions were met in the past 12 months: 1) a member of the household worried that there would not be enough food to eat because of a lack of money, 2) a member's food intake was reduced as a result of there not being enough food to eat, or 3) the desired variety or quality of foods was not eaten because of a lack of money. This exposure variable was operationalized as a binary variable with levels of food secure vs. food insecure.
223624437|NCT03679728|BEHAVIORAL|First trimester|Analysis of sensorimotor outcomes
223624438|NCT03679728|BEHAVIORAL|Second trimester|Analysis of sensorimotor outcomes
223624439|NCT02304939|PROCEDURE|changeover|
223624440|NCT02304939|DEVICE|use of automatic infusion pump|
223624441|NCT02304939|BEHAVIORAL|datas collection|
223624442|NCT00928902|DRUG|low-dose IL-2|low-dose IL-2, administered daily for 6 weeks, to begin either at week 1 (group 1) or week 4 (group 2)
223624443|NCT00928902|BIOLOGICAL|melanoma vaccine|six melanoma vaccines given over a 6-week period
223624444|NCT01102036|OTHER|Cultura L casei F19, acidophilus La5 , B lactis Bb 12|2 weeks consumption,250 ml/day
223624445|NCT01102036|OTHER|Yoghurt without probiotics|Yoghurt without probiotics
223624446|NCT00395746|DRUG|sulfonylurea|SU agent
223624447|NCT00395746|DRUG|liraglutide|Liraglutide 0.6 mg/day or placebo. Injected s.c. (under the skin) once daily.
223624448|NCT00395746|DRUG|liraglutide|Liraglutide 0.9 mg/day or placebo. Injected s.c. (under the skin) once daily.
223624449|NCT00359255|BEHAVIORAL|Education manual|The control arm was given education on stroke, the affected arm post strooke, bone health, and healthy living. This information was given in a booklet format and administered once weekly by the site coordinator.
223624450|NCT00359255|BEHAVIORAL|An inpatient homework based exercise program for the upper limb post stroke|"The experimental arm was given arm exercises graded based on motor impairment and administered by the site coordinator. The exercises were given in a booklet with written and photographic instructions. These exercises were monitored on a twice-weekly basis.~The intervention was to be completed once daily for 45 minutes, 5 days per week, and supervised by the site coordinator. Exercises consisted of range of motion, strengthening, and use of the arm in daily activites such as buttoning, pouring and throwing."
223624451|NCT03596502|DRUG|Direct oral anticoagulants (DOACs)|Exposure to DOACs will be defined as a new prescription for apixaban (ATC B01AF02), dabigatran (ATC B01AE07), or rivaroxaban (ATC B01AF01) at cohort entry date in patients diagnosed with non-valvular atrial fibrillation.
223624452|NCT03596502|DRUG|Warfarin|Exposure to warfarin will be defined as a new prescription for warfarin (ATC B01AA03) at cohort entry date in patients diagnosed with non-valvular atrial fibrillation.
223624453|NCT01034514|DEVICE|Real-time Position Management system|Standard of Care
223624454|NCT01034514|DEVICE|Discovery ST multislice PET/CT scanner|Standard of Care
223624455|NCT01034514|DEVICE|Infinia Hawkeye SPECT/CT gamma camera|Standard of Care
223624456|NCT01034514|DEVICE|Pinnacle3 treatment planning system|Standard of Care
223624457|NCT01034514|DEVICE|SKYLight nuclear camera|Standard of Care
223624458|NCT01034514|DRUG|DTPA|1 mCi; inhalation
223624459|NCT01034514|DRUG|TECHNETIUM TC 99M MAA|3 mCi; iv
223624460|NCT02609061|PROCEDURE|Open flap debridement (OFD)|Open flap debridement (OFD) alone
223624461|NCT02609061|PROCEDURE|OFD with Platelet rich fibrin (PRF)|Open flap debridement (OFD) with Platelet rich fibrin (PRF) placement
223624462|NCT02609061|PROCEDURE|OFD with Platelet rich fibrin (PRF)+1% Alendronate (Drug) in gel form|Open flap debridement (OFD) with Platelet rich fibrin (PRF)+1% Alendronate gel placement
223624463|NCT06123078|BEHAVIORAL|CaCBT|Culturally adapted Self help guide and modules total eight 80 hour session per week
223624464|NCT06313216|PROCEDURE|duoteck membrane|the dehisced bone defect will be covered with duoteck membrane
223624465|NCT06313216|PROCEDURE|autogenous demineralized tooth graft|the dehisced bone defect will be covered with autogenous demineralized tooth graft
223624466|NCT06313216|PROCEDURE|autogenous demineralized tooth graft and plate|the dehisced bone defect will be covered with autogenous demineralized tooth graft combined with autogenous demineralized tooth plate
223624467|NCT01019070|DRUG|BMS-650032|Capsules, Oral, 200 mg, BID, 7 Days
223624468|NCT06313229|PROCEDURE|implant placement 6 months after ridge augmentation|the deficient ridge was grafted first followed by implant placement after 6-monthes
223624469|NCT06313229|PROCEDURE|implant placement Simultaneously with ridge augmentation|the deficient ridge was grafted and followed by implant placement simultaneously
223624470|NCT04854785|OTHER|[18F]FEPPA PET scan|One \[18F\]FEPPA PET for TSPO VT, and one MRI scan
223624471|NCT04854785|OTHER|[11C]SL25.1188 PET scan|One \[11C\]SL25.1188 PET scan for MAO-B VT, and one MRI scan
223624472|NCT05173883|DRUG|injection ，CU-20401|Subcutaneous injection，cohort A 6 sites
223624473|NCT05173883|DRUG|injection ，placebo|Subcutaneous injection，just one site
223624474|NCT04699656|DRUG|Plazomicin Injection|single dose of plazomicin
223624475|NCT06148207|RADIATION|[18F]BF3-BPA Injection for PET Imaging|Two dosing dose groups were designed, 5±1 mCi or 9±1 mCi, with 20 subjects in each dose group, and the high dose group study was conducted after enrollment in the low dose group was completed.
223624476|NCT05135377|OTHER|Observational|Not applicable - observational study
223762149|NCT00351234|DRUG|Carnitine (drug)|Oral L-carnitine will be obtained from Sigma Tau Pharmaceuticals. Supplementation will be initiated at 50mg/kg body weight and increased to 100mg/kg body weight after one week.
223762150|NCT05699070|DRUG|DWC202211 100mg|"DWC202211 for 5 days~Aspirin 100mg"
223624477|NCT02210728|DRUG|methylphenidate or amphetamine product|Medication is titrated over a 4-week period with stepwise increments each week. Patients and significant others complete ADHD symptom scales at baseline and before each medication visit. Patients also complete side effects scales at baseline and before each medication visit. The gradual increase will continue until there is no further improvement in symptoms and in the Clinical Global Improvement Scale or side effects are such that further increases are not indicated. Once the optimal dose is reached, the subjects remain on this dose for the remainder of the study.
223624478|NCT02210728|BEHAVIORAL|Cognitive behavioral therapy|12 sessions of group cognitive behavioral therapy. Participants also receive individual coaching 3 times a week (twice over telephone and once in person). Coaching sessions are 15 minutes each in duration and are aimed at implementation, practice, and generalization of skills acquired in therapy.
223762151|NCT05699070|DRUG|DWC202212 5mg|"DWC202212 for 3 days~Rabeprazole 5mg"
223762152|NCT05699070|DRUG|DWC202211 100mg + DWC202212 5mg|"DWC202211 + DWC202212 for 5 days~Aspirin 100mg, Rabeprazole 5mg"
223762153|NCT05431062|DRUG|Bupivacain|%0.25
223762154|NCT05373511|OTHER|"3D/4D spine and posture analysis DIERS FORMETRIC 4D ,The Biodex Balance System SD-"|"3D/4D spine and posture analysis DIERS FORMETRIC 4D for postural analysis assessment~,The Biodex Balance System SD- for balance assessment"
224213646|NCT05043727|COMBINATION_PRODUCT|Exer gaming|exer gaming treatment plan will include perfect ten balance, wii skiing, wiicycling. Each Patient will receive twenty four sessions. Each treatment session was of 50 minutes with two minutes rest between each exercise.
224213647|NCT05043727|COMBINATION_PRODUCT|conventional treatment plan|it will receive conventional treatment plan which includes balance training, gait training, stretching and strengthening exercises.Each patient will receive twenty four sessions of conventional physical therapy. Treatment session will be of 50 minutes with 2 minutes rest period between each exercise.
224213648|NCT01037101|BEHAVIORAL|In Vivo Exposure Therapy|Three hours of exposure therapy in a high place
224213649|NCT01037101|BEHAVIORAL|Virtual Reality Exposure Therapy|Three hours of exposure therapy using a virtual reality system
224213650|NCT01037101|DRUG|D-Cycloserine|50 mg of DCS administered 30 minutes before the session
224213651|NCT01037101|DRUG|Placebo|50 mg placebo administered 30 minutes before the session
224213652|NCT01746563|DRUG|Ranibizumab|Intravitreal injection
224213653|NCT01746563|PROCEDURE|Laser therapy|Laser therapy
224213654|NCT00581386|DEVICE|LTS-D|supra-glottic airway device
224213655|NCT00581386|DEVICE|ProSeal Laryngeal Mask Airway|pre-existing double-lumen supra-glottic device
224213656|NCT00581386|DEVICE|Esophageal Tracheal Combitube (ETC)|disposable double-lumen tube
224213657|NCT02639819|DRUG|ɛ-Aminocaproic Acid|Intervention: intravenous ε-Aminocaproic Acid within 3 hours of symptom onset
224213658|NCT05787210|OTHER|Conventiional Physiotherapy|The Control group will be administered with Conventional Physiotherapy that Includes 5 minutes of trunk control training, 5 minutes walking in the hall with And without the therapist assistance, walker or crutches, and finally 5 minutes of Breathing exercises for Relaxation
224213659|NCT05787210|OTHER|Quadriceps Strength Training|The experimental group will be administered with the same baseline treatment such as 5 minutes of trunk control training, 5 minutes walking in the hall with or without the therapist assistance, walker or crutches and 5 minutes breathing exercises for relaxation. In addition, they were given strength training protocol intervention other than the baseline treatment. This strength training protocol include progressive resistance training program in which we gave leg lift (knee flexion and extension), Hip rotations, seated marching and the quadriceps muscles would be specifically targeted.
224213660|NCT01252836|DEVICE|AWBAT-D|Application of AWBAT-D bioengineered device
224213661|NCT01355523|DRUG|Melatonin (N-acetyl-5-methoxytryptamine)|6 mg oral melatonin daily 1 hour before bedtime
224213662|NCT01355523|DRUG|Placebo|6 mg oral placebo daily 1 hour before bedtime
223624479|NCT05568446|BEHAVIORAL|Social virtual reality|The participants will receive eight training sessions in 4 weeks (2 sessions per week). Each session is about 20 minutes.
223762155|NCT03523377|OTHER|prolonged overnight fasting|Three phone calls using motivational interviewing, support via SMS text.
223762156|NCT03523377|OTHER|usual care|Eat a heart-healthy diet and exercise for at least 30 minutes five days a week
223762157|NCT04787939|BEHAVIORAL|Early Feeding|Subjects will be permitted to drink liquids by mouth on the first day after surgery. Outcomes related to their care, wound healing, and quality of life will be followed for 30 days after surgery.
224213663|NCT05011019|DRUG|AL2846 capsules|AL2846 is a multi-target receptor tyrosine kinase inhibitor.
224213664|NCT00720733|BEHAVIORAL|Skills-Building Intervention|A 5-week intervention including 5 weekly sessions covering 8 varied coping skills with daily home practice. The skills are: 1) noting daily positive events; 2) capitalizing on positive events; 3) gratitude; 4) mindfulness; 5) positive reappraisal; 6) focusing on personal strengths; 7) setting and working toward attainable goals; and 8) small acts of kindness. Sessions are 1 hour long and include approximately 30 minutes per day.
224213665|NCT00720733|BEHAVIORAL|Personal Interview Group|There are 5 weekly sessions which will be approximately one hour long and will consist of personal interview. The interviews will include both quantitative and qualitative questions. Each session will have a separate theme including: Life 1) History; 2) Health History; 3) Personality; 4) Social Networking; and, 5) Meaning \& Purpose.
224213666|NCT01949207|PROCEDURE|EVLA|Endovenous laser ablation of great saphenous vein
224213667|NCT01949207|PROCEDURE|phlebectomies|removal of incompetent veins
224213668|NCT01949207|PROCEDURE|TRansluminal Occlusion of Perforators (TRLOP)|TRansluminal Occlusion of Perforators (TRLOP) closure of incompetent perforators.
224213669|NCT01168700|DRUG|aged garlic extract|Aged garlic extract, 1.2 g per day for 12 weeks
224213670|NCT01168700|DRUG|Placebo|Placebo 1.2 g per day for 12 weeks.
224316554|NCT04614246|DRUG|Elagolix|Tablet, oral administration
224316555|NCT04614246|DRUG|Placebo|Tablet, oral administration
224316556|NCT01851200|DRUG|Brentuximab Vedotin|Intravenous Brentuximab Vedotin at the dose of 1.8 mg/Kg every 3 weeks until disease progression or onset of unacceptable toxicity
224316557|NCT00973609|DRUG|5-Fluorouracil, Folic acid, Capecitabine; Bevacizumab|"Induction (and reinduction) treatment regimen for 24 weeks: Fluoropyrimidine, oxaliplatin and bevacizumab.~Following induction treatment regimen (for maintenance treatment): No maintenance treatment."
224213671|NCT01278199|OTHER|Medicals measures|"Rest in bed. Monitoring of respiratory frequency. Fixation of intravenous route. Administration of nasal oxygenotherapy in order to maintain SpO2 \> 90%. Administration of antituberculosis treatment, in case with active pulmonary tuberculosis known at admission or diagnosed during the stay.~If necessary a bronchial wash out of will be realized by a bronchial fibroscopy with measures of use of cold serum, adrenalin xylocain or terlipressin.~The administration of antibiotherapy by general mode according to the clinician appreciation.~The administration of terlipressin according to the clinician appreciation. Against the cough treatment administration according to the clinician appreciation."
223624480|NCT05568446|BEHAVIORAL|Traditional social skills|The participants will receive eight training sessions in 4 weeks (2 sessions per week). Each session is about 20 minutes.
223624481|NCT04273334|DRUG|68Ga-NEB|68Ga-NEB were injected into the patients before the PET/CT scans
223624482|NCT06659978|DEVICE|Device tolerance|"After being fed (breastmilk or formula), video will be turned on and the infant is placed on the Gentle Touch Stimulator (GTS) in deactivated mode. After a baseline period of 5- minutes the device will be activated. It will be deactivated after 10 minutes or earlier if there are any signs of distress from the infant. A 10-minute washout observation period will be followed.~Higher levels of comfort will be considered as fewer instances of stress behaviours. The sessions will be videoed, and coded at a later date using Observation of infant behaviours."
223624483|NCT06659978|OTHER|Acceptability questionnaire|Parental and clinical staff acceptability of the device assessed by interviewing person(s) of parental responsibility and clinicians involved in the trial. Interviews will be conducted by researcher following the intervention.
223624484|NCT02728180|DRUG|Xingnaojing injection|Xingnaojing injection (20 ml), IV (in the vein), every 12 hours for 10 days.
223624485|NCT02728180|OTHER|Standard care|Guidelines-based standard care for acute ischemic stroke.
223624486|NCT06667089|OTHER|Povidone-Iodine|The povidone-iodine group will receive a 10% povidone-iodine solution or gel applied directly to the wound after gentle cleaning, with the treatment applied according to a set frequency, typically twice daily. This antiseptic will be left on the wound for a brief period to enhance its antimicrobial action.
223624487|NCT06667089|OTHER|Chlorhexidine|The chlorhexidine group will receive a chlorhexidine solution, usually at a concentration of 0.5% to 2%, applied similarly after cleaning the wound. This solution will remain on the wound according to protocol guidelines, also typically applied twice daily. Both groups will be monitored for adverse reactions, signs of infection, and the overall effectiveness of wound healing throughout the treatment period.
223624488|NCT06928376|DRUG|Azacytidine;Cytarabine;Aclacinomycin;Chidamide;Venetoclax;Granulocyte colony-stimulating factor|"Azacytidine (75 mg/m2/day, days 1 to 7). Cytarabine (75-100 mg/m2 bid, days 1 to 5). Aclacinomycin(20 mg/day, days 1,3,5). Chidamide (30 mg/day , days 1,4,8,11). Venetoclax (400 mg/day, days 1 to 14,Combined with posaconazole reduced to 100 mg/day,Combined with voriconazole reduced to 200 mg/day ).~Granulocyte colony-stimulating factor (300 μg/day, day 0 until agranulocytosis recovery)"
223624489|NCT06928376|DRUG|"3+7"|"IA regimen:~Idarubicin (8-10 mg/m2) for 3 days . Cytarabine (75-100mg/m2, every 12 hrs) for 7 days.~DA regimen:~Daunorubicin(60 mg/m2) for 3 days. Cytarabine (75-100mg/m2, every 12 hrs) for 7 days."
223624490|NCT06938204|DRUG|INV-101|SAD MAD
223624491|NCT06938204|DRUG|INV-101 Placebo|SAD MAD
223624492|NCT05328752|DRUG|XXB750|XXB750
224213672|NCT01278199|OTHER|bronchial artery embolization|The bronchial artery embolization is practised within 48 hours which follow the hospital admission for non-severe acute hemoptysis.
224213673|NCT00707122|OTHER|Albumin and Crystalloids|"From day 2 to day 28 (or until ICU discharge, whichever comes first), fluid will be administered as follows:~1\. treated group: albumin will be infused on a daily basis, aimed to maintain its serum concentration equal or above 30 g/l (8). In particular, after the daily determination of its serum level:~1. if lower than 25 g/l, 300 ml of 20% of albumin solution (total amount of 60 gr) will be infused;~2. if equal or higher than 25 g/l and below 30 g/l, 200 ml of 20% of albumin solution (total amount of 40 gr) will be infused;~3. if higher than or equal to 30 g/l, no albumin will be infused. Albumin solutions will be infused over a period of 3 hours. Further infusion of crystalloids will be allowed, when necessary, according to the clinical judgment. No infusion of colloids, other than albumin, will be admitted."
224213674|NCT00707122|OTHER|Crystalloids|"Volume replacement will be performed in both the treated and the control group according to the early-goal directed therapy.~control group: crystalloids infusion will be allowed whenever necessary on a clinical basis. Albumin administration will be restricted to emergency use, as clinically judged and documented according to the standard criteria of each participating unit. No other colloids will be allowed."
224213675|NCT03875430|DIETARY_SUPPLEMENT|Humulus lupulus L|Patients with this intervention will receive a dietary supplement to relieve the symptoms of menopause
223624493|NCT05328752|DRUG|Placebo|Placebo
223624494|NCT05322226|BEHAVIORAL|Addiction follow-up before and after liver transplantation|Addiction consult and follow-up
223624495|NCT01329315|BEHAVIORAL|BMI-T|Brief Motivational Intervention (BMI-T): social worker/therapist-delivered intervention (25-minute tailored structured module).
223624496|NCT01329315|BEHAVIORAL|BMI-C|Computer-delivered intervention (BMI-C): computerized tailored 25-minute intervention.
223624497|NCT02031575|BEHAVIORAL|Interactive Treatment|Mobile phone text messaging service about reproductive health
223624498|NCT02031575|BEHAVIORAL|Basic Treatment|Mobile phone text messaging service about reproductive health
223624499|NCT02031575|OTHER|Control, comparator arm|
223624500|NCT04172584|BEHAVIORAL|correct use of the contraceptions|know the emergency contraception and how to use
223624501|NCT03346434|DRUG|Dupilumab|Solution for injection, subcutaneous (SC)
223624502|NCT03346434|DRUG|Matching placebo|Solution for injection, subcutaneous (SC)
223624503|NCT00297310|DRUG|tacrolimus|
223624504|NCT03525444|DRUG|VX-445/TEZ/IVA|Participants received VX-445/TEZ/IVA orally once daily in the morning.
223624505|NCT03525444|DRUG|IVA|Participants received IVA orally once daily in the evening
223624506|NCT03525444|DRUG|Placebo|Participants received placebo matched VX-445/TEZ/IVA orally once daily in the morning and placebo matched to IVA orally once daily in the evening.
223624507|NCT01544296|DRUG|KHK6188|
223624508|NCT01544296|DRUG|Placebo|
223624509|NCT05134688|DRUG|Magnesium sulfate|Tocolytic to stop preterm labor
224213676|NCT02221622|DRUG|Allopregnanolone injection (intravenous solution)|Allopregnanolone intravenous infusion
224213677|NCT02221622|DRUG|Placebo injection (intravenous solution)|Placebo intravenous infusion
224213678|NCT03753373|OTHER|Acupuncture|Acupuncture treatments will be utilizing the KB-2 points with manual manipulation accomplished by vigorously running the acupuncturists thumb nail up and down the handle until a perceived sensation change is noted in the subject's posteromedial tibia. A single, sterile 100mm needle will be inserted into the upper third of the medial tibiofibular ligament, followed by a second needle approximately 2-4 cm below the second needle. The needles will be manipulated as detailed above to achieve the sensation change along the posteromedial tibia. The needles will then be irregularly stimulated over the course of 5-7 minutes. The needles will be removed after the treatment is complete, which will last approximately 5-10 minutes (standard care).
224213679|NCT03753373|OTHER|Home Exercise Program|Subjects will be given a study diary to document the number of times they performed the standard of care prescribed home exercise program. Subjects will be advised to complete the stretching exercises daily and the strengthening exercises every other day.
224213680|NCT03746301|DRUG|Rivaroxaban(Xarelto,BAY 59-7939)|10mg, 15mg and 20 mg film-coated tablets
223624510|NCT02332538|PROCEDURE|532nm-laser photoselective vapo-enucleation of the prostate)|using Greenlight (532nm-laser) modified vaporization technique, PVEP (photoselective vapo-enucleation of the prostate)
223762158|NCT04458714|PROCEDURE|Aortoiliac angioplasty|In the CO2 arm we used manual injection of CO2 from a medicinal CO2 cylinder connected to a particle filter. Under water aspiration was used to prevent air contamination. Using a twenty mls syringe the required amount of CO2was aspirated using a three way tap and was followed my aspirating 3mls of saline to provide a fluid barrier. In the ICM arm the injection of contrast was done using 10-ml syringes with 5 mls of iodinated contrast media and 5 mls of saline solution per injection. The ICM used in all cases was Omnipaque 300 (Iohexol), a nonionic low osmolar contrast commonly in use in both hospitals.
223762159|NCT04512911|PROCEDURE|Endocardial ablation|Endocardial ablation of VT
224213681|NCT06530043|OTHER|Senobi exercises|Senobi exercise began with the comfortable sitting of participants with slow inhalation, filling the lungs for a count of 4-5 seconds and holding the breath for 2-3 seconds.
224213682|NCT06530043|OTHER|Jacobsons Muscular relaxation exercises|Jacobsons Muscular relaxation exercises started by tensing the muscles in the toes and then moving up the body tensing and relaxing each muscle group in turn (feet and toes, calves, thighs, hips, lower back, upper back, shoulders, arms, hands, neck, and head) and hold it for 5-7 seconds and released it for 5-7 seconds.
224213683|NCT04031066|DRUG|Velmanase Alfa|infusion i.v. treatment
224213684|NCT04031066|DRUG|Placebo|infusion i.v. treatment
224213685|NCT01005264|DEVICE|non-removable fiberglass|Two types of fiberglass bandages (Softcast3M®, 3M Health Care, St. Paul, MN (USA)) were used for construction of the pressure-relief apparatus
224213686|NCT01005264|DEVICE|Stabil-D®|Stabil-D Stabil-D® is composed of a specifically designed rigid, boat shaped, and rocker sole
224213687|NCT01433952|DIETARY_SUPPLEMENT|Thiamine|Vitamin B1
224213688|NCT01433952|DIETARY_SUPPLEMENT|Placebo|Placebo
224213689|NCT00503932|PROCEDURE|Proton Therapy|Radiation therapy 1 time a day, for 5 days in a row (Monday-Friday) for 6 -7 weeks (30-35 treatments in all).
224213690|NCT00503932|DRUG|Capecitabine|825 mg/m\^2 by mouth (PO) twice daily on days receive radiation.
224213691|NCT05221385|DRUG|Gentulizumab|Gentulizumab is administered IV once a week, with every 4 weeks as an administration cycle.
224213692|NCT02444156|OTHER|Indoor rowing|
224213693|NCT02107937|BIOLOGICAL|DCVAC/OvCa with Standard of Care|DCVAC/OvCa is the experimental therapy added on to Carboplatin and Paclitaxel
224213694|NCT02107937|BIOLOGICAL|DCVAC/OvCa sequentially chemotherapy|DCVAC/OvCa added sequentially after Carboplatin and Paclitaxel
224213695|NCT02107937|DRUG|Standard of Care|Carboplatin and Paclitaxel is Standard of Care First Line Chemotherapy
224213696|NCT05459051|DIAGNOSTIC_TEST|Rest-angina physiological assessment|The degree of stenosis required to cause angina at rest will be measured under double-blinded placebo controlled conditions using sequential intracoronary balloon inflations. This will then be correlated with various physiological indices, including FFR and NHPR.
223624511|NCT02332538|PROCEDURE|Holmium laser enucleation of prostate|Holmium-Yag laser enucleation of the prsotate
223624512|NCT02332538|PROCEDURE|Bipolar TURP|Bipolar transurethral resection of the prostate in saline
223624513|NCT04879030|DRUG|Beta-Lactams|The patient was randomized to use beta-lactams antibiotic
223624514|NCT04879030|DRUG|Fluoroquinolone|The patient was indicated to use a combination of beta-lactams and fluoroquinolones
223762160|NCT04512911|PROCEDURE|Endocardial- Epicardial ablation|Epicardial ablation of VT in addition to endocardial ablation
223762161|NCT04512911|DRUG|Antiarrhythmic medications|Addition of anti arrhythmic medication or dose increase
223624515|NCT04391374|PROCEDURE|an arterial reconstructive procedure|
223624516|NCT04227808|DRUG|Lenvima 4 mg Oral Capsule|The participants will receive treatment with lenvatinib for 12 months after recruitment or until disease recurrence, intolerance AEs, or death. In case of treatment-related adverse effects, interruption or reduction is allowed.
223624517|NCT01052727|PROCEDURE|Laparoscopic Cholecystectomy|
224213697|NCT05459051|DIAGNOSTIC_TEST|Exercise-angina physiological assessment|The degree of stenosis required to cause angina during exercise will be measured under double-blinded placebo controlled conditions using sequential intracoronary balloon inflations. This will then be correlated with various physiological indices, including FFR and NHPR.
224213698|NCT00644098|DIETARY_SUPPLEMENT|soluble fibre complex and medium chain triglycerides|
224213699|NCT00644098|DIETARY_SUPPLEMENT|cellulose and soybean oil|
224213700|NCT02169661|OTHER|Burger and Beetroot Study|50% fat, 10% beetroot extract
224213701|NCT03318328|OTHER|survey|
224316558|NCT00973609|DRUG|5-Fluorouracil, Folic acid, Capecitabine; Bevacizumab|"Induction (and reinduction) treatment regimen for 24 weeks: Fluoropyrimidine, oxaliplatin and bevacizumab.~Following induction treatment regimen (for maintenance treatment): Fluoropyrimidine + Bevacizumab."
224316559|NCT00973609|DRUG|5-Fluorouracil, Folic acid, Capecitabine; Bevacizumab|"Induction (and reinduction) treatment regimen for 24 weeks: Fluoropyrimidine, oxaliplatin and bevacizumab.~Following induction treatment regimen (for maintenance treatment): Bevacizumab monotherapy."
224213702|NCT05260983|BEHAVIORAL|Diabetes Prevention Education and Acceptance and Commitment Therapy|A brief diabetes prevention education and acceptance and commitment therapy engagement facilitation intervention. Acceptance and Commitment Therapy-informed materials (i.e. video, workbook, and activities) will retain facts about the condition, but will modify health messaging to clarify common inaccurate illness perceptions, reduce body size discrimination, and encourage psychological flexibility through framing illness perceptions, controllability awareness (i.e. ability to distinguish modifiable from unmodifiable components), non-judgmental awareness of what is occurring, willingness to allow experiences to occur, and the ability to step back from cognitions, acting according to personal values.
224213703|NCT05260983|BEHAVIORAL|Diabetes Prevention Education Only|A brief standard diabetes prevention education engagement facilitation intervention modeled from the Center for Disease Control and Preventions's National Diabetes Prevention Program.
224213704|NCT01308983|DRUG|Amiloride|Amiloride 10 mg orally once a day for 16 weeks
224213705|NCT01497873|DRUG|Topotecan|1.5 mg/m\^2 IV days 1, 2, 3, 4, 5 of each 21-day cycle until 6 cycle or more
224213706|NCT01497873|DRUG|Belotecan|0.5 mg/m\^2 IV days 1, 2, 3, 4, 5 of each 21-day cycle until 6 cycle or more
224213707|NCT01611168|OTHER|Treatment Algorithms|subjects in the intervention group will receive diabetes care from a well-trained registered nurse (RN) who will follow approved treatment algorithms/protocols for glycemia, high blood pressure, lipids and microalbuminuria.
224213708|NCT05016076|DRUG|Dexamethasone 8 mg|In the designated patients, 8 mg of dexamethasone or placebo will be given intravenously within 10 minutes after the induction of anesthesia.
224213709|NCT05016076|DIAGNOSTIC_TEST|Applied inspiratory pressure (10, 15, 20, or 25 cmH2O)|A two-handed head-tilt jaw-thrust maneuver will be performed to establish an open airway. Once apnea determined by end-tidal capnography occurs, a mechanical ventilation with the assigned peak inspiratory pressure will be initiated. The pressure-controlled mode will be used with an inspiratory-to-expiratory ratio of 1:2 and no positive end-expiratory pressure (PEEP), at a frequency of 15 breath·min-1 and with 100% oxygen, by the ventilator (Carestation 620, Datex-Ohmeda, Inc., Madison, WI, USA).
224316560|NCT01680497|DEVICE|Crosslinked hyaluronic acid dermal filler|All treatment details are at the discretion of the Investigator and should be guided by the Directions for Use. Up to 3 treatments will be administered: Initial treatment, optional top-up treatment at Day 14 post-initial treatment, and optional repeat treatment at Month 12 post-initial treatment.
224316561|NCT00725205|BIOLOGICAL|PegIntron (Peginterferon alfa-2b)|Peginterferon alfa-2b (injection pen) administered according to the product's labeling and current practice in Hungary (1.5 micrograms \[mcg\]/killogram \[kg\]) for 12 weeks. Those participants whose continued treatment was warranted beyond week 12 based on response received therapy for 24 or 48 weeks depending on the viral genotype.
223624518|NCT03470688|BIOLOGICAL|Originator|Originator anti-TNF agents
223624519|NCT03470688|BIOLOGICAL|Biosimilar|Biosimilar anti-TNF agents
223624520|NCT05813106|DRUG|Dexmedetomidine Hydrochloride|Intravenous dexmedetomidine 0.2 mcg/kg
223624521|NCT05813106|DRUG|normal saline|normal saline
224316562|NCT00725205|DRUG|Rebetol (Ribavirin)|Ribavirin capsules administered according to the product's labeling and current practice in Hungary (weight based daily) for 12 weeks. Those participants whose continued treatment was warranted beyond week 12 based on response received therapy for 24 or 48 weeks depending on the viral genotype.
223624522|NCT01221896|PROCEDURE|C11-Choline PET/CT|
223624523|NCT04436354|PROCEDURE|vaginoscopic office hysteroscopy|comparison of procedural time and pain scores of patients in different gynecologycal positions
223624524|NCT04461275|OTHER|ERAS 2.0|ERAS 2.0 accelerated protocol with adequate fluid management, pain control and truly minimally invasive surgery (intracorporeal anastomosis)
223624525|NCT01183689|BEHAVIORAL|Small Behavior Changes|"The Self-Regulation Plus Small Behavior Changes Intervention will focus on making small changes in diet and physical activity on a daily basis to prevent weight gain.~Diet: The dietary approach used in this group is to identify small changes in what and how much participants eat each day. The general concept is that these are small, manageable changes that will produce small reductions in overall intake and can easily be made on a daily basis and maintained over time.~Exercise: At the start of the program, participants will be given a pedometer and asked to record their current or baseline number of steps. They will then be given the goal of increasing their daily steps by 2000 steps per day over this baseline level."
223624526|NCT01183689|BEHAVIORAL|Large Behavior Changes|"The focus of this intervention group will be on periodically making large changes in diet and physical activity, with the goal of losing 5-10 pounds to buffer against the weight gain that often occurs during young adulthood.~Diet: Individuals with a BMI of 21-24.9 kg/m2 will be encouraged to lose 5 pounds; those with a BMI of 25-30 kg/m2 will be encouraged to lose 10 pounds.~Exercise: The Large Changes group will be instructed to gradually increase their minutes of physical activity until achieving 250 minutes per week (5 days/week with 50 minutes per day) using activities similar in intensity to brisk walking."
223624527|NCT03960749|DEVICE|Sprotte 25G needle, stylet reinserted|Lumbar puncture with small bore atraumatic needle, stylet reinserted before needle withdrawal
223624528|NCT03960749|DEVICE|Sprotte 25G needle, stylet not reinserted|Lumbar puncture with small bore atraumatic needle, stylet not reinserted before needle withdrawal
223762162|NCT06205849|DRUG|IRE + intratumoral mitazalimab (CD40 antibody) injection|Surgical IRE will be performed using the NanoKnife System with intraoperative ultrasound guidance via laparotomy under general anesthesia. Mitazalimab (CD40 antibody) will be administered 5 minutes after completion of IRE by slow injection into the center of the ablated zone using a small needle. Core needle biopsies of the tumor will be obtained immediately prior to IRE for identification of candidate tumor antigens. Peripheral blood will be obtained immediately prior to and 12 weeks after the study intervention for analysis of systemic immune effects.
224316563|NCT06084897|DRUG|TP (Paclitaxel with cisplatin or carboplatin) or PF (Fluoropyrimidine with cisplatin or carboplatin) regimen depended on investigator's choice.|"A maximum of six cycles was recommended for chemotherapy.~* Fluoropyrimidine (fluorouracil or capecitabine) with carboplatin or cisplatin;~* Paclitaxel (or Albumin-bound paclitaxel) with carboplatin or cisplatin."
224316564|NCT06084897|BIOLOGICAL|PD-1 inhibitor|Nivolumab or Pembrolizumab or Tislelizumab or Serplulimab or Toripalimab or Sintilimab or Camrelizumab
223624529|NCT03960749|DEVICE|Sprotte 22G needle, stylet reinserted|Lumbar puncture with larger bore atraumatic needle, stylet reinserted before needle withdrawal
223624530|NCT03960749|DEVICE|Sprotte 22G needle, stylet not reinserted|Lumbar puncture with larger bore atraumatic needle, stylet not reinserted before needle withdrawal
223624531|NCT03960749|DEVICE|Spinocan 25G needle, stylet reinserted|Lumbar puncture with small bore cutting needle, stylet reinserted before needle withdrawal
223624532|NCT03960749|DEVICE|Spinocan 25G needle, stylet not reinserted|Lumbar puncture with small bore cutting needle, stylet not reinserted before needle withdrawal
223624533|NCT02675946|DRUG|CGX1321|
223624534|NCT02675946|DRUG|Pembrolizumab|
223624535|NCT02675946|DRUG|encorafenib|
223624536|NCT02675946|DRUG|cetuximab|
223624537|NCT00546806|OTHER|Programs of Care|Two physiotherapy programs of care for the experimental groups; Physician-based education and activation for the active comparator group.
223624538|NCT01419236|DRUG|Testosterone Solution 2%|Administered topically
223624539|NCT01419236|DRUG|Placebo Solution|Administered topically
223624540|NCT01140529|DRUG|Dexmedetomidine|Bolus and continuous infusion
223624541|NCT01140529|DRUG|Haloperidol|Bolus doses
223624542|NCT01140529|DRUG|Saline|Bolus and continuous infusion
223624543|NCT00001483|DRUG|buproprion (Wellbutrin)|
223624544|NCT00001483|DRUG|sertraline (Zoloft)|
223624545|NCT00001483|DRUG|venlafaxine (Effexor)|
223624546|NCT04504734|DRUG|Bucillamine|100mg tablets
223624547|NCT04504734|DRUG|Placebo|100mg tablets
223624548|NCT04504734|DRUG|Bucillamine|200mg tablets
223624549|NCT01452906|DRUG|PA21 and Omeprazole with food|The maximum dose of PA21 will be 15.0 g/day. The maximum dose of Omeprazole will be 40 mg/day
223624550|NCT01452906|DRUG|No PA21; Omeprazole with food|The maximum dosage of Omeprazole will be 40 mg/day
223624551|NCT01452906|DRUG|PA21 with food, Omeprazole 2hrs later|The maximum dose of PA21 will be 15 g/day. The maximum dose of Omeprazole will be 40 mg/day
223624552|NCT06233240|DRUG|Sitagliptin and Metformin Hydrochloride Tablets Test product|Sitagliptin and Metformin Hydrochloride Tablets 50 mg/1000 mg Manufactured by: Mankind Pharma Limited, India
223624553|NCT06233240|DRUG|Sitagliptin and Metformin Hydrochloride Tablets Reference product|Sitagliptin and Metformin Hydrochloride Tablets 50 mg/1000 mg Manufactured by: Patheon Puerto Rico, Puerto Rico 00674
223624554|NCT03021785|BIOLOGICAL|TK001|TK001 will be administered intravitreal injection.
223624555|NCT00896857|GENETIC|RNA analysis|
223624556|NCT00896857|GENETIC|polymerase chain reaction|
223624557|NCT00896857|GENETIC|protein expression analysis|
223624558|NCT00896857|GENETIC|reverse transcriptase-polymerase chain reaction|
223624559|NCT00896857|GENETIC|western blotting|
223624560|NCT00896857|OTHER|immunoenzyme technique|
223624561|NCT00896857|OTHER|immunohistochemistry staining method|
223624562|NCT00896857|OTHER|laboratory biomarker analysis|
223624563|NCT00896857|PROCEDURE|breast duct lavage|
223624564|NCT04326972|DEVICE|ultrasound|• All patients with inclusion criteria do for them chest ultrasound .
223624565|NCT06397170|OTHER|Graded repetitive arm supplementary program|Patients in Group A will receive Graded repetitive arm supplementary program
223624566|NCT06397170|OTHER|Task based training|Patients in Group B will receive Task based training.
223624567|NCT01703910|DRUG|Arm A chemotherapy|
223624568|NCT01703910|DRUG|arm B chemotherapy|
223624569|NCT04621981|DRUG|Sodium Bicarbonate Ringer's Solution|This group was treated with Sodium Bicarbonate Ringer's Solution.
223624570|NCT04621981|DRUG|Normal Saline|This group was treated with normal saline.
223624571|NCT04292275|DEVICE|Biobeat Wrist Watch|Standard of care procedures and therapies for managing heart failure will be carried out according to each investigator's standard procedures. In addition, participants will be provided with a Biobeat wrist watch for continuous measurement and reporting of blood pressure data and with a smartphone to report weight.
223624572|NCT04292275|OTHER|Standard of Care|Standard of care procedures and therapies for managing heart failure will be carried out according to each investigator's standard procedures.
223624573|NCT00828243|DRUG|Nutrient|We administer stable isotopically labeled precursors of surfactant phospholipids (\[1-13C1\] acetate) and of surfactant protein-B (\[5,5,5-2H3\] leucine) to infants with neonatal respiratory distress syndrome. Using mass spectrometry, we measure incorporation of stable isotopically labeled precursors in tracheal aspirates and compare surfactant phospholipid and surfactant protein-B turnover.
223624574|NCT03010917|DRUG|Fish Oil with ethanol and placebo ethanol infusions|Fish Oil with ethanol and placebo ethanol infusions
223624575|NCT03010917|DRUG|Placebo with ethanol and placebo ethanol infusions|Placebo with ethanol and placebo ethanol infusions
223624576|NCT03156101|BIOLOGICAL|BinD19|Autologous T cells purified from the peripheral blood mononuclear cells of subjects, transduced with TCR-ζ/4-1BB lentiviral vector, expanded in vitro and then frozen for future administration.
223624577|NCT06285435|DIAGNOSTIC_TEST|prothrombin fragment 1+2|Blood sample
223624578|NCT05034367|DIAGNOSTIC_TEST|Mannitol challenge|Inhalation challenge with dry powder of mannitol with a maximal cumulative dose of 635 mg
223624579|NCT02250326|DRUG|nab-paclitaxel IV|nab-Paclitaxel intravenous (IV) infusion
223624580|NCT02250326|DRUG|CC-486|Oral CC-486
223624581|NCT02250326|DRUG|Duravalumab|
223624582|NCT05150028|BEHAVIORAL|Patient participation|Questionnaire
223624583|NCT05150028|OTHER|Clinician barrier reports|How many times a 7 question Survey on medication education practices is opened
223624584|NCT01109264|DRUG|Bendamustine hydrochloride injection|d1-2, i.v.gtt, 100mg/m2, 28 days per cycle, at most 6 cycles
223624585|NCT01109264|DRUG|Chlorambucil|d1-d2, d15-d16, p.o., 0.4mg/kg/day, 28 days per cycle, at most 6 cycles
223680530|NCT03177629|DRUG|treatment : H. pylori eradication|"treatment: H. pylori eradication (pantoprazole, amoxicillin, clarithromycin, metronidazole) to treatment group at visit 1 and to control group 2nd stage at visit 4.~Day 1-5: pantoprazole 40mg bid, amoxicillin 1000mg bid, PO Day 6 - 10: pantoprazole 40mg bid, clarithromycin 500mg bid, metronidazole 500mg tid, PO"
223624586|NCT04388592|OTHER|Nurse Practitioner (NP) Led Care Arm|The NP will conduct baseline consultation visits with the participants and their caregivers (if applicable). They will then initiate treatment for the participant's symptoms as appropriate (ie: depression treatment for depressive symptoms, fatigue management strategies), connect to resources in the community as needed (ie: rehabilitation programs, home care support, psychologist support) to optimize functioning. There will be scheduled follow visits and/or phone calls with the NP at 3 and 6 months.
223624587|NCT02867410|OTHER|No intervention|
223624588|NCT04098822|DEVICE|Virtue male sling|The Coloplast Virtue® Male Sling is a Class II, implantable, sub-urethral, permanent, non-absorbable support sling indicated for the surgical treatment of male SUI resulting from in-trinsic sphincter deficiency (ISD). The sling is manufactured from polypropylene and is sold for single use only. The device is a quadratic sling and consists of a knitted monofilament polypropylene mesh. The body of the device provides surface area for supporting the bulbous urethra.
223624589|NCT03743441|OTHER|Low-level Laser Therapy|LLLT, 904 nm wavelength, 3 Joules per treatment point in accordance with World Association for Laser Therapy (WALT) guidelines.
223624590|NCT03743441|OTHER|Sham Low-level Laser Therapy|Same procedure as in the LLLT group with the exception of laser irradiation (0 mW mean output power).
223624591|NCT03743441|OTHER|Exercise therapy|Concentric and eccentric exercises with a total duration of approximately 20 minutes.
223624592|NCT03743441|OTHER|Cryotherapy|Twenty minutes of cryotherapy applied to the Achilles tendon.
223624593|NCT03779542|PROCEDURE|cataract surgery|phacoemulsification and intraocular lens implantation
223624594|NCT00925834|BEHAVIORAL|Verbal suggestions|Verbal suggestions of a vasodilatory effect on cardiac vessels
223624595|NCT04310111|PROCEDURE|EUS-RFA|Use EUS-RFA to treat unresectable pancreatic cancer
223624596|NCT05306626|BEHAVIORAL|Building Emotion Awareness and Mental Health (BEAM)|The BEAM Program is based on best-practices in telehealth and science-based program design principles aimed at promoting maternal mental health and supportive parenting. The BEAM Program mobile application is designed and managed by Tactica Interactive and hosted on the University of Manitoba secure servers. The weekly group telehealth sessions will be led by clinical coaches (a mental health professional or trainee) and will use the secure videoconferencing platform Zoom (Healthcare license). Parent coaches will be mothers who have recently participated in another research group-based mental health intervention. Parent coaches will engage with participants on the community peer support forum and attend weekly telehealth sessions. The therapeutic aims of the BEAM program are to improve anxiety and depression symptoms and parenting skills using content that draws from the Unified Protocol, and emphasizes self-compassion, effective communication practices, and social support networks.
223624597|NCT00866177|OTHER|Laboratory Biomarker Analysis|Correlative studies
223624598|NCT00866177|DRUG|Selumetinib|Given orally
223624599|NCT05510089|DRUG|Etoposide|D1\~D2: 75mg/m\^2
223624600|NCT05510089|DRUG|Cytarabine|D1\~D2: 300mg/m\^2, q12h
223624601|NCT05510089|DRUG|PEG-rhG-CSF|D6: 6mg
223762163|NCT06205849|DEVICE|NanoKnife|Non-thermal tumor ablation using short pulses of high voltage electrical current delivered using 19-gauge needles placed via laparotomy using ultrasound guidance
224213710|NCT05016076|DEVICE|Tracheal intubation using video intubating stylet, video laryngoscopy, or direct laryngoscopy|In video intubating stylet group, a tracheal tube (ConvaTec, Berkshire, England, UK) in appropriate sizes is preloaded over the Trachway® video intubating stylet (TVI-4050, Markstein Sichtec Medical Corp, Taichung, Taiwan), which is introduced into oral cavity to visualize the epiglottis and guided to glottis via a monitor after full neuromuscular blockade is achieved. In video laryngoscopy group, a tracheal tube is preloaded over a GlideRite® stylet, which is specifically designed to work with GlideScope® video laryngoscope (Verathon Medical, Bothell, WA, USA). GlideScope® blade size 3 (GS-3) or 4 (GS-4) is used in all patients. In direct laryngoscopy group, tracheal tubes are prepared with a hockey stick-shaped stylet, and direct laryngoscopy is performed using a size-3 or -4 Macintosh blade (Rüsch Inc., Duluth, GA, USA).
223624602|NCT05161897|OTHER|Individualized Nutrition Therapy|Explained in arm/group description.
223624603|NCT05025839|OTHER|No Intervention|No Intervention takes place, Patients are being observed and classified according to disease severity
223624604|NCT02253914|DRUG|BILR 355 BS, solution|
223624605|NCT02253914|DRUG|BILR 355 BS, tablet|
223624606|NCT02253914|DRUG|Ritonavir|
223624607|NCT02253914|DRUG|Placebo|
223624608|NCT03585660|PROCEDURE|Diagnostic MRI|Participants will be scanned using a standard clinical prostate MRI protocol.
223624609|NCT03585660|PROCEDURE|Diagnostic Prostate Biopsy|Participants will undergo a prostate biopsy as their standard of care treatment. The provider performing biopsy will select areas to be biopsies as part of normal clinical judgment.
223624610|NCT03585660|DEVICE|Risk Map DSS tool|The Risk Map DSS tool will select up to 2 additional areas to be biopsied based on analysis of MRI images. The clinical provider will make final decision on areas to be biopsied.
223624611|NCT00204152|BEHAVIORAL|(Condition 1) Behavioral Activation; (Condition 2) Behavioral Activation and Stress Innoculation|
223624612|NCT00435409|DRUG|Sunitinib + Capecitabine|"Sunitinib administered orally at a starting dose of 37.5 mg once a day on a continuous regimen.~Capecitabine administered orally at a starting dose of 2000 mg/m\^2 per day \[1000 mg/m\^2 bid (twice daily)\] from days 1-14 every 3 weeks. Study treatment should be given until progression or withdrawal from the study for other reasons."
223624613|NCT00435409|DRUG|Capecitabine|Capecitabine administered orally at a starting dose of 2500 mg/m\^2 per day \[1250 mg/m\^2 bid (twice daily)\] from days 1-14 every 3 weeks. Study treatment should be given until progression or withdrawal from the study for other reasons. At the time of progression, patients may be eligible to crossover to single agent sunitinib, administered orally at a starting dose of 37.5 mg daily.
223624614|NCT00116103|DRUG|Tacrolimus Inhalation Aerosol|
223624615|NCT01295385|OTHER|NUCLEAR MAGNETIC RESONANCE IMAGING|"Techniques of nuclear magnetic resonance offer interesting perspectives in this context, and particularly to quantify the myocardial blood flow at rest and after cold pressor test in a population of healthy volunteers."
223762164|NCT05402397|DRUG|Losartan Potassium|Patients will receive losartan potassium for 30 days.
223624616|NCT01295385|OTHER|NUCLEAR MAGNETIC RESONANCE IMAGING|Techniques of nuclear magnetic resonance offer interesting perspectives in this context, and particularly to quantify the myocardial blood flow will be obtained by estimating myocardial blood flow at the venous coronary sinus site. This allows us to quantify a possible endothelial dysfunction in a reproducible way. No MRI study in diabetic patients has ever been led until now with this technique and to estimate the metabolic and structural abnormalities in this population.
223624617|NCT05836441|RADIATION|Exposure to white patches|Exposure to white patches
223624618|NCT05836441|RADIATION|Exposure to edge of white patches and normal skin around white patches|Exposure to edge of white patches and normal skin around white patches
223624619|NCT01553656|DRUG|cabozantinib capsules|cabozantinib capsules administered as 25-mg and 100-mg strengths once-daily until disease progression
223624620|NCT01553656|DRUG|cabozantinib tablets|cabozantinib tablets administered as 20-mg and 60-mg strengths once-daily until disease progression
223624621|NCT05635461|DRUG|CVN424|150 mg of either tablet or suspension formulation
223624622|NCT04794855|DIAGNOSTIC_TEST|laboratory tests|routine laboratory tests and biomarkers tests
223624623|NCT01666249|BIOLOGICAL|Immunoglobulin Anti-RhD|Participants will receive a single intramuscular administration of 300 mcg/2mL, correponding 1500 UI of Human Immunoglobulin Anti-RhD (Kamrho-D - Panamerican), up to 72 hours post exposition (child-birth).
223762165|NCT06165354|DRUG|0.9% NaCl physiological saline|Vaginal-spraying 0.9% NaCl physiological saline is prepared by extracting 10 mL from 0.9% NaCl intravenous infusion 500 mL PP bottle (B.Braun, Germany, product declaration No. VD-32732-19), and then pouring it into the same opaque metallic spraying 20 mL-bottle.
224213711|NCT05016076|DEVICE|Goal-directed hemodynamic therapy targeting cardiac index|Subjects of the GDHT group will be managed according to the ERAS algorithm utilizing ProAQT® parameters to maintain the cardiac index ≥ 2.5 l·min-1·m-2. In brief, if cardiac index \< 2.5 l·min-1·m-2, a bolus of 150 ml of crystalloid fluid will be given until the stroke volume variation is \< 10%. If cardiac index \< 2.5 l·min-1·m-2 despite the stroke volume variation of ≥ 10% following fluid challenge, continuous intravenous infusion of dopamine 5-10 μg·kg-1·min-1 will be administered. If mean arterial pressure is \< 70 mmHg despite cardiac index ≥ 2.5 l·min-1·m-2, intravenous infusion of norepinephrine 2-10 μg·min-1 will be used.
224213712|NCT05016076|DRUG|Placebo (0.9% sodium chloride)|Placebo of 0.9% sodium chloride will be given intravenously within 10 minutes after the induction of anesthesia.
224213713|NCT01981629|DEVICE|USCOM|The USCOM device will be used in addition to cardiac ultrasound in patients with shock.
224213714|NCT05077683|DRUG|Rivaroxaban 2.5 MG [Xarelto]|Experimental group: usual DAPT strategy (aspirin (≤100mg per day), clopidogrel (75mg per day) or ticagrelor (90mg twice daily)) + rivaroxaban 2.5mg twice daily.
224213715|NCT05077683|DRUG|DAPT strategy|usual DAPT strategy (aspirin (≤100mg per day), clopidogrel (75mg per day) or ticagrelor (90mg twice daily)) +
224213716|NCT05528926|OTHER|Non-Violent Resistance|"The program's core features are parental self-control and emotional support. In the NVR program, parents recruit supporters to help them deal with their children's problematic behaviours. Developing emotional control means that the parent opposes non-violent resistance to his child's behaviour, not escalating the explosive situation.~10 sessions (5 sessions per day for 2 consecutive days and two booster sessions at M1 and M3 after completion)."
224213717|NCT05528926|OTHER|Parent Management Training|"The gold-standard treatment for disruptive behaviour disorder in children and adolescents. The objective is to train parents to cope with the difficult situations they encounter, to teach them effective control strategies that are coherent and adapted to the 'deviant' behaviour of their children to reduce the intensity of events and their repercussions within the family.~10 sessions (5 sessions per day for 2 consecutive days and two booster sessions at M1 and M3 after completion)."
224213718|NCT05528926|DRUG|Treatment As Usual|The TAU group receives non-pharmacological and pharmacological therapies as usually provided in the participating centres but without having had a structured parent program in the last 6 months assessed at baseline, M1 and M3.
223624624|NCT05322798|PROCEDURE|High-frequency SCS|Continous high-frequency stimulation (frequency - 1kHz, pulse width - 30 µs).
223624625|NCT05322798|PROCEDURE|Low-frequency SCS|Continuous conventional stimulation (frequency - 30-60 Hz, pulse width - 250-500 µs).
223624626|NCT03860649|OTHER|Nordic Walking|24 sessions will be held twice a week, with each session taking an average of 60 minutes.
223624627|NCT03860649|OTHER|Jogging|24 sessions will be held twice a week, with each session taking an average of 60 minutes.
223624628|NCT03860649|OTHER|Dance|24 sessions will be held twice a week, with each session taking an average of 60 minutes.
223624629|NCT03860649|OTHER|Pilates Training|24 sessions will be held twice a week, with each session taking an average of 60 minutes.
223624630|NCT04581278|DIAGNOSTIC_TEST|KTD Innov-2|"The main objective of the present study (KTD Innov-2) is to validate the feasibility of SDI within a limited time frame to ensure its clinically relevant use, with a high level of evidence to consider its labelling as a medical device by health authorities prior to routine transfer and/or future marketing.~300 kidney transplant patients will be included in the KTD Innov-2 study with data collection, blood, urine and graft biopsies for biomarker analysis and conversion to SDI (decisional algorithms) and interactive multi-dimensional presentation on a web interface for use of the tool by transplant physicians and their patients."
223624631|NCT03519074|DRUG|TS-1 combined with cisplatin|Cisplatin 60mg/m2, day 1, every 21 days Oral TS-1 30mg/m2 bd, days 1-14, every 21 days (absolute dose of oral TS-1 will be 40-60mg bd days 1-14, every 21 days, depending on body surface area)
223624632|NCT06052475|DEVICE|Physiological Pacing Upgrade (Conduction System Pacing or Biventricular Pacing)|The approach for physiological pacing upgrade will be either His bundle pacing or left bundle pacing at the operator's discretion. If both of these are not achieved biventricular pacing will be performed.
223624633|NCT06052475|DEVICE|Continued RV Pacing (Right Ventricular Pacing)|Right ventricular pacing (apical or septal lead locations as per the implanting physicians' normal practice).
223624634|NCT03753334|COMBINATION_PRODUCT|MAG-EPA|5g/day of omega-3-rich fish oil including 4g of purified monoglycerides EPA, capsules, taken once daily, for 12 months
223624635|NCT03753334|DIETARY_SUPPLEMENT|Placebo group|5g/day of placebo (high oleic sunflower oil), capsules, taken once daily, for 12 months
223624636|NCT04436991|DIAGNOSTIC_TEST|Blood sampling|"At predefined time points through a venous catheter already in place. Max. volume to be withdrawn: Maximum 4ml/sample. Maximum 10 samples/patient.~A last blood sample will be taken, if necessary, after the end of antibiotic therapy, between day 7 and day 14. Though blood results preferably will be used from available data from tests already done during standard treatment.~Samples are collected in lithium-heparin tubes (without gel) and centrifuged immediately (within a maximum of 30 minutes after sampling) at room temperature: 8 minutes at 1885g.~Plasma is then collected and divided in two separated labelled Eppendorf tubes 1.5 ml and immediately frozen at - 80 °C. If this is not immediately possible, tubes are frozen at - 20 °C and at regular time points transferred to a freezer at - 80 °C (minimum twice a day)."
223624637|NCT04436991|DIAGNOSTIC_TEST|Sputum sample|Bacteriological specimen, such as blood cultures, urine samples, sputum ea., which are usually collected in every patient according to standard care will be retained. If there is bacterial growth, MIC's will be calculated on these strains for study purpose.
223624638|NCT04436991|DIAGNOSTIC_TEST|Hemoculture|Bacteriological specimen, such as blood cultures, urine samples, sputum ea., which are usually collected in every patient according to standard care will be retained. If there is bacterial growth, MIC's will be calculated on these strains for study purpose.
223624639|NCT04436991|DIAGNOSTIC_TEST|Urine sample|Bacteriological specimen, such as blood cultures, urine samples, sputum ea., which are usually collected in every patient according to standard care will be retained. If there is bacterial growth, MIC's will be calculated on these strains for study purpose.
223624640|NCT05884554|DRUG|PF-07817883|Experimental
223624641|NCT05344950|BEHAVIORAL|Audio + Radio (AURA)|Participants will receive personalized self-care information based on their symptoms and signs of complications (e.g., fatigue) from interacting with our voice assistant device, connected to a system that integrating the patient-reported outcome and objective data from passive RF sensing to provide continuous monitoring of patients' symptoms and complications after they are discharged home.
223624642|NCT04474470|DRUG|NT219|Dose escalation of NT219 as a single agent in adult subjects with recurrent and/or metastatic solid tumors
223624643|NCT04474470|DRUG|NT219 and ERBITUX® - Dose Escalation|Dose escalation of NT219 in combination with standard dose ERBITUX® in adult subjects with recurrent and/or metastatic squamous cell carcinoma of the head and neck and colorectal adenocarcinoma
223624644|NCT04474470|DRUG|NT219 and ERBITUX® - Expansion|Expansion cohort of NT219 at its RP2D in combination with standard dose ERBITUX® in adult patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck
223624645|NCT04391231|DRUG|Pentoxifylline Oral Product|Blinded Pentoxifylline (in suspension with SyrSpend SF)
223762166|NCT06165354|COMBINATION_PRODUCT|LiveSpo X-secret|"In Vietnam, LiveSpo X-SECRET is manufactured as two product lines: (1) Class-A medical device product (Product declaration No.220003286/PCBA-HN) under manufacturing standards approved by Hanoi Department of Health, Ministry of Health, Vietnam and ISO 13485:2016 (Certificate No YT117-19) and (2) comestic (Product declaration No.14981/22/CBMP-HA) under manufacturing standards approved by Hanoi Department of Health, Ministry of Health, Vietnam (Certificate No 118/CNĐĐKSXMP. Both product lines have the same probiotic composition.~The cosmetic type was used for the clinical trial conducted at Hanoi OGH. The Class-A medical device type was used for the clinical trial conducted at Bac Ninh CDC."
223762167|NCT01246791|DRUG|NPC-01|NPC-01, contains 1mg norethisterone and 0.02mg ethinyl estradiol will be administered orally under the fasting condition
223762168|NCT06580197|OTHER|Auricular Acupoint Therapy|Ear point diagnosis and treatment is one of acupuncture and moxibustion methods, which originates from the theory of acupuncture and moxibustion meridians and is the product of the combination of modern Chinese medicine and western medicine, including two parts: auricular acupoint diagnosis and auriculotherapy. Ear point diagnosis refers to the determination of auricle positive reaction points through vision, touch, pressure and other methods to diagnose diseases in some parts of the body on the basis of ear point theory. Ear point treatment refers to the use of certain therapeutic devices on ear points to achieve the purpose of prevention and treatment of diseases by stimulating ear points, which are often carried out simultaneously in clinical practice.
224316565|NCT06084897|RADIATION|Consolidation Radiation|IMRT/VMAT technique. Patients receive radiotherapy once daily, 5 days a week for an average of 5 weeks. Radiotherapy is delivered to achieve a dosage of 49.22Gy/23f or 50Gy/25f to PGTV for lymphnode metastasis only patients and 40.66Gy/19f or 40Gy/20f for organ metastasis patients. Radiation treatment is planned after chemotherapy completed.
223624646|NCT04391231|DRUG|Placebo|Placebo (SyrSpend SF only)
223624647|NCT05070936|OTHER|vestibular rehabilitation|Vestibular rehabilitation consisted of a total of 4 sessions, rearranged every 15 days. These exercises were prepared gradually to increase the vestibulo-ocular reflex and vestibulospinal reflex. The following exercises were done with the patients: both sitting and standing gaze stabilization exercises, neck joint range of motion exercises, 20 minutes walks outside, walking backward both open-and-closed eyes, and walking in tandem with both open-and-closed eyes. The therapist gave the patients a home exercise program. It was emphasized that the exercises should be applied as 10 repetitions. After the session, the exercises shown to the patients were explained in written form and given as home exercises. They were also asked to do home exercises 3 times a day, 10 repetitions, for 15 days. Evaluation of the patients was done at the beginning of the first session and the 4th session. Thus, 3 separate exercise sessions and a home exercise program were applied to the patients.
223624648|NCT04875325|OTHER|Standardized surveillance|Standardized 3-monthly surveillance with routine imaging and serum tumor marker testing.
223624649|NCT01853020|DRUG|THC|"Very low dose (0.0015 mg/kg = 0.21 mg in a 70 kg individual) THC, dissolved in alcohol. Administered intravenously over 10 minutes.~Low Dose (0.015 mg/kg = 1.05 mg in a 70 kg individual) THC, dissolved in alcohol. This dose is roughly equivalent to smoking approximately ¼ of a marijuana cigarette, or joint. Administered intravenously over 10 minutes.~Medium dose (0.03 mg/kg = 2.1 mg in a 70 kg individual) THC, dissolved in alcohol. This dose is roughly equivalent to smoking approximately ½ of a marijuana cigarette, or joint. Administered intravenously over 10 minutes."
223624650|NCT01853020|DRUG|Placebo|Control: small amount of alcohol intravenous (quarter teaspoon), with no THC over 10 minutes.
223624651|NCT05953532|OTHER|A1Control|diabetes self-management and diabetes technology education software
224213719|NCT05802095|DEVICE|Supplemental Feeding Tube Device|One end of the catheter is in such a way that milk comes into the bottle. The tip of the feeding catheter can be fixed to the mother's breast with a plaster so that it is in the baby's mouth. The tip of the catheter is placed inside the baby's mouth while the baby is sucking on its mother. While the mother is breastfeeding, milk is supplied to the baby from both the mother and the bottle. The baby will continue to suckle as he feels that plenty of milk is coming. To increase the flow of milk from the bottle, the mother hangs the bottle around her neck with the teat side down. The higher the bottle or milk container is held, the greater the flow of milk. It is an easy and safe method.
224213720|NCT00087399|DRUG|gabapentin|
224213721|NCT00087399|DRUG|antidepressant|
224213722|NCT01835470|DRUG|Abatacept|
223624652|NCT02498925|BEHAVIORAL|Behavioral Activation|Behavioral Activation is a psychosocial treatment for depression focused on gradually re-engaging patients with sources of reinforcement and reward in their environment (e.g., increasing activites and interpersonal interactions). In contrast to Cognitive Behavioral Therapy, and as the name implies, Behavioral Activation focuses on behavioral change strategies to improve mood and places little emphasis on cognitive restructuring techniques.
223624653|NCT03891706|DRUG|tumor-specific TCR-T cells|On day 0 and day 14, 0.5-5x10\^9 TCR-T cells will be infused intravenously (IV) over 1 hour,patients may choose to receive more cell infusions if they benefit from the treatment.
223762169|NCT00989820|DRUG|hyperbaric oxygen|30 session inhalation of 100% oxygen in a pressure chamber under 2.4 ATA for 90 minutes a day before surgery and 10 session hyperbaric oxygen therapy (as mentioned before) after surgery
224213723|NCT01405885|BIOLOGICAL|INO-3605|0.9mg of INO-3605 vaccine delivered ID followed by electroporation on Day 0, Week 8 and 24.
224213724|NCT01405885|BIOLOGICAL|INO-3609|0.9mg of INO-3609 vaccine delivered ID followed by electroporation on Day 0, Week 8 and 24.
224213725|NCT01405885|BIOLOGICAL|INO-3401|0.9mg of 3401 vaccine delivered ID followed by electroporation on Day 0, Week 8 and 24.
224213726|NCT01405885|BIOLOGICAL|INO-3609|0.3mg of INO-3609 vaccine delivered ID followed by electroporation on Day 0, Week 8 and 24.
224213727|NCT01405885|BIOLOGICAL|INO-3605 AND INO-3609|0.45mg each of INO-3605 AND INO-3609 vaccine delivered ID followed by electroporation on Day 0, Week 8 and 24.
224213728|NCT01405885|BIOLOGICAL|INO-3510|0.3mg each of INO-3605, INO-3609 AND INO-3401 vaccine delivered ID followed by electroporation on Day 0, Week 8 and 24.
224213729|NCT01405885|BIOLOGICAL|INO-3609|0.9mg of INO-3609 vaccine delivered ID followed by electroporation on Day 0, Week 16 and 24.
224213730|NCT01405885|BIOLOGICAL|INO-3609|0.9mg of INO-3609 vaccine delivered ID followed by electroporation on Day 0 and Week 8
224213731|NCT01405885|BIOLOGICAL|Seasonal Influenza vaccine|0.5ml of vaccine delivered IM
223624654|NCT03891706|DRUG|Interleukin-2|Aldesleukin 3,000,000 IU. IV.QD beginning within 24 hours of cell infusion and continuing for up to 5 days .
223624655|NCT05511259|OTHER|exercise|Square stepping exercise
223624656|NCT05517135|OTHER|Arm 1|Concurrent chemoradiotherapy (CCRT) using cisplatin (100 mg/m2 IV) or carboplatin (AUC 5 IV) with radiotherapy +/- adjuvant chemotherapy (AC). For AC, physicians can choose between cisplatin-5FU d1-4, q4w for 3 cycles, or capecitabine 650 mg/m2 bid for 12 months or 1000 mg/m2 bid oral, d1-21, q3w for 6 months
223624657|NCT05517135|OTHER|Arm 2|IC using cisplatin (80 mg/m2 IV) or carboplatin (AUC 3-5 IV) in combination with gemcitabine (1000 mg/m2 d1,8) or 5-fluorouracil (1000 mg/m2 bolus IV d1-4) or docetaxel (75 mg/m2 IV), and CCRT +/- metronomic capecitabine (650 mg/m2 bid oral for 12 months)
223624658|NCT05517135|OTHER|Arm 3|"IC using cisplatin (80 mg/m2 IV) or carboplatin (AUC 3-5 IV) in combination with gemcitabine (1000 mg/m2 d1,8) or 5-fluorouracil (1000 mg/m2 bolus IV d1-4) or docetaxel (75 mg/m2 IV), followed by either of the following:~1. RIBBON-LA-01 (NCT06093061)~2. CCRT + metronomic capecitabine (650 mg/m2 bid oral for 12 months)"
223624659|NCT05517135|OTHER|Group 1|Combination chemotherapy (using cisplatin or carboplatin with gemcitabine, 5-fluorouracil or docetaxel) and consolidative RT to the nasopharynx and neck (if good response to chemotherapy) +/- metastasis-directed therapy (surgery, radiofrequency ablation or RT) +/- immune checkpoint blockade (ICB) or capecitabine
223762170|NCT05843084|PROCEDURE|7T MRI network analysis for deep brain stimulation in Parkinson's disease|We hypothesize that the implementation of 7T MRI network analysis can enhance the effectiveness of DBS by improving motor symptoms and quality of life in PD patients.
224213732|NCT01405885|BIOLOGICAL|INO-3609|1.8mg of INO-3609 vaccine delivered ID followed by electroporation on Day 0, Week 8 and 24.
224213733|NCT00343811|DRUG|Modafinil|
224213734|NCT01272193|DRUG|insulin degludec/insulin aspart|Injected subcutaneously (under the skin) once daily prior to the largest meal of the day as monotherapy or combined with no more than 2 oral anti-diabetic drugs (OADs).
224213735|NCT01272193|DRUG|insulin glargine|Administered according to approved labelling either as monotherapy or combined with no more than 2 OADs.
224213736|NCT04839237|DRUG|Liraglutide|The treatment of Liraglutide lasted three months,During the first week: 0.6mg per day, subcutaneous injection;During the second week: 1.2mg per day, subcutaneous injection; From third week onwards,1.8mg per day, subcutaneous injection.
224213737|NCT04839237|DRUG|Liraglutide;metformin|The treatment of Liraglutide combined with metformin lasted three months.For Liraglutide,during the first week: 0.6mg per day, subcutaneous injection;during the second week: 1.2mg per day, subcutaneous injection; from third week onwards,1.8mg per day, subcutaneous injection.For metformin,during three months:0.5g each time, 3 times per day,oral.
224213738|NCT05031871|DRUG|HR17031 injection ；INS068 injection；SHR20004 injection|HR17031 injection dose+INS068 injection dose+SHR20004 injection dose+(INS068+SHR20004) injection dose
224213739|NCT05031871|DRUG|HR17031 injection ；INS068 injection；SHR20004 injection|INS068 injection dose+(INS068+SHR20004)injection dose+ HR17031 injection dose +SHR20004 injection dose
224213740|NCT05031871|DRUG|HR17031 injection ；INS068 injection；SHR20004 injection|SHR20004 injection dose+ HR17031 injection dose +(INS 068+SHR20004) injection dose+ INS068 injection dose
224213741|NCT05031871|DRUG|HR17031 injection ；INS068 injection；SHR20004 injection|(INS 068+SHR20004) injection dose+ SHR20004 injection dose+ INS068 injection dose+ HR17031 injection dose
224213742|NCT01222871|DRUG|Triamcinolone|Triamcinolone soaked nasopore dressing
224213743|NCT01222871|DRUG|Saline soaked sponge|saline soaked sponge
224213744|NCT01700751|DRUG|brentuximab vedotin|
223624660|NCT05517135|OTHER|Group 2|Combination chemotherapy (using cisplatin or carboplatin with gemcitabine, 5-fluorouracil or docetaxel) with or without ICB +/- maintenance ICB or capecitabine
224213745|NCT01472809|DRUG|ZYGK1|"ZYGK1 Tablets: 0.125, 0.25, 0.5, 1, 2, .... mg.~Dose escalation will continue till single AE occurs in any block of 3 volunteers on ZYGK1 or pharmacokinetic (dose linearity) saturation is reached or desired PK/PD effect is achieved"
224213746|NCT01472809|DRUG|Placebo|Placebo Tablets: 0.125, 0.25, 0.5, 1, 2, ... mg
224213747|NCT05250947|DEVICE|Angel® Concentrated Platelet Rich Plasma System|Angel® Concentrated Platelet Rich Plasma System and Angel® cPRP Processing Set will be used to process the PRP.
224213748|NCT05250947|DRUG|Platelet Rich Plasma|6 ml will be injected in up to 4 facet joints (2 levels) at 1.5 ml per joint
224213749|NCT01440647|PROCEDURE|Extubation to NIPPV|After extubation infants were placed on NIPPV as soon as all the extubation criteria were met
224213750|NCT01440647|PROCEDURE|Extubation to CPAP|After extubation infants were placed on CPAP
224213751|NCT05952427|OTHER|ACE Questionnaire|The only intervention consists of completing the validated ACE questionnaire
224213752|NCT02046473|PROCEDURE|Volumetric Flow in TIPS|Subjects who have a TIPS (transjugular intrahepatic portal-systemic shunt) for portal hypertension will undergo a clinical 3D ultrasound to determine if the TIPS is working properly. Additional ultrasounds will be obtained during the subject's clinically ordered ultrasound(s). These measurements will be taken by using a second ultrasound probe (plastic hand held device that is rubbed along the subject's abdomen). 15 minutes will be added to your clinically ordered exams that are completed 4 times a year.
224213753|NCT03867227|DEVICE|left atrial appendage occluder implantation|all patients will get implantation of LAA occluder
224213754|NCT04036227|DRUG|GS-248|GS-248 oral solution
224213755|NCT04036227|DRUG|Placebo|Placebo oral solution with the same composition to match active drug
224213756|NCT00543582|DRUG|MGCD0103 and Azacitidine|"In Part 1 of the study, up to 22 people to enroll will receive a single, oral dose (75 mg gelcap) of MGCD0103 and FB-MGCD0103 during their first 2 weeks in the study. Up to 22 additional people will receive a single dose of both MGCD0103 and TA-FB-MGCE0103. The next group of people to enroll will receive 2 different single doses (25, 50, 100 mg) of FB-MGCD0103 or TA-FB-MGCD0103 during their first 2 weeks in the study.~In Part 2 of the study, from Day 1-5 of each 28-day cycle, all subjects will receive a dose of azacitidine (75 mg/m2) either subcutaneously or through an intravenous device, and on days 5, 8, 10, 12, 15, 17, 19, 22, 24, 26, a single, oral dose (85 mg) of MGCD0103 until progression or unacceptable toxicity develops."
224213757|NCT02609282|BEHAVIORAL|Hourly prompts to stand delivered by Microsoft Outlook|
224213758|NCT02354365|DEVICE|Transpulmonary Pressure measurement|Transpulmonary pressure measurements are done by placing a catheter (often combined with a feeding tube) into the esophagus of a patient. Intermittently, the esophageal pressure is measured by inflating a small balloon on this catheter. The resulting esophageal pressure is accepted as representing the pleural pressure. The difference between this pressure and the airway pressure is the transpulmonary pressure and PEEP is raised or lowered to make this value zero so that the forces distending the alveoli are just balanced with the natural elasticity of the lung which wants to collapse the alveoli.
223624661|NCT05208476|PROCEDURE|Osteopathic manipulative medicine|A set of hands-on techniques used by osteopathic physicians to help diagnose, treat and prevent illness or disease.
223624662|NCT06114121|PROCEDURE|erector spinae plane block (ESP)|nerve block for abdominal pain. administered once immediately prior to spinal anesthetic standard of care.
223624663|NCT06114121|DRUG|Duramorph|100 micrograms (mcg) of morphine administered in the spinal medications one time.
223624664|NCT06114121|DRUG|Ropivacaine|Ropivacaine 0.5% between 20-40 milliliters will be administered once in the ESP block (in the spine) depending on patient weight to keep under the maximum dose.
223624665|NCT06114121|DRUG|Bupivacaine Injection|Bupivacaine 0.75% 1.4-1.7 milliliters (10-12 milligrams) spinal medication. administered one time.
223624666|NCT06288581|OTHER|Traditional toothbrush group|Children in this group will use a traditional brush with a traditional toothpaste first to clean their teeth then after 30 days they will use a U shaped brush with a traditional toothpaste for another 30 days.
223624667|NCT06288581|OTHER|U shaped toothbrush group|Children in this group will use a U shaped brush with a traditional toothpaste first to clean their teeth then after 30 days they will use a traditional brush with a traditional toothpaste for another 30 days.
224213759|NCT02086526|DRUG|Metformin|Approximately 37 patients will start metformin therapy 3 months after their visit 2. All other patients will receive metformin therapy at their visit 2.
224213760|NCT02565082|OTHER|Blood sampling - healthy volunteers|Four citrate blood sampling tubes (blue cap, 2.7ml) will be taken only once.
224213761|NCT02565082|OTHER|Blood sampling - sickle cell patients arm - stable condition|Four citrate blood sampling tubes (blue cap, 2.7ml) will be taken only once.
223624668|NCT05120830|BIOLOGICAL|Biological NTLA-2002|CRISPR/Cas9 gene editing system delivered by LNP for IV administration
223624669|NCT05120830|OTHER|Normal Saline IV Administration|The administration of IV normal saline
223624670|NCT04101968|DIAGNOSTIC_TEST|PET scan|3 PET scans to analyze the dopamine metabolism, acetylcholine and tau protein deposition in the brain.
223624671|NCT04101968|DIAGNOSTIC_TEST|neuroQWERTY|Analysis of free-text typing in a computer and/or a touch-screen device.
223624672|NCT05749146|BEHAVIORAL|Home Palliative Care|Patients/caregivers will be cared for by an interdisciplinary team that includes a social worker, nurse, community health worker, nurse practitioner, and physician.
223624673|NCT03760029|OTHER|Visit frequency|All subjects need to visit sites more frequently than in routine clinical practice.
224213762|NCT02565082|OTHER|Blood sampling - sickle cell patients arm- exsanguinotransfusion needed|Four citrate blood sampling tubes (blue cap, 2.7ml) will be taken only once, before and after the exsanguinotransfusion.
224213763|NCT02565082|OTHER|Blood sampling - sickle cell patients arm - vaso-occlusive crisis.|Four citrate blood sampling tubes (blue cap, 2.7ml) will be taken only once.
224213764|NCT03312582|DRUG|1% local metformin gel|After providing manual debridement in deep peri-implant probing depths, 1% metformin gel will be applied.
223624674|NCT05973942|BEHAVIORAL|Wingman-Connect|Training occurs in three 2-hr blocks over several days. Targeted Skills focus on protective factors (Four Cores) supportive of mental health, theoretically linked to reduced suicide risk, and essential to an Airmen's job success: (1) Healthy relationships and accountability spanning USAF and family/intimate relationships (Kinship); (2) Meaning and value in work and life (Purpose), (3) Informal and formal help-seeking (Guidance); and (4) Activities that give strength and balance emotions (Balance). Activities progress from individual to group skill-building activities. Kinship modules at operational base (FTAC) expand focus on growing and sustaining relationships with intimate partners, friends, and family; and Guidance more on senior mentors at work.
223624675|NCT05804838|OTHER|Mindfulness stress reduction program group|Conscious Awareness Based Stress Reduction program will be applied to women in this group, which will last for 8 weeks. Informed Voluntary Consent Form, Descriptive Characteristics Information Form, Psychological Well-Being Scale, Beck Depression Scale, Prenatal Attachment Scale and Conscious Awareness Scale will be administered to the pregnant women who make up the intervention group before the implementation of the Mindfulness-Based Stress Reduction program. The intervention group will receive 1 session per week. Each session will last 80 minutes. After completing the 8-week MBSR program, data collection forms will be re-applied to the pregnant women in the intervention group and posttest-1 measurements will be made. After the posttest-1 measurements, the pregnants in the intervention group will be given posttest-2 measurements of the pregnants in the intervention group, 1 month after the measurements.
223624676|NCT05941793|DRUG|MBS-COV|MBS-COV for inhalation
223624677|NCT05941793|DRUG|Placebo|Placebo for inhalation
223624678|NCT03137654|OTHER|Affective Training|Intervention includes up to 12 training sessions (\~45 minutes each). Training sessions includes practice on cognitive tasks embedded with emotionally salient stimuli. Tasks include a dual modality n-back and a directed attend/ignore memory task.
223624679|NCT03137654|OTHER|Neutral Training|Intervention includes up to 12 training sessions (\~45 minutes each). Training sessions includes practice on cognitive tasks embedded with neutral stimuli. Tasks include a dual modality n-back and a directed attend/ignore memory task.
223624680|NCT04890652|BEHAVIORAL|Digital intervention|All participants will receive a digital intervention designed to reduce stress and alcohol consumption over a 4-week period. The intervention will include two weekly sessions that integrate alcohol intervention with breathing-based stress management techniques.
223624681|NCT02969122|PROCEDURE|standard gastrectomy with D2 lymphadenectomy|standard distal or total gastrectomy and accorded D2 lymphadenectomy
223624682|NCT02969122|PROCEDURE|hyperthermic intraperitoneal chemotherapy|Intraperitoneal docetaxel of 100mg/m2 at 42℃ for 30 minutes
223624683|NCT02969122|PROCEDURE|Extensive intraperitoneal lavage|Lavage of peritoneal cavity with 1000ml saline for 10 times
223624684|NCT02969122|OTHER|Preoperative chemotherapy|Oxaliplatin 130mg/m2 D1 S-1 40-60mg Bid D1-14 Repeated every 3 weeks.
224213765|NCT03312582|PROCEDURE|Placebo|
223624685|NCT02969122|OTHER|Postoperative chemotherapy|SOX regimen postoperative chemotherapy (Oxaliplatin 130mg/m2 D1, S-1 40-60mg Bid D1-14, Repeated every 3 weeks) for surgery-first arm. Regimen for chemotherapy-first arm is determined according to the postoperative pathologic evaluation of response.
223680531|NCT01043042|OTHER|No interventions will be used in this study|No interventions will be used in this study
224213766|NCT01849939|DRUG|Fludarabin (post-allograft immunosuppressive therapy modulation and DLI Mononuclear cells from allogenic blood)|
224213767|NCT01363401|BIOLOGICAL|HYNR-CS inj|Intrathecal injection with 1ml/10kg of body weight at an interval of 26 days.
224213768|NCT01363401|OTHER|Control group|No treatment of HYNR-CS inj
224213769|NCT02267850|OTHER|Fixed Orthodontic Appliance Treatment|Patients are treated for full mouth fixed orthodontic appliance treatment by the qualified Principal Investigator (PI). Treatment and follow-up appointments per the traditional practices of the PI and dental office.
224213770|NCT02267850|DEVICE|OrthoPulse™|Patients carry out daily OrthoPulse™ treatments at home.
223680532|NCT02973633|DEVICE|Diffusion Tensor MRI (DTI)|Diffusion Tensor MRI (DTI) measures the diffusion of water in the heart, which allows the orientation of the muscle fibers in the heart to be determined.
223680533|NCT02973633|DRUG|Gadolinium DOTA Meglumine|Late Gadolinium enhancement
223680534|NCT05399576|DRUG|Nicorandil|Prophylactically combined intracoronary of Nicorandil and verapamil
223680535|NCT05399576|DRUG|Saline|intracoronary of 4ml saline
223680536|NCT03095547|DRUG|cyclosporine A|Pharmacokinetic assessment Area Under the plasma concentration: time Curve (AUC) 0-t
223680537|NCT03095547|DRUG|Posaconazole|Pharmacokinetic assessment AUC 0-tau
224213771|NCT02267850|DEVICE|Non-Functional OrthoPulse™|Patients carry out daily sham-OrthoPulse™ treatments at home. This is a non-functional device so patients do not receive photobiomodulation therapy.
224213772|NCT02934386|DEVICE|WinMedical WinPack device|
224213773|NCT01907724|DRUG|IDX719|IDX719 will be supplied as a 50 mg tablet for oral administration.
224213774|NCT01907724|DRUG|Simeprevir|Simeprevir will be supplied as 75 mg capsules for oral administration.
223680538|NCT03095547|DRUG|Pantoprazole|Pharmacokinetic assessment AUC 0-tau
224213775|NCT01907724|DRUG|TMC647055|TMC647055 will be supplied as 150 mg capsules for oral administration.
224213776|NCT01907724|DRUG|RTV|RTV will be supplied as 80 mg/mL solution for oral administration.
224213777|NCT03005379|DRUG|Fecal Microbiota Therapy (FMT)|Oral capsule-delivered FMT
224213778|NCT03005379|DRUG|Placebo|Oral capsule-delivered placebo
224213779|NCT05438290|DRUG|DPCP|topical immunomodulator
224213780|NCT02869295|DRUG|NKTR-214|Participants in the dose escalation cohorts will be treated every 21 days (q21d) or every 14 days (q14d) until tumor progression.
224213781|NCT02938910|OTHER|non interventional study|Non invasive imaging study without interventional procedures
224213782|NCT04749810|DRUG|Elizaria®|Induction cycle: 900 mg (3 vials of 30 mL, 10 mg/mL) intravenous infusion for 30 minutes once a week for 4 weeks. Maintenance therapy: 1200 mg (4 vials of 30 mL, 10 mg/mL) intravenous infusion for 30 minutes in Week 5, followed by 1200 mg every 14 days.
224213783|NCT02360410|BEHAVIORAL|Check Yourself App with Feedback|
224213784|NCT01505595|OTHER|Proprioceptive training|12 weeks
224213785|NCT01505595|OTHER|Sham proprioceptive training|Three times daily inspiratory muscle training (2x30 breaths) at an intensity of 10% Pi,max
224213786|NCT02545010|DRUG|Paclitaxel|"All patients will receive weekly paclitaxel at a pre specified dose of 80 mg/m2, 70 mg/m2, 60mg/m2 or 50 mg/m2 via intravenous infusion according to institution specific standard practices.~Cycles of chemotherapy will be administered weekly without interruption on Days 1,8,15,22,29,36 for a total of 6 weekly cycles in combination with LDWART. Post treatment assessments will be conducted starting Day 43.~Patients will then continue chemotherapy off trial protocol with weekly paclitaxel without concurrent LDWART starting Day 50 till disease progression, intolerable toxicity, patient refusal or deemed inappropriate to continue treatment by treating physician."
223624686|NCT04806724|BEHAVIORAL|Opening the Conversation|The intervention includes 5 weekly sessions (1.5 hours each), plus participant educational materials, and is delivered to couples via videoconference by a trained interventionist. Participants are asked to complete home activities between sessions. Sessions focus on development of communication and coping skills, with a focus on reproductive and sexual health distress.
223624687|NCT04806724|BEHAVIORAL|Side by Side|The intervention includes 4 weekly sessions (1.5 hours each), plus participant educational materials, and is delivered to couples via videoconference by a trained interventionist. Participants are asked to complete home activities between sessions. Sessions focus on development of communication and coping skills, with a focus on general cancer-related distress.
223624688|NCT02542657|DRUG|Clarithromycin|Given PO
223624689|NCT02542657|DRUG|Dexamethasone|Given PO
224213787|NCT02545010|RADIATION|LDWART (Low Dose Whole Abdominal Radiation Therapy)|"LDWART will be given at 60 cGy fractions, twice daily for two days, with a minimum of 4 hours inter fraction interval, starting on day 1 of each cycle of weekly paclitaxel for 6 weeks.~LDWART will not be administered if doses of weekly paclitaxel are withheld for any reason since it functions as a chemosensitizer. LDWART will be administered together weekly paclitaxel immediately at point of recovery from toxicity and patient is deemed to be able to continue with treatment by investigator."
224213788|NCT04335110|BEHAVIORAL|STELLA (Support via TEchnology: Living and Learning with Advancing Alzheimer's disease and related dementias)|STELLA consists of 8 sessions: 4 sessions one-to-one, with the Care Partner and a Guide, and then 4 sessions with one Guide with up to four Care Partners (total small group will include as few as two and as many as 4 Care Partners) Each weekly session takes about 1 hour. The first four sessions allow for development of the Care Partner-Guide working relationship. In these sessions, the Care Partners identify behaviors (both the person with dementia's and the Care Partner's) which are upsetting to the family. Care Partners will be taught to use an Activator, Behavior, Consequence (ABC) approach to identify activators of behaviors, the behaviors, and consequences of the behaviors. After they identify the ABCs, they will develop a plan to address the behavior and then test it. After the four one-to-one sessions, Care Partners will meet in small groups with a Guide. Effective communication strategies, engagement in pleasant events, and coping will be addressed.
224213789|NCT01805310|OTHER|Bowel preparation|Subjects randomized to the mechanical bowel preparation arm will be instructed to consume 300cc of magnesium citrate no later than 3PM on preoperative day number one.
224213790|NCT01805310|OTHER|No bowel preparation|Subjects randomized to no bowel preparation will be instructed to continue a regular diet on preoperative day number one.
224213791|NCT00803946|DRUG|Ibuprofen Tablets, 800 mg|
224213792|NCT04514146|OTHER|Water-only fasting|In-patient water-only fasting for at least 10 days followed by at least 5 days of refeeding
224213793|NCT00350519|DRUG|Epoetin alfa|Participants will receive epoetin alfa 300 IU/kg once daily subcutaneously for 10 days prior to surgery, on the day of surgery, and for four days after surgery.
224213794|NCT00350519|DRUG|Standard of Care|Participants will receive standard of care based on the Institution's treatment policy.
224213795|NCT06173895|DRUG|LY3454738|Administered subcutaneously (SC)
224213796|NCT06536790|OTHER|hang clean training|This include hang clean training thrice a week for twelve weeks
224213797|NCT06536790|OTHER|half squat training|This include half squat training thrice a week for twelve weeks
224213798|NCT04170959|DRUG|Metformin|Metformin 500 mg given 14 days before start until the end of radiation therapy. Once daily during the first 7 days, afterwards twice daily until the end of treatment.
224213799|NCT04170959|OTHER|No metformin|Standard of care without metformin.
224213800|NCT00591487|DRUG|Lidocaine|Subcutaneous infiltration with Active/Placebo solutions with tumescent technique previous to suction assisted lipectomy. Patient abdomen and back will be divided in 4 zones anterior and posterior, one side (left or right) will be infiltrated with active solution and the other with placebo. The allocation of the side will be made with random numbers.
224213801|NCT05183100|PROCEDURE|Tibial Nerve Neurodynamics|The patient will lie supine with the trunk and neck in neutral position. During the first stage, participants will receive passive straight leg raise of the affected side held for 20 seconds for 3 repetitions. In the second stage, hip adduction and internal rotation, ankle dorsiflexion, and ankle eversion are added in the straight leg raise position. Slow oscillations of the ankle movement for 1 minute will be applied, followed by holding the position for 20 seconds, for 3 repetitions. In the third stage, the head of the patient will be held in flexion with pillows while the same oscillation procedure as the second stage is performed. There will be a 2-minute rest between the stages.
224213802|NCT05183100|PROCEDURE|Lying in supine|Lying in supine position for about 13 minutes.
224316566|NCT06084897|RADIATION|Salvage Radiation|IMRT/VMAT technique. Patients receive radiotherapy once daily, 5 days a week for an average of 5 weeks. Radiotherapy is delivered to achieve a dosage of 49.22Gy/23f or 50Gy/25f to PGTV for lymphnode metastasis only patients and 40.66\~49.22Gy/19f \~23f or 40\~50Gy/20\~25f for organ metastasis patients. Radiation treatment is planned after disease progression when recommended by multidisciplinary team.
223624690|NCT02542657|DRUG|Ixazomib Citrate|Given PO
223624691|NCT02542657|DRUG|Pomalidomide|Given PO
223624692|NCT05195710|DRUG|Yttrium-90 (Y-90) resin microspheres|Given by scan
223624693|NCT04108364|BEHAVIORAL|Voice adaptive training for aphasia|Training with the VoiceAdapt tablet-based therapy app 25 hours (1 hr/day x 5 days/week x 5 weeks)
223624694|NCT03122639|DRUG|Atorvastatin 10mg|Atorvastatin 10 mg daily for 28 days will be randomly allocated to OSA patients regardless of adherence with CPAP. CPAP is a standard of care for OSA and will be prescribed by care providers not associated with this study based on clinical indications. The investigators will have no role in prescribing CPAP. Atorvastatin and placebo will be encapsulated to appear identical and dispensed by the research pharmacy.
224213803|NCT01361906|BEHAVIORAL|Sensomotoric training|"The intervention will be given once a week (2h per occasion) for twelve weeks.~Each occasion is planned to have the following structure:~10 min initial conversation about how participants are feeling today and how it felt after the last time.~70 min guided sensory motor learning. 10 min final talks, reflections on how it felt today."
224213804|NCT02997956|DRUG|Tocilizumab|Participants will receive Tocilizumab (ACTEMRA®) at 4, 6, or 8 mg/kg IV dose escalation on days 1, 29 and 57.
224213805|NCT02997956|PROCEDURE|Transcatheter Arterial Chemoembolization|Minimally invasive procedure performed in interventional radiology to restrict a tumor's blood supply
224213806|NCT03038178|DRUG|LAI plus multi-drug regimen|Liposomal Amikacin for Inhalation (LAI) is the experimental treatment which, in this single arm will be taken in conjunction with standard of care multi-drug treatment regimen
224213807|NCT01866488|DRUG|Misoprostol|
224213808|NCT01866488|OTHER|Placebo|
224213809|NCT00071409|DRUG|INGAP-Peptide|1.5 mL, once daily, self-administered SC injection for 90 days
224213810|NCT00071409|DRUG|INGAP-Peptide|1.5 mL, once daily, self-administered SC injection for 90 days
224213811|NCT00071409|DRUG|placebo|1.5 mL, once daily, self-administered SC injection for 90 days
224213812|NCT00410215|DRUG|picosalax plus bisacodyl|10 mg bisacodyl three and two nights prior to colonoscopy, followed by two sachets picosalax
224213813|NCT00410215|DRUG|picosalax|two sachets of picosalax taken orally the day prior to colonoscopy
224213814|NCT00410215|DRUG|sodium phosphate|two 45 ml bottles of sodium phosphate the day prior to colonoscopy
224213815|NCT01838161|BEHAVIORAL|Part II|Parents will be exposed to an educational video intervention if they are enrolled in this intervention condition.
223624695|NCT03122639|DRUG|Placebo|Placebo daily for 28 days will be randomly allocated to OSA patients regardless of adherence with CPAP. CPAP is a standard of care for OSA and will be prescribed by care providers not associated with this study based on clinical indications. The investigators will have no role in prescribing CPAP. Atorvastatin and placebo will be encapsulated to appear identical and dispensed by the research pharmacy.
224213816|NCT01838161|BEHAVIORAL|Part III|•video educational
223624696|NCT05846126|BEHAVIORAL|RehabCovid_Telematic|A multimodal and digitally-based cognitive training, physical exercise, and mindfulness intervention delivered remotely.
223624697|NCT05846126|BEHAVIORAL|RehabCovid_ImmersiveVR|A multimodal and digitally-based cognitive training, physical exercise and mindfulness intervention delivered face to face and through 360MK Virtual Reality technology
223624698|NCT05846126|BEHAVIORAL|Control_Condition|Traditional paper or pdf format multimodal intervention that will combine cognitive, mediation and physical activities.
223624699|NCT02455193|BEHAVIORAL|Exercise|
223624700|NCT02455193|BEHAVIORAL|Diet|
223624701|NCT05766514|DRUG|Cladribine|Subjects will be given 5 mg/m2 cladribine intravenously on days 1-5 of cycle 1 and on days 1-3 of cycles 2, 5, 6, 9, 10, 13, 14, 17 and 18.
223624702|NCT05766514|DRUG|Cytarabine|Subjects will be given 20 mg cytarabine subcutaneously twice daily on days 1-10 of cycles 1, 2, 5, 6, 9, 10, 13, 14, 17 and 18.
223624703|NCT05766514|DRUG|Decitabine|Subjects will be given 20 mg/m2 decitabine intravenously on days 1-5 of cycles 3, 4, 7, 8, 11, 12, 15 and 16
223624704|NCT05766514|DRUG|azacitidine or decitabine|Subjects will be given either 20 mg/m2 decitabine intravenously on days 1-5 of each cycle or 75 mg/m2 azacitidine intravenously or subcutaneously on days 1-7 of each cycle. The treating physician will determine which drug each subject will receive.
223624705|NCT05766514|DRUG|Venetoclax|Subject will take 400 mg venetoclax orally once daily on days 1-21 of each cycle.
224213817|NCT01838161|BEHAVIORAL|Part I|Parental Interviews
224316567|NCT00227110|DRUG|Pioglitazone|30 mg/d for 8 weeks and titrated to 45 mg/d until completing 6 months of treatment.
224316568|NCT00227110|DRUG|Placebo|Placebo is given to match pioglitazone.
223624706|NCT05380973|OTHER|Short fiber resin composite|resin composite reinforced with short glass fibers
223624707|NCT05380973|OTHER|Polyethylene ribbon fiber|resin composite reinforced with polyethylene ribbon fiber
223624708|NCT05828862|PROCEDURE|hypotension prediction index guidance|using hypotension prediction index guidance to prevent intraoperative hypotension
223624709|NCT05972278|DRUG|Obicetrapib|1 tablet daily
223624710|NCT05174247|OTHER|FFRct analysis|Software analysis of Cardiac CT to show extent of pericardial stenoses
223624711|NCT04688359|BEHAVIORAL|Guided Self Determination|Nurse lead intervention in primary care
223624712|NCT00001917|DRUG|O15|
223624713|NCT00001917|DRUG|[F-18] FP-TZTP|
224213818|NCT00237328|DRUG|Heparin|Heparin will be used as the intra-operative anticoagulant
224213819|NCT02595528|DRUG|AGN-199201 ophthalmic solution|1 drop of AGN-199201 ophthalmic solution Doses A, B, C in the eye.
224213820|NCT02595528|DRUG|AGN-190584 ophthalmic solution|1 drop AGN-190584 ophthalmic solution doses A, B and C in the eye.
224213821|NCT02595528|DRUG|AGN-190584 vehicle|Vehicle to AGN-190584
224213822|NCT02595528|DRUG|AGN-199201 + AGN-190584 Combination|1 drop AGN-199201 and AGN-190584 fixed combination ophthalmic solution in the eye.
224213823|NCT02595528|DRUG|AGN-199201 vehicle|Vehicle to AGN-199201
224213824|NCT02345928|DRUG|Part 1: CNTO 7160|Participants will receive Drug CNTO7160 administered IV infusion at escalating doses (with a starting dose of 0.001 mg/kg).
224213825|NCT02345928|DRUG|Part 2 (Asthma): CNTO 7160|Participants will receive Drug CNTO 7160 administered IV infusions (3 dose administrations over 4 weeks).
224213826|NCT02345928|DRUG|Part 2 (Atopic Dermatitis): CNTO 7160|Participants will receive Drug CNTO 7160 administered IV infusions (3 dose administrations over 4 weeks).
224213827|NCT02345928|DRUG|Part 1 and Part 2: Placebo|Participants will receive single IV infusion of placebo matched to CNTO 7160.
224213828|NCT02391883|DRUG|Clopidogrel|
224213829|NCT02177747|OTHER|Ophthalmoscopy conducted using a smartphone equipped with a compact addon|
224213830|NCT02177747|DEVICE|Smartphone|
224213831|NCT00407433|DRUG|Gemcitabine (Gemzar®), Oxaliplatin (Eloxatin®)|
224213832|NCT02358954|PROCEDURE|Quantitative sensory testing|Measurement of warm and cold detection and pain thresholds
224213833|NCT02358954|PROCEDURE|CHEPS|Measurement of amplitude and latency of cortically evoked potentials
224213834|NCT02358954|PROCEDURE|3D Turntable|
224213835|NCT02358954|PROCEDURE|Vection stimulation|
224213836|NCT06565728|DRUG|Vitamin D3 2000 UNT Oral Tablet|To assess the role of vitamin D3, versus sildenafil citrate, versus control group in pregnancies complicated by fetal growth restriction
224213837|NCT05103397|DRUG|methyl prednisolone|Low dose group .Group (A) 10 mg/Kg methyl prednisolone will be received after induction and before separation to (CPB).
224213838|NCT05103397|DRUG|Methyl Prednisolonate|High dose group.Group (B) 30 mg/Kg will be received after induction and before separation (CPB)
224213839|NCT05103397|DRUG|Placebo|Placebo group.Group (C) (25 patients) patients will receive placebo in form of normal saline
224213840|NCT02104128|DRUG|Bupropion|Bupropion MR will be given open label to all participants in the depression group. Participants will receive 150mg od for one week. The dose will then be increased to 150mg bd for the following 5 weeks. Participants in the control group will recieve no drug. Note that the study is not assessing the safety or efficacy of buprion-- it is using bupropion to assess the neural effects of altering central dopaminergic function in depressed patients.
224213841|NCT04283747|DIAGNOSTIC_TEST|Serum immunoglobulin titer|Serum IgG and IgM levels, VZV titer every 6 month at before rituximab administration 3 times
224213842|NCT00630682|DRUG|Dextroamphetamine|1 week placebo and 8 weeks 60mg d-AMP QD.
224213843|NCT00630682|DRUG|Placebo|9 weeks of placebo 60mg capsules QD.
224213844|NCT03392376|DRUG|Haloperidol Injection|ICU patients with diagnosed delirium are treated with 2,5mg haloperidol x 3 daily intravenously with additional as needed doses to a maximum of 20mg/daily.
224213845|NCT03392376|OTHER|Saline (0,9%)|ICU patients with diagnosed delirium are treated with 0,5ml isotonic saline x 3 daily and as needed doses to a maximum of 4ml/daily, corresponding to the algorithm in the experimental arm.
224213846|NCT04595227|DEVICE|Computerized pupillary light reflex assessment device|CPLRAD may serve as an effective screening tool for glaucomatous optic neuropathy, since they can dynamically detect abnormal pupillary responses from a novel sequence of light stimuli and functionally-shaped stimuli. CPLRAD can collect the clinical examination data and objectively measure the pupil dynamic parameters monocularly and/or binocularly as indicators from the retina and optic nerve in glaucoma patients.
223624714|NCT04146168|DIAGNOSTIC_TEST|Ultrasound|Closure of previously treated veins (with Venaseal) will be assessed via ultrasound.
223624715|NCT00493493|PROCEDURE|surgery (Pore Excision, Curettage, and Injection of Cymetra)|
223624716|NCT06271408|DRUG|Albuterol Sulfate, 2.5 Mg/3 mL (0.083%) Inhalation Solution|Aerosolized albuterol
223624717|NCT06271408|DEVICE|Vibrating Mesh Nebulizer|A vibrating mesh nebulizer will be used to deliver aerosolized albuterol
224213847|NCT00096382|BIOLOGICAL|aldesleukin|high dose: 720,000 IU/kg intravenously over 15 minutes every 8 hours for up to 5 days (maximum 5 doses) or low dose: 250,000 IU/kg subcutaneously daily for 5 days, after a two day rest, 125,000 IU/kg subcutaneously daily for 5 days for five weeks (2 days rest per week)
224213848|NCT00096382|BIOLOGICAL|filgrastim|10 mcg/kg/day daily subcutaneously until neutrophil count \>1x10\^9/1.
224213849|NCT00096382|BIOLOGICAL|therapeutic tumor infiltrating lymphocytes|Lymphocytes that are isolated from the tumor, grown in the laboratory to high amounts and then infused into the patient.
224213850|NCT00096382|DRUG|cyclophosphamide|60 mg/kg/day x 2 days intravenously over 1 hour
224213851|NCT00096382|DRUG|fludarabine phosphate|25 mg/m\^2/day intravenous piggyback daily over 15-20 minutes for 5 days
224213852|NCT00096382|RADIATION|radiation therapy|Patients will receive 2Gy of total body irradiation (TBI) at a rate of 0.07 Gy/minute using a linear accelerator.
224213853|NCT03836729|DRUG|Tenofovir alafenamide/emtricitabine|TAF/FTC will be available as 25/200 milligrams (mg) tablet. Subjects will be administered TAF/FTC 25/200 mg QD via the oral route.
223624718|NCT06271408|DEVICE|Metered Dose Inhaler|A metered dose inhaler will be used to deliver aerosolized albuterol
224213854|NCT03836729|DRUG|GSK3640254|GSK3640254 will be available as 100 mg capsule. Subjects will be administered GSK3640254 200 mg capsule QD via the oral route.
224213855|NCT00948025|DEVICE|Hollow tube nerve conduit, synthetic or biosynthetic|Appropriately size matched hollow tube nerve conduit (Neurotube, NeuroLac, NeuraGen, NeuroMatrix, NeuroFlex)
223624719|NCT06271408|DEVICE|Jet Nebulizer|A jet nebulizer will be used to deliver aerosolized albuterol
224213856|NCT00948025|OTHER|Processed Human Nerve Tissue|Implantation of appropriate length of processed human nerve tissue at time of surgery.
224213857|NCT06274125|PROCEDURE|Robotic-Assisted Laparoscopic Radical Prostatectomy|To evaluate kidney damage in patients undergoing robotic radical prostatectomy, NGAL measurement will be performed.
224213858|NCT05837065|OTHER|observing whether HCC patients having tumor micronecrosis|whether HCC patients having tumor micronecrosis or not
224213859|NCT04878874|DEVICE|Magnetic Tape|Magnetic tape® is applied without creating any tension over low back
224213860|NCT04878874|DEVICE|Kinesiology Tape|Kinesiology Tape is applied without creating any tension over low back
223624720|NCT05884307|OTHER|Trans Care Web App|an educational and interactive website designed to improve coping strategies of TNB individuals
223624721|NCT04534244|DEVICE|VBox Hybrid|Medical device intended to treat permanent venous insufficiency of saphenous veins and tributary veins in patients with superficial venous reflux
223624722|NCT02284204|DRUG|Midazolam, Ketamine and Sevoflurane|The combination of these three drugs were administered for the children of the intervention group in a attempt to improve the behavioral control. Midazolam and ketamine orally, sevoflurane inhaled.
223624723|NCT02284204|DRUG|Midazolam and Ketamine|The combination of these two drugs were administered orally for the children of the control group.
223624724|NCT06305286|DRUG|AT-1501|AT-1501 is a monoclonal antibody for Injection is a humanized immunoglobulin G1 (IgG1) kappa monoclonal anti-CD40L antibody that blocks CD40L binding to its receptor, CD40.
223624725|NCT01784731|BEHAVIORAL|Willingness to pay|
224213861|NCT03295539|DEVICE|'Indigo' Mechanical thrombectomy system|"Removal of acute clot from the artery causing ischaemia, using the mechanical aspiration system by Penumbra Inc called INDIGO"
224213862|NCT04013022|BEHAVIORAL|Exercise History|The groups will be divided based on their exercise history
224213863|NCT00216944|PROCEDURE|Tracheal intubation for respiratory care in preterm infants|Premedication with atropine 0.02 mg/kg and morphine 0.03 mg/kg
224213864|NCT00216944|PROCEDURE|Tracheal intubation for respiratory care in preterm infants|Premedication with glycopyrronium 0.005 mg/kg, thiopental 2-3 mg/kg (\< 2 kg 2 mg/kg), suxamethonium 2 mg/kg and remifentanil 0.001 mg/kg
224213865|NCT03167814|DIETARY_SUPPLEMENT|Diet group|In the diet, there is no long-chain triglycerides. Fat and protein needs are met with adding medium-chain-fat acid as oil and protein supplements to the diet. Diet has been constructed together with clinical nutrition specialist.
224213866|NCT04188223|BIOLOGICAL|Recombinant Hepatitis B (Bio Farma) Vaccine|Recombinant Hepatitis B vaccine produced by Bio Farma
224213867|NCT04188223|BIOLOGICAL|Recombinant Hepatitis B (Bio Farma) Vaccine®|Registered Recombinant Hepatitis B vaccine produced by Bio Farma
224213868|NCT00482287|DRUG|MTR105|Intravenous administration, dose escalating (4 arms), single dose
224213869|NCT00001633|PROCEDURE|Coronary magnetic resonance angiography imaging|
223624726|NCT00938158|BIOLOGICAL|albiglutide|single dose of subcutaneously injected albiglutide
223624727|NCT04854018|DRUG|Indocyanine green|Intravenous or intraparenchymal injection
223624728|NCT04289181|OTHER|Medically Tailored Meals|4 weeks of medically tailored meals
223624729|NCT04733326|DRUG|Ketorolac Tromethamine|final rinse with non-steriodal anti-inflammatory drug during single visit endodontic treatment in mandibular molar teeth with symptomatic irreversible pulpits and apical periodontitis
223624730|NCT04733326|OTHER|Cryotherapy|final rinse with cold saline during single visit endodontic treatment in mandibular molar teeth with symptomatic irreversible pulpits and apical periodontitis
223624731|NCT04733326|OTHER|Saline|final rinse with saline at room temperature during single visit endodontic treatment in mandibular molar teeth with symptomatic irreversible pulpits and apical periodontitis
223624732|NCT02222935|BEHAVIORAL|Balance Exercise Training|Balance exercise - 5 type (single leg squat, dead lift, step ups, forward reaches), 10 Repetition Maximum, 2 sets, five times a week and 2 weeks
223624733|NCT02222935|BEHAVIORAL|Routine Back exercise program|Back strengthening 5 exercises - pelvic bridges, prone plank, side plank, dead bug and prone lift ups, 10 Repetition Maximum, 2 sets, five times a week, 2 weeks
223624734|NCT03596827|BIOLOGICAL|E. coli strain E1392-75-2A dose 1E10 CFU|Diarrhoeagenic E. coli strain E1392/75-2A serotype O6:H16 belongs to Pathogen class 2 . The strain has a deletion of genes encoding the heat-labile (LT) and heat-stable (ST) toxins and can not produce any toxins. However, it continues to express Colonization Factor Antigen II (CFA/II) and provides 75% protection against challenge with an LT, ST, CFA/II strain
223624735|NCT03596827|BIOLOGICAL|E. coli strain E1392-75-2A dose 1E9 CFU|Diarrhoeagenic E. coli strain E1392/75-2A serotype O6:H16 belongs to Pathogen class 2 . The strain has a deletion of genes encoding the heat-labile (LT) and heat-stable (ST) toxins and can not produce any toxins. However, it continues to express Colonization Factor Antigen II (CFA/II) and provides 75% protection against challenge with an LT, ST, CFA/II strain
223624736|NCT03596827|BIOLOGICAL|E. coli strain E1392-75-2A dose 1E8 CFU|Diarrhoeagenic E. coli strain E1392/75-2A serotype O6:H16 belongs to Pathogen class 2 . The strain has a deletion of genes encoding the heat-labile (LT) and heat-stable (ST) toxins and can not produce any toxins. However, it continues to express Colonization Factor Antigen II (CFA/II) and provides 75% protection against challenge with an LT, ST, CFA/II strain
224213870|NCT03103659|OTHER|personalised care plan|Quality of life assessement in elderly cancer patients
224213871|NCT03640000|DIAGNOSTIC_TEST|Impedance measurements in Cardiac Resynchronization therapy|Bioimpedance measurements
223624737|NCT03596827|BIOLOGICAL|E. coli strain E1392-75-2A dose 1E7 CFU|Diarrhoeagenic E. coli strain E1392/75-2A serotype O6:H16 belongs to Pathogen class 2 . The strain has a deletion of genes encoding the heat-labile (LT) and heat-stable (ST) toxins and can not produce any toxins. However, it continues to express Colonizat
223680539|NCT03095547|DRUG|F901318|Pharmacokinetic assessment AUC 0-tau
223680540|NCT03095547|DRUG|Tacrolimus|Pharmacokinetic assessment AUC 0-t
223680541|NCT01830777|DRUG|Brentuximab Vedotin|Intravenously on Day 1 during re-induction therapy. Intravenously every 21 days during maintenance therapy
223680542|NCT01830777|DRUG|Mitoxantrone|Intravenously on Days 3-7 of re-induction therapy.
223680543|NCT01830777|DRUG|Etoposide|Intravenously on Days 3-7 of re-induction therapy.
224213872|NCT01456585|OTHER|Gemcitabine|
224213873|NCT01456585|DRUG|CP-870,893|
224213874|NCT01140178|DRUG|HPPH|Given IV
224213875|NCT02020733|DEVICE|Balloon catheter|
224213876|NCT02020733|DEVICE|metal cannula|
224213877|NCT05827783|PROCEDURE|Implementation of Bee Buzzy|"Implementation of Bee Buzzy It is defined as the use of a device called Bee Buzzy, which applies cold and vibrates in the form of a toy bee, by the researcher for fear and pain during phlebotomy in children.~Nurse performs phlebotomy on pediatric patients in the pediatric phlebotomy unit. During this application, the researcher puts the Bee Buzzy device on the child's arm just above the area from which blood was taken, and remains attached to the arm during the phlebotomy procedure. This device applies cold and vibrates. Pain and fear during the procedure are evaluated by the researcher, the nurse, and the child's parent."
224316569|NCT03862755|DRUG|Chemoprophylaxis with Low Molecular Weight Heparin (LMWH)|Early chemoprophylaxis means low-molecular weight heparin (LMWH) 3075 IU (WHO Units) injection subcutaneously one time a day no later than 24 hours after surgery. Early ambulation means activity out of bed no later than 24 hours after surgery. According to different risk level, patients received different thromboprophylaxis strategies. Early ambulation alone was for patients at low risk (Caprini 0-4), early chemoprophylaxis plus early ambulation was for patients at moderate (Caprini 5-8) or high risk (Caprini ≥9).
224316570|NCT04468516|DEVICE|KKT|Vibroacoustic sound waves applied focally.
224316571|NCT04468516|DEVICE|sham KKT|sham KKT
224213878|NCT05827783|PROCEDURE|Implementation of Puppet Zuzu|"Implementation of puppet zuzu It is defined as the use of a puppet that is seized and made to talk by the researcher for fear and pain during phlebotomy in children.~Nurse performs phlebotomy on pediatric patients in the pediatric phlebotomy unit. During this practice, a puppet is seized by the researcher and made to talk, and the child's attention is tried to be drawn. While this procedure is in progress, the researcher, the nurse, and the child's parent evaluate the pain and fear during the procedure."
224213879|NCT03639961|BEHAVIORAL|Integrated leading, managing and governing for results model|Integrated leading, managing and governing for results model is an intervention launched to improve institutional delivery.
224213880|NCT03639961|BEHAVIORAL|Traditional model|Traditional model is a health service delivery model already in place in the government health system.
224213881|NCT05940883|DRUG|Y-2 Sublingual Tablet|Subjects will receive one Y-2 sublingual tablet sublingually once daily for Day1 and Day 19 and twice daily for Day 6 to Day 18.
224213882|NCT05940883|DRUG|Y-2 Sublingual Tablet|Subjects will receive two Y-2 sublingual tablets sublingually once daily for Day1 and Day 19 and twice daily for Day 6 to Day 18.
224213883|NCT05940883|DRUG|Y-2 Sublingual Tablet|Subjects will receive Y-2 sublingual tablet with 3 different conditions once daily for Day1 Day 6 and Day 11. Day 1 with condition A, Day 6 with condition B and Day 11 with condition C.
224213884|NCT05940883|DRUG|Y-2 Sublingual Tablet|Subjects will receive Y-2 sublingual tablet with 3 different conditions once daily for Day1 Day 6 and Day 11. Day 1 with condition B, Day 6 with condition C and Day 11 with condition A.
224213885|NCT05940883|DRUG|Y-2 Sublingual Tablet|Subjects will receive Y-2 sublingual tablet with 3 different conditions once daily for Day1 Day 6 and Day 11. Day 1 with condition C, Day 6 with condition A and Day 11 with condition B.
223624738|NCT03596827|BIOLOGICAL|E. coli strain E1392-75-2A dose 1E6 CFU|Diarrhoeagenic E. coli strain E1392/75-2A serotype O6:H16 belongs to Pathogen class 2 . The strain has a deletion of genes encoding the heat-labile (LT) and heat-stable (ST) toxins and can not produce any toxins. However, it continues to express Colonizat
223624739|NCT02655328|OTHER|blood sample|blood sample
223624740|NCT02655328|OTHER|urine sample|urine sample
223624741|NCT04721678|BEHAVIORAL|Interpersonal psychotherapy|Internet-based interpersonal psychotherapy aimed at reducing symptoms of depression. The content of the intervention is divided into three parts: the assessment phase (the first four weeks), the focus phase (the following five weeks), and the end phase (the last week).
223624742|NCT03255902|BEHAVIORAL|Parenting classes|Parenting Classes:The Incredible Years curriculum
223762171|NCT05503173|BEHAVIORAL|MCBMAP|MCBMAP integrates motivational interviewing (MI) and cognitive-behavioral skill training interventions for unhealthy drinking with cognitive-behavioral and self- management approaches for chronic pain. The intervention is delivered through internet-based videoconferencing and supplemented with web-based content to support the intervention. The initial treatment session provides a rationale for addressing alcohol and pain together in the context of HIV management, and initiates MI related to alcohol use. Participants receive 6 additional treatment sessions over the subsequent weeks.
224213886|NCT05940883|DRUG|Placebo|Placebo, sublingually, single and multiple ascending dosing in group 1 and 2 subjects.
224213887|NCT01637961|DRUG|Alisertib|Given PO
224213888|NCT01637961|OTHER|Laboratory Biomarker Analysis|Correlative studies
224213889|NCT01918111|PROCEDURE|Renal denervation|Renal denervation will be performed via common femoral artery with standard endovascular technique and simplicity catheter
224213890|NCT01918111|DRUG|adenosine infusion treatment|Continue hypertensive medication
224213891|NCT04629183|OTHER|integrated clinical evaluation|30-day follow-up (telephone/database query) to define outcome Patients will receive standard care, independent of study participation.
224213892|NCT01838083|DRUG|Insulin glargine new formulation HOE901|Pharmaceutical form: solution Route of administration: subcutaneous
223624743|NCT01324817|DEVICE|Kai Spot (v 2.1)|The Kai Spot (v 2.1) provides a measurement of respiratory rate at a single point in time for neonates, pediatrics, and adults.
223624744|NCT01324817|DEVICE|Kai Continuous (v 1.0)|The Kai Continuous (v 1.0) provides a continuous monitor, measurement, and display of the respiratory rate, respiratory patterns, depth of breath, history/events and respiratory activity of a subject for neonates, pediatrics, and adults.
223624745|NCT02905097|PROCEDURE|Knee Replacement|Surgical replacement of arthritic knee with an implant
224213893|NCT04651283|OTHER|Traditional seat group|"Each child in the control group was asked to conduct or follow instructions given for him or her to conduct the following hand function tasks for three successive months of treatment, three times per week (every other day):~1. Building towers and shapes with different textures weights and bright colors.~2. Inserting different shapes in the correct hole.~3. Dropping pellets.~4. Stringing beads.~5. Copying square and triangle.~6. Opening the bottle and close it.~7. Folding and Crumpling paper.~8. Cutting paper by scissors.~9. Tracing line and connecting dots.~10. Reaching above the level of shoulder.~11. Reaching across the midline.~12. Squeezing water out of a sponge.~13. Buttoning and unbuttoning button.~14. Playing clapping games.~15. Turning pages in a book.~16. Lacing string.~17. Picking up a small piece of food and bringing it into the palm.~18. Moving a penny from the palm to the fingers.~19. Removing socks.~20. Brush the teeth."
224316572|NCT05911880|BEHAVIORAL|Plant-based diet for 14 days in patients with rheumatoid arthritis.|Patients with low to moderate disease activity of rheumatoid arthritis (2.6-5.1 DAS28-CRP) underwent a dietary intervention consisting of an individualized, isocaloric, and plant-based diet with 57% carbohydrates, 25% lipids, and 18% proteins (80% of plant origin) for 14 days, without any modification of their medication regimen and with restricted consumption of processed foods.
224316573|NCT02792608|BEHAVIORAL|Mindfulness-based Therapy|MBT will be delivered in group format, 135 minutes per week, for 5 consecutive weeks with 10-20 participants per group.
223624746|NCT04550858|DRUG|Rebamipide|rebamipide use for ttt of h.pylori infection
223624747|NCT04073121|DEVICE|Luminor DCB and Angiolite DES|Patient to undergo angioplasty with Luminor DCB and Angiolite DES
223624748|NCT03393585|OTHER|touchless vital signs monitoring|We measure Respiratory Rates in the Triage of Patients entering an Emergency Department by three different methods.
223624749|NCT05971316|DEVICE|Foam Roller|General Warm-up + Foam Roller
223624750|NCT04401735|DRUG|Polydeoxyribonucleotides|PDRN injection to epidural space
223624751|NCT04401735|DRUG|Normal saline|Normal saline
223624752|NCT01360671|DRUG|Sildenafil|Loading dose of 0.1 mg/kg for 30 minutes followed by maintenance treatment of 0.03 mg/kg.h for up to 14 days
223624753|NCT02926872|OTHER|There is no intervention in the study|
224213894|NCT04651283|OTHER|Adaptive seating equipment group|"Each child in the study group was asked to conduct or follow instructions given for him or her to conduct the following hand function tasks for three successive months of treatment, three times per week (every other day):~1. Building towers and shapes with different textures weights and bright colors.~2. Inserting different shapes in the correct hole.~3. Dropping pellets.~4. Stringing beads.~5. Copying square and triangle.~6. Opening the bottle and close it.~7. Folding and Crumpling paper.~8. Cutting paper by scissors.~9. Tracing line and connecting dots.~10. Reaching above the level of shoulder.~11. Reaching across the midline.~12. Squeezing water out of a sponge.~13. Buttoning and unbuttoning button.~14. Playing clapping games.~15. Turning pages in a book.~16. Lacing string.~17. Picking up a small piece of food and bringing it into the palm.~18. Moving a penny from the palm to the fingers.~19. Removing socks.~20. Brush the teeth."
224213895|NCT03317145|DEVICE|Neuromuscular electrostimulation (NMES) device|A mobile peroneal nerve stimulator
224213896|NCT03317145|DEVICE|Intermittent pneumatic compression (IPC) device|A foot pump or foot compression device
224213897|NCT01878747|BEHAVIORAL|Provider Tailored Intervention for Perioperative Stress|Provider Tailored Intervention for Perioperative Stress (P-TIPS) is developed based on the proximal-distal theory that suggested that in acute procedural settings specific adult behaviors directly affect children's distress and coping behaviors. P-TIPS aims at reducing preoperative anxiety in children via modifying adults' behavior.
224213898|NCT04321733|DRUG|Amoxicillin Clavulanate|Intravenous drug intake of our drug.
223624754|NCT02646826|OTHER|Placebo|Subjects are treated with Placebo tablets
223624755|NCT02646826|DRUG|Paxerol - Dose Level 1|Subjects are treated with the first dose level of Paxerol
224213899|NCT03536247|PROCEDURE|Initial therapy with papillary balloon dilation|patients will first undergo papillary dilation
224213900|NCT03536247|PROCEDURE|Initial therapy with intraductal lithotripsy|patients will first undergo intraductal laser or electrohydraulic lithrotripsy
223624756|NCT02646826|DRUG|Paxerol - Dose Level 2|Subjects are treated with the second dose level of Paxerol
223624757|NCT02646826|DRUG|Paxerol - Dose Level 3|Subjects are treated with the third dose level of Paxerol
223624758|NCT03979898|BIOLOGICAL|ASTROSTEM|Intravenous injection of Autologous Adipose derived mesenchymal stem cells. Dose : 15kg below : 0.5x10\^7cells/5mL 15kg \~ 25kg : 1x10\^8cells/10mL 25kg over : 1.5x10\^8cells/15mL
223624759|NCT05106881|DEVICE|Training with Gait Enhancing and Motivating System (GEMS-H) Robot|Training consists of 15 minutes task-specific training and 30 minutes functional gait training on varied environments with device.
223624760|NCT01752426|OTHER|Heavy Water (2H2O)|50 ml 70% 2H2O 3 times a day for the first 5 days followed by 60 ml daily for a total of 4 weeks. After the 5-day loading period, a 60 ml maintenance dose of 2H2O will be drunk at bedtime. At end of the 4th week, subjects stop drinking 2H2O (washout phase) and be followed from 6-12 weeks until beginning treatment with PCI-32765.
223624761|NCT01752426|DRUG|PCI-32765|420 mg orally once daily.
223624762|NCT01081691|BIOLOGICAL|CNTO 5825|10 mg/kg single dose IV or matching placebo
223624763|NCT01081691|BIOLOGICAL|CNTO 5825|3 mg/kg single dose IV or matching placebo
223624764|NCT01081691|BIOLOGICAL|CNTO 5825|For atopic patient:10 mg/kg single IV dose or matching placebo
223624765|NCT01081691|BIOLOGICAL|CNTO 5825|For atopic patient: 3 mg/kg single dose SC or matching placebo
223624766|NCT01081691|BIOLOGICAL|CNTO 5825|0.3 mg/kg single dose IV or matching placebo
223624767|NCT01081691|BIOLOGICAL|CNTO 5825|0.1 mg/kg single dose Intravenously (IV) or matching placebo
223624768|NCT01081691|BIOLOGICAL|CNTO 5825|1 mg/kg single dose IV or matching placebo
223762172|NCT05503173|OTHER|Brief Advice and Information|Through videoconferencing an interventionist will provide participants psychoeducation about the effects of alcohol and pain on HIV symptoms, advice/recommendations to reduce alcohol use, and a list of local treatment resources for alcohol and chronic pain.
223624769|NCT00941941|PROCEDURE|Non-mesh Hernia Repair|Non-mesh method for treatment of inguinal hernia without the use of a foreign material (mesh). It involves reinforcement of the weakened posterior wall of inguinal canal with a small, undetached strip of aponeurotic tissue of external
223624770|NCT00941941|PROCEDURE|Mesh Hernia Repair|Mesh method for treatment of inguinal hernias by use of an implant (mesh) to reinforce the weakened posterior wall of the inguinal canal. The mesh is made of polypropylene material.
223624771|NCT03658122|BEHAVIORAL|Parent-Child Care|Parent-Child Care (PC-CARE) is a 6-week parenting intervention for children aged 1-10 years and their caregivers. This behavioral intervention involves weekly behavioral assessments, teaching of new skills, in-the-moment practice using the new skills, and discussion of how to incorporate skills at home.
223624772|NCT06401369|PROCEDURE|Lingual brackets|These brackets will be used on the lingual surfaces of the upper and lower teeth.
223624773|NCT06401369|PROCEDURE|Buccal brackets|These brackets will be used on the vestibular surfaces of the upper and lower teeth.
223624774|NCT04365972|BEHAVIORAL|Attention Bias Modification (ABM)|A home-delivered version of ABM will be administered in this open trial. ABM will be comprised of 5 sessions with a variation of the dot-probe task in which the target probe always replaces the neutral stimuli to induce diversion of attention away from threat. This condition was found effective in reducing anxiety symptoms.
223624775|NCT04681235|OTHER|Training on VR|The training is aimed at improving the functioning of the motor sphere, including balance, gait, and upper limb function, as well as increasing the level of motivation and reducing the level of anxiety and depression. Game applications were selected based on therapeutic tasks of motor recovery.
223624776|NCT02269124|DEVICE|Hearing aid|The subject will wear a hearing aid at all times for a 3-month period. At school, he/she will wear this hearing aid in addition to using conventional measures (FM system and preferential seating).
223624777|NCT03278314|DRUG|tezacaftor/ivacaftor|orally administered TEZ/IVA combination therapy
223624778|NCT05814185|DEVICE|Periodontal distractor|different activation protocols of periodontal distractor
223624779|NCT04808115|DRUG|KDS-1001|"Cycles 1-6 (14 days per cycle)~1 x 109/KDS-1001 cells/infusion administered on day 1 of each cycle"
223762173|NCT04332653|DRUG|NT-I7|Administered by intramuscular (IM) injection
223624780|NCT03663829|OTHER|Non-Interventional|Non-Interventional
223624781|NCT03663829|OTHER|Non-Interventional|Non-Interventional
223624782|NCT06464354|PROCEDURE|The mammary artery harvesting by the pedicle technique|The mammary artery harvesting by the pedicle technique was used in the LIMA pedicle study group.
224213901|NCT04272177|OTHER|Shared decision making with the used of patient decision aids|PDA is used to explain choices of reversal drugs using SDM approach during consultation. The patients and medical staff explore the preferences with PDA and make decision together.
223624783|NCT06464354|PROCEDURE|The mammary harvesting using the skeletonization technique|The mammary harvesting using the skeletonization technique was used in the LIMA skeletonized study group.
223624784|NCT06464354|PROCEDURE|No intervention|No intervention was used in the control study group.
223624785|NCT04579146|OTHER|coronary computed tomographic angiographic (CCTA)|x-ray examination with contrast by a 64-slice CT coronary angiography.
224213902|NCT02292433|DRUG|PF-04937319 high dose|tablets, 150 mg with breakfast plus 100 mg with lunch, 7 days
223624786|NCT04790188|DIETARY_SUPPLEMENT|Nootropic|10g of Evo-Gamers® lemon flavor (HSN®). The nutritional composition per service is: L-Tyrosine (1000mg), Acetyl L-Carnitine HCL (500mg), Citicoline sodium (200mg), L-alpha-Glycerylphosphorylcholine (Alpha-GPC; 100mg), Vitamin C (150mg), Vitamin E (12.1mg), Vitamin B6 (3mg), Vitamin B2 (3mg), Vitamin A (810μg), Vitamin D (10μg), Vitamin B12 (5μg), Taurine (500mg), Caffeine (300mg), L-Theanine (150mg), Mango Leaves (2000mg), Huperzia Leaves (200mg). The dose to be administered is that recommended on the labeling and nutritional information of the nootropic which has been produced under GMP procedures and approved by the EFSA.
224213903|NCT02292433|DRUG|PF-04937319 low dose|tablets, 50 mg with breakfast plus 50 mg with lunch, 7 days
224213904|NCT02292433|DRUG|Placebo|tablets, breakfast plus lunch, 7 days
224213905|NCT06093828|DEVICE|TriFlo Tricuspid Flow Optimizer|An introducer sheath is inserted into the femoral vein over a stiff guidewire; the sheath extends into the common iliac vein and inferior vena cava and in the right atrium. The TFO device is oriented coaxiality to the tricuspid. Once released, the delivery catheter and the steerable catheter are removed the access site closure performed by a cardiovascular or vascular surgeon or with pre-implanted percutaneous sutures per site preference.
224213906|NCT04324398|OTHER|Cryotherapy|cold application
224213907|NCT03602898|BIOLOGICAL|Anti-Thymocyte Globulin|Given IV
224213908|NCT03602898|DRUG|Busulfan|Given IV or PO
223624787|NCT04790188|DIETARY_SUPPLEMENT|Placebo|10g of maltodextrin lemon flavor (HSN®).
223624788|NCT03274284|COMBINATION_PRODUCT|chemoradiation|chemoradiation in case of T1G3 BC after BCG failure.
223624789|NCT00335491|BEHAVIORAL|exercise intervention|12 weeks of 3x/week training on a recumbent eccentric stepper
223624790|NCT00335491|PROCEDURE|complementary or alternative medicine procedure|12 weeks of 3x/week training on the eccentron
223624791|NCT00335491|PROCEDURE|fatigue assessment and management|The visual analog scale will be used to assess muscle soreness from the previous exercise session
223624792|NCT00335491|PROCEDURE|physical therapy|12 weeks of 3x/week training on the eccentron
223624793|NCT01692184|DRUG|50 mg AVL-292|
223624794|NCT01692184|DRUG|100 mg AVL-292|
223762174|NCT04332653|DRUG|pembrolizumab (KEYTRUDA®)|Administered by intravenous (IV) injection
224213909|NCT03602898|DRUG|Cyclophosphamide|Given IV
224213910|NCT03602898|DRUG|Cyclosporine|Given IV or PO
224213911|NCT03602898|DRUG|Fludarabine Phosphate|Given IV
224213912|NCT03602898|DRUG|Methotrexate|Given IV
224213913|NCT03602898|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo peripheral blood stem cell transplantation
224213914|NCT03602898|OTHER|Quality-of-Life Assessment|Ancillary studies
224213915|NCT03602898|OTHER|Questionnaire Administration|Ancillary studies
224213916|NCT03602898|DRUG|Tacrolimus|Given IV or PO
223624795|NCT01692184|DRUG|200 mg AVL-292|
223624796|NCT01692184|DRUG|350 mg AVL-292|
223624797|NCT01692184|DRUG|Placebo capsules|
223624798|NCT01600885|DRUG|Guanfacine|Subjects will be given 3mg of guanfacine before the fMRI scan. Then when in the scanner, a bolus of ketamine (0.23mg/kg over 1 min) will be given during the visual fixation scan. Immediately after completion of the 1 min bolus, the participant will receive a steady state ketamine infusion of 0.58 mg/kg/hour and brain activation will be measured during a spatial working memory task. The entire scan will last approximately two and a half hours and the ketamine infusion will be up to one hour and 15 minutes.
223624799|NCT01600885|DRUG|Placebo|Subjects will be given a placebo before the fMRI scan. Then when in the scanner, a bolus of ketamine (0.23mg/kg over 1 min) will be given during the visual fixation scan. Immediately after completion of the 1 min bolus, the participant will receive a steady state ketamine infusion of 0.58 mg/kg/hour and brain activation will be measured during a spatial working memory task. The entire scan will last approximately two and a half hours and the ketamine infusion will be up to one hour and 15 minutes.
223624800|NCT00738998|BEHAVIORAL|Questionnaire|Questionnaires about pain and other symptoms, quality of life, and ability to work will be completed.
223624801|NCT00738998|OTHER|Phone Calls|A telephone system will call every 2 weeks so that you can rate your symptoms and how they interfere with daily activities. Each call will take about 5 minutes.
223624802|NCT05189275|DIETARY_SUPPLEMENT|Daily Beverage Intervention|Individuals will consume one of 4 beverages, daily for 8 weeks.
223680544|NCT01830777|DRUG|Cytarabine|Intravenously on Days 3-7 of re-induction therapy.
223680545|NCT00476801|DEVICE|German manufactured UVA1 light emitting device|The UVA1 dose will be up to 130 J/cm2.
223762175|NCT04049760|DRUG|migalastat HCl 150 mg|migalastat HCl 150 mg capsule
224213917|NCT03602898|RADIATION|Total-Body Irradiation|Undergo TBI
224213918|NCT01483222|DEVICE|QUIKDRAW Pro, Aspen Medical Products|Wearing an inelastic lumbar support (QUIKDRAW Pro, Aspen Medical Products) for 6 months
224213919|NCT01483222|DEVICE|MUELLER 4581, Mueller Sports Medicine|Wearing an elastic lumbar support (MUELLER 4581, Mueller Sports Medicine) for 6 months
224213920|NCT03671265|DRUG|SHR-1210|SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody.
224213921|NCT03671265|RADIATION|IMRT or VMAT|The IMRT or VMAT technique was used in our study.
224213922|NCT03671265|DRUG|Apatinib|Apatinib is a small molecule tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor-2.
224213923|NCT03101293|DRUG|TAK-831|TAK-831 film-coated tablet.
223624803|NCT01457651|PROCEDURE|Alveolar recruitment|"Four approaches:~1. CPAP 40 cm H2O~2. Peak pressure 40 cm H2O~3. PEEP 15 cm H2O for 300 sec~4. no intervention (controls)"
224213924|NCT02833857|DRUG|Etelcalcetide|A single IV-bolus dose of 0.035 mg/kg etelcalcetide into the venous line of the dialysis circuit at the end of a hemodialysis session.
223624804|NCT02910817|DRUG|Metformin|The metformin-treated group received metformin (1000 mg per day) with the start of controlled ovarian stimulation (COH) until the day of the pregnancy check.
223624805|NCT02910817|OTHER|Placebo|Placebo
223624806|NCT00716963|DRUG|Fluticasone propionate (Flovent Diskus) 250 mcg|Flovent Diskus 250 mcg
223624807|NCT00716963|DRUG|budesonide 400 mcg|budesonide 400 mcg
223624808|NCT00716963|OTHER|Placebo|Placebo
223624809|NCT03497663|OTHER|VIA Family intervention|Family based intervention
223624810|NCT03497663|OTHER|Treatment As Usual|Treatment As Usual
223624811|NCT00450970|DRUG|Oral Satraplatin|The SPERA protocol states that satraplatin may be continued until evidence of disease progression (at the discretion of the investigator), intolerable toxicity, withdrawal of informed consent, or non compliance. The treatment consists of satraplatin 80 mg/m2 administered by mouth once daily for five consecutive days (days 1-5) plus prednison 5 mg po twice daily. The treatment cycle is repeated every 35 days.
223624812|NCT00883363|PROCEDURE|Precondition|Precondition on a arm in four intervals at start of surgery for ruptured aortic aneurysm
223624813|NCT06404814|BEHAVIORAL|Transcutaneous electrical nerve stimulation (TENS)|(TENS) is a method of pain relief involving the use of a mild electrical current
223762176|NCT06514521|OTHER|Lutetium vipivotide tetraxetan|This is an observational study. There is no treatment allocation. The decision to initiate Lutetium vipivotide tetraxetan will be based solely on clinical judgement.
223762177|NCT05541783|PROCEDURE|laparoscopy-assisted distal gastrectomy Group|LADG
224213925|NCT04718857|BEHAVIORAL|Online education|health education
224213926|NCT03182920|DRUG|Lasmiditan|Oral administration
224213927|NCT03182920|DRUG|Placebo|Oral administration
224213928|NCT00190320|PROCEDURE|Induction of labor vs waiting|
224213929|NCT03637673|OTHER|No intervention|No intervention
224213930|NCT02542150|DRUG|acetate|acetate infusion, saline infusion, functional magnetic resonance imaging (fMRI) scan
223624814|NCT06404814|DIAGNOSTIC_TEST|Muscle Energy Technique|n Spencer's technique, there are seven steps as follows: shoulder extension along with elbow flexion, shoulder flexion with elbow extension, circumduction with compression, circumduction with distraction, shoulder abduction and internal rotation with elbow flexion, shoulder adduction and external rotation with elbow
223624815|NCT05953545|DRUG|Peginterferon Lambda|Study intervention for this protocol includes a weekly subcutaneous injection of peginterferon lambda at a dose of 180 mcg and an oral twice daily dosing of Lonafarnib at 50mg boosted with twice daily Ritonavir at 100mg for 48 weeks. Following 48 weeks of treatment the subjects will be monitored for outcomes during an additional 6-month time period.
223762178|NCT05541783|PROCEDURE|Totally laparoscopic distal gastrectomy|TLDG
223762179|NCT05407324|DRUG|Dazucorilant 300 mg|300 mg of dazucorilant will be administered once daily in 4 softgel capsules of 75 mg dazucorilant/capsule.
223762180|NCT05407324|DRUG|Dazucorilant 150 mg|Dazucorilant and placebo will be administered once daily in 4 softgel capsules, 2 capsules with 75 mg dazucorilant/capsule and 2 capsules of placebo equivalent.
223762181|NCT05407324|OTHER|Placebo|Placebo will be administered once daily in 4 softgel capsules of placebo equivalent.
223762182|NCT06120855|DRUG|Regulated cannabis from authorized pharmacies|"The intervention group is allowed to purchase regulated cannabis in authorized pharmacies. The intervention includes various offers: Participants can choose between cannabis sorts and delivery methods, and they are encouraged to shift from smoking cannabis to vaping cannabis-containing e-liquids, vaporizing cannabis blossoms or using oral cannabis. Vaping / vaporizing electronic devices are also recommended. At the same time, pharmacists offer opportunistic smoking cessation and problematic cannabis, alcohol use and further drug use counseling that conforms to motivational interviewing principles.~Study participants can choose between different cannabis-containing products such as dried cannabis flowers, cannabis concentrates (colloquially called hashish or hash), e-liquids and oral cannabis. Besides the cannabis products, participants can buy vaping or vaporizing electronic devices at the pharmacy (they are not considered as study products)."
223762183|NCT06120855|DRUG|Cannabis from the illicit market|The control group receives no intervention and is expected to continue purchasing cannabis from the illicit market.
224213931|NCT02542150|DRUG|alcohol|"a jello shot containing alcohol, a jello shot containing no alcohol, fMRI scan."
224213932|NCT06019130|DRUG|Nivolumab|Nivolumab during induction chemotherapy in all groups and during radiochemotherapy in patients with SD or PD after induction or metastases
224213933|NCT06019130|DRUG|Cisplatin|Cisplatin during induction chemotherapy and during radiochemotherapy in all groups
224213934|NCT06019130|DRUG|5-Fluorouracil|5-Fluoruracil during induction chemotherapy in all groups except of adults \> 25 years with metastatic disease at diagnosis
224213935|NCT06019130|DRUG|Gemcitabine|Gemcitabine during induction chemotherapy in patients \> 25 years with metastatic disease at diagnosis
224213936|NCT06019130|RADIATION|Radiotherapy|After induction therapy in all patients
224213937|NCT06019130|DRUG|Interferon beta-1a|In patients \< 26 years after end of radiochemotherapy for 6 months
224213938|NCT06019130|PROCEDURE|MRI|At diagnosis and 17 to 22 days after the beginning of cycle 3 of induction therapy
224213939|NCT06019130|PROCEDURE|PET|At diagnosis and 17 to 22 days after the beginning of cycle 3 of induction therapy, either as PET-CT or PET-MRI
224213940|NCT06019130|BEHAVIORAL|Patient-Reported Outcomes|For all patients at baseline, before radiochemotherapy, at day 100, and 2 years after enrolment
224213941|NCT05610930|OTHER|Front-of-pack label NutriScore 2.0|"Participants in the experimental arm can see, in case the product is ultra-processed, a black banner surrounding the Nutri-Score, with the word ultra-transformé, meaning ultra-processed, and no black banner otherwise. Participants in the control arm had no label at all. The intervention (the Nutri-Score 2.0) was added on the packaging on the products included in the 3 sets of images that participants recieved via the questionnaire."
224213942|NCT03862625|DEVICE|a modular adaptive seating system|
224213943|NCT03862625|OTHER|home exercise program for scoliosis|
224213944|NCT03899974|OTHER|Test meal|"Participants received in random order the three test meal (700Kcal, 80g available carbohydrates) containing breads prepared with amylose-rich wheat flours (70% or 85%) or conventional flour. Blood samples were collected at fasting and every 30 minutes over 4 hours. Breath hydrogen was evaluated as a marker of intestinal fermentation. Participants underwent Visual Analogue Scale to assess subjective appetite sensations.~After 4 hours, all participants consumed a standard lunch (700 kcal, 100 g available carbohydrates) identical on all the three experimental days to evaluate the second meal effect from breakfast to lunch."
224213945|NCT01326702|DRUG|Bendamustine Hydrochloride|Given IV
224213946|NCT01326702|OTHER|Pharmacological Study|Correlative studies
224213947|NCT01326702|BIOLOGICAL|Rituximab|Given IV
224213948|NCT01326702|DRUG|Veliparib|Given PO
224213949|NCT03426319|DIAGNOSTIC_TEST|Cardiovascular evaluation|Cardiovascular evaluation includes anamnesis, physical examination, laboratory tests, analysis of endothelial function, 24h blood pressure profile, Holter ECG, echocardiography and cardiac MRI.
224213950|NCT03615079|BEHAVIORAL|Cognitive behavioral therapy|An 8-week, internet-based cognitive behavioral therapy (CBT) program for depression
223624816|NCT00005906|DRUG|Octreotide|Treatment with octreotide starts at a dose of 50 micrograms(ug) twice a day which is increased to 100 ug twice a day after two weeks and to 200 ug twice a day two weeks later. After two months, if there is no response the dose shall be increased to 400 ug twice a day.
224213951|NCT05489679|DRUG|AC682|Participants will receive AC682 by mouth daily in 28-day cycles.
224213952|NCT01110499|DRUG|AGN-210961 Formulation 1|AGN-210961 Formulation 1 in one eye once daily for 7 days.
224213953|NCT01110499|DRUG|AGN-210961 Formulation 2|AGN-210961 Formulation 2 in one eye once daily for 7 days.
224213954|NCT01110499|DRUG|AGN-210961 Formulation 3|AGN-210961 Formulation 3 in one eye once daily for 7 days.
224213955|NCT01110499|DRUG|AGN-210961 Formulation 4|AGN-210961 Formulation 4 in one eye once daily for 7 days.
224213956|NCT01110499|DRUG|AGN-210961 Formulation 5|AGN-210961 Formulation 5 in one eye once daily for 7 days.
224213957|NCT01110499|DRUG|AGN-210961 Formulation 6|AGN-210961 Formulation 6 in one eye once daily for 7 days.
224213958|NCT01110499|DRUG|AGN-210961 Formulation 7|AGN-210961 Formulation 7 in both eyes once daily for 4 weeks.
224213959|NCT01110499|DRUG|bimatoprost ophthalmic solution 0.03%|bimatoprost ophthalmic solution 0.03% (LUMIGAN®) in both eyes once daily for 4 weeks.
224213960|NCT05683470|DRUG|RBS2418|RBS2418 will be administered orally at 200 mg two times per day (BID).
224213961|NCT04681456|BEHAVIORAL|There is no medical intervention for the purposes of this Registry.|There is no medical intervention for the purposes of this Registry.
224213962|NCT03630588|COMBINATION_PRODUCT|Surimi intervention|"The bioactive compounds used to obtain the surimi product are:~* Inulin (3.4 grams per 100 grams of surimi, 1.7 grams per 50 grams of surimi): Obtained from Chicory originating in Europe.~* EPA + DHA (740 mg per 100 g of surimi, therefore 370 mg per 50 g): Obtained from sardine and anchovy fish oil, encapsulated in tilapia gelatine, originating in the United States.~* Probiotic BPL1~It was a 3 months nutritional intervention. Volunteers will eat 50g per day of enriched surimi."
224213963|NCT03630588|COMBINATION_PRODUCT|Placebo|"Conventional surimi~It was a 3 months nutritional intervention. Volunteers will eat 50g per day of conventional surimi."
224213964|NCT03524937|DRUG|MELATONIN (HIGH DOSE)|Enteral melatonin (3mg) will be given at 21:00h daily, starting on the day of enrolment until ICU discharge, death, or up to 14 days
223624817|NCT04078841|DIETARY_SUPPLEMENT|ReaLife+ (RLP)|RLP is a dietary supplement containing Acetogenins, vitamin, mineral and amino acids.
224213965|NCT03524937|DRUG|MELATONIN (LOW DOSE)|Enteral melatonin (0.3mg ) will be given at 21:00h daily, starting on the day of enrolment until ICU discharge, death, or up to 14 days
224213966|NCT03524937|DRUG|PLACEBO|Study drug will be given at 21:00h daily, starting on the day of enrolment until ICU discharge, death, or up to 14 days.
224213967|NCT01255228|OTHER|Low glycemic index diet|The study expect that long-term low GI diet intervention have beneficial effects on regulate body composition of obese women
224213968|NCT02599883|RADIATION|Low-Dose Computed Tomography|Low-Dose Computed Tomography will be administered to COPD patients as part of COPD phenotypization.
223624818|NCT04078841|OTHER|Inert Brown powder|Brown powder Inert brown powder to look similar to RLP
223624819|NCT03821896|BEHAVIORAL|Conversation Cards for Adolescents and Goal-Setting|The intervention includes using an adolescent-tailored tool (a deck of cards) created by researchers at the University of Alberta and adolescents with obesity seeking weight management care. It contains a list of factors that make it easy or hard for teens to make and maintain healthy lifestyle changes. Its use will be paired with a S.M.A.R.T. goal-setting activity using principles of shared decision-making.
223624820|NCT03821896|BEHAVIORAL|Goal-Setting|Collaborative setting of S.M.A.R.T. goals using principles of shared decision-making.
223624821|NCT03584750|OTHER|Floating|Floating in specialized tank with full floatation and sensory deprivation.
223624822|NCT03584750|OTHER|Placebo floating|Floating in specialized tank with reduced floatation and sensory deprivation.
223624823|NCT00286442|DRUG|Alogliptin and metformin|Alogliptin 12.5 mg, tablets, orally, once daily and metformin for up to 26 weeks.
224213969|NCT05028686|OTHER|No intervention|Observational cohort
224213970|NCT01846832|DRUG|TMC435|150 mg taken orally (by mouth) as a capsule with food once daily for 12 weeks.
224213971|NCT01846832|DRUG|Pegylated interferon alfa-2a (PegIFNα-2a)|180 mcg administered according to the manufacturer's prescribing information as a 0.5 mL subcutaneous (under the skin) (SC) injection once a week in the morning or evening for up to 24 weeks.
224213972|NCT01846832|DRUG|Ribavirin (RBV)|1000 mg or 1200 mg administered according to the manufacturer's prescribing information for up to 24 weeks. If the participant's baseline body weight is \< 75 kg, the total daily dose of RBV will be 1000 mg, administered orally (by mouth) as 400 mg (2 tablets of 200 mg, intake with food) in the morning and 600 mg (3 tablets of 200 mg, intake with food) in the evening. If the baseline body weight is \> or = 75 kg, the total daily dose will be 1200 mg, administered as 600 mg in the morning and evening (3 tablets of 200 mg per intake, with food).
224213973|NCT05291156|DRUG|Cetuximab|"Cetuximab will be administered at 1st dose at 400 mg/m2 by i.v. infusion over 120 minutes.~The 2nd dose and subsequent doses will be performed at 250 mg/ m2 by i.v. infusion over 60 minutes, every week."
224316574|NCT04990427|DRUG|CLBS201|1 x 10\^6 to 300 x 10\^6 autologous CD34+ cells
224213974|NCT05291156|DRUG|Avelumab|Avelumab will be administered as a 1-hour IV infusion at flat dose of 800 mg every 2-week treatment cycle.
224213975|NCT05101356|BIOLOGICAL|Antineoplastic Vaccine|Given LabVax 3(22)-23 ID
224213976|NCT05101356|BIOLOGICAL|Sargramostim|Given SC
224213977|NCT05101356|BIOLOGICAL|Pembrolizumab|Given IV per standard of care
223624824|NCT00286442|DRUG|Alogliptin and metformin|Alogliptin 25 mg, tablets, orally, once daily and metformin for up to 26 weeks.
223624825|NCT00286442|DRUG|Metformin|Alogliptin placebo-matching tablets, orally, once daily and metformin for up to 26 weeks.
223624826|NCT04780165|DEVICE|Blephademodex|During the first 28 days of the trial, subjects will use one Blephademodex® eyelid hygiene wipe every evening per eye to clean the eyelids of both their eyes. At the start of the second period the Investigator will assess based on the GDS if the condition is resolved and manage accordingly: subjects will either continue with this regime if GDS is unchanged (further treatment phase) or revert to Blephaclean wipes every evening instead (maintenance phase), again to clean the eyelids of both their eyes.
223762184|NCT05929495|DRUG|Metformin|"The investigator will identify potential participants and confirm the diagnosis of GBM. Subjects will be screened within 6 weeks before starting treatment.~Treatment will involve:~* Administration of the standard or partial Stupp protocol (Radiotherapy + Temozolomide) in combination with Metformin for 6 weeks,~* Treatment with only Metformin for 4 weeks;~* Resumption of adjuvant TMZ + Metformin treatment continuously until the end of the enrollment period."
224213978|NCT03448809|BEHAVIORAL|Mind My Mind|An individual, modular and flexible cognitive and behavioural therapy
223624827|NCT03113032|OTHER|P-SEC Pre-Surgical Care|The P-SEC protocol is designed to deliver a focal mode of exercise-conditioning for motor performance to the knee extensor musculature. The latter requires a brief, machine-based gravity-resisted joint' movements (\<2 seconds). An exercise session (6-minutes, approximately) will require a patient to undertake 4 sets of movement, with sets separated by 60-seconds recovery (delivering a total of 36 exercises across 3 interspersed days).
223624828|NCT03113032|OTHER|Normal pre-surgical care|Routine pre-surgical care
224213979|NCT03448809|BEHAVIORAL|TAU (Treatment as Usual)|The children were offered anonymous counselling, supportive talk therapy, pedagogical advice, network meetings, and/or individual support in the school setting. A few were offered group-based CBT-programs for selected problems, but the access to manualized treatment was generally very restricted.
224213980|NCT04075188|DRUG|Aflibercept Injection|Patients will be treated with combined therapy to determine the synergy of this treatment, causing anti- Vascular Endothelial Growth Factor (anti-VEGF) to block neovascular exudation and photodynamic therapy to close aneurismal vessel and reduce choroidal vascular congestion.
224213981|NCT04987307|DRUG|Efavaleukin alfa|Efavaleukin alfa will be administered by subcutaneous (SC) injection.
224213982|NCT04987307|DRUG|Placebo|Placebo will be administered by SC injection.
223624829|NCT05289115|DEVICE|Experimental group/ Active HD-tDCS|Patients enrolled in this group will received 20 minutes of anodal HD-tDCS ( tDCS 1x1, developed by Soterix Medical Inc.) during 10 sessions. It will be delivered a 3mA intensity electrical current accordingly 10/20 International System on cortical representation zone of left diaphragmatic motor cortex using HD-tDCS.
223624830|NCT05289115|DEVICE|Control Group / Sham Group|10-sessions of anodal HD-tDCS( tDCS 1x1, developed by Soterix Medical Inc.) associated to respiratory training; for 20 minutes (each session) with a 3mA intensity.The device will provide a 30-second ramp-up followed immediately by a 30-second ramp down.
224213983|NCT04637685|DEVICE|Centurion Phacoemulsification System|Infusion Pressure
224213984|NCT02688309|DRUG|Ozurdex|Patients from the clinic will be considered for enrollment if they are receiving an intraocular injection of a steroid as part of standard care for macular edema or progressive fibrosis. Clinic patients who are receiving an intraocular injection of steroid (Ozurdex) as part of standard care who agree to participate will have an AC tap just prior to the intraocular injection of steroid and a second AC tap at a follow up visit 6 ± 2 weeks after the steroid injection.
224213985|NCT02688309|PROCEDURE|Surgery|The 60 patients from the operating room will be patients undergoing surgery for one of the following conditions: (1) Proliferative Diabetic Retinopathy, (2) rhegmatogenous retinal detachment with PVR, (3) rhegmatogenous retinal detachment without PVR, (4) macular pucker, (5) macula hole. All patients will be administered an AC (Anterior Chamber) tap just prior to the surgical procedure while in the OR.
224213986|NCT02688309|PROCEDURE|Anterior Chamber (AC) Tap|A paracentesis removing about 0.1 ml of fluid from the front part of the eye (the aqueous chamber) will be performed in the operating room just prior to surgery or in the clinic. In the operating room, the AC tap is done after the eye is anesthetized and cleaned with 5% povidone iodine for the surgery. A 30-gauge needle attached to a tuberculin syringe is inserted into the AC and 0.1 ml of aqueous is removed. The wound is self-sealing and has no effect on the surgery. In the clinic, the AC tap is done after drops of proparacaine and 5% povidone iodine is placed in the eye and a lid speculum is inserted. The patient is seated at a slit lamp and a 30-gauge needle attached to a tuberculin syringe is inserted into the AC and 0.1 ml of aqueous is aspirated and then the needle is removed.
224316575|NCT05622240|DRUG|99mTc-MIRC213|99mTc-MIRC213 were intravenous injected into the patients before the wholebody and SPECT/CT scans
224316576|NCT03962283|DRUG|Rifaximin|Rifaximin 200mcg four times daily
224316577|NCT03962283|DRUG|Placebo oral tablet|Placebo Rifaximin four times daily
224316578|NCT01229579|DRUG|Zinc Sulfate|2.5 ml Zinc supplement syrup daily containing 10 mg of elemental zinc from day 14 to 18 weeks of age.
223624831|NCT01445444|BEHAVIORAL|Habit Reversal Training|"* 8 weekly therapy sessions lasting 50 minutes based on the protocol outlined by Woods (2001).~* The overall focus of treatment is to provide patients with tools to help them manage and reduce hair-pulling.~* components:~* Session 1. (a) to develop an understanding of the subject's hair-pulling through an initial interview; and (b) to establish a protocol for ongoing assessment.~* Session 2. implement habit reversal, including awareness training, competing response training, and social support.~* Sessions 3-8. For subjects with a single hair-pulling site, Session 3 will review and practice HRT procedures and name solutions to problems that may have arisen. For those with multiple hair-pulling sites, treatment will be reviewed for the first site in the hierarchy."
223762185|NCT05349591|BIOLOGICAL|cePolytreg|The treatment group will receive cePolyTregs 2 weeks after islet transplantation as immunotherapy to improve islet survival and reduce the need for immunosuppression drugs.
223762186|NCT02312102|DRUG|Lenalidomide|Chemotherapy
224213987|NCT05319977|BEHAVIORAL|Mobile incentive-based intervention|a technology-based behavioral intervention to address maternal alcohol use with mobile breathalyzer technology or/and urinalysis for biochemical verification of alcohol use, contingent financial incentives on alcohol abstinence, and text-based health promotion.
224316579|NCT01229579|OTHER|Placebo|2.5 ml placebo syrup daily with containing no elemental zinc from day 14 to 18 weeks of age.
224316580|NCT03904589|DIAGNOSTIC_TEST|Quality of Life assessment|Quality of life will be assessed by means of the Seattle Angina Questionnaire and the Patient Health Questionnaire.
224316581|NCT00125112|BEHAVIORAL|Internet-based intervention designed to reduce binge eating and improve healthy weight regulation|
223762187|NCT02312102|DRUG|Velcade|Chemotherapy
223762188|NCT06272344|OTHER|Teleconsultation|Teleconsultation at 6 months
223762189|NCT05147272|DRUG|RP-6306 (oral PKMYT1 inhibitor)|RP-6306 in combination with gemcitabine
224213988|NCT00028938|BIOLOGICAL|epoetin alfa|
224213989|NCT00028938|DRUG|carboplatin|
224213990|NCT00028938|DRUG|paclitaxel|
224213991|NCT00028938|RADIATION|radiation therapy|
224213992|NCT03333382|DEVICE|Plastic biliary stent|Plastic biliary stent which functions largely as a wick to siphon bile flow from the site of anastomotic leak.
224316582|NCT03197181|DEVICE|transcranial direct current stimulation|Participants receive anodal or sham transcranial direct current stimulation while performing effort-based decision tasks.
223513619|NCT02193347|DRUG|Temozolomide|Subjects are treated with temozolomide (TMZ) at a targeted dose of 50-100mg/m2/d for 21 days every 28 days for up to 12 cycles. Subjects that have transitioned to a higher grade brain tumor at time of surgery will receive TMZ and radiation therapy per standard of care before starting TMZ cycles.
224316583|NCT02551484|DEVICE|Measurements using NIRS|
224316584|NCT02551484|DEVICE|TCPO2 measurements|
223513620|NCT06168006|BEHAVIORAL|Exercise|The experimental group will undergo an exercise program using the Recovery App. Participants will receive guidance from researchers about the functionality of the app. The Recovery App includes flexibility, strength, and aerobic training exercises, aiming for a progressive intensity and volume over the weeks.
223513621|NCT06168006|BEHAVIORAL|Control|They will receive an exercise booklet based on the Brazilian Physical Activity Recommendations (MINISTRY OF HEALTH, 2021), which recommend 150 minutes of physical activity for adults and seniors.
223513622|NCT01234714|OTHER|Non-invasive Magnetic Resonance Imaging (MRI)|Conventional pre-operative MRI
223513623|NCT01234714|PROCEDURE|Major liver resection|Hepatectomy of \>= 3 liver segments
223513624|NCT05855096|OTHER|Google Form Questionnaire|Google form questionnaire is performed by responders.
223513625|NCT03003065|DRUG|Temoporfin|A single treatment with Temoporfin (Foscan) 3 mg given intravenously followed by PDT with laser light at 652 nm (Ceralas, Biolitec, Germany) within 72 hours
223513626|NCT02096926|DRUG|Placebo|
223513627|NCT02096926|DRUG|Ibuprofen|400 mg PO
223513628|NCT02594072|RADIATION|stereotactic ablative radiotherapy|Linac-based prostate stereotactic radiotherapy, using Volumetric Modulated Arc Therapy planning and delivery, with fiducial marker and cone-beam CT based image guidance.
223513629|NCT02594072|RADIATION|external beam radiation therapy|Conventional intensity modulated radiotherapy, with fiducial marker or cone-beam CT based image guidance.
223513630|NCT02594072|DRUG|Zoladex ®|The preferred agent for the protocol is goserelin acetate (Zoladex ®) 3-month depot, but other LHRH agonists are permitted. The total duration of ADT will be 6 months for men with intermediate risk disease, and 18 months for those with high risk disease. ADT is to be initiated prior to the start of RT.
223513631|NCT03201380|OTHER|TEP scanner with choline|
223513632|NCT03692026|PROCEDURE|Immediate implant placement|implants will be placed in freshly extraction sockets with or without application of Hyaluronic acid and Melatonin mixture.
223513633|NCT03692026|DRUG|Hyaluronic acid and Melatonin Mixture|a mixture of hyaluronic acid and melatonin will be prepared and added topically to the implant surface, extraction socket and peri-implant area for the study group
223513634|NCT03399747|DRUG|Abb-R-CHOP|"Completely Excised LocalizedGastrointestinal CD20 (+) Diffuse Large B-cell Lymphoma~3 Cycles(1 Cycle:4weeks) of Rituximab Plus CHOP (Cyclophosphamide, Adriamycin, Vincristine, and Prednisolone) Immunochemotherapy"
223762190|NCT05750667|BEHAVIORAL|Cascade screening|FH is a genetic condition that causes high LDL cholesterol starting at birth. When one individual with FH is diagnosed, it is important that biological family members are also screened, since there is a 50% chance that each first-degree relative will have also inherited FH. More distant relatives may also have inherited FH. This evidence-based process is known as cascade screening.
224213993|NCT03333382|DEVICE|FCSEMS|FCSEMS has a relatively larger expansile diameter and membrane coating to provide an actual seal at site of anastomotic leak.
224213994|NCT02257827|RADIATION|IMRT|"The IMRT plan consisted of five - seven fields to deliver the same dose prescribed at the isodose line covering 95% of PTV.~The 3DCRT plan consisted of six fields to deliver a total dose of 70 Gy/ 25 fractions of a single daily dose of 2.8 Gy."
224213995|NCT04363294|DIAGNOSTIC_TEST|PYP scan|99mTc-labeled pyrophosphate
224316585|NCT02551484|OTHER|2-minute walk test|
224316586|NCT01062711|DIETARY_SUPPLEMENT|Whey or soy protein|Whey and casein are isolated milk proteins
224316587|NCT01144247|DRUG|alloreactive CTL|cellular immunotherapy with alloCTL
224316588|NCT03940625|DIAGNOSTIC_TEST|Cardiac MRI and echocardiography, laboratory parameters|Cardiac MRI including cine imaging (volumetric determination of LV-EF), late gadolinium enhancement, strain analysis, T1 mapping and T2 mapping Echocardiography including 3D-EF, diastolic function and strain analysis Determination of laboratory parameters including cardiac enzymes (Troponin T and high sensitivity Troponin T) and cardiac markers (BNP and NT-pro BNP)
224316591|NCT04054557|OTHER|Telemedicine|Participate in virtual visits with oncologist
223762191|NCT06367361|DRUG|Oxfendazole|Human studies have shown that doses up to 60 mg/kg (approximately 3.6 g for a 60-kg human, which is considered the average weight of an adult in developing countries) are safe and that repeated doses of 15 mg/kg (approximately 900 mg for a 60-kg human) daily for 5 days are safe. A single dose of OXF results in significant plasma drug concentrations that reach a Cmax plateau after doses of 15 mg/kg.75 The dose to be studied in this trial is 20 mg/kg (1200 mg maximum dose), a dose only slightly higher than that achieving a Cmax plateau. This dose was conservatively selected to account for interindividual variation in plasma levels and deemed well tolerated and safe based on laboratory and ECG evaluations.
224213996|NCT06539091|DRUG|Fluzoparib|The study treatment was followed by a 3-week treatment cycle. First day of each dosing cycle, subjects are required to complete various examinations, including vital signs, physical examination, laboratory examination, physical status score, and BMD testing to evaluate the safety and tolerability of continued treatment.
224213997|NCT06539091|DRUG|Apatinib Mesylate|The study treatment was followed by a 3-week treatment cycle. First day of each dosing cycle, subjects are also required to complete various examinations, including vital signs, physical examination, laboratory examination, physical status score, and BMD testing to evaluate the safety and tolerability of continued treatment.
224213998|NCT03706274|DRUG|CX-188|CX-188
224213999|NCT00550420|DRUG|Rosiglitazone XR|experimental drug
224214000|NCT03296774|BEHAVIORAL|Healthy Beyond Pregnancy|Web-based intervention grounded in behavioral economics and designed to improve adherence with postpartum care.
224214001|NCT03296774|BEHAVIORAL|Usual Care|
224214002|NCT01099280|DRUG|SYNPITAN FORT 5 IU|A standard intravenous oxytocin was administered 6 hours after the insertion of the vaginal pessary. An initial dose of 2 mU/min was increased at 30 minute intervals by 2 mU/min to a maximum dose 32 mU/min or until four contractions in 10 minutes was achieved. Once started, oxytocin infusion was continued to delivery unless otherwise indicated. The pessary has been removed if it was still present 12 h after placement; or if worrisome FHR pattern persisted
224214003|NCT01099280|DRUG|Propess,SYNPITAN FORT|a single dose sustained-released dinoprostone into the posterior vaginal fornix. A standard intravenous oxytocin was administered 6 hours after the insertion of the vaginal pessary. An initial dose of 2 mU/min was increased at 30 minute intervals by 2 mU/min to a maximum dose 32 mU/min or until four contractions in 10 minutes was achieved
224214004|NCT05110430|OTHER|Deep learning based detection of metastatic bone disease on bone scintigraphy scans.|The aim is to investigate whether deep learning algorithms can detect bone metastasis with high accuracy and specificity.
224214005|NCT02554825|BEHAVIORAL|Healthy Futures|Healthy Futures is an age-appropriate program that targets change at different social ecological levels-individual, interpersonal, and organizational. The main component is a classroom-based relationship education curriculum, Nu-CULTURE, offered in 6th, 7th, and 8th grade for eight 50-minute sessions each year. A number of supplemental efforts aim to enhance the Nu-CULTURE program and create social supports: 1) virtual classrooms where participating youth are encouraged to visit age-appropriate youth websites; 2) daily interactive parental connection forms linked with Nu-CULTURE, a parent website, and workshops (True Connections); 3) a 10-week after-school program, Rhymin' it Write, encourages youth leadership; 4) a 6-week summer program, Code A, engages youth during out-of-school time after 8th grade.
224214006|NCT02554825|BEHAVIORAL|Control|The Control Curriculum offers students in the control group two 50-minute classes each year on general health education topics. Students in the 6th grade receive a class on puberty/reproduction and a class on bullying prevention; students in the 7th grade receive two classes on dating-violence prevention; and students in the 8th grade receive two classes on mental health promotion.
224214007|NCT05309174|PROCEDURE|USG-guided iSLN block|Ultrasound-guided internal branch of the upper laryngeal nerve block (USG-guided iSLN block) bilaterally with 5 ml of 0.375% ropivacaine , before general anesthesia.
223513635|NCT01991886|DEVICE|Vapotherm Precision Flow|Application of nasal High Flow using 6-7 l/min delivered by nasal prongs from birth
223513636|NCT02174445|DRUG|Imatinib|Imatinib, 400 to 800 mg p.o., daily
223513637|NCT02174445|DRUG|Nilotinib|300mg p.o., twice-daily
223513638|NCT00085020|BIOLOGICAL|trastuzumab|
223513639|NCT00085020|DRUG|lapatinib ditosylate|
223513640|NCT00276380|DRUG|EGb761|EGb761 (Tanakan) 40 mg tablets (2 tablets t.i.d. (3 times a day)) 240 mg/day for 6 months.
223513641|NCT00276380|DRUG|Placebo|Placebo 40 mg tablets (2 tablets t.i.d.) 240 mg/day for 6 months.
223513642|NCT00276380|DRUG|Acetylsalicylic acid|Acetylsalicylic acid 325 mg/day (1 tablet once daily), for 6 months.
223513643|NCT03903341|OTHER|fMRI|bold signal in visual pathway
223513644|NCT02956148|RADIATION|Radioligand [18F]MNI-659|The effective radiation dose for the injection of \[18F\]MNI-659 is approximately 5.6 mSv (approximately 2 years of background radiation in Sweden) for an average person weighing 70 kg.
223513645|NCT00552279|BIOLOGICAL|Cervarix TM|Intramuscular administration into the deltoid region of the non-dominant arm according to a 0, 1, 12-month schedule.
223513646|NCT00552279|BIOLOGICAL|Cervarix TM|Intramuscular administration into the deltoid region of the non-dominant arm according to a 0, 1, 6-month schedule.
223513647|NCT03411187|DEVICE|used of the Pressure adjustable foot-control method|Whether The Pressure adjustable foot-control method is used.
223513648|NCT03411187|DEVICE|direct exhaust|direct exhaust through the trocar.
223513649|NCT05350267|BEHAVIORAL|HALO|"Health and Lifestyle Behaviors in Offspring, or HALO is designed for mothers who recently had bariatric surgery who have a school-aged child. HALO focuses on providing each mother with education and parenting strategies to improve her child's healthy lifestyle behaviors, such as her child's eating and physical activity, while she is engaged in her own lifestyle behavior change after bariatric surgery."
223513650|NCT05350267|BEHAVIORAL|Enhanced Standard of Care|The comparator group will receive monthly mailings of publicly available and age-appropriate handouts on healthy eating, physical activity, screen time, and healthy sleep habits
223513651|NCT05121090|BEHAVIORAL|Educational program|"The educational program is based on dietary, physical activity, psychology, and sophrology approaches dispensed by health care professionals. Evaluations will consist of anthropometric measurements (height, weight, body mass index), behavioural questionnaires, and basic physical tests (handgrip, squats, balance, …).~Optionally, a saliva collection will be proposed to obtain the DNA required for genetic analyses."
223513652|NCT04829214|DRUG|OTO-313|Single intratympanic injection
223513653|NCT04829214|DRUG|Placebo|Single intratympanic injection
223513654|NCT06002594|OTHER|group low-volume irrigation|Before the procedure, infants' physiological parameters were measured using the Nellcor Bedside SpO2 Patient Monitoring System. The procedure duration and crying duration were recorded using the stopwatch on a Samsung Galaxy A50 phone. Nasal irrigation was performed using 4 ml of 0.9% sodium chloride(NaCl) solution. Physiological parameters were measured immediately after the procedure and five minutes later. Subsequently, breastfeeding was initiated for the baby. Physiological parameters during breastfeeding were measured, and parental satisfaction levels were evaluated. Then, the frequency of procedure repetitions was recorded.
224214008|NCT06379022|BEHAVIORAL|Plaque control|Subjects are motivated for optimal oral hygiene
223513655|NCT06002594|OTHER|group high-volume irrigation|Before the procedure, infants' physiological parameters were measured using the Nellcor Bedside SpO2 Patient Monitoring System. The procedure duration and crying duration were recorded using the stopwatch on a Samsung Galaxy A50 phone. Nasal irrigation was performed using 20 ml of 0.9% NaCl solution. Physiological parameters were measured immediately after the procedure and five minutes later. Subsequently, breastfeeding was initiated for the baby. Physiological parameters during breastfeeding were measured, and parental satisfaction levels were evaluated. Then, the frequency of procedure repetitions was recorded.
224214009|NCT00685022|DRUG|Levalbuterol HFA MDI followed by Racemic albuterol HFA MDI|"1. Subjects will receive both treatments: (a) levalbuterol HFA MDI; 45 micrograms (16 cumulative doses); followed by (b) racemic albuterol HFA MDI; 90 micrograms (16 cumulative doses)~2. Arm #A~3. Xopenex HFA MDI, albuterol HFA MDI"
224214010|NCT00685022|DRUG|Racemic Albuterol followed by levalbuterol HFA MDI|"1. Subjects will receive both treatments: (a) racemic albuterol HFA MDI; 90 micrograms (16 cumulative doses) followed by (b) levalbuterol HFA MDI; 45 micrograms (16 cumulative doses)~2. Arm #B~3. albuterol HFA MDI, Xopenex HFA MDI"
224214011|NCT03606239|RADIATION|isotoxic hypofractionated group|the normal tissue limits are uniform, such as: V20% ≤ 30%, spinal cord 0\> 45Gy, etc., and used hypofractionated radiotherapy technology so that each patient received the maximum individualized radiation dose as possible，and the same time use the Platinum-containing drugs: docetaxel + lobaplatin Docetaxel 60 mg/m2, d1; Lobaplatin 30 mg/m2, d1, repeated every 28 days. The first cycle of chemotherapy started on the first day of radiotherapy.Consolidate chemotherapy up to 4 cycles after radiotherapy, as above.
224316592|NCT04054557|OTHER|Best Practice|Receive 4 in-office visits with oncologist
223513656|NCT06284798|DRUG|NNC0650-0013 A|NNC0650-0013 will be administered subcutaneously or intravenously.
223513657|NCT06284798|DRUG|Placebo|Subcutaneous administration.
223513658|NCT06446778|DEVICE|Pipeline embolization device with or without shield technique|The patients undenwent Pipeline embolization device implantation with or without shield technique due to market availability, choice and preferences of the surgeon.
223513659|NCT01122368|DRUG|micafungin|IV
223513660|NCT01122368|DRUG|placebo|IV
223513661|NCT06290011|DEVICE|Pain key group|mixed real pain treatment software, pain treatment scenarios in MR
223513662|NCT06640400|DEVICE|Cardiovascular ultrasound|Participants in the intervention group will be treated with a medical LIPUS device (838C-M-L-I/II, Shenzhen, China) for 10 days in addition to conventional medical treatment. The ultrasound therapy instrument is equipped with a sound head comprising 5 transducer units, operating at an ultrasonic frequency of 0.84MHz with a sound intensity range of 1 W/cm2 -1.25 W/cm2. The therapeutic ultrasound sessions necessitate a controlled environmental temperature. Patients will assume the supine position, exposing the precordial region, with the five-pronged head positioned parallel to the heart\&amp;amp;amp;amp;#39;s long axis, covering the entire precordial region including the right and left coronary arterial trunks and the aortic root. The ultrasound therapy device operates in a pulsed mode, with each treatment session lasting 20 minutes, comprising 2 daily sessions for a total of 20 treatments.
223513663|NCT06402474|PROCEDURE|sunbed position|30° reverse trendelenburg legs together 30° hip flexion (sunbed position)
223513664|NCT02594956|DEVICE|no nasogastric tube|
223513665|NCT02594956|DEVICE|nasogastric tube|
223513666|NCT02739828|BIOLOGICAL|Adalimumab|Adalimumab
223513667|NCT03031730|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223513668|NCT03031730|PROCEDURE|Bone Marrow Aspiration and Biopsy|Undergo bone marrow aspiration and biopsy
223513669|NCT03031730|DRUG|Carfilzomib|Given IV
223513670|NCT03031730|DRUG|Dexamethasone|Given PO
223513671|NCT03031730|DRUG|Dexamethasone Sodium Phosphate|Given IV
223513672|NCT03031730|PROCEDURE|Echocardiography|Undergo echocardiography
223513673|NCT03031730|DRUG|Lenalidomide|Given PO
223513674|NCT03031730|DRUG|Navtemadlin|Given PO
223513675|NCT03178890|DEVICE|OHMG|Device will be implanted in all enrolled patients.
223513676|NCT01392495|DRUG|Imatinib|200 mg or 400 mg qd
223513677|NCT02384343|DRUG|Dexmedetomidine|An intravenous bolus of dexmedetomidine 30 mcg (7,5 mL) administered at least five minutes after birth, in participants with shivering grade 3 or 4 on a scale described by Crossley and Mahajan.
223513678|NCT02384343|DRUG|Normal saline|An intravenous bolus of normal saline (7,5 mL) administered at least five minutes after birth, in participants with shivering grade 3 or 4 on a scale described by Crossley and Mahajan.
223513679|NCT02990143|PROCEDURE|Ologen|Ologen® CM,a biodegradable scaffold matrix, induces a regenerative non-scarring wound healing process without using anti-fibrotic agents.
223513680|NCT02571244|BEHAVIORAL|Motivational Interview plus text message|After discharge the experimental group has received extended care including a counseling session and text messages. The session provided basic information about smoking and successful quitting. The counselor has used motivational interview techniques to build coping skills with the goal of helping the participant build and implement a quit plan. The focus was to increase motivation to make quit attempt, including confidence building, medication use, and cessation planning. The session lasted approximately 30 minutes. Participants in the experimental arm were offered up to 30 text messages to help them to implement the quit plan discussed during the phone call. Patients motivated to quit in the next 30 days or those that had already quit have received 30 messages (2 per day) and patients unwilling to quit 16 (2 per day). The messages followed the self efficacy theory.
223624832|NCT04055675|DIAGNOSTIC_TEST|Urine dipstick test|A sample of urine will be tested using a Mission Urinalysis Reagent Strip.
223624833|NCT01882673|BEHAVIORAL|Brief Computer Motivational Interviewing for Smoking Cessation|Brief computer motivational interviewing intervention to motivated tobacco quitline use
223762192|NCT06367361|DRUG|Triclabendazole|The standard of care for the treatment of fascioliasis according to the same guidelines is two 10 mg/kg doses of TCBZ 24 hours apart administered with a fat containing meal. The subjects in one of the arms of the study will receive this treatment as the standard of care. Subjects from any of the arms that fail to achieve parasitological cure will receive rescue treatment off the study with two doses of TCBZ as recommended by the Peruvian guidelines.
224214012|NCT02264301|DRUG|Puerarin injection 400 mg|
224214013|NCT02264301|DRUG|Qingkailing injection 40 ml|
224214014|NCT00670267|DRUG|nadolol|Nadolol, oral taken daily, doses will be escalated every two weeks over 13 weeks following a 2 week run-in.
224214015|NCT02270840|DEVICE|CRT-D|Biventricular upgrade. Subjects meeting the inclusion criteria (and if exclusion criteria are not present) patients will be randomized to CRT-D upgrade or ICD only (either continued ICD therapy in patients currently implanted with a defibrillator or implantation of a defibrillator in eligible patients who are currently implanted with pacemaker-only).
224214016|NCT00006096|DRUG|cisplatin|
224214017|NCT00006096|RADIATION|radiation therapy|
224214018|NCT06173986|DRUG|PD-1inhibitor|PD-1 inhibitor, Q3W, until disease progression or unacceptable toxicity or treatment reaches 1 year
224214019|NCT06173986|DRUG|nab-paclitaxel + cisplatin|Induction phase: nab-paclitaxel + cisplatin, Q3W × 2 cycles; Concurrent ICRT phase: nab-paclitaxel + cisplatin, QW × 5 cycles
224214020|NCT06173986|RADIATION|Radiotherapy|Primary tumor and metastatic lymph nodes, DT:45-50Gy/25fx, starting within 4 weeks following the completion of the last induction immunochemotherapy cycle
224316593|NCT04054557|OTHER|Questionnaire Administration|Ancillary studies
223513681|NCT04298333|DRUG|BP-C1|"BP-C1, 0.05% solution for injection, will be administered intramuscularly once per day. The cumulative dose range will be 0.64-1.12 mg/kg body weight depending on design level (design level 1-3). The daily dose range will be 0.02-0.035 mg/kg body weight (0.04-0.07 mL/kg) depending on design level (design level 1-3).~Dose level 1: 0.02 mg/kg body weight (0.04 mL/kg) intramuscularly once daily for 32 consecutive days; dose level 2: 0.03 mg/kg body weight (0.06 mL/kg) intramuscularly once daily for 32 consecutive days; dose level 3: 0.035 mg/kg body weight (0.07 mL/kg) intramuscularly once daily for 32 consecutive days.~Changes in the cumulative dose of BP-C1 between patients in the sequence are predefined and will be adjusted by escalation/deescalation rules based on changes in toxicity observed in the previous design level.~The duration of BP-C1 treatment will be 32 days."
223513682|NCT02560792|BEHAVIORAL|Positive Affect Condition|"Participants read: Most people exercising at this intensity say that it feels good, and that it makes them feel energized and more positive, and more relaxed afterwards. Thinking about your exercise prescription, please list the reasons or ways in which you, personally, might expect this exercise to lead to positive feelings, and what specifically about this exercise might make you, personally, feel good."
223513683|NCT02560792|BEHAVIORAL|Negative Affect Condition|"Participants read: Most people exercising at this intensity say that it doesn't feel very good, and that it makes them feel tired and not so positive, and not very relaxed afterwards. Thinking about your exercise prescription, please list the reasons or ways in which you, personally, might expect this exercise to lead to negative feelings, and what specifically about this exercise might make you, personally, feel bad."
224214021|NCT00677586|PROCEDURE|simultaneous resection of liver metastasis and the rectal primary tumor|simultaneous resection of liver metastasis and the rectal primary tumor
224214022|NCT00677586|PROCEDURE|staged resection of liver metastasis and the rectal primary tumor|Patients received resection of the rectal tumor. 1 months later received resection of liver metastasis
224214023|NCT01177319|DRUG|Glutathione|
224214024|NCT01178112|DRUG|Trientine|Starting dose 750 mg by mouth four times a day, two times with meals and two times without meals for 28 days.
223513684|NCT02560792|BEHAVIORAL|Control Condition|Participants receive no information about affective response
223624834|NCT01882673|BEHAVIORAL|Nutrition Control|Computer delivered nutrition education control condition
223624835|NCT05221411|DRUG|Mycophenolate Mofetil|Mycophenolate mofetil will be started at a dose 500mg twice daily. When tolerated and an AUC within range, patients will be titrated to 1000mg twice daily at week two.
223624836|NCT05221411|DRUG|Tacrolimus|Meltdose tacrolimus will be started at a dose of 0.07 mg/kg/day. The drug will be taken orally once-daily in the morning. Dose will be adjusted to reach target AUC and trough levels.
224214025|NCT01178112|DRUG|Carboplatin|Starting dose area under curve (AUC) 4 by vein over two hours on day 1, and once every 28 days.
224214026|NCT01178112|DRUG|Trientine MTD|Maximum tolerated dose found in MTD Dose Escalation Group; Carboplatin PK Group A, instead of starting on Day 1 of Cycle 1, starts taking trientine daily beginning on Day 2 of Cycle 1. Trientine PK Group B, 1500 mg of trientine is given once without food on Day 21 of Cycle 1 and once without food after the completion of carboplatin on Day 1 of Cycle 2.
223762193|NCT01436812|PROCEDURE|zero end-expiratory pressure|positive end expiratory pressure 0 cm H2O during peumoperitoneum
224214027|NCT01178112|DRUG|Carboplatin MTD|Maximum tolerated dose found in MTD Dose Escalation Group
224214028|NCT01178112|OTHER|PK Testing|Blood samples of 4 mL at following time points: 0, 30, 60 minutes, 2, 3, 4, 6, and 24 hours.
224316594|NCT04054557|OTHER|Quality-of-Life Assessment|Ancillary studies
224316595|NCT04054557|OTHER|Survey Administration|Complete electronic survey
224316596|NCT04054557|BEHAVIORAL|Behavioral Intervention|Use smart pill bottle
224316597|NCT04054557|OTHER|Educational Intervention|Receives time-specific reminders and messages
224316598|NCT05304039|BEHAVIORAL|Questionnaires|Questionnaires about asthma control and quality of life
224316599|NCT05304039|DEVICE|Spirometry|Spirometry monitoring at home
224214029|NCT04753918|DRUG|Porfimer sodium|Photofrin 2mg/kg was iv injected 48-50 hours before light illumination.
224214030|NCT04753918|DRUG|Ethiodized oil|In hybrid operation room setting, a navigational bronchoscope guide sheath was inserted to the proximal end of the tumor region. About 5 ml Lipiodol was infused to full cover whole the tumor.
224214031|NCT04753918|PROCEDURE|Novel light delivery methods of photodynamic therapy|Using high-refraction index contrast medium: lipiodol as a light diffusor to enhance the range of photodynamic therapy
224316600|NCT05304039|DEVICE|Fractional Exhaled Nitric Oxide (FeNO)|Measuring fractional exhaled nitric oxide at home
224316601|NCT05304039|DEVICE|Corsano watch|Monitoring vital parameters at home
224316602|NCT05304039|DEVICE|e-Nose|Breathprint will be performed using e-Nose
223762194|NCT01436812|PROCEDURE|positive end expiratory pressure|PEEP 0 cmH2O
223762195|NCT03784573|BEHAVIORAL|Dog + handler|Dog + handler
223762196|NCT03784573|BEHAVIORAL|No dog|No dog
223762197|NCT05251246|BEHAVIORAL|recovery management program|The recovery management program consists in training the nurses and physicians during a 15-day training course to optimize their recovery abilities : sleep management according to the schedules by anticipation and recovery, and stress management through cardio-feedback techniques (cardiac coherence) also called controlled breathing techniques and mental imagery.
223762198|NCT03156010|DEVICE|Neuro Kinetics IPAS|Testing with PAS device
223762199|NCT03156010|DEVICE|Oculogica EyeBox|Testing with Oculogica EyeBox device
224214032|NCT04753918|DEVICE|Fiber optic|A cylindrical laser fiber was then inserted through the guide sheath to the tumor region then illuminate light to complete the photodynamic therapy.
224214033|NCT03733184|PROCEDURE|Cytoreduction and Heated Intraperitoneal Surgery|Cytoreductive Surgery is a procedure that aims for the complete removal of all visible tumours affecting the protective lining of the abdomen. After the surgical procedure is completed, the surgeon introduces a heated, sterile solution mixed with chemotherapy drugs into the abdominal cavity (the HIPEC).
224316603|NCT05304039|PROCEDURE|Nasopharyngeal swabs and nasal lining fluid|Nasopharyngeal swabs and nasal lining fluid will be performed
223513685|NCT00635466|PROCEDURE|laparoscopic surgery for rectal carcinoma|Laparoscopic resection of the rectum with adequate lymphadenectomy is performed according to the General Rules for Clinical and Pathological Studies on Cancer of the Colon, Rectum and Anus edited by the Japanese Society for Cancer of the Colon and Rectum. The extent of lymphadenectomy and site of ligation and division of the inferior mesenteric vessels were decided by the surgeon in charge. Pneumoperitoneal approaches are used to explore the abdomen, mobilize the left side colon, identify critical structures and ligate the vascular pedicle. Mobilization of the rectum, excision of the mesorectum, rectal transection, removal of the specimen, and reconstruction are performed by the pneumoperitoneal approach or the extracorporeal approach via a small incision (\<8 cm).
223513686|NCT06492720|DEVICE|Focused ultrasound (FUS) treatment|The mechanism of action of FUS neuromodulation involves the activation of voltage-gated ion channels to induce temporary neuromodulation.
223513687|NCT02355509|DRUG|Acarbose|"Acarbose dose was progressively titrated (50 mg/day per week up to 150 mg/day) to reduce the known adverse effects of acarbose such as flatulence, bloating, diarrhea, abdominal pain.~The treatment for three months"
223513688|NCT02355509|DRUG|Placebo|Placebo pills are given instead of acarbose in this group
223513689|NCT05984862|DEVICE|Bandage|To determine if using bandage versus no-bandage, plays a role in limiting severity and duration of signs and symptoms of acute inflammation post follicular harvesting procedure
223513690|NCT00000603|PROCEDURE|stem cell transplantation|
223513691|NCT06571578|DEVICE|Threshold Inspiratory muscle trainer|threshold inspiratory muscle trainer device Each subject will breathe through a separate mouthpiece through attach the mouthpiece firmly While putting a nose clip and inhale deeply through the mouthpiece to generate an inspiratory pressure greater than the indicated presetting threshold pressure to compress the spring and open the valve. Using High - intensity interval training technique
223762200|NCT03156010|DEVICE|SyncThink EyeSync Device|Testing with SyncThink EyeSync device
223762201|NCT01526889|DRUG|LFG316|LFG316 administered intravitreally (IVT)
223762202|NCT01526889|DRUG|Conventional Therapy|Conventional Therapy administered in accordance with its prescribing info.
223762203|NCT05928910|DEVICE|SmileyScope VR|The SmileyScope Virtual Reality Headset is a VR headset to reduce pain and anxiety undergoing medical procedures. The device comes pre-loaded with a static virtual reality scenario. Participants will use the device in person when coming to clinic during an in-person, one time PNE procedure.
224214034|NCT02377284|OTHER|Photograph|Add a photograph to a chef card.
224214035|NCT04394052|DIAGNOSTIC_TEST|MR imaging|Medical imaging
223762204|NCT05928910|OTHER|Standard of Care Treatment|Participants in this group will receive standard of care treatment during an in-person, one time PNE procedure.
223762205|NCT03438890|DEVICE|Warm saline|In subjects allocated to the warm saline group, a thermos flask, which was filled with heated sterile water, was used. A 1000 ml bottle of sterile water was heated to 60 ˚C in a stove for an hour at minimum. Just before introducing into the abdominal cavity, the laparoscope was placed into the thermos flask for 30 seconds at minimum . After each incidence of laparoscopic lens fogging (LLF), the scope was briefly inserted into the thermos flask about 10 seconds, and was then wrapped gauze around the lens before abdominal reinsertion.
224214036|NCT02577900|DEVICE|Acticoat absorbent|Apply Acticoat absorbent daily onto diabetic foot ulcer in 12-week study interval
224214037|NCT02577900|DEVICE|Honey gel sheet|Apply Honey gel sheet daily onto diabetic foot ulcer in 12-week study interval
224316604|NCT05304039|DEVICE|Sputum culture|If patients produce sputum, the sputum will be analysed
224316605|NCT05304039|PROCEDURE|Blood sample|Blood sample for standard care and 10 ml extra will be taken
224316606|NCT06381596|DEVICE|OcuMet Beacon|OcuMet Beacon is a novel fundus camera the can detect, capture, and assess FPF.
224316607|NCT06137261|DIAGNOSTIC_TEST|Screening for heart failure|"• Anamnesis and Physical examination: Focus on signs of HF; will be performed by a trained employee.~• ECG: A standard 12-lead ECG will be recorded by a trained employee and will be interpreted by an experienced cardiologist.~• Echocardiography: A standard full echocardiogram will be acquired by a trained employee.~• Blood biomarkers: Venous blood samples will be taken and circulating levels of a broad range of markers related to obesity and/or heart failure will be determined. Also, an extra 10 mL blood sample will be drawn during the same venepuncture to be stored to determine additional biomarkers at a later stage.~• EQ-5D-5L questionnaire: EQ-5D-5L comprises five dimensions (mobility, self-care, usual activities, pain/discomfort and anxiety/depression), which are divided into five degrees of severity, ranging from 'no problems' to 'extreme problems'."
224214038|NCT02577900|DEVICE|Jelonet|Apply Jelonet daily onto diabetic foot ulcer in 12-week study interval
224214039|NCT02639507|PROCEDURE|Vitrectomy|
223624837|NCT04629755|BEHAVIORAL|Intervention|The intervention was delivered via daily text messages to mobile phones during two weeks in the midst of the Covid-19 pandemic. Each message provided a link to a brief suggestion for an action or actions to take each day to improve relational closeness and well-being. Critical to the rationale for this intervention was the position that relationship science has developed key insights into what works and does not work to build and maintain closeness. These insights could be translated into brief and effective suggestions that individuals could implement daily, thereby quickly improving relational well-being and decreasing depression and loneliness at a critical time.
223624838|NCT01299844|BEHAVIORAL|Diabetes Peer Counseling|16 Home visits from a bilingual/bicultural diabetes peer counselor.
224214040|NCT03851107|BEHAVIORAL|Engagement in 6-week community-based activity program|Participants engage in a 6-week community-based activity program of their choice. In order to engage in the selected activity, an Occupational Therapist (OT) will meet with each youth in their home. Using the PREP 5 steps (Make goals; Map out a plan; Make it happen; Measure the process and outcomes; Move forward) the youth will choose a community program. The OT will then search for the appropriate program, identify and remove potential environmental barriers for participation in that activity (e.g., accessibility, equipment) and educate program instructors regarding the youth's specific needs. This process, which includes up to 12 hours of working with the OT, will set the stage for enrolment of the youth in a community program for a period of 6 weeks - the actual intervention phase.
224214041|NCT00415311|DRUG|Intravenous Recombinant Human Mannose-Binding Lectin (rhMBL)|Intravenous(i.v.) administration for 8 weeks. Patients will be randomized to one of three cohorts: 0 mg/kg; 0.5 mg/kg, or 1.0 mg.kg
224316608|NCT06229171|OTHER|adherence support system based on a vocal assistant|"Participants in the intervention group will receive a vocal assistant device and the instructions/support for the activation of the system at their homes. The device will remind the participant, at the times defined during set-up, which therapy should be taken and with what dosage. The participant will have 30 minutes from the first reminder to confirm vocally that the therapy has been taken, which will otherwise be considered as not having been taken.~Participants in the control group will receive verbal advice from the physician about the need to follow the treatment recommendations and simple indications on possible solutions to maintain adherence, as by the usual practice of the Centre."
223624839|NCT00188552|DRUG|pentoxifylline|
223624840|NCT00188552|DRUG|α-Tocopherol|
223624841|NCT03617562|PROCEDURE|Superior Capsular Reconstruction|Residual rotator cuff defect is reconstructed with a dermal allograft secured to the glenoid and humeral head.
223624842|NCT03617562|PROCEDURE|Partial Repair|Rotator cuff is repaired with residual defect remaining.
223624843|NCT04571944|DRUG|Suvorexant|Suvorexant administered at a dose of 15 mg QD via oral tablet
223624844|NCT04571944|DRUG|Placebo|Suvorexant-matching placebo administered QD via oral tablet
223624845|NCT06527014|PROCEDURE|Pulse Radiofrequency to the suprascapular nerve|Pulse radiofrequency ablation to the Suprascapular nerve
223624846|NCT04630665|OTHER|immediate implant placement|immediate implant placement in thin and thick buccal bony plates
223624847|NCT06344871|DEVICE|NeuroLF|NeuroLF Scan
223762206|NCT03438890|DEVICE|anti-fog agent|In the anti-fog agent group, Ultra-Stop TM (Sigmaphrarm, Vienna, Austria), which is a commercial anti-fogging solution containing alcohol, surfactant, and water for medical optical devices, was used. Wiping the lens with gauze soaked in Ultra-Stop TM and allowing the surfactant to act for 5 seconds, the laparoscope was introduced into the abdominal cavity. After each laparoscopic lens fogging (LLF), the scope was removed from the abdomen and cleaned using the same corresponding method.
223762207|NCT03438890|DEVICE|chlorhexidine|In the chlorhexidine group, the lens was wiped with gauze soaked in 4% chlorhexidine detergent solution (Firson, Cheonan, Korea) for 5 seconds before introducing into the abdominal cavity, and chlorhexidine was reapplied on the lens at the occurrence of laparoscopic lens fogging (LLF).
223762208|NCT06325384|DEVICE|Lifelight|Contactless Vital Signs Measurement via RPPG
223762209|NCT06325384|DEVICE|Blood Pressure Cuff|Standard Blood Pressure Cuff Digital
224214042|NCT00415311|DRUG|Intravenous Recombinant Human Mannose-Binding Lectin (rhMBL)|Intravenous(i.v.) administration for 8 weeks. Patients will be randomized to one of three cohorts: 0 mg/kg; 0.5 mg/kg, or 1.0 mg.kg
224214043|NCT00415311|DRUG|Intravenous Recombinant Human Mannose-Binding Lectin (rhMBL)|Intravenous(i.v.) administration for 8 weeks. Patients will be randomized to one of three cohorts: 0 mg/kg; 0.5 mg/kg, or 1.0 mg.kg
223762210|NCT01192971|DRUG|Apatinib|apatinib p.o. once daily for 4 weeks
224214044|NCT02917928|DIETARY_SUPPLEMENT|carnosine|Each participant will be given a daily oral dose 2 g of carnosine (4 tablets of 500mg each) for 14 weeks
224214045|NCT02917928|DRUG|Placebo|Each participant will be given a daily oral dose 2 g of placebo (4 tablets of 500mg each) for 14 weeks
224316609|NCT05497180|DEVICE|passive myofunctional appliance|passive myofunctional appliance
224316610|NCT05497180|DEVICE|standard oral appliance|standard oral appliance
224316611|NCT06002204|OTHER|Observational Study|No Treatment or Intervention Provided
223624848|NCT06344871|DEVICE|Conventional PET scan|Scan on conventional PET system
223624849|NCT01150526|DIETARY_SUPPLEMENT|CaHMB|CaHMB capsules with each capsule containing 0.8 g of HMB
223624850|NCT01150526|DIETARY_SUPPLEMENT|HMB Free Acid Gel|HMB Free acid in a gel form with each dose supplying 0.8 g of HMB free acid
223624851|NCT01150526|DIETARY_SUPPLEMENT|Placebo|Placebo capsules similar in size and color to the CaHMB capsules used in the study
223624852|NCT01150526|DIETARY_SUPPLEMENT|Placebo Gel Dosage|A corn syrup based placebo with flavoring and taste similar to the HMB Free Acid Gel
223624853|NCT04477265|DRUG|Solifenacin Succinate 5mg/tab daily|participants will be taking oral medication for 3 months
223624854|NCT04477265|BEHAVIORAL|biofeedback-assisted pelvic floor muscle training|participants will be doing biofeedback-assisted pelvic floor muscle training for 3 months
223762211|NCT01990677|DRUG|25mg Eplerenone|Patients will be given 25mg Eplerenone (or 50mg Eplerenone) or placebo throughout the study and the dosage will be based on the serum potassium/creatine levels. Patients will be randomized 2:1 such that 36 patients in each group will receive eplerenone and 16 patients in each group will receive placebo
223762212|NCT01990677|DRUG|Placebo|Patients will be given placebo throughout the study from day one, other patients may be tapered down to placebo based on the serum potassium/creatine levels. 16 patients in each group will receive placebo.
224214046|NCT03157310|DRUG|Gefitinib|Daily oral administration of 250 mg Gefitinib
224214047|NCT06327477|PROCEDURE|Biopsy|Undergo biopsy
224214048|NCT06327477|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
224214049|NCT06327477|PROCEDURE|Computed Tomography|Undergo CT
224214050|NCT06327477|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IG-IMRT
223513692|NCT06571578|OTHER|posture correction exercises|"conventional exercise consists of~* Cervical isometric exercises will be performed in the sitting position by resisting at the forehead (cervical ﬂexion, extension, rotation and side bending) for 10 seconds with 15 seconds breaks between holds with 10-15 repetitions in a progressive manner 3time/week for 12 weeks.~* Postural correction exercise consists of gently rolling of pelvis forward to an upright neutral sitting position, followed by scapular correction and occipital lift. Also, for the sub-occipital muscles stretching~* stretching exercises for scalene and levator muscles"
223513693|NCT03818074|DEVICE|Boston Wavewriter 1000Hz Spinal cord Stimulation|High frequency spinal cord stimulation.
223513694|NCT01755403|DRUG|Benznidazole|
223513695|NCT02776176|PROCEDURE|Enhanced Recovery After Surgery Program|optimized peri-operative protocol
223513696|NCT02776176|PROCEDURE|Traditional Program|traditional standard protocol
223513697|NCT03175588|OTHER|Virtual Rehabilitation|Nintendo Wii program with balance board, which is the most frequently preferred game consoles in rehabilitation will be used
223513698|NCT02417337|PROCEDURE|Root Canal Treatment|A standardized endodontic procedures performed.
223513699|NCT02417337|DRUG|Paracetamol|
223513700|NCT02417337|DRUG|Ibuprofen|
223513701|NCT02417337|DRUG|Mefenamic acid|
223513702|NCT02417337|DRUG|Diclofenac|
223513703|NCT04296682|PROCEDURE|Alveolar Ridge Preservation With Gingival Graft|Closure of the alveolus with the placement of a free gingival tissue graft removed from the individual palate.
223513704|NCT01895179|OTHER|Time-Restricted Feeding|Time-restricted feeding is a variant of intermittent fasting that involves eating all of one's calories within a few hours each day (typically 4-9 hours), followed by a daily fast of 15-20 hours.
223513705|NCT01895179|OTHER|Grazing|Grazing involves eating meals spread out over the course of the day.
223513706|NCT01988558|DRUG|DL - Lactic Acid|Treated group to receive DL - Lactic Acid Syrup (Raspberry flavored)
223513707|NCT01988558|DIETARY_SUPPLEMENT|Raspberry flavored syrup|Placebo group to receive Raspberry flavored Syrup
223513708|NCT02003157|PROCEDURE|hypnosis during embryo transfer or usual transfer procedure|
223513709|NCT03955185|PROCEDURE|minimally invasive surgery|Laparoscopic or robotic assisted radical hysterectomy
223513710|NCT03955185|PROCEDURE|open abdominal surgery|Traditional open abdominal radical hysterectomy
223513711|NCT03599297|PROCEDURE|Bilateral synchronous simultaneous stone surgery|Patients undergoing Bilateral synchronous simultaneous stone surgery (one kidney undergoing percutaneous nephrolithotomy, other kidney undergoing ureteroscopy at the same time in a single patient)
223513712|NCT01284738|OTHER|Physiopathology|"Three sequential biological evaluations will be performed for each patient and will consist in :~* the dosages of MP carried out by the UMR 608 in Marseille,~* the evaluation of the oxidative stress markers and of iron performed in the UMR 773 in Paris-Bichat.~In vitro production of MP of transfused red blood cells origin will also be evaluated in erythrocytes concentrates during the storage of the units."
223513713|NCT01284738|OTHER|Physiopathology|"Three sequential biological evaluations will be performed for each patient and will consist in :~* the dosages of MP carried out by the UMR 608 in Marseille,~* the evaluation of the oxidative stress markers and of iron performed in the UMR 773 in Paris-Bichat."
223513714|NCT04629521|DEVICE|CyPass Micro-Stent|The CyPass Micro-Stent is a small tube with a through-lumen designed to redirect aqueous fluid from the front into the back of the eye. The device is implanted after completion of cataract surgery.
223513715|NCT04629521|PROCEDURE|Cataract Surgery|Cataract surgery involves the removal of the natural lens, which has become clouded (called a cataract), and insertion of an artificial lens (called an intraocular lens). This procedure is done through a small surgical incision in the eye.
223513716|NCT04551924|DRUG|HR18034|HR18034（Ropivacaine Liposome for Injection） is a sustained-release liposome
223513717|NCT04551924|DRUG|Naropin|Local infiltration of Naropin to produce anesthesia for surgery and analgesia in postoperative pain management. Naropin 150mg \[0.5%, 5mg/mL\] x 30mL
223513718|NCT02893436|PROCEDURE|Surgery with tracheal intubation curarisation|
223513719|NCT00163852|DRUG|Normal saline IV, salt tablets|
223513720|NCT01623284|DRUG|C-11 PiB|One time intravenous administration of 740 megabecquerel (MBq) of \[N-methyl-11C\]2-(4'-methylaminophenyl)-6-hydroxybenzothiazole (PiB) (range 370 - 740 MBq).
223513721|NCT01623284|DRUG|F-18 FDG|One time intravenous administration of 629 megabecquerel (MBq) of \[18-F\]-fluoro-deoxy-glucose (FDG) (range 555 - 740 MBq).
223513722|NCT02239484|DRUG|Tadalafil|
223513723|NCT02239484|DRUG|Tamsulosin|
223513724|NCT02239484|DRUG|Tadalafil + Tamsulosin|
223513725|NCT05362136|PROCEDURE|perforation of the sinus floor|perforation of the cortical layer of the sinus floor prior to inserting the augmentation material during sinus floor elevation
223513726|NCT05362136|PROCEDURE|no perforation of the sinus floor|standard procedure for sinus floor elevation
223513727|NCT04792970|DRUG|Talc|All patients randomized to the Talc arm will receive Talc therapy through the pleural catheter.
224214051|NCT06327477|PROCEDURE|Resection|Undergo surgical resection
224214052|NCT06327477|RADIATION|Spatially-fractionated Radiation Therapy|Undergo P-SFRT
224214053|NCT06280027|OTHER|survey|An online survey was generated to quantitatively evaluate the level of esthetic perception.
224214054|NCT01862120|DRUG|Dose D1 of interleukin-2|subcutaneous injection of Interleukin-2 during 5 days, once daily repeated administration(Induction period). At day 15 single administration of Interleukin-2 every two weeks during one year (maintenance period).
224214055|NCT01862120|DRUG|placebo|subcutaneous injection of Interleukin-2 during 5 days, once daily repeated administration(Induction period). At day 15 single administration of Interleukin-2 every two weeks during one year (maintenance period).
224214056|NCT01862120|DRUG|Dose D2 of Interleukin-2|subcutaneous injection of Interleukin-2 during 5 days, once daily repeated administration(Induction period). At day 15 single administration of Interleukin-2 every two weeks during one year (maintenance period).
223624855|NCT06456827|OTHER|Bite force and Gcf|"change in bite force will be measured by bite force measuring device at, T0(at the time of retainer delivery), T1(1 month of retainer delivery), T2(3 months of retainer delivery) and T3 (6 months of retainer delivery) ,T4 (12 months of retainer delivery) time interval.~Changes in the following parameters - changes in change in levels of bone turnover markers CTX and BALP using ELISA at T0(at the time of retainer delivery), T1(1 month of retainer delivery), T2(3 months of retainer delivery) and T3 (6 months of retainer delivery) ,T4 (12 months of retainer delivery) time interval"
223624856|NCT06092762|DRUG|AK120|subcutaneous injection every 2 weeks
223624857|NCT01099371|OTHER|exercise|progressive resistance training
223624858|NCT05936112|OTHER|Fecal calprotectin dosage|Dosing calprotectin in infants' feces + questionnaire/interview with parents
223624859|NCT05936112|OTHER|Questionnaire and interview with parents|Dosing calprotectin in infants' feces + questionnaire/interview with parents
223624860|NCT06036277|OTHER|General data|General data will be collected to ensure that both groups are comparable : maternal age, maternal BMI, gestational age, parity, number of children in current pregnancy, history of caesarian section, newborn child weight
224214057|NCT01862120|DRUG|Dose D3 of interleukin-2|subcutaneous injection of Interleukin-2 during 5 days, once daily repeated administration(Induction period). At day 15 single administration of Interleukin-2 every two weeks during one year (maintenance period).
224214058|NCT02773446|BIOLOGICAL|ETEC strain B7A (O148:H28 CS6+ LT+ST+) (Lot 0481) in Buffer|ETEC Bacteria
224214059|NCT04378010|DRUG|EDP-305 1.5 mg|Tablet
224214060|NCT04378010|DRUG|EDP-305 2 mg|Tablet
224214061|NCT04378010|DRUG|Placebo|Tablet
224214062|NCT01596816|RADIATION|First part of treatment : Conformal irradiation|23 fractions (2 Gy/session), are delivered over 42 days maximum, for a total dose of 46 Gy
224214063|NCT01596816|PROCEDURE|Fiducials placement|Placement of intra-prostatic markers for the tracking
224214064|NCT01596816|RADIATION|Second part : hypofractionated stereotactic boost|3 fractions (6Gy/session) are delivered over 5 to 9 days (at least 48 hours between sessions) for a total dose of 18 Gy
223762213|NCT00974571|DRUG|montelukast sodium|montelukast 10 mg tablet orally once daily at bedtime for 6 weeks
223762214|NCT00974571|DRUG|Comparator: cetirizine|cetirizine 10 mg tablet orally once daily at bedtime for 6 weeks
223762215|NCT00974571|DRUG|Comparator: placebo|placebo tablet orally once daily at bedtime for 6 weeks
223762216|NCT00273728|DRUG|hydroxy-ethyl starch (MW 130; 0.4) vs. normal saline|hydroxy-ethyl starch together with ringer's lactate versus physiologic saline together with saline
223762217|NCT03879889|DRUG|Nicotine patch|Four weeks of nicotine patch will be provided at the first contact, which will be prescribed using the guidelines based on the subject's daily cigarette consumption. At week-4 visit, four more weeks of NRT will be provided.
224214065|NCT02513459|DRUG|Risankizumab 600 mg IV|Re-induction treatment; 3 infusions every 4 weeks, after which eligibility was assessed if clinical response was re-gained
223624861|NCT06036277|OTHER|Other data|Other data collected will be used to estimate primary and secondary outcomes : request for an epidural anesthesia by the parturient, medical indication for peridural anesthesia, duration of childbirth, delivery methods, occurrence of maternal or neonatal complications.
223762218|NCT04852744|OTHER|Brain MRI|"Anatomical MRI The anatomical data will be acquired by means of a 3T Signa Premier General Electric Healthcare MRI, allowing the acquisition of classic anatomical sequences (T1, T2) and a high-resolution hippocampal sequence allowing to accurately apprehend its various sub-fields. (total acquisition time: 10 min).~The hippocampal volume, the orbital-frontal cortex and the cingulate cortex will be measured by voxel-based morphometry (VBM; Ashburner \& Friston, 2000\]) using the SPM software (Statistical Parametric Mapping; Friston et al., 2006). The voxel-by-voxel morphometric analysis of T1 MRI images makes it possible to classify and segment the different brain tissues (gray matter versus white matter) and to analyze the focal differences in volume within these tissues between the different groups."
223762219|NCT03507556|PROCEDURE|Triple paste and induced bleeding|
223762220|NCT03507556|DRUG|Triple Paste metronidazole, ciprofloxacin and minocycline mixed with sterile glycol|triple paste of metronidazole, ciprofloxacin and minocycline mixed with sterile glycol
223762221|NCT00966238|BIOLOGICAL|VAX125|STF2.HA1(SI) (VAX125), which is a recombinant fusion protein that consists of Salmonella typhimurium flagellin type 2 (STF2), a Toll-like receptor 5 (TLR5) ligand, fused at its C-terminus to the globular head domain of the hemagglutinin (HA) antigen of influenza A HA1 Solomon Islands (SI).
223762222|NCT06028711|OTHER|Education program|Patients in a study group will participate in daily education program using an original brochure containing information on the benefits of appropriately adapted physical activity, practical tips on airway clearance techniques or physical exercise, and risk factors for exacerbation of COPD.
224214066|NCT02513459|DRUG|Risankizumab 180 mg SC|Maintenance treatment every 8 weeks (q8w) from Visit 2 through the end of trial (EOT) visit. Participants who re-gained their clinical response following the re-induction treatment could continue with maintenance treatment beginning at Visit 5.
224214067|NCT00838500|DRUG|Immediate spa treatment|1st year, soon after randomization: Spa treatment of 18 days. Spa treatment : the most adapted to the concerned pathology and common to all of spa resorts(walk in a specially pool, whirlpool bath with automatic air and water massages cycles, massaging shower...)
224214068|NCT00838500|DRUG|Late spa treatment|2nd year, soon after 12 months visit: Spa treatment of 18 days. Spa treatment : the most adapted to the concerned pathology and common to all of spa resorts(walk in a specially pool, whirlpool bath with automatic air and water massages cycles, massaging shower...)
224214069|NCT05842083|BEHAVIORAL|On-site supportive communication training|On-site supportive communication training
224214070|NCT03237611|DRUG|Aprepitant 125 mg|Patient scheduled for the first cycle of carboplatin-based chemotherapy will be offered to receive low doses of aprepitant (125mg of oral aprepitant) or 115mg of fosaprepitant intravenously for prevention of chemotherapy-induced nausea and vomiting
224214071|NCT03237611|DRUG|Fosaprepitant 115 MG|Patient scheduled for the first cycle of carboplatin-based chemotherapy will be offered to receive low doses of aprepitant (125mg of oral aprepitant) or 115mg of fosaprepitant intravenously for prevention of chemotherapy-induced nausea and vomiting
224214072|NCT03237611|DRUG|Dexamethasone|Dexamethasone will be given as a part of standard CINV prophylaxis for patients receiving carboplatin-based chemotherapy, dosed at 20mg on day 1 of chemotherapy
224214073|NCT03237611|DRUG|Ondansetron 16 MG|Ondansetron will be given as a part of standard CINV prophylaxis for patients receiving carboplatin-based chemotherapy, dosed at 16mg on day 1 of chemotherapy
224214074|NCT05450497|DRUG|Propofol|comparing sedative agents
224214075|NCT05450497|DRUG|Dexmedetomidine|comparing sedative agents
224214076|NCT05450497|DRUG|Dexmedetomidine and propofol|comparing sedative agents
224214077|NCT03806894|DIAGNOSTIC_TEST|Quantification of platelet aggregation|Platelet aggregation will be determined by vasodilator-stimulated phosphoprotein (VASP) assay
224214078|NCT01724476|DRUG|folate with B12|
224214079|NCT01724476|DRUG|placebo|
224214080|NCT04674176|DRUG|Rifaximin|550 mg of Rifaximin 3 times a day for 12 days at the start of the diet.
224214081|NCT02496260|PROCEDURE|Research Cardiac MRI|Cardiac MRI has increased use in evaluating structural and functional cardiac pathologies. For detection of coronary artery disease, MRI outperforms SPECT and dobutamine stress echocardiography for the detection of ischemia. MRI also can detect wall-motion abnormalities and other dysfunction. Dynamic contrast-enhanced MRI (DCE-MRI) can evaluate microvascular parameters such as vessel permeability and fluid volume fraction as an assessment of tissue perfusion. Cardiac MRI holds promise for early detection of subclinical cardiac abnormalities after radiotherapy and could potentially identify patients for intervention to prevent cardiac events. All patients will follow the protocol calendar requiring research MRIs, but will receive standard radiation treatment determined by their physician. Treatment will not be altered based on MRI.
224214082|NCT02496260|PROCEDURE|Biomarkers|"We have identified potential candidates based on other processes affecting heart function in a way similar to probable mechanisms of RT-related injury. For fibrosis and left ventricular dysfunction, these include galectin-3 and N-terminal-Pro brain natriuretic peptide. For myocyte destruction, troponin; for inflammation and oxidative stress, C-reactive protein, myeloperoxidase, and growth differentiation factor 15. Additional blood will be collected and stored for future assessment of other candidate biomarkers.~All patients will follow the calendar of protocol required research blood draws for biomarker collection, but will receive standard radiation treatment as clinically indicated by their physician. Treatment will not be altered based upon the data collected from these samples."
224214083|NCT04023994|DRUG|RO7126209|Participants will be administered single-ascending intravenous doses of RO7126209 with at least 2 weeks between each dose level. After the starting dose, the subsequent doses will be selected in an adaptive design. Sentinel dosing will be employed.
224214084|NCT04023994|DRUG|Placebo|Participants will be administered a single intravenous dose of matching placebo.
224214085|NCT03063489|DRUG|Loteprednol Etabonate Ophthalmic Gel|Formulated LE into a gel (loteprednol etabonate ophthalmic gel, \[Lotemax® gel\])
224214086|NCT00923195|DRUG|MART-1: 26-35(27L) Peptide|"Day 0:Autologous transduced CD8+PBL (anti-gp100:154 TCR PBL and anti-MART-1 F5 TCR PBL) infusion will be administered intravenously over 20 to 30 minutes (minimum 5 x 10e8 and up to a maximum of 2 x 10e11 of each transduced lymphocyte population).~One mg of either the gp100:154-162 or the MART-1:26-35(27) emulsified in IFA by deep subcutaneous injection into each thigh to be administered prior to cell infusion and on days 7 and 14."
224214087|NCT00923195|DRUG|Montanide ISA 51 VG|"Day 0:Autologous transduced CD8+PBL (anti-gp100:154 TCR PBL and anti-MART-1 F5 TCR PBL) infusion will be administered intravenously over 20 to 30 minutes (minimum 5 x 10e8 and up to a maximum of 2 x 10e11 of each transduced lymphocyte population).~One mg of either the gp100:154-162 or the MART-1:26-35(27) emulsified in IFA by deep subcutaneous injection into each thigh to be administered prior to cell infusion and on days 7 and 14."
224214088|NCT00923195|DRUG|gp100:154-162 Peptide|"Day 0:Autologous transduced CD8+PBL (anti-gp100:154 TCR PBL and anti-MART-1 F5 TCR PBL) infusion will be administered intravenously over 20 to 30 minutes (minimum 5 x 10e8 and up to a maximum of 2 x 10e11 of each transduced lymphocyte population).~One mg of either the gp100:154-162 or the MART-1:26-35(27) emulsified in IFA by deep subcutaneous injection into each thigh to be administered prior to cell infusion and on days 7 and 14."
224214089|NCT00923195|PROCEDURE|Radiation|2Gy of TBI twice on day -2 and once on day -1 (total dose 6 Gy) at a rate of 0.07 Gy/minute
224214090|NCT00923195|DRUG|Aldesleukin|Within 24 hours of cell infusion administration of aldesleukin will be initiated as 720,000 IU/kg/dose IV over 15 minutes every 8 hours for up to 5 days (maximum 15 doses).
224214091|NCT00923195|DRUG|Fludarabine|Day -6 to -2: Fludarabine 25 mg/m2/day IVPB daily over 15-30 minutes for 5 days
224214092|NCT00923195|DRUG|Cyclophosphamide|Day -6 to -5: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with mesna15 mg/kg/day over 1 hr X 2 days.
224214093|NCT00923195|GENETIC|Anti-gp 100:154 TCR PBL|"Day 0:Autologous transduced CD8+PBL (anti-gp100:154 TCR PBL and anti-MART-1 F5 TCR PBL) infusion will be administered intravenously over 20 to 30 minutes (minimum 5 x 10e8 and up to a maximum of 2 x 10e11 of each transduced lymphocyte population).~One mg of either the gp100:154-162 or theMART-1:26-35(27) emulsified in IFA by deep subcutaneous injection into each thigh to be administered prior to cell infusion and on days 7 and 14"
224214094|NCT00923195|GENETIC|Anti-MART-1 F5 TCR PBL|"Day 0:Autologous transduced CD8+PBL (anti-gp100:154 TCR PBL and anti-MART-1 F5 TCR PBL) infusion will be administered intravenously over 20 to 30 minutes (minimum 5 x 10e8 and up to a maximum of 2 x 10e11 of each transduced lymphocyte population).~One mg of either the gp100:154-162 or theMART-1:26-35(27) emulsified in IFA by deep subcutaneous injection into each thigh to be administered prior to cell infusion and on days 7 and 14"
223762223|NCT06028711|OTHER|Pulmonary rehabilitation|The patients will participate in a 14-day rehabilitation program (Monday to Saturday). Treatments and therapies will be continued for a maximum of two hours daily. The program will be applied individually to each patient and include active and assisted exercises, effective cough exercises, pursed-lips breathing, positive expiratory pressure exercises, exercises to strengthen the diaphragm and intercostal muscles and cardiopulmonary exercises.
224214095|NCT03953365|PROCEDURE|Prophylactic Mesh|Prophylactic Mesh after closure of the abdominal wall after Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy
224214096|NCT04725526|DEVICE|Mobile phone compatible with iOS or Android|MHealth (mobile health) intervention is an act whose purpose is to improve, maintain, promote or modify health, functioning or health conditions.
224214097|NCT02314520|DEVICE|peripherally inserted central catheter|Any complication associated with central access
224214098|NCT02314520|DEVICE|centrally inserted central catheter|Central access not associated with any complication
224316612|NCT06780176|OTHER|Biospecimen Collection|Blood collection at baseline and time of surgery
223624862|NCT04383509|BEHAVIORAL|Cognitive Control Training|Cognitive Control Training (CCT) makes use of a very basic cognitive task that strongly loads on working memory and cognitive control processes, namely the adaptive Paced Auditory Serial Addition Task (aPASAT) where participants are given a number every 3 seconds and are asked to add the number they just heard with the number they heard before. Task difficulty is modified based on the participants current task performance, allowing training of cognitive control. Participants in the intervention group will start the CCT training after completion of ECT with a maximum time interval of 7 days. Training sessions will be performed on a tablet or computer and participants will complete five sessions per week (20 minutes per session) for a period of two weeks.
223624863|NCT04383509|BEHAVIORAL|Active Control|Participants in the active control group will start placebo training after completion of ECT with a maximum time interval of 7 days. The placebo task consists of a task similar to the experimental condition but that does not train cognitive control. Prior research confirmed that this condition controls for non-specific effects of the training and motivational issues. Participants will perform the sessions on a tablet or computer and complete five sessions per week (20 minutes per session) for a period of two weeks.
223624864|NCT04335617|DRUG|MMPF (Micronized purified Flavonoid-Fraction)|500mg film-coated tablet, oral route, tablets should be taken at meal times. 4-day course of 6 tablets daily, followed by 4 tablets over the next 3 days followed by 2 tablets daily, one at midday and one in the evening
223624865|NCT04335617|OTHER|Placebo|4-day course of 6 tablets daily, followed by 4 tablets over the next 3 days followed by 2 tablets daily
223624866|NCT05620316|DRUG|BOTOX® Injection|100 MU of botulinum toxin type A (BOTOX® - Allergan Inc. - Dublin - Ireland) were diluted in 2ml of saline. Patients were injected with 10 MU of BTXA per side at two sites into the masseter muscle bilaterally. The first site was the inferior prominent part of the masseter muscle observed when the subject was asked to clench, and the other site was 5 mm below the first point
223624867|NCT05620316|OTHER|Prick skin|patients were pricked twice at the inferior prominent part of the masseter muscle observed using the stinger pen used in the blood glucose meter; it is less painful and provides psychological benefits, instead of injecting the physiological saline into the muscle to avoid the severe pain without a benefit to the patient which would not conform to the ethical standards.
223624868|NCT03761927|DEVICE|Hearing Aid without NR enabled|Each participant will be fitted with noise reduction disabled. Disabled means that no sound processing algorithm that removes noise from the speech signal is active.
223624869|NCT03761927|DEVICE|Hearing Aid with NR(1)|Each participant will be fitted with the noise reduction program on the same hearing aid. The principle of the noise reduction algorithm is to remove noise from a speech signal with the aim of improving the speech intelligibility and comfort.
223762224|NCT01589302|DRUG|ibrutinib|Patients receive ibrutinib orally (PO) once daily (QD) on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
224214099|NCT01673165|OTHER|Skimmed mother's milk|Fortified skimmed mother's milk will be given to the skimmed mother's milk group. The fortifier is a standard fortifier we use in our population
224214100|NCT01673165|OTHER|Specialized Formula|Infants will receive our standard of care - specialized formula
224214101|NCT01613131|DRUG|Mirena|Mirena (levonorgestrel-releasing intrauterine system), 52 mg (20 mcg/day), 5 year duration (study duration 6 months).
224214102|NCT01613131|DRUG|Estradiol|Topical, .06%, Applied once daily for 50 days.
224214103|NCT01613131|DRUG|Placebo Gel|Topical Gel, Applied once daily for 50 days, Placebo comparator.
224214104|NCT02423174|PROCEDURE|Total Mesorectal Excision|Surgical intervention with the FMwand Surgical System
224214105|NCT02423174|DEVICE|FMwand Surgical System|
224214106|NCT02427373|DIETARY_SUPPLEMENT|fish oil ethyl ester|
224214107|NCT02427373|DIETARY_SUPPLEMENT|fish oil triglyceride|
224214108|NCT02427373|DIETARY_SUPPLEMENT|krill oil|
224214109|NCT06382467|DRUG|Remimazolam besylate + propofol MCT|remimazolam besylate 3mg/kg/hr for induction, and 0.5 mg/kg/hr for maintenance + propofol MCT 1-4 mcg/ml using target-controlled infusion
224214110|NCT06382467|DRUG|Propofol MCT|Propofol MCT 2-8 mcg/ml using target-controlled infusion
224214111|NCT04568369|DEVICE|rTMS|See treatment arm description.
224214112|NCT06479044|DIAGNOSTIC_TEST|Herrmann Brain Model|The test comprises 120 multiple-choice items on academic, daily, and professional scenarios
224214113|NCT04641572|OTHER|Choose comfortable position|Standing or walking, Squatting, Sitting, Hands /knees, and Kneeling, positions will be taken by the participant during labor.Then the researcher will register the time ( minutes/hours) will be taken and which that will be more preferable by the participant
224214114|NCT00787566|DRUG|Intranasal granisetron|0.5 mg, 1.0 mg or 2.0 mg dose of TRG prior to the administration of a highly-emetogenic chemotherapy regimen
224214115|NCT00543790|DRUG|PRA-027|PRA-027 capsules; cohort-specific doses or 40, 120, 240 or 500 mg; 1 dose daily for 28 days
224214116|NCT02700802|OTHER|Feed1st|Feed1st is a unique hospital-based hunger mitigation program that, since 2010, has operated low-cost, self-serve food pantries at Comer Children's Hospital. All parents and caregivers with a hospitalized child have 24/7 free access to these self-serve pantries with the option to eat food in the pantry, carry out as much food as needed, and contribute back to the pantry with food, volunteerism, or other resources. The program also offers free phone/text/email navigation for food support and other basic needs resources. We aim to conduct a 3-arm, randomized comparative effectiveness study to evaluate the impact, versus usual care, of two alternative referral strategies to increase Feed1st program utilization and impact.
224214117|NCT00689403|DRUG|AZD1305|Extended release capsules, oral single doses
224214118|NCT00689403|DRUG|AZD1305|Extended release capsules, oral single doses
224214119|NCT03094208|OTHER|dual task balance training|balance exercises with cognitive and motor dual tasks
224214120|NCT03094208|OTHER|traditional balance training|balance exercises
224214121|NCT05822700|PROCEDURE|Kirschner wire|Transfixing femoral head Kirschner wire
224214122|NCT01814761|DRUG|Bimatoprost 0.01%|One drop of bimatoprost 0.01% (Lumigan® 0.01%) in the affected eye(s) every evening for 12 weeks.
224214123|NCT00038883|DRUG|Campath-1H|10 mg/day x 5, starting with the first day of chemotherapy
224316613|NCT06780176|DIAGNOSTIC_TEST|Surgical Tissue Collection|Tissue collection will be attempted at time of surgery
224316614|NCT06780176|BEHAVIORAL|Survey Collection|Survey collection at baseline, post-surgery, at 1, 3 and 5 year follow up visits
223624870|NCT03761927|DEVICE|Hearing Aid with NR(2)|Each participant will be fitted with a second noise reduction program on the same hearing aid. The parameterization of this NR algorithm differs from that in NR(1).
223624871|NCT05330013|DRUG|Dapagliflozin|Subjects will be instructed to take dapagliflozin 10 mg once daily for 6 months (with or without food).
223624872|NCT05330013|DEVICE|MRI scan|For subjects, depending on the subject's heart rate, base, mild, or apex short-axis slices will be acquired during the first pass of the contract (60 measurements).
223762225|NCT01589302|OTHER|Correlative laboratory samples|Blood samples will be collected and used for pharmacodynamic testing. Samples will be collected pre-dose on Cycle 1 Day 1 and 2 hours post-dose Cycle 1 Day 1, pre-dose on Day 2 and Day 8 of Cycle 1 and pre-dose on Day 1 of Cycles 2 and 3 and then every 3 cycles thereafter for 1 year (Cycle 15 Day 1). Samples will also be collected at the time of relapse and at any time when bone marrow biopsy is performed.
223762226|NCT01589302|OTHER|quality of life assessment|During screening, sociodemographic information (e.g., age, race, marital status) and reports of recent (last year) stressful events will be obtained. The assessment will consist of measures of emotional distress, depressive symptoms, and quality of life. Quality of life measures will be administered during screening and on Days 1 (±3), 8 (±3),, 15 (±3),, 22 (±3), of Cycle 1, Day 1 (±3), of Cycle 2 and on day 1 (±7) of Cycles 3, 6, and then every 3 months thru month 24.
224214124|NCT06020105|BEHAVIORAL|NURLIFE|After the first consultation with the surgeon, the patients will be referred to the case manager, who will carry out the first face-to-face consultation, with consequent monitoring and clarification of identified needs, following the flowchart in figure 3, being referred to the different specialties, psychology, nutrition and nursing, fostering the case manager as the central pillar of the process, which will monitor each process individually, namely the number of consultations and necessary referrals.
224214125|NCT03413527|DEVICE|rTMS|rTMS Treatment
224214126|NCT01416376|DRUG|SRT2379|SRT2379 is supplied as hard gelatin capsules containing either 25mg or 250mg free-base equivalent of SRT23790 drug substance as its succinate salt.
224214127|NCT01416376|DRUG|Placebo|For the placebo capsules, the SRT2379 drug substance will be replaced by microcrystalline cellulose (Avicel PH200) to visually match the SRT2379 investigational product.
224214128|NCT03214757|OTHER|treatment of anemia.|drug treatment of anemia.
224214129|NCT05961254|DEVICE|assesment of difficult endotracheal intubation by airway ultrasound|preoperative assesment of airway by ultrasound to predict difficult endotracheal intubation in patients undergoing general anesthsia
224214130|NCT00626483|BIOLOGICAL|RNA-loaded dendritic cell vaccine|Only one dose of DCs (2 x 10\^7) is being assessed.
224214131|NCT00626483|DRUG|basiliximab|Basiliximab 20 mg and 40 mg is being assessed depending on dose-cohort enrollment.
224214132|NCT06531291|DRUG|Surufatinib|250 mg, po, qd, q3w
224214133|NCT06531291|DRUG|Serplulimab|200 mg, iv, d1, q3w
224214134|NCT06531291|DRUG|standard chemotherapy|Decided by PI
224214135|NCT04031027|DRUG|Apremilast|Apremilast is prescribed in accordance with the terms of the SmPC and the marketing authorizations.
224214136|NCT05245981|DEVICE|BRI.MAG 2|Patients presenting with dislocated isolated or combined fracture of the medialis malleolus, will be screened for eligibility. Every effort will be made to ensure eligibility of the patients prior to enrollment. 20 patients will be recruited for the study.
224214137|NCT05699577|DIAGNOSTIC_TEST|serum sample for ELIZA|ELIZA for Ca15-3 and interferon gamma
224214138|NCT00878137|DEVICE|INR by point-of-care instruments and venopuncture|Three fingersticks will be performed and from each one drop of capillary or venous whole blood collected from a fingerstick performed by the primary investigator to measure PT/INR using the CoaguChekXSTM (10 microliters), ProTimeTM (27 microliters), the investigational ProTime, and INRatioTM 15 microliters) point-of-care instruments and one i.v. blood draw (20 mL of blood) will be performed by a phlebotomist.
224214139|NCT03014531|OTHER|almond|
224214140|NCT03014531|OTHER|high-carbohydrate control food|
224214141|NCT02348619|DRUG|JZP-110|
224214142|NCT06537986|BEHAVIORAL|Neurocognitive and psychosocial intervention module|"The module comprised of various intervention methods that include- I. Cognitive Retraining: Pen-and-paper-based cognitive rehabilitation program that is divided into five hierarchically graded modules: Attention, Visual Processing, Memory, Information Processing, and Executive Functions.~2.Cognitive-behavioral interventions. Cognitive-behavioral interventions would be carried out for activities scheduling, problem-solving teachings, anger management techniques, modifications of negative cognitions, stigma address measures, and irrational beliefs about epilepsy, etc.~3\. Marital/Family counseling: Marital/family counseling would be done to ensure family understanding of the patient's illness, his/her treatment, prognosis, and outcome. Family complications arising due to illness would also be discussed. Individual and personal needs of the husband, a wife will also be discussed."
223624873|NCT05330013|DEVICE|CMR imaging|Enrolled subjects will undergo stress vasodilator and rest perfusion CMR
223624874|NCT05647681|DRUG|Douloff|topic gel
223624875|NCT05647681|DRUG|paracetamol|tablets
223624876|NCT03740048|OTHER|Hemodialysis|Hemodialysis frequency will differ in the first six weeks of hemodialysis therapy between the two treatment arms.
223624877|NCT03740048|DRUG|Patiromer Oral Product|Participants in the intervention group who develop hyperkalemia, during the first six weeks of receiving hemodialysis twice per week, will be treated with Patiromer.
223624878|NCT01985295|DRUG|pazopanib|A dose escalation trial of Pazopanib, starting at 400mg daily, orally in combination with the standard 25 x 2Gy preoperative radiotherapy in newly diagnosed extremity sarcoma patients. Dose of pazopanib will be escalated via 600mg to maximally 800mg. Overall treatment time of pazopanib is 40 days.
223624879|NCT02337868|BIOLOGICAL|HydroVax-001|HydroVax-001 West Nile Virus inactivated vaccine, alum-adsorbed given at doses of 1 mcg (low dose) and 4 mcg (high dose) IM on days 1 and 29
223624880|NCT02337868|OTHER|Placebo|0.9% Sodium Chloride Injection diluent will be given IM on days 1 and 29
224214143|NCT00811200|DRUG|ranibizumab|three initial monthly intra vitreal injections with 0.5 mg ranibizumab
224214144|NCT00811200|DRUG|triamcinolone acetonide|at baseline one intra vitreal injection with 4.0 mg triamcinolone acetonide
224214145|NCT00811200|OTHER|sham|at baseline one sham-injection
224214146|NCT01261962|DIETARY_SUPPLEMENT|zinc|zinc sulfate, 35 mg twice daily for 4 months
224214147|NCT01261962|OTHER|Placebo|Placebo, One capsule, twice daily for 4 months
223624881|NCT01476722|DEVICE|OPTI-FREE PureMoist multipurpose disinfecting solution|FDA-approved, multipurpose disinfecting solution used as indicated for cleaning, rinsing, reconditioning, disinfecting, and storing silicone hydrogel and soft contact lenses on a daily wear basis for 30 days
223624882|NCT00737646|BEHAVIORAL|Usual care|No intervention will be conducted in this arm of the study.
223624883|NCT00737646|BEHAVIORAL|Clinic-focused intervention|The clinic-focused intervention consists of CRC screening training sessions for clinicians and clinical staff. The provider training sessions will include the presentation of CRC screening statistics and information, and will be heavily interactive and skills-based. The provider training sessions will also focus on the provision of tools for improving clinical staff- and clinician-patient interactions about CRC screening and for office system changes/improvements to identify eligible patients and to track screening.
223624884|NCT00737646|BEHAVIORAL|Clinic- and patient-focused|This arm will combine the clinic-focused intervention and the patient-focused intervention. The clinic-focused intervention consists of CRC screening training sessions for clinicians and clinical staff as described in Arm 2. The patient-focused intervention includes sending a CRC screening education packet (CDC-developed educational text tailored for use within the study sites), accompanied by a letter from the patient's physician, to patients meeting study inclusion criteria.
223762227|NCT01567969|BEHAVIORAL|Intensive In-home Child and Adolescent Psychiatric Service|A six to seven month intensive intervention provided by a clinical team consisting of a master's-level clinician and a bachelor's-level mental health counselor delivering comprehensive psychiatric and case management services in the child's home. One or both members of the team works with the child and the family three times a week in the home. Delivery of direct and indirect services average 5.5 hours of service per week.
224214148|NCT06293690|DRUG|Toripalimab|Patients received preoperative neoadjuvant therapy: SBRT 12gy on the first day, and Toripalimab (iv 240mg, q3W) combined with platinum-containing dual drugs on the second day. Two cycles in total.
224214149|NCT06293690|DRUG|Toripalimab|Patients received preoperative neoadjuvant therapy: SBRT 12gy on the first day, and Toripalimab (iv 240mg, q3W) on the second day. Two cycles in total.
224214150|NCT00142844|DRUG|Naltrexone|
224214151|NCT00142844|DRUG|Disulfiram|
224214152|NCT00142844|DRUG|Placebo|
224214153|NCT02270931|DEVICE|CA 15-3 Assay|Physicians use the CA 15-3 test result to manage their patients
224214154|NCT03744065|PROCEDURE|lumbar plexus block|Injection with ultrasound guidance of 40 mL of levobupivacaine 0.25% with 5 micrograms of epinephrine per mL and dexamethasone 4 milligrams, in the posteromedial quadrant of psoas muscle
224214155|NCT03744065|PROCEDURE|suprainguinal fascia iliaca block|Injection with ultrasound guidance of 40 mL of levobupivacaine 0.25% with 5 micrograms of epinephrine per mL and dexamethasone 4 milligrams, underneath the fascia iliaca at the suprainguinal level
223624885|NCT02097862|PROCEDURE|Adipose Stem Cells|Injection of adipose derived stem cells intra-discally
223762228|NCT01567969|BEHAVIORAL|Home-based Child Treatment Coordination|A six to seven month home-based case management service delivered by a master's level clinician. The coordinator meets with the child's parent/legal guardian in the child's home once a month and conducts weekly phone conversations to facilitate referral and access to appropriate mental health services for the child.
223762229|NCT02927457|DRUG|GSK2646264 1%|A cream for topical application with a concentration of 1% GSK2646264.
224214156|NCT02869932|RADIATION|Lung CT scan|Lung CT scan without injection
224214157|NCT02282111|DEVICE|22-gauge Procore needle (ProCore, Cook Medical Inc., Winston-Salem, NC)|Using a linear EUS with color and pulsed Doppler to scan the area for vessels, the lesion was then sampled with a 22-gauge beveled needle (using the slow capillary suction and fanning techniques with 5 to 15 to-and-fro movements with each pass). A total of 4 passes were performed and after that, the procedure terminated.
224214158|NCT02282111|DEVICE|conventional needle-knife sphincterotome (Microknife XL; Boston Scientific Inc, Natick, Mass)|Using a conventional needle-knife sphincterotome connected to an electrosurgical unit, and under direct endoscopic vision, a 6-12mm linear incision was made from the periphery of the lesion to its highest convexity zone. A conventional biopsy forceps was then deeply introduced through the hole, and 2 bites were obtained per pass. A total of 4 passes were performed by passing the biopsy forceps through the incision on each occasion. The mucosal incision was then closed with endoclips whenever possible.
223762230|NCT02927457|DRUG|Placebo|Subjects will receive matching Placebo topically.
223624886|NCT05603117|BEHAVIORAL|Collaborative Interpersonal Strategy Building with Audio Reflection (CISBAR)|CISBAR incorporates collaborative, individualized goal-setting, metacognitive strategy training, audio feedback, reflection, and practice, integrated with the Conversational Rating System for ABI (CoRS-ABI) and adding a new method for selecting individualized and equivalently challenging conversation practice topics.
223624887|NCT03261336|DRUG|Calcitriol, Ketoconazole, Hydrocortisone|Calcitriol (0.5 mcg caplets) given in escalating doses, orally QD X3 consecutive days every week Ketoconazole, 200 mg tablets, 2 tablets orally TID Hydrocortisone 20mg AM, 10mg PM orally starting in the evening before the first dose of Calcitriol
223624888|NCT00647179|PROCEDURE|Transsphenoidal adenomectomy|Surgery
223762231|NCT01068938|DEVICE|three different perimeters: HFA, Octopus, MATRIX|visual fields
223762232|NCT00804336|DRUG|SOM230|Given subcutaneously twice a day for four weeks then given intramuscularly once every four weeks thereafter
224214159|NCT02583178|DEVICE|Aegis Sierra Ligation System|The SLS is a series of devices designed for epicardial ligation of the left atrial appendage through a minimally invasive transcatheter approach.
224214160|NCT00423488|DRUG|Ezetimibe 10 mg|1 x 10-mg tablet, provided as blinded study treatment
224214161|NCT00423488|DRUG|Simvastatin 20 mg|1 x 20-mg tablet, provided as open-label study treatment
224214162|NCT00423488|DRUG|Ezetimibe Placebo|1 tablet matching ezetimibe 10-mg tablet, provided as blinded study treatment
224214163|NCT00423488|DRUG|Simvastatin 20 mg|1 x 20-mg tablet, provided as blinded study treatment
224214164|NCT00423488|DRUG|Simvastatin Placebo|1 tablet matching 20-mg simvastatin tablet, provided as blinded study treatment
224214165|NCT01217528|DEVICE|device settings for group A|VT zone: 350ms VF zone: 280ms
224214166|NCT01217528|DEVICE|Device settings for group B|VT zone: 320ms VF zone: 250ms
224214167|NCT02991261|DRUG|SPARC001 type I|Treatment type I
224214168|NCT02991261|DRUG|SPARC001 type II|Treatment type II
224214169|NCT02991261|DRUG|Reference001 type I|Hydrocodone-acetaminophen
224214170|NCT02991261|DRUG|Reference001 type II|Hydrocodone Acetaminophen
224214171|NCT02633761|DRUG|Mifepristone|200mg mifepristone followed in 24 hours by 200mcg buccal misoprostol every 3 hours.
224214172|NCT02633761|DRUG|Placebo|placebo followed in 24 hours by 200mcg buccal misoprostol every 3 hours.
224214173|NCT02633761|DRUG|Misoprostol 200mcg|Buccal misoprostol 200mcg
224214174|NCT02729493|BIOLOGICAL|EPCAM-targeted CAR-T cells|This study have only one arm that is CAR-T experimental arm. Firstly all participators will be attended the screening, who passed the screening for the treatment of CAR-T cells, the CAR-EPCAM-modified T cells can recognize and kill tumor cells in the body，follow-up 35 months.
224214175|NCT00056082|DRUG|celecoxib|Celecoxib daily for 12 months
224214176|NCT04664569|OTHER|observational study|observational study
224214177|NCT03933319|DRUG|pegylated liposomal doxorubicin|Eligible patients will be treated with the PLD+trastuzumab regimen until the disease progresses or intolerable toxicity
224214178|NCT04844996|PROCEDURE|Surgical induction of endometriotic explants|"Surgical induction of endometriosis was done as: A 5-cm vertical midline incision was made and a distal segment 1 cm in length of the right uterine horn was resected. The segment was split longitudinally, and a 5 X 5 mm piece was sectioned.~This piece of uterine tissue was transplanted without removing the myometrium onto the inner surface of the right abdominal wall with the serosal surface apposed and secured with single nonabsorbable 5-0 polypropylene suture at the middle to the abdominal wall. The abdominal incision was closed in two layers~Drug administration:~Vehicle treatment (1 mL/kg/day saline) was administered orally to the control group with the gavage methodology. Ezetimibe (1 mg/kg/day (Ezetrol®, Merck Sharp Dohme, Istanbul, Turkey) was administered orally with gavage methodology to the rats in the study for 28 days postoperatively"
224214179|NCT06319521|BEHAVIORAL|Rehabilitation therapy|"Rehabilitation therapy includes Diet management: Avoiding consumption of irritant foods and beverages, such as spicy foods, caffeine, alcohol, and acidic foods. Controlling portion sizes and meal timing, and adopting smaller, more frequent meals.~Lifestyle adjustments: Avoiding lying down or bending immediately after meals, maintaining a sitting or upright position for at least 2 hours. Adjusting sleeping positions by elevating the head of the bed to reduce nighttime acid reflux. Avoiding excessive exertion and managing stress levels.~Rehabilitation training: Strengthening the control of esophageal and gastric muscles through rehabilitation exercises to improve the function of the gastroesophageal sphincter and prevent gastric fluid reflux."
224214180|NCT06319521|PROCEDURE|Stellate ganglion block|The percutaneous approach via the paratracheal route was used for Stellate ganglion block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
224214181|NCT06319521|DRUG|Lidocaine hydrochloride|Based on the invention above, the patients in the observation group were provided with Stellate ganglion block, using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate ganglion block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
224214182|NCT06319521|PROCEDURE|Placebo injection|1 milliliter of normal saline will be used for injection. The percutaneous approach via the paratracheal route was used for Stellate ganglion block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
224214183|NCT01637675|DRUG|20 mg sildenafil citrate by mouth|20 mg sildenafil citrate tablets by mouth three times a day for 8 weeks
223513728|NCT00449852|BEHAVIORAL|Interactive Voice Response|The IVR group will receive a telephone call from the IVR system three, 14, 30, 90, 120 and 150 days after hospital discharge.
223513729|NCT06269601|DIAGNOSTIC_TEST|Upper Limb Rotation Test|The athletes were instructed to perform a 90° abduction and 90° external rotation of the shoulder, accompanied by trunk rotation for a duration of 15 seconds. The number of repetitions was recorded. The tested side was the upper extremity in which the closed kinetic chain position was maintained. The test was repeated three times, and the average of the results was calculated.
223513730|NCT00873886|DRUG|Oseltamivir (Tamiflu)|"The following procedures will be performed on two occasions: once at least three days prior to the scheduled pregnancy termination procedure and again about eight weeks after the termination procedure.~A) Subject will take 75 mg of oseltamivir pill by mouth~B) Multiple blood draws (1 teaspoon each) over the next 48 hours after taking oseltamivir. Urine samples also will be collected."
223513731|NCT00873886|PROCEDURE|Blood Draws|Two blood draws (1 teaspoon each) will be performed: once during third trimester of pregnancy and again about eight weeks after delivery.
223513732|NCT02770365|DRUG|estrace cream (Perrigo)|
223513733|NCT02770365|DRUG|estrace cream (Reference)|
223513734|NCT02770365|DRUG|Placebo cream|
223513735|NCT03000751|OTHER|Simple Audit Report|The simple audit provides comparison and feedback on radiation doses.
223513736|NCT03000751|OTHER|Multi-Component Intervention|The multi-component intervention gives tailored feedback on needed changes plus guidance using quality improvement methods that facilitate organizational change. Provides access to experts, detailed audit, collaborative calls, and site visits (as needed).
223513737|NCT03000751|OTHER|In-Person Meeting|Collaborator meeting with an emphasis on quality improvement.
223513738|NCT05835596|DEVICE|Access to MumCare app|Education, push warning to book cardiovascular health follow-up at own general practitioner , registration of BP and lipids, HbAc
223624889|NCT03918616|DRUG|Memantine, Dopamine receptor-agonists|The study do not provide any experimental drugs. Patientes will receive treatment routinary used by Neurologist for these diseases.
223624890|NCT05478408|OTHER|Questionnaires set|Participants will be asked to respond to the demographic information，the Depression Anxiety Stress Scale（DASS-21）and the Internet Addiction Test（IAT）.
223624891|NCT02306681|OTHER|No treatment given|This study comprises of a two-part SAQ (Self-Assessment Questionnaire). Paired responses to SAQ1 and SAQ2 will be used to estimate the differences in the frequency of hypoglycaemic episodes between the retrospective and prospective periods.
223624892|NCT00254917|BIOLOGICAL|Diphteria, Tetanus, Polio, Acellular Pertussis, Hib vaccine|0.5 mL, IM
223624893|NCT00254917|BIOLOGICAL|Diphteria, Tetanus, Polio, Acellular Pertussis, Hib vaccine|0.5 mL, IM
224214184|NCT01637675|DRUG|sodium tanshinone IIA sulfonate diluted with 5% glucose solution,20mg sildenafil citrate by mouth|sodium Tanshinone IIA sulfonate injection 80 mg diluted with 5% glucose solution(0.9% sodium chloride injection will also be permitted if necessary) 250ml iv drip once a day for 8 weeks,as well as 20mg sildenafil citrate tablets by mouth three times a day for the same duration of treatment
224214185|NCT01498107|BEHAVIORAL|SilverCloud Platform|The SilverCloud online intervention will be provided as an alternative choice to paper manuals to support guided self-help for depression in a primary care mental health service. Participants will receive up to eight progress reviews on a weekly or fortnightly basis as agreed with their therapist with the intervention running not more than three months.
224214186|NCT04514770|DRUG|Misoprostol|rupture of membrane early and late
224214187|NCT00065897|PROCEDURE|Amniocentesis|
224214188|NCT00065897|PROCEDURE|Transabdominal chorionic villus sampling (TA CVS)|
224214189|NCT00947245|DRUG|BMS-791325|Capsules, Oral, 300 mg, Single Dose, One day
224214190|NCT00947245|DRUG|BMS-791325|Capsules, Oral, 900 mg, Single Dose, One day
223624894|NCT00292942|DRUG|Intravenous Artesunate|Three doses of Intravenous Artesunate drug at 2, 4, or 8 mg/kg in diluent Phosphate Buffer (0.3 M, pH 8.1)
223624895|NCT00292942|DRUG|Placebo|Mannitol (200 mg/vial) diluted in Phosphate Buffer and given IV in equivalent volume by subject's weight.
223624896|NCT05975723|BEHAVIORAL|MIND diet education|An intensified education program following a localized modified MIND diet for 1 year, which recommends 11 brain healthy food groups (green leafy vegetables, dark red and yellow vegetables, other vegetables, nuts, berries, beans, whole grains, seafood, poultry, olive/tea-seed oil and green tea) and limits intake of 4 unhealthy food groups (red meat and products, animal oil, pastries and sweets, and fried/fast food).
223624897|NCT05975723|BEHAVIORAL|Routine follow-up and general advice|Routine follow-up administered by trained staff.
223624898|NCT00683111|DRUG|esomeprazole 20 mg daily|oral famotidine 40 mg daily vs. oral esomeprazole 20 mg daily for up to 12 months
223624899|NCT00683111|DRUG|famotidine 40 mg daily|oral famotidine 40 mg daily vs. oral esomeprazole 20 mg daily for up to 12 months
223624900|NCT02848469|DIETARY_SUPPLEMENT|1000mg of eicosapentaenoic acid and 1000mg docosahexaenoic acid|
223624901|NCT02027012|DEVICE|Percutaneous renal denervation with the Vessix™ Renal Denervation System|
223624902|NCT04976985|PROCEDURE|Osteopathic Manipulative Therapy (OMT)|"Osteopathic Manipulative Therapy (OMT) is a non-pharmacological, noninvasive form of manual medicine. Osteopathic physicians receive special training in the musculoskeletal system to detect somatic dysfunction. Osteopathic physicians then move a patient's muscles and joints using techniques that include stretching, gentle pressure and resistance to improve muscle tonicity, treat structural abnormalities, relieve joint restriction, and decrease activation of the pain proprioception pathway.~OMT Standardized Protocol A:~1. Occipital- Alanto release~2. Muscle energy and soft tissue to mid trapezius muscle~3. Muscle energy to cervical spine in all three planes of flexion/extension, rotation and side bending~4. Screening for tender points of C2-C6 at transverse and spinous processes and treatment with counterstain if tender point identified~5. Soft tissue to cervical paraspinal muscles~6. Myo-fascial release of frontal forehead~7. CV4 cranial technique"
223624903|NCT04976985|OTHER|Standard of care|Receiving standard of care for migraine headaches with pharmacological medications, with no more than two prophylactic medications during the study period. Participants may also take abortive migraine medications.
223624904|NCT02141087|DRUG|Pirfenidone|
223624905|NCT03496259|DEVICE|On-Q pump|Type of pain control device used
223624906|NCT03496259|DEVICE|Epidural catheter|Type of pain control device used
223762233|NCT00804336|DRUG|RAD001|Given orally once a day
224214191|NCT00947245|DRUG|BMS-791325|Capsules, Oral, ≤1200 mg, Single Dose, One day
224214192|NCT00947245|DRUG|BMS-791325|Capsules, Oral, 300 mg, Every 12 hours, 14 days
224214193|NCT00947245|DRUG|BMS-791325|Capsules, Oral, 900 mg, once daily 14 days
224214194|NCT00947245|DRUG|BMS-791325|Capsules, Oral, ≤1200 mg, Every 12 hours or once daily, 14 days
224214195|NCT00947245|DRUG|Placebo|Capsules, Oral, Single Dose, One day
224214196|NCT00947245|DRUG|Placebo|Capsules, Oral, Every 12 hours, 14 days
224214197|NCT00947245|DRUG|Placebo|Capsules, Oral, Once Daily, 14 days
224214198|NCT00947245|DRUG|Placebo|Capsules, Oral, Every 12 hours or once daily, 14 days
224214199|NCT01693276|DRUG|Gemcitabine|"gemcitabine 1000mg/m2 given on day 1,8, and 15 of a 28 day cycle for 2 cycles prior to chemoradiation and post RT.~Gemcitabine 450 mg/m2, 30-minute infusion, given weekly during chemoradiation for a total of 6 weeks."
224214200|NCT01693276|DRUG|Abraxane|Abraxane® 100 mg/m2 given on day 1,8, and 15 of 28 day cycle for 2 cycles prior to RT and each cycle post RT
224214201|NCT01693276|RADIATION|Radiation Therapy|IMRT Dose escalation: 60 Gy (2 Gy/fraction)
224214202|NCT04014101|DRUG|SHR-1210|SHR-1210 is a humanized anti-PD-1 IgG4 monoclonal antibody
224214203|NCT04014101|DRUG|apatinib|Apatinib is a selective VEGFR2 inhibitor.
224214204|NCT03798522|PROCEDURE|bilateral ultrasound guided erector spinae plane block|ESPB on both sides at T7 before GA
224214205|NCT03798522|DRUG|Nalbuphine|in nalbuphine for analgesia after GA
224214206|NCT02012205|PROCEDURE|wet cupping|Participants assigned to the treatment group will receive wet-cupping therapy 3 times per week for 2 weeks
224214207|NCT02368769|DEVICE|During Tele-expertise|
223762234|NCT00748956|DRUG|Low dose NPY|50nmol, administered intranasally
223762235|NCT00748956|DRUG|High dose NPY|100nmol administered intranasally
223762236|NCT00748956|DRUG|Placebo|placebo comparator (0nmol)) administered intranasally
224214208|NCT05728216|OTHER|Dynamic full-field optical coherence tomography analysis of kidney biopsy|Dynamic full-field optical coherence tomography analysis of kidney biopsy in the nephrology department before conventional histopathological analysis
224214209|NCT06542770|DEVICE|Early implant of cardiac monitor|ICM implant 3-4 days after the stroke and prior to discharge. All devices (Abbott Confirm or Jot) were implanted subcutaneously under local anaesthesia in the left chest region and programmed with an specific algorithm for AF detection set at 30 seconds for detection. All patients were included in remote monitoring system (Merlin), which was programmed to send alerts in case of registering episodes qualifying for AF detection, and a monthly routine registration. All ICM recordings were reviewed by a specialized cardiologist.
224214210|NCT05959707|BIOLOGICAL|VRC01.23LS|VRC01.23LS will be administered IV over approximately 30 to 60 minutes.
224214211|NCT05959707|BIOLOGICAL|PGT121.414.LS|PGT121.414.LS will be administered IV over approximately 30 to 60 minutes.
224214212|NCT05959707|BIOLOGICAL|PGDM1400LS|PGDM1400LS will be administered IV over approximately 30 to 60 minutes.
224214213|NCT00363129|DIETARY_SUPPLEMENT|vitamin E|Given orally
224316615|NCT00586534|BEHAVIORAL|I/GDC + VR/CER|NIDA approved Individual/Group Drug Counseling (I/GDC) cocaine treatment plus virtual reality (VR) based cue exposure/extinction software and cellular phone-based computerized extinction reminder (CER) technology for use in high-risk situations outside treatment sessions.
223513739|NCT03763266|OTHER|1 day low residue diet|Patients are interviewed and instructed by a nurse prior the colonoscopy. They receive oral and written dietary information. In case of morbidity associated with bad preparation they are given bisacodyl the night before the colonoscopy.
223513740|NCT03763266|OTHER|3 day low residue diet|Patients are interviewed and instructed by a nurse prior the colonoscopy. They receive oral and written dietary information. In case of morbidity associated with bad preparation they are given bisacodyl the night before the colonoscopy.
223513741|NCT03674450|BEHAVIORAL|Heart Rate Variability Biofeedback Training|The study will utilize the Physiolab GP8 heart rate variability and respiration system on a laptop computer used solely for the study with the proper security passwords to protect participant information. The equipment consists of two electrocardiogram sensors (one per wrist) attached by sports wrist bands, a respiration monitoring belt placed around the upper abdomen, two galvanic skin conductance sensors attached to the fingertips, and a thermistor sensor attached to one of the finger tips. Participants will perform a series of monitored breathing exercises.
224214214|NCT00363129|OTHER|placebo|Given orally
224214215|NCT02162030|BEHAVIORAL|Acceptance and Commitment Therapy|Half of the participants will receive an eight-session ACT intervention whereby each component of the psychological flexibility model will be covered. Half of the participants will receive an eight-session act intervention whereby each component except self as context will be covered.
224214216|NCT06375837|DEVICE|an alkasite-based restorative material|Cention N
224214217|NCT06375837|DEVICE|hybrid resin composite|Gradia Direct Anterior
224214218|NCT06375837|DEVICE|a highly filled flowable resin composite|G-aenial Universal Flo
224214219|NCT03046147|PROCEDURE|Roux-en-Y gastric bypass|Roux-en-Y gastric bypass surgery for morbid obesity
224214220|NCT04528277|DRUG|rifapentine plus isoniazid|receive the 1-month regimen of three times weekly rifapentine (450mg po) plus isoniazid (400mg po)
224214221|NCT00924183|OTHER|Treatment-as-usual|
224214222|NCT06537635|DEVICE|Cubii seated compact elliptical trainer|The Cubii® Pro is an under-desk seated elliptical trainer. This device provides 8 levels of resistance and documents the total number of strides, distance covered in miles, and calories expended during an activity session.
224214223|NCT03125915|BEHAVIORAL|Communication skills training video|This video includes 4 scenes of gay couples discussing issues related to HIV prevention, testing, sexual agreements, and drug use. Each scene is viewed twice. The first viewing includes common communication errors. The second viewing portrays more skillful interpersonal communication and a more adaptive resolution to the conversation.
224214224|NCT03125915|BEHAVIORAL|substance use module|This activity involves completion of a calendar detailing partners' substance use in the past month and a structured debriefing activity designed to facilitate the formation of couples' goals and limits around substance use.
224214225|NCT03125915|BEHAVIORAL|Couples HIV Testing and Counseling|CHTC delivered as per the CDC protocol.
224214226|NCT05780515|BIOLOGICAL|ANX009|ANX009 will be administered per schedule specified in the arm description.
224214227|NCT04534088|BEHAVIORAL|Standard Behavioral Weight Loss plus Non-Weight-Related VR app|Standard Behavioral Weight Loss Program
224214228|NCT04534088|BEHAVIORAL|Standard Behavioral Weight Loss plus Weight-Related VR app|Standard Behavioral Weight Loss plus Weight-Related VR app
223513742|NCT01584297|DRUG|Ketoconazole|Patients will receive ketoconazole, 400 mg three times a day. Study treatment period will be during 6 months or up to progression disease, unacceptable toxicity, death or withdraw from the study for any reason.
223513743|NCT00002461|BIOLOGICAL|filgrastim|
223513744|NCT00002461|BIOLOGICAL|sargramostim|
223513745|NCT00002461|DRUG|carmustine|
223513746|NCT00002461|DRUG|cisplatin|
223513747|NCT00002461|DRUG|cyclophosphamide|
223513748|NCT00002461|DRUG|etoposide|
224316616|NCT00586534|BEHAVIORAL|I/GDC|NIDA approved Individual/Group Drug Counseling (I/GDC) cocaine treatment
224316617|NCT02267044|DRUG|Ropivacaine|The drug used for the interscalene blocks
223513749|NCT00002461|PROCEDURE|autologous bone marrow transplantation|
223513750|NCT00002461|PROCEDURE|in vitro-treated bone marrow transplantation|
223513751|NCT00002461|PROCEDURE|peripheral blood stem cell transplantation|
223762237|NCT05611086|DRUG|N-Acetylcysteine|Subjects in treatment group will be given capsules containing 600 mg of NAC
224316618|NCT03722589|BIOLOGICAL|Flublok|0.5 mL intramuscular dose of Flublok
224316619|NCT03722589|BIOLOGICAL|Flucelvax|0.5 mL intramuscular dose of Flucelvax
224316620|NCT03722589|BIOLOGICAL|Fluarix|0.5 mL intramuscular dose of Fluarix
224316621|NCT03722589|BIOLOGICAL|Fluzone|0.5 mL intramuscular dose of Fluzone
224316622|NCT03722589|BIOLOGICAL|Fluzone High-Dose|0.5 mL intramuscular dose of Fluzone
223624907|NCT03327493|DIAGNOSTIC_TEST|Biological|"We will assess in all patients under ECLS for the treatment of a cardiogenic shock at day 0 (ECLS initiation) day 3 and day ECLS weaning :~Biological assessment:~1. Adrenoreceptors α1, α2, β1, β2, β3 on monocytes and lymphocytes T helper by flow cytometry~2. Lymphocytes Th1/Th2 pattern by flow cytometry~3. Cytokines on plasma : Interleukin (IL) 4, IL 12, TNF α, INF γ , IL1, IL6, IL10~Clinical assessment:~1. Hemodynamic parameters~2. Cumulated doses of catecholamines~3. Cardiac output variation measured by echocardiography during a standardized weaning procedure of ECLS at a constant mean arterial pressure (only on day 3 and Day ECLS weaning)"
223624908|NCT03045367|PROCEDURE|Phacoemulsification, intraocular lens implant, vitrectomy.|Cataract extraction, intraocular lens implant, vitrectomy, epiretinal membrane and inner limiting retinal membrane peeling.
223624909|NCT00049023|RADIATION|90Y-DOTA-tyr3-OCTREOTIDE|
223624910|NCT06389630|OTHER|video-assisted training group|This group will be taught subcutaneous insulin injection through video-supported training.
224214229|NCT04800913|DIAGNOSTIC_TEST|Multimodal imaging|Preoperative 2D/3D TOE and MDCT, operative 2D/3D TOE and fluoroscopy/angiography, postoperative 2D/3D TOE and MDCT
224214230|NCT04800913|DIAGNOSTIC_TEST|Standard imaging|Preoperative MDCT, operative 2D/3D TOE and fluoroscopy/angiography, postoperative 2D/3D TOE and MDCT
224214231|NCT04542330|BIOLOGICAL|BCG-Denmark|Mycobacterium bovis BCG live attenuated BCG-Denmark vaccine (AJ Vaccines, Copenhagen, Denmark) administered by intradermal injection in the left deltoid region.
223624911|NCT06389630|OTHER|low fidelity simulation model group|This group will be taught subcutaneous insulin injection on a low-fidelity simulation model.
223624912|NCT02774460|DRUG|Zestril®|Treatment step up: 1-2 weeks (10 mg tablet) Target dose: 5-7 weeks (20 mg tablet)
223624913|NCT02774460|DRUG|Atacand®|Treatment step up: 1-2 weeks (8 mg tablet) Target dose: 5-7 weeks (16 mg tablet)
223762238|NCT05611086|DRUG|Placebo|subjects in the control group will be given capsules containing placebo (lactose)
223624914|NCT02774460|DRUG|Norvasc®|Treatment step up: 1-2 weeks (5 mg tablet) Target dose: 5-7 weeks (10 mg tablet)
223624915|NCT02774460|DRUG|Hydrochlorthiazide®|Treatment step up: 1-2 weeks (12,5 mg tablet) Target dose: 5-7 weeks (25 mg tablet)
223624916|NCT02774460|DRUG|Treatment X|Each patient receives all four treatments, and in addition repeats two of the treatments, labeled X and Y. The repeated arms will be given with the same duration and dosing as the other arms.
223624917|NCT02774460|DRUG|Treatment Y|Each patient receives all four treatments, and in addition repeats two of the treatments, labeled X and Y. The repeated arms will be given with the same duration and dosing as the other arms.
223624918|NCT02774460|DRUG|Placebo|This is an unblinded placebo run-in which we use to generate baseline values. Each patient will initiate their participation with these 2 weeks of placebo treatment, taking 1 capsule daily.
223624919|NCT02826746|DRUG|Magnesium Sulfate|adminstration of intravenous magnesium as bolus of 50 mg/kg, followed by continuous infusion at rate of 10 mg/kg/h
223762239|NCT02561130|DRUG|insulin glargine|Dose is titrated to achieve fasting normoglycemia
224214232|NCT04542330|BIOLOGICAL|Saline|Participants randomized to the control group will receive one 0.1 ml dose sterile 0.9 % NaCl by intradermal injection in the left deltoid region.
223624920|NCT02826746|DRUG|Normal saline|the same bolus and infusion volumes of normal saline
223624921|NCT00651924|BEHAVIORAL|IVR-based Cognitive-behavior therapy|Standard cognitive-behavior therapy for chronic pain management using Interactive Voice Response (IVR) compatible materials and handouts
223624922|NCT05405010|OTHER|Stair climbing and descending for 1 minute|Stair climbing and descending for 1 minute
223624923|NCT05405010|OTHER|Stair climbing and descending for 3 minutes|Stair climbing and descending for 3 minutes
223624924|NCT05405010|OTHER|Seated control|Seated control
223624925|NCT00960063|DRUG|Temozolomide|
223624926|NCT00960063|DRUG|Vincristine|
223624927|NCT00960063|DRUG|Ifosfamide|
223624928|NCT00960063|DRUG|Irinotecan|
223624929|NCT00960063|BIOLOGICAL|Robatumumab|
223624930|NCT00960063|DRUG|Doxorubicin|
223624931|NCT00960063|DRUG|Cyclophosphamide|
223624932|NCT00960063|DRUG|Etoposide|
223762240|NCT02561130|DRUG|metformin|Dose is titrated to 1 g bid or maximal tolerated dose
223762241|NCT02561130|DRUG|Forxiga|Dose is titrated to 10 mg po daily or maximal tolerated dose
223762242|NCT02561130|BEHAVIORAL|Lifestyle therapy|Lifestyle intervention includes individualized dietary and exercise advice and frequent visits for goal reinforcement, behavior modification and problem-solving
223762243|NCT00225836|DEVICE|OVA (TENS apparatus)|
224214233|NCT03564509|DRUG|FE 999302 (1 μg) and follitropin delta|Daily dose of 1 μg of FE 999302, a recombinant human chorionic gonadotropin (rhCG) solution for subcutaneous injection; individualized follitropin delta dose.
224214234|NCT03564509|DRUG|FE 999302 (2 μg) and follitropin delta|Daily dose of 2 μg of FE 999302, a rhCG solution for subcutaneous injection; individualized follitropin delta dose.
224214235|NCT03564509|DRUG|FE 999302 (4 μg) and follitropin delta|Daily dose of 4 μg of FE 999302, a rhCG solution for subcutaneous injection; individualized follitropin delta dose.
224214236|NCT03564509|DRUG|FE 999302 (8 μg) and follitropin delta|Daily dose of 8 μg of FE 999302, a rhCG solution for subcutaneous injection; individualized follitropin delta dose.
224214237|NCT03564509|DRUG|FE 999302 (12 μg) and follitropin delta|Daily dose of 12 μg of FE 999302, a rhCG solution for subcutaneous injection; individualized follitropin delta dose.
224214238|NCT03564509|OTHER|Placebo and follitropin delta|Daily dose of placebo; individualized follitropin delta dose.
224214239|NCT05938335|GENETIC|sequencing of a panel of 14 genes in leptin melanocortin pathway|sequencing (NGS) of a panel of 14 genes in leptin melanocortin pathway in french children with severe obesity
224214240|NCT01253876|DIETARY_SUPPLEMENT|soy milk, Caw's milk|
224214241|NCT00170456|BIOLOGICAL|rPA vaccine containing alhydrogel|
224214242|NCT05811260|OTHER|Myofascial Release technique|on low back 3 repetitions (30 second rest between reps), lasting for 30 s for each myofascial track for 1 set to targeted muscles (plantar fascia, gastrocnemius, hamstrings, and erector spinae). The position will be held for 10-15 seconds when a pain point is found lacrosse ball excellent for this type of massage because their surface area is much less than that of foam rollers.
224214243|NCT05811260|OTHER|Post facilitation stretch .|static stretching exercises for the low back (plantar fascia, gastrocnemius, hamstrings, and erector spinae). Static stretching involved 3 sets of 3 repetitions for each muscle with a 30-second hold and 30-second rest interval for each repetition.
224214244|NCT05688527|OTHER|Cleansing Balm|DermResults Cleansing Balm w/ Avocado Oil twice daily
224214245|NCT05688527|OTHER|Toning Essence|DermResults Advanced Toning Essence w/ Mineral Booster twice daily
224214246|NCT05688527|OTHER|Facial Serum|DermResults Advanced Serum w/ Hyaluronic Acid twice daily
224214247|NCT05688527|OTHER|Moisturizer|DermResults Advanced Moisturizer w/ Hyaluronic Acid twice daily
224214248|NCT05688527|OTHER|Eye Cream|DermResults Advanced Eye Cream w/ Hyaluronic Acid twice daily
224214249|NCT06025786|COMBINATION_PRODUCT|Benazir Nashonuma Program (BNP)|"Benazir Nashonuma Program (BNP)~Dietary supplement for pregnant women and lactating mothers during the first six months of lactation:~Maamta is a 75-gram sachet made from peanut butter with 400 kcal of energy~Dietary supplement for children aged 6-23 months:~Wawamum is a lipid-based nutrient supplement consisting of skimmed milk powder, micronutrients, vegetable oil, roasted chickpeas and antioxidants. Wawamum covers the recommended daily dose of most micronutrients and 255 kcal of energy.~Conditional Cash Transfer (CCT):~This includes stipends of PKR 2000 during pregnancy contingent on three antenatal care visits, consuming SNF, attending awareness sessions on health and nutrition, getting two doses of tetanus toxoid and institutional delivery. After delivery PKR 2000/- for boys and 2500/- for girls are paid as incentives conditioned on getting child's birth registered, routine immunization and consumption of SNF by the child from 6-23 months"
224214250|NCT00281827|DRUG|carboplatin|Day 1 of Cycles 1, 2 and 3 - intravenously (IV) 30 minutes (Area Under the Curve = 5.5)
224214251|NCT00281827|DRUG|gemcitabine hydrochloride|Days 1 and 8 of Cycles 1, 2 and 3 - 30 minute IV, 1000 mg/m2.
224214252|NCT00281827|DRUG|thalidomide|Oral administration: Cycle 1 - Day 1 50 mg, Day 2 100 mg, Day 3 150 mg, Day 4 and continuing until end of study treatment 200 mg.
224214253|NCT00281827|PROCEDURE|conventional surgery|Resection - between 2 and 6 weeks following last dose of chemotherapy.
224214254|NCT01413685|OTHER|Pharmacokinetics/dynamics|Determination of tacrolimus concentrations in whole blood and of calcineurin activities in lymphocytes at D8, D15, D21 (pharmacokinetics on 4 times samples), D28, M2 and M3 (residual measurement)
224214255|NCT01164137|BEHAVIORAL|Medication Reconciliation|A pharmacist-led home intervention conducted within 72 hours of hospital discharge aimed at correcting and identifying medication discrepancies.
224214256|NCT03668925|RADIATION|magnetic resonance imaging (MRI) of the sacro-iliac region HLA B27 test C-reactive protein (CRP) measurement|magnetic resonance imaging (MRI) of the sacro-iliac region HLA B27 test C-reactive protein (CRP) measurement
224214257|NCT04523831|DRUG|Ivermectin and Doxycycline|Ivermectin 6 mg, 2 tab stat and Doxycycline 100 mg twice daily for 5 days
224214258|NCT04523831|DRUG|Standard of care|Paracetamol, Vitamin D, Oxygen if indicated, Low molecular weight heparin, dexamethasone if indicated
224214259|NCT04556838|DRUG|VVN001 Ophthalmic Solution 1%|VVN001 Ophthalmic Solution 1%
224214260|NCT04556838|DRUG|VVN001 Ophthalmic Solution 5%|VVN001 Ophthalmic Solution 5%
224214261|NCT04556838|DRUG|Vehicle|VVN001 Ophthalmic Solution Vehicle
224214262|NCT03912350|DRUG|Balovaptan|Participants will receive 1 tablet of balovaptan once daily (QD) on Days 1 through 14.
224214263|NCT02999919|PROCEDURE|spinal anesthesia|12.5 mg hyperbaric bupivacaine intrathecally following a successful dural puncture performed with a 27G Quincke spinal needle at the L3-4 or L4-5 intervertebral space in the sitting position
224214264|NCT01854515|DRUG|Budesonide|
224214265|NCT01854515|DRUG|Dexamethasone acetate|
224214266|NCT01880541|OTHER|hypnosedation|hypnosedation
224214267|NCT01880541|OTHER|general anesthésia|general anesthesia
224214268|NCT02579369|OTHER|Allogeneic mesenchymal stem cells|Dressing for Dystrophic Epidermolysis Bullosa wound.
224214269|NCT02579369|DEVICE|Polyurethene Film|Dressing for Dystrophic Epidermolysis Bullosa wound.
224214270|NCT01406769|PROCEDURE|Bioelectric Impedance Analysis|Undergo preoperative and postoperative lower-extremity lymphedema assessment
224214271|NCT01406769|PROCEDURE|Lymphadenectomy|Undergo lymphadenectomy
224214272|NCT01406769|PROCEDURE|Therapeutic Conventional Surgery|Undergo radical vulvectomy or radical local excision
224214273|NCT06365931|DEVICE|Percutaneous neuromodulation|Patients will receive a needle circuit approaching the deep peroneal nerve in an echoguided manner. They will receive a symmetrical biphasic current of 20-30Hz and 250 μs at tolerable intensity.
224316623|NCT06235489|OTHER|Palfique Bulk Flow|removal of caries in primary molars and placement of restorative materials
224316624|NCT06239077|OTHER|Non Invasive Prenatal Test via blood sample|Maternal - blood draw, Paternal - blood draw/Saliva sample
224316625|NCT01200069|DRUG|Placebo infusion|Identically appearing placebo dose administered IV prior to ECT and subsequently on ECT treatments 2 and 3
224316626|NCT01200069|DRUG|ibuprofen intravenous|IV ibuprofen 800mg/8ml given over 30 minutes prior to ECT and subsequently on ECT treatments 2 and 3
223513752|NCT00002461|RADIATION|radiation therapy|
223513753|NCT01065766|DRUG|Sitagliptin/metformin|Sitagliptin/metformin 50/500 mg, 50/850 mg, or 50/1000 mg tablet administered twice daily with meals.
223513754|NCT00202852|OTHER|Placebo|Placebo infusions at Weeks 0, 2, and 6 and every 8 weeks through Week 22 + MTX
223513755|NCT00202852|DRUG|MTX|Placebo infusions at Weeks 0, 2, and 6 and every 8 weeks through Week 22 + MTX; MTX dose \>=12.5 mg/week given orally or parenterally, maximum 20 mg/week
223513756|NCT00202852|BIOLOGICAL|Infliximab|Infliximab 3 mg/kg given as an infusion at Weeks 0, 2, and 6 and every 8 weeks through Week 22 + MTX
223513757|NCT00202852|DRUG|MTX|3 mg/kg infliximab infusions at Weeks 0, 2, and 6 and every 8 weeks through Week 22 + MTX; MTX dose \>=12.5 mg/week given orally or parenterally, maximum 20 mg/week
223513758|NCT03907579|BEHAVIORAL|Inflatable colon educational module|Participants attend a brief educational presentation in an inflatable colon, learning about colorectal cancer prevention and screening.
223513759|NCT00567229|BIOLOGICAL|rituximab|
223513760|NCT00567229|DRUG|lenalidomide|
223513761|NCT00567229|GENETIC|microarray analysis|
223513762|NCT00567229|OTHER|flow cytometry|
223513763|NCT00567229|OTHER|laboratory biomarker analysis|
224214274|NCT06365931|DEVICE|Transcutaneous neuromodulation|Patients will have a superficial electrode circuit placed over the belly of the tibialis anterior muscle. They will receive a symmetrical biphasic current of 20-30Hz and 250 μs at tolerable intensity.
224214275|NCT06365931|DEVICE|Placebo-percutaneous|Patients will have the neuromodulation circuit placed with needles at 0 intensity, approaching the deep peroneal nerve in an ultrasound-guided manner.
224214276|NCT06365931|DEVICE|Placebo-transcutaneous|patients will have the electrodes placed over the tibialis anterior muscle at intensity 0.
224214277|NCT06365931|DEVICE|Percutaneous neuromodulation or Transcutaneous neuromodulation (optional)|Study participants who wish to continue may be randomized to receive a 10-session intervention program. The intervention to be received will consist of 10 sessions of percutaneous neuromodulation or 10 sessions of transcutaneous neuromodulation, two sessions per week.
223513764|NCT06140238|DRUG|Parecoxib|Parecoxib administration 15 minutes before start surgical operation
223513765|NCT06140238|DRUG|Normal saline|Normal saline administration 15 minutes before start surgical operation
223513766|NCT04637347|DEVICE|Catheterization approach|In plane infraclavicular subclavian vein VS in plane supraclavicular subclavian vein catetherization
223513767|NCT01455090|DRUG|BMS-650032|
223513768|NCT01455090|DRUG|BMS-790052|
223513769|NCT01455090|DRUG|BMS-791325|
223513770|NCT01455090|DRUG|Ribavirin|
223513771|NCT06626997|DIETARY_SUPPLEMENT|Kombucha tea|"During Visit 1 (week 0), a fasting blood test must be performed at the IMDEA Alimentación facilities to obtain different markers: blood lipids, blood glucose, etc. Approximately 20 mL will be extracted (for comparison, keep in mind that a donation requires 450 mL). The blood sample will be extracted by qualified nursing staff from the UNILABS Laboratory. The blood tests based on the security and privacy requirements for handling samples will be carried out by the same laboratory.~You will also be asked to provide the stool sample that you must have collected at home prior to attending that visit with the material provided at the screening visit (V0) and at the intermediate visit (V2)."
223513772|NCT02501785|BEHAVIORAL|Caregiver Reaction Assessment (CRA)|
223513773|NCT02501785|BEHAVIORAL|The Caregiver Quality of Life - Cancer (CQOLC)|
223513774|NCT04146207|DRUG|SHR0302|SHR0302 po QD
223513775|NCT04146207|DRUG|Prednisone|Prednisone 1mg/kg/d po
223513776|NCT06267508|PROCEDURE|Maternal HIV viral load testing at delivery for VHT risk assessment|Maternal HIV viral load testing will be performed for all mothers enrolled in the study at delivery. Results will be used along with WHO-defined clinical criteria to determine risk status for VHT. The intervention also includes personnel to support the additional testing volume and management of high-risk cases and eHealth solutions for communication of test results between health facilities.
223513777|NCT04818086|DRUG|Lemborexant|Participants will complete 2 inpatient visits which may last up to 24 hours. The two visits will be approximately 14 days apart. During the inpatient visit they will receive 5 mg of lemborexant (first visit) and 10 mg of lemborexant (second visit).
223513778|NCT04818086|DRUG|Placebo|Participants will complete 2 inpatient visits which may last up to 24 hours. The two visits will be approximately 14 days apart. During the inpatient visit they will receive a placebo which is encapsulated to look the same as the intervention drug.
223513779|NCT04818086|DRUG|Buprenorphine-naloxone|Participants will receive 16 mg/4 mg of buprenorphine-naloxone sublingually as a film.
223513780|NCT05157893|DEVICE|Virtual reality based analgesic therapy|The intervention is a single 15 min VR therapy. The VR therapy is consisted of VR device and software. The model of VR device used is Pico Neo 3 Pro. The software run on the VR device delivers two types of contents: 1) A 7min of computer-generated 360 video of underwater scene with therapeutic music to distract patients' attention on pain and make patients passively relax. 2) An 8min guided relaxation in which patients are transported to seaside with narrative to achieve image and breathing relaxation.
223513781|NCT01595815|OTHER|Calcium ionophore|Oocytes were activated with calcium ionophore after ICSI
223513782|NCT01595815|OTHER|Strontium chloride (SrCl2)|Oocytes were activated with strontium chloride after ICSI
223513783|NCT03319654|DIAGNOSTIC_TEST|DNA fragmentation by TUNEL assay|Direct DNA fragmentation testing with terminal deoxyuridine nick end labeling (TUNEL) assay.
223513784|NCT04128228|BEHAVIORAL|8-week outpatient treatment|Individuals with AUD participated in an 8-week treatment program integrating cognitive behavioral techniques focused on emotion regulation with breathing-based stress management.
223513785|NCT05453357|DEVICE|iGlucose|The patient will use the monitor as instructed by their healthcare team to monitor their blood glucose.
223513786|NCT03114644|OTHER|Physiologically evaluate the impact of reading history on the mother-baby synchronies in a context of premature birth requiring hospitalization in neonatal medicine.|Physiologically evaluate the impact of reading history on the mother-baby synchronies in a context of premature birth requiring hospitalization in neonatal medicine.
223513787|NCT05358912|DRUG|Vasopressor Agent|"Patients will receive vasopressor agents according to Surviving Sepsis Campaign Guidelines 2021"
223513788|NCT05358912|DRUG|Crystalloid Solutions|"Patients will receive crystalloid solutions according to Surviving Sepsis Campaign Guidelines 2021"
223513789|NCT05358912|PROCEDURE|Invasive Blood Pressure Monitoring|Invasive blood pressure monitoring will be performed through an intra-arterial cannula placed in the radial artery. Philips Intellivue mx 500 monitors will be used for bedside monitoring.
223513790|NCT05358912|PROCEDURE|Intra-Abdominal Pressure Monitoring|"IAP will be measured indirectly by monitoring the pressure in the bladder.~Bladder pressure will be measured through an indwelling Foley catheter every twelve hours. Twenty-five mL of sterile normal saline will be injected in each measurement and readings will be recorded with a pressure transducer."
223513791|NCT05358912|OTHER|Abdominal Perfusion Pressure|APP will be calculated with the following formula: (Mean arterial pressure) - (Intra-abdominal Pressure)
224214278|NCT00350194|DIETARY_SUPPLEMENT|Omega-3 fatty acids|Total of 1.8 grams of EPA +DHA in the form of fish oil capsules (3/day)
224214279|NCT01667965|BEHAVIORAL|questionnaires|Questionnaires will be given before the patient watches a video educational tool to aid informed consent about palliative radiation therapy; and (2) after the patient watches the video educational tool. (3) If the patient receives PRT, a final questionnaire that assesses the patient's impression of the video will also be administered at the conclusion of radiation therapy.
224316627|NCT01313377|DRUG|gemcitabine hydrochloride|
224316628|NCT01313377|DRUG|oxaliplatin|
223624933|NCT03341416|DEVICE|deep brain stimulation on stimulation - active|bilateral deep brain stimulation reaching the dentate nucleus turned ON - phase active
223624934|NCT03341416|DEVICE|deep brain stimulation off stimulation - sham|bilateral deep brain stimulation reaching the dentate nucleus turned OFF - phase sham
223624935|NCT03771755|DRUG|Ibuprofen|800 mg IV - Ibuprofen every 6 hours. In case required - followed with Morphine (PCA) 1-2 mg every 5 minutes
223624936|NCT03771755|DRUG|Acetaminophen|1000mg IV Acetaminophen every 6 hours. In case required - followed with Morphine (PCA) 1-2 mg every 5 minutes
223624937|NCT04480320|PROCEDURE|pericapsular nerve group block|Branches of both the FN and ON provide innervation to the anterior hip capsule. High and low branches of FN provided the majority of innervation to the lateral and superomedial hip capsule. The AON innervates the medial capsule.Both of the nerve close to the periosteum between the iliopubic eminence and AIIS ,by using ultrasound guided technique,these sites can be potential bony landmarks provid approch to the nerve group.
223624938|NCT01636765|DRUG|No Intervention|No intervention.
223624939|NCT01386164|BIOLOGICAL|Gardasil|Subjects will receive three doses of the study vaccine administered intramuscularly according to a Day 0, Week 6, and Month 6 vaccination schedule.
224214280|NCT04196582|DEVICE|Comparison of LMA Gastro Airway® and Gastro-Laryngeal Tube in patients who will undergo biliopancreatic procedures.|comparing efficiency and complications of second generation airway devices which can use for gastrointestinally procedures
224214281|NCT02962115|BEHAVIORAL|Decision Aid Invitation|electronic invitation to complete web-based decision aid
224214282|NCT00006385|BIOLOGICAL|MART-1 antigen|
224214283|NCT00006385|BIOLOGICAL|gp100 antigen|
224214284|NCT00006385|BIOLOGICAL|incomplete Freund's adjuvant|
224214285|NCT00006385|BIOLOGICAL|recombinant interferon alfa|
224214286|NCT00006385|BIOLOGICAL|sargramostim|
223624940|NCT01386164|BIOLOGICAL|Cervarix|Subjects will receive three doses of the study vaccine administered intramuscularly according to a Day 0, Week 6, and Month 6 vaccination schedule.
224214287|NCT00006385|BIOLOGICAL|tyrosinase peptide|
224214288|NCT06222411|OTHER|evaluate the impact of organizational interventions for physician development on wellbeing|There is an increasing demand for healthcare organizations and hospitals to address factors contributing to stress and burnout as well as provide effective solutions at an organizational level
224214289|NCT02780999|DEVICE|Whale orthosis|Participants will be teach how to use the Whale orthotic to be carried for a period of three months during night and during the day in dose activities that cause pain
224214290|NCT02780999|DEVICE|Colditz orthosis|Participants will be teach how to use the Colditz orthotic to be carried for a period of three months during night and during the day in dose activities that cause pain.
224214291|NCT00296452|BEHAVIORAL|behavior|
224214292|NCT00430638|DRUG|olmesartan medoxomil + hydrochlorothiazide, if necessary|olmesartan medoxomil + hydrochlorothiazide, if necessary. Oral tablets administered for once daily for 12 weeks
224214293|NCT00430638|DRUG|Placebo|Oral tablets administered for once daily for 12 weeks
224214294|NCT03078530|DRUG|Placebo|This is a pill with inactive ingredients
224214295|NCT03078530|DRUG|Visbiome|This is a probiotic mixture available to randomized study participants, starting with subject 29
224214296|NCT03078530|DRUG|VSL#3|This is a probiotic mixture available to the first 28 subjects randomized to the study
224214297|NCT02858167|DEVICE|FDG-PET|FDG injection followed by cerebral examination with X ray spiral CT after 40 minutes and FDG-PET after 60 minutes
224214298|NCT01779349|DEVICE|"Dynamic Urine Vibration Holter"|"each subject will undergo intervention for the diagnosis of bladder outlet obstruction first using the Dynamic Urine Vibration Holter and then urodynamically by pressure flow study"
224214299|NCT04297553|PROCEDURE|CAPA-Fresh|Receiving FSH (Menopur, Ferring) for 2 days on day 2/3 of the menstrual cycle (spontaneous/ OCP administration) and an ultrasound scan will be performed subsequently. Oocytes retrieval will be performed 42 hours after the last injection. Receiving hCG 5000IU x 2 (10000IU) after Oocytes retrieval. Pre-maturation will last for 24-30 hours. ICSI will be used for insemination. Fresh embryos transfer will be performed on day 3 using HRT protocol with a maximum of 2 embryos transferred.
224214300|NCT04297553|PROCEDURE|CAPA-Freeze-only|Receiving FSH (Menopur, Ferring) for 2 days on day 2/3 of the menstrual cycle (spontaneous/ OCP administration) and an ultrasound scan will be performed subsequently. Oocytes retrieval will be performed 42 hours after the last injection. Pre-maturation will last for 24-30 hours. ICSI will be used for insemination. Freeze-only on day 3 and frozen embryo transfer will be performed on the subsequent cycle using HRT protocol with a maximum of 2 embryos transferred.
224214301|NCT04716400|BEHAVIORAL|Stop sexual harassment|Teachers will be introduced to a digital course on the prevention of sexual- and gendered harassment. In the course they will provided with a manual containing eight lessons to be held for the pupils. Each lesson will last 45 minutes and consist of a short lecture and practical activities for the pupils.
224214302|NCT05725707|BEHAVIORAL|Friendship Group|Whether face-to-face or online delivery, each FG session followed the same broad format - (1) Group meditative exercise and reminder of group agreement (10 mins); (2) Check in with support group members and main session (50mins); (3) Summary of group discussion and homework activity planning (10mins); (4) Final group meditative exercise and closing of group (10mins). Session length was up to 80 minutes (see table 2) and each facilitator was provided with a manual describing each section as well as some hints and tips to promote discussion and engagement. While all FG's would follow this structure, group members would drive the content (particularly during Step 2).
224316629|NCT01313377|OTHER|clinical observation|
224316630|NCT01313377|PROCEDURE|adjuvant therapy|
224316631|NCT01313377|PROCEDURE|quality-of-life assessment|
224316632|NCT02390947|DRUG|Famitinib|25 mg p.o. qd
223624941|NCT00976131|DRUG|CoQ10|"Capsules taken daily for two weeks prior to Cycle 3 chemotherapy infusion OR Capsules taken daily for two weeks prior to Cycle 4 infusion.~Dose Level 1: 300mg/d CoQ10 (2 capsules) Dose Level 2: 600mg/d CoQ10 (4 capsules) Dose Level 3: 1200mg/d CoQ10 (8 capsules)"
223624942|NCT00976131|OTHER|CoQ10 Placebo|"Capsules taken daily for two weeks prior to Cycle 3 chemotherapy infusion OR Capsules taken daily for two weeks prior to Cycle 4 infusion.~Dose Level 1: 300mg/d placebo (2 capsules) Dose Level 2: 600mg/d placebo (4 capsules) Dose Level 3: 1200mg/d placebo (8 capsules)"
223624943|NCT00976131|DRUG|Doxorubicin|Standard of care chemotherapy medication used to treat cancer.
223624944|NCT00976131|DRUG|Cyclophosphamide|Standard of care chemotherapy medication used to treat cancer.
224214303|NCT06177509|OTHER|Graded Aerobic Exercise|Participants will follow a sub-symptom aerobic exercise program (approx. 30 min) 3 - 5 times pr week for twelve weeks. Sub-symptom threshold aerobic exercise means to exercise at 80-90% of the maximum threshold heart rate achieved during the BCTT. To ensure proper exercise dose and progression, participants will be retested every three weeks. During the first three weeks, the participants will be offered one weekly guided exercise session. The other 2 - 4 weekly sessions the participants will carry out on their own, choosing activities based on experience, preferences and possibilities (e.g. walking, jogging, stationary bike, swimming). The intensity of the sub-symptom threshold aerobic exercise will be monitored using a heart rate monitor and the BORG scale. Compliance with the sub-symptom threshold aerobic exercise program will be recorded by the patients in an exercise diary, which is followed up by a weekly reminder over the phone/sms by a physiotherapist in the project.
224214304|NCT04667273|PROCEDURE|Neuromuscular Electrical Stimulation (NMES)|"In Neuromuscular Electrical Stimulation (NMES) application, 4 surface electrodes will be placed in the swollen part of the lower trapezius and serratus anterior muscles of each patient.~NMES will be applied for 20 minutes in rehabilitation mode with a 4-channel device.~Frequency: 80 Hz Amplitude: 0-100 mA (0-0.01 V) Current time-Pulse: 200 μsec Wave form: Biphasic Cycle time: 8 seconds of tetanic muscle stimulation for all patients, with a 2 second rise and fall time and stimulation It will be set as 3 seconds between. It is important to visually observe the contraction to determine the intensity of stimulation."
223624945|NCT03975010|DRUG|Buprenorphine Transdermal Patch|"This is an open-label, randomised, single-dose, 3 arms study design. Subjects will be randomised into one of 3 arms, in a 1:1:1 ratio, wearing BUP TDS 20 mg for 3 days or 40 mg for 3 days or 40 mg for 4 days. Safety follow-up will be planned at 7\~9 days after patch removal.~The study patch will be applied under the cover of naltrexone to reduce opioid related side-effects. Naltrexone 50 mg will be taken orally every 12 hours, from the evening of Day 00 (13 hours prior to IMP application), until the evening of the patch removal."
223624946|NCT04839939|OTHER|Conventional physical therapy|Stretching for tight muscles, weak muscles Strengthening, Postural reactions training, Proprioceptive training, and Walking training
223624947|NCT04839939|OTHER|Ankle Foot Orthosis|Solid prescribed AFO with a wearing schedule of 6-12 hours per day
223624948|NCT04839939|OTHER|Combination Taping|Combination between elastic and inelastic taping
223624949|NCT05313113|BEHAVIORAL|Experimental|Pregnant women were trained to implement fetal movement count and position tracking. The training was provided face to face and lasted 30-45 minutes. The training content included topics such as setting a comfortable environment and suitable position for the pregnant, when the fetus is active and asleep during the day, how to count and how to evaluate the movements. How to determine the position of the fetus and I. and II. Leopold maneuvers are also taught. In the second stage, the pregnant women were interviewed twice a week by telephone.Thus, it was provided that pregnant women had fetal tracked at least once a day, at any time of the day, when the fetus was awake and most active, in a suitable position and a comfortable environment, for at least 15-20 minutes continuously for four weeks. Pregnant women phoned the researcher when they wanted. At the same time, the participants continued to their routine prenatal care.
223624950|NCT05083351|DEVICE|MightySat|Noninvasive pulse oximeter
223624951|NCT01152658|BIOLOGICAL|PRGF|enriched plasma fraction will be then injected to the trial group in sterile conditions under ultrasound control in the ssp gap
223624952|NCT01152658|OTHER|NACL|Nack 0.9 5 will be then injected to the control group group in sterile conditions under ultrasound control
223624953|NCT01792700|DRUG|esomeprazole|
223624954|NCT01792700|DRUG|tripotassium dicitrate bismuthate|
223624955|NCT01792700|DRUG|metronidazole|
223624956|NCT01792700|DRUG|tetracycline|
224214305|NCT04667273|PROCEDURE|Exercise Training (ET)|"Patients will do Wand exercises under the supervision of a physiotherapist. Wand exercises will include shoulder flexion, external rotation and abduction in the scaption position. In the first and second week, these exercises will be performed on the back, and from the third week on standing exercises.~Exercises with the Theraband will be done in 3 sets, each set will consist of 10 repetitions. There will be a 1 minute rest period between sets. When the three sets are easily completed and there is no reported fatigue by the patient, the resistance will be increased by moving from yellow to red, from red to green, respectively, after 4 weeks.~\*For shoulder external rotators and serratus anterior muscles are strengthened without weight for the first 2 weeks, then 0.5 kg of dumbbells, in the supine position.~While standing, the lower trapezius, upper trapezius and shoulder external rotators will be strengthened with theraband."
224316633|NCT02390947|DRUG|Placebo|25 mg p.o. qd
223624957|NCT01792700|DRUG|moxifloxacin|
223624958|NCT01792700|DRUG|amoxicillin|
223624959|NCT04937985|OTHER|Performance Tests|Performance tests consist of Six Minute Pegboard Ring Test, 30-Second Push-Up Test and Arm, Shoulder and Hand Injury Questionnaire (DASH), Neck Disability Index, New York Posture Rating Chart and Short Form-36 Health Survey.
223624960|NCT03184064|DIETARY_SUPPLEMENT|Blackcurrant extract (low dose)|Participants will consume a small beverage that contains blackcurrant extract (low dose) immediately before a high-carbohydrate meal.
223624961|NCT03184064|DIETARY_SUPPLEMENT|Placebo|Participants will consume a small beverage that contains no fruit extracts immediately before a high-carbohydrate meal.
223624962|NCT03184064|DIETARY_SUPPLEMENT|Citrus extract (low dose)|Participants will consume a small beverage that contains citrus extract (low dose) immediately before a high-carbohydrate meal.
223624963|NCT03184064|DIETARY_SUPPLEMENT|Blackcurrant extract (high dose)|Participants will consume a small beverage that contains blackcurrant extract (high dose) immediately before a high-carbohydrate meal.
223624964|NCT03184064|DIETARY_SUPPLEMENT|Blackcurrant and citrus extracts (low dose / low dose)|Participants will consume a small beverage that contains blackcurrant and citrus extracts (low dose / low dose)immediately before a high-carbohydrate meal.
223624965|NCT01402440|DRUG|AEB071|
223624966|NCT04097431|BEHAVIORAL|Response Blocking|Physically preventing the response (i.e., precursor) from occurring.
223624967|NCT00259909|OTHER|GSK questionnaire|GSK questionnaire will demonstrate the validity, reliability and responsiveness as a tool for measuring subject-reported outcomes during an acute exacerbation of chronic obstructive pulmonary disease.
223762244|NCT01494610|DRUG|SERETIDE Rotacaps|The study consists of four treatment periods of 10 +/- 1 days each in a cross-over fashion. Each patient will be administered SERETIDE delivered via a capsule-based inhaler (Rotacaps) twice for two treatment periods and a placebo delivered via a capsule-based inhaler (Rotacaps) twice for two treatment periods in a randomised, double-blind, double-dummy fashion. Dosing is twice daily in the morning and evening over the duration of each treatment period.
224214306|NCT03791255|DRUG|Calcium silicate liner|new light-cured resin-modified calcium silicate-filled base/ liner material designed for direct and indirect pulp capping
223624968|NCT00259909|OTHER|St. George's Respiratory Questionnaire|The SGRQ is a 50-item questionnaire with 76 weighted responses. It provides a Total score and three component scores: Symptoms (distress caused by respiratory symptoms), Activity (physical activities that cause or are limited by breathlessness), and Impacts (social and psychological effects of the disease). The Total score and each of the SGRQ sub-scores are scored from 0 to 100 where 0 indicates best and 100 indicates worst health.
223624969|NCT00259909|OTHER|Acute Short Form 12 version 2|The Acute SF-12v2 is a multipurpose short-form questionnaire with only 12 questions with two summary scores, the SF-12 Physical Component Summary (PCS-12) and the SF-12 Mental Component Summary (MCS-12). The scoring range for the PCS-12 and MCS-12 is 0 to 100, with a lower score indicating a poorer level of health
223624970|NCT00259909|OTHER|Global Efficacy questionnaire|Global Efficacy questionnaire will be administered in an electronic form to validate test-retest reliability, responsiveness and minimum important difference (MID)
224214307|NCT03791255|DRUG|Calcium hydroxide liner|Calcium hydroxide is the gold standard for pulp capping, allows for the formation of a reparative dentin bridge
224214308|NCT04454957|BEHAVIORAL|Mastering Diabetes|Virtual (on-line) lifestyle change program, focused on a plant-based, whole food diet and physical activity.
224214309|NCT04626557|PROCEDURE|biopsy|biopsy of the endometrium
224214310|NCT06617013|OTHER|Discontinuation of GERD therapy|GERD therapy will be discontinued at time of enrollment.
224214311|NCT04659837|BEHAVIORAL|No-Added-Sugar Diet|All participants received a no-added-sugar dietary intervention and followed the diet during the course of the study.
224214312|NCT02953132|DRUG|MT-4129|
224214313|NCT02953132|DRUG|Placebo|
224214314|NCT05061459|GENETIC|circANKRD36 as a new biomarker|expression levels of circANKRD36 in the development and progression of DN
224214315|NCT06697977|DIETARY_SUPPLEMENT|phytosterols|2 grams of phytosterols given as 7 pills per day
224214316|NCT06697977|DIETARY_SUPPLEMENT|placebo|placebo 7 pills per day
224214317|NCT06696729|PROCEDURE|Topical Mirabilite Application for Postoperative Gastrointestinal Patients|Participants in this group will receive an external application of 500 grams of Mirabilite (sodium sulfate decahydrate) beginning on postoperative day 1. The Mirabilite will be wrapped in a double layer of gauze and placed on top of the sterile dressing over the patient's abdominal incision, with the gauze bag secured by an abdominal binder. The application will be regularly replaced when it becomes damp and hardened to maintain continuous efficacy.
224214318|NCT06696729|PROCEDURE|Standard Postoperative Care for Gastrointestinal Patients|Participants in this group will receive standard postoperative care without the application of Mirabilite or any alternative topical treatment. Their surgical sites will be kept dry and clean, with regular sterile dressing changes as part of standard care protocols.
224214319|NCT06696469|DIAGNOSTIC_TEST|Feasibility and reliability of using BeCureTM Virtual Reality in the evaluation of upper extremity motor functions in stroke patients|The applicability and reliability of virtual reality systems are important factors to consider. Based on this, this study aimed to investigate the feasibility of using BeCureTM virtual reality in the evaluation of upper extremity functions after stroke.The feasibility of using BeCureTM virtual reality in stroke patients will be determined according to the System Usability Scale (SUS) score.The safety of the use of BeCureTM virtual reality in stroke patients will be assessed with a patient feedback questionnaire. The relationship between the use of BeCureTM virtual reality and cognitive functions in stroke patients will be determined by the Montreal Cognitive Assessment Scale and Mini Mental State Examination.It was aimed to examine the effects of demographic characteristics, accompanying cognitive disorders and upper extremity motor disorders that may affect the evaluation and response to treatment on virtual reality applications.
224214320|NCT03503201|DIETARY_SUPPLEMENT|Chromium|chromium supplementation as capsules of 200 micrograms of chromium picolinte (Arab company for pharmaceuticals and medicinal plants) daily for 2 months before ICSI cycle
224214321|NCT03185949|DEVICE|Endobar Infusion Catheter System|Bariatric embolization with microspheres using Endobar Infusion Catheter System
224214322|NCT03185949|BEHAVIORAL|Behavioral therapy|Healthy diet and exercise
224214323|NCT06702085|BEHAVIORAL|Lifestyle Management|patients administered supervised changes in their lifestyle (walking exercise for 40 minutes applied on treadmill for three time per week and low caloric diet) for twelve weeks
224214324|NCT06702098|DRUG|iNK cells|Induced pluripotent stem cells derived NK cells.
224214325|NCT06702189|DEVICE|EXOPULSE MOLLII SUIT (active)|"Exopulse Mollii suit is a new assistive device that has been developed by Exoneural Network (initially Inerventions AB), a Swedish med-tech company.~Exopulse Mollii suit is a full-body garment with integrated 58 electrodes that can transcutaneously stimulate several groups of muscles. The device is CE labelled and is intended to use for reducing spasticity and improving blood circulation. The outfit is very easy to put on, it can be used for one hour every day and the analgesic effects last 24 hours or more. EXOPULSE Mollii suit consists of transcutaneous stimulation of several muscles by means of a feeble electric current (i.e., low frequency \~20 Hz, low-intensity 2mA), aiming to reduce pain.~This treatment method theoretical background primarily refers to the theory of gate control. Based on this theory, the stimulation of large proprioceptive fibers would inhibit the nociceptive information transmitted by small fibers."
224214326|NCT06702189|DEVICE|EXOPULSE MOLLII SUIT (sham)|It consists of applying the same parameters used for the active session (low frequency: 20 Hz; current intensity: 2 mA; pulse width ranging from 25 to 175 µs) but for a shorter duration of time (1 minute).
224214327|NCT02161939|DRUG|Daclatasvir (BMS-790052)|
224214328|NCT02161939|DRUG|Sofosbuvir|
224214329|NCT06702306|DIAGNOSTIC_TEST|Ultrasound Surveillance|Lower limb arterial ultrasound, ankle and toe blood pressure checks before every in-person clinic appointment at 1, 6 and 12 months.
223624971|NCT00672698|PROCEDURE|SURGERY|ELECTIVE SURGICAL PROCEDURES
223624972|NCT01759420|DRUG|Ondansetron|4mg of intravenous ondansetron
223624973|NCT05219357|OTHER|Ayu-Care|Ayurveda treatment modalities includes three parts to manage mental health Satwawajay Chikitsa, Yuktivyapashray and Daivyapashray Chikitsa. It is based on personalised whole person approach.
223624974|NCT05219357|DRUG|Usual-Care|Management strategies includes restraints, emergency medications, behavioral interventions, with a special focus on the pharmacological interventions.
223624975|NCT04326920|DRUG|Sargramostim|Inhalation via mesh nebulizer and/or IV administration upon Clinical deterioration
223624976|NCT04326920|OTHER|Control|Standard of care
223624977|NCT01998256|DEVICE|AV optimization|Iterative DFT (diastolic filling time) method for AV optimization. Optimal AV delay for both atrial sensed and atrial paced settings was defined by two experienced echocardiographists, after 3 separate measurements.
223624978|NCT05106127|DRUG|EG-007|A Repurposed Drug
223762245|NCT01494610|DRUG|SERETIDE Diskus|The study consists of four treatment periods of 10 +/- 1 days each in a cross-over fashion. Each patient will be administered SERETIDE delivered via a multi-dose dry powder inhaler (Diskus) twice for two treatment periods and a placebo delivered via a multi-dose dry powder inhaler (Diskus) twice for two treatment periods in a randomised, double-blind, double-dummy fashion. Dosing is twice daily in the morning and evening over the duration of each treatment period.
224214330|NCT06703762|OTHER|He-Ne low level laser (LLL)|Patients in the experimental group will receive treatment with LLLT. The ulcer bed will be irradiated locally with red light (660 nm). The ulcer size and its depth will be used as the basis to calculate the duration of exposure needed to deliver 3-10 J/cm² for 15 to 20 minutes. The application will take place in 3 sessions per week for 4 weeks. Each patient will be asked to lie in a supine position with the ulcer easily exposed to the laser beam, and they will be instructed to wear laser glasses and avoid looking directly at the beam until the end of the session.
224214331|NCT06703762|OTHER|Conventional traditional treatment|All patients in both the groups will receive the required, conventional treatments of diabetic wound care, including dressing, antibiotics, controlling diabetes, cholesterol, and blood pressure along with aggressive drug treatment and wound debridement when needed.
224214332|NCT06702826|DRUG|Cadonilimab combined with SRS|Eligible subjects were treated with stereotactic radiotherapy for brain metastases plus Cadonilimab followed by maintenance therapy with Cadonilimab alone
224214333|NCT06702735|BEHAVIORAL|Rainbow tool|The Rainbow tool visualizes perception based on lung function measurements and VAS scores.
224214334|NCT06702735|BEHAVIORAL|Feedback|Feedback sessions with health care professional based on the Rainbow tool.
224214335|NCT05290272|DEVICE|ViFIVE Digital Care Progrma|ViFive DCP (Digital Care Program) is a highly structured, protocolized, and individually tailored intervention consisting of personalized exercise therapy modules. ViFive DCP is delivered by a physical therapy team consisting of DPTs and a personal coach. The DCP consists of ten modules and its advancement will be determined by each patient's progress after the treatment team's review every week.
224214336|NCT01998035|DRUG|RomiDEPsin 10 MG/M2|"Romidepsin is an anti-cancer (antineoplastic or cytotoxic) chemotherapy drug. Romidepsin is classified as a Histone Deacetylase Inhibitor.~Dose escalation (10 mg/m2)"
224214337|NCT01998035|DRUG|Oral 5-Azacitidine 100 MG|"A pyrimidine nucleoside analogue of cytidine with antineoplastic activity.~Dose escalation (100 mg)"
224214338|NCT01998035|DRUG|Romidepsin 14 MG/M2|"Romidepsin is an anti-cancer (antineoplastic or cytotoxic) chemotherapy drug. Romidepsin is classified as a Histone Deacetylase Inhibitor.~Dose escalation (14 mg/m2)"
224214339|NCT01998035|DRUG|Oral 5-Azacitidine 200 MG|"A pyrimidine nucleoside analogue of cytidine with antineoplastic activity.~Dose escalation (200 mg)"
224214340|NCT01998035|DRUG|Oral 5-Azacitidine 300 MG|"A pyrimidine nucleoside analogue of cytidine with antineoplastic activity.~Dose escalation (300 mg)"
224214341|NCT03910010|DRUG|Placebos|Positive treatment expectations will be induced by giving participants capsules containing inert material and telling them that the capsules contain an effective drug that has been approved for treating Chronic Pain. They will be requested to take two capsules four times a day and report their pain on paper forms organized as a calendar or on REDCap.
224214342|NCT06313294|OTHER|Tracking application app|An app will be implemented for mobile monitoring in patients who use continuous postoperative ambulatory regional analgesia.
224214343|NCT06313294|OTHER|Telephone interview|Patients who use continuous postoperative outpatient regional analgesia will be followed up using the current traditional method of post-discharge telephone call.
224214344|NCT05392712|DEVICE|Magnetometer|inspection equipment for magnetocardiography
223624979|NCT05106127|DRUG|Pembrolizumab 100 mg/4 mL (25 mg/ml) Injection|Pembrolizumab will be provided as a sterile, preservative-free, clear to slightly opalescent, colorless to slightly yellow solution that requires dilution for intravenous infusion. Each vial contains 100 mg of pembrolizumab in 4 mL of solution.
223624980|NCT05106127|DRUG|Lenvatinib Capsules|Lenvatinib will be provided as 4-mg and 10-mg capsules. Lenvatinib is formulated with calcium carbonate, mannitol, microcrystalline cellulose, hydroxypropyl cellulose, low-substituted hydroxypropylcellulose, and talc.
223624981|NCT03561675|DRUG|ACETAZOLAMIDE oral capsule|Administration of 1x125mg acetazolamide in the morning, 2x125mg in the evening, starting 24 hours before departure to 3'100m
223624982|NCT03561675|DRUG|Placebo oral capsule|Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3'100m
223624983|NCT04325802|DRUG|Naltrexone|50mg Naltrexone daily
223624984|NCT04325802|OTHER|Placebo|Placebo (Mannitol) daily
223624985|NCT03920345|DEVICE|MultiZYTE|Subjects can be treated either unilateral or bilateral, depending on their condition and the recommended treatment by the surgeon. The decision is a clinical one and is not influenced by the decision of whether to be included in the study or the subsequent outcomes and QoL analysis.
223624986|NCT04896528|DRUG|Avatrombopag|"* Participants meeting the eligibility criteria receive Avatrombopag treatment (orally, 60 mg/day), for a maximum course of 20 days.~* Investigation product withdrawal: PLT ≥75×109/L or increases by at least 50×109/L from the lowest value after targeted therapy and immunotherapy combination treatment."
223624987|NCT02970799|DEVICE|Intranasal Neurostimulator|The device delivers small electrical currents, activating nerves that stimulate the body's natural tear production system.
223762246|NCT00020670|BIOLOGICAL|CD 40|
224214345|NCT03914937|OTHER|Virtual reality|A virtual reality device will be worn over the eyes that allows the patient to feel that they are at a quiet seaside beach.
223624988|NCT05597202|DRUG|Semaglutide, 2.0 mg/mL|Semaglutide 2.0 mg/mL, administered subcutaneously once per week for a period of 6 months.
223624989|NCT00547508|DRUG|tadalafil|10 mg tablet taken orally, no more than once a day, at anytime during the 2-4 week equilibration phase and then 24 hours prior to sexual intercourse for 4-6 weeks in the assessment phase
223624990|NCT00547508|DRUG|placebo|Placebo tablet taken by mouth, no more than once a day, anytime during the 2-4 week equilibration phase and then 24 hours prior to sexual intercourse for 4-6 weeks in the assessment phase
223624991|NCT00547508|DRUG|tadalafil|20 mg tablet taken orally, no more than once a day, at anytime during the 2-4 week equilibration phase and then 24 hours prior to sexual intercourse for 4-6 weeks in the assessment phase
223762247|NCT04505891|BEHAVIORAL|Education|Kidney health education will be delivered prior to discharge by trained nurse educators.
224214346|NCT03914937|OTHER|Music|Music of the patient's choice will be played
224214347|NCT05166421|BIOLOGICAL|AZD7442|AZD7442 will be administered via IM route.
224214348|NCT05166421|BIOLOGICAL|AZD8895 (clonal cell line material)|AZD8895 will be administered via IM route.
224214349|NCT05166421|BIOLOGICAL|AZD1061 (clonal cell line material)|AZD1061 will be administered via IM route.
224214350|NCT05166421|BIOLOGICAL|AZD8895 (cell pool material)|AZD8895 will be administered via IM route.
224214351|NCT05166421|BIOLOGICAL|AZD1061 (cell pool material)|AZD1061 will be administered via IM route.
224214352|NCT03008629|DEVICE|Podofix nail brace|Podofix nail brace
224214353|NCT03008629|DEVICE|Combiped nail brace|Combiped nail brace
224214354|NCT03008629|DEVICE|Podofix and then Combiped nail brace|Podofix and then Combiped nail brace
224214355|NCT05824468|DRUG|Zimberelimab|Injectable solution
224214356|NCT05824468|DRUG|Lenvatinib|Capsule
223762248|NCT04505891|BEHAVIORAL|Education and follow-up|In patients allocated to the education and follow-up arm, education along with a a post-discharge healthcare visit from a multidisciplinary care team will be performed.
223762249|NCT05374265|OTHER|Cardiovascular Magnetic Resonance Scan|Patients will receive a baseline CMR scan to detect viability within 7 days of index admission
224214357|NCT04129034|DEVICE|Neurolyser XR|Non-Invasive Thermal Ablation of the Medial Branch Nerves
224214358|NCT02543086|DRUG|KAE609|Study drug
224214359|NCT02543086|DRUG|Piperaquine Phosphate|Pre-administration of Piperaquine Phosphate will be done to eliminate the asexual form of the parasite and induce gametocytaemia before characterizing the activity of KAE609 in clearing sexual blood stage parasites from the blood of healthy subjects in the Induced Blood Stage Malaria Challenge model in Part B of study
224214360|NCT01027637|OTHER|5 mm vessel clips|evenly placed vessel clips placed at surgery and tracked by ultrasound
224214361|NCT00969059|DRUG|GW856553|GW856553 is a film coated white tablet, 9mm round, biconvex, plain faced. It will be administered 7.5mg bid, orally with food at breakfast and dinner.
223624992|NCT00547508|DRUG|tadalafil|20 mg tablet taken orally, no more than once a day, at anytime during the 2-4 week equilibration phase and then 36 hours prior to sexual intercourse for 4-6 weeks in the assessment phase
223624993|NCT00547508|DRUG|tadalafil|10 mg tablet taken orally, no more than once a day, at anytime during the 2-4 week equilibration phase and then 36 hours prior to sexual intercourse for 4-6 weeks in the assessment phase
223762250|NCT00356551|BEHAVIORAL|Family Spirit curriculum|
223762251|NCT01942629|OTHER|their will be no intervention in any of the groups, the study is retrospective|
224214362|NCT00969059|DRUG|PLACEBO|Matching Placebo is a film coated white tablet, 9mm round, biconvex, plain faced. It will be administered orally with food at breakfast and dinner.
224214363|NCT02685956|DEVICE|Vela Sentosa SA HSV1/2 Qualitative PCR Test|medical device test using Vela Sentosa SA HSV1/2 Qualitative PCR Test
223762252|NCT04482569|DRUG|XNW4107|Single or multiple dose ascending study for XNW4107 alone or multiple dose study of XNW4107 in combination with imipenem/cilastatin
223762253|NCT00000403|DRUG|Doxycycline|
223762254|NCT02133729|OTHER|Blood sampling and OGTT|
224214364|NCT02661282|BIOLOGICAL|Autologous Cytomegalovirus-specific Cytotoxic T-lymphocytes|Given IV
224214365|NCT02661282|OTHER|Laboratory Biomarker Analysis|Correlative studies
223762255|NCT03395314|DRUG|Ketamine|1 single dose of IV ketamine
223762256|NCT03395314|DRUG|Midazolam|1 single dose of IV midazolam
224214366|NCT02661282|DRUG|Temozolomide|Given PO
224214367|NCT02661282|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
224214368|NCT00612482|OTHER|drug prevention curriculum|"Participants in the experimental arm of the study will receive the 5-lesson, science-based drug prevention curriculum in their science classes."
224214369|NCT04137991|DEVICE|Nol-Index guided analgesia|Monitor that indicates the level of nociception-antinociception balance
224214370|NCT04137991|OTHER|Standard Analgesia|Administration of remifentanil based guided by heart rate, blood pressure, and experience
224214371|NCT02194166|DRUG|Trastuzumab|Trastuzumab IV or SC will be administered as described.
224214372|NCT02194166|DRUG|Paclitaxel|Paclitaxel will be administered in accordance with local hospital practice.
224214373|NCT02194166|DRUG|Docetaxel|Docetaxel will be administered in accordance with local hospital practice.
224214374|NCT00184431|BEHAVIORAL|Physical therapy technique and exercises|The experimental group receives task specific physical therapy three times a week for the first four weeks after discharge from hospital and one session pr week for the next eight weeks in addition to ordinary physical therapy The active comparator group receives only ordinary physical therapy during this period.
224214375|NCT01017458|DRUG|MK0773|Three 25mg oral tablets MK0773 bid, for 12 weeks
224214376|NCT01017458|DRUG|Comparator: testosterone enanthate|intramuscular injection 200mg testosterone enanthate q14d, for 12 weeks
224214377|NCT01017458|DRUG|Comparator: placebo oral tablet|placebo oral tablet bid, for 12 weeks
224214378|NCT01017458|DRUG|Comparator: placebo injection|placebo intramuscular injection q14d, for 12 weeks
224316634|NCT01541085|DRUG|Darunavir/Ritonavir (DRV/r)|Darunavir/Ritonavir (DRV/r) + Tenofovir/Emtricitabina regimen
224316635|NCT01541085|DRUG|Efavirenz (EFV)|Efavirenz (EFV) + Tenofovir/Emtricitabina regimen
224316636|NCT02925481|BEHAVIORAL|Moderate Online yoga participation|Phase 1: Testing yoga videos for emotional regulation and self-compassion which will inform the selected videos for Phase 2 prescription Phase 2: 150 minutes of Online streaming yoga videos completed at home. Week 1/2 introductory videos that include short video clips breaking down each pose Weeks 3-12 increase in difficulty (all videos are appropriate for beginners)
224316637|NCT02925481|BEHAVIORAL|Stretching and toning|Phase 1: Developing 12 week prescription for online control videos Phase 2: Online streaming stretching and toning videos completed at home which consist of a warm-up, 1 balance, 2 core, 2-3 upper body and lower body exercises, 6 stretches, cool-down
224316638|NCT02925481|BEHAVIORAL|Low dose online yoga participation|Phase 1: Testing yoga videos for emotional regulation and self-compassion which will inform the selected videos for Phase 2 prescription Phase 2: 60 minutes of Online streaming yoga videos completed at home. Week 1/2 introductory videos that include short video clips breaking down each pose Weeks 3-12 increase in difficulty (all videos are appropriate for beginners)
224316639|NCT01405482|DRUG|Botulinum Toxin Type A|Botulinum Toxin Type A 100 units injected under EMG guidance one time into the anterior,middle scalenes and pectoralis minor muscle
223624994|NCT00547508|DRUG|placebo|Placebo tablet taken by mouth, no more than once a day, anytime during the 2-4 week equilibration phase and then 36 hours prior to sexual intercourse for 4-6 weeks in the assessment phase
224214379|NCT05074563|OTHER|REsOluTioN (Resilience Enhancement Online Training for Nurses)|The online REsOluTioN training involves virtual or face-to-face mentorship sessions and facilitated online interactive group sessions on four topics (Building hardiness and maintaining a positive outlook, Intellectual flexibility and Emotional Intelligence; Achieving life balance and enabling spirituality and Reflective and critical thinking). The training will be of four-week duration. Over the four-week period, the training will comprise 4x120 minute facilitated online group sessions; 4x30 minute independent learning activities; and eight 3:1 online mentoring sessions delivered between 30 and 60 minutes at flexible timings.
224214380|NCT05074563|OTHER|Control|Nurses randomised to the control group will only be invited to take part in the pre- and post- intervention surveys, but will not use the online training. However, after completing the survey, nurses will be given the opportunity to complete the pre-work and access the facilitated sessions of the training so that they can receive their CPD certificate.
224214381|NCT03627195|DRUG|DSP-1349M|DSP-1349M injectable
224214382|NCT03627195|DRUG|placebo|placebo injection
224316640|NCT01405482|OTHER|Normal Saline injection|10 cc of Normal Saline will be injected under EMG guidance into the Anterior and Middle Scalenes and Pectoralis Minor muscle of individual diagnosed with Thoracic Outlet Syndrome.
224316641|NCT05113368|DRUG|Regorafenib|Oral regorafenib in a ReDOSplan (80 mg week#1, 120 mg week#2, 160 mg week#3 for cycle #1 then adjust final dose for subsequent cycles based on tolerance during cycle #1) \[3 weeks on/1 week off\] combined with intramuscular injection of fulvestrant 500 mg day #1 (day #15 will be planned only in cycle #1) in a 28-day cycle till disease progression or unacceptable toxicities
224316642|NCT05113368|DRUG|Fulvestrant|500 mg day #1 (day #15 will be planned only in cycle #1) in a 28-day cycle till disease progression or unacceptable toxicities
224316643|NCT05364073|DRUG|Furmonertinib|Furmonertinib tablet
224316644|NCT05364073|DRUG|Furmonertinib|Furmonertinib tablet
224316645|NCT05364073|DRUG|Furmonertinib|Furmonertinib tablet
224316646|NCT05364073|DRUG|Furmonertinib|Furmonertinib tablet
223624995|NCT06064630|DEVICE|Automatic continuous positive airway pressure|Automatic continuous positive airway pressure (APAP) is the routine and first line treatment for patients with sleep apnea
224214383|NCT01968681|PROCEDURE|Alexandrite laser|3 different alexandrite laser settings are used in respectively 3 different treatment areas and compared with a non-treated control area.
224316647|NCT05364073|DRUG|Furmonertinib|Furmonertinib tablet
223762257|NCT02385799|DRUG|Sertraline Liquid Placebo|Liquid placebo given in parallel to active medication
224316648|NCT04998851|DRUG|Ocrelizumab|Women will receive the ocrelizumab dose regimen as per the locally-approved label. The ocrelizumab dose will be administered as an initial split dose of two 300 mg infusions separated by 14 days or a single 600 mg infusion according to the local prescribing information.
224316649|NCT00268385|OTHER|Laboratory Biomarker Analysis|Correlative studies
224316650|NCT00268385|OTHER|Pharmacological Study|Correlative studies
224316651|NCT00268385|DRUG|Temozolomide|Given orally
224316652|NCT00268385|DRUG|Vorinostat|Given orally
224316653|NCT00070499|DRUG|Dasatinib|Given PO
224316654|NCT00070499|DRUG|Imatinib Mesylate|Given PO
224316655|NCT00070499|OTHER|Laboratory Biomarker Analysis|Correlative studies
223513792|NCT06509074|DRUG|Beta blocker|Pragmatic design. Any beta-blocker with alpha or NO activity may be used
223513793|NCT04056637|OTHER|Choice of follow-up option|Participant will be given the opportunity to choose from 3 follow-up options.
223513794|NCT04056637|DEVICE|Multi-level pregnancy test|The Multi-level pregnancy test (MLPT) strategy involves the use of the MLPT to estimate a pregnant person's baseline hCG range prior to beginning their abortion (i.e. prior to mifepristone administration). A follow-up test is then administered one week later to again estimate the woman's hCG range. A decline in hCG range reliably signifies absence of an ongoing pregnancy. Among clients ≤63 days' LMP at initiation of treatment, this strategy has shown to be highly effective: 100% of clients (n=1487/1487) with a decline in hCG range did not have an ongoing pregnancy and 100% of clients (n=21/21) with an ongoing pregnancy showed steady or increase in hCG range on their follow-up MLPT.
224316656|NCT04149223|OTHER|Evidence-based standardized Cirrhosis order set|Standardized order sets for guidance in ascites, varices, hepatic encephalopathy, infections, and medication reconciliation (optimizing HE medication, medication prophylaxis, withdrawal of non-indicated proton pump inhibitors).
224316657|NCT05964387|DEVICE|SDF|38% SDF will be applied to the hypoplastic area of the enrolled first permanent molar.
224316658|NCT05964387|DEVICE|Placebo|An inert liquid will be applied to the hypoplastic area of the enrolled first permanent molar.
223624996|NCT05771103|DEVICE|thermal Radiofrequency neurolysis of Stellate ganglion|Stellate ganglion block with alcohol injection versus thermal RF neurolysis of Stellate ganglion
223624997|NCT00976807|OTHER|Pulmonary Rehabilitation|"Eight week programme of twice-weekly (sixteen sessions) supervised exercise and education sessions. Exercise will include aerobic cardiovascular and upper and lower limb strengthening exercises. Each session will comprise a warm-up period, followed by individualised exercises, and completed with a cool-down, and last approximately 40minutes.~Aerobic exercise will be prescribed based on the results of walking tests and include walking, step-ups, cycling, and strength prescription according to the repetition maximum principle. Patients will complete three sets using this weight.~Furthermore Borg scores will be used within each session to guide and direct exercise intensity. A home exercise programme will also be designed and accompanied by a manual detailing the individual warm-up, exercises and cool-down, and diary sections to record independent activity.~Each session will also include an education session where relevant."
223624998|NCT01969708|DRUG|aflibercept|
223624999|NCT01969708|DRUG|bevacizumab|
223625000|NCT04387448|DRUG|GFB-887|Investigational Medicinal Product (IMP)
223625001|NCT04387448|DRUG|Placebo|Matching
223625002|NCT05633563|DRUG|Trimetazidine|Oral intake of capsules
223625003|NCT05633563|DRUG|Placebo|Oral intake of capsules
223625004|NCT00724841|DRUG|Obatoclax Mesylate|Obatoclax Mesylate (GMX1777) at various doses in combination with temozolomide
223625005|NCT00724841|DRUG|Temozolomide|
223625006|NCT00300417|DRUG|VRC-WNVDNA020-00-VP|
224214384|NCT05778708|BEHAVIORAL|Tai-Chi intervention|The standardized 16-form Yang-style Tai-Chi exercise set will be adopted. Group classes will take place in a community center twice a week for 16 weeks, with each class lasting approximately 60 minutes. Classes will be taught by an experienced Tai-Chi master. Patients will be instructed to practice the Tai-Chi exercises at home at least 3 times a week (30 min each time for a total of 90 min). Patients will be provided with a daily exercise log to record their exercise type, frequency, and intensity.
224214385|NCT05778708|BEHAVIORAL|Aerobic exercise intervention|The aerobic exercise class will be designed to cover both aerobic and resistance exercises. Group classes will take place in an exercise center twice a week for 16 weeks, with each class lasting approximately 60 minutes. Each class will be led by a certified exercise specialist. Patients will be provided with a daily exercise log to record their exercise type, frequency, and intensity.
224214386|NCT02580318|DEVICE|breathalyzer|
223625007|NCT00000547|DRUG|enalapril|
223625008|NCT02553213|OTHER|Laparoscopic sleeve gastrectomy|The surgical procedure and aftercare is indicated and performed according to the routine clinical setting of the Hospital. Patients stay 5 days stationary after surgical treatment. They receive a defined easy digestible diet, starting with liquid and mash food.
223625009|NCT02553213|OTHER|Laparoscopic Roux-en-Y gastric bypass|The surgical procedure and aftercare is indicated and performed according to the routine clinical setting of the Hospital. Patients stay 5 days stationary after surgical treatment. They receive a defined easy digestible diet, starting with liquid and mash food.
223625010|NCT02553213|OTHER|Caloric restriction diet|Patients of the control group do not undergo surgical treatment. They undergo a caloric restriction diet for 5 days. This diet is adapted to the postoperative diet of the patients included in the two other groups.
223625011|NCT02553213|OTHER|easy digestible diet|
223762258|NCT02385799|DRUG|Sertraline|Active medication
223762259|NCT05716035|DRUG|Tocilizumab Injection|Participants will receive IV tocilizumab
224214387|NCT01808014|DRUG|nefopam|The chief investigator prepared the medications according to the selected randomized table, and investigators who were not involved in medication preparation recorded the pain and prevalence of complications in study subjects. The double-blind restriction was lifted if the patient withdrew from the study, and the next patient was classified into a group while blinded by using the randomized table.Intramuscular midazolam 0.05 mg/kg was administered as a premedication, and then a blood pressure machine, electrocardiogram, and pulse oximeter were connected to the patient in the operating room.
223625012|NCT04760847|OTHER|Intermittent Fasting|These subjects will will then receive information regarding intermittent fasting, which would include fasting for a 16-hour period each day, followed by ingestion of an appropriate number of calories for the remaining part of the day. See attached IF Quick Facts for details provided to the patient.
223625013|NCT04760847|OTHER|No intermittent fasting|These subjects will undergo standard caloric dietary guidance. Patients in group B will also be given the above information, though not be asked to intermittently fast
223625014|NCT03740256|BIOLOGICAL|CAdVEC|The intratumoral administration of CAdVEC will create a pro-inflammatory tumor microenvironment and will promote the recruitment and expansion of adoptively transferred HER2 specific CAR T cells via CAR (tumor antigen). We expect HER2 CAR T cells expanded at primary tumor sites will re-circulate and target metastasized tumors. The combination we propose to test has the potential to overcome each of the established individual limitations of oncolytic viruses and of CAR T-cells. Testing each element separately would not be beneficial or informative, since the combination therapy is anticipated to have unique profiles of both therapeutic benefit and potential toxicities.
223625015|NCT05797012|OTHER|To assess headache severity, head posture, cervical muscle endurance and neck disorders.|To assess headache severity, head posture, cervical muscle endurance and neck disorders.
223625016|NCT01780116|BEHAVIORAL|Adherence therapy|Systematic and highly structured medication adherence program using the motivational interviewing (MI) technique that focuses on six principles: expressing empathy, developing discrepancy between client's beliefs and evidence, supporting self-efficacy, avoiding argumentation, and rolling with resistance to behavioral change. MI is often able (with in-depth behavioral analysis) to focus on particular consequences of problem behavior, such as medication non-adherence, that have an obvious impact on patients.
223625017|NCT01713959|DEVICE|Ulthera System treatment|Ulthera System: Focused ultrasound energy delivered below the surface of the skin.
223625018|NCT01713959|DEVICE|Sham treatment|Sham Treatment: Use of the Ulthera System with the system adjusted to deliver 0 energy.
223762260|NCT00210314|DRUG|high dose methotrexate|
223762261|NCT00210314|DRUG|high dose cytarabine|
223762262|NCT00210314|RADIATION|radiotherapy|
223625019|NCT05668832|DIETARY_SUPPLEMENT|UVB-exposed button mushrooms|Healthy subjects will be randomized into two groups and received either UVB-exposed button mushrooms or non-UVB-exposed button mushrooms for 7 days. Blood samples from each subject will be taken at baseline (before the intake of the mushrooms, 3 h and 6 h thereafter, and at day 8. Three months later, another blood sample was taken.
223625020|NCT06519812|PROCEDURE|Combined Intrarenal Surgery and percutaneous nephrolithotomy|A study was conducted to compare endoscopic combined intrarenal surgery and percutaneous nephrolithotomy as modalities of treatment for staghorn stones.
224214388|NCT02165566|DRUG|Regular-insulin|patients are assigned in a random sequence to receive Regular-insulin or lispro-insulin infusion
224214389|NCT02165566|DRUG|Lispro-insulin|patients are assigned in a random sequence to receive Regular-insulin or lispro-insulin infusion
224214390|NCT04033900|DEVICE|Forced air warming devices|"In the treatment group, heating will be started with a pre-surgical forced-air blanket Outpatient Warming Blanket model 11101 Bair Hugger from 3M and a forced-air heating unit Bair Hugger Warming Unit Model 775 from 3M at 38-43º C which will be maintain during the stay in the pre-surgery room until the transfer to the operating room"
224214391|NCT03951870|BEHAVIORAL|Neuromodulation via fMRI Neurofeedback task|Two active neurofeedback groups will practice to up regulate their designated neural targets via identical experimental protocol (varying only the origin of the feedback).
224214392|NCT03951870|BIOLOGICAL|Hepatitis B vaccination|Subjects will be vaccinated against Hepatitis B
224214393|NCT04273152|DIAGNOSTIC_TEST|advanced glycation endproducts reader|advanced glycation endproducts reader
224214394|NCT01653470|DRUG|Paclitaxel|
224214395|NCT01653470|DRUG|5-Fluorouracil (5FU)|
224214396|NCT01653470|DRUG|Carboplatin|
224214397|NCT01653470|DRUG|Leucovorin|
223625021|NCT00663013|OTHER|Virtual Reality|Virtual reality (VR) gives patients an illusion of going into the 3-D computer generated environment/virtual world. During VR, the subject wears a head-mounted virtual reality helmet that positions two goggle-sized miniature LCD computer screens close to the subject's eyes. Position tracking devices keep the computer informed of changes in the patient's head location. An electro-magnetic head orientation device feeds the x, y, z coordinates of the patient's head to the computer, which can quickly change what the patient sees in virtual reality accordingly. The scenery in VR changes as the patient moves her head orientation (e.g., virtual objects in front of the patient in VR get closer as the patient, wearing the VR helmet, leans forward in the real world).
224214398|NCT01653470|DRUG|Irinotecan|
224214399|NCT01653470|DRUG|Paclitaxel|
224214400|NCT01653470|DRUG|BMS-906024|
224214401|NCT06290700|BEHAVIORAL|Neonatal Care education|Participants who met the study inclusion criteria were provided with information about the purpose and conduct of the study, and their consent to participate was then obtained. The interviews were conducted in the breastfeeding room at the Uşak Dikilitaş Family Health Centre. The data were collected between November 2022 and November 2023. The Family Health Centre has two vaccination rooms, two antenatal care rooms, two observation rooms, and two breastfeeding rooms. Each pregnant woman was individually enrolled in an education session held in the breastfeeding room. The breastfeeding room was approximately 20 m², which was considered standard for accommodating training for an average of three pregnant women. The breastfeeding room was quiet, had a suitable temperature, and was located on the first floor in the middle of the corridor.
224214402|NCT00004699|DRUG|insulin-like growth factor I|
224214403|NCT03526952|OTHER|Internet-Delivered Intervention for Sexual Re-Adjustment|Couples will meet with a therapist via video-conferencing for two 1.5-hr sessions. The therapist will facilitate couples' communication about their sexual and intimate relationship while providing psychoeducation about couple coping and sexuality after cancer and with an ostomy. Discussion will focus on current concerns, motivations for sex, relational strengths, and intimacy and sensual pleasure. Couples will also be encouraged to practice a sensate focusing exercise between sessions.
224214404|NCT03526952|OTHER|Written Educational Material|Couples will receive written educational material for patients coping with changes in intimacy and sexuality when living with a permanent ostomy. This educational material is published by the United Ostomy Associations of America, Inc. and is available for free download from their website. Couples will have two weeks to read this material.
224214405|NCT00042042|BEHAVIORAL|Family based educational program|
223625022|NCT03495466|PROCEDURE|Local only anesthesia vs Local with sedation anesthesia|The investigators are comparing two approved sedation types that are using during carpal tunnel surgery.
223762263|NCT04458064|OTHER|LMA i gel|insertion of LMA for maintaining airway during anesthesia
223762264|NCT00157599|PROCEDURE|various diagnostic measures for DVT (e.g., CUS)|
224214406|NCT01883999|DEVICE|GORE® EXCLUDER® Iliac Branch Endoprosthesis|
224214407|NCT05614999|OTHER|Endoscopy training curriculum|Eight sessions training in endoscopic tip control using Varix trainer model I.
224214408|NCT05198115|BEHAVIORAL|aerobic exercise|aerobic training for 8 weeks, 3 times a week, and 60 min each time
224214409|NCT05844683|OTHER|2% chlorhexidine digluconate solution|Bathing will be performed at least daily using 2% chlorhexidine digluconate solution with surface-active agents on all applicable bathing surfaces, which consists of the entire body surface of the patient except eyes, inner ear, oral mucosa, and areas of loss of skin continuity (such as burnt areas, pressure injuries, etc.)
224214410|NCT05844683|OTHER|usual baths|Bathing will be performed at least daily using shampoo and water (performed according to the current practice in each center) on all applicable bathing surfaces, which consists of the entire body surface of the patient except eyes, inner ear, oral mucosa, and areas of loss of skin continuity (such as burnt areas, pressure injuries, etc.)
223625023|NCT03494270|DRUG|Rosuvamibe|Rosuvastatin 10mg/Ezetimibe 10mg
223625024|NCT03494270|DRUG|Monorova|Rosuvastatin 20mg
223625025|NCT02416999|DRUG|Ultra-low dose Bevacizumab|
223625026|NCT02416999|DRUG|Temozolomide|
223625027|NCT01176734|DEVICE|tVNS-Device|Active treatment with the t-VNS device.
223762265|NCT00139568|DRUG|Tegaserod|
223762266|NCT04593901|BEHAVIORAL|Video and App Review|"Scenario Review: The scripts and/or videos will be iteratively reviewed by individual and small groups of home healthcare personnel using Zoom, Microsoft Teams, or similar. The participants will review scripts and/or recordings of the scripts and discuss how well each situation has been represented, how to improve it, and whether it is applicable in their agency.~App Review: Following review of the scenarios, participants will review the smartphone app currently under development, including the control buttons, their placements, and other features of the screen interface. The first 9-12 participants (approximately) will be asked to provide feedback on the app's layout, control locations, and overall appearance. Once suggested changes have been made, the app will then be reviewed by the remaining participants for final review and usability assessment."
223762267|NCT03758911|OTHER|Semi-structured Interview|
224214411|NCT01735877|OTHER|Mirror therapy|During the mirror practices, patients were seated close to a table on which a mirror (35×35cm) was placed vertically. The practice consisted of non paretic-side wrist and finger flexion and extension movements while patients looked into the mirror, watching the image of their noninvolved hand, thus seeing the reflection of the hand movement projected over the involved hand. Patients could see only the noninvolved hand in the mirror; otherwise, the noninvolved hand was hidden from sight. During the session patients were asked to try to do the same movements with the paretic hand while they were moving the non paretic hand.
224214412|NCT01735877|OTHER|Control group|The control group performed the same exercises for the same duration but used the nonreflecting side of the mirror in such a way that the paretic hand was hidden from sight. The same therapist delivered the control therapy to the patients. Both the treatment and the control group received limb activation.
224214413|NCT05105477|DEVICE|AcumenTM HPI Software Feature|The AcumenTM HPI Feature Software provides the clinician with physiological insight into a patient's likelihood of trending toward a hypotensive event. The AcumenTM HPI Feature Software suite is enabled by the minimally invasive Acumen IQ sensor.
224214414|NCT05105477|OTHER|Non-protocolized Standard of Care|Non-protocolized standard of care to treat subjects
224214415|NCT05540977|DRUG|Donepezil|Donepezil 5mg QN
224214416|NCT05540977|OTHER|Usual care|Usual care
224214417|NCT05102045|DEVICE|Repetitive Transcranial Magnetic Stimulation|TMS is a non-invasive application that induces changes in neuronal polarization and activity by causing the induction of weak electric currents in a rapidly changing magnetic field. Repetitive TMS (rTMS) refers to the application of regular TMS pulses at fixed intervals.
224214418|NCT05102045|OTHER|Aerobic Exercise|Brisk exercise that promotes the circulation of oxygen through the blood and is associated with an increased rate of breathing.
224214419|NCT05102045|DRUG|Acetylcholinesterase Inhibitors|Donepezil, Rivastigmine, Galantamine were given in combination for Alzheimer's disease.
223513795|NCT05493345|BEHAVIORAL|Bridge-building between municipality-based lifestyle programs and community-based physical activities|Four co-created bridge-building activities has been implemented in the municipality of Odsherred, including (1) A digital portal for information and sharing of knowledge, (2) Visits between municipal rehabilitation programs and community-based physical activities, (3) Co-created teams for the target group, and (4) a 'Bridge builder' coordinator.
223513796|NCT06465602|DRUG|Nicotinamide|The subjects will receive 1.5 grams per day of Nicotinamide, orally, for 30 days.
223513797|NCT06465602|DRUG|Placebo|The subjects will receive 1.5 grams per day of placebo, orally, for 30 days.
223513798|NCT06003621|BIOLOGICAL|Tiragolumab|600mg IV every 21 days from Cycle 1 Day 1
223513799|NCT06003621|BIOLOGICAL|Atezolizumab|1,200mg IV every 21 days from Cycle 2 Day 1
223513800|NCT06054815|DRUG|DA-1241|Route of Administration: Oral, with subjects in a fasting state
223513801|NCT06054815|DRUG|Sitagliptin|Route of Administration: Oral, with subjects in a fasting state
223513802|NCT06054815|DRUG|DA-1241 Placebo|Route of Administration: Oral, with subjects in a fasting state
223513803|NCT06054815|DRUG|Sitagliptin Placebo|Route of Administration: Oral, with subjects in a fasting state
223513804|NCT05685160|DIAGNOSTIC_TEST|MRI with contrast|MRI of the forefoot with contrast (Gadovist)
223513805|NCT05685160|DIAGNOSTIC_TEST|Ultrasound|Ultrasound imaging of the forefoot
223513806|NCT06585423|DIAGNOSTIC_TEST|Sterile commercially available bandage contact lens|Medical grade acrylic tip covered by a sterile commercially available bandage contact lens
223513807|NCT06585423|DIAGNOSTIC_TEST|Medical grade silicone of a thickness <100 µm|Medical grade acrylic tip coated with medical grade silicone of a thickness \<100 µm
223513808|NCT06585423|DIAGNOSTIC_TEST|Medical grade silicone of a thickness >100 µm|Medical grade acrylic tip coated with medical grade silicone of a thickness \>100 µm
223513809|NCT05520762|PROCEDURE|A strategy of first choice supraglottic airway|See description in Arms section
223513810|NCT05520762|PROCEDURE|A strategy of first choice endotracheal intubation|See description in Arms section
223513811|NCT05849662|DRUG|Trametinib|"PO or NG QD Days 1-28~For patients age \< 6 years: 0.032 mg/kg/day at max dose = 2mg/day~For patients age ≥ 6 years: 0.025 mg/kg/day at max dose = 2 mg/day"
223513812|NCT05849662|DRUG|Azacitidine|"IV over 30 minutes Days 1-5~Age \< 1 year or weight \<10kg:~2.5 mg/kg/day~Age ≥ 1 year and weight ≥ 10kg:~75 mg/m2/day"
223513813|NCT05849662|DRUG|Fludarabine|"IV over 30 minutes Days 6-10~30 mg/m2/day (1mg/kg if \<12 kg)"
223513814|NCT05849662|DRUG|Cytarabine|"IV over 3 hours Days 6-10~2000 mg/m2/day (67mg/kg if \<12 kg)"
223513815|NCT06157827|DRUG|LBL-024 for Injection|Initial dose-MTD; Q3W; intravenous infusion
223513816|NCT06157827|DRUG|Etoposide Injection|Initial dose（Dose was decided by the investigator according to the subject's condition）; Q3W; intravenous infusion
223513817|NCT06157827|DRUG|Carboplatin Injection|Initial dose（Dose was decided by the investigator according to the subject's condition）; Q3W; intravenous infusion
223513818|NCT06157827|DRUG|Atezolizumab injection|Initial dose; Q3W; intravenous infusion
223513819|NCT06157827|DRUG|Cisplatin injection|Initial dose（Dose was decided by the investigator according to the subject's condition）; Q3W; intravenous infusion
223513821|NCT01602666|RADIATION|3-Dimensional Conformal Radiation Therapy|Undergo 3D-CRT
223513822|NCT01602666|DRUG|Carboplatin|Given IV
224214420|NCT05102045|DRUG|Memantine|Memantine were given for Alzheimer's disease. .
224214421|NCT00245622|BIOLOGICAL|Tovaxin Autologous T cell vaccine|subcutaneous injections administered by healthcare provider at weeks 0, 4, 8, 12, and 24
224214422|NCT00245622|BIOLOGICAL|Placebo|subcutaneous injections administered by healthcare provider at weeks 0, 4, 8, 12, and 24
224214423|NCT05249010|PROCEDURE|acupuncture and moxibustion|Participants receive acupuncture and then measure the VAS and electric characteristic by the semiconductor analyzer Agilent B1500A first. The investigators add the burned moxa on the acupuncture as a method for moxibustion, and then measure the VAS and electric characteristic again.
224214424|NCT00274014|DRUG|Tiotropium|
224214425|NCT02108613|BEHAVIORAL|Exercise Sessions|8 weeks of weekly exercise classes taught by a certified exercise physiologist.
224214426|NCT02108613|BEHAVIORAL|Nutrition Education|Four monthly education sessions on nutrition topics. Presentations and materials are were created by a BCCA dietitian.
224214427|NCT02108613|BEHAVIORAL|Peer Support Volunteer|Participants will be assigned a peer support volunteer who will preform adherence calls to discuss goals and motivations about improving exercise and healthy eating.
224214428|NCT06526715|OTHER|Morton extension|A Morton extension with a height of 5 mm was insert from the proximal area of the first metatarsal head to the base of the proximal phalanx of the Hallux of the subjects' bare feet using a paper bandage. The material, shape, size, and thickness of the Morton Extension were the same.
224214429|NCT01835132|DEVICE|Gevokizumab|Subcutaneous injection of 60 mg gevokizumab
224214430|NCT00328237|PROCEDURE|Cord Blood Transplant|
224214431|NCT00856778|DEVICE|Virtue® Male Incontinence Sling|The VIRTUE® male sling is a Class II, implantable, sub-urethral, permanent, non-absorbable support sling indicated for the surgical treatment of male SUI resulting from intrinsic sphincter deficiency. The sling is manufactured from polypropylene and is sold for single use only.
224214432|NCT01294878|DRUG|omalizumab|The omalizumab dose has been calculated on the basis of body weight and basal levels of total serum IgE. Treatment was administered subcutaneously every 2 or 4 weeks (according to the calculated total dose) for a total of 48 weeks. Each vial contained 150 mg of the active compound, therefore the number of injections for each administration varied between 1 and 3, depending on the total dose used.
224214433|NCT00877682|PROCEDURE|Cryoablation|Under general anesthetic using ultrasonic guidance, freezing (cryoablation) portion of prostate.
224214434|NCT01333176|PROCEDURE|"Point-of-care finger-poke HbA1c determination."|"All volunteers receive finger-poke HbA1c test. Result: If \< 6: Offered a requisition to have gold standard testing for diabetes screening. If 6-6.5: Given requisition for FBG, HbA1c and OGTT. If A1c result \>6.5: Counseled that they may have diabetes. Given requisition as above.~Estimates about how many have undiagnosed diabetes will be calculated.~1. Did the clients who were counseled to do so get follow-up blood tests?~2. Were all the formal diagnostic tests performed?~3. Did the formal tests correlate to the POC HbA1c test or was there significant discrepancy? Thus is this new test for diagnosing diabetes confirmed as a valid test for screening in First Nation Communities in Canada?~4. Did the family physicians find this useful?"
224214435|NCT01333176|PROCEDURE|HbA1c blood test|All candidates will have a HbA1c blood test (Finger poke)
224214436|NCT01333176|PROCEDURE|HbA1c finger poke test|All study candidates will have the same HbA1c test performed
224214437|NCT01333176|PROCEDURE|Blood test|HbA1c blood test
224214438|NCT01333176|PROCEDURE|Blood test|HbA1c finger poke blood test
224214439|NCT03150030|OTHER|Combined hyper- and hypoglycaemic clamp|During the entire clamp, participants will be monitored by ECG, pulse oximetry, and blood pressure and plasma glucose will be measured bedside every fifth minute. Additionally, patients with type 2 diabetes will be monitored by a loop recorder (LR) and a continuous glucose monitor (CGM). Comparison of LR and CGM recordings with the recordings obtained by ECG Holter monitor and blood sampling will be used for validation of the method used in Part 2 of the study. Blood samples will be drawn and analysed for changes in electrolytes, insulin, glucagon, catecholamines and cortisone. A cardiac haemodynamic evaluation will be performed by echocardiography at baseline, hyperglycaemia, and hypoglycaemia.
224214440|NCT03150030|DEVICE|Loop recorder (Reveal LINQ, Medtronic, Minneapolis, MN, USA)|Implantation of a loop-recorder
224214441|NCT03150030|DEVICE|Continuous glucose monitoring (iPro2, Medtronic, Minneapolis, MN, USA)|Monitoring with a continuous glucose monitor
224214442|NCT02805374|DRUG|ASP1517|Oral
224214443|NCT00551486|PROCEDURE|ultrasound-guided fine needle aspiration biopsy|Fine needle aspiration (FNA)with cytologic analysis has become a mainstay of thyroid nodule evaluation was used. Nonpalpable nodules were aspirated under ultrasound guidance to facilitate precise targeting of the nodule and to sample the part most likely to improve diagnostic yield.
224214444|NCT03016663|PROCEDURE|Technique of Breast Lipofilling|"1. Identification of the donor site Procedure carried out in single sessions under GA. Abdominal site identified and outlined with a skin marker.~2. Fat Harvesting Berlin autologous lipotransplantation technique used according to the BEAULI protocol described by Ueberreiter et al.~   Infiltration solution -Klein'solution contains 1 cc of epinephrine (1:500,000) diluted in 500 cc of 0.001% lactate ringer solution (LRS).~3. Fat Processing After aspiration of nonviable components of the aspirate, fat graft washed using Lactate Ringer Solution for three times. The fat processing and washing were performed by the same assistant for all patients.~4. Fat Transfer (Injection) Fat is injected in small amounts as the needle is gradually withdrawn. Periglandular planes and intrapectoral planes are used. Intraparenchymal injection avoided."
224214445|NCT03709407|OTHER|cervical stimuli|Manouvres Godoy
224214446|NCT03709407|OTHER|terminus|Manouvres Vodder
224214447|NCT03709407|OTHER|Placebo|placebo manouvre
224214448|NCT03709407|OTHER|Control group|lie down
223513823|NCT01602666|DRUG|Etoposide|Given IV
223513824|NCT01602666|DRUG|Ifosfamide|Given IV
223513825|NCT01602666|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
223513826|NCT04227522|DRUG|Rucaparib|A starting dose of 600 mg Rucaparib is taken twice daily orally by the patients as maintenance after previous maintenance therapy (Bevacizumab) for a period of 12 to 15 months.
223513827|NCT04227522|DRUG|Placebos|Placebo is taken daily orally by the patients as maintenance after previous maintenance therapy (Bevacizumab) for a period of 12 to 15 months.
223513828|NCT01861275|DEVICE|Nasal CPAP|Nasal CPAP treatment for obstructive sleep apnoea
223625028|NCT05606666|OTHER|reliability of the NPQ|The aim of this study is to study the validity and reliability of the Modified Pain Neurophysiology Questionnaire in patients with neck pain.
224214449|NCT01577966|DRUG|Sulfasalazine|"Sulfasalazine has been the parent aminosalicylate in use for over 40 years in the treatment of inflammatory bowel disease. The drug is a conjugate of sulfapyridine linked to 5-aminosalicylic acid. In inflammatory bowel disease, the 5-ASA component is the active moiety~Sulfasalazine is a prodrug that consists of sulfapyridine bonded to mesalamine (5-ASA). Sulfasalazine is cleaved by colonic bacterial azo-reductases into sulfapyridine and the 5-ASA moiety. 5-ASA is metabolized to N-acetyl-5-ASA by an enzyme in the intestinal epithelium and the liver and then excreted in the urine as a mixture of free 5ASA and N-acetyl-5-ASA."
224316659|NCT06795724|OTHER|PENG block|For PENG block, patients are in the supine position is deposited. The convex ultrasound probe is initially placed over the anterior superior iliac spine, then the probe moves medially until the femoral artery is visualized. In this view, iliopectineal eminence (IPE), iliopsoas muscle and tendon, femoral artery and iliac muscle are observed. Between the psoas tendon and the IPE 22 gauge 80 mm block needle is guided and 20cc local anesthetic used in % 0.25 bupivacaine is administered by intermittent aspiration.
224316660|NCT06795724|OTHER|Control|Standard analgesia method will be applied and analgesia will be provided with tramadol hydrochloride and paracetamol.
224316661|NCT02883049|DRUG|Clofarabine|Given IV
224316662|NCT02883049|DRUG|Cyclophosphamide|Given IV
223625029|NCT00293657|DRUG|Lornoxicam 8 mg|
224214450|NCT06344988|OTHER|The exercise program|The exercise program developed by Chan et al., consists of a 30-minute exercise period with 5 minute warm-up (diaphragmatic breathing, general body movements) and 5-10 minute cool-down (stretching exercises in addition to the exercises in the warm-up period) periods. Exercises include 6 steps and 5 series (neck, shoulder, spine, abdominals, hip) according to difficulty level. The total exercise program takes 40-45 minutes.
224214451|NCT06344988|OTHER|Online education presentation|This online education presentation includes the role of postural and dynamic muscles, the importance of physical activity, gradual adaptation of the body to workload and physical stressors, rest, and injury management. The education takes 40 minutes and will be done once.
224214452|NCT06344988|DEVICE|Smart band|Participants will be given a Xiaomi Mi Smart Band 5 and will be asked not to remove the smart band except for bathing for 8 weeks, and to download the smart phone application (Zepp Life) compatible with the smart band to their phones, which will allow their steps to be recorded on a weekly basis.
224214453|NCT04278365|BEHAVIORAL|Positive affect training|Behavioral training involving position emotion enhancement
224214454|NCT02177773|PROCEDURE|Computed Tomography (CT)|Undergo Gallium Ga 68-DOTA-TOC PET/CT
224214455|NCT02177773|DRUG|Gallium Ga 68-Edotreotide|Given Intravenously (IV) before imaging
224214456|NCT02177773|PROCEDURE|Magnetic Resonance Imaging (MRI)|Undergo gallium Ga 68-DOTA-TOC PET/MRI
224316663|NCT02883049|DRUG|Cytarabine|Given IT, IV, or SC
224316664|NCT02883049|DRUG|Dasatinib|Given PO
224316665|NCT02883049|DRUG|Daunorubicin Hydrochloride|Given IV
224316666|NCT02883049|DRUG|Dexamethasone|PO or IV
224316667|NCT02883049|DRUG|Doxorubicin Hydrochloride|Given IV
224316668|NCT02883049|DRUG|Etoposide|Given IV
224316669|NCT02883049|DRUG|Hydrocortisone Sodium Succinate|Given IT
224316670|NCT02883049|OTHER|Laboratory Biomarker Analysis|Correlative studies
224316671|NCT02883049|DRUG|Leucovorin Calcium|Given PO or IV
224316672|NCT02883049|DRUG|Mercaptopurine|Given PO
224214457|NCT02177773|PROCEDURE|Positron Emission Tomography (PET)|Undergo gallium Ga 68-DOTA-TOC PET in combination with CT or MRI
224316673|NCT02883049|DRUG|Methotrexate|Given IT and IV
224316674|NCT02883049|DRUG|Pegaspargase|Given IV
224316675|NCT02883049|DRUG|Prednisone|Given PO or IV
224316676|NCT02883049|RADIATION|Radiation Therapy|Undergo radiation therapy
223625030|NCT00293657|DRUG|Lornoxicam 16 mg|
224316677|NCT02883049|DRUG|Thioguanine|Given PO
224316678|NCT02883049|DRUG|Vincristine Sulfate|Given IV
224316679|NCT05806606|OTHER|Dyadic empowerment based heart failure management program|The 16-week De-HF Program is delivered on a dyadic basis, The program consists of three core elements: i) joint dyadic interview in a home visit (1st-2nd week), ii) five ICT-enhanced empowerment-based modules (3rd-12th week; 2 sessions/ each module), and iii) post-module telephone follow-up (13th-16th week). The overall aim of the dyadic interview is to understand their usual pattern of collaboration, deficits, strengths and competing concerns in disease management. This is followed by the empowerment modules with the purpose to help the care dyads to get a consensus in disease interpretation (1st session: Perceptual and Cognitive Empowerment Session) and develop collaborative goal attainment process (2nd Session: Collaborative Gaol-Setting Process). This will be followed by two bi-weekly telephone calls to the care dyads using a speaker phone to monitor their level of goal attainment for the five modules, and to give further advice and counselling.
224316680|NCT05806606|OTHER|Dyadic education program|The 16-week HF education program comprises a home visit, five bi-weekly online training sessions, and the subsequent telephone follow-up for the care dyads. The nurse will first assess how they manage HF in terms of medication compliance, fluid and dietary control, symptom monitoring and responses in a home visit and clarify their major misconceptions in self-care. This will be followed by five bi-weekly online education sessions on the same topics as the empowerment modules in the De-HF program.
224316681|NCT04769921|DEVICE|dental implants and abutments from Nobel Biocare|The implants will be inserted in an All-on-4 configuration; Abutments will be connected to the implants and serve as support for a full-arch implant-supported restoration.
224316682|NCT06647056|DRUG|Psilocybin|Administration of psilocybin 25 mg
223625031|NCT00293657|DRUG|Placebo|
223680546|NCT05979545|DIAGNOSTIC_TEST|Rapid Diagnostics|Patients randomised to the intervention arm, will have the BioFire Blood Culture Identification 2 Panel (BCID2) used for positive blood cultures and/or the BioFire FilmArray Pneumonia plus PanelPneumonia Panel or Pneumonia plus Panel for respiratory tract specimens if having hospital-acquired pneumonia or ventilator-associated pneumonia. Standard of care diagnostics will also be used. Antibiotic guidelines will be provided to clinicians to aid interpretation of test results and treatment prescription. Ceftazidime-avibactam will be available for targeted use in patients with Pseudomonas aeruginosa or carbapenemase producing Enterobacterales.
223625032|NCT05833529|BEHAVIORAL|Virtual Reality Cue Exposure (VRCE) Therapy for Cocaine Craving - 2 weeks|"40 10 mins VRCEs for cocaine craving (desensitization to only cocaine craving cues; no others interventions). 4 VRCE and 2 different VRCE situations by meeting. Same VRCE situations spaced intra (30 mins) and inter meetings (48 hrs). 5 standard VRCE situations (appearance and dialogues adapted to Martinique field) varying from only peers cocaine use talk to peers and participant prepare and use cocaine and ranging from the lowest to the highest participant related cocaine craving level. Situation switch to another when its initial cocaine craving level has decreased to its half for 5 continuous VRCE mins (must be ≤ 3/10; 0 = none; 10 = very high). Meetings end with relaxation/relapse prevention in any case of distress still over convenient levels. VRCE use Meta Quest 2, are visuo-auditively immersive (360°; 1st person), interactive (using virtual objects), semi-stationnary (360°-rotating stool and teleportation system). Participant skin color and cocaine using mode individualized."
224214458|NCT04596462|DRUG|68Ga-FAPI|Intravenous injection of one dosage of 74-148 MBq (2-4 mCi) 68Ga-FAPI. Tracer doses of 68Ga-FAPI will be used to image lesions of SAPHO by PET/CT.
224214459|NCT02523729|DIETARY_SUPPLEMENT|Anke Malz|non-alcoholic malt drink
224214460|NCT02540720|DRUG|Dexamethasone|
224214461|NCT02540720|DRUG|Gamma globulin|
224214462|NCT02540720|PROCEDURE|Hemoperfusion|
224214463|NCT03538522|DRUG|N-831(Traneurocin) 10 mg QD|Oral administration of 10 mg capsule of NA-831 QD for 24 weeks
224214464|NCT03538522|DRUG|NA-831 (Traneurocin) 20 mg QD|Oral administration of 20 mg capsule of NA-831 QD for 24 weeks
224214465|NCT03538522|DRUG|NA-831 (Traneurocin) 40 mg QD|Oral administration of 40 mg capsule of NA-831 QD or for 24 weeks
224214466|NCT03538522|DRUG|Placebo oral capsule QD|Oral administration of oral placebo capsule QD or 24 weeks
224214467|NCT03901222|DEVICE|tDCS|20 minutes of anodal tDCS (C3 \& C4/FPZ) 2mA or sham
224214468|NCT03512067|DEVICE|Patients given EMV Ventilation|Baseline mechanical ventilation data with conventional pressure-limited assist/control ventilation mode will then be collected for a 4-hour period. The patients will then be transitioned to pressure-limited entrainment-based ventilation for a 4-hour period. Baseline ventilation monitoring will be carried out either immediately preceding or immediately following EMV in the same patient. The sequence of the control/baseline phase and the experimental phase of the study will be randomized.
224214469|NCT00819858|DIETARY_SUPPLEMENT|RUTF (Plumpynut®)|Intervention group receives 500 kcal/day of RUTF for 2 weeks Control group receives no food supplement
224214470|NCT02206724|RADIATION|STEREOTACTIC BODY RADIOTHERAPY to the prostate gland|
224214471|NCT03635619|OTHER|No intervention|No intervention
224214472|NCT00782275|DRUG|bevacizumab|
224214473|NCT00782275|DRUG|temsirolimus|
224214474|NCT01637259|DRUG|arm 1 nucleotide analogue reverse transcriptase inhibitors and boosted protease inhibitors|NRTI + PI
224214475|NCT01637259|DRUG|Arm 2 boosted protease inhibitors and maraviroc|PI + maraviroc
224316683|NCT06647056|OTHER|MRI|Two standard MRI + fMRI scans before (D-3) and after (D5) treatment
224316684|NCT06151626|OTHER|virtual-reality based rhythmic skill training|Participants wear VR headsets and Oculus Touch controllers and undergo rhythm skill training for a total of 35 minutes.
224316685|NCT06151626|OTHER|rhythmic skill training with visual feedback|The rhythm skill training activities in this group are the same as the virtual reality-based system. Participants received 35 minutes of rhythm skill training presented through a computer interface
224316686|NCT06151626|OTHER|strengthening group|Participants receive an upper limb strengthening exercise program under the supervision of a therapist to ensure that the strengthening exercises are performed correctly. This includes: proprioceptive neuromuscular facilitation, resistance training, and tendon gliding exercises.
224214476|NCT01637259|DRUG|Arm 3 nucleotide analogue reverse transcriptase inhibitors and maraviroc|NRTI + maraviroc
224214477|NCT03205007|BEHAVIORAL|Health promotion nutrition program|Health promotion nutrition program
224316687|NCT06151626|OTHER|breathing and muscle relaxation exercises|5 minutes of breathing and muscle relaxation exercises
224214478|NCT00406107|DRUG|pegaptanib sodium (Macugen)|Subjects were randomized 3:1 to intravitreous injections of pegaptanib 0.3mg or 1mg at baseline and at weeks 6 and 12 with subsequent injections at 6-week intervals at investigator discretion until week 48.
224214479|NCT00004861|DRUG|gemcitabine hydrochloride|
224214480|NCT00004861|DRUG|tacedinaline|
224214481|NCT00572247|BEHAVIORAL|Psychiatric Rehabilitation Approach to Weight Loss|The use of psychiatric rehabilitation as a way to lose weight
224214482|NCT00331773|RADIATION|Conventional 3D-CRT or IMRT|Radiation therapy will be given once daily, five days a week, at 1.8 Gy per fraction, for 41 fractions and a total dose of 73.8 Gy
224214483|NCT00331773|RADIATION|Hypofractionated 3D-CRT or IMRT|Radiation therapy will be given once daily, five days a week, at 2.5 Gy per fraction, for 28 fractions and a total dose of 70 Gy.
224214484|NCT04701476|DRUG|TATE and pembrolizumab|All liver metastatic lesions will be treated with TATE for maximally debulking. Pembrolizumab IV infusion per standard schedule every 3 or 6 weeks until progression or maximally 2 years.
224214485|NCT04701476|DRUG|TAS-102 pill|The comparator of the mCRC arm is TAS-102 at 60 mg BID 5 days per week for 2 weeks then 2 weeks off.
224214486|NCT04701476|DRUG|Regorafenib Pill|As an alternative to TAS-102 per treating physician's discretion. If selected, Regorafenib 160 mg oral daily for 3 weeks on and one week off, every 4 weeks per cycle. Do not take Regoarefnib if taking TAS-102.
224214487|NCT00612794|DRUG|exenatide once weekly|subcutaneous injection, once weekly
224214488|NCT00612794|DRUG|placebo|subcutaneous injection, once weekly
224214489|NCT03033589|DRUG|Marcaine 0.25 % Injectable Solution|For the adductor canal block, 20 mL of 0.25% marcaine will be injected with the use of ultrasound guidance into the adductor canal by the attending anesthesiologist on the case in the pre-op holding area.
224214490|NCT03033589|DRUG|Marcaine 0.25 % Injectable Solution|For the femoral nerve block, 30 mL of 0.25% marcaine will be injected with the use of ultrasound guidance around the femoral nerve sheath by the attending anesthesiologist on the case in the pre-op holding area.
224214491|NCT01122043|DEVICE|Endoglide|Device
224214492|NCT03432026|DEVICE|High resolution computed tomography scan of the chest.|High resolution computed tomography scan of the chest \& pulmonary function tests will be done for every patient to classify them.
224214493|NCT05654857|DIAGNOSTIC_TEST|PCR test in the stool|Patients will receive a prescription for a stool self-collection kit . Only the result of the PCR test in the stool will be considered for this arm. A positive test will determine Hp infection and the indication for treatment.
224214494|NCT06530420|PROCEDURE|Umbilical hernia repair surgery|collected information about: gender, age, comorbidities, body weight, time of surgery, hernia size and treatment methods and reccurence
224214495|NCT03384420|BIOLOGICAL|CD34+ cells enriched with MNV-BLD|Transplantation of autologous stem cell enriched with MNV-BLD (blood-derived mitochondria)
224214496|NCT00289731|BIOLOGICAL|TWINRIX™|Intramuscular injection, 3 doses
224214497|NCT00289731|BIOLOGICAL|Engerix™-B|Intramuscular injection, 3 doses
224214498|NCT00289731|BIOLOGICAL|HAVRIX™|Intramuscular injection, 2 doses
224214499|NCT00289731|BIOLOGICAL|HB VAX PRO™|Intramuscular injection, 3 doses
224214500|NCT00289731|BIOLOGICAL|Vaqta™|Intramuscular injection, 2 doses
224214501|NCT06290414|DIAGNOSTIC_TEST|infrared thermal camera|capturing thermographic imaging of gingiva to detect thermal changes due to inflammation as a result of periodontal disease
224214502|NCT05926336|DRUG|Propofol|The propofol group was both induced and maintained at an effect-site concentration (Ce) of 2.0-4.0 mcg/mL by a target-controlled infusion (TCI) system.
224214503|NCT05926336|DRUG|Sevoflurane|The sevoflurane group was maintained via sevoflurane vaporizer between 1% and 3% (target minimum alveolar concentration of 0.7-1.3 MAC)
224214504|NCT00403364|DRUG|Placebo amoxicillin pantoprazole clarithromycin tinidazole|
224214505|NCT02019979|DRUG|metformin|Addition of metformin 1000 mg po bid to standard of care platinum based chemotherapy
224214506|NCT02019979|BEHAVIORAL|carbohydrate restricted diet|addition of dietary counseling and metformin 1000 mg po bid to platinum based chemotherapy
224214507|NCT00353938|DRUG|3,4-methylenedioxymethamphetamine (125 mg)|Participants will receive an initial dose of 125 mg MDMA orally and, if investigator and participant deem appropriate, 2.5 hours later they will receive 62.5 mg MDMA orally.
224214508|NCT00353938|DRUG|3,4-methyelendioxymethamphetamine (25 mg)|Participants will receive a 25 mg MDMA orally, and if investigator and participant agree, 2.5 hours later they will receive 12.5 mg MDMA orally.
224214509|NCT00353938|BEHAVIORAL|Therapy|Non-directive therapy performed by a team of two co-therapists
224214510|NCT00330200|DRUG|ISIS 113715|
224214511|NCT03810833|DEVICE|Brilliance device sensor|Two separate sensors will be attached via standard, single-use adhesive pads to the left and right pectoralis major on each participant.
224214512|NCT03381885|BEHAVIORAL|Gentle Nudge|Clinicians ordering medium or high scoring imaging studies could bypass the usual mandatory phone call to radiology.
224214513|NCT03381885|BEHAVIORAL|Usual Standard Procedure|Clinicians ordering imaging studies required mandatory phone to radiology
224214514|NCT03168685|DEVICE|SureSource Engage application|"Eligible patients who choose to participate in the study will be asked to wear an actigraphy device \[ActiGraph GT9X Link Actigraph Link\] on their wrist continuously during both 4-week study phases.~The ActiGraph Link is a small (3.5 X 3.5 X 1 cm) wristwatch like device weighing approximately 14 grams that measures indicators of the wearer's activity and sleep patterns, including: acceleration, energy expenditure, steps, basal metabolic rate, activity intensity, sleep time, sleep efficiency, sleep latency, and body position.~The application being utilized is SureSource Engage application from Clinical Ink. The application is compatible to most Android and iOS devices.~Participants will also use a basic Bluetooth-enabled weight scale that syncs with the application."
224214515|NCT02600806|DRUG|Azithromycin|Patients are given oral azithromycin when procalcitonin levels are \< 0.5 ng/ml
224214516|NCT02600806|DRUG|Levofloxacin|Patients are given oral levofloxacin when procalcitonin levels are \>= 0.5 ng/ml.
224214517|NCT01585233|DRUG|ASKP1240|Intravenous
224214518|NCT01585233|DRUG|Placebo|Intravenous
224214519|NCT03335709|BEHAVIORAL|ADL intervention|Overall, an adaptational approach is being applied. The intervention sessions include changes related to the person, the environment and/or the occupation.
224214520|NCT05175456|OTHER|Bedjet|Bedjet is a sleep cooling system. All participants will be provided a Bedjet system as part of the study.
224214521|NCT05175456|DEVICE|FitBit|Each participant will receive a FitBit device to track sleep quality and related information.
224214522|NCT05329428|DIETARY_SUPPLEMENT|Vitamin D Supplementation 20 µg/day|At a routine visit at the antenatal care in early pregnancy (gestational week \<15) women will be provided with with vitamin D3 (cholecalciferol) supplements. Two tablets, with a total content of 20 µg (800 IE), are taken daily throughout pregnancy.
224214523|NCT05329428|DIETARY_SUPPLEMENT|Vitamin D Supplementation 40 µg/day|At a routine visit at the antenatal care in early pregnancy (gestational week \<15) women will be provided with with vitamin D3 (cholecalciferol) supplements. Two tablets, with a total content of 40 µg (1600 IE), are taken daily throughout pregnancy.
224214524|NCT05329428|OTHER|Usual Antenatal Care|In early pregnancy (gestational week \<15) women are advised by the regular midwife to take a daily supplement of Vitamin D throughout pregnancy, according to usual antenatal care routines.
224214525|NCT02856997|DRUG|Chidamide with ICE regimen|Chidamide and ICE regimen, dosage described in arm description
224214526|NCT00747747|BIOLOGICAL|Saline solution|3 sprays per nostrils twice a day (morning and evening); in case of need a third nebulization between the two is allowed
224214527|NCT00747747|DEVICE|Sinuclean DM Spray|3 sprays per nostrils twice a day (morning and evening); in case of need a third nebulization between the two is allowed
223625033|NCT05833529|OTHER|Memory Focused Cognitive Therapy (MFCT) - 1 week|"In accordance with the Memory Focused Cognitive Therapy for Cocaine Use Disorder Therapist Guide (Marsden and Goetz, 2018), MFCT meetings will consist in 5 sequential components: Cognitive case conceptualisation of cocaine use disorder maintaining processes to inform a treatment plan; Education about cocaine's cognitive and physical effects; Cocaine related cue-induction to elicit images and affective responses; Memory reconsolidation procedures; Standard CBT techniques (e.g. behavioural experiments of cocaine-related expectancies and skills for adaptive emotion regulation)."
223625034|NCT05833529|BEHAVIORAL|Pictures-based Cue Exposure (PCE) Therapy for Cocaine Craving - 3 weeks|"60 x 10 mins PCE (desensitization to only cocaine craving cues; no others interventions). A standard audio of VRE songs is played in PCE. 4 PCE and 2 different PCE situations by meeting. Same PCE situations spaced intra (30 mins) and inter meetings (48 hrs). 5 standard PCE situations (appearance and dialogues adapted to Martinique field) varying from only peers cocaine use talk to peers and participant prepare and use cocaine and ranging from the lowest to the highest participant related cocaine craving level. Situation switch to another when its initial cocaine craving level has decreased to its half for 5 continuous PCE mins (must be ≤ 3/10; 0 = none; 10 = very high). Meetings end with relaxation/relapse prevention if any distress over convenient levels. PCE use a laptop standard PowerPoint slide show (2D pictures from VRCE; non-spatialized audio from laptop speakers), are non-interactive (seated on a stool). Participant skin color and cocaine using mode individualized."
224214528|NCT04929197|DEVICE|PERSBRA|"After the patient is in the semi-prone position, the body shape and breast position images are obtained by the stereo scanning technology, and then using 3d printing technology to print PERSBRA.~PERSBRA maintain a favorable new breast position in the supine position during routine radiotherapy, the cardiopulmonary dose during radiotherapy can be reduced by wearing PERSBRA."
223625035|NCT02987725|BEHAVIORAL|Hypnosis|A 30-minute Hypnosis session with a trained clinician focused on relaxation and hypnotic suggestions for pain relief and reduced stress responses.
223625036|NCT02987725|BEHAVIORAL|Attention Control|A 30-minute historical story read by a research clinician.
223625037|NCT02897648|DRUG|Assessment of dermal administration of Beta-Lactams|Evaluation of Pharmacokinetic / Pharmacodynamic of dermal administration of Beta-Lactams
224214529|NCT04093947|OTHER|Observational study|Observational and prospective study
224214530|NCT02996253|PROCEDURE|FHL transfer|endoscopic transfer og flexor hallucis longus
224214531|NCT03339635|DRUG|Androgel (Testosterone gel)|Patients will be randomized to treatment with transdermal testosterone gel (Androgel) once daily during 20 weeks, followed by 20 weeks of active Androgel treatment in all participants.
224214532|NCT03339635|DRUG|Placebo gel|Patients will be randomized to treatment with transdermal placebo gel once daily during 20 weeks, followed by 20 weeks of active Androgel treatment in all participants.
224214533|NCT03273127|DRUG|Abediterol|A β2-adrenoceptor agonists, produce smooth muscle relaxation in the airways and improves lung function.
224214534|NCT03273127|DRUG|Placebo|Abediterol matching placebo without any pharmacological activity.
224214535|NCT04609527|PROCEDURE|Management of placenta accreta spectrum|Conservative and radical (hysterectomy) treatment of placenta accreta. Follow up to the patients to detect the impact of treatment imposed A novel technique which early identification and repait of uterine wall defects resulted from invasion of the uterine wall by the placenta.
223625038|NCT05255471|DRUG|Olaparib|Olaparib 300 mg, film-coated tablets, twice daily PO, d1- 28 continuously
223625039|NCT05255471|DRUG|Chemotherapy drug|"Platinum-based chemotherapy at the Investigator's choice among the following regimens:~* Carboplatin (AUC5) plus Pegylated Liposomal Doxorubicin (PLD) 30mg/m2 on day 1 every 28 days for a maximum of 8 cycles;~* Carboplatin (AUC4) plus Gemcitabine 1000mg/m2 on day 1, 8 every 21 days for a maximum of 8 cycles;~* Carboplatin (AUC5) plus Paclitaxel (175mg/m2) every 21days for a maximum of 8 cycles"
223625040|NCT00732212|DEVICE|Doppler endoscopic ultrasound probe for blood flow detection|Used for blood flow detection
223625041|NCT00732212|OTHER|Standard endoscopic hemostasis|Per current treatment guidelines for non-variceal UGI lesions - based upon stigmata of hemorrhage \& visual cues for risk stratification and completion of endoscopic treatment.
223625042|NCT01859234|DRUG|89Zr-bevacizumab|89Zr-bevacizumab will only be given once, prior for the PET scan. 5 mg will be given iv.
224214536|NCT00865982|DRUG|Docetaxel, Cisplatin, Capecitabine|"3 preoperative cycles with Docetaxel 75 mg/m² d1 Cisplatin 60 mg/m² d1 Capecitabine 1875 mg/m²/day d1-14 repeated every 3 weeks~followed by resection~and 3 postoperative cycles with Docetaxel 75 mg/m² d1 Cisplatin 60 mg/m² d1 Capecitabine 1875 mg/m²/day d1-14 repeated every 3 weeks."
224214537|NCT00125476|BEHAVIORAL|Exercise|
224214538|NCT02784860|DRUG|Lidocaine|Propofol (0.5 mg/kg or more) is titrated to provide loss of consciousness. Then in the lidocaine group, lidocaine 2% is administered as a bolus followed by a continuous intravenous infusion after loss of consciousness
224214539|NCT02784860|DRUG|normal saline|Propofol (0.5 mg/kg or more) is titrated to provide loss of consciousness. Then in the placebo group, the same volume of normal saline is administered after loss of consciousness
224316688|NCT05064423|BEHAVIORAL|Clinical Trials Education Program|The Community Health Educator (CHE) will provide CT education and outreach to increase clinical trial knowledge and the importance of clinical trials research and participation. The clinical trials educational activities will include the use of NCI Colorectal Cancer resources and materials, including a PowerPoint presentation, clinical trials information, and online resources. The CHE will tailor the PowerPoint slides to ensure that they are culturally tailored, visually appealing, low-literacy, language appropriate and include appropriate visuals. The CTs educational sessions will be delivered in Spanish and English and will take approximately 45 minutes to 1 hour.
224316689|NCT05133934|OTHER|Observational|A cohort study will be used to collect patient data, analyze the clinical characteristics, TCM syndromes, and treatment of knee osteoarthritis in China
223625043|NCT02611973|OTHER|Aspirin therapy interruption|Stop the treatment by aspirin 100mg/d in the experimental arm.
223625044|NCT02611973|OTHER|Usual treatment by aspirin 100 mg/d in the active comparator arm|HU+ aspirin maintenance
223625045|NCT02611973|OTHER|No interruption of aspirin in the Observational arm|patient with Contre indication to aspirin or required antithrombotic therapy
223625046|NCT02611973|DRUG|Hydroxyurea treatment (HU)|HU maintenance
223625047|NCT04258423|DRUG|Tacrolimus|Low dose Tacrolimus
223625048|NCT04258423|DRUG|Everolimus|Everolimus
224214540|NCT04042974|DRUG|vaginal dinoprostone|1 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia \& Upjohn, Puurs, Belgium) inserted by the patient 12 hours before the scheduled office hysteroscopy.
224214541|NCT04042974|DRUG|placebo|one tablet of placebo inserted by the patient 12 hours before the scheduled office hysteroscopy.
223625049|NCT04129593|BEHAVIORAL|Self Awakening - Natural Waking|subjects in this arm will be assigned to natural waking and self awaking conditions on Saturday and Sunday. they will be counterbalanced equally between Saturday: natural waking, Sunday: self awakening and Saturday: self awakening, Sunday: natural waking.
223625050|NCT04129593|BEHAVIORAL|Snooze - Natural waking|subjects in this arm will be assigned to snooze and natural waking conditions on Saturday and Sunday. they will be counterbalanced equally between Saturday: snooze, Sunday: natural waking and Saturday: natural waking, Sunday: snooze.
223625051|NCT00321789|BEHAVIORAL|spouse-assisted intervention|Couples assigned to this arm received nine monthly phone calls from a nurse. The patient created monthly goals and action plans related to diet, exercise, patient-provider communication, or medication adherence. The spouse created plans to support patient goal achievement.
223625052|NCT04970277|OTHER|drinking water group|Those randomized to drink water group were asked to drink 200 mL colorless water every 10 minutes, starting at the time of capsule ingestion until three times in total.
223625053|NCT04970277|OTHER|control group|Those randomized to control group were asked not to drink extra water after capsule ingestion.
224214542|NCT05644912|DEVICE|Transanal irrigation (TAI)|Transanal irrigation (TAI) with new catheter on subjects experienced in using TAI with balloon catheter.
224214543|NCT00525031|DRUG|Temozolomide (TMZ)|150 mg/m\^2 by mouth once daily for 7 days, followed by 7 days off (alternating weekly) for a total of 8 weeks.
224214544|NCT00525031|DRUG|Pegylated Interferon Alpha-2b (PGI)|0.5 mcg/kg subcutaneous injection once weekly for a total of 8 weeks.
224214545|NCT02516631|DRUG|Angusta™|One tablet of Angusta™ (25 µg) given every 2 hours
224214546|NCT02516631|DRUG|Cytotec®|1/8 of a tablet of Cytotec® (25 µg) given every 2 hours. Drug administration should be repeated every 2 hours until labour has commenced.
224214547|NCT02516631|DRUG|Angusta™|Two tablets of Angusta™ 25 µg given every 4 hours
224214548|NCT02516631|DRUG|Cytotec®|¼ of a tablet of Cytotec® given every 4 hours. Drug administration should be repeated every 4 hours until labour has commenced.
224214549|NCT02516631|DRUG|Angusta™|Two tablets of Angusta™ (total dose of 50 µg), given every 4 hours
224214550|NCT02516631|DRUG|Cytotec®|¼ of a tablet of Cytotec® (50 µg), given every 4 hours. Subjects should not swallow for a period of 5 minutes. Drug administration should be repeated every 4 hours until labour has commenced.
224214551|NCT04485286|DRUG|[68Ga]CBP8|Up to 15 mCi of \[68Ga\]CBP8 will be administered to each subject. Each subject will undergo baseline imaging prior to radiation and again 3-6 months after radiation therapy.
224214552|NCT06013709|DEVICE|PRESAE CARE|"PRESAGE CARE is a medical device CE marked based on artificial intelligence to prevent and reduce emergency department visits and unplanned hospitalization among frail older adults living at home.~These device is based on the use of a short questionnaire focused on functional and clinical autonomy (ie, activities of daily life), possible medical symptoms (eg, fatigue, falls, and pain), changes in behavior (eg, recognition and aggressiveness), and communication with the home care aides (HAs)or their surroundings. This questionnaire is composed of very simple and easy-to-understand questions, giving a global view of the person's condition. For each of the 27 questions, a yes/no answer was requested. Data recorded by HAs were sent in real time to a secure server to be analyzed by our machine learning algorithm, which predicted the risk level on emergency hospitalization risk and some health clinical situations and displayed it on a web-based secure medical device."
224214553|NCT02490566|OTHER|Telehealth|Tablet with chronic disease apps will be given to this group, apps will be focused on patient's condition. Follow-up visits will be conducted through video-conferencing.
224214554|NCT00652379|DRUG|Pegvisomant|Pegvisomant s.c 15-30 mg 2 times a week
224214555|NCT00652379|DRUG|Somatostatin analog (lanreotide or octreotide)|Study arm 2: usual dosage of a somatostatin analog Study arm 1: half dosage of somatostatin analog
224214556|NCT02140164|DRUG|Minocycline|Oral dose of 100 mg (or appropriate weight-adjusted pediatric dose) of minocycline twice daily for 12 months.
224214557|NCT01234259|DEVICE|Venus Freeze (MP2 V2 System|Facial wrinkles and temporary cellulite and circumference reduction treatments
224214558|NCT00780715|DRUG|Gliclazide MR|30mg daily increased to 60mg if HbA1c \> 7% at 3 months
224214559|NCT00780715|DRUG|Sitagliptin|Sitagliptin 100mg daily for 6 months
224214560|NCT00780715|DRUG|Pioglitazone|Pioglitazone 30mg daily , increased to 45mg daily if HbA1c \>7% at 3 months. 6 months duration
224214561|NCT00780715|DRUG|Metformin|Metformin 500 mg od for 1 week, bd for 1 week, 1g mane 500 mg nocte 1 week, 1g bd there after. Total of 6 months treatment
224214562|NCT02468661|DRUG|INC280 single agent|
224214563|NCT02468661|DRUG|erlotinib|
224214564|NCT03339791|PROCEDURE|Sleeve Gastrectomy|Laparoscopic Sleeve Gastrectomy. Technique: complete mobilization of the greater curvature and gastric fundus up to the angle of Hiss; stapling beginning at 3 to 4 cm away from the pylorus; bougie size 32 French; oversuture of the staple line; hiatoplasty in selected cases; routine drainage of the abdominal cavity
223625054|NCT00534365|DEVICE|tension-free vaginal tape|Retropubic mid-urethral sling
224214565|NCT03339791|PROCEDURE|Gastric Bypass|Laparoscopic Gastric Bypass. Technique: Pouch size 30 to 40 ml, biliopancreatic limb 70 to 100 cm, alimentary limb 100 to 120 cm, antecolic, routine closure of the mesenterial defects, routine drainage of the abdominal cavity
224214566|NCT04663126|DRUG|Tc-99m tilmanocept|IV 250 µg Tilmanocept, labelled with 370 MBq of Tc-99m
224214567|NCT03309410|DIAGNOSTIC_TEST|Venous to arterial conversion (v-TAC)|This was an observational study. Paired arterial blood gas and venous blood gas was drawn from each patient and compared. Venous blood gas was converted to arterial blood gas values using v-TAC.
224214568|NCT06463938|OTHER|Active comparator|CPP-ACP paste will be applied on exposed area
224214569|NCT06463938|DEVICE|Experimental group|Lasotronix will be applied following its protocol
224214570|NCT06463938|COMBINATION_PRODUCT|Combination of laser and paste|This group will receive the combination of above two treatments
224214571|NCT06463938|BEHAVIORAL|Control group|this will be a control group
224214572|NCT01872689|DRUG|Lebrikizumab|Lebrikizumab will be administered at a dose of 250 mg via SC injection once every 4 weeks.
224214573|NCT01872689|DRUG|Pirfenidone|Pirfenidone will be administered orally at a stable dose of 2403 mg per day or at MTD.
224214574|NCT01872689|DRUG|Placebo|Placebo matched to lebrikizumab will be administered via SC injection once every 4 weeks.
224214575|NCT05817526|DRUG|BMAC/ collagen|Bone marrow aspirate concentrate loaded on collagen in the peri-implant defect
224214576|NCT05817526|PROCEDURE|Autograft harvesting from chin|Autograft
224214577|NCT05065463|DRUG|AZD8233|Participants will receive a single subcutaneous (SC) dose of AZD8233 into the region of the abdomen.
224214578|NCT03587181|PROCEDURE|Cryoablation of the pulmonary veins and myocardial biopsy|"Before intervention blood samples will be collected for biobank storage. After left atrial appendage thrombus exclusion, a cardiac biopsy from intraventricular and interatrial septum will be performed. PV isolation will be performed with cryoablation. Successful PV isolation will be confirmed by the confirmation of bi-directional block. Phrenic nerve function will be assessed in a standard fashion during intervention of the right PVs using high output phrenic nerve pacing from the superior vena cava. Loop recorder implantation will be performed during the same procedure.~In patients with recurrent atrial tachyarrhythmias an EP study will be performed to assess the mechanism of recurrence. PV reconnections will be re-isolated and linear lesions performed as required."
224214579|NCT00599183|OTHER|MRI-Diffusion Tensor Imaging and Tractrography|MRI scan: Baseline: Conventional MRI (as part of clinical care) with additional diffusion tensor imaging (DTI)sequence (research). 6-week follow up: MRI with DTI and tractography as part of the research
224214580|NCT03859661|DIETARY_SUPPLEMENT|Fitabisc|Fitabisc is a chocolate cookie with vanilla cream filling which contains the most important antioxidants Vitamin C, Vitamin E, and the mineral Selenium. Fitabisc is not commercially available and for the purposes of this study it will be manufactured by Calerrific Ltd, which already produces a biscuit called CalBisc 100 as a simple calorie and nutritional supplement. Production takes place in a BRC Global Standard Grade A certified bakery operated by Farringford Foods in Portadown, Northern Ireland.
224214581|NCT06546111|DRUG|Placebo|Drug :placebo tab PO BID for 14 days.
224214582|NCT06546111|DRUG|Daflon|Daflon 500 mg tab PO BID for 14 days.
224214583|NCT04214951|DRUG|Eltrombopag|Patients will be given eltrombopag 50mg once daily for 6 weeks.
224214584|NCT04214951|DRUG|Recombinant human thrombopoietin (rh-TPO)|Patients will be given rh-TPO 300 U/kg once daily for 21 days.
224214585|NCT03202628|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo ASCT
224214586|NCT03202628|DRUG|Dexamethasone|Given PO
224214587|NCT03202628|DRUG|Ixazomib Citrate|Given PO
224214588|NCT03202628|OTHER|Laboratory Biomarker Analysis|Correlative studies
224214589|NCT03202628|DRUG|Pomalidomide|Given PO
224214590|NCT00001427|DRUG|9-aminocamptothecin|
224214591|NCT00686374|BIOLOGICAL|Adalimumab|Participants who enrolled into the study from blinded therapy in Study M06-806 received open-label (OL) therapy at a dose dependent on their body weight. Participants weighing ≥ 40 kg received 40 mg of adalimumab every other week (eow), and those who weighed \< 40 kg received 20 mg of adalimumab eow. Starting at Week 8, participants who had a disease flare may have been switched to every week (ew) treatment at the same dose of adalimumab received while on eow treatment. Participants who enrolled from OL therapy in Study M06-806 continued to receive the same dose they were receiving (i.e., 40 mg ew or 20 mg ew) at the Week 52 visit of Study M06-806. Adalimumab dose could have been decreased to the next lower treatment level for those with body weight changes. Participants who responded to treatment may have also had their dosage frequency decreased from ew to eow dosing, as well as a decrease in dosage.
224214592|NCT05021627|PROCEDURE|Cardiac autonomic nerve modification|Patients with sinus bradycardia undergoing cardiac autonomic ganglion ablation. Specific anatomic ablation of the 4 major left atrial GP and aorta-superior vena cava (Ao-SVC) GP was performed. Briefly, catheter ablation was performed under the guidance of an electroanatomic mapping system (CARTO,BiosenseWebster,DiamondBar,California). After completed the electroanatomic mapping of the left atrium was complete and pulmonary vein (PV) ostia identified, presumed GP clusters were ablated 1 to 2cm outside the PV-left atrium junctions at the following sites: the left superolateral area (leftsuperior GP\[LSGP\]), the leftinfer oposterior area(left inferior GP\[LIGP\]), the right superoanterior area (rightanterior GP\[RAGP\]), the right inferoposterior area(right inferior GP\[RIGP\]), and the Ao-SVC fat pad (Ao-SVCGP), and in that sequence.
224214593|NCT05021627|PROCEDURE|Pacemaker implantation|Patients with sinus bradycardia received pacemaker implantation. The patient lay flat on the bed, puncture the subclavian vein and insert two guide wires. Cut the skin under the guide wire to make a skin bag, and stop bleeding accurately to avoid continuous bleeding of the skin bag. The pacemaker electrode is inserted into the heart cavity by guiding the guide wire, one is placed in the ventricle and the other in the atrium, and the corresponding parameters of the electrode, such as pacing threshold, impedance, etc., are measured at the same time. If the parameters are good, fix the electrode, connect the electrode with the pacemaker, place the pacemaker in the skin bag, fix the pacemaker and electrode, suture the skin layer by layer, and the operation is completed.
224214594|NCT03706326|BIOLOGICAL|Anti-MUC1 CAR-T cells|Using the T cells from the patients' blood to produce anti-MUC1 CAR-T Cells and then the cells will be infused back to the patients.
224214595|NCT03706326|BIOLOGICAL|PD-1 knockout Engineered T cells|Using the T cells from the blood of the patients to prepare PD-1 knockout T cells, then the cells will be infused back to the patients.
224316690|NCT04648696|DRUG|Vancomycin CI|The CI group will have their total daily cumulative dose of vancomycin converted to a 24-hour intravenous infusion upon discharge - the CI will begin with the first scheduled OPAT dose of vancomycin
224214596|NCT03706326|COMBINATION_PRODUCT|CAR-T combined with PD-1 Knockout T cells|Using the T cells from the blood of the patients to prepare anti-MUC1 CAR-T Cells and PD-1 knockout T cells, then the cells will be infused back to the patients
224214597|NCT00087191|DRUG|EF5|Given IV
224214598|NCT00087191|DRUG|motexafin lutetium|Given IV
224214599|NCT00087191|OTHER|pharmacological study|Correlative studies
224316691|NCT04648696|DRUG|Vancomycin II|Study candidates that are randomized to the II group will continue their current intravenous dosing upon discharge
224316692|NCT03761940|OTHER|EQ5D questionnaire and a demographic questionnaire|questionnaires
224316693|NCT06160219|DRUG|Hydroxycobalamin|prophylactic use of hydroxycobalamin in vasoplegia in high risk patients undergoing cardiac surgeries
224214600|NCT03552120|BEHAVIORAL|MORE|MORE is a manualized integrative treatment strategy that targets transdiagnostic mechanisms in stress-related conditions. MORE is made up of three primary components: mindfulness training, cognitive restructuring, and savoring. Mindfulness training aims to increase attentional control to reduce cognitive bias toward negative information. Cognitive reappraisal promotes restructuring of maladaptive cognitions, which would otherwise intensify negative emotion and addictive behavior. Finally, MORE promotes savoring - mindful attention to and appreciation of pleasant events in life as a means of increasing positive emotion regulation.
224214601|NCT03552120|BEHAVIORAL|Supportive Psychotherapy|Supportive psychotherapy is a form of non-directive talk therapy, which follows a Rogerian person-centered approach. The therapist's primary objectives during a session will be (1) to communicate unconditional positive regard for the participant, (2) to communicate engagement and empathic understanding, and (3) to mirror a participant's affect.
224214602|NCT03903640|DEVICE|Optune|-Optune is programmed by Novocure to deliver 200 kHz TTFields in two sequential, perpendicular field directions at a maximal intensity of 707mARMS.
223625055|NCT00534365|DEVICE|TVT-SECUR device|Mid-urethral mini-sling
223625056|NCT02681198|DRUG|Lofexidine|All subjects will receive two single doses of lofexidine HCl; one 0.4 mg dose taken alone on Day 1 and one 0.4 mg dose taken with 40 mg once daily paroxetine HCl at steady-state on Day 13.
223625057|NCT02681198|DRUG|Paroxetine|All subjects will receive daily single doses of paroxetine HCl; one 20 mg dose taken Days 4-6, one 40 mg dose taken Days 7-19, one 20 mg dose taken Day 20, one 10 mg dose taken Days 21-22.
223625058|NCT04896996|DIETARY_SUPPLEMENT|whole eggs|whole eggs
224214603|NCT03903640|BIOLOGICAL|Nivolumab|-Standard of care
224214604|NCT03903640|BIOLOGICAL|Ipilimumab|-Standard of care
224214605|NCT00004686|DRUG|methotrexate|
224214606|NCT00004686|DRUG|prednisone|
224214607|NCT01523795|OTHER|Motion-controlled video gaming|Play of motion-controlled video games for one hour
224214608|NCT01523795|OTHER|Traditional video gaming|Participants played traditional video games for one hour
224214609|NCT01523795|OTHER|Television watching|Participants watched television for one hour
224214610|NCT06389279|OTHER|PENG block group|Ultrasound-guided PENG block is performed approximately 30 minutes before surgery in patients undergoing hip surgery in a separate regional anaesthesia room with standard anaesthesia monitoring.
224214611|NCT06389279|OTHER|FIC block group|Ultrasound-guided FIC block is performed approximately 30 minutes before surgery in patients undergoing hip surgery in a separate regional anaesthesia room with standard anaesthesia monitoring.
224214612|NCT06389279|OTHER|Femoral block group|Ultrasound-guided femoral block is performed approximately 30 minutes before surgery in patients undergoing hip surgery in a separate regional anaesthesia room with standard anaesthesia monitoring.
224214613|NCT06389279|OTHER|Control group|No intervention
224214614|NCT01422733|DRUG|Hydrocortisone|10mg/m2/per day PO at bedtime (X12 weeks)
224214615|NCT01422733|DRUG|dexamethasone|1 mg PO twice
224214616|NCT01422733|DRUG|Cosyntropin|250 micrograms IV twice
224214617|NCT01422733|DRUG|rhCG|25 mcg IV twice
223625059|NCT04896996|DIETARY_SUPPLEMENT|yolk-free egg substitutes|yolk-free egg substitutes
223625060|NCT02346045|PROCEDURE|Renal sympathetic denervation|"In the experimental arm, Intervention is renal sympathetic denervation using Symplicity® system (Medtronic Ardian Inc, Mountain View, CA, USA) and antihypertensive medications previously prescribed~1. After femoral puncture guiding catheter is engaged in renal artery~2. Symplicity radiofrequency ablation catheter is inserted into renal artery and by circular sequence, from distal to proximal portion, ablation energy is applied to the wall of renal artery~3. 4-5 ablations are applied in each renal artery.~In the sham comparator, intervention is renal angiogram and continue antihypertensive medications previuosly decribed"
224214618|NCT05364099|DRUG|Lidocaine 1% Injectable Solution|2.5 ml of 1% Lidocaine will be administered via injection in suprascapular nerve in the suprascapular notch
224214619|NCT05364099|DRUG|Triamcinolone Injection|0.5 ml 40mg/ml Triamcinolone will be administered via injection in suprascapular nerve in the suprascapular notch
224214620|NCT05364099|PROCEDURE|Suprascapular Nerve Block|This procedure involves injection of a lidocaine and triamcinolone mixture into the suprascapular nerve in the suprascapular notch using ultrasound guidance for proper placement of drugs.
224214621|NCT01563471|DRUG|activated recombinant human factor VII|Subjects will be randomised to one of four treatment sequences. Subjects will receive single bolus i.v. injection of 40, 80 or 160 mcg/kg body weight of trial drug or placebo on each day of the three separate visits
224214622|NCT01563471|DRUG|placebo|Subjects will be randomised to one of four treatment sequences. Subjects will receive single bolus i.v. injection of 40, 80 or 160 mcg/kg body weight of trial drug or placebo on each day of the three separate visits
224214623|NCT06528249|DRUG|Engineered erythrocytes (or red blood cells) covalently conjugated with commercially available anti-PD-1 antibodies on their membranes|Engineered erythrocytes (or red blood cells) covalently conjugated with commercially available anti-PD-1 antibodies on their membranes
224214624|NCT01907659|OTHER|Release of test results|Subjects will be randomized to have viral testing and serum PCT results released or no additional testing performed other than that ordered as standard of care
223625061|NCT03243617|OTHER|Placebo|"Subjects are instructed in the use of the spray bottle and asked to self-administer the Test Product as follows:~* LEFT side of the body where skin is affected: Five (5) pumps of Spray (BOTTLE LABELED: LEFT) must be applied twice-a-day to the entire area affected by KP once in the morning and once in the evening for 28 days.~* RIGHT side of the body where skin is affected: Five (5) pumps of Spray (BOTTLE LABELED: RIGHT) must be applied twice-a-day to the entire area affected by KP once in the morning and once in the evening for 28 days.~* Subjects may not wash their body with soap and water AFTER the applications"
223625062|NCT03243617|OTHER|AO+Mist|"Subjects are instructed in the use of the spray bottle and asked to self-administer the Test Product as follows:~* LEFT side of the body where skin is affected: Five (5) pumps of Spray (BOTTLE LABELED: LEFT) must be applied twice-a-day to the entire area affected by KP once in the morning and once in the evening for 28 days.~* RIGHT side of the body where skin is affected: Five (5) pumps of Spray (BOTTLE LABELED: RIGHT) must be applied twice-a-day to the entire area affected by KP once in the morning and once in the evening for 28 days.~* Subjects may not wash their body with soap and water AFTER the applications"
224214625|NCT03575559|BEHAVIORAL|Individual planning|Each participant forms up to three action and up to three coping plans individually, without consulting the participating friend, but discussing the plans with the experimenter. CONTENT: The planning materials and forms have the following sections: (a) information on the importance of planning (b) instructions of what should be included in a good plan (the when, where, and how components), (c) formulating action and coping plans based on the if-then structure. Action plans (referring to when, when, and how the individual will act) as well as coping plans (referring to how to overcome potential difficulties, risky situations or temptations to not engage in physical activity).
224214626|NCT03575559|BEHAVIORAL|Collaborative planning|Both friends together create up to three if-then plans on when, where, and how both will implement PA together. In addition, up to three coping plans will be formed together. This jointly developed plan is discussed with the experimenter. CONTENT: The planning materials and forms have the following sections: (a) information on the importance of planning (b) instructions of what should be included in a good plan (the when, where, and how components), (c) formulating action and coping plans based on the if-then structure. Action plans refers to when, when, and how the individual will act) as well as coping plans (referring to how to overcome potential difficulties, risky situations or temptations to not engage in PA). All materials are formulated using the plural.
224214627|NCT03575559|BEHAVIORAL|Education and motivation treatment|Adolescents will watch a movie from the Federal Office of Public Health Switzerland including the guidelines of physical activity (PA) for adolescents. All adolescents respond to a quiz afterwards. After the quiz, the experimenter repeats the guidelines for PA based on a brochure that all adolescents can take home with them. In addition, the experimenter asks for barriers and benefits of PA the adolescents perceive. Next to it, the experimenter explains that a weight gain might be possible due to PA in the beginning. Furthermore, the experimenter presents how the data of the accelerometer should look like if one is sufficiently physical active. As a last part self-efficacy as an important aspect of goal success is mentioned. The materials exclude any planning statements.
224214628|NCT01686178|BEHAVIORAL|Anti-smoking social marketing campaign|We will utilize industry market research tools to define the target audience (segment of community with high smoking prevalence and high social influence) and directly counter tobacco industry lifestyle marketing strategies through local promotion of a smokefree brand and branded bar and club events.
224214629|NCT04999228|DRUG|Infliximab|Infliximab will be administered intravenously at a dose of 5 mg/kg for 0, 2, and 6 weeks, then every 8 weeks for 1 year.
224214630|NCT04999228|DRUG|Corticosteroids|Corticosteroid will be given at a dose of 1-2mg/kg/day (maximum 60 mg/kg/day),oral or intravenously for 12 to 14 weeks.
224214631|NCT05305183|DRUG|Minodronate Tablets and Alendronate Sodium Tablets-matching placebo;Alendronate Sodium Tablets and Minodronate Tablets -matching placebo|all subjects will receive Calcium Carbonate and Vitamin D3 Tablets as basic medication.
224214632|NCT02143947|DEVICE|Maximal Arch Subtalar Stabilization|Custom made semi-rigid thermoplastic heel cup extending to the base of the metatarsals with a full foot length 3.0mm thick EVA and ultra-suede top cover
224214633|NCT02143947|DEVICE|Full Contact Orthosis|"The Full Contact orthosis is constructed from a 5/32 blue polypropylene with posting material comprised of white polypropylene."
224214634|NCT00174499|DRUG|2 mg nicotine gum|2 mg nicotine gum
224214635|NCT00174499|DRUG|4 mg nicotine gum|4 mg nicotine gum
224214636|NCT01244815|DRUG|asenapine|Asenapine tablets, administered sublingually twice daily at one of three dose levels (2.5 mg, 5.0 mg, or 10.0 mg)
224214637|NCT01244815|DRUG|Placebo to match asenapine|Placebo tablets to match asenapine tablets, administered sublingually twice daily
224214638|NCT01244815|DRUG|Rescue medication|For participants whose symptoms worsen or are not adequately controlled on assigned treatment, rescue medication may be administered during the trial in the following circumstances. For the control of agitation, anxiety, insomnia, restlessness, or akathisia and extrapyramidal symptoms (EPS) some benzodiazepines and EPS medications (i.e., anticholinergics) are allowed. Benadryl (diphenhydramine) and beta blockers are also permitted, provided that they are not taken within 8 hours of efficacy assessments.
224214639|NCT03888833|DEVICE|ECMO|ECMO installation
224214640|NCT02702752|OTHER|DYNASDY|Measurement of SDF-1 alpha levels i patients' blood samples.
224214641|NCT01887509|DEVICE|Probe-based confocal laser endomicroscopy|"Patients will undergo:~* Conventional rectoscopy~* pCLE exam following injection of fluorescein, fluorescent contrast agent~* EUS : echoendoscopy~* Biopsies for histopathology : location identical to those of pCLE~* Tumor resection will be performed according to standard oncologic principles.~All visible lesions will be documented. Both healthy and tumor tissue will be examined. Location of sites of interest will be documented on a schema, completed with photographs of endoscopic view.~Biopsies will be harvested in both healthy and tumor tissue as well.~After all procedures are complete, a second assessment of pCLE images by a third party will be performed."
224214642|NCT01887509|PROCEDURE|Rectoscopy|"Patients will undergo:~* Conventional rectoscopy~* pCLE exam following injection of fluorescein, fluorescent contrast agent~* EUS : echoendoscopy~* Biopsies for histopathology : location identical to those of pCLE - Tumor resection will be performed according to standard oncologic principles.~All visible lesions will be documented. Both healthy and tumor tissue will be examined. Location of sites of interest will be documented on a schema, completed with photographs of endoscopic view.~Both healthy and tumor tissue will be examined."
224316694|NCT06303843|OTHER|Transfer with an electric ride-on car|The children in the experimental group will be transported to the operating theatre by a electric ride-on car.
223625063|NCT03053375|DEVICE|MDCure|Battery powered portable pulsed electromagnetic therapy device
224316695|NCT03597919|BIOLOGICAL|Sabin IPV|We select one Sabin IPV product, produced by Kunming Bio institute, which is available for China's National Immunization Program in the selected study sites.
223625064|NCT04068701|OTHER|MaNMT Biofeedback|neuromuscular training intervention that incorporates biofeedback training
223625065|NCT00706368|DEVICE|Point of care tests|Several point-of-care tests are offered: OSOM TV rapid trichomonas test; OSOM BV Blue rapid test; pHEMalert vaginal pH test. All subjects receive the OSOM TV test, while the other two are optional.
223625066|NCT03309020|PROCEDURE|Cataract surgery|Cataract surgery and aqueous humor sampling.
223625067|NCT05009875|OTHER|Medical Food SBD111|Two capsules administered twice daily with morning and evening meals for 52 weeks
223625068|NCT05009875|OTHER|Placebo|Two capsules administered twice daily with morning and evening meals for 52 weeks
223625069|NCT04520607|DRUG|Placebo|Healthcare professional-administered intra-articular injection of vehicle.
223625070|NCT04520607|DRUG|Lorecivivint|Healthcare professional-administered intra-articular injections of lorecivivint.
224214643|NCT01887509|PROCEDURE|EUS|"Patients will undergo:~* Conventional rectoscopy~* pCLE exam following injection of fluorescein, fluorescent contrast agent~* EUS : echoendoscopy~* Biopsies for histopathology : location identical to those of pCLE - Tumor resection will be performed according to standard oncologic principles.~All visible lesions will be documented. Both healthy and tumor tissue will be examined. Location of sites of interest will be documented on a schema, completed with photographs of endoscopic view."
224214644|NCT01887509|PROCEDURE|Biopsy and resection|"Patients will undergo:~* Conventional rectoscopy~* pCLE exam following injection of fluorescein, fluorescent contrast agent~* EUS : echoendoscopy~* Biopsies for histopathology : location identical to those of pCLE~* Tumor resection will be performed according to standard oncologic principles.~All visible lesions will be documented. Both healthy and tumor tissue will be examined. Location of sites of interest will be documented on a schema, completed with photographs of endoscopic view.~Biopsies will be harvested in both healthy and tumor tissue as well."
224214645|NCT05122585|PROCEDURE|MagSeed and MagTrace in breast cancer patiënts|Combining MagSeed and Magtracer to perform a wide local excision breast conserving surgery and sentinel node biopsy.
224214646|NCT02466100|BEHAVIORAL|goals of care|. Patients in the GoC intervention group, telephone coaching by a research nurse to help patients role-play talking with their HF providers. Both patients and their providers, will be provided with summaries of individualized, patient-centered information about patient preferences for communicating about end-of-life care and patient self-identified barriers to and facilitators of communication about end-of-life care with tips on how to initiate goals of care discussions. Providers of patients in the intervention group will also be provided with patient-specific prognostic information based on the Seattle Heart Failure Model.
224214647|NCT01173159|DRUG|Omegaven|For the first two days of treatment, subjects will receive Omegaven® at 0.5 g/kg per day to assess tolerance and will progress to a maintenance dosage of up to 1g/kg per day over 12 hours at an infusion rate of 1 g/kg/12 hours (10 ml/kg/12 hours). Dosing is based on previously described dosing of fish-oil emulsions as monotherapy noted within the literature. Omegaven® will be infused intravenously through either a central or peripheral catheter in conjunction with other parenteral nutrition containing dextrose and amino acids. Omegaven® is isotonic. It is compatible with parenteral nutrition solutions and may be co-infused via y-site.
224214648|NCT05172856|DRUG|IBI321|IBI321 at a dose no higher than RP2D, D1 IV Q3W.
224214649|NCT01300845|PROCEDURE|Humidification|From randomization, oxygen therapy is humidified
224214650|NCT01300845|PROCEDURE|No Humidification|oxygen therapy is never humidified
224214651|NCT02352506|OTHER|Blood draw for measurement of MIF|Observational study, no intervention
224214652|NCT01380314|DRUG|Miltefosine + Imiquimod|150 mg x d during 28 days and cream applied every other day during 3 weeks
224214653|NCT01380314|DRUG|Miltefosine 150 mg x day + Placebo|150 mg x d during 28 days and cream applied every other day during 3 weeks
224214654|NCT02872402|BEHAVIORAL|Lifestyle intervention|Women who are still breastfeeding at the first postpartum visit will be encouraged to pursue. References to local breastfeeding supporting groups will be done, if needed. The intervention will be conducted in order to reach recommendations for food servings and nutrient needs. Particular attention will be paid to increase fruits, vegetables, fish and whole grains intake, and decrease added sugars and high fat meat/dairy products. Women will be strongly encouraged to be active at least 150 min/week. They will be provided with targeted strategies for exercising, types of exercises and tips for including physical activity into the daily routine as well as fun exercises for the whole family.
224214655|NCT02872402|BEHAVIORAL|Active control lifestyle intervention|Participants in the control group will receive standard lifestyle recommendations in the form of written information at each visit.
224214656|NCT04376489|BEHAVIORAL|Messages (participants experiencing negative affect & cigarettes are available)|Participants receive messages tailored for situations when they experiencing negative affect \& cigarettes are available.
224214657|NCT04376489|BEHAVIORAL|Messages (participants not experiencing negative affect & cigarettes are available)|Participants receive messages tailored for situations when they cigarettes are available.
224214658|NCT04376489|BEHAVIORAL|Messages (participants experiencing negative affect & cigarettes are not available)|Participants receive messages tailored for situations when they experiencing negative affect.
224316696|NCT01589718|DRUG|Macugen|one intravitreal injection of Macugen prior to vitrectomy surgery
224316697|NCT01589718|DRUG|Sham|The subject in cohort 2 will receive one sham comparator, sham injection prior to vitreous surgery.
223625071|NCT03217708|DEVICE|Jawbone UP4|Wrist worn wearable technology will be utilized to study HR, temperature, sleep, activity changes before and after surgery.
223625072|NCT01777074|OTHER|Data collection|Questionnaire, Vaccination book
223625073|NCT04028713|PROCEDURE|Venapuncture|Blood samples will be collected to determine the serum trough levels and anti-drug antibodies of adalimumab.
223625074|NCT04028713|PROCEDURE|Dried blood spot|A subset of patients will sample additionally by using the dried blood sampling technique.
223625075|NCT04028713|DRUG|Dose reduction|Adalimumab dosing frequency will be lowered in patients who have supratherapeutic serum trough levels of adalimumab.
223625076|NCT01078610|BIOLOGICAL|adalimumab (Humira)|40 mg adalimumab (Humira) every other week.
223625077|NCT02025179|DRUG|Teriparatide|Teriparatide 20 ug daily Sub-Q over 12 months
223625078|NCT02025179|DEVICE|Vibration|Vibration 10 min/day for 12 months
223625079|NCT00402168|DRUG|Belatacept|IV, IV Infusion, 5 mg/kg once every 28 days for one year
223625080|NCT00402168|DRUG|Cyclosporine A|Tablets, Oral, Trough of 100-250 ng/mL, 2\* daily for one year
223625081|NCT00402168|DRUG|Tacrolimus|Tablets, Oral, Trough of 5-10 ng/mL, 2\* daily for one year
223625082|NCT02362724|DEVICE|Sapphire|silicone hydrogel contact lens
223625083|NCT02362724|DEVICE|Pearl|silicone hydrogel contact lens
223625084|NCT03146611|DIAGNOSTIC_TEST|nCD64|neutrophil CD64
223625085|NCT03146611|DIAGNOSTIC_TEST|Neutrophil/Lymphocyte Ratio|Neutrophil/ lymphocyte ratio
223625086|NCT01854359|DRUG|Idebenone|
223625087|NCT02961608|DRUG|Drug conversion from Tacrolimus (Prograf® or Adoport®) to LCP-Tacrolimus (Envarsus®)|Drug conversion from Tacrolimus (Prograf® or Adoport®) to LCP-Tacrolimus (Envarsus®)
223625088|NCT05853341|DRUG|RID-TDS 13.3 mg/24 h|3 consecutive applications of 1 patch (1st patch for 4 days, 2nd patch for 3 days, 3rd patch for 4 days) covering an 11-day period
223625089|NCT05853341|DRUG|Exelon® 13.3 mg/24 h|11 consecutive applications of 1 patch (each patch will be applied for 1 day) covering an 11-day period
223625090|NCT00656929|DIETARY_SUPPLEMENT|Vitamin D3|Vitamin D3 (cholecalciferol) 50 mcg (2000 IU) daily x 3 months
223625091|NCT00656929|OTHER|Placebo|Placebo tablets
223625092|NCT03770312|DRUG|Low intensity statin|Use of low intensity statin for primary prevention of cardiovascular disease.
223625093|NCT03770312|DRUG|Moderate intensity statin|Use of moderate intensity statin for primary prevention of cardiovascular disease.
223625094|NCT02435004|DEVICE|Spinal Modulation Axium™|"The participants will undergo implantation of electrodes for stimulation of fuor dorsal ganglia (Spinal Modulation, Inc., Menlo Park, CA, USA). Each participant will have one to four electrodes positioned according to the individual distribution of pain in the extremities. After implantation the electrode will be connected to an external neurostimulator: Spinal Modulation Axium™ for 3-30 days to evaluate their effectiveness (test stimulation).~If during the trial treatment the pain will decrease significantly (\> 50%) a neurostimulator will be 'implanted for the continuation of the permanent neurostimulation. The neurostimulator is implanted in the abdomen in a subcutaneous pocket."
224214659|NCT04376489|BEHAVIORAL|Messages (participants not experiencing negative affect & cigarettes are not available)|Generic messages for situations when participants are neither experiencing negative affect nor cigarettes are available.
224214660|NCT04376489|BEHAVIORAL|Moodsurf|"Smart phone app that teaches participants a mindfulness-based technique in which participant surf the mood."
224316698|NCT06121934|DRUG|Carica Papaya Leaf Extract|Active drug: CPLE 500mg 2 capsule t.i.d for 5 dayseive CPLE or placebo once daily for 5 days.
224316699|NCT06121934|DRUG|Placebo|Placebo: visually matched placebo 2 capsule t.i.d for 5 days
224316700|NCT05096429|BEHAVIORAL|PROVIDENT|Each of the state's 39 municipalities will be randomised to the intervention (PROVIDENT) or comparator condition. An interactive, web-based tool will be developed to visualize the PROVIDENT model predictions. Municipalities assigned to the treatment arm will receive neighborhood risk predictions from the PROVIDENT model, and state agencies and community-based organizations will direct resources to neighborhoods identified as high risk. Municipalities assigned to the control arm will continue to receive surveillance information and overdose prevention resources, but they will not receive neighborhood risk predictions from this study.
224316701|NCT05173441|BIOLOGICAL|Human COVID-19 immunoglobulin (pH4) for intravenous injection|The initial infusion rate is 0.01 \~ 0.02 ml/kg body weight/minute (1ml is about 20 drops). If there was no adverse reaction after 15 minutes, the infusion rate could be gradually accelerated. However, it should not exceed 0.08 ml/kg body weight/minute.
224316702|NCT05173441|DRUG|Placebo|The initial infusion rate is 0.01 \~ 0.02 ml/kg body weight/minute (1ml is about 20 drops). If there was no adverse reaction after 15 minutes, the infusion rate could be gradually accelerated. However, it should not exceed 0.08 ml/kg body weight/minute
224316703|NCT04107792|BEHAVIORAL|parental sense of competence workshop|The intervention will be a two-hour parent education workshop that provides education and teaches parent-mediated strategies for managing children's behaviours associated with SPIs.
224316704|NCT05495698|DRUG|single-inhaler triple therapy (Trimbow)|Patients in the intervention group will receive the triple therapy in one inhaler in stead of multiple inhalers. The actual medication is the same.
224316705|NCT05495698|DEVICE|E-health application: Curavista app & FindAir e-device|Patients in intervention group 2 will receive Trimbow and will use the health app of Curavista and the smart-inhaler of FindAir
224316706|NCT05495698|DRUG|multi-inhaler triple therapy (Qvar + Bevespi)|Patients in the intervention group will receive the triple therapy in multiple inhalers. The actual medication is the same.
224316707|NCT01887171|DRUG|Tacrolimus|1000 ml of HTK solution (Custodiol, Dr. Franz Köhler Chemie GmBH) cooled to 2-4˚C containing 20 ng/ml Tacrolimus would be given through intraportal (under gravity pressure of 40 cm H2O) and intraarterial infusion (under pressure of 40-50 mm Hg) followed by intraportal infusion of 200 ml 5% solution of Albumin containing 20 ng/ml Tacrolimus under gravity pressure of 40 cm H2O.
223625095|NCT04254393|BEHAVIORAL|Early Adolescent Skills for Emotions (EASE) Program|EASE has been developed to manage and reduce symptoms of depression, anxiety and distress in adolescents. EASE is designed to be delivered by non-specialists in low resource settings such as a trained school-health counsellor. The intervention comprises of 7 young adolescent group sessions, each lasting 90 minutes and involves the empirically supported components of psycho education, problem solving, stress management (slow breathing), behavioural activation, and relapse prevention and 3 caregiver group sessions, each lasting 120 minutes and involve psycho education, active listening, quality time, praise, caregiver self-care and relapse prevention.
223625096|NCT04254393|OTHER|Treatment As Usual (TAU)|Evidence based health practices are not available in schools to manage the mental health problems of children. No structured programs are being implemented in school settings for at-risk children. During the study, participants in TAU showing severe psychiatric symptoms that require immediate specialist treatment and follow-up, will be referred to the Institute of psychiatry (IoP)-the tertiary mental health care facility of the region.
223625097|NCT01128049|BEHAVIORAL|Subjective Questionnaire|The team will use a one page questionnaire to obtain subjective input before the first set of measurements and after instilling the Saline drop.
224214661|NCT04376489|BEHAVIORAL|Meditate|Smart phone app that teaches participants a mindfulness-based meditation designed for smoking cessation.
224214662|NCT04376489|BEHAVIORAL|Joy|Smart phone app that teaches participants to practice breathing exercise.
224214663|NCT04376489|BEHAVIORAL|Imagine|Smart phone app that teaches participants to use their imagination to explore and manage their thoughts and feelings.
224214664|NCT04376489|BEHAVIORAL|Notice|Smart phone app that teaches participants to accept their thoughts and feelings.
223625098|NCT01128049|PROCEDURE|Measurement with wavefront sensor (right eye, then left eye)|The wavefront instrument measures the eye's ability to create a sharp image by briefly shining a laser light from the wavefront sensor into the eye and measuring the light that bounces back through the cornea. For these measurements, subjects will sit on a chair and be instructed to place their chin in a chin rest and lean their forehead against a forehead rest. The subject will be instructed to hold his/her head steady, look in a certain direction, blink or not blink. We will obtain the measurements over a short period of up to approximately 45 seconds. We will start recording data asking the subject to either blink naturally or to hold his/her eye open for a few (up to 10) seconds, and repeat the blink and hold sequence usually for up to four times.
223625099|NCT01128049|DRUG|Instill Saline Drop|One drop will be instilled in both eyes and patient will wait 5 minutes prior to repeating the questionnaire and wavefront sensor. A single drop is approximately 30 µL and will be placed into the inferior cul-de-sac while the patient looks up.
223625100|NCT05182723|PROCEDURE|renal replacement therapy|Extracorporeal Methods for Removing Mediators of Systemic Inflammation
223625101|NCT02783365|BEHAVIORAL|Photo-elicitation and online group support|See above information.
223625102|NCT04234620|DRUG|Toripalimab injection|240 mg/6 mL/vial. The recommended dose of Toripalima is 3 mg/kg, intravenous infusion every 2 weeks until disease progression or intolerable toxicity.
223625103|NCT00707785|DIETARY_SUPPLEMENT|Vitamin A|50,000 IU of Vitamin A 50,000 IU of vegetable oil
224214665|NCT00697112|DRUG|Sirolimus|Non interventional. Sirolimus administered by Principal Investigator per standard practice and labeling.
224214666|NCT04847297|PROCEDURE|Preoperative drainage and pancreatoduodenectomy|Preoperative biliary drainage before surgical removal of the tumor
224214667|NCT04847297|PROCEDURE|Pancreatoduodenectomy|Pancreatic tumor resection without previous preoperative biliary drainage
224214668|NCT02997969|BIOLOGICAL|DNA-HIV-PT123 vaccine|Contains a mixture of 3 DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C ZM96 gag, 2) clade C ZM96 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose 4 mg administered as 1 mL intramuscularly (IM)
224214669|NCT02997969|BIOLOGICAL|Protein/MF59 vaccine|clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, each at a dose of 100 mcg, mixed with MF59 adjuvant, administered as 0.5 mL IM
224214670|NCT02997969|BIOLOGICAL|Placebo|Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products
224214671|NCT02841605|PROCEDURE|Rectosigmoidoscopy with colonic biopsies|Rectosigmoidoscopy with colonic biopsies performed for Alzheimer patient and both control groups Parkinson and PSP
224214672|NCT02841605|PROCEDURE|Colonoscopy with colonic biopsies|Colonoscopy with colonic biopsies performed only in patient at risk of colic cancer
224214673|NCT01946971|DRUG|Lansoprazole|
224214674|NCT01946971|DRUG|Placebo|
224214675|NCT03007537|DRUG|Erythropoietin|10000 IU erythropoietin, subcutaneous injection
224214676|NCT03007537|DRUG|0.9% sodium chloride|0.9% sodium chloride 1ml, subcutaneous injection
224214677|NCT03007537|PROCEDURE|cardiac surgery|included valve, coronary artery bypass graft or surgery for congenital heart diseases
224214678|NCT03066440|DRUG|Normal saline|All intravenous fluids used in the treatment of pediatric diabetic ketoacidosis will be based in normal saline for participants in the interventional arm instead of normal saline (as given to participants in the control arm).
224214679|NCT03066440|DRUG|Lactated Ringers|All intravenous fluids used in the treatment of pediatric diabetic ketoacidosis will be based in lactated ringer's solution for participants in the interventional arm instead of normal saline (as given to participants in the control arm).
224214680|NCT00736333|DRUG|Pegylated Liposomal Doxorubicin|Pegylated Liposomal Doxorubicin (Caelyx) 50 mg/m\^2, given for up to 6 cycles
223625104|NCT02567981|DIETARY_SUPPLEMENT|21 micronutrient-fortified supplement|21 micronutrient fortified supplement: Dose: 18.75g/day. Contains the following daily amounts per dose: Zinc 9 mg, Copper 300mcg, Iron 12mg, Vitamin D 5 mcg, Folic Acid 160mcg, Vitamin E 5mg, Iodine 90mcg, Calcium 200mg, Vitamin A 250mg, Phosphorus 150 mg, Vitamin C 40mg, Magnesium 40mg, Vitamin B12 0.9mcg, Selenium 17mcg, Thiamine 0.5mg, Manganese 0.17mg, Niacin 6mg, Biotin 8mg, Riboflavin 0.5mg, Vitamin B5 1.8mg, Vitamin B6 0.5 mg. Formula (percentage by weight): Maize 64.08%, Soy Beans 30%, Vitamins and Minerals 5.92%, BHA 0.006%. Energy: 73kcal, Protein 4g, Fat 1g, Dietary Fiber 2g, Carbohydrates 12g.
224214681|NCT05433337|DEVICE|Digital ACT|Study participants will continue to receive Digital Acceptance and Commitment Therapy in addition to their standard care for fibromyalgia
224214682|NCT03723590|DEVICE|Esterified Hyaluronic Acid Matrix|A non-woven pad composed of esterified hyaluronic acid, covered with a semipermeable silicone layer to protect the wound and control water vapor loss
224214683|NCT05226156|BEHAVIORAL|Digitally delivered exercise and education treatment Joint Academy|The Joint Academy® (www.jointacademy.com) program for people with LBP consists of video instructed and progressively adaptable daily exercises, patient education through text lessons and a continuous asynchronous chat function with a personal reg. physiotherapist who supervises the patient during the full participation period. The program also contains three telephone consultations with a physiotherapist that were compulsory, one at the start, one after six weeks and one after three month.
224214684|NCT04184479|BEHAVIORAL|LEVAmethod by Bertz et al|Ordinary treatment
224214685|NCT00418756|DRUG|Nilotinib|Semi-synthetic antibiotic derivative of rifamycin B and is known to induce cytochrome P-450 (CYP) enzymes.
224214686|NCT04403373|BEHAVIORAL|Waitlist control|waitlist control
224214687|NCT04403373|BEHAVIORAL|Moderate-intensity walking exercise|walking exercise
224214688|NCT04403373|BEHAVIORAL|Vigorous-intensity walking exercise|walking exercise
224214689|NCT01990898|DRUG|Cyclosporine|Drug will be provided to patient's at study visit. Drug is to be taken twice daily. Dosage will be calculated at study visit and provided to patient.
224214690|NCT01106352|DRUG|Radium-223 dichloride (Xofigo, BAY88-8223)|Alpharadin (Radium-223 dichloride) is administered intravenously as a bolus injection.
224214691|NCT01106352|DRUG|Docetaxel|Docetaxel (75 mg/m\^2) will be administered intravenously every 3 weeks with 5 mg prednisone twice a day continuously and pre-medication with dexamethasone. Step-down to 60 mg/m\^2 is allowed as per the approved docetaxel label.
224214692|NCT00476684|PROCEDURE|radiofrequency treatment|Radiofrequency-neurotomy of the medial branch at 80 degr. C needle temperature for 70 seconds, after diagnostic blocks
224214693|NCT00476684|PROCEDURE|sham neurotomy|Radiofrequency-neurotomy of the medial branch at 37 degr. C needle temperature for 70 seconds, after diagnostic blocks
223625105|NCT02567981|DIETARY_SUPPLEMENT|Cereal Fortificado (Fortified Cereal)|"Cereal Fortificado Dose: 45g/day. Contains the following daily amounts per dose: Vitamin A 226.6mcg, Thiamine 0.058mg, Riboflavin 0.202mg, Niacin 2.16mg, Panthotenic acid 3.015mg, Vitamin B6 0.765mg, Folate 27mcg, Vitamin B12 0.9mg, Vitamin C 45mg, Vitamin D 1.8mcg, Vitamin E 3.735mg, Vitamin K 45mcg, iron 3.6mg, Zinc 1.8mg, Iodine 18mcg, potassium 180mg, phosphorus 90 mg, calcium 58.50mg. Percentage weight: 58% corn, 20% soy, Skim dry milk 8%, Sugar 9%, Soy Oil 3%, Vitamins and Minerals 0.2%, calcium phosphate 1.23%, Potassium chloride 0.27%. Energy 184.5 kcal, protein 7.2%, Fat 4.1%, Fiber 1.4%, Ash 4.6%."
223625106|NCT02567981|DIETARY_SUPPLEMENT|Ferrous sulphate|"Ferrous sulfate drops children \<12 months: 12,5mg elemental iron/day (continuous). Children from 12-23.9months: elemental iron 25mg/day (continuous).~Chidlren from 24 to 59 months: 1ml/day for two months, every 6 months."
223625107|NCT02567981|DIETARY_SUPPLEMENT|Vitamin A|Vitamin A Capsules: children \<12 months: 100.000 IU/6 months. Children 12-59 months: 200.000 IU/6 months.
224316708|NCT01691235|DEVICE|SIMpill device|The SIMpill device is an automated pill dispensing device that records a time stamp each time the device is opened and a dose of medication is taken. This works through a computer chip that is housed inside of the pill dispensing device that is activated each time the pill box is opened. Physicians can download this data and generate a precise account of the patient's adherence to the medication dosing schedule. In addition, if a dose is missed, the SIMpill device can be set to automatically notify the patient by text message if a dose is overdue.
223625108|NCT06042959|OTHER|Laughter therapy|We used laughter yoga to investigate the potential effects on first year nursing students' whose in the preclinical period of education.
223680547|NCT04241679|DEVICE|Auditory Nerve Test System|"The Auditory Nerve Test System provides an electrically-evoked signal from within the cochlea to facilitate intraoperative auditory nerve monitoring. The auditory nerve can be measured both at the root entry zone of the brainstem (eCNAP) and with scalp electrodes (eABR). Data on the health of the auditory nerve will be collected immediately prior to tumor dissection, during tumor dissection, and immediately after tumor dissection. The main purpose of this study is to determine feasibility of this novel intraoperative monitoring protocol.~Secondarily, if the auditory nerve is visually confirmed to be intact following tumor resection then the patients will receive a cochlear implant during the same surgery."
224214694|NCT02958748|OTHER|taking blood sample|
224214695|NCT02649608|DRUG|0.04 mg Lu AE04621|0.04 mg dose group
224214696|NCT02649608|DRUG|0.08 mg Lu AE04621|0.08mg dose group
224214697|NCT02649608|DRUG|0.2 mg Lu AE04621|0.2 mg dose group
224214698|NCT02649608|DRUG|0.4 mg Lu AE04621|0.4 mg dose group
224214699|NCT02649608|DRUG|0.6 mg Lu AE04621|0.6 mg dose group
224214700|NCT02649608|DRUG|0.8 mg Lu AE04621|0.8 mg dose group
224214701|NCT02649608|DRUG|1.0 mg Lu AE04621|1.0 mg dose group
224214702|NCT02649608|DRUG|1.2 mg Lu AE04621|1.2 mg dose group
224214703|NCT03944707|DRUG|LOU064 100 mg|LOU064 100 mg once daily orally administered as two 50 mg capsules
224316709|NCT03456388|DRUG|Ammoxetine Hydrochloride Enteric-coated Tablets|There will be 7 ascending cohorts. The first cohort will be administered 2.5 mg once. The second cohort will be administered 7.5 mg. The third cohort will be administered 15 mg once. The forth cohort will be administered 30 mg once. The fifth cohort will be administered 45 mg once. The sixth cohort will be administered 65 mg once.The seventh cohort will be administered 100 mg once. The results of each dose group were shown to be safe and tolerable, and then the next dose group was tested.
224316710|NCT03456388|DRUG|placebo enteric-coated tablets|There will be 7 ascending cohorts. The first cohort will be administered 2.5 mg once. The second cohort will be administered 7.5 mg. The third cohort will be administered 15 mg once. The forth cohort will be administered 30 mg once. The fifth cohort will be administered 45 mg once. The sixth cohort will be administered 65 mg once.The seventh cohort will be administered 100 mg once. The results of each dose group were shown to be safe and tolerable, and then the next dose group was tested.
224316711|NCT00620685|DRUG|Placebo|Tablet, once daily for 4 weeks
224316712|NCT00620685|DRUG|PH-797804|Tablet, 1 mg PH-797804, once daily for 4 weeks
224316713|NCT00620685|DRUG|PH-797804|Tablet, 5 mg PH-797804, once daily for 4 weeks
224214704|NCT03944707|DRUG|Placebo|Placebo once daily administered orally as capsules
224214705|NCT05724316|DIETARY_SUPPLEMENT|Vitamin D supplement|N/A (says not to repeat information here)
224214706|NCT01220089|BEHAVIORAL|Standard maintenance|Participants will receive written materials in months 7-18
224214707|NCT01220089|BEHAVIORAL|Intensified maintenance|Participants will continue with in-person counseling visits in months 7-18
224214708|NCT05450042|DEVICE|SELUTION SLR DCB|Sirolimus DCB
224214709|NCT05450042|DEVICE|Paclitaxel DCB|Paclitaxel DCB
224214710|NCT05627349|DEVICE|wrist splinting|standard wrist splinting at night for 2 weeks
224214711|NCT05627349|DEVICE|FSN|FSN is a single-use disposable needle(Trocar Acupuncture Needle, Nanjing FSN Medical Co. , Ltd, China.). The needle body is solid, and covered with a plastic tube. The needle penetrates the skin with insertion device. Under the guidance of ultrasound, the needle enter the loose subcutaneous layer obliquely without penetrating into the muscle. This is the difference from traditional acupuncture. The insertion point is midpoint of the anterior forearm. The needle tip is toward the carpal tunnel. After the needle is inserted, SM and RA are performed. The frequency of SM is 200 times in two minutes. The method of SM is to make a horizontal fan swaying with the base of the needle as the fulcrum. RA is performed while SM-slowly make a fist for 10 seconds and then relax for 5 seconds. Eight times of RA in two minutes. After the FNS treatment, the needle was withdrawn.
224214712|NCT02444182|DIETARY_SUPPLEMENT|Probiotics|A half of the participants will be randomly allocated to the probiotics group. They will receive a probiotics lozenge twice a day for 4 weeks. Pre and Post intervention clinical exam will be conducted
224214713|NCT02444182|DIETARY_SUPPLEMENT|Placebo|A half of the participants will be randomly allocated to the placebo group. Lozenges with no probiotics will be given twice daily for 4 weeks. Pre and Post intervention clinical exam will be conducted
224214714|NCT01412710|DRUG|Cholecalciferol|4000 IU or 6000 IU given vitamin D3 once daily, orally for 6 months.
224316714|NCT05009511|BEHAVIORAL|Learning through feedback|The goal of this investigation is to examine the influence of feedback timing on learning and brain function.
223625109|NCT06489145|DEVICE|Technology-enhanced Rehabilitation|"Based on their individualized rehabilitation project, patients will undergo robot-assisted therapy (RAT) and/or virtual reality (VR)-based treatment.~RAT will consist of the use exoskeleton devices intended for the treatment of upper limbs (Armeo-Spring™) or for the lower limbs (Lokomat™) impairments.~VR-based rehabilitation will be conducted non-immersive VR devices: the ProKin 252™ (TechnoBody SRL, Italy), the D-Wall™ (TechnoBody SRL, Italy), and the Walker View™ (TechnoBody SRL, Italy).~Technology-enhanced treatment duration (number of sessions, minutes of use) will strictly depend on patients' rehabilitation needs and individualized rehabilitation program. Overall, part of the duration of the whole treatment will be dedicated to the use of the technological device, resulting in the same amount of rehabilitation for all participants."
223625110|NCT06489145|OTHER|Multidisciplinary Traditional Rehabiltiation|Patients will receive traditional treatment consisting of two daily one-hour session (4 weeks, 20 sessions) and including rehabilitation activities like range of motion exercises (passive, active assisted and active), progressive resistive exercises, balance and strength training, and aerobic conditioning. The intervention procedures will follow the routine multidisciplinary clinical practice of the Institute where the study will be carried out. Procedures will be adapted according to patient's medical diagnosis, disability severity, and to the consequent rehabilitation objectives in favor of an individualized rehabilitation project and program. If necessary, patients might therefore undergo parallel rehabilitation activities (ie, occupational therapy, speech therapy, cognitive stimulation) that will be kept under control throughout data collection and analyses.
223625111|NCT06400017|DEVICE|microelectrode stimulation of DBS|"Contact selection: According to the electrode position in the image (target reconstruction through CT scan), the electrode located in the substantia nigra is selected as the negative electrode, the contact near the upper part of the substantia nigra is selected as the positive electrode, and the bipolar stimulation mode is selected.~Stimulation parameters: The frequency was selected as 0/10/130Hz, the pulse width remained unchanged at 90μs, the side effects of patients were observed, and the voltage was slowly increased to 2.0V; The patient voltage was 0 during the spurious stimulation. The washout period was 1 hour"
223625112|NCT02106000|DEVICE|Inhalation profile recorder|Up to three inhalation profiles will be recorded whilst inhaling with maximal effort
224214715|NCT02300818|DEVICE|Pulsed Electromagnetic Field Therapy|Pulsed Electromagnetic Field Therapy widely termed as (PEMF) is a reparative technique used for treatment of eye therapy has proved to be a beneficial treatment for those suffering from glaucoma. This therapy helps in increased blood flow and show positive results on latent, initial and advanced glaucoma with ten sessions of seven minutes' each.
223625113|NCT00601835|BIOLOGICAL|Tetanus and Diphtheria Toxoids Adsorbed (Td) Vaccine|0.5 mL, Intramuscular, single dose
224214716|NCT02300818|DRUG|Seawater eyedrops|Eye-drops daily 1 time a day for 12 weeks
224214717|NCT04009473|COMBINATION_PRODUCT|SEGOVA procedure|SEGOVA procedure includes - Stem cell therapy, G - Growth factor Platelet Plasma Rich therapy and in Vitro Activation of the ovaries.
224214718|NCT01457729|BEHAVIORAL|Motivation by Telephone Call|Telephone call not exceeding 10 minutes according to a protocol
224214719|NCT03428048|PROCEDURE|Hybrid procedure|Ablation of the posterior aspect of the heart, an area thought to be the origin of chaotic arrhythmias in persistent Afib patients.
223762268|NCT03298750|PROCEDURE|Resection of ovarian tissue and mechanical stimulation|"he women will undergo a surgical laparoscopy during which one of the two technique will ensue.~1. One of the ovaries will be scratched ( 2 mm depth) with a knife. Simultaneously, a piece of the ovary will be preserved for further histologic analysis and research in the laboratory.~2. A piece of one ovary will be resected (up to one third of the ovary's volume, without harming the other ovary.~The resected ovarian tissue will be transferred immediately to the laboratory where the cortex will be divided from the medulla and sliced to small pieces of 1-2 square millimeters.~These pieces will be transferred back to the operation room in order for them to be transplanted under the serosa layer of the remaining ovary.~Any bleeding would be stopped using a stiches or hemostatic mesh (diathermy will not be used).~Simultaneously, a piece of the ovary will be preserved for further histologic analysis and research in the laboratory."
223762269|NCT03074903|DEVICE|Intrauterine system|Women having the Skyla intrauterine system at different times during their menstrual cycle report their bleeding patterns through daily texts.
224214720|NCT03428048|PROCEDURE|Endocardial ablations|ablations occurring inside the heart isolating the pulmonary veins - blocking energy from creating irregular or chaotic heart beats with use of a catheter
224214721|NCT03428048|PROCEDURE|left atrial appendage occlusion|A procedure to isolate the left atrial appendage of the heart. this anatomic body is the origin of clot formation which can lead to stroke. the clot formation as a result of Afib
224214722|NCT02366065|DRUG|Acetaminophen|Before treatment, study subjects will have their intraocular pressure measured at 8 am, 10 am, 12 pm and 4 pm. They will then take acetaminophen 650 mg qid for 7 days and the intraocular pressures again measured at 8 am, 10 am, 12 pm, and 4 pm. Subjects will then stop the acetaminophen and return one week later for one more set of intraocular pressure measurements at 8 am, 10 am, 12 pm, and 4 pm.
224214723|NCT04805281|OTHER|monolithic zirconia (5Y-TZP/3-YTZ) ZirCAD Prime.|wear of the new material of monolithic zirconia (5Y-TZP/3-YTZ) ZirCAD Prime in posterior teeth
224214724|NCT04805281|OTHER|Lithium Dislicate IPS e.max crown|wear of lithium disilicate IPS e.max crown in posterior teeth
224214725|NCT00984906|OTHER|Empty inhalers|Empty Easyhaler inhalers (type A and type B) and empty Turbohaler inhaler
224214726|NCT01861119|DRUG|Silicone gel Kelo-cort™;|
224214727|NCT01861119|DRUG|Onion extract gel Contractubex™|
224214728|NCT05606692|DRUG|Propofol 1%|The propofol group was both induced and maintained at an effect-site concentration (Ce) of 2.0-4.0 mcg/mL by a target-controlled infusion (TCI) system.
224214729|NCT05606692|DRUG|Sevoflurane/Ultane|The sevoflurane group was maintained via sevoflurane vaporizer between 1% and 3% (target minimum alveolar concentration of 0.7-1.3).
224316715|NCT00490984|DEVICE|Aspire Medical Advance System|The treatment includes a device that is surgically implanted in the tongue and lower jaw. The purpose of the implant is to prevent obstruction of the upper airway thereby improving breathing during sleep.
223625114|NCT00601835|BIOLOGICAL|Tetanus and Diphtheria Toxoids Adsorbed (Td) Vaccine|0.5 mL, Intramuscular, Single dose
223625115|NCT02338726|OTHER|Gynecological examination|Comparison of questionnaires and gynecological examination
223625116|NCT01668303|BEHAVIORAL|Miami Juvenile Drug Court-MDFT|MDFT assesses and intervenes in five domains: 1) Interventions with the adolescent, 2) interventions with the parent, 3) interventions to improve the parent-adolescent relationship, 4) interventions with other family members, and 5) interventions with external systems.
223625117|NCT01668303|BEHAVIORAL|Miami Juvenile Drug Court -TAU|Each client is provided with a primary outpatient counselor who develops a treatment plan to address long-range goals. Family members are included in an assessment and treatment planning session at the beginning of treatment, but no formal family therapy is provided. Group therapy topics include self-esteem enhancement, decision-making skills, stress/anger management, communication skills, health education, teen pregnancy prevention, and occupational/career planning.
223625118|NCT00358930|DRUG|ARQ 501|
223625119|NCT03073421|OTHER|Qualitative interview|This interview will be 2 hours in length and will be conducted with a Peer Research Assistant (PRA). The PRAs will be women living with HIV.
223625120|NCT03847844|BIOLOGICAL|Umbilical cord derived mesenchymal stem cell|Umbilical cord derived mesenchymal stem cell
223625121|NCT03847844|OTHER|Placebo|Normal saline
224214730|NCT04126733|DRUG|Regorafenib (Stivarga, BAY73-4506)|Regorafenib administered as oral tablets given every day for 3 weeks of each 28 days treatment cycle (i.e., 3 weeks on, 1 week off)
224214731|NCT04126733|BIOLOGICAL|Nivolumab (Opdivo)|Administered on day 1 of every treatment cycle.
224214732|NCT01092390|DIETARY_SUPPLEMENT|Lovaza (fish oil)|4 grams per day
224214733|NCT03346928|PROCEDURE|Head and neck reconstruction|Head and neck free flap reconstruction
224214734|NCT05880628|OTHER|datas of medical record.|"Analysis datas of medical record:~* Feasibility of the technique~* Safety of the technique~* Efficacity (sclerose of the lesion)"
224214735|NCT06295575|DIETARY_SUPPLEMENT|probiotics containing Bifidobacterium infantis and Lactobacillus|Patients were provided with probiotics containing Bifidobacterium infantis and Lactobacillus. This intervention was started the day after patients' administration and lasted until the day before discharge.
224214736|NCT06295575|DIETARY_SUPPLEMENT|placebos containing lactose|Patients received lactose as placebo.This intervention was started the day after patients' administration and lasted until the day before discharge.
224214737|NCT00459381|DRUG|pazopanib hydrochloride|Given orally
224214738|NCT00459381|OTHER|laboratory biomarker analysis|Correlative studies
224214739|NCT06398145|DIETARY_SUPPLEMENT|D-chiro-inositol and lactalbumin (high dose)|From 0 to 3 months: 1200mg D-chiro-inositol and 120mg lactalbumin per day
224214740|NCT06398145|DIETARY_SUPPLEMENT|D-chiro-inositol and lactalbumin (low dose)|From 3 to 6 months: 600mg D-chiro-inositol and 60mg lactalbumin per day
224214741|NCT05502068|DIETARY_SUPPLEMENT|Vitamin D 25 (OH) 12000 IU in the form of a sublingual sprayable microemulsion|This is a prospective, randomized, double blind, and controlled clinical study to investigate the impact of the high dose vitamin D supplementation on laboratory markers of systemic inflammation such as CRP, ferritin and IL-6 in hospitalized patients with COVID-19. Patients included in the study will be randomized into two groups and receive a placebo (as a control group) or cholecalciferol administered sublingually for 5 day
224214742|NCT00276705|DRUG|cisplatin|
224214743|NCT00276705|DRUG|cyclophosphamide|
224214744|NCT00276705|DRUG|doxorubicin hydrochloride|
224214745|NCT00276705|DRUG|thalidomide|
224214746|NCT00276705|PROCEDURE|adjuvant therapy|
224214747|NCT00276705|PROCEDURE|conventional surgery|
224214748|NCT00276705|PROCEDURE|neoadjuvant therapy|
224214749|NCT02058433|OTHER|dosage of paclitaxel|Based on pharmacokinetics. Observe the toxicity in an individual patient after a fixed Paclitaxel dose depending on BSA and then the dosage of Paclitaxel is adjusted depending on pharmacokinetics follow up to avoid excess toxicity in subsequent cycles.
224214750|NCT02058433|OTHER|dosage of paclitaxel|Based on body surface area. The dosage of Paclitaxel is based on the BSA of the patient. Paclitaxel/carboplatin up to 4 cycles or disease progression or intolerable toxicity.
224214751|NCT05463783|DRUG|Biktarvy|microRNA profiles of subjects on Biktarvy, will be compared with those who are on Symtuza, at various time points.
224214752|NCT05463783|DRUG|Symtuza|microRNA profiles of subjects on Symtuza, will be compared with those who are on Biktarvy, at various time points.
224214753|NCT02598193|DRUG|Nintedanib|Participants with IPF will receive nintedanib at the 200-300 mg/day dose up to 24 weeks.
224214754|NCT02598193|DRUG|Pirfenidone|Participants with IPF will receive pirfenidone at 1602-2403 mg/day dose up to 24 weeks.
224316716|NCT04320043|PROCEDURE|Anterior cervical decompression|Any of the following anterior surgical techniques used to decompress the cervical nerve roots or spinal cord; corpectomy, Anterior Cervical Discectomy (ACD), Anterior Cervical Decompression and Fusion (ACDF) or ACDF with Plating
223625122|NCT00644696|DRUG|Irinotecan and Bortezomib|Dose level-1a: IV Irinotecan 30 mg/m2/day, IV bortezomib 1.2mg/m2/day Dose level-1: IV Irinotecan 35 mg/m2/day, IV bortezomib 1.2mg/m2/day Dose level-2: IV Irinotecan 40 mg/m2/day, IV bortezomib 1.2mg/m2/day Dose level-3: IV Irinotecan 45 mg/m2/day, IV bortezomib 1.2mg/m2/day Dose level-4: IV Irinotecan 50 mg/m2/day, IV bortezomib 1.2mg/m2/day
223625123|NCT04406766|DEVICE|Connected nutrition pump system|"For the patient, it consists of the installation of the connected pump at his home for a duration of one month.~Infusion data and events will be continuously collected and transmitted by the 4 different modes (LoRaAN, BLE , GSM and multimodality).Transmitted data won't be used to change the follow up of the patient.~At the end of the month, patients will be solicited by an ergonomic engineer to complete a specific questionnaire in order to evaluate the future acceptability of the proposed solution."
223625124|NCT01315171|DIETARY_SUPPLEMENT|Medium chain triglycerides|4 tablespoons/day for 2 weeks
223625125|NCT04070365|DEVICE|FLEX Vessel Prep System followed by angioplasty|Eligible Arteriovenous Fistula (AVF)/Arteriovenous Graft (AVG) will be treated with the FLEX Vessel Prep system followed by angioplasty.
223680548|NCT05765981|DRUG|VGN-R09b|VGN-R09b will be injected into bilateral putamen by stereotactic surgery.（Through the SmartFlow Ventricular Cannula or the parenchymal injection tube actually used in the research center）
223680549|NCT02112955|BEHAVIORAL|Stroke self-management program|A nurse-led community-based self-efficacy enhancing stroke self-management program.
223680550|NCT02112955|BEHAVIORAL|Usual care|Usual care such as hospital-based or community-based health education or services.
223625126|NCT00855621|PROCEDURE|Deep brain stimulation of the subthalamic nucleus|Chronic bilateral deep brain stimulation in the nucleus subthalamicus is performed using the most effective of four electrode contacts identified during testing of stimulation settings. Stimulation settings will be variable and adjusted according to the symptoms of each individual patient. Stimulation parameters will be recorded at each individual examination. Dopaminergic and other necessary medication will be given according to the need of each patient.
223625127|NCT02982564|BEHAVIORAL|Exercise Program Low Intensity|This arm includes a low-intensity intervention and will have a duration of six months. Participants will be provided with a heart rate monitor to train at the intensity according to group assignment. Progression for both programs in the endurance component will be slower and more gradual for deconditioned participants, and may require multiple shorter periods (5-10 minutes) with rest intervals.
223625128|NCT02982564|BEHAVIORAL|Exercise Program Moderate Intensity|This arm includes a moderate-intensity intervention and will have a duration of six months. Participants will be provided with a heart rate monitor to train at the intensity according to group assignment. Progression for both programs in the endurance component will be slower and more gradual for deconditioned participants, and may require multiple shorter periods (5-10 minutes) with rest intervals.
223625129|NCT02804334|PROCEDURE|Psychiatric Questionnaires|
223625130|NCT02804334|PROCEDURE|Blood draw|
223625131|NCT05279859|DRUG|ERAS-007|Administered orally
223625132|NCT05279859|DRUG|ERAS-601|Administered orally
223625133|NCT05279859|DRUG|Gilteritinib|Administered orally
223625134|NCT00871910|DRUG|SCH 727965|SCH 727965 2 hour IV infusion on Day 1 of each 3 week cycle, administered in dose-escalating cohorts (Part 1 of the trial)
223625135|NCT00871910|DRUG|SCH 727965|SCH 727965 8 hour IV infusion on Day 1 of each 3 week cycle,in dose-escalating cohorts
223625136|NCT00871910|DRUG|SCH 727965|SCH 727965 24 hour IV infusion on Day 1 of each 3 week cycle, in dose-escalating cohorts
223625137|NCT00871910|DRUG|SCH 727965|SCH 727965 29.6 mg/m2 2 hour IV infusion on Day 1 of each 3 week cycle
223625138|NCT00871910|DRUG|Aprepitant|Oral aprepitant in Cycle 1 or Cycle 2, depending on the study arm: 125 mg 1 hour prior to the SCH 727965 infusion on Day 1, and 80 mg on Days 2 and 3.
223762270|NCT02016963|BIOLOGICAL|Raxibacumab|Raxibacumab will be supplied in 50 milliliter (mL) sterile, single-use vials containing 34.9 mL of liquid formulation per vial. Each vial contains 50 milligram (mg)/mL raxibacumab in 0.13 mg/mL citric acid, 2.8 mg/mL sodium citrate, 10 mg/mL sucrose, 18 mg/mL glycine, 0.2 mg/mL polysorbate 80, pH 6.5
223625139|NCT00871910|DRUG|Ondansetron|Ondansetron 32 mg IV 30 minutes prior to the SCH 727965 infusion on Day 1 of Cycles 1 and 2.
223625140|NCT00871910|DRUG|Dexamethasone|Oral dexamethasone in Cycles 1 and 2: 12 mg 30 minutes prior to the SCH 727965 infusion on Day 1, and 8 mg in the morning on Days 2, 3, and 4.
223625141|NCT04903561|DEVICE|ColliPee|The GP will hand over the self-sampling kit to the women, after obtaining informed consent, and the women then takes the self sample at home or in the doctor's office (predefined), according to the respective users manual.
223625142|NCT06524102|DEVICE|Magnetic Activated Cell Sorting|"The MACS® ART Annexin V System has been designed for the in vitro elimination of apoptotic human spermatozoa in fresh, cryopreserved or otherwise manipulated semen samples. Samples processed by this technique can be subsequently used in any assisted reproduction procedure.~Annexin V recognizes externalized phosphatidylserine (ePS) on the plasma membrane of apoptotic spermatozoa. Depletion of the altered sperm begins with magnetic tagging of the sperm. The system selectively retains unwanted sperm by utilizing the natural ability of annexin V to recognize the ePS on the plasma membrane of the altered sperm, because annexin V is conjugated to metal microspheres. The labeled cells pass through a separation column in a fixed magnetic field. Unwanted (altered) spermatozoa are selectively retained in the separation column. Unlabeled spermatozoa pass through the column where they are collected for later use."
223625143|NCT04434417|DEVICE|2019-nCoV IgG/IgM Rapid Test Cassette|The specimen (whole blood, serum, plasma) will be loaded into the cassette and will migrate via capillary action along the membrane to react with the gold conjugate. The result will be available in 10 minutes
223625144|NCT02747186|DRUG|Lidocaine|Intraoral maxillary field block
223762271|NCT00384813|BEHAVIORAL|Project ASPIRE Home-Based Family Intervention|Home-based psychoeducational family intervention jointly conducted by psychology postdoctoral fellow and respiratory therapist over 4 months
223762272|NCT00384813|BEHAVIORAL|Project ASPIRE Enhanced Treatment As Usual|Psychoeducational family intervention addressing the written asthma action plan during a single home visit, conducted by a respiratory therapist
223762273|NCT01441427|DRUG|recombinant human G-CSF, and rhEPO|G-CSF 4.5 microgram /kg/day enteral EPO 88 mIU/kg/day enteral
224214755|NCT04383704|OTHER|New Dietary pattern ( Mediterranean-DASH Intervention for Neurodegenerative Delay (MIND))|A new brain-protection pattern that has been designed after the Mediterranean and DASH diet to improve some of their dietary factors to have the highest impact on brain health and cognitive performance.
224214756|NCT05138198|BEHAVIORAL|Mediterranean Diet & Physical Activity|"At the beginning of each week (1-10), members were sent a text message introducing the week and providing the link to the week's website. This website includes downloadable material for this group with recipes and other important nutrition information, as well as the weekly topic information and informative video. After receiving the link to the website, members received a Qualtrics survey with a teach-back question related to the video and a goal-setting question related to the topics of the week. At the end of each week, members received another Qualtrics survey with a question regarding the goal of the past week.~* Visit 1: discuss Mediterranean diet score results from baseline and ways to improve~* Visit 2: discuss anti-inflammatory diet scorecard and ways to improve~* Discuss optimal dietary pattern (Med Diet pyramid handout)~* Personal dietary and exercise goals, reviewed baseline intake form, social support, self-efficacy, challenges, or barriers to achieving goals"
223625145|NCT01849601|DEVICE|percutaneous transluminal angioplasty balloon catheter|
223625146|NCT00582361|PROCEDURE|Standard Wound Dressing|Group A patients will have a standard dressing applied following initial treatment of their open fracture. They will return to the operating room approximately 48 hours following the initial trauma, and approximately every 48 hours thereafter, for irrigation and debridement and concomitant wound cultures (qualitative and quantitative) until such time as the wound is judged by the surgeon to be ready for either delayed primary closure or flap/skin graft coverage.
223625147|NCT00582361|DEVICE|VAC|Group B patients will have a Vacuum Assisted Closure (VAC) device applied following initial treatment of their open fracture. They will return to the operating room approximately 48 hours following the initial trauma, and approximately every 48 hours thereafter, for irrigation and debridement and concomitant wound cultures (qualitative and quantitative) until such time as the wound is judged by the surgeon to be ready for either delayed primary closure or flap/skin graft coverage.
223625148|NCT05563129|OTHER|First aid lessons|The school children will have first aid training
223625149|NCT03007550|PROCEDURE|Laparoscopic total gastrectomy|LTG with D1+/D2-10 lymphadenectomy for patients with clinical stage I (T1N0M0、T1N1M0、T2N0M0) gastric adenocarcinoma
223625150|NCT03007550|PROCEDURE|Open total gastrectomy|OTG with D1+/D2-10 lymphadenectomy for patients with clinical stage I (T1N0M0、T1N1M0、T2N0M0) gastric adenocarcinoma
223625151|NCT02365155|OTHER|Multicomponent training intervention.|The intervention group will be included in a program specifically developed for this study based on the multidimensional continuous care of patients with heart failure and frailty diagnosis or prefrailty. A joint interdisciplinary nursing intervention including a physical part (endurance, strength, flexibility and balance).
223625152|NCT02365155|OTHER|Nutrition intervention|Both groups will be included in a program of quarterly monitoring receiving nutritional support: nutritional advice plus enteral supplementation should specify.
223625153|NCT02365155|OTHER|Cognitive intervention|Both groups will be included in a program of quarterly monitoring receiving cognitive support: detection and treatment of depression and delirium in medical consultation.
223625154|NCT02365155|OTHER|D-vitamin intervention|Both groups will be included in a program of quarterly monitoring receiving hormonal support: supplementation of vitamin D if required with adjustment for guides.
223625155|NCT02365155|OTHER|Occupational intervention|The intervention group will be included in a program specifically developed for this study based on the multidimensional continuous care of patients with heart failure and frailty diagnosis or prefrailty. A joint interdisciplinary nursing intervention including occupational support.
223625156|NCT02365155|OTHER|Heart failure follow up.|Both groups will be included in a program specifically developed for this study based on the multidimensional continuous care of patients with heart failure and frailty diagnosis or prefrailty. A joint interdisciplinary medical intervention including and pharmacological treatment of heart failure and comorbidities adjusted according to recent clinical guidelines requirements.
223625157|NCT00000235|DRUG|Buprenorphine|
224214757|NCT05138198|BEHAVIORAL|Usual Care|As part of usual care, members attended one-on-one monthly counseling sessions with the assigned dietitian and reviewed their current eating habits and physical activity, as well as other environmental factors that may be affecting their weight such as work, home environment, sleeping issues, and medications. After reviewing current practices, the RD provided medical nutrition therapy (MNT), a specific application of the Nutrition Care Process in clinical settings that focuses on the management of diseases (e.g. diabetes, heart disease, etc.). Specific dietary recommendations are based on the Bull's Eye Food Guide, used by Stony Brook University Hospital for outpatient nutrition counseling. Individuals in the standard care received more individualized calorie recommendations (usual care) than the Mediterranean diet group.
224214758|NCT03376074|DEVICE|Hypothermic oxygenated perfusion (HOPE)|25 patients: Application of HOPE for 2 hours, perfusion rate 100-150 ml/min, pressure controlled, perfusion pressure \< 3 mm Hg, perfusion route portal vein, recirculating system, perfusion volume 2 L, perfusate solution (UWMP®), perfusate temperature 4-12 °C, perfusate oxygenation 40 KPa
223513829|NCT03000166|BEHAVIORAL|Step-Up Intervention|Intervention group participants will meet with a study facilitator during 5 regularly scheduled visits for chemotherapy. The facilitator will provide education about the benefits of physical activity and strategies to overcome barriers to physical activity, help the participants to set physical activity goals based on ability and preferences, and educate the participant on using a physical activity tracker.
223513830|NCT00694928|DRUG|clindamycin phosphate/butoconazole nitrate|semi-solid, single dose
223513831|NCT00694928|DRUG|butoconazole nitrate|semi-solid, single dose
223513832|NCT00674843|RADIATION|Far Infrared Radiation|Radiation: Far Infrared Radiation (5μm to 20μm wavelength) Far Infrared radiation for 30 to 40 minutes per treatment session.
223513833|NCT01444924|DRUG|Bupivicaine|The TAP block will be placed using a standardized ultrasound-guided approach. Subjects assigned to the study group will have an injection of 30 mL 0.25% bupivacaine, a local anesthetic with 3 mcg/mL of epinephrine, placed into the plane between the internal oblique and the transversus abdominis
223513834|NCT01444924|DRUG|Placebo|The placebo block will be placed in a similar manner, using a standardized ultrasound-guided approach. The placebo injection will consist of 30 mL sterile, preservative-free saline.
223513835|NCT02743754|OTHER|Standard therapy|The standard of care for improving oxygen delivery to the kidney. These may include blood transfusions for anemia, treatment of low blood pressure and oxygen for low blood oxygen levels.
223513836|NCT02743754|OTHER|Hyperbaric Oxygen|The standard of care therapies and in addition will be treated in the hyperbaric chamber within 12 hours of surgery. There will be 4 hyperbaric oxygen treatments in 48 hours (1 every 12 hours), each treatment will last 90 minutes with 100% oxygen at 2.4 ATA.
223513837|NCT05118529|OTHER|Routine care|Mobilization to chair
223513838|NCT00215657|DRUG|Degarelix|Degarelix 120 mg (20 mg/mL). Participants received same dose as in main study (FE200486 CS07; NCT00818623). Administration intervals were individualised for each participant (based on the duration of testosterone suppression in study FE200486 CS07).
223513839|NCT00215657|DRUG|Degarelix|Degarelix 120 mg (40 mg/mL). Participants received same dose as in main study (FE200486 CS07; NCT00818623). Administration intervals were individualised for each participant (based on the duration of testosterone suppression in study FE200486 CS07).
223513840|NCT00215657|DRUG|Degarelix|Degarelix 160 mg (40 mg/mL). Participants received same dose as in main study (FE200486 CS07; NCT00818623). Administration intervals were individualised for each participant (based on the duration of testosterone suppression in study FE200486 CS07).
223513841|NCT00215657|DRUG|Degarelix|Degarelix 200 mg (40 mg/mL). Participants received same dose as in main study (FE200486 CS07; NCT00818623). Administration intervals were individualised for each participant (based on the duration of testosterone suppression in study FE200486 CS07).
223625158|NCT04874714|BIOLOGICAL|MM09-MG01(30.000-30.000)|Mite mixture (Dermatophagoides pteronyssinus and Dermatophagoides farinae) with a concentration of 30,000 AU / mL and grasses mixture (Phleum pratense, Holcus lanatus, Poa pratensis, Festuca elatior, Lolium perenne and Dactylis glomerata) with a concentration of 30,000 AU / mL: Purified allergenic extract, adsorbed in aluminum hydroxide and polymerized with glutaraldehyde
223625159|NCT04874714|BIOLOGICAL|MG01(30.000)|Grasses mixture (Phleum pratense, Holcus lanatus, Poa pratensis, Festuca elatior, Lolium perenne and Dactylis glomerata) with a concentration of 30,000 AU / mL: Purified allergenic extract, adsorbed in aluminum hydroxide and polymerized with glutaraldehyde
223625160|NCT04874714|BIOLOGICAL|MM09(30.000)|Mite mixture (Dermatophagoides pteronyssinus and Dermatophagoides farinae) with a concentration of 30,000 AU / mL: Purified allergenic extract, adsorbed in aluminum hydroxide and polymerized with glutaraldehyde
223625161|NCT04874714|BIOLOGICAL|Placebo subcutaneous|The same solution, presentation, method of administration, frequency, and duration as the active treatment, but without active ingredients.
223762274|NCT01441427|DRUG|rh G-CSF|Dosage: 4.5 µg/ kg (diluted into 1 ml distilled water) administered once daily by an orogastric tube till the enteral intake reached 100 mL/kg of milk, or after a maximum of seven days.
224214759|NCT03376074|OTHER|Conventional cold storage|75 patients transplanted in Rennes between 2010 and 2015 with a cold stored grafts, matched (ratio 1: 3) using a propensity score calculated according to some parameters
224214760|NCT00002747|DRUG|cisplatin|
224214761|NCT00002747|DRUG|fluorouracil|
224214762|NCT00002747|PROCEDURE|conventional surgery|
224316717|NCT03003650|DEVICE|ACURATE TF™|ACURATE TF™Transfemoral Aortic Bioprosthesis is intended for subjects with severe symptomatic Aortic Stenosis and are considered high risk for surgical conventional Aortic Valve Replacement .
224316718|NCT00004492|DRUG|clotrimazole|
224316719|NCT00004492|DRUG|hydroxyurea|
224316720|NCT02713009|DIETARY_SUPPLEMENT|Pregnancy multi-vitamin (including 10μg vitamin D3)|
223513842|NCT00215657|DRUG|Degarelix|Degarelix 200 mg (60 mg/mL). Participants received same dose as in main study (FE200486 CS07; NCT00818623). Administration intervals were individualised for each participant (based on the duration of testosterone suppression in study FE200486 CS07).
223513843|NCT00215657|DRUG|Degarelix|Degarelix 240 mg (40 mg/mL). Participants received same dose as in main study (FE200486 CS07; NCT00818623). Administration intervals were individualised for each participant (based on the duration of testosterone suppression in study FE200486 CS07).
223513844|NCT00215657|DRUG|Degarelix|Degarelix 240 mg (60 mg/mL). Participants received same dose as in main study (FE200486 CS07; NCT00818623). Administration intervals were individualised for each participant (based on the duration of testosterone suppression in study FE200486 CS07).
223513845|NCT00215657|DRUG|Degarelix|Degarelix 320 mg (60 mg/mL). Participants received same dose as in main study (FE200486 CS07; NCT00818623). Administration intervals were individualised for each participant (based on the duration of testosterone suppression in study FE200486 CS07).
223513846|NCT05761496|DEVICE|Biliary stents insertion|Endoscopic placement of plastic and metal biliary stents
223513847|NCT05181735|DRUG|Luspatercept Injection [Reblozyl]|All patients will receive Luspatercept subcutaneously on day 1 of each 21 day cycle (every 3 weeks) at the selected dose according to part A : 1.75mg/kg or 1.33 mg/kg or 0.8 mg/kg
223513848|NCT05181735|DRUG|Eprex|Epoietin alfa will be adminstered as a subcutaneous injection at the selected dose according to part A : 30 000 UI/week or 60 000 UI/week, every week
223513849|NCT05591300|DIAGNOSTIC_TEST|Microparticles research|The absolute count of the total circulating microparticles will be carried out on the patients' plasma using the NanoSight NS300 instrument (Alphatest). Furthermore, the circulating microparticles will be stained with a combination of three monoclonal antibodies (Becton and Dickinson, NJ,USA) to detect microparticles released by the most abundant cell populations in the blood: leukocyte-derived microparticles (CD45+), endothelial-derived microparticles (CD31+), and PLT-derived microparticles (CD31+ CD41a+).
223513850|NCT03797326|BIOLOGICAL|Pembrolizumab|Administered as an IV infusion on Day 1 Q3W.
223513851|NCT03797326|DRUG|Lenvatinib|Administered orally once a day during each 21-day cycle.
223513852|NCT03769467|BIOLOGICAL|Tabelecleucel|Tabelecleucel is an off-the-shelf, allogeneic T-cell immunotherapy for the treatment of EBV+ malignancies and diseases.
223513853|NCT03769467|BIOLOGICAL|Pembrolizumab|pembrolizumab IV infusion
223513854|NCT03101982|DRUG|HBO|Hyperbaric oxygenation (HBO) is defined as breathing of 100% oxygen under elevated ambient pressure in a hyperbaric chamber. HBO is considered a pharmacological therapy.
223625162|NCT00016328|DRUG|temsirolimus|Given IV
223625163|NCT00016328|OTHER|laboratory biomarker analysis|Correlative studies
223625164|NCT00016328|OTHER|pharmacological study|Correlative studies
223762275|NCT01441427|DRUG|rh EPO|Dosage: 88 IU/ kg once daily (diluted into 1 ml distilled water) administered by an orogastric tube till the enteral intake reached 100 mL/kg of milk, or after a maximum of seven days.
224214763|NCT00002747|RADIATION|low-LET cobalt-60 gamma ray therapy|
224214764|NCT00002747|RADIATION|low-LET photon therapy|
224214765|NCT01598649|DIETARY_SUPPLEMENT|Fabricated foods with lupin protein|\- Foods containing altogether 25 g lupin protein isolate (bread, roll, sausage, spread)
224214766|NCT01598649|DIETARY_SUPPLEMENT|Mannitol|\- Placebo capsules containing mannitol (four capsules per day)
224214767|NCT01598649|DIETARY_SUPPLEMENT|Arginine|\- Capsules containing arginine (four capsules per day with a total daily dosage of 1,6 g)
224214768|NCT01598649|DIETARY_SUPPLEMENT|Fabricated foods with milk protein|Foods containing altogether 25 g milk protein isolate (bread, roll, sausage, spread)
224214769|NCT00006129|DRUG|testosterone|
224214770|NCT06542692|DEVICE|Whole Body Vibration|treatment duration, frequency
224214771|NCT06542692|DEVICE|physical therapy modalities|ultrasound, hot pack, tens
224214772|NCT03992612|OTHER|control group: usual medical care|The patients received usual medical care.
224214773|NCT03992612|BEHAVIORAL|MBPM- Mindfulness-Based Pain Management|8 group session of maindfulness-based treatment to management pain
224214774|NCT02480855|OTHER|Questionnaire and feedback|
224316721|NCT02713009|DIETARY_SUPPLEMENT|10μg vitamin D3|
224316722|NCT02713009|DIETARY_SUPPLEMENT|0μg vitamin D (placebo)|
223625165|NCT05467241|BEHAVIORAL|Self-induced therapeutic tremor (SITT) combined with mindfulness|"SITT is a way to reduce stress by turning on a natural shaking response. This can calm the participant's body. It involves doing simple exercises. The muscles will gently shake, and release built up stress. This shaking of the muscles lets the participant's body physically let go of tension and stress.~Mindfulness is the ability to be fully present in a moment. This allows focus on what the participant is sensing and feeling in the moment. It involves the acceptance of thoughts and feelings without judging them.~Practicing mindfulness involves breathing methods, guided imagery, and other practices to relax the body and mind, help reduce stress, and not be overwhelmed by what's going on around the participant."
223762276|NCT01441427|DRUG|rh G-GSF and rh EPO together|EPO dosage: 88 IU/ kg once daily i.e 88000 mU/kg/day (diluted into 1 ml distilled water) administered by an orogastric tube till the enteral intake reached 100 mL/kg of milk, or after a maximum of seven days.G-CSF dosage: 4.5 µg/ kg (diluted into 1 ml distilled water) administered once daily by an orogastric tube till the enteral intake reached 100 mL/kg of milk, or after a maximum of seven days.
224214775|NCT01684306|DRUG|Modafinil|Study subjects received, in a double blind fashion, either a single dose (100 mg) of modafinil or a placebo pill identical to the drug.
224214776|NCT01684306|DRUG|Placebo|Study subjects received, in a double blind fashion, either a single dose (100 mg) of modafinil or a placebo pill identical to the drug.
224214777|NCT06701500|BEHAVIORAL|Pavlovian-to-instrumental transfer (PIT) paradigm|"The paradigm consists of four parts:~In the first part, an instrumental learning task is completed in which subjects must learn which stimuli require a response and which do not. In the second part, a classical (Pavlovian) conditioning task is then completed in which subjects learn by passive viewing which stimuli are associated with certain amounts of money. The third part measures to which instrumental responses (learned in Part 1) are modulated by the presentation of the classically conditioned stimuli (learned in Part 2). At the same time drug-associated stimuli are presented in the background measuring to which extent they conflict with the learned instrumental behavior. In the last part, query trials are implemented in which the participants have to choose between two pictures to assess the relative cue value."
224214778|NCT06701500|BEHAVIORAL|Action Sequence Task (AST)|Participants need to press four keys according to the cue location; two keys are associated with high reward, while the other two are associated with low reward in case of correct and timely responses. The explicit goal is to maximize the reward. While in half of the trials the cues are presented in a random order, in the other half of the trials, participants repeatedly perform a fixed action sequence of 12 elements (habit condition). The degree of action sequence chunking (i.e. automation) is assessed via the differences in error rates and reaction times between the random and fixed order condition (habit parameter). Importantly, 15% of all trials are dual- target trials. In these the goal-directed system (press high reward key) and the action sequence (press sequence key) can either be in line (congruent trials) or in conflict (incongruent trials) with each other, thus the interference between goal-directed and habitual control can be tested.
224214779|NCT06701500|DIAGNOSTIC_TEST|Basic psychological assessment (interview)|"* Structured Clinical Interview for DSM Disorders (SCID) Current Depression:~  * SCID Mania~ * SCID alcohol use disorder (AUD)~ * SCID tobacco use disorder (TUD)~* Alcohol, Smoking and Substance Involvement Screening Test (ASSIST)~* Alcohol quantity-frequency~* Tobacco quantity-frequency~* Cannabis and other substances quantity-frequency"
224214780|NCT06701500|DIAGNOSTIC_TEST|Basic psychological assessment (questionnaires)|"* Sociodemographics~* Edinburgh Handedness Inventory (EHI)~* Fagerström Test for Nicotine depend (FTND)~* Barratt Impulsiveness Scale - Kurzversion (BIS-15)~* Alcohol Use Disorders Identification Test (AUDIT)~* Cannabis Use Disorders Identification Test (CUDIT)~* Adult ADHD Self-Report Scale (ASRS)"
224214781|NCT06701500|BEHAVIORAL|Neuropsychology tests|"* Digit-Symbol-Test (DST)~* Go/Nogo Simon task~* Counting Stroop Task~* Value-based decision-making task (VBDM)"
224214782|NCT01393548|DRUG|brompheniramine + phenylephrine|"Oral solution: brompheniramine (2mg/mL) and phenylephrine (2,5 mg/mL), t.i.d., according weight of patient.~OR Syrup: brompheniramine (2mg/5mL) and phenylephrine(5 mg/5mL), t.i.d., according weight of patient."
224214783|NCT01393548|DRUG|Brompheniramine + pseudoephedrine|Elixir: Brompheniramine (0,2mg/mL) and pseudoephedrine (3,0 mg/mL), t.i.d., according weight of patient
224214784|NCT00803530|DRUG|ATO + Ascorbic acid|"ATO will be diluted in 250 ml of normal saline solution at a dosage of 0.3 mg/Kg during the first week of therapy and at a dosage of 0.25 mg/Kg during the subsequent weeks (week 2 to 16), and administered intravenously over a 1-2 hour period.~The dose of ascorbic acid will be 1000 mg in 100 cc D5W or normal saline solution (NaCl 0.9 %) (protected from light and air) administered as an IV infusion over 15 to 30 minutes. The dosing solution is not to be mixed with any alkaline solution."
223762277|NCT01441427|DRUG|Placebo|distilled water :1 ml distilled water administered by an orogastric tube till the enteral intake reached 100 mL/kg of milk, or after a maximum of seven days.
223513855|NCT05455658|BIOLOGICAL|CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine|Given IV
223513856|NCT05455658|BIOLOGICAL|Sargramostim|Given ID
223513857|NCT04754399|DRUG|Cannabidiol (CBD)|"week 1: 25 mg twice daily, approximately 12 hours apart, with food~week 2: 50 mg twice daily, approximately 12 hours apart, with food~week 3: 75 mg twice daily, approximately 12 hours apart, with food~week 4+: 100 mg twice daily, approximately 12 hours apart, with food"
223513858|NCT05555576|DIETARY_SUPPLEMENT|Vitamin C|1000 mg vitamin C taken orally twice a day (one in the morning and one in the evening) for a 14-day period after ED discharge for the treatment arm
223513859|NCT05555576|OTHER|Placebo|Placebo taken orally twice a day (one in the morning and one in the evening) for a 14-day period after ED discharge for the treatment arm
223625166|NCT03137992|DRUG|Placebo|Single dose of placebo inhalation powder administered by test and reference dry powder inhalers.
223762278|NCT03009097|BIOLOGICAL|DFDBA|13 intrabony defects in chronic periodontitis patients were treated with allograft (DFDBA)
223762279|NCT03009097|DRUG|DFDBA with atorvastatin|13 intrabony defects in chronic periodontitis patients were treated with allograft (DFDBA) in combination with atorvastatin gel
223625167|NCT03137992|DRUG|Test Product (tiotropium bromide inhalation powder)|Double-Blind: Single dose of test product 18 mcg of test product Open-Label: once daily administration of test product (tiotropium bromide inhalation powder) 18 mcg administered by test dry powder inhaler.
224214785|NCT04720885|PROCEDURE|kind of surgery|hysteroscopy, curettage, other
224214786|NCT01382901|DRUG|Ferric Carboxymaltose (FCM)|
224214787|NCT01382901|DRUG|Placebo|
224214788|NCT02487979|DRUG|Glembatumumab Vedotin|Given IV
224214789|NCT02487979|OTHER|Laboratory Biomarker Analysis|Correlative studies
224214790|NCT02487979|OTHER|Pharmacological Study|Correlative studies
224214791|NCT00447694|DRUG|Deferasirox|Oral deferasirox 30mg/kg/day once per day for 77 weeks.
224214792|NCT04509752|OTHER|Survey|An online survey will be sent to each clinic to answer the survey questions.
224214793|NCT05309707|DEVICE|Endovascular exclusion|Endovascular exclusion by branch stent graft systems (Nexus stent-graft system®, Relay Branch® or Zenith arch branch graft®), with proximal landing at zone 0.
224214794|NCT00712907|DIETARY_SUPPLEMENT|vitamin C (Mayrhofer) 24mg/min i.v. for 64 min|Substance: Ascorbic acid (Mayrhofer) Manufacturer: Mayrhofer, Linz, Austria Dosage form: i.v. Dosage: 24mg/min over 64 min Dosage reference: Ting HH 1996
224214795|NCT00712907|DIETARY_SUPPLEMENT|Placebo|Substance: Physiologic saline solution 0.9% (placebo) Dosage form: i.v. Dosage: 24ml/min over 64 min
224214796|NCT00712907|OTHER|100% O2 (AGA) two times for 12 min|"Substance: 100% oxygen (AGA, Vienna, Austria, gases for human use) Manufacturer: AGA, Vienna, Austria, gases for human use Dosage form: Inhalation through an oxygenmask over a period of 12 minutes two times per study day.~Dosage reference: Strenn K 1997"
224214797|NCT05730088|OTHER|health education|Health Education: While they are still in the hospital, a 30-minute individually planned education about their disease will be given to patients using the COPD patient education booklet. step 1. Smoking cessation, step 2. Vaccination, step 3. Correct drug use, step 4. Regular exercise, step 5. Healthy eating, step 6. Coping with stress, step 7 Coping with attacks, step 8. Includes regular oxygen therapy. Let's learn nhaverug treatments in coping with COPD, under the title of pulmonary rehabilitation (Respiratory Rehabilitation), methods of coping with shortness of breath, indoor air pollution and outdoor air pollution subheadings.
224214798|NCT05730088|OTHER|Mobile application (Creating a WhatsApp group):|A group will be created through the WhatsApp application for participants in health education and visual and audio materials will be shared through this group every week. In the coming weeks, the researcher will provide consultancy services to those who have problems with the application.
224214799|NCT05730088|OTHER|Telephone interview:|Participants will be called every month by the researcher and asked if there are any hospital visits in that month, especially if they are chest disease visits.
224214800|NCT04514809|OTHER|human milk analized|After birth (24-72 hours) 15 ml, and end of the first month of birth 30 ml of milk from the mother will be milked in the appropriate way and put into the sterile milk collection container. The milk taken into the milk transport container will be delivered to the Nutrition Lab for analysis (moisture, protein, fat, lactose) by the researcher who arrives at the TUBITAK Mam Research Center as fresh within 3 hours
224214801|NCT05762263|BEHAVIORAL|Dietary|Depending on the allocation arm, participants will be advised to follow a particular dietary plan (either flexitarian eating, time-restricted eating or both combined).
224214802|NCT03796299|DIAGNOSTIC_TEST|Assessment of expression of MCM5 in the urine (ADX Bladder)|Each participant will be asked to urinate in a plastic container. Urine will be centrifuged afterwards, then the expression of MCM5 protein will be examined in cells from urine sediment. For this purpose, it is planned to use the Arquer Diagnostics ADXBLADDER test. It is an enzyme linked immunosorbent assay (ELISA) using two monoclonal antibodies directed against two different epitopes. Both antibodies have high affinity and specificity for the MCM5 antigen.
224214803|NCT02429401|BEHAVIORAL|Non-adapted brief motivational interview|1\) provide personalized feedback based on screening and baseline assessment, 2) explore decisional balance (pros and cons) of alcohol use from the patient's perspective, 3) build motivation for change through the assessment and discuss the patient's self-report of lf levels of importance, confidence, and readiness to change drinking, 4) enhance commitment to change by exploring the patient's options for change, and developing a change plan if indicated, 5) provide formal alcohol treatment referrals and community resources.
224214804|NCT02429401|BEHAVIORAL|Culturally adapted brief motivational interview|Addresses impact of acculturative stress and drinking norms based on screening results and 1) provide personalized feedback based on screening and baseline assessment, 2) explore decisional balance (pros and cons) of alcohol use from the patient's perspective, 3) build motivation for change through the assessment and discuss the patient's self-report of lf levels of importance, confidence, and readiness to change drinking, 4) enhance commitment to change by exploring the patient's options for change, and developing a change plan if indicated, 5) provide formal alcohol treatment referrals and community resources.
223625168|NCT03137992|DRUG|Reference Product (Spiriva®)|Reference product (Spiriva®) 18 mcg.
223625169|NCT06025006|OTHER|alternative to incarceration|place of respite with housing plus intensive follow-up
223625170|NCT02370420|BIOLOGICAL|Platelet-Rich Plasma|Autologous Platelet-Rich Plasma will be applied by a intra-articular injections
224214805|NCT03123211|DRUG|Veliparib|Veliparib will be administered orally.
224214806|NCT02182011|DRUG|Tenecteplase|
224214807|NCT02182011|DRUG|Alteplase|
224214808|NCT02182011|DRUG|Streptokinase|
224214809|NCT04896918|BEHAVIORAL|Tobacco use|
224214810|NCT03066635|DRUG|Botulinum Toxin Type A 25 IU|injection with 25 IU botulinum toxin towards the otic ganglion (symptomatic side) using image-guided navigation and the MultiGuide device
224214811|NCT03066635|DRUG|Botulinum Toxin Type A 12.5 IU|injection with 12.5 IU botulinum toxin towards the otic ganglion (symptomatic side) using image-guided navigation and the MultiGuide device
223625171|NCT02370420|BEHAVIORAL|rehabilitation exercises|Patients would been shown rehabilitation exercises, to perform them at home
223625172|NCT03077542|PROCEDURE|haploidentical stem cell transplant|haploidentical stem cell transplant
223625173|NCT03077542|DRUG|Sirolimus|conditioning regimen
223625174|NCT03077542|DRUG|Alemtuzumab|conditioning regimen
223625175|NCT03077542|DRUG|Pentostatin|conditioning regimen
223625176|NCT03077542|DRUG|Cyclophosphamide|conditioning regimen
224214812|NCT03496935|DEVICE|Tunneled versus non-tunneled dialysis catheter insertion|The study participants will be randomized either to tunneled or non-tunneled dialysis catheter insertion to commence renal replacement therapy for an acute kidney injury requiring either continuous or intermittent dialysis in the ICU.
224214813|NCT04821050|DEVICE|Sacral nerve stimulation|"A senior acupuncture doctor will pierce filiform needles through the sacral foramen into the S3 and S4 sacral nerves. These sites correspond to the Zhongliao and Xialiao acupoints in Traditional Chinese Medicine.~Electrodes will be clamped on the filiform needles and an electrical current of 0.5 mA will be delivered. The stimulation will last for 60 minutes every time, once a day for 2 weeks."
224214814|NCT04821050|DEVICE|Sham stimulation|"Shallow acupuncture stimulation will be performed at sites 8-10cm away from the acupoints in Group 1.~Electrodes will be clamped on the filiform needles and an electrical current of 0.5 mA will be delivered. The stimulation will last for 60 minutes every time, once a day for 2 weeks."
224214815|NCT02420665|DRUG|Proflavine|0.01% Proflavine applied topically to the cervix after colposcopy and HRME cervical images obtained.
224214816|NCT02420665|DEVICE|HRME Imaging|HRME images obtained from one visually normal cervical site, and from up to 3 visually abnormal lesions based on exam and/or colposcopic findings.
224214817|NCT02420665|BEHAVIORAL|Phone Call|Study staff follow up with participant by phone one month after procedure.
224214818|NCT02420665|PROCEDURE|Colposcopy|Colposcopy performed after visual inspection of cervix.
224214819|NCT02420665|DRUG|Acetic Acid|3 - 5% added to cervix before visual inspection.
224214820|NCT05178043|DRUG|Nivolumab|Nivolumab 240mg to be administered as an intravenous (IV) infusion every 2 weeks (Q2W).
224214821|NCT05178043|DRUG|GT90001|GT90001 7mg/kg to be administered as an intravenous infusion every 2 weeks (Q2W) after Nivolumab infusion.
224214822|NCT00279578|DRUG|ReFacto (Recombinant factor VIII) and Tranexamic acid|
224214823|NCT00730470|DRUG|U3-1287 (AMG888)|IV Infusion Dose Escalation (Part 1) - 5 Dose Cohorts Dose Expansion (Part 2) - 30 patients
224214824|NCT04822428|OTHER|Osteopathic manipulation|Osteopathic manipulative techniques including; suboccipital release technique,sacral release technique, diaphragmatic release, mesentery release, and Colonic manipulation
224214825|NCT00639665|OTHER|Cocoa|Polyphenol rich or poor cocoa was administered to study subjects to measure hemodynamic responses and the role of nitric oxide in the renal vasodilator response.
224214826|NCT05375682|OTHER|Integrated care program|Core Component 1: Fostering Collaboration and Capacity Core Component 2: Streamlined communication process for referrals and care planning Core Component 3: Coordinated Care Conferences
224214827|NCT01632683|DEVICE|C-MAC|C-MAC arm
223513860|NCT04163315|OTHER|dMRI, fMRI and electrocorticography|Patients included in the study will perform the pre-operative MRI (fMRI and fMRI) with a specific High Resolution Angular Diffusion (HARDI) sequence and a functional rest sequence. The additional scan time for this specific sequence is approximately 25 minutes, with no foreseeable negative impact on the patient
223513861|NCT04462393|OTHER|Admission to ICU for COVID-19|All patients admitted to Swedish ICUs with COVID-19 between 6 Mar - 6 May 2020
223513862|NCT04565756|DRUG|EXN407|EXN407 or placebo will be administered as a single 30 microliters drop twice a day, by unilateral eye drop administration to the study eye only.
223513863|NCT05377216|DRUG|Stellate Ganglion Block|Left sided percutaneous stellate ganglion block
223513864|NCT05226884|DIAGNOSTIC_TEST|Visual Acuity|Measurement of distance and intermediate visual acuity at variety targeted correction.
223513865|NCT05226884|DIAGNOSTIC_TEST|Defocus Curve|Measurement of a defocus curve
223513866|NCT05026632|DRUG|NPI-002 Intravitreal Implant|Implant inserted during vitrectomy.
223513867|NCT05614336|BIOLOGICAL|Blood sample|Blood serum samples will be collected for analysis of COVID-19 antibody levels. For participants who consent to the optional study, a second blood sample will also be drawn into EDTA tubes (plasma)
223513868|NCT03302429|OTHER|PRF/ BCP|Platelet rich fibrin combined with biphasic calcium phosphate(experimental group)
223513869|NCT03302429|OTHER|Autogenous bone graft|Bone obtained from the same individual who receiving the graft
223625177|NCT03077542|DRUG|Hydroxyurea|conditioning regimen
223625178|NCT03077542|DRUG|Filgrastim|A haploidentical relative donor will receive filgrastim (G-CSF) 10 to 16 µg/kg/d subcutaneously or intravenously for up to 6 days with apheresis collections of peripheral blood hematopoietic progenitor cells (PBPC) after the 5th day (and after the 6th day if required).
224214828|NCT01632683|DEVICE|Glidescope|Glidescope arm
224214829|NCT02059031|DRUG|GSK1265744 Reference formulation|GSK1265744 (micronized) reference formulation is available as 30 mg tablet to be orally administered with 240 mL of water
224214830|NCT02059031|DRUG|GSK1265744 New formulation 1|GSK1265744 (micronized) New formulation 1 is available as 30 mg tablet to be orally administered with 240 mL of water
224214831|NCT02059031|DRUG|GSK1265744 New formulation 2|GSK1265744 (un-micronized) New formulation 2 is available as 30 mg tablet to be orally administered with 240 mL of water
224214832|NCT06640244|OTHER|Sunscreen|To be used by all participants throughout the study
224214833|NCT06640244|OTHER|Cosmetic product G18|Cosmetic face care product
224214834|NCT06640244|OTHER|Cosmetic product N70|Cosmetic face care product
224214835|NCT06640244|OTHER|Cosmetic product D79|Cosmetic face care product
224214836|NCT06640244|OTHER|Cosmetic product E84|Cosmetic face care product
224214837|NCT06640244|OTHER|Cosmetic product C68|Cosmetic face care product
224214838|NCT02523274|DRUG|Resveratrol|Dietary compound commonly found in grapes and red wine. Will be given in 250 mg/day and 1000 mg/day dosages
224214839|NCT02523274|DRUG|Placebo|Vegetable-based cellulose
224214840|NCT02523274|BEHAVIORAL|Exercise|Multi-modal exercise regimen, 3 days/week
224214841|NCT02540473|BEHAVIORAL|Manualized Therapy|Relational psychotherapy mothers
224214842|NCT02540473|BEHAVIORAL|Control Group|one hour of free time to do with as they wish
224214843|NCT00570726|DRUG|Ranibizumab (Lucentis)|
224214844|NCT05103085|DIAGNOSTIC_TEST|Rapid diagnostic orientation test (TROD) for Hepatitis C|Inclusion of patients during the consultation with the gastroenterologist, before hospitalization in the digestive endoscopy department. Each consenting patient benefits from a HCV screening using TROD on the day of their hospitalization in the department.
223625179|NCT01333293|DRUG|injections|subcutaneous injections
223625180|NCT05983419|PROCEDURE|ESD|Complete resection of Barrett's esophagus harboring neoplasia with endoscopic submucosal dissection.
223625181|NCT00236353|DRUG|risperidone|
223625182|NCT06262386|DRUG|Cisplatin based chemottherapy|adjuvant therapy for high risk patient
223625183|NCT00795704|DRUG|Mulberry Leaf Extract|Mulberry Leaf Extract 1000 mg by mouth three times daily for 3 months
224214845|NCT05154188|DEVICE|Neuro Cochlear Implant system|Patients will be regular candidates for a cochlear implantation surgery, according to the indication criteria of the Neuro Cochlear Implant System and the device will be used according to its intended purpose
224214846|NCT04748809|OTHER|Diet 1|Dietary intervention
224214847|NCT04748809|OTHER|Diet 2|Dietary intervention
224214848|NCT00837031|DRUG|Lenalidomide|The starting dose of lenalidomide for the lead-in portion will be 25 mg orally daily on Days 1-21, followed by a 7-day rest period (28-day cycle). If the 25-mg dose of lenalidomide is found to be intolerable or unsafe (i.e., if more than one of the 6 patients experience a DLT), then the dose will be reduced to 20 mg orally daily, and 6 additional patients will be treated. All patients will receive lenalidomide at the confirmed tolerable dose (either 25 mg or 20 mg given orally daily on Days 1-21 of a 28-day cycle) until disease progression. If the 20-mg daily dose is found to be intolerable or unsafe, enrollment will be put on hold.
224214849|NCT00837031|DRUG|Gemcitabine|Gemcitabine 1000 mg/m2 IV will be administered on Days 1, 8, and 15 for a 28-day cycle.
224214850|NCT04106401|OTHER|carbon-monoxide rebreathing|Inhaled carbon monoxide (CO) administrated as a bolus into a rebreathing circuit serves as a marker to tag circulating hemoglobin molecules and to calculate total hemoglobin mass (Hbmass). The change in blood CO concentration from pre- to postadministration (delta carboxyhemoglobin concentration) and the dose of administrated CO allows for Hbmass determination. The other blood compartments (total red blood cell volume, plasma volume and total blood volume) are derived from Hbmass, hematocrit and/or hemoglobin concentration.
224214851|NCT04106401|OTHER|venous blood sampling|venous blood sampling at rest to evaluate blood viscosity, erythropoiesis and iron metabolism
224214852|NCT04106401|OTHER|physical activity monitoring|recording of physical activity by actimetry
224214853|NCT04106401|OTHER|apnea-hypopnea index and nocturnal oxygenation|recorded by ambulatory sleep recording device
224214854|NCT04106401|OTHER|24-hour blood pressure|recorded by ambulatory device
224214855|NCT05759169|OTHER|Foot Bath Tub|A foot bath is generally a form of rest and care where feet are put in water. Feet are body areas where fatigue is most felt as organs that carry the body's total weight. This study uses a specially designed foot bath bath bath bath to give the patients in the experimental group foot bath. The cuvette has four-stage water heating (35-45°C). It has a magnetic field and operates at 390 Watts. It has a splash guard. The sole features non-slip rubber feet. It has a heat shield feature because it has a double wall construction for heat isolation.
224214856|NCT04506125|OTHER|Haemoglobin 9.5 g/dL|transfusion of red blood cell concentrate if the haemoglobin level is less than 9,5 g/dL
223513870|NCT06122545|PROCEDURE|Greater Occipital Nerve Block|"Patients will receive Greater Occipital Nerve Block (GONB) either with local anesthetic (bupivacaine 0.5% 1.5 mL) or with onabotulinum toxin A injection.~Ultrasound-guided GONB will be performed to more accurately locate the nerve through searching for the occipital artery in the medial one-third of the superior nuchal line between the occipital tubercle and mastoid process and injection will be done medial to the artery"
223513871|NCT06122545|OTHER|Medical Treatment|Patients who will receive medical treatment
223625184|NCT00795704|DRUG|Placebo|Placebo 500 mg #2 capsules by mouth three times daily
223625185|NCT05287386|DRUG|Pemigatinib|The patients will receive 13.5 mg of pemigatinib once a day (QD) orally following a 2-week administration/1-week interruption regimen. They will be dosed until disease progression or intolerable toxicity. During treatment, clinical tumor imaging evaluation will be performed according to RECIST v1.1 every 6 weeks (± 7 days) and then every 9 weeks (± 7 days) after week 48. Safety will be assessed according to NCI-CTCAE 5.0.
223625186|NCT03980730|DRUG|Azeliragon|Azeliragon 5 mg capsule administered orally, once daily
223625187|NCT03980730|DRUG|Placebo|Matching placebo capsule administered orally, once daily
223625188|NCT00286585|DRUG|Inhalational anesthetic|Sevoflurane, dosage according to the physician in charge
223513872|NCT06122545|DRUG|bupivacaine or onabotulinum toxin A injection.|bupivacaine 0.5% 1.5 mL) or with onabotulinum toxin A injection.
223513873|NCT01205308|DIETARY_SUPPLEMENT|Vegetable oil based margarine with plant stanol ester enrichment|3 g plant stanols/ day
223625189|NCT00286585|DRUG|Intravenous anesthetic, propofol|Propofol, dosage according to the physician in charge
223625190|NCT01300728|DRUG|NewGam 10% IVIG|"Subjects will be randomized to receive either an infusion of IVIG at 0.4 g/kg or every 14 days for two months for a total of five infusions.~Fifty subjects will be enrolled and randomized in a 1:1 IVIG 2.0 g/kg: placebo ratio. Twenty-five subjects will receive IVIG and 25 subjects will receive placebo."
223625191|NCT01300728|OTHER|Placebo|Subjects will be randomized to receive either an infusion of 0.9% saline solution (placebo) every 14 days for two months for a total of five infusions. Fifty subjects will be enrolled and randomized in a 1:1 IVIG 2.0 g/kg: placebo ratio.
223625192|NCT05161923|PROCEDURE|Per oral endoscopy myotomy|The per-oral endoscopic myotomy, or POEM, is a minimally invasive surgical procedure for the treatment of achalasia wherein the inner circular muscle layer of the lower esophageal sphincter is divided through a submucosal tunnel.\[1\] This enables food and liquids to pass into the stomach, a process that is impaired in achalasia. The tunnel is created, and the myotomy performed, using a flexible endoscope, meaning the entire procedure can be done without external incisions.
223625193|NCT01949974|DRUG|Standard Palliative Chemotherapy|Standard Palliative Chemotherapy, depending on type cancer.
223762280|NCT02172313|DRUG|semaglutide|For oral administration.
223762281|NCT04464070|DIETARY_SUPPLEMENT|niacin|induce biosynthesis of PGD2
223625194|NCT01949974|OTHER|Integral Attention Program (PAI)|The PAI is a plan of care and treatment adapted in accordance with the evolution and needs of patients. This plan includes an initial comprehensive assessment of patients and their families during the first visit, including specialized psychological and social support when needed, voluntary art therapy and/or mindfulness. There will be outpatient monitoring, 24h phone assistance, home visits, support should hospitalization be required, and unscheduled visits by a palliative care team.
223625195|NCT00622037|DRUG|PEG-400 based artificial tear|Instill one drop in the randomized eye four times daily. Can be used more frequently if needed
223625196|NCT00622037|DRUG|Systane|Instill one drop in the randomized eye four times daily. Can be used more frequently if needed
223625197|NCT06152510|OTHER|Virtual Reality Rehabilitation System|In a single session to evaluate postural control, both children with ASD and typically developing peers will participate in an activity utilizing the Virtual Reality Rehabilitation System (VRRS) in conjunction with a stabilometric balance platform. During the assessment task, participants will stand on the balance platform with their eyes open, focusing on a fixed point displayed on the VRRS screen for a duration of one minute. This process will be repeated three times for each participant. The combined use of VRRS and the stabilometric balance platform aims to provide a comprehensive evaluation of postural control abilities in both groups, allowing for the observation and measurement of potential differences in stability and balance performance between children with ASD and their neurotypical counterparts.
223625198|NCT02392806|DEVICE|Bubble CPAP- BabiPlus, Respiralogics|Infant will be randomized to BabiPlus Bubbler at time of extubation
223625199|NCT02392806|DEVICE|Bubble CPAP- B&B Bubbler, B&B Medical devices|Infant will be randomized to B\&B Bubbler at time of extubation
223625200|NCT00395356|BEHAVIORAL|calorie controlled diet|
223625201|NCT06173414|OTHER|No intervention measures|No intervention measures
223625202|NCT00880620|DRUG|Placebo|Placebo
224214857|NCT04506125|OTHER|Haemoglobine 7.5g/dL|transfusion of red blood cell concentrate if the haemoglobin level is less than 7,5 g/dL
223625203|NCT00880620|DRUG|IPX066 95 mg LD|IPX066 capsule containing 95 mg LD/23.75 mg CD
223625204|NCT00880620|DRUG|IPX066 145 mg LD|IPX066 capsule containing 145 mg LD/36.25 mg CD
223625205|NCT00880620|DRUG|IPX066 195 mg LD|IPX066 capsule containing 195 mg LD/48.75 mg CD
223625206|NCT00880620|DRUG|IPX066 245 mg LD|IPX066 capsule containing 245 mg LD/61.25 mg CD
223762282|NCT04464070|DRUG|aspirin|inhibition of cyclooxygenase
224214858|NCT03763617|DEVICE|d-ptfe membrane|Socket preservation using d-ptfe membrane to inhibit the formation of osteoclasts
224214859|NCT04767217|DRUG|artemether-lumefantrine (ALN)|Assessing the efficacy on current 1st line antimalarial, and an alternative 1st line or 2nd line medicine
224214860|NCT04767217|DRUG|dihydroartemisinin-piperaquine (DHA-PPQ)|dihydroartemisinin-piperaquine (DHA-PPQ)
223625207|NCT02536898|OTHER|Fracture Liaison Service|
223625208|NCT02536898|OTHER|Current treatment|
223625209|NCT04435483|DRUG|Acalabrutinib Treatment A|Participants will receive a single dose of 100-mg acalabrutinib suspension via NG administration, under fasted conditions. A single dose of 20 mg rabeprazole will be administered with 240 mL water, 2 hours prior to administration of acalabrutinib suspension. Treatment with rabeprazole 20 mg twice daily (with meals) will be started 3 days prior to the receiving the first dose of acalabrutinib suspension.
223625210|NCT04435483|DRUG|Acalabrutinib Treatment B|Participants will receive a single dose of 100-mg acalabrutinib suspension via NG administration, under fasted conditions.
223625211|NCT04435483|DRUG|Acalabrutinib Treatment C|Participants will receive a single dose of 100-mg acalabrutinib capsule, under fasted conditions. The acalabrutinib capsule will be administered with 240 mL of water.
223625212|NCT03125226|DEVICE|Polyethylene Glycol Hydrogel|Given TracelT hydrogel via injection
223625213|NCT01467011|DRUG|Enteric-coated Mycophenolate Sodium|1440mg/day for 6 months posttransplant
223625214|NCT06206538|PROCEDURE|Stellate ganglion block|Based on the invention above, the patients in the observation group were provided with Stellate ganglion block , using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate ganglion block . The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
223762283|NCT04464070|OTHER|PGD2|labeled precursor
223762284|NCT00696956|DEVICE|Balloon angioplasty (uncoated conventional balloon)|endovascular therapy
223762285|NCT00696956|DEVICE|Balloon angioplasty (conventional but coated with 3 µg/mm2 paclitaxel)|endovascular therapy
224214861|NCT01776996|DRUG|Continued Access Arm|All subjects will be on maraviroc 300 mg twice a day, unless a dose adjustment is required due to certain concomitant medications. For those subjects in South Africa and Argentina who were previously receiving Combivir along with maraviroc in Study A4001026, Combivir will be supplied as tablets containing 150 mg lamivudine and 300 mg zidovudine. One Combivir tablet will be taken orally twice a day.
224214862|NCT01000142|PROCEDURE|Osteopathic Manipulative Treatment|Focused osteopathic musculoskeletal exam; paraspinal muscle inhibition and/or soft tissue kneading or stretching; rib raising and or rib mobilization; abdominal diaphragm release technique; abdominal mesenteric/colon release; thoracic inlet release technique; hip flexion/extension range of motion; shoulder range of motion with pectoral traction; cervical paraspinal muscle inhibition and/or soft tissue kneading or stretching; suboccipital release technique; specific OMT of significant somatic dysfunction (variable).
224214863|NCT01000142|PROCEDURE|Light Touch|Focused osteopathic musculoskeletal exam; contact ribs to simulate rib raising and paraspinal muscle inhibition; contact lower rib margin to simulate abdominal diaphragm release; palpate the four quadrants of the abdomen to simulate abdominal mesenteric/colon release; contact shoulders to simulate thoracic inlet release; contact suboccipital region to simulate thoracic inlet release.
224214864|NCT05100849|PROCEDURE|Kinect-based cognitive training|The Kinect-based group will be involved in the standard treatment protocol and will perform a 14-sessions cognitive training program that consists of instrumental activities of daily living simulations. The cognitive training content will be projected onto a wall and patients will interact with the content, i.e., the selection of the appropriate response, through movement (kinect).
223625215|NCT06206538|BEHAVIORAL|Rehabilitation therapy|"he study lasted 20d for each patient. During the treatment, All the participants were provided with the rehabilitation therapy, which included routine rehabilitation, cognitive training, swallowing function training and nutrition support.~Particularly, due to dysphagia, the patients enrolled might face difficulty in eating. For patients who were able to finish intake via mouth by compensatory means, the consistency, type, and size of food bolus was arranged. For those who cannot acquire sufficient nutrition through oral intake, the nasogastric tube feeding (NGT) was provided."
224214865|NCT05100849|PROCEDURE|Tablet-based cognitive training|The Tablet-based group will be involved in the standard treatment protocol and will perform a 14-sessions cognitive training program that consists of instrumental activities of daily living simulations. Patients will interact with the cognitive training content through a tablet.
224214866|NCT02354976|DRUG|Placebo|Placebo matching to Omega-3 carboxylic acids (olive oil)
224214867|NCT02354976|DRUG|Omega-3 carboxylic acid|4 g administered as 4 x 1 g capsules
223625216|NCT05006235|DRUG|Epinephrine Inhalation Solution|
223625217|NCT05006235|DRUG|Salbutamol|
223625218|NCT05006235|DRUG|Saline Inhalants|
223625219|NCT00301808|DRUG|Cisplatin|Cisplatin 75 mg/m2 every 3 weeks on days 1, 22, and 43
223625220|NCT00301808|DRUG|Docetaxel|Docetaxel 75 mg/m2 on day 1 of each cycle
224214868|NCT02354976|DRUG|Fenofibrate 200mg|200mg capsule administered once daily
224214869|NCT02354976|DRUG|Placebo|Placebo matching to fenofibrate 200mg
223625221|NCT00301808|DRUG|Pemetrexed disodium|Pemetrexed 500 mg/m2 every 3 weeks on days 1, 22, and 43
223625222|NCT00301808|RADIATION|Radiation therapy|Radiation therapy will begin within 24 hours of the first cycle of chemotherapy.
223625223|NCT01319981|DRUG|Rituximab|In CD20-positive patients, 375 mg/m2 by vein on day 1 and 8 for Courses 1 and 3; and day 1 and 8 of Courses 2 and 4.
223625224|NCT01319981|DRUG|Imatinib|600 mg by mouth daily days 1-14 for course 1 and continuously on all other courses for patients who are Philadelphia chromosome positive (Ph+).
223625225|NCT01319981|DRUG|Cyclophosphamide|300 mg/m2 by vein over 3 hours every 12 hours x 6 doses days 1, 2, 3 (total dose 1800 mg/m2) for courses 1, 3, 5, 7
223625226|NCT01319981|DRUG|Doxorubicin|50 mg/m2 by vein over 24 hours on day 4 after last dose of Cyclophosphamide for courses 1, 3, 5, 7
223625227|NCT01319981|DRUG|Mesna|600 mg/m2 by vein continuous infusion daily for 24 hours days 1-3 for courses 1, 3, 5, 7
224214870|NCT03621020|DIAGNOSTIC_TEST|T-TAS 01 PL Chip|Flow chamber microchip system specific for measuring primary hemostatic ability
224214871|NCT03621020|DIAGNOSTIC_TEST|PFA-100 Col/Epi and Col/ADP|System for measuring platelet dysfunction
224214872|NCT02179931|DRUG|Flupentixol/melitracen film-coated tablet|
224214873|NCT02179931|DRUG|Flupentixol/melitracen coated tablet (Deanxit®)|
223625228|NCT01319981|DRUG|VSLI|2.0 mg/m2 by vein on day 1 and day 8 for courses 1, 3, 5, 7
223625229|NCT01319981|DRUG|Solu-Medrol|40 mg by vein every 12 hours for 6 doses days 1-3 for courses 2, 4, 6, 8.
223625230|NCT01319981|DRUG|Methotrexate|200 mg/m2 IV over 2 hrs followed by 800 mg/m2 over 22 hrs on day 1 beginning after the completion of rituximab for Courses 2, 4, 6, and 8.
223625231|NCT01319981|DRUG|Ara-C|3 gm/m2 by vein over 2 hours every 12 hours for 4 doses on days 2, 3 for Courses 2, 4, 6, and 8.
223625232|NCT01319981|DRUG|G-CSF|10 µg/kg/day (rounded) given subcutaneously until neutrophil recovery to 1 x 10\^9/L or higher can be substituted or can be added if neutrophils have not recovered to 1 x 10\^9/L by day 21.
223625233|NCT01319981|DRUG|Pegfilgrastim|6 mg/kg (rounded) within 72 hrs after completion of chemotherapy.
224214874|NCT00085852|BIOLOGICAL|BLVR|10 mL Hydrogel
224214875|NCT00986154|DRUG|edoxaban tosylate(DU-176b)|edoxaban tosylate(DU-176b), film-coated tablet for oral use, 30 mg, two tablets (60 mg) once daily, maximum of 12 months treatment
223625234|NCT01319981|DRUG|Dexamethasone|40 mg by vein or by mouth daily days 1-4 and days 11-14 for courses 1, 3, 5, 7
223625235|NCT03798613|DEVICE|Apple Watch 4 Series Device|tracings from the apple watch 4 series watch
223625236|NCT03798613|DEVICE|Continuous Telemetry Monitor|tracings from the continuous telemetry monitor
223625237|NCT06102096|BEHAVIORAL|Culturally Adapted iCBT|A culturally adapted iCBT targeting mild to moderate mental health problems among Arabic-speaking refugee and migrant youth.
223625238|NCT04494074|OTHER|External Cooling|External Cooling
223625239|NCT02620839|DRUG|Alpelisib|Given PO
223625240|NCT02620839|DRUG|Cisplatin|Given IV
223625241|NCT03212898|OTHER|anticoagulation care|Patients in the intervention group will: 1) have a repeated pharmacist-led education on all aspects of warfarin treatment; 2) receive enhanced medication instructions and a care and follow up plan; 3) receive a pill box 4) be refered to the GP with proposal for dose change when outside the therapeutic range or therapy modification to avoid drug interactions with warfarin
223625242|NCT03332459|DRUG|Lumicitabine|Participants who received lumicitabine in a feeding Phase 2 study (64041575RSV2004) will be observed in this study.
223625243|NCT03332459|DRUG|Placebo|Participants who received placebo in a feeding Phase 2 study (64041575RSV2004) will be observed in this study.
223625244|NCT05971550|OTHER|Absence of antibiotic treatment|Absence of antibiotic treatment for at most 3 months after screening for asymptomatic NG pharyngeal infection (treatment if onset of symptoms related to STI or positive PCR at 3 months)
224214876|NCT00986154|DRUG|low molecular weight heparin/unfractionated heparin|"LMW heparin - subcutaneous injection, 1 mg/Kg twice daily or 1.5 mg/Kg once daily.~Unfractionated heparin - 5,000 IU bolus intravenous administration, 1,300 IU/hour continuous infusion, minimum of 5 days and maximum of about 12 days treatment"
224214877|NCT00986154|DRUG|warfarin|tablet for oral use; 0.5 mg, 1 mg, 2.5 mg, 5 mg; daily dosage, adjusted to maintain international normalized ratio (INR) between 2.0 and 3.0; maximum of 12 months treatment
224214878|NCT03944018|BEHAVIORAL|Intervention with rehabilitation coordinator|Intervention with rehabilitation coordinator in orthopedic care
224214879|NCT03726437|BEHAVIORAL|RealConsent|"This 3-hour web-based program consists of four 45-minute modules that are interactive and range in number of segments (1-14) and types of activities. Each of the modules involves interactivity, didactic activities and two episodes of a serial drama (Squad), which allow for the modeling of positive behaviors and illustrate both positive and negative outcome expectations. Behaviors modeled include drinking safely (e.g., eating before drinking, pacing, and drinking water), having a game plan before going out, communicating with male sex partners, engaging in protective dating behaviors, use of resistance strategies, self-defense strategies and bystander intervention with the goal of reducing risk of being sexually assaulted."
224316723|NCT05644197|OTHER|Multidisciplinary program|"Multidisciplinary program:~* APA interventions: 12 weeks Each week at home, cardio-respiratory endurance sessions for muscle strengthening and balance work from the Autohome interface (Neuradom) and one week supervised by an APA teacher.~* Nutrition interventions: A group nutrition workshop at the Hôpital Privé de Provence.~* Psychological intervention:~  5 sessions of 1h30 in group, the first session will take place at the Private Hospital of Provence and the others by videoconference.~An individual session the week following the last group session.~-Visit with the urologist, 5 weeks after the prostatectomy."
224214880|NCT03726437|BEHAVIORAL|Stress and Mood Management|"This 3-hour general health promotion web-based program consists of four 45-minute modules (Stress Management, Managing Depression, Managing Anxiety, and Treatments that work) that provide a range of activities related to reducing day-to day stress and alleviating anxiety through meditation and exercise."
224214881|NCT02328807|PROCEDURE|Radio-Frequency Ablation (RFA)|RFA is a minimally invasive procedure. It is an image-guided technique that heats and destroys cancer cells. In RFA, imaging techniques such as ultrasound or magnetic resonance imaging (MRI) are used to help guide a needle electrode into a cancerous tumor. High-frequency electrical currents are then passed through the electrode, destroying the cancer cells.
224214882|NCT00944385|DRUG|ulinastatin|Administer 30000U/ulinastatin. Comparison of different dosages of drug.
224214883|NCT00623909|DEVICE|AvicennaTM class IV laser application|AvicennaTM class IV laser for application over the skin of human subjects in the treatment of post-thoracotomy pain syndrome. Six sessions, twenty minutes applications over a period of six weeks.
224214884|NCT00068445|DRUG|lamotrigine|
224214885|NCT00068445|OTHER|Placebo|
224214886|NCT00520247|DRUG|enalapril plus folic acid|enalapril 10.0 mg daily for 8 weeks (the control group); enalapril 10.0 mg plus folic acid 0.4 mg daily for 8 weeks (Low-dose group); enalapril 10.0 mg plus folic acid 0.8 mg daily for 8 weeks (High-dose group)
224214887|NCT01111630|DRUG|recomon (Epoetin Beta)|administer once weekly
224214888|NCT01111630|DRUG|recomon (Epoetin Beta)|administer three times weekly
224214889|NCT06403566|OTHER|hand massage|three group randomized controlled trials
224214890|NCT01247896|DRUG|PF-05190457|Single Dose 2 mg
224214891|NCT01247896|DRUG|PF-05190457|Single Dose 10 mg
224214892|NCT01247896|DRUG|PF-05190457|Single Dose 30 mg
224214893|NCT01247896|DRUG|PF-05190457|Single Dose 100 mg
223762286|NCT06724679|OTHER|Utilisability of an immersive VR device in a functional restoration program (FRP) for patients with chronic low back pain.|"Patients participating will engage in three 20-minute VR sessions per week, in addition to the standard FRP program, for a duration of four to five weeks. The sessions will consist of a series of pre-programmed exercises designed to facilitate various trunk movements (flexion, extension, inclination, rotation) through exergames. Each exercise will last an average of 5 to 7 minutes. These exercises have been developed in collaboration between the company providing the VR device and the rehabilitation teams. Patients will be set up by a healthcare provider in a dedicated room for VR use. The provider will configure the device, assist the patient in donning it, and initiate the program, will remain present throughout the session to monitor for any adverse effect~. While the specific exercises may vary, the total duration of the session will be 20 minutes, consisting of various exercises interspersed with breaks. The principal investigator will propose a standardized series of exercises,"
223762287|NCT03343769|OTHER|BERG scale|Complete the BERG balance scale
223762288|NCT03343769|OTHER|Functional tests|timed up and go, Mini motor test, retropulsion test
223762289|NCT03343769|OTHER|Measurement of balance on a force platform|4 trials of 30 seconds x 2 conditions (eyes open; eyes closed)
224214894|NCT01247896|DRUG|PF-05190457|Single Dose 300 mg
224214895|NCT01247896|DRUG|PF-05190457|Single Dose 600 mg
224214896|NCT01247896|DRUG|PF-05190457|Single Dose - to be determined with food
224214897|NCT01247896|DRUG|PF-05190457|Single Dose - to be determined
224316724|NCT01050465|OTHER|health information prescription|Patients randomized to the email arm will receive a health information prescription via email on a health care topic following their clinic visit. Patients randomized to the paper arm will receive a health information prescription on paper on a health care topic following their clinic visit.
224214898|NCT01247896|DRUG|Placebo|Single Dose Placebo
224214899|NCT05817084|PROCEDURE|medial opening wedge high tibial osteotomy|medial opening wedge valgus high tibial osteotomy
224316725|NCT01392963|DRUG|botulinum toxin type A neurotoxin complex|29-40 U injection
224214900|NCT05817084|PROCEDURE|anterior cruciate ligament reconstruction|anterior cruciate ligament reconstruction
224214901|NCT04603079|BEHAVIORAL|Intervention for COVID-19 preventive protocols|The intervention will comprise (A) digital communication of written material and (B) monthly online training and discussion through skype and zoom, to allow for physical demonstrations, Q\&A and sharing of challenges. The five specific areas covered in the intervention for COVID-19 preventive protocols will include: (1) PPE fitting, (2) PPE removal, (3) hand hygiene, (4) cleaning, disinfection and sterilization, and (5) nurse uniform sterilization.
224214902|NCT00773552|DRUG|solifenacin succinate|5mg PO Qday x 90 days
224214903|NCT00773552|DRUG|placebo|1 tab PO Qday x 90 days
224214904|NCT00971399|DRUG|ramosetron|ramosetron 0.1mg q.d. SL on D1-5
224214905|NCT00971399|DRUG|ondansetron|ondansetron 8mg, b.i.d SL on D1-5
224214906|NCT05691699|DRUG|ABBV-903|Capsule; oral
224214907|NCT05691699|DRUG|Placebo for ABBV-903|Capsule; oral
224316726|NCT01392963|DRUG|Placebo|29-40 U 0.9% NaCl injection
224316727|NCT00369486|PROCEDURE|Focal laser photocoagulation|Focal laser photocoagulation (modified Early Treatment Diabetic Retinopathy Study technique)
223625245|NCT05971550|DRUG|Ceftriaxone|Ceftriaxone 1000 mg by parenteral intramuscular route, in a single dose, according to the national recommendations in force, to be repeated if pharyngeal PCR again positive for NG during follow-up
223625246|NCT05039957|OTHER|joint preparation|fixation of fracture with joint preparation
223625247|NCT05039957|OTHER|without joint preparation|fixation of fracture without joint preparation
223625248|NCT02186275|DRUG|Vitamin D3: 3000 or 4000 UI/day then 2,000 UI/day|"* Weight at inclusion \< 40 kg : 3 capsules of 1000 UI per day at induction and 2 capsules of 1000 UI per day at maintenance.~* Weight at inclusion ≥ 40 kg : 4 capsules of 1000 UI per day at induction and 2 capsules of 1000 UI per day at maintenance."
223625249|NCT02186275|DRUG|Vitamin D3 800 UI/day then 800 UI/day|"* Weight \< 40 kg: 2 capsules of 400 UI per day and 1 capsules of placebo at induction and 2 capsules of 400 UI per day at maintenance~* Weight ≥ 40 kg: 2 capsules of 400 UI per day and 2 capsules of placebo at induction and 2 capsules of 400 UI per day at maintenance"
223625250|NCT06443372|OTHER|Clinical periodontal measurements, GCF sampling|"Clinical periodontal measuements included PD, CAL, BOP (+/-), GI, and PI. Clinical recordings were performed at six points (mesiobuccal, buccal, distobuccal, mesiopalatal, palatal, and distopalatal) of all teeth, except the 3rd molars.~GCF samples were obtained 1 day following the clinical measurements. GCF was sampled with paper strips from two deepest pockets in periodontitis group; the most inflamed sites with clinical signs of redness or edema in gingivitis group; and the sites without visible inflammation in periodontally healthy group. GCF and saliva samples were stored at -80 °C until further analysis."
223762290|NCT03343769|OTHER|Measurement of maximal moment of the plantar flexor and dorsiflexor muscles|5-second repetitions
223762291|NCT03343769|OTHER|Measurement of the moment of the plantar flexors and dorsiflexors corresponding to RMS activity during balance measurements|3 10-second repetitions
223762292|NCT04950777|BEHAVIORAL|patient education document|The patient education will be designed to address and investigate the four domains of physical literacy including, knowledge and understanding, motivation and confidence, daily behavior, and physical competence, (i.e., referral based training/PT (passive), self-motivated/directed exercise choice (speaks to child ownership/motivation), simple play outside 60 minutes/day (middle)).
223762293|NCT04415541|BEHAVIORAL|Psychodynamic Psychotherapy|Intensive psychotherapy that is psychodynamically oriented.
223762294|NCT04415541|BEHAVIORAL|Usual Care|Conventional treatment offered in the community.
224214908|NCT05691699|DRUG|Itraconazole|Capsule; oral
224214909|NCT06133699|PROCEDURE|Orchofuniculectomy with simultaneous laparoscopic biopsy of the sentinel lymph node using indocyanine green dye with/without methylene blue dye.|Study participants will undergo orchofuniculectomy through an inguinal or laparoscopic approach. After completion of the orchofuniculectomy, indocyanine green (ICG) dye with or without methylene blue dye will be injected into the spermatic cord stump. Next step is detection with a gamma detector the sentinel lymph nodes and follow removing of one or more (up to 4) lymph nodes during laparoscopy. These lymph nodes will be sent for histological examination.
224214910|NCT06133699|DIAGNOSTIC_TEST|Radiopharmaceutical administration (Technetium/methylene blue)|24 hours before surgery, a radiotracer (RP) will be injected into the spermatic cord followed by SPECT to identify the regional sentinel lymph node(s).
223762295|NCT00477672|DRUG|Pimavanserin tartrate (ACP-103)|10 mg, tablet, once daily by mouth, 6 weeks
223762296|NCT00477672|DRUG|Pimavanserin tartrate (ACP-103)|40 mg, tablet, once daily by mouth, 6 weeks
223762297|NCT00477672|DRUG|Placebo|tablet, once daily by mouth, 6 weeks
224214911|NCT01896700|DRUG|Methylphenidate|Escalating dose of methylphenidate, 20mg, 40mg, 60mg/day, for 2 weeks each
224214912|NCT01896700|DRUG|Placebo|Escalating matched dose of placebo
224214913|NCT01886170|OTHER|Phase II of the Study: Information regarding Current Diabetes Control|Participants will receive information regarding their current diabetes control in different ways depending on their assigned study arm.
224214914|NCT03554642|DEVICE|Walkbot|Walkbot is a Robot Assisted Gait Training System. This system is designed to maximize muscle strength, range of joint motion, and gait function while participants engage in a virtual reality game.
224316728|NCT00369486|DRUG|40mg triamcinolone|Posterior peribulbar injection of 40 mg triamcinolone (Kenalog)
224316729|NCT00369486|DRUG|20mg triamcinolone|Anterior peribulbar injection of 20 mg triamcinolone
223513874|NCT03640624|COMBINATION_PRODUCT|Multidisciplinary treatment|"1. Assessment by gynaecologist and dermatologist, resulting in tailored vulvar care, including daily topical lidocaine 5% ointment. Other topical or oral medication, such as oestradiol cream or oral antidepressants will be prescribed on individual basis.~2. Tailored physiotherapy targeting muscular dysfunction, utilizing: Patient education, pelvic floor muscle exercises (contraction and relaxation), EMG-biofeedback. Low frequent electrical stimulation, massage, stretching and myofascial release and trigger point treatment of the pelvic floor. Desensitization exercises (manually or vaginal dilator). Relaxation and body awareness. Minimum one visit per month.~3. Guided imagery sessions, minimum twice a week using a sound track that is developed for vulvodynia patients."
223513875|NCT03640624|COMBINATION_PRODUCT|Treatment as usual|Treatment as usual in accordance with local guidelines by specialist in gynaecology, including a minimum of two visits (when diagnosis is made and after 3 - 6 months)
223513876|NCT03985995|DRUG|CBD 800 mg p.o|cannabidiol solution 100 mg/ml 8 ml in single-dose containers for per os administration. After a washout period of at least two weeks, the treatment group will be receiving a single-dose of the placebo solution 8 ml as a second intervention.
223513877|NCT03985995|DRUG|Placebo p.o|single dose of oral placebo solution 8 ml matched to the IMP. After a washout period of at least two weeks, the control intervention group will be receiving the cannabidiol solution 100 mg/ml 8 ml as a second intervention.
223513878|NCT05248243|PROCEDURE|Recruitment assessment|"Intervention Details:~Construction of the P/V curve with subsequent measurement of HR and Vmax."
223513879|NCT02390388|PROCEDURE|pudendal nerve block|nerve stimulator-guided Pudendal block
223513880|NCT02390388|PROCEDURE|caudal block|caudal block
223513881|NCT00968968|DRUG|Lapatinib|Oral Lapatinib 1000 mg once daily. Lapatinib was a small molecule, reversible inhibitor targeting HER2 tyrosine kinase receptor.
223513882|NCT00968968|BIOLOGICAL|Trastuzumab|IV Trastuzumab 6 mg/kg every three weeks. Trastuzumab was a humanized, monoclonal antibody directed against the extracellular domain of the HER2 tyrosine kinase receptor.
223625251|NCT03444610|BIOLOGICAL|Blood transfusion escalation rate|3+3 dose escalation (3 patients/cohort) each started on a fixed rate (standard is 5 ml/kg/ hr).1st cohort start at 6ml/kg/hr till complete prescribed volume. Rate escalation by 1ml/kg/each cohort until dose limiting toxicities (DLTs) or max of 10ml/kg/hr. If no DLTs new cohort enrolled at the next planned rate. If DLTs seen in 1 patient in the cohort, another 3 patients treated with the same dose level.1ry phase I end point is maximum-tolerated rate (MTR) of blood transfusion that can be infused safely ( max rate at which 1 or fewer of 3 patients experienced DLT) or dose of 10ml/kg/hr. DLT is transfusion related adverse event lead to stop of transfusion. MTR is highest dose at which no more than 1of 6 patients experienced a DLT.15 additional patients enrolled at MTR to confirm safety.
223625252|NCT00884546|DRUG|BMS-833923|Capsule, Oral, Once daily, 6 months
224214915|NCT03554642|BEHAVIORAL|Physical Therapy|30-minute session of standard physical therapy focused on pre-gait and/or gait training activities 5-days per week during the duration of their stay (14 days).
224214916|NCT03905499|DEVICE|Robotic assisted therapy with MJS (multi joint system) Tecnobody|The intervention will include 18 30-minutes trainings evenly distributed over a time period of 6 weeks and will be administered by the same two physiotherapists at the Schulthess clinic based on the standardized protocol
223625253|NCT00884546|DRUG|Lenalidomide|Capsule, Oral, Once daily, 6 months
223625254|NCT00884546|DRUG|Dexamethasone|Capsule, Oral, Once a week, 6 months
223625255|NCT00884546|DRUG|Bortezomib|Powder, IV, On days 1, 4, 8, 11, 6 months
223625256|NCT04527640|DIETARY_SUPPLEMENT|Synbiotics containing Lactobacillus acidophilus & Bifidobacterium longum 5x10^9 CFU and FOS 60 mg|Patients will undergo baseline examination including medical history and physical examination, blood samples will be collected for hemoglobin, WBC, platelet, urea, creatinine, albumin and indoxyl sulfate level. Patients will be asked to complete 2 questionnaires the PAC-SYM and PAC-QOL questionnaires, and will undergo food recall evaluations by a nutritionist. They will then be given 2 capsules of synbiotics per day for 30 days. After 1 month of intervention, the patients will be evaluated for food recall and side effects. Afterwards, the patients will receive 2 capsules of the same synbiotics per day for the next 30 days. After 2 months of intervention, the patients' history will be taken, they will be asked to complete the PAC-SYM and PAC-QOL questionnaires, undergo food recall examination, and side effects evaluation. Blood samples will be taken for indoxyl sulfate examination.
223625257|NCT04527640|OTHER|Placebo|Patients will undergo baseline examination including medical history and physical examination, blood samples will be collected for hemoglobin, WBC, platelet, urea, creatinine, albumin and indoxyl sulfate level. Patients will be asked to complete 2 questionnaires the PAC-SYM and PAC-QOL questionnaires, and will undergo food recall evaluations by a nutritionist. They will then be given 2 capsules of placebo per day for 30 days. After 1 month of intervention, the patients will be evaluated for food recall and side effects. Afterwards, the patients will receive 2 capsules of the same placebo per day for the next 30 days. After 2 months of intervention, the patients' history will be taken, they will be asked to complete the PAC-SYM and PAC-QOL questionnaires, undergo food recall examination, and side effects evaluation. Blood samples will be taken for indoxyl sulfate examination.
223625258|NCT05924880|DRUG|durvalumab|Durvalumab 1500 mg as a 60-minute IV infusion in combination with gemcitabine-based chemotherapy Q3W. Upon completing chemotherapy, or discontinuing chemotherapy due to toxicity, durvalumab 1500 mg IV Q4W alone or in combination with gemcitabine.
223625259|NCT00194805|BEHAVIORAL|Telehealth for Diabetes Self Management|
223625260|NCT00194805|OTHER|Telehealth for Diabetes Self Management|Web based education format delivered for a six month period
223625261|NCT06971926|BEHAVIORAL|Home visist|Caregivers and children will receive home visits twice a month delivered by the social assistance service within the PI-SUAS/CF during 12 months
223625262|NCT06483230|DEVICE|Intensive Visual Stimulation Device|The therapist installs the patient in front of the device. First, patient puts the healthy side on the table and the therapist records several movements. The software of the device flips the video in order to create a mirrored image of the movement (pretty close to the mirror therapy approach). When all the movements are recorded, patient installs the affected side on the table and the screen is placed over the hand. Likewise, patient has the impression the hand is moving again. Thanks to this action observation principle, therapist can encourage the patient in trying to move again and increase brain plasticity.
223625263|NCT02099864|DRUG|Enzalutamide|Given PO
223625264|NCT05345457|DRUG|Azithromycin Pill|Azithromycin will be dosed as single 500 mg dose (2-250mg oral tablets) administered immediately following randomization, yet prior to discharge to home, followed with 1-250mg oral tablet daily for 4 additional days (for a total of 5 days).
223625265|NCT05345457|DRUG|Amoxicillin Pill|Amoxicillin will be dosed as a single-500mg oral tablet three times daily for 7 days with first dose also being given prior to discharge home.
223625266|NCT05893862|DRUG|MK-8189|Oral Tablet
223625267|NCT05893862|DRUG|Moxifloxacin|Oral Tablet
223625268|NCT05893862|DRUG|Placebo|Oral Tablet
223625269|NCT05915299|DEVICE|OCS Heart|"The TransMedics® Organ Care System (OCS) Heart System is an FDA approved portable extracorporeal heart perfusion and monitoring system.~The OCS Heart System's innovative technology was designed to comprehensively overcome the historical limitations of cold storage. The OCS Heart System expands the utilization of donor hearts by enabling the use of donor hearts deemed unsuitable for procurement and transplantation at initial evaluation due to limitations of cold static cardioplegic preservation."
223625270|NCT02919761|DRUG|Acthar Gel|80 Units Acthar Gel per 1 mL for subcutaneous injection
223625271|NCT02919761|DRUG|Placebo|Matching placebo 1 mL for subcutaneous injection
223625272|NCT00035490|DRUG|Azimilide Dihydrochloride|125 mg azimilide, once a day for one year
223625273|NCT00035490|DRUG|placebo|placebo tablet, once daily for one year
224214917|NCT03905499|OTHER|Usual Care|Patients randomized in the usual care will receive standard of care treatment without receiving any active intervention
224214918|NCT01931137|DRUG|insulin 338 (GIPET I)|Dose level of 8100 nmol will be orally administered as one tablet per dose.
224214919|NCT04608578|BEHAVIORAL|Silver|A serious game to improve mental health in youth
224214920|NCT03140085|BIOLOGICAL|PYO Phage|Intravescial instillation
224214921|NCT03140085|DRUG|Antibiotics|Oral application
224214922|NCT03140085|OTHER|Sterile bacteriology media|Sterile bacteriology media, with identical color as bacteriophage preparation
223625274|NCT00035490|DRUG|Azimilide Dihydrochloride|75 mg azimilide, once a day for one year
223625275|NCT04566471|OTHER|prevalence/incidence|It is an observational study for prevalence/incidence, no intervention provided.
223625276|NCT00751686|PROCEDURE|Stool sample|Collection of the stool at least 48 hours after hospitalisation. Stool samples should be obtained preferably within 4 and no later than 10 days after the onset of the GE symptoms.
223625277|NCT00751686|OTHER|Data collection|Logbook, Health Economic Questionnaire, Telephone call.
223625278|NCT06590090|BIOLOGICAL|Natrunix 400 mg|"The active ingredient of Natrunix is an IgG4 monoclonal antibody indistinguishable from that naturally occurring in an IL-1a-immune healthy human.~Natrunix is formulated as 200 mg/mL sterile liquid in a stabilizing isotonic formulation buffered to pH 7.0. The product is filled into a 2 mL glass pre-filled syringe suitable for subcutaneous injection. The drug product is formulated and buffered to a neutral body pH of 7.0."
223625279|NCT06590090|DRUG|Placebo|Placebo is a sterile liquid solution filled into a 2 mL glass pre-filled syringe, suitable for subcutaneous injection, containing the exact same buffer matrix used for Natrunix drug product
223625280|NCT06590090|DRUG|Methotrexate (MTX)|Methotrexate may be administered in pill form by mouth, as liquid by mouth, or by subcutaneous injection.Subjects enrolled in this study should be receiving a stable minimum weekly dose of 10mg. Weekly methotrexate should not exceed 25 mg/week.
224214923|NCT04647461|DRUG|Brimonidine Tartrate 1.5mg|1 drop 3 times a day for 12 weeks to target eyes
223762298|NCT03978975|BEHAVIORAL|Food intake|"For all those session, subjects will take a standardized breakfast (570kcal) three hours before experimental session.~Control session (CON): subject will stand sited without any activity during 40 min.~Subjects will be submitted to three aquatic cycling exercise session:~* session 27°C :aquatic cycling at 27°C without water jet during 40 min~* session 27°C+ water jets : aquatic cycling at 27 °C with water jets during 40 min~* session 18°C : aquatic cycling at 187°C without water jet during 40 min Every exercise session will be set at 70% of theorical maximal heart rate During each session, oxygen consumption and carbon dioxide production will be analysed with gas analysis system. Appetite and hunger sensation will be measured with a specific scale at different time point of each day of experimental session. Thirty minutes after the end of each experimental session subjects will have a buffet meal for lunch time."
223625281|NCT03852134|PROCEDURE|MOCC Group|After 30 seconds of DCC, the cord will be clamped and cut 5 cm from the introitus in vaginal delivery or abdominal incision in the case of cesarean section before passing the infant with the long umbilical cord segment to the pediatric provider who will milk the cord one time towards the baby during resuscitation.
223625282|NCT03852134|PROCEDURE|DCC Group|"The OB provider will hold the baby at or below the level of placenta, provide warmth, stimulate the baby to breathe and suction the mouth/nose if needed for the first 30 seconds.~After these initial 30 seconds, if the baby is breathing then the obstetrician will continue DCC for a total of 60 seconds before clamping and cutting the cord close to the umbilicus and handing over the baby to the neonatal team for further stabilization as per standard NRP practice. If the baby is not breathing after the initial 30 seconds of DCC, then the OB provider will clamp and cut the cord close to the umbilicus and hand over the baby to the neonatal team to continue resuscitation of the baby as per the standard NRP guidelines."
223625283|NCT01586949|BEHAVIORAL|Daily Challenge|Web-based behavioral intervention aiming to improve individuals' well-being.
223625284|NCT01231958|BEHAVIORAL|The Heart Healthy Initiative for Hispanic Adults (HIP)|This randomized controlled pilot intervention study will include 150 Hispanic adults (45-75y) in the Greater Boston area. Participants will be randomized to either the intervention or control group after completing their baseline interview. The intervention group will receive 6 months of weekly group educational sessions, Zumba fitness classes and interactions with an embodied computer agent (ECA). The fitness classes and interactions with the ECA will continue for the second 6 months of the 1 year intervention. Intervention activities will occur at community centers in the greater Boston area. Control participants will receive standard of care for the first 6 months and will be offered the full intervention (weekly group educational sessions, Zumba fitness classes and interactions with the ECA) for the second 6 months of the study. Participants will complete an interview and blood draw at baseline, 6 months, and 12 months.
223625285|NCT01796925|DEVICE|aura6000 THN System|The aura6000 device is an implanted hypoglossal nerve stimulator designed to maintain wakeful muscle tone of the tongue during sleep. It is implanted through a short surgical procedure. The implant is programmed to provide the optimal stimulation parameters for the patient. The therapy is controlled by a hand-held remote control allowing the patient to start, stop, and pause the therapy during times of sleep.
223625286|NCT06699927|BEHAVIORAL|Span|The training program is a personal device-based adaptive version of a visual working memory span task, either devoid of game elements or embedded in a gamified platform game
223762299|NCT04427969|BEHAVIORAL|prone position|to lay in prone position at least 12 hour in a day at ICU
223625287|NCT06878690|OTHER|Online Questionnaire|Completion of an online questionnaire via the secure RedCap platform
224214924|NCT04647461|DRUG|Brimonidine Tartrate 1.5mg|1 drop 3 times a day for 12 weeks to target eyes
224214925|NCT03523507|DEVICE|Active: rTMS|Daily sessions will consist of 3000 left-sided excitatory pulses at 10 Hz (with 4-second trains and 26-second inter-train interval) followed by 1000 right-sided inhibitory pulses at 1 Hz (in a single train). The DLPFC treatment target will be determined using individualized resting-state network mapping.
224214926|NCT03523507|DEVICE|Sham: rTMS|Daily sessions will consist of the same total number of sham pulses, designed to have similar sound and tactile sensation, without producing active stimulation.
224214927|NCT00117585|OTHER|Treatment Phase 1|"* Patient Education~* Physical Therapy Exercises~* Increased Salt Intake~* Elevation of head of bed with 2-4 inch wedge~* Medication Review by MD, Pharma"
224214928|NCT00117585|DRUG|Treatment Phase 2|"Subjects receive Treatment Phase 2 if they are still orthostatic after receiving Treatment Phase 1.~* Fludrocortisone~* Salt tablet"
224214929|NCT00117585|OTHER|Treatment Phase 3|Subjects still experiencing orthostatic hypotension after receiving Treatment Phases 1 and 2 move on to Treatment Phase 3. Individualized treatment is based on subspecialty or orthostatic hypotension consultation at the medical center. Subjects are followed for the duration of their hospital stay, on average 4 weeks.
224214930|NCT02119182|BEHAVIORAL|In-Person Outcome Assessment|NIH Flexible Outcome Assessment Battery Framework Measures In-Person at 2 Weeks, 6 Months, and 12 Months, and by Phone at 3 Months.
224214931|NCT02119182|BEHAVIORAL|Phone Outcome Assessment|NIH Flexible Outcome Assessment Battery Framework Measures by Phone at 2 Weeks, 3 Months, 6 Months, and 12 Months.
224214932|NCT02119182|PROCEDURE|3T Magnetic Resonance Imaging (MRI)|3T Research MRI at 2 weeks and 6 months.
224214933|NCT02119182|PROCEDURE|Blood Draw for Plasma, DNA, Serum, RNA|Blood Draw for Plasma, DNA, Serum, RNA at baseline, in hospital (if applicable), 2 weeks, and 6 months (DNA at baseline only).
224214934|NCT02501031|DIETARY_SUPPLEMENT|Ground flaxseed|2 tablespoons of ground flaxseed taken daily for approximately 50 days.
224214935|NCT00886782|DRUG|Cdc7-inhibitor|Capsules, Oral, QD x 14 days until MTD is reached, 14d per 28 day cycle/QD 12 months
223513883|NCT04817579|DEVICE|Digital photography combined with eLABor_aid shade analyzing software|ELABor\_aid is a new approach to objective shade communication and shade reproduction in dentistry, based on numeric quantification obtained from standardized RGB (red-green-blue) images, and the formulation of a patient personal shade recipe using trichromatic subtractive color mixing laws, thus abandoning the use of visual assessment and shade guides entirely. This approach is currently enjoying increasing popularity for its ease of use, reliability as well as for its practically oriented features like its imaging ability or the digital try-in.
223513884|NCT04817579|DEVICE|Spectrophotometer|Spectrophotometric measurement methods employing computer calculations, based on color science and theories, allow quantitative evaluation which is objective and appears to be more accurate.
223513885|NCT04817579|DEVICE|Conventional visual shade matching|Visual shade matching is the most common method, in which a color standard from a commercially available dental shade guide is compared to and matched with the target tooth.
223513886|NCT04488094|DRUG|[18F]FSPG|A radioactive dose of 200 MBq of the study drug with a total quantity of ≤ 100 µg will be administered as slow intravenous bolus injection over up to 60 seconds. PET/CT examinations will be performed at 60-75 min after the administration of \[18F\]FSPG.
223513887|NCT02874352|DEVICE|high resolution impedance manometry with Automated Impedance Manometry analysis|
223513888|NCT05354258|DRUG|Albendazole|Anthelminthic drugs for the treatment of soil-transmitted helminths
223513889|NCT05354258|DRUG|Praziquantel|Anthelminthic drugs for the treatment of schistosomiasis
223513890|NCT05354258|DRUG|Amodiaquine|SMC partner drug
223513891|NCT05354258|DRUG|Sulfadoxine pyrimethamine|SMC partner drug
223513892|NCT04085003|PROCEDURE|Endovascular repair or Open surgery|The outcomes of different types of repair will be obtained for intact and ruptured abdominal aortic aneurysm
223513893|NCT03624036|BIOLOGICAL|brexucabtagene autoleucel|CAR-transduced autologous T cells administered intravenously
223513894|NCT03624036|DRUG|Fludarabine|Administered intravenously
223513895|NCT03624036|DRUG|Cyclophosphamide|Administered intravenously
223513896|NCT03409458|DRUG|PT-112|"The RP2D of PT-112 when used in combination with avelumab has been determined during dose escalation and is being confirmed in the NSCLC dose confirmation cohort.~For the NSCLC confirmation cohort, PT-112 will be administered at a dose of 360 mg/m2 on Days 1, 8 and 15."
223513897|NCT03409458|BIOLOGICAL|avelumab|Avelumab will be administered at a fixed dose of 800 mg on Days 1 and 15.
223680551|NCT02889562|DRUG|Apixaban|Study arm that patient can be randomized to. Apixaban is a novel, orally active, potent, direct selective inhibitor of coagulation FXa that directly and reversibly binds to the active site of FXa and exerts anticoagulant and antithrombotic effects by diminishing the conversion of prothrombin to thrombin.
223680552|NCT02889562|DRUG|Warfarin|Study arm that patient can be randomized to. Warfarin therapy has been the mainstay of therapy for patients with POAF. While the duration of therapy is usually short (3-4 weeks), complications of anticoagulation do occur. Additionally, warfarin therapy for POAF is associated with increased length of stay, need for monitoring, and bleeding complications.
223680553|NCT01943474|DEVICE|AccuCath IV Catheter Device|Vascular access and indwelling catheter placement via study device for infusion of fluids and removal of blood samples.
223680554|NCT01943474|DEVICE|Conventional IV Catheter Device|Vascular access and indwelling catheter placement via control device for infusion of fluids and removal of blood samples.
223680555|NCT00358072|BEHAVIORAL|Postremission consolidation based on MRD status|Application of combination chemotherapy aimed to reduce MRD burden in unselected patients, followed by MRD-adjusted therapy that range from maintenance chemotherapy (MRD-negative patients) to allogeneic SCT (MRD-positive patients) or high-dose therapy with autologous blood stem cell support (MRD-positive patients without compatible donor for allogeneic SCT)
223680556|NCT02246712|DRUG|Single oral dose of 100 mg racemic tramadol|Serial blood samples were collected up to 24 h after drug administration; Pain was evaluated at the same time of blood sampling using visual analog scale
223680557|NCT02246712|OTHER|CYP2D6 phenotype|"Patients were phenotyped using metoprolol (100 mg, single oral dose). Urine was collected up to 8 hours after metoprolol administration. Urinary concentrations of metoprolol and alfa-hydroxymetoprolol were determined by high performance liquid chromatography (HPLC), using fluorescence detector.~CYP2D6 phenotyped was determined by alfa-hydroxymetoprolol/metoprolol urinary rato"
223680558|NCT02246712|OTHER|CYP3A phenotype|"A single oral dose of midazolam (15 mg) was administered to all patients. Serial blood samples were collected up to 6 hours after the administration of midazolam.~The concentration of midazolam was determined in plasma in order to calculate midazolam clearance.~The in vivo activity of CYP3A was evaluated by midazolam oral clearance."
223680559|NCT02246712|GENETIC|CYP2B6 genotype|The single nucleotide polymorphism 516G\>T in CYP2B6 gene was evaluated using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP).
223680560|NCT00865488|BIOLOGICAL|ADHEXIL|Adhesions prevention
223680561|NCT04128787|DRUG|AG881 Formulation 1|AG881 uncoated tablets
223680562|NCT04128787|DRUG|AG881 Formulation 2|AG881 film-coated tablets
223680563|NCT04128787|DRUG|Omeprazole|Omeprazole capsules
223680564|NCT01470989|DRUG|ACZ885|canakinumab 150 mg s.c., given on demand upon new flares
223680565|NCT01470989|DRUG|Triamcinolone acetonide 40 mg|Participants received 40 mg intramuscular (IM)
223680566|NCT05409378|DEVICE|The HLT® Meridian® TAVR Valve (Meridian® with TriVentTM Anticalcification Treatment Valve and Pathfinder® Delivery System)|Aortic valve replacement with the HLT Meridian TAVR Valve to treat aortic regurgitation
223680567|NCT03346798|BEHAVIORAL|Food Photography|Participants will engage in food photography on their smart phones while eating
223625288|NCT06716437|BEHAVIORAL|Prehabilitation|"Patients will undergo a physiotherapy-led digitally-enabled prehabilitation program before lung resection surgery.~The intervention will be delivered through a mobile app and supported by tele-health and will consist of:~i) watching six educational videos embedded on the app on relevant topics to prepare for surgery, such as the importance of physical fitness, breathing exercises after surgery, and pain management.~ii) a physical activity coaching program to increase daily activity with feedback iii) a home-based, unsupervised exercise program consisting of 10 whole body strengthening exercises delivered in a video format iv) an inspiratory muscle training program using a hand-held device to be performed twice daily."
223680568|NCT03346798|BEHAVIORAL|Non-Food Photography|Participants will engage in non-food photography on their smart phones while eating
223680569|NCT03346798|BEHAVIORAL|No Phone Use|Participants will not use their smart phones while eating
223762300|NCT05832346|BEHAVIORAL|Laughter yoga programme|"Intervention for intervention group:~This is a 4-week laughter yoga programme (8 sessions) to help adolescents with intellectual and physical disabilities bring more happiness, laughter and joy to promote their mental health status. As laughter yoga therapy can reduce people's levels of stress, anxiety, depression, loneliness, strengthen the immune system and keep the mind positive. Each laughter yoga session will last for 15 minutes and in total there will be 8 sessions for four weeks (two sessions per week). Each laughter yoga session consists of hand clapping warming-up exercise, followed by deep breathing exercise, childlike playfulness exercise, and then laughter exercise. The intervention group also receives routine care provided by special school."
223762301|NCT01974193|DRUG|Floseal|application of floseal on intervention arm
223762302|NCT05309603|OTHER|Loaded Walking High|Walking three miles on a treadmill at a self-selected speed while wearing a backpack with weight carried high on the back
223762303|NCT05309603|OTHER|Loaded Walking Mid|Walking three miles on a treadmill at a self-selected speed while wearing a backpack with weight carried on the mid-back
223762304|NCT05309603|OTHER|Walking|Walking three miles on a treadmill at a self-selected speed
223762305|NCT03571516|DRUG|Teduglutide|SC injection of 0.05 mg/kg teduglutide will be administered QD into abdomen or into either the thigh or arm for 24 weeks.
223762306|NCT03571516|OTHER|Standard Medical Therapy|Standard medical therapy will be administered for 24 weeks.
223762307|NCT03571516|DEVICE|Syringe|Teduglutide will be administered using syringe (510k number: K980987).
223680570|NCT00969280|DEVICE|Standardized Acupuncture|"Acupuncture treatment will be applied 3 times per week, total 9 times for 3 weeks.~According to the guideline of WHO standard acupuncture point locations in the western pacific region, acupuncture treatment will be offered in all 17 acupoints: both BL2, GB14, TE23, Extra-1(Taiyang), ST1 and GB 20, and GV23, and Left SP3, LU9, LU10 and HT8, which are located in periorbit, forehead or temple of the head and Lt. forearm and back of the Lt. foot by a disposable 20\*30mm (Dongbang Co., korea) acupuncture needle.~All the acupuncture needles will be inserted, induced strong 'deqi' sensation and retained for 20 minutes."
224214936|NCT02569840|DIETARY_SUPPLEMENT|Amino Acid Feed|Each child will receive the amino acid based feed for a period of up to 4 weeks (28 days). The feed prescription will be determined on an individual basis by the Dietitian responsible for the child's nutritional management. The child will take the feed orally or via a pre-existing naso-gastric, gastrostomy or jejunostomy tube.
224214937|NCT05528289|DEVICE|AIRVO 2, with conventional symmetric nasal cannula|"The patients will be asked to breathe with HFNC at flow of 40 L/min with the standard cannula~The size of nasal cannula will be selected to occlude patient's nostril of about 2/3.~Temperature will be set according to the patient's tolerance starting from 31°C, up to 37°C, while FiO2 is adjusted to maintain SpO2 between 88 and 92%."
224214938|NCT05528289|DEVICE|AIRVO 2, the new asymmetric nasal cannula|"The patients will be asked to breathe with HFNC at flow of 40 L/min with the new asymmetric nasal cannula~The size of nasal cannula will be selected to occlude patient's nostril of about 2/3.~Temperature will be set according to the patient's tolerance starting from 31°C, up to 37°C, while FiO2 is adjusted to maintain SpO2 between 88 and 92%."
224214939|NCT03118765|DRUG|GSP304 (tiotropium bromide) Inhalation Solution|Once daily (QD) oral inhalation using a nebulizer
224214940|NCT03118765|DRUG|GSP304 Placebo Inhalation Solution|Once daily (QD) oral inhalation using a nebulizer
224214941|NCT03118765|DRUG|Spiriva® Respimat® inhalation spray|Once daily (QD) oral inhalation
224214942|NCT05691673|OTHER|No intervention|Observational during 16 weeks
224214943|NCT05012735|DRUG|Study Cleanser (Neutrogena Ultra Gentle Daily Cleanser with Pro Vitamin B5)|Participants will wash their face with the study cleanser (Neutrogena Ultra Gentle Daily Cleanser with Pro Vitamin B5) for up to 14 days.
224214944|NCT05012735|DEVICE|Prototype Ultrathin Hydrocolloid Bandage|Participants will cover their closed and popped pimples in the evening with one or two bandages from Days 0 through 6.
224214945|NCT00849524|BIOLOGICAL|ISF35|Subjects participating in this study will be treated with multiple doses of Ad-ISF35 given via intranodal injection using a fixed dose of 3.3 x 10\^10 ISF35 viral particles. Intranodal injections will be administered every 2-4 weeks up to six total injections.
224214946|NCT01258816|DRUG|Elacytarabine for infusion|Elacytarabine 2000 mg/m2/d will be administered as a continuous intravenous infusion (CIV) in a d 1-5 q3w schedule.
224214947|NCT01399021|OTHER|Early Drain Removal|Drain will be removed prior to patient's discharge on the day of the surgery
224214948|NCT01399021|OTHER|Late Drain Removal|Patient will be seen on the day following the surgery to have the drain removed
224214949|NCT00802633|DEVICE|Stapling device during radical cystectomy|Hemostasis
224214950|NCT00802633|DEVICE|Ligasure tissue sealing device|Efficacy of tissue sealing device during hemostasis
224214951|NCT04084054|DIAGNOSTIC_TEST|Ultrasound|Ultrasonic measurement of the optic nerve sheath diameter
224214952|NCT02440100|DRUG|PF-06648671|experimental Pfizer compound which will be dosed as oral suspension, once a day for 14 days
224214953|NCT02440100|DRUG|Midazolam|commercial available oral solution of 2 mg midazolam as CYP3A probe substrate for drug interaction evaluation. Midazolam will be given as single dose with and without co-administration of PF-06648671
224214954|NCT02440100|DRUG|Placebo|Matching placebo which will be given as oral suspension, once a day for 14 days
224214955|NCT02818179|RADIATION|THERMOGRAPHY IMAGING|
224214956|NCT00533884|OTHER|Assessment of therapy complications|Assessment of neurocognitive function, functional status, symptom prevalence and distress, and mood alterations
223625289|NCT06887335|PROCEDURE|Deep Sedation Under Proceduralist Direction with Pre-emptive Endotracheal Intubation|"If an eligible subject consents to participate in the study, deep sedation and preemptive endotracheal intubation will be performed, followed by bronchoscopy. Deep sedation will be administered according to the study protocol, with final approval of sedative administration given by the proceduralist. Oxygen will be supplied at a flow rate of 4-6 L/min via a nasal cannula before sedative administration.~To achieve a deep sedation state (Modified Observer's Assessment of Alertness/Sedation \[MOAA/S\] score ≤ 2, defined as the patient not opening their eyes despite repeated verbal stimuli), an initial dose of 50 mcg fentanyl will be administered, followed by 2.5-5 mg of remimazolam. The sedation depth will be assessed every two minutes using the MOAA/S score. If the patient has not reached deep sedation, an additional 2.5 mg of remimazolam will be administered.~Once deep sedation is achieved, lidocaine will be sprayed onto the trachea and bronchi using a bronchoscope for local anesthe"
223625290|NCT06726694|DEVICE|class II molar relation correction by advanced molar distalization appliance|correction of class II molar relation by a novel miniscrews distalizer
223762308|NCT03571516|DEVICE|Needle|Teduglutide will be administered using needle (510k number: K021475).
224214957|NCT00533884|OTHER|Neurocognitive assessment|Assessment of neurocognitive domains: attention/concentration, executive function, verbal learning, verbal memory, verbal fluency
224214958|NCT00533884|OTHER|Quality-of-life assessment|Assessment of quality of life using Cantrill's Ladder at baseline and 3 months post-treatment
223625291|NCT05229484|OTHER|an integrated multimodal lifestyle intervention (MLifeI)|The MLifeI program focused on the roles of health responsibility, review of lipid profile, complications of imbalanced lipid profile, lipid management and nutritional education.
223625292|NCT06837493|OTHER|Resistance based hand exercises and functional task-oriented hand exercise|The interventions for HEG were administered by a physiotherapist over a period of eight weeks, with three sessions conducted each week.
224214959|NCT02011802|DEVICE|Algosteril TM|
224214960|NCT02011802|DEVICE|Sorbact TM|
223762309|NCT06101979|DEVICE|Fortiva Tissue Matrix|Acellular Dermal Matrix used in hernia surgery
224316730|NCT00369486|DRUG|40mg triamcinolone + laser|Posterior peribulbar injection of 40 mg triamcinolone followed after one month by laser
224316731|NCT00369486|DRUG|20mg triamcinolone + laser|Anterior peribulbar injection of 20 mg triamcinolone followed after one month by laser
223625293|NCT06837493|OTHER|Cognitive training|The interventions for CTG were administered by a physiotherapist over a period of eight weeks, with three sessions conducted each week.
223625294|NCT06894342|DIAGNOSTIC_TEST|Ultrasonography|Ultrasonographic evaluation of the masseter muscle
223625295|NCT05086705|DEVICE|EMBr Wave|Use EMBr Wave
223625296|NCT05086705|OTHER|Questionnaire Administration|Ancillary studies
223625297|NCT06895928|DRUG|SHR-A2102|SHR-A2102 for injection.
223625298|NCT06895928|DRUG|Bevacizumab Injection|Bevacizumab injection.
223625299|NCT06895928|DRUG|Adebelimab Injection|Adebelimab injection.
223762310|NCT03569670|DEVICE|Posterior stabilized all-polyethylene tibial component|Patients randomized to this arm will have a Triathlon implant with a posterior stabilized, all-polyethylene tibial component used during surgery.
224214961|NCT02536131|OTHER|Gut-directed hypnotherapy|relaxation technique with hypnotic induction and suggestions aimed at fostering sense of control, acceptance and calming of bowels.
224214962|NCT04881591|DEVICE|Treatment as usual + APP|Participants at this condition will receive the usual medical treatment for their scoliosis but also they will be monitored daily using the Scoliosis Pain Monitor APP. Alarms will be generated in the face of certain preestablished undesired events. Physicians will be asked to call patients and change/stop treatment if an alarm is received.
224214963|NCT01340365|BEHAVIORAL|Tai Chi Exercise|Practicing Tai Chi exercise 4 times a week for 6 months - twice in a classroom and twice independently
224214964|NCT01340365|BEHAVIORAL|Tai Chi|Usual care, individuals attend testing sessions for 6 months with testing at times 0, 3, and 6 months. Individuals in Usual Care receive 3 months of Tai Chi at the study end.
224316732|NCT05815017|DEVICE|Yoomi Physical Therapy Software|Physical Therapy software via a computer/monitor will be set up for the patient. It will begin with a tutorial video for different exercises in the form of games and then ask patients to perform in sequence with prompting and motion tracking. Exercises include Frontal Bicep Curls, Arm Crosses, Press Ups, Arm Rotations, and Basketball Shots.
224316733|NCT00402116|DRUG|enzastaurin|"Phase 1 - 250 mg Cohort 1 with one dose escalation allowed to 500 mg for Cohort 2, oral, daily, 6 weeks then twelve 28 day cycles~Phase 2 - Phase 1 established dose, oral, daily, 6 weeks then twelve 28 day cycles"
224316734|NCT00402116|DRUG|temozolomide|75 milligrams per meter squared (mg/m\^2), oral, daily, 6 weeks then 200 mg/m\^2, oral, daily, twelve 28 day cycles
223625300|NCT06895928|DRUG|Ametinib Mesylate Tablets|Ametinib mesylate tablets.
223625301|NCT06895928|DRUG|Osimertinib Mesylate Tablets|Osimertinib mesylate tablets.
223625302|NCT06841731|DRUG|HRS-8427|HRS-8427 for injection.
223625303|NCT06841731|DRUG|Meropenem|Meropenem for injection.
223762311|NCT03569670|DEVICE|Cruciate retaining all-polyethylene tibial component|Patients randomized to this arm will have a Triathlon implant with a cruciate retaining, all-polyethylene tibial component used during surgery.
224214965|NCT00411801|BIOLOGICAL|Uniplas|Uniplas will be provided frozen in sterile plastic bags.
223762312|NCT02403245|OTHER|Psychosocial stimulation|"Intervention consists in a session of social stimulation during about 40 minutes through where the speaker introduced himself to the residents and introduces the residents to each others. The date of the day was done to residents. Social stimulation consists here to an exercise about the four seasons. Residents are asked to mention the 4 seasons and to give all the characteristics they can about each season. Two exercises were proposed: 4 pictures of landscapes and residents were asked to tell which season is represent on the pictures and pictures of some fruits and residents tried to tell in which season we find the fruits. Finally, the psychologist speaks about the four season of the compositor Vivaldi and propose to the residents to listen some extracts of each pieces of music."
223762313|NCT05881473|DIAGNOSTIC_TEST|pain assessment after clavicular fracture repair|This group includes (40) patients will have medial and lateral clavipectoral (CPB) block ultrasound guided using 20 ml Bupivacaine 0.5% for medial and lateral block equally after induction of general anesthesia.
224214966|NCT00411801|BIOLOGICAL|Cryosupernatant plasma|Cryosupernatant plasma will be provided frozen in sterile plastic bags.
223625304|NCT06937359|OTHER|Reiki healing|Each client received four treatments with Healing Space Reiki Therapy: a foundation of Reiki, combined with a fully customized treatment with trauma processing and adjustments in diet and lifestyle at Dojo In Reiki treatments. In the Dojo In, there were 8 futons, with two Reiki Therapists at each futon treating one client. During these sessions, participants receive 4 Reiki treatments, each lasting about an hour, over 4 consecutive weeks. During these days, 2 trained and/or still training Reiki Therapists per treatment table provide a Reiki treatment under the supervision of the founders of Healing Space.
223625305|NCT06937528|BIOLOGICAL|Extracellular vesicles|Intra-articular extravascular vesicles injection.
223625306|NCT06937138|PROCEDURE|AI-Assisted Screw Path Planning|The trajectory for screw placement during femoral neck fracture fixation will be guided by an AI algorithm based on intraoperative X-ray imaging. The system will automatically suggest the screw entry point and trajectory on the robotic navigation platform. The surgeon will proceed with the operation after confirming the feasibility of the AI-generated plan. In principle, surgeons are advised not to modify the AI-recommended trajectory unless necessary, to preserve the independent evaluative value of the AI-assisted plan. If significant disagreement arises between the surgeon's judgment and the AI-recommended trajectory, a third-party orthopedic specialist-blinded to group allocation-will conduct an independent postoperative assessment of the screw placement's appropriateness and accuracy.
223625307|NCT06937138|PROCEDURE|Surgeon-Directed Screw Path Planning|The screw trajectory will be entirely determined manually by the operating surgeon, based on personal experience and under guidance from the robotic navigation system and intraoperative fluoroscopy, without reliance on any AI recommendation module.
223625308|NCT06938425|OTHER|intratissue percutaneous electrolysis|Using fine needles guided by ultrasound to apply electrical stimulation directly to the affected tissue (for example, damaged muscles or tendons).
223625309|NCT06938425|OTHER|deep dry needling|Insertion of fine needles into muscle trigger points (without injection of drugs) to relieve muscle pain and release tension.
223625310|NCT06938425|PROCEDURE|Standard physiotherapy|It includes manual techniques such as therapeutic massage and mobilization, along with stretching and strengthening exercises to improve range of motion and reduce pain.
223625311|NCT06938633|OTHER|mass spectrometry analysis|The collected urine samples will be analyzed to determine medication adherence during study visits
224214967|NCT05862519|DIETARY_SUPPLEMENT|Reset|Pure for Men Reset is a Vegan, Proprietary Blend of Toxin Eliminating Cleanser: Cascara Sagrada Bark, Senna Leaf, Psyllium Husk, Licorice Root, and Aloe Vera Gel. Taken on Day 1 to Day 5.
224214968|NCT05862519|DIETARY_SUPPLEMENT|Stay Ready Fiber|Stay Ready Fiber is a Vegan, 100% Natural, Proprietary Blend of Digestive Aids: Psyllium Husk, Aloe Vera Extract, Chia Seeds \& Flaxseed. Taken from Day 7 through Day 21.
224214969|NCT05862519|DIETARY_SUPPLEMENT|Libido|Supplement designed to support endurance and increased arousal. Contains L-Citrulline, L-Arginine and Black Pepper Fruit Extract (Piper Nigrum). Taken from Day 7 through to Day 28.
224214970|NCT05862519|DIETARY_SUPPLEMENT|Testosterone supplement|Supplement designed to enhance testosterone production. Contains Ashwagandha, Zinc, Vitamin D, Maca, and Tongkat Ali. Taken from Day 28 through Day 84.
223625312|NCT06938932|OTHER|High temperature exposure|Subjects will be exposed to 35 degree Celsius and 45% relative humidity for 3 hours, resting during the whole periods.
223625313|NCT06938932|OTHER|Moderate temperature exposure|Subjects will be exposed to 24degree Celsius and 45% relative humidity for 3 hours, resting during the whole periods.
223625314|NCT02429830|DEVICE|LINX device|The LINX device is a permanent implant placed at the area of the lower esophageal sphincter (LES) and is designed to augment a weak LES and minimize or eliminate GERD-related symptoms.
224214971|NCT05717283|DIAGNOSTIC_TEST|Nasal swab|We will take nasal swabs from anterior and middle nostril, once a week for each newborn included.
223625315|NCT02696213|OTHER|Systematic, Comprehensive, One to One Training (SCOOT)|An occupational therapist trained by the principal investigator will perform 1.5 hour SCOOT sessions with participants one to two times a week over a period of 6 weeks. SCOOT will provide instruction and practice for performing scooter skills (i.e., instruction on driving, basic and advanced scooter skills) that are embedded in self-selected activities that participants want to perform using their scooters.
223625316|NCT02696213|OTHER|Six Week Delay|Participants will begin the SCOOT intervention after a six week delay.
223625317|NCT01789437|DEVICE|Dexamethasone Intravitreal Implant (Ozuredex)|
223625318|NCT04306263|DIETARY_SUPPLEMENT|Enriched infant formula|Infant formula enriched with dairy ingredients: osteopontin, prebiotics and probiotics
223625319|NCT04306263|DIETARY_SUPPLEMENT|Standard formula|Infants receiving a standard infant formula.
223625320|NCT04306263|DIETARY_SUPPLEMENT|Breastfeeding arm|Infants exclusively or predominantly breastfed (\>75%).
223625321|NCT03167775|DRUG|Elemene Injection/Elemene Oral Emulusion|
223625322|NCT01216137|OTHER|Exercise: Vestibular Rehabilitation|Balance and eye movement training
223625323|NCT01216137|OTHER|Exercise|Bicycle ergometry and stretching
223625324|NCT04721223|DRUG|JAB-3068|JAB-3068 administrated orally as a tablet.
223762314|NCT02264002|DRUG|Cilobradine low dose 1|
223762315|NCT02264002|DRUG|Cilobradine low dose 2|
224214972|NCT01431235|BEHAVIORAL|cognitive behavioral therapy for treating ADHD symptoms|5 sessions of one hour CBT for treating ADHD symptoms by a trained health care worker
224214973|NCT06105619|DRUG|PLB1001|PLB1001 is a capsule in the form of 300mg,twice daily.
224214974|NCT06105619|DRUG|Temozolomide|100-150mg/m2/d,day 1 to 7 and day 15 to 22 of each 28-day cycle
224214975|NCT06105619|DRUG|Cisplatin combined with Etoposide|Cisplatin:80-100mg/m2/3 days,28 days/cycle Etoposide:100mg/m2/d,3 days,28 days/cycle
223762316|NCT02264002|DRUG|Cilobradine medium dose|
223762317|NCT02264002|DRUG|Cilobradine high dose 1|
223762318|NCT02264002|DRUG|Cilobradine high dose 2|
223762319|NCT02264002|DRUG|Metoprolol succinate tablets|
223762320|NCT02264002|DRUG|Placebo|
224214976|NCT01638793|DEVICE|Microcap (Oridion, Needham, MA, USA)|
224214977|NCT01638793|DEVICE|Smart Capno Line Plus O2 (Oridion, Needham, MA, USA)|
224214978|NCT02722824|DEVICE|Electro-stimulation|
224316735|NCT00402116|RADIATION|radiation therapy|1.8-2.0 Gy x 30 fractions, 5 days/week, for 6 weeks
223625325|NCT04721223|DRUG|PD1 inhibitor|JS001 administrated as an intravenous(IV) infusion.
223625326|NCT00003229|BIOLOGICAL|aldesleukin|
223625327|NCT00003229|BIOLOGICAL|gp100 antigen|
223625328|NCT00003229|BIOLOGICAL|tyrosinase peptide|
224214979|NCT02722824|OTHER|Placebo|
224214980|NCT03386149|DRUG|Bosinji|"Product name : Bosinji Granule Manufacturer : Tsumura \& Co. Ingredient : Bosinji granule 2.5g (Bosinji extract 1.523g)~Bosinji extract is composed of following proportion of ingredient~* Rehmannia Root 1.7g~* Achyranthes Root 1.0g~* Cornus Fruit 1.0g~* Dioscorea Rhizome 1.0g~* Psyllium Husk 1.0g~* Alisma Rhizome 1.0g~* Hoelen 1.0g~* Moutan Root Bark 1.0g~* Cinnamon Bark 0.3g~* Pulvis Aconiti Tuberis Purificatum 0.3g"
224214981|NCT03386149|DRUG|Loxonine tab.|Product name : Loxonine tab. Manufacturer : Dong Wha Pharm. Co., Ltd Ingredient : Loxoprofen Sodium 68.1mg (Loxoprofen 60mg)
224214982|NCT03386149|PROCEDURE|Acupuncture|"Acupuncture treatment will be performed on 20 predefined acupoint using 0.25mm x 40mm acupuncture needle. The time for needle retaining is 15 minutes.~1. Both EX-B2 of herniated intervertebral disc level, its upper level and its lower level (6 acupoints)~2. Both side BL24, BL25, BL26, EX-B7, BL28 (10 acupoints)~3. Symptomatic side GB30, GB34, BL57, ST36 (4 acupoints)"
224214983|NCT02953197|RADIATION|FDG-PET guided radiation dose escalation|Selective dose escalation
224214984|NCT05278585|PROCEDURE|RAP TAVI|All patients undergoing TAVI with no pre-existing pacemaker and in sinus rhythm at the time of the procedure will receive RAP by placing the temporary wire in the right atrium
223625329|NCT00948064|DRUG|Vorinostat|200 mg by mouth three (3) times per day with food for 5 days (Days 1 - 5)
224316736|NCT01998945|BEHAVIORAL|Exposure-based Cognitive Behavioral Therapy|Eight 75-minute, in-home sessions delivered twice weekly for 4 weeks of exposure-based cognitive behavioral therapy, a time-limited treatment that focuses on confronting avoided memories and situations and identifying and managing distressing thoughts.
224316737|NCT01998945|BEHAVIORAL|Relaxation Training|Eight 75-minute, in-home sessions delivered twice weekly for 4 weeks of Relaxation Training, that focus on muscle relaxation and diaphragmatic breathing to address the physical symptoms of anxiety.
224316738|NCT04214197|DRUG|Crisaborole 2% Top Oint|Crisaborole is a low molecular weight benzoxaborole PDE-4 inhibitor for the treatment of mild-to-moderate atopic dermatitis in adults and children 2 years and above. Crisaborole ointment 2% is topically applied as a thin layer twice daily for 4 weeks to all AD lesions.
224316739|NCT04588545|RADIATION|Radiation Therapy|Participants will receive radiation therapy (RT), either whole brain radiation therapy or focal brain/spine RT. The goal of RT is to palliate symptoms and improve the flow of Intrathecal (IT) therapy through the cerebrospinal fluid (CSF). As such, various RT schedules and targets are permitted. It is expected that the majority of patients will receive WBRT with 30 Gy in 10 fractions. However, shorter fractions of 20 Gy in 5 fractions of WBRT are permitted. In those patients who have more localized leptomeningeal disease in the spine, focal RT in up to 10 fractions may be administered with the exact dose left up to the discretion of the treating radiation oncologist.
223625330|NCT00948064|DRUG|Azacitidine|75 mg/m\^2/day given intravenously over 15 - 30 minutes daily for 5 days (Days 1 - 5)
223625331|NCT02231515|DEVICE|Selective laser trabeculoplasty (SLT)|Selective laser trabeculoplasty
223625332|NCT02231515|DEVICE|Pattern laser trabeculoplasty (PLT)|Pattern laser trabeculoplasty (PLT)
223625333|NCT02962401|DRUG|Obinutuzumab|"6 cycles every 28 days Cycle 1 :Obinutuzumab 1000mg I.V.(2 parts) 100mg day 1 and 900mg day 2 day 1, 8 and 15~Cycle 2 - 6 :~Obinutuzumab 1000mg I.V.day 1"
223625334|NCT02962401|DRUG|Idelalisib|"6 cycles every 28 days~Cycle 1 :~Idelalisib 150 mg x 2 p.o. day 1 to 28 Cycle 2 - 6 Idelalisib 150 mg x 2 p.o. day 1 to 28 Consolidation Idelalisib alone 150 mg twice a day until day 672 = 2 years after the beginning of the treatment"
223625335|NCT05550779|BEHAVIORAL|Mental Exercise|Participant perform a 10-minute mental exercise
223625336|NCT06551051|DRUG|duloxetine|Patients were treated with duloxetine at a recommended dose of 40mg/day, increasing to a maximum dose of 60mg/day after seven days of non-significant discomfort.
223625337|NCT03349723|DRUG|BI 1265162|Single rising dose groups
223625338|NCT03349723|DRUG|Placebo|Single rising dose groups
223625339|NCT05482139|PROCEDURE|Incisional hernia repair with mesh|open or laparoscopic repairs of incisional hernia with mesh
223625340|NCT00684866|DRUG|Levalbuterol HFA MDI followed by Racemic albuterol HFA MDI|(a) Subjects will receive both treatments: (a) levalbuterol HFA MDI; 45 micrograms (16 cumulative doses); followed by (b) racemic albuterol HFA MDI; 90 micrograms (16 cumulative doses)
223625341|NCT00684866|DRUG|Racemic Albuterol followed by levalbuterol HFA MDI|(a) Subjects will receive both treatments: (a) racemic albuterol HFA MDI; 90 micrograms (16 cumulative doses) followed by (b) levalbuterol HFA MDI; 45 micrograms (16 cumulative doses)
223625342|NCT02923141|BEHAVIORAL|Neutral Writing|
223625343|NCT02923141|BEHAVIORAL|Expressive Writing|
223625344|NCT02923141|BEHAVIORAL|Contingency Management|
223625345|NCT01441999|DEVICE|Less rigid rod|Titanium rod with semi rigid end
223625346|NCT01441999|DEVICE|Rigid Rod|Rigid Titanium rods
223625347|NCT05717361|DRUG|ketamine-lidocaine|"In the KL group, patients will be administered in a total volume of 20 mL,1mL/10 kg of the solution containing ketamine, lidocaine at predefined concentrations.~As maintenance, they will be receiving 1mL/10kg/h of the aforementioned solution"
223625348|NCT05717361|DRUG|Remifentanil|In the Remifentanil group, patients will be administered in a total volume of 20 mL, 2 mcg/kg of fentanyl. As maintenance, they will be receiving 1 mL/10kg/h of a remifentanil solution
223625349|NCT03991221|OTHER|Dental Exam|Visual examination of the child oral cavity bi non-orthodontist experts and orthodontist expert
224214985|NCT01198119|DEVICE|Location of the suspected lesions|"The suspected lesions will be located before the excision, during the surgery.~1. With traditional light~2. NBI technique The images will be recorded and compared"
224214986|NCT01198119|PROCEDURE|Biopsy|In case of suspected lesions detected by the NBI technique, this area is biopsied
224214987|NCT01198119|PROCEDURE|Lesion excision/Surgery|In case of positive biopsy, the suspected lesions is excised
224214988|NCT01574599|OTHER|Occupational therapy- Repetitive Facilitative Exercise|Occupational therapy program - Repetitive facilitative exercise therapy protocol including 40 min of RFE and 20 minutes of task-specific activity. 3 treatment sessions weekly for a total of 4 weeks.
224214989|NCT05824156|BIOLOGICAL|5 mg/kg CM-101|CM-101, Monoclonal Ab blocking CCL24
223625350|NCT03991221|OTHER|Orthodontics consult|Consultation with an orthodontics specialist if a malocclusion requiring early intervention is detected
223625351|NCT03991221|OTHER|Call back at 6 month|Telephone call back at six months of inclusion in the study if a malocclusion requiring early intervention is detected
223625352|NCT00805350|DRUG|Eplivanserin|one 5 mg tablet once a day
223625353|NCT00805350|DRUG|Placebo|Placebo of Eplivanserin one tablet once a day
223762321|NCT02723149|BEHAVIORAL|Marijuana Approach Avoidance Training|Approach Avoidance Training (AAT) is a novel computerized procedure that modifies implicit approach tendencies by training individuals to selectively avoid drug- related stimuli, thereby overriding habitual approach tendencies. Participants are randomized to either the treatment or sham condition. Treatment duration involves 6 training sessions of approximately 15 minutes each (400 trials). AAT requires minimal training and involves only a computer and a joystick, in which participants are either pulling or pushing the joystick when different marijuana or non-marijuana images are displayed with either yellow (pull) or blue (push) border.
224214990|NCT05824156|OTHER|Placebo|Placebo
224214991|NCT02173626|BEHAVIORAL|Mindfulness Training|Participants enrolled on a first-come, first-serve basis, engaging in three 90-minute in person trainings, weekly online video-module trainings, and weekly teleconference coaching calls. Video-module trainings were available at all times, to be accessed at the participants' convenience. Journals and a guided meditation audio library were also provided.
223625354|NCT01095185|DRUG|Simvastatin|Simvastatin 20 mg for 15 days, then 40 mg until the end of the study.
223625355|NCT01095185|DRUG|Placebo|Simvastatin placebo
223625356|NCT04697667|OTHER|Exercise|Supervised exercise program
223625357|NCT04697667|BIOLOGICAL|PRP|Intra-articular PRP injections to knee joint
223625358|NCT00460876|DRUG|Topotecan|
223625359|NCT02741128|BIOLOGICAL|CYD Dengue Vaccine|0.5 mL, Subcutaneous at Day 0, 6 and 12 months, respectively
223625360|NCT02741128|BIOLOGICAL|Placebo (NaCl 0.9%) vaccine group|0.5 mL, Subcutaneous at Day 0, 6 and 12 months, respectively
223625361|NCT03589716|OTHER|Vital Moto Mod|All participants receive vital signs measurement using the Vital Moto Mod device and reference devices. The vital signs measured are blood pressure, heart rate, respiratory rate, oxygen saturation and temperature.
223625362|NCT03589716|OTHER|Welch Allyn Connex Spot Vital Signs Monitor|This is the FDA approved reference device to measure heart rate, SpO2 and temperature.
223625363|NCT03589716|OTHER|Capnostream 20 Portable Bedside Capnograph|This is the reference device to be used to obtain etCO2 waveforms for respiratory rate assessment.
223625364|NCT03589716|OTHER|Welch Allyn 767 Mobile Aneroid Sphygmomanometerand 3M Littmann Master Classic II Teaching Stethoscope|These reference devices will be used together for blood pressure measurements.
223625365|NCT03589716|OTHER|Scifit 1000R cycle ergometer|This is the device that will be used for exercise testing
223625366|NCT05000398|OTHER|Stretching the intrinsic muscles|Participants will be asked to dorsiflex the foot and stretch for 30 seconds. It will be done with 5 repetitions.
223625367|NCT05000398|OTHER|Thumb Abduction with MTF Joint Traction|participants will be held for 30 seconds by passively abducting the thumb within the limits of pain, and will be applied with 5 repetitions.
223625368|NCT05000398|OTHER|Thumb active extension exercise|An elastic band will be placed around the thumb, stretching enough to ensure proper alignment of the thumb and passively correct the position. It will be desired to move the feet away from each other without moving the heels from the ground and the extension movement of the thumbs.2 sets will be performed as 10 repetitions. 30 seconds of rest will be given to prevent fatigue between sets.
223625369|NCT05000398|OTHER|Toe spread out|In the first stage, active finger extension and abduction will be requested while the heel and metatarsal heads are in contact with the ground. In the second stage, while the other fingers are in extension, the smallest finger will be brought laterally and flexed to contact the ground. In the third stage, while in the second stage position, the thumb will be brought into abduction and flexion slowly and contact with the ground will be requested. These 3 phases will be repeated sequentially.2 sets will be performed as 10 repetitions. 30 seconds of rest will be given to prevent fatigue between sets.
223762322|NCT02653651|DRUG|Ketamine|Ketamine infused at 0.1 mg/kg/hour
223762323|NCT02653651|DRUG|Lidocaine|Lidocaine infused at 1 mg/kg/hour
223762324|NCT02653651|DRUG|Placebo|An equal volume of saline
223762325|NCT05231265|OTHER|Walking task|Treadmill walking task with study of fractal variability (complexity) for 10 minutes.
224214992|NCT05045794|DEVICE|VitaSmart Liver Machine Perfusion System|Following donor liver retrieval, preservation using static cold storage, and back table preparation in the transplant center operating room, the organ will be flushed with Belzer UW Machine Perfusion Solution (MPS) and perfused through the cannulated portal vein using cold, actively oxygenated MPS that is circulated at low pressure for 90 minutes to 5 hours. After disconnection from the device, donor liver implantation and reperfusion will proceed in accordance with institutional care standards.
224214993|NCT05045794|OTHER|Static cold storage|Donor liver retrieval and preservation using standard of care cold storage methods
224214994|NCT03806322|OTHER|Intermittent Pneumatic Compression|The group received ultrasound, transcutaneous electrical nerve stimulation, electrical stimulation, exercise, and intermittent pneumatic compression.
224214995|NCT03806322|OTHER|Cold-pack|The group received ultrasound, transcutaneous electrical nerve stimulation, electrical stimulation, exercise, and cold packs.
224214996|NCT01264393|BEHAVIORAL|Shape Up Rhode Island + Online Resources|Participants will receive Shape Up Rhode Island, which is a 12-week statewide physical activity and weight loss campaign in addition to online weight loss resources
224214997|NCT01264393|BEHAVIORAL|Shape Up Rhode Island + Online Weight Loss Program|Participants will receive Shape Up Rhode Island, a 12-week statewide physical activity and weight loss campaign in addition to an online weight loss program
224214998|NCT01264393|BEHAVIORAL|Shape Up Rhode Island + Online Weight Loss Program + Group sessions|Participants will receive Shape Up Rhode Island, a 12-week statewide physical activity and weight loss campaign in addition to an online weight loss program and the option of attending group sessions
224214999|NCT00063960|DRUG|floxuridine|
224215000|NCT00063960|DRUG|irinotecan hydrochloride|
224215001|NCT01773174|DRUG|dabigatran etexilate|age \& weight adjusted equivalent of adult dose
223625370|NCT05000398|OTHER|Short foot|While standing , the medial arch will be raised by trying to bring the metatarsal heads closer to the heel . The patient will be asked to move the big toe closer to the heel without bending the toes and without lifting the heel off the ground.2 sets will be performed as 10 repetitions. 30 seconds of rest will be given to prevent fatigue between sets.
223625371|NCT05000398|OTHER|Heel rise|After taking a 5 cm high tape measure against the wall, the person will be asked to stand up on her heel by at least 5 cm.2 sets will be performed as 10 repetitions. 30 seconds of rest will be given to prevent fatigue between sets.
224215002|NCT00879970|DRUG|pioglitazone|Pioglitazone30 mg and 45 mg tablets are over-encapsulated with Swedish orange size DB-AA capsule shell.
224215003|NCT00879970|DRUG|rosiglitazone|Rosiglitazone 4 mg and 8 mg tablets are over-encapsulated with Swedish orange size DB-AA capsule shell.
224215004|NCT00879970|DRUG|placebo|Placebo to match is Swedish orange size DB-AA capsule filled with white to off-white non-active powder blend.
224215005|NCT00879970|DIETARY_SUPPLEMENT|Vitamin D|Vitamin D factor intervention
224215006|NCT00879970|DIETARY_SUPPLEMENT|Placebo|Vitamin D factor intervention
224215007|NCT03492983|DIETARY_SUPPLEMENT|Intervention group|10 g/day of high cocoa content chocolate for six months.
224215008|NCT03218735|PROCEDURE|Labor induction at 37.0 weeks to 37.6 weeks of gestation|Diagnosis of LGA with induction at 37 weeks 0 days of gestation to 37 weeks and 6 days
224215009|NCT03218735|PROCEDURE|Expectant monitoring and delivery|Diagnosis of LGA with expectant monitoring and delivery as indicated by standard obstetric practices
224215010|NCT02352740|DIETARY_SUPPLEMENT|A form Arginine|3 capsules containing 0.5g of A form of L-arginine (1.5g) 3 times daily (4.5g per day) for 1 week
224215011|NCT02352740|DIETARY_SUPPLEMENT|B form Arginine|3 capsules containing 0.5g of B form of L-arginine (1.5g) 3 times daily (4.5g per day) for 1 week
223762326|NCT04817228|DRUG|EscharEx (EX-02 formulation)|EscharEx (EX-02 formulation) gel is topically applied on a wound surface of up to 80 cm2 , up to 8 consecutive applications or until a complete debridement is achieved, whichever occurs first.
223762327|NCT02480556|PROCEDURE|manual seperation of the placenta|manual separation of the placenta will be done immediately after fetal extraction \& cord clamping, where the fingers of the surgeon will be insinuated between the margin of the placenta and the uterine cavity, then by sawing movement and controlled traction by the other hand till placenta is separated from the uterine cavity
223762328|NCT02480556|PROCEDURE|Conservative separation of placenta|"Conservative separation of placenta:~in group B but following fetal extraction and cord clamping, the placenta will be left insitu \& uterus is massaged awaiting spontaneous placental separation"
223625372|NCT05000398|OTHER|Towel toe curl|Patients will be asked to place their feet on the edge of the towel on the floor. An elastic band will be placed around the thumb, stretching enough to ensure proper alignment of the thumb and passively correct the position. Next, they will be asked to grasp the towel with their fingers, flexing their toes, and forcefully dragging them under their feet.2 sets will be performed as 10 repetitions. 30 seconds of rest will be given to prevent fatigue between sets.
223762329|NCT00259506|BEHAVIORAL|Mindfulness-Based Cognitive Therapy (MBCT)|
223762330|NCT02385175|OTHER|Different objective clinical tests of Eustachian tube function|
223762331|NCT02385175|OTHER|Different patient-completed questionnaires relating to Eustachian tube dysfunction|
223762332|NCT00208195|DRUG|Divalproex ER|
223762333|NCT03810274|DEVICE|3DV+TPS；VARIAN TPS；FonicsPlan|
223762334|NCT01467999|DRUG|Guanfacine|Guanfacine, 4mg given once daily
223762335|NCT04643262|PROCEDURE|Sleeve Gastrectomy|Once the left crus is reached, an optimal exposure of the hiatus is mandatory to find incidental hiatal hernias and a complete dissection of the left crus performed to prevent retained fundus. The greater omentum was opened close to the stomach wall in some part in between the fundus and the antrum to have greater curvature completely detached from the stomach; this dissection starts at 2 cm or \_\_\_\_\_proximal to the pylorus and continued along the greater curvature to the left crus. Posterior adhesions if present, were carefully divided. The left gastrophrenic ligament was divided to expose the angle of His to identify the complete hiatus and fundus. A bougie was positioned before starting resection of the stomach. We use a 36French bougie or --------- we have chosen cartridges Black at the antrum level and finished with a purple cartridge. We always checked the posterior wall before firing.
223762336|NCT05207020|DEVICE|Glycemia estimated by exhaled air analyzer|Measurement of volatile compounds in the air exhaled by the volunteer on 3 different MIBs (3 breaths in total) at 7 times: T0, 30min, 1H, 1H30, 2H, 2H30, 3H after test meal
224215012|NCT06399419|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
224215013|NCT06399419|PROCEDURE|Bone Scan|Undergo bone scan
224215014|NCT06399419|BIOLOGICAL|CBM588 Capsules|Given PO
224215015|NCT06399419|PROCEDURE|Computed Tomography|Undergo CT
224215016|NCT06399419|BIOLOGICAL|Ipilimumab|Given IV
224215017|NCT06399419|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
224215018|NCT06399419|BIOLOGICAL|Nivolumab|Given IV
224215019|NCT00729196|BEHAVIORAL|Lifestyle Modification|Weekly group therapy for 20 weeks, followed by bi-weekly group therapy for 20 weeks
224215020|NCT00401856|DRUG|Eplerenone|50mg oral route
224215021|NCT00401856|DRUG|Placebo|Placebo is identical to eplerenone but the active ingredient is absent
224215022|NCT06479759|DRUG|LM-108 antibody and sintilimab|Cohort 1 receive LM-108 monoclonal antibody combined with sintilimab
224215023|NCT06479759|DRUG|LM-108 antibody and sintilimab and chemotherapy|Cohort 2 receive LM-108 monoclonal antibody combined with sintilimab and chemotherapy for 4-6 cycles. LM-108 monoclonal antibody combined with sintilimab will be maintained
224215024|NCT01431755|DEVICE|Restylane SubQ|Treatment with up to 2 ml of the product
224215025|NCT01431755|DEVICE|Restylane SubQ Lidocaine|Treatment with up to 2 ml of the product
224316740|NCT04588545|DRUG|Pertuzumab|Participants will be treated at 1 of 4 dose levels of pertuzumab, beginning at 10 mg and increasing up to 80 mg or Maximum Tolerated Dose (MTD).
224316741|NCT04588545|DRUG|Trastuzumab|Participants will be treated at a fixed dose of 80 mg trastuzumab.
223762337|NCT05207020|BEHAVIORAL|Questionnaire|The questionnaire focuses on the methods and feelings of the blood glucose self-monitoring that he is currently carrying out, a first feedback on user experience on the operation of the prototype and the collection of his expectations for a future commercial device
223762338|NCT05207020|BIOLOGICAL|Veinous glycemia|Measurement of the veinous glycemia at 7 times: T0, 30min, 1H, 1H30, 2H, 2H30, 3H after test meal
223762339|NCT05207020|BIOLOGICAL|Capillary glycemia|7-step capillary glycemia measurement: T0, 30min, 1H, 1H30, 2H, 2H30, 3H after test meal
223762340|NCT05207020|BIOLOGICAL|constitution biological collection|Sampling for storage of serum at 7 times: T0, 30min, 1H, 1H30, 2H, 2H30, 3H after test meal
223762341|NCT05207020|BIOLOGICAL|Blood sample|Single blood sample before mealtimes for HbA1C molecular analysis
223762342|NCT05207020|OTHER|Test meal|taking a test meal before the various blood sugar measurements
223762343|NCT03806920|DIETARY_SUPPLEMENT|Intervention A|
223762344|NCT03806920|DIETARY_SUPPLEMENT|Intervention B|
223762345|NCT03806920|DIETARY_SUPPLEMENT|Intervention C|
223762346|NCT03806920|DIETARY_SUPPLEMENT|Intervention D|
223762347|NCT02239809|PROCEDURE|Stimulation of the trigeminal nerve (active stimulation)|"Participants will be randomized to active vs. sham stimulation during a period of 24 weeks with a one-way cross over at 12 weeks.~After 12 weeks, the participants receiving active electrical stimulation will continue under active stimulation until completion of the study.~Participants randomized to sham stimulation will be shifted to active stimulation and will be followed-up until completion of the study.~The study will be unblinded after 6 months of randomized stimulation. The second part of the study will be an open label prospective trial for evaluate long-term follow-up. The duration of the open label trial will be more 24 weeks."
223762348|NCT02239809|PROCEDURE|Placebo stimulation of the trigeminal nerve (placebo)|"Participants will be randomized to active vs. sham stimulation during a period of 24 weeks with a one-way cross over at 12 weeks. Patients of the placebo group will be implanted with a lead in the V1 branch of the trigeminal nerve, but will not receive stimulation.~After 12 weeks, the participants receiving active electrical stimulation will continue under active stimulation until completion of the study.~Participants randomized to placebo stimulation will be shifted to active stimulation and will be followed-up until completion of the study.~The study will be unblinded after 6 months of randomized stimulation. The second part of the study will be an open label prospective trial for evaluate long-term follow-up. The duration of the open label trial will be more 24 weeks."
223762349|NCT01742793|DRUG|lenalidomide (Revlimid) and romidepsin (Istodax)|
224215026|NCT02638961|OTHER|IMT|Patients allocated to IMT arm will receive standard medical treatment and will be instructed to train at home twice daily, for 20 minutes each session, and during 12 weeks using a threshold inspiratory muscle trainer (Threshold IMT®, Respironics Inc.). All of them will be instructed by a respiratory therapist and educated to maintain a diaphragmatic breathing during the training period. The subjects start breathing at a resistance equal to 25-30% of their maximal inspiratory pressure (MIP) for 1 week. The respiratory therapist examines the patients at weekly intervals by checking the diary card and measuring their MIP each time. The resistance is modified each session according to their 25-30% of their MIP measured.
224215027|NCT02638961|OTHER|FES|Patients allocated to FES arm will receive standard medical treatment and will be trained in a FES program of both legs by a physiotherapist for 45 minutes a day, 2 days per week for a total of 12 weeks. Eight adhesive electrodes are positioned on the skin over the quadriceps and gastrocnemius muscles of both legs. The stimulator is configured to deliver a direct electrical current at 25 Hz for 5 seconds followed by a 5-second rest. The intensity of the stimulation is adjusted to achieve a visible muscle contraction without discomfort.
224215028|NCT02638961|OTHER|Standard treatment|Patients allocated to this arm will not receive any physical therapy, only standard medical treatment. They will be checked weekly by a physiotherapist who measures their maximal inspiratory mouth pressure each time.
224316742|NCT01822626|BEHAVIORAL|motivational counseling|A family pediatrician-lead counselling was offered to children assigned to the intervention group. The counselling program consisted of 5 motivational interviews based on Stages of Change Theory. Child and family always had to leave the meeting having agreed two objectives, one concerning food and one physical activity improvements, clearly defined and achievable. During each subsequent interview was assessed the degree of achievement of the objectives of the previous meeting. Based on the assessment the objective could be reinforced or redefined. After each change the objectives were recorded.
224316743|NCT04778904|BIOLOGICAL|ChAdOx1-HBV|Chimpanzee Adenovirus Oxford 1-vectored Hepatitis B virus vaccine
224316744|NCT04778904|BIOLOGICAL|MVA-HBV|Modified Vaccinia Ankara-vectored Hepatitis B virus vaccine
224215029|NCT00316576|PROCEDURE|Blood sampling for PCR|
224215030|NCT04358731|BIOLOGICAL|NmCV-5|"The NmCV-5 is a fixed-combination available as the lyophilized powder containing meningococcal groups A and X polysaccharides conjugated to tetanus toxoid and meningococcal groups C, W and Y polysaccharides conjugated to CRM197 protein. The vaccine will be reconstituted with normal saline just prior to administration.~The NmCV-5 lyophilized powder component contains sucrose, sodium citrate and trometamol as excipients. This component is presented as a freeze-dried powder in a single dose vial. No preservative or adjuvant is present in the vaccine.~The normal saline diluent is a sterile clear colorless liquid in a single dose glass ampoule."
224215031|NCT04358731|BIOLOGICAL|Menactra|The control vaccine is the licensed meningococcal serogroups ACYW conjugate vaccine (Menactra), manufactured by Sanofi Pasteur Incorporated. Menactra is supplied as a single 0.5 mL dose formulated in sodium phosphate buffered isotonic sodium chloride solution to contain 4 mcg each of meningococcal A, C, Y, and W polysaccharides conjugated to approximately 48 mcg of diphtheria toxoid protein carrier. No preservative or adjuvant is added during manufacture.
224215032|NCT01770197|DRUG|IV rt-PA|IV rt-PA treatment
224215033|NCT03966196|OTHER|Measurements of oxygen saturation and finger pressure during deep inspiration|Measurements during deep inspiration of oxygen saturation with pulse oximeter and finger pressure with pressure cuff
224316745|NCT04778904|BIOLOGICAL|Nivolumab|Human immunoglobulin G4 monoclonal antibody
223625373|NCT05000398|OTHER|Gastrocnemius active static stretching exercise|The patient will be placed on the wall at eye level, 50 centimeters away from the wall. The leg that is desired to be stretched will be brought back, while the knee is straight, it will be requested to flex the front leg. During the test, it will be requested that the back heel does not rise from the ground and wait 30 seconds. 5 repetitions to be done
223762350|NCT01076829|OTHER|Spice polyphenols|spice
223762351|NCT00386412|DRUG|Valganciclovir|900 mg/ 12 h oral, 2 weeks 900 mg/ 24 h oral, 2 weeks
223625374|NCT05000398|OTHER|Plantar fascia and gastrocnemius stretching exercise on step|The patient will be asked to place both feet on the step and slowly stretch the heel downwards until a stretch is felt in the arch of the foot and wait 30 seconds. 5 repetitions will be done
223625375|NCT01649349|DEVICE|two-piece nasogastric tube|one week period
224215034|NCT06530992|OTHER|tucking break|"All participants will provide a semen sample for sperm analysis after 2-7 days of abstinence from ejaculation, a venous blood sample will be taken at the same time, and quality of life will be assessed using a questionnaire.~Participants in the study group are then asked to refrain from tucking or wearing tight underwear for at least 73 days. At least 73 days (10.5 weeks) after the first spermiogram, another semen collection is scheduled after 2-7 days of abstinence from ejaculation for the preparation of a spermiogram, a venous blood sample is taken at the same time, and quality of life is assessed in all participants. At this point, depending on the participant's wishes, it is possible to perform sperm cryopreservation for fertility preservation before starting gender affirming hormonal treatment."
224215035|NCT03479242|OTHER|no interventions|no interventions are planned
224215036|NCT06247293|PROCEDURE|intraperitoneal hyperthermic perfusion chemotherapy|"（1）Partial hepatectomy: The reasonable resection method was selected according to the tumor location, residual liver volume and the operation process. The tumor margin should be more than 1 cm, the abdominal cavity was flushed with sterile warm distilled water. In the control group,1-2 abdominal drainage tubes were placed on the hepatic cross-section, in the exposed group,4 abdominal perfusion tubes were placed in the right hepatic apex, splenic fossa, left and right pelvic cavity to perform HIPEC postoperatively.~(2) HIPEC: Temperature setting:43 °C perfusion time:60 min, perfusion speed:400-600 mL/min ,perfusion volume:3000 mL.~（3）Hepatic artery embolization：Through the common femoral artery, the catheter passed through the abdominal aorta, celiac trunk, the common hepatic artery and the inherent hepatic artery to the blood supply target artery of liver cancer. The embolic agent Lipiodol was mixed and injected to embolize the bleeding artery to stop bleeding."
224215037|NCT00437437|DRUG|Brivanib|Tablet, Oral, Brivanib 800 mg, QD after single dose Pk comparison of food effect, until progression
223625376|NCT01404741|PROCEDURE|allogeneic stem cell transplantation|donor available, after 4 cycles 5-azacytidine allogeneic stem cell transplantation after reduced conditioning
223625377|NCT01404741|PROCEDURE|5-azacytidine until progress|if no donor available 5-azacytidine until progress or toxicities
223625378|NCT05378165|OTHER|Music group|The study was divided into three stages; before; during; and after colonoscopy. Patient's hemodynamics parameters, including systolic and diastolic blood pressures, heart rate, and oxygen saturation, were measured about 5 to 10 min before, during and within 10 min after the colonoscopy procedure was complete. All of the patients who participated in the study underwent the standard protocol used in the Endoscopy Unit of our institution. Colonoscopy was performed on patients in all groups without the use of anesthesia. After positioning the patients in the left lateral position for the colonoscopy procedure, and vemcain local anesthetic and vaseline was applied to the anal area before starting colonoscopy using a Fujinon flexible colonoscope. The music group listened to Acemasiran-type classical Turkish music.Acemasiran-type music affects the human brain and provides a sense of creativity to people. This musical tone has pain- relieving and antispasmodic
223680571|NCT00969280|DEVICE|Non-acupuncture point shallow penetration acupuncture|"Acupuncture treatment will be applied 3 times per week, all 9 times for 3 weeks.~Acupuncture treatment will be offered in 17 non-acupuncture points by a disposable 20\*30mm acupuncture needle. A strong 'deqi' sensation will not be induced, but inserted acupunctures will be leaved for 20 minutes."
223680572|NCT04288544|DIETARY_SUPPLEMENT|Microalgae|Open, monocentric intervention study in crossover design
223680573|NCT04288544|DIETARY_SUPPLEMENT|Omega-3-fatty acid capsule|Open, monocentric intervention study in crossover design
223680574|NCT04288544|DIETARY_SUPPLEMENT|sea fish|Open, monocentric intervention study in crossover design
223680575|NCT01705782|BIOLOGICAL|E. coli endotoxin, US standard|
223680576|NCT04935450|DIAGNOSTIC_TEST|Bronchoalveolar lavage|Low volume Broncho alveolar lavage. During optic flexible bronchoscopy through the tracheal tube or the tracheostomy cannula a maximum of 4 aliquots of 20 ml normal saline will be instilled in a wedged position in the right medium lobe of the patients and then aspirated untill reaching a total of 25ml of fluid (BALF) for analysis
223680577|NCT04441762|DRUG|Intravenous Ketorolac Tromethamine|30 mg ketorolac single dose
223680578|NCT04441762|DRUG|Intranasal Ketorolac Tromethamine|30 mg ketorolac single dose
223680579|NCT01809977|PROCEDURE|collagen cross-linking procedure (total removal)|patients underwent Corneal collagen cross-linking procedure with totally corneal epithelium removing. Total removal was performed by mechanical debridement of the corneal epithelium over the central 9 mm.
223680580|NCT01809977|PROCEDURE|collagen cross-linking procedure (partial removal)|patients underwent Corneal collagen cross-linking procedure with partially corneal epithelium removing. Partial removal was performed by removing a 3-mm width ring and leaving the central 3 mm of the cornea intact.
223680581|NCT00070733|DRUG|testosterone enanthate|
223680582|NCT00070733|DRUG|duastride|
223680583|NCT05996991|OTHER|Positive expectation speech regarding spinal manipulative therapy|Patients will watch a short video with positive expectations regarding spinal manipulative therapy.
223680584|NCT05996991|OTHER|Neutral expectation speech regarding spinal manipulative therapy|Patients will watch a short video with neutral expectations regarding spinal manipulative therapy.
223680585|NCT05996991|OTHER|Negative expectation speech regarding spinal manipulative therapy|Patients will watch a short video with negative expectations regarding spinal manipulative therapy.
224215038|NCT03956511|OTHER|Spontaneous Breathing Trial|It involves placing an infant from invasive mechanical pressure limited time cycled ventilation ventilation to endotracheal continuous positive end-expiratory pressure (ET-CPAP) for a period of 5 minutes during which saturation and heart rate are closely monitored. The infant would pass the test if there is no hypoxia or bradycardia during the test. If the infant has either bradycardia for more than 15 seconds and/or a fall in SpO2 below 85% despite a 15% increase in FIO2, the study will be stopped and ventilation will be restarted.
223625379|NCT05378165|OTHER|Stress ball group|"The study was divided into three stages; before; during; and after colonoscopy. Patient's hemodynamics parameters, including systolic and diastolic blood pressures, heart rate, and oxygen saturation, were measured about 5 to 10 min before, during and within 10 min after the colonoscopy procedure was complete. Colonoscopy was performed on patients in all groups without the use of anesthesia. After positioning the patients in the left lateral position for the colonoscopy procedure, and vemcain local anesthetic and vaseline was applied to the anal area before starting colonoscopy using a Fujinon flexible colonoscope. The stress ball group was given stress balls which was medium hard and made of high-quality silicone approximately 10 minutes before colonoscopy. The patients in stress ball group were instructed to squeeze the balls twice after counting up to five and repeat until the end of the entire procedure."
223625380|NCT05378165|OTHER|Video group|"The study was divided into three stages; before; during; and after colonoscopy. Patient's hemodynamics parameters, including systolic and diastolic blood pressures, heart rate, and oxygen saturation, were measured about 5 to 10 min before, during and within 10 min after the colonoscopy procedure was complete.~All of the patients who participated in the study underwent the standard protocol used in the Endoscopy Unit of our institution. Colonoscopy was performed on patients in al groups without the use of anesthesia. After positioning the patients in the left lateral position for the colonoscopy procedure, and vemcain local anesthetic and vaseline was applied to the anal area before starting colonoscopy using a Fujinon flexible colonoscope. Video group allowed to watch a licensed virtual reality application,A walk on the beach, through an Android mobile phone placed in Cardboard Super Flex Goggles, started 10 minute before the colonoscopy until the procedure was completed."
223625381|NCT05378165|OTHER|Control group|"The study was divided into three stages; (1) before; (2) during; and (3) after colonoscopy. Patient's hemodynamics parameters, including systolic and diastolic blood pressures, heart rate, and oxygen saturation, were measured about 5 to 10 min before, during and within 10 min after the colonoscopy procedure was complete.~All of the patients who participated in the study underwent the standard protocol used in the Endoscopy Unit of our institution. Colonoscopy was performed on patients in al groups without the use of anesthesia. After positioning the patients in the left lateral position for the colonoscopy procedure, and vemcain local anesthetic and vaseline was applied to the anal area before starting colonoscopy using a Fujinon flexible colonoscope. Control group, without any additional intervention."
223625382|NCT02973100|DRUG|Dulaglutide|Administered SC
223625383|NCT02973100|DRUG|Placebo|Administered SC
223625384|NCT01419769|DEVICE|AXIOS Stent & Delivery System|"The AXIOS Stent \& Delivery System study is a prospective, multi-center, non-blinded, single-arm(nonrandomized) study that will be conducted at up to 10 sites in the United States, European Community and/or Japan will enroll a total of 24 patients. A majority of the patients will be enrolled in the United States.~Patients between the age of 18 and 75 scheduled for endoscopic drainage of symptomatic pancreatic pseudocysts that are equal or greater than 6 cm in diameter, adherent to the bowel wall, and have ≥ 70% fluid contents are potential study candidates.~Study patients will undergo the following clinical follow-up evaluations of study endpoints conducted at 30 days, 60 days, 1 week post stent removal and possibly at 3 and 6 months post stent removal."
223625385|NCT00878501|DRUG|AZD1386|oral, during 4 weeks
223625386|NCT00878501|DRUG|AZD1386|oral, during 4 weeks
223625387|NCT00878501|DRUG|Placebo|Oral, during 4 weeks
223625388|NCT05410522|DEVICE|EMS Program|Lower limb electrostimulation therapy is scheduled for lung transplant patients. The therapy consists in the application of 2 daily 30-minute sessions that begin in the first 48 hours post-transplantation and are maintained daily until discharge from the hospital.
223625389|NCT00960622|DRUG|Truvada|Truvada (tenofovir 300mg / emtricitabine 200mg) capsule once daily for 6 months
223625390|NCT00960622|DRUG|Combivir|Continue on Combivir (150 mg of lamivudine, 300 mg of zidovudine) two tablets daily for 6 months
223625391|NCT00960622|DRUG|Trizivir|Continue on Trizivir (300 mg of abacavir as abacavir sulfate, 150 mg of lamivudine, and 300 mg of zidovudine)
223625392|NCT00799786|BEHAVIORAL|Building Better Caregivers Online Workshop|
223625393|NCT03562364|OTHER|AlterG anti-gravity treadmill|The AlterG treadmill is an FDA approved device that allows patients to perform early partial weight bearing exercises in a tightly controlled and safe environment
223625394|NCT04985617|OTHER|Warmed Fluids|The IV fluid given to the patients in the intervention group was heated to 36ºC using the medical heating device.
223625395|NCT01650532|BEHAVIORAL|Yoga Condition|Classes lasting one hour, held 3 times per week for 8 weeks.
223625396|NCT01650532|BEHAVIORAL|Stretching Condition|Classes lasting one hour, held 3 times per week for 8 weeks.
223625397|NCT05893745|OTHER|Supervised Exercise Program|Participants in the control group will receive a supervised exercise program that consists of three weekly sessions in addition to home exercises, over the course of four weeks. This program will include stabilization, flexing, extension, and rotation exercises for the cervical region and self-mobilization targeting the deep neck muscles. Participants will be instructed to perform the exercises at home three times a week in a manner that did not cause pain.
223625398|NCT05893745|OTHER|Supervised Exercise Program plus Dermoneuromodulation Techniques|Participants in the study group will receive the same supervised exercise program as the control group, with home exercises, in addition to two dermoneuromodulation techniques for the Dorsal Cutaneous Nerve (C3-T1), which are the skin stretch technique and kitten technique. Patients in this group will receive 3 sessions/week for a total of 4 weeks.
223625399|NCT00852683|DRUG|Pregabalin|75 mg twice a day
223625400|NCT00852683|DRUG|Placebo|75 mg twice a day
224215039|NCT01749033|OTHER|Group 1 Classic|"Active Comparator: Group 1 classic~Group 1 Using the classic inserting technique and completely deflated LMA recommended in the LMA manual."
224215040|NCT01749033|OTHER|Group 2 pre-inflated|Group 2 (pre-inflated): Using the recommended inserting technique with the pre-inflated volume that exists in a LMA (Laryngeal Mask Airway) from the manufacturer.
223625401|NCT02941081|DIETARY_SUPPLEMENT|IHAT|1 dose/day single IMP containing IHAT powder bioequivalent to 12.5 mg Fe (i.e. 20 mg Fe taking into account IHAT's relative bioavailability to FeSO4)
223625402|NCT02941081|DIETARY_SUPPLEMENT|Ferrous Sulphate|1 dose/day single IMP containing FeSO4 powder equivalent to 12.5 mg Fe
223625403|NCT02941081|OTHER|Placebo|1 dose/day containing a placebo powder (no-iron, 'sugar' compound)
223625404|NCT00812708|DEVICE|Morcher iris diaphragm implantation|Surgical implantation of Morcher iris device(s)
223625405|NCT01082016|OTHER|Sleep Enhancement Program (SEP)|Sleep promotion in the ICU Multifaceted tool to promote sleep in ICU patients
223625406|NCT02266368|DEVICE|Antimicrobeal coated stents|Patients in the intervention arm will undergo placement of (Silver Sulphdiazine) antimicrobeal coated stents
223625407|NCT01959503|DEVICE|Progel Vascular Sealant|
223625408|NCT01959503|DEVICE|Gelfoam Plus|
223625409|NCT05641337|DRUG|Insulin Degludec and Insulin Aspart|The hypoglycemic scheme of the experimental group was that the initial dose of Insulin Degludec and Insulin Aspart was 0.3U/kg multiplied by the patient's weight, plus 5 mg of linagliptin and 0.5 g of metformin three times a day. The control group was treated with traditional four needle insulin.
223625410|NCT05482997|DIETARY_SUPPLEMENT|Whey Protein Concentrate|whey-based protein powder 32g powder mixed with 8-12 oz water
223625411|NCT05482997|DIETARY_SUPPLEMENT|Pea Protein Isolate, Rice Protein Concentrate, Hemp Protein|plant-based protein powder. 32g powder mixed with 8-12 oz water
223625412|NCT02857517|DRUG|conbercept|0.05ml conbercept
223625413|NCT01600326|PROCEDURE|Tenotomy (no injection)|Subjects randomized to this group will fill out a pre-treatment pain survey and have a blood draw They will be be contacted by the investigator by telephone or email on day 7 and day 14 to complete another pain survey. Subjects must avoid non steroidal anti-inflammatory medications for 2 weeks before the study. Two weeks after enrollment subjects see their referring physician to begin physical therapy.
223625414|NCT01600326|DRUG|Ultrasound guided platelet rich plasma injection|"Subjects will fill out a pre-treatment pain survey, then will undergo ultrasound and have blood drawn from their arm.~The blood sample will be separated into blood cells and plasma. The plasma portion of the blood (liquid minus the cells) will be injected into the tendon under sterile conditions. Ultrasound will help guide the injection. This is called Ultrasound guided platelet rich plasma injection.~Subjects will be be contacted by the investigator by telephone or email on day 7 and day 14 to complete another pain survey. Subjects must avoid non steroidal anti inflammatory medications for 2 weeks before the study and 2 weeks after the study.~Subjects will see their referring physician two weeks after treatment to begin physical therapy."
223625415|NCT03043014|DRUG|Mifépristone versus Misoprostol|The women will be randomized into two groups: Mifépristone group and Misoprostol group. The main endpoint will be the per-operating pain. The other endpoints are the pre and post-operative pain, the complications (cervical tearing, uterine perforation, hemorrhage requiring the use of blood products or an hemostatic intervention), the surgical time necessary to terminate the pregnancy, the side-effects of the drugs. The amount of per-operating bleeding and the duration of the intervention . The investigators assume that the use of Mifepristone in the cervical preparation of the surgical abortion under LA would reduce the per-operating pain. The number of patients required is 55 in each arm.
224215041|NCT01749033|OTHER|Group 3 ELL-PIC|Group 3 (ELL-PIC): Using the ELL-PIC technique
224215042|NCT03577119|DIETARY_SUPPLEMENT|Full-fat yogurt|Controlled diet that includes three daily servings of whole (3.25% fat) yogurt.
224215043|NCT03577119|DIETARY_SUPPLEMENT|Non-fat yogurt|Controlled diet that includes three daily servings of fat-free yogurt.
224215044|NCT03886428|OTHER|100% portion size|Entree portion size 100% of baseline
223625416|NCT01414803|DRUG|Lipid modification|rosuvastatin 10 mg/fenofibrate 160 mg per day
223762352|NCT05289609|PROCEDURE|Liver Transplantation|Individuals with end-stage liver disease will be subjected to liver transplantation from deceased or living donors
223762353|NCT03044197|DEVICE|MRI/ultrasound transperineal prostate biopsy|3-6 targeted biopsy cores from each prostate region of interest
223762354|NCT03044197|DEVICE|transrectal ultrasound-guided prostate biopsy|12 systematic biopsy cores
223625417|NCT01414803|DRUG|Lipid modification|rosuvastatin 10 mg per day
224215045|NCT03886428|OTHER|125% portion size|Entree portion size 125% of baseline
224215046|NCT03886428|OTHER|150% portion size|Entree portion size 150% of baseline
223625418|NCT03484754|BIOLOGICAL|botulinum toxin|injection of botulinum toxina in two different facial sites
223625419|NCT03128294|OTHER|Retrospective, cross-sectional descriptive analysis|This study is a retrospective, cross-sectional descriptive analysis, and concerns the extraction of data from anonymised patient files. A database will be constructed and descriptive statistics will be used to summarise the data.
223762355|NCT05090761|DRUG|Bupivacaine 0.25% Injectable Solution|Injection of Bupivacaine 0.25% Injectable Solution for SAPB
223762356|NCT05090761|DRUG|Bupivacaine 0.25% Injectable Solution, Magnesium Sulfate 150 mg|Injection of Bupivacaine 0.25% Injectable Solution for SAPB Addition of 150 mg of Magnesium Sulfate as adjuvant
223762357|NCT05090761|DRUG|Bupivacaine 0.25% Injectable Solution, Magnesium Sulfate 150 mg, Buprenorphine 300 mcg|Injection of Bupivacaine 0.25% Injectable Solution for SAPB Addition of 150 mg of Magnesium Sulfate and 300mcg Buprenorphine as adjuvants
223762358|NCT03376243|OTHER|LIPIKAR BAUME AP+ emollient|Structured education on prevention guidelines
223762359|NCT00749931|DEVICE|MarginProbe|Device use to assess margin status of the excised specimen surface.
223762360|NCT00749931|PROCEDURE|Lumpectomy|Standard of care lumpectomy procedure
223762361|NCT05112666|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Retrospective cohort analysis using Clinical Practice Research Datalink (CPRD) GOLD and Aurum Hospital Episode Statistics (HES)-linked datasets in UK.
223762362|NCT05112666|DRUG|other DOACs|Retrospective cohort analysis using CPRD GOLD and Aurum HES-linked datasets in UK.
224215047|NCT03886428|OTHER|175% portion size|Entree portion size 175% of baseline
224215048|NCT04518449|PROCEDURE|medial border along the left side of SMA|to place the medial border along the left side of SMA in laparoscopic D3 lymphadenectomy for right colon cancer
224215049|NCT04518449|PROCEDURE|medial border along the left side of SMV|to place the medial border along the left side of SMV in laparoscopic D3 lymphadenectomy for right colon cancer
223625420|NCT06378944|OTHER|Application of green indocyanine colorant|The day of the surgery 1 ml of green indocyanine colorant will be applicated periareolar. After 5 minutes the lymph node will be detected and extracted
223625421|NCT06378944|DRUG|Technetium99|Application of a periareolar injectionof TEchnetium 99 in order to detect the axillary lymph node
223625422|NCT00848809|PROCEDURE|Blood sample|9 blood samples will be sent to the laboratory for the subjects in the SLED cohort
223625423|NCT00848809|PROCEDURE|Blood sample|10 blood samples will be collected and sent to the laboratory for the subjects in the intermittent hemodialysis cohort.
223625424|NCT06078241|DRUG|Intravenous lidocaine infusion|Intravenous lidocaine infusion
223625425|NCT06078241|OTHER|Erector spinae plane block (ESPB)|Unilateral erector spinae plane block
223625426|NCT06078241|OTHER|Intravenous infusion of normal saline|Intravenous infusion of normal saline
223625427|NCT06078241|OTHER|ESPB with normal saline|Unilateral ESPB with normal saline
223625428|NCT04696120|DRUG|Apixaban|Patients who are randomly assigned to apixaban group will receive apixaban 5mg or 2.5mg bid
223625429|NCT04696120|DRUG|Placebo|All patients who are assigned to placebo group will receive placebo
223625430|NCT00077246|DRUG|paclitaxel albumin-stabilized nanoparticle formulation|
223625431|NCT05734027|DEVICE|Sectional matrix|The sectional matrix is the best way to achieve a strong contact point in Class II restorations with composite resin in the posterior dental sector. The pre-wedging is essential to get a separation between teeth which avoid the matrix deformation during its insertion
223762363|NCT05112666|DRUG|LMWH|Retrospective cohort analysis using CPRD GOLD and Aurum HES-linked datasets in UK.
223625432|NCT05734027|DEVICE|Circumferential matrix|Circumferential matrix (thickness 0.038mm) ,the band encircle the tooth and secured by retainer on the buccal and lingual aspect
223625433|NCT05642351|OTHER|Autobiographical reminder|"The analysis of the specificity of Autobiographical Recall will be done through the following scale, developed for the study:~* 6 points for a recall involving a single personal event located in space AND time (e.g.,I remember when my parents took me to the sea for the first time..in 1962..in Dunkerque)~* 5 points for a recall involving a single personal event located in space OR time (I remember when my parents first took me to the sea...in 1962)~* 4 points for a recall involving a single personal event but without spatial/temporal details (I remember when my parents took me to the sea for the first time)~* 3 points for a recall involving a general personal event but located in space AND time (we used to go to Dunkerque in the summer)~* 2 points for a recall involving a general personal event but located in space OR time (we used to go to Dunkerque)~* 1 point for a recall involving a general personal event without spatial/temporal details (we used to go on vacation)"
223625434|NCT06046924|OTHER|Fruits and vegetables (F+V)|Participants will receive a prescribed amount of F+V designed to reduce their dietary acid intake by half. This typically amounts to 2-4 cups/day for each participant randomized to this group, depending on the type of F+Vs used, provided in weekly allotments. Participants will receive standard care for their medical concerns.
223625435|NCT06046924|DRUG|NaHCO3 Tablets|Participants will receive 0.4 mEq/kg bw NaHCO3 /day, an amount designed to match the alkali provided by the added F+V. This will be provided as 650 mg NaHCO3 tablets for an average of 4-5 tablets/day in 2 divided doses for each participant randomized to this group. Participants will receive standard care for their medical concerns.
223625436|NCT06046924|OTHER|Usual Care|Participants will receive standard care for their medical concerns and no additional alkali (F+V or NaHCO3).
223625437|NCT01796340|BEHAVIORAL|Food cue exposure|Participants will be exposed to several kinds of their favorite food. The aim of this exposure is to increase the food cravings as much as possible.
223762364|NCT04431791|DRUG|Regorafenib|oral regorafenib
223625438|NCT01796340|BEHAVIORAL|Psycho-education|General information about nutrients, calories, exercise and the energy balance will be provided. In addition, psychological problems that accompany overweight will be discussed.
223625439|NCT02161770|DRUG|AZD9291 tablet dosing|Part A - single 80mg oral dose AZD9291 (administered as 1 80mg tablet). Part B - 80mg oral dose AZD9291 od.
223625440|NCT02161770|PROCEDURE|Pharmacokinetic sampling - AZD9291|Blood sampling to measure AZD9291 pharmacokinetic parameters.
223625441|NCT02161770|PROCEDURE|Pharmacokinetic sampling - AZ5140 and AZ7550|Blood samples to measure the pharmacokinetic parameters of AZ5104 and AZ7550.
223762365|NCT04431791|DRUG|Fruquintinib|oral fruquintinib
223762366|NCT04935476|DRUG|Dapsone 85 mg PO BID|Participants will receive standard of care and study medication Dapsone 85 mg per os (PO) twice daily for 21 days. If a dose is missed, it will not be replaced.
223762367|NCT04935476|DRUG|Placebo 85 mg PO BID|Placebo oral tablet, twice daily for 21 days.
223762368|NCT00974714|DRUG|L-arginine|Oral L-arginine 2 g twice a day for 14 weeks
224215050|NCT02530879|DRUG|Omeprazole, Lansoprazole, Esomeprazole, Rantidine|1.Omeprazole- Dose range oral, 20mg once a day, up to 40mg twice a day 2.Lansoprazole-Dose range 15mg per day- 30mg twice a day 3.Esomeprazole- Dose range oral, 20mg once a day, up to 40mg twice a day 4.Rantidine-Dose range: 150 mg twice a day or 300 mg
223625442|NCT05862753|DRUG|induction by Etomidate bolus|General anesthesia induction by Etomidate bolus with different concentration in either of the two arms. First arm, has the concentration (0,2 mg/kg) commonly used of Etomidate to induce anesthesia. Second arm, has the concentration (0,3 mg/kg) usually proposed in medical literature.
223625443|NCT06403787|DRUG|Aerobic exercise + Ginkgo Biloba Extract|12 weeks of intervention for the participants, divided into 3 stages implementing an exercise adaptation period. The adaptation period will span the first 4 weeks of the intervention, during which participants will be brought to an intensity between 50% and 60% of their maximum heart rate (HRmax). From week 5 to 8, the HRmax range will be increased from 60% to 70%, and during the last 4 weeks, it will be maintained at 70% of HRmax combined with 240 mg of LIFE EXTENSION® brand ginkgo biloba extract in 120 mg tablets
223625444|NCT06403787|DRUG|Aerobic exercise + Calcined magnesia (placebo)|12 weeks of intervention for the participants, divided into 3 stages implementing an exercise adaptation period. The adaptation period will span the first 4 weeks of the intervention, during which participants will be brought to an intensity between 50% and 60% of their maximum heart rate (HRmax). From week 5 to 8, the HRmax range will be increased from 60% to 70%, and during the last 4 weeks, it will be maintained at 70% of HRmax combined with calcined magnesia (homogenized to the same weight of ginkgo biloba)
223625445|NCT06403787|DRUG|Aerobic exercise + Atorvastatin|12 weeks of intervention for the participants, divided into 3 stages implementing an exercise adaptation period. The adaptation period will span the first 4 weeks of the intervention, during which participants will be brought to an intensity between 50% and 60% of their maximum heart rate (HRmax). From week 5 to 8, the HRmax range will be increased from 60% to 70%, and during the last 4 weeks, it will be maintained at 70% of HRmax combined with 20 mg of atorvastatin
223625446|NCT06333249|BIOLOGICAL|rAAV2tYF-GRK1-RPGR|Adeno-associated virus vector expressing a human RPGR gene
223625447|NCT05213975|DEVICE|Kinesio tape|Kinesio taping
223625448|NCT06272240|OTHER|Ovarian Cancer Organoids|To characterize in vitro interactions and molecular pathway among tumor cells, immune cells, and resident microbiota (intratumoral bacteria and/or microbial-derived molecules)
223625449|NCT00149877|DRUG|Tegaserod|
223625450|NCT01716286|DIETARY_SUPPLEMENT|low fat vs. essence yoghurt|
223625451|NCT06333184|OTHER|Food|Fruit ingested in whole form or as either commercially available, or home-made smoothies
223625452|NCT02324881|BEHAVIORAL|Telephone-Based Intervention|Use PSMA
223625453|NCT02324881|OTHER|Questionnaire Administration|Ancillary studies
223625454|NCT04529733|DEVICE|IB10 sphingotest PCT+|Whole blood in EDTA for procalcitonin POC testing on IB10 sphingotest PCT+ device
223625455|NCT03770234|DRUG|Transtec 35 µg/hour transdermal patch|Transdermal patch containing 20 mg buprenorphine in an active surface area of 25 squared centimeters. Buprenorphine release rate 35 µg/hour.
223625456|NCT02113696|DIETARY_SUPPLEMENT|Omega 3 intake, morbid obesity|Individuals of both sexes with ages between 18 and 65 years took 3g of omega 3, and 1.8g eicosapentaenoic acid (EPA) and 1.2g docosahexanoic acid (DHA) for 8 weeks.
224215051|NCT02530879|BEHAVIORAL|Voice therapy|Evaluation is completed over two, one-hour sessions. Once the evaluation is complete, the subject will begin weekly, individual voice therapy for 55 minute sessions per week with a second year graduate student under the direct supervision of the clinical faculty member.Treatment sessions will include a counseling component and an active exercise program.
223625457|NCT02113696|DIETARY_SUPPLEMENT|Placebo Capsules|They received gelatin (colorless) capsules. A nutritional evaluation was performed, a 24-h recordatory was applied to verify macro and micronutrients intake, biochemical evaluation before and after the intervention. Macro and micronutrients were calculated using the Avanutri 2.0 system. Clinical history was verified through a questionnaire previously filled out by a physician.
224215052|NCT02530879|OTHER|Combination of anti-reflux medication and voice therapy|Subjects will receive both anti-reflux medication as detailed above and voice therapy as detailed above.
224215053|NCT03998774|BEHAVIORAL|Evaluate the anxiolytic effect during dental care with MEOPA in children|"Primary Purpose: The main objective of this study is to evaluate the anxiolytic effect of EMONO in children during dental care.~Enrollment: 30"
224215054|NCT02693600|PROCEDURE|Ligamentoplasty with partial trapeziectomy|
224215055|NCT02693600|PROCEDURE|Ligamentoplasty with total trapeziectomy|
224316746|NCT02896712|BEHAVIORAL|Acceptance and Commitment Therapy (ACT)|ACT will assist cocaine patients to notice internal cravings and triggers, abandon attempts to manage these triggers via active avoidance, suppression or other control-based strategies, and to make commitments to engage in behaviors consistent with chosen values or goals. ACT encourages clients to experience thoughts and feelings from an observer perspective, and helps clients not to believe distressing thoughts and feelings as if those thoughts and feelings are literally true and in need of action. ACT treatment will be based on the ACT therapy manual developed and tested previously.
223625458|NCT04823403|DRUG|Nivolumab|Intravenous Nivolumab (1mg/kg) will be given every 6 weeks for a maximal period of 6 months within the study.
223625459|NCT04823403|DRUG|Ipilimumab|"Ipilimumab, single intra-arterial (IA) injection per patient, at 3 dose-levels\*.~* (D1) Starting dose : 50 mg; n=3 to 6~* (D2) 2nd dose-level : 100 mg; n=3 to 6~* (D3) Maximal tested dose : 150mg; n=3 to 6 (if no limiting toxicities) \*Dose level (D-1) : 25 mg will be tested if de-escalation is needed at D1 (\>1/3 DLT at D1)"
223625460|NCT02389166|DEVICE|Optiflow|"Patients receive high flow oxygen delivery system, Optiflow, conventional clinical management and sequential used of NIV for a period of 36 hours at least.~High flow oxygen nasal therapy (Optiflow) : The flow will be set at 40l/min to 60l/min The inspired fraction of oxygen (FiO2) is the same as that defined at the end of VNI session and may be adjusted in order to obtain a SaO2 between 94% and 98%."
223625461|NCT02389166|DEVICE|Conventional oxygen therapy|Patients receive conventional oxygen therapy with high concentration mask, conventional clinical management, and sequential use of NIV Conventional oxygen therapy: The inspired fraction of oxygen (FiO2) is the same as that defined at the end of VNI session and may be adjusted in order to obtain a Arterial Oxygen Saturation (SaO2) between 94% and 98%.
223625462|NCT02476149|PROCEDURE|Corneal Cross-linking|All participants recruited for the study will be scheduled for corneal crosslinking treatment
223625463|NCT06390722|DRUG|Upadacitinib|Oral Tablet
223625464|NCT06390722|DRUG|Placebo for Upadacitinib|Oral Tablet
223625465|NCT01372709|DEVICE|Ovation™ or Ovation Prime™ Abdominal Stent Graft System|Single occurrence permanent implant of AAA device.
223762369|NCT00974714|OTHER|placebo|oral placebo 2 g twice a day for 14 weeks
223762370|NCT01470391|PROCEDURE|Adductor-Canal-Blockade|US-guided Adductor-Canal-Blockade with Ropivacaine
223762371|NCT01470391|PROCEDURE|Femoral Nerve Block|US-guided Femoral Nerve Block with Ropivacaine
223625466|NCT04419025|DRUG|N-acetylcysteine|Oral formulation: 600 mg capsules of N-acetylcysteine
223762372|NCT01153581|DRUG|Ganirelix acetate|Ganirelix acetate: .25 ml/day by subcutaneous injection
223762373|NCT01153581|DRUG|17β-Oestradiol|17 beta estradiol: 0.2 mg/day (patches)
223762374|NCT01153581|DRUG|Progesterone|progesterone, 200 mg day-1 oral
223762375|NCT00989833|DRUG|budesonide|400 yg x 1
223762376|NCT00989833|DRUG|terbutaline|0.4 mg as-needed
223762377|NCT00989833|DRUG|budesonide/formoterol|160/4.5 yg as-needed
223762378|NCT02518477|OTHER|exercise|progressive resistance training
223762379|NCT04784286|OTHER|Telemedicine 30-day post-op visit|Consented subjects randomized to the telemedicine visit arm will do their 30-day post-op visit via secure telemedicine video application through the Center of Connected Care. A survey will be asked via telephone about their post-op care visit, costs incurred, and feedback.
223625467|NCT03224130|OTHER|Nurse Phone Call|We will complete a single center, parallel, randomized, standard-of-care-controlled prospective study to determine the efficacy of a one-time nurse phone call, an intervention adapted from those studied in other populations (i.e., adults, high-risk infants), in improving pediatric patient transitions from hospital to home
223625468|NCT03224130|OTHER|Standard of Care|Control patients will be randomized to receive standard-of-care at discharge. This care at our institution includes pediatric hospitalist to PCP (primary care physician) verbal and written communication prior to discharge, written documentation for the family regarding prescribed medication regimen, recommended follow-up with outpatient PCP and relevant consultant(s), and delivery of prescribed medications from the hospital pharmacy to the patient's bedside.
223625469|NCT02985827|DRUG|Rohto (r) Hydra|Rohto (r) Hydra; Over the counter Eyedrop, 1 gtt OU single-masked in-office dose
223625470|NCT02985827|DRUG|Systane (r) Ultra|Systane (r) Ultra; Over the counter Eyedrop, 1 gtt OU single-masked in-office dose
223625471|NCT02198014|OTHER|Manual Therapy|"5 minutes. Thermotherapy shallow to 50 cm away from the knee. 15 minutes. Joint traction, grade I-II. Fixation of distal femur with cinch and manual fixation of proximal tibia. Patient in prone position and the traction is carried out in the submaximal ranges of flexion and extension.~10 minutes. Passive muscle stretching of quadriceps (within the limits of mobility), through compression muscle, passive muscle stretching and relaxation of muscle.~10 minutes. Isometric and resisted exercises of quadriceps, in submaximal ranges, of flexion and extension.~10 minutes. Proprioception exercises with unipodal support, with and without visual support, and posterior destabilization.~10 minutes. Local cryotherapy with ice pack."
223625472|NCT02198014|OTHER|Educational Physiotherapy|"* Theory. Introduction to hemophilia: clinic and treatment; Anatomy and biomechanics of knee; Anatomy of ankle musculature; Function of muscles and haematomas treatment; Haemarthrosis, synovitis and arthropathy: clinical manifestations; Proprioception: definition and importance in hemophilia; and Physical activity and sport: risks and benefits.~* Practice: exercises in favor of gravity; active exercises for mobility and pain management; knee proprioception exercises; isometric and isotonic exercises of quadriceps; swimming and cycling technique."
223625473|NCT05119777|DEVICE|HArmonyCa Injectable Gel|Subdermal or deep dermal injection
223625474|NCT05849142|DEVICE|MRIdian Linac|Radiation therapy (RT) will be delivered with an integrated MRI-RT delivery system (MRIdian Linac). Participants will then receive standard-of-care RT with a dose prescription of 70 Gy in 35 fractions on the MRIdian Linac. Adaptive RT (ART) planning will occur every 5th fraction of RT.
223625475|NCT03886285|OTHER|Questionnaire|Completion of the questionnaire by the patient after consultation with the general practitioner
223625476|NCT05366335|DRUG|Live Combined Bifidobacterium and Lactobacillus|The invesitigators give patients Live Combined Bifidobacterium and Lactobacillus solution infusion during their colonoscopy examination for a single time in the Live Combined Bifidobacterium and Lactobacillus group.
223625477|NCT05366335|DRUG|Normal saline|The invesitigators give patients normal saline as a placebo infusion during their colonoscopy examination for a single time in the control group.
223762380|NCT04784286|OTHER|In-Person 30-day post-op visit|Consented subjects randomized to the in-person visit arm will physically come to a clinical visit with the bariatric surgery midlevel providers. A survey will be asked via telephone about their post-op care visit, costs incurred, and feedback.
223762381|NCT02469610|OTHER|Intercostal block Bupivacaine based|Intercostal Bupivacaine block of 100ml over five intercostal spaces.
223762382|NCT00040885|BIOLOGICAL|infliximab|
223762383|NCT00040885|DRUG|docetaxel|
224215056|NCT01853007|BEHAVIORAL|COACH Program|
224215057|NCT00068237|PROCEDURE|salivary gland transfer|Seikaly and Jha method of submandibular salivary gland transfer at the time of surgery for the primary tumor and neck nodes on Day 1
224215058|NCT00068237|RADIATION|Post-operative radiation therapy|Dose ranging from 54-70 Gy over 5.5-7 weeks, at 2.0 Gy/fraction. Starts within 4-6 weeks of surgery.
223762384|NCT00040885|OTHER|placebo|
223625478|NCT05366335|DRUG|Basic treatment|The invesitigators give patients general treatment and drug treatment including oral Live Combined Bifidobacterium and Lactobacillus tablets as basic treatment.
223625479|NCT03287791|DRUG|Generic Azelaic Acid Foam|Topical foam, generic formulation of the brand product.
223762385|NCT03301324|DEVICE|Intubation Assist Dashboard|The ZOLL X Series Intubation Assist Dashboard feature guides the operator through a three-step auscultation process to verify the proper placement of an endotracheal tube.
223762386|NCT00584038|BEHAVIORAL|educational instruction and phone follow-up|Educational instruction and phone follow-up.
223762387|NCT00584038|BEHAVIORAL|educational instruction in clinic|Educational instruction in clinic.
223762388|NCT01637350|PROCEDURE|digestive tract reconstruction|Subtotal gastrectomy with BillrothⅠ or BillrothⅡ, total gastrectomy with jejunal interposition or Roux-en-Y reconstruction
223762389|NCT02419118|DRUG|Daratumumab|Treatment of myeloma patients with Daratumumab
223762390|NCT02419118|DRUG|Lenalidomide|Treatment of myeloma patients
223762391|NCT02419118|DRUG|Dexamethasone|Treatment of myeloma patients
223762392|NCT01243346|DRUG|Crenolanib besylate (CP-868,596-26), Dose: 140mg BID|Highly potent inhibitor of both PDGFR receptors alpha and beta
223762393|NCT00969293|DRUG|FOV2302 (Ecallantide)|"Single intravitreal injection into the relevant eye.~Five dose levels will be studied from 5 to 90µg and a maximum of 6 subjects will be included at each dose level.~Duration of Treatment: Single injection with 3 months follow-up."
224215059|NCT03453502|BEHAVIORAL|Quality improvement of breast milk feeding|During the Intervention phase and Sustainability phase ,The NICUs will receive training of multiple evidence based quality improvement methods.
224215060|NCT01019109|DEVICE|Posterior Spinal Fusion Device: Titanium rod arm used titanium rods, and CoCr rod arm used Cobalt Chrome rods as a part of the construct.|PASS LP Implant System is designed to contribute to correction and surgical stabilization of the thoracic, lumbar and sacral spine only. These implants are designed to stabilize the spine during normal development of solid bony consolidation which takes about 18 months. The internal fixation devices are composed of screws, hooks,rods, plates, cross links, connection and locking devices. The range of different sizes and shapes of the implants allows the surgeon to adapt to the pathology and morphology of each of his patients.
223625480|NCT03287791|DRUG|Finacea® (Azelaic Acid) Foam|Topical foam, brand product.
223625481|NCT03287791|DRUG|Vehicle Foam|Topical foam, placebo. Has no active ingredient.
223625482|NCT03287791|OTHER|Cleanser|A mild cleanser provided to participants, so they can wash their face prior to applying the study drug.
223625483|NCT03287791|OTHER|Sunscreen|Sunscreen provided to participants, so they can apply it to their face when outdoors.
223625484|NCT03287791|OTHER|Towel|A soft towel provided to participants, so they can pat their face dry after washing and prior to applying the study drug.
223625485|NCT03287791|OTHER|Moisturizing Lotion|Moisturizing lotion provided to participants, so they can apply it to their face, as needed.
223625486|NCT00966836|DRUG|Pre-emptive strategy with valganciclovir plus everolimus|Patients will be monitored for CMV infection and receive valganciclovir only for positive PCR or antigenemia. Everolimus plus cyclosporine and prednisone will be used for maintenance immunosuppression
223625487|NCT00966836|DRUG|Prophylaxis with valganciclovir plus mycophenolate|Patients will receive 3 months of oral valganciclovir with mycophenolate and standard cyclosporine and prednisone for maintenance immunosuppression
223625488|NCT00966836|DRUG|Prophylaxis with valganciclovir plus everolimus|Patients will receive valganciclovir for 3 months after transplant. Everolimus plus reduced cyclosporine and prednisone will be used for maintenance immunosuppression
223762394|NCT03880851|RADIATION|Plan adaptation of Radiation Treatment in case of anatomical changes|Image guided radiotherapy is given to 60Gy in 20 fractions. Intervention: Radiation treatment plan adaption in case of volume changes of target volume or not meeting OAR constraints due to volume changes.
223762395|NCT04044417|PROCEDURE|currettage|open flap debridement
223762396|NCT04044417|DRUG|curcumin simvastatin paste|Curcumin is the primary active constituent of turmeric. Simvastatin is chemical modification of lovastatin.
223762397|NCT04044417|DRUG|EDTA root conditioning|EDTA is an aminopolycarboxylic acid and a colourless, water-soluble solid
224215061|NCT00825669|DRUG|TACE|TACE: The chemotherapeutic drugs and 2 to 10 ml lipiodol are given via hepatica propria artery. The chemotherapeutic drugs include 5-Fu 1500 mg, epirubicin 30 mg, cisplatin 30 mg.
224215062|NCT00825669|PROCEDURE|Laser ablation|Laser ablation is given to the PVTT.
224215063|NCT00262184|DRUG|Soy Isoflavone|
224215064|NCT02813785|DRUG|Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody|Atezolizumab will be administered at a fixed dose of 1200 milligrams (mg) via intravenous (IV) infusion on Day 1 of each 21-day cycle.
224215065|NCT02813785|DRUG|Docetaxel|Docetaxel will be administered as 75 milligrams per square meter (mg/m\^2) via IV infusion on Day 1 of each 21-day cycle.
223762398|NCT01926795|PROCEDURE|Short leg cast|
223625489|NCT00966836|DRUG|Pre-emptive mycophenolate|Patients will be monitored for CMV infection and receive valganciclovir only for positive PCR or antigenemia. Mycophenolate plus standard cyclosporine and prednisone will be used for maintenance immunosuppression
223762399|NCT01926795|PROCEDURE|No Immobilization|
223762400|NCT06975176|BEHAVIORAL|Stigma reduction intervention|"Care providers will complete the Stigma Reduction Intervention curriculum. The intervention is a multi-day stigma reduction training program for providers.~Content design is greatly informed by materials developed in our pilot R34 study, and which may be modified prior to the intervention if the team gains new insights from the baseline round of unannounced visits and each of the two CABs. Briefly, the intervention consists of both didactic and experiential learning components. Didactic sessions include instruction on syphilis epidemiology, clinical management, and public health significance. Experiential sessions include discussion sessions that are facilitated by pre-recorded videos, followed by role play with trained SPs."
223762401|NCT00573027|PROCEDURE|noninvasive tests|clinically indicated coronary angiography with adenosine coronary flow reserve measurement and acetylcholine provocative testing in the cardiac catheterization laboratory; Peripheral Artery Tonometry (PAT) testing; Cardiac Magnetic Resonance (CMR) imaging.
223762402|NCT04219865|DRUG|Group 1: Compound Edaravone/Placebo Injection|Compound Edaravone 30mg-600mg (containing edaravone 30 mg and 2-aminoethanesulfonic acid 600 mg) / placebo single intravenous infusion for 30min
223762403|NCT04219865|DRUG|Group 2: Compound Edaravone/Placebo Injection|Compound Edaravone 60mg-1200mg (containing edaravone 60 mg and 2-aminoethanesulfonic acid 1200 mg) / placebo single intravenous infusion for 30min
223762404|NCT04219865|DRUG|Group 3: Compound Edaravone/Placebo Injection|Compound Edaravone 90mg-1800mg (containing edaravone 90 mg and 2-aminoethanesulfonic acid 1800 mg) / placebo single intravenous infusion for 30min
223762405|NCT04219865|DRUG|Group 4: Compound Edaravone/Placebo Injection|Compound Edaravone 120mg-2400mg (containing edaravone 120 mg and 2-aminoethanesulfonic acid 2400 mg) / placebo single intravenous infusion for 30min
223762406|NCT04219865|DRUG|Group 5: Compound Edaravone/Placebo Injection|Maximum tolerated dose of drug / placebo for a single intravenous infusion for 30 minutes three times a day at an interval of 8 h until the last dose on the morning of Day 3, after which the sequential test drug 30 mg-600 mg / placebo will be administered daily from Day 3 night Intravenous infusion, 30 minutes at 12-hour intervals until morning on Day 7
223762407|NCT05278429|DEVICE|Myosuit robotic device|The Myosuit is a partially soft, exoskeleton-type, wearable robot that supports the synergistic extension of the hip and knee joints.
223762408|NCT01806896|DRUG|PF-02545920|"* Dose will be titrated up every 2 days by 5mg increments: 5mg Days 1-2, 10mg days 3-4, 15mg days 5-6, and reach 20 mg from Days 7 to Day28.~* Orally, approx. Q12H (range 10-14 hours), administered at least one hour prior to, or two hours after meals.~* Treatment for 28 days."
223762409|NCT01806896|DRUG|Placebo|"\- Orally, approx. Q12H (range 10-14 hours), administered at least one hour prior to, or two hours after meals.~Dosing for 28 days."
223625490|NCT03441477|DEVICE|Nidek Tonoref III|The auto ref/kerato/tono/pachymeter TONOREF III is a medical device which measures objective refractive errors, corneal curvature radius, intraocular pressure and corneal thickness of the patient's eye.
223625491|NCT03441477|DEVICE|Haag-Streit Goldmann Manual Tonometer|Haag-Streit Goldmann Manual Tonometer measures intraocular pressure to aid in the screening and diagnosis of glaucoma
223625492|NCT03441477|DEVICE|NIDEK CEM-530|Nidek CEM-530 is a non-contact ophthalmic microscope, optical pachymeter, and camera used for examination of the corneal endothelium and for measurement of the thickness of the cornea.
223625493|NCT00144807|DRUG|rituximab|
223625494|NCT00144807|DRUG|doxorubicin|
223625495|NCT00144807|DRUG|cyclophosphamide|
223625496|NCT00144807|PROCEDURE|autologous stem cell transplantation|
223625497|NCT02506543|BEHAVIORAL|COMPASS|COMPASS (Creating Opportunities through Mentoring, Parental involvement and Safe Spaces) is a program for 13-19 year old girls in three refugee camps in Ethiopia. The program is a structured intervention that is intended to engage adolescent girls, through life skills training and establishing or supporting community-supported safe spaces for girls where they can come and gather among themselves and participate in a structured life-skills curriculum.
223762410|NCT01806896|DRUG|PF-02545920|"* 5mg dose~* Orally, approx. Q12H (range 10-14 hours), administered at least one hour prior to, or two hours after meals.~* Dosing for 28 days."
223762411|NCT01806896|DRUG|Placebo|"* Orally, approx. Q12H (range 10-14 hours), administered at least one hour prior to, or two hours after meals.~* Dosing for 28 days."
223762412|NCT05982535|DEVICE|Easy Dew MD Regen Cream|The subject applies the provided medical device twice a day (morning and evening) to areas with symptoms of dry skin so that it can be absorbed well.
223762413|NCT02922270|OTHER|Peritoneal dialysis patients at the Istanbul Medical Faculty|The aims of this study were to evaluate patient and technique survival rates, investigate peritonitis rates and evaluate factors affecting mortality in peritoneal dialysis (PD) patients over a period of 20 years at Istanbul Faculty of Medicine Peritoneal Dialysis Unit.
223762414|NCT02434770|BIOLOGICAL|BBIBP Bivalent Oral Poliomyelitis Vaccine Lot 1|Each dose of bOPV (2 drops, 0.1 ml) contains attenuated Sabin strains of poliovirus serotypes 1 and 3, with at least 10\^6 cell culture infectious dose 50% (CCID50)/dose and 10\^5.8 CCID50/dose, respectively.
223762415|NCT02434770|BIOLOGICAL|BBIBP Bivalent Oral Poliomyelitis Vaccine Lot 2|Each dose of bOPV (2 drops, 0.1 ml) contains types 1 and 3 attenuated polioviruses (Sabin), with at least 10\^6 CCID50/dose and 10\^5.8 CCID50/dose, respectively.
223625498|NCT02506543|BEHAVIORAL|No intervention|Wait list control group will not receive an intervention. After the follow-up study, the wait-list control group will receive the regular COMPASS program
223625499|NCT01512485|DRUG|Clopidogrel|Clopidogrel Tablets 75 mg
223625500|NCT05529108|DIETARY_SUPPLEMENT|control biscuits|Consumption of plain biscuits everyday during intervention period.
223625501|NCT05529108|DIETARY_SUPPLEMENT|autoclaved BSG-containing biscuits|Consumption of autoclaved BSG-containing biscuits everyday during intervention period.
223625502|NCT05529108|DIETARY_SUPPLEMENT|bio-transformed BSG-containing biscuits|Consumption of bio-transformed BSG-containing biscuits everyday during intervention period.
223762416|NCT02434770|BIOLOGICAL|BioFarma Bivalent Oral Poliomyelitis Vaccine|Each dose of the WHO prequalified Bio Farma bOPV (2 drops, 0.1 ml) contains attenuated Sabin strains of poliovirus serotypes 1 and 3, with at least 10\^6 and 10\^5.8 infective units per dose, respectively.
223762417|NCT03672695|COMBINATION_PRODUCT|S 64315 (also referred as MIK665) and venetoclax|"The treatment combination period can only begin after the planned dose of venetoclax is reached. Depending on the administration dosing schedule, the combination treatment at the planned doses may be preceded by a 2-week Lead-In Dose period of S64315 (fixed dose) during which the patient continues to receive venetoclax daily. Once the planned dose of both drugs is reached the schedule will be a 21-day cycle with a weekly regimen for S64315 and a daily regimen for venetoclax.~S64315 should be administered 2 to 4 hours after venetoclax intake, via IV infusion. The dose escalation will start at 50 mg once a week and doses up to 250 mg once a week might be explored.~Venetoclax will be administered orally once a day. The dose escalation will start at 100 mg daily and doses up to 600 mg daily might be explored. Venetoclax must be taken with a meal (ideally during breakfast) in order to avoid reduced efficacy."
223625503|NCT02474446|DIETARY_SUPPLEMENT|Vitamin D|150,000 IU of Vitamin D3 Oral solution
223762418|NCT00245765|DRUG|Certolizumab Pegol|"* Pharmaceutical Form: solution for injection in pre-filled syringe~* Route of Administration: subcutaneous use"
224316747|NCT02896712|BEHAVIORAL|Drug Counseling (DC)|The investigators will use the manual-guided individual DC modeled after the NIDA Collaborative Cocaine Treatment Study and used as the active control therapy in previous studies. DC approximates clinical practice as it is considered the most common type of evidence-based treatment in the community for patients actively using cocaine.
223625504|NCT03261648|OTHER|State-Trait-Anxiety Inventory (Forme Y) questionnaire|after admission in the emergency department, patient and his partner will completed STAI Y questionnaire.
223625505|NCT03261648|OTHER|pain level scale|as usual caregiver will ask to the patient to evaluated his pain level with a scale of one to ten
223625506|NCT00777140|DRUG|Deferoxamine|"Intravenous deferoxamine: bolus 10mg/Kg (initiated during thrombolytic infusion, iv tPA), followed by intravenous perfusion of 20/40/60mg/Kg during 72h. It's a dose-finding study with 3 different doses of deferoxamine, with 20 patients (15 active:5 placebo) in each step.~Bolus + 72h perfusion of saline solution for the placebo group."
223625507|NCT05443308|DIAGNOSTIC_TEST|Cerebral [15O]H2O PET before and after diamox infusion|Cerebral \[15O\]H2O PET before and after diamox infusion
223625508|NCT04471714|DRUG|Baclofen|Participants will come in for two visits. In a randomized manor, they will receive baclofen on one visit and a placebo on the other. During each visit the soleus H-reflex will be measured and conditioned by common peroneal nerve stimulation to assess presynaptic inhibition.
223625509|NCT03095651|BIOLOGICAL|MK-5160 16 nmol/kg|MK-5160 16 nmol/kg, subcutaneous injection administered daily for 12 days
223625510|NCT03095651|BIOLOGICAL|MK-5160 32 nmol/kg|MK-5160 32 nmol/kg, subcutaneous injection administered daily for 12 days
223625511|NCT03095651|BIOLOGICAL|MK-5160 64 nmol/kg|MK-5160 64 nmol/kg, subcutaneous injection administered daily for 12 days
223625512|NCT03095651|BIOLOGICAL|Glargine 0.4 U/kg|Glargine 0.4 U/kg, subcutaneous injection administered daily for 12 days
223625513|NCT03095651|BIOLOGICAL|Placebo to Glargine|Placebo to glargine, subcutaneous injection administered daily for 12 days
223625514|NCT03095651|BIOLOGICAL|Placebo to MK-5160|Placebo to MK-5160, subcutaneous injection administered daily for 12 days
223625515|NCT03095651|DRUG|Dextrose|20% solution of dextrose; adjusted to maintain the various glycemic levels at 100 mg/dL given as a continuous intravenous infusion for 6-30 hours.
223625516|NCT03095651|BIOLOGICAL|Glargine 0.6 U/kg|Glargine 0.6 U/kg, subcutaneous injection administered daily for 12 days
223625517|NCT00610870|DRUG|atorvastatin|atorvastatin 80mg/day before primary coronary intervention
224316748|NCT02896712|BEHAVIORAL|Contingency Management (CM)|The investigators will use the same high-magnitude CM schedule shown previously to be feasible and effective in facilitating initial cocaine abstinence. Subjects will earn vouchers for cocaine-negative urine samples collected at scheduled clinic visits each week. Under an escalating reinforcement schedule, voucher values will begin at $15 and increase by $10 for each consecutive negative urine. Bonus vouchers of $10 will be given for three consecutive negative urines. Provision of a cocaine-positive urine or failure to provide a scheduled sample will result in no vouchers earned and will reset the schedule to the initial value of $15.
224316749|NCT02896712|DRUG|Placebo|The placebo capsule will be filled with corn starch and riboflavin.
224316750|NCT02896712|DRUG|Modafinil|Modafinil capsules will start at 200 mg (day 1) and increase to the fixed dose of 300 mg (day 2) and will also contain riboflavin.
224316751|NCT05048329|OTHER|Non-invasive continuous remote monitoring with structured escalation pathway|Continuous patient monitoring through non-invasive biosensors coupled with machine learning algorithms, with a structured escalation and communication pathway for home health providers and colorectal clinical team
224316752|NCT05048329|OTHER|Affective Analysis of Participant Response to Continuous Remote Patient Monitoring|Surveys and interviews with enrolled participants
224316753|NCT01437930|DIETARY_SUPPLEMENT|n-3 PUFA|"products (sausage, bread rolls, milk beverage, wafers) enriched with Intervention a-c): n-3 rich plant oils/powder~1. linseed oil (20g/d)(PPM, Magdeburg)~2. echium oil (20g/d) (HARKE Nutrition)~3. microalgae powder(12g/d)(HARKE Nutrition)"
224316754|NCT03057821|OTHER|3% hydrogen peroxide|The treatment group will also undergo skin preparation with 3% hydrogen peroxide.
224316755|NCT03524521|BEHAVIORAL|Interval Training|Interval training is prescribed 3 days per week using 5 body weight exercises in a progressive fashion.
224316756|NCT03524521|BEHAVIORAL|Standard of Care|Walking prescribed to meet current exercise guidelines; 150 minutes per week.
223625518|NCT02921035|DRUG|Rebif (Interferon beta-1a)|Rebif will be administered at a dose of 44 mcg, sc, tiw.
223762419|NCT00245765|OTHER|Placebo|Matching Placebo to Certolizumab Pegol
223762420|NCT01483196|PROCEDURE|ultrasound imaging|Undergo TCD
223762421|NCT01483196|OTHER|questionnaire administration|Complete neurocognitive questionnaires
223762422|NCT01483196|PROCEDURE|assessment of therapy complications|Undergo TCD
223762423|NCT01483196|PROCEDURE|quality-of-life assessment|Ancillary studies
223762424|NCT01483196|PROCEDURE|magnetic resonance imaging|Undergo MRI
223762425|NCT00660348|DRUG|morphine sulfate|This is morphine given in the traditional methods.
223762426|NCT00660348|DEVICE|Medtronic intrathecal pump|This pump will be inserted into the research subject and then the pump will deliver morphine.
223762427|NCT01703793|DRUG|Test Product 49778|
223762428|NCT01703793|DRUG|Test Product 10156|
224316757|NCT03772717|DEVICE|Non-invasive vagus nerve stimulation (nVNS)|The nVNS study intervention will be delivered using a handheld electrical neuromuscular stimulator device (VitalStim 400). Participants will deliver nVNS twice per day for 60 minutes each time at least 5 days per week. The two electrodes for the device will be placed on the subjects left cervical (neck) region. Parents will be trained on where to place electrodes, how to ensure that the electrodes make a good contact with the skin, and how to set the stimulation parameters. The stimulation frequency (number of pulses) and amplitude (amount of current) will be set during the initial baseline session in the clinic at a level that prevents discomfort and does not impact cardiorespiratory parameters. The stimulator will be placed in a comfortable position, such as next to the pillow. The stimulators are battery-powered and allow configuration of the stimulation parameters to the comfort of the patient.
224316758|NCT03772717|OTHER|Standard of care treatment|Patients will be asked to continue their standard medication regimens which include in most cases will involve 3 weekly infusions of intravenous immunoglobulin (IVIG) (1 gm/kg) and rarely plasma exchange (PLEX).
224316759|NCT02358902|DEVICE|tDCS|tDCS - DC stimulator, Neurocom, Germany
224316760|NCT02358902|PROCEDURE|active intervention of aerobic exercise|different types of aerobic exercise
224316761|NCT02358902|DEVICE|placebo tDCS|only 30 seconds of cortical stimulaion , with the power turned off for the remaining time (tDCS - DC stimulator, Neurocom, Germany)
224316762|NCT02358902|PROCEDURE|placebo AE|the procedure was a training on the treadmill, but heart rate was maintained within 5% of the resting heart rate at the minimum speed on the treadmill
224316763|NCT04138043|DRUG|Placebo|Placebo is 0.9 percent sodium chloride solution. It will be administered as SC injection to abdomen by study personnel. Three injections will be used to match active doses.
224316764|NCT04138043|DRUG|GSK2330811|GSK2330811 will be available as SC injection 150 mg/mL.
224316765|NCT02856802|DRUG|Sumatriptan 10 mg Nasal Spray|100 μL nasal spray once
224316766|NCT02856802|OTHER|Sumatriptan Placebo Nasal Spray|100 μL nasal spray once
223625519|NCT00783523|DRUG|Doxycycline or Placebo|Randomized to Doxycycline 100mg 2x/day or Placebo 2x/day for 1 or2-weeks pre-operatively.
223625520|NCT00656357|DRUG|SYN117 Placebo|Placebo
223625521|NCT00656357|DRUG|SYN117 80 mg|SYN117 80 mg
223625522|NCT00656357|DRUG|SYN117 160 mg|SYN117 160 mg
223625523|NCT00656357|DRUG|Cocaine 10mg|IV Cocaine 10mg
223625524|NCT00656357|DRUG|Cocaine 20mg|IV Cocaine 20mg
223625525|NCT00656357|DRUG|Cocaine 40mg|IV Cocaine 40mg
223625526|NCT00656357|DRUG|Saline|IV Cocaine Placebo
223625527|NCT00520949|DRUG|Augmentin (Amoxicillin-clavulanic)|Amoxicillin-clavulanic acid 1 gram b.i.d
223625528|NCT00520949|DRUG|Furoxone (furazolidone)|furazolidone 200 mg b.i.d
223762429|NCT01703793|DRUG|Vehicle (placebo)|
223762430|NCT03346122|DRUG|JNJ-64991524 Dose Level 1|Participants will receive JNJ-64991524 at a Dose Level 1 in SAD Part 1 of study.
223762431|NCT03346122|DRUG|JNJ-64991524 Dose Level 2|Participants will receive JNJ-64991524 at a Dose Level 2 in SAD Part 1 of study.
223762432|NCT03346122|DRUG|JNJ-64991524 Dose Level 3|Participants will receive JNJ-64991524 at a Dose Level 3 in SAD Part 1 of study.
223762433|NCT03346122|DRUG|JNJ-64991524 Dose Level 4|Participants will receive JNJ-64991524 at a Dose Level 4 in SAD Part 1 of study.
223762434|NCT03346122|DRUG|JNJ-64991524 Dose Level 5|Participants will receive JNJ-64991524 at a dose of Dose Level 5 in SAD Part 1 of study.
224316767|NCT05787626|OTHER|manipulation|miofascial technique in diaphragmatic region
223762435|NCT03346122|DRUG|JNJ-64991524 Dose Level 6|Participants will receive JNJ-64991524 at a Dose Level 6 in SAD Part 1 and MAD part 2 of study.
223762436|NCT03346122|DRUG|Placebo|Participants will receive matching placebo in all cohorts on Day 1 in Part 1 and Part 2 of the study.
223762437|NCT03346122|DRUG|JNJ-64991524 Dose Level 7|Participants will receive JNJ-64991524 at a dose of Dose Level 7 in MAD Part 2 of study for 14 days.
223762438|NCT03346122|DRUG|JNJ-64991524 Dose Level 8|Participants will receive JNJ-64991524 at a Dose Level 8 in MAD Part 2 of study for 14 days.
223762439|NCT03346122|DRUG|JNJ-64991524 Dose Level 9|Participants will receive JNJ-64991524 at a Dose Level 9 in MAD Part 2 of study for 14 days.
223762440|NCT02581774|OTHER|normal delivery tracking|normal delivery tracking
223762441|NCT04272190|OTHER|clinical routine treatments|The cohort stratified by four factors: preoperative treatment (not received, neoadjuvant chemotherapy, preoperative radiotherapy); surgical approach (laparoscopic, abdominal, vaginal, robotic); hysterectomy types (type A, type B, type C1, type C2), primary treatment (Radical hysterectomy + pelvic lymph node dissectionp; radiochemotherapy)
223762442|NCT00425399|PROCEDURE|Shiatsu|Shiatsu treatment provided in 40-minute sessions, twice a week for 4 weeks
223762443|NCT01617603|OTHER|Cocoa Polyphenols|20g/d of product, two active products provide 20 mg/d epicatechin, on visiting occasions, an acute dose of 40g product to be given
223762444|NCT00873548|DEVICE|PFNA-Asia|"The operation is performed under regional or general anesthesia and involves the following main steps:~1. Positioning of the patient~2. Definition of the CCD-angle~3. Fracture reduction~4. Determination of the nail diameter~5. Incision~6. Insertion of the device"
224215066|NCT05940519|OTHER|Dynamic taping technique|The dynamic taping method as specified in the literature will be applied to the right and left lumbar paravertebral muscles in the dynamic taping group. Patients' pain will be evaluated with Numerical Rating Scale, pain threshold Jtech Commander digital algometer, lumbar muscle endurance Modified Sorenson Test, balance functional reach test, lumbar joint mobility universal goniometer and functional movement levels of patients with timed get up and go test. Evaluations will be carried out in 3 stages: before taping, 2 hours after taping and 3 days after taping. The measurements of the dynamic and sham taping applications of the 2 hours after and 3 days will be compared with the pre-taping and post taping results between two groups.
224316768|NCT06553352|DRUG|Zanubrutinib combined with Obinutuzumab|Zanubrutinib combined with Obinutuzumab (ZO), a specific dose on specific days.
223762445|NCT01331070|OTHER|cerebral fMRI|the central breathing control with cerebral fMRI in COPD patients
223762446|NCT01331070|OTHER|cerebral fMRI|the central breathing control with cerebral fMRI in Accepts Healthy Volunteers
224316769|NCT05114213|RADIATION|SBRT|online adaptive MR-guided hypofractionated stereotactic radiotherapy
224316770|NCT05114213|DRUG|SOC chemotherapy|The chemotherapy is given according to current standard of care, consisting of in minimum doublet - chemotherapy and excluding monotherapy regimens.
223762447|NCT04516265|PROCEDURE|neurodevelopmental treatment|A personally designed treatment program will be applied in line with the principles of neurodevelopmental treatment.
224316771|NCT05646459|DRUG|cannabidiol|This group will locally apply cannabidiol to a posterior, localized 6-9 mm bleeding periodontal pocket.
224316772|NCT05646459|DEVICE|floss|This group will use floss alone at the test site (posterior, localized 6-9 mm bleeding periodontal pocket).
223625529|NCT00520949|DRUG|Cebes (colloidal bismuth subcitrate)|colloidal bismuth subcitrate 240 mg b.i.d
223625530|NCT00520949|DRUG|Esso (esomeprazole)|esomeprazole 40 mg b.i.d for 14 days
223625531|NCT00817297|DEVICE|noninvasive ventilator|Experimental V60 Mask noninvasive Ventilator for treating patients with COPD, then Comparator Conventional Mask noninvasive Ventilator for treating patients with COPD in crossover study design
223762448|NCT04516265|PROCEDURE|video-based trunk training|Games developed for the use of children with cerebral palsy will be used for trunk training.
224316773|NCT05646459|DEVICE|proxabrush|This group will use floss alone at the test site (posterior, localized 6-9 mm bleeding periodontal pocket).
224316774|NCT00005884|DRUG|eflornithine|
224316775|NCT03635476|OTHER|Qualitative interview study|The group in question is part of a research program aimed at developing and evaluating the LIFANA Nutrition Solution, a meal planning recommended system, which suggests meals based on the user's personal profile. This may include general preferences, such as culture, taste, and budget, but more importantly automated and personalised nutritional recommendations based on advice provided by professional nutritionists and allergists.
223625532|NCT05596136|DIAGNOSTIC_TEST|Artery Alert|A device for the measurement of the protein of interest that can be administered in a physician's office without requiring any capital equipment
223625533|NCT02292108|BEHAVIORAL|dietetic counselling|
223625534|NCT02292108|BEHAVIORAL|Hypnosis and self-hypnosis|Erickson's hypnosis and self-hypnosis
223625535|NCT06593483|BEHAVIORAL|Motivational Interview with Self-Talk Video|Participants will engage in an interview based in motivational interviewing techniques and then record a self talk video discussing their goals and reasons for reducing their drinking.
223625536|NCT06593483|BEHAVIORAL|Motivational Interviewing|Participants will engage in an interview based in motivational interviewing
223625537|NCT05478941|COMBINATION_PRODUCT|Progressive Muscular Relaxation via Zoom, and Exposure to a Virtual Reality scenarios deployed by an Head mounted tool (Oculus Quest 2).|"* Four individual PMRT sessions via Zoom.~* In vivo PMRT relaxing session and Virtual Reality exposure (T1; day 7).~* Follow-up phase (T2; day 14), after two weeks. Recovering the virtual reality scenario based on an in-imagination session, and the PMRT session."
223762449|NCT04516265|PROCEDURE|Video-based trunk training will apply with Theratogs|Video-based trunk training will apply with Theratogs
223762450|NCT04222738|DIETARY_SUPPLEMENT|GINOFF1|The intervention lasted for six weeks and consisted of the administration of powdered ginger extracts in the form of capsules at a dose of 2g/day.
223762451|NCT06854081|COMBINATION_PRODUCT|EluPro Antibiotic-Eluting BioEnvelope|Utilization of an EluPro Antibiotic-Eluting BioEnvelope with the CIED during the participant's CIED implant procedure.
223762452|NCT06863701|DRUG|Etoricoxib + Betamethasone fixed dose|One tablet of 90 mg / 0.25 mg a day
223762453|NCT06863701|DRUG|Etoricoxib fixed dose|One pill of 90 mg a day
224215067|NCT05940519|OTHER|Sham taping|Sham taping will be applied with a surgical patch while the patient is in a comfortable position without any technique or stretching.Evaluations will be carried out in 3 stages: before taping, 2 hours after taping and 3 days after taping. Patients' pain will be evaluated with Numerical Rating Scale, pain threshold Jtech Commander digital algometer, lumbar muscle endurance Modified Sorenson Test, balance functional reach test, lumbar joint mobility universal goniometer and functional movement levels of patients with timed get up and go test. Evaluations will be carried out in 3 stages: before taping, 2 hours after taping and 3 days after taping. The measurements of the dynamic and sham taping applications of the 2 hours after and 3 days will be compared with the pre-taping and post taping results between two groups.
224215068|NCT01358708|DRUG|LACTEOL® 340 mg|LACTEOL® 340 mg will be taken for a 4-week duration (28 days) as three capsules a day: two capsules in the morning and one capsule in the evening.
224215069|NCT01358708|DRUG|PLACEBO|Matched LACTEOL® 340 mg Placebo will be taken for a 4-week duration (28 days) as three capsules a day: two capsules in the morning and one capsule in the evening.
224215070|NCT01831531|DRUG|S-1|S-1 40 mg (BSA ≤ 1.6 m2) or 50 mg (BSA \>1.6 m2) p.o bid d1-28
224215071|NCT01831531|RADIATION|Radiation therapy|A total dose of 61.2 Gy will be delivered in 34 fractions at 1.8 Gy/fraction, 5 fractions per week in 6.8 weeks.
224215072|NCT04783792|DIETARY_SUPPLEMENT|Ascorbic acid / phytochemical supplement|Ascorbic acid / phytochemical supplement
224215073|NCT04783792|DIETARY_SUPPLEMENT|Ascorbic acid|Ascorbic acid
223625538|NCT05478941|COMBINATION_PRODUCT|Progressive Muscular Relaxation via Audio-track, and Exposure to a Virtual Reality scenarios deployed by an Head mounted tool (Oculus Quest 2).|"* Four individual PMRT sessions via Audio-track.~* In vivo PMRT relaxing session and Virtual Reality exposure (T1; day 7).~* Follow-up phase (T2; day 14), after two weeks. Recovering the virtual reality scenario based on an in-imagination session, and the PMRT session."
223625539|NCT05478941|BEHAVIORAL|Progressive Muscular Relaxation via Zoom, and Exposure to a Guided Imagery Exposure.|"* Four individual PMRT sessions via Zoom.~* In vivo PMRT relaxing session and Guided Imagery conducted by the Psychotherapist (T1; day 7).~* Follow-up phase (T2; day 14), after two weeks. Recovering the in-imagination relaxing scenario and PMRT session."
223625540|NCT05691894|DRUG|18F-FAPI|Patients will receive a tracer dose of 18F (8-10mCi) labelled FAPI
223625541|NCT05691894|DRUG|68Ga-FAPI|Patients will receive a tracer dose of 68Ga (2-5mCi) labelled FAPI
224215074|NCT03056001|DRUG|Pembrolizumab|IV infusion on day 1 of each 3 week cycle, at dose of 200 mg
224215075|NCT03056001|DRUG|Doxorubicin|IV injection on day 1 of each 3 week cycle, starting at dose of 60 mg/m2 (may be escalated to 75 mg/m2 per investigator discretion after Cycle 1)
224215076|NCT01836003|OTHER|Tokafatso programmatic intervention|"Tokafatso programmatic intervention:~* SMS-based platform for delivery of CD4 test results~* Participatory educational session for clinic staff~* Loan program for HIV and CD4 testing supplies~* Facilitation of tracing of HAART-eligible pregnant women"
224215077|NCT04380701|BIOLOGICAL|BNT162a1|Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection.
224215078|NCT04380701|BIOLOGICAL|BNT162b1|Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection.
223625542|NCT04758702|BIOLOGICAL|L-PRF (Leucocyte- platelet rich fibrin)|Leucocyte-Platelet rich fibrin is a high density fibrin clot. it serves as a biological healing matrix by supporting cell migration and cytokine release, expanding the range of its potential applications greatly. Patient's own blood is centrifuged using (Intra-spin) FDA approved centrifuge on 45 degrees angle on 2700 rpm for 12 minutes.
224215079|NCT04380701|BIOLOGICAL|BNT162b2|Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection.
223762454|NCT03318614|DIETARY_SUPPLEMENT|Probiotics M-63|B. infantis M63 (2.5 x 109 cfu/g per sachet) was given to Probiotics M-63 group for three months.
223762455|NCT03318614|OTHER|Control group|No probiotic intervention was given to the control group for three months.
223762456|NCT06137950|DRUG|gel Interferon arm|0.2 ml gel interferon will be administered into vaginal using 1 ml syringe with measurement line. Patients will be trained how to fill the syringe and put into the vagina. Gel will be administered 2 times per day during the non menstruating day totally for 28 days.
224215080|NCT04380701|BIOLOGICAL|BNT162c2|Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection.
223625543|NCT04758702|BIOLOGICAL|H-PRF (Horizontal -platelet rich fibrin)|Platelet rich fibrin is a high density fibrin clot. it serves as a biological healing matrix by supporting cell migration and cytokine release, expanding the range of its potential applications greatly.Horizontally centrifuged platelet rich fibrin using (Bio-prf) centrifuge on 700 g force for 8 minutes. On a horizontal centrifugation, the cells separate much more efficiently throughout the entire membrane. This leads to better layer separation and also favors cells that are evenly distributed throughout the PRF clot.
223625544|NCT04758702|DEVICE|Surgical stent|An essix surgical stent will be obtained using a high vacuum suction and used to protect the denuded donor site after suturing the wound. (Biostar® Scan/Biostar®V) will be used to make the stent.
223625545|NCT03635463|DEVICE|twin block appliance|a functional appliance that enhances mandibular growth in growing patients made from vaccum sheets (esthetic)
224215081|NCT04162730|OTHER|Pressure pain threshold and behavioural data|Pressure pain threshold level of the knee region will be collected and behavioural data will be measured
224215082|NCT00868114|BIOLOGICAL|KLH-pulsed autologous dendritic cell vaccine|5 X10e7 KLH-pulsed autologous dendritic cell vaccine once weekly times three weeks
224215083|NCT04564040|DRUG|Acalabrutinib Treatment A|Participants will receive 100 mg AT suspension in water via NG tube.
224316776|NCT03352739|DEVICE|DBS of the fornix, power on|"DBS of bilateral columns of the fornix is performed, with the power of the device on since the 1st month after the implantation. Observations will start at the time when the device is turning on .~DBS system includes:~Pins G102 Implantable Neurostimulator; Pins L301 DBS Electrode； Pins E202 DBS extension lead"
224316777|NCT03352739|DEVICE|DBS of the NbM, power on|"DBS of bilateral NbMs is performed, with the power of the device on since the 1st month after the implantation. Observations will start at the time when the device is turning on .~DBS system includes:~Pins G102 Implantable Neurostimulator; Pins L301 DBS Electrode； Pins E202 DBS extension lead"
223625546|NCT03635463|DEVICE|modified twin block appliance|a convetional twin block functional appliance that enhances mandibular growth in growing patients
223625547|NCT00205335|DEVICE|Ascencia Breeze Glucose meter|All study participants received glucose meter and test strips.
223625548|NCT00205335|DEVICE|Breeze Glucose Monitor (Bayer)|Each participant received a Breeze monitor and glucose test strips.
224215084|NCT04564040|DRUG|Acalabrutinib Treatment B|Participants will receive 100 mg acalabrutinib capsule suspension via NG tube.
224215085|NCT04564040|DRUG|Acalabrutinib Treatment C|Participants will receive 100 mg AT suspension in water via NG administration plus 20 mg rabeprazole.
224215086|NCT04564040|DRUG|Acalabrutinib Treatment D|Participants will receive 100 mg AT orally.
223762457|NCT06137950|DRUG|gel Interferon and interferon suppository arm|"0.2 ml gel interferon will be administered into vaginal using 1 ml syringe with measurement line. Patients will be trained how to fill the syringe and put into the vagina. Gel will be administered 2 times per day during the non menstruating day totally for 28 days.~3MIU suppository will be given to patients and will be trained how to use. Each patient in the arm will use the suppository twice a day for 10 days with vaginal therapy."
223762458|NCT02632708|DRUG|AG-120|
223762459|NCT02632708|DRUG|AG-221|
223762460|NCT02632708|DRUG|cytarabine|
223762461|NCT02632708|DRUG|daunorubicin|
223762462|NCT02632708|DRUG|idarubicin|
223762463|NCT02632708|DRUG|mitoxantrone|
223762464|NCT02632708|DRUG|etoposide|
224215087|NCT02266966|DRUG|F2695|
224215088|NCT02266966|DRUG|Placebo|
224215089|NCT03457337|DRUG|S-1 plus Gefitinib|S-1: According to the body surface area (BSA) to determine the dose, twice daily, after breakfast and dinner orally Gefitinib: 250mg, 1 day, orally, fasting or with the same service
224215090|NCT03457337|DRUG|Gefitinib|Gefitinib: 250mg, 1 day, orally
223762465|NCT06386497|DEVICE|Nocturnal translational vestibular stimulation|Nocturnal (overnight) translational vestibular stimulation applied by the rocking bed (Somnomat Casa) for two months in patients familiar home environment.
223762466|NCT03316872|DRUG|Pembrolizumab|Pembrolizumab is a humanized monoclonal antibody (mAb) of the IgG4/kappa isotype designed to directly block the interaction between PD-1 and its ligands, PD-L1 and PD-L2.
223762467|NCT03316872|RADIATION|Stereotactic Body Radiotherapy (SBRT)|SBRT involves delivery of high doses of radiation therapy in smaller fractions
224215091|NCT03707522|BEHAVIORAL|Growth mindset|10 minute interactive article describing neuroplasticity
224215092|NCT03707522|BEHAVIORAL|Modifiable risk factor (MRF) information|10 minute interactive article describing modifiable risk factors for depression and anxiety
224215093|NCT03707522|BEHAVIORAL|Control|10 minute interactive article describing activity scheduling
224215094|NCT04363736|DRUG|Tociliuzumab|Participants will receive IV TCZ.
224215095|NCT05980858|DIETARY_SUPPLEMENT|Beta-hydroxybutyrate|Each subject receive Beta-hydroxybutyrate 300mg/kg x 3 for five days. After the treatment period effect variables will be examined.
224215096|NCT05980858|OTHER|Placebo|Each subject receive a placebo drink 3 x day for five days. After the treatment period effect variables will be examined.
223625549|NCT05363553|DIETARY_SUPPLEMENT|Infant formula based on whole goat milk|Infant formula based on whole goat milk, nutritionally suitable for infants aged 0-6 months
223625550|NCT05363553|DIETARY_SUPPLEMENT|infant formula based on cow milk proteins|Infant formula based on cow milk proteins, nutritionally suitable for infants aged 0-6 months
223625551|NCT04673214|DRUG|Azithromycin / Ivermectin / Ribaroxaban / Paracetamol|In the patient with the presence of COVID-19 confirmed by the PCR-COVID-19 positive test, the drug is randomly assigned to belong to group A of Azithromycin / Ivermectin / Ribaroxaban / Paracetamol to be followed for 14 days by video call (approximately 15 to 20 min per day) to the patient and the presence or absence of clinical symptoms, adverse reactions being recorded daily
223625552|NCT04673214|DRUG|Azithromycin / Ribaroxaban / Paracetamol|In the patient with the presence of COVID-19 confirmed by the PCR-COVID-19 positive test, the drug is randomly assigned to belong to group B of Azithromycin / Ribaroxaban / Paracetamol, to be followed for 14 days by video call (approximately 15 to 20 min per day) to the patient and the presence or absence of clinical symptoms, adverse reactions being recorded daily
223625553|NCT03684863|DRUG|Capecitabine|observation
223762468|NCT01966926|BEHAVIORAL|weighing frequency instructions and tips|Weekly emails with nutrition, physical activity, and weight tracking tips sent for 24 weeks
223762469|NCT07010094|DEVICE|BM shockwave devices|Use the BM shockwave devices for pre-treatment of coronary calcification lesions.
223762470|NCT06873139|BEHAVIORAL|text messages|There will be two arms for the texting intervention: high and low. Both arms will receive text messages, but the frequency of the messages will vary by arm. Text intervention messaging will be sent through an automated text messaging service programmed by the CM Research Informatics team, which has been approved by the institution.
224215097|NCT06569693|BEHAVIORAL|My Sleep Our Sleep (MSOS) Program|"MSOS is a sleep intervention developed by the investigator aimed at improving sleep health for patient-sleep-partner caregiver dyads using behavioral education in sleep behaviors, sleep cognition and sleep in relationship.~MSOS will be delivered over four weeks, in weekly one-hour sessions, one session per week."
224215098|NCT06569693|BEHAVIORAL|Brief Behavioral Treatment for Insomnia (BBTI)|"BBTI is brief patient-focused intervention for patient-sleep-partner caregiver dyads, aimed at altering participants' sleep behaviors to improve sleep. BBTI utilizes behavioral education in sleep restriction and stimulus control. For sleep restriction, participants will be instructed to limit the time they spend in bed, which serves to increase sleep efficiency. For stimulus control, participants will be instructed to go to bed only when feeling sleepy and reserve the bed for sleep and intimacy.~BBTI will be delivered over four weeks, in weekly one-hour sessions, one session per week."
223625554|NCT06420882|OTHER|The experimental group.|In the experimental group, in addition to home exercises, patella mobilization, muscle strengthening exercises, range of motion exercises and home exercises will be performed 3 days a week for 3 sessions with a therapist.
223625555|NCT06420882|OTHER|The home exercise group|Participants in both groups will be included in a 3-week treatment programme.
223625556|NCT06215534|DIETARY_SUPPLEMENT|first reference product series 1|dextrose (containing 25 grams of carbohydrates)
223625557|NCT06215534|DIETARY_SUPPLEMENT|second reference product seies 1|dextrose (containing 25 grams of carbohydrates)
223625558|NCT06215534|DIETARY_SUPPLEMENT|third reference product series 1|dextrose (containing 25 grams of carbohydrates)
223625559|NCT06215534|DIETARY_SUPPLEMENT|first concept product series 1|Standard tube feed (containing 25 grams of carbohydrates)
223625560|NCT06215534|DIETARY_SUPPLEMENT|second concept product series 1|Tube feed with added fibers (containing 25 grams of carbohydrates)
223625561|NCT06215534|DIETARY_SUPPLEMENT|third concept product series 1|Tube feed with extra energy (containing 25 grams of carbohydrates)
223625562|NCT06215534|DIETARY_SUPPLEMENT|4th concept product seris 1|Tube feed with extra energy and added fibers (containing 25 grams of carbohydrates)
223762471|NCT05875246|BEHAVIORAL|Micro-interventions|Group 1: No intervention Group 2: Brief stress reduction messages Group 3: App based stress reduction audio activity
223762472|NCT06117397|OTHER|Text Messaging Intervention|A text messaging intervention that includes enhanced content such as tailoring, video links and a chat function
223625563|NCT06215534|DIETARY_SUPPLEMENT|5th concept product series 1|Plant based oral nutritional supplement for disease related malnutrition (containing 25 grams of carbohydrates
223762473|NCT02285504|DRUG|SAGE-547|Intravenous injection
223762474|NCT06686771|RADIATION|SBRT|Please refer to the current NCCN NSCLC guidelines for possible treatment options
223625564|NCT06215534|DIETARY_SUPPLEMENT|6th concept product series 1|Oral nutritional supplement for disease related malnutrition in patients with malabsorption and/or maldigestion (containing 25 grams of carbohydrates
223625565|NCT06215534|DIETARY_SUPPLEMENT|1st reference product series 2|dextrose (containing 25 grams of carbohydrates)
223625566|NCT06215534|DIETARY_SUPPLEMENT|2nd reference product series 2|dextrose (containing 25 grams of carbohydrates)
223625567|NCT06215534|DIETARY_SUPPLEMENT|3rd reference product series 2|dextrose (containing 25 grams of carbohydrates)
223625568|NCT06215534|DIETARY_SUPPLEMENT|1st concept product series 2|High energy plant based tube feed (containing 25 grams of carbohydrates)
223762475|NCT06686771|OTHER|Second-line standard of care therapy|Please refer to the current NCCN NSCLC guidelines for possible treatment options.
223762476|NCT04656600|DRUG|Cerezyme® / Imiglucerase|Pharmaceutical form: lyophilisate for solution for infusion Route of administration: intravenous
224215099|NCT04722081|OTHER|physical therapy|physical therapy-specific exercises
224215100|NCT00383019|DRUG|Xalatan|latanoprost 0.005%, one rop once daily in evening
224215101|NCT00383019|DRUG|Xalacom|latanoprost 0.005% adn timolol 0.5%, one drop, once daily
224215102|NCT05469503|DIETARY_SUPPLEMENT|TOTUM-854|12 weeks of TOTUM-854 supplementation
224215103|NCT05469503|DIETARY_SUPPLEMENT|Placebo|12 weeks of placebo supplementation
224215104|NCT01190826|DRUG|ASM-024|Target dose of 10 mg ASM-024 administered once by inhalation
223625569|NCT06215534|DIETARY_SUPPLEMENT|2nd concept product series 2|High energy plant based tube feed with added fibers (containing 25 grams of carbohydrates)
223625570|NCT06215534|DIETARY_SUPPLEMENT|3rd concept product series 2|High protein tube feed (containing 25 grams of carbohydrates)
223625571|NCT06215534|DIETARY_SUPPLEMENT|4th concept product series 2|High protein, high energy tube feed based on peptides (containing 25 grams of carbohydrates)
223625572|NCT06215534|DIETARY_SUPPLEMENT|5th concept product series 2|Oral nutritional supplement for disease related malnutrition in patients with muscle loss (containing 25 grams of carbohydrates)
223625573|NCT06215534|DIETARY_SUPPLEMENT|6th concept product series 2|Oral nutritional supplement for disease related malnutrition (containing 25 grams of carbohydrates)
224215105|NCT01190826|DRUG|ASM-024 100 mg|Target dose of 100 mg ASM-024 administered once by inhalation
223625574|NCT02743585|DEVICE|Filmarray Blood Culture ID (BCID) panel|The BCID panel is an FDA-approved nucleic acid amplification test (based on nested polymerase chain reaction) which detects Gram positive, Gram negative, the major Candida species and antimicrobial resistance markers (mecA for methicillin resistance, van A/B for vancomycin resistance, blaKPC for KPC carbapenemase) directly from positive blood cultures in \< 1 - 1.5 hours
223625575|NCT02743585|DEVICE|Rosco Diagnostica ESBL/carbapenemase screen kit|These kits are CE-marked (Approved in the European Union) rapid chromogenic tests for extended-spectrum beta-lactamase / carbapenemase detection from both blood cultures and cultured bacterial colonies.
223625576|NCT06472284|DEVICE|TetraGraph|etraGraph is a unique, EMG-based portable device for quantitative (objective) monitoring of neuromuscular function. It is a precise and easy to use tool for monitoring depth of block, ensuring adequate recovery of muscle function, and aiding the clinician to reduce the incidence of residual block.
223625577|NCT00005567|BEHAVIORAL|Parental knowledge and beliefs about infant sleep position|
224215106|NCT01190826|DRUG|Placebo|Placebo administered once by inhalation
224215107|NCT05735782|DIAGNOSTIC_TEST|Clinical, mental health and psychosocial profile of Post-COVID-19 syndrome|Evaluation of persistent symptoms of COVID-19 and its association with psychological, cognitive and social status in comparison to a healthy control group
224215108|NCT05735782|DIAGNOSTIC_TEST|Diagnostic performance of echocardiographic and biological markers in Post-COVID-19 syndrome|Determine the inflammatory, immune profile and ventricular function in post-COVID-19 participants compared to a control group
224215109|NCT06588413|DRUG|Olanzapine|Subjects will be randomized to either olanzapine 2.5 mg or 5 mg
224215110|NCT06585943|BEHAVIORAL|Forced Rate Exercise + Rehab|The FE+rehab group (N=33) will complete FE on the cycle designed to augment pedaling rate to \>75 RPM. Target heart rate zone will be set to 60-80% of HR reserve. The session will consist of a 5-min warm-up, 35-min main exercise set, and 5-min cool down. Following FE, abbreviated sessions of motor learning-based training will be administered by a neurologic OT and PT experienced in stroke rehabilitation, with 30 min focused on restoration of UE function (OT) and 15 min focused on LE motor function/ gait training (PT).
223625578|NCT01393834|PROCEDURE|Delayed cord clamping|Delay cord clamping for 30 seconds after birth
223625579|NCT01393834|PROCEDURE|Milking of the cord|Milking of the cord 4 times in 10 seconds
223625580|NCT03793751|DRUG|Dexmedetomidine Injection|Dexmedetomidine Injection at a dose of 1 mcg/kg over 10 min, after Spinal Anaesthesia and before start of surgery, followed by a continuous infusion at a rate of 0.4 mcg/kg/h until the end of surgery.
223625581|NCT00301795|BIOLOGICAL|oblimersen sodium|Given IV
223625582|NCT00301795|BIOLOGICAL|rituximab|Given IV
223625583|NCT00301795|OTHER|laboratory biomarker analysis|Correlative studies
223625584|NCT06073613|DIAGNOSTIC_TEST|oral health status|"* CSDs medical records: Information related to epidemiological characteristics and chronic inflammatory skin conditions (psoriasis, atopic dermatitis, autoimmune bullous diseases, or systemic lupus erythematosus,…) were recorded from medical records:~  * Pemphigus~ * Mixed connective tissue disease~ * Atopic dermatitis~ * Psoriasis~ * Erythroderma~* oral health status: oral clinical parameters were evaluated:~  * Full mouth bleeding on probing scores~ * Pocket probing depth~ * Clinical attachment level~ * debris index~ * calculus index~ * the number of oral lesions"
223625585|NCT02230735|DRUG|Bipivacaine 0.5% with epinephrine|Total of 14 ml of bupivacaine hydrochloride 0.5% with epinephrine 1:200,000, 7ml in right uterosacral ligament, 7ml in left uterosacral ligament
223625586|NCT02230735|DRUG|Normal Saline|(placebo for bupivacaine)
224215111|NCT06585943|BEHAVIORAL|Rehabilitation|The rehab group will receive consecutive, full-length sessions of motor learning-based training, administered by a neurologic OT and PT experienced in stroke rehabilitation, with 45 min focused on restoration of UE function (OT) and 45 min focused on LE motor function/ gait training (PT).
224215112|NCT02336698|DRUG|Placebo|Placebo will be administered once every 4 weeks for 16 weeks by subcutaneous (SC) injection (injection under the skin) into the thigh or abdomen.
224215113|NCT02336698|DRUG|Fulranumab 1 mg|Fulranumab will be administered once every 4 weeks for up to 16 weeks by SC injection into the thigh or abdomen.
224215114|NCT02336698|DRUG|Fulranumab 3 mg|Fulranumab will be administered once every 4 weeks for up to 16 weeks by SC injection into the thigh or abdomen.
224215115|NCT02582801|DRUG|18F-Alfatide Ⅱ PET/CT|Inject 18F-Alfatide Ⅱ by vein and then perform PET/CT scan after 60 min
224215116|NCT00990093|DEVICE|test intermittent catheter|CH 12 hydrophilic coated catheter
223762477|NCT07018752|DRUG|roginolisib|Roginolisib daily intake
223762478|NCT07018752|DRUG|golcadomide|Golcadomide daily intake
223762479|NCT07018752|DRUG|azacitidine|oral 5-azacitidine daily intake
223625587|NCT06527170|PROCEDURE|Sleeve gastrectomy|Each patient undergoes bariatric surgery. Each patient is diagnosed before surgery for erectile dysfunction. Similar tests are done 1 year after
223625588|NCT04393415|COMBINATION_PRODUCT|stem cells|giving stem cells to patients with covid - 19
223625589|NCT01906333|OTHER|Exercise|
223625590|NCT01906333|OTHER|Glucose|
223762480|NCT07019285|BEHAVIORAL|High intensity interval walking training|High intensity intermittent walking training for a period of 8 weeks. The intensity of the training is 90 to 110% of 6MWTdistance. The frequency of the training is three times a week
223762481|NCT07019285|BEHAVIORAL|Moderate-intensity interval walking training|Moderate intensity intermittent walking training for a period of 8 weeks. The intensity of the training is 60 to 80% of 6MWTdistance. The frequency of the training is three times a week
223762482|NCT07018531|PROCEDURE|VST augmentation with TPT|"For TPT group, vertical soft tissue augmentation will be performed simultaneously with implant placement using a 2 mm healing abutment. Than, to ensure tension-free primary closure, mucoperiosteal flaps will be mobilized through vertical releasing incisions. Wound closure will be achieved using horizontal mattress sutures, followed by simple interrupted sutures for optimal tissue adaptation. The healing abutment will act as a mechanical support to maintain space and prevent soft tissue collapse. This tented space is expected to allow blood to accumulate, clot, and gradually reorganize into connective tissue, thereby promoting an increase in vertical soft tissue thickness around the implant.~After 2 months , the initial 2-mm healing abutment will be removed, and a 4 mm healing abutment will be placed by mading a small semilunar incision without touching the bone."
223762483|NCT07018531|PROCEDURE|TPT-PRF|In the PRF group, the same surgical protocol as the TPT group will be followed. However, prior to wound closure, the tented space surrounding the healing abutment will be filled with PRF membranes.
224215117|NCT00990093|DEVICE|Intermittent catheterization|CH 12 hydrophilic catheter
224215118|NCT02218515|PROCEDURE|Open Flap Debridement|Open Flap Debridement (Control Group)
224215119|NCT02218515|BIOLOGICAL|EmdogainⓇ(Enamel Matrix Derivative)|Open Flap Debridement+Enamel Matrix Derivative
223625591|NCT01906333|OTHER|Fasted|
223625592|NCT04498078|DIETARY_SUPPLEMENT|Creatine|Creatine monohydrate (20 g per day)
223625593|NCT01233596|DEVICE|Canalicular intubation|Intubation through the inferior canaliculus performed under general anaeshesia. The tubes were removed 3-4 months after the tube placement.
223625594|NCT05252897|PROCEDURE|Endoscopic necrosectomy with step up approach|Endoscopic necrosectomy will be performed with a forward-viewing gastroscope into the WON cavity. Debridement of necrotic tissue will be performed with irrigation and/or mechanical removal with endoscopic instruments. For this arm, step up approach will be adopted.
223625595|NCT05252897|PROCEDURE|Endoscopic necrosectomy with direct approach|Endoscopic necrosectomy will be performed with a forward-viewing gastroscope into the WON cavity. Debridement of necrotic tissue will be performed with irrigation and/or mechanical removal with endoscopic instruments. For this arm, the direct approach will be adopted.
223625596|NCT03474614|DRUG|Propranolol|The medication will be administered so that patient receives a minimum of 7- days and maximum of 10-days of treatment with propranolol prior to planned surgical resection of CCM (routine care)
223625597|NCT03474614|GENETIC|DNA and RNA Analysis|During the operative procedure, a small sample of the patient's blood will be obtained and small (1 to 2cc) tissue sample from the resected cavernous malformation will be collected. The blood and tissue samples will be labeled and stored for subsequent DNA and RNA analysis
223625598|NCT06526260|BEHAVIORAL|Very Brief Exposure to Facial Expressions|In Very Brief Exposure (VBE): a series of rapid micro- exposures to images depicting feared stimuli (e.g., for SAD, judgmental faces). Each image is followed by a masking stimulus to prevent its conscious recognition. This sequence of image-mask stimuli is repeated many times in an exposure session.
223625599|NCT04179097|DIAGNOSTIC_TEST|Finger photoplethysmography|Bilateral finger photoplethysmogray, bilateral brachial artery Doppler, Aorta artery Doppler
224215120|NCT02218515|BIOLOGICAL|EmdogainⓇEnamel Matrix Derivative+Autogenous Bone|Open Flap Debridement+EmdogainⓇ(Enamel Matrix Derivative)+Autogenous Bone
224215121|NCT03820778|DIAGNOSTIC_TEST|Whole Body MRI|WBMRI with axial and coronal STIR (short inversion time inversion recovery) images + DWI (diffuse weighted imaging) will be performed and compared to regional MRI to assess value of this diagnostic test for the identification of suspicious looking lesions (i.e. diffuse nodular lesions or atypical plexiform neurofibroma)
223625600|NCT06553092|OTHER|Turkish Version of the Hospital for Special Surgery Shoulder Surgery Expectations Survey|The Hospital for Special Surgery (HSS) Shoulder Surgery Expectations Survey is a patient-reported outcome measure designed to assess a patient's expectations before undergoing shoulder surgery. It helps clinicians understand what patients anticipate regarding pain relief, functional improvement, and overall recovery from the procedure.The HSS Shoulder Surgery Expectations Survey contains 20 questions. Each question addresses a specific aspect of shoulder function or a potential outcome that patients might expect from their surgery.Each question is scored between 1-5.It is evaluated out of a total of 80 points. A higher score indicates a greater expectation of improvement.
223625601|NCT05740254|BEHAVIORAL|Early Time Restricted Eating|Early Time Restricted Eating 7 AM to 3 PM
223625602|NCT05740254|BEHAVIORAL|Late Time Restricted Eating|Late Time Restricted Eating 12 PM to 8 PM
223625603|NCT04851691|BEHAVIORAL|EHR CDS|"When a clinician initiates a new antipsychotic prescription for a patient with dementia, a three-pronged electronic health record clinical decision support tool pops up: (1) Alerting clinicians that antipsychotic prescriptions increase patient mortality; (2) Offering non-pharmacological behavioral resources for caregivers via a link to the IDEA! strategy resources on how caregivers can best manage a patient's behavioral disturbance non-pharmacologically, which will be available in the EHR to include in the patient's after visit summary; and (3) Defaulting prescriptions to a low supply of pills in to order to minimize harm. In addition, the PI will email all providers randomized to the intervention arm in order to make them aware of the components of this intervention and its motivation."
224215122|NCT05285631|DEVICE|Speckle tracking echocardiography (STE)|"Two-dimensional (2D) and 3D STE are based on the quantitative analysis of spatial dislocation (tracking) of acoustic markers (speckles) generated by the interaction between the ultrasound beam and myocardial fibers during the cardiac cycle."
224215123|NCT04196088|DEVICE|Ultivision Artificial Intelligence Software|Screening Colonoscopy
224215124|NCT04196088|DEVICE|No Artificial Intelligence Software enhancement|Screening Colonoscopy
224215125|NCT03760965|DRUG|sotagliflozin (SAR439954)|"Pharmaceutical form: tablet~Route of administration: oral"
224215126|NCT03760965|DRUG|placebo|"Pharmaceutical form: tablet~Route of administration: oral"
223762484|NCT07018531|PROCEDURE|TPT-PBM|The PBM group will follow the same surgical protocol as the TPT group. In addition, this group will receive photobiomodulation therapy using red-light irradiation at a wavelength of 630 nm, applied to the occlusal site immediately after surgery and repeated after 7 days.
223762485|NCT07018531|PROCEDURE|Group control: implant placement without TPT|The negative control group will consist of patients randomly selected from the recruited population, in accordance with the study's inclusion criteria. Participants in this group will not receive any intervention aimed at VST augmentation during implant placement. This will allow for a clear assessment of the effect of the TPT on VST gain and its impact on MBL. In accordance with ethical guidelines, patients in the control group will undergo VST augmentation at a second stage, prior to the initiation of the prosthetic phase.
224215127|NCT00995930|DRUG|ACZ885|ACZ885 150 mg was administered subcutaneously once a month for 12 months.
223762486|NCT07018973|OTHER|GAISMA|After the pre-test and randomization, the experimental group will first start the morphological analysis application. After completing a certain period of time, copies of the matrix and suggestion studies will be taken and they will be allowed to use the generative artificial intelligence application. At the end of the application, a post-test will be applied. In addition, an opinion form will be given and their opinions about the morphological analysis method, the use of generative artificial intelligence and the use of artificial intelligence with the morphological analysis method and how it affects them will be taken.
224215128|NCT00995930|DRUG|Placebo|Matching placebo to ACZ885 was administered subcutaneously once a month for 12 months.
224215129|NCT02680730|BEHAVIORAL|Listening Project Protocol|The filtered-music intervention will consist of listening to computer-altered acoustic stimulation, designed to modulate the frequency band of vocal music passed to the participant. The frequency characteristics of the acoustic stimulation are selected to emphasize the relative importance of specific frequencies in conveying the information embedded in human speech. Modulation of the acoustic energy within the frequencies of human voice, similar to an exaggerated vocal prosody, are hypothesized to recruit and modulate the neural regulation of the middle ear muscles and to functionally reduce sound hypersensitivities and improve auditory processing.
224215130|NCT03327142|DIAGNOSTIC_TEST|Endoscopic Ultrasound-Guided FNA|Endoscopic Ultrasound Guided Fine Needle Aspiration of Puncture of Adrenal Glands
224215131|NCT06611475|OTHER|MMSE ≤26|A dataset comprising participants with MMSE scores of ≤26 and 30 will be used to evaluate the classification performance of various machine learning techniques.
224215132|NCT06114810|BIOLOGICAL|polio vaccines: nOPV2, bOPV, IPV|Co-administration of nOPV2 with bOPV along with IPV with different sequential or combination schedules.
223625604|NCT04851691|OTHER|Usual Care|Patients will receive usual care from their physicians.
223625605|NCT05702463|DRUG|Aspirin 81Mg Ec Tab twice daily for 7 days|Participants with incomplete platelet aggregation will be instructed to take EC ASA 81 mg twice daily for 7 days.
224316778|NCT03352739|DEVICE|DBS of the fornix, power off|"DBS of bilateral columns of the fornix is performed, the power of the device is going to keep off during the first 7 months after the implantation. Observations will start after 1 month of the implantation.~DBS system includes:~Pins G102 Implantable Neurostimulator; Pins L301 DBS Electrode； Pins E202 DBS extension lead"
223625606|NCT05702463|DRUG|Aspirin 40Mg Chew Tab twice daily for 7 days|Participants with incomplete platelet aggregation will be instructed to take chewable ASA 40 mg twice daily for 7 days.
223625607|NCT05702463|DRUG|Aspirin 162 mg EC Tab once daily for 7 days|Participants with incomplete platelet aggregation will be instructed to take EC ASA 162 mg once daily for 7 days.
224316779|NCT03352739|DEVICE|DBS of the NbM, power off|"DBS of bilateral NbMs is performed, the power of the device is going to keep off during the first 7 months after the implantation. Observations will start after 1 month of the implantation.~DBS system includes:~Pins G102 Implantable Neurostimulator; Pins L301 DBS Electrode； Pins E202 DBS extension lead"
223625608|NCT05901298|DEVICE|My Breastfeeding Guide|Development of the content of the mobile nursing application had began with a literature review on breastfeeding, Dennis' Breastfeeding Self-Efficacy Theory and Pender's Health Promotion Model and after content is created. The mobile nursing application can be download via the Google Play Store® and the Apple Store®. The application consist of three parts. In the first part includes mother and baby information which is asked with scales and forms, the second part includes literature knowledge and the third section includes the expert consultation and blog section. Mothers receive notifications consisting of sentences every two days to increase their breastfeeding self-efficacy. The application web page can allow the mothers' information to be kept in the system.
223625609|NCT04055220|DRUG|Treatment by Regorafenib|"Treatment for 13 cycles (12 months) maximum.~During each cycle, patient will take once a day, during 21 days, followed by 7 days without treatment :~* 3 tablets daily, corresponding to a total of 120 mg of Regorafenib (3 weeks out of 4 weeks) in patients ≥ 16 years old and patients \< 16 years old with BSA ≥ 1.70m²;~* 2 tablets daily corresponding to a total of 80 mg of Regorafenib (3 weeks out of 4 weeks) in patients \< 16 years old with 1.30m² ≤ BSA \< 1.70m²;"
223625610|NCT04055220|DRUG|Treatment by Placebo|"Treatment for 13 cycles (12 months) maximum.~During each cycle, patient will take once a day, during 21 days, followed by 7 days without placebo treatment :~* 3 placebo tablets (3 weeks out of 4 weeks) in patients ≥ 16 years old and patients \< 16 years old with BSA ≥ 1.70m²;~* 2 placebo tablets (3 weeks out of 4 weeks) in patients \< 16 years old with 1.30m² ≤ BSA \< 1.70m²;"
223625611|NCT05642741|OTHER|Response to medical and research questionnaires|Patients will receive by mail or email the study information note, the medical questionnaire, the SF36 and the research questionnaire to be completed (then again 3 weeks later). The patients will return the questionnaires by mail or by post.
223625612|NCT04247347|BEHAVIORAL|Biofeedback Training|"Use of a heart-rate variability (HRV) tracking device to enable one to learn to alter physiology to improve health. Devices are used to measure physiological activity, e.g., breathing and heart function, and provide rapid, accurate feedback to the user, thereby enabling desired physiological changes that can endure over time without continued use of the device and to continue to influence behavior."
223625613|NCT04247347|OTHER|Dementia Education|An educational program designed to teach family caregivers about the characteristics, types, causes, and risk factors of dementia, as well as teach about health promotion, the stages of dementia, behavior changes, communicating with a family member with dementia, and caring for oneself. The content to be presented within an audiovisual format using a tablet computer follows recommendations and guidelines developed through research and by the Alzheimer's Association and the National Institute on Aging.
223625614|NCT04247347|BEHAVIORAL|Resourcefulness Training|A cognitive-behavioral intervention presented within an audiovisual format using a tablet computer that consists of teaching and reinforcing personal (self-help) and social (help-seeking) resourcefulness skills.
223625615|NCT05413590|OTHER|Questionnaires completion|Cognitive tests, completing questionnaires, balance test, measuring cardiac variability and post-ischemic hyperemia. Assessments of neuromuscular function on a semi-recumbent ergometric bicycle.
223625616|NCT05413590|OTHER|Isometric forces|Measurement of the maximum isometric forces of the knee flexors, the plantar flexors of the ankle and the grip strength of the hand.
223625617|NCT05413590|OTHER|Energy cost|Measurement of feet pressure and measurement of the energy cost. Maximum test on an endocycle (classic) to determine VO2max.
223625618|NCT03066206|DRUG|Poziotinib|Given PO
224215133|NCT06442826|OTHER|Non-invasive auricular stimulation|"Single session TniAS stimulation will be achieved by applying four stimulation patches. These patches consist of stainless steel spheres with a diameter of 1.2 mm, covered with adhesive circular paper measuring 8 mm in diameter.~Point 1. Located in the Triangular Fossa, upper and central level at the vertex of the Fossa, at junction between the upper root and the lower root of the Antihelix.~Point 2. Located in the inner part of the Cymba (upper) conchae, in the angle formed by the lower root of the antihelix and the ascending branch of the Helix.~Point 3. Located in the middle depression of the Cavum (lower) conchae.~Poinit 4. It is located at the inner superior quadrant of Lobe, below the external curve of the Intertragus notch, in a depression 3-4 mm from the insertion of the lobe to the face."
224316780|NCT02522923|OTHER|Physical Therapist|The participant will receive an evaluation and intervention from a physical therapist. The patient will be referred onward to other providers as needed.
223762487|NCT07018973|OTHER|Control|In the control group, morphological analysis will be applied. Post-tests will be applied at the end of the application. Finally, their opinions about the morphological analysis method and how it affects them will be taken by giving an opinion form.
223762488|NCT07019402|BEHAVIORAL|Internet-based Mindfulness-Based Stress Reduction (iMBSR)|The iMBSR program is an adaptation of Jon Kabat-Zinn's Mindfulness-Based Stress Reduction (MBSR) to be delivered in an online and asynchronous manner. MBSR was developed by Kabat-Zinn in the 1970s as a method to help individuals manage stress and pain through mindfulness meditation. Mindfulness practice has been linked to numerous benefits such as boosting cognitive control and emotion regulation. MBSR includes practices such as orienting attention to the present moment, often through an object like the breath, nonjudgmental awareness of thoughts and emotions, mindful listening, mindful eating, and body scan meditation.
223625619|NCT03562195|DRUG|Mepolizumab 100 milligrams|Mepolizumab will be given as a lyophilized cake in sterile vials for individual use. The vial will be reconstituted with Sterile Water for Injection, just prior to use.
223625620|NCT03562195|DRUG|Placebo|Placebo will be given as 0.9 percent sodium chloride solution.
223625621|NCT03562195|DRUG|Salbutamol|Salbutamol MDI will be given as a rescue medication to be used on an as needed basis in this study.
223625622|NCT05641545|BIOLOGICAL|IVAC|IVAC is a personalized peptide vaccine
223625623|NCT03949569|BEHAVIORAL|Therapy Dog|Children will undergo a 5 minute unstructured session with either a certified therapy dog or with a dog who is trained and certified for animal-assisted interventions and/or animal-assisted activities. Children will be allowed to talk to, pet, and play with the therapy dog during the interaction.
224316781|NCT02522923|OTHER|Primary Care Provider|The participant will receive an evaluation and intervention from a primary care provider. The patient will be referred onward to other providers as needed.
224316782|NCT04678050|DRUG|Ketamine/ propofol|ketamine/propofol mixture, each mL contains 5 mg of ketamine plus 10 mg of propofol). A loading dose of 0.125 mL/kg will be administered intravenously (IV) over 10 min, followed by maintenance infusion at a rate of 0.05-0.125 mL/kg/h.
223625624|NCT03949569|BEHAVIORAL|Stuffed Toy Dog|Children will undergo a 5 minute unstructured session with a stuffed toy dog. Children will be allowed to talk to, pet, and play with the stuffed toy dog during the interaction.
223625625|NCT03949569|BEHAVIORAL|5 Minute Puppy Video|Children will watch a 5 minute puppy video.
223625626|NCT02730858|BEHAVIORAL|Palliative and Oncology Care|Patients randomized to the intervention will receive collaborative care from palliative care and oncology for the remainder of their illness. The initial five visits with palliative care will be conducted in accordance with the study specific clinical practice guidelines and occur at least monthly.
223625627|NCT02730858|BEHAVIORAL|Standard Oncology Care|Patients randomized to oncology care alone will continue to receive routine care identical to what they would have received if they had not participated in the trial. Either patients or their oncologists can request palliative care consultation at any point in time.
223625628|NCT06247813|DIETARY_SUPPLEMENT|Inflammation Support Formula|Turmeric Extract (400mg), Bioperine (Black pepper, 10mg), Ashwagandha (500mg), and Olive Leaf Extract (250mg).
223625629|NCT06247813|DIETARY_SUPPLEMENT|Nerve Health Formula|Hydroxocobalamin (Vitamin B12, 1000mcg), Pyridoxal-5-Phosphate (Vitamin B6, 50mg), LMethylfolate (400mcg) and Trimethyl Glycine (Betaine, 750mg).
223625630|NCT06247813|DIETARY_SUPPLEMENT|Redox Support Formula|N-Acetyl-L-Cysteine (500mg), CoQ10 (250mg), Acetyl-L-Carnitine (200mg), Alpha Lipoic Acid (200mg), Benfotiamine (300mg), Selenium (250mcg), Riboflavin (50mg), Zinc (15mg) and Copper (1.8mg).
223625631|NCT05355571|DIETARY_SUPPLEMENT|LAB4 + Saccharomyces boulardii|Probiotic containing lactic acid bacteria and Saccharomyces boulardii at a dose of 35 billion per day
223625632|NCT05355571|DIETARY_SUPPLEMENT|Placebo|Placebo
223625633|NCT05682170|DRUG|ZN-d5 ZN-c3|Oral agent
224215134|NCT06442826|OTHER|Sham auricular stimulation (SAS)|"Sham intervention will be conducted following the exact same procedure as the TniAS group, with the only difference being the use of sham stimulation patches. These sham patches will consist of the same patches utilized in the TniAS group, except for the absence of the stainless steel spheres. During the application of these sham patches, the investigator will adhere to the identical process as in the TniAS group, with the exception that no palpation will be performed to locate the exact points, and only minimal pressure required for patch adherence will be applied to minimize any substantial stimulation. Participants in the SAS group will also be explicitly instructed not to stimulate the points until the removal of the patches.~The removal of the sham stimulation patches will follow the precise protocol applied in the TniAS group, ensuring consistency in the study procedures across both groups."
223762489|NCT07019402|BEHAVIORAL|Internet-based Lifestyle Education (iLifeEd)|iLifeEd is an online and asynchronous lifestyle education program. Participants will be presented with information and activities about healthy aging topics, including physical activity, sedentary behavior, sleep, stress, nutrition and hydration, social support, and cognitively stimulating activities. Stretching and toning exercises will also be included.
223762490|NCT06875908|OTHER|Turkish Validity and Reliability of The GSDS-T in patients with multiple sclerosis|The aim of this study is to investigate the validity and reliability of the Turkish version of general sleep disturbance scale (GSDS-T) in patients with multiple sclerosis. It has 21 questions. This study will be conducted on patients with multiple sclerosis. In order to evaluate the validity of the GSDS-T, the Pittsburgh Sleep Quality Index (PSQI) which can evaluate sleep quality and has been validated in Turkish, will be used. Scales will be repeated after 15 days to assess test-retest reliability.
223762491|NCT04918303|DEVICE|SKNA recording|"The coupled recording of the sympathetic nervous activity of the skin and of an ECG will be carried out using the ME6000 device, CE marked, from the Bittium company.~It will be performed for a maximum period of one hour at Day 1, Post-procedure between Day 1 and discharge from hospital, and month 6"
223625634|NCT05682170|DRUG|ZN-c3|Oral agent
223625635|NCT06068309|OTHER|CareAide App Usage|The study participant uses the CareAide app in addition to prescribed usual therapeutic care
223625636|NCT02529852|DRUG|Lenalidomide|"Phase I Starting Dose Level: 15 mg by mouth on Days 1 - 14 of each 21 day cycle.~Phase II Starting Dose Level: Maximum tolerated dose from Phase I."
223625637|NCT02529852|DRUG|Obinutuzumab|Phase I and II: 1000 mg by vein on Days 1, 8, and 15 of Cycle 1 and Day 1 of Cycles 2 - 6.
223625638|NCT02529852|DRUG|Cyclophosphamide|Phase I and II: 750 mg/m2 vein over about 1 hour on Day 1 of all cycles.
223625639|NCT02529852|DRUG|Doxorubicin|Phase I and II: 50 mg/m2 by vein over about 15 minutes each on Day 1 of all cycles.
223625640|NCT02529852|DRUG|Vincristine|Phase I and II: 1.4 mg/m2 by vein on Day 1 of all cycles.
223625641|NCT02529852|DRUG|Prednisone|Phase I and II: 100 mg by mouth daily on Days 1 - 5 of each 21 day cycle.
224215135|NCT03996707|OTHER|Weight Bearing|Immediate protected weight bearing in a CAM walking boot following foot \& ankle surgery
224215136|NCT03996707|OTHER|Strict non-weight bearing|Strict non weight bearing for 6 weeks following foot \& ankle surgery
223625642|NCT04087018|DRUG|zimberelimab|zimberelimab is a fully human immunoglobulin G4 (IgG4) monoclonal antibody targeting human PD-1. Participants in each cohort will receive zimberelimab intravenously Q3W. Treatment will continue until progressive disease, unacceptable toxicity, withdrawal of consent, or other reasons for which investigational product discontinuation occurs.
223625643|NCT06585046|PROCEDURE|pancreatic surgery|patients who did pancreas-related surgery
223625644|NCT06408870|DRUG|BI 1015550|BI 1015550
223625645|NCT03839524|DRUG|TG4050|Subcutaneous injections weekly for the first 6 weeks and then every 3 weeks.
223625646|NCT03354013|PROCEDURE|AOA|100% ICSI-AOA will be performed.
223625647|NCT03354013|DIAGNOSTIC_TEST|Genetic screening|Patients will donate a saliva sample. Genetic screening will take place for PLCzeta (male) and Dux4 (male and female). Also other possible genes involved in embryo development could be tested.
223625648|NCT03354013|DIAGNOSTIC_TEST|Calcium pattern analysis|Male patients will donate a sperm sample. Calcium pattern analysis will take place by injecting the patients' sperm into mouse and/or human (in vitro matured) oocytes (research-donated control oocytes). This will estimate the sperm capability to induce calcium oscillations in the oocyte.
223625649|NCT06235515|OTHER|rehabilitation program|conventional treatment (hotpack and TENS and exercise)
223625650|NCT06235515|OTHER|virtual reality|virtual reality treatment
223625651|NCT04584424|OTHER|The study does not required|The study is prospective multi-center COVID-19 patient cohort
223625652|NCT05512403|DRUG|PET/CT with 18F-DOPA|"A 18F-FDOPA PET exam is then performed (acquisition of 30 minutes in List Mode format) according to the French guidelines for PET neuro-oncological indications (Verger et al. Med Nuc, 2020, (5)).~Patient preparation and acquisition:~* 4 hours of fasting~* No carbidopa premedication~* 2 MBq / kg of 18F-FDOPA~* Dynamic acquisition in List Mode format for 30 min starting simultaneously with the patient's injection~* Low dose scanner for attenuation correction"
223625653|NCT04885569|BEHAVIORAL|Motivational interviewing with CBT (MICBT)|The culturally adapted MICBT will include approaches of motivational interviewing and offer ways of managing difficulties from a cognitive behavioural formulation.
223625654|NCT04885569|BEHAVIORAL|Mindfulness based Relapse Prevention (MBRP)|MBRP will incorporate cognitive-behavioural skills (i.e., effective coping skills, self-efficacy, and recognizing common antecedents of relapse) with mindfulness-based practices to decrease the probability of relapse by increasing awareness and flexible responding in the presence of substance use triggers.
223625655|NCT04885569|BEHAVIORAL|CAMIAB|This will be integrated CBT based motivational interviewing plus mindfulness based relapse prevention intervention group.
223625656|NCT06361563|DRUG|Nivolumab|As per product label
223762492|NCT04471168|DEVICE|Cryo-Auriculotherapy|3 sessions of cryo-auriculotherapy with device with nitrous oxyde on 10 auricular points at one month intervals.
223762493|NCT04471168|DEVICE|Sham comparator|3 sessions of cryo-auriculotherapy with device without nitrous oxyde on 10 auricular points at one month intervals.
223762494|NCT06316063|DEVICE|Apnoeic oxygenation with high-flow nasal oxygen|The subjects in the intervention group will be oxygenated with HFNO during the surgical procedure.
223762495|NCT06316063|OTHER|Mechanical ventilation|Study subjects in the comparator group will be tracheally intubated and mechanically ventilated
223762496|NCT07024147|BIOLOGICAL|JWCAR239|A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells targeting CD19/CD20
224316783|NCT04678050|DRUG|Dexmedetomidine|Dex solution (4 µg/mL). A loading dose of 2 µg/kg will be administered IV over 10 min, followed by a maintenance infusion of 0.1-1 µg/kg/h
224316784|NCT03324295|DIAGNOSTIC_TEST|cortical cataract|Blood urea
224316785|NCT06257381|OTHER|VO2max|"Overall design 16 non-smoking individuals with COPD and 16 controls (non-smokers) matched for age and sex on a group level will be included in the study. The study consists of two study days. Separation between the study days are at least 48 hours and maximum 10 days.~Before entering the study: Informed written and oral consent.~Study day 1: Medical examination, full lung function testing (dynamic spirometry, whole-body plethysmography, diffusion capacity) followed by a maximal oxygen consumption test (VO2peak), VO2-verification bout and VO2kinetic test (duration 3h).~Study day 2: Participants will undergo a maximal oxygen consumption test (VO2peak), VO2-verification bout and VO2kinetic test (duration 1,5h)."
224316786|NCT06194617|DRUG|Direct oral anticoagulant|Patients take DOACs according to their condition, with the dosage determined by the clinical physician.
223625657|NCT03422835|PROCEDURE|R-TME|Conventional Robotic Total Mesentery Excision
223625658|NCT03422835|PROCEDURE|R-TaTME|Robotic Transanal Total Mesentery Excision
223625659|NCT05125159|PROCEDURE|angioplasty guidewire-assisted transseptal puncture or Standard conventional transseptal puncture|"Patients randomized to the angioplasty guidewire-assisted transseptal puncture (GW-TSP) group will undergo transseptal puncture with angioplasty guidewire-assistance.~Patients randomized to the conventional transseptal group (Standard Group) will undergo transseptal puncture with BRK needle (St. Jude Medical)."
223625660|NCT04179552|DEVICE|PAAG-OA|Intra-articular injection with PAAG-OA (polyacrylamide hydrogel)
223625661|NCT05772819|DIAGNOSTIC_TEST|exercise MRI|All patients are subjected to two types of in-magnet exercise tests consisting of exercise cardiac magnetic resonance imaging (exCMR) and Phosphorus 31 magnetic resonance spectrography (31P MRS) of the quadriceps muscle, during exercise at various exercise intensities in a supine position using a MR-compatible ergometer (Lode MR Ergometer Pedal, Lode BV, Groningen, the Netherlands).
223625662|NCT02102789|DRUG|mFOLFOX6|Patients will receive mFOLFOX6 every 28 days: Oxaliplatin 85 mg/m2 IV over 3 hours on Day 1, 15; Leucovorin (l-LV) 200mg/m2 IV over 2 hours on Day 1, 15; followed by 5-Fluorouracil 2.4 g/m2 for 46 hours continuous infusion on Day 1, 15.
223625663|NCT02102789|DRUG|HAI|"Patients will receive HAI every 28 days: 0.12 mg/kg/day floxuridine (FUDR) and 25 mg dexamethasone in normal saline to a total volume of 300 ml will be administered through the HAI pump.~This will be repeated on Day 1 of each 28 day cycle. FUDR administration will be a 14-day continuous infusion using the HAI pump."
223625664|NCT02253615|OTHER|Machines exercises|Resistance training in pneumatic machines.
223625665|NCT02253615|OTHER|Elastic exercises|Resistance training with elastic tubes.
223625666|NCT05259345|PROCEDURE|Bilateral SE-TAP|A 20 mL of local anesthetic solution (10 mL of 5% bupivacaine + 5 mL of 2% lidocaine + 5 mL of saline) will be given between the internal oblique and transversus abdominis muscles toward the lateral border of the semilunar along the costal margin.
223762497|NCT07024147|DRUG|Fludarabine|Administered according to package insert
223762498|NCT07024147|DRUG|Cyclophosphamide|Administered according to package insert
223762499|NCT07024004|BEHAVIORAL|Exergame-Based Exercise + Conventional Physical Therapy|"Participants in this group will engage in a combined intervention consisting of:~Multicomponent physical exercise (aerobic, strength, balance, and flexibility), delivered twice per week for 12 weeks.~Exergames training using the Nintendo Switch console and Ring Fit Adventure game. Sessions include warm-up, gameplay involving full-body movements (e.g., squats, running, balance tasks), and cooldown.~Sessions are adapted to individual physical capacities and supervised by a trained kinesiologist.~The intensity is monitored using the Borg Scale, following ACSM guidelines."
224316787|NCT03092219|DEVICE|TEOSYAL RHA Redensity|A sterile, biodegradable, biocompatible, viscoelastic, clear, colorless, homogenized gel implant. It consists of cross-linked hyaluronic acid produced by fermentation of streptococcus zooepidemicus, formulated to a concentration of 15 mg/g and 0.3% w/w lidocaine in a physiologic buffer.
224316788|NCT05289869|DRUG|High-dose oxytocin|Starting dose 6 mU/min and increased by 6 mU/min every 30 minutes until adequate contractions achieved, at the discretion of the obstetric providers.
224316789|NCT05289869|DRUG|Low-dose oxytocin|Starting dose 2 mU/min and increased by 2 mU/min every 30 minutes until adequate contractions achieved, at the discretion of the obstetric providers.
223625667|NCT05259345|PROCEDURE|Bilateral M-TAPA|A 20 mL of local anesthetic solution (10 mL of 5% bupivacaine + 5 mL of 2% lidocaine + 5 mL of saline) will be given into the layer between the transverse abdominal muscle and the inferior plane of the costal cartilage at the midclavicular line, in the sagittal plane.
223625668|NCT05259345|PROCEDURE|Bilateral RSB|A 20 mL of local anesthetic solution (10 mL of 5% bupivacaine + 5 mL of 2% lidocaine + 5 mL of saline) will be given between the rectus muscle and posterior rectus sheath bilaterally.
223625669|NCT00003663|BIOLOGICAL|rituximab|
223762500|NCT07024004|BEHAVIORAL|Conventional Physical Therapy|"Participants in this group will receive a standard multicomponent physical exercise program consisting of:~Exercises for aerobic capacity, strength, balance, and flexibility.~Delivered in-person twice per week for 12 weeks at senior care centers.~Sessions include warm-up (5-10 min), main activity (30-40 min), and cooldown (5-10 min).~Intensity is controlled using the Borg Scale and monitored by a supervising kinesiologist."
223625670|NCT00003663|DRUG|dexamethasone|
223625671|NCT03222700|PROCEDURE|surgical procedure|In robotic thyroidectomy group, patients are received surgery using robotic system. In open thyroidectomy group, patients are received conventional open surgery.
223625672|NCT05870514|DRUG|Fospropofol disodium for injection|Patients in the experimental group received fospropofol disodium for injection at an initial infusion rate of 10 mg/kg/h and adjusted to maintain a Narcotrend index between 13 and 64.
223625673|NCT05870514|DRUG|Propofol|Propofol
223625674|NCT03564288|DRUG|SKI-G-801|SKI-G-801 is administered as an IV infusion over 10 minutes
223625675|NCT04694235|DIETARY_SUPPLEMENT|Egg intervention|Eggs are boiled until the white and yolk are firm (ca. 8 minutes) to maintain quality and safety and ensure the eggs are safe for consumption.
223625676|NCT06207786|OTHER|Povidone-Iodine Swabs|Undergo nasal swab of both nostrils for 30 seconds into each nostril, allowing two minutes to dry, immediately (e.g. within 30 minutes) prior to performing skin reconstruction.
223625677|NCT06207786|DIAGNOSTIC_TEST|Staphylococcus nasal swab|Undergo a nasal swab to identify patients with preoperative nasal Staphylococcus aureus colonization
223625678|NCT06207786|DRUG|Antibiotic|Receive an oral anti-staphylococcal antibiotic (e.g. oral cephalexin) with standard dosing only if indicated for antibiotic prophylaxis per the Mayo Clinic Dermatologic Surgery Antibiotic Prophylaxis protocol that is currently standard practice for patients undergoing Mohs micrographic surgery (MMS)
223625679|NCT03296514|BEHAVIORAL|MBSR|Eight week class on MBSR in addition to an orientation class and a half day retreat
223625680|NCT05003466|BIOLOGICAL|SARS-CoV-2 Vaccine (Vero Cells), Inactivated|"2 doses of SARS-CoV-2 Vaccine (Vero Cells), Inactivated with a 28-day interval constitute a primary immunization course. The third dose on 6 months after primary course is the booster dose.~Administer as an intramuscular injection into the lateral deltoid of the upper arm."
223625681|NCT05003466|BIOLOGICAL|Placebo|2 doses of Placebo should be administered as an intramuscular injection into the lateral deltoid of the upper arm with a 28-day interval.
223625682|NCT01968486|DRUG|PDT standard fluence, ranibizumab|In the verteporfin PDT combination therapy arm patients were treated on day one with 0.5 mg (10 mg/ml) IVR injection and after seven days with PDT standard fluence (wavelength, 689 nm; dose, 50 J/cm2; light intensity, 600 mW/cm2 for 83 s). Ranibizumab pro re nata (PRN) could be administered with a 30-day interval if re-treatment criterion were met. Re-treatment was based on increase of intraretinal or subretinal fluid \> 50 μm on OCT; loss of 5 letters or more on BCVA Early Treatment Diabetic Retinopathy Study (ETDRS) chart; fluorescein leakage from the CNV on FA images.
223625683|NCT01968486|DRUG|PDT reduced fluence, ranibizumab|In the verteporfin PDT combination therapy arm patients were treated on day one with 0.5 mg (10 mg/ml) IVR injection and after seven days with PDT reduced fluence ( wavelength, 689 nm; dose, 25 J/cm2 ; light intensity, 300 mW/cm2 for 83 s).Ranibizumab pro re nata (PRN) could be administered with a 30-day interval if re-treatment criterion were met. Re-treatment was based on increase of intraretinal or subretinal fluid \> 50 μm on OCT; loss of 5 letters or more on BCVA Early Treatment Diabetic Retinopathy Study (ETDRS) chart; fluorescein leakage from the CNV on FA images.
223625684|NCT01968486|DRUG|ranibizumab|In the ranibizumab monotherapy arm patients were treated with a loading phase of three consecutive 0.5 mg (10 mg/ml) IVR injections every six weeks. Ranibizumab pro re nata (PRN) could be administered with a 30-day interval if re-treatment criterion were met. Re-treatment was based on increase of intraretinal or subretinal fluid \> 50 μm on OCT; loss of 5 letters or more on BCVA Early Treatment Diabetic Retinopathy Study (ETDRS) chart; fluorescein leakage from the CNV on FA images.
224316790|NCT05146830|OTHER|Safety and Efficacy Assessments|Safety evaluations, disease-specific assessments, and other assessments to monitor for long-term complications of gene therapy intervention.
224316791|NCT01867463|BIOLOGICAL|Pfs25-EPA/Alhydrogel|The Pfs25-EPA conjugate was produced by reaction between thiolated PpPfs25 and maleimideactivated EcEPA, followed by purification using size-exclusion chromatography. The cGMP Pfs25-EPA conjugate Lot# WRAIR1634 was manufactured at Walter Reed Bioproduction facility in cGMP compliance in May 2010. Alhydrogel (Brenntag, Denmark) is an aluminum hydroxide gel and has been extensively used as an adjuvant in licensed human vaccines. Alhydrogel is supplied as a sterile product in water without preservatives. Pfs25- EPA/Alhydrogel WRAIR Lot #1668 was manufactured and filled as single-use vials at Walter Reed Bioproduction facility in cGMP compliance in October 2010. Each vial contains 78 g/mL conjugated Pfs25, 93 g/mL conjugated EPA and 1600 g/mL Alhydrogel in a volume of 0.8 mL. The vial label reads: 78 g/mL Conjugated Pfs25 on Alhydrogel .
223625685|NCT00800566|DRUG|Oral Clofarabine|The starting dose will be 1 mg orally daily x 21 days every 4 weeks +/- 4 days.
223625686|NCT00973726|OTHER|Glucose test|Subjects ingest an oral glucose tolerance test.
223625687|NCT03282461|DRUG|ABY-029|A sample size of 6-12 patients in this open label, single center, clinical trial of ABY-029. Administration will occur as a single intravenous injection to subjects with operable head and neck cancer approximately 1-3 hours prior to surgery.
223762501|NCT07024667|DEVICE|Pixel CO2 Laser for the Treatment of Vulvo-Vaginal Atrophy (VVA)|Pixel CO2 Laser for the Treatment of Vulvo-Vaginal Atrophy (VVA)
223762502|NCT07024771|DEVICE|Automated Pupillometer|An automated pupillometer will be used to measure pupil size and calculate NPi in newborns with HIE
223762503|NCT07025278|BEHAVIORAL|Medium difficulty fixed priority group|During the intervention process, participants carried out cognitive and motor tasks simultaneously. They were told to divide attention equally between them and not prioritize one over the other.
223625688|NCT05853016|DIAGNOSTIC_TEST|Urine collection for NEPHROCLEAR CCL14 Test|Urine will be collected and banked for future analysis with the NEPHROCLEAR CCL14 Test
223625689|NCT03965975|DEVICE|Lab Gold Standard|"First intervention (assigned to the All participants arm)."
223625690|NCT03965975|DEVICE|S-There|"Second intervention (assigned to the All participants arm)."
223625691|NCT05239052|OTHER|computer task intervention|subject received programs for upper arm movement training with providing computer screen task activities
223625692|NCT05239052|OTHER|conventional long-term care services|stroke subjects with wheelchair users receive conventional long-term care services
223625693|NCT04480489|OTHER|VR|"Task 1: Students will be first taken to the anesthesia lounge. Here the students will receive VR instructions on how to navigate Route 1 (i.e. they will watch a 360-degree immersive video using Samsung VR headset).~Task 2: After completing the Route 1 walkthrough, the same group will be given traditional instructions (2D video) on navigating Route 2, followed by an observed walkthrough of Route 2.~Students in the arm Group A will perform Task 1 using VR and then Task 2 using Traditional video. Meanwhile students in the arm Group B will perform Task 1 using Traditional video and Task 2 using VR"
223625694|NCT04480489|OTHER|Traditional|"Task 1: Students will be first taken to the anesthesia lounge. Here the students will receive traditional instructions (2D video) on how to navigate Route 1.~Task 2: After completing the Route 1 walkthrough, the same group will be given VR instructions on how to navigate Route 2, followed by an observed walkthrough of Route 2.~Students in the arm Group A will perform Task 1 using VR and then Task 2 using Traditional video. Meanwhile students in the arm Group B will perform Task 1 using Traditional video and Task 2 using VR"
223762504|NCT07025278|BEHAVIORAL|Medium difficulty variable priority group|During the intervention process, participants performed medium-difficulty cognitive and motor tasks simultaneously. Participants alter focus between the motor task and the cognitive task every half of the intervention time.
223762505|NCT04154111|DEVICE|Real TBS to the vmPFC|This will be delivered with the Magventure Magpro system; double blinded
223625695|NCT03282058|DEVICE|Silastic Stent|The silastic stent is a splint made of silicone.
223762506|NCT04154111|DEVICE|Sham TBS to the vmPFC|The MagVenture MagPro system has an integrated active sham that passes current through two surface electrodes placed on the skin beneath the coil.
223762507|NCT04154111|DEVICE|Real TBS to the dlPFC|This will be delivered with the Magventure Magpro system (double blinded).
223762508|NCT04154111|DEVICE|Sham TBS to the dlPFC|The MagVenture MagPro system has an integrated active sham that passes current through two surface electrodes placed on the skin beneath the coil.
223762509|NCT07024264|OTHER|Total energy requirement calculated by predictive equation|Critically ill patients are highly susceptible to malnutrition, making accurate caloric estimation essential to prevent both underfeeding and overfeeding during the acute phase in the ICU. Although predictive equations (PE) are widely used to estimate energy requirement, indirect calorimetry (IC) remains the gold standard. This study aimed to compare energy requirements estimated by PE and IC across different BMI categories.
223762510|NCT06698497|BEHAVIORAL|Communication Campaign|A social media vaccine communications campaign is deployed once increasing amounts of SARS-CoV-2 RNA are identified in the New York State wastewater surveillance network. The social media campaigns on Facebook, Instagram, and NextDoor social media platforms will run for 11 weeks. The campaign disseminates information about the wastewater surveillance network and vaccination (not COVID-19 specific) to residents in intervention counties. These social media platforms not only allow for quick and cost-effective exposure, but also allow for participation and interaction with participants. The campaign ads include a call-to-action link to the New York State wastewater surveillance network webpage which has information and links regarding vaccines for respiratory transmitted pathogens (COVID-19, influenza, and RSV) and how to schedule an appointment.
224215137|NCT05381883|OTHER|Questionnaire|"Participants will answer socio-demographic questions, questions about the lifetime experience of potentially traumatic events, the presence of a known psychological or medical disorder and the taking of medication, and a series of psychological assessment questionnaires.~The questionnaires, performed outside routine care, are as follows :~Posttraumatic stress disorder Checklist for Diagnostic and Statistical Manual of Mental Disorders-5 Beck Depression Inventory-Fast Screen General Anxiety Disorder-7 Coping Inventory for Stressful Situations Maslach Burnout Inventory Medical Outcomes Study Short-Form~The total time for completing the questionnaires is estimated at 20 minutes"
224215138|NCT01458119|DRUG|migalastat hydrochloride|Oral capsule QOD
224215139|NCT05969782|DEVICE|EVAR|Endovascular repair of aortoiliac aneurysm using Zenith or Endurant
224215140|NCT05003167|DEVICE|Expiratory Muscle Strength Training (EMST-150)|All participants will forcefully breathe out into an Expiratory Muscle Strength Training device (EMST-150) 25 times per day for 6 weeks. The EMST device will be set at a moderate intensity level (50% of each participant's maximum expiratory pressure).
224215141|NCT01116765|OTHER|no stimulation of the oral structure|
223625696|NCT05594550|OTHER|Data collection|"Demographic data:~Age, Sex, weight, height, main history and treatments.~\- Biological data: CRP, PCT, albumin, pre-albumin"
223625697|NCT05594550|OTHER|analysis of thoracic scans|muscle area calculated on the T7 and T12 thoracic slices
224215142|NCT01116765|OTHER|stimulation of the oral structure|
224215143|NCT04741139|DRUG|Acetaminophen and Diphenhydramine Only Product|Using a scheduled medication regimen of diphenhydramine and acetaminophen following IVIG medication to evaluate feasibility of enrollment, medication adherence, side effects related to study medication and IVIG.
223625698|NCT00323323|DRUG|CHOP|CHOP will be given 60-120 minutes following SQ administration of Alemtuzumab as follows: cyclophosphamide 750 mg/m2 IV on day 1, doxorubicin 50 mg/m2 IV on day 1, vincristine 1.4 mg/m2 (maximum dose = 2 mg) IV on day 1, and prednisone 100 mg PO on days 1-5.
223625699|NCT00323323|DRUG|Alemtuzumab|Single agent Alemtuzumab given subcutaneously (SQ) on week #1. Dose escalation will occur during the first week of therapy, starting with 3 mg of Alemtuzumab administered SQ on day 1. If well tolerated, this will be followed by 10 mg SQ on day 3 and 30 mg (split into 2 injection sites) on day 5.
223625700|NCT00323323|PROCEDURE|Plasma Samples|Plasma samples will be obtained for Alemtuzumab pharmacokinetics (PK) during the first week of single agent Alemtuzumab stepped up dosing and subsequently before and after the 5th and the 8th Alemtuzumab/CHOP dose.
223762511|NCT07023887|OTHER|6-12-25 Training Regimen|A conditioning regimen involving three exercises performed consecutively with minimal rest. Includes 4-6 repetitions at 4-0-1-0 tempo, 10-12 repetitions at 3-0-1-0 tempo, and 20-25 repetitions at 2-0-1-0 tempo.
223762512|NCT07023887|OTHER|8x8 Training Regimen|A conditioning regimen optimizing high volume with short rest periods. Six exercises are performed consecutively with a 2-0-1-0 tempo and no rest between sets.
224215144|NCT02367781|DRUG|Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody|"Atezolizumab was administered as IV infusion at a dose of 1200 milligrams (mg) on Day 1 of each 21-day cycle. Atezolizumab was administered to participants who were randomized to Arm A (Atezolizumab + Nab-Paclitaxel + Carboplatin) and to participants in Arm B (Nab-Paclitaxel + Carboplatin) who cross over at progression."
224215145|NCT02367781|DRUG|Carboplatin|Carboplatin was administered at area under the concentration curve (AUC) 6 milligrams per milliliter per minute (mg/mL/min) on Day 1 of each 21-day cycle.
224215146|NCT02367781|DRUG|Nab-Paclitaxel|Nab-paclitaxel was administered as IV infusion at a dose of 100 milligrams per square meter (mg/m\^2) on Days 1, 8, and 15 of each 21-day cycle.
224215147|NCT02367781|DRUG|Pemetrexed|Switch maintenance to pemetrexed can be administered within 6 weeks of Day 1 of the last induction cycle.
224215148|NCT02517099|DRUG|Beclometasone|Beclometasone dipropionate 200mcg bd for 4 months
224215149|NCT02517099|DRUG|Co-amoxiclav|Co-amoxiclav 0.3ml/kg bd for 4 weeks
224215150|NCT02517099|DRUG|Azithromycin|Azithromycin 10mg/kg od for 4 weeks
224215151|NCT01123980|DRUG|biphasic insulin aspart 30|Treat-to-target titration according to titration algorithm. Subcutaneous (under the skin) injection once daily.
224215152|NCT01123980|DRUG|metformin|"China: Tablets, 500 mg. Min. 1500 mg/day.~Japan: Tablets, 250 mg. Min 500 mg/day."
224215153|NCT01123980|DRUG|glimepiride|"China: Tablets, 2 mg. Min. 4 mg/day.~Japan: Tablets, 1 mg. Min. 4 mg/day."
224215154|NCT01123980|DRUG|insulin glargine|Treat-to-target titration according to titration algorithm. Subcutaneous (under the skin) injection once daily.
224215155|NCT01225991|DRUG|Milnacipran|All subjects will be free of antidepressant medications or opiates, or any other medications used to treat pain for at least 2 weeks prior to initiation of dose titration. Patients will be allowed to escalate up to 100 mg a day: Day 1: 12.5 mg once a day; Days 2-3: 25 mg/day (12.5 mg twice daily); Days 4-7: 50 mg/day (25 mg twice daily); After Day 7: 100 mg/day (50 mg twice daily). The stable-dose phase will be a 10-week period during which patients will take medications at the final dose achieved (either 100 mg per day in divided doses, or the maximum tolerated dose of less than 100 mg per day).
224215156|NCT05550675|OTHER|Questionnaires|Disease specific questionnaires
224215157|NCT03491319|PROCEDURE|Group X - head low tilt|spinal anaesthesia was given with table in neutral positon. 10 degree head low position was maintained for 10 minutes following spinal anaesthesia
224215158|NCT03491319|PROCEDURE|Group Y - head low tilt|the table was put in 10 degree head low position before proceeding to give spinal anaesthesia. Head low position was maintained for 10 minutes following spinal
224215159|NCT03491319|PROCEDURE|Group C - neutral|spinal anaesthesia was given with table in neutral positon. Patient was maintained in supine position for 10 minutes following spinal anaesthesia
224215160|NCT05329415|DIAGNOSTIC_TEST|TB Drug Levels|TB drug levels at 1-2 time points at weeks 2, 8 and 16
223762513|NCT07023887|OTHER|5/5/5 Cluster Set Training Regimen|A hypertrophy regimen where an individual performs 5 repetitions at a tempo of 4 seconds during the eccentric movement of the exercise, while performing the concentric motion in 1 second then resting for 20 seconds and repeating the sequence two additional times to total three clusters of 5 repetitions.
223762514|NCT07023887|OTHER|Double Training Regimen|A hypertrophy regimen adding an additional set of lesser repetitions for a specified exercise at the end of a tri-set of exercises.
223762515|NCT07024459|DEVICE|Monitoring|Participants will be monitored with secondary monitor collecting data from parameters under evaluation
223762516|NCT02198911|OTHER|NO GUM|For the NO GUM condition, participants will not chew gum before engaging in a computer task that will allow participants to earn points for MCC ice cream that they can consume.
223762517|NCT02198911|OTHER|MCC (Mint Chocolate Chip gum)|For the MCC gum condition, participants will chew MCC gum before engaging in a computer task that will allow participants to earn points for MCC ice cream that they can consume.
223762518|NCT02198911|OTHER|C (Cinnamon gum)|For the C gum condition, participants will chew Cinnamon gum before engaging in a computer task that will allow participants to earn points for MCC ice cream that they can consume.
223762519|NCT06876441|BEHAVIORAL|HDTC training program|Participants will receive usual care plus HDTC training program, including four parts: (1)30-minute educational seminar via Tencent: provide disease knowledge, propose strategies to replace sedentary behavior, and introduce Tai Chi. (2)1-hour online nurse-lead dyadic coaching session: introduce dyadic Tai Chi, clarify the roles and responsibilities, and establish a shared goal among dyads. (3)1-hour preliminary Tai Chi training session: face-to-face, introduce online Tai Chi learning, demonstrations on using heart rate monitor, and suggestions for safe home environment. (4)12-week Tai Chi training: Dyads learn Tai Chi following Tai Chi master online. Each session will last 30 minutes in week 2, increase to 40 minutes in week 3, and reach 50 minutes in week 4. The dyads' mastery of Tai Chi will then be assessed either onsite or online. Subsequently, they will practice Tai Chi with the master once a week and follow instructional videos twice a week, with each session lasting 50 minutes.
223762520|NCT06876441|OTHER|Usual Care Group|HF-caregiver dyads in the control group will receive the usual care, including a 30-min online comprehensive education and nurse-led support through telephone consultations in the aspects of symptom management, medication, dietary and exercise suggestions, psychosocial support, and regular monthly follow-up every month.
223625701|NCT00271635|DRUG|Placebo|Placebo 4 capsules b.i.d. during 1 year
223625702|NCT00271635|DRUG|ascorbic acid|Ascorbic acid 1000 mg (4 capsules of 250 mg) b.i.d. during 1 year
223625703|NCT03897959|DEVICE|Kohli vs Foley catheter|Alternative suprapubic catheter used for bladder drainage.
223625704|NCT04900012|PROCEDURE|Distal pancreatectomy|We are going to collect all cases
223625705|NCT01378559|OTHER|Erectile Dysfunction Inventory of Treatment Satisfaction (EDITS) Questionnaire|A questionnaire accessing satisfaction with a penis prosthesis
223625706|NCT00923520|DRUG|DMS 612|DMS 612 on day 1 and 2 with doses starting at 3.5mg/m2 to 18.5mg/m2 every 21 days until MTD is reached
223625707|NCT02571712|DRUG|bimatoprost 0.03% plus timolol 0.5%|1 drop of bimatoprost 0.03% plus timolol 0.5% (GANFORT®) instilled in the affected eye once daily.
223625708|NCT02056743|DRUG|CYP cocktail|Each group administered CYP cocktail (Caffeine 200mg + Losartan 50mg + Omeprazole 20mg + Dextromethorphan 30mg + Midazolam 7.5mg) under fasting conditions.
223625709|NCT02056743|DRUG|Fexofenadine 30mg|Each group administered Fexofenadine 30mg under fasting conditions.
223625710|NCT02056743|DIETARY_SUPPLEMENT|Red ginseng|During 4\~17th days, end of the period 1, the group of red ginseng administered red ginseng extract.
223625711|NCT02056743|DIETARY_SUPPLEMENT|Fermented-red ginseng|During 4\~17th days, end of the period 1, the group of fermented-red ginseng administered fermented-red ginseng extract.
223625712|NCT05357573|DRUG|KRN23|KRN23 is a sterile clear colourless and preservative free solution supplied in single use 5 mL vials containing 1 mL of KRN23 at a concentration of 30mg/mL
223625713|NCT02913703|DRUG|Ghrelin|Boluses of Ghrelin will be given over a 1 minute period at 3 ug/kg. Ensure (2 cans) will also be given.
223625714|NCT02913703|OTHER|Saline|Boluses of saline will be given over a 1 minute period. Ensure (2 cans) will also be given.
223625715|NCT06306833|OTHER|Surface Electromyography (sEMG) Biofeedback|Biofeedback sEMG therapy through the use of virtual aids like digital therapeutics would help reduce chronic low back pain in patients by overcoming their psychophysiological manifestations. All participants in the intervention group will receive sEMG biofeedback as an alternative therapy.
223625716|NCT00976846|DEVICE|Dialyzer Baxter Xenium XPH 210|High-Flux dialyzer
223625717|NCT01022736|DRUG|Gabapentin|Subjects will be administered gabapentin (600 mg, orally) 1 hour prior to cardiac bypass surgery, 1 hour following extubation, then every 8 hours for a total of 4 doses.
223625718|NCT04664153|DRUG|PF-07038124 ointment|PF-07038124 ointment at 0.01% with QD dosing for 6 weeks
223625719|NCT04664153|DRUG|Vehicle ointment|Vehicle ointment with QD dosing for 6 weeks
224215161|NCT06529276|OTHER|Augmented reality clinical learning|Clinical learning of emergency airway management including endotracheal intubation using video laryngoscope and other AGPs, such as bag-valve-mask ventilation, using augmented reality immersive learning technology.
224215162|NCT06529276|OTHER|Control arm regular clinical learning|Regular bedside learning of emergency airway management including endotracheal intubation using video laryngoscope and other AGPs, such as bag-valve-mask ventilation,
224215163|NCT03779685|PROCEDURE|General anesthesia|Sevoflurane and morphine
223625720|NCT06373016|DIETARY_SUPPLEMENT|Glucose|A glucose drink is administered midway through one of the scan sessions.
223625721|NCT06373016|DIETARY_SUPPLEMENT|Ketones|A ketone drink is administered midway through one of the scan sessions.
223625722|NCT01184586|DEVICE|Intervention - ESWT Storz Duolith high energy|Three weekly sessions of extracorporeal shockwave therapy with focussed shock waves (2000 impulses, 0,35-1,25mJ/mm2)
223625723|NCT01184586|DEVICE|CONTROL SHAM-ESWT Storz Duolith [0.01mJ/mm2]|Three weekly sessions of sham extracorporeal shock wave (2000 impulses, 0,01mJ/mm2)
223762521|NCT06718413|DRUG|hyaluronidase plus saline|Injection of study drug with saline
224215164|NCT03779685|PROCEDURE|Regional anesthesia|Paravertebral block
223625724|NCT00097500|DRUG|exenatide|subcutaneous injection, titrated up to a maximum of 20mcg three times a day in order to meet defined blood glucose targets
223625725|NCT00097500|DRUG|Insulin glargine|subcutaneous injection, once a day, titrated as necessary in order to meet defined blood glucose targets
223625726|NCT00097500|DRUG|Metformin|Patients usual dosage
223625727|NCT04891614|DEVICE|PRISM|Subjects will complete 15 neurofeedback training sessions delivered twice per week, on non-consecutive days, over 8 consecutive weeks.
223625728|NCT03388346|DRUG|Ga-68 PSMA-HBED-CC PET|Ga-68 PSMA-HBED-CC is an investigational PET drug (radionuclide), that binds to the prostate specific receptors. The dose will be about 5mCi (range 3-7 mCi) and administered intravenously.
223625729|NCT01199354|PROCEDURE|Mastectomy, preservation of the skin envelope,followed by immediate reconstruction with autologous latissimus dorsi flap.|Mastectomy, preservation of the skin envelope, removal of the nipple-areolar complex and dissection of the axillary lymph nodes followed by immediate reconstruction with autologous latissimus dorsi flap with or without prosthesis.
223625730|NCT00189098|DRUG|Sulfamethoxazole-trimethoprim|18 mg/kg, two times a day
223625731|NCT00189098|DRUG|Placebo|
223625732|NCT01029496|PROCEDURE|different time of umbilical cord clamping|"1. for normal birth(apgar score over 7),include:term ,preterm,normal birth or cesarean section : experimental group1: waiting until the ceased of the umbilical cord pulsing, then cut the cord.before cutting the cord, the baby is keeping warm and put over mother's abdomen.~   control group 1-1: clamping and cut the cord within 10 second after birth. control group1-2: clamping and cut the cord 90 second after birth.~2. for in case of asphyxia(regardless term or preterm,normal birth or cesarean section born):~experimental group2: resuscitate on bed site with the cord unclamped until the umbilical cord ceased pulsing.~control group 2-1 clamping and cut the cord within 10 second. and resuscitate the baby after transfer to the Irradiation table."
223625733|NCT01404507|DRUG|Gp 2b 3a inhibitor|bolus injection of abciximab via intracoronary route single injection during primary PCI dosage : 0.25mg/kg
223625734|NCT01404507|DEVICE|aspiration thrombectomy|Aspiration thrombectomy via aspiration catheter
223625735|NCT01404507|OTHER|Both use|Both use of intracoronary abciximab and aspiration thrombectomy
223762522|NCT06718413|DRUG|saline|injection of normal saline and no study drug
223762523|NCT04074317|DRUG|PRAM9|SC injection
223762524|NCT04074317|DRUG|Regular Insulin + Pramlintide|Separate SC injections
223762525|NCT04074317|DRUG|Regular Insulin|SC injection
223762526|NCT06923553|BEHAVIORAL|NDBIs|Caregivers will meet with clinicians virtually weekly to (a) watch the newly developed NDBI videos that demonstrate the strategy use, (b) discuss how this might be applied to their own child, (c) receive individualized homework planning, (d) record and upload videos of their practice of strategy use with their own child, and (e) review the videos with clinicians to receive individualized feedback on their strategy use. This will occur for 10 weeks. Each session will be video recorded to assess the clinicians' intervention fidelity. After 10 weeks, pre-post tests will be conducted to assess parents' confidence on implementing these strategies, their child's social communication, and satisfaction of providers and caregivers.
223625736|NCT05320081|BIOLOGICAL|CD30 CAR-T|"Subjects need to complete a series of checks before reinfusion of CD30 CAR-T cells as baseline information for subjects after non-myeloablative pretreatment. The subject was reinfused with CD30 CAR-T cells (10±3)×10\^6/kg on the 0th day of the first dosing cycle (the investigator decided the specific reinfusion dose based on the subject's own/disease conditions and preparation conditions in vitro ), concurrent oxygen inhalation and monitoring (ECG, blood pressure and blood oxygen monitoring). The reinfusion was completed in about 30 minutes, and the tube was flushed with saline.~Note: CAR-T cell infusion and reinfusion dose are based on the subject's condition."
223625737|NCT05320081|DRUG|Camrelizumab|Received Camrelizumab treatment on the 15th day after CAR-T cell reinfusion, and then received Camrelizumab treatment every 2 weeks.
223625738|NCT00474123|DRUG|Simvastatin 80 mg/day for 6 weeks|Simvastatin 80 mg/day, single dose, for 6 weeks.
223625739|NCT00474123|DRUG|Ezetimibe 10 mg / Simvastatin 20 mg|"Ezetimibe 10 mg / Simvastatin 20 mg~Patients were treated with daily Ezetimibe 10 mg / Simvastatin 20 mg for 6 weeks"
223625740|NCT04306471|DRUG|Evolocumab 140mg/mL Injector 1milliliter (mL) Pen x 3 for a monthly dose of 420 mg for 12 months.|The study subjects randomized to the treatment study arm will receive monthly subcutaneous injections of evolocumab 420 mg in the abdomen, thigh or upper arm. The study drug (evolocumab) prefilled injector pens are to be provided by Amgen.
223625741|NCT04306471|OTHER|Placebo 1 milliliter (mL) Injector Pen x 3 monthly for 12 months|The study subjects randomized to the control study arm will receive monthly subcutaneous injections of placebo 1 mL x 3 in the abdomen, thigh or upper arm. The study placebo prefilled injector pens are to be provided by Amgen.
223625742|NCT00330577|DRUG|timolol maleate 0.5%|
223625743|NCT00330577|DRUG|latanoprost/timolol fixed combination|
223625744|NCT00330577|DRUG|placebo (artificial tears)|
223625745|NCT00987376|DEVICE|Diagnostic Imaging: C11 choline PET; C11 acetate PET; and MRI Spectroscopy|C11 Choline, C11 Acetate PET and MRI
223625746|NCT00639197|PROCEDURE|To tunnel|Using the standard Seldinger technique and under the guidance of ultrasound, the catheter will pass through a 3-5cm subcutaneous tunnel before it is eventually secured to reside at the internal jugular vein.
223625747|NCT00639197|PROCEDURE|Standard (not to tunnel)|Using the standard Seldinger technique and under the guidance of ultrasound, the catheter is secured to reside at the internal jugular vein, without a subcutaneous tunnel.
223625748|NCT05475249|OTHER|Implant placement and prothesis made with different types of abutment|Dental implants (Tapered internal implants; BioHorizons, Birmingham, EEUU) will be placed in healed residual ridges (minimum of 4 months after tooth extraction). After connecting healing abutments, the flaps will be sutured around the abutments for non-submerged healing. An abutment composed of white yttrium oxide stabilized zirconia abutment (PYRCA; BioHorizons, Birmingham, EEUU) previously immersed in fluorescent liquid (Zirkonzahn, South Tirol, Italy) will be placed in the test group, whether in the control group the same abutment will be used but without fluorescent layer. The selected abutment is machined and designed for use with cemented restorations. A single experienced restorative dentist using one dental laboratory carried out all the prosthetic procedures. Single crowns full ceramic will be performed and cemented with RelyX™ Luting Cement.
223625749|NCT00642356|DRUG|Carbidopa/levodopa/entacapone|Carbidopa/levodopa/entacapone 25/100/200 mg tablets plus placebo immediate release carbidopa/levodopa capsules, administered orally for 8 weeks. Total daily dosage and frequency of dosing for each patient was determined by the investigator and stabilized upon entry into the study.
223625750|NCT00642356|DRUG|Immediate release carbidopa/levodopa|Immediate release carbidopa/levodopa 25/100 mg capsules plus placebo carbidopa/levodopa/entacapone tablets, administered orally for 8 weeks. The maximum daily dose is 800 mg. Total daily dosage and frequency of dosing for each patient was determined by the investigator.
223625751|NCT04389775|DRUG|Cohort A|"Participants in each cohort (A1 to A6) will be randomised to receive a SC dose of XW003 on Day 1 after overnight fasting by body weight range:~1. Proposed XW003 Dose Levels (50 kg-75 kg): 0.03mg, 0.1mg, 0.2mg, 0.4mg, 0.8mg and 0.6mg respectively for Cohorts A1 to A6.~2. Proposed XW003 Dose Levels (76 kg-90 kg): 0.03mg, 0.1mg, 0.25mg, 0.5mg, 1.0 mg and 0.6mg.~These doses are subject to change following SRC review of each cohort - XW003 dose level will not exceed 2.0 mg."
223625752|NCT04389775|DRUG|Placebo A|"Participants in each cohort (A1 to A6) will be randomised to receive a SC dose of volume-matching placebo on Day 1 after overnight fasting by body weight range:~1. Proposed Placebo Dose Levels (50 kg-75 kg): 0.03mg, 0.1mg, 0.2mg, 0.4mg, 0.8mg, and 0.6mg respectively for Cohorts A1 to A6.~2. Proposed Placebo Dose Levels (76 kg-90 kg): 0.03mg, 0.1mg, 0.25mg, 0.5mg, 1.0 mg and 0.6mg.~These doses are subject to change following SRC review of each cohort - dose level will not exceed 2.0 mg."
223762527|NCT06735222|DIETARY_SUPPLEMENT|Hydroxytyrosol acetate (HT-Ac)|Hydroxytyrosol acetate (15 mg) orally co-administered with 2 g EPA
223762528|NCT06735222|DIETARY_SUPPLEMENT|Hydroxytyrosol eicosapentanoate (HT-EPA)|Oral intake of hydroxytyrosol eicosapentanoate (15 mg) solubilized in an EPA-enriched oil matrix.
223762529|NCT06735222|DIETARY_SUPPLEMENT|Oleacore®|Oleacore® (containing 15 mg of hydroxytyrosol) orally co-administered with 2 g EPA
223762530|NCT06893627|BEHAVIORAL|Body Project|Dissonance-based, online, peed-led eating disorder prevention intervention, consisting of 4 x 1 hour with a week a part.
223762531|NCT06893627|BEHAVIORAL|Expressive writing|Participants are encouraged to write about their body 40 min. per week
223762532|NCT06894836|BEHAVIORAL|Third wave VR therapy|All participants in this trial will receive the VR intervention which is adapted from third wave CBT protocols (including mindfulness and Acceptance and Commitment Therapy) and focuses on decentering-the ability to step back and view thoughts and emotions as temporary, objective events rather than identifying with them. Decentering has been linked to improved emotional regulation, reduced rumination, and better psychological flexibility, which in turn can lead to improvements in depression and anxiety symptoms. The intervention is clinician-delivered in a clinical setting, one-on-one, over 4-5 sessions (60 min each) across 10-12 weeks. Each session includes psychoeducation, a 15-minute VR experience, and debriefing. Sessions cover three core techniques targeting improvement in decentering ability: 1) arousal reduction via controlled breathing, 2) sitting with discomfort without reacting, and 3) cognitive defusion by changing perception of negative thoughts.
223762533|NCT06895759|DEVICE|Soda lime|Respiration into a snow air pocket through an experimental rebreathing circuit with the integration of a soda lime canister.
223762534|NCT06895759|DEVICE|Sham|Respiration into a snow air pocket through an experimental rebreathing circuit without the integration of a soda lime canister.
223625753|NCT04389775|DRUG|Cohort B|"Participants in cohorts B1 to B3 (n=10 per cohort) will receive multiple SC doses of XW003 (n=8) once weekly for 6 weeks following an overnight fast of at least 10 hours.~1. Subject to change following SRC review of each cohort.~2. Following 4 weeks of once weekly dosing, the SRC will review the safety data (and PK data for Cohort B1 only) to determine the treatment for the following cohort and whether dosing can commence in parallel.~3. At least 3 days prior to Cohort B3 Week 3 (i.e., 3 days prior to the third dose in Cohort B3), the SRC will review the safety and PK data for Cohorts B1 and B2 to determine whether Cohort 3 dosing for Weeks 3 to 6 may commence."
223625754|NCT04389775|DRUG|Placebo B|"Participants in cohorts B1 to B3 (n=10 per cohort) will receive multiple SC doses of matching placebo (n=2) once weekly for 6 weeks following an overnight fast of at least 10 hours.~1. Subject to change following SRC review of each cohort.~2. Following 4 weeks of once weekly dosing, the SRC will review the safety data (and PK data for Cohort B1 only) to determine the treatment for the following cohort and whether dosing can commence in parallel.~3. At least 3 days prior to Cohort B3 Week 3 (i.e., 3 days prior to the third dose in Cohort B3), the SRC will review the safety and PK data for Cohorts B1 and B2 to determine whether Cohort 3 dosing for Weeks 3 to 6 may commence."
223625755|NCT05030025|COMBINATION_PRODUCT|abacavir, dolutegravir and lamivudine dispersible tablets|Abacavir, Dolutegravir and Lamivudine Dispersible Tablets, 60 mg/5 mg/30 mg Dose: 60 mg/5 mg/30 mg (1 x 60 mg/5 mg/30 mg)
223625756|NCT05030025|COMBINATION_PRODUCT|Triumeq Dispersible Tablets 5 mg GSK1349572 [Dolutegravir]/ 60 mg Abacavir/ 30 mg Lamivudine|Triumeq Dispersible Tablets 5 mg GSK1349572 \[Dolutegravir\]/ 60 mg Abacavir/ 30 mg Lamivudine Dose: 60 mg/5 mg/30 mg (1 x 60 mg/5 mg/30 mg)
223625757|NCT03469752|BEHAVIORAL|Parent education classes|8 weekly classes for fathers and youth (10-14 years) at community centers focused on improving parenting skills, youth energy balance related behaviors and weight status
223625758|NCT01009060|DRUG|GSK239512|Histamine H3 Antagonist
223625759|NCT01009060|DRUG|Placebo|Placebo to match GSK239512
223625760|NCT01304264|DEVICE|Color Doppler Imaging|Color Doppler imaging (CDI) system for measurements of blood flow in the ophthalmic (OA), central retinal (CRA), and nasal (NPCA) and temporal (TPCA) posterior ciliary arteries. In each vessel, peak systolic velocity (PSV) and end diastolic velocity (EDV) were determined, and Pourcelot's resistive index will be calculated (RI = (PSV-EDV)/PSV).
224316792|NCT01867463|BIOLOGICAL|Euvax B|Euvax B consists of highly purified, noninfectious particles of HBsAg absorbed onto aluminum salts as an adjuvant and preserved with thimerosal.
223625761|NCT02749396|DRUG|Betaseron (Interferon beta-1b, BAY86-5046), Bayer HealthCare AG|Information will be obtained from the databses DPP (FIN) and MBR (SWE, NOR)
223625762|NCT02749396|DRUG|Extavia (interferon beta-1b), Novartis Pharma AG|Information will be obtained from the databses DPP (FIN) and MBR (SWE, NOR)
223762535|NCT00323154|DRUG|Nalbuphine|
223762536|NCT02601287|BIOLOGICAL|Botulinum Toxin Type A|Botulinum Toxin Type A into detrusor muscle on Day 1
223762537|NCT06853249|OTHER|liquid meal|An isocaloric amount (500 kcal) of a commercially available liquid meal with a matched macronutrient composition is consumed. After 5 hours, lunch is eaten ad libitum.
224316793|NCT01867463|BIOLOGICAL|Menactra|Menactra , Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine, is a sterile, intramuscularly administered vaccine that contains Neisseria meningitidis serogroup A, C, Y and W-135 capsular polysaccharide antigens individually conjugated to diphtheria toxoid protein. N meningitidis A, C, Y and W-135 strains are cultured on Mueller Hinton agar (3) and grown in Watson Scherp (4) media. The polysaccharides are extracted from the N meningitidis cells and purified by centrifugation, detergent precipitation, alcohol precipitation, solvent extraction and diafiltration.
223625763|NCT02749396|DRUG|Rebif (interferon beta-1a), Merck Serono Europe Ltd|Information will be obtained from the databses DPP (FIN) and MBR (SWE, NOR)
223625764|NCT02749396|DRUG|Plegridy (peginterferon beta-1a), Biogen Idec Ltd|Information will be obtained from the databses DPP (FIN) and MBR (SWE, NOR)
223762538|NCT06853249|OTHER|semi-solid meal|An isocaloric amount (500 kcal) of a commercially available semi-solid oatmeal with a matched macronutrient composition is consumed. After 5 hours, lunch is eaten ad libitum.
223625765|NCT02749396|DRUG|Avonex (interferon beta-1a), Biogen Idec Ltd|Information will be obtained from the databses DPP (FIN) and MBR (SWE, NOR)
223625766|NCT02749396|DRUG|MSDMDs other than Betaseron (Interferon beta-1b, BAY86-5046)|Information will be obtained from the databses DPP (FIN) and MBR (SWE, NOR)
223762539|NCT06853249|OTHER|caloric drink + semi-solid meal|A predefined amount of a caloric drink (= liquid meal) together with an ad libitum amount of a semi-solid meal is consumed. After 5 hours, lunch is eaten ad libitum.
223762540|NCT06853249|OTHER|non-caloric drink + semi-solid meal|A predefined amount of a non-caloric drink (= water, sucralose, flavor) together with an ad libitum amount of a semi-solid meal is consumed. After 5 hours, lunch is eaten ad libitum.
223762541|NCT01101841|DRUG|Brisdelle (paroxetine mesylate)|Eligible subjects will be randomized to receive either Brisdelle (paroxetine mesylate) Capsules 7.5 mg or placebo capsules in a 1:1 ratio.
223762542|NCT01101841|DRUG|Placebo capsules|Eligible subjects will be randomized to receive either Brisdelle (paroxetine mesylate) Capsules 7.5 mg or placebo capsules in a 1:1 ratio.
223762543|NCT04041505|BEHAVIORAL|(feeding modality)|The intervention is a change in feeding modality: in both arms, infant's will consume mother's milk. The difference in arms is the modality in which human milk is consumed: either directly from the breast, or from a bottle.
223762544|NCT03154619|DRUG|0.1% TR 987|TR 987 0.1%
224316794|NCT00373763|PROCEDURE|Fetoscopic tracheal balloon occlusion|
223625767|NCT02749396|OTHER|No MSDMDs therapy (control)|Information will be obtained from the databses DPP (FIN) and MBR (SWE, NOR)
223625768|NCT01628146|DEVICE|SUPRACOR LASIK treatment|The SUPRACOR algorithm uses the subjective refraction of the eye to create a treatment for the distance vision correction.
223625769|NCT03939546|OTHER|B. infantis EVC001|"Bifidobacterium longum subspecies infantis strain EVC001, designated a Foods for Special Dietary Use (FSDU)"
223625770|NCT06247917|DRUG|Fludarabine, Busulfan and Melphalan|Use Fludarabine, Busulfan and Melphalan as myeloablative conditioning regimen for untreated MDS-EB patients.
223762545|NCT03154619|DRUG|Placebo gel|Placebo gel twice weekly for 4 weeks, then once weekly for 8 weeks. Gel will be applied to cover the wound cavity and wound surface to a thickness of 5 mm.
223762546|NCT00445614|BEHAVIORAL|Effects of trout on CVD risk markers and plasma proteome|
223762547|NCT05780242|BEHAVIORAL|Self-questionnaire Eating Attitudes|self-diagnostic and quantitative questionnaire of 40 questions evaluating the behavior, severity and evolution of anorexia nervosa
223762548|NCT05780242|BEHAVIORAL|Situational Anxiety and Trait Anxiety|"assess anxiety as a personality trait (feelings of apprehension, tension, nervousness and worry that the subject usually feels), and anxiety as a ' emotional state linked to a particular situation"
223762549|NCT05780242|BEHAVIORAL|Beck Depression Inventory (BDI) scale|a diagnostic self-questionnaire allowing a quantitative estimation of the intensity of depressive symptoms in adults and adolescents
223762550|NCT05780242|BEHAVIORAL|• Post-traumatic Check List Scale|questionnaire includes 20 items, each question is to be rated between 1 and 5 depending on the intensity and frequency of symptoms during the previous month.
223762551|NCT02381392|DEVICE|Accuvein AV400|This device is FDA approved for assistance with intravenous access. It has been shown to cause no harm to patients. The device utilizes infrared technology to provide a visible map of the subject's blood vessels where the light is shone.
223762552|NCT02718105|GENETIC|KIR HLAC determinations|We will take blood samples for KIR HLA-C determinations.
223762553|NCT02616250|DRUG|Brimonidine 0.33% gel (Br)|
223762554|NCT02616250|OTHER|CD07805/47 (Br) placebo gel|
223762555|NCT02616250|DRUG|Ivermectin 1% cream (IVM)|
224316795|NCT04107272|DEVICE|Real repetitive transcranial magnetic stimulation|"The real rTMS will be delivered over M1 (hand representation) of dual hemispheres with 10 trains of 10 Hz pulses for 10 seconds, with a total of 1,000 pulses per hemisphere. The real rTMS intensity will be set as 80% resting motor threshold and the interval between each train of pulses will be set as 50 seconds. The real rTMS will be delivered as daily session for five consecutive days, followed by two fortnightly maintenance sessions during the follow-up period after the completion of five daily sessions. The real rTMS will be delivered by designated physical therapists using figure-of-8 shaped coil."
224316796|NCT04107272|DEVICE|Sham repetitive transcranial magnetic stimulation|The sham rTMS of this study will be delivered with the same active coil angled 90-degree way from the scalp. The intensity of sham rTMS will be set at lowest stimulator output that can generate similar noise to the real rTMS. The sham rTMS will be delivered in the same manner and duration with real rTMS.
223625771|NCT02868112|OTHER|Usual Oncology Care|Participants receiving usual oncology care will not meet routinely with geriatric clinicians, though they may receive a geriatrics consult at their request or at the discretion of their treating team.
223762556|NCT02616250|OTHER|CD5024 (IVM) placebo cream|
223762557|NCT03950284|DEVICE|immediate loading with all on four technique in FFF|All cases will undergo surgery under local regional anesthesia. Injection of local anaesthesia (Articaine 4% and 1:100000 epinephrine) for regional infiltration. Sequential drilling then insertion of the dental implant fixtures and abutments on which the prefabricated temporary prosthesis will be fixed.
223762558|NCT02520024|BEHAVIORAL|self-directed care|
223762559|NCT04484246|OTHER|Prevalence of sarcopenia in older patient with prostate cancer|All patients are screened for sarcopenia with the SAR-F questionnaire test score ≥4/10 suspected of sarcopenia will undergo a dual-X-ray exam to dertemine their skeletal muscle mass and the prevalence of sarcopenia before oncological treatment.
223762560|NCT05337059|OTHER|PEEP and Tidal Volume Titration|PEEP and Tidal Volume Titration According to Inspiratory and Expiratory Transpulmonary Pressures
223762561|NCT00653224|DRUG|levocetirizine dihydrochloride|5 mg daily (oral tablet) for 14 days
223762562|NCT00653224|DRUG|placebo|0 mg daily (matching oral tablet) for 14 days
223762563|NCT03732092|DIAGNOSTIC_TEST|Coma Recovery Scale-Revised|Patients with disorders of consciousness were assessed by Coma Recovery Scale-Revised (CRS-R). In addition, we selected three stimuli: 1) 1-octene-3-ol, 2) pyridine, 3) water. We presented these three stimuli in front of the patients nose for 3 seconds.
223762564|NCT01088516|DRUG|Lopinavir/Ritonavir (200/50 mg) Tablets + Zidovudine + 3TC|Zidovudine 300mg PO BID + 3TC 150 mg PO BID + Lopinavir/Ritonavir (200/50 mg) two tablets PO BID
223762565|NCT00931905|DRUG|Homeopathic medication Plumbum metallicum|The homeopathic medication Plumbum metallicum 15CH was used and was diluted and dynamized using the Hahnemann centesimal scale, whose matrix was obtained from the Schraiber laboratory in 4CH in 70% ethanol. From this solution, the matrix was elevated to 14CH in 70% ethanol. The 15CH dynamization was prepared in 30% ethanol, which was the recommended solution for administration.The drugs were administered orally (ten drops) twice daily - at the beginning and the end of the shift and under supervision for 30 days. The patients were instructed not to take other medication without medical guidance during the time they were participating in the research.
223762566|NCT00931905|OTHER|Hydroalcoholic solution|The placebo was composed of a hydroalcoholic solution also prepared in 30% ethanol. It was administered orally (ten drops) twice daily - at the beginning and the end of the shift and under supervision for 30 days. The patients were instructed not to take other medication without medical guidance during the time they were participating in the research.
223762567|NCT06371040|DRUG|CD19-BCMA Targeted CAR-T Dose 1|5.0 e5/ kg CD19-BCMA CAR-T positive T cells
223762568|NCT06371040|DRUG|CD19-BCMA Targeted CAR-T Dose 2|1.5 e6/ kg CD19-BCMA CAR-T positive T cells
223762569|NCT06371040|DRUG|CD19-BCMA Targeted CAR-T Dose 2|5 e6/ kg CD19-BCMA CAR-T positive T cells
223762570|NCT06784167|OTHER|Non-Interventional Study|Non-interventional study
224215165|NCT01676259|DRUG|siG12D-LODER|The implantation of siG12D-LODERs is selected to meet current gastroenterology endoscopic ultrasound (EUS) biopsy procedures, proved to be highly effective and safe.
224215166|NCT01676259|DRUG|Gemcitabine+nab-Paclitaxel|Gemcitabine+nab-Paclitaxel
224215167|NCT01676259|DRUG|Folfirinox|Folfirinox or modified Folfirinox
224215168|NCT02942173|BIOLOGICAL|CD45RA-depleted peripheral blood mononuclear cells|Infusion of escalating doses of CD45RA-depleted donor-derived allogeneic peripheral blood mononuclear cells
224215169|NCT04934111|DRUG|LNP-nCOV saRNA-02 Vaccine|a self-amplifying ribonucleic acid (saRNA) vaccine encoding the S glycoprotein of SARS-CoV-2, the causative agent of COVID-19
224316797|NCT03013816|BEHAVIORAL|Organ Donation Education: Testimonial Messaging|The testimonial messaging video intervention will be shown
224316798|NCT03013816|BEHAVIORAL|Organ Donation Education: Informational Messaging|The informational messaging video intervention will be shown
224316799|NCT03013816|BEHAVIORAL|Organ Donation Education: Blended Messaging|The blended messaging video intervention will be shown
223625772|NCT02868112|OTHER|Transdisciplinary Intervention|Patients randomized to the transdisciplinary intervention will undergo evaluation with a board-certified geriatric clinician, who will tailor their care based on the results of a brief geriatric screening tool, completed prior to their visit. We will test a two-visit transdisciplinary intervention with the first visit occurring within four weeks of enrollment and the second visit four weeks after the initial visit.
223625773|NCT03553901|PROCEDURE|Acupressure|Acupressure was performed before the injection onto GB30 point
223625774|NCT06011499|OTHER|Internet-Based Exercise Intervention|Participate in online supervised, group resistance training sessions (iLIVE)
223625775|NCT06011499|OTHER|Internet-Based Diet Intervention|Receive online access to an interactive website with a series of weekly self-directed and interactive sessions on various topics associated with diet and weight loss (iLIVE)
223625776|NCT06011499|OTHER|Education Intervention|Receive usual care receiving educational information about diet and exercise for cancer survivors
223762571|NCT05301270|DIAGNOSTIC_TEST|EMG Evaluation|Muscle activations in the lower extremity and trunk muscles during compensatory postural responses will be evaluated. The Delsys Trigno IM (Delsys Inc. Natick, Massachusetts, USA) wireless surface electromyography (EMG) system will be used to evaluate muscle activation. In the lower extremity; Muscle activations of tibialis anterior, gastrocnemius, quadriceps and hamstring muscle groups and erector spinae in the trunk will be evaluated. While the muscle groups above the stump on the amputated side of the individuals in the amputation group will be evaluated, all muscle groups specified on the healthy side will be evaluated. In the control group, all muscle groups on the dominant side, but on the non-dominant side, all other muscles except the tibialis anterior and gastrocnemius muscles will be evaluated in order to be compatible with the amputation group.
223762572|NCT05181033|DRUG|Lenvatinib + Letrozole|"Patient will receive letrozole 2.5mg daily plus lenvatinib 14mg daily until disease progression/unacceptable toxicity.~Patient review, safety evaluations, thyroid function monitoring and urine dipstick will be done. Toxicities will be graded using NCI CTCAE toxicity grading vs 4.0. Patient should be discontinued if drug cannot be resumed within 28 days due to toxicities.~Drugs should be withheld when subject has imminent risk to develop hypertensive crisis/has significant risk factors for severe complications of uncontrolled hypertension. Drugs can be resumed once patient received same hypertensive medications for at least 48 hours and the BP is controlled.~Lenvatinib should be withheld for at least 1 week prior to elective surgery, at least 2 weeks after major surgery, until adequate wound healing.~For risk of ONJ, oral dental examination and preventive dentistry should be considered prior to lenvatinib intake.~There is no dose modifications for letrozole."
223762573|NCT05181033|DRUG|Fulvestrant|Patients will be treated with Fulvestrant 500mg injections that are administered into the muscles (intramuscularly). This is injected at 2-weekly interval for the first 3 doses, followed by 4-weekly interval dosing.
223762574|NCT03940508|BEHAVIORAL|Making Connections Intervention|The MCI is a one to two session intervention that addresses barriers to mental health treatment and helps adolescents build skills to get the most out of their treatment experience. It is designed to be delivered by a trained clinician in conjunction with an evidence-based treatment.
223762575|NCT03940508|BEHAVIORAL|IPT-A|IPT-A is a time-limited, manualized treatment for depression focused on maladaptive communication patterns and interpersonal interactions.
223762576|NCT04612179|DEVICE|The SUPRAFLEX CRUZ™ Sirolimus eluting coronary stent system|"Investigational device: SUPRAFLEX CRUZ™ Sirolimus eluting Coronary Stent System The SUPRAFLEX CRUZ™ Sirolimus eluting coronary stent system consists of a balloon ex-pandable Sirolimus eluting stent, premounted on a stent delivery system. The active pharmaceutical ingredient in the SUPRAFLEX CRUZ™ Sirolimus eluting coronary stent is Sirolimus (also known as Rapamycin).~The SUPRAFLEX CRUZ™ Sirolimus eluting coronary stent system is indicated for improving coronary luminal diameter in patients with symptomatic Ischemic heart disease due to discrete de-novo stenotic lesions and in-stent restenotic lesions in native coronary arter-ies with a reference vessel diameter of 2.00 mm to 4.50 mm."
224215170|NCT06248073|BEHAVIORAL|on-line self-management training|To encourage adherence to the home program among early-stage Parkinson's disease participants, the investigators have developed various self-management topics, including medication adherence and exercise benefits. The home program is categorized into two dimensions: daily function and exercise. The investigators will provides participants with detailed guidelines to ensure safe execution of the program independently.
224215171|NCT06248073|BEHAVIORAL|onsite task-related training|Participants will receive interventions at Chang Gung Memorial Hospital. A certified occupational therapist will conduct the interventions. These sessions will involve functional tasks tailored to each participant's skill level, with two to four varied tasks per session. Additionally, participants will be given booklets to guide them in self-managing similar exercises at home, mirroring the home program of the self-management group.
224316800|NCT05469295|DEVICE|CGM MB-1701 device treatment|This is a pre-approved motorized traction device.
224316801|NCT05469295|DEVICE|CGM MB-1701 Sham device treatment|It is manufactured in the same way as the test device and the operation pattern. However, the actual effect of the massage is minimized.
224316802|NCT03637010|OTHER|Breakfast in the Classroom|For all breakfasts, the students will use the 'grab and go' approach from hallway kiosks. The students will take the breakfasts back to their respective classroom and consume them there.
223625777|NCT01460212|DRUG|SSRI antidepressants|SSRI antidepressants are Selective serotonin reuptake inhibitors. They include fluoxetine (Prozac); sertraline (Zoloft); paroxetine (Paxil); citalopram (Celexa) ;escitalopram (Lexapro) and fluvoxamine (Luvox). It will be chosen according to special condition of every patient.
223625778|NCT01460212|BEHAVIORAL|Cognitive-Behavior Therapy|The essence of CBT is a learning process through which an appropriate pattern in cognitive and behavioral could be learn and stored as memory
223625779|NCT00015210|DRUG|Nefazodone|
224316803|NCT04767438|OTHER|Pregnant women|All pregnant women that present to the 12-week scan in the Obstetrics Unit
224316804|NCT05175703|DEVICE|Passeo-18 Lux Paclitaxel releasing Balloon Catheter|collect short term and long term clinical evaluation data of the Passeo-18 Lux Paclitaxel releasing balloon catheter, subject to patients who visit hospital from arteriosclerosis in the infrainguinal arteries in actual clinical environment.
223625780|NCT00015210|BEHAVIORAL|Psychosocial Treatment|All subjects attended a weekly 1-hour therapy session during the 8 week treatment period.
223625781|NCT02264730|DRUG|ClotFoam|Patient has not received blood products between screenings
224316805|NCT03232671|DIAGNOSTIC_TEST|MIF ELISA|Blood sample
223762577|NCT04861402|DEVICE|The ICP monitoring will be performed in a non-invasive method developed by Brain4Care|"The ICP monitoring will be performed in a non-invasive way through the cranial deformation method developed by Brain4Care Inc.~The selected patients will be monitored until 1h/day for 7 sequential days or even discharge. The clinical outcomes such as ventilatory status will be noted (if the subject is under oxygen supplementation, using non-invasive mechanical ventilation or intubated), the ventilatory parameters during the monitorization will be analyzed in the intubated group (or those from a non-intubated group who was intubated during the seven days of hospitalization) including IFO2, CV, PEEP, driving pressure, and pressure plate as well as ventilatory asynchronies. Some changes in ventilatory parameters during monitorization will be noted. These procedures will be applied to all groups, excepted to the healthy group. This last group will be monitored only once for 30 minutes at the Federal University of São Carlos (UFSCar)."
223762578|NCT06096324|BEHAVIORAL|Job announcements plus HIV prevention text messages, educational sessions, economic resources, and mentoring.|Participants will receive job announcements plus HIV prevention text messages, educational sessions, economic resources, and mentoring.
223625782|NCT05706298|BEHAVIORAL|Active Breaks|Participants will be asked to interrupt sitting with 3 min bouts of walking every 30 min from 9am-5pm
223625783|NCT03003026|OTHER|Novel task-specific bike skills training program|Participants randomised to the intervention group will participate in a novel task-specific bike skills training program. The intervention involves seven key components: it is group-based, intensive (2 hours per day for 3 days plus a home program for the remaining days of the one week period), task-specific, goal-directed, and therapist led, with parent involvement and conducted in an ecological setting. Each program will be run by a physiotherapist and allied health assistant during the school holidays.
223625784|NCT03003026|OTHER|Parent-led home-based bike skills training program|The comparison group will involve a parent-led home-based bike skills training program. Parents of children randomized to the comparison group will receive written information and telephone support from a physiotherapist on training bike skills. They will be encouraged to work with their child towards their bike skills goals for at least 30-45 minutes per day over a one week period during the school holidays in home and community environments.
223625785|NCT05906719|OTHER|video recording|Patients' performance of MDS-UPDRS III will be recorded.
223625786|NCT03379181|DRUG|Propranolol|Patients receive a single dose of 80 mg propranolol p.o.
223625787|NCT04197245|DRUG|saline injection therapy in post-acne atrophic scars|saline injection contains 0.9% isotonic sodium chloride solution
223625788|NCT06322186|OTHER|Ready-Heat Chemical Heating Blankets|Ready-Heat blankets are 4-panel half blankets that generate an oxygen-activated exothermic effect in 8-15 minutes (i.e., no electricity required), providing warmth over 8 hours at up to 40 degrees Celsius.
223625789|NCT06322186|OTHER|Warmed blankets or FAWB|The current standard of care for hypothermic patients is applying two warmed blankets or forced air warming blankets (FAWB).
223625790|NCT04232319|BEHAVIORAL|Sleep Hygiene Training|"The intervention will last approximately 45 minutes, and will be provided once/week for 3 weeks. The intervention is delivered live using web-cameras (e.g., Microsoft Zoom).~Registered and licensed occupational therapists will deliver the intervention. Each week, the interventionist will guide the participant through a workbook to provide knowledge regarding sleep hygiene strategies and examples on how to apply these strategies to improve sleep quality."
223625791|NCT04592939|PROCEDURE|immediate weight bearing after surgery|immediate weight bearing
223625792|NCT04592939|PROCEDURE|6 weeks of toe-touch weight bearing after surgery|6 weeks of toe-touch weight bearing
223625793|NCT04918420|DEVICE|Flow Diverter (Tonbridge)|The device is a self-expanding vascular stent system, which consists of a stent and a delivery system. The stent is made of platinum core nickel-titanium alloy material. The delivery system is composed of a delivery guide wire and an introducer sheath. The stent and the delivery guide wire are pre-installed in the introducer sheath.
223625794|NCT05575453|OTHER|Kvatchii Portal|Online education portal
223762579|NCT06096324|BEHAVIORAL|Job announcements|Participants will receive job announcements only.
223762580|NCT04988503|DEVICE|Coil embolization|coil embolization for ruptured intracranial aneurysm with bare platinum coils or second-generation hydrogel coils
223762581|NCT05683171|DRUG|Rituximab|Given by IV (vein)
223762582|NCT05683171|DRUG|Lenalidomide|Given by PO
223625795|NCT00259662|DRUG|atorvastatin|
223625796|NCT06527560|DRUG|Cefuroxime|Intravenous cefuroxime 750 mg every 8 hours
223762583|NCT05683171|DRUG|Valemetostat|Given by PO
223625797|NCT06527560|DRUG|Cefuroxime Axetil|Oral cefuroxime 500 mg every 12 hours
223625798|NCT04005846|DEVICE|Transcranial Direct Current Stimulation (tDCS)|The active session of tDCS will consist in applying two anodes over M1 bilaterally (C3 and C4 according to the 10-20 international EEG placement) and the cathodes over the occipital areas (O1 and O2), and to inject 2 mA for 20 minutes through sponge electrodes (35 cm²) placed on the scalp using the Startsim 8 (Neuroelectrics, Barcelona). The sham tDCS will use the same montage and device but direct current will only be injected for 30 seconds, with a ramp-up and ramp-down 15 seconds period, to mimic the somatosensory effects of active tDCS.
223625799|NCT00265564|BEHAVIORAL|Modified Seeking Safety integrated into std outpatient SUD care|The Seeking Safety treatment involves two (one hour) sessions of manualized group therapy for 12 weeks.
223625800|NCT00265564|BEHAVIORAL|Standard outpatient SUD care|"Patients assigned to standard care meet twice weekly in Recovery 1 groups, which focuses on building abstinence."
223625801|NCT03043534|OTHER|shave gel|"Non marketed pre-shave gel with the following INCI list of ingredients:~WATER, GLYCERIN, DIMETHICONE, LAURETH-23, PETROLATUM, ACRYLAMIDE/SODIUM ACRYLOYLDIMETHYLTAURATE COPOLYMER, ISOPROPYL PALMITATE, HYDROXYETHYLCELLULOSE, FRAGRANCE, PEG-23M, C13-14 ISOPARAFFIN, DMDM HYDANTOIN, DISODIUM EDTA, LAURETH-7, IODOPROPYNYL BUTYLCARBAMATE"
223762584|NCT05797792|DRUG|Intraarterial alteplase|See arm/group descriptions.
224316806|NCT00269425|BEHAVIORAL|American Heart Association Step 2 diet|Low fat diet with patient education and diet analysis
224316807|NCT00269425|BEHAVIORAL|Mediterranean diet|Mediterranean style diet with patient education and diet analysis
223625802|NCT03043534|OTHER|Brush|All subjects randomized to brush will use the brush with each shave
223625803|NCT00119847|PROCEDURE|PCI|
223625804|NCT00119847|DRUG|Optimal Medical Therapy|Guideline-directed drug therapies after MI
223625805|NCT02641847|DRUG|docetaxel|
223625806|NCT02641847|DRUG|doxorubicin or epirubicin|
223625807|NCT02641847|DRUG|cyclophosphamide|
223625808|NCT02641847|DRUG|gemcitabine|
223625809|NCT02641847|DRUG|cisplatin|
223625810|NCT05931081|DEVICE|Thermal imaging in diagnostics of chronic ulcers|atypical: vasculitic or pyoderma gangraenosum ulcers
223625811|NCT06001203|PROCEDURE|Reflexology|Reflexology is a method that creates nervous, hormonal and energetic effects in the body using pressure, rubbing and stretching applied with special hand and finger techniques to reflex points corresponding to all parts, organs and systems of the body in the ears, hands and feet
223625812|NCT06184633|DRUG|Semaglutide 3.2 MG/ML|Intervention arm receives semaglutide in addition to combined lifestyle intervention
223625813|NCT06184633|DRUG|Placebo|Control arm receives placebo in addition to combined lifestyle intervention
223625814|NCT04257890|BEHAVIORAL|Cognitive behavioral therapy|The CBT focuses on cognitive restructuring to reduce the specific key maladaptive beliefs on Internet gaming suggested by King's model, and develop useful coping skills (self-regulation/control, emotion regulation, problem-solving coping) that are adapted from previous CBT for adolescent IGD. In addition, it provides training on relapse-prevention and maintenance techniques.
223762585|NCT05308901|DRUG|Pembrolizumab|200 mg IV every 3 weeks for a maximum of 2 years.
224215172|NCT00955188|OTHER|computer-assisted intervention|
224215173|NCT00955188|OTHER|educational intervention|
224215174|NCT00955188|OTHER|medical chart review|
223762586|NCT05308901|DRUG|Lenvatinib|20 mg daily for a maximum of 2 years.
223625815|NCT04257890|OTHER|Education material about IGD|Printed education material introducing IGD will be distributed.
223625816|NCT04257890|OTHER|Education material about CBT|Printed education material introducing CBT will be distributed.
223625817|NCT02601157|DRUG|3-months DAPT|Contrast to the conventional 1-year DAPT, patients in this group will be followed with 3-months DAPT schedule after the stenting
223625818|NCT02601157|DRUG|1-year DAPT|Patients in this group will be followed with the conventional 1-year DAPT schedule after the stenting
223762587|NCT03621631|BEHAVIORAL|Optimized Tai Chi intervention|Optimized Tai Chi intervention
223625819|NCT02726620|PROCEDURE|Attending real-time decision support|Near real-time decision support elements will notify the attending anesthesiologists of a blood pressure drop below the threshold for intraoperative hypotension (mean arterial pressure below 60 mmHg). The notification is presented through the pager system. The page will also display the associated increased risk of organ injury due to organ ischemia.
223762588|NCT03621631|BEHAVIORAL|Traditional Tai Chi intervention|Traditional Tai Chi intervention
223762589|NCT04262167|BIOLOGICAL|Lung Spheroid Stem Cells 100 million|LSCs grown from autologous trans-bronchial biopsy specimens
223762590|NCT04262167|BIOLOGICAL|Lung Spheroid Stem Cells 200 million|LSCs grown from autologous trans-bronchial biopsy specimens
223625820|NCT02726620|PROCEDURE|In-room real-time decision support|Near real-time decision support elements will notify the in-room anesthesia provider of a blood pressure drop below the threshold for intraoperative hypotension (mean arterial pressure below 60 mmHg). The notification is presented through the anesthesia information management system. The decision support system will display the associated increased risk of organ injury due to organ ischemia.
223625821|NCT02726620|PROCEDURE|Attending feedback emails|Attending anesthesiologists will be notified through email within 24 hours after the end of an anesthetic case, when the patient had an episode of intraoperative hypotension (mean arterial pressure below 60 mmHg or lower for a particular duration) that is associated with an increased risk of organ injury due to organ ischemia.
223762591|NCT03968744|DRUG|Safinamide|Safinamide taken per Os for 12 weeks
223762592|NCT05518279|DRUG|Tranexamic Acid Pill|Patients will receive 1950mg of an oral tranexamic acid pill (3 pills total) while down in the Emergency Department after being diagnosed with a hip fracture. After they receive the oral TXA and are medically optimized, they will be taken to the operating room for fracture fixation.
223762593|NCT05518279|DRUG|Placebo Oral Tablet|Patients in the control arm will receive 3 placebo pills while down in the Emergency Department after being diagnosed with a hip fracture. After they receive the placebo pills and are medically optimized for surgery, they will be taken to the operating room for fracture fixation.
223762594|NCT02863978|OTHER|Multimodal signal acquisitions|"Cardiac and respiratory signals are collected from the clinical monitoring routinely gathered in hospital neonatal units.~Movement quantification and baby's sounds are extracted thanks to a dedicated system which will collect images and sound with microphones and cameras."
223762595|NCT00178945|DRUG|Botulinum Toxin Type A|
223625822|NCT02726620|PROCEDURE|In-room provider feedback emails|In-room anesthesia providers will be notified through email within 24 hours after the end of an anesthetic case, when the patient had an episode of intraoperative hypotension (mean arterial pressure below 60 mmHg or lower for a particular duration) that is associated with an increased risk of organ injury due to organ ischemia.
223625823|NCT02726620|DEVICE|Anesthesia Information Management System (AIMS)|The anesthesia electronic record keeping system
223625824|NCT02726620|DEVICE|Perioperative Data Warehouse (PDW)|The data warehouse that is used to gather perioperative data and create user reports. In this instance the PDW will be used to send the postoperative feedback emails.
223625825|NCT02726620|PROCEDURE|General anesthesia|Any anesthetic drugs that are used to induce general anesthesia above the level of sedation.
223625826|NCT02726620|DEVICE|Pager system|The mobile pager system through which alerts can be sent
223625827|NCT02726620|PROCEDURE|Central neuraxial anesthesia|Regional anesthesia effectuated through the placement of local anesthetics around the nerves of the central nervous system, e.g. spinal anesthesia and epidural anesthesia.
224215175|NCT06177041|DRUG|M108 monoclonal antibody|M108 monoclonal antibody will be administered as a minimum 2-hour IV infusion.
224215176|NCT06177041|DRUG|Placebo|Placebo will be administered as a minimum 2-hour IV infusion.
224215177|NCT06177041|DRUG|Oxaliplatin|Oxaliplatin will be administered as a 2-hour IV infusion.
224215178|NCT06177041|DRUG|Capecitabine|Capecitabine will be administered orally twice daily (bid).
223625828|NCT02726620|PROCEDURE|Non-cardiac surgery|Any surgical intervention that is not aimed at surgical correction of the heart
224215179|NCT02094937|DRUG|Fluticasone Furoate/Vilanterol|FF/VI 100mg/25 mcg is available as a dry white powder to be given once daily in the evening via dry powder inhaler
224215180|NCT02094937|DRUG|Fluticasone Furoate 100 mcg|FF 100 mcg is available as a dry white powder to be given once daily in the evening via dry powder inhaler
224215181|NCT02094937|DRUG|Fluticasone Propionate 250 mcg|FP 250 mcg is available as a dry white powder to be given twice daily (morning and evening) via dry powder inhaler
223625829|NCT02726620|DRUG|Propofol|Anesthetic drug used to maintain general anesthesia
223625830|NCT02726620|DRUG|Sevoflurane|Anesthetic drug used to maintain general anesthesia
223625831|NCT02726620|DRUG|Desflurane|Anesthetic drug used to maintain general anesthesia
223625832|NCT02726620|DRUG|Isoflurane|Anesthetic drug used to maintain general anesthesia
223625833|NCT02726620|DRUG|Ephedrine|Cardiovascular drug used to treat intraoperative hypotension
223625834|NCT02726620|DRUG|Phenylephrine|Cardiovascular drug used to treat intraoperative hypotension
223625835|NCT02726620|DRUG|Norepinephrine|Cardiovascular drug used to treat intraoperative hypotension
223625836|NCT02726620|DRUG|Epinephrine|Cardiovascular drug used to treat intraoperative hypotension
223625837|NCT02726620|DRUG|Dobutamine|Cardiovascular drug used to treat intraoperative hypotension
223625838|NCT02726620|DRUG|Dopamine|Cardiovascular drug used to treat intraoperative hypotension
223625839|NCT02726620|DRUG|Isoproterenol|Cardiovascular drug used to treat intraoperative hypotension
223625840|NCT02726620|DRUG|Milrinone|Cardiovascular drug used to treat intraoperative hypotension
223625841|NCT02726620|DRUG|Atropine|Cardiovascular drugs used to treat intraoperative hypotension
223625842|NCT02726620|DRUG|Glycopyrrolate|Cardiovascular drug used to treat intraoperative hypotension
223625843|NCT02726620|DRUG|Vasopressin|Cardiovascular drug used to treat intraoperative hypotension
223625844|NCT02726620|DRUG|Terlipressin|Cardiovascular drug used to treat intraoperative hypotension
223625845|NCT02726620|DRUG|Sodium Chloride 0.9%|Intravenous fluid used to treat intraoperative hypotension
223625846|NCT02726620|DRUG|Ringer's lactate|Intravenous fluid used to treat intraoperative hypotension
223625847|NCT02726620|DRUG|Hydroxyethyl starch solutions|Intravenous fluid used to treat intraoperative hypotension
224215182|NCT02094937|DRUG|Fluticasone Propionate 100 mcg|FP 100 mcg is available as a dry white powder to be given twice daily (morning and evening) via dry powder inhaler
224215183|NCT02094937|DRUG|Fluticasone Furoate Placebo|Matching placebo of Fluticasone Furoate will be given once daily in the evening via dry powder inhaler
224215184|NCT02094937|DRUG|Fluticasone Propionate Placebo|Matching placebo of Fluticasone Propionate will be given twice daily (morning and evening) via dry powder inhaler
224215185|NCT01133392|DRUG|Insulin lispro A|20 units (U) subcutaneously (SC).
223762596|NCT03899610|DRUG|Neoadjuvant chemotherapy+Durvalumab+Tremelimumab|"1. Neoadjuvant treatment:~   Standard chemotherapy + Durvalumab + Tremelimumab Durvalumab : 1500mg q3 weeks (total 3 dosing) Tremelimumab : 75mg q 3 weeks (total 3 dosing) Chemotherapy regimen: Paclitaxel 175 mg/m2 , Carboplatin AUC 5-6 q3 weeks (total 3 dosing)~2. Interval debulking surgery~3. Adjuvant treatment:~Standard chemotherapy + Durvalumab Durvalumab; 1120mg q3 weeks (total 12 dosing) Chemotherapy regimen: Paclitaxel 175mg/m2, carboplatin AUC 5-6 q 3weeks (total3 dosing)"
223762597|NCT00989729|DRUG|Methylprednisolone|A single preoperative dosage 30 mg/kg Methylprednisolone suspended in physiological saline (100 ml in total) given intravenously as a 30 minute infusion, 2 hours before surgery.
223625848|NCT02726620|DRUG|Fresh Frozen Plasma|Intravenous fluid used to treat intraoperative hypotension
223625849|NCT02726620|DRUG|Packed Red Blood Cells|Intravenous fluid used to treat intraoperative hypotension
223625850|NCT02726620|DRUG|Albumin solutions|Intravenous fluid used to treat intraoperative hypotension
223625851|NCT02726620|DRUG|Plasma-Lyte|Intravenous fluid used to treat intraoperative hypotension
223625852|NCT02726620|DRUG|Lidocaine|Local anesthetic used for central neuraxial anesthesia.
223625853|NCT02726620|DRUG|Bupivacaine|Local anesthetic used for central neuraxial anesthesia.
223625854|NCT02726620|DRUG|Levobupivacaine|Local anesthetic used for central neuraxial anesthesia.
223625855|NCT02726620|DRUG|Ropivacaine|Local anesthetic used for central neuraxial anesthesia.
223625856|NCT02726620|DRUG|Mepivacaine|Local anesthetic used for central neuraxial anesthesia.
223625857|NCT02726620|DRUG|Tetracaine|Local anesthetic used for central neuraxial anesthesia.
223625858|NCT02726620|DRUG|Prilocaine|Local anesthetic used for central neuraxial anesthesia.
223625859|NCT02726620|DRUG|Procaine|Local anesthetic used for central neuraxial anesthesia.
223625860|NCT02726620|DRUG|Chloroprocaine|Local anesthetic used for central neuraxial anesthesia.
223625861|NCT02726620|DRUG|Benzocaine|Local anesthetic used for central neuraxial anesthesia.
223625862|NCT02726620|DRUG|Articaine|Local anesthetic used for central neuraxial anesthesia.
223625863|NCT00737776|DRUG|biphasic insulin aspart 30|Dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
223625864|NCT00811603|DRUG|Cefazolin (Timing of Antibiotic Prophylaxis)|Patients scheduled for a cesarean delivery will be randomly assigned to receive Cefazolin (antibiotic prophylaxis) either prior to skin incision or after the clamping of the umbilical cord
223625865|NCT05644119|DEVICE|V- loop Bonded Orthodontic Retainer|The V- loop bonded retainer is a unique design that not just provides tooth stability but also allows flossing with ease.
223625866|NCT05644119|DEVICE|Straight Wire Retainer|The straight wire retainer is a fixed bonded orthodontic retainer. This involves attaching a metal wire to the back of the teeth to keep it in position.
223625867|NCT00920751|PROCEDURE|Water infusion|Water infusion in lieu of air insufflation during colonoscope insertion
223625868|NCT00920751|PROCEDURE|Air insufflation|Conventional air insufflation colonoscopy
223625869|NCT02608944|DRUG|Adenosine|Adenosine: 0.14mg/kg/min for 6 min. IV injection for MRI perfusion
223625870|NCT02608944|DRUG|Regadenoson|Regadenoson: 0.4mg in 5ml, given as a rapid (10 seconds) IV injection for MRI perfusion.
223625871|NCT02608944|DRUG|O-15 labeled radioactive water|O-15 labeled radioactive water: Up to 50mCi IV injection at rest and again at hyperemia for PET Imaging
223625872|NCT02608944|DEVICE|MRI|Pass dynamic contrast enhanced MRI scans will be performed at rest and during hyperemia caused by either adenosine infusion or regadenoson
223625873|NCT02608944|DEVICE|PET Imaging|Quantitative PET imaging with O-15 labeled radioactive water will be given at a different day.
223762598|NCT00989729|DRUG|Physiological Saline|A single preoperative dosage 100 ml given intravenously as a 30 minute infusion, 2 hours before surgery
223762599|NCT00640510|DRUG|Rapid Acting Intramuscular Olanzapine|10mg/injection, IM. If patients do not respond to the first study medication or if patients do not have enough improvement based on the investigator's judgment, and in addition, if the investigator judges it is reasonable, the patient will receive a second injection at the same dose strength as the first injection after 2 hours following the first injection (no later than 8 hours after the first injection).
223762600|NCT00640510|DRUG|Isotonic sodium chloride solution|0.9% sodium chloride (NaCl) solution. If patients do not respond to the first study medication or if patients do not have enough improvement based on the investigator's judgment, and in addition, if the investigator judges it is reasonable, the patient will receive a second injection at the same dose strength as the first injection after 2 hours following the first injection (no later than 8 hours after the first injection).
223762601|NCT05765968|PROCEDURE|Double Stimulation Protocol|cummulative live birth outcome after two cycles of in virto fertilization using double stimulation protocol, which refers to two cycles of ovarian stimulation in both follicular phase and luteal phase within the same menstrual cycle
223762602|NCT05765968|PROCEDURE|Antagonist Stimulation Protocol|cummulative live birth outcome within no more than two cycles of in virto fertilization using classical antagonist protocol
223762603|NCT01647867|OTHER|Met analysis on tissue and blood|10 mL of blood and 4 pieces of tissue (2 of tumor tissue, 2 of healthy tissue) all taken at the same time as surgery or bronchoscopy, depending on the stage of the disease
223762604|NCT00820924|DRUG|LAPATINIB|LAPATINIB 1500MG ORAL DOSE DAILY
223762605|NCT02677090|DRUG|Placebo (including Maltodextrin)|
223762606|NCT02677090|DRUG|Dose 1 - Promitor®|
223762607|NCT02677090|DRUG|Dose 2 - Promitor®|
223762608|NCT02677090|DRUG|Dose 3 - Promitor®|
223625874|NCT05661344|DRUG|BI 1015550|BI 1015550
223625875|NCT02848963|DRUG|Ketamine-propofol mixture|Ratio of Ketamine-propofol mixture will be compare for every groups.
223625876|NCT03188159|DRUG|Vinorelbine|Vinorelbine 25 mg/m2 intravenously on day-1 and day-8 of a 3 week cycle to commence following confirmation of eligibility into the study for a maximum of 12 months, until disease progression, intolerable toxicity or withdrawal of patient consent (whichever event occurs first).
223625877|NCT02738814|DRUG|propofol|When severe emergence agitation(PAED \> 13) is occurred, Pharmacologic treatment of emergence agitation relies on the administration of IV propofol 0.8 or 1 mg/kg.
223625878|NCT02360566|BEHAVIORAL|Participatory Video Intervention for Early Psychosis|The Participatory Video intervention consists of 12 semi-structured, 2 hour group workshops over the course of a 6-month time period. Through facilitated discussion, participants will learn how to effectively work collaboratively as a member of the video production team. Together, they will choose what story of their shared experience with psychosis they would like to tell through documentary-video and how they plan to share it. Participants will be trained to operate all equipment required to bring their vision to life. Individuals will also have the opportunity, during the Participatory Video process, to create and share their own video clips, independent of the group, allowing participants to share their own video-narrative with others (friends, family members, public) as a means of engaging in dialogue around their personal experience with psychosis.
223625879|NCT01180465|DRUG|LIPO-102|LIPO-102 High dose
223625880|NCT01180465|DRUG|LIPO-102 Low|LIPO-102 Low dose
223625881|NCT01180465|DRUG|LIPO-102, Placebo|Placebo
223762609|NCT04731844|DRUG|Curcumin plus Piperine|Curcumin with piperine is a well-tolerated over-the-counter supplement.
223762610|NCT05393375|OTHER|No intervention|No intervention
223762611|NCT01479907|DIETARY_SUPPLEMENT|Synbiotics|12 gr in 250 cc of water once daily X 15 days
223762612|NCT01479907|DIETARY_SUPPLEMENT|Placebo|12 gr in 250 cc of water once daily X 15 days
223762613|NCT02733978|DEVICE|the ozone generator device (Human Pro medic, German)|noninvasive oxygen-ozone treatments with 52 ug/mL ozone (total volume: 20-50 mL) in a special bag for 30 min per day for 20 days using the ozone generator device (Human Pro Medic, German)
223762614|NCT02777762|BEHAVIORAL|Fun First|8 weekly interactive small-group sessions with a health coach
223762615|NCT02777762|BEHAVIORAL|Close at Hand|8 weekly check-ins with a state of the art, engaging mobile app
223762616|NCT00952094|DRUG|KRN1493|KRN1493 25mg tablet 2,3 or 4 tablets single oral administration
223762617|NCT01872871|DRUG|Paracetamol|paracetamol with local anesthetic eye drop versus placebo with local anesthetic eye drops
223762618|NCT01872871|DRUG|Topical anaesthetic drop with placebo|
223762619|NCT05789732|DRUG|Placebo|Patients will receive placebo treatment once daily.
223762620|NCT05789732|DRUG|Silodosin|Patients will receive Silodosin 8 mg once daily.
223762621|NCT05789732|DRUG|Tadalafil|Patients will receive Tadalafil 5 mg once daily.
223762622|NCT05789732|DRUG|Silodosin and Tadalafil|Patients will receive Silodosin 8mg in combination with Tadalafil 5 mg once daily.
223762623|NCT05476562|OTHER|Tyrosine Kinase Inhibitors (TKIs)|The study included patients with CML who were previously treated with TKIs, who are relapsed/refractory to/intolerant of TKIs on third or later lines of therapy in the US.
223762624|NCT00192075|DRUG|Gemcitabine|900 mg/m2 IV over 90 minutes after Folinic Acid weekly for 6 weeks every 8 weeks until progression.
223762625|NCT00192075|DRUG|avastin|5 milligrams per kilogram (mg/kg)
223762626|NCT00192075|DRUG|5FU/folinic acid|"Folinic Acid: 100 milligrams per square meter (mg/m2) intravenous (IV) over 60 minutes (A+FFG).~Folinic Acid: 200 mg/m2 as a 2-hr infusion on Days 1 and 2 of a 14-day cycle (A+FOLFOX 4).~5-Fluorouracil: 450 mg/m2 as an IV bolus in middle of Folinic Acid (A+FFG). 5-Fluorouracil: 400 mg/m2 bolus plus a 600 mg/m2 22-hour infusion on Days 1 and 2 of a 14-day cycle (A+FOLFOX 4)."
223762627|NCT00192075|DRUG|oxaliplatin|85 mg/m2 as a 2-hour infusion on Day 1 of a 14 day cycle.
223762628|NCT00649116|DRUG|Metoprolol Tartrate Tablets 100 mg|100mg, single dose fed
223762629|NCT00649116|DRUG|Lopressor® Tablets 100 mg|100mg, single dose fed
223762630|NCT04024475|OTHER|Observation|
223762631|NCT01341184|DRUG|Rifabutin|Rifabutin 300 mg orally on days 20-41
223762632|NCT01341184|DRUG|Rifampin|Rifampin 600 mg orally on days 20-41
223762633|NCT01341184|DRUG|TMC207|TMC207 400 mg orally on days 1 and 29
223762634|NCT05637645|PROCEDURE|Midline Approach|In the midline approach, the spinal approach to the intrathecal space is midline with a straight line shot. After infiltration with lidocaine, the spinal needle is introduced into the skin, angled slightly cephalic. The needle traverses the skin, followed by subcutaneous fat. A single dose of 12.5mg of 0.5% bupivacaine (preservative free) will be used for the spinal anesthetic, the effects of this will last approximately 2 hours.
224215186|NCT01133392|DRUG|Insulin lispro B|20 U subcutaneously (SC).
224215187|NCT04765189|DIETARY_SUPPLEMENT|Placebo|Placebo product is 100% maltodextrin. Daily dosage is 500 mg in 2 capsules.
224215188|NCT04765189|DIETARY_SUPPLEMENT|Verum A|Verum A is 200 mg of mangosteen extract. Daily dosage is 200 mg in 2 capsules.
224215189|NCT04765189|DIETARY_SUPPLEMENT|Verum B|Verum B is 400 mg of mangosteen extract. Daily dosage is 400 mg in 2 capsules.
224215190|NCT04765189|DIETARY_SUPPLEMENT|Verum C|Verum C is 200 mg mangosteen extract + 300 mg grape extract. Daily dosage is 500 mg in 2 capsules.
224215191|NCT01031134|BEHAVIORAL|Shared Decision Making|Shared decision-making, in contrast to traditional medical decision-making, involves a collaborative process where patients discuss personal values and preferences and clinicians provide information to arrive at an agreed upon treatment decision. The focus of the intervention is to empower elderly depressed primary care patients and help them efficiently arrive at a treatment decision that can be successfully implemented.
224215192|NCT01031134|OTHER|Usual Care|Usual Care reflects the standard of care in primary care practice: following physician recommendation for treatment. Physicians will recommend some form of depression treatment. This may take the form of an antidepressant prescription or psychotherapy referral. The physician will encourage patients to telephone with any questions. Following the treatment recommendation provided to the patient, the physician will provide care as usual.
224215193|NCT06696313|DEVICE|Insignia|"* Insignia hip stem~* Trident hemispherical shell~* X3 polyethylene liner~* Metal or ceramic head"
224215194|NCT00891501|PROCEDURE|Bone Marrow Aspiration|Autologous bone marrow is aspirated from the iliac crest (hip bone) of the patient using a 21-gauge bone marrow aspiration needle under complete aseptic conditions and proper anaesthesia
224215195|NCT00891501|PROCEDURE|Bone marrow mesenchymal stem cell implantation|The culture expanded mesenchymal stem cell pellet will be implanted into the osteochondral knee defect via open surgery or arthroscopically under complete sterile aseptic conditions and proper anaesthesia. The defect will be covered with an autologous periosteal flap from the proximal tibia and then sealed with human fibrin glue to seal the defect and retain the cell pellet in place
224215196|NCT06652685|DRUG|D5-PBCR(-) IA arm|"Induction: IA Drug: idarubicin, intravenously, 10 mg/m\^2 on D1-3 Drug: cytarabine, intravenously, 100 mg/m\^2 on D1-7~Consolidation:~Subjects who achieve composite complete remission (CRc) proceed with consolidation therapy.~In consolidation therapy phase, subjects in the group with favorable/intermediate risk and MRD negetive, will receive cytarabine intravenously at 2g/m\^2/q12h\*6 doses. Subjects in the group with adverse risk or MRD positive will receive cytarabine intravenously at 2g/m\^2/q12h\*6 doses together with venetoclax 400mg on D4-10. Dose ramp-up of venetoclax is not required.~After two cycles of consolidation, a multi-disciplinary team will discuss whether the patient need allogeneic hematopoietic stem-cell transplant (allo-HSCT) according to ELN risk stratification and MRD status."
224316808|NCT00862615|OTHER|Measurement of muscle protein synthesis using stable isotopes and muscle biopsies.|"Measurement of muscle protein synthesis using stable isotopes and muscle biopsies.~Isotopes are :~(13C)bicarbonate (0.09 mg/kg fat-free mass) and L(1-13C)leucine (1.3 mg/kg fat-free mass) (intravenous way) L-(5,5,5 2H3) leucine(0.09 µmoles/(kg de fat-free mass.min) (oral way)"
223625882|NCT06555185|OTHER|Potentiation warm-up protocol|The intervention protocol consisted of i) 1st set - six hurdle jumps, with a distance of 70 cm between each, followed by a 15-m sprint with COD; (ii) 2nd set - six lateral hurdle jumps (three to the left and three to the right) followed by a 10-m sprint with COD; (iii) 3rd set - six bouncy strides, followed by a 15-m sprint with COD; (iv) 4th set - six broad jumps followed by a 10-m sprint with COD. All COD circuits had different configurations, changing the sprint distance and the angle of the COD curve. All repetitions and sets were separated by 90-second recovery intervals, and each set was performed three times.
223625883|NCT06555185|OTHER|Usual warm-up protocol|The usual warm-up consisted of (i) The first phase included dynamic stretching and drills to increase body temperature. This phase lasted 5-min and included slow jogging, light skipping, and dynamic stretches for hip flexors, glutes, quads, hamstrings, abductors, gastrocnemius and lower limb joints. (ii) The second phase was composed of exercises that intended to mimic specific movements of the football match, both with and without ball possession. This phase lasted 15 minutes and included exercises with and without possession of the ball, such as acceleration, COD, jumping over hurdles, and playful games with ball possession. In this group, the players only rested in a slow jog when they moved from the first to the second phase.
223625884|NCT04187898|BIOLOGICAL|Eflapegrastim|"Administered in Cycle 1, 30 minutes after TC chemotherapy.~Administered in Cycles 2-4, on day 2 of each cycle."
223625885|NCT04187898|BIOLOGICAL|Eflapegrastim|"Administered in Cycle 1, 3 hours after TC chemotherapy.~Administered in Cycles 2-4, on day 2 of each cycle."
223625886|NCT04187898|BIOLOGICAL|Eflapegrastim|"Administered in Cycle 1, 5 hours after TC chemotherapy.~Administered in Cycles 2-4, on day 2 of each cycle."
223625887|NCT04187898|BIOLOGICAL|Eflapegrastim|Administered in Cycles 1-4, 30 mins after TC chemotherapy.
223625888|NCT04187898|DRUG|Docetaxel|"75 mg/m\^2 IV infusion.~Administered on Day 1 of each cycle."
223625889|NCT04187898|DRUG|Cyclophosphamide|"600 mg/m\^2 IV infusion.~Administered on Day 1 of each cycle."
223625890|NCT06249685|DEVICE|Bilateral hearing devices|Three week trial while wearing bilateral hearing devices.
223625891|NCT02828475|OTHER|CALYPSO|Software platform of machine-learning based predictive models of surgical complication.
223625892|NCT02828475|BEHAVIORAL|Standard Care|Previous standard of care based on surgeon judgement alone.
223625893|NCT04740983|OTHER|Heliotherapy (a sole sun-bathing)|16-week heliotherapy regimen based on the predicted anti psoriasis effective irradiance values.
223625894|NCT00966186|PROCEDURE|Insertion fo ProSeal laryngeal mask airway|Insertion fo ProSeal laryngeal mask airway using each of Standard technique or Rotational technique
223625895|NCT04139330|DRUG|NPC-06|Infuse NPC-06 intravenously
223625896|NCT04610359|DRUG|MR-MC-01|Submucosal injection of 2.0 x 10,000,000/5ml (1mL \* 5 sites)
223625897|NCT00471653|DRUG|temozolomide|
223625898|NCT00471653|GENETIC|comparative genomic hybridization|
223625899|NCT00471653|GENETIC|polymorphism analysis|
223625900|NCT00471653|OTHER|laboratory biomarker analysis|
223625901|NCT00471653|OTHER|pharmacological study|
223625902|NCT00471653|RADIATION|radiation therapy|
223625903|NCT03864835|BEHAVIORAL|Moderate intensity aerobic exercise|Subjects that meet requirements for the exercise arm (12 total) will be required to exercise 30 minutes, five days per week at a moderate intensity (HR target corresponding to 45-55% of their relative VO2max). Each session will be supervised in-person at the Penn State University Fitness Center with an ACSM certified exercise physiologist. This is feasible as Zhang et al.(87) found 66 out of 70 subjects (95%) completed the twelve-month supervised in-person moderate-intensity exercise protocol five-days a week.
223625904|NCT03442816|DEVICE|MHRC Camera|Evaluate the technical capabilities of the device to obtain quality images in reflectance and fluorescence imaging modes in a diverse population.
223625905|NCT03380897|OTHER|Intervention for outpatient group was to go home|Intervention for outpatient group was to go home and assess the the pain
223762635|NCT05637645|PROCEDURE|Paramedian Approach|The paramedian approach involves inserting the spinal needle 1 cm away from the midline in medial direction. A single dose of 12.5mg of 0.5% bupivacaine (preservative free) will be used for the spinal anesthetic, the effects of this will last approximately 2 hours.
223762636|NCT05637645|PROCEDURE|Taylors approach|his arm will have the procedure of spinal anesthetic performed via 'Taylor's approach' which is a paramedian approach to interspace L5 - S1. A single dose of 12.5mg of 0.5% bupivacaine (preservative free) will be used for the spinal anesthetic, the effects of this will last approximately 2 hours.
224215197|NCT06652685|DRUG|D5-PBCR(+) IA+Venetoclax arm|"Induction: IA+Ven Drug: idarubicin, intravenously, 10 mg/m\^2, on D1-3, Drug: cytarabine, intravenously, 100 mg/m\^2 on D1-7 For D5-PBCR (+) patients, Venetoclax will be combined. Drug: Venetoclax. Orally once daily, on D6-14. A 3-day dose ramp-up is required for the first induction (100mg D6, 200mg D7, 400mg D8-14) If a second induction is needed, the dose of IA is the same as the first cycle, and dose ramp-up of venetoclax is not required.~Consolidation:~Subjects who achieve composite complete remission (CRc) proceed with consolidation therapy.~In consolidation therapy phase, subjects in the group will receive cytarabine intravenously at 2g/m\^2/q12h\*6 doses together with venetoclax 400mg on D4-10. Dose ramp-up of venetoclax is not required.~After two cycles of consolidation, a multi-disciplinary team will discuss whether the patient need allogeneic hematopoietic stem-cell transplant (allo-HSCT) according to ELN risk stratification and MRD status."
223762637|NCT00004091|OTHER|Papanicolaou test|
223762638|NCT00004091|OTHER|cytology specimen collection procedure|
223625906|NCT03380897|OTHER|Intervention for inpatient group was to stay at ward|Intervention for inpatient group was to stay at ward and assess the pain
223762639|NCT00004091|OTHER|fluorescent antibody technique|
223762640|NCT00004091|PROCEDURE|colposcopic biopsy|
224215198|NCT06702345|OTHER|encapsulated 10^4 CFU toxigenic. C. difficile spores|12 consecutive days of once a day a capsule with 10\^4 CFU toxigenic C. difficile spores.
224215199|NCT06702345|DRUG|Vancomycin|oral vancomycin pretreatment, 4 times a day 250mg, given the five days before toxigenic C. difficile exposure.
223762641|NCT00004091|PROCEDURE|study of high risk factors|
223762642|NCT04257682|DRUG|Bupivacaine|Bupivacaine is a long-lasting dense sensory-motor block that can last up to four hours. It will be administered once, as part of the spinal anesthetic. The dosage varies based on age and joint, from 6.75 mg to 8.25 mg for the knee, and 7.5 mg to 9 mg for the hip.
223625907|NCT02229058|DRUG|Albumin Bound Paclitaxel|120 mg/m2, D1,D8,every 3 weeks until disease progress or intolerable toxicity.
223625908|NCT02229058|DRUG|S-1|40mg QD D1-D14,every 3 weeks,for BSA\<1.25 m2, 50mg QD D1-D14,every 3 weeks,for BSA=1.25～1.5m2, 60mg QD D1-D14,every 3 weeks,for BSA\>1.5m2,until disease progress or intolerable toxicity.
223625909|NCT02753803|DRUG|Evogliptin, Pioglitazone, Evogliptin+Pioglitazone|Evogliptin : Evogliptin 5mg QD Pioglitazone : Pioglitazone 30mg QD Evogliptin+Pioglitazone : Evogliptin 5mg QD + Pioglitazone 30mg QD
223625910|NCT02753803|DRUG|Pioglitazone, Evogliptin, Evogliptin+Pioglitazone|Pioglitazone : Pioglitazone 30mg QD Evogliptin : Evogliptin 5mg QD Evogliptin+Pioglitazone : Evogliptin 5mg QD + Pioglitazone 30mg QD
223625911|NCT02753803|DRUG|Evogliptin, Evogliptin+Pioglitazone, Pioglitazone|Evogliptin : Evogliptin 5mg QD Evogliptin+Pioglitazone : Evogliptin 5mg QD + Pioglitazone 30mg QD Pioglitazone : Pioglitazone 30mg QD
223625912|NCT02753803|DRUG|Pioglitazone, Evogliptin+Pioglitazone, Evogliptin|Pioglitazone : Pioglitazone 30mg QD Evogliptin+Pioglitazone : Evogliptin 5mg QD + Pioglitazone 30mg QD Evogliptin : Evogliptin 5mg QD
223625913|NCT02753803|DRUG|Evogliptin+Pioglitazone, Evogliptin, Pioglitazone|Evogliptin+Pioglitazone : Evogliptin 5mg QD + Pioglitazone 30mg QD Evogliptin : Evogliptin 5mg QD Pioglitazone : Pioglitazone 30mg QD
223625914|NCT02753803|DRUG|Evogliptin+Pioglitazone, Pioglitazone, Evogliptin|Evogliptin+Pioglitazone : Evogliptin 5mg QD + Pioglitazone 30mg QD Pioglitazone : Pioglitazone 30mg QD Evogliptin : Evogliptin 5mg QD
223625915|NCT04669808|DRUG|STP705|Dry powder for intra-and peri-lesional injection.
223625916|NCT06005935|OTHER|Survey|Participants will complete a one-time survey including questions on demographics, health status, reproductive health history, environmental and occupational factors one may or may not have been exposed to. The survey can be completed online or over the phone, and should last approximately 30-45 minutes.
223762643|NCT04257682|DRUG|Ropivacaine|Ropivacaine is a long-acting local anesthetic that is known for its differential sensory-motor block. It will be administered once, as part of the spinal anesthetic. The dosage varies based on age and joint, from 9 mg to 11 mg for the knee, and 10 mg to 12 mg for the hip.
223762644|NCT04257682|DRUG|Mepivacaine|Mepivacaine is an intermediate-acting local anesthetic producing shorting and motor-sparing blocks. It will be administered once, as part of the spinal anesthetic. The dosage varies based on age and joint, from 40 mg to 50 mg for the knee, and 45 mg to 55 mg for the hip.
223762645|NCT04869735|OTHER|Data collection: DTPolio vaccine delivery|"with information about booster vaccination group: Sending of information concerning booster vaccination against DTPolio at 25 years using letters, emails and SMS without information about booster vaccination group: no intervention"
223625917|NCT05794425|DRUG|Cyclosporine A|3-5 mg per kilogram per day.
223625918|NCT05794425|BIOLOGICAL|Umbilical cord blood & Umbilical cord derived mesenchymal stem cells|Intravenous infusion of umbilical cord blood and umbilical cord derived mesenchymal stem cells (5-8×10\^7) at 1 week interval.
223625919|NCT05388786|BEHAVIORAL|Delphi Questionnaire|"An invitation email, including a link to the survey, will be sent to the panel of experts in ILND for penile cancer, vulvar cancer, and melanoma.~The Delphi questionnaire will be administered via Welphi.com. In the first survey, panel members will outline the ILND complications and adverse events definition and classification with a series of 5-point Likert scale assessments and options for free-text responses relating to the surgeon's perception.~The experts will fill out the online questionnaire. For the questions that do not reach a consensus of more than 80% in the first round or need further explanation, additional rounds of the survey may be performed."
223625920|NCT02536612|OTHER|Lottery|Opportunity for entry in lottery (each time, at months 3 and 6).
224215200|NCT06702345|DRUG|Clindamycin|oral clindamycin pretreatment, 3 times a day 600mg, given the five days before toxigenic C. difficile exposure
224215201|NCT06701786|PROCEDURE|Compressive Sutures (CSs) group|The extent of the depth of the recession will be reported on the anatomical papillae and, after adding 1mm, 2 horizontal incisions of approximately 3mm will be made at the base of the surgical papillae laterally to the recession.Two divergent releasing incisions will be made extending approximately 2-3mm into the alveolar mucosa.The surgical papillae will be detached in partial thickness. A full thickness dissection will be performed from the bottom of the recession to expose approximately 3mm of the crest bone.A partial thickness dissection will be performed in the most apical portion of the flap until complete passivation of the flap is obtained.The harvesting of the epithelial-connective graft will be performed . The de-epithelialised graft will be sutured at the level of the de-epithelialised anatomical papillae; then the flap will be repositioned coronally suturing the anatomical papillae on the surgical ones. Three compressive sutures will be placed on the repositioned flap.
224316809|NCT00547586|DRUG|N-methylnaltrexone bromide (MOA-728)|Oral
224316810|NCT00547586|OTHER|placebo|placebo
223625921|NCT02536612|OTHER|No Lottery|Transport compensation for study visits at baseline and at months 3 and 6. No chance to win lottery ticket.
223625922|NCT01665196|DRUG|18F-FDG|Intravenous injection of single dose of 18F-FDG before treatment and after 4-week treatment, respectively.
223762646|NCT03863210|OTHER|"60-minute lecture titled Change of lifestyle and nutrition habits to reduce cardiovascular risk"|"All participants were exposed to the intervention. The intervention consisted of a 60-minute lecture titled Change of lifestyle and nutrition habits to reduce cardiovascular risk. The lecture was delivered in family medicine offices by four specialists of family medicine individually to the groups of 6-8 participants. The lecture was verbal, harmonized among four family physicians, and contained instructions for changing nutrition habits, smoking habits and instructions for increasing physical activity. At the end of the lecture, each participant received a personally tailored decision aid, which included the list of her risk factors, assessment of the 10-year risk of fatal CVD (based on the data provided by the participants before the lecture), and instructions on what she should do in terms of changing the lifestyle habits."
223762647|NCT00355238|DRUG|brivanib (active)|Tablet, Oral, Brivanib 800 mg, once daily, until progression
223762648|NCT02821585|BEHAVIORAL|Nutritional Counseling|Carbohydrate counting will be reviewed, as well as hypoglycemia management. The 9 following visits will focus on different aspects of each diets: types of fats, meat and alternatives, grain products, milk and alternatives, fruits and vegetables, salt intake, energy density and restaurants.
223762649|NCT04403321|DRUG|Tacrolimus|Tacrolimus will be given at 1mg bid with the target trough concentration to be 4-10 ng/mL.
223762650|NCT04403321|DRUG|Placebo (for Tacrolimus)|placebo will be given at 1mg bid.
223762651|NCT01107470|DRUG|hFSH（Fostimon）|After down-regulation (short protocol), all patients will be stimulated with hFSH (human-derived FSH).
223762652|NCT01107470|DRUG|hFSH（Fostimon）|After down-regulation (short protocol), all patients will be stimulated with hFSH (human-derived FSH).
223762653|NCT01107470|DRUG|hFSH（Fostimon）|After down-regulation (long protocol), all patients will be stimulated with hFSH (human-derived FSH).
223762654|NCT01107470|DRUG|hFSH（Fostimon）|After down-regulation (long protocol), all patients will be stimulated with hFSH (human-derived FSH).
223762655|NCT02407106|DIETARY_SUPPLEMENT|Streptococcus Salivarius BLIS K12|Once daily tablet of BLIS K 12 to be slowly dissolved orally every evening.
223762656|NCT01956110|DRUG|Follitropin Delta (FE 999049)|
223762657|NCT01956110|DRUG|Follitropin Alfa (GONAL-F)|
223762658|NCT02135224|DRUG|Fentanyl|
223762659|NCT02135224|DRUG|Normal saline|
223762660|NCT00968591|DRUG|Everolimus|
223762661|NCT06178874|DRUG|Insulin Glargine|hyperglycemic control
223762662|NCT06178874|DRUG|Insulin Degludec|hyperglycemic control
223762663|NCT06178874|DRUG|Insulin regular|hyperglycemic control
223762664|NCT02573610|DRUG|DE-108|Subjects will be assigned to receive DE-108 ophthalmic solution to be administrated one drop a time 3 times daily for 3 days prior and for 14 days following cataract surgery.
223625923|NCT04913610|DRUG|ABBV-4083|Oral Capsule
223625924|NCT04913610|DRUG|Placebo for ABBV-4083|Oral Capsule
223625925|NCT04913610|DRUG|Albendazole|Oral encapsulated tablets
223625926|NCT04913610|DRUG|Placebo for Albendazole|Oral Capsule
223625927|NCT01754103|OTHER|Tactile Training|Tactile Training to induce neuroplasticity in the visual pathway, measured with functional connectivity MRI
223625928|NCT03936998|COMBINATION_PRODUCT|Vancomycin plus VE416 before PNOIT|Vancomycin PO QD x 5 days, followed by VE416 PO QD x 6 weeks followed by PNOIT
223625929|NCT03936998|COMBINATION_PRODUCT|Vancomycin plus VE416 with PNOIT|Placebo for vancomycin for 5 days and placebo for VE416 x 6 weeks, followed by Vancomycin PO QD x 5 days, followed by VE416 PO QD x 6 weeks with concomitant PNOIT
223625930|NCT03936998|COMBINATION_PRODUCT|Placebo plus VE416 with PNOIT|Placebo for vancomycin for 5 days and placebo for VE416 x 6 weeks, followed by placebo for vancomycin PO QD x 5 days, followed by VE416 PO QD x 6 weeks with concomitant PNOIT
223625931|NCT03936998|COMBINATION_PRODUCT|Placebo plus placebo with PNOIT|Placebo for vancomycin for 5 days and placebo for VE416 x 6 weeks, followed by placebo for vancomycin PO QD x 5 days, followed by placebo for VE416 PO QD x 6 weeks with concomitant PNOIT
223625932|NCT05408338|OTHER|Low Added Sugar Meal|Consumption of a single 1,250 kcal meal containing 16 g of added sugars (5% of total energy)
223625933|NCT05408338|OTHER|High Added Sugar Meal|Consumption of a single 1,250 kcal meal containing 61 g of added sugars (20% of total energy)
223762665|NCT02573610|DRUG|Levofloxacin 0.5%|Subjects will be assigned to receive Levofloxacin 0.5% ophthalmic solution to be administrated one drop a time 3 times daily for 3 days prior and for 14 days following cataract surgery.
223762666|NCT05897177|BEHAVIORAL|Subjective Scale of Stigma and Discrimination (SISD).|"Subjective Scale of Stigma and Discrimination (SISD) A sixdimension self-administered scale will be used that included statements with which the participants agreed or disagreed. The scale consists of 23 Likert-type items and responses range from 1 (completely in disagreement) to 5 (completely in agreement), grouped together to represent the six indicators making up this part of the scale"
223762667|NCT03085329|DEVICE|Seattle-PAP|Seattle-PAP is a modified bubble CPAP device that has been given 510(k) clearance by the US FDA (K131502, October 11, 2013) and is thus recognized as substantially equivalent to other approved devices on the market. Results of a recently completed study in infants indicate that Bn-CPAP is associated with lower effort to breathe by spontaneously breathing premature infants.
223762668|NCT03085329|DEVICE|Conventional bubble nasal CPAP|Infants enrolled in the study and randomized to this arm will be given respiratory support by bubble nasal CPAP using the Fisher \& Paykel bubbler device, which is the standard of care at Nationwide Children's.
224215202|NCT06701786|PROCEDURE|Without Compressive Sutures (WCSs) group|The extent of the depth of the recession will be reported on the anatomical papillae and, after adding 1 mm, 2 horizontal incisions of approximately 3 mm will be made at the base of the surgical papillae laterally to the recession.Two divergent releasing incisions will be made extending approximately 2-3 mm into the alveolar mucosa.The surgical papillae will be detached in partial thickness. A full thickness dissection will be performed from the bottom of the recession to expose approximately 3mm of the crest bone.A partial thickness dissection will be performed in the most apical portion of the flap until complete passivation of the flap is obtained.The harvesting of the epithelial-connective graft will be performed. The de-epithelialised graft will be sutured at the level of the de-epithelialised anatomical papillae; than then the flap will be repositioned coronally suturing the anatomical papillae on the surgical ones.
224215203|NCT06700837|OTHER|Impact of hypoxic burden on objective and subjective sleepiness in patients treated for Obstructive Sleep apnea|To determine whether hypoxic load is a predictive marker of objective residual sleepiness measured by MCT in a treated OSAHS population.
223762669|NCT03169491|DEVICE|Continuous positive airway pressure (CPAP)|CPAP dispositives will be used by the children in the study every night for two weeks. Devices AutoSet Spirit from ResMed.
223762670|NCT00742313|BIOLOGICAL|FloSeal Matrix|10 ml of FloSeal Matrix will be applied to the endoscopic wound bed.
224215204|NCT06697821|PROCEDURE|D2＋CME|Whether to perform the whole mesogastric excision
224215205|NCT06700772|PROCEDURE|mixing bone marrow aspirate concentrate from maxillary tuberosity with bovine bone|open sinus lifting using bone marrow aspirate concentrate from maxillary tuberosity and mixing it with bovine bone .
224215206|NCT06700772|PROCEDURE|mixing autogenous bone with bovine bone|open sinus lifting using autogenous bone from retromolar area mixed with bovine bone
223762671|NCT05353192|DRUG|Recombinant human growth hormone|Recombinant human growth hormone (15IU/5mg/3ml/bottle)，0.05 mg/kg/d by subcutaneous injection for 52 weeks
223762672|NCT01962558|DEVICE|VNS Treatment|VNS is given in brief bursts over a 2.5 hour period. The subject also has headphone connected to a computer, and hears audio tones through the headphones that occur during VNS.
224215207|NCT04815408|DRUG|BGB-A317|PD-1 antibody，Tislelizumab (BGB-A317)
224215208|NCT04815408|DRUG|albumin-bound paclitaxel 260mg/m2 , Carboplatin AUC 5|albumin-bound paclitaxel 260mg/m2 , Carboplatin AUC 5
223762673|NCT01962558|DEVICE|VNS Control|This is the sham-control group; subjects in this group will receive both tones and VNS, but in a manner that is expected to be ineffective.
223762674|NCT00193401|DRUG|Topotecan|
223762675|NCT01919424|DRUG|Methacholine Chloride|"Choline ester that acts as a non-selective muscarinic receptor agonist in the parasympathetic nervous system~Low risk - commonly used to diagnose asthma"
223762676|NCT01919424|DEVICE|Trudell AeroEclipse*II BAN nebulizer|Generates aerosol after a certain inspiratory flow has been reached and then stops nebulization the moment the inspiratory flow falls below this value
223625934|NCT06490289|OTHER|Denpro oral gel|Experimental group was given Denpro oral gel (Gennec Health Sciences PVT, LTD, Karachi, Pakistan)
223762677|NCT01919424|DEVICE|The English-Wright nebulizer|"Continuous-mode nebuilzer, designed to operate continuously with tidal breathing~Roxon Medi-Tech, Montreal, PQ, Canada"
223762678|NCT04488705|DRUG|ETD002 - single dose|Single ascending doses of ETD002
223762679|NCT04488705|DRUG|Placebo - single dose|Single doses of placebo
223762680|NCT04488705|DRUG|ETD002 - 7 day repeat dose|Twice daily doses of ETD002 for 7 days
223625935|NCT01999452|BEHAVIORAL|Paleolithic diet|
223625936|NCT01999452|BEHAVIORAL|Diabetes diet|
223625937|NCT00280982|BIOLOGICAL|tumor lysate-loaded autologous dendritic cells|50x10e6 cells per vaccination, 3 times, 2 weeks interval
223625938|NCT00771394|DRUG|Tamsulosin hydrochloride|oral
223625939|NCT00771394|DRUG|Solifenacin succinate|oral
223625940|NCT05358236|OTHER|Episiotomy Wound Care and Genital Hygiene Training|"Episiotomy wound healing and genital hygiene training were given face-to-face by researchers to the mothers assigned to the training group. The trainings were given to each mother individually in their rooms. The total training lasted an average of one hour. At the end of the training, the mothers were given a written and illustrated training brochure.~Training content~* Primarily, external reproductive organs were shown to mothers through pictures.~* Urethra, Vagina, Anus, Perineum areas were mentioned.~* The definition of Episiotomy was made; and where and how it was applied was explained with visual materials. It was explained how to care for the episiotomy area to heal more rapid and healthier.~* Information was given on how to change their menstrual pads.~* Information was provided on what to look for when using underwear~* What to watch out while taking a bath:~* What to pay attention to in your stitch area"
223625941|NCT00659061|DIETARY_SUPPLEMENT|SPRINKLES|"Sprinkles is a multiple micronutrient fortificant. It is packed as a single serving sachets each containing micro encapsulated iron (12.5 mg), zinc (7.5 mg), vitamin C (30 mg), vitamin A (300 µg), vitamin D (5 µg), folic acid (150 µg) and iodine (90µg).~Two month supply of the Sprinkle sachet along with advice on its benefits as well as its appropriate use will be given by the LHWs. The LHWs will also provide their age-appropriate nutritional advice as per their regular door to door community services."
223762681|NCT04488705|DRUG|Placebo - 7 day repeat dose|Twice daily doses of Placebo for 7 days
223762682|NCT04488705|DRUG|ETD002 - 14 day repeat dose|Twice daily doses of ETD002 for 14 days
223762683|NCT04488705|DRUG|Placebo - 14 day repeat dose|Twice daily doses of Placebo for 14 days
223762684|NCT04488705|DRUG|Salbutamol|Twice daily doses of salbutamol for 3 days (Days 5, 6 \& 7)
223762685|NCT03325166|DRUG|Ferumoxytol|Given IV
223762686|NCT03325166|OTHER|Laboratory Biomarker Analysis|Correlative studies
223762687|NCT03325166|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223762688|NCT03325166|BIOLOGICAL|Pembrolizumab|Given IV
223762689|NCT04150081|PROCEDURE|Surgery or Endoscopic treatment|All the patients in the cohort will receive surgery o local (endoscopic) treatment, in some cases additional surgical treatment will be performed after an endoscopic primary treatment. This decision will have been taken based on daily clinical practice and does not represent a study intervention.
223762690|NCT03431116|RADIATION|ultrasound|to detect the placental site
223762691|NCT05782595|OTHER|Aquatic therapy|"• Each session was divided into three phases:~1. Aquatic environment adaptation phase~2. stretching phase~3. a phase of static and dynamic exercises for balance"
223762692|NCT00614016|DRUG|Sodium ST20|single administration of oral dosage form
223625942|NCT00659061|BEHAVIORAL|Nutrition education|Nutrition education will be provided by LHWs as per their regular routine monthly door to door community services
223762693|NCT00428545|DRUG|Bevacizumab|Starting Dose 2.5 mg/kg By Vein On Day 1 Every 21 Days
223762694|NCT00428545|DRUG|Bortezomib|Starting Dose 0.7 mg/m\^2 By Vein On Days 1 and 8 Every 21 Days
223762695|NCT03268616|DEVICE|inspiratory threshold load device and NPPV|"before experiment ,every subject use a flanged mouthpiece attached to a manually operated occlusion valve in order to measure maximal inspiratory pressure (MIP)at functional residual capacity .~healthy subjects:increase the pressure in a water-sealed inspiratory threshold loading device in order to increase the neural respiratory drive.~COPD patients:increase the pressure in a non-invasive positive pressure ventilation in order to decrease the neural respiratory drive"
223762696|NCT06263335|OTHER|Mindfulness Based Stress Reduction Intervention|During an eight-week intervention period, clients were to engage in mindfulness practices lasting between 45 minutes to an hour each session. The intervention would incorporate various components of the Mindfulness-Based Stress Reduction (MBSR) program, including mindfulness of the present moment, body scans, mindful eating, walking meditation, yoga exercises, and discussions on applying mindfulness to everyday experiences and stress management. Sessions would typically range from 30 to 90 minutes per week, with an additional full-day retreat session towards the end of the program. In addition to mindfulness practice, participants were to receive teachings on stress management and its application to interpersonal and daily life situations.
223762697|NCT01436279|DRUG|Mifepristone|200 mg po 20-24 hours prior to the procedure
223762698|NCT01436279|DEVICE|osmotic dilators|osmotic dilators placed in the cervix 20-24 hours prior to the procedure
223762699|NCT02096458|DRUG|Dexlansoprazole|Dexlansoprazole delayed-release orally disintegrating tablets
223625943|NCT06066216|DRUG|Cadonilimab|Injectable solution
223625944|NCT06066216|DRUG|Carboplatin|Injectable solution
223625945|NCT06066216|DRUG|Cisplatin|Injectable solution
223625946|NCT06066216|DRUG|Paclitaxel|Injectable solutionS
223625947|NCT01811771|BIOLOGICAL|Shanchol vaccine|Shanchol vaccine contains whole cell inactivated heat killed and formalin killed bacteria consisting of 600 ELISA Units (EU) of lipopolysaccharide (LPS). It consists of formalin-killed V. cholerae Inaba, El Tor biotype (strain Phil 6973). It also contains 300 EU LPS of heat-killed V. cholerae Ogawa classical biotype (Cairo 50); 300 EU LPS of formalin killed V. cholerae Ogawa classical biotype (Cairo 50); 300 EU LPS of heat-killed V. cholerae Inaba, classical biotype (Cairo 48); and 600 EU LPS of formalin killed V. cholerae O139 (4260B) (9). The vaccine has no detectable cholera toxin. Vaccine is packaged as liquid formulations in 1.5-ml doses. No buffer is needed for administered.This vaccine is licensed in India and WHO prequalified.
223762700|NCT03160924|OTHER|Enhanced Recovery After Surgery (ERAS)|"same as above as described in the arms."
223762701|NCT01400841|DEVICE|HAART 300 Annuloplasty Device|Implantation of device for aortic valve repair
223762702|NCT05121584|PROCEDURE|Placement of an anterior crown restoration as a final restoration|Placement of an anterior crown restoration as a final restoration
223762703|NCT00910715|DRUG|doxycycline|doxycycline 100 mg bid, 10 days
223762704|NCT00910715|DRUG|doxycycline|doxycycline 100 mg bid, 15 days
223762705|NCT00910715|DRUG|placebo|control subjects without a history of Lyme borreliosis
224215209|NCT01612052|DRUG|Antibiotic Prophylaxis|Comparing the antibiotic treatment related to surgery
224215210|NCT05220904|DEVICE|spectacles|Spectacle is the the most common treatment for refractive errors.
224215211|NCT05220904|DEVICE|perceptual learning|Blurred vision from the eyes can be improved by enhancing the brain's visual processing.
224215212|NCT01368757|DRUG|Revlimid|"Dose escalation 5mg - 10mg - 15mg - 20mg in cohorts of three patients~The first step of phase I will be 5 mg lenalidomide in a daily regimen, the next step will be 10 mg in a daily regimen, the dosis of the following steps will be increased by 5 mg each until dose limiting toxicity (DLT) is reached.~Phase II will be started at the MTD (1 dose step below DLT) and will be administered in a daily regimen."
223625948|NCT01210716|DEVICE|Therapeutic plasma exchange|Patients are randomized to either Therapeutic plasma exchange procedures on AMICUS or Spectra first. The second procedure (based on time interval determined by physician) will be completed on the other instrument.
223625949|NCT06427213|DRUG|Zanubrutinib,Obinutuzumab|"Zanubrutinib, 160mg PO BID. C1D17 continuously for 1 year or until progressive disease； Obinutuzumab ：Obinutuzumab will be administered 1,000 mg intravenously on days 1, 8, and 15 of cycle 1, then 1,000 mg on day 1 of cycles 2 to 6, then 1,000 mg every 8 weeks，up to 20 doses. 1 cycle = 28 days.~Maintenance: Zanubrutinib, 160mg PO BID"
223762706|NCT01280188|DRUG|Desmopressin Oral Melt|Oral melt formulation starts on Day 2. The target initial dose of the orally disintegrating tablet is 180µg/day (60µg taken 3 times a day) and adjusted to optimally stabilise the participant's condition.
223762707|NCT01280188|DRUG|Desmopressin intranasal|Self-administered intranasal desmopressin throughout the pre-study observation period (Days -30 to Day 0) and on study Day 1
223762708|NCT03913078|BEHAVIORAL|Group Fitness|Traditional Group Fitness consisting of aerobic and strength exercises performed in a group setting and led by a trained instructor.
223762709|NCT03913078|BEHAVIORAL|PlayFit|Modified sports fitness exercise program consisting of games played in groups and led by a trained instructor.
224215213|NCT03902600|RADIATION|Moderately Hypofractionated RT|Patients will be treated with moderately hypofractionated radiation treatment
224215214|NCT03235765|DIAGNOSTIC_TEST|MACROGEN Pan Cancer Panel (Tier 2)|This study will utilize a MACROGEN Pan Cancer Panel (Tier 2), which is a hybrid capture-based NGS assay interrogating the coding regions of 170 cancer-related genes.
224215215|NCT01284569|BIOLOGICAL|ALX-0061|Intravenous administration, single dose (0.3-1-3-6-8 mg/kg) or multiple dose (Biologically effective dose, once every 4 weeks or once every 8 weeks, for 24 weeks)
224215216|NCT01284569|BIOLOGICAL|Placebo|Intravenous administration, single dose or multiple dose (once every 4 weeks or once every 8 weeks, for 12(/24) weeks; switch to ALX-0061 in weeks 13-24 if no response after first 12 weeks)
224215217|NCT00115258|OTHER|parenteral nutrition titrated to measured REE|
224215218|NCT05721716|BEHAVIORAL|Mindfulness Booster Course|The mindfulness booster course will consist of eight 30-minute sessions, which participants will be asked to commit to. These will be online and occur weekly for 8-weeks. Within these sessions, there will be a 15-minute mindfulness practice followed by a 15-minute discussion. This discussion time will involve reflecting on the mindfulness practice and speaking about between-session practice. Participants will be encouraged to practice mindfulness for home work between the sessions.
224215219|NCT05721716|BEHAVIORAL|Usual care|Participants will be encouraged to continue with whatever activities they usually undertake to manage their stress and support their wellbeing.
224215220|NCT01915381|OTHER|multimodal intervention|All subjects received a multimodal intervention consist in a multimodal program with an educational approach, where therapist advice about benefits of PA during the exercises, to promote PA with brochure-based decalogue
224215221|NCT00343642|DRUG|Active fructo-oligosaccharide|2 teaspoons of active fructo-oligosaccharides daily and Time and attention administering usual dietary recommendations for a healthy diet based on 2005 Dietary Guidelines for Americans
224215222|NCT00343642|DRUG|Placebo fructo-oligosaccharide|2 teaspoons of placebo fructose powder ( to serve as the placebo equivalent of active treatment with fructo-oligosaccharides daily) and Time and attention administering usual dietary recommendations for a healthy diet based on 2005 Dietary Guidelines for Americans
224215223|NCT00343642|DIETARY_SUPPLEMENT|Diet|A restrictive anti-inflammatory diet developed by the research team and 2 teaspoons of placebo fructose powder ( to serve as the placebo equivalent of active treatment with fructo-oligosaccharides daily)
224215224|NCT05674071|BEHAVIORAL|Articulation/HVT|Osteopathy 1
224215225|NCT05674071|BEHAVIORAL|Soft-tissue massage|Osteopathy 2
224215226|NCT05674071|BEHAVIORAL|Craniosacral techniques|Osteopathy 3
224215227|NCT05674071|BEHAVIORAL|Combination of the three interventions: HVT, soft-tissue and craniosacral techniques|This intervention will use a combination of the three interventions: HVT, soft-tissue and craniosacral techniques
224215228|NCT01854073|DRUG|Hyoscine butyl bromide|
223762710|NCT06368063|DRUG|Huaier granule|Huaier Granules: Oral administration, 10g once, 3 times a day, starting from 15-30 days after surgery until the end of the study, intolerable toxicity, withdrawal from the study for any reason, or death, whichever occurs first; Or the researcher determines that the subjects no longer benefit.
224215229|NCT01854073|DRUG|Normal saline|
224215230|NCT03352219|BEHAVIORAL|Reality Check|
224215231|NCT03352219|BEHAVIORAL|Physical Activity Attention Control|
224215232|NCT05205668|BIOLOGICAL|F-652|IL-22 fusion protein administered intravenously
224215233|NCT05205668|BIOLOGICAL|Placebo|Placebo administered intravenously
224215234|NCT00420160|BEHAVIORAL|Smoking cessation treatment plus moderate intensity exercise|
223762711|NCT06368063|DRUG|chemotherapy drugs|"Accept treatment with Class 1A chemotherapy drugs recommended by CSCO (choose any one to receive treatment)~· Gemcitabine combine with capecitabine~Gemcitabine 1000mg/m\^2 intravenous infusion for more than 30 minutes, day 1, 8, 15,repeat every 4 weeks for a total of 6 cycles.~· mFOLFIRINOX solution~Oxaliplatin 85mg/m\^2 intravenous infusion for 2 hours, day 1 Ilitacan 150mg/m\^2 intravenous infusion for more than 30-90 minutes, day 1 Leucovorin calcium 400mg/m\^2 intravenous infusion for 2 hours, day 1 5-FU 2400mg/m\^2, continuous intravenous infusion for 46 hours, repeated every 2 weeks, administered until 24 weeks.~* Gemcitabine monotherapy~  1000mg/m\^2 intravenous infusion, day 1 qw x 7, rest for 1 week Afterwards, qw × 3, take a week off, and administer medication for 6 months.~* Tegio capsules monotherapy~Take tegio capsules orally, 80mg/d, day 1-28, repeated every 6 weeks, administered until 6 months."
223762712|NCT00770120|DRUG|everolimus|
223762713|NCT05729620|DEVICE|Implant of STARgraft-3 shunt in the upper arm and subsequent use for hemodialysis access|After healing from the surgical procedure, the graft will be routinely cannulated for hemodialysis sessions. Periodic evaluations of blood flow by ultrasound imaging will be made over the study period. Established standards of care will be followed as needed to maintain dialysis function.
224215235|NCT00420160|BEHAVIORAL|Smoking cessation treatment plus health education|
224215236|NCT00205465|DRUG|VX-765|
224215237|NCT03634631|OTHER|Focused Ultrasound|Test ultrasound in 7T MRI scanner
224215238|NCT00860574|DRUG|treosulfan|Given IV
224215239|NCT00860574|DRUG|fludarabine phosphate|Given IV
224215240|NCT00860574|RADIATION|total-body irradiation|Low dose starting at 2Gy
224215241|NCT00860574|PROCEDURE|peripheral blood stem cell transplantation|Given IV per institutional standard practice
224215242|NCT00860574|DRUG|tacrolimus|Given IV or PO
224215243|NCT00860574|PROCEDURE|allogeneic bone marrow transplantation|Given IV per institutional standard practice
224215244|NCT00860574|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Given IV per institutional standard practice
224215245|NCT00860574|DRUG|methotrexate|Given IV
223625950|NCT06427213|DRUG|Zanubrutinib and R-BAC|"Induction: Zanubrutinib and R-BAC 6 cycles~Consolidation: ASCT（If eligible for transplantation），Otherwise, the patient was directly entered into maintenance treatment~Maintenance: Zanubrutinib continued until progression"
223762714|NCT05949476|OTHER|ozone therapy|"Ozone in the gaseous state produced by a machine at concentrations for medical use (sssssssssss9) injected after anesthesia in the surgery site and in the post-extraction alveolus after suture.~* Topical ozone in the form of a gel (indicate the brand) to be applied to the post-surgical site 2 times a day for 7 days."
223762715|NCT00394966|DRUG|SCH 619734 Dose 1|SCH 619734 10 mg (4 capsules) x 1 orally approximately 2 hours prior to the administration of the first chemotherapeutic agent on Day 1 of Cycle 1 and on Day 1 of all subsequent cycles (up to five additional cycles)
223762716|NCT00394966|DRUG|SCH 619734 Dose 2|SCH 619734 25 mg (4 capsules) x 1 orally approximately 2 hours prior to the administration of the first chemotherapeutic agent on Day 1 of Cycle 1 and on Day 1 of all subsequent cycles (up to five additional cycles)
223762717|NCT00394966|DRUG|SCH 619734 Dose 3|SCH 619734 100 mg (2 capsules) x 1 orally approximately 2 hours prior to the administration of the first chemotherapeutic agent on Day 1 of Cycle 1 and on Day 1 of all subsequent cycles (up to five additional cycles)
223762718|NCT00394966|DRUG|SCH 619734 Dose 4|SCH 619734 200 mg (4 capsules) x 1 orally approximately 2 hours prior to the administration of the first chemotherapeutic agent on Day 1 of Cycle 1 and on Day 1 of all subsequent cycles (up to five additional cycles)
223762719|NCT00394966|DRUG|Placebo|Matching placebo x 1 orally approximately 2 hours prior to the administration of the first chemotherapeutic agent on Day 1 of Cycle 1 and on Day 1 of all subsequent cycles (up to five additional cycles)
223762720|NCT02985294|OTHER|Multiple Excitability Measures of peripheral nerves|The technique of threshold tracking can be used to obtain several measures of peripheral nerve excitability (Multiple Excitability Measures or MEM), such as refractoriness, supernormality, strength-duration time constant and 'threshold electrotonus' (i.e. the changes in threshold produced by long-lasting depolarizing or hyperpolarizing current pulses). Each of these measurements depends on membrane potential and on other biophysical properties of the axons. Many of these excitability parameters are very constant among different subjects, while other, such as the current/threshold parameters and the super/sub-excitability parameters, appear to be characteristic of an individual
223762721|NCT00033384|DRUG|CI-1040|
223762722|NCT03078998|DEVICE|Leap Motion Based Exercises|Game based exercise
223762723|NCT03930459|PROCEDURE|Static cold storage (SCS)|The liver is flushed and cooled with specialist preservation fluid, then stored in an icebox.
223762724|NCT03930459|DEVICE|Normothermic machine perfusion (NMP)|During NMP, the liver is perfused with oxygenated blood, medications and nutrients at normal body temperature to maintain a physiological milieu.
223625951|NCT00231426|DEVICE|ICD|
223625952|NCT03530397|BIOLOGICAL|MEDI5752|Subjects will remain on treatment until unacceptable toxicity, documentation of progressive disease, or development of other reason for treatment discontinuation.
223625953|NCT03530397|DRUG|Pemetrexed|Subjects will remain on treatment until unacceptable toxicity, documentation of progressive disease, or development of other reason for treatment discontinuation
223625954|NCT03530397|DRUG|Carboplatin|Subjects will remain on treatment until unacceptable toxicity, documentation of progressive disease, or development of other reason for treatment discontinuation
223625955|NCT03530397|BIOLOGICAL|Pembrolizumab|Subjects will remain on treatment until unacceptable toxicity, documentation of progressive disease, or development of other reason for treatment discontinuation
223625956|NCT03530397|DRUG|Paclitaxel or Nab-Paclitaxel|Subjects will remain on treatment until unacceptable toxicity, documentation of progressive disease, or development of other reason for treatment discontinuation
223625957|NCT02571426|DRUG|Sevoflurane|anesthetic agent
223762725|NCT00222495|DRUG|quetiapine|
223762726|NCT00222495|DRUG|olanzapine|
223762727|NCT00222495|DRUG|risperidone|
223762728|NCT04138927|DRUG|Fostamatinib disodium|Fostamatinib is supplied in two (2) dosage strengths: 100 mg and 150 mg.
223762729|NCT01467076|DRUG|Aerosolized Normal Saline|Two initial doses of IPGE1 will be tested - 150 and 300 ng/kg/min. Thus, there will be three arms to the study - IPGE1 \[150\], IPGE1 \[300\], and placebo (normal saline). This design will allow comparison of the two doses of IPGE1 with each other and controls; and also allow comparison of any IPGE1 with controls. Placebo will be administered over a maximum duration of 72 hours.
224215246|NCT01704235|OTHER|Demographic Form and Semi-Structured Interview Guide|"The demographic form will include the following items: age, age at immigration, years lived in the United States, Vietnamese speaking ability, and marital status. In addition for participants who are primary health care providers, the following items will be included: annual income before taxes, gender, race and ethnicity, specialty area of practice, and number of years practicing as a primary health care provider, practice setting, and country received Pap test training.~A semi-structured interview guide will also be used and will include possible probing questions. A semi-structured interview guide was developed with the research team."
224215247|NCT01246986|DRUG|LY2157299|Administered orally
224215248|NCT01246986|DRUG|Sorafenib|Administered orally
224215249|NCT01246986|DRUG|Ramucirumab|Administered IV
224215250|NCT04948255|OTHER|Health and Safety Executive's (HSE) Management Standards Indicator Tool (MSIT) to measure work-related stress|Questionnaire
224215251|NCT05948436|PROCEDURE|Clamping the uterine artery bilaterally during Cesarean section|We clamped the uterine artery by Darmklemmen clamp, which grasps the tissue delicately without damage, after the delivery of the baby before the delivery of placenta. The clamp is released after the suturing of Munro-Kerr incision is finished, before bleeding control. The duration of clamping time is recorded.
224215252|NCT02006407|RADIATION|Cranial Radiotherapy|Standard cranial radiotherapy administered dependent upon patient and brain tumor type.
223625958|NCT02571426|DRUG|propofol|anesthetic agent
224215253|NCT02006407|DEVICE|MRI with Diffusion Tensor Imaging (DTI)|Magnetic Resonance Imaging (MRI) with Diffusion Tensor Imaging (DTI)
224215254|NCT02006407|BEHAVIORAL|Neuro-cognitive Testing (CogState)|CogState is a computerized software testing system that offers various cognitive assessments based traditional expansive neurocognitive tests.
224215255|NCT01655433|DEVICE|Velomedix APLS device|Velomedix, Automated Peritoneal Lavage System
224215256|NCT01655433|OTHER|No Hypothermia Treatment|
223625959|NCT05104853|DRUG|CNP-104|CNP-104 is comprised of PDC-E2 peptide dispersed within a negatively charged polymer matrix of poly (lactic-co-glycolic acid) (PLGA) particles at a target concentration of \~1 μg of PDC-E2 peptide per mg of PLGA particles.
223625960|NCT05104853|DRUG|Placebo|CNP-104 Placebo
223762730|NCT01467076|DRUG|Inhaled PGE1|Two initial doses of IPGE1 will be tested - 150 and 300 ng/kg/min. Thus, there will be three arms to the study - IPGE1 \[150\], IPGE1 \[300\], and placebo (normal saline). This design will allow comparison of the two doses of IPGE1 with each other and controls; and also allow comparison of any IPGE1 with controls. In this Pilot RCT, two doses of IPGE1 (300 and 150 ng/kg/min) will be administered over a maximum duration of 72 hours to determine the optimal dose and duration of therapy.
223762731|NCT02866838|DRUG|Tranexamic acid|intravenous
223762732|NCT02866838|DRUG|Saline 0.9%|intravenous
223762733|NCT03025022|DRUG|14C-JNJ-42847922 40 mg|Participants will receive a single 40 mg oral dose of 14C-JNJ-42847922 containing maximally 100 MicroCurie as a 40 milliLitre (mL) solution.
223762734|NCT01383902|OTHER|Food type|1ml, 1ml, 5ml, 50ml, 6ml, 20ml, 60ml and 200ml of chocolate dessert or 1 g, 1 segment (5 segments to a bar) repeated 6 times, 2 bars repeated twice of chocolate bars
223762735|NCT06126484|PROCEDURE|transcatheter cardiac intervention|Balloon atrial septostomy, PDA stent implantation, Pulmonary valvuloplasty, Aortic valvuloplasty, Balloon angioplasty of coarctation, PDA closure in preterm neonates
223762736|NCT04465045|PROCEDURE|Laparoscopy-hysteroscopy|Under general anesthesia, we start by a first look in laparoscopy, to look for endometriosis mainly, tubal infertility, ovarian cysts or any abnormalities that may not have been suspected on the first exam. Then we check tubal patency after a look at the uterine cavity by hysteroscopy. Then we treat everything possible to treat to improve fertility, spontaneous or with ART.
223762737|NCT05380661|PROCEDURE|Self-catheterization|Participants will perform self-catheterization, following the same routine for intermittent catheterization at home
223762738|NCT05380661|PROCEDURE|Catheterization performed by urology nurse, participant blinded to time of procedure|Participant will undergo procedure to completely empty bladder; Participant in supine position, and resting blood pressure and heart rate will be recorded for period of 5 minutes prior to catheterization; Perineum and genital areas will be draped and they will be not aware about exact timing of catheterization Catheterization will be conducted following standard clinic procedure by experience urology nurse.
223762739|NCT05380661|PROCEDURE|Catheterization performed by urology nurse, participant aware of time of procedure|Participant will undergo procedure to completely empty bladder; Participant in supine position, and resting BP and HR will be recorded for period of 5 minutes prior to catheterization; Perineum and genital areas will be visible to participant and they will be fully aware about exact timing of catheterization Catheterization will be conducted following standard clinic procedure by experience urology nurse.
224215257|NCT02542228|OTHER|questionnaire survey|The HR-QOL PIDD survey will be administered to the patient by the site PI or the study coordinator. A second survey will be handed to the patient to take home with them and completed at 48-120 hrs. after the clinic visit. The study coordinator will contact the patient during this period to ensure that the patient completes this second survey and returns it to the local study site. A case report form (CRF) of their clinical condition and demographics will be collected at the time of informed consent.
224215258|NCT04937751|DIAGNOSTIC_TEST|biomarkers|galactomannan, betaDglucan, resistance markers
224215259|NCT04329650|DRUG|Siltuximab|A single-dose of 11mg/Kg of siltuximab will be administered by intravenous infusion.
224215260|NCT04329650|DRUG|Dexamethasone|A dose of 6mg/24 hours of dexamethasone during 10 days will be administered orally or by intravenous infusion.
224215261|NCT00045604|DRUG|cisplatin|
224215262|NCT00045604|DRUG|imatinib mesylate|
224215263|NCT00045604|DRUG|irinotecan hydrochloride|
224215264|NCT03582501|OTHER|Lower body negative pressure|Simulated hypovolemia by applied suction to lower extremities to cause venous pooling.
224215265|NCT02845635|OTHER|Personal history of multiple sclerosis|Participants will be stratified into one of four cohorts based on their experience (or lack of experience) with the three major forms of multiple sclerosis.
224215266|NCT03569163|DEVICE|Spry Loop oximeter|Oximetry was performed on the subjects and accuracy was determined based on comparison with blood gas analysis.
224316811|NCT00573378|DRUG|PEG-IFN-a2b|Patients will receive pegylated interferon α-2b (Pegintron®) (PEG-IFN-α2b) 150 µg subcutaneously, once a week. Patients and/or caregivers identified by the patient will be taught how to perform subcutaneous injections of the PEG-IFN-α2b by trained nurses in the chemotherapy infusion center at the University of Michigan Comprehensive Cancer Center. Those patients who do not feel comfortable receiving the injections outside of the cancer center, or are deemed unreliable in administering injections per the training nurse, will return to the cancer center infusion room on a weekly basis to receive subsequent injections.
223625961|NCT03607214|OTHER|Placebo|"Placebo nasal spray~Film Sequence"
223625962|NCT05179252|DRUG|Shen-Fu injection|Chinese patent medicine made by modern technology
224215267|NCT00201734|DRUG|Capecitabine|Level 1: 500 mg/m2 orally twice daily Days 8 - 21 of each cycle. Level 2: 750 mg/m2 orally twice daily Days 8 - 21 of each cycle. Level 3 - 5: 1000mg/m2 orally twice daily Days 8 - 21 of each cycle.
224215268|NCT00201734|DRUG|Carboplatin|Levels 1-5: AUC of 6 every 4 weeks.
224215269|NCT00201734|DRUG|Paclitaxel|Level 1-3: 60 mg/m2/week. Level 4: 80 mg/m2/week. Level 5: 100 mg/m2/week.
224316812|NCT02101125|DRUG|BMS-986020|
224316813|NCT02101125|DRUG|Rosuvastatin|
224316814|NCT03032848|DRUG|Conjugated Estrogen|use of 1 gram per day
224316815|NCT03032848|DRUG|Promestriene|use of 1 gram per day
223625963|NCT05179252|DRUG|normal saline|0.9% normal saline, used for sham control
223625964|NCT00329966|BIOLOGICAL|Surface Antigen, Inactivated, Influenza (form.2006-07)|
223625965|NCT00872963|BIOLOGICAL|RTS,S/AS01E|0.5MLS of RTS,S/AS01E at 0,1,2 monthly schedule 0.5mls Rabies vaccine at 0,1,2 monthly schedule
223625966|NCT03399058|OTHER|Group 1 5+5+5 (Control)|The standard of care in Cambodia is known as the basic health and nutrition service package or 5+5+5. The participants in the first group will be the control group and will only be implementing the standard of care, 5+5+5 package (Group 1).
223625967|NCT03399058|BEHAVIORAL|Group 2: 5+5+5 & PDH|The participants in the second group will receive contextualized Hearth messages through on-going PDH programs in addition to the basic standard of care (Group 2).
223625968|NCT03399058|BEHAVIORAL|Group 3: 5+5+5 & PDH lite+mHealth|The participants in the third group will receive a PDH lite program and receive follow-up through mobile support phone calls (Group 3).
223762740|NCT05814120|BEHAVIORAL|BLS training program|BLS training program was in accordance with the 2020 AHA cardiopulmonary resuscitation (CPR) guidelines. The BLS training program adopts 4D teaching techniques, namely description (Describe), demonstration (Demo), implementation (Do), feedback (Debriefing).
223762741|NCT00020111|DRUG|arsenic trioxide|
223762742|NCT05963542|BEHAVIORAL|ACT for tinnitus|The intervention will be based on the ACT model and adjusted for tinnitus.
223762743|NCT05963542|OTHER|Customized sound therapy|The music will be modulated through a smartphone app using a set program to generate customized tinnitus relieving sound.
224215270|NCT00438958|BIOLOGICAL|filgrastim|Given on day 0.
224215271|NCT00438958|PROCEDURE|allogeneic bone marrow transplantation|Given on day 0
224215272|NCT00438958|PROCEDURE|peripheral blood stem cell transplantation|Given on day 0
223762744|NCT00981500|PROCEDURE|gastric bypass|Roux-en-Y gastric bypass
223762745|NCT00981500|PROCEDURE|gastric banding|laparoscopic adjustable gastric banding
223762746|NCT00981500|PROCEDURE|sleeve gastrectomy|vertical sleeve gastrectomy
223762747|NCT01429766|OTHER|Respiratory Training|"All patients shall be sent for respiratory training to the physiotherapy department. Patients shall be counseled about respiratory training by trained staff in their own vernacular. Whenever possible, patients shall be provided one Spiroball device and taught how to use the device. In addition/alternatively patients will be taught to do pranayam(breath exercises). Patients provided with spiroball shall be instructed to use the spiroball by the prescribed technique. The following visit schedule shall be observed~1. st visit Within one day of the date of simulation~2. nd visit Date of Radiotherapy start Subsequently 2 visits per week during radiotherapy course shall be conducted (Tuesdays, Thursdays)"
224215273|NCT02624921|OTHER|There was no intervention.|Participants were transported one day to a urban setting, one day to a green space, one day to a beach. No intervention was done.
224215274|NCT06263465|OTHER|Lactobacillus cispatus|10\^9 cfu,5 days
224316816|NCT03032848|DRUG|Estriol|use of 1 gram per day
224316817|NCT03032848|DRUG|Vaginal Moisturizer - Cream|use of 1 gram per day
224316818|NCT04797026|OTHER|Letters to increase social connection with goal to alleviate loneliness|Our hypothesis is that a social program connecting patients in residential care facilities with high school students through monthly letter writing would positively impact quality of life for both, reducing quantitative and qualitiative measures of loneliness
224316819|NCT03054701|OTHER|Hip specific resistance exercise|Hip specific resistance exercise
224316820|NCT03054701|OTHER|Knee specific resistance exercise|Knee specific resistance exercise
224316821|NCT02487914|DEVICE|iontophoresis of Lidocaine 10% with interferential current (Dynatron 438)|drug delivery through interferential current.
224215275|NCT06263465|OTHER|placebo|0 cfu,5 days
224215276|NCT02911779|PROCEDURE|change of medilateral angle line during crowning of the head|change of medilateral angle line during crowning of the head
224215277|NCT06250400|BIOLOGICAL|human histaglobulin|once 12 mg/2ml/bottle, 2 subcutaneous injection once a week, using 4 times in a row, a total of 28 d;
224215278|NCT06250400|BIOLOGICAL|placebo|once 12 mg/2ml/bottle, 2 subcutaneous injection once a week, using 4 times in a row, a total of 28 d;
224215279|NCT06250400|DRUG|Loratadine 10 Mg|orally, 10mg once a day for 4 weeks
224215280|NCT01683552|DRUG|Aprepitant|125 mg on day 1; 80 mg on day 3; 80 mg on day 5
224215281|NCT01683552|DRUG|Prednisone|In the refractory group (VAS score ≥7), Aprepitant (125 mg on day 1; 80 mg on day 3; 80 mg on day 5) is administered after at least one week of standard systemic treatment (prednisone 25 mg/die and/or fexofenadine 180 mg/die),
224215282|NCT01683552|DRUG|Fexofenadine|In the refractory group (VAS score ≥7), Aprepitant (125 mg on day 1; 80 mg on day 3; 80 mg on day 5) is administered after at least one week of standard systemic treatment (prednisone 25 mg/die and/or fexofenadine 180 mg/die)
224215283|NCT06217952|DRUG|SPL84|SPL84 solution for nebulization
224215284|NCT06217952|OTHER|Placebo|Placebo solution for nebulization
224215285|NCT02410070|PROCEDURE|Incision|The objective of this report is to compare a minimal invasive approach with the conventional flexor carpi radialis approach for volar plating of distal radial fractures.
223625969|NCT01277744|PROCEDURE|Hyperthermic Peritoneal Perfusion (HIPEC)|HIPEC, technique for combining hyperthermia and chemotherapeutic agents delivered intraoperatively to the peritoneal and retroperitoneal surface via a recirculating perfusion circuit, performed after cytoreductive surgery and lysis of adhesions.
223625970|NCT01277744|DRUG|Cisplatin|100 mg/M2 per perfusion catheter. The perfusion is continued for 90 minutes after adding the cisplatin.
223625971|NCT01885429|DIETARY_SUPPLEMENT|Positive Control|Subject consumes 25g of whey protein following unilateral exercise
223625972|NCT01885429|DIETARY_SUPPLEMENT|Negative Control|Subject consumes 6.25g of whey protein following unilateral exercise
223625973|NCT01885429|DIETARY_SUPPLEMENT|Low Protein Low Leucine Spike|Subject consumes 6.25g of whey protein plus 3g of leucine following unilateral exercise
223625974|NCT01885429|DIETARY_SUPPLEMENT|Low Protein High Leucine Spike|Subject consumes 6.25g of whey protein plus 5g of leucine following unilateral exercise
224215286|NCT04551352|DRUG|RO7293583|RO7293583 will be administered at a dose and per schedule as specified for the respective cohort.
224215287|NCT04551352|DRUG|Tocilizumab|Tocilizumab will be administered as required for the management of severe cytokine release syndrome (CRS).
224215288|NCT04551352|DRUG|Obinutuzumab|If implemented, it will be given either on D-7 or D-7 and D-6.
224316822|NCT02487914|DRUG|Lidocaine 10% was sprayed at the identified region|
224316823|NCT02487914|DEVICE|interferential current|
224316824|NCT00459355|BEHAVIORAL|Home Safety Toolkit|Health literacy-verified booklet and home safety items to promote competence to make home safety modifications.
224316825|NCT00287586|DRUG|Testosterone Gel (Androgel)|7.5 g of 1% testosterone gel to achieve a nominal delivery of 75 mg testosterone daily for 3 years
224316826|NCT00287586|DRUG|Placebo|Placebo-matching testosterone gel daily for 3 years
223762748|NCT05018572|BEHAVIORAL|I AM|"I am has a biopsychosocial perspective with a focus on pain management in migraines. The cognitive behavioural interventions being tested are Mindfulness, Acceptance and Commitment Therapy (ACT), Compassion Focused Therapy and Physiotherapist-led cardiotherapy. The treatment program consists of ten modules of texts, animated films with a fictional person to identify with, recorded audio exercises adapted for patients with migraines and filmed physiotherapeutic exercises with physiotherapists.The interventions in I am are personalised in that the first three modules and module 10 are for those who are being helped by a shorter treatment. The other modules, four to ten, are a more in-depth treatment for those who have frequent or chronic migraines. The participants are in contact with processors via message function as well as via phone at startup, at the middle of treatment and termination. The duration of treatment is 4-10 weeks."
223762749|NCT05305599|DRUG|ZED1227|ZED1227 is a peptidomimetic designed to inhibit the activity of human tissue transglutaminase 2 (TG2).
223762750|NCT05305599|DRUG|Placebo|Placebo
223762751|NCT04027218|DEVICE|Dry heat|The application is made with two sacks of carob seeds during 7 minutes. The sacks are placed on antebrachial anatomical zone, together, and previously heated in the microwave for 0.30 seconds at 850 W of power.
223762752|NCT04027218|DEVICE|High pressure|It will be carried out with the use of the manual aneroid sphygmomanometer fixed at 100 millimeters of mercury. Brand (QUIRUMED) with European Conformity (CE) marking 0197. A pressure lower than the systolic blood pressure, and in each subject will be monitored the radial pulse.
224215289|NCT04551352|DRUG|Adalimumab|If implemented, it will be given as a single dose approximately 6 days prior to the first dose of RO7293583.
224215290|NCT01335399|DRUG|Lenalidomide|Capsules, Oral, 25 mg, once daily, on Days 1-21, Repeat every 28 days until subject meets criteria for discontinuation of study drug
224215291|NCT01335399|DRUG|Dexamethasone|Tablets, Oral, 40 mg, weekly, on Days 1, 8, 15, 22, Repeat every 28 days until subject meets criteria for discontinuation of study drug
224215292|NCT01335399|DRUG|Dexamethasone|Tablets, Oral, 28 mg, once daily, on Days 1, 8, 15, 22 (cycles 1\&2) ; Days 1 \&15 (cycles 3-18); Day 1 (cycle 19 and beyond), Repeat every 28 days until subject meets criteria for discontinuation of study drug
224316827|NCT01025414|DRUG|enteral nutrition|Group A - enteral feeding was started 2 to 4 hours after catheter placement via enteral tube inserted via endoscope below the Treitz's ligament into first intestinal loop (location of the tip) (Nutricial Ltd. Flocare). The initial flow rate was 10 ml/ hour, final 125 ml/ hour. Energy requirements was calculated using following rule: 0.15-0.2 gN/ kg and 130-170 kcal/ gN. Diet: Peptisorb (Nutricia Ltd.) - oligopeptide diet well tolerated by intestines
224316828|NCT01025414|DRUG|Parenteral nutrition|Parenteral nutrition was started 2 to 4 hours after venous catheter placement (standard Arrow type, the tip located 5 cm over right vestibule, the location confirmed on chest X-ray) and continued until oral diet covering at least 60% of daily caloric and protein demand. The energy requirements were calculated using following rule: 0.15-0.2 gN/ kg and 130-170 kcal/ gN. Parenteral diets: Aminoplasmal 10%, Lipofundin LCT/MCT 10 and 20%, 40% Glucose, Tracutil (microelements and trace elements), Cernevit (vitamins), electrolytes
223762753|NCT04027218|DEVICE|Combination of dry heat and high pressure|"The application is made with two sacks of carob seeds during 7 minutes. The sacks may be placed on antebrachial anatomical zone, together, and previously heated in the microwave for 0.30 seconds at 850 W of power; according to instructions for use.~After 7 minutes, the pressure is applied with the use of the manual aneroid sphygmomanometer fixed at 100 millimeters of mercury. Brand QUIRUMED with CE Marking 0197. A pressure lower than the systolic blood pressure, and in each subject will be monitored the radial pulse."
223762754|NCT03199703|DEVICE|Baylis transseptal system group|
223762755|NCT03199703|DEVICE|Standard conventional transseptal group|
223762756|NCT02530294|DRUG|glycopyrronium Topical Wipes|Topical wipes containing glycopyrronium
224316829|NCT03101605|OTHER|e-learning teaching module|As described
224316830|NCT03101605|OTHER|Standard teaching method|As described
224316831|NCT02197819|DEVICE|Sling|
224316832|NCT02197819|DEVICE|External Rotation Brace|
224316833|NCT03831711|DRUG|Gallium Ga 68-labeled GRPR Antagonist BAY86-7548|Given IV
224316834|NCT03831711|PROCEDURE|Magnetic Resonance Imaging|Undergo PET/MRI
224316835|NCT03831711|PROCEDURE|Positron Emission Tomography|Undergo PET/MRI
224316836|NCT03831711|DEVICE|Investigational software and coils in PET/MR scan|General Electric (GE) Healthcare non-approved PET scanner coils and software
224316837|NCT03743415|BEHAVIORAL|Handbook|see arm/group descriptions
224316838|NCT03743415|BEHAVIORAL|TIP-C plus Handbook|see arm/group descriptions
224316839|NCT03612921|DRUG|oral Amantadine sulfate|oral amantadine
223762757|NCT02530294|OTHER|Vehicle|Vehicle (placebo) topical wipes
223762758|NCT02285985|DRUG|Saxagliptin|Tablets: 5 mg
223762759|NCT02285985|DRUG|Placebo|Tablets: 5mg
224316840|NCT03612921|DRUG|i.v Amantadine Sulfate|intra venous amantadine
224316841|NCT03612921|DRUG|placebo tablet|placebo tablet
224316842|NCT04598399|BEHAVIORAL|Mindfulness Based Relapse Prevention|7 x 60-120 minute sessions with different themes: Automatic pilot/triggers/relapse/high-risk situations/ mindfulness in daily life. There will be a welcoming time, with a focus on at-home practice and difficulties, a theoretical presentation of new concepts, practical meditation exercises and a debriefing.
224316843|NCT04598399|BEHAVIORAL|Relaxation/ meditation|7 x 60-120 minute sessions each with a different sound from nature with unguided, closed relaxation group with a maximum of 12 participants
224316844|NCT02460367|DRUG|Docetaxel|
224316845|NCT02460367|BIOLOGICAL|Tergenpumatucel-L|
224316846|NCT02460367|DRUG|Indoximod|
223625975|NCT01885429|DIETARY_SUPPLEMENT|Low Protein + High Leucine + BCAA Spike|Subject consumes 6.25g of whey protein plus 5g of leucine plus valine and isoleucine (BCAA) following unilateral exercise
223625976|NCT05602493|DRUG|Soludronate®|In the first visit, the randomized process will take place. Tooth extraction procedure will be performed.
223625977|NCT05602493|DRUG|sterile saline|sterile saline
223762760|NCT02506816|DRUG|Olaparib|Drug exposure has a limited duration 28 (+/- 5) days and at lower dose (600mg/day) than therapeutical accepted (800mg/day).
223762761|NCT04577326|DRUG|cyclophosphamide|A preconditioning regimen of one dose of intravenous (IV) cyclophosphamide 1.5 g/m\^2 will be administered 2-7 days before the infusion.
223762762|NCT04577326|BIOLOGICAL|CAR T cells|A single dose of M28z1XXPD1DNR CAR T cells will be instilled into the pleural cavity via a pleural catheter or through an interventional radiology-guided needle. Cohorts of 3 patients will be treated at each dose level, up to a maximum of 3 x 10\^7 T cells/kg or until the MTD has been reached.
224215293|NCT01335399|DRUG|Dexamethasone|Tablets, Oral, 40 mg, once daily, on Days 8 \& 22 (cycles 3-18); Days 8, 15, 22 (cycle 19 and beyond), Repeat every 28 days until subject meets criteria for discontinuation of study drug
224215294|NCT01335399|DRUG|Dexamethasone|Solution, Intravenous (IV), 8 mg, Once daily, on Days 1, 8, 15, 22 (cycles 1\&2) ; Days 1 \&15 (cycles 3-18); Day 1 (cycle 19 and beyond), Repeat every 28 days until subject meets criteria for discontinuation of study drug
224215295|NCT01335399|BIOLOGICAL|Elotuzumab (BMS-901608; HuLuc63)|Solution, Intravenous (IV), 10 mg/kg, weekly, on Days 1, 8, 15, 22 (cycles 1\&2); Days 1 and 15 (cycles 3-18), Repeat every 28 days until subject meets criteria for discontinuation of study drug
224215296|NCT01335399|BIOLOGICAL|Elotuzumab (BMS-901608; HuLuc63)|Solution, Intravenous (IV), 20 mg/kg, Day 1 (cycle 19 and beyond), Repeat every 28 days until subject meets criteria for discontinuation of study drug
223762763|NCT00901940|BIOLOGICAL|Meningococcal (Groups A, C, Y and W-135) Conjugate|2 x 0.5 mL dose
223762764|NCT00901940|BIOLOGICAL|Meningococcal polysaccharide A, C, Y and W135 and Menveo|1 x 0.5 mL dose of ACWY Vax, 1 x 0.5 mL dose of Menveo
224215297|NCT01416142|DEVICE|PureVision2 HD contact lenses|Lenses to be worn through 1/2 of an HD movie. Following the movie, all subjects were to wear the dispensed contact lenses on a daily wear basis for approximately one week.
224215298|NCT01416142|DEVICE|Spectacles|Spectacles to be worn throughout 1/2 of an HD movie.
223762765|NCT04751591|PROCEDURE|Endoscopic resection|Endoscopic submucosal dissection (ESD) or endoscopic full-thickness resection (EFTR) for patients with 2-5cm gastric GISTs
223762766|NCT04751591|PROCEDURE|Laparoscopic partial gastrectomy|Laparoscopic partial gastrectomy for patients with 2-5cm gastric GISTs
223762767|NCT00175903|DRUG|Levetiracetam|Daily dose of 1000 to 3000 mg film-coated oral tablets, 250-500 mg twice daily.
224215299|NCT05183399|DEVICE|GORE® VIABAHN® Endoprosthesis|
224215300|NCT00003299|DRUG|cisplatin|
224215301|NCT00003299|DRUG|etoposide|
224316847|NCT06521099|BEHAVIORAL|Evaluative Conditioning with positive stimuli|In the pre-conditioning phase, participants will be exposed to pictures that vary in their emotional (negative, positive) and social (non-social, social) content. For each picture, they are required to indicate their immediate perceived valence (between negative to positive), degree of social motivation (between none to high) on Likert-scales. In the conditioning phase, emotional social pictures will be selected and paired with non-social positive stimuli for trials in random order, for 6 sessions across 3 weeks. In the post-conditioning phase, participants will be asked to evaluate the valence of the stimuli again similar to that in pre-conditioning phase.
224316848|NCT06521099|BEHAVIORAL|Conditioning with neutral stimuli|In the pre-conditioning phase, participants will be exposed to pictures that vary in their emotional (negative, positive) and social (non-social, social) content. For each picture, they are required to indicate their immediate perceived valence (between negative to positive), degree of social motivation (between none to high) on Likert-scales. In the conditioning phase, emotional social pictures will be selected and paired with with neutral non-social stimuli for trials in random order, for 6 sessions across 3 weeks. In the post-conditioning phase, participants will be asked to evaluate the valence of the stimuli again similar to that in pre-conditioning phase.
223625978|NCT01622439|DRUG|Valproate|Valproate is given in escalating doses to establish maximum tolerable dose when given together with standard treatment in patients with diffuse large B-cell lymphoma; this is the phase I part of the study. When maximum tolerable dose is established, this dose will be given to remaining patients in the phase II part of the study.
223625979|NCT01622439|DRUG|Rituximab|Vill be given intravenously, 375 mg/m2, every second or third week depending on cycle length (14 or 21 days), for a total of 6 cycles.
223762768|NCT00175903|DRUG|Carbamazepine Controlled Release (CBZ-CR)|Daily dose of 600-1600 mg CR oral tablets, 200 mg and 400 mg twice daily.
223762769|NCT00175903|DRUG|Valproate Extended Release|Daily dose of 1000-2000 mg ER oral tablets, 300 mg and 500 mg twice daily.
224215302|NCT00003299|DRUG|paclitaxel|
224215303|NCT02464059|DRUG|Vitamin D3|Oral supplementation with 50,000 IU vitamin D3 weekly for eight weeks in individuals with reduced vitamin D levels.
224215304|NCT02050607|OTHER|fecal microbiota transplantation from healthy lean donors|fecal microbiota transplantation from healthy lean donors
224215305|NCT05888207|DRUG|Savolitinib|Savolitinib will be administered as a single oral dose on Day 1 of Period 1 and on Day 5 of Period 2.
223625980|NCT01622439|DRUG|Cyclophosphamide|Vill be given intravenously, 750 mg/m2, every second or third week depending on cycle length (14 or 21 days) for a total of 6 cycles.
223625981|NCT01622439|DRUG|Doxorubicin|Vill be given intravenously, 50 mg/m2, every second or third week depending on cycle length (14 or 21 days), for a total of 6 cycles.
223625982|NCT01622439|DRUG|Vincristine|Vill be given intravenously, 1.2 mg/m2, every second or third week depending on cycle length (14 or 21 days), for a total of 6 cycles.
223762770|NCT05130411|DIETARY_SUPPLEMENT|DLM - Test product|The group will receive 60 gummies each (to take two gummies per day) across a four-week period. Each participant shall take two gummies per day
223762771|NCT03056703|DRUG|Acetylsalicylic acid (Aspirin, BAY1019036)|One Fast Release Tablet containing 1000 mg acetylsalicylic acid
223762772|NCT03056703|DRUG|Acetylsalicylic acid (Aspirin, BAY1019036)|Two Fast Release Tablets containing 500 mg acetylsalicylic acid each
223762773|NCT01753453|DRUG|Plerixafor|240mcg/kg, solution, subcutaneous injection
223762774|NCT01753453|DRUG|Granulocyte-colony stimulating factor (G-CSF)|10 mcg/kg, solution, subcutaneous injection
223762775|NCT02744846|DRUG|Antibiotics exposure|
223625983|NCT01622439|DRUG|Prednisone|Vill be given orally, 50 mg/m2, day 1-5 every cycle, for a total of 6 cycles.
223625984|NCT01706172|OTHER|Injection of 20% dextrose/ 0.2% lidocaine|Injection at 0, 1, and 2 months of 1 ml of a solution consisting of 20% dextrose and 0.2% lidocaine.
223625985|NCT01706172|OTHER|Injection of 1 ml of 0.8 Sterile water /0.2% lidocaine|Injection at 0, 1, and 2 months of 1 ml of a solution consisting of 0.8 sterile water and 0.2% lidocaine
223625986|NCT00637611|DRUG|Fexofenadine HCl|
223625987|NCT03080155|DEVICE|MIRA device imaging|MIRA Device imaging for adjunctive detection of breast cancer
223625988|NCT04657679|DRUG|Ribociclib|Patients will receive ribociclib 600 mg oral (PO) daily for 21 consecutive days of 28-day cycles and endocrine therapy with either letrozole or fulvestrant. Fulvestrant 500 mg intramuscular (IM) will be administered on days 1, 15, 29 of cycle one, and then monthly. Letrozole 2.5 mg oral daily continuously. If premenopausal women have not undergone bilateral salpingo- oophorectomy, they will receive a luteinizing hormone-releasing hormone (LHRH) agonist (e.g., goserelin leuprolide) for ovarian suppression in combination with fulvestrant or letrozole and ribociclib.
223625989|NCT05305352|OTHER|Very low carbohydrate dietary intervention|The experimental group will be counseled about very low carbohydrate diet i.e., \<10% carbohydrate,40-50% protein and lipid in diet).
223625990|NCT01476670|OTHER|Monitoring|Transcranial Doppler will be used to assess the cerebral autoregulation and carbon dioxide reactivity of patients with posterior fossa tumor
223625991|NCT06119126|DRUG|SDF1|Topical SDF application
223625992|NCT06119126|DEVICE|Diode Laser|Irradiating Enamel by Diode laser
223625993|NCT06119126|DRUG|Pit Fissure Sealant|Sealing occlusal pits and fissures
223625994|NCT04944459|DEVICE|Muse-S headband; InteraXon Inc., RRID:SCR_014418|"Muse-S is used as a technology-supported Mindfulness Training (tsMT) device as a way to introduce meditation as a method for managing chronic pain in individuals as it facilitates the learning process, requires minimal training to use and provides mechanisms to enhance compliance and track progress. The availability of direct feedback data from Muse-S may encourage the participant to perform meditation sessions and may increase time spent in the calm brain state."
223625995|NCT00664547|BEHAVIORAL|Diet Weight Loss|
223625996|NCT00664547|BEHAVIORAL|Exercise Weight Loss|
223625997|NCT00664547|BEHAVIORAL|Exercise Without Weight Loss|
223625998|NCT02028923|DRUG|Morphine gel|Topical
223625999|NCT02028923|OTHER|Neutral gel|Topical
223626000|NCT06387823|DRUG|Sivelestat sodium|Sevilastat sodium 4.8 mg/kg/d IV continuous infusion for 14 days or ICU length of stay (within 14 days)
223626001|NCT06387823|DRUG|Dexamethasone|Dexamethasone 10 mg IV once a day for 5 days or until extubation (within 5 days)
223626002|NCT06387823|DRUG|Sivelestat sodium placebo|Sivelestat sodium placebo 4.8 mg/kg/d IV continuous infusion for 14 days or ICU length of stay (within 14 days)
223626003|NCT06387823|DRUG|Dexamethasone placebo|Dexamethasone placebo 10 mg IV once a day for 5 days or until extubation (within 5 days)
224215306|NCT05888207|DRUG|Fluvoxamine|Only fluvoxamine will be administered as a twice daily oral dose from Days 1 to 4 of Period 2. On Day 5 of Period 2, subject will receive a twice daily oral dose of fluvoxamine along with savolitinib. On Day 6 of Period 2, subject will receive a twice daily oral dose of fluvoxamine alone.
223626004|NCT02971917|RADIATION|Chest x-ray image acquisition|Obtain a digital X-ray chest image of the patient
223626005|NCT02971917|RADIATION|Creation of TRUVIEW ART applied image|"Application of TRUVIEW ART to the original chest x-ray image to create a new set of TRUVIEW ART applied image.~Outcome: 2 versions of chest image~1. Original Chest X-ray (w/o TRUVIEW ART)~2. TRUVIEW ART applied image"
223626006|NCT02971917|RADIATION|Comparison of TRUVIEW ART image with original image|Comparison of 2 versions of chest image side by side Performance evaluation may consist of detailed categories such as expression of chest structure, visibility level of pulmonary vascular system, etc. For all categories visibility and preference will be scored and each category will be analyzed to point out any statistical difference
223626007|NCT05485740|OTHER|cognitive multisensory rehabilitation|sensorimotor rehabilitation approach, in which the patient is asked to solve sensory discrimination exercises with closed eyes or to solve multisensory discrimination exercises, e.g., by comparing feeling shapes with seeing shapes.
223626008|NCT05485740|OTHER|the selected exercise program|Upper Extremity Range of motion (ROM) exercises Passive Prolonged Stretching and positioning Weight-bearing exercise
223626009|NCT00056095|BIOLOGICAL|therapeutic allogeneic lymphocytes|
223626010|NCT00056095|DRUG|cyclophosphamide|
223626011|NCT00056095|DRUG|cyclosporine|
223626012|NCT00056095|DRUG|fludarabine phosphate|
223626013|NCT00056095|PROCEDURE|allogeneic bone marrow transplantation|
223626014|NCT00056095|PROCEDURE|peripheral blood stem cell transplantation|
223626015|NCT05860088|OTHER|Beef Diet|Controlled-Feeding Diet Intervention
223626016|NCT05860088|OTHER|Vegetarian Diet|Controlled-Feeding Diet Intervention
223626017|NCT00086866|BIOLOGICAL|D1/3-MAGE-3-His fusion protein|
223626018|NCT00086866|BIOLOGICAL|SB-AS02B adjuvant|
223626019|NCT00086866|BIOLOGICAL|SB-AS15 adjuvant|
223626020|NCT00697502|DRUG|Capecitabine|"Capecitabine (XELODA) is supplied as biconvex, oblong film-coated tablets for oral administration and will be obtained from NUH Cancer Centre pharmacy.~Each light peach-colored tablet contains 150 mg capecitabine and each peach-colored tablet contains 500 mg capecitabine. Capecitabine is to be administered orally within 30 minutes after the end of a meal (breakfast, dinner). Tablets should be swallowed with about 200 mL of water (not fruit juices). Capecitabine will be administered for 14 days followed by a 7 day rest period."
223626021|NCT04076085|OTHER|exercise|Stretching exercise for warmup, All arm exercise with and without weights as tolerated by the patients. Similarly lower limb exercise in different positions like lying standing as tolerated by the patients
223626022|NCT00646139|DRUG|Src kinase inhibitor KX2-391|
223626023|NCT00646139|OTHER|immunoenzyme technique|
224215307|NCT03402178|DRUG|E2082|Solution (0.2 mg) or tablet (0.5 mg and 5 mg).
224215308|NCT03402178|DRUG|Placebo|Solution (0.2 mg) or tablet (0.5 mg and 5 mg) matched to E2082.
224215309|NCT03503227|DRUG|prednisolone|daily oral low dose prednisolone (10 mg/day) :a glucocorticoid
224215310|NCT03503227|DRUG|Acetyl Salicylic acid|daily oral low dose Acetylsalicylic acid (75 mg) : Antiplatelet agent
223626024|NCT00646139|OTHER|pharmacological study|
223626025|NCT02367573|PROCEDURE|2D laparoscopic TAPP inguinal hernia repair|
223626026|NCT02367573|PROCEDURE|3D laparoscopic TAPP inguinal hernia repair|
223626027|NCT02571114|DIETARY_SUPPLEMENT|Saskatoon Berry Frozen Yogurt|Frozen yogurt containing a defined amount of powder prepared from Saskatoon berries (serving size = 25 g available carbohydrate)
223626028|NCT02571114|DIETARY_SUPPLEMENT|Frozen Yogurt|Unflavoured frozen yogurt (serving size = 25 g available carbohydrate)
224215311|NCT05755594|PROCEDURE|Robot-assisted Pancreaticoduodenectomy|By performing pancreaticoduodenectomy on the subject using the latest generation Da Vinci robotic surgical system and assisted by another surgeon for the entire procedure
224215312|NCT02557594|DRUG|Viread 300mg|single dose administration after 10hr fasting
224215313|NCT02557594|DRUG|DA-2802 319mg|single dose administration after 10hr fasting
223762776|NCT04894981|DEVICE|Immersive condition (CAVE)|Driving course with obstacles in a CAVE system
223762777|NCT04894981|DEVICE|Immersive condition (HMD)|Driving course with obstacles with a virtual reality headset
223762778|NCT04894981|DEVICE|Non Immersive condition (Screen alone)|Driving course with obstacles on a screen with physical simulator
223762779|NCT04894981|DEVICE|Non Immersive condition (Screen with physical simulator)|Driving course with obstacles on a screen only
223762780|NCT06145308|DRUG|Cohort 1 (HER2-positive, RC48-ADC)|"Neoadjuvant / conversion phase: After 2-6 cycles of protocol therapy, patients are re-evaluated. Those deemed resectable undergo surgery of the primary tumour ± metastatic sites, followed by radiotherapy or other modalities (e.g., radiofrequency ablation) at the investigator's discretion. Patients who remain unresectable after six cycles continue the same regimen until disease progression, intolerable toxicity, withdrawal of consent, or investigator decision to stop.~Adjuvant phase: Treatment is administered for 2 years, or until intolerable toxicity or withdrawal of consent.~Salvage phase: Therapy continues until disease progression, intolerable toxicity, withdrawal of consent, or investigator decision to terminate."
223762781|NCT06145308|DRUG|Cohort 2 (NTRK-fusion or NTRK-mutant)|"Neoadjuvant / conversion phase: After 2-6 cycles of protocol therapy, patients are re-evaluated. Those deemed resectable undergo surgery of the primary tumour ± metastatic sites, followed by radiotherapy or other modalities (e.g., radiofrequency ablation) at the investigator's discretion. Patients who remain unresectable after six cycles continue the same regimen until disease progression, intolerable toxicity, withdrawal of consent, or investigator decision to stop.~Adjuvant phase: Treatment is administered for 2 years, or until intolerable toxicity or withdrawal of consent.~Salvage phase: Therapy continues until disease progression, intolerable toxicity, withdrawal of consent, or investigator decision to terminate."
223762782|NCT06145308|DRUG|Cohort 3 (AR-positive, leuprolide + bicalutamide + abiraterone)|"Neoadjuvant / conversion phase: After 2-6 cycles of protocol therapy, patients are re-evaluated. Those deemed resectable undergo surgery of the primary tumour ± metastatic sites, followed by radiotherapy or other modalities (e.g., radiofrequency ablation) at the investigator's discretion. Patients who remain unresectable after six cycles continue the same regimen until disease progression, intolerable toxicity, withdrawal of consent, or investigator decision to stop.~Adjuvant phase: Treatment is administered for 2 years, or until intolerable toxicity or withdrawal of consent.~Salvage phase: Therapy continues until disease progression, intolerable toxicity, withdrawal of consent, or investigator decision to terminate."
224215314|NCT01447329|OTHER|Ear Acupuncture|Ear acupuncture utilizes up to 10 needles. The ear Acupuncture points on the right ear include Cingulate gyrus, thalamus, omega 2, shen-men, point zero. The ear Acupuncture points on the left ear include Cingulate gyrus, thalamus, omega 2, shen-men, point zero. The subject will receive five needles intra-operatively on each ear.
224215315|NCT01447329|DRUG|Standard Treatment|
224215316|NCT01698762|OTHER|Multimedia Patient Decision Aids (MM-PtDAs)|Patient group will watch a DVD of information about their disease type.
223626029|NCT02571114|DIETARY_SUPPLEMENT|Control 1|White bread (serving size = 25 g available carbohydrate)
223626030|NCT02571114|DIETARY_SUPPLEMENT|Control 2|White bread (serving size = 25 g available carbohydrate)
223626031|NCT02934802|DEVICE|Total Knee prothesis e motion PS Pro|
224215317|NCT01698762|OTHER|Comparative Effectiveness Research Summary Guide (CERSG)|Patient group to read a booklet about their disease type.
224215318|NCT01698762|BEHAVIORAL|Questionnaires|Questionnaires completed at baseline, 3, and at 6 months.
224215319|NCT04261478|DEVICE|Carotid artery stenting|The type of stent should be one commonly used for ICA stenting. Balloon angioplasty before and/or after stent placement will be allowed as required. Stenting should be performed after intracranial thrombectomy unless specific technical circumstances suggest that access to the intracranial circulation requires anterograde stenting. Embolic protection devices should not be used routinely during ICA stent placement.
224316849|NCT05242315|DRUG|Envarsus Oral Product|as described in arm/group description
224316850|NCT05242315|DRUG|Prograf (SOC)|Prograf (SOC)
224316851|NCT04610879|DRUG|Carbamazepine|Treatment will be procured, prescribed and issued as per routine NHS practice. Generics can be prescribed.
224316852|NCT04610879|DRUG|Levetiracetam|Treatment will be procured, prescribed and issued as per routine NHS practice. Generics can be prescribed.
223626032|NCT00780195|PROCEDURE|glucose clamp|2 hour hyperinsulinemic euglycemic clamp (90 mg/dl)
223626033|NCT00780195|PROCEDURE|glucose clamp|2 hour hyperinsulinemic hypoglycemic clamp (70 mg/dl)
223626034|NCT00780195|PROCEDURE|glucose clamp|2 hour hyperinsulinemic hypoglycemic clamp (60 mg/dl)
223626035|NCT00780195|PROCEDURE|glucose clamp|2 hour hyperinsulinemic hypoglycemic clamp (50 mg/dl)
223626036|NCT02812836|DEVICE|Manometry|Each patient will be investigated first by anorectal manometry, standard protocol of conventional parameters will be recorded such as: resting pressure, squeeze pressure, bear down manoeuver, thresholds of sensation and threshold of recto anal inhibitory reflex. 3D picture of anal canal will be recorded. After that balloon with 50 ml of water will be inserted into the rectum and patient will be asked to expel the device within 1 min in privacy.
223626037|NCT02319941|DRUG|ticagrelor|
223626038|NCT02319941|DRUG|clopidogrel|
223626039|NCT02179008|DRUG|DE-117 Low Dose ophthalmic solution|Low Dose DE-117 ophthalmic solution
223626040|NCT02179008|DRUG|DE-117 Low/Middle Dose ophthalmic solution|Low/Middle Dose DE-117
223626041|NCT02179008|DRUG|DE-117 Middle Dose ophthalmic solution|Middle Dose DE-117
223626042|NCT02179008|DRUG|DE-117 Middle/High Dose ophthalmic solution|Middle/High Dose DE-117
223626043|NCT02179008|DRUG|DE-117 High Dose ophthalmic solution|High Dose DE-117
223626044|NCT02179008|DRUG|latanoprost ophthalmic solution 0.005%|0.005% latanoprost
224215320|NCT04261478|DRUG|Antiplatelet Agents|The following antiplatelet regimen should be used: For patients having received IV thrombolysis, immediate post-procedural oral or intrarectal single antiplatelet agents, (Aspirin 325mg PO or 650mg PR). A second agent (usually Clopidogrel 300mg PO) is added after follow-up brain imaging at 12-24 hours confirms absence of significant ICH. For patients having not been treated with IV thrombolysis, dual antiplatelet therapy (Aspirin 325mg PO or 650mg PR and Clopidogrel 300-600mg PO) is given immediately post-procedure. Routine use of GPIIb/IIIa inhibitors, periprocedural IV Heparin is discouraged.
224215321|NCT05469854|DRUG|Linaprazan glurate|"Linaprazan glurate base formulation, 25 mg oral tablets (300 mg and 600 mg doses).~Linaprazan glurate hydrochloride (HCl), 25 mg and 100 mg (as base) oral tablets (200 mg and final dose level of maximum 400 mg)."
224215322|NCT05469854|DRUG|Placebo|Single dose, oral tablets
224215323|NCT02008331|DIETARY_SUPPLEMENT|SYNBIOTIC|"INTERVENTION: Probinul neutro® assumed three times a day far from meals as 5 g powder packets dissolved in water. Probinul neutro® contains 5×109 Lactobacillus plantarum, 2×109 Lactobacillus casei subp. rhamnosus and 2×109 Lactobacillus gasseri, 1×109 Bifidobacterium infantis and 1×109 Bifidobacterium longum, 1×109 Lactobacillus acidophilus, 1×109 Lactobacillus salivarus and 1×109 Lactobacillus sporogenes and 5×109 Streptococcus termophilus, prebiotic inulin (2.2 g; VB Beneo Synergy 1) and 1.3 g of tapioca-resistant starch.~PLACEBO: Tapioca-resistant starch powder similar in colour, texture and taste to the symbiotic mixture, assumed three times a day far from meals as 5 g powder packets dissolved in water."
224215324|NCT06530082|BIOLOGICAL|CircFam53B-219aa DC vaccine|Dendritic cell vaccine loaded with circular RNA-encoded cryptic peptide. Administer intradermally once every 3 weeks according to a dose-escalation gradient of 0.5-1×10⁷, 1.5-2×10⁷, and 4-5×10⁷ cells.
224215325|NCT06530082|DRUG|camrelizumab|Camrelizumab for Injection, 200 mg IV infusion, administered once every 3 weeks.
224215326|NCT00820391|BEHAVIORAL|KIDNET|Narrative Exposure Therapy for Children - a short term intervention for the treatment of trauma after war, organized violence, torture, abuse and other detrimental life events
223762783|NCT06145308|DRUG|TROP2 ADC|"Neoadjuvant / conversion phase: After 2-6 cycles of protocol therapy, patients are re-evaluated. Those deemed resectable undergo surgery of the primary tumour ± metastatic sites, followed by radiotherapy or other modalities (e.g., radiofrequency ablation) at the investigator's discretion. Patients who remain unresectable after six cycles continue the same regimen until disease progression, intolerable toxicity, withdrawal of consent, or investigator decision to stop.~Adjuvant phase: Treatment is administered for 2 years, or until intolerable toxicity or withdrawal of consent.~Salvage phase: Therapy continues until disease progression, intolerable toxicity, withdrawal of consent, or investigator decision to terminate."
223762784|NCT06145308|DRUG|TKI|"Neoadjuvant / conversion phase: After 2-6 cycles of protocol therapy, patients are re-evaluated. Those deemed resectable undergo surgery of the primary tumour ± metastatic sites, followed by radiotherapy or other modalities (e.g., radiofrequency ablation) at the investigator's discretion. Patients who remain unresectable after six cycles continue the same regimen until disease progression, intolerable toxicity, withdrawal of consent, or investigator decision to stop.~Adjuvant phase: Treatment is administered for 2 years, or until intolerable toxicity or withdrawal of consent.~Salvage phase: Therapy continues until disease progression, intolerable toxicity, withdrawal of consent, or investigator decision to terminate."
223762785|NCT06145308|DRUG|Albumin-paclitaxel + platinum|"Neoadjuvant / conversion phase: After 2-6 cycles of protocol therapy, patients are re-evaluated. Those deemed resectable undergo surgery of the primary tumour ± metastatic sites, followed by radiotherapy or other modalities (e.g., radiofrequency ablation) at the investigator's discretion. Patients who remain unresectable after six cycles continue the same regimen until disease progression, intolerable toxicity, withdrawal of consent, or investigator decision to stop.~Adjuvant phase: Treatment is administered for 2 years, or until intolerable toxicity or withdrawal of consent.~Salvage phase: Therapy continues until disease progression, intolerable toxicity, withdrawal of consent, or investigator decision to terminate."
223762786|NCT06145308|DRUG|Albumin-paclitaxel + carboplatin + apatinib + camrelizumab|"Neoadjuvant / conversion phase: After 2-6 cycles of protocol therapy, patients are re-evaluated. Those deemed resectable undergo surgery of the primary tumour ± metastatic sites, followed by radiotherapy or other modalities (e.g., radiofrequency ablation) at the investigator's discretion. Patients who remain unresectable after six cycles continue the same regimen until disease progression, intolerable toxicity, withdrawal of consent, or investigator decision to stop.~Adjuvant phase: Treatment is administered for 2 years, or until intolerable toxicity or withdrawal of consent.~Salvage phase: Therapy continues until disease progression, intolerable toxicity, withdrawal of consent, or investigator decision to terminate."
224215327|NCT00820391|BEHAVIORAL|Meditation-Relaxation|a protocol of traditional/local meditation and relaxation exercises, such as breathing meditation, chanting, body relaxation
223626045|NCT02212808|OTHER|Antimicrobial restriction|All prescriptions for targeted antibiotics will require phone approval by the trained PharmD during this arm. Prescribers will be instructed to contact the pharmacist via pager or phone call to discuss the patient details and the rationale for the desired antimicrobial. The pharmacist will then decide if the targeted antibiotic is approved or denied. If the pharmacist denies the use of the targeted antibiotic, the pharmacist will provide recommendations for alternative antibiotics for the specific clinical scenario. The pharmacist will document this interaction in the REDCap database.
223626046|NCT02212808|OTHER|Post-antimicrobial prescription review|All prescriptions for targeted antibiotics will be reviewed by the study pharmacist approximately 72 hours after initially written. The pharmacist will review and document the patient's current symptoms, pertinent clinical data, and the indication for the targeted antibiotic documented in the chart. Based on this review, the pharmacist will decide if the targeted antibiotic is necessary and/or if it needs to be modified. If a change is recommended, the pharmacist will then contact the prescriber to discuss the pharmacist's recommendations. The interaction will be documented in the REDCap database.
224215328|NCT05148130|DIAGNOSTIC_TEST|oral glucose tolerance test|GDM should be diagnosed at any time in pregnancy if one or more of the listed criteria are met following a 75-gram glucose load: fasting plasma glucose ≥5.1 mmol/l; 1-hour plasma glucose ≥10.0mmol/l; 2-hour plasma glucose 8.5-11.0 mmol/l. Those women diagnosed with diabetes or pre-diabetes (impaired fasting glucose or impaired glucose tolerance) before pregnancy were excluded from the study.
224215329|NCT03209830|DRUG|OSU 6162|All patients will receive a dose of OSU6162 15 mg BID x 2 per day. The expected duration of therapy is 12 weeks. After 1 week of treatment, patients who do not respond to treatment will have their dose increased to maximum 30 mg BID x 2 per day.
224215330|NCT03209830|DRUG|Placebo Oral Tablet|All patients will receive a dose of placebo 15 mg BID x 2 per day. The expected duration of therapy is 12 weeks. After 1 week of treatment, patients who do not respond to treatment will have their dose increased to maximum 30 mg BID x 2 per day.
224215331|NCT00150930|DEVICE|narrowband UVB phototherapy at home|
223762787|NCT06145308|DRUG|albumin-bound paclitaxel+trastuzumab+pyrotinib|"Neoadjuvant / conversion phase: After 2-6 cycles of protocol therapy, patients are re-evaluated. Those deemed resectable undergo surgery of the primary tumour ± metastatic sites, followed by radiotherapy or other modalities (e.g., radiofrequency ablation) at the investigator's discretion. Patients who remain unresectable after six cycles continue the same regimen until disease progression, intolerable toxicity, withdrawal of consent, or investigator decision to stop.~Adjuvant phase: Treatment is administered for 2 years, or until intolerable toxicity or withdrawal of consent.~Salvage phase: Therapy continues until disease progression, intolerable toxicity, withdrawal of consent, or investigator decision to terminate."
224215332|NCT00155441|BEHAVIORAL|cognitive-behavioral therapy|
224215333|NCT06545734|PROCEDURE|Direct Ischemic Post-conditioning|After thrombectomy, the balloon was inflated to a pressure of no more than 4 atm at the occlusion site to block blood flow for 2 minutes, as confirmed by angiography. The balloon was then deflated, allowing blood flow to resume for 2 minutes. These steps were repeated four times.
224215334|NCT06545734|PROCEDURE|Endovascular therapy|Thrombectomy alone.
224215335|NCT02932384|BEHAVIORAL|Intervention-Passport and Peer Mentor|In addition to the passport and incentives described below for the control condition, participants assigned to the intervention will select a peer mentor trained in motivational interviewing. The mentor will help guide the participant to complete passport items and address priorities. Participants will also be incentivized for regular meetings with his peer mentor.
224215336|NCT02932384|BEHAVIORAL|Control-Passport Only|"A trained staff member will use a needs assessment and the participant's own priorities to develop a 'Passport to Wellness,' a personalized set of services whose access may encourage HIV prevention or address barriers to HIV testing.~Example passport items include: getting an HIV test, attending an informational session about PEP/PrEP, meeting with a PrEP provider, attending 12-step meetings, yoga classes, a massage or Reiki session, or reviewing specific HIV prevention information online. Participants will be incentivized for each passport item they complete."
224215337|NCT03218410|PROCEDURE|surgical pulmonary embolectomy|
224215338|NCT03218410|COMBINATION_PRODUCT|catheter-directed thrombolysis|
224215339|NCT03036995|DRUG|Apremilast|Patient will receive narrow UVB treatment and apremilast (2 tablets for day) during 24 weeks. If the patient is responder (response is defined as an increase of at least 30 % in the VASI score at W24 compare to Baseline), he will receive narrow UVB treatment according the and apremilast during 24 weeks.
223626047|NCT03295435|OTHER|Composition of functional tooth units|"Composition of functional tooth units measured by trained oral health therapists and was categorised into 3 groups:~Group A: Natural units only Group B: Natural \& Prosthetic units present Group C: No natural units present"
224316853|NCT04610879|BEHAVIORAL|Parent based sleep (PBS) intervention|The PBS intervention is an e-learning package for parents/primary carers and children with epilepsy. The PBS intervention offers parents education about normal sleep, advice about sleep-promoting practices and targeted strategies parents can employ to help their children to ''learn'' an appropriate set of sleep behaviours/habits and/or to unlearn inappropriate sleep behaviours.
224316854|NCT06340711|DRUG|OBP-301|2×10(12) viral particles per injection given intratumorally every 2 weeks for a total of 4 injections starting on Day 1 of the study
224316855|NCT06340711|DRUG|Pembrolizumab|400 mg IV given every 6 weeks starting on day 4 of the study and given for up to 2 years
224316856|NCT02816411|DIETARY_SUPPLEMENT|Milk protein isolate|"Milk protein isolate in a powder form consisted of 80% casein and 20% whey protein. 20g were diluted into 500 ml water.~Placebo consisted of 365 ml water, 125 ml sugar-free cordial and 2g of low-calorie glucose/dextrose powder."
224316857|NCT02816411|DIETARY_SUPPLEMENT|Placebo|500 mL drink that contained water (375 mL), sugar-free cordial (125 mL) and 2 g of low-calorie glucose/dextrose powder.
224316858|NCT01577940|PROCEDURE|Infusion of ropivacaine|TAP block with ropivacaine 20 ml 0,5%. Catheter with infusion of ropivacaine 0,2% 5 ml/h 24 hours on one side of the abdomen.
224316859|NCT01577940|PROCEDURE|Infusion of saline|TAP block with ropivacaine 0,5% 20 ml. Catheter with infusion of saline 5 ml/h 24 hours.
224316860|NCT00834496|PROCEDURE|Liver biopsy|percutaneous liver biopsy
224316861|NCT04651413|DIAGNOSTIC_TEST|PCR Value|Data collection and interpretation
224316862|NCT04808336|OTHER|PRP injection.|Group 1: thirty patients were injected in the facet joint capsule with a series of three ultrasound-guided PRP injections at four-week intervals,
223626048|NCT02098330|DRUG|Ginkgo biloba & Methylprednisolone|Ginkgo biloba 160 mg/day (per oral, 80 mg twice a day) for 1 month. Methylprednisolone 48 mg/day(per oral, once a day for first 9 days. And then methylprednisolone tapering was started every 2 days. The entire duration of methylprednisolone treatment was 14 days.
224316863|NCT04808336|PROCEDURE|fixation surgical procedure|Group 2: thirty patients underwent surgery
223626049|NCT02098330|DRUG|Ginkgo biloba|Ginkgo biloba 160 mg/day (per oral, 80 mg twice a day) for 1 month.
223626050|NCT01918124|RADIATION|radiotherapy|Pelvic radiation to 45 Gy, 1.8 Gy per day, five days per week (25 fractions) or intensive modulated pelvic radiotherapy, with brachytherapy boost to the vagina if total abdominal hysterectomy and bilateral salpingo-oophorectomy was done in surgery, or with paraaortic radiation if paraaortic lymphnode metastases were found after surgery.
223626051|NCT01918124|DRUG|Cisplatin|Two courses cisplatin (50mg/m2) given on days 1 and 28 during radiotherapy.
223626052|NCT01918124|DRUG|Cisplatin and Doxorubicin and Cyclophosphamide|Four courses of cisplatin (50mg/m2) and doxorubicin (60mg/m2) and cyclophosphamide (600mg/m2) chemotherapy given at 3 week intervals following completion of radiotherapy.
223626053|NCT01918124|DRUG|Paclitaxel and Carboplatin|Or four courses of Paclitaxel(135mg/m2) and carboplatin (AUC=5) given at 3 week intervals following completion of radiotherapy.
223762788|NCT06145308|DRUG|HER2,trastuzumab deruxtecan± pertuzumab|"Neoadjuvant / conversion phase: After 2-6 cycles of protocol therapy, patients are re-evaluated. Those deemed resectable undergo surgery of the primary tumour ± metastatic sites, followed by radiotherapy or other modalities (e.g., radiofrequency ablation) at the investigator's discretion. Patients who remain unresectable after six cycles continue the same regimen until disease progression, intolerable toxicity, withdrawal of consent, or investigator decision to stop.~Adjuvant phase: Treatment is administered for 2 years, or until intolerable toxicity or withdrawal of consent.~Salvage phase: Therapy continues until disease progression, intolerable toxicity, withdrawal of consent, or investigator decision to terminate."
223762789|NCT06145308|DRUG|AR,darolutamide + goserelin+pertuzumab/trastuzumab|"Neoadjuvant / conversion phase: After 2-6 cycles of protocol therapy, patients are re-evaluated. Those deemed resectable undergo surgery of the primary tumour ± metastatic sites, followed by radiotherapy or other modalities (e.g., radiofrequency ablation) at the investigator's discretion. Patients who remain unresectable after six cycles continue the same regimen until disease progression, intolerable toxicity, withdrawal of consent, or investigator decision to stop.~Adjuvant phase: Treatment is administered for 2 years, or until intolerable toxicity or withdrawal of consent.~Salvage phase: Therapy continues until disease progression, intolerable toxicity, withdrawal of consent, or investigator decision to terminate."
223762790|NCT06145308|DRUG|AR,darolutamide +goserelin +docetaxel|"Neoadjuvant / conversion phase: After 2-6 cycles of protocol therapy, patients are re-evaluated. Those deemed resectable undergo surgery of the primary tumour ± metastatic sites, followed by radiotherapy or other modalities (e.g., radiofrequency ablation) at the investigator's discretion. Patients who remain unresectable after six cycles continue the same regimen until disease progression, intolerable toxicity, withdrawal of consent, or investigator decision to stop.~Adjuvant phase: Treatment is administered for 2 years, or until intolerable toxicity or withdrawal of consent.~Salvage phase: Therapy continues until disease progression, intolerable toxicity, withdrawal of consent, or investigator decision to terminate."
223762791|NCT06145308|DRUG|ivonescimab + investigator-choice platinum doublet+|"Neoadjuvant / conversion phase: After 2-6 cycles of protocol therapy, patients are re-evaluated. Those deemed resectable undergo surgery of the primary tumour ± metastatic sites, followed by radiotherapy or other modalities (e.g., radiofrequency ablation) at the investigator's discretion. Patients who remain unresectable after six cycles continue the same regimen until disease progression, intolerable toxicity, withdrawal of consent, or investigator decision to stop.~Adjuvant phase: Treatment is administered for 2 years, or until intolerable toxicity or withdrawal of consent.~Salvage phase: Therapy continues until disease progression, intolerable toxicity, withdrawal of consent, or investigator decision to terminate."
223762792|NCT06145308|DRUG|iparomlimab + tuvonralimab|"Neoadjuvant / conversion phase: After 2-6 cycles of protocol therapy, patients are re-evaluated. Those deemed resectable undergo surgery of the primary tumour ± metastatic sites, followed by radiotherapy or other modalities (e.g., radiofrequency ablation) at the investigator's discretion. Patients who remain unresectable after six cycles continue the same regimen until disease progression, intolerable toxicity, withdrawal of consent, or investigator decision to stop.~Adjuvant phase: Treatment is administered for 2 years, or until intolerable toxicity or withdrawal of consent.~Salvage phase: Therapy continues until disease progression, intolerable toxicity, withdrawal of consent, or investigator decision to terminate."
224215340|NCT03036995|OTHER|Placebo|Patient will receive narrow UVB treatment and placebo (2 tablets for day) during 24 weeks. If the patient is responder (response is defined as an increase of at least 30 % in the VASI score at W24 compare to Baseline), he will receive narrow UVB treatment according the and placebo during 24 weeks.
224215341|NCT02112812|DRUG|Eradication therapy for H.pylori infection|Patients who were positive for H.pylori infection received an eradication therapy consisting of oral esomeprazole 40 md daily, oral clarithromycin 500mg bd and oral amoxicillin 1000mg bd for 14 days.
224215342|NCT02112812|DRUG|Eradication of Helcobacter Pylori|Patients who are positive on urea breath test are given eradication therapy for 14 days, Eradication therapy includes esomeprazole 40mg daily, clarithromycin 500mg bd, amoxicillin 1g bd
224215343|NCT02112812|DRUG|Eradication therapy for Helicobacter pylori|
224215344|NCT05516212|DIETARY_SUPPLEMENT|CAFMONO supplementation|"CAFMONO supplementation - random blind acute intake of in individual dose providing 3mg/kg BM of CAF.~CAFMONO - Caffeine (anhydrous caffeine), Ostrovit Sp. z o.o., Zambrów, POLAND"
224215345|NCT05516212|DIETARY_SUPPLEMENT|CAFMIPS_1 supplementation|"CAFMIPS\_1 supplementation - random blind acute intake of in individual dose providing 3mg/kg BM of CAF.~CAFMIPS\_1 - Olimp Redweiler, Olimp Laboratories Sp. z o.o., Dębica, POLAND~CAFMIPS\_1 - Olimp Redweiler, Olimp Laboratories Sp. z o.o., Dębica, POLAND"
224215346|NCT05516212|DIETARY_SUPPLEMENT|CAFMIPS_2 supplementation|"CAFMIPS\_2 supplementation - random blind acute intake of in individual dose providing 3mg/kg BM of CAF.~CAFMIPS\_2 - Muscle Clinic Furious, Noblepharma UG, BerlinVertrieb, GERMANY."
223626054|NCT01650558|DRUG|Standard of Care prophylaxis|Daily trimethoprim sulfamethoxazole
223626055|NCT01650558|DRUG|Chloroquine (CQ) prophylaxis|Discontinue standard of care and start weekly CQ.
223626056|NCT01110824|DRUG|Enalapril and carvedilol|Enalapril 2.5 to 10 mg BID Carvedilol 6.25 to 25 mg BID
223626057|NCT03062735|OTHER|Inspiratory Muscle Training|The Inspiratory Muscle Training (IMT) group will perform 30 inspiratory efforts, 5 times a week, twice a day, for 12 weeks, against a pressure threshold load equivalent to 50% of maximal inspiratory pressure.
223626058|NCT03062735|OTHER|Sham Inspiratory Muscle Training|The Sham Inspiratory Muscle Training (Sham-IMT) group will perform 30 inspiratory efforts, 5 times a week, twice a day, for 12 weeks, against a pressure threshold load equivalent to 15% of maximal inspiratory pressure.
223626059|NCT02578407|OTHER|accommodative/vergence therapy|12 weekly accommodative/vergence therapies
223626060|NCT05919407|DRUG|Pyridostigmine|Participants will receive pyridostigmine 10 mg tablets.
223626061|NCT05919407|DRUG|Amifampridine (base) with modified release|Participants will receive amifampridine (base) with modified release 15 mg or 30 mg tablets.
223626062|NCT05919407|DRUG|Placebo|The placebo tablets will be identical apart from the active substance (pyridostigmine)
223626063|NCT05919407|DRUG|Placebo|The placebo tablets will be identical apart from the active substance (amifampridine base)
223626064|NCT02719808|DRUG|Tenofovir1|receive tenofovir （300mg/d）from （28±2）weeks of pregnancy to one month after delivery, it is the observational exposure.
223626065|NCT02719808|DRUG|Tenofovir2|receive tenofovir （300mg/d）from（28±2）weeks of pregnancy to one month after delivery, it is the observational exposure.
224215347|NCT05516212|DIETARY_SUPPLEMENT|Placebo treatment|Placebo treatment - random blind acute intake of placebo preparation. Placebo will match the remaining test preparations with taste, colour and consistency, however it will be free of caffeine and any other substances possessing ergogenic potential.
223626066|NCT02719808|DRUG|Tenofovir3|receive tenofovir （300mg/d）from （20±2）weeks of pregnancy to one month after delivery, it is the observational exposure.
223626067|NCT02719808|DRUG|Tenofovir4|receive tenofovir （300mg/d）from （20±2）weeks of pregnancy to one week after delivery, it is the observational exposure.
223626068|NCT03207126|DIAGNOSTIC_TEST|Ultrasound guided biopsy|For women needed a hysteroscopy guided biopsy as part of routine standard of care, women will now receive an ultrasound guided biopsy first
224215348|NCT00000512|DRUG|lovastatin|Lovastatin was begun at a dose of 20 mg twice a day (in the morning and at bedtime). If the LDL cholesterol level did not fall below 3.1 mmol per liter after three months, the dose of lovastatin was increased to 40 mg twice a day.
224215349|NCT00000512|DRUG|colestipol|Colestipol was begun at a dose of 5 g three times a day with meals and increased to 10 g three times a day after 10 days, unless side effects delayed the increase. Psyllium hydrophic mucilloid (Metamucil) was provided if dietary bran was insufficient to control constipation.
224215350|NCT00000512|DRUG|niacin|Niacin was started at 125 mg twice a day and gradually increased to 500 mg four times a day (with meals and at bedtime) at one month and 1 g four times a day at two months. If the LDL cholesterol level did not fall below 3.1 mmol per liter (120 mg per deciliter) after three months, the dose of niacin was increased to 1.5 g (three tablets) four times a day, but no further.
223626069|NCT00040586|DRUG|Monoclonal Antibody J591|
223626070|NCT00040586|DRUG|Recombinant Interleukin-2|
223626071|NCT03367728|DRUG|Ropivacaine|TAP and Rectus Sheath Block Injections of Ropivacaine
223626072|NCT03367728|DRUG|Normal saline|TAP and Rectus Sheath Block Injections of Normal Saline
223626073|NCT04123522|PROCEDURE|anterior approach|anterior approach
223626074|NCT04123522|PROCEDURE|posterior appraoch|posteiror appraoch
223626075|NCT04499755|DRUG|Nucleo CMP Forte|Nucleo CMP Forte twice daily for 6 weeks
223626076|NCT01480661|DRUG|Roflumilast|Roflumilast 500 µg, once a day in the morning during 6 months
223626077|NCT01480661|DRUG|Placebo of Roflumilast|Placebo 500 µg, once a day in the morning during 6 months
223626078|NCT01480661|RADIATION|Functional Respiratory Imaging|CT scan of thorax, at baseline and after 6 months
223626079|NCT01155713|DRUG|TKI258|
223626080|NCT03901417|DEVICE|Fraxel Restore (Non-ablative Fractional Laser)|In the study, one side of the face will be treated with non-ablative fractional laser monthly for three months.
223626081|NCT03901417|DEVICE|Fraxel Restore (Non-ablative fractional laser) and SkinPen (Microneedling Device)|In the study, one side of the face will be treated with a combination of non-ablative fractional laser and microneedling monthly for three months.
223626082|NCT02528084|PROCEDURE|yoga|patients watch and follow an online yoga video.
223626083|NCT02528084|PROCEDURE|standard exercises|patients watch and follow an online standard exercises video.
224215351|NCT00000512|OTHER|Placebo for colestipol|Placebo for colestipol.
224215352|NCT00000512|OTHER|Placebo for lovastatin|Placebo for lovastatin
224215353|NCT04856995|OTHER|exposure to surgical smoke during surgery|No intervention was made. During the surgery, complaints and throat cultures were taken before and after exposure to surgical smoke. Simultaneously, 45 air samples are taken in the operating room before, during and after the operation.
224215354|NCT02355795|BEHAVIORAL|low-fat diet|Energy from total fat, protein and carbohydrates are 20%, 14% and 66%, respectively
224215355|NCT02355795|BEHAVIORAL|moderate-fat diet|Energy from total fat, protein and carbohydrates are 30%, 14% and 56%, respectively
224215356|NCT02355795|BEHAVIORAL|high-fat diet|Energy from total fat, protein and carbohydrates are 40%, 14% and 46%, respectively
224215357|NCT03134417|DIETARY_SUPPLEMENT|Vitamin D and magnesium|Daily vitamin D and magnesium supplements are given to participants daily for 12 weeks.
224215358|NCT03134417|DIETARY_SUPPLEMENT|Vitamin D|Daily vitamin D supplements are given to participants daily for 12 weeks.
224215359|NCT03134417|DIETARY_SUPPLEMENT|Placebo|Daily placebo are given to participants daily for 12 weeks.
224215360|NCT01615302|PROCEDURE|Mucosa advancement flap|Mucosa advancement flap will be performed at the starting point of the fistula in the rectum
224215361|NCT01615302|OTHER|Platelet rich plasma (PRP)|"The PRP will be injected into the fistula, after the mucosa advancement flap was created.~For the PRP we will need to take 55 millilitres of blood of the patient. This blood will be centrifuged into PRP."
224215362|NCT00240084|DRUG|nesiritide (Natrecor(TM))|administration of IV nesiritide
224215363|NCT05676138|OTHER|Measuring PK and PD indices in patients who receive conventional treatment|Measuring plasma concentration of commonly used antibiotics in NTM-PD
224215364|NCT05506475|PROCEDURE|Blood samples|venous blood collected in a 5 mL EDTA tube
224215365|NCT04897100|PROCEDURE|Achilles tendon tenotomy|Achilles tendon tenotomy during Ponseti treatment for clubfoot
224215366|NCT05692752|OTHER|No intervention|Expression of miR-133a \&208b at 4, 8, 12, 24 and 48 hours from the first appearance of myocardial infarction (MI) symptoms
224215367|NCT02060552|DRUG|Diacerein|oral administration of IL-1βinhibitory
224215368|NCT02060552|DRUG|Colchicine|"Colchicine is a toxic natural product and secondary metabolite, originally extracted from plants of the genus Colchicum (autumn crocus, Colchicum autumnale, also known as meadow saffron). It was used originally to treat rheumatic complaints, especially gout as the positive control"
223762793|NCT06145308|DRUG|cadonilimab|"Neoadjuvant / conversion phase: After 2-6 cycles of protocol therapy, patients are re-evaluated. Those deemed resectable undergo surgery of the primary tumour ± metastatic sites, followed by radiotherapy or other modalities (e.g., radiofrequency ablation) at the investigator's discretion. Patients who remain unresectable after six cycles continue the same regimen until disease progression, intolerable toxicity, withdrawal of consent, or investigator decision to stop.~Adjuvant phase: Treatment is administered for 2 years, or until intolerable toxicity or withdrawal of consent.~Salvage phase: Therapy continues until disease progression, intolerable toxicity, withdrawal of consent, or investigator decision to terminate."
224215369|NCT02060552|DRUG|Febuxostat|A urate lowering drug, an inhibitor of xanthine oxidase that is indicated for use in the treatment of hyperuricemia and gout
224215370|NCT06467500|DRUG|Cadonilimab (AK104)|Subjects participated in a study where they received cadonilimab intravenously at 6mg/kg every two weeks, prepared in 100mL of normal saline (0.9% NaCl), with a final concentration range of 0.2-5.0mg/mL. The infusion solution must be used within 4 hours of preparation. Treatment continued until disease progression (PD), unacceptable toxicity, or 24 months, whichever came first. Patients who investigators deemed could still benefit from cadonilimab post-PD were allowed continued treatment. Chemotherapy regimens were selected by investigators based on prior medication use, including gemcitabine, pemetrexed, docetaxel, albumin-bound paclitaxel, or vinorelbine as second- or third-line therapy
224215371|NCT03078842|DIETARY_SUPPLEMENT|Zinc tablets, 20 mg per day|Participants will receive rehydration, dietary counseling, and 1 tablet per day for 14 days of zinc-tablets, each of which contains 20 mg of zinc
224215372|NCT03078842|DIETARY_SUPPLEMENT|Zinc tablets, 10 mg per day|Participants will receive rehydration, dietary counseling, and 1 tablet per day for 14 days of zinc-tablets, each of which contains 10 mg of zinc
224215373|NCT03078842|DIETARY_SUPPLEMENT|Zinc tablets, 5 mg per day|Participants will receive rehydration, dietary counseling, and 1 tablet per day for 14 days of zinc-tablets, each of which contains 5 mg of zinc
224215374|NCT01180842|OTHER|Yoga treatment program|yoga program designed specifically for the patient with CF
224215375|NCT00568152|DIETARY_SUPPLEMENT|Low PA apple puree|Golden Delicious apple puree 230grams consumed daily for 14 days
223626084|NCT05818488|OTHER|Experimental mind-body intervention|A meditation will be guided by an audio through headphones. The audio will last 15 minutes with an initial invitation to centering (full attention to the state of the body and the breath, bringing the attention to the present moment), followed by body scanning, followed by targeting the seven dimensions of interoceptive capacity (noticing, not being distracted, not worrying, attentional regulation, emotional awareness, self-regulation, and trust), and the passive control group (waiting room)
223626085|NCT01798693|DIETARY_SUPPLEMENT|Placebo (maltodextrin)|
223626086|NCT01798693|DIETARY_SUPPLEMENT|Multi-nutrient Blend|
223626087|NCT00002643|BIOLOGICAL|filgrastim|
223626088|NCT00002643|DRUG|amifostine trihydrate|
223626089|NCT00002643|DRUG|cyclophosphamide|
223626090|NCT00002643|DRUG|doxorubicin hydrochloride|
223626091|NCT00002643|DRUG|etoposide|
223626092|NCT00002643|DRUG|ifosfamide|
223626093|NCT00002643|DRUG|topotecan hydrochloride|
223626094|NCT00002643|DRUG|vincristine sulfate|
223626095|NCT00002643|PROCEDURE|conventional surgery|
223626096|NCT00002643|RADIATION|low-LET cobalt-60 gamma ray therapy|
223626097|NCT00002643|RADIATION|low-LET electron therapy|
223626098|NCT00002643|RADIATION|low-LET photon therapy|
224215376|NCT00568152|DIETARY_SUPPLEMENT|High PA apple puree|High PA apple puree (Mitchalin) consumed daily for 14 days
224215377|NCT00568152|DRUG|Aspirin|75mg dispersable aspirin taken daily for 14 days
224215378|NCT01011907|DRUG|varenicline|12 weeks of oral tablet treatment in an escalating dosing regimen (0.5 mg 1x daily, days 1-3; 0.5mg 2x daily, days 4-7, 1.0 mg 2x daily, days 8-84).
224215379|NCT01011907|DRUG|placebo|12 weeks of oral tablet treatment in an escalating dosing regimen (1 - 2x daily).
224215380|NCT05680311|BIOLOGICAL|measurement of serum autotaxin serum level|autotaxin expression
224215381|NCT01281878|DRUG|Vitamin B 6|Oral solution of pyridoxal phosphate start with 5mg per kg body weight per day in two dosages over 6 weeks, increase stepwise by 5mg/kg body weight every 6 weeks up to 20 mg/kg body weight/d.
224215382|NCT02642107|RADIATION|Elective neck irradiation|Whole neck irradiation is given in the involved neck. Elective neck irradiation of Level II,III and Va lymph node area is given in the uninvolved neck, and Level IV and Vb lymph node area were not irradiated in the uninvolved neck.
224215383|NCT02642107|RADIATION|Whole neck irradiation|Whole neck irradiation is given regardless of the involved or uninvolved neck.
224215384|NCT02505711|BEHAVIORAL|Homestead Food Production program|Training and support for vegetable gardening and poultry rearing, and education on young child nutrition, hygiene and health topics, in women's groups, as designed by the international non-governmental organization (NGO) Helen Keller International (HKI).
224215385|NCT00569283|BIOLOGICAL|therapeutic allogeneic lymphocytes|
224215386|NCT03187054|PROCEDURE|anterior or posterior colporrhaphy|will be performed in a traditional manner with midline plication of the fibromuscular layer using 2-0 delayed absorbable sutures.
223626099|NCT06060236|DRUG|Ibuprofen 800 mg|Ibuprofen 800 Mg İv
223626100|NCT06060236|DRUG|Dexketoprofen|Dexketoprofen 50 Mg İV
223626101|NCT02462044|DRUG|240 mg Iodine|
223762794|NCT06145308|DRUG|CDK4/6 inhibitor+AI or fulvestrant|"Neoadjuvant / conversion phase: After 2-6 cycles of protocol therapy, patients are re-evaluated. Those deemed resectable undergo surgery of the primary tumour ± metastatic sites, followed by radiotherapy or other modalities (e.g., radiofrequency ablation) at the investigator's discretion. Patients who remain unresectable after six cycles continue the same regimen until disease progression, intolerable toxicity, withdrawal of consent, or investigator decision to stop.~Adjuvant phase: Treatment is administered for 2 years, or until intolerable toxicity or withdrawal of consent.~Salvage phase: Therapy continues until disease progression, intolerable toxicity, withdrawal of consent, or investigator decision to terminate."
223626102|NCT02462044|DRUG|300 mg Iodine|
223626103|NCT02462044|DRUG|370 mg Iodine|
223762795|NCT06145308|DRUG|alpelisib+fulvestrant|"Neoadjuvant / conversion phase: After 2-6 cycles of protocol therapy, patients are re-evaluated. Those deemed resectable undergo surgery of the primary tumour ± metastatic sites, followed by radiotherapy or other modalities (e.g., radiofrequency ablation) at the investigator's discretion. Patients who remain unresectable after six cycles continue the same regimen until disease progression, intolerable toxicity, withdrawal of consent, or investigator decision to stop.~Adjuvant phase: Treatment is administered for 2 years, or until intolerable toxicity or withdrawal of consent.~Salvage phase: Therapy continues until disease progression, intolerable toxicity, withdrawal of consent, or investigator decision to terminate."
224215387|NCT00304954|DRUG|Intravenous Daclizumab|Participants randomly assigned to intravenous (IV) daclizumab received 8 mg/kg of IV daclizumab at baseline, then 4 mg/kg of IV daclizumab at Week 2 and then 2 mg/kg of IV daclizumab monthly for the rest of the 6-month study.
224215388|NCT00304954|DRUG|Intravenous Infliximab|Participants randomized to IV infliximab received 3 mg/kg of IV infliximab monthly for 6 months.
224215389|NCT00304954|OTHER|Observation|Participants randomly assigned to the observation group were given injections of either bevacizumab (1.25 mg/0.05 mL or 2.5 mg/0.1 mL) or ranibizumab (0.5 mg) if they presented with recurrence of intraretinal or subretinal fluid as seen on Stratus Optical Coherence Tomography.
223762796|NCT06145308|DRUG|PARP inhibitor|"Neoadjuvant / conversion phase: After 2-6 cycles of protocol therapy, patients are re-evaluated. Those deemed resectable undergo surgery of the primary tumour ± metastatic sites, followed by radiotherapy or other modalities (e.g., radiofrequency ablation) at the investigator's discretion. Patients who remain unresectable after six cycles continue the same regimen until disease progression, intolerable toxicity, withdrawal of consent, or investigator decision to stop.~Adjuvant phase: Treatment is administered for 2 years, or until intolerable toxicity or withdrawal of consent.~Salvage phase: Therapy continues until disease progression, intolerable toxicity, withdrawal of consent, or investigator decision to terminate."
224215390|NCT00304954|DRUG|Oral Rapamycin|Participants randomly assigned to rapamycin received 2 mg in capsule form every other day for 6 months.
224215391|NCT00359554|BIOLOGICAL|VAXIGRIPPE|
224215392|NCT02175654|DRUG|Regorafenib|
224215393|NCT01058382|DRUG|Progesterone Vaginal Suppositories|Progesterone Vaginal Suppositories 200 mg three times daily for 10 weeks following embryo transfer
224316864|NCT04800549|OTHER|Oral Mucositis|The data of the study were obtained by conducting six interviews with each child and the family. The first interview was conducted before starting to treatment on the first day of the treatment, the second interview was conducted on the 2nd day after the treatment and the following interviews were conducted on the 4th, 8th, 16th, and 21st days and in-mouth mucosa of the patient was evaluated by taking in-mouth pictures following interviewing with the child and the family. Oral care application was conducted four times a day with sodium bicarbonate solution and a lollipop made with black mulberry syrup (after meals and before going to the bed at night). Oral care was first conducted by the researcher, the oral care was then taught to the patient and patient's relatives and the application was evaluated. Figure 1 shows the study design.
223626104|NCT00562367|DRUG|Cytomel (liothyronine)|Cytomel (liothyronine) 25-50 mcg/day for 4 weeks
223626105|NCT01869738|DEVICE|MGuard Prime|
223626106|NCT01869738|DEVICE|(BMS/DES)|
223626107|NCT03174353|DRUG|Lanreotide Prefilled Syringe|All patients enrolled in this study will receive SOMATULINE DEPOT 120 mg immediately prior to planned pancreatic resection. The pharmacist will dispense loaded syringes of the study drug. The single preoperative dose will be given in the pre-surgical center at the University of Washington by a trained health care professional. The study drug will be injected via the deep subcutaneous route in the superior external quadrant of the buttock.
223626108|NCT06240637|OTHER|Telemonitoring|A networked platform that enables the telemonitoring of both compliance data and the patient's ventilatory pattern, allowing the assessment of flow/pressure curves as well as leaks or events related to the upper airway.
223626109|NCT01069484|OTHER|Postpartum pelvic floor muscle training|Beyond a customary leaflet and thorough initial instruction on how to contract the PFM correctly, the training participants will attend one weekly supervised exercise class led by an experienced physiotherapist, and perform daily training at home. The intervention starts 6-8 weeks postpartum and last for 4 months. General principles for strength training are followed: 3 sets of 8-12 contractions close to maximum (Bø 1990, Haskell 2007). Emphasis will be on progression in force development. The participants are provided with a DVD of the program (www.corewellness.co.uk). At week 4 during the intervention, the PFM strength will be assessed for each participant. Training adherence at home will be recorded in a training diary, whereas the physical therapist will record group session adherence.
223626110|NCT02296164|DRUG|Valchlor|Valchlor gel 0.016%
223626111|NCT02710656|DEVICE|Legflow® balloon|Percutaneous angioplasty performed with a Drug coated balloon (DCB) with Paclitaxel
223626112|NCT02710656|DEVICE|Standard PTA|Percutaneous angioplasty performed with a standard balloon
223626113|NCT01052792|DRUG|Naproxen Sodium|Naproxen Sodium Tablets 550 mg
223626114|NCT02282852|DEVICE|Wireless Capsule Endoscopy|
223626115|NCT02282852|DEVICE|Magnetically steerable capsule endoscopy|
223626116|NCT00644358|DRUG|vilazodone|titration to 40 milligrams (mg) every day (qd) for 1 year
223626117|NCT05476445|PROCEDURE|Control|Root canal treatment
223626118|NCT05476445|PROCEDURE|Laser|Root canal treatment+Laser application
223626119|NCT05476445|PROCEDURE|Cryotherapy|Root canal treatment + Cryotherapy application
223626120|NCT05769296|DEVICE|Headpulse measurements|Placement of headset on subject
223762797|NCT06145308|DRUG|enfortumab vedotin|"Neoadjuvant / conversion phase: After 2-6 cycles of protocol therapy, patients are re-evaluated. Those deemed resectable undergo surgery of the primary tumour ± metastatic sites, followed by radiotherapy or other modalities (e.g., radiofrequency ablation) at the investigator's discretion. Patients who remain unresectable after six cycles continue the same regimen until disease progression, intolerable toxicity, withdrawal of consent, or investigator decision to stop.~Adjuvant phase: Treatment is administered for 2 years, or until intolerable toxicity or withdrawal of consent.~Salvage phase: Therapy continues until disease progression, intolerable toxicity, withdrawal of consent, or investigator decision to terminate."
223762798|NCT06145308|DRUG|HER2, pyrotinib + pertuzumab/trastuzumab|"Neoadjuvant / conversion phase: After 2-6 cycles of protocol therapy, patients are re-evaluated. Those deemed resectable undergo surgery of the primary tumour ± metastatic sites, followed by radiotherapy or other modalities (e.g., radiofrequency ablation) at the investigator's discretion. Patients who remain unresectable after six cycles continue the same regimen until disease progression, intolerable toxicity, withdrawal of consent, or investigator decision to stop.~Adjuvant phase: Treatment is administered for 2 years, or until intolerable toxicity or withdrawal of consent.~Salvage phase: Therapy continues until disease progression, intolerable toxicity, withdrawal of consent, or investigator decision to terminate."
223762799|NCT05550155|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS) Treatment|a 4-month maintenance procedure of active rTMS
223762800|NCT05550155|DEVICE|Sham Repetitive Transcranial Magnetic Stimulation (rTMS)|a 4-month maintenance procedure of sham rTMS
223762801|NCT05771155|BIOLOGICAL|Intravenous (IV) infusions|Intravenous (IV) infusions of a dose of 300mg, on Weeks 0, 2 and 6, 14, 22, 30, 38 and 46
223762802|NCT03761628|DEVICE|pHyph generation I|A vaginal tablet for the treatment of VVC to be administered every 48 hours
223762803|NCT05275777|DRUG|ADG106|Administered as an intravenous infusion over 60-90 minutes in the initial cycle and over 30 minutes in subsequent cycle if well tolerated.
223762804|NCT05275777|DRUG|Doxorubicin|Administered as an intravenous infusion.
223762805|NCT05275777|DRUG|Cyclophosphamide|Administered as an intravenous infusion.
223762806|NCT05275777|DRUG|Paclitaxel|Administered as an intravenous infusion.
223626121|NCT02843269|BEHAVIORAL|Multi-component lifestyle intervention|The exact same intervention was given to the three Stepped-wedge groups - but each of the three groups were started up three months apart. The waiting groups served as control groups. Thus, the intervention were for all three groups a multi-component intervention consisting of Intelligent Physical Exercise training (IPET), Dietary Advice and Weight loss (DAW) and Cognitive Behavioral Therapy (CBT)
223626122|NCT01599156|PROCEDURE|Reflexology|Reflexology is a therapy whereby diagnosis and treatment are done on the patient's feet. According to reflexology, our feet are a micro-cosmos of our bodies and contain all the body's systems and internal organs. The treatment is palpation and massage of specific reflex points that respond to the body organs. This massage or palpitation of reflex points improves the physical function of the corresponding organ or system
223626123|NCT05605808|OTHER|Aerobic exercises|Aerobic exercise by using the treadmill, two times per week. Its intensity was equivalent to 60-85% of each patient's maximum heart rate and lasted 20 minutes in the first week and 30 minutes in weeks 2-12.
223626124|NCT05605808|OTHER|Diet protocol|A specific diet for three months is designed to boost the immune system through edible seeds and nuts which are rich in proteins, fats, fibers, minerals, and vitamins.
223626125|NCT06276062|PROCEDURE|Distal radius fracture fixation in pediatrics.|using double short titanium elastic nails in treatment of pediatric distal radius fractures.
223626126|NCT00409643|DRUG|valsartan+amlodipine combination|
223762807|NCT05235074|BIOLOGICAL|OH2 injection|OH2: Oncolytic Type 2 Herpes Simplex Virus
223762808|NCT01827657|DRUG|GSK2336805|Two 30 mg GSK2336805 tablets for a 60 mg single dose will be administered in this study
223762809|NCT02416427|DRUG|Atorvastatin|Atorvastatin will be administered at 80 mg/day for 3 weeks in the time window between diagnostic biopsy and curative surgery
224215394|NCT01058382|DRUG|Intramuscular Progesterone-in-Oil|Progesterone-in-Oil 50 mg IM once daily for 10 weeks following embryo transfer
224215395|NCT03229382|DRUG|Obinutuzumab|Patients, in whom all inclusion criteria have been confirmed and all exclusion criteria have been ruled out, will receive 4 intravenous infusions of obinutuzumab (GA101, Gazyvaro) at a dose of 1000 mg on Days 1, 8, 15 and 22.
223762810|NCT00007033|DRUG|magnesium gluconate|
223762811|NCT00007033|DRUG|magnesium sulfate|
223762812|NCT01505686|PROCEDURE|MRI scan|MRI scan with a 1,5 T MRI scanner
223762813|NCT06060574|DEVICE|Platelet rich fibrin device|"Within the scope of the study, a total of 2 tubes of venous blood samples will be obtained from the forearm region (antecubital vein) of each individual by the clinical staff specialist nurse of the Department of Periodontology. PRF samples will be created using appropriate equipment and devices from blood samples obtained from each individual. In the study, 10 ml glass-coated plastic tubes will be used. Apart from this, 5 mL of blood taken will be used for complete blood count and evaluation of hormones on the relevant day.~PRF Preparation: In all age groups, PRF will be prepared by centrifugation with 700xg (=2700 rpm, Intra-Spin L-PRF device) for 12 minutes."
224215396|NCT00524576|BIOLOGICAL|Engerix™-B|One dose (10µg Hepatitis B surface antigen (HBsAg))
224215397|NCT00228540|DRUG|Modafinil|
224215398|NCT06161740|PROCEDURE|muscle strengthening|The study involved adults aged 18 to 59 diagnosed with COVID-19 in the past year, experiencing mild or moderate symptoms, dyspnea, and either sedentary or engaging in physical exercise at least twice a week. Excluded were those with certain medical conditions. The participants were divided into two groups: one focused on global muscle strengthening (GF), and the other on low-intensity aerobic training with global muscle strengthening (GAF). The study assessed various parameters, including BMI, quality of life, aerobic capacity, dyspnea, and muscle strength. The sessions varied in duration and intensity. Volunteers were recruited from a clinic in Ubá-MG and randomly assigned to groups. The study aimed to evaluate the impact of the interventions on post-COVID-19 recovery.
223626127|NCT00409643|DRUG|valsartan|
223626128|NCT00409643|DRUG|amlodipine|
223626129|NCT03032562|DIAGNOSTIC_TEST|Multimodal measurement of respiratory muscle function and strength|Sleep-studies, capnography, spiromanometry, phrenic nerve conduction studies, magnetic phrenic nerve stimulation, diaphragmatic ultrasound
223626130|NCT02732600|OTHER|Facilitated Implementation|Facilitated Implementation sites will receive one year of support based on the i-PARIHS implementation model which includes training, implementation planning, ongoing external facilitation, feedback and consultation
224316865|NCT06632808|OTHER|Exercise|Deep cervical flexor muscle exercises target the deep neck muscles that play a crucial role in the stabilization of the cervical spine and the maintenance of proper posture. These muscles, particularly the longus colli and longus capitis, are responsible for the correct alignment of the head and neck. The exercises typically involve gentle flexion of the neck (bringing the chin towards the chest) with low-intensity, controlled movements. The goal is to strengthen these muscles, enhance spinal stability, and alleviate symptoms such as tension-type headaches. Additionally, these exercises support postural control and can reduce excessive strain on the neck.
223626131|NCT00435916|DRUG|SGN-40|1-8 mg/kg IV (in the vein) on Days 1, 4, 8, 15, 22 and 29 of Cycle 1; 8 mg/kg IV (in the vein) on Days 1, 8, 15, and 22 for Cycles 2-12.
223626132|NCT02151487|DRUG|Ropivacaine|Ropivacaine alone
224215399|NCT04162392|OTHER|shared decision making|Patients can choose the intervention that they want. There are different physiotherapy interventions were the patients have to do physical activity during the hospital stay. The physiotherapist explains the advantages and disadvantages of each treatment before they choose.
224215400|NCT04162392|OTHER|control group|Patients receive a physiotherapy intervention but they do not have the opportunity to choose the treatment
224215401|NCT01692080|BEHAVIORAL|Asthma education|Two separate asthma education classes are conducted to target two age groups: 6-10 yrs and 10-15 yrs. With the guidance of pharmacy faculty, student pharmacists develop innovative educational activities directed at three of the most common barriers to proper asthma control: avoidance of asthma triggers; compliance with asthma medications and proper usage of inhalers; and the importance of an asthma action plan. There is a different group of student pharmacists participating in each camp and this allows for variation in educational activities, all reinforcing the same important aspects of optimal asthma management. Students create age-appropriate activities for each group. Parents are required to attend camps with their child and participate in the asthma education sessions.
224316866|NCT02242045|DRUG|Idelalisib|150 mg tablet(s) administered orally twice daily
224316867|NCT03039270|OTHER|With sonic activation (SMART Device®)|The operator applied a desensitizing gel containing 5% potassium nitrate and 2% sodium fluoride (Desensibilize KF 2%, FGM, SC, Brazil) on the vestibular surfaces of the participant's anterior teeth. In the sonic activation side, immediately after the gel's application, sonic activation(Smart Sonic Device, FGM, SC, Brazil) was performed for 1.5 minutes in total for side (30 seconds per tooth). After the time of 30 seconds in each of the three anterior teeth of the respective side, the gel was removed from teeth with cotton. After removal of the desensitizing gel, gingival tissues were isolated and the bleaching gel were applied.
224316868|NCT03039270|OTHER|Control (Without sonic activation)|The operator applied a desensitizing gel containing 5% potassium nitrate and 2% sodium fluoride (Desensibilize KF 2%, FGM,SC, Brazil) on the vestibular surfaces of the participant's anterior teeth. In the side allocated for application without sonic activation, gel was kept for 10 minutes, after which it was removed from the teeth. After removal of the desensitizing gel, gingival tissues were isolated and the bleaching gel were applied.
224316869|NCT02473523|OTHER|PedsQL Cancer Module|The PedsQL cancer module acute version is a 27 item assessment that includes eight scales including pain (2 items), nausea (5 items), anxiety related to procedures (3 items), anxiety related to treatment (3 items), worry (3items), cognitive problems (5 items), perceived physical appearance and communication (3 items). This assessment will take approximately 15-30 minutes to complete.
223626133|NCT02151487|DRUG|Ropivacaine and dexamethasone|Ropivacaine combination with dexamethasone
224316870|NCT02473523|OTHER|PedsQL Multidimensional Fatigue Scale|The Multidimensional Fatigue Scale is an 18 item questionnaire encompassing 3 subscales including general fatigue (6 items), sleep and rest fatigue (6 items) and cognitive fatigue (6 items). This assessment will take approximately 10-20 minutes to complete.
223762814|NCT02489747|DIETARY_SUPPLEMENT|WBE|wheat bran extract (3 g/day)
223762815|NCT02489747|DIETARY_SUPPLEMENT|Placebo|Placebo
223762816|NCT03922568|OTHER|Density Gradient Centrifugation|semen was layered over 50 % and 90% discontinuous Density Gradient layers in a 15ml conical tube, then centrifuged at 250 g for 8 min at room temperature. supernatant was aspirated and the resulted pellet was washed using Sperm wash media and centrifuged at 250 g for 8 min at room temperature. The final pellet was re suspended in residual volume
223762817|NCT03922568|DEVICE|Physiological ICSI|Semen processing is done by double layer density gradient method followed by adding Sperm to the dot of hyaluronan on the PICSI dish, within minutes the bound sperm are attached by their acrosome to the surface of the dot. Hyaluronan bound sperms are selected for oocyte injection
223626134|NCT02151487|DRUG|Ropivacaine and clonidine|Ropivacaine combination with clonidine
223626135|NCT02151487|DRUG|Ropivacaine, dexamethasone and clonidine|Ropivacaine combination with dexamethasone and clonidine
223626136|NCT01616628|BEHAVIORAL|Fruit and vegetable rewards|Participants earn reward points at 50% the rate of how much they spend on fruit and vegetables. The earned reward points are distributed as money added to gift cards to be redeemed at the market.
223626137|NCT02929953|OTHER|chart review|data from charts and from registries will be compared
223626138|NCT01269866|DRUG|Cymbalta|Cymbalta 60 to 120 mg PO QD
223626139|NCT01356160|DRUG|GS-5885|tablet, 30 mg QD
223626140|NCT01356160|DRUG|GS-9451|tablet, 200 mg QD
223626141|NCT01356160|BIOLOGICAL|peginterferon alfa-2a|(solution for injection) 180 µg/week
223626142|NCT01356160|DRUG|ribavirin tablet|ribavirin tablet (weight based: 1000 mg/day \<75 kg; 1200 mg/day ≥ 75 kg) divided twice daily (BID)
223626143|NCT01356160|DRUG|GS-9451 Placebo|Placebo to match GS-9451 QD
223762818|NCT03922568|DEVICE|Magnetic Activated Cell Sorting|Semen processing is done by double layer density gradient method. The resulted pellet is labeled with Annexin V microbeads followed by separation on MACS column, the eluted fraction contains non apoptotic sperms suitable for oocyte injection.
223626144|NCT05249023|OTHER|Sodium butyrate bolus|On the test day participants suffering from IBS and healthy participants will undergo a distal colonoscopy procedure for the collection of mucosal biopsy specimens pre- and post-administration of a sodium butyrate solution (100 mM) at a selected area in the descending colon. Biopsies will be obtained from the colon pre- and 90 min post-administration of the intervention solution. Blood samples will be collected before and at six time-points after the intervention solution administration.
223626145|NCT00528957|DRUG|Tenofovir DF|Tenofovir DF (oral powder or tablet): 300-mg tablets for participants \> 37 kg; 8-mg/kg oral powder (up to 300 mg) for participants ≤ 37 kg. During the extension phase, participants whose weight increases to \> 37 kg may be switched from the oral powder to the tenofovir DF tablet.
223626146|NCT00528957|DRUG|Zidovudine|Zidovudine as prescribed by the investigator prior to study entry (pediatric participants \< 30 kg: 1 mg/kg/dose given every 12 hours; pediatric participants ≥ 30 kg: 30 mg twice daily).
223626147|NCT00528957|DRUG|Stavudine|Stavudine as prescribed by the investigator prior to study entry (pediatric participants 6 weeks to 12 years of age: 160 mg/m\^2 every 8 hours; pediatric participants \> 12 years of age: 300 mg twice daily).
223626148|NCT04400357|PROCEDURE|Robotic pancreaticoduodenectomy|Patients in this arm will undergo a pancreaticoduodenectomy with robotic-assisted techonology.
223626149|NCT04400357|PROCEDURE|Open pancreaticoduodenectomy|Patients in this arm will undergo an open pancreaticoduodenectomy which is the standard surgical approach.
223626150|NCT03678272|PROCEDURE|HERNIOPLASTY WITH PANAVALE MESH|Polypropylene mesh fixed with 3 points. Preformed polypropylene mesh will be used by fixing it with one point to the pubis, another to the inguinal ligament and another to the joint tendon.
223626151|NCT03678272|PROCEDURE|HERNIOPLASTY WITH PARIETEX PROGRIP MESH|"Preformed polypropylene mesh will be used which presents a self adhesive system not based on glue, but on the arrangement of the fibers of the mesh as hooks, and to which we will give a single point to the pubis."
223626152|NCT03678272|PROCEDURE|HERNIOPLASTY WITH ADHESIX MESH|It will use a self-adhesive mesh without giving points to fix this one, since it is a mesh that integrates the glue.
224215402|NCT04961229|BIOLOGICAL|The Pfizer mRNA-based BNT162b2 vaccine|"participants who gave informed consent to participate in either the prospective non-randomised study or RCT will receive a single vaccine dose.~In addition, participants in the RCT will be randomised into two groups:~1. Third booster dose of BNT162b2 (one standard dose) with no change in immunosuppression protocol~2. Third booster dose of BNT162b2 (one standard dose) with immunosuppression reduction according to protocol (mycophenolic temporary cessation 4 days before (5 half-lives) and one week (expected antibody response) after vaccination (to allow for antibody response)."
223762819|NCT06308991|OTHER|Yakson touch|Yakson touch method will be started 5 minutes before the endotracheal aspiration procedure and continued until the completion of the procedure.The Yakson method continued for 15 minutes with steady touch (5 minutes), compassionate caressing (5 minutes), and repetition of steady touch (5 minutes).
223762820|NCT06308991|OTHER|Gentle Human Touch|Gentle Human Touch (GHT) method will be started 5 minutes before the endotracheal aspiration procedure and continued until the completion of the procedure.The GHT method continued for 15 minutes.
223762821|NCT06308991|OTHER|Routine care|Infants in the Routine care will be applied swaddling. It will be started 5 minutes before the endotracheal aspiration procedure and continued until the completion of the procedure.
223762822|NCT04400513|DEVICE|Use of Eko CORE and Eko DUO electronic stethoscopes|Auscultation of heart sounds using electronic stethoscopes
223762823|NCT06529003|DEVICE|Transcutaneous Electrical Nerve Stimulation (TENS) unit|All participants in this study will receive the standard of care, which includes oral ibuprofen and a paracervical block at the time of laminaria insertion. Those in the treatment group will receive an adjunctive TENS unit with specific instructions for use in the interval between laminaria insertion and dilation and evacuation the next day. TENS is a non-invasive, inexpensive, over-the-counter, nonpharmacologic option to relieve pain. All participants will be provided with 15 tabs of ibuprofen 200 mg for outpatient pain control after the procedure. Participants will be instructed to take 600-800 mg of ibuprofen with food every 6 hours as needed for pain during the time period after laminaria insertion and before dilation and evacuation surgery, which is generally less than 24 hours.
224215403|NCT00894465|DRUG|midazolam|Children are randomized to receive oral midazolam .5 mg/kg prior to undergoing VCUG
224215404|NCT00894465|DRUG|placebo|Children are randomized to receive a placebo prior to undergoing VCUG
223626153|NCT03678272|PROCEDURE|HERNIOPLASTY WITH TIMESH MESH|Titaniumized polypropylene mesh will be used without fixing points, since liquid cyanoacrylate (Ifabond) will be used to fix it.
223626154|NCT00531765|OTHER|sodium bicarbonate infusion|short infusion of sodium bicarbonate
223626155|NCT03273426|PROCEDURE|Minimally-invasive biopsy|Intervention (core needle biopsy (14G) or vacuum-assisted biopsy(10G)) for complete clinical response (cCR) or near-cCR predicted by MRI.
223626156|NCT03273426|PROCEDURE|wide excision|Surgical wide excision of the biopsied area.
224215405|NCT01406873|DRUG|Mexiletine|150 mg/kg Mexiletine capsules taken by mouth, three times daily for 6 months
224316871|NCT02473523|DEVICE|Biodex System 3 Dynamometer|"The Biodex System 3 Dynamometer will be used to measure isometric quadriceps muscle contractions. Participants will be stabilized in the chair with abdominal and shoulder straps. The isometric tests for knee extension will be done on both dominant and non-dominant leg. The tests consist of 3 maximal muscle contractions each lasting five seconds separated by 40 second rest intervals. This assessment will take approximately 10 minutes to complete."
223626157|NCT03762408|DEVICE|ENKO 1|50 mg of HA/ 50 mg of CS in 5 ml
223626158|NCT03762408|DEVICE|Durolane|60 mg HA crosslinked in 3 ml
223626159|NCT03360903|DRUG|Placebo|"Anesthetized volunteers will be allowed to wake after injection of saline (placebo control).~Other Names:~* Saline"
223626160|NCT03360903|DRUG|Caffeine|"Anesthetized volunteers will be allowed to wake after injection of caffeine (15 mg/ kg).~Other Names:~* Caffeine citrate"
224215406|NCT01406873|DRUG|Placebo|150 mg/kg placebo capsules taken by mouth, three times daily for 6 months
224215407|NCT01497574|DRUG|insulin detemir|On two dosing visits, 0.4 U/kg insulin detemir will be administered followed by 0.4 U/kg insulin glargine after a 24 hours' interval and repeated in opposite order at next dosing visit. Administrated subcutaneously (s.c., under the skin)
224316872|NCT02473523|DEVICE|Jamar Hydraulic Hand Dynamometer|"A calibrated Jamar hydraulic hand dynamometer will be used to measure grip strength. The participant will be seated in a chair with elbow flexion to 90 degrees against torso and the forearm in neutral. The participant will grasp the device and the handle will be adjusted so that digits are able to comfortably grasp the device. The maximum score after 2 trials will be recorded as grip strength for both right and left hand. This assessment will take no more than 5 minutes to complete."
224316873|NCT02473523|OTHER|Sit and Reach Test|Hamstring flexibility will be assessed by the Sit and Reach Test. The sit and reach is a test to measure hip, hamstring and lower back flexibility. To measure flexibility participants will perform the YMCA sit and reach test. Participants will sit down without shoes or socks with the soles of their feet against the vertical platform of the sit-and-reach box located at the 26 cm (a little over 10 inches) mark. Participants keep their legs straight and their hands overlapped, while reaching for a less than maximum distance twice as a warm-up. This test will take no more than 5 minutes to complete.
224316874|NCT02473523|OTHER|Test of Motor Proficiency|The Bruininks-Oseretsky Test of Motor Proficiency is a 9 item standardized assessment that includes standing with feet on a line with eyes open and closed, standing on a line with one foot with eyes open and closed, standing on a balance beam on one leg with eyes open and closed and standing heel to toe on a balance beam. These tests will be administered no more than two times with a maximum score of 10 seconds. Two additional subtests include walking forward on a line and walking heel to toe on a line for a maximum of 6 steps for both tasks. Total time to complete this test is approximately 10-20 minutes.
224316875|NCT02473523|OTHER|Verbal Numeric Pain Scale|The verbal numeric pain scale will be administered before and after each yoga session. The principal investigator (PI) will ask the participant about his/her pain on a scale of 0-10 and the PI will record the number. This will take less than 10 seconds.
223626161|NCT04842708|DIAGNOSTIC_TEST|vaccination against COVID19|subjects will undergo breath biopsy sampling before, 4-7 days post-first vaccination dose, and 7-10 days post-second vaccination dose.
223626162|NCT02051764|DRUG|Flortaucipir F18|370 megabecquerel (MBq) IV single-dose
223626163|NCT02051764|DRUG|Florbetapir F 18|370 megabecquerel (MBq) IV single-dose
223626164|NCT02051764|PROCEDURE|Brain PET Scan|positron emission tomography (PET) scan of the brain
223626165|NCT03624881|DEVICE|Catheter ablation with EPU|Subjects undergoing electrophysiology mapping and RF ablation with THERMOCOOL SMARTTOUCH ® SF (STSF) and THERMOCOOL SMARTTOUCH ® (ST) catheters with VISITAG SURPOINT Module with External Processing Unit for pulmonary vein isolation
223626166|NCT05449418|BEHAVIORAL|Full Intervention|A small group of employees who work at facilities randomized to this arm will be invited to develop tailored COVID-19 vaccination promotion materials in teams with other long-term care staff sharing the same or similar language and/or cultural affinity. These employees will also help promote these materials to all of the employees who work at their facilities.
223626167|NCT05449418|OTHER|Enhanced Usual Care|Employees who work at facilities randomized to this arm will see COVID-19 vaccine promotion materials from the Centers for Disease Control and Prevention \[CDC\] or other national organization.
223626168|NCT00357630|DRUG|gemcitabine hydrochloride|
223626169|NCT00357630|PROCEDURE|quality-of-life assessment|
224316876|NCT02473523|OTHER|:Yoga Therapy|Those who consent will participate in 60-minute yoga sessions 2-3 times per week for 4-6 weeks. Only specified yoga poses will be implemented during the classes. Additional detail is included in the Description sections of this registration. The principal investigator is a Certified Yoga Therapist (CYT) and is a registered yoga teacher with 500 hours of training (RYT 500).
224316877|NCT00866879|DRUG|Sirolimus|Sirolimus will initially be given at a dose of 2-4 mg orally (PO) daily. The dose will be modified to achieve 24 hours trough concentrations of 6-10 ng/ml by high-performance liquid chromatography (HPLC) assay. This medication will be given in an open label fashion. The first dose of sirolimus will be given at the time of randomization to those patients assigned to have tacrolimus switched to sirolimus.
224316878|NCT00866879|OTHER|Demographic Data, Medical History, and Donor Data|Age at transplant, sex, race, cause of end-stage renal disease, medical history, donor age, cadaveric vs. living kidney transplant, histocompatibility/cross match data, viral serology, history of acute rejection and delayed graft function, use of induction therapy and immunosuppressants, use of Angiotensin Converting Enzyme Inhibitor (ACEI) and/or Angiotensin Receptor Blockers (ARB) level of renal allograft function-estimated GFR (e-GFR(12) using Modification of Diet in Renal Disease (MDRD) formula, proteinuria.
223626170|NCT03590444|DRUG|Ranibizumab 0.5 MG/0.05 ML Intraocular Solution|"Focal laser treatment will be performed using argon laser photocoagulation (VISULAS 532s®, Carl Zeiss Meditec) operating at 532nm and Ranibizumab 0.5 MG/0.05 ML Intraocular Solution.~Ranibizumab 0.5 MG/0.05 ML Intraocular Solution"
223626171|NCT04303455|DIAGNOSTIC_TEST|blood sampling|sampling serum renin
223626172|NCT02113917|BIOLOGICAL|Identification of biological markers|
223626173|NCT05435339|BIOLOGICAL|GEN1053|GEN1053 will be administered as an intravenous (IV) infusion every 3rd week. The dose levels will be determined by the starting dose and the escalation steps taken in the trial.
223626174|NCT00988832|BIOLOGICAL|Infliximab|Infliximab as prescribed by a physician in normal practice for Crohn's disease
223626175|NCT04672642|DEVICE|SpyGlass DS|Detection by the SpyGlass DS of residual pancreatic stones not detected by the standard method (CT scan and ERCP)
223626176|NCT04609098|DRUG|Dihydroartemisinin/Piperaquine|Tablets containing 40 mg dihydroartemisinin/320 mg piperaquine (Eurartesim, Sigma Tau), administered according to weight as per the manufacturer instructions.
223626177|NCT04609098|DRUG|Tafenoquine 100mg [Arakoda]|Extemporaneous preparation of 1mg/mL Tafenoquine solution, from tablets containing 100mg primaquine (Arakoda, 60degrees pharmaceuticals, DC) dissolved in 100mL water with a non-interacting fruit-flavoured syrup. Solution will be given according to weight as indicated per treatment arm in 5kg bands.
223626178|NCT05255523|DRUG|pyrotinib|After 4-6 cycles of taxane chemotherapeutics combined with trastuzumab±pertuzumab, the assessment result reaches CR or PR, and the subsequent sequential pyrrotinib plus capecitabine±trastuzumab to CNS Progress
223626179|NCT06430697|DRUG|paracetamol administration|Patient hospitalized in Intensive Care Unit with a continuous measurement of blood pressure with a catheter and who have an administration of paracetamol by intravenous or per os
223626180|NCT03521349|OTHER|Whole Egg Intervention|Participants will consume an isocaloric muffin containing important bioactives from whole eggs.
223626181|NCT03521349|OTHER|Egg White Control|Participants will consume an isocaloric muffin containing egg white, lacking important bioactives from whole eggs.
223626182|NCT04731636|DEVICE|Thoracoabdominal aortic stent system|Patients who meet all inclusion criteria and don't meet any exclusion criteria were implanted with thoracoabdominal aortic stent system.
223626183|NCT02892994|OTHER|ultrasound|
223626184|NCT03473236|DRUG|GB002|Inhaled GB002
223626185|NCT03473236|DEVICE|Generic Dry Powder Inhaler|dry powder inhaler used for inhalation of active drug or placebo
223626186|NCT03473236|DRUG|Placebo|Inhaled placebo
223626187|NCT04050046|DEVICE|Transcranial Direct Current Stimulation|tDCS is a neuromodulatory technique that delivers a small electric current (about the equivalent of a 9V battery) to the head. A fixed current between 1 and 2 mA is typically applied. tDCS works by applying a positive (anodal) or negative (cathodal) current via electrodes to an area, facilitating the depolarization or hyperpolarization of neurons, respectively.
223626188|NCT04050046|BEHAVIORAL|Computer-based cognitive therapy (CBCT)|Repetitive, drill-like training usually presented in the form of a game that targets a specific cognitive construct.
223626189|NCT06406764|OTHER|Plyometric training|Participants undergo a plyometric training program. The plyometric training consists of exercises in the horizontal, lateral, and vertical directions of movement. Exercises are progressively focused on maximal performance with short ground contact (\<250 ms). The training sessions are twice per week.
224215408|NCT01497574|DRUG|insulin glargine|On two dosing visits, 0.4 U/kg insulin glargine will be administered followed by 0.4 U/kg insulin detemir after a 24 hours' interval and repeated in opposite order at next dosing visit. Administrated subcutaneously (s.c., under the skin)
224215409|NCT00781131|DRUG|Pregabalin|pregabalin 75 or 150 mg
223513898|NCT03390491|BEHAVIORAL|OnTrack>TheGame (OTG)|OTG clients will be informed that the game can be played on a computer or a tablet and the time estimate for completing the game is approximately 5-8 hours. OnTrack\>The Game offers players the opportunity to immerse in a fictional neighborhood that centers around four domains for supportive recovery as defined by SAMHSA: health, home, purpose and community. The player interacts with other game characters including new acquaintances, friends/peers, a family member, and a treatment team, allowing the player to practice social and communication skills, while fostering personal relationships and building a support network. Additionally, the game provides players with helpful resources including psychoeducation materials and videos of real people who have experienced a first episode of psychosis, sharing their stories of hope and recovery. As a whole, the game provides a safe environment to promote goal attainment and recovery.
223626190|NCT06406764|OTHER|Control training|Participants continues their regular sports activities without additional plyometric training. The training sessions are twice per week.
223626191|NCT03796650|OTHER|Fecal microbiota transplantation|50 g donor feces suspended in saline with added glycerol, administered by a enema kit.
224215410|NCT00781131|DRUG|Placebo|lactulose placebo
224215411|NCT03990389|DEVICE|Chatbot Intervention|a chatbot will be used to monitor depression severity
224215412|NCT04133090|PROCEDURE|Autogenous block bone graft|Vertical and horizontal osteotomies were performed by means of a 6-mm diameter separation disc under copious irrigation with saline.The harvested bone graft was immediately placed in sterile saline solution to prevent dehydration. Sharp edges around the block graft were rounded under saline irrigation using a 4-mm round bur. The screw holes were properly made on both the recipient site and the block graft using a 1.3 mm drill. The graft was firmly fixed with 1.3 mm screws and a compatible driver. The periphery of the graft and the underlying gap between the screws and the recipient site, were covered with a mixture of particulate allograft and sterile saline solution to minimize resorption and to improve the adaption of the graft. All augmentation sites were covered by L-PRF membrane and flap closure was effected with 4/0 silk suture.
223626192|NCT03796650|DRUG|Vancomycin|Peroral vancomycin 125 mg q.i.d. for ten days.
223626193|NCT04038541|DIETARY_SUPPLEMENT|Prebiotics (Prebiotin Prebiotic Fiber Stick Pac)|"Commercially available Prebiotin Prebiotic.~2 packets (Inulin 4000 mg), Twice Daily (Total of 16 g Daily)"
223626194|NCT04038541|DIETARY_SUPPLEMENT|Probiotics (Visbiome®)|"Commercially available Probiotics Visbiome extra strength, which is a combination of live lactic acid bacteria probiotics that have been cultivated, freeze-dried and mixed in very high concentrations.~2 packets (450 billion CFU), Twice Daily (Total of 3,600 billion Daily)"
223626195|NCT05546151|DRUG|BMS-986322|Specified dose on specified days
223626196|NCT05546151|OTHER|Placebo for BMS-986322|Specified dose on specified days
223626197|NCT06268652|OTHER|Organoid-guided personalized treatment|After the organoid culture is successful, the personalized drug library customized by our team will be used for screening. Sensitive drugs are selected based on the results of drug screening, and the most appropriate personalized treatment plan is selected based on NCCN guideline recommendations, drug safety, and conventional drugs used in the treatment of breast cancer. The personalized drug library customized by our team contains 55 drugs approved by the FDA. For specific usage, dosage and time intervals, please refer to the instructions of the corresponding drug.
223626198|NCT06268652|DRUG|Gemcitabine|1000mg/m2，IV, days 1, 8, q3w
223626199|NCT06268652|DRUG|Capecitabine|1000mg/m² , PO, bid, days1-14, q3w
223626200|NCT06268652|DRUG|Vinorelbine|25mg/m2, IV or 60mg/m² (oral), days 1 and 8, q3w
223626201|NCT06268652|DRUG|Eribulin|1.4mg/m², IV, days 1 and 8, q3w
223626202|NCT01820286|BEHAVIORAL|Positive psychology intervention|
223626203|NCT01820286|BEHAVIORAL|Recollection intervention|
223626204|NCT03155724|DEVICE|MultiPole Pacing|CRT non-responders are programmed with MultiPole pacing ON.
223626205|NCT03633851|DEVICE|Toric intraocular MX60T lens|one eye will receive toric MX60T lens
223626206|NCT03633851|OTHER|Standard MX60 plus corneal incisions|the other eye will receive standard MX60 lens with corneal incisions
223626207|NCT02893709|DRUG|Omeprazole|Oral administration of omeprazole at therapeutic dose (20 mg daily) for a duration of 7 days
223626208|NCT02172144|DRUG|BI 1744 CL solution for inhalation|
223626209|NCT02172144|DRUG|Placebo matching BI 1744 CL|
224215413|NCT04133090|PROCEDURE|i-PRF enriched allograft material+ screw tent pole technique|The i-PRF preparation was performed as follows: the blood sample collected in an 8 ml, non-coated plastic tube without anticoagulant was immediately centrifuged at a protocol of 2700 rpm for 2 min. After centrifugation, the liquid autologous fibrin material which comprised the 1 mL upper layer of the tube was collected, using a disposable syringe. The screw holes were made on the recipient site using a 1.3 mm drill. 7 mm long screws were fixed 2mm or 4mm higher than on the recipient site to provide the desired augmentation distance and stabilized by a compatible driver. i-PRF was mixed with allograft material in a sterile metal box. Polymerization was done in 3 to 5 minutes, then this material was applied to the underlying gap between the screws and the recipient site.All augmentation sites were covered by L-PRF membrane and flap closure was effected with 4/0 silk suture.
223762824|NCT06529003|DEVICE|Placebo|Participants in the placebo group will be given a TENS unit without a battery with similar to the intervention group but will be advised that they may or may not feel a sensation from the electrodes. All participants will be provided with 15 tabs of ibuprofen 200 mg for outpatient pain control after the procedure. Participants will be instructed to take 600-800 mg of ibuprofen with food every 6 hours as needed for pain during the time period after laminaria insertion and before dilation and evacuation surgery, which is generally less than 24 hours.
223762825|NCT06572475|DIAGNOSTIC_TEST|USPIO enhanced MRI|Ferumoxytol (Feraheme©, AMAG pharmaceuticals, US) enhanced MRI
223762826|NCT00607945|DRUG|Rosiglitazone (Avandia) OR other diabetes medication currently prescribed to participant|Rosiglitazone 4-8mg/day, pill, from week -4 to week 32 OR other diabetes medication taken as prescribed from week -4 to week 32
223762827|NCT00607945|DIETARY_SUPPLEMENT|conjugated linoleic acid (CLA)|3.2 g/day, capsule, week 0 to week 32
224215414|NCT02149550|OTHER|NF135 n=5|Subjects will be infected with the NF135.C10 strain of Plasmodium falciparum through the bites of 5 infected Anopheline mosquitoes.
223762828|NCT00607945|DIETARY_SUPPLEMENT|conjugated linoleic acid (CLA)|6.4 g/day, capsule, week 0 to week 32
223762829|NCT06066151|DIETARY_SUPPLEMENT|Minayo Yeast Drink Product|Participants need to drink one piece of the products each day, for 4 consecutive weeks.
223762830|NCT06579573|DRUG|Cenobamate|Cenobamate will be orally administered once daily.
224215415|NCT02149550|OTHER|NF135 n=2|Subjects will be infected with the NF135.C10 strain of Plasmodium falciparum through the bites of 2 infected Anopheline mosquitoes.
224215416|NCT02149550|OTHER|NF135 n=1|Subjects will be infected with the NF135.C10 strain of Plasmodium falciparum through the bite of 1 infected Anopheline mosquito.
223762831|NCT05366660|OTHER|Interrogation/programming|As the study investigates remote programming, we will describe two locations: local (patient side) and remote (expert side). Local support is defined by a physician or a technician under the direct responsibility of a nearby physician who connect the patient to the remote programming system. Similar to a conventional check-up, an external defibrillator will be located in the near vicinity of the patient. The patient will first be connected to the programmer as during a conventional follow-up. The programmer will then be connected to a local PC which captures the programmer VGA video output and controls the programmer through a mouse emulator. This local PC will be remotely controlled by the remote PC using Cisco Webex, a communication software used worldwide to support telemedicine.
223762832|NCT05339932|OTHER|Manual Wheelchair Skills Training|The intervention involves manual wheelchair skills training.
223762833|NCT04355884|DIAGNOSTIC_TEST|Standard 12-lead ECG, NT-proBNP, echocardiography|Cardiac assessment
224215417|NCT02149550|OTHER|NF166 n=5|Subjects will be infected with the NF166.C8 strain of Plasmodium falciparum through the bites of 5 infected Anopheline mosquitoes.
224215418|NCT02149550|OTHER|NF166 n=2|Subjects will be infected with the NF166.C8 strain of Plasmodium falciparum through the bites of 2 infected Anopheline mosquitoes.
224215419|NCT02149550|OTHER|NF166 n=1|Subjects will be infected with the NF166.C8 strain of Plasmodium falciparum through the bite of 1 infected Anopheline mosquito.
224215420|NCT00699634|DRUG|Nabilone|Nabilone 0.5 mg at hs for 1 week, then 0.5 mg BID for 1 week. After a reassessment of the outcome measures, the dose is increased to 0.5 mg in the morning and 1 mg at hs for 1 week, followed by an increase to 1 mg BID in the last week of the study.
224215421|NCT06298279|BEHAVIORAL|Tunneled Delivery|Participants will be offered a pre-determined pathway to completing the 8-week course
224215422|NCT06298279|BEHAVIORAL|Personalized Delivery|Participants will be able to complete course modules at their own pace and in the order that most interests them.
224215423|NCT06298279|BEHAVIORAL|Standard Resources|Participants will receive the resources as typically included in the Self-Guided PSP Wellbeing Course.
224215424|NCT06298279|BEHAVIORAL|Enhanced Social Learning Resources|Participants will receive additional intervention content.
223762834|NCT04176159|OTHER|MOTOR IMAGERY AND TASK-ORIENTED TRAINING|"The intervention will be divided into two modules. A first module will include activities of activation and relaxation of the body, prediction and sequencing of movement and motor imagery. The second module, task-oriented training, will be divided into analytical work phase (visual coordination, balance, muscular strength, fine motor skills ...), a second phase of integration into specific tasks and, at end, the inclusion of the free (and supervised) practice of a sport.~The investigators will apply 20 sessions of 40 minutes."
223762835|NCT06442462|DRUG|SPG302|small synthetic molecule
223762836|NCT06442462|DRUG|Placebo|Placebo
223762837|NCT06456411|PROCEDURE|Functional Near-Infrared Spectroscopy|Undergo fNIRS
223762838|NCT06456411|OTHER|Questionnaire Administration|Ancillary studies
223762839|NCT06456411|OTHER|Virtual Technology Intervention|Undergo relaxation period using VR
223762840|NCT06456411|OTHER|Cold Stimulation|cold stimulation using ice pack
223762841|NCT03118492|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo HCT
223762842|NCT03118492|DRUG|Cyclophosphamide|Given IV
223762843|NCT03118492|DRUG|Fludarabine|Given IV
223762844|NCT03118492|BIOLOGICAL|Glycosylated Recombinant Human G-CSF AVI-014|Given IV
223762845|NCT03118492|OTHER|Laboratory Biomarker Analysis|Correlative studies
223762846|NCT03118492|DRUG|Melphalan|Given IV
223762847|NCT03118492|DRUG|Mycophenolate Mofetil|Given PO
223762848|NCT03118492|DRUG|Tacrolimus|Given IV or PO
223762849|NCT03118492|RADIATION|Total-Body Irradiation|Undergo TBI
223626210|NCT02172144|DRUG|Moxifloxacin (Avalox®)|
223626211|NCT05139043|DRUG|Dexamethasone|Given IV and PO
223626212|NCT04540263|DIAGNOSTIC_TEST|Flow Cytometric analysis|Measuring the level of IL-1β, IFN-α2, IFN-γ, TNF-α, MCP-1 (CCL2), IL-6, IL-8 (CXCL8), IL-10, IL-12p70, IL-17A, IL-18, IL-23, IL-33 cytokines in the serum
223626213|NCT00849940|DEVICE|CAS NIRS FORE-SIGHT oximeter|Comparison of non-invasive tissue oxygen saturation with blood sample-derived (calculated) tissue oxygen saturation.
223626214|NCT02316730|DRUG|Sanchi-Tongshu Capsule (Enteric coated pellets)|Take 0.7g (2 Capsules) of test preparation orally.
223762850|NCT05400603|COMBINATION_PRODUCT|Ex Vivo Expanded Allogeneic γδ T Cells in Combination with Dinutuximab, Temozolomide, Irinotecan and Zoledronate|"The cell dose will be based on the subject's body weight. Subjects will receive a single infusion of third party, ex vivo expanded, frozen then thawed γδ T cell product at a dose of 3 x 106 cells/kg on Day 6 and then if they meet criteria for subsequent γδ T cell dose will receive a second dose of 3 x 106 cells/kg on Day 13. The dose will be escalated to 1 x 10\^7 and then 3 x 10\^7 cells/kg. In absence of any dose limiting toxicity, 3 x 10\^7 cells/kg will be accepted as the maximal dose.~Dinutuximab (17.5 mg/m2), temozolomide (100 mg/m2),irinotecan (50 mg/m2) and zoledronic acid (0.0125 mg/kg/dose) will be consistent across all dose levels."
223762851|NCT01888198|BEHAVIORAL|(EORTC QLQ-C30) questionnaire|
223762852|NCT01888198|BEHAVIORAL|EuroQol EQ-5D 7-item questionnaire|
223762853|NCT05279664|OTHER|Remote ischemic conditioning (RIC) + Standard of Care for NEC|RIC will consist of 4 cycles of limb ischemia (5 min) followed by reperfusion (5 min), repeated on two consecutive days. An appropriately sized blood pressure cuff (covering 2/3 of the distance between the shoulder and the elbow) will be applied by a trained research fellow or nurse to an arm (or leg if the arm is not available because of medical reasons such as central line insertion). The systolic blood pressure will be measured before the first RIC cycle using a different cuff of same size connected to a monitor. During ischemia time, the cuff will be inflated to a pressure of 15 mmHg above the child's systolic pressure. Neonates in this arm will continue to receive standard of care for NEC.
223762854|NCT05279664|OTHER|Standard of Care for NEC|Neonates in this arm (i.e. the control arm) will receive standard of care for NEC.
223762855|NCT04934306|OTHER|Nasometry|Repetition of several stimuli (syllables, sentences ) in the microphones of the Nasometer
223762856|NCT06332404|DEVICE|Hypoglossal nerve stimulation Inspire system (Inspire Medical Systems Inc., USA)|Hypoglossal nerve stimulation therapy
223762857|NCT03856658|DRUG|Floxuridine (FUDR)|Together the FUDR and the HAI pump are experimental because they are being used to treat hepatic liver metastases of Pancreatic adenocarcinoma. They have not yet been FDA approved for this indication, although they are both approved for other indications. The intervention is surgical placement of an HAI pump with subsequent delivery of FUDR via the pump in 28-day cycles. FUDR will be delivered via the HAI pump for 6 months, in 28 day cycles: 2 weeks of therapy, followed by 2 weeks of heparinized saline.
223762858|NCT03856658|DEVICE|Hepatic Artery Infusion Pump|Together the FUDR and the HAI pump are experimental because they are being used to treat hepatic liver metastases of Pancreatic adenocarcinoma. They have not yet been FDA approved for this indication, although they are both approved for other indications. The intervention is surgical placement of an HAI pump with subsequent delivery of FUDR via the pump in 28-day cycles. The primary tumor will be resected or ablated with irreversible electroporation at the time of HAI pump placement. FUDR will be delivered via the HAI pump for 6 months, in 28 day cycles: 2 weeks of therapy, followed by 2 weeks of heparinized saline.
223762859|NCT03856658|DRUG|Heparinized Saline|Together the FUDR and the HAI pump are experimental because they are being used to treat hepatic liver metastases of Pancreatic adenocarcinoma. They have not yet been FDA approved for this indication, although they are both approved for other indications. FUDR will be delivered via the HAI pump for 6 months, in 28 day cycles: 2 weeks of therapy, followed by 2 weeks of heparinized saline.
223762860|NCT06513624|DRUG|ETC-159|ETC-159 will be administered orally.
223762861|NCT06513624|DRUG|Pembrolizumab|Pembrolizumab will be administered intravenously.
223762862|NCT06513624|DRUG|Denosumab / Zoledronic Acid|Denosumab will be administrated subcutaneously. Zoledronic Acid will be administered intravenously if denosumab has no response.
223762863|NCT05359211|DRUG|Cyclophosphamide|Given IV
224215425|NCT06298279|BEHAVIORAL|Transdiagnostic Self-Guided ICBT|An ICBT course that is completed without the guidance of a therapist.
224215426|NCT00172302|DRUG|vitamin C, intravenous injection|
223762864|NCT05359211|DRUG|Fludarabine|Given IV
223762865|NCT05359211|BIOLOGICAL|Lisocabtagene Maraleucel|Given IV
223762866|NCT05359211|DRUG|Polymer-conjugated IL-15 Receptor Agonist NKTR-255|Given IV
223762867|NCT05359211|PROCEDURE|X-Ray Imaging|Undergo x-ray imaging
223626215|NCT02316730|DRUG|Sanchi-Tongshu Capsule|Take 0.4g (2 Capsules) of reference preparation orally.
223626216|NCT00297388|DRUG|Risperidone, long-acting injectable|
223626217|NCT01991808|RADIATION|Radiotherapy|
223626218|NCT03980015|OTHER|antibiotic treatment|Patients were treated with: ceftriaxone intravenously 2 g OD for 14 days or doxycycline orally 100 mg bid for 10 to 14 days or cefuroxime axetil orally 500 mg bid for 14 days or amoxicillin orally 500 mg tid for 14 days
223626219|NCT02752594|BIOLOGICAL|probiotic|Probiotic was administered for a period of 14 consecutive days. Saliva was collected on Day 1, before intervention and on Day 15, after intervention
223626220|NCT02752594|OTHER|placebo|placebo was administered for a period of 14 consecutive days. Saliva was collected on Day 1, before intervention and on Day 15, after intervention
223626221|NCT04687306|DIAGNOSTIC_TEST|X-rays- total of 4|X-rays of the sacral scope, pelvic femoral angle and cup ante-inclination in both sitting and standing positions
224215427|NCT06149195|DIAGNOSTIC_TEST|Standard medical care for heart failure|Standard treatment and care for heart failure patients from the heart failure center of Sichuan Provincial People's Hospital.
224215428|NCT01809795|OTHER|Blueberry Smoothie|
224215429|NCT01809795|OTHER|Sham Smoothie|
224215430|NCT00207714|DRUG|Golimumab|Type=exact, unit=mg/ml, number= 50 to 100 , form=powder for solution for infusion, route=sub cutaneous.
224215431|NCT00207714|DRUG|MTX|Type=exact, unit=mg/ml, number= 10, form=powder for solution for infusion, route=sub cutaneous
224215432|NCT00207714|DRUG|Placebo|Type=exact, unit=mg/ml, form=powder for solution for infusion, route=sub cutaneous
224215433|NCT00207714|DRUG|Infliximab|Type=exact, unit=mg/ml number= 10, form=powder for solution for infusion, route=sub cutaneous
223626222|NCT02585401|DRUG|Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321)|The physician questionnaire will contain primarily closed-ended questions (e.g., multiple choice, true/false), with few free-text response fields, eliciting responses measuring physician knowledge and understanding of the key information in the Eylea vial preparation instruction card, the intravitreal injection procedure video, and the product monograph.
223762868|NCT05359211|PROCEDURE|Echocardiography|Undergo ECHO
223762869|NCT05359211|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
223762870|NCT05359211|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy and aspiration
223762871|NCT05359211|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow biopsy and aspiration
223762872|NCT05359211|PROCEDURE|Lumbar Puncture|Undergo LP
223762873|NCT05359211|PROCEDURE|Computed Tomography|Undergo PET/CT
223762874|NCT05359211|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
223762875|NCT05359211|PROCEDURE|Biospecimen Collection|Undergo blood and CSF sample collection
223762876|NCT05359211|PROCEDURE|Biopsy|Undergo tissue biopsy
223762877|NCT05027139|DRUG|Zanidatamab|Administered intravenously (IV)
223762878|NCT05027139|DRUG|Evorpacept|Administered IV
223762879|NCT03806309|DRUG|FOLFIRI|Intravenous (IV); folinic acid 400 mg/m\^2, irinotecan 180 mg/m\^2, 5-FU bolus 400 mg/m\^2 and continuous infusion 2,400 mg/m\^2
223762880|NCT03806309|DRUG|OSE2101|subcutaneous injection on days 1 and 15, every 4 weeks for 6 doses then every 8 weeks until month 12 and then every 12 weeks for a maximum treatment duration of 24 months
223762881|NCT04522323|BIOLOGICAL|MEDI5752|MEDI5752
223762882|NCT04522323|DRUG|Axitinib|INLYTA
223762883|NCT04522323|DRUG|Lenvatinib|LENVIMA
223762884|NCT04176003|OTHER|Qualitative interview|Qualitative interview to explore experiences and perceptions of living with CPPD, and outcome measures to use in future studies
223762885|NCT04176003|OTHER|Member checking|Participants will be sent a short report with the researchers' findings from the qualitative interview, and asked to check the accuracy of these and provide brief written feedback.
223762886|NCT04114552|OTHER|questionnaires|"6 weeks after the trauma,during the call, an oral questionnaire will be proposed to collect data on patients' management since they have left the emergency department.~After the call, socio-demographic characteristics, trauma mechanism, medics management will be extracted from the patient's medical records"
224215434|NCT03254719|OTHER|Study assessments|All participants will be asked to complete study assessments at baseline visit, and weeks 3, 5, 7, and 10. Study participants will receive spinal manipulation and appropriate adjunctive therapies provided by doctors of chiropractic.
224215435|NCT03503708|DRUG|Livitol-70|Livitol-17 detoxifies, purifies and rejuvenates liver, kidney and spleen. Participants will be given the intervention in two bottles at each visit. Participant will be instructed to take two capsule twice daily at a fixed time in the day.
223626223|NCT04777617|OTHER|DD-cfDNA|We are obtaining samples for donor derived cell free DNA in an observational manner. There is no intervention in this study
224215436|NCT02939638|OTHER|Plant-based diet|Weekly instructions will be given to the participants in the intervention group about following vegan diet.
224215437|NCT02939638|OTHER|Control Diet|Participants will be asked to continue their usual diets for the 16-week study period.
224215438|NCT05064865|DIETARY_SUPPLEMENT|Freeze-dried table grape powder|Consumption of 46g/day freeze-dried table grape powder
224215439|NCT05064865|DIETARY_SUPPLEMENT|Placebo of the table grape powder|Consumption of 46g/day placebo version of the freeze-dried table grape powder
224215440|NCT00538187|DRUG|obatoclax mesylate|Given IV
224215441|NCT00538187|DRUG|bortezomib|Given IV
224215442|NCT00538187|OTHER|laboratory biomarker analysis|correlative study
223762887|NCT04388943|OTHER|Observation|Physiological Measurements Patient reported questionnaire Blood sampling
223762888|NCT02756793|RADIATION|Stereotactic Ablative Radiotherapy (SABR)|Patients will receive stereotactic ablative radiotherapy to all sites of progressive disease, with continuation of current systemic agents.
223762889|NCT02756793|OTHER|Standard of Care Treatment|"May include:~* Continue with current systemic agent(s)~* Observation~* Switch to next-line treatment~Palliative radiotherapy is allowed in this arm."
224215443|NCT00538187|OTHER|pharmacological study|correlative study
224215444|NCT01503359|DIETARY_SUPPLEMENT|Sarcosine|"Sarcosine group patients will receive 2 grams of sarcosine once a day in the morning for 6 months.~Placebo group patients will receive 2 grams of placebo once a day in the morning for 6 months."
224215445|NCT04340700|DRUG|THC or Placebo|A standard dose of THC (8 mg or 2 mg) will be placed in a Volcano Vaporizer chamber. The first THC dose is 8 mg, followed by approximately three doses of 2 mg each. Placebo will also be administered through a Volcano Vaporizer via inhalation. The first placebo dose is 8 mg, followed by approximately three doses of 2 mg each to match the THC procedures.
224215446|NCT00945152|DRUG|Vancomycin 1.25-1.50% in a complex gel formulation trademarked Vancogel(R)|Topical use for open wounds culturing out MRSA. One to three applications of the compound over a weeks time. Consists of Vancomycin 1.25-1.50% in a complex gel formulation.
224215447|NCT00945152|DRUG|Placebo, complex gel formulation without Vancomycin|Complex gel formulation applied as the placebo and is unknown because of the trial design. Complex gel formulation without Vancomycin
224215448|NCT00736099|DRUG|linagliptine 5 mg|safety and efficacy of linagliptine 5 mg open label
223626224|NCT00416208|DRUG|Bortezomib|1.6 mg/m2 i.v. d1 d8 d15 d22 for 4 cycles each of 35 days
223626225|NCT04960449|PROCEDURE|shoulder arthroscopy|Patients underwent ubacromial bursectomy and acromioplasty , cuff debridement and cuff repair, side to side suture of rotator cuff combined with suture anchor.
223626226|NCT00507013|DEVICE|QuickClose device|
223680586|NCT05996991|PROCEDURE|Spinal Manipulative Therapy|One session of Spinal Manipulative Therapy. The researcher will administer a posterior and inferior push on the opposite anterior superior iliac spine (ASIS) while passively rotating the subject on the side to be manipulated. The spinal manipulations will be repeated four times during a 5-minute period, with impulses oscillating between the right and left ASIS. In addition, we will administrate mobilizations (anterior-posterior central mobilization), applied for 1 minute in each lumbar vertebra (from L5 to L1), using grade I joint mobilization (patients positioned in the ventral decubitus position).
223762890|NCT05555472|BEHAVIORAL|Halt-intervention|The main aim of the Halt-intervention is to reduce the risk for reoffending. Seven sub-goals are implemented to work towards this main aim: (1) youths gain insight in (the consequences of) their behaviour; (2) strengthening youths' social skills; (3) youths are able take responsibility for the consequences of their behaviour; (4) victim-offender reconciliation; (5) youths are able to access support from own social network and, if necessary, access to formal support; (6) parents gain insight their child's behaviour; and (7) if youths complete the intervention, they do not receive a registration on their criminal record. With a compulsory screening and risk assessment at the start of the intervention, it is determined which sub-goals fit the adolescents' needs. The intervention gives Halt professionals the opportunity to identify adolescents (and families) in vulnerable circumstances and to guide them towards formal support, like youth care organisations or addiction treatment centres.
223762891|NCT05555472|BEHAVIORAL|Youth Initiated Mentoring (YIM) approach|"The YIM approach focuses on strengthening naturally existing relationships between youth and non-parental adults within their own social network (Van Dam \& Schwartz, 2020). It stems from the idea it takes a village to raise a child (Educational Civil Society), which implies that other adults are co-responsible for the development of youth in their environment (Bowers et al., 2015). The YIM approach can be implemented in a formal context; expertise from the own social network is then combined with expertise from professionals (Van Dam \& Verhulst, 2018). Professionals support youth in identifying and positioning a YIM as part of a broader intervention (Van Dam \& Schwartz, 2020). Youths are responsible for asking their YIM and once agreed upon, the YIM is positioned. The YIM offers advice/support and plays a role during the intervention followed by the youth. Youth, parents, YIMs and professionals work together to set expectations and goals for the engagement of the YIM."
223626227|NCT02864589|BEHAVIORAL|Internet-delivered habit reversal training|The I-HRT group will receive a 10-week therapist-guided, parent-assisted, Internet-delivered behavioural treatment. The treatment is based on existing literature on habit reversal training (i.e. Woods, D.W. (2008). Managing Tourette syndrome: A behavioral intervention for children and adults therapist guide. OUP, USA.) with added interactive features as videos and illustrations. In short, the participants practice to become more aware of their tics and inhibit them by performing competing responses (movements). The treatment is therapist guided: the participants have regular (up to 5 days a week) contact with a personally assigned therapist via written text in the platform and occasionally via the telephone. The children and parents have separate logins and access partly different content.
223626228|NCT02864589|BEHAVIORAL|Internet-delivered exposure and response prevention|The I-ERP group receives a 10-week therapist-guided, parent-assisted, Internet-delivered behavioural treatment. The treatment is based on existing literature on exposure and response prevention (i.e. Verdellen, C. et al. (2011). Tics: Therapist manual \& workbook for children. Boom, Amsterd.) with added interactive features as videos and illustrations. In short, the participants practice to suppress their tics for longer and longer times, at the same time as premonitory urges are intentionally provoked. The treatment is therapist-guided: the children and parents have regular (up to 5 days a week) contact with a personally assigned therapist via written text in the platform and occasionally via the telephone. The children and parents have separate logins and access partly different content.
223626229|NCT01102114|BIOLOGICAL|NicVAX Vaccine|NicVAX vaccine given 6 times over 6 months
223626230|NCT01102114|BIOLOGICAL|Placebo Vaccine|Placebo vaccine given 6 times over 6 months
223762892|NCT03307759|DRUG|Pembrolizumab|Pembrolizumab
224215449|NCT00736099|DRUG|linagliptine 5 mg and pioglitazone 30 mg|efficacy and safety of the combination linagliptine and pioglitazone
224215450|NCT05543070|RADIATION|Low-dose radiotherapy|Electron Beam/3D-CRT/IMRT/VMAT
224215451|NCT00328042|BEHAVIORAL|Self-Management Workshop|The workshop is a once per week 2.5 hour group that meets for six weeks.
224215452|NCT00328042|BEHAVIORAL|Information Only|This is an individual self-paced at home study program.
224316879|NCT00866879|PROCEDURE|Blood Draws for Control Group|Subjects maintaining standard of care drug treatment of TAC and MMF will have monthly labs in addition to the baseline pre-randomization labs, at 6, 12, and 24 Months post-randomization. Peripheral blood leukocytes will be obtained.
224316880|NCT00866879|PROCEDURE|Blood Draws for Experimental Group|This group will have monthly labs taken but will also have weekly labs during the period of conversion to monitor renal function and bone marrow function. In addition to the baseline pre-randomization labs, and labs collected at 6, 12, and 24 Months post-randomization, peripheral blood leukocytes will be obtained.
223626231|NCT04859088|DIETARY_SUPPLEMENT|Partial Enteral Nutrition|Dietary intervention (Liquid food replacement intervention)
224215453|NCT01039285|DRUG|Curosurf|2.5 ml/kg instilled in the trachea
224215454|NCT01039285|OTHER|Air|2.5ml/kg of Air will be instilled in the trachea
224215455|NCT00410852|PROCEDURE|Computer-assisted IV insulin infusion protocol (algorithm A)|Computer assisted insulin protocol (CAIP), with continuous intravenous insulin adjustments aiming blood glucose levels between 100 mg/dl and 130 mg/dl.
223762893|NCT03307759|RADIATION|Radiotherapy (SABR)|Radiotherapy
223762894|NCT05358821|DRUG|SAGE-718|SAGE-718 oral softgel lipid capsules
223762895|NCT05358821|DRUG|Placebo|SAGE-718-matching oral capsules
223626232|NCT03466385|DEVICE|Nasal High Flow|Patients admitted to emergency department with COPD exacerbation combined with mild to moderate acute or acute on chronic hypercapnic respiratory failure will be randomized in one of the two study groups. In case of NHF it will be commence immediately with pre-defined settings
223626233|NCT03466385|DEVICE|Non-Invasive Ventilation|Patients admitted to emergency department with COPD exacerbation combined with mild to moderate acute or acute on chronic hypercapnic respiratory failure will be randomized in one of the two study groups. In case of NIV it will be commence immediately with pre-defined settings
223626234|NCT03107481|DRUG|Acetaminophen|Acetaminophen 1g IV
223626235|NCT03107481|DRUG|Hydromorphone|Hydromorphone 1mg IV
223626236|NCT04618003|BEHAVIORAL|Adaptation of autonomic nervous system to activity in virtual reality|heart rate variability assessed at rest and during a physical activity in virtual reality.
223626237|NCT02859714|OTHER|screening data|
223626238|NCT05930119|DRUG|HMPL-453|300 mg HMPL-453
223626239|NCT05930119|DRUG|Rabeprazole|20 mg of rabeprazole will be administered by mouth once daily.
223626240|NCT00003316|DRUG|gemcitabine hydrochloride|
223626241|NCT06630494|DRUG|Recombinant human thrombopoietin for injection (rhTPO)|Single abdominal subcutaneous injection of the study drug will be given on D1. The administration and follow-up observation period will be 29 days (D1\~D29). Participants may be discharged at D7 at the judgment of the investigator. PK blood samples will be collected from D-1 to D14, tolerance and safety will be observed from D1 to D29, and blood samples for PD and anti-drug antibody (ADA) will be collected from screening to D29. After completion of relevant assessments on D29, participants will be considered as having completed this study.
223626242|NCT01400698|DRUG|Saizen® A|Continuous or intermittent treatment with recombinant human Growth Hormone (r-hGH) 0.067 milligram/kilogram/day (mg/kg/day) subcutaneously (sc).
223626243|NCT01400698|DRUG|Saizen® B|Observed until the first signs of puberty and then continuous treatment with r-hGH 0.067 mg/kg/day sc or observed without treatment.
224215456|NCT00410852|PROCEDURE|Leuven Strict glycemic control protocol (Algorithm B)|Leuven protocol: continuous intravenous insulin infusion aimiming blood glucose levels between 80mg/dl and 110mg/dl.
223626244|NCT01400698|OTHER|Observation only|Subjects were only observed.
223626245|NCT06612879|DRUG|Omaveloxolone|Administered as specified in the treatment arm.
223626246|NCT00000140|DRUG|Perfluoropropane|
224215457|NCT00410852|PROCEDURE|Conventional Intermittent Insulin Protocol (Algorithm C)|Conventional treatment: intermitent subcutaneous insulin according to a sliding scale, starting with blood glucose levels higher than 150mg/dl.
224215458|NCT03564756|DIETARY_SUPPLEMENT|Vitamin C|1000mg Vitamin C per day
224215459|NCT03893409|OTHER||this is a observation study, no any intervention in patients
224215460|NCT04275661|PROCEDURE|Ultrasound (US) bi-level erector spinae block|nerve block
224215461|NCT04275661|DRUG|levobupivacaine|20 ml 0.25% levobupivacaine injected into fascial plane deep to erector spinae muscle
224215462|NCT04275661|DRUG|Ketamine|2 mg /kg ketamine.injected into fascial plane deep to erector spinae muscle
224215463|NCT04275661|DRUG|Magnesium Sulfate|2mg/kg Magnesium Sulfate .injected into fascial plane deep to erector spinae muscle
224215464|NCT02290028|DEVICE|Sentus QP left ventricular lead|Implantation of quadripolar left ventricular lead in patients with CRT-D indication
224215465|NCT03202511|DRUG|Probenecid Oral Tablet|Included in arm/group descriptions.
223626247|NCT00000140|DRUG|Sulfur Hexafluoride|
223626248|NCT00000140|DRUG|Silicone Oil|
223626249|NCT06039553|PROCEDURE|pulmonary artery banding|Patient in this group will undergo pulmonary artery banding surgery for congenital heart disease.
223626250|NCT06704412|BEHAVIORAL|floss band|"The floss band intervention used the standard floss band technique, wrapping a floss band (lime green Sanctband Comprefloss™, 2 × 3.5 m; PENTEL, Shah Alam, Malaysia) made of natural rubber tightly around the ankle on the affected side. It was started at the fifth metatarsal and wrapped horizontally around the metatarsals twice, in a figure eight to the medial malleolus, over the Achilles tendon and the lateral malleolus three times, and around the medial malleolus again, before being passed twice from the medial mal-leolus over the Achilles tendon to the lateral malleolus, forming an end knot"
223626251|NCT06704412|BEHAVIORAL|Sham (No Treatment)|The wrap used in the sham group lacked the elasticity of a floss band; the ankle was wrapped in the same manner, but loosely to facilitate blood circulation. Similarly, the participants were instructed to perform low-intensity active exercise involving ankle DF and plantar flexion for 2 minutes after applying the sham floss band. Finally, the sham floss band was removed, and the patient was asked to walk lightly on level ground for about 1 minute under the same conditions as in the floss band group.
223680587|NCT05985980|DIAGNOSTIC_TEST|Exercise Treadmill Test (ETT)|The study population consists of premenopausal women who applied to the outpatient clinic with chest pain. ETT is ordered as a routine diagnostic workup. Two ETTs are performed on each participant. The early follicular phase ETT is planned on the 3rd day of menstrual bleeding, while the menstrual bleeding continues. The late follicular phase ETT is planned on the 3rd day after the menstrual bleeding ends. Hormone levels are measured before each ETT to ascertain the phase of the menstrual cycle.
224215466|NCT03202511|DRUG|Tenofovir disoproxil fumarate/Emtricitabine|Included in arm/group descriptions.
223680588|NCT06480760|DRUG|Carnosine|Food ingredient (supplement)
223680589|NCT06013215|OTHER|Cochlear implant (Oticon) stimulation parameter optimization|The pulse amplitude and/or the pulse phase duration will be optimize to improve the intensity resolution of the cochlear implant which may benefit speech perception
223680590|NCT06823479|DRUG|Nivolumab|3 mg/kg
223680591|NCT06823479|DRUG|Ipilumimab|1 mg/kg
223680592|NCT04896697|DRUG|vilastobart (XTX101)|vilastobart (XTX101) monotherapy
224215467|NCT02601911|DRUG|Ketorolac Tromethamine|10 mg Ketorolac tromethamine is applied 45 minutes before the injection.
224316881|NCT00866879|PROCEDURE|Donor Blood Draws|Peripheral blood leukocytes from living donors obtained at the time of randomization. These donor leukocytes will be used as stimulator cells to study the functional activity of the recipient's lymphocytes function.
224316882|NCT00866879|OTHER|Donor Information|Donor age, cadaveric vs. living donor, and histocompatibility and cross match to recipient
223680593|NCT04896697|DRUG|Atezolizumab|1200 mg administered every 3 weeks in combination with vilastobart (XTX101)
223680594|NCT04896697|DRUG|vilastobart (XTX101)|In combination with Atezolizumab
223680595|NCT06984107|DEVICE|MRONJ resection plus PN+HA|Surgical management will be performed by reflecting a full-thick flap to expose the entire affected area, followed by removal of necrotic bone until a vital, unaffected bony margin will be obtained. After bone resection, the PN+HA (Regenfast®) will be applied on the residual bone surface. Wound management will be done via primary closure.
223680596|NCT04445792|OTHER|Pharmacogenetic testing|Genetic testing of CYP2D6 and CYP2C19
223680597|NCT04445792|OTHER|Clinical decisions support|Prescribing recommendations to the provider based on the pharmacogenetic testing results
223680598|NCT06987864|BIOLOGICAL|eculizumab|Intravenous infusion of BCD-148 every 2 weeks
223680599|NCT05671809|OTHER|NCRT with surgery, or NCT with surgery, or surgery|The eligible patients who voluntarily sign the consent form will undergo either NCRT with surgery, or NCT with surgery, or surgery according to treatment guidelines.
223680600|NCT06995027|PROCEDURE|BBAP and RAA pacing|Bachmann's bundle area pacing and conventional pacing in the right atrial appendage during regular pacemaker implantation procedures are applied for acute electrocardiogram and echocardiogram testings.
223626252|NCT06704568|OTHER|exercise|Unlike the control group; core exercises for 20-30 minutes, 3 days a week for 8 weeks, and respiratory exercises combined with core exercises for the respiratory exercises group: Slow and controlled breathing exercises will be performed starting with 5 seconds of inhalation and 5 seconds of exhalation twice a day for 10 minutes, 5 days a week for eight weeks, with a 10-second diaphragmatic breathing cycle (6 breaths/minute). The finger counting method will be recommended so that participants can easily follow the 5-second inhalation and 5-second exhalation cycles. The exercises can be done sitting or lying down. The individuals will be taught the differences between the two by switching between normal and deep breathing a few times. The respiratory exercises will be finished with relaxation exercises.
223626253|NCT06922305|DRUG|HR19042 Capsule, Tarpeyo®, Budenofalk®|In each period under fasting conditions, subjects received oral administration of either HR19042 Capsule 16 mg, Tarpeyo® 16 mg, or Budenofalk® 15 mg.
223626254|NCT06725082|BIOLOGICAL|Recombinant Humanized Type III Collagen Injection|rhCOL3/saline will be injected around the tumor (at four points: outer upper, inner upper, outer lower, and inner lower) before surgery, with 500ul per site. After the surgical margin is confirmed to be safe by rapid frozen pathology during surgery, a second injection of 2ml will be administered around the surgical area skin (at points spaced along the skin incision), followed by routine tissue flap revision and suture.
223626255|NCT06750458|DRUG|Dapagliflozin placebo|Twenty-five non-diabetic glioma patients on levetiracetam, and not on SGLT2 inhibitors will receive Dapagliflozin 10 mg once daily for 14 days pre-operative
224215468|NCT02601911|DRUG|Acetaminophen|10 mg Ketorolac tromethamine/ 1000mg Acetaminophen application before injection.
223626256|NCT06750458|DRUG|Placebo|Twenty-five non-diabetic glioma patients on levetiracetam, and not on SGLT2 inhibitors will receive placebo tablets once daily for 14 days pre-operative.
223626257|NCT06750458|DRUG|DexamethasoneGroup III (n=25) (Dexamethasone group)|Twenty-five non-diabetic glioma patients on levetiracetam, and not on SGLT2 inhibitors will receive Dexamethasone 8 mg tablets once daily for 14 days pre-operative.
223626258|NCT06881342|BEHAVIORAL|Enhanced School Mental Health Program (eSMHP)|The first-stage intervention is eSMHP Plus in the intervention arm and eSMHP in the control arm. In the intervention arm, adolescents receive eSMHP Plus from teachers and non-specialists, while in the control arm, they receive eSMHP from teachers. eSMHP, based on developmental, behavioral, social, and cognitive theories, enhances teachers' mental health literacy, training them in early identification, basic counseling, life skills, positive discipline, parental engagement, referrals, and teacher well-being. The second-stage intervention is a CBT-based self-help app. At six weeks, adolescents scoring ≥28 on PSC in both arms (indicating psychosocial distress) are re-randomized to continue their initial treatment (eSMHP Plus or eSMHP) or receive a step-up, CBT-based guided self-help app for two months.
224215469|NCT02601911|OTHER|Placebo|This group receive the caplet including placebo 45 minutes before the injection.
224215470|NCT02982447|DEVICE|blue laser imaging colonoscopy|Insertion to cecum was performed under white light(WL) and once the cecum was reached, the Blue Laser Imaging mode was switched on during withdrawal of endoscope for complete colonic examination. Second colonoscopic examination was performed in a similar manner after the first complete withdrawal of the colonoscope. WL was used on insertion and WL was used on withdrawal
224215471|NCT02982447|DEVICE|conventional white light colonoscopy|In this arm, WL was used for both insertion and withdrawal of the colonoscope during the first-pass and second-pass examinations.
224215472|NCT00833547|DRUG|eszopiclone|3 mg of eszopiclone at bedtime on two consecutive nights
223626259|NCT06939010|DEVICE|3d-interlocking miniplate|3d-interlocking miniplate
223626260|NCT06939010|DEVICE|Conventional miniplates|double miniplates in the conventional configuration
223626261|NCT06938542|BEHAVIORAL|Family Centered pediatric palliative care for family caregivers of children with rare diseases.|Child with rare disease who is unable to participate in medical decision making/family caregiver/support person triads will be randomized at a 1:1 ratio to one of two study arms, either the 3 session FACE-Rare intervention or the enhanced Treatment as Usual. Assessments will be completed at baseline, 3, 6 and 12 month outcomes.
223626262|NCT06939244|DIETARY_SUPPLEMENT|Krill oil|Krill oil supplement
223626263|NCT05132153|DRUG|Milrinone|will be given by nebulization
223626264|NCT05132153|DRUG|Normal saline|will be given by nebuliztion
223626265|NCT05011981|DEVICE|Left Atrial Appendage Occlusion|Interventional left atrial appendage occlusion with the Amulet or Watchman device
223626266|NCT05020821|PROCEDURE|Single-shot superior trunk block with intravenous dexmedetomidine|During surgery, dexmedetomidine will be administered. After intravenous administration of 2 mcg/kg for 30 minutes, 0.5 mcg/kg/hr will be administered until the end of surgery. After surgery, a single-shot superior trunk block will be performed under ultrasound guidance. 15 mL of 0.5% ropivacaine with 1:200,000 epinephrine will be administered.
223626267|NCT05020821|PROCEDURE|Continuous superior trunk block|During surgery, an equivalent volume of the placebo solution was administered in a similar manner as dexmedetomidine. The superior trunk block catheter will be inserted under ultrasound guidance using 15 mL of 0.5% ropivacaine after the operation and utilize patient-controlled analgesia infusion pump with a 300 mL reservoir of ropivacaine 0.2%, and programmed the pump to deliver 5 mL per hour with an optional patient-controlled analgesia bolus of 4 mL at 30-minute lockout intervals. Patients were typically discharged home on POD 1, and block was continued until reservoir completion.
223626268|NCT01657864|DRUG|Lamotrigine|Lamotrigine is an anticonvulsant drug used in the treatment of epilepsy and bipolar disorder
224215473|NCT00833547|DRUG|placebo|Placebo capsules looking identical to eszopiclone at bedtime on two consecutive nights
224215474|NCT01188954|DRUG|doxycycline|50 ml/mg
224215475|NCT01188954|OTHER|No intervention|Normal Saline/Water
224215476|NCT02521454|BEHAVIORAL|MBRT|
224215477|NCT03569254|DEVICE|Neomedlight Phototherapy Blanket|The NeoMedLight® phototherapy blanket is an innovative new fiber-optic device based on LED light. Its light emitting surface area is 40.5x30 cm or 1200 cm2. The device size is 40.5 x30 cm. It incorporates fiber optic mesh and is protected by a vinyl cover and a disposable liner for patient comfort and hygiene. This device provides therapeutic light (404-515nm) to a wide extension of the body surface area. Its average irradiation footprint is 35uW / cm2 / nm ± 15%. The phototherapy was done intermittently in periods of 2 hours with 1 hour of rest for a total time of 6 hours in kangaroo position.
224215478|NCT03569254|DEVICE|Ohmeda-Fiber Optic Phototherapy Blanket|This device is a high performance version of Ohmeda Medical's Biliblanket that uses a fiber optic cable to deliver light from a high-intensity lamp to a device composed of a fiber optic fabric. The device has a disposable liner and is left in direct contact with the patient. The patient is exposed to a light with a wavelength between 400 and 550 nanometers. The phototherapy system consists of a light emitting unit, a fiber optic cable four feet long (121.9 cm) and a lightweight mattress. It has two available sizes: 4.38 x 9.38 inches (11.12 x 23.83 cm) and 4.00 x 6.00 inches (10.16 x 15.2 cm).
223762896|NCT05198791|DRUG|Stratified medicine - Microvascular dysfunction and eplerenone therapy, tablets|Stratified medicine including interventional diagnostic procedure (IDP) and linked treatment with eplerenone. Patients with an increased IMR (strata with microvascular dysfunction, IMR ≥25) will be eligible for randomization to this arm. Patients randomized to receive eplerenone will be commenced on 25 mg once daily, and uptitrated to 50 mg once daily after two weeks. Treatment will be continued for a period of six months.
224215479|NCT01400854|DRUG|Effentora®|prescribed as per local Summary of Product Characteristics (SmPC) for 4 weeks duration
224215480|NCT05967312|DIAGNOSTIC_TEST|Minuteful Kidney Test Kit|The Minuteful Kidney Test is an Artificial Intelligence (AI) based innovative technology to enable people at risk of CKD to undertake an ACR test at home using smartphone technology
223762897|NCT05198791|OTHER|Stratification and standard care|Interventional diagnostic procedure (IDP) without linked treatment i.e., standard care. Patients with an increased IMR (strata with microvascular dysfunction, IMR ≥25) will be eligible for randomization to this arm. In the standard care group, the IDP is performed but the results are not disclosed. The IDP is therefore a sham procedure. Patients randomized to receive eplerenone will be commenced on 25 mg once daily, and uptitrated to 50 mg once daily after two weeks. Treatment will be continued for a period of six months.
223762898|NCT06263608|DEVICE|(Cardio)Respiratory polygraphy (NOX T3s)|This home-based device enables the detection of obstructive sleep apnea by calculating the apnea hypopnea index (AHI).
223762899|NCT06263608|DIAGNOSTIC_TEST|Polysomnography|Polysomnography allows both sleep and respiration monitoring during an overnight stay in a dedicated sleep clinic.
223762900|NCT06263608|DEVICE|Devices to deliver Continuous Positive Airway Pressure (CPAP), Bilevel Positive Airway Pressure (BiPAP) or Adaptive support ventilation (ASV)|Devices can be used to deliver CPAP, BiPAP, or ASV treatment to open up the airways, making breathing during sleep possible.
223762901|NCT06263608|DEVICE|Fitbit smartwatch|The smartwatch enables the semi-continuous monitoring of the heart rhythm via the installed FibriCheck algorithm.
223762902|NCT04649151|BIOLOGICAL|mRNA-1273|Sterile liquid for injection
223762903|NCT04649151|BIOLOGICAL|Placebo|0.9% sodium chloride (normal saline) injection
223762904|NCT04649151|BIOLOGICAL|mRNA-1273.222|Sterile solution for injection
223762905|NCT06034535|BIOLOGICAL|CD62L depleted donor lymphocyte infusion|Intravenous infusion of CD62L depleted donor lymphocytes
223762906|NCT06142448|DEVICE|Cueing app|"All participants that are included come to the movement lab for the baseline measurement. The baseline measurement consists out of extensive clinimetrics (for example MDS-UPDRS) to identify patient characteristics. With the use of an objective gait assessment, the effectiveness of both internal and external cueing is determined. This will divide the participants in three groups; responders, non-responders and in between. Participants who clearly respond to either internal or external cueing (determined as the responders) are asked to apply the working form of cueing in daily life during the six-month follow-up. During this period the participants will use a mobile application that can provide them with a rhythmic auditory stimulus and records the use of this application.~After 6 months, both the responders and non-responders are asked to return to the lab for the follow up measurement in which the baseline measurement is repeated to evaluate the effect of long-term cueing."
223762907|NCT06567886|DEVICE|Light Therapy|"Participants will self-administer the daily light therapy within a few minutes of their assigned wake up time for one hour.~Researchers will provide a light log to note light on/off times, any interruptions to light therapy, and primary activity during light therapy."
223762908|NCT06567886|BEHAVIORAL|Sleep Stabilization|All participants will be asked to follow a fixed sleep schedule.
223762909|NCT02631811|OTHER|Supportive /palliative care intervention|patients will be seen by palliative care team at least once a month until the 12th week, more if needed. The symptom and suffering will be assessed by a multidisciplinary palliative specialist team of physician, nurse and psychologist. Physical, psychological, social and existential suffering will be addressed.
223762910|NCT03752619|DEVICE|Contracting Producing Peripheral Nerve Stimulation|The stimulation system includes an external stimulator, percutaneous lead and pad. The stimulator snaps onto the pad. The pad has an embedded power source but also serves as the anode. The 1-channel stimulator outputs a biphasic current waveform with current pulse parameter ranges suitable for Peripheral Nerve Stimulation (PNS). The percutaneous lead is inserted using an introducer (like a hypodermic needle) which is withdrawn and the lead is retained in the muscle by a barb at its tip. After a 1-week stabilization period, stimulation is initiated (6 hrs/day). The duty cycle and daily dose remain constant, but stimulus parameters may be adjusted by the research staff as deemed appropriate. The treatment period is 3 weeks after which the lead will be removed.
224215481|NCT00164606|BEHAVIORAL|Positive Parenting Program (Triple-P)|
224215482|NCT02459639|OTHER|Anthroposophic integrative care rehabilitation program|"The programme for chronic pain at AIC consists of two phases:~1. A three-week in-patient period. During the first three-week in-patient stay, patients meet regularly with a multi-professional team. Usually, each patient receives two of the following therapies 2-4 times per week: art therapy, massage, physiotherapy, eurhythmy and baths. Nursing care is provided twice daily. Moreover, patients are offered to participate in group activities.~2. Two-three day inpatient follow-up and treatment period closure. The second phase of the treatment programme consists of a 2-3 day inpatient stay, 6 months after closure. During this time, physician, nurse and therapist appointments are made according to individual needs. The patients who have been engaged in group activities are gathered in groups."
224316883|NCT00866879|PROCEDURE|Kidney Biopsy|Kidney biopsy at 24 Months to compare to the standard of care biopsy taken at 12 Months. This information will help evaluate renal allograft pathology and renal allograft tissue gene expression profiles of the two groups. Renal allograft biopsies will be stored in RNA later (preservative) to further extend knowledge on the effect of calcineurin-inhibitors (CI) free immunosuppression on gene expression profiles.
223626269|NCT00851357|DRUG|Nicotine Patch|Subjects are randomized into 1 of 3 conditions: active, placebo or usual care. Usual care subjects are not mailed patches; however, we facilitate their use by providing a certificate that can be used by the State Medicaid program and some insurance companies to obtain free patches. For those mailed patches directly, we will mail 8 weeks of patches. Dosage depends on the number of cigarettes per day (cpd). Light smokers (6-10 cpd) will receive 6 weeks of 14 mg and 2 weeks of 7 mg patches. Heavy smokers (11+ cpd) will receive 4 weeks of 21 mg, 2 weeks of 14 mg and 2 weeks of 7 mg patches. Placebo patches will have no nicotine, but will be packaged to mimic the active patches.
223626270|NCT00851357|BEHAVIORAL|Telephone Counseling|"Subjects call the Helpline and are screened for services. Eligible clients who give consent will be randomly assigned to a group.~Subjects will be randomized into one of 2 behavioral conditions: telephone counseling or self-help materials. Telephone counseling includes a comprehensive pre-quit session (to include motivation, planning, and setting of a quit date and discussion of nicotine patch use) plus up to 5 proactive follow-up calls. Telephone counseling has several distinguishing features, namely proactive follow up counseling calls, a manualized protocol, and relapse-sensitive scheduling."
224215483|NCT02459639|OTHER|Conventional multi-modal care rehabilitation|The standard approach at Linköping University Hospital admits patients for bio-psycho-social assessment, pharmacological treatment and multimodal rehabilitation (main components: education, intense physical exercise, cognitive behavioural therapy and workplace interventions) for a 6 week intensive phase period (75%) followed by 4 weeks (25%). Here a number of professional disciplines collaborate and form a team of professionals focused on individual patient needs The multimodal rehabilitation outpatient program delivered by this team has the following aims: 1) reduce pain and psychological burden, 2) improve work capacity and decrease sick-leave and 3) increase perceived health and quality of life. These general aims are combined with the aims of the patient in a plan of rehabilitation.
224215484|NCT00686790|BIOLOGICAL|Peginterferon alfa-2b (PegIntron, SCH 54031)|Peginterferon alfa-2b 1.5 mcg/kg/wk subcutaneously (SC) for 52 weeks.
224316884|NCT02495259|DEVICE|ZU-bend stylet|Laryngoscopy and intubation after induction of anesthesia will be done using the GlideScope and the ZU-bend stylet. The ZU-bend is a specific shaping technique of the intubating stylet that is closely related to the GlideScope blade curvature. Zu-bend stylet is withdrawn as a part of placement procedure during the DLT advancement. Thereafter, GlideScope is removed and placement of the double-lumen endobronchial tube is verified with capnography and fiberoptic bronchoscopy in the usual manner.
224316885|NCT02495259|DEVICE|GlideScope|Laryngoscopy and intubation after induction of anesthesia will be done using the the GlideScope technique. The GlideScope is a video laryngoscope that provides a real-time view of the airway and tube placement during intubation. GlideScope is removed after DLT is in the trachea, and placement of the double-lumen endobronchial tube is verified with capnography and fiberoptic bronchoscopy in the usual manner.
224316886|NCT02495259|DEVICE|GlideRite stylet|Laryngoscopy and intubation after induction of anesthesia will be done with the GlideScope using the GlideRite stylet. The GlideRite stylet is specifically designed to work with the GlideScope and provides the necessary rigidity and curvature to an otherwise flexible tube. GlideRite stylet is withdrawn as a part of placement procedure during the DLT advancement. Thereafter, GlideScope is removed and placement of the double-lumen endobronchial tube is verified with capnography and fiberoptic bronchoscopy in the usual manner.
224316887|NCT02495259|DEVICE|Macintosh blade|Direct laryngoscopy and intubation after induction of anesthesia will be done with the Macintosh blade and a regular double-lumen endobronchial tube (DLT) stylet. The Macintosh blade is used to facilitate visualization of the larynx during double or single lumen endobronchial tube placement. After intubation the Macintosh laryngoscope is removed and the confirmation of the successful placement of the double-lumen endobronchial tube in done in the standard fashion.
224316888|NCT02495259|DEVICE|Regular Double-lumen endobronchial tube (DLT) Stylet|Direct laryngoscopy and intubation after induction of anesthesia will be done with a regular double-lumen endobronchial tube (DLT) stylet and the Macintosh blade. The DLT stylet is withdrawn as a part of placement procedure during the DLT advancement. Thereafter, Macintosh laryngoscope is removed and placement of the double-lumen endobronchial tube is verified with capnography and fiberoptic bronchoscopy in the usual manner.
224316889|NCT04278716|OTHER|Safe return to play checklist|this objective checklist will be utilized by the physical therapy staff and surgeon to determine whether an athlete is safe to return to their sport
223626271|NCT00851357|DRUG|Placebo|Placebo nicotine patch
224215485|NCT01974570|DIETARY_SUPPLEMENT|Marealis refined peptide concentrate|2 tablets, once per day before noon
224316890|NCT03443271|PROCEDURE|TAP Block with Bupivicaine|Ultrasound guided TAP block will be performed and patient will be administered 20 ml of 0.25 % Bupivicaine on each side.
224316891|NCT03443271|PROCEDURE|TAP Block with Placebo drug|Ultrasound guided TAP block will be performed and patient will be administered 20 ml of 0.9% Saline on each side.
224316892|NCT03563911|BEHAVIORAL|Brief Mindfulness-Based Intervention (BMBI)|The BMBI is be based on a BMBI which demonstrated analgesic effects in a previous study. Relative to full-length interventions, we will employ a brief intervention; the 20-minute BMBI session will include education on the foundational concepts of mindfulness and its relevance to chronic pain (5 minutes) and a guided mindfulness practice involving focused attention on the breath and monitoring of thoughts, feelings, and body sensations (15 minutes). BMBI participants will be encouraged to practice the taught mindfulness technique at home at least 20 minutes/day for 1 week (a handout and link to an online guided mindfulness practice will be provided).
223626272|NCT00851357|OTHER|Self-Help Materials|"Subjects call the Helpline and are screened for services. Eligible clients who give consent will be randomly assigned to a group.~Subjects will be randomized into one of 2 behavioral conditions: telephone counseling or self-help materials. Reading materials and written consent will be mailed to all study subjects the next business day."
223626273|NCT02437045|DRUG|Meropenem|Meropenem is a carbapenem anti-bacterial used for the treatment of serious infections in patients.
224215486|NCT01974570|DIETARY_SUPPLEMENT|Placebo|2 tablets, once per day before noon
224215487|NCT04261933|DRUG|semaglutide|Patients will be treated with commercially available semaglutide in a prefilled pen injector (FlexTouch® variant) according to routine local clinical practice at the discretion of the treating physician. Other anti-hyperglycaemic treatments will be prescribed at the physician's discretion.
223762911|NCT03752619|DEVICE|Non Contracting Producing Peripheral Nerve Stimulation|The stimulation system includes an external stimulator, percutaneous lead and pad. The stimulator snaps onto the pad. The pad has an embedded power source but also serves as the anode. The 1-channel stimulator outputs a biphasic current waveform with current pulse parameter ranges suitable for Peripheral Nerve Stimulation (PNS). The percutaneous lead is inserted using an introducer (like a hypodermic needle) which is withdrawn and the lead is retained in the muscle by a barb at its tip. After a 1-week stabilization period, stimulation is initiated (6 hrs/day). The duty cycle and daily dose remain constant, but stimulus parameters may be adjusted by the research staff as deemed appropriate. The treatment period is 3 weeks after which the lead will be removed.
223762912|NCT03752619|OTHER|Physical Therapy|All participants receive eight 1.0 hr. sessions of physical therapy (PT) over a 4-wk period from a therapist blinded to Peripheral Nerve Stimulation (PNS) treatment assignment. Each participant also performs home exercises. The primary objective of physical therapy (PT) and the home exercise program is to prevent re-injury by educating and training participants in the biomechanics and proper use of the shoulder and upper limb. During each in-lab session, participants are trained in the implementation of these exercises, which are individually adjusted and progressed with increasing external loads by using weights and elastic rubber bands.
223762913|NCT05677412|BEHAVIORAL|suggestive relaxation|suggestive story before sleep onset
223762914|NCT05677412|BEHAVIORAL|Neutral story|neutral story before sleep
223626274|NCT02437045|DRUG|Piperacillin-tazobactam combination product|Piperacillin-tazobactam is used for the treatment of patients with systemic and/or local bacterial infections.
223626275|NCT05690139|PROCEDURE|Pre-operative LSG patients|Baseline
223626276|NCT05690139|PROCEDURE|Post-operative patients 1st month|1 month after surgery
223626277|NCT05690139|PROCEDURE|Post-operative patients 3rd month|3 months after surgery
223626278|NCT05690139|PROCEDURE|Post-operative patients 6th month|6 months after surgery
223626279|NCT03820596|DRUG|Sintilimab|"To evaluate the short-term objective efficacy of sintilimab combined with chidamide in the treatment of refractory and relapsed ENKTCL patients, and to determine the MTD, DLT/RP2D of chidamide.~To evaluate the long-term efficacy and safety of sintilimab combined with chidmide in the treatment of refractory and relapsed ENKTCL patients. Exploring biomarkers that may have predictive effects."
223626280|NCT03820596|DRUG|Chidamide|"To evaluate the short-term objective efficacy of sintilimab combined with chidamide in the treatment of refractory and relapsed ENKTCL patients, and to determine the MTD, DLT/RP2D of chidamide.~To evaluate the long-term efficacy and safety of sintilimab combined with chidmide in the treatment of refractory and relapsed ENKTCL patients. Exploring biomarkers that may have predictive effects."
223626281|NCT02847377|OTHER|Injection of [18F]-ODS2004436 radiotracer|
223626282|NCT02714400|DRUG|Venlafaxine|Venlafaxine 50mg before sleep
223626283|NCT02714400|DRUG|Placebo|One piece of placebo before sleep
223626284|NCT05328609|DIETARY_SUPPLEMENT|Semaine Hormonal Imbalance & The Daily|All participants will undergo a menstrual cycle without intervention to establish a baseline, and then will be given the intervention (dietary supplement) for a second menstrual cycle.
223626285|NCT03793049|DEVICE|CADence testing will be performed|CADence is a noninvasive, handheld device comprised of acoustic and ECG technology and software
223626286|NCT01682239|OTHER|RVAP|In this arm pacemaker leads will be placed in the RV apex.
223626287|NCT01682239|OTHER|RVSP|In this arm pacemaker leads will be placed in the RV septum.
223626288|NCT04006041|DRUG|Toripalimab|Patients received toripalimab 240 mg IVDRIP on days 1 and 22 during neoadjuvant radiotherapy.
223626289|NCT04006041|DRUG|Paclitaxel/cisplatin|Patients received 4 cycles of paclitaxel/cisplatin (paclitaxel 50mg/m2 and cisplatin 25 mg/m2) on days 1, 8, 15, 22 during neoadjuvant radiotherapy.
223762915|NCT04565015|BIOLOGICAL|GC5107|Intravenously infused at a dose of 300 - 900 mg per kg (of body weight) every 21 or 28 days for 12 months
223762916|NCT06146166|DIETARY_SUPPLEMENT|Oral herbal supplement|Oral supplement containing an oral blend taken once daily
223762917|NCT06146166|DIETARY_SUPPLEMENT|Oral placebo supplement|Oral placebo supplement taken once daily
223762918|NCT06959901|BEHAVIORAL|PATHS-UP Mobile Phone Application|Youth in the intervention will be given access to a health-based mobile phone application and a remote bluetooth scale. The app is focused on promoting health education and self-monitoring. For 30 days youth will be asked to engage with content focused on promoting healthy sleep, physical activity, and dietary habits every day. Youth will also be asked to self-monitor health behaviors using the app as it pulls in data on daily steps from the accelerometer embedded within the smartphone, information on weight from daily weigh-ins using the remote scale, sleep via a weekly survey within the app, and caloric intake using a daily food log that is powered through artificial intelligence within the app.
223762919|NCT05430893|OTHER|Botulinum Toxin A|100 UI IM in the adductor longus
223762920|NCT00769847|PROCEDURE|Endoscopic strip craniectomy|Surgery
223762921|NCT00527813|PROCEDURE|prone position|prone position for at least 16 hours per day
223762922|NCT03907683|BEHAVIORAL|Short Message with Text and Optional Image|"Messages can be up to 256 characters of text and with or without an image. Move more and sit less messages were written to target established cognitive and affective constructs associated with physical activity (e.g., prompts to action plan, guidance for maximizing pleasure by regulating intensity)."
223762923|NCT03400332|DRUG|BMS-986253|Specified dose on specified days
223762924|NCT03400332|BIOLOGICAL|Nivolumab|Specified dose on specified days
223762925|NCT03400332|BIOLOGICAL|Ipilimumab|Specified dose on specified days
223762926|NCT03400332|OTHER|Placebo|Specified dose on specified days
223762927|NCT00118807|DRUG|Amodiaquine plus artesunate (AQ/AS)|
223762928|NCT00118807|DRUG|Sulfadoxine-pyrimethamine plus chloroquine (SP/CQ)|
223762929|NCT00118807|DRUG|Sulfadoxine-pyrimethamine plus amodiaquine (SP/AQ)|
223626290|NCT04006041|RADIATION|Intensity-modulated radiotherapy|All patients received external-beam radiation using intensity-modulated radiotherapy. The prescribed dose is 44 Gy in 20 fractions over 4 weeks.
223626291|NCT04006041|PROCEDURE|Esophagectomy|A transthoracic (Ivor-Lewis) esophagectomy is performed 6-8 weeks after CRT completion.
223626292|NCT03664531|OTHER|Purified gluten|1 low FODMAPs, vegan muesli bar containing purified gluten per day for 1 week, for a total of 10 g purified gluten per day.
223626293|NCT03664531|OTHER|Non-purified gluten (containing ATIs)|1 low FODMAPs, vegan muesli bar containing whole wheat flour with non-purified gluten per day for 1 week, for a total of 10 g non-purified gluten per day.
223626294|NCT03664531|OTHER|Nocebo|1 gluten-free, ATI-free, low FODMAPs, vegan muesli bar per day for 1 week. This is a nocebo because we expect that participants will feel worse even though there is no potential irritant.
223626295|NCT02435186|DRUG|p53 gene|p53 gene will be given intraperitoneally.
223626296|NCT02435186|DRUG|Cisplatin|150 mg/m\^2 cisplatin will be given intraperitoneally.
223626297|NCT02435186|DRUG|Paclitaxel|Paclitaxel (175 mg/m2, 3 h) will be given by iv
223762930|NCT06764095|PROCEDURE|Biospecimen Collection|Undergo urine and blood sample collection
223626298|NCT01760057|BEHAVIORAL|Online HIV testing motivational videos and messages sent via mobile-phone text messaging, e-mail or instant messaging|
223626299|NCT01760057|BEHAVIORAL|Standard online message with an invitation for free HIV testing similar in content to other Peruvian websites|
224215488|NCT05136456|DRUG|SHR1459 Low Dose|SHR1459 oral tablets taken once daily (QD) for 24weeks
224215489|NCT05136456|DRUG|SHR1459 High Dose|SHR1459 oral tablets taken once daily (QD) for 24 weeks
224215490|NCT05136456|DRUG|Placebo|Placebo oral tablets taken once daily (QD) for 24 weeks
224215491|NCT04886570|DEVICE|hip arthroplasty|Hip arthroplasty is a kind of joint reconstruction surgery, which has been successfully utilized for treatment of osteoarthritis or hip fracture for decades. In this surgery, implants is applied to reconstruct hip joint, and usually comprised of four components, including femoral stem, femoral head, acetabular cup and liner.
224215492|NCT06373406|DRUG|MHB036C|An antibody-drug conjugate therapy
224316893|NCT03563911|BEHAVIORAL|Control/Nutrition Education|The Control intervention will involve nutrition education, adapted from an existing manual of cognitive-behavioral therapy for opioid-treated chronic pain. Control intervention protocol will match the BMBI in terms of time / structure to control for the non-specific, non-mindfulness effects of BMBI. The 20-minute Control session will include education on the relationship between diet and pain (10 minutes) and recommendations for a healthy diet (10 minutes). Control participants will be encouraged to prepare healthy meals at home at least 20 minutes/day for 1 week (a handout and link to online resources will be provided).
224316894|NCT00976911|DRUG|Bevacizumab|10m/kg iv every 2 weeks or 15mg/kg iv every 3 weeks
223762931|NCT06764095|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
223762932|NCT06764095|PROCEDURE|Cystectomy|Undergo cytoreductive cystectomy
224316895|NCT00976911|DRUG|liposomal doxorubicin|40mg/m2 iv every 4 weeks
224316896|NCT00976911|DRUG|paclitaxel|80mg/m2 iv on days 1, 8, 15 and 22 of each 4-week cycle
224316897|NCT00976911|DRUG|topotecan|4mg/m2 iv on days 1, 8 and 15 of each 4-week cycle, or 1.25 mg/kg on days 1-5 of each 3-week cycle
224316898|NCT02101580|DRUG|ADI-PEG 20|
223626300|NCT05851651|BEHAVIORAL|Antenatal milk expression and breastfeeding self-efficacy enhancement|A face-to-face breastfeeding education in lactation clinic at 37 weeks of gestation will be arranged. The session will approximately last for 45minutes. GDM leaflet and GAME fact sheet are used to facilitate the teaching. The benefits of breastfeeding for women with GDM will be addressed. Maternal metabolic control, calories consumed, and weight loss are addressed for the extra benefits of breastfeeding for GDM women. The possible challenges of GDM on breastfeeding will be supported. The antenatal human milk expression will be taught by International Board-Certified Lactation Consultant. Participants will be encouraged to express colostrum twice daily for up to 10 minutes until admitted to hospital to give birth. They will receive a weekly phone follows up from 38 weeks before delivery and they can contact the researcher by phone in the information sheet if any questions.
223762933|NCT06764095|DRUG|Enfortumab Vedotin|Given IV
223626301|NCT03623113|BEHAVIORAL|BCC intervention|Structured training and education i basic carbohydrate counting principles
223626302|NCT03623113|BEHAVIORAL|ABC-ACC intervention|Structured training and education i advanced carbohydrate counting principles including the use of a automated bolus calculator carbohydrate
223762934|NCT06764095|PROCEDURE|Local Therapy|Undergo MDT
223762935|NCT06764095|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223626303|NCT03623113|BEHAVIORAL|Standard dietary education|Personalized individual dietary counselling based on overall meal planning, dietary guidelines and the patient's need and preferences
223626304|NCT00811161|DEVICE|Airgent|HA needle free injection, 3-4 treatments, 3-4 weeks apart
223626305|NCT00543036|DEVICE|H-Coil deep TMS|
223762936|NCT06764095|BIOLOGICAL|Pembrolizumab|Given IV
223762937|NCT06764095|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
223762938|NCT06764095|OTHER|Questionnaire Administration|Ancillary studies
223762939|NCT06764095|PROCEDURE|Ureterectomy|Undergo ureterectomy
223762940|NCT00234988|DRUG|sibutramine hydochloride monohydrate|10 mg QD with the option to increase dose to 15 mg QD up until Week 4
223762941|NCT06232421|DRUG|Foscelantan|"Foscelantan, medicinal plate 4.0x5.0 cm in package No. 1 produced by UNITEHPROM BSU, Republic of Belarus"
223762942|NCT06232421|DRUG|Povidon-iodine|Povidone-iodine solution 100 mg/ml produced by BelAseptika CJSC, Republic of Belarus
223626306|NCT02383381|PROCEDURE|lateral rectus recession|typical surgery for correcting intermittent exotropia
223626307|NCT02587520|BIOLOGICAL|Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed Formulation 1|0.5 milliliter (mL), Intramuscular
223626308|NCT02587520|BIOLOGICAL|Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed, Formulation 2|0.5 mL, Intramuscular
223626309|NCT02587520|BIOLOGICAL|Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed, Formulation 3|0.5 mL, Intramuscular
223626310|NCT02587520|BIOLOGICAL|Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed, Formulation 4|0.5 mL, Intramuscular
223762943|NCT00937417|DRUG|docetaxel|
224316899|NCT05209594|BEHAVIORAL|Healthy Relationships Program (HRP) for 2SLGBTQIA+ Youth|The Healthy Relationships Program (HRP) for Two-Spirit, Lesbian, Gay, Bisexual, Trans, Queer, Intersex, and Asexual + (2SLGBTQIA+) Youth is a small group positive mental health promotion program for gender, sexual, and romantic minority youth. It helps build resiliency and promote well-being among 2SLGBTQIA+ youth. It affirms, validates, and celebrates sexual and gender diversity, cultivates a caring and supportive community, and helps 2SLGBTQIA+ youth develop skills and strategies that promote healthy relationships. This trauma-informed, strengths-focused program explores stressors unique to 2SLGBTQIA+ youth, including identity and expression invalidation, stigma, prejudice and discrimination, internalized oppression, coming out, safety, and microaggressions. This program includes 17 sessions, each lasting approximately 45 minutes. It may be delivered in school-based Genders and Sexualities Alliances/Gay-Straight Alliances (GSA) or 2SLGBTQIA+ youth group settings.
224316900|NCT05209594|BEHAVIORAL|Standard GSA Programming|Students at comparison sites will participate in standard GSA programming, a safe space for 2SLGBTQIA+ youth and their allies to meet, develop relationships, support each other, socialize, and learn about sexuality and gender-related topics, and lobby for social change.
224316901|NCT02954991|DRUG|Glesatinib|Glesatinib is a small molecule multi-targeted receptor tyrosine kinase inhibitor
223626311|NCT02587520|BIOLOGICAL|Licensed Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed|0.5 mL, Intramuscular
223626312|NCT02587520|BIOLOGICAL|Licensed Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine|0.5 mL, Intramuscular
223680601|NCT06993727|OTHER|Blood sampling|For the analysis of the autoimmune endocrine disease related antibodies (Ab) before the start of the immunotherapy, a blood sample will be collected aligned with the first visit with the treating gastro-enterologist/oncologist/pneumologist for analysis of: anti-thyroglobulin Ab (aTg), anti-thyroperoxidase Ab (aTPO), TSH receptor antibodies (TRAb), pituitary Ab, adrenal Ab, and anti-glutamic acid decarboxylase (GAD) Ab.
223680602|NCT06993701|BEHAVIORAL|Vimala Massage Training for Fathers|Fathers will receive Vimala massage training and apply it regularly to their babies at home.
223680603|NCT06993701|OTHER|Control Intervention|babies in the control group will not receive any intervention
223680604|NCT06993701|BEHAVIORAL|Vimala Massage Training for Mothers|Mothers will receive Vimala massage training and apply it regularly to their babies at home.
223680605|NCT06995664|PROCEDURE|radiotherapy|External Beam Radiotherapy - hypofractionated, short radiotherapy regime of 30Gy in 5 fractions (6Gy per fraction) delivered on alternate days over 2 weeks
223680606|NCT06995768|OTHER|Sweat patch|Wear sweat patch during regular team sports practice session
223680607|NCT06995222|DIAGNOSTIC_TEST|renal resistive index with Doppler ultrasound|"Renal resistive index uses doppler ultrasonography which assesses blood flow velocity in the renal arteries. The Renal Resistive Index (RI) is calculated by substracting diastolic velocity from systolic velocity then dividing result by systolic velocity~Where:~Systolic velocity is the peak velocity of the blood flow during the systolic phase of the cardiac cycle.~Diastolic velocity is the velocity of blood flow during the diastolic phase."
223680608|NCT06993532|OTHER|Validity and Reliability|The TASD questionnaire, the Thumb Disability Examination (TDX) questionnaire, the Visual Analogue Scale (VAS) for pain, as well as hand grip and pinch strength measurements using the Jamar® Hydraulic Hand Dynamometer and Jamar Hydraulic Pinch Gauge Dynamometer were employed to assess thumb function and muscle strength. The questionnaires were administered twice, with a 7-day interval, during which no medical or rehabilitation intervention was made that could alter the clinical condition of the patients.
223680609|NCT06995443|OTHER|Photobiomodulation|12 sessions of photobiomodulation (1 per week) Visit 1 to 4 : photobiomodulation (NOVOTHOR) + cortical stimulation (VEILIGHT) Visit 5 to 12 : cortical stimulation (VEILIGHT)
223680610|NCT06995599|PROCEDURE|Thoracic Duct Ligation (TDL)|Following the minimally invasive right-sided lung cancer resection, during mediastinal lymph node dissection, the posterior aspect of the azygos vein is identified. The mediastinal pleura is then longitudinally incised along the medial border of the azygos vein and posterior to the esophagus. Between the azygos vein and aorta, the thoracic duct is meticulously localized as a milky-white translucent structure measuring 2-3 mm in diameter. A 5-mm segment of the duct is carefully mobilized and double-clamped with vascular clips under direct thoracoscopic visualization. The surgical field is thoroughly inspected to confirm the absence of chylous leakage, and the procedure is concluded after standard closure and confirmation of hemostasis.
223680611|NCT06988592|DRUG|GemCis plus PD-1/PD-L1 inhibitor|"Gemcitabine: 1000 mg/m², intravenous infusion, on Day 1 and Day 8 Cisplatin: 25 mg/m², intravenous infusion, on Day 1 and Day 8 PD-1/PD-L1 inhibitor: An approved agent (e.g., Pembrolizumab, Nivolumab, Atezolizumab, etc.) will be selected based on clinical practice and administered at standard doses and schedules.~Each treatment cycle lasts 21 days, continuing until disease progression, unacceptable toxicity, or patient/physician decision to discontinue."
223680612|NCT06995560|DEVICE|Active Transcranial Electrical Stimulation|Active tES delivered using the Soterix Medical MXN-33 HD-tES stimulator. Stimulation is applied via high definition electrodes targeting either the left DLPFC or L-aINS at intensities up to 1.9 mA. Stimulation is performed for up to 45 minutes during task execution. Participants perform the ROBoT-r task during stimulation.
223680613|NCT06995560|DEVICE|Sham Transcranial Electrical Stimulation|Sham tES using the same Soterix Medical MXN-33 HD-tES stimulator and electrode placements. Stimulation ramps up and down over 20 seconds to mimic sensation but provides no continuous current. Participants perform the ROBoT-R task under sham conditions.
223680614|NCT06995040|DIAGNOSTIC_TEST|Cerebral MRI without contrast agent injection|Cerebral MRI at inclusion or after
223762944|NCT00937417|DRUG|vandetanib|
224215493|NCT02926378|PROCEDURE|Acupuncture Treatments|Every participant will receive six acupuncture treatments across a three to four-week period. The treatments will last a total of about one hour, including a 10 minute initial assessment, needling, and 45 min of lying down with the needles. Two treatments a week will be performed by Dr. Siminovich-Blok, the PI of this study and a NYS licensed acupuncturist at NYU Langone Medical Center (NYULMC) Ambulatory Care Center. Each acupuncture treatment will consist of 1) a combination of a fixed set of points suggested by the literature, and 2) an individualized set of points based on the evaluation by the licensed acupuncturist. The first set of points will consist of 4 acupoints used consistently in the treatment of stroke through the literature.
223762945|NCT00937417|GENETIC|proteomic profiling|
223762946|NCT00937417|OTHER|laboratory biomarker analysis|
224215494|NCT04573400|OTHER|HADS|"The HADS is a 14-item self-report questionnaire assessing levels of anxiety (seven items) and depression (seven items) over the past week. Each question is assessed on a 4-point Likert Scale: I feel tense or 'wound up' (0= not at all 3= most of the time). Consistent with recommendations by Bjelland et al cut-off of 8 for each HADS subscale will be used to differentiate normal from mild to severe distress."
224215495|NCT04339088|OTHER|Questionnaires|Questionnaires to assess quality of life
223762947|NCT00937417|OTHER|pharmacological study|
223762948|NCT06783283|DEVICE|Transcranial Alternating Current Stimulation|Transcranial Alternating Current Stimulation (tACS) is a non-invasive electrical stimulation that will be used to stimulate the dorsolateral prefrontal cortex (dlPFC) and temporal cortices and in turn enhance Theta-Gamma Coupling (TGC) and working memory in Mild Cognitive Impairment (MCI). Each participant will receive daily stimulation for 10 days. To deliver the tACS, multiple electrodes embedded in a cap placed on the participant's head. Sham-tACS will follow the same procedure.
224215496|NCT00285415|DRUG|Docetaxel and Carboplatin|docetaxel (75 mg/m2) + carboplatin (AUC 6) IV every 3 weeks X 6 cycles
224215497|NCT04133571|DRUG|0.05% Lidocaine|0.05% lidocaine with normal saline as a bladder irrigation solution after transurethral surgery intravenous pethidine to decrease CRBD if needed
224215498|NCT00265083|BIOLOGICAL|golimumab|100 mg sc injections every 4 wks from wk 0 up to 5 yrs
224215499|NCT00265083|BIOLOGICAL|Golimumab (CNTO 148); placebo|SC injections every 4 wks thru wk 20 (unless early escape at wk 16);golimumab - if early escape, 50mg sc inj every 4wks from wk 16 up to 5yrs ;golimumab -50mg sc injection beginning wk 24 up to 5 yrs (unless early escape); golimumab- Dr's discretion after unblinding, dose adjust from 50 to 100mg
224215500|NCT00265083|BIOLOGICAL|golimumab|50 mg sc injs every 4wks from wk 0 thru 5yrs (unless early escape at wk 16); golimumab - If early escape, 100mg sc injections every 4 wks beginning wk 16 up to 5 yrs ; golimumab - Dr's discretion after unblinding, dose adjust from 50 to 100mg
224215501|NCT03208933|DRUG|Pirfenidone|Pirfenidone 2403 mg/d capsules orally will be given in divided doses (TID) after titration period of 14 days.
224215502|NCT03476447|OTHER|B. infantis EVC001|A once-daily oral feeding of B. infantis EVC001 will be mixed with breast milk and provided to infants for 28 consecutive days.
223762949|NCT06783283|DEVICE|Sham tACS|During sham-tACS, the device will ramp up to the desired intensity over 60 seconds, and then will immediately ramp down, and the stimulation will be shut off, until the end of the session. At the end of the session, the device will again ramp up for 60 seconds and then ramp down. Sham-tACS will also target dlPFC and temporal cortices (similar to active). Each participant will receive daily sham-tACS for 10 days. To deliver the sham-tACS, multiple electrodes will be embedded in a cap placed on the participant's head.
223762950|NCT03901963|DRUG|Daratumumab|Daratumumab 1800 mg will be administered by SC injection weekly during Cycles 1 and 2, every 2 weeks during Cycles 3 through 6, and every 4 weeks from Cycle 7 onward until confirmed progressive disease (PD), unacceptable toxicity, or until end of study treatment for a maximum of 36 cycles.
223762951|NCT03901963|DRUG|Lenalidomide|Lenalidomide 10 mg will be administered orally from Day 1 to Day 28 (continuously) of each 28-day cycle until confirmed PD, unacceptable toxicity, or until end of study treatment for a maximum of 36 cycles. After 3 cycles of maintenance therapy, if well tolerated, the lenalidomide dose may be increased to 15 mg daily, at the discretion of the investigator.
223762952|NCT05634811|BIOLOGICAL|VLA15|6-valent OspA-based Lyme disease vaccine
223762953|NCT05634811|OTHER|Normal Saline|0.9% sodium chloride solution for injection
223762954|NCT01188577|DRUG|Epinephrine Inhalation Aerosol, HFA|10 inhalations of epinephrine inhalation aerosol, 125 mcg/inhalation
223762955|NCT01188577|DRUG|Epinephrine Inhalation Aerosol|Epinephrine Inhalation Aerosol, 220 mcg/ inhalation, 10 inhalations
224316902|NCT02954991|DRUG|Sitravatinib|Sitravatinib is a small molecule inhibitor of receptor tyrosine kinases.
224316903|NCT02954991|DRUG|Mocetinostat|Mocetinostat is an HDAC inhibitor.
224316904|NCT02954991|DRUG|Nivolumab|nivolumab is a programmed death receptor-1 (PD-1) blocking antibody
223513899|NCT03390491|BEHAVIORAL|Recovery Videos (RV)|As described, RV clients will have access to a website that includes recovery videos and static psychoeducation materials. In this condition, mental health providers will also ask about possible reactions to viewing the recovery videos and information on the website.
223513900|NCT02801773|DIETARY_SUPPLEMENT|Treatment Gingivitis with Probiotic|Gingivitis Treatment (scaling and coronary polish) and one lozenge containing Lactobacillus reuteri per day during 3 months
223513901|NCT02801773|OTHER|Treatment Gingivitis conventional|gingivis treatment (scaling and coronary polish) and and one lozenge containing Placebo (mint lozenge) per day during 3 months
223513902|NCT00600782|BIOLOGICAL|GSK Biologicals' Candidate Tuberculosis (TB) Vaccine (692342)|Intramuscular injection, 2 doses at 0, 1 month
223513903|NCT02380872|PROCEDURE|Connective tissue graft|gingival recession treated with connective tissue graft
223513904|NCT02380872|PROCEDURE|Platelet Rich Fibrin|gingival recession treated with platelet rich fibrin
223513905|NCT01321645|DRUG|Azadirachta Indica|To start with subjects will be prescribed Azadirachta Indica in 6 potency to be taken in form of pills 4 times a day for seven days. Dosage and frequency will be changed, if required, based on the condition of subject and their response according to homoeopathic principles.
223513906|NCT01909401|DRUG|boceprevir|
223513907|NCT00308282|DRUG|LY2127399|30 mg, 60 mg or 160 mg, IV (in the vein) in weeks 0, 3 and 6. Treatment duration: 6 weeks.
223513908|NCT00308282|DRUG|Placebo|IV (in vein) in weeks 0, 3 and 6. Treatment duration: 6 weeks.
224215503|NCT03476447|OTHER|Lactose|A once-daily oral feeding of a lactose placebo will be mixed with breast milk and provided to infants for 28 consecutive days.
224215504|NCT04901754|DRUG|Camrelizumab Plus Apatinib|"-Drug: camrelizumab Camrelizumab intravenous infusion was administered at a dose of 200 mg on Day 1 of each 21-day cycle,until PD.~Other Name: SHR-1210~-Drug: Apatinib Mesylate Apatinib capsules 250 mg given orally , once daily in 21-day cycle ,until PD."
224215505|NCT02214498|DRUG|Enalapril/hydrochlorothiazide|The intervention implies that morning and evening administration of enalapril/hydrochlorothiazide will be compared
224215506|NCT02214498|DRUG|Placebo|
224215507|NCT03836274|DIETARY_SUPPLEMENT|AYMES MONACO|AYMES MONACO is a Food for Special Medical Purposes (FSMP) and must, therefore, be used under medical supervision. It is not designed as a sole source of nutrition.
224215508|NCT06529640|PROCEDURE|SCTG followed by coronally postionting flap|The SCTG will be harvested from the palate followed by coronally postionting flap
224215509|NCT06529640|PROCEDURE|periosteal flap followed by coronally postionting flap|he periosteal pedicle graft obtained is then turned over the exposed root surface then followed by coronally postionting flap
224215510|NCT00407043|DRUG|Lotemax|
224215511|NCT00407043|DRUG|Restasis|
224215512|NCT04242186|OTHER|Injury Liaison Service|The Injury Liaison Service nurse will coordinate deprescribing of fall-related medications, osteoporosis management, staff support of behavior management using video case conferencing, and shared decision making with residents and/or families.
224215513|NCT02757534|DRUG|Domperidone|The study drug will be given to relieve the symptoms of gastroparesis, including nausea and vomiting.
224215514|NCT01980082|DRUG|Cefazolin|Antibiotic
224215515|NCT01980082|DRUG|Placebo|Placebo
224215516|NCT02952794|PROCEDURE|endoscopic submucosal dissection (ESD) and endoscopic mucosal band ligation (EMBL) for early cancer|
224215517|NCT00004161|DRUG|fenretinide|
224215518|NCT00004161|DRUG|Placebo|
224215519|NCT00047294|DRUG|celecoxib|
224215520|NCT00047294|DRUG|temozolomide|
224215521|NCT00047294|DRUG|thalidomide|
224215522|NCT00047294|PROCEDURE|adjuvant therapy|
224215523|NCT05585619|OTHER|Pain treatment|Any pain treatment to include medications, procedures, or referrals
223680615|NCT06995040|GENETIC|saliva sample|Saliva sample for DNA analysis at inclusion or send to their home.
224215524|NCT01797419|DRUG|GS-5806|Single dose, oral liquid, .5 mL/kg
224215525|NCT01797419|DRUG|Placebo|Single dose, oral liquid, .5 mL/kg
224316905|NCT06079567|DIAGNOSTIC_TEST|Validation of new COMs for FSHD2 patients|Monitoring of commonly used and new COMs in FSHD2 patients
224316906|NCT00576316|DRUG|Symbicort Turbuhaler 160/4.5|
223513909|NCT00949936|DEVICE|CAdisc™-L (Total Disc Replacement)|
223513910|NCT04663217|OTHER|Exercise|After placement of the right heart catheter patients will undergo an exercise challenge in semi-supine position until exhaustion
223680616|NCT06995040|OTHER|Questionnaires|Quality of life and cognitive questionnaires at inclusion
223680617|NCT06995157|BIOLOGICAL|Offering HPV vaccine|During regular cervical cancer prevention visit with the gynecologist, HPV vaccine will be offered to participants 35 years or younger.
223680618|NCT06995287|DRUG|Xeomin|One injection will be performed via hysteroscopy under local anesthesia.
223680619|NCT06995287|DRUG|Placebo|One injection will be performed via hysteroscopy under local anesthesia.
223680620|NCT05463367|DRUG|Carbidopa-Levodopa 25 Mg-100 Mg Oral Tablet|Subjects will receive a single dose of carbidopa/levodopa, when applicable.This will be double-blinded, as neither participants nor study staff will know what medication the participant is receiving.
223680621|NCT05463367|DRUG|Naproxen 500 Mg|Subjects will receive a single dose of naproxen 500mg alongside carbidopa/levodopa, when applicable.This will be double-blinded, as neither participants nor study staff will know what medication the participant is receiving.
223680622|NCT05463367|DRUG|Opioids|Subjects will be pre-screened in regards to their opioid medication. They will receive a single dose of their opioid dose, when appropriate. This will be double-blinded, as neither participants nor study staff will know what medication the participant is receiving.
223680623|NCT04081896|OTHER|Exercise|"Exercise prescribed to participants includes spine-specific strengthening exercises targeting core musculature (i.e. Multifidus, Erector Spinae, Transversus Abdominus, Obliques, and Rectus Abdominus). The in-clinic exercise program recommends a minimum of 20 visits at 2 visits/week, with a goal of 24 total visits over a 12-week period. Exercise is progressed by 5-10% of their exercise load once they are able to do \>20 repetitions. If they are able to reach \>10 but \<20 repetitions, exercise load remains the same. If they are unable to reach 10 repetitions, exercise load is decreased 5-10% at their next visit.~The online exercise program includes non-machine based home exercises targeting the same muscles of interest, and are personalized to each participant based on their home resources and comfort level.~Concurrent interventions may or may not include nutrition education, mindfulness, cognitive behavioral therapy."
223680624|NCT06326489|DEVICE|Switching to the Medtronic 780G insulin pump|Patients using a Medtronic 740G insulin pump will receive the 780G model for three months
223680625|NCT00717444|BEHAVIORAL|contingency management|"contingency management for abstinence plus 12-step facilitation therapy~prizes awarded for target behaviors"
223680626|NCT00717444|BEHAVIORAL|contingency management|"contingency management for abstinence plus 12-step facilitation therapy and contingency management for completing healthy activities~prizes awarded for target behaviors"
223680627|NCT01074905|DRUG|Artesunate|2 mg/kg/day as single daily dose given for 5 days; maximum dose range is 1.6 to 2.4 mg/kg/day or a total of 8 to 12 mg/kg.
223680628|NCT01074905|DRUG|Chloroquine|25 mg base/kg given in divided doses (10,10,5) over 3 days; Absolute range 20-30 mg/kg.
223680629|NCT01074905|DRUG|Chloroquine/Primaquine|Chloroquine 3 days and Primaquine 14 days
223680630|NCT01848197|DRUG|paclitaxel|
223680631|NCT03529812|BEHAVIORAL|CBCT-informed training|Cognitively-Based Compassion Training (CBCT) is a secularized compassion meditation program adapted from the Tibetan Buddhist mind training (lojong) tradition. Lojong practices utilize a cognitive, analytic approach to challenge one's unexamined thoughts and emotions toward other people, with the long-term goal of developing altruistic emotions and behavior towards all people.
223680632|NCT01322308|DRUG|pioglitazone|30 mg tablet QD (taken once daily)
223762956|NCT05582018|DEVICE|BioTraceIO 360|Use of the device for planning, monitoring and assessment of liver tissue ablations
223762957|NCT06422767|DRUG|Bepirovirsen|Bepirovirsen will be administered.
223762958|NCT06422767|DRUG|Placebo|Placebo will be administered.
223762959|NCT02917083|GENETIC|CAR T Cells|"Three dose levels will be evaluated based on safety data from our current study of CD30 CAR T cells. Cohorts of three to six patients will be enrolled at each dose level. Each patient will receive one infusion of CAR modified T cells according to the following dosing schedule:~Dose Level One: 2x10\^7 cells/m2. Dose Level Two: 1x10\^8 cells/m2. Dose Level Three: 2x10\^8 cells/m2."
223762960|NCT04081792|PROCEDURE|Antibiotic therapy|Postoperative randomizations regarding the duration of systemic antibiotics
223762961|NCT05904093|DRUG|Fostamatinib|Fostamatinib will be administered orally, at a dose of 100 mg twice a day for 14 days and if tolerated, will be escalated to a dose of 150 mg, orally, twice a day for 28 days (total 42 days).
223762962|NCT05292378|OTHER|2500 ppm Carbon Dioxide|2.5 hour exposure to 2500 ppm carbon dioxide
223762963|NCT05292378|OTHER|600 ppm Carbon Dioxide|2.5 hour exposure to 600 ppm carbon dioxide
223762964|NCT04848571|COMBINATION_PRODUCT|Fetal Protection Pill|A Chinese medicine used in pregnant women for fetal protection, including mainly Rehmannia glutinosa.
223762965|NCT02650986|DRUG|Cyclophosphamide|Given IV
223762966|NCT02650986|DRUG|Decitabine|Given IV
224215526|NCT02976012|DRUG|Aflibercept|. Study eyes will receive one preoperative intravitreal aflibercept injection (IAI) \<21 days prior to vitrectomy and one intraoperative intravitreal aflibercept at end of surgery. Eyes will be randomized on the day of surgery or 1-2 weeks post-operatively to either a q8week IAI dosing regimen group or a q16week IAI dosing regimen group.
224215527|NCT02976012|PROCEDURE|Endolaserless Vitrectomy|Endolaserless vitrectomy and intraoperative and postoperative IAI in patients with PDR-related vitreous hemorrhage
223762967|NCT02650986|OTHER|Laboratory Biomarker Analysis|Correlative studies
224316907|NCT06410235|OTHER|Thoracic manipulation and exercise program|The group received exercises and manipulation with physiotherapist follow-up for eight weeks and thoracic manipulation was performed once a week.
224316908|NCT06410235|OTHER|exercise program|The group received exercise
223762968|NCT02650986|PROCEDURE|Leukapheresis|Undergo leukapheresis
223762969|NCT02650986|BIOLOGICAL|TGFbDNRII-transduced Autologous Tumor Infiltrating Lymphocytes|Given IV
223513911|NCT04268212|DIETARY_SUPPLEMENT|Bitter melon juice (100 ml)|Fresh bitter melon fruits were purchased from certified local groceries. The seeds of bitter melon were removed, and the juice was obtained from the raw fruit using a blender. Every 140 g of bitter melon fruit produced approximately 100 ml bitter melon juice.
223513912|NCT04268212|BEHAVIORAL|Exercise|The walking exercise was started 15 minutes after the glucose load. Walking speed was determined to elicit 65% of the maximum heart rate (HRmax) during exercise for each participant. HRmax was estimated using the America College of Cardiology prediction model, HRmax=208 - 0.7 × age. All participants wore a heart rate monitor (Polar, Vantage, XL) around the chest to assess exercise intensity. A rate of perceived exertion was assessed every 2 minutes based on the Borg's scale.
223513913|NCT06131463|DEVICE|Electrocardiogram (ECG) feature in smart watches|A study participant that is randomly assigned to the experimental group should enable the ECG function on his or her smart watch and make sure that there is synchronization with a corresponding application on his or her mobile phone. The ECG function must stay enabled, and the participant should wear the smartwatch every day for 30 days.
223513914|NCT03782103|DRUG|ZuraPrep Clear Solution|Apply topically.
223513915|NCT03782103|DRUG|ChloraPrep|Apply topically.
223513916|NCT03782103|DRUG|ZuraPrep Vehicle|Apply topically.
223513917|NCT04612621|DIAGNOSTIC_TEST|combination of diagnostic tests|capsule endoscopy, MRE , intestinal ultrasound, fecal microbiota, blood and serum biomarkers as described
223513918|NCT01260415|DRUG|Panitumumab, Oxaliplatin, 5-FU|"* Panitumumab 6 mg / kg, given over 60 minutes~* Oxaliplatin 85 mg / m2 combined with leucovorin 400 mg / m2, given over 2 hours OR~* Irinotecan 180 mg / m2 , given over 90 minutes, concurrent with leucovorin 400 mg / m2, given over 90 minutes~* 5FU 400 mg / m2, by bolus infusion~* 5FU 2400 mg / m2, given over 46 hours"
223513919|NCT00211900|BIOLOGICAL|S. aureus Type 5 & 8 Capsular Polysaccharide Vaccine|single IM dose totalling 200 mcg of conjugate
223513920|NCT00270569|DRUG|PhyxolTM, Cisplatin|
223513921|NCT00930176|BIOLOGICAL|Human Coagulation FACTOR X|Standard dose 25IU/kg to be administered at the Baseline Visit (1st PK assessment) and at the repeat PK assessment. Also administered to treat a bleed or to prevent a bleed.
223762970|NCT06548412|DRUG|Gemcitabine|Given by IV
223762971|NCT06548412|DRUG|Cisplatin|Given by IV
223762972|NCT06548412|DRUG|Durvalumab|Given by IV
223762973|NCT06548412|DRUG|CTX-009|Given by IV
223762974|NCT06003127|DEVICE|Transcranial Magnetic Stimulation-Electroencephalography|Transcranial magnetic stimulation of the cerebral cortex and measurement of TMS-evoked potentials in the EEG.
223762975|NCT03263208|DRUG|Cyclophosphamide|patients will receive a standard pre-conditioning regime with cyclophosphamide 0.6-0.8g/m2/day IV for 2 days(Day-5 to day-4).
223762976|NCT03263208|DRUG|Fludarabine|Fludarabine 25-30mg/m2/day IV for 3 days(Day-5 to day-3).
223762977|NCT03263208|BIOLOGICAL|CD19 CAR-T|CD19 CAR-T cells will be administered after completion of the chemotherapy.
223762978|NCT02018458|BIOLOGICAL|LA TNBC: DC vaccine+Preop chemo|LA TNBC patients will receive standard preop AC followed by TCb chemo for 24 weeks. Chemo and DC vaccinations will be given intratumoral and subcutaneous for 4 times prior surgery. During the AC cycles, vaccines will be given on any day between Days 9-12 of Cycles 1 and 3 of AC. Vaccines will be given on any day between Days 11-15 of Cycles 1 and 3 of TCb. Patients will undergo biopsies of their cancer prior to treatment and 1-2 days prior to or on Day 1 of Cycle 4 of AC. After this, patients will have surgery, locoregional radiation therapy to the breast or chest wall and regional lymphatics per standard of care, and will receive 3 boost DC vaccinations subcutaneously, rotating injection sites in the upper arm. The 1st vaccination will occur after the surgery and prior to radiation; 2nd will occur 30 days ± 3 days after radiation; the 3rd will occur 90 days ± 3 days after the 2nd boost.
224316909|NCT05576883|BEHAVIORAL|Transdiagnostic emotion regulation intervention|"The intervention under study includes 5 therapeutic approaches, namely: Positive psychology \[PP\], Mindfulness, Acceptance and Commitment Therapy \[ACT\], Breathing and relaxation, and Self-compassion \[SC\].~The intervention consists of 4 core features:~(i) monitoring through filling in EMAs assessing participants emotional states~(ii) feedback through visualization of participant emotional states upon every completion of the EMAs~(iii) exercises targeting different emotion regulation skills \[i.e., upregulation of positive affect, mindfulness, cognitive defusion, breathing and relaxation, self-compassion) and health facts (i.e., control intervention) describing health information including nutrition, exercise, sleeping habits.~(iv) psychoeducative articles describing the 5 therapeutic approaches (PP, ACT, Mindfulness, Breathing and Relaxation, SC)"
224316910|NCT01624701|OTHER|Ex vivo expanded cord blood cells|Cord blood cells will be expanded ex vivo using a combination of stem cell factor (SCF), thrombopoietin (TPO), Flt3 ligand and IGFBP2 with mesenchymal stromal cell (MSC) co-culture.
223626313|NCT03866070|OTHER|Experimental|Two exercises will be done to strengthen the external rotation (using elastic bands): standing with 90 degrees of shoulder abduction and elbow flexion and also in standing with the shoulder in neutral position and the elbow flexed to 90 degrees. Subjects will perform 3 sets of 10 repetitions with the band slightly stretched, at a distance of 0.70 m from the wall. Dumbbell exercises will be performed through 4 exercises: flexion in the horizontal plane of 135º, external rotation in lateral decubitus, horizontal abduction with external rotation, and extension in prone position. There will be 5 repetitions each exercise of 3 seconds each, with 2 minutes of rest between exercises.
223626314|NCT03866070|OTHER|Control|Two exercises will be done to strengthen the external rotation, using elastic bands. The first, standing, with 90 degrees of shoulder abduction and elbow flexion. The second, also in standing, with the shoulder in neutral position and the elbow flexed to 90 degrees. Subjects will perform 3 sets of 10 repetitions with the band slightly stretched, at a distance of 0.70 m from the wall. The band will be subject to a surface, at an equal distance from the subject's elbow to the ground. The repetitions will last one second in concentric external rotation and two seconds in eccentric external rotation, with a rest of 30 seconds between series.
223626315|NCT03976765|OTHER|Rehabilitation program|The patients follow different rehabilitation programs (surgery, anesthetic, post-operative). Hospital discharge is authorized only after validation of objective, clinical and para clinic criteria
223626316|NCT00167115|DRUG|Alcohol|
224316911|NCT04130750|COMBINATION_PRODUCT|treatment of drug screening|Patients in experimental group will receive a drug screening in vitro to select sensitive chemotherapy drug. And neoadjuvant chemotherapy will be performed according the results of drug screening.
224215528|NCT04537702|BEHAVIORAL|Streamlined Education|After completion of the baseline surveys, the SG subjects will watch an approximately eight minute long genetics education video. This video will be made with the assistance of Duke University genetic counselors and gynecologic oncology providers. It will consist of a discussion of genes and mutations, the recommendation of universal testing for high grade epithelial ovarian cancer, a review of genes associated with ovarian cancer predisposition, the possibility of uncertain results including variants of undetermined significance, the potential for undetected mutations in known or unknown cancer susceptibility genes, the potential impact on personal treatment and on family members, the possibility of genetic discrimination and the legal protection of genetic information.
224316912|NCT03876262|DRUG|Moxidectin|2mg tablets, encapsulated for blinding
224316913|NCT03876262|DRUG|Ivermectin|3mg tablets, encapsulated for blinding
224316914|NCT02220062|PROCEDURE|EUS-CPN|After initially identifying the celiac trunk on endoscopic ultrasound, each injection of 5\~10cc ethanol would be performed as bilateral injections at the celiac trunk.
224316915|NCT02220062|PROCEDURE|EUS-CGN|First, identify celiac ganglia. If the celiac ganglia are visualized under linear EUS, the injection of 2\~3cc ethanol are applied directly into the each ganglia. If the ganglia are not identified by EUS, bilateral EUS-CPN would be performed
224316916|NCT01577589|DRUG|600 mg ceftaroline fosamil in 50 ml infusion volume|IV infusion
224316917|NCT01577589|DRUG|Placebo in 50 ml infusion volume|IV infusion
224316918|NCT01577589|DRUG|600 ceftaroline fosamil in 250 ml infusion volume|IV infusion
224316919|NCT01577589|DRUG|Placebo in 250 ml infusion volume|IV infusion
224316920|NCT01577589|DRUG|600 mg ceftaroline in 100 ml infusion volume|IV infusion
223626317|NCT02572544|DEVICE|Trayner Pinhole Glasses (Trayner Glasses, Ivybridge Devon, U.K.)|Wearing multiple and single pinhole glasses
223626318|NCT02237326|PROCEDURE|Visual Inspection with Acetic Acid|Visual Inspection with Acetic Acid is the application of acetic acid to a cervix, followed by examination with a light source. It is not a new drug or device, and has been used in resource-limited settings for several decades. The purpose of this trial is to compare the two screening techniques, which had not been done previously.
223626319|NCT02237326|PROCEDURE|Visual Inspection with Lugol's Iodine|Visual Inspection with Lugol's Iodine is the application of lugol's iodine to a woman's cervix, followed by examination with a light source with the goal of detecting precancerous lesions. Like Visual Inspection with Acetic Acid, it is not a new drug or device.
223680633|NCT01322308|DRUG|placebo|tablet taken once a day
223680634|NCT01481129|DRUG|Akt Inhibitor MK2206|Given PO
223680635|NCT01481129|OTHER|Laboratory Biomarker Analysis|Correlative studies
223680636|NCT01481129|OTHER|Pharmacological Study|Correlative studies
224316921|NCT01577589|DRUG|Placebo in 100 ml infusion volume|IV infusion
224316922|NCT06486857|DIAGNOSTIC_TEST|a novel gas detection method for dyslipidemia screening|Multidimensional Mass Spectrometry Technologies Based on Exhaled Metabolic Fingerprint Spectra for Dyslipidemia Detection
224316923|NCT00967460|BEHAVIORAL|Lifestyle intervention|Promoting unstructured spontaneous physical in childcare through an adaptation of the built environment and the provision of a supportive social environment
224316924|NCT01823601|BEHAVIORAL|Behavioral Management Program|Consists in 10 Sessions of 120 minutes of duration, to train diaphragmatic breathing; autogenic training of muscle relaxation; progressive self-focus meditation and cognitive-behavioral training.
224316925|NCT01823601|BEHAVIORAL|Seminars in Health|Volunteers that participate in 10 weekly sessions of seminars in health
224316926|NCT05467696|DRUG|CTP-543|For each period, subjects will be dosed with CTP-543 12 mg (1 x 12 mg tablet)
224316927|NCT05321641|BEHAVIORAL|Mobile phone message reminders.|Utilising mobile messaging service to send reminders to people with epilepsy to take antiseizure medications and sending reminders to primary health facilities to restock anti-seizure medications.
223626320|NCT05118971|DIAGNOSTIC_TEST|muscle activation of the vastus lateralis, vastus medialis, gluteus medius, tibialis anterior, rectus abdominis and paravertebral muscles|understand the pattern of muscle activation during modalities used in this study with the selected population, it becomes extremely important, allowing the quantification of muscle functions and, therefore, prescribing exercises more adequately to achieve therapeutic goals.
223626321|NCT00315835|DRUG|Buprenorphine transdermal delivery system|
223626322|NCT05690451|DIAGNOSTIC_TEST|non-contrast abbreviated MRI|"Liver MRI without contrast injection. The following sequences will be obtained from all of the participants.~* Axial heavily and regular T2 WI~* precontrast fat-suppressed T1 WI~* Diffusion-weighted image using b-value of 0, 50 or 400, and 800 or 1000"
223626323|NCT05690451|DIAGNOSTIC_TEST|Contrast enhanced liver CT|"Liver CT with iodine contrast injection This test will be served as a standard diagnostic test. The following phases will be obtained~* precontast, arterial phase, portal venous phase and delayed phase"
223626324|NCT03868215|DIAGNOSTIC_TEST|Next-generation sequencing (NGS)|NGS test for colorectal tumor-specific plasma ctDNA methylation markers prior to endoscopy and before surgical resection.
223626325|NCT04620785|OTHER|methylene blue / IPL|therapeutic
223626326|NCT04620785|OTHER|IPL|therapeutic
223626327|NCT04620785|OTHER|saline|placebo
223762979|NCT02018458|BIOLOGICAL|ER+/HER2-BC:DC vaccine+Preop chemo|ER+/HER2- BC patients will receive standard preop AC followed by weekly T given for 22 weeks. Chemo and DC vaccinations will be given intratumoral and subcutaneous, for 4 times prior surgery. During the AC cycles, vaccines will be given any day between Days 9-12 of Cycles 1 and 3 of AC. Vaccines will be given on Day 1 during Cycle 2 or Cycle 3 and on Day 1 during either Cycle 8 or Cycle 9 of T. Vaccine will be given after T infusion is completed. Patients will undergo biopsies of their cancer prior to treatment and 1-2 days prior to or on Day 1 of Cycle 4 of AC. Patients will have surgery, locoregional radiation therapy to the breast or chest wall and regional lymphatics per standard of care, and will receive 3 boost DC vaccinations subcutaneously, rotating injection sites in the upper arm. The 1st vaccination will occur after surgery and prior to radiation; the 2nd will occur 30 days ± 3 days after radiation; and the 3rd will occur 90 days ± 3 days after the 2nd boost.
224316928|NCT01161134|DRUG|Meloxicam|Meloxicam Tablets 15 mg
224316929|NCT02193334|DRUG|KP-100IT|
224316930|NCT02193334|DRUG|Placebo|
223626328|NCT00208728|DEVICE|PC/SMART cardiopulmonary bypass circuit|
223626329|NCT00208728|DEVICE|PMEA modified cardiopulmonary bypass circuit|
223626330|NCT00208728|DEVICE|Standard of care uncoated cardiopulmonary bypass circuit|
224316931|NCT04795596|PROCEDURE|secondary cytoreductive surgery|resection of isolated recurrent ovarian carcinoma in platinum resistant disease
224316932|NCT04795596|DRUG|Chemotherapy|second line chemotherapy according to investigator's choice
224316933|NCT04831359|DEVICE|Doppler ultrasound|Tissue Doppler ultrasound on pediatric patients
224316934|NCT00026299|DRUG|ZD1839|
224316935|NCT00026299|DRUG|oxaliplatin|
224316936|NCT01105871|DRUG|naloxone|4 mg naloxone in 10 ml saline given iv bolus
224316937|NCT01105871|DRUG|Placebo|10 ml of normal saline iv bolus
224316938|NCT06173271|DIETARY_SUPPLEMENT|multi-intervention program and protein foods supplementation|This study aimed to investigate the effects of a multi-intervention program (protein-rich food supplement, nutrition education, and exercise) on reducing the risk of sarcopenia.
224316939|NCT04414345|DRUG|CNM-Au8|"Drug: CNM-Au8~Administration: Oral~Dosage: 30 mg or 60 mg daily"
223626331|NCT05427981|DRUG|Belbuca Buccal Product|Buprenorphine Buccal Films
223626332|NCT05427981|OTHER|Placebo|Placebo Buccal Films
223626333|NCT03924622|DEVICE|Mepilex|Mepilex Border Sacrum dressing is a multi-layered soft silicone dressing that is a recommended strategy to augment standard nursing interventions (i.e., repositioning, offloading) to prevent pressure injuries. The dressing will be placed on the sacrum.
224316940|NCT04414345|DRUG|Matching Placebo|"Drug: Matching Placebo~Administration: Oral~Dosage: 2 bottles daily"
223626334|NCT03924622|DEVICE|LiquiCell|LiquiCell is a thin layer of low-viscosity fluid contained in a series of bursa-like pouches. Baffles within each pouch channel the liquid to disperse pressure and the volume of liquid in the pouch is so small that there is no pressure-build up. LiquiCell is available commercially as a 36 X 18-inch mattress overlay (LiquiCell Shear Reducing Mattress Overlay) with a soft pliable top and a non-slip bottom. The overlay is positioned from the shoulders to below the hips to minimize shear.
223626335|NCT04446416|DEVICE|NaviFUS System|Open the BBB using focused ultrasound and contrast agent SonoVue®
223626336|NCT04446416|DRUG|Bevacizumab|An anti-angiogenic agent to block tumor growth
223626337|NCT06322849|BEHAVIORAL|Psychoeducation|Psychoeducation is a potential active element of Project ABC. In psychoeducation, participants learn about the cognitive model of behavior and how they can take action to change their moods.
223626338|NCT06322849|BEHAVIORAL|Testimonials and Saying is believing exercises|Testimonials and Saying is believing exercises is a potential active element of Project ABC. In this element, participants learn about how others have taken action to improve their mood and complete one exercise where they give advice to a virtual peer who is stuck in a negative spiral.
223626339|NCT06322849|BEHAVIORAL|Action planning|Action planning is a potential active element of Project ABC. In this element, participants plan in detail an action they can take to get out of the negative mood spiral.
223626340|NCT06322849|BEHAVIORAL|Breathing exercise|Participants will be presented with a one-minute breathing exercise.
223626341|NCT02398916|BEHAVIORAL|Music listening|
224316941|NCT00001605|BIOLOGICAL|Nontypeable Haemophilus influenzae|
224316942|NCT05529446|DEVICE|Combination therapy (CT)|Two therapeutic modalities at the same site is described as combination therapy (CT). The most commonly used CT is US \& TENS where this approach was effective in pain modulation
224316943|NCT04573114|PROCEDURE|Verticalization|Progressive levels of verticalization
224316944|NCT01935518|DRUG|Fasudil|All the patients will take the fasudil treatment for 14 days (30mg twice a day, intravenous). 3 months later they will repeat the treatment mentioned before.
223626342|NCT04166422|OTHER|Cardiac rehabilitation program|Aerobic treatment plus strength exercises
223626343|NCT04166422|OTHER|Experimental intervention|Aerobic treatment plus strengh exercises plus virtual reality
223626344|NCT04992312|DRUG|Glucagon Nasal Powder [Baqsimi]|Administered intranasally
223626345|NCT05782868|OTHER|Expressive writing in response to vignette|Participants will read a vignette, which describes the experience and response of a young adult who experiences rejection from a close friend after a first disclosure of their gender identity. Participants will then be asked to write in response to three prompts: 1) identify expressions of internalized transphobia in the vignette character, 2) reflect on times the participant has experienced similar feelings, 3) identify thoughts and feelings that promote and support a positive and affirming identity in contrast to negative emotions and thoughts.
223626346|NCT05782868|OTHER|Expressive writing about events of the day|Participants in the control condition will be asked to write about the events of their day and thoughts and feelings that occurred in response to those events.
223762980|NCT02857452|OTHER|SLA Questionnaire|
223762981|NCT02857452|OTHER|Lupus Qol Questionnaire|
223626347|NCT05782868|OTHER|Letter of Gratitude|Participants will be directed to compose a brief letter of gratitude to an individual to whom they have not previously expressed gratitude, and who has provided meaningful and affirming support to them as a TNB person.
223762982|NCT04364529|OTHER|The pit crew model|The pit crew model
223762983|NCT02509065|DEVICE|Bionic Pancreas|Participant wears the bionic pancreas, including an insulin and/or glucagon pump depending on which arm they are in. The 100 mg/dl arm for type 1 diabetes patients will deliver insulin and glucagon. The 100 mg/dl arm for type 2 diabetes patients will deliver just insulin. The 115 mg/dl arm will deliver insulin and glucagon. The 120 mg/dl arm will deliver just insulin. The 145 mg/dl arm will deliver just insulin. The 130 mg/dl and 110 mg/dl arms will deliver insulin and placebo, or insulin and glucagon, and will be double blinded.
223762984|NCT02509065|OTHER|Usual Care|Participant cares for their diabetes according to their usual practice, with blinded CGM monitoring. No medication will be administered by the study in this intervention.
224215529|NCT04537702|BEHAVIORAL|Traditional Education|The TG subjects will then meet with the genetic counselor at the previously scheduled appointment time. During this visit, they will receive approximately thirty to sixty minutes of counseling regarding genetic testing and potential results. The discussion is based on the American Society of Clinical Oncology (ASCO) and National Comprehensive Cancer Network (NCCN) guidelines of informed consent for genetic testing. After counseling, participants will be given the option to undergo a multi-gene panel genetic test either via saliva or blood sample. Those who agree to testing will also complete the standard genetic testing consent form. As per standard practice of the clinical genetic service at DCI, patients will also be asked to provide consent for somatic tumor testing of surgical specimen (non-cytologic).
224215530|NCT04928833|OTHER|Pilates Training|Pilates training was carried out as group exercises for about 1 hour, 3 days a week for 8 weeks. Before starting the exercise training, all subjects were taught the key elements of Pilates in 1 session. Pilates training started with standing exercises for warming up and centering in the supine position. Training continued with upper and lower extremity movements. The intensity of the exercises was increased using different positions and elastic bands. Stretching exercises and posture exercises were used during the cooling period. All exercises were started with 10 repetitions and then increased to 20. In order for the patients to perform the movements correctly, each movement was first demonstrated by the physiotherapist. The movements that the patients could not do were applied by modifying them in a suitable way.
223762985|NCT03382483|DEVICE|Low intensity pulsed ultrasound|bone growth stimulator
224215531|NCT04928833|OTHER|Control group|Breathing exercises, active range of motion exercises and relaxation exercises were given to the control group as a home program. They were asked to do the exercises 3 days a week for 8 weeks.
223626348|NCT02412306|DRUG|Blinatumomab|Continuous intravenous infusion over four weeks per treatment cycle
223762986|NCT01718756|DRUG|Placebo|The placebo group received 12 hourly 20-mL i.v. boluses of 0.9% saline starting 20 min before induction of anaesthesia, followed by a constant infusion at 10 mL/h, for 48 hrs after surgery.
223762987|NCT01718756|DRUG|Continuous infusion|"The continuous infusion group received 20-mL i.v. boluses of lornoxicam 0.8 mg/mL starting 20 min before induction of anaesthesia followed by a 12 hourly 20-mL i.v. boluses of 0.9% saline and a constant infusion at 10 mL/h of lornoxicam 0.13 mg/mL, for 48 hrs. after surgery"
223762988|NCT01718756|DRUG|Scheduled|"The scheduled group received an 12 hourly 20-mL i.v. boluses of lornoxicam 0.8 mg/mL starting 20 min before induction of anaesthesia followed by a constant infusion at 10 mL/h of 0.9% saline, for 48 hrs after surgery (supplied by Xefo, JPI, Saudi Arabia), starting 20 min before induction of anaesthesia."
223762989|NCT02861950|DRUG|Caudal block with ropivacaine|Patients in this arm will receive a caudal block with ropivacaine
223762990|NCT02861950|DRUG|penile nerve block with bupivacaine|Patients in this arm will receive a penile block with bupivacaine
223762991|NCT05851729|OTHER|Kegal exercises with postural correction|Kegal exercises with postural correction
223762992|NCT05851729|OTHER|Kegal exercises without postural correction|Kegal exercises without postural correction
223762993|NCT01552239|RADIATION|IMRT/IGRT, Tumor resection, Brachytherapy|"All:~Preoperative IMRT with small safety margins (GTV according to MRT plus 1.5cm laterally / 3cm proximodistally) to 50Gy total dose, 2 Gy single dose, 5 fractions per week, daily IGRT with in-room CT (Tomotherapy)~Tumor resection after 4-6 weeks~Stratum C: Interstitial Brachytherapy to tumor bed with 15 Gy total dose, 3 Gy single dose b.i.d. in second week after tumor resection"
223762994|NCT04033159|DRUG|DYN101|DYN101, is a constrained ethyl gapmer ASO directed against human DNM2 RNA
223762995|NCT04151602|BEHAVIORAL|Smoked illicit drug use|The exposure of interest is current smoked illicit drug use, particularly methamphetamine and/or methaqualones
223626349|NCT02818309|DRUG|Lesogaberan|120 mg bid
223626350|NCT02818309|DRUG|Placebo|Placebo
223626351|NCT05387083|DRUG|Low Dose TP-05|Healthy Volunteers will receive a single low dose of TP-05 on Day 1.
223626352|NCT05387083|DRUG|High Dose TP-05|Healthy Volunteers will receive a single high dose of TP-05 on Day 1.
223626353|NCT05387083|DRUG|Placebo Comparator|Healthy Volunteers will receive a single dose of placebo on Day 1.
223762996|NCT00661700|DRUG|Levitra (Vardenafil, BAY38-9456)|10mg Vardenafil for 4 weeks followed by an 8 week titration period when subjects may be titrated up to 20mg Vardenafil or down to 5mg Vardenafil followed by 14 weeks treatment at preferred dose.
223762997|NCT00661700|DRUG|Placebo|10mg placebo for 4 weeks followed by an 8 week titration period when subjects may be titrated up to 20mg placebo or down to 5mg placebo followed by 14 weeks placebo at preferred dose
223762998|NCT06437210|DIETARY_SUPPLEMENT|Viusid Oral Solution|Patients in the experimental intervention group will be administered Viusid Oral Solution (CATALYSIS S.L., Madrid, Spain) 30 mL orally 3 times a day with the main meals (breakfast, lunch and dinner) for 30 days.
223762999|NCT06437210|DIETARY_SUPPLEMENT|Placebo|Patients in the experimental intervention group will be administered Placebo (CATALYSIS S.L., Madrid, Spain) 30 mL orally 3 times a day with the main meals (breakfast, lunch and dinner) for 30 days.
223763000|NCT01307566|DEVICE|Continuous Positive Airway Pressure CPAP|CPAP treatment
223763001|NCT02888899|BEHAVIORAL|Biofeedback|
223763002|NCT02888899|DRUG|Loperamide|
223763003|NCT02888899|DRUG|Stool bulking agent (sterculia or ispaghula husk)|
223763004|NCT02888899|OTHER|PTNS|
223763005|NCT01617057|DRUG|tiludronic acid|400 mg / day for 3 months
224215532|NCT04303052|DEVICE|Angiodynamic Bioflo Picc IR-KIT (145 cm guidewire) or|Before Power-PICC-line catheter implantation, the patients undergo an examination of the planned intervention site and ultrasound check, and analysis of the blood tests. An informed consent discussion and the patient's signature on the informed consent are obligatory. The length of the catheter and the optimal position of the catheter tip are verified by fluoroscopy. After catheter implantation, the tip location is verified by a final chest x-ray. The follow-up visit and the control of the puncture site until removal of the catheter are performed during hospitalization or subsequently by the treating family doctor.
223763006|NCT01617057|DRUG|Placebo|400 mg / day for 3 month
223763007|NCT03584269|DEVICE|NIV Device + LTOT|Respiratory assistance by a facial mask without intubation or tracheotomy
224215533|NCT04303052|DEVICE|Angiodynamic Bioflo Picc MST-KIT (70 cm guidewire)|Before Power-PICC-line catheter implantation, the patients undergo an examination of the planned intervention site and ultrasound check, and analysis of the blood tests. An informed consent discussion and the patient's signature on the informed consent are obligatory. The length of the catheter and the optimal position of the catheter tip are verified by fluoroscopy. After catheter implantation, the tip location is verified by a final chest x-ray. The follow-up visit and the control of the puncture site until removal of the catheter are performed during hospitalization or subsequently by the treating family doctor.
224215534|NCT00379587|DRUG|Rituximab|Rituximab at months 3, 6, 9 and 12 post-transplant
224215535|NCT00379587|DRUG|375 mg/m2 RRituximab|Rituximab 375 mg/m2 q3months
224215536|NCT03198637|DRUG|Cisatracurium's monitoring by TOF (train-of-four) WATCH device.|Neuromuscular blockade's monitoring by Cisatracurium thanks to TOF (train-of-four) WATCH device.
223763008|NCT03584269|DEVICE|LTOT|Long term oxygenatory tyherapy without NIV
223763009|NCT04107571|PROCEDURE|A type of operation for coranary heart disease patients.|A type of operation for coranary heart disease patients.
224215537|NCT03198637|DRUG|clinical assessment|
224316945|NCT04149093|DIAGNOSTIC_TEST|Calretinin staining|"A paraffin-embedded hematoxylinphloxin-safran sections will be performed on tissue specimens of proximal resection margins to evaluate the presence or absence of ganglion cells.~Immunohistochemistry (IHC) will then be done on paraffin-embedded sections for calretinin staining."
223763010|NCT00116558|DEVICE|Early NIPPV|Early intervention with non-invasive positive pressure ventilation (NIPPV) at 80% forced vital capacity (FVC).
223763011|NCT00116558|DEVICE|Standard NIPPV|Standard of care non-invasive positive pressure ventilation (NIPPV) at 50% forced vital capacity (FVC).
223763012|NCT06428019|DRUG|Venetoclax|Oral: Tablet
224215538|NCT06045585|BIOLOGICAL|infusion of JY231 injection|Infusion of JY231 Injection by dose of 1-10 x10\^6 TU/kg、 1-5 x10\^7 TU/kg、 5-10 x10\^7 TU/kg Administration method: intravenous infusion、intraperitoneally infusion、Lymph node infusion； Subjects will be treated with Fludarabine and Cyclophosphamide before cell infusion（PI evaluation is required）.
223763013|NCT06428019|DRUG|Acalabrutinib|Oral: Tablet
223763014|NCT06428019|DRUG|Obinutuzumab|Intravenous Infusion
223763015|NCT02027844|BEHAVIORAL|Cartoon|Cartoon watching by children during inhalational induction of sevoflurane
224215539|NCT05948293|DEVICE|Machine learning model called IDoser|Patients in the intervention arm will be prescribed the first dose of FSH by IDoser, that will take into account the age of the patient, BMI, AFC and AMH. These data will be retrieved from the patient's clinical file after their first visit to the clinic, after providing the patient with informed consent documentation.
224215540|NCT05948293|PROCEDURE|Standard clinical practice|Patients in the control group will be prescribed their first dose of FSH by the clinician according to standard clinical practice.
223763016|NCT02027844|BEHAVIORAL|parental presence|parental presence during inhalational induction of sevoflurane
223763017|NCT05217550|BEHAVIORAL|Veggie Brek|Offering vegetables to children at breakfast alongside their main breakfast food for three consecutive weeks (five days a week) between baseline and follow-up weeks where vegetables are also offered to children at breakfast alongside their main breakfast food for five days a week.
223513922|NCT01363830|BEHAVIORAL|Two-Week Post-Operative Restriction|Surgeon recommends the patient restrict bending, lifting, and twisting for two-weeks following discectomy.
223513923|NCT01363830|BEHAVIORAL|Six-Week Post-Operative Restriction|Surgeon recommends patient restrict bending, lifting, and twisting for six-weeks following discectomy.
223513924|NCT02027194|DRUG|Cure-Allergic Rhinitis Syrup|Delivered one bottle for two weeks to the participants twice
223513925|NCT02027194|DRUG|Yu-ping-fung San|Delivered one bottle for 2-week usage to the participants twice
223513926|NCT02027194|DRUG|Placebo|Delivered one bottle (wheat power with favors) for 2-week usage to the participants twice
223513927|NCT03315559|DRUG|[14C]-GSK2269557 IV infusion|The \[14C\]-GSK2269557 solution will be available in dosing strength of 10 µg, administered as single dose IV infusion over 15 minutes. It will be prepared by dissolving a hemisuccinate salt (GSK2269557T) in normal saline.
223626354|NCT04231669|BEHAVIORAL|Anzansi Family Program|"the ANZANSI that combines Family Economic Empowerment (EE) with Multiple Family Groups (MFG). Family EE includes: 1) Workshops on asset building, future planning, and protection from risks; 2) Child Development Account (CDA); and 3) Family income-generating/microenterprise promotion (IGA) component:~MFG a family-centered, group-delivered, evidence-informed intervention designed for children and adolescents whose families struggle with poverty and associated stressors. The MFG is based on building family support through opportunities for parents and children to communicate in a safe setting with other families who have shared experiences, and allow each family to learn from one another. MFG builds protective factors for healthy parent-child relationships while addressing familial, social and community stressors and barriers to adolescent girls' well-being. Both adolecsnt girls and their caregivers will receive the intervention."
223626355|NCT00628368|GENETIC|gene expression analysis|
223626356|NCT00628368|GENETIC|mutation analysis|
223626357|NCT00628368|GENETIC|polymorphism analysis|
223626358|NCT00628368|OTHER|laboratory biomarker analysis|
223626359|NCT00628368|PROCEDURE|biopsy|
223626360|NCT00628368|PROCEDURE|endoscopic biopsy|
223626361|NCT04340895|OTHER|Faecal Calprotectin Home Test|"A non-invasive, in vitro diagnostic test for the determination of FC levels in human stool samples in combination with the dedicated 'CalproSmart' smartphone application.~This test helps participants to self-monitor their FC levels at their own homes, ensuring an adequate and effective medical treatment regimen performed by the investigator."
223626362|NCT04340895|OTHER|PRO-2 Scoring|Monitoring of clinical symptoms will be performed by PRO-2 scoring, which includes rectal bleeding (RB) and stool frequency (SF) assessment obtained within the last 3-days.
223626363|NCT05845385|PROCEDURE|lumbar epidural analgesia with bupivacaine|postoperative analgesic method
223626364|NCT05845385|PROCEDURE|transversus abdominis plane block with bupivacaine|postoperative analgesic method
223626365|NCT05845385|PROCEDURE|wound infiltration with bupivacaine|postoperative analgesic method
223626366|NCT00566774|OTHER|Full drug coverage|Patients randomized to first-dollar coverage will have their pharmacy benefits changed so that they have no out-of-pocket costs for any beta-blocker, angiotensin converting enzyme inhibitor (ACEI) or angiotensin II receptor blocker (ARB) antagonist, or statin for every subsequent prescription after randomization. All co-pays and co-insurance will be waived at the point of care (i.e. pharmacy) as will any contribution that the cost of these drugs contributes to a patient's deductible
223626367|NCT00566774|OTHER|Usual coverage|Patients randomized to usual coverage will have no change in their existing benefits
224215541|NCT03895593|OTHER|rescue fecal microbiota transplantation|Fecal microbiota transplantation refers to the infusion of fecal microbiota from healthy donor into patients' gastrointestinal tract. The delivering ways for FMT include but are not limited to gastroscopy, colonoscopy, edema, nasogastric tube, transendoscopic enteral tube, and etc.
223626368|NCT06024941|RADIATION|Radiation|Radiation to one or more progressive lesions. Preferably 1x10Gy, but also 3x8Gy, 10x 3Gy, 5x4Gy or 1x20-24Gy is possible.
223626369|NCT05708196|OTHER|Alloplast bone grafting material (EthOss, Ethoss Regeneration Ltd, Silsden, UK).|After tooth extraction, the tooth socket will begrafted with Alloplast grafting material
223626370|NCT05708196|OTHER|Allograft bone grafting material.|After tooth extraction, the tooth socket will be grafted with allograft grafting material
223626371|NCT02085967|DRUG|rifampin 600 mg|
224215542|NCT05478005|PROCEDURE|Femoral nerve block|Patients who receive a femoral nerve block during surgery, fill out a questionnaire and undergo a muscle strength test before surgery, undergo functional tests, a muscle strength test and are asked about pain intensity after surgery.
224215543|NCT05478005|PROCEDURE|Intra-articular block|Patients who receive an intra-articular block at the time of surgery, fill out a questionnaire and undergo a muscle strength test before surgery, undergo functional tests, a muscle strength test and are asked about pain intensity after surgery.
223626372|NCT02085967|DRUG|itraconazole 200 mg|
223626373|NCT02085967|DRUG|midazolam 2 mg with bupropion 75 mg|
223626374|NCT02085967|DRUG|E2006|
223626375|NCT03804840|DRUG|Dronabinol|THC (Marinol® \[dronabinol\]; Solvay Pharmaceuticals) will be orally administered in doses of 7.5 mg and 15 mg, in opaque capsules with dextrose filler. Placebo capsules contain only dextrose. These doses of THC are known to produce performance impairments as well as subjective intoxication.
223626376|NCT03804840|DRUG|Placebo|Placebo
223626377|NCT03656003|DEVICE|Procore biopsy needle|EBUS-TBNA with the EchoTip ProCore needle (Cook Medical Inc., Bloomington, Ind., USA)
223626378|NCT03656003|DEVICE|Conventional biopsy needle|EBUS-TBNA with the conventional 22-gauge EBUS-TBNA needle (Vizishot, Olympus, Japan)
223626379|NCT04951115|DRUG|Carboplatin|AUC = 5-6 mg/mL per min on Day 1 of each 21-day cycle, for 4 cycles
223626380|NCT04951115|DRUG|Cisplatin|75-80 mg/m2 on Day 1 of each 21-day cycle, for 4 cycles
223626381|NCT04951115|DRUG|Etoposide|80-100 mg/m2 on Day 1, Day 2, and Day 3 of each 21-day cycle, for 4 cycles
223626382|NCT04951115|DRUG|Durvalumab|1500 mg on Day 1 of each 21-day cycle, for 4 cycles. Following this, 1500 mg once every 4 weeks until disease progression
223626383|NCT04951115|RADIATION|Stereotactic Body Radiotherapy|6 Gy of radiotherapy targeting multiple sites of intrathoracic disease on Days 1-5 of cycle 1.
223626384|NCT06446921|DIETARY_SUPPLEMENT|Ginger formula|supplement delivering a minimum of 20 mg of gingeroids / d
223626385|NCT06446921|DIETARY_SUPPLEMENT|Placebo|arabic gum
223626386|NCT04335253|DRUG|EOS884448|Multiple Ascending Dose
223626387|NCT04126798|OTHER|Behavioural|Assessment of the 2BALANCE protocol: dual-task protocol consisting of a motor task, cognitive task, and motor-cognitive dual-tasks
223626388|NCT06070779|OTHER|neuro linguistic programming|neuro linguistic programming
223626389|NCT06498583|DRUG|Ropivacaine|0.25 % ropivacaine ( 0.5ml / kg )
223626390|NCT06498583|PROCEDURE|erector spinae plane block|After the operation, unilateral erector spinae plane block was performed at the T5 level under ultrasound guidance.
223626391|NCT06498583|PROCEDURE|Incision infiltration of local anesthesia|After the operation, Incision infiltration of local anesthesia is performed around the surgical incisions.
223626392|NCT05955612|PROCEDURE|Procalcitonin measurement|Daily measurement of serum procalcitonin concentrations to guide de-escalation of antibiotics
223626393|NCT05351944|BEHAVIORAL|Dialectical behavioral therapy skills for the intervention experimental group A|Our hypothesis is that impulsive aggression as evidenced by inflammatory biomarkers might improve by targeting executive dysfunctions with Dialectical Behavioural Therapy skills modules directed to the children and their parents in the form of response inhibition dysfunctions with Dialectical Behavioural Therapy mindfulness and distress tolerance skills modules, emotion regulation executive dysfunctions with Dialectical Behavioural Therapy emotion regulation skills module and socioenvironmental factors with interpersonal effectiveness and walking the middle path Dialectical behavioural therapy skills modules.
223626394|NCT05351944|DRUG|psychoeducation or Atomoxetine or stimulants according to ADHD severity|the control group (group B) will receive psychoeducation and medications targeting ADHD symptoms (Atomoxetine or stimulants according to FDA approved dose according to age and weight ) according to the international guidelines for management of ADHD according to symptom severity
223626395|NCT05835206|DRUG|Microbiome Therapeutic|"Participants will receive a single course of study treatment (IP, Encapsulated Microbiota): Orally delivered, non-frozen, encapsulated investigational intestinal microbiota, consisting of 16 capsules. One dose (8 capsules) is administered daily (QD) for 2 days. The capsules are to be taken orally with water on an empty stomach. Each dose will be taken approximately every 24 hours, with a minimum of 12 hours from the previous dose to a maximum of 36 hours. Both doses must be completed within the stated 36 hours ±12 hours. Depending on the time of the first dose, dosing may occur over 3 calendar days.~A second cycle will begin and a second treatment will be given if the participant is still MDRO positive on Day 14 of Cycle 1. If applicable, Cycle 2 will begin within 7 days of Day 14."
223626396|NCT05835206|DRUG|Placebo|"Participants will receive a single course of study treatment (Color-matched placebo capsules containing microcrystalline cellulose (MCC) powder), consisting of 16 capsules. One dose (8 capsules) is administered daily (QD) for 2 days. The capsules are to be taken orally with water on an empty stomach. Each dose will be taken approximately every 24 hours, with a minimum of 12 hours from the previous dose to a maximum of 36 hours. Both doses must be completed within the stated 36 hours ±12 hours. Depending on the time of the first dose, dosing may occur over 3 calendar days.~A second cycle will begin and a second treatment will be given if the participant is still MDRO positive on Day 14 of Cycle 1. If applicable, Cycle 2 will begin within 7 days of Day 14."
223626397|NCT04364386|DEVICE|InPress Device|Treatment with InPress Device for Postpartum Hemorrhage
223626398|NCT06511973|DRUG|Naproxen (BAYH006689)|BAYH006689 gel will be dispensed directly on the patch
223626399|NCT06511973|DRUG|Placebo Gel|Placebo gel will be dispensed directly on the patch
223626400|NCT06511973|DRUG|A solution of 0.9% Saline|0.9% Saline will be dispensed directly on the patch
223763018|NCT00378014|DRUG|everolimus|Start dose of everolimus was 1.5 mg in the morning followed by 1.5 mg in the evening. After one week, the dose was adjusted to achieve trough levels between 5-12 ng/mL. Once trough levels were above 5ng/mL, the CNI dose was reduced to 70%. At week 8 post-baseline (latest at week 16 post baseline), CNI was completely discontinued. For patients receiving Ciclosporin A (CiA) as CNI, the everolimus dosage was adjusted to achieve a trough level of 8-12 ng/mL, prior to discontinuation of CiA. After discontinuation of CNI, everolimus was maintained at a trough level of 5-12 ng/mL.
223626401|NCT06511973|DRUG|A solution of 0.2% SLS|0.2% SLS will be dispensed directly on the patch.
223626402|NCT04014829|DIAGNOSTIC_TEST|Pain-Pressure Threshold|Performed on bilateral trapezius muscles. Pressure will be applied at 90 degrees downward with an algometer, with the speed of pressure increase approximately 1kgf/s. Upon the sensation of pain, the patient will vocalize or raise her hand to terminate the test, and the highest reading will be recorded (up to maximum 6kgf). If two values are recorded within 0.2kgf of each other, the mean value will be recorded. If two values are greater than 0.2kgf of each other, a third test will be performed and the mean obtained.
223626403|NCT04014829|DIAGNOSTIC_TEST|Mechanical Temporal Summation|"Pinprick hyperalgesia will be evoked using a Von Frey filament, applied to the volar aspect of the dominant forearm. Participants will report using the numerical rating scale the intensity of pain from the first stimulus. Subsequently, ten repetitive stimuli one second apart will be applied with the same filament within an area of 1cm diameter of the same forearm. Subjects will report the rate the pain intensity of the tenth stimulus. The magnitude of MTS is calculated as the difference between the last to the first pain scores. The investigators will classify the participants according to evoked MTS if the last stimulus is rated higher than the first, or no MTS if the last stimulus is rated equal or lower than the first. The research team administering the test will follow a set script."
223626404|NCT04014829|DIAGNOSTIC_TEST|Hospital Anxiety and Depression Scale|Standardized questionnaire to determine the level of anxiety and depression.
223626405|NCT04014829|DIAGNOSTIC_TEST|Pain Catastrophizing Scale|Standardized questionnaire to determine the level of pain catastrophizing.
223626406|NCT04014829|DIAGNOSTIC_TEST|Central Sensitization Inventory|Standardized questionnaire to determine the level of central sensitization.
223626407|NCT04014829|DIAGNOSTIC_TEST|Fear-Avoidance Component Score|Standardized questionnaire to determine the level of fear and avoidance.
223626408|NCT04014829|DIAGNOSTIC_TEST|EQ-5D|Standardized questionnaire to assess generic health-related quality of life.
223626409|NCT04014829|DIAGNOSTIC_TEST|heart rate variability|Heart rate variability will be determined from the R-to-R intervals obtained from a 5-minute ECG recording.
224316946|NCT04140162|DRUG|Daratumumab|"Induction: 16 mg/kg actual body weight IV weekly (weeks 1-8; total of 8 doses) then every 2 weeks (weeks 9-24; total of 8 doses).~Consolidation: 16 mg/kg actual body weight IV every four weeks (weeks 25-36)~Maintenance: 16 mg/kg actual body weight IV every eight weeks (weeks 37-88)~Sites will continue to use IV daratumumab to treat existing study patients until the IV daratumumab stock on site has been exhausted. The sites will then transition existing patient to SQ daratumumab. New patients will be started on SQ 1800mg daratumumab.~Induction- Cycles 1-2 (days 1, 8,15, 22), Cycles 3-6 (Weeks 9-24- two weeks (days 1, 15 ) Consolidation- Every 4 weeks on day 1 Maintenance- Every 8 weeks on day 1"
224316947|NCT04140162|DRUG|Lenalidomide|"Induction: 25 mg PO once daily, on days 1-21 of each 28-day cycle (weeks 1-24)~Consolidation: 25 mg PO once daily, on days 1-21 of each 28-day cycle (weeks 25-36)~Maintenance: 10 mg PO once daily, on days 1-21 of each 28-day cycle until progression or intolerance~Maintenance: 10 mg PO once daily, on days 1-21, weeks 37+ until progression"
223626410|NCT04014829|DIAGNOSTIC_TEST|Anxiety, anticipated pain, anticipated analgesia|Preoperative anxiety (0 to 100), anticipated pain (0 to 100), and anticipated analgesia requirement (0 to 5).
223626411|NCT04014829|DIAGNOSTIC_TEST|State-trait anxiety inventory|Standardized questionnaire to assess anxiety.
223626412|NCT04014829|DIAGNOSTIC_TEST|Beck's Depression Inventory|Standardized questionnaire to assess depressive symptoms.
223626413|NCT05953181|PROCEDURE|Active surveillance|Patients enrolled in the active surveillance arm will undergo diagnostic evaluations every 3 months in the first year after completion of neoadjuvant treatment, every 4 months in the second year, every 6 months in the third year and yearly in the 4th and 5th year of follow up, or when symptoms or results of any diagnostic test require shorter assessment intervals. In the active surveillance arm, surgical resection will be offered only to those patients, in whom a locoregional regrowth is highly suspected or proven, without any signs of distant dissemination.
223626414|NCT05976256|OTHER|Kinesio taping|Kinesio tape is a thin, elastic tape that applies pressure to the skin (because of the elasticity of the tape), reducing pain by reducing nociceptive stimulation.
224215544|NCT03108079|DEVICE|Cystosure Urinary Access System|"1. Demonstrate the 3D bladder wall anatomy with 300 cc of fluid infused with each of the following bladder drainage mechanisms~   1. The traditional Foley catheter (Catheter A)~  2. The novel FDA approved Cystosure catheter (Catheter B)~2. Compare the fluid flow pattern during bladder drainage for~   1. The traditional Foley catheter (Catheter A)~  2. The novel FDA approved Cystosure catheter (Catheter B)~3. Compare the 3D bladder wall anatomy after emptying the bladder with~   1. The traditional Foley catheter (Catheter A)~  2. The novel FDA approved Cystosure catheter (Catheter B)"
224316948|NCT04140162|DRUG|Bortezomib|Consolidation: 1.5 mg/m2 SQ on day 1, 8, 15 and 22 of each 28-day cycle (weeks 25-36)
224316949|NCT04140162|DRUG|Dexamethasone|Induction and Consolidation: 40 mg (or reduced dose of 20 mg) PO or IV weekly
224316950|NCT04194294|DRUG|Lidocaine|Before induction of anesthesia; children in group LID received an iv bolus dose of LIDOCAINE 1 mg/kg over 5 minutes followed by 1 mg Kg-1 h-1 ivi until the start of skin closure.
224316951|NCT04194294|OTHER|Na CL 0.9%|Before induction of anesthesia; children in group C equivalent volumes of Na Cl 0.9% over the same period instead of LIDOCAINE.
223763019|NCT00378014|DRUG|basiliximab|All patients who met the eligibility criteria were treated with 2 doses of basiliximab on Day 0 (transplantation) and Day 4.
224316952|NCT01014793|DRUG|cabergoline|cabergoline doses were increased at 6-week intervals, starting at 1.0mg/week followed by 2.0 and 3.5mg/week. Hormonal evaluations (IGF-I, GH and PRL) started before the first dose and were repeated at 6-week intervals after each cabergoline dose and after cabergoline withdrawal
224316953|NCT00425373|DRUG|Valsartan + amlodipine 40/2.5 mg|Valsartan + amlodipine 40/2.5 mg tablet plus 3 tablet and 2 capsule placebos taken once daily
223513928|NCT03315559|DRUG|GSK2269557 via DPI|GSK2269557 DPI will be available with dosing strength of 1000 µg, administered as oral inhalation intended to inhale twice. It will be prepared by blending GSK2269557 hemisuccinate salt (GSK2269557H) with lactose and magnesium stearate.
223513929|NCT03315559|DRUG|[14C]-GSK2269557 oral solution|The \[14C\]-GSK2269557 solution will be available with dosing strength of 800 µg, administered as single dose orally. It will be prepared by dissolving \[14C\]-GSK2269557 hemisuccinate salt (GSK2269557T) in water.
223513930|NCT04169659|DEVICE|Kyphoplasty with insertion of Sctructured Titanium Microspheres|Under fluoroscophy, we introduce a transpeduncolar trocar inside the vertebral body where is performed a kyphoplasty with insertion of baloons. When the dome is cretated we introduce structured titanium microspheres until the dome is full of material.
223513931|NCT04169659|DEVICE|Kyphoplasty with Polimethylmetacrilate (convetional surgery)|Under fluoroscophy, we introduce a transpeduncolar trocar inside the vertebral body where is performed a kyphoplasty with insertion of baloons. When the dome is cretated we introduce Polimethylmetacrilate until the dome is full of material.
223513932|NCT06203665|DIAGNOSTIC_TEST|Recruitment Maneuver|The surgery would be performed under general anaesthesia according to the common practice using protective lung ventilation ( Vt= 6 ml /Kg ideal body weight , RR to maintain end-expiratory CO2 35-45 cmH2O and PEEP= 6- 8 cm H20). An incremental and decremental positive end-expiratory pressure alveolar recruitment maneuver would be performed after release of pneumoperitoneum.
223513933|NCT02413346|DRUG|Sarecycline|Administered based on participant's body weight.
223513934|NCT05318378|DIAGNOSTIC_TEST|BIXAM|Series two consisted of inverted and conventional X-rays of the same subject (BIXAM) shown together
223513935|NCT00006215|BIOLOGICAL|filgrastim|
223513936|NCT00006215|DRUG|docetaxel|
223513937|NCT00006215|DRUG|vinorelbine tartrate|
223513938|NCT04941365|DIAGNOSTIC_TEST|single arm|Blood samples will be collected at baseline(Visit 1), and during therapy at visit 2 (around one month after the treatment starting) and at Visit 3 (around three months after the treatment starting. And, optionally, in case of a disease progression (PD).
223513939|NCT06253728|DIETARY_SUPPLEMENT|High fiber and protein meal|In the intervention participants are assigned to eat high protein and fiber meal that differ in protein source or structure.
223513940|NCT06253728|DIETARY_SUPPLEMENT|Control|The control meal is low fiber and low protein meal.
223513941|NCT00398242|DEVICE|above or below elbow cast for the last 3 weeks of treatment|
223513942|NCT06499220|DEVICE|Spinal Cord Stimulator|Spinal Cord Stimulation (SCS) as an aid in the management of chronic, intractable pain of the trunk and/or limbs.
223513943|NCT02903381|DRUG|Nivolumab|Intravenous, predetermined dosage, Days 1 and 15 during cycles 1-12 and
223513944|NCT02903381|DRUG|Lenalidomide|Oral, predetermined dosage, Days 1-21 of cycle 1-12
223513945|NCT02903381|DRUG|Dexamethasone|Oral, Days 1, 8, 15 of cycle 1-6
223626415|NCT05976256|OTHER|sham tape (leukotape classic)|leuko tape classic is used in this study to explore the possible placebo effect of kinesiotape
223626416|NCT05976256|OTHER|standard treatment|standard treatment is the treatment with oral analgesics and a sling (if shoulder injury)
224316954|NCT00425373|DRUG|Valsartan + amlodipine 40/5 mg|Valsartan + amlodipine 40/5mg tablet plus 3 tablet and 2 capsule placebos taken once daily
224316955|NCT00425373|DRUG|Valsartan + amlodipine 80/2.5 mg|Valsartan + amlodipine 80/2.5 mg tablet plus 3 tablet and 2 capsule placebos taken once daily
224316956|NCT00425373|DRUG|Valsartan + amlodipine 80/5 mg|Valsartan + amlodipine 80/5mg tablet plus 3 tablet and 2 capsule placebos taken once daily
224316957|NCT00425373|DRUG|Valsartan 40 mg|Valsartan 40 mg tablet plus 3 tablet and 2 capsule placebos taken once daily
224316958|NCT00425373|DRUG|Valsartan 80 mg|Valsartan 80 mg tablet plus 3 tablet and 2 capsule placebos taken once daily
223513946|NCT02446938|PROCEDURE|Esophagus balloon catheter insertion.|Esophagus balloon catheter will be inserted and the position of the balloon will be confirmed by a air injection test.A bolus of 30 ml of air was injected to the gastric lumen of the catheter just next to the distal edge of the balloon, during the onset of end-expiratory phase. The presence of a positive disturbing wave (PDW) in esophageal pressure waveform to this air injection will be the indicator of the right balloon position.
223513947|NCT05363215|DRUG|S-217622|Tablet for oral administration
223513948|NCT04612127|DIETARY_SUPPLEMENT|Dietary supplement consumption and physical exercise|"The consumption time of the experimental product was 90 days and the control consumption time was 90 days.~During this time, training should be done three times a week."
223513949|NCT04853537|DIETARY_SUPPLEMENT|intermittent fasting diet|intermittent fasting diet to obese pregnant women \>30 BMI and incidence of gestational diabetes
223513950|NCT05496738|DRUG|PF-07264660 intravenous single ascending dose|PF-07264660 will be administered intravenously in single ascending doses
223513951|NCT05496738|DRUG|PF-07264660 subcutaneous multiple ascending dose|PF-07264660 will be administered subcutaneously in multiple ascending doses
223513952|NCT05496738|OTHER|Intravenous placebo|Placebo will be administered intravenously in single ascending doses
223513953|NCT05496738|OTHER|subcutaneous placebo|Placebo will be administered subcutaneously in multiple ascending doses
223513954|NCT04465149|PROCEDURE|Third Molar Germectomy|Surgical extraction of Third Molars that exhibits at least a third of its root in formation, with a periodontal ligament discernible on panoramic x-ray (defined as germectomy).
223513955|NCT06494514|DRUG|nal-IRI+Oxaliplatin+5-FU/LV+PD-1|These drugs are given on d1, d15, 28 days as one cycle. 6-6 treatment cycles. SBRT is performed in third cycles.
223513956|NCT06494514|DRUG|Gemcitabine + albumin-paclitaxel+PD-1|These drugs are given on d1, d8, 21 days as one cycle. 6-6 treatment cycles. SBRT is performed in third cycles.
223513957|NCT02483910|BEHAVIORAL|Direct Instruction-Language for Learning (DI-LL) via telehealth (e.g., Zoom or WebEx)|"DI-LL is composed of up to 150 lessons (15 sets of 10 lessons each - e.g., lessons 1-10, 11-20, 21-30, etc.) that build on one another. The program uses demonstrations and pictures to expand vocabulary and teach language skills to children in manageable steps. The curriculum focuses on teaching spoken language across six areas: actions, description of objects, general information, standardized prompts (show me or point to or say the whole thing), classification, and problem-solving strategies. For example, DI-LL moves from the identification of familiar objects to the description and classification of these objects. Children learn the precise meaning of both familiar and new concepts and use these concepts in statements and questions. The DI-LL also incorporates 15 assessment tests (one for each set of 10 lessons). These assessment tests are given after each set of 10 lessons to confirm mastery of the material and the child's readiness to move on to the next set of 10 lessons."
223513958|NCT02483910|BEHAVIORAL|Standard of care delivered via telehealth (e.g., Zoom or WebEx)|Usual care including speech therapy in school, community or both
223513959|NCT03672981|BEHAVIORAL|Exercise Intervention|Undergo resistance training program and cardiovascular exercise
223513960|NCT03672981|OTHER|Quality-of-Life Assessment|Ancillary studies
223513961|NCT03672981|OTHER|Questionnaire Administration|Ancillary studies
223513962|NCT03672981|BEHAVIORAL|Telephone-Based Intervention|Participate in phone calls with exercise physiologist
223513963|NCT00257855|DRUG|Lamotrigine|
223513964|NCT02687165|DRUG|Milnacipran and D-cycloserine|Milnacipran augmented by D-cycloserine
223513965|NCT01856829|DIETARY_SUPPLEMENT|Omega-3|The capsule will be take daily for 4 weeks before and for the duration of the tests of the perceptual-cognitive training protocol. The testing period will held at intervals of 3 to 7 days for 5 sessions (maximum of 5 weeks testing). Taking products will be made more specifically 30 minutes before the start of the sessions.
223513966|NCT01856829|OTHER|Placebo|The capsule will be take daily for 4 weeks before and for the duration of the tests of the perceptual-cognitive training protocol. The testing period will held at intervals of 3 to 7 days for 5 sessions (maximum of 5 weeks testing). Taking products will be made more specifically 30 minutes before the start of the sessions.
223513967|NCT01124266|PROCEDURE|standard of care colonoscopy|Single inspection by endoscopist during colonoscopy
223513968|NCT01124266|PROCEDURE|standard of care colonoscopy|Dual inspection by both endoscopist and nurse during colonoscopy
223513969|NCT02382263|DRUG|Nab-paclitaxel 150 mg/m2 + Gemcitabine 1000 weeks 1,3/4|Nab-paclitaxel 150 mg/m2 + Gemcitabine 1000 days 1 \& 15 in a 28 days cycle
223513970|NCT02382263|DRUG|Nab-paclitaxel 100 mg/m2 + Gemcitabine 1000 weeks 1,2,3/4|Nab-paclitaxel 100 mg/m2 + Gemcitabine 1000 days 1,8 \& 15 in a 28 days cycle
223513971|NCT02382263|DRUG|Nab-paclitaxel 125 mg/m2 + Gemcitabine 1000 weeks 1,3/4|Nab-paclitaxel 125 mg/m2 + Gemcitabine 1000 days 1 \& 15 in a 28 days cycle
223513972|NCT02382263|DRUG|Nab-paclitaxel 125 mg/m2 + Gemcitabine 1000 weeks 1,2,3/4|Nab-paclitaxel 125 mg/m2 + Gemcitabine 1000 days 1,8 \& 15 in a 28 days cycle
223513973|NCT06308926|DRUG|MRG-001 (Low-dose)|MRG-001 is subcutaneously administered.
223513974|NCT06308926|DRUG|MRG-001 (High-dose)|MRG-001 is subcutaneously administered.
223513975|NCT06308926|OTHER|Placebo|Saline placebo will be administered subcutaneously based on bodyweight and similar dose as the treatment group.
223513976|NCT06689189|OTHER|Blood fluorescence metabolite analysis|This is an observational study and does not involve intervention. In both the early and late stages of sepsis, a significant increase in inflammatory free radicals changes the optical properties of the patient\&#39;s blood, distinguishing it from that of healthy individuals. To explore this phenomenon, 4 cc of fasting blood is drawn from patients who pass our screening criteria. This sample is then centrifuged in accordance with our detailed standard operating procedures to ready it for analysis. Subsequently, the fluorescence intensity of the blood is measured quantitatively using a precisely calibrated blood fluorometer, which is specifically designed to detect subtle variations indicative of both early and late sepsis. This entire process is executed under stringent quality control protocols to ensure the reliability and accuracy of the results, which are pivotal for the timely diagnosis and intervention in septic patients.
223626417|NCT02081924|OTHER|Kisspeptin 0.1|"Participants will receive kisspeptin hormone at a dose rate of 0.1nmol/kg/hour via a subcutaneous pump device for 8 days during the early follicular phase of their menstrual cycle.~LH, FSH and oestradiol will be measured on day 1 and 8, at 10minute intervals for 8 hours and on Days 3 and 5 they will have a single blood measurement of the same hormones."
223626418|NCT02081924|OTHER|Saline|"Participants will receive placebo (saline) via a subcutaneous pump device for 8 days during the early follicular phase of their menstrual cycle.~LH, FSH and oestradiol will be measured on day 1 and 8, at 10minute intervals for 8 hours and on Days 3 and 5 they will have a single blood measurement of the same hormones."
223626419|NCT02081924|OTHER|Kisspeptin 0.3|"Participants will receive kisspeptin hormone at a dose rate of 0.3 nmol/kg/hour via a subcutaneous pump device for 8 days during the early follicular phase of their menstrual cycle.~LH, FSH and oestradiol will be measured on day 1 and 8, at 10minute intervals for 8 hours and on Days 3 and 5 they will have a single blood measurement of the same hormones."
223626420|NCT02081924|OTHER|Kisspeptin 1.0|"Participants will receive kisspeptin hormone at a dose rate of 1.0 nmol/kg/hour via a subcutaneous pump device for 8 days during the early follicular phase of their menstrual cycle.~LH, FSH and oestradiol will be measured on day 1 and 8, at 10minute intervals for 8 hours and on Days 3 and 5 they will have a single blood measurement of the same hormones."
223626421|NCT04904692|PROCEDURE|Blood draw|8x9mL EDTA tubes. In subjects treated with hydroxychloroquine treatment an extra EDTA tube (4mL) will be collected for the REVIVE substudy.
223626422|NCT04904692|PROCEDURE|Bronchoalveolar lavage|Only in case of diagnostic or therapeutic indication.
223626423|NCT04904692|PROCEDURE|SARS CoV-2 swabs|Nasopharyngeal, oropharyngeal and nasal swabs
223626424|NCT06258369|OTHER|Patients with primary coxarthrosis (any stage).|Patients who do not undergo surgery will be called specifically for the study to attend a consultation dedicated to gait assessment.
223626425|NCT06258369|OTHER|Patients with primary coxarthrosis (any stage) and operated with Total Hip Prosthesis (THP).|Patients scheduled for THP (Total Hip Prosthesis) will be seen at the consultation the day before surgery, in the same hospital as the THP, or at an existing dedicated consultation scheduled for all THP patients. During these scheduled visits, they will be received in the gait analysis laboratory for a gait assessment (V1). Patients will be seen again at 6 months post-operatively for a second gait assessment (V2).
223626426|NCT06258369|OTHER|Patients with primary coxarthrosis (any stage) and operated with RTH (Hip resurfacing).|Patients scheduled for RTH (Hip Resurfacing) will be seen at the consultation the day before surgery, in the same hospital as the RTH, or at an existing dedicated consultation scheduled for all RTH patients. During these scheduled visits, they will be received in the gait analysis laboratory for a gait assessment (V1). Patients will be seen again at 6 months post-operatively for a second gait assessment (V2).
223763020|NCT00378014|DRUG|CNI|Patients who met the screening eligibility received CNI-based immunosuppressive therapy for 1 month. Then at week 4 (or week 8 at maximum), patients randomized to the CNI arm continued on CNI-based immunosuppressive therapy.
223763021|NCT06098950|OTHER|Artificial Intelligence model predictions without explanation|During 6 clinical vignettes, participants will see AI model predictions without a corresponding AI explanation. The AI model will provide a score for each diagnosis (heart failure, pneumonia, COPD) on a scale of 0-100 estimating how likely the patient's presentation was due to each of these diagnoses. In 3 of the clinical vignettes, participants will be shown standard AI model predictions and 3 vignettes they will be shown systematically biased AI model predictions, with the model specifically biased against one of the three diagnoses.
224215545|NCT03108079|DEVICE|Foley Catheter|"1. Demonstrate the 3D bladder wall anatomy with 300 cc of fluid infused with each of the following bladder drainage mechanisms~   1. The traditional Foley catheter (Catheter A)~  2. The novel FDA approved Cystosure catheter (Catheter B)~2. Compare the fluid flow pattern during bladder drainage for~   1. The traditional Foley catheter (Catheter A)~  2. The novel FDA approved Cystosure catheter (Catheter B)~3. Compare the 3D bladder wall anatomy after emptying the bladder with~   1. The traditional Foley catheter (Catheter A)~  2. The novel FDA approved Cystosure catheter (Catheter B)"
224215546|NCT00661674|DRUG|Palonosetron|"Over 3 study visits, patients will receive one of the following treatment regimens:~* Placebo saline IV and sugar pill~* 0.75 mg Palonosetron IV and sugar pill~* 0.75 mg Palonosetron IV and 100 mg hydroxyzine PO"
224215547|NCT00661674|DRUG|Hydroxyzine|"Over 3 study visits, patients will receive one of the following treatment regimens:~* Placebo saline IV and sugar pill~* 0.75 mg Palonosetron IV and sugar pill~* 0.75 mg Palonosetron IV and 100 mg hydroxyzine PO"
223626427|NCT05543265|BEHAVIORAL|Default appointment scheduling|Default primary care appointment scheduling
223626428|NCT05543265|BEHAVIORAL|Targeted messaging|Patient-specific messages about the importance of postpartum care transition
223626429|NCT05543265|BEHAVIORAL|Nudge Reminders|Primary care appointment reminders
223626430|NCT05316597|BEHAVIORAL|Forest bathing|Participants will be seated in a forest environment for an hour-long exposure to the forest
223626431|NCT06345716|DRUG|paracétamol tramadol|Each patient received 1 tablet \* 2/day synalvic (325 mg of paracetamol + 37.5 mg of tramadol) for 7 days
223626432|NCT06345716|DRUG|Paracétamol cafeine|Each patient received 1 tab \* 3/d stopalgic extra (65mgcaffeine+500mg paracetamol) for 7 days
223626433|NCT06345716|DRUG|Placebo|Each patient received 1 tab \* 3 / d of placebo (flour) every day for 7 days
223626434|NCT04776083|DRUG|first line systemic therapy|first line systemic therapy according to the genetic mutation 0f the patient
223626435|NCT04776083|RADIATION|3D radiotherapy or IMRT|Hypo-fractionated radiotherapy to the primary lesion
223626436|NCT06472661|DEVICE|Echopulse or Echopulse HD|The Echopulse/Echopulse HD device delivers focused ultrasound ablation (FUSA) therapy. FUSA is a technology that delivers continuous high-intensity focused ultrasound to ablate (heat and destroy) tissue. A series of sound waves will be focused on the tumor using the Echopulse or the Echopulse HD device to cover the planned target area. The targeted area is 33% of the tumor, up to 3.5 cubic centimeters. An ultrasound will be used to guide the beam of the FUSA treatment to the targeted site. FUSA will be applied to up to two tumors in the session. Participants are sedated during the FUSA treatment.
223626437|NCT06472661|DRUG|PolyICLC|PolyICLC (polyinosinic-polycytidylic acid that is stabilized with carboxymethylcellulose and polylysine) is a drug that may help the body build an effective immune response to kill tumor cells. A single injection of .9 mg of polyICLC into one tumor will be given within 4 hours after the FUSA.
223626438|NCT05526716|BIOLOGICAL|V116|Pneumococcal 21-valent conjugate vaccine with 4 μg of each of the pneumococcal polysaccharides (PnPs) antigen: 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15C, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F, and 35B in each 0.5 mL sterile solution
223626439|NCT05526716|BIOLOGICAL|QIV|Single 0.5 mL IM injection
223763022|NCT06098950|OTHER|Artificial intelligence model predictions with explanation|During 6 clinical vignettes, participants will see AI model predictions with explanation. The AI model will provide a score for each diagnosis on a scale of 0-100. In 3 clinical vignettes, participants will be shown standard AI model predictions and 3 vignettes they will be shown systematically biased AI model predictions with the model specifically biased against one of the three diagnoses. If the AI model provides a score above 50 an AI model explanation will be shown as gradient-weighted class activation mapping (Grad-CAM) heatmaps overlaid on the chest X-ray that highlighted which regions of the image most affecting the AI model's prediction.
224215548|NCT00661674|OTHER|Placebo|"Over 3 study visits, patients will receive one of the following treatment regimens:~* Placebo saline IV and sugar pill~* 0.75 mg Palonosetron IV and sugar pill~* 0.75 mg Palonosetron IV and 100 mg hydroxyzine PO"
223763023|NCT06098950|OTHER|AI model biased against heart failure|In 3 clinical vignettes, participants will be shown systematically biased AI model predictions with the model specifically biased against heart failure, always predicting that heart failure is present with high likelihood in survey vignette patients with a body mass index (BMI) at or above 30. Standard predictions will be shown for the other 2 diagnoses (pneumonia, COPD).
224215549|NCT00933660|OTHER|ERC-training by instructor|Standard way of training with an instructor
224215550|NCT00933660|OTHER|Web-based training only|Experimental way of training with a web based training application
224215551|NCT00933660|OTHER|Web-based training with a personal training manikin|Experimental way of training with a web based training application and a simple personal training manikin
223763024|NCT06098950|OTHER|AI model biased against pneumonia|In 3 clinical vignettes, participants will be shown systematically biased AI model predictions with the model specifically biased against pneumonia, always predicting that pneumonia is present with high likelihood in survey vignette patients 80 years or older. Standard predictions will be shown for the other 2 diagnoses (heart failure, COPD).
223763025|NCT06098950|OTHER|AI model biased against COPD|In 3 clinical vignettes, participants will be shown systematically biased AI model predictions with the model specifically biased against COPD, always predicting that COPD is present with high likelihood in survey vignette patients where a pre-processing filter was applied to the patient's X-ray. Standard predictions will be shown for the other 2 diagnoses (heart failure, pneumonia).
224215552|NCT04835766|DIAGNOSTIC_TEST|Urodynamic study|Uroflowmetry, voiding cystometrogram, maximum flow rate (Qmax) and detrusor pressure at maximum flow (Pdet Qmax).
224215553|NCT01401920|OTHER|leg elevation|bilateral passive leg elevation for 30 seconds
224215554|NCT01401920|OTHER|Trendelenburg position|Trendelenburg position (15 degrees) for 30 seconds
224215555|NCT01401920|OTHER|Trendelenburg position + passive leg elevation|Trendelenburg position + passive leg elevation
223763026|NCT02748577|OTHER|Questionnaires|Before the experimental session, participants will use REDCap to complete several questionnaires used to assess outcomes.
223763027|NCT02748577|OTHER|Quantitative Sensory Testing (QST) Pain Measurements|Investigators will administer noxious thermal stimulation to assess pain threshold temperatures and assess responses to pain on measures of pain intensity and pain unpleasantness
224215556|NCT01401920|OTHER|control group|supine position without passive leg elevation or trendelenburg position
224215557|NCT06118359|BEHAVIORAL|Intervention to Support Interhospital Transfer Decisions (SITe)|The SITe intervention and implementation toolkit was developed in Aim 1 through stakeholder activities. SITe, an intervention to support interhospital transfer decisions regarding older EGS patients, includes a checklist and script to be utilized by accepting providers during their conversations with referring providers. The investigators and stakeholders also developed a toolkit for implementation with resources to reduce barriers to and support facilitators of utilizing the tools. The toolkit includes: (1) the checklist and script; (2) methods to train accepting providers on the tools including a PowerPoint presentation and demonstration video; and (3) resources to familiarize other parties (transfer center nurses, referring providers, referring hospitals) with the SITe intervention.
224215558|NCT04917900|DRUG|Pyrotinib combined with albumin-bound paclitaxel and trastuzumab|Pyrotinib: 400mg, po,qd,with warm water within 30 minutes after breakfast, q3weeks, 6 cycles in total. Albumin-bound paclitaxel: 260mg/m2, iv, Day1, q3weeks, 6 cycles in total. Trastuzumab: The first cycle dose is 8mg/kg, and each subsequent cycle is 6mg/kg, iv, Day 1, q3weeks, a total of 6 cycles.
223626440|NCT05526716|BIOLOGICAL|Matching Placebo for V116|Single 0.5 mL of sterile saline IM injection
224215559|NCT02476552|DRUG|Niraparib Oral Capsules (Labeled)|Single 300 mg dose of niraparib
224215560|NCT02476552|DRUG|Niraparib IV (Labeled)|Intravenous (IV) infusion of 100 μg niraparib (containing approximately 1 μCi of \[14C\]-niraparib)
224215561|NCT02476552|DRUG|Niraparib Oral Capsules (Unlabeled)|Single 300 mg dose of niraparib (unlabeled active pharmaceutical ingredient)
224215562|NCT03094806|DEVICE|Acapella Vibratory PEP Therapy Device plus usual care|The acapella® Vibratory PEP Therapy System (PEP-FV) device is a handheld device that operates in same principle as standard FV. Unlike standard FV, it is not gravity dependent. It comes in two different devices to accommodate for different flows rates of the patient. It has similar properties of a standard FV and may be better tolerated.
224215563|NCT03094806|DEVICE|Sham Acapella Vibratory PEP Device plus usual care|The Sham Acapella Vibratory PEP Device is the same as the Therapy Device, except the flutter valve has been removed from the device.
224215564|NCT06530537|DRUG|Cilostazol|Cilostazol 100mg twice daily
224215565|NCT06530537|DRUG|Aspirin|Aspirin 100mg once daily
224215566|NCT06404697|RADIATION|Boost irradiation|High-risk patients will undergo boost irradiation to the SCV with a cumulative dose of ≥60 Gy.
223626441|NCT05763017|OTHER|Relative Motion Splint|Six weeks relative motion splint wear.
223626442|NCT05763017|OTHER|Metacarpophalangeal Joint Blocking Splint|Six weeks metacarpophalangeal joint blocking splint wear.
223626443|NCT02997631|DEVICE|MEDi Robot|Distraction therapy using an interactive humanoid robot
223626444|NCT05989126|DRUG|aflibercept 8 mg PFS|Sterile aqueous solution in a single-dose PFS administered by intravitreal (IVT) injection
224316959|NCT00425373|DRUG|Amlodipine 2.5 mg|Amlodipine 2.5 mg capsule plus 4 tablet and 1 capsule placebos taken once daily
224316960|NCT00425373|DRUG|Amlodipine 5 mg|Amlodipine 5 mg capsule plus 4 tablet and 1 capsule placebos taken once daily
223626445|NCT03541850|DRUG|Antiandrogen Therapy|Receive luteinizing hormone-releasing hormone agonist or gonadotropin-releasing hormone antagonist, and oral anti-androgen
224215567|NCT01780727|PROCEDURE|EGHEM|Echocardiography guided hemodynamic management. Subjects in this arm will undergo intraoperative transesophageal echocardiography as part of the study.
223763028|NCT01262313|BEHAVIORAL|Lifestyle Counseling|"Participants in the intervention group will attend an 8-week group intervention discussing Healthy Creations lifestyle changes."
223763029|NCT04495114|OTHER|40g carbohydrate load (Apple juice)|A 40g carbohydrate drink will be administered to subjects with non-insulin dependent type 2 diabetes 3 hours prior to their operation. This is standard practice in subjects without diabetes.
223763030|NCT00354172|BIOLOGICAL|aldesleukin|10 Million units subcutaneous every other day on days -13 (after Natural killer cell graft), -11, -9, -7, -5, -3) If \< 45 kilograms (Kg) - interleukin (IL)-2 at 5 MU/m2
223763031|NCT00354172|BIOLOGICAL|filgrastim|All patients will receive filgrastim (same as granulocyte-colony stimulating factor or G-CSF) 5 mcg/kg/day intravenous (IV) (dose rounded to vial size) based on the actual body weight beginning on day +1 after umbilical cord blood (UCB) infusion. Granulocyte Colony Stimulating Factor (G-CSF) will be administered daily until the absolute neutrophil count (ANC) exceeds 2.5 x 10\^9/L for three consecutive days and then discontinued. If the ANC decreases to \<1.0 x 10\^9/L, G-CSF will be reinstituted.
224215568|NCT00180830|DRUG|Glivec|
224215569|NCT00180830|DRUG|Gleevec|
223763032|NCT00354172|BIOLOGICAL|natural killer cell (NK) therapy|All CD3 depleted cells will be given (less those required for product monitoring). The minimum size of a starting NK cell unit will be 700 million mononuclear cells before processing. NK cells (CD56+) and NK cell precursors (CD34+/CD7-, CD34+/CD7+, CD34-/CD7+) will be monitored and reported but will not serve as lot release.
223763033|NCT00354172|DRUG|cyclophosphamide|Cyclophosphamide to be administered with high volume fluid flush and mesna on days-18 and -17 after fludarabine. Cyclophosphamide 60 mg/kg/day intravenously (IV) x 2 days, total dose 120 mg/m2 (days -18 and -17)
223763034|NCT00354172|DRUG|cyclosporine|Patients will receive cyclosporine (CSA) therapy beginning on day -1 maintaining a level of \>200 ng/mL. For adults the initial dose will be 2.5 mg/kg intravenously (IV) over 2 hours every 12 hours. For children \<40 kg the initial dose will be 2.5 mg/kg IV over 2 hours every 8 hours.
223763035|NCT00354172|DRUG|fludarabine phosphate|Fludarabine 25 mg/m2/day intravenously (IV) x 3 days, total dose 75 mg/m2 (days -18 to -16)
223763036|NCT00354172|DRUG|methylprednisolone|"This modification will be enacted based on the engraftment stopping rule on all subsequent patients to stop natural killer (NK) cell reaction.~Methylprednisolone bolus 1000 mg intravenously (IV) will be administered day -1 and day 0 (before umbilical cord blood transplant) to suppress natural killer (NK) cell activity before transplant. Starting cyclosporin and mycophenolate mofetil (MMF) will also contribute to suppressing residual NK cell activity."
223763037|NCT00354172|DRUG|mycophenolate mofetil|"All patients will begin mycophenolate mofetil (MMF) on day -1. Patients~≥ 45 kilograms will receive MMF at the dose of 3 grams/day divided into 2 or 3 doses. Pediatric patient (\<45 kilograms) will receive MMF at the dose of 15 mg/kg. Use intravenous (IV) route between days -1 and +5, then, if tolerated, may change to by mouth (PO) between days +6 and +30.~Stop MMF at day +30 or 7 days after engraftment, whichever day is later, if no acute Graft Versus Host Disease. (Definition of engraftment is 1st day of 3 consecutive days of absolute neutrophil count \[ANC\] \> 0.5 x 10\^9 /L)."
223763038|NCT00354172|PROCEDURE|Umbilical Cord Blood Transplantation (UCBT)|The product is infused via intravenous (IV) drip directly into the central line without a needle, pump or filter.
224215570|NCT00460473|DRUG|Dexmedetomidine|
224215571|NCT00460473|DRUG|Placebo|
224215572|NCT00218686|BEHAVIORAL|psychoeducational|psychoeducational
224215573|NCT00218686|BEHAVIORAL|control|VTC
224215574|NCT06245616|DIETARY_SUPPLEMENT|Consumption of olive pomace olive oil by alzheimer's patients|Consumption of olive pomace olive oil by alzheimer's patients as part of a breakfast containing 3 bread slices and coffee with or without skimmed milk.
224215575|NCT06245616|DIETARY_SUPPLEMENT|Consumption of high-oleic sunflower oil by alzheimer's patients|Consumption of high-oleic sunflower oil by alzheimer's patients Consumption of olive pomace olive oil by alzheimer's patients as part of a breakfast containing 3 bread slices and coffee with or without skimmed milk.
224316961|NCT00425373|DRUG|Placebo|4 tablet and 2 capsule placebos taken once daily
224316962|NCT05257226|BEHAVIORAL|frailty|questionaire
224316963|NCT06088030|DRUG|Arsenic trioxide|Patients should be treated with the corresponding first-line chemotherapy regimen first, for example: Neuroblastoma: CAV (cyclophosphamide, pinarubicin, vincristine), PVP (cisplatin, etoposide) ,CT (cyclophosphamide, topotecan).If patients was evaluted as PD/SD after treatments, arsenic trioxide (ATO) will be administered 0.18mg/kg per day over six hours IV daily for ten days in combination with previous chemotherapy regimen on the third day of each treatment cycle. Other pediatric tumors with TP53 mutations not mentioned above will have similar treatment regimens. If the efficacy of the conventional standard chemotherapy regimen is evaluated as PD/SD, then the next course of treatment will be combined with ATO on the basis of the standard chemotherapy regimen.
224316964|NCT01342757|DRUG|vorinostat|Given orally
223626446|NCT03541850|OTHER|Quality-of-Life Assessment|Ancillary studies
223626447|NCT03541850|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
223626448|NCT04709068|DEVICE|Current Health|wearable device and tablet used to collect health measures at home
223626449|NCT04019379|OTHER|High Phosphorus Diet|Controlled research diet of high phosphorus (with low calcium)
223626450|NCT04019379|OTHER|Low Phosphorus Diet|Controlled research diet of low phosphorus (with low calcium)
223626451|NCT04002141|DRUG|Placebo oral tablet|1 tablet oral daily
223626452|NCT04002141|DRUG|Letrozole|5mg oral daily
224316965|NCT01342757|DRUG|temozolomide|Given orally
224316966|NCT01342757|PROCEDURE|magnetic resonance spectroscopic imaging|Undergo MRI
224316967|NCT01342757|OTHER|survey administration|Ancillary studies
223626453|NCT04750824|DRUG|Afatinib|Afatinib
223626454|NCT04750824|DRUG|other systemic therapy|other systemic therapy
224215576|NCT03557710|BEHAVIORAL|Devaluing energy-dense foods for cancer-control|A 3-arm randomized controlled trial experiment study over 12 months. At baseline, participants will complete behavioral, neural, and self-report measures related to food, specifically measures of food valuation and of the proximal neural systems hypothesized to be linked to each of the 2 experimental arms. We will also measure food intake and body composition at baseline. Then participants will be randomized to one of 3 arms (2 experimental + 1 active control) for 8 30-min sessions to occur twice weekly at the University of Oregon for 30 days. At endpoint (\~1 month following baseline), all behavioral, neural, and self-report measures will be reassessed, as will eating, habit, and body composition measures. Follow-ups at 3, 6, and 12 months will assess all measures except neuroimaging.
224215577|NCT02058810|DEVICE|Nasal high flow|
223763039|NCT00354172|RADIATION|Total body irradiation (TBI)|"TBI 165 Gray (cGy) will be given twice daily for a total dose of 1320 cGy (days~-16 to -13)."
223763040|NCT05888168|PROCEDURE|CABG|All participants in the study will undergo the standard procedure of CABG. Continuous electrocardiogram monitoring and electrocardiography were used to identify the cardiac rhythm.
223763041|NCT00001839|DRUG|Antithymocyte globulin|
223763042|NCT00001839|DRUG|Cyclosporine|
223763043|NCT03912727|DIETARY_SUPPLEMENT|Alpha-Lipoic acid plus renal replacement therapy|Alpha lipoic acid (ALA) is a vitamin-like antioxidant
224215578|NCT02058810|DEVICE|Conventional nasal oxygen|
224215579|NCT02770716|DRUG|Terlipressin|Terlipressin solution for injection
224215580|NCT02770716|OTHER|Placebo|Matching placebo solution for injection
224215581|NCT04569955|BEHAVIORAL|Knowledge and perception of clinical trial participation|This study aims to get a current picture of the patients' knowledge and perception of clinical trial participation in Breast cancer female patients in Egypt, as an example to Low/Middle income countries
224215582|NCT04697355|DIETARY_SUPPLEMENT|naringenin and beta carotene|Subject will ingest 300 mg naringenin three times/day and 6 mg beta carotene two times/day for eight weeks
224215583|NCT01725113|DRUG|Calcitriol|3 times weekly
223763044|NCT03912727|OTHER|renal replacement therapy|standard renal replacement therapy
223763045|NCT06448741|OTHER|Replantation of amputated penis|Replantation of the amputated penis done macroscopically, but testicular replantation was not done because of lack of microsurgical access
223763046|NCT04145570|DRUG|Erlotinib HCl 150 mg|"Concentrations of erlotinib were measured from the samples collected over a 72 hour interval after receiving either Erotinib generic or Tarceva original. Later, after 14 days, a crossover was took place with the same measures.~dosing in each period."
223763047|NCT04145570|DRUG|Tarceva®|Tarceva® 150 mg
223763048|NCT06216392|BIOLOGICAL|GR1802 injection|150mg/1ml. 2 ml every two weeks Route of administration: Subcutaneous
224215584|NCT01725113|DRUG|Paricalcitol|3 times weekly
224215585|NCT05269719|PROCEDURE|Suture of digital nerve|The digital nerves were sutured according to the discretion of the treating surgeon and the standard procedure was three epineural sutures 8.0 or 9.0 nylon under loop magnification. Concomitant tendon injuries were also sutured according to the discretion of the treating surgeon, most commonly with two loop sutures (four strand core) and a peritendinous PDS suture.
224215586|NCT04504864|DRUG|low-dose aspirin|50mg aspirin is used to prevent recurrent stroke.
224215587|NCT04504864|DRUG|conventional-does aspirin|100mg aspirin is used to prevent recurrent stroke.
224215588|NCT03989115|DRUG|RMC-4630|RMC-4630 for oral administration
224215589|NCT03989115|DRUG|Cobimetinib|Cobimetinib for oral administration
224316968|NCT01859910|PROCEDURE|compression and scrub of lid margin|compression and scrub of lid margin for 5 circles before cataract surgery
224316969|NCT01859910|PROCEDURE|routine preparation for cataract|
223626455|NCT05136976|DRUG|Rituximab infusion|2 infusions of 1 gram of rituximab at a 2 week interval (day 1 followed by day 15).
223626456|NCT05136976|DRUG|Placebo infusion|2 infusions of placebo at a 2 week interval.
224215590|NCT03989115|DRUG|Drug: Osimertinib|Osimertinib for oral administration
224215591|NCT01777685|DRUG|Sulpiride|
224215592|NCT00077688|DRUG|TOCOSOL Paclitaxel|
223763049|NCT06216392|BIOLOGICAL|placebo|0mg/1ml. 2 ml every two weeks Route of administration: Subcutaneous
223763050|NCT02271308|BEHAVIORAL|Low-resistance elastic band training|The residents in experimental group will receive a low-resistance elastic band training (30 minutes), including warm-up and cold-down period, three times per week for 12 weeks.
223763051|NCT04992559|DRUG|Consolidation Toripalimab|Toripalimab consolidation therapy after radiotherapy or chemoradiotherapy, 240mg IV, every 3 weeks, until progressive disease (PD), start new anti-cancer therapy, intolerable toxicity, withdraw informed consent or other conditions that require study treatment discontinuation. Toripalimab will be given at a maximum of 12 months.
224215593|NCT05559554|DRUG|AK104 (before the change)|Dose 1 and dose 2 in pilot study, and recommended dose in pivotal study.
224215594|NCT05559554|DRUG|AK104 (after the change)|Dose 1 and dose 2 in pilot study, and recommended dose in pivotal study.
223763052|NCT01054703|DEVICE|Ethmoid Sinus Spacer|Ethmoid Sinus Spacer and Access System used for the local delivery of Kenalog-40
223763053|NCT05492058|OTHER|tactile stimulation group|The tactile stimulation group will be asked to touch their own abdomen during the NST procedure.
223763054|NCT05492058|OTHER|listen music|Pregnant women in the music group will listen to a song they want with headphones during the NST procedure.
223763055|NCT05492058|OTHER|virtual reality group|Pregnant women in the virtual reality group will be shown a nature walk video with nature sounds (stream, bird, etc.) during the NST procedure.
224316970|NCT04504123|DRUG|Doxycycline Hyclate|Doxycycline Hyclate capsules, USP 50 mg
224316971|NCT04504123|DRUG|Placebo|Placebo
224316972|NCT05097365|DIETARY_SUPPLEMENT|Vitamin B12 + folic acid supplementation|A 12 weeks parallel-group randomised controlled trial will be performed, in which erythematous lupus patients will complete a vitamin B12 and folic acid supplementation, in addition to the usual therapy. The dietary supplementation will be by capsules, which will content 400 mcg of folic acid and 2000 mcg of vitamin B12 each.
224316973|NCT05097365|DIETARY_SUPPLEMENT|Placebo supplementation|A 12 weeks parallel-group randomised controlled trial will be performed, in which erythematous lupus patients will complete a placebo supplementation.The placebo and vitamin B12 + folic acid supplement will be indistinguishable in terms of taste, smell, and appearance.
223626457|NCT05136976|DRUG|Premedications|"Premedications prior to rituximab or placebo infusions:~* IV Dexchlorpheniramine Maleate IV: 10 mg~* IV Methylprednisolone: 40 mg~* PO Paracetamol : 1 gram"
224316974|NCT05378594|DIAGNOSTIC_TEST|Nasal allergen challenge|graded nasal allergen challenge to increasing concentrations of allergen with monitoring of nasal symptoms and peak nasal inspiratory flow
224316975|NCT04117802|OTHER|Maple syrup|Substitution of refined sugar by an equivalent quantity of maple syrup (5% of daily energy intake) in the participant diet. A dietitian will help study subjects to target added sugar sources in their usual diet and suggest ways to substitute it with maple syrup.
224316976|NCT04117802|OTHER|Placebo|Substitution of refined sugar by an equivalent quantity of maple-flavored sucrose syrup (5% of daily energy intake) in the participant diet. A dietitian will help study subjects to target added sugar sources in their usual diet and suggest ways to substitute it with the placebo (sucrose syrup).
224316977|NCT04974203|DEVICE|AptameX|DNA aptamer-based test using patient's saliva
224316978|NCT03032679|OTHER|Non interventional study|No intervention
223626458|NCT04672590|OTHER|Primary exposure is hypoxia (no intervention)|The primary exposure, hypoxia, will be defined as severe, non-severe or none for each participant, based on pre-defined criteria.
223626459|NCT00807911|DRUG|Adjuvant FL|5-Fluorouracil 380 mg/m2, leucovorin 20 mg/m2 on D1-5 q 4 weeks X 4 cycles
223626460|NCT00807911|DRUG|Adjuvant FOLFOX|oxaliplatin 85 mg/m2, leucovorin 200 mg/m2 on D1, 5-Fluorouracil bolus 400 mg/m2 on D1, 5-Fluorouracil continuous infusion 2400 mg/m2 for 46 hours q 2 weeks X 8 cycles
223626461|NCT03859024|DRUG|Oxycodone|oxycodone tablet
223626462|NCT03859024|DRUG|Acetaminophen|acetaminophen tablet
223626463|NCT03859024|DRUG|Gabapentin|gabapentin tablet
223626464|NCT03859024|DRUG|celebrex|Celebrex tablet
223626465|NCT03859024|DRUG|Bupivacaine|bupivacaine injection
223626466|NCT03859024|DRUG|Ibuprofen 800 mg|ibuprofen tablet
223626467|NCT03859024|DRUG|Dexamethasone|Dexamethasone injection
223626468|NCT04530981|DRUG|Ripretinib|Oral KIT/PDGFRA kinase inhibitor
223626469|NCT04530981|DRUG|Repaglinide|Oral antihyperglycemic agent
223626470|NCT05040659|DEVICE|AROMHA Longitudinal Smell Test|The AROMHA Longitudinal Smell Test is a self-administered, at-home smell test intended for use as a screening test by asymptomatic individuals to help prevent exposure to and spread of SARS-CoV-2, the virus that causes COVID-19, through a serial testing approach. The device consists of six versions of a smell card, each containing three unique odors.
223626471|NCT04921670|DIAGNOSTIC_TEST|Infliximab Assay|Participants will be assigned to standard of care or proactive drug monitoring, which is measuring infliximab levels/antibodies before every infusion
223626472|NCT05627271|OTHER|ocrelizumab|Non-interventional, cross-sectional, qualitative study. There is no treatment allocation. Patients prescribed with Disease-modifying therapy in the commercial setting are eligible to enroll into this study.
223626473|NCT05627271|OTHER|natalizumab|Non-interventional, cross-sectional, qualitative study. There is no treatment allocation. Patients prescribed with Disease-modifying therapy in the commercial setting are eligible to enroll into this study.
223626474|NCT05627271|OTHER|ofatumumab|Non-interventional, cross-sectional, qualitative study. There is no treatment allocation. Patients prescribed with Disease-modifying therapy in the commercial setting are eligible to enroll into this study.
223626475|NCT01290458|DIETARY_SUPPLEMENT|Antioxidant vitamins|Oral supplementation with one tablet of 1 g of vitamin C (Lamberts Healthcare Ltd, UK) and one tablet of 400 IU of vitamin E (Lamberts Healthcare Ltd, UK)
223626476|NCT05626101|DRUG|BCG|Intravsical induction and maintenance BCG injections.
223626477|NCT05626101|DRUG|Gemcitabine|Intravsical induction and maintenance gemcitabin injections.
223626478|NCT02854072|DRUG|GV1001|At week 1, GV1001 will be administered intradermally on day 1, day 3 and day 5. This will be followed by a once weekly schedule for weeks 2, 3, 4 and 6. After that, GV1001 will be administered once monthly until withdrawal from trial treatment due to patient choice, intolerable toxicity or disease progression. GM-CSF will be used as an adjuvant, given 10-15 minutes prior to each administration of GV1001.
223626479|NCT02854072|DRUG|Gemcitabine|Gemcitabine 1000 mg/m\^2 will be intravenously administered on day 1,8 and 15 followed by 7 days' rest.
223626480|NCT02854072|DRUG|Capecitabine|Capecitabine 830 mg/m\^2 will be orally given in the morning and evening (total dose of 1660 mg/m\^2) for 21 days followed by 7 days' rest.
223626481|NCT02325596|GENETIC|miRNA mimics or inhibitors|DCs are transfected by the miRNA mimics or inhibitors after they are separated from peripheral blood mononuclear cells in CRS patients
223626482|NCT03628092|DEVICE|CO2 Fractional Ablative Laser|Vaginal / vulval laser treatment
223626483|NCT03628092|DEVICE|Placebo|Sham Device
223626484|NCT04006418|OTHER||
223626485|NCT00111046|DRUG|Ibuprofen|
223626486|NCT00111046|DRUG|Tramadol|
223626487|NCT04357717|DIAGNOSTIC_TEST|ExoDx Prostate|Urine-based biomarker tool to support decision to biopsy in patients with PSA between 2-10ng/ml
223626488|NCT01584869|DEVICE|capsule endoscopy|
223626489|NCT00701454|OTHER|No intervention|No intervention
224316979|NCT06171100|DRUG|Tolvaptan|"Oral ingestion of low dose Tolvaptan (7.5mg daily) for management of inpatient hyponatraemia for 1st dose Tolvaptan group.~Oral ingestion of low dose Tolvaptan (7.5mg daily) or standard dose Tolvaptan (15mg daily) for 2nd dose Tolvaptan group."
224316980|NCT05350605|BEHAVIORAL|Breastfeeding position education with lactation simulation model|pregnant women will receive training with a lactation simulation model once in the last trimester.The pregnant woman will wear the lactation simulation model during the education period and show what she has learned practically on the model.Mothers who have given birth will be supported to practice the breastfeeding position in the postpartum service.
224316981|NCT04516993|DRUG|Tenecteplase|Intravenous (IV) tenecteplase 0.25 mg/kg (single bolus; maximum dose 25 mg)
224316982|NCT04516993|DRUG|The best treatment selected by local doctors(Aspirin, Recombinant Tissue Plasminogen Activator, Urokinase, Thrombectomy)|Best treatment arm
224316983|NCT01266031|DRUG|vorinostat|Vorinostat 400mg/day will be administered on day 1 to 7 and day 15 to 21 orally on a 28 day cycle in the arm with combination of vorinostat and bevacizumab. Vorinostat will be administered orally. Vorinostat capsules should not be opened or crushed and must be administered whole.
224316984|NCT01266031|DRUG|bevacizumab|Bevacizumab 10mg/kg will be administered on day 1 and 15 intravenously on a 28 day cycle in both arms.
223626490|NCT01325077|OTHER|model of health care service|Conventional model(C): Nurses give fixed-dose analgesic according to surgeons' prescription Study model(S): Nurses give initial-dose analgesic according to surgeons' prescription. In case of inadequate pain relief, another half of initial dose will be given twice at 15-min interval and acute pain service will be consulted if there is still pain.
223626491|NCT04780867|BEHAVIORAL|Delayed vaccination|First and second hepatitis B vaccinations will be delayed by 1 month in the interventional group to establish whether changes in psychosocial and lifestyle factors during training impact immune health.
223626492|NCT00759590|PROCEDURE|CT scan and Pressure volume curve|CT scan
223626493|NCT00099801|DRUG|FTY720|
223626494|NCT02570984|DRUG|Omalizumab|anti-ige injection
223626495|NCT02570984|DRUG|Placebo|placebo comparator arm, injection similar to active
223626496|NCT01149993|DRUG|Myfortic (mycophenolic acid)|720mg twice a day for 7 days prior to transplantation
223626497|NCT01149993|DRUG|Myfortic (mycophenolic acid)|720mg twice a day after transplant
223626498|NCT01149993|DRUG|Thymoglobulin (anti-thymocyte globulin)|up to 25 mg will be infused into the renal artery of a donor kidney prior to transplantation into the recipient.
223626499|NCT01149993|DRUG|Thymoglobulin (anti-thymocyte globulin)|standard of care for Georgetown University Hospital: 1.5 mg/kg/day infused over 6 hours.
223626500|NCT05500287|OTHER|Virtual Care|Children in the virtual care group had distance asthma education, case management and virtual care
223763056|NCT02784301|DEVICE|Belly breathing with biofeedback app|This intervention consists of learning how to belly breathe using a smartphone biofeedback application that coaches children how to breathe slowly and deeply. The app consists of a cartoon avatar in a hot air balloon that inhales and exhales bubbles. The goal of the biofeedback game is to a) teach a voluntary deep breathing protocol, b) detect compliance to the breathing protocol using the attached audio-based pulse oximeter sensor and c) to raise the hot air balloon in accordance to this compliance in order to motivate the children. Scenery changes as the balloon rises, driven by biofeedback, until it eventually reaches outer space.
224215595|NCT03367026|DRUG|Ivabradine Oral Product|"Patients in the ivabradine treatment arm receive an additional enteral preparation (orally, via nasogastric tube or Jejunum tube) of ivabradine for 4 days.~Day 1 :~2.5 mg ivabradine b.i.d. if heart rate ≥90 bpm~Day 2,3,4:~2.5 mg ivabradine b.i.d. if 60bpm≥heart rate\<90bpm. 5.0mg ivabradine b.i.d. if heart rate ≥90bpm"
224215596|NCT00542516|DRUG|Hydroxyethyl Starch|Dosage: 30ml/kg; frequency: one time; duration: 60min
224215597|NCT00542516|DRUG|Ringer's lactate|Dosage: 30ml/kg; frequency: one time; duration: 60min.After 10ml-kg-h both groups
224215598|NCT04417790|DIAGNOSTIC_TEST|Lung ultrasound and EVLW measurement by transpulmonary thermodilution.|Lung ultrasonography by 8 Quadrant protocol of Volpicelli et al. Transpulmonary thermodilution for extravascular lung water measurement
223626501|NCT04538521|DIETARY_SUPPLEMENT|Niacin|The dose for a slow-released form of niacin will be 500-1000 mg/day. The daily niacin dose, 250 mg/day, is gradually escalated by 250 mg/month so that the full dose is reached after 2 months. The intervention time with the full niacin dose is 8 months and subsequently total intervention time 10 months.
223626502|NCT01616966|DRUG|Sevoflurane|Maintenance of anesthesia with sevoflurane 1.0 Vol%
224316985|NCT00013091|BEHAVIORAL|Self-management therapy; Psychoeducational group therapy|
223626503|NCT01616966|DRUG|propofol|Maintenance of anesthesia with propofol
223626504|NCT06174246|BEHAVIORAL|Pain self-management program|"Agir pour moi (Acting for me) is a chronic pain self-management program designed to be followed independently online. The eight modules, normally spread over eight weeks and taking about 60 to 90 minutes per week to complete, focus on different strategies for managing pain on a daily basis.~The structured lessons include videos, audio capsules, activities, and written information, also provided in an audio format. The program covers goal setting, stress management through relaxation, breathing and mindfulness, pacing, physical activity, thoughts and emotions, sleep, nutrition, flare-up management, and planning.~The program was developed through a partnership between various chronic pain interest groups, and is hosted and managed by the Leadership Chair in Chronic Pain Education.-MEDISCA de l'Université Laval, Québec, Canada.~See ClinicalTrials entry NCT05319652 https://gerermadouleur.ca/agir-pour-moi/"
223626505|NCT06174246|BEHAVIORAL|Additional support for self-management program|"This intervention is designed to give extra support to patients completing the online pain education program. It consists of two visits with a physiotherapist, and one group session led by a peer living with chronic musculoskeletal pain.~Sessions with the physiotherapist will occur at the beginning of the program and at the midway point. They will be used first to present the objectives and the components of the self-management program, to reinforce its potential to improve the participant's ability to manage their pain, and then to answer the participant's questions on the program and follow up on the regular completion of the lessons.~The group session will be co-facilitated by a physiotherapist and a patient-partner, and will include participants who have completed at least six weeks of the program. It will serve as a discussion forum to share helpful pain self-management strategies, lived experiences with pain and facilitators in completing the program."
223626506|NCT00335699|DRUG|Rosuvastatin|
224316986|NCT05908292|PROCEDURE|Pelvic Floor Scar Tissue Self-Scar Massage|Self scar-massage intervention of healed pelvic floor scar tissue for 5 minutes, 3x/week for 6 weeks.
223626507|NCT01951443|DIETARY_SUPPLEMENT|Ginseng|400mg of encapsulated Rg3-KRG
223626508|NCT01951443|DIETARY_SUPPLEMENT|Wheat Bran|400mg of encapsulated wheat bran
223626509|NCT03101969|OTHER|Call|not called, not reached, and spoken to
223626510|NCT03547518|DEVICE|PTNS treatment|One-week induction consisting of three active PTNS treatments, each 2 hours long
223626511|NCT03547518|DEVICE|Sham treatment|One-week induction consisting of three active PTNS treatments, each 2 hours long
223626512|NCT01533792|PROCEDURE|Supra/subgingival scaling using periodontal curette scraping|The experimental group received supra and subgingival therapy with periodontal curettes
223626513|NCT01533792|PROCEDURE|Supra and subgingival scaling|The experimental group received supra and subgingival scaling.
223626514|NCT04854135|DEVICE|CGM4Home|FreeStyle Libre 2 Continuous Glucose Monitoring System manufactured by Abbott
223626515|NCT04228588|DRUG|Mepolizumab 100 MG [Nucala]|Mepolizumab 100mg, SC, every 4 weeks
223626516|NCT04457739|OTHER|Tidal volume challenge|Increasing tidal volume from 6 to 8 mL/kg during 1 min
224316987|NCT04399486|OTHER|Physical Therapy|Physical Therapy is a therapeutic exercise, education and functional activities provided on a one to one basis with a licensed Physical Therapist to meet functional goals.
223626517|NCT04457739|OTHER|End-expiratory occlusion test|Interrupting the ventilator at end-expiration for 15-30 s and assessing the resulting changes in cardiac output
223626518|NCT04457739|OTHER|Trendelenburg maneuver|Patients remained in prone position with a 13° upward bed angulation throughout the study and then be positioned in a declining position at -12 ° for 1 minute
223626519|NCT06050265|DEVICE|DEXCOM Continuous Glucose Monitor (CGM)|Dexcom CGMs are placed every 10 days and provide a continuous assessment of blood glucose.
223626520|NCT04252911|OTHER|Bispectral index score|Bis value from two sites gives similar results
223626521|NCT00360841|PROCEDURE|Auricular acupuncture|Subjects will be randomized to one of these arms. The subjects in arm A and B will receive auricular acupuncture. Before subjects receive chemotherapy within one day, they will be treated by auricular acupuncture, sham acupuncture, or control group.
223626522|NCT00360841|PROCEDURE|Sham auricular acupuncture|
223626523|NCT03359629|DEVICE|Spectrophon Glucometry Monitor|Wearable smartwatch with integrated non-invasive glucose detection system
223626524|NCT03359629|DEVICE|YSI 2300 Stat Plus|Reference commercial glucometer
223626525|NCT06552286|BEHAVIORAL|STRW-T|The STRW-T intervention consists of 15 weekly caregiver group sessions and caregiver-teen dyad sessions delivered via Zoom. The targeted daily living skills (DLS) have been identified and refined through our prior studies and include: Morning routine, laundry, kitchen/cooking, grocery shopping, and money management. Evidence-based strategies are utilized to facilitate acquisition, mastery, and generalization of specific DLS at home and in the community. During dyad sessions, teens will work on DLS in their home environment and will receive coaching and instruction from both their caregiver and the therapist. During caregiver group sessions, the therapist will discuss the content of dyad sessions and engage in problem solving with each caregiver (e.g., using and fading rewards, implementing strategies to increase success, teen motivation/buy-in).
223626526|NCT06552286|BEHAVIORAL|PEERS-T|PEERS-T is a 15-week intervention with concurrent caregiver and teen group telehealth sessions that target social skills (e.g., building friendships, conversing, dealing with bullying). PEERS-T was chosen as the control because it is one of the few evidence-based interventions for autistic adolescents and does not address daily living skills. PEERS-T is also matched to STRW-T on duration and is clinically meaningful to families.
223626527|NCT05282095|OTHER|Follow up|Participants will be followed up at baseline, 3th, 6th, 9th and 12th months with HPV viral integration tests, HPV genotyping tests, thinprep cytologic tests (TCT) for cervix and vaginal secretion tests. Colposcopies and biopsies will be performed on the participants at 6 - and 12-month follow-up.
223626528|NCT05563103|OTHER|Daily acute intermittent hypoxia|Each participant will be exposed to 8 sessions of daily acute intermittent hypoxia via air generators over the span of two weeks. The generator will fill reservoir bags attached to a non-rebreathing facemask. Each session will consist of 15 episodes which include intervals of 1.5 minute hypoxia (FIO2=0.10±0.02, i.e. 10% O2) and 1 minute normoxia (FIO2=0.21±0.02).
223626529|NCT05563103|OTHER|Room air (SHAM)|Each participant will be exposed to 8 sessions of daily room air via air generators over the span of two weeks. The generator will fill reservoir bags attached to a non-rebreathing facemask. Each session will consist of 15 episodes of 1.5 minute normoxia (FIO2=0.21±0.02).
223626530|NCT05563103|OTHER|Walking + tSTIM|Individuals will participate in 45 minutes of gait training while having transcutaneous spinal cord stimulation. Stimulation intensity will be 80% involuntary motor threshold.
224316988|NCT01287026|PROCEDURE|Cardiac Real-time MRI RHC (Right Heart Catheterization)|
223626531|NCT05563103|OTHER|Walking + Sham transcutaneous spinal stimulation (tSHAM)|Individuals will participate in 45 minutes of gait training while having SHAM transcutaneous spinal cord stimulation. The stimulation will briefly increase to 80% involuntary motor threshold and then brought down to 0 within 30 seconds.
224316989|NCT01434810|DEVICE|Filtered-sunlight phototherapy|Infants will receive six hours per day of filtered-sunlight phototherapy for 1 to 10 days. The filtering will be done using window tinting film. Window tinting films by Solutia, Inc., and V-KOOL, Inc.
224316990|NCT01434810|DEVICE|Conventional phototherapy|Infants will receive six hours per day of conventional phototherapy for 1 to 10 days.
223626532|NCT06396598|OTHER|Educational Activity|Review education materials
223626533|NCT06396598|OTHER|Electronic Health Record Review|Ancillary studies
223626534|NCT06396598|OTHER|Internet-Based Intervention|Participate use the electronic symptom monitoring program to log symptoms
223626535|NCT06396598|OTHER|Media Intervention|Watch a video
223626536|NCT06396598|OTHER|Survey Administration|Ancillary studies
223626537|NCT01154920|DRUG|Paclitaxel|135 mg/m\^2 weekly, Weeks 1 - 6
223626538|NCT01154920|DRUG|Carboplatin|AUC of 2 weekly, Weeks 1 - 6
223626539|NCT01154920|DRUG|Cetuximab|"PCC Arm: 400 mg/m\^2 by vein over about 1-2 hours on Day 1; 250 mg/m\^2 weeks 2 - 6.~C-TPF Arm: 250 mg/m2 weeks 2, 4, 5, 7 and 8."
223626540|NCT01154920|DRUG|Docetaxel|75 mg/m\^2 by vein over 1 hour on Day 1 of each 21 day cycle for 3 cycles of induction therapy
223626541|NCT01154920|DRUG|Cisplatin|100 mg/m\^2 by vein over 1-3 hours on Day 1 of each 21 day cycle for 3 cycles of induction therapy
224316991|NCT04550923|COMBINATION_PRODUCT|Z-Brace interbody fusion device|Use non-rigid (Titanium Alloy, Z-Brace, Baui Biotech) interbody fusion device in Anterior Cervical Discectomy and Fusion (ACDF) surgery
223626542|NCT01154920|DRUG|Fluorouracil|700 mg/m\^2 continuous infusion Days 1-4 on Day 1 of each 21 day cycle for 3 cycles of induction therapy
223763057|NCT02784301|BEHAVIORAL|Belly breathing without biofeedback app|This intervention consists of learning how to belly breathe without the biofeedback application prior to the blood collection and continuing with self-directed belly breathing during the procedure itself.
224316992|NCT04550923|COMBINATION_PRODUCT|PEEK interbody fusion device|Use rigid (PEEK) interbody fusion device in Anterior Cervical Discectomy and Fusion (ACDF) surgery
224316993|NCT03718650|DRUG|Pimonidazole|Patients will take a single dose of 0.5 g/m\^2 (approximately 13 mg/kg) of oral pimonidazole HCI 16 to 24 hours prior to surgery.
224316994|NCT03718650|PROCEDURE|Surgical Resection|Patients will undergo Pancreaticoduodenectomy or Whipple procedure, which involves the resection of the pancreatic head, duodenum, gallbladder, and a portion of the stomach, 16 to 24 hours after consuming oral pimonidazole.
223763058|NCT02784301|BEHAVIORAL|Belly breathing + visual distraction|This intervention consists of learning how to belly breathe without the application plus receiving visual distraction by watching a cartoon avatar in the hot air balloon rising through space. The avatar will not coach the child to breathe as the visual cues for breathing (words and bubbles) will not be present and the avatar will not rise in response to correct belly breathing. Participants will be instructed to continue with self-directed breathing while also watching the visual distraction during the blood collection procedure.
223763059|NCT03192839|OTHER|Low dose PUFA|Low dose PUFA
223626543|NCT01154920|RADIATION|Radiotherapy (RT)|Radiation about 2-4 weeks after induction therapy, Monday through Friday for about 7 weeks, or as recommended by the treating radiologist.
223763060|NCT03192839|OTHER|High dose PUFA|High dose PUFA
223626544|NCT01154920|OTHER|Chemotherapy|PCC group receives 6 and C-TPF group receives 3 chemotherapy treatment cycles. If receiving radiation + chemotherapy, weekly Cisplatin 40 mg/m\^2 by vein over 1-3 hours or Carboplatin AUC 2 by vein over 1 hour beginning 2 to 3 weeks after conclusion of induction program.
223626545|NCT06245941|DRUG|TQ05105 tablets|TQ05105 is a Janus kinase 1 (JAK1) and Janus kinase 2 (JAK2) Inhibitor
223626546|NCT06245941|DRUG|TQB3909 tablets|TQB3909 is an inhibitor targeting B-cell lymphoma-2 (BCL-2) protein.
223763061|NCT03192839|OTHER|Placebo|Placebo
223763062|NCT01964911|DRUG|Ropivacaïne|"The first 3 days, analgesic treatments will be provided, as usual, depending on pain intensity (EN \<3/10 : non opioids, EN 3-5/10 : weak opioids, EN\>5/10 : strong opioids).~If NRS is still over 5/10, continuous nerve block will be proposed. Patients will receive ropivacaïne, 5 mL/h during 7 days, with possibility of one bolus before wound care, through a stimulating catheter stimulong sono®.~In association, analgesic treatments will be provided, as usual, depending on pain intensity (as during the first 3 days)."
223763063|NCT05984134|DRUG|NL005 Middle Dose|Patients in this treatment group will receive NL005 for 0.5 ug/kg respective.Continuous administration for 7 days.
223763064|NCT05984134|DRUG|NL005 High Dose|Patients in this treatment group will receive NL005 for 1.5 ug/kg respective.Continuous administration for 7 days.
223763065|NCT05984134|DRUG|Placebo|30 subjects will be randomly assigned to the placebo for 7 days
223763066|NCT00117143|DRUG|Romiplostim|Administered subcutaneously on day 1 and on day 15 or 22 if the platelet count was ≤ 50 x 10⁹/L and not rising, peak platelet count was ≤ 450 x 10⁹/L and no serious adverse events related to treatment were observed.
223763067|NCT02493634|PROCEDURE|pressure gradient measurement|A guidewire is used to introduce and position a pressure catheter under magnetic resonance guidance to conduct flow and pressure measurement in the aortic arch to evaluate vascular resistance.
223763068|NCT02493634|DEVICE|MRWire|
223763069|NCT02803112|PROCEDURE|Emergent craniotomy for traumatic brain injury|Emergent craniotomy for traumatic brain injury (either for removal of an epidural hematoma, subdural hematoma, intraparenchymal hematoma or decompressive craniectomy).
223763070|NCT02672735|OTHER|Corrective Exercise Programming|Participants will be given a four-week corrective exercise protocol, with four corrective exercise sessions prescribed each week. Participants in the CEP Group will be required to complete a minimum of three of these four training sessions per week throughout the four-week corrective exercise program intervention. All corrective exercise programming will be created through the Fusionetics Human Performance System. This system, along with weekly compliance questionnaires, will also assess the compliance-level among the participants.
223763071|NCT03302702|OTHER|Exercise program|Exercise program including breathing control, pursed-lip breathing, diaphragmatic and thoracic breathing, aerobic and strengthening training
223763072|NCT05157100|DRUG|Ingrezza Pill|Participants will receive Ingrezza 40 mg and 80 mg tablets for 12 weeks.
223763073|NCT04589403|DRUG|OPT101|15-mer peptide with sequence based on the mouse CD154 domain interacting with CD40
224316995|NCT04036838|COMBINATION_PRODUCT|PyloPlus UBT System|Breath will be analyzed for change in carbon 13 content in breath after ingestion of enriched carbon 13 urea.
224316996|NCT04036838|DIAGNOSTIC_TEST|Histology|Biopsy specimen fixed with 10% buffered formalin were cut into 4mm sections, stained with Giemsa stain, and examined by experienced pathologist
224316997|NCT04036838|DIAGNOSTIC_TEST|Rapid Urease Test|Biopsy specimen obtained and placed onto Rapid Urease Test
224316998|NCT04036838|DIAGNOSTIC_TEST|H.pylori Culture|Biopsy specimen obtained and sent to lab for culture analysis
224316999|NCT05388513|PROCEDURE|Surgical Resection|Surgically treated patients included
223763074|NCT02287896|DRUG|ROLEDUMAB|See Arm description
224317000|NCT04893018|BIOLOGICAL|Efineptakin alfa|Given IM
224317001|NCT06358235|OTHER|Music Therapy|30-minute music therapy session.
223626547|NCT05830812|DIAGNOSTIC_TEST|Invasiveness diagnosis|To predict the invasiveness of patients with small-sized lung adenocarcinoma intraoperatively based on multi-modal information.
223626548|NCT05820412|OTHER|Intensive interdisciplinary therapy|Intensive interdisciplinary therapy includes an intense burst of physical, occupational, and/or speech therapy with high intensity and frequency in a duration (e.g. 3-6 hours/day, 3-5 days/week for 4 weeks)
223626549|NCT05131945|OTHER|Standard Suction Thoracentesis|a procedure that removes excess fluid from the space in between your lungs and chest wall
223626550|NCT05131945|OTHER|Gravity Thoracentesis|a procedure that removes excess fluid from the space in between your lungs and chest wall
223626551|NCT06572865|OTHER|Screening for depression and anxiety|Parents respond to questionnaires assessing depression and anxiety.
223626552|NCT04310540|PROCEDURE|Biopsy|Undergo biopsy
223626553|NCT04310540|PROCEDURE|Computed Tomography|Undergo CT
223626554|NCT04310540|DRUG|Gallium Ga 68 Gozetotide|Given IV
223626555|NCT04310540|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223626556|NCT04310540|PROCEDURE|Positron Emission Tomography|Undergo PET
223763075|NCT01314924|DIETARY_SUPPLEMENT|Dark chocolate|70% cocoa
223763076|NCT03663595|OTHER|Model 1|Model 1 will be composed of exercises focusing on local (knee) and proximal (hip) factors.
223763077|NCT03663595|OTHER|Model 2|Model 2 will be composed of exercises focused on the local (knee) and distal (ankle and foot) factors.
224317002|NCT06358235|OTHER|No Music therapy|The practice where patients are simply fitted with headphones and rest quietly without listening to music.
224317003|NCT04022408|DIAGNOSTIC_TEST|Liquid based cytology|Liquid based cytology
223626557|NCT06360302|DIAGNOSTIC_TEST|Exercise test|"Metabolic effort test on cycloergometer with gas measurement. Gas exchanges (V'O2 and V'CO2) will be measured cycle-by-cycle using a gas analyzer connected to a flow meter Measurements will be taken every 6 minutes, at rest and during exercise on a cycloergometer, in five 6-minute increments, corresponding to intensities of 0% (rest), 20%, 30%, 40%, 50 and 60% of the subject's estimated maximum power, for a total duration of around 45 minutes."
224317004|NCT04022408|DIAGNOSTIC_TEST|Conventional cytology|Conventional cytology
224317005|NCT06006390|BIOLOGICAL|CEA-targeted CAR-T cells|Administration method: intravenous infusion； Subjects will receive conditioning therapy by Fludarabine and Cyclophosphamide before cell infusion.
224317006|NCT06006390|BIOLOGICAL|CEA-targeted CAR-T cells|Administration method: intraperitoneal injection；Subjects will receive conditioning therapy by Fludarabine and Cyclophosphamide before cell infusion.
224317007|NCT01886079|DRUG|dexmedetomidine|0.4 mcg/kg/h, IV, The infusion of study drug is started after anesthesia induction and continued until 24 hours after surgery
224317008|NCT01886079|DRUG|Saline|0.4 mcg/kg/h, IV
224317009|NCT01350570|OTHER|acupuncture|acupuncture group1, acupoints ST25 and BL25 will be used in this trial.
224317010|NCT01350570|OTHER|acupuncture group2|Acupoints LI11 and ST37 will be used in this group. LI11 is located at upper limb while ST37 is located at the lower limb.
224317011|NCT01350570|OTHER|acupuncture group3|All acupoints used in acupuncture group1 and group2 will be used in this group.
223626558|NCT06360302|DIAGNOSTIC_TEST|Blood sample|"A catheter will be placed in a forearm vein to take blood samples at rest and at the end of the 5-stage stress test.~Sampling times synchronized with stress test measurements"
223626559|NCT06360302|DIAGNOSTIC_TEST|Impedancemetry|measurement of anthropometric data (weight, height, waist circumference). impedancemetry will enable body composition to be analyzed by placing surface electrodes on the body. The participant will lie on an examination table and must remain at rest for 5 minutes.
223763078|NCT04765007|OTHER|mindfulness-based stress reduction|"Eight sessions of two hours and a half, one day per week during eight weeks. In addition, patients will perform a day of intensive silent practice of 6-8 hours of duration.~The content of each session balances three activities: the presentation of a topic, moments of dialogue and group exploration (using appreciative inquiry) and a Mindfulness practice.~The sessions will take place in online format, through the google meet application"
223763079|NCT04765007|OTHER|Minimal intervention|A guided meditation program of eight weeks of duration will be provided to the patients and they will be informed about the procedure and the beneficial effects of the therapy.
224317012|NCT01350570|DRUG|Loperamide|Loperamide will be used in this group for a dose of 2mg a time, three time a day.
224317013|NCT05575609|OTHER|children with Diabetes Mellitus, Type 1|assessment of Relation between anthropometric measurements and balance in children with type 1 diabetes
224317014|NCT04030715|DRUG|bismuth-containing quadral therapy based on antibiotic susceptibility|the different mucosal pathology graded by New Sydney System
224317015|NCT00003911|RADIATION|stereotactic radiosurgery|
224317016|NCT00627861|DRUG|Aliskiren|150mg orally daily for 6 weeks. Dose may increase to 300mg orally daily dependent upon blood pressure parameters set by the protocol.
223626560|NCT05253209|DRUG|L-citrulline|Intravenous L-citrulline given for up to 48 hours
223626561|NCT05253209|DRUG|Plasmalyte A|Intravenous Plasmalyte A given for up to 48 hours
223626562|NCT00072462|DRUG|tamoxifen citrate|Tamoxifen 20mg + Anastrozole placebo
223626563|NCT00072462|DRUG|Anastrozole|Anastrozole 1mg + Tamoxifen placebo
223626564|NCT06383858|DIAGNOSTIC_TEST|Screening method|All pregnant women in the group were screened for pre-eclampsia risk according to the clinical risk factors listed in NICE Guidelines (2019).
223626565|NCT06383858|DIAGNOSTIC_TEST|Screening method|In the first trimester, pregnant women with routine MAP and PLGF (with UtA-PI detection conditions plus UtA-PI) were tested, and the risk of preeclampsia was evaluated based on Bayes rule combined with maternal factors. In the second and third trimester of pregnancy, routine determination of PLGF or sFlt-1/PLGF was used to evaluate the risk of preeclampsia.
223626566|NCT05621070|DRUG|JS002|JS002 will be administered per auto-injector. Participants will receive JS002 every 2 weeks subcutaneously.
223626567|NCT05621070|DRUG|JS002|JS002 will be administered per auto-injector. Participants will receive JS002 every 4 weeks subcutaneously.
223763080|NCT00232310|DRUG|CELIVARONE (SSR149744C)|
224317017|NCT00627861|DRUG|Extended-release metoprolol|50mg orally daily for 1 week, dose will increase to 100mg orally daily or decrease to 25mg daily for a second week dependent upon blood pressure parameters set by the protocol. Subjects will take metoprolol for a total of 2 weeks, then be tapered off of it over 5-7 days.
224317018|NCT02645331|BEHAVIORAL|Remind-to-move|
224317019|NCT02645331|BEHAVIORAL|Modified constraint induced movement therapy|
224317020|NCT02645331|BEHAVIORAL|Conventional rehabilitation|
224317021|NCT02122029|BEHAVIORAL|Lifestyle counselling|Behavioral techniques for weight management
224317022|NCT02122029|PROCEDURE|Bariatric Surgery|Vertical Banding Gastroplasty
224317023|NCT03857269|OTHER|Acupoint Massage|The operators is trained for two weeks. At 9 o'clock in the morning, the elderly are organized by Nursing home to perform acupressure.Intervention frequency will be monday to saturday per week for 6 months.
224317024|NCT03857269|OTHER|lavender essential oil|Modulated by an international aroma therapist,The cotton ball containing essential oil is replaced by the operator at 9 am.Intervention frequency will be monday to saturday per week for 6 months.
224317025|NCT03857269|OTHER|Acupoint Massage and lavender essential oil|At the same time as the acupressure, patients began to smell the essential oil.Intervention frequency will be monday to saturday per week for 6 months.
224317026|NCT03685201|DIETARY_SUPPLEMENT|Orange Juice1|100% Orange Juice
224317027|NCT03685201|DIETARY_SUPPLEMENT|Orange Juice2|100% Orange Juice with enzyme-treated orange pomace fiber
224317028|NCT03685201|DIETARY_SUPPLEMENT|Raw Orange|Raw Orange
224317029|NCT02153463|BEHAVIORAL|Physical Activity Counselling|Physical Activity Counselling weekly for 8 weeks
223626568|NCT05621070|DRUG|Placebo|Placebo will be administered per auto-injector. Participants will receive placebo every 2 weeks subcutaneously.
223626569|NCT05621070|DRUG|Placebo|Placebo will be administered per auto-injector. Participants will receive placebo every 4 weeks subcutaneously.
223626570|NCT04066283|OTHER|No intervention|There was no intervention in this study
223626571|NCT04984031|DIAGNOSTIC_TEST|ELISA assessment of apoptosis markers in gingival crevicular fluid|Gingival crevicular fluid (GCF) samples will be collected to assess the level of caspase-3,8,9 and apoptosis inducing factor (Aif)
224215599|NCT05775809|DRUG|selective serotonin reuptake inhibitors|"Research Treatment Drug treatment The patient did not take antidepressant treatment at least 14 days before enrollment (the patients treated with fluoxetine before enrollment should stop using it for at least 28 days). During 8 weeks, all subjects with major depressive disorder received effective dosages of selective serotonin reuptake inhibitors, and all subjects with major depressive disorder were limited to a single class of antidepressants. If the treatment of selective serotonin reuptake inhibitors is not effective after eight weeks, the drugs can be considered for replacement. The drugs for replacement include but are not limited to selective serotonin reuptake inhibitors.~Other treatment Settings Psychotherapy and TMS are allowed. The method, frequency, and duration of therapy should be recorded."
224215600|NCT05775809|DEVICE|TMS|TMS are allowed. The method, frequency, and duration of therapy should be recorded.
224215601|NCT02579083|DRUG|MB66|10 mg of HSV8-N and 10 mg of VRC01-N monoclonal antibodies per MB66 film
224215602|NCT02579083|DRUG|Placebo Film|The placebo film is composed of the identical excipients as MB66 without the monoclonal antibodies.
223763081|NCT01639040|DRUG|Dupilumab|Dupilumab 300 mg once weekly (QW) for 4 weeks
224215603|NCT01808209|DEVICE|stenfilcon A|Participants wear a first pair of lenses for one week and then crossover and wear an alternate second pair of lenses for one week.
224215604|NCT01808209|DEVICE|filcon II 3|Participants wear a first pair of lenses for one week and then crossover and wear an alternate second pair of lenses for one week.
223763082|NCT01639040|DRUG|Placebo (for Dupilumab)|Placebo (for Dupilumab) once weekly (QW) for 4 weeks
223763083|NCT01639040|OTHER|Topical Corticosteroid (TCS)|TCS such as methylprednisolone aceponate 0.1%, mometasone furoate 0.1%, or betamethasone valerate 0.1%
223763084|NCT06372249|DRUG|Inulin|Soluble tapioca starch from Ingredion.
223763085|NCT06175221|BIOLOGICAL|Tumor lysate, particle only (TLPO) vaccine|A novel technology in which a patient's tumor lysate (TL) is loaded into microparticles for DC phagocytosis and antigen processing allows for vaccine efficacy, while minimizing tissue demands by only requiring approximately 250-500ug of tumor. Immature DCs avidly phagocytose small particles in the range of 1-5 microns. Tumor tissue collected from the patient undergoes a process of freeze-thaw cycling to create a TL suspension. The microparticles, yeast-cell wall particles (YCWP), are created from Saccharomyces cerevisiae by NaOH/HCl digestion of all non-cell wall components and washed, producing β-glycan shells. The TL is then loaded into these YCWP.
223763086|NCT04784767|BIOLOGICAL|25 µg SpFN_1B-06-PL + ALFQ (QS21 Adjuvant)|SpFN\_1B-06-PL will be provided in a sterile, 2 mL single-use vial at 0.7 mL/vial, 90-110 ug/mL; ALFQ will be provided in a sterile 3 mL vial at 0.6 mL/vial
223763087|NCT04784767|DRUG|Sodium chloride, USP, for injection (0.9% NaCl)|Normal saline will be provided in a sterile, single-use 10 mL vial
223763088|NCT04784767|BIOLOGICAL|50 µg SpFN_1B-06-PL + ALFQ (QS21 Adjuvant)|SpFN\_1B-06-PL will be provided in a sterile, 2 mL single-use vial at 0.7 mL/vial, 90-110 ug/mL; ALFQ will be provided in a sterile 3 mL vial at 0.6 mL/vial
223626572|NCT04349891|DEVICE|Transcutaneous Electroacupuncture|Weak electrical current will be generated by the device and delivered via skin surface electrodes to acupuncture points related to gastrointestinal functions.
223763089|NCT05783505|OTHER|Multicomponent intervention program|Non-pharmacological interventions combined with goal directed sedation using dexmedetomidine if needed
223763090|NCT05598047|BEHAVIORAL|Executive Functioning Training|Those in the Executive Functioning Training Group will engage in exercises requiring one to set shift; that is, to maintain at least two sets of rules and decide which is appropriate to determine the response. In using these training exercises in the TOPS study, the effects size was quite large (d=-0.89). Dosage of 20 hours of training is considered an upper range on how much training is needed to produce an optimal therapeutic effect.
224215605|NCT01465776|OTHER|laboratory biomarker analysis|Correlative studies
224215606|NCT01465776|OTHER|preventative dietary intervention|lyophilized black raspberries(LBR) administration: 3 LBR troche lozenges (dissolved in mouth), 4 times/day beginning at minimum of 24 hrs following biopsy until night before surgery
223763091|NCT05143177|DRUG|Evogliptin|DA-1229 10 mg, 1 tab
223763092|NCT05143177|DRUG|Placebo|DA-1229 Placebo, 1 tab
224215607|NCT04877392|DIETARY_SUPPLEMENT|Lavender essential oil|Use of inhaled lavender essential oil
223763093|NCT05619692|DRUG|SAGE-718|Softgel lipid capsules.
223763094|NCT05619692|DRUG|SAGE-718-matching Placebo|Softgel lipid capsules.
223763095|NCT05201469|DRUG|VIB4920|Participants will receive 1500 mg of VIB4920 at Weeks 0, 2, 4, 8, 12, 16, 20, and 24 while continuing on MMF and prednisone
223763096|NCT05201469|DRUG|Placebo for VIB4920|Participants will receive placebo for VIB4920 at Weeks 0, 2, 4, 8, 12, 16, 20, and 24 while continuing on MMF and prednisone
223763097|NCT05909085|DEVICE|Traditional ultrasound|Labor epidural will be performed after marking patient skin using traditional ultrasound guidance
223763098|NCT05909085|DEVICE|Automated ultrasound|Labor epidural will be performed after marking patient skin using an automated ultrasound device
223763099|NCT05267054|DRUG|Ociperlimab|administered intravenously
223763100|NCT05267054|DRUG|Tislelizumab|Administered intravenously once every 3 weeks
223626573|NCT04349891|DEVICE|Sham TEA|Sham will be delivered via skin surface electrodes to acupuncture points related to gastrointestinal functions.
223626574|NCT01894139|OTHER|High-Protein/Low-GI Diet|
223626575|NCT01894139|OTHER|Low-protein/High-GI Diet|
223763101|NCT05267054|DRUG|Rituximab|Administered intravenously once every 3 weeks
223626576|NCT03679247|OTHER|Intervention|"The intervention will be a clinical decision support (CDS) system that contains three main features: 1) methods to synthesize electronic health record (EHR) data in order to identify under-diagnosed chronic conditions (synthesize existing medical data to increase recognition of CKD and uncontrolled HTN in CKD patients and deliver management recommendations based on this evidence), 2) improve the design and content of the CDS using human factors methods, specifically usability testing, and 3) the use of two behavioral nudges (pre-checked default orders and an email to obtain commitment from PCPs to obtain their commitment to follow the CDS recommendations)."
223626577|NCT03679247|OTHER|Control|Usual Care, PCP will receive an email with general information about CKD guidelines
223626578|NCT04230759|DRUG|Chemotherapy|"Patients receive chemotherapy cycles as followed:~Mitomycin-C 12 mg/m², day 1 (maximum single dose 20 mg) 5-FU: 1000 mg/m² per day, continuous i.v. infusion, on day 1-4 and 29-32"
223626579|NCT04230759|RADIATION|Radiation|PTV\_A (primary tumor): T1-T2\<4cm N+: 28 x 1.9 Gy=53.2 Gy, five fractions per week or PTV\_A (primary tumor): T2\>=4cm, T3-4 Nany: 31 x 1.9 Gy=58.9 Gy, five fractions per week PTV\_N (involved node): 28 x 1.8 Gy=50.4 Gy, five fractions per weeks PTV\_Elec (elective node): 28 x 1.43 Gy=40.0 Gy, five fractions per week
223626580|NCT04230759|DRUG|Durvalumab|1500 mg, 1h-civ, every 4 weeks (q4w) applied on day -14 (that is 14 days prior to initiation of RCT), day 15 (during RCT), and thereafter q4w (+/- 3d) for a total of 12 doses
223626581|NCT03800095|DRUG|Early palliative care integration|The follow-up time for each patient is 12 months with evaluation of the main objective by a standardized questionnaire: The Functional Assessment of Cancer Therapy-Anaemia (FACT-An) Scale at 6 months. Throughout the study, patients included will receive conventional haematological care and the interventional arm will benefit in addition to a monthly consultation by a palliative care team.
223626582|NCT03803293|DIAGNOSTIC_TEST|Pharmacogenomic testing|A comprehensive PGx interpretive report created by OneOme (www.oneome.com) provides information on how an individual patient's genes may affect medication response. OneOme utilizes algorithms and curated clinical PGx knowledge to generate a highly intuitive personalized report based on a patient's genomic results.
223626583|NCT02927301|DRUG|Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody|Atezolizumab was given as 1200 milligrams (mg) via intravenous (IV) infusion on Day 1 of each 21-day cycle.
223626584|NCT03028766|DRUG|AZD1775|AZD1775 is a potent, selective small molecule inhibitor of WEE1
223626585|NCT03028766|DRUG|Cisplatin|Chemotherapy drug
223626586|NCT03028766|RADIATION|Radiotherapy|Intensity Modulated Radiotherapy
223626587|NCT02616640|DRUG|Durvalumab|
223626588|NCT02616640|DRUG|Pomalidomide|
223626589|NCT02616640|DRUG|Dexamethasone|
223763102|NCT06255028|BIOLOGICAL|CNTY-101|CNTY-101 cells for intravenous (IV) infusion
223763103|NCT06255028|BIOLOGICAL|IL-2|IL-2 subcutaneous (SC) injection
223626590|NCT05796557|BIOLOGICAL|Platelet Transfusion|Participants will be transfused according to the assigned threshold for each group, with a transfusion dose of 10 mL/kg, up to one adult unit.
223626591|NCT06047093|PROCEDURE|Investigation of the intrahepatic compartment using the fine needle aspiration (FNA) technique|"The FNA will be performed at the Croix Rousse digestive pathology day hospital of the Hospices Civils de Lyon by a doctor from the hepatology department who has been trained to perform FNA.~After echography, a subcutaneous anesthesia with LIDOCAÏNE is administered. Two FNA passages will be performed for virological and immunological analyses. The patient will be monitored in the supine position for 1 hour after the procedure.~A single FNA will be performed during the study."
223626592|NCT06047093|BIOLOGICAL|Creation of a serum biobank|42ml blood sample for study of circulating peripheral blood mononuclear cells (PBMC) and new circulating hepatitis B markers. These samples will enable us to gain a better understanding of peripheral immune responses and to correlate intrahepatic virological data with new serum markers of HBV.
223626593|NCT06047093|OTHER|FNA feasibility and acceptability questionnaire|An FNA feasibility and acceptability questionnaire carried out at inclusion (V1) and after the FNA has been performed.
223626594|NCT04601818|PROCEDURE|Experimental: Preserving of Donor Lungs|lung transplants that have a proposed after hours start time will be delayed until 6am and the donor lungs will be preserved for no more than 12 hours at 10 degrees celsius cold static
223626595|NCT04080635|PROCEDURE|Venapuncture|Blood samples will be collected to determine the serum trough levels and anti-drug antibodies of brodalumab
223626596|NCT04080635|OTHER|Patient questionnaires|The study participant will complete the Dermatology Quality of Life Index (DLQI) and EQ5D5L
223626597|NCT03486821|RADIATION|Hypofractionated Radiation|All patients on this study will receive the same type of therapy, 2 treatment hypofractionated radiation therapy.
223626598|NCT03381521|PROCEDURE|Ultrasound-guided nerve hydrodissection|Ultrasound-guided nerve hydrodissection with 10cc normal saline between carpal tunnel and median nerve.
223626599|NCT03381521|PROCEDURE|Ultrasound-guided nerve hydrodissection|Ultrasound-guided nerve hydrodissection with 5cc normal saline between carpal tunnel and median nerve.
223626600|NCT03381521|DEVICE|Ultrasound|The ultrasound was used to measure cross-sectional area and injection guidance
223626601|NCT03381521|DRUG|Normal saline|The normal saline was used for injection solution
223626602|NCT00003461|PROCEDURE|surgical procedure|
223626603|NCT00003461|RADIATION|astatine At 211 monoclonal antibody 81C6|
223763104|NCT06255028|DRUG|Lymphodepleting Chemotherapy|LDC as prespecified in the protocol.
223763105|NCT02134301|DRUG|Oritavancin|
223626604|NCT02201524|DRUG|PF-04965842|Subjects will receive 200 mg PF 04965842 twice daily for 4 weeks
223626605|NCT02201524|DRUG|PF-04965842|Subjects will receive 400 mg PF 04965842 daily for 4 weeks
223626606|NCT02201524|DRUG|PF-04965842|Subjects will receive 200 mg PF 04965842 daily for 4 weeks
223626607|NCT02201524|OTHER|Placebo|Subjects will receive placebo for 4 weeks
223763106|NCT06031844|DRUG|DFV890|oral film-coated tablets
223763107|NCT06031844|DRUG|Placebo|oral film-coated tablets
223763108|NCT02276430|OTHER|Vena punction|Once 90 ml
223763109|NCT04729348|DRUG|Pembrolizumab|Oral, daily, dosage per protocol
223626608|NCT04833946|OTHER|Andrographis paniculata [150 mg]|One capsule to be taken orally, 30 minutes after breakfast \& 30 minutes before bedtime
223626609|NCT04833946|OTHER|Microcrystalline Cellulose (MCC)|One capsule to be taken orally, 30 minutes after breakfast \& 30 minutes before bedtime
223626610|NCT04384809|BIOLOGICAL|Leukocyte rich platelet rich plasma|Leukocyte rich platelet rich plasma will be obtained and prepared from a peripheral artery of the subject and then will be injected in the common extensor tendon
223763110|NCT04729348|DRUG|Lenvatinib|Oral, daily, dosage per protocol
223763111|NCT05841758|DRUG|Hydroxychloroquine|Hydroxychloroquine (200-400 mg /day during a 12 months double blind placebo-controlled period)
224215608|NCT05812105|OTHER|Healthy Buddy Program|The Healthy Buddy Program is a community-based initiative that pairs college students with transportation disadvantaged, community- dwelling older adults age 65 and older. The Spanish-language Healthy Buddy Program was developed to measure the transportation and health challenges of Hispanic/Latino older adults and determine the efficacy of the adapted HB program model.
224215609|NCT03430089|BIOLOGICAL|Shz QIV 0.25 mL, 2 doses|Administered intramuscularly in the anterolateral aspect of the thigh in infants (aged 6 to 12 months) or into the deltoid muscle (participants aged more than 12 months), 28 days apart.
224215610|NCT03430089|BIOLOGICAL|Shz QIV 0.5 mL, 2 doses|Administered intramuscularly into the deltoid muscle, 28 days apart
224215611|NCT03430089|BIOLOGICAL|Shz QIV 0.5 mL, single dose|Administered intramuscularly into the deltoid muscle.
224215612|NCT05084534|DRUG|Midodrine|"Midodrine starting at 0.25mg/kg/day in divided doses, increased to 0.5mg/kg/day after 7 days if MAP does not increase by \>10% (maximum dose - 15mg/day)~• Midodrine dosage will be decreased by 25% in case of arterial hypertension (\>95th centile BP for the age)"
223763112|NCT05841758|DRUG|Placebo|Placebo during a 12 months double blind placebo-controlled period
223763113|NCT04989608|OTHER|Neuroimaging|realization of a neuroimaging 1 and 3 years after the transient ischemic accident
223763114|NCT06441201|DIAGNOSTIC_TEST|Pulse flowmeter|Measures peripheral pulse volumes by an electrode applied non-invasively to the lower extremity (left or right) at the beginning of the endoscopic evaluation for the duration of the procedure, and up to 2 hours after the completion of the procedure.
223763115|NCT06491342|DIETARY_SUPPLEMENT|Probiotic|Probiotic-Lactobacillus Zeae and Lactobacillus reuteri
223763116|NCT06491342|DIETARY_SUPPLEMENT|Placebo|placebo
223763117|NCT02457598|DRUG|Tirabrutinib|Capsules or tablets administered orally
223763118|NCT02457598|DRUG|Idelalisib|Tablets administered orally twice daily
224215613|NCT05084534|OTHER|Standard medical treatment|"Standard Medical Treatment will be continued in all, which includes,~* To continue restriction of sodium to \< 2meq/kg/day~* To continue maximum tolerable dose of diuretics~* Repeat LVP with infusion of albumin (8 g/L) performed for tense, symptomatic ascites~* Albumin infusion for serum albumin \<2.5g/dl - dose 1g/kg/day (maximum 20g/day)"
223626611|NCT04384809|DEVICE|Percutaneous Tenotomy|Patients will undergo percutaneous tenotomy of the common extensor tendon using the Tenex tenotomy device
224215614|NCT04601662|PROCEDURE|Corticision|A special instrument will be used to cut the cortex of the alveolar bone at different locations between the lower anterior teeth
224215615|NCT04601662|OTHER|Traditional Non-accelerated Treatment|The normal sequence of treatment steps will be followed in this group without using any kind of acceleration methods
223763119|NCT02457598|DRUG|Entospletinib|Tablets administered orally
223763120|NCT02457598|DRUG|Obinutuzumab|Administered intravenously
223626612|NCT05635344|DRUG|Pembrolizumab|Single dose 200mg dose of Pembrolizumab given intravenously
223626613|NCT05851118|BEHAVIORAL|Quantified analysis of walking during a crossing task between two walkers|Functional test that reproduce a task of daily living.
223626614|NCT01508689|BEHAVIORAL|Receive Kellogg's Nutri-Grain® cereal bars first|First three weeks of study: consume perceived usual diet; Second three weeks of study: Receive 42 Kellogg's Nutri-Grain® cereal bars per person, consume 2 bars per day; Third three weeks of study: consume perceived usual diet
223626615|NCT01508689|BEHAVIORAL|Receive Kellogg's Nutri-Grain® cereal bars second|First six weeks of study: consume perceived usual diet; Last three weeks of study: Receive 42 Kellogg's Nutri-Grain® cereal bars per person, consume 2 bars per day
224215616|NCT01792856|OTHER|Recovery-oriented intervention|Life coaching is defined as a collaborative, solution-focused, outcome-oriented and systematic process which aims to facilitate enhancement of life experience and goal attainment of an individual in various life domains. It is based on the theoretical framework of positive psychology and behavioural change model, and targets at building up an individual's potential via fostering hope, motivation, self-efficacy and self-regulation. The principles of life coaching thus closely align with recovery orientation that emphasizes on self-initiation and empowerment via person-centred and strength-based approach.
223763121|NCT03794115|PROCEDURE|Treatment for ovarian cancer|The treatment for ovarian cancer includes the debulking surgery and platinum-based chemotherapy.
223763122|NCT01403974|DRUG|BI 836845|Intravenous infusion once every week
223626616|NCT01949935|DRUG|Mupirocin|
223763123|NCT06411678|DRUG|68GA-DOTA-dPNE|Patients with breast cancer receive intravenously 68GA-DOTA-dPNE followed by PET/CT after 40min of injection
223763124|NCT06022510|DEVICE|Fetoscopy Sets for Anterior and Posterior Placentas|Patients who choose to undergo fetoscopic surgery for a complicated monochorionic-diamniotic pregnancy will be offered participation in this study. All patients will undergo selective laser photocoagulation with the use of the fetoscopes in this study.
223626617|NCT04042220|DRUG|Glucocorticoids|Effect of glucocorticoids (which are often prescribed for cerebral edema) on clinical outcome
223626618|NCT00921271|DEVICE|Monitoring of StO2|Monitoring of lower limb anterior compartment StO2, taking measurements on an hourly basis for the duration of the study protocol.
223626619|NCT02022137|DIETARY_SUPPLEMENT|Red cereal bar|Consumption of the cereal bar with agave fructans or lactitol or lactose added each bar with 10 grams of dietary fiber and 1.2 grams of protein by weight and 20 to 30 grams of fiber.
223626620|NCT02022137|DIETARY_SUPPLEMENT|Green cereal bar|Consumption of the cereal bar with agave fructans or lactitol or lactose added each bar with 10 grams of dietary fiber and 1.2 grams of protein by weight and 20 to 30 grams of fiber.
223763125|NCT06272097|BEHAVIORAL|Intervention program based on TIME-CDST tool led by wound specialist nurses|Based on the TIME CDST tool led by wound specialist nurses, which includes the following five areas: A. Assess patient, well-being and wound; B. Bring in multidisciplinary team and informal carers to promote holistic patient care; C. Control or treat underlying causes and barriers to wound healing; D. Decide appropriate treatment; E. Evaluate and reassess the treatment and wound management outcomes; Give patients health education on wound care management.
223763126|NCT06272097|BEHAVIORAL|A routine wound care program|A routine wound care program of wound cleaning and dressing changes
223763127|NCT03518320|DRUG|Gemcitabine-Releasing Intravesical System (GemRIS)/TAR-200|TAR-200 will be placed in the bladder through an inserter and gradually release gemcitabine for four consecutive 21-day dosing cycles for a total period of approximately 84 days
223763128|NCT03518320|DRUG|Nivolumab Injection [Opdivo]|Nivolumab will be given intravenously on specified days for four consecutive 21-day dosing cycles for a total period of approximately 84 days
223763129|NCT03205618|OTHER|Non-Interventional|Non-Interventional
223763130|NCT00260754|BEHAVIORAL|Community-Popular Opinion Leader Model|
223763131|NCT00260754|BEHAVIORAL|Diffusion of Innovations|
224215617|NCT01792856|OTHER|psychoeducation|Subjects will receive group-based supportive therapy provided by case managers of JCEP project. The therapy provides patients with psychoeducation about psychosis, stress management, emotional and social support. Coaching and cognitive-behavioural techniques will not be incorporated. Therapy sessions and duration will be comparable to that of recovery-oriented coaching program.
224215618|NCT04882111|BEHAVIORAL|ALIGN|The ALIGN intervention was developed by the Holding Group, an independent partnership of palliative care-trained social workers. The intervention is theory driven, patient/caregiver centered, addresses palliative care and psychosocial issues, and integrates with health care teams. Working in collaboration with KPCO and Dr. Stacy Fischer (primary mentor), the Holding Group tested the ALIGN intervention in the LTAC and SNF setting (Preliminary Studies). The Holding Group will be the intervention personnel providing psychosocial care that targets communication, goal alignment, and caregiver support.
224215619|NCT02951884|PROCEDURE|Aspiration|A needle is placed into the knee joint and all of the blood that is in the joint is removed.
224215620|NCT02951884|DRUG|Bupivacaine|An injection of 20cc bupivacaine 0.5% with 1:200,00 epinephrine
224215621|NCT03911089|OTHER|UCD Anamix Infant|UCD Anamix infant with DHA and ARA is an amino acid based infant medical food containing only the essential amino acids, carbohydrate, fat, vitamins, minerals and trace elements.
224215622|NCT04229797|PROCEDURE|Mandibular distalization using extra-radicular miniscrews|Distalization of the Mandibular first molars using mandibular buccal shelf mini-screws in the presence of unerupted third molars
224215623|NCT06036654|DEVICE|infrared thermotherapy instrument|Only a single target nail was chosen among multiple onychomycosis to receive local hyperthermia treatment.
224215624|NCT05760378|DRUG|Famitinib|TKI
224317030|NCT01644630|PROCEDURE|Cemented crowns|"The final lithium disilicate crowns will be cemented with an adhesive cement after tightening the abutments with the torque indicated by the manufacturer and closing the screw access hole with white guttapercha. The abutment will be cleaned with ethanol. A retraction cord will be placed for cementation if indicated. The crown will be etched with hydrofluoric acid and subsequently silanized. A sufficient amount of cement will be filled in the crown without creating major excesses. When the crown is seated correctly, the cement will be light-cured for a few seconds to facilitate the removal of the now hard excess cement.~\- Excess cement will be meticulously removed with a carbon scaler. The removal of all excess cement will be checked with an X-ray and by visual and tactile inspection."
223513977|NCT06695286|OTHER|Multimodal rehabilitation training at high intensity|"In High Intensive Training patients received 1800 minutes of training globally.~In our practice, a single outpatient session varies from 60 to 90 minutes, the number of sessions per cycle from 10 to 20, and the frequency from 2 days a week to 5 days a week.~Irrespective of total course intensity, each session comprises at least 15 minutes of aerobic training (over ground or treadmill) and 10 minutes of flexibility and strengthening exercise.~No less than 10 minutes of balance training, 10 minutes of overground training in dual tasks, and 15 minutes of occupational therapy are additionally delivered. The duration of the single training components in each session may increase according to the patients' functioning profiles, requesting a more intensive practice of gait, balance or trunk alignment or a focused training of arm dexterity or basic ADL."
223513978|NCT06695286|OTHER|Multimodal rehabilitation training at low intensity|"In Low Intensive Training patients received less than 900 minutes of training globally.~In our practice, a single outpatient session varies from 60 to 90 minutes, the number of sessions per cycle from 10 to 20, and the frequency from 2 days a week to 5 days a week. Irrespective of total course intensity, each session comprises at least 15 minutes of aerobic training (over ground or treadmill) and 10 minutes of flexibility and strengthening exercise. No less than 10 minutes of balance training, 10 minutes of overground training in dual tasks, and 15 minutes of occupational therapy are additionally delivered. The duration of the single training components in each session may increase according to the patients' functioning profiles, requesting a more intensive practice of gait, balance or trunk alignment or a focused training of arm dexterity or basic ADL."
223513979|NCT06887881|GENETIC|PIMS screening|Couples in the PIMS group will have up to 6 blastocysts screened with PIMS and a single euploid embryo with the optimal state of whole-genome DNA methylation and the highest morphologic score will be selected for the initial transfer
224215625|NCT05760378|DRUG|Camrelizumab|PD1 inhibitor
224215626|NCT05760378|DRUG|nab-Palitaxel/Capecitabine/Eribulin Mesylate/Carboplatin|TPC
224317031|NCT01644630|PROCEDURE|Screw-retained crowns|The screw-retained crowns will be inserted and tightened with the torque indicated by the manufacturer. The screw access hole will to be closed with white guttapercha and a composite filling (Filtek, 3M ESPE).
224317032|NCT03074786|DRUG|Dapivirine|Silicone elastomer vaginal matrix ring
223513980|NCT06887881|GENETIC|PGT-A screening|Couples in the PGT-A group will have up to 6 blastocysts screened with PGT-A and a single euploid blastocyst with the highest morphologic score selected for the initial transfer.
223513981|NCT06753903|PROCEDURE|PCD-CT|Photon-counting detector computed tomography
223513982|NCT02408770|DRUG|ulipristal acetate|selective progesterone receptor modulator
223513983|NCT00954538|DRUG|[18F]MK-3328|IV dose of \~150 megabecquerel (MBq) \[18F\]MK-3328
223626621|NCT02022137|DIETARY_SUPPLEMENT|White cereal bar|Consumption of the cereal bar with agave fructans or lactitol or lactose added each bar with 10 grams of dietary fiber and 1.2 grams of protein by weight and 20 to 30 grams of fiber.
223626622|NCT00389948|DRUG|Lanzoprazole|
223626623|NCT02855203|RADIATION|Stereotactic Ablative Body Radiosurgery (SABR)|18-20Gy in 1 fraction
223626624|NCT02855203|DRUG|Pembrolizumab|Pembrolizumab at a dose of 200mg IV, 3-weekly will be delivered for a duration of 6 months, commencing 5 days (+/- 3 days) from the last dose of SABR.
223626625|NCT05404139|DRUG|Enzalutamide|Second-generation androgen pathway inhibitor (ARAT), oral tablet
223626626|NCT05404139|OTHER|Standard of Care SBRT and ADT|Standard of care stereotactic body radiation therapy (SBRT) and androgen deprivation therapy (ADT)
224215627|NCT02629133|BEHAVIORAL|SHE Program|The SHE program is specifically tailored, innovative and relevant to diverse, racial, and ethnic sheltered, battered women in a number of ways including the images and content used in the intervention. It is also tailored to participants' alcohol or substance use status, and designed to reach participants across levels of motivation for change. The content of SHE is theory-driven, consistent with the motivational interviewing model of behavior, and consistent with the literature on effective interventions that address IPV and substance use.
224215628|NCT00135291|PROCEDURE|Leukoreduced blood transfusion|
224215629|NCT03181178|DIETARY_SUPPLEMENT|Macro-micronutrient complementary food supplement|This intervention provided a 15 g complementary food supplement called KokoPlus with nutrition education
224215630|NCT03181178|DIETARY_SUPPLEMENT|A micronutrient powder|This intervention provided a 1 g micronutrient powder with nutrition education
224215631|NCT03181178|BEHAVIORAL|Nutrition education|This intervention provided nutrition education sessions
224215632|NCT02996370|OTHER|papilla fill index|The clinical photographs were taken baseline, 3 and 6 month. Two T shaped full-round hexagonal straight filaments, each 5 mm, were used in the taking of standardized images.
224215633|NCT02996370|OTHER|crestal bone loss|Crestal bone loss was measured on digital radiographs at baseline, 3 and 6 month with a Java program me (Image-J 3.0 NIH, Bethesda, USA)
223513984|NCT05362539|PROCEDURE|Cystoscopy|diagnostic cystoscopy for detection of any bladder lesions
223513985|NCT05362539|DIAGNOSTIC_TEST|Computed tomography|Computed tomography for patients to exclude bladder lesions
223513986|NCT05362539|GENETIC|DNA hypermethylation assay|DNA hypermethylation assay of six genes (GATA4, P16, P14, APC, CDH1 and CD99)
223513987|NCT05362539|DIAGNOSTIC_TEST|Urine cytology|voided urine cytology for all patients
223513988|NCT01639521|DRUG|cisplatin|Given IV
223513989|NCT01639521|DRUG|gemcitabine hydrochloride|Given IV
223513990|NCT01639521|DRUG|methotrexate|Given IV
223513991|NCT01639521|DRUG|vinblastine|Given IV
223513992|NCT01639521|DRUG|doxorubicin hydrochloride|Given IV
223513993|NCT01639521|BIOLOGICAL|pegfilgrastim|Given SC
223513994|NCT01639521|OTHER|laboratory biomarker analysis|Correlative studies
223513995|NCT01164969|DRUG|Antibiotics to which H. pylori can not develope resistance|Amoxicillin, metronidazole and tetracyclin as primary drugs to treat H. pylori infection in duration of 10 days.
223513996|NCT02541487|DIETARY_SUPPLEMENT|Alli-nutritional supplement|Obese participants in the FIT-PLESE clinical trial randomized to the nutritional restriction /AlliTM/physical activity arm that achieve pregnancy.
223513997|NCT00992394|DRUG|etanercept|etanercept 50 mg once weekly as requested.
223513998|NCT00992394|DRUG|etanercept|etanercept 25 mg or 50 mg as requested.
223513999|NCT01452217|DRUG|Secretin|Secretin 1 IU/kg over 3 min
223514000|NCT04345432|DRUG|Gabapentin|"Gradually increasing doses of medication from 100 mg on day 1 to 300 mg twice a day on day 6. On day 7, the patient received a 300-mg dose from the day 7 envelope, about two hours after a light breakfast and 1 hour before data collection. The relatively low dose and gradual titration were selected to enhance compliance and reduce adverse effects, based on a rectal mechanosensitivity study."
223514001|NCT01157429|DRUG|D-cycloserine|D-cycloserine 50 mg by mouth prior to sessions 5-12 of the 12-session CBT protocol.
223514002|NCT01157429|DRUG|Placebo pill|Placebo pill by mouth prior to sessions 5-12 of teh 12-session CBT protocol.
223514003|NCT01157429|BEHAVIORAL|CBT|12-session CBT protocol, called Youth PTSD Treatment.
223514004|NCT01319461|DEVICE|Hyalgan|Patients will receive intraarticular injection of 20mg /2ml /syringe Hyalgan® once a week for 5 consecutive weeks.
223514005|NCT01319461|DEVICE|sterile normal saline|Patients will receive intraarticular injection of sterile normal saline once a week for 5 consecutive weeks.
223514006|NCT05738889|DEVICE|Fixed lingual retainers applied with Bis-GMA containing composite|Bonding materials of fixed lingual retainers applied with Bis-GMA containing composite
223514007|NCT05738889|DEVICE|Fixed lingual retainers applied with Bis-GMA-free composite|Bonding materials of fixed lingual retainers applied with Bis-GMA-free composite
223514008|NCT05738889|DEVICE|Vacuum-formed retainers|vacuum-forming machine and vacuum formed plates
223514009|NCT05738889|DEVICE|Hawley retainers|Acrylic based hawley retainers
223514010|NCT01959971|DRUG|alirocumab|"Pharmaceutical form:Solution for injection~Route of administration: Subcutaneous"
223514011|NCT01959971|DRUG|Placebo|"Pharmaceutical form:Solution for injection~Route of administration: Subcutaneous"
223514012|NCT00588276|RADIATION|124I-Iodo-Azomycin Galacto-Pyranoside|You will receive the radioactive tracer through an injection in your vein. Blood (about 5 tablespoons in all) will be taken after the radioactive tracer has been given. Over the course of study day 1, bloods will be drawn 8 times and then 4 more times on study day 2. You will undergo three \*IAZGP PET scans, one shortly after you receive the injection, one later the same day and one the following day. Each scan will take about an hour. This means you would be asked to come back 2 days in a row.
223514013|NCT03983655|DEVICE|High Frequency Low Intensity TMS|125 hz, 10 gauss, 2 times daily for 6 monts
223514014|NCT01420003|PROCEDURE|Bone Marrow Aspiration|3 per study
223514015|NCT01420003|PROCEDURE|Tonsil Biopsy|Optional upon completion of study
223514016|NCT05476848|DIAGNOSTIC_TEST|ELISA test for Cytokines|ELISA tests specific for cytokines (IL-1, IL-6, IL-10) and immunoglobulins (IgA, IgG, IgM) will be performed by a biochemistry lab, both for blood samples and oral swap samples.
223514017|NCT04588363|OTHER|SARS-CoV-2 and/or MIS-C Exposure|This is an observational cohort study.
224215634|NCT02996370|OTHER|probing depth|The change of probing depth between baseline, 3 and 6month. Probing depth was measured with a plastic periodontal probe (mm)
224215635|NCT02996370|OTHER|Modified sulcus bleeding index|Modified bleeding index was measured baseline, 3 and 6 month. Presence of bleeding on probing were performed at four sites of implants.
223763132|NCT05164783|COMBINATION_PRODUCT|Sanacoach Parkinson (SCP)|A web-based monitoring tool for patients with PD, using questionnaires. It includes nine parts: 1) A 89-question, quarterly questionnaire about PD-symptoms. 2) Questionnaire responses are converted to scores on 16 PD-related domains. Both the current score and the score's change compared to the previous questionnaire are visible. 3) An interim evaluation is sent after 6 weeks with questions on any domains where a patient indicated problems. 4) A medication monitor can be initialized by the treating physician to evaluate the effect of a therapeutic change. 5) A consultation preparation module allows patients to indicate which topics they want to discuss during an outpatient visit. 6) Patients can ask for 'calling advise' if they are unsure whether to contact their physician. 7) Patients and healthcare providers can send each other text messages. 8) Interactive learning modules about PD. 9) Annual evaluation regarding patient satisfaction, self-management and healthcare consumption.
223763133|NCT01391975|PROCEDURE|Active ultrasound surveillance of fistula and proactive treatment of stenosis|Regular duplex ultrasound assessment of fistula from time of creation until 6 months post procedure with referral of all haemodynamically significant stenoses to further imaging and treatment
223763134|NCT05550051|PROCEDURE|Awake nasal fiberoptic intubation|Lignocaine nebulization for upper airway block during awake nasal fiberoptic intubation
224215636|NCT02996370|OTHER|Modified plaque index|Modified plaque index was measured baseline, 3 and 6 month. Presence of plaque index was performed at four sites of implants.
224215637|NCT04348344|BEHAVIORAL|pulmonary rehabilitation|"Patients receive health education of pulmonary rehabilitation, using the home-based rehabilitation exercise prescription, taking home exercise as the main form, using the sports bracelet and special respiratory rehabilitation app software, the home management system integrating home rehabilitation training, detection and feedback is mainly adopted, which is a combination of aerobic endurance training: walking, intermittent strength training: elastic band and inspiratory muscle training:apparatus, abdominal breathing training."
224215638|NCT02666365|PROCEDURE|Bolus infusion of Cefazolin|Subjects in the bolus infusion arm of the study will receive bolus infusions of cefazolin throughout the surgical procedure
224215639|NCT02666365|PROCEDURE|Continuous infusion of Cefazolin|Subjects in the continuous infusion arm of the study will receive a continuous infusion of the cefazolin throughout the surgical procedure
224215640|NCT03373266|DRUG|Sevoflurane|anesthesia was maintained with Sevoflurane 1-2%.
223763135|NCT02805530|OTHER|First line systemic treatment|Epidermal growth factor receptor (EGFR)-mutated with tyrosine kinase inhibitors (afatinib, erlotinib or gefitinib). Patients without driver mutation duplet of chemotherapy based on platin taking account histologic subtype (Carboplatin or Cisplatin plus pemetrexed for adenocarcinomas, gemcitabine for epidermoid or paclitaxel for both) at discretion of the treating physician.
223763136|NCT02805530|OTHER|Radical treatment|to the primary and to the metastases will be with surgery, radiotherapy, chemoradiotherapy, stereotactic radiosurgery or radiofrequency ablation.
223763137|NCT02805530|RADIATION|radiation therapy|Patients will receive dose and fraction regimen according to the metastatic site.
223763138|NCT02805530|OTHER|Chemoradiotherapy|Chemoradiotherapy with duplet based on platins (Carboplatin or cisplatin plus pemetrexed or paclitaxel or etoposide or vinorelbine) or monotherapy with carboplatin.
224215641|NCT03373266|DRUG|Isoflurane|anesthesia was maintained with isoflurane 1-2%.
224215642|NCT05081752|DEVICE|OTSC Stentfix|Stent placement with fixation of the esophageal stent using OTSC Stentfix.
224215643|NCT05081752|PROCEDURE|Stent Suturing / Endoscopic Clips|Stent placement with fixation of the esophageal stent using sutures / endoscopic clips.
224317033|NCT03074786|DRUG|Truvada|Tablets to be taken orally daily
223626627|NCT05036304|OTHER|Aerobic Exercise Indoors|Each session will consist of 10 min of warm-up, 40 min of aerobic exercise, and 10 min of cool-down. Aerobic exercise will be progressive and of moderate intensity. During training, each participant will wear a heart rate monitor and will be asked to work initially at approximately 45% of his/her target heart rate (i.e., heart rate reserve (HRR)) and gradually progress to reach the target of 70% of HRR over the 12-week study period. Participants will also subjectively monitor workout intensity using the 20-point Borg's Rating of Perceived Exertion. Participants will walk or jog on treadmills or cycle on stationary bikes in the Exercise Prescription Suite of the Centre for Hip Health and Mobility.
224317034|NCT01171755|DRUG|Gemcitabine TS-1|Gemcitabine (1,000mg/m2) will be administered on days 1 and 8 at every 3 weeks TS-1 will be administered orally according to body surface area (BSA) as follows : BSA\<1.25 M2, 80 mg/day; 1.25 M2≤BSA\<1.5 M2, 100 mg/day; 1.5 M2≤BSA, 120 mg/day for 14 consecutive days followed by a 7-day rest.
224317035|NCT01703624|DRUG|glycopyrronium bromide|glycopyrronium bromide suspension in HFA
223763139|NCT01125111|PROCEDURE|surgery(robot versus laparoscopy)|
223763140|NCT02277496|BEHAVIORAL|Toolkit Intervention|The toolkit intervention consists of strategies and activities to engage students (student toolkit) and school wellness councils (school toolkit) in addressing the six targeted behaviors of the 2010 Dietary Guidelines based on the principles of participatory action research. The intervention will promote goal setting and school-based food and physical promotion activities led by students as well as school wellness network development.
223763141|NCT00127140|DRUG|vorinostat|
223763142|NCT05393518|BEHAVIORAL|Anxiety-induced task|Subjects will be asked to describe their most anxious thoughts and write each of them in a detailed scenario. The scenarios will be based on the answers to the Worry and Anxiety Questionnaire, in order to validate the procedure by a standardized examination. During the task, the scenarios will be successively presented to the subjects, on a digital computer medium in written and oral format. Subjects will be asked to actively focus on these negative thoughts with maximum concern, without seeking to control their emotions.
223763143|NCT05393518|BEHAVIORAL|Neuropsychiatric assessment|Screening for depression and anxiety
223763144|NCT04270916|DIAGNOSTIC_TEST|High frequency pure tone audiometry|Hearing test carried out routinely, non invasive
223763145|NCT04464681|DRUG|M201-A Injection|Active Substance: M201-A Route of administration: continuous intravenous injection
223763146|NCT04464681|DRUG|Placebo|Placebo: M201-A Placebo Route of administration: continuous intravenous injection
223763147|NCT06020066|DRUG|EGFR-TK Inhibitor|Patients will receive EGFR-TKI until confirmed progression or unacceptable toxicity.
223626628|NCT05036304|OTHER|Aerobic Exercise Outdoors|Each session will consist of 10 min of warm-up, 40 min of aerobic exercise, and 10 min of cool-down. Aerobic exercise will be progressive and of moderate intensity. During training, each participant will wear a heart rate monitor and will be asked to work initially at approximately 45% of his/her target heart rate (i.e., heart rate reserve (HRR)) and gradually progress to reach the target of 70% of HRR over the 12-week study period. Participants will also subjectively monitor workout intensity using the 20-point Borg's Rating of Perceived Exertion. Participants will walk or jog pre-determined routes in trails of an urban forest (Pacific Spirit Park)
223626629|NCT04781478|OTHER|Application of Biorepair Gel|Professional application of Biorepair Gel after Scaling and Root Planing and Air-Perio polishing (glycine powders).
223626630|NCT04781478|OTHER|Irrigation of Chlorhexidine 1.00% gel|Irrigation of periodontal pockets with Chlorhexidine 1.00% gel afterScaling and Root Planing and Air-Perio polishing (glycine powders).
223763148|NCT06020066|RADIATION|Stereotactic radiotherapy|Patients with oligo-residual intracranial disease after treatment with EGFR-TKI will be treated with SRS of all intracranial lesions. The choice of dose-fractionation regimen is at the discretion of the treating radiation oncologist.
223763149|NCT05529212|PROCEDURE|ischemic reperfusion injury|ischemic reperfusion injury is a pathological process in which the ischemic myocardium is restored to normal perfusion, but the tissue damage is progressively aggravated when the coronary artery supply is completely blocked after cardiopulmonary bypass surgery and then recanalised at a certain time.
224215644|NCT01187160|PROCEDURE|Transoral robotic surgery (TORS)|The da Vinci® Robotic Surgical System (Intuitive Surgical, Inc., Sunnyvale, CA) is a manual image-guided surgery system that is computer enhanced rather than computer guided robotic surgery in which the surgeon programs the computer to do the surgery and the robot does the surgery (also known as a milling device). Use of the da Vinci® Robotic Surgical System in the aforementioned configuration in fact facilitates an exact translation of the surgeons hand and finger movements at the console to precise and tremor-free movements of the arms and instruments.
224317036|NCT05232812|RADIATION|3-[11C]-OHB|The PET tracer 3-\[11C\]-OHB is used to quantify 3-hydroxybutyrate uptake
224317037|NCT00569855|DRUG|Phenoxybenzamine|0.125 to 1 mg/kg given i.v. over 15 to 45 minutes in preparation for cardiopulmonary bypass; may be continued at 0.125 mg/kg/day in ICU
223626631|NCT02720393|OTHER|No-carrageenan diet|Diet of food items that have no carrageenan as selected by study dietician.
223626632|NCT02720393|OTHER|Regular Diet|Diet of food items that have carrageenan as selected by study dietician
223626633|NCT05472935|BEHAVIORAL|Mindfulness Based Stress Reduction (MBSR)|Mindfulness Based Stress Reduction (MBSR) is an evidenced based intervention utilized to reduce stress.
224215645|NCT03214458|DEVICE|Nasal high flow|The AIRVO 2 is for the treatment of spontaneously breathing patients who would benefit from receiving high flow warmed and humidified respiratory gases/
224215646|NCT05338710|OTHER|STELLA-FTD|Behavioral intervention for caregivers for those with FTD
224215647|NCT03187483|PROCEDURE|orthodontic treatment|orthodontic treatment in maxillary crowding
224317038|NCT06257095|BEHAVIORAL|Stepped-care social and mental health engagement|Each student will be matched to an older adult and the students will make one call o the older adult which lasts upto 1 hour each week for 8 weeks. Ending each call, the student will assess symptoms of depression anxiety through questionnaires. If the participant responds yes on two consecutive calls to any of these questions, they will be asked if they would like to receive a call from the University of Texas Health Science Center Trauma and Resilience Center to discuss free counseling services.
223626634|NCT02182622|DRUG|Docetaxel|
223626635|NCT02182622|DRUG|Prednisone|
223626636|NCT02182622|DRUG|LDE225|
223626637|NCT01261988|DEVICE|VIPER|Comparison of ostomy systems
223626638|NCT01261988|DEVICE|Esteem™ Cut to Fit One Piece Closed End Pouch|Comparison of ostomy systems
223626639|NCT05103007|PROCEDURE|DEB-TACE|It is suggested that the tumor feeding artery should be selected for the microcatheter. The mixed volume of pirarubicin 80mg + microsphere 2g is about 2ml, and the mixture of at least 10ml and contrast medium is slowly injected with 5-10min.
223626640|NCT05103007|PROCEDURE|PVL/PVE+DEB-TACE|DEB-TACE will be performed after the liver function recovered within 7-10 days. After that, conventional transarterial chemoembolization（cTACE) was performed every 2 months, a total of 2-3 times of chemoembolization.
223763150|NCT01575327|DEVICE|Automated settings on the oxygen delivery device|FreeO2 automatically adjusts the oxygen flow delivered to patients based on the SpO2 signal and collects the cardiorespiratory parameters
223763151|NCT01575327|DEVICE|Manual settings with FreeO2 system in collection mode|FreeO2 system does not adjust oxygen flow but collects the cardiorespiratory parameters
223763152|NCT04334460|DRUG|BLD-2660|BLD-2660 is a novel, synthetic, orally active, small molecule inhibitor of calpain (CAPN) 1, 2, and 9.
223763153|NCT00547703|DRUG|Nortriptyline|Nortriptyline 25mg capsule, orally administered, every night for 8 weeks
223763154|NCT00547703|DRUG|Placebo|An identical placebo capsule containing lactose, administered orally, every night for 8 weeks
223763155|NCT01606085|BEHAVIORAL|HF DM self care|Education in monitoring signs and symptoms of Heart Failure and Diabetes as well as self care instruction
223763156|NCT01606085|BEHAVIORAL|Usual Care|Educational materials on Heart Failure and diabetes at study enrollment. Full educational binder delivered at end of study.
223763157|NCT04062916|OTHER|BSGE pelvic pain questionnaire and VAS scores|Patients were evaluated using the BSGE pelvic pain questionnaire in terms of pre-operative and post-operative pain assessment in order to determine the effects of endometriosis surgery on the quality of life. The patients were asked to indicate their levels of dyspareunia, dysmenorrhea, and chronic pelvic pain on a VAS on the pelvic pain questionnaire.
224317039|NCT06257095|BEHAVIORAL|APS Usual care|Participants will receive a phone call for data collection. Then they will be offered to receive an abbreviated version of the stepped-care social and mental health engagement intervention, lasting only 6-weeks with the option to continue calls if agreeable between the student and older adult.
224317040|NCT05461196|BEHAVIORAL|CPMRx|Patients use a mobile application to track pain medication usage and pain scores.
223626641|NCT06385769|OTHER|Transcutaneous tibial nerve stimulation (TTNS)|The TTNS will be conducted unilaterally, with the patient in a supine position, using a surface electrode dual stimulation channel stimulation device. Two self-adhesive round surface electrodes will be positioned with the negative electrode 2 cm behind the medial malleolus and the positive electrode 10 cm proximal to it. The ground electrode will be placed on the ipsilateral limb. Channel 1 will provide active stimulation, while channel 2 will remain inactive.
224215648|NCT03700528|BEHAVIORAL|Acceptance and Commitment Therapy (ACT)|The process will involve, two, brief, one-to-one contact sessions, one at the beginning and one at the end of the intervention, in a way that is convenient for participants, including Skype, phone, or face to face in person. Following the first one-to-one session there will be eight short online sessions, about 20-30 minutes each. Participants will also be asked to complete some tasks between the sessions, in particular to record their progress briefly and any changes at their medication (i.e. type of drug, dose) in a diary weekly so that they can keep track of your developing skills.
224215649|NCT03172585|OTHER|High resolution computed tomography|High resolution computed tomography of the chest is the gold standard imaging modality for most pulmonary diseases
224215650|NCT03172585|OTHER|trans thoracic ultrasonography|Trans thoracic ultrasonograghy is used progressively for evaluation of pulmonary diseases . Its non invasive nature , relatively low price ,portability for bedside use, and high reproducible of results allows for incorporation of imaging findings with clinical data
224215651|NCT05986071|DRUG|M1774|• Phase I part = administration of M1774 in combination with fulvestrant in ER+/HER2- ABC resistant to CDK4/6 inhibitor and aromatase inhibitor-based endocrine therapy in order to detemine the recommended phase II dose Phase II part = administration of M1774 at RP2D in combination with fulvestrant
224215652|NCT05986071|DRUG|Fulvestrant injection|Phase I part = administration of M1774 in combination with fulvestrant in ER+/HER2- ABC resistant to CDK4/6 inhibitor and aromatase inhibitor-based endocrine therapy in order to detemine the recommended phase II dose Phase II part = administration of M1774 at RP2D in combination with fulvestrant
224215653|NCT01507831|DRUG|Placebo (for alirocumab)|Solution for injection, one subcutaneous injection in the abdomen, thigh, or outer area of upper arm with a pre-filled syringe.
224215654|NCT01507831|DRUG|Alirocumab|Solution for injection, one subcutaneous injection in the abdomen, thigh, or outer area of upper arm with a pre-filled syringe.
224215655|NCT01507831|DRUG|Lipid-Modifying Therapy (LMT)|Statin (rosuvastatin, simvastatin or atorvastatin) at stable dose with or without other LMT as clinically indicated.
224317041|NCT06206135|DRUG|the low-dose group (1.5 g/day) or the standard-dose group (4 g/day)|The initial dose of Nephoxil capsules for the subjects participating in this study shall be determined at the investigator's discretion, and subjects shall be classified into either the low-dose group (1.5 g/day) or the standard-dose group (4 g/day) according to the initial dose. It will be conducted with 13 visits over 48 weeks.
223763158|NCT01583010|DEVICE|ANV(R)|"Device: Advanced Needle Visualization Technology ®~Software update for SonoSites M-Turbo® and S-series™ ultrasound systems with enhanced 15-20Mhz ultrasound probe.~Arms: ANV ® Group"
223763159|NCT00358462|DRUG|Azithromycin|two 500mg tablets or four 250mg tablets administered as a single dose
223763160|NCT00358462|DRUG|Doxycycline|one 100mg capsule administered twice daily for seven days
223763161|NCT05498636|COMBINATION_PRODUCT|Selinexor combined with Prednisone, Etoposide, and Lenalidomide|Selinexor combined with Prednisone, Etoposide, and Lenalidomide
223763162|NCT01983657|DRUG|rhGM-CSF|GM-CSF will be given subcutaneously according to the rule in different groups.
223626642|NCT06385769|OTHER|Sham Transcutaneous tibial nerve stimulation (TTNS)|Sham TTNS group will be stimulated using the same electrotherapy device, with patients positioned identically and electrodes placed in the same positions as in the TTNS group. The current characteristics (pulse frequency 20 Hz and pulse width 200 ms) will also remain consistent across both channels. The second channel of the stimulation device will be designated as the channel connected to the patient but without delivering stimulation.
223626643|NCT00006088|DRUG|vinorelbine tartrate|
223626644|NCT03808116|DEVICE|SmartBx|"he SmartBx device is intended for the retention of a biopsy specimen and for preservation of the specimen's in-needle location and orientation.~The SmartBx is used as an aiding tool in biopsy procedures. When operated in conjunction with the standard equipment in a prostate biopsy procedure, the SmartBx may be used for the following:~* To preserve sample unity, including core fragments in their original location along the needle notch.~* Avoid sample damaging during sample removal from the needle and the following pathology process."
223626645|NCT01493323|BEHAVIORAL|Assessment of personality traits|suicide behaviour , psychic pain, social exclusion, decision making...
223763163|NCT01983657|PROCEDURE|Whole Lung Lavage(WLL)|using double lumen endotracheal tube (DLT) to selectively lavage one lung
223763164|NCT00957437|DRUG|AZD1305|Single Oral Dose, ER formulation 1
223763165|NCT00957437|DRUG|AZD1305|ER formulation 1, bid for 5 days
223763166|NCT00957437|DRUG|AZD1305|Single Oral Dose, ER formulation 2
223763167|NCT03995953|BEHAVIORAL|SHIELD intervention (Support for HIV Integrated Education, Linkages to care, and Destigmatization)|The SHIELD intervention includes a three-session, six-module program for AGYW that increases knowledge, skills, and self-efficacy to engage along the HIV prevention and care continuum, and a two-session, four-module program for caregivers to increase social support. In addition, the SHIELD intervention includes youth clubs to foster peer support.
223763168|NCT03995953|OTHER|Integrated wellness care (IWC) clinics|IWC clinics will be created within health facilities where AGYWs can receive sexual and reproductive health services, including HIV testing and treatment, family planning, sexually transmitted disease screening and treatment, and HPV vaccination in a youth-friendly environment.
223763169|NCT00685152|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS) (MagPro, Medtronic)|6 weeks of either Active or Sham Repetitive Transcranial Magnetic Stimulation (rTMS). Active treatment comprises of stimulation with rTMS frequency 20Hz, intensity 110% of Motor Threshold, 20 trains, 9 seconds per train, 51 seconds of intertrain interval that is applied over the Right Dorsolateral Prefrontal Cortex by a figure eight shaped coil. Treatment will be given 5 times a week for 4 weeks, 3 times a week during Week 5 and 2 times a week during Week 6. Sham treatment will mimic active treatment; The rTMS machine used is MagPro and the company name is Medtronic.
223626646|NCT01493323|BEHAVIORAL|Assessment of suicidal act|suicide behaviour , psychic pain, social exclusion, decision making...
223626647|NCT01493323|BEHAVIORAL|Assessment of depression|suicide behaviour , psychic pain, social exclusion, decision making...
223626648|NCT01493323|PROCEDURE|Cyber ball game|functional neuroimaging
223626649|NCT01493323|PROCEDURE|Iowa Gambling Task|functional neuroimaging
223626650|NCT01493323|PROCEDURE|Microcomputer|functional neuroimaging
223626651|NCT01493323|PROCEDURE|blood sample|blood sample
223626652|NCT02914639|DRUG|SF0166 Topical Ophthalmic Solution|
223626653|NCT04938908|DRUG|Ophthalmic Probiotic|Bacterial lysate of Lactobacillus sakei, hydroxypropylmethylcellulose (HPMC), boric acid, sodium chloride, purified water.
223626654|NCT04938908|DRUG|Opthalmic Placebo|Placebo contains complete formulation of the active drug except for bacterial lysate of Lactobacillus sakei (i.e. HPMC, boric acid, sodium chloride, purified water)
223626655|NCT04938908|DIETARY_SUPPLEMENT|Oral Probiotic Capsule|Live Lactobacillus sakei (5 billion cfus) in hydroxypropylmethylcellulose hard capsule, with maltodextrin excipient
223626656|NCT04938908|DIETARY_SUPPLEMENT|Oral Placebo Capsule|Hydroxypropylmethylcellulose hard capsule, filled with maltodextrin excipient
223626657|NCT04668469|DRUG|Ivermectin|"evaluation of the anti-parasitic medication efficacy Ivermectin (Ivermectin 400 mcg/kg body weight maximum 4 tablets (6mg / tablet) once daily dose before breakfast) plus standard care in the treatment of mild/moderate cases with COVID 19 infection"
223626658|NCT04668469|DRUG|Hydroxychloroquine|evaluation of hydroxychlorquine (400 every 12 hours for one day followed by 200 mg every 12 hours for 5 days) plus standard care in the treatment of mild/moderate cases with COVID 19 infection
223626659|NCT04668469|BEHAVIORAL|personal protective Measures|evaluation of personal protective Measures (hand hygiene, social distancing measures, avoiding touching the eyes, nose and mouth, wearing masks, and self-isolation) only as a prophylaxis for health care and or household contacts' from COVID-19 disease
223626660|NCT06079138|DEVICE|Transcranial direct current stimulation (Active)|"Participants will sit comfortably during the stimulation, and the scalp will be cleaned with alcohol beforehand. The Ybrain MINDD STIM current stimulator will be used with saline-soaked sponge-pad electrodes (35 cm2 in size). Electrode placement will follow the 10-20 EEG system, with the active (anodal) electrode (A) positioned at the vertex (Cz) on the more affected side and the reference (cathodal) electrode (C) placed over the supraorbital region on the less affected side. The electrodes will be attached to a cap before application.~In the experimental group, participants will receive real tDCS at 2.0 mA for 20 minutes, with a 30-second ramp-up and ramp-down period."
223626661|NCT06079138|DEVICE|Transcranial direct current stimulation (Sham)|Participants will sit comfortably during the stimulation, and the scalp will be cleaned with alcohol beforehand. The Ybrain MINDD STIM current stimulator will be used with saline-soaked sponge-pad electrodes (35 cm2 in size). Electrode placement will follow the 10-20 EEG system, with the active (anodal) electrode (A) positioned at the vertex (Cz) on the more affected side and the reference (cathodal) electrode (C) placed over the supraorbital region on the less affected side. The electrodes will be attached to a cap before application. The sham group will receive sham tDCS, where the current will only be delivered for the first 30 seconds and automatically stopped, while the electrodes remain in place for 20 minutes.
223626662|NCT06079138|OTHER|Telerehabilitation exercise|Telerehabilitation exercise will be provided via tele-conference meeting program. The program will consist of 3 parts. First part, there will be a limb exercise program for 20 minutes to prepare the joint range of motion and muscles. Second part, participants will receive functional balance training for 15 minutes to promote their postural balance during changing positions and static positions. Each exercise will perform 10 repetitions for each set and perform 3 sets. After 2-week of intervention, the set will be progressed to 4 sets. Final part, participants will receive 20 minutes of functional training of wheelchair/bed transferring exercise. Each wheelchair and bed transfer exercise will perform 10 repetitions for each completely transfer and perform 3 sets. After 2-week of intervention, the set will be progressed to 4 sets. After finishing all the programs, they will be asked to cool down by doing breathing exercises with torso stretching for 5 minutes.
223626663|NCT01460108|DEVICE|AeriSeal System|20 mL
223626664|NCT02457390|PROCEDURE|CE-LUS|"To assess the use of contrast enhanced LUS during robot assisted primary CRC surgery. Does CE-LUS detect any unrecognized liver metastases.~The patient will get a contrast-enhanced CT scan 3 month after surgery as a control to the CE-LUS procedure."
223626665|NCT03025425|DEVICE|Trilogy 100 ® (Philips Respironics)|Mouth piece Ventilation (MPV) using Trilogy 100 ® (Philips Respironics).
223626666|NCT01018030|DRUG|FFNS 110 mcg QD|Active Nasal Spray (AM) and Placebo Nasal Spray (PM)
223763170|NCT03279939|DEVICE|OCT Angiography|OCT Angiography offers clinicians a non-invasive three-dimensional visualization of vasculature in the retina and choroid. The visualization of perfused vasculature in a three-dimensional layout, offers clinicians an aid in the identification of retinal and choroidal pathologies such as retinal ischemia, microaneurysms, retinal neovascularization and choroidal neovascular membranes.
223763171|NCT03279939|DEVICE|Color Fundus Photography|Non-contact white light photography.
223763172|NCT03279939|DEVICE|Fluorescein Angiography|An imaging procedure where dye is injected into a vein and images are taken of the back of the eye to visualize the perfusion of retinal vessels in two dimensional images.
223763173|NCT03279939|DEVICE|Indocyaine Green Angiography|An imaging procedure where dye is injected into a vein and images are taken of the back of the eye to visualize the perfusion of choroidal vessels in two dimensional images.
224317042|NCT06467396|DEVICE|Large Vessel Occlusion Biomarkers Test|Duplex Point of Care test to measure the concentration of blood biomarkers (FABP+NT-proBNP) associated to Large Vessel Occlusion in blood samples used in combination with an APP.
223626667|NCT01018030|DRUG|FFNS 110 mcg BID|Active Nasal Spray (AM) and Active Nasal Spray (PM)
223626668|NCT01018030|DRUG|Placebo Nasal Spray|Placebo Nasal Spray (AM) and Placebo Nasal Spray (PM)
223763174|NCT02422433|DEVICE|OFDI Capsule Marking|Marking and imaging of the esophagus using the OFDI Capsule and system.
223763175|NCT05692141|DEVICE|ultrasound|For each lesion, ultrasound Elastography would be performed using a Linear probe ;
223763176|NCT02130765|DEVICE|Cardiac catheter ablation with ICD/CRT-D|Cardiac ablation catheter system
223763177|NCT04252105|DIETARY_SUPPLEMENT|Antioxidant|Antioxidant-rich diet (added selected types of fruits, vegetables, nuts, cereals and oils)
223626669|NCT04392323|DIAGNOSTIC_TEST|COVID-19 PCR and Serology|PCR for COVID entails obtaining a nasopharyngeal swab (a cotton tip introduced via the nose to obtain a sample) to determine whether there is active viral replication and viral shedding. They will then have a second test with serology and PCR for COVID-19 infection 12-16 days after discharge from the hospital. Serology implies that a blood sample will be obtained by venipuncture. A volume of 50 ml (about 4 tablespoons) or less of blood will be obtained.
223626670|NCT03701776|BEHAVIORAL|Aerobic Training|Aerobic training on stationary bicycle for 30 minutes a day, 5 days a week for 6 months
223626671|NCT03701776|BEHAVIORAL|Balance Training|Standard of care
223626672|NCT06072911|BEHAVIORAL|Pelvic floor exercise program|General exercises will be prescribed along with a specialized pelvic floor program
223626673|NCT06072911|BEHAVIORAL|General exercise|A general progressive resistance exercise program
223626674|NCT06072911|BEHAVIORAL|Physical Activity Counseling|Advice on increasing physical activity
223626675|NCT01233804|OTHER|Opting Out|Usual care is for pregnant women to sign a consent to get the influenza vaccine. The intervention is to offer a group of women the option to sign only when they refuse the influenza vaccine.
223626676|NCT00252421|DRUG|Nitroglycerin ointment 15 mg/day daily for 24 month|Nitroglycerin ointment 15 mg/day applied daily for 24 mth
223626677|NCT00252421|DRUG|Placebo ointment daily for 24 month|Placebo ointment applied daily for 24 mth
223626678|NCT03596216|OTHER|PENS|This intervention consisted in the application of an asymmetric biphasic rectangular current of 150 microseconds and 10 Hz using a specifically developed medically certified device (Physio Invasive, Enraf Nonius, Prim, SPAIN). This is an invasive intervention by ultrasound and needles.
224317043|NCT00520819|DRUG|Antioxidant-rich food items|
224317044|NCT05368064|OTHER|observational|collection of phenotype data
224317045|NCT03300843|BIOLOGICAL|Peptide loaded dendritic cell vaccine|On days 0, 14 (+/- 5 days), 28 (+/- 5 days), and 42 (+/- 5 days). The vaccine will be administered as both an intravenous (IV) infusion and a subcutaneous (SQ) injection. The total dose will be divided equally between intravenous (IV) and SQ containing 1.0E7 to 8.0E7 cells per cycle depending upon the manufacturing yield.
224317046|NCT00549679|DRUG|GSK256066|PDE4 inhibitor
223514018|NCT00655746|DRUG|Dasatinib + Omeprazole|Tablet/Capsule, Oral, (Dasatinib 100 mg)/(Omeprazole 40 mg), once daily, 7 days
223626679|NCT03596216|OTHER|TENS|This intervention consisted in the application of an asymmetric biphasic rectangular current of 150 microseconds and 10 Hz using a specifically developed medically certified device (Physio Invasive, Enraf Nonius, Prim, SPAIN). This is a non-invasive intervention by self-adhesive electrodes.
223626680|NCT04053335|BEHAVIORAL|Multicomponent Physician Performance Peer-Comparison Feedback Intervention|"The intervention will consist of 5 components delivered simultaneously~* Clinical Leadership Team: Each site will develop a Clinical Leadership Team (CLT), typically consisting of quality officers, clinician champions, etc. to implement and monitor the intervention~* Speaker Series: VCHI will offer the CLTs access to national experts via a CME-approved speaker series and office hours to support the intervention.~* Education Materials: The CLTs will distribute clinician and consumer education throughout the health systems calling to avoid 9 low-value services.~* Clinician Report Cards: VCHI will distribute quarterly customized clinician performance report cards to the CLTs teams using the Milliman Health Waste Calculator and Virginia APCD~* Quality improvement training: The intervention will provide the CLTs with in-person quality improvement and clinician performance feedback training, using principles of self-determination theory, and will include monthly check-in calls"
223626681|NCT02481154|DRUG|AG881|AG-881 administered continuously as a single agent dosed orally on Days 1 to 28 of a 28-day cycle. Patients may continue treatment with AG-881 until disease progression or development of other unacceptable toxicity
223626682|NCT04605601|OTHER|Virtual reality treatment|Tennis, boxing, and baseball games of the Wii Sports package sre used for activating the upper extremity functions of the patients. In the tennis game, patients represent people holding rackets.
223626683|NCT04605601|OTHER|conventional physiotherapy|As the conventional physiotherapy, neuromuscular electrical stimulation and strengthening exercises for the deltoid, infraspinatus, triceps, biceps, supinator, and wrist extensor muscles, and passive, active, active assistive joint Rage of Motion, and stretching exercises for the shoulder, elbow and wrist joints are applied to the patients in the standardized program for the upper extremity in 10 repetitions.
223626684|NCT02802306|DEVICE|Tack Endovascular System|Repair of post-PTA dissections using the Intact Vascular Tack Endovascular System
224317047|NCT00549679|DRUG|Placebo|Placebo
223514019|NCT00775515|PROCEDURE|laparoscopic prostatectomy|laparoscopic prostatectomy
223514020|NCT02669108|DEVICE|PET/ MRI of the Testis|PET/MRI of the testis will be performed upon the patient achieving azoospermia (following the vasectomy), or 25 ejaculations and following proven azoospermia (via standard of care semen analysis).
223626685|NCT05397717|OTHER|observational|Observational, without interfering the patient care of treating doctors
223626686|NCT02843724|OTHER|Naturopathic Care|Naturopathic diabetes care will be selected from a pre-approved menu. Participants' other health concerns will be addressed at naturopathic doctors' discretion
223626687|NCT02843724|OTHER|Usual (Conventional) Care|2016 Canadian Diabetes Clinical Practice Guidelines (self-management, blood-glucose-lowering, vascular protection, pharmacotherapy) will be implemented
223626688|NCT04277975|OTHER|Liberal post-discharge opioid prescribing|Opioid prescribed all patients opioids 'in case they are needed' prior to surgery
224317048|NCT03883308|BEHAVIORAL|Multi-domain cognitive training|The cognitive exercises are designed to train executive functions and memory.
223514021|NCT06896734|DEVICE|Evaluation of the ECG signal in the nominal location and in three alternate positions|Evaluation of the ECG signal in the nominal location and in three alternate positions to determine if the three alternate positions are interpretable.
223514022|NCT03833089|COMBINATION_PRODUCT|Targeted serum potassium level|In the following order, following advices end prescriptions will be provided: 1) Potassium rich dietary advice, 2) Mineralocorticoid receptor antagonists, 3) Potassium supplementation,
223514023|NCT02345577|OTHER|Stochastic whole body vibration (WBV) therapy - Physiotherapeutical intervention|Physiotherapeutical intervention
223514024|NCT02345577|OTHER|Stochastic whole body vibration (WBV) therapy - Sham physiotherapeutical intervention|Sham physiotherapeutical intervention
223626689|NCT04277975|OTHER|Restricted post-discharge opioid prescribing|Opioid only if needed after discharge
223626690|NCT03617172|DRUG|Misoprostol 100Mcg Tab|Two 100mcg capsules twice per day
223626691|NCT03617172|OTHER|Placebo|Two capsules twice per day
223626692|NCT05623332|DIAGNOSTIC_TEST|Maraciclatide|Imaging marker that binds to AVB3/5 lesions
223626693|NCT01153386|DRUG|Treprostinil diethanolamine|Treprostinil diethanolamine sustained release oral tablets.
223626694|NCT04789707|BEHAVIORAL|auto-questionnaire|Patients answer the auto questionnaire in last minutes of consultation.
223626695|NCT05993806|DRUG|L04RD1|1 tablet of L04RD1
223626696|NCT05993806|DRUG|L04TD3|1 tablet of L04TD3
223626697|NCT01333748|GENETIC|blood collection|blood collection for research quantification of allelic expression in the gene BRCA1.
223763178|NCT03183791|BEHAVIORAL|RELAXaHEAD app|The Research Volunteers (RV) will explain the rationale for PMR and load the RELAXaHEAD app onto the patients' smartphones. The RV will review the app with the subject, focusing on user knowledge, usability, and engagement. The patient will perform a 15 minute session of PMR during the study enrollment and discuss the optimal time and place to practice PMR at home. Subjects will also be taught to enter their headache log daily on the app.
223763179|NCT03183791|BEHAVIORAL|Monitored Usual Care (MUC)|"The Research Volunteers (RV) will load the app onto the patients' smartphones but the PMR component will be blocked on the version of the app that the MUC patients receive.~Subjects will be taught to enter their headache log daily on the app."
223763180|NCT01764607|DRUG|Sirolimus|Patients randomized to this arm of the study will receive sirolimus from the time of randomization at least until 5 weeks or the removal of the skin tumor. Nephrology will determine/manage the immunosuppressant therapy.
223626698|NCT01333748|GENETIC|blood collection|blood collection for research quantification of allelic expression in the gene BRCA1.
223763181|NCT03490084|OTHER|Association of day hospitalization with hospital-at-home|Patients receive the first administration of chemotherapy through day hospitalization in the hematology department, then 3 weekly administrations of chemotherapy at home.
223763182|NCT03490084|OTHER|Day hospitalization exclusively|Patients receive 4 weekly administrations of chemotherapy through day hospitalization in the hematology department.
223763183|NCT05650372|OTHER|High intensity resistive exercise|Participants of this group will be applied manual lymphatic drainage and compression bandaging every day of the week, and they will exercise for 25 minutes, three sets of each exercise at 80% intensity of 1 max repetition, 2 days of the week. Exercise training consist of warm-up and cool-down (10-15 repetitions of range of motion and 10 minutes of active stretching exercises) and resistive exercises.Each of the experimental sessions involved resistance exercises targeting all the major muscle groups in the upper body. Specifically, the exercises included the chest press, lat pull-down, bicep curl, triceps extension, lateral raise, and wrist curl.
223626699|NCT06473727|OTHER|Omnichoroma|Patients with anterior non-carious cervical lesions were treated with Omnichoroma. Colour measurements were taken from the middle third of the teeth to be treated using a spectrophotometer. The initial colour measurement was taken from the middle third of the restoration made in the same place and at the same time 24 hours after treatment.
223626700|NCT06473727|OTHER|Charisma Topaz One|Patients with anterior non-carious cervical lesions were treated with Charisma Topaz One. Colour measurements were taken from the middle third of the teeth to be treated using a spectrophotometer. The initial colour measurement was taken from the middle third of the restoration made in the same place and at the same time 24 hours after treatment.
223626701|NCT04205448|BEHAVIORAL|Physical exercize|10 weeks group exercize followed by community-based voluntary exercize
223626702|NCT01172106|BEHAVIORAL|drug compliance|Mothers and their caregivers will be encouraged to comply with the given medication
223626703|NCT01172106|BEHAVIORAL|Encouragement of drug compliance|Mothers and their caregivers in the placebo comparator will receive an intervention of drug compliance encouragement
223626704|NCT01172106|BEHAVIORAL|Family psychoeducation|The experimental group will receive family psychoeducation for 12 sessions
223626705|NCT05963334|DRUG|Carboplatin/paclitaxel|Weekly dose versus every three weeks dense dose of carboplatin/paclitaxel regimen in advanced epithelial ovarian cancer.
223626706|NCT00189540|GENETIC|HGF plasmid|Intramuscular injections into the index leg on days 0, 14, and 28
223626707|NCT00189540|GENETIC|Placebo|Intramuscular injections into the index leg on days 0, 14, and 28
224215656|NCT04656522|BEHAVIORAL|Participatory Comic Intervention|This participatory comic intervention promotes sexual violence prevention and post-rape care with refugee youth and health care providers. In 4-hour workshops, a customized comic book featuring eight sexual violence scenarios will be distributed. Each 1-page scenario speaks to a unique theme of sexual violence experiences among youth or post-rape care preferences. During the workshop participants will explore social, sexual, and psychological needs of youth in Bidi Bidi and practice ways of developing and maintaining healthy relationships (youth) as well as discuss post-rape care responses that attend to the needs and priorities of young refugees in Bidi Bidi who have experienced sexual violence (health care providers). Each workshop will include 20 participants and will be facilitated by trained staff from Real Medicine, Uganda. Further, each workshop will have at least 2 facilitators who are trained in the bystander model.
223763184|NCT05650372|OTHER|Low intensity resistive exercise|"participants in this group will be applied manual lymphatic drainage and compression bandaging every day of the week and they will exercise for 25 minutes, three sets of each exercise at 30% intensity of 1 max repetition 2 days of the week.~Exercise training consist of warm-up and cool-down (10-15 repetitions of range of motion and 10 minutes of active stretching exercises) and resistive exercises. Each of the experimental sessions involved resistance exercises targeting all the major muscle groups in the upper body. Specifically, the exercises included the chest press, lat pull- down, bicep curl, triceps extension, lateral raise, and wrist curl."
223763185|NCT04574947|DRUG|Intravenous lidocaine|Lidocaine IV 1.5 mg / kg BMI will be administered during induction into anaesthesia followed by infusion at a dose of 1.5 mg / kg / h until the end of the surgery.
223763186|NCT04574947|DRUG|Intravenous placebo|During induction and maintenance of anaesthesia, 0.9% sodium chloride solution will be injected intravenously at a rate equivalent to lidocaine solution.
223763187|NCT04574947|PROCEDURE|Intra-cuff lidocaine|The lidocaine solution will be applied to the intubation tube and the cuff will be filled with an alkalinised lidocaine solution.
224215657|NCT03875560|BIOLOGICAL|IC14|recombinant chimeric anti-human CD14 monoclonal antibody
223763188|NCT04574947|PROCEDURE|Intra-cuff placebo|The intubation tube will be lubricated 0.9% sodium chloride, the tube cuff will be filled with 0.9% sodium chloride solution.
223763189|NCT03522376|OTHER|Loaded inspiratory muscle test|Loaded inspiratory muscle tests will be set at 30% and 50% of maximal inspiratory pressure. The orders of the two loaded test conditions will be conducted in random order with at least 24 hours separation. This is an observational study. Subjects will perform only 15 breaths with each loaded test condition to exam the performance of their inspiratory muscles. Loaded inspiratory muscle test is not for training.
223763190|NCT03743948|GENETIC|Non invasive prenatal diagnosis|15 pregnant women and their spouses Search for the familial mutation on isolated circulating fetal trophoblastic cells from maternal blood
224215658|NCT03875560|DRUG|Placebo|Inactive
224215659|NCT04862104|BEHAVIORAL|Intervention group|In addition to the routine care they received, the patients in the intervention groups were given discharge training developed in the pre-discharge period. Discharge training consisted of a verbal and written information booklet containing instructions for the patient and the patient's caregiver on pain management, nutrition management, incision site care, strengthening self-care, returning to daily life activities, and colostomy care. Discharge training was given in the service after evaluating the surgical recovery status of the patient before discharge. The average duration of each training was 30-45 minutes. The patients were evaluated in terms of surgical recovery by calling by phone 2 weeks after discharge, 4 weeks and 8 weeks later. The developed education booklet was given to the patient and it was ensured that he could benefit from the information at home.
223763191|NCT00961324|DRUG|insulin degludec|The dose level will be 0.4 units per kg body weight injected subcutaneously (under the skin) once daily for 12 days
223763192|NCT00961324|DRUG|insulin glargine|The dose level will be 0.4 units per kg body weight injected subcutaneously (under the skin) once daily for 12 days
223763193|NCT02193594|RADIATION|Preoperative concurrent chemoradiotherapy|The patients will receive radiotherapy in the total amount of 50Gy(25 fractions) preoperatively,concurrently combined with chemotherapy,which consist of oxaliplatin 40mg/m2 administrated on days 1,8,15,22,29 and S-1® 30mg/m2 twice per day on days 1 to 5 per week.
224215660|NCT02282826|DRUG|GZ402668|Pharmaceutical form:solution Route of administration: intravenous
224215661|NCT02282826|DRUG|placebo|Pharmaceutical form:solution Route of administration: intravenous
223763194|NCT02193594|PROCEDURE|Radical D2 total gastrectomy|Within 5-6 weeks after the completion of neoadjuvant therapy,the patients in CCRT group will receive the radical total gastrectomy with D2 lymphadenectomy,and patients in the CT group will receive the surgery right after randomization.
223763195|NCT02193594|DRUG|Adjuvant chemotherapy|Within 2 months after surgery,the patients will receive chemotherapy for 6 to 8 cycles ,consist of oxaliplatin 130mg/m2 administrated on day1 and S-1® 40-60mg twice per day on days 1 to 14 per 3 weeks.The S-1® dosage depends on the patient BSA(BSA\<1.25m2 40mg,1.25 m2≤BSA≤1.5 m2 50mg ,BSA\>1.5 m2 60mg). Patients in the CCRT group will receive 6 cycles of chemotherapy and patients in the CT group will receive 8 cycles of chemotherapy.
223763196|NCT03440879|DRUG|Zoladex|Patients currently treated with Zoladex
223763197|NCT02459691|BEHAVIORAL|Vida Sana|Vida Sana is a Diabetes Prevention Program-based, culturally-adapted intervention that will have 2 distinct stages: The intensive treatment stage will implement a culturally adapted year-long Group Lifestyle Balance curriculum. The curriculum uses a goal-based approach to promote positive outcome expectancies and foster self-efficacy. The maintenance stage will be focused on (1) facilitating continued behavior change; (2) fostering participants' self-efficacy and independence; and (3) reinforcing problem-solving and behavior maintenance skills. These will be done via secure e-messaging.
224215662|NCT02282826|DRUG|GZ402668|Pharmaceutical form:solution Route of administration: subcutaneous
224215663|NCT02282826|DRUG|placebo|Pharmaceutical form:solution Route of administration: subcutaneous
224215664|NCT02282826|DRUG|acyclovir|Pharmaceutical form:tablet Route of administration: oral
224317049|NCT03883308|BEHAVIORAL|Cross-word puzzle training|The active control group will be asked to complete a variety of crossword puzzles using the same curriculum assigned to the TG group.
223514025|NCT06214520|BEHAVIORAL|App-based Motivational Interviewing & Human health coaching|"Patients in the intervention arm will be given a smartwatch wearable device and will be encouraged to wear it for at least 10 hours per day. Patient's daily activities such as number of steps taken, sedentary time, heart rate, sleep time and exercise will be captured and synced to the EMPOWER+ app for real-time tracking.~App-based Motivational Interviewing \& Human health coaching:~The health coach will conduct 1:1 or group-based health coaching as appropriate virtually over the EMPOWER+ app, videoconferencing platform or telephone call."
223514026|NCT06214520|BEHAVIORAL|Empower+ App & Smartwatch wearable tracker|Patients in the intervention arm will be given a smartwatch wearable device and will be encouraged to wear it for at least 10 hours per day. Patient's daily activities such as number of steps taken, sedentary time, heart rate, sleep time and exercise will be captured and synced to the EMPOWER+ app for real-time tracking.
223514027|NCT04938466|DRUG|Long-Acting Growth Hormone (LAGH)|Long-acting growth hormone (LAGH) treatment
223514028|NCT00684138|DEVICE|ACRYSOF® ReSTOR® Aspheric +4.0 D Add Power Intraocular Lens|Intraocular Lens
223514029|NCT00684138|DEVICE|ACRYSOF® ReSTOR® Aspheric +3.0 D Add Power Intraocular Lens|Intraocular Lens
223514030|NCT03061214|DRUG|Semaglutide 0.5 mg|Up to 0.5 mg semaglutide injected subcutaneously (s.c., under the skin) once-weekly (OW) for 30 weeks
223514031|NCT03061214|DRUG|Semaglutide 1.0 mg|Up to 1.0 mg semaglutide injected subcutaneously once-weekly for 30 weeks
223514032|NCT03061214|DRUG|Sitagliptin placebo|Sitagliptin placebo tablets taken once-daily for 30 weeks
223514033|NCT03061214|DRUG|Sitagliptin|100 mg sitagliptin tablets taken once-daily for 30 weeks
223514034|NCT03061214|DRUG|Semaglutide placebo 0.5 mg|Semaglutide placebo (0.5 mg) injected subcutaneously once-weekly for 30 weeks
223514035|NCT03061214|DRUG|Semaglutide placebo 1.0 mg|Semaglutide placebo (1.0 mg) injected subcutaneously once-weekly for 30 weeks
223626708|NCT03826706|DEVICE|C-MAC Videolaryngoscope D blade|C-MAC videolaryngoscope D blade An intubating device that is used for endotracheal intubation. Endotracheal intubation was applied by anesthesiologist with C-MAC videolaryngoscope.
223763198|NCT02459691|OTHER|Usual Care Only|Patients assigned to this group will continue medical care as usual. That is, they will continue to see their primary care provider and any specialist he/she may recommend. They may also access additional health education resources available at the Palo Alto Medical Foundation. They will continue to receive general age and gender-appropriate reminders of health maintenance tests/exams and immunizations, per Palo Alto Medical Foundation standard practice.
223763199|NCT03357406|PROCEDURE|ultrasound implant site preparation|piezoelectric bone surgery will be used to create implant bone ostectomy
224215665|NCT05769192|OTHER|Classical physiotherapy and classical massage|Within the scope of classical physiotherapy, hot pack will be applied for 20 minutes to the muscles in the lumbar region in the prone position. Stretching and strengthening exercises for the abdominal, lumbar and hip muscles will be given. Classical massage, known as Swedish massage, will be applied on the lumbar region in prone position. All applications will be done 5 days a week for 3 weeks.
224215666|NCT05769192|OTHER|Classical physiotherapy and placebo massage|Within the scope of classical physiotherapy, hot pack will be applied for 20 minutes to the muscles in the lumbar region in the prone position. Stretching and strengthening exercises for the abdominal, lumbar and hip muscles will be given. In addition, placebo massage, applied without using any technique, will be applied to the lumbar region in the prone position. All applications will be done 5 days a week for 3 weeks.
223763200|NCT03357406|PROCEDURE|conventional implant site preparation|twist drills will be used to create implant bone ostectomy
224215667|NCT04283838|BEHAVIORAL|Humanistic Care|Psychological and physical rehabilitation based humanistic care regimen
224317050|NCT05162508|OTHER|Nasopharyngeal swab|Nasopharyngeal swab available in Standard Of Care (SOC) will be analysed (Full-length SARS-CoV-2 RNA sequencing and Transcriptomic analyses)
223763201|NCT00167934|DRUG|Valproate|Depakote ER 500 mg to 3000 mg taken every night
223763202|NCT00167934|DRUG|Placebo|Placebo given at same frequency as Valproate
223763203|NCT00397995|PROCEDURE|above- or under elbow cast|
224317051|NCT06474208|DRUG|Formulation 1|Oral suspension of Vericiguat (BAY1021189) in single dose (SD).
224317052|NCT06474208|DRUG|Formulation 2|Oral suspension of Vericiguat (BAY1021189) with increased level of sucralose in SD.
224317053|NCT06474208|DRUG|Formulation 3|Oral suspension of Vericiguat (BAY1021189) with increased level of flavor in SD.
223626709|NCT03826706|DEVICE|McGrath MAC Videolaryngoscope X3 blade|McGrath MAC videolaryngoscope X blade An intubating device that is used for endotracheal intubation. Endotracheal intubation was applied by anesthesiologist with McGrath MAC videolaryngoscope.
223626710|NCT00004249|BIOLOGICAL|QS21|
223763204|NCT00808938|DEVICE|MST|Magnetic Seizure Therapy
223763205|NCT04688164|DRUG|REL-1017|REL-1017 tablet
223763206|NCT04688164|DRUG|Placebo|Placebo tablet
223763207|NCT04514991|DEVICE|Foundation|Collagen-based, bone filling augmentation material used to stimulate bone formation in extraction sockets or bone defects in the alveolar ridge.
223763208|NCT06313372|DIAGNOSTIC_TEST|Respiratory oscillometry|This a Delphi study where we are obtaining expert opinion and input on the use of respiratory oscillometry (a diagnostic respiratory test) in the assessment and management of patients with asthma or chronic obstructive pulmonary disease. The participants are respiratory specialists/pulmonologists. They are sharing their insights into the clinical use of respiratory oscillometry via a series of online surveys. The Delphi process is used in an attempt to achieve consensus as to how respiratory oscillometry is used in clinical practice. As such there is no intervention being used on the study participants, but they are sharing insights on how the respiratory test is used in their clinical practice in order to obtain consensus on this use.
223763209|NCT00325806|DRUG|Ramipril|
223763210|NCT04707534|DRUG|Dexamethasone|Dexamethasone
223763211|NCT00791791|PROCEDURE|standardized pain stimulus|a tetanic stimulus (30s, 50 Hz, 60mA) applied as standardized pain stimulus
223763212|NCT00464724|PROCEDURE|3T Magnetic Resonance Spectroscopic Imaging|Part 1 of Study = One MRSI exam with an air-filled endorectal coil (AIR-MRSI) and one with a PFC-filled endorectal coil (PFC-MRSI); Part 2 of Study = MRSI exam with PFC using an endorectal coil only.
223763213|NCT04951622|DRUG|Nipocalimab|Nipocalimab will be administered as an IV infusion.
223763214|NCT04951622|DRUG|Placebo|Matching placebo will be administered as an IV infusion.
224317054|NCT06474208|DRUG|Formulation 4|Oral suspension of Vericiguat (BAY1021189) with increased level of sucralose and flavor in SD.
224317055|NCT06474208|DRUG|Formulation 5 (placebo)|Matching placebo of formulation 1 in SD.
224317056|NCT06964113|DRUG|Filgotinib Maleate|Administered as oral tablets.
224317057|NCT03660306|PROCEDURE|opioid anesthesia|opioid anesthesia means using sufentanil during surgery
223763215|NCT04951622|DRUG|Nipocalimab SC-LIV|Nipocalimab will be administered subcutaneously.
223763216|NCT05117463|OTHER|Optic Flow Stimulation|The optic flow will be displayed at different speeds. The subject will need to look at the center of the optic flow.
224317058|NCT03660306|PROCEDURE|opioid free anesthesia|opioid free anesthesia means giving no opioids during surgery
224317059|NCT04625491|OTHER|Observational|Observational
224317060|NCT00273689|DRUG|montelukast vs pretreatment with albuterol|montelukast 5 or 10 mg once daily for 3 days vs albuterol 2 puffs, 15 minutes before exercise
223626711|NCT00004249|BIOLOGICAL|keyhole limpet hemocyanin|
223626712|NCT00004249|DRUG|polysialic acid|
223626713|NCT05072158|OTHER|None, this is an observational study|This is a qualitative study, we will be asking for patient experiences with PFDs and the impact on their sexual function.
223626714|NCT00068068|DRUG|Talaporfin sodium (LS11)|
223626715|NCT00068068|DEVICE|LED-based light infusion device|
224317061|NCT00273689|DRUG|montelukast|Montelukast 5 or 10 mg once daily for 3 days vs Albuterol inhlare 2 puffs, 15 minutes before exercise
224317062|NCT03296878|OTHER|Own-Price Elasticity|The price of eggs will be 75%, 100%, or 125% of the reference price, but the price of other foods will remain the same.
224317063|NCT03296878|OTHER|Cross-Price Elasticity|The price of eggs will remain the same, but the price of other foods will be 75%, 100%, or 125% of the reference price.
223626716|NCT00068068|DEVICE|Light emitting diodes (LED)|
223626717|NCT00068068|PROCEDURE|Photodynamic therapy|
223626718|NCT00068068|PROCEDURE|Phototherapy|
223626719|NCT00068068|PROCEDURE|Chemotherapy|
223626720|NCT01089504|DRUG|phenobarbital|Phenobarbital, 4-5 mg/kg/d, by mouth, for 4 months
223763217|NCT05117463|OTHER|Auditory Reaction Time|Two different pitches of tones will be played. The participants will need to press a button on the right or left hand based on the pitch of the tone.
224215668|NCT03105089|PROCEDURE|ischemic preconditioning|) ischemic preconditioning will be done after induction and before cardiopulmonary bypass by inflation the cuff of blood pressure above 200mmhg in the lower limb every 5 min for 3cycles
224215669|NCT03966469|OTHER|Preoperative support person present|Participants who bring a support person to their preoperative appointment.
223626721|NCT01089504|DRUG|placebo|Matched placebo, same volume as active drug, by mouth daily for 4 months
223626722|NCT00062439|DRUG|cisplatin|During induction:50 mg/m2,IV on Days 1, 8, 29 \& 36. In any appropriate vehicle over 60 minutes
223626723|NCT00062439|DRUG|docetaxel|During consolidation: 75 mg/m2 IV on Day 1, every 21 days for 3 cycles over 60 minutes
224317064|NCT01117571|DEVICE|iUni® Unicompartmental Knee Resurfacing Device|The iUni® Unicompartmental Resurfacing Device is an FDA cleared and CE Marked implant designed for patients with damage isolated to either the medial or lateral tibiofemoral compartment of the knee. The patient-specific iUni is designed from a CT scan of an individual patient's knee using a design process which interactively maps the diseased area and defines the extent of misalignment present in the knee. This process allows definition of the shape and size of the femoral and tibial components of the implant, as well as the disposable instrumentation
224317065|NCT00187993|DRUG|Growth hormone|
224317066|NCT02533180|BIOLOGICAL|Immunosuppression withdrawal|"Participants will initiate calcineurin inhibitor (CNI) withdrawal after at least 3 weeks of stable liver function, as documented by liver function tests (direct bilirubin, alanine aminotransferase and gamma-glutamyl transferase) separated by at least 1 week in the 3 week period prior to withdrawal.~CNI withdrawal will occur in eight 3 week intervals with each subsequent reduction based on liver function tests over the prior 3 week interval.~Participants on CNI and prednisone will undergo withdrawal from the two therapies concurrently.~If participants are weaned off the CNI successfully, they will initiate non-CNI withdrawal. The non-CNI withdrawal includes two dose reductions of approximately 50% over a 6 week period each, after which the drug will be discontinued."
224317067|NCT05549531|DRUG|ACT-1004-1239 (10 mg)|ACT-1004-1239 will be administered as 1 capsule of 10 mg strength to be taken under fed conditions.
224317068|NCT05549531|DRUG|Itraconazole (200 mg, o.d.)|Itraconazole 200 mg will be administered as capsules (2 x 100 mg capsule) to be taken under fed conditions.
224317069|NCT04264676|DRUG|Metronidazole Oral Tablet|Supplement of metronidazole 0.4g three times per day for 7 days before each two cycles of chemotherapy (mFOLFOX6 once every 4 weeks, CapeOX once every 6 weeks), which is 6 treatments for mFOLFOX6 and 4 treatments for CapeOX totally.
224317070|NCT04264676|DRUG|Placebo oral tablet|Supplement of placebo oral tablet 0.4g three times per day for 7 days before each two cycles of chemotherapy (mFOLFOX6 once every 4 weeks, CapeOX once every 6 weeks), which is 6 treatments for mFOLFOX6 and 4 treatments for CapeOX totally.
223626724|NCT00062439|DRUG|etoposide|During induction: 50 mg/m2, IV on Days 1 - 5 Days 29 - 33. In 250 ml of NS over 60 minutes.
223626725|NCT00062439|PROCEDURE|conventional surgery|If, based upon the evaluation in Section 7.4a, there is no evidence of progression (see Section 10.2d for definition), patients will proceed to the next appropriate step: Registration #2 and surgery followed by Registration #3 and additional chemotherapy (Sections 7.5 and 7.6). Response determinations (CR,PR, SD) will be required. If criteria for progressive measurable or nonmeasurable disease (see Section 10.0) are met, the patient will then be removed from protocol treatment and receive follow-up according to the schedule. Surgery will be performed 3 - 7 weeks after completion of chemoradiotherapy.
223626726|NCT00062439|RADIATION|radiation therapy|Radiotherapy is to begin within 24 hours following the start of chemotherapy. Day 1 of radiotherapy must be a Monday, Tuesday or Wednesday, but no later in the week to insure simultaneous therapy for the majority of each chemotherapy cycle. The total dose to the prescription point will be 4,500 cGy given in 25 fractions. The patient will be treated with one fraction per day with all fields treated per day. 180 cGy will be delivered to the isocenter.
223626727|NCT03351842|DRUG|cis Platinum/Carboplatin, Pemetrexed Disodium|Intravenous inject Pemetrexed Disodium for Injection over 10 minutes, waiting for at least 30 minutes, then followed by cis Platinum/ Carboplatin over 2 hours
223626728|NCT03351842|PROCEDURE|Undergo surgery|Therapeutic conventional surgery, R0 resection
223763218|NCT04531943|DRUG|Estrogen|Feminizing hormone therapy consisting of estrogen alone, as prescribed by the participant's healthcare provider.
223763219|NCT04531943|DRUG|Estrogen plus Progesterone|Feminizing hormone therapy consisting of estrogen and progesterone, as prescribed by the participant's healthcare provider.
223763220|NCT05051254|OTHER|Esogastric pressure measurement|"Measurement of work of breathing and respiratory muscles strength using an esogastric catheter.~One measurement or before and after (6 months and 1 year) the initiation of a pharmacological treatment in order to assess the effect of the treatment on respiratory muscle function."
224215670|NCT03966469|OTHER|Patient Present Only|Patient presents to their preoperative appointment without a support person.
224215671|NCT02112422|DRUG|Control|The control group will receive 0.15 mg/kg of intravenous dexamethasone (maximum dose 20mg) in 100ml normal saline immediately prior to skin incision.
224215672|NCT02112422|DRUG|Intervention|Patients in the intervention group will receive 0.15 mg/kg of intravenous dexamethasone (maximum dose 20mg) in 100ml normal saline 45-60 minutes prior to the OR.
224215673|NCT00332345|DRUG|brimonidine/timolol fixed combination|
224215674|NCT04334330|DRUG|Palbociclib, Trastuzumab, Pyrotinib and Fulvestrant|ER/PR positive, HER2-positive breast cancer patients with brain metastatic lesions receive palbociclib PO daily on days 1-21, combined with trastuzumab IV every three weeks, pyrotinib PO daily and fulvestrant IM every 4 weeks. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
224215675|NCT04103411|OTHER|24h-Ambulatory Blood Pressure|Effect of High Intensity Interval Training compared to Hydrochlorothiazide on ambulatory Blood Pressure.
224215676|NCT00193570|DRUG|Topotecan|
224215677|NCT00193570|DRUG|Docetaxel|
224317071|NCT01970774|OTHER|MTM with PGx|Patients will attend MTM sessions and receive PGx testing
224317072|NCT00447876|BIOLOGICAL|Botulinum toxin type A|Botulinum type A toxin (Dysport®): 200 Units injected at the root of the plantar fascia
224317073|NCT00447876|DRUG|Placebo|0.9% sodium chloride: 2 ml injected at the root of the plantar fascia
224317074|NCT05909280|OTHER|Pressure-volume loop measurements|Pressure-volume loop measurements using a conductance catheter
224317075|NCT05762692|DEVICE|High-flow nasal oxygenation device|The patients included will be oxygenated by HFNO device during the operation
224317076|NCT03753191|DEVICE|transcranial direct current stimulation|Each subject will undergo one tDCS stimulation session lasting for 20 minutes. A constant current of 2 mA will be applied with a linear fade in, fade out of 10 seconds to prevent electrical transients.
223626729|NCT01924845|DRUG|BMN 701|BMN 701 20 mg/kg for intravenous administration over approximately 4 hours every 2 weeks over a 24-week Treatment Period (total of 13 doses), and every 2 weeks over a 240-week Extension Period (up to 120 additional doses).
223626730|NCT01994252|DEVICE|Optimal Medical therapy plus ICD|
224215678|NCT05569733|DIAGNOSTIC_TEST|simultaneous fluor-18 fluorodeoxyglucose (FDG) positron emission tomography with magnetic resonance imaging (PET/MRI)|All subjects fast at least for 4 hours prior to 18F-FDG injection. 18F-FDG is injected intravenously (150 megabecquerel (MBq)) in standard ambient conditions, supine in a dark, noise free room with eyes and ears open. 18F-FDG PET images are acquired for 20 min on a simultaneous GE Signa 3 Tesla (3T) PET/MR scanner with integrated Time-of-Flight (TOF) (GE Healthcare, Chicago, USA). Simultaneous with the 18F-FDG PET/MR acquisition, zero-echo-time (ZTE) MR data are acquired for attenuation correction and a 3D volumetric T1-weighted BRAVO MR sequence using a vendor supplied high-resolution 8-channel phased array head coil (GE Healthcare, Milwaukee, USA).
224215679|NCT04943055|PROCEDURE|Low temperature plasma lacrimal duct obstruction ablation combined with lacrimal duct catheterization|The operation used a tear point dilator to expand the patient's upper and lower tear points, YAG laser/low-temperature plasma knife was used to clear the obstructed site of the patient, and normal saline was used to rinse to ensure the patency of the lacrimal passage. The silicone lacrimal duct drainage tube was selected to put the lacrimal duct drainage tube in the upper and lower lacrimal dots of the patient, and the metal probe was removed after using a crochet, and the drainage tube was moderately pulled upward from the center of the upper and lower lacrimal dots to facilitate the smooth passage of the drainage tube through the whole lacrimal duct and achieve the purpose of dredging the blocked site again. Adjust the length of the drainage tube in the nasal vestibule and leave it in the nasal cavity.
224317077|NCT02397876|OTHER|Partially Hydrolyzed Whey formula|Patients who tolerate partially hydrolyzed whey formula will be continued on this formula for two years. Patients who do not tolerate the formula will be continued on their prior diet of cows milk avoidance.
224317078|NCT03042091|DRUG|Polyethylene Glycol|Given orally
224317079|NCT03042091|DRUG|Neomycin|Given orally
224317080|NCT03042091|DRUG|Metronidazole Hydrochloride|Given orally
224317081|NCT03042091|PROCEDURE|Therapeutic Conventional Surgery|Undergo colorectal resection
223626731|NCT01994252|DEVICE|Optimal Medical therapy plus CRT/ICD|
223626732|NCT00380939|DRUG|Atorvastatin|
223626733|NCT00380939|DRUG|Pravastatin|
223626734|NCT01889667|DRUG|ORMD-0801 Dose # 1|Oral Insulin Formulation
223626735|NCT01889667|DRUG|ORMD-0801 Dose # 2|Oral Insulin Formulation
223626736|NCT01889667|DRUG|Placebo|Oil Capsules
223626737|NCT04424537|DIETARY_SUPPLEMENT|Control diet|Meal replacement beverages made with whey protein
223626738|NCT04424537|DIETARY_SUPPLEMENT|Low branched-chain amino acids(BCAA) diet|meal replacement beverages (MRBs) made with BCAD2 powder (lacking BCAAs).
223626739|NCT04424537|DIETARY_SUPPLEMENT|Low protein diet|meal replacement beverages(MRBs) containing low protein
223626740|NCT03828032|PROCEDURE|Mannitol injection|Standard mannitol injection to decrease intracranial pressure of patients
223626741|NCT03828032|PROCEDURE|Hypertonic saline injection|Standard Hypertonic saline injection to decrease intracranial pressure of patients
223626742|NCT05856877|OTHER|Human nasal insulin|single dose of 160 U of human insulin as nasal spray
223626743|NCT05856877|OTHER|Placebo|Single dose of placebo solution as nasal spray
223763221|NCT06538623|DRUG|Liposome Irinotecan Injection II combined with Oxaliplatin, Fluorouracil, Leucovorin|Liposome Irinotecan: 60 mg/m², Oxaliplatin: 85 mg/m², Fluorouracil: 2400 mg/m², Leucovorin: 400 mg/m², every 3 weeks (Q3W), administered via hepatic arterial infusion (HAIC);
223763222|NCT06538623|DRUG|Tegodor|Tegodor: 40 mg per dose, twice daily for seven days, every 3 weeks (Q3W), taken orally.
224317082|NCT04914169|DEVICE|ICRS|The ICRS enables a stationary bike to automatically adjust the pedaling resistance (i.e. training intensity) according to the subject's heart rate. The training intensity is determined by monitoring whether the subject is able to maintain a 50-70 cycles/min cadence with 60-80% HRR. Subjects heart rate was detected by a wearable device for heart rate, synching with the stationary bike.
224317083|NCT05537974|PROCEDURE|Endotracheal aspiration|Clearance of endotracheal secretions via a catheter.
224317084|NCT05705076|DRUG|catheter induced thromboprophylaxis|Direct oral anticoagulation for catheter induced thromboprophylaxis
224317085|NCT03171974|DRUG|Dexamethasone|dexamethasone will be injected intracapsular under US
224317086|NCT03171974|DEVICE|US|dexamethasone will be injected intracapsular under US
224317087|NCT05012826|OTHER|Osteopathic Manipulative Treatment in addition to Physiotherapy|Participants in this group will receive OMT in addition to the same interventions of PT group. The frequency of treatment will be decided based on the clinical judgment of the osteopath who is accompanying each case, not exceeding 7 consultations in total. At each visit, the participants will receive a full-body osteopathic examination which include clinical exams, observation, screening tests, palpation, and motion testing. The OMT entail direct (high-velocity low-amplitude; muscle energy; and myofascial release), indirect (functional techniques and balanced ligamentous tension), visceral, and cranial techniques(Giusti, 2017). Selection of specific OMT will follow the 'TART' criteria-Tissue texture changes, Asymmetry, Restriction of motion, Tenderness (Basile et al., 2017; Cerritelli et al., 2011; Giusti R., 2017; Pizzolorusso et al., 2011; Seffinger M.A, 2018).
224215680|NCT04943055|PROCEDURE|YAG lacrimal duct laser combined with lacrimal duct catheter|The operation used a tear point dilator to expand the patient's upper and lower tear points, YAG laser/low-temperature plasma knife was used to clear the obstructed site of the patient, and normal saline was used to rinse to ensure the patency of the lacrimal passage. The silicone lacrimal duct drainage tube was selected to put the lacrimal duct drainage tube in the upper and lower lacrimal dots of the patient, and the metal probe was removed after using a crochet, and the drainage tube was moderately pulled upward from the center of the upper and lower lacrimal dots to facilitate the smooth passage of the drainage tube through the whole lacrimal duct and achieve the purpose of dredging the blocked site again. Adjust the length of the drainage tube in the nasal vestibule and leave it in the nasal cavity.
224215681|NCT02866123|OTHER|ultrasonography|
223763223|NCT05675371|BEHAVIORAL|Assessment by Expert Clinician During Behavioral Intervention (ABA or similar)|Assessment (e.g., responder vs. non-responder status) utilizing gold-standard clinical reference assessments performed by expert clinicians as the subject undergoes Applied Behavioral Analysis (ABA) or similar intervention for autism spectrum disorder and related developmental delays
223763224|NCT05675371|DEVICE|Assessment by the EarliPoint Assessment For Autism Spectrum Disorder|Assessment by The EarliPoint™ Evaluation for Autism Spectrum Disorder (ASD), a medical device which employs Dynamic Quantification of Social-Visual Engagement (DQSVE) to aid clinicians in the diagnosis, assessment, and treatment monitoring of ASD related developmental delays, is a diagnostic tool which measures an individual's visual preferential attention to social information in the environment relative to normative age-specific benchmarks.
224215682|NCT02866123|RADIATION|pulmonary radiography|
224215683|NCT03659968|OTHER|Physical activity training|brisk walking on treadmill and exercises of muscular strengthening with varying durations and intensities depending on physical capabilities of patients
224215684|NCT01721967|DRUG|Ranolazine|
224215685|NCT03296553|DRUG|Valganciclovir|The experimental group will receive Valganciclovir 900 mg twice in a day before the initiation of cART until viral load of HHV-8 is undetectable.
224215686|NCT03296553|DRUG|Antiretroviral Combinations|Patients will receive standard antiretroviral treatment as recommended
224215687|NCT06352931|DEVICE|transcranial and transcranial dopp;er|"All patients will be subjected to Transcranial ultrasound examination and compared with other neuroimaging modalities: CT brain or MRI brain and/or MRA \& MRV.~Patients suspected to have ischemic or hemorrhagic disorder, CNS infection or increase intracranial pressure will be evaluated with transcranial Doppler ultrasound and compared with other neuroimaging modalities."
223763225|NCT05718258|DRUG|Venglustat (GZ402671)|"Pharmaceutical form: tablet~Route of administration: oral"
224215688|NCT03612401|DRUG|Mirabegron|Beta-3 adenoreceptor agonist
224215689|NCT02295280|DRUG|Metoclopramide|IV
224215690|NCT02295280|DRUG|Diphenhydramine|iv
224215691|NCT02295280|DRUG|Codeine|PO
224317088|NCT05012826|OTHER|Physiotherapy|Participants in this group will receive physiotherapy sessions with a maximum frequency of 2 weekly sessions, as defined by the physiotherapist, according to personalized therapeutic plans for a period of 8 weeks. The physiotherapy approach for patients with long COVID includes motor and respiratory rehabilitation aiming at maintaining and/or improving joint mobility, muscle strength, and functional exercise capacity (Thomas et al., 2020). At each visit, the participants respond by self-report about their general condition. Depending on the case, the physiotherapist will perform a reevaluation with specific tests. The PT group will receive physiotherapy treatment offered by five physiotherapists, with more than 5 years of experience each, duly registered with their class council.
223626744|NCT00001832|DRUG|gp100:209-217 (210M)|"gp100 = gp100:209-217(210M) peptide - 1 mg in IFA SQ (in the subcutaneous tissue of each thigh) on the morning of the cell infusion, plus gp100:209-217(210M) peptide, 1 mg, in IFA injected into the subcutaneous tissue in two equal volumes, 1.0 mL for each injection, within 2cm of each other, in the thigh daily for five days starting on the morning of the cell infusion and then weekly for 3 more injections.~MART-1 = MART-1:26-35(27L) peptide- 1 mg in IFA SQ (in the subcutaneous tissue of each thigh) on the morning of the cell infusion, plus MART-1:26-35(27L) peptide, 1 mg, in IFA injected into the subcutaneous tissue in two equal volumes, 1.0 mL for each injection, within 2cm of each other, in the thigh daily for five days starting on the morning of the cell infusion and then weekly for 3 more injections."
224215692|NCT01521767|DRUG|tolterodine tartrate|4 mg single dose of extended release capsules
224215693|NCT01521767|DRUG|tolterodine tartrate|4 mg single dose of microspheres in powder blend
224317089|NCT04355065|BEHAVIORAL|Cognitive Traning with The Secret Trail of Moon|Patients are pharmacologically stable and receive a cognitive intervention with our videogame once a week in the hospital.
224317090|NCT04355065|BEHAVIORAL|Cognitive Traning with Therapeutic Chess|This group is pharmacologically stable. This group performs cognitive training through a therapeutic chess protocol designed by a chess psychologist. The training is done from home and we contact them weekly to correct the exercises done and to follow up.
224317091|NCT04355065|DRUG|Control Group|"These patients continue their stable pharmacological treatment and do not receive any additional cognitive intervention.~They are contacted weekly by phone to follow up on the group."
224215694|NCT01521767|DRUG|tolterodine tartrate|4 mg single dose of microspheres in powder blend
224215695|NCT01521767|DRUG|tolterodine tartrate|4 mg single dose of microspheres in powder blend
224215696|NCT01521767|DRUG|tolterodine tartrate|4 mg single dose of microspheres in powder blend
224215697|NCT02194231|DRUG|Trabectedin|Patients will receive 1.1 mg/m2 intravenous trabectedin infusion in 5% glucose via central venous catheter over 3 hours every 21 days. Trabectedin infusion will be preceded by 20 mg of intravenous dexamethasone
224215698|NCT04981626|OTHER|Clinical and experimental session|"Psychologic profile with standardized interview and scales (see below for details: SCID, BDI, STAI, BPQ, EDE Q, Pictorial Body Image Scale (PBIS) and EDI).~Measure the stomach-brain synchrony during EEG/EGG resting state, the distribution of voluntary actions across the respiratory phase, and the distribution of saccadic eye movements across the cardiac-cycle."
224215699|NCT03229239|PROCEDURE|corneal stroma implantation|During the operation,implant the corneal stroma to the diseased cornea of keratoconus.
224215700|NCT00032708|BIOLOGICAL|Dryvax|
224215701|NCT02523079|BEHAVIORAL|Cognitive Behavioral Group Therapy for Insomnia|
223626745|NCT00001832|DRUG|Montanide ISA-51|MART-1 = MART-1:26-35(27L) peptide- 1 mg in IFA SQ (in the subcutaneous tissue of each thigh) on the morning of the cell infusion, plus MART-1:26-35(27L) peptide, 1 mg, in IFA injected into the subcutaneous tissue in two equal volumes, 1.0 mL for each injection, within 2cm of each other, in the thigh daily for five days starting on the morning of the cell infusion and then weekly for 3 more injections.
223763226|NCT03337100|BEHAVIORAL|Co-Dispensing|"Implementation of a naloxone co-dispensing pharmacy program.~The intent of this program is to provide patients prescribed chronic opioid therapy naloxone under the terms of a standing order for potential opioid overdose reversal. Prior to implementing the program, a naloxone standing order will be implemented and pharmacy operational staff will provide training to pharmacy staff about the standing order and a naloxone co-dispensing protocol. Under a co-dispensing protocol, pharmacy staff members will identify opioid prescriptions meeting criteria for co-dispensing, prepare naloxone fills, offer patients naloxone, and provide counseling on its use."
223626746|NCT00001832|DRUG|IL-2|"125,000 IU/kg dose intravenous for 5 days for 6 weeks with 2 days rest per week.~720,000 IU/kg intravenous every 8 hours for a maximum of 12 doses."
223626747|NCT00001832|DRUG|MART-1:26-35(27L)|MART-1 = MART-1:26-35(27L) peptide- 1 mg in IFA SQ (in the subcutaneous tissue of each thigh) on the morning of the cell infusion, plus MART-1:26-35(27L) peptide, 1 mg, in IFA injected into the subcutaneous tissue in two equal volumes, 1.0 mL for each injection, within 2cm of each other, in the thigh daily for five days starting on the morning of the cell infusion and then weekly for 3 more injections.
223763227|NCT04037553|OTHER|Intracuff pressure measurement|Intracuff pressure values were monitorized and noted before and after head and neck positions and during the surgeries at 15th, 30th, 60th and 90th minutes at related positions and just before extubation at neutral position.
223763228|NCT04037553|OTHER|Intracuff pressure measurement|Intracuff pressure values were monitorized and noted before and after head and neck positions and during the surgeries at 15th, 30th, 60th and 90th minutes at related positions and just before extubation at neutral position.
223763229|NCT04037553|OTHER|Intracuff pressure measurement|Intracuff pressure values were monitorized and noted before and after head and neck positions and during the surgeries at 15th, 30th, 60th and 90th minutes at related positions and just before extubation at neutral position.
224215702|NCT02523079|BEHAVIORAL|Cognitive Behavioral Self-help Therapy for Insomnia|
223763230|NCT03521453|OTHER|PEPPER robot|Presence of a Robot (PEPPER Robot), designed and programmed to give informations, using a screen and vocal. All the patients in the second period will have access to,the robot, while waiting for the visit.
223763231|NCT04970758|OTHER||no intervention
223763232|NCT01248858|DRUG|GSK2126458 and GSK1120212|GSK2126458 and GSK1120212 are experimental treatments for patients with cancer.
223763233|NCT06259331|DRUG|SPN-812 (600mg, QD)|Viloxazine ER
224215703|NCT02523079|BEHAVIORAL|Sleep Hygiene Guidance|
224215704|NCT04700735|DEVICE|geko Neuromuscular Electro Stimulator (NMES)|Neuromuscular Electro Stimulator (NMES)
224215705|NCT04888260|OTHER|Laboratory parameter levels in blood samples|Mannose and lipid parameters (triglyceride, LDL, HDL, VLDL) will be analysed in blood samples by using ELISA method.
224215706|NCT04352491|OTHER|No intervention|No intervention
224215707|NCT01469988|DRUG|Testosterone|Patients will be dosed accordingly: Female: 0.3g once daily (or matching placebo) gel;Males: 5g once daily (or matching placebo) gel.
224215708|NCT06305637|DRUG|Ketoconazole Shampoo, 2%|The investigational product was applied on a single occasion topically to the damp skin of the affected area and a wide margin surrounding this area for 5 minutes and then rinsed off with water.
223763234|NCT04233281|OTHER|Kori tofu|16.5 gram Kori-tofu mixed in a high carbohydrate test meal
223763235|NCT04233281|OTHER|Whey protein|high carbohydrate test meal with whey protein, matched in macronutrient content
223763236|NCT02460770|DRUG|Autologous mesenchymal stem cells|After bone-marrow aspiration by an authorized person, mesenchymal stem cells were isolated and cultured during 17 days by the French Blood Establishment. Then, patients receive intramyocardial injections of mesenchymal stem cells during device surgery.
223626748|NCT00001832|BIOLOGICAL|Abl cells|Abl cells IV = Lymphocytes 10\^9-10\^11 IV over 30 minutes on day 0, repeated in 14 to 21 days Abl cells IA = Lymphocytes 10\^9-10\^11 IA over 30 minutes on day 0, repeated in 14 to 21 days
223626749|NCT00001832|DRUG|Fludarabine|5x25 mg/m\^2 intravenous
223626750|NCT00001832|DRUG|Cyclophosphamide|2x30 mg/kg, 2x60 mg/kg intravenous
223626751|NCT00001832|BIOLOGICAL|GCSF (Growth colony stimulating factor)|Beginning on day 1 or 2, GCSF will be administered subcutaneously at a dose of 5mcg/kg/day (not to exceed 300 mcg/day. Filgrastim administration will continue daily until neutrophil count \> 1.0 x10\^9/L x 3 days or \> 5.0 x10\^9/L.
223626752|NCT00001832|PROCEDURE|Apheresis|
223626753|NCT03382132|BEHAVIORAL|momHealth|Mobile health program delivered via an iPad. Program delivers information and support related to breastfeeding education, Ten Steps of the Baby Friendly Hospital Initiative, healthy eating and active living topics, and depression prevention information.
223626754|NCT03382132|BEHAVIORAL|Standard of Care|Participants will receive standard health care via their prenatal provider, including routine prenatal education and postpartum support.
223763237|NCT02800148|DRUG|Azelaic acid foam|
223763238|NCT02800148|DRUG|Azelaic acid foam|
223763239|NCT02800148|DRUG|Azelaic acid foam - Placebo|
223763240|NCT06451042|DIAGNOSTIC_TEST|FET-PET/MRI|Radiation planning target volume (PTV) when planned with FET-PET/MRI to PTV when planned with conventional (Standard of Care) MRI only. 0-(2-18F-Fluoroethyl)-L-Tyrosine (FET) 180-200 megabecquerel (MBq) administered intravenously prior to PET/MRI imaging.
224317092|NCT06239857|PROCEDURE|Epidural pulsed radiofrequency|The radiofrequency treatment is applied under sterile conditions in the operating room environment. The target epidural area is reached under fluoroscopy guidance using a radiofrequency needle. After control of the needle position, radiofrequency treatment is given. Radiofrequency parameters are set as maximum temperature 42 degrees, 45 volts, duration 6 minutes, pulse rate 2 hertz and pulse width 20 milliseconds.
223626755|NCT04944277|OTHER|ThoughtFullChat Application|A subscription-based mobile platform that empowers users to proactively engage with their mental health via self-serve tools and 1-on-1 daily bite-sized coaching with certified mental health professionals.
223763241|NCT06361823|DRUG|Semaglutide|Giving Semaglutide via subcutaneous injections on a weekly basis for a duration of 3 months. The dosage is 0.25 mg for the initial month, then upped to 0.5 mg for patients who could handle it in the second month, and eventually escalated to 1.0 mg for patients who continued to tolerate it in the third month.
223763242|NCT06361823|DIETARY_SUPPLEMENT|Low calorie diet|Low calorie diet (max 1200 kcal/day)
224215709|NCT06305637|DRUG|Ketoconazole Shampoo, 2% (Reference Standard)|The investigational product was applied on a single occasion topically to the damp skin of the affected area and a wide margin surrounding this area for 5 minutes and then rinsed off with water.
224215710|NCT06305637|DRUG|Placebo|The investigational product was applied on a single occasion topically to the damp skin of the affected area and a wide margin surrounding this area for 5 minutes and then rinsed off with water.
224215711|NCT00124449|DRUG|Abatacept|"solution, intravenous injection, monthly, 169 days~weight based:~\<60 kg = 500 mg~60 to 100 kg = 750 mg~\>100 kg = 1 g"
224215712|NCT00124449|DRUG|placebo|solution, intravenous injection, 0 mg, monthly, 169 days
223763243|NCT06244862|DRUG|Ruxolitinib|Oral ruxolitinib twice a day (10 mg x 2 during 28 days) in association with standard of care in HS.
224215713|NCT02087228|DEVICE|Genesys HydroTherm Ablator|Heated water is circulated inside the uterus to destroy the lining of the uterus
224215714|NCT02087228|DEVICE|radiofrequency energy ablation device|
223763244|NCT01455012|DRUG|Rotigotine|Rotigotine 1 mg/24 h, 2 mg/24 h, and 3 mg/24 h. Subjects will be titrated to their optimal/maximal dose in weekly increments of 1 mg/24 h during a Titration Period. During Maintenance Period the subjects will continue on their optimal/maximal dose for 28 days. Following the Maintenance Period, subjects will be de-escalated over 7 days, depending on their optimal/maximal dose.
223763245|NCT01455012|DRUG|Placebo|Matching Placebo. Subjects will be titrated to their optimal/maximal dose in weekly increments of 1 mg/24 h during a Titration Period. During Maintenance Period the subjects will continue on their optimal/maximal dose for 28 days. Following the Maintenance Period, subjects will be de-escalated over 7 days, depending on their optimal/maximal dose.
223763246|NCT01121692|BEHAVIORAL|Couples Intervention|The Couples intervention is a merged intervention of three interventions (Women CoOp, men as partners's and couples). Couples attend together for two half day workshops and work on exercises on communication and problem solving, including a commitment pledge of fidelity.
223763247|NCT01121692|BEHAVIORAL|Women's CoOp|The Women's CoOp is a gender-focused intervention discussing women's risk in relationship to HIV and also discusses issues of HIV with South African women including skills for violence prevention. During this intervention, participants will also demonstrate the proper use of male and female condoms on penile and vaginal models. They attend two half day workshops.
223763248|NCT01121692|BEHAVIORAL|Women's CoOp and Men's Intervention|The Men's CoOp is adapted from Men as Partners, the Women's CoOp and the Couples intervention and contain similar material with a concentration on gender roles and violence prevention. Men attend two half day workshops.
224215715|NCT02182258|DRUG|BIBF 1120 soft gelatine capsule|
224215716|NCT02182258|DRUG|BIBF 1120 intravenous solution|
224317093|NCT00005957|RADIATION|Standard Breast Irradiation|Standard Breast Irradiation - A dose of 5000 cGy in 25 fractions at a rate of 200 cGy per day, 5 days a week for 5 weeks will be prescribed to the standard tangent fields.
224317094|NCT00005957|RADIATION|Breast Radiation plus Regional Radiation|Breast Radiation plus Regional Radiation - A dose of 5000 cGy in 25 fractions at a rate of 200 cGy per day, 5 days a week for 5 weeks will be prescribed to the modified wide tangent fields.
224317095|NCT01510626|DIETARY_SUPPLEMENT|Food proteins|Food proteins
224317096|NCT01510626|DRUG|Omalizumab|Drug
223626756|NCT05926817|DEVICE|Placebo-VR headsets|Patients in the Placebo-VR group watched a 10-minute relaxation-based 2D film through VR headsets along with receiving conventional analgesia.
223626757|NCT05926817|DEVICE|QTC-VR headsets|Patients in the QTC-VR group engaged in 10-minute interactive pain relief 3D VR programs while wearing VR headsets along with receiving conventional analgesia.
223763249|NCT04488965|OTHER|Autologous transplant|Autologous transplant obtained from cortical biopsy
223763250|NCT02550847|DEVICE|The imaging biomarkers determined by MR-PET|The aim of this study was to evaluate MR/PET with both functional and molecular imaging on the prediction of prognosis in patients with suspected pancreatic cancer.
224215717|NCT02182258|DRUG|Placebo ampoule|
224215718|NCT02888925|OTHER|Mooney test|
224215719|NCT02888925|OTHER|Benton Face Recognition test|
224215720|NCT02888925|OTHER|Face inversion effect test|
224215721|NCT02888925|OTHER|Face composite effect test|
223763251|NCT04110483|PROCEDURE|Thulium fiber laser en-bloc resection of non-muscle-invasive bladder cancer|After cystoscopy and determining tumor topography, a circumferential incision around the tumor is made in the visually intact bladder mucosa (approximately 10 mm from the edges of the tumor). It allows for accurate morphological evaluation of the surgical margin. After that, the incision is continued deeper into the muscular layer. Having identified the layer, the surgeon resects the base of the tumor with the muscular layer using traction and incisions of the muscle fibers. Making incisions in the muscular layer requires precision, a full bladder and adequate guidance with visualization techniques. Traction may be employed with the help of the tip of the resectoscope or working element. After complete tumor resection, local hemostasis was performed.
224215722|NCT02888925|OTHER|Cambridge Face Memory Test|
224317097|NCT05056662|DIAGNOSTIC_TEST|Invasive functional evaluation with either Pd/Pa, FFR, iFR or contrast FFR|Enrolled patients will undergo invasive functional evaluation of coronary stenosis followed by percutaneous revascularization if appropriate. Patients in Group 3 will have target lesion re-assessed using either PdPa, FFR, iFR or contrast FFR.
224317098|NCT04475172|COMBINATION_PRODUCT|Self-Adhesive Flowable Composite|"Fusio Self-Adhesive Flowable Composite combines the benefits of adhesive and restorative technology into one product . Immediately upon application Fusio conditions, bonds, and seals without the need for an etchant or an adhesive.~It is based on the bonding technology that uses glycerophosphate dimethacrylate(GPDM)to etch enamel and dentin, and hydroxyethyl methacrylate (HEMA) to enhance wetting and penetration by resin into dentin."
224317099|NCT02354625|BIOLOGICAL|Autologous human Schwann cells|Schwann cells harvested from the sural nerve of the participant will be autologously transplanted into the epicenter of the participant's spinal cord injury.
224317100|NCT00292786|BEHAVIORAL|Walking Practice with Functional Electrical Stimulation|
223763252|NCT04110483|PROCEDURE|Transurethral resection of non-muscle-invasive bladder cancer|After cystoscopy and determining tumor topography, a step-by-step resection of a tumor is done. Firstly, visible tumor is resected, then resection continues to the apparently normal mucosa on the border of the tumor, than resection of the muscle layer at the base of the tumor is performed until normal muscle fibers are visible.
223763253|NCT02178384|PROCEDURE|Altered cast technique|This techniques deals with the procedures that are employed when constructing the removable partial denture on working casts.
223763254|NCT02178384|DEVICE|Precision Attachments|These are minor attachments used to split the loading forces during appliance wear
223763255|NCT02178384|PROCEDURE|Resilient layer|This is a layer beneath the appliance which helps in reducing the transmission of loading forces to the underlying soft tissues
223763256|NCT02643654|DRUG|MABp1|This is a sterile injectable liquid formulation of 50 mg/mL MABp1 in a stabilizing isotonic buffer (pH 6.4). Each 10-mL serum vial contains 6 ml of the formulation, and is sealed with a 20-mm grey bromobutyl stopper and flip-off aluminum seal
223763257|NCT02643654|DRUG|Placebo|The placebo dosage form is a sterile isotonic formulation buffer at pH 6.2-6.5. Each 10-ml Type I borosilicate glass serum vial contains 6mL of the formulation buffer, and is sealed with a 20-mm Daikyo Flurotec butyl rubber stopper and flip-off aluminum seal.
223514036|NCT05673291|OTHER|No intervention|Volunteers who will be included in the research will be informed about the research and an informed consent form will be signed. Questionnaire evaluating sociodemographic characteristics and working positions; The Extended Nordic Musculoskeletal Questionnaire (7) and measurements made with the Spinal Mouse device for posture analysis will be applied when individuals feel comfortable. Questionnaires and device and posture analysis will be carried out after the purpose of the research is explained to the individuals and their consent is obtained. The data will be analyzed in the SSPS program. Number, percentage, standard deviation and mean from descriptive statistics will be used in the evaluation of the data. The relationship between posture and musculoskeletal pain will be evaluated by correlation analysis. The confidence interval of the research will be 95% and the significance level will be considered as p\<0.05.
223514037|NCT05405166|DRUG|Isatuximab IV|Pharmaceutical form: Concentrate solution for IV infusion; Route of administration: Intravenous
223514038|NCT05405166|DRUG|Isatuximab SC|Pharmaceutical form: Solution for subcutaneous administration; Route of administration: Subcutaneous (SC)
223514039|NCT05405166|DRUG|Dexamethasone|Pharmaceutical form: Tablet; Route of administration: Oral
223514040|NCT05405166|DRUG|Pomalidomide|Pharmaceutical form: hard capsules; Route of administration: Oral
223514041|NCT05405166|DRUG|Dexamethasone|Pharmaceutical form: As per local commercial product; Route of administration: Oral; Auxiliary Medicinal Product (AxMP) i.e., background treatment; ATC code: H02AB02
223514042|NCT05405166|DRUG|Montelukast|Pharmaceutical form: As per local commercial product; Route of administration: Oral; AxMP i.e., background treatment; ATC code: R03DC03
223514043|NCT05405166|DRUG|Paracetamol / Acetaminophen|Pharmaceutical form: As per local commercial product; Route of administration: Oral; AxMP i.e., background treatment; ATC code: N02BE01
223514044|NCT05405166|DRUG|Diphenhydramine|Pharmaceutical form: As per local commercial product; Route of administration: As premedication- oral; for management of infusion reactions-IV (or oral equivalent); AxMP i.e., background treatment and rescue medication (in case of infusion reactions); ATC code: R06AA02
223514045|NCT05405166|DRUG|Methylprednisolone|Pharmaceutical form: As per local commercial product; Route of administration: As premedication-IV; for management of infusion reactions- IV (or oral equivalent); AxMP i.e., background treatment and rescue medication (in case of infusion reactions); ATC code: H02AB04
223514046|NCT05693935|DRUG|TV-44749 - Dose level 1|In Period 1, 2 monthly injections. In Period 2, up to 12 monthly injections
223514047|NCT05693935|DRUG|TV-44749 - Dose level 2|In Period 1, 2 monthly injections, In Period 2 up to 12 monthly injections
223514048|NCT05693935|DRUG|TV-44749 - Dose level 3|In Period 1, 2 monthly injections. In Period 2, up to 12 monthly injections
223514049|NCT05693935|DRUG|Placebo|In Period 1, 2 monthly injections (Period 1 only)
223514050|NCT04857281|DEVICE|nVNS (gammaCore)|The treatment will be self-administered using nVNS and will be applied for 4 weeks; a member of the study will provide the proper training on the correct use of nVNS. The patient will be instructed to use the nVNS in place of the rescue medications. When the nauseas gets bad enough that they feel to use a rescue medication they will first use the device on one side of the neck for two 2-minute stimulations and wait fifteen minutes to check if the stimulation works. If this does not help either, they will stimulate with an additional 2 stimulations and wait for another fifteen minutes. If there is no improvement rescue medication will be used. nVNS can be used up to, but no more than, 8 times a day.
223514051|NCT01569763|DEVICE|Aurora Endometrial Ablation|Endometrial Ablation using the Aurora Endometrial Ablation system
223763258|NCT06016634|DRUG|Alendronate Sodium|Administer oral alendronate 70 mg once a week x 24 weeks to all study participants
223763259|NCT06966063|PROCEDURE|4-7-8 breathing along with standard management.|"For 4-7-8 breathing, Patient is asked sit in comfortable position. Patient is asked place the tip of your tongue up against the back of your front teeth. Keep it there through the entire breathing process. Instruct the patient to breathe in silently through your nose to the count of four (4sec) and Hold your breath to the count of seven (7sec). Exhale through your mouth to the count of eight (8sec), making an audible whoosh sound. That completes one full breath. Repeat the cycle another three time, and gradually in increase the cycle four time.~Total 4 weeks protocol. Two sessions per week will be supervised by physiotherapist and 5 days at home. Week 01 and 02 Frequenc: 01 session/day Intensity: Start with comfortable duration. Time: 10 minutes Week 03 and 04 Frequecy: 02 sessions/day Intensity: 4 sec inhale, 7 sec hold and 8 sec exhale Time: 15 minutes"
224215723|NCT02888925|OTHER|Matching different view test|
224215724|NCT02888925|OTHER|Memorizing and recognition of new faces test|
224215725|NCT02888925|OTHER|Memorizing and recognition of new objects test|
224215726|NCT02888925|OTHER|Recognition of celebrities and access to semantic information test|
223514052|NCT01569763|DEVICE|Rollerball Ablation/Resection|Hysteroscopic rollerball resection/ablation
223514053|NCT02730169|DRUG|BGS649|Capsules were taken weekly for a maximum of 24 weeks
223514054|NCT02730169|DRUG|Placebo|Capsules were taken weekly for a maximum of 24 weeks
223514055|NCT05522556|DRUG|Ritlecitinib|capsules
223626758|NCT00517764|DRUG|escitalopram|Patients started on 20mg of escitalopram and this dose was increased based on tolerability and therapeutic response to a maximum dose of 40mg by week 12. The trial was 16 weeks. The treatment trial has completed and is no longer accepting patients.
223626759|NCT04922086|PROCEDURE|Conventional aesthetic crown lengthening surgery|The demarcation of the gingival zenith final position will be done on the teeth using a periodontal probe. This demarcation will be done through visual examination based on the crown length/width ratio and the position of the cemento-enamel junction (CEJ). The gingival margin of the central and canine incisors will be positioned at similar heights and a more coronal gingival contour will be determined for the lateral incisors. An internal bevel incision will be made with a blade on each tooth, preserving the interdental papillae. The incised gingival tissue will be removed using a periodontal curette in both groups. An internal bevel incision will be made in the involved teeth and a full thickness flap will be displaced up to the the mucogingival junction level to expose the bone crest (BC). Carbide drills and manual chisels will be used for bone resection to obtained a CEJ-BC distance of 3 mm. Simple interproximal interrupted sutures will be performed.
223626760|NCT04922086|PROCEDURE|Guided dual aesthetic crown lengthening surgery|The double guide will be positioned and an internal bevel incision on each tooth will be made following the guide demarcation. After the initial incision, the incised gingival tissue will be removed using a periodontal curette. An internal bevel incision will be made in the involved teeth and a full thickness flap will be displaced up to the the mucogingival junction level to expose the bone crest (BC). The dual guide will be positioned again and the bone tissue will be removed using carbide drills and manual chisels following the double guide. No interproximal crestal bone will be removed. Simple interproximal interrupted sutures will be performed to stabilize the flap.
223626761|NCT01700413|DRUG|Idarubicin|
223626762|NCT02546609|DRUG|Leu-Met-Sil 0.5|NS-0200 low dose
223626763|NCT02546609|DRUG|Leu-Met-Sil 1.0|NS-200 high dose
223626764|NCT02546609|DRUG|Placebo|Placebo
223763260|NCT06966063|PROCEDURE|Control Group|"Patients will recieve medication as prescribed by pulmonologist through stepwise approach according to symptoms and severity.~Total 4 weeks protocol. Before and after 4 weeks pre and post interventional values will be taken.~Week 01 and 02 Patients will receive medications prescribed by pulmonologist. Week 03 and 04 Patients will receive medications prescribed by pulmonologist."
223763261|NCT03634553|OTHER|Training with e-health product|The training program follows the recommendations for training from ACSMS and SoS who states the importance that exercise programs should include muscle strengthening, cardiovascular as wells as balance exercises. Therefore, the training program includes: Strengthening exercises for the upper and lower extremities (number: 5-8 pc. with progression in three levels), daily (5-7 times / week), 30 minutes walks and balance training.
223763262|NCT03634553|OTHER|Usual care|usual care, i.e. participates in regular training regime at the physiotherapy department
223763263|NCT03409432|DRUG|Brentuximab Vedotin|Given IV
223626765|NCT02616510|PROCEDURE|cardiovascular screening|cardiovascular screening: serum, urine, ECG, carotid intima media thickness (IMT), cardiac ultrasound
223626766|NCT02517931|PROCEDURE|Sphenopalatine Ganglion Block|Subjects will be asked to blow out each nostril. They will then be laid supine with a small shoulder roll and intranasal phenylephrine 0.25% (RhinallⓇ) will be sprayed once into each nostril to preemptively minimize bleeding. SPGB will be performed by inserting long cotton tipped applicators saturated in 2% viscous lidocaine into nostril until properly seated in the posterior nasopharynx. These will be left in place for 10 minutes and then 1mL of 0.5% bupivacaine will be administered down the plastic hollow shaft of each applicator via an 18g angiocatheter. The applicators will remain in place for 10 more minutes and then be removed.
223626767|NCT02517931|PROCEDURE|Placebo|Subjects will be asked to blow out each nostril. They will then be laid supine with a small shoulder roll and intranasal phenylephrine 0.25% (RhinallⓇ) will be sprayed once into each nostril to preemptively minimize bleeding. SPGB will be performed by inserting long cotton tipped applicators saturated in carboxymethylcellulose based lubricant (i.e. K-Y Jelly®) into nostril until properly seated in the posterior nasopharynx. These will be left in place for 10 minutes and then 1 mililiter of normal saline will be administered down the plastic hollow shaft of each applicator via an 18g angiocatheter. The applicators will remain in place for 10 more minutes and then be removed.
223626768|NCT00914849|DRUG|AMD3100|
223626769|NCT00914849|PROCEDURE|Leukopheresis|
223763264|NCT03409432|OTHER|Laboratory Biomarker Analysis|Correlative studies
223763265|NCT03409432|DRUG|Lenalidomide|Given PO
224215727|NCT02888925|PROCEDURE|Lobectomy|In patients with anterior temporal epilepsy, at 6 to 12 months after inclusion, depending on surgery decision taken after pre-surgery conventional intercritical assessment
224215728|NCT02971605|DRUG|Psilocybin|25 mg/70 kg Psilocybin
224215729|NCT01938300|DRUG|Magnesium Sulfate|
224215730|NCT01938300|DRUG|Normal saline|
224215731|NCT00601328|DRUG|Calcitriol|
224215732|NCT04318002|BIOLOGICAL|RH5.1/Matrix-M|3 doses of RH5.1/Matrix-M at different concentrations: RH5.1(10µg)/Matrix-M (50µg), RH5.1(50µg)/ Matrix-M (50µg), RH5.1(10µg)/ Matrix-M (25µg), RH5.1(50µg)/ Matrix-M (25µg)
224215733|NCT03901027|BEHAVIORAL|Therapeutic Conversation Interventions|Parents (N=31) at the Children's Hospital at the National University Hospital of Iceland, got two sessions of the FAM-SOTC intervention focusing on emotional support, evidence based information and recommendations and on the strengths of family members. The parents meet with the Advanced Practice Nurse at the Children´s Hospital without the child in both sessions, but each session lasted for 45 to 90 minutes. The sessions were offered with 4-8 weeks interval.
224215734|NCT00812227|BEHAVIORAL|Psychodynamic Psychotherapy|Screened and eligible patients will receive 16 individual sessions of psychodynamic psychotherapy, each lasting 45-50 minutes.
224215735|NCT05446480|DRUG|Desloratadine|Oral ingestion 10mg pill 2 hours prior to heat strain trial. Second 10mg dose 24-hours later.
224215736|NCT05446480|DRUG|Placebo|Oral ingestion 10mg inert pill 2 hours prior to heat strain trial. Second dose 24-hours later.
224215737|NCT05446480|OTHER|No Intervention|No pill ingestion during the trial - to discern the presence of a placebo effect from baseline inflammatory response
224215738|NCT01677169|DIETARY_SUPPLEMENT|Noni juice|Ingestion of noni juice, a source of iridoids, daily for 30 days.
224215739|NCT01677169|DIETARY_SUPPLEMENT|Placebo|
224215740|NCT03952936|OTHER|Vestibular Rehabilitation|standard vestibular rehabilitation with gaze stability, balance training, habituation tailored to the subject
224317101|NCT00292786|BEHAVIORAL|Walking Practice|
224317102|NCT04478812|DIAGNOSTIC_TEST|Single Group Assignment|Tbit™ System will detect S100B and GFAP concentrations with the blood specimen collected
224317103|NCT01609023|DRUG|Rituximab|Rituximab will be administered in combination with chemotherapy according to SPC and routine clinical practice.
224317104|NCT06435910|BIOLOGICAL|DC vaccines|Antigen-presenting and immune modifying DCvacs to treat MM
224317105|NCT03904108|DRUG|Ramucirumab|platinum doublets chemotherapy plus ramucirumab, intravenously(IV)
224317106|NCT02715570|DRUG|PC945 - single doses|Safety and tolerability of single doses
224317107|NCT02715570|DRUG|Placebo - single doses|Safety and tolerability of single doses
224317108|NCT02715570|DRUG|PC945 - repeat doses|Safety and tolerability of repeat doses
223626770|NCT00914849|PROCEDURE|Stem cell transplant|
223626771|NCT00000306|DRUG|Dextroamphetamine|
223626772|NCT03541551|PROCEDURE|CTT with ologen® Collagen Matrix|ologen® Collagen Matrix approved by Indian health authority with registration numberof MD-1517 will be provided by Aeon Ajanta India Pvt. Ltd. free of cost for this clinical research only.
223763266|NCT05328830|OTHER|Instrument assisted soft tissue mobilization|Myofascial release technique will be applied to the Quadriceps, Hamstring and Gastrocnemius muscles of the participant's dominant lower extremity with the Graston technique®. The application will be at 450 angles for each muscle, 2 minutes, for a total of 6 minutes. The IASTM application will include sweep-fan-sweep strokes and cycle through each muscle for the specified time.
223763267|NCT05328830|OTHER|Foam Roller|Will be applied to the Quadriceps, Hamstring and Gastrocnemius muscles of the participant's dominant lower extremity using rigid Foam Roller. A total of 6 minutes will be applied to a person, 2 minutes for each muscle. Pressure intensity; According to the Visual Analog Scale, which is the point where pain will not be felt but moderate to severe discomfort will be felt, it will be done at a severity of 7/10.
223763268|NCT01938274|OTHER|Educational intervention|A 30-minute discussion and slide presentation with a trained member of the research team.
223763269|NCT00110058|BIOLOGICAL|recombinant interferon alfa|
223763270|NCT00110058|BIOLOGICAL|therapeutic allogeneic lymphocytes|
223763271|NCT00110058|DRUG|cyclosporine|
223763272|NCT00110058|DRUG|fludarabine phosphate|
223763273|NCT00110058|DRUG|imatinib mesylate|
223763274|NCT00110058|DRUG|mycophenolate mofetil|
224317109|NCT02715570|DRUG|Placebo - repeat doses|Safety and tolerability of repeat doses
224317110|NCT03518645|DEVICE|OPN strategy|Predilatation with OPN balloon will be performed as a lesion preparation for BVS Absorb implantation.
223626773|NCT03541551|PROCEDURE|Trab Trab|combined trabeculotomy with trabeculectomy
223626774|NCT05106959|BEHAVIORAL|Motivational Interviewing Informed Shame Resilience Training|Shame resilience involves four elements. Understating shame, normalizing shame thoughts, reaching out, and speaking shame. Motivational interviewing will be used to elicit and guide participants through these four elements.
223626775|NCT01559636|BIOLOGICAL|bivalent oral polio vaccine|vaccine given during immunization campaigns
223763275|NCT00110058|PROCEDURE|peripheral blood stem cell transplantation|
223763276|NCT00110058|RADIATION|radiation therapy|
224215741|NCT04695639|OTHER|Test of Arm Selective Control|It will be used to assess selective voluntary motor control. It is a reliable and valid evaluation tool used to quantify and describe selective voluntary motor control in children with spastic cerebral palsy. The goal of the assessment is to systematically evaluate a person's ability to move the upper extremity with selective voluntary motor control by observing movement control, coordination, fluency, mirroring, and speed at each joint, and then assigning a grade, all in 'real time. Clinically this measure may guide the selection of medical, surgical, or therapy interventions and may improve outcome prognosis after brief training. Raters demonstrated excellent reliability in assessing upper extremity SVMC in a group of children with hemiplegic, diplegic, and quadriplegic CP using the Ttest of arm selective control
224215742|NCT04695639|OTHER|Hand Held Dynamometer|Hand held dynamometer (Camry Digital Hand Dynamometer Grip Strength, Model EH101-37, China) will be used to assess hand grip strength of the affected upper extremity. It is generally small, portable and relatively cheap reliable measurement instruments to measure muscle strength of the arm and hand in children with spastic cerebral pasly. It is used to measure strength; maximal voluntary isometric contraction; objectively in kilograms, pounds or newtons. Such devices have been proven to have good to excellent reliability in different populations. It represents an easily accessible way to assess muscle weakness in children with cerebral palsy and the overall reliability is considered to be good.
224317111|NCT03518645|DEVICE|standard strategy|Predilatation with standard balloon will be performed as a lesion preparation for BVS Absorb implantation.
224317112|NCT01109147|OTHER|Imagery|All the subject will be submitted to an functional magnetic resonance imaging (fMRI) examination.
224317113|NCT01109147|GENETIC|pharmacogenetic sampling|A pharmacogenetic sample will be done with an additional consentment.
224317114|NCT00451945|PROCEDURE|biopsy|
224317115|NCT00451945|DEVICE|3d-ultrasound and fusion of UL and PET/CT|
224317116|NCT01320891|BEHAVIORAL|balanced solutions|during the general anaesthesia until 8 o'clock of the day after the operation the subject will receive only balanced fluids that means balanced crystalloid and colloids dissolved in balanced solution. 12 ml /Kg/h during operation time. ratio 3:1 between crystalloid and colloid.
224317117|NCT01320891|BEHAVIORAL|not balanced|during the operation time until the 8 o'clock of the day after the operation, the subjects will receive only normal saline and colloid dissolved in normal saline.
223763277|NCT03419728|BEHAVIORAL|Healthy Families, Healthy Futures|Home visiting program for pregnant and parenting teens
223763278|NCT01215227|DRUG|Preladenant|Daily for 40 weeks: 2, 5, or 10 mg preladenant tablet each morning; 2, 5, or 10 mg preladenant tablet each evening (approximately 8 hours after the morning dose)
223763279|NCT01215227|DRUG|Rasagiline|Daily for 40 weeks: 1 mg rasagiline capsule each morning
224317118|NCT03585920|BEHAVIORAL|Expanded Corn Snack|A standard expanded snack will be used in each of the 3 arms, the content and type of fat added to the snack is varied in the two experimental arms.
224317119|NCT00479960|BEHAVIORAL|commercially available omega-3 fatty acids supplementation|
223626776|NCT00080158|DRUG|fluoxetine|
223626777|NCT00080158|DRUG|sertraline|
223626778|NCT00080158|DRUG|citalopram|
223626779|NCT00080158|DRUG|escitalopram|
223763280|NCT01215227|DRUG|Placebo to preladenant|Placebo to match preladenant given daily for 40 weeks: placebo tablet each morning; placebo tablet each evening (approximately 8 hours after the morning dose)
224215743|NCT04695639|OTHER|Quality of Upper Extremity Skill Test|It will be used to assess function of the affected upper extremity. It is a reliable and valid outcome measure designed to evaluate movement patterns and hand function in children with cerebral palsy. It is designed to be used with children who have neuromotor dysfunction with spasticity and has been validated with children from 18 months to 8 years of age.
224215744|NCT04613895|DRUG|DWP14012|DWP14012 40 mg, orally, once daily just after a meal up to 4 weeks
224215745|NCT04613895|DRUG|DWP14012|DWP14012 40 mg, orally, once daily before a meal up to 4 weeks
223763281|NCT01215227|DRUG|Placebo to rasagiline|Placebo to match rasagiline given daily for 40 weeks: placebo capsule each morning
223763282|NCT00001731|DRUG|Cyclosporin A|
223763283|NCT04581642|DEVICE|PMD200|The NOL technology is comprised of a console and designated finger probe with 4 sensors. The Sensors are Photoplethysmography (PPG) Galvanic Skin Response (GSR), Accelerometer (ACC) and Thermistor (TMP)
223763284|NCT00925483|PROCEDURE|dialysis|different dialysis schedules for each arm
223763285|NCT02253810|DRUG|Tranexamic Acid|Medication administered intra-operatively to promote blood clotting.
223763286|NCT02253810|DRUG|Placebo|Saline solution
223763287|NCT04925063|DRUG|Metformin|The starting daily dose of metformin is 500mg once daily, and add a dose of 500mg per week until the target dose of 2000mg once daily if tolerated. Metformin will be continued until disease progression.
223763288|NCT00605046|DRUG|SPECT scan|AV151-01: Evaluation of \[123I\] AV151 and SPECT as a marker of beta-amyloid protein deposition in subjects with Alzheimer disease in comparison to healthy subjects
223763289|NCT02787473|DRUG|pemetrexed|Pemetrexed 500mg/m2 IV on day 1 every 4 weeks for 2 cycles
223763290|NCT02787473|DRUG|cisplatin|Cisplatin 25mg/m2 IV on day 1-3 every 4 weeks for 2 cycles
223763291|NCT02787473|RADIATION|thoracic radiation therapy|Chemoradiotherapy, radiation 60Gy with 2 cycles of pemetrexed+ carboplatin/cisplatin
223763292|NCT02787473|DRUG|docetaxel|Docetaxel 60 mg/m2 IV on day 57 every 3 weeks for 2 cycles
224317120|NCT05786846|DRUG|Iodinated contrast agents|Patients who use iodinated contrast agents clinically
224317121|NCT02952586|DRUG|Avelumab|Avelumab + SOC Chemoradiation
224317122|NCT02952586|OTHER|Chemoradiation|Cisplatin + Radiation Therapy
224317123|NCT03766607|DRUG|Trastuzumab|Trastuzumab (8 mg/kg loading dose; 6 mg/kg maintenance) administered intravenously every 21 days
223626780|NCT00080158|DRUG|bupropion|
223626781|NCT00080158|DRUG|mirtazapine|
223626782|NCT00080158|DRUG|venlafaxine|
223626783|NCT00080158|DRUG|lithium|
223626784|NCT00080158|BEHAVIORAL|Cognitive Behavioral Therapy|
223763293|NCT00882258|DRUG|12.5 mg Proellex|12.5 mg Proellex administered orally daily
223763294|NCT00882258|DRUG|25 mg Proellex|25 mg Proellex administered orally daily
223763295|NCT00882258|DRUG|Placebo|Administered orally daily
223763296|NCT06431893|DRUG|Pegtibatinase|Full Target Dose of pegtibatinase BIW
224317124|NCT03766607|DRUG|Ramucirumab|Ramucirumab 8 mg/kg administered intravenously on days 1 and 15 every 28 days
224317125|NCT03766607|DRUG|Paclitaxel|Paclitaxel 80 mg/m2 administered intravenously on days 1, 8, and 15 every 28 days
224317126|NCT02961088|OTHER|Pasta as part of a low GI/GL diet|
224317127|NCT00008307|BIOLOGICAL|anti-thymocyte globulin|
224317128|NCT00008307|DRUG|cyclosporine|
224317129|NCT00008307|DRUG|fludarabine phosphate|
224317130|NCT00008307|DRUG|melphalan|
224317131|NCT00008307|DRUG|methylprednisolone|
224317132|NCT00008307|DRUG|mycophenolate mofetil|
224317133|NCT00008307|PROCEDURE|allogeneic bone marrow transplantation|
224317134|NCT00008307|PROCEDURE|peripheral blood stem cell transplantation|
223626785|NCT03558659|DEVICE|Positional therapy belt|The positional therapy belt produced by SlumberBUMP will be used by stroke patients during sleep, which helps to avoid sleep in the supine position.
223626786|NCT02452736|DEVICE|Resolute Integrity™ Zotarolimus-Eluting Coronary Stent System|
223626787|NCT05467059|OTHER|Napping|Patients are already equipped with electrodes when they pass a test battery before the nap to evaluate mechanisms potentially correlated with tinnitus modulation. Then they do a nap, the nap is stopped when several periods of sleep are seen on EEG (electroencephalogram). Then the test battery is done backwards to evaluate the same measures.
223626788|NCT01292486|DEVICE|Spectra Optia Apheresis System|In this study, the safety and effectiveness of the new device will be assessed in two ways. First, MNC collections in growth-factor mobilized cancer patients will be evaluated to confirm that the Spectra Optia is able to collect stem cells. Second, following stem-cell collection and transplant, the number of days required for the collected hematopoetic stem cells to engraft/recover will be compared with historical COBE Spectra engraftment/recovery data.
223626789|NCT05177393|OTHER|Assessment of patient-reported outcomes (PROs)|Questionnaires will be administered to participants
223763297|NCT05132764|PROCEDURE|Microosteoperforations|2 inter radicular bone microosteoperforations using temporary anchorage device tip.
223763298|NCT04106310|DEVICE|High-flux dialyzer|a dialyzer meeting the definition of high-flux
223763299|NCT04106310|DEVICE|Theranova dialyzer|a middle cut-off dialyzer
223763300|NCT04854915|BEHAVIORAL|LOOP + mHealth technology assisted exercise counselling|Participants will complete a 3 month exercise and physical activity intervention supported by mHealth technology
223763301|NCT04854915|BEHAVIORAL|LOOP Only|Participants will complete the LOOP @ Alder Hey programme
224317135|NCT00008307|PROCEDURE|syngeneic bone marrow transplantation|
224317136|NCT05654311|OTHER|Nasal surgery|Nasal surgery under general anesthesia using inhalational agent (sevoflurane)
224317137|NCT05088811|DIAGNOSTIC_TEST|WRAP53, UCA-1|Diagnostic value of UCA-1 and WRAP53 in HCC
224317138|NCT00237393|DRUG|Quetiapine|Dosage initiated at 25 mg HS with gradual titration to target dose of 400 mg HS, up to maximum of 800 mg HS.
224317139|NCT00237393|DRUG|Placebo|Dosage initiated at 25 mg HS with gradual titration to target dose of 400 mg HS, up to maximum of 800 mg HS.
224317140|NCT02498028|PROCEDURE|Cervical Fusion|Cervical Fusion is performed with a titanium cage (Company Peter Brehm, Weisendorf, Germany) and a plating system (Company Aesculap, ABC plating system, Tuttlingen, Germany)
224317141|NCT02498028|PROCEDURE|Cervical disc Prostheses|The total disc replacement is performed with eiter a Freedom® Cervical Disc, AxioMed Spine Corporation, Garfield Heights, Ohio, USA or Active® C, Company, Aesculap, Tuttlingen, Germany
223763302|NCT03585452|DRUG|Dexmedetomidine Infusion|Patients with additional dexmedetomidine infusion
224317142|NCT02208804|DEVICE|Holmium-166-poly (L-lactic acid) microspheres|
224317143|NCT01932918|DRUG|Patient controlled analgesia|"1. PCA with morphine in liver transplant:~   Intravenous patient controlled analgesia with morphine was used for postoperative pain control in liver transplant recipients.~2. PCA with morphine and ketorolac:~   Patient controlled analgesia with morphine and ketorolac was used for postoperative pain control in liver transplant and thoracic surgery patients.~3. Intravenous PCA in thoracic surgery Intravenous patient controlled analgesia was used for postoperative pain control in thoracic surgery patients.~4. PCEA in thoracic surgery Patient controlled epidural analgesia was used for postoperative pain control in thoracic surgery patients."
223626790|NCT04662021|OTHER|Aerobic Exercises|Participants perform one hour of regular moderate to vigorous physical activities about (70 % to 90 %) of the maximum heart rate which was calculated according to this formula (HR max= 220- age)
223626791|NCT04514887|OTHER|mild intraoperative hyperventilation|Intraoperative mechanical ventilation of patients was adjusted so that end-tidal CO2 readings lie between 30-32 mmHg
223626792|NCT03136887|DEVICE|JOURNEY II XR Total Knee System|JOURNEY II XR Total Knee System
223626793|NCT05537909|OTHER|Biological sample collection|All patients and their controls will be asked to provide a urine, stool, saliva and blood sample during a follow-up visit. Patients will not be specifically asked to take these samples, they will be taken during a follow-up visit, during which these samples are usually already taken.
223626794|NCT04367727|DEVICE|Light emitting diode|Light emitting diode at a wavelength of 890 nm is produced by an array of 60 gallium aluminum arsenide light-emitting diodes located on flexible pads and the near infrared photo energy is delivered in a noninvasive, drug-free manner
223626795|NCT05383118|BEHAVIORAL|Education Intervention|"Participants in the intervention group will be provided e-learning about dementia prevention and promoting brain health, consisting of following components:~1. One multimedia e-learning lesson on promoting brain health and preventing dementia;~2. A series of 12 'micro-learning' emails (3 emails/week) with small segments of content to reinforce the material from the lesson.~3. Curated resources related to dementia risk factors"
223626796|NCT05383118|BEHAVIORAL|Education Control|"Participants in the control group will be provided e-learning about mild cognitive impairment, consisting of following components:~1. One multimedia e-learning lesson on mild cognitive impairment;~2. A series of 12 'micro-learning' emails (3 emails/week) with small segments of content to reinforce the material from the lesson.~3. Curated resources related to mild cognitive impairment"
224215746|NCT03823365|BIOLOGICAL|Blinatumomab Expanded T-cells (BET)|"Two to five days after the last chemotherapy infusion, BET will be administered. An accelerated titration dose escalation design will be used. During dose escalation, up to four dose levels (see table) will be evaluated or until (Maximum Tolerated Dose) MTD is reached.~Dose level BET dose(Counted on CD3+ cells)~1. (starting dose) 3.0 x 109~2. 6.0 x 109~3. 9.0 x 109~4. 12.0 x 109"
224317144|NCT04743687|DRUG|Zanubrutinib|Oral Zanuburutinib, 160mg twice a day
224317145|NCT03254498|DEVICE|Endocuff|It is a randomised back to back study to compare cap and Endocuff to detect adenoma in colonoscopic examination
223763303|NCT03585452|DRUG|Propofol based general anesthesia|Patients with typical anaesthetic regimens
224317146|NCT03254498|DEVICE|cap assisted colonoscopy (CAC)|cap assisted colonoscopy (CAC)
224317147|NCT04520009|BEHAVIORAL|Activity Restriction|Standard post-operative activity instructions (i.e., no bending, twisting, or lifting more than 10 lbs for 4 weeks, no return to work until cleared to do so).
224317148|NCT04520009|BEHAVIORAL|Activity as Tolerated|Instructions advising activity as tolerated and return to work based on patient discretion
223626797|NCT04602390|DRUG|ANK-700|Intravenous (IV) infusion
223626798|NCT04602390|DRUG|Placebo|Intravenous (IV) infusion
223626799|NCT06458283|OTHER|hiybrid simulation|The intervention group students were given practical training on breast milk and breastfeeding management in the professional skills laboratory, accompanied by a high-reality simulator accompanied by a scenario, and the control group students were given practical training on breast milk and breastfeeding management in the professional skills laboratory, accompanied by an adult standard patient care model.
223626800|NCT06458283|OTHER|control grup|low fidelity simulator
223626801|NCT01553084|DRUG|Varenicline|Participants will receive 12 weeks of pharmacotherapy during the post-quit period plus an additional 7 day pre-quit run-in. Participants will be asked to take a 0.5 mg pill once a day for the first 3 days and then increase to a 0.5 mg pill twice a day (8 hours apart) for 4 days. On the 8th day, their target quit date, they will increase to their target maintenance dose of a 1 mg pill twice daily. If participants report significant adverse events such as nausea, a dose reduction to two 0.5 mg doses per day will be advised.
223626802|NCT01553084|DRUG|Nicotine lozenge|Participants will receive 12 weeks NRT. Participants will be given 2 mg or 4 mg lozenges based on morning smoking latency, and will be given package insert use instructions. Medication use will start on the morning of their assigned quit day. They will be urged to use at least 5 pieces/day, unless this amount produces adverse effects.
223626803|NCT01553084|DRUG|Nicotine Patch|Participants will receive 12 weeks NRT. Patch dosing will be 8 weeks of 21 mg, then 2 weeks of 14 mg, then 2 weeks of 7 mg (those smoking 5-10 cigs/day will receive reduced patch dosing). Medication use will start on the morning of their assigned quit day. They will be urged to use 1 patch/day, unless it produces adverse effects.
223626804|NCT01452438|BIOLOGICAL|MenACWY-CRM|MenACYW-CRM vaccination received as part of routine clinical care and as registered in the vaccine records.
224317149|NCT02910011|DRUG|Nanodox 1% (doxycycline monohydrate hydrogel)|Subjects will be asked to apply NanoDOX® Hydrogel 1% once daily at bedtime for up to four weeks or until complete clearance whichever is sooner
224317150|NCT04575311|DRUG|AB680|AB680 is a Cluster of Differentiation (CD)73 Inhibitor
224317151|NCT04575311|OTHER|Placebo|Matching Placebo
224317152|NCT06319040|OTHER|Muscle strength measurement|Muscle strength of both legs, maximal reciprocal concentric isokinetic knee extension (quadriceps) and flexion (hamstring) at 60°/s, 90°/s and 180°/s speeds were evaluated
224317153|NCT06319040|OTHER|Knee joint proprioception|Knee joint proprioception was assessed by joint position sense. Joint position sense was measured by the previously taught ability to actively find joint position (EPAB)
224317154|NCT06319040|OTHER|Balance|The patients and healthy individuals participating in our study were evaluated with the General Stability Index (GSI) for general balance ability, Anterior-Posterior Stability Index (APSI) for anterior-posterior balance ability, Medial-Lateral Stability Index (MLSI) for lateral balance ability and Fall Risk Index (DRI) and Biodex Balance System (Biodex Inc., Shirley, New York, USA) for fall risk. High values obtained indicate deterioration in balance and increased risk of falling.
223763304|NCT01995799|DEVICE|Ferumoxytol enhanced MRI|Ferumoxytol enhanced MRI scan
223763305|NCT02453958|DEVICE|Multi-modal assessment system|Subjects were assessed using a multi-modal concussion assessment battery incorporating eye-tracking, balance, and neurocognitive tests
223763306|NCT01977586|OTHER|Magnetic Resonance Imaging (MRI)|
223763307|NCT00146718|DRUG|Amodiaquine and Sulphadoxine/Pyrimethamine|
224215747|NCT05485857|PROCEDURE|Arrangement of small intestine order before close the abdomen|After the completion of laparoscopic-assisted colorectal cancer surgery, the chief surgeon performed laparoscopic small bowel arrangement before closing the abdomen, straightening the small bowel from the colon-small bowel anastomosis or the ileocecal valve to the ligament of Trevor, and restoring the original position of the small bowel. Afterward, close the abdomen.
223763308|NCT03437122|PROCEDURE|Bronchoscopy|Multiple level sampling of the respiratory mucosa (cytology brush and biopsies forceps)
224215748|NCT00028730|BIOLOGICAL|anti-thymocyte globulin|
224215749|NCT00028730|BIOLOGICAL|filgrastim|
224215750|NCT00028730|DRUG|cyclophosphamide|
224317155|NCT06319040|OTHER|Fall risk test|Biodex Balance System (Biodex Inc., Shirley, New York, USA) for fall risk
224317156|NCT06319040|OTHER|Tegner Activity Level|Tegner Activity Level and the Turkish version of the Lysholm Knee Scoring Scale by Çelik et al. were used to subjectively determine the functional level in individuals undergoing ACL reconstruction surgery.
224317157|NCT06319040|OTHER|Lysholm Knee Scoring Scale|Tegner Activity Level and the Turkish version of the Lysholm Knee Scoring Scale by Çelik et al. were used to subjectively determine the functional level in individuals undergoing ACL reconstruction surgery.
223514056|NCT03578172|DRUG|human menopausal gonadotrophin|experimental group:Women will be given HMG 37.5-150IU daily followed by monitoring of the follicular growth (folliculometry) when serum Estradiol (E2)\<100pg/ml，progesterone (P)\<1ng/ml. Final oocyte maturation will be induced by administration of human chorionic gonadotropin (HCG) when there will be at least one leading follicle ≥20mm in diameter followed by luteal phase support (using progesterone supplements) after 24 hours.
223514057|NCT03578172|DRUG|hormone replacement therapy|Women will be given 17 β-estradiol hemihydrate 2 mg and estrogen gel 5 g daily from day 3 of the cycle then the endometrial thickness will be assessed on day 7 by transvaginal sonography (TVS). If the endometrium is ≥ 9 mm, luteal phase support (using progesterone supplements) will be started but if the endometrium is \< 9 mm, estradiol will be continued until reaching appropriate endometrial thickness and then the luteal phase support will be started. The cycle will be cancelled If the estradiol administration \>60 days.
223514058|NCT01387867|PROCEDURE|Strength training|Supervised strength training in groups 2 x 1 hour weekly and un-supervised strength training 1 hour weekly for 4 months
223626805|NCT03988400|BEHAVIORAL|Sensory Augmentation|Participants will complete 8 training sessions over 4 weeks, in which they walk on a treadmill at their self-selected speed. During training sessions, the magnitude of the vibration delivered over the hip abductor musculature will scale with the mechanical state of the pelvis at the start of each step. For example, if the step begins with the pelvis far mediolaterally from the stance foot, the swing leg hip abductors will receive strong vibration. If instead the step begins with the pelvis close mediolaterally to the stance foot, the stance hip abductors will receive strong vibration.
223626806|NCT03988400|BEHAVIORAL|Random Vibration|Participants will complete 8 training sessions over 4 weeks, in which they walk on a treadmill at their self-selected speed. During training sessions, the magnitude of the vibration applied to the hip abductors will vary randomly (following a normal distribution) on a step-by-step basis.
223626807|NCT00245323|BEHAVIORAL|Smoking status as a routine vital sign|
223626808|NCT02199002|DEVICE|multi-pH-impedance manometry catheter|a special catheter will be placed in the esophagus of all study groups. Measurment of pH, impedance and pressure will be performed.
223626809|NCT03560297|BEHAVIORAL|SeRenade Parent-Child Music Class|Parent-Child Music Class involving parent training, peer inclusion, and musical play
223626810|NCT03560297|BEHAVIORAL|Delayed Intervention|Participants receive intervention after delay
223763309|NCT02825836|DRUG|TL-895|TL-895 is an experimental tyrosine kinase inhibitor anticancer drug taken by mouth.
223763310|NCT02825836|DRUG|Navtemadlin|Navtemadlin is an experimental MDM2 anticancer drug taken by mouth.
223763311|NCT05534763|BEHAVIORAL|IERGD|A 10 week behavioral treatment focusing on gender minority stress, maladaptive and adaptive emotion regulation, emotional awareness, the functionality of emotions, interpersonal skills and values and valued actions.
223763312|NCT05534763|OTHER|IER SUPPORT|A 5-week behavioral course for a designated support person (family, friend, other) to the person with GD. The course focuses on teachings on living with minority stress, maladaptive and adaptive emotion regulation, emotional awareness, validation, interpersonal skills and values.
224215751|NCT00028730|DRUG|fludarabine phosphate|
224215752|NCT00028730|DRUG|thiotepa|
224215753|NCT00028730|PROCEDURE|allogeneic bone marrow transplantation|
224215754|NCT00028730|RADIATION|radiation therapy|
224215755|NCT03703739|DIETARY_SUPPLEMENT|Reference meal 1|1 ml Ferrous sulfate solution (4mgFe/ml) was added in cooked comercial Rice Prior to served to participant. The meal served with 30 g mixed vegetable Sauce and 300 ml nanopure water
224317158|NCT02490644|PROCEDURE|Blood sampling|Blood sampling 5ml
224317159|NCT03742791|DRUG|TS-134|5 mg to 80 mg oral solution
224317160|NCT03742791|DRUG|Placebo|Matched Placebo oral solution
224317161|NCT04844060|OTHER|Lumbar punction|Lumbar punction
223763313|NCT02677792|BEHAVIORAL|Behavioral Family Intervention (BFI)|Participating families will receive standard medical care through the Wellness and Weight Clinic, as well as the BFI. The BFI is based on family systems (Minuchin et al., 1975) and social-cognitive (Bandura, 1998) theories. Each dyad will participate in simultaneous, but separate, 75-minute parent and child groups over a 3 month period. The groups will start off meeting every week for 8 weeks and then bi-weekly for 1 month. Thus, dyads will attend a total of 10 group meetings over the 3 month period (12.5 hours of total treatment contact).
223763314|NCT00256919|DRUG|GW856553|
223763315|NCT04566796|DRUG|Sugammadex|give 2 mg/ kg as muscle reversal drug in premature infants
223763316|NCT04566796|DRUG|Neostigmine|give 0.02 mg/ kg atropine and 0.05 mg/kg neostigmine IV. as muscle reversal drug in premature infants
223763317|NCT02856542|DRUG|calcipotriol/betamethasone dipropionate gel in Applicator|Topical treatment of scalp using applicator device. The study as such is non-interventional as the intervention has been decided prior to and independently from the inclusion of the patient in the cohort to be observed.
223763318|NCT02745964|DEVICE|LMA supreme|Anesthesia is maintained using LMA supreme in LMA supreme group or using I-gel in I-gel group according to the randomly allocated groups.
223763319|NCT02745964|DEVICE|I-gel|Anesthesia is maintained using LMA supreme in LMA supreme group or using I-gel in I-gel group according to the randomly allocated groups.
224215756|NCT03703739|DIETARY_SUPPLEMENT|Reference 2|1 ml Ferrous sulphate solution (4mgFe/ml) was added in cooked comercial Rice Prior to served to participant. The meal served with 30 g bean Sauce and 300 ml nanopure water
223763320|NCT01434290|RADIATION|36.25 Gy IMRT|36.25 Gy in 5 fractions of 7.5 Gy twice a week over 15-17 days. A minimum of 72 hours and a maximum of 96 hours will separate each treatment. IMRT or similar techniques that use inverse treatment planning or protons are required.
223763321|NCT01434290|RADIATION|51.6 Gy IMRT|51.6 Gy in 12 fractions of 4.3 Gy 5 days a week over 16-18 days. IMRT or similar techniques that use inverse treatment planning or protons are required.
223763322|NCT06481202|BIOLOGICAL|Complarate®|The test drug Complarate® was administered as an intravenous infusion at a single dose of 8 mg/kg.
223763323|NCT06481202|BIOLOGICAL|Actemra®|The reference drug Actemra® was administered as an intravenous infusion at a single dose of 8 mg/kg.
223763324|NCT04625751|OTHER|CO2-enriched air|To assess cardiovascular reactivity
223763325|NCT04625751|OTHER|Meal response test|Meal response test to assess changes in splanchnic blood flow.
223763326|NCT03821012|OTHER|in-hospital process optimization|
223763327|NCT03821012|OTHER|PPCI hospital-based regional STEMI transfer network construction|
223763328|NCT03821012|OTHER|the whole-city STEMI care network construction|
223763329|NCT02012595|OTHER|[11C]donepezil PET|Positon Emission Tomography (PET) imaging of acetylcholinesterase using the ligand \[11C\]donepezil
223763330|NCT05952622|DEVICE|Continuous passive motion therapy|Patients will be supplied with a continuous passive motion device which will allow additional individual treatment of the affected shoulder for 6 weeks.
223763331|NCT05882227|BEHAVIORAL|video|The patients will receive the discharge information through the visualization of a video with discharge information extracted from the optimized hip prosthesis recovery program document; information for patients, relatives or caregivers. The video will consist of two parts: a first part where it will be explained what will happen in the next hours in the unit, the documentation that will be delivered at discharge and the pharmacological treatment. The second part will consist of a video explaining wound care at discharge, discharge recommendations, symptoms that may appear after surgery and alarm symptoms.
223514059|NCT01387867|PROCEDURE|Nordic Walking|Supervised Nordic Walking in groups 2 x 1 hour weekly and un-supervised Nordic Walking 1 hour weekly for 4 months
223514060|NCT01387867|PROCEDURE|Unsupervised home based exercise|Unsupervised home based exercise as recommended by the Danish Arthritis Association 1 hour 3 x weekly for 4 months
223514061|NCT03190421|DIAGNOSTIC_TEST|Expanded Urinary Culture|involves the inoculation of 100X (0.1mL) more urine onto diverse types of media (BAP, chocolate agar, colistin and nalidixic acid (CNA) agar, CDC anaerobe 5% BAP) with incubation in more environments and temperatures (5% CO2 at 35°C for 48 h, aerobic conditions at 35°C and 30°C for 48 h, Campy gas mixture (5% O2, 10% CO2, 85% N) or anaerobic conditions at 35°C for 48 h). The level of detection for EQUC is 10 CFU/mL, represented by 1 colony of growth on any of the plates. EQUC is designed to isolate a broad array of Gram-negative and Gram-positive bacteria, including anaerobes and fastidious bacteria that grow slowly.
223763332|NCT05882227|BEHAVIORAL|Traditional information|"Patients will receive the information at discharge by means of the document entitled Optimized Hip Replacement Recovery Program; information for patients, relatives or caregivers, which will act as a control group."
223763333|NCT03761732|BEHAVIORAL|Islamic Trauma Healing|6 session behavioral intervention program designed to reduce PTSD and related symptomatology
224215757|NCT03703739|DIETARY_SUPPLEMENT|Test meal A|"Fortified extruded Rice was mixed with Commercial Rice (mixing Ratio: 1:100) The meal served with 30 g vegetable Sauce and 300 ml nanopure water.~\*\* composition of extruded Rice: Ferric pyrophosphate, zinc oxide and ethylenediaminetetraacetic acid"
224215758|NCT03703739|DIETARY_SUPPLEMENT|Test meal B|"Fortified extruded Rice was mixed with Commercial Rice (mixing Ratio: 1:100) The meal served with 30 g vegetable Sauce and 300 ml nanopure water.~\*\* composition of extruded Rice: Ferric pyrophosphate, zinc sulfate and ethylenediaminetetraacetic acid"
224215759|NCT03703739|DIETARY_SUPPLEMENT|Test meal C|"Fortified extruded Rice was mixed with Commercial Rice (mixing Ratio: 1:100) The meal served with 30 g vegetable Sauce and 300 ml nanopure water.~\*\* composition of extruded Rice: Ferric pyrophosphate, zinc sulfate, citric acid and trisodium Citrate."
224215760|NCT03703739|DIETARY_SUPPLEMENT|Test meal D|"Fortified extruded Rice was mixed with Commercial Rice (mixing Ratio: 1:100) The meal served with 30 g vegetable Sauce and 300 ml nanopure water.~\*\* composition of extruded Rice: Ferric pyrophosphate, zinc sulfate and sodium pyrophosphate."
223514062|NCT03190421|DIAGNOSTIC_TEST|Standard Urine Culture (SUC)|involves inoculation of 0.001 mL of urine onto 5% sheep blood agar plate (BAP) and MacConkey agar plate with the plates being incubated aerobically at 35°C for 24 h. Thus, the level of detection for standard culture is 103 CFU/mL, represented by 1 colony of growth on either plate. Standard culture is designed specifically to grow Gram-negative rods, especially UPEC.
223626811|NCT05335330|OTHER|Evaluation of biomechanics and viscoelastic properties of Thoracolumbar fascia|The biomechanical and viscoelastic properties of the Thoracolumbar fascia will be measured in the side line position. Measurements will be taken from three different points; L1, L3-4 and L5 level.
223626812|NCT03448796|PROCEDURE|HTO|Group that receives high tibial osteotomy combined with supervised physiotherapy as treatment.
223626813|NCT03448796|OTHER|Supervised physiotherapeutic program|Group that receives only supervised physiotherapy as treatment.
223626814|NCT03909789|DIETARY_SUPPLEMENT|Plant based bioequivalent Nitrate supplementation|The nitrate supplement consists of nitrate-rich beetroot extract 20mg, thiamine mononitrate 90mg, potassium nitrate 480mg, ascorbic acid 150mg, folic acid 200mcg, methylcobalamin 200mcg, calcium 115mg, pomegranate fruit extract 5mg and green coffee bean extract 115mg.
223626815|NCT03909789|DIETARY_SUPPLEMENT|Placebo|Placebo
223626816|NCT05682508|OTHER|Education group|"Based on the Health Belief Model, a educational booklet on diet and fluid control in individuals receiving hemodialysis treatment has been prepared. The training content consists of information on the structure and function of the kidneys, information about chronic renal failure, possible complications in case of non-adherence with the desired fluid control and diet, perceived benefits, the information on diet and fluid control consisted of perceived benefits, barriers, coping with barriers, perceived susceptibility in this regard, and information on the development of self-efficacy to improve dietary compliance and fluid control.~Individuals in the education group were given individual training by the researcher. The training was conducted in a single meeting of 20-30 minutes in the first hour when haemodialysis started and the patient's condition was stable."
223626817|NCT05139680|DRUG|tafamidis|80 or 61 milligrams (mg)
223626818|NCT06369870|DRUG|Levobupivacaine Hydrochloride 0.25 % Injectable Solution|After wound closure, the IPP-PSP block is performed at the level of the 4th rib. At the pre-axillary line, the pectoralis major, the pectoralis minor and the serratus anterior muscle are identified. At first, the needle is positioned in the fascial plane between the pectoralis minor and the serratus anterior muscle. The needle position is confirmed by hydro-dissection of this plane with 2 mL of normal saline 0.9%.The 20 ml syringe with trial drug solution is injected in this pectoserratus plane (PSP). The needle tip is repositioned in the interpectoral plane between both the pectoralis major and minor muscle. The 10 ml syringe with trial drug solution is administered in this interpectoral plane (IPP).
223626819|NCT06369870|DRUG|Sodium chloride 0.9%|Unilateral (right) IPP-PSP block with 30 mL normal saline 0.9%, administered after the closure of the wounds. The IPP-PSP block procedure will be carried out as described in the intervention description of the IPP-PSP block.
223626820|NCT04201431|BIOLOGICAL|PvDBPII/Matrix-M1|50ug PvDBPII in 50ug Matrix M1
223626821|NCT03591718|DRUG|BI 456906|Solution for injection
223626822|NCT03591718|DRUG|Placebo|solution for injection
223626823|NCT01546857|DRUG|Placebo|Normal Saline
223626824|NCT01546857|DRUG|Gapabentin|400mg orally at 9pm day of surgery and the first evening post operatively.
223626825|NCT06289933|DRUG|BR3005|One tablet administered alone, Once a day
223626826|NCT06289933|DRUG|BR3005-1|One tablet administered alone, Once a day
223626827|NCT06289933|DRUG|BR3005-2|One tablet administered alone, Once a day
223626828|NCT06322563|DRUG|LTC004+regorafenib|LTC004,90μg/kg,IV,Day 1,Q3W; Regorafenib:Orally once daily for the first 21 days of each cycle, with 28 days as 1 cycle. Cycle 1 was dose-escalation with a starting dose of 80 mg/d, increasing by 40 mg per week until 160 mg/d, i.e., 80 mg/d in week 1 (D1\~D7), 120 mg/d in week 2 (D8\~D14), and 160 mg/d in week 3 (D15\~D21);
223626829|NCT04260685|DRUG|Lidocaine|IV bolus of 1.5mg/kg lidocaine 1% followed by continuous infusion of 1.5mg/kg/h
223626830|NCT04260685|DRUG|Esmolol|IV bolus of esmolol 0.5 mg/kg followed by continuous infusion of 100-300 ug/kg/min
223626831|NCT03106571|DRUG|Pomaglumetad methionil|Tablets twice daily
223626832|NCT03106571|DRUG|Placebo|1-4 tablets twice daily
223626833|NCT03106571|DRUG|Methamphetamine|intravenous methamphetamine
223626834|NCT00826644|DRUG|Belotecan|Belotecan : 0.5mg/㎡/day for Day 1 to 4, repeated every 3 weeks
223626835|NCT00826644|DRUG|Etoposide|Etoposide 100mg/㎡/day for Day 1 to 3, repeated every 3 weeks
224215761|NCT03703739|DIETARY_SUPPLEMENT|Test meal E|"Fortified extruded Rice was mixed with Commercial Rice (mixing Ratio: 1:100) The meal served with 30 g bean Sauce and 300 ml nanopure water.~\*\* composition of extruded Rice: Ferric pyrophosphate, zinc sulfate, citric acid and trisodium Citrate."
224215762|NCT03145610|OTHER|Placebo toothpaste|During an experimental 3-week period of undisturbed mechanical plaque accumulation in the implants, implants randomly assigned to Placebo group will be submitted to a chemical plaque control (three times per day) using a Triclosan toothpaste.
223626836|NCT00826644|DRUG|Cisplatin|Cisplatin 60mg/㎡/day for Day 1, repeated every 3 weeks
223626837|NCT01264341|DRUG|Bevacizumab|Bevacizumab 10mg/kg intravenous every 2 weeks until disease progression, unacceptable toxicity or consent withdrawal.
223626838|NCT01264341|DRUG|Temsirolimus|Temsirolimus 25mg intravenous once weekly until disease progression, unacceptable toxicity or consent withdrawal.
223626839|NCT01879111|OTHER|patient-targeted feedback|Using a randomised-controlled study design half of the patients will receive a patient-targeted written screening feedback. This feedback contains information about depression in general, depression-severity adapted treatment guidelines and contact-information for treatment.
223626840|NCT04459143|BEHAVIORAL|Advance directives|A workshop will take place during the third week of patient care to inform them about COPD, exacerbations, prognostic and advance directives. Then, a personal interview with patients who have participated to this workshop will take place at the end of their hospital stay, to collect their advance directives and their degree of satisfaction about this process.
223626841|NCT04841863|DEVICE|MyPlan digital health platform|Inclusion in the active group involves the use of MyPlan digital health tool that aims to improve clinical-patient communication, enahnce patient empowerment, improve early detection of side effects and allows professionals to individualize interventions.
223626842|NCT04841863|OTHER|Satndard care|Inclusion in the control group do not involves the use of MyPlan digital health tool. Patients will receive the standard of care.
223626843|NCT05774353|OTHER|Patient questionnaire|Patients included in the study will complete an online questionnaire (LimeSurvey).
223626844|NCT05767515|DRUG|metformin|Treatment of infertile female with PCOS with inositol isomers and Acetyl-L-Carnitine
223626845|NCT05699187|PROCEDURE|Face allotransplantation|Facial allotransplantation
223626846|NCT05343754|DRUG|Hyperbaric oxygen|Hyperbaric treatment will consist of 30 daily treatments in the first 6 weeks of the study, except during the weekends. After compression for 10 minutes patients will receive 80minutes (4 times 20 minutes) 100% O2 with 3 airbrakes (21% O2) of 5 minutes at 2.4-2.5 ATA, and then 10 minutes decompression with the first part of decompression till 0.3 ATA with 100% oxygen (this will usually take seven minutes). The last 0.3 ATA will be decompressed with air. In total one hyperbaric session will be 110 minutes. Treatment will start directly at the beginning of the study.
223626847|NCT05343754|OTHER|Control group|In order to compare efficacy, patients that do not wish to undergo hyperbaric treatment, will serve as a control group. At baseline they will be asked for the reason they do not wish to undergo hyperbaric treatment. All patients and controls will be asked to report pain scores using a numeric pain rating scale (NRS) and quality of life (Wound-Q) questionnaires. They will continue to receive standard care as deemed necessary by their primary physician.
223626848|NCT04418024|DRUG|AG10|TTR stabilizer administered orally twice daily (BID)
223626849|NCT04418024|DRUG|Placebo|Non-active control
223626850|NCT02358473|BIOLOGICAL|mogamulizumab|Mogamulizumab will be administered by IV infusion.
223626851|NCT02358473|DRUG|Docetaxel|Docetaxel will be administered by IV infusion.
223763334|NCT02776228|DRUG|Brotizolam|Every patient which will enroll to the study will fill up The Pittsburgh Sleep Quality Index in there admission to the cardiac surgery unit. in the discharge day the patient will receive 0.25 mg brotizolam once a day before sleep for six weeks. one week and six weeks after discharge day, there is routine follow up in our outpatient clinic. in those appointed time the patient will fill again The Pittsburgh Sleep Quality Index.
223763335|NCT02776228|DRUG|placebo|Every patient which will enroll to the study will fill up The Pittsburgh Sleep Quality Index in there admission to the cardiac surgery unit. in the discharge day the patient will receive 0.25 mg LACTOSE once a day before sleep for six weeks. one week and six weeks after discharge day, there is routine follow up in our outpatient clinic. in those appointed time the patient will fill again The Pittsburgh Sleep Quality Index.
223763336|NCT04657497|DRUG|FOY-305|Specified Dosage and Duration of Treatment
223763337|NCT04657497|DRUG|Placebo|Specified Dosage and Duration of Treatment
223763338|NCT00213148|DRUG|Anastrozole 1 mg|Subjects will be administered orally with 1 mg of anastrozole once daily for 5 days in Cycle 1, 2 and 3 (each cycle = approximately 1 month).
223763339|NCT00213148|DRUG|Anastrozole 5 mg|Subjects will be administered orally with 5 mg of anastrozole once daily for 5 days in Cycle 1, 2 and 3 (each cycle = approximately 1 month).
223763340|NCT00213148|DRUG|Anastrozole 10 mg|Subjects will be administered orally with 10 mg of anastrozole once daily for 5 days in Cycle 1, 2 and 3 (each cycle = approximately 1 month).
224215763|NCT03145610|OTHER|triclosan/copolymer/fluoride toothpaste|During an experimental 3-week period of undisturbed mechanical plaque accumulation in the implants, implants randomly assigned to triclosan/copolymer/fluoride group will be submitted to a chemical plaque control (three times per day) using a triclosan/copolymer/fluoride toothpaste.
224215764|NCT00606268|DRUG|Micafungin|IV
224215765|NCT06152159|OTHER|data collection|Data collection
224215766|NCT02540707|DRUG|solifenacin|solifenacin 5 mg per day for 12 weeks
223763341|NCT00213148|DRUG|Clomiphene Citrate 50 mg|Subjects will be administered orally with 50 mg of clomiphene citrate once daily for 5 days in Cycle 1, 2 and 3 (each cycle = approximately 1 month).
223763342|NCT00213148|DRUG|Clomiphene Citrate 100 mg|Subjects will be administered orally with 100 mg of clomiphene citrate once daily for 5 days in Cycle 2 and 3 (each cycle = approximately 1 month).
223763343|NCT06391788|PROCEDURE|thoracoscopic Morrow surgery|minimally invasive trans-mitral Morrow septal myectomy
223763344|NCT06391788|PROCEDURE|modified Morrow surgery|median open modified enlarged Morrow septal myectomy
224317162|NCT04944186|OTHER|Structured Pressure Injury Patient Education (mySPIPE)|It consists of PI education topics which include four main topics; 1) Pressure Injury: Why Me, which will be covering the basic information that patient need to know about PI; 2) Look After Your Skin, in this topics, patient will be thought about how skin checking was done and why it need to be done; 3) Preventing pressure injury, in this topic, patient will be emphasized on the suitable repositioning for them and the benefit of support surfaces and preventive wound dressing; 4) Help your PI heal, in this topic patient will be guided on what are condition that help PI healing and dietary needs to support wound healing
223763345|NCT03533062|DRUG|botulinum toxin A|botox A injection trigonal or trigonal sparing with trial of anticholinergics 6 months post operative for 3 months
224317163|NCT04944186|OTHER|Standard Patient Education|No fixed content/ duration of patient education. Basically, patient repositioning emphasized verbally after wound dressing completed.
223763346|NCT01677091|OTHER|Cervical vibration|Vibration of neck muscles during 10 minutes
223763347|NCT01677091|OTHER|Prism adaptation|Prism adaptation during 10 minutes
223763348|NCT01677091|OTHER|Conventional rehabilitation|conventional rehabilitation
224215767|NCT02540707|DRUG|mirabegron|mirabegron 25 mg per day for 12 weeks
224317164|NCT00181558|DRUG|Atrasentan|
224317165|NCT00181558|DRUG|Zoledronic Acid (Zometa)|
224317166|NCT00641225|DRUG|SBI-087|Single IV doses of SBI-087 from 0.015 mg/kg to 2 mg/kg and Single SC doses of SBI-087 from 50 mg to 300 mg.
224215768|NCT03445247|OTHER|Extracorporeal low-intensity shockwave|Omnispec device to give a total of 1200 shockwaves, with low energy density at 0.1 mj/mm2 and a frequency of 120 shocks/min per kidney per treatment session, totally 12 times.
224215769|NCT04918537|DIETARY_SUPPLEMENT|Walnuts|30g of plain walnuts in addition to habitual food intakes
224215770|NCT03124056|DEVICE|Extracorporeal photopheresis|Extracorporeal photopheresis using non-open system
224215771|NCT06007209|OTHER|Manual Pressure Point|Compression of the subclavian artery against the 1st rib and of the common femoral artery against the pelvis.
224215772|NCT01389206|DRUG|observational study with patients treated with Tracleer, Ventavis, Veletri, Opsumit and/or Uptravi|observational study with patients treated with Tracleer, Ventavis, Veletri, Opsumit and/or Uptravi
224215773|NCT05353491|BEHAVIORAL|Technology assisted Thinking Healthy Program (THP-TA)|A technology adapted version of the Thinking Healthy Program (THP) delivered by peers using multimedia android based app.
224317167|NCT00356655|BEHAVIORAL|Psychoeducation|
223626852|NCT06415890|OTHER|4-7-8 Breathing Technique|The 4-7-8 breathing technique to be applied to the patients in the experimental group; the patient will be asked to sit or lie in a comfortable position with his/her hands on his/her lap, press the tip of his/her tongue on the tissue protrusion behind the upper front teeth and hold it there during the breathing cycle, breathe in through the nose for four counts, hold the breath for seven counts and then slowly exhale through the mouth for eight counts and complete a set. Within one set of practice, this cycle repeats four times.
223626853|NCT05773846|DRUG|Ropivacaine|A long acting formulation of ropivacaine
223626854|NCT04097470|DRUG|Decitabine|Decitabine dosage 20mg/m2 i.v.
223626855|NCT04097470|DRUG|Midostaurin|Midostaurin 50 mg b.i.d.
223626856|NCT05476289|OTHER|No intervention|No intervention
223626857|NCT02588690|PROCEDURE|Fingerstick cholesterol test|A finger stick draws approximately four drops of blood. The total cholesterol (TC), High Density Lipoprotein Cholesterol (HDL-C), Triglycerides, Low Density Cholesterol (LDL-C), and Glucose tests are done.
223626858|NCT02588690|OTHER|Atherosclerosis Cardiovascular Disease Risk assessment|"This Risk Estimator enables estimation of 10-year and lifetime risks for atherosclerotic cardiovascular disease (ASCVD), defined as coronary death or nonfatal myocardial infarction, or fatal or nonfatal stroke, based on the Pooled Cohort Equations and lifetime risk prediction tools. The Risk Estimator is intended for use in those without ASCVD with a LDL-cholesterol \<190 mg/dL.~The information required to estimate ASCVD risk includes age, sex, race, total cholesterol, HDL cholesterol, systolic blood pressure, blood pressure lowering medication use, diabetes status, and smoking status."
223626859|NCT02588690|PROCEDURE|Blood pressure measurement|Blood pressure measurement
223626860|NCT06292169|PROCEDURE|Pectoralis Minor Release|The pectoralis minor is a muscle on the anterior chest wall attaching to the coracoid process. In the group undergoing pectoralis minor release, through the same deltopectoral incision that will not be extended or different as compared to the RSA only group, the pec minor will be exposed on the medial aspect of the coracoid at the upper part of the incision. It will be cut from its insertion on the coracoid while being careful to protect any neurovascular structures.
223626861|NCT06292169|PROCEDURE|RSA|RSA is the current Standard of Care (SOC)
223626862|NCT05234411|OTHER|Evaluation of ketogenic diet impact on ketonemia|Ketonemia and glycemia levels monitoring during different phases of menstrual cycles
223626863|NCT00002403|DRUG|Zintevir|
223626864|NCT00316537|DRUG|ATG002 (study drug)|
223626865|NCT06103396|BIOLOGICAL|Transplantation of autologous MSCs in nonunion fracture|"At surgery, fibrotic tissue is removed from the nonunion sites. MSCs/Col/PRP clots are implanted in the site of nonunion.~Patients received conventional orthopedic treatment as they needed (osteotomy, external and/or internal fixation systems, etc.)"
223626866|NCT06103396|BIOLOGICAL|Transplantation of allogeneic MSCs in nonunion fracture|"At surgery, fibrotic tissue is removed from the nonunion sites. MSCs/Col/PRP clots are implanted in the site of nonunion.~Patients received conventional orthopedic treatment as they needed (osteotomy, external and/or internal fixation systems, etc.)"
224215774|NCT05353491|BEHAVIORAL|Standard Thinking Healthy Program|This intervention paper-based manual delivered by lady health workers ie government employed community health workers with health training background.
224215775|NCT05491278|DRUG|Fospropofol disodium for injection|Fospropofol disodium for injection continuous infusion to reach a RASS score of -3 to 0. Remifentanil continuous infusion of 4 to 9 ug/kg/h for. The dosage adjustment plan was determined by the attending physician. Whether to use other sedative drugs is up to the attending physician.
223626867|NCT01259817|DRUG|PEGASYS|Patient will start at 45 micrograms per week and gradually increase to 180 micrograms per week. Pegasys will be supplied in prefilled syringes and are to be given subcutaneously.
223626868|NCT01259817|DRUG|Aspirin|81 or 100 mg daily.
223626869|NCT01527123|DRUG|GSK2585823|CLDM1%/BPO3%
223626870|NCT05719649|DIETARY_SUPPLEMENT|Lactic acid bacteria NTU 101|"One NTU 101 Lactic Acid Bacteria Vegetable Capsule a day for a total of 12 weeks.~Product ingredients: microcrystalline cellulose, corn starch, NTU 101 Lactobacillus paracasei subsp. paracasei NTU 101 (1.8 x 10\^10 CFU); capsule shell composition: HPMC (hydroxypropyl methylcellulose), purified water, titanium dioxide, gellan gum."
223626871|NCT05719649|DIETARY_SUPPLEMENT|Placebo|Maltodextrin was used as a placebo
223626872|NCT04350281|DRUG|Interferon Beta-1B|Daily subcutaneous injection of interferon β-1b 1mL (0.25mg; 8 million IU) consecutively on day 1 to day 3
223626873|NCT04350281|DRUG|Hydroxychloroquine|Hydroxychloroquine 800mg on day 1, then 400mg daily for 2 days
223626874|NCT01213394|DRUG|mycophenolate mofetil|"Introduction of CellCept or increase in the dose of CellCept to a maximum of 2 g/day. In patients not already receiving CellCept, azathioprine (AZA), enteric-coated mycophenolate sodium (EC-MPS) or sirolimus (SRL) will be discontinued and replaced by CellCept in divided doses to a maximum of 2 g/day. CNI doses will be reduced to conform to the target trough levels in the low-dose CNI arms of the ELITE-Symphony study +/- steroid dose reduction. Any CNI dose change will require measurement of CNI trough levels at 7 days post dose change +/- 3 days.~Target CNI trough levels in the Symphony study:~* Low-dose CsA: Initial oral dose of 1-2 mg/kg bid, to achieve a target trough level of 50-100 ng/mL.~* Low-dose TAC: Initial oral dose of 0.1 mg/kg/day divided into two doses\* with a target trough level of 3-7 ng/mL (\*Advagraf may also be used at a dose of 0.1 mg/kg once daily with a target trough level of 3-7 ng/mL)"
223626875|NCT01213394|OTHER|standard immunosuppression|Current immunosuppressive therapy will be maintained throughout the study unless a change is required for safety reasons.
224215776|NCT05491278|DRUG|Propofol|Propofol for injection continuous infusion to reach a RASS score of -3 to 0. Remifentanil continuous infusion of 4 to 9 ug/kg/h for. The dosage adjustment plan was determined by the attending physician. Whether to use other sedative drugs is up to the attending physician.
224317168|NCT04230902|BIOLOGICAL|Microfragmented Adipose Tissue Transplant|Autologous Microfragmented Adipose Tissue derived using Lipogems® Kit
224317169|NCT04230902|DRUG|Corticosteroid injection|intra-articular knee injection of corticosteroid
223626876|NCT05967598|DEVICE|Noninvasive transcutaneous auricular vagus nerve stimulation at 100Hz|Noninvasive electrostimulation will be applied to the left cyma conchae through the Nemos® electrode with the following parameters: square-shaped pseudobiphasic pulse, interpulse duration 80μs, pulse width 300μs, pulse intensity 0,1mA above the perceptual threshold at 100Hz. The intensity for each separate stimulation will be adjusted for each participant at the beginning of the experiment
223626877|NCT05967598|DEVICE|Noninvasive transcutaneous auricular vagus nerve stimulation at 25Hz|Noninvasive electrostimulation will be applied to the left cyma conchae through the Nemos® electrode with the following parameters: square-shaped pseudobiphasic pulse, interpulse duration 80μs, pulse width 300μs, pulse intensity 0,1mA above the perceptual threshold at 25Hz. The intensity for each separate stimulation will be adjusted for each participant at the beginning of the experiment.
223626878|NCT05967598|DEVICE|Sham cyma conchae stimulation|The electrode will be placed at the cymba conchae location, however no electrical current will be applied. All other experimental conditions will be the same as for the active taVNS stimulation.
223626879|NCT04262700|DEVICE|LifeScan's new BGMS|LifeScan new Blood Glucose Monitoring System (BGMS)
223626880|NCT02240485|BEHAVIORAL|Integrative Couple Treatment for Pathological Gambling (ICT-PG)|"The experimental couple treatment is offered over 8 to 12 sessions of 90 minutes. The couple treatment called (Integrative Couple Therapy for Pathological Gambling - ICT-PG) is inspired by the Alcohol Behavior Couple Therapy from Epstein and McCrady, to which the team added diverse components to adjust to gamblers. During the sessions, the focus is on a) reducing/stopping gambling behaviors, b) helping the partner to stop behaviors facilitating gambling habits and rise the frequency of behaviors incompatible with gambling habits and c) improve marital components (communication, sharing positive moments, negotiation, mutual support)."
223626881|NCT02240485|BEHAVIORAL|Usual individual/group treatment|The control group receive individual or group treatment as already offered by the specialized centers in addiction.Their partner can receive individual intervention if desired.
223626882|NCT00953667|DRUG|Immediate Release Niacin, Extended Release Niacin, Endotoxin|Subjects receive a one-time 1000mg dose of immediate release Niacin (Niacor pills), a one-time 1000mg dose of extended release Niacin (Niaspan pill) and one-time 1ng/kg injection of endotoxin (LPS).
223626883|NCT00213863|DEVICE|Vocal fold medialization (thyroplasty) prosthesis by insertion of a new implant allowing very easy and quick setting|The porous titanium prosthesis is implanted under local anaesthesia. Neck incision is performed in order to expose the thyroidal cartilage. A window is then opened in this cartilage, and the implant is placed in contact with the vocal muscles. The patient is then asked to speak in order to achieve the implant best setting.
224215777|NCT00995332|DRUG|Cytarabine, all-trans retinoic acid, valproic acid|ATRA: 22.5 mg/m2 twice daily for 2 weeks every third month Valproic acid: continuous therapy, dosage guided by serum levels Cytarabine: 10 mg/m2 once daily for up to 10 days every third month
224215778|NCT04808765|PROCEDURE|Immediate Breast reconstruction|immediate mastectomy with breast reconstruction with implants or expanders
224215779|NCT02440932|DIETARY_SUPPLEMENT|Phenylketonuria-type diet|Breakfast, lunch and open buffet dinner
224215780|NCT02440932|OTHER|Normal (control) diet|Breakfast, lunch and open buffet dinner
223763349|NCT02635191|DRUG|Tailored Group|All the patients who enrolled in this arm will be received endoscopy followed by biopsy for antimicrobial susceptibility testing and cytochrome P450 isoenzyme 2C19 genotype. 10 days tailored therapy will be given including one Proton Pump Inhibitor ( Rabeprazole0.4-0.5mg/kg.d,bid. or Esomeprazole0.8-1.0mg/kg.d,bid) and two antibiotics (Amoxicillin30-50mg/kg.d bid, Clarithromycin15-20mg/kg.d bid, Metronidazole15-20mg/kg.d bid ) based on the cytochrome P450 isoenzyme 2C19 genotype and the antimicrobial susceptibility.
223763350|NCT02635191|DRUG|Standard group|All the patients who enrolled in this arm will be treated by Omeprazole(0.8-1.0mg/kg.d,bid), Amoxicillin (30-50mg/kg.d bid)and Clarithromycin (15-20mg/kg.d bid) .
223763351|NCT01828372|OTHER|additional blood withdrawals|Blood withdrawals by either venous puncture or placement of permanent venous catheter.
223763352|NCT00558103|DRUG|lapatinib|Oral administration
223763353|NCT00558103|DRUG|Pazopanib|Oral administration
223763354|NCT04947332|PROCEDURE|Auto-inoculation|A wart will be excised from the body, minced and will be inoculated in a subcutaneous pocket on forearm.
224215781|NCT05166655|BEHAVIORAL|Movement task|Computer task with experimental conditions manipulating sensory and motivation cues for movement.
224215782|NCT00227656|BIOLOGICAL|PEG-interferon alfa-2a|Once a week subcutaneous injection for 21 days, beginning at 180 mcg per week. Repeated for additional 21 days to begin at the same time as repeat 21 day Capecitabine cycle.
224215783|NCT00227656|DRUG|Capecitabine|1000 mg/m\^2 twice daily during first 14 days of each 3-week cycle (2 weeks on, 1 week rest).
224215784|NCT04785833|DRUG|T cell injection targeting CD7 chimeric antigen receptor|Drug name: T cell injection targeting CD7 autologous chimeric antigen receptor. Package specification: 10-50ml bag, 1-4 bags / person, which is determined according to the body weight of the subject and the effective content of cell preparation
223626884|NCT03320668|OTHER|Otago Exercise Program (OEP)|"A nurse/physiotherapist supported by an instructor-trained professional will give Otago Exercise Program (OEP) education to 10-people groups in 5 sessions (1st, 2nd, 4th and 8th week and one reinforcement session after 6 months). Telephone calls to participants will be made during non-training months (following a predefined telephonic interview protocol) to follow up. The OEP reduces the number of falls and fall-related injuries, improving balance and strength, confidence in performing everyday activities without falling. Whilst it has been shown to be effective in 4 controlled trials in New Zealand, it has not been tested in a primary care setting in Spain for feasibility, impact, acceptability and cost-effectiveness."
223626885|NCT00391885|DEVICE|Closed-loop anesthesia system|
223626886|NCT04819945|DEVICE|GATT-Patch|Use of GATT-Patch for minimal, mild or moderate bleeding sites in open liver surgery
223626887|NCT03038321|DRUG|sofenacin|solifenacin 10 mg, 6 hours after IVI of BCG and continue for another 2 days post instillation
224215785|NCT06562530|DEVICE|high tone power therapy|sessions are applied for 30 minutes, 3 times per week, for 3 months
224215786|NCT06562530|DEVICE|transcutaneous electrical nerve stimulation (TENS)|sessions are applied for 30 minutes, 3 times per week, for 3 months
224215787|NCT06562530|OTHER|selected physical therapy program|sessions are applied for 1 hour, 3 times per week, for 3 months in form o fstretching exercise , range of motion exercises , conventional gait training progressive resistance exercises
224215788|NCT01760694|OTHER|Multi-Modality; IORT, Surgery, Radiation, Chemotherapy|
224215789|NCT03439293|DRUG|Ixazomib|Ixazomib capsule.
224215790|NCT03439293|DRUG|Daratumumab|Daratumumab IV infusion.
224215791|NCT03439293|DRUG|Dexamethasone|Dexamethasone tablets.
223626888|NCT03038321|DRUG|Tavanic|levofloxacin 500 mg, 6 hours after IVI of BCG and continue for another 2 days post instillation.
223626889|NCT03038321|DRUG|Xefo|lornoxicam 8 mg, 6 hours after IVI of BCG and continue for another 2 days post instillation.
223626890|NCT03602677|DEVICE|ICG fluorescence imaging|The use of indocyanine green fluorescence imaging as an addition to standard surgical procedure.
223626891|NCT00475670|DRUG|Trastuzumab|4 mg/kg i.v. loading dose on Day 1, followed by 2 mg/kg i.v. weekly; or 8 mg/kg i.v. loading dose, followed by 6 mg/kg i.v. every 3 weeks until disease progression, unacceptable toxicity, withdrawal or death.
223626892|NCT00475670|DRUG|Taxane (docetaxel or paclitaxel)|Docetaxel 100 mg/m2 i.v. every 3 weeks, or paclitaxel administered in a dose of 75 mg/m2 i.v. weekly or 175 mg/m2 i.v. every 3 weeks for at least 18 weeks, or more at the discretion of the investigator. Choice of taxane at the discretion of the investigator. Taxane may be administered at the same time, or 24 hours after, administration of trastuzumab.
223626893|NCT05407389|DRUG|KT-301 (formerly US-APR2020)|KT-301 (formerly US-APR2020) will be administered orally at 2 capsules per day (a total dose of 90 Billion CFUs per day of the Live BioTherapeutic).
223626894|NCT06576505|PROCEDURE|peripheral blood sampling, bronchoscopy, upper airway and faeces sampling|"1. Repeated peripheral blood sampling at diagnostic and follow-up visits, in total a maximum of 400 ml/year but never more than 100 ml/ month.~2. Upper airway sampling wih swab, aspirate and curettage, maximum 3 times/year.~3. Faeces sampling, the patients do this themselves and leave it to the research unit, maximum 3 times/year.~4. Bronchoscopy with lavage and a maximum of 6 mucosal biopsies before and after 6-12 months treatment."
223626895|NCT04949191|DRUG|Pemigatinib|Pemigatinib tablets taken by mouth once daily as per protocol
223626896|NCT04949191|DRUG|Retifanlimab|Retifanlimab is administered over 60 minutes once every 4 weeks (Day 1 of a 28-day cycle)
223626897|NCT04949191|DRUG|Pembrolizumab|Commercially labeled products
223626898|NCT03011788|DRUG|Golytely Oral Solution|Bowel purge prior to,colonoscopy
223626899|NCT01460966|PROCEDURE|Filtrap™ + Thrombus aspiration catheter|Combination of distal protection device (Filtrap™ )and thrombus aspiration catheter
224215792|NCT00493181|DRUG|Interleukin-11 (IL-11 or Neumega)|10 mcg/kg under the skin (usually of the arms, legs or abdomen) three times weekly. If the treatment is well tolerated but there is not enough of a platelet improvement, the dose and frequency of injections may be increased.
224215793|NCT00660049|DEVICE|SNaP Advanced Wound Care System|Application of negative pressure device daily per instructions
224215794|NCT00660049|OTHER|SNaP|Daily use
224215795|NCT00660049|OTHER|SNaP|Daily application per protocol
223763355|NCT05886959|OTHER|Session 1: How We Evolved - Threat, Impulse, and Soothing Systems|"The practice of Breath break with kindness will be applied for 5 minutes. Afterwards, 15 minutes of information on threats, impulses and soothing systems, A safe place application for 11 minutes, Courtesy meditation for 10 minutes. After each application, 10 minutes of feedback will be received from the participants."
223763356|NCT05886959|OTHER|Session 2: Threat and Self-Compassion|"The practice of breathing with kindness will be done for 7 minutes. The practice of Building a compassionate relationship with resilience will be held for 12 minutes, and the practice of Kindness meditation: a benevolent will take place for 11 minutes. A hand over your heart application will be made for 3 minutes and A compassionate comrade application will be done for 10 minutes. After each application, 3 minutes of feedback will be received from the participants."
223763357|NCT05886959|OTHER|Session 3: Unraveling the Knots of Desire and Patterns|"The practice of breathing with kindness will be done for 7 minutes. Building a compassionate relationship with desire 12 minutes, Guided meditation to discover the inner pattern 10 minutes and Courtesy meditation: a good friend 11 minutes. Except for the breath break with kindness application, 3 minutes of feedback will be received from the participants after each application"
223763358|NCT05886959|OTHER|Session 4: Internalizing compassion|"The pretend-to-be practice for the participants to observe themselves will be made for 10 minutes. The practice of internalizing compassion will be done for 7 minutes, kindness meditation: a neutral person practice for 10 minutes, and kindness towards your body for 10 minutes. After each application, 3 minutes of feedback will be received from the participants."
223763359|NCT05886959|OTHER|Session 5: Me and others - Expanding the circle|"The a compassionate letter practice with the participants will continue for 15 minutes. meditation: the 'difficult' person 8 minutes, compassion and breathing: yourself 10 minutes and compassionate breathing: others 7 minutes. A compassionate break application is performed for 7 minutes."
224317170|NCT06551870|OTHER|Physical activity|The complexity of the games will increase as the levels of the sports games advance, which leads to faster movements with greater demands to progress in the sequence of the games, which allows reaching increases in intensity.
224317171|NCT05518188|BIOLOGICAL|MELPIDA|MELPIDA, a recombinant serotype 9 adeno-associated virus (AAV) encoding a codon-optimized human AP4M1 transgene
223626900|NCT01460966|PROCEDURE|Thrombus aspiration catheter|Thrombus aspiration catheter only
224317172|NCT03672253|DRUG|CAR-T Re-treatment|Patients will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) or use their mononuclear cells that preserved in the laboratory for the production of CAR-T cells. After a pre-treatment lymphodepletion therapy, patients will receive the re-treatment of CAR-T therapy by intravenous injection.
224317173|NCT01013662|PROCEDURE|glycemic control|exogenous insulin
223626901|NCT02483780|BEHAVIORAL|Storytelling|The intervention will center on stories about living with hypertension, with patients speaking in their own words.
223626902|NCT01742273|DRUG|Vitamin K1|Vitamin K1 to slow vascular calcification
223626903|NCT02121379|BEHAVIORAL|pulmonary rehabilitation|
224317174|NCT02871323|BIOLOGICAL|Durvalumab|Given IV
224317175|NCT02871323|OTHER|Laboratory Biomarker Analysis|Correlative studies
223626904|NCT05043350|DRUG|Loratadine|107 patients will receive standard pharmacotherapy according to the treatment protocols of the National Committee of COVID-19 in addition to IV famotidine 40 mg twice daily (Manufactured by AMOUN Pharmaceutical Company) until the day of discharge + LORATIDINE (Manufactured by AMOUN Pharmaceutical Company)Oral: 10 mg once daily.
223626905|NCT05043350|DRUG|Famotidine|107 patients will receive standard pharmacotherapy according to the treatment protocols of the National Committee of COVID-19 in addition to IV famotidine 40 mg twice daily (Manufactured by AMOUN Pharmaceutical Company) until the day of discharge + LORATIDINE (Manufactured by AMOUN Pharmaceutical Company)Oral: 10 mg once daily.
223626906|NCT03659799|DRUG|Insulin FiAsp|An insulin bolus of FiAsp will be given 5 minutes before breakfast
223626907|NCT03659799|DRUG|Insulin Aspart|An insulin bolus of Aspart will be given 5 minutes before breakfast
223626908|NCT03659799|OTHER|60-minutes postprandial exercise|A 60-minute exercise at 60% of VO2 peak will be performed 60 minutes after breakfast
223763360|NCT05886959|OTHER|Session 6: Growing happiness|"The practice of Revisiting the good is carried out for 10 minutes with the participants. Forgive yourself, wish for forgiveness, forgive others, gratitude practices will be held for 5 minutes each and will take 20 minutes in total. Courtesy meditation: groups and all beings will be practiced for 10 minutes. After each application, 3 minutes of feedback will be received from the participants."
223763361|NCT05886959|OTHER|Session 7: Weaving Wisdom and Compassion into Daily Life|"Participants will be given 10 minutes to choose a day in their life and allow a few minutes to pause mindfully. The practice of a breather for wise and compassionate action is 10 minutes, the practice of calmness meditation is 8 minutes, and the practice of sharing the joy meditation is 8 minutes. After each application, 3 minutes of feedback will be received from the participants."
223763362|NCT05886959|OTHER|Session 8: Living with the Heart|"The participants are told about the applications they can apply for, where they need help to develop compassion towards self-healing skills, and the entire training will be evaluated for 20 minutes. The river of life application is carried out for 20 minutes. 10 minutes of feedback will be received after the application."
223763363|NCT02409862|DRUG|Oxytocin Spray|This group will receive the single dose of 24 IU oxytocin, self-administered intranasally (IN). Prior to administration a saliva sampling will be done. Afterwards, they will participate in the Choices Study during EEG and eye tracking recording.
223763364|NCT02409862|DRUG|Placebo Spray|This group will receive the single dose of 24 IU placebo, self-administered intranasally (IN). Prior to administration a saliva sampling will be done. Afterwards, they will participate in the Choices Study during EEG and eye tracking recording.
223763365|NCT03759067|DRUG|clopidogrel 75mg|clopidogrel once daily 75mg
223763366|NCT03759067|DRUG|Clopidogrel 300 mg|clopidogrel 300mg reloading
223763367|NCT03759067|DRUG|clopidogrel 600mg|clopidogrel 600mg loading
223763368|NCT01547416|DRUG|epidural 250mL of 0.2% ropivacaine and 2 μg/mL of fentanyl, 5 mL/hr continuous infusion and 0.5 mL bolus dose|"Before the induction of anesthesia, epidural catheter was inserted in group GE at T8/9, T9/10, or T10/11 interspinous space with a 17-gauge Tuohy needle in lateral decubitus position and advanced 5 cm cephalad. .~Epidural analgesia was maintained using the patient-controlled analgesia technique containing 250 mL of 0.2% ropivacaine and 2 μg/mL fentanyl with setting of 5 mL/hr for continuous infusion and 0.5 mL of bolus dose. Lockout time was set to 15 min.~General anesthesia was induced with 2 mg/kg of propofol and 50 mg of rocuronium. After tracheal intubation, anesthesia was maintained with sevoflurane. All the patients were ventilated with controlled mode of 8 mL/kg of ideal body weight and respiratory rate was adjusted to maintain end-tidal carbon dioxide between 35-40 mmHg."
224317176|NCT01516918|DRUG|VX-222|tablet, 400-mg twice daily
224317177|NCT01516918|DRUG|telaprevir|tablet, 1125-mg twice daily
224317178|NCT01516918|DRUG|ribavirin|tablet, 1000-mg per day for subjects weighing \<75 kg and 1200 mg per day for subjects weighing ≥75 kg, twice daily
223626909|NCT03659799|OTHER|120-minutes postprandial exercise|A 60-minute exercise at 60% of VO2 peak will be performed 120 minutes after breakfast
223626910|NCT04268082|DEVICE|Visual biofeedback with the use of sensorized insoles|Between the 4th and the 10th day post surgery, both groups performed the same rehabilitation protocol. The experimental group was re-educated to the correct gait dynamics by wearing the sensorized insoles and by using a specific software's graphical interface as a visual biofeedback.
223626911|NCT04268082|OTHER|Standard rehabilitation based on physiotherapist's verbal instructions|Between the 4th and the 10th day post surgery, both groups performed the same rehabilitation protocol.The Control group did not wear the insoles, but it carried out the rehabilitation programme under the physiotherapist supervision and with his verbal feedbacks.
223626912|NCT00523757|DRUG|Spironolactone|
223626913|NCT00523757|DRUG|Placebo|
223626914|NCT05071170|BEHAVIORAL|Ad libitum energy intake|Investigate post meal satiety and subsequent post meal energy intake according to degree of food processing and eating behaviour
223626915|NCT06052228|OTHER|Assessment Group|Evaluation forms will be applied to the participant who meets the inclusion criteria by face-to-face interview method. The sociodemographic information of the participants and the time taken to answer the questions in the questionnaires will vary according to each participants but will take approximately 45 minutes. The second interview will be conducted with the patients for test-retest application at 1-week intervals.
223763369|NCT01547416|DRUG|no epidural drug administered|"Patients allocated to general anesthesia group and DID NOT receive epidural anesthesia.~General anesthesia was induced with 2 mg/kg of propofol and 50 mg of rocuronium. After tracheal intubation, anesthesia was maintained with sevoflurane. All the patients were ventilated with controlled mode of 8 mL/kg of ideal body weight and respiratory rate was adjusted to maintain end-tidal carbon dioxide between 35-40 mmHg."
223763370|NCT01266213|DRUG|Fulvestrant plus Goserelin|Fulvestrant s.c. plus Goserelin s.c.
223763371|NCT01266213|DRUG|Anastrozole plus Goserelin|Anastrozole 1 mg p.o. plus Goserelin s.c.
223763372|NCT01266213|DRUG|Goserelin|Goserelin s.c.
223763373|NCT01458327|DRUG|Midomafetamine|125 mg MDMA followed by 62.5 mg MDMA 1.5 to 2.5 hours later
223763374|NCT01458327|BEHAVIORAL|Therapy|Non-directive therapy
223763375|NCT06420154|BIOLOGICAL|anti-CD19-CAR-T cells|"The subjects received infusions of anti-CD19 CAR-T cells following completion of lymphodepleting preconditioning chemotherapy.~Dosage：1×10\^5 cells/Kg; 3×10\^5 cells/Kg; 1×10\^6 cells/Kg~frequency：single infusion"
224317179|NCT01516918|BIOLOGICAL|peginterferon-alfa-2a|subcutaneous injection, 180-mcg, once weekly
224317180|NCT03872687|DEVICE|single tufted brush with IDB|Subjects in this group will receive a single tufted brush and interdental brushes of an appropriate size that will fit the interdental spaces around the implant.
224317181|NCT03872687|DEVICE|interdental brushes|Subjects in this group will only receive interdental brushes
224317182|NCT03149796|OTHER|laboratory blood tests|Serum concentrations of leptin, adiponectin, resistin, interleukin-6 and high sensitivity C reactive protein were measured by ELISA in both study groups
223626916|NCT06360146|OTHER|Early mobilisation|Breathing exercises, inspiratory muscle strength, postural drainage, functional exercise (stand up and sitting down on the chair, walking inward, back-ward ,and sideways), weight shifts from left to right, step up inside the patch , one leg stand, squatting leaning against wall) for three times per the day and repetition fifteen times (3 times per day for 15 repetition) and supervised walking with increments of 2 minutes, as tolerated up to 6 minutes or more at the morning, afternoon, evening and at night.
223626917|NCT02707068|BEHAVIORAL|Quality Of LIfe Tool for IBD (QOLITI)|The cognitive-behavioural therapy (CBT)-inspired manual will contain several chapters each of which addresses a different topic with information, guidance in setting goals for behaviour change and accompanying tasks to aid implementation which will be completed at home in the participant's own time. Key themes are likely to include symptom management, dealing with social implications of the disease and interacting effectively with healthcare professionals among others. Each chapter will address a theme providing information, sign posting to appropriate organisations, step-by-step tasks and quotes from pwIBD among others, drawing on relevant therapeutic approaches for self-management including CBT and certain elements of Acceptance and Commitment Therapy.
223626918|NCT01988714|OTHER|(TCT) plus evidence-based SE|Targeted cognitive computer training (TCT) plus evidence-based SE in a community setting
223626919|NCT01988714|OTHER|(CG) plus evidence-based SE|(CG) plus evidence-based SE
223626920|NCT02913482|DRUG|Risdiplam|Risdiplam will be administered orally.
223626921|NCT03360266|COMBINATION_PRODUCT|Sodium Fluoride with CPP-ACP varnish|for children with ECC, this varnish effectively remineralizes the white spot lesion
223626922|NCT03360266|COMBINATION_PRODUCT|sodium fluoride with ACP varnish|for children with ECC, this varnish effectively remineralizes the white spot lesion
223626923|NCT03360266|DRUG|5% Sodium Fluoride Varnish|ffor children with ECC, this varnish effectively remineralizes the white spot lesion
223626924|NCT06421857|PROCEDURE|suturing|laparoscopic cystectomy for endometrioma and hemostasis was done using suturing
223626925|NCT06421857|PROCEDURE|bipolar electrocoagulation|laparoscopic cystectomy for endometrioma and hemostasis was done bipolar electrocoagulation
223626926|NCT04183114|BIOLOGICAL|Measles-Rubella vaccine Bio Farma|MR vaccine produced by Bio Frama with 3 consecutive batches
223626927|NCT04183114|BIOLOGICAL|MR Vaccine SII|MR Vaccine produced by SII (Already registered in Indonesia)
223626928|NCT04508166|DRUG|Dexmedetomidine|Volunteers receive a single dose of dexmedetomidine sublingually at scheduled bedrest in the sleep laboratory
223763376|NCT04999046|DEVICE|NaviFUS System|FUS treatment will be conducted with following exposure parameters: intracranial spatial-peak temporal-average intensity (ISPTA) ceiling level: 2.8 W/cm2 (the focused ultrasound intensity in brain area considering transcranial attenuation), burst length: 3 ms, duration: three consecutive 5-minute FUS exposures with two 5-minute intermission intervals.
223763377|NCT04035304|OTHER|Mindfulness Coach|"Mindfulness Coach provides 4 primary treatment components: 1) psychoeducation about PTSD and Mindfulness (e.g., What is Mindfulness?, Why Practice Mindfulness?, Mindfulness for Veterans, Benefits of Mindfulness for PTSD, Practice Challenges with PTSD, and PTSD Symptoms During Practice), 2) self-monitoring tools for tracking mindfulness practice, 3) 9 audio- guided mindfulness exercises (e.g., Mindful Breathing, Body Scan, Clouds in the Sky, etc.), and 4) reminders to regularly practice mindfulness exercises."
224215796|NCT02991833|OTHER|A New Incontinence Care Product|The novel incontinent care product is dressed and removed removed by opening both sides. In the part surrounding the waist and thights of the novel incontinent care product flexibility is achieved by planting rubber bien. When developing new incontinence care products was taken counselling from a faculty member from Department of Textile Engineering of one University Faculty of Engineering. The insurance policies was prepared for each patients attended to the study (Number: 481360).New care product is put on the experimental group. Perineal care was made to patients twice a day and after each defecation. After each perineal care, the novel incontinent care product was changed.
224215797|NCT02991833|OTHER|Diaper|In patients of the diaper group was used the optimum adult diaper (Pads, Linea TENA, SCA, Hygiene, Goteborg, Sweden) which was available in the market. Perineal care was made to patients twice a day and after each defecation. After each perineal care, the diaper was changed.
224215798|NCT05429853|DIETARY_SUPPLEMENT|Sondalis® HP 2 kcal (with or without fibre)|The participants will take the study product during the two months of the study.
223626929|NCT04508166|DRUG|Gamma-Hydroxybutyrate|Volunteers receive a single oral dose of gamma-hydroxybutyrate at scheduled bedrest in the sleep laboratory
223626930|NCT04508166|DRUG|Placebo|Volunteers receive an oral (saline) or sublingual (orodispersible tablet) at scheduled bedrest in the sleep laboratory
223626931|NCT04508166|BEHAVIORAL|Experimental Model Trauma Film|Each volunteer views experimental model trauma film before scheduled bedrest in the sleep laboratory. This video is ca. 15 minutes in duration and is composed of short (a few seconds to a few minutes) individual and unrelated scenes of violent death and injury of varying description. Six versions of the film without re-occurring scenes will be presented in balanced order across drug order conditions.
223626932|NCT04532671|OTHER|Poly ether ether ketone (PEEK)|PEEK has been used in dentistry so far in certain fields as for, removable and fixed dental prostheses, implants, and implant abutments as well as orthodontic devices, whereas in literature, it is mostly mentioned in relation to prosthetics. PEEK was predominantly processed out of CAD/CAM-supported milled out of prefabricated blanks. Producing dental restorations via Additive manufacturing is still hardly widespread
223626933|NCT04532671|OTHER|CADCAM Poly ether ether ketone (PEEK)|Increased demand for long-lasting restoration's properties have led to many improvements in the production techniques of posterior restorations such as CAD/CAM systems. This technique simplifies the production of indirect restorations and make it possible to use advanced materials as PEEK
223626934|NCT04532671|OTHER|indirect resin composite|CADCAM resin composite blocks using milling process
224215799|NCT04128449|DIETARY_SUPPLEMENT|docosahexaenoic acid|5 dragees every 24 hours
224215800|NCT04128449|DIETARY_SUPPLEMENT|Placebo|5 dragees every 24 hours
224215801|NCT04379388|BEHAVIORAL|Web + text smoking cessation intervention|Participants will receive referral to a quit smoking hotline and 12-week web and text-based smoking cessation intervention
224317183|NCT03977142|DIAGNOSTIC_TEST|Radical 7 Masimo Hemoglobin pulse co-oximeter non invasive monitor|Measure hemoglobin levels non invasively by pulse co-oximeter
223626935|NCT01983228|BEHAVIORAL|Intervention Condition|Intervention participants will complete 6 sessions of telephone coaching over a 10-12 week period, using a patient workbook with visual aids (e.g., diagram of the pain/inactivity cycle) and worksheets that they will complete during the counseling sessions. Participants are expected to receive approximately 180 minutes of total therapist time during the study.
223626936|NCT03155165|DEVICE|Retroview™ colonoscope|The colonoscopy will be performed twice, with 2 different scopes, in tandem, by 2 endoscopists trained on retroflex withdrawal. First a conventional HD colonoscope with I-Scan will be used following the standard withdrawal technique and then the second endoscopist blinded to the first colonoscopy results, will perform the second colonoscopy using the Retroview™ scope with a combining withdrawal (retroflexed + standard withdrawal). The endoscopist that will perform each colonoscopy will be chosen randomly. After the examination, the endoscopist will fill a questionnaire detailing each polyp / adenoma found including the size and location.
223626937|NCT04338672|OTHER|COVID-19 Pandemic|Exposure: the novel coronavirus disease (Covid-19) outbreak
223626938|NCT04472052|OTHER|appendectomy|Surgical standard treatment for acute appendicitis All patients receive preoperative single-shot antibiosis, usually 2000 mg cefotaxime combined 500 mg metronidazole. Appendectomy is performed usually within 24 h of admission in patients with acute appendicitis. The laparoscopic appendectomy using the 3-trocar technique represents the surgical standard. In uncomplicated or non-perforated appendicitis, drainage is generally not required. Wounds are closed intra-cutaneous with absorbable sutures. Patients without postoperative complications are discharged home two days after surgery.
223626939|NCT06032910|DEVICE|Surgical mesh|Prophylactic synthetic non-absorbable keyhole mesh placement upon construction of ileal conduit.
224215802|NCT01492712|DRUG|Propofol|Patients in the low-high-low group will receive an infusion of propofol with an initial blood target concentration of 2 mcg/ml. After 15 minutes the target will be increased to 5 mcg/ml and after a further 15 minutes the target will be reduced back to 2 mcg/ml for a further 15 to 30 minutes.
224215803|NCT01492712|DRUG|Propofol|Patients in the high-low-high group will receive an infusion of propofol with an initial blood target concentration of 5 mcg/ml. After 15 minutes the target will be reduced to 2 mcg/ml and after a further 15 minutes the target will be increased back to 5 mcg/ml for a further 15 to 30 minutes.
223763378|NCT02045771|BEHAVIORAL|Behavioral Activation|"Behavioral activation is a therapy, which has been shown to be quite effective in the treatment of depression (Kanter, Manos et al. 2010; Martell, Dimidjian et al. 2010). Although previous therapies have focused more on the cognitive element, behavioural activation on its own has also been significantly effective for depression treatment (Jacobson, Dobson et al. 1996). The treatment works by increasing behaviours that help a patient with depression interact with an environment and providing consequences to positively reinforce antidepressant behaviour (Martell, Dimidjian et al. 2010)."
223763379|NCT02045771|BEHAVIORAL|Support Group|In addition to usual care, the control group will be offered a support group therapy format delivered at the same place, same visit frequency and duration of program as the intervention group. This support group is intended to simulate the intervention group format to minimize risk of biased estimate of BA effectiveness by reducing the potential placebo effect which can be seen due to frequent clinic visits and having additional attention beyond usual care.
224215804|NCT00811265|DEVICE|ExAblate MRgFUS for prostate cancer|Simulated use of ExAblate MRgFUS system
224215805|NCT05946642|DRUG|Sulphadoxine-Pyrimethamine/Amodiaquine|Co-blister packaging of sulfadoxine-pyrimethamine (SP) dispersible tablets administered on the first day and amodiaquine (AQ) dispersible tablets administered once daily for three days. The dose of SPAQ will be determined according to the child's age.
224215806|NCT05946642|DRUG|Dihydroartemisinin/Piperaquine (DP) plus Ivermectin (IVM)|"DP will consist of tablets containing 320/40 mg and 160/20 mg piperaquine/dihydroartemisinin per tablet. A full course of DP should be administered in accordance with the manufacturer's instructions, once a day for 3 days, according to body weight. DP should be taken orally with water and without food. It will be given in association with Ivermectin.~Ivermectin (IVM) will be available as 3 mg or 6 mg tablets to be administered at the doses of 300- 400μg/kg/day for 3 days (to the nearest whole tablet). IVM should also be taken with water on an empty stomach."
223626940|NCT00768612|DRUG|SCA-136 50mg/day|
223626941|NCT00768612|DRUG|SCA-136 150 mg/day|
223626942|NCT00768612|DRUG|SCA-136 300mg/day|
224215807|NCT01356186|BEHAVIORAL|Post Admission Cognitive Therapy (PACT)|Individual psychotherapy; 6 sessions; 60-90 minutes in duration; administered over preferably 3 days of psychiatric hospitalization
224215808|NCT05408533|DEVICE|2-Way Foley Urethral Urinary Catheter|Comparing two types of catheter (silver-coated silicone versus silicone) after Pelvic Reconstructive Surgery (PRS) to compare Urinary Tract Infection (UTI) rates
223626943|NCT00768612|DRUG|Risperidone 4mg/day|
223626944|NCT03028298|DRUG|Low dose sildenafil citrate|
223626945|NCT03028298|DRUG|High dose sildenafil citrate|
223626946|NCT00788463|DRUG|Intranasal Beclomethasone aerosol|Beclomethasone aerosol intranasal, 100ug each nostril, twice daily for 6 months.
223626947|NCT00788463|DRUG|Intranasal Beclomethasone spray|Beclomethasone spray intranasal, 100ug each nostril, twice daily for 6 months.
223626948|NCT00830544|DRUG|Neoadjuvant chemotherapy|Docetaxel 75 mg/m2, day 1 Epirubicin 80 mg/m2, day 1 Cyclophosphamide 500 mg/m2, day 1 Navelbine 25 mg/M2 in 250 cc NS over 60 min on day 1 and day 8 Bevacizumab 5 mg/kg in 100 cc NS over 90 min day 1 and day 8 Capecitabine 825 mg/M2 p.o. bid from day 1-14. Trastuzumab
223626949|NCT00830544|DRUG|Chemotherapy|Neoadjuvant chemotherapy
223626950|NCT00830544|DRUG|Neoadjuvant chemotherapy|Experimental chemotherapy regimen
223626951|NCT05622630|PROCEDURE|Four-cell bath|Four-cell bath:Treatment with direct current
223626952|NCT05622630|PROCEDURE|Gravel bath|Gravel bath:In this procedure, the patients are given a footbath with heated stones (granules) of different sizes for a period of 20 minutes, during which the patients are encouraged to move their feet (and, if applicable, hands) evenly.
223626953|NCT00790426|DRUG|TKI258|
223626954|NCT02987231|PROCEDURE|CAF|Periodontal plastic surgery for root coverage by the trapezoidal flap
223626955|NCT02987231|DEVICE|ES|Local electric stimulation for 120 seconds, once a day for a week
223626956|NCT02987231|DEVICE|SHAM|Simulation of electric stimulation protocol. In Sham stimulation non current will be applied
223626957|NCT00443144|DRUG|recombinant human growth hormone|
223626958|NCT02003326|OTHER|Inflammatory markers|
223626959|NCT01140841|DRUG|Fipamezole ODT|Subjects take three daily doses of Fipamezole ODT, with each dose escalating from 30 to 60, 90, 120, 150 and up to 180 mg over 8 weeks.
223626960|NCT01140841|DRUG|Placebo|1 to 2 tablets three times per day to be taken according to the same schedule as the active study drug.
223626961|NCT06317558|DRUG|Neoadjuvant immunotherapy|Immune checkpoint inhibitors are used as neoadjuvant settings for NSCLC patients.
223626962|NCT06317558|DRUG|Other drugs for neoadjuvant treatment|Drugs other than immune checkpoint inhibitors are being used as a new adjuvant setting for patients with NSCLC.
223626963|NCT00878241|DEVICE|Compression Anastomosis Ring: CAR™ 27|Creation of anastomosis in colorectal surgeries using CAR™ 27
223626964|NCT01046565|DRUG|adapalene cream 0.1%|adapalene cream 0.1% - apply once daily on one side of the face for 3 weeks
224215809|NCT01086735|BIOLOGICAL|donor lymphocyte infusion|Donor T-cell transduction
224215810|NCT00760188|DEVICE|Cementless Oxford Partial Knee|Cementless Oxford Partial Knee Replacement
223763380|NCT04405609|DEVICE|ArmAssist|"The usability study protocol include 3 ArmAssist systems (2 designed for the left hand and one for the right hand) that could not be used in parallel because the aim of the study was to bring the systems to the home environment during part of the evaluation.~The usability study is carried out in two phases:~1. First phase: 5 weeks.~2. Second phase: 3 weeks. Each phase included a week of training at the Hospital or IMIBIC facilities with a physiotherapist, and then 2 weeks at the patient's home, being the first one with the physiotherapist supervision and the second one by their own with the possibility of physiotherapist remote support."
223763381|NCT03993938|DEVICE|PVI measurement|Masimo Radical-7® probe to be attached to patient's finger along with standard ASA monitors at the start of procedure. After placement of arterial line, stroke volume variation (SVV) and pulse pressure variation (PPV) to be recorded along with pleth variability index (PVI) every 5 minutes. Intraprocedure left atrial pressure (LAP) (v-wave and mean) to be recorded prior to and after MitraClip deployment. Data to be analyzed - age, sex, BMI; Preprocedure ejection fraction (EF), pulmonary artery pressure (PAP), rhythm, mitral regurgitation severity; heart rate, systolic blood pressure (SBP), diastolic blood pressure (DBP), mean arterial pressure (MAP) every 5 minutes; SVV, PPV, PVI every 5 minutes; LAP prior to mitraclip deployment; LAP after mitraclip deployment
223763382|NCT03164798|PROCEDURE|Conventional inpatient rehabilitation|comprehensive inpatient rehabilitation for 2 weeks
223763383|NCT04466475|BIOLOGICAL|Astatine At 211 Anti-CD38 Monoclonal Antibody OKT10-B10|Given IV
223763384|NCT04466475|DRUG|Melphalan|Given via infusion
223763385|NCT04466475|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo PBSC transplantation
224215811|NCT03143088|BEHAVIORAL|Medical clown|Blood pressure will be taken to children admitted to the pediatric emergency department with and without the presence of a medical clown.
224215812|NCT00897429|PROCEDURE|laboratory biomarker analysis|Correlative studies
223626965|NCT01046565|DRUG|adapalene lotion 0.1%|adapalene lotion 0.1% - apply once daily on the opposite side of the face for 3 weeks
223626966|NCT01813396|OTHER|joint mobilization plus massage|
223626967|NCT01813396|OTHER|joint mobilization/shoulder physical activity guide|
223626968|NCT01998230|DIETARY_SUPPLEMENT|early oral feeding|In the early oral feeding group, the patients are encouraged to intake liquid food on post operative day 1.
223626969|NCT03395483|OTHER|Haemodynamic monitoring|see Group description
223626970|NCT04400630|OTHER|Physical exercise|The experimental group will receive supervised physical exercise treatment by high-intensity interval training (HIT), alternating high and moderate intensities (20 min). The participants will exercise two non-consecutive days per week for 16 weeks under supervision by exercise specialists.
223626971|NCT04722614|OTHER|Music|Classic music hearing at amplitude approximately 60-80 dB using MP3 player connected to headphone with noise canceling property
223626972|NCT04722614|OTHER|Essential oil|Bergamot oil inhalation through a piece of cotton gauze (2 × 2 cm square shape) with 0.5 cc of bergamot oil. It will be attached to the collar of the patient's clothes gown, approximately 15 cm below their nose.
223626973|NCT04722614|OTHER|Control|The routine intensive care unit sedation protocol
224215813|NCT05001399|BEHAVIORAL|Holographic Memory Resolution® (HMR)|Clients will participate in Holographic Memory Resolution® (HMR) administered by a trained HMR practitioner. Clients will be introduced to relaxation techniques and safe scene identification. This exercise encourages the client to identify a place in which they feel safe and where nobody can be there without client's invitation. Clients will then describe the place and associated colors of the experience, how the colors move in their body, and how they move through their safe scene. The subsequent 2-3 sessions will continue to explore safe scene and color therapy.
224215814|NCT03743675|BEHAVIORAL|Diet-Induced Weight Loss|Diet-Induced Weight Loss: The goal of the diet intervention is to produce a weight loss of approximately 5-10% of body weight over the six-month period, which is consistent with the goals for obesity treatment outlined by the Academy of Nutrition and Dietetics (AND). According to the 2016 AND position paper for obesity-related interventions, this level of weight loss produces clinically significant reductions in biometrics (biochemical and anthropometrics measurements) and associated risk factors for chronic disease. Additionally, obese older adults who achieve weight loss intentionally through lifestyle changes experience improved physical function. This intervention will last for 6-months with bi-weekly face-to-face counseling sessions with a registered dietitian.
224215815|NCT03743675|BEHAVIORAL|Aerobic Exercise Training|"Exercise Intervention: Subjects will exercise on a cycle ergometer during the training sessions. Each session will consist of 1) a 5-10 minute warm up at light intensity; 2) a 20 to 30-minute training phase at moderate-to-vigorous intensity; and 3) a 5-minute cool down phase at light. The training will be conducted 3 days per week for 6 months."
224215816|NCT00189267|DRUG|Imiquimod 5 % Cream|
223626974|NCT01815723|DRUG|FP187|500 mg FP187 daily, two tablets of 125 mg twice daily, from 125 mg daily up-titrated to full dose over a 4-week phase, total treatment phase of 20 weeks
223626975|NCT01815723|DRUG|Dimethyl fumarate|720 mg Fumaderm® daily, two tablets of 120 mg three times daily, from 30 mg daily up-titrated to full dose over a 9-week phase, total treatment phase of 20 weeks
223626976|NCT01815723|DRUG|FP187 placebo|FP187 matching placebo tablets in the same regimen as for FP187 arm
223626977|NCT01815723|DRUG|Fumaderm® placebo|Fumaderm® matching placebo tablets in the same regimen as for Fumaderm® arm
223626978|NCT00918385|DRUG|Nilutamide|Nilutamide 150mg orally each day for 28 days per cycle. After first progression, Nilutamide 150mg orally each day in combination with Dasatinib 100mg orally each day for 28 days per cycle.
223626979|NCT00918385|DRUG|Dasatinib|Dasatinib 100mg orally daily x 28 days per cycle. After first progression, Dasatinib 100mg orally each day in combination with Nilutamide 150mg orally each day for 28 days per cycle.
223626980|NCT00079326|BIOLOGICAL|trastuzumab|Given IV
223626981|NCT00079326|DRUG|ixabepilone|Given IV
223626982|NCT00079326|OTHER|laboratory biomarker analysis|Correlative studies
223763386|NCT04116645|OTHER|genital and rectal swab|6\. Swabs for GBS culture should be obtained, ideally before digital examination or use of lubricants, from both the lower vagina (vaginal introitus) and rectum (insert swab through the anal sphincter) to achieve maximum sensitivity. Either two swabs (one for each site) or a single swab can be used; one swab is more cost saving. The swabs will be obtained by the patient herself after appropriate instruction or by the provider healthcare, as studies have shown equivalent sensitivity between the healthcare provider and the patient herself.
223763387|NCT05053672|DEVICE|ReOxy|"ReOxy therapy is a protocol which employs passive (the patient is at rest), short (up to 10 min) mild normobaric hypoxic exposures alternated with similar duration intervals of breathing hyperoxia (up to 5 min). The gas mixtures are supplied to a patient via facial mask on continued measuring of oxygenation status of the patients, lasting about 45 min in total per treatment session.~The hypoxic load will be individually adjusted, based on the results of a preliminary hypoxic test. The patient inhales air with low oxygen content (10-14%) at atmospheric pressure in a continuous mode through a mask withing 10-min.~During the ReOxy - treatment session, the software automatically adjusts the gas mixture switching, based on changes in physiological parameters (blood oxygen saturation and heart rate) in response to hypoxic and hyperoxic impact (biofeedback control)."
223763388|NCT05053672|DEVICE|Sham ReOxy|Placebo treatment with 'sham' ambient air breathing to simulate ReOxy-therapy sessions. Placebo-mode breathing set visually similar to standard breathing set but have a mask with open intake valve. The masks are chosen in a way to provide maximum degree of similarity to reduce the risk of unblinding on the patient-side.
223763389|NCT00371943|PROCEDURE|band ligation|
223763390|NCT06468709|DRUG|Glucocorticoids|The study subjects were randomly divided into a GC monotherapy maintenance group and a GC combined with MMF maintenance group in a 1:1 ratio. The randomization sequence was generated online using a computer randomization scheme. Group A was the GC monotherapy maintenance group
223763391|NCT06468709|DRUG|Glucocorticoids+MMF|The study subjects were randomly divided into a GC monotherapy maintenance group and a GC combined with MMF maintenance group in a 1:1 ratio. The randomization sequence was generated online using a computer randomization scheme. Group B was the GC+MMF maintenance group
224215817|NCT00447187|DRUG|LX201|"LX201 is a novel sustained-release silicone implant containing 30% cyclosporine A by weight.~LX201 was available in two different lengths, 0.50 and 0.75 inch. Each implant was 0.08 inch wide and 0.04 inch in height. The implants were flat on one side (the posterior surface, which is applied to the episclera) and the anterior surface and ends were rounded."
224215818|NCT00447187|OTHER|Placebo|The placebo was a silicone implant 0.75 inch in length. It contained no cyclosporine A
224215819|NCT04663269|DRUG|4mg PF Dexamethasone|analgesic provided in the erector spinae block is 20mL of 0.5% Bupivicaine with 4mg of PF Dexamethasone
224215820|NCT04663269|DRUG|Control Test|Peritubal block - standard local analgesic administration
224215821|NCT00751972|DEVICE|HeartWare® VAS|The HeartWare® LVAD is an implantable centrifugal pump that was designed to provide flows up to 10 L/min in a small device which is both lightweight and simple to use.
224215822|NCT01866683|BEHAVIORAL|1 month respiratory training|Bhastrika yoga respiratory training: 30 kapalabhati and 1 surya bedhana form 1 bhastrika
224215823|NCT01866683|BEHAVIORAL|1 month waiting period|waiting or detraining period
224215824|NCT00035399|PROCEDURE|Acupuncture|
223763392|NCT02069522|OTHER|Standard Milk-based Formula Containing Carotenoid|Fed ad libitum
223763393|NCT02069522|OTHER|Investigational Milk-based Formula Containing Carotenoid|Fed ad libitum
223763394|NCT03470337|DRUG|Phlogenzym|Bromelain / Trypsin / Rutoside
223763395|NCT03470337|OTHER|Placebo|
224215825|NCT05005650|PROCEDURE|debulking surgery|debulking surgery as primary debulking surgery or interval debulking surgery
224215826|NCT01940237|BEHAVIORAL|Psychotherapy|Interpersonal psychotherapy in the treatment of major depressive disorder.
224215827|NCT01771861|OTHER|Trauma team activation|When admitting a potentially seriously injured patient, a trauma team is activated when prehospital information fulfills one or more prespecified criteria. The trauma team consist of a group of medical personnel including a surgeon, anesthesiologist and radiologist.
224215828|NCT04857216|DEVICE|Perfusion Index|perfusion index in the prediction of peripheral block success was previously reported for infraclavicular brachial plexus block, axillary brachial plexus block, interscalene brachial plexus block, and supraclavicular brachial plexus in adult patients
224215829|NCT06526130|PROCEDURE|General anaesthesia|Intravenous or volatile general anesthesia was preformed with different type of airway management (endotracheal tube, laryngeal mask and bag mask ventilation)
224215830|NCT06526130|PROCEDURE|Neuraxial anaesthesia|spinal or epidural injections of local anesthetic with or without opioid
223626983|NCT03597815|DRUG|Aflibercept 40 MG/ML [Eylea]|Intravitreal injection, form of anti-VEGF therapy
223626984|NCT03597815|DIAGNOSTIC_TEST|OSA diagnostic test - overnight sleep study|Overnight with specialist care in hospital - heart, lung and brain activity monitored.
224215831|NCT02766400|BEHAVIORAL|Guided Training|
224215832|NCT02766400|BEHAVIORAL|Directed Training|
223626985|NCT03597815|DEVICE|CPAP therapy for OSA positive patients|positive airway pressure ventilator, applies mild air pressure in a continuous basis to keep the airways continuously open in patients who are able to breath spontaneously on their own.
223626986|NCT03191617|DIETARY_SUPPLEMENT|Human milk fortifier|Fortification of breastmilk with liquid human milk fortifier in premature infants
223626987|NCT01893541|PROCEDURE|ENDOSCOPIC BAND LIGATION|The procedures will be performed using standard technique with a multiband ligation device. Elastic bands will be placed according to physician decision, starting at esophagogastric junction. All varices will be treated during the same session. Endoscopic band ligation sessions will be repeated at intervals of 3 to 4 weeks until all varices will be obliterated.
223763396|NCT04696705|BIOLOGICAL|Ex-vivo expanded allogeneic γδT cells|Cells will be extracted from a healthy donor by apheresis, followed by ex-vivo expansion and activation. The ex-vivo expanded γδT cells from donors will be adoptively transfused.
223763397|NCT07030894|DRUG|"Nefecon®,Ambrisentan"|"Subjects who meet the screening criteria will be treated with Budesonide in combination with Ambrisentan.~Budesonide (Nefecon®), 16mg/d for 36 weeks, taken orally. Ambrisentan , 5mg/d for 36 weeks, taken orally."
223763398|NCT06757413|OTHER|Enhanced Virtual reality|"This study evaluates a 4-week multidisciplinary intervention for patients with chronic non-specific low back pain, combining physiotherapy and psychological approaches. Both components leverage virtual reality (VR) technology to address physical and psychological aspects of pain management, operating in parallel to maximize patient outcomes. The physiotherapy intervention consists of a therapeutic exercise program based on the principles of the Back School. Over 8 sessions (2 per week), patients perform VR-guided exercises where visual-proprioceptive information is manipulated.~The psychological positive body image-based intervention consists of 4 sessions approaching 5 different clinical modules: Pain Psychoeducation, Body Awareness, Pain Acceptance, Body Appreciation and Functionality and Gratitude. 2 sessions (Body Awareness and Pain Acceptancce) will include virtual reality environments to enhance the clinical outcomes."
223763399|NCT06757413|OTHER|Active Comparator: Treatment as usual|Participants will receive the usual treatment applied at the hospital
223763400|NCT07172113|DEVICE|CBT + VR|This CBT intervention is conducted in VR using Embodied AI technology. A virtual therapist will present in a virtual therapy room. Participants can freely talk to and interactive with the virtual therapist.
223763401|NCT07173751|DRUG|Pumitamig|Solution for intravenous (IV) infusion
223763402|NCT07173751|DRUG|Nab-paclitaxel/Paclitaxel|IV infusion
223763403|NCT07173751|DRUG|Gemcitabine|IV infusion
223763404|NCT07173751|DRUG|Carboplatin|IV infusion
223763405|NCT07173751|DRUG|Eribulin|IV infusion
223763406|NCT07173751|DRUG|Matching placebo|IV infusion
224215833|NCT04207554|DEVICE|Test Device-Strip Format|Sponsor's investigational device
224215834|NCT04207554|DEVICE|Test Device-Cassette Format|Sponsor's investigational device
224215835|NCT04207554|DEVICE|Predicate Device|Commercially available device
223763407|NCT07174206|DEVICE|Smartwatch - all data|Single-lead ECG, blood pressure (BP), oxygen saturation (SpO2), and continuous heart rate (HR).
224215836|NCT00204932|DRUG|conjugated linoleic acid|4 grams per day of 39% cis-9, trans-11 CLA; 39% trans-10, cis-12 CLA, and 22% safflower oil for 6 months
224215837|NCT00667433|DRUG|Raltegravir + Truvada|Raltegravir 400 mg tablet BID PO X 104 weeks; Truvada 200/300 mg tablet once a day PO x 104 weeks
224215838|NCT01230385|DRUG|Lersivirine|Lersivirine 500 mg QD fasted (wet granulated tablet) for 21 days
223763408|NCT07174206|DEVICE|Portable holter system|continuous ECG monitoring for 14 days for comparison with the data from the smartwatch
223763409|NCT07174206|PROCEDURE|Telemonitoring|Remote consultations triggered by critical alerts based on predefined thresholds.
223763410|NCT07174206|OTHER|AI Model Development|Data analysis using artificial intelligence for prioritization of patients based on health data collected from wearables.
223763411|NCT07174206|DEVICE|Smartwatch - ECG and HR|Single-lead ECG and continuous heart rate (HR)
223763412|NCT07172633|OTHER|scenario-based simulation teaching with virtual technology|5-week scenario-based simulation teaching with a virtual coach acting as an older adult with dementia in addition to regular dementia care lectures
223763413|NCT07172633|OTHER|traditional dementia case discussions|5-week traditional dementia case discussions in addition to regular dementia care lectures
224215839|NCT01230385|DRUG|Lersivirine|Lersivirine 500 mg QD fed (wet granulated tablet) for 21 days
223763414|NCT07172841|DEVICE|"Intervention group Virtual OFF"|"Patients randomized to shunt setting Virtual Off at the three month follow-up visit. After 5-7 days, the setting will be restored to the previous setting."
223763415|NCT07172841|DEVICE|Control group (no change in shunt setting)|Patients randomized to continue their shunt setting unchanged
223763416|NCT07172854|OTHER|Pelvic Floor Muscle Training|Supervised PFMT with biofeedback, 3 times per week for 12 weeks, plus home exercises.
223763417|NCT07172854|OTHER|Aerobic Exercise|Treadmill walking, moderate intensity (Borg 4-6), 60 minutes/session, 3 times per week for 12 weeks.
223763418|NCT07172854|OTHER|Relaxation Training|Guided breathing, imagery, and meditation, once weekly for 12 weeks, in addition to home practice.
223763419|NCT07172854|OTHER|Patient Education|Standardized education on urinary incontinence, pelvic anatomy, lifestyle modification, and stress management.
224215840|NCT01230385|DRUG|Lersivirine|Lersivirine 750 mg QD fasted (wet granulated tablet) for 21 days
224215841|NCT01230385|DRUG|Lersivirine|Lersivirine 750 mg QD fed (wet granulated tablet) for 21 days
224215842|NCT01230385|DRUG|Lersivirine|Lersivirine 500 mg QD fasted (dry granulated tablet) for 21 days
224215843|NCT04834999|OTHER|Validation of questionnaires in Kinyarwanda|Four questionnaires, three self-report instruments (Medication Adherence Rating Scale, Internalized Stigma of Mental Illness Inventory - 9-item Version and the Mood Disorder Questionnaire) and one clinical interview (the Young Mania Rating Scale)
224215844|NCT05211752|OTHER|eVOG (Mobile VideoOculoGraphy)|"* Eyes movements assessed with e-VOG (mobile application, that uses the face detection features of the front camera to detect and record eye movements).~* Study duration is about 20 minutes, the day the subject performs his standard video-oculography examination in routine care (using Eye-Tracker®T2)"
224215845|NCT03593772|BEHAVIORAL|Mission Reconnect|This four-year randomized controlled trial with one intervention arm and one wait-list control arm will utilize mixed methods to evaluate the effectiveness and perceived value of the MR program in relation to physical and psychological symptoms, global health, and social outcomes.
224215846|NCT05338437|DEVICE|Neuromuscular electrical stimulation|Bilateral quadriceps muscle stimulation
224317184|NCT01491191|DIETARY_SUPPLEMENT|Palmitoylethanolamide|Before surgery: 600 mg cp twice a day After surgery: 600 mg microgranules twice a day for 10 days then 600 mg cps once a day for 20 days
224317185|NCT01491191|DIETARY_SUPPLEMENT|Placebo|Before surgery: 1 sugar pill twice a day for 8 days After surgery: 1 sugar microgranules twice a day for 10 days then 1 sugar pill once a day for 20 days
223626988|NCT01893541|DRUG|PROPRANOLOL|The initial propranolol dose will be orally BID 40 mg, irrespective of patient's weight. The objective of the administration of propranolol will be induce beta-adrenergic blockade evaluated by reduction in heart rate to 55 bpm or a 25% drop in baseline heart rate. A baseline electrocardiogram will be obtained from all patients. The doses will be adjusted during weekly visits until beta-adrenergic blockade. After the adequate dose will be reached, the visits will be scheduled monthly during the first 3 months (until EV eradication) and then at a 3-month interval until the end of follow-up.
223626989|NCT01893541|DEVICE|a multiband ligation device|
223626990|NCT03829085|OTHER|EARLY ORAL REFEEDING|the oral refeeding will be started after admission. Patients will receive a low fat solid diet with more and less 1500 calories, 35 g fat day
223626991|NCT02478008|DEVICE|CardiAQ TMVI System (Transapical DS)|
223626992|NCT04446637|DRUG|Ipratropium/Levosalbutamol 20/50 mcg Fixed Dose Combination (2 inhalations) via pMDI|Ipratropium/Levosalbutamol 20 mcg/50 mcg Aerosol Inhalation, Suspension 2 inhalations in the morning (single day)
223626993|NCT04446637|DRUG|Salbutamol 100 mcg Inhaler (2 inhalations) + Ipratropium 20 mcg Inhalation Aerosol (2 inhalations) Free Combination via MDI|Salbutamol 100 mcg Inhaler, 2 inhalations + Ipratropium 20 mcg Inhalation Aerosol,2 inhalations in the morning (single day).
223626994|NCT03669614|DRUG|Inhaled AR-501|single and multiple ascending doses of inhaled AR-501
223626995|NCT03669614|DRUG|Inhaled Placebo|single and multiple ascending doses of inhaled placebo
223626996|NCT04773951|BIOLOGICAL|JS004, a recombinant humanized, IgG4κ monoclonal antibody (mAb) specific to B- and T-lymphocyte attenuator (BTLA); Toripalimab Injection|Biological: JS004, Intravenous infusion; Toripalimab Injection, Intravenous infusion
223626997|NCT02843230|RADIATION|Avastin|
223626998|NCT02843230|RADIATION|Lomustine|
223626999|NCT02843230|RADIATION|Temozolomide|
223627000|NCT02843230|DEVICE|MRI|
223627001|NCT02843230|DEVICE|MRS|
223627002|NCT02843230|DEVICE|DSC|
223627003|NCT05114824|BEHAVIORAL|Mindfulness-Based Cognitive Therapy|The intervention is based on a mixed MBCT program with training in mindfulness strategies for 8 weeks. The adapted MBCT intervention will consist of eight weekly group sessions of 1 hour and 30 minutes, led by a certified instructor, to address the symptoms in the university population. In addition, complemented with the inclusion of audiovisual material, aimed at guiding self-applied daily exercises.
223627004|NCT00549692|DRUG|Omega-3 fatty acid ethylester90|Dosage form :1g soft capsule Dosage : two capsules, twice a day.
223627005|NCT03201796|DRUG|Prulifloxacin 600 mg|Oral administration of one tablet once daily for 28 days of prulifloxacin 600 mg. The investigational drug will be taken with a glass of water, preferably in the evening and at about the same time each day, 2 hours before or at least 4 hours after the eventual administration of cimetidine, antacids containing aluminum and magnesium or preparations containing iron and calcium.
223627006|NCT03201796|DRUG|Levofloxacin 500mg|Oral administration of one tablet once daily for 28 days of levofloxacin 500 mg. The investigational drug will be taken with a glass of water, preferably in the evening and at about the same time each day, 2 hours before or at least 4 hours after the eventual administration of cimetidine, antacids containing aluminum and magnesium or preparations containing iron and calcium.
223627007|NCT05765422|OTHER|salivar and gum sampling|Saliva will then be collected by salivary spit and a mucosal smear will be taken using a swab passed at the junction of the tooth and the gum
223627008|NCT00382772|BIOLOGICAL|2-dose oral live attenuated G1P[8] human rotavirus vaccine|
223627009|NCT00771914|DRUG|Aspirin|Aspirin 81mg tablet
223627010|NCT00771914|DRUG|Lovaza|Lovaza 4 grams
223627011|NCT00771914|DRUG|Both Aspirin and Lovaza|Lovaza 4 grams plus aspirin 81 mg
223627012|NCT00771914|OTHER|Placebo|Capsule resembling fish oil and a tablet resembling aspirin
223627013|NCT03655145|OTHER|Haplo donor stem cell transplantation|The algorithm for selection of haploidentical donor has been defined by the french society for stem cell transplantation The stem cell source will be bone marrow for haploidentical transplantation.The bone marrow collection is carried out according to the practice of each centre with a minimal target dose of 3x108 TNC/kg.
223627014|NCT03655145|OTHER|HLA 10/10 MUD stem cell transplantation|HLA 10/10 matched unrelated donor myeloablative transplantation
223627015|NCT05421949|OTHER|Exercise group|Incremental Shuttle Walking Test
223627016|NCT02192515|DRUG|APD356 10 mg|One tablet of APD356 10 mg will be orally administered in fasted state.
223627017|NCT02192515|DRUG|APD356 XR-20 mg|One tablet of APD356 XR-20 mg will be orally administered in fasted state.
223627018|NCT02192515|DRUG|APD356 10 mg matching Placebo|One tablet of APD356 10 mg matching placebo will be orally administered in fasted state.
224317186|NCT01044108|DRUG|NNC 0070-0002-0453|Administration of a single subcutaneous (under the skin) dose. Up to 7 escalating dose levels will be investigated. Progression to next dose level will be based on a safety evaluation.
224317187|NCT01044108|DRUG|'2-0453|Administration of multiple subcutaneous (under the skin) doses for 10 weeks. Up to 4 escalating dose levels will be investigated. Progression to next dose level will be based on a safety evaluation.
224317188|NCT01044108|DRUG|placebo|Placebo will be administered as a comparator at each dose level.
223627019|NCT02192515|DRUG|APD356 XR-20 mg matching Placebo|One tablet of APD356 XR matching placebo will be orally administered in fasted state.
223627020|NCT02192515|DRUG|APD356 20 mg|Two tablets of APD356 10 mg will be orally administered in fasted state.
223627021|NCT02192515|DRUG|APD356 20 mg matching Placebo|Two tablets of APD356 10 mg matching placebo will be orally administered in fasted state.
223627022|NCT02192515|DRUG|APD356 XR-20 mg (orange tablet)|One tablet of APD356 XR-20 mg orange tablet will be orally administered in fasted state.
223627023|NCT02192515|DRUG|APD356 XR-20mg (orange tablet, fed state)|One tablet of APD356 XR-20 mg orange tablet will be orally administered 30 minutes after the start of a meal.
223627024|NCT02654782|DRUG|Lactated Ringer's|Crystalloid fluid given for hemodynamic resuscitation based off of individual patient needs.
223627025|NCT02654782|DRUG|5% Human Albumin|Colloid given for hemodynamic resuscitation based off of individual patient needs.
223627026|NCT04565626|OTHER|Additional weekend physiotherapy|Patients randomized to intervention would receive a Medical Exercise Bike Pedal Exerciser Mini Peddler to allow for an additional 20 minutes a day of unsupervised physiotherapy both during the week and on weekends.
223627027|NCT02978417|DRUG|Naltrexone for extended-release injectable suspension|Opioid-dependent Drug Court clients enrolled in the study will receive monthly injections of Vivitrol for up to 12 months if they continue to be medically eligible and willing.
223627028|NCT02978417|DRUG|Oral naltrexone|Opioid-dependent Drug Court clients enrolled in the study will receive prescriptions for oral naltrexone for up to 12 months if they continue to be medically eligible and willing.
223763420|NCT04943016|DRUG|CD19 Chimeric Antigen Receptor (CAR) T Cells|This study seeks to examine the feasibility and safety of the administration of autologous T cells that have been modified through the introduction of a chimeric antigen receptor targeting the B cell surface antigen CD19 following administration of chemotherapy lymphodepletion regimen in children and adults with relapsed/refractory B cell malignancies. The overall goal of this study is to validate the safety profile of administration CD19 CAR T cells and describe the toxicities in children and adults with relapsed/ refractory B cell malignancies. Each patient implements leukapheresis 2 weeks after enrollment and infuse CD19 CAR-T cell around 2 weeks after leukapheresis, and administrated chemotherapy lymphodepletion regimen 1 week before infusion. Furthermore, the treated subject would be following up around 2 years.
223763421|NCT06545955|DRUG|Nadofaragene Firadenovec|vector-based gene therapy for NMIBC treatment to potentiate durable therapeutic responses by interferon (IFN) alfa-2b (IFN-α2b) amplification. It is a non-replicating recombinant adenovirus serotype 5 vector containing a transgene encoding the human IFN-α2b gene.
223763422|NCT06545955|DRUG|Gemcitabine|Intravesical Gemcitabine chemotherapy, used in combination with Docetaxel.
223763423|NCT06545955|DRUG|Docetaxel|Intravesical Docetaxel chemotherapy, used in combination with Gemcitabine.
223763424|NCT06545955|DRUG|Pembrolizumab|Pembrolizumab is an FDA approved immune checkpoint inhibitor which restores the anti-tumour immune response by blocking the programmed cell death protein 1 (PD-1). Pembrolizumab is administered via intravenous (IV) infusion.
223763425|NCT03640663|OTHER|Midwife led continuity model of care|Midwives from the hospitals provided outreaching caseload ante- and postnatal care to women in rural villages clinics and homes
223763426|NCT04519632|OTHER|Qualitative study|Qualitative interviews
223763427|NCT03548584|DRUG|Brexpiprazole|Oral tablets
223763428|NCT03548584|OTHER|Placebo|Oral tablets
223763429|NCT04196556|BEHAVIORAL|Active Families|This intervention, based on the methodology of meaningful learning, will have two components: group education aimed at parents (caregivers) and and education directed to children in the reviews in consultation. Group education (caregivers) groups will consist of 6 sessions, which will be given every two weeks, as determined in the program's follow-up annex, in the 3 months after the initial assessment. The content of the sessions is defined in attached annex. Regarding the proposed methodology, it has nuances and tools different from the traditional ones to achieve significant learning in the field of health. It is based on participatory methods and a more profound modification of knowledge, skills, emotions and attitudes than the brief advice that is used in family intervention in scheduled consultations.
223763430|NCT04196556|OTHER|Madrid's Primary Healthcare Standardized Service portfolio|"An anamnesis or functional assessment on the following aspects:~o Family history of obesity up to 2nd degree inbreeding. o Nutritional status - metabolic that includes at least no meals/day and daily consumption of liquids, fruits, vegetables, dairy, fats and sugars. o Activity - exercise that includes at least the type and intensity of exercise and time spent on sedentary activities (television, video games or the like). o Self-concept that includes at least the existence or not of behavioral problems and body image problems. o Role - relationships that include at least the performance of extracurricular activities.~A care plan in relation to identified problems and/or situations reviewed on a biannual basis.~They will be supplemented with the study-specific variables listed in the data collection notebook."
223627029|NCT00994552|OTHER|Pressure support ventilation|Pressure support ventilation
223627030|NCT00994552|OTHER|Pressure control ventilation|Pressure control ventilation
223627031|NCT00752700|OTHER|Conventional resistance training|Conventional resistance training program (CRT)
223627032|NCT00752700|OTHER|Whole body vibration resistance training|Whole body vibration resistance training (WBV) on the FITVIBE-platform
223763431|NCT06005025|OTHER|Reminder message|"Experimental group will be counselled for 6 months after the training and a reminder message will be sent via SMS on Monday every week as Check your modifiable risk factors for breast cancer and their feedback will be received."
224317189|NCT00999817|DRUG|reference [dextromethorphan]|single 30 mg oral dose
224317190|NCT00999817|DRUG|test [PF-00299804 + dextromethorphan]|single 45 mg oral dose of PF-00299804 and a single 30 mg oral dose of dextromethorphan
223627033|NCT04818658|OTHER|Assessment of the stainless steel crown using the Hall Technique and Compomer Restoration on primary molars|Intra-oral clinical examination is performed and restorations are evaluated by the practitioner. Periapical radiography is taken according to national guidelines.
223627034|NCT03111875|DEVICE|aggressive warming|Patients will be pre-warming 30 minutes before induction of anesthesia and aggressively warmed during surgery to a target intraoperative core temperature between 37 and 37.5°C.
223627035|NCT03111875|DEVICE|routine thermal management|A forced-air cover will be positioned but will not initially be activated. The warmer will be activated when core temperature decrease to 35.5°C.
224317191|NCT01117649|DRUG|HES 10%|HES 10% dissolved in plasma adapted Ringer's solution (balanced solution).
224317192|NCT01117649|DRUG|HES 6%|HES 6% dissolved in plasma adapted Ringer's solution (balanced solution)
224317193|NCT01117649|DRUG|balanced electrolyte solution|plasma adapted Ringer's solution
223627036|NCT01361555|DRUG|Placebo matching with BMS-820836|Tablet, Oral, 0.0 mg, Once daily, 54 weeks
223627037|NCT01361555|DRUG|BMS-820836|Tablet, Oral, 0.5 mg, Once daily, 54 weeks
223627038|NCT01361555|DRUG|BMS-820836|Tablet, Oral, 1.0 mg, Once daily, 54 weeks
223627039|NCT01361555|DRUG|BMS-820836|Tablet, Oral, 2.0 mg, Once daily, 54 weeks
223627040|NCT03485924|DIAGNOSTIC_TEST|EUS-FNA with ROSE|EUS-FNA with ROSE vs EUS-FNB without ROSE
223627041|NCT03485924|DIAGNOSTIC_TEST|EUS-FNB without ROSE|EUS-FNA with ROSE vs EUS-FNB without ROSE
223627042|NCT02522247|PROCEDURE|UPP|surgery with cold steel in general anesthesia
223627043|NCT05890248|PROCEDURE|Technique|Paravertebral block versus Erector spinea block versus quadratus lamborum block
223627044|NCT05288816|DRUG|ALXN1210|Participants received a single dose (400 mg or 800 mg) and multiple doses (800 mg) of ALXN1210.
223763432|NCT03852329|DEVICE|Lateral skull base navigation|"Patient preparation: The participant is prepared for the surgery according to clinical standards.~System setup: The hardware components of the investigational device are set up~Tripod fixation: The tripod with integrated registration fiducials is fixed on the participant's skull.~CBCT imaging: A CBCT image of the participant is acquired~Image processing: The CBCT data is loaded on the navigation platform. The registration fiducials are automatically detected in the image data and relevant anatomy is segmented using an otologic planning software.~Measurements: The navigation software is started, and the fiducial positions and segmentations loaded. The measurements are conducted.~Treatment: The surgery is conducted by the surgeon according to clinical standards"
223763433|NCT02516124|PROCEDURE|Autologous HSCT|1st AHSCT
223763434|NCT03142295|PROCEDURE|urine transfusion|Two transfusions of 100 ml of urine within 5 days by transurethral catheterization after an antibiotic free interval of 3 days.
223763435|NCT00936026|DRUG|Neramexane|Drug-Drug Interaction Study
223763436|NCT01046955|DRUG|Anti-Thymocyte Globulin vs Campath-1H vs Daclizumab|comparison of induction therapies.
223763437|NCT03836092|PROCEDURE|Radiofrequency ablation|RF applications were delivered with a maximal temperature of 43°C at the catheter tip (SmartTouch Navistar Thermocool catheter) and at the power between 25-50 watts. The primary end points during RF ablation were either complete elimination of areas with CFAE or conversion of AF to normal sinus rhythm (SR). When areas with CFAE were completely eliminated but the atrial arrhythmias persisted (organized atrial flutter or atrial tachycardia), they were subsequently mapped and ablated (occasionally in conjunction with ibutilide, 1 - 2 mgs intravenously over 10 minutes).
223763438|NCT00965068|OTHER|Cholesterol|
223763439|NCT03905551|PROCEDURE|Cold Dialysis|Dialysate temperature reduced to 35oC for a period of 7 months.
223763440|NCT03905551|PROCEDURE|Typical Dialysis|Dialysate temperature is set at 37oC for a period of 7 months
223763441|NCT03905551|PROCEDURE|Exercise|Aerobic Intradialytic exercise training
224317194|NCT02203409|PROCEDURE|Laparoscopic ALPPS|Laparoscopic Associating Liver Partition and Portal Vein Ligation for Two-stage Hepatectomy
223763442|NCT03481959|DRUG|Methylphenidate|"Methylphenidate delay shape, 10 and 30 mg and matching Placebo capsules. Treatment should be started at a dose of 10 mg per day or 20 mg/d (depending on the weight of patients), with increasing weekly, according to the clinical tolerance, in order to get an effective dose on the symptoms of ADHD to S4, not more than 1 mg/kg/d (capped at 60 mg/d).~This gradual dose treatment will be resumed in the same manner in M3 at the beginning of the phase in open, allowing the respect of the average of the ADHD support (no), without loss of chance for the Group at 3 months, because it is customary to discontinue treatment during holiday periods)."
223763443|NCT03481959|OTHER|Matching Placebo|"Methylphenidate delay shape, 10 and 30 mg and matching Placebo capsules. Treatment should be started at a dose of 10 mg per day or 20 mg/d (depending on the weight of patients), with increasing weekly, according to the clinical tolerance, in order to get an effective dose on the symptoms of ADHD to S4, not more than 1 mg/kg/d (capped at 60 mg/d).~This gradual dose treatment will be resumed in the same manner in M3 at the beginning of the phase in open, allowing the respect of the average of the ADHD support (no), without loss of chance for the Group at 3 months, because it is customary to discontinue treatment during holiday periods)."
223763444|NCT05750641|OTHER|removing milk and dairy products from diets without medical treatment|A specialist dietician prepared a diet list based on providing adequate balanced nutrition and is handed over to the diet group without any medical treatment
223763445|NCT05750641|OTHER|According to current standard algorithms and guidelines, appropriate treatment for FD types.|According to current standard algorithms and guidelines, appropriate treatment for FD types was arranged for the patient group who preferred to receive a free diet
224317195|NCT04022876|DRUG|ALRN-6924|ALRN-6924 administered IV on Days 0-2 prior to carboplatin and pemetrexed administered IV on Day 1 of every 21-day cycle.
223627045|NCT00467246|DRUG|Levemir|
224317196|NCT04022876|DRUG|Carboplatin|Carboplatin administered IV on Day 1 of every 21-day cycle.
223627046|NCT03416868|BEHAVIORAL|Ambulatory voice biofeedback|Patients will be provided cues regarding their vocal behavior in daily life. Specifically, the patient will receive 100% feedback = a vibrotactile cue on a smartwatch every time the patient voices incorrectly. The specific objective voice measure for biofeedback will depend upon which measure is most strongly associated with improvements during voice therapy.
223627047|NCT01323582|DRUG|Erythromycin|200mg/5ml elixir administered orally three times a day half an hour prior to meals.
223627048|NCT01323582|DRUG|Azithromycin|The dose of Azithromycin given was determined based on the following study on 10 healthy subjects. In random order, each of ten healthy subjects underwent OBT studies following administration of AZI, at doses of 50mg, 100mg, and 133mg. The T½ and Tlag was then compared for the three doses by a randomized block analysis using Analysis of Variance followed by Tukey's multiple comparison. Results: The T½ for each of the respective doses of AZI (50mg, 100mg, and 133mg) was 129 ± 27, 128 ± 31, and 128 ± 16 minutes (p = 0.98). This data suggested that AZI at doses of 50mg, 100mg and 133 mg have fairly similar activity in its effects on gastric emptying in healthy subjects. Based on this analysis , we decided to use a dose of 50 mg/5 ml for administered TID prior to meals.
223627049|NCT05129748|DRUG|Sodium Thiosulfate + Mannitol|Drug delivery will be sequential, where Mannitol will be infused over 30 minutes and Sodium Thiosulfate will be infused over 15 minutes.
223627050|NCT03755713|DRUG|ASP0892|Intradermal
224317197|NCT04022876|DRUG|Pemetrexed|Pemetrexed administered IV on Day 1 of every 21-day cycle.
224317198|NCT04022876|DRUG|Placebo|Placebo administered IV on Days 0-2 prior to carboplatin and pemetrexed administered IV on Day 1 of every 21-day cycle.
224317199|NCT04022876|DRUG|ALRN-6924|ALRN-6924 administered IV on Days 0-4 prior to topotecan administered IV on Days 1-5 of every 21-day cycle.
224317200|NCT04022876|DRUG|Topotecan|Topotecan administered IV on Days 1-5 of every 21-day cycle.
224317201|NCT00215280|DRUG|ivermectin and albendazole|
224317202|NCT04698226|PROCEDURE|25-gauge pars plana vitrectomy with complete internal limiting membrane peeling and SF6 tamponade|Standard 3 port 25-gauge pars plana vitrectomy with complete internal limiting membrane peeling around the macular hole after brilliant blue dye staining and sulfur hexafluoride (SF6) tamponade
223627051|NCT03755713|DRUG|Placebo|Intradermal; normal saline solution
223627052|NCT06313255|DRUG|PegIFNα2b|The patients receive PegIFNα2b therapy
223627053|NCT06313255|DRUG|PegIFNα2b+probiotics|The patients receive both PegIFNα2b and probiotics therapy
223627054|NCT06313255|DRUG|Nucleoside analog|The patients receive nucleoside analog therapy
223627055|NCT06313255|DRUG|Nucleoside analog+probiotics|The patients receive both nucleoside analog and probiotics therapy
223627056|NCT05359458|BEHAVIORAL|Emotional Freedom Liberation Technique|The investigators will apply Emotional Freedom Liberation Technique
223627057|NCT06444035|DRUG|HA35 injection|HA35/B-HA injection (Registration number L20200708MP07707; Ministry of Health). The subjects can continue to take oral analgesics during the treatment period, and the comparison of the dose and interval days of the analgesics before and after the treatment can also be used as the effect judgment of the injection.
223627058|NCT01422161|DRUG|Botulinum Toxin commonly known as BOTOX®|"A total dose between 200-300 units of Botulinum toxin will be administered across 12 muscles of the affected hand.~There will be 1 treatment cycle during the 9 week study."
223627059|NCT01422161|DRUG|Placebo|The control group will receive a placebo injection.
223627060|NCT00956163|PROCEDURE|magnetic resonance imaging|Undergo whole-body MRI
223627061|NCT00956163|RADIATION|fluorine F 18 sodium fluoride|Undergo fluorine F 18 sodium fluoride PET/CT scan
223627062|NCT00956163|PROCEDURE|positron emission tomography|Undergo fluorine F 18 sodium fluoride PET/CT scan
223627063|NCT00956163|PROCEDURE|computed tomography|Undergo fluorine F 18 sodium fluoride PET/CT scan
223627064|NCT00956163|RADIATION|technetium Tc 99m methylene diphosphonate|Undergo technetium Tc 99m methylene diphosphonate bone scan
223627065|NCT00956163|OTHER|laboratory biomarker analysis|Correlative studies
223627066|NCT03260179|DRUG|AL3810|Fasting，oral ，4w on or 3w on/1w off
223627067|NCT03260179|DRUG|AL3810|Fasting，oral ，4w on or 3w on/1w off
223627068|NCT03260179|DRUG|AL3810|Fasting，oral ，4w on or 3w on/1w off
223627069|NCT01593826|DRUG|Charcoal and Budesonide/formoterol Easyhaler 320/9 microg|2 inhalations as a single dose
223627070|NCT01593826|DRUG|Charcoal and Symbicort Turbuhaler|2 inhalations as a single dose
223627071|NCT01593826|DRUG|Budesonide/formoterol Easyhaler 320/9 microg|2 inhalations as a single dose
223627072|NCT01593826|DRUG|Symbicort Turbuhaler forte|2 inhalations as a single dose
223627073|NCT04040374|DIAGNOSTIC_TEST|AI-based diagnosis|AI-based diagnosis will be performed based on analysis of endoscopic images (Olympus Optical, Tokyo, Japan). The investigators will use the Single Shot MultiBox Detector (SSD), a deep neural network architecture (https://arxiv.org/abs/1512.02325), and an optimal diagnostic cutoff from a prior report2. The AI system reviewed endoscopy images and reported those in which gastric cancer was detected, together with the coordinates (X, Y) of the lesions.
223627074|NCT04040374|DIAGNOSTIC_TEST|The expert endoscopists-based diagnosis|The expert endoscopists are two physicians with experience of more than 20,000 endoscopies. The expert endoscopists will review the endoscopy images of each patient for 5 min. They will then report endoscopy images in which gastric cancer was detected and manually annotate the lesions in those images.
223627075|NCT01486875|DRUG|biphasic insulin aspart 30|Dose individually adjusted, and administered subcutaneously (under the skin) once or twice daily
224317203|NCT04698226|PROCEDURE|25-gauge pars plana vitrectomy with inverted flap technique and SF6 tamponade|"Standard 3 port 25-gauge pars plana vitrectomy with inverted flap technique after brilliant blue dye staining and SF6 tamponade. Flower petal type of inverted flap will be performed - multiple small ILM flaps will be created around the macular hole and placed over the macular hole."
224317204|NCT04860674|DRUG|PD-1 inhibitor +ICE|PD-1 inhibitor (tirelizumab) combined with ifosfamide, carboplatin and etoposide (ICE) regimen
223627076|NCT00960375|BEHAVIORAL|BTSCS|BTSCS lasts 3 months, includes two 60-minute group meetings per week (24 group meetings total), and is delivered in small groups of 4-8 participants run by a trained interventionist. BTSCS includes: (1) An individual motivational enhancement meeting during the first week of treatment to help participants think about individual reasons for smoking cessation; (2) Breath carbon monoxide monitoring and goal-setting at the beginning of each meeting; (3) Skills for reducing smoking; (4) Social Skills Training; (5) Education about the biology of SPMI and smoking and the physiological harm caused by smoking; (5) Relapse prevention training; (6) Education about and assistance with nicotine replacement therapy for participants who are interested in learning about and trying it.
223627077|NCT00960375|BEHAVIORAL|StSST|The StSST program is adapted from a 9-session weekly smoking cessation group program developed at the Outpatient Research Program of the Maryland Psychiatric Research Center and designed for people with schizophrenia. In this study, the StSST program meet twice per week for 3 months (24 sessions total). Participants complete a breath carbon monoxide (CO) test at the start of each group. StSST groups provide education about smoking and support for quitting.
223627078|NCT04743115|DRUG|BS HH 002.SA|"The Dose Escalation Part is a 3+3 design dose escalation study to determine the MTD of BS HH 002.SA in up to approximately 30 patients with the protocol AML indication or high risk MDS. Cohorts of 3 patients will be sequentially assigned to receive BS HH 002.SA at escalating DLs following the standard 3+3 dose escalation design, with 3 to 6 patients at each DL.~Cohort Expansion Part: Following determination of the MTD, the study will continue at the MTD and/or a lower DL"
223627079|NCT01416818|DRUG|Xiaoyao Pill|herb extracts,were received two times a day for 12 weeks without dose changing.
223627080|NCT01416818|DRUG|Bupleurum+Ginkgo|herb extracts, were received two times a day for 12 weeks without dose changing.
223627081|NCT01416818|DRUG|placebo|The placebo looked like herb extracts and were also received two times a day for 12 weeks without dose changing.
223627082|NCT05919576|DEVICE|Near infrared imaging|In the study, all volunteers are recorded with the itero Element 5D by activating the NIRI mode. The recording method does not involve ionizing radiation. 850 nm wavelength beams are used.
223627083|NCT00704210|DEVICE|SpineMed Table, Cert HealthSciences LLC|For Group A (the treated group) the following tension adjustments will be used: starting treatment tension will equal 1/4 body weight minus 10 lbs. Incremental increases of 4 lbs. per session will be implemented until optimum tensions are reached, which would be a maximum of ¼ body weight plus 25 lbs, unless distraction tensions cause discomfort, which would require a reduction of the tensions applied.
223763446|NCT05010174|DRUG|MDR product|Observation of patients previously receiving MDR product(s)
223627084|NCT00704210|DEVICE|SpineMed Table, Cert HealthSciences LLC|Group B will receive sham decompression treatment (i.e. tension not exceeding 15 lbs) for 30 minutes and ice treatment for 15 minutes once a day during each treatment session. No incremental increases will be used for Group B.
223627085|NCT00364585|DEVICE|GreenLight Model 120 Laser System|
223627086|NCT03557970|DRUG|Edicotinib|Given PO
223627087|NCT03557970|OTHER|Pharmacokinetic Study|Correlative studies
223627088|NCT00112736|DRUG|erlotinib|Given orally
223627089|NCT00112736|DRUG|temsirolimus|Given IV
223763447|NCT02215070|DRUG|Pasireotide|Eligible subjects will receive pasireotide daily for 5 days before stem cell transplant, the day of the stem cell transplant, and daily for 8 days following the stem cell transplant. Preparatory regimen will be given 4 days before stem cell transplant.
224215847|NCT02224300|BEHAVIORAL|Internet-based education of venous leg ulcer nursing care|Intervention is delivering the ELC (Electronic Learning of venous leg ulcer nursing care) to home health-care nurses (registered nurses, public health nurses and licensed practical nurses) . The ELC development was based on the integrative literature review about nurses' knowledge gaps on venous leg ulcer nursing care. The pedagogical basis of the ELC is constructivism and blended learning approach. The ELC comprises contact learning and distance learning. Content of ELC is evidence-based information already existing in Internet and the basis of the information is the Finnish Current Care Guidelines for Chronic leg ulcers (2014), which are evidence-based clinical practice guidelines. They are intended as basis for ulcer treatment decisions, and guidelines can be used by nurses and other healthcare professionals.
224317205|NCT05523466|OTHER|Acupuncture Active|Immediately after the placement of the Polar V800, an instrument for analyzing heart rate variability, the placing of needles at the points carefully selected for this research begins. The needling will proceed for the Active acupuncture using specific Traditional Chinese Acupuncture points: E36, BP6, F3, IG4, for 20 minutes.
223763448|NCT01786408|DEVICE|TAP20-C|
223763449|NCT01786408|DEVICE|SAFE-T-FILL CAPILLARY BLOOD COLLECTION SYSTEM|
223763450|NCT06080620|PROCEDURE|Modified radical mastectomy for breast cancer|Modified radical mastectomy for breast cancer
223763451|NCT06080620|PROCEDURE|neoadjuvant therapy|"neoadjuvant chemotherapy（Drugs： DoxorubicinPaclitaxelAlbumin paclitaxelCyclophosphamide）, endocrine therapy（Drugs：ToremifenZoladexAromatase inhibitors）, targeted therapy（Drugs：trastuzumabPertuzumab）"
223763452|NCT06080620|PROCEDURE|Systematic treatment|"chemotherapyDrugs： DoxorubicinPaclitaxelAlbumin paclitaxelCyclophosphamide）, endocrine therapy（Drugs：ToremifenZoladexAromatase inhibitors）, targeted therapy（Drugs：trastuzumabPertuzumab），radiotherapy（Yikeda Versa HD linear acceleratorVarian Trilogy linear accelerator）"
223763453|NCT00004917|BIOLOGICAL|epoetin alfa|
223763454|NCT00004917|DRUG|cisplatin|
223763455|NCT00004917|RADIATION|radiation therapy|
223763456|NCT05489094|COMBINATION_PRODUCT|Nutrition Education and Growing Up Milk for 1 - 3 years old|Nutrition education is a basic information related balanced nutrition for 1 - 3 children including the details of food types and calories. while Intervention product is formulated to deliver macro- and micronutrients as part of the dietary intake for children at 1-3 years old with Iron-C formula
223763457|NCT05489094|BEHAVIORAL|Nutrition Education|Nutrition education is a basic information related balanced nutrition for 1 - 3 children including the details of food types and calories.
223763458|NCT05766891|BEHAVIORAL|Group 1|Participants will receive hypnosedation will be restarted after arriving in the operating room and will continue for the whole time of surgery
223763459|NCT05766891|BEHAVIORAL|Group 2|Participants will receive standard general anesthesia and medications to control your pain after arriving in the operating room
223627090|NCT00112736|PROCEDURE|therapeutic conventional surgery|Undergo surgical resection
223627091|NCT00112736|OTHER|laboratory biomarker analysis|Correlative studies
223627092|NCT00112736|OTHER|pharmacological study|Correlative studies
223627093|NCT04055064|DIETARY_SUPPLEMENT|glucose control nutritional shake, nutrition education|Participants in the treatment group were educated about improving their diet by consuming more low-fat high-quality protein sources, vegetables, complex carbohydrates and less simple carbohydrates. They were also instructed to consume two servings (474 ml) of a commercially produced Glucose Control Nutritional Shake between meals throughout the day for 12 weeks or until complete healing. The supplements provided a total of 500 kilocalories, 28 grams of high-quality protein and essential vitamins and minerals.
223627094|NCT03215017|DEVICE|Transanal irrigation|Effect of Transanal irrigation (TAI) using Peristeen® anal irrigation system - Coloplast
223627095|NCT03215017|DRUG|Medication|Medication to help control of the bowel movement (One or a combination of Loperamide, Sorbitol, Sterculia gum)
223763460|NCT05766891|BEHAVIORAL|Group 3|Participants will receive standard general anesthesia and medications during surgery to control your pain.
223763461|NCT02904252|OTHER|Transient elastography|Transient elastography (TE) is an ultrasound-based device used for measuring the degree of liver stiffness. A transducer probe is used to create mild amplitude and low frequency vibrations (50 Hz) that transmitted through the liver tissue. This results in an elastic shear wave that propagates through the underlying liver tissue. The probe then utilizes pulse-echo ultrasound to follow the propagation of the shear wave and to measure its velocity. The velocity of the wave is directly related to tissue stiffness which correlates with fibrosis. The sensitivity and the specificity of TE is between 68%-88% and between 66%-100%, respectively for the detection of significant liver fibrosis (METAVIR score F\>2).
223763462|NCT02283216|DEVICE|noise sound stimulation (Tucker-Davis Technologies)|Band-limited white noise stimulus, comfortable loudness level, presented via headphones or earphones with Tucker-Davis Technologies device.
223763463|NCT02283216|DEVICE|body electrical stimulation (Digitimer device)|Single pulse electrical stimulation on different body regions, comfortable current level, presented via surface pads or clips with Digitimer device.
223763464|NCT02283216|DEVICE|transcranial magnetic stimulation (Magstim)|Single pulse magnetic stimulation over frontal cortex, comfortable level at 110% resting motor threshold, presented via magnetic coil with Magstim device.
223627096|NCT02656277|OTHER|Decision Tool|
223627097|NCT02656277|OTHER|Information on Shoulder Dislocation|
223763465|NCT03250728|BIOLOGICAL|Peripheral blood puncture|"Endothelial progenitor cells will be isolated from peripheral blood by density gradient and cultured in 10%FBS EGM2 medium~On the EPCs we will study:~* the endothelial permeability~* the protein C system"
223763466|NCT00585065|DEVICE|CRT device implant|The purpose of this study is to collect information on patients with chronic heart failure who have already been identified by their physician as candidates for CRT. All tests, including device implantation are standard of care for patients undergoing CRT. The only test involved in this study that is not standard of care is the quality of life questionnaire. Patients who undergo CRT system implant will be followed post-implant (up to 1 week), and at one month, three months, six months and twelve months. The only test involved in this study that is not standard of care is the quality of life questionnaire.
223763467|NCT03040258|OTHER|Health-E-PALS-Pilot|Intervention to promote Healthy Eating and Physical Activity in Lebanese School-Children It comprises in class-activities, meetings with parents, improvement of school food service
223763468|NCT04453852|BIOLOGICAL|COVID19 vaccine|COVID19 recombinant spike protein with Advax-SM adjuvant
223763469|NCT04453852|BIOLOGICAL|Saline|Saline control
224215848|NCT04793828|BEHAVIORAL|Velibra|Velibra is an internet-based cognitive behavioral therapy program developed by GAIA AG. It consists of six modules which are meant to be completed over a span of 6 weeks. The first module educates participants about anxiety and the treatment program. The second module focuses on cognitive techniques for dealing with anxiety. In the third module, relaxation techniques are practiced. The fourth module encourages the participant to practice non-anxious behaviors. In the fifth module, the central topic is the experience of social situations in non-anxious ways. The sixth and final module consists of a summary and recapitulation of the most important content.
223763470|NCT01701466|OTHER|Aveeno cream|Twice a day
223763471|NCT01701466|OTHER|Flamazine cream|Twice a day, when there is dry desquamation
223763472|NCT01701466|OTHER|NeoVIDERM cream|Three times a day
223763473|NCT05117827|DEVICE|Power Wheelchair Standing Device|A power wheelchair standing device is a power wheelchair that allows a child to electronically move between sitting and standing. It can be driven in either position. The Permobil F5 Corpus VS is the specific power wheelchair standing device to be used in this study.
223763474|NCT05078736|OTHER|Moderate intensity intermittent training|In group A participants will receive moderate intensity intermittent training including running of 5 km with 1-min at 70% of maximal aerobic speed with interval of 1-min passive recovery, exercises will be performed by gym trainer for 5 weeks including 3 days/week
223763475|NCT05078736|OTHER|Moderate intensity continuous training|In group B participants will receive moderate intensity continuous training ran continuously the same 5 km at 70% of maximal aerobic speed, exercises will be performed by gym trainer for 5 weeks including 3 days/week.
223763476|NCT04485559|DRUG|Everolimus|Given PO
223763477|NCT04485559|DRUG|Trametinib|Given PO
223763478|NCT01167712|BIOLOGICAL|Bevacizumab|Given IV
223763479|NCT01167712|DRUG|Carboplatin|Given IV
223763480|NCT01167712|PROCEDURE|Computed Tomography|Correlative studies
223763481|NCT01167712|DRUG|Paclitaxel|Given IV
224215849|NCT03801213|DEVICE|urinary catheterization|Urinary catheterization with pain controlled
223514063|NCT03741374|PROCEDURE|Minimally-invasive non-surgical therapy (MINST)|A non-surgical minimally-invasive treatment protocol, named MINST, has been proposed (Ribeiro et al. 2011) for the treatment of periodontitis, in order to minimise patient discomfort and maximise the healing potential. This technique usually involve the use of magnification lenses or microscopes and small instruments which would reduce the risk of tissue trauma compared with traditional instruments.
223514067|NCT06358144|BEHAVIORAL|Packaging imagery|Participants in the four intervention conditions will be shown four cannabis edibles packages that have been altered to contain one of the imagery themes. All participants will see the same four products, and each condition will see the products with the same imagery theme.
223514068|NCT06358144|BEHAVIORAL|No Imagery (Control)|Participants in the control condition will see the same four product packages, but without any added imagery.
223514069|NCT04804709|DRUG|Panobinostat 15 MG|After each instance of opening the BBB using specific parameters of focused ultrasound in the specific number of tumor sites (one, two, or three), the subjects will receive oral Panobinostat (15 mg/m\^2).
223514070|NCT04804709|DEVICE|Focused Ultrasound with neuro-navigator-controlled sonication|"The purpose of this study is to evaluate the feasibility of opening the BBB safely using specific parameters of focused ultrasound in progressive/recurrent diffuse midline gliomas in one, two, or three tumor sites. The trial will follow a 3+3 Number of Tumor Sites (NOTS) escalation scheme. The number of tumor sites in reference to here is the number of openings in the blood-brain barrier using Focused Ultrasound (FUS). Subjects will start the first cycle of the treatment arm with 1 tumor site and move on to incrementing NOTS levels if no dose-limiting toxicities (DLTs) are observed."
223514071|NCT00148538|BEHAVIORAL|Resistance and/or Aerobic Exercise|Resistance and/or Aerobic Exercise
223627098|NCT00786669|DRUG|Bevacizumab|Bevacizumab (IV) 15 mg/Kg on day 1 every 3 weeks for up to 6 cycles
223514072|NCT00485342|DRUG|Peg-interferon alpha 2a and ribavin|"Date of ribavirin AUC : Day 0 (beginning of treatment) Bitherapy : Peg-interferon alpha 2a (180 µg/week) with ribavirin (1000 mg/day if weight \< 75 kg and 1200 mg/day if weight ≥ 75 kg).~Duration of treatment : 48 weeks Duration of study for patients : 72 weeks"
223514073|NCT00485342|DRUG|ribavirin with adaptation dose|"Date of ribavirin AUC : Day 0 (beginning of treatment) Bitherapy : Peg-interferon alpha 2a (180 µg/week) with ribavirin (dose adaptation) Dose adaptation : Day 7, dependant of result of AUC Ribavirin dose increments : 200 mg, 400 mg or 600 mg with a maximum of 50% of the initial dose (600 mg) applied every 4 days up to the adjusted dose proposed in order to reach the targeted AUC.~The maximum daily dose will not exceed 3600 mg Duration of treatment : 48 weeks Duration of study for patients : 72 weeks"
223763482|NCT01167712|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
223763483|NCT03633396|BIOLOGICAL|Imsidolimab|Administered by subcutaneous injection once a month
223763484|NCT03633396|DRUG|Placebo|Administered by subcutaneous injection once a month
223763485|NCT01012817|OTHER|Laboratory Biomarker Analysis|Correlative studies
223763486|NCT01012817|OTHER|Pharmacogenomic Study|Correlative studies
223763487|NCT01012817|OTHER|Pharmacological Study|Correlative studies
223763488|NCT01012817|DRUG|Topotecan Hydrochloride|Given IV
224215850|NCT03801213|PROCEDURE|manual bladder stimulation technique|manual gentle tapping in the suprapubic area at a frequency of 100 taps per minute for 30 seconds followed by lumbar paravertebral massage maneuvers for 30 seconds. The renal and bladder stimulation will be performed in less than 3 minutes, with a maximum of two attempts spaced about 20 minutes
224215851|NCT00089115|BIOLOGICAL|autologous immunoglobulin idiotype-KLH conjugate vaccine|
224215852|NCT00089115|BIOLOGICAL|rituximab|
224215853|NCT00089115|BIOLOGICAL|sargramostim|
224215854|NCT04135456|DRUG|Mannitol|When the neurosurgeon starts the skin incision, 20% mannitol administered through the venous catheter with fulldrip in 5-10 minutes. Neurosurgeons evaluate the degree of brain relaxation after dura opening in 4 point scale (1=bulging brain, 2=firm brain, 3=satisfactorily relaxed, 4=perfectly relaxed).
224215855|NCT03499249|DRUG|N-Acetyl cysteine|Intravenous NAC therapy (6.25 mg/kg/hour of 10 mg/ml solution, or 0.625 ml/kg/hour, to give 150 mg/kg/day), starting within 24 hours of completion of KP and lasting for a total of 7 days
223514074|NCT04356703|OTHER|Neuropsicomotor developmental test|Children will be evaluated trough Bayley III and PEDI scale. They also will be examined by pediatrician, neurosurgeon, orthopedics and phisiatry
224215856|NCT01297569|DRUG|Ranibizumab|
223514075|NCT02290574|RADIATION|Hyperthermia with concurrent chemo-radiation therapy|
223514076|NCT06114472|DRUG|aromatherapy blend containing Lavender|hree drops of aromatherapy blend containing Lavender essence 10% were poured on cotton in cast containers, and the patient was asked to inhale it for 5 minutes from a distance of 10 cm
223514077|NCT03211858|DRUG|Insulin aspart|SAR341402 100 units per milliliters (U/mL) (dose range of 1 unit to 80 units) self-administered by SC injection, immediately (within 5-10 minutes) before meal intake. Dose adjusted to achieve a 2-hour postprandial plasma glucose (PPG \<10 millimoles/liter \[mmol/L\] \[\<180 milligram/deciliter {mg/dL}\]) while avoiding hypoglycemia.
223514078|NCT03211858|DRUG|NovoLog/NovoRapid|NovoLog/NovoRapid 100 U/mL (dose range of 1 unit to 60 units) self-administered by SC injection, immediately (within 5-10 minutes) before meal intake. Dose adjusted to achieve a 2-hour postprandial plasma glucose (PPG \<10 mmol/L \[\<180 mg/dL\]) while avoiding hypoglycemia.
224215857|NCT05365347|BEHAVIORAL|Cognitive Enhancement Therapy (CET)|Cognitive enhancement therapy is an evidence based intervention for schizophrenia focused on improving the cognitive domains of memory, attention span and learning ability. It has shown efficacy in reducing substance use as an indirect outcome but this will be the focus of this intervention.
224215858|NCT03163069|COMBINATION_PRODUCT|in-office bleaching with the conventional whitening dentifrice|Participants will receive in-office tooth bleaching with 40% hydrogen peroxide (Opalescence Boost PF 40%) for the maxillary anterior teeth (2 sessions, with a 1-week interval). During the tooth bleaching procedure and 3 weeks after the procedure, the participants will be instructed to brush their teeth twice with the conventional whitening dentifrice.
224215859|NCT03163069|COMBINATION_PRODUCT|in-office bleaching with the whitening dentifrice containing blue covarine|Participants will receive in-office tooth bleaching with 40% hydrogen peroxide (Opalescence Boost PF 40%) for the maxillary anterior teeth (2 sessions, with a 1-week interval). During the tooth bleaching procedure and 3 weeks after the procedure, the participants will be instructed to brush their teeth twice with the whitening dentifrice containing blue covarine.
224215860|NCT03163069|COMBINATION_PRODUCT|in-office bleaching with the regular dentifrice|Participants will receive in-office tooth bleaching with 40% hydrogen peroxide (Opalescence Boost PF 40%) for the maxillary anterior teeth (2 sessions, with a 1-week interval). During the tooth bleaching procedure and 3 weeks after the procedure, the participants will be instructed to brush their teeth twice with the regular dentifrice.
224215861|NCT02503566|DEVICE|Optical coherence tomography|Optical coherence tomography performed during regular coronary angiography
224215862|NCT02731833|OTHER|stannous fluoride|0.454% weight by weight (w/w) stannous fluoride containing 1100ppm fluoride
224215863|NCT02731833|OTHER|sodium monofluorophosphate|0.76% w/w sodium monofluorophosphate containing 1000ppm fluoride
224215864|NCT00512356|BIOLOGICAL|Anti-Adhesion Product|Anti-Adhesion Product (AAP) is a biological two-component product of human origin. The components of AAP are lyophilized Anti-Adhesion Protein Concentrate (AAPC), containing fibrinogen, lyophilized Thrombin Concentrate (TC) and the respective diluents for the reconstitution of the components.
224215865|NCT02026037|BEHAVIORAL|Brief Treatment for Acutely Burned Patients (BTBP)|Brief Treatment for Acutely Burned Patients (BTBP) adapts CBT principles that have been validated with non-burn trauma survivors to the treatment of hospitalized burn patients. BTBP consists of three 1 to 1½ hour sessions per week for two weeks, as well as two sessions for family members or partners/spouses.
224215866|NCT05117866|DRUG|prasugrel Monotherapy|Prasugrel Monotherapy according to the local dosage (Loading : 20mg, maintenance: 3.75mg/day)
224215867|NCT05966259|OTHER|Intervention Group- Intensive Multilevel Intervention|intensive multilevel intervention, with a minimum of 26 contact hours, for a period of 5 months. The children will be re-evaluated in the eighth month (three months after intervention) and in the eleventh month (six months after intervention). The monthly activities were composed of four weekly contacts: Individual Attendance, Food and Nutrition Education (at home), Group Food and Nutrition Education in the basic health unit and Telephone monitoring. There will be five monthly themes: food, physical activity, sedentary behavior, sleep, and mental health.
224215868|NCT05966259|OTHER|Control Group|The children in the Control Group were followed in a similar way, observing the activities so that they did not exceed 26 hours of contact, during the 5 months.
224215869|NCT05155020|BIOLOGICAL|AK120|AK120 regimen 1-subcutaneous injection every two weeks up to week 24, and follow up to week 32.
224215870|NCT05155020|BIOLOGICAL|AK120|AK120 regimen 2(first dose doubling)-subcutaneous injection and then every two weeks up to week 24, and follow up to week 32.
223627099|NCT00786669|DRUG|Temozolomide|100 mg/m2/day po on Days 1-5 every 3 weeks for up to 6 cycles. For patients under 0.5 m2 BSA, TEM = 3.3 mg/kg/day po on Days 1-5.
223627100|NCT00786669|DRUG|Vincristine|1.5 mg/m2 on Day 1 (max dose 2 mg) administered as an IV bolus every 3 weeks for up to 6 cycles. For patients \<0.5 m2 BSA, VCR dose = 0.05 mg/kg (maximum dose 2 mg).
223627101|NCT00786669|DRUG|Irinotecan|90 mg/m2/day po on Days 1-5 every 3 weeks for up to 6 cycles
223627102|NCT00786669|DRUG|Cefixime|8 mg/kg/day (max. daily dose 400 mg) of cefixime or 5 mg/kg/dose bid (max. daily dose 400 mg) of cefpodoxime starting Day -1 BEFORE chemotherapy and continuing EVERY DAY while on study, or for 2 days after last dose of chemotherapy if treatment stopped early for disease progression or toxicity
223627103|NCT04386200|OTHER|web-based thecnologies|"Integration of traditional face-to-face educational approach with web-based technologies."
223627104|NCT04386200|BEHAVIORAL|traditional approach|"traditional face-to-face educational approach"
223627105|NCT06221995|DIAGNOSTIC_TEST|Indirect Calorimetry|Resting energy expenditure measurement
223627106|NCT01796717|DRUG|C Group|Controlled group will receive piperacillin/tazobactam of 4.5g Q6h, intermittent infusion for 30 minutes
223763489|NCT01012817|DRUG|Veliparib|Given PO
224215871|NCT05155020|BIOLOGICAL|AK120|AK120 regimen 3(first dose doubling)-subcutaneous injection and then every two weeks up to week 24, and follow up to week 32.
224215872|NCT05155020|BIOLOGICAL|Placebo|Placebo subcutaneous injection every two weeks up to week 24, and follow up to week 32.
224215873|NCT04289584|OTHER|Strength and proprioception exercises|Strength and proprioception exercises will be performed with the athlete in different positions depending on the exercise. There will be 3 series with 30 repetitions and 10-second breaks between sets. Each exercise session will be held for 15 minutes. Theraband® exercises are: unipodal balancing on hard surface with open and closed eyes, unipodal balancing on soft surface, squats, lateral walk, isometric contractions with garter and dynamic leg opening, tiptoe, and eccentric hamstring curl with garter.
224215874|NCT02903316|PROCEDURE|Fluids|
224215875|NCT04363931|PROCEDURE|Manual Therapy|Participants in this group received 4 weeks of manual therapy and massage of the masticatory muscles intra and extra orally together with massage of the cervical muscles. Massage and Manual Therapy brings about benefits by increasing local circulation and decreasing muscle tonus . Additionally, stretching exercises aiming to decrease pain and elongate shortened masticatory muscle fibers by autogenic inhibition of the masseter muscle were performed.
224215876|NCT04363931|PROCEDURE|Kinesio Taping|Participants in this group had an application of Kinesio Taping on the masseter muscles. The material used for bruxism Kinesio Taping application was Kinesio Tex Gold Finger Prints (Kinesio Holding Corporation, Albuquerque, USA), a 100% cotton, latex-free, 5-cm wide, elastic tape. Kinesio Taping placement was chosen according to principles described by Kase et al. Tapes were cut 2.5 cm in width (cut in half vertically from 5 cm width). Two strips of Kinesio Tape were crossed over the masseter muscle area with 0-5% tension in maximum stretched epidermis position. Web-cut strips epidermis-dermis-fascia technique were used. Tape was applied bilaterally after every session of manual therapy.
224215877|NCT05802979|DRUG|Adjuvants, Anesthesia|testing the effect of adding ketamine versus neostigmine to the analgesic efficacy of serratus anterior plane block in modified radical mastectomy surgeries
224215878|NCT03812601|PROCEDURE|Simultaneous bi-atrial electroanatomic mapping and ablation|Simultaneous bi-atrial electroanatomic mapping during atrial fibrillation and during pacing from 3 different vectors at varying cycle lengths followed by pulmonary vein isolation and AcQMap guided ablation of non-pulmonary vein mechanisms.
223763490|NCT03756558|DEVICE|Cross-Seal System|Use of the Cross-Seal system to close the femoral arteriotomy
223763491|NCT02307578|DRUG|Perampanel|Perampanel will be available in 2-milligrams (mg), 4-mg and 8-mg tablets and as 0.5 milligram per milliliter (mg/mL) oral suspension. Participants will start this EAP with the dose that they were receiving at the end of their participation in Study E2007-G000-332, Study E2007-G000-311, E2007-G000-238, E2007-G000-338 or EAP E2007-G000-401. Doses of perampanel can be adjusted based on clinical judgment.
223627107|NCT01796717|DRUG|E Group|Therapy group will receive piperacillin/tazobactam of 4.5g Q6h, prolonged infusion for 4 hours
223627108|NCT02579200|DEVICE|POWERbreathe®KHA (IMT group)|2 training sessions/day consisting of 30 breaths (\~50% maximal inspiratory pressure; Pi,max), 7 days/week (once/week supervised at research center), for 8 weeks using an electronic tapered flow resistive loading (TFRL) device (POWERbreathe®KH2, HaB International Ltd., Southam, UK). Measurements of PImax will be performed every week and training loads will be increased continuously to maintain the actual \~50% Pimax values.
223627109|NCT02579200|DEVICE|POWERbreathe®KH2 (sham group)|2 training sessions/day of 30 breaths at an inspiratory load of no more than 10% of their initial Pi,max (POWERbreathe®KH2, HaB International Ltd., Southam, UK). This training load will not be changed during the entire study period.
223763492|NCT06956339|PROCEDURE|Early anterior cruciate ligament surgery|Participants randomised to early anterior cruciate ligament reconstruction surgery (ACLR) will be referred to a study orthopaedic surgeon. Participants will have surgery within 8 weeks of randomisation. The ACLR will reflect usual care for each surgeon. Participants will undergo routine preoperative care, including an anaesthetic consultation to assess fitness for surgery and general anaesthesia. Surgeons will choose their preferred surgical technique and graft, and treat concomitant injuries surgically if indicated and aligned with their usual practice. Participants will follow the surgeon's standard recommendations regarding post-operative care and appointments. Participants will be provided with 15 funded physiotherapy consultations within 12 months of surgery and undertake a physiotherapist-supervised goal-oriented exercise-based rehabilitation program.
223627110|NCT01863823|DRUG|Amoxicillin and Tetracyclines|202 symptomatic and 148 asymptomatic individuals were recruited and tested using Saliva H. pylori antigen tests (HPS), H. pylori flagellin (HPF), the urea breathe test (UBT) and the polymerase chain reaction (PCR) test. Test subjects also received various treatments.
223627111|NCT01863823|DRUG|Mouth washing|Two time washing mouth per day
223627112|NCT06002620|DIETARY_SUPPLEMENT|CSB+|standard care
223627113|NCT06002620|DIETARY_SUPPLEMENT|Enriched nutrition food (CEF)|enriched cricket flour at 20%
223627114|NCT06002620|BEHAVIORAL|Nutrition education|regular videos, sms reminders and face to face interaction
223763493|NCT06956339|OTHER|Novel bracing protocol|"Participants will undertake the Cross Bracing Protocol under the supervision of a study physiotherapist (23 funded physiotherapy sessions within 12 months). Medical oversight and venous thromboembolism prophylaxis will be provided by the study sports and exercise medicine physician.~A specialised knee brace will be fitted within 21 days of ACL injury. The knee is kept at 90° flexion in the brace at all times for the first four weeks. The brace is then adjusted weekly by the physiotherapist to allow progressive increases in knee range (60-90° flexion at 5 weeks, 45-90° flexion at 6 weeks, 30° to full flexion at 7 weeks, 20° to full flexion at 8 weeks, 10° to full flexion at 9 weeks, unrestricted range at 10 weeks, brace off at 12 weeks). Whilst braced and after brace removal, the participant will undertake physiotherapist-supervised goal-oriented exercise-based rehabilitation within the available knee range."
223763494|NCT05970575|DRUG|NE3107|Participants will take 20mg twice daily (BID) approximately 12 hours apart. The dose will be stable the duration of the study intervention (6 months)
223763495|NCT04373902|PROCEDURE|Physiological-based cord clamping|See 'Arm'
223763496|NCT04386967|BIOLOGICAL|OH2 injection|Oncolytic Type 2 Herpes Simplex Virus
223763497|NCT04386967|DRUG|Keytruda|Anti-PD-1 antibody
223763498|NCT05757817|PROCEDURE|Oropharyngeal or oral cavity reconstruction|"Oropharyngeal or oral cavity reconstruction will be performed using a free super thin external pudendal artery flap (STEPA flap).~Post-operative follow-up and adjuvant treatment: Post-operative follow-up of patients will be performed according to the standards of the participating centers."
224215879|NCT01374906|DRUG|pasireotide LAR|Pasireotide long-acting was administered as an intra-muscular depot intragluteal injection once every 28 days (±2 days). Patients were administered pasireotide long-acting 10 mg or 30 mg for four months, followed by either continuation of the starting dose, or dose up-titration (if mUFC was still \>1.5xULN unless titration was precluded by safety reasons).
224215880|NCT01374906|DRUG|SOM230 LAR 30 mg|starting dose of 30 mg i.m. administered once every 28 days for 4 months, followed by dose up-titration or continuation of starting dose.
224215881|NCT01374906|DRUG|SOM230 LAR 10 mg|starting does of SOM230 LAR 10 mg i.m. administered once every 28 days for 4 months, followed by dose up-titration or continuation of the starting dose.
224215882|NCT06545448|PROCEDURE|Percutaneous Coronary Intervention (PCI)|A percutaneous coronary intervention (PCI) is a minimally invasive procedure to open blocked coronary (heart) arteries. An older name for PCI is coronary angioplasty with stenting or angioplasty for short.
223763499|NCT05427500|DRUG|5 mL of 0.5% preservative-free bupivacaine|IV will be inserted. Patient will be connected to cardiorespiratory monitors. The neck will be cleansed twice. A high frequency (15-6 MHz) linear ultrasound probe will be used to identify the arteries, jugular vein, and other important vasculature. Once a clear path for the needle is identified, the skin is anesthetized. A cutting tip spinal needle is then inserted at the lateral aspect of the field and advanced in-plane under ultrasound visualization. A test injection is injected to verify placement, then 5 mL of 0.5% preservative-free bupivacaine will be injected. Per standard SGB procedure, vitals will be measured post-SGB and participants will remain in the clinic for approximately 15 minutes to monitor for any serious adverse events.
224215883|NCT04559165|OTHER|sericin and chitosan cream|sericin and chitosan cream
224215884|NCT02505165|BEHAVIORAL|IMPACT|• The intervention is 6 sessions lasting approximately 45 minutes reviewing ways to help prevent and respond to illness uncertainty. Sessions occur weekly at already scheduled clinic appointments. Interventions will be delivered by a trained interventionist.
224215885|NCT02505165|OTHER|ESO|This control is 6 sessions lasting approximately 45 minutes providing education on cancer etiology, medical treatments, side effects, potential short- and long-term effects of treatment and resources that are often helpful to parents of children with cancer. Sessions occur weekly at already scheduled clinic appointments. Interventions will be delivered by a trained interventionist.
224215886|NCT01796041|DRUG|Indocyanine Green|
223514079|NCT03211858|DRUG|Insulin glargine (HOE901)|Insulin glargine 100 U/mL injected QD subcutaneously consistent with the local label. Doses adjusted to achieve glycemic target for fasting, preprandial plasma glucose between 4.4 to 7.2 mmol/L (80 to 130 mg/dL) without hypoglycemia.
223514080|NCT02973152|PROCEDURE|Thyroplasty|This medialisation/augmentation technique is a static technique, performed under local anaesthesia that aims to improve the positioning of the paralysed vocal fold. It uses a silastic implant readily available in different sizes according to size of larynx and gender of the patient. The correct size can be determined intraoperatively by using a measuring device while listening and visualising the larynx with flexible fiberoptic scope simultaneously.
223514081|NCT02973152|PROCEDURE|Reinnervation|For laryngeal reinnervation, ansa cervicalis to recurrent laryngeal nerve repair technique will be used. In this technique, the functioning ansa cervicalis nerve that overlies the internal jugular vein and the distal stump of injured recurrent laryngeal nerve (RLN) will be identified and anastomosed without tension (Crumley RL. Teflon versus thyroplasty versus nerve transfer: a comparison. The Annals of otology, rhinology, and laryngology. 1990;99(10 Pt 1):759-63).
223514082|NCT04314206|DRUG|VNRX-5024|"Part 1: one dose~Part 2:~Cohort 1: 10 doses (once a day for 10 days) Cohort 2: 19 doses (once every 12 hours \[q12h\] dosing for 9 days with a single morning dose on Day 10) Cohort 3: 28 doses (once every 8 hours \[q8h\] dosing for 9 days with a single morning dose on Day 10)"
223514083|NCT04314206|DRUG|Placebo for VNRX-5024|"Part 1: one dose~Part 2:~Cohort 1: 10 doses (once a day for 10 days) Cohort 2: 19 doses (once every 12 hours \[q12h\] dosing for 9 days with a single morning dose on Day 10) Cohort 3: 28 doses (once every 8 hours \[q8h\] dosing for 9 days with a single morning dose on Day 10)"
223514084|NCT01625078|DEVICE|Placement and use of Baska mask|Use of Baska mask as a supraglottic airway during general anesthesia
223514085|NCT03810365|BEHAVIORAL|Brief behavioral treatment for insomnia|Brief Behavioral Treatment for Insomnia includes content on sleep restriction, stimulus control, and sleep hygiene content with 1 month for primary outcome followed by 3 month 12 month follow-up visits.
223514086|NCT03810365|BEHAVIORAL|Healthy Eating Control|Healthy eating control involves healthy eating content with 1 month for primary outcome followed by 3 month and 12 month follow-up visits.
223514087|NCT01357746|PROCEDURE|Transthoracic pulmonary doppler recording|A 30 min recording of doppler signals from the right chest wall including measurements while the patient performs Valsalva maneuvers
223514088|NCT00600704|PROCEDURE|Fluid Restriction Policy|Infusion of Hes 130/0.4 up to 500 ml until the beginning of Cardiopulmonary bypass
223763500|NCT00978731|DRUG|Dasatinib|"Tablets, Oral, The dosing ranges from 50mg to a total of 240mg daily with the following 3 schedules:~* 5 days on, 2 days off~* 6 days on, 1 day off~* Continuous daily dosing~Once Daily (QD) or Twice Daily (BID) dosing, Subjects will be treated until progression of disease despite escalation/reductions of dose to the level deemed safe by available data, until intolerable/unacceptable toxicity or until subject withdrawal from the study or discontinuation of the study"
223627115|NCT06002620|COMBINATION_PRODUCT|Combined nutrition and education|combined enriched cricket flour and nutrition education
223763501|NCT03366077|DIETARY_SUPPLEMENT|Probiotic|Probiotic
223763502|NCT01163383|DRUG|131 I-Metaiodobenzylguanidine (131 I-MIBG)|131 I-MIBG 1-18mCi/kg given intravenously on day 1. Subjects may receive multiple courses every 4-8 weeks depending on the dose given.
223763503|NCT01163383|DRUG|131 I-MIBG|131-I-MIBG will be infused intravenously over 60-90 minutes once per course. The dose will be determined by the treating physician.
223763504|NCT06361888|DRUG|Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine|"Drug: Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine~1. Surufatinib: 250mg or 200mg, qd~2. Camrelizumab: 200mg, IV drip, Q3W, D1~3. Nab-paclitaxel: 125 mg/m2, IV drip, D1,D8~4. Gemcitabine : 1000 mg/m2, IV drip, D1, D8"
223763505|NCT06361888|DRUG|Nab-paclitaxel Plus Gemcitabine|"Drug: Nab-paclitaxel Plus Gemcitabine~1. Nab-paclitaxel: 125 mg/m2, IV drip, D1,D8~2. Gemcitabine : 1000 mg/m2, IV drip, D1, D8"
223763506|NCT06361888|DRUG|Surufatinib with Nab-paclitaxel, and Gemcitabine|"Drug: Surufatinib with Nab-paclitaxel, and Gemcitabine~1. Surufatinib: 250mg or 200mg, qd~2. Nab-paclitaxel: 125 mg/m2, IV drip, D1,D8~3. Gemcitabine : 1000 mg/m2, IV drip, D1, D8"
223763507|NCT05592912|DRUG|HydroLenz Injection|The HydroLenz injection will be administered at the conclusion of the vitrectomy procedure on the operative day
223763508|NCT05592912|OTHER|No HydroLenz Injection|No HydroLenz injection will be administered at the conclusion of the vitrectomy procedure on the operative day.
223763509|NCT04644224|OTHER|Educational Activity|Attend health coaching session
223763510|NCT04644224|OTHER|Educational Intervention|Attend resource navigation session
224215887|NCT04412876|DRUG|Duloxetine|Duloxetine 30 mg qd
224215888|NCT04412876|DRUG|Imipramine|Imipramine 25mg qd
223514089|NCT00600704|PROCEDURE|Free fluid infusion|Free fluid infusion unless Hb\< 6g/dl(allogenic blood use), until the beginning of Cardiopulmonary bypass
223514090|NCT04917510|PROCEDURE|Erector spinae block|See experimental arm group description
223514091|NCT04917510|PROCEDURE|Local block|See control and study arm group descriptions for the local block
223514092|NCT04632381|DRUG|Zotatifin|Zotatifin is a potent and sequence-selective inhibitor of eukaryotic translation initiation factor (eIF) 4A1-mediated translation that imparts its regulation through a reversible enhancement of eIF4A1 binding to RNAs (ribonucleic acids) with specific polypurine motifs within the 5'-untranslated region (UTR).
223514093|NCT04632381|DRUG|Placebo|5% dextrose injection, USP
223514094|NCT06243926|OTHER|Sperm selection for ICSI|Sperm selection for ICSI is a critical step to ensure the use of viable and healthy sperm for fertilization in vitro. The goal is to choose a sperm that has the best chance of resulting in a successful pregnancy.
223514095|NCT04198337|PROCEDURE|Endoscopic Full Thickness Resection|Endoscopic full thickness resection achieved by resecting the submucosal tumor using retraction techniques and submucosal dissection, followed by closure
223514096|NCT01532219|BEHAVIORAL|Internet-delivered Psychodynamic Treatment|Ten weeks of guided self-help + therapist contact, via the Internet.
223514097|NCT01532219|BEHAVIORAL|Internet-delivered structured support|Ten weeks of therapist contact, via the Internet.
223514098|NCT02672605|OTHER|Pennsylvania State Abortion Consent|Measuring the level of stigma felt pre- or post-exposure to the abortion consent language.
223514099|NCT03780062|BIOLOGICAL|S100B protein dosing|Patients under antiplatelet therapy and who have a minor traumatic brain injury will have a blood samples with protein S100B dosage on arrival to the emergency room and after they will have a brain scanner between 4 and 8 hours after the trauma to analyse the negative predictive value with a treshold of 0.105 μg/L
223514100|NCT01918020|BEHAVIORAL|Go Wild with Fruits and Veggies!|Fruits and Vegetables
223514101|NCT01918020|BEHAVIORAL|Go Wild with Fruits and Veggies! delayed|Go Wild with Fruits and Veggies! delayed
223514102|NCT00842465|BIOLOGICAL|blood collection for hormonal status analysis|for hormonal status analysis
223514103|NCT00842465|PROCEDURE|breast Biopsy or surgery|breast Biopsy or surgery
223514104|NCT00842465|GENETIC|blood collection|blood collection for prlR gene sequencing
223514105|NCT00842465|OTHER|ultrasonography (pelvis and breast), bone mineral density|ultrasonography (pelvis and breast), bone mineral density
223514106|NCT02918630|DRUG|Nicotine Patch|Participants will receive nicotine patch (21 mg) starting study Week 1. Participants will be instructed to apply a new patch each morning.
223514107|NCT02918630|DRUG|E-cigarette|The e-cigarette will consist of 1) a 3.3 V, 1000 mAh battery; and 2) a 1.5 Ohm, dual-coil cartomizer (SmokTech; Shenzhen, China). Study staff will load the cartomizer with 1 ml tobacco flavored 70% propylene glycol/30% vegetable glycerin liquid containing nicotine concentrations 36 mg/ml (AVAIL; Richmond, Virginia, USA).
223514108|NCT04705233|OTHER|sputum colour chart|5-point Sputum Colour Chart plus best standard care
223514109|NCT01620047|DRUG|Fentanyl|Fentanyl 3 µg/ml continuously infused for a 24 hour period at a basal rate of 10ml/hour starting from the time the patient entered the post anesthesia care unit (PACU)through a femoral nerve sheath catheter.
223514110|NCT01620047|DRUG|Ropivacaine|Ropivacaine 0.1% delivered through a femoral nerve sheath catheter continuously for a 24 hour period at a basal rate of 10ml/hour starting from the time the patient entered the post anesthesia care unit (PACU).
223514111|NCT01620047|DRUG|Fentanyl|0.9% normal saline delivered through a femoral nerve sheath catheter in addition to a continuous intravenous infusion of fentanyl 3 µg/ml via a PCA pump for a 24 hour period at a basal rate of 10ml/hour starting from the time the patient entered the post anesthesia care unit (PACU).
223514112|NCT02389738|DRUG|Regadenoson|Regadenoson administration on post-op day 2 after temozolomide administration. Temozolomide plasma and dialysate concentrations will be obtained over 18 hours post temozolomde administration.
223763511|NCT04644224|OTHER|Informational Intervention|Receive handbook
223514113|NCT02389738|DRUG|Temozolomide|Temozolomide administration on post-op day 1 and 2. Temozolomide plasma and dialysate concentrations will be obtained over 18 hours post temozolomde administration.
223514114|NCT02389738|DEVICE|Microdialysis catheter|Microdialysis catheter placement post surgical resection and removed at the bedside after completion of obtaining all dialysate collections.
223514115|NCT03188380|DIAGNOSTIC_TEST|Plain abdominal radiography|After meeting enrolment criteria each patient will have an AR performed. One image will be obtained with a vertical beam and a horizontal beam, with the patient supine.
223514116|NCT03188380|DIAGNOSTIC_TEST|Abdominal ultrasound|If the AR is inconclusive or no abnormalities typical for NEC are recorded, an AUS will be ordered.
223514117|NCT02155855|OTHER|Telemedicine|Study group will test blood glucose at least 4 times a day Each time the meter timestamps the reading. All meter readings will upload to the cloud via Myglucohealth website, where they can be accessed by caregivers, including providers and parents. Parents will be notified by device about the blood glucose testing results. Provider will set device to alert patient or patient's family or send alerts if uploaded numbers are outside an identified range (\<70 mg/dL \> 300 mg/dL). As per the standard of care, parents are trained to administer sugar containing liquids, or inject extra insulin for hyperglycemia correction. Parents will be encouraged to contact study personnel if they are concerned about the diabetes control. Study personnel will access home blood glucose monitor data, and provide insulin dosing advice. Parents will be asked to upload blood glucose readings prior to each visit.
223514118|NCT02155855|OTHER|Control|Routine care
223514119|NCT02402907|DEVICE|2% chlorhexidine gluconate (CHG) cloth|administration of a 2% CHG cloth at home on the night before and approximately 3 hours prior to cesarean delivery on the morning of the surgery.
223514120|NCT02402907|DEVICE|Placebo cloth|administration of a cloth with the placebo (commercial cleansing cloth) at home on the night before and approximately 3 hours prior to cesarean delivery on the morning of the surgery.
223514121|NCT06569654|DEVICE|Saebo splint|"The SaeboFlex orthosis was fitted individually for each participant in the intervention group. The orthosis was adjusted to ensure proper alignment and comfort.~Participants were instructed on how to don and doff the orthosis correctly and safely.~The orthosis positions the wrist and fingers in extension in preparation for grasp and release activities, enabling participants to perform functional tasks despite limited voluntary movement.~Task-Oriented Repetitive Training:~The intervention consisted of 45-minute sessions, conducted twice a week, over a period of 12 weeks.~Each session focused on repetitive, task-oriented exercises designed to improve motor function and enhance neuroplasticity.~Training Activities:~* Moving the Ball~* Bringing the Ball to the Mouth~* Reaching Towards a Target~* Manipulating the Ball Around a Target~* Placing the Ball into Tubes~* Throwing the Ball~* Catching a Rolling Ball"
223514122|NCT02920294|DIETARY_SUPPLEMENT|Probiotic 1|Fresh fermented dairy drink containing yoghurt ferments
223514123|NCT02920294|DIETARY_SUPPLEMENT|Probiotic 2|Fresh fermented dairy drink containing probiotic strain
223514124|NCT02920294|DIETARY_SUPPLEMENT|Placebo|Acidified dairy drink without ferments
223514125|NCT03379493|BIOLOGICAL|ET190L1 ARTEMIS™ T cells|Autologous T cells transduced with lentivirus encoding an anti-CD19 (ET190L1) ARTEMIS™ expression construct, administered by intravenous (IV) infusion
223514126|NCT04845555|OTHER|Observation of the association between clotting factor level and risk of bleeding whilst physical activity|"The participants of this study will be monitored for a period of twelve months regarding individual clotting factor level, bleeding episodes as well as type and intensity of physical activity. By doing so, bleeding events, factor consumption as well as the course of the individual factor clotting factor level will be documented via the mobile application myPKFiT. This individual factor treatment regime will be compared with the retrospective treatment outcome in the last twelve months before the first study visit."
223514127|NCT03570515|BEHAVIORAL|Yoga|Yoga group participants will attend two, 75-minute yoga classes/week for 4 weeks, then one class/week for 8 weeks, and do a 30-minute home practice on non-class days, recording their practice on a yoga homework log provided to them.
223514128|NCT03570515|BEHAVIORAL|Educational film|Educational film group participants will attend one, 75-minute film class/week for 12 weeks, recording any RLS treatments they use at home.
223514129|NCT00131742|DRUG|telbivudine|
223514130|NCT00131742|DRUG|lamivudine|
223514131|NCT00449787|DRUG|Sumatriptan 100 mg|Sumatriptan 100mg tablet
223514132|NCT00449787|DRUG|Naproxen|Naproxen 500mg tablet
223514133|NCT05524792|OTHER|no interventional study|no interventional study
223763512|NCT04644224|OTHER|Questionnaire Administration|Ancillary studies
223763513|NCT04644224|PROCEDURE|Support Group Therapy|Attend support group
223763514|NCT04581460|OTHER|Questionnaire|Questionnaire intended for patients on the course of pregnancy and postpartum, the neonatal period and contraceptive modalities.
223763515|NCT06219551|OTHER|Mobile messages via What's App|The information article that was prepared by taking the opinions of academics experienced in adult education, and were prepared as a video by the primary Rheumatologist who performs the randomization and will be shared in the Whatsapp group as information. Additionally, information will be provided once a week regarding the appointment date of the smoking cessation clinic.
223763516|NCT05991037|BIOLOGICAL|Blood sampling for psychoactive drugs dosage|4 blood samples for psychoactive drugs identification and dosage will be taken on arrival at the emergency room during fall management
223763517|NCT05041803|DRUG|CTP-543|Twice daily dosing
223763518|NCT06771128|DRUG|Ginkgo Biloba oral tablet|patients receive Ginkgo Biloba oral tablet 120 mg once daily
223763519|NCT06771128|DRUG|Desmopressin Acetate 0.2 mg Tablets|patient receives desmopressin 0.2 mg oral tablet once daily
223763520|NCT06771128|DRUG|Placebo|patients receive Placebo oral tablet once daily
223763521|NCT06109870|BEHAVIORAL|PRECEDE-PROCEED|delivered self-sampling (CHWSS) to increase screening participation.
223763522|NCT06208410|DRUG|JS105|JS105 is administered once daily, orally
223763523|NCT06208410|DRUG|Fulvestrant injection|Fulvestrant intramuscularly,The first cycle was injected once in D1 and D15, and then once in each cycle D1, and 28 days was 1 cycle
223763524|NCT06208410|DRUG|Dalpiciclib Isetionate Tablets|Dalpiciclib Isetionate Tablets, QD, oral, taken continuously for 21 days, then stopped for 7 days, 28 days for a cycle
223763525|NCT06208410|DRUG|Toripalimab Injection|Toripalimab Injection,Intravenous infusion, once every 3 weeks, 21 days for 1 cycle
223763526|NCT06208410|DRUG|Paclitaxel for Injection (Albumin Bound)|Paclitaxel for Injection (Albumin Bound),Intravenous infusion, D1, 8, 15 infusion, every 28 days for a cycle
224215889|NCT01837485|DRUG|Lactol|The Symbiotic Lactol® (Bioplus Life Sciences Pvt.) was applied 3 times a day for 3 months. Lactol is composed of the followings; Lactobacillus Sporogenes (15 × 107 Spores), Fructo-Oligosaccharides, Microcrystalline Cellulose, Sodium starch Glycolate, Povidone, Hypermellose Stearate, Sillicon Dioxide, and Propylene Glycol.
224215890|NCT01837485|DRUG|Placebo|Placebo pill was applied 3 times a day for 3 months
223763527|NCT06208410|DRUG|Fluzoparib Capsules|Fluzoparib Capsules is administered once daily, orally
223763528|NCT06208410|DRUG|Pyrotinib Maleate Tablets|Pyrotinib Maleate Tablets is administered once daily, orally
223763529|NCT06208410|DRUG|Capecitabine Tablets|Capecitabine Tablets is administered once daily, orally
224215891|NCT05050357|DEVICE|Hormonal intrauterine device|insertion of hormonal IUD during menstrual period
224215892|NCT05050357|DRUG|Progestins Norethindrone|oral ethisteron twice daily for three months
224215893|NCT04992338|DEVICE|Mobile app|The CarpeDiem application is a mobile application, designed in collaboration with the Health and Nutrition Technology Unit (UTNS, Eurecat) and the translational research group on respiratory medicine of the Institut de Recerca Biomèdica de Lleida. The application is available for devices with Android as the operative system and its advanced interface allows the user to monitor their physical activity, sleep and diet and motivate them to meet personalized goals through gamification. To do this, the user must answer the questionnaires that they will find on the main page of the application with a predetermined frequency, as well as perform missions that will help them acquire healthier habits. In addition, the user will receive motivational messages and recommendations through notifications that will help and guide them to achieve their missions and achieve their goals, and as a result of changing habits.
224215894|NCT00783562|OTHER|Extension-oriented exercise program|The exercise program was composed of six graded sessions, two per week for three consecutive weeks. Sessions, each of one hour length, were conducted after the working hours in a wide room of the nursery school, gathering together all the teachers from each school. The exercises were selected in order to reinforce lumbar extension and to strengthen the primary stabilizers of the spine (transversus abdominis, oblique abdominal, multifidus, quadratus lumborum and erector spinae muscles)
224317206|NCT05523466|OTHER|Acupuncture Sham|Immediately after the placement of the Polar V800, an instrument for analyzing heart rate variability, the placing of needles at the points carefully selected for this research begins. The needling will proceed for the Sham acupuncture using sham points (points not recognized as Acupuncture points), with the duration of 20 minutes
224215895|NCT00783562|OTHER|Informative Brochure|The brochure showed the correct way to lift loads, and provided ergonomic suggestions to prevent musculoskeletal complaints, according to the Italian legislation
224215896|NCT02475980|BEHAVIORAL|Comprehensive contraception counseling|The study intervention will consist of comprehensive contraceptive counseling through a standardized bundle of services, including a 10-minute educational DVD, handouts on contraceptive methods, and one-on-one contraceptive counseling by the PED physician.
224215897|NCT05219773|DEVICE|NuvoAir Air Next spirometer|"* The collection of medical history and demographic data~* Spirometry testing in both the clinic and home setting.~* The measurement of height and weight.~* The evaluation of the perception of home spirometry via a survey."
224215898|NCT05554874|OTHER|Pulsed electromagnetic fields|receiving Pulsed electromagnetic fields 3 times, immediately after the onset of delayed muscle soreness, 24 and 48 hours later.
224215899|NCT05554874|OTHER|Sham Pulsed electromagnetic fields|Sham application will be applied with the same device without applying magnetic current.
224317207|NCT06241625|DIAGNOSTIC_TEST|Virtual Reality (VR) Contrast Function Test|Patients perform a new Virtual Reality (VR) Contrast Function Test
223763530|NCT04661124|DEVICE|SPECTRALIS|ophthalmic imaging device with head and chinrest
223763531|NCT04661124|DEVICE|SPECTRALIS with Flex Module|ophthalmic imaging device on mobile instrumentation stand
223763532|NCT01896895|DRUG|IncobulinumtoxinA (Xeomin), 25 Units|IncobotulinumtoxinA (active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl). Main Period: 25 Units per eye.
224215900|NCT04455594|DRUG|Almonertinib|Oral, 110mg QD
224215901|NCT04455594|DRUG|Erlotinib|Oral, 150mg QD
224215902|NCT04455594|DRUG|Cisplatin|Cisplatin(75mg/m2) be administered with pemetrexed (500mg/m2) on Day 1 of every 3-week cycle for 3 cycles
224215903|NCT04455594|DRUG|Carboplatin|Carboplatin (AUC=5) to be administered with pemetrexed (500mg/m2) on Day 1 of every 3-week cycle for 3 cycles
224317208|NCT00751192|DEVICE|HIV-testing motivational videos|
224317209|NCT00751192|DEVICE|Standard public health text|
224317210|NCT04413110|DEVICE|Polysomnography|PSG was carried out for 41 patients with subjective cognitive impairment and 41 age and sex-matched controls. PSG with standard EEG montage that includes bilateral EOG and four EEG leads were used. A single attended overnight PSG study was performed at the Clinical Neurophysiology Unit of Mansoura University Hospitals. Patients were studied in a quiet, darkened room with no medications were used to induce sleep. All participants underwent one night of laboratory-based PSG.
224317211|NCT03740581|DRUG|Insulin|Basal Bolus regimen (Participant to receive, Insulin \>= 3 times per day)
224317212|NCT00098423|DRUG|tanespimycin|Given IV
224317213|NCT00098423|DRUG|cytarabine|Given IV
223514134|NCT05890573|DRUG|Bailing capsule|6 Bailing capsules,po,tid,12 weeks
223514135|NCT03701074|DRUG|Ibuprofen and acetaminophen|Intravenous ibuprofen given concomitantly with oral acetaminophen
223514136|NCT03701074|DRUG|Ibuprofen and placebo|Intravenous ibuprofen given concomitantly with oral placebo
223514137|NCT00443014|DEVICE|Cognitive, physical and social stimulation|Sessions of 30 minutes daily five days a week for one year
223514138|NCT06117631|BEHAVIORAL|Centering Parenting|See Arm description.
223514139|NCT06117631|BEHAVIORAL|Bright by Text|See Arm description.
223514140|NCT02852837|DRUG|Daratumumab|Intravenous (IV) infusion of 8 mg/kg or 16 mg/kg daratumumab.
223514141|NCT02317419|DRUG|RO6927005|RO6927005 administered intravenously on Days 1, 3, and 5 of each 21-day treatment cycle (QOD x 3).
223627116|NCT03383861|DIAGNOSTIC_TEST|Dual-Energy X-ray Absorptiometry (DXA)|BMD t-score derived from DXA scan
223627117|NCT03142386|OTHER|Osteopathic manipulative treatment|
223627118|NCT03142386|OTHER|Physiotherapy|
223627119|NCT02195908|OTHER|single point Neiguan(PC6) plus antiemetic drug|
223627120|NCT02195908|OTHER|single point Zhongwan(CV12) plus antiemetic drug|
223627121|NCT02195908|OTHER|matching points Neiguan(PC6) and Zhongwan(CV12) plus antiemetic drug|
223627122|NCT02195908|DRUG|only antiemetic drug|
223627123|NCT03467347|DRUG|VR: 200 mg DPV + 320 mg LNG|One silicone elastomer vaginal ring (VR) containing the active ingredients dapivirine (DPV) and levonorgestrel (LNG), formulated as IPM VR: 200 mg DPV + 320 mg LNG (Ring-102)
223627124|NCT02172963|BIOLOGICAL|Decidual Stromal Cell therapy|Intravenous injection with placenta derived Decidual Stromal Cells. 1-2x10\^6 cells/kg.
223627125|NCT03315741|DRUG|Pirfenidone 267 MG [Esbriet]|Tolerability of drug
223627126|NCT02552914|DEVICE|Colli-Pee|Participants will be asked to use the colli-pee to collect first-void urine and to send it back to the Institute of Tropical Medicine by regular mail.
223627127|NCT00872235|DRUG|fixed-dose combination of quinapril 20 mg and hydrochlorothiazide 25 mg tablets|
223627128|NCT01927497|PROCEDURE|Biological mesh assisted perineal closure|The eAPR procedure will be performed in an identical way as described for the control arm of the study, and this is preferably followed by an omental plasty. The intervention in the experimental arm consists of suturing an acellular biological mesh derived from porcine dermis in the pelvic floor defect (Strattice™, 6x10 cm). The mesh will be sutured at each side of the coccyx or distal sacrum with Prolene or PDS to the discretion of the surgeon. Laterally, the mesh is attached to the remainings of the levator complex and, anteriorly, to the transverse perineal muscle or posterior vaginal wall. A suction drain will be inserted and positioned on top of the mesh. The perineal subcutaneous fat and skin will be subsequently closed in layers similar to primary simple closure as performed in the standard arm.
224215904|NCT04455594|DRUG|Pemetrexed|Pemetrexed (500mg/m2) to be administered with Cisplatin(75mg/m2) or Carboplatin (AUC=5) on Day 1 of every 3-week cycle for 3 cycles
223763533|NCT01896895|DRUG|IncobotulinumtoxinA (Xeomin), 12.5 Units|IncobotulinumtoxinA (active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl). Main Period: 12.5 Units per eye.
223763534|NCT01896895|DRUG|Placebo|Main Period: Placebo to IncobotulinumtoxinA (Xeomin), powder for solution for injection, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).
223763535|NCT01896895|DRUG|IncobotulinumtoxinA (Xeomin), 35 Units|"IncobotulinumtoxinA (active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).~Open-Label Extension: up to 35 Units per eye."
223627129|NCT01927497|PROCEDURE|Primary perineal closure|The perineal phase of the APR will be performed according to the principles of an extralevator APR, which means that the levator muscles will be laterally transected in order to leave a muscular cuff around the tumour. The coccyx will not be routinely resected, but only if indicated based on surgical exposure or oncological principles. The extent of excision of perineal skin and ischioanal fat will be as limited as oncologically justified. Preferably, an omental plasty is positioned in the pelvic cavity following resection. Closure of the perineum in the control arm consists of stitching the perineal subcutaneous fat together using interrupted Vicryl sutures in one or two layers. Subsequently, the skin will be closed using interrupted sutures according to the preference of the surgeon. Placement of a transabdominal or transperineal drain will be at the discretion of the surgeon.
223627130|NCT03052790|PROCEDURE|manually instrumented total knee arthroplasty|Manually instrumented implantation of a total knee prosthesis involves use of cutting guides or jigs that are secured to the femur and the tibia. The femoral guide is secured to the femur after an intramedullary referenced guide is placed into the femur and the rotational alignment is then assessed with use of the epicondylar axis. An extra-medullary tibial alignment guide will be used to create the tibial cut.
223627131|NCT03052790|DEVICE|robotic assisted total knee arthroplasty|Robotically assisted surgery is used in conjunction with the preoperative CT scan and intra-operative bony registration of the patient's knee. Femoral and tibial trackers are placed and then the bone is registered using bony landmarks to allow the computer and robot to know where the patients' femur and tibia are in space. Once this is complete the preoperative templated surgical plan (performed by the PI) is used to register where to make the bony cuts in order to implant the knee components. The cutting process is performed by the surgeon with the robot assisting in guiding the cuts based on the registered CT anatomy. The surgeon has complete control of the cutting process with the assistance of the robot for placement of the cuts.
223763536|NCT03348761|DEVICE|rTMS group|
223763537|NCT01795924|DRUG|PD-616|Patients may continue treatment through 1 year post-C1D1 or until withdrawal of consent or development of any toxicity meeting the definition of Dose-Limiting Toxicity or progressive disease, whichever occurs first.
223763538|NCT03595111|PROCEDURE|myocardial biopsy|Myocardial cell edema either focal or diffuse was detected in histopathological examination
223763539|NCT05081323|BEHAVIORAL|Self-applied treatment for phobias|The proposed treatment consists of four stages that use different visual elements to represent and replace a real rat in a gradual exposure treatment for specific phobia for animals. With the order of the stages, the intensity of the phobic stimulus increases. In each stage the participant is gradually exposed to a certain amount of elements that represent a phobic situation or object. Graduality considers an approach with realism, interaction, and intensity. The treatment also includes a virtual therapeutic assistant that guides, provides information, and tries to reduce any alteration captured by the participant's heart rate monitoring through deep breathing exercises.
223763540|NCT02321865|DRUG|NPC-02|
223763541|NCT00293384|DRUG|Aprepitant|Aprepitant 80mg once daily in the morning on days 2 and 3
223763542|NCT00293384|DRUG|Cyclophosphamide|Cyclophosphamide 4 gm/m2 I.V. over 90-120 minutes
224215905|NCT05991245|OTHER|Collecting datas|Blood, Tissue and Urine samples
224215906|NCT02665611|BEHAVIORAL|intervention for improvement of adherence|intervention for improvement of adherence
224215907|NCT02665611|BEHAVIORAL|treatment as usual|The control group will be treated according to the usual stadard of care.
224215908|NCT00031837|DRUG|dalteparin|
224215909|NCT00031837|DRUG|gemcitabine hydrochloride|
223627132|NCT06265181|BEHAVIORAL|Diabetes coaching|Diabetes coaching intervention will be provided to the participants in the intervention group by the researcher, who is a specialist nurse who has received 140 hours of Level 2 Professional Coaching Training and 20 hours of diabetes coaching training. Since each individual's needs and values will be different, diabetes coaching interventions will be tailored specifically to the individual by the researcher within the general coaching framework, but by taking into account the individual's views, awareness, needs and current situation regarding self-management regarding diabetes. This flexibility, which supports the individual-specific approach within the coaching paradigm, is among the key elements in the success of coaching interventions (43). The individual will determine the coaching agenda according to his/her own needs.
223763543|NCT00293384|DRUG|Dexamethasone|Dexamethasone orally 10 mg 1 hour prior to cyclophosphamide administration.
223763544|NCT00293384|DRUG|Granisetron hydrochloride|Kytril 1 mg orally or I.V., 1 hour prior to cyclophosphamide administration.
223627133|NCT03914417|DRUG|Imiquimod 3.75% Cream|Approximately two weeks after Day 0, the entire treatment area was treated with imiquimod 3.75% cream. Subjects utilized the 2 weeks on, 2 weeks off, 2 weeks on regimen. Subjects were followed every 2 weeks during treatment (week 2, 4 and 6) and then at 4 and 8 weeks post last-imiquimod application (week 10 and 14).
223627134|NCT05408377|OTHER|MA group|We will select Ashi points (the most obvious local pain over the breast), Tanzhong(CV17), bilateral Wuyi (ST15), Rugen (ST18), Tianzong(SI11), Geshu (BL17), Ganshu(BL18), Hegu(LI4), Sanyinjiao (SP6) and Taichong (LR3)in this trial.After insertion, all needles will be manually manipulated (equal manipulations of twirling, lifting, and thrusting)to achieve De qi sensation.
223763545|NCT03194763|DIAGNOSTIC_TEST|coronary angiography|computed tomography acquisitions performed on a revolution CT
223763546|NCT02333578|PROCEDURE|Convalescent Plasma Treatment|This pilot trial will treat subjects in the ECP Group with ECP derived from two donors. ECP will be provided as ECPSDU each comprising 90 - 110mL of plasma from two individual ABO-compatible donors. Two ECPSDU will be administered as immediately sequential infusions. Subjects may receive up to three doses of ECP not less than 48 hours apart. ECP will be provided as Plasma Frozen Within 24 Hours After Phlebotomy (PF24).
223763547|NCT01942941|DEVICE|geko™ electrical stimulation|applied to stimulate peroneal nerve and cause active muscle twitch
224215910|NCT00031837|PROCEDURE|quality-of-life assessment|
224215911|NCT02134769|DEVICE|Bionecteur|Using Bionecteur at each lumina of the catheter; handling according to institutional guideline
224215912|NCT01925807|BEHAVIORAL|Group Intervention|The intervention will consist of 6 psycho-educational group sessions for caregivers and 6 psycho-educational group sessions for adolescents. Adolescent and caregiver sessions will be held separately and will focus on different issues. For adolescents, the group sessions will focus on coping strategies and emotional regulation. For caregivers, the group sessions will be focused on attachment, family environment, and validation.
224215913|NCT00017030|DRUG|trabectedin|
224215914|NCT05747833|OTHER|Children Preparation With a Toy IV Catheter Before Peripheral Cannula application|THE EFFECT OF PROCESSING PREPARATION WITH A TOY IV CATHETER BEFORE PERIPHERAL CANNULA APPLICATION ON CHILDREN'S PAIN, FEAR and EMOTIONAL INDICATORS
224215915|NCT03333681|BIOLOGICAL|Autologous mesenchymal stem cells|A single intravenous administration of autologous bone marrow derived mesenchymal stem cells(1000000 to 2000000 cells/Kg)
224215916|NCT00124566|DRUG|Irofulven|Subjects will receive irofulven in a 30 minute intravenous (IV) infusion at a dose of 0.45 mg/kg on Days 1 and 8 every 3 weeks.
224215917|NCT00124566|DRUG|Prednisone|Subjects will also receive oral prednisone at a dose of 10 mg per day in the morning.
224215918|NCT00124566|DRUG|Mitoxantrone|Subjects will receive mitoxantrone in an intravenous (IV) infusion (5 to 15 minutes) at a dose of 12 mg/m\^2 per day, once every 3 weeks.
224215919|NCT00124566|DRUG|Capecitabine|Subjects will receive oral capecitabine at a dose of 1000 mg/m\^2 twice daily for 15 days every 28 days.
224215920|NCT00124566|DRUG|Irofulven|Subjects will receive irofulven in a 30 minute intravenous (IV) infusion at a dose of 0.4 mg/kg on Days 1 and 15 every 4 weeks.
223763548|NCT02191488|DRUG|5-aminolevulinic acid|
223763549|NCT04482179|DEVICE|Active TMS|Active TMS will be delivered at 100% motor threshold
223763550|NCT04482179|BEHAVIORAL|CILT|60-90 minutes of CILT will be administered during each treatment session
223763551|NCT04482179|DEVICE|Sham TMS|Sham TMS will be administered
223763552|NCT05422248|DEVICE|Series Topical Oxygen Therapy|Standard care provided to the whole wound followed by intervention device care to the whole wound.
223763553|NCT05422248|DEVICE|Paired Topical Oxygen Therapy|Care provided to one portion of wound by intervention device and standard care to remaining portion of wound.
223763554|NCT06629220|OTHER|Tools|In the co-creation meetings, developed tools will be presented. Participants will be asked to provide feedback and input to tailor these tools to the needs and preferences of men with suicidal thoughts/behavior.
223763555|NCT04817254|DRUG|TMZ|150 mg/m2 on days 1-5 of cycles 1-6
223763556|NCT04817254|DRUG|ipilimumab 3mg/kg|3 mg/kg q 4 weeks for cycles 1-4
223763557|NCT04817254|DRUG|Nivolumab|1 mg/kg IV q2weeks for cycles 1-4, then 480 mg q 4 weeks for cycles 5-16
224215921|NCT02313116|DEVICE|Interferometric Synthetic Aperture Microscopy|Optical coherence tomography with interferometric synthetic aperture microscopy will be used to image ex vivo breast tissue specimens.
223763558|NCT04817254|DRUG|ipilimumab 1mg/kg|1 mg/kg q 4 weeks for cycles 1-4
223763559|NCT06032780|OTHER|Eccentric Resistive Training + Aerobic training Group|"Eccentric Resistive training includes upper limb (biceps and triceps) and lower limb large muscle training (quadriceps and hamstrings) 2 sets of 12 repetitions (reps) for each group of muscles in lengthened position for eccentric training in approx. 20 minutes (min). Intensity will be based on 1 repetition maximum (1RM) starting from 20% of (1RM) and its intensity in percentage will be progress by 10% after every two weeks. Stair descending training and squatting position and eccentric hamstring curls with weights at ankle for lower limb eccentric training progressive as per tolerance in response to modified Borg scale (with cut off of showing dyspnea of 4 somewhat hard) and Numeric Pain rating scale (with cut off of showing 7 on scale, crossing moderate pain) . (approx. 20 min).~\+ Aerobic training as a control will be given to this group as well for approximately 30 minutes per session."
224215922|NCT01318265|DRUG|Regorafenib (BAY73-4506); Regorafenib (BAY73-4506) plus ketoconazole|Treatment 1: A single 160 mg dose of BAY73-4506. Treatment 2: Ketoconazole 400 mg once daily from Day -4 to Day 3. A single 160 mg dose of BAY73-4506 on Day 1.
223763560|NCT06032780|OTHER|Resistance Training + Aerobic training Group|"Resistive training (concentric) includes Upper limb (biceps and triceps) and lower limb large muscle training (quadriceps and hamstrings), 2 sets of 12 reps for each group of muscles in approx. 30 min. Intensity will be based on 1 repetition maximum (1RM) starting from 20% of (1RM) and its intensity in percentage will be progress by 10% after every two weeks. Stair climbing training and quadriceps training + standing hamstring curls with weight at ankle for lower limb concentric training progressive as per tolerance in response to modified Borg scale (with cut off of showing dyspnea of 4 somewhat hard) and Numeric Pain rating scale (with cut off of showing 7 on scale, crossing moderate pain)~\+ Aerobic training as a control will be given to this group as well for approximately 30 minutes per session."
223763561|NCT06032780|OTHER|Aerobic training Group|Aerobic training as a control will be given to this group as well for approximately 60 minutes per session. Aerobic training exercise will be completed via a ergometer/stationary cycle; type will be continuous aerobic exercise and intensity of 60% of max HR (or peak VO2) in HF individuals.
223763562|NCT06268613|DRUG|SB27|Will be administered intravenously at a fixed dose of 200 mg every 3 weeks, maximum 18 cycles over about 51 weeks
223763563|NCT06268613|DRUG|EU sourced Keytruda|Will be administered intravenously at a fixed dose of 200 mg every 3 weeks, maximum 18 cycles over about 51 weeks
223763564|NCT06268613|DRUG|US sourced Keytruda|Will be administered intravenously at a fixed dose of 200 mg every 3 weeks, maximum 18 cycles over about 51 weeks
223763565|NCT06273488|OTHER|Auriculotherapy|Treatment of pain, drug addictions, or other ailments by stimulating the various points on the external ear (EAR AURICLES). It is based on the ancient Chinese practices of EAR ACUPUNCTURE, but sometimes magnets and other modes of stimulation are used.
224215923|NCT01988428|DRUG|Ceftriaxone 2000 mg|Ceftriaxone 2000 mg
224215924|NCT00789828|DRUG|Everolimus|Everolimus was formulated as tablets of 1.0-mg strength and was blisterpacked under aluminum foil in units of 10 tablets.
223763566|NCT04147312|DRUG|Fufang E'Jiao Jiang|Fufang E'Jiao Jiang, 20milliliters(mL) once, 3 times a day, continuous intervention for 21 days each cycle, and use 2 cycles
224215925|NCT00789828|DRUG|Placebo|Placebo was provided as a matching tablet and was blisterpacked under aluminum foil in units of 10.
224215926|NCT01140984|DRUG|Methylprednisolone (Intra-arterial continuous infusion of corticosteroids)|Sedation/anesthesia of patient followed by placement of a 4F vascular sheath and a diagnostic and hepatic angiogram. Angiographic catheter tip to be placed in the proximal proper hepatic artery, secured in place externally and connected to an arterial line pressurized system which allows continuous drip infusion of methylprednisolone diluted in normal saline (600mg/m2 with maximal total dose of 100mg diluted in 480cc in normal saline administered at 20cc/hr for 24 hours).
224215927|NCT00056459|DRUG|Vatalanib|
223763567|NCT04147312|DRUG|placebo containing low-dose fufang E'Jiao Jiang|placebo containing low-dose Fufang E'Jiao Jiang, 20mL once, 3 times a day, continuous intervention for 21 days each cycle, and use 2 cycles
224215928|NCT02476734|OTHER|There is no intervention|Subjects undergo FDG-PET CT scans in order to determine lesional FDG intake and changes in lesional FDG uptake.
224215929|NCT00181116|DRUG|Levetiracetam|
224215930|NCT04252352|DEVICE|Ablative fractional CO2 laser resurfacing/Radio-frequency microneedling|Intra-person split-face trial
224215931|NCT00584896|DRUG|PB127 for Injectable Suspension|0.062 mg/kg continuous IV infusion (100-250 mL/hr) during echocardiography, not to exceed 60 minutes infusion, single dose.
224215932|NCT00560183|DRUG|Q8003 (morphine sulfate and oxycodone hydrochloride)|Capsules, four different mg dosage strengths
224215933|NCT00560183|DRUG|Placebo|Capsules
224215934|NCT06682949|BEHAVIORAL|Sleep Extension|Participants, their parent, and a researcher will review the participants actigraphy data from the two week baseline period. They will discuss sleep patterns and behaviors related to sleep. The researcher will prescribe a sleep prescription that includes set sleep and wake times and stimulus control. Participants will adhere to the sleep prescription for two weeks.
224215935|NCT06682949|BEHAVIORAL|Daytime Routine|Participant, their parent, and researcher will meet to discuss daily routines for the child and family. They will collaborate to choose one behavioral routine to modify for the following two weeks.
224215936|NCT05416359|DRUG|TQB3915 tablets|TQB3915 binds to estrogen receptors through covalent bonds, and blocks intracellular signal transmission by changing the conformation of ERα, thereby inhibiting the growth of tumor cells.
224215937|NCT06701383|DEVICE|Cryoablation|Pulmonary vein isolation using cryoablation
224317214|NCT02455895|DEVICE|iLid Cleanser|Application of iLid Cleanser to reduce bacterial load on the lid and lash margins
223514142|NCT02317419|DRUG|RO6927005|RO6927005 administered intravenously on Days 1, 3, and 5 of each 28-day treatment cycle (QOD x 3).
223514143|NCT02317419|DRUG|gemcitabine|gemcitabine administered according to local label on Days 1, 8, and 15 of each 28-day cycle.
223514144|NCT02317419|DRUG|nab-paclitaxel|nab-paclitaxel administered according to the local label on Days 1, 8, and 15 of each 28-day cycle.
223514145|NCT03410745|BEHAVIORAL|Exercise.|Moderate to heavy intensity resistance exercise consisting of leg press.
223514146|NCT05074381|OTHER|Dry Needling|Dry needling (DN) is a myofascial treatment technique, in which a thin, solid filiform needle is inserted directly into the MTrP. During dry needling, local twitch responses (LTR) can be elicited. These are involuntary contractions of muscle fibers, leadi
223514147|NCT05074381|OTHER|Sham Needling|During sham needling, a solid, filiform needle is inserted in the skin surface at the trigger point location, without penetrating the fascia and muscle tissue.
223514148|NCT00019838|DRUG|7-hydroxystaurosporine|
223514149|NCT00019838|DRUG|fludarabine phosphate|
223514150|NCT02631785|OTHER|Cognitive Behavioral Therapy|"Psychologists will deliver the COPING CAT treatment for reducing anxiety symptoms. It is a manualized treatment that was extensively used before. The treatment will include 10- 14 sessions, mostly individual but also two parents meetings. All the treatments will occur in the Department of Psychology in Haifa University as a part of a clinical trial. The treatment will take place in a room that was designed for this purpose fully equipped with cameras, microphone and double sided mirror. All sessions will be audio and video recorded and will be closely monitored by the PI. To increase protocol adherence and verify the adequacy of the treatment delivered, all clinicians will complete routine forms with the content of each session."
223514151|NCT03616093|OTHER|Test Beet Shot|Active supplement containing 6.2 mmol nitrate
223627135|NCT05408377|OTHER|SA group|The SA group will use a special needle in which the tip is blunt and the pedestal is opaque. There is an adhesive pad below the base to ensure that the whole pedestal can adhere to the points. Participants will receive superficial touch at bilateral sham GV8(Jinsuo), sham GV7(Zhongshu), sham GV6(Jizhong), sham GV5(Xuanshu), sham GV4(Mingmen), sham BL37(Yinmen), and sham BL57(Chengshan), the needles will touch the skin and not be inserted into the skin, then lift and twist each point evenly for 3 times, make the subject feel the similar sensation of deqi.
224215938|NCT06702215|DEVICE|Cross-modal paired associative stimulation (cm-PAS) protocol|The cross-modal Paired Associative Stimulation (cm-PAS) will consist of a visual stimulus depicting a hand being touched repeatedly paired with a transcranial magnetic stimulation (TMS) pulse delivered over the right primary somatosensory area, for a total of 150 paired stimuli delivered at a fixed frequency of 0.1 Hz. The time interval between the visual-touch onset and the TMS pulse will be 20 ms for the experimental session and 100 ms for the control session.
223763568|NCT00004238|DRUG|pralatrexate|
223763569|NCT06146569|DEVICE|Transcutaneous Auricular Vagus Nerve Stimulation (taVNS)|Current will be applied bilaterally from the tragus and turbinate parts of the ear with the VagustimTM device. The current frequency to be used in modulation mode is 10 Hz, and the pulse width is 300 μs (In modulation mode, the pulse rate and width are automatically changed in a loop pattern. The pulse width is reduced by 50% from its original setting in 0.5 seconds; then, the pulse rate is changed in 0.5 seconds, reduced by 50% from the original setting. Total cycle time is 1 second.). The current intensity will be applied for 5 minutes, keeping the current constant where the participant feels comfortable.
224215939|NCT06701760|DRUG|Sodium Lactate|sodium lactate
224215940|NCT06701760|DRUG|placebo|infusion of sodium chloride
224215941|NCT02521831|DRUG|Spinal Anesthesia (bupivacaine)|Bupivacaine is an amide-type, long-acting local anesthetic. Brand names include Exparel, Marcaine, and Sensorcaine.
224215942|NCT02521831|DRUG|General Anesthesia (isoflurane)|Isoflurane is a fluorinated ether with general anesthetic and muscle relaxant effects. Brand names include Forane and Terrell.
224215943|NCT00049010|GENETIC|comparative genomic hybridization|
224215944|NCT00049010|GENETIC|cytogenetic analysis|
223763570|NCT06146569|DEVICE|Sham Transcutaneous Auricular Vagus Nerve Stimulation (taVNS)|For 5 minutes, sham applications will be applied using a current-free headset specifically designed for this purpose. Participants will observe the device's functionality, but it will not supply any current.
223763571|NCT04067362|OTHER|food containing dietary fiber|commercially available chicory root flour and chicory root fiber
224215945|NCT00049010|GENETIC|fluorescence in situ hybridization|
224215946|NCT00049010|OTHER|immunohistochemistry staining method|
224215947|NCT06703411|DRUG|Iron Sucrose IV|IV iron sucrose 200mg per visit
224215948|NCT06703411|DRUG|Standard Medical Therapy|Standard of care (HFrEF 4 pillars treatment)
224215949|NCT06702943|DRUG|Tigecycline (Tygacil)|tigecycline-based regimen administered both intravenously (IV) and intraventricularly (IVT) for 14-21 days
224215950|NCT06702943|DRUG|Colistimethate sodium (CMS)|Colistimethate sodium-based regimen (standard therapy for MDR infections) administered both IV and IVT for 14-21 days.
224215951|NCT06704113|DRUG|meloxicam 7,5mg|Comparison of analgesic efficacy of Meloxicam Vs Ibuprofen
224215952|NCT06704048|OTHER|Cardiac rehabilitation|Standard hospital-based cardiac rehabilitation according to SEPHIA and SWEDEHEART protocols 2 times a week for 12 weeks with individualized physical evaluation before and after the intervention.
224215953|NCT06703970|DRUG|Corticosteroid Injection|5 milliliters (mL) injection of corticosteroid (1cc Kenalog, 4cc Xylocaine) Kenalog - 40 (triamcinolone acetonide injectable suspension, USP) Xylocaine - MPF (lidocaine HCl Injection, USP)
224215954|NCT06703970|DEVICE|Platelet Rich Plasma Joint Injection|\~3 milliliters (mL) injection of autologous PRP Magellan Autologous Concentration System, ISTO Biologics
224215955|NCT06703372|OTHER|Diode Laser 980 nm, 0.2W|diode laser will be used at an operating wavelength of 980 nm, with adoption of the due safety measures in all cases. Laser irradiation will be applied bilaterally to the skin over the area of the submandibular and parotid glands. Irradiation will be applied externally to the parotid gland on a continuous basis and likewise to the submandibular gland moving the laser very slowly over the gland zone
223627136|NCT02111421|DRUG|Dexmedetomidine 01|Initial dose of dexmedetomidine was 1.0 μg/kg, with dose adjustment intervals of 0.1μg/kg in first three turning points and 0.05μg/kg in the last four turning points,after the umbilical cord was clapped.The wight used to calculate the dose of dexmedetomidine would be that the total weight of the mother minus the weight of the placenta, amniotic fluid and fetal.
223763572|NCT02426281|DRUG|nab-paclitaxel|nab- paclitaxel 125mg/m2 D1, 8 15 every 4 weeks.
224215956|NCT06703372|OTHER|Placebo Diode laser|the tip of the instrument will be sealed with blue rubber to prevent the passage of light
224215957|NCT06704035|DIAGNOSTIC_TEST|Early OGTT Results Revealed|Early pregnancy screening with a three-time point (fasting, 1h, 2h) 75g oral glucose tolerance test before 16 weeks' gestation with plasma glucose results revealed to the patient and clinician for appropriate management of any diabetes (gestational and type 2, if diagnosed) from early pregnancy onwards.
224215958|NCT02934568|DRUG|LEE011|Single agent LEE011 or in combination with other treatments
223763573|NCT02426281|DRUG|gemcitabine|gemcitabine 1000mg/m2 D1, 8 15 every 4 weeks.
223763574|NCT06333795|PROCEDURE|Faecal Microbiota Transplantation (FMT)|Treatment is given as capsules.
223763575|NCT06333795|PROCEDURE|Placebo|Treatment is given as capsules.
223763576|NCT00145509|DRUG|Asenapine|Asenapine 5 or 10 mg twice daily (BID) sublingually for 40 weeks
223763577|NCT00145509|DRUG|Placebo|Fast-dissolving tablet; twice daily (BID) sublingually for 40 weeks
223763578|NCT05473533|DRUG|Placebo|Placebo; formulated as solution for inhalation without active substance.
223763579|NCT05473533|DRUG|PRS-220|PRS-220; formulated as solution for inhalation.
223763580|NCT03422341|DEVICE|Comparison between GenePOC CR and Reference Method|The collected swab will be tested with both the GenePOC Strep A, C/G assay and the Reference Method defined as standard microbiology culture and strain identification using a MALDI TOF.
223763581|NCT00419562|DRUG|Oral Insulin|7.5 mg oral insulin or placebo given before breakfast on a daily basis.
223763582|NCT00419562|DRUG|Placebo|Placebo capsule designed to match active drug
223627137|NCT02111421|DRUG|Dexmetomidine 02|Initial dose of dexmedetomidine was 1.0 μg/kg, with dose adjustment intervals of 0.1μg/kg in first three turning points and 0.05μg/kg in the last four turning points,as soon as the spinal anesthesia
223627138|NCT02856412|OTHER|Veterans Group Exercise (VGX)|Integrative Exercise incorporates elements of strength training, flexibility, cardiovascular training, and controlled breathing exercises.
223627139|NCT02856412|OTHER|Illness Management and Recovery|Illness Management and Recovery is an educational program focused on helping individuals more effectively manage their illnesses to pursue their personal recovery goals. The classes include the following topic areas which have been adapted for use in PTSD: recovery, practical facts about PTSD, stress-vulnerability, building social support, medications for PTSD, drug and alcohol use, reducing relapse, coping with stress, coping with persistent symptoms, getting needs met in the VA healthcare system, and living a healthy lifestyle.
223514152|NCT03616093|OTHER|Placebo Beverage|Placebo supplement containing negligible nitrate
223514153|NCT01423084|BIOLOGICAL|Serogroup B meningococcal vaccine|"All subjects will receive two rMenB+OMV NZ vaccinations one month apart and will be followed for a total of 2 months. Subjects will be randomized to 1 of 2 treatment arms to receive either two doses of rMenB+OMV NZ vaccine Lot 1 or two doses of rMenB+OMV NZ Lot 2.~A total of 2 blood samples will be collected (at the first vaccination and 1 month after the 2nd vaccination). An additional blood draw will be collected in a subset of approximately 160 subjects (approximately 80 subjects in Group 1 and approximately 80 subjects in Group 2) at 2 weeks after the second vaccination"
223627140|NCT06757075|DRUG|Ibuprofen|10 mg/kg/dose of ibuprofen will be given every 6 hours for 24 hours post surgery
223627141|NCT06757075|DRUG|Acetominophen|15 mg/kg/dose of acetominophen will be given every 6 hours for 24 hours post surgery
223627142|NCT06926790|DRUG|Nivolumab & Ipilimumab|This study evaluates the safety and efficacy of neoadjuvant nivolumab plus ipilimumab for IIA-IIIB NSCLC. Based on preliminary trial results, this study proposes a new treatment regimen.
224215959|NCT06703684|OTHER|Cross-sectional observational study|This is a cross-sectional observational study. No intervention will be given.
224215960|NCT06703008|OTHER|TEE hemodynamic monitoring|Transesophageal echocardiography monitoring to guide administration of fluids, vasopressor and inotropes during liver transplantation in order to avoid hypotension.
224215961|NCT06702904|PROCEDURE|Peripheral Nerve Stimulation|Peripheral Nerve Stimulation (PNS) is a neuromodulation technique used to treat chronic pain. The procedure starts with a preoperative assessment, including imaging to identify the target peripheral nerve. Under local anesthesia, a thin, insulated electrode is implanted near the nerve, usually with the help of fluoroscopic or ultrasound guidance for precision.
224215962|NCT06702904|PROCEDURE|Spinal cord stimulation|Spinal Cord Stimulation (SCS) is a neuromodulation that involves the implantation of a device that delivers electrical impulses to the spinal cord through an electrode placed in the epidural space. The stimulation alters pain signals before they reach the brain, effectively masking or reducing the sensation of pain.
224215963|NCT06702904|PROCEDURE|Dorsal Root Ganglion Stimulation|Dorsal Root Ganglion Stimulation (DRGS) is a targeted neuromodulation technique for managing chronic pain. The procedure begins with a thorough preoperative assessment, including imaging to locate the specific dorsal root ganglion (DRG) associated with the pain. Under local anesthesia, a small electrode is implanted near the DRG. This is done through a minimally invasive procedure, often guided by fluoroscopy or CT imaging to ensure precise placement.
224215964|NCT06702904|PROCEDURE|Motor Cortex Stimulation|Motor Cortex Stimulation (MCS) is a neuromodulation technique that involves the surgical implantation of electrodes over the motor cortex, typically targeting the precentral gyrus, to deliver electrical stimulation. The procedure involves placing an electrode grid or strip on the dura mater overlying the motor cortex, which is identified via neuroimaging techniques such as functional MRI or neuronavigation. Once implanted, the electrodes are connected to an implanted pulse generator (IPG), which delivers adjustable electrical impulses.
224215965|NCT03086642|DRUG|Talimogene laherparepvec|"T-Vec will be administered by intratumoral injection into pancreatic tumors accessible endoscopically with ultrasound guidance (at least one pancreatic lesion must be injected during each treatment).~On day 1 of week 1 the first dose of talimogene laherparepvec will be up to 4.0 mL of 10\^6 PFU/mL. The second injection up to 4.0 mL of 10\^6, 10\^7, or 10\^8 PFU/mL should be administered no sooner than day 1 of week 4 but should not be delayed more than 7 days after the scheduled time point. The maximum volume of T-Vec administered at any one time is 4.0 mL for any individual lesion."
224215966|NCT06724939|OTHER|self-adhesive bulk-fill resin composite|surefil one self-adhesive bulk-fill composite
224215967|NCT00452998|PROCEDURE|Q-switched fd Nd:yag in Laser Iridotomy|
224215968|NCT06702956|PROCEDURE|laser corticotomy|stimulation of tooth movement during orthodontics treatment using Waterlase MDTM Turbo all-tissue laser therapy
224215969|NCT06702956|PROCEDURE|Conventional tooth movement|tooth movement us done using wires and brackets
224215970|NCT01275521|DRUG|BONT-A intra-prostatic injection|"• Intra prostatic injection of 200 IU of BONT-A (2 x 100 IU to dilute in 10 cc salted serum), divided into 4 injections, 2 in each prostate lobe for a volume intra injected 2.5 cc per site.~Interruption of the medical therapy 1 month after the injection;"
223763583|NCT01621399|DRUG|Product 55394|Product 55394 vaginal gel in a prefilled applicator.
224215971|NCT01275521|DRUG|Optimized medical BPH treatment|Optimization of the medical therapy according to recent guidelines
224215972|NCT06512389|DRUG|Oral solution|300 mg taken morning and evening
223763584|NCT01621399|DRUG|Placebo Vehicle (non-treatment)|The vehicle vaginal gel in an applicator (placebo).
223763585|NCT01403038|DRUG|Elagolix|Elagolix Dose Regimen 1 for 84 days
223763586|NCT01403038|DRUG|Elagolix|Elagolix Dose Regimen 2 for 84 days
223763587|NCT01403038|DRUG|Elagolix|Elagolix Dose Regimen 3 for 84 days
223763588|NCT01403038|DRUG|Elagolix|Elagolix Dose Regimen 4 for 84 days Other interventions may be added
223763589|NCT01403038|DRUG|Elagolix|Elagolix Dose Regimen 5 for 84 days
223763590|NCT01403038|DRUG|Elagolix|Elagolix Dose Regimen 6 for 84 days
223763591|NCT01403038|DRUG|elagolix|Elagolix plus Activella Dose Regimen 7 for 84 days
223763592|NCT04101266|OTHER|Interscalene block|30 minutes before anaesthesia induction interscalene nerve block will be applied with ultrasound guidance with %0,25 bupivacain 20 cc .The sham block consisted of after patients were placed in the lateral decubitus position skin preparation, ultrasound scanning of the suprascapular region, and a dry-needling, all performed to preserve patient blinding in the ISB group patients.
223763593|NCT04101266|OTHER|suprascapular and infraclavicular nerve block|30 minutes before anaesthesia induction suprascapular with %0,25 bupivacain 10 cc .and infraclavicular nerve block with %0,25 bupivacain 10 cc will be applied with ultrasound guidance
223763594|NCT03199378|OTHER|Neuropsychological Testing|Each group will be administered a battery of neuropsychological tests
223763595|NCT06021067|BIOLOGICAL|Death mesenchymal stem cell|A standard treatment regimen combined with a pre-specified starting dose of dead mesenchymal stem cells (2.0×10\^7 for 60kg patient), infusion every 3 days, continuous infusion 4 times, treatment duration is 4\~6 weeks.
223763596|NCT02789176|OTHER|Surveys|Regarding development, epilepsy, and family impact
223763597|NCT02789176|OTHER|EEG|
223763598|NCT03393221|BEHAVIORAL|ER|Emotion regulation content
223763599|NCT03393221|BEHAVIORAL|SBWC|
224215973|NCT06195267|DRUG|Sivelestat|The total 24-hour dose of Sivelestat sodium (4.8mg/kg) was dissolved with 50 ml normal saline. The drug flow rate was set at 2ml/h with an intravenous microinfusion pump, and the constant speed infusion was completed in 24h.
223763600|NCT00772096|DRUG|n-3 fatty acids|
223763601|NCT00968175|PROCEDURE|Ultrasound guided celiac plexus neurolysis (CPN)|Initial procedure and rescue procedure if applicable
223763602|NCT00596011|DRUG|Polyphenon E|Polyphenon E, at a dose of 400 mgs EGCG (200 mgs BID) for 1 year in men diagnosed with HGPIN and ASAP.
223763603|NCT00596011|DRUG|Placebo|Matching placebo BID
223763604|NCT04675424|DEVICE|ANSwatch|"ANSwatch wrist sphygmomanometer and the specific database from monitors in ICUs may be a feasible way to predict outcome among ICU patients. Two measurements will be obtained:~1. Pulse diagnosis: Pulse diagnosis done on radial artery is recorded by traditional Chinese medicine physician and ANSwatch wrist sphygmomanometer at the same time.~2. Heart rate variability: Heart Rate Variability represents significant information on autonomic nervous system (ANS)'s regulating function and balance status."
223763605|NCT05018715|DIAGNOSTIC_TEST|Machine learning model diagnosis|Machine learning model diagnosis
223763606|NCT04583813|DRUG|Empagliflozin|Empagliflozin 10 mg oral tablet, once daily, for 24 months
223763607|NCT04583813|OTHER|Placebo|Empagliflozin matching placebo, once daily, for 24 months
223763608|NCT03693768|BEHAVIORAL|Health coaching|Health coaching
223514154|NCT05497245|OTHER|mobile app-based breastfeeding education|"The main screen of the application used to be six screens. These six screens; Breastfeeding, Expressing, Contingencies, Frequently asked questions and my Breastfeeding Log and Breastfeeding diary. Mothers could record the number and duration of breastfeeding, milking status, the baby's height and weight, if it was a measure, the breastfeeding problem and solutions they encountered, on the Breastfeeding Introduction tab, and they could follow their breastfeeding status in the Breastfeeding Diary tab."
223514155|NCT01141764|PROCEDURE|Positron Emission Tomography (PET) Scan|"The PET procedure consists of an intravenous injection of 18F-FDG followed by a 45-minute period of quiet resting. PET images will be acquired on an integrated PET/CT scanner.~This process will be repeated with the stimulator on during the first PET image acquisition and off during the second PET image acquisition. On and off PET image acquisitions will be performed on two separate days."
223514156|NCT01141764|PROCEDURE|Magnetic Resonance Imaging (MRI)|MRI will be performed on a 1.5T system, using a combination of different sequences including sagittal T1, coronal and axial T2, FLAIR and proton density and axial 3D T1 weighted images.
223763609|NCT00460941|DRUG|Placebo|sc weekly
223763610|NCT00460941|DRUG|Taspoglutide 20mg|sc weekly
223763611|NCT00460941|DRUG|Taspoglutide 20mg-30mg|sc weekly
223763612|NCT00460941|DRUG|Taspoglutide 20mg-40mg|sc weekly
223763613|NCT03182348|PROCEDURE|Optical coherence tomography|As part of the clinical angioplasty procedure the patient will have a coronary guidewire passed down the artery usually from the groin to the heart which is used to position balloons and stents. OCT passes over the wire in the same way. From the patients perspective the procedure may take a small amount of additional time - maximum 10-15 minutes. We would like to be able to pass a second wire down the same coronary artery called a 'buddy wire' which is sometimes required in coronary procedures. This would be used to inflate a balloon at low pressure near the area of interest in the heart in order either to exclude blood or to oppose the OCT catheter to the vessel wall if required.
224215974|NCT06195267|DRUG|Blank control|Patients only received standard treatment and care.
224215975|NCT01262391|DRUG|Solifenacin succinate suspension 2.5 mg|Adolescents and children are given a single dose of solifenacin succinate liquid suspension orally via syringe in the morning of day 1 followed by a glass of water. Doses are calculated per weight of the participant, targeting to have equivalent doses of 2.5 mg of solifenacin once daily in adults.
224215976|NCT01262391|DRUG|Solifenacin succinate suspension 5 mg|Adolescents and children are given a single dose of solifenacin succinate liquid suspension orally via syringe in the morning of day 1 followed by a glass of water. Doses are calculated per weight of the participant, targeting to have equivalent doses of 5 mg dose of solifenacin once daily in adults.
224215977|NCT01262391|DRUG|Solifenacin succinate suspension 10 mg|Adolescents and children are given a single dose of solifenacin succinate liquid suspension orally via syringe in the morning of day 1 followed by a glass of water. Doses are calculated per weight of the participant, targeting to have equivalent doses 10 mg dose of solifenacin once daily in adults.
224215978|NCT05788237|BIOLOGICAL|RSVpreF+qIRV|RSVpreF containing 2 stabilized RSV prefusion F antigens, in equal amounts from virus subgroups A and B combined with Quadrivalent influenza modRNA vaccine (qIRV) encoding HA of 4 strains as recommended for the influenza season (2 A strains, 2 B strains)
224215979|NCT05788237|BIOLOGICAL|qIRV|Quadrivalent influenza modRNA vaccine (qIRV) encoding HA of 4 strains as recommended for the influenza season (2 A strains, 2 B strains)
224215980|NCT05788237|BIOLOGICAL|RSVpreF|RSVpreF containing 2 stabilized RSV prefusion F antigens, in equal amounts from virus subgroups A and B
223627143|NCT04785495|OTHER|Quality-of-life assessment|Patients will be provided the Functional Living Index - Emesis (FLIE) quality of life survey to be completed at time zero (before the application of chemotherapy) and then after 6 day, after application of chemotherapy.
224317215|NCT06500325|PROCEDURE|retrograde titanium elastic nails for fixation of proximal third tibial shaft fractures in children|Two TENs were used in all cases using the double-C construct in most cases to gain three point of fixation. The starting point for nail insertion is 1.5-2.0 cm proximal to the physis of distal tibia. Both nails are then inserted through the entry holes and advanced to pass the level of the fracture site to achieve fixation. The two incisions for nail entry are closed in a layered fashion, and the wounds are well padded with gauze.
224317216|NCT04233996|DRUG|Piperacillin-Tazobactam 4 g-0.5 g|Patients with FN who empirical treatment with piperacillin-tazobactam 4g/6h
224317217|NCT04233996|DRUG|Cefepime 2000 mg|Patients with FN who required empirical treatment with cefepime 2g/8h
224317218|NCT04233996|DRUG|Meropenem 1000 mg|Patients with FN who required empirical treatment with meropenem 1g/8h
224317219|NCT03396003|DEVICE|GALILEI G6 Lens Professional|Eight measurements of the eye using the GALILEI G6 Lens Professional will be taken using two different devices and 2 different operators
223514157|NCT01141764|OTHER|Neuropsychological Testing|"On the same day or separate visit, depending on the timing of the PET imaging, they will be required to attend one half-day session for neuropsychological testing. Patients will arrive at the Toronto Western Hospital, the stimulator will be turned off for 30 minutes prior to neuropsychological testing with testing repeated with the stimulator on."
223514158|NCT00656695|DRUG|Iminoral|Iminoral in form of capsules 25,50 and 100 mg giving in the dose of 3-7 mg/kg twice daily
223514159|NCT00656695|DRUG|Neoral|Neoral in form of capsules 25,50 and 100 mg giving in the dose of 3-7 mg/kg twice daily
223627144|NCT06350786|OTHER|P-Dragees blue Lichtenstein, Placebo dragees|"In the intervention group, open-label placebos are administered within the framework of a mind-body management intervention approach, which in turn is consistent with the biopsychosocial model of pain and with a patient-centred approach. The verbal interaction follows the four discussion points:~1. Opioids work by telling the body that participants are not experiencing as much pain;~2. Placebos should be taken every time an opioid is taken which supports the reduction of opioid medication (shown by previous studies);~3. By pairing the pills together the brain will learn to release chemicals like endorphins that cause pain-relief in response to the placebo, just as it does in response to the opioid;~4. At a certain point, placebos might provide adequate pain relief, and the participants might need less opioids."
223763614|NCT01233375|DRUG|CO-1.01|"1250 mg/m2/day administered on Days 1, 8, and 15 in 4-week treatment cycles.~Patients who have SD or better at the Week 8 assessment and who adequately tolerated the first 2 cycles of treatment may continue CO-1.01 at the same or an increased dose (1400 mg/m2) for Cycle 3 and subsequent cycles."
223763615|NCT02037711|DRUG|Levobupivacaine 0.5%|Group I (Chirocaine group) (n=20): Levobupivacaine 0.5% will be instilled during insufflations of CO2 at the beginning of surgery at a dose of 2mg/kg.
224215981|NCT05788237|DRUG|Placebo|0.9% saline for injection
224215982|NCT05788237|BIOLOGICAL|RSVpreF + qIRV 1.0 mL formulation|RSVpreF containing 2 Stabilized RSV prefusion F antigens, in equal amounts from virus subgroups A and B plus qIRV Encoding HA of 4 strains as recommended for the influenza season (2 A strains and 2 B strains) plus sterile water as diluent for injection
223514160|NCT02695771|DRUG|Mitomycin C|Cancer chemotherapeutic agent
223514161|NCT02695771|DRUG|Gemcitabine|Cancer chemotherapeutic agent
223763616|NCT02037711|DRUG|Normal saline|Group II (control group) (n=20): laparoscopy done with instillation of normal saline instead of levobupivacain
224215983|NCT05788237|BIOLOGICAL|RSVpreF + qIRV 0.5 mL formulation|RSVpreF containing 2 Stabilized RSV prefusion F antigens, in equal amounts from virus subgroups A and B plus qIRV Encoding HA of 4 strains as recommended for the influenza season (2 A strains and 2 B strains)
224215984|NCT05824975|DRUG|GI-102 subcutaneous (SC)|0.12 mg/kg, 0.24 mg/kg or Recommended phase 2 dose of GI-102 will be administered via SC injection Q3W up to 2 years (approximately 35 years).
224215985|NCT05824975|DRUG|GI-102|Dose level will be escalated from 0.06 mg/kg to 0.45 mg/kg and Recommended phase 2 dose (or RP2D-1, RP2D+1) of GI-102 will be administered via IV infusion Q3W up to 2 years (approximately 35 years).
224215986|NCT05824975|DRUG|doxorubicin|Doxorubicin will be administered intravenously at a dose of 75 mg/m2 on Day 3 every 3-week (21-day) cycle for up to 6 cycles.
224215987|NCT05824975|DRUG|paclitaxel|Paclitaxel will be administered intravenously over 1 hour at a dose of 80 mg/m2 each time weekly as a diluted solution according to the prescribing information.
224215988|NCT05824975|DRUG|bevacizumab|Bevacizumab will be administered intravenously at a dose of 10 mg/kg every 2 weeks.
224215989|NCT05824975|DRUG|eribulin|Eribulin will be administered intravenously at a dose of over 1.4 mg/m2 over 2 to 5 minutes on Days 3 and 10 every 3-week (21-day) cycle.
224317220|NCT03396003|DEVICE|Oculus Pentacam AXL|A single measurement of the eye will be taken using the Oculus Pentacam AXL
224317221|NCT03222310|DRUG|Ipatasertib|Ipatasertib 100 mg tablet orally once daily.
224317222|NCT03222310|DRUG|Itraconazole|Itraconazole 100 mg capsules orally once daily.
224317223|NCT05630911|OTHER|Standing tasks with different task difficulty|The three different standing positions will include wide-base standing on foam (WBF) with low-level of task difficulty, narrow-base standing on foam (NBF) with moderate-level of task difficulty, and tandem standing on foam (TAF) with high-level of task difficulty.
224317224|NCT01322867|DRUG|alprazolam tablet|0,25 mg oral tablets given once
224317225|NCT01322867|DRUG|alprazolam oral solution|0,75 mg/ml Oral Solution (Drops) given once
224317226|NCT02695810|DRUG|Dapagliflozin|10 mg per day as monotherapy for 13 weeks
224317227|NCT02695810|DRUG|Metformin|2 x 850 mg per day as monotherapy for 13 weeks
224317228|NCT02695810|BEHAVIORAL|Exercise|Interval training, 5 times per week, 30 min per session
223627145|NCT06350786|OTHER|Control group (EM)|"In the EM control group, the focus lies on the electronic monitoring (EM) of the opioid intake. The treatment rationale is designed to facilitate the reduction of opioid medication by promoting a positive attitude towards the implementation of the reduction. The verbal interaction follows the four discussion points:~1. The collection of EM data allows for greater patients' sense of agency over medication treatment;~2. Tracking of opioid medication use supports the reduction of opioid medication (shown by previous studies);~3. The EM is a useful tool, and daily recording of opioid medication intake should be done;~4. At a certain point, EM might provide adequate pain relief, and participants might need less opioids."
223627146|NCT06922006|PROCEDURE|Percutaneus nephrolithotomy (PCNL)|Percutaneus nephrolithotomy (PCNL) for removal of large kidney stones
223627147|NCT06938555|BEHAVIORAL|Prolonged Nightly Fasting|At the start of the intervention (week 1) PNF participants will be asked to engage in fasting (14 hours a night, starting no later than 8pm) six nights a week (for the 8-week study duration). Participants will be asked to track their fasting start/stop times on a tracking sheet provided by study staff. During the nightly fast, participants will be allowed to drink water, coffee or tea (without dairy or sweeteners). Study staff will meet with participants via phone for weekly check-in calls (\~10-15 mins) to collect weekly fasting start/stop dates/times (entered into REDCap); alternately, participants may elect to email or text their fasting start/stop date/times to the study staff.
223627148|NCT06938555|BEHAVIORAL|Health Education Videos|Provision of HED is a retention strategy and can influence outcomes. Thus, all participants will receive HED. Each week, participants will receive hyperlinks to videos focused on health educational content unrelated to fasting, diet and outcome measures. Participants will be asked to view the videos (\~10-15 min) prior to their weekly check-in calls with the study staff (\~5-10 mins for HED-Only Control group). They will receive each week's videos on a Monday, and receive a reminder to view on Friday. Study staff will follow a scripted HED weekly check-in call to ensure consistency of data collected. Weekly topics are as follows: W1: Internet safety, W2: Sun safety, W3: Home safety, W4: Driving safety, W5: Hydration, W6: Dental health, W7: Working environment, W8: Communication. Data collected on electronic forms during all participant/staff check-in calls will be stored in participant-specific ASU Dropbox files.
223627149|NCT00673777|BIOLOGICAL|URLC10, VEGFR1 and VEGFR2|Patients will be vaccinated twice a week for 8 weeks. On each vaccination day, the URLC10-117 peptide(1mg), VEGFR1 peptide(1mg) and VEGFR2 peptide(1mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection.
223627150|NCT05981469|DEVICE|Cervical Stiffness Assessmenr|The cervical stiffness is assessed by using the licensed, CE-marked Pregnolia System, during a sterile speculum examination. The single-use, sterile Pregnolia Probe is placed on the anterior lip of the cervix at 12 o'clock position and a recording of cervical stiffness is generated over maximum 60 seconds (typically ̴15 seconds) and displayed as Cervical Stiffness Index (CSI) in mbar. The measurement is repeated 3 consecutive times without any time lag.
223627151|NCT05981469|OTHER|Bishop's Score Assessment|Sterile digital vaginal examination to illicit the Bishop's score (0-12).
223627152|NCT02790801|OTHER|observation|observation
223627153|NCT00211328|DRUG|anecortave acetate|
223627154|NCT03125551|DIETARY_SUPPLEMENT|Ginger|Ginger dosage at daily recommended allowance
223627155|NCT03125551|DIETARY_SUPPLEMENT|Garlic|Garlic dosage at daily recommended allowance
223627156|NCT03125551|DIETARY_SUPPLEMENT|Ginkgo Biloba|Ginkgo Biloba dosage at daily recommended allowance
223763617|NCT01633944|DRUG|Buprenorphine|Buprenorphine HCl Buccal Film at doses ranging from 75-600 mcg twice daily
224215990|NCT05824975|DRUG|trastuzumab deruxtecan (T-DXd)|T-DXd will be administered initially as a 5.4 mg/kg (or 6.4 mg/kg only for gastric cancer) IV over 30 - 90 minutes every 3 weeks.
224215991|NCT05824975|DRUG|pembrolizumab|pembrolizumab will be administered at a dose of 200 mg as IV infusion Q3W.
224215992|NCT05824975|DRUG|GI-102|Recommended phase 2 dose (or RP2D-1, RP2D-2) of GI-102 will be administered via IV infusion Q3W up to 2 years (approximately 35 years).
224215993|NCT02842086|DRUG|F/TAF|200/25 mg tablet administered orally once daily
224215994|NCT02842086|DRUG|F/TDF|200/300 mg tablet administered orally once daily
224215995|NCT02842086|DRUG|F/TAF Placebo|Tablet administered orally once daily
223627157|NCT03125551|DIETARY_SUPPLEMENT|Ginseng|Ginseng dosage at daily recommended allowance
223627158|NCT03125551|OTHER|Placebo|Daily dosage strategy
223627159|NCT03057015|DRUG|Clonidine|50 mcg Clonidine added to the solution of 0.5% ropivacaine, 2 mg dexamethasone and 5 mcg/ml epinephrine for adductor canal block-present in the treatment group.
223627160|NCT03057015|DRUG|Placebo|Normal saline added to the solution of 0.5% ropivacaine, 2 mg dexamethasone and 5 mcg/ml epinephrine for adductor canal block-present in the placebo group.
223763618|NCT01633944|DRUG|Placebo|Matching Placebo Buccal Film twice daily
223763619|NCT03191539|DRUG|Apremilast|30 mg twice a day during 52 weeks. In the first 6 days will be a dose escalation
223763620|NCT00054561|BIOLOGICAL|recombinant interferon alfa|
223763621|NCT00054561|DIETARY_SUPPLEMENT|vitamin E|
223763622|NCT00054561|DRUG|isotretinoin|
224215996|NCT02842086|DRUG|F/TDF Placebo|Tablet administered orally once daily
224215997|NCT06425146|PROCEDURE|Cytobrush sample|Healthy oral mucosa will be collected using a cytobrush, which is a minimally invasive method for patients
224215998|NCT06425146|PROCEDURE|Blood sampling|Blood sampling (6 mL), taken from a routine biological exam
224215999|NCT01961635|DEVICE|dental implants|place implant according fabricant guidelines, 2mm sub-crestally
224216000|NCT01961635|DEVICE|Zirconia abutments|place zirconia abutment on the day of implant placement
224216001|NCT01961635|DEVICE|Titanium Abutments|place titanium abutment on the day of implant placement
224216002|NCT01961635|DEVICE|cad-cam acrylic abutments|place cad-cam acrylic abutment on the day of implant placement
224216003|NCT01961635|PROCEDURE|Subcrestal|place implant 2mm below crestal bone
224216004|NCT01961635|DEVICE|platform-switch|abutment platform is narrow than implant diameter
224216005|NCT01961635|PROCEDURE|one-time one-abutment|place the final abutment on the day of surgery and not remove it
224216006|NCT01961635|PROCEDURE|Torque 20 n/cm2|the amount of torque applied to the abutment
224216007|NCT03751124|DRUG|Relugolix|Relugolix 40 mg tablet administered orally once daily
223627161|NCT03057015|DRUG|Ropivacaine|Clonidine or Placebo added to the solution of 0.5% ropivacaine, 2 mg dexamethasone and 5 mcg/ml epinephrine for adductor canal block-present in both treatment and placebo groups.
223627162|NCT03057015|DRUG|Dexamethasone|Clonidine or Placebo added to the solution of 0.5% ropivacaine, 2 mg dexamethasone and 5 mcg/ml epinephrine for adductor canal block-present in both treatment and placebo groups.
223627163|NCT03057015|DRUG|Epinephrine|Clonidine or Placebo added to the solution of 0.5% ropivacaine, 2 mg dexamethasone and 5 mcg/ml epinephrine for adductor canal block-present in both treatment and placebo groups.
223627164|NCT02631980|DRUG|IV iron|Intravenous iron 15 mg/kg (max 1000 mg) in 250 ml 0.9% saline
223627165|NCT02631980|DRUG|IV placebo|Intravenous 0.9% saline (250 ml)
223627166|NCT00399308|DEVICE|Celaderm (Frozen Cultured Epidermal Allograft)|Four biweekly applications of Celaderm plus compression therapy
224216008|NCT03751124|DRUG|Estradiol/norethindrone acetate|Capsule containing co-formulated tablet of estradiol 1.0 mg and norethindrone acetate 0.5 mg administered orally once daily
224216009|NCT03751124|DRUG|Placebo for relugolix|Placebo tablet administered orally once daily and manufactured to match the relugolix tablet in size, shape, color, and odor
224216010|NCT03751124|DRUG|Placebo for E2/NETA|Placebo capsule administered orally once daily and designed to match the E2/NETA capsule in size, shape, color, and odor
223763623|NCT00054561|PROCEDURE|adjuvant therapy|
223763624|NCT03435549|BEHAVIORAL|Remote monitoring|Patients given an activity tracker to wear for 6 weeks after LEJR replacement surgery. For 2 weeks after surgery, they will also receive a daily text messages asking what their pain is on a scale of 0 to 10. They will be asked to reply to the text with their pain score. They will also be sent occasional messaging about their recovery, tips of what to do, and feedback on their progress. They will also also be sent a text message if they stop using their activity tracker for 3 days.
223763625|NCT03435549|BEHAVIORAL|Remote monitoring plus goal setting and social support|Patients given activity tracker to wear for 6 weeks after LEJR surgery. For 2 weeks after surgery, they will receive a daily text messages asking what their pain is on a scale of 0 to 10 and asked to reply by text. They will be sent occasional messaging about their recovery, tips of what to do, and feedback on their progress. They will also also be sent a text message if they stop using their activity tracker for 3 days. Patients will be asked to identify a a friend or family member to act as support partner. The study will share progress updates with support partner and contact this individual if patient stops wearing the activity tracker for over 3 days. This partner will also be able to provide supportive messages to help encourage them to reach their activity goals.
223763626|NCT01988870|RADIATION|Intra-operative Radiation Therapy (IORT)|IORT is a form of APBI (accelerated partial breast irradiation) that allows for a high degree of dose homogeneity, exclusion of non-affected structures, and reduction of the volume of breast tissue exposed.
223627167|NCT00399308|DEVICE|Celaderm (Frozen Cultured Epidermal Allograft)|Four weekly applications of Celaderm plus compression therapy
223627168|NCT00399308|DEVICE|Control (compression bandaging)|Multi-layer compression bandaging
223627169|NCT03409796|DIETARY_SUPPLEMENT|Gluten|Gluten powder.
223763627|NCT01588782|DRUG|Period 1: Abiraterone|1000 mg abiraterone acetate tablet administered orally on Day 1
223763628|NCT01588782|DRUG|Period 2: Abiraterone/Ketoconazole|400 mg ketoconazole tablets administered orally on Days 11 to 16
223763629|NCT01588782|DRUG|Period 2: Abiraterone/Ketoconazole|1000 mg abiraterone acetate tablet administered orally on Day 14
223627170|NCT01679288|DEVICE|Ultrasound (Trademark:VScan; Manufacturer:General Electrics)|Standardized measurements were made and aorta was tried to be visualized in its entirety, and a minimum of three hard copy images were obtained: upper transverse subxiphoid section, lower transverse section for distal view of aorta, and longitudinal section (with origin of celiac trunk or superior mesenteric artery), determining the maximum diameter in centimeters (cm).
223627171|NCT04307797|DRUG|0.9% Sodium-chloride|Part A - 0.9% saline infusion during cardiac PET-MRI scan
223627172|NCT04307797|DRUG|Exenatide (50ng/min for 30 minutes loading followed by 25ng/min maintenance) and glucagon 12.5ng/kg/min|Part A - exenatide and glucagon infusion during cardiac PET-MRI scan
223627173|NCT04307797|DRUG|Glucagon 12.5ng/kg/min and 0.9% saline|Part A - Glucagon and 0.9% saline infusion during PET-MRI scan
223627174|NCT04307797|DRUG|0.9% Sodium-chloride|Part B - 0.9% saline infusion during 7T 31P MRS scan
223627175|NCT04307797|DRUG|Exenatide (50ng/min for 30 minutes loading followed by 25ng/min maintenance) and glucagon 12.5ng/kg/min|Part B - exenatide and glucagon infusion during 7T 31P MRS scan
223627176|NCT04307797|DRUG|Glucagon 12.5ng/kg/min|Part B - Glucagon infusion during 7T 31P MRS scan
223627177|NCT06280924|BEHAVIORAL|Supported Exercise|Participants will take part in a prehabilitation exercise program prior to undergoing a stem cell transplant.
223627178|NCT06280924|BEHAVIORAL|Standard Care|Participants will receive standard care
223627179|NCT02452307|BIOLOGICAL|Peptide vaccine|subcutaneous
223627180|NCT02452307|DRUG|Montanide ISA-51|subcutaneous
223627181|NCT02452307|DRUG|Granulocyte macrophage colony stimulating factor (GM-CSF)|intradermal
223763630|NCT06388551|DRUG|LY03017|single dose, administered orally
223763631|NCT06388551|DRUG|LY03017-Placebo|single dose, administered orally
223763632|NCT02836171|DRUG|Apatinib Mesylate Tablets|apatinib was administered in the morning after an overnight fast of at least 10 h
223763633|NCT02836171|DRUG|Itraconazole Capsules|rifampicin was administered in the morning 0.5 hours after breakfast
223763634|NCT01872572|DRUG|Subcutaneous RB006 0.5 mg/kg|Subcutaneous RB006 0.5 mg/kg
223763635|NCT01872572|DRUG|Subcutaneous RB006 1.0 mg/kg|Subcutaneous RB006 1.0 mg/kg
223763636|NCT01872572|DRUG|Subcutaneous RB006 3.0 mg/kg|Subcutaneous RB006 3.0 mg/kg
223763637|NCT01872572|DRUG|Subcutaneous RB006 2.0 mg|"* Arm 1: 4 subjects received an IV bolus injection of 1 mg/kg RB007 at 72 hours post-RB006 administration~* Arm 2: 4 subjects received an IV bolus injection of 1 mg/kg RB007 at 24, 72, and 120 hours post-RB006 administration."
223763638|NCT01872572|DRUG|Placebo|Placebo
224216011|NCT04777591|DRUG|Liposomal bupivacaine TAP block|Group will receive Liposomal bupivacaine TAP block (mixed with plain bupivacaine) intraoperatively during free flap breast reconstruction as part of the multimodal pain control.
223627182|NCT02452307|DRUG|Imiquimod|epicutaneous
223627183|NCT02452307|DRUG|mRNA|subcutaneous
223627184|NCT02452307|DRUG|Protamin|subcutaneous
223627185|NCT02452307|PROCEDURE|local hyperthermia|
223627186|NCT01579903|DRUG|moroctocog alfa (AF-CC)|Treatment A: 3000 IU moroctocog alfa (AF-CC) dual chamber syringe (including diluent); Treatment B: 1000 IU + 2000 IU moroctocog alfa (AF-CC) vials and separate diluent syringes
223627187|NCT01579903|DRUG|moroctocog alfa (AF-CC)|Treatment B: 1000 IU + 2000 IU moroctocog alfa (AF-CC) vials and separate diluent syringes; Treatment A: 3000 IU moroctocog alfa (AF-CC) dual chamber syringe (including diluent)
223627188|NCT04462640|OTHER|Management of Infant Digestive Disorders and Quality of Life|The variation of the QUALIN score on D30 compared to inclusion (D0) will be described and compared using a Student test for paired data in the case of a normal distribution or a test of the ranks signed by Wilcoxon otherwise.
223627189|NCT03195881|OTHER|Ocular ultrasound|Post-cardiopulmonary arrest patients meeting inclusion/exclusion criteria for targeted temperature management will undergo ocular ultrasound at three time points: within 6 hours (h) of initiation of hypothermic protocol, between 10-24 h after hypothermic protocol initiation, and between 24-36 h after hypothermic protocol initiation.
223627190|NCT04299165|DEVICE|Kaia COPD Application|The study intervention consists of training sessions conducted daily by the patient via the COPD-App.
223763639|NCT06036069|OTHER|Conventional physical therapy|"* Standing with feet together while the therapist was sitting behind and manually locking the child knees.~* Step standing with the therapist behind the child.~* High step standing and trying to keep balanced. The child stood on exercise mattress.~* Single leg stance unilateral standing with assistance. The child was standing on exercise mattress.~* Standing on a declined surface by using wedge. The child was standing on wedge towards the descending direction.~* Standing with manual locking of the knees.~* Changing position.~* Gait training.~* Static and dynamic muscle contraction."
223763640|NCT05459493|DRUG|TJAOA101|Once enrolled, participants will be administrated TJAOA101
223627191|NCT04299165|OTHER|Usual Care|The control group will also be an active control as participants receive a leaflet to convey an active lifestyle and a list of exercises to do at home.
223763641|NCT04088461|DRUG|Linagliptin / Metformin Oral Tablet|Linagliptin 2.5 mg + Metformin 850 mg twice daily plus a lifestyle modifications program
223763642|NCT04088461|DRUG|Metformin|Metformin 850 mg twice daily plus lifestyle modifications program
223763643|NCT04276350|PROCEDURE|Acupuncture|Acupuncture sessions - 2-3 times/week, each session lasting 1 hour, over a period of 10 weeks (with allowed deviation up to 2 weeks due to scheduling)
223763644|NCT04276350|PROCEDURE|Best Medical Therapy|Best Medical Therapy - 3 biofeedback sessions over a period of 10 weeks (with allowed deviation up to 2 weeks due to scheduling), where subjects learn and practice the exercises daily
223763645|NCT06193135|DRUG|Corifolitropin Alfa|Patients will receive a single dose of Colifolitropin alfa, then will receive daily dose of Folitropin Beta since triggering criteria are met.
224317229|NCT05354739|DEVICE|The vibration cold device (BUZZY)|If the patient fulfils the inclusions criteria, the research nurse will obtain informed consent from a parent or legal guardian and assent form if the child is 7years or older. She will assess the ability of the child to use the Faces Pain Scale-Revised (FPS-R), as a pain assessment instrument used by the child. It is a six cartoon faces showing a normal facial expression if no pain, progressing into the facial expression with very severe pain. FPS-R is graded from zero to ten; the child will be asked to quantify the pain by: no hurt, hurt, or very much hurt. This scale is widely used not only in research but also in a routine bases in ours and other units by the nursing staff and are familiar with it. The research nurse is one of the nurses used the same scale during the routine work and will be trained further to ensure consistency, she will document the findings prior, during and after the procedure. This instrument was reliable, valid, and standardized
223763646|NCT06193135|DRUG|Folitropin Beta|Patient will receive daily dose of Folitropin Beta since triggering criteria are met.
223763647|NCT05907135|DIETARY_SUPPLEMENT|Beet|Beet-based powder with other ingredients
223763648|NCT05907135|DIETARY_SUPPLEMENT|Placebo|Placebo powder.
223763649|NCT03527212|DRUG|SJP-0035 0.001%|Self-administration of 1 drop (approximately 40 µL) of 0.001% SJP-0035 ophthalmic solution into each eye 4 times daily for 4 weeks
223763650|NCT03527212|DRUG|Placebo|Self-administration of 1 drop (approximately 40 µL) of placebo ophthalmic solution into each eye 4 times daily for 4 weeks
223763651|NCT06161792|DRUG|0.8 mg RCN3028|Oral
223627192|NCT01602224|DRUG|Placebo|Administered IV
223627193|NCT01602224|DRUG|Dexamethasone|Administered orally
223627194|NCT01602224|DRUG|Bortezomib|Administered SQ
223627195|NCT01602224|BIOLOGICAL|Tabalumab|Administered IV
223627196|NCT06473389|PROCEDURE|Suprascapular nerve pulse radiofrequency ablation|Pulse RF application will be applied to the suprascapular nerve once under US guidance with a TOP-TLG10 STP generator at a maximum temperature of 42 degrees, 2 Hz, 20 ms and 45 V for 2 minutes.
223627197|NCT06473389|PROCEDURE|Suprascapular Nerve Block Group|Suprascapular block will be applied once with a mixture consisting of 5 ml (1 ml betamethasone, 2% lidocaine 2 ml, 0.9% saline 2 ml).
223627198|NCT06473389|PROCEDURE|Steroid Group|Intra-articular steroid application will be made with a mixture consisting of 5 ml (2 ml of 2% lidocaine, 2 ml of 0.9% saline and 1 ml of betamethasone 5 mg).
223627199|NCT05757713|BIOLOGICAL|teplizumab|CD3-directed humanized monoclonal antibody
223627200|NCT01352117|DRUG|efavirenz/emtricitabine/tenofovir disoproxil fumarate|600 mg efavirenz/200 mg emtricitabine/300 mg tenofovir disoproxil fumarate taken orally at night
223763652|NCT06161792|DRUG|Placebo|Oral
223763653|NCT02886585|DRUG|Pembrolizumab|
223763654|NCT02886585|RADIATION|MRI|
223763655|NCT02886585|RADIATION|PET/CT|
223763656|NCT02886585|PROCEDURE|Stereotactic Radiosurgery|
223763657|NCT01363778|DRUG|tivozanib|Tivozanib is a novel and potent pan-vascular endothelial growth factor (VEGF) receptor (VEGFR) tyrosine kinase inhibitor with potent activity against all 3 VEGFRs (VEGFR-1, -2, and -3). In nonclinical models and studies performed in humans, tivozanib has shown strong antiangiogenesis and antitumor activity.
223763658|NCT02583256|BIOLOGICAL|Adjuvanted QIV (aQIV)|Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine (aQIV)
223763659|NCT02583256|BIOLOGICAL|Non-adjuvanted QIV|Non-adjuvanted Quadrivalent Influenza Vaccine (QIV)
223627201|NCT01352117|DRUG|etoposide|50 mg taken orally daily from days 1-7 of each 2-week cycle. For participants without PR or CR after two cycles of therapy and no toxicity greater than Grade 2, the dose of ET was escalated to 100 mg/day orally, days 1-7, every 2 weeks. A cycle could be delayed for a maximum of 14 days. ET could not be initiated prior to 7 days after the last dose in previous cycle. ET could be administered up to a maximum of eight cycles (2 cycles during dose titration and 6 cycles at maximum dose). Participants who could not tolerate escalation of the ET dose to 100 mg/day were treated for a maximum of six cycles.
223627202|NCT00633477|DRUG|Resatorvid|Resatorvid 1.2 mg/kg emulsion, injection for 30 minutes and resatorvid 2.4 mg/kg per-day emulsion, injection, continuous infusion for 96 hours.
223763660|NCT04555135|DEVICE|EndoVigilant Software|While using this device, colonoscopy will continue to be performed in the standard manner as is done without the use of this device. The video signal from the colonoscope will be fed into a computer running the EndoVigilant software in addition to the standard video output to the procedure monitor. The gastroenterologist performing the procedure will therefore be able to observe a standard colonoscopy video on the primary monitor and the augmented video on the second monitor. The gastroenterologist may rely on the second monitor (with augmented video generated from EndoVigilant software) for polyp detection, but the standard procedure monitor with the original feed will always be operational and available for maneuvers such as fast insertion, polypectomy etc.
223763661|NCT03304899|DRUG|RiaSTAP Injectable Product|"RiaSTAP, Fibrinogen Concentrate (Human) is a human blood coagulation factor indicated for the treatment of acute bleeding episodes.~Dose (mg/kg body weight) =~(\[Target level (mg/dL) - measured level (mg/dL)\])/(1.7 (mg/dL per mg/kg body weight))"
223763662|NCT03364049|DRUG|MK-7162|oral tablets
223763663|NCT03364049|BIOLOGICAL|Pembrolizumab|IV infusion
223763664|NCT05818371|DIAGNOSTIC_TEST|Sonographic determination of the optic nerve sheath diameter|Ultrasound-based determination of the optic nerve sheath diameter
223763665|NCT05052424|DIAGNOSTIC_TEST|Analysis of cytokines and immun cell related markers|blood samples
223763666|NCT04942275|DRUG|Pre-therapeutic imaging test|The radiopharmaceutical used for lung perfusion PET consists in human albumin macroaggregates labeled with Ga-68 (68Ga-MAA). 68Ga- MAA are administrated intravenously.
224216012|NCT04777591|DRUG|Bupivacain|Group will receive plain bupivacaine TAP block intraoperatively during free flap breast reconstruction as part of the multimodal pain control.
224216013|NCT05647694|OTHER|V-NAV indoor navigation prototype|Users will use the V-NAV prototype as an augmentation to their indoor navigation activities.
224317230|NCT05011318|OTHER|Baseline|5-min urban park video clip (Presented on a TV)
223627203|NCT00633477|DRUG|Placebo|Resatorvid placebo-matching emulsion, injection for 30 minutes and resatorvid placebo-matching emulsion, injection, continuous infusion for 96 hours.
223627204|NCT00261690|BEHAVIORAL|Virtual Reality Distraction|Using virtual reality distraction during a procedure
223627205|NCT02539823|DRUG|CBD 400 mg|Subjects in Arm CBD 400 mg will receive 400mg of Cannabidiol in each of the three test sessions
223627206|NCT02539823|DRUG|CBD 800 mg|Subjects in Arm CBD 800 mg will receive 800mg of Cannabidiol in each of the three test sessions
223627207|NCT02539823|DRUG|Control (placebo)|Subjects will receive a harmless, inactive solution to compare and validate the results of the other arms of the study
224317231|NCT05011318|OTHER|Fatigue Manipulation|20-min 2-back task (Presented on a computer)
223627208|NCT00770653|DRUG|Pioglitazone and Metformin|Pioglitazone 15 mg/metformin 850 mg combination tablets, orally, twice daily and glimepiride placebo-matching tablets, orally, once daily and metformin placebo-matching tablets, orally, twice daily for up to 24 weeks.
223627209|NCT00770653|DRUG|Glimepiride and Metformin|Pioglitazone/metformin placebo-matching combination tablets, orally, twice daily and glimepiride 2 mg, tablets, orally, once daily and metformin 850 mg, tablets, orally, twice daily for up to 24 weeks.
223627210|NCT02022059|DRUG|Lidocaine = group A|Patient requiring a SNG for nutrition entérale benefiting from a pre-medication by spray of lidocaïne during the insertion (group A = lidocaine)
223763667|NCT00418691|DRUG|IR Methylphenidate|10 mg by mouth (PO) twice daily x 4 Weeks
223627211|NCT02022059|DRUG|Group B placebo|Patient requiring a SNG for nutrition entérale benefiting from a pre-medication by placebo during the insertion
223627212|NCT04505059|PROCEDURE|Precision cardiac anesthesia|Aperi-operative anesthetic management through target-controlled infusion to accurately control the patient blood concentration, with combination of bispectral index and neuromuscular monitoring to adjust the dosage of general anesthetics.
223627213|NCT04505059|PROCEDURE|Conventional cardiac anesthesia|The anesthesia strategy is mainly depending on the anesthesiologist's clinical experience
223627214|NCT01024517|DRUG|GLPG0259 solution|single oral dose, GLPG0259, 50 mg oral solution
223627215|NCT01024517|DRUG|GLPG0259|single oral dose, GLPG0259, 50 mg solid formulation
223627216|NCT02996344|OTHER|Didactic training|Six online training modules pertaining to suicide prevention in primary care.
223763668|NCT00418691|DRUG|Modafinil|200 mg PO Once Daily x 4 Weeks
223763669|NCT00418691|DRUG|SR Methylphenidate|18 mg PO Once Daily x 4 Weeks
223763670|NCT05118594|BEHAVIORAL|Pre-treatment psychotherapy recommendations|After patients complete an intake evaluation and prior to starting therapy, the assigned therapist will receive automatized feedback that consists of recommendations regarding the most suitable interventions (i.e., cognitive, behavioral, interpersonal or patient-centered) for each individual patients, based on patients' baseline characteristics and a machine learning algorithm developed in a previous study. Besides the interventions recommended, therapist will receive within the system guideline and tutorial videos showing how to deliver adequately the specific interventions recommended.
223763671|NCT06319326|OTHER|Evaluation of intestinal perfusion with color Doppler abdominal ultrasound before and after feeding.|This is an observation study involving measurement of intestinal perfusion with color Doppler abdominal ultrasound before and after feeding. No intervention is given to study participants.
223763672|NCT02103478|DRUG|ASTX727 Dose Escalation|Oral investigational product and approved IV decitabine
223763673|NCT02103478|DRUG|ASTX727 Dose Confirmation|Randomization cross over design for courses 1 and 2
223763674|NCT02103478|DRUG|ASTX727 Fixed-Dose Combination|Fixed-dose investigational product
224317232|NCT02072343|DEVICE|No-DCCM|
224317233|NCT02072343|DEVICE|DCCM|
224317234|NCT02072343|OTHER|Water 5ml in tracheal tube|
223627217|NCT02996344|OTHER|Standardized patient interaction|Two standardized patient practice interactions - 1 face-to-face, 1 remote/telehealth.
223763675|NCT04182100|DRUG|P1101|P1101 (ropeginterferon alfa-2b) will be administered subcutaneously every 2 weeks at the starting dose of 100 μg every two weeks (or 50 μg in patients under another cytoreductive therapy). The dose should be gradually increased by 50 μg every two weeks (in parallel, other cytoreductive therapy should be decreased gradually, as appropriate) until stabilization of the hematological parameters is achieved (hematocrit \<45%, platelets \<400 x 10\^9/L and leukocytes \<10 x 10\^9/L). The maximum recommended single dose is 500 μg injected every two weeks. The dose will be maintained at the highest level which can be tolerated and delivers best possible disease response.
224216014|NCT04594200|BEHAVIORAL|Audit and Feedback (A&F)|"In this protocol, we propose comparing 2 intervention design elements in a multifactorial design. Specifically, we will evaluate:~i) an emphasis on antibiotic-associated harms in comparison to messages that focus on lack of benefit; ii) simple versus adjusted peer comparators to represent a target for the prescribing quality indicators~We will also investigate the effects of the inclusion of materials developed by Choosing Wisely Canada (CWC) - namely the viral prescription pad - to help physicians act upon the feedback to reduce their prescribing"
224216015|NCT00555399|DRUG|Vorinostat|"Phase I/Arm 1: Level 0 = 300 mg PO x 14 days; Level I = 400 mg PO x 14 days; Level II = 500 mg PO x 14 days.~Phase I/Arm 3: Level -II = 300 mg PO x 14 days; Level -I = 400 mg PO x 14 days; Level 0 = 400 mg PO x 14 days; Level I = 500 mg PO x 14 days."
224216016|NCT00555399|DRUG|Isotretinoin|"Phase I/Arm 1: Level 0 = 100 mg/m\^2/day PO x 21 days; Level I = 100 mg/m\^2/day PO x 21 days; Level II = 100 mg/m\^2/day PO x 21 days.~Phase I/Arm 2: Level 0 = 100 mg/m\^2/day PO x 21 days; Level I = 100 mg/m\^2/day PO x 21 days; Level II = 100 mg/m\^2/day PO x 21 days.~Phase I/Arm 3: Level -II = 100 mg/m\^2/day PO x 21 days; Level -I = 100 mg/m\^2/day PO x 21 days; Level 0 = 100 mg/m\^2/day PO x 21 days; Level I = 100 mg/m\^2/day PO x 21 days; Level II = 100 mg/m\^2/day PO x 21 days."
224216017|NCT00555399|PROCEDURE|Surgical Resection|Surgical Resection for recurrent Glioblastoma Multiforme
224216018|NCT00555399|DRUG|Temozolomide|"Phase I/Arm 2: All Levels = 150 mg/m2/day PO X 14 days.~Phase I/Arm 3: Level 0 = 150 mg/m2/day PO X 14 days; Level I = 150 mg/m2/day PO X 14 days; Level -I = 125 mg/m2/day PO X 14 days; Level -II = 125 mg/m2/day PO X 14 days; Level -III = 100 mg/m2/day PO X 14 days."
224216019|NCT05525429|BEHAVIORAL|Nutrition Education|Multidimensional nutrition education will be provided.
224216020|NCT04905927|OTHER|phone survey|A questionnaire about the current symptoms and satisfaction for received treatment will be conducted over the phone for patients.
223763676|NCT04182100|DRUG|Low-dose aspirin|Low-dose aspirin (acetylsalicylic acid) (75-150 mg/day) will be given as background therapy during the 12 months of study treatment, unless contraindicated.
223763677|NCT04182100|PROCEDURE|Phlebotomy|Phlebotomy is performed aiming at a hematocrit \< 45%. When the hematocrit value is 45% or higher, phlebotomy is performed. The volume of phlebotomy per procedure should be 200 to 400 mL while monitoring the circulatory dynamics such as blood pressure and pulse. In the elderly and patients with cardiovascular disorders, a small volume (100-200 mL) should be considered to avoid rapid changes in hemodynamics.
223763678|NCT05206695|BEHAVIORAL|Multi-condition Pathway Intervention|See Experimental/Arm 1 description
223763679|NCT04706013|DRUG|Pyridoxal Phosphate|Oral tablets 50 mg
223627218|NCT01417546|DRUG|NHS-IL-12|NHS-IL12 is an investigational agent supplied to investigators by the manufacturer EMD Serono, Inc.
223627219|NCT01373021|DRUG|Fentanyl|Fentanyl 2500mcg+NS50ml
223627220|NCT01373021|DRUG|Dexmedetomidine|Fentanyl 2500mcg+Dexmedetomidine 500mcg + NS 45ml
223627221|NCT00289653|DRUG|Nicoderm|
223627222|NCT04580355|PROCEDURE|One-Stage Full Mouth Debridement|Periodontal debridement
223627223|NCT04580355|DRUG|Amoxicillin 500mg|Administration of Amoxicillin 500mg prescribed on the day of treatment tid for 7 days.
223763680|NCT04988295|DRUG|Lazertinib|Lazertinib will be administered orally.
223763681|NCT04988295|DRUG|Amivantamab|Amivantamab will be administered as an IV infusion.
223627224|NCT04580355|DRUG|Metronidazole 400mg|Administration of Metronidazole 400mg prescribed on the day of treatment tid for 7 days.
223627225|NCT04580355|DRUG|Amoxicillin Placebo|Administration of Placebo on the day of treatment tid for 7 days.
223763682|NCT04988295|DRUG|Pemetrexed|Pemetrexed will be administered as an IV infusion.
223763683|NCT04988295|DRUG|Carboplatin|Carboplatin will be administered as an IV infusion.
223763684|NCT01683279|BIOLOGICAL|Autologous CD19 CAR+ EGFTt + T cells|Autologous T cell modified to express a CD19 specific CAR and a truncated EGFRt tag
223763685|NCT03032796|BEHAVIORAL|Body-Brain Trainer|A novel video game-based intervention that incorporates i) adaptive algorithms critical for cognitive training, ii) physiological measures such as heart rate into the core game mechanics, and iii) motion capture technology to incorporate whole-body kinematics into game play. This group will train for 36 minutes per day, 3 days a week for 8 weeks.
224317235|NCT02072343|OTHER|Water 10ml in tracheal tube|
223627226|NCT04580355|DRUG|Metronidazole Placebo|Administration of Placebo on the day of treatment tid for 7 days.
223627227|NCT02217839|DRUG|DG3173|
223627228|NCT02217839|DRUG|DG3173+Octreotide|
223627229|NCT02217839|DRUG|Octreotide|
223627230|NCT02217839|DRUG|DG3173 Placebo|
223627231|NCT02217839|DRUG|DG3173 Placebo+Octreotide Placebo|
223627232|NCT02217839|DRUG|Octreotide+DG3173 Placebo|
223627233|NCT00187291|DEVICE|T-Wave Alternans test|
223627234|NCT02044354|DRUG|Taxotere|
223627235|NCT02044354|DRUG|Jevtana|
223627236|NCT01962792|DRUG|Ibrutinib|
223627237|NCT01962792|DRUG|Carfilzomib|
223627238|NCT01962792|DRUG|Dexamethasone|
223627239|NCT01439789|DRUG|rhNRG-1|day1\~day10:0.6ug/kg/day,10hours per day for vein infusion
223627240|NCT01439789|DRUG|Placebo|day1\~day10:0.6ug/kg/day,10hours per day for vein infusion
224317236|NCT03280381|OTHER|Nifty feeding cup|The 40 mL Nifty Feeding Cup features an extended reservoir off the lip of the cup that holds a small bolus of milk, ensuring efficient delivery of milk, is made of a durable, soft, silicone material that protects the infant's mouth from injury, has embossed measurements help with tracking volume and intake of milk, is ergonomically designed for frequent use and to enhance finger and wrist control of milk flow and is made from a quick-drying, ultraviolet radiation-resistant, durable, affordable silicone that can be boiled for sterilization. Mothers can directly express into the cup, reducing possible cross-contamination from other containers.
224317237|NCT03280381|OTHER|Generic medicine cup|The generic cup that will be used in this study is a small medicine cup 30 ml in size.Small medicine cups are manufactured by a variety of manufacturers and are commonly used in health facilities to feed breastmilk to infants who are having breastfeeding difficulties. The cups are generally translucent, calibrated with a variety of measurements including 2.5-30 mL.
224317238|NCT04538482|BEHAVIORAL|DASH Diet|Participant will receive foods following the DASH dietary pattern for 28 days.
223627241|NCT04906499|BEHAVIORAL|Physical Activity Promotion|"After enrolling, participants will be outfitted with a Fitbit Charge 2 activity monitor. The monitor will be worn during all waking hours, and compliance will be considered as a day with ≥ 1,000 steps. Participants will complete a 14-day run-in observation period while wearing the Fitbit but no PA promotion will occur. Individuals who are noncompliant during the run in period (\<10 days with \<1,000 steps) will be removed. Participants will receive a text message each morning with a personalized, daily step count goal and a link used to confirm receipt of the goal. The preceding 10 days of step data will be rank ordered and the 60th percentile step count will be set as the goal for the next day."
223627242|NCT05503836|PROCEDURE|abdominal surgeries|abdominal surgeries
223627243|NCT00002044|DRUG|Zidovudine|
223627244|NCT02326623|OTHER|distraction|distraction using an iPad with a selection of child-appropriate games
223627245|NCT02326623|OTHER|topical anesthetic cream|standard care is to use a topical anesthetic cream at the site of planning IV access
223627246|NCT02318160|OTHER|measurement of oxidant status in AIT|measurement of thyroid-stimulating hormone (TSH) and free thyroxin (FT4), as well as anti-thyroid peroxidase antibodies (TPOAb) and anti-thyroglobulin antibody (TgAb) were done in addition to assessment of malondialdehyde (MDA) and total antioxidant capacity (TAC) levels as an oxidative stress markers
223627247|NCT01198886|OTHER|Successful Aging Program|Once per week discussion on lifestyle topics important to older adults. Classes conclude with a gentle upper body stretching routine.
223627248|NCT01198886|OTHER|Exercise-Nutrition Program|Targeted exercise program offered 3-days per week at the study participants place of residence (senior housing facility). Other means to encourage physical activity outside of these exercise classes will be available. A nutrient-rich protein carbohydrate experimental beverage will be taken following the exercise sessions.
223627249|NCT06378021|DRUG|Calcium Chloride|5 % calcium chloride injection in cardiac ganglionic Plexus during On pump Coronary artery bypass graft
224317239|NCT04538482|BEHAVIORAL|standard American diet|Participants will receive foods following the standard American diet for 28 days.
224317240|NCT03799432|OTHER|COAST-IS|COAST-IS has been designed to equip organizations with the knowledge, motivation, and skill needed to thoughtfully match implementation strategies to identified determinants by applying intervention mapping. The COAST-IS intervention will include four different modes of delivery: 1) dissemination of educational materials; 2) five web-based interactive education sessions on the need for tailoring implementation strategies and the application of intervention mapping; 3) site visits to discuss change objectives necessary to successfully implement trauma-focused cognitive behavioral therapy; and 4) organizational coaching related to using an intervention mapping approach.
224317241|NCT03799432|OTHER|TF-CBT Learning Collaborative|The learning collaborative model was adapted from the Breakthrough Series Collaborative model. Leadership of the collaboratives includes experts in evidence-based practices, implementation, and quality improvement. Main components include: 1) three face-to-face learning sessions (2-days each) that provide clinical training; 2) post-learning session action periods structured to facilitate therapists' application of learned skills; 3) a secure website to facilitate faculty-to-participant and peer-to-peer learning and document use of quality improvement methods; 4) fidelity monitoring and coaching; 5) a senior leader track supporting organizational change; 6) monthly outcomes monitoring; and 7) sustainability planning.
223627250|NCT06378021|DRUG|Sodium Chloride 0.9% Inj|0.9% sodium chloride injection during on pump during Coronary artery bypass graft
223627251|NCT03121313|DRUG|tegafur-uracil|
224317242|NCT06037694|PROCEDURE|Conventional Free Gingival Graft|Implant site with insufficient dimensions of KM will be covered by a conventional free gingival graft.
223627252|NCT01723098|BEHAVIORAL|Exercise group|"Supervised physical conditioning program of three 55-60 minute sessions per week during whole pregnancy (from week 9 to 38). Each session consists of 25-30 minutes of cardiovascular exercise,10 minutes of specific exercises (strength and balance exercises), and 10 minutes of pelvic floor muscles training~Aerobic activity was prescribed at light to moderate intensity, aiming for 55-60 of maximal heart rate. All subjects wore a heart rate (HR) monitor (Polar FT7) during the training sessions to ensure that exercise intensity was light to moderate."
223627253|NCT01502748|OTHER|endovascular sampling|Paired sampling from the distal arterial(endovascular catheter) and peripheral venous (femoral sheath) locations: withdrawal of 3ml of blood from vasculature distal to the occlusive thrombus
223627254|NCT06465940|DEVICE|Total hip arthroplasty|Replacement of hip joint
223627255|NCT03058120|OTHER|Deferral of admission for stress test|Early discharge; admission and stress test are deferred.
223627256|NCT03897426|BEHAVIORAL|Mediterranean Diet - Remote Coaching using a Mobile App|Patients randomized to the intervention arm will be then given an instruction booklet on using Mobile App, directed to a website for additional instruction on its use, and have the app set up to establish connectivity to the RD.
223627257|NCT03323892|OTHER|second masturbation|Husbands will be asked to produce a second sperm sample in the masturbatorium
223627258|NCT04935658|DEVICE|Hypnotic relaxation induced by virtual reality (device)|A virtual reality device will be install on the patient 3-5 minutes before the beginning of the oocyte retrieval. The device will be wearing by the patient during the entire intervention and 2 minutes after the end of the ponction.
223627259|NCT04935658|DRUG|local anesthesia|standard anesthesic procedure
223627260|NCT04862715|DRUG|Ferinject|"Active study medication Medication name: Ferinject® Active ingredient: Ferric carboxymaltose Dosage form: 50 mg iron/ml solution for injection/infusion. Appearance: Dark brown, non-transparent aqueous solution Excipients: Sodium hydroxide, hydrochloric acid and water for injection Strength/Packaging: Each 2 ml vial contains 100 mg of iron as ferric carboxymaltose.~Each 10 ml vial contains 500 mg of iron as ferric carboxymaltose. Each 20 ml vial contains 1,000 mg of iron as ferric carboxymaltose. Manufacturer: Vifor Pharma UK Limited"
223627261|NCT04862715|OTHER|Placebo: NaCl (sodium chloride 0.9%)|Medication name: NaCl (sodium chloride 0.9%) Active ingredient: NaCl (sodium chloride 0.9%) Dosage form: 0.9% w/v NaCl as sterile solution in water for injection Excipients: Water Strength/Packaging: 100 ml container with 100 ml normal saline Manufacturer: As per local hospital supplier
223627262|NCT01288573|DRUG|plerixafor|160 μg/kg subcutaneous (SC) injection
223627263|NCT01288573|DRUG|plerixafor|240 μg/kg subcutaneous (SC) injection
224216021|NCT06516549|OTHER|Skipping rope and informational pamphlet|The provision of a skipping rope and an informational pamphlet to the intervention arm participants will happen during the participant interview within the overall DASH cohort study. The enumerator conducting the survey interview will provide each participant in the intervention group with a skipping rope and pamphlet and will read a short script explaining how to use the rope, outlining the main benefits of physical activity for adolescents, and asking participants to read the pamphlet in their own time.
224216022|NCT04440345|DRUG|IBI362|Administered by subcutaneous injection
224216023|NCT04440345|DRUG|Placebo|Administered by subcutaneous injection
224317243|NCT06037694|PROCEDURE|'Mesh Free Gingival Graft|Implant site with insufficient dimensions of KM will be covered by a expanded meshed free gingival graft.
224317244|NCT03236415|DEVICE|Xience Drug Eluting Stent|Patients will undergo insertion of a drug eluting stent with assessment of strut coverage using optical coherence tomography at 4 to 6 weeks after implantation.
224317245|NCT03236415|DEVICE|ABSORB Bioresorbable Vascular Scaffold|Patients will undergo insertion of a bioresorbable vascular scaffold with assessment of strut coverage using optical coherence tomography at 4 to 6 weeks after implantation.
224317246|NCT05937828|OTHER|data collection|description of the long-term health of adult patients, identification of the heterogenous genetic underlying pathophysiologic contexts, study of the benefit-risk balance of treatments, including the growing development of targeted therapies.
223627264|NCT01288573|DRUG|plerixafor|320 μg/kg subcutaneous (SC) injection
223627265|NCT03449511|OTHER|Ginger aromatherapy|Three sniffs of aromatherapy inhaler four times daily for seven days.
223627266|NCT03449511|OTHER|Orange aromatherapy|Three sniffs of aromatherapy inhaler four times daily for seven days.
223627267|NCT03449511|OTHER|Lavender aromatherapy|Three sniffs of aromatherapy inhaler four times daily for seven days.
223627268|NCT03449511|OTHER|Jojoba aromatherapy|Three sniffs of aromatherapy inhaler four times daily for seven days.
223627269|NCT04478201|OTHER|back sleep positioning|sleeping on the back.
224317247|NCT03651882|DRUG|Oxytocin|Oxytocin given in a combined regimen: after delivery 10 IE of oxytocin are applied intramyometrially and 10 IE of oxytocin are given over an infusion of 1000ml of 0.9% NaCL over 12 hours intravenously.
223627270|NCT04478201|OTHER|side sleep positioning|sleeping on the side
223627271|NCT03029806|OTHER|Aldosterone response to AngII LS|Change in aldosterone from baseline to after Ang II infusion on a LS diet
223627272|NCT03029806|OTHER|Renal blood flow response to salt|Change in renal blood flow: High salt to low salt diet
223627273|NCT03029806|OTHER|Vascular Stiffness|Change in vascular stiffness, baseline compared to AngII
223627274|NCT01901159|DRUG|RO4995819|Oral doses of RO4995819 (tablet)
223627275|NCT01901159|DRUG|RO4995819|Oral doses of RO4995819 (capsule)
224317248|NCT03651882|DRUG|Carbetocin|Carbetocin is given 0.1mg intravenously as a bolus after delivery.
224317249|NCT03850925|PROCEDURE|Laser therapy|4 consecutive sessions of laser therapy
223627276|NCT04861129|PROCEDURE|Bowen therapy|Intervention is provided weekly for 6 sessions lasting 30-40 mins per treatment session
223627277|NCT04861129|PROCEDURE|Sham Bowen therapy|Sham Intervention is provided weekly for 6 sessions lasting 30-40 mins per treatment session
223627278|NCT00179621|DRUG|Lenalidomide 5 mg|Lenalidomide 5 mg daily 28/28 days
223627279|NCT00179621|DRUG|Lenalidomide 10 mg|Lenalidomide 10 mg daily 21/28 days
223627280|NCT00179621|DRUG|Placebo|Placebo, matching to active study drug arms
223627281|NCT05622734|BEHAVIORAL|VOCALE LBD+|Intervention employs a web-based platform that allows participants to engage asynchronously in an eight-week online intervention involving didactic training, peer-to-peer support, and moderated problem-solving skill enactment.
223627282|NCT03432325|DEVICE|Neural Enabled Prosthesis|Surgically implanted neural enabled prosthesis
223627283|NCT03084211|OTHER|Light exercise discharge instructions|Participants in the intervention group will receive discharge instructions prescribing light exercise following mild traumatic brain injury.
223627284|NCT00270985|BEHAVIORAL|Almonds in a calorie controlled diet|Prescribed daily dose of Almonds in calorie controlled diet for adults with pre-type 2 diabetes
223627285|NCT00270985|BEHAVIORAL|Nut free diet|Calorie controlled diet free of nuts for adults with pre-type 2 diabetes
223627286|NCT03567564|DIAGNOSTIC_TEST|Abdominal muscles ultrasound|Abdominal muscles ultrasound during a spontaneous breathing trial using the M-mode to calculate the thickening fraction of the anterior and lateral abdominal muscles under multiple circumstances (tasks performed by the patients)
223627287|NCT01866540|DRUG|FLUENZ|live attenuated influenza vaccine
224216024|NCT04194905|DRUG|Levonorgestrel 0.1 mg and Ethinyl estradiol 0.02 mg Test Product|Coated Tablets
224216025|NCT04194905|DRUG|Levonorgestrel 0.1 mg and Ethinyl estradiol 0.02 mg Reference Product|Coated Tablets
224216026|NCT00534092|DEVICE|X STOP® Interspinous Process Decompression System|The X STOP is a titanium implant that fits between the spinous processes of the lumbar spine. It is made from Ti-6AI-4V Eli titanium alloy (ISO 5832/3) and consists of two components: a spacer assembly and a wing assembly.
224216027|NCT06012058|DIAGNOSTIC_TEST|ROTA assessment by AI|The RNFL is imaged with OCT for ROTA and the data are analyzed with a deep learning model.
224216028|NCT06012058|DIAGNOSTIC_TEST|Optic disc assessment by AI|The optic disc is imaged with color fundus camera and the data are analyzed with a deep learning model.
223627288|NCT05858541|BEHAVIORAL|Music Listening|The LUCID AI-based system for song selection responds to the collected measurement data (video and HRV) and music preference information (like/dislike button, music taste profile) to recommend the playlist for the listener. The songs are selected using 76 different musical features and raw audio information. The system uses these features to recommend and optimize recommendations for the listener
223627289|NCT05858541|BEHAVIORAL|Listening to Audiobooks|A selection of 40 audiobooks spanning 4 genres (10 each from Literary Classics, Fantasy, Mystery, Non-fiction) will be available. For each session, the participant and their caregiver will be given a prompt to make a genre selection. After making the genre selection, one of the ten stories associated with that genre will be selected at random. All stories were sampled from the Audible audiobook database. Stories had to be 30 minutes in length to align with the length of the music interventions and the selected stories had to have had a 4- or 5-star rating to ensure quality.
223627290|NCT04272918|BEHAVIORAL|Caregiver Support Model|Examine the effectiveness of the Caregiver Support Model (CSM) on improving caregivers' well-being.
223627291|NCT04272918|BEHAVIORAL|Psycho-education Program|Examine the effectiveness of the Psycho-education Program (PP-E) on capacity building, empowerment, and improving well-being.
223627292|NCT04027855|PROCEDURE|collection of peripheral blood mononuclear cells from healthy volunteers|"1. Screening period: All volunteers are required to sign a written informed consent form for the study; after the signing of informed consent form, the demographic data and medical history of the volunteers will be collected, and physical examinations and local laboratory tests will be performed to assess the eligibility of the volunteers. Volunteers who meet all the inclusion criteria and do not meet any exclusion criteria (except for the basic biological indicators of UCAR-T product preparation) will receive peripheral venous whole blood sampling, and the volunteers receiving apheresis based on the assessment results will be enrolled.~2. Apheresis period: 5 volunteers who meet the inclusion criteria will undergo collection of peripheral blood mononuclear cells (PBMC) by means of apheresis."
223627293|NCT02722564|BEHAVIORAL|self estimation of breath alcohol content|
223763686|NCT03032796|BEHAVIORAL|Body Trainer|"A novel video game-based intervention that incorporates physiological measures such as heart rate into the core game mechanics, with motion capture technology to incorporate whole-body kinematics into game play. This group will train for 36 minutes per day, 3 days a week for 8 weeks. The Body Trainer group will train using closed-loop adaptive algorithms to challenge physical performance as guided by heart rate, such that the amount of movement needed to respond on each task will dynamically change depending upon the participant being below/above a predetermined derived level of exertion. During Body Training, participants will only perform a basic reaction task in each level/module to ensure only the most minimal cognitive challenge is present"
223627294|NCT02722564|DEVICE|breath alcohol content as measured by Alco Sensor IV device|
223627295|NCT02722564|OTHER|drink a beer|drink a beer, repeat until breath alcohol content 0.1
223763687|NCT03032796|BEHAVIORAL|Brain Trainer|"The Brain Trainer group will train using the aforementioned closed-loop adaptive algorithms to challenge cognitive performance, except while sitting down and playing with an Xbox control pad (thus removing all physical training aspects). This group will train for 36 minutes per day, 3 days a week for 8 weeks."
223627296|NCT02250742|OTHER|dry needling|Dry needling uses traditional acupuncture needles without injecting any liquid. Dry needling is based on traditional Western medicine whereby the needle insertion sites are located in known anatomical landmarks such as skeletal muscles, fascia and occasionally joints, tendons and bone/tendon junctions.
223627297|NCT05602298|OTHER|Quality of Recovery 15 survey|QOR 15 is a patient reported outcomes measure (PROM) tool used as a global measure of patient recovery after surgery and anesthesia. It uses fifteen questions to assess various domains of patient health: pain, physical comfort, physical independence, psychological support, and emotional state.
223627298|NCT06235372|DEVICE|Specular microscopy|Specular microscopy is a noninvasive photographic technique that analyze the corneal endothelium. Using computer-assisted morphometry, modern specular microscopes analyze the size, shape and population of the endothelial cells. The instrument projects light onto the cornea and captures the image that is reflected from the optical interface between the corneal endothelium and the aqueous humor. The reflected image is analyzed by the instrument and displayed as a specular photomicrograph .
223763688|NCT03032796|BEHAVIORAL|Expectancy Matched Control|The placebo-matched control group will engage in a battery of three apps (playing each app 10 minutes per day, 5 days a week for 8 weeks completed in the laboratory that we believe will have no significant impact on the cognitive or physical fitness measures we are assessing: i) an app with 100 different logic games of varying difficulty and length, ii) a language-learning app with 10 language options, and iii) an app that offers a guided Tai Chi program. We have pre-determined that this approach generates matched expectancy compared to our training groups: we asked 100 naïve individuals to predict how they would expect to improve performance on our outcome measures after training on one of these platforms, revealing that placebo training generates equivalent expectations of improvement across each outcome measure as the BBT group.
224216029|NCT03243539|PROCEDURE|Lung Protective Ventilation|Neuro lung protective ventilation for patients with acute brain injury is designed to target a normal partial pressure of arterial carbon dioxide and decrease initial tidal volumes toward a target 6 ml/kg predicted body weight PBW (range 6 to 8 ml/kg PBW)
224317250|NCT01822366|BEHAVIORAL|Trauma-focused Cognitive Behavioral Therapy|
223627299|NCT03422913|PROCEDURE|controlled low central venous pressure|Anesthesiologists will control the amount of fluid input and the use of composite intravenous anesthesia to make CVP at 0\~5cm H2O, if CVP is still \>5cm H2O, intravenous infusion of nitroglycerin will be used to reduce CVP. Maintaining arterial systolic blood pressure (SBP) \> 90 mmHg, urine output more than 1ml/kg/h, and CVP was continuously monitored. Arterial pressure, pulse oxygen saturation ( SPO2), PaCO2 and electrocardiogram (II and V5 leads) were continuously monitored by radial artery cannulation. CVP will Returned to normal level (6 \~ 12 cmH2O) after resection to observe the wound if active bleeding still exist. Intraoperative hepatic blood flow blocking intermittent Pringle block method also required during surgery, 10-15 minutes for once, and more than 5 minutes interval can be repeated.
223627300|NCT00837252|DRUG|Finasteride|Participants received 5mg of oral finasteride daily for three months.
223627301|NCT05887869|BEHAVIORAL|Telehealth solution|Telehealth solution offered for nutrition education and breastfeeding support.
224317251|NCT03096912|DRUG|Ribociclib|Ribociclib Oral 600 mg x 1 a day 21 days on 1 week off in 28 days cycles
224317252|NCT00025259|BIOLOGICAL|Bleomycin Sulfate|Given IV or SC
224317253|NCT00025259|DRUG|Cisplatin|Given IV
223763689|NCT04833348|OTHER|Motor function measurement using inertial sensors|"Measurement of motor skills at M0: start of the administration of the innovative therapy and then 1 month, 3 months, 6 months, 1 year and then 2 years later:~* Free motor skills in the supine position~* Motricity in the supine position stimulated by a play frame~* Measurement of the proximal and distal activity of the upper limbs in motor skills stimulated by the play gantry~* Measurement of activity in a supported sitting position Longitudinal study, the subject is his own control"
223763690|NCT05429203|DEVICE|Duodenoscope with single-use distal cover|Newer duodenoscope with a single-use distal cover
223763691|NCT05429203|DEVICE|Conventional duodenoscope|Conventional duodenoscope with standard methods of reprocessing
223763692|NCT04731610|OTHER|Radiotherapy|postoperative radiotherapy after complete resection of thymoma
223763693|NCT04731610|OTHER|Surveillance after resection|Surveillance after tumour resection
223763694|NCT05074186|DEVICE|neurological thrombectomy device is an investigational device.|Revascularization device is an investigational device.
223763695|NCT05176561|BEHAVIORAL|Auditory-Cognitive Training|"Treatment Participants will complete 8 weeks of training for 2 hours per week and participate in a 1 hour meeting with clinician. Participants with spend 1 hour auditory training use Angel Sound and one hour of auditory cognitive training using auditory portions of Posit Science. A clinical paradigm including reviewing results, providing strategies and positive feedback and strategies in the 1 hour virtual meeting of clinician and participant. Practice for next week is assigned.~Control group intervention follows the same time and procedure but the materials are non-auditory puzzles (Sudoku, Cross Word Puzzles, Spot the Difference, Ken-Ken and Word Search)."
223763696|NCT05176561|BEHAVIORAL|Non-auditory Cognitive Training|Participant will complete 8 weeks of training for 2 hours per week and participate in a 1 hour meeting with clinician. Control group intervention follows the same time and clinical paradigm, but the materials are non-auditory puzzles (Sudoku, Cross Word Puzzles, Spot the Difference, Ken-Ken and Word Search).
224317254|NCT00025259|DRUG|Cyclophosphamide|Given IV
224317255|NCT00025259|DRUG|Cytarabine|Given IV
224317256|NCT00025259|DRUG|Dexamethasone|Given IV
224317257|NCT00025259|DRUG|Doxorubicin Hydrochloride|Given IV
224317258|NCT00025259|DRUG|Etoposide|Given IV
224317259|NCT00025259|BIOLOGICAL|Filgrastim|Given SC
224317260|NCT00025259|RADIATION|Involved-Field Radiation Therapy|Undergo IFRT
223627302|NCT03896139|DRUG|Kinase inhibitor|Patients treated with kinase inhibitors for cancer or other conditions
223627303|NCT00907595|DRUG|Ramelteon|After 2 weeks of baseline sleep study, subjects will be randomized to take either Ramelteon or Placebo for 4 weeks.
223627304|NCT00907595|DRUG|Placebo|After 2 weeks of baseline sleep study, subjects will be randomized to take either Ramelteon or Placebo for 4 weeks.
223763697|NCT06553794|OTHER|Gastroscopy with duodenal mucosal tissue biopsies|"Subjects will undergo a standardized heavy water dosing protocol for 2 days (1 loading day, 1 maintenance day) and consume a standardized diet for 2 days. On the experimental test day, a gastroscopy with collection of duodenal mucosa tissue samples will be performed."
223763698|NCT05491083|DRUG|Pembrolizumab & ADG106 (Phase Ib)|"Drug: ADG106~Administered as an intravenous infusion over 60-90 minutes in the initial cycle and over 30 minutes in subsequent cycle if well tolerated.~Pembrolizumab~Administered as an intravenous infusion over 30 minutes"
223763699|NCT05491083|DRUG|Pembrolizumab & ADG106 (Phase II)|"Drug: ADG106~Administered as an intravenous infusion over 60-90 minutes in the initial cycle and over 30 minutes in subsequent cycle if well tolerated.~Pembrolizumab~Administered as an intravenous infusion over 30 minutes"
224317261|NCT00025259|DRUG|Prednisone|Given orally
224317262|NCT00025259|DRUG|Vincristine Sulfate Liposome|Given IV
224317263|NCT01767948|DRUG|PCI-32765|PCI-32765 140 mg will be administered as a single dose, orally, on Day 1.
224317264|NCT01449370|DRUG|TAK-117|oral administration of TAK-117, daily and intermittent schedules.
224317265|NCT06629831|OTHER|group with complications|Complications in patients undergoing cytoreduction surgery for ovarian cancer
224317266|NCT06629831|OTHER|group without complications|Complications in patients undergoing cytoreduction surgery for ovarian cancer
224317267|NCT05343546|DEVICE|Use of either copper T380A or Levonorgestrel LNG 52 IUS after medical management of first trimester incomplete abortion|"Use of either copper T380A or Levonorgestrel LNG 52 IUS after medical management of first trimester incomplete abortion within seven days of giving Misoprostol Early insertion or 2-4 weeks after Misoprostol use Standard insertion"
224317268|NCT01888510|PROCEDURE|computed tomography|Undergo conventional free breathing CT
224317269|NCT01888510|PROCEDURE|4-dimensional computed tomography|Undergo 4D CT
224317270|NCT01888510|PROCEDURE|computed tomography|Undergo ABC CT
224317271|NCT01888510|PROCEDURE|cone-beam computed tomography|Undergo ABC CBCT
224317272|NCT01888510|PROCEDURE|cone-beam computed tomography|Undergo free breathing CBCT
224317273|NCT04792424|OTHER|Regional citrate anticoagulation|Starting RCA 4 mmol/L (adjust the rate by BFR)
224317274|NCT04792424|DRUG|Vasopressor|Vasopressors such as Norepinephrine, dopamine, milrinone, dobutamine
224317275|NCT04792424|DRUG|Antibiotic|Antibacterial agents deemed appropriate by physicians in the ICU
224317276|NCT04792424|DEVICE|Dialysis with continuous renal replacement therapy|Prismaflex
224317277|NCT01709929|DRUG|insulin detemir|Administered subcutaneously (s.c., under the skin). Dose individually adjusted.
224317278|NCT00464789|DRUG|Bazedoxifene/Conjugated Estrogens 20 mg/0.625 mg tablet|
224317279|NCT02290223|BEHAVIORAL|Behavioral Based Treatment Model|Behavioral based treatment consists of four 90 minute group sessions, one meeting per week. The sessions addressed: empowering patients to take an active role in pain management and overall health; pain management lifestyle practices; use of health information technology resources for active self-care; education on neurobiology of pain and opioids; and improving communication with providers.
224317280|NCT00534404|DRUG|Nicotine patches|Participants will wear nicotine patches.
224317281|NCT00534404|BEHAVIORAL|Telephone counseling|Participants receiving telephone counseling will receive five phone calls over a 2-month period to discuss their personal smoking cessation plan.
224317282|NCT00534404|BEHAVIORAL|iQuit Smoking website|Participants will access the Project Quit (iQuit Smoking) website.
223763700|NCT05026060|DIAGNOSTIC_TEST|Imaging|4-minutes eASL sequence without injection of contrast product added to each of the clinical MRs with standard ASL sequences performed for the care of the patient for 3 years.
223763701|NCT00433654|DEVICE|Implantable Pulse Generator (IPG) and Pacing Leads (wires)|Pacer and leads
223763702|NCT00433654|OTHER|Magnetic Resonance Imaging (MRI) scan|One hour MRI scan on the head and lower back.
223763703|NCT06471920|BEHAVIORAL|Standardized Education|Patients randomized to the standardized education group will receive registered access to a study website with access to evidence-based education for patients with chronic LBP. Each participant will have unique login credentials to allow for tracking of individual patient use. The website will include important education on the etiology of chronic LBP and evidence-based suggestions for self-management of symptoms. Education will focus on the importance of maintaining healthy levels of physical activity and avoiding bedrest.
223763704|NCT06471920|BEHAVIORAL|Telerehabilitation|Based on prior SBTS risk stratification, participants in the risk-informed telerehabilitation group will receive subsequent care using an evidence-based treatment protocol designed for video visits to be informed by a participant's baseline risk score with elements ranging from standard physical therapy telehealth visits (low-to-medium risk) to PIPT telehealth visits (high-risk).
223763705|NCT03194165|BIOLOGICAL|Dolutegravir|Dosage
224216030|NCT05740670|OTHER|Dr. Kellyann's Bone Broth|Participants will have two bone broth phases, each three weeks in length. Bone broth phases will be separated by a one-week maintenance phase. A one-week maintenance phase will also occur after the second bone broth phase. Each week of a broth phase will consist of five feeding days and five fasting days. On feeding days, participants will consume one packet of bone broth, twice each day, as snacks between meals. On fasting days, participants will consume one packet of bone broth every two hours for a total of seven packets each day.
223763706|NCT03194165|BIOLOGICAL|Raltegravir|Dosage
223763707|NCT03194165|BIOLOGICAL|Rilpivirine|Dosage
223763708|NCT03194165|BIOLOGICAL|Nevirapine|Dosage
224216031|NCT01683253|DRUG|Levodopa/Carbidopa(200mg/50mg)|
224216032|NCT01683253|DRUG|Dopaminergic Agonists|Treated for at least 6 months after diagnosis of Parkinson's Disease.
224216033|NCT01928446|DRUG|Lithium|Lithium in the form of extended release lithium carbonate. Subjects will be started on 600 mg/day (300mg bid) until steady state at target plasma levels between 0.6 and 0.8 meq/liter is achieved. The lowest dose will be 300 mg/day. Lithium will be prescribed for the duration of follow-up (1 year).
223763709|NCT03194165|BIOLOGICAL|Atazanavir|Dosage
224216034|NCT01928446|DRUG|Placebo|Oral placebo tablets will be administered for the duration of follow-up (1 year).
224317283|NCT01898273|DRUG|I-124-CLR1404|single-dose, intravenous
223627305|NCT02726503|DRUG|Lenvatinib|"All patients will receive lenvatinib 24 mg orally once daily at almost the same time. The treatment will be started within 1 week after enrollment. 1 cycle consists of 4 weeks.~The administration will be continued until patients meet withdrawal criteria. If any toxicity manifested that cannot be ruled out causal association with the study drug, drug withdrawal or dosage reduction will be conducted in accordance with drug withdrawal/dosage reduction criteria."
223763710|NCT03194165|BIOLOGICAL|Darunavir|Dosage
223763711|NCT03194165|BIOLOGICAL|Ritonavir|Dosage
223763712|NCT04158297|PROCEDURE|ESWL vs SOPIL|To compare the efficacy of single operator pancreatoscopy (SOP) with intracorporeal lithotripsy (SOPIL) to extracorporeal shock wave lithotripsy (ESWL) for the treatment of main pancreatic duct stones (MPDS) in patients with chronic pancreatitis.
223763713|NCT06050395|BEHAVIORAL|Quality fo Life Questionnaire (FHSI)|Participants will take a survey at baseline and visit 2 (weeks 6-8), and visit 3 (week 10-14). The Functional Assessment of Cancer Therapy Hepatobiliary Cancer Symptom Index-8 (FHSI) questionnaire uses a 5-point Likert-type scale, 0=not at all and 4=Very much. A lower total score indicates better quality of life.
223763714|NCT06050395|BEHAVIORAL|Vioscreen Food Frequency Questionnaire (FFQ)|Participants will receive a web-based link and information to complete VioScreen, a web-based food frequency questionnaire, which allows participants to choose the average frequency of consumption of food items over a given time frame (1 month, 3 month, 1 year, etc.) on a Likert scale with choices ranging by individual questions. Total energy and nutrient intake is estimated by summing intakes from each food based on the selected portion size, reported frequency of consumption, and nutrient content of each food item. Anti-inflammatory and pro-inflammatory dietary patterns are calculated using the energy-adjusted dietary inflammatory index (DII) score to represent the inflammatory potential of an individual's overall diet, using data from FFQ responses. Higher DII scores represent more pro-inflammatory diets while lower (i.e., more negative) DII scores represent more anti-inflammatory diet.
223763715|NCT06050395|BEHAVIORAL|Educational Handouts|Participants will receive educational handouts on diet.
223763716|NCT06050395|BEHAVIORAL|NutritionCoaching|Participants will receive bi-weekly nutrition coaching on anti-inflammatory dietary patterns and foods.
223763717|NCT06050395|BEHAVIORAL|Follow-Up Survey|Participants will complete a custom exit/follow up survey regarding relevance, acceptability, intervention length and timing, an barriers/facilitators. This survey contains 38 questions scored from 1 -Strongly agree to 5-Strongly disagree. A lower score indicates patient satisfaction with the program and the skills and knowledge gained in the program.
223763718|NCT06050395|BEHAVIORAL|Functional Assessment of Anorexia/Cachexia Treatment (FAACT) Questionnaire|The FAACT questionnaire uses a 5 point Likert-type scale, 0=Not at all, 4=Very much. A higher score indicates better appetite and quality of life.
223763719|NCT06050395|BEHAVIORAL|Patient Reported Outcomes Measure- Cognitive Function (PROMIS-Cog) Questionnaire|Participants will complete the PROMIS-Cog form which measures self-reported cognitive deficits. The questionnaire uses a 5 point Likert-type scale, 1=Very often and 5=Never. A higher score indicates higher cognitive function.
223763720|NCT03100227|OTHER|PET [18F] FDG|Measurement of carbohydrate metabolism at the individual level. Standardization of the individual imaging data in a standard anatomical space and then calculation of an average image through the group-level controls.
223763721|NCT03100227|OTHER|Anatomical MRI|All subjects will benefit from a 3D anatomical MRI to control the normality of their MRI and an automatic segmentation of 73 brain regions by multi-atlas segmentation.
223763722|NCT04984551|OTHER|Extension of Community Health (ECHO) Telementoring Clinic|Participate in ECHO clinics presenting cases for guidance and feedback
223627306|NCT02438163|DEVICE|Theta Burst Stimulation|"During the first session, After determining the parameters of stimulation (stimulated target : part of the left motor cortex responsible for the contraction of the right first dorsal interosseous muscle ; Activity Motor Threshold (AMT) ; Intensity of Stimulation providing a Motor Evoked Potential (MEP) with an Amplitude of 1mV (MEP 1mV)), a Baseline consisting of 15 MEP (intensity MEP 1mV) is measured. Then each subjet receive a TBS protocol (cTBS or iTBS) (intensity of stimulation 80% of AMT). After receiving the stimulation, sets containing 10 MEP are regularly measured by each subject.~During a second session, the same protocol is done again with the other TBS stimulation (cTBS or iTBS) the subject didn't get during the first session."
224216035|NCT02473328|DRUG|Atazanavir 200 mg/r|"1. In patients signed an informed consent and meeting all the eligibility criteria at the time of the run-in (S-4),~2. switch of antiretroviral therapy Atazanavir 300 mg/ritonavir 100 mg once a day to Atazanavir 200 mg/ritonavir 100 mg once a day without changing the combination of 2 NRTIs associated.~The administration will be done once a day orally for 48 weeks.~The usual recommended dose of atazanavir is 300 mg once daily with 100 mg of ritonavir once daily with food. Ritonavir acts by potentiating the pharmacokinetics of atazanavir."
223763723|NCT04984551|OTHER|In-Country Workshops|In-Country Workshops Participate in hands-on training and workshops
223763724|NCT04984551|OTHER|Professional Oncology Educations Programs|Receive 5 core online lectures
223763725|NCT04984551|OTHER|Medical Chart Review|Medical charts are reviewed for data collection
223763726|NCT04984551|OTHER|Questionnaire Administration|Complete questionnaire(s)
223763727|NCT05432336|DIAGNOSTIC_TEST|NGS for endohtalmitis / Multiplex PCR for keratitis|"For endophtalmitis : optimizing culture and NGS will be realized~For keratitis: Multiplex PCR will be added on ocular samples"
224216036|NCT03808220|BEHAVIORAL|postoperative pain intensity|estimate the postoperative pain intensity by using a scaling system via questionnaire
223763728|NCT05874544|DRUG|Vonoprazan|Proton pump inhibitor
223763729|NCT05874544|DRUG|Bismuth Potassium Citrate|Gastric mucosal protective drug with anti-H. pylori effect
223763730|NCT05874544|DRUG|Tetracycline|Antibiotics for H. pylori eradication
223763731|NCT05874544|DRUG|Metronidazole|Antibiotics for H. pylori eradication
223627307|NCT03641417|DRUG|GLWL-01|"Small molecule inhibitor of Ghrelin-O-Acyltransferase (GOAT) to reduce levels of circulating acyl ghrelin.~(Defined as a mechanistic study by MHRA; intervention not for therapeutic purposes in this study.)"
223627308|NCT03641417|OTHER|Placebo|Same as GLWL-01, but no active ingredient
224216037|NCT03808220|BEHAVIORAL|preoperative pain frequency|estimate the preoperative pain intensity by using a scaling system via questionnaire
224216038|NCT03808220|BEHAVIORAL|Side effect|investigate the presence of any side effect
224216039|NCT04146220|DRUG|Prednisolone|Patients of the low and the high dose groups recieved prednisolone in different dose for initial 4 weeks, then tapered gradually. Both groups received pulse I/V methylprednisolone 500 mg/day daily for initial 3 days and monthly cyclophosphamide infusion 750-1000 mg/m2 body surface area.
224216040|NCT06527976|DRUG|Dexmedetomidine|dexmedetomedine added to bupivacaine for adductor canal block
224216041|NCT06527976|DRUG|Dexamethasone|dexamethasone added to bupivacaine for adductor canal block
223627309|NCT03084146|OTHER|12-week elimination diet|individualized 12-week elimination diet based on the 4 most reactive foods +/- a gluten-free diet if there is detection of positive anti- tissue transglutaminase (tTG) IgG and IgA and anti-deamidated gliadin peptide (DGP) IgG and IgA
223763732|NCT05874544|DRUG|Amoxicillin|Antibiotics for H. pylori eradication
223763733|NCT05874544|DRUG|Rifabutin|Antibiotics for H. pylori eradication
224216042|NCT00628394|DRUG|Atomoxetine|40mg 2po qam
224216043|NCT00628394|DRUG|Placebo|40mg 2po qam
224216044|NCT05999981|PROCEDURE|Transversalis Fascia Plane Block|40 ml %0.25 bupivacaine divided into 2 equal doses will be injected by the anesthesiologist under ultrasonography guidance between transversus abdominis muscle and transversalis fascia bilaterally
224216045|NCT05999981|PROCEDURE|Transversus Abdominis Plane Block|40 ml %0.25 bupivacaine divided into 2 equal doses will be injected by the anesthesiologist under ultrasonography guidance in the fascial plane between internal oblique muscle and transversus abdominis muscle bilaterally
224317284|NCT05232188|PROCEDURE|Percutaneous nephrolithotomy|percutaneous nephrolithotomy surgery, 22F amplatz sheath is used in one group, while 28F amplatz sheath is used in the other group.
223763734|NCT06564532|BEHAVIORAL|Evaluatively conditioning participant to like partner|The intervention is a computerized learning task that leads the participant to associate the partner with positive stimuli
223763735|NCT06564532|BEHAVIORAL|Evaluatively conditioning partner to like participant|The intervention is a computerized learning task that leads the partner to associate the participant with positive stimuli
223763736|NCT05431699|DIAGNOSTIC_TEST|ScreenFire HPV test|ScreenFire HPV test (Atila BioSystems, Inc, Mountain View, CA) uses isothermal amplification to detect 13 high risk (hr)HPV types directly from clinical samples in approximately one hour. The test can be run on any real-time PCR machine and gives separate results for hrHPV types 16 and 18, as well as a pooled positive result for 13 other hrHPV types. The human cellular gene beta-globin is used as an internal control to measure sample adequacy. ScreenFire can be self-collected and does not require batching. AmpFire® obtained CE-mark in 2017.
223763737|NCT05431699|DIAGNOSTIC_TEST|careHPV test|The careHPV (QIAGEN, Gaithersburg, MD) test was developed in a public-private partnership specifically for use in low-resource settings. It is a simplified, robust, and affordable HPV test that does not distinguish specific HPV types; rather, it gives a positive result if any of 14 hrHPV types is present in the specimen. Electricity is necessary to run the test, but it does not need running water or air conditioning. In order to be most cost effective, the samples must be run with a full plate of 96 samples. Results take 3-4 hours to complete.
223763738|NCT05431699|PROCEDURE|Colposcopy and biopsy|A colposcopic exam with biopsy entails visual magnification of the cervix and the removal of a small piece of cervical tissue. After the application of acetic acid 5% onto the cervix, a device called a colposcope allows the clinician to visually identify changes consistent with HPV. Areas of the cervix where lesions appear (or if not, randomly selected sections) are then biopsied (small piece of sample removed) and an endocervical curettage is performed (removing a small section from the inside of the cervix). Tissue specimens are then sent to the lab for pathology diagnosis.
223627310|NCT01305720|DEVICE|near infrared spectroscopy: invos 5100|NIRS device used in this study, the optical field includes a volume of tissue approximately 2 cm deep to the surface probe with a 4-mm source-detector distance, and thus, organ-specific monitoring is feasible in small patients. With informed consent, the investigators applied NIRS probes to the forehead and abdomen for cerebral (rSO2C) and abdominal (rSO2P) regional oxygen saturation measurements.
223627311|NCT06456567|BIOLOGICAL|Telitacicept|Subcutaneous injection
223763739|NCT05431699|PROCEDURE|Gas-based cryotherapy|"Cryotherapy is performed to treat high-grade cervical precancer. First, a speculum is introduced into the vagina to identify the cervix. Acetic acid 5% is applied to the cervix for one minute and the cervix is observed to look for changes consistent with precancer. If the cervix is able to be fully evaluated and there are no signs of invasive cancer, a metal probe is inserted into the vagina and the tip is pressed against the cervix. Compressed carbon dioxide or nitrous oxide gas at a temperature of approximately -50ºC/-58ºF freezes the tip and creates an ice ball on the cervix. The ice ball ablates or destroys the abnormal cells."
223763740|NCT05431699|PROCEDURE|Thermal ablation|Thermal ablation is utilized to treat high-grade cervical precancer. First, a speculum is introduced into the vagina to identify the cervix. Acetic acid 5% is applied to the cervix for one minute and the cervix is observed to look for changes consistent with precancer. If the cervix is able to be fully evaluated and there are no signs of invasive cancer, the tip of the device is heated to 100ºC and applied directly to the cervix for 1-2 minutes, which ablates or destroys the abnormal cells.
223763741|NCT06561685|DRUG|LY4050784|Oral
224216046|NCT02323295|RADIATION|Radiation (Surgical Arm)|For surgical candidates, the standard treatment includes pre-operative radiation of 50.4 Gy, followed by a recovery period of approximately 4 to 5 weeks. After this surgery will take place. After approximately 6 weeks of recovery, to allow the surgical incision to heal, the patient is treated with another 19.8 Gy up to 27 Gy of radiation postoperatively depending on the final margin status (higher for gross residual disease)
224216047|NCT02323295|RADIATION|Radiation (Non-surgical Arm)|Non-surgical candidates receive 72 up to 77.14 Gy of radiation depending on the histology (72 Gy for osteosarcoma and chondrosarcoma and 77.4 Gy for chordoma)
223763742|NCT06561685|DRUG|Pembrolizumab|Administered IV.
223763743|NCT06561685|DRUG|Cisplatin|Administered IV.
223763744|NCT06561685|DRUG|Carboplatin|Administered IV.
223763745|NCT06561685|DRUG|Pemetrexed|Administered IV.
224216048|NCT02323295|PROCEDURE|Malignant Tumor Surgery|Surgery involves removing the malignant tumor in the sacrum in one piece, preferably with a cuff of normal tissue around the tumor
224216049|NCT00830063|BIOLOGICAL|tanezumab 10 mg|tanezumab 10 mg one dose at weeks 0 and 8
224216050|NCT00830063|BIOLOGICAL|tanezumab 5 mg|tanezumab 5 mg one dose at weeks 0 and 8
224216051|NCT00830063|DRUG|naproxen|naproxen 1000 mg daily for 16 weeks
224317285|NCT05191537|OTHER|Sustained Natural Apophyseal Glides|The patient sits well supported in a chair. The cervical spine and head are set in a neutral position. A painless passive posterior to anterior (PA) glide is applied in the plane of the facets on either the spinous process or the articular pillar/cervical lamina. While the glide is sustained the patient actively moves their neck in the direction that previously produced the symptoms. If symptom-free, the patient applies over-pressure further into the movement restriction. 3-6 repetitions are performed
224317286|NCT05191537|OTHER|shoulder Mobilization with arm movement|The patient is seated. The therapist contacts the length of the spinous process with the medial aspect of the thumb. A transverse glide is applied by the therapist's index finger against the thumb contacting the spinous process. The direction of the glide is to the contralateral side of the pain. While the mobilisation is sustained the patient moves their arm through a pain-free abduction range. 3-5 sets of 6-10 repetitions may be performed.
223627312|NCT06456567|DRUG|Placebo|Subcutaneous injection
223627313|NCT01102335|PROCEDURE|Transcatheter arterial chemoembolization (TACE)|The procedure is performed under local anaesthesia. The femoral artery at groin region is punctured for arterial access. Angiography is performed for demonstration of vascular structures before embolization.The arteries supplying the tumor are selectively catheterized, this includes the hepatic arteries or other extrahepatic collateral arteries.The chemotherapeutic agent(s) is mixed with lipiodol (an oily contrast) to enhance tumour uptake. Following delivery of the lipiodol/chemotherapy mixture, small gelfoam particles may be injected to reinforce the effect of treatment.
223627314|NCT01102335|DRUG|Telbivudine|anti-HBV drug
223627315|NCT05077826|DEVICE|North Coast Medical Activadose II|tES device model Activadose II (North Coast Medical, Morgan Hill, CA, USA) programed to deliver tES.
223627316|NCT02602366|OTHER|HEC Placebo Gel|
223627317|NCT02602366|OTHER|Placebo Vaginal Insert|
223627318|NCT02602366|OTHER|Placebo Vaginal Film|
223763746|NCT06561685|DRUG|Paclitaxel|Administered IV.
223763747|NCT06561685|DRUG|Nab paclitaxel|Administered IV.
223763748|NCT03748641|DRUG|Niraparib|Participants will receive niraparib 200 mg capsules or tablets once daily.
223763749|NCT03748641|DRUG|Abiraterone Acetate|Participants will receive AA 1000 mg tablets once daily.
223763750|NCT03748641|DRUG|Prednisone|Participants will receive prednisone 10 mg tablets daily.
223763751|NCT03748641|DRUG|Placebo|Participants will receive matching placebo once daily.
223763752|NCT03748641|DRUG|New Formulation of Niraparib and Abiraterone Acetate (AA)|Participants will receive a new formulation of niraparib 200 mg and AA 1000 mg tablets once daily.
223763753|NCT06505031|DRUG|TAK-861|Oral tablet.
223763754|NCT06505031|DRUG|Placebo|TAK-861-matching placebo tablet.
223763755|NCT01351961|BIOLOGICAL|blood sampling|take a sample of blood, 46 ml
223763756|NCT01351961|PROCEDURE|brain MRI and TEP cerebral|magnetic resonance imaging
223763757|NCT01351961|OTHER|Assessment of cognitive functions|Folstein MMSE, Mac Nair scale, Depression (GDS) scale, The Benton Visual Retention Test, Test of verbal fluency, formal and categorical, Trail Making Test, Grober et Buschke scale (RL/RI-16), Apathy Robert scale, Praxis rating Scale .
223763758|NCT01351961|OTHER|Electrocardiogram and blood pressure|Electrocardiogramm Blood pressure monitoring
223763759|NCT01351961|PROCEDURE|Vascular explorations|Pulse wave velocity, VWF, IMT
224216052|NCT00830063|OTHER|placebo|placebo to match tanezumab and naproxen dosing
223627319|NCT02602366|OTHER|Placebo Intravaginal ring (IVR)|
223627320|NCT04445935|DRUG|Bivalirudin Injection|The patients will receive iv Bivalirudin according to the institutional HIT protocol.
223627321|NCT04445935|DRUG|Standard treatment|This group will receive standard anticoagulation with LMWH/UFH
223627322|NCT01273766|DRUG|deferasirox|Given orally
223627323|NCT01273766|OTHER|laboratory biomarker analysis|Correlative studies
223627324|NCT01273766|OTHER|enzyme-linked immunosorbent assay|Correlative studies
223627325|NCT01262417|PROCEDURE|- use of resorbable membrane Seprafilm|use of resorbable membrane during the first surgery for the resection of hepatic metastases, 1 to 4 membranes should be used around the liver
223627326|NCT01262417|PROCEDURE|without resorbable barrier (seprafilm)|non use of resorbable membrane during the first surgery for the resection of hepatic metastases
223627327|NCT00262860|DRUG|bortezomib|
224216053|NCT03011463|DRUG|intravenous infusion of 2 mg trospium chloride|intravenous infusion of 2 mg trospium chloride in 20 ml saline within 60 min and 240 ml tap water p.o
224216054|NCT03011463|DRUG|oral administration of 30 mg trospium chloride|oral administration of 30 mg trospium chloride with 240 ml tap water
224216055|NCT03011463|DRUG|oral administration of 300 mg ranitidine|oral administration of 300 mg ranitidine with 240 ml tap water
224216056|NCT03011463|DRUG|oral administration of 500 mg clarithromycin|oral administration of 500 mg clarithromycin with 240 ml tap water
224216057|NCT00380913|DRUG|Cesamet™ (nabilone)|
224216058|NCT02459613|DRUG|99mTc-Annexin V-128 SPECT|
224216059|NCT04562584|DEVICE|MyHomeDoc|MyHomeDoc device SpO2 measurements and parallel blood gas analysis to determine oxyhemoglobin saturation (SaO2) using an ABL-90 multi-wavelength oximeter.
224216060|NCT00744887|DRUG|Darunavir|
223627328|NCT00262860|DRUG|gemcitabine hydrochloride|
223763760|NCT01351961|BIOLOGICAL|Urine sample|
223763761|NCT01970683|DIETARY_SUPPLEMENT|VSL #3 BID|
224216061|NCT05056337|DRUG|Lenvatinib 4 MG Oral Capsule [Lenvima]|patients will be treated with lenvatinib in combination with toripalimab and TACE (on demand)
224216062|NCT05056337|DRUG|Toripalimab|patients will be treated with lenvatinib in combination with toripalimab and TACE (on demand)
223627329|NCT02363920|DEVICE|HOF|the addition of high oxygen flow to patients breathing spontaneously
223627330|NCT02363920|DEVICE|noninvasive mechanical ventilation (NIV)|the addition of a ventilatory support delivered with a oro-nasal interface
223763762|NCT00951431|DRUG|Esomeprazole|Esomeprazole 20mg daily for 8 weeks
223627331|NCT00368888|DEVICE|Urine collection bag for infants|
223627332|NCT03612817|DRUG|Tafluprost/timolol fixed combination|Evaluation of 24-hour pressure control with tafluprost/timolol given in the evening or morning
223627333|NCT04450238|BEHAVIORAL|Routine care inpatient treatment|All participants are receiving inpatient treatment consisting of a variety of psychological interventions such as cognitive-behavioral therapy, third-wave interventions, psycho-education and in some cases medication.
223627334|NCT04230889|OTHER|Usual Diet Group|three main meals and two snacks
223627335|NCT04230889|OTHER|Group 1 Nutritional Shake|2 servings per day
223627336|NCT04230889|OTHER|Group 2 Nutritional Shake|2 servings per day
223627337|NCT02273479|DRUG|Asasantin®|Asasantin® extended release (RAD-SP)
223627338|NCT02273479|DRUG|Placebo|
223627339|NCT00281463|DEVICE|Pushrim Activated Power Assist|The PAPAW is an electrically-powered add-on unit for common manual wheelchairs. The unit automatically supplements the users manual pushrim input with additional rear-wheel torque for up to six kilometers/hour traveling velocity. The amount of added torque is provided proportional to the user input to the pushrims. Movement and braking assistance is provided for both forward and rearward travel. Several types and sizes are available based on users operating strength, needs and anthropometry. The PAPAWs to be tested during this study will be the JWII (Yamaha Motor Corporation).
223627340|NCT03965130|BIOLOGICAL|Glucagon|PINTA study with glucagon
223627341|NCT03965130|OTHER|Control Study|The same participants will not receive glucagon during the PINTA study
223627342|NCT02632799|DEVICE|NHF small cannula|NHF 8 l/min by Airvo 2 by small cannula
223763763|NCT00951431|DRUG|Placebo|Placebo in the form of study drug
223763764|NCT04397263|DRUG|Guselkumab|Guselkumab will be administered intravenously for the first 3 doses and then subcutaneously for the subsequent doses.
224216063|NCT05056337|PROCEDURE|TACE|Hepatic arterial chemoembolization
224216064|NCT02580578|OTHER|No Intervention|No intervention is administered in this study.
224216065|NCT02619071|PROCEDURE|Tumor sampling|Bone marrow aspirate, blood sampling
224216066|NCT02619071|BIOLOGICAL|Constiutional DNA sampling|Buccal swab or Hair follicles
224216067|NCT00775983|DEVICE|laminaria|place device in cervix for dilation
224216068|NCT00775983|DEVICE|Dilapan-S|Place in cervix for dilation.
224216069|NCT04602351|BEHAVIORAL|Communication|policies on communication and informed consent in ICU
224216070|NCT03253978|RADIATION|Stereotatic Radiotherapy|SABR to prostate / seminal nodes
224216071|NCT05146466|BEHAVIORAL|E-MATVR|It involves using computer software uploaded onto wireless virtual reality (VR) technology (similar to downloading an app on a mobile phone) and will be delivered using a headset, handheld controllers, and voiceover (all wireless). E-MATVR comprises three serious gaming levels aimed at familiarising men with the normal look and feel of the testes, common testicular symptoms and diseases, and the importance of early help-seeking.
224216072|NCT05146466|BEHAVIORAL|E-MATE|It involves using the same information as EMATVR delivered as plain text (e.g., PDF) with still images from E-MATVR. Participants will be given approximately 10 minutes to read the text/look at images using a tablet (e.g., iPad).
224216073|NCT01155063|OTHER|Aromasin (exemestane)|Aromasin (exemestane), tablets 25 mg, once a day
224216074|NCT01314703|DRUG|ChloraPrep One-Step|10.5 ml applicator preoperative skin preparation
224216075|NCT01314703|DRUG|70% isopropyl alcohol|10.5 ml applicator
224216076|NCT03504332|PROCEDURE|intracanal disinfection in revascularization|a procedure to create vital cells in the pulp space of immature teeth which enables thickening of the dentinal walls of the root.
224216077|NCT05547815|BIOLOGICAL|5 doses program|Inoculate 5 doses of rabies vaccine, and collect blood at fixed time points to detect neutralizing antibody
224216078|NCT03797976|DEVICE|MIP and MEP|Pre-op, Post-op of, 1 month after surgery, 3 months after surgery
223763765|NCT02605668|BEHAVIORAL|Intensified psychological intervention|12 sessions of Cognitive Behavioral Therapy a 100 minutes, over the course of 6 weeks (2 sessions per week/week 1 and 2, 3 sessions per week/week 3 und 4, 1 session per week/week 5 and 6)
223627343|NCT02632799|DEVICE|NHF big cannula|NHF 8 l/min by Airvo 2 by large cannula
223627344|NCT02632799|DEVICE|CPAP|Nsal CPAP 5cm H2o by face mask
223627345|NCT04530617|DRUG|Camostat Mesilate|Tablets
223627346|NCT04530617|DRUG|Artemisia Annua Leaf|Tea bags
223627347|NCT02356276|PROCEDURE|D2 lymphadenectomy|
223627348|NCT02356276|PROCEDURE|Hyperthermic Intraperitoneal Chemotherapy|The first HIPEC is conducted within 48 h after surgery: Normal saline 3000 -4000ml, Paclitaxel 75mg/m\^2, 43°C, 60min. The second HIPEC is performed after 24 hours of the first HIPEC. The regimens are Paclitaxel 100 mg/m\^2, 43°C, 60min.
223627349|NCT02356276|DRUG|Systemic chemotherapy (XELOX or SOX regimens)|"XELOX regimen: Oxaliplatin: 130 mg/m\^2, IV, d1; Capecitabine: 1 g/m\^2 bid, days 1-14, every 3 weeks for a total of 6-8 cycles.~SOX regimen: Oxaliplatin: 130 mg/m\^2, IV, d1; S-1, 40 mg/m\^2 bid, po, day 1-14 (S-1: BSA \<1.25m\^2, 40mg bid, 1.25m\^2≤ BSA ≤1.5m\^2, 50mg bid, BSA\>1.5m\^2, 60 mg bid) bid, d1-14, po, every 3 weeks for a total of 6-8 cycles."
223627350|NCT01364896|PROCEDURE|Venous blood samples, anal swab samples, vaginal swab samples, high resolution anoscopy (HRA), anal biopsy samples|"Before and at least 6 months after starting a new non-steroid immunosuppressive agent for IBD treatment, eligible participants who are attending for routine colonoscopy will have:~1. Anal swab samples (and vaginal swab samples for female participants) for human papillomavirus PCR typing (6, 11, 16, 18, 31, 33, 45, 52, 58)~2. High-resolution anoscopy and biopsy of all visible high-grade dysplastic lesions based on validated colposcopic criteria~3. Anal cytology testing"
223763766|NCT02605668|BEHAVIORAL|Standard intervention|12 sessions of Cognitive Behavioral Therapy a 100 minutes, over the course of 10 weeks (2 sessions per week/week 1 and 2, 1 session per week/week 3 to 10)
223763767|NCT03172936|DRUG|MIW815|MIW 815 (ADU-S100) is a STING agonist
223763768|NCT03172936|BIOLOGICAL|PDR001|PDR001 is an anti-PD-1 antibody
223627351|NCT02249663|DRUG|Azelastine hydrochloride and Fluticasone propionate|137/50 mcg Nasal Spray
223627352|NCT02249663|DRUG|Dymista™|137/50 mcg Nasal Spray
223627353|NCT02249663|OTHER|Placebo|Nasal spray with no pharmaceutically active content
223627354|NCT06357481|PROCEDURE|Endodontic Retreatment|A single operator procedured in one visit of non-surgical endodontic retreatment. Teeth were anesthetized using articaine hydrochloride with epinephrine 1:200,000 for mandibulary premolar teeth with one root canal. Each tooth was isolated with a rubber dam and then coronal restorations and caries were removed using sterile high-speed burs under water cooling. After preperation of the cavity access and localization of the canal orifice, all microorganisms that may have entered the root canal system are eliminated by removing the old canal filling with the One Flare and MicroMega REMOVER files in the MicroMega retreatment kit.
223627355|NCT01361230|DEVICE|"Sedation Trial Monitor is the name of the device used."|This is a pilot unblinded randomised controlled trial comparing sedation management using responsiveness (new intervention) with usual care (control group).
223627356|NCT03693703|DIAGNOSTIC_TEST|bi-parametric MRI|Axial T2-weighted and diffusion-weighted imaging with no endorectal coil nor intravenous contrast agent administration
223627357|NCT03693703|DIAGNOSTIC_TEST|multi-parametric MRI|T2-weighted imaging in the three planes, diffusion-weighted and dynamic contrast-enhanced imaging using endorectal coil and intravenous contrast agent administration
224216079|NCT03872960|PROCEDURE|Transfer to cardiac arrest centre|Patients in the intervention arm will be taken directly to a the catheter lab of a heart attack centre.
224216080|NCT06012591|OTHER|Quality improvement recommendations (action plans)|Developed and implemented at facility level to address key quality gaps emerging from the baseline assessment
224216081|NCT04303494|BIOLOGICAL|immunisation|combined diphtheria, tetanus, acellular pertussis, poliomyelitis, hepatitis B, ± Haemophilus influenzae type B and simultaneous pneumococcus (PCV13) vaccination
224216082|NCT01551550|PROCEDURE|GDD|The surgery includes conjunctival incision, placement and securing the GDD plate in one quadrant, paracentesis and tube insertion into the anterior chamber, tube fixation to the episclera.
224216083|NCT01551550|PROCEDURE|Amniotic Membrane Graft|For subjects assigned to the treatment group, Amnioguard is used to cover the shunt tube. The conjunctiva is then closed.
224216084|NCT01551550|PROCEDURE|Pericardial Graft|For subjects assigned to the control group Tutoplast is used to cover the tube. The conjunctiva is then closed.
224216085|NCT00881959|DEVICE|Puros® Dermis versus Alloderm®|Puros Dermis and Alloderm (both Allograft Tissue Matrix)
224216086|NCT02189876|BEHAVIORAL|Standard of Care|All participants will be provided a STD/HIV pre-test counseling session. This session will be provided by either certified project staff or clinical staff at a Los Angeles clinic that conduct State of CA Fam Pact services for patients who are of child bearing age, including our current study partner St. John's Well Child and Family Center and our former study partner, JWCH (John Wesley Community Health) Institute-Wesley Health Center Clinics. Following the counseling session, the participant will be asked to provide a sample of urine to test for Chlamydia and Gonorrhea.
224216087|NCT02189876|BEHAVIORAL|FemAALES|Women will attend 9 small group sessions over 4 weeks. Three of these sessions will focus specifically on participants learning to use a computer, set up an email account, communicate with the team and the group using the Internet, and developing a prevention message for display on project website and social media accounts. The other 6 sessions will include discussions on the following topics: being a Black woman in American, Black history, assessing personal health, changing current behaviors, HIV/AIDS information, and education, self-empowerment, communication skills, reasons to change, and goal setting.
224216088|NCT01363791|OTHER|Dietary fructose|Oral dietary fructose in free (unbound) form in isocaloric exchange for other non-fructose carbohydrate sources (isocaloric trials) or added to a control diet as a source of excess energy (hypercaloric trials).
224216089|NCT04912466|DRUG|Biological: IBI322|Recombinant anti-human CD47/PD-L1 bispecific antibody injection
224216090|NCT04200703|OTHER|Adult and Child Survivor Centered Approach|Child welfare workers and supervisors, and community partners will be trained in the Adult and Child Survivor Centered Approach, and supervisors will receive ongoing coaching and training.
223763769|NCT05775978|BEHAVIORAL|Más Presente, the UGRComp program|Más Presente, the UGRComp program is based upon the European LifeComp framework (Sala, Punie, Garkov and Cabrera Giraldez 2020) and covers intra and interpersonal, emotional, cognitive and metacognitive aspects. Created at the University of Granada by an interdisciplinary group of experts, it focuses on three core elements (self-regulation, empathy and growth mindset) as they are the pre-requisites for developing all other elements across framework areas. It consists of 8 weekly classes, 2 hours each, together with a day of intensive practice. The program is structured along the following topics: The Underpinnings of Más Presente; Awareness and Concentration: our Body; Managing our Emotional Laberynth; Walking with Directionality, Sense and Conscience; Empathy, Presence and Connection; Empathic Listening and Honest Expression: Non-violent communication; Growth Mindset, Creativity and Divergent Thinking; And Now what? The First Day of the Rest of My Life.
223763770|NCT05775978|BEHAVIORAL|The MBSR program|"The MBSR program is a group-based therapy which teaches mindfulness skills through a range of formal and informal mindfulness practices. Created by Kabat-Zinn (1982), in the current study it is taught by an officially accredited instructor and is compliant with the guidelines established by Brown University and the University of Massachusetts, USA. It originally consists of 8 weekly classes, 2 hours each (18 hours direct instruction), together with a day of intensive practice. The program is structured along the following topics: The Underpinnings of MBSR; The Perception of Reality; Power in Being Present; Understanding Stress: The Mind-Body Relation; Responding to Stress; Communication and Personal Relations; Daily Life Management; My Personal Plan: What lies ahead."
223763771|NCT05775978|BEHAVIORAL|Neuro-muscular stimulation|Subjects will receive weekly sessions with a combination of educational sessions and specific physical exercises to enhance physical wellbeing and prevent neuro-degeneration . After spotting the therapeutic targets for each subject, a 4-phase program will be designed for each subject aimed at improving lifestyle habits and general wellbeing.
223763772|NCT01428193|DRUG|Flutamide|Subjects weighing \> 50 kg will receive 250 mg orally twice a day, and subjects weighing \< 50 kg will receive 125 mg orally twice a day.
224317287|NCT06283732|DIETARY_SUPPLEMENT|Greens powder|Participants are to consume one scoop (8.5 g) of the greens powder mixed in 8-10 oz of water every morning before breakfast for two weeks.
224317288|NCT04004585|BEHAVIORAL|Get Up For Your Health|"The intervention is a 4-week behaviour change intervention underpinned by the Theoretical Domains Framework (TDF) that aims to reduce sedentary behaviour. The intervention consists of one individualized face-to-face session and 3 subsequent weekly points of contact (face-to-face meetings or phone calls).~Behaviour change techniques will be provided including education, verbal persuasion, environmental restructuring and goal-setting."
224317289|NCT01307748|OTHER|aroma|Comparison of known stress reducing aroma to placebo aromas without stress-reducing effects
224317290|NCT05589506|DEVICE|Removable partial denture PEEK|A removable partial denture incorporating PEEK and acrylic resin in its composition used as definitive prosthesis to rehabilitate partial edentulism in the maxilla or mandible.
224317291|NCT02180737|DRUG|Dexmeditomedine|
224317292|NCT04800679|DRUG|receive 4 monthly IVB injections and then rescue IVB|IVB group that receive 4 monthly IVB injections and then rescue IVB
224317293|NCT04800679|DRUG|PRP group|PRP group that undergo full PRP in 2 or 3 sessions and then rescue IVB
224317294|NCT04800679|DRUG|IVB injections and a modified laser|Combination group that receive 2 bimonthly IVB injections and a modified laser (1 session anterior to the equator) and then rescue IVB or laser
224317295|NCT05421364|BIOLOGICAL|Intrauterine administration of autologous peripheral blood mononuclear cells (PBMC)|Approximately 9 ml blood from each patient will be collected on the day of the LH peak by peripheral venipuncture using a 21G butterfly catheter affixed via vacutainer to negative pressure receiving tubes (BD vacutainer acid-citrate-dextrose (ACD-A), REF:366645). PBMC will be isolated by density gradient centrifugation in room-temperature centrifuge set to 400 g for 25 min. PBMCs (1x106cells/ml) suspended in RPMI 1640 supplemented with 10% HSA will be incubated in the presence of 10 IU/ml hHCG for 48 h. On day 2 after LH peak, fresh PBMCs (1x107 cells) will be also obtained from the same patients, these fresh PBMCs will be immediately combined with the 2-day cultured PBMC and suspended in PBS (2x107 cells/200µl). This cell suspension will be carefully introduced in the uterine cavity by catheter on day 2 after LH peak.
224317296|NCT07115069|DRUG|GLP-1 receptor agonist|Any FDA-approved GLP-1 receptor agonist
224317297|NCT07115069|PROCEDURE|Gastric Bypass Surgery (laparoscopic)|Patients undergo laparoscopic gastric bypass with a roux limb between 75 - 150 cm and biliopancreatic limb between 50 - 150 cm as determined by the primary surgeon.
224317298|NCT07115069|PROCEDURE|Gastric Bypass Surgery (robotic)|Patients undergo robotic gastric bypass with a roux limb between 75 - 150 cm and biliopancreatic limb between 50 - 150 cm as determined by the primary surgeon.
224317299|NCT06653803|PROCEDURE|Rhomboid Intercostal Block (RIB)|Intraoperative Ipsilateral Ultrasound-guided RIB
223514162|NCT02758028|BEHAVIORAL|Brief counseling|"Peer counselling is delivered based on the queries and the needs of individual clients, according to the smoking status, dependency level and the perceived barriers of each individual with the use of motivational intervention approach.~The subjects will be followed up at 1-week, 1-, 3-, 6-, 9-, 12- and 24-month via telephone assessing their smoking status and reinforce intervention."
223514163|NCT00396370|BIOLOGICAL|BCG strain Connaught|Connaught strain Bacillus Calmette-Guerin (BCG), 8-32 x 10\^5 CFU vaccine for intradermal administration.
223514164|NCT00396370|BIOLOGICAL|BCG strain Danish|Bacillus Calmette-Guerin (BCG) strain Danish from the Statens Serum Institute (SSI BCG). 1.2 X 10\^8 colony-forming units (CFU) oral (PO) in 60 mililiters phosphate buffered saline (PBS).
223763773|NCT01428193|DRUG|Progesterone|oral progesterone suspension (20 mg/ml, 25-100 mg) three times a day at 0700, 1500, and 2300 hr for seven days
223763774|NCT01428193|DRUG|estrace|0.5-1 mg once a day for seven days
224317300|NCT06653803|PROCEDURE|Retrolaminar Block (RLB)|Intraoperative Ipsilateral Ultrasound-guided RLB
224317301|NCT07134166|OTHER|data collection|data collection
224317302|NCT07133802|BIOLOGICAL|Placebo Group|Each human dose: 0.2 mL
224317303|NCT07133802|BIOLOGICAL|Test Group|Each human dose is 0.2 mL
224317304|NCT07134647|BEHAVIORAL|video animation-supported inhaler medication training|"The training is presented not verbally but with the prepared Video Animation Support"
224317305|NCT07133750|DRUG|PM8002|IV infusion
224317306|NCT07133750|DRUG|Chemotherapy Regimen 1|IV infusion
224317307|NCT07133750|DRUG|Chemotherapy Regimen 2|Oral administration and IV infusion
223627358|NCT05471271|OTHER|[18F]AlF-RESCA-IL2 PET scan|Patients will undergo \[18F\]AlF-RESCA-IL2 PET imaging twice; the first \[18F\]AlF-RESCA-IL2 PET scan will be performed at baseline, before starting therapy. The second \[18F\]AlF-RESCA-IL2 PET scan will be performed after 2 weeks of treatment
223627359|NCT01557153|DRUG|Amlodipine|Starting dose will be 5mg/day for four weeks. All participants will be titrated up to the maximum of 10mg/day after 4 weeks. If they do not tolerate this dose, it will be reduced again to 5mg/day and they will continue on their maximum tolerated dose for 12 weeks (for a total of 16 weeks of medication or placebo)
223627360|NCT01557153|DRUG|Placebo|Starting dose will be 5mg/day for four weeks. All participants will be titrated up to the maximum of 10mg/day after 4 weeks. If they do not tolerate this dose, it will be reduced again to 5mg/day and they will continue on their maximum tolerated dose for 12 weeks (for a total of 16 weeks of medication or placebo)
223627361|NCT06131632|PROCEDURE|Breast conserving surgery|Remove only a small part of the breast
223627362|NCT06131632|PROCEDURE|Radical modified mastectomy|Remove all the breast parenchyma, nipple and skin
223763775|NCT03762083|DEVICE|pHyph generation I|A vaginal tablet for the treatment of BV with administration every 48 hours.
223763776|NCT00002524|BIOLOGICAL|Bleomycin Sulfate|
223763777|NCT00002524|BIOLOGICAL|Filgrastim|
223763778|NCT00002524|DRUG|Cisplatin|
224216091|NCT02918838|BEHAVIORAL|Own Adherence Group|Participant chooses their adherence level to be reached at next clinic visit (at least 80%, but can be higher). If they reach that percentage measured using the MEMS cap, they can participate in a lottery for an airtime reward of none, a small amount, and a larger amount. Participants also receive a weekly motivational message reminding them of their incentive to adhere. If they respond to the message they will receive airtime top-up.
224216092|NCT02918838|BEHAVIORAL|Fixed Adherence Group|Participant is told to meet a pre-determined target of 90%. If they reach that percentage measured using the MEMS cap, they can participate in a lottery for an airtime reward of none, a small amount, and a larger amount. Participants also receive a weekly motivational message reminding them of their incentive to adhere. If they respond to the message they will receive airtime top-up.
223627363|NCT00414635|DRUG|Intermitent Dosing|"Intermittent dosing treatment is the maintenance of the 5/2 schedule, where the regimen, 300 mg tenofovir td, 600 mg efavirenz, 200 mg emtricitabine is dosed for 5 consecutive days - typically Monday through Friday - followed by two days off of medication, 300 mg tenofovir td, 600 mg efavirenz, 200 mg emtricitabine. ."
223627364|NCT01977547|BIOLOGICAL|Short storage RBC age|IND obtained to cover the expiration date on the red blood cell unit
223627365|NCT00991861|DRUG|LAS41007 o.d.|Once daily, topical application
223627366|NCT00991861|DRUG|LAS41007 b.i.d.|Twice daily, topical application
223627367|NCT00991861|DRUG|LAS106521|Twice daily, topical application
223627368|NCT05243823|DRUG|Vagifem®|According to local clinical practice - independent of inclusion in this study
223627369|NCT05243823|DRUG|Non-Vagifem® LDVE, Estradiol|According to local clinical practice - independent of inclusion in this study
223627370|NCT01841281|DRUG|L-Arginine|L-arginine tablets containing 1 g of elemental L-arginine (1204 mg of L-arginine HCL) developed by Jarrow Formulas in Los Angeles.
223627371|NCT01841281|DRUG|Placebo|Matching placebo tablets do not contain L-arginine. Placebo tablets were manufactured by Jarrow Formulas and contain cellulose and other excipients.
223627372|NCT05440097|OTHER|QIP intervention|"The QIP includes pulmonologist-targeted guideline education and guideline implementation.~Guideline education includes the initial comprehensive training and reinforcement learning. The initial comprehensive education will be delivered at each participating hospital by a dedicated national asthma expert team, immediately after last patient enrolled at each site. The PI of respiratory departments from participating hospitals are responsible for arranging the delivery of hospital-level reinforcement learnings and ensuring the quality and success of hospital-level guideline implementation.~The pulmonologists' guideline adherence and performance at participating hospitals will be regularly assessed during the study period."
223627373|NCT00631514|DRUG|acetaminophen|acetaminophen 1000 mg t.i.d. per os ibuprofen 400-600 mg t.i.d. per os piroxicam 10-20 mg o.d. per os
223627374|NCT00631514|DRUG|ibuprofen|acetaminophen 1000 mg t.i.d. per os ibuprofen 400-600 mg t.i.d. per os piroxicam 10-20 mg o.d. per os
223763779|NCT00002524|DRUG|Cyclophosphamide|
223763780|NCT00002524|DRUG|Cytarabine|
223763781|NCT00002524|DRUG|Doxorubicin Hydrochloride (DOX)|
223763782|NCT00002524|DRUG|Etoposide|
223763783|NCT00002524|DRUG|Fluorouracil|
223763784|NCT00002524|DRUG|Ifosfamide|
223763785|NCT00002524|DRUG|Leucovorin calcium|
224216093|NCT02918838|BEHAVIORAL|Control Group|
223763786|NCT00002524|DRUG|Methotrexate|
223763787|NCT00002524|DRUG|Methylprednisolone|
223763788|NCT00002524|DRUG|Pentamidine|
223763789|NCT00002524|DRUG|Prednisone|
223763790|NCT00002524|DRUG|Trimethoprim-Sulfamethoxazole|
223763791|NCT00002524|DRUG|Vincristine Sulfate|
223763792|NCT00002524|DRUG|Zidovudine (AZT)|
223763793|NCT00002524|RADIATION|Radiation Therapy|
223763794|NCT00722917|DRUG|TAK-379|TAK-379 25 mg, tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 12 weeks
223763795|NCT00722917|DRUG|TAK-379|TAK-379 100 mg, tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 12 weeks
223763796|NCT00722917|DRUG|TAK-379|TAK-379 200 mg, tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 12 weeks
223763797|NCT00722917|DRUG|Pioglitazone|Pioglitazone 30 mg, tablets, orally, once daily and TAK-379 placebo-matching tablets, orally, once daily for up to 12 weeks
223763798|NCT00722917|DRUG|Placebo|TAK-379 placebo-matching tablets, orally, and pioglitazone placebo-matching tablets, orally, once daily for up to 12 weeks
223763799|NCT03081416|DRUG|Ketamine|Intranasal ketamine administration
223763800|NCT03081416|DRUG|Normal saline|
223763801|NCT03081416|DRUG|Metoclopramide|Standard therapy
223763802|NCT03081416|DRUG|Ketorolac|standard therapy
223763803|NCT03081416|DRUG|Dexamethasone|Standard therapy
223763804|NCT03081416|DRUG|Benadryl|Standard therapy
223763805|NCT02142530|DRUG|Carfilzomib|
223763806|NCT02142530|DRUG|Belinostat|
224216094|NCT04033133|DEVICE|tDCS|Subjects will get tDCS at intensities of 0, 1, 2, 3, and 4 mA.
223763807|NCT06371222|DRUG|Ivabradine|5 mg for 3 months
224216095|NCT01710852|DRUG|ISIS CRP Rx|
224216096|NCT01710852|DRUG|Placebo|
224216097|NCT00861237|DRUG|Nux vomica (active comparator)|Patients receive Nux vomica in a homeopathic potentiation
224216098|NCT00861237|DRUG|Placebo (placebo comparator)|Patients receive Placebo looking similar to active drug
224216099|NCT03230032|DEVICE|pacifier-activated device|The utilization of the pacifier-activated-music player combines the sound of the mother's voice with a pacifier routinely used with each patient during their inpatient NICU stay
224216100|NCT02135874|DRUG|Clofarabine|Given IV
224216101|NCT02135874|DRUG|Cytarabine|Given IV
223763808|NCT06371222|DRUG|Beta blocker|controlled group
223763809|NCT01888289|DRUG|Isotretinoin|Isotretinoin Capsules,40 mg
223763810|NCT00000781|DRUG|Nevirapine|
223763811|NCT00000781|DRUG|Zidovudine|
224216102|NCT02135874|DRUG|Dexamethasone|Given IV
224216103|NCT02135874|DRUG|Idarubicin|Given IV
224216104|NCT02135874|BIOLOGICAL|Rituximab|Given IV
224216105|NCT02135874|DRUG|Sorafenib|Given PO
224216106|NCT02135874|DRUG|Sorafenib Tosylate|Given PO
224216107|NCT02135874|DRUG|Vincristine|Given IV
224216108|NCT02135874|DRUG|Vincristine Sulfate|Given IV
224216109|NCT04259411|DEVICE|MitraClip procedure|MitraClip procedure with MitraClip NTR System or MitraClip XTR System
224216110|NCT02655354|BEHAVIORAL|Motivational Interviewing|
223763812|NCT00000781|DRUG|Zalcitabine|
224216111|NCT02655354|BEHAVIORAL|Cognitive Behavioral Therapy Elements|
224216112|NCT02655354|BEHAVIORAL|Care Management|
223763813|NCT00000781|DRUG|Didanosine|
223763814|NCT00005758|BIOLOGICAL|ALVAC(2)120(B,MN)GNP (vCP1452)|
223763815|NCT00005758|BIOLOGICAL|HIV-1 Immunogen|
223763816|NCT05626049|OTHER|Primary Spine Provider Model|Patients with LBP seeking care at intervention clinics will be offered an appointment with a DC or PT at the initial point of contact.
224216113|NCT02655354|DRUG|Fluoxetine|Anti-depressant
224216114|NCT02655354|DRUG|Fluvoxamine|Anti-depressant
224216115|NCT02655354|DRUG|Paroxetine|Anti-depressant
224216116|NCT02655354|DRUG|Sertraline|Anti-depressant
224216117|NCT02655354|DRUG|Citalopram|Anti-depressant
224216118|NCT02655354|DRUG|Venlafaxine|Anti-depressant
224216119|NCT02655354|DRUG|Duloxetine|Anti-depressant
224216120|NCT02655354|DRUG|Mirtazapine|Anti-depressant
224216121|NCT02655354|DRUG|Diphenhydramine|Sleep medication
224216122|NCT02655354|DRUG|Trazodone|Sleep medication
224216123|NCT02655354|DRUG|Prazosin|Sleep medication
224216124|NCT03287466|DRUG|Oxygen|targeted oxygen therapy
224216125|NCT00106262|DRUG|Velcade (bortezomib)|
224216126|NCT00106262|DRUG|Irinotecan|
224216127|NCT00947063|DRUG|Promethazine HCl 50 mg Tablets (Sandoz, Inc)|
224216128|NCT00947063|DRUG|Phenergan (Promethazine HCl) 50 mg Tablets (Wyeth Laboratories)|
224216129|NCT01987284|DRUG|SER100|
224216130|NCT01987284|DRUG|Placebo|
224216131|NCT05768828|DIAGNOSTIC_TEST|Nociceptive Blink Reflex|Noxious trigeminal electrical stimulation at different interstimulus intervals using 1.5x the pain threshold in order to provoke a release of trigeminal CGRP
224216132|NCT00701428|DRUG|Losartan|Losartan 50 mg daily during 6 + 6 weeks
224216133|NCT00701428|OTHER|CPAP|CPAP during the second 6 week-period
224216134|NCT02786498|DRUG|Vitamin D3|
224216135|NCT02786498|OTHER|Placebo|
224216136|NCT05861609|PROCEDURE|Usual care|Usual care with respect to Spinal Cord Stimulation implantation
224216137|NCT05861609|PROCEDURE|Standardized pain medication tapering|A standardized pain medication tapering program before Spinal Cord Stimulator implantation.
224216138|NCT05861609|PROCEDURE|Personalized pain medication tapering|A personalized pain medication tapering program before Spinal Cord Stimulator implantation.
224216139|NCT05139693|DEVICE|Respiree|The aim of this project is to test the accuracy of pulse oximeters during mild, moderate and severe hypoxia. This is done by comparing the reading of the pulse oximeter during brief, steady state hypoxia with a gold-standard measurement of blood oxyhemoglobin saturation (arterial blood sample processed in a laboratory hemoximeter). The data obtained is submitted by pulse oximeter manufacturers to the FDA for device approval
224216140|NCT01697007|BIOLOGICAL|HIVIS DNA vaccine|
224216141|NCT01697007|DEVICE|Zetajet|
224216142|NCT01697007|DEVICE|Derma Vax Electroporation|
224216143|NCT01697007|BIOLOGICAL|Modified Vaccinia Ankara (MVA-CDMR)|
224216144|NCT01427920|DRUG|biphasic insulin aspart 30|Administered subcutaneously (under the skin) using FlexPen® twice daily for 20 weeks. Directions for use were given to each subject at each dispensing visit. Subjects continued on their pre-trial metformin dose. Any previous basal insulin analogue and OAD (oral anti-diabetes drug) treatments (except for metformin) were discontinued.
224216145|NCT04096391|DEVICE|Flowonix Prometra® II Programmable Infusion System|The Flowonix Prometra® II Programmable Infusion System consists of an implanted infusion pump and catheter, and external components including a clinician programmer, refill and catheter access port kits, the PTC™(a subject operated controller).
224216146|NCT04096391|DRUG|Pain Medicine|Injections, spinal cord stimulation, peripheral nerve stimulation, pain medication, etc.
224216147|NCT02788331|OTHER|No intervention|
224216148|NCT03086720|PROCEDURE|Sodium hypochlorite|Application of 10% sodium hypochlorite (60 seconds) after the etching procedure and before the adhesive system.
224216149|NCT03086720|PROCEDURE|Water|Treatment of acid etched dentin with sterilized water for 60 s before adhesive system application
224216150|NCT01749176|BEHAVIORAL|SMS texting intervention|
224216151|NCT01749176|BEHAVIORAL|Control-Usual Care|
224216152|NCT02783391|DEVICE|ECoG and intracortical electrodes|
224216153|NCT02755480|DEVICE|Ultralow Dose Thoracic Computed Tomography|Ultralow dose chest CT (uLDCTT) at a radiation dose comparable to 2 chest X-rays
224216154|NCT00003557|DRUG|dolastatin 10|
224317308|NCT07134634|DEVICE|tremor device|tremor ball on versus tremor ball off
224317309|NCT07133815|DRUG|SHR-1918|SHR-1918
223627375|NCT00631514|DRUG|piroxicam|acetaminophen 1000 mg t.i.d. per os ibuprofen 400-600 mg t.i.d. per os piroxicam 10-20 mg o.d. per os
223627376|NCT01195766|DRUG|Ofatumumab|Ofatumumab in addition with ESHAP therapy
224216155|NCT04228302|DRUG|EC5026 oral capsule|"5 sequential cohorts of 8 subjects randomly assigned to receive single ascending oral doses of EC5026 (n=6 per cohort) or matching placebo (n=2 per cohort).~Oral doses of EC5026 tested in each cohort: 0.5 mg (Cohort 1), 2 mg (Cohort 2), 8 mg (Cohort 3), 16 mg (Cohort 4), and 24 mg (Cohort 5).~A blinded sentinel group of 2 subjects (1 active and 1 placebo) will be dosed at least 2 days before the remaining 6 subjects (5 active and 1 placebo) will receive blinded doses of active study drug or placebo."
223763817|NCT05626049|OTHER|Usual Care|Patients in this arm will receive usual care (no change to medical care).Usual care is defined as any care designated by a primary care physician (PCP).
224216156|NCT04228302|OTHER|Placebo oral capsule|5 sequential cohorts of 8 subjects randomly assigned to receive single ascending oral doses of EC5026 (n=6 per cohort) or matching placebo (n=2 per cohort)
224216157|NCT01990885|DRUG|BL-7010|
224216158|NCT01990885|DRUG|Placebo|
224216159|NCT05273385|DEVICE|Nanodropper|Device to apply liquid medication to eyes
224216160|NCT05900661|DRUG|myo-inositol|myo-inositol 600µgm + folic acid 0.2 mg) 2 capsules at the morning and 2 capsules at the evening on empty stomach for 12 weeks produced by a Lo.Li pharma international ,Rome.Italy .
224216161|NCT05900661|DRUG|Somatropin|growth hormone 2:Somatropin (4 IU for 1month), SEDICO ,6th of october .Egypt. 1 s.c injection every 3 days for at least 1 month.
224216162|NCT05900661|DRUG|Dehydroepiandrosterone|DHEA 50 mg twice per day for 12 weeks in the last group , NATROL UK.Ltd.
224216163|NCT03070210|PROCEDURE|EUS-celiac ganglia block (EUS-CGB)|The intervention technique of EUS-CGB is the realization of EUS-guided celiac block with injection of bupivacaine directly into the ganglia for patients with chronic pancreatitis.
224216164|NCT03070210|PROCEDURE|EUS-celiac plexus block (EUS-CPB)|In the arm of EUS-CPB, the procedure is going to be performed with the standard EUS-guided celiac plexus block with injection of bupivacaine into the retroperitoneal space.
223763818|NCT05386043|DRUG|FET F-18|PET scan with FET prior to biopsy
223763819|NCT05386043|DRUG|O-15 Radioisotope|PET scan with O-15 Water prior to biopsy
223763820|NCT05386043|PROCEDURE|CT scan|CT scan prior to biopsy
223514165|NCT00396370|BIOLOGICAL|BCG strain Danish|Bacillus Calmette-Guerin (BCG) strain Danish from the Statens Serum Institute (SSI BCG). 2-8 X 10\^5 colony-forming units (CFU) intradermal in 100 microliters diluent.
223763821|NCT05386043|PROCEDURE|MRI with gadolinium-based contrast|MRI prior to biopsy
223514166|NCT00396370|OTHER|Placebo|0.1 mL of sterile Sauton medium for intradermal administration.
223514167|NCT00396370|OTHER|Placebo|60 mL of sterile phosphate buffered saline (PBS) for oral administration.
223514168|NCT03582397|DEVICE|Virtual Reality Mirror Therapy|Virtual reality mirror therapy (WiseMind) developed by Realiteer and delivered via Oculus Rift virtual reality platform.
223514169|NCT03602495|DRUG|Donafenib|Donafenib 0.3g Bid orally, continuously. Dose interruptions or reductions were allowed for subjects who experienced treatment-related toxicity.
223514170|NCT03602495|DRUG|Placebo|Matching placebo Bid orally, continuously.
223514171|NCT00661687|DEVICE|Currently Marketed PureVision Contact Lens.|Contact lens for continuous wear
223514172|NCT00661687|DEVICE|Alternate Design of the PureVision Contact Lens.|Contact lens for continuous wear
223514173|NCT05388968|BIOLOGICAL|Metatranscriptomic|Analysis with metatranscriptomic next generation sequencing of trophoblast obtained by chorionic villi sampling
223514174|NCT05388968|DIAGNOSTIC_TEST|Specific microbiologic diagnosis|If a microorganism is detected by metatranscriptomic NGS, specific diagnosis (PCR and serology) will be done in maternal and neonatal samples (blood, urine, saliva)
223514175|NCT03574389|BIOLOGICAL|13vPnC|suspension in prefilled syringe for intramuscular injection, 0.5 mL, only one dose
223514176|NCT03574389|BIOLOGICAL|Hib|suspension in prefilled syringe for intramuscular injection, 0.5 mL, only one dose
223514177|NCT06316765|PROCEDURE|Intubation with stylet|The cohort of premature infants was intubated with stylet.
223514178|NCT00921544|OTHER|Sucrose|0.2 ml sucrose 24% given by mouth using a syringe and pacifier
223514179|NCT00921544|OTHER|Sterile water|Sterile water administered 2 mins prior to eye exam
223514180|NCT04628052|PROCEDURE|Colonoscopy|Music vs. No-Music
223514181|NCT02013908|PROCEDURE|Acupuncture plus standard ED management|
223514182|NCT02013908|PROCEDURE|Standard ED management alone|
223514183|NCT01177306|DRUG|extended release guanfacine|1-4 mg daily. Dose determined by response of ADHD symptoms to drug and by body mass limitations
223514184|NCT02729012|DRUG|hypertonic saline solution (NACL 3%+NAHCO3)|Treatment with nebulized hypertonic saline solution (NACL 3%+NAHCO3)
223514185|NCT02729012|OTHER|Saline Solution (NACL 0,9%)|Treatment with nebulized Saline Solution (NACL 0,9%)
223514186|NCT00001476|DRUG|Gene Therapy Method for CGD|
223514187|NCT00001476|DEVICE|Isolex 300i Magnetic Cell Selector|
223514188|NCT01548326|DRUG|Atorvastatin|one 40 mg Atorvastatin tablet orally per day for 10 days
223514189|NCT01548326|DRUG|placebo|one Placebo tablet orally per day for 10 days
223514190|NCT01893450|DRUG|Methimazole|
223514191|NCT01893450|DRUG|Bromocriptine|
223514192|NCT01893450|DRUG|Pentoxifylline|
223514193|NCT05052892|DIAGNOSTIC_TEST|Hepatic venous pressure gradient|All patients underwent measurement of HVPG under local anesthesia.
223514194|NCT05084885|OTHER|Online therapy|Standard counseling provided over the internet.
223514195|NCT05167058|DEVICE|Cardiologs Platform|Smartwatch recordings interpreted by Cardiologs AI done simultaneously with each 12-lead ECG
223514196|NCT00636974|PROCEDURE|Combined spinal epidural anaesthesia|
223514197|NCT02094885|BIOLOGICAL|Bioseal Fibrin Sealant|
223514198|NCT02094885|OTHER|Manual Compression|
223514199|NCT03917901|OTHER|Anxiety Sensitivity Training|Computerized Single-Session Anxiety Sensitivity Reduction Program
223514200|NCT03917901|OTHER|Health Control|Computerized Single-Session Health Information Control
224216165|NCT03723291|COMBINATION_PRODUCT|Arm B: A combination of pentoxifylline and tocopherol acetate in addition to best standard care [a structured programme of rehabilitation exercises] for 6 months|• Arm B: A combination of pentoxifylline 800 mg/d in two 400-mg tablets and 1,000 IU/d of tocopherol acetate in two 500-IU aliquots in addition to best standard care \[a structured programme of rehabilitation exercises\] for 6 months
224216166|NCT03723291|PROCEDURE|• Arm A: Best standard of care only [a structured programme of rehabilitation exercises] for 6 months|Prophylactic swallowing exercises consist of strap muscle exercises, airway protection exercises and base of tongue exercises
224216167|NCT06047158|DRUG|Omega-3 fish oil fat emulsion|Use omega-3 fish oil fat emulsion
224216168|NCT06529315|OTHER|Point-of-Care Ultrasound|The investigators will use point-of-care ultrasound to exam participants including lungs, heart, liver, spleen, kidney and bladder, etc.
224216169|NCT05033223|OTHER|PTSD evaluation of emergency room staff 9 and 12 months after the end of second lockdown in France during COvid-19 pandemic|PCL-5 autoquestionnaire to make the PTSD diagnosis
224216170|NCT06552377|DEVICE|Ultrasound Attenuation imaging measurement|Participant to undergo conventional ultrasound scanning with attenuation measurement as well.
223763822|NCT05386043|PROCEDURE|Biopsy Collection|Biopsy collection during standard of care neurosurgery for glioma diagnosis/excision
223763823|NCT05472623|DRUG|Adagrasib|Oral Adagrasib 600 mg twice daily for 6 weeks prior to surgery.
224216171|NCT05940870|DEVICE|Nerivio|Patients with migraine who received the Nerivio device for migraine prevention therapy
223763824|NCT05472623|COMBINATION_PRODUCT|Adagrasib/Nivolumab|Oral Adagrasib 400 mg twice daily for 6 weeks and IV nivolumab 240mg every 2 weeks for 3 doses prior to surgery.
223763825|NCT01351870|RADIATION|Standard Fractionation Regimen|"1.8 Gy daily, 5 fractions per week~Cranio-spinal axis:~23.4 Gy in 13 fractions of 1.8 Gy~Posterior fossa:~30.6 Gy in 17 fractions of 1.8 Gy"
224216172|NCT06312774|OTHER|This is observational study|This is observational study
224216173|NCT03263871|DIETARY_SUPPLEMENT|PTM202|PTM202 given twice daily for 30 days.
224216174|NCT03263871|DIETARY_SUPPLEMENT|micro-nutrient sprinkles|Micro-nutrient sprinkles will be given twice daily for 30 days.
223763826|NCT01351870|RADIATION|Hyperfractionated Radiotherapy|"1 Gy b.d. (minimum interval between fractions 8 hours). 10 fractions per week~Craniospinal axis:~36 Gy in 36 fractions of 1 Gy~Posterior fossa:~24 Gy in 24 fractions of 1 Gy~Tumour Bed:~8 Gy in 8 fractions of 1 Gy"
223763827|NCT06388720|DRUG|Mitomycin-C|Intravesical instillation of Mitomycin-c 40 mg in 20 ml as the first agent in sequential treatment.
223763828|NCT06388720|DRUG|gemcitabine|Intravesical instillation of Gemcitabine 2000 mg in 50 ml following Mitomycin-c administration.
223627377|NCT05296226|PROCEDURE|dry needling and ischemic compression|dry needling is an invasive procedure where a fine Needle or acupuncture needle is inserted into the skin and muscle Ischemic compression is one of the least invasive trigger point therapies. Ischemic compression is a mechanical treatment of myofascial trigger points that consists of application of sustained pressure for a long enough time to inactivate the trigger points.
223627378|NCT01572597|DRUG|10RAC+acetylcystein|10-days rabeprazole 20mg b.i.d + clarithromycin 500mg b.i.d + amoxicillin 1000mg b.i.d + N-acetyl-cystein 600mg b.i.d
223627379|NCT01572597|DRUG|10RAC+metronidazole|10-days rabeprazole 20mg b.i.d + clarithromycin 500mg b.i.d + amoxicillin 1000mg b.i.d + metronidazole 500mg b.i.d
223627380|NCT03282656|BIOLOGICAL|single infusion of autologous bone marrow derived CD34+ HSC cells transduced with the lentiviral vector containing a short-hairpin RNA targeting BCL11a|single infusion of autologous bone marrow derived CD34+ HSC cells transduced with the lentiviral vector containing a short-hairpin RNA targeting BCL11a
223763829|NCT01589757|OTHER|Standard Care|Standard dietary advice for women with GDM with special emphasis on use of high fiber or whole grain carbohydrate foods with a medium to high GI. What's on Your Plate? and 3-dimensional food models will be used to teach servings size and meal planning. This groups will be provided with food substitution lists (key-foods method) composed of medium to high GI foods.
223627381|NCT02891174|DRUG|Ibuprofen|At the time of delivery, eligibility will be reviewed. If the participant remains eligible, she will be randomized by the study pharmacy to begin post-partum analgesic therapy with ibuprofen followed by acetaminophen.
223763830|NCT01589757|OTHER|Low GI diet|"Nutrition education according to standard care similar to the control group with supplementary GI-education. GI-education will be taught using the Stop-Light-Method. This groups will be provided with food substitution lists (key-foods method) composed of low-GI carbohydrate-containing food. The GI-education tool(s) will build on standard care education where patients are taught which food groups contain carbohydrate."
223763831|NCT05971849|DRUG|kisspeptin 112-121|IV infusion of kisspeptin 112-121 x 24 hours; up to two IV boluses of kisspeptin
223763832|NCT05086731|OTHER|Best Practice|Receive standard of care
223763833|NCT05086731|OTHER|Informational Intervention|Receive reminders
224216175|NCT03937973|BEHAVIORAL|Social rejection|Social rejection paradigm
224216176|NCT05187312|PROCEDURE|Endoscopic retrograde Cholangio- pancreatography|Endoscopic intervention in the biliary or pancreatic duct
224216177|NCT05187312|PROCEDURE|Endoscopic ultrasound|Endoscopic investigation/intervention with ultrasound
224216178|NCT05959369|DIAGNOSTIC_TEST|y balance test, core endurance and strength test, foot posture ındex|First, the athlete's bare feet will be photographed on a flat surface for foot posture analysis. Modified push-up test and sit-up test will be used for core stabilization evaluation. For the endurance assessment of core muscles, lateral bridge test, static trunk extension test (Sorensen test) and trunk flexors endurance test will be used. The 'Y' balance test will be used for balance evaluation. The athlete will be asked to lie in three different directions at the same time with the other foot while balancing on one foot.
224216179|NCT02145403|DRUG|Carfilzomib|"Carfilzomib will be administered starting at dose level 1 (20 mg/m2 IV) on day +1, +2, +6 and +7.~Dose escalation will be performed on the day +6 and day +7 doses only in each dose level. Day +1 and day+2 doses will be fixed at 20 mg/m2 IV in all dose levels."
224216180|NCT02145403|DRUG|Tacrolimus|Tacrolimus will be administered at 0.03 mg/kg continuous infusion over 24 hours, starting on day -3 as standard graft-versus-host disease prophylaxis.
224216181|NCT01260428|DEVICE|threshold PEEP|Various set of pressures : 0, 5, 10 cm H20; pursed lips breathing
224216182|NCT03947788|BEHAVIORAL|OKQ Training Program|The OKQ training program helps clinicians more efficiently meet the needs of women's pregnancy intentions and provide evidence-based care.
223763834|NCT05086731|OTHER|Medical Device Usage and Evaluation|Receive a SMRxT smart pill bottle
223627382|NCT02891174|DRUG|Acetaminophen|At the time of delivery, eligibility will be reviewed. If the participant remains eligible, she will be randomized by the study pharmacy to begin post-partum analgesic therapy with acetaminophen followed by ibuprofen.
223763835|NCT05086731|OTHER|Quality-of-Life Assessment|Ancillary studies
223763836|NCT05086731|OTHER|Survey Administration|Ancillary studies
223763837|NCT05475184|DRUG|JPI-547|"Poly-(ADP-ribose) polymerase (PARP) \& tankyrase (TNKS) inhibitor.~* The investigational product (IP) will be administered once daily for 28 days (4 weeks) with 1 cycle.~* 1 capsule (JPI-547 150 mg) will be administered once daily at the same time (e.g., a fixed time in the morning) in a fasted condition within 2 hours before or after a meal."
223763838|NCT05153382|BEHAVIORAL|Dialectical behavioral therapy|DBT will be conducted over 1 year, and divided into two modalities: skills training, conducted in 60 minute biweekly meetings and individual therapy conducted in 60 minute biweekly sessions. Family participation in skills training is highly encouraged. Skills training proceeds as follows: psychoeducation, mindfulness skills, emotion regulation skills, distress tolerance skills, interpersonal skills, and walking the middle path skills. Individual therapy sessions aim to aid the youth in applying skills in their daily lives. We adopt the standard DBT hierarchy of treatment targets, whereby the individual therapist selects behaviors to focus on based on the following priorities: 1) decreasing life-threatening behaviors, 2) decreasing therapy-interfering behaviors, 3) decreasing quality-of-life interfering behaviors, and 4) increasing behavioral skills. Therapists will be available to participants by cell phone for in-vivo skills coaching between sessions.
223763839|NCT04697628|DRUG|tisotumab vedotin|2.0 mg/kg every 3 weeks (Q3W)
223627383|NCT04649541|DRUG|MRX-8|novel semi-synthetic polymyxin B analog.
223627384|NCT04649541|DRUG|Placebo|5% dextrose in water
223627385|NCT04785443|DRUG|ICG|"During thyroidectomy surgery, the patient will received 2 or 3 injections of 5 mg as a bolus. The first one during the dissection of the first lobe, then during the dissection of the second lobe and finally if needed, a 3rd injection will be done at the end of the dissection.~Patients will then be followed during 6 months."
223627386|NCT04785443|PROCEDURE|Control group|"During thyroidectomy surgery, patients are treated according to traditional surgery with detection of parathyroids with the naked eyes.~Patients will then be followed during 6 months."
223627387|NCT02541097|BEHAVIORAL|Language therapy|Participants will receive semantic and phonological therapy for words they cannot retrieve spontaneously. They will be given an opportunity to practice the words in a group setting.
223627388|NCT04124939|DRUG|OnabotulinumtoxinA 100 Units|"BOTOX for injection is an acetylcholine release inhibitor and a neuromuscular blocking agent indicated for:~• Treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and frequency, in adults who have an inadequate response to or are intolerant of an anticholinergic medication."
223627389|NCT03732339|DEVICE|GILUPI CellCollector®|Use of GILUPI CellCollector® to detect CTC
223627390|NCT06211920|OTHER|Non-invasive ventilation|The application of NIV will be performed using af a facemask as soon as possible after the patient has been randomized by opening the opaque envelope. All patients will receive the same standardized ventilator settings at initiation. The IPAP will be set at 12 cm H2O and the PEEP at 5 cm H2O. Oxygen delivery will be adjusted to an arterial oxygen saturation of 88-92%. Further adjustment of ventilator settings and evaluation of treatment effect will be at the discretion of the prehospital physician.
223627391|NCT03512821|DRUG|Ursodiol 500 MG|Ursodiol 500mg tablets followed by Urso Forte 500mg tablets
223627392|NCT03512821|DRUG|Urso Forte 500Mg Tablet|Urso forte 500mg tablets followed by Ursodiol 500mg tablets
223627393|NCT04427319|DIETARY_SUPPLEMENT|β-alanine|7 days of consumption
223627394|NCT04427319|DIETARY_SUPPLEMENT|wheat semolina|7 days of consumption
223627395|NCT05719103|BEHAVIORAL|With and Without Awake Prone Positioning|"1. HFNC flow at 60 L/min or maximum tolerable flow at supine position~2. HFNC flow at 60 L/min or maximum tolerable flow at prone position~3. CPAP with full face mask at 10 cmH2O at supine position~4. CPAP with full face mask at 10 cmH2O at prone position~5. MC at supine position~6. MC at prone position"
223627396|NCT04235140|DRUG|LUM/IVA|LUM/IVA granules for oral administration
223627397|NCT04404426|DIETARY_SUPPLEMENT|L-citrulline|Administration of citrulline enterally for 7 days.
223627398|NCT04404426|OTHER|Placebo|Administration of placebo (water) enterally for 7 days
223627399|NCT06201260|OTHER|intermittent pneumatic compression protocol|A 30 min IPC protocol at about 200mmHg
223627400|NCT06201260|OTHER|Placebo treatment|The electrodes of an electrostimulation device (SP 4.0, Compex, Guildford, United Kingdom) will be positioned on participants' quadriceps. Participants will be informed that they are engaging an innovative microcurrent treatment. This procedure will last for 30 min.
223763840|NCT04697628|DRUG|topotecan|1 or 1.25 mg/m2 intravenous (IV) on Days 1 to 5, every 21 days
223763841|NCT04697628|DRUG|vinorelbine|30 mg/m2 IV on Days 1 and 8, every 21 days
223627401|NCT06107777|PROCEDURE|Pharmacopuncture|Pharmacopuncture is a treatment that combines 2 of the most frequented Korean medicine treatment methods - traditional acupuncture and herbal medicine - by injecting herbal medicine extract at acupoints.
223627402|NCT06107777|PROCEDURE|Korean medical treatment|acupuncture treatment, chuna, pharmacoacupuncture, Korean herbal medicine
223627403|NCT01517932|DRUG|dexmedetomidine|"In this arm,midazolam(0.03-0.05mg/kg), propofol(1.5-2.5mg/kg),sufentanil(0.6-0.82μg/kg )and rocuronium(0.8-1.0mg/kg) were used in anesthesia induction.~Anaesthesia was maintained with propofol（4-6mg kg-1h-1），remifentanil (0.1-0.2 μg kg-1 min-1）and sevoflurane（1%).Propofol was titrated to maintain intraoperative Narcotrend values between 20 and 46.~Patients in this arm received dexmedetomidine 0.2μg/kg i.v. during 10 minutes 1 hour before the end of surgery"
223763842|NCT04697628|DRUG|gemcitabine|1000 mg/m2 IV on Days 1 and 8, every 21 days
223763843|NCT04697628|DRUG|irinotecan|100 or 125 mg/m2 IV weekly for 28 days, every 42 days
223763844|NCT04697628|DRUG|pemetrexed|500 mg/m2 IV on Day 1, every 21 days
223763845|NCT06133426|DEVICE|"Connected scale Body Comp Pro from Withings"|Use once a day from inclusion to week 7.
223763846|NCT04943874|DEVICE|Technology Based Intervention Group 1|In Phase 1, all participants will use the same technology. In Phase 2, participants will be blinded to the two specific groups. They will not be aware of the technology used in the group they are not assigned too.
223627404|NCT01517932|DRUG|saline placebo|"In this arm,midazolam(0.03-0.05mg/kg), propofol(1.5-2.5mg/kg),sufentanil(0.6-0.82μg/kg )and rocuronium(0.8-1.0mg/kg) were used in anesthesia induction.~Anaesthesia was maintained with propofol（4-6mg kg-1h-1），remifentanil (0.1-0.2 μg kg-1 min-1）and sevoflurane（1%).Propofol was titrated to maintain intraoperative Narcotrend values between 20 and 46.~Patients in this arm received saline placebo of the same volume i.v. during 10 minutes 1 hour before the end of surgery"
223627405|NCT00375271|PROCEDURE|perioperative hemodynamic optimization protocol|
223627406|NCT00434681|DRUG|paracetamol 4.8% paediatric oral suspension|
223627407|NCT00945958|DRUG|SPARC0913|One drop of SPARC0913 in affected eye once daily for 24 weeks
223514201|NCT05853939|DEVICE|repetitive transcranial magnetic stimulation|Repetitive TMS targeted by neuronavigation to left lower visual field of primary visual cortex. Randomized to 10 Hz or 1 Hz on different treatment days. Stimulation at 110% of phosphene threshold, or 110% resting motor threshold if phosphenes not detectable. 1 Hz: 1000 pulses total over 1000 seconds. 10 Hz: 1000 pulses over 10 10 second pulse trains, with 50 second intertrain intervals
223514202|NCT03707821|DEVICE|senofilcon A TEST Lens|JJVC Investigational Contact Lens
223514203|NCT03707821|DEVICE|senofilcon A CONTROL Lens|Acuvue Oasys
223514204|NCT00916916|OTHER|Blood draw|A blood draw will occur to take 10cc of blood to measure lanreotide levels.
223627408|NCT06223711|RADIATION|Thoracic Radiochemotherapy|Radiotherapy to the primary tumor including mediastinal lymph node metastases is delivered in single fractions of 1.8Gy once daily up to a cumulative dose of 63.0Gy by intensity modulated radiation therapy (IMRT) or volumetric modulated arc therapy (VMAT).
223627409|NCT06223711|DRUG|durvalumab|Durvalumab is administered in fixed dose 1500mg in q3w cycles concomitant to chemotherapy and q4w cycles during maintenance treatment
223627410|NCT06223711|RADIATION|Stereotactic radiotherapy of further tumor locations|Stereotactic radiotherapy is delivered to the up to four further tumor locations during durvalumab maintenance therapy and will be performed according to local standards with established dose and fractionation schemes in ablative doses depending on the affected organ system.
223627411|NCT06223711|DRUG|Chemotherapy|Concomitant chemotherapy consists of further two cycles platinum/etoposide q3w (summarized cycle 3-4).
223627412|NCT00672555|PROCEDURE|Limberg-flap|Complete excision of the pilonidal sinus and covering of the defect by a Limberg-flap from one buttock
223627413|NCT03531489|DEVICE|AIR-AD|Non-significant risk medical device as decided by institutional review board
223627414|NCT01865266|DRUG|Ulinaststin for injection|
223627415|NCT01865266|DRUG|placebo|
223627416|NCT00866463|DRUG|Sildenafil|Single Dose of 50 mg Sildenafil Oral Tablet With Water
223627417|NCT00866463|DRUG|Sildenafil|Single Dose of 50 mg Sildenafil Experimental Tablet With Water
223627418|NCT00866463|DRUG|Sildenafil|Single Dose of 50 mg Sildenafil Experimental Tablet Without Water
223627419|NCT00003343|DRUG|endocrine-modulating drug therapy|
223627420|NCT00003343|DRUG|mitoxantrone hydrochloride|
223627421|NCT00003343|DRUG|prednisone|
223763847|NCT04943874|DEVICE|Technology Based Intervention Group 2|Participants will be blinded to the two specific groups. They will not be aware of the technology used in the group they are not assigned too.
223763848|NCT06300554|DEVICE|Healthy Minds Program App|freely available well-being app
223763849|NCT02321696|DEVICE|Acupuncture|
223763850|NCT02321696|OTHER|Physiotherapy and eccentric exercise|
224216183|NCT00918632|DRUG|AG-013736|A single dose of a FCIR tablet of AG-013736 will be administered under overnight fasting (Treatment A), high-fat, high-calorie meal (Treatment B), or moderate-fat, standard-calorie meal (Treatment C) in the following order A -\> B -\> C. Each of these treatments will be separated by a 7 day washout period.
224216184|NCT00918632|DRUG|AG-013736|A single dose of a FCIR tablet of AG-013736 will be administered under overnight fasting (Treatment A), high-fat, high-calorie meal (Treatment B), or moderate-fat, standard-calorie meal (Treatment C) in the following order A -\> C -\> B. Each of these treatments will be separated by a 7 day washout period.
224216185|NCT00918632|DRUG|AG-013736|A single dose of an FCIR tablet of AG-013736 will be administered under overnight fasting (Treatment A), high-fat, high-calorie meal (Treatment B), or moderate-fat, standard-calorie meal (Treatment C) in the following order B -\> C -\> A. Each of these treatments will be separated by a 7 day washout period.
224216186|NCT00918632|DRUG|AG-013736|A single dose of a FCIR tablet of AG-013736 will be administered under overnight fasting (Treatment A), high-fat, high-calorie meal (Treatment B), or moderate-fat, standard-calorie meal (Treatment C) in the following order B -\> A -\> C. Each of these treatments will be separated by a 7 day washout period.
224216187|NCT00918632|DRUG|AG-013736|A single dose of a FCIR tablet of AG-013736 will be administered under overnight fasting (Treatment A), high-fat, high-calorie meal (Treatment B), or moderate-fat, standard-calorie meal (Treatment C) in the following order C -\> A -\> B. Each of these treatments will be separated by a 7 day washout period.
223514205|NCT05507047|DRUG|Enamel Matrix Protein|Enamel matrix derivated is used with transcrestal sinus lifting treatment
223627422|NCT00003343|DRUG|prinomastat|
223627423|NCT03600272|PROCEDURE|Combined spinal-epidural analgesia|Combined spinal-epidural analgesia during labor is a labor analgesia technique which reported maybe associate with a shorter labor duration compared to the traditional epidural labor analgesia.
223627424|NCT03600272|PROCEDURE|Epidural analgesia|Epidural analgesia is a well-accepted technique using for pain relief during labor.
223627425|NCT04864756|OTHER|Simulation based learning|Learning for medical students using simulation based techniques including scenario execution as a complement to conventional teaching methodologies
223763851|NCT02321696|OTHER|Watchful waiting and eccentric exercise|
223763852|NCT02321696|OTHER|eccentric exercise|
223763853|NCT00041431|DRUG|Hormone Replacement Therapy|
223763854|NCT03929965|DRUG|Anlotinib|Anlotinib
223763855|NCT03789201|DEVICE|TMS EEG|attempt to use TMS EEG to measure connectivity between cortical areas
223763856|NCT03789201|DEVICE|TMS fMRI|compare measurements to established functional connectivity measures; e.g., EEG coherence and fMRI
223763857|NCT01438320|DIETARY_SUPPLEMENT|Quercetin|Bioflavonoid
223627426|NCT01836588|PROCEDURE|conventional cervix biopsy|"Object of this study is the evaluation of two different methods of gaining cervical tissue in order to determine whether, and if so in what extent, a CIN is existent. The first method is a cervical biopsy, the second method is a gentle tissue saving curettage of the cervix uteri. Also is to be investigated that the latter method shows a reduction of pain and morbidity after the procedure.~For this reason the pathological outcome of the two methods will be compared to the result of a conisation, which will be received by the patient to cure their cervical lesions."
223627427|NCT02102035|PROCEDURE|Direct and reversed dorsal digital island flap|The direct dorsal digital island flap is used to cover the defects of adjacent fingers. The reversed dorsal digital island flap is used to cover the defects of the same fingers.
223627428|NCT01192997|BIOLOGICAL|Menveo|Single dose Menveo (a MenACWY vaccine conjugated to CRM-197).
223627429|NCT01192997|BIOLOGICAL|MenACWY-TT|Single dose MenACWY-TT (MenACWY vaccine conjugated to Tetanus Toxoid, TT)
223627430|NCT02152891|BEHAVIORAL|CHAP-EMS/CP@clinic|Community Paramedicine program to assess cardiovascular, diabetes, and fall risk; discuss lifestyle changes and goals; and refer to appropriate resources.
223627431|NCT05260671|DRUG|Penpulimab combined with cetuximab|PD-1 antibody combined with EGFR inhibitors, biweekly
223627432|NCT04052490|OTHER|Abutment with flat occlusal reduction with feather edge finish|Non vital teeth require a full coverage restoration to withstand the functional stresses and prevent any further destruction of tooth/crown complex. The zirconia all-ceramic crowns yield a high flexure strength and are used as an esthetic alternative to ceramo-metallic crowns. Several studies linked the effect of preparation designs to the survival of the restoration. Others, studied the effect of the finish line geometries as deep chamfer and shoulder on the marginal integrity of restorations. The feather edge finish line is used with zirconia crowns with limited data regarding its success. However, there is no presented research dealing with the effect of finishing line designs in combination with different occlusal reduction schemes on the marginal fit of full contour zirconia crowns.
223627433|NCT05045768|DRUG|(Gelsectan, Devintec Sagl)|Patients included in the study will receive for 28 days a capsule containing Xyloglucan, Pea Protein and Grape Seed Extract and a prebiotic Xylo-oligosaccharide (Gelsectan, Devintec sagl) twice daily.
223627434|NCT04101071|OTHER|Modular ketogenic feed|Dietician prescribed, and consisting of Betaquik® (from Vitaflo, Nutritional company) to provide medium chain triglycerides), Renapro Shot® (protein), Maxijul® (carbohydrate) and multivitamins according to nutritional need (energy and protein requirements) based on clinical status of the participant. Ketogenic feed to be given continuously via nasogastric tube for 10 days
223627435|NCT04101071|OTHER|Standard feed|Standard Enteral feed. Dietician prescribed based on clinical status of the participant, as per individual Trust protocols. Standard feed to be given continuously via nasogastric tube for 10 days
224216188|NCT00918632|DRUG|AG-013736|A single dose of a FCIR tablet of AG-013736 will be administered under overnight fasting (Treatment A), high-fat, high-calorie meal (Treatment B), or moderate-fat, standard-calorie meal (Treatment C) in the following order C -\> B -\> A. Each of these treatments will be separated by a 7 day washout period.
223627436|NCT03246971|DRUG|Wafermine™ 50 mg|Administered as needed for 12 hours
223627437|NCT03246971|DRUG|Wafermine™ 75 mg|Administered as needed for 12 hours
223627438|NCT03246971|DRUG|Placebos|Administered as needed for 12 hours
223627439|NCT03246971|DRUG|Wafermine™ 25 mg|Administered as needed for 12 hours
223627440|NCT01913561|DEVICE|Master Caution Garment|"Master Caution Garment is embedded with 10/13 textile dry electrodes that enable 12/15-lead ECG.~The electrodes are dry, textile ECG electrodes."
223627441|NCT01913561|DEVICE|ECG gel electrodes|Standard gel electrodes that are been in use in hospital for ECG monitoring.
224216189|NCT06272851|DEVICE|optical coherence tomography|measuring choroidal thickness using optical coherence tomography
223763858|NCT02703636|DRUG|Rivastigmine Patch|Alzheimer's disease patient who is applicable to 1 step titration method (initial loading dose is a rivastigmine patch 9.0 mg/day and will be up-titrated after 4 weeks to reach the maintenance dose of 18 mg/day). Rivastigmine patch is a marketed drug, therefore the dose, dose regimen and titration scheme are in accordance with product label.
223763859|NCT01505127|DRUG|TAK-438|
224216190|NCT03716102|DEVICE|PCI with implantation with DES|PCI with implantation with DES
223627442|NCT01941511|DRUG|Rivipansel|Subjects will receive in a randomized sequence rivipansel 4gA IV, moxifloxacin 400 mg, and placebo IV.
223627443|NCT00308802|PROCEDURE|Kidney transplantation|Participants in this study will have had a kidney transplant
223627444|NCT01046981|PROCEDURE|Tumescent Antibiotic Delivery of cefazolin with or without metronidazole|TAD of cefazolin with or without metronidazole followed by sequential serum and interstitial fluid samples over 14 to 24 hours for antibiotic concentrations
223627445|NCT01046981|PROCEDURE|Intravenous Antibiotic Delivery|Intravenous antibiotic delivery of cefazolin with or without metronidazole followed by sequential serum sampling for antibiotic concentration of subsequent 12 to 24 hours.
223627446|NCT06169202|DEVICE|fruquintinib|4 mg orally once daily, D1-14, repeated every 3 weeks.
223627447|NCT06169202|DRUG|Irinotecan|180 mg/m2, IV, day 1, repeated every 3 weeks. (Note: If patient has UGT1A1\*28 and \*6 as pure or double heterozygous variants, irinotecan dose 150 mg/m2, IV, day 1, repeated every 3 weeks, with close clinical observation).
223627448|NCT06169202|DRUG|Capecitabine|1000 mg/m2 orally twice daily, D1-14, repeated every 3 weeks.
223627449|NCT01383746|DEVICE|Yttrium microsphere injection|Radiation therapy
223627450|NCT04356495|DIETARY_SUPPLEMENT|Vitamins|2 tablets daily from the first day (day 0) to day 9
223627451|NCT04356495|DRUG|Telmisartan|1 tablet daily from the first day (day 0) to day 9
223627452|NCT04356495|DRUG|Ciclesonide|2 puffs twice a day in an inhalation chamber from the first day (day 0) to day 9
223627453|NCT04356495|DRUG|interferon β-1b|A 10-minute nebulization, once a day, from the first day (day 0) to day 4, of 9.6 MIU / 300 µg of IFN-β-1b (EXTAVIA®) diluted in 2 mL of water
223627454|NCT00419393|DRUG|Keppra XR (Levetiracetam XR)|500 mg tablets, 1000 - 3000 mg/day, flexible dosing for duration of the study (planned: approximately 6 months-3 years).
223627455|NCT00350025|DRUG|Cetuximab|Cetuximab 250mg/m2 IV weekly for each 28 day cycle.
223627456|NCT00350025|DRUG|Paclitaxel|Paclitaxel 80mg/m2 IV weekly for each 28 day cycle.
223627457|NCT03021057|DRUG|pembrolizumab|200mg i.v. once every 3 weeks Number of Cycles: until progression or unacceptable toxicity develops
223627458|NCT04516746|BIOLOGICAL|AZD1222|AZD1222 is a recombinant replication-defective chimpanzee adenovirus expressing the SARS-CoV-2-5 surface glycoprotein.
224216191|NCT05890326|BEHAVIORAL|Pain neuroscience education (PNE)|Pain neuroscience education (PNE) is a health education intervention that aims to provide up-to-date information on neuroscience developments in the field of chronic pain. All patients were trained once a week for 12 weeks, in groups of 3-4 people, for a maximum of 6 sessions and a minimum of 60 minutes. During the intervention, psychological factors such as self-efficacy, pain intervention/injury, coping with pain, catastrophic thoughts, emotional response to pain, anxiety, frustration/anger, fear of harm, concerns about pain, and fear of pain were examined. and discussed with patients. The sessions aimed to provide patients with a better understanding of their chronic pain by addressing the multifactorial aspects of chronic pain, sensitization and the plasticity of the brain, thus involving patients in treatment.
224216192|NCT05890326|BEHAVIORAL|Motor imagery-based exercise protocol (MIEP)|"All patients performed sessions of maximum 60 minutes in groups of 3-4 people twice a week for 12 weeks. This study protocol was developed in accordance with the Consolidated Standards of Reporting Trials (CONSORT) guidelines. The key standard was to practice simple and safe exercises that would encourage the patient to repeat the program at home. The exercises proposed in MIEP were selected according to the following principles: slowness, painlessness, arousing attention, easy to imagine. The main purpose of the motor imagery exercises was to bring the patient back to the state of feeling and self-perception of the execution of the movement. More important than the quantity of repetition was the painless quality of movement. It was performed in 3 phases: relaxation (3 minutes), MI (8.5 minutes per image) and refocus (3 minutes), which included both kinesthetic imagery (KI) and visual imagery (VI)."
224216193|NCT05890326|BEHAVIORAL|Combination Group|Subjects received 6 sessions of Pain neuroscience education (PNE) and 12 weeks (2 times a week) of Motor imagery-based exercise protocol (MIEP).
224216194|NCT05371418|PROCEDURE|surgical (guided tissue regeneration)|In group 1 (G1), ten teeth over erupted with angular bone loss were treated by guided tissue regeneration (GTR) followed by Orthodontic intrusion
224216195|NCT05371418|DEVICE|orthodontic intrusion followed by guided tissue regeneration GTR|. In group 2 (G2), ten teeth over erupted with angular bone loss were treated by Orthodontic intrusion (OI) followed by guided tissue regeneration (GTR)
224216196|NCT00183469|DRUG|Lamotrigine|If the participant is naive to LAM, LAM will be started at 25 mg every day for the first 2 weeks, then 50 mg per day for the next 2 weeks. The dose of LAM can be increased to 100 mg at week 5 and increased to maximum of 200 mg at week 6 based on symptoms, tolerability, and ratings of the rating scales. If the participant is already taking LAM, the dose will be increased to up to 200 mg using the same guide lines. Upon randomization the participant in the placebo comparator will have their dosage titrated to doubled since the potentiating effect of the Divalproex will no longer exist. It will remain at this dosage until the end of the study with the possibility of one adjustment for side effects.
224216197|NCT00183469|DRUG|Divalproex (DIV) ER|If the participant is naive to DIV and if LAM was initiated before the start of treatment with DIV, DIV can be started at any point of time in the study provided the participant has been on LAM for at least 2 weeks. DIV will be started at 500 mg and titrated by increments of 500 mg every 3 to 4 days until a therapeutic blood level is attained up to 2500 mg.
224216198|NCT00183469|DRUG|Placebo|During the randomized phase participants randomized to placebo comparator group will discontinue DIV and will start taking the placebo in the same fashion.
224216199|NCT03433326|DRUG|Elbasvir/Grazoprevir|Administration of MK-8742 (Elbasvir)/MK-5172 (Grazoprevir) for 12 weeks
224216200|NCT01462474|DRUG|Famitinib|Either at 12.5 mg, 16.5 mg、20 mg or 25 mg qd p.o., 2 weeks before concurrent chemoradiotherapy and D1-D49, exception D1, D22, and D43.
224216201|NCT01462474|DRUG|Cisplatin|100 mg/m2, D1, D22, and D43(q3w)
224216202|NCT01462474|RADIATION|radiation（IMRT）|IMRT (Intensity-Modulated Radiation Therapy). Radiation is delivered to GTV at 70 Gy in 32-33 fractions, CTV1 at 60 Gy in 32-33 fractions and CTV2 at 54 Gy in 32-33 fractions
223627459|NCT04516746|BIOLOGICAL|Placebo|Commercially available 0.9% (n/V) saline for injection.
223627460|NCT05809921|DRUG|alteplase|Intravenous thrombolysis with alteplase (0.9 mg/kg, maximum 90 mg) with 10% of the dose given as a bolus followed by an infusion lasting 60 minutes.
223627461|NCT05809921|DRUG|Alteplase + possible complementary IVT with tenecteplase|Intravenous thrombolysis with alteplase (0.9 mg/kg, maximum 90 mg, with 10% of the dose given as a bolus followed by an infusion lasting 60 minutes) and depending on the MRI-2 results, an additional IVT with tenecteplase (0.25mg/kg, maximum 25 mg, with 100% of the dose given as a bolus) could be given in case of persistent occlusion and with no contraindication according to the study protocol.
223627462|NCT02629029|PROCEDURE|Pre-op CTA with IV contrast|Preoperative mapping of perforators by computed tomography angiography (CTA) could prove valuable in head and neck free flap transfer and shorten the operation time significantly. This modality could provide useful information for H\&N cancer reconstruction in difficult cases, especially in patients with large or through-and-through defects that might need multiple perforators in flap design. In addition, near-infrared (NIR) fluorescence imaging using indocyanine green (ICG) angiography can provide robust, intraoperative, objective data to optimize the free flap skin paddle design while potentially minimizing patient morbidity.
224216203|NCT02528318|COMBINATION_PRODUCT|Lucinactant for inhalation|Lucinactant for inhalation refers to the active investigational agent, lucinactant, in combination with the investigational delivery device (drug-device combination product)
224216204|NCT02528318|DEVICE|nCPAP alone|nCPAP therapy
224216205|NCT00965913|DRUG|Nicotine Patch|15 mg nicotine patch applied on the lower back, according to treatment sequence, daily for 21 days
224216206|NCT00965913|DRUG|Nicotine Patch Comparator|15 mg nicotine patch applied on the lower back, according to treatment sequence, daily for 21 days
224216207|NCT00965913|DRUG|Placebo Patch|Placebo patch applied on the lower back, according to treatment sequence, daily for 21 days
224216208|NCT04540120|DRUG|dapansutrile capsules|Hard opaque capsules containing 250 mg of API.
224216209|NCT04540120|DRUG|placebo capsules|Hard opaque capsules containing 0 mg of API.
224216210|NCT02577042|DRUG|Raltegravir|Switching the PI by raltegravir 400mg every 12 hours, plus Kivexa or Truvada, for 24 weeks.
223627463|NCT02629029|DEVICE|Computed tomography angiography (CTA)|
223627464|NCT00206635|DRUG|Interferon beta-1b (Betaseron, BAY86-5046)|Betaseron was not administered as part of this study, only the treatment and disease status was assessed. As part of the MRI analysis Gadolinium was administered in patients who underwent this procedure
223627465|NCT01640002|DRUG|Propantheline Bromide|15MG OF PROPANTHELINE BROMIDE, THREE TIMES DAILY FOR 02 MONTHS.
223627466|NCT01640002|DRUG|Placebo|PLACEBO CAPSULE, 03 TIMES DAILY FOR 02 MONTHS
223627467|NCT00778934|OTHER|Intimate Health Gel|Intimate Health Gel
223627468|NCT00315926|DRUG|Melatonin|Melatonin 50 mg during surgery and 10 mg every night for 3 nights
223627469|NCT00315926|DRUG|Placebo|a mixture of ethanol and physiological saline
223627470|NCT01751061|BEHAVIORAL|Decision aid|A web-based decision aid to assist surrogate decision makers in prolonged mechanical ventilation decisions
223627471|NCT01751061|OTHER|Usual care|usual ICU care
223627472|NCT02446977|DRUG|Vitamin B2 Streuli®|4ml IV
224216211|NCT02577042|DRUG|PI-based regimen|Continue with the same PI-based regimen, plus Kivexa or Truvada, for 24 weeks.
224216212|NCT02577042|DRUG|Atorvastatin|Atorvastatin, 20mg/day, will be added after 24 weeks of study for 48 weeks
224216213|NCT05373433|DRUG|SSD8432 750mg|Experimental group:SSD8432 750mg and Ritonavir 100mg, Day1--Day5,BID
224216214|NCT05373433|DRUG|SSD8432 placebo|Control group :SSD8432 placebo and Ritonavir placebo, Day1--Day5,BID
224216215|NCT00751998|DEVICE|SpyGlass|The SpyGlass Direct Visualization System is an integrated product platform that is designed to provide a direct intraluminal view of the biliary duct system and direct therapeutic devices.
224216216|NCT02713503|OTHER|Driving Observation|Driving observation using the DriveSafety CDS-250 Driving Simulator.
223514206|NCT05369156|OTHER|Chiropractic Care|The actual force applied to the patient's spine depends on the chiropractor, the patient, and the spinal location of the subluxation, the general shape of the force-time history of spinal adjustments is very consistent and the duration of the thrust is always less than 200 milliseconds.
223514207|NCT05369156|OTHER|Control Group|The participants head and/or spine will be moved in ways that include passive and active movements, similar to what is done when assessing the spine by a chiropractor. The sham intervention will also include the participants moving into adjustment setup positions similar to how the chiropractor would typically set up a patient with no joint pre-loading or adjustive thrust
223627473|NCT02446977|OTHER|Solution for injection|4ml IV
223627474|NCT01048008|DRUG|DM-CHOC-PEN|"DM-CHOC-PEN will be dosed @ 39 mg/M2, escalated in 1-patient cohorts at 40% dosage.~At the 1st DLT - expand to 3-6 patient cohorts/dose with escalations at 33% increments.~The MTD will be where 2 DLTs are noted and the study is discontinued."
223627475|NCT02590796|OTHER|No intervention given to participants|This is an observational study. Participants will receive no intervention.
223627476|NCT00733785|DRUG|Rosiglitazone XR|Rosiglitazone extended release formulation
223627477|NCT06186323|BEHAVIORAL|Affordances in the Home Environment for Motor Development-Infant Scale|Affordances in the Home Environment for Motor Development-Infant Scale is a parent-filled assessment to determine the nature and amount of factors affecting infant motor skill development in the home environment, including the availability of toys, materials, and the availability of spaces.
223627478|NCT06186323|BEHAVIORAL|Peabody Developmental Motor Scales-2|"Peabody Developmental Motor Scales \| Second Edition (PDMS-2) combines in-depth assessment with training or remediation of gross and fine motor skills of children from birth through 5 years. Used to evaluate children's motor development with separate tests and rating scales for both gross motor skills and fine motor skills"
223627479|NCT06186323|BEHAVIORAL|Test Of Sensory Functions In Infants (TSFI)|his test helps you identify infants with sensory integrative dysfunction-including those at risk for developing learning disabilities as they grow older. The TSFI provides objective criteria that allow you to determine whether, and to what extent, an infant has deficits in sensory functioning. Designed for use with children from 4 months to 18 months old, the TSFI provides an overall measure of sensory processing and reactivity, as well as scores on the following subdomains: Reactivity to Tactile Deep Pressure Visual Tactile Integration Adaptive Motor Function Ocular Motor Control Reactivity to Vestibular Stimulation
223627480|NCT02490735|BIOLOGICAL|Cytokine-induced Killer Cells|chemotherapy plus 3 cycles of Cytokine-induced Killer Cells(CIK) treatment
223627481|NCT00875186|OTHER|aerobic endurance training|participants exercises 2 times weekly for 1 hour (aerobic endurance training)
223627482|NCT00875186|OTHER|aerobic endurance training|participants exercised 1 time weekly for 1 hour (aerobic endurance training)
223627483|NCT02455921|DRUG|neostigmine - atropine|Efficacy, safety and effect on cognitive and behavioural function
223627484|NCT02455921|DRUG|Sugammadex|Efficacy, safety and effect on cognitive and behavioural function
223627485|NCT00503750|DRUG|Pre operativeTrastuzumab|"Trastuzumab one-time loading dose of 4 mg/kg as 90 minute infusion, followed by 20 weekly treatments at 2 mg/kg as 30 minute infusion.~As per standard treatment of HER2-positive breast cancers, patients will continue to receive trastuzumab every 3 weeks at 6 mg/kg beginning week 21 through week 52."
223627486|NCT00503750|DRUG|ABI-007 (Abraxane)|ABI-007 will be administered every 2 weeks at a dose of 260mg/m2 as 30 minute infusion on the same days as trastuzumab for a total of 4 cycles (weeks 1 -8).
223627487|NCT00503750|DRUG|Vinorelbine|Beginning week 9, patients will then receive weekly vinorelbine at a dose of 25mg/m2 for 12 weeks on the same day as trastuzumab for a total of 4 cycles (weeks 9-20).
223763860|NCT01505127|DRUG|Lansoprazole|
223763861|NCT01505127|DRUG|Amoxicillin|
223763862|NCT01505127|DRUG|Clarithromycin|
224216217|NCT02713503|OTHER|VisionCoach|Visual field evaluation using VisionCoach
224216218|NCT01538316|DIETARY_SUPPLEMENT|Quercetin supplement|500 mg/d quercetin (+ vitamin C + folic acid + vitamin B3) over a period of six months; crossover design (6 month-periods): followed by genistein and placebo supplement.
223763863|NCT00393939|DRUG|Sunitinib malate|Sunitinib 37.5 mg daily by oral capsule in schedule 2/1 with Docetaxel 75 mg/m2 every 3 weeks or 37. 5 mg daily in continuous dosing (in absence of docetaxel)
223763864|NCT00393939|DRUG|Taxotere|Docetaxel 100 mg/m2 every 3 weeks in the comparator arm
224216219|NCT01538316|DIETARY_SUPPLEMENT|Genistein supplement|100 mg/d genistein (+ vitamin C + folic acid + vitamin B3) over a period of six months; crossover design (6 month-periods): followed by placebo and quercetin supplement.
223763865|NCT04932590|OTHER|End-expiratory occlusion test|The test consists in interrupting the ventilator at end-expiration for 15 seconds and assessing the resulting changes in cardiac output. Delays necessary to allow sufficient pulmonary transit time to allow good pulmonary venous return and therefore an increase in cardiac preload.
223763866|NCT01105507|DRUG|canakinumab (company code: ACZ885D)|
223763867|NCT04628962|PROCEDURE|Collection and Raman analysis of saliva for the database|Saliva will be collected and processed for the Raman analysis. The collected data will be computed for the creation of the classification model
223763868|NCT03778931|DRUG|Elacestrant|400 mg/day once daily oral dosing
223763869|NCT03778931|DRUG|Standard of Care|"* Fulvestrant: 500 mg administered intramuscularly (IM) into the buttocks as two 5 mL injections on C1D1, C1D15 and C2D1 and Day 1 of every subsequent 28-day cycle~* Anastrozole 1 mg/day on a continuous dosing schedule~* Letrozole: 2.5 mg/day on a continuous dosing schedule~* Exemestane: 25 mg/day on a continuous dosing schedule"
223763870|NCT02961426|DRUG|sofosbuvir + ravidasvir|combination of sofosbuvir + ravidasvir
223763871|NCT03917134|DRUG|cephalosporin + Metronidazole Vaginal|administration of cephalosporin in doses of 2 grams administered intravenously before surgery and metronidazole vaginal ovules 500mg twice a day for 5 days after performing laparoscopic hysterectomy
223763872|NCT03917134|DRUG|cephalosporin + Placebos|administration of cephalosporin in doses of 2 grams administered intravenously before surgery and vaginal ovules of placebo twice a day for 5 days after performing laparoscopic hysterectomy
223763873|NCT00270972|DEVICE|Bilayered Cellular Matrix (OrCel)|
223763874|NCT00006184|DRUG|Myeloma Immunoglobulin Idiotype Vaccine|3 subcutaneous (SC) injections of myeloma protein within 10 weeks before stem cell collection the first (week 0), second (week 2), and third injection (week 6) with Id-KLH (0.5 mg SC day 1)
223763875|NCT00006184|DRUG|Bortezomib|Induction chemotherapy: 1.3 mg/m\^2 bolus intravenous injection twice weekly for 2 weeks (days 1, 4, 8, 11) followed by 10 day rest period (day 12-21)
223763876|NCT00006184|DRUG|Cyclophosphamide|Induction chemotherapy: 600 mg/m\^2 day 4 Transplant: 1200 mg/m\^2 intravenous x 4 days (days -6, -5, -4, -3)
223763877|NCT00006184|DRUG|Cyclosporine|Transplant: 2 mg/kg intravenous every 12 hours continuous intravenous or by mouth (PO) until day + 180
224216220|NCT01538316|DIETARY_SUPPLEMENT|Placebo|vitamin C + folic acid + vitamin B3 over a period of six months; crossover design (6 month-periods): followed by quercetin and genistein supplement.
224216221|NCT05566379|OTHER|Mindfulness - Mindful Awareness Practices ( MAPs)|All participants will attend a virtual 6-week course entitled Mindful Awareness Practices (MAPs) created, hosted and led by expert facilitators from the Mindful Awareness Research Center at UCLA. Participants will learn Mindful concepts and a variety of Mindfulness practices. This intervention will consist of a mix of lecture, practice, group feedback, and discussion regarding mindfulness. Mindfulness is the mental state achieved by focusing one's awareness on the present while acknowledging and accepting any feelings, thoughts, or bodily sensations. MAPs classes meets weekly for two hours per week for six weeks. Participants are encouraged to complete some daily meditation practice starting at five minutes a day and working up to 20 minutes daily by the end of the course.
223514208|NCT01450267|DRUG|Inhaled Reduced Glutathione|10 mg/kg, twice daily, 12 months
223514209|NCT01450267|DRUG|Physiological solution|0,13 ml/kg body weight, twice daily, 12 months
223514210|NCT04334811|RADIATION|Stereotactic ablative radiotherapy|Stereotactic ablative radiotherapy (SAbR) delivers of a potent, ablative or nearly ablative dose of radiation in oligofractions (ie, five or fewer fractions) primarily to create a compact dose delivered accurately to the intended target with steep gradients in all directions (geometric avoidance) and avoid damaging normal tissues.
223514211|NCT04720170|PROCEDURE|Revascularization|Angiogram and IVUS with revascularization of the lateral plantar artery and pedal arch on target foot.
223514212|NCT00756314|BEHAVIORAL|Personalized contraceptive counseling|The intervention comprised a personalized and comprehensive (face-to-face) contraceptive counseling regarding to individual contraceptive history and needs. The counseling intervention was conducted by three trained gynecologists according to standard one day training.
223514213|NCT04394000|OTHER|thromboprofylaxis protocol|This individualised protocol contains three cornerstones: an increase in dosage of prophylactic LMWH close to therapeutic doses, introduction of routine venous ultrasonography and daily measurements of plasma anti-factor Xa activity
223514214|NCT04394000|OTHER|standard protocol|This protocol contains a routine low dose pharmacological venous thromboembolism (VTE) prophylaxis with LMWH
223514215|NCT03696667|DEVICE|BCI|As participants listen to the music, the EEG waves of their affective states and their variations detected in real-time is converted into an auditory signal providing direct feedback to participants about their affective states and assisting participants to learn and practice emotion regulation.
223514216|NCT05157763|DRUG|EscharEx 5% (EX-02 formulation)|EX-02 5% will be topically applied in a thick layer of 2-3 mm on the lesion surface for 8-12 hours including 5-10 mm margins and covered with an occlusive dressing. A new vial should be used for each application. Each patient will be treated with 7 applications.
223514217|NCT02232932|PROCEDURE|CAPECITABINE-Radiotherapy -Liver Transplantation|CAPECITABINE (800 mg/m2 twice a day during 5 weeks) + External Radiotherapy (50 grays during 5 weeks) then Liver transplantation
223514218|NCT02232932|PROCEDURE|RESECTION|Intent-to-treat R0 liver resection
223514219|NCT05788354|PROCEDURE|IUD insertion during cesarean section|placement of IUD during cesarean section after placental delivery
223514220|NCT02605967|DRUG|Spartalizumab|Spartalizumab was administered via intravenous infusion at a dose of 400 mg every 4 weeks (Q4W). Spartalizumab is a humanized anti-PD-1 IgG4 antibody which blocks the binding of PD1 to its ligands PD-L1 and PD-L2.
223514221|NCT02605967|DRUG|Investigator choice of chemotherapy|Commonly used chemotherapy as per investigator's choice. The dose and route of administration was the one described in each drug's label.
223514222|NCT00109070|DRUG|Avastin (bevacizumab)|
223514223|NCT02957903|DRUG|Ropivacaine|All 20 study participants will receive both treatment A and B in form of a nerve block injection around the lateral femoral cutaneous nerve. Treatment A and B will be randomized to be given in either right or left lower extremity. If the participant is randomized to receive treatment A in the right lower extremity, treatment B will be given in the left lower extremity, and vice versa. Each participant will thus constitute as their own control.
223627488|NCT00322777|BEHAVIORAL|Spirituality Teaching Program|The Spirituality Teaching Program is a home study program delivered through audio CDs over an 8-week period. The program consists of weekly 90 minute teaching sessions, based on the content of a workshop developed to assist users in developing a more spiritual outlook on life and coping resources. Using didactic comment and storytelling, the following spiritual concepts are addressed in the sessions: self-transcendence, connectedness, forgiveness, self-acceptance, detachment, compassion and gratitude. Each session concludes with a relevant guided visualization practice. In addition, a 15-minute progressive relaxation exercise is included that is to be used on a daily basis. The presented content is nondenominational to ensure compatibility with any beliefs participants may hold.
223627489|NCT05138302|OTHER|Observation|This study is an observe research
223627490|NCT02489435|DRUG|VM-1500|VM-1500
223627491|NCT02489435|DRUG|Placebo|Placebo
223627492|NCT04834570|BEHAVIORAL|Quality of life in Breast Cancer Survivors|"The patient will receive the following questionnaires to be completed :~* EORTC QLQ-C30~* EORTC QLQ - BR-23~* FACT-B"
223627493|NCT03827408|DRUG|Midazolam group (MDZ)|IV Ampules of Dormicum 15mg/ 3ml, Hoffman-La Rouche Ltd., Basel, Switzerland
224216222|NCT05330845|BIOLOGICAL|IL6 assessment|Blood IL6 will be assessed during trial
224216223|NCT05330845|BIOLOGICAL|CRP and PCT assessment|Blood CRP and PCT will be assessed during trial
223763878|NCT00006184|DRUG|Doxorubicin hydrochloride|Induction chemotherapy: 10 mg/m\^2 day continuous intravenous (CIV) days 1-3
223763879|NCT00006184|DRUG|Etoposide|Induction chemotherapy: 50 mg/m\^2 day continuous intravenous days 1-3
224216224|NCT03216954|DRUG|Alcohol|During each arm, subjects will receive doses of alcohol, designed to raise BALs to 0.015 and 0.03 g/dl.
224216225|NCT03216954|DRUG|Placebos|Subjects will receive placebo capsules
224216226|NCT03216954|DRUG|N-acetyl cysteine|Subjects will receive n-acetyl cysteine capsules
223763880|NCT00006184|DRUG|Fludarabine phosphate|Induction chemotherapy: 25 mg/m\^2 day intravenous days 1-3 Transplant: 30 mg/m\^2 day x 4 days (days -6, -5, -4, -3 )
223763881|NCT00006184|DRUG|Prednisone|60 mg/m\^2 day 1-4
223763882|NCT00006184|DRUG|Vincristine Sulfate|Induction chemotherapy: 0.5 mg/m\^2 day continuous intravenous days 1-3
223763883|NCT00006184|DRUG|Methotrexate|Transplant: 5 mg/m\^2 intravenous on days +1, +3, +6, +11
223627494|NCT03827408|DRUG|Dexmedetomidine group (DEX)|IV Ampules of Precedex 4mcg/ml, Hospira. Inc., Lake Forest,IL USA.
223763884|NCT00006184|BIOLOGICAL|GMCSF (granulocyte macrophage colony stimulating factor)|250 mcg/m\^2 subcutaneously every day, days 1-4
223763885|NCT00006184|BIOLOGICAL|GCSF (granulocyte colony stimulating factor)|10 mcg/kg per day subcutaneously daily from day 5 until absolute neutrophil count (ANC) \> 1000/ul x 2 days
223627495|NCT03827408|DRUG|Combination of Midazolam and Dexmedetomidine (MDZ/DEX)|Combination of Nebulized solution of 0.3 mg/kg Midazolam, and 3µg/kg Dexmedetomidine respectively.(
223627496|NCT03473678|DIETARY_SUPPLEMENT|Nitrate-rich beetroot juice|concentrated beetroot juice
223627497|NCT03473678|DIETARY_SUPPLEMENT|Nitrate-depleted beetroot juice|concentrated beetroot juice
223627498|NCT02537977|BIOLOGICAL|CD19-directed CAR-T cells|CD19-directed CAR-T cell infusion will be given by vein
223627499|NCT01419002|RADIATION|neoadjuvant RTx|Neoadjuvant radiotherapy with external intensity modulated beam radiation followed by duodenopancreatectomy and adjuvant chemotherapy according to German S3 guidelines.
223627500|NCT01419002|PROCEDURE|Surgery|Surgery and adjuvant chemotherapy according to German S3-guidelines
223763886|NCT04341181|DRUG|Alectinib|Alectinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Alectinib might be expected based on their molecular tumor profile.
223763887|NCT04341181|DRUG|Atezolizumab|Atezolizumab treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Atezolizumab might be expected based on their molecular tumor profile.
223763888|NCT04341181|DRUG|Avelumab|Avelumab treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Avelumab might be expected based on their molecular tumor profile.
224216227|NCT03618459|OTHER|Phone questionnaire|Patients were contacted by phone 6 months after surgery and, after oral consent, a standardized questionnaire was administered in order to inquiry about the length and nature of post-operative pain, the incidence of post-discharge pain, its characteristics, its impact on daily life, its treatment and its rate of chronicity
224216228|NCT05193331|DRUG|3% Diquafosol tetrasodium|3% Diquafosol tetrasodium eye drops will be used to assess its usefulness in diabetic dry eye symptoms
224216229|NCT02487368|DEVICE|Needle stimulation pad|
224216230|NCT02955810|DRUG|Daratumumab|
224216231|NCT02955810|DRUG|Cyclophosphamide|
224216232|NCT02955810|DRUG|Bortezomib|
224216233|NCT02955810|DRUG|Dexamethasone|
224216234|NCT04437082|DEVICE|optical coherence tomography|imaging structural and vascular features of the eye
224216235|NCT05867173|OTHER|Experimental Speech Processing Strategy|Patient's will listen with an experimental speech processor, programmed with a dynamic focusing strategy.
224216236|NCT03184103|DIAGNOSTIC_TEST|anti streptolysin o titre and serum complement test|diagnostic lab test
224216237|NCT01965535|DRUG|LDV/SOF|LDV/SOF (90/400 mg) FDC tablet administered orally once daily
224216238|NCT01965535|DRUG|RBV|RBV (200 mg tablets) administered orally in a divided daily dose based on weight (1000 mg per day for participants weighing \< 75 kg; 1200 mg per day for participants weighing ≥ 75 kg)
224216239|NCT01965535|DRUG|Placebo to match LDV/SOF|Placebo to match LDV/SOF administered orally once daily
224216240|NCT01965535|DRUG|Placebo to match RBV|Placebo to match RBV administered orally in a divided daily dose
224216241|NCT00656396|DEVICE|Coagucheck XS Plus (Point of care monitor of coagulation intraoperative)|Coagucheck XS Plus® is used for intraoperative measurement of Prothrombin time
224216242|NCT00656396|PROCEDURE|Control Intervention|Standard care
224216243|NCT01004796|GENETIC|cytogenetic analysis|
224216244|NCT01004796|GENETIC|microarray analysis|
224216245|NCT01004796|GENETIC|mutation analysis|
224216246|NCT01004796|OTHER|immunohistochemistry staining method|
224216247|NCT01004796|OTHER|immunologic technique|
223627501|NCT04789252|BIOLOGICAL|Bioinformatics analysis of single cell transcriptomics data|"1. Sample collection: Myeloid cell purification + Single cell sequencing~2. Primary analysis: QC sequencing data + Reads alignment + UMI quantification~3. Bioinformatics analysis: Quality Control (Number of genes, UMI content,%mitochondrial genes, % riboprotein genes,Filtering low quality cells) + Normalization and scaling (Normalization, Remove unwanted sources of variation, HVG detection) + PCA Clustering Markers (PCA and PC selection, Clustering, t-SNE, Differential expression for markers identification)~4. Validation: FACS analysis + immunohistochemistry"
223627502|NCT02226393|BEHAVIORAL|Prolonged exposure|The PE treatment includes 12-15 60 minutes' sessions. The 2 main components of the treatment are psychoeducation about common reactions to trauma and in-vivo exposures (gradual exposure to trauma related situations and objects) and repeated recounting of the traumatic memory, Trauma memory recounting and in-vivo exposures are conducted during several successive sessions so the child learns that the exposures themselves pose no real harm to him, indicating that when one confronts what one is afraid of it becomes easier to manage.
224216248|NCT01004796|OTHER|mass spectrometry|
224216249|NCT02641171|OTHER|Specimen sampling|exhaled air samples blood samples fecal samples
224216250|NCT01124682|PROCEDURE|diagnostic cystoscopy|
224216251|NCT01124682|PROCEDURE|diffusion-weighted magnetic resonance imaging|
224216252|NCT01124682|PROCEDURE|implanted fiducial-based imaging|
224216253|NCT01124682|PROCEDURE|quality-of-life assessment|
224216254|NCT01124682|RADIATION|3-dimensional conformal radiation therapy|
224216255|NCT01124682|RADIATION|image-guided radiation therapy|
224216256|NCT01124682|RADIATION|selective external radiation therapy|
224216257|NCT03126851|OTHER|Label|Labels vary based on presence or absence of age range information, and inclusion of an explicit warning in words, with or without a pictographic icon.
224216258|NCT00118573|PROCEDURE|EVAR (Endovascular repair of Abdominal Aortic aneurysm)|AAA repair with endografting
224216259|NCT00118573|PROCEDURE|Surveillance|Surveillance of AAA without any repair until AAA will reach 5.5cm, become tender or rapidly grow
224216260|NCT03786809|DRUG|Cimifuga Racemosa|Experimental group will use 160mg of Cimifuga Racemosa for 28 days
224216261|NCT03786809|DRUG|Placebo|patients of the placebo group will use placebo once a day for 28 days
224216262|NCT02983227|DRUG|GDC-0853|GDC-0853 was administered orally at a dose of 200mg, as per the dosing schedules described above.
224216263|NCT04677582|BEHAVIORAL|Vidas Activas, famiLias saludablEs (VALE)|Families and Children allocated to the intervention will receive weekly group-based meetings over a 10-week period consisting of education and activities on healthy lifestyles. Graduate students/Research Assistants trained in nutrition, exercise and clinical psychology will lead the meetings. All activities will be culturally relevant (i.e. cooking healthy Latino recipes) and Spanish speaking students will be recruited to deliver the intervention. Participants will be involved on deciding activities and projects and while some sessions will meet as a family group with parents/guardians, others will meet separately.
223763889|NCT04341181|DRUG|Axitinib|Axitinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Axitinib might be expected based on their molecular tumor profile.
224216264|NCT02965469|BEHAVIORAL|Breathe2Relax|The app teaches diaphragmatic breathing and has audiovisual coaching
224216265|NCT04188496|OTHER|Pulmonary Function Test group|The interventional group received the same conventional Chest physiotherapy Techniques for 30 minutes followed by 10 minutes rest. The patients then received additional 15 minutes protocol of thoracic joint mobilization
224216266|NCT04188496|OTHER|Control Group|received conventional Chest physiotherapy Techniques for 30 minutes (including deep breathing, diaphragmatic breathing exercises, Self-stretching exercises for accessory respiratory muscles, Respiratory Resistance training by incentive spirometer) followed by 10 min rest.
224216267|NCT05622552|DEVICE|active group of tDCS|"Transcranial direct current stimulation(tDCS) is a neurostimulation that has aroused concern in psychiatry. As a non-invasive brain modulation that delivered a weak direct current (0.5-2 mA) via two scalp electrodes (an anode and a cathode) overlying targeted cortical areas. It can produce polarity-dependent effects, like inducing functional changes in resting membrane potential and cerebral blood flow. Specifically, a depolarization of the neurons membranes by anodal stimulation and thus invokes an increase of the spontaneous neuronal firing rate, whereas cathodal stimulation induces neuronal hyperpolarization.~In the active group, current stimulations were gradually ramped up to 2 mA (in 30 seconds) intensity for 20 minutes, once a day, for 10 days."
224216268|NCT05622552|DEVICE|sham group of tDCS|"Transcranial direct current stimulation(tDCS) is a neurostimulation that has aroused concern in psychiatry. As a non-invasive brain modulation that delivered a weak direct current (0.5-2 mA) via two scalp electrodes (an anode and a cathode) overlying targeted cortical areas. It can produce polarity-dependent effects, like inducing functional changes in resting membrane potential and cerebral blood flow. Specifically, a depolarization of the neurons membranes by anodal stimulation and thus invokes an increase of the spontaneous neuronal firing rate, whereas cathodal stimulation induces neuronal hyperpolarization.~For sham stimulation, the procedure was identical, except that the current was gradually ramped up to 2mA and rapidly down to zero (in 30 seconds), thus leading to the same initial sensations of tDCS."
224216269|NCT01212731|RADIATION|Photon treatment plans|10 of the 30 subjects on Cohort 1 will receive photon treatment plans.
224216270|NCT01212731|RADIATION|Proton Treatment Plans|20 subjects from Cohort 1 will receive proton treatment plans with malignancies involving the base of skull.
224216271|NCT01212731|BEHAVIORAL|Neurocognitive evaluation|Verbal and Visual memory; immediate attention, working memory, and processing speed; executive functions and affect and depression.
224216272|NCT01212731|DEVICE|Advanced MRI imaging|Anatomic Imaging, Blood volume measurements, Diffusion Tensor Imaging, DTI Image Processing
224216273|NCT02693652|BIOLOGICAL|CVI-HBV-002|"* Investigational product: CVI-HBV-002~* Dose: 20ug or 40ug~* Frequency: 3 or 6 times~* Vaccination schedule: 0, 1, 2 months or 0, 1, 2, 3, 4, 5 months~* Administration route: Intramuscular injection"
224216274|NCT01032759|DRUG|Memantine|20 mg, BID
224216275|NCT01032759|DRUG|Placebo|BID
224216276|NCT01227096|DEVICE|Electrical acupuncture stimulation|electroacupuncture would be administered on the bilateral P6 acupoint after anesthesia induction, but prior to surgery.
223627503|NCT02226393|BEHAVIORAL|Child-parent Play Therapy|Is consisted of 12-15 weekly 60 minute sessions of parent-child centered therapy it focus on establishing a trusting, empowering, and validating therapeutic relationship. Participants are allowed to choose when, how, and whether or not to address their trauma memory. Therapists provide active listening, empathy,and encouragement to talk about feelings and express belief in the participants ability to cope. In sessions 4 and 8, participants are asked how they feel about their trauma. With this exception, participants direct the sessions.
223627504|NCT03972059|OTHER|Exercise training - Phase 1|Phase 1 is the first 4 weeks of the 12-week training program.
223627505|NCT03972059|OTHER|Exercise training - Phase 2|Phase 2 is the next 4 weeks following phase 1 of the 12-week training program. The exercise intensity during exercise bouts in this phase is increased compared to the exercise intensity applied in phase 1.
223627506|NCT03972059|OTHER|Exercise training - Phase 3|Phase 3 is the last 4 weeks of the 12-week training program. The exercise intensity during exercise bouts in this phase is increased compared to the exercise intensity applied in the previous phases.
223627507|NCT04604600|DRUG|amyloid PET|Dynamic PET acquisition for 70 minutes will be acquired after injection of 10±5 mCi 11C-PiB.
223627508|NCT06005415|DIETARY_SUPPLEMENT|Wire-cut cookie|Investigation of the impact of wheat particle size on the postprandial glycemic response, gastric emptying and oral processing behavior after consumption of wire-cut cookies.
223627509|NCT01176201|DRUG|SLV337 suspension|400 mg experimental
223627510|NCT01176201|DRUG|SLV337 capsule|5 x 200 mg immediate release capsule
223627511|NCT03869658|BEHAVIORAL|COCO application|All participants will complete a screening survey to determine their eligibility for the study, if eligible and willing to participate, he or she will sign an informed consent form. Once participants are enrolled in the study, a demographics questionnaire will be completed along with 5 days of food tracking on the COCO application. Between days 3 and 7, participants will complete two 24-hr diet recall, one a day, and a patient satisfaction questionnaire.
223627512|NCT05732298|DEVICE|intermittend theta burst stimulation (iTBS)|600 pulses of iTBS per day with 120% resting motor threshold applied four weeks at Monday-Friday
223627513|NCT01870206|BIOLOGICAL|Trivalent OPV Birmex|Newborns who receive OPV vaccine produced in Vero cells by Birmex one dose of vaccine immediately after random allocation (at birth). A second dose is given four weeks after the first application.
223627514|NCT01870206|BIOLOGICAL|Trivalent OPV Sanofi Pasteur|Newborns who receive OPV vaccine produced in Vero cells by Sanofi Pasteur one dose of vaccine immediately after random allocation (at birth). A second dose is given four weeks after the first application.
223627515|NCT02698696|OTHER|ECo program|
223627516|NCT02698696|OTHER|CRT program|
223627517|NCT02698696|OTHER|Supportive psychotherapy|
223627518|NCT01190397|DEVICE|Warming goggles|
223627519|NCT01190397|DEVICE|warm and moist compresses|
223627520|NCT04386304|DRUG|(+)-Epicatechin|(+)-Epicatechin is a synthetic flavanol
223627521|NCT00446849|DRUG|MMX Mesalamine|MMX™ mesalamine 2.4g/day to 4.8g/day once-daily (QD) (two to four 1.2g tablets MMX™ mesalamine, dosed QD,respectively).
223627522|NCT03954366|DRUG|Rucaparib|Rucaparib 600 mg BID commencing on Day 5 until Day 23.
223627523|NCT03954366|DRUG|Rosuvastatin|Single dose of 20mg oral rosuvastatin on Day 1 and Day 19 only.
223627524|NCT03954366|DRUG|Oral Contraceptives|Single dose of combined oral contraceptive (30 μg ethinylestradiol and 150 μg levonorgestrel) on Day 1 and Day 19 only.
223627525|NCT00904943|DRUG|Topiramate Capsules, 25 mg|2 x 25 mg Capsules
223627526|NCT00904943|DRUG|Topamax® Capsules, 25 mg|2 x 25 mg Capsules
223627527|NCT04456127|PROCEDURE|Fractional CO2 Laser|The UltraPulse® fractional ablative CO2 Laser will be employed with the DeepFX™ hand piece. Number of passes and laser settings, including fluency, density, spot size, will be chosen during the time of treatment as determined by the operating surgeon.
223627528|NCT02367898|OTHER|Lumosity Cognitive Training|adaptive online cognitive training
223627529|NCT02367898|OTHER|Crossword Puzzles|timed online crossword puzzles
223627530|NCT06297369|DRUG|N acetyl cysteine|N-acetylcysteine 600 mg twice daily (acetylcystein ® 600 mg effervescent instant granules sachets, Sedico, Egypt)
223627531|NCT00412009|PROCEDURE|Comprehensive package of activities|
223627532|NCT03850379|DRUG|Levofloxacin|This is a prospective study comparing consecutive patients who will be be receiving ciprofloxacin prophylaxis vs. levofloxacin prophylaxis for Stem cell transplant till engraftment defined as ANC \>1000
223627533|NCT03850379|DRUG|Ciprofloxacin|This is a prospective study comparing consecutive patients who will be be receiving ciprofloxacin prophylaxis vs. levofloxacin prophylaxis for Stem cell transplant till engraftment defined as ANC \>1000
223627534|NCT05203614|BEHAVIORAL|Household Contribution|Questionnaires
223627535|NCT05203614|BEHAVIORAL|Outside Contribution|Questionnaires
223627536|NCT05203614|BEHAVIORAL|Control|Questionnaires
223627537|NCT03371498|DRUG|Methylprednisolone|Ventilated patients presenting moderate to severe ARDS with a procollagen III alveolar level above 9 µg/L
223627538|NCT03371498|DRUG|Methylprednisolone placebo|Ventilated patients presenting moderate to severe ARDS with a procollagen III alveolar level above 9 µg/L
223627539|NCT01223534|DRUG|Preventive treatment with Isoniazid.|If TST positive: participant will be treated with Isoniazid 300 mg/d, for 6 months.
223627540|NCT01223534|DRUG|Preventive treatment with Isoniazid|If QFT-IT positive, Isoniazid 300 mg/d, for 6 months.
223627541|NCT03446794|OTHER|Non Intervention|To assess the procedural safety and efficacy on stroke and bleeding prevention of LAAC in patients with NVAF and ESCKD on HD
223627542|NCT05525897|OTHER|Psychoeducational|The focus of the course is to teach students the fundamental theories, and practices of soft skills, as well as providing cases and material that give students the opportunity to learn from real life experiences.
223627543|NCT05326087|DRUG|GnRH antagonist|GnRH antagonist (Cetrorelix 0.25mg) once subcutaneously daily from day 6 of ovarian stimulation till the day of the ovulation trigger
223627544|NCT05326087|DRUG|MPA|oral MPA 10mg qd from Day 3 of ovarian stimulation till the day of ovulation trigger.
223627545|NCT01194830|DRUG|Linagliptin|Active drug 1 tablet PO QD
223627546|NCT01194830|DRUG|Placebo|1 Tablet PO QD
224216277|NCT00812305|DRUG|SKY0402 300mg in healthy patients|SKY0402, single administration of 300 mg via local infiltrations (subcutaneous) in healthy patients
223627547|NCT03115359|BEHAVIORAL|Mindfulness Based Therapy|"The Mindfulness Based Therapy intervention will teach participants the mindfulness meditation-based strategies, tailored to the needs of those with opioid-treated chronic lower back pain. It consists of eight weekly 2-hour group sessions guided by trained therapists. In addition to session attendance, participants are asked to practice at home at least 6 days/week, 30 minutes/day during the study.~In addition to the intervention, the participants will receive usual care for opioid-treated CLBP through their regular clinicians, per their recommendations."
223627548|NCT03115359|BEHAVIORAL|Cognitive Behavioral Therapy|"The Cognitive Behavioral Therapy (CBT) intervention will teach participants the CBT-based strategies, tailored to the needs of those with opioid-treated chronic lower back pain. It consists of eight weekly 2-hour group sessions guided by trained therapists. In addition to session attendance, participants are asked to practice at home at least 6 days/week, 30 minutes/day during the study.~In addition to the intervention, the participants will receive usual care for opioid-treated CLBP through their regular clinicians, per their recommendations."
223627549|NCT00698854|DEVICE|Vanguard™ Complete Knee System|Primary Total Knee System, Cruciate-Retaining (CR) or Posterior-Stabilized (PS)
223627550|NCT00698854|DEVICE|Vanguard™ Patient-Specific Femur|Primary Total Knee System used with Signature technique to provide a patient-specific femur
223627551|NCT00061087|DRUG|Methylphenidate|Methylphenidate 80mg/day
223627552|NCT00061087|DRUG|Bupropion|Bupropion 400mg/day
223627553|NCT00061087|OTHER|Placebo|Placebo
223627554|NCT00162487|DRUG|Albuterol (1,200 μg) through metered-dose inhaler|
223627555|NCT04861597|BEHAVIORAL|Internet based cognitive behavioral therapy|Participants with elevated psychological distress will receive 8 weeks of internet-based cognitive behavioral therapy
223627556|NCT04861597|BEHAVIORAL|Digital mood tracking|Participants with elevated psychological distress will receive 8 weeks of digital mood tracking
223627557|NCT01815918|DRUG|Hydrocortisone|Patients randomized to treatment arm will three doses of 100 mg of hydrocortisone at the following times: prior to surgery, 8 hours after the first dose and 16 hours after the first dose.
223627558|NCT01815918|DRUG|Placebo|Patients receive placebo prior to surgery, 8 hours after the first dose and 16 hours after the first dose.
224216278|NCT00812305|DRUG|SKY0402 300mg in hepatically impaired patients|SKY0402, single administration of 300 mg via local infiltrations (subcutaneous) in hepatically impaired patients
223627559|NCT06435936|DRUG|Single Ascending Dose of SAB-176|Single ascending dose
223627560|NCT06435936|DRUG|Single Ascending Dose of Placebo|Single ascending dose
223763890|NCT04341181|DRUG|Erlotinib|Erlotinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Erlotinib might be expected based on their molecular tumor profile.
224216279|NCT01887379|DRUG|GRDF furosemide|The GRDF furosemide tablet contains Fe3O4, which serves as an inactive magnetic marker to allow monitoring of the tablet transit through the gastrointestinal tract, using the MMM imaging technique.
224216280|NCT00919802|DRUG|Oxytocin|A single dose of oxytocin 40 IU (20 IU to each nostril) will be dispensed in a random fashion to subjects. A log will be kept so that the subject will receive a single does of saline as an alternate agent on the second day if needed.
224216281|NCT00919802|OTHER|Saline as a nasal spray|A single dose of saline will be dispensed in a random fashion to subjects. A log will be kept so that the subject will receive a single does of oxytocin 40 IU as an alternate agent on the second day if needed.
224216282|NCT03603431|DRUG|MRG-110|Single ascending doses of MRG-110
224216283|NCT03603431|DRUG|Placebo|Single doses of placebo
224216284|NCT03603431|DRUG|MRG-110|Multiple ascending doses of MRG-110
224216285|NCT03603431|DRUG|Placebo|Multiple doses of Placebo
224216286|NCT00165711|DRUG|Mecobalamin|
224216287|NCT04769128|OTHER|Traditional physical therapy programe|thoracic manipulation spine at the level of T3 and T4 facet joints (Maitland (screw) technique grade V). Using hypothenar eminence of hands, applying direct downward pressure and additional force-directed caudal with one hand and cephalic with the other hand on the transverse processes.
223627561|NCT04682197|DEVICE|Cereset Research|The upgraded platform for medical research using the HIRREM technology has been rebranded as Cereset Research® (CR). This system uses the same core technology and algorithms to echo brainwaves in real-time using audible tones, as with HIRREM. The CR system also includes 64-bit processing architecture for faster feedback, the use of 4 sensors, and the use of standard protocols (with flexibility regarding the length and sequencing of the standard protocols), all done with eyes closed. Four sensors are applied to the scalp at a time. However, only two sensors are actively echoing feedback. The software automatically switches from one sensor pair to the other when needed. This reduces the number of sensor placement changes needed, resulting in shorter session time and fewer interruptions.
223627562|NCT00148278|DRUG|norepinephrine and dobutamine|continuous infusion of norepinephrine titrated to maintain a mean arterial pressure at 70mmHg or more and dobutamine could be added as a continuous infusion when cardiac index was of less than 2.5 liters per squared meter of body surface
223627563|NCT00148278|DRUG|epinephrine plus placebo of dobutamine|epinephrine was titrated to maintain a mean arterial pressure at 70mmHg or more and placebo of dobutamine was titrated in case of a cardiac index lower than 2.5 liters per squared meters of body surface
223763891|NCT04341181|DRUG|Vemurafenib plus Cobimetinib (combination)|Vemurafenib plus Cobimetinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Vemurafenib plus Cobimetinib might be expected based on their molecular tumor profile.
223763892|NCT04341181|DRUG|Trastuzumab plus Pertuzumab (combination)|Trastuzumab plus Pertuzumab treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Trastuzumab plus Pertuzumab might be expected based on their molecular tumor profile.
224216288|NCT00240305|DRUG|Rosuvastatin|
224216289|NCT01946282|OTHER|FIT Invitation Only|Patients meeting the inclusion / exclusion criteria are mailed invitations to complete a free colorectal cancer screening. POLYMEDCO Fecal Immunochemical Tests (FIT) are mailed to patient homes with instructions, followed up with live and TELEVOX reminder phone calls.
224216290|NCT01946282|OTHER|FIT plus $5 Incentive|Patients meeting the inclusion / exclusion criteria are mailed invitations to complete a free colorectal cancer screening. POLYMEDCO Fecal Immunochemical Tests (FIT) are mailed to patient homes with instructions, followed up with live and TELEVOX reminder phone calls. Patients are offered a small incentive to complete their screening.
223627564|NCT03284710|BIOLOGICAL|ALVAC-HIV (vCP2438)|Expresses the gene products ZM96 gp120 (clade C strain) linked to the sequences encoding the HIV-1 transmembrane (TM) anchor sequence of gp41 (28 amino acids clade B LAI strain) and gag and pro (clade B LAI strain); formulated as a lyophilized vaccine for injection at a viral titer ≥ 1 × 10\^6 cell culture infectious dose (CCID)50 and \< 1 × 10\^8 CCID50 (nominal dose of 10\^7 CCID50) and reconstituted with 1mL of sterile sodium chloride solution (NaCl 0.4%) for intramuscular (IM) injection as a single dose
223627565|NCT03284710|BIOLOGICAL|Bivalent Subtype C gp120/MF59|Consists of 2 subtype C recombinant monomeric proteins, TV1.C gp120 Env and 1086.C gp120 Env, each at a dose of 100 mcg, mixed with MF59 adjuvant (an oil-in-water emulsion); delivered as a 0.5 mL IM injection
223627566|NCT03284710|BIOLOGICAL|Bivalent Subtype C gp120 admixed with Al(OH)3 Suspension|Consists of 2 subtype C recombinant monomeric proteins, TV1.C gp120 Env and 1086.C gp120 Env, each at a dose of 100 mcg, admixed with Aluminum Hydroxide Suspension (\~625 mcg aluminum content); delivered as a 0.5 mL IM injection
223627567|NCT03284710|BIOLOGICAL|Bivalent Subtype C gp120|Consists of 2 subtype C recombinant monomeric proteins, TV1.C gp120 Env and 1086.C gp120 Env, each at a dose of 100 mcg, mixed with sodium chloride for injection, 0.9%; delivered as a 0.5 mL IM injection
223627568|NCT06430996|DIETARY_SUPPLEMENT|caffeine|The participants chewing either caffeine Gum (CAF trial, containing 3 mg/kg of caffeine) or Placebo Gum (PL) for 10 minutes. After rested for 15 minutes, the participants underwent tests.
223627569|NCT00023959|DRUG|hydroxyurea|Given orally
223627570|NCT00023959|DRUG|fluorouracil|Given IV
223627571|NCT00023959|BIOLOGICAL|bevacizumab|Given IV
223627572|NCT00023959|RADIATION|radiation therapy|Undergo radiotherapy
224216291|NCT01946282|OTHER|FIT plus $10 Incentive|Patients meeting the inclusion / exclusion criteria are mailed invitations to complete a free colorectal cancer screening. POLYMEDCO Fecal Immunochemical Tests (FIT) are mailed to patient homes with instructions, followed up with live and TELEVOX reminder phone calls. Patients are offered a small incentive to complete their screening.
224216292|NCT01493531|DRUG|Lesinurad|Tablets, 200 mg QD
224216293|NCT01493531|DRUG|Lesinurad|Tablets, 400 mg QD
224216294|NCT01493531|DRUG|Placebo|Tablets, Placebo QD
224216295|NCT01493531|DRUG|Allopurinol|Tablets
224216296|NCT05595174|BIOLOGICAL|self ligating bracket with micro osteoperforation|A standardized wire sequence of .012'', 0.014'',0,016'', and 0.016''×0.022'' nickel-titanium were followed to achieve leveling and alignment. Micro-osteoperforations will be formed
224216297|NCT05595174|BIOLOGICAL|conventional bracket with micro osteoperforation|A standardized wire sequence of .012'', 0.014'',0,016'', and 0.016''×0.022'' nickel-titanium were followed to achieve leveling and alignment. Micro-osteoperforations will be formed.
224216298|NCT05595174|BIOLOGICAL|conventional bracket without micro osteoperforation|A standardized wire sequence of .012'', 0.014'',0,016'', and 0.016''×0.022'' nickel titanium were followed to achieve leveling and alignment
223627573|NCT00023959|BIOLOGICAL|filgrastim|Given subcutaneously
223627574|NCT00023959|OTHER|laboratory biomarker analysis|Correlative studies
223627575|NCT04445285|DRUG|Pulmozyme/ Recombinant human deoxyribonuclease (rh-DNase)|2.5mg Pulmozyme/ Recombinant human deoxyribonuclease (rh-DNase) aerosolized treatment once every 24 hours for five (5) consecutive days; a total of five (5) doses
223627576|NCT04445285|DRUG|0.9%sodium chloride|Placebo of 0.9% sodium chloride every 24 hours for five (5) consecutive days; a total of 5 doses
223627577|NCT04714606|OTHER|Sibling support group|The intervention is a novel, 8 session sibling support group which has been created for the purpose of the study.
223627578|NCT04714606|OTHER|None - control condition|The second arm of the study is a control condition in which participants will be given a tailored booklet to complete at home as it was deemed unethical to provide them with nothing.
224216299|NCT05595174|BIOLOGICAL|self ligating bracket without micro osteoperforation|A standardized wire sequence of .012'', 0.014'',0,016'', and 0.016''×0.022'' nickel-titanium were followed to achieve leveling and alignment.
223627579|NCT04595968|DEVICE|Vestal DM Active device|Battery powered non-invasive neurostimulation device
223627580|NCT04595968|BEHAVIORAL|Lifestyle modification|Subjects are prescribed a low calorie (500kcal deficit) diet if their BMI is ≥25. If a subject has a BMI of ≤24.9, they will be provided with guidance on ensuring their recommended daily dietary intake is achieved throughout the course of the trial (i.e 2,500kcal/day for men and 2,000kcal/day for women)
224216300|NCT04668222|DRUG|Yu-Ping-Feng formula|Yu-Ping-Feng formula produced by PuraPharm International (H.K) Ltd is a registered Chinese medicine formula by Chinese Medicine Council of Hong Kong (registration number: HKC-08255). The intake dosage is 5g twice daily.
224216301|NCT04668222|DRUG|Xiang-Sha-Liu-Jun formula|Xiang-Sha-Liu-Jun formula produced by PuraPharm International (H.K) Ltd is a registered Chinese medicine formula by Chinese Medicine Council of Hong Kong (registration number: HKC-08252). The intake dosage is 5g twice daily.
224216302|NCT04668222|DRUG|Liu-Wei-Di-Huang formula|Liu-Wei-Di-Huang formula produced by PuraPharm International (H.K) Ltd is a registered Chinese medicine formula by Chinese Medicine Council of Hong Kong (registration number: HKC-08273). The intake dosage is 5g twice daily.
224216303|NCT04668222|DRUG|"Placebo for Deficiency of Qi and Yang"|"Placebo for the group of deficiency of Qi and Yang is composed of 5% Yu-Ping-Feng formula+Xiang-Sha-Liu-Jun formula"
224216304|NCT04668222|DRUG|"Placebo for Deficiency of Qi and Yin"|"Placebo for the group of deficiency of Qi and Yin is composed of 5% Yu-Ping-Feng formula+Liu-Wei-Di-Huang formula"
224216305|NCT04380324|DRUG|LY3471851|LY3471851 drug product is a sterile liquid for SC injection that may be diluted with sterile 0.9% sodium chloride solution for injection (USP) prior to administration.
224216306|NCT04380324|DRUG|Placebo|The placebo dosing solution is 0.9% sodium chloride for injection (USP).
223627581|NCT04595968|DEVICE|Vestal DM Sham device|Placebo comparator sham device (no active stimulation)
223627582|NCT03285724|DEVICE|Harpoon Artificial ePTFE Chords|The Harpoon Medical Transapical device is intended to be used to reduce the degree of degenerative mitral regurgitation by delivering and anchoring one or more ePTFE cords to the affected mitral valve leaflet(s) via a small left thoracotomy on the beating heart in patients with anterior, bi-leaflet or posterior prolapse.
224216307|NCT06536634|OTHER|SAES|The experimental intervention consists of SAES with a glove or adhesive electrodes at 20Hz, 300µs, intensity between 2-10mA, during 30 minutes per day, 5x/week, for 5 weeks, combined with conventional occupation therapy. The subsequent therapy sessions will take place at home, with in-between telephone checks.
224216308|NCT06536634|OTHER|TAU|Treatment as usual
224216309|NCT01279590|DRUG|PPD10558|"PPD10558 40 mg capsule and matching placebo capsule twice a day for 4 weeks, then~PPD10558 80 mg (two 40 mg capsules) twice a day for 8 weeks"
224216310|NCT01279590|DRUG|Atorvastatin|"Atorvastatin 40 mg capsule and matching placebo capsule in the morning and 2 placebo capsules in the evening for 4 weeks, then~Atorvastatin 80 mg (two 40 mg capsules) in the morning and 2 placebo capsules in the evening for 8 weeks"
224216311|NCT01279590|DRUG|Placebo|2 placebo capsules twice daily for 12 weeks
224216312|NCT05860790|DIAGNOSTIC_TEST|Clinical Prediction Model for Venous Thromboembolism Following Neurosurgery|This is a clinical prediction model that uses perioperative clinical indicators and laboratory tests to predict the occurrence of VTE after neurosurgery.
224216313|NCT01362959|DRUG|Transdermal nicotine patch|The test product is a transdermal nicotine patch. The dosage of the test product depends on the amount of cigarettes used by a specific patient (21 or more or less than 21) delivering 21 or 14 mg nicotine/24 hrs. During the study period of thirty (30) days a patch will be applicated daily.
224216314|NCT01362959|OTHER|Cutaneous patch, containing no active substances|During the study period of thirty (30) days, the control product will be applicated daily.
224216315|NCT05991570|PROCEDURE|Video Assisted Thoracoscopic Surgery (VATS)|VATS is minimally invasive procedure for exploration to diagnose and treat thoracic injuries alternative to exploratory thoracotomy.
224317310|NCT06982430|OTHER|phone call|"Included patients were evaluated on day 7 after discharge from the ED through a telephone call.~This evaluation aimed to identify a recurrence of RC, defined as a NRS score greater than 3 within the 7 days following inclusion and/or a return visit for the same complaint"
224317311|NCT06982404|DIAGNOSTIC_TEST|Time Zero Donor Heart Biopsy for Molecular Analysis|"This intervention involves obtaining a right ventricular myocardial biopsy from the donor heart at the time of organ procurement (Time Zero), prior to transplantation. The biopsy is divided into two parts: one for routine histopathological evaluation and the other preserved in RNAlater® for molecular analysis using microarray technology. This molecular profiling is designed to detect early tissue injury and gene expression patterns associated with graft viability and transplant outcomes. The intervention is performed only once per donor and does not alter the standard clinical care of the recipient."
223627583|NCT01673308|DRUG|Lenalidomide|Lenalidomide 10 mg orally on days 1 to 21 of a 28-day cycle for at least 4 cycles until intolerance or disease progression.
224216316|NCT00179452|BEHAVIORAL|Yoga|
224216317|NCT00388570|DEVICE|The Aerocrine NIOX MINO® Airway Inflammation Monitor|
224216318|NCT01195389|DEVICE|Resonator|Treatment group vs. Placebo group
223627584|NCT03238716|OTHER|Electric DN|Dry needling with electric stimulation to the erector spine and paraspinal muscles in the lumbar / sacral region and tibialis anterior / posterior. Dry needling with electric stimulation of peri-neural tissue associated with lumbar / sacral nerve roots, pudendal nerve and posterior tibial nerve. 8-12 treatment sessions over 6 weeks.
223627585|NCT03238716|OTHER|NM Re-ed|"sEMG targeting type I slow-twitch fibers and type II fast-twitch fibers. Type I fibers maintain continuous muscle activity over prolonged periods of time; therefore, training of type I fibers will be achieved through endurance and repetition training of the pelvic floor muscles. Type II fibers are recruited during sudden increases in intra-abdominal pressure, and these fibers will be recruited with The Knack training. The Knack is a term created to use rhythm or timing to the pelvic floor. Neuromuscular re-education will be performed during the first treatment, but it will be performed as needed on subsequent treatments."
223627586|NCT03238716|OTHER|Exercise|Impairment-specific strength training, which may include transversus abdominis (TrA), gluteus maximus/medius/minimus and/or hip abductor/adductor muscle training. Treadmill, riding the recumbent bike at \> 2 METs and/or stair climbing. Exercise training will be performed 7-11 treatment sessions over 6 weeks (following treatment 1).
223763893|NCT04341181|DRUG|Trastuzumab emtansine|Trastuzumab emtansine treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Trastuzumab emtansine might be expected based on their molecular tumor profile.
223763894|NCT04341181|DRUG|Vismodegib|Vismodegib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Vismodegib might be expected based on their molecular tumor profile.
224216319|NCT01537965|DEVICE|Fibroscan® of Echosens, Aixplorer® of Supersonic Imagine, Aplio XG of Toshiba, QRS software developed by Pr I.Bricault, Acuson S2000 of Siemens|"Five ultrasounds exams are realised:~* elastography with Fibroscan®~* ultrasound elastography in supersonic mode with Aixplorer®~* ultrasound analysis of the surface liver with QRS software,~* quantification of acoustic structure with Aplio XG,~* elastography ARFI with Acuson S2000."
224216320|NCT03779594|DRUG|Acetazolamide|Patients will be assign and treated by acetazolamide from time of allocation until surgery (2-6 weeks after treatment initiation). The maximal dose of acetazolamide will be the same dose used to treat glaucoma, considering similarity of patients' characteristics, such as age and polypharmacy. We will start at a low dose of 250 mg once a day, and increase it slowly to a maximal dose of 500 mg twice a day. Dose will be individualized according to side-effects and tolerability. Renal and liver function tests will be performed before initiation of treatment, and will be examined again two weeks after treatment had begun.
224216321|NCT02128867|OTHER|Assisted Autogenic Drainage (AAD)|
224216322|NCT02128867|OTHER|bouncing and AAD|
224216323|NCT02128867|OTHER|bouncing|
224216324|NCT01027884|DRUG|Placebo|Placebo (900 mg/day) 2 tabl (150 mg each) x 3 times orally with meals
224216325|NCT01027884|DRUG|Idebenone|Idebenone (900 mg/day) 2 tabl (150 mg each) x 3 times orally with meals
223627587|NCT04723511|OTHER|Global Postural Re-education|"treatment techniques include corrective exercises both local and global to correct forward head posture.~first session will be to educate participants on the treatment sequence. This will be a session of Kendall's exercises as described below. This will followed be by performing GPR techniques of Anterior Chain stretch in the supine frog-like position for 20 minutes followed by posterior chain stretch against the wall for another 20 minutes. This is repeated in the first 6 sessions. Starting from the seventh session the time of holding each position is decreased to 15 minutes and a third position (standing against the wall) is introduced and performed for 15 minutes. Starting from the eighth session fourth position of sitting on the floor position is introduced and performed for another 15 minutes. total of a session will then take about 90 minutes.~Pre-treatment diaphragmatic release and deep breathing exercises are applied at the beginning of each session"
224216326|NCT01147016|BIOLOGICAL|HER2Bi-armed activated T cells|Total of 4 of the T cell infusions intravenously over a period of 1 month.
223627588|NCT04723511|OTHER|Kendall exercises|"exercises that correct upper crossed syndrome:~The treatment sequence will be:~a) Strengthen deep Cervical Flexors via Chin tucks. Repetition will be repeated 10 times for 5 sets.~(b) Stretching the cervical extensors. This is held for 1 minute and repeated 5 times.~(c) Strengthening shoulder retraction. Repetition will be repeated 10 times for 5 sets.~(d) Stretching the pectoralis muscle. This is held for 1 minute and repeated 5 times.~Exercises will be progressed as the sessions develop."
223627589|NCT04739644|DEVICE|Specific wrist rehabilitation by WRISTBOT device|The WRISTBOT is a fully backdrivable manipulandum that allows for movements along its 3 Degrees of Freedom (DoFs) in a human-like Range Of Motion (ROM) of the wrist: 62° flexion/extension (FE), -40°/+45° in ulnar/radial deviation (RUD), and 60° pronation/supination (PS). In addition, the robot permits motions along planes that involve combined multi-DoFs movements. Mechanically, the robot was developed to have low values of inertia, emulating the fluency of natural movements. Each DOF is measured by high resolution incremental encoders and actuated by one brushless motor or two in case of the RUD planes, providing both gravity compensation and continuous torque values necessary to manipulate the human wrist joints. Depending on the torques exerted, the device can be used in either active or assistive/passive modality. The system is integrated with a Virtual Reality environment (VR), useful to provide a visual feedback to the user while he/she is requested to complete the tasks.
223627590|NCT04739644|OTHER|Specific wrist rehabilitation performed by the physiotherapist|Passive, active and assisted mobilization
223627591|NCT04739644|OTHER|General rehabilitation|Exercise with elastic bands or weights, exercise of manipulation and dexterity, simulation of daily life activities supervised by the physiotherapist
223627592|NCT03078114|OTHER|Spinal Manipulation|The subject will be asked to lay down and bend in a specific way. The clinician will apply force to certain areas to manipulate the spine.
223627593|NCT03078114|OTHER|Placebo Spinal Manipulation|The subject will be asked to lay down and bend in a specific way. The clinician will apply force to certain areas to simulate manipulating the spine.
223627594|NCT06220214|DIAGNOSTIC_TEST|CEDM|Contrast Enhanced Digital Mammography
224216327|NCT01147016|DRUG|cyclophosphamide|As prescribed by physician, standard of care.
224216328|NCT01147016|DRUG|doxorubicin hydrochloride|As prescribed by physician, standard of care.
224317312|NCT06983587|RADIATION|Bone densitometry scan|"Each study participant will undergo a bone density measurement scan. The equipment used in this study will be the STRATOS DR X-ray bone densitometer (APELEM, 9 Avenue du Canal Philippe Lamour, 30660 Gallargues-le-Montueux, France). This device is indicated for diagnosing osteoporosis, assessing the risk of fracture in weakened bone areas, monitoring bone density, monitoring body composition and diagnosing vertebral anomalies (vertebral compression, fractures).~In general, the time for a scan is less than 1 min for the spine, less than than 1 min for the femur, less than 1 min for the forearm and around 4 min for the whole body.~The total duration of the patient's participation in this research will be approximately 2 hours."
224317313|NCT05973292|OTHER|resin cement containing phosphate ester monomer 10-methacryloyloxydecyl dihydrogen phosphate|Adhesive resin cement containing an MDP agent that is added to bonding agents to enhance bonding to ceramics like Ziconia and E-max
224317314|NCT05973292|OTHER|Non MDP containg resin cement|Adhesive resin cement not containing an MDP agent
224317315|NCT06983535|DEVICE|cervical balloon catheter|Patients will be randomized to inpatient or outpatient setting while having the cervical ripening balloon catheter
224216329|NCT01147016|DRUG|paclitaxel|As prescribed by physician, standard of care.
224216330|NCT01147016|OTHER|laboratory biomarker analysis|Immune studies will be done pre-immunotherapy, prior to the third infusion of activated T-cells, at the time of surgery, and 1 month after immunotherapy. If there are positive findings, additional optional studies will be done at 3, 6, and 12 months, if the immune studies show changes worthy of follow-up studies.
224216331|NCT01147016|PROCEDURE|neoadjuvant therapy|As prescribed by physician, standard of care.
224216332|NCT01147016|PROCEDURE|therapeutic conventional surgery|As recommended by physician, post immunotherapy.
223627595|NCT06220214|DIAGNOSTIC_TEST|CEDBT|Contrast-Enhanced Digital Breast Tomosynthesis
223627596|NCT06220214|DRUG|Omnipaque 350mgI/mL Solution for Injection|Injection of an FDA approved iodinated contrast agent is required to undergo the imaging procedures. It is not the intent of the study to evaluate the contrast agent, but it will be administered at the time of experimental imaging.
223627597|NCT02994238|DEVICE|Remote Health Management Sensor Platform|The Propeller sensor monitors the use of inhaled medications, capturing the date, time, and number of uses. The sensor then transmits this information using Bluetooth to a paired smart phone or hub. Data can be uploaded to the caregiver's smart phone and to the patient's web portal, which their healthcare team will have access to help overall management.
223627598|NCT02348177|DRUG|lopinavir with ritonavir in 1:1 ratio|During co-treatment of rifampicin containing tuberculosis treatment and lopinavir/ritonavir (4:1) based therapy, additional ritonavir is given to make lopinavir/ritonavir 1:1 ratio
224216333|NCT03670537|DIAGNOSTIC_TEST|Iron parameters|Serum iron, total iron binding capacity, TSAT (Fe/TIBC), serum ferritin
224216334|NCT01925742|OTHER|Integrated prenatal screening for Down's syndrome|Analysis of several serum biochemical markers, and fetal nuchal translucency by ultrasound, with computation of an individual risk of fetal aneuploidy.
224216335|NCT01925742|OTHER|Serum QUAD Assay for aneuploidy screening|Series of biochemical markers with results integrated into a computational estimate of risk of fetal aneuploidy
223627599|NCT02348177|DRUG|Lopinavir/ritonavir 4:1|This is the conventional dosing of LPV/r 4:1 for HIV when TB treatment has not been started or has been stopped
223627600|NCT02592031|DRUG|XM17|300 IU corresponds to an injection volume of 0.5 mL.
223627601|NCT02592031|DRUG|Gonal-f®|300 IU corresponds to an injection volume of 0.5 mL.
223627602|NCT02592031|DRUG|Zoladex®|3.6 mg
223627603|NCT03154866|DIETARY_SUPPLEMENT|Lactobacillus kefiri LKF01 DSM32079|Lactobacillus kefiri LKF01 DSM32079 in drop formulation. 5 drop/daily for 21 days
223627604|NCT03154866|DIETARY_SUPPLEMENT|Placebo|Placebo in drop formulation. 5 drop/daily for 21 days
223627605|NCT05941702|BEHAVIORAL|Body Signal Integration Training|Information and protocol uploaded to documents.
223627606|NCT05889728|DRUG|[68Ga]GA-NeoB|Is a positron emission tomography (PET) imaging agent, intended as a selection tool for \[177Lu\]Lu-NeoB treatment in patients with tumors overexpressing gastrin releasing peptide receptor (GRPR).
223763895|NCT04341181|DRUG|Niraparib|Niraparib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Niraparib might be expected based on their molecular tumor profile.
224216336|NCT01925742|OTHER|Semiconductor MPSS NIPT assay using ccfDNA in maternal blood|Analysis by next-generation sequencing of ccfDNA (circulating cell-free DNA) from maternal blood, using a targeted NIPT assay.
224216337|NCT01925742|OTHER|Optical-based MPSS NIPT assay using ccfDNA in maternal blood|Analysis by next-generation sequencing of ccfDNA (circulating cell-free DNA) from maternal blood, using an un-targeted NIPT assay.
224216338|NCT01925742|OTHER|Harmony™ Test (Ariosa Diagnostics)|Test that is commercially available (Ariosa Diagnostics). (will be used for benchmarking purposes in a subset of each arm)
224216339|NCT03241407|OTHER|Placebo toothpaste|During an experimental 3-week period of undisturbed mechanical plaque accumulation in the implants, implants randomly assigned to Placebo group will be submitted to a chemical plaque control (three times per day) using a placebo toothpaste.
224216340|NCT03241407|OTHER|triclosan/copolymer/fluoride toothpaste|During an experimental 3-week period of undisturbed mechanical plaque accumulation in the implants, implants randomly assigned to triclosan/copolymer/fluoride group will be submitted to a chemical plaque control (three times per day) using a triclosan/copolymer/fluoride toothpaste.
224216341|NCT05997485|DRUG|Nirmatrelvir/Ritonavir|Patients administered oral Paxlovid as prescribed according to national Morocco treatment guidelines for Covid.
224216342|NCT02226809|DEVICE|Accelerometry|Application of TOF stimulus (40 mA, three to four times) and recording TOFr in the PACU
224317316|NCT06982898|PROCEDURE|Fixed prosthesis with bimanual CR and intraoral scan|"Tooth-supported fixed prostheses were fabricated using centric relation records obtained by two different methods:~1. Bimanual manipulation technique, with jaw relation records captured using an intraoral scanner.~2. Neuromuscular deprogramming technique, with jaw relation records obtained using a jaw movement tracking and analysis device."
224317317|NCT04288479|BEHAVIORAL|Single high-intensity interval training session|10 minutes warming up at low-to-moderate intensity, 8x30 seconds high intensity interval training with fetal heart rate measurement after each 30 second work-bout, 2 minutes recovery at low-to-moderate intensity. Continuous monitoring of maternal heart rate.
223627607|NCT05535946|DRUG|ABX464|Administered once daily, preferably in the morning, with food
223627608|NCT05535946|DRUG|Placebo|Administered once daily, preferably in the morning, with food
223627609|NCT00568295|DRUG|acetaminophen|Acetaminophen Extended Release: Caplets 650 mg x 2, oral, C-112-10AP - Subjects were instructed to dose every eight hours according to the specified dosing schedule and to record the designated parameters in the subject diary on a daily basis throughout the course of the study until the final visit at the end of Week 4 or until discontinuation of study medication.
223627610|NCT00568295|DRUG|Rofecoxib|Rofecoxib: Capsules 12.5 mg, oral, C-904-1A - - Subjects were instructed to dose every eight hours according to the specified dosing schedule and to record the designated parameters in the subject diary on a daily basis throughout the course of the study until the final visit at the end of Week 4 or until discontinuation of study medication.
223763896|NCT05608785|DRUG|IBI315|IBI315 is a recombinant fully humanized anti-programmed death receptor 1 (PD-1) and humanized anti-human epidermal growth factor receptor 2 (HER2) bispecific antibody injection.
223763897|NCT05608785|DRUG|Oxaliplatin|Oxaliplatin is a type of chemotherapy. It is used as a treatment for different types of cancer, including gastric cancer.
223763898|NCT05608785|DRUG|Capecitabine|Capecitabine is a type of chemotherapy. It is used as a treatment for different types of cancer, including gastric cancer.
224216343|NCT00032370|PROCEDURE|Vascular surgery with best medical treatment|Patients undergo scheduled vascular surgery
223627611|NCT00568295|DRUG|Rofecoxib|Rofecoxib: Capsules 12.5 mg x 2, oral, C-904-1A - Subjects were instructed to dose every eight hours according to the specified dosing schedule and to record the designated parameters in the subject diary on a daily basis throughout the course of the study until the final visit at the end of Week 4 or until discontinuation of study medication.
223627612|NCT03480048|BEHAVIORAL|Breastfeeding and weight loss support|The intervention is based on the Loving Support peer counseling breastfeeding model developed by the Special Supplemental Program for Women Infants and Children (WIC) with added components to promote postpartum weight loss.
223627613|NCT02814916|DRUG|Dalbavancin|Dalbavancin was administered intravenously over 30 (± 5) minutes.
223627614|NCT02814916|DRUG|Vancomycin|Vancomycin was administered intravenously over 60 (± 10) minutes every 6 (± 1) hours.
223627615|NCT02814916|DRUG|Oxacillin|Oxacillin was administered intravenously over 60 (± 10) minutes every 6 (± 1) hours.
223627616|NCT02814916|DRUG|Flucloxacillin|Flucloxacillin was administered intravenously over 60 (± 10) minutes every 6 (± 1) hours.
223627617|NCT02814916|DRUG|Cefadroxil|Cefadroxil was administered orally every 12 hours.
223763899|NCT05608785|DRUG|TST001|TST001 is a high-affinity humanized monoclonal antibody targeting Claudin 18.2 with enhanced antibody-dependent cytotoxic (ADCC) and complement-dependent cytotoxic (CDC) activity, showing potent antitumor activity in xenograft assays.
224317318|NCT05967871|BIOLOGICAL|Fecal Microbiota Transplant|Participants will receive approximately 50 grams of human stool/150mL (approximately 107 microbes/mL of suspension) in saline, prepared as per standard collection, preparation, and screening protocols for FMT infusion developed by our institutional stool bank in accordance with recognized standards. Fecal microbiota transplant infused via existing enteral feeding tube or upper elective endoscopy (with infusion into the duodenum) x1.
223627618|NCT02814916|DRUG|Clindamycin|Clindamycin was administered orally every 8 hours.
223627619|NCT05626738|DEVICE|ENDORAIL|In case caecal intubation time is longer than 10 minutes, the balloon catheter is inserted in the tool channel, advanced beyond the colonoscope tip and filled with Ferromagnetic Fluid. By applying the Endorail Handpiece over the patient abdomen, the balloon can be magnetically anchored. The anchored balloon guide allows to straighten the scope and the colon itself. The colonoscope can thus be easily moved back and forward along the anchored guide to facilitate colonoscope positioning and colonoscopy completion. Afterward, Endorail is removed and the straightened colonoscope can be easily pushed forward to achieve colonoscopy completion according to standard endoscopic technique.
223627620|NCT04819451|OTHER|Magnesium-Rich Artificial Cerebrospinal Fluid (MACSF)|The Magnesium-Rich Artificial Cerebrospinal Fluid (MACSF) is composed of several qualified clinical intravenous injections according to a specific formula, which has similar physical and chemical properties to physiological CSF. MACSF will be freshly made and used. It will be prepared by trained professionals on a specific workbench and sent to the patient wards in a special container. Finally, it will be used in the CSF replacement. Aseptic principles should be enforced strictly during the whole procedures, including preparation, transportation and application.
223627621|NCT04959435|OTHER|biological samples collection|samples of blood, faeces, saliva, dental plaque, oral mucosa, genital mucosa
223627622|NCT05700669|DRUG|AsiDNA|All patients will receive a loading dose of AsiDNA intravenously (D1, D2, D3) followed by weekly intravenous administrations in combination with Olaparib.
224317319|NCT06983886|DRUG|Tranexamic Acid|A local anesthetic solution was prepared by mixing 10 ml of 1% lidocaine with adrenaline (1:100,000) and 5 ml of tranexamic acid (50 mg/ml), resulting in a total volume of 15 ml. The solution was injected at the planned mandibular osteotomy sites on both the medial and lateral aspects of the ramus of the mandible. The injection was administered after completion of general anesthesia, followed by a 5-minute waiting period to allow the anesthetic to take effect before the surgical incision was made.
224317320|NCT06983886|DRUG|Normal Saline Solution (NSS)|A local anesthetic solution was prepared by mixing 10 ml of 1% lidocaine with adrenaline (1:100,000) and 5 ml of normal saline (NSS), resulting in a total volume of 15 ml. The solution was injected at the planned mandibular osteotomy sites on both the medial and lateral aspects of the ramus of the mandible. The injection was administered after the induction of general anesthesia, followed by a 5-minute waiting period to allow the anesthetic to take effect before making the surgical incision.
224317321|NCT06983886|DRUG|Lidocaine (drug)|A local anesthetic solution was prepared by mixing 10 ml of 1% lidocaine with adrenaline (1:100,000) and 5 ml of normal saline (NSS) or 5 ml of tranexamic acid (50 mg/ml) depends on allocated group, resulting in a total volume of 15 ml. The solution was injected at the planned mandibular osteotomy sites on both the medial and lateral aspects of the ramus of the mandible. The injection was administered after the induction of general anesthesia, followed by a 5-minute waiting period to allow the anesthetic to take effect before making the surgical incision.
224317322|NCT04070235|DRUG|SH229 tablets|SH229 400 mg was provided in 4 tablets, 100mg each；SH229 600 mg was provided in 6 tablets , 100mg each；SH229 800 mg in was provided in 8tablets , 100mg each。
223627623|NCT05700669|DRUG|Olaparib|Olaparib is given orally in combination with AsiDNA
224317323|NCT04070235|DRUG|Daclatasvir dihydrochloride|Daclatasvir dihydrochloride was provided in a single tablet of 60 mg.
224317324|NCT04961463|BEHAVIORAL|psychoeducation|
224317325|NCT05079581|OTHER|Pelvic floor exercises|"The participants in the intervention group will be taught exercises involving strengthening the muscles around the pelvic floor in sitting, standing and lying positions by a physiotherapist who has been trained in women's health for 4 years and will be asked to perform them as home exercises every day for 8 weeks. The exercises are as follows:~They will be asked to tighten the muscles around the urethra, vagina and rectum as hard as possible, upwards and inwards (from the bottom up) and hold it in this way for 8-10 seconds. It will be applied in different positions as in the table."
224317326|NCT01363024|DRUG|MFGR1877S|Intravenous escalating dose
223627624|NCT01958372|DIETARY_SUPPLEMENT|soy isoflavones|Given PO
223627625|NCT01958372|DRUG|cisplatin|Given IV
223627626|NCT01958372|DRUG|etoposide|Given IV
223763900|NCT05608785|DRUG|TQB2450|TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.
223763901|NCT05608785|DRUG|Anrotinib|Anlotinib is a novel multitarget tyrosine kinase inhibitor for tumor angiogenesis and proliferative signaling.
223627627|NCT01958372|DRUG|pemetrexed disodium|Given IV
223627628|NCT01958372|RADIATION|radiation therapy|Undergo RT
223627629|NCT05002868|DRUG|RP12146|starting dose of 100 mg QD
224216344|NCT00032370|PROCEDURE|Coronary artery bypass grafting (CABG)|Coronary artery bypass grafting prior to vascular surgery
224216345|NCT00032370|PROCEDURE|Percutaneous transluminal coronary angioplasty (PTCA)|Cardiac revascularization via PTCA prior to vascular surgery
224216346|NCT02059187|DRUG|MK-1293|MK-1293 (insulin glargine) 100 units/mL administered subcutaneously once daily for 24 weeks. Participants not taking insulin at study entry will initiate MK-1293 at 10 units daily. Participants taking insulin will initiate MK-1293 at an appropriate dose based on prior insulin dosing. After initiation, the dose will be titrated to the suggested target for fasting finger stick glucose. MK-1293 dosing once daily at times other than bedtime will be permitted for participants with a previously established dosing time.
223627630|NCT00910104|DRUG|Omegaven®|10% Omegaven® 1g/kg/day, IV (in the vein) until the patient no longer requires parenteral nutrition or until participation in the study is terminated
223627631|NCT05720143|PROCEDURE|Osseodensification|Procedure: the horizontal and vertical osteotomy will make by Piezo and bone splitting will do by osseodensification bur. After that Immediate implantation will be done.
223627632|NCT05720143|PROCEDURE|Magnetic mallet|Procedure: the horizontal and vertical osteotomy will do by Piezo and bone splitting will make by chisels of magnetic mallet. Immediate implantation will be done after splitting.
223627633|NCT05720143|PROCEDURE|Piezo-surgery|Procedure: the horizontal and vertical osteotomy will do by Piezo and bone splitting will make by inserts of piezosurgery and bone expander. Finally, immediate implantation will be placed.
223627634|NCT03583099|OTHER|COPD plus CAPTURE education and patient-level information|Basic COPD Education plus CAPTURE education and patient-level CAPTURE information will be provided to all practice personnel randomized to the 'CAPTURE + COPD Education' arm.
223627635|NCT03583099|OTHER|COPD Education Only|Practice clinicians will receive basic COPD education only. Patient-level CAPTURE information will not be provided.
223627636|NCT06310187|OTHER|High Oxidant Unflavored Little Cigar - Group A|Subjects will be provided with high oxidant unflavored little cigars (One to take home and use ad lib and upon return to the lab, subjects will be given an additional high oxidant unflavored little cigar to use for outcome measure data collection in the lab)
223627637|NCT06310187|OTHER|Low Oxidant Unflavored Little Cigar - Group B|Subjects will be provided with low oxidant unflavored little cigars (One to take home and use ad lib and upon return to the lab, subjects will be given an additional low oxidant unflavored little cigar to use for outcome measure data collection in the lab)
223627638|NCT06310187|OTHER|High Oxidant Flavored Little Cigar - Group C|Subjects will be provided with high oxidant flavored little cigars (One to take home and use ad lib and upon return to the lab, subjects will be given an additional high oxidant flavored little cigar to use for outcome measure data collection in the lab)
223627639|NCT06310187|OTHER|Low Oxidant Flavored Little Cigar - Group D|Subjects will be provided with low oxidant flavored little cigars (One to take home and use ad lib and upon return to the lab, subjects will be given an additional low oxidant flavored little cigar to use for outcome measure data collection in the lab)
223763902|NCT05225961|DRUG|Tirofiban|An intravenous bolus of 500 micrograms of Tirofiban will be intravenously administered in five minutes with an infusion pump (infusion rate: 120 milliliters / hour), which is equivalent to 500 micrograms of Tirofiban. After five minutes, a dose reduction will be programmed to 200 micrograms / hour (infusion rate: 4 milliliters / hour for 24 hours (maximum total infused dose of 96 milliliters). Tirofiban infusion started in the neuroradiology room should be maintained until a control brain computerized tomography (CT) scan is performed at 20 hours (+/-2 hours). Once the absence of parenchymal hematoma is demonstrated in control CT, loading doses of acetylsalicylic acid and clopidogrel will be intravenously administered in the Tirofiban group, and the perfusion must be maintained simultaneously of Tirofiban and oral double antiplatelet therapy for four hours, after which the administration of the experimental drug should be discontinued.
224216347|NCT02059187|DRUG|Lantus™|Lantus™ (insulin glargine \[rDNA origin\]) 100 units/mL administered subcutaneously once daily for 24 weeks. Participants not taking insulin at study entry will initiate Lantus™ at 10 units daily. Participants taking insulin will initiate Lantus™ at an appropriate dose based on prior insulin dosing. After initiation, the dose will be titrated to the suggested target for fasting finger stick glucose. Lantus™ dosing once daily at times other than bedtime will be permitted for participants with a previously established dosing time.
224216348|NCT02059187|DRUG|Prandial insulin|Participants taking prandial insulin will continue their current prandial insulin regimen during the insulin glargine titration. After the insulin glargine titration phase, the prandial insulin may be adjusted if the investigator determines it to be necessary for glucose control.
224216349|NCT03774927|DEVICE|10 Hz treatment group|10 Hz stimulations over left DLPFC occurred at a power of 110% of MT for 27-s intervals with 20s inter-train interval. 20 minutes were administered each day (Monday-Friday) for 8 consecutive weeks.
224317327|NCT04688905|DIAGNOSTIC_TEST|Invasive hemodynamics of left ventricle via conductance catheter at rest, with exercise and with temporary vena cava occlusion|Invasive hemodynamics of left ventricle will be done by the conductance method. Left ventricular stiffness constant will be obtained by temporary vena cava occlusion. Right heart catherization will be done by pulmonary artery catherization and cardiac output will be estimated by thermodilution and Fick´s method.
224317328|NCT06633185|DRUG|phenytoin cream|application of the cream after internal anal sphincterotomy versus non application.
224317329|NCT06633185|DRUG|no phenytoin cream|Non application of the phenytoin cream
224317330|NCT04917471|DIETARY_SUPPLEMENT|Beet root juice|70 ml bid
224317331|NCT04917471|DIETARY_SUPPLEMENT|Placebo juice|70 ml bid
224317332|NCT01026311|DRUG|Coenzyme q 10|200 mg of Coenzyme q 10
224317333|NCT01026311|DRUG|placebo|1 placebo q d during treatment period
224317334|NCT02793505|DRUG|metformin|This is not an intervention but an observed exposure.
224317335|NCT02793505|DRUG|any drug not known as a major teratogen or major fetotoxicant|This is not an intervention but an observed exposure.
224317336|NCT00111553|BIOLOGICAL|Leish-111f + MPL-SE vaccine|
224317337|NCT00822978|DRUG|ACHN-490 Injection vs placebo|Escalating doses beginning with test dose given once, followed by 4 mg/kg with a single dose then multiple dose. Dose escalation to continue up to 15 mg/kg as long as the treatment is deemed safe.
224317338|NCT03371459|DRUG|AS MDI|AS MDI 1+1+2+4+8 inhalations of 90 μg per inhalation
224317339|NCT03371459|DRUG|Proventil|Proventil 1+1+2+4+8 inhalations of 90 μg per inhalation
224317340|NCT03870165|BEHAVIORAL|Resistance exercise|Participants will perform leg press and leg extension immediately prior to ingestion of salmon or isolated mixture
224317341|NCT03870165|OTHER|Salmon|Participants will ingest salmon immediately after resistance exercise
224317342|NCT03870165|DIETARY_SUPPLEMENT|Isolated amino acids and fatty acids|Participants will ingest a mixture of isolated amino acids and fatty acids immediately after resistance exercise
224317343|NCT05761665|OTHER|Evaluation|Kinesiophobia=Tampa scale Balance=Berg Balance Scale Falling=The Fall Activity Scale( Tinetti) Walking speed=Timed Get Up and Walk Test ,Two-Minute Walking Test Fragility=Frail Fragility Questionnaire, Clinical Fragility Scale
224317344|NCT04688892|DEVICE|Cupping|dynamic cupping
224317345|NCT01462812|DRUG|Sumatriptan|Sumatriptan 20mg
224317346|NCT01462812|DRUG|Placebo|Matching placebo
224216350|NCT03774927|DEVICE|20 Hz treatment group|20 Hz stimulations over left DLPFC occurred at a power of 110% of MT for 20 intervals with 28s inter-train interval. 20 minutes were administered each day (Monday-Friday) for 8 consecutive weeks.
224216351|NCT03774927|DEVICE|Control Group|all procedures were identical to 10Hz group except they were the non-magnetized steel cylinders, instead of cylindrical magnets, that were rotated.
224216352|NCT02220140|BEHAVIORAL|The Resilience Program|See the CONSORT trial protocol at http://myresilience.org/ at the subsite 'about us'.
224216353|NCT03070431|RADIATION|High-precision RT 5x5 Gy in 1 week|Patients included in this study will receive a high-precision radiotherapy with 5x5 Gy in 1 week
224216354|NCT01889862|DRUG|BMN165 20mg/day|BMN165 20mg/day self-administered daily
224216355|NCT01889862|DRUG|BMN165 40mg/day|BMN165 40mg/day self-administered daily
224216356|NCT01889862|DRUG|Placebo|Non-drug placebo, self-administered daily
224216357|NCT04337190|BIOLOGICAL|blood sampling|blood sampling at the day of admission, day 3 and day 7
224216358|NCT02087579|DRUG|Aripiprazole, oral formulation|Aripiprazole tablets will be administered orally (by mouth), at no dose restriction, as per the locally approved label indications.
224216359|NCT02087579|DRUG|Olanzapine, oral formulation|Olanzapine tablets will be administered orally, at no dose restriction as per the locally approved label indications.
224216360|NCT02087579|DRUG|Paliperidone, oral formulation|Paliperidone prolonged-release/extended-release (XR) formulation tablets will be administered orally, at no dose restriction, as per the locally approved label indications.
224216361|NCT02087579|DRUG|Paliperidone, LAI|Paliperidone long-acting injectable (LAI) i.e., paliperidone palmitate injections, will be administered per the locally approved label indications.
224216362|NCT02087579|DRUG|Quetiapine, oral formulation|Quetiapine immediate-release (IR) formulation or extended-release (XR) formulation tablets will be administered orally, at no dose restriction, as per the locally approved label indications.
224216363|NCT02087579|DRUG|Risperidone, oral formulation|Risperidone tablets will be administered orally, at no dose restriction, as per the locally approved label indications.
224216364|NCT02087579|DRUG|Risperidone, LAI|Risperidone LAI injections will be administered will be administered per the locally approved label indications.
224216365|NCT00266552|DRUG|risperidone|
223627640|NCT06310187|OTHER|Usual Cigarette - Group E|Subjects will use one of their own cigarettes in the collection of outcome measure data in the lab.
224216366|NCT02857374|PROCEDURE|Diagnostic Microscopy|Undergo intravital microscopy
224216367|NCT02857374|DRUG|Fluorescein Sodium Injection|Given IV
224216368|NCT02857374|OTHER|Laboratory Biomarker Analysis|Correlative studies
224317347|NCT04095312|PROCEDURE|Revo-i robotic surgery system (Model MSR-5100)|for evaluating the clinical safety and effectiveness of the automated robotic robot, Revo-i Surgical Robot System (Model MSR-5100), used for general HBP surgery
224216369|NCT02857374|PROCEDURE|Sentinel Lymph Node Biopsy|Undergo standard of care sentinel node biopsy
224216370|NCT00004187|DRUG|capecitabine|
224216371|NCT00004187|DRUG|oxaliplatin|
224216372|NCT03884933|OTHER|Mobile team community mental health services|The intervention focuses on changing mental health care systems to be able to provide community-based mental health care for people with severe mental illness. This will be done through the development and implementation of multidisciplinary community mental health teams (CMHTs) in each of the implementation sites, consisting of at least one nurse, psychiatrist, psychologist, social worker, and peer worker (person with lived experience of a severe mental illness). The structure and delivery method of the community mental health teams is part of an evidence-based service delivery model providing flexible, assertive community mental health teams providing integrated services to people with severe mental illness (SMI) in order to structurally attain their recovery goals, as well as timely and appropriate care in the event of a crisis.
224216373|NCT04744896|DEVICE|cryolipolysis(3 max cool shaping)|cryolioplysis applied over abdomen area
224216374|NCT04744896|DEVICE|Treadmill (jkexer focus 8020A)|aerobic training ( high intensity interval training)
224216375|NCT05145296|COMBINATION_PRODUCT|Each patient will undergo in the first step of the study belatacept treatment and in the second apheresis and daratumumab|"Four consecutive cohorts each comprising 3 patients are planned. STEP I: Patients receive Belatacept 10mg/kg, administered on days 1, 5, end of week 2, 4 and 8 .~Patients without a significant decrease in the global cPRA (cPRA or TGI ≥99%) or significant reduction of anti-HLA Ab MF will continue to the second step.~STEP II: (15 weeks) One week after the last injection of belatacept, patients will undergo 4 sessions of apheresis (plasmapheresis (PF) or Immunoadsorption (IA)) which will be given every 48h. At week 11, patients will receive 4 doses of daratumumab (8mg/kg) every two weeks until week 17. Daratumumab will be alternated with 4 additional doses of belatacept 5 mg/kg FOLLOW-UP (24 weeks) All patients exiting the study, either having completed all treatment courses or exiting prematurely (transplanted or not), will be proposed monthly follow-up visits"
224317348|NCT04095312|PROCEDURE|Revo-i robotic surgery system (Model MSR-5100)|for evaluating the clinical safety and effectiveness of the automated robotic robot, Revo-i Surgical Robot System (Model MSR-5100), used for general Uro surgery
224317349|NCT04095312|PROCEDURE|Revo-i robotic surgery system (Model MSR-5100)|for evaluating the clinical safety and effectiveness of the automated robotic robot, Revo-i Surgical Robot System (Model MSR-5100), used for general colorectal surgery
224317350|NCT00471952|DRUG|Maxalt 10mg MLT plus Caffeine 75mg|One migraine attack will be treated
224317351|NCT00471952|DRUG|Maxalt 10mg MLT plus Placebo|One migraine attack will be treated with Maxalt 10mg plus placebo
224317352|NCT00471952|DRUG|Placebo + Placebo|One migraine attack will be treated with double placebo
224317353|NCT00198237|DRUG|docetaxel & capecitabine|
224317354|NCT05603377|DIAGNOSTIC_TEST|functional endoscopic evaluation of swallow|functional endoscopic evaluation of swallow
224317355|NCT00006460|DRUG|hyperbaric oxygen|
223627641|NCT06310187|OTHER|Unlit Little Cigar - Group F|Subjects will be provided with an unlit little cigars to use for outcome measure data collection in the lab. This will be the control group for outcome measure data.
223627642|NCT05562128|BEHAVIORAL|Active forest therapy|Participants take part in a two-hour active clinical forest therapy in Berlin-Wannsee on two days (with a break day in between). In this setting, a trained clinical forest therapist teaches exercises on the perception of nature and the connection between nature and health.
223627643|NCT05562128|BEHAVIORAL|Passive forest therapy|Participants take part in a two-hour passive clinical forest therapy in Berlin-Wannsee over two days (with a break day in between). In this setting, a trained clinical forest therapist will guide participants to various locations in the forest where participants can stay and let nature have its effect on them.
224216376|NCT02481479|DRUG|Saxagliptin|Eligible patients will undergo baseline CMR, commence treatment and then after 6 months undergo repeat CMR
224216377|NCT02481479|DRUG|Saxagliptin|Eligible patients will undergo baseline echocardiogram, commence treatment and then after 6 months undergo repeat echocardiogram
224216378|NCT02481479|DRUG|saxagliptin|Eligible patients will undergo baseline venipuncture, commence treatment and then after 6 months undergo repeat venipuncture
223627644|NCT04141605|DEVICE|SherpaPak Cardiac Transport System|"The Paragonix SherpaPak Cardiac Transport System (SherpaPak CTS) is an ultraportable hypothermic preservation and transport system intended for use with donor hearts. The device is a legally marketed, FDA cleared medical device in the United States and CE Marked medical device in the European Union.~The SherpaPak CTS consists of multiple components: 1) outer transport shipper which contains within various non-ice based temperature controlled packaging elements, 2) an inner and outer hard shell assembly which provides a rigid barrier enclosure in which the heart is immersed and suspended in a cold storage solution cleared for use in storing and transporting donor hearts, 3) a data logger that monitors and displays the temperature of the cold storage solution in which the heart is stored during transport, and 4) four size heart connectors designed to accommodate various size aortic stem diameters by which donor hearts are attached."
223627645|NCT03767933|DRUG|Ibuprofen|10mg/kg, maximum 600mg; Oral liquid
223627646|NCT03767933|DRUG|Acetaminophen|15mg/kg, maximum 1000mg; Oral liquid
223627647|NCT03767933|DRUG|Hydromorphone|0.05mg/kg, maximum 5 mg; Oral liquid
223627648|NCT03767933|DRUG|Acetaminophen placebo|Oral liquid
223627649|NCT03767933|DRUG|Hydromorphone placebo|Oral liquid
223627650|NCT06314217|DEVICE|Everads Injector|Single suprachoroidal injection of triamcinolone acetonide, 4 mg in 100 μl using Everads Injector
224216379|NCT00845026|DRUG|LY2140023|80 milligram (mg), oral tablets, twice daily: 40 mg in the morning, 40 mg in the evening, for 24 weeks. The dose may be adjusted to a minimum of 40 mg or a maximum of 160 mg.
224216380|NCT00845026|DRUG|aripiprazole|10 mg, oral tablets, once a day in the evening for three days. Followed by a dose increase to 20 mg, 2-10 mg oral tablets, once a day in the evening, for 23 weeks and 4 days. The dose may be adjusted to a minimum of 10 mg or a maximum of 30 mg (3-10 mg oral tablets).
224216381|NCT00845026|DRUG|olanzapine|10 mg dose (2-5 mg oral tablets) once every evening, for 3 days. Followed by an increase to 15 mg (3-5 mg oral tablets) once every evening, for 23 weeks and 4 days. The dose may be adjusted to a minimum of 10 mg or a maximum of 20 mg (4-5 mg oral tablets).
224216382|NCT00845026|DRUG|risperidone|2 mg dose, 2-1 mg oral tablets, given once or twice a day for 3 days. Followed by an increase to 4 mg (4-1 mg tablets), given once or twice a day, for 23 weeks and 4 days. The dose may be adjusted to a minimum of 2 mg/day or a maximum of 6 mg/day (6-1 mg tablets).
224216383|NCT01517334|DRUG|Minocycline HCl Microspheres|
223627651|NCT03392896|DRUG|DCR-PHXC|DCR-PHXC is a novel, potent, and long-acting small interference ribonucleic acid (siRNA) molecule conjugated to N-acteylgalactosamine (GalNAc) that is designed to decrease liver oxalate production. DCR-PHXC is delivered via subcutaneous (SC) injection.
223627652|NCT03392896|DRUG|Placebo|Single SC administration of placebo, which will be a sterile, preservative-free normal saline 0.9% solution for SC injection, which is of similar osmolality to the DCR-PHXC formulation.
223627653|NCT06204679|DRUG|Bemnifosbuvir (BEM)/Ruzasvir (RZR) FDC under fasting conditions|A Fixed-Dose Combination of Bemnifosbuvir (BEM) and Ruzasvir (RZR)
223627654|NCT06204679|DRUG|Bemnifosbuvir (BEM)/Ruzasvir (RZR) FDC under fed conditions|A Fixed-Dose Combination of Bemnifosbuvir (BEM) and Ruzasvir (RZR)
223627655|NCT06204679|DRUG|Bemnifosbuvir (BEM) and Ruzasvir (RZR) as reference formulation under fasting conditions|Bemnifosbuvir (BEM) and Ruzasvir (RZR) as separate formulations
223627656|NCT04204447|OTHER|Hepatitis C Educational Brochure|Subjects will receive information about Hepatitis C through a brochure
223627657|NCT04204447|OTHER|Hepatitis C Educational Video|Subjects will receive information about Hepatitis C through a video
223627658|NCT04024865|DRUG|Domperidone|Women who received a prescription for domperidone (ATC A03FA03) during the six months following delivery.
223627659|NCT04024865|DRUG|No domperidone|Women with no prescription for domperidone during the six months following delivery.
223627660|NCT06512961|DEVICE|Tissue Flossing|Tissue Flossing ia a elastic band that when applied exerts an external pressure above or below a muscle or joint of the extremities.
224317356|NCT00006460|RADIATION|radiation therapy|
224317357|NCT03193073|DIAGNOSTIC_TEST|detailed echocardiography|Detailed Echocardiography including ejection fraction, interventricular septum thickness, posterior wall thickness, left ventricular end -diastolic and end- systolic diameter and left ventricular mass index will be correlated with body surface area for both groups serum FGF-23
224317358|NCT03193073|DIAGNOSTIC_TEST|serum fibroblast growth factor-23|serum levels of FGF-23
224317359|NCT03193073|DIAGNOSTIC_TEST|flow mediated dilatation of forearm|superficial sonar assess the diameter of brachial vessel on exposure to stress
223627661|NCT06512961|DEVICE|Blood Flow Restriction Cuff|Inflatable device that exerts an external pressure above a muscle or joint of the extremities.
223627662|NCT06512961|OTHER|Training Protocol|The upper limb resistance training protocol will follow that recommended in the study by Patterson et al. for resistance training, and will last 15weeks, with 3 training sessions per week, with a day break between sessions.
223627663|NCT01489319|DRUG|Salsalate|4 out of 10 subjects will receive salsalate 2.0 gm twice a day for 12 weeks; 4 out of 10 subjects will receive PCE 200 mg containing 20% resveratrol twice a day for 12 weeks.
223627664|NCT01489319|DRUG|Salsalate|4 out of the 10 subjects will receive salsalate 2.0 gm twice a day for 12 weeks; 4 out of 10 subjects will receive PCE 200 mg containing 20% resveratrol twice a day for 12 weeks.
223627665|NCT05871541|BIOLOGICAL|JCXH-105|As IM injection
223627666|NCT05871541|BIOLOGICAL|Active Control (Shingrix)|As IM injection
223627667|NCT06005194|BEHAVIORAL|InMotion|A manualized physical activity counseling program that is based on the Diabetes Prevention Program (DPP) that has been adapted for TBI
223627668|NCT00642200|PROCEDURE|Lichtenstein hernioplasty|
223627669|NCT00642200|PROCEDURE|Laparoscopic TEP|
223627670|NCT04489316|OTHER|Narrative medicine curriculum|The curriculum will consist of three sessions in narrative medicine- i.e. discussing texts and poetry, and engaging in reflective writing as a group
223627671|NCT01706458|BIOLOGICAL|sipuleucel-T|Given IV
223627672|NCT01706458|BIOLOGICAL|DNA Vaccine|Given ID
224216384|NCT02393534|OTHER|Telephone Visit|Eligible patients that are randomized to the telephone follow-up arm will have their next medical visit with their primary care provider via a telephone call.
224317360|NCT00151346|DRUG|Bupivacaine and Fentanyl (for CSE)|Bupivacaine 0.25% x 1 cc + Fentanyl 20 mcg, followed by infusion of Bupivacaine 0.0625% with Fentanyl 2 mcg/mL at 12 cc/hr
223627673|NCT04645368|DRUG|bovhyaluronidase azoxymer|3000 IU intramuscularly once every 5 days with a course of 15 injections
223627674|NCT05095636|DRUG|Apatinib Mesylate|oral Apatinib once everyday
223627675|NCT05095636|DRUG|Camrelizumab|intravenous camrelizumab 200mg once every two weeks
223627676|NCT01028443|DRUG|Sandimmune|
223627677|NCT01028443|DRUG|Artelose|
223627678|NCT00176696|DEVICE|Use of FACE monitor and BIS monitor|Face monitor records facial muscle activity
223627679|NCT04557410|DRUG|PolyMVA|"One-half teaspoon of PolyMVA contains the following:~* Daily Value Thiamin (B-1) 23mg 1,533 Riboflavin (B-2) 0.45mg 26 Vitamin B-12 460mcg 7,666 Proprietary Blend 32mg - contains the following ingredients (no FDA value has been established on any of the following): Palladium, Alpha Lipoic Acid, Molybdenum, Rhodium, Ruthenium, Formyl Methionine, N-acetyl Cysteine.~For each ml of Poly-MVA, the exact dosages are as follows:~Palladium: 3.97mg Molybdenum: 0.044mg Ruthenium: 0.0014mg Rhodium: 0.014mg Lipoic Acid: 7.68mg Thiamine (B1): 9.26mg Riboflavin (B2): 0.174mg B12: 0.185mg Formyl Methionine: 0.026mg N-Acetyl cysteine: 0.185mg Vitamin A acetate 100 IU~Other Ingredients: Distilled water, purified water, thiamine hydrochloride, Vitamin B12 as cyanocobalamin."
223627680|NCT03938311|OTHER|early rehabilitation|"The three study groups share a same intervention protocol in addition to the initiation timing of intervention from the stroke onset. The frequency and intensity of the intervention is titrated according to functional activity baseline and monitored daily and adjusted with recovery. Encourage patients to move out of bed as soon as possible.~Definition of bed movement: Encourage and help patients to perform functional actions, focusing on activities such as sitting, standing, walking out of the bed."
223627681|NCT03228446|BEHAVIORAL|filter training|one-week filter training on the computer: computerized visual change detection experiment (selective attention )
223627682|NCT03228446|BEHAVIORAL|memory training|one-week storage training on the computer: computerized visual change detection experiment (memory storage)
223627683|NCT03228446|OTHER|no training (control)|no training applied
223627684|NCT02492035|BEHAVIORAL|Lifestyle intervention|
223627685|NCT00006359|DRUG|LHRH agonist|Lupron: 22.5mg IM injection q 12 wks x 2 OR Zoladex: 10.8 mg subQ injection q 12 wks x 2
223627686|NCT00006359|DRUG|antiandrogen|flutamide 250 mg PO tid for 4 wks OR casodex 50 mg PO daily for 4 wks
224216385|NCT01325532|DEVICE|Active CES|CES current
223627687|NCT00006359|RADIATION|radiation therapy|4500 cGy total dose given days 1-5 for 5 weeks following initiation of androgen suppression (25 fractions)
223627688|NCT00006359|RADIATION|Brachytherapy boost|Iodine 125 0.3 to 0.5 U per seed OR palladium 103 1.04 to 1.4 U per seed as implant; prescribed dose of I-125 100 Gy (TG-43) and Pd-103 90 Gy
223627689|NCT00702481|DRUG|Nimotuzumab|Patients will receive nimotuzumab 200 mg weekly for 8 weeks. Nimotuzumab will be started together with concurrent chemoradiation, and continued 1 week after the completion of chemoradiation.
223627690|NCT00702481|DRUG|Cisplatin|Concurrent chemotherapy with cisplatin 100 mg/m2 will be given on week 1, 4, and 7 of radiotherapy.
223627691|NCT00702481|RADIATION|Radiation|Concurrent radiotherapy will be given to the primary tumor and upper neck at 2 Gy per fraction, once a day, five days a week to a total of 70 Gy in 35 fractions in seven weeks.
223627692|NCT00907426|DRUG|Bimatoprost 0.03% solution|Once daily, one drop of Bimatoprost 0.03% solution using a single-use per eye applicator will be applied to the upper eyelid margin (where the eyelashes meet the skin).
223627693|NCT00907426|DRUG|Vehicle solution|Once daily, one drop of vehicle solution using a single-use per eye applicator will be applied to the upper eyelid margin (where the eyelashes meet the skin).
223627694|NCT00375063|PROCEDURE|Percutaneous Coronary Intervention|
224216386|NCT01325532|DEVICE|Sham CES|Sham CES (device off) for 20-minutes each day 5 days/week for 3 weeks.
224216387|NCT04032275|OTHER|Chronic hepatitis B infection|Chronic hepatitis B infection patients
224216388|NCT03580759|BEHAVIORAL|PREHAB|After three supervised training sessions, subjects will be asked to participate in a daily exergaming activity tailored to their physical activity capabilities and needs. Subjects will be taught to rate their perceived exertion and monitor their target heart rate using a Fit Bit Charge HR. Daily exercise diaries will be used to monitor subject-perceived progress throughout the intervention period.
224216389|NCT03012815|DRUG|Gabapentin|Gabapentin administered as a taper
224216390|NCT03012815|DRUG|Benzodiazepines|Benzodiazepines administered using a symptoms triggered protocol
224216391|NCT03012815|DRUG|Divalproex Sodium|Given in addition to gabapentin in high risk patients (i.e. seizures, TBI history, DT history)
224216392|NCT00889785|BEHAVIORAL|Comprehensive intervention (disease management program)|The intervention will include participation in a comprehensive disease management program that includes: (1) application of treatment algorithms, (2) phone assessment from a diabetes nurse practitioner and dietician to assess barriers and promote problem solving, treatment adherence and management, and (3) a behavioral Internet-administered self-management problem solving component.
224317361|NCT00151346|DRUG|Bupivacaine and Fentanyl (for traditional epidural)|Bupivacaine 0.0625% with Fentanyl 2 mcg/mL x 15 cc, followed by infusion of Bupivacaine 0.0625% with Fentanyl 2 mcg/mL at 12 cc/hr
224317362|NCT03766412|OTHER|High School start time|The time that the school starts
223627695|NCT00375063|PROCEDURE|Coronary Artery Bypass Grafting|
223627696|NCT05672654|DIAGNOSTIC_TEST|Blood draw|Blood draw
223627697|NCT02314468|PROCEDURE|Negative pressure wound therapy|NPWT changed twice a week.
223627698|NCT02314468|PROCEDURE|Glycerol Preserved Allografts (GPA)|GPA changed every 7 to 10 days.
224317363|NCT03597464|DRUG|Voclosporin|Calcineurin inhibitor, oral, 23.7 mg twice daily (BID)
224216393|NCT00889785|BEHAVIORAL|Usual Care|Will receive usual care and monthly phone calls as an active control.
224216394|NCT03957278|DEVICE|DAISe System|The DAISe System is indicated for revascularization of patients with acute ischemic stroke for the removal of fresh thrombi from vessels in the neurovasculature.
224216395|NCT04627220|DIAGNOSTIC_TEST|taken venous sample|Venous blood samples taken during the operation and at the 48th hour after the operation will be examined after appropriate procedures.
224216396|NCT05178147|DEVICE|Compression bandaging without reference to GraduCheck pressure measurements|To apply compression bandages to legs of volunteers without guidance from the Graducheck device (that lies below the bandages) to assess use of the device.
224216397|NCT05178147|DEVICE|Compression bandaging using GraduCheck pressure measurements to monitor compression pressure|To apply compression bandages to legs of volunteers using the guidance from the Graducheck device (that lies below the bandages) to assess use of the device.
224216398|NCT01252238|DRUG|Aliskiren|Aliskiren 150 mg daily for 10 weeks, force titrated after initial 2 weeks.
224216399|NCT01252238|DRUG|Valsartan and Aliskiren|Subject taking combination of valsartan and aliskiren.
223627699|NCT05989581|DRUG|Labetalol or Nifedipine|The choice of anti-HTN will be based on the patient and provider's experience and preference. First line anti-HTN recommended in pregnancy- labetalol or nifedipine- will be administered to patients. At least weekly, a study team member will review the participants' BPs and, if randomized to intervention and a higher dose is needed to maintain BPs \<130/80 mmHg, the study team member will communicate with the clinical team, led by a University of Alabama Maternal Fetal Medicine Attending, in order to ensure coordination between the research and clinical care teams. Labetalol will be initiated at 200 mg twice daily and escalated in 200mg /dose daily until BP\<130/80mmHg to a maximum dose of 2400mg/day. Procardia will be initiated at 30mg XL once daily and uptitrated in 30mg increments until a maximum dose of 120mg daily. Postpartum, titration will occur in similar fashion. The patient will be transitioned to her primary care provider for BP management after the 6-week postpartum visit.
223627700|NCT02956395|OTHER|Integrated care intervention|"Integrated care intervention is implemented by a multidisciplinary team from the hospital and from the Primary Care.~The intervention after hospital discharge a) Phone call at 24 hours; b) Home visit at 72 hours after discharge by one member of the transitional care team, if is needed; During this visit, the therapeutic plan for each patient will be customized to their individual frailty factors and shared with the primary care team. Reinforcement of the logistics for treatment of co-morbidities and social support will be done accordingly; c) Accessibility to the point of care available 24 hours/day ; d) Accessibility to the individualized PHF, as self-management tool ; d) appointment at 1m after discharge and after 12 m"
223627701|NCT04962711|OTHER|Heart Failure intervention (Cardio-Oncology Disease Management Plan (CO-DMP)|A clinical review to ensure optimal risk factor control and cardioprotection along with exercise intervention.
223627702|NCT04962711|OTHER|Usual care|provided by participants' usual healthcare professional(s)
224216400|NCT01252238|DRUG|Amlodipine|Taking Amlodipine as prescribed by MD for management of high blood pressure.
224216401|NCT05827900|BEHAVIORAL|Metacognitive Training|Minimum of 6 sessions; but planned 10-12 sessions of metacognitive group training
224216402|NCT02467088|OTHER|Individualised Homeopathic Remedy|Each participant will receive an individualised homoeopathic remedy prescribed according to the individualised symptoms of their PMS.
224216403|NCT02065791|DRUG|Canagliflozin|One 100 mg over-encapsulated tablet orally once daily
224216404|NCT02065791|DRUG|Placebo|One matching placebo capsule orally (by mouth) once daily
224216405|NCT00272961|DRUG|Placebo|placebo tablet once daily for 12 weeks
224216406|NCT00272961|DRUG|TBC3711|10 mg tablets once daily for 10 weeks
224216407|NCT00272961|DRUG|TBC3711|50 mg tablet once daily for 10 weeks
224216408|NCT00272961|DRUG|TBC3711|100 mg tablet once daily for 10 weeks
224216409|NCT00272961|DRUG|TBC3711|200 mg tablet once daily for 10 weeks
224216410|NCT01090128|DRUG|Nanoparticle Albumin Bound Paclitaxel|IV administered over 30 minutes. 100 mg/m2 on days 1 and 8
224216411|NCT01090128|DRUG|doxorubicin|50 mg/m2 every 3 weeks
224216412|NCT01090128|DRUG|cyclophosphamide|500 mg/m2 given every 3 weeks
224216413|NCT00772252|OTHER|liver support treatment|plasma exchange for liver support treatment
224216414|NCT05603078|RADIATION|Preoperative MRI-guided tumor-bed boost and postopreative ultra-hypofractionated radiotherapy (26 Gy/5.2Gy/5)|Preoperative tumor-bed boost was performed under MRI Linac, and a single dose of 10Gy is prescribed. The postoperative radiotherapy of 26Gy/5.2Gy/5 fractions is within 6 weeks following surgery. Adjuvant chemotherapy, targeted therapy and endocrine therapy are initiated no more than 12 weeks after surgery.
224216415|NCT00390156|BIOLOGICAL|bevacizumab|5 mg/kg
224216416|NCT00390156|DRUG|cyclophosphamide|Current dose 50 mg
224216417|NCT00390156|DRUG|imatinib|Current dose 400 mg
224216418|NCT00618423|DRUG|Placebo|50 ml syringes provided by the HUG pharmacy will contain 1% ketamine or 0.9% NaCl. After induction and before start of surgery, patients will receive an intravenous bolus of 0.025 ml/kg of the study solution (corresponding to 0.25 mg/kg ketamine). Maintenance will be with a syringe driver at a rate of 0.025 ml/kg/h (corresponding to 0.25 mg/kg/h ketamine) until one hour before the end of surgery, and will then be decreased to a rate of 0.01 ml/kg/h (corresponding to 0.1 mg/kg/h ketamine) throughout the stay in the recovery room (usually 2 to 3 hours). The infusion will be stopped when the patient leaves the recovery room.
224216419|NCT00618423|DRUG|Ketamine|50 ml syringes provided by the HUG pharmacy will contain 1% ketamine or 0.9% NaCl. After induction and before start of surgery, patients will receive an intravenous bolus of 0.025 ml/kg of the study solution (corresponding to 0.25 mg/kg ketamine). Maintenance will be with a syringe driver at a rate of 0.025 ml/kg/h (corresponding to 0.25 mg/kg/h ketamine) until one hour before the end of surgery, and will then be decreased to a rate of 0.01 ml/kg/h (corresponding to 0.1 mg/kg/h ketamine) throughout the stay in the recovery room (usually 2 to 3 hours). The infusion will be stopped when the patient leaves the recovery room.
224216420|NCT00748813|BIOLOGICAL|Influenza Vaccine, Formulation 2008-2009|1 dose of Surface Antigen, Inactivated, Influenza Vaccine, Formulation 2008-2009
224216421|NCT02921347|PROCEDURE|switching between invasive and noninvasive ventilation|As defined criteria, patients are switched between invasive and noninvasive ventilation until the ventilator is successfully weaned.
224317364|NCT03597464|DRUG|Placebo Oral Capsule|Voclosporin placebo, oral, 3 capsules twice daily (BID)
224216422|NCT02265887|OTHER|standard of care|No intervention, this a patient registry and is purely an observational study
224216423|NCT01377961|DRUG|Randomized pills either containing combination of lycopene and isoflavones (dietary supplements) or Placebo to be taken for 12 weeks|"After the screening and OGTT, the treatment group each subject will be in is decided by randomization. Neither subject nor the researchers will be allowed to choose which group a subject is assigned to. A single patient/subject cannot be assigned more than 1 allocation number. Each subject will be assigned randomly (like drawing straws) to receive either on the pills containing the combination of 6mg lycopene and 50mg isoflavones or placebo. Each subject has a 1 in 2 chance of receiving one of these treatments.~The subject are advised to take one capsule of Laflavon/Placebo by mouth daily for 12 weeks."
224216424|NCT01377961|OTHER|Screening|Volunteer will be screened as an out patient with a history, physical examination, baseline fasting plasma glucose or A1C, creatinine, AST/ALT, TSH. We may utilize the lab results of the subject available upto 3months prior to the consent date. Pregnancy tests will be performed for female candidates. Information of the level of physical activity, diet, supplements and medications will be obtained.
224216425|NCT01377961|OTHER|OGTT|OGTT will be done after the screening at Baseline and at the completion of the 12 weeks of taking the supplements by the subject.
224216426|NCT01377961|OTHER|Anthropometrics and Blood pressure|Measurements of height, weight, hip, waist and Blood Pressure are done before and after 12 weeks of taking the supplements.
224216427|NCT01377961|OTHER|Screening|Volunteer will be screened as an out patient with a history, physical examination, baseline fasting plasma glucose or A1C, creatinine, AST/ALT, TSH. We may utilize the lab results of the subject available upto 3months prior to the consent date. Pregnancy tests will be performed for female candidates. Information of the level of physical activity, diet, supplements and medications will be obtained.
224216428|NCT01377961|OTHER|Blood Drawing|The blood will be drawn at the baseline and at the completion of the 12 weeks of taking the capsules of laflavon /placebo.
224216429|NCT00001428|DRUG|5-fluorouracil|
224216430|NCT01840683|DEVICE|H.E.L.P. therapy (H.E.L.P. Plasmat Futura System)|
224216431|NCT05480527|DEVICE|Transcutaneous pulsed radiofrequency current|Active treating group: 80 volts, 2Hz, 20 ms pulsed radiofrequency current will be applied to the tibial nerve trace in the ankle with electrodes. Sham group: Elelctrodes will be attached but radiofrequency current will not be applied.
224216432|NCT01796431|DRUG|Eviplera®|
224216433|NCT05153291|PROCEDURE|Bachmann's bundle lead placement|Atrial lead placement at Bachmann's bundle area
224216434|NCT05153291|PROCEDURE|Right atrial appendage lead placement|Atrial lead placement in the right atrial appendage
224216435|NCT03675191|DRUG|Orlistat 120Mg Cap|Drug,Orlistat 120Mg Cap, three times a day, within 1hour after meal
224216436|NCT03675191|DRUG|Phentermine Pill|Drug,Phentermine Pill 37.5mg, both in two arms, one time a day, within 1hour after meal
224216437|NCT05114226|DRUG|Tetrahydrobiopterin|BH4 was applied when skin damage≥ Grade I occurred. A sterile gauze was soaked with BH4 solvent, wringed out, and applied to the treated skin area for 15 minutes. It was applied three times a day (morning, noon, and evening), until three months after the end of treatment.
224216438|NCT01423565|DEVICE|Deep Brain Stimulation (Medtronic, Activa PC)|"Following subthalamic nucleus deep brain stimulation patients will be randomized to receive either constant current or constant voltage stimulation and subsequently crossed over to receive the other type of stimulation"
224216439|NCT05450666|OTHER|mobility exercises|Before starting the exercise program, a video and exercise program including the importance of shoulder mobilization and stabilization and the knowledge of how to contract the right muscle groups will be shared in order to raise awareness of the athletes. Following the evaluations, in addition to the classical training programs, the athletes will perform the Wall Angels and Anterior Shoulder Stretch, Shoulder Circle Rotation, Prone Shoulder Controlled Articular Rotations and Shoulder Side Stretch exercises, Prone I, T, W, Y's 3 days a week for 8 weeks, accompanied by the same physiotherapist.
224216440|NCT06259942|OTHER|İntervention 1 group (underbody heater group only)|Resistive heaters can be set to 38-40°C and are used together with the control unit to which they are connected. In the study, an underbody heater (MEDWARM W 300 IM 190MS branded) system measuring 1900x500x40mm was used. In this study, the underbody heater was set to 38°C for patients. Before use, a surgical drape was placed over it to prevent direct patient contact.
223627703|NCT05817890|DRUG|Fadraciclib|Open-label Study of the Absorption, Metabolism, and Excretion of \[14C\]-CYC065 Following a Single Oral Dose in Healthy Male Subjects
224216441|NCT06259942|OTHER|İntervention 2 group (group using both underbody heater and heated iv liquid)|IV fluids should be warmed to protect patients from unwanted hypothermia during surgery. One liter of saline solution given at room temperature decreases body temperature by 0.25˚C in adults. Therefore, the fluids given to the patient should be heated to 33 40˚C. In the guideline published by the Turkish Anesthesia Society, it is stated that if more than 1000 2000 mL of fluid is to be given to patients, it should be heated at 37°C (TARD, 2013). In this study, both IV fluids were heated between 37 and 39°C and given to the patient and heated with carbon fiber underbody heaters.
224216442|NCT06259942|OTHER|Control Group|no active heating treatment was applied in this group
224216443|NCT03857685|PROCEDURE|In-vitro model|In-vitro model of posterior capsule opacification by culturing the lens capsule
224216444|NCT01947556|DRUG|insulin aspart|After hyperglycaemia (18-23 mmol/l) has been reached (by decreasing or interrupting exogenous insulin administration 12-24 hours before the experiment), aspart insulin (in a dose of 1.5 times the amount of insulin needed to reduce blood glucose to 6 mmol/l calculated by the insulin-sensitivity factor) will be administered subcutaneously by Insujet pen or conventional insulin pen, on two separate occasions, or vice versa. The injection will be given by the subject under supervision of the research staff.
223627704|NCT04592874|DRUG|AL002|Administered via intravenous (IV) infusion
223627705|NCT04592874|DRUG|Placebo|Administered via intravenous (IV) infusion
223627706|NCT06222866|DIAGNOSTIC_TEST|Anticoagulation monitoring|Evaluation of different monitoring modalities to find the most appropriate anticoagulation monitoring tool for UFH therapy
223627707|NCT05361395|DRUG|Tarlatamab|Tarlatamab will be administered as an intravenous (IV) infusion.
223627708|NCT05361395|DRUG|Carboplatin|Carboplatin will be administered as an intravenous (IV) infusion.
223627709|NCT05361395|DRUG|Etoposide|Etoposide will be administered as an intravenous (IV) infusion.
224216445|NCT02236156|DRUG|Metronidazole oral tablets 500mg|One tablet taken orally twice daily for seven consecutive days
224216446|NCT02236156|DRUG|1% SPL7013 Gel|5g inserted in to the vaginal on alternate days (i.e. every other day) for 16 consecutive weeks.
224216447|NCT02236156|DRUG|Placebo gel|5g inserted in to the vagina on alternate days (i.e. every other day) for 16 consecutive weeks
224216448|NCT04816188|OTHER|Exercise Therapy and Activity Modification|Daily lower leg strengthening exercises Therapy and pain-guided activity modification.
224216449|NCT03315156|DIAGNOSTIC_TEST|Electrogustometery|Taste assessment using EGM
224216450|NCT04534192|DEVICE|JADE Balloon|Suitable TASC C and D lesions will be treated with non-compliant high pressure JADE balloon.
224216451|NCT00130481|DRUG|Atorvastatin 20 mg daily for 3 months|
224216452|NCT04882683|DRUG|Prednisone|0.75 mg per kilogram per day for three months
224216453|NCT04882683|DRUG|Azathioprine|1 mg per kilogram per day for three months
224216454|NCT04882683|DRUG|Adalimumab|40mg every two weeks for three months
224216455|NCT04882683|BIOLOGICAL|umbilical cord blood mononuclear cells|Peripheral intravenous infusion method, infusion of umbilical cord blood mononuclear cell suspension 50ml (cell number 2×10\^8).
224216456|NCT03077633|PROCEDURE|Cervical Cerclage placement|Cervical Cerclage placement
224216457|NCT03077633|DRUG|Vaginal Progesterone|200mg tab of vaginal progesterone administered daily from time of randomization until delivery.
224216458|NCT06537492|PROCEDURE|REBOA|"The REBOA device used in this study will be a computer-aided aortic balloon occlusion catheter with safety feedback and automatic inflation and deflation. The device will be used to temporarily inflate a balloon in the descending aorta through a femoral artery introducer sheath which, when inflated, redirects blood flow to the central circulation.~The REBOA will be inserted into the aorta via the femoral artery through an introducer sheath. Once positioned, the balloon will be inflated to occlude the aorta. The REBOA assistant will be attached to the patient's skin with the adhesive on the underside of the assistant."
224317365|NCT01796938|DRUG|Lacosamide tablet|Single dose of 100 mg Lacosamide tablet
224317366|NCT02128061|DRUG|Lenalidomide|
224317367|NCT02128061|DRUG|Rituximab|
224317368|NCT04197661|DRUG|HSK3486|Intravenously infuse 0.2 mg/kg HSK3486 in the morning on an empty stomach. Complete infusion within 1 min.
224317369|NCT04197661|DRUG|HSK3486|Intravenously infuse 0.3 mg/kg HSK3486 in the morning on an empty stomach. Complete infusion within 1 min.
224317370|NCT04197661|DRUG|HSK3486|Intravenously infuse 0.4 mg/kg HSK3486 in the morning on an empty stomach. Complete infusion within 1 min.
224317371|NCT04197661|DRUG|HSK3486|Intravenously infuse 0.4 mg/kg HSK3486 in the morning on an empty stomach. Complete infusion within 1 min.
224317372|NCT01371383|DIETARY_SUPPLEMENT|n-3 fatty acids|EPA 1680 mg/d + DHA 880 mg/d
224216459|NCT06537492|DEVICE|Head-Up Cardiopulmonary Resuscitation (AHUP-CPR)|Conventional CPR will be performed using an automated head and chest elevation device during cardiopulmonary resuscitation (AHUP-CPR).
224216460|NCT06537492|DEVICE|Mechanical Chest Compression Device with Active Chest Decompression|In addition to head and thorax elevation, mechanical chest compression will be performed with active chest compression-decompression using a specific mechanical chest compression device.
224216461|NCT06537492|DEVICE|Impedance Threshold Device|In addition to REBOA, AHUP-CPR and ACD, an impedance threshold device will be used with a dedicated device.
224216462|NCT04696562|BEHAVIORAL|Deep Breathing Exercise with Triflo|The investigators will do deep breathing exercises 5-10 times an hour with the triflo device.
224216463|NCT01203774|DRUG|Glargine insulin|20-180 units per day
224216464|NCT03909321|BEHAVIORAL|Beach tennis training group|Beach Tennis Training Group (BTG) will perform two sessions of 40-60 min of beach tennis during 12 weeks. BT sessions will be composed by a warm up of 5-10 min of BT technical exercises (i.e., serve, volley, forehand and backhand exercises) followed by 3 BT small games of 10-15 min each.
224216465|NCT03058497|DEVICE|Temperature-Controlled Laminar Airflow Device (Airsonett®)|
224216466|NCT02309203|DEVICE|FRED|Flow Re-Direction Endoluminal Device
224216467|NCT05907200|OTHER|combination ultrasound therapy and manual therapy|The proposed manual therapy lasted 90 minutes and involved a combination of three different techniques: McMennel manipulation, connective tissue massage and mobilization technique of pumping. Patients in the treatment group also received a treatment with US (I-Tech medical device certified UT2 CE0476) in combination with manual therapy. Dipping technique was applied with a frequency of 1 MHz, intensity of 1W/cm2, duty cycle of 60% and a duration of 15 minutes per session.
224216468|NCT05907200|OTHER|manual therapy|manual treatment lasting 90 minutes which involved a combination of three different techniques: McMennel manipulation, connective tissue massage and pumping mobilization technique.
224216469|NCT03932487|OTHER|urinary iodine and urine BPA|urinary iodine and urine BPA
224216470|NCT06129552|PROCEDURE|Conchotomy, aesthetic nose surgery or functional endoscopic sinus operation|Conchotomy involves the reduction or removal of hypertrophic nasal turbinates, aesthetic nose surgery is a surgical procedure that aims to enhance the appearance of the nose, while functional endoscopic sinus surgery is a minimally invasive procedure focused on treating sinus conditions by removing obstructions and improving sinus drainage.
224216471|NCT02565485|DRUG|Lactated Ringer's|1500 cc of IV Fluid (crystalloid) used for preload prior to epidural administration in the treatment arm. Control arm receives 500 cc.
224216472|NCT05730985|DIETARY_SUPPLEMENT|Miotrof® formula|1 sachet per day for 4 months
224317373|NCT01371383|DIETARY_SUPPLEMENT|placebo|Soybean oil
224317374|NCT05852561|OTHER|Group Superficial+Deep Serratus Anterior Plan Block|The block will be performed after induction of general anesthesia and surgical positioning. 15 ml of 0.375% Bupivacaine + epinephrine 5 µg/ml will be administered between the serratus anterior and latissimus dorsalis muscles. The same concentration of block fluid will be applied between the serratus anterior and the outer intercostal muscle.
224317375|NCT05852561|OTHER|Group Deep Serratus Anterior Plan Block|30 ml 0.375% Bupivacaine + epinephrine 5 µg/ml will be administered between the serratus anterior and outer intercostal muscle.
224317376|NCT02143076|BEHAVIORAL|Demographic Questionnaire|At study enrollment, participants will complete a questionnaire to collect demographic information about the participant's family background, education and living situation.
223627710|NCT05361395|DRUG|Atezolizumab|Atezolizumab will be administered as an intravenous (IV) infusion.
224216473|NCT05730985|DIETARY_SUPPLEMENT|Placebo formula|1 sachet per day for 4 months
224216474|NCT04981405|BIOLOGICAL|COVID-19 Vaccines|"Gam-COVID-Vac EpiVacCorona COVIVAC"
224216475|NCT02845102|OTHER|Pre-Post Feasibility|The feasibility testing phase will include 25 subjects. Total duration of pre-post feasibility testing will be 6 weeks upon retrieval of the RA-CBT tablet and follow up questionnaires, quantitative exit interview, and/or an optional extended qualitative exit interview. The extended exit interview is a qualitative semi-formal interview focusing on gathering participant experiences working with the intervention, the barriers and facilitators encountered, as well as overall feedback for the pre-post feasibility study and the relational agent.
224216476|NCT02169583|DRUG|GSK1325756 Solution|Solution containing 2 mg/mL GSK1325756 in sterile water for injection, to be administered intravenously.
224216477|NCT02169583|DRUG|GSK1325756 Solution Matching Placebo|Solution containing sterile water for injection matching GSK1325756 solution, to be administered intravenously.
224216478|NCT02169583|DRUG|GSK1325756 Tablet|A white film coated tablet containing 50 mg GSK1325756 to be administered orally.
224216479|NCT02169583|DRUG|GSK1325756 Tablet Matching Placebo|A white film coated tablet matching GSK1325756 tablet, to be administered orally.
224216480|NCT01610167|DEVICE|NUPRO Classic Prophy Paste|Abrasive, flavored dental prophylaxis paste for cleaning and polishing teeth.
224216481|NCT01610167|DEVICE|NUPRO Sensodyne Prophy Paste with Novamin with fluoride.|Abrasive, flavored dental prophylaxis paste for cleaning and polishing teeth.
224216482|NCT01610167|DEVICE|NUPRO Sensodyne Prophy Paste with Novamin without fluoride.|Abrasive, flavored dental prophylaxis paste for cleaning and polishing teeth.
224216483|NCT05483439|DRUG|cytotoxic chemotherapy (docetaxel or epirubicin or cyclophosphamide or carboplatin)|Drug: cytotoxic chemotherapy (docetaxel or epirubicin or cyclophosphamide or carboplatin)
224216484|NCT05483439|DRUG|anti-Her2 monoclonal antibody (Trastuzumab, Pertuzumab)|anti-Her2 monoclonal antibody (Trastuzumab, Pertuzumab)
224216485|NCT05483439|DRUG|traditional herbal medicine|traditional herbal medicine
224216486|NCT05339828|PROCEDURE|unroofing curettage|Surgery was performed with the patient lying in the prone position under local anesthesia. The tract was identified by passing small artery forceps along its length and was then opened by cutting directly down onto the forceps. The sinus and all its tracts were completely unroofed, and the base was curetted to remove all necrotic content, hair, and granulation tissue using a dry gauze. The fibrotic back wall was left as intact as possible to avoid delayed healing. Hemostasis was achieved using diathermy with no drainage needed.
223627711|NCT05361395|DRUG|Durvalumab|Durvalumab will be administered as an intravenous (IV) infusion.
224216487|NCT03662711|DRUG|Bronchodilator Agents|Fluticasone furoate/vilanterol
224216488|NCT03662711|DRUG|Bronchodilator Agents|Tiotropium
224216489|NCT03662711|DRUG|Bronchodilator Agents|Indacaterol
224216490|NCT03662711|DRUG|Bronchodilator Agents|Umeclidinium/vilanterol
224216491|NCT03662711|DRUG|Bronchodilator Agents|Fluticasone propionate/salmeterol
224216492|NCT03662711|DRUG|Bronchodilator Agents|Beclometasone dipropionate/formoterol
224216493|NCT03662711|DRUG|Bronchodilator Agents|Budesonide formoterol
224216494|NCT03662711|DRUG|Bronchodilator Agents|Glycopyrronium
224216495|NCT03662711|DRUG|Bronchodilator Agents|Aclidinium
224216496|NCT03662711|DRUG|Bronchodilator Agents|Umeclidinium
224216497|NCT03662711|DRUG|Bronchodilator Agents|Formoterol
224216498|NCT03662711|DRUG|Bronchodilator Agents|Indacaterol glycopyrronium
224216499|NCT03662711|DRUG|Bronchodilator Agents|Salmeterol
224216500|NCT03662711|DRUG|Bronchodilator Agents|Tiotropium olodaterol
224216501|NCT03662711|DRUG|Bronchodilator Agents|Aclidinium/formoterol
224216502|NCT03662711|DRUG|Bronchodilator Agents|Olodaterol
224216503|NCT03662711|DRUG|Bronchodilator Agents|Formoterol/glycopyrronium bromide/beclometasone dipropionate
224216504|NCT03662711|DRUG|Bronchodilator Agents|Fluticasone furoate/umeclidinium bromide/vilanterol
224216505|NCT05377866|OTHER|Remote proctoring using HoloLens|Assess Microsoft HoloLens as an interactive communication device in remote proctoring, and enhancement of teamwork in complex CTO procedures.
224216506|NCT05517005|DIETARY_SUPPLEMENT|Hype Bites Supplement|"The ingredients of the vitamin supplement are:~Chocolate liquor Sugar Cocoa butter Vanilla extract Vitamin B12 (as methylcobalamin) Tapioca Gum arabic Coloring (radish, apple, black currant) Carnauba Wax"
223627712|NCT02384551|OTHER|Dietary Carbohydrate|9 week menu of dietary carbohydrate modification
223627713|NCT04088877|BEHAVIORAL|Exercise|The participants will attend the exercise facility at Wellspring two times a week. Sessions are completed under the supervision of an exercise physiologist and the duration of each session ranges from 1.0 - 1.5 hours. Each session includes a warm up on an aerobic exercise machine, a full body progressive RET program followed by balance and stretching exercises.
223627714|NCT04088877|BEHAVIORAL|Art Sculpting Class|The sculpting program will take place once a week for 2 hours over an 8-week period. Sessions will be themed around body image and facilitated by an artist and registered psychologist who will lead the group in art techniques and self-reflection, respectively. Each group session will focus on a theme related to body image, and the participants will have the opportunity to reflect through their art and social interactions with one another.
223627715|NCT04297904|BEHAVIORAL|Sedentary behaviour|To assess sedentary behaviour each participant will wear an activity monitor (PAL Technologies, Scotland). The resident will wear the monitor on their right thigh for 24 hours per day over seven days continuously.
223627716|NCT04297904|DIAGNOSTIC_TEST|Urinary Incontinence|The presence of IU, assessed by the Minimum Data Set (MDS) version 3.0, and used together with the International Consultation on Incontinence Questionnaire-Short Form to characterize the incontinence.
223627717|NCT03679923|DIETARY_SUPPLEMENT|NEM® brand eggshell membrane|Dietary supplement for the support of joint health.
223627718|NCT03679923|DIETARY_SUPPLEMENT|Placebo|Placebo
223627719|NCT06350032|DRUG|preservative-free parenteral treprostinil|Continuous infusion of either SC or IV preservative-free treprostinil. The dosing is not stipulated by the study protocol and will be done according to patient needs.
223627720|NCT05442749|DRUG|Niraparib|"Eligible patients will receive niraparib once daily, per os, continuously until loss of clinical benefit, unacceptable toxicity, death, patient or physician decision to withdraw, or pregnancy, whichever occurs first.~300 mg/day, continuously for patients with TB \>1.5- 3 ULN and/or ASAT/ALAT ≤5ULN.~Or 200mg/day initial dosing for patients with TB \>1.5 ULN and up to 3ULN and/or ASAT/ALAT \> 2.5 ULN and up to 5 ULN with increase to 300mg/day if 1) liver safety lab tests improve to Grade 1 according to NCI criteria (based on total bilirubin and AST/ALT) with bilirubin \< 1.5ULN) and 2) no grade \>1 related AE are reported."
223627721|NCT04935034|DIETARY_SUPPLEMENT|Vitamin D supplement|This intervention will compare the effect of changing the lipid component of a vitamin D enriched dairy drink on postprandial change in 25OHD concentrations.
223627722|NCT06579768|DIAGNOSTIC_TEST|different types of computed tomography (CT) scans|For enrolled patients with jaw cystic lesions, depending on their group, either a maxillofacial spiral CT scan or a cone beam CT scan is performed before surgical treatment.
223627723|NCT05164120|DRUG|Belnacasan|Oral administration
223627724|NCT05164120|DRUG|Placebo|Tablet containing 0mg of API
223627725|NCT05682625|OTHER|No intervention|No intervention
223627726|NCT04853173|OTHER|Assess pain management modalities in adult outpatient tonsillectomy surgery|use a post-operative analgesia protocol suitable for outpatient surgery. Namely a protocol of analgesia based on the taking of drugs per bone (by mouth) and not intravenous. Pain evaluation.
223627727|NCT06211114|DRUG|PD-(L)1 inhibitor|Toripalimab 240mg or Tirelizumab 200mg or pembrolizumab 200mg intravenously every 3 weeks
223627728|NCT06211114|DRUG|Axitinib|axitinib 5mg orally twice daily
223627729|NCT04192565|DEVICE|ColubrisMX Endoluminal Surgical (ELS) System|Robotic Transanal Endoluminal Resection of Colorectal Lesions using the ColubrisMX Endoluminal Surgical (ELS) System
224216507|NCT06235645|DIAGNOSTIC_TEST|Lung ultrasound (LUS)|"If included, an LUS will be performed by an experienced operator, blinded to the results of the chest CT and PFT.~A linear probe (4 to 12 MHz) will be used. The patient will be installed́ in a semi-seated position with the homolateral arm above the head for the anterior and axillary evaluation then, depending on his comfort, in a seated position or in right then left lateral decubitus, arms alongside the body, for the posterior evaluation. It will be practiced by experienced operators (pneumologist) and according to a validated protocol allowing the exploration of 14 intercostal spaces. LUT will be timed, recorded and anonymized.~The operator will note the 3 ultrasound signs (total number of B lines, pleural line thickening and percentage of pleural line irregularity), their location and severity.~The radiologist, on his part, will evaluate the patient's chest CT (gold standard), blinded to the results of the LUS, to make or not the diagnosis of RA-ILD."
224216508|NCT00424931|DRUG|JNJ-17216498|50mg one time
224216509|NCT00424931|DRUG|JNJ-17216498|10mg one time
224216510|NCT00424931|DRUG|Modafinil|200 mg X 2
224216511|NCT01847625|OTHER|simulator|
224216512|NCT01399073|BEHAVIORAL|virtual reality setup|testing for neglect in a virtual reality setup
224216513|NCT01399073|BEHAVIORAL|paper and pencil tests|testing for neglect with the classical paper-and-pencil tests
224216514|NCT01399073|OTHER|c-mri|structural and functional (resting state) imaging
224216515|NCT00420355|DRUG|atazanavir|Atazanavir 300 mg daily on Days 6-12.
224216516|NCT00420355|DRUG|lopinavir/ritonavir|Lopinavir/ritonavir 400 mg/100 mg twice daily on Days 6-16, then 800 mg/200 mg daily on Days 17-21.
223627730|NCT02439853|BEHAVIORAL|Monthly Check-in Session|Subjects in the Check-In group will have an online session with a speech-language pathologist 3-, 4-, and 5-months from the subject's enrollment date.
223627731|NCT04742556|DRUG|BI 3011441|BI 3011441
223627732|NCT03631940|PROCEDURE|Umbilical Cord Milking|At delivery, the umbilical cord is grasped, and blood is pushed toward the infant 4 times before the cord is clamped. This procedure infuses a placental transfusion of blood into the infant and can be done in 15-20 seconds.
223627733|NCT03631940|PROCEDURE|Early Cord Clamping|The umbilical cord is clamped within 60 seconds of delivery.
223627734|NCT03789669|DEVICE|IntraLase iFS femtosecond laser and patient interface|Commercial ophthalmic laser surgical system
223627735|NCT03789669|DEVICE|Cheetah femtosecond laser and cheetah patient interface|Ophthalmic laser surgical system
223627736|NCT04206124|PROCEDURE|Brown Fat Harvest During Anterior Neck Surgery|During previously indicated thyroid gland removal or anterior cervical spine surgery, as scheduled at UNMHSC, the surgeon will identify the large muscle on the side of the neck in the surgical field. Using minimal dissection adjacent to the muscle, they will then remove 5-10mg of brown fat from this region. These samples will be further analyzed using various biochemical tools.
223627737|NCT06306105|DIETARY_SUPPLEMENT|Marine Collagen Peptides|consume 1 bottle per day
223627738|NCT06306105|DIETARY_SUPPLEMENT|placebo drink|consume 1 bottle per day
224216517|NCT06135519|PROCEDURE|Autologous Mesenchymal stem cells injection|Autologous Mesenchymal stem cells will be seperated from harvested fat and injected in acne scars
224216518|NCT06135519|PROCEDURE|Homogenized fat injection|Autologous fat will be harvested, homogenized and injected.
224216519|NCT05895214|PROCEDURE|oncological relevance of the mesopancreas|Invasion status Invasion depth in mm Depth of mesopancreas in mm Treitz fascia intact (histopathological examination)
224216520|NCT03216681|DRUG|Hoat Huyet Nhat Nhat|Administered orally twice a day, 2 tablets each time, for 45 days.
224216521|NCT03216681|DRUG|Tanakan 40mg|Administered orally three times a day, 1 tablet each time, for 45 days.
224216522|NCT06526923|COMBINATION_PRODUCT|SP-101 and doxorubicin Cohort 1|Single inhaled dose of SP-101 and doxorubicin Dose 1
224216523|NCT06526923|COMBINATION_PRODUCT|SP-101 and doxorubicin Cohort 2|Single inhaled dose of SP-101 and doxorubicin Dose 2
224216524|NCT03649906|PROCEDURE|Optimized Localization Technique|The small pulmonary nodules of the subjects will be located using an optimized pre-loaded microcoil puncture locating method.
224216525|NCT03029000|DRUG|Tbo-filgrastim|solution for subcutaneous injection
224216526|NCT06015217|DRUG|"Cetaphil Healing Ointment"|"Subjects will use Cetaphil Healing Ointment on the diaper rash area with every diaper change"
224216527|NCT01845090|DRUG|Lanthanum carbonate|the effect on serum FGF23
224317377|NCT02143076|BEHAVIORAL|Medical Adherence Measure Questionnaire|"At the two-month follow-up visit, participants will be asked to complete a questionnaire describing all medications prescribed for them, when they take their medications, how much medication they take each time, how many times during the week they missed taking or were late taking each medication, reasons why they missed or were late, and how they manage their medications.~In the case that a participant's clinic schedule is delayed greater than two months from the time of consent (e.g., missed appointment, change in clinic appointment frequency), procedures scheduled for the anticipated 2-month visit will take place at the participant's next clinic appointment."
223627739|NCT05757505|DEVICE|Intracranial Stent (Tonbridge)|Endovascular treatment with Intracranial Stent (Tonbridge).
223627740|NCT05757505|DEVICE|Wingspan Stent System (Stryker Neurovascular)|Endovascular treatment with Wingspan Stent System (Stryker Neurovascular).
223627741|NCT02162550|DRUG|Bydureon|once weekly injection
223627742|NCT02162550|DRUG|placebo|once weekly injection
223627743|NCT01105819|PROCEDURE|Lactobacillus plantarum 299 for oral care|The study group will be attended in the same manor but the swabs used for cleansing are soaked with carbonated water directly from freshly opened bottles. As the final part of the procedure oral mucosal surfaces are pencilled with a suspension of the probiotic bacterium Lactobacillus plantarum 299 Cultures from the oropharynx and tracheal secretions are taken at inclusion (day 1) and then on days 2,3,5,7,10,14 and 21 or before extubation if this occurs on a non-culture day
223627744|NCT01105819|PROCEDURE|Chlorhexidine for standard oral care|"A The control group will receive the standard oral care of the department (general ICU, Lund University Hospital).~This includes suction of secretions, brushing of teeth cleansing of the oral cavity with swabs soaked with a chlorhexidine solution. This procedure is performed twice a day. In between, suction whenever needed and cleansing with swabs soaked with carbonated bottled water is performed Cultures from the oropharynx and tracheal secretions are taken at inclusion (day 1) and then on days 2,3,5,7,10,14 and 21 or before extubation if this occurs on a non-culture day"
224216528|NCT01845090|DRUG|Calcium Carbonate|Calcium carbonate 500mg\~1000 mg tid for 6 months
223627746|NCT05175092|PROCEDURE|Living Donor Liver Transplantation|The LDLT will be performed by the UW Division of Transplantation in accordance with the standard of care for this operation.
223627747|NCT05894460|DEVICE|Chocolate balloon|Vascular preparation with chocolate balloons prior to drug-coated balloon angioplasty
223627748|NCT01814774|OTHER|No Intervention|No treatment (intervention) was administered.
223627749|NCT03078322|DRUG|AV-101|Oral capsules taken once daily (in addition to open-label treatment with a commercially available antidepressant)
223627750|NCT03078322|DRUG|Placebo|Oral capsules taken once daily (in addition to open-label treatment with a commercially available antidepressant)
223627751|NCT05472337|DRUG|Colchicine|Oral colchicine (1 mg loading dose followed by 0.5 mg 1 hour later, administered 6 to 24 hours before angioplasty, followed by 0.5 mg (1 comp.) per day for 6 weeks.
223627752|NCT03284177|DRUG|Calcium (13C)Carbonate|C13-CAC breath test containing Calcium (13C) Carbonate was performed twice under fasting conditions.
223627753|NCT03284177|DRUG|Gastric acid inhibitors|Gastric acid inhibitor was orally administrated once daily for 4weeks after first C13-CAC breath test.
223627754|NCT03284177|OTHER|Gastric pH monitoring|Gastric pH monitoring was performed once under fasting condition.
224216529|NCT00296582|BEHAVIORAL|Gastric Motor Function Measurement|
224216530|NCT03465982|PROCEDURE|Surgery after 8 weeks from chemoradiation treatment|Minimally invasive surgery after 8 weeks from chemoradiation treatment
224216531|NCT03465982|PROCEDURE|Surgery after 12 weeks from chemoradiation treatment|Minimally invasive surgery after 12 weeks from chemoradiation treatment
224216532|NCT01874730|OTHER|Combined epidural-general anesthesia (CEGA)|Combined epidural-general anesthesia (CEGA) will be used intraoperatively and patient-controlled epidural analgesia (PCEA) will be used postoperatively in a multimodal analgesic regimen.
224216533|NCT01874730|DRUG|Volulyte® (6% HES 130/0.4 in balanced solution)|"For the SOC Group: Intraoperative fluid management includes Volulyte® (6% HES 130/0.4 in balanced solution) as the only colloid solution to be used, the daily dosage of Volulyte® is restricted to 50 ml/kg.~For the ERS Group:~GDFT regimen will be utilized using Volulyte® (6% HES 130/0.4 in balanced solution) during surgery. The daily dosage of Volulyte® is restricted to 50 ml/kg."
223627755|NCT03690817|BEHAVIORAL|RBANS-H, virtual Morris Water Maze|Cognitive tasks for respectively: general cognition and spatial cognition
223627756|NCT02529917|DIETARY_SUPPLEMENT|Hemp powder|Hemp powder supplement
223627757|NCT02529917|DIETARY_SUPPLEMENT|Soy Powder|Soy powder supplement
223627758|NCT03243851|DRUG|Temozolomide+Metformin|Low dose temozolomide+metformin for 24 weeks
223627759|NCT03243851|DRUG|Temozolomide+Placebo|Low dose temozolomide+placebo for 24 weeks
223627760|NCT00497029|DRUG|fluoride varnish|
223627761|NCT00497029|BEHAVIORAL|patient education|
223627762|NCT02004730|DEVICE|ABSORB implantation|ABSORB implantation for long (\> 24mm) single vessel disease
223627763|NCT00628121|DRUG|Cetrorelix|1, 2 or 3mg, subcutaneouly dosed with single dose
223627764|NCT00746681|DRUG|Tolterodine & Pregabalin|Tolterodine SR Oral, 2mg, once daily for 4 weeks Pregabalin, Oral, 75 mg, twice daily for 4 weeks
223627765|NCT00746681|DRUG|Tolterodine|Tolterodine SR, Oral, 4 mg, once daily for 4 weeks
223627766|NCT00746681|DRUG|Placebo|Placebo, Oral, twice daily for 4 weeks
223627767|NCT00746681|DRUG|Tolterodine & Pregabalin|Tolterodine SR Oral, 4mg, once daily for 4 weeks Pregabalin, Oral, 150 mg, twice daily for 4 weeks
223627768|NCT00746681|DRUG|Pregabalin|Pregabalin, Oral, 150 mg twice daily for 4 weeks
224216534|NCT01874730|OTHER|Patient-Controlled Epidural Analgesia (PCEA)|For the ERS Group, patient-controlled epidural analgesia (PCEA) will be used postoperatively in a multimodal analgesic regimen.
224216535|NCT04615286|OTHER|Short course (2-3 weeks) of antibiotics|Shorter course of antibiotic than standard care of 4-6 weeks
224216536|NCT04615286|OTHER|Standard (long course) of antibiotics|4-6 weeks of antibiotics
224216537|NCT02061709|BIOLOGICAL|Ragweed-SPIRE|
224216538|NCT02061709|BIOLOGICAL|Placebo|
224216539|NCT02010307|OTHER|blood extraction|6 ml blood extraction from each patients in all 3 arms of the study
223627769|NCT00860808|DRUG|AM-101|Triple intratympanic injection (one on each day 1, 2, and 3)
223627770|NCT04935385|OTHER|Collecting blood specimens|Blood samples will be collected from all study participants at different required timelines
223627771|NCT06406712|OTHER|retroclavicular block|regional anesthesia
223627772|NCT04294121|OTHER|Food marketing on product packaging|Participants will be exposed to product packages displaying varying child- and parent-appealing marketing techniques and different degrees of marketing power
223627773|NCT05749341|DIAGNOSTIC_TEST|Three-Dimensional Poly(dimethylsiloxane) Scaffold|The rest blood samples from patients with and without endometriosis (No. 20 VS 20) would be collected for testing on a Microchip Embedded with Three-Dimensional Poly(dimethylsiloxane) Scaffold.
223627774|NCT01149850|BIOLOGICAL|bevacizumab|Given IV
223627775|NCT01149850|DRUG|temozolomide|Given orally
223627776|NCT01149850|OTHER|laboratory biomarker analysis|Correlative studies
223627777|NCT01149850|OTHER|immunohistochemistry staining method|Correlative studies
223627778|NCT01149850|GENETIC|microarray analysis|Correlative studies
223627779|NCT01149850|GENETIC|DNA methylation analysis|Correlative studies
223627780|NCT04043910|DEVICE|fNIRS|The auditory cortical imaging will be performed by fNIRS measures. This non-invasive functional imaging technique relies on the use of a sensor-bearing cap, measuring cortical activity through scalp, during auditory stimulation. As head movement does not alter measurement that much, fNIRS is well adapted to children.
223627781|NCT04043910|OTHER|Speech intelligibility|Speech intelligibility will be evaluated with French sentences comprehension in noise, from the Common Test or Adaptive Auditive Speech Test before 6 years, from the Common Test or Hearing in Noise Test for Children (Hint-C) from 7 to 11 years, and from the Hint-C or Marginal Benefit of Acoustic Amplification after 11 years, both with a Signal over Noise Ratio of +10 decibel at 65 decibel
224216540|NCT03022929|BEHAVIORAL|Enhanced Antimicrobial Stewardship Commitment and Feedback|Goes beyond the GetSmart recommendations to discern whether these recommendations can be improved upon.
224317378|NCT02143076|BEHAVIORAL|Acceptability Questionnaire|"At the two-month follow-up visit, participants will be asked to complete a questionnaire about their perceptions of using the Wise electronic medication container.~In the case that a participant's clinic schedule is delayed greater than two months from the time of consent (e.g., missed appointment, change in clinic appointment frequency), procedures scheduled for the anticipated 2-month visit will take place at the participant's next clinic appointment."
223627782|NCT04043910|OTHER|Sound localisation|Sound localisation will be evaluated with a left-right discrimination test before 7 years and a 12 loudspeakers sound localisation test after 7 years.
223763903|NCT05225961|DRUG|Acetylsalicylic acid|A single dose 500 milligrams of Acetylsalicylic acid (ASPIRINA®, 500 mg) will be intravenously administered. The solution for injection should be prepared on the spot and used immediately after preparation. It is highly recommended to administer as soon as possible after femoral puncture and always before stent placement, allowing a 10-minute delay after placement of the cervical endoprosthesis. In case of exceeding this time, the patient will be withdrawn from the trial. It will not be necessary to maintain aspirin infusion. In the Acetylsalicylic acid group, a head computerized tomography scan will also be performed at 20 (+/- 2 hours) after the endovascular procedure. Once the absence of parenchymal hematoma is demonstrated, a load of clopidogrel and 100 mg of Acetylsalicylic acid will be administered. Oral antiplatelet medication can be administered orally if the patient has a good level of consciousness and is not associated with dysphagia; or by placing a nasogastric tube.
224216541|NCT02431715|DRUG|[18 F]-6-L-fluorodihydroxyphenylalanine (18F-FDOPA)|"All patients will have their weight and baseline vital signs recorded.~The study subject will have an intravenous catheter inserted and receive a slow bolus intravenous dose of 185 - 370 MBq (5 -10mCi) 18F-FDOPA.~The patient will rest in a comfortable reclining chair in a warm, private shielded room for 45 to 60 minutes.~Patients are positioned supine and centered on the scanner bed for an average total scan time (CT and PET) of approximately 30 minutes.~Images will be interpreted by qualified and experienced physicians. Findings of significance from the PET/CT scan, and any incidental findings of significance from the CT scan, will be included in the single final report that will be issued to referring physicians."
224216542|NCT03448601|OTHER|Culturally tailored brochure intervention group|Culturally-tailored Alzheimer's Disease and precision medicine educational brochure.
223627783|NCT04043910|OTHER|Speech assessments|Speech assessments will be performed by dedicated speech therapists, with child age specific tests, and 2 global speech scores: the Category of Auditory Performances scale - second edition, and the Speech Intelligibility Rating scale.
223627784|NCT04043910|OTHER|Quality of Life|Quality of Life (QoL) evaluation will be based on the generic QoL scale, and the Speech Spatial and Qualities of hearing (SSQ) deafness specific scale. Each scale exists in age specific modalities.
223627785|NCT00497458|DRUG|Testosterone|testosterone 40 or 80 mg once a day
223627786|NCT06491186|OTHER|Point of Care Ultrasound|Point-of-care ultrasound will be used to image the femoral vessels and to assess the presence or absence of a pulse and the compressibility of the artery during rhythm checks.
223627787|NCT01101217|DRUG|Zinc Supplement|in 50 patients zinc sulfate 220 mg per day orally for 6 weeks
223627788|NCT01101217|DRUG|placebo|placebo daily for 6 weeks
223627789|NCT00000376|BEHAVIORAL|Cognitive therapy|
223627790|NCT00000376|DRUG|Desipramine|
223627791|NCT04410497|OTHER|Porcine xenograft (wound dressings)|commercial porcine xenograft, derived from acellular dermis from porcine.
223627792|NCT04410497|OTHER|Silver foam (wound dressings)|commercial silver containing foam dressing
223627793|NCT05288309|OTHER|RAINSTİCK|When the child, who was taken to Experimental Group 1, sat on the patient's chair, the sound of the rain stick was started to be played 1 minute before the blood draw. At that time, the nurse began to prepare the child for the blood draw. The tourniquet insertion procedure and the determination of the vein from which blood will be drawn from the antecubital region were performed by the nurse. Blood collection was taken from the antecubital region in one go by the same nurse by means of a vacuum blood collection tube, and blood flowed to the vacuum within 5 seconds, showing that the procedure was successful. This process took about 2-3 minutes and the children listened to the sound of rain sticks throughout the process.
223627794|NCT05288309|OTHER|KALEİDOSCOPE|The child, who was taken into Experimental Group 2, was started to watch the kaleidoscope 1 minute before the blood draw, as he sat on the patient's chair. At that time, the nurse began to prepare the child for the blood draw. The tourniquet insertion procedure and the determination of the vein from which blood will be drawn from the antecubital region were performed by the nurse. Blood collection was taken from the antecubital region in one go by the same nurse by means of a vacuum blood collection tube, and blood flow to the vacuum within 5 seconds showed that the procedure was successful. This process took about 2-3 minutes and children were watched with kaleidoscope throughout the process.
223627795|NCT01903356|DRUG|Trajenta duo|Linagliptin and Metformin
223627796|NCT01387828|PROCEDURE|Laparoscopic splenic aneurysm repair, eventual splenectomy|Aneurysmectomy and eventual artery reconstruction or splenectomy performed with a laparoscopic approach
223627797|NCT01387828|PROCEDURE|Laparotomic splenic artery aneurysm repair, eventual artery reconstruction or splenectomy|Aneurysmectomy and eventual artery reconstruction or splenectomy performed with a laparotomic approach
223627798|NCT03488095|BEHAVIORAL|BCI for SLT and BQ Use in Adolescents: A CRT|BCI for SLT and BQ Use in Adolescents: A CRT is aimed towards changing Adolescenst behaviors regarding their SLT and BQ use to as to reduce Oral cancer Burden within population because of this.
223627799|NCT00160186|DRUG|Pancreatin|2 capsules Pancreatin with 25 000 lipase units per main meal (3 meals) and 1 capsule per snack (2-3 snacks)
223627800|NCT00160186|DRUG|Placebo|Placebo
223627801|NCT05366023|BEHAVIORAL|BUD1|10 hours of bottom-up driven computerized cognitive training designed to improve processing speed and divided attention
223627802|NCT05366023|BEHAVIORAL|BUD2|10 hours of bottom-up driven computerized cognitive training designed to improve divided attention
223627803|NCT05366023|BEHAVIORAL|TDD1|10 hours of top-down driven computerized cognitive training designed to improve multiple object tracking
223627804|NCT05366023|BEHAVIORAL|TDD2|10 hours of top-down driven computerized cognitive training designed to improve executive function
223627805|NCT05366023|BEHAVIORAL|CSA10|10 hours of computerized games
223627806|NCT05366023|BEHAVIORAL|CSA20|20 hours of computerized games
223627807|NCT05366023|BEHAVIORAL|CSA30|30 hours of computerized games
223627808|NCT05366023|BEHAVIORAL|CSA40|40 hours of computerized games
223627809|NCT00060528|DRUG|Recombinant Fowlpox-GM-CSF|
223627810|NCT00060528|DRUG|Recombinant Fowlpox-PSA (L155)-TRICOM (PROSTVAC-F/TRICOM)|
223627811|NCT00060528|DRUG|Recombinant Vaccinia-PSA (L155)-TRICOM (PROSTVAC-V/TRICOM)|
223627812|NCT00060528|DRUG|Recombinant Human GM-CSF|
224216543|NCT03448601|OTHER|Culturally tailored video intervention group|Culturally-tailored Alzheimer's Disease and precision medicine educational video.
223627813|NCT00933699|DRUG|LACTIC ACID(ND)|Treatment duration: 21 consecutive days
223627814|NCT04265963|BIOLOGICAL|CD123 CAR-T cells|CD123 CAR-T cell therapy
223627815|NCT00967564|OTHER|epidemiologic study|QoL assessment
223627816|NCT02990026|BEHAVIORAL|Specialty Mental Health Probation|Specialty mental health probation includes the following components: (1) exclusively mentally ill caseload of probationers; (2) reduced caseload of 40-45 probationers; (3) problem-solving supervision orientation; (4) ongoing training and consultation; and (5) greater connection with local mental health services
223627817|NCT03969485|DEVICE|Hybrid Fractional Laser|Hybrid Fractional Laser Device
223627818|NCT06460545|BIOLOGICAL|sIPV (booster dose at 18 months of age)|Sabin-strain-based inactivated vaccine (Vero cells), 0.5mL for each dose at 18 months of age for the booster one
223627819|NCT06460545|BIOLOGICAL|HepA-L|Freeze-dried/lyophilized live-attenuated hepatitis A virus vaccine, 1.0mL for each dose at 18 months of age
223627820|NCT06460545|BIOLOGICAL|HepA-I|Inactivated hepatitis A virus vaccine, 0.5mL for each dose, two doses at 18 and 24 months of age, respectively
223627821|NCT03939143|DRUG|DA-1229_01(A), Sugamet SR Tab 5/1000mg®|"Period 1: Single oral administration of 1 tablet of test drug together with 150 mL of water containing 30 g sugar.~The wash-out for fed study is 14 days. Period 2: Single oral administration of 1 tablet of reference drug together with 150 mL of water containing 30 g sugar."
223627822|NCT03939143|DRUG|Sugamet SR Tab 5/1000mg®, DA-1229_01(A)|"Period 1: Single oral administration of 1 tablet of reference drug together with 150 mL of water containing 30 g sugar.~The wash-out for fed study is 14 days. Period 2: Single oral administration of 1 tablet of test drug together with 150 mL of water containing 30 g sugar."
223627823|NCT03188016|BEHAVIORAL|Intensive Interaction with Music|Intensive Interaction is a form of non-verbal communicative behaviour performed by a support worker to encourage and develop spontaneous communicative behaviour by the treatment subject, for which support workers are prepared by a speech and language therapist. The music in the intervention is live music improvised by a (UK) registered music therapist present in the room with treatment subject and support worker, who watches but does not participate socially in their interactions, and who develops musical input to encourage and enhance those interactions.
223627824|NCT03188016|BEHAVIORAL|Standard Intensive Interaction|Intensive Interaction is a form of non-verbal communicative behaviour performed by a support worker to encourage and develop spontaneous communicative behaviour by the treatment subject, for which support workers are prepared by a speech and language therapist.
224216544|NCT00411762|DRUG|Capecitabine|
223627825|NCT04196686|DEVICE|VR/AR|VR/AR headset with either passive or active content such as playing a game or watching a movie
223627826|NCT04196686|OTHER|Ice Bath|Participants immerse hand in ice bath and starting again with their original assigned group and keep hand submerged as long as they can withstand the cold or until 4 minutes have elapsed, whichever comes first. Participants will not be told of the specifics of the time limit, to avoid competitiveness and expectations and will be asked for pain scores every 30 seconds.
223627827|NCT04636125|DRUG|Doxycycline 100 MG Oral Tablet|Patients that are undergoing a single stage revision total shoulder arthroplasty will be enrolled in this study. As is standard of care, routine cultures will be taken from predetermined areas in the shoulder. All patients will be treated with 13 days of oral Doxycycline pending culture results.
223627828|NCT02944110|DRUG|Glucagon receptor antagonist LY2409021|single oral dose of 300mg
223627829|NCT02944110|DRUG|Placebo|Oral dose of placebo tablets
224216545|NCT00411762|DRUG|PHY906|
224216546|NCT03399435|COMBINATION_PRODUCT|Neosaxitoxin combined with bupivacaine low and epinephrine (T1)|A single injection: Neosaxitoxin from 1.25 to 60 µg. Bupivacaine 40 mg. Epinephrine 100 µg.
223627830|NCT02212015|DRUG|Pazopanib + Paclitaxel|pazopanib in combination with paclitaxel in the treatment of patients with advanced or metastatic angiosarcoma.
223627831|NCT02965911|DRUG|Fenofibrate|Fenofibrate is a drug of the fibrate class. it reduces both low-density lipoprotein (LDL) and very low density lipoprotein (VLDL) levels, as well as increasing high-density lipoprotein (HDL) levels and reducing triglyceride levels.
223627832|NCT02965911|DRUG|UDCA|Ursodeoxycholic acid，the abbreviation UDCA, is one of the secondary bile acids, which are metabolic byproducts of intestinal bacteria，it is the only FDA approved drug to treat PBC.
223627833|NCT06225128|OTHER|Biobanking blood|Additional volume of 30mL (EDTA) At Screening, pre-Cycle 1 Day 1,Day 1 H8, Day 2, Day of post-cycle 1 and post-cycle 6 evaluation.
223627834|NCT06225128|OTHER|Bone marrow specimens|"Additional volume of 2mL (EDTA)~* at screening for correlative studies,at Day 7 for smears and for correlative studies.~* Post-cycle 1 and post-cycle 6 evaluations for correlative studies.~Optionnal :~Trephine biopsy at screening and at post-cycle 1 and 6 evaluations (performed at the same time as aspiration)"
223627835|NCT03809728|PROCEDURE|endoscopic biopsy|Per-endoscopic biopsies
223627836|NCT03809728|PROCEDURE|samples of the oral cavity|7 samples of the oral cavity with a swab
223627837|NCT03809728|PROCEDURE|Samples of the resected specimen|if patient has to undergo a digestive resection as part of his standard management, samples of the pathological area and samples at the end of the resection will be realised
223627838|NCT02385929|BEHAVIORAL|Swallowing therapy & resistance training|"i) Individual instructions in swallowing and mouth opening exercises 3 days per week by occupational therapist throughout radiotherapy, ii) Progressive resistance training twice weekly by physiotherapist, either individually or group based, throughout radiotherapy, iii) Daily home-based swallowing and mouth opening exercises from beginning of treatment until 2 months after end-of-treatment.~iv) Weekly follow-up phone contacts with occupational therapists from end-of-treatment and 2 months onwards."
223627839|NCT04970563|OTHER|Body odor samples|Participants will provide six body odor samples (mask and sweat samples) at inclusion
223627840|NCT04970563|OTHER|Body odor samples|Participants will provide six body odor samples (masks and compresses) at inclusion. A 7-day follow-up will be carried out to check, respectively, the absence of symptoms and the persistence of negativity on the SARS-COV-2 PCR test
223627841|NCT04989751|DIAGNOSTIC_TEST|Electromyography|Electromyography (EMG) would be used at the baseline for dignoisis and furtue analysis.
223627842|NCT04989751|DIAGNOSTIC_TEST|IDEAL MRI|Muscle-speciifc sequences (e.g. IDEAL) would be used to scan patients at baseline and follow-up stages to characterize the fat fraction and atrophy in different muscles.
224216547|NCT03399435|COMBINATION_PRODUCT|Bupivacaine low combined with epinephrine (C1)|A single injection: Bupivacaine 40 mg. Epinephrine dose 100 µg.
223627843|NCT05274997|DRUG|YY-20394|Linperlisib is a strong and selective small-molecule PI3K-δ (a protein involves in the survival of cells) inhibitor, which is able to interfere with the growth, migration and survival of T/NK lymphoma cells.
223627844|NCT03448406|DRUG|Empagliflozin|Film-coated tablet
224216548|NCT03399435|COMBINATION_PRODUCT|Bupivacaine high combined with epinephrine (C2)|A single injection: Bupivacaine 100 mg. Epinephrine 100 µg.
224216549|NCT03399435|COMBINATION_PRODUCT|Neosaxitoxin combined with bupivacaine low (T2)|A single injection: Neosaxitoxin from 1.25 to 60 μg. Bupivacaine from 10 to 80 mg.
224216550|NCT03399435|DRUG|Bupivacaine low (C3)|A single injection: Bupivacaine from 10 to 80 mg.
224216551|NCT03399435|DRUG|Bupivacaine high (C4)|A single injection: Bupivacaine 100 mg.
224216552|NCT03399435|DRUG|Neosaxitoxin (T3)|A single injection: Neosaxitoxin will be between 1.25 and 60 µg.
224216553|NCT03399435|COMBINATION_PRODUCT|Neosaxitoxin combined with epinephrine (T4)|A single injection: Neosaxitoxin will be between 1.25 and 60 μg. Epinephrine 100 µg.
224216554|NCT03399435|COMBINATION_PRODUCT|Neosaxitoxin combined with bupivacaine low and epinephrine|A single injection: Neosaxitoxin will be between 1.25 to 60 µg. Bupivacaine dose based on results from Part B (10 to 80 mg). Epinephrine 100 µg.
224216555|NCT03399435|COMBINATION_PRODUCT|Neosaxitoxin combined with bupivacaine low|A single injection: Neosaxitoxin will be between 1.25 to 60 μg. Bupivacaine dose based on results from Part B (10 to 80 mg).
223627845|NCT03448406|DRUG|Placebo|Film-coated tablet
223627846|NCT00823316|BIOLOGICAL|Human umbilical cord blood-derived mesenchymal stem cells|1x1,000,000 hMSC/kg, IV after unrelated HSCT
223627847|NCT00823316|BIOLOGICAL|Human umbilical cord blood-derived mesenchymal stem cells|5x1,000,000 hMSC/kg, IV after unrelated HSCT
223627848|NCT04369404|BEHAVIORAL|Pelvic organ prolapse decision aid|Paper-based educational tool to guide shared decision making conversations for treatment of pelvic organ prolapse
223627849|NCT04369404|BEHAVIORAL|Stress urinary incontinence decision aid|Paper-based educational tool to guide shared decision making conversations for treatment of stress urinary incontinence.
223627850|NCT04369404|BEHAVIORAL|Overactive bladder decision aid|Paper-based educational tool to guide shared decision making conversations for treatment of overactive bladder.
223627851|NCT03130738|DRUG|7-Day Miconazole Oil (Miconazole 2%)|7 days of 2x per day treatment with Miconazole Oil (Active Drug Product 2% Miconazole)
223627852|NCT03130738|DRUG|14-Day Miconazole Oil (Miconazole 2%)|14 days of 2x per day treatment with Miconazole Oil (Active Drug Product 2% Miconazole)
223627853|NCT03130738|DRUG|14-Day Placebo - Oil Vehicle|14 days of 2x per day treatment with Placebo - Oil Vehicle, Study Drug base without active ingredient
223627854|NCT01995708|BIOLOGICAL|CT7, MAGE-A3, and WT1 mRNA-electroporated Langerhans cells ( LCs)|Patients receive CT7/MAGE-A3/WT1 mRNA-electroporated autologous Langerhans-type dendritic cells ID on days 12, 30, and 90 after autologous stem cell transplant. Patients on the vaccine arm of the study will receive a total of 3 vaccinations, comprising a primary immunization on day +12 after ASCT followed by two boosters at days +30 and +90. Vaccines will be dosed at 9x10\^6 LCs per vaccine x 3.
223627855|NCT01995708|OTHER|Standard of care|No vaccines
223627856|NCT03516123|DRUG|CS3006|"In the dose escalation part, the dose levels will be escalated following a modified 3+3 dose escalation scheme.~In the dose expansion part, participants will receive CS3006 at specified dose level(s)."
223627857|NCT04309734|DRUG|AT-777|Administered orally as one or two 60 mg capsule(s) of AT-777 (inhibitor of HCV nonstructural protein 5A (NS5A)), depending on the arm.
223627858|NCT04309734|DRUG|Placebo|Administered orally, as one or two placebo capsules, depending on the arm.
223627859|NCT04309734|DRUG|AT-527|Administered orally as one 550 mg tablet of AT-527 (nucleotide prodrug inhibitor of HCV nonstructural protein 5B (NS5B) polymerase), depending on the arm.
223627860|NCT06184529|BEHAVIORAL|Virtual Reality|The virtual reality simulation includes a one time viewing of a brief video tutorial and then trying out a one time virtual reality simulation with a child avatar that takes 10-20 minutes to complete in-person.
223627861|NCT02344654|DRUG|Indocyanine green|
223627862|NCT02344654|DEVICE|Near-infrared illumination|To see the fluorescence from indocyanine green
223627863|NCT02344654|DRUG|Urografin|
223627864|NCT02344654|RADIATION|X-ray|
224216556|NCT06307678|DRUG|Calcium Hydroxide|"The samples were taken from the interstitial fluid of the apical tissues using 3 paper points before medicament placement.~Calcium hydroxide based medicament was placed in the canals using a file at a distance of 1 or 2 mm less than the root canal length.~At the second appointment, medicamentswere removed, and second samplingwas performed using the same method.~The RANKL/OPG, TNF alpha, TGF beta, PGE2 levels were measured by the enzyme-linked immunosorbent assay, and their ratio was calculated."
224216557|NCT06307678|DRUG|Calcium Silicate|"The samples were taken from the interstitial fluid of the apical tissues using 3 paper points before medicament placement.~Calcium silicate based medicament was placed in the canals using a file at a distance of 1 or 2 mm less than the root canal length. At the second appointment, medicaments were removed, and second sampling was performed using the same method.~The RANKL/OPG, TNF alpha, TGF beta, PGE2 levels were measured by the enzyme-linked immunosorbent assay, and their ratio was calculated."
224216558|NCT04664283|DEVICE|DCB for de Novo Lesions in Large Coronary Arteries Guided by Optical Coherence Tomography|DCB for de Novo Lesions in Large Coronary Arteries Guided by both angiogram and Optical Coherence Tomography
224216559|NCT02758951|OTHER|Perioperative systemic therapy|Neoadjuvant systemic therapy should start within four weeks after randomisation. Adjuvant systemic therapy should start within twelve weeks after CRS-HIPEC. In case of unacceptable toxicity or contraindications to oxaliplatin or irinotecan in the neoadjuvant setting, CAPOX or FOLFOX may be switched to FOLFIRI and vice versa. In case of unacceptable toxicity or contraindications to oxaliplatin in the adjuvant setting, CAPOX of FOLFOX may be switched to fluoropyrimidine monotherapy. Dose reduction, prohibited concomitant care, permitted concomitant care, and strategies to improve adherence are not specified a priori, but left to the discretion of the treating medical oncologist. Perioperative systemic therapy can be prematurely discontinued due to radiological or clinical disease progression, unacceptable toxicity, physicians decision, or at patients request.
224216560|NCT02758951|COMBINATION_PRODUCT|Perioperative CAPOX-bevacizumab|Four three-weekly neoadjuvant and adjuvant cycles of CAPOX (130 mg/m2 body-surface area \[BSA\] of oxaliplatin, intravenously \[IV\] on day 1; 1000 mg/m2 BSA of capecitabine, orally twice daily on days 1-14), with bevacizumab (7.5 mg/kg body weight, IV on day 1) added to the first three neoadjuvant cycles.
224216561|NCT02758951|COMBINATION_PRODUCT|Perioperative FOLFOX-bevacizumab|Six two-weekly neoadjuvant and adjuvant cycles of FOLFOX (85 mg/m2 body-surface area \[BSA\] of oxaliplatin, intravenously \[IV\] on day 1; 400 mg/m2 BSA of leucovorin, IV on day 1; 400/2400 mg/m2 BSA of bolus/continuous 5-fluorouracil, IV on day 1-2), with bevacizumab (5 mg/kg body weight, IV on day 1) added to the first four neoadjuvant cycles.
223627865|NCT03538197|OTHER|clinical and biological correlates|"To measure the rate of suicidal re attempt (SR) in a population of young adults aged 18 to 25 years.~To identify sociodemographic, clinical and biological characteristics of a population of suicidal young people, in an attempt to highlight potential risk factors"
223627866|NCT02542865|DIETARY_SUPPLEMENT|Fortified malt based food|Fortified malt based food
223627867|NCT06178796|DEVICE|Dental implant|Dental implant placement
223627868|NCT06285487|BEHAVIORAL|Group Program|Participants in both arms will receive 6 weeks of T2D-IPT or 6 weeks of T2DEd.
223627869|NCT05830708|DIETARY_SUPPLEMENT|Lactobacillus sp. probiotic|The probiotic product contains good bacteria Lactobacillus sp. and primarily maltodextrin as carrier. Sachets of products containing the probiotic appear as light-yellow powder. The probiotic products are kept at storage temperature range below 30oC according to the condition recommended by the manufacturer.
223627870|NCT05830708|BEHAVIORAL|Acceptance and commitment therapy|The ACT session is initiated by building good therapeutic rapport with the subject and gather important information such as experiential avoidance, external barriers, fusion past, unworkable actions, and strength of the subject, followed by formulation of the case. The session may began with coaching subjects on acknowledging and accepting their unpleasant thoughts and feelings. The therapy will also focus on defusion to reduce behavioral avoidance of unpleasant thoughts and feelings by acknowledging them but focus on the values identified. Mindfulness is also practice to allow focus onto the present and surrounding to create awareness among the subjects that they are many things in the surrounding which is more enjoyable that we can enjoy rather than making effort to distract or change or avoid the unpleasant thoughts and feelings.
223627871|NCT05830708|DIETARY_SUPPLEMENT|Placebo|The placebo are in powder form prepare in sachet which is light-yellow in color and should be stored in temperature at below 30oC, which is similar to the appearance of the probiotic. Nevertheless, it contains only maltodextrin in same amount as in the placebo.
223627872|NCT03337230|BEHAVIORAL|Physical Activity|Fitbit Activity Monitor and IPAQ to give level of physical activity. Participants will be provided with education about physical activity recommendations and will be encouraged to set goals for improvement.
223627873|NCT03337230|BEHAVIORAL|Diet|National Cancer Institute's ASA24 web-based dietary assessment tool to determine intake. Participants will be provided with education about healthy diets and will be encouraged to set goals for making enduring changes to dietary intake.
223627874|NCT03337230|BEHAVIORAL|Social Support|Social support will be determined via self report scale measure and objective collection of social media communications. Each participant will be contacted through social media regularly with dietary and physical activity information and asked to support other participants via encouragement and sharing of information.
223627875|NCT01961505|DRUG|Topical compound tripterygium|Topical compound tripterygium was applied for the pain and swollen joints on non-woven fabric for 1 hour, twice per day.
223627876|NCT01961505|DRUG|Placebo|The topical placebo recipe composes viscous agent which matches by the sucrose, and the usage and dosage were the same as the topical compound tripterygium group.
223627877|NCT02005016|BEHAVIORAL|Naming therapy|Participants will receive behavioral therapy which is designed to stimulate semantic (meaning) representations which are required for successful naming (word production). Therapy will be administered for 4 weeks on an intensive schedule (5 days a week, approximately 4.5 hours per day).
223627878|NCT00083889|DRUG|Interferon-alfa|3 MIU first week, 6 MIU second week, and 9 MIU thereafter three times a week (non-consecutive days) until progression or unacceptable toxicity
223627879|NCT00083889|DRUG|SU011248|50 mg orally daily for 4 weeks and 2 weeks off treatment until progression or unacceptable toxicity
223627880|NCT03178214|DRUG|Infacort|Immediate-release multiparticulate formulation of hydrocortisone.
223627881|NCT03402802|DRUG|monitoring of adherence with medication|persons taking routine postoperative eye drops will have their frequency of drop taking monitored
224216562|NCT02758951|COMBINATION_PRODUCT|Perioperative FOLFIRI-bevacizumab|Six two-weekly neoadjuvant cycles of FOLFIRI (180 mg/m2 body-surface area \[BSA\] of irinotecan, intravenously \[IV\] on day 1; 400 mg/m2 BSA of leucovorin, IV on day 1; 400/2400 mg/m2 BSA of bolus/continuous 5-fluorouracil, IV on day 1-2) and either four three-weekly (capecitabine (1000 mg/m2 BSA, orally twice daily on days 1-14) or six two-weekly (400 mg/m2 BSA of leucovorin, IV on day 1; 400/2400 mg/m2 BSA of bolus/continuous 5-fluorouracil, IV on day 1-2) adjuvant cycles of fluoropyrimidine monotherapy, with bevacizumab (5 mg/kg body weight, IV on day 1) added to the first four neoadjuvant cycles.
224216563|NCT02758951|PROCEDURE|CRS-HIPEC, experimental arm|CRS-HIPEC is performed according to the Dutch protocol in all study centres. Until publication of the PRODIGE7 trial, the choice of HIPEC medication (oxaliplatin or mitomycin C) has been left to the discretion of the treating physician, since neither one had a favourable safety or efficacy until then. After publication of the PRODIGE7 trial in 2021, oxaliplatin-based HIPEC was omitted in all centres (and therefore automatically omitted in the present study), and all centres switched to mitomycin C-based HIPEC. CRS-HIPEC should be performed within six weeks after completion of neoadjuvant systemic therapy in case of sufficient clinical condition, and at least six weeks after the last administration of bevacizumab in order to minimise the risk of bevacizumab-related postoperative complications.
224216564|NCT02758951|PROCEDURE|CRS-HIPEC, control arm|CRS-HIPEC is performed according to the Dutch protocol in all study centres. Until publication of the PRODIGE7 trial, the choice of HIPEC medication (oxaliplatin or mitomycin C) has been left to the discretion of the treating physician, since neither one had a favourable safety or efficacy until then. After publication of the PRODIGE7 trial in 2021, oxaliplatin-based HIPEC was omitted in all centres (and therefore automatically omitted in the present study), and all centres switched to mitomycin C-based HIPEC. CRS-HIPEC should be performed within six weeks after randomisation.
224216565|NCT05727592|DIETARY_SUPPLEMENT|Althernanthera Sissoo|15g of Althernanthera Sissoo consumed with lunch or dinner per day.
224216566|NCT05727592|BEHAVIORAL|Dietary Consultation|Dietary consultation to improve the intakes of vegetables daily
223627882|NCT04468646|DRUG|NK-1R antagonist|NK-1R antagonist, 80 mg daily once for 3-5 days along with dexamethasone 6 mg daily for 5 days
223627883|NCT02923973|OTHER|Transvaginal ultrasound cervical length screening|Serial transvaginal ultrasound cervical length scan every week from 16 to 24 weeks
223627884|NCT04875013|DEVICE|Vestibular rehabilitation with dynamic posturography|Rehabilitation exercises guided by an interactive display and measured by a footplate sensor
223627885|NCT00828971|DRUG|Avelox (Moxifloxacin, BAY12-8039)|Sequential IV/PO moxifloxacin 400/400 mg every 24 hours, for 7 to 21 days.
224216567|NCT01238211|DRUG|Cytarabine|Given IV
224216568|NCT01238211|DRUG|Dasatinib|Given PO
224216569|NCT01238211|DRUG|Daunorubicin Hydrochloride|Given IV
224216570|NCT01238211|OTHER|Laboratory Biomarker Analysis|Correlative studies
224216571|NCT01311310|OTHER|RIPC (remote ischemic preconditioning)|RIPC will be performed by four 5-min cycles of lower limb ischemia and 5 in reperfusion using blood-pressure cuff inflated to a pressure 15 mmHg greater than the systolic arterial pressure measured via arterial line.
224216572|NCT04428502|DRUG|Enbrel|As provided in real world practice
224216573|NCT01933139|OTHER|Audio-visual presentation|
224216574|NCT04127968|DRUG|Vitamin A|Children in intervention group will receive 50,000 IU vitamin A after being randomized.
224216575|NCT04127968|DRUG|Oil|Children in control group will receive equal volume of oil.
224216576|NCT01468168|DRUG|DE-101 Ophthalmic Suspension|Ophthalmic suspension; QID
224216577|NCT01468168|DRUG|DE-101 Ophthalmic Suspension|Ophthalmic suspension; QID
224216578|NCT01468168|DRUG|DE-101 Ophthalmic Suspension Vehicle|Ophthalmic suspension vehicle; QID
224216579|NCT04658446|DEVICE|Augmented Reality-Assisted Indirect Bonding|Virtual Orthodontic attachments are overlaid on top of the patient's teeth using an augmented-reality headset to guide the bracket positioning procedure.
224216580|NCT04658446|DEVICE|Digitally-Asssited Indirect Bonding|3D printed models with precise brackets positioned as virtually pre-planned. To aid in the transfer of the planned bracket positions to the patient's physical teeth.
223627886|NCT00828971|DRUG|Amoxicilline/clavulanic|IV Amoxicilline/clavulanic acid 2000/200 mg TID followed by PO amoxicilline/clavulanate 875/125 mg TID for a total of 7 to 21 days
223627887|NCT05135871|DRUG|Mavacamten|Single fasted oral dose of Mavacamten 15/25 mg on Day 1
223627888|NCT00959608|BEHAVIORAL|Think Health! program|Brief 10-15 minute counseling with Primary Care Provider for weight management, Participant binder with eating, physical activity and stress management educational materials, adapted from the Diabetes Prevention Program (DPP)(Knowler et al, 2002; DPP Research Group, 2002), physical activity resource guide, and telephonic health related messages (year 2).
223627889|NCT00959608|BEHAVIORAL|Basic Plus program|15 minute counseling sessions with lifestyle coach, in addition to the Basic Think Health! program intervention.
223627890|NCT05200065|PROCEDURE|Thulium laser enucleation of the prostate|Using the thulium laser to achieve complete endoscopic enucleation of the prostate.
223627891|NCT05200065|PROCEDURE|Bipolar enucleation of the prostate|Using the bipolar plasma energy to achieve complete endoscopic enucleation of the prostate.
223627892|NCT05998122|OTHER|nCRT → (CapeOX+Sintilimab)×6 → Surgery/W&W|"Radiation: Long-course chemoradiotherapy is delivered in 50 Gy/25 fractions with concurrent Capecitabine (825mg/m2, P.O. Bid, 5d/w).~Drug: CapeOX (Capecitabine 1000mg/m2, P.O. Bid, d1-d14, q3w; Oxaliplatin 130mg/m2, i.v., d1, q3w), and Sintilimab (200mg, i.v. , d1).~Surgical Approach: TME surgery, The surgical approach can be open, laparoscopic or robotic depending on the patient."
223627893|NCT04217382|OTHER|patient with melanoma pre transplantation|survival time without melanoma recurrence
224216581|NCT04839315|BIOLOGICAL|mRNA COVD19 vaccine|Subjects will receive two doses of mRNA based COVID19 vaccines.
224216582|NCT01682278|DEVICE|Removal of dental amalgam restorations|"Patients in the amalgam cohort will have all dental amalgam restorations removed and replaced with other restorative materials used in modern dentistry. Amalgam removal will be performed by the patient's regular dentist or another dentist chosen by the patient."
224216583|NCT00646178|DRUG|adalimumab|40 mg adalimumab eow Week 0 - Week 12
224216584|NCT00646178|DRUG|placebo for adalimumab|placebo eow Week 0 - Week 12
224216585|NCT00827073|DRUG|tetracaine 0.5%|betadine 5%
224216586|NCT00827073|DRUG|Lidocaine 2% Jelly|Betadine 5%
224216587|NCT04180189|OTHER|Weighted fiber blanket|Using weighted blanket for four weeks
224216588|NCT02375646|DRUG|Warfarin|
224216589|NCT02375646|DRUG|LMW Heparin|
224317379|NCT05996562|PROCEDURE|Pulmonary Artery Denervation|"Contrast pulmonary artery (PA) angiography will be performed to localize the pulmonary artery bifurcation level and calculate the PA diameter. Once the anatomy deemed acceptable, the radiofrequency ablation catheter will be introduced into ostium of the left PA and the distal bifurcation area of the main PA.~The catheter will be manoeuvred within the PA to allow energy delivery in a circumferential manner to ensure that the electrodes are tightly in contact with the endovascular surface. About three ablations at 45-55°C for 120 seconds each will be performed in ostium of the left PA and the distal bifurcation area of the main PA."
224317380|NCT04334694|DEVICE|Atrial flow regulator (Occlutech® AFR device)|Atrial septostomy followed by implantation of AFR.
224317381|NCT00115427|DRUG|Liatermin (r-metHuGDNF)|
224317382|NCT01279720|BIOLOGICAL|Intravenous infusion of transduced cells|Intravenous infusion of transduced cells
224317383|NCT00397774|BEHAVIORAL|Physical exercise|Physical exercise twice a week for 8 weeks, and best supportive care
223627894|NCT03650491|DRUG|FOR46|FOR46 is an intravenously (IV) administered antibody-drug conjugate (ADC) directed against CD46
223627895|NCT03140514|DRUG|Rejection treatment according to clinical standard-of-care|Standard-of-care treatment is based on the severity and phenotype of biopsy-proven rejection
224216590|NCT01315366|DIETARY_SUPPLEMENT|Euro D and Ci-CalD|Ci-Cal D (1000mg/day) and vitamin D (500IU/day) daily, plus a supplement of vitamin D3 (20,000 IU/wk) for one year.
224216591|NCT01315366|DIETARY_SUPPLEMENT|Euro D, Ci-CalD|Ci-Cal D(1000mg/day) and vitamin D (500IU/day) Ci-CalD daily, plus a weekly placebo Euro D supplement for one year.
224216592|NCT02055183|DRUG|BAT|Noninterventional, retrospective, observational phase 4 patient Registry
224216593|NCT02073305|OTHER|No Sleep Apnea|No intervention
224317384|NCT00397774|OTHER|best supportive care|
223627896|NCT01548547|OTHER|Simulation-based mastery learning|Hands-on coached deliberate practice on a simulator. Training until mastery achieved.
223627897|NCT04924816|PROCEDURE|Awake prone position|The prone position in awake patients consists of asking the patient to voluntarily change to prone position, in a swimmer's posture
224317385|NCT00000474|BEHAVIORAL|behavior therapy|
224317386|NCT00708773|DRUG|Irinotecan|"90 minute IV infusion once every 3 weeks.~Dose will be based on sex and genotype determination."
223627898|NCT02899936|DRUG|3 drug dose - IDA|Lymphatic Filariasis Mass Drug Administration (MDA) with triple drug therapy of ivermectin, diethylcarbamazine, and albendazole (IDA)
223627899|NCT02899936|DRUG|2 drug dose - DA|Lymphatic Filariasis Mass Drug Administration (MDA) with the currently used standard of care combination drug therapy of diethylcarbamazine, and albendazole (DA)
224216594|NCT02073305|OTHER|Sleep Apnea - untreated|No intervention
224216595|NCT02073305|DEVICE|Sleep Apnea - treated|Sleep Apnea treatment by positive pression ventilation (CPAP/BIPAP) or sleep apnea oral appliance
224216596|NCT01856374|DEVICE|Sirolimus-eluting stent (Cypher SelectTM, Cordis, Miami, FL)|Patients with native coronary arteries fulfilling all enrollment criteria will be randomly assigned to each DES group; Xience Prime® vs. Cypher SelectTM and pravastatin 20mg vs. atorvastatin 40mg.
224216597|NCT01856374|DEVICE|Everolimus-eluting stent(Xience Prime®, Abbott Vascular, Santa Claea, CA)|Patients with native coronary arteries fulfilling all enrollment criteria will be randomly assigned to each DES group; Xience Prime® vs. Cypher SelectTM and pravastatin 20mg vs. atorvastatin 40mg.
224216598|NCT01856374|DRUG|Pravastatin 20mg|2x2 randomization by the treatment of dyslipidemia (In patients of dyslipidemia: pravastatin 20mg/day vs. atorvastatin 40mg and the types of the implanted cypher vs xience.
224216599|NCT01856374|DRUG|Atorvastatin 40mg|2x2 randomization by the treatment of dyslipidemia (In patients of dyslipidemia: pravastatin 20mg/day vs. atorvastatin 40mg and the types of the implanted cypher vs xience.
224216600|NCT00449930|DRUG|sitagliptin phosphate|(1) sitagliptin 100mg tablet once daily (q.d.) for a 24-wk treatment period
223627900|NCT04731285|DIAGNOSTIC_TEST|Pressure wire fractional flow reserve|Pressure wire is inserted into coronary arteries. The ratio of the average distal pressure and average aorta pressure is FFR.
224216601|NCT00449930|DRUG|Comparator: metformin hydrochloride|(4) Metformin 500mg tablets once daily (q.d.) for a 24-wk treatment period.
224216602|NCT00002973|DRUG|melphalan|
224216603|NCT00002973|PROCEDURE|hyperthermia treatment|
223627901|NCT04731285|DIAGNOSTIC_TEST|CFD-based RuiXin-FFR|"CT-FFR was evaluated in a blinded fashion with a Coarse-to-Fine Subpixel algorithm for lumen contour"
223627902|NCT00434408|BEHAVIORAL|chx once|4.0% chlorhexidine cleansing of the cord applied once by a project worker visiting the newborn in the home as soon as possible after birth
223627903|NCT00434408|BEHAVIORAL|CHX x 7 days|4.0% chlorhexidine cleansing of the cord during home visits by project workers for the first 7 days after birth
223627904|NCT00434408|BEHAVIORAL|dry cord care|Household members are instructed to apply nothing to the newborn's umbilical cord stump.
223627905|NCT06235866|OTHER|Pulmonary rehabilitation|According to the pulmonary rehabilitation guidelines, patients with severe COVID-19 were given regular rehabilitation treatment, including breathing exercises and physical rehabilitation exercises.
223627906|NCT01427582|DRUG|Trabectedin|Trabectedin i.v. formulation at a dose of 1.5 mg/m2 i.v. over 24 hours on Day 1 every 21 days
223763904|NCT05186467|DRUG|intraperitoneal Magnesium sulfate|Intraperitoneal (IP) group will receive 100 ml normal saline infused over 10 min immediately before the induction of anesthesia and then continuous infusion of 500 ml normal saline intraoperatively then intraperitoneal wash of 100 ml normal saline containing 30 mg/kg MgSO4 at the end of laparoscopy.
223763905|NCT05186467|DRUG|intravenous magnesium sulfate|Intravenous (IV) group will receive 100 ml normal saline containing MgSO4 30 mg/kg infused over 10 min immediately before the induction of anesthesia and then continuous infusion of 500 ml normal saline containing MgSO4 (8mg/kg) intraoperatively then intraperitoneal wash using 100 ml normal saline at the end of laparoscopy.
223763906|NCT05690295|OTHER|Prolonged resistance-type exercise training|All volunteers will be subjected to 12 weeks of whole-body resistance-type exercise training (3x/wk).
223763907|NCT00087633|DRUG|peginterferon alfa-2a [Pegasys]|135 micrograms subcutaneously (SC) weekly for 4 weeks followed by 180 micrograms SC weekly for 44 weeks
224216604|NCT06128031|OTHER|questionaire|"Psychiatric interview: this will be assessed by (SCID-5)semi structural clinical interview based on Diagnostic and Statistical manual of Mental disorders-5 criteria~-Psychometric assessment include; Hamilton depression rating scale(7) and Hamilton anxiety rating scale(8) , used to score the symptoms of anxiety or depression Quality of life assessment: will be assessed by the Patient assessment of constipation-quality of life questionnaire"
224216605|NCT01864525|DRUG|Octanoic acid|
224216606|NCT01864525|DRUG|Inactive capsule|
224216607|NCT01124526|DRUG|Rituximab Fludarabine Cyclophosphamide|"Patients receiving from 4 to 6 cycles of chemotherapy (R F C) each 4 weeks depending on haematological tolerance:~RITUXIMAB(R)375 mg/m2 iv,day 3 C1 and day 1 C2-C6,(total dose 375 mg/m2) FLUDARABINE(F):25 mg/m2 iv, day 1-3,(total dose 75 mg/m2) CICLOPHOSPHAMIDE(C)1000 mg/m2 iv, day 1,(total dose 1000 mg/m2)"
224216608|NCT02252497|DRUG|Active comparator : Tranexamic Acid (Exacyl)|"* 1g Exacyl Intra Venous, just before surgery~* Then infusion of 1g of Exacyl over eight hours ."
224216609|NCT02252497|DRUG|Placebo comparator : physiologic serum|"* 1g Intra Venous just before surgery~* Then infusion of 1g of physiologic serum over eight hours"
224216610|NCT03438331|BEHAVIORAL|Cognitive Behavioural Therapy for Insomnia (CBT-I)|The intervention will consist of 8 weekly group sessions (90-min, 5-8 adolescents in each group) of CBT-I delivered within a 10-week window. The treatment components in the CBT-I aim to address the behavioural, cognitive and physiological perpetuating factor of insomnia and include: psycho-education about sleep and sleep hygiene, stimulus control, sleep restriction, relaxation training, structured worry time, cognitive restructuring (targeting sleep-related dysfunctional cognitions), and relapse prevention.
224216611|NCT03438331|BEHAVIORAL|Cognitive Behavioural Therapy for Depression (CBT-D)|The intervention will consist of 8 weekly group sessions (90-min, 5-8 adolescents in each group) of CBT-D delivered within a 10-week window. The main treatment elements of CBT-D include: psycho-education about depression, self-monitoring, behavioural activation, improving social skills, communication skills and problem solving skills, cognitive restructuring (addressing negative and irrational thoughts often associated with depression in adolescents), relaxation techniques, and relapse prevention.
224216612|NCT03156582|OTHER|Data collecting|
224216613|NCT04610073|BEHAVIORAL|Interactive multimedia training and illustrated booklet|The experimental groups conducted interactive multimedia training and illustrated booklet
224216614|NCT01856231|BEHAVIORAL|Lifestyle physical activity - self-efficacy|Subjects will come into an exercise lab 2 days per week and perform 10-20 minutes of walking, 13 strength training exercises, stretching and a behavioral intervention including goal setting, etc.
224216615|NCT06538168|BEHAVIORAL|Diabetes Self-Management Education (DSME)|The intervention, Diabetes Self-Management Education (DSME), involves a structured educational program including daily reminders regarding medication, and foot care, educational-led video weekly, and handouts for the management od diabetes and foot care to enhance knowledge and skills in managing diabetes and preventing complications like diabetic foot ulcers (DFUs).
224216616|NCT03138239|RADIATION|Ga-68-PSMA scan, and PET -CT F-18-FDG|"The patient will do tow mappings on two different days. It should be noted that there is no importance to the order between the two tests on the condition that they be performed within 7-10 days of each other.~Both tests will be performed with the Discovery 690 camera, which is located at the Nuclear Medicine Institute.~First test PET-CT with F-18-FDG PET-CT second test with Ga-68-PSMA"
224216617|NCT01884116|DRUG|NSAID patch|
224216618|NCT01884116|DRUG|NSAID patch + transcutaneous electric nerve stimulation|The patients of the experimental groups will be divided in to three groups according to what they are administered: NSAID patch plus transcutaneous electric nerve stimulation, NSAID patch plus heating pad, and NSAID patch plus topical capsaicin. All the groups will be observed for two weeks.
223627907|NCT02883569|PROCEDURE|open or endoscopic discectomy|FDA approved surgical procedures
223627908|NCT02883569|PROCEDURE|epidural block|epidural block
223627909|NCT02883569|OTHER|exercise|educated exercise
223627910|NCT02883569|DRUG|ibuprofen, naxoprofen, Cox-2 inhibitor, aceclofenac|FDA approved medication such as ibuprofen, naxoprofen etc.
223627911|NCT02883569|PROCEDURE|decompression|FDA approved surgical procedure such as lamiectom and, laminotomy
223627912|NCT02883569|PROCEDURE|instrumentation and fusion|FDA approved surgical procedure such as PLIF, ALIF, DLIF, OLI and TLIF
223763908|NCT00087633|DRUG|Copegus|400 mg orally (PO) daily escalating to 1200 mg PO daily, for 48 weeks
223627913|NCT02883569|DRUG|codeine, oxycontine, IRcodone, Tramadol|FDA approved opioid drug such as codeine, oxycontin, IRcodon
223627914|NCT02883569|PROCEDURE|epidural adhesiolysis|FDA approved epidural adhesiolysis with catheter or endoscope
223627915|NCT04261556|DEVICE|Real tDCS + CCT|"40 min/day of computerised cognitive training (CCT) + 20 min/day of real anodal transcranial direct current stimulation (tDCS).~In the first 20 min of the 40 min-intervention, real anodal tDCS and CCT will be provided simultaneously."
223627916|NCT04261556|DEVICE|Sham tDCS + CCT|"40 min/day of computerised cognitive training (CCT) + 20 min/day of apparent (sham) tDCS.~In the first 20 min of the 40 min-intervention, sham tDCS and CCT will be provided simultaneously."
223627917|NCT04403334|DRUG|Levofloxacin Ophthalmic|0.1 ml of unpreserved 0.5% levofloxacin
223627918|NCT04403334|DRUG|Moxifloxacin Ophthalmic|0.1 ml of unpreserved 0.5% moxifloxacin
223627919|NCT06179199|DEVICE|SOOMA™ tDCS™|The SOOMA™ tDCS™ device is designed to treat chronic pain, with a stimulation current of 2milliampere and a duration of 20 minutes
223627920|NCT05295212|DRUG|Atezolizumab|Pemetrexed (500mg/m2)/Paclitaxel (260mg/m2) Carboplatin (AUC=4-5) Atezolizumab(1200mg) ivgtt, every 21 days Range from 4 cycles
223627921|NCT06052761|DEVICE|Making Toys from Medical Materials|"Rabbit Making: The two fingers and the palm of the medical glove will be filled with cotton and the bottom part will be tied. The finger part of the glove will form the rabbit's ears, and the palm part will form its face. After the glove is shaped, the rabbit's eyes and mouth will be drawn with a pencil.~Cat Making: Three abeslangs will be cut to appropriate sizes to create the cat. The cut pieces will be combined to form the cat's head, feet, and tail. After the assembly process is completed, the cat's eyes, nose and beard will be drawn with a pencil.~Plane Making: The 10 cc syringe and needle tip removed from its packaging will be combined. Children will be asked to color the two abeslangs given to them in the color they want. The abeslangs painted by the children will be fixed to the syringe with a plaster, one on the bottom and the other on the top."
224216619|NCT01884116|DRUG|NSAID patch + heating pad|The patients of the experimental groups will be divided in to three groups according to what they are administered: NSAID patch plus transcutaneous electric nerve stimulation, NSAID patch plus heating pad, and NSAID patch plus topical capsaicin. All the groups will be observed for two weeks.
224216620|NCT01884116|DRUG|NSAID patch + topical capsaicin|The patients of the experimental groups will be divided in to three groups according to what they are administered: NSAID patch plus transcutaneous electric nerve stimulation, NSAID patch plus heating pad, and NSAID patch plus topical capsaicin. All the groups will be observed for two weeks.
224216621|NCT02786186|DRUG|Secikinumab|
224216622|NCT05269017|DRUG|Vitamin D3|Devarol S amp containing 200,000 units per 2 ml giving a concentration of 5,000 units per drops for four weeks
224216623|NCT05269017|DRUG|Budesonide nasal spray|64 µg per puff in a dose of 1 puff for each nostril twice daily for four weeks
224216624|NCT06457464|DRUG|Chemotherapy|combination regimens including VCD (Velcade, cyclophosphamide, and dexamethasone ) or (MP) combination (melphalan and prednisolone) or VRD (Velcade, lenalidomide, dexamethasone) or VDT (Velcade, thalidomide, dexamethasone) or CRD (Cyclophosphamide, lenalidomide, dexamethasone ) or CDT (Cyclophosphamide, thalidomide, dexamethasone)
224216625|NCT06339021|PROCEDURE|OCT-guided PCI|OCT-guided PCI based on MLD MAX algorithm
224216626|NCT06339021|PROCEDURE|Conventional angiography-based PCI|Conventional angiography-based PCI
223627922|NCT06176742|OTHER|Active Cycle Breathing Technique|This study will be Randomized Clinical trial, Subject diagnosed with asthma meeting predetermined inclusion and exclusion criteria and will be divided into two groups. The baseline treatment for both groups would be diaphragmatic breathing exercises. While group A will be treated with ACBT. Each subject will receive 18 sessions with 3 treatments per week. Post treatment values will be recorded after the session and recorded values will be analyzed using SPSS 25.
223627923|NCT06176742|OTHER|Bubble Positive Expiratory Pressure Device|This study will be Randomized Clinical trial, Subject diagnosed with asthma meeting predetermined inclusion and exclusion criteria and will be divided into two groups. The baseline treatment for both groups would be diaphragmatic breathing exercises. While group B will be treated with bubble-PEP. Each subject will receive 18 sessions with 3 treatments per week. Post treatment values will be recorded after the session and recorded values will be analyzed using SPSS 25.
223627924|NCT03454295|BEHAVIORAL|Focus Group|Participants will be asked to reflect on their caregiving experience and specifically, when the receipt of a supportive intervention that addresses existential distress would have been most appropriate and well received.
223627925|NCT03454295|BEHAVIORAL|Meaning-Centered Psychotherapy for Cancer Caregivers / MCP-C|MCP-C is structured as a 7-session (1-hour weekly or biweekly sessions) individual intervention that utilizes a mixture of didactics, discussion and experiential exercises that focus around particular themes related to meaning and cancer caregiving
223763909|NCT00581282|RADIATION|PET scan|positron emission tomography PET scan
223763910|NCT00581282|OTHER|fMRI|functional magnetic resonance imaging fMRI
223763911|NCT04035772|OTHER|Wiki101 and WikiTrauma|Wiki101 is a theory-based continuing professional development course to teach healthcare professionals how to use WikiTrauma. WikiTrauma is a wiki containing implementation tools built upon the Google Sites platform.
223763912|NCT04579913|OTHER|Review of medical history, administration of questionnaires, uroflowmetry and PVR as measured by ultrasound|Administration of questionnaires to assess patient LUTS, quality of life, sexual behavior and erectile function, in addition to performing PVR and uroflow tests.
223763913|NCT06042088|OTHER|Regular Size Glove and Bigger One|Different sizes of surgical gloves will be worn by participants
223763914|NCT03697200|OTHER|APA|Light touch using vaccaria seeds on specific points of the ear
223763915|NCT03697200|OTHER|Sham APA control|Light touch using vaccaria seeds on different points of the ear (compared to the APA group).
224216627|NCT06339021|DRUG|DAPT de-escalation|Aspirin and clopidogrel 30 days after DES implantation
224216628|NCT06339021|DRUG|default DAPT regimen|Aspirin and ticagrelor 30 days after DES implantation
224216629|NCT04117217|DIAGNOSTIC_TEST|Labs drawn|We will collect blood samples/biomarkers at the time of enrollment.
224216630|NCT01339884|DRUG|Resveratrol|Resveratrol 1g daily (500mg twice daily) for 12 weeks Resveratrol 5 daily (2.5g twice daily) for 12 weeks
224216631|NCT03954964|BEHAVIORAL|Education on disposal of opioids|Current class curriculum including education about pain management with additional education about the disposal of opioids.
223627926|NCT03454295|BEHAVIORAL|Enhanced Usual Care / EUC|"The enhancement to usual care in this study involves the inclusion of screening and targeted referral components as suggested by Reynolds et al. \[79\]. Research study assistants conducting the screening and providing feedback and referrals will be trained in the NCCN guidelines for distress management and will discuss the screening results and associated recommendations with the study PI (NCCN) \[63\]. As of November, 2017, ICs of patients seen in the Neurology Service at MSKCC are not consistently screened for distress and offered targeted referrals. Participants randomized to EUC will receive feedback about their level of distress (based on the Distress Thermometer administered at screening) after randomization. Within a week of randomization, and post-baseline, the study RSA will send EUC participants appropriate targeted referrals based on levels of distress and problem areas endorsed."
223627927|NCT03226002|DEVICE|Airtraq NT|channeled video laryngoscope for nasotracheal intubation
223627928|NCT01276262|DRUG|fostamatinib|Oral tablets, repeated doses for 21 days (2 x 50mg BID)
223627929|NCT01276262|DRUG|Microgynon® 30 (Oral contraceptive)|Oral tablets, repeated doses
223627930|NCT01276262|DRUG|Placebo|Oral tablets BID, repeated doses for 21 days
223627931|NCT04863391|DIAGNOSTIC_TEST|Referrable versus Non Referral AMD diagnostic test|Artificial intelligence read reports Referrable versus Non Referral AMD
224216632|NCT00067288|BEHAVIORAL|Meaning-Centered Group Psychotherapy|
224216633|NCT00067288|BEHAVIORAL|Standard Supportive Group Psychotherapy|
224216634|NCT01890785|DRUG|Lisdexamfetamine Dimesylate|Single dose of a 70 mg capsule on Day 1
224216635|NCT00029328|DRUG|etanercept|
224216636|NCT04822961|DRUG|Placebo|Senaparib-matched placebo capsules
224216637|NCT04822961|DRUG|Senaparib|20 mg capsules
224216638|NCT01484171|DRUG|idarubicin|idarubicin 10-12 mg/m2 for three days
224216639|NCT01484171|BIOLOGICAL|microtransplantation|idarubicin 10-12mg/m2 for four days. After chemotherapy infusion granulocyte colony-stimulating factor-mobilized HLA-mismatched donor peripheral blood stem cells following each of three cycles of high dose cytarabine chemotherapy
223627932|NCT05167435|OTHER|Myofascial Release Experimental|Myofascial release is a gentle sustained pressure that elongates fascial adhesions so that tissue can return to proper realignment.
223627933|NCT05167435|OTHER|Posterior-Anterior Glide|Posterior-anterior mobilization is a standard assessment and treatment technique for most clinicians. It is a mobilization technique that involves passive oscillatory movements applied to a vertebral segment in a posteroanterior direction (Back to front).
223627934|NCT03991845|DRUG|Vit D|Vit D supplementation was done
223627935|NCT05164081|COMBINATION_PRODUCT|antibiotic loaded bone cement (gentamicin+clindamycin) COPAL G+C (Heraeus).|Hospitals are cluster-randomized to either arm for 2 years and then cross-over to the other arm for another 2 years.
223627936|NCT05164081|COMBINATION_PRODUCT|antibiotic loaded bone cement (gentamicin) Paladins R+G (Heraeus) or Refobacin (Biomet).|antibiotic loaded bone cement (gentamicin) Paladins R+G (Heraeus) or Refobacin (Biomet).
223627937|NCT01897025|DEVICE|real-tDCS with MI-BCI|As in Arm Description
224216640|NCT03712228|BIOLOGICAL|Factor XIIa antagonist monoclonal antibody|Factor XIIa antagonist monoclonal antibody for intravenous and subcutaneous use
224216641|NCT03712228|DRUG|Placebo|Buffer without active ingredient
224216642|NCT03513978|OTHER|IAI Exercises Protocol|Progressive exercises to improve the strength and propioception of the male soccer players.
224216643|NCT03513978|OTHER|FIFA 11+|"Progressive exercises protocol to prevent injuries in male soccer players which has been created by FIFA. It is based in different body wieght exercises to improve the neuromuscular control and stabilization."
224216644|NCT04660409|DIAGNOSTIC_TEST|Blood test for serum Adropin|Blood test for serum Adropin
224216645|NCT05798871|PROCEDURE|Subgingival erythritol air polishing|"The intervention will start with supragingival debridement followed by subgingival erythritol air polishing by perioflow.~subgingival debridement"
224216646|NCT05798871|PROCEDURE|Conventional root planing|The intervention will start with supragingival debridement followed by root planing by curette.
224216647|NCT04001205|DRUG|Anticoagulation Therapy|Long term oral anticoagulation with VKA (vitamin K antagonist) or NOAC (non-vitamin K oral anticoagulant)
224216648|NCT01964105|DEVICE|3D Imaging|
224216649|NCT04477083|DRUG|inhalable hydroxychloroquine (HCQ)|inhalable hydroxychloroquine (HCQ) plus supportive and symptomatic treatment
224216650|NCT04477083|DRUG|supportive and symptomatic treatment|supportive and symptomatic treatment
224216651|NCT03049137|PROCEDURE|Computer Guided Stent Augmentation|Defective alveolar ridge is to be replaced by simultaneous implant placement with ring graft augmentation (Trephine Drill to obtain the ring graft autogenous bone) using computer guided stent and covered with Platelet-rich fibrin (PRF), by using venous blood from the patient, a centrifuge will be used to obtain the top layer after centrifuging blood at 3000 Revolution Per Minute (RPM) for 10 minutes.
224216652|NCT03049137|PROCEDURE|Free Hand Augmentation|Defective alveolar ridge is to be replaced by Free Hand simultaneous implant placement with ring graft augmentation (Trephine Drill to obtain the ring graft autogenous bone) and covered with Platelet-rich fibrin (PRF), by using venous blood from the patient, a centrifuge will be used to obtain the top layer after centrifuging blood at 3000 RPM for 10 minutes.
224216653|NCT03049137|DRUG|Platelet-rich fibrin (PRF)|
224216654|NCT03049137|DEVICE|implant|
224216655|NCT04793438|BEHAVIORAL|Motive-specific intervention|Three appointments are made with the patients of the intervention group within two weeks. With an adaptation of the Autobiographical Memory Test (AMT) participants will be asked to recall events from the past and to imagine future events. The time frame of 45 minutes for each intervention must be strictly adhered to. Patients are additionally asked to complete tasks between the sessions. All appointments take place in the Psychiatric University Hospital directly on the ward.
224216656|NCT04793438|BEHAVIORAL|Supportive conversations|Since we want to check whether the patients benefit from the specific intervention and not only from getting more speaking time, patients without the motive-specific intervention should also be given three sessions, in which no intervention takes place. They will be carried out in the sense of supportive conversations (i.e. conversations that do not follow a specific psychotherapy concept). All appointments take place in the Psychiatric University Hospital directly on the ward.
224216657|NCT05803538|DEVICE|SMS, telephone interview or diary card|SMS, telephone interview or diary card
224216658|NCT00358774|PROCEDURE|homeopathic nasal spray|
223627938|NCT03836625|OTHER|CareConekta|CareConekta is a smartphone app that uses the phone's GPS to prospectively characterize mobility and allow for intervening in real-time. CareConekta uses the phone's built-in GPS system to record location coordinates.
223627939|NCT00980187|DRUG|Hydrochlorothiazide|orally, 25 mg, once a day, with Quinapril 10-40 mg, 6 months
224216659|NCT05201820|DEVICE|Cryoanalgesia|Cryoanalgesia will be applied during surgery on 6 intercostal nerves each side
224216660|NCT02077751|DRUG|biotin labelled RBCs|Autologous red blood cells are biotin labelled and transfused to the subject. Survival of these red blood cells is tracked through examination of blood samples until no biotin labelled red blood cells remain.
224216661|NCT04171986|DRUG|Mecapegfilgrastim|Mecapegfilgrastim; 6 mg, d7, q3w, total 2 cycles.
224317387|NCT05600465|BEHAVIORAL|Behavioral Activation + Occupational Therapy|In the BA-OT Approach, the PI will use an evidence-based 4-step process (Goal-Plan-Do-Check) to assist the older adults to develop strategies to plan and execute daily health self-management activities. BA-OT teaches older adults with MCC and functional limitations to 1) set achievable and meaningful activity goals, 2) engage in action planning that includes brainstorming strategies to overcome barriers, 3) evaluate the results after performing the activity, and 4) to modify the plan or choose a new goal, then generalize strategies to new problems. By assisting participants to develop daily routines and integrate safe health self-management activities into these routines, occupational therapists are providing strategies that support adaptation in the face of stressful situations.. Goal examples may include adapting and scheduling exercise plans, or exploring assistive devices and strategies for safe and healthy meal preparation.
223627940|NCT00980187|DRUG|Indapamide|1.5 mg SR, orally, once a day,with Quinapril 10-40 mg, 6 months
223627941|NCT00210574|DRUG|topiramate|
223627942|NCT01121796|DIETARY_SUPPLEMENT|Vitamin D|
223627943|NCT01121796|OTHER|Water or milk|
223627944|NCT01121796|DIETARY_SUPPLEMENT|Vitamin D enriched milk|
223627945|NCT03167892|DEVICE|Oral screen|Oral screen training three times per day with an effective training time of 1.5 minutes, for 3 mo
223627946|NCT06378775|PROCEDURE|Coronary Artery Bypass Graft|Coronary Artery Bypass Graft
223627947|NCT06378775|PROCEDURE|Robotically-assisted minimally-invasive direct coronary artery bypass|Robotically-assisted minimally-invasive direct coronary artery bypass
223627948|NCT06378775|PROCEDURE|Percutaneous Coronary Intervention|Percutaneous Coronary Intervention
223627949|NCT00949182|DRUG|sorafenib tosylate, HACE : Doxorubicin Hydrochloride and Mitomycin C|After Sorafenib Tosylate has been administered the actual HACE procedure is performed using Doxorubicin Hydrochloride or Mitomycin C
223627950|NCT00949182|OTHER|laboratory biomarker analysis|
223627951|NCT03661320|BIOLOGICAL|Nivolumab|Specified dose on specified days
223627952|NCT03661320|DRUG|Gemcitabine|Specified dose on specified days
223627953|NCT03661320|DRUG|Cisplatin|Specified dose on specified days
223627954|NCT00310765|DRUG|Pregabalin 75 or 150 mg BID for 7 weeks followed by open label pregabalin 150 mg BID for 4 weeks|First 7 weeks 75 or 150 mg of pregabalin po BID. Start at 75 mg and increase to 150 mg po BID if no improvement after 3 days and treat for 7 weeks. Followed by open label pregabalin for 4 weeks at 150 mg BID
223627955|NCT00310765|DRUG|Placebo first followed by open label pregabalin|Look alike placebo 75 mg po BID and increase to 150 mg BID after 3 days if no improvement for 7 weeks. Open label pregabalin 150 mg BID for last 4 weeks of study.
223627956|NCT04247217|RADIATION|HDR salvage brachytherapy|In patients receiving HDR salvage brachytherapy for locally relapsed prostate cancer serial biopsies will be performed at 4 different time points.
223627957|NCT06132269|DIETARY_SUPPLEMENT|AKK formula prebiotic sachet|"5 g/sachet, containing AKK formula, Indigestible Maltodextrin, Crystalline Maltitol, Calcium Carbonate, Citric Acid, Steviol Glycosides, and flavor.~Subjects will consume 1 sachet per day for 8 weeks."
224216662|NCT00899665|GENETIC|fluorescence in situ hybridization|
224216663|NCT00899665|GENETIC|microarray analysis|
224216664|NCT00899665|GENETIC|molecular diagnostic method|
224216665|NCT00899665|OTHER|immunohistochemistry staining method|
224216666|NCT00899665|OTHER|laboratory biomarker analysis|
224216667|NCT00899665|PROCEDURE|biopsy|
224216668|NCT00899665|PROCEDURE|immunoscintigraphy|
224216669|NCT02898766|OTHER|Enteral Nutrition Formula|
224317388|NCT05600465|BEHAVIORAL|Enhanced Usual Care|Fitbit, 1 hour training, handout on managing chronic conditions
224317389|NCT03159338|BIOLOGICAL|Platelet rich fibrin|Platelet rich fibrin will be prepared by taking 20 cc blood and centrifugation with 28000 rpm.
224317390|NCT03159338|BIOLOGICAL|Placebo|In control group , after spliting the osteotomy site before fixation a placebo gel will be placed
223627958|NCT06132269|DIETARY_SUPPLEMENT|Placebo sachet|"5 g/sachet, containing Indigestible Maltodextrin, Crystalline Maltitol, Calcium Carbonate, Citric Acid, Steviol Glycosides, and flavor.~Subjects will consume 1 sachet per day for 8 weeks."
223627959|NCT01239849|DRUG|Atorvastatin, 10mg, 20mg, 40mg|"If initial LDL cholesterol between 100\~ 129mg/dl then starting dose of Atorvastatin is 10mg, 130\~159 mg/dl is 20 mg, 160\~220mg/dl is 40mg.~After 4weeks treatment, if LDL cholesterol is below 100mg/dl then continue starting dose and if not reach below 100mg/dl then titration double dose.~After 4 weeks treatment, recheck the LDL cholesterol"
223627960|NCT00328939|DRUG|ARIXTRA infusion|
223627961|NCT00328939|DRUG|Enoxaparine infusion|
223627962|NCT00000669|DRUG|Didanosine|
223763916|NCT03697200|OTHER|Education control|Participants in the Education Control will receive four, 15-minute weekly individual sessions in which the scheduling and duration of interaction with the study staff are identical to the APA and Sham interventions. Materials will be tailored so that they can be delivered within 15 minutes for each session
224216670|NCT02079922|DRUG|PF-06678552|PF-06678552 or placebo will be administered as an extemporaneously prepared solution every 12 hours for 14 days.
224216671|NCT02079922|DRUG|Placebo|PF-06678552 or placebo will be administered as an extemporaneously prepared solution every 12 hours for 14 days.
224216672|NCT02079922|DRUG|PF-06678552|PF-06678552 or placebo will be administered as an extemporaneously prepared solution every 12 hours for 14 days.
224216673|NCT02079922|DRUG|Placebo|PF-06678552 or placebo will be administered as an extemporaneously prepared solution every 12 hours for 14 days.
224216674|NCT02079922|DRUG|PF-06678552|PF-06678552 or placebo will be administered as an extemporaneously prepared solution every 12 hours for 14 days.
223627963|NCT05656534|DRUG|Suvorexant|This study is a double-blind study. Participants will complete an initial screening visit and pre-treatment lab visits (EMG, fMRI). Suvorexant (SUV) will be placed in opaque capsules with dextrose filler. After the pre-treatment visits participants will take one pill of SUV at the Acute Drug Challenge under medical supervision. Ninety minutes post ingestion participants will complete an EMG. Laboratory assessments will occur during peak concentration, 2 hours post-ingestion. At the end of the visit, participants will be given a blister pack with 28 pills. Participants will be instructed to take one pill orally about 30 minutes prior to sleep time each night for 28 days. Participants will be provided education about common side effects. Participants will complete daily surveys to monitor side effects and potential drug-drug interactions. At the end of the 28 days, participants will complete post-treatment lab visits.
224216675|NCT02079922|DRUG|Placebo|PF-06678552 or placebo will be administered as an extemporaneously prepared solution every 12 hours for 14 days.
224216676|NCT02079922|DRUG|PF-06678552|PF-06678552 or placebo will be administered as an extemporaneously prepared solution every 12 hours for 14 days.
224216677|NCT02079922|DRUG|Placebo|PF-06678552 or placebo will be administered as an extemporaneously prepared solution every 12 hours for 14 days.
224216678|NCT02079922|DRUG|PF-06678552|PF-06678552 or placebo will be administered as an extemporaneously prepared solution either once daily (QD), every 12 hours (Q12H), or every 8 hours (Q8H) for 14 days.
224216679|NCT02079922|DRUG|Placebo|PF-06678552 or placebo will be administered as an extemporaneously prepared solution either once daily (QD), every 12 hours (Q12H), or every 8 hours (Q8H) for 14 days.
224216680|NCT02079922|DRUG|PF-06678552|PF-06678552 or placebo will be administered as an extemporaneously prepared solution either once daily (QD), every 12 hours (Q12H), or every 8 hours (Q8H) for 14 days.
224317391|NCT05856643|DRUG|SZ011 CAR-NK|In the escalation study, the minimum initial dose was 5.0×10\^6 cells, then increased to 1.0×10\^8, 2.0×10\^8and 5.0×10\^8 cells. The infusion is given every 2 weeks.
223627964|NCT05656534|OTHER|Placebo|This study is a double-blind study. Participants will complete an initial screening visit and pre-treatment lab visits (EMG, fMRI). The placebo pill will be identical in appearance to suvorexant but will contain only dextrose. Following the pre-treatment visits, participants will take one pill at the Acute Drug Challenge under medical supervision. Ninety minutes post ingestion participants will complete the EMG paradigm. At the end of the visit participants will be provided a blister pack with 28 pills. Participants will be instructed to take one pill orally about 30 minutes prior to sleep time each night for 28 days. Participants will be provided education about common side effects. Participants will complete daily surveys to monitor side. At the end of the 28 days, participants will complete post-treatment lab visits.
223627965|NCT02103309|DEVICE|Nelfilcon A contact lenses|
223627966|NCT02103309|DEVICE|Etafilcon A contact lenses|
223627967|NCT00711698|PROCEDURE|Patient controlled analgesia|Patients in this arm will be treated with a bolus of narcotic followed by PCA
223627968|NCT00711698|DRUG|nurse-administered intermittent IV bolus opioid therapy (NAIBOD)|In this arm patients will receive the current standard of care of IV bolus narcotic therapy
223627969|NCT02168868|DIAGNOSTIC_TEST|Blood draw|A blood sample (5 mL) will be collected.
223627970|NCT02168868|DIAGNOSTIC_TEST|Stool Sample Collection|Subjects will be provided a dry, plastic, screw-top specimen container and will be asked to collect a stool sample at home.
223627971|NCT02168868|DIAGNOSTIC_TEST|Urine Sample Collection|Subjects will be provided a dry, plastic, screw-top specimen container and will be asked to collect a urine sample at home.
223627972|NCT05139472|DRUG|Empagliflozin 10 MG|Daily Empagliflozin
224216681|NCT02079922|DRUG|Placebo|PF-06678552 or placebo will be administered as an extemporaneously prepared solution either once daily (QD), every 12 hours (Q12H), or every 8 hours (Q8H) for 14 days.
224216682|NCT04703725|BEHAVIORAL|Psychosocial Care|"1. First Follow-Up: One of the implementation of the module~2. Second Follow-up: Implementation of the second module; Breathing Exercises and EFT~3. Third Follow-up: Emotional preparation about egg pick up process, individual application of coping methods~4. Fourth Follow-up: Implementation of the second module; Briefing about Breathing Exercises and EFT embryo transfer process~5. Fifth Follow-up: Implementation of the second module; Breathing Exercises and EFT~6. Sixth Follow-up: Individual application of coping methods until the learning process of pregnancy test result~7. Seventh Follow-up: Providing information about the first periods of pregnancy after treatment resulting in pregnancy and providing information about the psychosocial problems that may be encountered. Identifying psychosocial problems that may be encountered after unsuccessful treatment and individual application of coping methods to help cope."
224216683|NCT04034199|DRUG|Denosumab|Denosumab is a human monoclonal antibody against receptor activator of nuclear factor kappa-B ligand (RANKL) and its use is associated with a reduced risk of vertebral, non-vertebral and hip fracture in post-menopausal women. RANKL plays a crucial role in the pathogenesis of glucocorticoid-induced osteoporosis (GIOP). Its production is increased by GC, resulting in stimulated osteoprotegerin ligand production and increased bone resorption. Recent randomized controlled trial from Saag et al have shown that denosumab is more efficacious than risedronate in the improvement of BMD in GIOP patients. Denosumab has been confirmed efficacious in GIOP patients but its efficacy in high-risk osteopenia patients are not well studied. It is given subcutaneously at 60mg every 6 months.
224216684|NCT04034199|DRUG|Zoledronic Acid|Zoledronic acid belongs to bisphosphonates and is licensed for the treatment of GIOP and 2 RCTs found zoledronic acid has superior efficacy in improvement in BMD at lumbar spine or femoral neck at 12 months when compared to risedronate. It is given intravenously every year at a dosage of 5mg.
224216685|NCT02766387|OTHER|Evaluation of the correlation between walking speed in the 6MWT and in 2MWT, and the walking speed observed in the continuous 2km walk test and in the 10 meters walk test.|
224216686|NCT05280873|DRUG|Pirfenidone, methylprednisolone|Methylprednisolone 2 mg / kg / d+ pirfenidone (starting from 200mg tid, increasing to 600mg tid within one week and maintaining) . Methylprednisolone was reduced according to the researcher's evaluation of the patient's condition and the specific course of treatment was determined.
224317392|NCT02542605|DRUG|Erenumab|Administered once on day 1 of Part B of the study by intravenous infusion.
224317393|NCT02542605|DRUG|Placebo|Administered once on day 1 of Part B of the study by intravenous infusion.
223627973|NCT01805011|OTHER|minimum 4 months of breastfeeding|
223627974|NCT05420935|DIAGNOSTIC_TEST|IgG group|"Will be performed :~* a blood sampling of 5 ml (for realization of a basophil activation test)~* a blood sampling of 250 ml"
223627975|NCT05420935|DIAGNOSTIC_TEST|IgE group|"Will be performed :~* a blood sampling of 5 ml (for realization of a basophil activation test)~* a bone marrow sampling"
223627976|NCT05420935|DIAGNOSTIC_TEST|IgG group + IgE group|"* a blood sampling of 5 ml (for realization of a basophil activation test)~* a blood sampling of 250 ml~* a bone marrow sampling"
223627977|NCT04818619|DIAGNOSTIC_TEST|flow cytometry test|Blood samples will be stained with TIGIT by flow cytometry test
223627978|NCT05242029|DRUG|Placebo|Participants will receive placebo in a clinical setting.
223627979|NCT05242029|DRUG|Psilocybin|Participants will receive 40mg psilocybin in a clinical setting.
223627980|NCT02501252|PROCEDURE|trained midwives and nurses working in the community to provide skilled SBA services|After the completion of all the necessary preparations, trained CORNs will be deployed for ten months in their respective study sites (arms) to provide the required RH services at home, community and health posts.
223627981|NCT00821808|DEVICE|Compression Device|"The compression device will be worn for 8 hours each day on one leg. The device will be applied by the same clinician every morning.Interface pressure measurements will be made in both the sitting and standing position at three locations on the leg at the following time intervals:~* Immediately following device application~* 1 hour~* 4 hours~* 8 hours"
223627982|NCT00821808|DEVICE|Profore®|"Profore® will be worn for 8 hours each day on opposite leg. Profore® will be applied by the same clinician every morning.Interface pressure measurements will be made in both the sitting and standing position at three locations on the leg at the following time intervals:~* Immediately following device application~* 1 hour~* 4 hours~* 8 hours"
223627983|NCT03469063|DIETARY_SUPPLEMENT|AferBio|Patients will use the product (AferBio/Placebo) once a day for seven days, and then twice a day, continuously (for a total of three months of use).
223627984|NCT05549817|OTHER|Synchronous Exercise Program|The exercise program consisted of exercises by recommended guidelines for shoulder tendinopathy patients which includes various strengthening, stretching, and proprioceptive exercises with progression.
223627985|NCT05549817|OTHER|Asynchronous Exercise Program|The exercise program consisted of exercises by recommended guidelines for shoulder tendinopathy patients which includes various strengthening, stretching, and proprioceptive exercises with progression.
223627986|NCT02490449|DRUG|Dexlansoprazole MR|Administration of drug after or before diet
224216687|NCT05280873|DRUG|Methylprednisolone|Methylprednisolone 2 mg / kg / d . Methylprednisolone was gradually reduced after the improvement of symptoms and imaging. The treatment course was 6-8 weeks
223627987|NCT01247324|DRUG|Interferon beta-1a|
224216688|NCT00406822|DEVICE|OculusGen Biodegradable Collagen Matrix Implant|
223627988|NCT01247324|DRUG|Ocrelizumab-matching placebo|
223627989|NCT01247324|DRUG|Ocrelizumab|
223627990|NCT01247324|DRUG|Interferon beta-1a-matching placebo|
223627991|NCT05069051|DRUG|Belimumab 200 MG/ML [Benlysta]|Patients obtain belimumab treatment in combination with rituximab and venetoclax
223627992|NCT05069051|DRUG|standard of care|Patients obtain the standard of care: combination rituximab and venetoclax
223627993|NCT00426920|DRUG|Insulin|
223627994|NCT04084171|DEVICE|Tandem t:slim X2 with Control-IQ Technology + Dexcom G6|Subjects will use the Tandem t:slim X2 with Control- IQ Technology and Dexcom G6 CGM to control their glycemia. The Tandem t:slim X2 with Control-IQ device is an automated insulin delivery pump that automatically adjusts insulin delivery to predicted and prevailing glucose levels, as measured by a Dexcom G6 continuous glucose monitor \[CGM\].
223627995|NCT06593132|PROCEDURE|endoscopic breast conserving surgery|Breast endoscopy technology completes complex surgical operations through small incisions, achieving aesthetically pleasing results while ensuring tumor safety.
223627996|NCT06627283|DEVICE|IMT|Description: A pressure threshold loading device will be used: the POWERbreathe Medic (load range 10-90 cmH2O). Participants will be instructed to exhale passively during normal tidal breathing through the training device (until functional residual capacity) and to perform deep inspirations against the external load. The first week, the resistance will be fixed at 30% of the baseline measured maximal inspiratory pressure (MIP). Participants will be instructed to increase the resistance by 10% of the baseline set resistance each week.
223627997|NCT06627283|DEVICE|EMT|A pressure threshold loading device will be used: the POWERbreathe Ex1 EMT Medic (load range 10-90 cmH2O) or POWERbreathe Ex1 EMT MR (load range 35-175 cmH2O) depending on their baseline MEP measurement. Participants will be instructed to inhale quietly during normal tidal breathing through the training device and to perform rapid and deep exhalation against the external load. The first week, the resistance will be fixed at 30% of the baseline measured MEP. Participants will be instructed to increase the resistance by 10% of the baseline set resistance each week.
223763917|NCT05431920|DIETARY_SUPPLEMENT|Vitamin D₃ (25-hydroxy vitamin D)|Vitamin D3 oral supplementation
223763918|NCT05431920|DIETARY_SUPPLEMENT|Vitamin D₃ (25-hydroxy vitamin D)|Vitamin D3 oral supplementation
223763919|NCT06439758|DRUG|Metformin|Metformin 1000 mg/day for 6 months
224216689|NCT05535595|DRUG|genotyping and selection of renin-angiotensin system blocker|"One of perindopril or candesartan was chosen based on genotyping results on two NELL1 variants.~* perindopril 4 mg/d after genotyping~* candesartan 8 mg/d after genotyping"
224216690|NCT05535595|DRUG|Perindopril|perindopril 4 mg/d without genotyping
224216691|NCT02219295|DIETARY_SUPPLEMENT|sweet block|oral application of the above mentioned substances in 300 ml tap water in 5 min. , collection of blood at 0,15,30, 60 ,120,180 minutes for measurement of incretins GIP(gastrointestinal polypeptide) and GLP-1 (glucagon like peptide 1), Protein hormones PYY(Peptide YY),CCK (cholecystokinin), Leptin and Insulin
224216692|NCT02219295|DIETARY_SUPPLEMENT|bitter block|oral application of the above mentioned substances in 300 ml tap water, collection of blood samples at -15,0,15,30,60,120,180 min for Insulin, GIP,GLP-1, PYY and glucose
224216693|NCT02219295|DIETARY_SUPPLEMENT|umami-block|oral application of umami substances as glutamate with and without IMP, collection of blood samples as above
224216694|NCT02219295|OTHER|gastroscopy|gastroscopy with and without oral application of saccharin, tissue samples from th upper duodenum by endoscopy for the detection of taste receptor cells in the upper bowel
223627998|NCT06627283|DEVICE|Sham|A pressure threshold loading device will be used: the POWERbreathe Ex1 EMT Medic or MR, but with the resistance mechanism inside removed and replaced by a plastic ball. The same instructions will be given as for the EMT group, except that there will be no or minimal resistance (less than 6 cmH2O). There will be no change in resistance over the weeks.
224216695|NCT03382210|OTHER|Enhanced recovery protocol|Standardized enhanced recovery protocol including 21 perioperative items.
224216696|NCT05680207|BEHAVIORAL|Diabetes self- management education (DSME) program|We offered a two-hour course each week, comprising of two sessions of lectures (40 minutes each), two breaks (10 min each) and interactive session (20 min). In the interactive session, patients could communicate with each other in groups or raise any questions to the investigators.
224216697|NCT00558519|DRUG|cyclophosphamide|
224216698|NCT00558519|DRUG|cytarabine|
224216699|NCT00558519|DRUG|daunorubicin hydrochloride|
224216700|NCT00558519|DRUG|dexamethasone|
224216701|NCT00558519|DRUG|doxorubicin hydrochloride|
224216702|NCT00558519|DRUG|mercaptopurine|
224216703|NCT00558519|DRUG|methotrexate|
224216704|NCT00558519|DRUG|pegaspargase|
224216705|NCT00558519|DRUG|thioguanine|
224216706|NCT00558519|DRUG|vincristine sulfate|
224216707|NCT00558519|RADIATION|radiation therapy|
224216708|NCT05862116|OTHER|Survey form|Patients will be asked to fill a survey form that consists of socio-demographic information, Turkish Health Literacy Scale -32, Short Form-36 Health Survey and Oswestry Disability Index.
224216709|NCT05402319|COMBINATION_PRODUCT|Antibiotic combination therapy|Anti-infective treatment with at least two different types of sensitive antibiotics.
224216710|NCT05504616|OTHER|Health technology-based intervention strategy|Patient-centered, technology-based intervention strategy aimed at increasing physical activity in patients with axSpA
224216711|NCT01755611|DRUG|Minocycline 100mg|Test product
224216712|NCT01755611|DRUG|Minocycline 100mg|Reference product
224216713|NCT04573361|OTHER|Chiropractic care (one visit)|One visit to the chiropractor based on the use of spinal manipulative therapy, mobilization and other forms of manual therapy, exercise therapy, patient education, advice and reassurance
224216714|NCT04573361|OTHER|Chiropractic care (more than one visit)|More than one visit to the chiropractor based on the use of spinal manipulative therapy, mobilization and other forms of manual therapy, exercise therapy, patient education, advice and reassurance
224216715|NCT01710878|DEVICE|Intergard Synergy Graft|
224216716|NCT02204683|DRUG|Aflibercept|Intravitreal aflibercept
223627999|NCT06199713|DIAGNOSTIC_TEST|18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography|research scan 3-4 weeks after start of immunotherapy
223628000|NCT06925243|DRUG|Neoadjuvant apatinib combined with sintilimab and perioperative SOX|Sintilimab: 200mg, iv, day 1 Oxaliplatin: 130 mg/m², iv, day 1 S-1: 40-60 mg/m², po, day 1-14 (BSA \< 1.25 m², 40 mg bid, 1.25 m² ≤ BSA \< 1.5 m², 50 mg bid, BSA ≥ 1.5 m², 60 mg bid) Apatinib: 250mg, po, day1-21, for 3 cycles preoperatively
223628001|NCT06925243|DRUG|Neoadjuvant sintilimab combined with perioperative SOX|Sintilimab: 200mg, iv, day 1 Oxaliplatin: 130 mg/m², iv, day 1 S-1: 40-60 mg/m², po, day 1-14 (BSA \< 1.25 m², 40 mg bid, 1.25 m² ≤ BSA \< 1.5 m², 50 mg bid, BSA ≥ 1.5 m², 60 mg bid)
223628002|NCT05016479|DEVICE|Accelerated repetitive Transcranial Magnetic Stimulation|arTMS is a non-invasive brain stimulation technique. It will be used a MagPro R30 with a Cool-B80 figure-of-eight coil (MagVenture, Falun, Denmark).
223628003|NCT00263094|DRUG|Rofecoxib|
223628004|NCT04464863|OTHER|Kinematic metrics|kinematic metrics recorded with Kinect (register brand) and extracted with Akira (register brand)
223628005|NCT01941485|DEVICE|WaveLight® Refractive Suite|Excimer EX500 and Femtosecond FS200 lasers (Wavelight® Refractive Suite) used during LASIK surgery for corneal flap creation and corneal ablation
224216717|NCT00732771|DRUG|LCI699|
224216718|NCT03001011|DRUG|Placebo|"Pharmaceutical form: tablet~Route of administration: oral"
224216719|NCT03001011|DRUG|Sevelamer Carbonate (GZ419831)|"Pharmaceutical form: tablet~Route of administration: oral"
224216720|NCT01276028|PROCEDURE|Acupuncture|"For the Acupuncture group: Women will be eligible to receive from 1 to 20 treatments over a six month period. These women will receive an initial evaluation by a acupuncturist and will be given a Traditional Chinese Medicine (TCM) diagnosis as well as a recommended treatment schedule which they can then negotiate.~Women in the waitlist group will not receive any acupuncture for 6 months. At the end of the 6 month period the participants will be allowed to begin the acupuncture treatments."
224216721|NCT02868905|PROCEDURE|Blood sample|
224216722|NCT00990028|DRUG|Rosuvastatin|20 mg oral, for 10 days
224216723|NCT00990028|DRUG|Placebo|20 mg vehicle
224216724|NCT02494687|DRUG|Oral Domperidone|10 mg of oral domperidone administered (four times a day) for two weeks
224216725|NCT02494687|DRUG|Oral Domperidone|Increased to 20 mg four times a day for 2 weeks at the Investigator's discretion
224216726|NCT02494687|DRUG|Oral Domperidone|Increased to 30 mg four times a day at the Investigator's discretion
224216727|NCT00567528|DRUG|Ibuprofen|Apply by rubbing into skin for 30 to 60 seconds placebo ibuprofen 10% gel, 0.5cc to skin over injured area 3 times a day and taking active capsules of ibuprofen 3 times a day 10-40mg/kg per day, not to exceed 1200mg per day for 2 weeks.
224216728|NCT00567528|DRUG|ibuprofen|Apply by rubbing into skin for 30 to 60 seconds active ibuprofen 10% gel, 0.5cc to skin over injured area 3 times a day and taking placebo capsules of ibuprofen 3 times a day 10-40mg/kg per day, not to exceed 1200mg per day for 2 weeks.
224216729|NCT02795130|PROCEDURE|Sclerotomy closure|Comparison between two suture materials: 1) 8-0 polyglactin 910, 2) 6-0 plain gut
224216730|NCT02875067|BIOLOGICAL|Pembrolizumab|
224216731|NCT02875067|DRUG|Lenalidomide|
224216732|NCT01070277|DRUG|Tinidazole and Albendazole|Tinidazole 2 gr/daily for 2 days followed by Albendazole 400mg X2 /day for 7 days
224216733|NCT01070277|DRUG|Placebo control|"2 placebo pills X2 /day for 2 days followed by~1 placebo Pill X2 / day for 7 days"
224216734|NCT05415826|PROCEDURE|slow-release dexamethasone implant|The eyes with proliferative diabetic retinopathy underwent PPV with silicone oil filling with or without slow-release dexamethasone implant at the end of surgery.
224216735|NCT00065065|DRUG|Rosiglitazone|4mg orally twice daily for 12 weeks
224216736|NCT00065065|DRUG|Placebo|pill that looks identical to rosiglitazone
223628006|NCT01941485|PROCEDURE|LASIK surgery|Surgical procedure for treating refractive error based on corneal reshaping
223628007|NCT01414868|DRUG|leukotriene receptor antagonist (montelukast)|montelukast (10 mg, once per night)
223628008|NCT05493202|DEVICE|Mira Fertility Tracker|Non-interventional: observational, documenting urine E3G levels during gonadotropin stimulation.
224216737|NCT04575974|OTHER|No intervention|No intervention
224216738|NCT00397839|DRUG|Ibandronate|Ibandronate orally (tablet) at a dose of 150 mg once per month
224216739|NCT00397839|DRUG|placebo|Placebo orally (tablet) at a dose of 150 mg once per month
224216740|NCT01535157|DRUG|Fenretinide/LXS + Ketoconazole|Starting dose is: Fenretinide/LXS 800 mg 4-HPR/m2/day and Ketoconazole 400 mg/day
224216741|NCT01241565|DEVICE|ENDO GIA™ Stapler with TRI-STAPLE™ Technology|All patients will have surgery with ENDO GIA™ Stapler with TRI-STAPLE™ Technology
224216742|NCT01800669|OTHER|CHICA MLP Module|The MLP module screens families for medical-legal issues, alerts the physician to there presences and provides guidance and referral materials to help the physician resolve the issues.
224216743|NCT01800669|OTHER|CHICA without the MLP module|Clinics in the control group will have the CHICA system, but without the MLP module. It will screen for medical-legal issues but will not provide additional guidance and referrals to help resolve them.
223628009|NCT06486025|DRUG|maintenance magnesium sulphate1g/h|Women will receive a routine loading infusion of 5 g of MgSO4 over 20 minutes, followed by a maintenance dose rate of 1 g/h.
223628010|NCT06486025|DRUG|maintenance magnesium sulphate2g/h|Women will receive a routine loading infusion of 5 g of MgSO4 over 20 minutes, followed by a maintenance dose rate of 2 g/h.
223628011|NCT01910285|DRUG|Remifentanyl - sufentanil placebo|Induction of general anesthesia with 3 mg/kg of propofol combined with 3 µg/kg of remifentanil and 10 ml of isotonic sodium chloride for the double blind. The trachea is then intubated after waiting the time of action of each product.
223628012|NCT01910285|DRUG|Sufentanil - remifentanyl placebo|Induction of general anesthesia with 3 mg/kg of propofol combined with 0.3 mg/kg of sufentanil and 25 ml of isotonic sodium chloride for the double blind. The trachea is then intubated after waiting the time of action of each product.
223628013|NCT03270436|BEHAVIORAL|Wholeness, Oneness, Righteousness, Deliverance Diabetes Prevention Program|Faith based diabetes curriculum that teaches participants to connect faith and health.
223628014|NCT03270436|BEHAVIORAL|Partnership for Improving Lifestyle Intervention Diabetes Prevention Program|Family and community based diabetes prevention curriculum that teaches participants to engage their social support to have a healthy weight.
223628015|NCT03887923|BEHAVIORAL|Vestibular Physical Therapy|Balance, Gaze Stabilization, Habituation, and Walking exercises
223628016|NCT03400735|COMBINATION_PRODUCT|Cefdinir/clavulanic acide 300/125 mg film-coated tablets|Cefdinir is already an approved drug. In this study, developed cefdinir/clavulanic acide combination will be compared against to cefdinir alone.
223628017|NCT03400735|DRUG|Cefdinir 300Mg Capsule|Cefdinir is used as comparator
223628018|NCT01929421|DRUG|Gemcitabine/S-1|
223628019|NCT04475458|PROCEDURE|Ultrasound-guided dorsal penile nerve block|This block is performed by the anesthesiologist, after sedation. With an in-plane approach, the tissues around the dorsal penis nerves are visualized. The needle has to pass through Buck's fascia and there the local anesthetic is released.
223628020|NCT00431990|DRUG|depsipeptide|Cohort 1. Dose escalation, IV, Weeklyx3 in a 4week cycle. Cohort 2A. 12mg/m2, IV, Weeklyx3 in a 4week cycle. Cohort 2B. 12mg/m2, IV, Weeklyx2 in a 3week cycle.
223628021|NCT00431990|DRUG|bortezomib|Cohort 1 and 2A. 3.5mg/m2, IV, day 1, 4, 8, 11 in 28 day cycle. Cohort 2B. 3.5mg/m2, IV, day 1, 4, 8, 11 in 21 day cycle
223628022|NCT00431990|DRUG|dexamethasone|20mg for 2 days with each dose of bortezomib
223763920|NCT06439758|BEHAVIORAL|Lifestyle|Dietary lifestyle modifications
223763921|NCT00159523|DIETARY_SUPPLEMENT|Probiotic|
223763922|NCT00159523|BIOLOGICAL|placebo|
223763923|NCT02705950|DRUG|Intrathecal baclofen bolus|An intrathecal baclofen bolus injection of 50 µg (1ml) will be injected at L3/L4 level.
223763924|NCT02705950|OTHER|Placebo|1 ml of physiological saline (isotonic saline) will be injected subcutaneously at L3/L4 level simulating
223763925|NCT03985813|BEHAVIORAL|Screening Wizard|Screening Wizard is a decision support tool to guide the primary care provider to make a referral that reflects patient clinical needs and patient and parental treatment preferences and perceived barriers to treatment.
223763926|NCT05486949|DRUG|AZD4205 and carbamazepine|All subjects will receive AZD4205 single dose on Day 1, and the second dose of AZD4205 along with carbamazepine after the wash-out period.
223763927|NCT05486949|DRUG|AZD4205 and itraconazole|All subjects will receive AZD4205 single dose on Day 1, and the second dose of AZD4205 along with itraconazole after the wash-out period.
224216744|NCT00064779|DRUG|IL13-PE38QQR|
224216745|NCT00064779|PROCEDURE|targeted fusion protein therapy|
224216746|NCT00064779|PROCEDURE|surgery|
224216747|NCT02713243|DRUG|LJN452|Capsules containing LJN452
224216748|NCT02713243|DRUG|Placebo to LJN452|Capsules containing placebo to LJN452
224216749|NCT00449579|DEVICE|Excercise stress test with high frequency ECG recording (HyperQ™ System)|
224216750|NCT02873468|DRUG|Florence 30 μg/mL|10 mL, oral, twice a day.
224216751|NCT02873468|DRUG|Florence 60 μg/mL|10 mL, oral, twice a day.
224216752|NCT02873468|DRUG|Florence 90 μg/mL|10 mL, oral, twice a day.
224216753|NCT02873468|OTHER|Placebo|10 mL, oral, twice a day.
224216754|NCT03841565|BIOLOGICAL|Daratumumab|Given IV
224216755|NCT03841565|DRUG|Dexamethasone|Given PO
224216756|NCT03841565|DRUG|Pomalidomide|Given PO
224216757|NCT02445989|DRUG|NuvaRing|Provide NuvaRing to women seeking contraception
224216758|NCT02135367|BIOLOGICAL|PRP|injections of Platelet rich Plasma
224216759|NCT03020836|BEHAVIORAL|Referral to primary care physician for hypertension control|Referral to primary care physician for hypertension control
224216760|NCT03020836|BEHAVIORAL|Referral to smoking quit line|Referral to Maryland Tobacco/Smoking quit line for help with smoking cessation
224317394|NCT02542605|DRUG|PACAP-38 Challenge Agent|"Administered by intravenous infusion during Part A of the study for dose selection for Part B.~Administered by intravenous infusion on day 8 in Part B as a challenge agent to induce a migraine-like attack."
223628023|NCT06031519|PROCEDURE|Percutaneous Intramyocardial Septal Radiofrequency Ablation for hypertrophic obstructive cardiomyopathy (Liwen Procedure)|Under transthoracic echocardiography (TTE) guidance, the puncture site is positioned at the apex. A guiding line is applied along the septal long axis and the radiofrequency ablation electrode needle(17G, Cool-tip™ RF Ablation System and Switching Controller; Medtronic, Minneapolis, MN, USA) pierced towards the hypertrophic anterior interventricular septum (AIVS) 8-10 mm from the subaortic valve. Each ablation lasts up to 12 min, and the ablation power gradually increases from 30-40W. Then, the ablation needle is withdrawn 10 mm to prepare for the next application. Overall, 3-4 applications are performed in each patient. The ablation creates an area of thermal coagulative myocardial necrosis that appears as a hyperechogenic reflection detected by TTE. If deemed necessary, we repeat the procedure at the posterior interventricular septum (PIVS).
223628024|NCT04540185|BIOLOGICAL|Biological: oral polio vaccine|Bivalent OPV (GSK), 0.1 ml administered orally on a sugar lump
223628025|NCT04540185|BIOLOGICAL|Comparable Placebo|Placebo of a vaccine 0.1 ml administered orally on a sugar lump
223628026|NCT04540185|DRUG|NA-831|Drug: NA-831 30 mg of NA-831 in a capsule administered orally
223628027|NCT04540185|DRUG|Comparable Placebo of drug|Placebo 30 mg in a capsule administered orally
223763928|NCT00764075|DEVICE|Beutel TM|application of BeutelTM
224216761|NCT06174519|DEVICE|Medical device simulation|For the subjects included, investigators used the iAST® tool to predict which antibiotics would have been recommended as the top three choices both for empiric and semi-targeted therapy and recorded this data with the percentage of coverage predicted (the first three antibiotics in the iAST® ranking that have been tested in the antibiogram of the center where the study was carried were chosen). Investigators checked the final microbiological reports and logged if the recovered bacteria were susceptible to the drug prescribed by doctors and simulated by the iAST® tool according to the final antibiogram results.
224216762|NCT03888716|DRUG|KL1333|25 and 100 mg KL1333 encapsulated tablets
224216763|NCT03888716|DRUG|Placebo Oral Tablet|25 and 100 mg placebo encapsulated tablets
224216764|NCT00004158|DRUG|melphalan|
224216765|NCT00004158|PROCEDURE|peripheral blood stem cell transplantation|
224216766|NCT00004158|RADIATION|holmium Ho 166 DOTMP|
224216767|NCT02622503|DRUG|Rituximab|This is an observational study. Patients with rheumatoid arthritis and having received treatment previously will be assessed for the treatment responses.
224216768|NCT02260141|DIETARY_SUPPLEMENT|d-ribose|giving ribose in those with a diagnosis of Alzheimer's and/or dementia
223763929|NCT00764075|OTHER|standard|standard procedure will be applied but no Beutel TM software
224216769|NCT01050673|DEVICE|VERSAJET|Hydro-surgery debridement
224216770|NCT01050673|PROCEDURE|Scalpel or blade|Conventional Surgical Debridement
224216771|NCT05288673|DRUG|ALXN1210|ALXN1210 was administered by IV infusion over 5 periods, 1 dose per period: Period 1, induction; Periods 2-5, maintenance. Participants received a total of 5 doses of 400 or 800 mg, each administered every 28 days.
224216772|NCT05288673|DRUG|Placebo|Placebo was administered by IV infusion over 5 periods, 1 dose per period. Participants received the same volume and infusion rate as specified for each ALXN1210 dose (400 or 800 mg).
224216773|NCT03820973|BEHAVIORAL|Brief CBT for Anxiety|All participants will receive psychoeducation on anxiety and bCBT treatment approach, work on setting goals, begin self-monitoring, and select skill sessions that fit his/her most pressing needs. Available skills: Relaxation-Diaphragmatic breathing is a simple relaxation technique that increases oxygen flow and reduces the unpleasant physiological sensations associated with anxiety; Exposure - designed to educate Veterans about the role of avoidance in maintaining anxiety problems, as well as information about how to reduce avoidance through exposure exercises; Cognitive - Veterans may opt to address anxiety and worry through modifying negative thinking patterns. Two available options - Increasing Helpful Thoughts and Managing Unhelpful Thoughts.
224216774|NCT00690768|DRUG|Bevacizumab|Intravitreal bevacizumab (1.5 mg; 0,06 ml) 1 week after baseline; pars plana vitrectomy 3 weeks after baseline
224216775|NCT00690768|PROCEDURE|pars plana vitrectomy|pars plana vitrectomy 3 weeks after baseline
224317395|NCT02682927|DRUG|ZX008 (Fenfluramine Hydrochloride)|ZX008 drug product is an oral aqueous solution of fenfluramine hydrochloride buffered to pH 5. The product is sugar free and is intended to be compatible with a ketogenic diet.
224317396|NCT02682927|DRUG|Matching Placebo|Placebo solution for ZX008. The product is sugar free and is intended to be compatible with a ketogenic diet.
224317397|NCT00005827|DIETARY_SUPPLEMENT|genistein|
224216776|NCT02762968|DIETARY_SUPPLEMENT|Placebo|Placebo capsules similar to the experimental treatments.
224216777|NCT02762968|DIETARY_SUPPLEMENT|HMB|Capsules containing calcium HMB.
224216778|NCT02762968|DIETARY_SUPPLEMENT|BC30|Bacillus Coagulans GBI-30, 6086 (BC30) mixed in water.
224216779|NCT04618952|DRUG|Calcium D|calcium D supplementation given to postmenopausal females
224216780|NCT04618952|DRUG|Placebo|Placebo
224317398|NCT04605874|OTHER|Package Quantity (cigarillos)|After a 5-day period of smoking their own preferred brand of cigarillos, participants will begin a 15-day experimental period when they will be randomized to one of two conditions, 2 cigarillos per pack versus 4 cigarillos per pack.
224317399|NCT04473066|PROCEDURE|Adenotonsillectomoy +/- turbinate reduction|Tonsillectomies were performed by bipolar electrocautery while adenoidectomies were done by monopolar suction diathermy. Turbinate reduction (by either submucosal bipolar diathermy or radiofrequency) would be offered if the subject had on-going history of allergic rhinitis and examination revealed at least grade II turbinate hypertrophy. (Grade I = no turbinate hypertrophy; Grade II = turbinate hypertrophy without touching the septum; Grade III = turbinate hypertrophy touching the septum).
224317400|NCT01621477|DRUG|clofarabine|Given on Day -9 and Day -8 (Day 0 is first stem cell infusion). Drug class: antineoplastic agent
224317401|NCT01621477|DRUG|cytarabine|Given on Day -9 and Day -8 (Day 0 is first stem cell infusion). Drug class: antineoplastic agent
223763930|NCT00764075|DEVICE|software Beutel TM|application of BeutelTM to patients data for determination of site of latest contraction
223763931|NCT02425631|DEVICE|SImmetry Sacroiliac Joint Fusion System|Minimally invasive surgery for implantation of the SImmetry System
224216781|NCT02758587|DRUG|Defactinib|cross reference with arm/group descriptions
224216782|NCT02758587|DRUG|Pembrolizumab|cross reference with arm/group descriptions
223628028|NCT04540185|COMBINATION_PRODUCT|Combination of oral polio vaccine and NA-831|Combination of biological: Bivalent OPV (GSK), 0.1 ml administered orally on a sugar lump and drug NA-831 30 mg in a capsule administered orally
223628029|NCT04540185|COMBINATION_PRODUCT|Comparable Placebo of Oral Polio Vaccine and Placebo of drug|Combination of biological placebo 0.1 ml administered orally on a sugar lump and drug placebo 30 mg in a capsule administered orally
223628030|NCT06272799|DRUG|T-DM1 adjuvant|Evaluate the tolerability of treatment with adjuvant T-DM1 after failure to respond complete pathology to neoadjuvant treatment in terms of adverse events
223628031|NCT04435704|DRUG|Oxytocin|Intravenous Oxytocin
223628032|NCT03035032|DRUG|Leuprolide|Subcutaneous Injection
223628033|NCT06289751|DRUG|Cadonilimab|10 mg/kg (body weight), 60 min, IV. Repeat every 3 weeks for a total of 3 cycles
223628034|NCT06289751|DRUG|Paclitaxel-albumin|260 mg/m2 for 30 min. Repeat every 3 weeks for a total of 3 cycles.
223628035|NCT06289751|DRUG|Cisplatin|75-80 mg/m2, IV, 1 mg/min. Repeat every 3 weeks for a total of 3 cycles.
223628036|NCT06289751|PROCEDURE|Extrafascial hysterectomy|Extrafascial hysterectomy + pelvic lymphadenectomy (or SLN mapping) (For participants who meet ConCerv criteria)
223628037|NCT06289751|PROCEDURE|Radical hysterectomy|Radical hysterectomy + pelvic lymphadenectomy ± para-aortic lymphadenectomy (or SLN mapping) (For participants who do not meet ConCerv criteria)
223628038|NCT06289751|PROCEDURE|Cone biopsy|Cold knife conization (CKC) (For participants with tumor size ≤2 cm after 3 cycles of chemo-immunotherapy)
223628039|NCT04961710|DRUG|Hetrombopag Olamine|Hetrombopag Olamine; once daily
224216783|NCT00762983|DRUG|loratadine|"Claritin Tablet 10 mg, Claritin RediTabs 10 mg: For pediatric patients aged 7 years and older, 10 mg of loratadine is orally administered once daily after a meal in usual cases.~Claritin Dry Syrup 1%: For pediatric patients aged 3 to \< 7 years, 5 mg loratadine (0.5 g dry syrup); and for pediatric patients aged 7 years and older, 10 mg of loratadine (1 g dry syrup) is dissolved immediately before use and orally administered once daily after a meal in usual cases.~The observation period will not be specified."
224216784|NCT00751153|DRUG|Raltegravir and Atazanavir|Rategravir 400 BID, Atazanavir 400 mg daily
224216785|NCT02741362|OTHER|Intravenous injection of Stromal Vascular Fraction Cells (SVF) containing ADSCs|
224216786|NCT02741362|OTHER|Lipoaspiration|
224317402|NCT01621477|DRUG|busulfan|Given on Day -7 and Day -6 (Day 0 is first stem cell infusion). Drug class: antineoplastic agent
223628040|NCT04961710|DRUG|Placebo|Placebo; once daily
223628041|NCT06566989|DRUG|[¹⁴C]Opevesostat|Oral solution
223628042|NCT06566989|DRUG|Prednisone|Tablet
223628043|NCT06566989|DRUG|Fludrocortisone|Tablet
223628044|NCT06581705|PROCEDURE|Video Laryngoscope|Evaluation of the success rates (SR) of anesthetists aged ≥45 years for intubating neonates and infants using the C-MAC videolaryngoscope (VL) in comparison to the use of the standard laryngoscope (SL).
223628045|NCT04745910|DRUG|Pegloticase|Given IV
223628046|NCT04745910|DRUG|Rasburicase|Given IV
223628047|NCT06123325|PROCEDURE|Clipping|Microsurgical clipping of intracranial aneurysms involves craniotomy to access the brain, locating the aneurysm, and placing a small metal clip across its neck, thereby isolating it from normal blood circulation to prevent rupture.
223628048|NCT06123325|PROCEDURE|Endovascular embolization|Any endovascular embolization of intracranial aneurysms that involves navigating microcatheters through the vascular system to the site of the aneurysm and deploying materials like coils, flow-diverting stents, or endosaccular flow disruptors to occlude the aneurysm and reduce the risk of rupture.
223628049|NCT06123325|DIAGNOSTIC_TEST|Surveillance imaging|Surveillance imaging for brain aneurysms is a diagnostic approach that uses imaging techniques such as MRI, MRA, CTA, or DSA to regularly monitor the status of detected brain aneurysms. The goal is to track changes in the aneurysm's size, shape, or structure over time, which may indicate an increased risk of rupture. This ongoing assessment helps healthcare providers decide whether to continue monitoring or to consider treatment options, such as surgical clipping or endovascular coiling, based on the aneurysm's characteristics and the patient's risk factors.
223628050|NCT03122041|DRUG|Sitagliptin|
224216787|NCT01254045|DRUG|placebo|intranasal placebo (48 international units)
224216788|NCT01254045|DRUG|oxytocin 24IU|intranasal oxytocin (24 international units) and intranasal placebo (24 international units)
224216789|NCT01254045|DRUG|oxytocin 48IU|intranasal oxytocin (48 international units)
224216790|NCT03624270|DRUG|Oral arsenic Trioxide, ATRA and ascorbic acid|Oral arsenic trioxide-based frontline induction, consolidation and maintenance will be provided to patients with newly diagnosed acute promyelocytic leukemia.
224216791|NCT03951597|DRUG|combined therapy using oxaliplatin and gemcitabine chemotherapy, Lenvatinib and PD1 antibody (JS001)|"1. Gemox chemotherapy Day1 oxaliplatin 85mg/m2+ gemcitabine 1g/m2, Day8 gemcitabine 1g/m2 Three weeks is a course of treatment with a total of 6 courses.~2. Lenvatinib (8mg/d), continuous use for 1 year.~3. PD-1 antibody (JS001) (240mg every 3 weeks), continuous use for 1 year."
224216792|NCT03406689|DRUG|Nepafenac 0.1% Oph Susp|One drop of Nepafenac 0.1% will be instilled 45' prior to the IVI.
224216793|NCT03406689|DRUG|Nepafenac 0.3% Oph Susp|One drop of Nepafenac 0.3% will be instilled 45' prior to the IVI.
224216794|NCT03406689|DRUG|Artificial tear|One drop Artificial Tears will be instilled 45' prior to the IVI.
224317403|NCT01621477|DRUG|Plerixafor|Given on Day -7 and Day -6 (Day 0 is first stem cell infusion). Drug class: Hematopoietic Stem Cell Mobilizer
224317404|NCT01621477|DRUG|cyclophosphamide|Given on Day -5 and Day +4 (Day 0 is first stem cell infusion). Drug class: antineoplastic agent; immunosuppressive agent.
223628051|NCT03122041|BEHAVIORAL|Lifestyle intervention|
223628052|NCT06133244|DIAGNOSTIC_TEST|Imaging, blood samples, fuctional tests and physical examination|Imaging, blood samples, fuctional tests and physical examination
223628053|NCT06227871|PROCEDURE|Exploratory laparotomy|Exploratory laparotomy with interventions addressing pancreatic injuries Grade 1-5 including pancreatic interventions including subtotal pancreatectomy, distal pancreatectomy, pancreatic ligation, pyloric diversion, or simple drainage of the pancreas.
224317405|NCT01621477|DRUG|antithymocyte globulin (rabbit)|Given on Day -4, Day -3, Day -2, and Day -1 (Day 0 is first stem cell infusion). Drug class: immunosuppressive agent.
223628054|NCT00836589|DEVICE|ICD Therapy - ICD Lead Registry|Collecting long-term safety and efficacy data on a family of market-released ICD leads.
223628055|NCT00115570|DRUG|Insulin glulisine|Subcutaneous injection
224216795|NCT05204940|BEHAVIORAL|Mechanisms of Late life depression (LLD)-dementia through functional Magnetic Resonance Imaging (fMRI)|Analyzing mechanisms of the LLD-dementia relationship through fMRI acquisitions and analyses, to capture the specific brain networks implicated in executive function and episodic memory decline.
223628056|NCT00115570|DRUG|insulin lispro|Subcutaneous injection
223628057|NCT00115570|DRUG|insulin glargine|Subcutaneous injection once daily
223628058|NCT00115570|DRUG|NPH insulin|subcutaneous injection twice daily
223628059|NCT02259673|OTHER|Fun exercise|Intervention group 3 times a week for 20 minutes during 2 months, fun physical exercises (including activities carried out with the use of sports equipment such as beach ball, stretch, bird toys, etc)
223628060|NCT02259673|OTHER|fun exercise|"Intervention group 3 times a week for 20 minutes during 2 months, fun physical exercises~(including activities carried out with the use of sports equipment such as beach ball, stretch, bird toys, etc)"
224216796|NCT05204940|BEHAVIORAL|Neuropsychological Data|Neuropsychological Data, including Montreal Cognitive Assessment (MoCA), Wide Range Achievement Test-4 (WRAT-4) Reading subtest, Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) and Delis-Kaplan Executive Function System (D-KEFS) (Color Word Interference, Trail Making and Verbal Fluency).
224216797|NCT05204940|BEHAVIORAL|Clinical Scales|Clinical scales, including the Everyday Cognition Scale (E-Cog), Global Clinical Dementia Rating (CDR), Performance Assessment of Selfcare Skills (PASS)--CIADL (Cognitive Instrumental Activities of Daily Living) Short version, Patient Health Questionnaire (PHQ-9), and Suicide Risk Assessments (Suicide Questions, Baseline Suicidal Ideation, Suicide Intent Scale, Beck Lethality Scale, Decision Outcome Inventory, Columbia-Suicide Severity Rating Scale, and High Suicide Risk Protocol).
224216798|NCT06536686|GENETIC|Silent myocardial ischemia, STEMI|Silent myocardial ischemia association with genetic polymorphisms, miRNA and EVs
224216799|NCT02341963|DRUG|Oral Ketamine|Oral ketamine (Ketamine HCL injection, 100 mg/ml, USP, Hospira)
223628061|NCT00447720|BEHAVIORAL|PATH|We have chosen to translate two proven prevention programs for delivery to the SMI populations by their case managers. These interventions are the Brief Counseling intervention from the Project Respect program and the Community-Based Outreach Program (CBOM). Together we will translate them into ongoing case management for SMI persons who also abuse substances in the Preventing AIDS through Health Project (PATH). Consistent with other findings regarding HIV infections among the SMI, in our preliminary studies we found that these individuals are at much higher risk within the population of persons being served in Philadelphia.
223628062|NCT03326596|DRUG|Tranexamic Acid 1000 mg/10ml normal saline infusion|Infusion of Tranexamic Acid (Cyklokapron) to all consented women with the delivery of the anterior shoulder of the infant
223628063|NCT04453865|BEHAVIORAL|Project EMPOWER|Project EMPOWER is a web-based, self-administered SSI for parents that takes about 30 minutes to complete
223628064|NCT04453865|OTHER|Online Resources and Referrals|Information sheet containing materials about the nature of child anxiety and a list of national resources related anxiety treatment.
223628065|NCT01481922|DEVICE|whitacre 24 gauge|Whitacre 24 gauge spinal needle 3 inches 1/2. Manufactured by Becton Dickinson
223628066|NCT01481922|DEVICE|whitacre 22 gauge|Whitacre 22 gauge spinal needle 3 inches 1/2 manufactured by Becton Dickinson
223628067|NCT04637386|PROCEDURE|Transversus Abdominis Plane Block|A 22-gauge spinal needle was introduced from medial to lateral in-plane to the ultrasound probe, and 20 mL of bupivacaine 0.25% was injected under visualization in the plane between the transversus abdominis muscle and the fascia deep to the internal oblique muscle on each side.
223628068|NCT04637386|PROCEDURE|Local anesthetic wound infiltration|40 mL of bupivacaine 0.25% was injected subcutaneously into the surgical wound (20 mL on each of the upper and lower sides) by the obstetrician before skin closure
223628069|NCT04414241|DRUG|Hydroxychloroquine|A loading dose of 600mg of hydroxychloroquine orally on the first day, followed by 400mg of hydroxychloroquine orally every-other-day and use of standard measures of personal protection provided from the hospital for 8 weeks.
224216800|NCT02527616|DEVICE|FFR Infusion Microcatheter and standard intra-venous (IV) infusion|Cross-over design where FFR is measured twice in the same lesion using standard standard intra-venous (IV) infusion and new method
224216801|NCT00627627|DRUG|IPI-504|dose of 400 mg/m2 as a 30-60 minute IV infusion as part of a 21-day treatment cycle
224216802|NCT06583538|OTHER|Giraffe Healthcare|"An online personalised rehabilitation platform consisting of exercise videos with written and audio instruction, an exercise diary, advice and in-built messaging system between therapist and participant.~The exercise prescription consists of strengthening, aerobic and stretching. 40mins per session, twice per week, for 12 weeks"
224216803|NCT05088525|PROCEDURE|MRI|MRI for standard of care meniscus root repair surgery - noting with an added stabilization suture if it is able to successfully slow down the progression of osteoarthritis versus a standard root repair surgery.
224216804|NCT03567330|BEHAVIORAL|Family-based attachment-focused intervention|5 2-hour biweekly sessions involving parent and/or adolescent(s).
224216805|NCT03567330|BEHAVIORAL|Psychoeducation|Provides equivalent number of American Cancer Society psychoeducational sessions involving only parents.
224317406|NCT01621477|BIOLOGICAL|stem cells|Patients undergo T cell replete Hematopoietic stem cell infusion on Day 0 and Day +1. Patients undergo natural killer (NK) cell transplantation on day +6 (Day 0 is first stem cell infusion).
224317407|NCT01621477|DRUG|Tacrolimus|Given on Day +11 (Day 0 is first stem cell infusion). Drug class: immunosuppressive agent.
224317408|NCT01621477|DRUG|mycophenolate mofetil|Given on Day +11 (Day 0 is first stem cell infusion). Drug class: immunosuppressive agent.
224317409|NCT00203593|BEHAVIORAL|Exercise|
224317410|NCT00203593|DEVICE|Blood volume|
223628070|NCT00495768|BEHAVIORAL|Group Training|Participants will be trained in techniques that are useful to cope with possible side effects of treatment, such as: keeping a journal (expressive writing), breathing exercises, cognitive behavioral therapy, mindfulness meditation, and exercise.
223628071|NCT01598935|OTHER|nutrition|protein-based food
223628072|NCT00120926|DRUG|Parenteral Nutrition|
223628073|NCT02763059|DRUG|Ibuprofen 600 mg|This group receives 1 hour before surgery 600 mg ibuprofen (and another 600 mg dose 6 hours after the first dose);
223628074|NCT02763059|DRUG|Dexamethasone 4 mg|This group receives 1 hour before surgery 4 mg dexamethasone (and another 4 mg 6 hours after the first dose)
223628075|NCT02763059|DRUG|Placebo|This group receives 1 hour before surgery placebo.
224216806|NCT05036915|PROCEDURE|Pacifier randomly|"Common Action Steps:~1. Legal representatives of newborns are informed about the study purpose, participants read and sign the informed consent form so their consent is obtained.~2. Inclusion and exclusion criteria are evaluated.~3. Study group is determined in line with the randomization order of the newborn to be included in the study.~4. First part of the patient information and follow-up form is completed.~5. Feeding content, amount and method are determined by the physician.~Action Steps of the Control Group:~\* Pacifier is randomly given to the infant for 30 min independent from feeding during the day.~1. Common procedure steps are applied.~2. Procedure steps are applied in accordance with the Neonatal Nursing Protocols according to the newborn's feeding method.~3. Second part of the patient information and follow-up form is completed daily."
224216807|NCT05036915|PROCEDURE|Pacifier other|"Procedure Steps of the Experimental Group:~* Pacifier is randomly given to the infant for 30 min independent from feeding during the day. In addition, pacifier is given to the infant for 5 min before each feeding.~  1. Common procedure steps are applied.~ 2. Pacifier is given for 5 min before each feeding.~ 3. Procedure steps are applied in accordance with the Neonatal Nursing Protocols according to the newborn's feeding method.~ 4. Second part of the patient information and follow-up form is completed daily."
224216808|NCT03355859|BIOLOGICAL|JWCAR029|Subjects will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of JWCAR029. During JWCAR029 production, subjects will receive a conditioning chemotherapy regimen of cyclophosphamide and fludarabine for the purpose of lymphocytes depletion. After lymphodepletion, subjects will receive one dose treatment with JWCAR029 by intravenous (IV) injection.
224216809|NCT05042453|DEVICE|Splentis® POP Tissue Anchoring System|Anterior cervicopexy with bilateral sacrospinous ligament fixation using Splentis
224216810|NCT06053879|OTHER|Biofeedback electrical stimulation|biofeedback stimulation for faecal incontinence post Posterior Sagittal Anorectoplasty
224216811|NCT01563432|DRUG|Feburic®|80 mg\*1 tablet
224216812|NCT01563432|DRUG|TMX-67|40 mg\*2 tablets
224216813|NCT02740933|DRUG|Demeclocycline|
224216814|NCT00202657|PROCEDURE|echocardiography|
224216815|NCT03777787|DIETARY_SUPPLEMENT|Denatonium Benzoate|A single intragastric administration of denatonium benzoate (1 µmol/kg)
224216816|NCT03777787|DIETARY_SUPPLEMENT|Water|A single intragastric administration of water
224216817|NCT00883259|DRUG|Metformin|850 mg twice daily
224216818|NCT00883259|OTHER|Placebo|Microcristallyne cellulose 1 table twice daily
224216819|NCT06279481|OTHER|Nonpharmacological method|Virtual reality
224216820|NCT05912179|DIAGNOSTIC_TEST|Liver biopsy - percutaneous|liver biopsy obtained using percutaneous ultrasound guided technique
224216821|NCT05912179|DIAGNOSTIC_TEST|Liver biopsy - transjugular|liver biopsy obtained using an interventional transjugular approach
224216822|NCT05912179|DIAGNOSTIC_TEST|liver biopsy - EUS guided|liver biopsy obtained during endoscopic ultrasound
223628076|NCT02763059|DRUG|Acetaminophen 1000 mg|A Rescue medication (1000 mg acetaminophen) was given to each patient who was instructed to take it if necessary.
223628077|NCT05730296|DEVICE|TMS|10 rTMS sessions combined with cognitive training
223628078|NCT05730296|DEVICE|TMS|10 rTMS sessions
224216823|NCT00657397|DRUG|Methadone|Methadone sirup once daily
224216824|NCT02453100|BEHAVIORAL|Mobility and pelvic floor exercise|Mobility and pelvic floor exercises
224216825|NCT02453100|BEHAVIORAL|Education|Education on simple ways to manage incontinence
224216826|NCT06203288|BEHAVIORAL|Mindfulness-based social and emotional learning (MBSEL) program for educators|MBSEL for educators is a program designed to improve teachers' ability to deal with stress and enhance their well-being and teaching. Lessons include: (1) Introduction to the Science, (2) Brain, Attention, \& Well-being, (3) Positive Neuroscience, (4) Mindful Teaching, (5) Embracing Self-Compassion, (6) Finding Your Compass: Intentions for Mindful Living. This 2-hour program is self-paced and delivered online.
224216827|NCT06203288|BEHAVIORAL|Mindfulness-based social and emotional learning (MBSEL) program for students|MBSEL program for students consists of 17 lessons taught about once a week (40-50 minutes per lesson). The core mindfulness program practices (done every day for 3 minutes three times a day) consist of focusing on one's breathing and attentive listening to a single resonant sound. The lessons focus on promoting prosocial behavior (e.g., kindness, altruism), resiliency, well-being, and reducing stress in students. It also incorporates an eco-behavioral systems orientation.
224216828|NCT06037031|DRUG|Drug: PF-07923568|A single dose of PF-07923568 administered orally as 4 capsules
224216829|NCT02795780|DRUG|Flortaucipir F18|370 megabecquerel (MBq) IV single-dose
224216830|NCT02795780|PROCEDURE|PET Scan|positron emission tomography (PET) scan
224216831|NCT02830490|OTHER|functional tests|Test-retest reliability of physical function in hemodialysis patients
224216832|NCT01671735|OTHER|Survey|A clinical demonstration project funded by NCP will involve screening Veterans and enrolling veterans with pre-diabetes into the VA DPP program. This research project will recruit VA DPP eligible participants enrolled in the VA DPP program and Veterans enrolled in MOVE! that are VA DPP eligible as a comparison group. The research is not truly an intervention but similar to a program evaluation.
224216833|NCT00000394|PROCEDURE|Acupuncture therapy|
224317411|NCT00203593|PROCEDURE|VO2max test|
224317412|NCT00203593|PROCEDURE|Lower body negative pressure|
224317413|NCT00203593|BEHAVIORAL|Heart Rate|
224317414|NCT00203593|PROCEDURE|Blood Pressure|
223628079|NCT05730296|DEVICE|TMS|10 sham coils sessions without cognitive training
223628080|NCT03813355|DEVICE|transcranial Direct Current Stimulation (tDCS)|transcranial Direct Current Stimulation (tDCS) during 20 sessions
223628081|NCT00013572|BIOLOGICAL|ALVAC-HIV MN120TMG (vCP205)|
223628082|NCT06366607|OTHER|high-alert medication administration|high-alert medication administration
223628083|NCT01962935|DRUG|AZD4721|Part A - multiple ascending dose, daily; Part B - one dose decided after part A, daily
223628084|NCT01962935|DRUG|Placebo|Part A - multiple ascending dose daily
223628085|NCT01962935|DRUG|AZD5069|Part B - one dose decided after part A, twice a day
223628086|NCT03213340|OTHER|Catechin Cohort 1|\- 4 capsules taken with water 1 hour prior to meal
223628087|NCT03213340|OTHER|Curcuminoid Cohort 2|\- 2 capsules taken with water 1 hour prior to meal
223628088|NCT03213340|OTHER|Flavonoid Cohort 3|\- \~ 1 oz. serving consumed 30 minutes before meal
223628089|NCT02571023|PROCEDURE|microscope surgery|
223628090|NCT02571023|PROCEDURE|neuroendoscope surgery|
224216834|NCT04218006|GENETIC|Mutation Analysis|Specific members of nuclear and extended family relatives will be contacted to propose genetic counseling. Approvals for genetic testing will be asked and necessary information forms will be provided. A total of 5 ml of blood will be collected from each patient for DNA analysis. Blood samples will be analyzed at the Damagen Genetic Diagnosis Center (Ankara), after which no samples will be stored and all samples will be destroyed.
224216835|NCT03516838|DRUG|ACTIVA™ BioACTIVE|Restorative Dental Material: Permanent resin containing filling dental material with bioactive properties to restore decayed teeth
224216836|NCT03516838|DRUG|Compomer|Restorative Dental Material: Permanent resin containing filling dental material to restore decayed teeth
224216837|NCT01990066|BEHAVIORAL|Home Based Exercise|Subjects randomized to intervention will receive Physical Therapist instructed exercise teaching. They will receive a home exercise DVD and flip ring of exercises. Subjects will be asked to perform home exercise 3 days weekly consisting of 13 strengthening/stretching exercises and 20 mins of aerobic exercise, walking or seated aerobics using ergometer. Subjects will record their exercise on a log and return on day 1 of every cycle.
224216838|NCT00665626|DRUG|Fostamatinib disodium (R935788)|R935788 100 mg tablet, orally, twice-a-day
224216839|NCT00665626|DRUG|Placebo|Placebo, orally, twice-a-day
224216840|NCT04147611|DEVICE|BAHA|Participant's pediatric bone conduction hearing device.
224216841|NCT04147611|DEVICE|Wireless Audio Streaming Accessory|Cochlear Corporation's Mini Microphone 2+ Wireless Audio Streaming Accessory is an accessory used to transmit speech and sound. It consists of a microphone and a transmitter that transfers the signal to a receiver that's connected to a hearing device.
224216842|NCT04147611|DEVICE|Digital Adaptive RM System|Sonova's Roger Digital Adaptive RM system is an accessory which can be connected to a compatible hearing aid. It offers an external microphone which streams signals directly to the connected hearing aid.
224216843|NCT04147611|DEVICE|Hearing Aid|Participant's unilateral hearing aid with contralateral plug.
224216844|NCT01532037|OTHER|Cognitive behavioural therapy based self help|Comparison of cognitive behavioural therapy based pure self help and guided self help (support of a therapist) compared to treatment as usual
223628091|NCT06459375|OTHER|modified otago exercises|patients will receive modified Otago exercises with conventional treatment.
223628092|NCT06459375|OTHER|Action Observation Training|Patients will receive Action Observation Training with conventional treatment.
223628093|NCT02275702|DRUG|Dexamethasone IV|It will be administered at the induction of the anesthesia
223628094|NCT02275702|DRUG|Saline solution|
223628095|NCT00442169|BIOLOGICAL|ChimeriVax-WN02 Low Dose|Single dose formulation given in a volume of 0.5 mL by subcutaneous injection to the deltoid region.
223628096|NCT00442169|BIOLOGICAL|ChimeriVax-WN02 Medium Dose|Single dose formulation given in a volume of 0.5 mL by subcutaneous injection to the deltoid region
224216845|NCT01532037|OTHER|Treatment as usual|Usual care from healthcare professionals with regard to patients symptoms of fatigue
224216846|NCT00435825|DRUG|peginterferon alfa-2a [Pegasys]|90 or 180 micrograms subcutaneous weekly for 24 weeks or 48 weeks.
224216847|NCT00530439|OTHER|Lifestyle intervention|Dietician counselling and physical training
224216848|NCT00530439|OTHER|Control|Repeated measuring of maternal weight gain, blood samples and ultrasound
224216849|NCT00530439|BEHAVIORAL|Physical activity, dietetic counselling|"The active intervention consisted of two major components: dietary counseling and physical activity. Dietary counseling was performed by trained dieticians on four separate occasions at 15, 20, 28 and 35 weeks gestation.~Energy requirements for each participant were individually estimated according to weight and level of activity during pregnancy. Women in the active intervention group were encouraged to be moderately physically active 30-60 minutes a day.Women in this group also had free full time membership in a fitness center for six months. In the fitness centers they had closed training classes with trained physiotherapists for one hour each week."
224216850|NCT04427930|BIOLOGICAL|JOINTSTEM|Autologous Adipose Tissue derived MSCs
224216851|NCT01259700|BEHAVIORAL|High-risk patient standardized management package|A primary-care based high cardiovascular risk management package delivered by village doctors
223628097|NCT00442169|BIOLOGICAL|ChimeriVax-WN02 High Dose|Single dose formulation given in a volume of 0.5 mL by subcutaneous injection to the deltoid region
224216852|NCT01259700|BEHAVIORAL|Community based salt reduction program|A community-based salt reduction program delivered mainly by community health educators
224317415|NCT00203593|BEHAVIORAL|Total Peripheral Resistance|
224317416|NCT03878771|BIOLOGICAL|Platelet rich fibrin gel in Orabase|applied on oral mucositis and /or ulcer 3 times per day
224317417|NCT03878771|DRUG|Dermovate cream in Orabase|applied on oral mucositis and /or ulcer 3 times per day
223628098|NCT00442169|BIOLOGICAL|0.9% Saline solution|Single dose formulation given in a volume of 0.5 mL by subcutaneous injection to the deltoid region
223628099|NCT00442169|BIOLOGICAL|ChimeriVax-WN02 High Dose|Single dose formulation given in a volume of 0.5 mL by subcutaneous injection to the deltoid region
223628100|NCT00442169|BIOLOGICAL|0.9 % NaCl solution|Single dose given in a volume of 0.5 mL by subcutaneous injection to the deltoid region
223628101|NCT01526499|DRUG|Docetaxel and Cyclophosphamide (TC)|Docetaxel 75mg/m2 IVGTT D1 Cyclophosphamide 50mg PO D1-21;every 21days
223628102|NCT01526499|DRUG|Docetaxel (T)|Docetaxel 75mg/m2 IVGTT D1;every 21days
223763932|NCT05481619|DRUG|Vedolizumab|"Recommended dose in patients with UC: 300 mg intravenously at weeks 0, 2, and 6 and every 8 weeks thereafter.~Discontinue vedolizumab at week 14 in patients who do not show treatment benefit."
223763933|NCT01851005|DRUG|Dexmedetomidine|Infusion of dexmedetomidine (0.4 ug/kg/hr)
223763934|NCT01851005|DRUG|Sevoflurane|Control Vol% to maintain BIS 40\~45
223763935|NCT01851005|DRUG|Propofol and Remifentanil|Control effect site concentration for maintain BIS 40\~45 and changes of vital signs within 20%.
223628103|NCT00242931|OTHER|Nonmyeloablative stem cell conditioning regimen|"Conditioning:~Fludarabine 30 mg/m2/day x 3, day -4 to day -2 TBI 200 cGy x 1, day 0~Hematopoeitic Stem Cell Transplantation:~Infusion of peripheral blood stem cells, day 0~Immunosuppression:~For related donors: cyclosporine (CSP) 5 mg/kg p.o. bid, day -3 to day +56, then taper by 20% every 5 days to be completed by day +81 For related donors: mycophenolate mofetil (MMF) 15 mg/kg p.o. q 12 hours, day 0 to day +27, then stop~For unrelated donors: cyclosporine (CSP) 5 mg/kg p.o. bid, day -3 to day +56, then taper by 20% every 5 days to be completed by day +81 For unrelated donors: mycophenolate mofetil (MMF) 15 mg/kg tid day +0 to day +29, 15 mg/kg bid day +30 to day +149, and then taper by 25% per week from day +150 to day +180. Discontinue by day +181."
223628104|NCT05874674|DRUG|Nafamostat Mesylate|Comparison effect of nafamostat and cnoxan
223628105|NCT05081908|PROCEDURE|Radiosurgery|Multisession radiosurgery (hypofractionated radiotherapy) with Cyberknife
223628106|NCT04731701|DIAGNOSTIC_TEST|Hemophilia Joint Health Score (HJHS)|Joint examination with Hemophilia Joint Health Score (HJHS)
223628107|NCT02570178|OTHER|balance training|Participants complete 2 sessions per week for 30 minutes each, over a period of three months and are distributed in groups of four individuals carrying out the exercises at once.The groups were led by monitors who had received standardized training. Each participant was barefoot on the balance board, carrying out the different exercises in the balance area of the Wii Fit™ game, according to the indications made on the screen.Eight out of the nine balance exercises were used from the Wii Fit™ game (balance bubble, soccer heading, ski jump, table tilt, ski slalom, penguin slide, snowboard slalom, tightrope walk);.The number of repetitions of each exercise varied depending on the skill of the participants but the total time dedicated to each exercise was the same for all group participants.
223628108|NCT01890343|DRUG|florbetapir 18F|Subjects received a one-time intravenous (IV) bolus injection of 300 megabecquerels (MBq) florbetapir 18F.
223628109|NCT01890343|DRUG|18F-FDG|FTD subjects received a one-time IV bolus injection of 185 MBq of 18F-FDG.
223628110|NCT02595983|DRUG|Revusiran|500mg Revusiran by subcutaneous (sc) injection
223628111|NCT05856500|DIETARY_SUPPLEMENT|basic nutrition|An adequate supply of energy and protein in diet, oral nutrition supplement or tube feeding enteral nutrition supplement when diet is deficient.
223628112|NCT05856500|DIETARY_SUPPLEMENT|oral supplement of creatine and curcumin|Creatine and curcumin are orally added other than basic nutrition treatment.
223628113|NCT01626326|BEHAVIORAL|San Francisco Stop Smoking iPhone app|iPhone app designed to help people quit smoking
224216853|NCT01176474|BIOLOGICAL|NY-ESO-1 157-165 (165V)|"The vaccine contains two peptides from two different proteins (peptides are pieces that make up proteins) called gpl00 and NY-ES0-1.~Route of Administration: When prepared as a vaccine emulsion with Montanide ISA 51 VG, the vaccine is given by deep subcutaneous injection.~Method of Administration: The 0.5 mg vaccine emulsion dose is administered as a 1 mL injection (0.5 mg/1 mL) as a deep subcutaneous injection in the anterior thigh of the same extremity. Injections should be separated by at least 3 cm to avoid the formation of coalescent granulomas. All 4 peptides (total of 6 injections) will be administered in the same thigh and alternating thighs will be used for each subsequent treatment."
224216854|NCT01176474|DRUG|Nivolumab|"Nivolumab (BMS-936558) is a fully human monoclonal antibody (HuMAb) against programmed death-1 (PD-1).~Nivolumab will be given at the following dosages: 1, 3, or 10 mg/kg.~Nivolumab will be administered as an i.v. infusion, using a volumetric pump with a 0.2 micron in-line filter at the protocol-specified dose(s) and rate."
224216855|NCT01176474|BIOLOGICAL|gp100:280-288 (288V)|"The vaccine contains two peptides from two different proteins (peptides are pieces that make up proteins) called gpl00 and NY-ES0-1.~Route of Administration: When prepared as a vaccine emulsion with Montanide ISA 51 VG, the vaccine is given by deep subcutaneous injection.~Method of Administration: The 0.5 mg vaccine emulsion dose is administered as a 1 mL injection (0.5 mg/1 mL) as a deep subcutaneous injection in the anterior thigh of the same extremity."
224216856|NCT01176474|DRUG|Montanide ISA 51 vegetable grade (VG)|"Route of Administration: Administer peptide vaccine emulsions prepared with Montanide® ISA 51 VG by deep subcutaneous injection.~Method of Administration: Divide peptide vaccine emulsion dose volumes of greater than 1.5 mL into 2 or more injections. Administer injections typically into the anterior thigh deep subcutaneous tissue. Perform subsequent injections in rotating sites. Use a 20 or 21 gauge needle for deep subcutaneous injection of the peptide vaccine emulsion."
224216857|NCT01176474|DRUG|Ipilimumab|"Ipilimumab will be given at the following dosage: 3 mg/kg.~Ipilimumab will be administered as an i.v. infusion, using a volumetric pump with a 0.2 micron in-line filter at the protocol-specified dose(s) and rate."
224216858|NCT01176474|PROCEDURE|Apheresis Procedure|"Some blood will be removed from the participant's veins and processed by a machine to remove a small portion of the white cells. The rest of the blood will be returned into their veins. This procedure is called apheresis. Apheresis is done to collect cells to allow the investigators to understand how their immune system is functioning before and after receiving nivolumab and vaccine. This will be done for research purposes only. The red cells and blood clotting cells will not be permanently removed during this procedure. White blood cells will need to be removed by apheresis before participants receive the study drug."
223628114|NCT02918370|DRUG|Aripiprazole|Aripiprazole is an atypical antipsychotic drug that is used to treat mental/mood disorders. It works to restore the balance of neurotransmitters.
223628115|NCT02918370|DRUG|Placebo|Inactive ingredient matching the active comparators in appearance.
223628116|NCT05817903|DRUG|Axitinib|Axitinib will be started at the standard dose of 5 mg BID until progression of disease, unacceptable toxicity, patient' or physician' decision.
223763936|NCT01851005|DRUG|Normal saline|Use as placebo
223763937|NCT01851005|DRUG|Rocuronium|0.8 mg/kg for induction
223763938|NCT06463535|DRUG|Omega 3|SRP + OMEGA 3
223763939|NCT06463535|PROCEDURE|SRP alone|Scaling and root planning
223763940|NCT02161718|DRUG|Samidorphan + olanzapine (ALKS 3831)|Oral tablet, taken once daily
223763941|NCT02161718|DRUG|Placebo + olanzapine|Oral tablet, taken once daily
223763942|NCT06322602|PROCEDURE|Intracranial Catheter Placement|Undergo Ommaya reservoir placement
223763943|NCT06322602|PROCEDURE|Lumbar Puncture|Undergo LP
223763944|NCT06322602|PROCEDURE|Biopsy|Undergo biopsy
223628117|NCT05817903|DRUG|Nivolumab|Nivolumab will be administered at a flat dose of 480 mg IV every four weeks until progression of disease, unacceptable toxicity, patient' or physician' decision
223628118|NCT02456012|DRUG|oral esomeprazole 20 mg twice daily|for 36 weeks
223628119|NCT02456012|DRUG|oral esomeprazole 20 mg once daily|for 36 weeks
223628120|NCT03550118|DEVICE|Adjustable socket|The adjustable prosthetic socket will be used to test the influence of socket size adjustments during sitting, standing, and walking activities to determine if these strategies can be used to improve socket fit and reduce fluctuations in limb volume.
223628121|NCT04156022|OTHER|Dystonia Coalition is an observational study.|This is not an interventional study.
223628122|NCT06082206|PROCEDURE|thoracic paravertebral block (TPVB)|Bupivacaine 0.25% 20 ml was injected between the costotransverse ligament and the parietal pleura.
224216859|NCT04654156|DIAGNOSTIC_TEST|Contrast Boost post processing technique|Contrast Enhancement Boost is a post-processing technique that uses an iodine density map generated by subtracting a pre- and post-contrast CT acquisition to artificially enhance pulmonary artery enhancement.
224216860|NCT05598463|DEVICE|OASIS Pro|This device can track the joint movement and provide real-time feedback on the exercise performance and accuracy using Kinect camera sensor, and Wearable sensor (IMU). This device is connected to the website, which available for medical staff prescribe the exercise protocol and monitor individual exercise adherence.
224317418|NCT07134192|PROCEDURE|Fluorescent-guided Surgery|Surgical treatment of the patient group will include the administration of a fluorescent dye and intraoperatively the resection will be aided and guided by the fluorescent signal. The wound bed will be inspected, areas with fluorescent signal will be excised and obtained separately for histopathology. Patients will receive the current post-operative standard of care for sarcoma patients
224317419|NCT07133620|DEVICE|Transcutaneous electrical acupoint stimulation|"Before the operation, the patient received transcutaneous electrical acupoint stimulation (TEAS) at bilateral Zusanli (ST 36), Neiguan (PC 6), and Ciliao (BL 32) acupoints with sterilized electrode patches. The stimulation intensity and current intensity that gave the patient an effective pricking sensation (Qi arrival) were maintained for 30 minutes. The stimulation method in the post-anesthesia care unit (PACU) was consistent with that before the operation."
223628123|NCT06082206|PROCEDURE|PECS group|entering the plane between the pectoralis minor muscle and serratus anterior muscle, and bupivacaine 0.25% 10 ml was deposited in this space
223628124|NCT04910295|DRUG|COVID-19 vaccine|Subjects will be vaccinated with COVID-19 vaccines approved in Korea. Data on specific vaccines will be gathered.
223628125|NCT03908034|OTHER|presence of uncontrollable risk factor|the presence of an uncontrollable / unremovable risk factor for a disease
223628126|NCT03908034|OTHER|induction of anticipated regret|higher level of elaboration on potential regret
223628127|NCT04404179|OTHER|COVID-19 FACILITY|A COVID-19 facility was setup within the Prison. All positive prisoners were managed in the facility. If further intervention was required they were to be shifted to Services Hospital , Lahore.
223628128|NCT01187017|DRUG|Cyclophosphamide|60 mg/kg
223763945|NCT06322602|PROCEDURE|Biospecimen Collection|Undergo CSF sample collection
223763946|NCT06322602|PROCEDURE|Computed Tomography|Undergo CT
223763947|NCT06322602|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
224216861|NCT01973270|BEHAVIORAL|Neuroadaptive cognitive training|TCT exercises consist of three modules: an Auditory Processing Module (40-50 hours of training); a Visual Processing Module (30 hours); a Cognitive Control Module prototype (20 hours). \[Based on the results of our current RCT, Posit Science has revised aspects of the training modules in order to further optimize its effectiveness for treatment of schizophrenia. In this study, we will use updated versions of the training software: an Auditory Module (20 hours), and a Social Module (10 hours). Features from the Cognitive Control module prototype have been expanded and incorporated into these new modules.
224317420|NCT07133620|DEVICE|Sham transcutaneous Electrical Acupoint Stimulation|Before the operation, disinfection patches with electrodes were applied to Zusanli (ST 36), Neiguan (PC 6), and Ciliao (BL 32) acupointst, but no electrical stimulation was conducted. The stimulation method in the post-anesthesia care unit (PACU) was the same as that before the operation.
223628129|NCT01187017|DRUG|Fludarabine|125 mg/m squared
223628130|NCT01571102|BEHAVIORAL|Therapy|week 1 - 4: 3 times/week, week 5 - 8: 2 times/week, duration 40min.
223628131|NCT01571102|BEHAVIORAL|Exercise therapy|week 1 - 4: 3 times/week, week 5 - 8: 2 times/week, duration 30 min.
223628132|NCT06256185|PROCEDURE|esophagectomy|Resection of esophageal tumor and lymph node dissection
223628133|NCT02931188|DRUG|Anacetrapib|No drug administration will occur on this sub-study. Participants will receive treatment on the main trial HPS3/TIMI 55: REVEAL (NCT01252953)
223628134|NCT02931188|DRUG|Statin|No drug administration will occur on this sub-study. Participants will receive treatment on the main trial HPS3/TIMI 55: REVEAL (NCT01252953)
223628135|NCT02931188|DRUG|Placebo|No drug administration will occur on this sub-study. Participants will receive treatment on the main trial HPS3/TIMI 55: REVEAL (NCT01252953)
223628136|NCT04107662|DEVICE|Tbit system|Suspected traumatic brain injury with head CT
223763948|NCT06640556|BEHAVIORAL|watching animation show|The intervention group will watch the animation titled 'A Green Future with the Hand of a Midwife' on days 7, 21, and 30 to mothers who have just given birth, and the scale will be evaluated on three separate days in total.
223763949|NCT06444646|OTHER|Adipose tissue biopsy|From each patient, two biopsies will be taken during surgery; one from the subcutaneous and one from the visceral adipose tissue.
223763950|NCT06444646|OTHER|Blood sampling|From each patient, two venous blood samples (citrate, LiHe and EDTA plasma) will be taken before surgery.
223763951|NCT06444646|OTHER|Questionnaire|Before bariatric surgery, every patient will fill out questions about general health (physical activity, sedentary behavior, sleeping pattern, ...), physical condition before surgery (nausea, food intake, ...), etc.
224216862|NCT01308658|DRUG|Darunavir (DRV)|2x400-mg DRV tablet or 800-mg tablet
224216863|NCT01308658|DRUG|ritonavir|on Day 3
224216864|NCT03352817|OTHER|Cardiac rehabilitation|A questionnaire and an information sheet are provided. The questionnaire had to be completed anonymously and individually by the patient, to avoid any influence.
224317421|NCT07134452|DIAGNOSTIC_TEST|Baseline Assessments|Evaluation of isokinetic muscle strength, grip strength, upper extremity weight-bearing capacity, proprioceptive sense, reaction time, and functional performance in both groups
223628137|NCT05595655|BEHAVIORAL|Motivational Interviewing|Motivational Interviewing (MI) is a directive client-centred counselling approach for eliciting behavioral change by helping people to explore and resolve ambivalence. MI considers several critical factors to improving self-care in patients with HF and is based on brief interventions, which are feasible in several healthcare settings.
223628138|NCT02399215|OTHER|Laboratory Biomarker Analysis|Correlative studies
223628139|NCT02399215|DRUG|Nintedanib|Given PO
224216865|NCT05709054|OTHER|Experimental: Diaphragmatic Manual Therapy Group A|"Experimental: Diaphragmatic Manual Therapy plus Breathing Retraining Exercises group:~Diaphragm manual therapy will be carried out and consists of a technique intended to stretch and mobilise the diaphragmatic muscle fibers indirectly. The maneuver will be performed in two sets of 10 repetitions, within a 1-minute interval for 10 minutes.~Breathing retraining exercises will be implemented for 30 minutes, consisting of:~i) recognition of the abnormal breathing pattern ii) diaphragmatic breathing ii) nose breathing iii) slow breathing and controlled breath holding after exhalation iv) adaptation of the new breathing pattern in everyday life activities and various positions (supine, semi-sitting, sitting) v) breathing control in speech."
224216866|NCT05709054|OTHER|Sham Breathing Retraining Exercises Group B|"Sham Breathing Retraining Exercises Group B:~Breathing retraining exercises will be implemented for 30 minutes, consisting of :~i) recognition of the abnormal breathing pattern ii) diaphragmatic breathing ii) nose breathing iii) slow breathing and controlled breath holding after exhalation iv) adaptation of the new breathing pattern in everyday life activities and various positions (supine, semi-sitting, sitting) v) breathing control in speech."
224216867|NCT01529749|DRUG|EFV/FTC/TDF + Losartan|EFV/FTC/TDF --\> oral, 600/200/245 mg, od Losartan --\> initial dose 50 mg/24h, in patients with good tolerance, dose will be increased to 100 mg/24H in week 12.
223628140|NCT02399215|OTHER|Pharmacological Study|Correlative studies
224216868|NCT01529749|DRUG|EFV/FTC/TDF|600/200/245 mg, od, oral
224216869|NCT01529749|DRUG|FTC/TDF + MK-0518|FTC/TDF --\> 200/245 mg, oral MK-0518 --\> 400 mg, oral
224216870|NCT01529749|DRUG|FTC/TDF+MK-0518+Losartan|FTC/TDF --\> 200/245 mg, oral MK-0518 --\> 400 mg, oral Losartan --\> -\> initial dose 50 mg/24h, in patients with good tolerance, dose will be increased to 100 mg/24n in week 12.
224216871|NCT05356351|DRUG|RC48- ADC|RC48-ADC 2.0 mg/kg D1,Triplizumab 3mg/kg D2，Q2W
224216872|NCT03423706|PROCEDURE|the new model of haplo-HSCT for r/r B-ALL|take advantage of high-dose CTX、CD19-CART、donor CD34+HSC and Tregs to create a new model of haplo-HSCT for the patients in r/r B-ALL,to improve the quality of HSCT.
224216873|NCT04918615|PROCEDURE|PCI|Patients in experimental group will undergo PCI with drug coated balloon catheter to treat the side branch of the coronary bifurcation lesion.
223628141|NCT02399215|OTHER|Quality-of-Life Assessment|Ancillary studies
223628142|NCT04068025|OTHER|Assigned Interventions|"Information: In the information step of the bladder training program given through the IMB model, training was given about pelvic floor muscle exercises, bladder program formation, and lifestyle change. The training was conducted face-to-face by the nurse researcher for about 15-20 min, and the training booklet was given to the patients.~Motivation: The patients in the intervention group were interviewed by the nurse researcher by phone or face-to-face in the 1st, 3rd, and 6th months after the training. The patients were motivated by providing information and counseling on the necessary issues. This process was carried out using motivational interviewing principles. Patients were given positive behavioral feedback and encouraged to control urinary incontinence.~Behavioral Skills: Behavioral skills related to urinary incontinence were evaluated 6 months after the training,together with their effects on urinary incontinence symptom score and quality of life."
224216874|NCT02778763|DRUG|CBLB612|4 μg CBLB612 SQ
224216875|NCT02778763|DRUG|Placebo|
224216876|NCT00378482|DRUG|CP-675,206 (Tremelimumab)|15 mg/kg IV every 3 months as long as required
224216877|NCT06700941|BIOLOGICAL|HPV vaccine|"The intervention of interest in this observational study is the HPV vaccine, which was introduced as part of Colombia's national immunization program in 2012. The vaccine is administered to girls between the ages of 9 and 17 to prevent cervical cancer, preneoplastic cervical lesions, and genital warts caused by HPV infection. The vaccine schedule typically includes two doses given over six months.~This study does not involve administering the vaccine as part of the research. Instead, it retrospectively analyzes the healthcare records of individuals who received the vaccine as part of routine care and compares outcomes with those who were not vaccinated."
224216878|NCT06186440|DRUG|Cisplatin Plus Temozolomide|Cisplatin Plus Temozolomide . Cisplatin 20mg/mCisplatin days 1-5
224216879|NCT06186440|DRUG|Temozolomide|Temozolomide
224216880|NCT03156517|DEVICE|Deep Brain Stimulation|
224216881|NCT06232863|DRUG|BH009|Every 28 days constitutes a treatment cycle, and administration on day 1, day 8, day 15 of each cycle
224216882|NCT01324063|BIOLOGICAL|sargramostim|
224216883|NCT01324063|DRUG|amsacrine|
223628143|NCT04616755|OTHER|Measuring changes of Little´s irregularity index ( sum of 5 contact point discrepancies together) measured in mm 2 years after retention have been I place.|Measuring changes occurred under 2 years which the retention devices have been in place between the groups
223628144|NCT06061874|DIAGNOSTIC_TEST|FAPI PET/CT|The radiopharmaceutical 68Gallium-FAPI-46 (FAPI) is applied intravenously for molecular imaging of FAP expression with FAPI PET/CT.
223628145|NCT03603782|DIETARY_SUPPLEMENT|2.5% protein|2.5%
223628146|NCT03603782|DIETARY_SUPPLEMENT|protein 5%|5%
223628147|NCT03603782|DIETARY_SUPPLEMENT|protein 10%|10%
224216884|NCT01324063|DRUG|cytarabine|
223628148|NCT03603782|DIETARY_SUPPLEMENT|protein 15%|15%
223628149|NCT03603782|DIETARY_SUPPLEMENT|A2: Peptamen 1.5 Vanilla without Breakfast|Peptamen withoug breakfast
224216885|NCT01324063|DRUG|daunorubicin hydrochloride|
224216886|NCT01324063|PROCEDURE|quality-of-life assessment|
223628150|NCT03603782|DIETARY_SUPPLEMENT|B2: only breakfast (no product)|only breakfast
223628151|NCT03603782|DIETARY_SUPPLEMENT|C2: 5% protein with breakfast|C2: 5% protein consumed with breakfast
223628152|NCT03603782|DIETARY_SUPPLEMENT|D2: 5% protein 30 min before breakfast|D2: 5% protein consumed 30 min before breakfast
223628153|NCT00298324|DRUG|Myfortic|1440mg twice daily
224216887|NCT05471219|OTHER|Primiparous pregnant women who will undergo vaginal examination by focusing on visual traces|Informed consent was obtained from the mothers to take pictures of newborns who were delivered in the delivery room, routinely cared for, dressed and breastfed by the researcher. A 10-minute visual track was created to be turned into a slide from approximately 70 photos. Vaginal examination was performed between the 4th and 6th minutes while focusing on this visual trace.
224216888|NCT02309918|DRUG|LDV/SOF FDC|Ledipasvir/Sofosbuvir fixed dose combination (FDC) tablet (LDV 90 mg/SOF 400 mg) once daily
224216889|NCT04684810|BEHAVIORAL|Community Lay Therapist-Administered EBT|Community Therapists Used CBT and EMDR Interventions
224216890|NCT01375010|DRUG|Vitamin D3|2000 mg QD
224216891|NCT01375010|OTHER|Placebo|An inactive treatment that is intended to provide baseline measurements for the experimental protocol of a clinical trial, in this case, the vitamin D3.
224216892|NCT01375010|DRUG|Vitamin Supplements|Specially formulated supplements (Tishcon, Inc.) that contain 500 mg of calcium (carbonate) and 500 IU of vitamin D3 to be taken twice daily with breakfast and dinner (1000 mg of elemental calcium and 1000 IU of vitamin D).
224216893|NCT02172716|PROCEDURE|Nonsurgical periodontal treatment|"All patients with GCP will receive full-mouth scaling and root planning under local analgesia in one session. Hopeless teeth will be treated similarly and extracted after de 30 days visit. Oral hygiene instructions will be given as needed.~Supragingival scaling Periodontally healthy subjects will receive supra-gingival scaling and polishing in one appointment as needed. Oral hygiene instructions will be given as needed."
224216894|NCT03456869|DEVICE|Patient Specific Implant|The patient specific implant is used to simultaneously complete the reposition and fixation of the chin.
223628154|NCT00298324|DRUG|Prednisone and Cyclosporine|Prednisone and Cyclosporine given according to protocol. The drugs are tapered according to patient response
223628155|NCT05390073|DIAGNOSTIC_TEST|growth hormone level and insulin like growth factor 1|laboratory test
223628156|NCT03854058|DIAGNOSTIC_TEST|magnetic phrenic nerve stimulation|cervical and cortical stimulation of N. Vagus
223628157|NCT01824238|DRUG|Anacetrapib|
224216895|NCT05767255|DRUG|insulin degludec + liraglutide|The association of insulin degludec with liraglutide in the same device (IDegLira) is a potent and safe drug that reduces the risk of hypoglycemia.
224216896|NCT05767255|DRUG|Insulin Glargine - Insulin Aspart|The insulin dose of the basal group will be adjusted according to the blood glucose reports presented by the patients.
224216897|NCT05751395|DEVICE|Central Venous Access|"Critically ill patients in severe MODS need a CVC and in some cases also a second line for e-g- blood purification techniques.~All CVCs are positioned via the ECG method with the CVC tip placed at P-max. Within 24 h a chest radiograph is obtained for assessment of the CVCs, especially their tips."
224216898|NCT01416649|DRUG|Exenatide|Exenatide is started for the treatment of type 2 diabetes as determined by the patients regular physician. The dose will be 5-10 micrograms twice daily which is the standard dose. The medication is given by self-administered subcutaneous injection. The medication may continue for the treatment of the type 2 diabetes after the study is completed after 3 months.
224216899|NCT03618966|DEVICE|Neuromuscular magnetic stimulation (NMMS)|It is a non-invasive, stimulation technique that does not induce high-intensity cutaneous electric fields and does not activate skin nociceptors, thus resulting in a painless and better-tolerated procedure. rNMMS is delivered through a high-frequency magnetic stimulator connected to a conventional circular cooled coil. Magnetic stimulator is placed above the flexor muscles of the forearm. rNMMS is delivered at a 5-Hz frequency and with a 100% stimulation intensity of 100% of the maximum intensity in 140 trains of 50 stimuli. sNMMS is delivered with a sham coil producing similar acoustic sensations and mechanical skin perceptions.
224216900|NCT04733235|DRUG|Progesterone|ultrasound measurements of endometrial thickness at the end of the estrogen phase and the day of embryo transfer.
224317422|NCT06904846|DEVICE|iCan o3 CGM Continuous Glucose Monitoring System|"A continuous Glucose Monitoring System (CGM System) is a real-time, continuous glucose monitoring device indicated for the management of diabetes for adult persons (age 18 and older). It is intended to replace finger prick blood glucose testing for diabetes treatment decisions. The CGM System also shows trends and tracks patterns, and aids in the detection of episodes of hyperglycemia and hypoglycemia, facilitating both acute and long-term therapy adjustments. Interpretation of the CGM System results should be based on the glucose trends and several sequential readings over time.~The CGM System can be used in conjunction with smart devices with corresponding applications (apps) where the user manually controls actions for therapy decisions. During this study, Self-Monitoring Blood Glucose (SMBG) assessed by an iCan o3 CGM System blinded to the patient for 15 days as the baseline and unblinded observation period using an iCan o3 CGM System for 45 days occurs."
224317423|NCT05929378|PROCEDURE|Lightweight mesh fixation|Lightweight mesh fixation in 3 points
223628158|NCT01824238|DRUG|Placebo for anacetrapib|
223628159|NCT00118183|DRUG|docetaxel|Given IV
223628160|NCT00118183|BIOLOGICAL|cetuximab|Given IV
223628161|NCT00118183|DRUG|bortezomib|Given IV
223628162|NCT04529083|DEVICE|Mr. MAPP|Mixed reality device to provide virtual mirror therapy to patients with phantom pain
223628163|NCT02669810|DRUG|PROTHERACYTES|ProtheraCytes endocardiac injections performed with the HELIX and Morph catheters
223628164|NCT02669810|DRUG|Standard Treatment for CHF post AMI|
223628165|NCT03120884|PROCEDURE|ICSI|A technique that involves microinjection of spermatozoa into mature oocytes.
223628166|NCT03120884|PROCEDURE|IVF|A process of fertilisation where an an egg is combined with sperm outside the body, in vitro.
223628167|NCT06240234|DEVICE|Capnodynamic method|All patients will be ventilated using the novel capnodynamic method, incorporated in a modified Maquet servo I ventilator. For this reason, all patients will be anesthetized using total intravenous anesthesia.
224216901|NCT00086879|DRUG|carmustine|
224216902|NCT00086879|DRUG|erlotinib hydrochloride|
224216903|NCT00086879|DRUG|temozolomide|
223628168|NCT01293903|DRUG|Qiliqiangxin capsule|Qiliqiangxin capsule is administrated based on the standard heart failure treatment in China. Dosage: 1.2g/times. Frequency: 3 times/day. Duration: The whole study period.
224216904|NCT02614703|DRUG|Chromoendoscopy using Acetic Acid 2.5%|Spraying esophageal mucosa during random biopsies for Barrett's esophagus
224216905|NCT02614703|OTHER|Standard random esophageal biopsies|Random esophageal biopsies performed as per protocol
224216906|NCT02402933|DRUG|Nasal Glucagon|3 mg nasal glucagon powder
224216907|NCT00994032|PROCEDURE|percutaneous injection of cement into the vertebral body|percutaneous injection of cement into the vertebral body
224216908|NCT00994032|OTHER|Medical treatment|standard antalgic medical treatment
224216909|NCT02580188|DRUG|sugammadex|Maintenance dose of 0.4-0.9 mg/kg/hr rocuronium as continuous infusion during surgery for the maintenance of post tetanic count 1-2 (deep block).
224216910|NCT01265888|DRUG|Inhaled Nitric Oxide|Inhaled nitric oxide 80 ppm via nasal cannula at 1 LPM for 15 minutes followed by placebo washout of 15 minutes inhalation of medical grade air (or prescribed supplemental oxygen), and then inhaled nitric oxide 80 ppm via nasal cannula at 1 LPM
224216911|NCT01265888|DRUG|Inhaled Nitric Oxide|Inhaled nitric oxide 80 ppm via nasal cannula at 1 LPM for 15 minutes followed by placebo washout of 15 minutes inhalation of medical grade air (or prescribed supplemental oxygen), and then inhaled nitric oxide 80 ppm via nasal cannula at 2 LPM
224216912|NCT01265888|DRUG|Inhaled Nitric Oxide|Inhaled nitric oxide 80 ppm via nasal cannula at 1 LPM for 15 minutes followed by placebo washout of 15 minutes inhalation of medical grade air (or prescribed supplemental oxygen), and then inhaled nitric oxide 80 ppm via nasal cannula at 4 LPM
224216913|NCT00852956|DRUG|Betahistine|"The study will be comprised of three treatment periods for a total of 4 weeks treatment duration:~Period I 1 week (Days 1-7) administration of betahistine 48 mg three times daily (144 mg/day total) or matching placebo Period II 1 week (Days 8-14) titration of olanzapine once daily (from 2.5 mg up to 10 mg) and continuation of betahistine or matching placebo administration (three times daily as in Period I) Period III 2 weeks (Days 15-28) of co-administration of betahistine or matching placebo (three times daily; as in Periods II and III) and olanzapine once daily (7.5 or 10 mg, as tolerated)~On Day 1, after a 7-day screening period, eligible subjects will be randomized to one of the two treatment groups in a 1:1 ratio:~Betahistine 48 mg TID; 08:00, 13:00 and 18:00 (144 mg/day total) Matching placebo TID; 08:00, 13:00 and 18:00"
224216914|NCT03049956|DIAGNOSTIC_TEST|Ocular vestibular evoced myogenic potentials|The oVEMP technique is an accepted standard for testing otolith function in vestibular patients. It represents a quick, simple and non-invasive technique utilizing repetitive stimulation of the otolith organs with bone-conducted vibration to elicit an extraocular muscle response. Repetitive oVEMP stimulation leads to a characteristic decrement in patients with myasthenia, which can be quantified with surface electromyography from the inferior oblique muscle underneath the eye.
224216915|NCT01681771|BEHAVIORAL|Cognitive behaviour therapy|Internet based, weekly home task and weekly feedback provided by health care professional.
224216916|NCT01681771|BEHAVIORAL|Discussion group|Internet moderated discussion group. Patients will be provided weekly question which will be used by the participant to start discuss with each others.
224216917|NCT05006183|PROCEDURE|PCI|Percutaneous coronary intervention with Drug-Eluting Stents
224216918|NCT03560505|DIAGNOSTIC_TEST|Ultrasound protocol|High-resolution ultrasound protocol at pre-defined sites bilaterally. Pre-defined sites: Sciatic nerve (proximal and distal), tibial nerve (proximal and distal), common fibular nerve (proximal and distal), superficial fibular nerve (proximal and distal) and sural nerve (proximal and distal).
224216919|NCT01951547|PROCEDURE|Nonsurgical periodontal therapy|Periodontal intervention All patients were instructed in oral hygiene methods using a soft bristled toothbrush, a compact-tuft toothbrush, interdental brushes and dental floss utilizing the modified Bass technique. Full mouth debridement, which consisted of scaling and root planing, was done in a single visit for all subjects using an ultrasonic scaler and gracey curettes. Additionally, all patients were given a 0.12% Chlorhexidine mouthrinse (Hexipro®). They were instructed to rinse three times a day using 15ml each time for a period of 14 days commencing immediately after completion of full mouth debridement. Thereafter at each recall visit, all participants were re-motivated and professional prophylaxis was performed.
224216920|NCT01951547|PROCEDURE|Oral hygiene instructions|All patients were instructed in oral hygiene methods using a soft bristled toothbrush, a compact-tuft toothbrush, interdental brushes and dental floss utilizing the modified Bass technique.
224216921|NCT02823873|DEVICE|Pulsewave oscillometric wrist cuff blood pressure monitor|Blood pressure monitor utilizing wrist cuff administered and measured using mobile technology.
224216922|NCT01917903|BEHAVIORAL|Gait-cognitive training|Participants will engage in a four week treadmill training program with a secondary cognitive component aimed at improving both walking and multitasking.
224216923|NCT01917903|BEHAVIORAL|Identification of at risk variables|Participants will complete walking under three conditions: walking alone for six minutes; standing from a chair, walking 3 meters, turning, and returning to a seated position (TUG); and standing from a chair, walking 3 meters turning and returning to a seated postion while subtracting numbers (TUG Cognitive). Spatiotemporal measures of gait will be collected.
224216924|NCT03154333|DRUG|diacerein 1% ointment|diacerein 1% ointment administered topically
224216925|NCT03154333|DRUG|A placebo ointment|vehicle ointment administered topically
223628169|NCT01293903|DRUG|Placebo|Placebo, similar in color and taste to Qiliqiangxin capsule, is administrated based on the standard heart failure treatment in China. Dosage: 1.2g/times. Frequency: 3 times/day. Duration: The whole study period.
223628170|NCT06009939|OTHER|Occlusion of the circulation in the arm and foot|A blood pressure cuff occludes the circulation in the upper arm as well as around the ankle.
223628171|NCT02051452|DRUG|Methylphenidate|
223628172|NCT02051452|OTHER|Saline|
223628173|NCT04141748|DEVICE|Symphonie Aqua SystemTM|a water filled cylinder that can be pressurized around the residual limb to support body weight
223628174|NCT04141748|PROCEDURE|Hand Casting|plaster of Paris or fiberglass bandages are wrapped around the residual limb
224216926|NCT04116294|OTHER|Computer-assisted prescription|The intervention is based on a computer-assisted prescription: when a PAR will be ordered, an alert will arise and explain the recognized indications for this examination and ask a confirmation for the prescription. This is a non-blocking system: physicians will be able to prescribe PAR even if the PAR is not appropriate.
223628175|NCT03171402|DIAGNOSTIC_TEST|Astringency and bitterness perception|Participants will be involved in 1-4 experiments that test how they rate and differentiate between bitter and astringent flavored beverage samples
223628176|NCT06556706|DIETARY_SUPPLEMENT|Mitopure (Urolithin A)|"UA is produced by the gut microbiome following the digestion of dietary precursors (polyphenols such as ellagitannins and punicalagins) present in fruits and nuts such as pomegranate, nuts and berries.~In mouse models of aging and muscle dystrophy, UA was shown to induce mitophagy and mitochondrial function in the skeletal muscle. This was associated with improved muscle strength and endurance (Nat. Med, 2016; Sci Tran Med, 2021). In humans, UA was shown to be safe and bioavailable in multiple clinical studies (Nat. Met, 2019; Cell Rep Med, 2022; JAMA Network Open, 2022)."
223628177|NCT06556706|DIETARY_SUPPLEMENT|Placebo|Placebo containing excipients other than Urolithin A (Mitopure)
223628178|NCT02196896|OTHER|deprexis®|Online self-help program in addition to inpatient psychosomatic treatment for 90 days.
223628179|NCT02196896|OTHER|Information|The patients receive online information about depression once a week for 90 days.
223628180|NCT04400877|DIAGNOSTIC_TEST|Diagnostic examination for venous thromboembolism|Patients who have done a diagnostic examination for suspected VTE (pulmonary embolism och deep venous thrombosis) within the health care system of Region Östergötland. Patients without matching diagnostic examination but with a new diagnosis of pulmonary embolism or deep venous thrombosis during the same time periods will also be taking into account.
223763952|NCT06444646|OTHER|Patient phenotyping|Length and weight will be measured to calculate body mass index (BMI). Waist and hip circumference will be assessed, as well as blood pressure (both systolic and diastolic) and heart rate at rest. Body composition will be determined using a bioelectrical impedance analysis (BIA) in the hospital. Medication use and comorbidities (that are allowed within the in-/exclusion criteria) will also be derived from the patient's medical files with patient's permission.
223763953|NCT04108208|DRUG|Apalutamide|Apalutamide 240 mg (4\*60 mg tablets) will be administrated orally once daily.
223763954|NCT04108208|DRUG|Placebo|Matching placebo will be administered orally.
223763955|NCT04108208|DRUG|Androgen-deprivation Therapy (ADT)|Participants will continue to receive ADT with gonadotrophin-releasing hormone agonists (GnRHa) who have not been surgically castrated.
223763956|NCT06644040|DRUG|TeriQ Patch|"Participants will receive two single doses of either of the TeriQ patch (Strength- 28.2 µg, 56.5 µg, and 113.0 µg) approximately 1 week apart.~Route of administration- Dermal patch"
223763957|NCT06644040|DRUG|Teribone Inj.|"Participants may receive either one single dose Teribone Inj. or Forteo Inj. following TeriQ patch.~Route of administration: Sub-cutaneous Injection"
224216927|NCT01773694|BEHAVIORAL|Early Water Exposure|"The Early Water Exposure (Intervention) group will receive written and verbal instructions to remove the dressing after 6 hours and wet the wound for at least 10 minutes. Wetting of the wound will include shower, tub bath, or pool exposure.~On subsequent days, all participants, regardless of group assignment, will wash the wound daily with soap and water, reapply white petrolatum and a dry dressing."
224216928|NCT06200389|DIAGNOSTIC_TEST|microbiology testing|Vulvovaginal Candidiases patients diagnosed by microbiology testing can be included
224216929|NCT02351973|DRUG|Hydrochlorthiazide|"HCTZ 25mg to 50mg All drugs will be provided in an acceptable container where the active agent is not identified on the drug label.~In Phase 1 (weeks 0-12) patients will have 1 tablet from each of 2 bottles. These will contain either a) HCTZ 12.5mg in both bottles; b) amiloride 5mg in both bottles; OR c) one bottle of each.~In Phase 2 (weeks13-24) patients will take 2 tablets from each of 2 bottles. These bottles will have the same contents as in Phase 1, except that the number of tablets will be twice as many."
224216930|NCT02351973|DRUG|Amiloride|"Amiloride 10mg to 20mg All drugs will be provided in an acceptable container where the active agent is not identified on the drug label.~In Phase 1 (weeks 0-12) patients will have 1 tablet from each of 2 bottles. These will contain either a) HCTZ 12.5mg in both bottles; b) amiloride 5mg in both bottles; OR c) one bottle of each.~In Phase 2 (weeks13-24) patients will take 2 tablets from each of 2 bottles. These bottles will have the same contents as in Phase 1, except that the number of tablets will be twice as many."
224216931|NCT02351973|DRUG|Hydrochlorthiazide and Amiloride|"HCTZ 12.5 to 25mg \& + Amiloride 5mg to 10mg All drugs will be provided in an acceptable container where the active agent is not identified on the drug label.~In Phase 1 (weeks 0-12) patients will have 1 tablet from each of 2 bottles. These will contain either a) HCTZ 12.5mg in both bottles; b) amiloride 5mg in both bottles; OR c) one bottle of each.~In Phase 2 (weeks13-24) patients will take 2 tablets from each of 2 bottles. These bottles will have the same contents as in Phase 1, except that the number of tablets will be twice as many."
224216932|NCT02096029|OTHER|Nicotine Replacement Therapy (NRT) Sampling|2 week supply of 4 mg nicotine lozenge and 14 mg nicotine patch
224216933|NCT02096029|BEHAVIORAL|Ask, Advise, Refer (physician brief advice)|
224216934|NCT04023630|DRUG|Rivaroxaban 15 MG Oral Tablet|One 15 mg tablet once daily for up to twelve months
224216935|NCT04023630|DRUG|Clopidogrel 75 Mg Oral Tablet|One 75 mg tablet once daily for up to twelve months
224216936|NCT04023630|DRUG|Ticagrelor 90 MG Oral Tablet|One 90 mg tablet twice daily for up to twelve months
224216937|NCT03945344|DRUG|Tiotropium|Oral capsule 20 μg
224216938|NCT03945344|DRUG|Tiotropium|Oral capsule 20 μg
224317424|NCT06352593|DRUG|Intraoperative Dexmedetomidine|Patients will be administered DEX 0.5 μg/kg for 10 min and then 0.4 μg/kg/h adjusted to 0.2-0.6 μg/kg/h.
224317425|NCT06352593|OTHER|Placebo|Patients will receive normal saline.
223628181|NCT06510660|DRUG|adebrelimab|The study was divided into two cohorts based on CPS score, with those with CPS scores ≥10 receiving induction therapy with adebrelimab alone and those with CPS scores \<10 receiving induction therapy with adebrelimab in combination with chemotherapy. At the end of the induction period, concurrent radiotherapy treatment was administered
223628182|NCT05661149|DEVICE|Hybrid closed loop insulin delivery systems|Tandem Control-IQ ; DBLG1 system ; MiniMed 780G system
223628183|NCT06310876|DRUG|ABBV-CLS-7262|• single oral Dose 1
223628184|NCT06310876|DRUG|ABBV-CLS-7262|• single oral Dose 2
223628185|NCT06310876|DRUG|Placebo|• single oral dose
223628186|NCT06310876|DRUG|Moxifloxacin 400mg|• single oral dose
224216939|NCT03157063|DIAGNOSTIC_TEST|Data Collection Procedures|"Orientation (Consent, Screening Questionnaires) Clinic Measurements Body composition, via dual energy X-ray absorptiometry (DXA) Resting metabolic rate (RMR), via indirect calorimetry; Metabolic responses to a meal, via thermic effect of feeding (TEF) Subjective aspects of eating behavior using the Three Factor Eating Questionnaire (TFEQ) and Control of Eating Questionnaire (CEQ) Appetite, via visual analogue scales (VAS) pre- and post a prepared fixed meal and hormones related to satiety and hunger (insulin, leptin, ghrelin, peptide YY, glucagon-like peptide-1) obtained during blood samples (BLOOD) from an indwelling catheter.~Home assessments - Data collected at home during a 14 day window Fitness Test (VO2submax and VO2max) and DXA functional magnetic resonance imaging (fMRI)"
224216940|NCT06091410|BIOLOGICAL|Omicron-containing COVID-19 vaccine|The COVID-19 vaccine approved for use in the 2023-2024 season
224216941|NCT06091410|BIOLOGICAL|influenza vaccine|inactivated vaccine containing 15μg hemagglutinin antigen/strain in each 0.5-mL dose, containing four influenza vaccine strains from the 2023-2024 northern hemisphere season
224216942|NCT01792284|DRUG|LY2605541|
224216943|NCT01792284|DRUG|Insulin Lispro|All participants will be administering insulin lispro SQ as their pre-meal insulin during the course of the trial.
224216944|NCT01652118|DRUG|clarithromycin treatment for prophylaxis of bronchopulmonary dysplasia|
224216945|NCT01652118|DRUG|Saline|
224216946|NCT00145756|DRUG|low sodium high potassium salt substitute|
224216947|NCT03595709|DRUG|3-in-1 tablet (EFV 400mg, TDF 300mg, 3TC 300mg)|All eligible subjects will receive 3-in-1 tablet (EFV 400mg, TDF 300mg, 3TC 300mg) once daily for 24 weeks orally on empty stomach before bedtime. If the event of toxicity or tolerability issues requires a change from study drug, switching to the best available treatment will be recommended.
224216948|NCT01403454|BEHAVIORAL|Interactive Health Communication Application|web-based application
224216949|NCT04636398|BEHAVIORAL|MESSAGE - mHealth intervention|A group-based moderated six-week intervention with didactic, discussion, and text communication components.
224216950|NCT05926882|DRUG|Apremilast 30mg|Patients will be given Oral Apremilast 30 mg twice daily after 05 days titration dose.
224216951|NCT06504108|PROCEDURE|Calcium silicate-based sealer full Pulpotomy|Using calcium silicate-based sealer as a capping agent after full pulpotomy
224216952|NCT06504108|PROCEDURE|Calcium silicate-based premixed putty full Pulpotomy|Using calcium silicate-based premixed putty as a capping agent after full pulpotomy
224216953|NCT06504108|PROCEDURE|Full Pulpotomy|Using combination between calcium silicate-based sealer and calcium silicate-based premixed putty as a capping agent after full pulpotomy
224216954|NCT02919475|DRUG|JTE-051|Active drug tablets containing JTE-051
224216955|NCT02919475|DRUG|Placebo|Placebo tablets identical in appearance to the active drug tablets
224216956|NCT05683795|OTHER|Consensus study|Modified-Delphi study and consensus meetings
224216957|NCT01123785|DRUG|INO-8875|eye drops for 14 days in one eye
224216958|NCT01123785|DRUG|Placebo|Matched vehicle-control
224216959|NCT04370184|PROCEDURE|Ultrasound guided Costoclavicular Brachial Plexus Block|Ultrasound images from patients scheduled for upper limb surgery under costoclavicular brachial plexus block (one kind of regional anesthesia) have been routinely collected at our institute. These images will be reviewed.
224216960|NCT00532519|DRUG|citalopram (cipralex)|10-20 mg/day, for 12 weeks.
224216961|NCT03781297|OTHER|Narrative Exposure Therapy|Narrative Exposure Therapy attempts to place the trauma within a narrative of the person's life. Anecdotal evidence of using this approach in the homeless population is that constructing an autobiography helps to give meaning to their problems and provide the initial steps in constructing a core sense of belonging and identity. Six sessions of individual therapy allows for participants to work with a therapist one-on-one to position their experiences of trauma within their life story.
224216962|NCT03781297|OTHER|Genealogical Services|At the start of their involvement in the, study participants randomized to this group will be provided with the option to access services from a professional genealogist, to trace their family history. Participants will be made aware of the fact that new family information will be revealed through this process, and also be informed of the standard methods that will be used to extract this information which could involve research through publicly available historical records or voluntary DNA testing.
224216963|NCT01274728|PROCEDURE|Percutaneous coronary intervention|Percutaneous coronary intervention with at least use of drug-eluting balloon and if necessary cross-over to bail-out stenting with BMS.
224216964|NCT00425789|PROCEDURE|Treatment with Hyperbaric oxygen|
224216965|NCT03757962|OTHER|Dietary intervention|Limiting dietary exposure to benzoic acid, sorbic acid, polysorbates and related food additives; limiting eating out to a maximum of 2 days per week.
224216966|NCT03674710|PROCEDURE|Standard suction, slow-pull, wet suction|"Patients will be sampled for a total of 3 consecutive FNA passes with a sequential method of standard suction, slow-pull, and wet suction. After completing all the passes, the obtained specimen will be packed individually and sent to pathologists who are blind to the method sequence."
224216967|NCT03674710|PROCEDURE|Standard suction, wet suction, slow-pull|"Patients will be sampled for a total of 3 consecutive FNA passes with a sequential method of standard suction, wet suction, and slow-pull. After completing all the passes, the obtained specimen will be packed individually and sent to pathologists who are blind to the method sequence."
224216968|NCT03674710|PROCEDURE|Slow-pull, standard suction, wet suction|"Patients will be sampled for a total of 3 consecutive FNA passes with a sequential method of slow-pull, standard suction, and wet suction. After completing all the passes, the obtained specimen will be packed individually and sent to pathologists who are blind to the method sequence."
224216969|NCT03674710|PROCEDURE|Slow-pull, wet suction, standard suction|"Patients will be sampled for a total of 3 consecutive FNA passes with a sequential method of slow-pull, wet suction, and standard suction. After completing all the passes, the obtained specimen will be packed individually and sent to pathologists who are blind to the method sequence."
223628187|NCT06433791|DRUG|Ascorbate-Meglumine|Ascorbate, meglumine and sodium salt made by combining 375 mM sodium ascorbate,125 mM ascorbic acid and 125 mM meglumine in sterile water for injection
223628188|NCT05671107|DIAGNOSTIC_TEST|NET|Online survey measuring a variety of developmental domains including anxiety, motor, daily living skills, challenging behaviors, social communication, restrictive and repetitive behaviors, ADHD, executive functioning, mood, quality of life, and sleep
223628189|NCT03941756|DRUG|Indocyanine Green|Given IV
223628190|NCT03941756|PROCEDURE|Lymphangiography|Undergo lymphangiography
223628191|NCT03941756|PROCEDURE|Lymphovenous Bypass|Undergo LVB
223628192|NCT04899843|DIETARY_SUPPLEMENT|Zinc sulphate tablet 20 mg|Zinc sulphate tablet 20 mg daily orally for 8 weeks along with topical retinoids.
223628193|NCT04899843|DIETARY_SUPPLEMENT|Placebo tablet 20 mg|Placebo tablet 20 mg daily orally for 8 weeks along with topical retinoids
223628194|NCT03098641|PROCEDURE|pelvic organ prolapse repair|Surgery to repair pelvic organ prolapse through the vagina using stitches with the addition of surgical mesh.
224216970|NCT03674710|PROCEDURE|Wet suction, standard suction, slow-pull|"Patients will be sampled for a total of 3 consecutive FNA passes with a sequential method of wet suction, standard suction, and slow-pull. After completing all the passes, the obtained specimen will be packed individually and sent to pathologists who are blind to the method sequence."
224216971|NCT03674710|PROCEDURE|Wet suction, slow-pull, standard suction|"Patients will be sampled for a total of 3 consecutive FNA passes with a sequential method of wet suction, slow-pull, and standard suction. After completing all the passes, the obtained specimen will be packed individually and sent to pathologists who are blind to the method sequence."
224216972|NCT06156969|DEVICE|Robot-Assisted Gait Training|"Training will be performed using the LokomatPro. The Lokomat consists of a driven (motorized) gait orthosis (DGO) and an advanced body weight support system, combined with a treadmill. It uses computer-controlled motors which are integrated in the gait orthosis at each hip and knee joint. The exoskeleton is secured to a person's lower limbs using straps.~Training protocol: Each training session will include 30 minutes of gait training. Training will take over a period of about 6-7 weeks. Sessions will last approximately 60 minutes."
224216973|NCT04663880|OTHER|Exposure to placebo in EEC|Patients are exposed to placebo (saline solution) in the EEC for 4h maximum
224216974|NCT04663880|OTHER|Exposure to three concentrations of HDM allergen in EEC|Patients are exposed to different concentrations of airborne HDM allergen (Der p1) in the EEC for 4h maximum
224216975|NCT04663880|OTHER|Exposure to a single concentration of HDM allergen in EEC|Patients are exposed to a single concentration of airborne HDM allergen (Der p1) in the EEC for 4h maximum
224216976|NCT02915510|DIETARY_SUPPLEMENT|Glycomacropeptide-based protein substitute|
224216977|NCT06346236|DRUG|L-thyroxine at a dose of 7.5 µg/kg/d for THOP|Subjects diagnosed with THOP (as previously defined) and treated with L-thyroxine at a dose of 7.5 µg/kg/d are less likely to have an impaired ASQ score at 4 years of corrected age.
224216978|NCT06346236|OTHER|THOP without treatment|Subjects diagnosed with THOP (as previously defined) and who received no L-thyroxine treatment.
224216979|NCT06346236|OTHER|NoTHOP|Subjects diagnosed no-THOP (as previously defined)
224216980|NCT03809013|DRUG|RC48-ADC|2.0mg/kg IV every 2 weeks
224216981|NCT04916925|DRUG|Vitamin D|Adding vitamin D to PCOS patients who are resistant to clomiphene regime for induction will or not improve the Clinical pregnancy rate and will or not increase chances of ovulation and pregnancy.
224216982|NCT04916925|DRUG|Clomid|CLOMID is adrug used for ovulation induction
224216983|NCT05139407|DIAGNOSTIC_TEST|Teaching intervention|Different teaching methods are used to teach the experimental group and the control array in the classroom.
224216984|NCT00116415|DRUG|efavirenz; didanosine EC; lamivudine|
223628195|NCT01801566|PROCEDURE|Single implant-retained mandibular overdenture|60 patients treated with single implant retained complete mandibular denture (overdenture) opposed to a conventional maxillary denture, allocated into 2 experimental groups according to the implant loading protocol (conventional and immediate), evaluated at baseline and after 1, 3, 6 and 12 months after treatment.
223628196|NCT00154570|DEVICE|EGG, 24 hour esophageal pH monitor|
223628197|NCT04948047|DIAGNOSTIC_TEST|Pathological examinations as the golden diagnosis criteria|Pathological diagnosis, as the golden standard for diagnosing pulmonary nodules, is achieved by two experienced pathologists and validated by the third senior pathologist.
223628198|NCT04948047|DIAGNOSTIC_TEST|Breath test combined with computed tomography|"Exhaled breath of each participant will be collected with Tedlar bags. The volatile organic compounds will be detected by a high-resolution high-pressure photon ionization time-of-ﬂight mass spectrometry (HPPI-TOFMS).~The Imaging markers of pulmonary nodules, including the size, three-dimensional shape, and appearance characteristics, are derived from the chest computed tomography within 2 weeks before surgery resection."
224216985|NCT03337737|DIETARY_SUPPLEMENT|Extreme Endurance|Study will compare (in a crossover) placebo vs dietary supplement Extreme Endurance.
224216986|NCT03337737|OTHER|Placebo|
224216987|NCT00478361|DRUG|Gemcitabine hydrochloride|Gemcitabine 900 mg/m\^2 IV over 90 minutes repeat every 14 days.
224216988|NCT00478361|DRUG|Paclitaxel|135 mg/m\^2 IV over 1 hour
224216989|NCT00478361|DRUG|Doxorubicin hydrochloride|Doxorubicin 40 mg/m\^2 IV over 20 minutes
223628199|NCT04361370|DRUG|Olaparib-Pembrolizumab-Bevacizumab|"* Olaparib 300mg (twice daily \[BID\])~* Pembrolizumab 200mg every 3 weeks (Q3W) from 2nd infusion for up to 35 infusions~* Bevacizumab 15mg/kg or 7.5mg/kg every 3 weeks (Q3W)"
223628200|NCT03081702|DRUG|Hydroxychloroquine|Hydroxychloroquine is approved/used for the treatment of rheumatoid arthritis, and discoid and systemic lupus erythematosus, as well as suppressive treatment and treatment of acute attacks of malaria.
223628201|NCT03081702|DRUG|Itraconazole|Itraconazole is approved and used for the treatment of certain systemic fungal infections.
223628202|NCT01429675|DRUG|bonviva|150mg Ibandronate once a month
223628203|NCT01176032|DRUG|Aliskiren|Aliskiren 300 mg film coated tablets
223628204|NCT01176032|DRUG|Losartan|Losartan 100 mg tablets
223628205|NCT01176032|DRUG|Amlodipine|Amlodipine 5mg was given to patients who did not achieve the required blood pressure (\<140/90 mmHg) after 8 weeks (visit 3)of treatment at the maximum doses of study medication in addition to the study medication in order to reach the required BP. at visit 4 (week 18) the dose of amlodipine was increased to 10mg if the required level (\<140/90 mmHg) was still not achieved.
223628206|NCT01176032|DRUG|Hydrochlorothiazide (HCTZ)|HCTZ 12.5mg was prescribed at visit 5 (week 26) if the required values (\<140/90 mmHg) had not been reached.
223628207|NCT01469221|DRUG|Apaziquone|6 weekly multi-instillation of Apaziquone 4 mg in 40 mL
224216990|NCT00478361|DRUG|Pegfilgrastim|Subcutaneously injection on day 1.
223628208|NCT01469221|DRUG|Placebo|6 weekly multi-instillation of matching placebo in 40mL
223628209|NCT06022861|DRUG|LY01015|Intravenouslly (IV) 240mg every 2 weeks (Q2W) during the combined chemotherapy period, thereafter, 480mg every 4 weeks(Q4W) during the maintenance treatment period
224216991|NCT04891588|DRUG|Switching the preserved prostaglandin analog-timolol FC to Fixalpost (preservative free prostaglandin analog-timolol FC)|"switching preserved prostaglandin analog- timolol FC (fixed combination) in the period of three months in patients with ocular hypertension and open angle glaucoma who exhibit ocular surface disease (OSD) signs and symptoms to an equally effective and safe preservative - free (PF) latanoprost - timolol FC (Fixalpost).~form: preservative free latanoprost - timolol fix combination (50 micrograms/ml latanoprost + 5 mg/ml timolol), ocular solution dosage: once daily, at 8.00 p.m. duration: 3 months"
224216992|NCT02962882|DEVICE|Mepilex Border|Multi-layer Foam Dressings
224216993|NCT02615327|DIETARY_SUPPLEMENT|8 g Polydextrose|8g of Polydextrose
224216994|NCT02615327|DIETARY_SUPPLEMENT|12 g Polydextrose|12 g of Polydextrose
224216995|NCT02615327|DIETARY_SUPPLEMENT|16 g Polydextrose|16 g of Polydextrose
224216996|NCT02615327|DIETARY_SUPPLEMENT|Placebo|0 g of Polydextrose
224216997|NCT03387410|DRUG|Intravenous IRDye 800BK|Fluorescence of the ureter using IRDye 800BK
224216998|NCT04315012|OTHER|receive mobile app-based education|to receive mobile app-based education on quality of life of women diagnosed with breast cancer implementation of adjuvant endocrine hormonal therapy.
224216999|NCT01663714|BIOLOGICAL|cycolophosphamide, vacristine, and pednisone (CVP) x6 cycles followed by tositumomab and iodine I 131 tositumomab.|cycolophosphamide, vacristine, and pednisone (CVP) x6 cycles followed by tositumomab and iodine I 131 tositumomab. CVP will be repeated every 21 days for a total of six cycles. tositumomab and iodine I 131 tositumomab will begin within 56 days following the first day of the sixth cycle of CVP. Patient will undergo two dosing phase for the tositumomab and iodine I 131 tositumomab therapy.
224217000|NCT00597584|DRUG|peginesatide|"Participants received peginesatide by intravenous (IV) or subcutaneous (SC) injection once every 4 weeks. The starting dose was based on the participant's total weekly epoetin alfa or beta dose during the last week of the Screening Period; the first dose was administered one week after the last epoetin alfa or beta dose. Participants who received epoetin alfa or beta IV at the time of screening received peginesatide IV during the study, and participants who received epoetin alfa or beta SC at the time of screening received peginesatide SC during the study.~The dose was adjusted to maintain hemoglobin levels in a target range of 10.0-12.0 g/dL and ± 1.5 g/dL from baseline during the Titration and Evaluation Periods, and 10.0-12.0 g/dL during the Long-Term Safety and Efficacy Period."
224217001|NCT00597584|DRUG|Epoetin alfa or Epoetin beta|"Participants continued to receive commercially available epoetin alfa or beta by intravenous or subcutaneous injection, at the same starting dose, frequency and route of administration as received during the last week of the Screening Period, with the first study dose of epoetin alfa or beta administered after randomization at Week 0.~The dose was adjusted to maintain hemoglobin levels in a target range of 10.0-12.0 g/dL and ± 1.5 g/dL from baseline during the Titration and Evaluation Periods, and 10.0-12.0 g/dL during the Long-Term Safety and Efficacy Period."
224217002|NCT05334602|PROCEDURE|Addition of dermal fat graft as protection over bone graft|A barrier membrane
224217003|NCT04063384|OTHER|alcohol beverage|Participants will be provided alcohol during study visits and changes in behavior/neural activity after consuming alcohol will be examined.
224217004|NCT04063384|OTHER|Placebo beverage|placebo beverage conditions.
224217005|NCT02209779|DRUG|BIBR 796 BS|
224217006|NCT02209779|DRUG|Placebo|
224217007|NCT00004797|DRUG|fructose|
224217008|NCT00004797|DRUG|placebo|
223628210|NCT06022861|DRUG|Fluorouracil|Intravenouslly (IV) l 800mg/m2 every 4 weeks (（on Day 1 through Day 5)during the combined chemotherapy period
223763958|NCT06644040|DRUG|Forteo Inj.|"Participants may receive either one single dose Teribone Inj. or Forteo Inj. following TeriQ patch.~Route of administration: Sub-cutaneous Injection"
224217009|NCT02896088|OTHER|decayed tooth surfaces|The main variable is the number of new decayed tooth surfaces between the end and the beginning of the research. The caries experience will also be evaluated and expressed by the index 'dmfs' (accumulation of decayed tooth surfaces over those missing or filled due to caries). The secondary variable will be the expression of the retention of AS. The comparison of caries incidence between the two groups of teeth (with and without AS) will take into account the membership of the teeth to the same subject by means of the statistical test Chi-McNemar two. Regression models logistics and Poisson regression will be used to test the effect of independent variables on the appearance of new cavities. The Stata statistical software will be used.
223763959|NCT03463889|DRUG|Gallium Ga 68-labeled PSMA-11|Given IV
223763960|NCT03463889|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI in combination with PET
224217010|NCT06391905|DRUG|PCSK9 inhibitor in combination with standard advanced first-line regimen group|Fluorouracil and platinum as the base chemotherapy regimen, with or without targeted therapy, was administered subcutaneously at a fixed dose of 150 mg of PCSK9 inhibitor every two weeks starting on day 1 of patient enrollment
224217011|NCT06391905|DRUG|standard advanced first-line regimen group|Fluorouracil and platinum were used as the basic chemotherapy regimens, with or without targeted therapy, and no additional injection of PCSK9 inhibitors
224217012|NCT02832297|OTHER|Vectra DA|
224217013|NCT02832297|OTHER|Usual Care|
223628211|NCT06022861|DRUG|Cisplatin|Intravenouslly (IV) 80mg/m2 every 4 weeks (Q4W) during the combined chemotherapy period
223763961|NCT03463889|PROCEDURE|Positron Emission Tomography (PET)|Undergo PET in combination with MRI
223763962|NCT01753089|BIOLOGICAL|WDVAX|
223763963|NCT06731816|OTHER|Neck and stabilization exercise group|Participants in this group will attend 2 sessions per week for 8 weeks, for a total of 16 sessions. In addition to neck stretching, range of motion, and isometric exercises applied in the neck exercise group, they will also apply spinal and cervical region stabilization exercises.
223763964|NCT06731816|OTHER|Neck exercise group|Participants in this group will attend 2 sessions per week for 8 weeks, for a total of 16 sessions. They will perform neck stretching, range of motion and isometric exercises.
223763965|NCT05831592|DIAGNOSTIC_TEST|Muscle ultrasound|Muscle ultrasound assessment (sensitivity, specificity) in undernutrition in patients
223763966|NCT06279312|DIETARY_SUPPLEMENT|Placebo drink|consume 1 drink per day for 4 weeks
224217014|NCT06481696|DIETARY_SUPPLEMENT|Resveratrol-based multivitamin supplement|Natural polyphenol and vitamins
224217015|NCT06481696|DIETARY_SUPPLEMENT|Folic acid|Supplementation with folic acid at the standard dosage of 0.4 mg/die
224217016|NCT06481696|PROCEDURE|IVF/ICSI|In vitro fertilization/IntraCytoplasmic Sperm Injection
224217017|NCT06481696|DRUG|Follitropin Alfa|Controlled Ovarian Stimulation
224217018|NCT06481696|DRUG|Ganirelix Acetate 0.5 MG/ML [Fyremadel]|GnRH Antagonist
224217019|NCT06481696|DRUG|hCG 10.000 IU or triptorelin 0,3 mg, subcutaneously|For the induction of oocyte maturation
224217020|NCT01901991|PROCEDURE|Radioactive seed localization (RSL)|Localization of nonpalpable breast lesions with Radioactive seed localization
224217021|NCT01901991|PROCEDURE|Wire-guided localization (WGL)|Localization of nonpalpable breast lesions with Wire-guided localization
224217022|NCT05002465|DRUG|68Ga-PSMA-11|Injection of 68Ga PSMA-11
224217023|NCT05002465|PROCEDURE|Positron Emission Tomography/Computed Tomography|PET/CT scan after 68Ga PSMA-11 injection
224217024|NCT00515073|DRUG|Paclitaxel|50 mg/m\^2 IV over one hour on Day 1, 8, 15, 22, and 29 during radiation therapy followed by 4 additional courses at 135 mg/m\^2 IV over 3 hours every 21 days, 4-6 weeks after pelvic radiation is completed.
224217025|NCT00515073|RADIATION|Pelvic Radiation|Radiation therapy to the pelvis daily for 25 treatments. Beginning Day 1 or 2 and given for 5 days for 5 weeks, giving a total dose of 45 Gy with external beam radiation to the pelvis. The vaginal apex boost given either with last 3 external beam treatments or after external beam radiation completed for an additional 3 days depending on patient preference. No chemotherapy given with vaginal apex boost.
224217026|NCT00515073|DRUG|Dexamethasone|20 mg IV given 30 minutes prior to chemotherapy
224217027|NCT00515073|DRUG|Cimetidine|300 mg IV given 30 minutes prior to chemotherapy
224217028|NCT00515073|DRUG|Diphenhydramine|50 mg IV given 30 minutes prior to chemotherapy
224217029|NCT03440281|DIAGNOSTIC_TEST|Uterine artery doppler|Uterine artery Doppler pulsatility indices
223628212|NCT06022861|DRUG|Opdivo®|Intravenouslly (IV) 240mg every 2 weeks (Q2W) during the combined chemotherapy period, 480mg every 4 weeks(Q4W) during the maintenance treatment period within 24 weeks, thereafter converted to LY01015 480mg every 4 weeks(Q4W).
223628213|NCT01349426|DEVICE|LigaSure Force Triad Vessel Sealing System|Quality of parenchymal pneumostasis comparison after fissure closure: LigaSure vs automatic staplers
223763967|NCT06279312|DIETARY_SUPPLEMENT|Adaptogen Elixir drink|consume 1 drink per day for 4 weeks
224217030|NCT03440281|DIAGNOSTIC_TEST|Maternal serum homocysteine estimation|
224217031|NCT05510713|DEVICE|Hemodialysis Catheter|We add a dialysis catheter to the patient, i.e., replace single-cannula in femoral venous with dual-cannula in jugular-femoral venous
224217032|NCT03392090|OTHER|More Good Days video&brief questionnaire|Help patients with advanced cancer think about what a good day means to them and to help them think about questions they may have for their physicians when discussing treatments
223628214|NCT04771156|DRUG|Ketorolac|Ketorolac 0.5mg/kg will be administered intra-operatively at the conclusion of the case and 3 more doses scheduled every 8 hours in the first 24 hours post-operatively for a total of 4 doses of Ketorolac
223628215|NCT04771156|DRUG|Placebo|0.9% Normal Saline will be administered intra-operatively at the conclusion of the case and 3 more doses scheduled every 8 hours in the first 24 hours post-operatively for a total of 4 doses of normal saline.
223628216|NCT04768504|DRUG|Tofacitinib 10 mg|Tofacitinib 10 mg PO BID for 30 days
223628217|NCT03546309|DEVICE|RIC group|Patients allocated to the RIC group will undergo RIC procedure during which bilateral arm cuffs are inflated to a pressure of 50 mmHg over systolic blood pressure for five cycles of 5 min followed by 5 min of relaxation of the cuffs.
223763968|NCT00283933|DRUG|migalastat HCl|
223763969|NCT05397665|DRUG|AT-007|AT-007, aldose reductase inhibitor
223763970|NCT05397665|DRUG|Placebo|Liquid oral suspension
223628218|NCT03546309|OTHER|Medication group|Patients allocated to Medication group will accept medication treatment by professional neurologists
223628219|NCT04471350|DEVICE|HEMOBLAST™ Bellows|Surgeon has chosen to use HEMOBLAST™ Bellows as an adjunct to hemostasis when control of minimal, mild, or moderate bleeding by conventional procedures is ineffective or impractical in spine surgery.
223763971|NCT02985242|DRUG|Empagliflozin|Empagliflozin film-coated tablet
224217033|NCT02613065|DIETARY_SUPPLEMENT|Consumption of NOW Foods eggwhite protein shake|Consumption of NOW Foods egg white protein shake at beginning of 3 daily meals that in total, is approximately 20% of caloric needs.
224217034|NCT02613065|DIETARY_SUPPLEMENT|Consumption of NOW Foods maltodextrin shake|Consumption of NOW Foods maltodextrin shake at beginning of 3 daily meals that in total, is approximately 20% of caloric needs.
224217035|NCT02323659|DRUG|Methotrexate|Methotrexate 20mg per dose, administered orally, once every week
224217036|NCT02323659|DRUG|Interferon Alfa-2b|Interferon Alfa-2b 3 million international units (MIU), administered 3 times per week
224217037|NCT02791659|RADIATION|Automatic beam adjustment function|The fluoroscopy system has an automatic beam adjustment function to maintain a good quality of image output.
224217038|NCT01456052|DRUG|Telotristat Etiprate|500 mg telotristat etiprate (LX1606) administered orally.
224217039|NCT01456052|DRUG|Placebo|Matching placebo administered orally.
224217040|NCT06267599|PROCEDURE|ACAR-Style Bladder Suture|In cases where dissection is not possible, the upper border of the bladder is opened transversely with a cutter, and the ureteral catheters and trigone inside the bladder are observed. The bladder invasion border is re-evaluated intravesically. The uterine arteries are held bilaterally with a sensitive clamp that does not crush the uterine arteries. Then, the uterus is incised from the upper border of the bladder without damaging the bladder and the predetermined myometrial invasion area is resected. After the placenta is removed, the cervical canal is found and marked with a number one vicryl suture. In these patients, the placental material is removed in pieces in the cervix area where the bladder is invaded. After the removal of the placenta, the cervix in the lower segment of the uterus is orientated and sutured together with the bladder, and this area is closed.
224217041|NCT04536233|BIOLOGICAL|MSCs Derived Pleiotropic Factors|The pleiotropic factor derived from mesenchymal stem cells was injected on the wound
224217042|NCT04536233|OTHER|physiological saline|The physiological saline was injected on the wound
223628220|NCT06478420|BIOLOGICAL|Omicron BA.5 SARS-CoV-2 challenge virus|The SARS-CoV-2 challenge virus strain was originally obtained from a nose/throat swab taken from a patient who developed respiratory symptoms consistent with Covid-19. All manufacturing steps are carried out in accordance with GMP by BioMARC, operating out of Colorado State University.
223628221|NCT03833323|COMBINATION_PRODUCT|Implantable System for Remodulin (treprostinil)|All patients will be implanted with the Implantable System for Remodulin (treprostinil).
223628222|NCT00375999|DRUG|Docetaxel and epirubicin|
223628223|NCT05414461|DRUG|Combinations|PD-1 inhibitor-based combinaiton treatment
223628224|NCT02397798|BEHAVIORAL|Person-centered high-intense training under supervision|A person-centered training program including a person-centered high-intense aerobic / strength training
224217043|NCT03526107|OTHER|CF Control|CF Control: 587 mg of cocoa flavanols, \<1 mg caffeine and \<1 mg theobromine
224217044|NCT03526107|OTHER|CF-Theobromine|CF-Theobromine: 575 mg of cocoa flavanols, 11 mg caffeine and 93 mg theobromine
223628225|NCT02397798|BEHAVIORAL|Personalized exercise program to perform at home|Introduction to health-enhancing physical activity, personalized exercise program to perform at home three times a week
223628226|NCT04749940|OTHER|Half of the harvested area will be dressed with PRF dressing, and half with Aquacel®.|Half of the harvested area will be dressed with PRF dressing, and half with Aquacel®.
223628227|NCT00792844|DIETARY_SUPPLEMENT|Bio-K capsule formulation|Bio-K 1 capsule formulation daily for the duration of antibiotic treatment and for 7 days after termination of antibiotics or until hospital discharge, whichever occurs first
223628228|NCT00792844|DIETARY_SUPPLEMENT|Bio-K drink|Bio-K 98 g of diary-free soy beverage formulation for the duration of antibiotic treatment and for 7 days after termination of antibiotics or until hospital discharge, whichever occurs first
223628229|NCT03882060|DRUG|erythropoietin|Recombinant human erythropoietin (500 U/kg IVS x 3 times) is administrated to increase the neovascularization after revascularization surgery.
223628230|NCT03882060|DRUG|Normal saline|Control group, no intervention.
223628231|NCT00936234|DRUG|Vildagliptin|Vildagliptin, 50 mg twice a days, orally for 30 days followed by placebo
223628232|NCT05005260|DRUG|Bupivacaine HCl|Subjects randomized to the continuous interscalene nerve block group will receive a loading dose of 15-20 mL bupivacaine HCl 0.5% followed by a continuous catheter infusion of bupivacaine 0.2% at 8 mL per hour for 72 hours.
223628233|NCT05005260|DRUG|Liposomal bupivacaine + Bupivacaine Hcl 0.5% Inj|Subjects will receive a one-time interscalene nerve block injection of 5 mL of bupivacaine 0.5% (25 mg) admixed with 10 mL of liposomal bupivacaine (133 mg).
223628234|NCT03960541|DRUG|Efprezimod alfa (human CD24 extracellular domain and human IgG1 Fc fusion protein)|Efprezimod alfa will be given as IV infusion, 240 mg per infusion, on Days 0, 14, and 28.
223628235|NCT03960541|DRUG|Saline Solution|Sterile saline solution (0.9% sodium chloride) will be given as placebo via IV infusion, 100 ml per infusion, on Days 0, 14, and 28.
223628236|NCT04756310|DIETARY_SUPPLEMENT|Retilut|antioxidants, antiangiogenic, antiinflammatory micronutrients
223628237|NCT04756310|DIETARY_SUPPLEMENT|Theavit|antioxidants micronutrients
223628238|NCT01561014|DRUG|erlotinib hydrochloride|Given PO
223628239|NCT01561014|DRUG|oxaliplatin|Given IV
223628240|NCT01561014|DRUG|fluorouracil|Given IV
223628241|NCT01561014|RADIATION|radiation therapy|Undergo radiotherapy
223628242|NCT01561014|PROCEDURE|conventional surgery|Undergo surgical resection
223628243|NCT01561014|OTHER|immunohistochemistry staining method|Correlative study
223628244|NCT01561014|PROCEDURE|positron emission tomography|Correlative study
223628245|NCT01561014|PROCEDURE|computed tomography|Correlative study
224217045|NCT03526107|OTHER|CF-Caffeine|CF-Caffeine: 587 mg of cocoa flavanols, 112 mg caffeine and \<1 mg theobromine
224317426|NCT04679701|DEVICE|Amparo Confidence Socket|"The Amparo Confidence Socket technology takes a different approach by starting with a prefabricated socket (https://www.amparo.world/confidence-socket-en). The socket is made from a moldable thermoplastic and has the attachment point pre-assembled. This prefabricated socket is essentially an off-the-shelf product that can be heated, then molded directly to the patient's residual limb. This removes many of the intermediate steps in traditional socket fabrication. The product's molding temperature is between 60-70 ˚C but the insulation of a silicone liner between the plastic and limb ensures safe temperatures for the patient. This process is currently used in several workshops in Europe and with approximately 50 patients currently using the product. In general, it has been shown to be safe and effective in creating below-knee prosthesis."
224317427|NCT04734405|DRUG|Prof-001|Prof-001 cream
224217046|NCT05008237|DRUG|docetaxel plus Cisplatin|D1, D8 Docetaxel 35 mg/m2 + D5W 100mL MIV over 1hr D1 Cisplatin 70mg/m2 + NS 150mL MIV over 1hr every 3 weeks Treatment will be continued until disease progression or unacceptable toxic effects.
224217047|NCT01402115|DIETARY_SUPPLEMENT|Polycan|polycan 150 mg/d for 12 weeks
224217048|NCT01402115|DIETARY_SUPPLEMENT|Placebo|Placebo 150mg/d for 12 weeks
224217049|NCT04648761|BIOLOGICAL|OPTIMAL algorithm|The OPTIMAL algorithm titrates anti IL 5 treatment by addjusting the intervals between injections by FEV1, blood eosinophils and exacerbations.
224317428|NCT04734405|DRUG|Fluconazole 150 mg|Fluconazole capsule
223628246|NCT01561014|PROCEDURE|laboratory biomarker analysis|Correlative study
223628247|NCT01561014|GENETIC|gene expression analysis|Correlative study
223628248|NCT01561014|RADIATION|fludeoxyglucose F 18|Undergo F18 PET and CT scan
223628249|NCT03186209|BIOLOGICAL|Benralizumab|Benralizumab subcutaneously on study week 0 until study week 40 inclusive.
223628250|NCT03186209|BIOLOGICAL|Placebo|Placebo subcutaneously on study week 0 until study week 40 inclusive.
223628251|NCT03164668|OTHER|menthol flavored e-cigarette|menthol flavored e-cigarette
223628252|NCT03164668|OTHER|tobacco flavored e-cigarette|tobacco flavored e-cigarette
223628253|NCT05219825|BEHAVIORAL|Breathwork workshop|Participants will complete 1.5 hours of breathwork session in addition to a total of 6 hours of brief psychotherapeutic intervention in a span of 1 week. The therapy sessions will occur both before and after the breathing session.
223628254|NCT01626014|BEHAVIORAL|Usual Care Educational Website|Using the control website: Participants access a website with standard ovarian cancer informational handouts.
224217050|NCT00077428|DRUG|bortezomib|Given IV
224217051|NCT00077428|DRUG|doxorubicin hydrochloride|Given IV
223628255|NCT01626014|BEHAVIORAL|Prototype System|An interactive system for patients and their caregivers includes features allowing users to create their own profile, share a journal with others, and post to respective discussion forums. In addition, core intervention components include distress monitoring, educational items, details about the healthcare team and an areas to keep track of questions for providers.
223628256|NCT01099696|DIETARY_SUPPLEMENT|B. infantis 35624|B. infantis 35624 in white capsules
224217052|NCT00077428|OTHER|laboratory biomarker analysis|Correlative studies
224217053|NCT05774509|BIOLOGICAL|Extracellular vesicle-enriched secretome of cardiovascular progenitor cells differentiated from induced pluripotent stem cells|Repeated (X3) intravenous infusions of the extracellular vesicle-enriched secretome of cardiovascular progenitor cells (differentiated from human induced pluripotent stem cells)
224217054|NCT01904383|DRUG|Trazenta|1 tablet of 5 mg Trazenta tablets once daily
224217055|NCT00123383|DRUG|Modafinil|
224217056|NCT05995145|BEHAVIORAL|Active hamstring flexibility exercises with hip flexion mobilization|8 weeks x 5 times per week for 20 min. In the experimental intervention, the exercise program will be based on participant education, home-based individual exercises, and regular group meetings for check-ups by a physiotherapist according to a precise set schedule.
224217057|NCT05886699|OTHER|PRP combined with DFDBA|Periodontal intrabony defects were treated with open flap debridement followed by placement of PRP combined with DFDBA
224217058|NCT05886699|OTHER|DFDBA|Periodontal intrabony defects were treated with open flap debridement followed by placement of PRP combined with DFDBA
224217059|NCT05237700|OTHER|Patient positioning on operating table|The patients are either positioned in Trendelenburg with lithotomy positioning or in Trendelenburg without lithotomy positioning on the operating table when undergoing robotic assisted laparoscopic surgery or laparoscopic surgery.
224217060|NCT02134574|BIOLOGICAL|hematologic malignancy|hematologic malignancy with a sampling of blood
223628257|NCT01099696|DIETARY_SUPPLEMENT|placebo|white placebo capsules
223628258|NCT01122641|DRUG|Vildagliptin|Vildagliptin 50mg bid
223628259|NCT01122641|DRUG|Placebo|Matched tablets
223628260|NCT01762696|BEHAVIORAL|MET|Motivational Enhancement Therapy only
223628261|NCT01762696|BEHAVIORAL|MOMENT|The full MOMENT intervention: Motivational Enhancement Therapy + momentary and daily mobile self-monitoring + motivational feedback messages prompting participants to consider their individualized coping strategies to avoid using marijuana
223628262|NCT04993651|DEVICE|CPAP|CPAP is a form of noninvasive positive pressure ventilation (NPPV). CPAP works to maintain adequate levels of PO2 and PCO2 through improved alveolar ventilation and maintenance of upper-airway patency.
223628263|NCT04706364|BEHAVIORAL|Neuropsychological Testing|Includes an IQ test, Autism Diagnostic Observation Schedule-2 (ADOS-2), and Autism Diagnostic Interview-Revised (ADI-R) assessments.
224217061|NCT03446560|DEVICE|CPAP, conventional follow up|Positive airway pressure to splint the airway and to prevent apneas during sleep. Follow up of patients after initiation of treatment according to clinical routine at the study site. Patients are informed to call or visit the sleep center in case of problems with the CPAP device. At 3 months a follow up visit is scheduled at the sleep center. CPAP compliance data will be downloaded and all patients fill in a number of questionaires related to the CPAP treatment effects on sleep apnea symptoms and health related quality of Life. Mask fitting will be tested.
223628264|NCT04706364|GENETIC|(Optional) Saliva Collection|"The sample is to test for genes (BDNF/APOE/COMT) that everyone has, but people have different varieties of these genes.~Genetic testing is funded by Boston Children's Hospital."
223628265|NCT04706364|DEVICE|Sensory Testing|"Three different tests will be completed:~the tactile prepulse inhibition test (PPI) texture perception indentation testing (Mechanical Detection Threshold).~Investigators will also apply mild electrical stimulation to the median nerve of the hand (on the wrist).~The second sensory visit will be another version of the PPI testing involving hearing and sound."
223628266|NCT04706364|DEVICE|Electroencephalogram (EEG)|A cap will be placed on the participants head that will be filled with electrodes (small discs). The EEG will allow investigators to measure how the brain reacts to the sensory testing.
223628267|NCT04706364|DEVICE|Transcranial Magnetic Stimulation|"Single pulses of TMS, as well as PAS (a second type of TMS), will be applied to the cortex.~There will be two - four identical TMS testing visits."
223628268|NCT03814811|DIAGNOSTIC_TEST|Circulating Osteocalcin-positive (cOC) cells|Quantitative measurement of osteocalcin-positive cells in the peripheral blood mononuclear cells by flow cytometry
223628269|NCT03382717|DEVICE|Excilor Forte|1 application per day during 6 months
223628270|NCT03382717|DRUG|Loceryl 5%|1 application per week during 6 months
223763972|NCT02985242|DRUG|Glimepiride|Glimepiride tablet
223763973|NCT02985242|DRUG|Empagliflozin placebo|Placebo tablet manufactured to mimic Empagliflozin 25 mg film-coated tablet
223763974|NCT02985242|DRUG|Glimepiride placebo|Placebo tablet manufactured to mimic Glimepiride 2 mg tablet
223763975|NCT04961892|PROCEDURE|surgical treatment|Anatomical contraction and termination reconstruction of the lateral ligament
223763976|NCT04961892|PROCEDURE|conservative treatment|Rehabilitation intervention training
224217062|NCT03446560|DEVICE|CPAP, telemedicine based follow up|Follow up of patients by means of a telemedicine solution for surveillance of CPAP treatment, Compliance with and efficacy of CPAP can be followed up by the sleep center personnel on a regular basis. Patients with low compliance and mask fitting problems will be contacted by phone. At the end of the 3 months period a visit at the sleep center will be scheduled only for patients with low compliance, low treatment efficacy, or high mask leakage. All patients will be asked to fill in a number of questionaires related to CPAP treatment effects on sleep apnea symptoms and health related quality of Life.
224217063|NCT03536676|OTHER|'Egg-cellent' Breakfast in the Classroom|Includes the additional 2 eggs per day
224217064|NCT03536676|OTHER|Breakfast in the Classroom|Receives the standard meal for Breakfast in the Classroom
224217065|NCT01294592|DRUG|Dutasteride plus tamsulosin|Take 1 capsule daily
224217066|NCT01294592|DRUG|tamsulosin|Take 1 capsule daily when escalation criteria met
224317429|NCT04734405|DRUG|Placebo cream|ointment base to mimic Prof-001
224317430|NCT04734405|DRUG|Placebo capsule|encapsulated lactose powder to mimic 150 mg fluconazole capsule
223628271|NCT05683847|OTHER|User controlled epilepsy follow-up by means of patient reported outcome measures (PROM)|Whenever they want to, but minimum every six months, users respond to standardized follow-up questions developed by the experts of EpilepsiNett. This ensures that a broader range of topics are covered, not just those related to seizures and adverse events. The incoming responses are handled by a trained epilepsy nurse, who contact the patient when needed, consulting the responsible medical doctor when needed. If current issues cannot be solved by telephonic contact with the epilepsy nurse and/or responsible medical doctor, the patient is offered an appointment at the outpatient clinic.
224217067|NCT01492257|OTHER|Shared Decision Making Intervention|Digital video discs and booklets produced by the Foundation for Informed Medical Decision Making and Health Dialog; a question-prompting phone call with a trained health coach; audio-recordings of the patient-surgeon consultation; and a copy of the surgeon's dictated note.
224217068|NCT03955666|BIOLOGICAL|PRV-3279 or placebo|bi-specific antibody-based molecule
224217069|NCT00190866|DRUG|Duloxetine|
224217070|NCT00190866|DRUG|placebo|
224217071|NCT05460026|OTHER|Routine Physical Therapy|Participants will receive routine physical therapy which includes ultrasound, nerve gliding, tendon mobilization, stretching, mobility and strengthening exercises for the wrist. Each session will last for 30 minutes with 12 sessions on alternate days (3 sessions / week).
224217072|NCT05460026|OTHER|Powerball Exercises|Participants will be using the Powerball™ for 5 minutes per hand, 3 times a week along with routine physical therapy exercises.
224217073|NCT02762565|DEVICE|PEFS system (Product Name: Intelligent Breast Exam™ or iBE™|
224217074|NCT02305420|DEVICE|EmbryoGen/ BlastGen media|Embryos will be cultured in media containing Gm-CSF (EmbryoGen/ BlastGen media)
224217075|NCT02305420|DEVICE|Standard Cook sequential media|Standard Cook IVF media will be used in the control arm
224217076|NCT02539030|PROCEDURE|Microfracture|simple microfracture
224217077|NCT02539030|DEVICE|CartiFill|add collagen when doing microfracture
224217078|NCT04292574|OTHER|Patient Registry|Participants who have volunteered to participate will complete various questionnaires relating to their conditions.
223628272|NCT03919396|DEVICE|Breath-O orthokeratology lenses|"Specially designed rigid gas permeable lenses which~1. reshapes corneal profile for myopia control~2. has higher elasticity compared to traditional lens material."
223628273|NCT03954639|DRUG|EXPAREL 13.3Mg/mL Suspension for Injection|Combined Sciatic and Adductor Canal Nerve Block with EXPAREL mixed with Bupivacaine (Single Dose)
223628274|NCT03954639|DRUG|Bupivacaine Hydrochloride|Combined Sciatic and Adductor Canal Nerve Block with Bupivacaine HCL
223628275|NCT06250699|PROCEDURE|Tubeless laparoscopic adrenalectomy|No drainage tube placed after laparoscopic adrenalectomy
223628276|NCT06250699|PROCEDURE|Drainage tube|Placing drainage tubes after laparoscopic adrenalectomy
223763977|NCT03802448|COMBINATION_PRODUCT|Study group|"Each pregnant woman in the study group received myofascial release technique, 3 sessions/week for 4 weeks. a myofascial release in addition to wearing a natural wrist splint during sleeping for 4 weeks.~Myofascial wrist retinaculum (Transverse carpal ligament) release.~• Second part; Interosseous membrane and forearm muscles myofascial release (Bilateral thumb pressure technique)."
223763978|NCT03802448|DEVICE|Control group|A neutral wrist splint was worn by all pregnant women in both groups daily at night, only all through the study time (4 weeks). This neutral wrist splint was used to keep the wrist in a straight position (neutral position) and to prevent the extreme wrist motion (flexion and extension) while sleeping.
223628277|NCT00790803|DRUG|Pegaptanib|Five patients will receive intravitreous injections of Macugen 0.3 mg every 6 weeks as needed for a total of no more than five.
223628278|NCT01575821|DIETARY_SUPPLEMENT|Eucalyptus honey|Parents were instructed to administer 10 grams of theirs child treatment product (single dose) within 30 minutes of the child going to sleep.
223628279|NCT01575821|DIETARY_SUPPLEMENT|Labiatae honey|Parents were instructed to administer 10 grams of theirs child treatment product (single dose) within 30 minutes of the child going to sleep.
223628280|NCT01575821|DIETARY_SUPPLEMENT|Citrus honey|Parents were instructed to administer 10 grams of theirs child treatment product (single dose) within 30 minutes of the child going to sleep.
224217079|NCT00526773|OTHER|telephone management plus a motivational intervention|heart failure intervention
224217080|NCT00526773|OTHER|telephone management with standard patient education|heart failure intervention
224217081|NCT01113710|DRUG|Neupro®|Neupro® is the exposure/intervention of interest in this non-interventional study.
224217082|NCT05654610|DEVICE|Halova|Halova is a class I medical device formulated as vaginal ovules and intended for intravaginal administration in order to promote and/or accelerate the hydration, healing, re-epithelialization and/or soothing of injured, atrophic or irritated vaginal mucosa. The ovules melt evenly in the vaginal mucosa forming a cream with a moisturizing and calming effect that support the restoration of the vaginal epithelium.
224217083|NCT00744510|OTHER|Reflexology|10 weekly sessions of 45 minutes each
224217084|NCT06482710|DEVICE|Pinwheel|The children in the intervention group were given breathing exercises with pinwheels.
224217085|NCT02102581|PROCEDURE|short time tourniquet|short time tourniquet: the tourniquet starting from the implantation of prosthesis to the completion of the operation.
224217086|NCT00623623|PROCEDURE|primary PCI|Standard primary PCI
224217087|NCT00623623|DRUG|enoxaparin|Adjunctive treatment
224217088|NCT00623623|PROCEDURE|catheterisation|Routine or rescue coronary intervention
224217089|NCT00623623|DRUG|tenecteplase|Single, weight-adjusted i.v. bolus of tenecteplase
224217090|NCT00623623|DRUG|clopidogrel|Adjunctive treatment
224217091|NCT02905721|PROCEDURE|Spectral cardiac CT scan|Cardiac CT scan : acquisition using the spectral mode imaging in order to identify inflammatory areas of the myocardium on the iodine map imaging.
224217092|NCT06144814|DRUG|Hyaluronic acid vaginal gel|. Group II received 5 mg of vaginal hyaluronic acid every day for 14 days, then 2 days a week for the next 2 weeks. Hyaluronic acid gel for vaginal use was supplied by ORTHOGEN®. The treatment period lasted 1 month in both groups.
224217093|NCT06144814|DRUG|Estrogen vaginal use form|Group I received 25 µg vaginal estrodiol (Vagifem®). 1 tablet a day for two weeks, then 2 times a week for the next 2 weeks.
224217094|NCT00701766|DRUG|BI 2536|
223628281|NCT01575821|DIETARY_SUPPLEMENT|Silan date extract|Parents were instructed to administer 10 grams of theirs child treatment product (single dose) within 30 minutes of the child going to sleep.
223628282|NCT00830999|BEHAVIORAL|Positive energy balance|Subjects will consume over a 24 hour period 33% more calories than they require to meet their energy demands.
224217095|NCT05004818|PROCEDURE|GVS stimulation coupled with inverse phase rotatory chair stimulation at sinusoidal harmonic acceleration protocol|GVS stimulation coupled with inverse phase rotatory chair stimulation at sinusoidal harmonic acceleration protocol
224217096|NCT05004818|PROCEDURE|Sham procedure|Participants with severe motion sickness were sited in the the rotatory chair with the videonystagmography recorder masking their eyes, while two galvanic vestibular stimulation electrodes were connected to the mastoid processes. No active stimulus was given.
224217097|NCT03150121|PROCEDURE|Uterine lavage|Uterine lavage is performed using an intrauterine insemination catheter or rigid pipelle uterine sampler. The catheter is inserted into the cervical canal. 10mL of saline are infused into the uterine cavity and fallopian tubes and immediately retrieved.
224217098|NCT03150121|PROCEDURE|Blood sample|5-10mL of blood will be drawn from participants.
224217099|NCT03150121|DEVICE|Uterine lavage catheter|Uterine lavage is performed using an intrauterine insemination catheter or rigid pipelle uterine sampler. The catheter is inserted into the cervical canal. 10mL of saline are infused into the uterine cavity and fallopian tubes and immediately retrieved.
224217100|NCT02186808|DEVICE|Procera® Bridge Zirconia|Patients planned for treatment with a tooth-supported 3 to 4-unit bridge in any position of the maxilla or the mandible.
224217101|NCT05270187|OTHER|Photobiomodulation therapy (laser therapy)|The Multiwave Locked System Laser will treat both the scan and point application groups. M6 laser equipment (ASA, Arcugnano, Italy) is used in this study in the physiotherapy and rehabilitation department, Faculty of Applied Medical Science, Umm Al-Qura University. It provides synchronized and overlapping continuous and pulsed emissions of Ga-Al-Ar laser emitted in a single hand piece. M6 has a continuous emission of a wavelength of 808 nm with peak power of 1000 mW, mean power of 500mW, spot diameter of 2 cm, and spot area of 3.14 cm2. Pulsed emission has a wavelength of 905 nm, peak power of 25 W, and mean power of 54mW with frequency of 1500 Hz.
224217102|NCT05270187|OTHER|Facial massage and facial expression exercises|Facial massage and facial expression exercises will be applied for all patients in the three treatment groups. It includes simple facial expression exercises, active graduated strengthening exercises in front of a mirror (active assisted, freedom, and resisted), proprioceptive neuromuscular facilitation exercises for facial muscles, and resisted exercises for neck muscles. Participants are taught to perform massage and exercises correctly by the physiotherapist. All treatment groups are given instruction to repeat the massage and exercises two times a day for at least 6 weeks. The patient or one of his/her family members will confirm that the participant carries out the massage and exercises at home.
224217103|NCT04956406|BEHAVIORAL|Motivational Interviewing for Adult Kidney Transplant Recipients|Motivational interviewing with individual sessions are planned to be conducted 3 times. Planned motivational interviews will be implemented the intervention group who are within 3th month, 4th month, 5th month and 6th month. Motivational interviewing will planned last 15-30 minutes with an interval of 10 days. The first interview will be performed face-to-face at the transplant outpatient clinic and the second and third ones will be phone interviews
224217104|NCT04956406|OTHER|Routine care|The control group will be provided with routine care( face-to-face care standard training) by the nurse educator at the transplant outpatient clinic.
224217105|NCT02265952|DRUG|REGN1500 250 mg SC/15 mg/kg IV/450 mg SC|Participants received single dose of REGN1500 subcutaneous (SC) injection of 250 milligrams (mg) at Week 0 (Day 1), followed by single dose of REGN1500 intravenous (IV) injection of 15 milligrams per kilogram (mg/kg) at Week 2 (Day 15) and then followed by 4 doses of REGN1500 SC injection of 450 mg once weekly starting from Week 12 (Day 85). Only the first 2 enrolled participants received 4 weekly REGN1500 450 mg SC doses at weeks 12, 13, 14, and 15 per the protocol. This dose regimen was removed under protocol amendment 4. Participants were followed for a period of 24 weeks (through Week 26 \[Day 183\]) after the last dose of study drug in the main study period.
224217106|NCT00444132|DRUG|clopidogrel|
223628283|NCT00830999|BEHAVIORAL|Energy balance with exercise|Subjects will consume over a 24 hour period 33% more calories than they require to meet their energy demands but will perform 2 hours of exercise that will be sufficient to burn off the excess calories consumed resulting in subjects being in net energy balance.
223628284|NCT00830999|BEHAVIORAL|Negative energy balance|Subjects will consume over a 24 h period only 66% of the calories required to meet their energy demands such that they will be in a net negative calorie balance in this trial.
223628285|NCT00830999|BEHAVIORAL|Negative energy balance with exercise|Subjects will consume over a 24 hour period the same amount of calories as ingested in the isocaloric trial but will also perform 2 hours of exercise that will be sufficient to burn off a third of the calories they consumed during this day resulting in subjects being in net negative energy balance in this trial
223628286|NCT00830999|BEHAVIORAL|Energy balance|Subjects will consume over a 24 hour period a sufficient amount of calories to meet their energy needs.
224217107|NCT01239147|OTHER|Diet rich in whole grain|Ready-to-eat breakfast cereals and other cereal products, rich in whole grain
224217108|NCT01239147|OTHER|Refined grain|Ready-to-eat breakfast cereals and other cereal products, low in whole grain
224217109|NCT02198677|PROCEDURE|Anterior to posterior pressures|Anterior to posterior pressures
224217110|NCT02198677|PROCEDURE|Lateral glide|Lateral glide
224217111|NCT01042977|DRUG|Dapagliflozin|10 mg tablet, oral, once daily, 24- week treatment and 80-week extension period
224217112|NCT01042977|DRUG|Placebo|matching placebo tablet, oral, once daily, 24- week treatment and 80-week extension period
224217113|NCT04028583|OTHER|PIM-Check|In the PIM-Check group, a medication review will be conducted using PIM-Check within 72 hours of patient's admittance to the unit. The physician will decide whether to accept these recommendations or not and implement prescribing changes if agreed.
223628287|NCT00176384|BEHAVIORAL|Aerobic endurance exercise training (ergometer)|
223628288|NCT00534326|PROCEDURE|Standard Reaming|Femoral reaming using standard reaming techniques of multiple reamers
223628289|NCT00534326|PROCEDURE|Reaming/Irrigating/Aspirating|Reaming using the Reamer/Irrigator/Aspirating
223628290|NCT03667482|DRUG|Cabozantinib|Cabozantinib will be initiated at 40 mg PO daily, with subsequent 20 mg or 40 mg doses as tolerated per the study design.
223628291|NCT03667482|DRUG|Cetuximab|Cetuximab will be administered at 500 mg/m\^2 intravenously every other week on Days 1 and 15 of each cycle, with a window of up to 3 days before the scheduled date. In an effort to prevent a hypersensitivity reaction, it is recommended that all patients pre-medications, hydration, and anti-emetics will be given according to institutional guidelines and/or per treating physician discretion.
223628292|NCT03572920|DEVICE|Objective sleep evaluation by actigraphy|Each subject will wear a wrist activity monitor (actigraphy) to detect his/her sleep behaviour during hospitalization.
223628293|NCT03572920|OTHER|Pittsburgh Sleep Quality Index (PSQI)|Each subject will fill twice the Pittsburgh Sleep Quality Index (PSQI), before hospitalization and after the 10th day, to evaluate his/her subjective sleep quality.
223628294|NCT03728907|DEVICE|Hearing aid fitting technique- audiologist or user-adjusted|See information under 'arm' description
223628295|NCT01363375|PROCEDURE|Foot orthosis, footwear|flat insole, total contact insole , carbon fiber plate; general shoe and rocker sole shoe
224217114|NCT04028583|OTHER|STOPP/START|In the STOPP/START group, medication lists will be analyzed within 72 hours of patient's admittance and optimized according to STOPP/START criteria. The second physician will decide whether to accept these recommendations or not and implement prescribing changes if agreed.
224217115|NCT02499354|DRUG|Ferumoxytol intravenous|IV iron, 2 vials of 510 mg given 2-7 days apart
223628296|NCT01363375|PROCEDURE|Foot orthosis, Footwear|flat insole, total contact insole, carbon fiber plate; general shoe and rocker sole shoe
224217116|NCT02499354|DRUG|Ferrous sulfate|Oral iron, 325 mg tabs taken morning and evening
224217117|NCT04119583|DEVICE|U-shape Automatic Electric Toothbrush|The U-shape Automatic Electric Toothbrush will be applied for 30-45 seconds on the teeth of both arches without the use of toothpaste.
224217118|NCT04119583|OTHER|Usual home toothbrushing procedure|Usual home toothbrushing procedure either with manual or electric toothbrush without the use of toothpaste.
223628297|NCT01363375|PROCEDURE|Foot orthosis, footwear|flat insole, total contact insole, carbon fiber plate; general shoe and rocker sole shoe
223628298|NCT00301899|BIOLOGICAL|pertuzumab|
223628299|NCT00301899|BIOLOGICAL|trastuzumab|
223628300|NCT02160080|DRUG|Boceprevir 800mg/TID+Pegylated interferon alfa+Ribavirin|Boceprevir 800mg/TID+Pegylated interferon alfa+Ribavirin
224217119|NCT04119583|OTHER|Conventional Electric Toothbrush|The Conventional Electric Toothbrush will be applied for 2 minutes on the teeth of both arches without the use of toothpaste.
224317431|NCT03533023|BEHAVIORAL|Time Restricted Eating + Standard of Care|Participants in this arm will adhere to a daily, consistent 10-hr eating window for the course of the study as well as receive nutritional counseling from the study dietician.
224217120|NCT05687045|DEVICE|High Flow Nasal Cannula|High Flow Nasal Cannula will be set at 60 liters per minute of air/oxygen admixture to reach a peripheral oxygen saturation equal or greater than 94%
224217121|NCT05687045|DEVICE|Conventional Oxygen Therapy|Conventional Oxygen Therapy will be administered through nasal cannula with a oxygen flow set to achieve a peripheral oxygen saturation equal or greater than 94%
224217122|NCT01823445|OTHER|Xylitol disk|
224217123|NCT05170828|DRUG|Cyclophosphamide|pre-transplant conditioning treatment
224217124|NCT05170828|DRUG|Fludarabine|pre-transplant conditioning treatment
224217125|NCT05170828|RADIATION|Total Body Irradiation|pre-transplant conditioning treatment
224317432|NCT03533023|BEHAVIORAL|Standard of Care|Participants in this arm will receive nutritional counseling from the study dietician, but will not be required to adopt a 10-hr eating window.
224317433|NCT05314816|DIAGNOSTIC_TEST|Blood culture identification panel|multiplex PCR panel to be performed on positive blood cultures
223628301|NCT04162249|OTHER|Conventional LSI/AI-guided pulmonary veins ablation.|Conventional (low-power and long-duration) radiofrequency application.
223628302|NCT04162249|OTHER|High-power pulmonary veins ablation.|Experimental (high-power and short-duration) radiofrequency application.
223628303|NCT04162249|OTHER|Esophageal temperature monitoring|Two probes were simultaneously used: a deflectable one and a non-deflectable one.
223628304|NCT04162249|DIAGNOSTIC_TEST|Esophageal endoscopy|Esophageal endoscopy for acute detection of esophageal thermal lesions \<72 hours after ablation.
223628305|NCT03882294|OTHER|Probiotics|Participants will be requested to consume the drinks (80 ml) twice a day - after lunch and dinner for 12 weeks.
223628306|NCT03882294|OTHER|Placebo|Participants will be requested to consume the drinks (80 ml) twice a day - after lunch and dinner for 12 weeks.
223628307|NCT05537753|DEVICE|Encore PFO closure device|The Encore PFO closure device comprises an implant component and a single-use delivery system.
223628308|NCT05537753|DEVICE|FDA-approved PFO closure device|Chosen by the investigator
223680637|NCT03983148|BEHAVIORAL|Motivational interviewing|There are 3 sessions. Each session is an about 60-minute individual motivational interviewing held by a trained registered nurse. The first session aims to develop an action plan that enables the parents to promote physical activity (PA) for their children. The second session targets to review the adherence to the action plan. The nurse will discuss the progress. In the last session, the aim is to motivate the parents promoting PA for their children in the long run. As such, the benefits of PA throughout the survivorship will be emphasized. And the nurse will work with the parents to identify the resources that can help maintain the designed action plan.
223680638|NCT03983148|BEHAVIORAL|Placebo control|"Other than usual medical care received by children, parents in this group will receive an individual, face-to-face intervention which mimics the time and attention received by those in the experimental group. The intervention includes three sessions of educational talk to parents of children with cancer on healthy diet for cancer patients, adverse effects of cancer treatment, methods to minimize adverse effects.~Subjects in both groups will receive a booklet developed by the advisory committee, which contains a various kind of physical activities specially designed for children with cancer."
223680639|NCT06202092|DEVICE|Phonophoresis|Ultrasound using honey as a media over the knee joint
223680640|NCT06202092|DEVICE|Ultrasound|ultrasound using gel as a media over the knee joint
223628309|NCT05872737|BEHAVIORAL|Facilitator-guided Acceptance and Commitment Bibliotherapy (FAB)|The Facilitator-guided Acceptance and Commitment Bibliotherapy (FAB) is a 12-week self-help parenting program that integrates Acceptance and Commitment Therapy (ACT) principles with web-based modules and group-based sessions. The program includes a self-help workbook/manual and ACT protocols that cover various self-help exercises such as guided imagery, grounding, mindfulness, and values clarifications. To make the programme more relatable to Hong Kong parents caring for children with NDD, storytelling vignettes and therapeutic narratives will be included. Parents will work on each module at their own pace within 2-3 weeks and meet with trained facilitators in a video-conferencing format after completing each module to review their progress and learn positive parenting techniques.
224217126|NCT05170828|DRUG|Busulfan|pre-transplant conditioning treatment
224217127|NCT05170828|DRUG|Mesna|given with cyclophosphamide
224217128|NCT05170828|DRUG|Sirolimus|post-transplant treatment for GVHD
224217129|NCT05170828|DRUG|Mycophenolate Mofetil|post-transplant treatment for GVHD
224217130|NCT05170828|DRUG|Filgrastim|post-transplant treatment for GVHD
224217131|NCT05170828|DRUG|Cyclophosphamide|post-transplant treatment for GVHD
224217132|NCT05170828|PROCEDURE|Bone Marrow Transplant|Transplant with investigational bone marrow product
224217133|NCT03900546|DEVICE|MostCare|CO measurement using echocardiography and PRAM before and after noradrenaline dose change due to clinical reason
224217134|NCT04303845|DRUG|Erenumab|140 mg of erenumab via subcutaneous injection
224217135|NCT03192683|DEVICE|Providence Pedi Cast-Sling|Custom made sling with readily available casting materials
224217136|NCT03192683|DEVICE|Regular sling|
224217137|NCT02883673|DEVICE|Jada System|It is a teardrop-shaped, soft silicone ring that is placed into the uterus, where gentle suction is applied to cause the uterus to contract and shrink in size, compressing the blood vessels so the bleeding stops.
224217138|NCT02903576|PROCEDURE|injection of hESC-RPE in suspension|The first six patients will receive a sub retinal injection of hESC-RPE in solution after a complete pars plana vitrectomy to access safety of the cell implant alone.
224317434|NCT07133581|OTHER|FEXO (Fun Exercise for Older Adults)|A 14-week supervised multicomponent playful exercise program for institutionalized older adults. It consists of 3 sessions per week (55-60 minutes), including aerobic, strength, balance, flexibility, and gait exercises in a group-based, game-like setting. The structure includes 2 weeks of familiarization followed by 3 progressive 4-week levels. The intervention aims to improve intrinsic capacity, reduce frailty, and enhance physical and cognitive function.
224317435|NCT07133672|OTHER|Exercise|Exercise sessions will begin with flexibility exercises targeting the shoulder and neck regions. This will be followed by breathing exercises utilizing fundamental respiratory techniques. Extremity exercises will include movements focused on the upper extremities and trunk, with progression applied according to a pre-established plan. Each session will conclude with cool-down exercises. Additionally, patients will be encouraged to engage in regular walking on a weekly basis.
223628310|NCT05872737|BEHAVIORAL|General Parenting Education and Advice|Both the FAB group and the Control Group will receive routine family support services from collaborating NGOs, including education on managing the emotional and behavioral symptoms of children with NDD. To control for the interaction/social effect present in the FAB group, the Control Group will also receive four video-conferencing sessions guided by a trained research assistant over 12 weeks. These sessions will facilitate parents to discuss their parenting challenges, identify parenting traps, and provide general parenting advice as recommended by the Child Assessment Services, Department of Health under the HKSAR government.
224217139|NCT02903576|PROCEDURE|injection hESC-RPE seeded in a substrate|Fifteen patients will receive a sub-retinal implantation of embryonic stem cell derived retinal pigmented epithelium seeded in a polymeric substrate to access safety of substrate seeded with RPE
224217140|NCT00499720|DRUG|Aztreonam Lysine for Inhalation|75 mg three times a day via inhalation for 28 days followed by 28 days off drug.
223680641|NCT06202092|PROCEDURE|conventional physiotherapy|TENS, Strengthening, and stretching exercises
223680642|NCT03455959|PROCEDURE|Bronchoscopy/BAL|Participants may receive 3 inhalations (90 ug ea) of albuterol to minimize bronchoconstriction. Medication includes midazolam by intravenous injection, and fentanyl by intravenous injection as judged necessary. 2% lidocaine is delivered via atomizer spray to the oral pharynx for local anesthesia. 1% lidocaine is delivered through the bronchoscope to the vocal cords and lung segments for local anesthesia. The bronchoscope is then passed through the vocal cords into the trachea. Throughout the procedure, all participants will have continuous blood pressure, heart rate, and oxygen saturation monitoring. Participants will be instructed to relate any discomfort or problems through a series of standardized hand signals. Once in the lung, aliquots of sterile saline are instilled into two subsegments of the right middle lobe (preferred and if not possible then the right upper lobe) and withdrawn into a trap by gentle suction.
224217141|NCT06528574|DEVICE|Conventional root canal treatment|Root canals will be irrigated by only side perforated needle
224217142|NCT06528574|DEVICE|Ultrasonic|Root canals will finally receive activation of the irrigant by the ultrasonic part of the IVAC system
224217143|NCT06528574|DEVICE|Apical negative pressure|Root canals will finally receive activation of the irrigant by the negative pressure part of the IVAC system
224217144|NCT06528574|DEVICE|Combined Ultrasonic and negative pressure|Root canals will finally receive activation of the irrigant by the IVAC system which is a combination of ultrasonic and apical negative pressure procedures.
224217145|NCT03955692|DEVICE|tDCS|Five sessions (active/sham) will be held on five consecutive days. The parameter of electrode size, current strength and current duration were previously tested for safety in children
224217146|NCT06102889|DIAGNOSTIC_TEST|liquid biopsy|Taking blood samples (liquid biopsy) for multiple analysis in genomics, proteomics, and metabolomics
224217147|NCT01514266|DRUG|Curcumin+Bioprine|The intervention arm is Curcumin+Bioprine at escalating doses of 1 gram of Curcumin and 5 mg of Bioprine bid for one month, then 1.5 grams of Curcumin and 5 mg of bioprine bid for one month, and finally 2 grams of curcumin with 5 mg of bioprine bid for additional one month.
224217148|NCT01514266|DRUG|Placebo|
224217149|NCT02025582|DEVICE|Kinesio Tape of the Ankle|Tibialis anterior facilitation/ gastrocnemius inhibition: Taping to be worn 3-5 days and repeated x 1
224217150|NCT02424565|DRUG|IODEX® balm|2 ± 0.2 g of test balm will be applied topically in a crossover fashion at a gap of 3 days between the two product applications.
223628311|NCT04739982|DEVICE|GuessWhat Mobile App|The GuessWhat app is a charades style game and app that engages parent and child in fluid social interaction where the parent must guess what the child is acting out based on the prompt shown on the phone screen. Participants will use their own personal phone to download the study app. Parent and child will be encouraged to play using the emojis and emotion game mode at least 3 individual game sessions per week. Parents are asked to play GuessWhat with their child 3-4 times per week for 4 weeks.
223628312|NCT05031819|OTHER|Nurse-led Task-Shifting Strategy for Hypertension Control (TASSH) plus Practice Facilitation.|"* TASSH includes CVD risk assessment; medication initiation and titration; lifestyle counseling and patient referral to physician care for complex cases.~* Practice Facilitation includes the training of external experts to support the HIV nurses implementing TASSH"
223628313|NCT06444659|BEHAVIORAL|Adaptive Physical Activity Classes|The intervention group received a 6 months adaptive physical activity intervention; the control group, on the other hand, continued their original regular physical activity programme for the same period of time and maintained their original lifestyle habits.
223628314|NCT04539496|DRUG|XZP-3287|"* 20-560 mg QD, oral~* 240-480 mg BID, oral"
224217151|NCT02424565|OTHER|Placebo balm|2 ± 0.2 g of placebo balm will be applied topically in a crossover fashion at a gap of 3 days between the two product applications.
223628315|NCT04539496|DRUG|XZP-3287;Letrozole;Anastrozole;Fulvestrant|XZP-3287: 360 mg BID, oral; Letrozole: 2.5 mg QD, oral; Anastrozole: 1 mg QD, oral; Fulvestrant: 500 mg intramuscular injection on C1D1, C1D15, the first day of each subsequent cycle (28 days a cycle)
223628316|NCT04539496|DRUG|XZP-3287|480 mg BID, oral
223628317|NCT05854966|DRUG|CPI 613|"For INDUCTION therapy (14 day cycles): Devimistat (CPI-613) 2,500mg/m2, days 1-5, 14-day cycles for cycles 1 and 2 only.~For MAINTENANCE therapy (21 day cycles): Devimistat (CPI-613) 2,500mg/m2, days 1-5, 21-day cycles until progression, intolerable toxicity or withdrawal of consent."
223628318|NCT05854966|DRUG|Metformin|"For INDUCTION therapy (14 day cycles):~Metformin 500 mg daily (taken with meals), days 1-2 for cycle 1 only. Metformin 500 mg twice daily (taken with meals), days 3-14 for cycle 1 only. Metformin 1,000 mg daily (taken with meals), days 1-2 for cycle 2 only. Metformin 1,000 mg twice daily (taken with meals) days 3-4 for cycle 2 only.~For MAINTENANCE therapy (21 day cycles): Metformin 1,000 mg twice daily (taken with meals) days 1-21 until progression, intolerable toxicity or withdrawal of consent"
223628319|NCT05854966|BIOLOGICAL|Blood draws|In the first induction cycle ONLY, extra blood will be withdrawn on day 1 before and after treatment with CPI-613 research purposes. Additional blood draws on days 2-5 to test blood before receiving CPI-613 to make sure participants are healthy enough to receive CPI-613.
223628320|NCT05854966|PROCEDURE|Bone marrow biopsy|After the second induction cycle participants will have a bone marrow biopsy. After this biopsy, participants will have other bone marrow biopsies every 3 months for the next year. After the first year, participants may have a bone marrow biopsy if the treating physician feels it is necessary.
223628321|NCT03234595|DRUG|Cerebraca wafer|Eligible patients will receive Cerebraca wafer implantation with adjuvant temozolomide (TMZ) for the safety and efficacy in this study. At Phase I, the MTD will be determined by DLT. At Phase IIa, up to 12 evaluable patients will be enrolled for the efficacy and safety of Cerebraca wafer implantation. At Phase IIa, the cavity surface after tumor removal will be maximally covered by Cerebraca wafer without exceeding the MTD defined at Phase I. Patients in Phase I receive treatment as designed for Phase IIa, the data will be incorporated into Phase IIa to reduce the patient number. The overall patient number in this study is therefore between 2 to 36 evaluable patients.
223628322|NCT04079296|BIOLOGICAL|ASP7517|Intravenous (IV)
223763979|NCT02948842|DRUG|Clostridium Histolyticum Collagenase|0.08ml of XIAFLEX® (0.58 mg of XIAFLEX® mixed with 0.39 mL of sterile diluent) in a single location within the stricture, chased by an additional 0.25 mL of reconstituted XIAFLEX® to allow for clearance of the original 0.08 mL of reconstituted XIAFLEX® from the transurethral syringe into the urethral stricture. This is based on 0.25 mL residual fluid that remains within the lumen of the injeTAK syringe. Thus, by adding the additional 0.25 mL of XIAFLEX® as a chase, we are expecting the original total of 0.08 mL of XIAFLEX® to be injected into the area of scarring.
224217152|NCT02140684|DEVICE|eNO monitoring|Patient undergoing review with eNO monitored using either NIOX MINO® and NIOX Flex®
224217153|NCT00647608|DRUG|Propranolol Hydrochloride Extended-Release Capsules 160 mg|160mg, single dose fed
224217154|NCT00647608|DRUG|Inderal® LA Capsules 160 mg|160mg, single dose fed
224317436|NCT07133672|OTHER|Standard care|Patients will receive education regarding the critical aspects to consider after hospital discharge. Standard postoperative care protocols will be implemented.
224317437|NCT07134712|BIOLOGICAL|Cord Blood Nucleated cells|MiSaver will be administered via peripheral intravenous injection. Based on dosage, the experimental group will be divided into two subgroups: 0.5 × 10⁷ or 1.6 × 10⁷ nucleated cells per kilogram of patient body weight.
224317438|NCT07134062|OTHER|Bridge technique MWM|Patient in supine, head resting on a pillow, cervical spine relaxed in a neutral position, physiotherapist sitting or standing at the head of the table. Hands support both sides of the head through the thenar eminence on each side, fingers in contact with the C7, T1or T2 articular pillar bilaterally.
224317439|NCT07134062|OTHER|Dry Needling|Participants in this group received two sessions per week of D.N. treatment for the trapezius muscle.
223628323|NCT06561451|PROCEDURE|intracytoplasmic sperm injection and artificial oocyte activation|A single sperm will be injected within 4 hours after the follicular aspiration. All injected oocytes will be incubated in the calcium ionophore A23187 activation solution (C9275-1MG, Sigma, USA) for 10 min, and cultured in the cleavage medium (Cleavage Medium , Cook, United States) under standard conditions.
223628324|NCT06561451|PROCEDURE|intracytoplasmic sperm injection|A single sperm will be injected within 4 hours after the follicular aspiration.
223763980|NCT02948842|OTHER|Saline|0.08ml of injectable normal saline
224217155|NCT01573923|BIOLOGICAL|mesenchymal stem cells|Conventional therapy plus UC-MSC intravenous administration (4x107/40ml, once per three months, four times in one year)
224217156|NCT01573923|BIOLOGICAL|Conventional therapy|Conventional therapy without cell therapy
224217157|NCT00003966|DRUG|defibrotide|
224217158|NCT00796484|DRUG|XL888|Administered orally
224217159|NCT03650400|DRUG|Fevipiprant|Chewable tablet
224317440|NCT07133490|DRUG|intraperitoneal chemotherapy|Through a peritoneal access port, irinotecan will be administered at the same time as systemic (chemo)therapy
223628326|NCT06280950|DRUG|Everolimus|"* The first step is the addition of everolimus to participants in this group pre-randomization.~* Participants on a mycophenolate compound will stop taking it within 7 days of initiating everolimus, either by immediate discontinuation or a 7-day taper.~* Participants taking prednisone will taper off prednisone by 6 months post-transplant.~* The second step is tacrolimus minimization and withdrawal to everolimus monotherapy in this group after randomization."
223628327|NCT06280950|DRUG|Tacrolimus (continued reduction)|"* Participants randomized in this cohort will have their tacrolimus dose reduced by 50% following randomization.~* They will maintain this daily dose for 4 weeks/1 month (28-30 days). Tacrolimus withdrawal will occur in intervals of 30 days or 4 weeks.~* Each subsequent reduction will be based on LFT stability over the prior time interval before the next reduction"
223628328|NCT06280950|DRUG|Tacrolimus (maintain 50% reduction)|\- Participants randomized in this cohort maintain initial reduced dose of Tacrolimus and everolimus for study duration.
223628329|NCT06280950|DRUG|Everolimus|"* The first step is the addition of everolimus to participants in the interventional group pre-randomization.~* Participants on a mycophenolate compound will stop taking it within 7 days of initiating everolimus, either by immediate discontinuation or a 7-day taper.~* Participants taking prednisone will taper off prednisone by 6 months post-transplant.~* The second step is to continue on the reduced tacrolimus and everolimus regimen."
223628330|NCT05068752|DRUG|Vemurafenib|Vemurafenib 480 mg PO BID daily given with Sorafenib 200 mg PO BID
224217160|NCT03947606|BEHAVIORAL|CASCADE (CAre Supporters Coached to be Adept DEcision partners)|CASCADE (CAre Supporters Coached to be Adept DEcision partners) is a multicomponent, nurse coach-led supportive care intervention designed to increase family caregivers' skills in providing decision support to individuals with advanced cancer. In a series of weekly, one-on-one, 15-20 minute, in-person or telephone sessions, family caregivers receive psychoeducation on principles of providing effective social support and decision partnering, decision support communication, and Ottawa Decision Guide training.
224217161|NCT03430700|DRUG|Pembrolizumab|Intravenous infusion
224217162|NCT03010085|PROCEDURE|Open left-sided hepatectomy|Open left-sided hepatectomy Laparotomy (upper midline, inverted 'L', or Benz incision) Mobilization of the liver Glissonian approach or individual isolation technique Left lateral sectionectomy or left hemihepatectomy
224217163|NCT03010085|PROCEDURE|Laparoscopic left-sided hepatectomy|Trocar insertion Mobilization of the liver Glissonian approach or individual isolation technique Left lateral sectionectomy or left hemihepatectomy
224217164|NCT04820959|BIOLOGICAL|Biopsies|"Three endomyocardial intraoperative biopsies were performed on the left ventricle.~Resection of the left atrium in the event of atrial fibrillation."
224217165|NCT04820959|BIOLOGICAL|Blood sampling|Pre-operative blood sampling
224317441|NCT07133854|DIAGNOSTIC_TEST|Imaging PET/MRI|"MRI using 1H-MRS and Dixon sequences on a 3 T clinical MRI system (Ingenia, Philips Healthcare, Best, the Netherlands) will be performed.~\[11C\]-palmitate: 1 x i.v. injection of 175 MBq followed by TEP imaging. \[18F\]-FTHA: oral administration of 75 MBq followed by TEP imaging."
223628331|NCT05068752|DRUG|Sorafenib|Sorafenib 200 mg PO BID and Vemurafenib 480 mg PO BID daily
223628332|NCT06133816|BEHAVIORAL|Framed Introductory Message A|Randomly assign patients to receive introductory message encouraging them to complete the survey (version A).
223628333|NCT06133816|BEHAVIORAL|Framed Introductory Message B|Randomly assign patients to receive introductory message encouraging them to complete the survey (version B).
223628334|NCT06133816|BEHAVIORAL|Framed Introductory Message C|Randomly assign patients to receive introductory message encouraging them to complete the survey (version C).
223628335|NCT06133816|BEHAVIORAL|Framed Tobacco Use Message A|Randomly assign patients to receive norming message related to tobacco use (version A).
224217166|NCT05539183|PROCEDURE|Blood withdrawal|Blood withdrawal
224217167|NCT03422783|DEVICE|Standardized tetanic stimulation|"The intervention is not a drug, but it is standardized electrical stimulus applied with a muscle relaxation monitor on the forearm of the anesthetized patient. The NoL index is registered in response to this stimulus in an observational manner.~Device: Device PMD200TM offering intraoperative NoL Index"
224217168|NCT03422783|DIAGNOSTIC_TEST|Catastrophizing score|Pre-operative catastrophizing score is correlated with post-operative pain and opioid consumption
224217169|NCT03422783|DIAGNOSTIC_TEST|Nociceptive threshold|Nociceptive threshold for pressure, heat and electrical stimulation are associated with post-operative pain and will be assessed preoperatively to see if there is correlation between them and the NOL index response to the nociceptive stimulus (see intervention 1)
223628336|NCT06133816|BEHAVIORAL|Framed Tobacco Use Message B|Randomly assign patients to receive norming message related to tobacco use (version B).
223628337|NCT06133816|BEHAVIORAL|Financial Incentive|Randomly assigned patients to be entered into a drawing to receive a $100 gift card.
223628338|NCT06114537|DRUG|Acetazolamide|"The used intervention in this study is acetazolamide, which belongs to a class of drugs known as carbonic anhydrase inhibitors and has been used with other medications to treat high ocular pressure due to certain types of glaucoma~Patients in the treatment group will receive 250 milligrams of oral acetazolamide twice daily for 16 weeks.~Patients randomized to the treatment group will switch to 125 milligrams of oral acetazolamide twice daily for another four weeks when the central foveal thickness (CFT) on OCT is reduced by ≥25% at the evaluation visit at 16 weeks after the baseline visit. These patients will continue with this dose till the end of the study when the CFT on OCT is stable or further reduced. If the CFT on OCT has increased, they switch back to 250 milligrams of oral acetazolamide twice daily for another 12 weeks."
223628339|NCT01346358|BIOLOGICAL|IMC-CS4|
223628340|NCT02839096|DRUG|Placebo|Cellulose placebo that will be used in place of a second dose of ferrous sulfate in the subjects randomized to once daily dosing of ferrous sulfate
223763981|NCT00409292|DRUG|RAD001|Taken orally daily for as long as the participant continues to receive a benefit.
224317442|NCT07133854|DIAGNOSTIC_TEST|Stable isotope infusions|"\[6,6 D2\]-glucose infusion (0.22 µmol/kg/min, preceded by a bolus of 22 µmol/kg) will start from -180 until time + 360.~\[1,1,2,3,3-2H\]-glycerol (0.05 µmol/kg/min.) and of \[7,7,8,8-2H\] palmitate (0.01 µmol/kg/min) will start from time -60 until time +360."
224317443|NCT07133854|DIAGNOSTIC_TEST|meal test|A liquid meal will be administered at time 0. The liquid meal (400 ml) energy breakdown is 50% (101g) from glucose, 33% (31g) from fat, and 17% (40g) from protein; participants will consume the 400 ml in 4 aliquots of 100 ml over 20 min, supplemented with 0.9 g of U-\[13C\]-glucose and 9 μmol/kg lean mass of \[U-13C\]-palmitate.
223628341|NCT02839096|DRUG|Ferrous Sulfate|Subjects will receive once or twice daily dosing of ferrous sulfate. This will be provided by our hospital pharmacy and be identical in appearance to the placebo.
223628342|NCT06472427|DIETARY_SUPPLEMENT|Normoxic recovery and placebo (NPL)|Altitude: sea level Dietary supplement: placebo. Water: 98.3% w/w Bitter flavour type: 0.7% w/w Monk fruit extract: 0.04% w/w Tasteva: 0.03% w/w Citric acid: 0.6% w/w Flavor blend: 0.02% w/w Bitter masking flavour: 0.2% w/w Passion fruit flavour: 0.005% w/w
223628343|NCT06472427|DIETARY_SUPPLEMENT|Normoxic recovery and ketones (NKE)|Altitude: sea level Dietary supplement: Commercially available Ketone-IQ butanediol drink R-1,3-butanediol: 28.6% w/v in water
223628344|NCT06472427|DIETARY_SUPPLEMENT|Hypoxic recovery and placebo (HPL)|Altitude: 3,000m (simulated) Dietary supplement: placebo. Water: 98.3% w/w Bitter flavour type: 0.7% w/w Monk fruit extract: 0.04% w/w Tasteva: 0.03% w/w Citric acid: 0.6% w/w Flavor blend: 0.02% w/w Bitter masking flavour: 0.2% w/w Passion fruit flavour: 0.005% w/w
223628345|NCT06472427|DIETARY_SUPPLEMENT|Hypoxic recovery and ketones (HKE)|Altitude: 3,000m (simulated) Dietary supplement: Commercially available Ketone-IQ butanediol drink R-1,3-butanediol: 28.6% w/v in water
223628346|NCT05058365|BEHAVIORAL|dots Curriculum|"dots is a mindfulness curriculum developed by Mindfulness in Schools Project (MiSP) for children aged 3-6 in pre-school settings. The program consists of 15-minute twice weekly lessons that span for fifteen weeks. dots has various suggestions for Have A Go after each session - both in the classroom and at home."
223628347|NCT05687656|DEVICE|InnovaMatrix AC porcine placental ECM therapy|All eligible subjects will be treated with a weekly application of sterilized, porcine placental ECM followed by standard of care moist wound therapy and offloading
223628348|NCT04413071|OTHER|Passed infection of SARS-CoV-2|This is an observational design. Participants have passed infection from SARS-CoV-2 and a cardiac assessment is performed.
223628349|NCT03942289|OTHER|The role of the noradrenergic system across the life span (Healthy Subjects)|A sample (n=90) of balanced distribution of healthy males and females within a continuous segment of the adult life span from 20 to 80 years old will be recruited, with approximately 7 males and 7 females subjects for each decade of age. Each participant will undergo 1) a neuropsychological examination, 2) an olfactory screening and 3) a 90 min 11C-Yohimbine positron emission tomography (PET)/magnetic resonance imaging (MRI) scan in a resting state.
223628350|NCT03942289|OTHER|The role of the noradrenergic system across the life span (Parkinson's Disease Subjects)|Three groups of Parkinson Disease (PD) patients (each of them n=15) will be studied according to the duration and stage of the disease: early stage (the same group in Task 2); mid stage (5-7 years of disease duration; Hoehn and Yahr in Off 2-3); late stage (7-10 years of disease duration; Hoehn and Yahr in Off 3-4).
223628351|NCT05345353|BEHAVIORAL|Fat For Fight (FFF), The Aarhus Protocol|A multicomponent family-centered lifestyle intervention which included visits at home and weekly supervised physical activity. Intervention duration - one year maximum
223628352|NCT05345353|BEHAVIORAL|The Children's Obesity Clinic Treatment (TCOCT), The Randers Protocol|A multicomponent family-centered lifestyle intervention which included repeatedly visits (up to 8 times / year). Intervention duration - three years maximum
223763982|NCT04528758|DRUG|Rhodamine 6G|Rhodamine 6G radio-pharmaceutical will be injected to determine myocardial blood flow
223763983|NCT01408186|DRUG|Rabeprazole|Rabeprazole 20 mg daily
223763984|NCT01408186|DRUG|Famotidine|Famotidine 40mg daily
224217170|NCT03422783|BIOLOGICAL|Biomarkers|Some biomarkers of inflammation and endogenous opioids are associated with post-operative pain. Blood samples will be withdrawn at D0 before surgery starts, D1 (H24) and D2 (H48) after surgery to see if they correlate with NOL changes after the stimulus described in intervention 1 above
224217171|NCT03454633|PROCEDURE|the temperature of hypothermic circulatory arrest|Different temperature (mild 30 degree or moderate 25 degree) employed during the hypothermic circulatory arrest on aortic surgery.
224217172|NCT01319097|OTHER|Sorbion Sachet S|Dressing is indicated for moderately to heavily exuding wounds.
224217173|NCT01892995|DRUG|Ketamine|
224217174|NCT01759381|DEVICE|Negative pressure wound therapy (NPWT)|
224217175|NCT05710302|OTHER|Investigation of the diagnostic accuracy of EHMRG risk score in patients with acute heart failure|Prospective validation of the EHMRG score in patients with acute heart failure in the emergency department
224217176|NCT01426256|DIETARY_SUPPLEMENT|Cholecalciferol|Bolus dose of 250,000 IU during hospitalization + maintenance dose of 50,000 IU vitamin D every other week to be initiated 3 months after bolus dose
223628353|NCT04148807|BEHAVIORAL|Progressive Walking with Gait Retraining|A progressive walking program with gait retraining will be performed on a treadmill at self-selected comfortable walking speed wearing an inertial measurement unit (IMU) on the medial aspect of the distal tibia. The (vertical) peak positive acceleration (PPA) of the tibia is a measure of tibial shock. Subjects will be provided real-time audio feedback to reduce PPA by 20% of their average peak PPA. During retraining sessions, a faded feedback approach will be used. Feedback will be provided continuously during the first four sessions and will be faded over the last 4 sessions. Walking time will increase over the 8 sessions.
223628354|NCT04148807|BEHAVIORAL|Progressive Walking Program|A progressive walking program will also be performed on a treadmill where subjects will walk at a self-selected comfortable speed with the same walking times per session as the retraining group without any feedback or retraining cues.
223628355|NCT00207155|DRUG|Cetuximab|IV solution, IV, 400 mg/m2 initial dose + 250-400 mg/m2 weekly, Weekly, Until disease progression.
223628356|NCT03402542|PROCEDURE|Cholecystectomy|Cholecystectomy
223763985|NCT05867147|DRUG|Vanzacaftor|Tablets for oral administration.
223763986|NCT05867147|DRUG|Vanzacaftor Placebo|Placebo for oral administration.
223763987|NCT05867147|DRUG|Moxifloxacin|Tablets for oral administration.
223763988|NCT05867147|DRUG|Moxifloxacin Placebo|Tablets for oral administration.
223763989|NCT02558998|OTHER|Survey|
224217177|NCT04366700|PROCEDURE|Periapical surgery with autograft and collagen membrane|periapical surgery will be done and the defects will be filled with a mixture of autograft and prf and will be covered with a collagen membrane
224217178|NCT04366700|PROCEDURE|Periapical surgery with collagen membrane|periapical surgery will be done and the defects will be filled with blood clot and covered with a collagen membrane
224217179|NCT02561988|DRUG|Avapritinib|
224217180|NCT04866797|OTHER|cyclic merocyanine|long-UVA absorber
224217181|NCT04866797|OTHER|Placebo|Placebo
223628357|NCT05564949|OTHER|CKD|Patients/families will meet with the study dietician to discuss the CKD, ask questions, and plan clinic visits. Training will take place about diet, meal planning, and ketones/glucose monitoring. The dietitian will follow the patient throughout treatment. Patients will measure their urine ketosis with urine test strips and capillary ketones with blood ketone meters daily, and they will complete records from the start till the end of the study. Finally, they will meet with the dietitian at follow-up visits and on an as-needed basis.
223628358|NCT00003605|BIOLOGICAL|rituximab|
224217182|NCT05687305|OTHER|White Noise|White noise is produced by digitally combining sounds of equal frequency in the laboratory. Then, all of the frequencies in this sound are calibrated to generate noise at each frequency. If the contribution of each region to the noise level is the same, the noise is referred to as white noise. Waterfalls, ocean waves, and wind blowing through trees all produce similar to white noise. Patients in the intervention group are observed by the investigator on the 0th and 1st postoperative days.Before going to sleep, a bluetooth headset will be used to listen to white noise for 30 minutes and vital signs will be measured before and after the procedure.
224217183|NCT01460927|DEVICE|TriActive+ RF|"Radio frequency handpiece uses a multi-polar technology with a particular electrical frequency of 1MHz. The handpiece has a special skin contact identification system which delivers energy only when electrodes are adherent to the skin surface in order to avoid the prickling sensation when the treatment starts."
224217184|NCT03231527|PROCEDURE|coronary artery bypass grafting (CABG)|myocardial revascularization
224217185|NCT06106503|RADIATION|chest x-ray|chest x-ray after rigid bronchoscopy for patient with foreign body inhalation
224217186|NCT06106503|OTHER|clinical examination|no investigations well be done unless needed
224217187|NCT00447603|DRUG|hydrochlorothiazide (+) losartan potassium|losartan/hydrochlorothiazide 12.5mg tablet po qd; for a 4 week study period.
224217188|NCT00447603|DRUG|losartan potassium|Losartan 50mg titrating up to Losartan 100mg tablet po qd; for a 4 week study period
224217189|NCT00447603|DRUG|Placebo for Losartan|
224217190|NCT00447603|DRUG|Placebo for Losartan/HCTZ|losartan/hydrochlorothiazide 12.5mg Pbo tablet po qd; for a 4 week study period.
224217191|NCT02639208|OTHER|PatientsLikeMe (PLM)|
223628359|NCT00003605|DRUG|cyclophosphamide|
224217192|NCT01396642|OTHER|Topical Emollient|Neonates in this group will receive topical emollient application with coconut oil twice a day till 28th day of life
224217193|NCT02168647|BEHAVIORAL|Behavioral Lifestyle counseling|Participants in the intervention group will take part in one-on-one visits with a registered dietitian nutritionist (RDN) from no later than week 14 to child birth at the OBGYN clinic where the participant receives her routine prenatal care or the Nutrition Wellness Research Center in the Iowa State Research Park. These visits will be coordinated with her routine prenatal appointment; therefore a minimum of 6 face-to-face meetings will occur. The counseling sessions will focus on appropriate weight gain during pregnancy through the use of an individualized meal plan, physical activity goals, and behavioral modification. Weight gain will be plotted on an IOM weight gain chart and discussed with study RDN.
224217194|NCT02168647|OTHER|Control|Participants in the control arm will receive no form of lifestyle intervention. Women will be provided with usual care by their physician. Participants in the control arm will have their weight gain plotted on an IOM growth chart and sent electronically by research staff after each routine prenatal appointment. No other feedback on weight gain or behavior modification will be provided by the study RDN.
224217195|NCT00374543|DRUG|Ziprasidone|Ziprasidone, flexibly dosed from 40 to 160 mg/day, for 8 weeks.
223628360|NCT03285802|DRUG|Letrozole|Letrozole 2.5mg will be taken daily q 30 days
223628361|NCT03285802|DRUG|Everolimus|Everolimus 10mg daily q 28 days
224217196|NCT00374543|DRUG|Placebo|Placebo administered daily for 8 weeks
224217197|NCT02693496|OTHER|Installation or registration of smartphone application|Completed the installation and registration of mobile terminal software online
224217198|NCT06165120|PROCEDURE|Bracka's repair using preputial graft|"Staged repair:~1. Correction of ventral chordee: by degloving of the penile skin, transection of the urethral plate \&/or ventral corporotomy through the tunica albuginea. This will be according to the degree of ventral chordee after artificial erection test.~2. Preputial graft placement: a graft will be designed on the inner layer of the preputial hood, according to the length of the urethra defect. Fixation of the free graft will be performed along the whole defective urethral plate. A compression dressing will be used for the transplanted graft. At the end of the surgery, a urinary catheter will be placed through the ectopic meatus.~3. Tubularisation of the graft: this stage will be performed 6 months later. The new graft will be tubularised over a catheter. Then a protective layer may be made over the tubularization using a dartos or tunica vaginalis flap. After suturing of the penile skin and dressing of the penis, a urethral catheter would be retained for urinary diversion."
224317444|NCT07133854|DIAGNOSTIC_TEST|Indirect calorimetry|Indirect calorimetry (Vmax Series from Vyaire medical, licence # 22536), measured during10 minutes, every hour.
224317445|NCT07134036|DEVICE|Navigation system|Patients underwent total hip arthroplasty via the direct anterior approach using a computer navigation system to assist in intraoperative limb length measurement.
224317446|NCT07134036|PROCEDURE|Conventional total hip arthroplasty|Patients underwent total hip arthroplasty via the direct anterior approach conventionally.
223628362|NCT04984967|DEVICE|Insertion of peripheral venous catheter with micro-guide|After antisepsis, the vein is punctured using a needle. Then the micro-guide is inserted to the first landmark, which indicates the passage of the micro-guide beyond the end of the needle. After the needle removed, the peripheral venous catheter is placed on the micro-guide. The guide is then removed, the peripheral venous catheter can be used.
223628363|NCT04984967|OTHER|Classic insertion of peripheral venous catheter, without micro-guide|After antisepsis, the catheter is introduced into the vein by a needle which is subsequently removed while the catheter remains in place.
223628364|NCT00702702|DRUG|Proellex 25 mg|Proellex 25 mg, 1 - 25 mg capsule and 1 placebo capsule daily for 3 months
223628365|NCT00702702|DRUG|Proellex 50 mg|Proellex 50 mg, 2 - 25 mg capsules daily for 3 months
223628366|NCT00702702|DRUG|Placebo|Placebo, 2 capsules daily for 3 months
223628367|NCT06262152|DIAGNOSTIC_TEST|Actigraphy, blood and salivary sample, and sleep evaluation|"* For each subject, one 4 mL blood and one 2 mL saliva samples will be collected at each assessment.~* 7 days actigraph recording through wearing of Actiwatch spectrum plus at home~* Standardized sleep questionnaire administration"
223628368|NCT03228108|DRUG|Ciprofloxacin|see study arms.
223628369|NCT03228108|DRUG|Trimethoprim/Sulfamethoxazole|see study arms.
224217199|NCT06165120|PROCEDURE|STPIF (Staged Transverse Preputial Island Flap) repair using preputial flap|"Staged repair:~1. Correction of ventral chordee; by degloving of the penile skin, transection of the urethral plate \&/or ventral corporotomy through the tunica albuginea. This will be according to the degree of ventral chordee after artificial erection test.~2. Preputial flap placement: according to the distance between the ectopic meatus and the glans tip, a transverse rectangular flap will be dissected from the inner layer of the dorsal prepuce. The flap will be placed along the defective urethral plate. Eventually, a silicon indwelling catheter will be placed through the ectopic meatus.~3. Tubularisation of the flap: this stage procedure would be performed 6 months after the first procedure. Tubularisation of the the preputial flap will be done over a catheter. Byar's flaps may be created and transposed to cover the neourethra. Eventually, the penis will be dressed, and a urethral catheter will be retained for urinary diversion."
224217200|NCT06230120|DEVICE|Spinal Cord Stimulation|"Stimulation electrode tip (Vectris™ SureScan MRI percutaneous lead, Medtronic Inc, Minneapolis, US)~External electrical pulse generator (Wireless External Neurostimulator System (WENS), Medtronic)"
224217201|NCT06230120|DEVICE|Sham|Stimulation electrode tip (Vectris™ SureScan MRI percutaneous lead, Medtronic Inc, Minneapolis, US) with external stimulator turned off
224217202|NCT02784925|DEVICE|Ultrasound (US) B mode image|"Ultrasound (US) B mode image is an alternative method to measure tissue structure~and has proven to be an accurate technique to measure subcutaneous fat thickness."
224217203|NCT01956357|OTHER|Aquatic exercise|
224217204|NCT01956357|OTHER|Land Exercise|
224217205|NCT02406833|DRUG|TGF-β2 antisense oligonucleotide|intravitreal injection
224217206|NCT02406833|PROCEDURE|Trabeculectomy|Standard trabeculectomy with the use of antimetabolites (mitomycin C) for glaucoma patients with insufficient intraocular pressure (IOP) control
224217207|NCT05784571|OTHER|Body Composition Assessment|Assessment of body composition using bioelectrical impedance analysis.
224217208|NCT05784571|OTHER|Modified Physical Performance Test|A test of physical functioning
224217209|NCT05784571|OTHER|Hand grip strength|A test of hand grip strength using a hand dynamometer.
224217210|NCT05784571|OTHER|6-minute walk test|Self-paced test of walking capacity.
224317447|NCT07134894|BEHAVIORAL|Intensive Bimanual Therapy plus Conventional Physical Therapy|A combined rehabilitation program delivered over 8 weeks, three sessions per week. Each 60-minute session includes 30 minutes of Conventional Physical Therapy (CPT) to improve range of motion, muscle strength, balance, and gross motor function, and 30 minutes of Intensive Bimanual Therapy (IBT) to enhance bilateral hand coordination and functional independence. IBT tasks progress from basic grasping and object transfer to complex daily activities such as buttoning, puzzle assembly, water pouring, and feeding with utensils. Two sessions are supervised by a physiotherapist and one is completed at home under caregiver guidance.
223628370|NCT03228108|DRUG|Fosfomycin|see study arms.
223628371|NCT03228108|DRUG|Pivmecillinam/augmentin|see study arms.
223628372|NCT00373581|DRUG|Vigabatrin|
223628373|NCT00373581|DRUG|Cocaine|
223628374|NCT04635449|OTHER|Age-specific information booklet and targeted telephone call|age-specific information, complemented by a follow-up targeted telephone call to reduce psychological sequelae in the child and their parents after PICU discharge.
224217211|NCT05784571|PROCEDURE|Measurement of blood glucose and insulin|Blood will be drawn for measurement of glucose and insulin.
223628375|NCT00436449|DRUG|Avotermin|
223628376|NCT00818610|DRUG|Beta lactam (amoxicillin / clav. acid OR cefuroxime)|1.2 g 4x/d OR 1.5 g 3x/d IV
223628377|NCT00818610|DRUG|Beta-lactam (amoxicillin / clav. acid OR cefuroxime) AND macrolide (clarithromycin)|1.2 g 4x/d OR 1.5 g 3x/d IV AND 0.5 g 2x/d IV/PO
224217212|NCT03918551|DRUG|Febuxostat|Febuxostat is manufactured by Pharmtechnology LLC, Republic of Belarus. Each film-coated tablet contains 120 mg of febuxostat.
224217213|NCT03918551|DRUG|Adenuric|Adenuric is manufactured by Menarini - Von Heyden GmbH, Germany (MAH: Menarini International Operations Luxembourg S.A., Luxembourg). Each film-coated tablet contains 120 mg of febuxostat.
224217214|NCT02732561|DEVICE|Alpha Stim device|cranial electrotherapy stimulation device
224217215|NCT02732561|DEVICE|Sham device|Sham device
224217216|NCT06406647|OTHER|retrocalvicular block|retrocalvicular block in upper limb orthopedic Surgey
224217217|NCT00263081|DRUG|Lapaquistat acetate and current lipid-lowering treatment|"Cohort 1: Weight is less than 50 kg:~Lapaquistat acetate 50 mg, tablets, orally, once daily and current lipid-lowering treatment for up to 12 weeks.~Cohort 2: Weight is more than 50 kg:~Lapaquistat acetate 100 mg, tablets, orally, once daily and current lipid-lowering treatment for up to 12 weeks."
224217218|NCT00263081|DRUG|Current lipid-lowering treatment|Lapaquistat acetate placebo-matching tablets, orally, once daily and current lipid-lowering treatment for up to 12 weeks.
224217219|NCT02396069|DRUG|JPI-289|PARP-1 inhibitor
224217220|NCT02396069|DRUG|Placebo|Placebo
224217221|NCT01202994|DRUG|18F-Flutemetamol|"All subjects will undergo a PET scan with 18F-PIB, within six months of also undergoing an FDG-PET scan (PET scans will occur on separate days).~For the 18F-PIB PET scan: Approximately 185 MBq (5 mCi) of 18F-PIB will be injected intravenously and PET data collected for each subject.~The FDG-PET scan will follow the same procedures as routine scans obtained in a clinical setting (approximately 370 MBq of 18F-FDG will be injected intravenously and PET data collected for each subject). FDG-PET data will be used to correlate metabolic changes and for anatomic co-registration of 18F-PIB images."
224317448|NCT07134894|BEHAVIORAL|Conventional Physical Therapy|A standard physiotherapy program delivered over 8 weeks, three sessions per week, each lasting 40 minutes. Sessions focus on upper limb range of motion, strengthening, postural control, and functional mobility without targeted bimanual training. Exercises include assisted stretches, squats, heel raises, step-ups, knee lifts, yoga-based poses, animal walks, single-leg stance, and stair climbing to promote flexibility, balance, and gross motor performance. Two sessions are supervised by a physiotherapist and one is performed at home with caregiver supervision.
224317449|NCT07133425|DRUG|SAR445877|Given by IV
224217222|NCT05366556|BEHAVIORAL|Virtual reality|"The patient, whose blood will be drawn, will be asked to wear virtual reality glasses after sitting in the blood collection chair. One minute before the start of the blood collection process, Nature Hiking will be watched from the virtual reality. Meanwhile, the researcher will complete the preparations for blood collection and will start the blood collection process. It is thought that the blood collection process takes 2-3 minutes on average. During this period, virtual reality will be applied. While blood is being drawn from the patient, the researcher will assess the patient's level of pain with the VAS during the procedure. After the blood draw is completed, the virtual reality glasses will be removed. Then, the patient will be taken to the waiting area and the state anxiety scale will be applied."
224217223|NCT01533857|DIETARY_SUPPLEMENT|hot water|Hot water and placebo capsule
223628378|NCT05441384|BEHAVIORAL|Family Caregiver - Fear Of Recurrence Therapy (FC-FORT)|7 weekly sessions of 90-120 minutes each. During the 7 weeks, participants will be asked to participate in activities, participate in group discussions, and complete homework assignments.
223628379|NCT02113709|DEVICE|Occlusion therapy by Eye Patch|The good eye was occluded by a stick-on eye patch to stimulate the amblyopic eye and its neural connections to learn to see again.
223628380|NCT02113709|DEVICE|Occlusion therapy|To see how much improvement in visual acuity occurs by full-time occlusion therapy.
223628381|NCT04038359|DRUG|Duvelisib|Phosphoinositide 3-kinase (PI3K) inhibitor
223628382|NCT05776017|BIOLOGICAL|MSP3-CRM-Vac4All/ Alhydrogel®|30 microgram MSP3-CRM-Vac4All protein extemporaneously formulated with Alhydrogel® adjuvant
223628383|NCT05776017|BIOLOGICAL|Anti-Rabies Vaccine|Control vaccine
223628384|NCT01281618|PROCEDURE|24 hour pH study and upper endoscopy (EGD)|All subjects enrolled will undergo 24 hour pH followed by EGD.
223628385|NCT05604040|BEHAVIORAL|Lifestyle Modifications|Home BP monitoring with self-monitoring of emotions, diet, physical activity, with shared medical appointment program for lifestyle changes and coping skills
223628386|NCT03717688|DRUG|Entresto|Single dose administration of Entrestro 194 mg sacubitril / 206 mg valstartan
224217224|NCT01533857|DIETARY_SUPPLEMENT|Black tea and phenolic acids|Black tea extract and capsule with phenolic acids
224217225|NCT04128878|DRUG|Sotalol|The primary goal of the study will be to evaluate the change in endothelial function seen after initiating anti-arrhythmic medical therapy. Testing will be performed at baseline prior to the 1st dose of anti-arrhythmic therapy and again 1-3 months later at outpatient follow-up visit. We will record the resting flow (RF), biological zero (BZ) and peak flow (PF) as perfusion units (PU). Specifically, we will assess arterial stiffness and vasodilation in response to acetylcholine iontophoresis, nitroprusside iontophoresis, local thermal hyperemia and reactive hyperemia. Laser speckle contrast imaging will be employed to evaluate the microvasculature. SphygmoCor (arterial tonometry) will be used to assess macrovasculature.
224217226|NCT04128878|DRUG|Dofetilide|Same as described above with sotalol.
224217227|NCT02410837|PROCEDURE|Electromagnetic Navigation Bronchoscopy|
224217228|NCT02974413|BEHAVIORAL|self-care supported|The intervention to be performed will be based on the principles and steps of supported self-care, guided by Behavior Change Protocol (Behavior Change Protocol - BCP) and consists of an educational program with quarterly meetings, and individual at home, through home visits, and group in the Basic Health Unit (BHU), in addition to telephone monitoring in the interval between two meetings. This intervention will be applied together adult men with type 2 diabetes who are randomized in the intervention group (IG) for six months. Thus, these men will take part in three meetings, individual or group, and will receive four telephone calls in between the face meetings. Our objective is to draw with this intervention by the participant, an individual plan of self-care, based on concretras goals and supports you in the implementation of this plan, in order to improve their self-efficacy in self-care and therefore glycemic control.The study will also include a Control Group (CG).
223628387|NCT03717688|DRUG|Sitagliptin 100mg|2 x 100mg sitagliptin as single dose.
223628388|NCT03717688|DRUG|Placebos|No treatment
223628389|NCT05123534|COMBINATION_PRODUCT|SONALA-001 (ALA) and MR-Guided Focused Ultrasound device (MRgFUS)|SONALA-001(ALA) given 6-12 hours prior to receiving the MRgFUS.
223628390|NCT04239898|OTHER|Red cabbage microgreens|2 cups per day
224217229|NCT02356965|DRUG|Ketamine|Single dose of sublingual investigational medication administered when subjects develop moderate to severe pain after third molar extraction.
223628391|NCT04239898|OTHER|Red beet microgreens|2 cups per day
223628392|NCT00823251|DEVICE|IlluminOss device|The IlluminOss™ Bone Stabilization System is designed to deliver the device to the fracture site via the medullary canal of the bone using percutaneous techniques. Once the device is in place and has spanned the fracture site, the device is expanded and hardened to reduce and stabilize the fracture, to aid in the support and healing of the bone fracture by primary callous formation and remodeling.
223628393|NCT05816811|OTHER|Power-focused resistance training|Participants will undergo 10 weeks of power-focused resistance training.
224217230|NCT02356965|DRUG|Placebo (for Ketamine)|Sublingual sugar pill developed to mimic ketamine sublingual dose.
224217231|NCT03643406|OTHER|Mental Fatigue|modified stroop task
224217232|NCT03643406|OTHER|Control|documentary
224217233|NCT02603159|DRUG|Capecitabine(Aibin)|Capecitabine(Aibin)：625mg/m2, bid d1-5; q1w, po,5 or 10 weeks in total
224217234|NCT02603159|RADIATION|radiotherapy|Concurrent radiotherapy： 50Gy in total，2 Gy/d，5d/w，Until disease progression or unacceptable toxicity
223628394|NCT03101995|DRUG|Gemcitabine|"Gemcitabine 300 mg/m2, prepared in 0.5 liters of sodium chloride 0.9%, IV administered in 30 minutes weekly for a maximum of 6 weeks.~Radiotherapy will start the first week, or as soon as the blood count is normal or the patient has recovered after blood transfusion. Radiotherapy will be applied, using an external beam releasing 40-50.4 Gy in 20-28 fractions: 1.8 Gy/day for 5 days/week, during 4 to 6 weeks.~Intracavitary brachytherapy will be added to reach a total EQD2 dosage (α/β=10) of 78-86 Gy."
223628395|NCT03366545|DEVICE|Cardiac Resynchronization Therapy (CRT)|Observation and documentation of routine care for CRT patients
223628396|NCT02004236|DEVICE|tRNS Fronto-temporal cortex|This group receive 35 sessions of tRNS over fronto-temporal cortex
223628397|NCT02004236|DEVICE|tRNS over fusiform temporal cortex|This group receive 35 sessions of tRNS over fusiform temporal cortex
223628398|NCT02004236|DEVICE|tRNS with sham|the subjects receive 35 session with sham
224217235|NCT00842088|DRUG|Placebo|Matching placebo capsule. Administered orally once a day on dosing days.
223628399|NCT03484130|DIETARY_SUPPLEMENT|Sodium loaded diet|At baseline, and annually, participants will undergo aldosterone dynamic testing after \~5 days of a sodium loaded diet. The diet will consist of \>180 mmol/day of sodium, \~50 mmol/day of potassium, and 600mg/d of calcium.
223628400|NCT03484130|DIETARY_SUPPLEMENT|Restricted sodium diet|At baseline, and annually, participants will undergo aldosterone dynamic testing after \~5 days of a sodium restricted diet. The diet will consist of \<40 mmol/day of sodium, \~50 mmol/day of potassium, and 600mg/d of calcium.
223628401|NCT06175338|DRUG|Rituximab|Rituximab 1000 mg in 150 ml 0,9 % NaCl (total volume of infusion 250 ml)
223628402|NCT06175338|DRUG|MabThera®|MabThera® 1000 mg in 150 ml 0,9 % NaCl (total volume of infusion 250 ml)
223628403|NCT05983211|DEVICE|Repetitive Transcranial Magnetic Stimulation|"Stage 2 \[CURRENTLY ENROLLING\]:~Accelerated rTMS using continuous theta burst stimulation (cTBS) inhibitory paradigms over bilateral M1 including hand, leg, and bulbar regions outputted at 90% of resting motor threshold, using bursts of 3 pulses at 50 Hz. Bursts are repeated at 5 Hz for a total of 600, 1200, 1800, or 3600 pulses over 40 seconds, 1 minute 20 seconds, 2 minutes, or 4 minutes. ALS patients will receive rTMS bilaterally for up to 8 treatment sessions per day, delivered one per hour, over 5 days, followed by single-day maintenance treatments at a frequency of every 2 weeks for 12 weeks, then every 4 weeks for 12 weeks."
223628404|NCT05549219|DRUG|GLM101|GLM101 IV Infusion
223628405|NCT04535843|OTHER|Biomarkers and omics data|To detect disease-related biomarkers and omics data, in this prospective MG cohort.
223628406|NCT05121766|DRUG|Omega-3 (EPA+DHA)|"Dose is 2,100mg per day via 3 mini-capsules, 2x/day (a total of 6 mini-capsules per day).~Each capsule has 252mg of EPA and 102mg of DHA."
223628407|NCT05121766|DRUG|Placebo|3 Soybean Oil Placebo capsules
223628408|NCT05574322|OTHER|Progressive foot strengthening protocol|"This interventional group will perform the foot strengthening protocol (PRP) with physical tests as :~* Maximum muscle strength of the foot~* Foot muscle morphology"
223628409|NCT05574322|OTHER|Control group|The control group will not perform the foot strengthening protocol and will continue with all their daily activities with no change in lifestyle.
223628410|NCT03264274|DRUG|Aflibercept|Antiangiogenic
223628411|NCT03264274|PROCEDURE|Dynamic Contrast Enhanced Ultrasound|DCE-US (a technique using differential liver blood flow assessments using microbubble) will be performed at baseline, Week 2 and 8 of treatment.
223628412|NCT01579227|DEVICE|Topical Tocotrienol (TCT)|Natural Form Vitamin E topical cream(TCT)
224217236|NCT00842088|DRUG|HQK-1001|HQK-1001 capsules. 10 mg/kg, 20 mg/kg or 30 mg/kg administered once a day on dosing days.
223628413|NCT01579227|DIETARY_SUPPLEMENT|Oral Tocotrienol Capsules (TCT)|Natural Form Vitamin E Oral capsules (TCT)
223628414|NCT01579227|DEVICE|Tamoxifen Cream|Tamoxifen cream
223628415|NCT01579227|DEVICE|Placebo cream|Placebo cream
223628416|NCT01579227|DIETARY_SUPPLEMENT|placebo capsule|placebo capsule
223628417|NCT04325893|DRUG|Hydroxychloroquine|First dose of 400 mg will be taken immediately after inclusion at day 0, the second dose of 400 mg will be taken on the same evening and at least 4 hours after the first dose. The treatment will then be continued for the following eight days at a rate of 200 mg in the morning and evening.
223628418|NCT04325893|DRUG|Placebo|TFirst dose of 400 mg will be taken immediately after inclusion at day 0, the second dose of 400 mg will be taken on the same evening and at least 4 hours after the first dose. The treatment will then be continued for the following eight days at a rate of 200 mg in the morning and evening.
223628419|NCT01224119|DEVICE|Amplex|225 micrograms of B2A per cc of ceramic granules
223628420|NCT01224119|PROCEDURE|Autograft bone|Bone is collected through a separate incision at the iliac crest or tibia.
223628421|NCT02970981|BIOLOGICAL|Nivolumab|
223628422|NCT02970981|BIOLOGICAL|Ipilimumab|
223628423|NCT01404169|DRUG|E2020|In titration period, donepezil 5-mg tablet will be taken orally once daily for 6 weeks, following donepezil 10 mg tablets taken orally once daily for 18 weeks in the maintenance period.
223628424|NCT01404169|DRUG|Placebo|Placebo matched to donepezil 5 mg or 10 mg tablets taken orally once daily for 24 weeks.
223628425|NCT04281615|OTHER|Generic Message|Exposed to four sets of promotional materials hypothesized to increase perceptions of self-efficacy to meet Guidelines.
224217237|NCT00837577|DRUG|Comparator: Placebo|Placebo to sitagliptin once daily for 12 weeks (double-blind period)
224217238|NCT00837577|DRUG|Sitagliptin|"Sitagliptin/Sitagliptin arm only: Sitagliptin 50 mg once daily orally before breakfast for 12 weeks (double-blind period).~Both arms: Sitagliptin 50 mg once daily orally before breakfast for 40 weeks (open-label period). The dose of sitagliptin was increased up to 100 mg for participants who had an inadequate response to sitagliptin 50mg after treatment Week 20."
224217239|NCT00837577|DRUG|Voglibose|"All participants received a stable dose of voglibose, in~accordance with the package insert, throughout the study."
224217240|NCT03768882|DRUG|paracetamol|1000 mg of paracetamol (parol 10mg/ml Mefar, Turkey) intravenous (IV) was given 102 patients
224217241|NCT03768882|DRUG|Dexketoprofen|Second group: dexketoprofen 50 MG (Arveles ampoule -İE Ulagay -Menarini,Turkey) intravenous (IV) was given 98 patients
223628426|NCT06279741|BIOLOGICAL|Endotracheopulmonary Instillation, Suspension|"The endotracheal administration can be either by endotracheal tube instillation using a 5 French end-hole catheter or by endotracheal tube instillation using the secondary lumen of a dual lumen endotracheal tube.~The dose is adjusted to body weight and the endotracheal administration will be performed in an already intubated newborn infant."
223628427|NCT04578951|DEVICE|FHK® total knee prosthesis|FHK® prosthesis are intended to be implanted in the tibial and femoral regions during total knee arthroplasty in order to restore joint function.
223628428|NCT02447965|DRUG|Bupivacaine|Using ultrasound guidance bupivacaine will be injected into the active group's rectus abdominis sheath.
223628429|NCT02447965|DRUG|Normal Saline|Using ultrasound guidance normal saline will be injected into the placebo group's rectus abdominis sheath.
223628430|NCT03259230|OTHER|Blood Draws|
223628431|NCT03259230|OTHER|Data Collection|
224217242|NCT06527573|DEVICE|active repetitive transcranial magnetic stimulation|During the rTMS-active stage, treatment will be given for 7 consecutive days (two session daily). The participants will be placed in the semi-reclining position on either a normal chair or a wheelchair and each stimulation session will last 20 minutes with a frequency of 10 Hz (train duration: 1s; inter-train interval: 5s; 200 effective stimulation series; 2000 pulses at 90% of RMT).
223628432|NCT03239834|DEVICE|OncAlert|A noninvasive point of care salivary rinse test performed as 1) a one-time test for patients presenting with suspicion of OPMD and scheduled for biopsy and 2) a multi-administered test for patients presenting with suspicious lesions not scheduled for biopsy.
223628433|NCT01033240|DRUG|CS-1008 2 mg/kg|On a once a week basis CS-1008 will be administered intravenously starting at 2 mg/kg.
223628434|NCT01033240|DRUG|Sorafenib|On a daily basis, one sorafenib tablet, 400 mg, is taken orally twice a day. The total daily dose of sorafenib is 800 mg. The sorafenib tablets are taken at least 1 hour before or 2 hours after a meal.
223628435|NCT01033240|DRUG|CS-1008 6/2 mg/kg|A 6 mg/kg loading dose of CS-1008 will be administered intravenously, followed by a 2 mg/kg/week maintenance dose on a once-a-week basis.
223628436|NCT01033240|DRUG|CS-1008 6/6 mg/kg|A 6 mg/kg loading dose of CS-1008 will be administered intravenously, followed by a 6 mg/kg/week maintenance dose on a once-a-week basis.
223628437|NCT01033240|DRUG|CS-1008 4 mg/kg|On a once a week basis CS-1008 will be administered intravenously at 4 mg/kg if tolerated.
223628438|NCT01033240|DRUG|CS-1008 6 mg/kg|On a once a week basis CS-1008 will be administered intravenously at 6 mg/kg if tolerated.
223628439|NCT05123872|DEVICE|tDCS|trancranial direct current stimulation 30 sessions within 6 weeks (treatment on working days) 2mA with cathode on the right and anode an the left side
223628440|NCT05665439|RADIATION|radiation|radiation for patients with newly diagnosed bone metastases or patients with bone metastases after vertebroplasty
223628441|NCT00405080|DRUG|GW679769 (Casopitant) oral tablets|Casopitant tablets will be available with dose strength of 50 mg. Subjects will receive three 50 mg tablets for the dose of 150 mg. On Day 8 of Treatment Period 2, the dose of casopitant and rifampin is to be taken at the same time.
223628442|NCT00405080|DRUG|Rifampin oral capsules|Rifampin capsules will be available with dose strength of 300 mg. Subjects will receive two 300 mg capsules for the dose of 600 mg. On Day 8 of Treatment Period 2, the dose of casopitant and rifampin is to be taken at the same time.
223628443|NCT01773317|OTHER|Perturbation|All subjects complete study protocol. Subjects randomized to the perturbation group will complete the additional perturbation exercises
223628444|NCT01773317|OTHER|Control|Subjects will complete the study protocol (including nordic hamstrings, standing squats, drop jumps, triple single leg hopping, and tuck jumps)
223628445|NCT05302674|OTHER|Hot Dry|98°F (36.7°C) and 20% relative humidity environment
223628446|NCT02955589|DRUG|HBI-8000|Oral, twice weekly
223628447|NCT03894488|DIAGNOSTIC_TEST|FilmArray Gastrointestinal (GI) Panel|The FilmArray GI Panel tests for 22 of the most commonly associated pathogens related to gastroenteritis-all from one patient sample, one easy to use reagent, and results are available in about one hour.
223628448|NCT02655848|PROCEDURE|Arthroscopic rotator cuff repair|Arthroscopic rotator cuff repair using suture anchors
223628449|NCT02655848|PROCEDURE|LHB Tenodesis|Arthroscopic tenotomy and subsequent fixation of long head biceps proximal in the biceps groove
223628450|NCT02655848|PROCEDURE|LHB Tenotomy|Arthroscopic tenotomy of long head biceps
223628451|NCT00588926|DRUG|Remifentanil|After the mapping electrode is in situ, recording of baseline electrical activity is done for two-three minutes and an infusion of Remifentanil, 0.1 microgram per kilogram per minute is started. This procedure continues for a few minutes until the patient is sedated and then the infusion is stopped and the patient allowed to recover. The recordings continue during the whole procedure.
223628452|NCT00866424|PROCEDURE|Hyperbaric oxygen, Mock hyperbaric chamber|"Hyperbaric oxygen treatment for 10 days in treatment groups and mock hyperbaric chamber treatment for 10 days in control groups.~Hyperbaric oxygen treatment: While in the hyperbaric chamber the subjects breathe 100% oxygen saturation with mask at 2.0bars.~Mock hyperbaric chamber treatment: The subjects breathe air freely in the imitation environment chamber at 1.0bars."
223628453|NCT00723996|BEHAVIORAL|Behavioral Study in Women|A Randomized study to assess the knowledge of womens health related issues
223628454|NCT05035524|DRUG|Sodium Bicarbonate Solution|Inhalation of SB 8.4% via a jet nebulizer (5 ml every 4 h) starting at 7:00 to 23:00 hours every day for 30 days together with instillation of SB 8.4% drops 4-times daily (three drops for each nostril) were offered to all patients in the study group (El-Badrawy et al., 2019).
223628455|NCT05035524|DRUG|Placebo|Placebo
224217243|NCT06527573|DEVICE|sham repetitive transcranial magnetic stimulation|The sham coil will be used which has no magnetic field to send to the cerebral cortex while appearing to be the same shape as the active coil, with good approximation of auditory feedback.(train duration: 1s; inter-train interval: 5s; 200 effective stimulation series; 0 pulses at 90% of RMT).
223628456|NCT03838185|DRUG|J147|Single oral dose of J147
224217244|NCT02294552|DRUG|Cyclophosphamide|
223628457|NCT03838185|DRUG|Placebo|Single oral dose of corn oil
223628458|NCT02960217|DRUG|UX007|liquid for oral (PO) administration
223628459|NCT02960217|DRUG|Placebo|liquid safflower oil for PO administration
224217245|NCT02294552|DRUG|Busulfan|
224217246|NCT02294552|DRUG|Fludarabine monophosphate|
223628460|NCT02699658|DRUG|Levofloxacin|
223628461|NCT05826483|DRUG|Almonertinib|Almonertinib Mesilate Tablets
223628462|NCT02268890|DRUG|Bortezomib|Participants will receive a 1.3 milligram per square meter per dose (mg/m\^2/dose) of bortezomib intravenously on Days 1, 4, 8, and 11.
223628463|NCT01774201|OTHER|Breathing exercises|Breathing exercises with positive expiratory pressure.
223628464|NCT01182636|DRUG|Adapalene|0.1% Topical Gel
223628465|NCT01182636|DRUG|Differin®|0.1% Topical Gel
223628466|NCT01182636|DRUG|Placebo|Gel Base
223628467|NCT02919228|OTHER|Visible light exposure|Subjects will be exposed to visible colored light for 15 minutes. The visible light will be generated by red-green-blue light emitting diodes light cans.
224217247|NCT02294552|DRUG|Tacrolimus|
224217248|NCT02294552|DRUG|Mycophenolate mofetil|
224217249|NCT02294552|PROCEDURE|Allogeneic hematopoietic stem cell transplantation|
224217250|NCT05474937|DRUG|Sevoflurane Inhalation Solution|Patients in inhalational group will receive Sevoflurane at 7% dial concentration in 100% O2 by an appropriately sized face mask until adequate sedation occurs as adequate jaw relaxation for the endoscope insertion and attainment of Modified Ramsay Sedation Score (MRSS) 7 (i.e., Asleep, reflex withdrawal to painful stimuli only).
224317450|NCT07135193|DIETARY_SUPPLEMENT|Cordyceps cicadae|Cordyceps cicadae 500mg
223628468|NCT02153268|PROCEDURE|Single Arm - Liposuction procedure and BonoFill transplantation will be done for all subjects on study|"Liposuction - will be performed on Visit 2, BonoFill will be based on subject's autologous Human Adipose Tissue Derived Cells (HATDCs).~BonoFill Transplantation will be performed on Visit 6. BonoFill will be administrated to the subject in a single session at one tested cell dose."
223628469|NCT02244541|DRUG|ANAVEX2-73 Oral|
223628470|NCT02244541|DRUG|ANAVEX2-73 Intravenous|
223628471|NCT02244541|DRUG|ANAVEX2-73 Oral|30 mg hard gelatin capsule
223628472|NCT02244541|DRUG|ANAVEX2-73 Oral|50 mg hard gelatin capsule
223628473|NCT00161200|DRUG|Ranitidine & Pantoprazole|
223628474|NCT00625131|DRUG|Nicotine|Delivered through transdermal nicotine patch
223628475|NCT00625131|BEHAVIORAL|Cognitive Behavioral Therapy for Smoking Cessation|Manualized protocol for CBT in smoking cessation
223628476|NCT00625131|DRUG|Bupropion Sustained Release (SR)|Antidepressant
223628477|NCT00625131|DRUG|Placebo patch|Pre-treatment placebo transdermal patch
224217251|NCT05474937|DRUG|Midazolam, Ketamine and Propofol|Preoxygenation with 100% O2 for 1 minute, by proper sized face mask. Patients in Ketamine -midazolam -propofol (KMP) group will receive 1-1.5 mg/kg IV ketamine and 0.05mg/kg IV Midazolam and 1mg/kg IV Propofol as induction dose then followed by incremental doses of 0.5 mg/kg IV Propofol alone for maintenance and if procedure is prolonged propofol infusion at 100 μg/kg/min is given for maintenance of sedation. Induction dose will be considered as adequate if adequate jaw relaxation for endoscope insertion and Modified Ramsay Sedation Score (MRSS) ≥7 occurs with maintenance of spontaneous respiration. Induction time will be considered as time from beginning of IV agent to achievement of MRSS ≥7. After endoscope insertion, maintenance of oxygenation by nasal cannula at flow twice the minute ventilation of the patient
224217252|NCT01540682|DRUG|MLN8237|Three dose levels of MLN8237 are planned:30, 40 and 50 mg po bid.
223628478|NCT01003301|DRUG|Omalizumab|Injections subcutaneously (up to 3) every 2 or 4 wks based on the subjects weight and baseline total serum IgE level as approved for therapy in allergic asthma. Duration of therapy is approximately 14 wks.
223763990|NCT04649034|DIAGNOSTIC_TEST|Doppler echocardiogram exam|A complete echocardiographic study will be performed at enrollment. The echocardiographic images will be acquired as clinically recommended. The protocol will include the acquisition of 1) 2D images in parasternal axis long and short axis; 2) 2D and Doppler tissue images in the apical planes of 4, 2 and 3 chambers; 3) Pulsed, continuous and color Doppler M (DCMM) of transmitral LV flow and LV ejection; 4) 3-Chamber apical plane with and without color Doppler; and 5) 3D LV images. DCMM images will be obtained from the apical window using 4 and 5 chamber planes. Blood flow velocity will be obtained using Color and Gray mode in the 3 chamber view during 5-10 beats in apnea.
224217253|NCT01540682|DRUG|Cetuximab|\~ 1 week prior to the initiation of radiation therapy and continuing for a grand total of 12 weeks.
224217254|NCT01540682|RADIATION|Radiotherapy|Radiotherapy will be administered in 2-Gy fractions, 5 days a week to a total dose of \~70 Gy.
224217255|NCT00765323|DRUG|Octreotide Implant|84 mg octreotide subcutaneous implant for 6 months
224217256|NCT00765323|DRUG|Sandostatin LAR Depot|Injections of Sandostatin LAR (dose range \~10-40 mg every 28 days)
224317451|NCT07135193|DIETARY_SUPPLEMENT|Blank control|Blank control
223628479|NCT01003301|DRUG|Placebo|Injections subcutaneously (up to 3) every 2 or 4 wks based on the subjects weight and baseline total serum IgE level as approved for therapy in allergic asthma. Duration of therapy is approximately 14 wks.
223628480|NCT04279886|OTHER|Three-dimensional scans|All included healthy volunteers received 6 three-dimensional scans, utilizing 3 different scanning systems (2 scans per system)
223628481|NCT00918281|DRUG|Fluciclatide Injection|Fluciclatide Injection (AH111585 (18F) Injection)
223628482|NCT05683093|OTHER|History of being born to hypertensive or normal pregnancy|"CLARITY is an observational study whereby participants will attend one 4-hr visit the Division of Cardiovascular Medicine, University of Oxford at the John Radcliffe Hospital in Oxford, with the option to split the study visit over two days for convenience.~Participants will be invited by the ALSPAC study team to attend a study visit in Oxford where the investigators will use MRI and other imaging modalities to study the brain, heart, liver, kidneys, and vasculature using standardised protocols. A dataset including information from previous follow-up of these cohorts and the detailed pregnancy data available within ALSPAC will be generated by the study team in Bristol and integrated with available data from the Oxford cohorts."
223628483|NCT04321018|DIETARY_SUPPLEMENT|Mixed meal with medium chain triglycerides|Mixed macronutrient liquid meal (1.6kcal/ml, 15% protein, 47% carbohydrates, 35% fat, 3% fiber) with medium chain triglycerides (3g/100 kcal). An amount with energy supply equivalent to their 50% basal metabolic rate.
223628484|NCT04321018|DIETARY_SUPPLEMENT|Mixed meal with the replacement of medium chain triglycerides with unsaturated tryglicerides|Mixed macronutrient liquid meal (1.6kcal/ml, 15% protein, 47% carbohydrates, 35% fat, 3% fiber) without medium chain triglycerides (replaced it with long chain triglycerides). An amount with energy supply equivalent to their 50% basal metabolic rate.
223628485|NCT00801736|DRUG|Cisplatin, Paclitaxel|"* Cisplatin 75mg/m2, Day 1~* Paclitaxel 175mg/m2, Day 1"
223628486|NCT00175526|BEHAVIORAL|preeclampsia|This research project, 'a severity score for pre-eclampsia,' will develop such a clinical tool that is specific to the condition. To develop and validate the tool w
223628487|NCT01743469|DRUG|Tasquinimod|1 capsule: initially at 0.5 mg/day, increasing to 1 mg/day, maintaining 0.5 mg/day or decreasing to 0.25 mg/day after at least 2 weeks.
223628488|NCT01743469|DRUG|Tasquinimod|1 capsule: initially at 0.5 mg/day, increasing to 1 mg/day, maintaining 0.5 mg/day or decreasing to 0.25 mg/day after at least 2 weeks.
223628489|NCT01743469|DRUG|Tasquinimod|1 capsule: initially at 0.5 mg/day, increasing to 1 mg/day, maintaining 0.5 mg/day or decreasing to 0.25 mg/day after at least 2 weeks.
224217257|NCT03605537|DRUG|Drug-eluting Stent Mometasone|The subject will have a mometasone drug-eluting stent placed during their choanal atresia repair procedure instead of no stent being placed.
224217258|NCT03941171|PROCEDURE|PAO|PAO will be performed as the trans-sartorial approach or the anterior pelvic approach.
223628490|NCT01743469|DRUG|Tasquinimod|1 capsule: initially at 0.5 mg/day, increasing to 1 mg/day, maintaining 0.5 mg/day or decreasing to 0.25 mg/day after at least 2 weeks.
223628491|NCT00333125|DRUG|Travoprost 40 mcg/ml + Timolol 5 mg/ml eye drops, solution (DuoTrav)|One drop in the study eye(s) once daily, 9 PM, for 6 weeks
223628492|NCT00333125|DRUG|Dorzolamide 20 mg/ml + Timolol 5 mg/ml eye drops, solution (Cosopt)|One drop in the study eye(s) twice daily for 6 weeks
223628493|NCT00333125|OTHER|Timolol Vehicle|One drop in the study eye(s) once daily for 6 weeks
223628494|NCT00317473|BIOLOGICAL|FMP1/AS02A Malaria vaccine|Subjects vaccinated with FMP1/AS02 vaccine
223628495|NCT00317473|BIOLOGICAL|Imovax Rabies vaccine|Subjects vaccinated on corresponding FMP1/AS02A vaccination days
223628496|NCT04604145|DIAGNOSTIC_TEST|SARS-CoV-2 testing on the Eppendorf Thermal Cycler PCR system using self-collected saliva as the specimen|Obtain self-collected saliva sample, perform SARS-CoV-2 testing using the Eppendorf Thermal Cycler Polymerase chain reaction (PCR) system on 30 samples associated with a positive and 30 samples associated with a negative NP sample, then compare saliva results to healthcare worker collected NP sample results evaluated on either the BioFire® FilmArray® Torch® system or the Cepheid® GeneXpert® (gold standard).
223628497|NCT02848820|DRUG|Augmentin + Gentamicin|Amoxicillin/clavulanic acid (Augmentin) 25/2.5mg 6-hourly (total 100/10 mg/kg daily; maximum 6000/600mg a day) intravenously for 48 hours Oral amoxicillin/clavulanic acid 50/12.5 mg/kg 8-hourly (max 1500/375mg a day) for in total 7 days Gentamicin 7mg/kg once daily for 48 hours
223628498|NCT02848820|PROCEDURE|Appendectomy|Pre-, peri- and postoperative care according to local protocol. No routine postoperative antibiotics
223628499|NCT02830737|PROCEDURE|Traditional RFA|Radio frequency ablation via an ultrasound-guided electrode needle penetrating into the lesion center
223628500|NCT02830737|PROCEDURE|No-touch RFA|Radio frequency ablation via an ultrasound-guided electrode needle penetrating into the tumor-free zone (within 5mm along the edge of the tumor)
223628501|NCT03844776|DRUG|Co-Amoxiclav|amoxicillin + clavulanic acid orally
223628502|NCT03844776|DRUG|Paracetamol|paracetamol orally
223628503|NCT03844776|DRUG|Chlorhexidine mouthwash|0.2% chlorhexidine mouthwash
223628504|NCT03844776|DRUG|Normal saline|0.9% normal saline irrigation
223628505|NCT03844776|DRUG|Amoxicillin 500 Mg|Amoxicillin 500 orally
223628506|NCT03844776|DRUG|Metronidazole|metronidazole 500 mg orally
223628507|NCT00388349|DRUG|Gemcitabine|
223628508|NCT00388349|DRUG|Vinorelbine|
223763991|NCT04649034|DIAGNOSTIC_TEST|Cardiac magnetic resonance|"A cardiac MR will be acquired within 10 days after the enrollment. The protocol includes the following sequences: cine mode of short axis from LV base to apex and 2-3-4 chambers. 3D sequence of late enhancement of inversion-recovery. Images will be acquired after 3 min and 10 min of the administration of a total of 0.2 mmol / kg of Prohance®. Intraventricular thrombosis will be monitored. Phase contrast sequences in three orthogonal planes will be acquired. Morphological parameters of LV function (LVEF), contractility (Wall Motion Score ) and sphericity index will be measured."
223763992|NCT04649034|DIAGNOSTIC_TEST|Brain magnetic resonance|A brain MR will be acquired within 10 days after the enrollment. Axial, sagittal and coronal spin echo sequence in T1, axial images in diffusion sequences (DWI), enhanced spin echo T2 and FLAIR (fluid-attenuated inversion recovery) sequences shall be obtained. A cerebral infarction will be positive when finding the presence of a focal lesion of\> 3 mm in diameter that meets one of these three characteristics: (1) high signal on isotropic DWI images and low signal on the apparent coefficient map Broadcast (ADC). (2) Cavitary lesion hyperintense on T2, with no signal (or low) in the FLAIR sequence. (3) Hyperintense lesion T2 / T1 hypointense with prior distribution defect known or new in a follow-up study.
223763993|NCT04649034|DIAGNOSTIC_TEST|Coagulation blood test|5 ml of peripheral blood will be obtained for assessment of prothrombotic markers at enrollment.
223763994|NCT04649034|DIAGNOSTIC_TEST|Holter monitoring|At inclusion all patients will carry a Holter device for 24 hours to ensure absence of atrial fibrillation
224317453|NCT06484491|RADIATION|Dose-escalated intensity-modulated proton therapy (IMPT-74)|Heterogeneous simultaneous integrated boost of 74.0 Gy (RBE) to primary tumor \>15mm away form mediastinal envelope, and 64.0 Gy (RBE) to primary tumor =\< 15mm away from mediastinal envelope. The rest of the clinical target volume, including affected lymph nodes, receives 60.0 Gy (RBE).
223628509|NCT00388349|DRUG|Carmustine|
223628510|NCT00388349|DRUG|Etoposide|
223628511|NCT00388349|DRUG|Cyclophosphamide|
223628512|NCT00388349|PROCEDURE|Autologous HCT|
223628513|NCT00168844|DRUG|Tiotropium Inhalation Solution|
223628514|NCT00168844|OTHER|Placebo|
223628515|NCT05271981|OTHER|Retrospective data collection|Data collection from the medical file of the patients
223628516|NCT05271981|OTHER|Phone interview|Call for collecting fertility data and obstetrical issues of the patients
223628517|NCT04992117|OTHER|NO INTERVENTION|NO INTERVENTION
223628518|NCT01186263|DRUG|MAA for diagnostic SPECT imaging|Intraarterial application of 5ml containing 500.000 particles with an activity of 150MBq.
223628519|NCT01186263|DRUG|Diagnostic B20- SPECT imaging.|Intraarterial application of 5ml containing 150.000 particles with an activity of 150 MBq.
223628520|NCT00564681|BIOLOGICAL|botulinum toxin type A|Intramuscular injections into the affected muscles. Maximum dose of 360 units. Subjects may receive up to three treatments.
223628521|NCT00564681|BIOLOGICAL|botulinum toxin type A Formulation 2|Intramuscular injections into the affected muscles. Maximum dose of 360 units. Subjects may receive up to three treatments.
223628522|NCT00564681|DRUG|Normal Saline|Intramuscular injections of placebo (normal saline) into the affected muscles for treatment cycle 1.
223628523|NCT01648465|DRUG|Everolimus|Everolimus 10mg(2x5mg)orally once daily until disease progression, unacceptable toxicity or consent withdrawal
223628524|NCT05945420|DRUG|Desmopressin Acetate|This arm will receive tamsulosin and desmopressin acetate daily a
223628525|NCT05945420|DRUG|Placebo|This arm will receive tamsulosin and placebo
223628526|NCT03883256|DEVICE|high flow nasal cannula|High flow nasal cannula is a device that delivered heated and humidified high flow gases to at or near body temperature to avoid drying and possible injury to the nasal mucosa. In this study, subjects perform a constant-load exercise test with high flow nasal cannula.
224217259|NCT03941171|OTHER|Usual care after PAO|Patients commence post-operative rehabilitation as usual and follow the rehabilitation program guided by a physiotherapist specialized in hip problems until 4 months after the operation.
224317454|NCT06484491|DRUG|Cisplatin or carboplatin + pemetrexed for induction chemotherapy, cisplatin + docetaxel for concurrent chemotherapy|"Induction course:~-Cisplatin (75 mg/m2) or carboplatin (AUC 6) + pemetrexed (500mg/m2).~Concurrent chemoradiotherapy:~* Weekly cisplatin (20mg/m2) + docetaxel (20mg/m2) on Mondays.~* Radiotherapy will be given for 5x5 days."
223763995|NCT06052618|DRUG|Pacritinib|Pacritinib is administered orally as 200 mg twice daily for a total of 6, 28-day cycles
224217260|NCT03941171|OTHER|PRT|4 months of partly supervised progressive resistance training 2 times per week. After these 4 months (16 weeks), patients receive a free membership to a fitness center near their home address and are encouraged to train on their own 2 times per week until 12 months follow-up with one supervised session per month. The PRT program involves 10-min of warm up followed by 50-min of bilateral resistance exercises including sets of squats, hip extension, hip flexion, and hip abduction.
224217261|NCT04416828|DEVICE|Portable wireless ultrasonography devices|Patients with suspected ganglion cyst of the wrist or hand receive portable wireless ultrasound imaging
224317455|NCT06484491|DRUG|Immunotherapy: adjuvant durvalumab|"Adjuvant treatment will be given starting 1-6 weeks after chemoradiotherapy if no progression, good performance (PS 0-1), no other contra-indication for immunotherapy.~Doses:~* Start durvalumab 10 mg/kg 1x/14 days.~* If possible after 2 courses switch to 1500 mg flat dose 1x/4 wk.~* Continue for 12 months in total."
223514224|NCT02957903|DRUG|Isotonic Saline|All 20 study participants will receive both treatment A and B in form of a nerve block injection around the lateral femoral cutaneous nerve. Treatment A and B will be randomized to be given in either right or left lower extremity. If the participant is randomized to receive treatment A in the right lower extremity, treatment B will be given in the left lower extremity, and vice versa. Each participant will thus constitute as their own control.
223514225|NCT03956082|DEVICE|Ultravision™ Visual Field Clearing System|Laparoscopic surgery will be performed with the Ultravision Visual Field Clearing System. This system is indicated for the clearance of smoke and other particulate matter that is created during laparoscopic surgery. Ultravision Visual Clearing System removes surgical smoke by means of electrostatic precipitation
223514226|NCT03956082|DEVICE|Ultravision Ionwand™|The Ionwand™ is introduced into the abdomen through either the Ultravision™ 5mm Trocar or a 2.5 mm percutaneous catheter. The Ionwand™ provides the source of electrons that create the negative ions that transiently charge the surgical smoke particles and accelerate their sedimentation.
223514227|NCT05343650|DEVICE|NOVAPAK nasal packing applied to forearm|Novapak packing will be applied to the patient's skin for 30 minutes on the anterior aspect of the patients' non-dominant arm. In case of pre-existing wounds, it will be applied to the other forearm.
223514228|NCT05343650|DEVICE|NOVAPAK nasal packing applied to nasal cavity|A piece of Novapak material will be applied to the participant's nasal cavity at the level of the inferior turbinate for 15 minutes
223514229|NCT01079390|DEVICE|acupuncture|patient will receive high dose, low dose or sham acupuncture treatment.
223514230|NCT03823885|OTHER|e-cigarette|use e-cig for 30 minutes
223514231|NCT03823885|OTHER|empty (-cigarette sham control)|use empty e-cig (sham control)
223514232|NCT03002909|DEVICE|epidural catheter|
223514233|NCT03002909|DEVICE|preperitoneal catheter|
223514234|NCT00159874|DRUG|Sildenafil citrate|Oral, subjects with body weight ≥8 - 20 kg: 20 mg 3 times a day (tid) subjects with body weight \>20 - 45 kg: 40 mg 3 times a day (tid) subjects with body weight \>45 kg: 80 mg 3 times a day (tid)
223514235|NCT00159874|DRUG|Sildenafil citrate|Oral,10 mg 3 times a day (tid), only subjects with body weight \>20 kg
223514236|NCT00159874|DRUG|Sildenafil citrate|Oral, subjects with body weight ≥8 - 20 kg: 10 mg 3 times a day (tid); subjects with body weight \>20 - 45 kg: 20 mg 3 times a day (tid); subjects with body weight \>45 kg: 40 mg 3 times a day (tid)
223514237|NCT05439863|DEVICE|transcatheter heart valve|patients with severe aortic valve disease underwent transcatheter heart valve
223514238|NCT04019704|DRUG|AXS-05|Oral AXS-05 tablets, taken daily for 6 weeks.
223514239|NCT04019704|DRUG|Placebo|Placebo to match oral AXS-05 tablets, taken daily for 6 weeks.
223514240|NCT02088411|DRUG|Diclofenac|
223514241|NCT02088411|DIETARY_SUPPLEMENT|Wobenzym|
223514242|NCT02088411|OTHER|Placebo|
223514243|NCT05073731|OTHER|Telerehabilitation-based Upper Extremity Training|"Telerehabilitation has been defined as the delivery of rehabilitation services through information and communication technologies.~Synchronized telerehabilitation provides the participant with advantages such as customized treatment, instant feedback, and a social environment such as face-to-face training."
223514244|NCT05122143|DEVICE|Treatment A|"Nasal Spray with drug-free aqueous gel emulsion (AM-301) intended to help protect against airborne allergens.~One Spray of AM-301 per nostril"
223514245|NCT05122143|DEVICE|Treatment B|"Nasal Spray with drug-free aqueous gel emulsion (AM-301) intended to help protect against airborne allergens.~Two Sprays of AM-301 per nostril (with different spray angles)"
223514246|NCT05122143|OTHER|Treatment C|No treatment
223514247|NCT05704699|BEHAVIORAL|eTRE|eating between 0800h and 1600h daily
223514248|NCT05704699|BEHAVIORAL|eTRE with BISC|eating between 0800h and 1600h daily and completing 3 sessions of BISC per week of study duration
223514249|NCT01475825|DRUG|mipomersen sodium 200 mg|Subcutaneous mipomersen 200 mg once weekly
223514250|NCT01475825|DRUG|Placebo|Placebo vehicle for subcutaneous injection.
223514251|NCT01475825|DRUG|mipomersen sodium 70 mg|Subcutaneous mipomersen 70 mg thrice weekly
223514252|NCT01986023|BEHAVIORAL|SMS- Short Messaging Service|
223514253|NCT03649087|OTHER|Vitrification|Vitrification of ovarian tissue
223514254|NCT02570425|DEVICE|Training on BF Spiromax followed by SYMBICORT Turbohaler|Training with a placebo comparator: Budesonide Formoterol (BF) Spiromax® device using a 6-level system to examine the number of levels required to acquire mastery of device at baseline and maintenance and mastery at 4 and 8 weeks after initial training.
223628527|NCT03883256|DEVICE|nasal cannula|Nasal cannula is a device that delivered oxygen to patients. In this study, subjects perform a constant-load exercise test with nasal cannula.
223628528|NCT05249140|DEVICE|Repetitive Transcranial Magnetic Stimulation|rTMS involves a safe, non-invasive, painless application of a magnetic field over the skull to a target brain area in order to change its activity and function.
223628529|NCT00080665|DRUG|docetaxel|Docetaxel (15-30 mg/m2, IV, weekly on days 1, 8, and 15) each 28 day cycle
223628530|NCT00080665|DRUG|imatinib mesylate|Imatinib mesylate (400-600 mg, oral, once daily) each 28 day cycle
223628531|NCT02735967|OTHER|manual therapy|the positional release techniques will be performed while maintaining this position for 90 seconds procedure is repeated 3 times. Then, the therapist performs the ischemic compression technique on the myofascial trigger point, the compression is maintained for 90 seconds by 3 replications.
223628532|NCT02735967|DEVICE|diadynamic current|Through an electrotherapy device were applied diadynamic in that myofascial trigger point previously marked. 4 minutes from the fixed two-phase mode will be applied (DF), 4 minutes long periods (LP) and 4 minute short periods (CP), the first and second intensely in the sensitive line and the third motor threshold, both supportable according to each patient.
224217262|NCT04416828|DEVICE|Cart-based ultrasonography device|Patients with suspected ganglion cyst of the wrist or hand receive conventional cart-based ultrasound imaging
224217263|NCT01332513|DRUG|Investigational Medicinal Product (MR1)|Ezogabine MR1 at a dose strength of 300 mg will be orally administered with approximately 250 milliliter (mL) of water to group A subjects during the bioavailability phase. For the food effect phase subjects in group G will be orally administered MR1 tablets at a dose strength of 600 mg.
224217264|NCT01332513|DRUG|Investigational Medicinal Product (MR2)|Ezogabine MR2 at a dose strength of 300 mg will be orally administered to group B subjects with approximately 250 mL of water during the bioavailability phase. For the food effect phase subjects in group H will be orally administered MR2 tablets at a dose strength of 600 mg.
224217265|NCT01332513|DRUG|Investigational Medicinal Product (MR3)|Ezogabine MR3 will be orally administered with approximately 250 mL of water to group C subjects during the bioavailability phase. For the food effect phase subjects in group I will be orally administered MR3 tablets at a dose strength of 600 mg.
224217266|NCT01332513|DRUG|Investigational Medicinal Product (MR4)|Ezogabine MR4 will be orally administered with approximately 250 mL of water to group D subjects during the bioavailability phase. For the food effect phase subjects in group J will be orally administered MR4 tablets at a dose strength of 600 mg.
224217267|NCT01332513|DRUG|Investigational Medicinal Product (MR5)|Ezogabine MR5 will be orally administered with approximately 250 mL of water to group E subjects during the bioavailability phase. For the food effect phase subjects in group K will be orally administered MR5 tablets at a dose strength of 600 mg.
224217268|NCT01332513|DRUG|Investigational Medicinal Product (IR)|Ezogabine IR at dose strengths of 50 mg and 200 mg will be orally administered with approximately 250 mL of water.
224217269|NCT04624841|DRUG|Indocyanine Green|2.5-7.5 mg (0.05 mg/kg) injection
224217270|NCT01602198|DRUG|Exelon [rivastigmine] transdermal patch|Exelon patch 1/day for six months
224217271|NCT01602198|DRUG|Placebo transdermal patch|Placebo transdermal patch 1/day for 6 months
224317456|NCT06170944|DEVICE|Remote ischemic preconditioning|The patients in experiment group will receive treatment with RIC (5 cycles of cuff inflation for 5 minutes and deflation for 5 minutes to the bilateral upper limbs to 200 mmHg) for 1 year as an adjunct to guideline-based treatment.
223628533|NCT02854085|BEHAVIORAL|Art Therapy|The Art Therapy will consist of creating art pieces, narrating thoughts and inner experiences in relation to the pieces produced (2 sessions a month) and guided visits to the art gallery (one session a month) and art museum (one session a month); there will be 12 sessions weekly for 12 weeks. For the next 6 months, sessions will be fortnightly and consist of creating an art piece once a month alternating with a visit to either the art museum or gallery, once a month; there will be 12 sessions in 6 months. Each session will last 45 minutes and will begin with 5 minutes of mindful relaxation to help participants focus on the task ahead.
223628534|NCT02854085|BEHAVIORAL|Music Reminiscence Activity|Music Reminiscence activity will be held weekly for 12 weeks and fortnightly for 6 months. Each session will last 45 minutes and will begin with 5 minutes of mindful relaxation to help participants focus on the task ahead. Session will entail listening and watching music videos and discussing activities, events and experiences related to the music; additional prompts such as photographs may be used to facilitate therapy.
224217272|NCT03175783|DEVICE|Fitbit Zip Activity Tracker|Subjects from both treatment and control group will be put on wristband starting from one week before the scheduled operation until 7 post-operative days. Patients will be instructed to wear the wristband continuously 24 hours per day except during water based activity. The treatment group will receive normal wristband with indicator showing steps count, distance, and calories. Meanwhile, the control group will receive Fitbit Zip with a display covered with adhesive tape and will not receive automatic feedback on the mobility from the device.
224217273|NCT04075383|PROCEDURE|immediate dental implant|Replacement of a lost tooth with a titanium screw retained in the alveolar bone in the same session of tooth extraction.
224217274|NCT04075383|PROCEDURE|immediate-delayed dental implant|Replacement of a lost tooth with a titanium screw retained in the alveolar bone 8 weeks after tooth extraction.
223628535|NCT01848015|OTHER|detection of CTCs|
223628536|NCT04960527|DIETARY_SUPPLEMENT|Tart cherry juice|250 mL tart cherry juice (30 mL tart cherry concentrate \[CherryActive, UK\] diluted with 220 mL water) is consumed on a single occasion by each participant. This will be consumed immediately following the baseline measurements one laboratory visit.
223628537|NCT04960527|OTHER|Water|250 mL water is consumed on a single occasion by each participant. This will be consumed immediately following the baseline measurements one laboratory visit.
223628538|NCT06472674|OTHER|No intervention|No intervention
224317457|NCT06570369|DRUG|SP-624|Oral dose, once daily for 2 weeks
224317458|NCT06570369|DRUG|Placebo|Oral dose, once daily for 2 weeks
224217275|NCT02684383|BIOLOGICAL|rDEN3∆30|10\^3 plaque-forming units (PFUs); administered by subcutaneous injection in the deltoid region of the upper arm
223628539|NCT02066363|DIETARY_SUPPLEMENT|Dietician advise|Dietician advise 5 times, during 24weeks. Prescription of a diet plan if wanted from the patient.
223628540|NCT02066363|DIETARY_SUPPLEMENT|Parenteral nutrition|Supportive parenteral nutrition.
223628541|NCT02249338|DRUG|BIIL 284 BS|
223628542|NCT02249338|DRUG|Placebo|
223628543|NCT06039839|PROCEDURE|Closure of the donor area after CTG harvesting without the use of collagen matrix|"1. Incision the mucosa at the alveolar ridge, mucosal-periosteal flap elevation, placement of the dental implant~2. Harvesting of free connective tissue graft from the maxilla tuberosity area and it's fixation to the vestibular mucosal-periosteal flap, tight suturing of the wound in the recipient area~3. Suturing of the wound in the donor site."
223628544|NCT06039839|PROCEDURE|Closure of the donor area after CTG harvesting with collagen matrix|"1. Incision the mucosa at the alveolar ridge, mucosal-periosteal flap elevation, placement of the dental implant~2. Harvesting of free connective tissue graft from the maxilla tuberosity area and it's fixation to the vestibular mucosal-periosteal flap, tight suturing of the wound in the recipient area~3. Adaptation of sterile collagen matrix to the donor site~4. Suturing of the wound in the donor site"
223628545|NCT06131255|DRUG|Citalopram|Patients will be administered citalopram, regardless of inclusion or non-inclusion in this study, on medical indication, as per normal clinical practice for disease management and according to the Summary of Product Characteristics (SPC). Patients will have two MRI scans done (at baseline and at 12 weeks after the start of therapy) to assess: brain volumetry, tissue amount of gray matter - GM - and white matter - WM
223628546|NCT01026844|DRUG|erlotinib|Taken orally once a day
223628547|NCT01026844|DRUG|hydroxychloroquine|Taken orally once a day
223628548|NCT01260649|DRUG|ketamine|eligible patients will be randomly assigned to a double-blind administration of ketamine (0.5 mg/kg) or IV Saline, followed by the routine anesthetic agent and muscle relaxant. ECT will be administered as per standard of care
223628549|NCT01260649|OTHER|IV Saline|eligible patients will be randomly assigned to a double-blind administration of ketamine (0.5 mg/kg) or IV Saline, followed by the routine anesthetic agent and muscle relaxant. ECT will be administered as per standard of care
223628550|NCT01260649|PROCEDURE|ECT|ECT will be administered as per standard of care
224217276|NCT02684383|BIOLOGICAL|Placebo|Administered by subcutaneous injection in the deltoid region of the upper arm
224217277|NCT02910453|PROCEDURE|Pulmonary lobectomy|
224217278|NCT01807962|DRUG|rapidocain and bethametsaone|"lidocaine (Rapidocain(R)): 4ml of 1% Lidocaine~bethametasone (Diprophos): 1ml ampoule (containing 5mg/ml dipropionate de betamethasone and 2mg/ml phosphate disodique de betamethasone)"
223628551|NCT01260649|DRUG|Muscle Relaxant|All participant will receive routine course of muscle relaxant with ECT as per standard of care
223628552|NCT01260649|DRUG|Anesthetic Agents|All participant will receive routine course of anesthetic agents with ECT as per standard of care
223628553|NCT02245477|DEVICE|obstetric Ultrasound|Transabdominal ultrasound was performed to confirm foetal number, viability, gestational age, exclusion of congenital anomalies, and assessment of amniotic fluid index and localization of the placenta.
223628554|NCT02245477|OTHER|serum Vascular Endothelial Growth Factor|Maternal blood samples (10 cc) were taken from an antecubital vein. Plastic clean sterile tubes were used for collection of blood. Two cc of the blood sample were put in other clean sterile tubes containing ethylene diamine tetra-acetic acid (EDTA) to be used in measuring maternal hemoglobin concentrations and evaluating the complete blood count. The rest of maternal blood samples were centrifuged within 3 hours and sera collected equally in 2 suitable containers and stored at -80 degrees until assayed (first container for routine laboratory investigations and the second for VEGF assay).VEGF sample was allowed to clot for 30 minutes before centrifugation for 15 minutes. Serum is removed and assay immediately or sample was stored at -80 degrees
223628555|NCT02138890|DEVICE|APS|Intra-articular Injection
223628556|NCT02138890|DEVICE|Saline|Intra-articular injection
223628557|NCT04932395|DRUG|Anshen Buxin Liuwei Pill|15 capsules/time, 2 times/day, orally.
223628558|NCT04932395|DRUG|Placebo|Placebo simulated as the Anshen Buxin Liuwei Pills with same appearance，smell and taste,15 capsules/time, 2 times/day, orally.
223628559|NCT04564417|BIOLOGICAL|W0180|Participants will receive W0180 in a 21-day cycle.
223628560|NCT04564417|DRUG|Pembrolizumab|Participants will receive Pembrolizumab 200 mg flat dose as IV infusion every three weeks (Q3W) in a 21-day cycle.
223763996|NCT05939206|PROCEDURE|rTARUP|robotic assisted transabdominal retromuscular umbilical prosthetic repair
223763997|NCT04568057|DEVICE|NIR Transcranial phototherapy device|1068 nm NIR helmet
223763998|NCT04568057|DEVICE|Placebo Transcranial Device|The placebo device looks like the active device.
223763999|NCT02350309|DRUG|Lemborexant 5 mg|Lemborexant 5 mg tablet.
223764000|NCT02350309|DRUG|Lemborexant 10 mg|Lemborexant 10 mg tablet.
224217279|NCT01807962|DRUG|sterile saline|Placebo = 5ml of sterile saline solution
224217280|NCT06181682|DRUG|Dexmedetomidine|Intranasal Dexmedetomidine
224217281|NCT06181682|DRUG|Midazolam|Intranasal midazolam
224217282|NCT03501199|OTHER|platelet-rich fibrin placement|filling the buccal gap with platelet-rich fibrin after immediate dental implant placement
224217283|NCT03501199|OTHER|xenogenic graft placement|filling the buccal gap with xenogenic graft after immediate dental implant placement
224217284|NCT03501199|OTHER|no extra material|filling the buccal gap with no material after immediate dental implant placement
224217285|NCT03501199|PROCEDURE|tooth extraction|extraction of tooth which is unrestorable
224217286|NCT03501199|PROCEDURE|immediate implant placement|putting dental implant into a socket which has been prepared with compatible drills
224217287|NCT03501199|OTHER|collagen membran placement|placing collagen membran on extraction socket after dental implant placement to cover all
224217288|NCT03501199|PROCEDURE|raising flap|raising the buccal flap with two vertical incision to cover extraction socket for primary closure
224217289|NCT04804982|OTHER|Questionnaire|The participants will have to fill in a questionnaire about their knowledge and their attitude regarding auditory risk.
223628561|NCT01605006|DEVICE|NeuRx Diaphragm Pacing System (DPS)|The NeuRx DPS is a percutaneous, intramuscular, diaphragm stimulation system which is implanted using standard laparoscopic surgical techniques in an outpatient procedure. The implanted intramuscular diaphragm electrodes are connected to a four channel external stimulator at a percutaneous exit site. DPS is designed to help ALS patients breathe by providing conditioning stimulation of the diaphragm muscles. Recommended frequency of diaphragm conditioning is at least 3 times per day with each session lasting at least 30 minutes. Patients may find it helpful to use the DPS for longer periods to help with breathing. DPS may be used at the same time as non-invasive ventilation. Patents may also sleep with the DPS to assist with breathing difficulties at night.
223628562|NCT06165809|DRUG|TQB3015 tablets|TQB3015 is a protein inhibitor
223628563|NCT05112575|RADIATION|Postoperative imaging with magnetic resonance imaging or computed tomography|Postoperative imaging control with magnetic resonance or computed tomography after craniotomy for vascular or neurooncological operations.
223628564|NCT02211560|OTHER|Phosphatidylserine|
223628565|NCT02211560|OTHER|Placebo|
223628566|NCT05208502|DEVICE|DSA monitor|Next Generation SedLine features an enhanced signal processing engine, which provides processed EEG parameters. This four channel EEG monitor for the monitoring of perioperative anesthesia depth prevent overdose of medication and may help for individualized anesthetic plan
224217290|NCT03031431|DEVICE|Non-Electric Infant Warmer|Electric warmers are the standard of care in developed countries, but are extremely costly, complicated with risk of causing both hypo and hyperthermia with misuse, and often not feasible in settings without stable electricity. Through a multi-institutional collaboration, the investigators have developed an electricity-free infant warmer.
224217291|NCT01205529|DRUG|Procainamide|One time intravenous infusion of Procainamide administered over 30 minutes. Dosage is calculated as 10mg/kg based on subject's ideal body weight.
224217292|NCT03398460|DIAGNOSTIC_TEST|Survey|Burnout rates before and after the introduction of a bereavement card Burnout rates before and after an ICU rotation for physicians
224217293|NCT03346031|PROCEDURE|music therapy|patients will listen to music with an MP3 headset
224217294|NCT03779516|OTHER|Saline|Effect of saline on postoperative sore throat
224217295|NCT03779516|OTHER|Lidocaine|Effect of nebulized lidocaine on postoperative sore throat
224217296|NCT00971685|DRUG|Lenalidomide and dexamethasone|RD regimen: Lenalidomide 25 mg/die for 21 days every month for 6 cycles, with once-weekly dexamethasone (40 mg).
224217297|NCT01039571|PROCEDURE|double row repair|double row repair for torn rotator cuff were performed to compare with the conventional single row repair
224217298|NCT04975282|DEVICE|Bottle feeding|Bottle was used as an alternative oral feeding method for preterm infants.
224217299|NCT04975282|DEVICE|Cup feeding|Cup was used as an alternative oral feeding method for preterm infants.
224217300|NCT03598452|DRUG|Ganciclovir|Intravitreal Injection of Ganciclovir (IVG) was conducted in a week interval. The initial dose was 6mg/0.1ml at the first injection and it was reduced to 4.5mg/0.1ml at the second time; 3mg/0.1ml of IVG was maintained until the CMV could not be detected in aqueous humor.
224217301|NCT00938600|DIETARY_SUPPLEMENT|Vitamin D3|Vitamin D3 oral liquid 70,000 IU once
223628567|NCT01598766|DEVICE|16 Channel SPEEDER Flex Coil|This is a 16 element MRI coil, flexible, lightweight. Multiple uses.
223628568|NCT01283555|DRUG|Tenofovir|Delivered using prefilled and user-filled applicator
224217302|NCT00938600|DIETARY_SUPPLEMENT|Vitamin D3|Vitamin D3 oral liquid 70,000 IU as loading dose, then 35,000 IU weekly thereafter for 10 weeks (non-pregnant) or until delivery (pregnant)
224217303|NCT00938600|DIETARY_SUPPLEMENT|Vitamin D3|Vitamin D3 14,000 IU per week by mouth, starting at 27-30 weeks gestation and continued until delivery.
224217304|NCT04110275|DRUG|Recombinant human tissue-type plasminogen activator derivative|Recombinant human tissue-type plasminogen activator derivative(rPA,chemical name: Reteplase,brand name:Ruitongli) 18mg/10ml/stick, provided by AngDe Biotech Pharmaceutical Co.,LIMITED(LTD)
224217305|NCT04110275|DRUG|Recombinant human tissue-type plasminogen activator|Recombinant human tissue-type plasminogen activator(rt-PA,chemical name:Alteplase,brand name: Actilyse)50mg/stick,provided by Boehringer Ingelheim Pharma Gesellschaft mit beschrankter Haftung(GmbH)\&Co,
223628569|NCT01446159|DRUG|MEDI-573|Intravenous infusion of MEDI-573 (10 or 30 or 45 mg/kg) will be administered on Day 1 of each 21-day cycle until unacceptable toxicity, documentation of disease progression, or withdrawal for other reasons.
223628570|NCT01446159|DRUG|Aromatase Inhibitor|Aromatase inhibitor of the investigator's choice (letrozole, anastrozole, or exemestane) will be provided orally once daily until unacceptable toxicity, documentation of disease progression, or withdrawal for other reasons.
223628571|NCT03546023|OTHER|Patient Interview|BPI scores will be asked by the Doctor or the Research Nurse
223628572|NCT03104881|DEVICE|3D exoskeleton type robot|3 dimension exoskeleton type upper extremity robot
223628573|NCT03104881|DEVICE|2D end-effector type robot|2 dimension end-effector type upper extremity robot
223628574|NCT03766789|DEVICE|Cell phone application|cell phone to organize medications
223628575|NCT04444817|DRUG|Tacrolimus|Similar to the clinical routine, as soon as a patient is able to swallow and has a sufficient gastrointestinal activity, Tacrolimus-based immunosuppression using Prograf®, Advagraf® or Envarsus® will be started. Furthermore, calcineurin inhibitors-based immunosuppression will be used (initial dose based on the patients' body weight) with the goal of tough levels of 3-7 ng/mL in the first seven days after liver transplantion, depending on immune status and indication for transplantation. Further tough levels will be determined based on factors such as patients' history and indication for liver transplant.
223628576|NCT02267239|DRUG|essential oils, immersion|A single, 30-second immersion in 1 mL of essential oils in a hydroalcoholic solution (Listerine Mentol, Listerine®, Johnson \& Johnson, Madrid, Spain) (I-EO).
223764001|NCT02350309|DRUG|Lemborexant-matched placebo.|Lemborexant-matched placebo tablet.
223628577|NCT02267239|DRUG|Chlorhexidine, immersion|A single, 30-second immersion in 1 mL of 0.2% chlorhexidine (Oraldine Perio®, Johnson and Johnson, Madrid, Spain) (I-0.2% CHX).
223628578|NCT02267239|DRUG|essential oils, mouthwash|A single, 30-second mouthwash with 20 mL of essential oils in a hydroalcoholic solution (Listerine Mentol, Listerine®, Johnson \& Johnson, Madrid, Spain) (M-EO).
223628579|NCT02267239|DRUG|chlorhexidine, mouthwash|A single, 30-second mouthwash with 10 mL of 0.2% chlorhexidine (Oraldine Perio®, Johnson and Johnson, Madrid, Spain) (M-0.2% CHX).
223764002|NCT02350309|DRUG|Flurazepam 30 mg|Flurazepam 30 mg capsule.
224217306|NCT06468735|DIAGNOSTIC_TEST|sarcopenia assessment|"Quadriceps muscle thickness measurement at the midpoint between the anterior superior iliac spine and the upper pole of the patella.~Sarcopenia assessment The quadriceps muscle thickness (mm) was divided by the BMI to get the sonographic thigh adjustment ratio (STAR) values. Grip strength was assessed using an electronic hand dynamometer on the dominant hand side. Three measurements were obtained from the dominant hand and the maximum value was taken for the analyses. Participants in the chair stand test (CST) were instructed to rapidly rise and fall from a chair five times while keeping their arms folded across their chests. The test was repeated three times, and the mean time was recorded. Together with low STAR values (\<1.0 for females and \<1.4 for males), having low grip strength (\<19 kg for females or \<32 kg for males) and/or prolonged CST duration (≥12 seconds) were used to diagnose sarcopenia"
224217307|NCT06468735|DIAGNOSTIC_TEST|visceral fat thickness measurement|Intraabdominal visceral adipose tissue thickness was calculated by placing the probe 2-cm proximal to the midline of the umbilicus with minimal pressure and measuring the distance from the inner surface of the linea alba to the anterior wall of the abdominal aorta. Subcutaneous maximum fat thickness was measured from the distance between the subcutaneous tissue and the linea alba from the same point. Preperitoneal fat thickness was measured from the distal neighborhood of the xiphoid process, 1.5 cm to the right side of the widest distance between the parietal peritoneum and the linea alba. Minimum subcutaneous fat thickness was calculated as the distance measured from the distal neighborhood of the xiphoid process, measured as the shortest distance between the outer part of the linea alba and the subcutaneous fat tissue.
224217308|NCT04669899|DRUG|JTX-8064|Specified dose on specified days
224217309|NCT04669899|DRUG|pimivalimab|Specified dose on specified days
224217310|NCT01094366|PROCEDURE|Paracervical Block|Subject receives 20 mL paracervical block with 18 mL of 1% Lidocaine solution buffered with 2 mL 8.4% sodium bicarbonate for pain control.
224217311|NCT01094366|PROCEDURE|Sham Paracervical Block|In the non-intervention group, the surgeon performs a sham PCB during which 2 mL buffered lidocaine solution are injected at the tenaculum site, after which a capped needle gently simulates the standard PCB procedure.
224217312|NCT00095095|DEVICE|Lumbar Interbody Fusion|
224217313|NCT02362854|PROCEDURE|Conventional peri-implantitis treatment|Elimination of the bacterial plaque. Establishing optimal healing conditions. Detoxification of the affected environment.
224217314|NCT02362854|DEVICE|DL application in peri-implantitis|Diode laser application in the diseased implants.
224217315|NCT02712385|OTHER|'The Healthy Brain Rehabilitation Manual'|The Healthy Brain Rehabilitation Manual is a home-based rehabilitation manual developed for the post-TIA and minor stroke population caused by ischaemic events. The manual addresses all the secondary prevention factors required post-ischaemic TIA/minor stroke, e.g. smoking cessation, physical activity promotion.
224217316|NCT02712385|DEVICE|Pedometer|Pedometer used to measure step counts as an objective measurement of level of physical activity.
224217317|NCT02712385|PROCEDURE|Usual care|Usual care provided by healthcare system for patients who suffer a TIA or minor stroke will be recorded and form 'active comparator' control.
224217318|NCT02712385|BEHAVIORAL|Telephone follow-up|Telephone follow-up by either a General Practitioner (GP) or Stroke nurse.
224217319|NCT02861183|DEVICE|OVT (Sodium Hyaluronate)|A Peri-osteotendinous injection of OVT will be administered into the soft tissue 1 cm from the lateral epicondyle at the point of greatest pain in two planes using a fanning technique. Two injections will be performed with a 22-25 gauge needle and spaced one week apart.
224217320|NCT02861183|DEVICE|Saline|A Peri-osteotendinous injection of sterile saline will be administered into the soft tissue 1 cm from the lateral epicondyle at the point of greatest pain in two planes using a fanning technique. Two injections will be performed with a 22-25 gauge needle and spaced one week apart.
224217321|NCT00411697|BIOLOGICAL|Engerix™-B Kinder|Intramuscular injection, 1 dose
224217322|NCT04857385|DEVICE|Radial artery hemostasis|Each of the devices will be assessed for radial artery hemostasis.
224217323|NCT03449056|DRUG|salbutamol|T2 - T1+1h30: High-nasal flow and salbutamol nebulization
224217324|NCT06254209|DIETARY_SUPPLEMENT|Botanicals extracts|Powder included in capsules for daily administration
223628580|NCT02267239|PROCEDURE|professional oral cleaning|scaling and polishing teeth of the volunteers
223628581|NCT02267239|PROCEDURE|Plaster cast|Taking a plaster cast of the volunteers' mouth
223628582|NCT02267239|DEVICE|IDODS|Specific intraoral device which carries six glass disks
223628583|NCT02327546|DRUG|AKB-6548|
223628584|NCT02327546|DRUG|Ferrous Sulfate|
223764003|NCT03033407|OTHER|Tailored mobile coaching messages|Intervention was adding tailored mobile coaching to current usual diabetes care. The participants received regular mobile messages via Switch app according to entered data, such as self-monitoring of blood glucose, blood pressure, exercise, dietary record, medication record, and body weight. Contents of messages were alert for the unused, weather, behavioral recommendation, education about diabetes, and individualized advices.
223764004|NCT04698356|BEHAVIORAL|Auditory-cognitive training paradigm|The investigators developed an American English version of the Nottingham (UK) PLUS training paradigm in which listeners are asked to focus and listen to one speaker while ignoring another speaker. The paradigm is designed to optimally enhance the possibility of benefit: an adaptive procedure is employed in order to train each individual at their own level and to make the task challenging. A short-term memory component was also added to the original training paradigm, to enhance the cognitive skills of our participants. To provide maximal speech-in-noise benefit for older, normal-hearing adults, a validation of our new training materials is required. The investigators will evaluate this in young, normal-hearing adults (18-30 years) by studying our outcome measure (speech reception threshold) for the different sentence-scenarios and test-retest sessions.
223628585|NCT00004380|DRUG|relaxin|
224217325|NCT06254209|DIETARY_SUPPLEMENT|Placebo|Maltodextrin included in capsules for daily administration
224217326|NCT01510665|DIETARY_SUPPLEMENT|Magnesium citrate|Magnesium citrate tablets 950 mg, two pills once daily (Total daily dose of 300 mg elemental magnesium)
224217327|NCT01510665|DIETARY_SUPPLEMENT|Placebo|Identical appearing placebo with inactive ingredients, two pills once daily.
224217328|NCT01510665|BEHAVIORAL|Dietary modification|Nutritionist counseling session and advice on following a magnesium rich diet
224217329|NCT00430157|DRUG|GSK256066|
224217330|NCT02415010|DEVICE|Enterprise 2 Vascular Reconstruction Device|Stenting Assisted coiling procedure
224217331|NCT02415361|OTHER|Cleft lip and palate|Comparison between Arm A who will receive standard care and Arm B who will receive systematic follow up performed by a special trained nurse will be performed.
224217332|NCT00630669|PROCEDURE|Rubber band ligation|placing rubber bands around the internal hemorrhoids
224217333|NCT00630669|PROCEDURE|Bipolar coagulation|using electricity to cauterize
224217334|NCT03307512|DRUG|inhaled human insulin|Dance 501 (Human Insulin Inhalation Solution and Inhaler) will be administered by inhalation
224217335|NCT03307512|DRUG|Insulin Lispro (Humalog U-100)|Insulin Lispro (Humalog U-100) will be administered by subcutaneous injection
224217336|NCT04837625|OTHER|no interventions|no interventions
224217337|NCT01428024|DEVICE|Restylane Lip Volume|Treatment of up to 1,5 ml product for upper and lower lip, respectively at week 0 and optional at week 12.
224217338|NCT01428024|DEVICE|Restylane Lip Refresh|Treatment of up to 0,5 ml product for upper and lower lip, respectively at week 0 and optional at week 12.
224217339|NCT02139345|DEVICE|TC-A PS Total Knee Replacement System|Subject will be implanted with the TC-A PS Total Knee Replacement System
224217340|NCT02139345|DEVICE|TC-PLUS Solution PS Total Knee Replacement System|Subject will be implanted with the TC-PLUS Solution PS Total Knee Replacement System
224217341|NCT04678453|BIOLOGICAL|SNK01|Patient-specific ex vivo expanded autologous natural killer cells
224217342|NCT02416583|DRUG|Oxytocin|
224217343|NCT02416583|DRUG|Dinoprostone|
224217344|NCT02416583|PROCEDURE|Membrane sweeping|
224217345|NCT02042690|PROCEDURE|Haplo-identical HSCT|Haplo-identical Protocol: myeloablative human leukocyte antigen (HLA) haploidentical stem cell transplantation (haplo-SCT) using pretransplant ATG and granulocyte colony-stimulating factor (G-CSF)-stimulated grafts (ATG+G-CSF) GVHD prevention regimen: CSA/MMF/MTX, CSA 1.25mg/kg/d, i.v administrated in two doses from day -109 until bowel function returned to normal, at which time patients receive oral CSA until 12months after HRD-HSC and then gradually tapered. Every 12h, 0.5g MMF(0.25g for children) was administrated orally from day -10 to +30 and subsequently 0.25g from days +30 to +60. MTX was administrated at a dose of 15mg/m2 on day +1 and 10mg/m2 on days +3,+6, and +11.
224217346|NCT02042690|DRUG|Chemotherapy|Patients receive 6 cycles of consolidation chemotherapy after randomization, including Hyper-CVAD-B regimen-Hyper-CVAD-A regimen/Hyper-CVAD-B regimen/Hyper-CVAD-A regimen/Hyper-CVAD-B regimen/Hyper-CVAD-A regimen.Maintenance treatment includes MTX 20mg/m2/w，po，6-mercaptopurine 60 mg/m2/d，po，d1-d28，VP（VDS 4mg,d1, Prednisone 1mg/kg d1-7) every one month for 2 years.
224217347|NCT04402515|DRUG|TIO/OLO|Tiotropium/Olodaterol
224217348|NCT04402515|DRUG|ICS|inhaled cortocosteroids
224217349|NCT00106028|DRUG|risedronate sodium (Actonel)|risedronate tablet once a day for one year followed by risedronate once a day for two years
224217350|NCT00106028|DRUG|Placebo|placebo tablet once a day for one year followed by risedronate once a day for two years
223514255|NCT02570425|DEVICE|Training on SYMBICORT Turbohaler followed by BF Spiromax|Training with a placebo comparator: SYMBICORT Turbohaler® device using a 6-level system to examine the number of levels required to acquire mastery of device at baseline and maintenance and mastery at 4 and 8 weeks after initial training.
223514256|NCT00309946|DRUG|cediranib maleate|Given orally
223514257|NCT03622931|DRUG|Standard chemotherapy|Chemotherapy
223514258|NCT03622931|DRUG|Romiplostim|
223514259|NCT03622931|DRUG|Placebos|
223514260|NCT03840889|OTHER|Data collection|"he different modes of active data collection:~* Data collection by telephone~* Data collection by mail~* Collection from discharge database summaries (PMSI)"
223514261|NCT05686720|DRUG|SZ011 CAR-NK|In the escalation study, the minimum initial dose was 5.0×10\^6 cells, then increased to 5.0×10\^7 and 2.0×10\^8 cells. The infusion is given every 2 weeks.
223514262|NCT01066910|BEHAVIORAL|Behavioral treatment for childhood obesity|Behavioral treatment for childhood obesity includes nutrition and physical activity recommendations, and behavior therapy skills for parent and child.
223514263|NCT01066910|BEHAVIORAL|Behavioral treatment for childhood obesity|Behavioral treatment for childhood obesity includes nutrition and physical activity recommendations, and behavior therapy skills for parent and child.
223514264|NCT03854981|BEHAVIORAL|Exercise|Subjects will be asked to exercise 5 days/week in addition to receiving standard care before bariatric surgery.
223514265|NCT03854981|PROCEDURE|Standard Care|Standard preoperative care of bariatric surgery
223514266|NCT00609349|DEVICE|ETED, CPET, RHC|"exercise tricuspid echo doppler (ETED): allows the estimation of systolic pulmonary arterial pressure at exercise cardiopulmonary exercise test (CPET) allows to measures exercise capacity (peakVO2)~right heart catheterisation (RHC): is the gold standard for the measurement of pulmonary arterial pressure values"
223514267|NCT03631693|PROCEDURE|Simplified papilla preservation flap|The simplified papilla preservation flap (SPPF) surgery is a conservative surgical procedure aimed at the preservation of the tissues between the teeth providing access for the debridement of the root surface in sites with residual pockets.
223514268|NCT03631693|PROCEDURE|Resective periodontal flap with osseous recontouring|The Resective periodontal flap with osseous recontouring (RPFO) is a surgical procedure that achieves predictable pocket depth reduction by soft and hard tissue resection to obtain a more convenient soft and hard tissue architecture for oral hygiene.
224217351|NCT04281056|PROCEDURE|Tooth removal and their replacement by means of a denture|Teeth have been removed and replaced by means of dentures for at least one year
224217352|NCT01548469|OTHER|Bio Mineral toothpaste|Frequency: 2 times everyday/Duration: 4 weeks/Dosage: 1ml at once
224217353|NCT01548469|OTHER|Perio Total Care toothpaste|Frequency: 2 times everyday/Duration: 4 weeks/Dosage: 1ml at once
224217354|NCT01280981|DRUG|Tranexamic acid|Tranexamic acid at an oral dose of 1.3 g administered 3 times per day for up to 5 days (maximum of 15 doses) during menstruation for 9 menstrual periods.
224217355|NCT04008342|OTHER|Multisensory intervention|The intervention group (IG) was submitted to 16 individual multisensory stimulation sessions that followed the protocol. In each session, at least two senses are stimulated in a safe, quiet and confidential environment. The sessions lasted 30 minutes and were conducted twice a week, on the same day and time whenever possible. Nonetheless, the session could be interrupted when the participant wished or if the therapist observed that the patient was uncomfortable. A nondirective approach and one-to-one intervention were adopted.
224217356|NCT06438783|DRUG|1200mg of TQB2928 injection+Anlotinib|TQB2928 is a novel humanized immunoglobulin G4 (IgG4) subtype monoclonal antibody targeting Cluster of Differentiation 47 (CD47).
224217357|NCT06438783|DRUG|1800mg of TQB2928 injection+Anlotinib|TQB2928 is a novel humanized igG4 subtype monoclonal antibody targeting CD47.
224217358|NCT00743691|OTHER|Community Based|In Arm 2 health extension workers will make a diagnosis of Neonatal infection and treat with antibiotics
224217359|NCT05064696|OTHER|Non-stick gauze dressing|Group 1 (Control group): surgical site will be dressed with a standard non-stick gauze dressing
224217360|NCT05064696|DEVICE|PICO dressing|Group 2 (Treatment group): surgical site will be dressed with PICO dressing
224217361|NCT05498831|OTHER|Pain assessment at 15 minutes, 30 minutes, 60 minutes, 120 minutes after initial assessment by the triage nurse|Pain will be assessed using a numerical scale
224217362|NCT04773171|OTHER|Computer-assisted Cognitive Remediation|Drill practice and bridging activities
224217363|NCT04773171|OTHER|Conventional training programmes|Existing conventional activities in the settings
224217364|NCT05147285|OTHER|stabilization exercises|Patients will be applied only online supervised stabilization exercises three times a week for 8 weeks.
224217365|NCT05147285|OTHER|combined exercises|Patients will be applied online supervised aerobic exercise training and stabilization exercises.Aerobic exercises will be performed for 8 weeks, for 30-45 minutes, at 65-75% of the maximum heart rate, 3 days a week, on the days when stabilization exercises are not performed.
224217366|NCT05147285|OTHER|Physical activity recommendations|The importance of physical activity will be explained to the patients and appropriate physical activity recommendations will be made.
224217367|NCT05599204|OTHER|schroth exercise|the patients will receive the Schroth three-dimensional exercise. patient first assumes a posture in the cervico-cranial and shoulder girdle and the thoracic region is held in the correct posture. The patient inspires air into the concave side and during the exhalation phase isometric and isotonic muscle tensing occur. While the patient is breathing, the therapist should observe the posture and movement of the thoracic cage and diaphragm. Basic posture correction in sitting and walking and Sensorimotor training by the ball will be applied
224217368|NCT05599204|OTHER|postural correction exercise|the patients will receive postural correction exercises, stretches, and exercises to the pectoralis major, elevator scapulae, upper trapezius, serratus anterior, rhomboids, and deep neck flexors. The stretches included sitting chair stretches, Brugger's, wall angels, and doorway stretches. The exercises included push up- plus, head-neck-retraction, and Kibler squeeze
224217369|NCT04974359|DRUG|Lu AG06466|Lu AG06466 - capsules
224217370|NCT04974359|DRUG|Placebo|Placebo - capsules
224217371|NCT02996617|DRUG|rhG-CSF regimen|Patients weren't preventive use of rhG-CSF.If their WBC≤1×10\^ 9/L,they were administered rhG-CSF:5ug/kg/day until their WBC≥4×10\^ 9/L.Chemotherapy regimen: CHOP: Epirubicin：70 mg/m2 , Cyclophosphamide：750 mg/m2, Vincristine: 1.4 mg/m2 , Prednison：100mg/d; CHOPE: Epirubicin：70 mg/m2, Cyclophosphamide：750 mg/m2,Vincristine: 1.4 mg/m2,Prednison：100mg/d,Etoposide: 100 mg/（m2•d）;EPOCH:etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin;Hyper-CVAD(A):hyperfractionated cyclophosphamide, vincristine,doxorubicin, dexamethasone, cytarabine and methotrexate;GemOx-R:Gemcitabine, Oxaliplatin;GDP:gemcitabine, dexamethasone, and cisplatin
224217372|NCT02996617|DRUG|Pegylated rhG-CSF regimen|Patients were administered pegylated rhG-CSF 6mg（weight≥45Kg）or 3mg（weight≤45Kg）once 24 hours after the end of chemotherapy drugs of every chemotherapy cycle.Chemotherapy regimen: CHOP: Epirubicin：70 mg/m2 , Cyclophosphamide：750 mg/m2, Vincristine: 1.4 mg/m2 , Prednison：100mg/d; CHOPE: Epirubicin：70 mg/m2, Cyclophosphamide：750 mg/m2,Vincristine: 1.4 mg/m2,Prednison：100mg/d,Etoposide: 100 mg/（m2•d）;EPOCH:etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin;Hyper-CVAD(A):hyperfractionated cyclophosphamide, vincristine,doxorubicin, dexamethasone, cytarabine and methotrexate;GemOx-R:Gemcitabine, Oxaliplatin;GDP:gemcitabine, dexamethasone, and cisplatin
224217373|NCT00486499|PROCEDURE|I-125 versus Pd-103 radioactive seed insertion|
223628586|NCT06222632|OTHER|Mind diet intervention|These participants will receive four nutrition information sessions, 60 minutes per session, on four consecutive weekdays at the participating community centre. A 7-day sample menu will be developed and explained to the participants as a reference. A nutritionist with the help of a research assistant will conduct each session. The nutritionist-to-participant ratio for each session will be 1:10, 1:11 or 1:12. The following topics will be covered: (1) overview of the MIND diet; (2) discussion with the participants about their ability, motivation and opportunity to adopt the MIND diet; and (3) instruction on how to adopt the MIND diet and how to fill out a logbook for adherence checks.
223628587|NCT06222632|OTHER|Mind plus FB intervention|The sessions will include four nutritional sessions about the MIND diet and four FB sessions. The participants will be instructed on the MIND diet as previously mentioned. In addition, the MIND-FB participants will undertake four 2 h FB sessions in a country park on four consecutive weekends during daytime hours. The FB sessions will take place during the day if it is sunny, cloudy or lightly raining. The distance covered on each forest visit will be 1-2 kilometres. If it is raining heavily, the session will be cancelled. The participants will gather at the entrance of the country park on the day of FB. The participants will gather at the entrance of the country park on the day of FB. An FB coach will brief the participants and begin the forest trip with a set of experiences on the forest environment. The participants will also be instructed to self-practice FB for 2h per session at weeks 8 \&amp; 12 of the intervention.
224217374|NCT05742854|PROCEDURE|C-sections operations|Immediately after the delivery of the baby, uterotonic agents will be applied before the placenta is removed and by a manual check of the fundus of the uterus and the anterior wall, followed by an examination of the uterine tone by the surgeon
224217375|NCT05742854|DRUG|Oxytocin|Oxytocin
224217376|NCT05742854|DRUG|Carbetocin|Carbetocin
224217377|NCT05600179|DRUG|Dexamethasone intravitreal implant|Dexamethasone intravitreal implant
224217378|NCT06043999|PROCEDURE|Radical total mesorectal excision|Standard TME surgery was performed 3-4 weeks after local resection. The operation is roughly divided into the following steps:After abdominal exploration, gradually ligation and from the inferior mesenteric vessels, pay attention to protect the left ureter, reproductive blood vessels and upper abdominal nerve; The descending colon was fully mobilized and the splenic flexure was mobilized if necessary. Follow the principle of TME, perform sharp resection of the total mesorectum, and pay attention to the protection of the prostate, vagina, pelvic nerve, etc.For can be removed through double stapling technique in low former (LAR) need not inline sphincter resection (excluding cases), to must be inline sphincter resection can be turned to the anus operation (ditto), consistent way can choose according to the intraoperative situation drag anastomosis or manual suture or stapling anastomosis. Prophylactic loop colostomy of transverse colon or ileostomy is recommended.
224217379|NCT06043999|OTHER|Salavge Adjuvant Chemoradiotherapy|Concurrent adjuvant chemotherapy:5-Fu or 5-Fu analogues based chemotherapy regimens were selected. CapeOx or capecitabine monotherapy or FOLFOX is recommended, and no more than 3 months.Adjuvant radiotherapy protocol:long-course radiotherapy protocol.a. Target definition: areas at high risk for recurrence of the primary tumor and regional lymphatic drainage.b. Radiotherapy technology: conventional radiotherapy, three-dimensional conformal radiotherapy, intensity modulated radiotherapy, image guided radiotherapy, etc.c. Radiation dose:DT of 45Gy,1.8Gy per fraction in 25 fractions, was recommended for the high-risk recurrence area of the primary tumor and the regional lymphatic drainage area.
224217380|NCT04312919|BEHAVIORAL|Family Based Activity Intervention|Providing youth and their families with access to the knowledge and resources to increase their physical activity will allow them to lead more healthy lifestyles will provide them with the foundation for a healthier life, and future ahead.
224217381|NCT03292783|DRUG|NOV1501 (ABL001)|VEGF/DLL4 targeting bispecific antibody
224217382|NCT04675060|DRUG|TQ-B3139 capsules|TQ-B3139 capsules administered 600mg orally, twice daily in 28-day cycle.
224217383|NCT04726514|DEVICE|SleepFlex|SleepFlex Program
224217384|NCT04655482|DRUG|Aflibercept Injection|"Intravitreal injection of aflibercept using treat-and-extend regimen~:Three monthly loading injections followed by proactive treatment using TAE regimen. Extension of injection interval by 2 weeks. The maximum injection interval was set as 16 weeks."
224217385|NCT03263520|DRUG|Nandrolone Decanoate|Drug administration
224217386|NCT03263520|DRUG|Dexamethasone|Drug administration
224217387|NCT02448472|OTHER|Observational study, none intervention|
224217388|NCT06371079|DEVICE|phakic intraocular lens implantation traditional|patients with refractive errors undergo surgical implantation of a lens inside the eye (implantable collamer lens or ICL) to correct these refractive errors. The procedure is done with help of use of both cohesive and dispersive OVD
223628588|NCT06222632|OTHER|Usual care|Participants will receive a health talk and be given pamphlets provided by the Department of Health and/or Hospital Authority about the protective factors and risk factors of CVDs.
223628589|NCT05830552|OTHER|Receving feedback|Receving regular feedback from a health provider
224217389|NCT06371079|DEVICE|phakic intraocular lens implantation reduced OVD|patients with refractive errors undergo surgical implantation of a lens inside the eye (implantable collamer lens or ICL) to correct these refractive errors. The procedure is done with help of use of only cohesive OVD without using dispersive OVD.
224217390|NCT01256398|BIOLOGICAL|Alemtuzumab|Given IV
223628590|NCT05830552|OTHER|No regular feedback|No regular feedback from a health provider
224217391|NCT01256398|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo peripheral blood allogeneic HCT
224217392|NCT01256398|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo peripheral blood autologous HCT
224217393|NCT01256398|DRUG|Cyclophosphamide|Given IV
224217394|NCT01256398|DRUG|Cytarabine|Given IV
224217395|NCT01256398|DRUG|Dasatinib|Given PO
224217396|NCT01256398|DRUG|Daunorubicin Hydrochloride|Given IV
224217397|NCT01256398|DRUG|Dexamethasone|Given PO or IV
224217398|NCT01256398|DRUG|Etoposide Phosphate|Given IV
224217399|NCT01256398|BIOLOGICAL|Filgrastim|Given SC
224217400|NCT01256398|DRUG|Fludarabine Phosphate|Given IV
223628591|NCT00537394|DRUG|Enfuvirtide|90mg subcutaneously twice daily
224217401|NCT01256398|PROCEDURE|In Vitro-Treated Peripheral Blood Stem Cell Transplantation|Undergo peripheral blood autologous or allogeneic HCT
224217402|NCT01256398|OTHER|Laboratory Biomarker Analysis|Correlative studies
224217403|NCT01256398|DRUG|Leucovorin Calcium|Given IV or PO
223764005|NCT03414346|OTHER|Exclusively ice pack|Each subject will receive an experimental intervention of exclusively 500 grams of crushed ice. The intervention will last 20 minutes, and the order of application, expressed in % of water X ice, will be according to the randomization (realized in the first day). The pack will be wrapped in a band for improvement of the contac area. The subject will be asked to mark his pain level on the visual analogue scale (no pain score of 0 and pain as bad as it could be score of 10) every minute until the total time of the intervention.
224217404|NCT01256398|DRUG|Melphalan|Given IV
224217405|NCT01256398|DRUG|Mercaptopurine|Given PO
224217406|NCT01256398|DRUG|Methotrexate|Given IT, IV, or PO
224217407|NCT01256398|BIOLOGICAL|Pegfilgrastim|Given SC
224217408|NCT01256398|OTHER|Pharmacological Study|Correlative studies
224217409|NCT01256398|DRUG|Tacrolimus|Given IV or PO
224217410|NCT01256398|DRUG|Vincristine Sulfate|Given IV
224217411|NCT01552005|DRUG|Saxagliptin|No Intervention
224217412|NCT05854173|DIAGNOSTIC_TEST|Pendulum Exercises|Compare The Effect of Pendulum Exercises Among the Patients of Adhesive Capsulitis
224217413|NCT05854173|DIAGNOSTIC_TEST|Kaltenborn Mobilization|Compare The Effect of Kaltenborn Mobilization Among the Patients of Adhesive Capsulitis
224217414|NCT00152386|DRUG|Certolizumab pegol (CDP870)|
224217415|NCT00414986|BEHAVIORAL|Standard CQI intervention|In-practice change facilitator assists the practice in implementing a chronic disease registry
224217416|NCT00414986|BEHAVIORAL|Chronic Care Improvement (CCI) Intervention|An in-practice change facilitator will assist the Improvement Team in enhancing the relationship infrastructure of the practice and in implementing diabetes and depression office systems.
224217417|NCT00414986|BEHAVIORAL|Self-directed practice comparison|Practices will have access to all tools used in Arm 1 via a project website
224217418|NCT03276962|BIOLOGICAL|RTS,S/AS01E (Full dose)|Participants will receive intramuscular injection of RTS,S/AS01E (full dose: 0.5 ml).
224217419|NCT03276962|BIOLOGICAL|RTS,S/AS01E (1/5th dose)|Participants will receive intramuscular injection of RTS,S/AS01E (1/5th dose: 0.1 ml).
224217420|NCT03276962|BIOLOGICAL|Rabies vaccine|Participants will receive intramuscular injection of rabies vaccine (0.1 ml).
224217421|NCT05155072|DRUG|DW1903|DW1903
224317459|NCT05207891|DEVICE|Intervention mattress|The intervention mattress, Tidewave, will be compared to the regular care mattress, CuroCell 4AD. Primary outcome will be change in pressure injury occurence, assessed according to the NPIAP 2019 Clinical Guidance, and marked up on pressure injury body-map figures. Secondary outcomes will be experienced quality of life, assessed with the Spinal Cord Injury Quality of Life Basic Data Set. Further mattress comfort, assessed with the Mattress Comfort Scale, sleep-wellness, assessed with the Insomnia Severity Index, and pain, assessed with the Brief Pain Inventory. Satisfaction in the participants and in the nursing staff will be assessed with custom made Likert scales. Resource use and experienced stain in the nursing staff will be assessed with custom made forms asking for number of persons needed in position change, number of position changes needed during bed-rest, and experienced strain related to the position changes.
224317460|NCT06478706|DRUG|ETD001|Twice daily doses
224317461|NCT06478706|DRUG|Placebo|Twice daily doses
223514269|NCT02969226|PROCEDURE|Once daily screening|RTs will screen invasively ventilated patients between approximately 06:00 - 08:00 hours daily. To pass the 'readiness to wean screen' and undergo an SBT, specific criteria must be met.
224217422|NCT05155072|DRUG|DW1903-R1|DW1903-R1
224217423|NCT05155072|DRUG|DW1903-R2|DW1903-R2
224217424|NCT00000773|DRUG|Atovaquone|
224217425|NCT05614388|DIAGNOSTIC_TEST|COVID-19 Self testing and related messaging|Provisioning of voluntary, free self-testing for COVID-19 (approved and validated in the country) and related Information, Education and Communication (IEC) messages
224217426|NCT05203588|DRUG|Denosumab 60 mg/ml Injectable Solution [Prolia]|Denosumab, 60mg(1ml), subcutaneously, totally two times, with one time at 1-week postoperatively and another time at 26-week postoperatively.
224217427|NCT05203588|DRUG|calcium and vitamin D|calcium (≥1·0 g) and vitamin D (≥400 IU).
223514270|NCT02969226|PROCEDURE|Twice daily screening|In the 'at least twice daily' screening arm patients will be screened at a minimum between approximately 6:00-8:00 hours and 13:00-15:00 hours daily. To pass the 'readiness to wean screen' and undergo an SBT, specific criteria must be met.
223514271|NCT02969226|PROCEDURE|PS SBTs|Patients are assigned a SBT technique. All SBTs for these patients must be conducted on PS \>0 and =\< 8 cm H2O with PEEP\>0 and =\< 5 cm H2O
223514272|NCT02969226|PROCEDURE|T-piece SBTs|Patients are assigned a SBT technique. All SBTs for these patients must be conducted with T-piece (off the ventilator)
223514273|NCT04740346|DIAGNOSTIC_TEST|Computed tomography, Chest X-ray, and blood test|CT will be performed every 3 months after gastrectomy in the 3-months follow-up group. CT will be performed every 6 months after gastrectomy in the 6 months follow-up group.
223514274|NCT04398225|DRUG|Centanafadine|Extended release capsule
223514275|NCT04156100|DRUG|AGEN1223|AGEN1223 is a bispecific antibody.
223514276|NCT04156100|DRUG|AGEN1223 and balstilimab|AGEN1223 is a bispecific antibody and balstilimab an anti-PD-1 Monoclonal Antibody.
223514277|NCT05534490|OTHER|therapatic Foot massaje (sweden technic)|Everything is explained to the individuals on the day of surgery. After the surgery, when the individuals regains consciousness in the service, the Swedish massage technique is applied bilaterally for 10 minutes. In addition to the demographic data of the patient before the application and in the preoperative period; pain, mental level, delirium status, mobility, kinesiophobia, balance, and functional independence level measurement evaluations are made. Massage is continued for a total of 20 minutes, 10 minutes for each foot, once a day until the patient is discharged. The measurements are repeated on the day the individual will be discharged.
223514278|NCT04045145|DRUG|Crinecerfont|Crinecerfont administered orally for 14 consecutive days.
223514279|NCT01006486|OTHER|Anticoagulation clinic|Patients randomized to this arm will be cared at an anticoagulation clinic, with educational measures and standardized procedures related to the use of coumarins.
223514280|NCT01006486|OTHER|Standard anticoagulation care|Patients randomized to this arm will be cared by their physician, with standard care. No standardized protocol of the use of coumarins will be established.
223514281|NCT01358305|OTHER|Protein Blend|Single intake of approximately 20 grams of total protein
223628592|NCT00537394|DRUG|Raltegravir|400 mg twice daily
223628593|NCT00537394|DRUG|Darunavir|Two 300-mg tablets twice daily, given with ritonavir 100mg twice daily (ritonavir not provided by the study)
223628594|NCT00537394|DRUG|Tipranavir|Two 250-mg capsules twice daily, given with ritonavir 100mg twice daily (ritonavir not provided by the study)
224217428|NCT02488707|PROCEDURE|laparoscopic intersphincteric resection (LISR group)|the patient undergo laparoscopic mesorectal excision with high inferior mesenteric vein ligation combined with transanal distal resection of the rectum
224217429|NCT02488707|PROCEDURE|Transanal minimally invasive Total mesorectal excision (TAMIS group)|Transanal minimally invasive total mesorectal excision assisted with minilaparoscopy to ligate the inferior mesenteric vessels and splenic flexure mobilization.
223628595|NCT00537394|DRUG|Etravirine|Two 100-mg tablets twice daily
223628596|NCT00537394|DRUG|Maraviroc|Dosage dependent on regimen in which maraviroc is included
223628597|NCT06342934|DIAGNOSTIC_TEST|Ultrasound|Ultrasound images are collected and stored. The images stored during your preoperative ultrasound will be exported in anonymous format from the ultrasound system, and sent to the coordinating center (Fondazione IRCCS Istituto Nazionale dei Tumori di Milano). There, images will be submet to radiomic analysis through the application of a dedicated software; that will allow to evaluate the intrinsic characteristics of the tissue according to different parameters (shape, intensity, grade of heterogeneity and many others) of the 'pixels' (gray dots) that constitute the ultrasound imag
223628598|NCT04828421|DIETARY_SUPPLEMENT|Lactobacillus rhamnosus and Bifidobacterium lactis|Probiotics
223628599|NCT04828421|DIETARY_SUPPLEMENT|Placebo|Placebo
223628600|NCT06005467|PROCEDURE|Open reduction and internal fixation of mandibular angle fracture using V shaped plate|its a new plate that have been used in fixation of fractures in various areas of the mandible,V shaped plate was used in the treatment of three angle fracture cases which provided the advantage of including both lines of osteosynthesis which are the superior border and the lateral surface of the external oblique ridge using one plate.
223628601|NCT04712188|DIAGNOSTIC_TEST|Musculoskeletal ultrasonography|The ultrasonographic assesment will be used to examine the supraspinatus tendon thickness, the long head of the biceps brachii tendon thickness and acromio-humeral distance before and after wheelchair propelling test.
223628602|NCT04712188|OTHER|Wheelchair propelling test|Participants will use their own wheelchairs with their preferred stroke pattern for 20 minutes at a speed of 1 m / s on a motorized treadmill for a wheelchair propelling test. Wheelchair propelling videos will be recorded during the test. Shoulder kinematics will be analyzed using Kinovea motion analysis software and stoke pattern will be confirmed
224217430|NCT03654092|BEHAVIORAL|Exercise|"Home-based exercise training program that requires only minimal equipment, and is individually adaptable to the participant's exercise level (6 times per week; 15-20 min; 38 exercise cards and one interactive training agenda booklet). After randomization, a health care professional (HOMEX coach) will visit the intervention group participants at their home to set up the training location, to instruct the exercises and to establish individualized goals. Follow-up visits are planned after 3 and 8-9 weeks. Regular telephone calls will be conducted by the same HOMEX coach to motivate the patients, to discuss training progress and concrete benefits and barriers, and to adapt goals and the training program. Additional intervention elements are that a relative or friend is involved as a sparring partner to support the participant. The general practitioner is informed about the participation of his/her patient in the intervention."
224317462|NCT04936737|DIETARY_SUPPLEMENT|Beta-alanine supplementation|The supplementation will be administrated in the dosage of 20mg.kg-1. On the first and the sixth (last one), one dose of beta-alanine will be taken. On the other four days of supplementation, the volunteers will take 2 doses (20mg.kg-1) of Beta-alanine.
223628603|NCT06126614|DRUG|Chlorhexidine Gluconate|0.05% chlorhexidine gluconate solution for irrigation
223628604|NCT06126614|DRUG|Vancomycin Hydrochloride|2 grams of topical vancomycin hydrochloride added to the wound
223628605|NCT06126614|OTHER|Povidone-Iodine|0.35% povidone-iodine solution for irrigation
223628606|NCT06126614|OTHER|Saline|saline for irrigation
223628607|NCT00995761|DRUG|Docetaxel and Cisplatin|splitted administration of docetaxel and cisplatin.
223628608|NCT01468285|DRUG|betahistine dihydrochloride|betahistine dihydrochloride 24 mg tablet b.i.d. six weeks treatment
223628609|NCT01468285|OTHER|placebo|placebo tablets b.i.d., six weeks treatment
223628610|NCT02558725|DRUG|two capsules of aktiferrin F|two capsules of Aktiferrin F or Foliferrin
223628611|NCT06082934|DRUG|Olverembatinib plus venetoclax and dexamethasone|Olverembatinib: orally every other day at a dose of 40mg Venetoclax: in a daily ramp-up strategy (100 mg d4, 200 mg d5, 400 mg d6-17) Dexamethasone: intravenously 10mg, d1-14, 5mg, d15-28
223628612|NCT04894968|DIAGNOSTIC_TEST|Assessment of the presence of heart failure with preserved ejection fraction, according to guideline recommendations from the European Society of Cardiology 2016|"Patient will be screened for the presence of heart failure with preserved ejection fraction, according to guideline recommendations from the European Society of Cardiology 2016.~This requires patients to fulfill all of the four criteria listed below:~1. Symptoms of heart failure (e.g. dyspnea on extertion)~2. Preserved ejection fraction (Left ventricular ejection fraction ≥50%~3. NT-proBNP ≥125 pg/mL~4. Echocardiographic signs for structural heart disease or diastolic dysfunction (at least one of the criteria below)~   * Left atrial volume index \>34 mL/m²~  * Left ventricular mass index ≥115 g/m² for males or ≥95 g/m² for females~  * E/e' ≥13~  * Septal e' \<9 cm/s"
223628613|NCT00334880|DRUG|NRP104|
224217431|NCT00904189|RADIATION|Standard of care given for treatment of cancer|Subjects receiving a known dose of radiation during Total Body Irradiation.
224217432|NCT03172260|DEVICE|E Balance Pro Therapy|Micro-current treatment
224217433|NCT02995694|DRUG|Estradiol|Estradiol Vaginal Cream
224217434|NCT02995694|DRUG|Placebos|Placebo with no active pharmaceutical ingredients. Topical vaginal cream
224217435|NCT02995694|DRUG|Reference|Estrace Vaginal Cream
224217436|NCT01146431|DRUG|Inhaled anesthetics|Inhaled anaesthetic drugs (sevoflurane or desflurane) concentration will be changed on the basis of hemodynamic parameters (mean arterial pressure and heart rate greater or less than 20% compared to preoperative values).
223628614|NCT03523819|DRUG|CS1002|Dose levels will be escalated following a modified 3+3 dose escalation scheme
223628615|NCT03523819|DRUG|CS1003|Fixed dose at 200mg in combination with CS1002 on a specified dose level
223628616|NCT01794429|DRUG|Exenatide|Subcutaneum injection of exenatide once-weekly for 3 months
223628617|NCT01794429|DRUG|Placebo|Subcutaneum injection of placebo once-weekly for 3 months
223628618|NCT06100588|OTHER|Dry Needling|Dry needling (DN) is a myofascial treatment technique, in which a thin, solid filiform needle is inserted directly into the MTrP. During dry needling, local twitch responses (LTR) can be elicited. These are involuntary contractions of muscle fibers, leading to muscle relaxation, an increase in blood flow,recovery of the muscle metabolism and thus a reduction of pain and stiffness.
223628619|NCT06100588|OTHER|Manual therapy|Manual therapy comprises stretching of muscles, mobilizations, traction and translation of vertebrae, Sustained Natural Apophyseal Glides (SNAG), dynamic soft tissue mobilization, Muscle Energy Techniques (MET) and home-exercises.
223628620|NCT05023642|OTHER|resistance training|"Interventions will include a three-phase strengthening training protocol.~1. Adaptation phase: three sessions, emphasis on learning the technique, body self-awareness, and movement coordination;~2. Basic phase: 12 sessions, to increase muscle strength; and~3. Specific phase: 21 sessions, to intensify the process of strength gain and muscular hypertrophy.~Participants will perform the following exercises during the strength-training protocol intervention: pec deck/seated lever fly, adductor, pulldown, abductor strengthening, alternating dumbbell curl, leg press at a 45-angle, triceps pulley, lateral raise, knee flexion and extension, ankle joint flexion and extension in the leg press, and crunches. If the participant has difficulty performing a specific exercise, an equivalent activity will replace it. From the eighth week onwards, participants will perform additional exercises focused on strengthening the gastrocnemius and soleus."
223628621|NCT02559284|OTHER|A postoperative care after ethmoid sinus surgery|"A comparison of two products used for nasal cavity cleansing, at the rate of 4 washes/day (240mL per wash), as local postoperative care following endoscopic sinus surgery. This surgery, known as an ethmoidectomy, aims to improve sinus ventilation, treat the chronically infected area, and remove polyps that cause nasal obstruction.~Detailed information concerning the purpose of nasal irrigation, as well as how to use and clean the device, will be given to patients upon inclusion.~The nasal washing procedure will be as follow:~* Washing both nostrils using 180mL of solution distributed equally on each side to remove crusting and clotting~* Gentle blowing of the nose~* Rinsing both nostrils with the remaining 60mL of solution distributed equally on each side (no nose-blowing)."
223628622|NCT02578147|BEHAVIORAL|Mighty Girls|
223628623|NCT02578147|BEHAVIORAL|Game Girls|
224217437|NCT01146431|DRUG|Inhaled anesthetics|Inhaled anaesthetic drugs (sevoflurane or desflurane) concentration will be changed on the basis of Bispectral Index (BIS) value which will be maintained between 40 and 50.
224217438|NCT04307030|DIAGNOSTIC_TEST|Heart Auscultation and Echocardiography|Heart auscultation will be done by cardiovascular pediatrician and echocardiography by echocardiologist
223628624|NCT03756519|BEHAVIORAL|Exercise|A standardized exercise program tailored to the individual based on their directional preferences and current functional abilities.
224217439|NCT03836365|OTHER|Preoperative counseling office visit|All patients undergo a preoperative counseling session prior to surgery. Participants in this arm will have an in person preoperative counseling office visit.
224217440|NCT03836365|OTHER|Preoperative counseling phone call|All patients undergo a preoperative counseling session prior to surgery. Participants in this arm will have a preoperative counseling phone call.
224217441|NCT04472065|DIETARY_SUPPLEMENT|Lactobacillus reuteri|1 chewable tablet of probiotic dietary supplement (200 million CFU of L. reuteri DSM 17938 and ATCC PTA 6475) consumed once per day orally for 6 weeks beginning at Baseline (between 1 to 3 days postpartum) to 6 weeks postpartum.
224317463|NCT04936737|OTHER|High intensity interval exercise|The HIIE sessions will consist of 10 series of 1 min of effort, divided into two blocks of 5 series each. There will be an interval of 5 min of passive recovery; within each block, the interval between sets will be 1 min of active recovery. The exercise will be conducted in a mechanical brake cycle ergometer, with load applied by placing washers on a load plate (Biotec 2100, Cefise, Brazil).
223628625|NCT03756519|BEHAVIORAL|Advice to stay active and engaged in usual activities.|Participants will be advised that staying physically active and continuing to participate in usual activities improves recovery. This verbal advice will be reinforced with a written handout.
223628626|NCT03756519|BEHAVIORAL|Advice on use of ice or heat|Participants will be advised on the appropriate use of ice or heat to manage pain. This verbal advice will be reinforced with a written handout.
223628627|NCT03756519|OTHER|Advise regarding use of medications|Participants will receive education regarding the use of non-steroidal anti-inflammatory medications (NSAIDs) for pain relief, if needed and if the patient is appropriate for NSAIDs. Information regarding specific recommended doses, potential benefit and risk will be discussed.
223628628|NCT05324293|DRUG|HMI-115|Once Every 2 weeks, subcutaneously injection
223628629|NCT05099809|OTHER|Hyperthermia|Hyperthermia would be delivered once/twice a week for 60 to 90 minutes depending on patient's tolerance. A shortwave diathermy unit operating at 27.1 MHz would be used to deliver locoregional hyperthermia.
224217442|NCT04472065|OTHER|Placebo|1 chewable placebo tablet containing all the same ingredients except L. reuteri (DSM 17938 and ATCC PTA 6475) consumed once per day orally for 6 weeks beginning at Baseline (between 1 to 3 days postpartum) to 6 weeks postpartum.
223628630|NCT06348927|DRUG|sunvozertinib in combination with Anlotinib|"Drug: Sunvozertinib combination with Anlotinib~Sunvozertinib 300 mg once daily (QD) with Anlotinib 8mg once daily （QD in Day 1-14），21 days in one cycle."
224217443|NCT05322265|PROCEDURE|laparoscopic surgery for renal and adrenal diseases|type of treatment for patients underwent to laparoscopic surgery for renal and adrenal diseases with intraoperative complications
224217444|NCT04930198|BEHAVIORAL|PeerNaija|All participants (N=50) will receive daily medication reminders and access to the virtual support group on the PEERNaija app. Participants will be randomized to receive a social incentive (n=25) or a social plus financial incentive (n=25), PEER+, and be followed for 24 weeks.
224217445|NCT04974645|DEVICE|W-SUDs|Woebot (W-SUDs) is an automated conversational agent, available through a smartphone application, that delivers evidence-based psychotherapeutics, empathy, and emotional health psychoeducation.
224317464|NCT03383523|DRUG|Emodepside (BAY 44-4400)|2 tablets compared to the liquid formulation
223628631|NCT03291496|OTHER|Blood Collection Preterm|Blood will be collected on day 4 of life and then approximately every 3 days until 21 days of life. Thereafter, one sample will be collected weekly until discharge. For preterm neonates that have suspected sepsis an additional sample will be collected within 24-48 hours of the initial sepsis evaluation.
223628632|NCT03291496|OTHER|Blood Collection Term|A single 250 µl blood sample will be collected once the term neonate is \>24 hours old.
223628633|NCT03291496|OTHER|Adult Blood collection|One Time 1 ml of whole blood collected
223764006|NCT03414346|OTHER|Ice pack added 10% of water|Each subject will receive an experimental intervention of ice pack added to 50 mL of water. The intervention will last 20 minutes, and the order of application, expressed in % of water X ice, will be according to the randomization (realized in the first day). The pack will be wrapped in a band for improvement of the contac area. The subject will be asked to mark his pain level on the visual analogue scale (no pain score of 0 and pain as bad as it could be score of 10) every minute until the total time of the intervention.
224217446|NCT04974645|OTHER|Digitally-delivered Psychoeducation|A form of psychoeducation for those seeking treatment for their alcohol and/or substance use concern. Psychoeducation is commonly provided for those with substance use. Psychoeducation in substance use is intended to increase the users' knowledge of their substances of use, and effects on the body, behaviors, and consequences. The recipient of psychoeducation is expected to increase their own awareness of their substance use and ideally incorporate this newfound knowledge when making changes to their substance use. The information provided in this group are from factsheets found on NIAAA, NIDA, and CDC web pages.
224217447|NCT02190383|BEHAVIORAL|Habit Reversal Training|awareness training, competing response training
224217448|NCT01166997|DEVICE|EkoSonic Endovascular System|The EkoSonic Endovascular System will be used to deliver \< 20 mg of rt-PA ( Actilyse) directly into the occlusive pulmonary thrombus.
224217449|NCT01166997|DRUG|Unfractionated heparin|Intravenous unfractionated heparin used for anticoagulation treatment
224217450|NCT05924451|BEHAVIORAL|Immediate Loading|Clinical and radiographic examination of the periimplant soft and hard tissue will be analysed by using gingival index, plaque index, and pocket depth immediately post operative.
224217451|NCT00297986|DEVICE|Helmet|Evaluation of different interfaces for NPPV
224217452|NCT03550794|DRUG|Thiamine Hydrochloride|Thiamine hydrochloride is a water soluble vitamin (vitamin B1). 200mg of thiamine hydrochloride in 50ml 0.9%NACL will be administered twice daily for 3 days.
224217453|NCT03550794|DRUG|Placebo|50ml of 0.9% NACL will serve as the placebo
224217454|NCT01626131|BEHAVIORAL|exercise training|"Participants will engage in 3 aerobic and resistance exercise sessions (\~60-75 min total per session) weekly for 8 consecutive weeks.~Aerobic exercise will be performed for 30 minutes on a treadmill 3 times weekly. Before beginning, 10 min of stretches will be performed. Each exercise bout will begin and end with a 5-min warm-up and 5-min cool-down on the treadmill, not included in the prescribed exercise duration.~Eight resistance exercises will be performed immediately following the aerobic exercise: lat pulldown, triceps pushdown, seated chest press, upright row, bicep curls, leg press, shoulder press, and abdominal crunches. Participants will perform two sets of 10 repetitions of each. A rest interval of 60 seconds will be taken between exercises. Research staff will initially assist the participants in choosing the proper resistance to use, and weight will be increased once 15 repetitions can be performed while maintaining proper form."
224217455|NCT01626131|BEHAVIORAL|Stretching training|Participants will engage in stretching sessions that will focus on whole-body flexibility. Participants will perform 3 sessions per week (\~60 min) of 3 sets of 14 stretches focused on the muscle groups targeted by the exercise training (i.e., deltoids, pectorals, lats, forearms and biceps, triceps, quadriceps, hamstrings, and groins). Each stretch will be performed for 20 seconds and a rest interval of 60 seconds will be taken between each set.
224217456|NCT05465707|BIOLOGICAL|CM313 2 mg/kg|Once 1 week, intravenous infusion.
224317465|NCT03358706|DRUG|Ustekinumab IV Infusion|Participants will receive a single IV infusion dose of ustekinumab (dosage to be decided based on body weight) on Day 8.
224317466|NCT03358706|DRUG|Ustekinumab SC Injection|Participants will receive a Ustekinumab 90 mg SC maintenance dose on Day 64. A second optional maintenance dose may be administered on Day 120 based on participants clinical response assessed by investigator.
223628634|NCT04983017|DIETARY_SUPPLEMENT|Dietary supplement|iron bisglycinate manganese chloride vitamin D2 guar gum indole-3-carbinol L-methionine piceatannol biotin caffeine beta-carotene lutein zinc sulfate
223628635|NCT04983017|OTHER|Placebo|Matched Placebo to Intervention
223628636|NCT04997486|BEHAVIORAL|Time restricted eating|Participants will be asked consume all meals/snacks during a \~9-h daily eating period (\~15-h fasting).
223628637|NCT05942365|DRUG|ZSP1273|Drug Warfarin oral Drug midazolam oral
223628638|NCT05565365|PROCEDURE|Transversalis fascia plane (TFP) block|Patients will receive unilateral US-TFP block with 0.3 mL/kg bupivacaine 0.25% 15 minutes before skin incision
223628639|NCT05565365|PROCEDURE|Erector Spinae Plane (ESP) Block|Patients will receive unilateral US-ESP block with 0.3 mL/kg bupivacaine 0.25% 15 minutes before skin incision
223628640|NCT00685165|DRUG|Primidone 50 mg Tablet|50 mg tablet administered after an overnight fast of at least 10 hours.
223628641|NCT00685165|DRUG|Primidone (Mysoline®) 50 mg Tablet|50 mg tablet administered after an overnight fast of at least 10 hours.
223628642|NCT00506870|DEVICE|INRatio / Coaguchek XS|INR measured by patient himself using INRation or Coaguchek device. And one follow-up of INR per month, measured in laboratory.
223628643|NCT00506870|DEVICE|Conventional follow-up of anti-coagulation|At least, one follow-up of INR per month. Measured in laboratory.
223764007|NCT03414346|OTHER|Ice pack added 100% of water|Each subject will receive an experimental intervention of ice pack added to 500 mL of water. The intervention will last 20 minutes, and the order of application, expressed in % of water X ice, will be according to the randomization (realized in the first day). The pack will be wrapped in a band for improvement of the contac area. The subject will be asked to mark his pain level on the visual analogue scale (no pain score of 0 and pain as bad as it could be score of 10) every minute until the total time of the intervention.
223764008|NCT00136292|DRUG|daptomycin|
223764009|NCT05427435|DEVICE|Marshall ethanolisation|Destruction of Marshall bundles by ethanol 96% infusion (3 separate injections of 3.3ml)
224217457|NCT05465707|BIOLOGICAL|CM313 4 mg/kg|Once 1 week, intravenous infusion.
223628644|NCT05058222|OTHER|Deep Breathing Exercise after every 3hrs, each session consists of 10 deep breaths Exercise|• The control program will consist of Deep Breathing Exercises (from Morning to night every three hours; each session consisting of 10 deep breaths with a few seconds pause between each set, for 3 days) in addition with progressive Exercises.
223628645|NCT05058222|OTHER|Deep Breathing Exercise after every 3hrs, each session consist of 30 deep breaths Exercise|• The intervention group will perform additional Deep breathing Exercises (from Morning to night every three hours; each session consisting of 30 deep breaths with a few seconds pause between each set, for 3 days).
223680765|NCT02496507|OTHER|Sit-stand workstation|After baseline, each participant had a sit-stand workstation installed on their existing workplace desk. A single or dual monitor WorkFit-A with Worksurface+ workstation was installed, dependent on the number of monitors. The monitor(s) and keyboard were housed on the workstation and the workstation could be quickly raised up and down by hand to enable seated or standing work. Participants were not prescribed an amount of time to use the station. Ergotron Ltd provided and installed the workstations and gave participants basic face-to-face training and ergonomic information on correct use. Participants received a web link to manufacturer ergonomic guidelines via an email from the research team. After end-intervention data collection, manufacturer staff uninstalled the workstations.
223764010|NCT03037788|DRUG|WO3979|Application of cream to each axilla
223764011|NCT03037788|DRUG|WO3970|Application of cream to each axilla
224217458|NCT05465707|BIOLOGICAL|CM313 8 mg/kg|Once 1 week, intravenous infusion.
224217459|NCT05465707|BIOLOGICAL|CM313 16 mg/kg|Once 1 week, intravenous infusion.
224217460|NCT05465707|BIOLOGICAL|Placebo|Once 1 week, intravenous infusion.
224217461|NCT01543815|BEHAVIORAL|Well-Being Therapy based on Web Mobile Technology|The techniques included in WBT may be used in overcoming impairments in environmental mastery, purpose in life, personal growth, autonomy, self-acceptance and positive relations with others.
224217462|NCT01543815|BEHAVIORAL|Cognitive Behavior Therapy|CBT involves several essential features: identifying and correcting inaccurate thoughts associated with depressed feelings (cognitive restructuring); helping patients to engage more often in enjoyable activities (behavioral activation); enhancing problem-solving skills; providing instruction and guidance in specific strategies for solving problems.
224217463|NCT01543815|OTHER|Standardized Care Management|CM will consist of reviewing the patients' clinical status, and providing the patient with support and advice if necessary.
224217464|NCT00018746|DEVICE|repetitive transcranial magnetic stimulation|
224217465|NCT06309472|DRUG|Mirtazapine|30mg mirtazapine at night, escalated to 45mg after 4 weeks if \<20 percent improvement in depression from baseline. Total treatment duration 12 weeks.
224217466|NCT06309472|DRUG|Placebo|1 placebo capsule at night, escalated to 2 capsules after 4 weeks if \<20 percent improvement in depression from baseline. Total treatment duration 12 weeks.
224217467|NCT02688816|DEVICE|Xpert HPV|Point-of-care HPV DNA PCR test
224217468|NCT02688816|DEVICE|OncoE6|Point-of-care E6 oncoprotein test
224217469|NCT05792410|DRUG|SHR-A1811 & Dalpiciclib Isethionate Tablets|SHR-A1811：Lyophilized powder injection, 100mg / bottle, intravenous drip Dalpiciclib Isethionate Tablets：Tablet, 25mg / tablet, 50mg / tablet, 125mg / tablet, 150mg / tablet, oral
224217470|NCT05792410|DRUG|SHR-A1811 & Fulvestrant|SHR-A1811：Lyophilized powder injection, 100mg / bottle, intramuscular Fulvestrant：Injection, 5 ml: 0.25g/bottle, intramuscular
224217471|NCT05792410|DRUG|SHR-A1811 & Bevacizumab injection|SHR-A1811：Lyophilized powder injection, 100mg / bottle, intravenous drip Bevacizumab injection: injection, 100mg / bottle, intravenous drip
224217472|NCT04908956|DRUG|Osimertinib|"Osimertinib is a Tyrosine Kinase Inhibitor (TKI). It is an irreversible inhibitor of Epidermal Growth Factor Receptors (EGFRs) harboring sensitising-mutations (EGFRm) and TKI-resistance mutation T790M.~The appropriate number of osimertinib tablets (80 mg or 40 mg if the dose is reduced due to toxicity) will be provided to patients to be self-administered at home."
224217473|NCT04908956|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|SBRT will be delivered using risk-adapted SBRT with a maximum of 5 SBRT fractions.
224217474|NCT00786266|BEHAVIORAL|Sleep Enhancement Training System|4 week program of readings and relaxation programs
224217475|NCT00786266|BEHAVIORAL|NIOSH shiftwork booklet|weekly readings about coping with shiftwork
224217476|NCT05723341|DRUG|Bupivacain|%0,25
224217477|NCT05723341|DRUG|Morphine|In this group, patients will be postoperatively administered patient-controlled analgesia with morphine only.
224217478|NCT03125057|DRUG|Hemoporfin PDT|Photodynamic therapy is performed using hemoporfin. Hemoporfin（5mg/kg）is infused for 20 minutes, followed by light illumination at 10 minutes from the start of infusion. Different light dose of PDT is applied to the patients.
224217479|NCT01485224|DRUG|Thalidomide|"Eligible patients will receive thalidomide at a starting dose of 50 mg/day by mouth at bedtime for 4 weeks. In the event of unsatisfactory/no response, thalidomide dosage will be progressively increased by 50 mg/day every 4 weeks until complete or partial response, to a maximum dose of 200 mg/day.~Treatment will be continued until one of the following criteria is met:~* 8 additional weeks of treatment after the achievement of complete response~* 16 additional weeks of treatment after the achievement of partial response~* 24 weeks of treatment completed without response~* unacceptable toxicity. Then, patients will be followed off of thalidomide for 24 weeks."
224217480|NCT00447018|DRUG|20% mannitol|
224217481|NCT00447018|DRUG|7.45% hypertonic saline solution|
224217482|NCT03056352|DRUG|Metoclopramide|Intravenous medication drip
224317467|NCT03358706|DRUG|Midazolam 2 mg|Participants will receive 2 milligram per milliliter (mg/ml) syrup of midazolam as a component of the Cytochrome P 450 probe cocktail orally.
223764012|NCT03037788|DRUG|WO3992|Application of cream to each axilla
223764013|NCT03037788|DRUG|Placebo (WO3988)|Application of cream to each axilla
223764014|NCT01256710|DEVICE|Trifecta™ aortic bioprosthesis|Surgical aortic valve replacement with the Trifecta™ valve.
224217483|NCT03056352|DRUG|Diphenhydramine|Intravenous medication drip
224217484|NCT05719610|OTHER|Cawthorne Cooksey Exercises for Balance Training|Group of Exercises used to Increase balance
224217485|NCT05719610|OTHER|Swiss Ball Exercises|Swiss Ball Exercises
224217486|NCT02122510|DRUG|Bupivacine group|Bupivacaine group(n=30) will receive post-delivery bilateral TAP block with 10 ml of bupivacaine 0.5 % mixed with 10 ml saline and 10 μg dexmetonedine in 20 ml syringe
223628646|NCT01377584|BEHAVIORAL|Couple-oriented intervention|The first session will occur before the patient receives his/her CPAP and will last approximately 2 hours. This session will provide the couple with education on sleep apnea and CPAP and information on different types of PAP therapy and cleaning procedures, explore patient's concerns about starting CPAP treatment, and provide a goal setting exercise. The second face to face session will occur one week after the patient receives his/her CPAP and will last approximately one and a half hours. The second session will provide the couple with information on CPAP usage and pre- and post-treatment AHI, explore barriers to CPAP use and benefits of CPAP use, and provide a goal setting exercise. The individual telephone follow-up sessions will occur two weeks after the patient has received his/her CPAP and will last approximately 20 minutes. This session will review CPAP usage and explore barriers and facilitators of CPAP use.
224217487|NCT02122510|DRUG|Dexmedetomidine|Dexamedtomedine group will receive post-delivery bilateral TAP block with 10 ml of bupivacaine 0.5 % mixed with 10 ml saline and 10 μg dexmetonedine in 20 ml syringe
223680766|NCT05949944|DRUG|Linperlisib in combination with CHOP|Patients will receive six cycles of induction therapy of linperlisib in combination with CHOP regimen. All patients with CR and PR after induction therapy receive linperlisib maintenance therapy every 28 days until disease progression or other reasons lead to discontinuation, and the duration of linperlisib maintenance does not exceed 24 months.
224217488|NCT03884595|DIAGNOSTIC_TEST|IG, IPF, NRBC, CRP, PCT, presepsin|Assessment of blood cell count parameters and inflammation markers - IG, IPF, NRBC, CRP, PCT, presepsin according to study group.
224217489|NCT01077115|PROCEDURE|Laparoscopic cholecystectomy|
224217490|NCT01077115|PROCEDURE|Open Surgery|
224217491|NCT04322968|DRUG|A single low dose ketamine infusion as compared to the IV infusion of active placebo - ketorolac on chronic pain and PTSD symptoms.|Subjects were randomized into 4 treatment groups: chronic pain subjects treated with ketorolac, chronic pain subjects treated with ketamine, chronic pain+PTSD subjects treated with ketorolac, and chronic pain+PTSD subjects treated with ketamine.
224217492|NCT00796159|DRUG|Olmesartan medoxomil|olmesartan medoxomil 20 mg and HCTZ 12.5 mg
224217493|NCT02529085|OTHER|blood samples|blood samples for the bank
224217494|NCT04971915|OTHER|minimalist footwear|The intervention consists of wearing the minimalist footwear in recommended progression during the interventional period (6months). The intial load starts at 2,500 steps a day and will be gradually increased up according to the participant´s tolerance rate to the footwear wearing to fully use over the final period. Participants are instructed to report all issues and difficulties possibly connected to the intervention. There will be the opportunity to consult any issue connected with footwear or their wearing through the duration of the research.
224217495|NCT00691145|DRUG|tacrolimus ointment|transdermal
224217496|NCT05020054|DEVICE|Tecartherapy Intervention|therapeutic therapy with effective application, connected equipment
224217497|NCT05020054|DEVICE|placebo tecartherapy|tecartherapy with equipment turned off
224217498|NCT02581761|DRUG|CYTOTEC|synthetic prostaglandin E1
224217499|NCT02581761|OTHER|Placebo|no active material
224217500|NCT00949390|BEHAVIORAL|Questionnaire|Survey given at appointment time, then dropped in specified box anonymously.
224217501|NCT05146869|DRUG|DBPR108 tablets|DBPR108 tablets, oral, once daily on Day 1 and Day 3-9 for a total of 8 doses.
224217502|NCT01956682|DIETARY_SUPPLEMENT|HA formula + starch + L. reuteri|
224217503|NCT01424774|DRUG|CardioGen-82|CardioGen-82 is not administered to patients in this study, however to be able to qualify for enrollment, the patients must have received CardioGen previously
224217504|NCT04036578|DEVICE|A 12-week PFMT bio-assisted surface electromyographic program|
224217505|NCT00597207|DEVICE|AutoPulse|Mechanical device that provides chest compression
224217506|NCT00597207|OTHER|Manual|Manual chest compression
224217507|NCT00520351|DRUG|ClearCare|contact lens care system
224217508|NCT00520351|DRUG|Optifree Replenish|contact lens care system
224217509|NCT02917954|DEVICE|ePRO Tool Intervention|The ePRO tool includes two features: 1) My Goal Tracker and 2) Health Journal. My Goal Tracker allows patients and providers to collaboratively create goal-oriented patient care-plans, and helps patients to track outcomes related to their goals using a mobile device. The Health Journal allows patients, their caregivers and primary care providers to monitor patients' symptoms and outcomes.
224217510|NCT06398080|DRUG|aflibercept 8 mg|No intervention will be provided to study patients. Any treatment decision, including the decision for aflibercept 8 mg treatment, is at the discretion of the attending physician, made in accordance with his/her experience and following approved clinical guidelines.
224217511|NCT04229277|DIAGNOSTIC_TEST|optical coherence tomography|comparison of four imaging technologies in skin tumour diagnosis
224217512|NCT03845322|DRUG|Curcumin Pill|Curcumin (turmeric extract), over the counter supplement (1 capsule/three times a day). According to the Company, each capsule contains: 270 mg of pure curcuminoids (curcumin) and 3 mg of black pepper extract. Recommended serving size is 3 capsules per day in total, the patients will receive 810 mg of pure curcumin and 9 mg of black pepper extract (peperine/BioPerine) per day.
224217513|NCT03845322|DRUG|Placebo pills|The placebo pill is a vegetarian cellulose capsule, with cellulose powder inside. The composition is cellulose and magnesium stearate.
224317468|NCT03358706|DRUG|Warfarin 10 mg|Participants will receive 10 mg tablet of warfarin as a component of the Cytochrome P 450 probe cocktail orally.
223680767|NCT01348971|DIETARY_SUPPLEMENT|Sodium nitrate|Preoperative oral administration of sodium nitrate. 700 mg the night before surgery and 700 mg three hours before surgery
223680768|NCT01348971|OTHER|Sodium chloride|Preoperative oral administration of sodium chloride the night before surgery and three hours before surgery
223680769|NCT00321061|DRUG|VRC-HIVDNA016-00, VRC-HIVADV014-00|
223680770|NCT01656174|DEVICE|Procleix Dengue Virus Assay|in vitro diagnostic assay
223680771|NCT00736177|PROCEDURE|Embryo cryopreservation|Subjects in the Test group will have their embryos cryopreserved for transfer in a subsequent cycle.
223680772|NCT00736177|PROCEDURE|Fresh embryo transfer|Subjects in the Control group will receive fresh embryo transfer.
223680773|NCT06265480|OTHER|FallFitness intervention group|Eight week group-based fallprevention intervention. A total of eight session (1-hour once a week).
223680774|NCT00179244|DRUG|Rispridone (drug) and Bupropion ER (drug)|
223628647|NCT01377584|BEHAVIORAL|Patient-oriented intervention|The first session will occur before the patient receives his/her CPAP and will last approximately one and a half hours. This session will provide the patient with education on sleep apnea and CPAP and information on different types of PAP therapy and cleaning procedures, explore patient's concerns about starting CPAP treatment, and provide a goal setting exercise. The second face to face session will occur one week after the patient receives his/her CPAP and will last approximately 45 minutes. The second session will provide information on CPAP usage and pre- and post-treatment AHI, explore barriers to CPAP use and benefits of CPAP use, and provide a goal setting exercise. The telephone follow-up session will occur two weeks after the patient has received his/her CPAP and will last approximately 20 minutes. This session will review CPAP usage and explore barriers and facilitators of CPAP use.
223628648|NCT01377584|DEVICE|Continuous positive airway pressure (CPAP)|CPAP is treatment for obstructive sleep apnea. CPAP therapy keeps the airway open during the night by providing a stream of air through a mask that is worn while sleeping.
223628649|NCT01377584|OTHER|No intervention|No intervention will be received.
223628650|NCT01336933|DRUG|prednisone|Given PO
223628651|NCT01336933|DRUG|cyclophosphamide|Given IV
223628652|NCT01336933|DRUG|etoposide|Given PO or IV
223628653|NCT01336933|DRUG|Vincristine|Given IV
223628654|NCT01336933|DRUG|pralatrexate|Given IV
223628655|NCT01336933|OTHER|laboratory biomarker analysis|Correlative studies
223628656|NCT01336933|GENETIC|comparative genomic hybridization|Correlative studies
223628657|NCT01336933|GENETIC|gene expression analysis|Correlative studies
223628658|NCT01336933|GENETIC|nucleic acid sequencing|Correlative studies
223628659|NCT01336933|GENETIC|mutation analysis|Correlative studies
223628660|NCT01336933|OTHER|immunohistochemistry staining method|Correlative studies
223628661|NCT01336933|GENETIC|microarray analysis|Correlative studies
224217514|NCT02838290|OTHER|Induction|Participants will be randomly assigned (computer generated straight away after clicking the link to the research) to one of 4 experimental conditions: stress at work, dealing with a patient's death, managing stress at work or all topics together. Each module includes brief reflection parts and quizzes. Participants will be asked to fill in an online survey just before the induction and a week after. The survey is about current occupational distress and organizational factors.
223628662|NCT01336933|GENETIC|RNA analysis|Correlative studies
224217515|NCT02838290|OTHER|Control group|Participants in the control group will be asked to fill in an online survey, but will not have any task at time-1. However, participants in the control group will be invited to complete induction programme after time-2 (a week time after time-1) in ensure the same expectations in both, experimental and control, groups.
223628663|NCT02960386|OTHER|Machine Learning Algorithm|The algorithm will help participants improve physical activity by sustaining long term engagement with their fitness tracker.
224317469|NCT03358706|DRUG|Vitamin K 10 mg|Participants will receive 10 mg tablet of vitamin K as a component of the Cytochrome P 450 probe cocktail orally.
223628664|NCT06365879|DRUG|CMAB007|300mg, SC, Q4W
223628665|NCT06365879|DRUG|Xolair|300mg, SC, Q4W
223628666|NCT00788307|BIOLOGICAL|Ad5-CMV-NIS|
223628667|NCT00788307|DRUG|liothyronine sodium|
223628668|NCT00788307|GENETIC|reverse transcriptase-polymerase chain reaction|
223628669|NCT00788307|OTHER|laboratory biomarker analysis|
223628670|NCT00788307|RADIATION|iodine I 131|
223628671|NCT03917797|BIOLOGICAL|MSC treatment|Umbilical cord-derived Mesenchymal Stromal Cell
223628672|NCT03917797|DRUG|Standard of Care|Methylprednisolone; Cyclophosphamide; Prednisone; Mycophenolate
223628673|NCT03917797|DRUG|Placebo|MSC infusion vehicle
223628674|NCT04729725|BIOLOGICAL|Anti-TGF-beta Monoclonal Antibody SAR-439459|Given IV
223628675|NCT04729725|BIOLOGICAL|Cemiplimab|Given IV
223628676|NCT02602886|BEHAVIORAL|Exposure and Response Prevention Therapy|The treatment includes both therapist-supervised and self-controlled exposure and ritual prevention exercises. 2 sessions per week, up to 15 sessions in total. Session time is 90 minutes. The majority of in-session time is spent conducting in vivo exposures. When engaging in E/RP tasks, patients are instructed to refrain from ritual engagement. Between-session homework is given the patient practicing the within-session E/RP task up to 90 minutes each day. Clinicians supplement E/RP with other cognitive-behavioral interventions including motivational strategies for resistant patients, Socratic dialogue, and behavioral experiments to test the validity of erroneous cognitions.
223628677|NCT04340635|OTHER||Without intervention
223628678|NCT02364908|OTHER|therapeutic education|This is the group sessions aimed to convey additional information to patients about their disease. The main objective is to learn how to better anticipate any medical problems and better manage daily life with the disease.
223628679|NCT00153296|DRUG|Carbamazepine|
223628680|NCT00062712|DRUG|Allogeneic Bone Marrow, Anti-Thymocyte Globulin (Sangstat) & Sirolimus (Wyeth-Ay|
223628681|NCT02819921|DRUG|Desvenlafaxine succinate 100mg|Pristiq 100mg
223628682|NCT02819921|DRUG|Desvenlafaxine succinate 50mg|Pristiq 50mg
223628683|NCT02819921|DRUG|Placebo|Placebo
223628684|NCT04728958|BEHAVIORAL|Gratitude|A positive psychology intervention using expressions of gratitude
223628685|NCT06157515|DEVICE|Breath-actuated vibrating mesh nebulizer|The intervention utilizes a breath-actuated vibrating mesh nebulizer system consisting of a controller module with microphone for respiratory phase detection and algorithm for inspiration triggering. This interfaces with the vibrating mesh nebulizer module which incorporates a micro-pump chip using piezoelectric effects to eject fluid through a mesh aperture plate holes. By detecting the onset of inspiration based on characteristic acoustic patterns using machine learning models, the controller module sends signals activating the piezoelectric vibration mechanism to generate aerosol only during the inspiratory phase through precision timing control, shutting off mist during expiration. The core module is attached to a standard commercial vibrating mesh nebulizer using the standard adult reusable mouthpiece interface.
223628686|NCT06157515|DEVICE|Continuous vibrating mesh nebulizer|When the continuous vibrating mesh nebulizer powered on, the micro-pump chip provides sustained vibrations onto the aperture plate, forcing fluid through micron-scale pores under pressure to continuously produce aerosol throughout inspiration and expiration phase.
223628687|NCT05208944|DRUG|6-Thio-2'-Deoxyguanosine|small molecule telomere targeting agent
223628688|NCT05208944|DRUG|Cemiplimab|programmed cell death protein 1 (PD-1) inhibitor
223628689|NCT05849272|DRUG|toludesvenlafaxine hydrochloride sustained-release tablets|orally once a day
223628690|NCT04029233|DEVICE|Occlutech PFO Occluder|The Occlutech PFO Occluder is a medical device for transcatheter closure of PFO.
223628691|NCT02367508|BEHAVIORAL|MODEL Care|The Mindfully Optimizing Delivery of End-of-Life Care (MODEL Care) intervention is two-pronged and mutually interactive with: (1) a patient and family caregiver group, and (2) an oncology provider group. Patients and family caregivers meet as a group for 6 weekly sessions of 2 hours each, for a total of 12 hours of class time. Oncology providers will have 5 class sessions for a total of 16 hours of class time. One class is held conjointly with patients, family caregivers, and providers to practice newly-learned skills. The course curriculum is generally based on mindfulness practices, group discussion, and didactic teaching with an emphasis on embodying interpersonal mindfulness in dialogue in daily life.
223628692|NCT04767659|DEVICE|MAMMOT2|Breast cancer patients candidate for neoadjuvant chemotherapy will be evaluated with optical imaging prior to commencement of NAC/baseline, 2-5 days post-NAC, 6-8 days post-NAC, 2 weeks post-NAC, half-way through and on completion of NAC. 2 additional optical evaluations will be carried out on the first 5 patients enrolled, one before breast biopsy and one after the positioning of the metallic clip, in order to evaluate the potential artefacts related to these procedures.
223628693|NCT06097221|BEHAVIORAL|CRT-Advance|Psychotherapy with focus on advancing sleep timing, using diaries on sleep and zeitgebers.
223628694|NCT06097221|BEHAVIORAL|Treatment as usual|Treatment as usual in the outpatient psychiatric unit.
223628695|NCT06347731|DEVICE|Proton Radiation Therapy|All enrolled participants will be treated with Proton radiation therapy using the medical device Varian ProBeam360° Proton Therapy System. The screening period from informed consent to enrollment is expected to be 4 weeks, while the treatment period is 1 to 8 weeks. The period after the last treatment is divided into short-term follow-up which is 3 months after treatment completion and long-term follow-up which is 5 years after treatment completion.
224217516|NCT02996006|PROCEDURE|stepwise vascular control|"Before liver parenchymal resection, we performed total hepatic vascular preparation for occlusion with portal triad (PT), infra-hepatic inferior vena cava (IIVC), and supra-hepatic inferior vena cava (SIVC) preparation in order. Then we performed step-by-step vascular occlusion according to the individual bleeding situation."
224217517|NCT01977859|DRUG|Nesiritide|
224217518|NCT01977859|DRUG|Saline|
224217519|NCT01993433|DRUG|DRM02|
224217520|NCT01993433|OTHER|Vehicle|
224217521|NCT03275168|BEHAVIORAL|Intervention|Sexual partners will receive dyadic counseling and support for condom negotiation after receipt of individual evidence based HIV/STI prevention intervention (Sister-to-Sister (female) and Focus on the Future (male).
224217522|NCT03275168|BEHAVIORAL|Individual evidence-based STI/HIV prevention intervention|Sexual partners will receive individual evidence-based HIV/STI prevention counseling without partner debrief and/or practice negotiating condom use.
224217523|NCT02122471|DRUG|Plecanatide|
224217524|NCT02122471|DRUG|Placebo|
224217525|NCT03459833|DRUG|Hyaluronic Acid|Glans penis augmentation using multiple puncture technique as described by Abdallah et al. (2012) with minor modifications. HA is injected at two circular levels: one at the level of corona of glans penis and a second circular level is mid-way between the corona and urethral meatus. Six injections are injected at coronal level and four are injected in the second level, each injection is of 0.2 ml and is injected into deep dermis.
224217526|NCT02293811|OTHER|Analysis|"An additional blood sample (10ml) will be taken on the day of hospitalization to achieve the genomic studies in search of mutations in constitutional DNA of circulating lymphocytes and acquired mutations of DNA circulating.~We will use the technique of tissue-microarray to analyze the expression level of P2RX7 both in epithelial cells than in stromal cells inflammatory.~Genotyping will be conducted partly on colonic biopsies and also on blood samples (to demonstrate the feasibility of this technique much less debilitating)."
223628696|NCT06211179|DRUG|Treatment A: Mavacamten intact oral capsule|Specified dose on specified days
223628697|NCT06211179|DRUG|Treatment B: Mavacamten open capsule in suspension|Specified dose on specified days
223628698|NCT06211179|DRUG|Treatment C: Mavacamten open capsule in suspension administered via nasogastric tube (NGT)|Specified dose on specified days
223628699|NCT06584890|OTHER|decision|decision-making process regarding patient discharge from the Intensive Care Unit (ICU)
223628700|NCT00556075|DRUG|Proellex 25 mg|1 capsule daily for 4 months
224217527|NCT00629486|GENETIC|Polymorphism of IL-1 beta and TNF-alpha|To analyze the role of polymorphisms of IL-1beta and TNF-alpha gene on risk of hepatitis B-related chronic liver disease and hepatocellular carcinoma
224217528|NCT02001428|DRUG|dihydroartemisinin-piperaquine|Participating infants with uncomplicated malaria will be treated with a three day course (1 dose/day) of DHP (containing 40 mg dihydroartemisinin and 320 mg piperaquine) administered as a total dose over three days of 6mg/kg of dihydroartemisinin and 57 mg/kg of piperaquine.
223628701|NCT00556075|DRUG|Placebo|1 capsule daily for 4 months
223628702|NCT00556075|DRUG|Proellex 50 mg|2 capsules daily for 4 months
224217529|NCT04390074|OTHER|COVID-19 and Intensive Care|No intervention, observational.
224317470|NCT03358706|DRUG|Omeprazole 20 mg|Participants will receive 20 mg capsule of omeprazole as a component of the Cytochrome P 450 probe cocktail orally.
224317471|NCT03358706|DRUG|Dextromethorphan 30 mg|Participants will receive 30 mg capsule of dextromethorphan as a component of the Cytochrome P 450 probe cocktail orally.
223628703|NCT02485691|DRUG|cabazitaxel XRP6258|Pharmaceutical form: solution Route of administration: intravenous
223628704|NCT02485691|DRUG|enzalutamide|Pharmaceutical form: capsule Route of administration: oral
223628705|NCT02485691|DRUG|abiraterone acetate|Pharmaceutical form: tablet Route of administration: oral
223628706|NCT02485691|DRUG|prednisone|Pharmaceutical form: tablet Route of administration: oral
224217530|NCT00890227|PROCEDURE|Traditional technique|All level open instrumented posterior spinal fusions
224217531|NCT00890227|PROCEDURE|Minimally invasive technique|Open surgery for all the levels except the proximal segment (most proximal instrumented level) where minimally invasive technique will be used.
224317472|NCT03358706|DRUG|Caffeine 100 mg|Participants will receive 100 mg tablet of caffeine as a component of the Cytochrome P 450 probe cocktail orally.
224317473|NCT06297421|PROCEDURE|Fecal Microbiota Transplantation|Oral Fecal Microbiota Transplantation Capsule
224317474|NCT06297421|PROCEDURE|Placebo|Oral Placebo Capsule
223628707|NCT04871841|BIOLOGICAL|Sputnik V|Participants will receive intramuscular (IM) injection of a single dose of rAd26-S and rAd5-S at day 0 and day 21, respectively.
223628708|NCT02428777|DRUG|Tramadol|Women will receive oral tramadol 100 mg 1 hour before the procedure.
223628709|NCT02428777|DRUG|Diclofenac|Women will receive oral diclofenac 100 mg 1 hour before the procedure
223628710|NCT02428777|DRUG|Placebo|Women will receive an oral placebo 1 hour before the procedure
223628711|NCT04918706|GENETIC|Allogeneic MSC|These MSCs will originate from bone marrow that will be aspirated from healthy volunteer donors screened by a trained physician of the center for stem cell therapy of LUMC
224217532|NCT04170049|BEHAVIORAL|Sensory Stimulative Activitiy ( proprioceptive intervention, music intervention )|Music intervention: Listening to soft music was found to be an effective method of relaxation, as indicated by a shift of the autonomic balance toward parasympathetic activity. Participants listen to preferred soft music for 30 minutes before sleeping. Proprioceptive intervention: The proprioceptive intervention can activate the parasympathetic nervous system through pathways of the central nervous system, providing calming effects that significantly reduce anxiety, hyperactivity and agitation in various populations.Participants do 10-minute joint compression exercise three times per day by themselves.
223628712|NCT04918706|DRUG|Placebo|The placebo will be an equivalent volume NaCl 0,9% and DMSO 5%
223628713|NCT02869711|OTHER|Health care quality management|
223628714|NCT01420861|DRUG|GTx-758|two GTx 758 tablets per day
223628715|NCT05569434|DRUG|68Ga-P16-093|Intravenous injection of 68Ga-P16-093 with the dosage of 1.5-1.8 MBq (0.04-0.05 mCi)/kg. Tracer doses of 68Ga-P16-093 will be used to image lesions of glioma by PET/CT.
223628716|NCT00402857|BEHAVIORAL|Incredible Years Program|The Incredible Years Program is a 10-week group parenting intervention. Parent training sessions will take place once per week for 10 weeks, and will last approximately 2 hours each. Sessions will focus on teaching positive parenting skills, such as appropriate play and use of praise and rewards, as well as limit-setting techniques, such as ignoring, allowing children to experience the natural consequences of their actions, and assigning time-outs.
223628717|NCT00271674|DEVICE|Q-switched YAG laser|
223628718|NCT05666323|BEHAVIORAL|Single Text Messaging (TM1)|Receives single text message
223628719|NCT05666323|BEHAVIORAL|Patient Navigation (PN)|Receive phone calls from trained MAPS counselors
223628720|NCT05666323|BEHAVIORAL|Multiple Text Messaging (TM+)|Receives multiple scheduled text messages
223628721|NCT04764162|DIETARY_SUPPLEMENT|Choline|1000 mg (2 x 500 mg) choline bitartrate capsules (over-the-counter supplement)
223628722|NCT04764162|DIETARY_SUPPLEMENT|Placebo|Choline-matched 1000 mg (2 x 500 mg) placebo (maltodextrin) capsules
223628723|NCT03361137|DRUG|Emicizumab|Emicizumab via SC injection at a loading dose 3 mg/kg once weekly for the first 4 weeks, followed by 1.5 mg/kg once weekly, or by any other approved maintenance regimen, as long as the participant continues to derive sufficient benefit. Dosing was to be adjusted if the participant had a significant change in body weight.
224217533|NCT04711863|DRUG|Fluvoxamine|Up to 200 mg per day as tolerated until discharge from community treatment center or for approximately 10 days
224217534|NCT04711863|DRUG|Placebo|Up to 200 mg per day as tolerated until discharge from community treatment center or for approximately 10 days
224217535|NCT00061958|DRUG|arsenic trioxide|Given IV
224217536|NCT01336309|BEHAVIORAL|Yoga Research Tool|We will be collecting data from a literature search, focus groups, cognitive interviews, and an online survey to build a measure for yoga researchers.
224217537|NCT06516393|DEVICE|The radial shock wave device|The r-ESWT+Kinesio Tape Application
224217538|NCT00614458|DRUG|Raltegravir; valproic acid|raltegravir 400mg po BID; valproic acid 1000mg - 2000mg daily
224217539|NCT01284595|DRUG|[14C] AZD8931|Single 160 mg oral dose administered on Day 1
224217540|NCT00348218|DEVICE|NeuroVision|
224217541|NCT00842894|DRUG|insulin detemir|Safety and effectiveness data collection in connection with the use of the drug.
224217542|NCT00842894|DRUG|biphasic insulin aspart 30|Safety and effectiveness data collection in connection with the use of the drug in daily clinical practice.
224217543|NCT02949778|PROCEDURE|QL-block|Bilateral quadratus lumborum block using either ropivacaine 3.75mg/ml or sodium chloride 0.9% is the intervention studied
224217544|NCT02949778|DRUG|Ropivacaine|Ropivacaine 3.75mg/ml administered in QL-block as active treatment
224217545|NCT02949778|DRUG|Sodium Chloride|Sodium chloride 9mg/mL administered in QL-Block as placebo
224217546|NCT00729365|DRUG|Ramipril|"ACE inhibitor known as Ramipril~Subjects with nighttime blood pressure that does not drop during the night (non-dippers) maybe randomized into this group and given an ACE inhibitor (study medication). Therefore, the Non-Dippers groups II and III will be randomized to receive either drug or placebo."
224217547|NCT00729365|DRUG|Placebo|Dippers (category of subjects with a nighttime dip in blood pressure) will all be given Placebo. Control group.
224217548|NCT00729365|DRUG|Placebo|"Subjects with nighttime blood pressure that does not drop during the night (non-dippers) maybe randomized into the control group and given Placebo."
224217549|NCT03178422|DRUG|CQSS2|Nicotine Replacement Therapy
224217550|NCT03178422|DRUG|NicoDerm CQ Patch|Nicotine Replacement Therapy
224217551|NCT06375031|DRUG|HR011408 injection; HR011408 injection Placebo|"Medication regimen-A:~HR011408 injection, ante cibum; HR011408 injection Placebo , post cibum"
224217552|NCT06375031|DRUG|NovoRapid®; HR011408 injection Placebo|"Medication regimen-B:~NovoRapid®, ante cibum; HR011408 injection Placebo, post cibum"
224217553|NCT06375031|DRUG|HR011408 injection Placebo; HR011408 injection|"Medication regimen-C:~HR011408 injection Placebo, ante cibum:~HR011408 injection, post cibum"
224217554|NCT02717936|PROCEDURE|Immunohistochemistry using Pancytokeratin Staining|
224217555|NCT00869089|DRUG|CC-10004|30mg,oral medication, BID, for 24 weeks (60mg total DAILY)
224217556|NCT05571657|BEHAVIORAL|Reminder/Recall Sent Via Preferred Method of Communication|Parents of 12-17 year-old patients due for COVID-19 booster dose will receive a one-time vaccine reminder/recall via the parent's preferred method of communication (mailed letter, text message, email)
223628724|NCT03269526|DRUG|EGFR BATs after standard of care chemo|Subjects will receive one dose of standard of care chemotherapy prior to twice weekly or weekly infusions of EGFR BATs for 4 weeks.
224217557|NCT01770782|PROCEDURE|Surgically Assisted Rapid Maxillary Expansion (SARME)|Surgical technique is performed with subtotal LeFort I osteotomy with separation of the pterygomaxillary fissure.The procedure was performed under general anesthesia using endotracheal intubation. Following the osteotomies, the expander screw was activated to 1.6 mm intraoperatively until a small diastema was observed between the upper central incisors. The incision was sutured along two planes.
224217558|NCT01770782|OTHER|Laser Scanner|Laser Scanner Vivid 9i was used to digitize the study models. The 3d virtual dental casts is a reliable copy of the original dental casts. On this virtual casts all measurements (linear, area and volume of the palate) was done to evaluate the stability after SARME.
223628725|NCT03546556|DRUG|Fluorothymidine (FLT)|A total of 12 patients who have undergone allogenic bone marrow transplantation will undergo FLT-PET-MRI imaging on two separate occasions. In addition to the 12 allogenic transplant patients, 3 patients undergoing autologous stem cell transplant will also be imaged the same two time points in order to determine how much of the FLT signal observed after allogeneic transplant is unique to that population and the result of allo-antigen driven T cell expansion.
223628726|NCT03626727|DRUG|Sodium Oxybate Oral Solution [Xyrem]|Xyrem will be given to participants to determine if it is effective in treating post-traumatic narcolepsy and post-traumatic hypersomnia
223628727|NCT00149968|DRUG|Enteric-Coated Mycophenolate Sodium (EC-MPS)|Patient on MMF treatment completes questionnaire and switch to equimolar doses of Myfortic. Maximum daily dose 1440 mg
223628728|NCT03201068|DIETARY_SUPPLEMENT|Probiotic supplement|Probiotic supplement capsule
223628729|NCT03201068|DIETARY_SUPPLEMENT|Placebo|Placebo capsule
223628730|NCT03413891|DRUG|Tranexamic Acid|Mouthwash
223628731|NCT03413891|OTHER|Placebo|Mouthwash
223628732|NCT04555486|DRUG|DCR-PHXC|Intervention, drug, DCR-PHXC
223628733|NCT04555486|DRUG|Sterile Normal Saline (0.9% NaCl)|Placebo comparator
223628734|NCT05760365|OTHER|3D printed educational model|3D printed cardiac catheterization model
224217559|NCT03343977|DRUG|docetaxel 50mg/m2|50 mg/m2 of docetaxel will be given on day 1 every 14 days
224217560|NCT03343977|DRUG|docetaxel 75mg/m2|75 mg/m2 of docetaxel will be given on day 1 every 21 days
224217561|NCT00676026|DRUG|Fluoxetine|Fluoxetine 20 mg by mouth in the follicular and luteal phase of the menstrual cycle per participant.
224317475|NCT05229536|BIOLOGICAL|Meningococcal ACYW135 Polysaccharide Conjugate Vaccine|Group 1: 3/2/1 dose(s) according to age of subjects. Single intramuscular dose contains 10 µg each of Serogroup A, C, Y, and W135 polysaccharide conjugate.
224317476|NCT05229536|BIOLOGICAL|Meningococcal ACYW135 Polysaccharide Conjugate Vaccine|Group 2: 3/2/1 dose(s) according to age of subjects. Single intramuscular dose contains 5 µg each of Serogroup A, C, Y, and W135 polysaccharide conjugate.
223628735|NCT05760365|OTHER|Slide-based presention|Slide-based presention
223628736|NCT05358366|BEHAVIORAL|Infeccion de Amor (Love Infection)|"Love Infection is a filmed dramatized story (telenovela/soap opera) Infección de Amor (IA), or Love Infection - culturally tailored for US Latinas and delivered online. IA is a four-episode HIV prevention telenovela co-created with Latinas and a community-based participatory and interdisciplinary. Participants have one week window to watch the 10-minute episodes from their preferred device and location."
224217562|NCT00676026|DRUG|Zolpidem|Zolpidem 10 mg by mouth in the follicular and luteal phase of the menstrual cycle per participant.
224217563|NCT00676026|DRUG|Progesterone|Progesterone 800 mg by mouth will be administered to each participant once in the follicular and luteal phases of the menstrual cycle.
224317477|NCT01193179|DRUG|OPC-262|Oral administration of tablets for 52 weeks
224317478|NCT02743429|DRUG|dinutuximab beta|"Up to 5 cycles of continuous infusion of ch14.18/CHO is administered at a dose of 10 mg/m2/day over 10 days (total dose 100 mg/m2/cycle).~Cycle duration: 35-days."
223628737|NCT01264796|BEHAVIORAL|culturally tailored diabetes education|lifestyle modification group education
223628738|NCT06573996|DEVICE|Active TENS Device|"Description: The active TENS device, specifically the Dental Pain Eraser (DPE), is applied to the gums for about 2.5 minutes. This intervention is designed to modulate nerve activity to reduce pain during orthodontic alignment and leveling.~Arms Associated:~Arm 1: Upper Right Side - Active TENS Device Arm 3: Lower Right Side - Active TENS Device"
223628739|NCT06573996|DEVICE|Intervention 2: Placebo/Sham Device|"The placebo/sham device is identical in appearance to the TENS device but does not deliver electrical stimulation. It is applied to the gums for 2.5 minutes to serve as a control.~Arms Associated:~Arm 2: Upper Left Side - Placebo/Sham Device Arm 4: Lower Left Side - Placebo/Sham Device"
223628740|NCT06227234|OTHER|Dechoker|"Participants will be shown a short educational video for each intervention. A research assistant acting as an instructor will be present to answer any questions that the students have about each of the techniques.~After training of all three techniques is complete, participants will be asked to respond to a choking scenario, using an assigned technique (the first one in their randomized order). Participants will use a mannequin (Choking Charlie, Laerdal Medical AS, Stavanger, Norway), with a simulated food bolus placed per manufacturer's directions, to complete each scenario. Participants will have up to four minutes to complete the intervention.~Each participant will repeat the two more times so that they attempt each intervention."
223680775|NCT01251627|DRUG|Decitabine|Decitabine will be administered at a dose of 20 mg/m2 infused over a 1 hour period once daily for 5 consecutive days. The totale amount per course is 100 mg/m2. Cycles will be administered every 4 weeks (1 cycle of 28 days).It is recommented that patients be treated for a minimum of 4 cycles.
223680776|NCT03123185|DRUG|Placebo|Tablet and solution formulation
223680777|NCT03123185|DRUG|BI 705564 (Test)|Fed state
223680778|NCT03123185|DRUG|BI 705564 (Reference)|Fasting state
223680779|NCT02153476|DRUG|2.0mg of ALG-1001|
223680780|NCT02153476|DRUG|Balanced Salt Solution|
223680781|NCT02708082|DEVICE|OCT scanning and HFA perimetry|Imaging of the optic nerve and nerve fiber layer / measurement of visual field
223680782|NCT03254368|DRUG|ZGN-1061|ZGN-1061 is a methionine aminopeptidase 2 inhibitor
223680783|NCT03254368|DRUG|Placebo|Placebo has the same excipients and appearance as ZGN-1061
223628741|NCT06227234|OTHER|LifeVac|"Participants will be shown a short educational video for each intervention. A research assistant acting as an instructor will be present to answer any questions that the students have about each of the techniques.~After training of all three techniques is complete, participants will be asked to respond to a choking scenario, using an assigned technique (the first one in their randomized order). Participants will use a mannequin (Choking Charlie, Laerdal Medical AS, Stavanger, Norway), with a simulated food bolus placed per manufacturer's directions, to complete each scenario. Participants will have up to four minutes to complete the intervention.~Each participant will repeat the two more times so that they attempt each intervention."
223628742|NCT06227234|OTHER|Abdominal Thrusts|"Participants will be shown a short educational video for each intervention. A research assistant acting as an instructor will be present to answer any questions that the students have about each of the techniques.~After training of all three techniques is complete, participants will be asked to respond to a choking scenario, using an assigned technique (the first one in their randomized order). Participants will use a mannequin (Choking Charlie, Laerdal Medical AS, Stavanger, Norway), with a simulated food bolus placed per manufacturer's directions, to complete each scenario. Participants will have up to four minutes to complete the intervention.~Each participant will repeat the two more times so that they attempt each intervention."
223628743|NCT05168839|DRUG|FLUO+ : Intraoperative fluorescence angiography (IOFA) with indocyanine green (ICG).|"In the experimental arm (FLUO+), at least one 0.1mg/kg Infracyanine® bolus will be injected intravenously by the anesthesiologist.~The detection of indocyanine green in the proximal colon segment will be done open or intracorporeally using a dedicated infrared camera.~A surgical film describing the injection technique and fluorescence detection will be presented during the study set-up visits.~An additional injection is allowed at the surgeon's discretion if necessary (change of anastomosis site). The time from injection to indocyanine green detection and any adverse events will be recorded."
223628744|NCT04483206|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo ASCT
223628745|NCT04483206|DRUG|Melphalan|Given IV
223628746|NCT04483206|OTHER|Questionnaire Administration|Ancillary studies
223628747|NCT03044509|DIAGNOSTIC_TEST|Secreted cytokine assay|Blood collected in a sodium-heparin tube will be used for the assay using novel TB-specific antigens. After incubation the supernatant will be harvested and cryopreserved at -80 °C for further testing of cytokines. Cytokines will be measured using a bead-based multiplex assay reader (MAGPIX, Luminex Crop., Austin, USA).
223628748|NCT03044509|DIAGNOSTIC_TEST|Intracellular cytokine assay|Blood will be stimulated with recombinant MTB-specific antigens, ESAT-6, CFP-10, positive control or left unstimulated. Following an initial duration of stimulation, Brefeldin-A will be added and the blood incubated for a further 5 hours. White cells will be fixed and cryopreserved at - 80°. Batched analysis within 6 months of cryopreservation will be done using multi-colour flow cytometry.
223628749|NCT04905134|DEVICE|Nasopharyngoscope|Low-cost, flexible scope prototype will compared to standard of care scope used as standard of care.
223628750|NCT06455228|DEVICE|insert catheter|A fixed routine for pre-insertion cleaning and equipment was followed, including hand washing, placing the patient in a recumbent position, skin antisepsis, and preparation of the sterile field. Catheter insertion was performed by senior specialized nurses in the intravenous treatment room, which was a standardized setting for venipuncture.
223628751|NCT03009058|BIOLOGICAL|IMM-101|A suspension of heat killed whole cell Mycobacterium obuense NCTC 13365
223628752|NCT03009058|DRUG|Gemcitabine|Standard of Care chemotherapy
223628753|NCT03009058|DRUG|Nab-paclitaxel|Standard of Care chemotherapy
224217564|NCT00566215|PROCEDURE|Duodenal exclusion plus omentectomy|"Under open laparotomy, a duodenum section 2cm below the pylorus and a jejunum section below Treitz's Angle to create a excluded biliopancreatic limb of 150cm. A Roux-in-Y retrocolic anastomosis of the alimentary limb promotes the gastrojejunal continuity and the anastomosis of the excluded biliopancreatic limb is done 100cm below the jejunal-pyloric union.~Additionally, total omentectomy is performed."
224317479|NCT03310749|DRUG|Gemigliptin|A 7-day treatment period with gemigliptin 50 mg q.d., followed by a 5-day washout period; a 7 day treatment period with metformin 1000 mg twice a day followed by a 5-day washout period and a final 7-day treatment period with gemigliptin 50 mg q.d. + metformin 1000 mg twice a day
224317480|NCT03310749|DRUG|Gemigliptin 50 mg q.d. + metformin 1000 mg twice a day|A 7-day treatment period with gemigliptin 50 mg q.d. + metformin 1000 mg twice a day followed by a 5-day washout period; a 7-day treatment period with gemigliptin 50 mg q.d. followed by a 5-day washout period and a final 7-day treatment period with metformin 1000 mg twice a day
224317481|NCT03310749|DRUG|Metformin|A 7-day treatment period with 1000 mg metformin twice a day followed by a 5-day washout period; a 7-day treatment period with gemigliptin 50 mg q.d.+ metformin 1000 mg twice a day followed by a 5-day washout period and a final 7-day treatment period with gemigliptin 50 mg q.d.
224317482|NCT03667638|COMBINATION_PRODUCT|Platelet-Rich Plasma|Adding PRP to wound bed during surgical debridement
224217565|NCT00566215|PROCEDURE|Duodenal exclusion without omentectomy|Under open laparotomy, a duodenum section 2cm below the pylorus and a jejunum section below Treitz's Angle to create a excluded biliopancreatic limb of 150cm. A Roux-in-Y retrocolic anastomosis of the alimentary limb promotes the gastrojejunal continuity and the anastomosis of the excluded biliopancreatic limb is done 100cm below the jejunal-pyloric union.
224317483|NCT04530955|DEVICE|Prometra II Programmable Pump - Flowonix Medical|The valve gated Prometra II Programmable Pump will be replacing the prior peristaltic Synchromed II pump and a 20% dose decrease will be performed at the time of the replacement.
224317484|NCT02340481|DRUG|Loperamide hydrochloride + simethicone chewable tablet|Each tablet contains 2 milligram (mg) of loperamide hydrochloride and 125 mg of simethicone.
224317485|NCT02340481|DRUG|Loperamide hydrochloride|Each capsule contains 2 mg of loperamide hydrochloride
224317486|NCT02340481|DRUG|Loperamide hydrochloride + simethicone chewable placebo tablet|Placebo matched to loperamide hydrochloride and simethicone chewable tablet.
224317487|NCT02340481|DRUG|Loperamide hydrochloride placebo capsule|Placebo matched to loperamide hydrochloride capsule.
224317488|NCT04187755|DRUG|Ceftazidime Injection|Ceftazidime was administered intravenously with usual standard dose for serious infection (50 mg/kgBW/dose, 6 hourly)
223628754|NCT03009058|DRUG|Capecitabine|Standard of Care chemotherapy
223628755|NCT03009058|DRUG|Folinic Acid|Standard of Care chemotherapy
223628756|NCT03009058|DRUG|Fluorouracil|Standard of Care chemotherapy
224217566|NCT05385796|OTHER|Loop taping|The participant lays prone on the treatment table with his/her feet dangling off the table. The physiotherapist cleans the heel with alcohol wipes. Care is taken to avoid erasing skin markings for respective algometer and ultrasound assessment by these wipes. The therapist applies 1-inch-width Elastikon tape around the heel, encircling and bunching the fat pad to centralize it and enhance its fullness and resilience to compression. The tape starts at the middle distal end of the fat pad and loop around the periphery and ends by crossing the starting point at the middle distal end of the fat pad. Two to three overlapping loops will be applied to ensure strong support during weight-bearing activities. Participants will be instructed to wear the loop taping for 3 days and remove the taping after responding to an online survey 3-days post intervention.
224217567|NCT05385796|OTHER|Control taping|The participant lays prone on the treatment table with his/her feet dangling off the table. The physiotherapist cleans the heel with alcohol wipes. The therapist applies 1-inch-width Elastikon tape around the heel, lightly encircling the heel fat pad without any force/pressure or attempt to bunch or centralize the fat pad. The tape starts at the middle distal end of the fat pad and loop around the periphery and ends by crossing the starting point at the middle distal end of the fat pad. Two to three overlapping loops will be applied. Participants will be instructed to wear the control taping for 3 days and remove the taping after responding to an online survey 3-days post intervention.
224217568|NCT00097084|DRUG|insulin detemir|
224217569|NCT00097084|DRUG|insulin glargine|
224217570|NCT00097084|DRUG|insulin aspart|
224217571|NCT03849170|BEHAVIORAL|Stress Inoculation Technique|Teaches athletes to use cognitive-behavioral techniques to reduce their stress response during sporting events.
224217572|NCT03849170|OTHER|Health Intervention|Will provide basic dietary and lifestyle guidelines that athletes should follow in their daily lives to maintain their health
224217573|NCT02803645|BIOLOGICAL|blood sample|
224217574|NCT00904501|PROCEDURE|Bone marrow harvest|Implantation of placebo
224217575|NCT00904501|PROCEDURE|Bone marrow harvest|Implantation of bone marrow - mononuclear cells
224217576|NCT02954120|OTHER|no intervention provided|
224217577|NCT02736526|PROCEDURE|recession or resection of the horizontal extraocular muscles|
224217578|NCT04295044|DIETARY_SUPPLEMENT|high protein diet|receive 1.8g protein/kg
224217579|NCT04295044|DIETARY_SUPPLEMENT|normal protein diet|receive 1g protein/kg
224217580|NCT04643782|DEVICE|ANNE Sleep|ANNE sleep system
224217581|NCT03690726|DEVICE|repetitive transcranial magnetic stimulation|Repetitive transcranial magnetic stimulation of the leg motor cortex, in combination with resistance training
224217582|NCT03690726|OTHER|Sham stimulation|Imitated magnetic stimulation: An active coil will be activated under the subject's head, firing down into the mattress, while an inactive coil will be held over the scalp
224217583|NCT04888741|DRUG|Thymoglobulin|GVHD prophylaxis
224217584|NCT04888741|DRUG|Cyclophosphamide|Post transplant cyclophosphamide strategy for GVHD prophylaxis
224217585|NCT04888741|DRUG|Cyclosporine|immunosuppressant
224217586|NCT04888741|DRUG|Sirolimus|immunosuppressant
224217587|NCT04888741|DRUG|Mycophenolate Mofetil|immunosuppressant
224217588|NCT00206219|DRUG|Gefitinib|
224217589|NCT00206219|DRUG|methotrexate|
224217590|NCT00324090|BEHAVIORAL|High and low glycemic index|
223628757|NCT03009058|DRUG|Irinotecan|Standard of Care chemotherapy
223628758|NCT03009058|DRUG|Oxaliplatin|Standard of Care chemotherapy
223628759|NCT03009058|BIOLOGICAL|cetuximab|Standard of Care immunotherapy
223628760|NCT03009058|BIOLOGICAL|Anti-PD1|Standard of Care immunotherapy
224217591|NCT03390634|OTHER|Gastroesophageal reflux symptoms questionnaires|Reflux Disease Questionnaire (RDQ) Reflux Symptoms Index (RSI) Gastroesophageal Reflux Disease Health-Related Quality of Life (GORD-HRQL)
224217592|NCT04407468|PROCEDURE|Prone position|Position of the patient in which he is face down, for an improvement in oxygenation
224217593|NCT03768609|DRUG|Pimodivir|Participants will be administered pimodivir 600 mg orally as two tablets of 300 mg each.
224217594|NCT03768609|DRUG|Cyclosporine|Participants will be administered cyclosporine 400 mg orally as 4 capsules of 100 mg each.
224217595|NCT02495870|OTHER|Pork|
224217596|NCT00120068|BEHAVIORAL|Nursing inservices|
224217597|NCT00120068|PROCEDURE|Academic detailing to MDs; concurrent review and feedback|
224217598|NCT06070168|OTHER|Telephone Counseling|"Mothers in labor after normal birth at the postpartum clinic At least 6 hours later and for cesarean births, the researcher will visit the patient after 12 hours.~Mothers will be interviewed according to the inclusion criteria and exclusion criteria, and will be informed about the study.~will be given and their consent will be taken, the mother information form and the Edinburgh Postpartum Depression Scale (EPDS) form will be filled in, a pre-test will be done and the communication will be completed.~will get their numbers. The researcher will contact the experimental group by phone. He will introduce himself and 6 weeks (during postpartum) It will provide the mother with the consultancy service she needs about herself and the newborn 24 hours a day. After 6 weeks, the training will end and the third researcher will make post-tests of the depression scale to both groups without knowing the experimental and control groups."
224217599|NCT01989195|DRUG|'SEEMORE' - MANGANESE-ENHANCED MRI CONTRAST REAGENT|"EACH SUBJECT UNDERWENT 2 CARDIAC MRI PROCEDURES: ONE WITH MAGNEVIST (GADOLINIUM), ONE WITH SEEMORE (MANGANESE) REAGENT~* CARDIAC MRI USING STANDARD DOSE OF 0.2mMOL/KG MAGNEVIST IV (IN THE VEIN)~* CARDIAC MRI USING SEEMORE REAGENT, DOSE: 0.35CC/KG IV (IN THE VEIN) 1 WEEK AFTER GADOLINIUM MRI"
224217600|NCT04009954|OTHER|Fecal and blood samples collection for analysis|"Fecal sample analysis will consist of the following procedure : Microbial DNA extraction, amplicon library construction, sequencing and analysis; Clustering MiSeq reads into operational taxonomic units (OTUs)."
224217601|NCT02491619|PROCEDURE|orthodontic decompensation|Evaluation of the correlation between bone thickness and tooth inclination previously and after orthodontic treatment of decompensation due to orthognathic surgery
224217602|NCT04499235|DRUG|Mometasone furoate|Topical mometasone furoate
224217603|NCT04499235|DRUG|AKST4290|Oral AKST4290
224217604|NCT04499235|DRUG|Placebo|Oral placebo
224217605|NCT03882216|PROCEDURE|soft tissue augmentation using pouch technique|crestal incision with split thickness flap without vertical releasing incision till the mucogingival line then apply the harvested connective tissue graft through it.
223628761|NCT03009058|BIOLOGICAL|Ipilimumab|Standard of Care immunotherapy
223628762|NCT03009058|DRUG|Cyclophosphamide|Standard of Care chemotherapy
224217606|NCT03882216|PROCEDURE|soft tissue augmentation using modified pouch technique|tunneling will be done at the pontic site till the mucogingival line then a distant vertical incision near the tunnel at the lining mucosa where the harvested connective tissue graft wll be applied .
223628763|NCT03401775|OTHER|Cognitive rehabilitation program|Cognitive rehabilitation programs have been developed to improve the cognitive functions of the elderly or patients with cognitive impairments. The program includes sub-categories such as attention, working memory, memory and executive functions with various levels of difficulty.
223628764|NCT06132451|OTHER|Postponement of antihypertensive treatment|Hypertensive blood pressure values in medical in-patients will not be treated during hospitalisation until confirmed by ABPM 4 weeks after hospital discharge
223628765|NCT02936817|DEVICE|Aerobika® Device|For a period of 15 +/- 3 days subjects will use the Aerobika® device before administration of their stable standard of care treatment regimen (i.e. study patients should use the device before each inhalation medication administration, with a minimum use of the device of twice daily).
223628766|NCT02936817|RADIATION|HRCT scans|A HRCT scan at Functional Residual Capacity (FRC) and Total Lung Capacity (TLC) will be taken on visit 1, and visit 3. An upper airway (UA) scan will be taken on visit 1.
223628767|NCT02956694|BEHAVIORAL|Professional e-learning program on shared decision making|Clinicians will have access to a, e-learning program on shared decision making (e-TUDE) during one month. They will also receive five Decision Boxes (DB) dealing with difficult decisions often faced by seniors with dementia and their caregivers in primary care. They will receive five DBs by email, at a rate of 1 per week for 5 weeks.
223628768|NCT06253832|PROCEDURE|conservative surgery for placenta accreta spectrum|The surgical procedure involved a midline incision for the laparotomy approach. Dissection of the uterus from the posterior bladder wall extended down to the cervix, with coagulation of the vesicouterine vessels. Hysterotomy was executed in the upper segment, just above the area of myometrial invasion. Hemostasis of the lower uterus was achieved through either square compression sutures or ligation of the colpouterine vessels. A conservative approach to uterine surgery was considered viable only under conditions of stable hemodynamics and when at least 2 cm of healthy myometrium was visibly intact above the cervix. For cases involving conservative resection, all myometrium affected by invasion and the entire placenta were excised. Subsequently, the uterus was reconstructed using a continuous stitching technique.
223628769|NCT06253832|PROCEDURE|hysterectomy|hysterectomy for placenta accreta spectrum
223628770|NCT06253832|PROCEDURE|hysterectomy|hysterectomy for placenta accreta spectrum
223628771|NCT06399666|OTHER|Blood sampling|Blood sampling
223628772|NCT05254626|DRUG|Dapagliflozin 10Mg Tab|Dapagliflozin 10 mg, administered orally and to be prescribed for diabetic and non-diabetic patients with NASH for 24 weeks; in comparison to pioglitazone.
223628773|NCT05254626|DRUG|Pioglitazone 30 mg|Pioglitazone 30 mg, administered orally and to be prescribed for diabetic and non-diabetic patients with NASH for 24 weeks; as an active control and standard of care treatment.
223628774|NCT04990258|DRUG|Subcutaneous infliximab CT-P13 Remsima®SC|Patients will be switched from IV infliximab into subcutaneous infliximab Remsima®SC 120 mg.
223628775|NCT05556265|DRUG|Deucravacitinib|Specified dose on specified days
224217607|NCT04397250|BEHAVIORAL|High-intensity interval training|Arm-cranking exercise
224217608|NCT03262545|DRUG|apatinib|Patients in experimental group will take 500mg apatinib daily orally，and patients in control group will take placebo
224217609|NCT03262545|DRUG|Placebos|Physical properties of placebos are consistent with apatinib
224217610|NCT05627908|OTHER|Contrast-enhanced ultrasound|Patients data monitoring with medium- and high-grade trauma to the liver, spleen, and kidney
224217611|NCT02537067|DRUG|CHONDRON|"1. Harvesting of ankle or knee cartilage~2. The cells that fill the vial are sufficiently suspended, and a sufficient amount of suspension is grafted in the defect with fibrin glue."
224217612|NCT01565382|DRUG|florbetapir F 18|IV injection, 370MBq (10mCi), single dose (intervention for Study A05 participants, source of scans for this study)
224217613|NCT04703530|OTHER|hot footbath|The experimental group was given a hot footbath with a temperature of 41℃±1℃ for 20 minutes at about 1-2 hours before sleep
224217614|NCT01559818|BIOLOGICAL|IMM-101|IMM-101 10mg/mL, a suspension of heat-killed whole cell M. obuense in borate-buffered saline.
223628776|NCT05556265|OTHER|Placebo|Placebo was administered.
223628777|NCT02798393|OTHER|Infrared Phototherapy|Subjects will wear a cuff on their extremities for a set period of time at set intervals over a period of several weeks. The cuff will emit the Infrared Phototherapy treatment (or sham if randomized to the non-treat group).
223628778|NCT02798393|OTHER|Sham|
223628779|NCT05219695|PROCEDURE|Harmonic motion imaging guided focused ultrasound (HMIgFUS)|"Harmonic motion imaging guided focused ultrasound (HMIgFUS) is a combined treatment and imaging method, in which focused ultrasound (FUS) is used to thermally ablate tissue and harmonic motion imaging (HMI) is used for FUS guidance and monitoring. FUS applies high intensity focused ultrasound waves at its specified target to heat the tissue over a specified duration, causing cell death at the target area. HMI is an elasticity imaging technique which induces dynamic tissue vibrations at the target for tissue elasticity characterization.~One of the inclusion criteria for this study is that participants must be scheduled for surgical excision of their breast tumor. In this study, HMIgFUS will be applied to anesthetized participants immediately prior to their scheduled surgery. HMI imaging will also be performed immediately prior to and after HMIgFUS application."
223628780|NCT04359810|BIOLOGICAL|Convalescent Plasma (anti-SARS-CoV-2 plasma)|Convalescent Plasma that contains antibody titers against SARS-CoV-2
223764015|NCT05970224|DRUG|Ir-CPI|Participants receive a single intravenous dose of Ir-CPI during 48 hours
223764016|NCT00058825|BIOLOGICAL|Campath 1H|Day -5 to Day -2: Campath 1H dose schedule as per institutional SOP.
224217615|NCT04071626|DRUG|Ertugliflozin 5 mg|Ertugliflozin 5 mg once a day for 12 weeks
224217616|NCT04071626|DRUG|Placebo oral tablet|Placebo oral tablet once a day for 12 weeks
224217617|NCT04887974|PROCEDURE|canine retraction|Canine retraction using elastomeric chains activated every 4 weeks, using power arms to direct force through the center of resistance and TADs for direct anchorage.
224317489|NCT04187755|DRUG|Cefepime Injection|Cefepime was administered intravenously with usual standard dose for serious infection (50 mg/kgBW/dose, 8 hourly)
223764017|NCT00058825|DRUG|Fludarabine|Day -5 to Day -2: Fludarabine 30 mg/m2.
224217618|NCT05578833|DIAGNOSTIC_TEST|HPV DNA test with selective HPV 16/18 genotyping (cobas® 4800 HPV Test, Roche)|"The enrolled patients underwent standard conventional cytology plus a test for the detection of high-risk human papilomavirus (hrHPV) with selective genotype specification (HPV 16, 18 and other hrHPV) - combined screening. In defined cases of positive hrHPV, the patient underwent reflexive examination by CINtec plus technology.~After the initial combined screening the patients continued in the standard Czech screening practice (annual conventional cytology) or be treated according to the particular finding of the initial episode. For three years, the incidence of pre-cancers and invasive cervix carcinomas were monitored and data were entered into an electronic register.~The second combined screening episode followed in year 3. An evaluation of its results immediately followed."
224217619|NCT05578833|DIAGNOSTIC_TEST|p16 and Ki-67 biomarker detection in the form of dual cytological staining (CINtec Plus, Roche)|"The enrolled patients underwent standard conventional cytology plus a test for the detection of high-risk human papilomavirus (hrHPV) with selective genotype specification (HPV 16, 18 and other hrHPV) - combined screening. In defined cases of positive hrHPV, the patient underwent reflexive examination by CINtec plus technology.~After the initial combined screening the patients continued in the standard Czech screening practice (annual conventional cytology) or be treated according to the particular finding of the initial episode. For three years, the incidence of pre-cancers and invasive cervix carcinomas were monitored and data were entered into an electronic register.~The second combined screening episode followed in year 3. An evaluation of its results immediately followed."
224217620|NCT05578833|DIAGNOSTIC_TEST|standard conventional cytology PAP test|"The enrolled patients underwent standard conventional cytology plus a test for the detection of high-risk human papilomavirus (hrHPV) with selective genotype specification (HPV 16, 18 and other hrHPV) - combined screening. In defined cases of positive hrHPV, the patient underwent reflexive examination by CINtec plus technology.~After the initial combined screening the patients continued in the standard Czech screening practice (annual conventional cytology) or be treated according to the particular finding of the initial episode. For three years, the incidence of pre-cancers and invasive cervix carcinomas were monitored and data were entered into an electronic register.~The second combined screening episode followed in year 3. An evaluation of its results immediately followed."
224217621|NCT03755245|OTHER|[68Ga]Ga-DOTA-Siglec-9|Vascular Adhesion Protein 1 (VAP-1) targeted radiopharmaceutical
224217622|NCT00257088|BEHAVIORAL|whole day first grade program|
224217623|NCT05706428|DEVICE|NHFOV|The neonate patients with respiratory distress will have nasal high frequency ventilation as an initial mode of respiratory support.
224217624|NCT05706428|DEVICE|NCPAP|The neonate patients with respiratory distress will have nasal continuous positive airway pressure as an initial mode of respiratory support.
224217625|NCT00094315|DRUG|Cocaine (IV)|
224217626|NCT01588587|DRUG|Sitagliptin|The dosage, frequency and duration for each sitagliptin are variant.
224217627|NCT01588587|DRUG|Alogliptin|The dosage, frequency and duration for each alogliptin are variant.
224217628|NCT01588587|DRUG|Vildagliptin|The dosage, frequency and duration for each vildagliptin are variant.
224217629|NCT03175445|OTHER|CBCT scan by planmeca promax|software measurement tool of CBCT
224217630|NCT04632693|PROCEDURE|CAF with SCTG and Vitamin C injection|Injection of vitamin C after CAF with SCTG aiming to increase gingival thickness in patients with RT1 gingival recession.
224217631|NCT04632693|PROCEDURE|CAF with SCTG alone|Coronally advanced flap with subepithelial connective tissue graft.
224217632|NCT05436496|BIOLOGICAL|bi-4SCAR CD19/70 T cells|Infusion of bi-4SCAR CD19/70 T cells at 10\^6 cells/kg body weight via IV
224217633|NCT00373659|DRUG|Ranibizumab (Lucentis)|
224217634|NCT00902291|BIOLOGICAL|AGS-1C4D4|IV infusion
224217635|NCT00902291|BIOLOGICAL|Gemcitabine|IV infusion
224217636|NCT03673475|PROCEDURE|Assessment of fluid responsiveness|assessment of intravascular volume status using pleth variebility index and internal jugular vein distensibility in major abdominal surgery
224217637|NCT04359186|OTHER|Treatment Interruption Arm|Individuals with HIV on suppressive ART will interrupt their ART.
224217638|NCT01812291|BEHAVIORAL|Step 1: Diabetes-Specific CBT (5 group sessions)|"Diabetes-Specific CBT (5 group sessions) focusing on diabetes-related problems and distress ('DIAMOS - Strengthening Diabetes Motivation').~Includes:~* Diabetes problem analysis/ definition~* Diabetes problem solving intervention~* Cognitive restructuring of diabetes problems~* Activation of personal and social resources~* Goal definition and agreement"
224217639|NCT01812291|BEHAVIORAL|Step 2: Depression-Specific CBT (6 single sessions)|"Depression-Specific CBT (6 single sessions) focusing on depressive cognitions and affective problems (manualised).~Includes:~* Functional explanatory model of depression~* Cognitive restructuring of negative thoughts~* Practice of alternative beneficial thoughts~* Specific cognitive interventions regarding self-criticism, guilt, low self-esteem, fear, and inactivity."
224217640|NCT01812291|BEHAVIORAL|Step 3: Referral to Psychotherapist and/or Psychiatrist|Non-responders to previous treatment steps will be referred to an psychotherapist and/or psychiatrist for intensified treatment. Treatments procedures will be monitored and interventions will be scored to enable the evaluation of treatment effects.
224217641|NCT01812291|BEHAVIORAL|Standard Diabetes Education|"Standard diabetes education and professional care.~Includes:~* Health care and specific topics (e. g. blood pressure)~* Diabetes complications~* Healthy and unhealthy foods, cooking recommendations and recipes~* Foot care: exercises, care and control, injuries, and diabetic neuropathy~* Sports, activities and exercise~* Social aspects of living with diabetes"
224317490|NCT02115490|DRUG|Bisphosphonates|
224317491|NCT00408525|DRUG|donepezil|donepezil 5 mg tablets, total dose per day 10 mg for 6 week duration of study. Taken once per day.
224317492|NCT04981717|DRUG|REGN1908-1909|Subcutaneous (SC) for a total of 5 administrations
224317493|NCT04981717|DRUG|Matching Placebo|SC for a total of 5 administrations
223764018|NCT00058825|PROCEDURE|Stem Cell Transplant|Day 0: Donor stem cells infused.
223628781|NCT04359810|BIOLOGICAL|Non-convalescent Plasma (control plasma)|Non-convalescent plasma (does not contain antibody titers against SARS-CoV-2)
224217642|NCT05598645|DEVICE|Thulium Fibre Laser|Participants will undergo treatment using the TFL
224217643|NCT05598645|DEVICE|MOSES Holmium Laser|Participants will undergo treatment using the MOSES Holmium laser.
224217644|NCT06538129|PROCEDURE|Hypersensitivity prevention protocol with Er:YAG laser|1.Prophylaxis using airflow system with erythritol, potency 5, water regulator 5; 2.Initial assessment of hypersensitivity using visual analogue scale (VAS); 3.Color assessment (canines, central incisors and lateral incisors) with digital spectrophotometer (Vita Easyshade,); 4.Placement of dental dam followed by photoactivation with Valo cordless curing light 5.Hypersensitivity prevention protocol with Er:YAG laser in cervical region (central incisor, lateral incisor and canine); 6.Application of whitening gel (1 mm in thickness) with 35% hydrogen peroxide on maxillary arch (Clareador Whiteness HP; FGM), left to react for 15 minutes; 7.Removal of whitening gel; 8.Repeat procedures (steps 7 and 8); 9.Assessment of hypersensitivity immediately after hypersensitivity prevention procedure, immediately after bleaching, 48 after bleaching and one week after bleaching; 10.Color assessment with digital immediately after bleaching, 48 after bleaching and one week after bleaching.
224217645|NCT06538129|PROCEDURE|Hypersensitivity prevention protocol with neutral sodium fluoride gel|1.Prophylaxis using airflow system with erythritol, potency 5, water regulator 5; 2.Initial assessment of hypersensitivity using the VAS; 3.Color assessment (canines, central incisors and lateral incisors) with digital spectrophotometer (Vita Easyshade); 4.Placement of dental dam followed by photoactivation with Valo cordless; 5.Hypersensitivity prevention protocol with neutral sodium fluoride gel for 4 minutes (central incisor, lateral incisor and canine); 6.Application of whitening gel (1 mm in thickness) with 35% hydrogen peroxide on maxillary arch (Clareador Whiteness HP; FGM), left to react for 15 minutes; 7.Removal of whitening gel; 8.Repeat procedures (steps 7 and 8); 9.Assessment of hypersensitivity immediately after hypersensitivity prevention procedure, immediately after bleaching, 48 after bleaching and one week after bleaching; 10.Color assessment with digital spectrophotometer immediately after bleaching, 48 after bleaching and one week after bleaching.
224217646|NCT04307225|DEVICE|Zenicor|Handheld Thumb ECG monitoring device
224217647|NCT01203319|BIOLOGICAL|60mcg/1.0ml recombinant hepatitis B vaccine|to receive 60mcg/1.0ml recombinant HBV vaccines on day 0, 30 and 60
224217648|NCT01203319|BIOLOGICAL|30mcg/1.0ml recombinant hepatitis B vaccine|to receive 30mcg/1.0ml recombinant hepatitis B vaccines on day 0, 30 and 60.
224217649|NCT01203319|BIOLOGICAL|10mcg/1.0ml recombinant hepatitis B vaccine|to receive 10mcg/1.0ml recombinant hepatitis B vaccines on day 0, 30 and 60
224217650|NCT03539731|DRUG|Fluorine F 18 DASA-23|Given IV
224217651|NCT03539731|PROCEDURE|Positron Emission Tomography|Undergo PET scan
224217652|NCT02038400|DEVICE|KINETUBE medical Device|
224217653|NCT02038400|DEVICE|insertion of tympanic ventilation tubes (tympanostomy)|
224217654|NCT04130945|OTHER|erector spina plane block, cost analysis|in preopererative period, ESP block is going to utilise for postoperative analgesia for patients who undergo laparoscopic procedure and cost analysis will make after the end of 24 hour of operation
224217655|NCT02084979|BEHAVIORAL|telepsychiatry evaluation|telepsychiatry evaluation and consultation to primary care
224217656|NCT01354600|OTHER|Exercise or Sedentary|Daily cycling exercise at 50% maximal aerobic fitness for a total of \~120 minutes/day or no daily exercise (sedentary)
224217657|NCT03306784|OTHER|questionnaires|questionnaires, including RAPID3 and pain catastrophizing scales
224317494|NCT01519310|OTHER|Antibiotic (metronidazole and ciprofloxacin)/probiotic|"Antibiotic cocktail/yogurt as follows:~Group 1: antibiotics for 1 week, followed by probiotics for 3 weeks; Group 2: antibiotics for 1 week, followed by no probiotics for 3 weeks. Group 3: no antibiotics for 1 week, followed by probiotics for 3 weeks."
224317495|NCT04686955|DRUG|Xiao-Xian-Gui-Fu-Tang|The Xiao-Xian-Gui-Fu-Tang includes Xiao-Feng-San 2.0g, Dang-Gui-Yin-Zi 1.2g, Bai-Xian-Pi(Cortex Dictamni Radicis) 0.4g, and Di-Fu-Zi(Fructus Kochiae) 0.5g. The Xiao-Xian-Gui-Fu-Tang will be manufactured, packaged, and labeled by the KO DA Pharmaceutical Company (Taiwan), using good manufacturing practice standards.
223628782|NCT03479229|DEVICE|Geneveve Treatment|The active treatment group will receive a treatment dose of 90 J/cm\^2
223628783|NCT03479229|DEVICE|Sham Treatment|The sham group will receive a sub-therapeutic dose of ≤ 1 J/cm\^2.
223628784|NCT03240887|BEHAVIORAL|Peer Group Connection|Faculty advisors at each participating high school are trained to run the program and teach a daily leadership course to peer leaders. Eleventh and twelfth-grade peer leaders who participate in the daily leadership development class facilitate outreach sessions with their assigned group of ninth graders. PGC can be offered in either a half-year (semester) or full-year format. In either format, a minimum of 18, 45-minute outreach sessions are expected to be offered to PGC participants during the course of their ninth-grade year. Outreaches are created to facilitate the transition to high school and encourage students to attend school, set goals for themselves, and make healthy decisions.
223628785|NCT01486966|DRUG|insulin detemir|Dose individually adjusted. Administered subcutaneously/s.c. (under the skin) once daily using NovoPen®4
223628786|NCT01486966|DRUG|insulin aspart|Dose individually adjusted. Administered subcutaneously/s.c. (under the skin) three times a day before a meal using NovoPen®4
224217658|NCT04261517|DRUG|Hydroxychloroquine|Subjects take hydroxychloroquine 400 mg per day for 5 days, also take conventional treatments
224317496|NCT05050812|DEVICE|grounding mat|Participants will sleep on an Earthing Elite sleep mat produced and sold by Earthing.com
224317497|NCT02207634|BIOLOGICAL|Evolocumab|Administered subcutaneously using a spring-based prefilled 1.0 mL autoinjector/pen.
224317498|NCT02207634|DRUG|Placebo|Administered subcutaneously using a spring-based prefilled 1.0 mL autoinjector/pen.
223628787|NCT01486966|DRUG|insulin NPH|Dose individually adjusted. Administered subcutaneously/s.c. (under the skin) once daily using NovoPen®4
223628788|NCT01486966|DRUG|human soluble insulin|Dose individually adjusted. Administered subcutaneously/s.c. (under the skin) three times a day before a meal using NovoPen®4
223628789|NCT01486966|DRUG|metformin|For subjects previously treated with metformin, the dosage and frequency will be kept unchanged
223628790|NCT05737914|PROCEDURE|Endoscopic thoracic T3 sympathectomy|Interruption of intrathoracic sympathetic neural pathway surgically to treat hyperhidrosis by using video - thoracoscopy
224317499|NCT02207634|DRUG|Background Statin Therapy|Participants were required to be on a stable, high- to moderate-intensity statin background therapy consisting of an effective statin dose, ie, at least atorvastatin 20 mg daily or equivalent, and where locally approved, highly effective statin therapy (defined as at least atorvastatin 40 mg daily or equivalent) was recommended.
224317500|NCT03275142|DEVICE|Icare tonometer|Icare tonometry effects of keratometry readings, topography, and corneal staining to demonstrate that the Icare tonometer does not alter subsequent evaluation or testing. This would allow IOP testing to be performed by technical staff at any time during the examination process without affecting subsequent tests. A total of fifteen patients at each of four sites will be evaluated using Icare tonometers provided by Icare USA. The investigator will be masked as to which eye will undergo Icare tonometry. Both the study eye and the control eye will undergo pre-tonometry and post-tonometry testing; Keratometry readings, IOL master, Topography via Pentacam, and corneal staining with fluorescein using the Oxford scoring scale.
224317501|NCT00038025|DRUG|Deoxycoformycin (DCF)|Patients received Deoxycoformycin (DCF)/Pentostatin administered by intravenous bolus daily over a consecutive 3-day period. This course was repeated at 3-week intervals.
224317502|NCT00563329|PROCEDURE|Reduction Intervention + Adherence Intervention|
224317503|NCT00563329|BEHAVIORAL|Reduction Intervention|
223628791|NCT05737914|PROCEDURE|ThoracicT3 radiofrequency ablation|radiofrequency ablation at third thoracic spine it may be a good option for treatment of primary hyperhidrosis.
223628792|NCT06593964|DEVICE|Thermosensitive Nanogel Embolic Agent|Thermosensitive Nanogel Embolic Agent
224217659|NCT01992770|BEHAVIORAL|Hierarchical graded exposure|"Individual Behavioural goal identification, depending on risk profile~(1a). Catastrophising and/or fear-avoidance (2); hierarchical graded exposure, organized with individual coaching in connection to the physical training sessions, based on activities that each participant fear and/or avoid."
224217660|NCT01992770|BEHAVIORAL|Graded activity|"Individual Behavioural goal identification, depending on risk profile~(1b) Graded activity;(2) self-monitoring of everyday life activities (3) functional behavioural analyses to describe, predict, and verify factors controlling patient's current and future activity performance (4) training of motor skills, cognitive skills, and strategies to organise everyday life including social support. (5) gradual application of acquired skills in everyday life situations as formulated by Specific, Measureable, Activity-related, Realistic, and Time- specified (SMART) goal setting (6) generalisation of skills to additional activities and challenging situations, and (7) strategies for maintenance and relapse prevention."
224217661|NCT01992770|BEHAVIORAL|Physical exercises|Participants will be scheduled for supervised, regular physical training twice a week during eight weeks 8
224217662|NCT03855124|DEVICE|Posture shirt|Posture shirts are designed, and marketed to the general public and health service providers to improve posture and consequently alter muscle actitity, reduce musculoskeletal pain and discomfort.
224217663|NCT04123483|DRUG|EnBrace HR Softgel|Prescription folate prenatal supplement with other dietary ingredients; one multiphasic soft gelatin capsule 1x/day for 8 week study
224217664|NCT02828228|DRUG|Vitamin D 1200 IU|Vitamin D 1200 IU once a day for 26 weeks
224217665|NCT02828228|DRUG|Placebo|placebo once a day for 26 weeks
224217666|NCT01733719|PROCEDURE|ER plus RFA|
224217667|NCT01733719|PROCEDURE|ER plus APC|2 litres/minute, 70 watts
224217668|NCT06338683|DRUG|Olanzapine 2.5 MG|Oral olanzapine 2.5 mg once daily at bedtime until disease progression
224217669|NCT06338683|DRUG|Standard anti-tumor treatment|Clinicians choose the appropriate standard antitumor drug therapy based on the patient's specific situation
224217670|NCT06338683|DIETARY_SUPPLEMENT|Nutritional advice|All patients enrolled in the study were required to undergo a nutritional assessment and were provided with nutritional advice based on their condition
224217671|NCT00721461|BIOLOGICAL|V930|Intramuscular injection of phosphate buffered saline solution will be given and within 2 - 5 minutes will be followed by an electrostimulation pulse with the MedPulser DDS in the deltoid muscle of the right arm. 15 days later, the same procedure will take place using the left arm.
224217672|NCT02232269|OTHER|Black Coffee|
224317504|NCT00563329|PROCEDURE|control|
223628793|NCT06600295|OTHER|tests/questionnaires|EVA, LFPQ-fr, Taste strips, ETOC 6-items, CiTAS, Fr-sQOD, WHOQOL-Bref, HADS
223628794|NCT06600295|BIOLOGICAL|biological samples|blood, saliva, tongue mucus
224217673|NCT02232269|OTHER|Grapefruit Juice|
224217674|NCT02232269|OTHER|Water|
224217675|NCT02232269|DRUG|Felodipine|
224217676|NCT06419673|DRUG|Serplulimab|Serplulimab will be administered by intravenous infusion at a dose of 300mg on Day 1 of each 21-day cycle until unacceptable toxicity or loss of clinical benefit as determined by the investigator.
224217677|NCT06419673|DRUG|Cisplatin|IV infusion
223628795|NCT06600295|OTHER|evaluation|strength tests using handgrip tests, chair lifts or walking speed and sarcopenia tests for the over-70s
223628796|NCT06599827|RADIATION|moderately hypofractionated radiotherapy|35 Gy in 10 fractions to mesorectal and metastatic lymph nodes, and 30 Gy in 10 fractions to pelvic lymphatic drainage area, weekly over 5 days at 3-3.5 Gy/day.
224217678|NCT06419673|DRUG|Carboplatin|IV infusion
224217679|NCT06419673|RADIATION|Brachytherapy and External Beam Radiotherapy|Brachytherapy and External Beam Radiotherapy
224217680|NCT00293475|DRUG|Carboplatin|Given IA
224217681|NCT00293475|DRUG|Mannitol|Given IA
224217682|NCT00293475|DRUG|Methotrexate|Given IA
224217683|NCT00293475|OTHER|Quality-of-Life Assessment|Ancillary studies
224217684|NCT00293475|BIOLOGICAL|Rituximab|Given IV
224217685|NCT00293475|DRUG|Sodium Thiosulfate|Given IV
224217686|NCT02969733|DRUG|Xylocaine|Xylocaine is administered at a dose of 1.5 mg / kg for induction and then relay by syringe pump at a dose of 1.33 mg / kg / hour will be administered throughout the duration of the intervention and for 24 hours after the end of thereof, to obtain deemed effective plasma concentrations of the order of 0.5 to 5 mcg / mL.
224217687|NCT02969733|DRUG|Ketamine|Ketamine will be administered at a dose of 0.5 mg / kg and then relay by syringe pump at a dose of 0.05 mg / kg / hour for the duration of surgery and 24 hours after the end thereof.
224217688|NCT02969733|DRUG|isotonic saline serum intravenous administration|
224217689|NCT01963676|DEVICE|tDCS|
224217690|NCT01963676|DEVICE|Sham stimulation|
223628797|NCT06599827|DRUG|chemotherapy|CapeOx-Capecitabine 1000 mg/m² orally twice daily (days 1-14, every 21 days) + Oxaliplatin 130 mg/m² IV (day 1, every 21 days).
223628798|NCT06599827|DRUG|immunotherapy|Serplulimab 300 mg IV infusion on day 1 every 21 days.
223628799|NCT06599827|PROCEDURE|Total mesorectal excision (TME) surgery|Total mesorectal excision (TME) surgery assessment post 3 cycles of chemotherapy and immunotherapy; eligible patients undergo TME surgery.
223628800|NCT06592092|BIOLOGICAL|QH104 Cell injection|Patients will first be pre-screened for B7H3 expression of tumor and exist Meningeal Metastases.
223628801|NCT06603649|OTHER|ECPR for out-of-hospital cardiac arrest|Patient with out-of-hospital cardiac arrest enrolled in the ECPR protocol
223628802|NCT06589947|OTHER|Intensified BP control|Treatment goal in the intensified group will be lowering BP ≤60th pct.
223628803|NCT06589947|OTHER|Standard Treatment|Standard treatment is to achieve BP levels \&lt;90th pct.
223628804|NCT06600477|DRUG|olanzapine|7.5 mg
223628805|NCT06597045|DIAGNOSTIC_TEST|PET/CT with 18-FDG|"Study specific tests will include 18F-FDG PET/CT (specialised CT scan), electrocardiography (ECG), clinic blood pressure assessment, blood tests, urine sample, echocardiography (heart ultrasound) and tests on the fingertips (EndoPAT).~Positron emission tomography with computerised tomography (PET-CT) is a scanning technique in routine clinical use. It is the gold standard method for assessing blood vessel inflammation. A small amount of radioactive sugar (18F-FDG \[18F- fluorodeoxyglucose\]) is administered intravenously 90 minutes prior to the PET-CT scan. The distribution of uptake of this tracer is seen on the subsequent PET-CT scan. The CT component of this scan allows the PET image to be precisely aligned with anatomical structures (especially large blood vessels)."
223628806|NCT06592690|OTHER|Atrial pacing support|Use a pacing mode with atrial pacing including a rate-resposive sensor.
223628807|NCT06592690|OTHER|Atrial tracking pacing mode|A pacing mode which allows sensing of intrinsic sinus rhythm as much as possible to avoid unnecessary atrial pacing is the preferred programming in patients with CRT without atrial pacing indication. VDD pacing mode met these criteria.
223628808|NCT06603467|PROCEDURE|non-guided de-epithelialized free gingival graft harvested|gingival recession will be covered with de-epithelialized free gingival graft harvested without guide
223628809|NCT06603467|PROCEDURE|guided de-epithelialized free gingival graft harvested|gingival recession will be covered with de-epithelialized free gingival graft harvested with digital guide
223628810|NCT06599814|PROCEDURE|vital pulp therapy|vital pulp therapy using two bioactive materials TheraCal and RetroMTA as direct pulp caping materials conventionally and test using Diode laser before application of these materials
224217691|NCT05402631|PROCEDURE|Epidural Injection|patient receives an epidural injection due to lower back pain
224217692|NCT05402631|PROCEDURE|Periradicular Injection|patient receives a periradicular injection due to lower back pain
224217693|NCT00736931|DRUG|Brivaracetam|Brivaracetam 10 mg tablets
224217694|NCT00736931|DRUG|levetiracetam|500mg tablets
223628811|NCT06604221|BEHAVIORAL|Resistance exercise intervention|The exercise prescription, developed through expert meetings and integrated review summaries, consists of 27 items including: participant preparation, team preparation, exercise prescription FITT-VP, process monitoring, discontinuation criteria, termination criteria, recovery methods, outcome measures, and special considerations.
223628812|NCT06604221|BEHAVIORAL|Routine care|"1.Pre-dialysis Assessment:~1. Vital Signs: Monitor blood pressure, heart rate, temperature.~2. Access Care: Check the vascular access site for signs of infection and patency. 2.During Dialysis:~（1）Monitoring: Continuous vital signs and machine settings monitoring. （2）Fluid Management: Control fluid removal based on pre-dialysis weight. 3.Post-dialysis Care:~1. Observation: Monitor for complications like hypotension, cramps, or bleeding.~2. Weight Check: Weigh post-dialysis to verify fluid removal. 4.Education and Support:~（1）Diet: Educate on dietary restrictions (potassium, phosphorus, fluids). （2）Medications: Advise on medication adjustments. 5.Psychosocial Support:~（1）Provide emotional support and counseling."
223628813|NCT06586385|BEHAVIORAL|disaster education|The ADDIE Instructional Design Model will be used due to its suitability for adult education. General Disaster Awareness Training will be prepared according to the ADDIE instructional design model, which consists of five stages: analysis, design, development, implementation and evaluation. The trainings to be given will be given 1 week after the pre-test, 1 training per week, for a total of 3 trainings.
224217695|NCT00736931|DRUG|lorazepam|lorazepam 2 mg over encapsulated tablets
223628814|NCT06603415|PROCEDURE|Total thyroidectomy|Total thyroidectomy (with preservation of bilateral recurrent laryngeal nerves and all parathroid glands) for histopathology
223628815|NCT06601088|DEVICE|Neuromuscular Electrical Stimulation|Patients will be instructed to apply the wearable NMES-therapy continuously, both day and night at least 10h/daily.
224217696|NCT00736931|OTHER|placebo|placebo capsules
224217697|NCT01246973|DRUG|Curcumin|4 Curcumin C3 Complex 500mg capsules (2.0 g) taken orally 3 times/day throughout course of radiation treatments plus one week
224217698|NCT01246973|DRUG|Placebo|4 placebo capsules taken orally 3 times/day throughout course of radiation treatments plus one week
224217699|NCT00766506|DEVICE|Fentanyl IONSYS|Participants will receive 40 mcg of fentanyl dose up to a maximum of 240mcg (6 doses each of 10 minutes duration) per hour but not more than a maximum of 80 doses within a 24 hour period from an Iontophoretic Transdermal System (IONSYS).
224217700|NCT00766506|DEVICE|Morphine IV PCA|Morphine sulphate solution will be administered intravenously (IV) by a patient-controlled analgesia (PCA) pump using set bolus doses with a fixed lock out period as per physician's discretion (maximum total dose of 20 milligram per 2 hours) for 72 hours.
224217701|NCT05979051|DRUG|SHR-1703|SHR-1703 will be administered by Subcutaneous injection in Phase 2 and Phase 3.
224217702|NCT05979051|DRUG|SHR-1703 Placebo|SHR-1703 Placebo will be administered by Subcutaneous injection in Phase 3.
224217703|NCT01297192|DRUG|solifenacin succinate|Oral
224217704|NCT01297192|DRUG|mirabegron|Oral
224217705|NCT00769678|DEVICE|Stimulation of the diaphragm|Stimulation of the diaphragm using an electrode
224317505|NCT03691766|OTHER|Photobiomodulation Therapy|Photobiomodulation therapy, a mix of red lights thought to improve mitochondrial function will be applied in and acute and chronic manner to test whether muscle fatigue improves in persons with MS.
224317506|NCT03691766|OTHER|Placebo|Device with sham light source
224317507|NCT00264173|DRUG|Valproate sodium|
223628816|NCT00952991|DRUG|LAF237 = vildagliptin|
223628817|NCT06003283|DRUG|Rituximab|IV rituximab
223628818|NCT06596395|DIETARY_SUPPLEMENT|Acute caffeine and beetroot juice|Combined effect of beetroot juice and caffeine intake on muscular strength, power and endurance performance
223628819|NCT06596395|DIETARY_SUPPLEMENT|Acute caffeine|single effect of caffeine intake on muscular strength, power and endurance performance
223628820|NCT06596395|DIETARY_SUPPLEMENT|Acute beetroot juice|single effect of beetroot juice intake on muscular strength, power and endurance performance
224317508|NCT00591773|DRUG|Azilsartan medoxomil and chlorthalidone|Azilsartan medoxomil 40 mg, tablets, orally, once daily; azilsartan medoxomil 80 mg placebo-matching tablets, orally, once daily; and chlorthalidone 25 mg, tablets, orally, once daily for up to 6 weeks.
224317509|NCT00591773|DRUG|Azilsartan medoxomil and chlorthalidone|Azilsartan medoxomil 80 mg, tablets, orally, once daily; azilsartan medoxomil 40 mg placebo-matching tablets, orally, once daily and chlorthalidone 25 mg, tablets, orally, once daily for up to 6 weeks.
224317510|NCT00591773|DRUG|Chlorthalidone|Chlorthalidone 25 mg, tablets, orally, once daily; azilsartan medoxomil 80 mg placebo-matching tablets, orally, once daily and azilsartan medoxomil 40 mg placebo-matching tablets, orally, once daily for up to 6 weeks.
223628821|NCT06596395|DIETARY_SUPPLEMENT|Placebo|single effect of placebo on muscular strength, power and endurance performance
223628822|NCT06990529|DRUG|Leniolisib|All subjects will receive leniolisib film-coated tablets (FCTs) at the same dose they were receiving when they completed the preceding study (10, 30, or 70 mg twice daily \[BID\]).
223628823|NCT06998472|OTHER|Tuina|According to traditional Chinese medicine (TCM), children's physiological characteristics include immature and delicate internal organs, as well as underdeveloped qi and physical form. Pathologically, their organ systems are described as light and responsive, meaning they react quickly to both internal and external stimuli. Therefore, pediatric tuina must prioritize gentleness in technique. The applied pressure should not exceed 0.3 kilograms, and the depth of skin indentation should not go beyond 0.3 centimeters.
223628824|NCT06998472|OTHER|Maintain the original treatment approach|Maintain the original treatment approach
223628825|NCT06998368|DRUG|Nimodipine Capsules|Two times 30 mg nimodipine or placebo will be administered orally 45 minutes prior to the start of the 5G FR1 exposure. The verum and placebo capsules will look the same, in order to preserve the double-blinding.
223628826|NCT06998368|RADIATION|5G RF-EMF|Participants will be exposed to a standardized electromagnetic field of the latest mobile radio standard (5G) or a sham field for 30 minutes on each of the experimental nights. The active field is characterized by 3.6 GHz frequency \[TDD\] with 100 MHz bandwidth, 12-14 Hz modulation and is comparable to a phone call with a commercially available, modern cell phone. Both the 5G and sham exposures are performed with the same exposure apparatus, according to a double-blind study design.
224317511|NCT03579108|OTHER|Retrospective Chart Review|Chart review
224317512|NCT05439681|DEVICE|Theranova 400|medium cut off (MCO) membrane
224317513|NCT05439681|DEVICE|FX 10|low-flux membrane
223628827|NCT03755921|OTHER|bried and intensive therapy|Speech Therapy Exercises
223628828|NCT06999135|DRUG|Silodosin|Silodosin is an oral medication primarily used to treat benign prostatic hyperplasia (BPH) by relaxing the muscles in the prostate and bladder neck to improve urine flow. It belongs to a class of drugs called alpha-1 adrenergic antagonists, which block receptors responsible for muscle contraction in these areas. This action helps relieve symptoms such as difficulty urinating, urgency, and weak urine stream. Silodosin is taken once daily with food and is known for its high selectivity for alpha-1A receptors, contributing to its effectiveness and safety profile
223628829|NCT05376384|DIAGNOSTIC_TEST|ultrasound parameters|Annotation of ultrasonographic features of ovarian cyst. The parts examined are size, laterality, content, margins, and color score.
223628830|NCT05376384|PROCEDURE|intraoperative parameters|Annotation of intraoperative features of ovarian cyst. The characteristics under review are: surgeon experience, previous surgery, adhesions, and uterine manipulator use
223628831|NCT06932848|DRUG|Curcumin in Nanogels|Participants will apply curcumin nanogels to affected oral areas three times daily for 4 weeks.
223628832|NCT06932848|DRUG|0.1% Fluocinolone Acetonide Oral Paste|Participants will apply 0.1% fluocinolone acetonide oral paste to the affected oral mucosa three times daily for 4 weeks. This corticosteroid paste is the standard treatment for oral lichen planus.
223628833|NCT06937723|OTHER|Device: Smartwatch (Withings Scanwatch)|All-day monitoring of patients via smartwatch
223680784|NCT02920853|BEHAVIORAL|Biofeedback Training (BT-CPR)|Participants will receive biofeedback training (which will include electric stimulations) to reduce arousal and pain
223680785|NCT02920853|BEHAVIORAL|Biofeedback Training|Participants will receive biofeedback training to reduce arousal and pain
223680786|NCT06324916|RADIATION|Xray|X rays for ankle to see distal fibular remenant
223680787|NCT05818111|DRUG|steroid|triamcinolone 40mg 4cc
223680788|NCT05818111|DRUG|Xylocaine 2 % Injectable Solution|xylocaine 2% 4cc
223680789|NCT05818111|DRUG|Normal saline 2cc|normal saline 2cc
223680790|NCT05818111|DRUG|normal saline 12cc|normal saline 12cc
223680791|NCT02399436|BEHAVIORAL|School-Based Healthy Snacking Campaign|"The school-based healthy snacking campaign includes the following activities:~* Sales promotion of snack choices that meet federal Smart Snack guidelines during the school day and at school events, such as snack bars and after-school events;~* The installation of new filtered water fountains outfitted with water-filling stations;~* The distribution of re-usable water bottles to students at participating schools; and~* A social marketing campaign to support adoption of the healthy snacks and water consumption by students."
223680792|NCT02399436|BEHAVIORAL|Community Cooking Classes|Cooking classes will be delivered to groups of 8-12 adult participants as a series of 8 weekly classes in community venues. The content of each class is driven by topics and themes identified and prioritized by community members, namely cooking healthy on tight budget.
223680793|NCT04308798|PROCEDURE|Surgical glove changing|Changing surgical glove after draping and before cementation during total knee arthroplasty
223680794|NCT06214494|OTHER|Blood Flow Restricted High Intensity Treadmill Training|Blood Flow Restricted High Intensity Treadmill Training at 70% limb occlusion (on hemiparetic limb only) 2x weekly for 16 Sessions totaling minimum of 75 minutes weekly.
223680795|NCT06214494|OTHER|HITT|High Intensity Treadmill Training 2x weekly for 16 Sessions totaling minimum of 75minutes weekly.
223628834|NCT06939127|DRUG|Neoadjuvant Cryoablation Combined with Tislelizumab and Chemotherapy|"Eligible patients will start the study treatment (7-14 days between pathological diagnosis and cryoablation). Patients first undergo cryoablation of the primary tumor. Then, 7±3 days after cryoablation, they start treatment with tislelizumab (200 mg) plus platinum-based doublet chemotherapy, given every 3 weeks for 3-4 cycles.~The following platinum-based doublet chemotherapy regimens are allowed in this trial:~* Cisplatin/carboplatin + pemetrexed (non-squamous NSCLC)~* Cisplatin/carboplatin + albumin-bound paclitaxel/paclitaxel (squamous NSCLC)"
223628835|NCT06939127|PROCEDURE|Surgery|After completing neoadjuvant therapy, surgery should be performed as soon as possible within 4-6 weeks after the last dose of neoadjuvant therapy.
223628836|NCT06939127|DRUG|Adjuvant tislelizumab|"Patients receiving adjuvant therapy must meet the following criteria:~* ECOG performance status score of 0 or 1~* Recovery from surgery and adequate organ function as determined by the investigator based on laboratory values During the adjuvant phase, patients will receive tislelizumab as adjuvant therapy. The first dose of tislelizumab (cycle 1 of the adjuvant phase) should be administered within 2-8 weeks after surgery. Patients will continue to receive tislelizumab (400 mg, Q6W) as adjuvant therapy every 6 weeks until one of the following events occurs: completion of 8 cycles of tislelizumab adjuvant therapy, disease recurrence, unacceptable adverse events (AEs), death, or decision by the patient and/or investigator to discontinue study treatment."
223628837|NCT03906539|DRUG|Atorvastatin 10mg|Atorvastatin 10 mg per day
224217706|NCT02801851|BEHAVIORAL|SCREEN-ED|SCREEN-ED will have 4 key components: systematic screening for delirium using the CAM; informing providers of the screening result; a checklist protocol for initial delirium management based on clinical guidelines tailored to the ED, which includes identification of cause, risk factor modification, and behavioral interventions; documentation in the Electronic Health Record (EHR) and communication with inpatient providers of delirium screening results.
224217707|NCT04817098|BEHAVIORAL|Journey of Life|The concept underlying the JoL intervention is that caregivers and community members can support each other and their children through reflection, dialogue, and action. JoL addresses children's and adolescents' ecologies by working with caregivers, educators, and community members to understand the importance of their support in protecting children.
224217708|NCT04048720|BEHAVIORAL|Family Nurture Intervention|The mother-child pair will be asked to talk and play with each other as the pair customarily does. If the child becomes restless and dysregulated, the mother will be coached by the Nurture Specialist to bring the child back into a calm state through sustained physical contact, comforting touch, soothing words and eye contact. Each dyad will be offered eight group FNI sessions.
223628838|NCT03906539|DIETARY_SUPPLEMENT|Virgin Coconut Oil (VCO)|Capsule VCO (1000 mg/day)
223628839|NCT03906539|OTHER|Placebo|Placebo capsule - 1 capsule per day
224217709|NCT02686489|OTHER|Heated humidification|Water vapor (molecular water) will be added to the inspired gas of the spontaneously breathing tracheostomy patient by using the Fisher \& Paykel Healthcare, (Auckland, New Zealand) AIRVO 2 Humidification System. The AIRVO 2 will provide respiratory gas flow at 2-60 L/min) that is conditioned to 37° C, 34° C, or 31° C (based on patient comfort) and 100% relative humidity via a heated breathing circuit.
224217710|NCT02686489|OTHER|Cool bland aerosol|Aerosol (particles of water suspended in gas) generated by a flow of gas through a pneumatically powered large volume jet nebulizer filled with sterile water (for inhalation) attached to a gas source via a flowmeter set between 10-15 L/min will add moisture to the inspired gas of the spontaneously breathing tracheostomy patient. The cold bland aerosol set-up will consist of corrugated aerosol tubing with one end connected to the nebulizer output port and the other end connected to a tracheostomy mask.
223628840|NCT02962700|DEVICE|muscle microdialysis|Systemic haemodynamics and interstitial tissue concentrations of lactate, pyruvate, glucose and glycerol were obtained at baseline, 6, 12,18 and 24 hours after initiation of renal replacement by using muscle microdialysis.
223628841|NCT05685914|PROCEDURE|endoscopic surgery|Emergency or elective surgery
223628842|NCT02153086|DRUG|Ramelteon|Ramelteon tablets 8 mg
223628843|NCT04953494|DIAGNOSTIC_TEST|Patient information collection, exon sequencing and follow-up.|Clinical baseline data, disease characteristics, auxiliary examination results, EMG examination results, drug use and other information were collected. 4-6ml peripheral blood was collected for exon sequencing. The patients were followed up every three months by a specialist in the form of outpatient or telephone.
223628844|NCT02859220|OTHER|Determination of PTH following|"Determination of PTH following:~in group 1: intact PTH Elecsys Roche"
223628845|NCT02859220|OTHER|Determination of PTH following:|"PTH 1-84 complete (PAC) report and CAP / CIP, the package Duo PTH IRMA Scantibodies. The CIP is obtained by calculating the difference between total intact PTH and PTH 1-84 in the kit used."
223628846|NCT04457297|DRUG|trifluridine and tipiracil|Trifluridine and tipiracil will be orally administered twice daily on Days 1 to 5 and Days 8 to 12. The administration will be repeated until completion of 6 courses(one course consists of 28 days) or until any discontinuation criterion is met.
223628847|NCT04457297|DRUG|Placebo|Placebo will be orally administered twice daily on Days 1 to 5 and Days 8 to 12. The administration will be repeated until completion of 6 courses(one course consists of 28 days) or until any discontinuation criterion is met.
223628848|NCT05560477|DRUG|AM3101|Injectable drug product.
223628849|NCT05560477|DRUG|Saline Placebo|2 mL 0.9% normal saline
223628850|NCT01317472|DRUG|dexlansoprazole|60 mg dexlansoprazole QAM (1 hour AC) for 2 months
223628851|NCT01317472|DRUG|Placebo|1 tablet of placebo QAM (1 hour AC) for 2 months
223764019|NCT00058825|RADIATION|Total Body Irradiation (TBI)|Day -6: Total body irradiation of 600 cGy as two doses without blocks at a rate of less than or equal to 10 cGy/minute.
223764020|NCT00058825|DRUG|FK506 (Tacrolimus) or Cyclosporine|Day -2: FK506 or Cyclosporine as medically indicated to prevent GvHD.
224217711|NCT02228031|DRUG|Oxytocin|The experimental oxytocin group will receive 24 international units (IU) of oxytocin using an intranasal administration (self-administered nasal spray) one time before the experimental session
224217712|NCT02228031|OTHER|Placebo|The placebo comparator group will receive sterile saline through intranasal administration, consisting of the same salt solution in which the hormone will be dissolved , but lacking the hormone itself.
224217713|NCT01560091|DRUG|silodosin|8mg PO Qday
224317514|NCT05439681|DEVICE|FX CorDiax 800|high-flux membrane
224317515|NCT05439681|DEVICE|HDF|hemodiafiltration
223628852|NCT05158270|PROCEDURE|Ultrasound Guided Erector spinae plane block|Patient will be placed in lateral decubitus position. By palpation of spinous processes starting from C7 downward, T7 spinous process will be located. Under complete aseptic precautions, linear probe of US machine will be placed in a transverse orientation at this level to identify tip of T7 transverse process (TP). By probe rotation into a longitudinal orientation, a parasagittal view will visualize skin and subcutaneous tissue, trapezius, and erector spinae (ES) muscle layers superficial to TPs. After local anesthetic (LA) infiltration, a 20 gauge spinal needle will be inserted in-plane and directed cranio-caudally until it contacts T7 TP. Target site for injection will be fascial plane deep to ES muscle. 1 mL saline will be injected to confirm correct needle-tip position by visualization of lifting of ES muscle off TP without distending the muscle and spreading cranio-caudally. 20 - 30 mL of 0.25% bupivacaine will be injected. Procedure will be performed bilaterally.
223628853|NCT05158270|PROCEDURE|Ultrasound Guided Subcostal Anterior Quadratus Lumborum Block|Patients will be positioned lateral decubitus. A curvilinear 2-5 MHz ultrasound transducer (SonoSite S-Nerve, Bothell, WA) will be positioned posteriorly below the 12th rib in a parasagittal oblique plane at L1-2 level. The QL muscle was visualized and its point of insertion on the 12th rib identified. An 18-gauge Tuohy needle was advanced in the caudal-to-cranial direction between QL muscle and the psoas major muscle until a click could often be felt as the needle tip penetrated the anterior investing fascia of the QL muscle. After a negative aspiration, 30 mL of 0.25% bupivacaine was injected through the needle to help confirm the final needle tip position, anterior to the QL muscle at close proximity to the 12th rib.
223628854|NCT05158270|OTHER|Intravenous Multimodal Analgesia|Postoperative pain in the post-anesthesia care unit (PACU) and on the ward will be treated with a combination of IV multimodal analgesia in the form of Acetaminophen (15 mg/kg 4/day) and Ketorolac (0.5 mg/kg 3/day) using a fixed scheme. In addition, Nalpuphine, as 3 mg IV bolus at each dose, will be given when Numerical Rating Scale (NRS) ≥ 3. VAS will be assessed 5 - 10 min. after each opioid dose to assess the need for additional opioid doses.
223628855|NCT02546271|BEHAVIORAL|GPS|
224217714|NCT01560091|PROCEDURE|Extra-corporeal shock wave lithotripsy|ESWL
224217715|NCT01560091|DRUG|Tamsulosin|Tamsulosin 0.4mg PO Qday
223628856|NCT04829201|PROCEDURE|functional septorhinoplasty or oropharyngeal/orthognathic surgery|obtain pre- and postoperative data in order to describe the specific changes in airflow and upper soft tissue behavior that causes sleep apnea
223764021|NCT00861211|DRUG|senicapoc|Loading Dose: 80 mg twice daily x 3 days followed by Maintenance Dose: 40 mg daily x 11 days
224217716|NCT06412068|DRUG|Combined anti-PD-1 and R-CHOP|Sintilimab,200mg, d1, intravenous drip; Rituximab,375mg／㎡, d1,intravenous drip; Cyclophosphamide,750mg／㎡,d2,intravenous drip; Doxorubicin,50mg／㎡ （or Liposome doxorubicin ，40 mg／㎡）,d2,intravenous drip; Vincristine,1.4mg／㎡, d2（Maximum dose 2mg),intravenous drip; Prednisone, 60mg/ m2 , d1-d5,oral administration.
224217717|NCT02038101|BEHAVIORAL|Education and Feedback|"1. Formal Rounds on AUC for TTE~2. Appropriate Use for TTE Application for Smartphone~3. Individualized Feedback Reports provided by email"
224217718|NCT05487872|BEHAVIORAL|Mindfulness skills training to reduce experiential avoidance and anxiety symptoms|The intervention aimed to increase participants' mindfulness skills which may be critical in decreasing general experiential avoidance and anxiety symptoms
224217719|NCT02496221|DRUG|Albiglutide 50 mg|Albiglutide 50 mg pen is a single-use fixed dose, fully disposable pen injector system for SC delivery in the abdomen containing 67 mg lyophilized albiglutide and 0.65 mL diluents designed to deliver a dose of 50 mg in a volume of 0.5 mL after reconstitution
224217720|NCT02496221|DRUG|Placebo|Placebo is a single-use fixed dose, fully disposable pen injector system for SC delivery of 0.5 mL injector volume in the abdomen
223764022|NCT00861211|DRUG|Placebo|Placebo comparator
224217721|NCT02496221|DRUG|CCK (Kinevac)|CCK (Kinevac) will be infused intravenously. Kinevac is supplied in vials containing 5 microgram (mcg)/vial. Infusion prepared aseptically by adding 5 mL of Sterile Water for Injection United States Pharmacopeia (USP) to the vial to create a solution of 1 mcg/mL. Infuse 0.003 mcg/kg dose in 100 mL of Sodium Chloride Injection USP, 0.9%
224317516|NCT02998697|DRUG|Ferrous Sulfate|Ferrous sulfate 200 mg t.i.d for 90 days
223764023|NCT06049420|BEHAVIORAL|Lifestyle counseling and coaching|Each participant will be provided with personalized exercise therapy that is best suited for their personal goals and disease states. Participants in this study will be encouraged to establish accountability through setting SMART goals, and through monitoring their activity using wearable fitness technology provided to them. This program will also aim to create a sense of community as group activity classes will be available for those that wish to attend. Individualized exercise/physical activity prescriptions will be provided and discussed.
224217722|NCT04264559|DIAGNOSTIC_TEST|Infrared thermal imaging|A thermal imager is used to record thermal images.The baseline temperature of relevant acupoints or sites on the Heart and Lung meridians will be measured.
223628857|NCT05546476|DRUG|ponsegromab|Double-Blind ponsegromab Treatment followed by Open Label ponsegromab Treatment
223764024|NCT06419335|DRUG|CoQ10|The core component of this pilot study will be a single center open label randomized trial comparing low dose and high dose CoQ10 among 30 patients with Crohn's disease and fatigue (Cohort 1) and 15 healthy volunteers (Cohort 3).
224217723|NCT04264559|PROCEDURE|Moxibustion|"Two sessions of moxibustion intervention will be performed in the Heart meridian and Lung meridian successively. During moxibustion, the temperature change of relevant acupoints or sites in the Heart and Lung meridians will be measured by infrared thermal imaging.~* Intervention in the Heart meridian: moxibustion will be performed in acupoint HT3 of the Heart meridian for 15 minutes.~* Intervention in the Lung meridian: moxibustion will be performed in acupoint LU5 of the Lung meridian for 15 minutes."
224317517|NCT02998697|DRUG|Placebo Oral Capsule|Lactose 200 mg t.i.d for 90 days
224317518|NCT01068145|DRUG|SCH 527123|Very low dose SCH 527123, once daily for 7 days
223764025|NCT03536039|DRUG|NGR-hTNF|dose of 0.8 mcg/sqm
223764026|NCT03536039|OTHER|RITUXIMAB|dose of 375 mg/mq
223764027|NCT03536039|DRUG|Doxorubicin|dose of 50 mg/mq
224317519|NCT01068145|DRUG|SCH 527123|Low dose SCH 527123, once daily for 7 days
224317520|NCT01068145|DRUG|SCH 527123|Medium dose SCH 527123, once daily for 7 days
224317521|NCT01068145|DRUG|SCH 527123|High dose SCH 527123, once daily for 7 days
224317522|NCT01068145|DRUG|Placebo|Placebo capsules to match SCH 527123, once daily for 7 days
223628858|NCT05546476|DRUG|Placebo for ponsegromab|Double-Blind placebo Treatment followed by Open Label ponsegromab Treatment
223628859|NCT03985930|DEVICE|Distraction with virtual reality|Distraction content delivered through virtual reality goggles
223628860|NCT03985930|OTHER|Treatment as Usual|Treatment as Usual
223628861|NCT02012439|BEHAVIORAL|Mindfulness Based Cognitive Therapy|
223628862|NCT02012439|BEHAVIORAL|Cognitive Therapy|
223628863|NCT04013997|DEVICE|EksoGT|The intervention group received a minimum of 15 hours of standard of care, including physical and occupational therapy, for acute inpatient rehabilitation per week. After enrolling into the study, participants received locomotor training with the exoskeleton as part of their acute inpatient rehabilitation using the Ekso. Standing and walking with the Ekso started as soon as the clinical team determined it was safe for participants to begin standing, and continued until the participant was discharged from inpatient rehabilitation.
223628864|NCT00494182|DRUG|Carboplatin|Given IV
224217724|NCT01114542|DRUG|insulin degludec|Subjects were randomised to one of three possible dose levels (low, middle or high) and to one of two treatment sequences. A treatment sequence consisted of 2 periods of each 13 days. One dose once daily. The trial products were administered subcutaneously (under the skin)
224217725|NCT01114542|DRUG|insulin glargine|Subjects were randomised to one of three possible dose levels (low, middle or high) and to one of two treatment sequences. A treatment sequence consisted of 2 periods of each 13 days. One dose once daily. The trial products were administered subcutaneously (under the skin)
224217726|NCT06198985|PROCEDURE|Dynamic balance exercise with tecnobody prokin 252 balance device|Dynamic balance exercise with tecnobody prokin 252 balance device
224217727|NCT00332137|DRUG|Tolterodine|
224217728|NCT00185328|DRUG|Estradiol/DRSP (Angeliq, BAY86-4891)|1 tablet of 2 mg drospirenone and 1 mg estradiol, orally administered once daily, over three 28-day treatment cycles
224217729|NCT03262233|COMBINATION_PRODUCT|nicotine|
224217730|NCT03262233|OTHER|placebo|
224217731|NCT03276533|DRUG|Saline|Participants in the group CON were received normal saline infusion until 30 min before the end of the operation.Interleukin-6 and tumor necrosis factor-α levels in serum were measured at different time points: before administration of drugs (T1), at the end of the operation (T2), postoperative 2 hour (T3) and postoperative 24 hour (T4)
224217732|NCT03276533|DRUG|Lidocaine|Participants in the group LIDO received lidocaine infusion (1.5 mg/kg loading, 1.5 mg/kg/h infusion)until 30 min before the end of the operation.Interleukin-6 and tumor necrosis factor-α levels in serum were measured at different time points: before administration of drugs (T1), at the end of the operation (T2), postoperative 2 hour (T3) and postoperative 24 hour (T4)
223628865|NCT00494182|DRUG|Paclitaxel|Given IV
223628866|NCT00494182|DRUG|Sorafenib|Given PO
223628867|NCT06397079|BEHAVIORAL|Electric toothbrush|Teach Bass brushing technique and bursh teeth using electric toothbrush dental hygiene three times a day.
223628868|NCT06397079|BEHAVIORAL|Soft bristle toothbrush|Teach Bass brushing technique and bursh teeth using soft bristle toothbrush dental hygiene three times a day.
223628869|NCT03301311|OTHER|Specific Carbohydrate Diet (SCD)|Patients will be randomized to start with either a strict SCD or modified SCD. Participants will alternate between each diet in 8-week intervals for a total duration of approximately 34 weeks. Participants will complete two 8-week intervention periods on each diet.
224317523|NCT01068145|DRUG|SCH 527123|Low dose capsule SCH 527123, once daily for 14 days
223628870|NCT03301311|OTHER|Modified Specific Carbohydrate Diet (MSCD)|Patients will be randomized to start with either a strict SCD or modified SCD. Participants will alternate between each diet in 8-week intervals for a total duration of approximately 34 weeks. Participants will complete two 8-week intervention periods on each diet.
223764028|NCT03536039|DRUG|Cyclophosphamide|dose of 750 mg/mq
223764029|NCT03536039|DRUG|Vincristine|dose of 1.4 mg/mq (max 2 mg)
223628871|NCT04096430|BEHAVIORAL|ENGAGE approach (child-oriented goal-setting)|See description of experimental arm.
223628872|NCT06353997|DRUG|Pembrolizumab|Drug will be delivered per standard-of-care as established by trial Keynote-522.
223628873|NCT06353997|DRUG|INBRX-106|INBRX-106 is a hexavalent, recombinant humanized IgG1, OX40 agonist antibody that targets the human OX40 receptor (TNFRSF4, UniProtKB: P43489). INBRX-106 is based on a sdAb platform and, in detail, 3 identical humanized camelid heavy chain-only antibody binding domains (VHHs) targeting OX40 are joined end-to-end and with an Fc based on human IgG1 to create a molecule that homo-dimerizes into an antibody targeting a total of 6 OX40 receptors.
223628874|NCT03692598|DEVICE|MIA, Minimally Invasive Annuloplasty Device - Surgical|Eligible patients will receive implantation of MIA implants deployed using the MIA, Minimally Invasive Annuloplasty Device from an open surgical approach
223764030|NCT03536039|DRUG|Prednisone|75 mg
223764031|NCT04979585|DRUG|Camrelizumab|200mg ,IV,d1,Q3W.
223628875|NCT03692598|DEVICE|MIA, Minimally Invasive Annuloplasty Device - Percutaneous|Eligible patients will receive implantation of MIA implants deployed using the MIA, Minimally Invasive Annuloplasty Device from a percutaneous approach
223628876|NCT01782027|DRUG|3H-cholesterol bound to albumin|up to 100 uCi of \[3H\]-cholesterol (containing approximately 0.2 mg of cholesterol) mixed with a solution containing human serum albumin will be administered as an intravenous bolus injection
223628877|NCT02050061|OTHER|compression stocking|study the impact of compression stocking
223628878|NCT06177496|PROCEDURE|local ablation|treatment of HCC
223628879|NCT06177496|PROCEDURE|TACE|treatment of HCC
223628880|NCT06177496|DRUG|Sorafenib|treatment of HCC
223628881|NCT02953652|DRUG|HBI-8000|Orally twice weekly
223764032|NCT04979585|DRUG|Anlotinib|8mg,oral, d1-14,Q3W.
223764033|NCT04979585|DRUG|nab-Paclitaxel|260mg/m2,IV,d1,Q3W.
223764034|NCT01205165|DRUG|Adefor dipivoxil|All enrolled subjects were enrolled to adefovir dipivoxil arm.
224217733|NCT03276533|DRUG|Dexmedetomidine|Participants in the group DEX received dexmedetomidine infusion (0.5 µg/kg loading, 0.4 µg/kg/h infusion) until 30 min before the end of the operation. Interleukin-6 and tumor necrosis factor-α levels in serum were measured at different time points: before administration of drugs (T1), at the end of the operation (T2), postoperative 2 hour (T3) and postoperative 24 hour (T4)
224317524|NCT01068145|DRUG|SCH 527123|Medium dose capsule SCH 527123, once daily for 14 days
224317525|NCT01068145|DRUG|SCH 527123|High dose capsule SCH 527123, once daily for 14 days
223628882|NCT03217344|PROCEDURE|conservative treatment|immobilization on sling of the injured arm
223628883|NCT04982562|OTHER|7T MRI|Seven tesla brain MRI (7T MRI) at day 7 in patients suffering from post concussionnal symptoms after mild traumatic brain injury admitted to emergency departement of Poitiers CHU (University Hospital
223764035|NCT01149798|DRUG|Abraxane and Cisplatin combination|"Abraxane will be given at 125 mg/m2, venous infusion within 30 minutes, administered on days 1, 8 and 15.~Cisplatin at 75mg/m2, venous infusion for 120 minutes, will be administered on day 1."
223764036|NCT00003585|BIOLOGICAL|aldesleukin|
224217734|NCT03276533|DRUG|Lidocaine plus Dexmedetomidine|Participants in the group LIDO+DEX were received lidocaine (1.5 mg/kg loading, 1.5 mg/kg/h infusion) and dexmedetomidine infusion (0.5 μg/kg loading, 0.4 μg/kg/h infusion) until 30 min before the end of the operation, respectively. Interleukin-6 and tumor necrosis factor-α levels in serum were measured at different time points: before administration of drugs (T1), at the end of the operation (T2), postoperative 2 hour (T3) and postoperative 24 hour (T4)
224217735|NCT02980328|DEVICE|Low-level light therapy|we used a skin-adhesive LLLT device called the Color DNA-WSF (Color Seven Co., Seoul, Korea) which consists of body for power supply and two microprocessor-controlled light-emitting diodes. We selected two acupuncture points, conception vessel 4 (CV4; Guanyuan) and CV6 (Qihai), for treating overactive bladder. The participants attached the skin-adhesive LLLT device probes to both acupuncture points according to treatment schedule.
224217736|NCT02980328|DEVICE|Placebo|we used a placebo skin-adhesive LLLT device called the Color DNA-WSF (Color Seven Co., Seoul, Korea) which consists of body for power supply and two microprocessor-controlled light-emitting diodes. We selected two acupuncture points, conception vessel 4 (CV4; Guanyuan) and CV6 (Qihai), for treating overactive bladder. The participants attached the placebo skin-adhesive LLLT device probes to both acupuncture points according to treatment schedule.
224217737|NCT04945161|DRUG|ON101 Cream|Active ingredients: Extracts of Plectranthus amboinicus and Centella Asiatica
224217738|NCT04945161|OTHER|Placebo|Placebo
224217739|NCT01893983|BEHAVIORAL|Motivational Coaching|Telephone-based Motivational Interviewing aimed at getting Veterans to engage or retain mental health treatment
224217740|NCT00735033|OTHER|Physiotherapy with Swiss Ball|
223628884|NCT03560882|DRUG|Atorvastatin|Atorvastatin tablet, 80mg
223628885|NCT00772538|DRUG|tiotropium 5mcg/day|Intervention = randomisation: Patient to receive double-blind treatment with either 5mcg/day tiotropium inhalation solution or placebo
223628886|NCT00772538|DRUG|placebo|Matching placebo
223764037|NCT00003585|BIOLOGICAL|recombinant interferon alfa|
223764038|NCT00003585|DRUG|fluorouracil|
223764039|NCT00003585|DRUG|isotretinoin|
224217741|NCT00268151|DRUG|Oxaliplatin|
224217742|NCT00268151|DRUG|Capecitabine|
224217743|NCT00560547|DRUG|methoxy polyethylene glycol-epoetin beta|120, 200 or 360 micrograms / 4 weeks iv (starting dose)
224217744|NCT02872545|PROCEDURE|Rest tomoscintigraphy in forward tilted|Rest tomoscintigraphy in forward tilted position
224217745|NCT02872545|PROCEDURE|Rest tomoscintigraphy in semi sitting position|Rest tomoscintigraphy in forward tilted position, followed by a second rest tomoscintigraphy in semi sitting position, after max 30 min
224217746|NCT02872545|PROCEDURE|Rest tomoscintigraphy in dorsal decubitus position|Rest tomoscintigraphy in forward tilted position, followed by a second rest tomoscintigraphy in semi sitting position, after max 30 min
224217747|NCT03613077|PROCEDURE|surgical placement of an endosteal implant|Subjects, male or female at least 18 years old, with the need of dental implant therapy and restoration according to the cleared indications for the implant
224217748|NCT03816800|DIETARY_SUPPLEMENT|ImmunoBon|The dietary agent contains vitamin A, Zn, chelated iron and whey proteins.
224317526|NCT01068145|DRUG|Placebo|Placebo capsules to match SCH 527123, once daily for 14 days
224317527|NCT05768581|OTHER|Concurrent Training|Participants should perform strength training and aerobic exercises
224317528|NCT05768581|OTHER|Strength Training|Participants should perform strength exercises
223628887|NCT03381690|PROCEDURE|Epidural labor analgesia|Epidural catheter was inserted for labor analgesia using an 18-gauge Tuohy needle and a 20 gauge epidural catheter. In our institute, for epidural labor analgesia, 10 ml bolus of 0.075% levobupivacaine mixed with fentanyl 2 μg/ml was administered and same regimen was continuously infused by patient-controlled epidural analgesia (infusion rate : 10 ml/hr, bolus : 4 ml, lockout time: 30 min).
223628888|NCT04638907|PROCEDURE|Assessment of NM block|Observation of resulting course of NM block under teratment and monitoring as described.
223628889|NCT02262936|DRUG|Desmopressin|
223628890|NCT02262936|DRUG|Fesoterodine|
223628891|NCT00524511|DEVICE|Surgical skin staples|Standard method to close abdominal surgical wounds
223628892|NCT00524511|DEVICE|Dermabond|Alternative method (superglue) to close abdominal surgical wounds
223764040|NCT00003585|PROCEDURE|surgical procedure|
223764041|NCT04748146|OTHER|Brain stimulation|Theta-burst stimulation will be applied to selected regions of distributed networks to test whether distal stimulation can modulate hippocampus-mediated episodic recollection.
223764042|NCT06390033|DEVICE|Prosthetic foot|Experimental prosthetic foot.
223764043|NCT05256069|DRUG|Propranolol Pill|Participants will receive a β-blockade (propranolol pill, 1 mg/kg dosed based on participant weight).
223764044|NCT05256069|DRUG|Placebo|Participants will receive a placebo in pill form.
223764045|NCT02942017|DRUG|Placebo|Intravenous infusion of matching placebo for SAGE-547.
223764046|NCT02942017|DRUG|SAGE-547 90 μg/kg/h|Intravenous infusion of SAGE-547
224217749|NCT03816800|DIETARY_SUPPLEMENT|Placebo|the dietary agent does not contain vitamin A, Zn, chelated iron and whey proteins
224217750|NCT01120600|DRUG|Odanacatib|One 50 mg tablet once weekly
224217751|NCT01120600|DRUG|Placebo for Odanacatib|One 50 mg tablet once weekly
224217752|NCT01120600|DIETARY_SUPPLEMENT|Vitamin D3|5600 IU of open-label Vitamin D3 once weekly
224317529|NCT05768581|OTHER|Aerobic training|Participants should perform aerobic exercises
224317530|NCT03675061|OTHER|Current care|Tocolysis and a complete corticosteroid treatment.
224317531|NCT03675061|DEVICE|PartoSure Test negative|Biochemical test and nifedipine tocolysis, then return at home with the midwife's visit at home twice a week up to 34 weeks of amenorrhea .
223628893|NCT04161859|DIETARY_SUPPLEMENT|Nutraceutical|Nutraceutical with action on glycemia, dsylipidemia or hypertension will be considered.
223628894|NCT06410430|BEHAVIORAL|Ba-Duan-Jin|"Ba-Duan-Jin is a common form of self-healthcare Qigong exercise that has been practiced by Chinese people for at least eight hundred years.It consists of eight sets of simple movements. By combining meditation with slow, graceful ovements,deep breathing, and relaxation, Ba-Duan-Jin practitioners believe it has the ability to move vital energy (Qi) throughout the body. Ba-Duan-Jin is also considered to be a multicomponent intervention that integrates physical, psychosocial, emotional, spiritual, and behavioral elements. While the biological mechanisms remain unclear."
223628895|NCT02740946|OTHER|Exercise therapy|5 months of exercise therapy with two strengthening exercises focusing on m. deltoideus anterior and m. teres minor. Furthermore, a warm up exercise was applied.
223628896|NCT00020800|BIOLOGICAL|rituximab|
223628897|NCT00020800|DRUG|fludarabine phosphate|
223628898|NCT00713609|DRUG|Benzoyl peroxide gel|5% benzoyl peroxide in a gel applied topically once a day
223628899|NCT00713609|DRUG|Clindamycin gel|1% clindamycin phosphate applied topically once a day
223628900|NCT00713609|DRUG|Tazarotene cream|0.1 % tazarotene in a cream applied topically once a day
223628901|NCT00713609|DRUG|Vehicle gel|Vehicle gel is an identical gel without the active ingredients
223628902|NCT00713609|DRUG|Vehicle cream|Vehicle cream is an identical cream without the active ingredients
223628903|NCT00095693|DRUG|sorafenib tosylate|Given PO
224217753|NCT01120600|DIETARY_SUPPLEMENT|Calcium carbonate|Sufficient amount of open-label calcium carbonate so that daily calcium intake from both dietary and supplementary sources in approximately 1200 mg
223628904|NCT00095693|OTHER|laboratory biomarker analysis|Correlative studies
223628905|NCT00095693|OTHER|pharmacological study|Correlative studies
223628906|NCT00095693|RADIATION|fludeoxyglucose F 18|Correlative studies
223628907|NCT00095693|PROCEDURE|positron emission tomography|Correlative studies
223628908|NCT00095693|PROCEDURE|dynamic contrast-enhanced magnetic resonance imaging|Correlative studies
223628909|NCT03728868|DIETARY_SUPPLEMENT|Placebo|Dietary supplementation with placebo once a day for 8 consecutive weeks
223628910|NCT03728868|DIETARY_SUPPLEMENT|High dose F. prausnitzii and D. piger|Dietary supplementation with high dose F. prausnitzii and D. piger once a day for 8 consecutive weeks
223628911|NCT03728868|DIETARY_SUPPLEMENT|Low dose F. prausnitzii and D. piger|Dietary supplementation with low dose F. prausnitzii and D. piger once a day for 8 consecutive weeks
223628912|NCT05026528|OTHER|Digital diabetes self management education and support system|Digital diabetes self management and support system
223628913|NCT02144181|DEVICE|Ulthera System Treatment|Focused ultrasound energy delivered below the surface of the skin
223764047|NCT04126291|BEHAVIORAL|Evaluation of whiteboard videos|Participants will be provided an internet link via email to access the videos and questionnaires through REDCap (Research Electronic Data Capture), and responses will be tracked. Before viewing, participants will complete a pre-questionnaire to collect demographic and practice data and ratings of perceived self-efficacy/confidence and knowledge in talking about weight-related issues. This pre-questionnaire only needs to be completed once. Participants will then be asked to watch each video. Immediately after watching each video, participants will rate their perceived self-efficacy/confidence and knowledge to help elucidate outstanding educational gaps. For those who consent to do a follow up questionnaire four-six months later, they will be sent an email link to complete a satisfaction questionnaire and rate their perceived self-efficacy/confidence and change in practice to help elucidate outstanding educational gaps.
224217754|NCT01165242|BIOLOGICAL|Meningococcal vaccine GSK 134612|One intramuscular injection
224317532|NCT03675061|DEVICE|PartoSure Test positive|Biochemical test and tocolysis and a complete corticosteroid treatment. then if situation is stable, return at home with the midwife's visit at home twice a week up to 34 weeks of amenorrhea
224317533|NCT01437839|DRUG|Apixaban|Period I: 1 x 5 mg Commercial Image Tablet in fasting state(single dose on Day 1 only of each Period; subjects stay in clinic for a total of 4 days for each period), Period II: 1 x 5 mg Commercial Image Tablet in fed state (single dose on Day 1 only of each Period; subjects stay in clinic for a total of 4 days for each period)
224317534|NCT01437839|DRUG|Apixaban|Period I: 1 x 5 mg Commercial Image Tablet in fed state(single dose on Day 1 only of each Period; subjects stay in clinic for a total of 4 days for each period), Period II: 1 x 5 mg Commercial Image Tablet in fasting state (single dose on Day 1 only of each Period; subjects stay in clinic for a total of 4 days for each period)
223628914|NCT04814303|PROCEDURE|Intrathecal morphine|After applying standard monitoring of pulse oximetry, ECG, NIBP; while the patient in the sitting position following complete sterile aseptic condition after sterilization bovine bethidine spinal anesthesia will be induced with heavy bupivacaine 0.5% 12.5-15 mg (2.5-3 mL) at L3-4 or L4-5 inter-vertebral levels using a 25- gauge Whitacre needle. Intrathecal morphine 150 μg will be added to patients of both groups. Supplemental oxygen will be administered via a simple face mask.
223628915|NCT04814303|PROCEDURE|Adductor Canal block|The block will be performed in the mid adductor canal to block both the saphenous and the nerve to vastus medialis. After skin infiltration with 1 to 2 mL of 2% lidocaine, an 80-mm, 22-gauge, short-bevel echogenic needle is advanced in plane with the ultrasound beam in an anterior-to-posterior direction until the tip is located within the adductor canal deep to the vastoadductor membrane. After negative aspiration, 1-2 mL of local anesthetic is injected to confirm the proper injection plane. The study solution will be injected within the canal adjacent to the femoral artery. Patients in group 1 received 30 mL of 0.25% bupivacaine with 1:400,000 epinephrine and 4 mg dexamethasone.
223628916|NCT04814303|PROCEDURE|Peri-articular Infilteration|the surgeon will perform the PAI intra-operatively; 150 mL of 0.25% bupivacaine with 1:400,000 epinephrine, 30 mg of ketorolac, and 8 mg dexamethasone. Half of the solution will be administered into the posterior capsule and posterior soft tissues of the knee under direct vision after osteotomy but before insertion of the implants. The remaining half of the solution will be administered into the anterior soft tissues after placement of the implants and before skin closure. All local infiltration will be carried out while a thigh tourniquet (used to limit surgical bleeding) was inflated at a pressure of 300 to 350 mm Hg.
224217755|NCT01165242|BIOLOGICAL|Menactra®|One intramuscular injection
224217756|NCT00003070|DRUG|enalapril maleate|
224217757|NCT00003070|PROCEDURE|quality-of-life assessment|
223628917|NCT01615146|OTHER|Platelet Transfusion|"Patients allocated to the therapeutic platelet transfusion group will not receive routine prophylactic platelet transfusions. Platelet transfusions will be given to treat documented clinically relevant bleeding defined as WHO bleeding of grade 2 or greater. Patients may be transfused at the discretion of the treating physician. The indication for all platelet transfusions will be recorded by asking the ordering physician.~Patients allocated to the prophylactic platelet transfusions will receive a platelet transfusion when the measured platelet count is \< 10 x 109/L. Patients may receive additional platelet transfusions at the discretion of the treating physician. The indication for all platelet transfusions will be recorded."
223628918|NCT01434017|DRUG|Dexamethasone|Patients will receive dexamethasone 250 mcg/kg just after induction of anesthesia.
223628919|NCT01434017|DRUG|Dexamethasone and droperidol|Patients will receive dexamethasone 250 mcg/kg + droperidol 10 mcg/kg just after induction of anesthesia.
223628920|NCT01434017|DRUG|Dexamethasone and Ondansetron|Patients will receive dexamethasone 250 mcg/kg + ondansetron 150 mcg/kg just after induction of anesthesia.
223628921|NCT00521950|GENETIC|TPMT genotyping; Drug: azathioprine or 6-mercaptopurine|"Assessment of the polymorphisms G238C, G460A, and A719G in a venous blood sample to identify functional genetic variants (TPMT\*2, \*3A, \*3C) of the TPMT gene (chromosome 6) associated with reduced or negligible TPMT enzyme activity.~Patients are advised an initial treatment dose based on the enzyme activity:~* Normal: AZA 2-2.5 mg/kg/day or 6-MP 1-1.5 mg/kg/day (standard care);~* Reduced: AZA 1-1.25 mg/kg/day or 6-MP 0.5-0.75 mg/kg/day;~* Negligible: AZA 0-0.2 mg/kg/day or 6-MP 0-0.1 mg/kg/day;"
223628922|NCT00521950|DRUG|azathioprine (AZA) or 6-mercaptopurine (6-MP)|"Patients will be advised a standard initial treatment dose:~* AZA 2-2.5 mg/kg/day or 6-MP 1-1.5 mg/kg/day (standard care);"
223628923|NCT03868423|DRUG|Brigatinib|90 mg orally QD for 7 days followed by 180 mg orally QD continuously thereafter. One cycle of therapy will consist of 28 days of treatment.
223628924|NCT03868423|OTHER|Laboratory Biomarker Analysis|Correlative studies
223628925|NCT03868423|OTHER|Quality-of-Life Assessment|Ancillary studies
223628926|NCT03868423|OTHER|Questionnaire Administration|Ancillary studies
223628927|NCT05680714|OTHER|Implement coordination of care with multifactorial falls- and fracture risk assessment and tailored intervention|
223628928|NCT04665141|BIOLOGICAL|Mepolizumab|Mepolizumab will be prescribed freely by the treating physician according to real-life conditions.
223628929|NCT04665141|BIOLOGICAL|Omalizumab|Omalizumab will be prescribed freely by the treating physician according to real-life conditions.
224217758|NCT00798785|DRUG|ATG-MMF-TAC|"ATG-fresenium for max 6 consecutive days depending on CD3 count, starting the day before transplantation.~Tacrolimus levels for 2 years between 8-10 ng/ml.~At year 2: randomization:~group A: till 48 months: tacrolimus levels 8-10 ng/ml 48-60 months: tacrolimus levels 6-8 ng/ml group B: 24-36 months: 6-8 ng/ml 36-60 months: 4-6 ng/ml A subgroup of these patients will receive a sub clinical implant subcutaneous (total n=5) at the time of the first clinical implant in the liver."
224317535|NCT05409586|PROCEDURE|segmental mastectomy|The preferred method in the treatment of some patients diagnosed with IGM
223628930|NCT04665141|BIOLOGICAL|Reslizumab|Reslizumab will be prescribed freely by the treating physician according to real-life conditions.
223628931|NCT04665141|BIOLOGICAL|Benralizumab|Benralizumab will be prescribed freely by the treating physician according to real-life conditions.
223628932|NCT04665141|BIOLOGICAL|Dupilumab|Dupilumab will be prescribed freely by the treating physician according to real-life conditions.
223628933|NCT01048593|DRUG|IBI-10090|Single intraocular injection
223628934|NCT03780452|DEVICE|novel dynamic compression intramedullary nail|Tibiotalocalcaneal (TTC) arthrodesis with a novel dynamic compression intramedullary nail. The assignment of the device is at the discretion of the standard of care provider, not the study investigator.
223628935|NCT02991222|DRUG|SPARC001 type I|Treatment type I
223628936|NCT02991222|DRUG|SPARC001 type II|Treatment type II
223628937|NCT02991222|DRUG|Reference001 type I|Hydrocodone-Acetaminophen
223628938|NCT02991222|DRUG|Reference001 type II|Hydrocodone-Acetaminophen
223628939|NCT05132556|OTHER|Acute Beetroot Juice|Participants will ingest a beetroot juice supplement with and without inorganic nitrate to determine the effects of acute dietary nitrate ingestion on blood pressure and arterial stiffness
223628940|NCT02905461|BEHAVIORAL|Contraceptive text messages|
223628941|NCT02905461|OTHER|Text messages not about contraception|
223628942|NCT03992560|DEVICE|Guide CRT Software Prototype|The medical device in the trial is a software programme that allows image fusion of previously acquired MRI images with real-time X-Ray fluoroscopic images in the cardiac catheter laboratory. We are able to use the MRI information to assess the best location to place the left ventricular lead for a CRT device and then superimpose this location onto the real-time X-Ray fluoroscopic images during the left ventricular lead implantation
223628943|NCT04648462|OTHER|ProTRAIT|The participants are seen at the outpatient clinic by a physician, physician assistant or trial nurse at standard follow-up times at 2.5, 5, 7.5 and 10 years after radiotherapy.
223628944|NCT01001221|DRUG|cabazitaxel|"Pharmaceutical form: 60 mg/1.5 ml concentrate solution for infusion~Route of administration: Intravenous infusion over 60 minutes~Dosage:~* Study part 1: 15, 20 or 25 mg/m\^2 according to pre-defined dose escalation schedule~* Study part 2: MTD as determined in Study part 1"
223628945|NCT01001221|DRUG|gemcitabine|"Pharmaceutical form: According to United States Package Insert (USPI)~Route of administration: Intravenous infusion over 30 minutes~Dosage:~* Study part 1: 700, 900 or 1000 mg/m\^2 according to pre-defined dose escalation schedule~* Study part 2: MTD as determined in Study part 1."
223628946|NCT04935346|OTHER|no intervention group|The awareness of medical and nursing students were evaluated. there is no intervention
223628947|NCT02388269|DEVICE|gammaCore®-G|The gammaCore®-G device is a reusable, hand-held, portable device consisting of two 3.0 VDC batteries (not replaceable or user serviceable), signal generating and amplifying electronics, and two buttons for operator control of the signal amplitude. The device provides visible (light display) and audible feedback on device and stimulation status
224317536|NCT05415163|PROCEDURE|vascular photobiomodulation|application of photobiomodulation with the device O Ecco ILIB (Eccofibras, São Paulo, Brazil) containing its red wavelength 660 nm ± 10 nm and power 100 mW, with an application time of 30 minutes. The device will be positioned with the spot located in the radial artery of the participant's arm (right or left), and fixed to the wrist with a specific bracelet.
223628948|NCT03820843|OTHER|Art therapy and standard orthophonic rehabilitation|In addition to standard orthophonic rehabilitation, the patient will receive 12 sessions of art therapy
223628949|NCT03724136|PROCEDURE|Intravenous Bone Marrow Stem Cell (BMSC) Fraction|14 cc of BMSC fraction separated from bone marrow aspirate and filtered with 150 micron filter and administered intravenously.
224217759|NCT00798785|DRUG|ATG-Rituximab-MMF-TAC|"ATG-fresenium for max 6 consecutive days depending on CD3 count, starting the day before transplantation.~Rituximab: the day before transplantation, day 5; 12 and 19 after implantation. Tacrolimus levels for 2 years between 8-10 ng/ml.~At year 2: randomization:~group A: till 48 months: tacrolimus levels 8-10 ng/ml 48-60 months: tacrolimus levels 6-8 ng/ml group B: 24-36 months: 6-8 ng/ml 36-60 months: 4-6 ng/ml A subgroup of these patients will receive a sub clinical implant, subcutaneous at the time of the first clinical implant in the liver."
224217760|NCT00798785|DRUG|ATG-basilixumab-MMF-TAC|"First transplantation:~ATG-fresenium for max 6 consecutive days depending on CD3 count, starting the day before transplantation.~Second transplantation:~Basilixumab:~the day before the second transplantation followed by 4days after transplantation.~Tacrolimus levels for 2 years between 8-10 ng/ml.~At year 2: randomization:~group A: till 48 months: tacrolimus levels 8-10 ng/ml 48-60 months: tacrolimus levels 6-8 ng/ml group B: 24-36 months: 6-8 ng/ml 36-60 months: 4-6 ng/ml A subgroup of these patients will receive a sub clinical implant, subcutaneous at the time of the first clinical implant in the liver."
224217761|NCT00798785|PROCEDURE|omentum|"Two clinical implants: first in omentum followed by a clinical implant in the liver:~In a group of 10 patients, a clinical implant in the omentum will be implanted. If random C-peptide levels \>= 0.5 ng/ml are measured at 2 months post-transplantation, a second omental implant will be done. If no clinical relevant beta cell graft function is measured, two intraportal implants will be given as a compassionate use procedure. An interim analysis after 5 patients has to shown clinical relevant function at month 2 in 3 out of 5 patients before the subsequent 5 patients can be transplanted in the omentum."
224217762|NCT03252132|OTHER|12-week resistance training|Training will consist of a minimum of 5 supervised training sessions every 2 weeks and each session will be approximately 60 minutes in duration. Patients will be performing resistance training consisting of at least 3 exercises affecting the largest muscle groups of the body, training the most basic movement patterns that work the entire body as a coordinated system. Patients will train according to a linear progressive model with a slow increase in weight every training session focusing on the flexors, extensors of the ankle and knee and on flexors, extensors and abductors of the hip.
224217763|NCT03770000|DRUG|Tenalisib|Tenalisib, BID orally daily
224217764|NCT03770000|DRUG|Romidepsin|Romidepsin IV
224217765|NCT02917837|OTHER|Usual QCNL DI utilization report|See arm descriptions.
224217766|NCT02917837|OTHER|New DI utilization report|See arm descriptions.
224217767|NCT02917837|OTHER|Detailing|In-person detailing, usually with a small group of family physicians and a peer (physician) facilitator to discuss the topic over a 30-60 minute period.
224217768|NCT01234688|OTHER|Exercise training|Patients included in the exercise group were submitted to intra-dialytic exercise training, 3 times per week for 12 weeks.
224217769|NCT01318785|OTHER|Compression Armsleeves|"Type: Compression Class II (according to RAL)~The study is designed in a way, that per product after a one weak resting (preparing) cycle a 2 weeks wearing period will follow. Herewith the whole duration of the study is 6 weeks per patient."
224217770|NCT03687437|DIAGNOSTIC_TEST|Blood sample|Complete blood count
224217771|NCT00973778|OTHER|Preoperative Chemoradiotherapy|Patient will receive pre-operative radiotherapy with intensity modulated radiotherapy to primary and any grossly enlarged pelvic nodes 5Gy in 5 fractions over 5 days with concurrent capecitabine 1500mg p.o. bid for 1 week, then undergo surgery.
224217772|NCT05605028|BEHAVIORAL|Mental Health lifestyle intervention|The focus is to identify 10 potential groups of causes and working on reversing them. The 10 factors are: (1) Genetic, (2) Developmental, (3) Lifestyle, (4) Circadian Rhythm, (5) Addiction, (6) Nutrition, (7) Toxic, (8) Social/Complicated Grief, (9) Medical Condition, and (10) Frontal Lobe. Each of these factors will be dealt with in the lifestyle intervention.
224217773|NCT05605028|OTHER|Dietitian-led|A group of people that visit the dietitian will be used as comparison against the Mental Health lifestyle intervention
224217774|NCT05003128|DEVICE|LED screen (InnoLux, Taiwan)|Participants watch a short movie on an LED screen (InnoLux, Taiwan) for 15 minutes in a bright room. The viewing distance was approximately 1.5 meters.
223764048|NCT04399161|DRUG|Chlorhexidine mouthwash|A commercially available Chlorhexidine mouth rinse (Hexidine- 0.2 percentage Chlorhexidine gluconate) containing 0.2 percentage chlorhexidine gluconate per 10 ml will be used. 7.5 ml of the concentrate diluted with equal amounts of water to make 15ml will be used for rinsing.
224217775|NCT00651547|DRUG|budesonide/formoterol|
224217776|NCT00651547|DRUG|budesonide|
224217777|NCT00651547|DRUG|formoterol|
224217778|NCT04463277|BEHAVIORAL|Calorie Restriction|Participants assigned to this arm to consume food at a caloric deficit of 500 calories per day.
224217779|NCT04463277|BEHAVIORAL|Time Restricted Feeding|Participants assigned to this arm to consume food at maintenance calories (calories required per day to maintain weight, calculated based on height, weight and physical activity using the MyFitnessPal application) within an 8-hour window during daylight hours.
224217780|NCT04463277|BEHAVIORAL|Time Restricted Feeding with Calorie Restriction|Participants assigned to this arm to consume food at a caloric deficit of 500 calories per day within an 8-hour window during daylight hours.
224217781|NCT03031405|DRUG|Oxytocin nasal spray|
224217782|NCT03031405|DRUG|Placebos|Placebo nasal spray
223628950|NCT03724136|PROCEDURE|Intranasal Topical Bone Marrow Stem Cell (BMSC) Fraction|Approximately 1 cc of BMSC fraction separated from bone marrow aspirate and administered to the nasal mucosa topically.
223628951|NCT03724136|PROCEDURE|Near Infrared Light|Near Infrared Light will be administered using an FDA cleared medical device on the preoperative day and the first postoperative day as tolerated to the general area of the frontal bone.
223628952|NCT05612854|PROCEDURE|Mechanical embolectomy: by hydromechanical defragmentation by pigtail|Hydro-mechanical defragmentation (HMD) is one of the CDT modalities for high-risk PE patients, in which rapid pigtail rotation is combined with heparinized saline injection for thrombus fragmentation
223764049|NCT04399161|DRUG|Xylitol|Xylitol mouth rinse at 10 percentage concentration will be used. The mouth rinse will be prepared by dissolving 1.5 gm of xylitol powder in 15 ml of water.
223628953|NCT05612854|DEVICE|Suction embolectomy by the Penumbra Indigo aspiration system|"The Penumbra Indigo aspiration system (Penumbra Inc., Alameda, CA, USA) that will be used, is an 8-Fr device and its associated tubing, pump, and separator, has the flexibility for placement in segmental branches of the pulmonary arteries.~510(k) Number :K160449 FOIA Releasable 510(k) K160449 Device Name:Penumbra System, Penumbra Pump MAX"
223628954|NCT00603317|DRUG|Firstly : Amoxicillin-Clavulanic acid and secondly : Placebo|Amoxicillin : 2g twice daily Clavulanic acid : 125 mg twice daily
223628955|NCT00603317|DRUG|Firstly : Placebo and secondly : Amoxicillin-Clavulanic acid|Amoxicillin : 2g twice daily Clavulanic acid : 125mg twice daily seven consecutive days
223628956|NCT05741424|DIAGNOSTIC_TEST|Innovative diagnostic technologies|Samples from patients positive for Gram-negative bacteremia will be analyzed using the new BacT/Alert® VIRTUO®, BioFire® BCID2 and REVEAL® diagnostic solutions
223628957|NCT05741424|DIAGNOSTIC_TEST|Reference diagnostic technique|Analysis of samples using diffusion on Mueller Hinton (MH) agar medium according to EUCAST.
223628958|NCT02328924|OTHER|LH value|analyzed LH value in the the arms of the study, fixed and flexible protocols
223628959|NCT00854750|DRUG|ACTHAR|SQ weekly injections
223628960|NCT00854750|DRUG|ACTHAR|SQ weekly injections
223628961|NCT00854750|DRUG|ACTHAR|SQ weekly injections
223628962|NCT00854750|DRUG|ACTHAR|SQ weekly injection
224217783|NCT02544945|OTHER|3D printed bolus|Using the Cat Scan for treatment planning, a 3D plastic shell can be produced which is shaped exactly to the shape of the patient's chest wall. This shell will act as bolus - the substance that is placed on the skin during chest wall radiotherapy. The bolus allows the right dose of radiotherapy to get to the skin and the underlying chest wall.
224217784|NCT02544945|OTHER|Standard bolus|A standard 5mm-thick piece of rubber is placed on the patient's chest wall
224317537|NCT02147041|DRUG|EGCG(Epigallocatechin Gallate)|500mg, three times a day, duration:12 weeks
223628963|NCT00685412|BIOLOGICAL|VGX-3100|DNA plasmid delivered via IM injection + electroporation using CELLECTRA device
224217785|NCT01860482|DRUG|Newrabell® Tablet 10mg|
224217786|NCT05818631|DIAGNOSTIC_TEST|fusion cognitive prostate biopsy|A standard transrectal prostatic biopsy will be performed to both groups. To the group with suspicious lesions in the MRI (PI-RADS 3-5), an added directed cognitive fusion biopsy will be performed.
224217787|NCT02460874|DRUG|Glyburide|1.25mg, twice a day
224217788|NCT02460874|OTHER|Placebo|1.25mg, twice a day
224217789|NCT01690520|DRUG|Cyclophosphamide|Given IV
224217790|NCT01690520|DRUG|Cyclosporine|Given IV or PO
224217791|NCT01690520|BIOLOGICAL|Ex Vivo-Expanded Cord Blood Progenitor Cell Infusion|Given IV
223628964|NCT05321901|OTHER|Biopsychosocial Exercise Therapy approach (BETY)|The BETY intervention is grouped under 4 headings: Patient education on chronic pain, functional body stabilization exercises (mind-body information management), dance therapy-authentic movement (emotion-state information management), and sexual information management.
223628965|NCT05321901|OTHER|Control group|The control group participants were those who did not want to receive exercise treatment with telerehabilitation and took their routine medications during the 8 weeks period.
223628966|NCT04298320|DRUG|SHR-1210|SHR-1210 was administered 200mg iv every 2 weeks
223628967|NCT04298320|DRUG|AIN 457|AIN457 was administered 150mg or 300mg ih every 2 weeks
223628968|NCT02704325|BIOLOGICAL|rAAVrh74.MCK.GALGT2|Direct intramuscular injection of rAAVrh74.MCK.GALGT2 transferred to the extensor digitorum brevis muscle (EDB) of one foot and the other side receiving saline alone.
223628969|NCT02704325|OTHER|PLACEBO (Saline)|Direct intramuscular injection of rAAVrh74.MCK.GALGT2 transferred to the extensor digitorum brevis muscle (EDB) of one foot and the OTHER side receiving saline alone.
223628970|NCT03063528|BEHAVIORAL|Healthy Eating and Physical Activity|"Participants will be assigned to a group of 8-10 other pregnant women to work towards the same healthy eating or physical activity behavior challenge each week for a total of 12 weeks. The challenges will not require travel or financial support, but will focus on modifying or encouraging daily lifestyle activities, such as drink 8 full glasses of water 3 times this week. Participants will track their healthy eating and physical activity behaviors in a mobile app. The HEPA condition will have access to podcasts and informational tips for having a healthy pregnancy through the study website. The HEPA condition will be able to log their weight on a daily basis and track their overall weight gain on a chart through the study website."
223628971|NCT03063528|BEHAVIORAL|Stress Reduction and Management|"Participants will be put into a group of 8-10 other pregnant women to work towards the same stress reduction and management goal each week for a total of 12 weeks. The challenges will not require travel or financial support, but will focus on modifying or encouraging daily lifestyle activities, such as take a 15 minute technology break each day this week. Participants will track their stress reduction and management behaviors in a mobile app. In addition, the SRAM condition will have access to meditation podcasts and informational tips for having a healthy pregnancy through the study website. Lastly, the SRAM condition will be able to rate their stress level on a daily basis and track their stress on a graph."
223628972|NCT06205836|DRUG|Cemiplimab|Patients will receive cemiplimab (350 mg administered IV) on Day 1 of each 21 day cycle for a total of 4 cycles of treatment.
224217792|NCT01690520|DRUG|Fludarabine Phosphate|Given IV
224217793|NCT01690520|DRUG|Mycophenolate Mofetil|Given IV or PO
224217794|NCT01690520|DRUG|Thiotepa|Given IV
224217795|NCT01690520|RADIATION|Total-Body Irradiation|Undergo high dose or middle intensity TBI
224217796|NCT01690520|PROCEDURE|Umbilical Cord Blood Transplantation|Undergo single-unit or double-unit unmanipulated umbilical cord blood transplant
224217797|NCT00006031|PROCEDURE|Needle localized breast biopsy with specimen x-ray|
224217798|NCT00006031|PROCEDURE|Low dose radioactive seed followed by surgery and mammogram|either iodine I 125 or palladium Pd 103
224217799|NCT06274216|DRUG|Vitamin D3|5000 IU of vitamin D3 orally every day for 12 weeks
224217800|NCT06274216|DRUG|Vitamin E 400|400mg of vitamin E orally every day for 12 weeks
224217801|NCT03634332|DRUG|PEGPH20|PEGPH20 is a PEGylated, neutral-pH-active human hyaluronidase PH20 produced by recombinant DNA technology
224217802|NCT03634332|BIOLOGICAL|Pembrolizumab|Pembrolizumab is a potent and highly selective humanized monoclonal antibody (mAb) of the IgG4/kappa isotype designed to directly block the interaction between PD-1 and its ligands, PD-L1 and PD-L2
224317538|NCT02147041|DRUG|Placebo|
223628973|NCT06205836|DRUG|Fianlimab|Patients will receive fianlimab (1600 mg administered IV) on Day 1 of each 21 day cycle for a total of 4 cycles of treatment.
223628974|NCT02775188|DEVICE|interACTION|
223628975|NCT02775188|OTHER|Standard of Care Physical Therapy|
223628976|NCT00809263|DRUG|homeopathic remedy|Homeopathic remedy 12C potency, 10 drops TID X 7 days
223628977|NCT02490683|DIETARY_SUPPLEMENT|Luna Rich X|
223628978|NCT02490683|DIETARY_SUPPLEMENT|Placebo|Starch pill/or powder manufactured to mimic Luna Rich X and Reliv Now
223628979|NCT02490683|DIETARY_SUPPLEMENT|Reliv Now|
223628980|NCT03115944|DEVICE|Alma vShape Ultra|UltraSpeed ultrasound treatment, a series of four treatments
223628981|NCT03502005|DRUG|bictegravir/emtricitabine/tenofovir alafenamide|Discontinue ATRIPLA® and initiate BIKTARVY®
223628982|NCT01074775|BIOLOGICAL|Gut infection challenge with M bovis|Oral delivery of 100mg viable M bovis (approximately 10,000,000 viable bacilli) in 5mL 1.5% sodium glutamate solution on three occasions on days 0, 28 and 49
223628983|NCT05272007|PROCEDURE|EUS-biliary drainage|EUS-GBD with LAMS
223628984|NCT06230575|PROCEDURE|erector spinae block|Erector spinae plane block
224317539|NCT00033007|BEHAVIORAL|Behavior Therapy|
224317540|NCT01507311|DRUG|liraglutide|A single dose injected subcutaneously (under the skin)
223628985|NCT06230575|PROCEDURE|retrolaminar block|Retrolaminar block
223628986|NCT06230575|PROCEDURE|serratus anterior block|Serratus anterior plane block
223628987|NCT06230575|PROCEDURE|pectoral nerve block|Pectoral nerve block
223628988|NCT03763032|BEHAVIORAL|Counseling|The patient navigator will provide educational materials, assessments, and counseling to the patients
223628989|NCT02973386|DRUG|IMRT combine with cisplatin concurrent chemotherapy|Patients in the control arm received radical radiotherapy with IMRT, and cisplatin (100mg/m2 on day 1 and day 22) during RT.
223628990|NCT02973386|DRUG|IMRT combine with cisplatin concurrent chemotherapy plus capecitabine adjuvant chemotherapy|Patients in the experimental arm received radical radiotherapy with IMRT, and cisplatin (100mg/m2 on day 1 and day 22) during RT,followed by adjuvant chemotherapy with oral capecitabine(1000mg/m2/ twice a day for 14 days)every three weeks for eight cycles at 4 weeks later after RT.
223628991|NCT06204965|BEHAVIORAL|Time-restricted eating|Time-restricted eating (TRE) is a dietary pattern where food intake is restricted to 8 hours of the day with no limitation on nutrient quality or quantity. Participants assigned to the intervention group will eat their usual diet from 9:00 a.m. to 5:00 p.m., and then fast until the next day (protocol 8/16). During the 16-hour fast, only hot and cold drinks will be allowed, i.e. coffee, tea or tea and water, but all products and dishes with energy value (including coffee cream, sweet teas, alcohol, snacks, etc.) will be prohibited. The TRE protocol will be implemented 7 days a week for a period of 3 months (12 weeks).
223628992|NCT02726997|DRUG|Carboplatin|Given IV
223628993|NCT02726997|BIOLOGICAL|Durvalumab|Given IV
223628994|NCT02726997|OTHER|Laboratory Biomarker Analysis|Correlative studies
223628995|NCT02726997|DRUG|Paclitaxel|Given IV
223628996|NCT02726997|OTHER|Pharmacological Study|Correlative studies
223628997|NCT02726997|OTHER|Quality-of-Life Assessment|Ancillary studies
223628998|NCT05830500|DRUG|Anlotinib Hydrochloride Capsule|Anlotinib hydrochloride is a muti-target tyrosine kinase inhibitor that inhibits both tumor angiogenesis and tumor cell proliferation simultaneously.
223628999|NCT04549285|BIOLOGICAL|Human Cord Tissue Mesenchymal Stromal Cells (hCT-MSCs)|"Human Umbilical Cord Tissue-derived Mesenchymal Stromal Cells (hCT-MSC):~hCT-MSCs is an allogeneic cell product manufactured from donated umbilical cord tissue that is digested and expanded in culture, cryopreserved and banked. Doses contain 2x10\^6 cells/kg (up to a maximum dose of 100x10\^6 cells) diluted in plasmalyte-A with 5% HSA to a volume of 20-40mL."
223629001|NCT04205240|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic hematopoietic stem cell transplantation
223629002|NCT04205240|DRUG|Cyclophosphamide|Given IV
223629003|NCT04205240|BIOLOGICAL|Daratumumab|Given IV
223629004|NCT04205240|DRUG|Fludarabine|Given IV
223629005|NCT04205240|DRUG|Melphalan|Given IV
223629006|NCT04205240|DRUG|Mycophenolate Mofetil|Given IV or PO
223629007|NCT04205240|DRUG|Tacrolimus|Given PO or IV
223629008|NCT01810471|DEVICE|Applying ankle support device (white non-elastic tape, kinesiotape (TM), soft brace (Malleotrain TM)|
223629009|NCT01791244|DRUG|Rebif®|
223629010|NCT06560385|DIETARY_SUPPLEMENT|BLHK03|BLHK03 consists of a blend of probiotics (20 billion CFU in 1 sachet) and prebiotic compounds
223629011|NCT06560385|DIETARY_SUPPLEMENT|Active placebo|Active placebo contains 5mcg of Vitamin B7
223629012|NCT03197298|DRUG|Clopidogrel|
223629013|NCT03197298|DRUG|Ticagrelor|
223629014|NCT01402089|DRUG|Sunitinib|Patients with renal-cell cancer or GIST are receiving conventional treatment with sunitinib (50mg/day for 4 out of 6 weeks)
223629015|NCT01402089|DRUG|Erlotinib|Patients with non small-cell lung cancer receive conventional treatment with erlotinib 150mg/day.
224317541|NCT01507311|DRUG|placebo|A single dose injected subcutaneously (under the skin)
224317542|NCT01726829|DEVICE|MD-Logic Artificial Pancreas (MDLAP) system|
224317543|NCT01726829|PROCEDURE|sensor augmented pump therapy|
223629016|NCT01402089|DRUG|Midazolam|For phenotyping of CYP3A4, all patients receive one-time midazolam 2mg as a drinking solution at the start of study treatment.
223629017|NCT01402089|DRUG|Caffeine|For phenotyping of CYP1A2, patients with non small-cell lung cancer receive additionally one-time caffeine 100mg as a tablet.
223629018|NCT01383928|DRUG|Ixazomib|Ixazomib capsules
224317544|NCT02655731|DEVICE|PVI with HeartLight|Catheter ablation
224317545|NCT01542801|DRUG|Norfloxacin|Norfloxacin 400 mg per day
224317546|NCT01542801|DRUG|ciprofloxacin|Ciprofloxacin 750 mg per week
224317547|NCT02594865|DIETARY_SUPPLEMENT|Glucerna|Glucerna ® 1.5 kcal (Abbott, USA), the standard enteral formula used at our ICU and the investigational enteral feeding.
223629019|NCT01383928|DRUG|Lenalidomide|Lenalidomide capsules
223629020|NCT01383928|DRUG|Dexamethasone|Dexamethasone Tablets
223629021|NCT06562205|DEVICE|PAP System A (with Amalfi) then PAP System B (with CLA11)|PAP System A (with Amalfi) for 7 days followed by PAP System B (with CLA11) for 7 days
223629022|NCT06562205|DEVICE|PAP System B (with CLA11) then PAP System A (with Amalfi)|PAP System B (with CLA11) for 7 days followed by PAP System A (with Amalfi) for 7 days
223629023|NCT00367822|DRUG|Lisuride|
223629024|NCT00367822|DRUG|Ropinirole|
223629025|NCT00367822|DRUG|Placebo|
223629026|NCT04742491|DRUG|Immediate Intervention Arm Truvada in the US|Truvada in the United States
223629027|NCT04742491|DRUG|Deferred Intervention Arm Truvada in the US|Truvada in the United States
223629028|NCT04742491|DRUG|Immediate Intervention Arm Truvada in Brazil|Truvada in Brazil
223629029|NCT04742491|DRUG|Deferred Intervention Arm Truvada in Brazil|Truvada in Brazil
223629030|NCT04742491|DRUG|Immediate Intervention Arm Descovy in the US|Descovy in the United States
223629031|NCT04742491|DRUG|Deferred Intervention Arm Descovy in the US|Descovy in the United States
223629032|NCT05924984|DEVICE|perforator locator|During CT scan, the patient was lying on the examination bed in a supine position, with the patient's toes facing up and fixed with an ankle fixator, the perforator was placed on the outside of the patient's thigh, and the base was extended or shortened according to the length of the patient's thigh, so that the iliac pole was located on the anterior superior spine of the patient's iliac and the patella pole was located on the lateral border of the patient's patella, and the positioning point was marked on the skin with a pen. After CT examination, the position of the perforating branch was displayed after 3D reconstruction of blood vessels by computer, and the position of the perforating branch was calculated using the computer position. The perforating branch positioning rod was moved according to the calculated scale to make it correspond to the scale, and the corresponding skin position mark was made according to the perforating branch positioning rod.
224217803|NCT05944770|OTHER|DIY portable air cleaner with a highly effective filter|"A portable air filtration device that can be homemade (DIY), constructed by attaching a highly effective air filter (MERV13 rating or higher) to a 20 inch box fan to filter air pollutants including particulate matter of size 2.5 micrometers diameter or greater."
224217804|NCT05944770|OTHER|DIY portable air cleaner with sham filtration|"A portable air filtration device that can be homemade (DIY) by attaching an air filter to a 20 inch box fan. The portable air cleaner with sham filtration with have a filter that is not effective for filtration of fine particulate matter, including that in wildfire smoke."
223629033|NCT00212108|DRUG|celecoxib, gefitinib|The dose of ZD1839 to be administered is 250mg. ZD1839 will be taken once daily in the morning at approximately the same time each day. If the patient inadvertently did not take the dose in the morning, the patient may take that dose anytime up to 10pm that same day. The daily treatment will be resumed the next day at the scheduled morning dose. Celecoxib will be administered at 400 mg bd.
223629034|NCT01254136|DRUG|INCB007839 300mg BID|INCB007839 tablets (300 mg BID) in combination with trastuzumab and vinorelbine will be administered in an initial Cycle of 28 days and followed by continuous 21-day cycles subsequently. Trastuzumab will be administered in continuous 21-day cycles beginning on Day 8 of Cycle 1. Vinorelbine will be administered on a weekly schedule for a minimum of the first four cycles beginning on Cycle 1 Day 8. All drugs will be administered continuously as tolerated or until a protocol-defined stopping criteria is met.
223629035|NCT01254136|DRUG|Trastuzumab|INCB007839 tablets (300 mg BID) in combination with trastuzumab and vinorelbine will be administered in an initial Cycle of 28 days and followed by continuous 21-day cycles subsequently. Trastuzumab will be administered in continuous 21-day cycles beginning on Day 8 of Cycle 1. Vinorelbine will be administered on a weekly schedule for a minimum of the first four cycles beginning on Cycle 1 Day 8. All drugs will be administered continuously as tolerated or until a protocol-defined stopping criteria is met.
223629036|NCT01254136|DRUG|Vinorelbine|INCB007839 tablets (300 mg BID) in combination with trastuzumab and vinorelbine will be administered in an initial Cycle of 28 days and followed by continuous 21-day cycles subsequently. Trastuzumab will be administered in continuous 21-day cycles beginning on Day 8 of Cycle 1. Vinorelbine will be administered on a weekly schedule for a minimum of the first four cycles beginning on Cycle 1 Day 8. All drugs will be administered continuously as tolerated or until a protocol-defined stopping criteria is met.
223629037|NCT00259597|PROCEDURE|breast ductal lavage|breast ductal lavage and nipple aspiration done once
223629038|NCT05298514|OTHER|Not applicable - qualitative research study|We are not delivering interventions. This is a qualitative study in the form of focus groups.
223629039|NCT03770546|BIOLOGICAL|Amnion Injection|Per the manufacturer, this is considered an injection of tissue/organic matter.
223629040|NCT03770546|DRUG|Betamethasone injection|Routine steroid injection for these pathologies. Betamethasone Sodium Phosphate and Betamethasone Acetate injection.
223629041|NCT06218316|DRUG|botulinum toxin A|Botulinum Neurotoxin A (BoNT-A) Injections will administered directly into the bulk of the muscles, with two injection sites at each head of the gastrocnemius and two sites into the medial hamstring. one vial of BoNT-A in 2 mL of 0.9% sodium chloride solution. followed by a 3-month rehabilitation program. The entire intervention including rTMS, BoNT-A, and rehabilitation training program spanned a period of three months.
223629042|NCT06218316|DEVICE|Transcranial Magnetic Stimulation|Repeated Transcranial Magnetic Stimulation (rTMS) Stimulation coil will strategically place on the primary motor cortex (M1), The patients received 1500 pulses per session, two sessions per week for 3 months, in a combination with 3-month rehabilitation program.
224217805|NCT00119132|DRUG|artesunate-amodiaquine|
224217806|NCT00119132|DRUG|sulphadoxine-pyrimethamine|
224217807|NCT05549128|DEVICE|Photobiomodulation|The red laser (DMC) will be applied with the aim of reducing the anxiety of children during the dental consultation. It will be continuously and directly with 60J of energy, wavelength of 660nm and 100mW/cm2 of power. The application will be located in the unilateral radial artery for 10 minutes. The laser will be transmitted through an appropriate bracelet where the laser tip fits perfectly. It is a painless, non-invasive method that does not cause any discomfort during application.
224217808|NCT05549128|DEVICE|Photobiomodulation sham|The red laser (DMC) will be applied off. I
224317548|NCT02594865|DIETARY_SUPPLEMENT|Fresubin|Fresubin ® Energy Fibre (Fresenius, UK), the control enteral feeding.
223629043|NCT06218316|OTHER|Rehabilitation Training Protocol|Rehabilitation Training Protocol: As part of the study protocol, all participating children underwent a comprehensive weekly routine rehabilitation training program. Training Schedule: sessions will conduct for duration of 45 minutes. Training occurred four days a week.
223629044|NCT01490151|DEVICE|TTR controller (Medtronic)|Subjects will arrive in the morning and the TTR controller (Medtronic) will be initialized, and then they will give their usual premeal insulin bolus for breakfast. At lunch, they will either have a low glycemic index meal or a high glycemic index meal and the meal bolus will be omitted. The device will be turned off before dinner, they will have their usual insulin bolus for dinner, eat dinner, and then be discharged to home. On another admission, they will receive an insulin dose before lunch which will be 120% of their usual insulin bolus.
223629045|NCT05841186|OTHER|Timing of pegfilgrastim administration|Timing of pegfilgrastim administration
223629046|NCT03359538|DRUG|Rapamycin|tablets containing Rapamycin/placebo will be administered based on body surface area and adjusted taking into consideration plasma rapamycin dosage
223629047|NCT03359538|DRUG|Placebo Oral Tablet|tablets containing Rapamycin/placebo will be administered based on body surface area and adjusted taking into consideration plasma rapamycin dosage
223629048|NCT02925286|OTHER|Prevention program for gambling in the workplace|The intervention group will receive a gambling prevention program which includes generating and implementing policies and education on addiction and gambling. The full length of the program will be about 14 hours.
223629049|NCT06151405|OTHER|DGA Diet|"A fully provisioned isocaloric, isonitrogenous study diet following the Dietary Guidelines for Americans (DGA)~Including:~* A variety of vegetables and fruits~* Grains, at least half of which are whole grains~* Fat-free or low-fat dairy~* A variety of protein foods, including seafood, lean meats and poultry, eggs, legumes, nuts, and seeds~* This healthy eating pattern also limits saturated fats and trans fats, added sugars, and sodium."
223629050|NCT06151405|OTHER|MCT Diet|A fully provisioned isocaloric, isonitrogenous study diet following the Dietary Guidelines for Americans supplemented with medium chain triglycerides (MCT).
223629051|NCT06151405|OTHER|KETO Diet|A fully provisioned isocaloric, isonitrogenous ketogenic study diet.
223629052|NCT04293575|DEVICE|MitraClip|transcatheter MitraClip device (Abbott Vascular, Santa Clara, California)
223629053|NCT01863784|DRUG|JNJ-38518168|All participants will receive JNJ-38518168 30 mg tablet once daily from Day 1 to Day 14.
223629054|NCT04438486|BEHAVIORAL|Group A|specific dietary advice for Hyperuricemia
223629055|NCT04438486|DIETARY_SUPPLEMENT|Group B|Barely Green（three times a day, 5g(10 tablets)） dietary advice for Hyperuricemia as Group A
223629056|NCT00279175|BIOLOGICAL|Intracoronary infusion of enriched bone marrow-derived progenitor cells|
224217809|NCT04316897|DEVICE|Echocardiography|It is a an observational cross-sectional echocardiographic screening study in Assiut Governate conducted after seeking approval from the local institutional review board and human subjects' protection.
224217810|NCT03197805|DIAGNOSTIC_TEST|PAM 50 test|Patients with an equivocal-HER2 breast cancer (IHC Score 2 and equivocal ISH defined as HER2/Chr17 ratio \<2 and 4 ≤HER2 gene number copy \< 6) will be eligible for RNA genomic test (PAM 50 test). The use of genomic test could help the oncologist to define the better therapeutic decision in a HER2 equivocal population.
224217811|NCT01082445|DRUG|N-acetylcysteine|600 mg, 1 tablet 3 times a day for 3 months
224217812|NCT01082445|DRUG|Placebo|Placebo
224217813|NCT05350254|OTHER|Chiropractic maintenance care|Manual Therapy, individual exercises and lifestyle advice
224217814|NCT05350254|OTHER|Standard chiropractic care|Standard care based on clinician's judgement
224217815|NCT03980327|DIETARY_SUPPLEMENT|probiotic|Lactobacillus probiotic
223629057|NCT00279175|BIOLOGICAL|Placebo medium supplemented with autologous serum|
223629058|NCT01149096|PROCEDURE|Bone Marrow Donation|Undergo bone marrow harvest
223629059|NCT01149096|BIOLOGICAL|Filgrastim|Given subcutaneously
223629060|NCT01149096|OTHER|Laboratory Biomarker Analysis|Optional correlative studies
223629061|NCT05783141|DIETARY_SUPPLEMENT|New prebiotic follow-on formula, randomly assigned to healthy toddlers|Standard follow-on formula administered orally
223629062|NCT05783141|DIETARY_SUPPLEMENT|Standard follow-on formula, randomly assigned to healthy toddlers|Standard follow-on formula administered orally
223629064|NCT02866786|DRUG|Metformin|
223629065|NCT02866786|DRUG|ethinyl estradiol and cyproterone acetate|Oral Contraceptive Pill
224217816|NCT03980327|DIETARY_SUPPLEMENT|medium chain triglyceride oil|
224217817|NCT04512027|OTHER|Prolectin-M; a (1-6)-alpha-D-Mannopyranose class|A treatment to decrease viral load, detected through digital droplet PCR, in mild to moderate cases of RT-PCR positive COVID-19
224217818|NCT04512027|OTHER|Standard of Care|Currently approved standard of care for patients without symptoms requiring hospitalisation will be provided to all.
224217819|NCT04168762|OTHER|Transcranial Ultrasound Magnetic Stimulation|Transcranial Ultrasound Magnetic Stimulation is a paradigm that allows for concurrent and concentric ultrasound stimulation with transcranial magnetic stimulation (TMS).
224317549|NCT04417413|DEVICE|Fotona ProlapLase|Non-ablative SMOOTH mode intravaginal Er:YAG teratment for pelvic organ prolapse
223629066|NCT01350947|DRUG|5-Azacitidine|"Administered on Days 1-7 of each Cycle.~Subcutaneous administration:~To provide a homogeneous suspension, the contents of the syringe must be re-suspended by inverting the syringe 2-3 times and vigorously rolling the syringe between the palms for 30 seconds immediately prior to administration.~The 5-azacitidine suspension is administered subcutaneously.~Intravenous Administration:~5-Azacitidine solution is administered intravenously. Administer the total dose over a period of 10-40 minutes."
223629067|NCT00900653|DRUG|Gynoflor E (low dose estriol with lactobacillus)|The medication, in the form of one vaginal tablet, is administered in the evenings for 18 days
224217820|NCT03165266|DIAGNOSTIC_TEST|Two dimensional Echocardiography|"I- Routine transthoracic assessment for Left Atrium and Left Ventricle dimensions :~II- transthoracic assessment of the Right ventricular systolic function by:~1. . Right Ventricle fractional area change.~2. . Tricuspid annular plane systolic excursion .~3. . Tissue Doppler derived tricuspid annular systolic velocity.~4. . Right ventricle myocardial performance index . III- Assessment of Right ventricular diastolic function: is carried out by pulsed Doppler of the tricuspid inflow, or tissue Doppler of the lateral tricuspid annulus.~IV Assessment of Right Ventricle chamber quantification:~* Right ventricular basal, mid ,and longitudinal dimensions.~* Right ventricular Outflow Tract, and wall thickness V- Assessment of right atrial major ,and minor dimensions ,and right atrial End- systolic area IV- Assessment of longitudinal Right ventricular strain and strain rate by speckle tracking"
224217821|NCT01164735|OTHER|Laboratory Biomarker Analysis|Correlative studies
224217822|NCT04551079|DRUG|TAK-994|TAK-994 tablets.
224217823|NCT04551079|DRUG|Placebo|TAK-994 placebo-matching tablets.
224217824|NCT01050166|OTHER|Transplantation of labeled islets|
224217825|NCT01562470|OTHER|Cellulite reduction cream|1/8 tsp cellulite cream will be applied to the thigh twice daily - in the morning and at night, for a period of 16 weeks.
224217826|NCT02334956|OTHER|Brain MRI|
224217827|NCT03833037|OTHER|Soft tissue sarcomas in adults|Adult sinovial sarcoma
224217828|NCT00251628|OTHER|Standard Care|standard care
224217829|NCT00251628|OTHER|ATC Dosing|ATC dosing of a weight-appropriate dose of a nonopioid/opioid combination analgesic, every 4 hours around-the-clock for the first 3 days following surgery
224217830|NCT00251628|OTHER|Structured Pain Management Program|The structured pain management program consisted of a nurse coaching intervention which included an evaluation of the child's current condition, review of the pain intensity scores, verification that the child was taking the pain medication, re-education regarding the rationale for ATC dosing, review of strategies to facilitate medication administration, and re-education about potential side effects associated with analgesic administration.
224217831|NCT00251628|OTHER|As needed dosing|"As needed analgesic dosing with a weight-appropriate dose of a nonopioid/opioid combination analgesic, every 4 hours as needed for pain."
224217832|NCT03148288|DIETARY_SUPPLEMENT|Vitamin D|VItamin D
224217833|NCT03148288|DIETARY_SUPPLEMENT|placebo|placebo
224217834|NCT04852991|PROCEDURE|Modified Purandare cervicopexy|The modified Purandare's cervicopexy will be performed in low lithotomy position . Pfannenstiel incision was utilized and the abdomen was opened in layers maintaining perfect hemostasis. Uterus will be delivered through the incision and held with uterus holding forceps. The bladder was dissected inferiorly. A 25-30 cm long strip of polypropylene mesh was prepared by soaking. The mesh was fixed anteriorly at the level of isthmus by No.1 polypropylene sutures . The ends of the mesh were brought lateral to rectus muscle retroperitoneally on both sides taking care not to injure the inferior epigastric vessels. After confirming the correct fixation and haemostasis the uterovesical fold of peritoneum was approximated. The ends of the mesh were fixed to the rectus muscle by criss crossing using No. 1 polypropylene sutures. After confirming the haemostasis, the abdomen was closed in layers. Per speculum examination was done to note the reduction of prolapse.
224217835|NCT04852991|PROCEDURE|Abdominal sacral hysteropexy|After peritoneal entry through pfannenstiel incision was, the bladder is mobilized off the cervix. Windows are made in the broad ligament at the level of the isthmus. Posteriorly, the rectovaginal space is entered at the level of the uterosacral ligaments. Next, a 15x15-cm polypropylene mesh is used to fashion two 4.5- to 5-cm-wide strips of mesh; one is bisected for a distance of 5 cm to produce a Y-configuration for the anterior mesh.The anterior mesh arms are passed through the broad ligament windows and attached to the cervix and pubocervical fascia using interrupted 2-0 PDS. The posterior mesh is attached to the rectovaginal fascia using transverse-interrupted 2-0 PDS sutures. Once the sacral dissection has exposed the anterior longitudinal ligament, the proximal ends of the 2 mesh strips are attached to the sacral promontory using two 2-0 polyester sutures to provide elevation of the uterus without tension. The peritoneum is closed over the mesh using a 3-0 vicryl suture
224217836|NCT00361257|DRUG|Minocycline|Tetracycline antibiotic, 100 mg taken orally every 12 hours
224217837|NCT00361257|DRUG|Placebo (Tetracycline)|Tetracycline antibiotic placebo, orally every 12 hours
224217838|NCT06057285|DEVICE|An ACLs cart training course was developed using augmented reality (AR) technologies|The developed first aid cart learning system was applied to ACLs drills in a regular ACLs training program, and an AR group used this learning system to assist in their learning. The AR group scanned the dedicated AR marker using a mobile device
224317550|NCT04860609|OTHER|Conventional Physiotherapy|"The treatment will be given in the following way.~1. Tens~2. Infrared/Moist Heat heat for 10 minutes at low back region.~3. Lumbar Mobilization (Maitland) CPA 3 sets of 10 reps~4. Stretching Exercises (Calf, Hams, Back Extensors) 3 sets of 8-10 reps~5. Strengthening Exercises (Back Extensors) 3 sets of 8-10 reps~6. Postural Education~7. Home Plan~8. Bed Rest with lumbar Sacral Support~9. Home plan:~Exercises Posture Correction Precautions Contra indication"
224317551|NCT04860609|OTHER|Lumber Spinal Decompression|"The treatment will be given in the following way.~1. Tens~2. Infrared/Moist Heat heat for 10 minutes at low back region.~3. Lumbar Mobilization (Maitland) CPA 3 sets of 10 reps~4. Stretching Exercises (Calf, Hams, Back Extensors) 3 sets of 8-10 reps~5. Strengthening Exercises (Back Extensors) 3 sets of 8-10 reps~6. Postural Education~7. Home Plan~8. Decompression therapy session lumbar spinal decompression therapy for 30 minutes.~9. Home plan:~Exercises Posture Correction Precautions Contra indication"
224317552|NCT04813783|OTHER|Mucositis care training to be given in line with MASCC / ISOO 2019|Mucositis care training to be given in line with MASCC / ISOO 2019
224317553|NCT00040131|DRUG|IL-10|
224317554|NCT02524457|OTHER|This is an observational study. There are no interventions|
224317555|NCT02432157|DRUG|HTS 3%|3% HTS at a dose of 250 ml every 6 hours for 7 days
224317556|NCT02432157|DRUG|Standard fluid management|Routine fluid management strategy as pre-specified by our SAH management protocol.
224317557|NCT01038362|OTHER|NCEP Step 1 diet plus Almonds|NCEP Step 1 Diet Plus Almonds 3 oz per day for 6 weeks
223629068|NCT01630148|DRUG|Bemiparin|Bemiparin Sodium 3,500IU anti Xa/0.3 ml solution for injection in pre-filled syringe will be provided for each patient in Bemiparin group (Moderate, High and Highest risk groups for thromboembolism) 6 hours after surgery and then daily for up to 7 days.
223629069|NCT03288532|DRUG|Durvalumab|controlled infusion via an infusion pump into a peripheral or central vein
223629070|NCT03288532|DRUG|Tremelimumab|controlled infusion via an infusion pump into a peripheral or central vein
223764050|NCT04399161|DRUG|Probiotic|Probiotic mouth rinse will be prepared by using a commercially available probiotic product (Sporolac Plus powder- 1gm sachet containing not less than 1.5 billion cells of Lactobacillus acidophilus, Lactobacillus rhamnosus, Bifidobacterium longum, Bacillus coagulans, Saccharomyces boulardii). Each sachet will be dissolved in 15 ml of water in a measuring cup and used as a mouth rinse.
224217839|NCT01904578|OTHER|true accupressure|Four acupoints were chosen for subjects in the acupressure group. They were Shenmen on the wrist crease, Sanyinjiao point (SP6) on both feet, Fengchi on the hairline of the back neck (occipital area)and Yintang, at the top of the nose on the center line between the ends of the eyebrows.
224217840|NCT01904578|OTHER|sham acupressure|Non-acupoints, which were 1 to 3 traditional Chinese unit of length (CUN) away from true acupoints, were used in sham acupressure group.These points were out of the route of energy
224217841|NCT02519283|BEHAVIORAL|GUIDED-HF|"Participants in this arm will receive a tailored discharge plan via a transition nurse coordinator directed team (TNC Team).~1. Disease education: Health literacy screen will identify barriers to understanding discharge and medication instructions.~2. Lifestyle interventions: Includes receiving smoking cessation information and instructions to track daily weights.~3. Guideline recommendations for medications and device referral: Includes determining the need for prescriptions for ACEIs, ARBs, beta blockers, aldosterone antagonists, anticoagulants and referral for pacemaker/defibrillator consideration.~4. Outpatient follow-up appointment: TNC Team will provide a scheduled appointment within 7 days and will conduct a home visit within 48 hours of ED discharge."
223629071|NCT05890833|DIAGNOSTIC_TEST|The risk of falls|Heel-Rise-Test, Chair-Rise Test, Semi-tandem stand, Trunk Rise Test, and Foot-tapping speed. Test battery two includes Timed Up and Go test, 10 Meter Walk Test, Six Minute Walk test, The Falls Efficacy Scale International FES-I, The Morse Fall Scale.
223764051|NCT04685304|GENETIC|Pharmacogenetic Testing|Genetic results will be reported for CYP2D6, CYP2C19, CYP2C9, CYP2B6, CYP3A4, CYP3A5, SLCO1B1, TPMT, and VKORC1.
223764052|NCT04685304|OTHER|Pharmacist Consultation Note|Recommendations will be based on phenotypes translated from genetic data in accordance with CPIC guidelines. Drug interactions will be incorporated into phenotype assignments when appropriate.
224317558|NCT01038362|OTHER|No Almonds|NCEP Step 1 diet without almonds
224317559|NCT05734248|PROCEDURE|Facial filler injection|Hyaluronic acid will be injected on the cheek, based on the aesthetic evaluation of the face.
224317560|NCT04283968|BIOLOGICAL|Fecal Microbial Transplantation|Fecal Microbial Transplantation in adults with Atopic Dermatitis
224317561|NCT04283968|BIOLOGICAL|placebo fecal transplantation|placebo fecal transplantation
224317562|NCT00852722|OTHER|Low fat study diet|The low fat study diet is a very low-saturated-fat, plant food based diet. It will be approximately 10% fat, 14% protein and 76% carbohydrate.The diet is is starched based and also contains fresh or frozen fruits and vegetables and there is no animal meat used, including no use of fish. This diet is very low in saturated fats and enriched in unsaturated fats. Subjects do not take dietary supplements.
224317563|NCT04400422|DIETARY_SUPPLEMENT|Lipano formula|Subjects will be asked to take an MCT infant formula to assess the tolerability, compliance and overall acceptability of the product for patient with LCHAD
223629072|NCT03651765|DRUG|Setmelanotide|Once daily subcutaneous injection
223629073|NCT03853473|PROCEDURE|Remote Ischemic Preconditioning|Remote Ischemic Preconditioning (RIPC) occurs when a limb is made transiently ischemic (5 minutes) using a simple blood pressure cuff. We are proposing that study participants in the RIPC group perform the intervention daily at home for at least 14 days prior to scheduled surgery. They will inflate a blood pressure cuff on the upper portion of their nondominant arm, inflate it to 225 mmHg for 5 minutes, release the cuff for 5 minutes, and repeat this 5 times (for a total of 45 minutes). A study coordinator will monitor compliance with phone calls and daily log sheets that must be filled out.
223629074|NCT04268641|OTHER|Arm 1|"Materials used for the course :~1. : Standard Wheelchair~2. : Standard Wheelchair + Seat back + Positioning cushion~3. : Standard Wheelchair + Seat back + Positioning cushion + Belt"
223629075|NCT04268641|OTHER|Arm 2|"Materials used for the course :~1. : Standard Wheelchair~2. : Standard Wheelchair + Seat back + Positioning cushion + Belt~3. : Standard Wheelchair + Seat back + Positioning cushion"
223629076|NCT04268641|OTHER|Arm 3|"Materials used for the course :~1. : Standard Wheelchair + Seat back + Positioning cushion~2. : Standard Wheelchair + Seat back + Positioning cushion + Belt~3. : Standard Wheelchair"
223629077|NCT04268641|OTHER|Arm 4|"Materials used for the course :~1. : Standard Wheelchair + Seat back + Positioning cushion~2. : Standard Wheelchair~3. : Standard Wheelchair + Seat back + Positioning cushion + Belt"
223629078|NCT04268641|OTHER|Arm 5|"Materials used for the course :~1. : Standard Wheelchair + Seat back + Positioning cushion + Belt~2. : Standard Wheelchair~3. : Standard Wheelchair + Seat back + Positioning cushion"
223629079|NCT04268641|OTHER|Arm 6|"Materials used for the course :~1. : Standard Wheelchair + Seat back + Positioning cushion + Belt~2. : Standard Wheelchair + Seat back + Positioning cushion~3. : Standard Wheelchair"
223629080|NCT04910048|OTHER|POPOP (preoperative patient optimization program)|A 2 month structured program focused on reduction of BMI, body weight, visceral fat, body fat and improvement of lean body mass and intracellular fluid.
224217842|NCT02519283|BEHAVIORAL|Standard of Care|"Those in the standard care arm will receive structured ED discharge assessment to include:~1. discharge instructions;~2. medication reconciliation~3. encourage follow-up."
224217843|NCT05826249|DRUG|SIM0417/Ritonavir|Single oral dose of 750 mg SIM0417 coadministered with 100 mg ritonavir.
224217844|NCT02732587|DRUG|Saracatinib|Subjects will receive 125 mg Saracatinib for 8-11 days followed by an alcohol interaction lab session
224317564|NCT02352012|OTHER|Autologous blood|Autologous blood was perfused to the target pulmonary segment
223629081|NCT04910048|OTHER|SOC (standard of care)|Referral to a dietician for two months of self-directed weight loss
223629082|NCT04741581|DIETARY_SUPPLEMENT|ThickenUp® Gel Express|Thickening gel
223764053|NCT04685304|OTHER|Delayed pharmacogenetic testing|Pharmacogenetic testing and a pharmacist consultation note will be provided to participants provided to the standard care arm once 3 months have passed since their baseline visit.
224217845|NCT01169649|DRUG|MK-2206|MK-2206 will be given orally 200 mg qw as given in the prior Ph1 clinical trial that demonstrated safety, tolerability and adequate PK/PD values at this dose. Follow-up imaging scans will be performed every 12 weeks to evaluate response. Patients must take MK-2206 orally at least 2 hours before or 2 hours after food or a meal.
224217846|NCT01285531|DEVICE|Compass Lumbar Puncture Enhanced|Participants randomly assigned to this group will receive a lumbar puncture using the Compass device.
224217847|NCT00522327|OTHER|remote simultaneous medical interpreting|remote simultaneous medical interpretation
223629083|NCT05940103|OTHER|Augmented Reality (AR)|AR headset - a device that the participants will wear over their head and eyes and will add holographic elements to a live view of workplace training scenario
223629084|NCT04519008|DEVICE|Mobile app|Medical device for improving emotion dysregulation
223629085|NCT04519008|COMBINATION_PRODUCT|Treatment as usual|Bimonthly individual psychotherapy and psychostimulant medications
224217848|NCT00522327|OTHER|usual and customary|usual and customary interpreting
224217849|NCT00522327|OTHER|ENglish speaking|English speakers
224217850|NCT06192082|PROCEDURE|The conscious sedation group|The conscious sedation group (Group A) received sufentanil 0.05-0.1 5 minutes before examination μ G/kg, administration time 30 seconds, 1-2 mg of midazolam administered 2 minutes before examination; Evaluate the patient's MOAA/S score, insert a digestive endoscope at 2-3 minutes, and add 1-2mg of midazolam if the patient is unable to tolerate coughing or movement during the examination. Reevaluate the MOAA/S score, and continue the operation after 2-3 minutes;
224217851|NCT06192082|PROCEDURE|Intravenous general anesthesia group|Intravenous general anesthesia group (Group B): sufentanil 0.05-0.1 μ G/kg, administration time 30 seconds, 1mg/kg of propofol administered 2 minutes before examination. Depending on the patient's sleep status, 10mg of propofol can be administered every 30 seconds; Evaluate the patient's MOAA/S score. At 0-1 points, a digestive endoscope is inserted. If there is coughing or physical activity during the examination that the patient cannot tolerate, propofol 10-20mg can be administered multiple times. Evaluate the MOAA/S score again, and continue the operation after 0-1 points.
223764054|NCT06145009|BEHAVIORAL|Time restricted eating|Limit food intake to 10 hours per day as described in the experimental arm section.
223764055|NCT00457197|DRUG|Placebo|Inactive ingredient matching the active medication in appearance.
224217852|NCT05296681|DRUG|NBT-NM108|Patients receive irinotecan-based chemotherapy per standard of care.
223629086|NCT06469294|PROCEDURE|Control (C) - Saline Gel|After conventional periodontal treatment, saline gel will be applied in the periodontal pocket and, after 5 minutes, the laser application will be simulated with the device in inactive mode, in order to maintain blinding of the patients.
223629087|NCT06469294|PROCEDURE|Test (t) - Photodynamic therapy and 2% chlorexidine and 0,005% methylene blue|After conventional periodontal treatment, photosensitization will be performed with 2% chlorhexidine gel with 0.005% methylene blue (Fórmula e Ação Farmácia, São Paulo, SP, Brasil) for 5 minutes and photodynamic therapy will be applied with a rede laser (660nm) usinf DuoⓇ laser (MMOptics, São Carlos, SP, Brazil) with the optical fiber inside the periodontal pocket in back and forth movements, according to the manufacturer's protocol, for 90s, 9 joules of energy, dose of 508.5J/cm2, irradiance of 5.65W/cm2 and power of 100mW.
223629088|NCT04039087|DRUG|Sildenafil 40mg oral capsule|40 mg, sildenafil capsule taken by mouth thrice daily
223629089|NCT04039087|DRUG|Placebo Oral capsule|Placebo capsule taken by mouth thrice daily
223629090|NCT03039309|PROCEDURE|Endoscopic Submucosal Dissection|Endoscopic submucosal dissection is an endoscopic resection technique that utilises an endoscopic knife to remove lesions within the gastrointestinal tract in an en bloc fashion.
223764056|NCT00457197|DRUG|Quetiapine|Quetiapine is an atypical antipsychotic approved for the treatment of schizophrenia, bipolar disorder, and in the XR version along with an SSRI to treat major depressive disorder.
223764057|NCT00193882|DRUG|Cisplatin|80mg/m2 IV day 1
223629091|NCT06526494|DRUG|Metformin|Oral ingestion for 12 weeks
223629092|NCT06526494|OTHER|Placebo|Oral placebo for 12 weeks
223629093|NCT04572217|DRUG|Topiramate|Topiramate (starting dose 25 mg daily, max dose 100 mg daily)
223629094|NCT04572217|DRUG|Phentermine|Phentermine (starting dose 8 mg, max dose 16 mg)
223629095|NCT04786743|OTHER|endoscopic intervention|performing endoscopy
223764058|NCT00193882|RADIATION|Radiotherapy|35 Gy in 15 fractions
224217853|NCT04262310|OTHER|Small Bowel and Colonic Permeability Test|small bowel and colonic permeability based on oral probe molecules and urine excretion in 60 healthy white, female and male adults aged 18-70y
224217854|NCT02754791|DEVICE|Steripath|A device that diverts the first 2 ml of blood drawn in order to reduce contamination
224217855|NCT02754791|DEVICE|Soluprep|Wipes containing alcohol (70%) and chlorhexidine (2%) to achieve skin sterilization
224217856|NCT00273195|DEVICE|Implantable Cardioverter Defibrillator|
224217857|NCT00660790|OTHER|Intensified Treatment of risk factors|Patients received a target oriented, intensified treatment of risk factors according to current national treatment guidelines
224217858|NCT01093859|DRUG|PRX-105|Sterile solution for intravenous injection
224217859|NCT02961452|OTHER|Cross reaction detection|
224217860|NCT03648333|DRUG|Exforge tab. 10/160mg|
224217861|NCT03648333|DRUG|Lodivixx tab. 5/160mg|
224217862|NCT02947932|DRUG|Resveratrol|pre-ERCP intervention
224217863|NCT02947932|DRUG|Indomethacin|post-ERCP intervention in high risk patients
224217864|NCT03840811|DRUG|Cefixime|Mandatory rescue therapy consisting of cefixime 400 mg orally in a single dose: on patient request, at the onset of symptoms or on the 5th study day after inoculation.
224217865|NCT03840811|DRUG|Ceftriaxone|Mandatory rescue therapy consisting of ceftriaxone 250 mg intramuscularly in a single dose: on patient request, at the onset of symptoms or on the 5th study day after inoculation.
224317565|NCT02352012|DEVICE|Bronchial plug|Bronchial plug was placed to the target pulmonary segment
224317566|NCT05107596|DRUG|64Cu-DOTA-ECL1i|Inject PET Radioisotope for imaging
224317567|NCT01356212|DRUG|Ketorolac tromethamine|30 mg ketorolac (15 mg (100 ul) per nostril) administered intranasally
224317568|NCT01356212|DRUG|Ketorolac tromethamine|30 mg ketorolac (15 mg (100 ul) per nostril) administered intranasally
223629096|NCT06961552|OTHER|reflexology masaj group|The women in the reflexology group will receive a reflexology massage with proven regional applications, pressure sliding and circular pressure three times with baby oil for two cycles by the researcher, starting at the end of menstruation (5-7th days of the cycle), for a total of 30 minutes in a single session for each foot, starting at 15 minutes per foot. A total of 8 reflexology massage sessions will be performed, one session per week (Monday) for 8 weeks.
223629097|NCT01349543|BIOLOGICAL|RSV A Memphis 37|Intranasal administration
223629098|NCT03939624|DRUG|Sodium-glucose cotransporter 2 (SGLT2) inhibitors|Exposure to SGLT2 will be defined as a prescription for a SGLT2 inhibitor alone (canagliflozin, dapagliflozin, empagliflozin) or in combination with non-DPP4 inhibitor drugs at cohort entry date.
223629099|NCT03939624|DRUG|Dipeptidyl peptidase-4 (DPP-4) inhibitors|Exposure to DPP-4 will be defined as a prescription for a DPP-4 inhibitor (alogliptin, linagliptin, saxagliptin, sitagliptin, vildagliptin) alone or in combination with non-SGLT2 inhibitor drugs at cohort entry date.
223629100|NCT04829292|BEHAVIORAL|Supportive therapy and CBT|In this open trial participants are first offered supportive therapy followed by CBT
223629101|NCT00929214|DRUG|Standard Therapy|"Chemotherapy and/or Endocrine Therapy:~For 3 - 9 months, all patients will receive systemic chemotherapy agents appropriate for the tumor characteristics and patient's prior treatment history, and may also be placed on endocrine therapy as determined by the treating medical oncologist."
223629102|NCT00929214|PROCEDURE|Local Therapy|"Surgery and/or Radiation Therapy~With no more than 3 bone metastases, local treatments including high-dose radiation therapy and/or surgery will be given. Radiation therapy involves daily treatments during weekdays that may last 5 to 7 weeks in a row. Each daily treatment may last 30 - 40 minutes. Surgery, including recovery, may last 4 to 6 weeks."
223629103|NCT05800860|DRUG|GH001|GH001 administered via inhalation
223629104|NCT05800860|DRUG|Placebo|Placebo administered via inhalation
223629105|NCT03796559|DEVICE|Magseed Marker|Implantable Magseed marker for marking lesions in soft tissue, detected using the Sentimag handheld probe.
223629106|NCT04799964|DEVICE|Flow Diverter (Tonbridge)|The device is a self-expanding vascular stent system, which consists of a stent and a delivery system. The stent is made of platinum core nickel-titanium alloy material. The delivery system is composed of a delivery guide wire and an introducer sheath. The stent and the delivery guide wire are pre-installed in the introducer sheath.
223629107|NCT04799964|DEVICE|Tubridge (MicroPort)|Tubridge consists of a stent system and a microcatheter system. The stent system consists of a stent and a conveyor, the stent is self-expanding as well.
223629108|NCT03565783|BIOLOGICAL|Cemiplimab|Given IV
224217866|NCT03840811|DRUG|Ciprofloxacin|Mandatory antibiotic treatment failure therapy: Ciprofloxacin 500 mg orally in a single dose: if the subject has a positie test of cure 1 week post initial antibiotic treatment
224217867|NCT03840811|BIOLOGICAL|Neisseria gonorrhoeae strain FA1090 A26|0.4 mL of a suspension containing 10\^5 - 10\^6 CFU of Neisseria gonorrhoeae, in phosphate-buffered saline, delivered to the anterior urethra through a No.8 pediatric French catheter.
224317569|NCT01356212|DRUG|Ketorolac tromethamine|30 mg ketorolac (15 mg (100 ul) per nostril) administered intranasally
224317570|NCT00616512|PROCEDURE|GF Strong Water Protocol|The Purpose of the GF Strong water protocol is to allow clients who have thin liquid dysphagia to drink water under certain specified conditions according to the rules of the water protocol.
224317571|NCT01584817|OTHER|telephone education|A repeated instruction by telephone on the day before colonoscopy was conducted
224317572|NCT02047734|DRUG|Ozanimod|Oral capsule, daily for 24 months
224317573|NCT02047734|DRUG|Ozanimod placebo|Oral capsule, daily for 24 months
224317574|NCT02047734|DRUG|Interferon beta-1a|Intramuscular injection, 30 µg, weekly for 24 months
223629109|NCT05258240|OTHER|Virtual Reality|Virtual reality workout enhances balance control, self-reported balance and mental stability in healthy and stable adults. Sensory-based exercise and the response to visual acuity can increase the patient's ability to maintain their body in a stable position.
223764059|NCT00193882|DRUG|5-Fluorouracil|800mg/m2/day IV days 1 - 4
223764060|NCT03026621|DIETARY_SUPPLEMENT|Lignite Extract|"The study design is a double-blind case-control trial, whereby half of the participants will be cases and will be asked to take 5mL 'Restore' mineral supplement three times each day. The other half of the participants will be controls and will be asked to take 5mL of a placebo three times each day. Both the study leader and the participants will be blinded to who receives Restore and who receive placebo."
224217868|NCT03840811|BIOLOGICAL|Neisseria gonorrhoeae strain FA7537|0.4 mL of a suspension containing 10\^5 - 10\^6 CFU of Neisseria gonorrhoeae, in phosphate-buffered saline, delivered to the anterior urethra through a No.8 pediatric French catheter
224217869|NCT03197961|COMBINATION_PRODUCT|tenofovir/emtricitabine|At the enrollment visit, participants will be given a 14-day supply of tenofovir/emtricitabine 200mg/300mg to take once daily for 14 days. Drug concentrations will be measured as outlined in the outcomes section at the end of the two week period. The tenofovir/emtricitabine 200mg/300mg course will be repeated approximately 2 to 6 weeks later to allow washout of tenofovir/emtricitabine.
224217870|NCT03197961|DRUG|DMPA|After completion of the first 14 day course of tenofovir/emtricitabine depot medroxyprogesterone acetate 150 mg will be administered as intramuscular injection.
224317575|NCT02047734|DRUG|Interferon beta-1a placebo|Intramuscular injection, weekly for 24 months
224317576|NCT05798455|DRUG|Sodium Pentaborate|Capsules containing sodium pentaborate pentahydrate 500, 1000 and 1500 mg
224317577|NCT05158543|OTHER|conventional therapy|The conventional group will receive active and passive range of motion exercises, balance, and strength training for upper and lower limbs. One session per day, three sessions/week for total of 12 weeks.
224317578|NCT05158543|OTHER|Task oriented training (moderate intensity)|In the moderate-intensity group, patients will perform 100 functional tasks with a total (1000) repetitions. Single session/day, 4 sessions/week for 12 weeks.
224317579|NCT05158543|OTHER|Task oriented training (high intensity)|In the moderate-intensity group, patients will perform 100 functional tasks with a total (1000) repetitions. Two sessions/day, 5 sessions/week for 12 weeks.
224317580|NCT04302714|PROCEDURE|Hysteroscopic injection|Hysteroscopic injection
223629110|NCT05258240|OTHER|Conventional Physical Therapy|Postural training, standing, walking, and walking activities are included in the conventional physical therapy in domain of balance exercise training programs. These activities are usually boring and tedious because these exercises are repeated many times.
223629111|NCT05057312|OTHER|Enhancing Accessibility to Health Care|Receive enhanced access to vaccination
223629112|NCT05057312|OTHER|Informational Intervention|Receive standard CDC information
223629113|NCT05057312|OTHER|Informational Intervention|Receive video narratives
223629114|NCT05057312|OTHER|Informational Intervention|Receive written narratives
223629115|NCT05057312|OTHER|Interview|Ancillary studies
223629116|NCT05057312|OTHER|Questionnaire Administration|Ancillary studies
223629117|NCT01856270|DRUG|Amitriptyline|Participants with headache will be enrolled within the first 12 weeks after injury and will be randomly assigned to 2 groups (see Table 1 for summary of protocol). Group 1 will be assessed within 3 months of injury (baseline, Day 0) (when they will receive their initial ramp-up dosage containers; see Table 2 for dosing), Day 30 and Day 60 (to monitor compliance and distribute study drug), and for final outcome on Day 90. Group 2 will be assessed within 3 months of injury (baseline, Day 0) but will not receive medication until their Day 30 visit. Those in group 2 who report headache at Day 30 will receive their initial dosage container and will then be reassessed at Day 60 (to monitor compliance and distribute study drug) and Day 90 (final outcome).
223629118|NCT03655340|DRUG|Alprolix|Extended half-life factor IX product
223629119|NCT06105502|BEHAVIORAL|Psychotherapy education|Psychotherapy education, including supervision, lectures, and workshops
223629120|NCT06047210|OTHER|Blood Draws Data Collection|
223629121|NCT05625737|DRUG|Fruquintinib|Fruquintinib will be administrated as 4mg orally, once daily for 2 weeks on/1 week off.
223629122|NCT05625737|DRUG|Sintilimab|Sintilimab will be administrated as 200mg once every 3 weeks.
223629123|NCT06535880|DEVICE|Electric Current Stimulation|Electric stimulation with a Digitimer DS7AH HV Current Stimulator delivered with 4 shielded electrodes mounted on the participants head and arm
223764061|NCT03026621|OTHER|Herbal tea|This is an herbal tea that will look like the control
224217871|NCT01625845|DRUG|Pentoxifylline|Pentoxifylline 400 mg p.o. t.i.d. for 12 weeks
224217872|NCT01625845|OTHER|Placebo|Placebo pills will match the study drug for color, taste, texture, size, and smell. Participants will receive the same instructions as those randomized to pentoxifylline.
224217873|NCT01625845|BEHAVIORAL|Standard Treatment|BtB is a widely used, empirically supported, computer-based, CBT program for depression designed for use in primary care clinics. BtB utilizes an interactive, multimedia format to deliver and eight 50-minute, weekly therapy sessions. General topics covered include identifying and challenging automatic thoughts, cognitive errors, core beliefs, and attributional styles; activity scheduling; problem solving; graded exposure; task breakdown; sleep management; and relapse prevention. In addition to session work, patients are assigned homeworks that are customized to their needs and reviewed at the start of each session. A progress report, including whether the patient is experiencing suicidal ideation, is generated at the end of each session.
224217874|NCT01654146|DRUG|Carboplatin|AUC5 by intravenous infusion over 30-60 minutes
223629124|NCT06577181|DRUG|hCG + estradiol|Human chorionic gonadotropins
223629125|NCT06577181|OTHER|Observation arm|estradiol only wuithout giving hcg
223629126|NCT05502562|DRUG|Oral semaglutide|Participants will be treated with commercially available oral semaglutide according to local label and to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available oral semaglutide has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician based on local label before and independently from the decision to include the participant in this study.
223629127|NCT03680053|DRUG|Duphaston|Women will receive oral duphaston 20mg daily from Day 3 till the day of ovulation trigger.
223629128|NCT03680053|DRUG|Cetrorelix|Women will receive antagonist (Cetrorelix 0.25mg) once subcutaneously daily from day 6 of ovarian stimulation till the day of the ovulation trigger.
223629129|NCT06314711|DIAGNOSTIC_TEST|Ultrasound|High-frequency ultrasound of ex vivo specimen
223629130|NCT06563726|DIAGNOSTIC_TEST|point-of-care milk sodium testing|Data-driven interventions to improve early lactation success are lacking, and parents who deliver preterm are at high risk of lactation challenges. We will be studying feasibility, acceptability, and time cost of teaching lactating parents of hospitalized preterm infants how to test their breastmilk sodium (Na) using point-of-care (POC) meters. As a secondary aim, we will assess the potential to use these POC sodium results to guide personalized lactation care in the form of altered pumping schedules in an attempt to reduce breastmilk Na. A drop in Na is a sign of secretory activation in the breast that is associated with adequate short and long-term breast milk volumes in this vulnerable population.
223629131|NCT06504992|DRUG|Vancomycin 1000 MG|Powdered, intrawound vancomycin 1000 mg at the time of definitive surgery for open fracture fixation in addition to the current best practice of intravenous antibiotics with irrigation and debridement
223629132|NCT05992675|DEVICE|Lotrafilcon A contact lenses|CE-marked silicone hydrogel contact lenses
223629133|NCT05992675|DEVICE|Balafilcon A contact lenses|CE-marked silicone hydrogel contact lenses
223629134|NCT06437301|OTHER|Baseline measure of ETCO2 without mask|Baseline
223629135|NCT06437301|OTHER|Baseline ETCO2 with mask|Mask
223629136|NCT06437301|OTHER|ETCO2 after 200 meter walk with mask|200 meter walk and mask
223629137|NCT06437301|OTHER|ETCO2 after 200 meter walk without mask|200 meter walk
223629138|NCT02511665|DRUG|Metformin|Given metformin
223629139|NCT02511665|RADIATION|PET-MRI Scan|Patients will under go 2 PET-MRI scans in the PET-MRI substudy arm one before treatment with metformin and one after
223629140|NCT02511665|DRUG|Placebo|Given placebo
223629141|NCT00703014|DRUG|Corifollitropin Alfa 150 μg|In the Base Trial P05787, on the morning of day 2 or 3 of the menstrual cycle (Stimulation Day 1), a single SC injection of 150 μg (0.5 mL) Corifollitropin Alfa was administered in the abdominal wall.
223629142|NCT00703014|BIOLOGICAL|200 IU RecFSH/Follitropin beta (Days 1 to 7)|In the Base Trial P05787, daily SC injections with 200 IU fixed dose recFSH were started on Stimulation Day 1 and continued up to and including Stimulation Day 7.
224217875|NCT01654146|DRUG|Carboplatin|AUC2 by intravenous infusion over 30-60 minutes
224317581|NCT04302714|PROCEDURE|Cervical injection|Cervical injection
223629143|NCT00703014|DRUG|Placebo for Corifollitropin Alfa|In the Base Trial P05787, on the morning of day 2 or 3 of the menstrual cycle (Stimulation Day 1), a single SC injection from a pre-filled syringe containing an identical solution when compared to Corifollitropin Alfa was administered in the abdominal wall.
223629144|NCT00703014|DRUG|Placebo for RecFSH/Follitropin beta|In the Base Trial P05787, daily SC injections of an identical ready-for-use solution, but without the active ingredient, supplied in cartridges for SC injection with the Follistim Pen, were started on Stimulation Day 1 and continued up to and including Stimulation Day 7.
223629145|NCT00703014|BIOLOGICAL|200 IU RecFSH/Follitropin beta (Days 8 to hCG)|In the Base Trial P05787, from Stimulation Day 8 onwards a daily SC dose of 200 IU recFSH was administered up to and including the Day of hCG.
223629146|NCT00703014|DRUG|Ganirelix|In the Base Trial P05787, on Stimulation Day 5 a daily SC injection of 0.25 mg was started, which continued up to and including the day of hCG.
223629147|NCT00703014|BIOLOGICAL|hCG|In the Base Trial P05787, when 3 follicles \>= 17 mm were observed by USS, a single dose of 10,000 IU/USP hCG was administered; or, for those at risk for Ovarian Hyperstimulation Syndrome (OHSS), a lower dose of 5,000 IU/USP
223629148|NCT00703014|BIOLOGICAL|Progesterone|In the Base Trial P05787, on the day of OPU, luteal phase support was started by administering micronized progesterone of at least 600 mg/day vaginally, or at least 50 mg/day intramuscular (IM), which continued for at least 6 weeks, or up to menses.
223629149|NCT06410027|OTHER|Pain Neuroscience Education + Virtual Reality + Therapeutic Exercise|Patients will receive 1-hour pain neuroscience education session + 30-minutes exposure to exercise with virtual reality + therapeutic exercise
223629150|NCT06410027|OTHER|Therapeutic Exercise|Patients will receive therapeutic exercise
223629151|NCT02893293|DRUG|Ferumoxytol-enhanced magnetic resonance imaging|Eligible patients receive a single ferumoxytol-dose and follow-up magnetic resonance imaging to evaluate success of stem cell transplant
224217876|NCT01654146|DRUG|Paclitaxel|175mg/m2 by intravenous infusion over 3 hours
224217877|NCT01654146|DRUG|Paclitaxel|80mg/m2 by intravenous infusion over 1 hour
224217878|NCT04108169|PROCEDURE|Left atrial appendage occlusion surgery|CABG according to indications in the current guidelines on myocardial revascularization including surgical closure of left atrial appendage
224217879|NCT03735784|BEHAVIORAL|AWARE|AWARE consists of four group sessions. The AWARE curriculum involves sharing basic information on sexually transmitted diseases; providing condom use skills training; providing normative feedback on substance use and sexual risk behavior among young adults; discussing unrealistic beliefs about substance use and sexual risk; discussing potential benefits of both cutting down and stopping risky behaviors; and discussing risky situations and coping strategies.
224217880|NCT02960074|BIOLOGICAL|Fecal Microbiota Capsule|We will treat patients with oral encapsulated frozen FMT over 2 days.
223629152|NCT02893293|DEVICE|Magentic Resonance Imaging|Both arms will receive MRI
223629153|NCT01885156|DRUG|Naftin 1% Cream|Topically applied once a day
223629154|NCT01885156|DRUG|Placebo Cream|Topically applied once a day
223629155|NCT01806220|PROCEDURE|Biopsy of the retrocrycoid laryngeal mucosa|Biopsies of the retrocrycoid laryngeal mucosa were performeed under sedation using a forceps introduced by the working channel of the endoscope
223629156|NCT01806220|PROCEDURE|Biopsy of the distal esophageal mucosa|Biopsies were performeed under sedation using a forceps introduced by the working channel of the endoscope during upper digestive endoscopy
223629157|NCT01059097|PROCEDURE|Pancreaticoduodenectomy|
223629158|NCT05468814|PROCEDURE|Z-plasty|It is a surgical technique in which a Z-shaped section of the transverse carpal ligament is performed, to later join both ends with a resorbable stitch.
223629159|NCT05468814|PROCEDURE|Conventional|It is a surgical technique in which a complete section of the transverse carpal ligament is performed, without subsequent closure.
223629160|NCT04716426|DRUG|Tetracycline hydrochloride 3%|Proprietary formulation composed of FDA approved inactive ingredients and the active pharmaceutical ingredient tetracycline hydrochloride.
223629161|NCT04716426|DRUG|Placebo|Formulation composed of FDA approved inactive ingredients.
223629162|NCT02494193|OTHER|Partial caries removal|The caries infected dentin will be removed mantaining the affected caries tissue.
223629163|NCT02494193|OTHER|Provisional restoration - control|After partial caries removal, a provisional restoration will be performed using a layer of calcium hydroxide paste covered by a layer of calcium hydroxide cement and resin-modified glass ionomer.
223629164|NCT02494193|OTHER|Provisional restoration - experimental|After partial caries removal, a provisional restoration will be performed using only resin-modified glass ionomer.
223629165|NCT02494193|OTHER|Total caries removal|After two months of their placement, the provisional restoration will removed followed by tota caries tissue removal.
223629166|NCT02494193|OTHER|Definitive restoration|Definite restoration will be performed using composite.
223629167|NCT00773448|DEVICE|Comprehensive computed tomography of the abdomen/pelvis|Virtual colonoscopy and gastroscopy, a biphasic enhanced CT for hepatoma and renal cell carcinoma, parenchymal pancreatogram with minimum intensity projection (MinIP) reformation for pancreatic carcinoma, and finally uniphasic enhanced CT of distended bladder for bladder and ovarian carcinomas.
223764062|NCT06223594|OTHER|Intravenous Fluid Therapy|Evaluate the safety and efficacy of the Dallas acute pancreatitis protocol(DAPP) order set on Acute pancreatitis(AP) patients receiving aggressive, goal-directed Intravenous fluid(IVF )therapy.
224217881|NCT00480220|PROCEDURE|Global care and support program|
224217882|NCT02891265|BEHAVIORAL|Smoking cessation patch|To compare the smoking cessation outcome in patients with fractures with or without the help of smoking cessation patches.
223764063|NCT05981638|OTHER|group WM|Patients were given 5ml/kg dose of water and patients were mobilized.
224217883|NCT04832074|OTHER|Dry Needling|Real Dry Needling in the most active Myofascial Trigger Point
224217884|NCT04832074|OTHER|Sham Dry Needling|Sham Dry Needling in the same location, but not piercing the skin
224217885|NCT03446274|DRUG|Evenamide|This is an orally available small molecule that potently blocks voltage-gated sodium channels (VGSCs) in vitro and is indicated for the treatment of patients with schizophrenia, mania, and bipolar disorder.
224317582|NCT03413579|BIOLOGICAL|Nimotuzumab ( h-R3)|Humanized monoclonal antibody
224317583|NCT03413579|OTHER|Placebo|
223764064|NCT05981638|OTHER|group WR|Patients were given 5ml/kg dose of water and patients were rest.
223629168|NCT00773448|OTHER|Limited Malignancy Screening|"1\) A complete medical history and physical examination; 2) complete blood count; 3) liver function tests (AST, ALT, ALP, bilirubin, LDH); 4) renal function test (creatinine); 5) chest X-ray (if not performed in the past year)~In women, a pap smear/pelvic examination (if \> 18 and \< 70 years old and not performed during the past year),a mammogram (\> 50 years old) will be performed if not conducted in last year. Similarly for men, prostate examination +/- PSA testing (\>40 years old) will be performed if not conducted in the past year."
223629169|NCT05618522|PROCEDURE|vacuum-dehydrated amnion membrane (omnigen)|applying the lens loaded with Omnigen on the cornea
223629170|NCT05618522|DEVICE|the lens loaded with Omnigen|the lens loaded with Omnigen
223629171|NCT01228279|OTHER|DIANEAL|"Weeks 1 to 6 (6 weeks):~* CAPD (Continuous Ambulatory Peritoneal Dialysis)patients will receive three 4-6 hour dwells of DIANEAL during the day and one 8-10-hour dwell of DIANEAL during the night~* CCPD (Continuous Cycler Peritoneal Dialysis)patients will receive one-two 4-6 hour dwells of DIANEAL during the day and three to seven 2-4-hour dwells of DIANEAL during the night~Weeks 7 to 18 (12 weeks):~\*same regimen as weeks 1 to 6, for both CAPD and CCPD patients"
223629172|NCT01228279|OTHER|EXTRANEAL|"Weeks 1 to 6 (6 weeks):~* CAPD (Continuous Ambulatory Peritoneal Dialysis)patients will receive three 4-6 hour dwells of DIANEAL during the day and one 8-10-hour dwell of DIANEAL during the night~* CCPD (Continuous Cycler Peritoneal Dialysis)patients will receive one-two 8-12-hour dwells of DIANEAL during the day and three to seven 2-4-hour dwells of DIANEAL during the night~Weeks 7 to 18 (12 weeks):~* CAPD (Continuous Ambulatory Peritoneal Dialysis)patients will receive three 4-6 hour dwells of DIANEAL during the day and one 8-10-hour dwell of EXTRANEAL during the night~* CCPD (Continuous Cycler Peritoneal Dialysis)patients will receive one-two 8-12-hour dwells of DIANEAL during the day and one 8-12-hour dwell of EXTRANEAL during the night"
223629173|NCT06309940|OTHER|Prognostic factors of surgical evacuation of basal ganglionic haemorrhage|Surgical evacuation of basal ganglionic haemorrhage
224217886|NCT01729416|OTHER|Water Exchange Colonoscopy|"We will turn off the air pump. The colonoscope will be inserted into the rectum and gently advanced. We will suction air pockets as scope is advanced towards the cecum. Water will be infused when encountering closed up lumen. All the infused water will be suctioned out. We will use all other techniques used with conventional air method as needed. For example abdominal pressure, shortening of scope to reduce looping, change of patient position etc.~We will turn on air pump once cecum reached, or if unsuccessful with water method to open up a close lumen or to go past a tight turn.~On withdrawal we will continue air insufflation as needed, and closely examine for polyps and remove all visualized polyps. If there is any residual fluid, it will be suctioned out as the scope is withdrawn."
224217887|NCT01729416|OTHER|Air Colonoscopy|Air will be infused into the colon during colonoscopy.
224217888|NCT01078623|DRUG|Aclidinium 200 μg / formoterol 12 μg|Aclidinium bromide 200 μg + formoterol fumarate 12 μg fixed dose combination (FDC) twice daily
224217889|NCT01078623|DRUG|Placebo|Placebo control twice daily
224217890|NCT01078623|DRUG|Formoterol 12 μg|Formoterol fumarate 12 μg twice daily
223629174|NCT06175676|DRUG|Hydroxybutyl chitosan|Apply HBCS to the anastomosis of the nasal mucosal flap and the dacryocyst mucosal flap
223629175|NCT06175676|DRUG|5-Fluorouracil|Inject 0.3ml of 5-FU solution (25mg/ml) into the nasal mucosa around the anastomosis, and apply HBCS to the anastomosis of the nasal mucosal flap and the dacryocyst mucosal flap
223629176|NCT06175676|DRUG|Gelatin Sponge Sheet|Apply gelatin sponge sheet covered with thrombin and tobramycin and dexamethasone ophthalmic ointment to the anastomosis of nasal mucosal flap and dacryocyst mucosal flap
223629177|NCT03433937|DEVICE|Negative pressure wound therapy|Wound dressing
223629178|NCT03433937|OTHER|Micropore tape|Wound dressing
223629179|NCT02300207|DEVICE|electronic acupuncture treatment instrument|Electroacupuncture was performed using small-sized (1.5 cm) cutaneous electrode pads placed bilaterally at the PC-6 points of the forearms (Supplementary Figure 1). The intensity of the electrical stimulation was adjusted to produce the most intense tolerable electrical sensation without muscle contractions or uncomfortable feelings at a frequency of 50 Hz using the Hwato electronic acupuncture treatment instrument (Model No. SDZ-II; Suzhou Medical Appliances Co, Ltd, Suzhou, China).
223629180|NCT01901445|BEHAVIORAL|Educational action with focal group|
224217891|NCT01078623|DRUG|Aclidinium 200 μg|Aclidinium bromide 200 μg twice daily
224217892|NCT01078623|DRUG|Aclidinium 200 μg / Formoterol 6 μg|Aclidinium bromide 200 μg + formoterol fumarate 6 μg fixed dose combination (FDC) twice daily
224217893|NCT05305521|PROCEDURE|transcrestal sinus floor elevation|Under local anesthesia (articaine 4% with epinephrine 1:100.000), a minimally invasive full-thickness flap was elevated to expose the alveolar crest. Clinicians were left free to choose their preferred transcrestal antrostomy technique. After checking sinus membrane integrity with visual inspection and Valsalva maneuver, pre-heated (40°C) xenogeneic porcine bone substitute in gel form (Gel 40, Tecnoss, Giaveno, Italy) was injected through the crestal antrostomy in order to elevate the membrane and fill the sub-antral space. Duration of graft injection (in seconds) was recorded using a digital chronometer. Periapical intraoperative radiographs were taken to confirm membrane elevation of at least 10 mm.
224217894|NCT05305521|PROCEDURE|Implant placement|"Simultaneous implant placement was performed when it was possible to achieve adequate primary stability in the residual crestal bone, otherwise crestal antrostomy was sealed by collagen sponges (Hemocollagene, Septodont, Saint-Maur-des-Fossés, France) and implant insertion was postponed.~Flaps were sutured with Sentineri technique and single stitches using synthetic monofilament"
224317584|NCT00093275|DRUG|HP184|
223629181|NCT01590264|DEVICE|Bimodal rTMS|"High frequency (10 Hz) at 110% of the motor threshold TMS delivered over the left dorsolateral prefrontal cortex, subsequently, a low frequency TMS (1 Hz) at 110% motor threshold will be delivered over 31 minutes over the TPJ area, according to the protocol below.~DLPFC Stimulation Frequency 10 Hz Intensity 110% of motor threshold On 5 seconds Off 15 seconds Total Trains 80 per session Total pulses session 4000/session Duration session 26.6 minutes Total pulses (study) 40000~TPJ Stimulation Frequency 1 Hz Intensity 110% of motor threshold On 900 seconds Off 60 seconds Total Trains 2 per session Total Pulses session 1800 Duration session 31 minutes Total Pulses study 18000"
223629182|NCT03631485|OTHER|Exposure_having children with cancer|No intervention. The exposure is having children with cancer.
223764065|NCT05981638|OTHER|Group AR|Patients were given 5ml/kg dose of apple juice and patients were rest.
223629183|NCT03668873|BEHAVIORAL|Sleep Parent Training|SPT provides a comprehensive intervention that teaches parents the basic concepts and practical skills to address an array of sleep problems.
223629184|NCT03668873|BEHAVIORAL|Sleep Parent Education|SPE is a structured program intended to mimic treatment as usual. Thus, SPE is an accepted treatment and serves as an active comparator that controls for time and attention.
223629185|NCT00407121|DRUG|Bevacizumab|
223629186|NCT00407121|PROCEDURE|Intravitreal Injection of Bevacizumab|
223629187|NCT05088564|PROCEDURE|Hand-sewn|Doudenojejunal anastomosis by hand-sewn method
224217895|NCT02330679|DRUG|Desvenlafaxine|The intervention will consist of a 2-week single-blind placebo run-in phase followed by a 12-week open-label trial with desvenlafaxine (a SNRI medication)
224217896|NCT02330679|DRUG|Placebo|
224217897|NCT01162590|BIOLOGICAL|Rotarix ™|Oral, single dose
224217898|NCT01162590|BIOLOGICAL|Placebo|Oral, single dose
224217899|NCT04689958|DRUG|Standard therapy|Gabapentin, pregabalin, or amitriptyline
224217900|NCT04689958|DRUG|Vitamin D 5,000IU Oral Tablet|Vitamin D 5000 IU oral tablet once daily
224317585|NCT05850364|BIOLOGICAL|Sabin Strain Inactivated Poliovirus Vaccine|Totally 1440 healthy infants of 6 weeks old (42-47 days) are planned to be enrolled, and then randomized in a 1:1:1:1 ratio into four groups, i.e., co-administration group 1 (group C1), co-administration group 2 (group C2), staggered administration group 1 (group S1) and staggered administration group 2 (group S2). Participants in group C1 and C2 will receive sIPV at 6,10, 14 weeks old, administered concomitantly with routine infant vaccine (may include DTP-HepB-Hib vaccine, PCV10 or rotavirus vaccine in accordance with the local routine vaccination schedule). Participants in group S1 will receive sIPV at 6,10,14 weeks old, and receive routine infant vaccines at 8,12,16 weeks old. Participant s in group S2 will receive routine infant vaccines at 6,10,14 weeks old, and receive sIPV at 8,12, 16 weeks old.
224317586|NCT03872518|DEVICE|Urovac|The Urovac is simply a regular plastic handheld urinal attached by tubing to a pump that evacuates urine to a reservoir. The Urovac is simply a regular plastic handheld urinal attached by tubing to a pump that evacuates urine to a reservoir. There is also a removable cloth-covered platform to reduce spills.
223629188|NCT05088564|PROCEDURE|Hemi-double stapling|"Doudenojejunal anastomosis by hemi-double-stapling method EEA25 - Covidien EEA Circular Stapler DST Series 25.0mm x 4.8mm is used for anastomosis"
223629189|NCT02404961|OTHER|Vulvodynia|Comparison of reproductive, gynecological and environmental exposures, psychological trauma and psychiatric morbidity, and biological markers of immuno-inflammation and nerve fiber proliferation between cases and controls to determine potential etiology of vulvodynia.
223629190|NCT02135250|DRUG|Xinkeshu tablets|4 Xinkeshu tablets are given three times per day
223629191|NCT02135250|OTHER|placebo|the placebo is not drug.
223629192|NCT06079008|OTHER|calcified cardiac valve|patients have cardiac cardiac valve before surgery
223629193|NCT00007202|DRUG|Atazanavir|
223629194|NCT00007202|DRUG|Stavudine|
223629195|NCT00007202|DRUG|Didanosine|
223629196|NCT06062563|DRUG|Anlotinib Hydrochloride Capsule and Penpulimab|"Anlotinib hydrochloride is a muti-target tyrosine kinase inhibitor that inhibits both tumor angiogenesis and tumor cell proliferation by blocking VEGFR, FGFR, PDGFR, and c-Kit simultaneously.~Penpulimab is a novel structure Immune checkpoint inhibitor. The combination of Penpulimab and RAI might have synergistic effects for DTC."
223629197|NCT03793244|DIETARY_SUPPLEMENT|TARGET protocol EN 1.5 kcal/mL|Enteral nutrition
223629198|NCT02343835|DEVICE|NanoKnife LEDC System|Irreversible electroporation (IRE) is a new, minimal-invasive image-guided treatment method for tumors not amenable for surgical resection or thermal ablation, due to vicinity near vital structures such as vessels and bile ducts. With IRE, multiple electrical pulses are applied to tumorous tissue. These pulses alter the existing transmembrane potential of the cell membranes, and create 'nanopores', after which the cell dies through loss of homeostasis.
223629199|NCT03753802|OTHER|Chest Physiotherapy|During sessions, the child is lying on the back, he should not have eaten within two hours prior to the sessions. An extended slow expiration handling is performed on 3 respiratory cycles consecutive, this session is repeated for 10 minutes. Breaks are made regularly during the treatment to have approximately 5 to 6 minutes of handling and 4-5 minutes of rest on the total 10 minutes of treatment. Induced cough handlings will be conducted at five minutes and at ten minutes if the child has not coughed during the movements of chest physiotherapy. These are performed by a brief pressure above the jugular (suprasternal) notch of the patient. Only two consecutive trials of the induced cough handling are allowed, even if the handlings are unsuccessful the physiotherapist does not insist. The following 5 minutes of the session are 5 minutes of rest. During the sessions the physiotherapist wears a mask and respects the usual rules of hygiene.
223629200|NCT03753802|OTHER|Surveillance|The session is only a surveillance session with the physiotherapist. The physiotherapist is only watching over the child. The parents of the child wait in the waiting room during the physiotherapy session. They don't know which treatment (chest physiotherapy or no treatment) is applied to their child.
223629201|NCT01855529|DRUG|Ropivacaine in one arm and placebo (NaCl) in the other arm|
223764066|NCT05981638|OTHER|Group AM|Patients were given 5ml/kg dose of apple juice and patients were mobilized.
224217901|NCT05448859|PROCEDURE|intracytoplasmic sperm injection|injection of sperm into an oocyte in assisted reproductive technology
224217902|NCT00740259|DRUG|Flunarizine|For 1 week, 40 mg/day. From week 2 to 3, 20 mg/day. Form week 4 onwards, dosage increment or reduction of 10mg/day was allowed according to efficacy and tolerability.
224217903|NCT03476356|DRUG|oral clomiphene citrate|oral clomiphene citrate 50 mg tablet, two times per day will be received from the third day of the cycle until the seventh day of the cycle.
224217904|NCT03476356|DRUG|oral carnitine supplementation|oral carnitine supplementation 1g tablet, three times per day will be received from the third day of the cycle until the day of the pregnancy test.
224217905|NCT04104711|OTHER|Home visits, health education|
224217906|NCT02685761|PROCEDURE|Midline Vertical|Cesarean section performed using a midline vertical skin incision, located between the umbilicus and pubis
224217907|NCT02685761|PROCEDURE|High Transverse|Cesarean section performed using a transverse skin incision located above the pannus
224217908|NCT04387747|OTHER|SARCOPENIA IN STROKE PATIENTS|Demographic characteristics, duration of stroke, sarcopenia presence,thigh circumference , Hand grip strength , TANITA BIA analysis
223629202|NCT01874002|DEVICE|Combo stent|Percutaneous coronary intervention of patients with an indication for stent treatment with the COMBO stent, a stent with an endothelial progenitor cell attracting coating and abluminal sirolimus matrix. All consecutive patients treated with, or attempted treatment with, a COMBO stent are followed by telephone contact for 5 years.
223629203|NCT01521117|DRUG|Donepezil|Use 1 capsule (5 mg) of donepezil once per day for first 21 days than donepezil 10mg qday for 21 days.
223629204|NCT01521117|DRUG|Placebo|Use 1 capsule (5 mg) once per day for first 21 days than 10mg qday for 21 days.
223629205|NCT01394237|OTHER|Examination|Examination of recurrences of vaginal vault prolapse measured as objective anatomical results using the pelvic organ prolapse quantification (POP-Q) system
223629206|NCT03088696|OTHER|stimulation|activation of the acupuncture point
223629207|NCT03088696|OTHER|no stimulation|no activation of the acupuncture point
223629208|NCT01926223|OTHER|Home visiting|
223629209|NCT01857219|BEHAVIORAL|Tai chi|
223629210|NCT02480972|PROCEDURE|magnetic resonance imaging|"multiparametric MRI as follows:~1. diffusion weighted imaging using multiple b-values~2. Fat quantification sequence~3. perfusion MRI using ECCM agent~4. MR elastography~   \------------------------------------~5. routine MRI using hepatocyte specific agent (optional in patients with focal liver lesion)"
224217909|NCT02630745|PROCEDURE|Immediate periodontal surgery|Treatment involves immediate surgical periodontal therapy in form of open flap debridement after non surgical endodontic treatment and obturation with gutta-percha and zinc oxide eugenol (ZOE) sealer. in concurrent endodontic periodontal lesions with communication .
224217910|NCT02630745|PROCEDURE|Delayed periodontal surgery|Treatment involves surgical periodontal therapy after 3 months of non surgical endodontic treatment and obturation with gutta-percha and zinc oxide eugenol (ZOE) sealer. in the form of open flap debridement in concurrent endodontic periodontal lesions with communication .
224217911|NCT02300376|DRUG|Dosage of Calcium edetate de sodium|There is no medical data for the use of Calcium edetate de sodium as a tracer to assess GFR. Calcium edetate de sodium is a treatment for lead intoxication. The extension of use as a tracer comes from its exclusive elimination by glomerular filtration. Plasma and renal clearance of Calcium edetate de sodium and Inulin will be measured for every included patient during a hospital day care (V1). For transplanted patients, plasma clearance of Calcium edetate de sodium will be repeated within one week (more or less 48hours) during annual medical check-up of renal transplantation.
224217912|NCT04356573|DIETARY_SUPPLEMENT|Green Hayward Kiwifruit first, then Gold Kiwifruit|Subjects ate 2 peeled green kiwifruit with their midday meal for 2 weeks prior to testing.
224217913|NCT04356573|DIETARY_SUPPLEMENT|Gold Kiwifruit First, then Green Hayward Kiwifruit|Subjects ate 2 peeled gold kiwifruit with their midday meal for 2 weeks prior to testing.
224217914|NCT03645226|DIAGNOSTIC_TEST|Colonoscopy|All subjects will undergo standard mechanical bowel preparation with 4 liters of polyethylene glycol (Klean-Prep, Norgine Ltd., Middlesex, UK). Total colonoscopy will be performed by experienced endoscopists under conscious sedation with intravenous benzodiazepines and narcotics. A conventional intermediate-length colonoscope (Olympus Corporation, Tokyo, Japan) will be used. One mucosal biopsy will be taken in the descending colon. Biopsies will be performed using standard biopsy forces without needle (Olympus Corporation, Tokyo, Japan). Half of the samples will be immersed in 4 oC normal saline solution. All samples will be immediately sent to pathology department and will be stored in a -80 oC freeze for processing of microbiota analyses.
224217915|NCT05139966|DRUG|Mouthwash Product|The participants were requested to rinse 10 ml of the mouthwash 2 times / day (morning and evening) for 1 min after toothbrushing (a non-F dentifrice was used throughout the study).
223629211|NCT01423500|DRUG|VP16|patients with MSD receive as conditioning VP16 60mg/kg/d on day -3
223629212|NCT01423500|RADIATION|TBI|patients with a MSD receive TBI (12Gy in 6 fractions) as conditioning
223629213|NCT01423500|DRUG|VP16, ATG|patients with a HLA matched unrelated Donor (9/10 oder 10/10) receive VP16 60mg/kg/d on day -3 and ATG fresenius 20mg/kg/d on day -3,-2,-1
223629214|NCT01423500|RADIATION|TBI|patients with a HLA matched unrelated Donor (9/10 oder 10/10) receive TBI (12Gy in 6 fractions)
223629215|NCT01423500|DRUG|Fludarabine, OKT3, Treosulfan, Thiotepa|patients with a MMD (haploidentical or cord blood) receive Fludarabine 30mg/m²/d on day -9 to -5, ATG fresenius 20mg/kg/d on day -3,-2,-1, Treosulfan 14g/m²/d on day -7 to -5 and Thiotepa 2x5mg/kg/d on day -4
223629216|NCT01423500|DRUG|VP16, ATG|patients with MMD-transplantation (8/10)receive VP16 60mg/kg/d on day -4, ATG from day -3 to day-1 20mg/kg/d
223629217|NCT01423500|RADIATION|TBI|patients with a MMD-transplantation (8/10) receive 12 Gy in 6 fractions
223629218|NCT00784563|BEHAVIORAL|Continuous training|The maximal heart rate (HRmax) in the exercise prescription was based on age\[Goldberg, Elliot, and Kuehl1988\] and reduced by 20% in participants who used beta-blockers.\[Wonisch et al. 2003\] The duration of exercise sessions (3x/week) was advanced from 15 to 45 minutes over the first 6 weeks. The goal for continuous training was to remain within 70-80% of HRmax throughout the session.
223629219|NCT00784563|BEHAVIORAL|Interval training|Interval trainees alternated every 3 minutes between slower (60-70% of HRmax) and faster (80-90% of HRmax) walking \[Wisloff et al. 2007\].
223629220|NCT03874546|OTHER|Questionnaire|"* Two clinicians will complete a questionnaire that analyses their perception of the patient's prognosis at Day1 and Day7.~* At 6 months, another clinician will establish the patient prognosis using Glasgow Outcome Scale and Glasgow outcome scale extended. This clinician must not know the patient's IMPACT score and prognosis established at Day 1 and Day 7. His evaluation will be compare to the patient's prognosis established previously (Day1 and Day7)."
223629221|NCT03404817|DRUG|Original formulation EMB-001|Single oral dose (720 mg metyrapone/24 mg oxazepam)
223629222|NCT03404817|DRUG|New formulation EMB-001|Single oral dose (720 mg metyrapone/24 mg oxazepam)
223629223|NCT00033332|DRUG|dexamethasone|
223629224|NCT00033332|DRUG|pamidronate disodium|
223629225|NCT00033332|DRUG|thalidomide|
223629226|NCT00033332|DRUG|zoledronic acid|
223629227|NCT04134416|DRUG|Donepezil|Donepezil shall be administered at the times stipulated in the study design as follows: one 5 mg tablet at night for 4 weeks and then one 10 mg tablet at night until the end of the trial (week 10).
223629228|NCT04134416|BEHAVIORAL|Intensive-Language Action Therapy|All patients participating in the study will receive in weeks 9 and 10 daily three and a half hours of ILATplus therapy. This therapy consists of 30 minutes of specific repetition training (tailored and reinforced by the therapist) before starting with classic ILAT for 3 hours/day during 10 consecutive days.
223629229|NCT04134416|DEVICE|Transcranial direct current stimulation|Transcortical direct current stimulation (tDCS) will be applied using a STARSTIM neurostimulation device (Neuroelectrics, Barcelona). Each participant will receive either anodal or sham 20-minute sessions while receiving ILATplus. In the sham stimulation, the same helmet and electrode that is used in the active stimulation will be placed but, in this case, we will apply only a slight current at the beginning and end of the session with the objective of simulating the effects that are experienced with the active stimulation without producing significant cortical stimulation. The active electrode will be placed in the region of the lower right frontal rotation and the reference electrode in the extraencephalic zone (left clavicle). Combined rehabilitation sessions (ILATplus/tDCS) will be conducted, as indicated above, in weeks 9 and 10 of the trial.
223629230|NCT04117555|DIAGNOSTIC_TEST|Pupil response to light stimuli|Objective and accurate measurement of pupillary responses to light stimuli
223629231|NCT02228681|DRUG|Everolimus|10mg daily by mouth
223629232|NCT02228681|DRUG|Tamoxifen|20 mg daily by mouth on alternating weeks (even numbered) weeks
223629233|NCT02228681|DRUG|Letrozole|2.5mg once a day by mouth
223629234|NCT02228681|DRUG|Medroxyprogesterone Acetate|200 mg daily by mouth
223629235|NCT03559114|DRUG|Dalteparin|Dalteparin in prophylactic doses administered daily if screening criteria are satisfied.
223629236|NCT03559114|DRUG|Saline|Saline in prophylactic doses administered daily if screening criteria are satisfied.
223629237|NCT03305614|PROCEDURE|tDCS|C-tDCS during the first 20 minutes of aphasia therapy, at an intensity of 1mA or sham-tDCS at an intensity of 0mA
223629238|NCT03305614|PROCEDURE|Aphasia therapy|Based on linguistic tests, individualized aphasia therapy will be provided
223629239|NCT01241864|BIOLOGICAL|Allogenic islet cells (human, U. Chicago)|Human allogenic islet cells. Immunosuppression varies but may include prograf, cellcept, sirolimus, prednisone. Dosage will vary per patient based on weight. Patients will receive immunosuppression medications while islet cells are functioning.
223629240|NCT01241864|PROCEDURE|Intraportal infusion of islet cells|Intraportal infusion of islet cell through the portal vein in the liver.
223629241|NCT04003701|BEHAVIORAL|Usual care|Control group: minimal distraction
223629242|NCT04003701|BEHAVIORAL|Robot-assisted puncture procedure|Experimental group: distraction with robot
223629243|NCT02743208|DEVICE|Short stem hip arthroplasty (SHA)|Furlong Evolution femoral stem
223629244|NCT02743208|DEVICE|Total hip arthroplasty (THA)|Furlong H-A.C. femoral stem
223629245|NCT05684822|OTHER|Acupuncture|Acupoint:Taichong, Shenmen, Neiguan points with twice a week for total three weeks
223629246|NCT03896438|DEVICE|Transcranial Direct Current Stimulation (tDCS)|Three different stimulation montages will be programmed: right, left and sham. During the Ramp periods, 2 mA current will be delivered to both AF3 and AF4 with an ascending (RampUp) and descending ramp (RampDown) over 30 sec via two saline soaked electrode sponges (\~ 25cm²; current density = 0.08 mA/cm²). In this way, all subjects experience the same sensation on both sides to blind them to condition. During the Constant period, current will be set based on the Condition: Right - 2mA AF4 anode-AF3 cathode; Left - 2mA applied to AF3 anode-AF4 cathode; Sham - current turned off.
223629247|NCT03405220|BEHAVIORAL|Self affirmation, 10 items, written examples|"Participants will complete the 10 item self-affirmation kindness quiz and will be asked to provide written examples for each item they respond yes to."
223629248|NCT03405220|BEHAVIORAL|Self affirmation, 10 items, no examples|"Participants will complete the 10 item self-affirmation kindness quiz and will not be asked to provide examples for any items they respond yes to."
223629249|NCT03405220|BEHAVIORAL|Self affirmation, 10 items, imagined examples|"Participants will complete the 10 item self-affirmation kindness quiz and will be asked to imagine examples for each item they respond yes to."
223629250|NCT03405220|BEHAVIORAL|Self affirmation, 5 items, written examples|"Participants will complete a 5 item self-affirmation kindness quiz and will be asked to provide written examples for each item they respond yes to."
223629251|NCT03405220|BEHAVIORAL|Self affirmation, 5 items, no examples|"Participants will complete a 5 item self-affirmation kindness quiz and will not be asked to provide examples for any items they respond yes to."
223629252|NCT03405220|BEHAVIORAL|Self affirmation, 5 items, imagined examples|"Participants will complete a 5 item self-affirmation kindness quiz and will be asked to imagine examples for each item they respond yes to."
223629253|NCT03405220|BEHAVIORAL|Self affirmation, 3 items, written examples|"Participants will complete a 3 item self-affirmation kindness quiz and will be asked to provide written examples for each item they respond yes to."
224317587|NCT03639818|OTHER|individual sessions of cognitive remediation|The cognitive remediation will be led by a psychologist specialized in neuropsychology, trained and experienced in this method. Cognitive remediation will be performed at a rate of 1 to 2 sessions per week for the duration of the study. This treatment will be carried out individually for half in face-to-face session in the clinical immuno-hematology department, face-to-face with the neuropsychologist, half at home with computer-based home exercises using PRESCO software ® from HAPPYNEURON®
223629254|NCT03405220|BEHAVIORAL|Self affirmation, 3 items, no examples|"Participants will complete a 3 item self-affirmation kindness quiz and will not be asked to provide examples for any items they respond yes to."
223629255|NCT03405220|BEHAVIORAL|Self affirmation, 3 items, imagined examples|"Participants will complete a 3 item self-affirmation kindness quiz and will be asked to imagine examples for each item they respond yes to."
223629256|NCT04106297|DRUG|GLPG3970 oral solution|GLPG3970 for oral administration
223629257|NCT04106297|DRUG|Placebo oral solution|Placebo for oral administration
224317588|NCT02933437|DRUG|Ajmaline|Ajmaline 1milligram/kilogram max dose as bolus intravenous over 10 minutes with continuous ECG monitoring
223629258|NCT04106297|DRUG|GLPG3970 capsule|GLPG3970 for oral administration
223629259|NCT03025282|DRUG|CD10367 3% Solution - Non-desquamated zone|Once daily application for 3 weeks
223629260|NCT03025282|DRUG|CD10367 1% Solution - Non-desquamated zone|Once daily application for 3 weeks
223629261|NCT03025282|DRUG|CD10367 solution placebo - Non-desquamated zone|Once daily application for 3 weeks
223629262|NCT03025282|DRUG|Betneval ointment - Non-desquamated zone|Once daily application for 3 weeks
223629263|NCT03025282|DRUG|CD10367 3% Solution - Desquamated zone|Once daily application for 3 weeks
223629264|NCT03025282|DRUG|CD10367 solution placebo - Desquamated zone|Once daily application for 3 weeks
223629265|NCT02318316|OTHER|Exhaled breath condensate|Breath condensate samples will be collected with a commercially available condenser (EcoScreen®, Erich Jaeger, Germany). Subjects will breathe through a mouthpiece and a two-way non-rebreathing value in which inspiratory and expiratory air were separated, and saliva was trapped. They will be asked to breathe at a normal frequency and tidal volume for 15 minutes while wearing nose clips, allowing collection of 1.5-2.5 mL of condensate. After collecting this, pH will be measured and the waste collection will be stored at -80 degrees. Then 8 isoprostane and nitrotyrosine will be measured collectively
223629266|NCT03711513|BEHAVIORAL|Cognitive behavioral therapy|All conditions start with a psycho-education session (PE). Subsequently, participants in condition A follow four exposure sessions (EX). Participants in condition B follow two cognitive restructuring (CR) followed by two exposure sessions. Participants in condition C follow two relaxation exercises sessions (RE) followed by two exposure sessions. All sessions will take place at their school in a group of five to eight adolescents (week 9,10,11,12,13,14). The sessions will be provided by a psychologist who receives training and supervision by a certified CBT therapist. The psychologist is assisted by a master student in psychology.
223629267|NCT05862220|DIAGNOSTIC_TEST|D-Dimer vs CTPA|CTPA was performed after performing blood sampling using Siemens Somatom definition AS 24 slice scanners. Non-ionic water-soluble contrast Omnipaque 350 mg I/mg or Visipaque 320 mg I/mg was injected at 4 mm/s maximum dose 100 ml using a Medtron pressure injector.OR, A blood sample was taken before starting the patients on any thrombolytic treatment. The latex agglutination test was used to measure plasma D-dimer level; this was done using a Sysmex CA-7000 automatic coagulation unit. The positivity threshold was above 250 ng/ml.
223629268|NCT06038409|DRUG|Ketamine|The efficacy of the various approaches to prescribing Ketamine currently in use off-label. The focus will be to include ketamine within the treatment plan of those with chronic conditions
223629269|NCT03923166|DRUG|Pyrotinib|400mg qd
223629270|NCT03923166|DRUG|capecitabine|capecitabine 500mg tid
223629271|NCT00897481|GENETIC|gene expression analysis|
223629272|NCT00897481|GENETIC|mutation analysis|
223629273|NCT00897481|OTHER|diagnostic laboratory biomarker analysis|
223629274|NCT00897481|OTHER|immunohistochemistry staining method|
223629275|NCT00897481|PROCEDURE|sentinel lymph node biopsy|
223629276|NCT01456884|BEHAVIORAL|Live guitar and vocal music therapy|Live guitar and vocal music therapy. Subject is passive recipient for 30 minutes.
223629277|NCT01456884|BEHAVIORAL|Vibroacoustic Music Therapy|30 minutes using vibroacoustic mat.
223629278|NCT06584188|DRUG|anti-inflammatory ketorolac tromethamine|"* Intra- radicular anti-inflammatory {ketorolac tromethamine at room temperature}.~* Intra- radicular cold anti-inflammatory {ketorolac tromethamine at 2-5C}."
224317589|NCT06007833|BEHAVIORAL|Physical Therapy and Rehabilitation Modalities|In the experimental group, the subjects who were taken to the physical therapy modality in addition to conventional therapy. Total, each session was performed for 60 minutes, 8 weeks, 3 days a week, under the supervision of a physiotherapist, while the other days, the family member performed 3 times a day, each movement for 3 sets, 10-15 repetitions, for a total of 60 minutes. A rest interval of less than 2 minutes was given between each set. By making use of heat modalities before starting the exercises, the elongation ability of the warmed tense structure was increased and the risk of damage in stretching exercises was reduced. The cold application was applied to the soft tissues in the extended position for 1-2 minutes with a cold pack, as the application of cold immediately after the stretching would ensure the preservation of the range of motion. Progress in the exercise program; adjusted for strength, endurance, flexibility, balance and functionality parameters.
223629279|NCT04879056|DIAGNOSTIC_TEST|PIPS 5.1|Description: Scanning glass slides on PIPS 5.1. This intervention will be applied in the arm of intra-system and the arm of inter-system.
223629280|NCT02666872|BEHAVIORAL|Motivational interviewing|
223629281|NCT03541122|DIAGNOSTIC_TEST|pelvic X-ray examinations|Measurement indicators will include OFI, MUI, TBOI, CE angle, Sharp angle and AHI of the affected and healthy femoral heads.
223629282|NCT04907682|DRUG|Ribavirin iv|100 mg/kg Day 1 (dose is divided: 2/3 stat, 1/3 8 hours later, maximum dose is 7g/day), then 25 mg/kg days 2-7, 12.5 mg/kg days 8-10
223629283|NCT04907682|DRUG|Favipiravir|Day 1 2400mg(H0)-2400mg(H8)-1200mg(H16), Day 2-10 1200mg twice daily
223629284|NCT06009562|PROCEDURE|Laparotomic myomectomy during pregnancy|Surgical removal of symptomatic uterine fibroids in pregnancy by laparotomic access
223629285|NCT02468817|PROCEDURE|Treadmill Exercise|2 (two) 1-hour of vigorous exercise bouts under different thermal conditions
223629286|NCT02468817|PROCEDURE|Magnitude of Ca loss during Exercise at 26 degrees Celcius|Blood samples at 15-min intervals starting 15 min before exercise and ending 60 min after exercise
223629287|NCT00374140|DRUG|RAD001 (everolimus)|10 mg by mouth daily without interruption for 3-week cycles until disease progression or intolerable toxicities
223629288|NCT03220971|OTHER|lipoprotein and apolipoproteins|To find out the role of lipoprotein and apolipoproteins (apos) in pathogenic hepatic diseases
223629289|NCT04576988|BIOLOGICAL|Sotatercept|Sotatercept at a starting dose of 0.3 mg/kg with a target dose of 0.7 mg/kg administered subcutaneously (SC) every 21 days plus background PAH therapy.
223629290|NCT04576988|DRUG|Placebo|Placebo administered subcutaneously (SC) every 21 days plus background PAH therapy.
223629291|NCT04576988|DRUG|Background PAH Therapy|Background PAH therapy may consist of the following drug classes: an endothelin-receptor antagonist (ERA), a phosphodiesterase 5 (PDE5) inhibitor, a soluble guanylate cyclase stimulator, and/or a prostacyclin analogue or receptor agonist.
223629292|NCT06353594|DEVICE|Primary PCI|Coronary percutaneous revascularization
223629293|NCT04820595|DIAGNOSTIC_TEST|RASS|Richmond Agitation-Sedation Scale
223629294|NCT04820595|DIAGNOSTIC_TEST|CAM-ICU|Confusion Assessment Method for the ICU
223629295|NCT02547181|BEHAVIORAL|Behavioral Modification|Patient will be provided with tensor bandage and instructed on specific behaviors to prevent movement of the injured part of the hand.
223629296|NCT02547181|BEHAVIORAL|Splint|fibreglass splint
223629297|NCT03983733|OTHER|Dietary Intervention|To carry out an interventional dietary study using standardised meals to predict an individual's metabolic response to certain foods, using their gut microbiome, metabolic profile, and other measurable characteristics such as weight, sleep and exercise.
223629298|NCT02068924|OTHER|Slow freezing versus vitrification|
224217916|NCT06222463|DEVICE|Evone|Evone (Ventinova Medical B.V., Eindhoven, The Netherlands) is a ventilator, which is able to perform flow-controlled ventilation (FCV). Moreover it provides direct tracheal pressure measurements and combined with the constant gas flow of FCV a precise determination of dynamic compliance is feasible. Thus not only PEEP but also peak pressure can be titrated based on dynamic compliance. Additionally intratracheal pressure-volume loops can be measured and thus power dissipation calculated, which represents the primary outcome parameter of this trial.
224217917|NCT05314569|DRUG|Ketamine- dexmedetomidine|ketamine - Dexmedetomidine combination had superior cardioprotective effects as measured by cardiac markers as compared to sevoflurane- sufentanil anesthesia after cardiac surgery
224217918|NCT05314569|DRUG|Fentanyl- midazolam|Midazolam is known to have potential anti-inflammatory effects and antioxidant activity. They have been proven to provide protective effects for patients who underwent cardiac surgery.Fentanyl is one opioid that has been closely linked to inflammatory mediators and myocardial protection. It reduces the CPB-induced inflammatory response and ischaemic reperfusion injury during cardiac surgery
224217919|NCT05314569|DRUG|Isoflurane|Anesthetic inhalational gas
224217920|NCT02373384|DRUG|Oral alkalinization (Potassium citrate, Allopurinol)|"Eligible patients, who fulfilled the study criteria, will be instructed For; Oral alkalinization therapy~* Potassium citrate 20 mEq three times daily~* Hyperuricosuric patients (24-hours urine uric acid more than 750 mg/day in male and more than 650mg/day in females) will receive:~Allopurinol, a competitive inhibitor of xanthine oxidase, in a dose of 300 mg daily."
223629299|NCT02352480|DEVICE|Aurix|Aurix is a platelet-rich plasma (PRP) gel used in the treatment of non-healing chronic wounds. It will be administered twice weekly for 2 weeks then weekly.
223629300|NCT00617734|BIOLOGICAL|IMC-A12 (cixutumumab)|IMC-A12 10 milligrams per kilogram (mg/kg) over one hour every two weeks. A cycle is defined as four weeks of therapy. Participants will continue on study until evidence of progressive disease, or unacceptable toxicity develops.
223629301|NCT00617734|BIOLOGICAL|cetuximab (Erbitux ®)|IMC-A12 10 mg/kg over one hour followed by cetuximab 500 milligrams per square meter (mg/m\^2) over two hours. This sequence will be repeated every two weeks. Participants will continue on study until evidence of progressive disease or unacceptable toxicity develops.
223629302|NCT01844765|DRUG|nilotinib|Nilotinib supplied in 50mg, 150mg, and 200mg capsules. It was administered orally at 230mg/m2, twice daily for up to 66 cycles (1 cycle = 28 days). Dose administration was rounded to the nearest 50mg dose (to a maximum dose of 400mg).
223629303|NCT03371836|DRUG|Clobazam|Clobazam is used as an adjunct medicine for all participants.
223629304|NCT02847962|OTHER|Corn Soy Blend Plus (CSB+)|
223629305|NCT02847962|OTHER|Corn Soy Blend 14 (CSB14)|
223629306|NCT02847962|OTHER|White Sorghum Cowpea Blend Variety 1|
223629307|NCT02847962|OTHER|White Sorghum Cowpea Blend Variety 2|
223629308|NCT02847962|OTHER|Red Sorghum Cowpea Blend|
223629309|NCT02847962|OTHER|White Sorghum Soy Blend|
223629310|NCT05638256|DRUG|68Ga-NY104|Patients will receive a tracer (20-40mcg, IV) dose of 68Ga (2-5mCi) labelled NY104
223629311|NCT02973971|OTHER|volumeric MRI|
223629312|NCT06073626|BEHAVIORAL|Relational agent (RA) / Chatbot|Consists of clinical letter and engagement with genetic education and uptake of genetic testing for hereditary cancer risk among Black cancer survivors.
223629313|NCT06073626|BEHAVIORAL|Enhanced Usual Care (EUC)|Consists of clinical letter and recommendation for genetic testing for hereditary cancer risk among Black cancer survivors.
223629314|NCT01004952|BEHAVIORAL|screening questionnaire|Phase I involves in-home interviews of 25 participants to understand the factors that affect participants' decision-making about UVR protection (sunscreen use, shade-seeking, hat use, use of protective clothing). In Phase II, we plan to recruit a sample of 60 melanoma first degree relatives (FDRs) and use an electronic narrative diary to record their daily behaviors about UVR protection. They will be asked to carry a interactive voice response (IVR) system for 14 days and they should be in the continental United States.
223629315|NCT03678207|OTHER|Anesthesiologist phone call|Patients receiving ambulatory surgery with no prior diagnosis of hypertension but have elevated blood pressure prior to surgery. Patients will receive a phone call from a participating anesthesiologist 1-3 days after surgery notifying them of their high blood pressure and obtaining oral consent to participate in the study. Patients will receive reminders via mail about following up with their PCP.
223629316|NCT00869466|BEHAVIORAL|behavioral dietary intervention|
223629317|NCT00869466|BEHAVIORAL|exercise intervention|
223629318|NCT00869466|OTHER|counseling intervention|
223629319|NCT00869466|OTHER|educational intervention|
223629320|NCT00869466|OTHER|laboratory biomarker analysis|
223629321|NCT00869466|OTHER|questionnaire administration|
223629322|NCT00869466|PROCEDURE|quality-of-life assessment|
223629323|NCT00869466|PROCEDURE|support group therapy|
223629324|NCT01992588|DRUG|Faster-acting insulin aspart|"Subjects - in a euglycaemic clamp setting - will receive a priming (initial) dose followed by a continuous basal rate infusion and finally a bolus dose on top of the basal rate infusion.~The trial products will be administered subcutaneously (s.c. under the skin) by means of an insulin pump."
224217921|NCT02373384|BEHAVIORAL|Life style modification|"Eligible patients, who fulfilled the study criteria, will be also instructed for;~Adequate fluid intake in order to maintain urine volume between 2-3 L per day."
224217922|NCT02373384|DIETARY_SUPPLEMENT|Dietary recommendations (decrease purine rich diet as red meat and fish, increase vegetables)|Eligible patients, who fulfilled the study criteria and they are hyperuricosuric (24-hours urine uric acid more than 750 mg/day in male and more than 650mg/day in females) will be also instructed for; Dietary modification will be advised in the form of decrease purine rich diet as red meat and fish, increase vegetables.
224217923|NCT05499364|BEHAVIORAL|TinCat|7-10 minute personalized video sessions based in tobacco cessation modules.
223629325|NCT01992588|DRUG|insulin aspart|"Subjects - in a euglycaemic clamp setting - will receive a priming (initial) dose followed by a continuous basal rate infusion and finally a bolus dose on top of the basal rate infusion.~The trial products will be administered subcutaneously (s.c. under the skin) by means of an insulin pump."
224217924|NCT05499364|BEHAVIORAL|Quit.gov program|7-10 minute generic videos directing participants through quit.gov program
224217925|NCT03568500|DEVICE|Digital Medicine System|DMS components: a CoE product consisting of an approved antipsychotic medicinal product co-encapsulated with Conformité Européenne (CE)-marked miniature ingestible event marker in tablet; a CE-marked compatible medical device (a Proteus Patch \[Disposable Wearable Sensor Version 5\]); proprietary medical software (a local and remote computing application).
224217926|NCT03568500|DRUG|Aripiprazole|Dosage determined by the healthcare professionals.
224217927|NCT03568500|DRUG|Olanzapine|Dosage determined by the healthcare professionals.
224217928|NCT03568500|DRUG|Quetiapine|Dosage determined by the healthcare professionals.
224217929|NCT03568500|DRUG|Risperidone|Dosage determined by the healthcare professionals.
224217930|NCT00943800|DRUG|Fludarabine-Melphalan & Rabbit antithymocyte globulin (r-ATG)|Fludarabine is given through the vein daily for 5 days. Melphalan is given through the vein daily for 2 days. ATG is given every day in the vein for four days.
224217931|NCT00943800|PROCEDURE|Stem Cell Transplant|Infusion of haploidentical donor, umbilical cord blood
224217932|NCT00943800|PROCEDURE|Stem Cells Collections|Haploidentical cells will be T-cell depleted using the Miltenyi Clinimax device.
224217933|NCT00943800|DRUG|Fludarabine, Thiotepa, Antithymocyte globulin (ATG), and Total Body Irradiation (TBI)|Fludarabine is given through the vein daily for 5 days. Thiotepa is given through the vein daily for 2 days. ATG is given through the vein every other day for 4 days. TBI is given twice a day for 3 days.
223629326|NCT04762511|BIOLOGICAL|Lower dose formulation of HSV vaccine (GSK4108771A)|2 doses of the lower dose formulation of HSV vaccine (GSK4108771A) administered intramuscularly in the non-dominant arm, one each at Day 1 and Day 57.
223629327|NCT04762511|BIOLOGICAL|Low dose formulation of HSV vaccine (GSK4108771A)|2 doses of the low dose formulation of HSV vaccine (GSK4108771A) administered intramuscularly in the non-dominant arm, one each at Day 1 and Day 57.
224217934|NCT00943800|DRUG|Fludarabine, Busulfan, and ATG|Fludarabine is given through the vein daily for 5 days. Busulfan is given through the vein daily for 4 days. ATG is given through the vein every other day for 4 days.
224217935|NCT04264299|PROCEDURE|T tube drainage|closure of common bile duct over T tube
224217936|NCT04264299|PROCEDURE|Primary closure|Primary closure of common bile duct
224217937|NCT04264299|PROCEDURE|Antegrade stenting|Closure of common bile duct over antegrade plastic biliary stent
223629328|NCT04762511|BIOLOGICAL|Medium dose formulation of HSV vaccine (GSK4108771A)|2 doses of the medium dose formulation of HSV vaccine (GSK4108771A) administered intramuscularly in the non-dominant arm, one each at Day 1 and Day 57.
223629329|NCT04762511|BIOLOGICAL|High dose formulation of HSV vaccine (GSK4108771A)|2 doses of the high dose formulation of the HSV vaccine (GSK4108771A) administered intramuscularly in the non-dominant arm, one each at Day 1 and Day 57.
223629330|NCT04762511|DRUG|Placebo (saline)|2 doses of placebo (saline) administered intramuscularly in the non-dominant arm, one each at Day 1 and Day 57.
223629331|NCT04272294|DEVICE|Optical Spectroscopy|Using oral spectroscopy device to characterize treatment response in tumors
223629332|NCT05404828|OTHER|Polysomnography|Polysomnography: WASO, FUSP, TST, TIB, SEF, Global Wake Index, Sleep Latency, AHI
223629333|NCT05404828|OTHER|Questionnaires|STOP-BANG, ISI, ESS, PSQI, MTCQ, ICIQ-F/MLUTS, IRLS, TANGO, SF36
224217938|NCT03438799|DEVICE|Cordio System|App, cloud and web device
224217939|NCT04352842|OTHER|Echocardiography|An expert with 17-year professional experience performed all the echocardiography examinations using a GE LOGIQTM e portable color ultrasound diagnostic machine (GE Healthcare, WI, USA) that was specially used in the contaminated area. Two-dimensional and Doppler echocardiographic measurements were conducted following the recommendations of the American Society of Echocardiography
224217940|NCT04480099|DRUG|CHOP|Cyclophosphamide 750mg/m2, ivgtt D1, doxorubicin 50mg/m2,ivgtt D1 Vincristine 1.4mg/m2（max 2mg）, ivgtt D1 Prednisone 60mg/m2 （max 100mg）,PO,D1-D5 every 21 days for total 6 courses
224217941|NCT04480099|DRUG|CHOP+X|X: X(i.e. targeted drug) will decided by NGS results as following. Decitabine 10mg/m2 ivgtt D-5 to-1 if with TP53 gene muation. Azacitadine 100mg/day ivgtt D-7 to -1 if with TET2/KMT2D gene mutation. Chidamide 20mg/day po D1,4,8,11 if with CREBBP/EP300 gene mutation. Lenalidomide 25mg/day po D1-10 if without gene mutation above. X will be added from the second cycle CHOP:Cyclophosphamide 750mg/m2, ivgtt D1, doxorubicin 50mg/m2,ivgtt D1 Vincristine 1.4mg/m2（max 2mg）, ivgtt D1 Prednisone 60mg/m2 （max 100mg）,PO,D1-D5 every 21 days for total 6 courses
223629334|NCT05404828|OTHER|Blood and urine sample|Na, K, Creat, Osm, Urea
223629335|NCT05224271|OTHER|Electronic Health Record Review|Medical records are collected
224217942|NCT01181856|BIOLOGICAL|MVA 85A|Single injection of 1 x 108 pfu MVA85A
224217943|NCT02023632|BEHAVIORAL|Similar-Age-Same-Gender (SASG)|The core feature of the program is that it is exclusively for those of a similar age and same gender. Such an environment was reported to provide opportunities for social connectedness, as well as personal comfort. Secondly, exercise class instructors are volunteers- both providing 'similar-models' to enhance efficacy as well as reduce costs associated with instructors. Consistent with social identity and self-categorization perspectives, the program also makes use of a series of strategies to foster intra-group attraction and group identity. For many of the participants a major draw of the program is that it provides opportunities for the older adults to connect with one another after the classes have ended.
223629336|NCT05224271|OTHER|Medical Device Usage and Evaluation|Fitbit information is collected
223629337|NCT05224271|OTHER|Survey Administration|Complete surveys
224317590|NCT06007833|BEHAVIORAL|Conventional Group|As a conservative treatment in the control group, post-surgical plastering followed by orthoses and positioning was applied.
224317591|NCT01936506|BEHAVIORAL|Cognitive Training A|
224317592|NCT01936506|BEHAVIORAL|Cognitive Training B|
224317593|NCT03362606|BIOLOGICAL|OC-CTLs|2 to 4 infusions, once a week, for 1x10\^5\~4x10\^6 CTLs/kg via IV, abdominal cavity or tumor injection each time
224317594|NCT00005052|BIOLOGICAL|GM2-KLH vaccine|
224317595|NCT00005052|BIOLOGICAL|QS21|
224317596|NCT00005052|PROCEDURE|adjuvant therapy|
223629338|NCT00712751|BEHAVIORAL|questionnaires|"Participants randomized to the Usual Care arm will receive standard care . For women, this is defined as the care that participants who are not in the intervention receive; we will ask these participants what psychosocial care they are receiving to track usual care. For men, usual care will consist of a standardized referral to the men's Sexual Medicine Program at MSKCC and written information in the form of the American Cancer Society (ACS) booklet on Sexuality after Cancer. Individuals randomized to Usual Care will not receive any additional counseling sessions from the study interventionists until they are done with the follow up interviews and then it will be offered to them. Follow up questionnaires will assess all study participants at 4 and 8 months after baseline."
223629339|NCT00712751|BEHAVIORAL|CSI-SH- Cancer Survivorship Intervention|This involves four 1-hour individual sessions with three additional telephone booster/review sessions provided in between the four sessions. Sessions can be completed in person or conducted over the phone. Although every effort will be made to complete the booster session in between counseling sessions, if the patient is unavailable to complete the booster calls they may be skipped. Sessions one and two will focus on rehabilitation techniques and tools will be provided and discussed with participants during these first two sessions.
223629340|NCT06298084|DRUG|Patritumab deruxtecan|5.6 mg/kg every 21 days
223629341|NCT06298084|DRUG|Olaparib|100 mg b.i.d PO days 8-14 every 21 days
223629342|NCT03221556|BEHAVIORAL|Engagement-Focused Care Coordination (EFCC)|Engagement interviewing is embedded within a traditional PCMH structure using motivational interviewing and shared decision making; it explores treatment options in the context of a patient's life circumstances, and helps her work through ambivalence to receiving care. In one to two sessions, providers disclose the probable diagnosis of depression, provide psycho-education, present treatment options, and engage clients in shared decision making to determine the most appropriate referral.
223629343|NCT03221556|BEHAVIORAL|Problem Solving Education (PSE)|Problem solving sessions are one-on-one, workbook-based interactions. Sessions comprise seven sequential steps: 1-defining a problem, 2-establishing goals for problem resolution, 3-generating multiple solution alternatives, 4-Implementing decision making guidelines, 5-evaluating and choosing solutions, 6-Implementing the preferred solutions, and 7-evaluating the outcome.
223629344|NCT04414111|DIAGNOSTIC_TEST|Highly suppressive Treg measurement|Circulating highly suppressive Treg measurement
223629345|NCT04983277|OTHER|no intervention|no intervention
223629346|NCT04131023|BEHAVIORAL|Breezing Metabolic Rate Tracking|Metabolism (indirect calorimetry) data were collected every two weeks over 13 weeks of gestation across the second trimester (weeks 13-27) and the values obtained were provided to the participant without health education.
223629347|NCT01832077|DEVICE|90 D|rural doctors exam eye fundus by 90 D
223629348|NCT01832077|DEVICE|fundus camera and grader|taking fundus pictures and graded by graders in ZOC
223629349|NCT04061122|DIAGNOSTIC_TEST|airway epithelial smear test|all patients will be subjected to all scheduled procedures: airways epithelial smear test, measurement of VOCs in exhaled air and airways slide sample culture
223629350|NCT04350632|DIAGNOSTIC_TEST|Shear wave elastography assessment of the external anal sphincter|"Assessment of the external anal sphincter viscoelastic properties using shear wave elastography technology~* Women in lithotomy position with an empty bladder~* The linear probe is applied on transversal plane on the perineal with a transperineal approach~* The external anal sphincter will be identified in 2D ultrasound using a SL 18-5 linear probe~* Viscoelastic properties of the muscle will be assessed by measuring the shear modulus at rest, Valsalva maneuver and contraction~* Exactly the same investigations will be performed for the two visits planned in the protocol. In the first visit, it will be one single observer and for the second it will be 2 observers.~* Data about the mode of delivery and the occurrence of OASI will be collected into women's medical fil"
223629351|NCT00506350|BIOLOGICAL|Pandemic influenza candidate vaccine (GSK1562902A) - 1 dose|A single dose of Pandemic influenza candidate vaccine (GSK1562902A) administered intramuscularly in the deltoid region of the non-dominant arm at Day 0.
224217944|NCT02023632|BEHAVIORAL|Similar-Age-Mixed-Gender (SAMG)|The SAMG physical activity condition will mirror the SASG group condition, but will be open to older adults from both genders. The same strategies to those used within the SASG condition will also be utilized (development of a unique program name, T-shirts, opportunities to socialize after the program), and will be offered three days per week (Mon, Wed, Fri, or Tues, Thurs, Sat). Older adults will also be recruited to be instructors for the group classes (= 65 years), with both males and females invited to occupy these instructional roles. (As with the SASG condition, training will take place between September and December 2013, through the respective YMCA centres. The YMCA will oversee the training of these volunteers through their Fitness Leader Training Program).
224217945|NCT02023632|BEHAVIORAL|Mixed-Age-Mixed-Gender (MASG)|The third condition utilized within the RCT is designed to reflect 'standard' group based exercises that one sees in typical physical activity centres. Specifically, these classes are not restricted to participants on the basis of age or gender, and as such older adults will be participating in groups comprised of people younger than themselves as well as those of both gender.
224217946|NCT01577537|DRUG|1% SPL7013 Gel|Vaginal gel, daily for 7 days
224217947|NCT01577537|DRUG|Placebo|Vaginal gel, daily for 7 days
224217948|NCT04878978|DIAGNOSTIC_TEST|Amniocentesis|Amniocentesis will be used to sample the amniotic fluid for Biofire detection of microorganism and to direct antibiotic treatment
224217949|NCT04878978|OTHER|Routine care without amniocentesis|Routine clinical care
223629352|NCT00506350|BIOLOGICAL|Pandemic influenza candidate vaccine (GSK1562902A) - 2 doses|Two doses of Pandemic influenza candidate vaccine (GSK1562902A) administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and Day 21.
224217950|NCT04716959|PROCEDURE|Prepectoral Prosthetic Breast Reconstruction|The prepectoral approach involves placing the tissue expander on top of the pectoralis muscle.
224217951|NCT04716959|PROCEDURE|Subpectoral Prosthetic Breast Reconstruction|The subpectoral approach involves placing the tissue expander under the pectoralis muscle with or without acellular dermal matrix (ADM).
224217952|NCT04800107|BIOLOGICAL|Curcumin-phosphatidylcholine|500 mg of curcumin-phosphatidylcholine combined with 250 mg of boswellia-phosphatidyl
224217953|NCT04800107|BIOLOGICAL|Placebo capsule|Placebo capsule
224217954|NCT01410383|DRUG|Placebo|Tablets taken daily
224217955|NCT01410383|DRUG|Eprotirome|Tablets taken daily
224217956|NCT01410383|DRUG|Eprotirome|Tablets taken daily
224217957|NCT01809054|DRUG|Arixtra|
223629353|NCT05144373|BEHAVIORAL|Gross motor intervention, gross and fine motor intervention|"For gross motor intervention, participants will receive a home-based, parent-administered body-weight supported treadmill intervention from about 10 months of age until walking onset.~For gross and fine motor intervention, participants will receive the same treadmill intervention as illustrated above. In addition, participants will receive a fine motor intervention with practice of reaching and grasping using sticky mittens from about 10 months of age for five months."
223629354|NCT06569212|DRUG|Metoprolol|"Metoprolol Dosing:~Metoprolol Injection (instructions: 5mg, once) Metoprolol Tab (25mg PO, q12 hours, timed to start 1hr after Metoprolol Injection, 6 doses) If unable to take PO medication, Metoprolol Injection (instructions, 5mg q6hrs for 12 doses) Continue for 72-hours of administration unless reaching stopping criteria"
223629355|NCT06569212|DRUG|Placebo|"Placebo Dosing:~Placebo Injection (instructions: 5mL NS, once) Placebo Tab (1 tab PO, q12 hours, timed to start 1hr after placebo injection, 6 doses) If unable to take PO medication, Placebo Injection (instructions, 5mL q6hrs for 12 doses) Continue for 72-hours of administration unless reaching stopping criteria"
223764067|NCT01054638|DRUG|HAART Treatment|"Using pharmacy records, identify all patients with HAART dispensing during baseline \& follow-up periods. For combination medications, classify person-time according to individual therapeutic components. HAART exposure classification by 1)any HAART exposure, 2)by HAART class, and 3)by specific nucleoside reverse transcriptase inhibitor exposure. Specific evaluation of fosamprenavir and amprenavir.~Subdivide person-time according to recent, past \& non-use of HAART. Person-time for each patient partitioned into exposure windows of Recent use(From start of dispensing to end of days supplied plus 6 months), Past use(From end of current use to end of follow-up or new HAART dispensing following recent use), \& Non-use(Time prior to first dispensing or all time for those who did not receive a dispensing).~Determine cumulative duration of exposure based on days supplied per dispensing per patient over the baseline \& follow-up periods: Non-use, Less than 1 yr, 1-2 yrs, More than 2yrs."
223764068|NCT06198907|DRUG|Golidocitinib|Daily dosing of golidocitinib
224217958|NCT01809054|DEVICE|Pneumatic compression stockings|Pneumatic compression stockings (MCS, Active Care, medical compression systems Inc., Israel)
224217959|NCT01809054|DRUG|Aspirin|
224217960|NCT00950833|BIOLOGICAL|Pneumococcal vaccine GSK1024850A|1 or 2 intramuscular injections
224217961|NCT00593996|OTHER|Ergocalciferol (vitamin D2)|50,000 IU 3 times weekly for 4 weeks
224217962|NCT04699981|OTHER|Control (Patients colonized rectally with ESBL-producing enterobacteria without antibiotic pressure)|"For patients included in the Control group on discharge from hospitalization and 60 days after inclusion of patients, data will be collected either from the patient's medical file (T1Control) or during '' a telephone call from the patient (T2Control). The data collected concerns the occurrence of an infectious episode. They will also benefit from a stool sample at T1 control in order to assess the evolution kinetics of the relative fecal abundance of ESBL-producing enterobacteria in these patients who are not subjected to antibiotic pressure but subjected to other drug pressures (PPI, corticosteroids, etc.)."
224217963|NCT04699981|OTHER|Case (Patients colonized rectally with ESBL-producing enterobacteriaceae, with antibiotic pressure)|"A stool culture is performed on the first stool emitted after the start of antibiotic therapy. 72 hours after the start of antibiotic therapy, a blood sample (5 ml) and a stool sample will be taken. A stool sample will be taken at the end of the antibiotic therapy and 60 days after the end of the antibiotic therapy. In the event of normal transit (daily bowel movements), the stool emitted 48 hours after the start of antibiotic therapy will be analyzed. If the patient does not pass stool, an eswab rectal swab will be taken. In the event of discharge from the hospital before the end of the antibiotic therapy and / or the D60 after the end of the antibiotic therapy, the patient will be given a prescription and an appointment at the collection center of the center concerned for the sample stool."
224217964|NCT01104233|DEVICE|LAP Protector|The LAP Protector is a device that consists of two flexible rings made of superelasticity alloys covered with polyurethane polyamide, and a thin silicone rubber membrane that is attached to the outer rim of the two rings
224217965|NCT04965220|DRUG|HLX 208|take orally
224217966|NCT04625582|BEHAVIORAL|Face-to-face|"The intervention has been created specifically for this group of trainees, with the aim of acquiring or improving mediating personal skills in the processes of physical and mental well-being that help them cope with more motivation, enthusiasm and personal resources professional challenges.~It is based on conducting 4-hour face-to-face workshops, every four months throughout the period of specialized health training. They will be instrumented through group dynamics, communication exercises, leadership, corporality, and reflective and emotional writing.~Audiovisual media (videos, presentations, recordings) will be used. They will be developed in person in a classroom equipped with the necessary means for training, including versatility of the space."
224217967|NCT04625582|BEHAVIORAL|Online|"The online intervention will pursue the same objectives and will be nourished by the same content as the face-to-face intervention. The theoretical content will be adapted for online use, with the flexibility of access and organization that this entails for the participants, including videos, presentations, recordings ...~Group techniques will be carried out online, every four months during the entire period of specialized health professional training. They will be instrumented through group dynamics, communication exercises, leadership, corporality, and reflective and emotional writing."
223764069|NCT06198907|DRUG|Sintilimab|Sintilimab, 200mg, intravenous, every 3 weeks.
223764070|NCT06198907|DRUG|platinum doublet chemotherapy|Pemetrexed or nab-paclitaxel +carboplatin, intravenous, every 3 weeks for 2 cycles
223764071|NCT00006125|DRUG|doxorubicin hydrochloride|
223764072|NCT00006125|DRUG|topotecan hydrochloride|
223764073|NCT01736696|DRUG|tofacitinib|5 mg BID For 13 days and once on Day 14
223764074|NCT01736696|DRUG|tofacitinib|10 mg BID for 13 days and once on Day 14\*
223764075|NCT01736696|DRUG|tofacitinib|20 mg BID for 13 days and once on Day 14
223764076|NCT01736696|DRUG|tofacitinib|30 mg BID for 13 days and once on Day 14
223764077|NCT01736696|DRUG|tofacitinib|60 mg tablet once a day (QD) for 14 days
223764078|NCT01736696|DRUG|tofacitinib|50 mg tablets two times a day (BID) for 13 days and once on day 14
223764079|NCT00838565|DRUG|Placebo|intravenous infusion on three consecutive months
223764080|NCT00838565|DRUG|dose level 1|intravenous infusion on three consecutive months
224317597|NCT01608061|DEVICE|DBS-f on|deep brain stimulation of the fornix
224317598|NCT01608061|DEVICE|DBS-f off|deep brain stimulation of the fornix turned off
223629357|NCT05672550|DRUG|Bayesian based dose adjustment of enoxaparin|"A first recommended dose of enoxaparin 50 IU/kg subcutaneously is administered during transplantation or within the first 24 hours.~Then a Bayesian estimate of individual pharmacokinetics is performed to adapt the next twice daily (Hour 12;Hour 24) enoxaparin dose until achievement of the target on two consecutive measurements. Then anti-Xa activity will be evaluated once a day until day 7."
223629358|NCT05672550|DRUG|Usual dose adjustment of enoxaparin|A first recommended dose of enoxaparin 50 IU/kg is administered during transplantation or within the first 24 hours. Then anti-Xa activity is measured and twice-daily (hour 12 ; hour 24) enoxaparin empirical dose-adjustment is performed according to the usual practices in the investigating centers to target.
223629359|NCT05891379|DRUG|Inebilizumab|Inebilizumab: 300mg IV on Day1 and Day 15. The first dose of inelizumab is given during IVMP.
223629360|NCT05891379|DRUG|oral immunosuppressant|Oral immunosuppressants (azathioprine or mycolate mofetil) are initiated during IVMP.
223629361|NCT06219525|DIETARY_SUPPLEMENT|Higher dose of enteral zinc|Higher dose of zinc sulfate 10 mg/day; each 1 mL contains 10 mg of elemental zinc (osmolality 450 Osm/kg H2O). After randomization, nurses blinded to the study aims administered the assigned preparation 1 mL via tuberculin syringe, once daily, 1 hour after feeding. Zinc sulphate oral solution was prepared by the pharmaceutical compounding unit in the hospital. The supplement was given again to subjects who vomited within 15 minutes after the administration. All episodes of vomiting were reported on the record form. Vomiting episodes within 15 minutes were recorded. The supplement assigned was at discharge or at 44 weeks of postmenstrual age whichever came first. Both groups received multivitamin (MTV) products and iron supplement as routine preterm care.
223629362|NCT06219525|DIETARY_SUPPLEMENT|Standard dose of enteral zinc|Standard dose of zinc sulfate 1 mg/day; each 1 mL contains 1 mg of elemental zinc (osmolality 45 Osm/kg H2O). After randomization, nurses blinded to the study aims administered the assigned preparation 1 mL via tuberculin syringe, once daily, 1 hour after feeding. Zinc sulphate oral solution was prepared by the pharmaceutical compounding unit in the hospital. The supplement was given again to subjects who vomited within 15 minutes after the administration. All episodes of vomiting were reported on the record form. Vomiting episodes within 15 minutes were recorded. The supplement assigned was discontinued at discharge or at 44 weeks of postmenstrual age whichever came first. Both groups received multivitamin (MTV) products and iron supplement as routine preterm care.
223629363|NCT05795166|OTHER|No treatment given|No treatment given
223629364|NCT05367778|DRUG|HS-10370|HS-10370 will be administered orally once daily in a continuous regimen
223764081|NCT00838565|DRUG|dose level 2|intravenous infusion on three consecutive months
223764082|NCT00838565|DRUG|dose level 3|intravenous infusion on three consecutive months
224217968|NCT02798068|DRUG|Solu-medrol or placebo administration|patients will receive 500mg of methylprednisolone in 100ml NaCl 0,9% or placebo (100ml NaCl 0,9%) at anesthesia induction
224217969|NCT01666886|DEVICE|Mandibular Advancement Device (MAD)|
224217970|NCT03101163|BIOLOGICAL|Autologous peripheral blood stem cells and hyaluronic acid|Regimen of intra-articular PBSC and HA injections and postoperative physiotherapy
224217971|NCT03101163|OTHER|Hyaluronic acid|Regimen of intra-articular HA injections and postoperative physiotherapy
224217972|NCT03713710|BEHAVIORAL|Pap testing|Women will be approached in the community by a Peer Health Educator and scheduled an appointment for a Pap testing at the local health department
223764083|NCT00838565|DRUG|dose level 4|intravenous infusion on 3 consecutive months
223764084|NCT02974985|DEVICE|injection of Restylane Lyft and Restylane L|Intervention--Injections of volumizing products to the midface, nasolabial fold, and marionette folds in female patients in two different age groups
223764085|NCT01701661|PROCEDURE|Operative treatment|stripping of main trunk or if previously removed, removal or ligating the refluating trunk
224217973|NCT03713710|BEHAVIORAL|Choice|Women will be approached in the community by a Peer Health Educator and they will be given a choice between scheduling an appointment for a Pap testing at the local health department or engage in self-sampling for HPV testing at home
224217974|NCT03465410|DRUG|Standard dosage of Tacrolimus|Immediate release Tacrolimus (Prograf/Adoport)
224217975|NCT03465410|DRUG|Bayesian Prediction Tacrolimus dosage|Immediate release Tacrolimus (Prograf/Adoport)
224217976|NCT05842395|DRUG|Vitamin C|Participants with distal radius fractures will take vitamin C supplementation with a daily dose of 1g orally for three months.
224217977|NCT05842395|DRUG|Placebo|Participants with distal radius fractures will take daily Placebo orally for three months.
224217978|NCT05121181|OTHER|delphi project|delphy study
224217979|NCT02277223|DIETARY_SUPPLEMENT|Curcumin|"Eligible patients will be randomized to either intervention of placebo groups. Randomization will be performed separately for patients receiving corticosteroids for induction in-order to ensure similar heterogeneity within groups. Induction: oral prednisone 1mg/kg up to 40 mg once daily for 2 weeks and then tapered down by 5 mg per week or 5-ASA 75 mg/kg/day divided to two doses. Maintenance: 5-ASA 75 mg/kg/day divided to two doses.~Patients receiving corticosteroids for induction, whose PUCAI is \>35 points at 2 weeks will be regarded as treatment failure. Patients receiving 5-ASA for induction with induction treatment failure will be re-randomized to receive oral corticosteroids induction with or without curcumin."
224317599|NCT05204498|BEHAVIORAL|Education plan and adherence to exercise|"Through phone calls with a motivating sense at any time of the day, twice a week.~* It will be recorded in an Excel table each time the patient is called.~* A monthly survey will be applied where the adherence to the exercise during the previous month is measured.~* These activities will be carried out for 8 weeks. At the end of week 8, patients will be referred to the pulmonary rehabilitation unit to evaluate the anthropometric parameters, assess dyspnea with the modified scale of the Medical Research Council, the hospital anxiety and depression scale, the Saint George respiratory questionnaire , the pulmonary information You need the questionnaire and the 6-minute walk test again."
224317600|NCT01915745|OTHER|Use of SMS|Patients receive 3 SMS (at 15 days, 5 weeks and 3 months) after consulting in Emergency Department. Then they are called during 10 minutes at 6 months to check if bone densitometry will be performed and if antiosteoporotic treatment will be initiated.
223629365|NCT03201588|DIETARY_SUPPLEMENT|Formulaid|Arachidonic acids (AA) Docosahexaenoic Acids(DHA) 2:1
223629366|NCT01691794|DRUG|Atazanavir|
223629367|NCT01691794|DRUG|Ritonavir|
223629368|NCT04965324|OTHER|Anaesthesia Depth|
223629369|NCT01606072|DRUG|Desmopressin|20 patients in 5 groups 4 each, advancing progressively to each dose level.
223629370|NCT04972786|DEVICE|Repetitive Transcranial Magnetic Stimulation|TMS pulses will be delivered through an air-cooled coil in either a figure-eight or double-cone shape, with the latter being particularly useful for targeting deeper structures such as dACC. The first phase of the TMS protocol will involve a standardized motor-thresholding procedure, wherein peripheral responses evoked by single TMS pulses are recorded via an electromyographic recording device. In this phase, the TMS coil's stimulation intensity is titrated to a level that is comfortable yet effective at reliably exciting neuronal populations orthogonal to the coil (50% motor-evoked potentials ≥50 microvolts; typical duration≈20-40 mins). Then repetitive TMS (rTMS) will be administered to a pre-determined cortical target based on the individual's pre-TMS fMRI scan using a Localite Neuronavigation system (duration≈10-20 mins). The rTMS protocol will involve the delivery of a train of TMS pulses over a cortical target prior to performance of behavioral tasks during a post-rTMS fMRI scan.
223629371|NCT04563377|BIOLOGICAL|ChAdOx1.HTI and MVA.HTI|ChAdOx1. HTI dose 5 x 10\^10 vp MVA.HTI dose 2 x 10\^8 pfu
223629372|NCT02559102|DRUG|Dexmedetomidine sedation|Patients receive dexmedetomidine sedation
223629373|NCT02559102|DRUG|General sevoflurane anaesthesia|Patients receive general sevoflurane anaesthesia with endotracheal intubation
223629374|NCT02559102|PROCEDURE|Caudal anaesthesia|single shot caudal anaesthesia
223629375|NCT02559102|PROCEDURE|Inguinal hernia surgery|Infant inguinal hernia repair.
223629376|NCT01799096|DIETARY_SUPPLEMENT|Sucrose|Sucrose in carbonated soft drinks (4 x250ml total1800 kJ per day)
223629377|NCT01799096|DIETARY_SUPPLEMENT|Aspartame|Intensely sweetened soft drink (no energy content)
223629378|NCT04107246|DEVICE|use of the KaliJAR box|"KaliJAR® : validated device for single-dose eye drops collection. the patient will be asked to discard each single dose of eye drops in the KaliJAR box. The patient returns with the KaliJAR box at each consultation as part of normal practice. The KaliJAR box will be emptied at each consultation by the doctor and then returned to the patient.~No further examination or visit."
223629379|NCT02719821|BEHAVIORAL|Behavioral techniques|"Learning behavioral techniques designed to improve nighttime sleep quality and daytime activity for approximately 45-60 minutes on three occasions.~Device: Actiwatch-2 (Philips Respironics)"
223629380|NCT00628017|DIETARY_SUPPLEMENT|omega-3 polyunsaturated fatty acids ( EPA+DHA)|Group 1 received omega-3 PUFAs as 3 capsules twice daily (total daily omega-3 fatty acid dosage of 1080 mg of EPA and 720 mg of DHA). Group 2 received three identical placebo capsules twice daily which contained olive oil esters. Identical gelatin capsules were used. Both treatment and placebo capsules were vacuum deodorized and supplemented with tertiary-butyl hydroquinone, 0.2 mg/g, and tocopherols, 2 mg/g, as antioxidants. The source of the omega-3 fatty acids was menhaden fish body oil concentrate.
223764086|NCT01701661|OTHER|conservative treatment|Compression stockings class II
223764087|NCT05756322|DRUG|LBS-007|Open Label.
224217980|NCT02277223|DRUG|Placebo|"Eligible patients will be randomized to either intervention of placebo groups. Randomization will be performed separately for patients receiving corticosteroids for induction in-order to ensure similar heterogeneity within groups. Induction: oral prednisone 1mg/kg up to 40 mg once daily for 2 weeks and then tapered down by 5 mg per week or 5-ASA 75 mg/kg/day divided to two doses. Maintenance: 5-ASA 75 mg/kg/day divided to two doses.~Patients receiving corticosteroids for induction, whose PUCAI is \>35 points at 2 weeks will be regarded as treatment failure. Patients receiving 5-ASA for induction with induction treatment failure will be re-randomized to receive oral corticosteroids induction with or without curcumin."
223764088|NCT06566443|DRUG|Honokiol|Honokiol will be given orally at a starting dose of 1 capsule (250 mg/ capsule) per day for 2 weeks. Dose levels will escalate based on dose-limiting toxicity occurrence. We will start at one capsule (250 mg) once daily, dose 0 would be one capsule (250 mg) twice daily, dose +1 would be 500mg in the AM and 250mg in the evening, and +2 would be 500 mg twice daily.
223764089|NCT02114879|BEHAVIORAL|Enhanced Medical Rehabilitation|Daily PT/OT provided by therapists trained in Enhanced Medical Rehabilitation. This training focuses on improved communication, patient engagement, and intensity.
223629381|NCT02433626|DRUG|COTI2|COTI-2 is a third generation thiosemicarbazone.
223629382|NCT02433626|DRUG|Cisplatin|Cisplatin is approved to treat a range of solid tumors and lymphomas.
223629383|NCT00844844|DRUG|Eculizumab|All patients received open-label eculizumab administered intravenously on the following dose schedule: Induction dose - 900 mg per week for four weeks and a dose of 1200 mg one week later; Maintenance dose - 1200 mg every two weeks. Patients who received plasma exchange or infusion during the eculizumab treatment period received a supplemental dose of 600 mg within one hour before plasma infusion or within one hour after the completion of each plasma exchange.
223629384|NCT04604535|DIETARY_SUPPLEMENT|Concentrated beetroot juice|70mL concentrated beetroot juice (400mg nitrate)
223629385|NCT04604535|DIETARY_SUPPLEMENT|Placebo|70mL concentrated nitrate deplete beetroot juice (\<0.01mmol/L nitrate)
223629386|NCT00037167|DEVICE|Exercise poles|
223629387|NCT02512549|OTHER|Pulmonary Rehabilitation|
223629388|NCT04666285|OTHER|Experience of pandemic|Experience of the pandemic will be studied through online questionnaire responses
223629389|NCT03905096|DRUG|BI 425809|Film coated tablet
223629390|NCT03905096|DRUG|Donepezil|Film coated tablet
223629391|NCT00532662|DRUG|S(+)-ketamine|epidural or intravenous 1 mg kg-1 once concurrent with caudal anesthesia
223629392|NCT04778735|PROCEDURE|Liver Transplantation|Liver Transplantation is performed under spesific conditions to increase the life time of patients with liver diseases.
223764090|NCT02114879|BEHAVIORAL|Standard of Care Rehabilitation|Daily PT/OT provided by therapists not trained in the treatment intervention.
223629393|NCT01003808|BIOLOGICAL|IMF-001|100 or 200 mcg, subcutaneously every 2 weeks. Number of Injections: 6 times. (The treatment may be continued if it is beneficial to the subject).
223629394|NCT02893319|BEHAVIORAL|Feeding and growth differences, 5oz vs 8oz bottle|Group A: 5oz bottle Group B: 8oz bottle
223629395|NCT01943344|DEVICE|VIVASURE CLOSURE DEVICE™|implantation of VIVASURE CLOSURE DEVICE™
223629396|NCT04809831|OTHER|Domiciliary oral care with Biorepair Peribioma Toothpaste + Mousse|Patients will use Biorepair Peribioma Toothpaste and Mousse for domiciliary oral hygiene twice a day until T2 session.
223629397|NCT04809831|OTHER|Domiciliary oral care with Curasept Toothpaste (chlorhexidine 0,2%)|Patients will use Curasept Toothpaste (chlorhexidine 0,2%) for domiciliary oral hygiene twice a day until T2 session.
223629398|NCT05903508|OTHER|Functional task training and functional therapy program|Functional task training group this will receive walking and no walking activities
223629399|NCT05903508|OTHER|Functional therapy program Group|Functional therapy program Group this will receive goal directed training
223629400|NCT04761263|OTHER|Task-oriented circuit training|The task-oriented circuit training program consisted of 14 workstations. Time spent at each station will be 1.5 minutes. The children will complete the activity at one station and move to another station. The whole circuit will be completed in 21 minutes and it will be repeated twice per session with 3 minutes rest interval between the 2 circuits. Children will be encouraged to work as hard as possible at each workstation and will also be given verbal feedback and instructions aimed at improving performance. The progression of the task will be considered according to each child's ability and progressed as tolerated. Progressions include increasing the number of repetitions and increasing complexity of the exercise performed at each workstation, such as the distance reached in standing, reducing the height of the chair during sit-to stand, changing the height of blocks or by increasing speed of movement.
223629401|NCT04761263|OTHER|Selected Physical therapy program|"* Facilitation of balance reactions from standing position including; standing on one leg, weight shifting from standing position, stoop and recover from standing, squat from standing and standing on balance board.~* Facilitation of counterpoising mechanism through instructing the child to kick ball from standing position as well as catching and throwing ball with his hands.~* Gait training activities including: walking using different obstacles (rolls, wedges, stepper) and walking up and down stairs.~* Facilitation of protective reaction from standing position by pushing the child in different directions.~* Facilitation of rising mechanism through changing position as well as returning back to the original position e.g.: from lying to standing and from sitting to standing.~* Strengthening exercises for back and abdominal muscles as well as upper and lower limbs.~* Jumping in place and jumping a board."
223629402|NCT01581918|DRUG|Carbamazepine|Patients will receive Carbamazepine in first chemotherapy cycle as planned: - One tablet (200mg) at night on third day before chemotherapy; - One tablet (200mg) every 12 hours on second day before chemotherapy; - One tablet (200mg) every 8 hours from the day before until fifth day after chemotherapy.
224217981|NCT03027570|BEHAVIORAL|Control|Five-month interdisciplinary program, including: twice a week one-hour group exercise activity sessions, 3-5 group meetings with a dietician, 12-13 parent sessions with a social worker, and a healthy cooking workshop, each child will take part in individual sessions including: two appointments with a pediatrician, three sessions with a dietician and two sessions with a physical therapist serving as a consultant for physical activity.
223629403|NCT06026033|DRUG|Desflurane induction|Following tracheal intubation, the fresh gas flow will be set to 1 liters/minute, desflurane vaporizer will be set to maximum.
223629404|NCT02814006|OTHER|health educational video|visualization of health educational video
223629405|NCT02931617|OTHER|Chest Physiotherapy|
223629406|NCT02931617|DEVICE|Post-therapy lung volume measurements|In both intervention groups.
223629407|NCT02016781|PROCEDURE|Allogeneic Hematopoietic Cell Transplant|Bone marrow or peripheral blood stem cell transplant.from a fully matched related (6/6) or unrelated (8/8) donor. The specific transplant treatment regimen will be at the discretion of the treating physician but is required to be reduced-intensity.
223629408|NCT02016781|PROCEDURE|Hypomethylating Therapy / Best Supportive Care|The specific non-transplant treatment regimen will be at the discretion of the treating physician.
224217982|NCT03027570|BEHAVIORAL|Exergame activity_EXG|"In addition to the treatment given to the control group (as described above), the EXG group will obtain home access to the app Just Dance Now and part of a weekly exercise session will include a group activity with the app."
223629409|NCT00005800|BIOLOGICAL|Filgrastim|
223629410|NCT00005800|DRUG|Docetaxel|
223629411|NCT00005800|DRUG|Doxorubicin|
224217983|NCT03027570|OTHER|Application activity|"The application - Just Dance Now will be downloaded to the cellular phone of the child or parent. Exercise using the app will be used by cell phone connection to the child's home computer and as part of exercise group activity."
224217984|NCT04132232|DIAGNOSTIC_TEST|knowledge of expired maternal carbon monoxide and fetal carboxyhemoglobin levels|Will use the Smokerlyzer® device at each visit and be provided information on exhaled carbon monoxide and fetal carboxyhemoglobin. Risks of adverse perinatal outcomes related to maternal carbon monoxide and fetal carboxyhemoglobin level will be provided.
224217985|NCT02367053|DRUG|ZP4207|
224217986|NCT02367053|DRUG|Glucagon|
224217987|NCT06287697|OTHER|No intervention|No intervention
224217988|NCT00892697|DRUG|Telaprevir|Fifteen subjects will receive the same treatment: 12 weeks of telaprevir (750 mg q8h) with Peg-IFN- alfa-2a (Pegasys(R)) (180 mcg SQ qwk) and RBV (1200 mg per day if \>75 kg or 1000mg per day if \< 75 kg).
224217989|NCT00892697|DRUG|Peginterferon alfa-2a|Fifteen subjects will receive the same treatment: 12 weeks of telaprevir (750 mg q8h) with Peg-IFN- alfa-2a (Pegasys(R)) (180 mcg SQ qwk) and RBV (1200 mg per day if \>75 kg or 1000mg per day if \< 75 kg).
224217990|NCT00892697|DRUG|Ribavirin|Fifteen subjects will receive the same treatment: 12 weeks of telaprevir (750 mg q8h) with Peg-IFN- alfa-2a (Pegasys(R)) (180 mcg SQ qwk) and RBV (1200 mg per day if \>75 kg or 1000mg per day if \< 75 kg).
223629412|NCT00005800|PROCEDURE|Surgery|Within 6 weeks of completion of neoadjuvant chemotherapy, patients undergo surgery with mastectomy or lumpectomy and axillary lymph node dissection.
223629413|NCT06186050|DIETARY_SUPPLEMENT|Beetroot drink|Drink containing 10g of beetroot powder in 250 mL cold tap water
224217991|NCT04450498|BIOLOGICAL|Yuxi Walvax MPV ACYW® vaccine|Walvax MPV ACYW vaccine is a sterile formulation of polysaccharide A,C,Y,W-135. One dose of 0.5 mL contains 50 µg of each A,C,Y,W-135 purified polysaccharide. The vaccine is presented in two vials: one containing the lyophilized cake of A,C,Y,W purified polysaccharides and the other the sterile water for injection as diluent. After reconstitution the one dose of 0.5 mL is ready for subcutaneous injection. The antigen content is similar to other internationally marketed polysaccharide vaccines that have been in use for decades as Menomune® Sanofi and Mencevax® Pfizer , all containing 50 µg of each A,C,Y,W purified polysaccharide that as one dose schedule are recommended for use in subjects \> 2 years of age and have shown to be safe and immunogenic.
224217992|NCT04450498|BIOLOGICAL|Sanofi Pasteur Menactra® vaccine|The vaccine presentation is a full liquid formulation in a single dose of 0.5 mL with the following composition: Meningococcal group A polysaccharide 4 µg; Meningococcal group C polysaccharide 4 µg; Meningococcal group Y polysaccharide 4 µg; Meningococcal group W polysaccharide 4 µg; Diphtheria toxoid protein total 48 µg; Sodium phosphate 0.7 mg; Sodium chloride 4.35 mg.
224217993|NCT04244747|DEVICE|induction of labor by breast stimulation|
224217994|NCT04244747|DEVICE|induction of labor by catheter balloon|
224217995|NCT04738877|DIAGNOSTIC_TEST|Body fat measurement|Body fat measurement using skinfolds
223629414|NCT06186050|DIETARY_SUPPLEMENT|Placebo|Mio flavouring in 250 mL cold tap water. Trace amounts of sugar and sodium were added to match the content in the beetroot supplement
223629415|NCT06186050|DIETARY_SUPPLEMENT|Control|Low-fat meal with cornflakes, greek yogurt, skim milk, and orange juice
223629416|NCT05198921|DEVICE|repetitive Transcranial Magnetic Stimulation|"To apply the rTMS will be used the device Neuro-MS/D Variant-3 therapeutic advanced (Neurosoft, Russia) with double cone shape coil. The coil will be placed at Cz according to 10-20 system.~The rTMS protocol will be:~Train frequency - 10 Hz Train duration - 10 sec Inter train interval - 50 seconds Number of train - 25~\------------------------------------- Total pulses - 2500 Total session duration - 1500 seconds"
224217996|NCT04738877|DIAGNOSTIC_TEST|Cardiopulmonary exercise testing|Electrocardiographic exercise testing with ergospirometer on a treadmill
224217997|NCT04738877|DIAGNOSTIC_TEST|Echocardiography|Transthoracic echocardiography
224217998|NCT04738877|DIAGNOSTIC_TEST|Blood test|Blood test for measurement of haemoglobin, serum electrolytes, iron, ferritin and vitamins
224217999|NCT02944643|OTHER|Mindfulness and Support Groups|
224218000|NCT00368537|DRUG|Tigecycline|Treatment A: Tigecycline every 12 hours intravenous (IV) (an initial dose of 100 mg followed by 50 mg every 12 hours)
224218001|NCT00368537|DRUG|ampicillin-sulbactam|"Ampicillin-sulbactam: 1.5 g (1 g ampicillin plus 0.5 g sulbactam) to 3 g (3 g ampicillin plus 1 g sulbactam) intravenous (IV) every 6 hrs or Amoxicillin-clavulanate: 1.2 g (1000 mg amoxicillin plus 200 mg clavulanate) IV every 6 to 8 hrs.~A glycopeptide antibiotic (either vancomycin 1 g IV every 12 hrs or teicoplanin IV loading dose of 400 mg the first day followed by a maintenance dose of 200 mg daily) may be added to the aminopenicillin/betalactamase inhibitor regimen if infection with methicillin-resistant staphylococcus aureus (MRSA) is suspected or confirmed within the first 72 hrs of enrollment. If culture results fail to show a resistant organism, use of the glycopeptide may be discontinued."
224218002|NCT06379399|DRUG|Cetuximab|Cetuximab will be administered at a fixed dose of 500 mg/m2 once every 2 weeks;
224218003|NCT06379399|DRUG|Trifluridine/Tipiracil|"Phase I:~1. 6 patients (male and female) will be enrolled to evaluate safety. Patients will receive Trifluridine/Tipiracil at a dose of 35mg/m2 (maximum single dose of 80 mg). Patients will be followed up for Dose-Limiting Toxicities (DLTs) (2 Cycles, Day 1-Day 28). If ≤2 patients experience DLTs (2 Cycles, Day 1-Day 28), the study will proceed to Phase II with a dose of 35mg/m2. If ≥3 patients experience DLTs (2 Cycles, Day 1-Day 28), the study will proceed to Phase II with a dose of 30mg/m2.~2. Based on the results of the 35mg/m2 dose group, 6 patients (male and female) will be enrolled in the 30mg/m2 dose group to evaluate safety. Patients will be followed up for DLTs (2 Cycles, Day 1-Day 28). If ≤2 patients experience DLTs (1 Cycle, Day 1-Day 28), the study will proceed with a dose of 30mg/m2 in Phase II.~Phase II:~Trifluridine/Tipiracil: po, twice daily from Day 1-5, every two weeks, based on the recommended dose from Phase I;"
224218004|NCT04248855|DRUG|KAN-101|Intravenous (IV) infusion
224218005|NCT04248855|DRUG|Placebo|Intravenous (IV) infusion
224218006|NCT05483920|BEHAVIORAL|One-time educational video|One-time educational video
224218007|NCT05483920|BEHAVIORAL|One-time educational video plus automated text messaging|Educational video plus automated text messaging
224218008|NCT01368276|BIOLOGICAL|Talimogene Laherparepvec|Up to 4 mL of 10⁸ pfu/mL/per intratumoral injection
224218009|NCT01368276|DRUG|Granulocyte Macrophage Colony-Stimulating Factor (GM-CSF)|125 µg/m² subcutaneous injection
224218010|NCT02400320|DRUG|Topical Spray|Topical spray containing Diclofenac 1.16%, Linseed Oil 3%, Menthol 5%, Methyl salicylate 10%.
223629417|NCT05198921|DEVICE|sham repetitive Transcranial Magnetic Stimulation|Neuro-MS/D magnetic stimulator (Neurosoft, Russia) with Neuro-MS.NET software will be used. The synchronous sound will be performed using monitor speaker connected to magnetic stimulator via trigger unit and located near discharging coil. The 10-Hz electrical stimulation will be given trough electrodes fixed on the head along the front edge of the coil to mimic the sensation
223629418|NCT05998018|DEVICE|pdSTIM System Therapy|Stimulate the phrenic nerves in synchrony with inspiratory cycles of the ventilator which exercises the diaphragm
223629419|NCT05935553|DRUG|Baclofen 30 mg|"* baclofen 10 mg capsule (for the 30 mg-baclofen 30 mg arm)~* Dosage: 3 capsules of baclofen 10 mg per day~* route of administration: Oral~* duration of treatment: Total duration of treatment is 13 weeks including 1 week of dose escalation, 11 weeks of maintenance at full dose, and 1 week of dose de-escalation"
224218011|NCT02400320|DRUG|Topical Gel|Topical gel containing Diclofenac 1.16%, Menthol 5%, Methyl salicylate 10%
224218012|NCT02400320|OTHER|Saline|Saline
223629420|NCT05935553|DRUG|Baclofen 60 mg|"* baclofen 20 mg capsule (for the 60 mg baclofen arm)~* Dosage: 3 capsules of baclofen 20 mg per day~* route of administration: Oral~* duration of treatment: Total duration of treatment is 13 weeks including 1 week of dose escalation, 11 weeks of maintenance at full dose, and 1 week of dose de-escalation"
223629421|NCT05935553|DRUG|Placebo|"* placebo capsule (for the placebo arm)~* Dosage:3 capsules of placebo per day~* route of administration: Oral~* duration of treatment: Total duration of treatment is 13 weeks including 1 week of dose escalation, 11 weeks of maintenance at full dose, and 1 week of dose de-escalation"
223629422|NCT05379803|DRUG|Furmonertinib|furmonertinib 160 mg orally QD
223629423|NCT06044675|DRUG|MDMA assisted psychotherapy|This treatment combines MDMA with a well researched treatment for PTSD for dyads known as CBCT. Dyads will undergo a 7-week course of psychotherapy with two doses of MDMA will be used as an adjunct to psychotherapy.
224218013|NCT04281368|OTHER|Analysis of IUFD|Each team member in the audit group had access to all the medical patient charts from the hospitals and also the majority of the charts from the antenatal care clinics (ANC). Each team member independently assessed each case regarding causes of death, preventable/non-preventable deaths, the level of delay if there was any and the standard of healthcare provided to the patients with stillbirth, the postmortem examination of infant and mother and if there were any recommendations given for the next pregnancy
224218014|NCT00000819|DRUG|Prednisone|
224218015|NCT00685919|DRUG|Carbidopa|200 mg every 6 hours for 5 doses given orally
224218016|NCT00685919|DRUG|Placebo|every 6 hours for 5 doses, given orally, and matching Carbidopa
224218017|NCT01674478|DIETARY_SUPPLEMENT|Microlipid with fish oil|Fish oil will start with initial feeding after ostomy placement and Microlipid will start once infant tolerating enteral feeds at 20 ml /kg/d while weaning the Intralipid, which both will be continued until reanastomosis.
224218018|NCT01674478|DIETARY_SUPPLEMENT|Microlipid|A small amount (ml) of Microlipid to match the amount of fish oil in ML/FO group will start with initial feeding after ostomy placement and Microlipid will start once infant tolerating enteral feeds at 20 ml /kg/d while weaning the Intralipid, which will be continued until reanastomosis.
224218019|NCT00497471|DRUG|Deltaprim (3.125 mg pyrimethamine plus 25 mg dapsone)|
224218020|NCT00497471|DRUG|iron (2 mg/kg/daily)|
224218021|NCT02281409|BIOLOGICAL|Mogamulizumab (KW-0761)|
224218022|NCT04436328|PROCEDURE|Surgical treatment|Surgical treatment of native vertebral osteomyelitis consisting of debridement, spinal decompression and instrumentation using hardware. Additional standard antimicrobial therapy, according to the pathogen and its antimicrobial susceptibility (intravenous route during first 2 weeks, followed by oral route for additional 4 weeks).
224218023|NCT04436328|OTHER|Antimicrobial treatment|No surgical intervention, antimicrobial therapy only, bed rest or temporary external immobilization of affected spinal segment with orthopedic orthesis. Antimicrobial therapy will be administrated according to the pathogen type and antimicrobial susceptibility, with initial intravenous administration for 2 weeks, followed by oral antibiotics for 4 weeks to complete 6 weeks of total therapy.
224218024|NCT02933983|OTHER|no intervention, compare URT microbiome healthy control group-chronic rhinosinusitis patients|
224218025|NCT05311852|DIETARY_SUPPLEMENT|palmitoylethanolamide co-ultramicronized with antioxidant flavonoid luteolin (PEA-LUT)|assumption of the product at dosage of 700/70 mg 2 time/day for 8 weeks
224218026|NCT05311852|DIETARY_SUPPLEMENT|Placebo|assumption of a placebo product 2 time/day for 8 weeks
224218027|NCT05402449|OTHER|Placebo|Same Additives to Probiotic group but replace probiotics with Corn starch and Maltodextrin.
224218028|NCT05402449|DIETARY_SUPPLEMENT|Probiotics|Multi-strain probiotic supplement includes Lactobacillus reuteri GMNL-263 (heat-killed) and GMNL-89 (alive) and Lactobacillus rhamnosus GMNL-74 ( alive).
224218029|NCT00541281|DRUG|docetaxel|35mg/m² on day 2 and 9 (21days in a cycle)
224218030|NCT00541281|DRUG|estramustine|140mg caps x3 bid from day 1to 5 and day 8 to 12 of each cycle
224218031|NCT00541281|DRUG|prednisone|2x5 mg a day
223629424|NCT06044675|BEHAVIORAL|Psychotherapy|A manualized treatment for PTSD for dyads wherein one person has symptoms of PTSD. This intervention is 7-week course of psychotherapy that is designed to simultaneously improve PTSD symptoms and relationship functioning through education and skill training.
224218032|NCT02447510|PROCEDURE|group 1 bio-oss bone xenograft|bone substitute (bio-oss)
224218033|NCT02447510|PROCEDURE|group 2 platelet rich in growth factor (autogenous platelet rich in growth factor)|platelet rich in growth factor (autogenous platelet rich in growth factor)
223629425|NCT05701423|DRUG|Natalizumab|Administered as specified in the treatment arm.
224218034|NCT02447510|PROCEDURE|group 3 platelet rich fibrin (autogenous platelet rich fibrin)|platelet rich fibrin (autogenous platelet rich fibrin)
224218035|NCT01857791|BEHAVIORAL|multidisciplinary, behavior modification|
224218036|NCT00435695|DRUG|GSK163090|
224218037|NCT02579330|DEVICE|Coloshield|Coloshield is designed to occlude the rectum during surgery thus enabling the possibility for rectal washout and maintaining a clear operating field. The rod-shaped Instrument contains two silicon balloons which are inflated by means of a catheter. Several holes at the section in between the two balloons are connected to another catheter, which enable negative pressure to be established. By insufflation of the two balloons and establishment of a negative pressure between the balloons by means of connection to a closed drainage bottle the colon is occluded for the duration of surgery.
224218038|NCT02579330|OTHER|Control|In the control group no device is introduced but a rectal washout with 500ml of Saline solution in performed.
224218039|NCT01156571|DRUG|cangrelor P2Y12 (platelet) inhibitor|
224218040|NCT01156571|DRUG|Clopidogrel - 300 or 600 mg (study arm)|Over encapsulated tablets.
224218041|NCT01156571|DRUG|Clopidogrel 600 mg post cangrelor|over-encapsulated clopidogrel (600 mg)
224218042|NCT03192059|DRUG|Pembrolizumab|Efficacy of the combined treatment
224218043|NCT03192059|RADIATION|Radiation|Efficacy of the combined treatment
224218044|NCT03192059|DRUG|Vitamin D|Efficacy of the combined treatment
224218045|NCT03192059|DRUG|Aspirin|Efficacy of the combined treatment
224218046|NCT03192059|DRUG|Lansoprazole|Efficacy of the combined treatment
224218047|NCT03192059|DRUG|Cyclophosphamide|Efficacy of the combined treatment
224218048|NCT03192059|DIETARY_SUPPLEMENT|Curcumin|Efficacy of the combined treatment
223629426|NCT05279196|OTHER|Quadriceps microbiopsy and blood collection|"Microbiopsy of the quadriceps muscle using a needle, Tru-cut biopsy, associated with a blood sampling at the start and after 6 months of a muscle strengthening training program"
223629427|NCT06523569|OTHER|Digital Blood Pressure Monitoring System|As a part of the bundled digital health intervention, the participant will receive instructions on how to follow a link in their electronic patient portal that will allow direct input of home blood pressure readings for clinical review.
223629428|NCT06523569|OTHER|Mobile health application|As a part of the bundled digital health intervention, the participant will be given a lifestyle change mobile health application.
223629429|NCT04262388|BIOLOGICAL|Durvalumab|Durvalumab is a human immunoglobulin G (IgG)1 kappa monoclonal antibody directed against human PD-L1. Durvalumab selectively binds human PD-L1 with high affinity and blocks its ability to bind to PD-1 and cluster of differentiation (CD)80. The fragment crystallizable (Fc) domain of durvalumab contains a triple mutation in the constant domain of the IgG1 heavy chain that reduces binding to the complement component C1q and the Fc gamma receptors responsible for mediating antibody dependent cell mediated cytotoxicity.
223629430|NCT04262388|BIOLOGICAL|Oleclumab|Oleclumab is a human immunoglobulin G1 lambda monoclonal antibody (mAb) with a triple mutation in the heavy chain constant region for reduced effector function. Oleclumab selectively binds to cluster of differentiation 73 (ecto-5'-nucleotidase) (CD73) and inhibits CD73-associated ectonucleotidase activity, thereby inhibiting the CD73-mediated production of immunosuppressive adenosine. Extracellular adenosine contributes to the immunosuppressive effects of both regulatory T cells and myeloid derived suppressor cells, among others. This, in turn, leads to increased antitumor immunity.
223629431|NCT05313984|DEVICE|Sacral neuromodulation|"Sacral neuromodulation: the 2-staged tined lead procedure. (Interstim II therapy, Medtronic).~Stage I: Placement of a tined-lead electrode. 2 - 4 weeks test phase. Stage II: Placement of an implantable pulse generator."
223629432|NCT03406884|BIOLOGICAL|c-kit+ cells|The autologous c-kit+ cells will be harvested from participant's right atrial tissue obtained from participant's SOC Norwood Operation. The harvested c-kit+ cells containing up to a total of 12,500 cells/kg will be delivered through 6-10 intramyocardial injections of approximately 100uL per injection for a total volume of approximately 0.6 mL.
223629433|NCT05539027|DRUG|Branched-chain amino acids (BCAA), enriched solution (Aminoleban) and L-ornithine L-aspartate (LOLA)|patients will receive branched-chain amino acids (BCAA), enriched solution (Aminoleban) and L-ornithine L-aspartate (LOLA)
223629434|NCT05539027|DRUG|Branched-chain amino acids (BCAA), enriched solution (Aminoleban)|patients will receive BCAA enriched solution (Aminoleban)
223629435|NCT05189743|PROCEDURE|Skin transplantation to heal burn injuries|"The study compare two different treatment modalities, STSG (split-thickness skin graft) versus dermis graft after excision of devitalized/necrotic tissue.~A dermatome will be used for graft harvest."
223629436|NCT01766453|BEHAVIORAL|Standard Exercise|Aerobic exercise with a progressive increase in intensity over 12 weeks.
224218049|NCT00063128|DRUG|insulin|"* Administer subcutaneous regular human insulin 30 to 60 minutes before meals, or administer insulin lispro within 15 minutes before meals.~* Inject into abdomen only."
224218050|NCT00063128|DRUG|human insulin inhalation powder (HIIP)|"* Administer HIIP within 15 minutes before meals.~* Administer doses in one-capsule increments equivalent to approximately 2 IU or 6 IU of subcutaneous insulin.~* Target treatment goals during the treatment sequence are the same as for patients using preprandial injectable insulin"
224218051|NCT06118671|BEHAVIORAL|personalized lifestyle intervention by AI|The experimental group completed the basic information, diet structure, use of dietary supplements, living habits, and exercise according to the AI scale (AI scale can be entered through we-chat mini program search), and provided personalized lifestyle intervention plan according to the survey result.
224218052|NCT00962182|DRUG|STAN1|3-4 capsules/day at meals
224218053|NCT00962182|DRUG|Placebo enzyme|3-4 capsules/day at meals
224218054|NCT00962182|DRUG|STAN1+gluten|3-4 capsules/day at meals plus 500 mg gluten b.i.d
224218055|NCT00528879|DRUG|Dapagliflozin|Tablets administered orally as a 2.5-, 5-, or 10-mg dose once daily for up to 102 weeks
224218056|NCT00528879|DRUG|Placebo|Dapagliflozin-matching placebo administered as tablets orally once daily for up to 102 weeks
223629437|NCT01766453|BEHAVIORAL|Bhangra dance exercise|Bhangra Dance classes taught by an instructor.
223629438|NCT04886154|COMBINATION_PRODUCT|MenABCWY-2Gen low dose vaccine|MenABCWY-2Gen low dose vaccine is administered intramuscularly as 2 doses to participants in the ABCWY low dose Group in study Phase I, ABCWY low dose\_06 Group and ABCWY low dose\_02 Group in study Phase II (Formulation and Schedule-finding) and as 2 doses to participants in the ABCWY low dose\_01 Group, ABCWY low doseS\_02 Group and ABCWY low doseS\_06 Group in study Phase II (Sourcing).
224218057|NCT00528879|DRUG|Metformin|Open-label metformin administered as ≥1500 mg per day for up to 102 weeks
224218058|NCT05347030|OTHER|Acupuncture|During the 12-week treatment, acupuncture will be administrated 3 times a week (once every other day) in the first 6 weeks, and twice a week in the last 6 weeks (with an interval of 2-3 days). Each treatment session will last 30 minutes.
224218059|NCT05347030|OTHER|Sham Acupuncture|During the 12-week treatment, Sham Acupuncture will be administrated 3 times a week (once every other day) in the first 6 weeks, and twice a week in the last 6 weeks (with an interval of 2-3 days). Each treatment session will last 30 minutes.
224218060|NCT04133519|DEVICE|Arm 1 - Active behavioral Treatment Arm (Regulora; Gut-Directed Hypnotherapy Software as a Medical Device - SaMD)|The active treatment consists of 7 unique video/audio recordings administered via a mobile application every other week for 12 weeks (SaMD). Since subjects in both the active and comparator treatment arms receive a behavioral treatment, the subjects are blinded to active treatment.
224218061|NCT04133519|DEVICE|Arm 2 - Active Comparator behavioral treatment arm (MR-1; Muscle Relaxation, Software as a Medical Device - SaMD)|The comparator treatment consists of an identical treatment platform, scheduling platform, and reminder platform as the Active Treatment Arm, but in place of Gut-Directed Hypnotherapy there is a comparator relaxation treatment administered on an identical schedule: 7 unique video/audio recordings administered via a mobile application every other week for 12 weeks.
224218062|NCT00307619|DRUG|topiramate|
224218063|NCT05602935|DRUG|Camrelizumab|200mg, intravenously, d1
224218064|NCT05602935|DRUG|SOX|SOX (S-1: 40\~60mg, orally twice daily on days 1 to 14, oxaliplatin 130mg/m2 intravenously on day 1, 21 days per cycle)
224218065|NCT05602935|PROCEDURE|Surgery|Surgery
224218066|NCT04656093|BEHAVIORAL|Supportive counseling|"Participants in the control arm will receive 3 placebo sessions to control for the potentially confounding effect of personalized attention from the care coach on the relationship between the intervention and outcomes. The interventionist will review a patient education booklet for COPD self-management over the 3 sessions and address any question raised by the study subject."
224218067|NCT04656093|BEHAVIORAL|Education on SMB|Goal is to educate patient on SMB based on responses during 15-month interview and screener call, and assess patient's motivation for change.
224218068|NCT04656093|BEHAVIORAL|Psychoeducation on ATs for maladaptive beliefs (if applicable)|Goal is to educate patient on relationship between thoughts and SMB, and identify maladaptive beliefs, automatic thoughts, and cognitive distortions.
224218069|NCT04656093|BEHAVIORAL|Psychoeducation on emotional response (if applicable)|Goal is to educate patient on relationship between emotions and COPD + SMB, identify
224218070|NCT00916422|BIOLOGICAL|Allergen extract (Phleum pratense)|Subcutaneous immunotherapy with modified extract of Phleum pratense. A subcutaneous monthly treatment.
224218071|NCT00916422|BIOLOGICAL|Placebo|Subcutaneous monthly treatment
224218072|NCT04364724|OTHER|CT-based finite element analysis|"CTFEA is a computerized analysis of CT-scans which simulates stress testing of finite element models of various bones (in this study - femurs and vertebrae).~No intervention is planned - the study is observational. CT scans are performed for follow-up as an accepted standard of care. Secondary use of CT scans for CTFEA is in addition to the standard of care.~In a case when CTFEA analysis detects a high risk of pathologic fracture, the treating hematologist will be informed and will refer the patient for evaluation at the National Unit of Orthopedic Oncology."
223629439|NCT04886154|COMBINATION_PRODUCT|MenABCWY-2Gen high dose vaccine|MenABCWY-2Gen high dose vaccine is administered intramuscularly 2 doses to participants in the ABCWY high dose Group in study Phase I, ABCWY high dose\_06 Group and ABCWY high dose\_02 Group in study Phase II (Formulation and Schedule-finding) and as 2 doses to participants in the ABCWY high dose\_01 Group, ABCWY high doseS\_02 Group and ABCWY high doseS\_06 Group in study Phase II (Sourcing).
223629440|NCT04886154|COMBINATION_PRODUCT|Placebo|Placebo is administered intramuscularly as 2 doses to participants in the Placebo low dose Group, Placebo high dose Group in study Phase I and as 1 dose to participants in the ABCWY low dose\_06 Group, ABCWY low dose\_02 Group, ABCWY high dose\_06 Group, ABCWY high dose\_02 Group in study Phase II (Formulation and Schedule-finding).
223629441|NCT04886154|COMBINATION_PRODUCT|MenB vaccine|MenB vaccine is administered intramuscularly as 2 doses in a 0,6-months schedule to participants in the Control Group in study Phase II (Formulation and Schedule-finding).
223629442|NCT04886154|BIOLOGICAL|MenACWY vaccine|MenACWY vaccine is administered intramuscularly as 1 dose to participants in the Control Group in study Phase II (Formulation and Schedule-finding).
223629443|NCT04482660|PROCEDURE|Positron emission tomography with 18F-RO6958948|tau PET ()
223629444|NCT05305443|BEHAVIORAL|Navigation Services|Navigation services include assessment and support with service referrals. Each participant will meet with a peer navigator in person or on Zoom Conferencing for 30 minutes to go over results from their social and health needs assessment that is retrieved from the baseline assessment. The navigator shares information about COVID-19, answers questions about testing, and makes referrals to other needed services
223629445|NCT05305443|BEHAVIORAL|Brief Counseling|Brief Counseling is a 15-minute post-COVID-19 test session delivered by a trained licensed clinician in person or via Zoom Conferencing. In the session, the clinician shares the test results and offers recommendations and information about COVID-19 treatment and prevention.
223629446|NCT05305443|BEHAVIORAL|Critical Dialogue|Critical Dialogue includes three one-hour-long, open-group-sessions facilitated in person or online by a trained licensed facilitator. Group critical dialogue is prompted by thematic images developed by the NCCB to foster a deeper understanding of how systematic stigma, feelings of rage as victims of discrimination, and/or apathy may impact participants' beliefs and behaviors related to COVID-19 and empower participants to make critical choices to protect their health and the health of their communities.
223764091|NCT03629015|BIOLOGICAL|Stemchymal®|ALF/ ACLF patients will receive Stemchymal® through intravenous infusion
223764092|NCT00458484|RADIATION|stereotactic radiosurgery|"Series I: Radiation will be delivered in 4 fractions.~Series II: Radiation will be delivered in 3 fractions."
223764093|NCT00458484|PROCEDURE|Renal Biopsy|At 6 months,an optional percutaneous renal biopsy will be obtained of the targeted tumor, under ultrasound (US) or CT guidance.
223764094|NCT00458484|PROCEDURE|Serum Blood Markers|ELISA blood testing just prior to and immediately following each daily radiation therapy session. Approximately 5cc of blood will be collected within 2 hours prior to and following completion of fractionated radiation therapy to assess the levels of MIF (both MIF-1 and MIF-2) and VEGF.
223764095|NCT06368544|OTHER|lower-body positive-pressure|By increasing the chamber in the lower body around Pressure acts as a counterweight to gravity
223764096|NCT05059600|DRUG|ZULRESSO®|Intravenous infusion of ZULRESSO®.
223764097|NCT05954325|PROCEDURE|Immunoadsorption vs. sham immunoadsorption|5 treatments within 14 days
224218073|NCT03473834|OTHER|Modified exercise programme|The exercise will be modified from the standardized exercise program (Schenkman, 1998) includes a series of exercises based on the concept that muscle length and coordination.
224218074|NCT03473834|BEHAVIORAL|Medication|The control group will be received the normal medication from their doctor.
224317601|NCT03527953|OTHER|Tetric EvoCeram Bulkfill|The preparation will be etched with 37% phosphoric acid. It will be then rinsed with an air-water spray and dried, leaving the dentin slightly moist. An etch-and-rinse adhesive, ExciTE F, will be applied and agitated on the prepared surfaces for at least 10 seconds. The adhesive will be air-thinned and light-cured for 20 seconds with an LED curing unit. The sectional matrix will be placed and fixed with wooden wedges. Then the bulk-fill resin composite, TBF, will be placed in bulk in about 4-mm thickness and then will be cured for 20 seconds.
224218075|NCT05548218|OTHER|Automated health education using a digital health pathway|MyChart Care Companion is an interactive, individualized plan of care delivered to at-risk patients through user-friendly, accessible technology. Care Companion is a digital health pathway housed within EPIC. Care Companion features are integrated into the existing MyChart mobile app, which is part of Epic, and is available for iOS and Android devices. The interactive plan of care delivers notifications to patients' phones, prompts patients to complete educational session in the mobile app, analyzes questionnaire responses and patient-reported data, and orchestrates changes to the plan and escalations as needed to help patients, their caregivers, and care managers stay on top of the patient care. In addition to mobile phone, patients can also now access MyChart Care Companion on webpages via computers. The automated pathway assigns patient interactive health education materials during the study.
224218076|NCT02908828|DIETARY_SUPPLEMENT|Calanus oil|
224218077|NCT02908828|DIETARY_SUPPLEMENT|placebo dietary oil|
224218078|NCT04494178|DEVICE|2.0g G-PUR®|Oral administration (Intervention period I)
224218079|NCT04494178|DEVICE|2.0g G-PUR®|Oral administration (Intervention period II)
224218080|NCT04494178|OTHER|Placebo|Intervention period I
224218081|NCT04494178|OTHER|Placebo|Intervention period II
224218082|NCT02217345|DRUG|Growth hormone|growth hormone, Genotropin (Pfizer)
224218083|NCT02217345|DRUG|Placebo|placebo with identical drug pen delivery device and packaging as Genotropin (Pfizer)
224218084|NCT04846218|DRUG|hCG|
224218085|NCT04846218|DRUG|Progesterone|
224218086|NCT04846218|DRUG|Triptorelin|
224218087|NCT04455074|OTHER|FN scale auto-questionnaire|Patients will be asked to fill in the NF scale questionnaire together with other tests and rating scales, during a routine L-Dopa test, in 2 conditions: OFF-med and ON-med.
224218088|NCT03196791|DRUG|Sugammadex Sodium|"1. INDICATIONS AND USAGE BRIDION® is indicated for the reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide in adults undergoing surgery. BRIDION (sugammadex) injection is a sterile, clear, colorless to slightly yellow-brown, non-pyrogenic aqueous solution intended for intravenous infusion.~2. DOSAGE AND ADMINISTRATION BRIDION (sugammadex) injection, for intravenous use, should be administered by trained healthcare providers familiar with the use, actions, characteristics, and complications of neuromuscular blocking agents (NMBA) and neuromuscular block reversal agents."
224218089|NCT04607642|DRUG|BMX-001|BMX-001 consists of a porphyrin ring with pyridyl groups attached at each of the four methane bridge carbons. The nitrogen in the pyridyl ring is at the 2 position and has a side chain consisting of six carbons with an ether linkage. A manganese atom is chelated into the porphyrin ring and is the active center of the molecule. This molecule is an enzymatic scavenger of free radical species operating at close to diffusion-limited rates.
224218090|NCT04607642|RADIATION|Radiation Therapy|Treatment plan should include a continuous course of treatment delivered as single daily fractions of 2.0 to 2.1 Gy with a cumulative radiation dose between 60 Gy and 70 Gy. Planned radiation treatment volumes must include at least two oral mucosal sub-sites (buccal mucosa, retromolar trigone, floor of mouth, tongue, soft palate, hard palate) with a portion of each site receiving at least 50 Gy.
224218091|NCT04607642|DRUG|Cisplatin|Cisplatin is an IV chemotherapeutic agent approved to treat head and neck cancers. Cisplatin will be administered per institution's standard of care practice. Common standard of care practice includes dosing cisplatin at 100mg/m2 IV q21 days starting on Day 1 of RT for 2-3 doses or dosing cisplatin at 40 mg/m2 IV each week of RT for 6-7 total doses. Cisplatin will be infused per institutional guidelines.
224317602|NCT03527953|OTHER|Surefil SDR Flowable bulkfill|The preparation will be etched. A two-step etch-and-rinse adhesive, Prime\&Bond NT will be applied to all enamel/dentin surfaces, air-dried for 5 seconds, and will be light cured for 10 seconds. After the sectional matrix will be placed, the flowable bulk-fill resin composite, SureFil SDR™ flow (Dentsply Caulk, Milford, DE, USA), will be placed in a 4-mm bulk increment in the dentinal part cured for 20 seconds and will be followed by a covering layer of the nanohybrid resin composite, Ceram.X Mono that will be cured for 20 seconds.
224317603|NCT03527953|OTHER|everX fiber-reinforced resin|The enamel will be etched with 37% phosphoric acid for 10 seconds, then will be rinsed, and dried with an air/water syringe for at least 5 seconds. Self-etch adhesive, G-aenial Bond (GC Co., Tokyo, Japan), will be applied to all enamel/dentin surfaces and gently air thinned and then will be light cured for 10 seconds. After the matrix will be placed and wedged, mesial or distal walls will be built with 1-2-mm layers of G-aenial Posterior resin composite. The fiber-reinforced composite, everX Posterior, will be placed into the cavity in approximately 4-mm thickness. The last 2 mm of the cavity will be restored using the G-aenial Posterior composite as an overlay layer. Each increment will be light cured for 20 seconds using an LED unit.
223629447|NCT05305443|BEHAVIORAL|Referral and Digital Brochure|Referral will consist of a five-minute phone call where an outreach worker offers participants information about COVID-19 testing and encourages them to get tested within one week. A digital brochure containing IL recommendations is e-mailed or texted to participants.
223629448|NCT03676842|COMBINATION_PRODUCT|FLEX Dynamic Scoring Catheter with IN.PACT Admiral DCB|Treatment by the FLEX Scoring Catheter followed by an IN.PACT Admiral DCB
223629449|NCT05961722|OTHER|preoperative IV 0.9% saline 400 ml|Group 1 will be infused with IV 0.9% saline 400 mL.
223629450|NCT05961722|OTHER|preoperative dextrose 5% 400 ml|Group 2 will be infused with dextrose 5% Dekstroz 400 ml.
224218092|NCT04607642|OTHER|Placebo|The placebo to be used in this study is 0.9% Sodium Chloride Injection, USP.
224218093|NCT03786289|BIOLOGICAL|Recombinant human serum albumin/erythropoietin fusion protein|Recombinant human serum protein/erythropoietin fusion protein 150μg-1200μg single subcutaneous injection at Day1
224218094|NCT03786289|BIOLOGICAL|Recombinant erythropoietin injection (CHO cells)|Recombinant erythropoietin injection (CHO cells) 10000IU single subcutaneous injection at Day1
224218095|NCT02803723|PROCEDURE|Holding-cuddling|"The Holding-cuddling is started 5 minutes before veinipuncture."
224218096|NCT02803723|PROCEDURE|Sucrose|The sucrose adminstration is started 2 minutes before veinipuncture.
224317604|NCT00593905|DRUG|Sitaxsentan|Sitaxsentan sodium 100 mg tablet every morning
224317605|NCT00593905|DRUG|Bosentan, Ambrisentan|Bosentan 125 mg tablet twice daily Ambrisentan 5-10 mg tablet once daily
224218097|NCT03910803|DRUG|Brodalumab|"Brodalumab is a human monoclonal IgG2κ antibody directed against human interleukin-17 receptor A (IL-17RA). It is expressed in a Chinese Hamster Ovary (CHO) cell line. Brodalumab is comprised of 1312 amino acids and has an estimated molecular mass of 144,000 Daltons.~Brodalumab Injection is a sterile, preservative-free, yellow solution, delivered via subcutaneous injection. . Each Brodalumab single dose prefilled syringe delivers 1.5 mL of solution containing 210 mg of brodalumab formulated in glutamate (6.5 mg), polysorbate 20 (0.15 mg), proline (36 mg), and Water for Injection, USP at pH 4.8."
224218098|NCT05484375|DRUG|Capecitabine plus toripalimab|Capecitabine tablet: 650mg/m2, orally, twice a day, d1-d21, every 3 weeks Toripalimab: 240mg, intravenous drip, d1, every 3 weeks
224218099|NCT03754816|PROCEDURE|PECS II and parasternal block|10 ml of Levobupivacaine 0.375% injected between minor and major pectoralis muscles. 20 ml of Levobupivacaine 0.375% injected between minor and serratus muscles. 10 ml of Levobupivacaine 0.375% injected between major and intercostal muscles at II and IV intercostal space.
224218100|NCT03754816|DRUG|Levobupivacaine|Levobupivacaine
224218101|NCT00602550|DRUG|Zidovudine|
224218102|NCT04274088|PROCEDURE|Cataract surgery|Phacoemulsification surgery
224218103|NCT05841966|DIAGNOSTIC_TEST|Transoral Ultrasound|The tonsils and tongue base will be scanned transorally using high-frequency intraoperative ultrasound transducers. Direct contact with the tonsils through the mouth is achieved during general anesthesia.
224218104|NCT01094509|BEHAVIORAL|Tai Chi|Tai Chi classes and exercises
224218105|NCT01094509|BEHAVIORAL|Guided autobiography|Autobiographical writing in class and at home
224218106|NCT01094509|BEHAVIORAL|Qigong|Qigong classes and exercises (exploratory)
224218107|NCT01094509|BEHAVIORAL|Successful aging|Seminar series on the theme of successful aging
224218108|NCT01094509|BEHAVIORAL|Combination|Combination of Tai Chi exercises and autobiographical writing
224218109|NCT01094509|BEHAVIORAL|Comparison|No assigned behavioral activity (exploratory)
224218110|NCT00575328|DRUG|Maca Root|3g/day of Maca Root for 12 weeks.
224218111|NCT00575328|DRUG|Placebo|Placebo provided by research pharmacy daily for 12 weeks.
224218112|NCT06134973|DIAGNOSTIC_TEST|ultrasonic testing|ultrasonic testing
224218113|NCT01428726|DRUG|NT-KO-003|NT-KO-003 is a coated tablet, administered once a day
224218114|NCT04427514|DEVICE|Telemedicine software for data transmission and analysis in CAPD.|Telemedicine software is related to peritoneal dialysis. With the help of a tablet device running an Android system on patients and the care team and the smart devices attached to it (scales, blood pressure monitor), patients perform measurements in their homes in connection with solution changes. The resulting data is transmitted through the telemedicine system to the care team, which can take immediate intervention if necessary and notify the patient of any change in therapy.
224218115|NCT03301428|OTHER|Retrain pain educational website|Patients in this group will be invited to consult an educational website developped for patients with chronic pain
224218116|NCT03301428|OTHER|Booklet|Patients in this group will be invited toread an educational booklet developped for patients with chronic pain
224218117|NCT02680977|OTHER|MP-Equivalent|Mucuna pruriens powder at equivalent dosage than LD+DDCI. The dose of MP is calculated to obtain a 5-fold Levodopa dose than LD+DDCI.
224218118|NCT02680977|OTHER|MP-Low|Mucuna pruriens powder at low dosage. The dose of MP is calculated to obtain a 3.5-fold Levodopa content than LD+DDCI
223629451|NCT05961722|OTHER|preoperative and intraoperative dextrose 5% 400 ml|Group 3 will be infused with dextrose preoperative 200 ml and intraoperative 200 ml 5% dextrose infusion.
224218119|NCT02680977|OTHER|MP+DDCI|Mucuna pruriens powder plus Benserazide. The dosage of MP is calculated to obtain the same Levodopa content than LD+DDCI. Benserazide is given as 1:4 ratio with Levodopa.
224218120|NCT02680977|DRUG|LD+DDCI|Levodopa plus Benserazide
224218121|NCT02680977|DRUG|LD-DDCI|Levodopa without any DDCI
224218122|NCT02680977|OTHER|Placebo|Groundnuts powder
224218123|NCT04080882|BIOLOGICAL|AbobotulinumtoxinA dose 1|Treatment of platysmal bands
224218124|NCT04080882|OTHER|Placebo|Treatment of platysmal bands
224218125|NCT04080882|BIOLOGICAL|AbobotulinumtoxinA dose 2|Treatment of platysmal bands
224218126|NCT04080882|BIOLOGICAL|AbobotulinumtoxinA dose 3|Treatment of platysmal bands
224218127|NCT02163811|BEHAVIORAL|VETPALS|"VETPALS is an adaption of an empirically supported self-management program, PALS (Promoting Amputee Life Skills). The PALS program demonstrated improved physical and psychosocial functioning when delivered in community-based support groups for amputees, but this program has not been adapted for the needs of Veterans and implemented in the VA healthcare system.~VETPALS is a five session course for people with life changes after amputation. The five sessions are held weekly, and are facilitated by a VA clinician in conjunction with a peer facilitator (Veteran with limb loss). Veterans receive all usual care."
223629452|NCT05655299|DRUG|VTX958 Dose A|Dose A
223629453|NCT05655299|DRUG|VTX958 Dose B|Dose B
223629454|NCT05655299|DRUG|VTX958 Dose C|Dose C
223629455|NCT05655299|DRUG|VTX958 Dose D|Dose D
223629456|NCT05655299|DRUG|Placebo|Placebo
224218128|NCT02163811|BEHAVIORAL|Individual Education Support Program|VETPALS facilitator provide post-amputation education materials from the Amputee Coalition, including First Step - A Guide for Adapting to Limb Loss and Side Step - A Guide to Preventing and Managing Diabetes and Its Complications. Veterans receive all usual care.
224218129|NCT02522949|DEVICE|ColdZyme® mouth spray|
224218130|NCT02522949|DEVICE|Placebo|
224218131|NCT05031962|DEVICE|CELLIS Breast (Porcine Acellular Dermal Matrix, PADM)|Biological membrane used in breast reconstruction
224218132|NCT06079853|BEHAVIORAL|PureSomni Sleep Health Product Kit|PureSomni sleep health products offered: blue light blocking glasses, eye mask, nasal strips, white noise machine, lavender spray, herbal tea, ear plugs
223629457|NCT04386317|DRUG|Terazosin|Fifteen patients with defined pre-motor PD risk and abnormal baseline 123I-MIBG uptake, with or without 123I-Ioflupane uptake abnormality or PD motor symptoms, will be recruited to receive daily oral doses of terazosin 5 mg or 10 mg. The dosage of terazosin will be gradually increased from the initial recommended starting dose of 1 mg daily at bedtime and titrated stepwise to 2mg, 5mg or 10 mg weekly, according to patient tolerability, as measured by subjective complaints, arterial blood pressure and heart rate. The target dose will be 5 mg or 10 mg daily based on subject's tolerability. Development of incompatibility will be addressed by individually adjusting the dose of terazosin.
223629458|NCT02977403|BEHAVIORAL|Attention Bias Retraining|Attention retraining program on smartphone where the probe always replaces the neutral picture. There is a perfect correlation between picture type and probe location.
223629459|NCT02977403|BEHAVIORAL|Sham Comparator: AB Control|"Sham Comparator training where the probe randomly replaces the neutral or food pictures. There is no correlation between picture type and probe location"
223629460|NCT05036564|PROCEDURE|Lumbar puncture|"A lumbar puncture (spinal tap) is performed in patient lower back, in the lumbar region.~During a lumbar puncture, a needle is inserted between two lumbar bones (vertebrae) to remove a sample of cerebrospinal fluid (CSF). This is the fluid that surrounds brain and spinal cord to protect them from injury.~This procedure is usually performed at the time of diagnosis for disease staging and/or repeated in the course of the disease history, only if positive or for clinical reasons (i.e. suspicious of relapse progression).~In this study sequential CSF and peripheral blood samples of study population will be collected also at different time points, with the aim to improve diagnostics sensitivity, response assessment and monitoring early CNS relapse."
223629461|NCT02891447|DRUG|Cisplatin|Given intraperitoneally
223629462|NCT02891447|DRUG|Hyperthermic Intraperitoneal Chemotherapy|Undergo HIPEC
223629463|NCT02891447|DRUG|Mitomycin|Given intraperitoneally
224218133|NCT04257240|PROCEDURE|selective hepatic vascular exclusion|major hepatectomy with vascular control of blood inflow and outflow of the whole liver
224218134|NCT04257240|PROCEDURE|semielective hepatic vascular exclusion|major liver resection by selectively clamping the portal and hepatic vessels only of the lobe harboring the tumor
224218135|NCT05958810|DRUG|Artemether-lumefantrine|"Artemether-lumefantrine will be administered for 3 days according to body weight (Days 0 and 8 hours after, 1 and 2). Dosage depending on body weight or age if weight cannot be determined.~Dosage: 1 tablet contains 20 mg artemether and 120 mg lumefantrine Dosage per weight: 1 tablet (5 to \<16kg); 2 tablets (15 to \<25kg); 3 tablets (25 to \<35kg), 4 tablets for \>35 kg) Dosage per age, if weight cannot be determined: 1 tablet (6 months old to 3 years old); 2 tablets (4 to 8 years old); 3 tablets (9-13 years old), 4 tablets (\>13 years old)"
224218136|NCT05958810|DRUG|Primaquine|For Pf patients, primaquine at 0.75 mg base/kg body weight single dose will be given on Day 3 for Pf patients; For Pv patients primaquine will be withheld for 28 days and will be given after Day 28 follow-up, at 0.25 mg base/kg per day for 14 days.
224218137|NCT01392859|DRUG|Levocetirizine 0.5 Mg/mL Oral Solution|Subjects in two arms, will be enrolled in a classical, randomized, double blind, crossover, placebo controlled trial of Levocetirizine(LCT) with determination of the PD response to LCT as determined by suppression of histamine microvasculature response via HILD.
224218138|NCT02191579|BIOLOGICAL|onabotulinumtoxinA|155U onabotulinumtoxinA (BOTOX®) total dose per treatment by intramuscular injection every 12 weeks.
224218139|NCT02191579|DRUG|Topiramate|Topiramate up to a maximum oral dose of 100 mg/day.
224218140|NCT04407195|OTHER|Exposure to the SARS-CoV-2|This is an observational design. Participants are exposed to the Covid-19 pandemic.
224218141|NCT04403191|DRUG|Ondansetron|ondansetron 4 mg intravenous immediately once reached to I.C.U and another same dose after 6 hours while patients of group
224218142|NCT04403191|DRUG|isopropyl alcohol 70% inhalation|inhalation every 15 min for 4 times then repeated after 6 hours
224218143|NCT04403191|PROCEDURE|laparoscopic appendectomy|all patients received post operatively after laparoscopic appenectomy
224218144|NCT02681107|RADIATION|APBI 27Gy in 5 fractions|Patients will be treated with 3-D conformal, external beam, partial breast RT to deliver 27 Gy in 5 daily fractions using 3-5 beams on a linear accelerator. The target PTV will be the CT-visible seroma plus a 1cm margin to form the CTV (minus 5mm from skin and excluding chest wall) and a further 7mm to form the PTV. Real time review will ensure compliance with target and normal tissues dose constraints in this multi-institutional study. Any (or no) systemic therapy is permitted.
224218145|NCT00389649|DEVICE|heart rate setting|
224218146|NCT01399424|DRUG|CP|Immunization
224218147|NCT03932435|DRUG|Fisrt period TWLO_C|"First Period: Single oral administration of 1 tablet of Dong-a Bepotastine Besilate Tab(Bepotastine Besilate 10mg)"
224218148|NCT03932435|DRUG|Fisrt period TWLO|"First Period: Single oral administration of 1 tablet of Twolion Tab(Bepotastine Besilate 10mg)"
224218149|NCT03932435|OTHER|Washout period|7 days
224218150|NCT03932435|DRUG|Second period TWLO_C|"Second Period: Single oral administration of 1 tablet of Dong-a Bepotastine Besilate Tab(Bepotastine Besilate 10mg)"
224218151|NCT03932435|DRUG|Second period TWLO|"Second Period: Single oral administration of 1 tablet of Twolion Tab(Bepotastine Besilate 10mg)"
224218152|NCT06542185|OTHER|online education|online education
224218153|NCT00003669|DRUG|arzoxifene hydrochloride|
223629464|NCT05061238|DEVICE|Vibrating Device|The vibrating device strapped to different parts of your leg. The device will be secured to your leg with a Velcro strap.
223629465|NCT05017415|DEVICE|uroflow measurement|Non-invasive urodynamic measurement wireless uroflowmeter UROCAP™ IV, Goby System Laborie
223629466|NCT05017415|DEVICE|Bladder ultrasound|Ultrasound of post void residual urine bladderscan CUBEscan BioCon 700
223629467|NCT06642454|OTHER|Transcutaneous auricular vagus nerve stimulation|"Stimulation Target: Left cymba conchae.~25 Hz Non-Expiratory Gated taVNS: Stimulation is delivered for 30 seconds at a frequency of 25 Hz, followed by a 30-second interval.~25 Hz Expiratory Gated taVNS: One second of stimulation occurs during exhalation at a frequency of 25 Hz.~100 Hz Expiratory Gated taVNS: One second of stimulation is administered during exhalation at a frequency of 100 Hz."
223764098|NCT05390801|OTHER|Survey|Survey developed by ophthalmologists from the Ophthalmology Department of the Necker-Enfants Malades Hospital, fill out only once by patients with congenital aniridia in order to identify eye and systemic manifestations in congenital aniridia and to determine the patients' knowledge of their own disease.
223629468|NCT04160182|BEHAVIORAL|Energy Conservation Work Simplification Education|"The intervention will last approximately 45 minutes, and will be provided once/week for 6 weeks. The intervention is delivered live using web-cameras (e.g., Microsoft Zoom).~Registered and licensed occupational therapists will deliver the intervention. At beginning of the intervention, the participant and interventionist prioritize the 5 most critical fatigue-related problems that they would like to solve during the intervention. Each week, the interventionist will guide the participant through a workbook to provide knowledge and examples on how to apply the knowledge to everyday fatigue-related problems. The workbook contains: (a) information regarding fatigue in breast cancer survivors, (b) knowledge regarding fatigue management strategies, and (c) worksheets to develop skills to recognize and solve fatigue-related problems. Participants will retain the workbook after study completion."
223629469|NCT04527796|OTHER|Rehabilitation|"During the rehabilitation program a multidisciplinary team, consisting of a pneumologist, dietician, psychologist, social worker and several physiotherapists, coach the cystic fibrosis patients.~The physiotherapists help with autogenic drainage and aerosol therapy (2-3 times/day) and supervise physical activity (5, 1-hour lasting, training sessions/week: swimming 2, Fitness training 2, 1 session of choice). The dietician calculates basal and theoretical energy needs . A carbohydrate-rich snack before exercise, to improve exercise tolerance and a carbohydrate-protein-rich snack afterwards to improve recuperation is provided."
223629470|NCT06491446|DRUG|ABI-2280|"Different strength of ABI 2280 will be administered in different cohorts.~Other: Placebo Matching placebo will be administered."
223629471|NCT01406886|BEHAVIORAL|Eating rate|
223629472|NCT01071057|DRUG|Naloxone|Basal infusion of 20µg/kg/hour, bolus dose of 20µg /kg, lockout of 5 minutes with hourly maximum not to exceed 150µg /kg/hr, maximum 6 bolus doses. Subject pain relief will be assessed and documented by nursing staff and supervised by the Acute Pain Service (APS). Morphine will be titrated to subject need according to APS PCA protocol.
223629473|NCT01071057|DRUG|Saline/Morphine|Basal infusion of 20µg/kg/hour, bolus dose of 20µg /kg, lockout of 5 minutes with hourly maximum not to exceed 150µg /kg/hr, maximum 6 bolus doses. Subject pain relief will be assessed and documented by nursing staff and supervised by the Acute Pain Service (APS). Morphine will be titrated to subject need according to APS PCA protocol.
223629474|NCT00756366|OTHER|Positron Emission Tomography|PET imaging at baseline, 1 week and 6-8 weeks. CPAP begins after baseline PET scan.
223629475|NCT00756366|OTHER|Positron Emission Tomography|PET imaging at Baseline, 1 week and 6-8 weeks. CPAP begins after 6-8 week PET scan.
223629476|NCT00756366|OTHER|Positron Emission Tomography|PET scan at baseline and 6-8 weeks, no CPAP therapy
223629477|NCT05638165|DRUG|NCP112|The first two subjects for sentinel dosing are randomly assigned to either the test drug or placebo in a 1:1 ratio. After safety and tolerability were reviewed for sentinel participants up to 24 hours after dosing, the subsequent 7 subjects are randomized to the remaining treatment allocations, with 5 subjects to the test drug and 2 to the placebo.
223629478|NCT03081026|DIAGNOSTIC_TEST|Bilateral hip to ankle x-ray, exam and strength testing.|Only an X-Ray is performed and reviewed to identify any growth disturbances.
223629479|NCT03267550|DEVICE|SceneRay wireless and remote DBS system|Implement therapeutic programming in patients with network coverage at home
223629480|NCT04190914|OTHER|pulp regeneration for necrotic primary teeth|a pulp regeneration procedure will be applied for necrotic primary teeth with different intracanal medication compared to conventional pulpectomy used in treatment for necrotic primary teeth
223629481|NCT02413307|OTHER|Compassion Focused Therapy (self-practice)|Daily practice of the CFT exercises for a minimum of five minutes per day. This is completed for a period of three weeks.
223629482|NCT03844555|DRUG|Elafibranor|120mg oral single dose
223629483|NCT00879021|DRUG|Lyrica|study participants will start will be on 150mg of Pregabalin or placebo capsules by mouth , twice a day.They will be on drug approx. 49 weeks and followed for another 49 weeks after stopping the medication.
223629484|NCT00879021|DRUG|matching placebo|150 mg by mouth ,twice a day for 49 weeks
223629485|NCT01740713|DRUG|Deferiprone, dose level 1|a solution at 80 mg/mL will be administered orally
223629486|NCT01740713|DRUG|Deferiprone, dose level 2|a solution at 80 mg/mL will be administered orally
223629487|NCT01740713|DRUG|Deferiprone, dose level 3|a solution at 80 mg/mL will be administered orally
223629488|NCT02336282|DEVICE|transcranial Direct Current Stimulation (tDCS)|transcranial Direct Current Stimulation (tDCS) involves modulation of cerebral cortex excitability by the application of weak direct current to the scalp. tDCS is a technique that applies safe, low level direct current through large pads on the scalp to stimulate the underlying brain region, with current level \< 0.10 C/cm2. Direct current is transferred by a pair of saline-soaked sponges from the anode to the cathode.
223629489|NCT02336282|DEVICE|Sham|The sham intervention will be used in both arms with one arm receiving the sham intervention on day 1 and the other receiving the sham intervention on day 2. The sham procedure provides the same small current during ramp up to imitate the intervention, but the current is discontinued after ramp up and no intervention is provided. Direct current is transferred by a pair of saline-soaked sponges from the anode to the cathode.
223629490|NCT02336282|OTHER|Cognitive Assessment|"Three tests will be used to evaluate cognitive function: Dimensional Change Card Sort Test, Flanker Inhibitory Control and Attention Test, and List Sorting Working Memory Test. These measures have a computerized format and are nationally standardized.~The Gray Oral Reading Test measures reading comprehension. Participants are asked to read a set of passages and recall specific details from the stories.~The Woodcock Johnson Understanding Directions measures listening comprehension. Participants listen to a series of complex instructions, then follow the directions by pointing to various objects in a colored picture."
224218154|NCT04389619|DEVICE|Fractional Microneedling Radiofrequency|In every patient, each one of the two scars, or each side of a large scar will be assigned to fractional microneedling radiofrequency. Fractional microneedling radiofrequency parameters; Power: 6 v, Exposure time: 800 ms. Depth: 2.5 mm (using non-insulated micro-needles), Frequency: 2 Hz for 5 treatment sessions 4 weeks apart.
223764099|NCT05189457|DRUG|Luteinizing Hormone Releasing Hormone|During the first strike, LHRH will be administered for 12 to 18 weeks. During the second strike, participants will receive 4 cycles of LHRH
223629491|NCT02336282|OTHER|Brain Games Stimulation|Cognitive exercises using the Lumosity Brain Games program will be used simultaneously with the tDCS intervention. Participants will be asked to engage in training for 20 minutes a day, two days per week over 5 weeks. This program involves cognitive exercises designed to enhance executive function and processing speed.
223629492|NCT05506631|PROCEDURE|Outpatient Foley balloon placement|Cervical ripening with balloon placement in the outpatient setting
223629493|NCT05506631|PROCEDURE|Inpatient Foley Balloon placement|Cervical ripening with balloon placement in the inpatient setting
224218155|NCT04389619|PROCEDURE|Intralesional Steroid Injection with and without Microneedling|In every patient, each one of the two scars, or the other side of a large scar will be assigned to intralesional steroids injection, Triamcinolone acetonide will be injected in concentration 1:2 (20 mg/dl) using insulin syringe. o Scars treated with intralesional steroids will be subgrouped into two groups, one group treated with only intralesional steroids and the other group treated with intralesional steroids and followed by microneedling. Microneedling will be done using the same tip of the fractional microneedling radiofrequency at same depth. Patients will receive 5 treatment sessions 4 weeks apart.
224218156|NCT00203632|DRUG|rosiglitazone/placebo|
223629494|NCT06058442|DRUG|NORTASE®|10-15 capsules of NORTASE® per day - over 6 months
223629495|NCT06058442|DRUG|Placebo|10-15 capsules of placebo per day - over 6 months
223629496|NCT04945083|OTHER|Experimental Nutritional Pudding|High Calorie, High Protein pudding
223629497|NCT02216708|OTHER|Rapid dehydration|
223629498|NCT02216708|OTHER|Slow rehydration|
223629499|NCT02668497|DRUG|Botulinum Toxin Type A|
224218157|NCT04297488|DIETARY_SUPPLEMENT|Bifidobacteria and Lactobacilli triple viable capsules|Bifidobacteria and Lactobacilli triple viable capsules (provided by Shenzhen Wan he Pharmaceutical Co., Ltd., China) are bilayer mini pellets and are resistant to gastric acid. So Bifidobacterium billion Lactobacillus can only be released in intestine. Participants will take 1.27g (contain 3 billion Bifidobacterium and 1 billion Lactobacillus) once daily.
224218158|NCT00821990|DRUG|Chemotherapy|The administration of chemotherapy regimen (docetaxel or irinotecan) will be determined at the discretion of investigator, and depends on the patient's previous chemotherapy.
224218159|NCT00821990|OTHER|Best supportive care|It includes nutritional support, analgesics, antibiotics, antiemetics, transfusions, or any other symptomatic therapy (with the exception of cytotoxic chemotherapy) and/or assistance of a psychological support. Localized radiotherapy to alleviate symptoms such as pain is allowed provided that the total dose delivered is in a palliative range.
223629500|NCT06162988|DRUG|68Ga-NOTA-H006 is injected intravenously with a dose of 1.8 MBq[0.05MCi]/kg.|68Ga-NOTA-H006：PET imaging； 18F-FDG：PET imaging
223629501|NCT03724942|DRUG|Brexpiprazole|Brexpiprazole 1mg or 2mg will be orally once daily for 14 weeks
223629502|NCT00953602|OTHER|Genetically modified potato|Genetically modified potato
223629503|NCT01404039|BEHAVIORAL|Motor Learning|Subject will have to draw a set of shapes and words during 20 minutes.
223629504|NCT01404039|BEHAVIORAL|Somatosensory Learning|Subjects will perform a learning task involving sensory activation of the hand. The task will consist of learning letters of Braille.
223629505|NCT01404039|BEHAVIORAL|Observational Task|Subjects will watch a 10 second video of a right-handed person performing movements of their left index finger. Subjects will be instructed to watch the video without any other specific instruction.
223629506|NCT01404039|BEHAVIORAL|Mental Imagery|Subjects will be asked to perform mental imagery of motor practice - finger movements of the left hand for 10 minutes.
223629507|NCT01404039|DEVICE|transcranial direct current stimulation|Subjects will undergo active and sham tDCS stimulation in a randomized and counterbalanced order. During both active and sham stimulation, we will use electrodes of 35cm\^2, intensity of 2mA for a duration of 20 minutes. The anode electrode will be placed over the right primary motor cortex (M1) and the cathode will be placed over the contralateral supraorbital area. For active stimulation, the current will be on for the duration of 20 minutes. For sham stimulation, the current will ramp up, and then down again for 30 seconds to simulate the sensation of active tDCS.
223629508|NCT06236971|BEHAVIORAL|MRI scanning first at supine position and then turn into lateral position|Magnetic resonance imaging was used to scan the upper airway of sedated subjects, first at supine position and then turn into lateral position.
223629509|NCT06602518|PROCEDURE|Orthodontic Treatment|All the enrolled patients will undergo conventional fixed appliance therapy by bonding straight wire Roth appliance in the maxillary arch. The bonding procedure will be standardized in all patients and performed by the same operator using light-cured composite. Levelling and alignment will then be started using the following wire sequence: 0.014-in nickel titanium (NiTi), 0.018-in NiTi, 17×25-in Niti, and 19×25-in Niti arch wires. The upper arch will then be stabilized using a 19×25-in stainless steel (SS) arch wire for 2 months. This stage will require approximately 6 months of treatment.
223629510|NCT06598098|BEHAVIORAL|Exercise Modes|Moderate intensity aerobic exercise, moderate intensity resistance exercise, moderate intensity combination exercise
223629511|NCT06589284|PROCEDURE|Silk 0-0 suture covered by chlorhexidine gluconate dressing|The specific intervention will be securing radial arterial catheters with either skin adhesive or suture material. Both are largely accepted to be standard of care but to date there is a paucity of literature directly comparing the two for radial arterial lines. During the intervention the placement of radial arterial catheters will be done via standard sterile procedure and using seldinger technique which involves using a guidewire to slide the arterial catheter into the radial artery. After the catheter is placed, it will be secure with either straight suture with a cutting needle or via skin adhesive. Following securement, the area will be cleaned and a Tegaderm dressing with biopatch will be placed over the catheter. Data will be collected immediately after the procedure including length of procedure and complications as well as via chart review to determine the length of time the catheter was in place and evidence of premature failure.
223764100|NCT05189457|DRUG|New Hormonal Agent|During the first strike, if Abiraterone is chosen 1000mg of Abiraterone will be taken orally. If Enzalutamide is used, 160 mg will be taken orally every 24 hours.
224218160|NCT00831922|DRUG|masitinib (AB1010)|3 mg/kg/day
224218161|NCT00831922|DRUG|masitinib (AB1010)|6 mg/kg/day
224218162|NCT03940586|DRUG|Letermovir oral granules|Granules administered orally based on age, weight, and whether participant takes cyclosporin A as a concomitant medication.
223629512|NCT06589284|PROCEDURE|2-octyl cyanoacrylate covered by chlorhexidine gluconate dressing|The specific intervention will be securing radial arterial catheters with either skin adhesive or suture material. Both are largely accepted to be standard of care but to date there is a paucity of literature directly comparing the two for radial arterial lines. During the intervention the placement of radial arterial catheters will be done via standard sterile procedure and using seldinger technique which involves using a guidewire to slide the arterial catheter into the radial artery. After the catheter is placed, it will be secure with either straight suture with a cutting needle or via skin adhesive. Following securement, the area will be cleaned and a Tegaderm dressing with biopatch will be placed over the catheter. Data will be collected immediately after the procedure including length of procedure and complications as well as via chart review to determine the length of time the catheter was in place and evidence of premature failure.
224218163|NCT03940586|DRUG|Letermovir tablet|Tablet administered orally based on age, weight, and whether participant takes cyclosporin A as a concomitant medication.
224218164|NCT03940586|DRUG|Letermovir intravenous|Letermovir administered intravenously based on age, weight, and whether participant takes cyclosporin A as a concomitant medication.
224218165|NCT00964223|DRUG|Clindamycin and benzoyl peroxide gel (Duac® Topical Gel)|Subjects will apply Duac(clindamycin and benzoyl peroxide) gel to one-half of their face and and apply Epiduo (benzoyl peroxide/adapalene) gel on the other side of their face once a day for the first 2 weeks. Starting at week 2, subjects will apply Duac (benzoyl peroxide/clindamycin gel) to the entire face for an additional 6 weeks.
224218166|NCT00964223|DRUG|benzoyl peroxide and adapalene gel (EPIDUO™ Gel)|Subjects will apply Duac(clindamycin and benzoyl peroxide) gel to one-half of their face and and apply Epiduo (benzoyl peroxide/adapalene) gel on the other side of their face once a day for the first 2 weeks. Starting at week 2, subjects will apply Duac (benzoyl peroxide/clindamycin gel) to the entire face for an additional 6 weeks.
224218167|NCT01892423|OTHER|Cetaphil Moisturizing Lotion Daily Advance|
224218168|NCT06371716|PROCEDURE|ex-vivo RFA under US control at 10 Watts (W) of power in 3 differents arms of lesions|5 PDAC with neoadjuvant chemotherapy treated at 10 W with ex-vivo RFA 5 PDAC without previous neoadjuvant chemotherapy treated at 10 W with ex-vivo RFA 5 NET treated at 10 W with ex-vivo RFA
224218169|NCT06371716|PROCEDURE|ex-vivo RFA under US control at 30 Watts (W) of power in 3 differents arms of lesions|5 PDAC with neoadjuvant chemotherapy 5 PDAC without previous neoadjuvant chemotherapy 5 NETs
224218170|NCT06371716|PROCEDURE|ex-vivo RFA under US control at 50 Watts (W) of power in 3 differents arms of lesions|5 PDAC with neoadjuvant chemotherapy 5 PDAC without previous neoadjuvant chemotherapy 5 NETs
224218171|NCT04091685|DEVICE|Gamma camera imaging|Use gamma camera in detection of renal cortical defects
224218172|NCT03213561|DEVICE|Stable and Independent Brain-computer Interfaces for Communication|"The participants will perform an MRI head scan, which the investigators will use to construct 3D head models of participants. The investigators will use these modele to reconstruct the activity of brain sources from EEG signals. The participants will then take part in a series of EEG recording sessions. During the initial calibration sessions, the participants will react with real or attempted movements to visual cues. The investigators will use the EEG signals from these sessions to calibrate the text-entry interface used in the validation sessions that follow. During the validation sessions, the participants will control the text-entry interface to write messages using their EEG signals."
224218173|NCT03077828|DRUG|Carboplatin|Given IV
224218174|NCT03077828|DRUG|Etoposide|Given IV
224218175|NCT03077828|DRUG|Ifosfamide|Given IV
224218176|NCT03077828|OTHER|Laboratory Biomarker Analysis|Correlative studies
223629513|NCT06230627|OTHER|Home-Based Rehabilitation rogram|The intervention is distinguished from others in that it applies to patients' homes and the trial was followed up in the middle of complex conditions of the COVID-19 Pandemic. Also, the challenge was represented by the HBRP applied to patients with SCIs after 4-5 years of rehabilitation interruption.
223764101|NCT05189457|DRUG|Docetaxel|"During the second strike, participants will receive 4 cycles of Docetaxel at 75mg/m2 given intravenously at day 1 of ever 21 days. For participants with positive prostate biopsy or detectable PSA, the second strike will receive 2 additional cycles of docetaxel."
224218177|NCT03077828|BIOLOGICAL|Pembrolizumab|Given IV
224218178|NCT03536819|DEVICE|Votiva|The applicator uses radio-frequency energy to treat the vaginal canal
223764102|NCT05189457|DRUG|Tislelizumab|During the second strike, participants will receive 6 doses of Tislelizumab at 200 mg, given intravenously once every 3 weeks.
224218179|NCT05681377|DRUG|Flumazenil|After cessation of remimazolam infusion, flumazenil 0.2 mg is administered intravenously over 15 seconds. If consciousness is not adequately restored within 3-5 minutes, a second dose of 0.1 mg intravenously over 15 seconds is administered. If necessary, 0.1 mg may be administered repeatedly at 3-5 minute intervals, and the maximum dose of 1 mg should not be exceeded.
224218180|NCT02769000|RADIATION|10 GY in 5 daily fractions|Subjects 1-15 10 GY in 5 daily fractions
224218181|NCT02769000|RADIATION|20 GY in 10 daily fractions|Subjects 16-30 20 GY in 10 daily fractions
223764103|NCT04538664|DRUG|Amivantamab|Amivantamab will be administered as an IV infusion at a dose of 1400 mg (1750 mg if body weight is \>=80 kilogram \[kg\]) by once weekly up to Cycle 2 Day 1, then 1750 mg (2100 mg if body weight is \>=80 kg) on Day 1 of each 21-day cycle, starting with Cycle 3 and will continue the same treatment in OLE phase then in LTE phase.
223764104|NCT04538664|DRUG|Pemetrexed|Pemetrexed will be administered as 500 mg/m\^2 IV infusion (with vitamin supplementation) on Day 1 of each 21-day cycle and then as maintenance monotherapy until disease progression in Arm A and will continue the same treatment in OLE phase then in LTE phase.
224218182|NCT05202691|OTHER|Group 1 (Physical Therapy+Magnetic Field Therapy)|A Physical Therapy Protocol (including manual therapy, stretching and exercise for low back pain) adding a Magnetic Field Therapy using the Zimmer EmfieldPro device (Zimmer MedizinSysteme, Germany)
224218183|NCT05202691|OTHER|Group 2 (Physical Therapy)|A Physical Therapy Protocol (including manual therapy, stretching and exercise for low back pain)
224218184|NCT03788798|DEVICE|Patient infotainment system|The patient infotainment system is a quasi-interactive computer program connected to a server that pushes messages and educational programs ordered from the caring physicians or on-demand by the patients. The server has parallel data exchange gateways to the Hospital Information System (HIS), Picture Archiving Communication System (PACS), and can record the patients' responses to surveys and questionnaires.
223629514|NCT06601348|OTHER|Nutrition education, physical activity intervention, and health promoting school model trials|A nutrition education and physical activity intervention, combining a pilot health promoting school model that includes health education and recreational enhancement with the curriculum of a government-designated healthy school, was designed to reduce childhood overweight and obesity. The programme was implemented over 6 months. This program has been widely conducted in several countries, but there are still many differences from previous studies, especially in terms of strengthening qualitative studies in the first stage, then in the intervention stage using a Cluster Randomised Controlled Trial design. Another advantage of this study is the combination of intervention and health promoting school. In Indonesia, there are few intervention studies in reducing overweight and obesity in children, some only focus on descriptive studies such as nutritional knowledge, physical activity measures using questionnaires to determine the relationship or measure BMI.
223629515|NCT06275451|OTHER|Semi-structured interview|Semi-structured interview on emotional regulation and administration of questionnaires lasting approximately 2 hours.
223629516|NCT00668148|BIOLOGICAL|IMC-A12 (cixutumumab)|"Ewing's Sarcoma/PNET~10 milligrams per kilogram (mg/kg) intravenous (IV) infusion every two weeks.~A treatment cycle will be defined as 6 weeks, with radiological evaluation at every cycle."
223629517|NCT00668148|BIOLOGICAL|IMC-A12 (cixutumumab)|"Rhabdomyosarcoma~10 mg/kg IV infusion every two weeks.~A treatment cycle will be defined as 6 weeks, with radiological evaluation at every cycle."
224218185|NCT00345683|BIOLOGICAL|GSK Biologicals' Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine combined (792014)|Booster dose by intramuscular injection
224218186|NCT00345683|BIOLOGICAL|PedvaxHIB|Booster dose by intramuscular injection
224218187|NCT00345683|BIOLOGICAL|Prevnar|Booster dose by intramuscular injection
224218188|NCT00345683|BIOLOGICAL|M-M-R II|Single dose by subcutaneous injection
224218189|NCT00345683|BIOLOGICAL|Varivax|Single dose by subcutaneous injection
224218190|NCT00937053|OTHER|Transfusion level 120 g/dL|Patients whose hemoglobin falls below 120 g/dL will be transfused with red cells within 24 hours.
224218191|NCT00937053|OTHER|Transfusion level 70 g/dL|Patients whose hemoglobin falls below 70 g/dL will be transfused with red cells within 24 hours
224218192|NCT00937053|OTHER|Platelet transfusion|Patients whose platelets fall below 10 x 10\*9 will be transfused with platelets
224218193|NCT04288115|DRUG|Levothyroxine|Participants will be instructed to start the study medication the day after randomization. The study medication will be taken orally once a day.
224218194|NCT04288115|OTHER|Placebo|Participants will be instructed to start the study medication the day after randomization. The study medication will be taken orally once a day.
223629518|NCT00668148|BIOLOGICAL|IMC-A12 (cixutumumab)|"Leiomyosarcoma~10 mg/kg IV infusion every two weeks.~A treatment cycle will be defined as 6 weeks, with radiological evaluation at every cycle."
223629519|NCT00668148|BIOLOGICAL|IMC-A12 (cixutumumab)|"Adipocytic sarcoma~10 mg/kg IV infusion every two weeks.~A treatment cycle will be defined as 6 weeks, with radiological evaluation at every cycle."
223629520|NCT00668148|BIOLOGICAL|IMC-A12 (cixutumumab)|"Synovial sarcoma~10 mg/kg IV infusion every two weeks.~A treatment cycle will be defined as 6 weeks, with radiological evaluation at every cycle."
223629521|NCT01574586|DEVICE|Bifurcation stenting|Bifurcation stenting using 2-link stent Nobori versus 3-link stent Xience
223629522|NCT04689516|DEVICE|Thoracic fluid content estimation|The patient will be monitored for thoracic fluid content and LUS score. The infusion will stop if TFC reaches 40 k ohm-1 or after completion of the infused volume. LUS evaluation will be done before the start and after the end of the infusion.
223629523|NCT03710746|BEHAVIORAL|Project Health|A brief dissonance-based obesity prevention program delivered in six one-hour weekly sessions.
223629524|NCT03710746|BEHAVIORAL|Response and Attention Training|Individualized, computerized response and attention training consisting of five separate tasks designed to increase inhibitory control to reduce overeating.
223764105|NCT04538664|DRUG|Carboplatin|Carboplatin will be administered as AUC 5 IV infusion for up to 4 cycles on Day 1 of each 21-day cycle.
223764106|NCT04538664|DRUG|Pemetrexed|Pemetrexed will be administered as 500 mg/m\^2 IV infusion (with vitamin supplementation) on Day 1 of each 21-day cycle and then as maintenance monotherapy until disease progression in Arm B and will continue the same treatment in OLE phase then in LTE phase.
224218195|NCT04175678|OTHER|Diet|Participants will receive delivered meals every 4 weeks for three months of a variety of foods for breakfast, lunch, dinner, two snacks, and an additional snack or dessert for each day.
224218196|NCT04175678|OTHER|Exercise|Training will be supervised, individualized, and periodized, incorporating 3 sessions per week, 45-60 min per session for 36 sessions.
224218197|NCT04175678|OTHER|Standard care|Observational
224218198|NCT06543017|OTHER|Experimental group|This study included 16 male freestyle wrestlers from Sichuan Province, China. Participants were tested at three time points: the first day of slow weight reduction (T1), the first day of rapid weight reduction (T2), and the day before competition (T3), with measurements taken for physiological performance, mental state, and sleep quality.
224218199|NCT03797365|OTHER|Classical rehabilitation|"Participants will benefit from two-phases perineal rehabilitation:~First phase will include the PFM's awareness and voluntary contraction learning with manual, biofeedback technics and functional electro stimulation. These exercises will call out the manual rehabilitation technics, biofeedback and electro stimulation. Each classical rehabilitation session will take 30 minutes with 20 minutes of active working, twice per week. About the self-training, there will be no consensus for optimal homemade exercises.~For the second phase, a behavior analyze will be summarized in order to update the favoring and inappropriate situations. The strategy put in place will be organized in unlearning of deleterious perineal habits and learning new behavior program. The main goal will be the perineal locking set up, which must be systematic before and during efforts. During this phase, the physiotherapist will twice weekly perform evaluations (similar to those in the first phase)"
223629525|NCT06593353|OTHER|Systems Analysis and Improvement Approach (SAIA)|SAIA an evidence-based, multi-prong, implementation strategy to improve systems thinking amongst frontline care teams to optimize care quality and continuity. The intervention includes monthly meetings where patient care cascades, process mapping and continuous quality improvement are used to identify bottlenecks and prioritize clinic based solutions.
223629526|NCT01591707|BEHAVIORAL|ISC+PRT Intervention|Teachers will be trained to implement an intervention in preschool ASD classrooms that provides a learning environment in which social and communication skills are focused on.
223629527|NCT06651749|DRUG|Propofol injection|hemodynamic changes of a high dose versus low dose propofol during induction of anesthesia.
224218200|NCT03797365|BEHAVIORAL|Cognitive associated rehabilitation|The cognitive associated rehabilitation group randomized participants will have to execute twice a day the rehabilitation protocol. Each cognitive rehabilitation session will take three minutes. Participants will have to synergistically execute attentional tests (N-Back Test) and execute a perineal contraction during the contraction instructions. (10 randomized auditory stimuli in three minutes). The attentional tests' difficulty will be gradually increased each 15 days. N-Back Test modalities are the followings: the participant will visualize a series of random numbers. First difficulty step will be to click the dedicated button when the volunteer will see the indicated letter. The second difficulty step will be to click the dedicated button when she will see two consecutives times the same letter. The third difficulty step will be to click the dedicated button when she will see two times the same letter separated by one different letter, and so on…
224218201|NCT02720224|DRUG|Estetrol|15 mg \[14C\]-estetrol containing approximately 2.8 MBq (76 μCi) 14C
224218202|NCT04672057|OTHER|assessment of gait parameters|Gait parameters have been recourded with the use of BTS G-Walk Wireless Digital Walking Analysis System on a 10-meter smooth walking area.
224218203|NCT02717338|BEHAVIORAL|Competence|Participants will be assigned to review our donor coping website that combines text, videos, and interactive features to directly address common donor fears and to offer advice on empirically-validated strategies to reduce fear, pain, and syncopal reactions.
224218204|NCT02717338|BEHAVIORAL|Autonomy|Participants will be assigned to receive a brief telephone interview that we have developed that encourages blood donors to reflect upon their unique motivations for giving and how the act of donating is consistent with their broader life goals and values.
224218205|NCT02717338|BEHAVIORAL|Relatedness|Participants will be asked to join a closed Facebook group for one month. The group encourages participants to discuss their experiences with blood donation, including such things as posting images of their donations and/or reasons for donating. Posts will be designed to encourage social interaction around donation experiences, identity formation and group affiliation.
224218206|NCT01196481|DRUG|Carvedilol+VSL#3|Tablet Carvedilol 6.25 mg BD \& capsule VSL#3 1 TDS for 2 year
224218207|NCT01196481|PROCEDURE|Endoscopic variceal ligation|In the Endoscopic Variceal Ligation arm, Endoscopic Variceal Ligation will be performed using multibander devices by senior fully trained endoscopists or under their direct supervision. Varices will be banded starting at the gastroesophageal junction moving proximally upward in a spiral fashion. Patients will undergo Endoscopic Variceal Ligation every 3-4 weeks until eradication. Eradication is defined as the absence of varices or presence of grade I esophageal varices. Following eradication, the interval for the next endoscopy will be every 3 months to look for recurrence of varices. Endoscopic Variceal Ligation sessions would be repeated for the recurrent varices if they are sufficiently large.
224218208|NCT02271815|OTHER|Oral Hygiene|Oral Hygiene
224218209|NCT04553484|DIAGNOSTIC_TEST|No intervention|No intervention
224317606|NCT06501677|BEHAVIORAL|WBI|"The WBI will comprise of four sessions focusing on CRAFT principles including: (1) self-care, (2) positive communication including ways to increase responsiveness to the DP (PPR; i.e., actively listening, showing understanding, expressing interest in what their DP is thinking and feeling, and trying to see where the DPs is coming from), (3) understanding the DP's drinking reinforcers, and (4) supporting the DP if they want help and engaging in positive, healthy activities with the DP. ' partner.~Each module will take \~20-30 minutes and each session will: (1) instill optimism in CPs, (2) be solution-focused, (3) emphasize that the CP is not responsible for the DP's behaviors, and (4) use a nonjudgmental, non-confrontational, empathetic style. The WBI intervention is focused on reduced drinking in the DP and improved CP wellness."
224218210|NCT00349310|DRUG|Pramipexole|
223629528|NCT06661278|DIAGNOSTIC_TEST|Exercise tolerance test|Clinical routine exercise tolerance test using an exercise treadmill, according to the arrhythmia protocol (15 minute protocol utilising increasing speed and incline with a 6 minute recovery)
223764107|NCT05431088|DRUG|Osivelotor|Tablets which contain drug substance
224218211|NCT04271683|PROCEDURE|Pressure controlled ventilation with PEEP|The intervention consists of starting ventilation after apnoea during induction of general anesthesia with pressure controlled ventilation with PEEP instead of manually without PEEP.
224218212|NCT04271683|PROCEDURE|Manual ventilation without PEEP|The intervention consists of starting ventilation after apnoea during induction of general anesthesia manually instead of with pressure controlled ventilation with PEEP.
224218213|NCT05037409|DRUG|PF-06823859|low dose or high dose intravenous infusion
224218214|NCT05037409|DRUG|Placebo|Intravenous infusion
224218215|NCT01311856|BEHAVIORAL|Standard Arm (mail/telephone)|Participants will receive print materials on diet and exercise, telephone counseling calls (3 weekly calls, 2 semi-weekly calls, 4 monthly calls; 15-30 minutes in length), and customized mailed progress reports every 6 weeks to adhere to diet and exercise recommendations.
223629529|NCT06661278|OTHER|Physical activity & heart rate monitoring|Physical activity monitoring over two weeks using Actiheart and Pro-Diary monitors to record heart rate, heart rhythm, activities engaged in and estimated intensity of activities.
223629530|NCT05307874|DRUG|ICT01|anti-BTN3A mAb IV Q3W
223629531|NCT05307874|DRUG|Proleukin Injectable Product|1 MIU/m2 SC IL-2 daily x 5 days for the first 3 cycles
223629532|NCT05307874|DRUG|Pembrolizumab injection|200mg administered following ICT01 + LDSC IL-2 over 30 min Q3W
223764108|NCT03841058|DRUG|Abaloparatide|80 mcg delivered SC by a pen
223764109|NCT03841058|DRUG|Placebo|A pen to deliver a SC dose of placebo
223629533|NCT05762757|OTHER|Colposcopy educational material|-Will consist of a handout featuring education and information regarding colposcopies.
223629534|NCT06665945|DIAGNOSTIC_TEST|Platelet RNA expression|The SENTRY (Stability Enhanced Transcriptional Analytics) Study is to test whether combining a unique analytical approach with changes in platelet RNA expression accurately diagnoses ovarian cancer.
224218216|NCT01311856|BEHAVIORAL|Internet Arm|Participants will access print information online. Participants will also participate in a discussion forum facilitated by the intervention staff, have the opportunity to email questions directly to the intervention staff, and receive progress reports every 6 weeks by email.
224218217|NCT01311856|BEHAVIORAL|Surveys and Questionnaires|9 online surveys to be completed before intervention sessions. After 14 weeks on study, questionnaires will be mailed for completion at home and mailed back to the study staff.
224218218|NCT01311856|BEHAVIORAL|Exercise and Diet|15 minutes of strength exercise every other day, \>30 minutes of walking or other moderate-intensity exercise on 5 or more days of the week. Diet recommendations for both groups.
224218219|NCT00318344|DRUG|Atuna Racemosa|
224218220|NCT02097368|PROCEDURE|tongue strength measurement|tongue strength measurement
224218221|NCT02097368|PROCEDURE|respiratory function measurement|respiratory function measurement
224218222|NCT02097368|PROCEDURE|swallowing tests|swallowing tests
224218223|NCT02097368|OTHER|Magnetic resonance imaging|Magnetic resonance imaging
224218224|NCT04048174|OTHER|Topical probiotic treatment with Lactococcus lactis W136|Nasal and sinus irrigation with reconstituted live probiotic bacteria
224218225|NCT04048174|OTHER|Saline irrigation|Nasal and sinus irrigation with saline solution
224218226|NCT05358561|DIETARY_SUPPLEMENT|Flaxseed and Chia|Measuring blood glucose levels, plasma insulin and the satiety response levels of individuals after consumption of flaxseed, chia, flaxseed + chia and standart cakes
224218227|NCT03843255|OTHER|Part 1: DCM Cohort|Patients with a confirmed diagnosis of DCM will have samples that undergo whole genome sequencing and biomarker analysis
224218228|NCT03843255|OTHER|Part 2: Heritable CV Diseases and Family Members|Biomarker analysis will be undertaken on samples
224218229|NCT02611245|DRUG|Indocyanine green|This group of patients accepted intravenous injection from 0.5mg / kg to 5mg / kg ICG within 4 to 24 hours before surgery. All patients under general anesthesia to accept conventional thoracoscopy or thoracotomy. After entering the chest using fluorescence thoracoscopy system to collect the fluorescence and white-light images and record the video. After following the routine preoperative planning surgery, the researchers will carefully assess the possibility of the benign and malignant nodules and to communicate with the families of patients. If the patient's family expressed their willingness to dissect the nodules, the researchers will remove this extra pulmonary nodules. Resected specimens will send to routine pathological confirmation compared with the fluorescence results.
224218230|NCT02056405|DRUG|Mosapride|15 mg per day divided into 3 oral intakes of 5 mg each (1 pill of Mosapride every 8 hs with 30 ml tap water). This treatment will begin on postoperative day 1 until discharge from Hospital or unacceptable toxicity develops.
224218231|NCT02056405|DRUG|Placebo|1 pill of the same characteristics as Mosapride every 8 hs with 30 ml tap water. This will begin on postoperative day 1 until discharge from Hospital or unacceptable toxicity develops.
224218232|NCT03503656|DEVICE|epidural catheter placement|insertion of an epidural catheter using Compuflo System
224218233|NCT02669628|PROCEDURE|Surgical technique|Laparoscopic surgery
223629535|NCT05814094|OTHER|Red Blood Cell Transfusion|Following randomisation, if a patient's Hb concentration reads ≤ 70g/L, one unit of RBC will be transfused within 12 hours of the result becoming available. Additional units can be prescribed if required to raise the Hb concentration to above 70g/L. A transfusion above the restrictive threshold of 70g/L is discouraged.
223629536|NCT05814094|OTHER|Red Blood Cell Transfusion|Following randomisation, if a patient's Hb concentration reads ≤ 90g/L, one or more units of RBC will be transfused in order to raise the Hb concentration to greater than 90g/L within 12 hours of the result becoming available. A decision not to transfuse below the threshold of 90g/L is discouraged.
223629537|NCT06051435|OTHER|lumbar proprioception training|"a) Sensorimotor training: Sensorimotor training and reconditioning of proprioceptive senses have recently been found to be helpful in increasing motor performance and coordination, muscle strength, sensorimotor abilities, increasing intermuscular control, and improving one's response to sensory information and muscle tone. Reconditioning of proprioceptive senses and sensorimotor training increases one's muscle adjustment ability, maximizes the sensory input in different parts of the body and aids in improving one's motor adjustment ability (Hwang et al ., 2013).~Position Exercise methods as Hollowing exercise: Participants will be asked to contract the abdominal muscles, raising the center of movement toward the navel in a quadruped position."
223629538|NCT06051435|OTHER|Hot packs|hot application in the form of hot packs on the lower abdomen and lower back for a total duration of 30 minutes, once per day, during the first two days of menstruation
224218234|NCT02669628|PROCEDURE|Alcohol sclerotherapy|US-guided sclerotherapy
224218235|NCT04676516|DRUG|GSK3326595|GSK3326595 is a first-in-class small molecule PRMT5 inhibitor in form of an oral capsule.
224218236|NCT03648398|OTHER|EDUMICILOR|Patients will participate in the online therapeutic education program for about 6 months
224218237|NCT01783899|DEVICE|Hemospray|"Patients will be resuscitated as needed to achieve hemodynamic stability in preparation for endoscopy within 24 hours of hospital admission.~once the bleeding point will be identified at endoscopy, the delivery catheter will be inserted through the endoscope and positioned toward the lesion, leaving 1-2 cm between the bleeding site and the catheter tip.~Hemospray will be then delivered in short spray bursts (for 1-2 seconds) until hemostasis was confirmed.~Once bleeding was controlled , the bleeding site will be observed for 5 minutes under endoscopy.~Oral food and fluid will be with held from the patient for 24 hours. Intravenous octreotide and esomeprazole will given for up to 24 hours. Patients will be closely monitored for signs of recurrent bleeding for 24 hours post procedure.~Recurrent bleeding will be diagnosed any patient experiencing recurrent bleeding will treated according to the institutional standard of care"
224218238|NCT01210742|DEVICE|Synvisc One|Single intra-articular injection of a 6 mL of Hylan G-F 20 at baseline
224218239|NCT01210742|OTHER|Routine management|Routine non-operative management for knee OA (NICE guidelines)
223629539|NCT06051435|OTHER|Pelvic rocking exercise|Pelvic rocking exercise
223629540|NCT06596590|DEVICE|Rezum|The Rezum System is designed to treat patients with urinary symptoms associated with BPH. The Rezum System utilizes radiofrequency current to generate thermal energy in the form of water vapor, which is then injected into the transition zone and/or median lobe of the prostate in controlled 9-second doses. The vapor injected into the prostate tissue rapidly disperses through the interstitial space between the tissue cells. As the vapor cools, it condenses immediately on contact with tissue, and the stored thermal energy is released, denaturing the cell membranes and causing cell death.
223629541|NCT06599411|OTHER|Sampling|Collection of an additional volume of blood Superficial skin biopsy Skin swab
223629542|NCT06599411|OTHER|Sampling|Collection of an additional volume of blood Preservation of post-operative skin remnants Skin swab
223629543|NCT06589856|DIETARY_SUPPLEMENT|Placebo|Placebo (300 mL salt water, NaCl) = CTR
223629544|NCT06589856|DIETARY_SUPPLEMENT|LAC5|5 g lactate (300 mL lactate drink = 5 g D/L-lactate bound to Na) = LAC5
223629545|NCT06589856|DIETARY_SUPPLEMENT|LAC10|10 g lactate (300 mL lactate drink = 10 g D/L-lactate bound to Na) = LAC10
223629546|NCT06589856|DIETARY_SUPPLEMENT|LAC20|20 g lactate (300 mL lactate drink = 20 g D/L-lactate bound to Na) = LAC20
223629547|NCT06604377|OTHER|Observe|Ruijin
223629548|NCT03735875|DRUG|Quizartinib|Given PO
223629549|NCT03735875|DRUG|Venetoclax|Given PO
223629550|NCT06612320|BEHAVIORAL|Questionnaire about acceptance|Questionnaire about acceptance
223629551|NCT06612320|BEHAVIORAL|Questionnaire about refusal|Questionnaire about refusal
223629552|NCT06612944|DRUG|Prophylactic Intervention for Relapse Prevention Post-Allogeneic Transplantation|"1.1 AZA + BCL2 Inhibitor (Preferred Regimen) Subcutaneous injection of azacitidine at 32 mg/m² per day for 5 consecutive days, with a 28-day cycle; BCL2 inhibitor (VEN): 400 mg per day orally for one week (if combined with a CYP450 inhibitor, reduce to 100 mg per day).~1.2 AZA (DEC) + DLI For patients with TP53 mutations or those who do not respond to VEN, subcutaneous injection of azacitidine at 32 mg/m² per day for 5 consecutive days, with a 28-day cycle; decitabine at 5 mg/m² per day for 5 consecutive days, with a 28-day cycle (preferred for those with TP53 mutations). For patients without the option for DLI, regimen 1.1 is recommended.~DLI: Begins 3 months post-transplantation, starting with a dose of 1×10\^5 CD3+ T lymphocytes for haploidentical transplants, with doses increasing every 4-6 weeks to 5×10\^5 CD3+ T lymphocytes, 1×10\^6 CD3+, and 5×10\^6 CD3+ T lymphocytes; for full-matched transplants, the starting dose is 5×10\^5 CD3+ T lymphocytes with dose escalations as above to 1×1"
223629553|NCT06989905|BEHAVIORAL|Up-conditioning of the wrist extensor motor evoked potential|At the beginning of each session, EMG recording and nerve stimulating electrodes are placed over the arm. In all sessions, MEPs will be measured while the sitting subject provides a pre-set level of background muscle EMG with joint angles fixed. In 225 control trials of each baseline sessions and the first 20 trials of conditioning sessions the subject will receive no feedback as to MEP size (i.e., control MEPs). In 225 conditioning trials of each conditioning session, the subject will be encouraged to increase the target muscle MEP, and will receive immediate feedback as to whether MEP size was above a criterion (i.e., whether the trial was a success).
223629554|NCT06991569|PROCEDURE|Non-surgical perforation repair|Root perforation repair using MTA or other perforation repair material
223629555|NCT04498715|PROCEDURE|OSTEOSYNTHESIS|Routine procedure for anesthesia and infection prophylaxis according to the clinics routines will be followed. The patient is supine with the fractured leg positioned in traction table. The biplanar x-ray device is moved and adjusted for proper simultaneous AP and lateral view. Hip region is washed and dressed in sterile draping's. Using standard proximal femur osteosynthesis technique 2.0 mm diameter Kirschner wire is placed in the middle zone of the femoral neck in AP and lateral view. The canal is opened using 6 mm drill bit and measured length of dynamic hip screw is placed in the femoral head and neck.
223629556|NCT04498715|DRUG|Zoledronic Acid|Zoledronic acid (ZA), is a bisphosphonate, and has been shown to reduce the risk of hip fracture by 41% in post-menopausal women. For systemic injection, 4 mg (as per clinical protocol) will be injected intravenously 1-2 weeks after surgery. For local delivery, 1 or 2 mg Zoledronic Acid will be added to 5 or 10 mg CERAMENT BVF during mixing and the mixture will be injected.
223764110|NCT05339087|DRUG|Riociguat Oral Tablet|Riociguat Oral Tablet (1 mg, 1.5 mg, 2.0 mg or 2.5 mg three times daily) Titration phase: dose will be individually adjusted in accordance with the in-label titration regimen. Dose adjustment will be performed every two weeks by phone taking the systemic blood pressure of the patient, the subjects and physicians' subjective estimation and occurrence of adverse reactions into account. At week 8 the maintenance dose will be established and continued for the rest of the study
224218240|NCT00931385|DRUG|BI 1744|BI1744 Respimat Med Dose Once Daily
224218241|NCT00931385|DRUG|bi1744|1744 low dose
224218242|NCT00931385|DRUG|Placebo|Placebo Respimat and Foradil Placebo
224218243|NCT00931385|DRUG|Foradil|Foradil 12 mcg twice daily and Placebo Respimat
223629557|NCT04498715|DEVICE|CERAMENT BONE VOID FILLER (BVF)|"CERAMENT™\|BONE VOID FILLER is a synthetic, injectable, osteoconductive bone void filler. CERAMENT™I is biphasic, consisting of 60% calcium sulfate and 40% hydroxyapatite mixed with the radio-opacity enhancing component CERAMENT™\|C-TRU (iohexol 300 mg iodine/ml), which allows bone in-growth after curing. The high injectability of CERAMENT™ allows transcortical administration and ensures good intraosseous spread. In this trial, CERAMENT BVF paste will be injected by a sterilized metal needle (2-3 mm diameter and 15 cm length) through the hollow dynamic hip screw."
224218244|NCT00796211|DRUG|CRx-197|CRx-197 high dose topical cream (0.1% nortriptyline HCl +0.3% loratadine)
224218245|NCT00796211|DRUG|CRx-197|CRx-197 low dose topical cream (0.1% nortriptyline HCl + 0.1% loratadine)
224218246|NCT00796211|DRUG|Nortriptyline|0.1% nortriptyline HCl topical cream
224218247|NCT00796211|DRUG|Calcipotriol|0.005% calcipotriol topical cream
224218248|NCT00796211|OTHER|Placebo|Vehicle of CRx-197 topical cream (placebo)
224218249|NCT04401787|PROCEDURE|Anterior resection for upper rectal cancer in obese|Anterior resection for upper rectal cancer in obese
224218250|NCT00034515|DRUG|denufosol tetrasodium (INS37217) Inhalation Solution|
224218251|NCT00952185|OTHER|cytology specimen collection procedure|
224218252|NCT00952185|OTHER|fluorescent antibody technique|
223629558|NCT03968679|RADIATION|Unilateral elective nodal irradiation|After injection of nanocolloid tracer submucosally around the tumor, patients undergo lymph drainage mapping (LDM) using SPECT/CT. If no contralateral drainage is visualized, the patient receives unilateral elective nodal irradiation (ENI). In case of contralateral lymph drainage, a contralateral sentinel node procedure is performed. If pathologic evaluation finds no metastasis, the patient receives unilateral ENI. If (micro/macro) metastasis are found, the patient will receive bilateral ENI.
223629559|NCT06592404|DEVICE|Robot Tessa|"Tessa is a small flowerpot shaped robot with two amber LED-lit eyes. The robot is always connected to the power network and internet and speaks reminders at a preset time. These notifications are installed by the user, who can be the professional caregiver or in some cases the participant themselves, using an accessible web app.~Together with the participant and their professional caregiver, selected activities are translated into goals that the robot will support using Goal Attainment Scaling (Kiresuk \& Sherman, 1968), an individualized evaluation method to monitor the progress of (treatment) goals. The goals are evaluated weekly during the study period using a 5-point scale."
223629560|NCT06595173|BEHAVIORAL|Therapeutic Intervention|"group where therapeutic art activities such as mandala, drawing, third person singular method are applied.~Therapeutic artistic activities within the program (drawing, zentagle, etc.). The program will be implemented in 6 weeks. At the beginning and end of the program, children\&#39;s anxiety and psychological well-being levels will be evaluated."
223629561|NCT06585878|RADIATION|Stereotactic Ablative Radiotherapy (SABR)|Without altering the patients' systemic treatment plans, patients who meet the inclusion criteria after MDT discussion will receive SBRT radiotherapy for all lesions/all metastatic lesions based on the guideline-recommended medications. The radiotherapy plan is based on the SABR-COMET protocol and Timmerman's constraints.
223629562|NCT06615076|OTHER|Postpartum Visits|Postpartum visits with obstetric care providers
223629563|NCT06615076|OTHER|Postpartum Visits|Postpartum visits with study RN.
223629564|NCT02422706|DRUG|Nitazoxanide|Nitazoxanide based treatment regimens as a new treatment regimens for helicobacter pylori infection
223629565|NCT02422706|DRUG|Metronidazole(MTZ)|Metronidazole 500 mg twice daily
223629566|NCT02422706|DRUG|Omeprazole|Omeprazole 20 twice daily
223629567|NCT02422706|DRUG|Clarithromycin|KLacid twice daily
223764111|NCT05339087|OTHER|Placebo|Sham titration and adjustment to maintenance dose will be performed according to individual tolerability as in the experimental arm.
223764112|NCT04802174|DRUG|Lurbinectedin|Participants meeting inclusion and exclusion criteria will receive lurbinectedin (on day 1) and berzosertib (on day 1 and 2) administered every 21 days (1 cycle), either in the in-patient or out-patient setting, until disease progression or development of intolerable side effects.
224218253|NCT00952185|PROCEDURE|assessment of therapy complications|
224218254|NCT05215041|OTHER|Non intervention|If the vaginal delivery is failed after spontaneous labor for up to 24h, they will receive cesarean section
224218255|NCT03360656|DEVICE|Transnasal Thermal Regulating Device|Placement of transnasal thermal regulating device to reduce temperature in febrile patients for a period of 8 to 24 hours
224218256|NCT04612205|DEVICE|TECAR followed by pelvic floor exercises|The signal generator was an INDIBA® 448 kHz RF device (vagina/rectum) (INDIBA SA, Barcelona, Spain).
224218257|NCT04612205|OTHER|pelvic floor exercises|The patients will instructed to contract their pelvic floor muscles without contracting adjacent muscles, such as the abdomen, glutei and hip adductors muscles twenty repletion consisted of contraction and squeezing of the muscle ten seconds followed by relaxation for twenty second then rested for two minutes. The exercises program lasted for lasting 45 min. divided into 5 min. warming up, 35 min. actual treatment and 5 min. cooling down, three times a week for eight consecutive weeks. The patient will teach to contract their pelvic floor muscles before coughing or sneezing thus to prevent leakage. Home exercises through continuing practicing these contractions as frequent as possible according to her ability, at early morning before getting from bed from crock lying position, at afternoon from sitting and standing positions, at evening from sitting and standing positions and finally at night at bed time from crock lying position.
224218258|NCT05781477|BEHAVIORAL|Bmum supportive system|Bmum is a web-based online tracking system that aims to improve positive attitude about breastfeeding
224218259|NCT05700929|BEHAVIORAL|Communication skills training for nurses|Aim of the developed training will be to foster patient-centered communication skills of nursing professionals in Germany. The training consists of four modules in which participating nurses will get information regarding patient-centeredness and general communication techniques. Participants will also learn how to response to patients in escalating situations and how to communicate with seriously ill or dying patients. The underlying framework for the training is the Calgary-Cambridge Guide, a well-known model for structuring conversation with patients. Different didactic techniques (i.e. roll-play, video sequences, group discussion) will be applied. The training will be provided in small groups of 10-14 participants each. Two facilitators will give the training, one of them being a nursing professional trained according to the train-the-trainer approach, the other being a member of the research group, who was involved in the development of the training.
224218260|NCT02129530|BEHAVIORAL|Community Social Mobilization program|
224218261|NCT02619734|BIOLOGICAL|Infusion of Autologous Bone Marrow Mononuclear Cells|Autologous bone marrow-derived mononuclear cells will be administered by intramuscular injection into and around the leg ulcer. The number of injected cells will be from 5x108 to 1x109 total number of cells on Study Day 1.
224218262|NCT02693678|OTHER|Massage|
224218263|NCT02693678|DEVICE|DIathermy|
224218264|NCT02693678|DEVICE|Sham diathermy|
224218265|NCT05587478|DRUG|EDP-323|Oral administration
224218266|NCT05587478|DRUG|Placebo|Placebo to match EDP-323, oral administration
224218267|NCT05162885|PROCEDURE|Socket Preservation technique|Implant placement after Socket preservation Technique with sodium alderonate versus sticky bone in salama\&salama Class 3 labial wall defect
224218268|NCT00074009|DRUG|bortezomib|
223629568|NCT02422706|DRUG|Levofloxacin|Tavanic. Tavacin
223629569|NCT02422706|DRUG|Doxicycline|Vibramycin 100 mg twice daily
223764113|NCT04802174|DRUG|Berzosertib|Participants meeting inclusion and exclusion criteria will receive lurbinectedin (on day 1) and berzosertib (on day 1 and 2) administered every 21 days (1 cycle), either in the in-patient or out-patient setting, until disease progression or development of intolerable side effects.
223629570|NCT06998979|BEHAVIORAL|Music therapy|"The music was generated using a beta version of the RIFFUSION program, which is still in its development phase and being refined based on user input. This software operates using neural networks similar to Generative Adversarial Networks (GANs), known as diffusion models. These models begin with random noise and gradually transform it into a musical composition through a process that involves two phases: a diffusion phase-where an existing musical sample is disordered by adding random noise-and a reverse phase, in which the noise is removed to reconstruct a new and distinct musical piece.~The prompt entered into the program was: Relaxing slow music for people with great stress and extreme anxiety and panic caused by dental surgery with effects of wind and waterfall. A total of 20 songs were generated and merged to achieve a combined duration of 49.20 minutes."
223629571|NCT06600464|DIAGNOSTIC_TEST|Ultrasound|The thickness of the thenar eminence muscles (longitudinal thickness of the first dorsal interosseous muscle (FDI), abductor pollicis brevis (APB), and opponens pollicis (OPP)) was measured using musculoskeletal ultrasound.
223629572|NCT06600464|OTHER|Assessment of Muscle Strength in Both Hands|Muscle strength in both hands was evaluated using grip strength measured with a dynamometer (Jamar Hydraulic Hand Dynamometer, Nottinghamshire, UK)
223629573|NCT06600464|OTHER|Assessment of Pain Threshold|Pressure pain threshold (PPT) for painful and non-painful finger joints was assessed using a hand-held algometer
223629574|NCT06997991|PROCEDURE|adipose micro-grafts injection|Patients were positioned supine, and local anesthesia was administered. A small incision was made to introduce a blunt cannula attached to a Luer-lock 60-cc syringe. Klein sterile solution, containing saline and lidocaine, was injected into the subcutaneous fat layer of either the abdominal or thigh region. Subsequently, approximately 30 mL of adipose tissue was extracted. The collected lipoaspirate was processed under sterile conditions in a closed system using Rigenera® technology (HBW, Turin, Italy). Before injecting, the skin was sterilely dressed, and the injection of 2-3 mL of aMAT was performed into TMC joint with a superolateral approach, under fluoroscopic X-ray guidance and using a disposable 20G needle and a 3 mL Luer-Lock Syringe.
223629575|NCT06589310|DEVICE|Exact Sciences Multicancer Early Detection (MCED) Test|Exact Sciences MCED test, is a qualitative in vitro diagnostic (IVD) for the detection of alterations in circulating tumor DNA and tumor-associated protein levels, which are commonly associated with cancer. It is performed on plasma derived from peripheral blood specimens.
223629576|NCT06589492|DIAGNOSTIC_TEST|Measurement of MMP-9 and SIRT-1 levels in blood serum|Measurement of MMP-9 and SIRT-1 levels in blood serum, Collection of 5 ml Blood samples
224218269|NCT03821324|DEVICE|Venus Viva|The Venus Viva™ fractional RF device has been shown in clinical studies to improve various skin conditions related to aging and alter collagen structures such as wrinkles, rhytids and scars. Beginning with the Baseline visit (Visit 1), subjects will receive a total of 3 treatments approximately 3-5 weeks apart. The left and right side of the face will be treated and assessed as independent sites, and the same applicator tip configuration will be used to treat both sides at all 3 treatment visits.
224317607|NCT05547841|DEVICE|Echocardiography acquisition|Echocardiography examination of all participants using PHILIPS. Time points for heart image acquisition in pregnant women: As per the Guidelines for Pre-pregnancy and Pregnancy Health Care (2018) formulated by the Obstetrics Group of the Gynecology Branch of the Chinese Medical Association, a total of six echocardiographic examinations will be performed in the first trimester (11-14 weeks of gestation), the second trimester(20-24 weeks of gestation), the third trimester (29-32 weeks of gestation), prenatal term (37-40 weeks of gestation), 6 weeks and 3-6 months after delivery. Time points for fetal heart image acquisition: Fetal heart images will be collected in the second trimester(20 to 24 weeks of gestation).
223629577|NCT06997939|BIOLOGICAL|ABMSC|Autologous bone marrow-derived mesenchymal stem cells administered via Ommaya reservoir；2.0\*10\^7 cell/dose
223629578|NCT06997939|BIOLOGICAL|ABMSC|Autologous bone marrow-derived mesenchymal stem cells via intra-arterial route；Low-dose group; 2.5\*10\^6 cell/dose
223629579|NCT06997939|BIOLOGICAL|ABMSC|Autologous bone marrow-derived mesenchymal stem cells via intra-arterial route；High-dose group; 1.0\*10\^7 cell/dose
223629580|NCT06999057|DEVICE|Joint Effusion via 60 mL Sterile Saline|Injection of sterile saline into the knee joint to simulate joint swelling and induce quadriceps inhibition.
223629581|NCT06999057|DRUG|Intra-articular Lidocaine|Injection of 7 mL lidocaine into the knee joint to simulate deafferentation by temporarily blocking sensory input.
223629582|NCT06999057|OTHER|Sham injection|Simulated knee injection using a stage needle without skin penetration, used to blind participants and serve as control.
224218270|NCT04821492|DIAGNOSTIC_TEST|Dual-Energy X-ray Absorptiometry (DXA)|BMD expressed in absolute values as g/cm2 and T-scores
224317608|NCT03438292|DIETARY_SUPPLEMENT|Berberine|Two capsules of berberine. Each capsule contains 400 mg berberine. The total amount of berberine throughout is 800 mg.
223629583|NCT06999525|DEVICE|Therapeutic virtual reality headset (CRVT)|Contribution of the use of a Therapeutic Virtual Reality Headset in the management of anxiety and discomfort in digestive endoscopy
223629584|NCT06999434|DRUG|[ 18F]3F4AP|PET Scan #3
223629585|NCT06999434|DRUG|[18F]MK6240|PET Scan #2
223629586|NCT06999434|DRUG|[11C]PIB|PET Scan #1
223629587|NCT06601530|PROCEDURE|Transversus Thoracic Muscle Plane Block|Transversus thoracic muscle plane block is a single-shot nerve block technique that provides analgesia for the anterior chest wall Tramadol IV PCA (Patient Controlled Analgesia): Basal infusion 0.2 mg/kg/h, bolus 20 mg, lock time 20 minutes
224218271|NCT00196443|DEVICE|urea contained compressing stockings|
224218272|NCT00196443|DEVICE|compressing stockings|
224218273|NCT01298596|PROCEDURE|Loop Electrosurgical Excision Procedure (LEEP)|LEEP procedure uses a low-voltage electrified wire loop to cut out diseased part of cervix
224218274|NCT01298596|PROCEDURE|Cryotherapy|Cryotherapy procedure involves using a cryoprobe and carbon dioxide or nitrous oxide gas to freeze the diseased part of the cervix
224218275|NCT05907902|DRUG|Aspirin Enteric-coated Tablets|low-dose aspirin 100 mg once daily (one 100mg tablet).
224218276|NCT01364259|DRUG|Amifostine|Amifostine and CyberKnife stereotactic radiosurgery
224218277|NCT01364259|PROCEDURE|CyberKnife stereotactic radiosurgery|CyberKnife stereotactic radiosurgery
224317609|NCT03438292|DIETARY_SUPPLEMENT|TPGS emulsified berberine|Two capsules of TPGS/Quillaja extract emulsified berberine. Each capsule contains 400 mg berberine. The total amount of berberine throughout is 800 mg.
223629588|NCT06601530|DRUG|Tramadol|Tramadol IV PCA (Patient Controlled Analgesia): Basal infusion 0.2 mg/kg/h, bolus 20 mg, lock time 20 minutes
223629589|NCT06999512|PROCEDURE|Comprehensive Geriatric Assessment|"CGA:~* Preoperative geriatric consultation~* Perioperative tailored intervention if needed~* Postoperative geriatric follow-up~* M3 geriatric consultation"
223629590|NCT04243499|BIOLOGICAL|IV ICT01|humanized anti-Butyrophilin 3A (BTN3A) monoclonal antibody
223629591|NCT06998017|OTHER|Low Volume High Intensity Interval Training|Participants will conduct aerobic exercise on a total body recumbent stepper to get their heart rates to levels consistent with high intensity exercise.
223629592|NCT06998888|DEVICE|software Caaring (remote monitoring app)|Caaring is an electronic data collection notebook that allows patients to confidentially fill out data/ questionnaires on their mobile phone and report them through an application that will be installed on the patient's mobile phone. Besides, This group (G\_CAARING) will receive educational and prevention recommendations relative to cancer.
223629593|NCT06999356|DEVICE|CGM Device|Fruits and Vegetables and some groups will get CGM devices along with Fruits and Vegetables
223629594|NCT06999252|DRUG|Rimegepant|Take 75 mg every other day
223629595|NCT06999252|DRUG|PD-1|200mg intravenously every 3 weeks (Q3W), was administered until the occurrence of unacceptable toxic effects, or disease progression, withdrawal of consent, or withdrawal as judged by the investigator.
223629596|NCT06999785|BIOLOGICAL|Blood test|a blood test before and after the first oxygen therapy session, as well as after the last session
223629597|NCT06998797|OTHER|Data collection|Data collection from medical records
224218278|NCT02593734|DRUG|olanzapine|oral antipsychotic drug therapy
224218279|NCT02593734|DRUG|risperidone|oral antipsychotic drug therapy
224317610|NCT03438292|DIETARY_SUPPLEMENT|Quillaja extract emulsified berberine|Four capsules of Quillaja extract emulsified berberine. Each capsule contains 200 mg berberine. The total amount of berberine throughout is 800 mg.
224317611|NCT00799825|BIOLOGICAL|GSK Biological's HPV vaccine GSK580299 (Cervarix™)|All subjects will receive a 0.5 ml dose administered as an intramuscular injection, according to a 0, 1, 6-month schedule.
223629598|NCT06999941|DRUG|Deucravacitinib 6mg po qd|oral administration
223629599|NCT06998719|DRUG|Durvalumab|Neoadjuvant durvalumab (MEDI 4736)and platinum-based chemotherapy, followed by either surgery and adjuvant durvalumab or CRT and consolidation durvalumab, in borderline resectable stage III NSCLC
223629600|NCT04875975|DRUG|Rozanolixizumab|"* Pharmaceutical form: Solution for infusion~* Route of administration: Subcutaneous use~Subjects will receive rozanolixizumab in a pre-specified sequence during the Treatment Period."
223629601|NCT04875975|DRUG|Placebo|"* Pharmaceutical form: Solution for infusion~* Route of administration: Subcutaneous use~Subjects will receive placebo in a pre-specified sequence during the Treatment Period."
223629602|NCT05136586|OTHER|Biofeedback|"6 minutes of relaxing breathing exercise coupled with hert rate variability biofeedback guided on eMWave Pro software on a computer just before entering the examination circuit.~After the circuit, 6 minutes of free activity where the participants will not be given any instruction."
223629603|NCT05136586|OTHER|Meditation|"6 minutes of listening an audio tape made for the study that inspire mindfulness like meditation associated with psychological stimulation (positive encouragement) just before entering the examination circuit.~After the circuit, 6 minutes of free activity where the participants will not be given any instructions."
223629604|NCT05136586|OTHER|Control and biofeedback post OSCE|"6 minutes of standardised neutral video on general topics that generates no modification of affects just before entering the examination circuit.~After the circuit, 6 minutes of relaxing breathing exercise coupled with hert rate variability biofeedback guided on eMWave Pro software on a computer"
223629605|NCT05136586|OTHER|Control and control post OSCE|"6 minutes of standardised neutral video on general topics that generates no modification of affects just before entering the examination circuit.~After the circuit, 6 minutes of of free activity where the participants will not be given any instruction."
223629606|NCT06997952|DRUG|Febuxostat 40 mg|Febuxostat will be given daily for 12 weeks The prescribed dosage was 40 mg taken once daily, self-administered by the patients in addition to their standard treatment.
223629607|NCT06998459|OTHER|Bian-Stone therapy|Once a week, each session lasting 30 minutes, for a duration of six months.
224218280|NCT02593734|DRUG|amitryptaline|oral antidepressant drug therapy
224218281|NCT02593734|DRUG|fluoxetine|oral drug therapy for depression
224218282|NCT03564535|DEVICE|Self fixating group|Monofilament polyester mesh with polylactic acid (PLA) microgrips of size 11\*15 will be used. It is an isoelastic large-pore knitted fabric with a density of 73g/m2 at implantation and 38g/m2 after microgrips absorption which will be at 18 months. The resorbable micro grips provide immediate adherence to surrounding muscle and adipose tissue during the initial days post hernia surgery, serving as an alternate method of fixation to traditional sutures, tacks, staples, or fibrin sealants. No additional tacks, staples, sutures, or fibrin sealant will be used.
223629608|NCT06998459|OTHER|Maintain the original treatment approach|Maintain the original treatment approach
223629609|NCT06998238|BEHAVIORAL|Mediterranean-based, carbohydrate restricted, calorie reduced diet|Dietary intervention - calorie reduced (300-500 kcal/day below estimated energy needs), carbohydrate restricted (\<100 grams of available carbohydrates per day), Mediterranean-based (high fat diet with an emphasis on the addition of healthy fats - nuts, avocados, olive oil, increasing whole grains, increasing fruit and vegetables, replacing red meats with fish and poultry, reducing dairy, and reducing added sugars) diet.
223629610|NCT06434337|DIAGNOSTIC_TEST|"Novel point-of-care diagnostic test for detecting HPV (Rice HPV test)"|Given by Diagnostic Test
224218283|NCT03564535|DEVICE|Tacker fixation group|Patients will be undergoing polyester mesh ﬁxation with non-absorbable tacks. The tacks would be used such that they avoid bony prominences and vascular and neural structures. One or two tacks will be put at the Cooper's ligament and another applied laterally superior to the iliopubic tract in the anterior abdominal wall. In any patient, the maximum number of tacks applied will not exceed three.
224218284|NCT00280501|DRUG|Quetiapine (drug)|Quetiapine (Seroquel 100mg-film-coated tablet, AstraZeneca Vienna, Austria) Dose: 100 mg tablet oral single dose
224317612|NCT06168110|DEVICE|TENS|Transcutaneous electrical nerve stimulation (TENS) is a non-invasive treatment method widely used for pain control
223629611|NCT06998641|PROCEDURE|Chitosan-covered-gauze application|Effectiveness of chitosan-covered-gauze in terms of patients' comfort and satisfaction, hospital stay, total amount of bleeding, hemoglobin decline and other complications (infections, need for transfusion etc.) for the treatment of hemorrhagic obstetrical tears
223629612|NCT06998641|PROCEDURE|Suturation|Effectiveness of suturation in terms of patients' comfort and satisfaction, hospital stay, total amount of bleeding, hemoglobin decline and other complications (infections, need for transfusion etc.) for the treatment of hemorrhagic obstetrical tears
223629613|NCT06594172|DRUG|Memantine Oral Tablet|"Oral administration of Memantine Tablets (10mg/tablet):~Week 1: 5mg in the morning. Week 2: 5mg twice daily. Week 3: 10mg in the morning, 5mg in the evening. Weeks 4-24: 10mg twice daily."
223629614|NCT06594172|DRUG|Pioglitazone 15mg|"Simultaneous oral administration of Pioglitazone Tablets (15mg/tablet):~Weeks 1-24: 30mg once daily."
224218285|NCT00280501|DRUG|Sulpiride (drug)|Sulpiride (Dogmatil 200mg-tablet, Synthélabo Groupe, Le Plessis Robinson, France) Dose: one half of 200 mg tablet oral single dose
224218286|NCT00280501|DRUG|Placebo|Placebo
224218287|NCT06536829|OTHER|Myofacial release technique and sciatic nerve slider technique|Myofacial release technique, sciatic nerve slider technique 0 week,6 week 12 weeks
224218288|NCT06536829|OTHER|Myofacial release technique|0week,6 week, 12 weeks
224218289|NCT05113901|DRUG|Methylprednisolone|21 x 4mg tablets at 6 weeks, qualifying for MUA if ROM \<90° at 8 weeks
224218290|NCT05113901|DRUG|Placebo|21 sugar tablets at 6 weeks with standard management, qualifying for MUA if ROM \<90° at 8 weeks
224218291|NCT04716673|OTHER|Down-phase targeted auditory stimulation|The presentation of a soft, brief tone (50 ms of pink noise). The volume will be held low enough to avoid provoking arousals or awakenings. In case of a waking-up-reaction, the volume will be lowered in steps of 5 dB.
224218292|NCT04582409|DRUG|HSY244|HSY244 concentrate solution for injection via intravenous infusion
224218293|NCT04582409|OTHER|Placebo|Placebo concentrate solution for injection via intravenous infusion
224218294|NCT04128696|DRUG|feladilimab|feladilimab is available as an intravenous infusion.
224218295|NCT04128696|DRUG|Pembrolizumab|Pembrolizumab is available as an intravenous infusion.
224218296|NCT04128696|DRUG|Placebo|Placebo is available as an intravenous infusion.
223629615|NCT06594172|RADIATION|Hippocampal avoidance whole-brain radiotherapy (HA-WBRT)|Based on the RTOG 0933 protocol, hippocampal and perihippocampal regions are delineated, and hippocampal dose constraints are applied. The radiation dose to the perihippocampal region is determined based on the size, number, and volume of brain metastases (whole-brain radiation therapy: DT 30Gy/10F, weeks 1-2; with a simultaneous boost to the pathological local area if necessary, 10-20Gy).
223629616|NCT03234699|DRUG|Cenobamate|12.5 mg q.d.(Days 13-26), 25 mg q.d. (Days 27-40), 50 mg q.d. (Days 41-54), 100 mg q.d. (Days 55-70), 150 mg q.d. (Days 71-84), 200 mg q.d. (Days 85-110)
224218297|NCT00016835|PROCEDURE|Supra-gingival scaling and placebo|Included in arm/group description.
224218298|NCT00016835|PROCEDURE|Subgingival scaling and metronidazole|Included in arm/group description.
224218299|NCT00016835|PROCEDURE|Subgingival scaling and doxycycline|Included in arm/group description.
224218300|NCT05294198|DIETARY_SUPPLEMENT|Beetroot extract|Beetroot extract capsule
224218301|NCT00393835|DRUG|Azithromycin SR|
224218302|NCT03079674|OTHER|observational only- no intervention|observational only- no intervention
224218303|NCT02353429|DRUG|Toremifene|Patients will receive 60 mg daily and then 180 daily in case of progression
223629617|NCT03234699|DRUG|midazolam|2 mg midazolam syrup (Days 7, 69, 105)
224218304|NCT00585039|DRUG|xopenex|will receive xopenex rather than albuterol to treat acute exacerbation
224218305|NCT04166669|DRUG|APX001|Cohort 1 Day 1: APX001 500 mg IV BID over a 3-hour infusion; Day 18: APX001 500 mg IV BID over a 3-hour infusion. Cohort 2 Day 1: APX001 1000 mg IV BID over a 3-hour infusion; Day 24: APX001 1000 mg IV BID over a 3-hour infusion.
223629618|NCT03234699|DRUG|Warfarin Pill|5 mg (Days 7 and 105)
223629619|NCT03234699|DRUG|Omeprazole Pill|20 mg (Days 7 and 105)
224218306|NCT04166669|DRUG|Itraconazole|Cohort 1 Days 15-30: itraconazole 200 mg oral solution QD.
224218307|NCT04166669|DRUG|Rifampin|Cohort 2 Days 15-33: rifampin 600 mg oral QD.
224218308|NCT04863326|BEHAVIORAL|Making Proud Choices|
224218309|NCT04863326|BEHAVIORAL|Business as usual|
224218310|NCT05924568|OTHER|Educational session with Keep Your Move in the Tube and PrimusRS|
224218311|NCT01010230|DEVICE|LMHF mechanical stimulation active device|"Participants will be randomly assigned to stand on a low magnitude, high frequency mechanical stimulation device (vibrating) platform for 10 minutes twice daily for one year. The study hypothesizes participants in the intervention arm intervention will demonstrate improved total bone mineral content for height, spinal and tibial bone mineral density and tibial bone strength when compared to those who are randomized to the placebo intervention."
224218312|NCT01010230|DEVICE|LMHF mechanical stimulation placebo device|"Participants will be randomly assigned to stand on a low magnitude, high frequency mechanical stimulation device (vibrating) platform for 10 minutes twice daily for one year. The study hypothesizes participants in the intervention arm intervention will demonstrate improved total bone mineral content for height, spinal and tibial bone mineral density and tibial bone strength when compared to those who are randomized to the placebo intervention."
224218313|NCT01799213|DRUG|Meloxicam 15 mg po QD|Eligible subjects will be take Meloxicam 15 mg po QD
224218314|NCT01799213|BEHAVIORAL|Cognitive Behavioral Therapy|Subjects originally assigned to placebo will receive cognitive behavioral therapy for 10 weeks
224218315|NCT01188070|BEHAVIORAL|Usual Care|Educational materials
224218316|NCT01188070|BEHAVIORAL|Psycho-education|Educational group sessions
224218317|NCT01188070|BEHAVIORAL|Psycho-education plus physical exercise|Psychoeducation intervention plus an individualized exercise program
224218318|NCT01629693|DEVICE|Lotrafilcon B contact lenses|Silicone hydrogel contact lenses (sphere or toric) per subject's habitual prescription
224218319|NCT01629693|DEVICE|Comfilcon A contact lenses|Silicone hydrogel contact lenses (sphere or toric) per subject's habitual prescription
224218320|NCT04728737|OTHER|swallowing therapy|oral exercises, tongue movement, and compensatory techniques, swallowing maneuvers and food modifications, will be performed by an experienced speech and language therapist during intervention
224218321|NCT04728737|OTHER|IOPI therapy|tongue muscle strengthening and endurance exercises by using 15-min IOPI biofeedback program. The biofeedback will be 50%-60% of maximal strength. (total 1 hour/session for 10 sessions)
224218322|NCT04728737|OTHER|neuromuscular electrical stimulation (NMES) therapy|"The neuromuscular electrical stimulation (NMES) therapy with VitalStim therapeutic device will be done by one physician who is licensed practitioner and certified in use of the VitalStim device. The placement of 2-channel electrodes is depended on the dysphagic types and the clinical swallowing disorders with for oropharyngeal muscles~(1 hour/session for 10 sessions)"
224218323|NCT01818037|PROCEDURE|Cataract surgery|
224218324|NCT03779100|DRUG|Lenvatinib|12 mg (or 8 mg) once daily (QD) oral dosing.
224218325|NCT03779100|DRUG|PD-1 antibody|3mg/kg intravenously every 2 weeks
224218326|NCT00812435|DRUG|eptifibitide|Patients will be randomized to eptifibatide or no eptifibatide. If randomized to eptifibatide: 180 mcg/kg Bolus; 2 mcg/kg/min infusion immediately prior to primary PCI or at the time of PCI and for 18 - 24 hours following the PCI Second 180 mcg/kg Bolus 10 min after the first
224218327|NCT06078995|DRUG|Tenecteplase|Thrombolysis wtih rhTNK-tPA
224218328|NCT06078995|DRUG|Alteplase|Thrombolysis wtih rt-PA
224218329|NCT01782950|DRUG|Rifampicin, Isoniazid, Ethambutol, Pyrazinamide|Rifampicin, Isoniazid, Ethambutol, Pyrazinamide: 3, 4 or 5 tablets daily for weight below 55kg, above 55kg or above 70kg respectively for first 2 months followed by Rifampicin, Isoniazid: 3, 4 or 5 tablets daily for patients' weight below 55kg, above 55kg or above 70kg respectively for 4 months
224218330|NCT00951899|DRUG|Colesevelam|Colesevelam hydrochloride; three 625mg tablets taken orally twice per day before breakfast and before the evening meal over a 12-week treatment period.
224218331|NCT00951899|OTHER|Placebo|Three placebo tablets matching the active drug colesevelam in appearance, taken orally twice per day before breakfast and before the evening meal over a 12-week treatment period.
224218332|NCT00951899|BEHAVIORAL|Diet|Subjects were instructed to follow a weight maintenance diet (\~55% carbohydrate, 30% fat and 15% protein) for the 12 week study period.
224218333|NCT00951899|DRUG|Metformin|Subjects continued to take their pre-study therapeutic doses of metformin (Metformin 500mg tablets taken by mouth twice daily for a total daily dose of 1000 to 2000 mg) through the 12 week study period.
223629620|NCT03234699|DRUG|Bupropion Pill|150 mg (Days 1 and 99)
223629621|NCT00694629|DRUG|rifampin|tablet, 10 mg/kg, daily, 8 weeks
223629622|NCT00694629|DRUG|rifapentine|tablet, 10 mg/kg, daily, 8 weeks
224218334|NCT01101581|DRUG|Veltuzumab and 90Y-Epratuzumab Tetraxetan|Veltuzumab will be administered subcutaneously in phase 2. 90Y-Epratuzumab tetraxetan will be administered intravenously. Veltuzumab is given once weekly for 4 weeks. 90Y-Epratuzumab is also given at treatment weeks 2 \& 3 (days 8 \& 15).
223629623|NCT00694629|DRUG|rifapentine|tablet, 15 mg/kg, daily, 8 weeks
224218335|NCT01101581|DRUG|90Y-epratuzumab tetraxetan|
224218336|NCT01101581|DRUG|veltuzumab|Veltuzumab will be administered subcutaneously on days 1, 8, 15 and 23
224218337|NCT02151162|BEHAVIORAL|Mindfulness-based stress management program|Mindfulness-based stress management program will be conducted by senior nurses in four individual sessions within these three months. Senior nurses have taken a 7-hour workshop including lectures and role-playing sessions. The detailed manual and videos including lectures will be provided to the senior nurses.
224218338|NCT02151162|DIETARY_SUPPLEMENT|Omega-3 fatty acids pills|Omega-3 fatty acids pills will include 1200 mg of eicosapentaenoic acid and 600 mg of docosahexaenoic acid per day.
224218339|NCT02151162|BEHAVIORAL|Psychoeducation leaflet|Psychoeducation leaflet will include information about screening of stress, sleep hygiene, relaxation, and a list of consultants about mental health.
223629624|NCT00694629|DRUG|rifapentine|20 mg/kg, daily, 8 weeks
223629625|NCT06547619|DRUG|Insulin aspart|insulin aspart is perfused at 5 ascending concentrations (10\^-8M - 10\^-4 M) for 10 minutes each
223629626|NCT06084026|OTHER|ActivPal|Participants will wear the activity meter (a small button like device) on their thigh for a period of 7 days at the following time-points: baseline, 6, 12, 18, 24, 30 and 36 months. The meter will be placed on their thigh at a research visit and mailed back to the study team after 7 days.
224218340|NCT02151162|DIETARY_SUPPLEMENT|Placebo pills|Placebo pills will include rapeseed oil, soybean oil, olive oil and fish oil.
224218341|NCT04929522|PROCEDURE|local anesthesia|technique for local anesthesia
224218342|NCT01585831|DRUG|Testosterone gel 1%|Testosterone gel will be administered on a daily basis. The gel will be dispensed in a syringe, and the specific amount of gel to be applied each day will be determined by the study endocrinologist after reviewing labs.
224218343|NCT01585831|DRUG|Placebo gel|The placebo gel will be administered on a daily basis. The gel will be dispensed in a syringe, and the specific amount of gel to be applied each day will be determined by the study endocrinologist.
224218344|NCT04580524|PROCEDURE|Repair of ventral hernia using biologic mesh|Ventral hernia will be repaired using biologic mesh
224218345|NCT04580524|PROCEDURE|Repair of ventral hernia using suture repair or synthetic mesh|Ventral hernia will be repaired using the current treatment methods
224218346|NCT05182983|OTHER|Tongue images，coating on the tongue and clinical data|Take photos of the tongue of patients with gastrointestinal diseases and collect clinical information.
224317613|NCT03229135|DEVICE|other antibacterial agents，breathing machine|If treatment failure for patients in group A，group B，group C and group D，change dose of teicoplanin or other antibacterial agents. Mechanical ventilation was adopte.Treatment failure was defined as no improvement or worse of clinical symptoms, laboratory data, requiring change of teicoplanin therapy.
223629627|NCT05472090|DRUG|TNX-102 SL|Patients will take 1 tablet of randomly assigned study drug sublingually starting on Day 1 for 2 weeks. At the Week 2 visit, all patients will have the dose increased to 2 tablets for 12 weeks.
223629628|NCT05472090|DRUG|Placebo SL Tablet|Patients will take 1 tablet of randomly assigned study drug sublingually starting on Day 1 for 2 weeks. At the Week 2 visit, all patients will have the dose increased to 2 tablets for 12 weeks.
223629629|NCT04227470|DRUG|HBM9161 Injection|Subcutaneous injection; Weekly administered for a period of 4 weeks. All subjects are treated with the testing drug, add on intravenous methylprednisolone (ivMP) with gradually reduce the dose then to oral prednisone. After the administration of the testing drug, if the subject's symptoms get worsen, a rescue therapy need to be adopted as based on Investigator's judgement, the testing drug injection should be discontinued.
223629630|NCT05968716|OTHER|Social needs screening protocol|Pediatric hospital ward stakeholders will develop and implement a social needs screening protocol designed to screen families of hospitalized children for social risk factors and then provide resources to address their social needs. The intervention will consist of the protocol that is developed and implemented.
224218347|NCT01077349|PROCEDURE|high volume hemofiltration|(80 ml/kg/h or a maximum of 8L/h) for 48 hours following heart surgery. Hemofiltration will be stopped after 48h if diuresis \>1500 ml without diuretics and if IV infusion of catecholamines is less than 0.1 microg/kg/min of epinephrine, 0.2 microg/kg/min of norepinephrine or the sum of epinephrine + nor epinephrine/2 is less than 0.1 microg/kg/min. In other cases, hemodiafiltration (CVVHDF) will be initiated until the above objectives are reached, with equal flow rate of dialysate and reinfusion fluid, the sum of which being \<35 ml/kg/h (or a maximum of 3500 ml/h).
224218348|NCT01077349|PROCEDURE|standard care|"extra-renal replacement therapy (CVVHDF mode, total effluent \<35 ml/kg/h or a maximum of 3500 ml/h) will be initiated only if the following criteria are met:~* Serum creatinine \> 350 micromol/L or increase x3.0 from pre-operative value OR~* Diuresis \< 0.3 ml/kg/h for 24 hours despite adequate fluid resuscitation OR~* Or serum urea \> 36 mmol/l OR~* Or life threatening hyperkalemia"
224218349|NCT03222167|DRUG|Elbasvir/ Grazoprevir 50/100 mg fixed dose combination|Enrolled patients will be treated by Elbasvir/ Grazoprevir 50/100 mg fixed dose combination during 12 week. Followed-up on week 24. SVR12 will be evaluated.
224218350|NCT06016413|DRUG|Nab paclitaxel|All patients received nab-paclitaxel 260 mg/m2 intravenously on day 1 of each 3-week cycle for 3 cycles.
224218351|NCT06016413|DRUG|Carboplatin|All patients received carboplatin AUC=5 intravenously on day 1 of each 3-week cycle for 3 cycles.
224218352|NCT06016413|DRUG|adelbelimumab|All patients received carboplatin AUC=5 intravenously on day 1 of each 3-week cycle for 3 cycles.
224218353|NCT04621097|DEVICE|pulsed electromagnetic field|it is a device for magnetotherapy and it is one of the most recent noninvasive physical therapy modality which is used in multiple physical therapy fields . it consist of an appliance, motorized bed and solenoid . the appliance must be connected to electrical supplying 230 =10% at a frequency of 50 or 60 HZ with earth connection . the intensity and spatial lay out of the generated magnetic field depend on the type of solenoid used
224218354|NCT04621097|OTHER|treadmill training|supervised treadmill walking exercise. The exercise program consists of intermittent walking bouts to moderate claudication pain alternating with periods of rest in between for a total of 40-50 minutes .
224218355|NCT04621097|DRUG|Medication|regular medications
223629631|NCT03495661|PROCEDURE|Decompression|Central decompression of the stenotic segment(s) with undercutting of the lateral recesses.
223629632|NCT03827434|DEVICE|Continuous glucose Monitoring Devices and Clarity Software|Patients with DM2 at the intervention group will be managed by Continuous glucose Monitoring and Clarity software
224218356|NCT02015299|DRUG|Linagliptin|one tablet linagliptin 5 mg/day for 26 weeks
224218357|NCT02015299|DRUG|placebo|one tablet matching placebo/day for 26 weeks
224218358|NCT02046369|DRUG|Lurasidone|Lurasidone flexibly dosed 20-80 mg once daily
224218359|NCT02046369|DRUG|Placebo|Placebo Comparator once daily
224218360|NCT02398500|BIOLOGICAL|LMG324|IVT injection
224218361|NCT02398500|BIOLOGICAL|Ranibizumab 0.5 mg|IVT injection
224218362|NCT02398500|BIOLOGICAL|Sham|Fake injection used for masking purposes
224218363|NCT03120520|DRUG|Plecanatide|
223629633|NCT03827434|OTHER|Point of Care (POC) blood glucose|Testing Blood Glucose levels with Point of Care (POC) blood glucose
224218364|NCT03120520|DRUG|Matching placebo|
224218365|NCT05264766|DEVICE|Cooling helmet on|Cooling helmet with circulating cold water
224218366|NCT05264766|DEVICE|Cooling helmet off|Cooling helmet without circulating cold water
224218367|NCT04385199|BIOLOGICAL|Convalescent plasma|One 200mL transfusion of ABO compatible convalescent plasma over 3 hours
224218368|NCT01508156|DRUG|IDX719|IDX719 liquid suspension (1 - 100 mg) taken by mouth.
224218369|NCT01508156|DRUG|Placebo|Placebo liquid suspension matching IDX719 taken by mouth.
224218370|NCT03927781|DRUG|Pregabalin 300mg|One 300mg capsule will be administered PO 1 hour before surgery
223629634|NCT06699823|OTHER|Greek version of QoR-15|Greek version of QoR-15
223629635|NCT06705101|DRUG|Gabapentin Group (Group G): Patients will receive 300 mg of oral Gabapentin|In this study, the intervention involves administering 300 mg of oral gabapentin to patients in the intervention group two hours prior to surgery, aiming to assess its efficacy in attenuating the pressor response to laryngoscopy and tracheal intubation.
223629636|NCT06705101|OTHER|Placebo Oral Tablet|The placebo group will receive an identical capsule without active medication, administered two hours before surgery, to compare its effects with those of gabapentin on the pressor response to laryngoscopy and tracheal intubation.
224218371|NCT05023954|DIAGNOSTIC_TEST|Blood test|Drop of blood for RNA and metabolic analysis
224218372|NCT06085742|DRUG|Cyclophosphamide|60mg/m2 PO once a day (21 continuous days)
224218373|NCT06085742|DRUG|Methotrexate|10mg/m2 PO BID on days 1, 8, and 15
224218374|NCT06085742|DRUG|Capecitabine|825mg/m2 PO BID on days 1-14
224218375|NCT03707483|COMBINATION_PRODUCT|combination of vitamin C and platelet rich fibrin|combination of vitamin C and platelet rich fibrin
224218376|NCT06460987|DRUG|Finerenone|Taking the maximum tolerated dose of finerenone based on serum creatinine and blood potassium levels
224218377|NCT06460987|DRUG|RAS inhibitor|Receive RAS inhibitor treatment as specified in the KDIGO guidelines
224218378|NCT06460987|DRUG|Immune Suppressant|Receive immune suppressant treatment as specified in the KDIGO guidelines
224218379|NCT04147481|OTHER|Group Abdominal Nerve Block with local anesthetics|surgical under general anesthesia combined with transversus abdominis plane block (TAPB) and/or rectus sheath block (RSB) with 0.2% ropivacaine
224218380|NCT04147481|OTHER|Group Abdominal Nerve Block with saline|surgical under general anesthesia combined with transversus abdominis plane block (TAPB) and/or rectus sheath block (RSB) with not 0.2% ropivacaine but 0.9% saline.
224218381|NCT02551003|DRUG|Autologous cord blood|Autologous cord blood will be collected after birth and administered in divided aliquots during the first 3 days of life. At the same time, babies will referred to neonatal intensive care unit for hypothermia therapy of cooling to 33.5 ℃ body temperature for 72 hours and standard intensive care.
223629637|NCT06706089|OTHER|Nurse-led educational intervention|"This nurse-led educational intervention included: a) an oral training session regarding glaucoma by the P.I. lasting 15 minutes, b) provision of printed informational material (leaflet) and c) provision of appropriately selected free informational videos from the World Glaucoma Association on the YouTube -online platform. All of the above mentioned educational methods focused on the disease, its treatment and its long-term management. The oral training session took place in an appropriate, quiet and clean area, respecting the patient's privacy. During this process, study participants had the opportunity and time to ask questions and ask for clarifications or additional information."
223629638|NCT06722378|OTHER|Access to medical notes|Inpatient notes shared in real-time on a hospital-owned bedside tablet linked to their child's records.
223629639|NCT06749314|PROCEDURE|Lumbar Endoscopic - Unilateral Laminotomy for Bilateral Decompression|The LE-ULBD: Lumbar Endoscopic - Unilateral Laminotomy for Bilateral Decompression is a single portal through lamina with instrument to decompression both side of the spinal canal, giving strength of preserve facet joint, preserve spinal musculature, mitigate the risk of adjacent fusion and lesser bleeding
223629640|NCT06887582|PROCEDURE|Free-hand sinus lift augmanted by particulate autologous dentin graft + free-hand implant placement|The sinus will be lifted and augmented by particulate autologous dentin graft followed by simultaneous free-hand implant placement
223629641|NCT06887582|PROCEDURE|AI-assisted/computer-guided sinus lift augmanted by particulate autologous dentin graft + computer-guided implant placement|The sinus will be lifted and augmented by particulate autologous dentin graft followed by simultaneous implant placement. all the procedures will be computer-guided with assistance of artificial intelligence
223629642|NCT06887582|PROCEDURE|Free-hand sinus lift with autologous dentin block graft +free-hand immediate implant placement|The sinus will be lifted and augmented by autologous block dentin graft followed by simultaneous free-hand implant placement
223764114|NCT01485523|OTHER|Nasal provocation test|"TPNC to dust mite has an interest in the diagnosis of allergic rhinitis to dust mites when there remains a doubt due to the poly sensitization of the patient, or the lack of specific symptoms and / or the variability of the allergic symptoms during the year. However, this test has not completely validated with a study including a significant number of patients. That's why we plan a prospective single-center comparative open study with the main objective is to determine the sensitivity and specificity of conventional nasal provocation test (TPNC) in 120 patients of 18 to 65 years old with allergic rhinitis sensitized to dust mites and patients with allergic rhinitis not sensitized to dust mites. Our secondary objective is to compare the TPNC a faster TPN-called minute (60 minutes) and which allow a wider use. If we demonstrate the validity of TPN then it would become the gold standard needed to decide on a desensitisation to mites."
224218382|NCT02551003|DEVICE|Hypothermia|Hypothermia therapy of cooling to 33.5 ℃ body temperature for 72 hours and standard intensive care.
224218383|NCT02983526|DEVICE|Total hip replacement (2 different designs)|Patients will randomly receive either CFP or Corail stem
224218384|NCT00874900|OTHER|Educational game|"Quest for the Code is an educational asthma computer game. Participants randomized to this intervention will have access to the game for a minimum of one hour while receiving treatment in the Seattle Children's Emergency Department."
224218385|NCT00874900|OTHER|Educational game + motivational interview|"Quest for the Code is an educational asthma computer game. Participants randomized to this intervention will have access to this game for a minimum of one hour while receiving treatment in the Seattle Children's Emergency Department (ED).Before leaving the ED, participants in this group will have a brief asthma goal setting activity using motivational interview techniques."
224218386|NCT00874900|OTHER|Motivational interview|Participant randomized to this group will receive standard care for the treatment of their asthma, including an education asthma booklet developed by Seattle Children's. Before leaving the ED, participants in this group will have a brief asthma goal setting activity using motivational interview techniques.
224218387|NCT04124978|DEVICE|mandibular advancement device|use of prefabricated adjustable mandibular advancement device to improve OSA
224218388|NCT06025175|RADIATION|Low level Lazer therapy|30 patients will receive low level lazer therapy 3 times a week for 12 weeks.
224218389|NCT06025175|OTHER|Routine exercises|30 patients will receive only routine exercises 3 times a week for 12 weeks.
224218390|NCT00198978|DRUG|Cyclophosphamide|
224218391|NCT00198978|DRUG|Dexamethasone / Prednisolone|
224218392|NCT00198978|DRUG|Cytarabine|
224317614|NCT03955003|BEHAVIORAL|Group Drumming|Cancer patients will be led by a Board Certified Music Therapist to participate in group drumming for one hour per week, for six weeks.
224317615|NCT03955003|OTHER|Attention Control|This is intended to control for time, place, and group affect.
224218393|NCT00198978|DRUG|Idarubicin|
224218394|NCT00198978|DRUG|Granulocyte-Colony-Stimulating Factor|
223629643|NCT06887582|PROCEDURE|AI-assisted/computer-guided sinus lift with autologous dentin block graft +computer-guided immediate implant placement.|The sinus will be lifted and augmented by autologous block dentin graft followed by simultaneous implant placement. all the procedures will be computer-guided with assistance of artificial intelligence
223629644|NCT06784154|OTHER|Non-interventional|Non-interventional
223629645|NCT06887595|PROCEDURE|Free-hand linear micro perforation osteotomy and ridge splitting|AI-assisted/computer-guided linear micro perforation osteotomy and ridge splitting
224218395|NCT00198978|DRUG|Mercaptopurine|
224218396|NCT00198978|DRUG|Methotrexate|
224218397|NCT00198978|DRUG|Rituximab|
224218398|NCT00198978|DRUG|HDARAC|
224218399|NCT00198978|DRUG|Vincristine|
224218400|NCT00198978|DRUG|Depocyte|
224218401|NCT00198978|DRUG|Asparaginase|
223629646|NCT06887595|PROCEDURE|AI-assisted/computer-guided linear micro perforation osteotomy and ridge splitting|AI-assisted/computer-guided crestal ridge splitting expansion after linear micro perforation osteotomy will be performed using electromagnetic mallet
223629647|NCT05324358|DRUG|Ketorolac Tromethamine|Ketorolac tromethamine, alcohol free formulation, 1.0 mg/mL in saline solution (\~0.9% NaCl) adjusted to a pH of \~7.4. Contained in a sterile, 200 mL polyolefin bag (filled with 125 mL of NTM-001).
223629648|NCT05324358|DRUG|Morphine Sulfate|Morphine single use vials at 4 mg/mL, filled with 1 mL.
223629649|NCT05324358|OTHER|Intravenous Placebo for NTM-001|Placebo alcohol free saline solution (\~0.9% NaCl; matching active NTM-001). Contained in a sterile, 200 mL polyolefin bag (filled with 125 mL Placebo solution).
223629650|NCT05324358|OTHER|IV Placebo for Morphine|Placebo single use vials with saline (matching active morphine).
223629651|NCT05038475|DIAGNOSTIC_TEST|COVID-19 antibody test|FDA-approved Immunoassays were used in the study. At the beginning of the study, up to 3 months, ELISA and CLIA immunoassays were adopted to analyze the antibody titers. Thereafter, CLIA was used for longitudinal analysis of antibody titers for consecutive months. Anti
223629652|NCT03402737|RADIATION|Stereotactic body radiotherapy|"The range of dose-painting will be escalated in following levels:~* 2x 6-8Gy (day 1-4)~* 3x 6-8Gy (day 1-4-7)~* 3x 6-10Gy (day 1-4-7)~* 3x 6-12Gy (day 1-4-7)~Patients will take cyclophosphamide orally 50 mg tablets, 1 tablet a day from the first day of irradiation for 8 consecutive weeks.~Nivolumab will be considered as standard therapy in patients with cisplatin refractory locoregional disease recurrence. Nivolumab will be administered as per current standard of care. In case patients that are treated with nivolumab will be included in the trial, they will not be treated with cyclophosphamide."
223629653|NCT04079361|DIAGNOSTIC_TEST|Blood samples|Bood samples during prenatal and postnatal visits
223629654|NCT06933927|OTHER|(Group A: Bioflx crowns)|Minimal preparation will be required due to their flexural adaptability:1. Choose an appropriately sized Bioflex (Nusmile) crown of similar size to the mesiodistal width.2. The tooth will be prepared using a flame stone for occlusal reduction by 1-1.5 mm, including the central groove .3Proximal preparation will be around 0.5 mm, by using a fine, long, tapered diamond stone to cut interproximal slices mesially and distally.4. The crown will be placed with a snug fit and cemented using glass ionomer
223629655|NCT06933927|OTHER|(Group B) : Preformed Zirconia crown|1\. Size Determination can be achieved by holding a crown up to the existing tooth or, if available, using digital x-ray measurements to match the patient's interproximal width to the corresponding crown size.2. OcclusalPerform an occlusal reduction of about 1.5-2 mm, ensuring adequate space for the crown material. 3. Axial ReductionReduce the buccal and lingual surfaces uniformly, ensuring the removal of any prominent buccal bulges to allow for a passive crown fit. 4. Interproximal ReductionClearance: Ensure sufficient interproximal space by removing enough tooth structure to allow the crown to seat without interference.5. Subgingival PreparationMargin Placement: Extend the preparation subgingivally by approximately 2 mm to achieve optimal crown retention and aesthetics. This involves removing the chamfer margin at the tissue level and ensuring a smooth transition from the root to the coronal tooth structure
223629656|NCT06932198|DRUG|Selexipag Film Coated Tablets|1 tablet
223629657|NCT06932198|DRUG|Uptravi® Film Coated Tablets|1 tablet
223629658|NCT06935136|DRUG|Axicabtagene Ciloleucel|A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells
223629659|NCT03641937|DEVICE|INVSENSOR00011|INVSENSOR00011 - investigational sensor that will be placed on the subject's chest and/or back for the duration of the study.
223629660|NCT06706349|BEHAVIORAL|APA managed by qualified instructor|Each session will be led by a qualified APA professional and will include a mix of aerobic, anaerobic, and 'mind-body' activities like yoga, tailored to participant preferences. Intensity will range from moderate to vigorous, with activities such as walking, cycling, and club-based exercises for at least 20 minutes per session. Participants will be progressively involved in session planning to support continued practice post-study. Heart rate monitoring will be used during exercises like the 6-minute walk test and chair rise test, while a daily activity calendar will help ensure adherence, documenting session dates, durations, subjective intensity, and activity type.
223629661|NCT06706349|BEHAVIORAL|Autonomous APA|A leaflet highlighting the importance of non-sedentary behavior according to WHO recommendations will be provided to them. They will have the opportunity to engage in physical activity autonomously according to their preference.
223629662|NCT01350999|DRUG|omega-3-acid ethyl esters 90 (TAK-085)|Omega-3-acid ethyl esters 90 (TAK-085) capsules. Each one gram of fatty acid in TAK-085 contains approximately 465 mg of EPA plus 375 mg of docosahexaenoic acid-ethyl as ethyl esters.
223629663|NCT01350999|DRUG|Eicosapentaenoic acid-ethyl (EPA)|EPA-E capsules
223629664|NCT03593499|DRUG|omaveloxolone|
223629665|NCT01594619|DRUG|Naloxegol|Oral 25mg tablet
223629666|NCT01594619|DRUG|Diltiazem XR|Oral 240mg tablet
223629667|NCT03593044|DRUG|0.01% concentration atropine drops|One drop of 0.01% concentration atropine in each eye at night for seven days.
223629668|NCT05805020|PROCEDURE|cellvizio|During surgery an intravenous injection of fluorescein will be performed. The surgeon will, then, evaluate the ileal section margins on the mucosa, the serosa and the mesentery to evaluate if the section margin in microscopically inflammatory or not. She/he will then evaluate (in cm) the length between this section margin and the theorical section margin to be on a non-inflammatory tissue on the mucosa, serosa and mesentery. The data will be filled during surgery, blind from the pathological analysis. The pathological analysis will also be blind from the Cellvizio data. A video collection will be performed anonymously.
224218402|NCT04382456|DIETARY_SUPPLEMENT|acacia gum|Two sachets (à 5 g) in the morning and two sachets in the evening, reconstituted in 120 ml water and stirred until fully dissolved to be taken 10 minutes before meals.
224218403|NCT00003290|BIOLOGICAL|gonadotrophin releasing hormone|
224218404|NCT00003290|RADIATION|radiation therapy|
224218405|NCT06225778|OTHER|Exercise|6-week online exercise group
224218406|NCT02028702|DIETARY_SUPPLEMENT|Placebo|water with color
224218407|NCT02028702|DIETARY_SUPPLEMENT|Red Clover extract|Red Clover extract containing 80 mg Isoflavones. Dosage: 2 X 75 ml/day
223629669|NCT01869907|DRUG|Minocycline|100 mg once daily by mouth during 14 days
223629670|NCT01869907|DRUG|placebo|once daily by mouth during 14 days
223629671|NCT01869907|DRUG|Amitriptyline|25mg once daily by mouth during 14 days
223629672|NCT04449913|BEHAVIORAL|10 days intensive meditation retreat|The intervention consists in a 10 days contemplative retreat, with 6 to 8 hours of sitting and walking meditation per day, and 1 or 2 hours of meditation teachings. The meditation practice will mainly train in mindfulness practice. Mindfulness meditation intends to train attention to detect and regulate afflictive cognitive and emotional patterns. Mindfulness practice requires skills involved in openness to experience, in monitoring the focus of attention and in detecting distraction, disengaging attention from the source of distraction, and flexibly (re)directing and engaging attention to the intended object. A brief introduction to loving-kindness and compassion meditation will also be present throughout the retreat.
223629673|NCT04449913|BEHAVIORAL|Waiting for a 10 days intensive meditation retreat|At the time of measure, participants in this group are waiting to participate to the same meditation retreat as the active group. They may perform their own daily meditation practices as usual.
223629674|NCT05183178|DRUG|Prasugrel 10 mg p.o|Prasugrel 10 mg once daily p.o. Patient \>75 years of age or \<60 kg will receive 5 mg prasugrel OD.
223629675|NCT05183178|DRUG|Ticagrelor 90 mg|Ticagrelor 90 mg twice daily p.o.
223629676|NCT03316092|DIAGNOSTIC_TEST|optical coherence tomography|screening and monitoring all patients who are to use or have been using oral Hydroxychloroquine
224218408|NCT00512187|OTHER|low calorie diet|Low calorie diet was designed to achieve a loss of 5-10% of initial weight. All enrolled patients received a balanced diet scheme, based on a caloric intake reduction related to BMI and sex (range 1200-1500 Kcal/day for women, 1300-1600 Kcal/day for men). Calorie intake consisted approximately of 60% carbohydrates, 25% fat, 15% protein
224218409|NCT05482087|DRUG|XZP-3621|ALK inhibitor-treated ALK-positive NSCLC treatment
223629677|NCT00193336|DRUG|ZD1839|
223629678|NCT01766050|DRUG|Caffeine|
223629679|NCT01766050|DRUG|Losartan|
223629680|NCT01766050|DRUG|Omeprazole|
223629681|NCT01766050|DRUG|Dextromethorphan|
223629682|NCT01766050|DRUG|Midazolam|
223629683|NCT01766050|BIOLOGICAL|Belatacept|
223629684|NCT06349798|DRUG|Nefopam|20 mg nefopam in 50 ml of saline, during a 30 min infusion, before end of procedure, then a similer bolus every 4 h for 24 h (6 injections in total) + continuous intravenous infusion of placebo (2 mL/h saline)
223764115|NCT06414057|OTHER|Offering opportunistic HPV vaccine during routine sexual health clinic visits|Investigators will offer Gardasil-9 and HPV self-swab screening to up to 500 individuals across the three study sites, aiming to recruit 120-180 individuals within each of the three participating health boards over a 6-9 month timeframe. Participants will be asked to provide a vaginal swab sample for baseline HPV testing.
223764116|NCT04804462|DEVICE|Virtual Reality Meditation|After donning the VR headset, participants will be able to use a handheld controller to choose from several virtual outdoor settings, three types of meditation, and three session lengths. After choosing their desired option, participants will experience virtual reality meditation in the desired virtual location, of the desired meditation type, and for the allotted duration chosen.
224218410|NCT01901211|OTHER|Exergaming Intervention|The exergaming system will be installed into the participants' homes. Players will pedal the exergame bike in order to move their game avatar. Headsets allow players to communicate with each other in real-time. Participants will play the games 3 to 5 times per week, during scheduled game times. Players will wear a heart rate (HR) monitor and will achieve game benefits for reaching their target HR. They will be asked to exercise in a target HR zone of 40-65%HR reserve. Each week, participants will receive a call from a research assistant (RA), who will provide feedback on their exercise progress and a HR goal for each week. The RA will also record physical and social activities engaged in and any difficulties like leg pain or technical issues.
224218411|NCT04713228|DEVICE|ARTSENS Pen|ARTerial Stiffness Evaluation for Noninvasive Screening
224218412|NCT02133352|DRUG|Ranolazine|Single arm- ranolazine, initiated at 500 mg BID and increased to 1000 mg BID as tolerated
223629685|NCT06349798|DRUG|Nefopam|20 mg nefopam in 50 ml of saline, during a 30 min infusion, before end of procedure, then a bolus of placebo every 4 h for 24 h (6 injections in total) + continuous infusion of 100 mg nefopam over 24 h (in 48 mL saline, 2 mL/h)
224218413|NCT00133315|DRUG|Infliximab|
223629686|NCT06349798|DRUG|NaCl 0.9%|50 ml of saline, during a 30 min infusion, before end of procedure, followed by a bolus of placebo every 4 hours for 24 hours (6 injections in all) + continuous infusion of placebo (2 mL/h of physiological saline)
223629687|NCT03991780|DRUG|Fostamatinib|All patients will be given treatment with Fostamatinib. The initial treatment dose will be 100mg of Fostamatinib twice daily for 8 weeks. If after 8 weeks the participant has not experienced any side effects and are tolerant of this dose, then the dose will increase to 150mg twice daily. This dose will continue for the duration of the study.
224218414|NCT00133315|DRUG|Etanercept|
224218415|NCT00133315|DRUG|Adalimumab|
224218416|NCT04444752|DRUG|CBP-201|CBP-201 subcutaneous(SC) injection.
224218417|NCT04444752|DRUG|placebo|subcutaneous(SC) injection
223629688|NCT03057093|OTHER|Non interventional study|retrospective noninterventional study
223629689|NCT02361385|OTHER|this is not an interventional study|this is not an interventional study; this is a pilot feasibility study to see whether or not 11CPR28 will be taken up in joints of those known to have active arthritis clinically
223629690|NCT03577275|DRUG|NST-4016 600mg|Likely maximum therapeutic dose of NST-4016
223629691|NCT03577275|DRUG|Placebo oral capsule|Placebo for comparison with moxifloxacin and potential NST-4016 effects
223629692|NCT03577275|DRUG|Moxifloxacin 400mg|Active comparator with known effect on QT interval
223629693|NCT03577275|DRUG|NST-4016 2000mg|Supratherapeutic dose of NST-4016
223629694|NCT00782535|DRUG|CHF 4226 pMDI|Inhaled solution, single therapeutic dose
223629695|NCT00782535|DRUG|CHF 4226 pMDI|Inhaled solution, single supratherapeutic dose
223629696|NCT00782535|DRUG|Placebo|Inhaled solution, single dose of placebo
223629697|NCT05866666|DEVICE|Cardiac Performance System (NSR)|Participants will be asked to wear the Cardiac Performance System, a non-invasive sensor device on their upper abdomen. The Cardiac Performance System monitoring device will continuously monitor cardiac function.
223629698|NCT03609645|PROCEDURE|Fascia iliaca block|"FIB Placebo Block: 20mL of Normal Saline Active drug: 20mL of 0.25% Bupivacaine with epinephrine (1:400, 000)~FAB block Placebo Block: 20mL of Normal Saline Active Drug: 20mL of 0.25% Bupivacaine with epinephrine (1:400,000)"
223629699|NCT03609645|PROCEDURE|Femoral articular branches block(FAB)|"FIB Placebo Block: 20mL of Normal Saline Active drug: 20mL of 0.25% Bupivacaine with epinephrine (1:400, 000)~FAB block Placebo Block: 20mL of Normal Saline Active Drug: 20mL of 0.25% Bupivacaine with epinephrine (1:400,000)"
223629700|NCT01873937|RADIATION|Red LED|Phototherapy with red LED on temporomandibular area
223629701|NCT01873937|RADIATION|INFRARED LED|Phototherapy with infrared LED on temporomandibular area
224218418|NCT05683314|PROCEDURE|Tranditional open reduction and internal fixation|Under navigation and bone desity projecting method assisted 3D simulation and printing for minimal invasive surgrey
224317616|NCT05382403|DEVICE|Jada® System|This is a U.S. FDA-cleared device intended for treatment of PPH when conservative management is warranted. The device is made of medical grade silicone. The distal end, which is placed in the uterus, is an elliptical loop. The circular cervical seal, just outside the external cervical os, is filled with 60 - 120 mL sterile water. Low-level vacuum (80 ± 10 mm Hg) is applied and pooled blood is evacuated from the uterus as it collapses. Once there is no bleeding, the device remains in the uterus for at least 1 hour. The suction is then disconnected, the seal emptied of water, the device left in place, and the patient monitored for an additional 30 minutes. If bleeding remains controlled, the device is removed. If bleeding is uncontrolled with the Jada® System patients will have surgical intervention with options of uterine vascular ligation, uterine compression sutures or hysterectomy.
224317617|NCT05382403|OTHER|Standard care|Patients in this group will receive care according to the treatment algorithm for PPH from uterine atony at the two teaching hospitals in Ghana. Possible interventions include additional uterotonics, tranexamic acid, and condom catheter balloon uterine tamponade. If bleeding is uncontrolled, patients will have surgical intervention with options of uterine vascular ligation, uterine compression sutures or hysterectomy.
224317618|NCT05603403|DRUG|Probiatop|1 sachet orally, 2 times a day, for 42 days
224317619|NCT05603403|OTHER|Placebo|1 sachet orally, 2 times a day, for 42 days
224317620|NCT02439970|DRUG|Brincidofovir|
224317621|NCT02439970|DRUG|Valganciclovir|
224317622|NCT03092973|DIAGNOSTIC_TEST|Ultrasound|
224317623|NCT06072573|DRUG|Adezunap (AP707)|Sublingual spray with maximum application of 16 actuations per day or a maximum daily dose of 17,6mg THC distributed over 4 daily intakes.
224317624|NCT06072573|DRUG|Placebo|Sublingual spray with maximum application of 16 actuations per day distributed over 4 daily intakes.
224317625|NCT01492920|DIETARY_SUPPLEMENT|Acetyl-L-Carnitine Hydrochloride|Given orally
224317626|NCT01492920|OTHER|Placebo|Given orally
223629702|NCT01873937|RADIATION|LASER|Phototherapy with LASER INFRARED on temporomandibular area
223629703|NCT00576706|DRUG|Rebamipide|Rebamipide 100㎎, 12 weeks
223764117|NCT00872846|DEVICE|BALANCE System intestinal electrical stimulator|The BALANCE System stimulates the duodenum in a specialized way to strengthen the natural contractions and mimic the sensation of fullness (satiety). The patient is expected to feel full after eating smaller amounts of food than normal. In addition, duodenal stimulation has been shown to induce favorable changes in postprandial glucose levels, glucose tolerance testing and insulin levels.
223764118|NCT02372851|DEVICE|Pureit As+ Filter|The Pureit As+ water filter has been developed to effectively remove arsenic (both arsenite and arsenate) from over 300 µg/L to less than 10 µg/L in addition to removing microbial contamination (Institution of Public Health Engineers, 2011). It has an end-of-life indicator and consumables that do not re-contaminate the environment when disposed (Institution of Public Health Engineers, 2011). The technology requires no electricity, but only the replacement of the battery after 1000 L of water filtered (approximately 100 days based on a family of five drinking 2 L/day).
224317627|NCT01492920|OTHER|Questionnaire Administration|Ancillary studies
224317628|NCT01492920|OTHER|Quality-of-Life Assessment|Ancillary studies
224317629|NCT00161863|BIOLOGICAL|FSME-IMMUN NEW 0.25 ml|
224317630|NCT04218578|DIAGNOSTIC_TEST|speckle tracking analysis of transthoracic echocardiogram|analysis at workstation with 2D strain-Speckle tracking echocardiography of transthoracic cardiac echo at baseline and one-year follow up examination
224317631|NCT00492778|RADIATION|3-Dimensional Conformal Radiation Therapy|Undergo 3-dimensional conformal radiation therapy
224317632|NCT00492778|DRUG|Cisplatin|Given IV
223629704|NCT00576706|DRUG|Misoprostol|Misoprostol 200㎍ 12 weeks
223629705|NCT02288286|BIOLOGICAL|2.5IU/ml rabies vaccine(MRC-5 cell) in humans aged 10-20 years old|freeze-dried rabies vaccine(MRC-5 cell) of 2.5IU/ml, 5 doses, 4 weeks interval
223629706|NCT02288286|BIOLOGICAL|2.5IU/ml rabies vaccine(MRC-5 cell) in humans aged 21-50 years old|freeze-dried rabies vaccine(MRC-5 cell) of 2.5IU/ml, 5 doses, 4 weeks interval
224317633|NCT00492778|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
224317634|NCT00492778|RADIATION|Internal Radiation Therapy|Given intracavitarily or interstitially
224317635|NCT05331807|DIETARY_SUPPLEMENT|Omega-3 FA|Two capsules of 1000mg fish oil daily (Each soft gel capsule contains 180mg EPA and 120 mg DHA)
224317636|NCT05331807|DIETARY_SUPPLEMENT|Vitamin D|one capsule of vitamin D3 weekly (one D3 capsule contains 50,000 IU)
224317637|NCT05331807|COMBINATION_PRODUCT|Combined Omega-3 and Vitamin D Supplementation|Two capsules of 1000mg fish oil daily (Each soft gel capsule contains 180mg EPA and 120 mg DHA) and one capsule of vitamin D3 weekly (one D3 capsule contains 50,000 IU)
224317638|NCT01128309|BEHAVIORAL|Stress Reduction Intervention|eight week group program, plus daily homework practice
223629707|NCT02288286|BIOLOGICAL|2.5IU/ml rabies vaccine(MRC-5 cell) in humans aged 51-60 years old|freeze-dried rabies vaccine(MRC-5 cell) of 2.5IU/ml, 5 doses, 4 weeks interval
224317639|NCT01128309|BEHAVIORAL|Active Control intervention|weekly group meetings for eight weeks, plus daily homework practice
224317640|NCT03709511|OTHER|Cardiac rehabilitation|perioperative rehabilitation consists of education, inspiratory muscle training, active cycle of breathing techniques, and early mobilization.
223629708|NCT02288286|BIOLOGICAL|2.5IU/ml rabies vaccine(vero cell) in humans aged 10-20 years old|freeze-dried rabies vaccine(vero cell) of 2.5IU/ml, 5 doses, 4 weeks interval
223629709|NCT02288286|BIOLOGICAL|2.5IU/ml rabies vaccine(vero cell) in humans aged 21-50 years old|freeze-dried rabies vaccine(vero cell) of 2.5IU/ml, 5 doses, 4 weeks interval
223629710|NCT02288286|BIOLOGICAL|2.5IU/ml rabies vaccine(vero cell) in humans aged 51-60 years old|freeze-dried rabies vaccine(vero cell) of 2.5IU/ml, 5 doses, 4 weeks interval
223629711|NCT00089297|BIOLOGICAL|Cetuximab|"Induction: An initial dose of cetuximab (C225) 400 mg/m2 (over 2 hours) was given week 1 only. Then, C225 was administered at dose of 250 mg/m2 (over 1 hour) weekly for 5 weeks.~Concurrent Chemoradiation (Weeks 9-13): C225 was administered at 250 mg/m2/wk (over 1 hour).~Restaging Biopsy of Primary Site (Week 14): Patients with positive biopsy of the primary site at week 7 or patients without a clinical complete response at the primary site after induction therapy were scheduled for re-biopsy of the primary site at week 14 after concurrent therapy (50 Gy). If the biopsy were negative after concurrent therapy, the patients were scheduled to continue concurrent therapy to complete radiation (68-72 Gy).~Additional Concurrent Chemoradiation (weeks 15, 16 and 17): Concurrent therapy was consisted of C225 at 250mg/m2/week IV over 1 hour followed by paclitaxel 30mg/m2/week IV over 1 hour followed by carboplatin AUC = 1/week over 15 minutes and RT for three weeks."
223629712|NCT00089297|DRUG|Carboplatin|"Induction Therapy (Week 1-6): The induction chemotherapy starting at week 1 included paclitaxel 90 mg/m2 IV over 1 hour weekly and carboplatin AUC = 2 IV over 30 minutes weekly. The paclitaxel and carboplatin doses were given on the same day, 1 hour after C225 dose was administered. For paclitaxel and carboplatin therapy, rounding of doses (to next decimal if above 0.5 and to lower decimal if below 0.5) was permitted.~Concurrent Chemoradiation (Weeks 9-13): Concurrent chemotherapy was consisted of paclitaxel following cetuximab at 30 mg/m2/wk (over 1 hour) and carboplatin following paclitaxel at AUC = 1/week (over 15 minutes).~Additional Concurrent Chemoradiation (weeks 15, 16 and 17): Concurrent therapy was consisted of C225 at 250mg/m2/week IV over 1 hour followed by paclitaxel 30mg/m2/week IV over 1 hour followed by carboplatin AUC = 1/week over 15 minutes and RT for three weeks."
224218419|NCT04316052|OTHER|Aerobic training|After the baseline assessment, Following randomization into the exercise group, participants will undergo an exercise program orientation, which will be conducted individually.At the visit, participants will be first instructed in the use of the treadmill, which included heart rate assessment capability. Walking intensity and duration prescriptions will be accordance with recommendations of the American College of Sports Medicine. Participants will be instructed to walk for 45 minutes, including a 5-minute warm-up and 5 min cool-down, at 50% to 80% of their age-predicted maximum heart rate.Over the course of 4 months, each patient will complete 48 sessions. The morning after the 24th and 48nd sessions of aerobic physical exercise, each participant will be assessed completely
224218420|NCT04316052|OTHER|strength training|After the baseline assessment, participants will undergo exercise program orientation, which will be conducted individually. Participants will be instructed to perform 45 min session, two sets of 8 to 12 repetitions of each exercise (2 second hold each up and down hold) for the first 2 weeks to provide an introductory period. In the first session, muscular strength will be assessed using a standardized 10-repetition maximum approach, from which one repetition maximum (1-RM) will be estimated. The exercise prescription for strength training will be made at approximately 50% of the estimated 1-RM.The strength training activities included horizontal leg press, leg extension, leg curl, hip adduction, hip abduction, and seated rotary calf press.
224218421|NCT03137485|PROCEDURE|Conventional open lumbar discectomy|Removal of single level lumbar disc herniation through conventional discectomy.
224218422|NCT03137485|PROCEDURE|Percutaneous Endoscopic Translaminar lumbar discectomy.|Removal of single level Lumbar disc herniation using endoscope.
224218423|NCT03137485|DEVICE|Easy Go system Endoscopy|This system will be used to remove herniated disc in endoscopic group
224317641|NCT01371539|DEVICE|Lotrafilcon B contact lens|Commercially marketed, silicone hydrogel, multifocal contact lens for daily wear use.
224317642|NCT01371539|DEVICE|Comfilcon A contact lens|Commercially marketed (France), silicone hydrogel, multifocal contact lens for daily wear use.
224317643|NCT02006602|DRUG|Candesartan cilexetil (GW615775, Test formulation)|Test formulation candesartan cilexetil 16 mg will be supplied as round, biconvex white tablets with PX 16 embossed in one face and scored in the other face.
224317644|NCT02006602|DRUG|Candesartan cilexetil (Reference treatment)|Reference treatment of candesartan cilexetil 16 mg will be supplied as round, biconvex pink tablets, scored in one face and with embossment in both faces (016 embossment in the plain face and A CH in the scored face).
224317645|NCT06251089|DRUG|CPC mouthwash|0.07% CPC mouthwash
223629713|NCT00089297|DRUG|Paclitaxel|"Induction Therapy (Week 1-6): The induction chemotherapy starting at week 1 included paclitaxel 90 mg/m2 IV over 1 hour weekly and carboplatin AUC = 2 IV over 30 minutes weekly. The paclitaxel and carboplatin doses were given on the same day, 1 hour after C225 dose was administered. For paclitaxel and carboplatin therapy, rounding of doses (to next decimal if above 0.5 and to lower decimal if below 0.5) was permitted.~Concurrent Chemoradiation (Weeks 9-13): Concurrent chemotherapy was consisted of paclitaxel following cetuximab at 30 mg/m2/wk (over 1 hour) and carboplatin following paclitaxel at AUC = 1/week (over 15 minutes).~Additional Concurrent Chemoradiation (weeks 15, 16 and 17): Concurrent therapy was consisted of C225 at 250mg/m2/week IV over 1 hour followed by paclitaxel 30mg/m2/week IV over 1 hour followed by carboplatin AUC = 1/week over 15 minutes and RT for three weeks."
223764119|NCT02420028|DEVICE|Insertion of OptiVein IV catheter|Placement of OptiVein IV catheter inside the vein allowing for fluid or drug delivery or blood withdrawal.
223764120|NCT02420028|DEVICE|Insertion of Vasofix Certo IV catheter|Placement of Vasofix Certo IV catheter inside the vein allowing for fluid or drug delivery or blood withdrawal.
223764121|NCT00106782|PROCEDURE|Transcranial Electrical Polarization (TEP)|
223764122|NCT02155023|DRUG|Insulin dosing|
224317646|NCT06251089|DRUG|Placebo|placebo of the CPC mouthwash
224317647|NCT02393352|OTHER|Dry Needling Therapy|The dry needling therapy will be applied on active trigger points in occipital muscle, splenius capitis, sternocleidomastoid muscle, scalene muscles, trapezius, supraspinatus, infraspinatus muscle, latissimus dorsi, iliocostalis muscle, multifidus muscles, and quadratus lumbourm muscles.
224317648|NCT02393352|OTHER|Electrical Stimulation Therapy|
224317649|NCT03713632|DRUG|Secukinumab|Secukinumab 300mg every 2 or every 4 weeks
224317650|NCT03713632|DRUG|Placebo|Placebo 300mg every 2 or every 4 weeks
224317651|NCT01764399|BEHAVIORAL|Care4U|
223629714|NCT00089297|RADIATION|Radiation therapy|"Concurrent Chemoradiation (Weeks 9-13): Radiation was given at 200cGy/d/5 weeks for a total dose of 50Gy (5000 cGy). Patients with a negative initial biopsy at week 7 were scheduled to continue concurrent therapy to complete radiation (68-72Gy).~If the biopsy was negative after concurrent therapy, the patients were scheduled to continue concurrent therapy to complete radiation (68-72 Gy).~Additional Concurrent Chemoradiation (weeks 15, 16 and 17): Concurrent therapy was consisted of C225 at 250mg/m2/week IV over 1 hour followed by paclitaxel 30mg/m2/week IV over 1 hour followed by carboplatin AUC = 1/week over 15 minutes and RT for three weeks."
224218424|NCT02170129|DEVICE|50% AAB plus 50% autologous bone|"All patients were evaluated clinically and their medical histories were recorded. Preliminary screening, including the acquisition of intraoral and panoramic radiographs, was performed to evaluate potential patients' eligibility. Patients who met the selection criteria received oral hygiene instructions and debridement, if required, after which bone volumes were analysed using cone-beam computed tomography (CBCT; Imaging Sciences International, Hatfield, PA, USA).~A staged approach was carried out at all sites. Thus, sinus lift grafting procedures were followed by implant placement 7-8 months later.~Both groups received tapered implants with an anodised surface."
224218425|NCT02170129|DEVICE|100% AAB|"All patients were evaluated clinically and their medical histories were recorded. Preliminary screening, including the acquisition of intraoral and panoramic radiographs, was performed to evaluate potential patients' eligibility. Patients who met the selection criteria received oral hygiene instructions and debridement, if required, after which bone volumes were analysed using cone-beam computed tomography (CBCT; Imaging Sciences International, Hatfield, PA, USA).~A staged approach was carried out at all sites. Thus, sinus lift grafting procedures were followed by implant placement 7-8 months later. Both groups received tapered implants with an anodised surface."
224218426|NCT00471185|DRUG|Acyline|10, 20 and 40 mg of Oral acyline, given on 3 occasions, separated by 1 week.
223629715|NCT00403377|BEHAVIORAL|Intervention|In the intervention arm, photographs are taken of the participants and they then receive sunscreen lotion and sunless tanning lotion and instructions and benefits for using both. Participants also receive an educational pamphlet regarding skin cancer.
224218427|NCT00206622|DRUG|Climara PRO (Estradiol / Levonorgestrel transdermal)|2.2mg 17 Beta-estradiol/0.69mg levonorgestrel combination transdermal patch
224218428|NCT00206622|DRUG|Menostar (Estradiol transdermal)|1mg 17 Beta-estradiol transdermal patch
224218429|NCT00206622|DRUG|Placebo transdermal|Placebo
224218430|NCT02796898|DRUG|SM88 (Cohort 1)|"* Tyrosine Isomers - 230 mg qd~* Phenytoin - 50 mg qd.~* Methoxsalen - 10 mg qd~* Sirolimus - 0.5 mg qd"
224218431|NCT02796898|DRUG|SM88 (Cohort 2)|"* Tyrosine Isomers - 460 mg (230 mg bid)~* Phenytoin - 50 mg qd~* Methoxsalen - 10 mg qd~* Sirolimus - 0.5 mg qd"
224218432|NCT03782584|OTHER|modified pilates exercise|modified exercises from original pilates exercises.
224218433|NCT03782584|OTHER|daily life advises|they will be given daily life advises to prevent neck pain
224218434|NCT05734170|DIETARY_SUPPLEMENT|Chia Seeds and instant oatmeal breakfast|The final group was to consume one packet of instant oatmeal with two tablespoons of chia seeds mixed in with oatmeal for breakfast for 30 days.
224218435|NCT05734170|DIETARY_SUPPLEMENT|Cheerio Breakfast|Patients were instructed to consume one serving of Cheerios according to package instructions each morning for 30 days.
224218436|NCT05734170|DIETARY_SUPPLEMENT|Instant Oatmeal breakfast|The second group was assigned to consume one packet of instant oatmeal for 30 days.
224218437|NCT06528327|OTHER|Pre coated impants|Pre coated impants with microstructured bioactive antimicrobial coating with double threading for higher bone-to-implant contact and faster bone gathering on the surface.
224218438|NCT06528327|OTHER|Non coated implant surface|Non-coated implant with double threading for higher bone-to-implant contact and faster bone gathering on the surface.
224218439|NCT00579254|DRUG|CADUET (AMLODIPINE 5 mg/ATORVASTATIN 10 mg or 20 mg)|Patients who have been treated with Caduet 5/10 or 5/20 mg single pill treatment, based on their clinical conditions and latest locally approved packet insert recommendations will be eligible to be enrolled to this study
224218440|NCT01208259|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|
224218441|NCT01208259|BEHAVIORAL|Interpersonal Therapy (IPT)|
223629716|NCT05731583|DEVICE|Home pulse oximetry monitoring|A digital application and a wireless oximeter were provided to both groups. Oxygen saturation, heart rate and (optional) body temperature were monitored at least twice a day.
223629717|NCT02825693|PROCEDURE|Conventional cataract surgery (phacoemulsification)|
224218442|NCT02557672|DRUG|Prothrombin complex concentrate (Human)|PCC (Kcentra)
223629718|NCT02825693|PROCEDURE|Femtosecond laser assisted cataract surgery|
223629719|NCT02030808|DRUG|Muscle Relaxants (MR) group|patients received 0.2 mL/kg cisatracurium® (Nimbex) 0.2%, and a left-sided endobronchial double-lumen tube was placed when the TOF revealed one or two twitches
224317652|NCT03543215|OTHER|Radiomics: Analysis of textural features of imaging (MRI and Ultrasound)|All patients with confirmed endometrial cancer will have received Ultrasound and MRI as part of routine standard of care. Textural features from this will be analysed to see if can predict prognosis.
224317653|NCT03744299|OTHER|Questionnaire|Patients and caregivers are asked to complete a questionnaire
224218443|NCT02557672|BIOLOGICAL|Fresh frozen plasma (FFP)|FFP
224218444|NCT05485428|OTHER|High-intensity interval training|12-weeks of high intensity interval exercise, 30 minutes thrice weekly
224218445|NCT00875719|DEVICE|Oxygen concentrators versus constant flow axygen|Each patient performed 2 walking tests, and received oxygen supplementation from a portable concentrator or a liquid oxygen source, in a random order.
224218446|NCT00875719|DEVICE|oxygen concentrator|comparison walk distance and saturation with continuous oxygen compared to intermittent oxygen
224218447|NCT00376428|DRUG|Gentamicin|
224218448|NCT01531868|OTHER|Video|Video of physician
224218449|NCT01531868|OTHER|Video|Video of physician
224218450|NCT01531868|OTHER|Video|Video of physician
224218451|NCT01531868|OTHER|Video|Video of physician
224218452|NCT01531868|OTHER|Video|Video of physician
224218453|NCT01531868|OTHER|Video|Video of physician
224218454|NCT04768023|DRUG|Juvit D3|Dosage based on the BMI as followed: for BMI under 25 - 4000 IU/day, for BMI between 25 and 30 - 5000 IU/day, and for BMI over 30 - 6000 IU/day.
224218455|NCT04768023|DRUG|Placebo|Matching amount of vegetable oil to the vitamin D3.
223629720|NCT02030808|DRUG|Non- Muscle Relaxants (NMR) group|No cisatracurium® (Nimbex) will be administered
223629721|NCT03406377|DRUG|OPK-88003|OPK-88003 subcutaneous injection
223629722|NCT03406377|DRUG|Placebo|Placebo subcutaneous injection
223629723|NCT02900729|DEVICE|Radiofrequency ablation catheter|Subjects will be treated with the renal denervation procedure using WiseGo Catheter System after randomization.
223629724|NCT02900729|DRUG|Amlodipine, losartan potassium and hydrochlorothiazide|Standardised triple anti-hypertensive medications of amlodipine 5 mg per day, losartan potassium 50 mg and hydrochlorothiazide 12.5 mg per day in the first 90 days after randomization. Subjects will be allowed to adjust baseline antihypertensive medications where clinically necessary in the second 90 days after randomization.
223629725|NCT02167971|OTHER|Active Coil|The patients will undergo 10 sessions (2,000 pulses each, lasting 20 minutes) of repetitive transcranial magnetic stimulation over the left dorsolateral prefrontal cortex with the following parameters: 10Hz, 50 trains (40 pulses on each train), biphasic wave, 25 seconds between the trains.
223629726|NCT02167971|OTHER|Sham|The patients assigned to this group will undergo 10 sessions of rTMS but with an inactive coil, which will not generate electromagnetic pulses.
223629727|NCT01806441|OTHER|3-days high fat diet|During 3 days, subjects eat a diet high in fat (percent of total caloric intake: 15.0% from proteins; 49,8% from carbohydrates; 37.0% from fat).
223629728|NCT01806441|OTHER|3-days low fat diet|During 3 days, subjects eat a diet low in fat (percent of caloric intake: 15.0% from proteins; 61,8% from carbohydrates; 25.0% from fats).
223629729|NCT03742076|DIETARY_SUPPLEMENT|High-dose prebiotic|This is a spray-dried powder, yellowish-white in color, that is dissolvable.
223629730|NCT03742076|DIETARY_SUPPLEMENT|Low-dose prebiotic|This is a spray-dried powder, yellowish-white in color, that is dissolvable.
223629731|NCT03742076|DIETARY_SUPPLEMENT|Placebo|Powder fiber supplement, yellowish-white in color, that is dissolvable.
223629732|NCT01910298|PROCEDURE|Breast Reconstruction, Direct to Implant (DTI) with Strattice™|
223629733|NCT01910298|PROCEDURE|Two Stage Breast Reconstruction|
223629734|NCT01673607|PROCEDURE|Biopsie liver|
223629735|NCT04684888|PROCEDURE|Visumax Femto-flap|"Under topical anesthesia \[Tetracaine eye drop 0.5%\]. A-90 µm thick flap was done by using Visumax femtosecond laser. The flap hinge was set to be nasally placed. A nasal-hinge flap with 90 µm thickness, 8.8 mm flap diameter, and 90º side cut angles were created with 500 kHz Visumax FSL, 160 nJ energy \[Carl Zeiss, Meditec, Germany\]. The sphero- cylindrical refractive corrections with optical zone 6.5 mm and ablation zone 8.0 mm were done by excimer laser operating system \[Carl Zeiss, Meditec, MEL 90, Germany\]. Automatic iris registration and pupil-tracking system were activated before photoablation. The patient's eyes were examined postoperatively on a slit-lamp biomicroscope and all treatments that were given for home use have been explained in terms of frequency of instillation, possible side effects, and benefits before discharging them on the same day.~Follow up visits were scheduled clearly on printed patients' discharging cards."
223629736|NCT04684888|PROCEDURE|Sub Bowman's keratomileusis (SBK)-flap|"Under topical anesthesia \[Tetracaine eye drop 0.5%\] .A-90µm flaps done using Maria one use plus SBK mechanical microkeratome with a nasal located hinge. The sphero- cylindrical refractive corrections with optical zone 6.5 mm and ablation zone 8.0 mm were done by excimer laser operating system \[Carl Zeiss, Meditec, MEL 90, Germany\]. Automatic iris registration and pupil-tracking system were activated before photoablation. The patient's eyes were examined postoperatively on a slit-lamp biomicroscope and all treatments that were given for home use have been explained in terms of the frequency of instillation, possible side effects, and benefits before discharging them on the same day.~Follow up visits were scheduled clearly on printed patients' discharging cards~."
223629737|NCT00717574|DRUG|Sevoflurane group|Addition of 60% nitrous oxide for 20 minutes duration, then back to 1:1 oxygen/air mixture.
223629738|NCT00717574|DRUG|Propofol group|Addition of 60% nitrous oxide for 20 minutes duration, then back to 1:1 oxygen/air mixture.
223629739|NCT03795571|DRUG|Rituximab|Rituximab 375mg/m2，d0
223629740|NCT03795571|DRUG|Gemcitabine|Gemcitabine 1000mg/m2，d1，d5
223629741|NCT03795571|DRUG|Oxaliplatin|Oxaliplatin 75mg/m2，d1
223629742|NCT03795571|DRUG|Dexamethasone|Dexamethasone 40mg/d，d1\~d4
223629743|NCT03795571|DRUG|Lenalidomide Oral Capsule|Lenalidomide 10mg/d、15mg/d、20mg/d、25mg/d d1\~d10； 21days a cycle
223629744|NCT02755428|BIOLOGICAL|retinal pigment epithelium transplantation|Transplant retinal pigment epithelium derived from human embryonic stem cells into subretinal space of patients with dry age-related macular degeneration(dry AMD).
223629745|NCT03037385|DRUG|pralsetinib (BLU-667)|pralsetinib (BLU-667) is a potent and selective inhibitor of the RET mutations, fusions, and predicted resistant mutants
223629746|NCT00144547|DRUG|MRA(Tocilizumab)|8mg/kg(i.v.)/4weeks
223629747|NCT04058938|BEHAVIORAL|Educational handout instrument|The handout was single-paged (front and back), and was titled Pain After Surgery: What to Expect. The handout starts with information on rating pain and expectations for control of pain, not complete absence of pain, after surgery. Mutli-modal approach to pain control is then discussed, including pharmacologic and non-pharmacologic methods that may be used for pain control by the perioperative team and postoperatively.
223629748|NCT04058938|BEHAVIORAL|Control|Standard patient counseling
223629749|NCT00558142|DRUG|Acetylcysteine|Participants will receive packs of either 8 placebo capsules or 8 acetylcysteine (600mg) capsules. They will be asked to take 2 tablets at 08.00 and 22.00 on the day before the study and the day of the study. On the day of the study participants will receive an IV infusion of either normal saline or acetylcysteine (200mg/kg)
223629750|NCT00558142|DRUG|Visipaque 320|100mls IV dose as single dose
224317654|NCT01469078|DRUG|Monofer®|Single Bolus Injections
224317655|NCT02751671|PROCEDURE|POCUS|The use of Point-of-care ultrasound before urine sample procedure
223629751|NCT00558142|DRUG|Visipaque 320|The dose of Visipaque will be administered by the consultant cardiologist performing the coronary angiography
223629752|NCT04515771|BEHAVIORAL|PARTNER-MH|The study intervention consisted of a 6-month, manualized, peer-led navigation program. It involved assessing and addressing patients' unmet social needs and barriers to care, delivery of peer support services, navigation to VA mental health services, and psychoeducation.
223764123|NCT02155023|DEVICE|Glucose sensors IR-Glucose Reader (Joanneum Research, Austria), IR-CGM (IMM, Germany)|
224317656|NCT02751671|PROCEDURE|Standard|Urine sampling procedure without prior ultrasound
223629753|NCT01021020|DRUG|Colchicine|0.6mg tablet administered after a fast of at least 10 hours
223629754|NCT01021020|DRUG|Colchicine|0.6mg tablet administered after a standardized high-fat, high-calorie breakfast
223629755|NCT01021020|DRUG|Colchicine/Probenecid|0.5mg/500mg tablet administered after a fast of at least 10 hours
223629756|NCT02535481|DEVICE|Epidermal grafting|The Cellutome Epidermal Graft Harvesting System will be used to harvest epidermal grafts.
223629757|NCT02535481|PROCEDURE|Split thickness skin grafting|Split thickness skin grafting will be performed as per normal clinical practice.
223629758|NCT00879736|BEHAVIORAL|THT PACE Training|Patient training
224218456|NCT04972006|BEHAVIORAL|Remote, intensive intervention for injection phobia|The intervention consists of a 1.5 hour session that provides youth with education about anxiety and a 3 to 4 hour session consisting of graduated exposure to injection fear.
224218457|NCT05323500|OTHER|Senobi breathing exercises|The study participants will be screened first, then trained to perform SBE (1-minute maneuver). Participants will be instructed to stand upright and tighten their gluteal muscle and then ask them to put one foot in front of their body and placing most of their body weight on back foot. Then, ask them to breath in for three seconds simultaneously, by raising their hands in the air above their heads. After this, instruct them to exhale by using their whole body for pushing air out of the lungs. Participants will also guided to tighten all their body muscles while pushing air out. Exhale should last for seven seconds.
224218458|NCT00595387|OTHER|Supportive Psychotherapy|Participants will attend 18 supportive therapy sessions over 5 months. Supportive psychotherapy focuses on reflecting and expressing feelings about current life issues. Participants are supported and comforted when coping with difficult situations, depression, mood swings, or anger.
224218459|NCT00595387|OTHER|Cognitive Behavioral Therapy (CBT)|Participants will attend 18 CBT sessions over 5 months. CBT for depression targets depressive symptoms through a range of different treatments. This includes psychoeducation about the disorder and educating patients about the role of thoughts and behaviors in the maintenance of depressed mood. CBT also includes mood and activity monitoring, activity scheduling, and teaching participants to critically investigate and challenge negative thoughts and core beliefs that help to maintain depression.
224218460|NCT03705169|BIOLOGICAL|SAR441236|Administered by intravenous (IV) infusion(s) or subcutaneous (SC) injection(s)
224218461|NCT03705169|BIOLOGICAL|Placebo|Administered by intravenous (IV) infusion(s) or subcutaneous (SC) injection(s)
224218462|NCT06468683|BIOLOGICAL|After preconditioning with chemotherapy, F01 will be evaluated.|Biological: 0.5-3×10\^9 CAR+NK Cells, Treatment follows a lymphodepletion Drug: Fludarabine: 25-30 mg/m\^2 (D-5\~D-3) Drug: Cyclophosphamide: 250-300 mg/ m\^2 (D-5\~D-3)
224317657|NCT00141089|DRUG|Tegaserod|
224218463|NCT02555059|DRUG|Cipro (Ciprofloxacin, BAYQ3939)|Treatment parameters following the physician's decision based on the summary of product characteristics.
224218464|NCT05839860|OTHER|Salt 3 g|Placebo group taking a breakfast meal and 3g salt on tomatoes before fasting for 7 hours
224218465|NCT05839860|OTHER|Salt 6 g|Intervention group taking a breakfast meal and 6g salt on tomatoes plus 1 L water before fasting for 7 hours
224218466|NCT05839860|OTHER|Salt 9 g|Intervention group taking a breakfast meal and 9g salt on tomatoes plus 1 L water before fasting for 7 hours
224317658|NCT06304246|OTHER|Measurement Pain Threshold|Measurement Pain Threshold: Manual dolorimetry will be used to assess the pain threshold in the non-dominant hand of patients in the preoperative waiting room prior to spinal anesthesia. The dolorimeter head will be placed vertically on the wrist of the non-dominant hand, and pressure will be applied with increments of 1 kg/cm2/s. The pressure applied when the patient perceives pain will be recorded in kg/cm2. The measurement will be repeated three times for each patient, and the average will be recorded as the pain threshold value.
224317659|NCT06304246|OTHER|Measurement of Serum Asprosin|Measurement of Serum Asprosin: For serum asprosin measurements, blood will be drawn in the preoperative waiting room before the application of spinal anesthesia. The blood samples will be centrifuged, and the serum will be stored at -20°C to measure serum asprosin levels. After all patient blood is collected, serum asprosin will be evaluated with a commercially available double antibody sandwich enzyme-linked immunosorbent assay (ELISA) kit.
223629759|NCT00879736|BEHAVIORAL|THT PACE Training|Patient training
223629760|NCT00879736|OTHER|placebo|
224317660|NCT00067743|DRUG|Lenalidomide|supplied as 5 mg capsules. Dosing as directed by physician but to start at 10 mg per day
224317661|NCT04832022|OTHER|Biological samples|Serum and plasma samples. At baseline, 3, 6 and 12 months
224317662|NCT05810103|DRUG|DP303c|DP303c injection, 3.0 mg/kg, every 3 weeks.
224317663|NCT05854524|PROCEDURE|Aerobic exercise|The intervention is exercise and there are no drugs or devices used in this trial. The exercise consists of two intensity levels of a 30-minute aerobic exercise intervention with both arms crossing over to both conditions: low intensity exercise (60-70% of estimated maximum heart rate (EMRH)) and moderate-vigorous intensity exercise (75-85% of EMHR).
223629761|NCT02130817|DRUG|Belatacept|Belatacept will be added to the standard of care regimen and will be given at days 0,5, weeks 2, 4, 8 and 12 (10 mg/kg) and every 4 weeks (5 mg/kg) for one year.
224218467|NCT02053571|PROCEDURE|TIPS with 3D Overlay|
224218468|NCT02101320|DEVICE|TRECAM|using the camera during the surgery
223629762|NCT02130817|DRUG|Tacrolimus withdrawal|Tacrolimus dosing will begin on Days 1 through 5 post transplant at up to 2 mg BID to achieve target trough levels of 9-11 ng/ml. The dose will be tapered through the end of week 2 to achieve a trough level of 4 ng/ml which will be maintained for six weeks. Tacrolimus will be withdrawn at the end of eight weeks post transplant.
223629763|NCT02130817|PROCEDURE|Plasmapheresis/Intravenous Immunoglobulin G|Enrolled patients will start with standard of practice treatment including plasmapheresis and IVIG therapy twice after transplant, on days 2 and 4 and potentially once before transplant. Plasmapheresis and albumin exchange for one volume of blood will be performed in the infusion center at the University of Wisconsin Hospital and Clinics (UWHC). Each pheresis session will be completed by IVIG infusion. While plasmapheresis will help with the removal of circulating Donor Specific Antibodies (DSA), IVIG therapy will provide immunomodulatory characteristics that include sterilizing immunity from infections, inhibiting and scavenging activated complement fragments, modifying cell-mediated immune responses, inducing regulatory T cells and importantly, inhibiting deleterious antibody production.
223629764|NCT02130817|DRUG|Thymoglobulin (ATG)|Thymoglobulin (ATG) Induction. Thymoglobulin will be administered to a total cumulative dose of 4.5-6 mg/kg via a peripheral or central vein, starting in the operating room.
223629765|NCT02130817|DRUG|Myfortic|Patients will receive 720mg bid of Myfortic throughout the study, starting day 1 after surgery.
223629766|NCT02130817|DRUG|Steroids|Patients will receive Dexamethasone IV on the day of surgery (Day 0) with tapered doses through Day 4 followed by prednisone tapered to 10mg/d by day 30.,
223629767|NCT04625504|BEHAVIORAL|Mindfulness Based Intervention|Standardized 8-week Cognitive and Behavioral Psychotherapy group with 26 hrs of in-class training and homework, along with 1 all-day retreat in which core mindfulness skills are developed
223629768|NCT00948246|DEVICE|Easyband®|The Easyband adjustable gastric band device is implanted laparoscopically around the top of the stomach to create a small pouch. Adjustments to increase or decrease the stoma size are made non-invasively by telemetric connection between an internal and external antenna.
223629769|NCT00294450|DEVICE|Fistula Pouching System|3 different sizes of fistula pounching system
223629770|NCT02764385|OTHER|Teachable Moment Communication Process|A clinician-focused intervention designed to guide an approach to discussing smoking cessation during routine primary care visits.
223629771|NCT02764385|OTHER|AAC|A system-based change to the EHR that allows for eReferral to the Quitline coupled with role and process changes for medical technical assistants
223629772|NCT03598036|DRUG|Voclosporin|"Voclosporin softgel capsules. Up to 10 subjects will be enrolled into Cohort 1 and take up to 3 capsules twice daily (BID).~The dose of voclosporin for Cohort 2 (at least 10 subjects) will be determined by analysis of efficacy and safety data at Week 12 from the first 5 or 6 subjects in Cohort 1."
224218469|NCT03625817|BEHAVIORAL|Mountainous setting|The mountainous setting is characterized by lower temperatures (about 8-10C ambient air temp.) than those in urban setting, also having \>800m altitude.Each period will last for 1 week with a wash out period of minimum 2 days. Continuous skin temperature and ambient temperature monitoring will take place in the last day of each period, towards the end. During the 2 sampling days, 24-hour urine voids will be collected in different vials. Participants will be required to fulfill a diary with their daily activities, meal times, collection of urine times, sleep/wake times and times of leaving/entering a closed environment.
224218470|NCT00273247|DRUG|Interferon alpha-2b|
224317664|NCT03861624|PROCEDURE|Intramedullary nailing with standard SIGN nail|Patients meeting eligibility requirements are randomized to either study arm. Patients receive definitive fixation of AO/OTA-42 open tibia diaphyseal fractures using the standard SIGN nail (SIGN Fracture Care International, Richland, WA). The number of interlocking screws is at the discretion of the treating surgeon, who also has the option to use an external fixator for damage control, and later conversion to IMN when clinically appropriate. The experimental group procedure is less common in the study setting, and thus, viewed as the experimental group.
223629773|NCT04665401|BEHAVIORAL|Tailored MERIT|see arm description
223629774|NCT04665401|BEHAVIORAL|Standard MERIT|see arm description
223629775|NCT01820299|DRUG|Grape Seed Extract|All patients enrolled to the study will take Grape Seed Extract alone for 21 days.
223629776|NCT01820299|DRUG|Vitamin D|From Day 22 until Day 64 of the study, patients will take Grape Seed Extract and Vitamin D together. Patients will take Vitamin D once at a day at 4000 IU.
223629777|NCT00593216|DEVICE|Functional MRI imaging|The functional MRI imaging of whole brain will be obtained before, during and after the vestibular response which is induced by the designated caloric stimulation. Post-imaging analysis will reveal which region or neural pathways in the central nervous system may attributed to the development of vertigo.
223629778|NCT03005444|DRUG|Rivaroxaban|10mg/day, for 2 years
223629779|NCT03915197|DIAGNOSTIC_TEST|Pneumological evaluation|Consultation with a pneumopediatrician: collection of respiratory symptoms, respiratory treatments, evaluation of the atopic site and environmental risk factors for bronchial aggression, especially passive smoking
223629780|NCT05119647|DEVICE|Thrombus Aspiration Catheter(Ton-bridgeMT)|Thrombus Aspiration Catheter is a developed technique for treating acute stroke caused by artery occlusion. The catheter(Ton-bridgeMT) was specially designed for those patients who experience acute stroke within 24 hours.
223629781|NCT06600347|DIETARY_SUPPLEMENT|DASH diet|The participants will be treated with the DASH diet (1600-1800 calories/ day) for three months, in addition to antihypertensive drugs.
223629782|NCT06600347|OTHER|Progressive muscle relaxation|The participants will be treated with progressive muscle relaxation for 30 minutes, 3 times/week for 3 months, in addition to antihypertensive drugs.
224218471|NCT06424925|OTHER|Artificial intelligence for the prediction of clinical outcomes|Use of artificial intelligence (AI) for the prediction of clinical outcomes such as death and complications in patients hospitalized for COVID pneumonia during the 4 pandemic waves
224218472|NCT01305317|DRUG|Lipitor|Atorvastatin 20mg daily for 6 months
223629783|NCT06600347|DRUG|Anti hypertensive drugs|All participants in all groups will be treated with antihypertensive drugs as prescribed from the physician
223629784|NCT04199351|DRUG|AMG 171|2 SAD cohorts of 8 subjects per cohort randomized 3:1 in Part A; 1 cohort of 8 subjects 3:1 ratio in Part B; and 24 subjects enrolled into 1 of 3 cohorts with 8 subjects randomized to receive 2 to 3 consecutive doses (titration) 3:1 ratio in Part C.
223629785|NCT04199351|DRUG|Placebo|AMG 171 placebo
223629786|NCT01497041|DRUG|Docetaxel|Docetaxel (diluted in 250 ml of 5% dextrose solution, over 60 minutes) 35 mg/m2 IV (D1, D8) every 3 weeks
223629787|NCT01497041|DRUG|Oxaliplatin|Oxaliplatin (diluted in 500 ml of 5% dextrose solution, over 120 minutes) 60 mg/m2 IV D1 every 3 weeks
223629788|NCT04888117|PROCEDURE|Laparoscopic cholecystectomy|With the patient under general anesthesia, several small incisions are made in the abdomen. Ports are placed, the abdomen is insufflated, and laparoscopic instruments as well as a laparoscope are inserted to complete the cholecystectomy according to the surgeon's standard practice.
223764124|NCT01625247|PROCEDURE|Surgical drainage|Postoperative abdominal drainage were connected to a 200-mL closed suction reservoir. The drainage was removed if there are drainage amount less than 20 mL and color was serous color.
224317665|NCT03861624|PROCEDURE|External Fixation with uniplanar Dispofix external fixator|Patients meeting eligibility requirements are randomized to either study arm. Patients receive definitive fixation of AO/OTA-42 open tibia diaphyseal fractures using the uniplanar Dispofix external fixator with two Shanz screws placed proximally and two Schanz screws placed distally to fracture site with a single stainless steel bar.The active comparator group procedure is more common in the study setting, and thus, viewed as the comparator group.
224317666|NCT00687024|PROCEDURE|Magnetoencephalography|MEG will be performed on a whole head Omega 151-channel gradiometer system. At least 15 2-minute periods of spontaneous data are recorded. The sampling rate for data acquisition is 625Hz, with a bandpass filter of 3 to 70 Hz and a notch filter of 60Hz.
224317667|NCT00687024|PROCEDURE|MR imaging|MR imaging will be performed on a GE 1.5T system using a variety of sequences, including sagittal T1, axial T2, axial FLAIR, coronal dual echo, coronal FLAIR, axial 3D T2 frFSE and axial SPGR.
223629789|NCT04888117|PROCEDURE|Robotic-assisted cholecystectomy|With the patient under general anesthesia, several small incisions are made in the abdomen. Ports are placed, the abdomen is insufflated, and the da Vinci Robotic Surgical System (Intuitive) is docked to the patient and used to complete the cholecystectomy according to the surgeon's standard of care.
223629790|NCT01838694|BIOLOGICAL|Ala-Cpn10|
224218473|NCT05256732|DRUG|AT-527 fasted|AT-527 administered twice daily (BID) for 5 days fasted
224218474|NCT05256732|OTHER|Placebo Comparator fasted|Matching placebo administered twice daily (BID) for 5 days fasted
224317668|NCT00687024|PROCEDURE|Diffusion Tensor Imaging|Diffusion tensor imaging will be performed on the same scanner, using single shot diffusion-weighted echo planar imaging. Twenty-five 'xial contiguous slices are obtained aligned to the anterior commissure line to cover the whole brain, giving a total imaging time of 4min 40sec.
224317669|NCT06168487|DRUG|Telmisartan|Patients will be given telmisartan alone or with standard of care chemotherapy.
224317670|NCT06168487|OTHER|Standard of Care Regimen|Standard of Care Regimen
224317671|NCT05671536|BEHAVIORAL|motivational interview|Intervention arm will receive motivational interview by the researcher, once a month for 4 times at least 20 minutes. The researcher received education about motivational interview.
224317672|NCT02813941|OTHER|Current GRADE SoF table|The current GRADE SoF table will be the common comparator for the other two SoF tables
223629791|NCT01838694|DRUG|Placebo|
223629792|NCT05306925|DIETARY_SUPPLEMENT|Arginine|The intervention infants will receive either parenteral nutrition which contains additional arginine (up to 18% arginine content) or a separate arginine infusion to provide up to 18% arginine. This is in comparison to standard parenteral nutrition which has an arginine content of 6.3%.
223629793|NCT00055393|DRUG|Bupropion|18 subjects in this randomly controlled double blind study received bupropion.
223629794|NCT00055393|DRUG|Placebo|21 subjects received Placebo.
223629795|NCT03623243|DRUG|Siponimod|Siponimod 2mg tablets taken once daily
223629796|NCT04511481|OTHER|Radiomic Algorithm|Different radiomic and machine learning strategies for radiomic features extraction, sorting features and model constriction
223764125|NCT01248299|DRUG|FU-CDDP|"every 21 days:~* Fluoro-uracil \[800 mg/m2, day 1 to day 5\]~* CisPlatin \[75 mg/m2, day 1 or day 2\]"
223764126|NCT01248299|DRUG|LV5FU2-CDDP|"every 14 days:~* Elvorin \[200 mg/m2, 2h IV, day 1 and day 2\]~* Fluoro-uracil \[400 mg/m2 as a bolus, day 1 and day 2\]~* Fluoro-uracil \[600 mg/m2, 22h continous infusion, day 1 and day 2\]~* CisPlatin \[50 mg/m2, day 2\]"
223764127|NCT01248299|DRUG|FOLFOX|"every 14 days:~* Oxaliplatin \[85 mg/m2 by 2h infusion, day 1\]~* Fluoro-uracil \[400 mg/m2 as a bolus, day 1 and day 2\]~* Fluoro-uracil \[600 mg/m2, by 22h continous infusion, day 1 and day 2\]~* Elvorin \[500 mg/m2, day 1 and day 2\]"
224218475|NCT05256732|DRUG|AT-527 fed|AT-527 administered twice daily (BID) for 5 days fed
224218476|NCT05256732|OTHER|Placebo Comparator fed|Matching placebo administered twice daily (BID) for 5 days fed
224218477|NCT05256732|DRUG|AT-527|AT-527 administered twice daily (BID)
224218478|NCT05256732|DRUG|AT-527 single dose|AT-527 single dose fasted/fed cross-over
224218479|NCT01347398|PROCEDURE|PSG|Sleep study made by PSG (polysomnography)
224218480|NCT01347398|PROCEDURE|MicroMESAM system|Sleep study made by MicroMESAM system
224218481|NCT06653517|DRUG|Dabrafenib|"Dosage: 150 mg orally, twice daily (total daily dose of 300 mg) Administration: Administer at approximately 12 hours apart. Take at the same time each day. If a dose is missed and less than 6 hours remain until the next dose, skip the missed dose. Do not open, crush, or break the capsules.~Usage in Combination: When used in combination with trametinib, trametinib should be taken once daily at the same time as either the morning or evening dose of dabrafenib to ensure synchronization of the treatment schedule."
224218482|NCT06653517|DRUG|Trametinib|"Dosage: 2 mg orally, once daily Administration: Administer at least 1 hour before or 2 hours after a meal. Take at the same time each day. If a dose is missed, it should be taken no later than 12 hours before the next scheduled dose; otherwise, skip the missed dose.~Usage in Combination: When used in combination with trametinib, trametinib should be taken once daily at the same time as either the morning or evening dose of dabrafenib to ensure synchronization of the treatment schedule."
224218483|NCT05911347|DIETARY_SUPPLEMENT|Psyllium|15g psyllium added to inulin solution to form a gel
224218484|NCT05911347|DIETARY_SUPPLEMENT|Methylcellulose|15 g methylcellulose added to inulin solution to form a gel
224218485|NCT05911347|DIETARY_SUPPLEMENT|Maltodextrin|15g maltodextrin added to inulin solution to form a gel
224218486|NCT05214157|PROCEDURE|active gas aspiration|sucking remaining Co2 from the peritoneal cavity and local anaesthetic application at port sites
224218487|NCT02148783|DRUG|methylphenidate|This is an open-labeled 4 week methylphenidate administration, 30 mg twice daily by mouth. Placebo and methylphenidate will also be administered as a single dose before one of the two PET and TMS sessions, in a single blinded manner (the participant will not know whether active drug or placebo was administered). PET imaging with \[11C\]-raclopride, a D2/D3 receptor ligand will be performed after administration of placebo or oral methylphenidate to measure endogenous DA release in TBI patients. Structural MRI will be performed before methylphenidate administration. TMS after placebo or methylphenidate will be performed to measure intracortical inhibition and dopaminergic activity.
224317673|NCT02813941|OTHER|Alternative GRADE SoF table|The alternative GRADE SoF table format will be developed from a user-testing survey.
224317674|NCT02813941|OTHER|EPC SoF table|For the EPC SoF table, the investigators will use one of their format which was recently published
223629797|NCT00492245|PROCEDURE|PTK with mitomycin in Adenoviral Opacities|
223629798|NCT03365102|DEVICE|anodal tDCS over the rIFG,|tDCS at a constant current of 1.5 milliampere (mA) will be applied for one 20-minute session over the right inferior frontal gyrus . Resting-state EEG for 10 minutes will be recorded immediately prior to and after tDCS. After post-tDCS resting state EEG is acquired, EEG is recorded to extract Evoked Response Potentials in a single-blind procedure. The participants and assessors will be blind to experimental condition.
223629799|NCT03365102|DEVICE|anodal tDCS over the lOFC,|tDCS at a constant current of 1.5 mA will be applied for one 20-minute session over the left orbitofrontal cortex . Resting-state EEG for 10 minutes will be recorded immediately prior to and after tDCS. After post-tDCS resting state EEG is acquired, EEG is recorded to extract Evoked Response Potentials in a single-blind procedure. The participants and assessors will be blind to experimental condition.
223764128|NCT01248299|DRUG|TPF|"every 21 days:~* Docetaxel \[30 mg/m2, day 1 and day 8\]~* CisPlatin \[60 mg/m2, day 1\]~* Fluoro-uracil \[200 mg/m2/day by continous infusion\]~Or every 21 days:~* Docetaxel \[50 mg/m2, day 1\]~* CisPlatine \[70 mg/m2, day 1\]~* Fluoro-uracile \[700 mg/m2 /day, day 1 to day 5\]"
224218488|NCT02148783|DRUG|Placebo|
224218489|NCT00634192|DRUG|tobramycin|1x300mg/d inhaled
224218490|NCT00634192|DRUG|tobramycin|2x300mg/d inhaled
224218491|NCT06157333|DEVICE|The Magstim Rapid2 Plus Magnetic Stimulator (Magstim, Whitland, Dyfed, UK)|The Magstim Rapid2 Plus Magnetic Stimulator (Magstim, Whitland, Dyfed, UK) device available in our center was used.
224218492|NCT01759537|DEVICE|Ankylos dental endosseous implants-Sub-crestal|Implants placed subcrestally
224218493|NCT01759537|DEVICE|Ankylos dental endosseous implants-Epi-crestal|Implants placed Epi-crestally
224218494|NCT06315608|DRUG|MRG-001|MRG-001 is a clear liquid solution for subcutaneous injection
224218495|NCT06684405|DIETARY_SUPPLEMENT|sodium sodium fluoride solution (0.75 mg for subjects aged 12 and 1.0 mg for subjects aged 13)|
224218496|NCT06684405|DIETARY_SUPPLEMENT|Subjects in the control group received a daily dose of 0.5 ml sterile water to be added to 200 ml of milk.|
224218497|NCT05519267|BEHAVIORAL|MBSWSC|MBSWSC is a unique mindfulness-based programme for social work and self-care which has been specifically developed for online delivery. The MBSWSC programme is embedded within key cognitive and emotion regulation, and stress coping theory (Maddock et al. 2019a). This programme combines mindfulness practices with psychoeducation with the aim of allowing participants to reduce any negative thinking about the past and future by learning skills that will allow them to focus on the present. It will also focus on how to effectively apply these newly acquired mindfulness skills in social work practice. The MBSWSC programme comprises 6x1.5 hour sessions, delivered weekly, over a 6 week period. Homework, in the form of mindfulness practices, is given each week. This will take approximately 20-30 minutes to complete, on 6 out of 7 days, each week.
224218498|NCT05519267|BEHAVIORAL|MBSC|MBSC is a modified, condensed Mindfulness Based Intervention; with a key focus on self-compassion. Key practices in this condensed programme were chosen for their relevance and utility to social workers. The MBSC programme comprises 3x1 hour sessions delivered over a 6 week period, with one session every two weeks. Homework, in the form of mindfulness practices, is given each week. This will take approximately 20-30 minutes to complete, on 6 out of 7 days, each week.
224218499|NCT00420290|DRUG|kineret|100 mg administered subcutaneously every other day (3 days a week during hemodialysis) for 4 weeks
224218500|NCT00420290|DRUG|placebo|100 mg administered subcutaneously every other day (3 days a week during hemodialysis) for 4 weeks
224218501|NCT06542003|BEHAVIORAL|Movin' and Groovin' for Wellness|Movin' and Groovin' for Wellness (MGW) is a 10-week program consisting of facilitated drumming and dancing sessions. The sessions include guided activities involving drumming, dancing, and group improvisation. Each session lasts approximately 1.5 hours, with activities designed to improve mental well-being, enhance social connections, and foster creative expression. The sessions are guided by professional facilitators.
224317675|NCT01602393|DRUG|CHF 5074 1x|oral tablet, 1x, once a day in the morning for 48 weeks
224218502|NCT06703931|DEVICE|Measures performed on all subjects|In intensive care Medics will use a reference medical device and Thermodiag®. Simultaneous and synchronised measurements will be taken every minute.
223764129|NCT01248299|OTHER|Best Supportive Care|See European professionnal recommendations (ESMO 2009) Exemples : antalgic treatment, nutritional support, ...
224218503|NCT06703905|PROCEDURE|Expanded pancreaticoduodenectomy surgery|Traditional minimally invasive pancreaticoduodenectomy combined with the TRIANGLE procedure
224218504|NCT06703905|PROCEDURE|Pancreaticoduodenectomy|Traditional minimally invasive pancreaticoduodenectomy
224218505|NCT06703749|DEVICE|Treatment with BTL-899M|The treatment administration phase will consist of four (4) treatments, delivered 5-10 days apart. The applicators of BTL-899M will be applied over the designated area. Each therapy session will last 30 minutes. The starting intensity of the radiofrequency energy will be set to 100%. The intensities of both energies will be adjusted according to the patient's feedback.
224218506|NCT06703749|DEVICE|Treatment with BTL-899M with intensities below therapeutic threshold|The treatment administration phase will consist of four (4) treatments, delivered 5-10 days apart. The applicators of BTL-899M will be applied over the designated area. Each therapy session will last 30 minutes. The intensities of both energies will be set below the therapeutic threshold.
224317676|NCT01602393|DRUG|CHF 5074 2x|oral tablet, 2x, once a day in the morning for 48 weeks
224317677|NCT01602393|DRUG|CHF 5074 3x|oral tablet, 3x, once a day in the morning for 48 weeks
224317678|NCT01730924|PROCEDURE|Pulmonary vein isolation using contact force sensing catheter|
224317679|NCT05063851|DRUG|Memantine Hydrochloride Tablets|The recommended starting dose of memantine hydrochloride/placebo is 5 mg once daily. The dose should be increased in 5 mg increments to 10 mg/day (5 mg twice daily), 15 mg/day (5 mg and 10 mg as separate doses), and 20 mg/day (10 mg twice daily). The minimum recommended interval between dose increases is one week. The dosage shown to be effective in controlled clinical trials is 20 mg/day.
223764130|NCT03546751|DEVICE|Continuous Positive Airway Pressure|This device delivers air pressure non invasively through a mask to stent open the upper airway to prevent obstruction during sleep. This is an FDA approved device that has been used for several decades to treat OSA.
223629800|NCT03365102|DEVICE|sham tDCS stimulation condition|In the sham condition, the current will be ramped up to 1.5 mA for 30 seconds and then ramped back down to 0. As this commonly used sham procedure produces a brief tingling sensation, participants are kept unaware of their experimental condition. Resting-state EEG for 10 minutes will be recorded immediately prior to and after the sham tDCS. After post-sham stimulation resting state EEG is acquired, EEG is recorded to extract Evoked Response Potentials in a single-blind procedure. The participants and assessors will be blind to experimental condition.
223629801|NCT00331201|DRUG|SAFEstart|
223629802|NCT01801163|DRUG|Sorafenib|Sorafenib x 2 weeks followed by Stereotactic Radiotherapy and then sorafenib until disease progression.
223629803|NCT01801163|RADIATION|Stereotactic radiotherapy|Sorafenib x 2 weeks followed by Stereotactic Radiotherapy then Sorafenib until disease progression.
223629804|NCT02177695|DRUG|Gemcitabine|Gemcitabine, 1000 mg/m2, IV (in the vein) on Days 1 and 8 of each 21 day cycle. Number of Cycles: 4 cycles or until progression or unacceptable toxicity develops.
224218507|NCT06703112|DIAGNOSTIC_TEST|An auxiliary diagnostic model for ovarian tumors|Through collaboration among gynecological oncology teams from three research centers, the multimodal ovarian tumor auxiliary diagnosis system will undergo multicenter, prospective clinical application, with surgical pathology results used as the gold standard. The diagnostic performance of the multimodal ovarian tumor auxiliary diagnosis system, both overall and across different pathological categories, will be evaluated in the main and subsidiary centers by comparing metrics such as specificity, sensitivity, positive predictive value, negative predictive value, and area under the ROC curve (AUC).
224218508|NCT01883518|BIOLOGICAL|Autologous dendritic cell vaccine|Autologous dendritic cell vaccine loaded with allogeneic tumor lysate expression of cancer testis antigens
224218509|NCT03174509|PROCEDURE|Positive pressure extubation|Positive pressure ventilation without endotracheal aspiration/suction during extubation procedure.
224218510|NCT03174509|PROCEDURE|Traditional during extubation|Spontaneous ventilation with endotracheal aspiration/suction during extubation procedure.
224218511|NCT02597283|DEVICE|Biguard sirolimus-eluting bifurcation stent system|PCI with Biguard sirolimus-eluting bifurcation stent system
224218512|NCT02597283|DEVICE|Sirolimus-eluting stent system|PCI with sirolimus-eluting stent system
224218513|NCT02657083|DEVICE|DreaMed Substance Administration Device|"2 exercise days under DreaMed MD-AID control with afternoon exercise (in the time between 16:30 and 19:30).~New infusion set and two continuous glucose sensors (one for back-up) will be inserted in the subcutaneous tissue of the arm and then calibrated the day before each visit from 3 to 6.~The continuous glucose sensor continuously will measure interstitial glucose levels and these values will be sent by the Minilink™ via wireless, low-powered, radio frequency to the Paradigm Veo every 5 minutes for up to 6 days.~The DreaMed MD-AID uses a vendor-supplied and self-developed (communication module) communication application programming interface (API) in order to retrieve glucose / insulin data from the Paradigm Veo and set insulin treatment according to the algorithm decision."
224317680|NCT05063851|DRUG|Placebo|The recommended starting dose of memantine hydrochloride/placebo is 5 mg once daily. The dose should be increased in 5 mg increments to 10 mg/day (5 mg twice daily), 15 mg/day (5 mg and 10 mg as separate doses), and 20 mg/day (10 mg twice daily). The minimum recommended interval between dose increases is one week. The dosage shown to be effective in controlled clinical trials is 20 mg/day.
224317681|NCT01098474|BIOLOGICAL|GSK's investigational vaccine 692342|Intramuscular, 1 or 2 doses
224317682|NCT01098474|BIOLOGICAL|Tritanrix™ HB+Hib|Intramuscular, 3 doses
224317683|NCT01098474|BIOLOGICAL|Prevnar™|Intramuscular, 3 doses
224317684|NCT01098474|BIOLOGICAL|Polio Sabin™|Oral, 3 doses
224317685|NCT01098474|BIOLOGICAL|Menjugate™|Intramuscular, 3 doses
224317686|NCT01139229|OTHER|hybrid everted esophagogastric anastomosis|
224317687|NCT01139229|OTHER|the conventional hand-sewn anastomosis|
223629805|NCT02177695|DRUG|Cisplatin|"Cisplatin, 70 mg/m2, IV (in the vein) on Day 1 of each 21 day cycle (or Day 1 or 2 of each 14 day cycle).~Number of Cycles: 4 cycles or until progression or unacceptable toxicity develops."
223629806|NCT02177695|DRUG|Methotrexate|Methotrexate, 30 mg/m2, IV (in the vein) on Days 1 of each 14 day cycle. Number of Cycles: 4 cycles or until progression or unacceptable toxicity develops.
223629807|NCT02177695|DRUG|Vinblastine|Vinblastine, 3 mg/m2, IV (in the vein) on Days 1 or 2 of each 14 day cycle. Number of Cycles: 4 cycles or until progression or unacceptable toxicity develops.
223629808|NCT02177695|DRUG|Doxorubicin|Doxorubicin, 30 mg/m2, IV (in the vein) on Days 1 or 2 of each 14 day cycle. Number of Cycles: 4 cycles or until progression or unacceptable toxicity develops.
223629809|NCT02177695|DRUG|Filgrastim|Filgrastim, 5 mcg/kg, SubQ/IV (in the vein) on Days 3-7 of each 14 day cycle. Number of Cycles: 4 cycles or until progression or unacceptable toxicity develops.
223629810|NCT04445961|DIAGNOSTIC_TEST|Respiratory mechanics measurement|Measurement of peak inspiratory pressure, plateau pressure, calculation of static compliance and driving pressure
223629811|NCT04445961|DIAGNOSTIC_TEST|Gas exchange measurement|Measurement of arterial oxygen and tension and arterial dioxide tension, calculation of arterial partial oxygen tension to inspiratory oxygen fraction (PaO2/FiO2) ratio and alveolar dead space
223764131|NCT03546751|OTHER|Diet And Exercise|This will consist of weekly telephone and monthly face to face visits to monitor and suggest measures to improve diet and regular exercise as conducted by a registered dietician.
223629812|NCT04323696|PROCEDURE|Staple line suturing reinforcement methods - Plication and Over-sewing|Sleeve gastrectomy procedure will be performed laparoscopically. The greater curvature of the stomach will be mobilised, and stomach will be sleeved using 39F calibration tube as the stent using 5-6 60 mm-stapler reloads depending on the length and thickness of the stomach. The staple-line is then reinforced using 3/0 absorbable sutures continuously throughout the staple-line. The two staple-line suturing methods in this study include over-sewing (through and through) and plication (Lembert).
223629813|NCT02986217|OTHER|regular structured assessment of surgical performance|
224317688|NCT01139229|OTHER|a stapled anastomosis|
224317689|NCT04128189|BIOLOGICAL|Shingrix|Both arms receive standard 2 doses of Shingrix. Transplanted subjects may receive 3rd dose.
224317690|NCT05847829|DEVICE|T-REEX algorithm|Phase locked transcranial stimulation.
224317691|NCT05560386|BEHAVIORAL|Text messaging|text messaging content to support diabetes prevention.
224317692|NCT05560386|BEHAVIORAL|Virtual workshop|virtual workshop content to support diabetes prevention.
224218514|NCT02657083|DEVICE|Sensor Augmented Pump (SAP)|"2 exercise days under Sensor Augmented Pump with afternoon exercise (in the time between 16:30 and 19:30).~New infusion set and two continuous glucose sensors (one for back-up) will be inserted in the subcutaneous tissue of the arm and then calibrated the day before each visit from 3 to 6.~The continuous glucose sensor continuously will measure interstitial glucose levels and these values will be sent by the Minilink™ via wireless, low-powered, radio frequency to the Paradigm Veo every 5 minutes for up to 6 days.~During the exercise the group will turn off the insulin pump and lower their basal insulin for 20% for the next 4 hours after the exercise"
224218515|NCT03423589|DIETARY_SUPPLEMENT|VSL#3|VSL#3 is a commercially available probiotic supplement manufactured and distributed by Alfasigma USA, Inc of Covington, Louisiana, USA. As with other probiotics, VSL#3 is considered a supplement and is not FDA-approved or regulated. VSL#3 contains eight probiotic strains: bifidobacteria (B. longum, B. infantis, and B. breve), lactobacilli (L. acidophilus, L. casei, L. bulgaricus, and L. plantarum) and Strepococcus thermophiles.
224218516|NCT05689034|DRUG|Azvudine|Azvudine po. 5mg daily for 7 days
224218517|NCT05689034|DRUG|Placebo|Placebo po. 5 tablets daily for 7 days
224218518|NCT03877237|DRUG|Dapagliflozin|Tablets administered orally once daily. Treatment start within 24h after randomisation for 16 weeks.
224218519|NCT03877237|OTHER|Placebo|Tablets administered orally once daily. Treatment start within 24h after randomisation for 16 weeks.
224218520|NCT00944437|DEVICE|Helmet|Continuous positive airway pressure for up to 24 h. Initial pressure will be 5 cmH2O, and will be increased by 2-3 cmH2O up to 10 cmH2O, in order to maintain SpO2 ≥90%.
224218521|NCT00944437|DEVICE|Full-face mask|Continuous positive airway pressure for up to 24 h. Initial pressure will be 5 cmH2O, and will be increased by 2-3 cmH2O up to 10 cmH2O, in order to maintain SpO2 ≥90%.
224218522|NCT03843437|DEVICE|Tencel Therapeutic Garments|Children age 6 months to 3 years will wear a Tencel full body suit with feet and mittens, while children age 3-6 years will wear Tencel long-sleeve shirts and pants that do not cover the hands and feet. Children will wear the study garments at night but may also wear garments during the day if desired.
224218523|NCT03843437|DEVICE|Cotton Therapeutic Garments|Children age 6 months to 3 years will wear a cotton full body suit with feet and mittens, while children age 3-6 years will wear cotton long-sleeve shirts and pants that do not cover the hands and feet. Children will wear the study garments at night but may also wear garments during the day if desired.
224218524|NCT03610178|OTHER|Life-style modification, insulin therapy if needed|All patients are assigned to life-style modification (diet and physical exercise). If target glucose levels (\<5.1 mmol/L fasting and \<7.0 mmol/L postprandial) are not achieved insulin therapy is started
224218525|NCT03610178|OTHER|Life-style modification, insulin therapy if needed|All patients are assigned to life-style modification (diet and physical exercise). If target glucose levels (\<5.3 mmol/L fasting and \<7.8 mmol/L postprandial) are not achieved insulin therapy is started
224218526|NCT03104088|DIAGNOSTIC_TEST|CANTAB|CANTAB Cognitive Assessment (tablet based cognitive testing from CAMCOG)
224218527|NCT03104088|DIAGNOSTIC_TEST|MOCA|Montreal cognitive assessment (MOCA) in German
224218528|NCT05058937|DIAGNOSTIC_TEST|Comprehensive genomic profiling|TSO500 (523 genes + MTB + MSI)
224218529|NCT02464878|DRUG|Alpha 1-Antitrypsin|Patients will receive three times a week AAT infusions in the peri-transplant period for three weeks.
224218530|NCT02464878|PROCEDURE|Islet Transplantation|
224218531|NCT02464878|DRUG|Thymoglobulin|Patients will receive a total of 5 doses between Day -2 and Day +2
224218532|NCT02464878|DRUG|Basiliximab|Basiliximab will be used for subsequent transplants.
224218533|NCT02464878|DRUG|Etanercept|Etanercept will be given on the day of transplant and on Days 3, 7, and 10 post-transplant.
224218534|NCT02878278|DRUG|Chidamide BIW|Chidamide is given 30mg, twice a week
224218535|NCT02878278|DRUG|Chidamide QD|Chidamide is given 10mg,QD
224218536|NCT04180254|PROCEDURE|Effect of several processing on the auditory distance perception|The focus is a comparison of hearing instrument algorithms on the auditory distance perception
224218537|NCT01073683|PROCEDURE|laryngoscopy|Treatment of advanced larynx cancer with induction TPF, in order to decide between chemoradiation and laryngeal preservation surgery
224218538|NCT01073683|DRUG|Taxotere (Docetaxel), Cisplatin, 5FU|Taxotere 75 mg/m2 D1, Cisplatin 75 mg/m2 D1, 5FU 750 mg/m2 D1-4
224218539|NCT00959387|DRUG|Induction TP chemotherapy|3 cycles of paclitaxel 175mg/m2 and cisplatin 80mg/m2 q3w. All patients received supportive care during radiotherapy, including dietary measures, local antiseptics and laser therapy as preventive and curative support for oral mucositis.
224218540|NCT00959387|RADIATION|Chemoradiotherapy (CRT)|Patients were treated with 2-dimensional radiation therapy planning (6MV photon beams). A combination of lateral-opposed portals, anterior and lateral wedged fields was used to treat the primary tumor and the lymph nodes. The primary tumor, macroscopically affected lymph nodes and bilateral cervical plus supraclavicular lymph chains were treated with five fractions of 2Gy per week for 5 weeks (up to a total of 50Gy). Gross tumor volume was defined as the primary gross tumor or involved node, and this measure was based on clinical, radiological and endoscopic examinations. An additional margin of 1.0cm was added to the GTV to create the CTV. A boost of five fractions of 2Gy per week for 2 additional weeks (up to a total dose of 70Gy) was prescribed to the CTV plus a margin of 1.0cm.
224218541|NCT04719247|PROCEDURE|Pulpotomy|Irreversibly damaged dental pulp is partially removed and a dressing either Turmeric or Thymus Vulgaris or Nigella Sativa or Aloe Vera is placed. Clinical and Radiographic signs and symptoms are assessed and compared with Formocresol.
224218542|NCT00142454|DRUG|Imiquimod|Patients applied imiquimod cream at bedtime every day for 5 consecutive days (for the first 5 days of Cycles 1-3 and for the first 4 days of Cycle 4) at a dose of 250 mg as supplied in single-use packets to a 4 x 5 cm area of healthy skin, alternating among the extremities (upper inner arms and inner thighs) in each cycle. The cream was to be rubbed into the skin until it was no longer visible. Patients were encouraged to wash their hands before and after applying cream. The application site was not occluded. The next morning, 6 to 10 hours after initial application, the treated area was washed with mild soap and water to remove any residual cream.
224218543|NCT00142454|BIOLOGICAL|NY-ESO-1 protein|NY-ESO-1 protein was injected intradermally by a study physician or nurse at a dose of 100 μg into the imiquimod-pretreated area on Day 3 of each cycle for 4 consecutive 21-day cycles.
224218544|NCT00566098|BIOLOGICAL|MILs|
224218545|NCT00566098|DRUG|Melphalan|
224218546|NCT00566098|BIOLOGICAL|PCV13|
223629814|NCT02767817|PROCEDURE|Stereotactic Hematoma Evacuation|Stereotactic intracranial hematoma and insert the drainage tube to inhale haematoma. The drainage tube stayed in the position for 1-2 days until adequate drainage of hematomas, and then the drainage tube was pulled out.
224218547|NCT00562692|DRUG|Nesiritide|Nesiritide 4 hour infusion
224218548|NCT00562692|DRUG|Placebo|Placebo infusion
224218549|NCT02971865|BEHAVIORAL|CBT/CMT|Cognitive Behavioral Therapy (CBT - training to change nutritional thoughts and behaviors) and Chiropractic Manipulative Therapy (CMT - High Velocity, low amplitude chiropractic manipulation) were delivered in average total 8 visits in a year. The interventions were comparable in format (individual visit), duration (30 minute visits), frequency (monthly), and number of participants per group (see intervention details). Each intervention was delivered according to a protocol in which all instructors were trained. (Figure 3: Chiropractic/Behavioral health and Primary care Integration Protocol.) Routine care varied with patient complaints at the time of visit.
224218550|NCT02971865|OTHER|Control group traditional primary care|No change in care usually given
224218551|NCT05789680|PROCEDURE|Surgical treatment of parathyroid carcinoma|Radical treatment of suspected parathyroid carcinoma should consist of parathyroidectomy and en bloc ipsilateral hemithyroidectomy and central lymph node dissection.
224218552|NCT00595660|PROCEDURE|FNA - fine needle aspiration|Fine Needle aspiration
224218553|NCT00595660|PROCEDURE|FNA - fine needle aspiration|Fine needle aspiration
224218554|NCT00595660|PROCEDURE|FNA - fine needle aspiration|Fine needle aspiration
224218555|NCT00595660|PROCEDURE|FNA - fine needle aspiration|Fine needle aspiration
223629815|NCT02767817|BIOLOGICAL|MSCs Transplantation|Stereotactic intracranial hematoma and insert the drainage tube to inhale haematoma. The drainage tube stayed in the position for 1-2 days until adequate drainage of hematomas,and 10 million MSCs were transplanted into the hematoma cavity before the drainage tube was pulled out.
223629816|NCT02767817|BIOLOGICAL|Injectable Collagen Scaffold with MSCs Transplantation|Stereotactic intracranial hematoma and insert the drainage tube to inhale haematoma. The drainage tube stayed in the position for 1-2 days until adequate drainage of hematomas, and injectable collagen scaffold combined with 10 million MSCs were transplanted into the hematoma cavity before the drainage tube was pulled out.
224218556|NCT00595660|PROCEDURE|FNA - fine needle aspiration|Fine needle aspiration
224218557|NCT02945280|DRUG|apixaban|12 weeks of apixaban treatment to monitor for efficacy in the prevention of VTE-related mortality
224218558|NCT05481580|DIAGNOSTIC_TEST|Periodontal probing|"The teeth involved will be probed to assess probing depth, presence of furcation, bleeding.~A radiograph will be taken to assess the length of the root trunk and the presence of root canal treatment"
224218559|NCT01146730|BEHAVIORAL|Workcoping and IPS|Maximum 15 sessions of CBT-based counseling with workcoping as primary focus in addition to work support according to the IPS-model (individual placement and support)
224218560|NCT01146730|BEHAVIORAL|Ordinary care by GP or NAV|Ordinary care by the participants physician or the local Labour and Welfare Administration
224218561|NCT04317963|BIOLOGICAL|Bezlotoxumab|Bezlotoxumab 10 mg/kg IV infusion in addition to standard CDI treatment
223629817|NCT01011998|DRUG|Gleevec (imatinib), valproic acid|"Valproic acid: 250 mg three times per day and then adjusted according to attain a therapeutic level.~Gleevec will be continued at the dose the patient was taking at the time of entry onto the study."
223629818|NCT01106599|DRUG|GDC-0623|Repeating oral dose
223629819|NCT00979901|DRUG|Comparator: montelukast|10 mg montelukast tablet given once daily at bedtime for 2 weeks
223629820|NCT00979901|DRUG|Comparator: loratadine|10 mg loratadine tablet given once daily at bedtime for 2 weeks
223629821|NCT00979901|DRUG|Comparator: placebo|placebo tablet given once daily at bedtime for 2 weeks
223629822|NCT00979901|DRUG|Comparator: montelukast/loratadine|montelukast 10-mg/loratadine 10-mg combination tablet taken orally once daily at bedtime for 2 weeks
223629823|NCT00807118|DRUG|Fesoterodine|Single dose of 2 x 4 mg tab in formulation F under fed condition
223629824|NCT00807118|DRUG|Fesoterodine|Single dose of 1 x 8 mg tab in formulation F under fed condition
223629825|NCT00807118|DRUG|Fesoterodine|Single dose of 1 x 8 mg tab in formulation E(1) under fed condition
224218562|NCT04317963|DRUG|Standard CDI treatment|Standard CDI treatment includes one or a combination of oral vancomycin, oral vancomycin taper and/or pulse, fidaxomicin, and fidaxomicin taper and/or pulse
224218563|NCT05626010|DRUG|Acetaminophen|acetaminophen 1g iv dripping at end of surgery
224218564|NCT05626010|DRUG|Ibuprofen|ibuprofen 300mg iv dripping at end of surgery
224218565|NCT00076323|DRUG|Primaquine|
224218566|NCT02009956|DEVICE|Subjects receiving DESyne Novolimus Eluting CSS|
224218567|NCT01656954|PROCEDURE|Passive Leg Raise (PLR)|From the supine position, the legs are elevated to 45 degrees above the resting surface for a period of 3 minutes. At completion,the legs are lowered to the resting surface.
224218568|NCT03213054|BIOLOGICAL|OBP-301|OBP-301 administration on the Day 1, Day 18 and Day 32
224218569|NCT03213054|RADIATION|Radiation|Standard radiation therapy for esophageal cancer patient. total 60 Gy for 6 weeks
224218570|NCT02236754|DRUG|18 F-FP-DTBZ|The drug, no carrier added \[18 F\]-FP-DTBZ, is formulated in 5% (v/v) ethanol in 0.9% sterile saline solution to produce \[18 F\]-FP-DTBZ for injection. Subjects will receive a single i.v. administration of no more than 7.6 millicuries (mCi) of \[18 F\]-FP-DTBZ for injection immediately prior to imaging. The specific activity at time of injection will less than 1.0 mCi/microgram and thus for a 7.6 mCi dose the maximal mass dose will be less than 10 microgram.
224218571|NCT02236754|RADIATION|PET Scanning|Individuals will be imaged continuously (i.e. dynamically) for 2 hours.
224218572|NCT04006847|DRUG|Eicosapentaenoic Acid|Eicosapentaenoic Acid once per day orally
224218573|NCT04006847|DRUG|Tyrosine kinase inhibitor|Tyrosine kinase inhibitor to be administered at subjects' pre-study dose
224218574|NCT03341598|PROCEDURE|CAF|Periodontal surgical technique to treat gingival recessions.
224218575|NCT03341598|PROCEDURE|R|Restorative procedure to treat tooth structure loss.
224218576|NCT03341598|PROCEDURE|MC|Xenogenous graft placed in the surgical site.
223629826|NCT00807118|DRUG|Fesoterodine|Single dose of 1 x 8 mg tab in formulation F under fed condition
223629827|NCT00807118|DRUG|Fesoterodine|Single dose of 2 x 4 mg tab in formulation F under fasted condition
223629828|NCT00807118|DRUG|Fesoterodine|Single dose of 1 x 8 mg tab in formulation F under fasted condition
223629829|NCT03904017|OTHER|Oxygen|100% Oxygen air
223629830|NCT03904017|OTHER|placebo|medical air
223629831|NCT02228707|DRUG|BIIB061|Participants receive BIIB061
223629832|NCT02228707|OTHER|Placebo|Matched placebo
223629833|NCT04970745|OTHER|Transcranial parenchymal color Doppler ultrasound (TCS)|tracing the nigrostriatal echogenic area
223629834|NCT04970745|OTHER|Electromyography (EMG) tremor analysis|observed 1, frequency 2, amplitude (amplitude) 3, correlation between the two sides 4, load and post-drug test differences
223629835|NCT04800965|BEHAVIORAL|Patient MyChart Scheduling Link|Text message includes a link for patients to sign on to their patient portal (Epic MyChart) and schedule their COVID-19 vaccine appointment.
223629836|NCT04800965|BEHAVIORAL|Patient Educational Video|Text message includes a link to a patient education video that aims to encourage patients to obtain the COVID-19 vaccine.
223629837|NCT04800965|BEHAVIORAL|Enhanced Follow through Message|Text message includes information that will use enhanced language aimed at reducing psychological barriers that prevent patients from scheduling their appointment.
223764132|NCT04488120|DEVICE|transcatheter closure of secundum atrial septal defects in patients|transcatheter closure of secundum atrial septal defects in patients
224218577|NCT04242381|OTHER|Cold Application|At the beginning of each treatment session, gel ice packs were wrapped in a damp towel and applied to the patients' shoulder joints for 20 minutes.
224218578|NCT04242381|OTHER|Kinesiotaping Application|KT was applied to the deltoid muscle using the inhibition and mechanical correction technique and to the supraspinatus muscle using the inhibition technique (2 sessions with a 5-day interval)
224218579|NCT04242381|OTHER|Exercise treatment|EX treatment was administered for 10 days with 3 sessions/day. A triphasic exercise program was administered to the patients. Before starting the exercise program, the patients were instructed to not perform the movements exceeding 90° overhead. The exercise program was initiated using codman pendulum, passive joint motion range (with a 1-m stick), and posterior capsule stretching exercise. Shoulder wheel, finger ladder, and shoulder strengthening exercise with theraband were added to the exercise programs of patients with full or near total range of motion and pain relief. Exercise was administered twice a week under supervision; however, the patients were advised to exercise at home on the other days with 20 repetitions of each exercise. The patients were followed up via telephone to make sure they were adhering to their exercise programs.
224218580|NCT04242381|OTHER|Sham Kinesio taping application|Sham-KT was applied in 10 cm I-shaped stripes on the sagittal plane over the acromioclavicular joint without stretching and on the transverse plane distal to the deltoid area. The kinesiotape was applied twice for five days with 2-day intervals
224218581|NCT00010933|DRUG|chamomile tea|
224218582|NCT00010933|PROCEDURE|Relaxation/Guided Imagery|
224218583|NCT04089280|DIETARY_SUPPLEMENT|Sanprobi Barrier-multispecies probiotic|"Multi-strain probiotic Sanprobi Barrier (Bifidobacterium lactis W52, Lactobacillus brevis W63, Lactobacillus casei W56, Lactobacillus lactis W19, Lactobacillus lactis W58, Lactobacillus acidophilus W37, Bifidobacterium bifidum W23, Lactobacillus salivarius W24) or placebo. Patients will be randomized to one of the two products (A or B) each containing probiotic/placebo and administered for 12 weeks. After 12 weeks of supplementation, the probiotic/placebo product A or B will be discontinued and reintroduced again after next 4 weeks - patients will be switched to the other A or B group of probiotic/placebo arm. Patients will be administered with 4 capsules per day for 24 weeks (12 weeks for group A probiotic/placebo and 12 weeks for group B probiotic/placebo allowing 4 weeks washout between the group assignment)."
224218584|NCT04089280|OTHER|Placebo Comparator|Carrier material of Sanprobi Barrier-multispecies probiotic product, not containing bacterial strains,similar appearance as the probiotic
224218585|NCT01127191|OTHER|military equipment|Military exercise of 24 hours
224218586|NCT00382291|DRUG|Regular Titration|Sertraline will be administered in standard dosing. Treatment with sertraline will last 18 weeks.
224218587|NCT00382291|DRUG|Placebo|The placebo will be administered in the same manner as sertraline. Treatment with placebo will last 18 weeks.
224218588|NCT00382291|DRUG|Slow Titration|Sertraline will be administered in slow titration. Treatment with sertraline will last 18 weeks.
224218589|NCT04451382|BIOLOGICAL|OnabotulinumtoxinA (BoNTA)|
224218590|NCT04451382|PROCEDURE|Percutaneous tibial nerve stimulation (PTNS)|
224218591|NCT05992649|OTHER|physical therapy|Aquatic physiotherapy in warm water
224218592|NCT00163436|DRUG|Ciclesonide|
224218593|NCT01823484|DEVICE|AN 69 ST hemofilter|
224218594|NCT01823484|DEVICE|AN 69 hemofilter|
224218595|NCT01725815|BEHAVIORAL|HARP Intervention|The HARP intervention is a 6-week, 6-session, group format intervention to improve self-management of chronic medical diseases. Each group lasts 90 minutes and has 8-12 attendees. Between groups, participants work with partners from the group to troubleshoot problems and accomplish action plans identified during the session. At the end of the program, monthly alumni groups meet for six months to reinforce lessons from the intervention, monitor progress, and maintain peer support.
224218596|NCT01440478|DRUG|LY2140023|Administered orally
224218597|NCT01440478|DRUG|Ammonium chloride|Administered orally
224218598|NCT01440478|DRUG|Sodium bicarbonate|Administered orally
224218599|NCT02092961|DRUG|Fostamatinib|Fostamatinib 100mg twice daily.
224218600|NCT02092961|DRUG|Adalimumab|Adalimumab 40 mg by subcutaneous injection every 2 weeks for 24 weeks.
224218601|NCT02092961|DRUG|Placebo of Fostamatinib|Placebo bid for 6 weeks.
224218602|NCT02092961|DRUG|Placebo of Adalimumab|Placebo injection once every two weeks.
224218603|NCT02594345|OTHER|in vitro study|Exosomes will be mixed with healthy volunteers' blood in vitro
224218604|NCT02916160|DRUG|SACUBITRIL - VALSARTAN (formerly LCZ696, ENTRESTO®)|SACUBITRIL - VALSARTAN (formerly LCZ696, ENTRESTO®) is a new treatment of HF recently indicated class I, level B in the recent ESC guidelines 2016 on HF. It combines inhibitory prodrug neprilysin and valsartan.
224218605|NCT02301780|DRUG|Aspirin|"Participants who are screened with a high-risk of developing PET will be randomised into one of 2 arms of the trial (on the same day as screening or within 1 week of the screening visit). Randomised participants will be advised to start 150mg of Aspirin/Placebo once per night within 24 hours of randomisation until 36 weeks' gestation or when signs of labour commence.~The maximum duration for aspirin or placebo intake will be 180 days."
224218606|NCT02301780|DRUG|Placebo|"Participants who are screened with a high-risk of developing PET will be randomised into one of 2 arms of the trial (on the same day as screening or within 1 week of the screening visit). Randomised participants will be advised to start 150mg of Aspirin/Placebo once per night within 24 hours of randomisation until 36 weeks' gestation or when signs of labour commence.~The maximum duration for aspirin or placebo intake will be 180 days."
224218607|NCT05081076|DEVICE|Glazing|The zirconia surface will be submitted to a vitrification procedure (glazing) in a specific ceramic oven using the Ceramill Stain \& Glaze Kit, following the manufacturer's instructions.
224218608|NCT05081076|DEVICE|Polishing|The zirconia surface will be submitted to a polishing procedure using a polishing rubbers kit in the sequence indicated by the manufacturer (EVE DIACERA Finishing and Polishing Kit, EVE Ernst Vetter GmbH - Germany).
224218609|NCT01623830|BEHAVIORAL|Virtual Reality Exposure Therapy|Treatment will consist of 8 weekly sessions. Session 1: information gathering, treatment procedures and rationale. Session 2: Cognitive restructuring. Session 3: Breathing retraining and thought stopping. Session 4: Review cognitive restructuring and hyperventilation exposure. Sessions 5-8 Fear of flying exposure in the Virtual environment.
224218610|NCT00683150|OTHER|Endothelial Function Test|Endothelial function tests performed within 20 days before surgery, when surgery begins (at the time of incision), every hour during surgery and then 1, 2, 3, and 5 days after surgery.
224218611|NCT02754323|DEVICE|Apparatus CODESNA|The inclusion period is evaluated at one month and the participation of each patient is two days. One day or the subject performs the evaluation of chronic stress by CODESNA and following through questionnaires and another day to 3 weeks / one month apart, to perform a second chronic stress measurement with tool CODESNA to evaluate its reproducibility and reliability.
224218612|NCT03551366|BEHAVIORAL|Linear|The linear pedagogy arms consists of three, five-week phases of lesson delivery, commencing around two weeks after baseline assessments. The first phase focuses on dance, the second on gymnastics and the final phase on ball sports. Each phase has its own schemes of work which includes five lessons objectives, each taught over a two lesson period. The lesson objectives aligned to the aims of English national curriculum. Lessons are delivered twice a week by trained coaches, with each lesson lasting 60 minutes in total, with 45 minutes of on task teaching time. Linear curriculum lessons will be focused on the functioning of the body and children learning movement patterns. These lessons will be far more prescriptive and have clearly stated outcomes/goals for each lesson, with a typical lesson structure following the structure of warm up, isolated practice of technique or skill, simulated game and warm down.
224218613|NCT03551366|BEHAVIORAL|Nonlinear|The non-linear pedagogy arm consists of three, five-week phases of lesson delivery, commencing around two weeks after baseline assessments. The first phase focuses on dance, the second on gymnastics and the final phase on ball sports. Each phase has its own schemes of work which includes five lessons objectives, each taught over a two lesson period. The lesson objectives align to the aims of English national curriculum. Lessons are delivered twice a week by trained coaches, with each lesson lasting 60 minutes in total, with 45 minutes of on task teaching time. The nonlinear curriculum lessons will look to make sure that children are both engaged and empowered throughout the learning process. In adherence to representative learning design, we will look to contextualise lessons and guide learning through the use of books/stories, lived experiences and the sharing of ideas.
224218614|NCT05446090|DIAGNOSTIC_TEST|Spirometry including peak flow|Spirometry including peak flow to assess the degree of airway obstruction. Spirometry will be conducted according to a study SOP. The Global Lung Function (GLI) 2012 equations will be used. Reversibility testing will not be routinely performed. Thus, asthma medications will not normally be withheld for study visits and patients should take their inhalers as usual. The same type of device will be used at each visit.
224218615|NCT05446090|DIAGNOSTIC_TEST|Fractional Exhaled Nitric Oxide (FeNO)|Fractional Exhaled Nitric Oxide (FeNO) to assess the degree of airway inflammation. FeNO will be measured using a standard device (NIOXX Vero®) in accordance with the manufacturer's guidelines. The same type of device will be used at each visit. FeNO should be performed prior to any other respiratory assessment if possible.
224218616|NCT05446090|DIAGNOSTIC_TEST|Forced Oscillation Technique (FOT)|FOT is a non-invasive method that evaluates resistance and reactance in the respiratory system during tidal breathing. It should be performed after FeNO, but prior to Spirometry and will be conducted according to a study SOP.
224317693|NCT03498495|BEHAVIORAL|Self-Monitoring Activity-restriction and Relaxation Training (SMART)|SMART integrates real-time self-monitoring of symptoms and activities with interactive modules designed to increase self-efficacy through psychoeducation and training in problem solving/problem-focused coping strategies.
224317694|NCT00032786|DRUG|natalizumab|
224317695|NCT03389516|OTHER|Polymem|wound care dressings
224317696|NCT03389516|OTHER|Lanolin|wound care oinment
223629838|NCT00297544|DRUG|Viagra|
223629839|NCT00555958|DEVICE|Active, implantable, intra-abdominal vagal blocking medical device|Intermittent, programmable, intra-abdominal vagal blocking
223629840|NCT01718288|DRUG|iloprost|"The study, consists of two substudies, which deal with patients susceptible to medical therapy alone (substudy 1) or treated with classical surgical therapy (substudy 2).~For each substudy, pts will be divided into two groups, one that will receive conventional treatments but not prostanoids, other conventional treatments with addition of iloprost.~The 4 groups:~1A. Pts unsuitable to surgical or endovascular vascular therapy: conventional treatment~1. B. Pts unsuitable to surgical or endovascular vascular therapy: treatment with iloprost plus conventional treatment~2. A. Pts suitable to vascular surgical or endovascular therapy: conventional treatment~2B. Pts suitable to vascular surgical or endovascular therapy: treatment with iloprost plus conventional treatment"
223629841|NCT01718288|DRUG|Standard Treatment (aspirin.....),|"The standard treatment, as has already been explained in the submission is the best treatment that the guidelines suggest for that specific type of patient with those complications and with stage 2b severe PAD.~correction of concomitant risk factors, physical exercise, antiplatelet, standard heparin /low molecular weight heparin, hemorheological/vasodilators such as pentoxifylline/buflomedil, propionyl-L-carnitine, Defibrotide) but not prostanoids"
223629842|NCT00681044|BIOLOGICAL|filgrastim|16 mcg/kg daily beginning 3 days prior to SCC through day before final SCC
223629843|NCT00681044|DRUG|melphalan|70-100 mg/m2/day will be administered intravenously on Days -3 and -2
223629844|NCT00681044|PROCEDURE|Stem Cell Infusion|infusion of previously collected stem cells on Day 0
224218617|NCT05446090|PROCEDURE|Sputum Induction|Sputum Induction for the assessment of airway inflammation and microbiology. Sputum induction will be performed according to an SOP, which includes measures to protect the safety of participants. These consist of pre-treatment with Salbutamol, a short acting bronchodilator, stipulated levels of lung function in order to perform the test and stopping criteria. If the participant is unable to undergo the procedure, due to safety reasons, they will be asked to produce a spontaneous sputum sample. Sputum samples will be collected for a differential cell count, bacterial culture and sensitivity and storage for future research. Procedures for sampling and processing will be detailed in a study SOP.
224218618|NCT05446090|DIAGNOSTIC_TEST|Bloods|Blood will be collected for laboratory analysis, including Vitamin D, Haematology, WCC differential, C-Reactive protein.
224218619|NCT05446090|DIAGNOSTIC_TEST|Nasal lavage|Nasal lavage samples will be taken at the baseline (attack) visit. Samples will be obtained by injecting 5ml of sterile normal saline into the participant's nostrils via a nasal adaptor and then immediately aspirated. These will be placed in a sterile container and transported to the laboratory for viral identification. This procedure will be detailed in a study SOP.
224218620|NCT05446090|DIAGNOSTIC_TEST|Throat swab|A throat swab will be taken at the baseline (attack) visit for viral identification.
224218621|NCT05446090|DIAGNOSTIC_TEST|Nasal Brush.|Nasal brushings samples may be taken at baseline (attack) and at second visits for RNA and DNA extraction. This will be optional and specific consent from participants will be sought. Procedures for sampling and processing will be detailed in a study SOP.
224218622|NCT05446090|DIAGNOSTIC_TEST|Nasal absorption|Nasal absorption will be used to collect mucosal lining fluid from the respiratory tract for cytokines profiling at baseline (attack) and at second visits.
224218623|NCT05446090|OTHER|Medical History, Demographic, and Concomitant Medications|Medical history will include clinically significant diseases and prior surgeries and smoking history. A specific respiratory history will also be recorded. Demographic data will include age, sex and self- reported race/ethnicity. Medication use will also be collected.
224218624|NCT05446090|OTHER|Sino-nasal Outcome Test|The incidence of upper airway symptoms will be assessed using Sino-nasal Outcome Test (SNOT).
224218625|NCT05446090|OTHER|Gastroesophageal Reflux Disease Questionnaire|The incidence of Gastroesophageal Reflux Disease will be assessed using GERDQ questionnaire.
224218626|NCT05446090|OTHER|Pittsburgh Vocal Cord Dysfunction Index|The incidence of vocal cord dysfunction will be assessed using Pittsburgh Vocal Cord Dysfunction (VCD) Index
224218627|NCT05446090|OTHER|Nijmegen Questionnaire.|The incidence of dysfunctional breathing will be assessed using Nijmegen dysfunctional questionnaire.
224218628|NCT05446090|OTHER|Hospital Anxiety and Depression Scale|The incidence of anxiety and depression will be assessed using Hospital Anxiety and Depression Scale (HADS).
224218629|NCT05446090|OTHER|Compliance and adherence|In order to assess adherence as a factor in exacerbations, a participant's beliefs and attitudes towards medicines will be explored using the Medicines Adherence Report Scale (MARS) questionnaire. Non-intentional non-compliance with usual treatment will be assessed by checking inhaler technique; poor inhaler technique will be reported to the participant's clinical team. Also, GP records will be reviewed for information on medications prescribed in the last 12 months.
224218630|NCT05446090|OTHER|Acute Asthma Quality of Life Questionnaire|The impact of acute asthma on quality of life will be assessed using Acute Asthma Quality of Life Questionnaire at baseline and follow up.
224218631|NCT00381056|BEHAVIORAL|Labor and Delivery Team Coordination Course|
224218632|NCT02304874|OTHER|Phlebotomy|
224218633|NCT01304446|DIETARY_SUPPLEMENT|industrialized oral supplementation (IOS) and tube feeding regimen (TFR) with Nutren|The oral and tube supplement offered was Nutren Jr® (for patients aged 1 - 9 years) or Nutren 1.0- Nestlé Clinical Nutrition-Brazil (for those aged 10 years or over). This supplement was a whole powder formulation that presented a macro composition of 52% carbohydrates, 12% proteins and 36% lipids. Its vitamins were A, D, E, K, B complex, biotin and choline; its trace elements were iron, copper, zinc, manganese, selenium, chromium and molybdenum; its macroelements were potassium, calcium, sodium, chlorine, iodine, magnesium and phosphorus; and it contained taurine and L-carnitine presenting 1.0 kcal/ml.
224218634|NCT05316103|DEVICE|Probe-based confocal laser endomicroscopy targeted optical biopsy|After intravenous injection of fluorescein sodium, pCLE-based targeted optical biopsy will be performed.
224218635|NCT01847313|DRUG|Liraglutide|Daily administration of liraglutide for 6 months
224218636|NCT03706677|DEVICE|Cryoballoon (Arctic Front Advance Cryoballoon)|Ablation using a Cryoballoon catheter (Arctic Front Advance Cryoballoon Cardiac Ablation Catheter)
224218637|NCT03706677|DEVICE|Radiofrequency Catheter (ThermoCool Smarttouch)|Ablation using a Radiofrequency ablation catheter (ThermoCool Smarttouch catheter)
224218638|NCT04835298|OTHER|Dyspnea|questionnaires
224218639|NCT00204750|PROCEDURE|Bougie Dilation|Bougie dilation will be performed as standard
224218640|NCT00204750|PROCEDURE|Needle-knife incision|Needle-knife incision will be performed
224218641|NCT04312555|DRUG|Alprostadil|Alprostadil intravenous administration. (0.5 mg/1ml of Alprostadil + 49cm saline 0.9%) and 4 cm direct intravenously / 8 hours
224218642|NCT03555721|OTHER|Oral examination with incandescent light|Suspicious oral lesions will be identified by oral examination with incandescent light.
224218643|NCT03555721|OTHER|Oral examination with OralID|OralID uses a proven, optically based fluorescence technology that provides the clinician an aid in visualization of oral cancer, pre-cancer and other abnormal lesions.
224218644|NCT03555721|DIAGNOSTIC_TEST|Biopsy|Tissue will be collected to identify pre-cancerous or cancerous cells
224218645|NCT03555721|DIAGNOSTIC_TEST|CytID|CytID™ is an adjunctive process that is a noninvasive, pain-free, chair-side procedure for assessment of suspicious oral cavity lesions using a brush swab. The test is based on an objective measure of gross changes in the nuclear DNA content of oral epithelial cells; thereby, providing information about the pre-cancerous or cancerous state of a lesion.
224218646|NCT03555721|DIAGNOSTIC_TEST|hpvID|hpvID™ testing can detect all major HPV types and shows the current HPV status of the patient. This provides additional clinical information to correlate and compare hpvID™ trends with routine standard of care biopsy or cytology results.
224218647|NCT02853929|BIOLOGICAL|Infanrix hexa|All subjects will receive Infanrix hexa co-administered with Prevenar13 as a booster dose.
224218648|NCT03549130|DEVICE|Breathe Right Tan (small/medium) nasal strips|Participants of this treatment arm applied sufficient quantity of commercially available nasal strips (Breathe Right Tan), small/medium sized outside of the nose, from alar crease to alar crease, as per dispensing instructions, prior to sleeping. Participants used their assigned strip every night, for approximately 8 hours, but no more than 12 hours per night, for two weeks
224218649|NCT03549130|OTHER|Placebo nasal strip|Participants of this treatment arm applied sufficient quantity of Asymmetric Butterfly Placebo ABP-NH Nasal Strips, small/medium sized outside of the nose, from alar crease to alar crease, as per dispensing instructions, prior to sleeping. Participants used their assigned strip every night, for approximately 8 hours, but no more than 12 hours per night, for two weeks
224218650|NCT01026610|DRUG|LB80380 90 mg|LB80380 90 mg + placebo tablets, once daily, for 48 weeks
224218651|NCT01026610|DRUG|LB80380 150 mg|LB80380 60 mg + 90 mg tablets, once daily, for 48 weeks
224218652|NCT01026610|DRUG|entecavir 0.5 mg|entecavir 0.5 mg tablet, once daily, for 48 weeks
224218653|NCT00463866|DRUG|Budesonide/formoterol|
224218654|NCT03956433|DIETARY_SUPPLEMENT|Ready-made pancakes enriched with docosahexaenoic acid (DHA)|One portion of DHA-enriched pancakes will be eaten each day for 4 weeks.
224218655|NCT03956433|DIETARY_SUPPLEMENT|Ready-made pancakes enriched with beta-glucan (BG)|One portion of BG-enriched pancakes will be eaten each day for 4 weeks.
224218656|NCT03956433|DIETARY_SUPPLEMENT|Ready-made pancakes enriched with anthocyanins (AC)|One portion of AC-enriched pancakes will be eaten each day for 4 weeks.
224218657|NCT03956433|DIETARY_SUPPLEMENT|Ready-made pancakes enriched with docosahexaenoic acid and beta-glucan (DHA+BG)|One portion of DHA+BG-enriched pancakes will be eaten each day for 4 weeks.
224317697|NCT06416514|OTHER|Personalized intervention|Personalized intervention means implementing multi-component non-pharmacological interventions based on different health profiles，such as art therapy, exercise therapy, cognitive therapy and other monotherapies. Usual care means care as routine.
224317698|NCT05932043|DIAGNOSTIC_TEST|This is a non-interventional study|None (this is a non-interventional study)
224317699|NCT02165735|BEHAVIORAL|patient activation training|Patient activation training involves six, 90-minute, group (8-12 person) training sessions facilitated by trained peers and training staff and one (20-30 minute) pre-visit coaching session conducted by staff. The hands on group training includes: 1) HIV education; 2) use of a handheld smart device; 3) use of an HIV electronic personal health record app that runs on the smart device; 4) identification of patients' visit need priorities and skills for communicating with their HIV provider. The pre-visit coaching includes identification of patient concerns and patient behavioral rehearsal for asking about these concerns.
223629845|NCT03888443|DEVICE|"Bimanual 3D Motion Analysis  Be-API "|"Movements will be measured using an optoelectronic system (12 cameras) which captures the displacement of 26 markers placed on the upper limbs and trunk of the child, according to the standards of the International Society of Biomechanics.~The child is installed on a chair and table height (equipment adapted and approved for pediatrics). A game board is installed in front of the child, with objects to handle, set and placed according to its anthropometry (joystick, steering wheel, buzzer, board, chip)."
223629846|NCT03010696|OTHER|No interventions, questionnaire, collect specimen|
223629847|NCT04236817|BEHAVIORAL|Pre-packed blisters for distribution of medications|
224218658|NCT03956433|DIETARY_SUPPLEMENT|Ready-made pancakes enriched with docosahexaenoic acid and anthocyanins (DHA+AC)|One portion of DHA+AC-enriched pancakes will be eaten each day for 4 weeks.
224218659|NCT02947061|DRUG|S1 plus Docetaxel|S1 80mg to 120 mg per day on Days 1-14, every 21 days; Docetaxel 75mg/m2 on Day 1
224218660|NCT02947061|DRUG|Capecitabine plus Docetaxel|Capecitabine 1,000 mg/m2 per day on Days 1-14, every 21 days; Docetaxel 75mg/m2 on Day 1
224218661|NCT02785133|DEVICE|UVL1000 Treatment Station|"Non-coherent light source administered 365 nm, 630 nm, and 530 nm at an output intensity of 0.1 mW directly into an existing intravascular 20 gauge 1.0 catheter"
224218662|NCT02785133|DRUG|Normal Saline Solution|150 ml of 0.9% Sodium Chloride Solution
224218663|NCT02785133|DEVICE|Peripheral Catheterization|"20-gauge 1.0 catheter"
224218664|NCT03952910|OTHER|Online pain education program|Online pain education program
224218665|NCT01713712|BEHAVIORAL|Nutritional Counseling|Patients will keep a daily diary of nutritional intake as well as physical activity. They will also follow up with the nutritional counselor six weeks postpartum.
224218666|NCT01677910|DRUG|Telotristat etiprate|Telotristat etiprate tablets.
224317700|NCT02165735|OTHER|Usual care|Usual HIV care
224317701|NCT01271218|OTHER|Diet|Participants followed isoenergetic low fat diets with higher protein (HP) or higher carbohydrate (HC) macronutrient content. Participants consumed 1,200 kcals/d for 1-week (Phase I) and 1,600 kcals/d for 9-weeks (Phase II) during a 10-week weight loss period. Participants in the HC diet consumed a diet containing 55% carbohydrate, 15% protein, and 30% fat. Subjects in the HP group consumed a diet containing 7% carbohydrate, 63% protein, and 30% fat during Phase I of the diet and 15% carbohydrate, 55% protein, and 30% fat during Phase II of the diet. The final 4-weeks of the diet (Phase III) served as a weight maintenance period in which participants consumed 2,600 kcals•d-1 consisting of 55% carbohydrate, 15% protein, and 30% fat and were instructed to follow their respective Phase I diet (1,200 kcals/d) for 2-days only if they gained 1.35 kg (3 lbs).
224218667|NCT01677910|DRUG|Placebo-matching telotristat etiprate|Placebo-matching telotristat etiprate tablets.
224218668|NCT01814579|DEVICE|Unidirectional Barbed Suture (V-Loc)|Patients enrolled in the Unidirectional Barbed Suture arm will have their vaginal cuff closed using this device during their robotic hysterectomy.
224218669|NCT01814579|DEVICE|polyglactin 910 (Vicryl)|Patients in the Smooth Suture arm will have their vaginal cuff closed with this device during their robotic hysterectomy.
224218670|NCT05236075|DEVICE|shearing wave collar|Collar inducing shearing wave to treat obstructive sleep disorders
224218671|NCT05398575|BEHAVIORAL|Music|Participants listen to music during physiotherapy rehabilitation (tailored or radio music)
224218672|NCT02081170|PROCEDURE|Autologous platelet concentrate|"1. pars plana vitrectomy~2. internal limiting membrane removal~3. Fluid-air exchange~4. Intravitreal autologous platelet concentrate injection~5. Intravitreal gas (14% C3F8) injection~6. Keep prone position for 7-14 days after surgery"
223629848|NCT04236817|BEHAVIORAL|Routine distribution of medications|
223629849|NCT00688987|DRUG|Hydrocortisone|Subjects will receive in random order daily (split) dosing of hydrocortisone: a low dose of 15 mg (10 in AM, 5 in PM); a medium dose of 25 mg (15 in AM, 10 in PM) and high dose of 40 mg (30 in AM, 10 in PM) for 4 months.
223629850|NCT00688987|DIETARY_SUPPLEMENT|Isocaloric Diet|Subjects will eat an isocaloric diet for 4 weeks while taking hydrocortisone
223629851|NCT05665231|OTHER|A - Bone defect (clinical variables)|At T0, the edentulous space to be rehabilitated will be characterized in terms of the morphometric level of the existing defect in the vestibular cortical, according to the classification by Caplanis N. in EDS-1 or EDS-2.
224218673|NCT01768000|BEHAVIORAL|Family Cognitive Adaptation Training|Family CAT is a 4 month manualised intervention designed to be administered by families independent of clinician support. A self scoring checklist is provided to assess and tailor Family CAT to the individual, along with descriptions of strategies for bathing, dressing, dental hygiene, make-up, toileting, housekeeping/care of living quarters, laundry, grocery shopping, transportation, management of money and consumables, medication management, social skills, communication and telephone use, leisure skills, work skills, and orientation. Family members will watch the DVD to gain insight into how the strategies can be implemented in real world settings. Having identified the areas of need, family members will administer the interventions and evaluate their effectiveness for the individual.
224218674|NCT02207647|OTHER|no intervention|
223629852|NCT05665231|OTHER|B- Bacterial plaque index (O'Leary index)(clinical variables)|At time T-1 and T4, the investigator will analyse the existing plaque on teeth adjacent to the surgical site using a dichotomous score (0 = no visible plaque at the soft tissue margin, 1 = visible plaque at the soft tissue margin). The result will be present in percentage (0% (better)-100%(worse)) and will describe the change between T-1 and T4, and compare the results between implants type.
223629853|NCT05665231|OTHER|C- Probing depth|At Time T-1 and T4, the investigators will analyse the probing depth of the teeth adjacent to the site to be treated at 6 points: mesiobuccal, vestibular, distobuccal, mesiopalatal, palatine, distopalatal. The recordings will be carried out with a CP 15 UNC, Hu-Friedy® Chicago, IL, EUA manual probe.The result will be present in millimeters. The change between T-1 and T4 is also going to be analysed and compare implants results.
223629854|NCT05665231|OTHER|D- Bleeding on probing|At time T-1 and T4, the investigators will analyse the bleeding on probing of the teeth adjacent to the site to be treated at 6 points: mesiobuccal, vestibular, distobuccal, mesiopalatal, palatine, distopalatal. The recordings of bleeding on probing will be carried out with a CP 15 UNC, Hu-Friedy® Chicago, IL, EUA manual probe.The result will be present in percentage (0% (better)-100%(worse)) and will describe the change between T-1 and T4 and compare between implants type.
223629855|NCT05665231|OTHER|E- Gingival phenotype|At time T-1, the identification of the gingival phenotype is performed by clinical inspection with a periodontal probe. The gingival phenotype will be classified as thin, moderate or thick. The investigators will compare implant results.
223629856|NCT05665231|OTHER|F- Implant insertion torque (Clinical variables)|Recording of implant insertion torque, in Ncm during placement in T1, and compare implants results.
224218675|NCT01942798|DEVICE|Nintendo Wii|Subjects will receive the intervention for 40-minute sessions, 3x/week for 4 weeks. The interventions will be administered in combination of onsite group training and individualized home-based training.
223629857|NCT05665231|OTHER|G- Implant stabilization quotient (ISQ) (clinical variables)|Determination of the implant stability coefficient at the time of implant placement (T1) and in the 2nd surgical phase (T3) using the Osstell® device (minimum 1; maximum 100; high stability when ≥70) and analysis of the change between T1 and T3 and different implants results.
223629858|NCT05665231|OTHER|Morphometric results (Direct measurements - millimeter)|"Compare Direct measurements (millimeters) at the different times intervention with periodontal probe or gauge and analyse the change between times and compare implant results.~In T-1, T2 and T3c and T4 the investigators will evaluate interdental distance; BPD, cortical bone, papilla and volume, corresponding of measurements: a,b,c and r.~In T0, the investigators will evaluate interdental distance; BPD, cortical, bone and global volume corresponding to measurements: a, b, c, d, e, q, r, s, t, and u).~In T1 e T3, the investigators will evaluate interdental distance; BPD, cortical, bone and global volume, implant parameter corresponding to measurements: a, b, d, e, f, g, h, I, j, k, l, m, n, p, q, r and ISQ value."
223629859|NCT05665231|OTHER|Morphometric results (plaster models measurements - millimeter)|"Preparation of plaster models at times T-1 and T4 and the following measurements (millimeter) will be evaluated with the use of periodontal probe or gauge and will analyse the change between T-1 and T4 and compare implants results:~1. interdental distance~2. bucco-palatal distance (BPD)~3. presence of papilla~r. global volume."
223629860|NCT05665231|OTHER|Imaging Results (X-ray) (millimeter)|"The investigator will measure (millimeters, using the imaging software virtual ruler) the results of digital X-ray at times T-1, T1,T4 and analyse the variation and compare implants results. The measurements are:~a. interdental distance; i. implant - cemento-enamel junction (CEJ) of adject teeth distance; l. distance from the implant position depth to the buccal bone crest; n. implant diameter; o. implant length."
223629861|NCT05665231|OTHER|Imaging Results (CBCT)(millimeter)|"The investigator will measure (millimeters, using the imaging software virtual ruler) the results of CBCT at times T-1 and T4, analyse the variation and compare implants results. The measurements are:~1. interdental distance;~2. bucco-palatal distance (BPD);~d. buccal cortical distance; e. palatal cortical distance; f. mesial cortical distance; g. distal cortical distance; h. jumping distance; j. buccal cortical wall-implant distance; k. jumping distance space depth; l. distance from the implant position depth to the buccal bone crest; m. distance from the buccal cortex to the center of the implant; n. implant diameter; o. Implant length; q. global bone volume; r. global volume; s. alveolus buccal-palatal distance; t. alveolus mesial-distal distance; u. alveolus depth."
223629862|NCT05665231|OTHER|Photographic results PES/WES index|The investigator will analyse the intraoral photographs to describe the Pes/Wes index, in time T-1 (initial) and T4 (final), and compare the PES/WES results between implants.The score will range on 0-10, the best score is ≥8.
223629863|NCT02178345|PROCEDURE|diffusion weighted (DW) MRI|
223629864|NCT02178345|PROCEDURE|dynamic contrast agent (DCE) MRI|
223629865|NCT06178419|DEVICE|RIC|RIC is a non-invasive therapy that is performed by automated pneumatic cuffs placed on unilateral arms. The RIC protocol includes five cycles of 5-min inflation to 200mmHg and 5-min deflation.
223629866|NCT06178419|DEVICE|sham-RIC|Sham-RIC is a non-invasive therapy that is performed by automated pneumatic cuffs placed on unilateral arms. The sham RIC protocol includes five cycles of 5-min inflation to 60mmHg and 5-min deflation.
223629867|NCT01327625|DRUG|azithromycin + N-acetylcystein + inhaled corticosteroid|"* Azithromycin 500mg qd x 1 week --\> 250mg qod x 6 months~* N-acetylcystein 200mg tid x 6 months~* Fluticasone 250mcg puff x2/day x 6 months"
223629868|NCT03626454|DRUG|Norepinephrine Bolus|'Norepinephrine Bitartarte' bolus of 6 µg/mL for 30 seconds immediately after intrathecal injection
223629869|NCT03626454|DRUG|Norepinephrine infusion|an infusion of 6 µg/mL norepinephrine that was started at 6 µg/kg/h immediately after intrathecal injection
223629870|NCT03626454|DRUG|Normal Saline Flush, 0.9% Injectable Solution|10 ml normal saline in syringe for bolus for 30 seconds immediately after intrathecal injection
223629871|NCT03626454|DRUG|Normal Saline 0.9% Infusion Solution|50 ml syringe with normal saline infuse at a rate 1ml/kg/h immediately after intrathecal injection
223629872|NCT00001188|PROCEDURE|radiation therapy following surgery|
223629873|NCT01691534|DRUG|TMC207 (J)|TMC207 400 mg Day 1; 300mg Day 2; 200mg Days 3-14
224218676|NCT01942798|DEVICE|Wii Big Brain Academy Degree program|Subjects will receive the intervention for 40-minute sessions, 3x/week for 4 weeks. The interventions will be administered in combination of onsite group training and individualized home-based training.
224218677|NCT03040076|BEHAVIORAL|Cognitive Bias Treatment|Two computerized tasks will be administered during four intervention sessions. During the first task, the Word Sentence Association Paradigm, participants see a threat or benign word and then an ambiguous sentence. Participants press one if they believe the word and sentence are related and two if they believe the word and sentence are not related. Participants are given feedback that they responded correctly if they state that a benign word is related to the sentence or they state that a threat word is not related to the sentence. The second task is the Ambiguous Scenarios Task. In each trial, an ambiguous scenario, ending in a benign word, appears on the screen. After the scenario is presented, participants respond to a comprehension question and are given feedback on their performance.
224218678|NCT03040076|BEHAVIORAL|Relaxation Condition|Participants assigned to the active control group will complete four sessions of progressive muscle relaxation training. Two alternating relaxation scripts will be used. The scripts will be presented as Youtube videos with a blank black screen and will instruct participants to keep their eyes closed for the duration of the training. Participants will access the videos through Qualtrics to ensure that data can be gathered about their compliance. The relaxation scripts used in the present study will be modified versions of those currently being tested by other researchers utilizing cognitive bias modification paradigms. The relaxation training sessions will be matched to the length of the treatment condition and therefore will last approximately 30 minutes.
224218679|NCT01541462|OTHER|Weaning|Decrease assistance provided by the ventilator
224218680|NCT04457869|DRUG|F520|3mg/kg every 3 weeks
224218681|NCT04648410|OTHER|questionnaire|Members of European Society of Intensive Care will obtain an electronic survey considering their routine clinical practice regarding the administration of systemic corticosteroids among patients with COVID-19 ARDS
223629874|NCT01691534|DRUG|PA-824 (PA)|PA-824 200mg Days 1-14
223629875|NCT01691534|DRUG|pyrazinamide (Z)|1500mg Days 1-14 Dosed by Weight
223629876|NCT01691534|DRUG|clofazimine (C)|clofazimine 300mg Days 1-3 and clofazimine 100mg Days 4-14
223629877|NCT01691534|DRUG|Rifafour|Rifafour e-275 mg dosed by weight
223629878|NCT05829226|DRUG|LYT-200|monoclonal antibody (mAb), targeting galectin-9 protein
223629879|NCT05829226|DRUG|Venetoclax|Bcl-2 inhibitor
223629880|NCT05829226|DRUG|Azacitidine|Hypomethylating agent
223629881|NCT05829226|DRUG|Decitabine|Hypomethylating agent
223629882|NCT02516761|OTHER|Low-impact aerobic exercise combined with music therapy|Intervention consists in working the muscles which are mostly affected by fibromyalgia through group exercises, which are dynamic, smooth and aim functionality. Each session consists of 60 minutes with 3 parts: initial warming up time, main part through games, group dynamics and pure aerobic workout, and final cool down with stretching. This exercise is done to the rhythm of melodic music, adapted to the tastes of the participants and also adapted on the way to perform the exercise. For this, they were shown a list of 100 music compositions from which participants choose a minimum of 20 preferences. All exercises are performed with proper postural control both dissociated and global and within a framework of therapeutic proprioceptive gymnastics.
223629883|NCT02516761|OTHER|Low-impact aerobic exercise|Low-impact aerobic exercise. Then intervention is like the previous group but with the difference that physical activity is not performed to the rhythm of chosen melodic music. Therefore, exercises are done with general chill-out music throughout the session, without adaptation of the exercise to the music.
223764133|NCT04294134|BEHAVIORAL|MIO-CPP|"Mothering from the Inside Out (MIO) is an individual, 12-session, manualized, psychotherapeutic intervention designed to promote parental reflective functioning in mothers who are in treatment for SUDs and/or other mental health problems, and caring for a child in-utero through five years old. (Suchman N, Pajulo M, and Mayes LC, 2013).~Child-Parent Psychotherapy (CPP) is a two-generation approach that supports and strengthens parent-child attachment by integrating modalities derived from psychodynamic, attachment, trauma, cognitive-behavioral, and social learning theories. (Lieberman AF and Van Horn P, 2005 and 2008) Studies have revealed that CPP caregivers' outcomes include decreased depression, PTSD and other symptoms, increased empathy towards children and an increase in the quality of parent-child interactions. CPP focuses on working with families offering weekly sessions for nine-12 months."
223629884|NCT02516761|OTHER|Control group|With this group no intervention is done, but they are assessed like the other groups.
223629885|NCT05419583|DIAGNOSTIC_TEST|Coronary computed tomography angiography|CT scan of the heart arteries
223629886|NCT05419583|DIAGNOSTIC_TEST|Invasive coronary angiography|Invasive coronary angiography via the radial or femoral approach
223629887|NCT05419583|DIAGNOSTIC_TEST|Transthoracic echocardiography|Ultrasound scan of the heart
223629888|NCT05419583|DIAGNOSTIC_TEST|Cardiac MRI scan|An MRI scan to assess the heart structure and function
223629889|NCT05419583|DRUG|Antiplatelet Drug (Aspirin or Statin)|Antiplatelet therapy for coronary artery disease
224218682|NCT00622141|DRUG|generic GPO saquinavir and novir vs invirase and norvir|Norvir® 100mg capsules, Invirase® 1,000 mg capsules Generic GPO Saquinavir 1,000 mg capsules For phase 1 and 2 - At day 1 subjects of group A will receive a single dose of Invirase®/Norvir® 1,000 mg / 100mg, while group B will receive generic GPO saquinavir / Norvir® 1,000 mg / 100mg as single dose. The same day the first 24 hr PK curve will be done. After this, a 7-day washout period will follow. At day 8 group A will take generic GPO saquinavir / Norvir® and Group B will take Invirase®/Norvir®. At this day, the second 24 hr PK curve will be done
224218683|NCT02244437|DRUG|Ibuprofen|
224218684|NCT02244437|DRUG|Acetaminophen|
224218685|NCT06528587|PROCEDURE|narrow diameter implant|Rehabilitation of single edentulism in the anterior region with narrow diameter implants and computer guided surgery.
224218686|NCT05777265|OTHER|Circuit Training|CT will be applied to the participants, taking into account the recommendations of the American College of Sports Medicine (ACSM), 3 days a week, an average of 40 minutes a day, for a total of 16 weeks. Warm-up and cool-down protocols will be applied before and after each CT, and each exercise will be performed as 15 repetitions and an average of 40 seconds of rest will be given between exercises. Also, the intensity of CT will be determined according to the Borg scale (between 11 and 14). CT will include 'mini squat', 'step up', 'sit ups', 'reverse sit ups', 'leg press', 'leg curl', 'leg extension', 'crunches', 'lunge', 'prone bridge', and 'side bridge' exercises.
224218687|NCT02655627|OTHER|Internet based exercise training|
224218688|NCT02655627|OTHER|group exercise training|
223629890|NCT05419583|DRUG|Anticoagulants (Apixaban, Edoxaban, Rivaroxoban, Warfarin)|Anticoagulant therapy if atrial fibrillation identified (DOAC or Warfarin)
223629891|NCT05419583|DRUG|Guideline directed heart failure therapy|Use of guideline approved heart failure treatments (ACE-inhibitor / angiotensin receptor blocker (ARB) / ARB and neprilysin inhibitor, mineralocorticoid receptor antagonist, beta blocker, SGLT-2 inhibitor, diuretic therapy)
223629892|NCT05419583|DRUG|Statins (Cardiovascular Agents)|Statins will be recommended for patients with coronary plaque disease or hypercholesterolaemia
223629893|NCT00733668|DRUG|Quetiapine fumarate (Seroquel)|300 mg, PO, 100 mg morning, 200 mg evening, 4 weeks
223629894|NCT00956319|DRUG|Zolpidem MR|oral
223629895|NCT00956319|DRUG|Estazolam|oral
223764134|NCT04294134|BEHAVIORAL|MIO-CPP-CRS|"Mothering from the Inside Out (MIO) is an individual, 12-session, manualized, psychotherapeutic intervention designed to promote parental reflective functioning in mothers who are in treatment for SUDs and/or other mental health problems, and caring for a child in-utero through five years old. (Suchman N, Pajulo M, and Mayes LC, 2013).~Child-Parent Psychotherapy (CPP) is a two-generation approach that supports and strengthens parent-child attachment by integrating modalities derived from psychodynamic, attachment, trauma, cognitive-behavioral, and social learning theories. (Lieberman AF and Van Horn P, 2005 and 2008) CPP focuses on working with families offering weekly sessions for nine-12 months.~Certified Recovery Specialists (CRS) provide peer support services are an evidence-based…model of care which consists of a qualified peer support provider who assists individuals with their recovery from mental illness and substance use disorders."
224218689|NCT02655627|OTHER|Physical activity counselling via a brochure|
224218690|NCT04767789|DIETARY_SUPPLEMENT|NZ-GHMH-01|Each randomized subject will consume 1 capsule daily bringing 100 mg (≥ 2 x 109 CFU) of active ingredient during 16 weeks (from V2 to V5 visits).
224218691|NCT04767789|DIETARY_SUPPLEMENT|Placebo|Each randomized subject will consume 1 capsule with no active ingredient daily during 16 weeks (from V2 to V5 visits).
224218692|NCT01977326|BEHAVIORAL|basic counselling by lay-health workers|6 sessions of manual based counselling by trained lay health workers
224218693|NCT01977326|OTHER|Enhanced usual care|3 monthly phone calls by trained lay health workers (without counselling)
224218694|NCT02856074|BIOLOGICAL|prise de sang|
224218695|NCT02856074|OTHER|quality of life questionnaire|
223629896|NCT03170596|DRUG|tazarotene gel 0.1%|Patients will be instructed to apply 0.1% tazarotene gel as a thin film over the affected area once daily in the evening.
223629897|NCT03170596|DEVICE|Microneedling|Microneedling is a method of percutaneous collagen induction
223629898|NCT04234477|DRUG|Beta-blocker strategy|Clinicians within the intervention groups will be free to use whatever dosing amount and frequency of their assigned medication class that they deem as medically appropriate, including the decision to use intermittent IV boluses versus continuous infusions.
223629899|NCT04234477|DRUG|Calcium channel blocker strategy|Clinicians within the intervention groups will be free to use whatever dosing amount and frequency of their assigned medication class that they deem as medically appropriate, including the decision to use intermittent IV boluses versus continuous infusions.
223629900|NCT04234477|DRUG|Physician preference strategy|"This strategy allows for usual care, with providers selecting their preferred rate-control agent. IV beta-blockers available through the inpatient pharmacy include metoprolol or esmolol, and IV calcium channel blockers include diltiazem and verapamil."
224218696|NCT04945720|PROCEDURE|Hepatic artery infusion chemotherapy（HAIC）|hepatic arterial infusion (HAI) of oxaliplatin, fluorouracil/leucovorin (FOLFOX) treatment
224218697|NCT04945720|DRUG|Durvalumab|Patients received anti-PD-L1 agents will begin no earlier than 7 days following the first HAIC procedure. Anti-PD-L1 agents were used intravenously at the standard dose: Durvalumab was given every 3 weeks during HAIC treatment (Q3W) and every 4 weeks after HAIC treatment (Q4W).
223629901|NCT03351452|DEVICE|real anodal transcranial direct current stimulation|The MR-compatible neuroConn DC-Stimulator MR (neuroCare Group, Ilmenau, Germany) will be used.
223629902|NCT03351452|DEVICE|real transcranial alternating current stimulation|The MR-compatible neuroConn DC-Stimulator MR (neuroCare Group, Ilmenau, Germany) will be used.
223629903|NCT03351452|DEVICE|sham transcranial electric current stimulation|The MR-compatible neuroConn DC-Stimulator MR (neuroCare Group, Ilmenau, Germany) will be used.
224218698|NCT02558426|PROCEDURE|Venous Surgery|Patients with Varicose Veins will undergo to venous surgery procedure. Samples obtained from patients undergoing surgical removal of varicose veins will be collected and immediately preserved at -80°. Briefly, the venous tissueswill be excised, homogenized with a motor-driven homogenizer and total RNA will be isolated using the Trizol reagent (Invitrogen, Milan, Italy), according to the manufacturer's instructions. The expression of ERα, ERβ and GPER will be quantified by real-time PCR using the Step OneTM sequence detection system (Applied Biosystems Inc., Milan, Italy), following the manufacturer's instructions
223629904|NCT02682524|DRUG|Pelubiprofen CR 45mg tab.|
224317702|NCT01271218|OTHER|Exercise|All subjects participated in a supervised exercise program three days per week for 14-weeks. Each circuit-style workout consisted of 14 exercises (e.g. elbow flexion/extension, knee flexion/extension, shoulder press/lat pull, hip abductor/adductor, chest press/seated row, horizontal leg press, squat, abdominal crunch/back extension, pec deck, oblique, shoulder shrug/dip, hip extension, side bends and stepping). Participants performed as many repetitions in a 30-s time period. In a continuous, interval fashion, participants performed floor-based callisthenic (e.g. running/skipping in place, arm circles, etc.) exercises on recovery pads for a 30-s time period after each resistance exercise in an effort to maintain a consistent exercise heart rate that corresponded to 60% to 80% of their maximum heart rate.
223629905|NCT02682524|DRUG|Aceclofenac 100mg tab.|
223629906|NCT02851277|DRUG|ASP0892 Intradermal|Intradermal injection
223629907|NCT02851277|DRUG|ASP0892 Intramuscular|Intramuscular injection
223629908|NCT02851277|DRUG|Placebo Intradermal|Intradermal injection
223629909|NCT02851277|DRUG|Placebo Intramuscular|Intramuscular injection
223629910|NCT01489540|DEVICE|laser Doppler imager (Moor)|The laser Doppler imager measures the blood flow of the skin/burn
223629911|NCT02182895|DRUG|Saxagliptin|2.5-5 mg daily
223629912|NCT02102646|DRUG|Triptorelin|Androgen deprivation therapy by Pamorelin 22,5mg/24 weeks administered intramuscularly.
223629913|NCT02102646|PROCEDURE|Orchiectomy|Androgen deprivation therapy by bilateral subcapsular orchiectomy
223629914|NCT00017212|DRUG|exatecan mesylate|
223629915|NCT05635019|BEHAVIORAL|BWL+VOUCHER|This group will receive the BWL program as well as food vouchers, in the form of grocery store gift cards. Participants will be allowed to select to receive gift cards to a grocery store or supermarket from a pre-determined list of stores. Gift cards worth $40 will be emailed or mailed to every 2 weeks after the BWL session.
223629916|NCT05635019|BEHAVIORAL|BWL+HOME|This group will receive the BWL program as well as home-delivered boxes of groceries of low-energy density foods conducive to weight management guidelines. Groceries will include shelf-stable and perishable products like lean meats, fresh vegetables, and fruits. Every 2 weeks, participants assigned to this group will be allowed to select a choice of one of 4 boxes with slightly varied contents. Each box will have approximately $40 worth of groceries.
223629917|NCT05635019|BEHAVIORAL|Behavioral weight loss counseling (BWL)|The behavioral weight loss program consists of 14 individual lifestyle counseling sessions provided over 24 weeks. Each session will be approximately 15-20 minutes. Visits will be scheduled weekly for the first 4 weeks (weeks 1, 2, 3, and 4) and every-other week from weeks 6-24 (weeks 6, 8, 10, 12, 14, 16, 18, 20, 22, and 24). The sessions will provide behavioral, dietary, and physical counseling.
223629918|NCT05918523|BIOLOGICAL|Renal Autologous Cell Therapy (REACT)|No interventions in this trial
223629919|NCT00286468|DRUG|Alogliptin and glyburide|Alogliptin 12.5 mg, tablets, orally, once daily and glyburide for up to 26 weeks.
223629920|NCT00286468|DRUG|Alogliptin and glyburide|Alogliptin 25 mg, tablets, orally, once daily and glyburide for up to 26 weeks.
223629921|NCT00286468|DRUG|Glyburide|Alogliptin placebo-matching tablets, orally, once daily and glyburide for up to 26 weeks.
223629922|NCT05004727|DRUG|Guselkumab|Guselkumab 100 mg 1 mL liquid formulation in a single-dose pre-filled syringe administered by subcutaneous injection at Week 0, Week 4 and every 8 weeks thereafter (month 0 to month 24 for arm 1; week 24 to month 24 for arm 2).
223629923|NCT05004727|DRUG|Placebo|• Placebo to Guselkumab 1 mL liquid formulation in a single-dose pre-filled syringe administered by subcutaneous injection at Week 0, Week 4 and every 8 weeks thereafter (Month 0 to Week 20 for Arm 2).
223629924|NCT03494660|DEVICE|Subchondroplasty Procedure with AccuFill|Injection of the commercially available flowable calcium phosphate (CaP) synthetic bone-void filler, AccuFill®, into subchondral bone defects in the hip (Subchondroplasty (SCP) Procedure).
223629925|NCT06571253|BEHAVIORAL|Digital Exercise Intervention|Participants in this intervention arm used the Fiziu Digital Physiotherapy Platform. This digital platform provided a structured 6-week corrective exercise program through visual and auditory-guided videos. The intervention included interactive features such as reminders and progress tracking to enhance adherence and engagement.
223629926|NCT06571253|BEHAVIORAL|Paper-Based Exercise Intervention|Participants in this intervention arm followed a traditional paper-based exercise program. This included printed exercise instructions and illustrations for a 6-week period. The program was designed to mimic standard physical therapy exercises without digital support.
223629927|NCT06548126|BEHAVIORAL|Online Parenting Program|Online Parenting Program comprised of 12 online modules. Caregivers do one module per week for 12-15 weeks; each unit takes about 20 minutes to do. The Caregiver also practices the tools they learn for Parenting their Children between sessions.
223629928|NCT06548126|OTHER|No online parenting program|List of Parenting resources.
223629929|NCT01380353|DRUG|Diclofenac epolamine patch|Patch (10cm X 14cm) is comprised of an adhesive material containing 1.3% diclofenac epolamine which is applied to a non-woven polyester felt backing and covered with a polypropylene film release liner \[B\].
223629930|NCT03047941|DIAGNOSTIC_TEST|Determination of optimal cutoff values.|The results of the four scores will be compared with the results of the polysomnography (PSG). A statistical analysis will be performed to determine the optimal cutoff value of each of the four scores to detect severe OSA patient with hypoxemia.
223629931|NCT01472640|DRUG|liraglutide|1.8 mg sc QOD
223629932|NCT01472640|DRUG|placebo|1 U sc QOD
223629933|NCT04675970|OTHER|Observational|Product in a Institute of Bio-Stem Cell rehabilitation UAB - sponsored clinical trial who agree to participate in this study
224218699|NCT03341273|DRUG|Azithromycin|Azithromycin is an azalide antibiotic and is derived from erythromycin used to treat many different types of infections caused by bacteria, such as respiratory infections.
224218700|NCT03341273|OTHER|Placebo|Placebo will be a matching capsule the same size, weight, and color as the capsules containing Azithromycin tablets.
224218701|NCT03341273|DEVICE|VIDAS B.R.A.H.M.S Procalcitonin Test (PCT)|The VIDAS B.R.A.H.M.S PCT is an automated test for use on the VIDAS instruments for the determination of human procalcitonin in human serum or plasma using the Enzyme-Linked Fluorescent Assay (ELFA) technique.
224218702|NCT05779319|DEVICE|non contact measurement with the IOL Master 700|postoerpative we will perform non contact measurement with the IOL Master 700
223629934|NCT01285141|BIOLOGICAL|CN54gp140 glycoprotein-hsp70 conjugate vaccine|CN54gp140-hsp70 conjugate vaccine administered intravaginally 3 times over a 12-week period
223629935|NCT00003989|BIOLOGICAL|ISIS 3521|
223629936|NCT02470286|DRUG|SA001 60mg or Placebo|"* Study Drug: SA001 60mg~* Comparator: Placebo~* Cohort 1 in the part 1 (Dose escalation study)"
223629937|NCT02470286|DRUG|SA001 120mg or Placebo|"* Study Drug: SA001 120mg~* Comparator: Placebo~* Cohort 2 in the part 1 (Dose escalation study) and part 2 (Food effect study)"
223629938|NCT02470286|DRUG|SA001 180mg or Placebo|"* Study Drug: SA001 180mg~* Comparator: Placebo~* Cohort 3 in the part 1 (Dose escalation study)"
223629939|NCT02470286|DRUG|SA001 240mg or Placebo|"* Study Drug: SA001 240mg~* Comparator: Placebo~* Cohort 4 in the part 1 (Dose escalation study)"
223629940|NCT02470286|DRUG|SA001 300mg or Placebo|"* Study Drug: SA001 300mg~* Comparator: Placebo~* Cohort 5 in the part 1(Dose escalation study) and part 2 (Food effect study)"
223629941|NCT05399069|DRUG|VGR-R01|Gene Replacement Therapy
223629942|NCT03305666|DRUG|Liposomal bupivacaine injection|A single injection of liposomal bupivacaine is administered at the time of SSRF, directly to the fracture site via VATS
223629943|NCT03305666|DRUG|Bupivacaine indwelling catheter|Bupivacaine indwelling OnQ pain pump catheter is placed in the subscapular space at the time of SSRF for continuous bupivacaine infusion post op
223629944|NCT00783159|PROCEDURE|Power Training|Power training, Vitamin D substitution
223629945|NCT00783159|PROCEDURE|Strength Training|Strength training, Vitamin D substitution
224218703|NCT03435432|DIETARY_SUPPLEMENT|Glucose|Glucose drink
224218704|NCT03435432|DIETARY_SUPPLEMENT|Water|Control
224218705|NCT03967132|OTHER|Control Infant Formula|Ready to feed infant formula, feed ad libitum
223629946|NCT00783159|OTHER|Control|Vitamin D substitution, Lifestyle consultation
223629947|NCT00196547|DRUG|Montelukast (drug)|
223629948|NCT00739921|PROCEDURE|Nasal swab under endoscopic guidance|"After the application of pontocaine and neosynephrine spray, the following will be done:~* A small sponge applicator will be used to swab the inside of your mouth for saliva collection~* A blood sample (6cc - one tube) will be collected~* A small brush applicator called a cytology brush and an instrument called an endoscope will be used to swab the inside of your nose (middle meatus)~* Subjects will be asked to complete 2 standard quality of life questionnaires regarding how much your symptoms bother you~* You will be asked to bring in a vacuum cleaner bag from home at a follow-up appointment which will be swabbed as well~The samples will be refrigerated and analyzed using PCR to detect and speciate fungus."
223629949|NCT02096445|DEVICE|robot-assisted neurocognitive therapy of hand function|2 degrees-of-freedom hand rehabilitation robot to train fine motor skills during grasping and forearm rotation.
223629950|NCT02096445|OTHER|Conventional neurocognitive rehabilitation|Use sensory perception (tactile, proprioception but not vision!) to solve a by the therapist guided (passive) or patient controlled (active) therapy task, e.g. discrimination/identification of different spring resistances, sponges, different sized blocks, etc.
223629951|NCT06091475|DRUG|Other|Withdrawal of mineralocorticoid receptor antagonists and/or sodium glucose cotransporter 2 inhibitors
224218706|NCT03967132|OTHER|Experimental Infant Formula|Ready to feed infant formula, feed ad libitum
224218707|NCT03967132|OTHER|Reference Group|Human milk, breast feeding ad libitum
224218708|NCT01717456|OTHER|Education|Patient and caregiver will be taught which muscles are used in continence and defecation through the use of a training manual and anatomical drawings.
224218709|NCT01717456|DIETARY_SUPPLEMENT|Fiber supplements|Patients and caregivers will be taught to use fiber supplements to normalize stool consistency if patient reports diarrhea or constipation. Fiber supplements will be in the form of Metamucil beginning with 3.4 grams per day and increasing up to 13.6 grams per day if needed to control stool consistency.
224218710|NCT01717456|DRUG|Laxatives or anti-diarrheals|"Miralax at a dose of one packet (17 grams) daily may be used for constipation if unresponsive to fiber. Dose may be titrated up to two packets (34 grams) daily if needed.~Imodium at a starting dose of 2 mg/day may be used for diarrhea if unresponsive to fiber. Dose of Imodium may be titrated down to 1 mg or up to 4 mg if needed."
224218711|NCT01717456|BEHAVIORAL|Pelvic floor muscle exercises|Patients will be taught how to perform pelvic floor muscle contractions during digital rectal examination by a nurse. They will be asked to squeeze 100 times daily.
224218712|NCT01717456|BEHAVIORAL|Tips on how to prevent fecal incontinence|"Examples of behavioral tips are Walk, don't run to the toilet and Squeeze before you lift objects or sneeze."
224218713|NCT01717456|BEHAVIORAL|Daily diary|Both groups will keep a daily diary, but amount of detail differs: Active comparator group records bowel accidents, bowel movements, Bristol Stool ratings of stool consistency, number of times they do pelvic floor exercises, study medications, and comments for the nurse to read. Placebo comparator group records only bowel accidents, bowel movements, and Bristol Stool scores.
223629952|NCT01874236|DRUG|0.75% bupivacaine|Week 1: SI joint injection with .75% bupivacaine Week 2: SI joint injection with .75% bupivacaine Week 3: SI joint sham block
223629953|NCT01874236|DRUG|.75% bupivacaine|Week 1: SI join sham block Week 2: SI joint injection with .75% bupivacaine Week 3: SI joint injection with .75% bupivacaine
224218714|NCT01717456|OTHER|Protective pads or garments|In both groups, patients will be permitted to use pads or protective garments to avoid embarrassment. They will be told that fecal leakage that is stopped by a pad or protective garment should still be recorded as fecal incontinence.
223629954|NCT01874236|DRUG|.75% bupivacaine|Week 1: SI join injection with .75% bupivacaine Week 2: SI join sham block Week 3: SI joint injection with .75% bupivacaine
223629955|NCT01592734|DRUG|Polyethylene glycol with electrolytes|"Constipation treatment: 1-4 sachets/day according to the patient age. 1 sachet contains 6.9 g PEG-EL. Treatment period: 4 weeks.~Faecal impaction resolution: 4 sachets as initial dose and increasing 2 sachets a day until resolution or up to 7 days."
223629956|NCT01592734|DEVICE|Polyethylene glycol|"Constipation: 0.7 g/kg/day in 2 divided doses for children of less than 20 kg. For children \> 20 kg the daily dose was up to PEG 30 g daily. Treatment period: 4 weeks.~Faecal impaction resolution: 1.5 g/kg/day in 2 doses until resolution or up to 6 days."
223629957|NCT05842616|OTHER|Transcranial doppler pulsatility index guided protocol|Norepinephrine titration that will be guided by Transcranial doppler pulsatility index.
223629958|NCT05842616|OTHER|Mean arterial blood pressure guided protocol|Norepinephrine titration that will be guided by Mean arterial blood pressure (MAP).
223629959|NCT02913339|OTHER|mHealth Risk Assessment|Using mobile phone application to calculate CVD risk and to schedule interviews at local government clinics.
223629960|NCT00002298|DRUG|Ribavirin|
223629961|NCT02739230|DRUG|Exparel|
223629962|NCT02739230|DRUG|On-Q pain intra-articular catheter|
223629963|NCT04091620|PROCEDURE|Transanal Total Mesorectal Excision|As above
223629964|NCT04091620|PROCEDURE|Robotic Total Mesorectal Excision|As above
223629965|NCT02515916|OTHER|Not Interventional|This will be a prospective, non-randomized, uncontrolled study examining the effects of oncology treatments in women at risk for treatment induced ovarian failure.
223629966|NCT06540053|OTHER|Active Static Hamstring Stretch Exercise|In the first session, participants will be instructed on the principles of spinal protection. Following this, members of the experimental group will engage in active hamstring exercises within the office environment. These exercises will be conducted for 10 minutes, consisting of 10 repetitions of 30-40 seconds of stretching followed by 30 seconds of rest, five days a week for six weeks. Participants in the experimental group will be remotely supervised during the stretching exercises.
224218715|NCT06339593|DRUG|Hyperpolarized Xe129|Hyperpolarized Xe MRI is FDA Approved for Adults and Children 12 and above We have been performing Xe MRI for research in human subjects for over 20 years, and for over 10 years at CCHMC. Recent FDA approval of hyperpolarized Xe MRI for ventilation stands as a testament to its safety and value as a modern tool for exploring lung disease and function. Earlier studies using Xe MRI have shown its efficacy in exploring CF and other lung diseases in pediatric and adult populations, and it has been found to be much more sensitive to early lung disease than traditional metrics like spirometry and MBW
224218716|NCT02791776|OTHER|Scoliosis|"self-administered questionnaire (SRS 30) to assess the state of health and disability of patients.~Collection of patient's radiographic and clinical parameters"
224218717|NCT04872426|OTHER|Exercise, insulin infusion|Acute one-legged exercise, Insulin infusion 3 hours after one-legged exercise
224218718|NCT00991770|OTHER|Massage Therapy|Two 20 minute chair massages: one before surgery and one after
224317703|NCT00242424|BIOLOGICAL|2005-2006 trivalent inactivated influenza vaccine|Children enrolled at 6-12 weeks to receive first dose, 0.25 ml of trivalent inactivated influenza vaccine, 2005-6 pediatric Fluzone formulation (sanofi pastuer), with concomitant routine pediatric vaccines. Second dose administered 4 weeks later.
223629967|NCT06540053|OTHER|Waiting List|Participants will receive workplace training on spine protection principles and subsequently be placed on a waiting list. Throughout this process, individuals in the designated group will receive text messages on Mondays, Wednesdays, and Fridays over the course of six weeks. These messages will contain information aimed at assisting them in maintaining correct posture throughout the workday.
224218719|NCT00991770|OTHER|Attention Control|Two 20 minute sessions where the Massage Therapist will talk to the patient about how they are feeling, listen, and provide empathetic support.
224317704|NCT04450758|PROCEDURE|Bridge to Surgery (stent or stoma)|The study is an observational study and patients will not be randomized. Resection is defined as upfront surgical resection, Bridge to Surgery as a two stage procedure.
224317705|NCT00098618|DRUG|sorafenib tosylate|Given orally
223629968|NCT03962036|DEVICE|Bispectral index monitor|BIS monitor is a novel measure of the level of consciousness by algorithmic analysis of a patient's electroencephalogram during general anesthesia.
223629969|NCT02064803|PROCEDURE|Gastro-entero anastomosis only|Gastro-entero anastomosis only
223629970|NCT02064803|PROCEDURE|Gastric partitioning Plus Gastro-entero anastomosis|Gastric partitioning Plus Gastro-entero anastomosis
223629971|NCT03539406|BIOLOGICAL|UCB-NK cells|Intraperitoneal allogeneic UCB-NK cells infusion
223629972|NCT03539406|DRUG|Chemotherapy|Cyclofosfamide/fludarabine treatment
223629973|NCT02005549|DRUG|bevacizumab [Avastin]|15 mg/kg iv on Day 1 of each 3-week cycle, 5 cycles
223629974|NCT02005549|DRUG|docetaxel|75 mg/m2 on Day 1 of each 3-week cycle, 6 cycles
223629975|NCT02005549|DRUG|capecitabine [Xeloda]|950 mg/m2, orally twice daily, evening of Day 1 until morning of Day 15, followed by a 7 day rest period, every 3 weeks
223629976|NCT04673318|BEHAVIORAL|heat therapy|leg heated garments with circulating water to conduct heat therapy at home
223629977|NCT04673318|BEHAVIORAL|exercise training|A velocity based training program will be implemented at home using a mobile app allowing for the quantification the relative intensity.
223629978|NCT01950182|DRUG|Endocrine therapy combined with trastuzumab|Tamoxifen or aromatase inhibitors (Anastrozole, Letrozole, or Exemestane) combined with trastuzumab
223629979|NCT01950182|DRUG|Chemotherapy combined with trastuzumab|Capecitabine , Vinorelbine, or Gemcitabine combined with trastuzumab
223629980|NCT03799146|BEHAVIORAL|MyPlan 2.0|MyPlan 2.0 consists of five sessions. During these five sessions the following behaviour change techniques are used to motivate users to be more physically active or to sit less: exploring risk perceptions and perceived benefits, exploring social support, providing feedback, action planning, coping planning and monitoring.
223629981|NCT03799146|OTHER|Waiting List|Waiting List control group
224218720|NCT00800098|DRUG|herbal topical cream|
224218721|NCT02008721|DRUG|EGCG as putative neuroprotective agent|Treatment with 800 mg - 1200 mg EGCG as putative neuroprotective agent
224218722|NCT02008721|DRUG|Placebo|Placebo
224317706|NCT00098618|BIOLOGICAL|recombinant interferon alfa|Given orally
224317707|NCT00098618|OTHER|laboratory biomarker analysis|Correlative studies
224218723|NCT05033613|OTHER|heart rate、arrhythmia、blood pressure、central body temperature (ear temperature) and blood oxygen saturation level.|heart rate、arrhythmia、blood pressure、central body temperature (ear temperature) and blood oxygen saturation level.
224317708|NCT01238107|DRUG|MT-102|BETA BLOCKER
223629982|NCT05182086|OTHER|Group physical therapy and dietary improvements|20 patients allocated to intervention group. During 12 weeks, patients will participate in a combined lifestyle intervention, including a one-hour physical therapist guided exercise group twice a week and consultation by a nutritional scientist. In case of inadequate intake, dietary supplements will be provided.
223629983|NCT04195646|DEVICE|EndoVigilant CAD Software|The CAD software is deep learning algorithm used to aid in the detection of polyps (abnormal tissue growths in the wall of the colon and adenomas (pre-cancerous growths) during colonoscopy. In its current form, the CAD software is installed on a computer system unit that utilizes an an operating system.
223629984|NCT02728115|BIOLOGICAL|Cellavita HD Lower Dose|The first three participants enrolled in the study will be assigned to the lower dose arm with staggered treatment, with an interval of 30 days between the first administration of the first participant and the first administration of the second participant assigned to this arm. All participants will receive a total of 3 intravenous administration, one every 30 days.
223629985|NCT02728115|BIOLOGICAL|Cellavita HD Higher dose|The last three participants enrolled in the study will be assigned to the higher dose arm with staggered treatment, with an interval of 30 days between the first administration of the first participant and the first administration of the second participant assigned to this arm. All participants will receive a total of 3 intravenous administration, one every 30 days.
223629986|NCT02230410|DEVICE|CryoBalloon Focal Ablation|
223629987|NCT01729741|PROCEDURE|drain was inserted after thyroid surgery|insertion of drain after thyroid surgery
223629988|NCT06092723|DIETARY_SUPPLEMENT|Placebo|Subjects take two packs once a day, and make a 250 ml water solution for drinking.
223629989|NCT06092723|DIETARY_SUPPLEMENT|Probiotic 1,Lactococcus lactis subsp. lactis, LY-66|Subjects take two packs once a day, and make a 250 ml water solution for drinking.
223629990|NCT06092723|DIETARY_SUPPLEMENT|Probiotic 2,Lactobacillus plantarum, PL-02|Subjects take two packs once a day, and make a 250 ml water solution for drinking.
223629991|NCT06092723|DIETARY_SUPPLEMENT|Probiotic 3,Lactococcus lactis subsp. lactis, LY-66+Lactobacillus plantarum, PL-02|Subjects take two packs once a day, and make a 250 ml water solution for drinking.
223629992|NCT05671146|DEVICE|anti-gravity treadmill|participants will perform exercises with partial weight-bearing by using an anti-gravity treadmill
223629993|NCT05671146|OTHER|Weight-bearing exercises for knee flexors and extensors|Stretching and strengthening exercises will be performed in a weight-bearing position
223629994|NCT05671146|OTHER|Non weight-bearing exercises for knee flexors and extensors|Stretching and strengthening exercises will be performed in a non-weight-bearing position
223629995|NCT00169182|DRUG|DOCETAXEL|75 mg/m 2 on day 1
223629996|NCT00169182|DRUG|Cisplatin|75 mg/m 2 on day 1
223629997|NCT00169182|DRUG|5-Fluoro-3-Pyridinecarboxylic Acid|750 mg/m 2 by 24-hour continuous infusion for 5 days
223629998|NCT02135861|PROCEDURE|DCE-MRI scans|Subjects will be placed supine in the scanner and will be prepared for intravenous contrast agent administration. The contrast agent is administered using a power injector before imaging.
223629999|NCT02135861|OTHER|Gadobutrol|Gadobutrol at a dose less than or equal to 0.1 millimoles per kilogram (mmol/kg) will be given intravenously as a bolus using a power injector.
223630000|NCT01166139|DRUG|Nilotinib (Tasigna)|Patients will be treated with Nilotinib 400 mg two times a day for 6 months.
223630001|NCT02587221|BIOLOGICAL|MF59-adjuvanted Quadrivalent Subunit Inactivated Egg-derived Influenza Vaccine (aQIV)|1 dose approximately 0.5 mL of aQIV
223630002|NCT02587221|BIOLOGICAL|Non-Influenza Comparator (Boostrix)|1 dose approximately 0.5 mL dose of Non-influenza comparator vaccine (Boostrix)
223680796|NCT01264627|BEHAVIORAL|Mindful Breathing (MB) Intervention|"The Mindful Breathing (MB)intervention is based on MBSR developed by Jon Kabat-Zinn. Participants will attend 8 individual weekly MB sessions. MB consists of closely following the breath, throughout inhalation and exhalation, sustaining moment-to-moment awareness on the breathing process, and passively observing thoughts, affective states, from a non-evaluative or judgmental perspective. As attention wanders to concerns or thoughts, participants will be instructed to acknowledge and accept these without evaluation and return the focus of attention back to breathing. Participants in MB will have their breathing rate and PetCO2 monitored during the 8 training sessions with a breathing monitor."
223764135|NCT06447844|DEVICE|OsteoGen Plug|OsteoGen® Plug is contoured to fill the three roots of the socket. Plug is delivered dry into a thoroughly debrided and actively bleeding socket. The OsteoGen® Plug is condensed firmly into the socket.
223764136|NCT06447844|DEVICE|BioGide|BioGide is a resorbable collagen membrane
223764137|NCT04278144|DRUG|BDC-1001|Immune stimulating antibody conjugate (ISAC), consisting of an anti-HER2 monoclonal antibody conjugated to a TLR 7/8 dual agonist
223764138|NCT04278144|DRUG|Nivolumab|Programmed death receptor-1 (PD 1)-blocking antibody
224218724|NCT01844934|OTHER|Prehabilitation|The three week, 3 days / week prehabilitation exercise program will consist of resistance training, step training and stretching(flexibility) as well as cardiovascular endurance training. Intensity of training will increase over the three weeks. Classes will be delivered over a four week period with a gap during the third week allowing additional time for participants to practice their exercises. The home exercise program will be designed to account for the additional week.
224218725|NCT00149292|DRUG|LY2140023|
224218726|NCT00149292|DRUG|olanzapine|
224218727|NCT00149292|DRUG|placebo|
224317709|NCT00295061|DRUG|Alpha-1 MP|alpha-1 proteinase inhibitor (human), 60 mg/kg body weight
224317710|NCT00295061|DRUG|alpha-1 proteinase inhibitor (human)|Prolastin
224317711|NCT00101283|DRUG|pemetrexed disodium|500 mg/m2 IV over 10 minutes on day 1 of a 21-day cycle
224317712|NCT00101283|DRUG|gemcitabine hydrochloride|1000 mg/m2 IV over 30 minutes on days 1 and 8 of a 21-day cycle
224317713|NCT00101283|DRUG|carboplatin|Given by IV over 30 minutes at an area under the curve (AUC) of 5 on day 1 of a 21-day cycle
224317714|NCT04736745|BIOLOGICAL|IPN59011|Powder and solvent for solution for injection
224317715|NCT04736745|BIOLOGICAL|Azzalure|Powder for solution for injection
224317716|NCT04736745|DRUG|Placebo|Powder for solution for injection
223630003|NCT05247372|OTHER|The effect of Iyengar yoga practice on patients with multiple sclerosis|The study will be conducted as a longitudinal follow-up - at first patients will fbe examined 2 months before the start of the exercise, than they will be examined at the beginning and end of the exercise, which they will attend for 3 months. Patients will be re-examined 2 months after the end of the exercise to clarify the continuing effect of the exercise. The examination will include a basic kinesiological analysis and a neurological examination,TUG test, 6MWT along with the Borg Subjective Weight Rating Scale and T25FWT, BBS, NHPT and stable sitting time in wheelchairs. To evaluate the development of the chest, the respiratory amplitude will be examined and the position of the spine in statics and dynamics will be evaluated using a spinal mouse. Quality of life will be assessed through the MFIS, MSIS-29, MSQOL 54 questionares and Beck's anxiety inventory.
223630004|NCT00573222|DRUG|Symbicort|
223630005|NCT04268459|DEVICE|Provox prosthesis exchange|Each patient post laryngectomy will be randomly assigned to one arm of intervention. The voice prosthesis exchange in all patients will be performed in local anaesthesia. The microbiological samples with cotton swabs will be collected from tracheoesophageal fistula on prosthesis exchange. The clinical evaluation and patients satisfaction from prosthesis usage will be performed on each exchange.
223630006|NCT04558060|OTHER|Virtual Standardized Patient|Computer program that presented a virtual human patient
223630007|NCT04558060|OTHER|Academic Study|Study of a summary of motivational interviewing concepts and techniques.
223630008|NCT05852119|OTHER|Outpatient treatment with standard anticoagulant therapy|All patients included in the study will be treated on an outpatient basis, that is, they will be discharged within the first 24 hours of the diagnosis of PE in the Emergency Department.
223630009|NCT00241384|PROCEDURE|External beam radiation|
223630010|NCT00241384|PROCEDURE|Pd-103|
223630011|NCT06227481|PROCEDURE|Scar subcision|"* Subcision will be performed with18 gauge cannula at the margin of the scars on both sides of the face.~* The cannula will be directed in a forward and backward motion producing a tunnel. Then, the it will be passed in sideways in a sweeping action to freeing up the scars from their bases.~* Once finish, the pressure will be applied to reduce the bleeding and swelling. The topical antibiotic will be applied for 3 days."
223630012|NCT06227481|PROCEDURE|Platelet rich plasma injection|• 20 ml of autologous whole blood will be collected into tubes containing acid citrate dextrose and centrifuged at 1500 rpm for 10 minutes in order to get PRP at the top of the test tube. Then, the PRP will be further centrifuged at 3700 rpm for 10 minutes at room temperature of 22°C in order to obtain a platelet count 4.5 times higher than the base line. Platelet-poor plasma (PPP) will be partly removed and partly used to resuspend the platelets. Calcium gluconate will be added as an activator (1:9), i.e., 1 ml of calcium gluconate in 9 ml of PRP
223630013|NCT06227481|PROCEDURE|Polydioxanone mono threads insertion|"* Topical anesthetic cream will be applied for halfan hour on the involved area.~* polydioxanone mono threads (50 mm, 27 G) will be inserted at 1-cm spacing into the dermal layer of the skin; the threads will be arranged in a transverse and vertical line in the form of a mesh similar to cross-hatching technique.~* The total numbers will range from 8 to 10 each side. The skin of the face will be stretched by the non-dominant hand of the physician and the needle will be inserted by the other hand through the required point."
223630014|NCT06227481|DEVICE|Fractional carbon dioxide laser|"* Topical anesthetic cream will be applied for 30 minutes before the procedure.~* BX300 device from AMI inc.,Korea will be used.~* Different settings will be used according to each individual case regarding the type of scar, severity and skin type fluence ranging from 36 to 42 j/cm2 will be used and pulse duration 1.8 ms.~* In an attempt to avoid common side effects that occur with fractional laser treatment, a lower fluence will be used in the first session and depending on the results, the fluence will be increased per treatment session."
224218728|NCT05144620|DIAGNOSTIC_TEST|3D Mapping|3D model will be made from diagnostic imaging for pre-surgical planning
224218729|NCT02489890|BIOLOGICAL|Cytokine-induced Killer Cells|chemotherapy plus 3 cycles of Cytokine-induced Killer Cells(CIK) treatment
224218730|NCT06244303|DRUG|manual Tooth Brush + Colgate Total TP (0.454% SnF, 1100 ppm F)|Toothpaste, toothbrush \& mouthwash regime
223630015|NCT04612335|OTHER|Rate control|Rate control drugs are administered to obtain symptom relief and a heart rate of \<110 bpm, followed by a 4-week telemonitoring period.
223630016|NCT04612335|OTHER|Pharmacological or electrical cardioversion|Pharmacological or electrical cardioversion is performed to achieve restoration of sinus rhythm, either acutely or in a wait-and-see approach, all within 48 hours, and followed by a 4-week telemonitoring period.
223630017|NCT02862678|OTHER|diffusion-weighted MRI|Two diffusion-weighted MRI will be performed (one 8 days before chemoradiotherapy treatment and one 3 months after the end of chemoradiotherapy treatment).
224317717|NCT03266601|DRUG|Recombinant Human Interferon α-2b Spray|Recombinant human interferon α-2b spray (trade name Jeferon, specifications: 1 million U/support, 10mL/support or 2 million U/support, 20mL/support, 2-8 ℃ dark storage and transportation), 1 million U/day, used for 3 days, observed to the 4th day (until the 96th hour).
224317718|NCT03266601|DRUG|Ribavirin|Ribavirin Spray, spray once every 4-5 hours, 1-2 times a spray, used for 3 days, observed to the 4th day(until the 96th hour ).
223630018|NCT05225311|OTHER|Observation|Patients will be followed by the registry for life-long outcomes.
224218731|NCT06244303|DRUG|manual toothbrush + Colgate dental cream|toothpaste + toothbrush
224317719|NCT03260725|BEHAVIORAL|Parent-Child Interaction Therapy (PCIT)|PCIT is a short-term intervention that incorporates principles of play therapy into behavioral parent training, drawing on attachment and social learning theories to emphasize positive attention, consistency, problem solving, and communication. Treatment is delivered in the clinic.
224317720|NCT03260725|BEHAVIORAL|Internet-delivered PCIT (I-PCIT)|I-PCIT is a short-term intervention that incorporates principles of play therapy into behavioral parent training, drawing on attachment and social learning theories to emphasize positive attention, consistency, problem solving, and communication. Treatment is delivered to families in their own home in real-time via videoconferencing over the Internet by a remote therapist.
224317721|NCT04187170|OTHER|Strength physical training|progressive high-load strength training over 6 months, consisting in repeated physical exercises to increase the muscular mass and force by altering concentric and eccentric muscle contractions against high resistance.
224317722|NCT04663971|PROCEDURE|Any surgery|Any surgical procedures performed for inflammatory bowel diseases
223630019|NCT05711576|OTHER|Placebo mouthwash|Patients were treated with non surgical peri-implant mucositis therapy with non-surgical sub-marginal peri-implant instrumentation plus the use of a placebo mouthwash
223630020|NCT05711576|OTHER|Full mouth disinfection|Patients were treated with non surgical peri-implant mucositis therapy with non-surgical sub-marginal peri-implant instrumentation plus the use of full mouth disinfection (FMD) approach
224218732|NCT03410381|OTHER|Application EMMA|Emma proposes four types of assessments during 6 months:1) 5 times a day during 3 days, every month (5 minutes): patients can assess their emotions, their thoughts, their behavior and their occurrence context. 2) Weekly (7 minutes): consists of a summary of the week, about their emotions, thoughts, behavior, their relationships (family, work, friends, and their quality of life.3) Monthly (5 minutes): assessment of the usefulness and satisfaction about the application.4) Assessment available at any time An action plan is designed to support the participants, to help them facing difficult emotions and feelings, and to encourage them to ask for help. They can contact a relative or call the psychiatric emergency service directly by clicking on a button.
223630021|NCT06036225|BEHAVIORAL|Prehabilitation|Remote prehabilitation multi-component.
223630022|NCT03609073|DEVICE|Endomina|Suturing system then cutting the bridge between the diverticulum and the esophagus.
223630023|NCT04701814|OTHER|biomechanical scapular mobilization with movement and motor learning|the therapist applied posterior tilt and exteral rotation with upward rotation mobilization to scapula and therapist also warp bilt around GH joint to applied inferior and posterior glid then ask patient to elevate his arm. then we applied motor learning approach by asking patient to elevate his arm with maintaining of external rotation with posterior glid of scapula.
223630024|NCT04099563|DRUG|PF-04965842|"For this study, the investigational product is PF-04965842 (provided as 100 mg tablet).~PF-04965842 100 mg tablets will be provided by Pfizer. Investigational product will be presented to the participants in individual dosing containers"
223630025|NCT04732312|OTHER|Home help|Setting up of a formal home help
223630026|NCT04589741|DRUG|Toripalimab Combined With CAV/IE chemotherapy|"CAV/IE regimen alternate chemotherapy (regimen 1: CTX 1.2mg/m2 D1 + ADM 50mg/m2 D1 + VCR 1.4mg/m2 D1 and scheme 2: IFO 1.5g/m2 D1-5 + vp-16 90mg / m2 D1-5, IV drip). Regimen 1 and 2 were performed alternately, with a cycle of 3 weeks;~The patients were treated with toripalimab (240mg, 6ml) intravenously every 3 weeks;~If doxorubicin has reached the upper limit or reduced cardiac toxicity, liposome adriamycin (50mg/m2) or IE regimen can be used~After 6 courses of treatment, patients with disease control (CR + PR + SD) and tolerable adverse reactions were treated continuously. The study was completed when the researchers considered that the patients were not suitable for continuous medication or the efficacy evaluation was disease progression (PD). No other anti-tumor treatment can be carried out during the treatment."
224218733|NCT04881955|DRUG|[14C]-Ecopipam|\[14C\]-Ecopipam
224218734|NCT03139214|BEHAVIORAL|Parenting Intervention|
224218735|NCT01266174|DRUG|Eltoprazine|Comparison of eltoprazine, dosed orally, for 8 weeks
224218736|NCT01266174|DRUG|Placebo|Placebo to match eltoprazine
224218737|NCT01303991|OTHER|Hexvix PDT with Karl Storz T-Light|
224218738|NCT04090996|DIAGNOSTIC_TEST|Dual TAsk|"Motor assessment includes:~* posturographic examination in Single-task (ST) and Double-task (DT)~* an analysis of ST and DT walking;~* Timed Up and Go (TUG) performances in real (rTUG) and imagined (iTUG) versions;"
224218739|NCT04110795|OTHER|No Intervention|No Intervention
223630027|NCT04589741|DRUG|CAV/IE alternate chemotherapy|"CAV/IE alternate chemotherapy (regimen1: CTX 1.2mg/m2 D1 + ADM 50mg/m2 D1 + VCR 1.4mg/m2 D1 and regimen2: IFO 1.5g/m2 D1-5 + VP-16 90mg/m2 D1-5, IV drip), regimen 1 and 2 were performed alternately, with a cycle of 3 weeks.~Patiens with disease control (CR+PR+SD) and tolerable adverse reactions were treated continuously with a maximum of 8-10 cycles. If doxorubicin has reached the upper limit or reduced cardiac toxicity, liposome adriamycin (≥ 60 years old: 35mg/m2, \< 60 year old: 40mg/m2) or IE regimen can be used. The study was completed when the researchers considered that the patients were not suitable for continuous medication or the efficacy evaluation was disease progression (PD). No other anti-tumor treatment can be carried out during the treatment."
223630028|NCT03383601|OTHER|Heated Tobacco product IQOS/heatstick|Heated Tobacco Products: heatsticks heated by iQOS device
223630029|NCT03383601|OTHER|Smoking combustible cigarettes|Current smoking of combustible cigarettes
223630030|NCT00002088|DRUG|Saccharomyces boulardii|
223630031|NCT00000928|BEHAVIORAL|Group counseling intervention|Participants will engage in a multi-session group-based condom promotion program for approximately 12 months
223630032|NCT02157818|DRUG|midazolam|
224218740|NCT01989507|DRUG|Nicotine|
223630033|NCT02157818|DRUG|Dexmedetomidine|
223630034|NCT05214534|OTHER|blood supar measurement|The supar values will be measured afterwards on the tube bottoms of the patients included in the study from their usual collection
224218741|NCT01989507|BEHAVIORAL|behavioral counseling for smoking cessation|Brief session of Brief advice. Assess smoking and provide assistance with quitting via coping skills.
224218742|NCT03404661|DRUG|Synthetic Human Secretin|Subjects will receive a dose of 0.2ng/kg while the endoscope is positioned in the second portion of the duodenum.
224218743|NCT03867851|DRUG|IBsolvMIR|Study drug IBsolvMIR
224218744|NCT03867851|DRUG|Heparin|Clinical praxis
224218745|NCT00282555|DRUG|S-Tenatoprazole-Na (STU-Na)|
224218746|NCT05638152|OTHER|implementation of a bundle of non-pharmacological interventions aimed at stress reduction|"The bundle consists of 4 interventions:~* natural imagery in the PACU (wall length decorations and lighted ceiling panels with sky views~* Aromatherapy with fragrances selected for anxiolytic and antiemetic properties~* Music available to patients~* Comfort Talk communication course for PACU nurses"
224218747|NCT06084507|DRUG|GST-HG171/ritonavir|Single oral dose of GST-HG171 300 mg (2 × 150 mg tablets)/ritonavir 100 mg under fed or fasted conditions at 0 hour on Day 1
224218748|NCT06084507|DRUG|ritonavir|Single oral dose of ritonavir 100 mg at -12 hours prior to GST-HG171/ritonavir dosing, and ritonavir 100 mg will be dosed at 12 hours and 24 hours after GST-HG171/ritonavir dosing.
224218749|NCT02454309|DIETARY_SUPPLEMENT|Cranberry concentrate|
224218750|NCT02454309|DIETARY_SUPPLEMENT|Placebo|
224218751|NCT03285334|DEVICE|XP-endo Shaper|mechanical preparation in a 3D manner using Xp-endo Shaper
224218752|NCT03285334|DEVICE|iRace files|rotary mechanical preparation
224218753|NCT02199652|DRUG|Prazosin|
224218754|NCT02199652|DRUG|Placebo|
223630035|NCT03284463|DRUG|Glibenclamide|Glibenclamide is administered with a loading dose of 1.25 mg within 10 hours of stroke onset, orally or through gastric tube, followed by 0.625 mg every 8 hour for 5 days.
223630036|NCT03284463|DRUG|Placebo|Placebo is administered with a loading dose of 1.25 mg within 10 hours of stroke onset, orally or through gastric tube, followed by 0.625 mg every 8 hour for 5 days.
223630037|NCT04156841|DIAGNOSTIC_TEST|mapping agent|according to different tracer methods, patients are divided into the implementation of a single mapping agent and implementation of combination of blue dye and radiotracer agent.
223630038|NCT04156841|PROCEDURE|neoadjuvant chemotherapy|Patients were divided into two groups based on whether they were receiving neoadjuvant chemotherapy.
223630039|NCT00178295|RADIATION|Radiation Therapy|standard of care for the cancer being treated
223630040|NCT00364676|DRUG|VLI|Patients are dosed on Day 1 and Day 8 of a 21-day cycle.
223630041|NCT00364676|DRUG|VLI|Patients are dosed on Day 1 of a 21-day cycle.
223630042|NCT04623346|PROCEDURE|Observation for study group|Patients with Weber B-type Ankle fractures, extraarticular wrist fractures and proximal humerus fractures were followed with conservative manner( cast or sling)
223630043|NCT03162926|COMBINATION_PRODUCT|VC-02 Combination Product (aka PEC-Direct)|PEC-01 cells loaded into a Delivery Device
224218755|NCT00049634|DRUG|busulfan|
223630044|NCT03314103|BIOLOGICAL|One shot of the varicella-zoster virus vaccine|One shot of the live attenuated varicella-zoster virus vaccine (with live virus \>=4.3 LgPFU per dose)
223630045|NCT03314103|BIOLOGICAL|one shot of placebo|one shot of placebo with no live virus
223764139|NCT05548023|DEVICE|The AngioliteTM Durable Fluoroacrylate Polymer-based Sirolimus-Eluting Stent|The Angiolite stent is a thin-strut cobalt-chromium sirolimus-eluting stent with an open-cell design and a high overexpansion capacity that might overcomes some of these challenges in LMCA PCI. The ANGIOLITE randomized trial confirmed the non-inferiority of the Angiolite stent against the conventional DES
224218756|NCT00049634|DRUG|cyclophosphamide|
223630046|NCT05027321|BEHAVIORAL|Preparation in Self-Hypnosis by anchoring|Preparation in Self-Hypnosis by anchoring just before examination
223630047|NCT05027321|BEHAVIORAL|Conversational Hypnosis|Conversational Hypnosis during examination
223630048|NCT05027321|BEHAVIORAL|Preparation in Self-Hypnosis by anchoring + Conversational Hypnosis|Preparation in Self-Hypnosis by anchoring just before examination combied with Conversational Hypnosis during examination
223630049|NCT05674175|BIOLOGICAL|Autologous, humanized anti-CD22 CAR T cell therapy (CART22-65s)|CART22-65s are autologous T cells that have been engineered to express an extracellular single chain antibody (scFv) with specificity for CD22 linked to an intracellular signaling molecule consisting of a tandem signaling domain comprised of the TCRζ signaling module linked to the 4-1BB costimulatory domain
223630050|NCT05674175|BIOLOGICAL|Autologous, humanized anti-CD19 CAR T cell therapy (huCART19)|HuCART19 cells are autologous T cells that have been engineered to express an extracellular single chain antibody (scFv) with specificity for CD19 linked to an intracellular signaling molecule consisting of a tandem signaling domain comprised of the TCRζ signaling module linked to the 4-1BB costimulatory domain
223630051|NCT03873883|DRUG|EOS100850|Oral administration
223630052|NCT03873883|DRUG|Pembrolizumab|IV Infusion
223630053|NCT03873883|DRUG|Chemotherapy|Standard of Care IV Infusion
223630054|NCT05932329|BEHAVIORAL|Dietary Advice|Dietary Advice provided
223630055|NCT05444855|OTHER|Peer Leader Model|Teens will have an opportunity to interact with established peer leaders that are a part of the AccessKCTeen program. These leaders will receive a baseline training of their role, sexual and mental health. They will also receive health education and engage with a peer liaison via text messages throughout the study.
223630056|NCT06473922|PROCEDURE|Reginal anesthesia|General anesthesia
223630057|NCT06497959|DRUG|SonoVue|Placental contrast ultrasound using SonoVue by maternal intravenous injection
223630058|NCT04915846|DRUG|ApoTamox 10mg|All participants will receive tamoxifen (ApoTamox) for approximately 6 months (6 months + 1 week). Participants and study staff will be blinded as to whether the participants are starting with the placebo or the drug. Depending on randomization, drug or placebo will be dispensed at the end of the t=0 study visit (Phase 1). Dosing will commence the day after the t=0 study visit. At the end of Phase 1, participants will enter a 'washout' period, when they will cease treatment. After approximately 3 months of washout, participants will cross-over to the other treatment regimen and receive the other interventional product (IP) for the final 6 months of their study participation (Phase 2).
223630059|NCT04915846|DRUG|Placebo|placebo comparator
223630060|NCT05847192|DIAGNOSTIC_TEST|[18F]-PI2620 PET scan|The PET scan will measure the regional distribution of tau aggregation in AD patients with and without psychosis compared to Cognitively Unimpaired Healthy participants with the PET radiotracer \[18F\]-PI2620.
223630061|NCT02242942|DRUG|Chlorambucil|Chlorambucil 0.5 milligrams per kilogram (mg/kg) orally at Day 1 and Day 15 at of each 28 day cycle for 12 cycles.
224218757|NCT00049634|DRUG|cyclosporine|
224218758|NCT00049634|DRUG|methotrexate|
224218759|NCT00049634|PROCEDURE|in vitro-treated peripheral blood stem cell transplantation|
224218760|NCT04873349|DIETARY_SUPPLEMENT|Nusapure standardized olive leaves capsule, 750 mg (50% oleuropein)|two study groups; test group will receive Nusapure standardized olive leaves capsule, 750 mg (50% oleuropein) while placebo group will receive starch group
224218761|NCT05917093|BEHAVIORAL|Culturally tailored HLWD|"Participants receive the culturally tailored HLWD intervention for 6 weeks~* Week 0 - Baseline enrollment.~* Weeks 1-6 will consist of 6 separate group sessions. Diabetes self-management topics will be covered by 2 Black HLWD Facilitators. Participants will meet once a week, for a 2½-hour session, in community settings such as a community center, or church."
224218762|NCT05493033|PROCEDURE|Intracorporeal anastomotic after LRC|Complete laparoscopic dissection of the mesocolon is mandatory. D2 or D3/CME is optional. And the extent of colon resection is based on the location of the tumor while the ileocecal resection is excluded. After fully mobilization of the colon and mesentery, the terminal ileum and transverse colon will be transected by a laparoscopic linear stapler. The side-to-side anastomosis is performed laparoscopically. The enterotomy is closed by a double-layer suture. All the anastomotic procedures are completed laparoscopically. The specimen is then removed through a Pfannenstiel incision within a specimen bag.
223630062|NCT02242942|DRUG|Venetoclax|Venetoclax, oral tablet: 20 mg daily during Cycle 1, Day 22-28; 50 mg daily during Cycle 2, Day 1-7; 100 mg daily during Cycle 2, Day 8-14; 200 mg daily during Cycle 2, Day 15-21; 400 mg daily during Cycle 2, Day 22-28 and on Day 1-28 for all subsequent cycles until the end of Cycle 12.
223630063|NCT02242942|DRUG|Obinutuzumab|Obinutuzumab, IV infusion: 100 mg or 1000 mg, depending on splitting rules, at Cycle 1, Day 1 (if 100 mg was received on Day 1, 900 mg will be administered on Cycle 1, Day 2); 1000 mg at Cycle 1, Day 8 and Day 15; 1000 mg at Day 1 for all subsequent cycles until the end of Cycle 6
223630064|NCT03541083|DRUG|Blinatumomab|prephase and consolidation (I and II)
223630065|NCT06107140|OTHER|dual therapy|The evaluation will focus on the retention of patients living with hiv on dual antiretroviral therapy.
223630066|NCT04396535|DRUG|Bintrafusp Alfa|Given IV
223630067|NCT04396535|DRUG|Docetaxel|Given IV
223630068|NCT00551759|DRUG|5-Fluorouracil|given IV
223630069|NCT00551759|DRUG|Oxaliplatin|given IV
223630070|NCT00551759|DRUG|Cetuximab|given IV
223630071|NCT00551759|DRUG|Docetaxel|given IV
223630072|NCT00551759|PROCEDURE|Surgery|Patients underwent surgical resection within 4-8 weeks after completion of neoadjuvant chemoradiotherapy and cetuximab.
223630073|NCT00551759|RADIATION|Radiotherapy|Patients underwent radiotherapy once daily on days 1-5, 8-12, 15-19, 22-26, and 29-33.
223630074|NCT03358277|DRUG|MPH + APZ|MPH was administered with either Ritalin (from 10mg/day to 40mg/day) or Concerta (from 18mg/day to 36mg/day) according to clinical judgement for six weeks. APZ was administered with dose from 2.5mg/day to 5mg/day according to clinical judgement for six weeks.
223630075|NCT00802581|PROCEDURE|Circumferential spread of local anesthetic|The anesthetist will ensure, under ultrasound guidance, that local anesthetic (1 mL of 1% lidocaine) surrounds the sciatic nerve.
223630076|NCT00802581|PROCEDURE|Non-circumferential spread of local anesthetic|"The anesthetist will perform a single shot injection of local anesthetic (1 mL of 1% lidocaine) near the sciatic nerve under ultrasound guidance, without ensuring circumferential spread around the nerve."
223630077|NCT02506894|DRUG|Magnesium Sulfate|magnesium sulfate will be given for 24 hours
223630078|NCT02506894|OTHER|0.9% sodium chloride solution|normal saline will be given as intravenous drip over 24 hours
223630079|NCT00192933|PROCEDURE|NovoSeven treatment according to guideline|
223630080|NCT05167851|DRUG|Lazertinib , a combination group of SBRT|"\* Lazertinib 240mg once a day(QD) oral(PO)~-If there is no disease progression or unacceptable toxicity, treatment is performed at 1 cycle (28 days) interval . This is expected to be an average of one year."
223630081|NCT05167851|DRUG|Lazertinib single administration group|"\* Lazertinib 240mg once a day(QD) oral(PO)~-If there is no disease progression or unacceptable toxicity, treatment is performed at 1 cycle (28 days) interval . This is expected to be an average of one year."
224218763|NCT05493033|PROCEDURE|Extracorporeal anastomotic after LRC|The procedures of the mobilization and vessel ligation are similar. After that, the mobilized colon and terminal ileum are brought out through the upper mid-line incision with the wound protector. The colon and terminal ileum are similarly dissected distally to the specimen with a stapling device. The side-to-side anastomosis is completed and the anastomotic site is reinforced. The anastomotic bowel is returned to the abdominal cavity.
224317723|NCT04663971|PROCEDURE|Any medical treatment|Any treatment (including non-surgical) performed for inflammatory bowel diseases
224317724|NCT06651606|BEHAVIORAL|Progressive Ratio Training (PRT)|"Progressive ratio training (PRT) is used to prevent recurrence of the proxy response when extinction errors occur. PRT involves providing a reinforcer for the proxy response on a geometric progressive ratio (PR) scale. The schedule requirement will increase for the target response each time a reinforcer is delivered. For example, once a reinforcer is delivered on the PR-2 schedule, the requirement will increase to a PR-4, then to a PR-8, -16,~-32, etc."
223630082|NCT05914623|PROCEDURE|Repetitive transcranial magnetic stimulation|After enrollment, the patients received rTMS once a day for 5 consecutive days (stimulation plan: stimulation of M1 region on the affected side at 10Hz).
223630083|NCT05914623|PROCEDURE|Sham repetitive transcranial magnetic stimulation|After enrollment, the patients received sham-rTMS once a day for 5 consecutive days with the same parameters as the rTMS group, but the coil was rotated 90° away from the scalp.
223630084|NCT05042674|DIETARY_SUPPLEMENT|Placebo|after a blood draw placebo will be consumed followed by 2 additional blood draws
223630085|NCT05042674|DIETARY_SUPPLEMENT|Ergothioneine, 25 miligrams|after a blood draw 25 miligrams of ergothioneine will be consumed followed be 2 additional blood draws
223630086|NCT05042674|DIETARY_SUPPLEMENT|Ergothioneine, 25 miligrams, daily for 1 week|a blood draw will be administered after a week of consuming 25mg ergothioneine daily
223630087|NCT01095549|DEVICE|WSTM TY101 FIR emitter (Far infrared therapy)|A WSTM TY101 FIR emitter (WS Far Infrared Medical Technology Co., Ltd., Taipei, Taiwan) will be used for FIR therapy. The electrified ceramic plates of this emitter generate electromagnetic waves with wavelengths in the range between 3 and 25 μm (a peak between 5 to 6 μm). The irradiating power density is 10 and 20 mili watt\<mw\>/cm2 when the top radiator is set at a distance between 30 and 20 cm above the skin surface respectively. In this study, the top radiator will be set at a height of 25 cm above the surface of bilateral lower legs and the treatment time will be set at 40 minutes for patients on each HD section for a year.
223630088|NCT01095549|DEVICE|Placebo device|A device without far infrared therapy
223630089|NCT02099851|DEVICE|Carotid body ablation (Cibiem)|
223630090|NCT00214045|DEVICE|Flexible Cystoscopy|
223630091|NCT00214045|DEVICE|Rigid Cystoscopy|
223630092|NCT01124110|BEHAVIORAL|Tobacco Tactics Web-Based Intervention|The Tobacco Tactics Web-Based Intervention contains website, medications, and nurse counseling.
223630093|NCT01124110|OTHER|1-800-QUIT-NOW Telephone Hotline|The control group receives efficacious smoking cessation treatment via the 1-800-QUIT-NOW telephone hotline. The 1-800-QUIT-NOW hotline is a national program. The first time smokers call the hotline, they receive a personal coach who assists them in setting a quit date and making an individualized quit plan. The personal coach also provides on-going support with up to five telephone coaching sessions around the caller's quit date.
223630094|NCT04045860|PROCEDURE|Complete Decongestive Therapy|A combination of manual lymph drainage , compression bandaging, physical exercise and a skin care regimen
223630095|NCT04045860|OTHER|Observation|Standard of care is currently observation
223630096|NCT04435925|DRUG|Remifentanil|Loading dose: 0.5 mcg/kg Maintenance dose: 1 mcg/kg/minute
223630097|NCT04435925|DRUG|Fentanyl|Loading dose: 2 mcg/kg Maintenance dose: 0.4 mcg/kg/30-minutes
223764140|NCT04048642|BEHAVIORAL|DASH|7 days of a DASH diet
223764141|NCT04048642|BEHAVIORAL|Whole-Food, Plant-Based|7 days of a WFPB diet
223764142|NCT01059370|PROCEDURE|bowel emptying|Bowel is emptied using Peristeen® irrigation system one day, by digital stimulation another trial day or filling the bladder with saline water on a third trial day. BP is measured by Finometer Pro®, respiration frequency by BIOPACK and skin conductivity measured by Biopack and nor-epinephrine and epinephrine are measured in plasma three times during each examination.
223764143|NCT02440386|BEHAVIORAL|Conditional economic incentive|"Individuals in the intervention arm will receive the standard of care. In addition, individuals in the intervention arm receive a voucher worth R300. They are told that they will get this money if they:~1. Initiate ART at any clinic within 3 months from the time of their CD4 count test at the Tutu Tester; and~2. send a text message to the study team to let us know they have started ART;~3. Schedule a meeting with a member of the study team to show their clinic card and ARVs to confirm ART initiation."
223764144|NCT04552587|BEHAVIORAL|Heart APP|The HEART intervention includes a care planning visit for patients and caregivers and an App for caregivers focused on nutrition, self-care and support.
224218764|NCT03855319|BEHAVIORAL|SMR neurofeedback training to MCI|The intervention consisted to increase the synaptic strengths and sensitivity within this network. Electroencephalography signals for SMR/theta training was recorded at channel Cz according to the international 10-20 system. Theta rhythm was also recorded and, in this case, SMR was stimulated while theta waves were suppressed.A 32 channels system (EEGDigitrcak Biofeedback plus module, Inc Elmiko Medical) was used for the SMR/theta Neurofeedback training.
224218765|NCT06133088|DRUG|dalpiciclib; fluvestrant; compound gossypol acetate tablets|"Darcilie: 150mg orally for three weeks and stop for one week. Fluvestrant: 500mg every four weeks. A further 500mg dose two weeks after the first dose.~Compound gossyrol acetate tablet: 20mg daily."
224218766|NCT02021266|BIOLOGICAL|Enriched Hematopoetic Stem Cell Infusion|Enriched Hematopoetic Stem Cell Infusion
224218767|NCT04574778|DRUG|Acetaminophen|1000 mg of oral acetaminophen preoperatively administered
224218768|NCT05479968|DEVICE|Spectrocor device|This feasibility study is intended to document the feasibility, safety, and usability of the Investigational device.
224218769|NCT00313053|DRUG|Human mAb 216|Two treatment courses of mAb infusion will be given, with the same dose of antibody administered on Day 0 and on Day 7.
224218770|NCT00313053|DRUG|Vincristine|Vincristine 1.5 mg/m2/dose (max dose = 2 mg) IVP on weekly x 4 doses (Days 7, 14, 21, 28)
224218771|NCT01475669|BIOLOGICAL|Fibrinogen Concentrate (Human) (FCH)|Single dose infused intravenously within 5 minutes of the completion of the measurement of the 5-minute bleeding mass; the dose is determined individually based on the measured maximum clot firmness (MCF) and subject body weight
224218772|NCT01475669|BIOLOGICAL|Placebo|Single dose of sodium chloride solution infused intravenously within 5 minutes at a volume equivalent to that needed for FCH
224218773|NCT02505776|DRUG|Bimatoprost cutaneous solution 0.03%|Bimatoprost cutaneous solution 0.03% (GLASH VISTA™) prescribed as per standard of care in clinical practice.
224218774|NCT04248374|OTHER|Taste Intensity|Taste intensity with and without sour adaptation
224218775|NCT00914797|DRUG|inhaled and oral terbutaline|"Inhalation of 2 mg terbutaline as powder as a single dosage. Oral terbutaline 10 mg as a single dosage.~Inhaled: Bricanyl Turbohaler 0.5 mg/dose, MA no. 41076.~Oral: Tablet Bricanyl Retard 5 mg, MA no. 10954."
224317725|NCT06651606|BEHAVIORAL|Differential Reinforcement of Alternative (DRA) Behavior with Extinction|In DRA with extinction, the proxy for problem behavior is placed on extinction and no longer produces reinforcement. The proxy for communication behavior produces reinforcement on a fixed-ratio 1 schedule of reinforcement.
223630098|NCT04831645|DEVICE|DynaNail|Utilization of a novel dynamic compression pseudoelastic intramedullary nail
223630099|NCT04831645|PROCEDURE|Tibiotalocalcaneal Arthrodesis|Tibiotalocalcaneal (TTC) arthrodesis with a novel dynamic compression intramedullary nail.
223630100|NCT05397730|DIAGNOSTIC_TEST|Mycobacterium tuberculosis (MTB) cell-free DNA (cf-DNA)|Comparing the diagnostic accuracy between MTB cfDNA and PCR on diagnosing tuberculous pleuritis
223630101|NCT01862146|PROCEDURE|smoke expose|
223630102|NCT00688896|DRUG|JTT-705 600 mg and pravastatin 40 mg|"* JTT-705 300 mg tablets, 600 mg dose, 2 tablets, oral, once daily, immediately following breakfast and/or assessment~* Pravastatin 40 mg tablets, 40 mg dose, one tablet, oral, once daily, at bedtime"
223630103|NCT00688896|DRUG|JTT-705 300 mg and pravastatin 40 mg|"* JTT-705 300 mg tablets, 300 mg dose, 1 tablet, oral, once daily, immediately following breakfast and/or assessment~* Placebo tablets, one tablet, oral, once daily, immediately following breakfast and/or assessments~* Pravastatin 40 mg tablets, 40 mg dose, one tablet, oral, once daily, at bedtime"
223630104|NCT00688896|DRUG|Placebo and pravastatin 40 mg|"* Placebo tablets, 2 tablets, oral, once daily, immediately following breakfast and/or assessments~* Pravastatin 40 mg tablets, 40 mg dose, one tablet, oral, once daily, at bedtime"
223630105|NCT05003401|DEVICE|HabitAware Keen2|Participants will receive an awareness bracelet to be worn on the dominant wrist over a period of 4 weeks. The bracelet device will vibrate when the participant is engaging in hair pulling behaviors. As hair pulling behaviors may occur outside of awareness (i.e., automatic pulling behaviors), this vibration and detection is anticipated to increase the participants awareness of hair pulling behaviors.
223630106|NCT00474422|BEHAVIORAL|Proactive assignment to attend a breastfeeding clinic|
223630107|NCT02133495|PROCEDURE|Non Cadaveric Human Acellular Dermal Tissue|
223630108|NCT00517946|DRUG|pseudoephedrine hydrochloride|
224218776|NCT01373892|PROCEDURE|Bariatric surgery|
223630109|NCT00517946|DRUG|cetirizine hydrochloride|
224218777|NCT04987671|DRUG|AMX0035|Fixed dose combination of Sodium Phenylbutyrate and taurursodiol.
223630110|NCT02996201|OTHER|Completion of PRO-CTCAE items before consultation|Patients report PRO-CTCAE symptoms on a tablet computer before each cycle of chemotherapy
223630111|NCT00868634|DRUG|capecitabine|1000 mg/m2 twice daily, oral, days 1-14. Cycles are repeated every three weeks.
223630112|NCT00868634|DRUG|bevacizumab|15 mg/kg i.v., day 1 Cycles are repeated every three weeks.
223630113|NCT00868634|DRUG|capecitabine|1000 mg/m2 twice daily, oral, days 1-14. Cycles are repeated every three weeks.
223630114|NCT00868634|DRUG|bevacizumab|15 mg/kg i.v., day 1. Cycles are repeated every three weeks.
223630115|NCT00868634|DRUG|vinorelbine|25 mg/m2 i.v., days 1+8. Cycles are repeated every three weeks.
223630116|NCT06217042|DRUG|HR070803; Oxaliplatin; 5Fluorouracil; Calcium folinate|"Oxaliplatin 85 mg/m² D1 over 2 hours, followed by HR070803 60 mg/m² D1 over 90 minutes, after the Folinic acid infusion is started. Folinic acid 400 mg/m² D1, IV infusion over 1 hours. 5-FU 2400 mg/m² D1 IV continuous infusion over 46 hours.~These drugs are given once every 2 weeks, 12 cycles, 24 weeks."
223630117|NCT06217042|DRUG|gemcitabine; capecitabine|Gemcitabine 1000mg/m² is given as an i.v. infusion over 30 minutes, administered on day 1, 8 and 15 out of 28 days. Capecitabine 1660mg/m²/day in two divided doses administered orally for 21 days followed by 7 days'rest .
223630118|NCT06236906|DEVICE|Device supported behavioural treatment|The method involves behavioral change supported by a digital support system, including daily home weighings, a clear weight curve in a mobile app, and communication with the treatment team through the same app.
223630119|NCT04637568|DIAGNOSTIC_TEST|Computerized tomography|Obtained CT scans involving the head region were analyzed retrospectively.
223630120|NCT01828177|DRUG|PDI-320|
224218778|NCT03870997|BEHAVIORAL|Diabetes Digital Intervention|The Diabetes Digital Intervention is a digital campaign that provides interactive ways (e.g., videos, infographics, quizzes) for individuals to learn about influenza and related complications, and the importance of influenza vaccination. It is tailored to people living with diabetes and highlights the importance of influenza vaccination for this specific patient population.
224218779|NCT03870997|BEHAVIORAL|Generic Digital Intervention|The Generic Digital Intervention is a digital campaign that provides interactive ways (e.g., videos, infographics, quizzes) for individuals to learn about influenza and related complications, and the importance of influenza vaccination. It provides generic influenza vaccination interventions that can be applicable to any adult who should receive influenza vaccination.
224218780|NCT03832933|BEHAVIORAL|High Protein Diet|16 week weight loss and 36 weight loss maintenance intervention. Approximate macronutrient distributions (carbohydrate:protein:fat) will be 32%:40%:28%.
224218781|NCT03832933|BEHAVIORAL|Standard Protein Diet|16 week weight loss and 36 weight loss maintenance intervention. Approximate macronutrient distributions (carbohydrate:protein:fat) will be 53%:21%:25%.
224218782|NCT02039479|DRUG|Lithium Carbonate|Lithium as Add on to every necessary treatment as usual
224317726|NCT03638388|PROCEDURE|Dry needling (DN)|One to three filament needles (similar to an acupuncture needle) with no medication will be inserted into the tender area of my muscle. The needles will be repositioned a few times to make the muscle twitch. After several twitches occur, the researcher will leave the needles as they are, and the subject will sit in a chair without moving my arms or head, for 10 minutes. After 10 minutes the needles are removed and discarded.
223630121|NCT01828177|DRUG|PDI-320 Monad #1|
223630122|NCT01828177|DRUG|PDI-320 Monad #2|
223630123|NCT01828177|DRUG|Vehicle|
223630124|NCT01260493|OTHER|integrated health care chain|Geriatric assessment at ED, case manager with multiprofessional team in the community, support for informal caregivers
223630125|NCT04175223|DIETARY_SUPPLEMENT|Vivomixx|probiotic administration: administration of two sachets per day (one in the morning and one in the evening) during 6 months
223630126|NCT04094597|DRUG|Lactoferrin|lactoferrin is given orally in comparsion to placebp
223630127|NCT04094597|DRUG|Placebos|placebp is given in 2 ml saline
223630128|NCT02721940|PROCEDURE|Control group|Patients in the control group will be subjected to arthroscopic debridement and microfracture surgery.
223630129|NCT02721940|BIOLOGICAL|Mononuclear Cells|In the treatment group, patients will be given 200 μg zoledronic acid and purified bone marrow mononuclear cells will be injected into the necrotic zone, followed by injection of 5-10 mL normal saline. Finally, the holes for core decompression will be sealed with a small amount of bone wax to prevent leakage.
223764145|NCT06146530|DEVICE|Treatment|The intervention consists of 7 sessions of CBT for the treatment of GAD. Each session contains a range of information and tasks/exercises to help the user understand the condition of GAD, the treatment approach, and how it will be applicable to them. The intervention is based on an evidence-based treatment protocol; hence the sessions will flow from one to the other and the user will complete the sessions in a progressive direction. However, they can repeat a session before going on to the next session. Once all sessions have been completed, the user can go back over any of the sessions. There are anxiety management exercises, which the user can go to whenever they wish. There are also a therapy reflection journal and self-care resources including further anxiety management techniques, resources, and podcasts that the user will have access to whenever they want.
224218783|NCT02039479|DRUG|Placebo|Placebo as ADD-on to every necessary treatment as usual
224317727|NCT03638388|PROCEDURE|Dry needling with intramuscular electrical stimulation (DNES)|One to three filament needles (similar to an acupuncture needle) with no medication will be inserted into the tender area of the muscle. The needles will be repositioned a few times to make the muscle twitch. After several twitches occur, the researcher will leave the needles as they are, and attach alligator clips to the needles to provide electrical stimulus for 10 minutes while the subject sits in a chair without moving arms or head. After 10 minutes, the electrical stimulus will be turned off and detached, and the needles removed and discarded.
223630130|NCT02721940|BIOLOGICAL|Platelets|In the treatment group, patients will be given 200 μg zoledronic acid and purified bone marrow mononuclear cells will be injected into the necrotic zone, followed by injection of 5-10 mL normal saline. Finally, the holes for core decompression will be sealed with a small amount of bone wax to prevent leakage.
223630131|NCT02721940|DRUG|Zoledronic Acid|In the treatment group, patients will be given 200 μg zoledronic acid and purified bone marrow mononuclear cells will be injected into the necrotic zone, followed by injection of 5-10 mL normal saline. Finally, the holes for core decompression will be sealed with a small amount of bone wax to prevent leakage.
223630132|NCT02721940|DRUG|Normal saline|In the treatment group, patients will be given 200 μg zoledronic acid and purified bone marrow mononuclear cells will be injected into the necrotic zone, followed by injection of 5-10 mL normal saline. Finally, the holes for core decompression will be sealed with a small amount of bone wax to prevent leakage.
223630133|NCT01451606|DRUG|Duloxetine|30 mg dose once daily, administered orally for 1 week, 60 mg dose once daily, administered orally for 5 weeks, 30 mg dose once daily, administered orally for 1 week
223630134|NCT01451606|DRUG|Placebo|To serve as placebo for duloxetine. Administration schedule same as for active drug.
223630135|NCT02424396|DRUG|IL2|Induction period: repeated administration of low-dose IL-2 Maintenance period: treatment with IL-2
223630136|NCT02424396|DRUG|Placebo|
223630137|NCT02989493|DRUG|Doxazosin|Doxazosin
223630138|NCT02989493|OTHER|Placebo|Placebo
223630139|NCT03017963|DRUG|Sodium Thiosulfate Pentahydrate|Sodium Thiosulfate Pentahydrate is administered intravenously in 250 centiliters infusion fluid in two doses: first dose with an infusion rate of 16.66 milliliter (ml) per minute (min), second dose with 8.33 ml / min
223630140|NCT02163538|DEVICE|articulating Enseal|Vessel-sealing device used for laparoscopic hysterectomy.
223630141|NCT02163538|DEVICE|Ligasure device|Vessel-sealing device used for laparoscopic hysterectomy.
223630142|NCT04496817|OTHER|Docosahexaenoic Acid and Lutein Enriched Eggs|Consumption of 2 docosahexaenoic acid and lutein enriched eggs daily (at least 5 days our week) for 6 weeks
223630143|NCT04496817|OTHER|Regular Eggs|Consumption of 2 non enriched eggs daily (at least 5 days our week) for 6 weeks
223630144|NCT02014324|PROCEDURE|Endosonography|"Complete endosonographic mediastinal staging is performed in 2 steps:~1. Systematic EBUS (airways)~2. Systematic EUS-B (esophagus)"
224218784|NCT01736410|DRUG|Trastuzumab, TS ONE, Cisplatin|The initial dose of cisplatin is fixed to be 60 mg/m2 and intravenously administered over 1 hour on day 1 of the cycle. TS-ONE is orally administered consecutive 14-day followed by 7-day rest. The initial standard dose of TS-ONE is determined based on the body surface area tabled below. Trastuzumab is intravenously administered with the loading dose of 8 mg/kg followed by HER2-positive advanced GC 21 years or older No prior regimen HER2 protein HER2/neu detection procedure Tissue from (Gastric) Cancer FISH method IHC method negative positive HER-2 negative HER-2 positive Eligible 0 / 1+ 2+ 3+ HER-2 positive Eligible HER-2 negative iii Protocol S1/CDDP/Her V1.3 dated 21 May 10 maintenance dose of 6mg/kg in day 1 of each cycle. The study treatments are repeated every 3 weeks. Study treatment can continue until PD, but cisplatin can be skipped or discontinued if patients experienced unbearable toxicity which comes from cisplatin.
224218785|NCT05974748|DRUG|Sodium hypochlorite 5.25%|The participants will be randomly divided into two groups using the sealed envelope method during the instrumentation process. The clinician will use the irrigation in accordance with the protocol. Between each instrument in group A, 3 ml of 5.25% sodium hypochlorite (NaOCl) will be used to irrigate each canal.
224218786|NCT05974748|DRUG|Propolis 20%|In group B, a 20% hydroalcoholic propolis solution of 3 milliliters will be used to irrigate each canal, between each instrument.
224218787|NCT00089310|RADIATION|technetium-99|0.25 mCi in 4 equal doses
224218788|NCT05455749|DIETARY_SUPPLEMENT|holoBLG|holo-BLG (beta-lactoglobulin) - a major component of the protein fraction of raw milk, loaded with ligands (vitamin A, zinc and polyphenol-iron complexes)
224218789|NCT01178983|DEVICE|surface electromyography|Surface electromyography (SEMG) telebiofeedback
224218790|NCT01178983|DEVICE|surface electromyography|conventional biofeedback
224218791|NCT05778370|DEVICE|Swept Source Optical Coherence Tomography(Topcon DRI Triton)|Topcon DRI Triton
224218792|NCT00275535|DRUG|Anti-thymocyte globulin|Thymoglobulin 1.5 mg/kg/d (days 0,1,2,4,6)
224218793|NCT00275535|DRUG|Mycophenolate mofetil|Mycophenolate mofetil 750 mg p.o. b.i.d.- maintenance
224218794|NCT00275535|DRUG|Prednisone|Prednisone 500 mg/day initially, tapered to 5 mg/day by day 92
224218795|NCT00275535|DRUG|Tacrolimus|Tacrolimus - maintain trough levels of 6-8 ng/ml (whole blood Imx assay)
224218796|NCT00275535|DRUG|Sirolimus|Rapamycin 3 to 5 mg/day; adjust to the high-performance liquid chromatography (HPLC) blood level 15 to 20 ng ml
224218797|NCT05645679|DEVICE|Hybrid Argon Plasma Coagulation System|Hybrid Argon Plasma Coagulation System
224218798|NCT02572583|DRUG|Liugan Shuangjie Heji|
224218799|NCT02572583|DRUG|Shufeng Jiedu Capsule|
224218800|NCT02572583|DRUG|Oseltamivir Phosphate Capsule|
224218801|NCT05224921|OTHER|Not applicable (cohort study)|This is a prospective observational study and does not include interventions. The exposure is peripheral perfusion index and the outcome is the incidence of late onset sepsis. From the day when the very low birth weight infant is admitted into hospital, PPI monitoring should be recorded once a day, and continuous monitoring would be recorded until 1 month after birth. Before collection, the infant will be confirmed to be in supine position with neutral temperature, and at the same time, the infant will be in a quiet state, without the contact and operation of medical personnel.
224218802|NCT01188161|DEVICE|Rotating Chair|Subjects will be spun in rotating chair
223630145|NCT04420377|DIETARY_SUPPLEMENT|Carnipure|Supplement contains L-carnitine tartrate.
223630146|NCT04420377|OTHER|Resistance Training|5 weeks of whole-body resistance training, performed 2 times per week.
223630147|NCT04906928|DEVICE|MRI|"* standard imaging protocol prescribed as part of the usual treatment: sagittal T1 and T2 slices after injection of contrast product (Gadolinium), 3D STIR and 3D PSIR sequence.~* 3D FGAPSIR sequence at the level of the cervical cord for the duration of the additional sequence is 10 minutes, for a total examination time of 40 minutes (instead of 30 minutes)"
223630148|NCT01412996|PROCEDURE|surgery|single ACCESS laparoscopic cholecystectomy
223630149|NCT01412996|OTHER|SURGERY|CONVENTIONAL LAPAROSCOPIC CGOLECYSTECTOMY
223630150|NCT03037996|OTHER|patients' response|patients' satisfaction to anesthesia services
223630151|NCT04750317|DRUG|Tofacitinib|Tofacitinib was administered at a dose 10 mg twice daily on day 1, followed by 5 mg twice daily on day 2-5. The dosage was reduced up to 5 mg once daily in patients with moderate renal impairment or moderate hepatic impairment.
223630152|NCT03784872|PROCEDURE|Laparoscopic guided Ventrosuspension|Laparoscopy was done. Under vision the skin overlying the attachment of the round ligament to the anterior abdominal wall was incised followed by introduction of 30 curved needle attached to absorpable Vicryl 2/0 suture through the incision and withdrawn through grasper under laparoscopi vision. The needle was turned around the round ligament all through its length to plicate it then the needle was pushed again beside its entry side to appear at the skin incision. The same was repeated on the other side and both sutures were tied at the subcutaneous tissue simultaneously. then the laparoscopy was withdrawn followed by closure of the skin incision.
223630153|NCT04730440|OTHER|AD-TAR|Intervention description: 12 sessions in groups of 4 subject, over 6 weeks (2 sessions per week), using a rehabilitation program named Training of Affect Recognition (TAR).
223630154|NCT04730440|OTHER|AD-Cognitive Stimulation|Intervention description: 12 sessions in groups of 4 subject, over 6 weeks (2 sessions per week), using classic cognitive stimulation workshops.
223630155|NCT02356458|DRUG|Ibrutinib|"Combination therapy:~Trial treatment of ibrutinib in combination with bortezomib Cycles 1-6 (1 cycle = 21 days) Ibrutinib: p.o daily; Phase I: according to DL; Phase II: RP2D established in phase I~Maintenance therapy:~p.o daily: 560 mg"
223630156|NCT02356458|DRUG|bortezomib|"Combination therapy:~Trial treatment of ibrutinib in combination with bortezomib Cycles 1-6 (1 cycle = 21 days) Injection of Bortezomib (s.c.), dose of 1.3 mg/m2 on day 1, 4, 8, 11"
223630157|NCT05864729|DIAGNOSTIC_TEST|Coronary angiography with physiological lesion assessment by fractional flow reserve (FFR) and contrast fractional flow reserve (cFFR).|Hemodynamic invasive study employing FFR (after intracoronary adenosine administration) and cFFR (after intracoronary lopamidol contrast media administration) measurements of hyperemic intravascular pressure.
223630158|NCT06432153|OTHER|observation|Participants who receive routine clinical care, without additional intervention from the study
224218803|NCT03680482|OTHER|Intervention ingest a 48 mg of sucralose|Intervention: Subjects with type 2 diabetes who ingest a 48 mg of sucralose. Sucralose is a non-caloric sweetener derived from sucrose and is 600 times more sweet than sucrose. Your allowable daily intake is 15 mg / kg of body weight per day. 85% is not absorbed and is excreted unchanged in the stool; the rest that is absorbed is excreted unchanged by the urine
224218804|NCT03680482|OTHER|Intervention ingest a 96 mg of stevia|"Intervention: Subjects with type 2 diabetes who ingest a 96 mg of stevia (steviol glycosides). The word stevia refers to the whole plant of Stevia rebaudiana Bertoni (SRB), only some of the components of the stevia leaf are sweet. Steviol glycosides are up to 300 times sweeter than sucrose, do not provide calories and can be used as a substitute for sucrose or as a non-nutritive sweetener alternative. Your allowable daily intake is 4 mg / kg / body weight (expressed as steviol)"
224218805|NCT00349882|DEVICE|soft contact lens|
224218806|NCT00349882|DRUG|Marketed multipurpose disinfection regimen|
224218807|NCT00747422|DEVICE|Ulthera™ System|ultrasound treatment
224218808|NCT03362528|DEVICE|WM3.4NR|Investigational Medical Device collecting spectral raman data from tissue.
224218809|NCT05676879|OTHER|Ice massage was applied to the SP6 points|Ice massage was applied to the SP6 points (SP6 point is located 3-4 fingers above the posterior malleolus bone, that is, 4 fingers above the ankle) of the pregnant women in first stage of childbirth at 4-5 cm, 6-7 cm, and 8-9 cm cervical dilatations during 3 contractions.
224218810|NCT03365921|BIOLOGICAL|Participants would receive 3 doses of Recombinant Hepatitis E Vaccine (Escherichia Coli) intramuscularly at 0, 1, 6 month.|Participants would receive 3 doses of Recombinant Hepatitis E Vaccine (Escherichia Coli) intramuscularly at 0, 1, 6 month.
224218811|NCT02044276|DRUG|lipegfilgrastim|6 mg
224218812|NCT02044276|DRUG|pegfilgrastim|6 mg
224218813|NCT04074473|DRUG|propranolol|Propranolol 10mg BID initially and titrate dosage every week to achieve 25% drop of heart rate (keep heart rate\>55 or systemic blood pressure\>90mmHg)
224218814|NCT04074473|PROCEDURE|Esophageal varice ligation|Esophageal variceal ligation every 3-4 weeks to achieve variceal eradication under endoscopy
224218815|NCT04074473|OTHER|DC propranolol|Patients randomized to banding ligation group discontinue propranolol after eradication of esophageal varices.
224218816|NCT05273606|DEVICE|MiSight mutifocal soft contact lens|Subjects will wear MiSight™ multifocal soft contact lenses for 1 month.
224218817|NCT05273606|DEVICE|Proclear 1 Day soft contact lens|Proclear™ 1 Day soft contact lens will be worn for baseline evaluation.
224317728|NCT01078870|DRUG|Lexapro|10mg/cap 1\~2# QD
223630159|NCT04517123|OTHER|Prone Positioning|Prone Positioning
224218818|NCT00626587|DEVICE|Olympus NA-2C-1 Transbronchial needle aspiration (TBNA)|The TBNA apparatus (Olympus NA-2C-1) is inserted through the working channel, and is advanced until it reaches the target lesion which is localized by EBUS. Negative manual suction is applied with the 20 ml syringe. The specimens are then smeared on glass slides and immersed in 95% alcohol. At least 3 aspirates per lesion are obtained.
224218819|NCT06539806|DRUG|Losartan 50mg Tab|The efficacy of losartan on response rate in both metastatic and locally advanced pancreatic cancer patients
224218820|NCT00267007|DRUG|PROCRIT 40,000 IU QW|Epoetin alpha (PROCRIT) 40,000 IU every week (QW) for 18 weeks (IV or SC)
224218821|NCT00267007|DRUG|Placebo|Equivalent volume to PROCRIT (1 mL) administered (QW) for 18 weeks (IV or SC)
224218822|NCT03359928|BEHAVIORAL|Boxing|as already discussed
224317729|NCT01078870|DRUG|Cymbalta|30mg/cap 30\~60mg/QD
224317730|NCT01078870|DRUG|Placebo|1\~2#/cap QD
224317731|NCT02010645|DRUG|Eltrombopag|Starting dose of Eltrombopag is 100 mg by mouth daily for each 28 day cycle. East Asians will start at 50 mg by mouth daily for each 28 day cycle.
224317732|NCT02010645|DRUG|Decitabine|Starting dose of Decitabine is 20 mg/m2 by vein on Days 1-5 for each 28 day cycle.
223630160|NCT02991183|BEHAVIORAL|ACT|A psychological therapy to help people i) notice and accept difficult thoughts and emotions; ii) identify what they value in life and iii) make changes to their behaviour to promote these values.
223630161|NCT01283139|BIOLOGICAL|Sifalimumab 200 mg|Sifalimumab 200 mg intravenously every 2 weeks for 4 weeks and then monthly for 44 weeks for a total of 14 doses.
224218823|NCT03359928|BEHAVIORAL|Stair stepping|as already discussed
224218824|NCT03359928|BEHAVIORAL|Stair climbing|as already discussed
224218825|NCT01987661|DEVICE|BIPAP ST|non invasive ventilation, individually titrated for each patient, if necessary combined with oxygen, to improve hypercapnic respiratory failure.
224218826|NCT01987661|DEVICE|Airtrap|"Addional to the individally titrated BiPAP ventilation parameters the function AirTrap Control is added.~AirTrap Control helps to prevent dynamic hyperinflation and makes it possible for VENTImotion 2 to automatically regulate to the best frequency and expiration time."
224218827|NCT02400073|DEVICE|AutoSet for Her|3 months nightly usage of the AutoSet for Her device
224218828|NCT06568133|DRUG|UIC201603 and co-administration of UIC201603 and UIC201604|"* UIC201603 2 Caps/day for 7 days~* Wash out 7 days~* UIC201603 2 Caps/day + UIC201604 1 Tabs/day for 7 days"
223630162|NCT01283139|BIOLOGICAL|Sifalimumab 600 mg|Sifalimumab 600 mg intravenously every 2 weeks for 4 weeks and then monthly for 44 weeks for a total of 14 doses.
223630163|NCT01283139|BIOLOGICAL|Sifalimumab 1,200 mg|Sifalimumab 1,200 mg intravenously every 2 weeks for 4 weeks and then monthly for 44 weeks for a total of 14 doses.
224218829|NCT06568133|DRUG|UIC201604 and co-administration of UIC201603 and UIC201604|"* UIC201604 1 Tabs/day for 7 days~* Wash out 7 days~* UIC201603 2 Caps/day + UIC201604 1 Tabs/day for 7 daysadministration of UIC201603 and UIC201604"
224218830|NCT03760107|BEHAVIORAL|Connect Smokers to Treatment 1|Using a factorial experimental design, the investigators evaluate how coupling a population-based, direct mail intervention with (1) financial incentives and (2) proactive telephone outreach influences connections to evidence-based tobacco treatment services among low-SES smokers.
224218831|NCT03760107|BEHAVIORAL|Connect Smokers to Treatment 2|Using a factorial experimental design, the investigators evaluate how coupling a population-based, direct mail intervention with (1) financial incentives and (2) proactive telephone outreach influences connections to evidence-based tobacco treatment services among low-SES smokers.
224218832|NCT03760107|BEHAVIORAL|Connect Smokers to Treatment 3|Using a factorial experimental design, the investigators evaluate how coupling a population-based, direct mail intervention with (1) financial incentives and (2) proactive telephone outreach influences connections to evidence-based tobacco treatment services among low-SES smokers.
224218833|NCT03760107|BEHAVIORAL|Connect Smokers to Treatment 4|Using a factorial experimental design, the investigators evaluate how coupling a population-based, direct mail intervention with (1) financial incentives and (2) proactive telephone outreach influences connections to evidence-based tobacco treatment services among low-SES smokers.
224218834|NCT03760107|BEHAVIORAL|Connect Smokers to Treatment 5|Using a factorial experimental design, the investigators evaluate how coupling a population-based, direct mail intervention with (1) financial incentives and (2) proactive telephone outreach influences connections to evidence-based tobacco treatment services among low-SES smokers.
224218835|NCT03760107|BEHAVIORAL|Connect Smokers to Treatment 6|Using a factorial experimental design, the investigators evaluate how coupling a population-based, direct mail intervention with (1) financial incentives and (2) proactive telephone outreach influences connections to evidence-based tobacco treatment services among low-SES smokers.
224218836|NCT06568198|DEVICE|Real tACS|α-tACS at a frequency of alpha band at S1
224317733|NCT00398866|DRUG|Synvisc (Hylan G-F20; hyaluronan injection)|1 ml of hyaluronan (Synvisc) injected once a week for 2 consecutive weeks
224317734|NCT00398866|DRUG|Bupivicaine (local anesthesia injection)|1 ml of bupivicaine 0.5% injected once a week for 2 weeks
223514282|NCT00964522|OTHER|Nurse education and care program|Random allocation of the patients in two arms according to the nursing cares. The arm A is the one of standard education and care. They consist of receiving programmed oral and written information by the specialist before initiating the chemotherapy treatment and before each cycle of treatment. Also, the patients will be able to ask for information to the nurses when they need it. Arm B is the one of experimental education and care. They consist of receiving oral and written information by the specialist before initiating the chemotherapy treatment and before each cycle. In addition, the patients assigned to arm B will receive programmed education and care about the chemotherapy by a Oncology nurse before the beginning of the treatment and in each cycle, in a specific nurse consultation.
224218837|NCT06568198|DEVICE|Sham tACS|Sham tACS with no stimulation applied
224218838|NCT00054015|DRUG|triapine|
223514283|NCT04742023|DEVICE|Continuous Glucose Monitor Application|The Guardian™ Sensor glucose sensor is part of the Medtronic Continuous Glucose Monitoring (CGM) system. The system then uses these signals to provide sensor glucose values. Patients post-renal transplantation will have CGMs applied and values interpreted by nursing.
224218839|NCT03236493|DRUG|PF-06700841|PF-06700841 will be administered as tablet
224218840|NCT03236493|DRUG|Placebo|Matching placebo will be administered as tablet
223514284|NCT04742023|DIAGNOSTIC_TEST|Finger Stick Glucose Measurement|Patients post-renal transplant will have finger-stick glucose measurements checked prior to meals.
223514285|NCT04742023|DRUG|Insulin|Insulin will be administered.
223514286|NCT04742023|DEVICE|Continuous Glucose Monitor Placebo Applied|The Guardian™ Sensor glucose sensor is part of the Medtronic Continuous Glucose Monitoring (CGM) system. The system then uses these signals to provide sensor glucose values. Patients post-renal transplantation will have CGMs applied however values will not be interpreted.
223514287|NCT05757349|BEHAVIORAL|Face-down position time 1-day|Postoperative face-down position of subjects wearing the novel positioning sensor device for 1-day.
223514288|NCT05757349|BEHAVIORAL|Face-down position time 3-day|Postoperative face-down position of subjects wearing the novel positioning sensor device for 3-day.
223514289|NCT01918358|DRUG|Sequence 1 : Period 1 (VR 160/20 mg-1), Period 2(VR 160/20 mg-2), Period (V+R)|
223514290|NCT01918358|DRUG|Sequence 2 : Period 1 (VR 160/20 mg-2), Period 2 (V+R), Period 3 (VR 160/20 mg-1)|
223514291|NCT01918358|DRUG|Sequence 3 : Period 1 (V+R), Period 2 (VR 160/20 mg-2), Period 3 (VR 160/20 mg-1)|
223514292|NCT01918358|DRUG|Sequence 4 : Period 1 (VR 160/20 mg-1), Period 2 (V+R), Period 3 (VR 160/20 mg-2 )|
223514293|NCT01918358|DRUG|Sequence 5 : Period 1 (VR 160/20 mg-2), Period 2 (VR 160/20 mg-1), Period 3 (V+R )|
223514294|NCT01918358|DRUG|Sequence 6 : Period 1 (V+R), Period 2 (VR 160/20 mg-1), Period 3 (VR 160/20 mg-2)|
223514295|NCT02096887|BEHAVIORAL|Patient Education|"Patient Education using the following two instruments:~1. Framingham Risk Score calculator:~2. Know your numbers patient booklet"
223514296|NCT02219451|OTHER|exercise training|exercise training
223514297|NCT06549322|OTHER|The exercise in morning|"Resistance exercises are in the following order: squat, bench press, deadlift. Each exercise consists of 3 sets with 7 repetitions, using a load of 70% 1RM with 60 sec of rest between sets.~Exercise timing: AM 11:00-11:30"
223630164|NCT01283139|OTHER|Placebo|IV Placebo every 2 weeks for 4 weeks and then monthly for 44 weeks
223764146|NCT02660320|DEVICE|Dermabrasion|Preparing the graft bed before epidermal cell suspension The epidermis can be removed using ablative CO2 or Erbium laser. We will assess the efficacy of using instead micro-needles to create micro-holes that will allow the melanocytes to reach the lower layers of the epidermis and thus repigment the lesional skin.
223630165|NCT02666781|OTHER|ApneaLink Plus, BIA Device|The study is only observational. No interventions will be performed. ApneaLink Plus will be used to diagnose Obstructive Sleep Apnea in potential candidates and grade its severity on Postoperative night 2 in participants. A BIA Device will be used to detect segmental fluid shifts. A 3-D accelerometer will be used to detect head and neck position.
223630166|NCT03224208|DRUG|Vemurafenib|Vemurafenib will be orally adminitered at 960 mg b.i.d. on Days 1-28
223630167|NCT03224208|DRUG|Cobimetinib|Cobimetinib will be given orally at 60 mg qd on Days 1-21 of each 28-day treatment cycle
223630168|NCT03446625|DRUG|Resveratrol|Resveratrol treatment (2 g/day) will be administered for 9 days, starting from oocyte maturation day.
223630169|NCT03446625|DRUG|Placebo|Placebo treatment (2 g/day) will be administered for 9 days, starting from oocyte maturation day.
223630170|NCT01010828|PROCEDURE|Incision technique|Tri-Vector Approach retains the majority of 3 vectors of quadriceps.
223630171|NCT01010828|PROCEDURE|Incision technique|Mini Mid-Vastus Approach
224218841|NCT01834573|BEHAVIORAL|physical exercise|10 weeks physical exercise; three times a week
224218842|NCT02438865|DRUG|Immediate instillation of intravesical chemotherapy-Epirubicin-|
224218843|NCT02438865|DRUG|Maintainance therapy of intravesical chemotherapy-Epirubicin-|
224218844|NCT02740673|DEVICE|Driving simulator|Patients are asked to use a driving simulator to test their driving skills
224218845|NCT01270373|DRUG|FAC x 3 followed by Docetaxel x 3|5-Fluorouracil (500 mg/m2), Doxorubicin (50 mg/m2) and Cyclophosphamide (500 mg/m2) IV every 21 days, for 3 cycles; followed by Docetaxel 100 mg/m2 every 21 days, for 3 cycles
224218846|NCT01270373|DRUG|Docetaxel x 3 followed by FAC x 3|Docetaxel 100 mg/m2 IV every 21 days, for 3 cycles; followed by 5-Fluorouracil (500 mg/m2), Doxorubicin (50 mg/m2) and Cyclophosphamide (500 mg/m2) IV every 21 days, for 3 cycles
224317735|NCT00398866|DRUG|Kenalog (triamcinolone; corticosteroid injection)|1 ml (40mg) of triamcinolone (Kenalog) injected the first week, followed by a placebo injection of 1 ml 0.5% bupivacaine the second week; Kenalog is a non-suspension steroid preparation and is less likely to cause post-injection flares than a suspension preparation
224317736|NCT05550506|DRUG|Duloxetine|Patients who use duloxetine for chronic pain or fibromyalgia
224317737|NCT00247312|RADIATION|Pd-103|
224317738|NCT00078117|DRUG|Buprenorphine|
223630172|NCT01463501|OTHER|Neoadjuvant chemoradiotherapy|Paclitaxel/carboplatin and concurrent radiation (50.4Gy/28f) followed by surgery, consolidate paclitaxel/carboplatin 2 cycles.
223630173|NCT01463501|OTHER|Adjuvant chemoradiotherapy|Surgery followed by paclitaxel/carboplatin and concurrent radiation (50.4Gy/28f), consolidate paclitaxel/carboplatin 2 cycles.
223630174|NCT02642601|DRUG|Indomethacin(KAHIRA PHARMA&CHEM,IND,CO.CAIRO-EGYPT)|one dose of indomethacin 100 mg rectal suppository 1- 2 hours before embryo transfer
223630175|NCT04282161|DEVICE|Axys EX device|Rotational atherectomy system for endovascular treatment of peripheral arterial disease prior to adjunctive therapy, if needed
223630176|NCT00549146|DRUG|fluticasone propionate/salmeterol 250/50 DISKUS combination product|
223630177|NCT00549146|DRUG|fluticasone propionate DISKUS 500mcg|
223630178|NCT04692064|OTHER|There is no intervention|There is no intervention
223630179|NCT00762164|DRUG|Vytorin|Vytorin 10/80 split into 4
223630180|NCT00762164|DRUG|Simvastatin|Simvastatin 20 milligrams
223630181|NCT05707728|DEVICE|intraoperative ultrasound|intraoperative cranial ultrasound
223630182|NCT06246292|PROCEDURE|Ultrasound-guided ESPB|The ESPB is a truncal block guided by ultrasound, involving the injection of local anesthetic beneath the erector spinae muscle (ESM), positioned between the ESM and the transverse process (TP) of the vertebra.
223630183|NCT06246292|PROCEDURE|Anatomical landmark-guided ESPB|The ESPB is a truncal block guided by anatomical landmarks, involving the injection of local anesthetic beneath the erector spinae muscle (ESM), positioned between the ESM and the transverse process (TP) of the vertebra.
223630184|NCT02954536|DRUG|pembrolizumab|
223630185|NCT02954536|DRUG|trastuzumab|
223630186|NCT02954536|DRUG|capecitabine|
223630187|NCT02954536|DRUG|cisplatin|
223630188|NCT02954536|DRUG|Oxaliplatin|Oxaliplatin may be administered instead, at a dose of 130 mg/m2/day as an I.V.over approximately 2 hours on Day 1 every 21-day cycles, up to a maximum of 8 cycles in the absence of disease progression or until other withdrawl criteria are met. Patients may begin with reduced dose of oxaliplatin 104 mg/m2 as starting dose if deemed necessary per the treating physician discretion. Oxaliplatin will be administered after the completion of the pembrolizumab infusion.
223764147|NCT02660320|DEVICE|Laser placebo|The epidermis can be removed using ablative CO2 or Erbium laser. We will assess the efficacy of using instead micro-needles to create micro-holes that will allow the melanocytes to reach the lower layers of the epidermis and thus repigment the lesional skin.
223764148|NCT04116164|DRUG|111In-DOTA-h11B6|4-6 mCi 111In labeled to 2 mg DOTA-h11B6; 0, 8 or 18 mg additional h11B6.
224218847|NCT03673839|OTHER|Animal Proteins (crossover)|Animal proteins mixed with water and consumed as a beverage once by the subject in a 4x4 Williams square crossover design
224218848|NCT03673839|OTHER|Plant-based protein blends type 1 (crossover)|Plant-based protein blends mixed with water and consumed as a beverage once by the subject in a 4x4 Williams square crossover design
224218849|NCT03673839|OTHER|Plant-based protein blends type 2 (crossover)|Plant-based protein blends mixed with water and consumed as a beverage once by the subject in a 4x4 Williams square crossover design
224218850|NCT03673839|OTHER|Plant-based protein blends type 3 (crossover)|Plant-based protein blends mixed with water and consumed as a beverage once by the subject in a 4x4 Williams square crossover design
224218851|NCT03818919|DRUG|Celecoxib|Post-Operative Non Opioid Pain Protocol
224218852|NCT03818919|DRUG|Ketorolac|Post-Operative Non Opioid Pain Protocol
224218853|NCT03818919|DRUG|Gabapentin|Post-Operative Non Opioid Pain Protocol
224218854|NCT03818919|DRUG|Acetaminophen|Post-Operative Non Opioid Pain Protocol
224218855|NCT03818919|DRUG|Diazepam|Post-Operative Non Opioid Pain Protocol
224218856|NCT03818919|DRUG|Hydrocodone-Acetaminophen|Traditionally used narcotic pain protocol
224218857|NCT00175383|DRUG|luteinizing hormone-releasing hormone (LHRH) short acting or long acting|See Detailed Description.
223630189|NCT02954536|DRUG|5-Fluorouracil|Only for patients unable to take oral medications (because of certain circumstances such as malabsorption, difficulty swallowing, or other conditions that could affect intake of oral capecitabine medication), 5-FU may be administered instead, at a dose of 800 mg/m2/day as a continuous infusion over 5 days (Day 1 to Day 5 of each cycle), every 21 days. This decision should be made prior to registration by the treating physician; switching from capecitabine to 5-FU, or vice versa, will not be allowed during the study. 5-FU will be administered after completion of the cisplatin infusion.
223630190|NCT00788216|OTHER|Discussion & scoring of health states related to the treatment of cervical cancer|Subjects will be interviewed using the visual analog score and time trade off methods.
223630191|NCT04906564|OTHER|Identification of genetic variants|Identification of genetic variants
223630192|NCT04609956|OTHER|Virtual reality|Virtual reality consists of a headphones, a virtual reality headset and a smartphone.
223630193|NCT04609956|OTHER|Standard|Standard arm is the habitual procedure. They use hydroxyzine and music with headphones
223630194|NCT05487612|DEVICE|Minimal Invasive Extracorporeal Circulation|Cardiac surgery with Minimal Invasive Extracorporeal Circulation (MiECC).
223630195|NCT05487612|DEVICE|Conventional cardiopulmonary bypass|Cardiac surgery with conventional cardiopulmonary bypass (cCPB).
223630196|NCT00256594|DEVICE|prescription form|Two prescription pads contained modified forms and two prescription pads were similar to the prescription pads the prescriber had been using. Providers completed 100 standard and 100 modified prescriptions
223630197|NCT04611386|DRUG|computerized tomography|Anti Factor Xa level
223630198|NCT00181272|DRUG|azithromycin|
223630199|NCT00006394|DRUG|growth hormone|
223630200|NCT03216525|DRUG|Alvimopan|To determine if Alvimopan during radical cystectomy with urinary diversion results in faster return of bowel function.
223630201|NCT03216525|DRUG|Placebo|To determine if placebo during radical cystectomy with urinary diversion results in faster return of bowel function.
223630202|NCT03294694|DRUG|Ribociclib|Each treatment cycle lasts 28 days. Ribociclib, 1 time per day by mouth for 21 days, followed by 1-week of rest (28-day cycle)
223630203|NCT03294694|DRUG|PDR001|Each treatment cycle lasts 28 days. (PDR001) will be administered once every 28 days (by intravenous infusion) over about 30 minutes (or up to 2 hours, if necessary) for the first infusion and over about 30 minutes for all following infusions.
224218858|NCT02908698|DRUG|Prednisone|"Total treatment duration: 15 days~Doses are as follows:~5 days daily treatment with 0.75 mg/kg of body weight 5 days daily treatment with 0.5 mg/kg of body weight 5 days daily treatment with 0.25 mg/kg of body weight"
224317739|NCT05084924|DEVICE|Cross-frequency transcranial alternating current stimulation via the NeuroConn Direct Current Stimulator Plus|Stimulation will be delivered via the NeuroConn Direct Current Stimulator Plus, an investigational electrical non-invasive brain stimulation device that is being used for foundational neuroscience and translational research.
223630204|NCT03294694|DRUG|Fulvestrant|Each treatment cycle lasts 28 days. Fulvestrant will be administered during Cycle 1 on days 1 and 15, and then on day 1 of each 28-day cycle thereafter.
223630205|NCT04281290|PROCEDURE|Electrochemotherapy - electroporation with Cliniporator Vitae® and chemotherapy drug Bleomycin PHC 15 e. (United States Pharmacopeia - USP)|"Procedure: Electrochemotherapy Exploration, anesthesia, pancreatic cancer resection, bleomycin administration, electroporation, formation of all anastomoses.~Device: Cliniporator Vitae® Positioning of plate electrodes according to landmarks, 8-28 min after administration of bleomycin application of electric pulses (8 pulses, duration 100 microseconds, frequency 8 Hz with amplitude adequate to cover the whole treated lesion with electric field necessary for reversible plasma membrane permeabilization, approximately 1000V/cm), removal of electrodes.~The maximum duration of procedure is 90 minutes, after liver mobilization.~Drug: Bleomycin PHC 15 e. (United States Pharmacopeia - USP) Intravenous bolus administration of bleomycin (15 mg/m2)"
223630206|NCT05627973|DEVICE|Aortic Valve Replacement|Surgical replacement of aortic valves
223630207|NCT00347789|PROCEDURE|Glaucoma surgery- Bleb revision|
223630208|NCT03210558|DRUG|Testosterone cream 1% (Andro-Feme® )|Testosterone cream 10 mg (1 ml) daily, supplied every evening via a dose applicator to the upper outer thigh for 10 weeks.
223630209|NCT03210558|DRUG|Placebo cream|Placebo cream (1 ml) daily, supplied every evening via a dose applicator to the upper outer thigh for 10 weeks.
223630210|NCT06417840|DIETARY_SUPPLEMENT|N-trans-caffeoyltyramine (NCT) and N-trans-feruloyltyramine (NFT)|N-trans-caffeoyltyramine (NCT) and N-trans-feruloyltyramine (NFT) derived via synthetic biology (i.e., fermentation using a recombinant microorganism) to provide a high purity (\>85%) form of these compounds that are structurally identical to their naturally occurring counterparts. All ingredients in the encapsulated final test article, including the NCT and NFT, are manufactured under food GMPs and are of suitable quality for use in food, dietary supplements, and specialty nutrition products.
223630211|NCT06417840|DIETARY_SUPPLEMENT|Placebo Control|Placebo Control
223630212|NCT05054075|BIOLOGICAL|Marine liquid and fluids|Marine liquid and fluids extracted from freshwater bivalve of A. cygnea (under very specific conditions)
223630213|NCT05054075|BIOLOGICAL|Impregnation|SARS / COVID-19 fluid/liquid - impregnation
223630214|NCT05054075|BIOLOGICAL|Incubation|SARS / COVID-19 fluid-bivalve-incubation
223630215|NCT05054075|BIOLOGICAL|Manipulation|Bivalve Manipulation - Stress inducing
224317740|NCT01111955|DRUG|BMS-823778|Capsules, Oral, 2 mg, once daily, 28 days
224317741|NCT01111955|DRUG|BMS-823778|Capsules, Oral, 10 mg, once daily, 28 days
223630216|NCT05054075|BIOLOGICAL|Refrigeration|Refrigerated fluid to check for maintained response
223630217|NCT04897711|BEHAVIORAL|Perceptual Training|Each listener is familiarized/trained with a single speaker with dysarthria. Pretest/posttest transcription data will be used to build explanatory models of intelligibility improvement.
223764149|NCT03072134|BIOLOGICAL|Neural stem cells loaded with an oncolytic adenovirus|The primary objectives are to evaluate the safety of the combined therapy and determine the maximum tolerated dose (MTD) for a future Phase II study.
224218859|NCT02908698|DRUG|Placebo Control|Total treatment duration: 15 days. Doses will appear identical to prednisone arm.
224218860|NCT01303874|DRUG|Etanercept (ETN)|ETN 50 mg subcutaneous (SC) injections once weekly and MTX orally once weekly.
224218861|NCT01303874|DRUG|Placebo|ETN-matching placebo SC injections once weekly and MTX orally once weekly.
224317742|NCT01111955|DRUG|BMS-823778|Capsules, Oral, 20 mg, once daily, 28 days
223630218|NCT05977413|OTHER|CAC Notification|Patient-Clinician CAC Notification. The CAC Notification intervention sent to both patients and clinicians has five features. 1) Results of a high CAC score (\>100 AU) detected on the patient's prior chest CT, 2) an image of the patient's CAC clearly marked, 3) a recommendation to have a patient-clinician risk discussion, 4) specific statin dosing recommended by guidelines, and 5) a link to the prevention gidelines.
223630219|NCT05977413|OTHER|Clinician Guideline Reminder|The Guideline Reminder intervention sent to primary care clinicians has five features. 1) A reminder that all patients should have their 10-year risk for ASCVD events calculated, 2) a figure of the recommended treatment algorithm according to ASCVD 10-year risk, 3) a nudge that patients who qualify for lung cancer screening are generally at high ASCVD risk, 4) a reminder that patients at elevated risk should be engaged in shared decision-making to discuss statin therapy and other preventive interventions, and 5) access to the complete ACC/AHA Primary Prevention Guidelines and the online 10-year ASCVD risk estimator.
223630220|NCT05050331|PROCEDURE|Muscle Energy Technique|MET involves patient-generated muscle contractions 10-20% maximum voluntary contraction from a specific position and direction, resisted by the therapist to facilitate muscle relaxation and lengthening
223630221|NCT05050331|PROCEDURE|Trigger Point Release|Trigger point release involved applying 90 seconds of sustained thumb pressure to the trigger point, repeated three times with 30-second relaxation intervals, followed by three caudal-to-cranial longitudinal strokes along the taut band.
223630222|NCT05050331|PROCEDURE|Self-Stretching of Calf and Plantar Fascia|Participants performed a self-stretching program, comprising 5 repetitions of 20 seconds of stretching and 20 seconds of relaxation, twice daily
223630223|NCT03218384|DRUG|Ferric Carboxymaltose|Intravenous Ferric Carboxymaltose 750 mg mixed under sterile conditions in 100 ml of normal saline for final concentration of 7.5 mg/ml and administered via volumetric infusion pump over 15 minutes.
223630224|NCT03218384|DRUG|Placebo|100 ml of normal saline solution, and administered via volumetric infusion pump over 15 minutes.
224218862|NCT05666674|OTHER|TSA algorithms|Our study will be composed of an experimental and an active comparator (i.e., control) arm. Both arms will perform a postural tremor test (PTT) to elicit parkinsonian tremors. The PTT is where subjects stabilize their backs against a wall and position their hands in the air against gravity for two minutes. The experimental arm will receive VR plus activated Tremor Stabilization Algorithms (TSA-ON) while the active comparator arm will receive VR only (TSA-OFF). Thus, subjects in the experimental arm will not see their digital arms tremor while those in the active comparator arm will. Our primary outcome is the severity of PTT elicited tremors. Tremors will be recorded by VR motion-capture controllers.
224218863|NCT03095482|DEVICE|Transcranial Direct Current Stimulation (tDCS)|Participants will receive 20 minutes of either active or sham tDCS prior to in vivo exposure to feared targets.
224218864|NCT03095482|BEHAVIORAL|In vivo exposure therapy|Participants will receive 30 minutes of in vivo exposure to feared targets following either active or sham tDCS
224218865|NCT01595074|OTHER|medical chart review|Correlative studies
224218866|NCT01595074|OTHER|laboratory biomarker analysis|Correlative studies
224218867|NCT00465504|PROCEDURE|iontophoresis|See Detailed Description.
224218868|NCT02964065|BIOLOGICAL|Live-Attenuated influenza Vaccine(LAIV)|
224218869|NCT02964065|BIOLOGICAL|Placebo|
224218870|NCT05541601|OTHER|Blood and Urine samples|The samples will be used to identify a range of tests (including genetic, protein and other biomarkers), which along with the clinical data will hopefully identify those most at risk of developing HCC, and to identify HCC at the earliest possible time points.
224218871|NCT03109522|PROCEDURE|axillary reverse mapping (ARM)|"ARM/SLNB: patient will be injected with technetium-99 radiolabelled colloid (Tc-99) into the subareolar area of breast, then 1-2 mls of blue dye (patent blue dye) injected subcutaneously into the medial ipsilateral arm, just proximal to the medial epicondyle of the elbow, at the start of the surgical procedure. the SLN(s) will be identified (hot node) and removed, and any blue lymph nodes and lymphatics will be preserved intact, and only removed or disrupted if there is 'crossover (i.e. the blue node is also the SLN) or if clinically suspicious for metastatic disease. ARM/ALND: 1-2 mls of blue dye will be injected subcutaneously into the medial ipsilateral arm at the start of the surgical procedure. Surgeons will perform a standard level I and II axillary dissection and any blue lymph nodes or lymphatics will be preserved intact, and only removed or disrupted if blue nodes are suspicious for metastatic disease."
224218872|NCT03109522|PROCEDURE|Standard axillary surgery (SLNB or ALND)|The control group will have standard SLNB or ALND surgery without identifying or sparing upper-limb lymphatics and nodes (blue dye is not injected).
224218873|NCT04583839|BEHAVIORAL|Patient Navigation Program|SWEET is a GDM-focused intervention that will apply barrier-reduction patient navigation strategies to improve health after a pregnancy with GDM. Women in SWEET will receive GDM-specific, tapered, individualized navigation services, including logistical support, psychosocial support, and patient education, through 1-year postpartum.
224218874|NCT06568250|BEHAVIORAL|RAMP program|The RAMP program is a 12-week virtual program consisting of an individual session (50 minutes) with a Whole Health Coach followed by 11 weekly interactive group sessions (90 minutes each) with pre-recorded expert led education videos, mind-body skill training and practice, and facilitated discussions.
224218875|NCT00764803|DEVICE|Encore 3DKnee™ system|Subjects with rheumatoid arthritis, traumatic arthritis or osteoarthritis who were implanted with the Encore 3DKnee™ system and willing to participate in the study.
224218876|NCT00764803|DEVICE|Encore MJS™ Knee System|Subjects with rheumatoid arthritis, traumatic arthritis or osteoarthritis who were implanted with the Encore MJS™ Knee system and willing to participate in the study.
224218877|NCT03522090|DIAGNOSTIC_TEST|lower neck CT|Computerised tomography of the lower neck done as part of initial CT thorax and lower abdomen
224218878|NCT06383208|DIAGNOSTIC_TEST|lipid metabolomics|Extract 4 milliliters of fasting peripheral venous blood from enrolled patients for targeted lipid metabolism metabolomics research. Utilize a liquid chromatography-tandem mass spectrometry (LC-MS/MS) system to conduct metabolomics analysis on patient blood samples.
224218879|NCT00184964|PROCEDURE|CT-scan, PET-scan|
224218880|NCT04627870|DEVICE|drug (paclitaxel) coated balloon|use drug (paclitaxel) coated balloon catheter to treat intracranial in-stent restenosis
224218881|NCT04627870|DEVICE|PTA balloon|use traditional PTA balloon with NMPA approval of indication for treating intracranial stenosis
224218882|NCT02289027|BIOLOGICAL|cAd3-EBOZ vaccine|
223630225|NCT03218384|DEVICE|31P MRS/MRI|Each participant will perform the same rhythmic plantar extension exercise protocol twice, for sequential acquisition of magnetic resonance spectroscopy (MRS) and magnetic resonance imaging (MRI) measurements. For the exercise protocol, the participant will lay supine on the scanning table with the right leg inside the volume coil. The exercise consists of repeated plantar flexion movements using resistance bands at a frequency of one repetition per second for 1-2 minutes. Data are collected continuously for 2 minutes before the exercise (baseline), during exercise, and 5 minutes after the exercise for the MRS and MRI experiments.
223630226|NCT06024070|OTHER|Rigid Tape|"The patient was rested in supine or long sitting position on a table Pre-wrap was applied to cover all the area before tapping Two strips used separately as anchors at the two ends of the pre-wrap. Two Longitudinal stirrup of tape were used from medial side of the superior anchor to lateral side of the same anchor.~Two horizontal stirrup of tape were used from medial side of the distal anchor to lateral side of the same anchor to support the medial side of the foot.~Figure-of-eight straps were utilized for the taping. Lateral heel lock was applied.The tape then proceeded from the lateral side of the foot, looping around the heel, and returning to the same starting point by crossing over the Achilles tendon from behind.~Medial heel lock was applied, the tape application was similar to the lateral heel lock but was at the opposite direction.~Superior and inferior anchors were applied to support all the previous strips"
223630227|NCT05881018|DIETARY_SUPPLEMENT|Low glycaemic index|Diet will be supplemented with a drink containing a low glycaemic index carbohydrate
223630228|NCT05881018|DIETARY_SUPPLEMENT|High glycaemic index|Diet will be supplemented with a drink containing a high glycaemic index carbohydrate
223630229|NCT05881018|BEHAVIORAL|Physical activity|Participants will include physical activity units
224218883|NCT02289027|BIOLOGICAL|Placebo (for cAd3-EBOZ vaccine)|Diluent
224218884|NCT01825876|DRUG|Evacetrapib|Oral administration
223630230|NCT03247257|PROCEDURE|General Anesthesia|Patients will be put under general anesthesia for cholecystectomy
223630231|NCT03247257|PROCEDURE|Epidural Anesthesia|Patients will receive Epidural Anesthesia for cholecystectomy
223630232|NCT03760991|DRUG|INSULIN GLARGINE (U300)|"Pharmaceutical form: Solution for injection in a prefilled pen~Route of administration: Subcutaneous"
223764150|NCT03678155|OTHER|pain app|Pain Monitor app has been developed by a multidisciplinary pain expert panel, including physicians, psychologists, and nurses. Content has been validated in a previous study and usability has been shown to be excellent.
223764151|NCT02294877|DRUG|Vimizim® (elosulfase alfa)|Recombinant human N acetylgalactosamine 6 sulfatase (rhGALNS)
223764152|NCT03326011|DEVICE|Samsung Hip Assist v1|All subjects receive gait training 3 times per week for 8 weeks for 24 training sessions. Each session is directed by a licensed physical therapist and lasted 60 min including rest period of 10 min. Brain activity and gait assessment is performed at visits 0 (baseline), 24 (post-test), and at 3 months (follow-up) after training.
223764153|NCT04677556|OTHER|Esogastric pressures measurement|"Catheter placement : at least 2 hours after and within 24 hours following the initial ventilation support establishment (CPAP or NiPPV according to usual practice and clinical conditions). 2 periods of measurements : with the initial and with the 2nd ventilation support using a cross-over for each patient. For each period, the first serie of measurements will be carried out without modifying the settings of the support ( clinical setting), and the second one using esogastric pressures by adjusting the settings of the ventilation support in order to obtain an optimal normalization or reduction of the amplitude of the Pes and Pdi deltas (physiological setting). 5 minutes of spontaneous breathing with/without oxygen between period 1 and 2 (depending on the patient's conditions). All measurements will be performed for 5 minutes after a 15 minutes quiet breathing. After measurements, the optimal respiratory support will be continued."
224218885|NCT01825876|DRUG|Warfarin|Oral administration
224218886|NCT02272582|DEVICE|SOMVC001 Vascular Conduit Solution|SV harvesting will be uniformly performed using an open or endoscopic vein harvesting technique. Once harvested, the SV will be divided into segments and these vein segments from each patient to be immersed in one of two blinded solutions: SOMVC001 or heparin dosed saline. The patients will then be randomized and SVG segment allocations will be defined and grafted to the assigned target regions.
224218887|NCT02272582|OTHER|Standard of care Heparin-dosed saline|SV harvesting will be uniformly performed using an open or endoscopic vein harvesting technique. Once harvested, the SV will be divided into segments and these vein segments from each patient to be immersed in one of two blinded solutions: SOMVC001 or heparin dosed saline. The patients will then be randomized and SVG segment allocations will be defined and grafted to the assigned target regions.
224218888|NCT03333460|DEVICE|Repetitive Transcranial Magnetic Stimulation|rTMS is a non-invasive brain stimulation technique. The investigators will use a MagPro R30 with the Cool-B80 figure-of-eight coil (MagVenture, Falun, Denmark).
224218889|NCT05350982|DEVICE|SalivaBio +/- SaliPac|Sterile collection swab (SalivaBio), Modified dummy (SaliPac)
224218890|NCT04965402|DRUG|BMS-986166|Specified dose on specified days
224218891|NCT04965402|OTHER|Placebo|Specified dose on specified days
224218892|NCT03542318|OTHER|Pulmonary Rehabilitation|A multidisciplinary PR programme was delivered twice weekly for 12 weeks. Each class was of 2 hours in duration. The first hour had an exercise component. Inspiratory muscle training was carried out using the Respironics IMT Threshold trainer® during the class. Educational sessions covered various aspects of pulmonary fibrosis care and self-management delivered. Patients also received an individualized home exercise programme consisting of exercise similar to what was being carried out during the classes. Each participant was encouraged to perform at least 20 minutes of these exercises per day.
224218893|NCT05149287|DRUG|Ceftriaxone|single intravenous dose of 1 g of ceftriaxone
224218894|NCT05149287|OTHER|Placebo|1% lidocaine and saline
224218895|NCT05309837|DIETARY_SUPPLEMENT|Polydextrose|Polydextrose-enriched food products
224218896|NCT05309837|DIETARY_SUPPLEMENT|placebo-controlled|Control food products
224317743|NCT01111955|DRUG|Placebo|Capsules, Oral, 0 mg, once daily, 28 days
224317744|NCT01111955|DRUG|Metformin|Capsules, Oral, ≥ 1500 mg, once daily, 28 days
224317745|NCT03335514|DIAGNOSTIC_TEST|expression of GALNT4|Blood is obtained into ethylenediaminetetraacetic acid（EDTA） tubes from all subjects via antecubital venepuncture and the total RNA was extracted from blood.Realtime PCR was performed to measure the expression of GALNT4.
224317746|NCT00186524|BEHAVIORAL|Breast Cancer Support Group|
224317747|NCT04254341|OTHER|patients with OSA|Sleep study
223630233|NCT05153577|OTHER|Group A: $5 produce box|Participants receive free weekly produce boxes delivered to their home for the first 4 weeks of the study and are then randomized to pay $5 per box (with continued free weekly delivery) for the remaining 4 weeks of the study. Participants also complete survey at the beginning, middle, and end of the produce delivery program.
224218897|NCT03751020|BEHAVIORAL|Expressive Writing (EW) Intervention|The EW intervention will utilize the procedures piloted earlier with gay and bisexual male college students in urban and rural regions of the US. In this condition, participants will be instructed to write for 20 minutes across three consecutive days in a free-form manner about the most stressful or traumatic LGB-related event that they have encountered.
224218898|NCT03751020|BEHAVIORAL|Self-Affirmation (SA) Intervention|The SA intervention will ask participants to read a brief description, over the course of 3 consecutive days, of a (hypothetical) LGB youth who is facing minority stress. Each day's description will contain a different LGB youth facing a different stigma-related stressor derived from Phase 1 and 2 interviews. Participants will then be asked to write a letter for 20 minutes to advise the LGB youth how best to cope with minority stress drawing on their personal experiences.
223630234|NCT05153577|OTHER|Group B: $10 produce box|Participants receive free weekly produce boxes delivered to their home for the first 4 weeks of the study and are then randomized to pay $10 per box (with continued free weekly delivery) for the remaining 4 weeks of the study. Participants also complete survey at the beginning, middle, and end of the produce delivery program.
223630235|NCT00225901|DRUG|Recombinant human hepatocyte growth factor|
223630236|NCT00604565|DRUG|soluble ferric pyrophosphate (SFP)|"Subjects will be randomized to undergo dialysis with either Fe-HD (dialysate containing SFP) The experimental concentrate containing SFP (Fe-HD)has 95mg of SFP per gallon, or 10.9 mg total iron per gallon (96 µg of SFP per dL or 11 µg of total iron per dL).~Control concentrate lacking SFP (C-HD) does not contain SFP (total iron = 0)"
223630237|NCT00604565|OTHER|placebo|Subjects will be randomized to undergo dialysis with C-HD (conventional dialysate lacking SFP)
223630238|NCT02451059|BEHAVIORAL|WE CARE survey|The WE CARE survey, consists of 14 questions used to identify seven unmet material needs (education, employment, food security, housing, childcare, household heat, language). The survey will be administered with patient's developmental screening forms at all health supervision visits from birth to two years of age. The office staff will instruct parents to give the WE CARE survey, along with the developmental screening tool, to their child's provider at the visit.
223630239|NCT02451059|BEHAVIORAL|WE CARE Community Resource Handout|Providers will be trained to review the WE CARE survey at health supervision visits and generate referrals thru the EMR. Specifically, they will receive a one-hour teaching session one week prior to the study implementation. The goals for the session will include providing an overview of pediatric practice guidelines, introducing the WE CARE survey, reviewing the referral process, and discussing the role of peer patient navigators. Study staff will conduct periodic booster sessions; study staff will also train new providers should there be staff turnover
223630240|NCT02451059|BEHAVIORAL|Patient Navigator|The peer patient navigator will offer guidance to families with accessing community resources. They will be available at least .5 days per week at intervention health centers to meet with families and offer guidance as well as be available via a hotline number. The navigator will speak with families and offer guidance on community resources and offer assistance with completing applications. In addition, they will offer to schedule and, if desired, accompany parents to the agencies. Interpreter services will be utilized at the health centers in case the navigator does not speak the parent's language. The navigator will also place an update note in the EMR within 1-month post-visit and one week after any contact with families.
223630241|NCT04756427|DRUG|Sodium Citrate 4% Inj Syringe 3Ml|3 ml of sodium citrate 4% locking solution instilled into the central catheter daily during the period that parenteral nutrition is not infusing, and will be withdrawn and disposed of prior to resuming infusion of parenteral nutrition
223630242|NCT04292535|DRUG|Placebo into the intranasal mucosa|6 doses of 0.2mL saline solution administered into the intranasal mucosa using the MAD Nasal Atomizer
223630243|NCT04292535|DRUG|20 IU NovoLog Insulin aspart into the intranasal mucosa|5 doses of 0.2mL saline solution, 1 dose of 0.2mL NovoLog Insulin aspart (20 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer
223630244|NCT04292535|DRUG|40 IU NovoLog Insulin aspart into the intranasal mucosa|4 doses of 0.2mL saline solution, 2 doses of 0.2mL NovoLog Insulin aspart (40 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer
223630245|NCT04292535|DRUG|60 IU NovoLog Insulin aspart into the intranasal mucosa|3 doses of 0.2mL saline solution, 3 doses of 0.2mL NovoLog Insulin aspart (60 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer
223764154|NCT02895958|DRUG|Zepatier|Zepatier (elbasvir and grazoprevir +/- Ribavirin) will be administered in a community setting to HCV infected G1/4 treatment naïve patients on stable opiate substitution therapy with Cirrhotic and Non-cirrhotic liver disease
223764155|NCT05721274|BEHAVIORAL|Community mobilization and Conditional community incentives|Non-cash, incentives would be given to clusters which improve the polio vaccine coverage and reduce the refusals and these incentives would be decided with consensus by community and costs would be shared
224218899|NCT03751020|OTHER|Control|Participants randomly assigned to the control condition will be asked to write about what they have done since waking up that morning for 20 minutes across 3 consecutive days. This control matches the time and activity of the EW and SA arms and has been implemented across dozens of EW and SA studies.
224218900|NCT01740492|DRUG|Ketamine 0.15mg/kg|0.15mg/kg ketamine delivered IV (in the vein) following clinician assessment in ER. Number of cycles: until discharge or 6 hours elapses.
224218901|NCT01740492|DRUG|Ketamine 0.3mg/kg|0.3 mg/kg ketamine delivered IV (in the vein) following clinician assessment in ER. Number of cycles: until discharge or 6 hours elapses.
224218902|NCT01740492|OTHER|Placebo|Placebo injection of 0.9% normal saline of a similar volume (0.05ml/kg)
224218903|NCT02134691|BEHAVIORAL|Prolonged Exposure|
224218904|NCT02134691|BEHAVIORAL|Applied Relaxation|
224218905|NCT04938401|OTHER||
224218906|NCT02094430|DRUG|biological: human fibrinogen concentrate|
224218907|NCT05143086|OTHER|Mouthwash 100% Nano-F|Use 10 ml of mouthwash 100% Nanoencapsulated Fluoride after brushing for one week, twice a day.
223630246|NCT04292535|DRUG|80 IU NovoLog Insulin aspart into the intranasal mucosa|2 doses of 0.2mL saline solution, 4 doses of 0.2mL NovoLog Insulin aspart (80 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer
224218908|NCT05143086|OTHER|Mouthwash 50% Nano-F|Use 10 ml of mouthwash 50% Nanoencapsulated Fluoride after brushing for one week, twice a day.
224218909|NCT05143086|OTHER|Mouthwash standard|Use 10 ml of mothwash after brushing for one week, twice a day. It's for the positive control of fluoride.
224218910|NCT05143086|OTHER|Placebo|Use 10 ml of mouthwash without fluoride
224218911|NCT03374150|BEHAVIORAL|diet counseling|Subjects were given nutrition consultation, diet recipes, and logbook. Counseling was performed once weekly. During 8 weeks of diet program, subjects were instructed to reduce their daily caloric intake by 500 - 1000 kcal from their previous usual daily intake with limitation in low calorie diet range (800-1500 kcal.day) of calorie intake.Follow-up for each subject was performed once daily by person-to-person encounter. Besides, subjects were contacted by everyday cellphone texting and telephone twice a week to control subject's compliance. After 8 weeks of intervention, subjects were invited to revisit the clinic for anthropometry and body composition measurement after completing the program.
224218912|NCT00711867|DEVICE|VH2|Dynatherm vitalHeat2 (VH2) temperature management system.
224218913|NCT00711867|DEVICE|Bair Hugger|Arizant Bair Hugger temperature management system.
224218914|NCT01463566|DEVICE|Zimmer Gender(R) Solutions(TM) Natural-Knee(R) Flex System|Gender Solutions Natural Knee Flex System in total knee arthroplasty
224218915|NCT03230968|BEHAVIORAL|Integral Action Program for Respiration|
224218916|NCT06458725|DEVICE|Magnetic Resonance Imaging (MRI)|"\- Three MRI :~* two on an MR-Linac 1.5 Tesla (10 to 17 days apart)~* one on a standard 1.5 Tesla MRI"
224218917|NCT05161663|BEHAVIORAL|Peer-driven intervention|"This peer-driven intervention (PDI), modified based on respondent-driven sampling (RDS) or snowball sampling, is a chain referral approach. Index peers will be purposefully selected to reflect the diversity of African American (AA) and Hispanic/Latino (H/L) men who have sex with men (MSM) and are required to take a formal training about pre-exposure prophylaxis (PrEP) and HIV. These index peers will educate members of their social networks and encourage them to initiate PrEP. Those referred peers will schedule an appointment to complete a short survey and will be referred to our PrEP clinic if they are interested in PrEP uptake. The referred peers will serve as index peers for the following wave of recruitment. It is expected to achieve a robust sample of AA and H/L within six waves of recruitment. This PDI approach is potential to engage AA and H/L who are most at risk of HIV acquisition in PrEP uptake and could contribute to reducing the concentrated HIV epidemic."
224218918|NCT00667719|DRUG|Aliskiren|300 mg tablet
224218919|NCT00667719|DRUG|Amlodipine|5 mg tablet
224218920|NCT00667719|DRUG|Hydrochlorothiazide|12.5 mg and 25 mg capsule
224218921|NCT00078819|DRUG|Etanercept|Etanercept 0.8 mg/kg (up to an intended dose of 50 mg) by subcutaneous injection once a week
224218922|NCT00078819|DRUG|Placebo|Placebo matching to etanercept administered by subcutaneous injection once a week
224218923|NCT05693857|OTHER|Cardiovascular prevention guidelines|Cardiovascular prevention guidelines use estimated 10-year atherosclerotic cardiovascular disease (ASCVD) risk to guide treatment decisions and engage patients in shared decision-making
224317748|NCT01964079|DRUG|Amlodipine|Eligible subjects will be randomized 1:1 to either an amlodipine or a losartan group by a computer-generated random number table. For patients who fail to respond to 5 mg amlodipine, the dose will be titrated up to 10 mg amlodipine. At subsequent visits, additional antihypertensive therapy (hydrochlorothiazide) will be added if systolic (\>140 mmHg) or diastolic (\>90 mmHg) BP is inadequate. Study drugs are administered once a day for 24 weeks. The dose will be titrated up if SBP is over 90 mmHg or there are no symptoms of hypotension (syncope, loss of consciousness, or orthostatic hypotension). If up-titration is not tolerable, because of side effects or hypotension, the previous dose will be administered as the final tolerable dose.
223630247|NCT04292535|DRUG|100 IU NovoLog Insulin aspart into the intranasal mucosa|1 dose of 0.2mL saline solution, 5 doses of 0.2mL NovoLog Insulin aspart (100 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer
223764156|NCT04721249|DIETARY_SUPPLEMENT|D-serine|Patients will receive four 500mg capsules of D-serine each day over a course of six weeks (two after breakfast and two after dinner).
224218924|NCT03174041|DRUG|Midazolam|Single dose midazolam
224218925|NCT03174041|DRUG|GDC-0853|Multiple doses GDC-0853 for 6 days
224218926|NCT03174041|DRUG|Midazolam and GDC-0853|Multiple doses GDC-0853 and single dose midazolam
224218927|NCT03174041|DRUG|Rosuvastatin|Single dose rosuvastatin
224218928|NCT03174041|DRUG|Rosuvastatin and GDC-0853|Multiple doses GDC-0853 and single dose rosuvastatin
224218929|NCT03174041|DRUG|Simvastatin|Single dose simvastatin
223630248|NCT04292535|DRUG|120 IU NovoLog Insulin aspart into the intranasal mucosa|6 doses of 0.2mL NovoLog Insulin aspart (120 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer
223764157|NCT04721249|DIETARY_SUPPLEMENT|Placebo|Patients in the placebo group will receive four placebo capsules each day (two after breakfast and two after dinner). The placebo capsules will contain Mannotol / Mannitol-Silica (99.5/0.5, respectively) and will be indistinguishable from D-serine by matching colour, shape, size and packaging.
223764158|NCT05164237|OTHER|nerve flossing technique|subjects will receive NFT with conventional physical therapy modalities in the form of (splint and therapeutic exercises ) 3 sessions every week for 8 weeks.
223764159|NCT05164237|OTHER|multimodal electrotherapy|subjects will receive multimodal approach of electrotherapy (LLLT , US and IFC) with conventional physical therapy modalities in the form of ( splint and therapeutic exercises ) 3 sessions every week for 8 weeks.
223764160|NCT05164237|OTHER|exercises|subjects will receive with conventional physical therapy modalities only in the form of (splint and therapeutic exercises ) 3 sessions every week for 8 weeks.
223764161|NCT02906774|BIOLOGICAL|Fecal microbiota transplantation (FMT)|Fecal microbiota transplantation after antibiotic pretreatment
224218930|NCT03174041|DRUG|Simvastatin and GDC-0853|Multiple doses GDC-0853 and single dose simvastatin
224218931|NCT03174041|DRUG|GDC-0853|Single dose GDC-0853
224218932|NCT03174041|DRUG|Itraconazole|Multiple doses itraconazole for 6 days
224218933|NCT03174041|DRUG|GDC-0853 and itraconazole|Multiple doses itraconazole and single dose GDC-0853
223630249|NCT05708092|BEHAVIORAL|NeuroResource Facilitation (NRF)|"NRF is defined as a specialized service that promotes access to services and coordinates care specific to the needs of individuals with brain injury.~Possible resources include vocational services, medical assistance, Social Security (SSI or SSDI if appropriate), and other organizations that can support reentry. If needed to gain access to services and organizations, the facilitator will also provide participants with a summary that includes results from brain injury screenings questionnaire, neurocognitive (thinking abilities) tests, and symptoms. The researchers will share information and coordinate with prison and parole staff about participation in the study. Participant's information will also be shared with resources that could help participants after release, such as funding sources and brain injury services. After release from SCI, the NRF facilitator will assist the participant with all the preparation and logistics associated with the resources the participant applied to."
223630250|NCT00265694|DRUG|vinorelbine, gemcitabine and carboplatin|
223630251|NCT01739998|DIETARY_SUPPLEMENT|functional oil|
223630252|NCT01739998|DIETARY_SUPPLEMENT|Placebo|
223630253|NCT00121017|DRUG|Kaletra (lopinavir/ritonavir)|
223630254|NCT00121017|DRUG|Sustiva (efavirenz)|
223630255|NCT00121017|DRUG|Truvada (emtricitabine/tenofovir disoproxil fumarate)|
223630256|NCT06239584|PROCEDURE|Biopsies performed via bronchoscopy|An additional amount of lung tumor tissue will be collected compared to that normally obtained as standard clinical practice, during bronchoscopy, al in order to increase the probability of successful generation of organoids
223630257|NCT03674528|OTHER|Magnetic Resonance Elastography (MRE)|The MRE scan will several breath holds and will take approximately 30 minutes to complete.
223630258|NCT03674528|DIAGNOSTIC_TEST|Liver biopsy|Subjects undergoing WLS will be asked to allow for liver biopsy samples to be collected during their surgical procedure. The collection of these samples will take approximately 5 minutes to complete.
224218934|NCT01353924|BIOLOGICAL|Bet v 1aF1-Alum + Bet v 1aF2-Alum|subcutaneous injection of equimolar mixture (20µg each) of Bet v 1aF1-Alum and Bet v 1aF2-Alum, three times in monthly intervals and a booster injection after one year
224218935|NCT01353924|BIOLOGICAL|Alum-Placebo|subcutaneous injection of Alum-Placebo, three times in monthly intervals and a booster injection after one year
223630259|NCT03515577|PROCEDURE|Computed Tomography|Undergo PET/CT
223630260|NCT03515577|DRUG|Fluciclovine F18|Given fluciclovine F18
223630261|NCT03515577|DRUG|Gallium Ga 68-labeled PSMA-11|Given IV
223630262|NCT03515577|OTHER|Laboratory Biomarker Analysis|Correlative studies
223630263|NCT03515577|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
223630264|NCT04190459|PROCEDURE|LSG|Bariatric surgery
223764162|NCT06165796|DEVICE|routine cataract surgery and intraocular lens implantation|routine cataract surgery and intraocular lens implantation
223764163|NCT06383663|PROCEDURE|Supraclavicular lymph node dissection combined with radiotherapy|Breast cancer patients in the expreimental cohort with only ipsilateral supraclavicular lymph node metastasis were first treated with supraclavicular lymph node dissection and received standard radiotherapy after surgery.
223764164|NCT06383663|RADIATION|radiotherapy|Patients in the control group received only standard radiation therapy.
224218936|NCT04829279|OTHER|CONNECT AI system group|"A. During the Intervention period, paramedics wear equipment for multi-faceted data acquisition and press the start button of the system.~B. During the Intervention period, inside the ambulance, a application that implements a function that automatically evaluates the patient's severity, displays a list of optimal transfer hospitals based on this, and shares real-time information of the hospitals, is installed so that paramedics can refer to the work.~C. ED's medical staff will receive through ER-kiosk pre-hospital patient information collected and analyzed through the CONNECT AI system before arrival."
224218937|NCT04828902|PROCEDURE|cardiac surgery|Any heart surgery on or without cardiopulmonary bypass performed under general anesthesia in the Cardiac Surgical Department, Medical University of Gdańsk.
223630265|NCT04190459|PROCEDURE|LRYGB|Bariatric surgery
223630266|NCT05659108|BEHAVIORAL|CPR|HIGH QUALITY CPR
223630267|NCT03925623|OTHER|Novel approaches for the design of child resistant closures|"Two novel designs for child resistant closures are tested.~One is sized based on the anthropometric properties of adults and children's hands such that it should disallow children from engaging the system and enable adults (the physically based design strategy). The other replicates the first design, but is sized such that either of the two populations should be able to engage the closure.~In testing this way, we begin to differentiate the paradigm that holds the children out (the cognitively based design strategy-- they do not understand and/or a physical one- they are unable to use the closure).~Results (proportion of children opening within the first or second five minute periods of test and time to opening during the same) from each of these, will be compared to results from the third treatment, a standard, commercially available push and turn system."
223630268|NCT04146181|DRUG|PD-1|SCT-I10A, 200 mg intravenous (IV) on Day 1 of each 3-week cycle.
223630269|NCT02203734|PROCEDURE|Moderate Pressure Massage|The massage therapy will begin with the mother in a side-lying position, with pillows positioned behind her back and between her legs for support. The massage is given in the following sequence and repeated twice (10 minutes on each side for 20 minutes total) on the following areas: 1) Head and neck: 2) Back: 3) Arms: and 4) Legs. The effective moderate pressure (measured by a pressure meter) is 8 db or a slight indentation in the skin.
223764165|NCT06144736|PROCEDURE|Robot-assisted retroperitoneal lymph node dissection|"Robot-assisted, if possibe ipsilateral nerve-sparing, retroperitoneal lymph node dissection and metastasis resection in a unilateral dissection field (template)"
223764166|NCT06144736|DRUG|Adjuvant therapy with one cycle of cisplatin, etoposide and bleomycin|The patient is given the option for an adjuvant therapy with one cycle of cisplatin, etoposide and bleomycin two to four weeks after RA-RPLND
223764167|NCT04022135|DIETARY_SUPPLEMENT|Folic acid|Participants will supplement with 0.6mg/day for 16 weeks.
223764168|NCT04022135|DIETARY_SUPPLEMENT|(6S)-5-methyltetrahydrofolic acid|Participants will supplement with 0.625mg/day for 16 weeks.
223764169|NCT03794037|DRUG|dydrgesterone 10 mg( tab)/12hs/14 days|Dydrogesterone Oral Tablet 10 mg twice daily for 14 days to be taken from the day of ovum pickup
224218938|NCT04000828|DEVICE|Placement of Sensimed Triggerfish|Sensimed Triggerfish is placed on the corneal surface
224218939|NCT01726478|DRUG|2.5 units Oxytocin|Administration of 2.5 units of oxytocin after clamping of umbilical cord
223630270|NCT02203734|PROCEDURE|Light Pressure Massage|The light pressure massage group will receive light pressure massage in contrast to the treatment group who will receive moderate pressure massage. As with moderate pressure massage, each session will begin with the mother in a side-lying position, with pillows positioned behind her back and between her legs for support. The massage is given in the following sequence and repeated twice (10 minutes on each side for 20 minutes total) on the following areas: 1) Head and neck: 2) Back: 3) Arms: and 4) Legs.
223630271|NCT05759507|PROCEDURE|abdominal surgery|
224218940|NCT01726478|DRUG|10 units Oxytocin|Administration of 10 units of oxytocin after clamping of umbilical cord
223630272|NCT05236517|DRUG|Semaglutide D Dose 1|Tablet given orally
224218941|NCT00323609|PROCEDURE|Vertebroplasty|Vertebroplasty involves placement of a needle into the vertebral body. Cement is injected into the vertebral body.
224218942|NCT00323609|PROCEDURE|Kyphoplasty|Balloon Kyphoplasty involves two inflatable bone tamps placed into the vertebral body in the spine. After the tamps are removed, the void is filled with viscous bone cement.
224218943|NCT05401331|DEVICE|Treadmilll|Hemodynamic changes before and after treadmill use
224218944|NCT05401331|OTHER|mask|mask
224218945|NCT00267293|DRUG|Acetaminophen|Given for fever control 15mg/kg
224218946|NCT00267293|DRUG|Ibuprofen|Given for fever control 10 mg/kg
224218947|NCT00274144|DRUG|telmisartan 40 mg|
224218948|NCT00274144|DRUG|placebo 40 mg|
224218949|NCT01204060|OTHER|Nasal allergen challenge|Subjects will receive a nasal spray containing an allergen to which they are allergic
224218950|NCT01204060|OTHER|Nasal placebo challenge|Subjects will receive a nasal spray with allergen diluent
224218951|NCT04382157|DRUG|Mablet 360 mg|Slow-released magnesium hydroxide
224218952|NCT04382157|DRUG|Placebo|Placebo
223630273|NCT05236517|DRUG|Semaglutide D Dose 2|Tablet given orally
223630274|NCT05236517|DRUG|Semaglutide D Dose 3|Tablet given orally
223630275|NCT05236517|DRUG|Semaglutide C Dose 4|Tablet given orally
223630276|NCT05236517|DRUG|Semaglutide C Dose 5 (50 mg)|Tablet given orally
223630277|NCT05236517|DRUG|Placebo (Semaglutide C)|Tablet given orally
223630278|NCT05236517|DRUG|Placebo ( Semaglutide D)|Tablet given orally
223630279|NCT02488577|PROCEDURE|Transanal minimally invasive total mesorectal excision|
223630280|NCT02488577|PROCEDURE|transanal minimally invasive locoregional resection|
223630281|NCT01769313|DEVICE|Laser-assisted cataract surgery|The anterior capsulotomy and lens fragmentation will be performed by means of femtosecond laser surgery
224218953|NCT06547879|BEHAVIORAL|Hypertension Self Management Program|The HT self-management training program was continued in the form of one session per week, a total of 8 modules, for 8 weeks, with different module content each week. After these eight-week training and awareness sessions were completed, the implementation of the study was terminated (week 8), no additional intervention was given to the intervention group, and the evaluations at the 8th week (end of intervention-T1) and the 12th week (follow-up-T2) were carried out by the researcher during the routine checks of the participants at the outpatient clinic. It was carried out face to face.
224218954|NCT04607603|DRUG|Cannabidiol Oral Product|Cannabidiol is administered in capsules. Each capsule contains 200mg of CBD administered 3 times daily to a total of 600mg per die
224218955|NCT04607603|DRUG|Placebo|Placebo will be administered in capsules of identical appearance to CBD capsules in 3 doses per die
224218956|NCT05221879|OTHER|Dose adjustment of Enoxaparin in patients with sub-therapuetic (prophylactic) levels of factor 10a|We screened ICU patients who recieved DVT prophylaxis with fixed dose of Enoxaparin (40 mg SC daily) for peak blood levels of factor 10A. For patients who did not achieve therapuetic 10a levels (0.2-0.4) we increased the Enoxaparin dose to 60 mg SC daily.
224218957|NCT05163379|OTHER|MOBILIZATION|EARLY MOBILIZATION OF INTUBE PATIENTS AND ITS EFFECTS OF MOBILIZATION
224218958|NCT01850303|DRUG|Pemetrexed|
224218959|NCT01850303|DRUG|Gemcitabine|
224218960|NCT01850303|DRUG|Induction chemotherapy|4 cycles of carboplatin-paclitaxel
223630282|NCT01769313|DEVICE|Manually performed cataract surgery|The anterior capsulotomy and lens fragmentation will be performed manually.
223630283|NCT00517296|PROCEDURE|EUA with seton placement if necessary|Patients randomized to the combination therapy group, the surgeon will have access to EUS findings.
223630284|NCT00517296|DRUG|adalimumab|Patients began therapy with adalimumab using clinic standards for dosing.
223630285|NCT00517296|PROCEDURE|EUS|Patients in combination therapy group had an EUS done every 12 weeks to help guide therapy.
223630286|NCT05529498|BEHAVIORAL|Moderate paced continuous gait training|walking continuously for 20 minutes at a moderate pace
223630287|NCT05529498|BEHAVIORAL|High Intensity Interval gait training|20 minutes of interspersing 30 seconds of fast walking with 1 minute of rest
223630288|NCT00132392|DRUG|ALGRX 4975|
223630289|NCT00466544|DEVICE|Plasmaknife|
223630290|NCT00466544|DEVICE|Monopolar|
223630291|NCT02078206|OTHER|Neurocognitive stimulation|
223630292|NCT03021200|DEVICE|Green indocianine|Laser fluorescence using green indocianine guiding the surgical procedure.
223630293|NCT03660462|DIETARY_SUPPLEMENT|FeSO4 fortified rice test meal|Rice test meal extrinsically labeled with 2 mg ferrous sulfate (58FeSO4)
223630294|NCT03660462|DIETARY_SUPPLEMENT|FePO4 fortified rice test meal|Rice test meal extrinsically labeled with 2 mg ferric phosphate (58FePO4)
224218961|NCT05934279|DEVICE|Resistance Training|All training exercise involve balance and strength improvement. Consist of 8 weeks of trainings per 2 trainings in each week, ongoing 45 minutes.
224218962|NCT06452823|PROCEDURE|Catheter Ablation|catheter radiofrequency ablation therapy for atrial fibrillation involves the use of ablative energy to destroy the cardiomyocytes at the opening of the pulmonary veins, which blocks the electrical conduction pathway between the pulmonary veins and the left atrium, so that atrial fibrillation no longer occurs.
224218963|NCT02844179|DRUG|HTBZ|
224218964|NCT04926896|PROCEDURE|Traditional iliac crest bone harvesting surgery|The experimental group and the control group do not have special requirements; perform the surgery according to the normal operation methods of different sites.
224218965|NCT04926896|PROCEDURE|Minimally invasive bone harvesting surgery|Minimally invasive bone harvesting surgery
224218966|NCT04863456|PROCEDURE|Total resection|Total resection of HIPA in a single surgery
223764170|NCT03794037|COMBINATION_PRODUCT|montelukast 10 mg(tab) oral/24hs/ 7 days dydrgesterone 10 mg( tab) oral/12hs/14 days|montelukast 10 mg(tab) once daily oral for 7 days \& dydrgesterone 10 mg (tab) twice daily oral for 14 days \&
223764171|NCT01955057|BEHAVIORAL|Research interviews|
223764172|NCT01955057|BEHAVIORAL|Tests (Fagerström, Q-MAT, H.A.D.S, SCL 90-R)|
224218967|NCT04863456|PROCEDURE|Staged resection|HIPA was resected subtotally at first time, and the tumor remnant was removed at a later date
223764173|NCT01955057|BEHAVIORAL|Projective methods (Thematic apperception Test, Rorschach)|
224218968|NCT04863456|PROCEDURE|Subtotal resection followed by stereotactic radiation therapy|HIPA was resected subtotally at first time, and the tumor remnant was controled by the stereotactic radiation therapy
224218969|NCT01514656|OTHER|CPR Training using the Family and Friends CPR Anytime Video Self Instruction|Subjects will be trained using the American Heart Association's Family and Friends CPR Anytime Program. The subject's will undergo training in-hospital then they will be encouraged to take the training materials home with them to practice CPR with their family members and friends.
224218970|NCT01514656|OTHER|Implementation of a Hospital-based CPR Training Model|Nurses and Volunteers will be trained in the hospital-based CPR Training Model, and be encouraged to implement the training program in their respective hospitals.
224218971|NCT01514656|OTHER|Follow-up prompting to encourage skill retention|Subjects will be contacted every two months and encouraged to practice the skills that they have learned. Means of contact include: a) email b) text blasts c) phone calls d) social media e) mail
223514298|NCT06549322|OTHER|The exercise in evening|"Resistance exercises are in the following order: squat, bench press, deadlift. Each exercise consists of 3 sets with 7 repetitions, using a load of 70% 1RM with 60 sec of rest between sets.~Exercise timing: PM 05:00-05:30"
224218972|NCT00907036|BIOLOGICAL|alemtuzumab|
224218973|NCT00907036|BIOLOGICAL|donor lymphocytes|
224218974|NCT00907036|DRUG|cyclosporine|
224218975|NCT00907036|DRUG|fludarabine phosphate|
224218976|NCT00907036|DRUG|melphalan|
224218977|NCT00907036|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
224218978|NCT00950599|DRUG|Saxagliptin|Tablets, Oral, 2.5 mg, once daily, 12 weeks
224218979|NCT00950599|DRUG|Saxagliptin|Tablets, Oral, 5 mg, once daily, 12 weeks
224218980|NCT00950599|DRUG|Saxagliptin|Tablets, Oral, 10 mg, once daily, 12 weeks
224218981|NCT00950599|DRUG|Saxagliptin|Tablets, Oral, 20 mg, once daily, 12 weeks
224218982|NCT00950599|DRUG|Saxagliptin|Tablets, Oral, 40 mg, once daily, 12 weeks
224218983|NCT00950599|DRUG|Saxagliptin|Tablets, Oral, 100 mg, once daily, 6 weeks
224218984|NCT00950599|DRUG|Placebo|Tablets, Oral, 0 mg, once daily, 6 and 12 weeks
223514299|NCT02934217|DRUG|Injection of Cyclosporin|one single intravenous bolus injection of 2.5 mg/Kg
223514300|NCT02934217|DRUG|Placebo|One single intravenous bolus injection of Placebo
223514301|NCT02934217|PROCEDURE|Echocardiography|3 years after AMI
223514302|NCT00109668|DRUG|beclomethasone dipropionate (QVAR)|
223514303|NCT00934388|PROCEDURE|Pre peritoneal mesh placement|
223514304|NCT00934388|PROCEDURE|Laparoscopy|
223514305|NCT03975179|PROCEDURE|Omission of intraoperative frozen section biopsy for margin status|Omitting intraoperative frozen section biopsy for margin status in patients undergoing breast conserving surgery
223514306|NCT03975179|PROCEDURE|Frozen section biopsy for margin status|Performing intraoperative frozen section biopsy for margin status in patients undergoing breast conserving surgery
223514307|NCT02579057|DRUG|Furosemide Injection Solution (SCP-101)|
223514308|NCT02579057|DRUG|Furosemide Injection Solution, USP|
223514309|NCT04426513|OTHER|Kinesiotherapy with magnetotherapy|Individual kinesiotherapy. Parameters of magnetic field: 7 mT, f= 0-50 Hz, type of impulse: unipolar or bipolar, rectangular pulse
223514310|NCT01366274|OTHER|Protective manual hyperinflation|Manual hyperinflation for 10 minutes using a Mapleson C circuit and 100% oxygen with volume set at 8mls/kg and positive end expiratory pressure in the circuit appropriate to baseline levels
223514311|NCT01366274|OTHER|Usual method of MHI|Manual hyperinflation for 10 minutes using a Mapleson C circuit and 100% oxygen with volume set at 12mls/kg and no positive end expiratory pressure in the circuit
223514312|NCT02624687|BEHAVIORAL|Intervention|Participants participated in monthly, individual counselling with a trained interventionist to decrease sedentary behavior and improve pain self-management. Participants were provided with a sit-stand desk attachment and a wrist worn activity prompter..
223514313|NCT02624687|OTHER|No intervention|No contact control
223514314|NCT00111735|DRUG|Thyroxine|
223514315|NCT03111108|DRUG|EBR/GZR (50 mg/100 mg) FDC|One FDC tablet taken once daily by mouth for 8 or 12 weeks depending upon randomization.
223514316|NCT06154850|OTHER|Immersive virtual reality|Oculus Quest 2 will be used with NatureTrek application for 10 minutes.
223514317|NCT06154850|OTHER|Non-immersive virtual reality|Patients will watch a video including scenes from NatureTrek application on a screen.
223514318|NCT05095441|BIOLOGICAL|C5252|A single dose of C5252 will be administered up to 2mL as intratumoral injection on Day 1.
223514319|NCT00005038|BIOLOGICAL|aldesleukin|
223514320|NCT00005038|DRUG|histamine dihydrochloride|
223514321|NCT03307824|DEVICE|Synthetic glue IfabondTM|Use of the synthetic glue IfabondTM
223514322|NCT03307824|PROCEDURE|Glue-Free Suture Technique|Suture Technique
223514323|NCT00860769|BEHAVIORAL|ASHA LIFE|6-session education groups discussing HIV prevention, anti-retroviral therapy (ART), coping enhancement, nutrition, parenting and life skills
223514324|NCT00860769|BEHAVIORAL|USUAL Care|3 session educational group focusing on HIV prevention, anti-retroviral therapy and parenting
223514325|NCT06110195|DRUG|Xevinapant|Given orally during study treatment on days 1-14 of a 21-day treatment cycles. It will be given continuously during treatment with carboplatin, paclitaxel, and radiation (chemoRT). After completely of the chemoRT dosing, an additional 3 cycles of Xevinapant along will be given.
223514326|NCT06110195|DRUG|Carboplatin|Given with radiation weekly for 7 doses.
223514327|NCT06110195|DRUG|Paclitaxel|Given with radiation weekly for 7 doses.
223514328|NCT06110195|RADIATION|Radiation Therapy|Radiation will be given together with paclitaxel and carboplatin for 7 weeks.
224317749|NCT01964079|DRUG|Losartan|Eligible subjects will be randomized 1:1 to either an amlodipine or a losartan group by a computer-generated random number table. For patients who fail to respond to 50 mg losartan, the dose will be titrated up to 100 mg losartan. At subsequent visits, additional antihypertensive therapy (hydrochlorothiazide) will be added if systolic (\>140 mmHg) or diastolic (\>90 mmHg) BP is inadequate. Study drugs are administered once a day for 24 weeks. The dose will be titrated up if SBP is over 90 mmHg or there are no symptoms of hypotension (syncope, loss of consciousness, or orthostatic hypotension). If up-titration is not tolerable, because of side effects or hypotension, the previous dose will be administered as the final tolerable dose.
224218985|NCT05499156|OTHER|placenal MSC derived exosomes|placenta-MSCs derived exosomes Exosomes are extracellular vesicles that are 30 to 150 nm in diameter. these vesicles are secreted from various cells. Mesenchymal stem cells exhibit immunomodulatory and anti- inflammatory properties by the use of paracrine effects. Exosomes as a vehicle for signaling, are responsible for a major part of cell to cell signaling. The preclinical animal studies manifested high safety and efficacy for MSC derived exosome treatment on various fistulas and inflammatory bowel disease. In this study we aimed to evaluate the safety and efficacy of PlacentaMSCs derived exosomes in treatment of patients with complex preanal fistula (non-crohn's) in phase I and II of clinical trial
224218986|NCT04818151|DRUG|Warfarin|Warfarin treatment for VTE
224218987|NCT04818151|DRUG|Apixaban|Apixaban treatment for VTE
224218988|NCT00751569|OTHER|blood donation|obtaining cord blood
224218989|NCT00971672|OTHER|Questionnaire filling and laboratory analysis|"A questionnaire that included demographic characteristics, nutrition and iron supplementation in the first year, growth status, and laboratory results will be filled for each patient.~The laboratory analysis will include complete blood count and serum ferritin analysis."
224218990|NCT00971204|DEVICE|CardioFocus HeartLight Endoscopic Ablation System|PVI ablation
224218991|NCT00931567|BIOLOGICAL|Autologous platelets gel|"Application of autologous platelets gel (Platelet Rich Fibrin) after the  open palm  surgical treatment of Dupuytren's disease."
224218992|NCT00931567|DEVICE|Vaselitulle|"application of standardized wound dressing after the  open palm  surgical treatment of Dupuytren's disease."
224317750|NCT03893084|OTHER|Pregnancy preparation training|Pregnancy preparation education; folic acid use, physical activity, nutrition, addictions counseling issues are included.
224317751|NCT00386984|DRUG|Somatostatin (octreotide)|
224317752|NCT04891003|DIAGNOSTIC_TEST|Ultrasonography|The identification of optimal ultrasonografic tecniques for determining the location , size and the surgical methods of intestinal endometriotric nodules.
224317753|NCT05709379|BEHAVIORAL|Sedentary behavior|Interrupting sitting with walking/jogging at either high -or low physical activity intensity.
224317754|NCT03774407|DRUG|vaginal estriol|Estriol vaginal cream will be formulated by Twin Oaks specialty pharmacy-by the same compound specialist. 30 mg estriol powder will be mixed with 5 mL of propylene glycol and 22 g of vaginal base cream. The product can be stored at room temperature and has a shelf life of up to 4 months. It comes with an applicator.
224317755|NCT02417987|OTHER|Placebo|The skin was penetrated with a needle and few drops of saline injected in the soft tissue away from the tendon
224317756|NCT02417987|DRUG|High Volume injection|Injection with10 mls 0.5% bupivacaine hydrochloride and 20 mg of Depomedrol 40 mls saline (NaCl) around the tendon
224317757|NCT02417987|BIOLOGICAL|Autologous conditioned plasma (ACP)|Injection with 4 mls of ACP around the tendon
224218993|NCT05750225|OTHER|Standard of care|12 months after the IOL implantation: measurement of intraocular pressure, slitlamp and fundus examination, visual acuity, manifest refraction.
224218994|NCT05750225|OTHER|Patient satisfaction questionnare|VFQ- 25 (Visual Function Questionnare) to be completed during 12 month visit.
224218995|NCT02541695|BIOLOGICAL|E. coli strain E1392-75-2A|"At study day 14, after a standardized evening meal and an overnight fast, subjects will receive a single oral dose of the attenuated diarrhoeagenic E. coli strain E1392-75-2A (dose will be either 1E10 CFU (n=22) or 5E10 CFU (n=22)). Oral challenge will occur at 10.00 AM. Under supervision of the project team, subjects will get a NaHCO3 solution (100 ml 2% NaHCO3) to neutralize the gastric acid. After 5 minutes, they get a fruit juice (100 ml) containing the attenuated diarrhoeagenic E. coli strain at the above-mentioned dose. Subjects go home, but are not allowed to drink or eat for 1 hour.~At study day 35, after a standardized evening meal and an overnight fast, all subjects will receive a second inoculation 1E10 CFU of the diarrhoeagenic E. coli."
224218996|NCT05086081|DRUG|Ticagrelor 90mg|Any ticagrelor dispensing claim is used as the exposure group
224218997|NCT05086081|DRUG|Prasugrel 10mg|Any prasugrel dispensing claim is used as the reference group
224317758|NCT04841577|BIOLOGICAL|RSVPreF3 OA investigational vaccine|RSVPreF3 OA investigational vaccine administered intramuscularly in the deltoid region of the non-dominant arm.
224317759|NCT04841577|BIOLOGICAL|FLU-QIV|FLU-QIV administered intramuscularly in the deltoid region of the dominant (Co-Ad Group) arm or the non-dominant (Control Group) arm.
224317760|NCT06209840|OTHER|Control Group|The session is 50 minutes long and consists of 20 minutes of classical physiotherapy for gross motor functions and 30 minutes of classical physiotherapy for the upper extremity. A total of 16 sessions will be applied 2 days a week for 8 weeks.
224317761|NCT06209840|OTHER|Study (Music) Group|The session is 50 minutes long and consists of 20 minutes of classical physiotherapy for gross motor functions and 30 minutes of music therapy for the upper extremity. A total of 16 sessions will be applied 2 days a week for 8 weeks.
224317762|NCT00001725|DRUG|Dextromethorphan|
224317763|NCT06170216|DRUG|immunochemotherapies|Observing different immunochemotherapies in small B-cell non-Hodgkin lymphoma (iNHL), which are chosen by investigators, such as RCHOP, BR, RCVP, etc.
223514329|NCT04475380|DEVICE|Percutaneous coronary intervention|PCI for treatment of coronary or bypass graft lesions
223630295|NCT03660462|DIETARY_SUPPLEMENT|HiFePO4 1 fortified rice test meal|Rice test meal extrinsically labeled with 2 mg high surface ferric phosphate 1 (57FePO4)
223764174|NCT01955057|BEHAVIORAL|Carbon monoxide test|
224317764|NCT01134302|PROCEDURE|Norwood management strategy|Norwood palliation will be performed as per current clinical practice at The Hospital for Sick Children.
223630296|NCT03660462|DIETARY_SUPPLEMENT|HiFePO4 2 fortified rice test meal|Rice test meal extrinsically labeled with 2 mg high surface ferric phosphate 2 (57FePO4)
223764175|NCT04692337|PROCEDURE|Intra-operative Ommaya Reservoir placement|An Ommaya reservoir is a small device implanted under the scalp that enables percutaneous access to cerebrospinal fluid.
223764176|NCT06418386|PROCEDURE|manual saline IA|"* The procedural tooth is anesthetized and isolated with rubber dam. The tooth and adjacent rubber dam will be disinfected with tincture of iodine solution, All carious tissue will be removed by hight speed handpiece, distal cannel of mandibular primary molars and palatal cannel of maxillary primary molars will be chosen for sampling procedure.~* A sterile broach will be inserted to obtain root cannel content then sterile paper point inserted to root canal and will be left for 1 min ,The paper point will be removed with sterilized tweezer which will immediately transferred to tube containing transport medium (eppendrof of containing 200 μl nutrient broth medium),using manual k file starting with #15 and irrigation with normal saline~* Post irrigation sample and pre-preparation sample will be transferred to microbiological laboratory Canals will be filed with obturation material(Metapex)then crown will be restored with glass inomar and stainless steel crown"
224218998|NCT02356081|OTHER|ASyMS intervention Group|ASyMS is a mobile phone-based remote-monitoring system that enables the 'real-time' monitoring of patients' symptoms through use of a patient-reported outcome measure (PROM)
224218999|NCT05244824|OTHER|Adaptation into Turkish, Examining The Reliability and Validity for People with RA|Adaptation of Evaluation of Daily Activity Questionnaire into Turkish, examining the reliability and validity for people with rheumatoid arthritis
224219000|NCT02436135|DRUG|Idelalisib|Idelalisib tablets administered orally for 24 weeks
224219001|NCT02436135|DRUG|Ruxolitinib|Ruxolitinib will be administered per standard of care according to package insert
224219002|NCT06248034|DEVICE|Smartphone application with tele-monitoring rehabilitation|This Smartphone application includes an automated criterion-based progression based on participant's regular recorded self-measurement of knee range-of-motion and five-repetition-sit-to-stand. The rehabilitation program is designed to (i) increase knee range-of-motion, (ii) strengthen lower limb strength, (iii) improve postural balance, and (iv) improve physical function.
224219003|NCT06248034|PROCEDURE|Hospital-based rehabilitation program|Participants will be provided with the usual preoperative, inpatient physiotherapy and a physiotherapy house visit within the first 2-weeks postoperation. Participants will receive exercises, patient education, manual therapy and other modalities that were prescribed and progressed at the project physiotherapist's discretion.
224219004|NCT04189419|BIOLOGICAL|SCM-AGH|SCM-AGH will be administrated once a day for 3 days(D0, D1 and D2).
224219005|NCT04189419|OTHER|Placebo|Placebo will be administrated once a day for 3 days(D0, D1 and D2).
224219006|NCT03351413|OTHER|LIVE-LiFE to Prevent Falls Among Older Fallers|"LIVE-LiFE Intervention: Individually tailored program at the participant's home spaced across 12 weeks including:~* Home safety assessment and risk reduction strategies; incorporating strength and balance training into daily habits vision screening and referral; and education about fear of falling and falls~* Home repairs, modifications, and low cost assistive devices to address unsafe home environments increasing fall risk~* Medication review and feedback concerning medications with increased fall risk~Measurement intervals: Baseline, 4 months, 8 months (with $25 gift card given at each visit for your time)"
224219007|NCT05207319|OTHER|integrated Moral Reasoning Development Intervention (MRDI)|The MRDI is comprised of 4 components that are run concurrently: moral reasoning, strategies of anger management and problem-solving and social skills.
224219008|NCT01434706|OTHER|Nucleic Acid Amplification Testing|The Gen-Probe Transcription-Mediated Amplification (TMA) technology exponentially amplifies captured HIV-1 and HCV RNA in blood samples. The Gen-Probe system is available in two commercially available FDA approved products; 1) the Procleix assay is a multiplex system that is used to screen the blood supply for HIV and HCV. This assay will allow the simultaneous detection of all known HIV-1 subtypes with sensitivities designed to reduce the window period of false negative results from standard HIV antibody testing (EIA), while maintaining the ability to discriminate positive from negative specimens, even at very low copy numbers (Giachetti, Linnen et al., 2002).
224317765|NCT01134302|PROCEDURE|Hybrid Strategy|"Hybrid palliation will be performed as per current clinical practice at The Hospital for Sick Children.~The 'Hybrid' management strategy utilizes catheter-based and non-open heart surgical procedures in the neonatal period to stabilize the neonate.10 The majority of the reconstruction is thereby deferred to 4-6 months of age, at which time the second stage procedure including an aortic arch reconstruction is performed. The third stage procedure (Fontan) is identical between Norwood and Hybrid strategies."
224317766|NCT05102552|DRUG|SPN-817, Treatment B|SPN-817 Treatment B, is an Extended Release formulation of Huperzine A, an acetylcholinesterase inhibitor
223630297|NCT00096902|PROCEDURE|Tilt table test|
223630298|NCT05428969|DRUG|Bexmarilimab|Intravenous
223630299|NCT05428969|DRUG|Azacitidine|As per label, subcutaneous
224219009|NCT06356870|PROCEDURE|BMAC MIXED WITH ALLOGRAFT|Study group
224219010|NCT06356870|PROCEDURE|Cancellous bone from anterior iliac crest|Control group
224219011|NCT06496906|PROCEDURE|Tooth extraction|A regular closed tooth extraction was performed with the different devices from each arm.
224219012|NCT06496906|DEVICE|Benex|Benex was used to perform the intervention.
224219013|NCT06496906|DEVICE|Physics Forceps|Physics forceps were used to perform the intervention.
224219014|NCT06496906|DEVICE|Conventional Extraction Forceps|Conventional Extraction Forceps were used to perform the intervention.
224219015|NCT02420899|DRUG|rosuvastatin|10mg/d or 20mg/d,po
224219016|NCT00512174|OTHER|BladderScan BVI 3000|
224317767|NCT05102552|DRUG|SPN-817, Treatment C|SPN-817 Treatment C, is an Extended Release formulation of Huperzine A, an acetylcholinesterase inhibitor
224317768|NCT05102552|DRUG|BIS-001, Treatment A|BIS-001 is an Extended Release formulation of Huperzine A, an acetylcholinesterase inhibitor
224317769|NCT00943748|DRUG|deferiprone|A standard dose-escalation phase will be initiated, with a 3 ml of the deferiprone oral solution twice a day (breakfast and dinner) increase every 3 days up to a total of a fixed dose of 9 ml of deferiprone oral solution twice a day corresponding to 30 mg/kg/day in 2 doses
223630300|NCT05428969|DRUG|Venetoclax|Oral
223630301|NCT04733638|DEVICE|Viz ICH VOLUME|Viz ICH VOLUME software is a module that identifies and segments Intraparenchymal Hemorrhage (IPH) from NCCT imaging. This software is for investigational use in the study and is not FDA cleared. For subjects who undergo a brain scan, Viz will use deep learning algorithms to analyze computed tomography (CT) or magnetic resonance (MR) images of the brain for ICH in parallel to standard of care image interpretation. If a suspected ICH is detected, Viz will perform an automatic volumetric analysis and will send a notification to a specialist, such as a neurointerventionalist or a neurosurgeon. Notifications prompt the specialist to review the patient's case. Additionally, non-diagnostic previewing of DICOM images, and HIPAA-compliant text messaging and phone calls are available in the software platform. Viz ICH VOLUME is not intended for use in the diagnosis of disease or other conditions, or in the cure, mitigation, treatment, or prevention of disease, in man.
223630302|NCT06407414|OTHER|control|classical physiotherapy methods
223630303|NCT06407414|OTHER|Exercise|In addition to classical physiotherapy methods, neuromuscular exercise protocol will be applied.
223630304|NCT06270147|DRUG|Bupivacaine-epinephrine|A total of 60ml of 0.25% Bupivacaine with Epinephrine, divided into 4 aliquots, will be administered laparoscopically at two locations per side along the anterior axillary line between the costal margin and the iliac crest. TAP block timing will be disclosed to the operating surgeon to ensure the correct solution is administered at the appropriate time.
224219017|NCT01282827|DEVICE|rtACS (verum condition)|Repetitive, transorbital alternating current stimulation (rtACS) was applied with a multi-channel device generating weak current pulses in predetermined firing bursts of 2 to 9 pulses. The amplitude of each current pulse was below 1000 microA. Current intensity was individually adjusted according to how well patients perceived phosphenes, i.e. any sensation of flickering light in response to the rtACS stimulation.
224219018|NCT01282827|DEVICE|placebo stimulation|a clicking sound was presented and the same electrodes montage set-up was used during rtACS and placebo stimulation, except that placebo patients received no current (stimulator turned off).
224219019|NCT01484665|OTHER|PROCASE Decision-Aid|"VA health services researchers have developed a patient education pamphlet for prostate cancer screening. The pamphlet, titled The PSA test for prostate cancer: Is it Right for ME was created by members of the PROstate CAncer Screening Education (PROCASE) study team. A modified version of the PROCASE decision aid will be utilized in this study."
224219020|NCT05268731|PROCEDURE|External plastic endoprosthesis|Ultrasound- or fluoroscopy-guided bile duct puncture with insertion of an external plastic endoprosthesis if the duodenum or jejunum cannot be accessed by a guide wire
224219021|NCT05268731|PROCEDURE|Combined external internal plastic endoprosthesis|Ultrasound- or fluoroscopy-guided bile duct puncture with insertion of an external/internal plastic endoprosthesis if the duodenum or jejunum can be accessed by a guide wire. No definitive drainage intended in initial procedure.
224219022|NCT05268731|PROCEDURE|Primary metal stent|Ultrasound- or fluoroscopy-guided bile duct puncture with insertion of a self-expanding metal stent if the duodenum or jejunum can be accessed by a guide wire. A definitive drainage is intended in the initial procedure, for example in patients with malign bile duct obstruction
224317770|NCT00943748|DRUG|placebo|A standard dose-escalation phase will first be initiated, with a 3 ml of the placebo oral solution twice a day (breakfast and dinner) increase every 3 days up to a total of a fixed dose of 9 ml of placebo oral solution twice a day corresponding to 30 mg/kg/day in 2 doses
223630305|NCT06204341|RADIATION|HYPOPRIME treatment|Hypo fractionated pelvic radiotherapy with boost to primary tumour in the prostate with elective lymph node irradiation and minimized androgen deprivation therapy
223630306|NCT03497637|DIAGNOSTIC_TEST|measurement of FFR|use of pressure-derived FFR to assess the hemodynamic significance of coronary stenoses
223630307|NCT03497637|DIAGNOSTIC_TEST|measurement of Pd/Pa|use of resting distal coronary pressure to aortic pressure ratio (Pd/Pa) to assess the hemodynamic significance of coronary stenoses
223630308|NCT03755206|OTHER|Sustainability strategies|The investigators will work with each site to determine strategies that are relevant locally to help promote sustainability of the suicide prevention program.
223764177|NCT06418386|PROCEDURE|manual neem IB|"* The procedural tooth is anesthetized and isolated with rubber dam. The tooth and adjacent rubber dam will be disinfected with tincture of iodine solution~* . All carious tissue will be removed by high speed hand piece~  , distal cannel of mandibular primary molars and palatal cannel of maxillary primary molars will be chosen for sampling procedure.~* A sterile broach will be inserted to obtain root cannel content then sterile paper point inserted to root canal and will be left for 1 min 19 The paper point will be removed with sterilized tweezer which will immediately transferred to tube containing transport medium (eppendrof of containing 200 μl nutrient broth medium).~* using manual file and irrigation with neem leaf extract 100%~* Post irrigation sample and pre-preparation sample will be transferred to microbiological laboratory Canals will be filed with obturation material(Metapex)then crown will be restored with glass inomar and stainless steel crown"
224219023|NCT02729194|DRUG|Pazopanib|
224219024|NCT02729194|OTHER|Low Fat Diet|Registered subjects will take pazopanib by mouth with a low-fat meal (containing less than 400 calories and less than 10% fat or 10 grams per meal.
224219025|NCT05580926|BEHAVIORAL|Watch your Weight During Holidays|"Participants in this group will have an individual face-to-face session (with a maximum duration of half an hour) and a face-to-face group session. This intervention will include strategies for self-monitoring (body weight, diet and physical activity), information on healthy lifestyles, as well as information about the energy contained in local festive foods and their equivalent in minutes of physical activity or steps per day.~Participants will be asked to weight themselves at least twice a week, as a form of self-monitoring of weight, from the start of the intervention. They will have access to weekly forms with boxes, where they can fill in the data obtained for each day of weight self-monitoring, energy intake restriction report and minutes of physical activity performed."
223630309|NCT03844347|BEHAVIORAL|Stress management sessions|Stress management sessions are proposed to the patients and consist of small exercises focused on breathing and bodily sensations. Each accompanying person has access to different exercises. The sessions are adapted to the state of the patient to promote his well-being, before or after his/her operation. The duration of a preoperative session is 1 hour, the duration of the postoperative sessions is 15 minutes.
223630310|NCT05059652|DEVICE|Ischemic Preconditioning|The Ischemic Preconditioning (IPC) is characterized by the application of brief periods of circulatory occlusion (ischemia) and reperfusion of a limb in the minutes to hours that precede the exercise through the insufflations and deflations of a pressure cuff.
223630311|NCT05153837|OTHER|saline intravenous administration|Administration of 500 mL of saline (NaCl 0.9%) administered by the venous route
223630312|NCT05153837|OTHER|oral water|500 ml oral water
223630313|NCT06155526|OTHER|Activity|patients taking an active rest after swimming sets
223630314|NCT04444076|DEVICE|REGENETEN Bioinductive Implant|REGENETEN bioinductive Implant,a reconstituted bovine origin type I collagen mesh with a proprietary high porosity system that is commercialized sterile, dehydrated and desiccated in two sizes (20x26mm and 25x31mm). It will be implanted following supraspinatus tendon repair.
224219026|NCT05580926|OTHER|Control Group (minimal intervention)|Participants in this group will receive a printed information, as well as a PDF file, brochure during a face-to-face session at the beginning of the 8-week period. This information will be about having a healthy eating based on the norm for health promotion and education for healthy eating in Mexico (NOM-043-SSA2-2012).
224219027|NCT03931057|DRUG|ADV6209 (=gamma-cyclodextrin-Midazolam)|30 min. before anesthesia children have to swallow the anxiolytic drug (ADV6209)
224219028|NCT03931057|DRUG|Midazolam|30 min. before anesthesia children have to swallow the anxiolytic drug Midazolam
224219029|NCT05747365|DIAGNOSTIC_TEST|Blood and urine diagnostic evaluation|Blood and urine samples will be obtained from both case and control groups in order to evaluate EDCs concentrations
224219030|NCT03139565|BIOLOGICAL|Fluzone High-dose Influenza Vaccine|This treatment consists of 60 microgram of each influenza antigen provided as a single injection, which will be injected in the deltoid muscle of the non-dominant arm.
224219031|NCT03139565|BIOLOGICAL|Standard 2016-2017 Flu vaccine|The intramuscular preparation of the vaccine used for the control group will be the Standard influenza vaccine made available by public health. The intramuscular dose (standard 0.5 mL) will contain 15 microgram antigen from each strain and delivered in the deltoid muscle by trained personnel.
224219032|NCT01558531|DEVICE|DEB|paclitaxel-eluting balloon angioplasty
224219033|NCT01558531|DEVICE|POBA|conventional balloon angioplasty
224219034|NCT01710826|BIOLOGICAL|Genz-682452|Capsules for oral administration.
224219035|NCT01710826|BIOLOGICAL|Placebo|Placebo capsules matching the Genz-682452 capsules.
224219036|NCT03689140|BEHAVIORAL|Smoke Free Together - App-only|Pregnant smokers and their life partners will use a smoking cessation app.
224219037|NCT03689140|BEHAVIORAL|Smoke Free Together - Telemedicine counseling only|Pregnant smokers and their life partners will use telemedicine, real time video counseling on smoking cessation
224219038|NCT03689140|BEHAVIORAL|Smoke Free Together - app + telemedicine|Pregnant smokers and their life partners will use telemedicine and an app for smoking cessation
224219039|NCT06242522|OTHER|Telephone interview|Collection of gynaecology-obstetrics data on patients treated with AVELUMAB
224219040|NCT03227822|PROCEDURE|Short spot stenting|
224219041|NCT03227822|PROCEDURE|Long lesion stenting|
224219042|NCT00493363|DRUG|Artesunate|Artesunate 2 mg/kg/day for 7 days
224219043|NCT00493363|DRUG|Artesunate + Mefloquine|Artesunate 4mg/kg/day for 3 days plus mefloquine 15mg/kg on day 3 and 10mg/kg on day 4
224219044|NCT00274755|DRUG|chemotherapy|
224219045|NCT00274755|PROCEDURE|conventional surgery|
224219046|NCT00274755|PROCEDURE|magnetic resonance imaging|
224219047|NCT00274755|PROCEDURE|magnetic resonance spectroscopic imaging|
224219048|NCT00274755|RADIATION|radiation therapy|
224219049|NCT05535712|DEVICE|Lung Anatomic Resection (Da Vinci SP)|To evaluate the performance and safety of the da Vinci SP® Surgical System in anatomical lung resection
224219050|NCT03568825|PROCEDURE|Osteopatic Manual Therapy (OMT)|OMT consisting of following interventions; thoracic spine and diaphragm mobilisation, traction of the cardia and posture correction.
224219051|NCT04311138|OTHER|community-based reablement service|Experimental group receive a 10-wk diversified community-based reablement service including group exercise, cognitive training, health education for 1.5 hours, and individualized reablement for 1.0 hour.
223630315|NCT05891431|DEVICE|Untire mobile app|"The Untire app is an mHealth intervention (digitally delivered using a smartphone app).~Untire offers a comprehensive program to help you understand cancer fatigue and gives a physical activity program, stress reduction exercises and tips to manage your energy level."
223630316|NCT04609319|DRUG|Dacomitinib|This is a non-interventional, real world study of Asian patients being treated with dacomitinib as first-line treatment for EGFR+ NSCLC
223630317|NCT03573882|DRUG|Voxelotor|300mg or 500mg Tablet, Oral, With or Without Food
223630318|NCT04921436|PROCEDURE|cardiac surgery|prophylactic use of antibiotic-inhibitors
223630319|NCT04230187|DRUG|mFOLFOXIRI plus Bevacizumab|Bevacizumab (5 mg/kg on day 1) plus mFOLFOXIRI (oxaliplatin 85 mg/m2, irinotecan 150 mg/m2, and folinic acid 400 mg/m2 followed by 5-fluorouracil 2400mg/m2 as a 46-hour continuous infusion on day 1) for 8 cycles and followed by bevacizumab and fluoropyrimidine based maintence treatment
223630320|NCT04230187|DRUG|mFOLFOX6 Plus Bevacizumab|mFOLFOX6 (oxaliplatin 85 mg/m2, and folinic acid 400 mg/m2 followed by bolus 5-fluorouracil 400 mg/m2 and 5-fluorouracil 2400mg/m2 as a 46-hour continuous infusion on day 1) for 8 cycles and followed by bevacizumab and fluoropyrimidine based maintence treatment
223630321|NCT04191538|PROCEDURE|Conditioning electrical stimulation|Percutaneously, a small needle will be placed alongside the median nerve. Patients will receive 1 hour of 20Hz stimulation with voltage titrated to maintain patient comfort.
223630322|NCT04191538|PROCEDURE|Postoperative electrical stimulation|Immediately following carpal tunnel release, needles for electrical stimulation will be placed alongside the visualized median nerve. Patients will receive 1 hour of 20Hz stimulation with voltage titrated to maintain patient comfort.
223630323|NCT04191538|PROCEDURE|No electrical stimulation|Patients will receive sham stimulation (needles placed, no current delivered) pre- and post-operatively; however, no current will ever be delivered to the nerve. This is the control cohort.
223630324|NCT05121272|BEHAVIORAL|cognitive task|cognitive task
223630325|NCT04166006|BIOLOGICAL|Autologous DC vaccine|7-14×106 autologous dendritic cells loaded with autologous tumour homogenate given by intradermal injection (day 1)
223630326|NCT04166006|DRUG|Interleukin-2|Autologous DC vaccine is followed by IL-2, at a dose of 3 MU, given by subcutaneous injection daily for five days (days 3-7).
223630327|NCT05397145|OTHER|Postoperative analgesia management|Intravenous 0.5 mg/kg tramodol and 400 mg ibuprofen will be administered to all patients 30 minutes before the end of the surgical procedure. In the postoperative period, patients will be administered ibuprofen iv 400 mg 3x1. Postoperative patient evaluation will be performed by another pain nurse who is unaware of the procedure. Patients in all groups will be attached to IV PCA containing 10 mcg/ml fentanyl, 10 mcg bolus without infusion dose, 10 min lock time protocol. If the NRS score is ≥ 4, 0.5 mg kg-1 iv meperidine will be administered as a rescue analgesic.
223630328|NCT06559696|RADIATION|internal mammary nodal irradiation|chest wall/whole breast and supraclavicular +-axillary plus internal mammary nodal irradiation (50 Gy in 25 fractions or 40Gy in 15 fractions).
223630329|NCT06559696|RADIATION|No internal mammary node irradiation|chest wall/whole breast and supraclavicular +-axillary irradiation (50 Gy in 25 fractions or 40Gy in 15 fractions).
223630330|NCT04710901|BEHAVIORAL|uTECH + YMHP|"uTECH intervention utilizes a machine learning algorithm that leverages baseline data, individual social media use patterns, and strategic opportunistic learning questions to push messages to participants that offer strategic content about biomedical and behavioral HIV prevention. In addition, participants in this arm will also receive the YMHP intervention, which provides a four-session, evidence-based Motivational Enhancement intervention developed as part of the Young Men's Health Project (YMHP) and delivered via Zoom. Participants complete the four-session intervention during the first three months of their enrollment in the study."
223630331|NCT04710901|BEHAVIORAL|YMHP|YMHP intervention provides a four-session evidence-based Motivational Enhancement intervention developed as part of the Young Men's Health Project (YMHP) and delivered via Zoom. Participants complete the four-session intervention during the first three months of their enrollment in this study. Months 3-12 are inactive.
224219052|NCT04311138|OTHER|multicomponent training|control group receive a 10-wk multicomponent training including 1.5-hr group intervention (group exercise, cognitive training, and health education) and 1.0-hr placebo intervention.
224219053|NCT02580890|DEVICE|tDCS active|Stimulation will be performed with the anode placed over the right DLPFC, and the cathode placed on the left DLPFC. The applied electric current will be 2mA and is going to be applied for 20 minutes. The electrodes have a size of 35cm ² each and will be covered by sponges soaked with saline.
224219054|NCT02580890|DEVICE|tDCS sham|For the sham tDCS, the same setting will be used. However, the current is going to be applied for only 30 seconds, not being able to induce effects on neuronal excitability.
223630332|NCT04710901|BEHAVIORAL|uTECH|"uTECH intervention utilizes a machine learning algorithm that leverages baseline data, individual social media use patterns, and strategic opportunistic learning questions to push messages to participants that offer strategic content about biomedical and behavioral HIV prevention."
223630333|NCT01253291|DRUG|LY2127399|Administered subcutaneously every 4 weeks for 48 weeks
224219055|NCT04567199|OTHER|Observational, retrospective|retrospective analysis of observed results, for both study groups.
224219056|NCT03826485|DRUG|PRIC|Pranlukast hydrate 50mg
224219057|NCT03826485|DRUG|Pranlukast hydrate|Pranlukast hydrate 225mg/2.25g
224219058|NCT03154528|DIAGNOSTIC_TEST|serum vitamin D level by ELISA|The study will include 60 patients with androgenetic alopecia (30 males \& 30 females) and 30 age and sex-matched healthy volunteers. Study subjects will be recruited from the Dermatology Outpatients' Clinic, Assiut University Hospitals, Assiut, Egypt. Informed consent will be obtained from all subjects
224219059|NCT05187403|DRUG|Laquinimod|Eye-drops
224317771|NCT06198244|DEVICE|Transcutaneous Electrical Nerve Stimulation(TENS)|Defecation frequency per week, abdominal pain or discomfort, type of stool, severity of the constipation, frequency and consistency of stool, were measured before the commencement of treatment by using Romes-IV criteria, Visual Analogue Scale (VAS),Bristol Stool Scale (BSS),Gross Motor Functional Classification System (GMFCS) and Constipation Assessment Scale(CAS).After taking the measurements apply TENS on abdomen i.e. on the lower gastrointestinal tract, placed two skin electrodes of TENS on the abdomen lateral to the umbilicus and other two electrodes on back side at T9-L2 level for a month (20 minutes per session and 3 times a week) along with baseline treatment in which general movements were performed. After the completion of treatment same tools were used to re-assess the defecation frequency per week, abdominal pain or discomfort, type of stool, and severity of the constipation, frequency and consistency of stool for the measurement of final reading(Pre and post-treatment).
224219060|NCT05187403|DRUG|Placebo|Eye-drops
223630334|NCT05730023|DEVICE|Active tDCS|Active tDCS (anode will be applied over the left DLPFC with the cathode over the right supraorbital region);
223630335|NCT05730023|BEHAVIORAL|individualized language training|individualized language training
223630336|NCT05730023|DEVICE|Placebo tDCS|Placebo tDCS (the current will be turned off 10 seconds after the beginning and turned on for the last 10 seconds of the stimulation period);
223630337|NCT05090696|DEVICE|Mechanical In-Exsufflator (MI-E)|The feasibility will be estimated by quantifying relief and discomfort of four MI-E sessions (2 days x 2 sessions = 4 sessions). Vital signs will be also noted before and after such MI-E session.
224219061|NCT00475852|DRUG|Nesiritide|0.01 mcg/kg/min IV infusion (with or without 2 mcg/kg bolus) for 24 to 168 hrs
224219062|NCT00475852|DRUG|Placebo|matching placebo infusion:0.01 mcg/kg/min IV infusion (with or without 2 mcg/kg bolus) for 24 to 168 hrs
224219063|NCT02996435|BEHAVIORAL|Mobile Application Intervention|Mobile phone application that sends reminders and allows participants to self-manage their medication adherence. Monitoring of participant adherence from this tool will be performed by the central coordinating center, which will send notifications or contact the participant based on the adherence history in accordance with the study protocol.
223630338|NCT03826719|BIOLOGICAL|NBP607QIV|Purified inactivated influenza virus surface antigens of four strains(quadrivalent)
224219064|NCT02996435|OTHER|No Intervention|Participants will receive physician- or nurse-guided standard of care.
224219065|NCT04366466|OTHER|suicide attempt patient using PEPS Program|"The research protocol consists of two phases separated by randomization.~A Hospital Phase common to both groups:~Day zero is the day of the suicide attempt for which the patient came to the hospital.~A post-hospital phase including the P.E.P.S. program for the intervention group and telephone reminders for the usual treatment group."
224219066|NCT03850054|PROCEDURE|AADI glaucoma shunt|"Implantation of the nonvalved AADI glaucoma shunt instead of the Bearveldt tube shunt, in eyes with intractable glaucoma.~It is not a RCT study, but a prospective evaluation of the AADI device, and the study has been approved as a quality control study at the Department of Ophthalmology, at Odense University Hospital"
224219067|NCT02174900|DRUG|Artemether-Lumefantrine (AL) + 0.25 mg/kg primaquine|
224219068|NCT02174900|DRUG|Artemether-Lumefantrine (AL) combination|
224219069|NCT02174900|DRUG|Artemether-Lumefantrine (AL) + 0.4 mg/kg primaquine|
224219070|NCT02085707|PROCEDURE|Total hip replacement arthroplasty|treatment with total hip replacement arthroplasty with the implant chosen by the institution
224219071|NCT02085707|PROCEDURE|Closed reduction and internal fixation|treatment with closed reduction and internal fixation with 2 cannulated hip pins
224219072|NCT02076191|DRUG|Ruxolitinib|Ruxolitinib will be administered at doses of 5mg, 10mg, 15mg, or 25 mg taken orally every 12 hours throughout the treatment cycle.
224219073|NCT02076191|DRUG|Decitabine|Decitabine is administered intravenously at a dose of 20 mg/m2 daily for 5 days. Subsequent cycles of decitabine may be administered at 4 week intervals as clinically tolerated. Decitabine treatment may be deferred for up to 2 weeks to allow recovery from non-hematologic toxicity during the first 6 cycles and up to 2 weeks thereafter for hematologic toxicities as well. The first treatment cycle will last 35 days and will be the evaluable period for DLTs and RPTD determination for patients enrolled in the phase I portion only. Subsequent treatment cycles will be 4-6 weeks in duration as defined by decitabine administration.
224219074|NCT05332626|DIETARY_SUPPLEMENT|Probiotic group|The probiotic gorup is focused on the treatment of postmenopause osteoporosis women with a capsule cointained 1x10\^9 CFU of Lactobacillus acidophilus UALa-01™/day (30 people)
224219075|NCT05332626|DIETARY_SUPPLEMENT|Placebo group|The group is assigned on the treatment of postmenopause osteoporosis women without probiotic intervention (30 people)
224219076|NCT05085860|BEHAVIORAL|Moderate-intensity continuous training (MICT)|Participants will engage in exercise and record AF symptoms prospectively over 7 days
224219077|NCT05085860|BEHAVIORAL|High-intensity interval training (HIIT)|Participants will engage in exercise and record AF symptoms prospectively over 7 days
224219078|NCT02512770|PROCEDURE|endoscopic dilatation|
224219079|NCT05326152|BIOLOGICAL|hepatitis B vaccine immunotherapy of common warts (GeneVac-B 10 ml vial, Serum Institute of India Ltd., Pune, India)|Randomized placebo-controlled comparative effectiveness clinical trial
224219080|NCT05326152|BIOLOGICAL|Intralesional saline|Intralesional saline
224219081|NCT03433118|DEVICE|Acupuncture|Acupuncture administered by specially-trained therapeutic radiographers
224219082|NCT03216200|DEVICE|plasma treatment|application of cold atmospheric plasma to a fungal infected toenail
223514330|NCT02771145|DEVICE|FID 120947A contact lens disinfecting solution|Investigational 3% hydrogen peroxide solution that uses a platinum catalyst for neutralization and is intended for simultaneous cleaning, protein removal, disinfecting and storage of silicone hydrogel and soft contact lenses
223514331|NCT02771145|DEVICE|Soft contact lenses (SCL)|Commercially available soft contact lenses worn a minimum of 8 hours each day on a daily wear basis for the duration of the study (180 days). A fresh pair will be dispensed on Day 0, Day 30, Day 60, and Day 135.
223514332|NCT02771145|DEVICE|SCL preservative solution|Commercially available solution for rinsing soft contact lenses
223514333|NCT00879372|DRUG|tianeptine|tianeptine 12,5mg TID
223514334|NCT00879372|DRUG|Placebo|Placebo 12.5 mg TID
223514335|NCT04555239|PROCEDURE|Fascial Distortion Model (FDM)|"Only treatment of herniated trigger points, continuum distortions, and/or trigger bands will be performed.~* Herniated trigger points are single areas of sharp pain within soft tissue.~* Continuum distortions are single points of sharp pain overlying bony tissues.~* Trigger bands are lines of pain overlying either soft or bony tissues.~Treatment with FDM is performed using firm, direct pressure over the area of the patient's pain with the provider's thumb. This pressure is applied at a single point or area indicated by the patient for herniated trigger points and continuum distortions, and along the indicated line of pain for trigger bands."
223514336|NCT04555239|OTHER|Standard Care|"The usual standard of care for extremity pain varies from provider to provider and varies from patient to patient depending upon their comorbidities but often includes some combination of the following:~* X-rays, if suspicion for fracture exists~* Venous duplex ultrasound, if suspicion for DVT/SVT exists~* Computed tomography (CT) angiogram (CTA), if suspicion for arterial occlusion exists~* C-reactive Protein (CRP)/erythrocyte sedimentation rate (ESR)/arthrocentesis is suspicion if suspicion for septic arthritis exists~* Arthrocentesis if suspicion for gout exists~* Splinting/casting/immobilization~* NSAIDs, Tylenol, or opioids for pain control~* Possibly trigger point injections~* Possibly osteopathic manipulation~* Recommendations to use RICE (rest, ice, compression, elevation) at home~* Physical/occupational therapy referral~* Orthopedic referral"
223514337|NCT06328569|DEVICE|Virtual Reality Therapy|The therapist begins by assessing the patient's swallowing abilities and creating a personalized treatment plan. This involves determining the appropriate Virtual Reality Therapy scenarios, difficulty levels, and specific swallowing goals tailored to the patient's condition.
223514338|NCT06328569|BEHAVIORAL|Conventional dysphagia treatment|Conventional dysphagia treatment included oropharyngeal muscle movement training, orofacial alternating hot and cold stimulation, Masako swallowing training, Mendelsohn maneuver, therapeutic ingestion training, intermittent oral-esophageal tube feeding, etc., 30 min each time, once a day for 14 consecutive days.
223514339|NCT00168285|BEHAVIORAL|Pulmonary Rehabilitation|
223514340|NCT01414647|DIETARY_SUPPLEMENT|300 g of strawberry, raspberry and cloudberry|100 g of strawberry puree, 100 g of frozen raspberries and 100 g frozen cloudberries were concumed daily for 8 weeks. Bilberry consumption was restricted.
223630339|NCT03826719|BIOLOGICAL|Agrippal|Influenza virus surface antigens of three strains(trivalent)
223630340|NCT06098469|DEVICE|Neurofeedback sessions|10 Neurofeedback sessions, psychiatric interview (MADRS, QIDS-C16), reverse-correlation task, QIDS-SR16, EQ-5D-5L, motivation assessment
223630341|NCT01919528|PROCEDURE|ultrasound|catheterization of the axillary vein under ultrasound guidance
223630342|NCT04076540|DRUG|AZD4041|Administration by Oral syringe
223630343|NCT04076540|DRUG|Placebo|Administration by Oral syringe
223630344|NCT03808974|OTHER|Educational video|Short educational video describing the mid-urethral sling procedure
223630345|NCT03808974|OTHER|Educational leaflet|Standard educational leaflet describing the mid-urethral sling procedure
223630346|NCT05255575|DRUG|Ertapenem|Patients will receive ertapenem therapy.
223630347|NCT01344915|PROCEDURE|Locked knee brace|
223630348|NCT01344915|PROCEDURE|Locked knee brace|
223630349|NCT03373578|DEVICE|earmuffs|to compare the neonate's sleep with and without earmuffs during Quiet time at the NICU
224219083|NCT03686800|DEVICE|Rivelin® plain patches|The comfort and adherence of Rivelin® plain patches in Vulva Lichen Sclerosus patients
224317772|NCT06198244|OTHER|Baseline Treatment|In control group, after the recruitment of participants according to the inclusion criteria. The baseline measurement were recorded by using Romes-IV criteria, Visual Analogue Scale (VAS), Bristol Stool Scale (BSS),Gross Motor Functional Classification System (GMFCS) and Constipation Assessment Scale(CAS). The baseline treatment is given in which general movements were performed i.e. Double knee-to-chest movement, sitting, standing, rolling as well as stretching of calf, hamstrings, adductors of both sides. Again assess the patient severity of constipation, frequency and consistency of stool, abdominal pain and functional status after the end of last session of the treatment(Pre and Post-treatment method).
223630350|NCT02955056|DRUG|Forsteo|20 micrograms/80 microlitres solution for injection in pre-filled pen
223630351|NCT05672290|OTHER|Electrical stimulation 1|External electrical stimulation will be applied for 30 minutes 3 days a week during 6 weeks. Electrodes were placed around the pelvis.
223630352|NCT05672290|OTHER|Electrical stimulation 2|External electrical stimulation will be applied for 30 minutes one day a week during 6 weeks. Electrodes were placed around the pelvis.
223630353|NCT03799796|BEHAVIORAL|Flash Glucose Monitoring with Online Peer Support|Hispanic Adults who are Spanish-Speaking with type 2 diabetes who are not using insulin will be asked to use flash glucose monitoring and to sign up for an moderated online peer support group where they can ask questions and share progress.
223630354|NCT05772741|OTHER|Biological sample collection|Collection of biological samples
223630355|NCT00453895|DRUG|Sunitinib|50mg Sunitinib
223630356|NCT04783350|DEVICE|Transcranial alternating current stimulation (tACS)|tACS will be administered to the left angular gyrus at gamma frequency to improve cognitive functioning (MoCA score) and resting-state EEG signatures.
223630357|NCT00425035|DRUG|Panitumumab (ABX-EGF)|
223630358|NCT00004100|DRUG|cisplatin|
223630359|NCT00004100|DRUG|gemcitabine hydrochloride|
223630360|NCT00004100|DRUG|vinorelbine tartrate|
223630361|NCT02234843|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Age and body weight-adjusted dosing equivalent to 20 mg rivaroxaban in adults, once daily or twice daily, as tablets
223630362|NCT02234843|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Age and body weight-adjusted dosing equivalent to 20 mg rivaroxaban in adults, once daily, twice daily or three times daily, as oral suspension
223630363|NCT02234843|DRUG|Standard of Care|"LMWH (low molecular weight heparin) or fondaparinux or vitamin K antagonist (VKA) therapy.~dose : as per standard of care"
223630364|NCT03322956|OTHER|Physioterapy intervention|"In the experimental group (EGR), the 4MTOR® treatment method will be used for LBP. This 4MTOR® uses the following steps in a decision tree: T1 Testing (Physiotherapeutic examination), T2 Triggering (Manual Techniques), T3 Taping (Elastic Tape) and T4 Training (medical rehabilitation exercises).~The participants in the SGR received a sham multimodal physiotherapeutic intervention as control intervention, in which Sham technique were applied. The interventions consisted of combining Sham manual interventions, elastic tapes according to Kaze32 and Evidence Based Practice Therapy (Appendix III). The protocol in the SGR follows the similar steps: Testing, Taping, Triggering and Training like the 4MTOR®."
223630365|NCT02787564|BEHAVIORAL|Intervention Group|The intervention consists of providing free fruits and vegetables of the participants' liking for a period of 4 weeks. Each week, a total of 2 portions of either fruits and/or vegetables per day will be provided.
223630366|NCT00841841|DRUG|dipyrone and acetaminophen|The patients were randomly assigned to 2 groups of 15 patients, according to the drug prescribed as postoperative medication: Group I: dipyrone 500 mg every 6 hours (4 males, 11 females, mean age = 25.2 years) and Group II: paracetamol 750 mg every 6 hours (3 males, 12 females, mean age = 26.8 years)
223630367|NCT03816033|PROCEDURE|Cryotherapy|Catheter ablation treatment for the treatment of the studied arrhythmias
223630368|NCT03816033|PROCEDURE|radiofrequency catheter ablation|Catheter ablation treatment for the treatment of the studied arrhythmias
223630369|NCT06546163|BEHAVIORAL|Baseline survey|Baseline surveys contains a series of scaled questions, including sociodemographic variable (age, sex, etc), profile of mood states, perceived stress scale, Eating Loss of Control scale, Eating Disorder Examination Questionnaire, Brief Resilience Scale- BRS,Heart Rate Variability and coherence measures
223630370|NCT06546163|BEHAVIORAL|Heart rate variability biofeedback|Participants randomized to the intervention arm will receive a standardized HRV sensor and accompanying smartphone app, and a 30-minute HRVB training to use the biofeedback signals to generate a resonant frequency pattern of HRV (coherence) after collecting data at baseline in person. Participants will be asked to practice their HRVB skills at home for 10 minutes for two weeks.
224219084|NCT05599906|OTHER|questionnaires|Completion of 3 questionnaires (HADS; SF-12; FAS) at the beginning and end of the rehabilitation and after 3 months
224219085|NCT01218737|DRUG|0.3% gatifloxacin and 1.0% prednisolone acetate association|"Each patient will receive two medication bottles (eye drops) in a blinded fashion: one with the association and another with placebo. The patient must instill 01 drop of each bottle in each operated eye, with a 5-minute interval between the instillations.~This procedure should be performed 4 times a day (QID) during the wake hours, from Day 0 (surgery day) until Day 15."
223630371|NCT06546163|BEHAVIORAL|Educational materials|Participants randomized to the waitlist control arm will receive educational materials on eating disorders and stress management and will be sent home with these materials after completing the baseline survey. They will be encouraged to read the materials over the next two weeks before coming in for T2 survey.
223630372|NCT03111823|BEHAVIORAL|Exercise Intervention|Undergo aerobic exercise sessions
223630373|NCT03111823|OTHER|Quality-of-Life Assessment|Ancillary studies
223630374|NCT03111823|OTHER|Questionnaire Administration|Ancillary studies
223630375|NCT06206447|PROCEDURE|Tunnel-cuffed Catheter|Tunnel-cuffed Catheter in right internal jugular vein
223630376|NCT06206447|PROCEDURE|Non-ccuffed Catheter|Non-ccuffed Catheter in right internal jugular vein
223630377|NCT02254603|DEVICE|Acupuncture|Acupuncture about 30 mins will be performed by a traditional Chinese physician three times a week for 3 months.
223630378|NCT02254603|BEHAVIORAL|Yoga exercise|Subject will receive regular 60-minutes yoga exercise three times a week for 3 months.
223630379|NCT02432443|BEHAVIORAL|Motor and pre-literacy program|The program will run for 60 minutes once per week for 10 consecutive weeks and will consist of three components: direct FMS instruction, unstructured exploratory free-play, and an interactive storybook reading activity. The curriculum and teaching strategies to be used for the first two segments of our intervention have been successfully implemented in previous research to improve the motor skills of 4 year old children with autism (Bremer, Balogh, \& Lloyd, 2014). Specific strategies and books were selected from an existing evidence-based curriculum (Justice \& McGuinty, 2009). There will be active involvement of at least one parent in the direct instruction and reading components.
223630380|NCT02432443|OTHER|Wait-list Comparison|The participants will not participate in the motor and pre-literacy program for 10 weeks after enrollment and will continue with their normal daily life without any intervention. After the experimental arm completes the motor and pre-literacy program, the wait-list group will receive the exact same motor and pre-literacy intervention.
223630381|NCT04094285|DRUG|SAUERSTOFF|"SAUERSTOFF medizinisch, Messer GmbH, Industriestrasse 5, 2352 Gumpoldskirchen, Austria~Dose:~min. 95.5%, breathing for 30 minutes"
224219086|NCT01218737|DRUG|isolated 0.3% gatifloxacin and 1.0% prednisolone acetate|"Each patient will receive two medication bottles (eye drops) in a blinded fashion: one with the 0.3% gatifloxacin eye drops and another with 1.0% prednisolone acetate eye drops. The patient must instill 01 drop of each bottle in each operated eye, with a 5-minute interval between the instillations.~This procedure should be performed 4 times a day (QID) during the wake hours, from Day 0 (surgery day) until Day 15."
224219087|NCT04844307|OTHER|Shorter duration higher frequency PT|The standard PT session (30 mins) will be divided into two 15 minute sessions spread out during the day. Therefore, the total number of minutes of PT will not vary from the standard.
223630382|NCT04094285|DRUG|STICKSTOFF|"STICKSTOFF medizinisch, Messer GmbH, Industriestrasse 5, 2352 Gumpoldskirchen, Austria~Dose:~88% with 12% oxygen, breathing for 30 minutes"
224219088|NCT04844307|OTHER|Standard PT|The standard PT session is 30 minutes once daily. It routinely involves exercises designed to strengthen and increase mobility of the patient such as bed mobility, transfers, and ambulation. In this study group there will be no variation from this standard treatment.
223630383|NCT03550027|DEVICE|PleurX|Positioning of drainage PleurX
223630384|NCT03550027|DEVICE|Pleurocath|Positioning of drainage Pleurocath
223630385|NCT05497830|OTHER|RISK-INDEX|Presentation of RISKINDEX to the physician after approximately 2 hours. The ML RISKINDEX is a prediction model based on laboratory data from the ED. It is based on date of birth, sex and at least four laboratory data which are sampled within the first two hours of the ED visit. Laboratory data that are used as input include samples that are commonly drawn in patients that require treatment from an internal medicine physician, such as urea, albumin, C-reactive protein (CRP), lactate and bilirubin.
223630386|NCT02818907|OTHER|Additional biological samples|blood and tumor tissue samples
224219089|NCT01361607|DRUG|Nabiximols|
224317773|NCT00700362|PROCEDURE|Insulin infusion (aspart)|The insulin infusion, a fast acting insulin analog (aspart) in 1 Unit/ml of NaCl, starts when the patients full fill the eligibility criteria and has signed the informed consent. The intervention group continues for three full days with insulin infusion. After the transition day (the fourth day) multiple doses of mixinsulin continues until the study ends 4 weeks after the randomization.
224317774|NCT00700362|PROCEDURE|Standard care|Glucose control according to standard care at the ward, i.e., sliding scale insulin at the discretion of responsible physician.
223630387|NCT06209658|DIAGNOSTIC_TEST|breastfeeding education of Teach Back|breastfeeding education simple explanation is given and the woman is asked to explain and practice.
223630388|NCT06209658|OTHER|breastfeeding education simple explanation|breastfeeding education simple explanation
223630389|NCT05968820|BEHAVIORAL|Sleep Health Enhancement Intervention|The program is based on principles from CBT-I (time in bed restriction, stimulus control, relaxation techniques, sleep education) and includes behavioral strategies to entrain circadian rhythm, strengthen sleep homeostasis, reduce hyperarousal, and sleep hygiene techniques. Self-Determination Theory (SDT) and Social Cognitive Theory (SCT) will serve as the theoretic framework for behavior change techniques (BCT) threaded through the sleep health enhancement intervention. Participants will maintain a sleep diary during the program to aid in tailoring the program, self-monitoring of behavior, and feedback of behavior. Goals will be set by the participant at each session and reviewed at subsequent sessions, and motivational interviewing principles will be incorporated.
223630390|NCT01607957|DRUG|TAS-102|35 mg/m2/dose, orally, twice daily on days 1-5 and 8-12 of each 28-day cycle. Number of cycles: until at least one of the discontinuation criteria are met.
223630391|NCT01607957|DRUG|Placebo|Placebo tablets, orally, twice daily on days 1-5 and 8-12 of each 28-day cycle. Number of cycles: until at least one of the discontinuation criteria are met.
223630392|NCT01001975|DRUG|Sunscreen Test Code: V53-028|Sunscreen formula containing 15% Zinc Oxide, 3% Avobenzone, and 1% Ensulizole
223630393|NCT01001975|DRUG|Sunscreen Test Code: V53-030|Sunscreen formula containing 15% Zinc Oxide and 3% Avobenzone
223630394|NCT01001975|DRUG|Standard SPF 4 Sunscreen|8% Homosalate Standard SPF 4 Sunscreen
224317775|NCT00182325|BEHAVIORAL|personalized web prenatal information|
223630395|NCT02560259|OTHER|Physiotherapy|Physiotherapy
223630396|NCT02560259|OTHER|Conservative treatment|Conservative treatment
224219090|NCT01361607|DRUG|Placebo (GA-0034)|
223630397|NCT00670215|DRUG|Ciprofloxacin single dose|Patients randomized to this regimen will receive a single-dose of ciprofloxacin MR 1000 mg PO approximately 2 to 3 hours prior to the TRNBP. Patients will also receive two doses of matching placebo approximately 24 hours prior to and approximately 24 hours after the TRNBP.
223630398|NCT00670215|DRUG|Ciprofloxacin triple dose|Patients randomized to this regimen will receive three doses of ciprofloxacin MR 1000 mg PO. The doses will be approximately 24 hours prior to the TRNBP, approximately 2 to 3 hours prior to the TRNBP, and approximately 24 hours after the TRNBP.
223630399|NCT00945009|BIOLOGICAL|Dactinomycin|Given IV
223630400|NCT00945009|DRUG|Doxorubicin Hydrochloride|Given IV
223630401|NCT00945009|RADIATION|Radiation Therapy|Undergo radiation therapy
224219091|NCT05485688|OTHER|sleep apnea|This prospective observational study will enroll 60 moderate-to-severe OSA patients (AHI≧15/hour, 30 obese \[BMI\>=27\] \& 30 non-obese \[BMI\<27\]) and 40 age-, gender-, BMI-matched controls without OSA. Venous blood 10 ml will be collected to isolate neutrophils, which are later tested for their ability to produce neutrophil extracellular traps (NETs) under the effect of PMA (phorbol 12-myristate 13-acetate).
224219092|NCT04405193|DRUG|N-acetyl cysteine|Eligible patients will be randomised to receive N-acetylcysteine or placebo
224219093|NCT04405193|DRUG|Placebo|Matching Placebo
224219094|NCT05771831|BIOLOGICAL|Thrombosomes®|The intervention with TBX® is to be administered as an intravenous infusion as hemostatic blood product as part of the Massive Transfusion Protocol (MTP).
224219095|NCT05771831|BIOLOGICAL|Standard platelet concentrate|The administration of standard platelets is administrated, as part of the Massive Transfusion Protocol (MTP).
224219096|NCT04394910|DIETARY_SUPPLEMENT|Pomegranate Juice|
224219097|NCT04394910|DIETARY_SUPPLEMENT|Placebo Juice|
224219098|NCT01032681|BIOLOGICAL|EMD 521873|"Dose escalation steps:~Group 1: 0,075mg/kg - 0,15mg/kg - 0,225mg/kg - 0,3mg/kg - 0,45mg/kg - 0,6mg/kg - 0,9mg/kg (-1,8mg/kg - 2,1mg/kg - 2,5mg/kg - 3,0mg/kg)~Disease control and decision of continuation in patient who benefit from the treatment:~Every second cycle"
224219099|NCT01032681|BIOLOGICAL|EMD 521873|"Dose escalation steps:~Group 2: CPA plus 0,6mg/kg - 0,9mg/kg~Disease control and decision of continuation in patient who benefit from the treatment:~Every second cycle"
224219100|NCT01032681|BIOLOGICAL|EMD 521873|"Dose escalation steps:~Group 3: 0,9mg/kg - 1,2mg/kg - 1,5mg/kg (-1,8mg/kg - 2,1mg/kg - 2,5mg/kg - 3,0mg/kg)~Disease control and decision of continuation in patient who benefit from the treatment:~Every second cycle"
224219101|NCT00297479|BEHAVIORAL|MBAT Group Therapy|In-person group therapy/counseling (8 sessions over 8 weeks) using a Mindfulness-Based Addiction Treatment for nicotine dependence
224219102|NCT00297479|DRUG|Nicotine|6 weeks of nicotine patch therapy
223630402|NCT00945009|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgical resection
223630403|NCT00945009|DRUG|Vincristine Sulfate|Given IV
223630404|NCT05387278|DRUG|EV-Pure™ and WJ-Pure™|The treatment consists of administration of WJ-Pure™ and EV-Pure™ plus standard care
223630405|NCT05387278|DRUG|Placebo|Cryopreservation media plus standard care
223630406|NCT06220032|DRUG|Dexrazoxane|Day 1 Cycle 1-6: Dexrazoxane 500 mg/m2 (iv) will be given 30 minutes before doxorubicin infusion and should be infused during 15 minutes.
223630407|NCT06220032|DRUG|Rituximab|Day 1 Cycle 1-6: 375 mg/m2 (iv)
223630408|NCT06220032|DRUG|Cyclophosphamide|Day 1 Cycle 1-6: 750 mg/m2 (iv)
223630409|NCT06220032|DRUG|Doxorubicin|Day 1 Cycle 1-6: 50 mg/m2 (iv)
224219103|NCT00297479|BEHAVIORAL|Group Therapy|In-person group therapy/counseling (8 sessions over 8 weeks) based upon Treating Tobacco Use and Dependence Clinical Practice Guideline
224219104|NCT00297479|BEHAVIORAL|Individual Therapy|In-person individual counseling (4 sessions over 8 weeks) based upon Treating Tobacco Use and Dependence Clinical Practice Guideline
224219105|NCT01545687|DIETARY_SUPPLEMENT|Lactobacillus brevis CD2 lozenge|Dissolved orally
224219106|NCT01545687|OTHER|placebo|Dissolved orally
224219107|NCT03124485|PROCEDURE|Endoscopic Sleeve Gastroplasty|An oesophageal overtube is then inserted to facilitate passage of the endoscope mounted with Overstitch device. A series of full thickness sutures done with Overstitch in the triangular stitch pattern as mentioned by Lopez-Nava\[29\] will be placed according to the APC markings. The suturing is initiated from the antrum distally and moved proximally towards the gastric fundus. A total of 6 to 8 plications are placed to reduce the gastric lumen. Five sham dressings would also be applied to patient's abdominal wall during the first week to minimize the bias in pain scoring.
224219108|NCT03124485|PROCEDURE|Laparoscopic Sleeve Gastrectomy|Sleeve gastrectomy is then performed using lapaorscopic linear staplers, starting from a point 5-6cm proximal to the pylorus up to the angle of His along the left side of the Mid-sleeve tube. Haemostasis of the staple line is secured by suture plication with the Mid-sleeve tube in situ to ensure no compromise of the gastric tube lumen. All the wounds are closed with staples after local anaesthetic infiltration and covered with non-transparent dressings.
224219109|NCT03349177|DRUG|Epirubicin|100mg/m2
224219110|NCT03349177|DRUG|Fluorouracil|500mg/m2
224219111|NCT03349177|DRUG|Docetaxel|75mg/m2(TC), 100mg/m2(EC-T)
224219112|NCT03349177|DRUG|Cyclophosphamide|500mg/m2(FEC), 600mg/m2(EC-T and TC)
224219113|NCT03145883|OTHER|Home-Based Aerobic Exercise|
224219114|NCT01696383|DRUG|Travoprost 0.004%/Timolol 0.5% Fixed Combination (DuoTrav)|One drop self-administered topically to the study eye(s) once daily every evening at 8:00 pm for 12 weeks
224317776|NCT00182325|BEHAVIORAL|general web prenatal information|
224317777|NCT03617783|DRUG|Prebiotin|Prebiotin (12g/day), an oligofructose-enriched inulin (OEI)
224317778|NCT03617783|DRUG|Placebo|placebo-OEI
224317779|NCT01992185|DRUG|Photocil for Vitiligo|Photocil for Vitiligo
223630410|NCT06220032|DRUG|Vincristine|Day 1 Cycle 1-6: 1.4 mg/m2 (max 2 mg) (iv)
223630411|NCT06220032|DRUG|Prednisolone|Day 1-5 Cycle 1-6: 100 mg (oral)
223630412|NCT06220032|DRUG|Lenalidomide|Day 1-14 Cycle 1-6: 15 mg day (oral) Only in case of a double hit lymphoma.
223630413|NCT06220032|DRUG|Pegfilgrastim|6 mg (1 dose per cycle) in case of neutropenia. Pegfilgastim is mandatory in patients that receive R2-CHOP21.
223630414|NCT06037590|COMBINATION_PRODUCT|Levodopa Cyclops®|Orally inhaled dry powder levodopa from the Cyclops® dry powder inhaler
224317780|NCT01992185|OTHER|Placebo - Sunscreen (SPF 2)|Placebo - Sunscreen (SPF 2)
224219115|NCT03221439|BEHAVIORAL|Cognitive Functional Therapy|"There will be four main components in the intervention, following the protocol used by O'Keefe et al. (2015):~1. The cognitive component will focus on on the multidimensional nature of persistent pain about individual beliefs, and how emotions and behaviors (movement and lifestyle) can reinforce a vicious cycle of pain and disability.~2. Specific Functional training is designed to normalize maladaptive or provocative movement and posture.~3. Functional integration directed to activities of daily life that are avoided by the patient (rolling in bed, sitting, sitting to standing, walking, bending and lifting)~4. Patients will be advised to gradually increase physical activity based on their preference, also focusing on sleep hygiene, stress, and management strategies"
224317781|NCT02419781|PROCEDURE|Rescue endovascular therapy|endovascular treatment using any devises for acute ischemic stroke patients with large vessel occlusion and not respond to intravenous recombinant tissue plasminogen activator (rt-PA) therapy
224317782|NCT02419781|PROCEDURE|No endovascular therapy|
224317783|NCT00985244|DRUG|Azithromycin|Subjects in this group will receive 3 times a week 500 mg of the antibiotic azithromycin during 1 year.
224317784|NCT00985244|DRUG|Placebo|Persons in this group will receive 3 times a week placebo of azithromycin during 1 year.
223630415|NCT06037590|COMBINATION_PRODUCT|INBRIJA®|Orally inhaled dry powder levodopa from the ARCUS® dry powder inhaler
223630416|NCT06202482|OTHER|Connect Active Program|Younger adults will help older adults increase their digital literacy, skills, and desire to exercise and become more physically active via the proposed intervention. The Connect Active Program will consist of two components: walking exercises and mobile apps.
223630417|NCT06147986|BIOLOGICAL|Allogeneic umbilical cord mesenchymal stem cells|UMSC01 cells will be IC infusion followed by IV infusion with 24 months of follow up after treatment.
223630418|NCT06147986|OTHER|Control group|Standard-of-care for STEMI
223630419|NCT03583853|DEVICE|real time PCR|real time PCR will be used for determination of expression of autophagy genes
223630420|NCT05653973|DRUG|Acetylcholine|acetylcholine, and acetylcholine + L-NAME (Nitric oxide synthase inhibitor) are locally and acutely delivered to the cutaneous microvasculature to assess endothelium- and nitric oxide-dependent dilation
223630421|NCT05653973|DRUG|Endothelin-1|endothelin-1, endothelin-1 + BQ-788 (endothelin receptor type B-inhibitor), and endothelin-1 + BQ-123 (endothelin receptor type A-inhibitor) are locally and acutely delivered to the cutaneous microvasculature to assess endothelin-mediated constriction and the role of the receptor subtypes in this response.
223630422|NCT03919773|DRUG|IVIG|"If you participate in this study there will be 18 scheduled treatment infusions during the 30 week study period. All the study visits and treatment visits will be outpatient visits.~Once you qualify to participate in the study and begin treatment, there will be two 12 week treatment periods separated by a 6 week washout period. The infusion visits will take approximately 3-4 hours each."
224219116|NCT03221439|OTHER|Manual Therapy and Motor Control Exercise|According to the pragmatic clinical decision of the physiotherapist responsible for this intervention arm, participants allocated to the comparison group will be treated with joint mobilization or manipulation techniques applied to the lower back or pelvis. The active exercises will involve isolated contractions of the deep abdominal and multifidus muscles in different functional positions. Most patients in this group will receive exercises to perform at home. This will include general exercise or motor control exercise, but not related to CFT.
224219117|NCT04098549|OTHER|Rapid lowering of plasma glucose|Rapid lowering of plasma glucose using hypoglycemic clamp technique
224219118|NCT04098549|OTHER|Slow lowering of plasma glucose|Slow lowering of plasma glucose using hypoglycemic clamp technique
224219119|NCT04819347|DRUG|Albuvirtide|Long-Acting HIV-1 Fusion Inhibitor (chemically modified peptide targeting HIV-1 gp41)
224219120|NCT04819347|DRUG|3BNC117|Recombinant, fully human mAb of the IgG1κ isotype that specifically binds to HIV-1 gp120.
224219121|NCT04728087|DEVICE|ACCEL® Absorbable Hemostat Powder|Up to 2 bellows (10 grams nominal) of ACCEL®
224219122|NCT04728087|DEVICE|Gelfoam® (Absorbable Gelatin Sponge, Pfizer Manufacturer Part Number 0342-01)|Up to 12.5 cm x 8.0 cm of Gelfoam® or SURGIFOAM® .
224317785|NCT02513225|BEHAVIORAL|Project EMPWR|Participants will receive both Adapted Project EMPWR and Optimized Standard Care (OSC).
224317786|NCT02513225|OTHER|Optimized Standard Care (OSC)|Participants will receive Optimized Standard Care (OSC) alone.
224219123|NCT02964897|BEHAVIORAL|Peer-support plus usual care from the Health Care for Reentry Veterans program|a peer mentor who is also a veteran will establish a relationship with each subject and provide instrumental and emotional support to the subject during the first 6 months of the subject's release from incarceration. This is in addition to the usual reentry support provided by the Health Care for Reentry Veterans program.
224317787|NCT03188224|OTHER|MyTransition app|MyTransition app is designed to support youth moving from pediatric to adult healthcare.
224317788|NCT00237978|DRUG|Adapalen|
224317789|NCT00237978|RADIATION|VIS and wIRA|
224317790|NCT03692832|PROCEDURE|LH|Laparoscopic hysterectomy following AAGL class IV E, vault closed vaginally
224317791|NCT03692832|PROCEDURE|VH|Vaginal hysterectomy following Heaney technique
224317792|NCT00182546|PROCEDURE|Two diagnostic management strategies|
224317793|NCT06467708|DEVICE|Sparrow Ascent Transcutaneous Auricular Neurostimulation (tAN)|This method of simultaneous vagal and trigeminal stimulation via the external ear is known as transcutaneous auricular neurostimulation (tAN), as the targets of electrical stimulation include the auricular branch of the vagus nerve (ABVN) and auriculotemporal nerve (ATN), which is a branch of the mandibular division of the trigeminal nerve. Electrodes applied to select dermatome regions can target ear neural structures and deliver non-invasive vagus nerve stimulation (VNS) and trigeminal nerve stimulation (TNS).
224317794|NCT02782806|DEVICE|Masimo Rad-67 Pulse Oximeter|Noninvasive pulse oximeter
224317795|NCT01420965|DRUG|CT-011 (Anti-PD1 Antibody)|Immune Enhancer
224317796|NCT01420965|OTHER|Sipuleucel-T (Provenge)|Vaccine
223630423|NCT03919773|DRUG|Albumin|This will be the matching placebo used in the study.
223630424|NCT04659044|DRUG|Polatuzumab Vedotin|Given IV
223630425|NCT04659044|BIOLOGICAL|Rituximab|Given IV
223630426|NCT04659044|BIOLOGICAL|Rituximab and Hyaluronidase Human|Given SC
223630427|NCT04659044|DRUG|Venetoclax|Given PO
224317797|NCT01420965|DRUG|Cyclophosphamide|Low dose- Immune Enhancer
224317798|NCT00438217|DRUG|Triptorelin (GnRH agonists)|
223630428|NCT01708408|GENETIC|Biomarker studies|
223630429|NCT06297083|DRUG|Peanut Oral Powder [PEANUT POWDER]|Peanut oral immunotherapy at varying doses and build-up regimes given daily for 18 months
224219124|NCT02964897|BEHAVIORAL|Usual care from the Health Care for Reentry Veterans program|Health Care for Reentry Veterans program provides reentry planning while the veteran is incarcerated. An outreach worker visits the veteran in the incarceration facility to conduct a needs assessment and help create a reentry plan to cover issues such as where they will be housed, what health care appointments they will need in the first 30 days, whether they need legal assistance, etc.
224219125|NCT01664494|DRUG|Capecitabine|Capecitabine will be given according to the label text as monotherapy (1250 mg/m\^2 twice daily) or combination therapy (800 to 1000 mg/m\^2 or 1250 mg/m\^2 twice daily) for 14 consecutive days followed by a treatment break of 7 days.
224219126|NCT00851266|BIOLOGICAL|V512|"Subjects received 1 of 8 formulations of the BIPCV/IMX vaccine (V512) in a 3-dose regimen of 0.5 mL injections at Day 1, Month 2, and Month 6:~1\) 0.5 mcg each of A/M2 and B/HA0 peptides with 225 mcg MAA and 20 mcg IMX; 2) 0.5 mcg each of A/M2 and B/HA0 peptides with 225 mcg MAA and 60 mcg IMX; 3) 5 mcg each of A/M2 and B/HA0 peptides with 225 mcg MAA and 20 mcg IMX; 4) 5 mcg each of A/M2 and B/HA0 peptides with 225 mcg MAA and 60 mcg IMX; 5) 5 mcg each of A/M2 and B/HA0 peptides with 225 mcg MAA and 100 mcg IMX; 6) 20 mcg each of A/M2 and B/HA0 peptides with 225 mcg MAA and 20 mcg IMX; 7) 20 mcg each of A/M2 and B/HA0 peptides with 225 mcg MAA and 60 mcg IMX; 8) 20 mcg each of A/M2 and B/HA0 peptides with 225 mcg MAA and 100 mcg IMX;"
224219127|NCT00851266|BIOLOGICAL|Comparator: Placebo to V512|Subjects received placebo to the BIPCV/IMX vaccine (V512) in a 3-dose regimen of 0.5 mL injections at Day 1, Month 2, and Month 6.
224219128|NCT04513340|DRUG|WD-1603 CARBIDOPA and LEVODOPA EXTENDED-RELEASE TABLETS|CARBIDOPA and LEVODOPA EXTENDED-RELEASE TABLETS 25/100MG
224219129|NCT00362570|DRUG|Temozolomide|"p.o.(by mouth), 150 mg/m2/d x days 1-7 and 15-21, given every 28 days \[i.e., 7 days on/7 days off\] using a standardized dosing range.~Administration: Temozolomide will be administered on an empty stomach (i.e., 1 hour before or 2 hours after any oral intake)."
224219130|NCT04503252|OTHER|Blood samples for the measurement of the concentration of cefazolin|Blood samples for the measurement of the concentration of cefazolin will be collected on the 1st (mid-dose and trough sample), 3rd (mid-dose and trough sample),7th and 14th day (for both only trough sample) of cefazolin treatment (+/-1-5 day) and if applicable in weekly intervals during outpatient parenteral antibiotic treatment (usually within 4 weeks after inclusion; only in patients on outpatient continuous parenteral antibiotic treatment).
224219131|NCT04503252|OTHER|S. aureus culture isolate|The S. aureus culture isolate will be subjected to exact cefazolin MIC determination and to measurement of the level of cefazolin tolerance.
224219132|NCT04503252|OTHER|structured telephone interview|Structured telephone interview for Patient follow- up after 30 days
224219133|NCT04503252|OTHER|Sub-study quantitative measurement of Torque Teno virus|An additional EDTA sample will be drawn for quantitative polymerase chain reaction (PCR) of TTV DNA and analyses of cytokines and other parameters of the activation state of the immune system.
224219134|NCT04503252|OTHER|Sub-study investigating cefazolin concentrations in sweat|For each visit of included patients, a sweat sample will be collected via a CE certified Macroduct Sweat Collector. Eccrine sweat glands of the lower forearms are stimulated by pilocarpine (a parasympathomimetic) as well as a local current for 5min. Sweat is subsequently collected by capillary containers during 30min and transferred to small tubes on dry ice. Sweat sample analysis is conducted using mass spectrometry.
224219135|NCT04070456|OTHER|Tablet-based SDH tool|A tablet-based SDH tool, which integrates responses into the EpicCare electronic health record (EHR).
224219136|NCT00133107|DRUG|efalizumab|
224219137|NCT02948478|OTHER|Exposed|Precarious patients
224219138|NCT02948478|OTHER|Non exposed|Non precarious patients
224219139|NCT05935774|BIOLOGICAL|Atezolizumab|Given IV
224219140|NCT05935774|PROCEDURE|Biopsy|Undergo biopsy
224219141|NCT05935774|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
224219142|NCT05935774|PROCEDURE|Computed Tomography|Undergo CT
224219143|NCT05935774|OTHER|Electronic Health Record Review|Ancillary studies
223630430|NCT06297083|DIETARY_SUPPLEMENT|Probiotic (LGG®, Lactobacillus Rhamnosus) or placebo probiotic (maltodextrin)|Probiotic or placebo-probiotic given daily for 18 months
223630431|NCT04038619|PROCEDURE|Fecal Microbiota Transplantation|Undergo FMT via colonoscopy
223630432|NCT04038619|DRUG|Loperamide|Given PO
223630433|NCT04156373|BEHAVIORAL|Fuerte|Fuerte is a prevention program targeting youth at risk for psychological trauma who are recent immigrants to the United States. The program is evidence-informed using cognitive-behavioral principles and the Attachment, Regulation, and Competency (ARC) model for treating psychological trauma.
223630434|NCT04266873|DEVICE|AffloVest|Form of High Frequency Chest Wall Oscillation mimicking manual techniques on a patients thorax to assist with secretion clearance. Delivered for 30 minutes, twice a day
223630435|NCT02157532|PROCEDURE|mechanical thrombectomy|Mechanical thrombectomy using any already approved stent-retriever device
223630436|NCT02157532|DRUG|Best standard treatment|Intravenous r-tPA infusion or any other medical management option
223630437|NCT02641548|DEVICE|Sock of silicone|
223630438|NCT02641548|OTHER|Heel cream|
223630439|NCT04966013|DEVICE|RD-X19|Investigational device that uses safe electromagnetic energy to target the oropharynx.
223630440|NCT04966013|DEVICE|Sham|Investigational device that uses safe electromagnetic energy to target the oropharynx but at energy levels with a lower inactivation potential against SARS-CoV-2 in vitro..
223630441|NCT06342128|OTHER|No intervention|No intervention
224219144|NCT05935774|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
224219145|NCT05935774|DRUG|Trabedersen (OT-101)|Given IV
224219146|NCT01328392|DRUG|Dexlansoprazole|30mg a day, 3 months
224219147|NCT01301131|OTHER|Probiotics|80 ml of fermented dairy product containing L. casei shirota via nasogastric tube once daily and 80 ml of fermented dairy product containing L. casei shirota oral rinse once daily
224219148|NCT01301131|OTHER|control|usual oral care
224219149|NCT01002157|DIETARY_SUPPLEMENT|Menaquinone-7 (Vitamin K2)|Menaquinone-7 (Vitamin K2)
224219150|NCT01002157|OTHER|Placebo capsules|Capsules containing no Menaquinone-7
224317799|NCT00438217|DRUG|Leuprolide (GnRH agonists)|
223630442|NCT04315948|DRUG|Remdesivir|The lyophilized formulation of Remdesivir is a preservative-free, white to off-white or yellow, lyophilized solid containing 100 mg of Remdesivir to be reconstituted with 19 mL of sterile water for injection and diluted into IV infusion fluids prior to IV infusion. Following reconstitution, each vial contains a 5 mg/mL Remdesivir concentrated solution with sufficient volume to allow withdrawal of 20 mL (100 mg of remdesivir). It is supplied as a sterile product in a single-use, 30 mL, Type 1 clear glass vial.
223630443|NCT04315948|DRUG|Lopinavir/ritonavir|"The oral tablets of lopinavir/ritonavir contain 200 mg lopinavir, 50 mg ritonavir. They have a yellow colour, film-coated, ovaloid shape debossed with the a logo and the code KA. The oral solution for patients who cannot swallow is a light yellow to orange colored liquid containing 400 mg lopinavir and 100 mg ritonavir per 5 mL (80 mg lopinavir and 20 mg ritonavir per mL)."
223630444|NCT04315948|DRUG|Interferon Beta-1A|IFN-ß-1a is supplied as a sterile solution containing no preservative available in a prefilled syringe. It will be provided as a single-dose prefilled graduated syringe with 44 µg per 0.5 mL. The liquid should be clear to slightly yellow. Do not use if the liquid is cloudy, discolored or contains particles. Use a different syringe.
223630445|NCT04315948|DRUG|Hydroxychloroquine|Hydroxychloroquine is supplied as film-coated 200 mg tablets. Hydroxychloroquine sulfate tablets are presented as white or whitish, peanut-shaped, oblong or round film-coated tablets containing 200 mg of hydroxychloroquine sulfate (equivalent to 155 mg base).
223630446|NCT04315948|OTHER|Standard of care|Standard of care
223630447|NCT04315948|DRUG|AZD7442|AZD7442 will be supplied as separate vials of AZD8895 and AZD1061 containing 150 mg colorless to slightly yellow, clear to opalescent solutions for injection.
223630448|NCT04315948|OTHER|Placebo|Since April, 2021, the placebo will be a 0.9% (w/v) NaCl solution for infusion also called saline. The placebo will be supplied as a single 10-mL, clear and colorless vial.
223630449|NCT02601612|BIOLOGICAL|D46cpΔM2-2 vaccine|Delivered as nose drops
224219151|NCT02212431|DRUG|Cysteamine|Dose will be increased weekly from 450mg od to 450mg bd, to 450mg tds to 450mg qds, will remain on highest dose for 2 weeks
224219152|NCT03412019|OTHER|Music|Selections of Mozart piano sonatas
224219153|NCT03979677|BEHAVIORAL|Lifestyle Modifications|Written suggestions on common migraine triggering food/beverages to avoid, restful sleep tips, exercise suggestions, and eating set mealtimes will be provided as the intervention.
224219154|NCT03947047|DIAGNOSTIC_TEST|NA-NOSE|Breath and blood samples for distinguishing biomarkers.
224219155|NCT02273206|BEHAVIORAL|Prevention Care Management for Depression and Cancer Screening|
224219156|NCT02273206|BEHAVIORAL|Prevention Care Management for Cancer Screening|
224219157|NCT02238977|DRUG|Fluoxetine|Antidepressant
224219158|NCT02238977|DRUG|Bupropion|Antidepressant
224219159|NCT06189183|RADIATION|Adjuvant Hypofractionation Radiotherapy|Adjuvant Hypofractionation Radiotherapy for Thymic Epithelial Tumours After Complete Resection
223630450|NCT02601612|BIOLOGICAL|Placebo|Delivered as nose drops
223630451|NCT06229444|BEHAVIORAL|ILI Predictive Alerts, Reactive Content, and Proactive Content|Participants receive ILI-related education, feedback, and opportunities to self-monitor ILI symptoms, in addition they also receive alerts about potential ILI illness, and reactive and personalized content about protective health behaviors.
223630452|NCT06229444|BEHAVIORAL|ILI Predictive Alerts, Reactive Content|Participants receive alerts about potential ILI illness, and reactive and personalized content about protective health behaviors.
223630453|NCT06229444|BEHAVIORAL|Proactive Content|Participants receive ILI-related education, feedback, and opportunities to self-monitor ILI symptoms.
224219160|NCT01637311|PROCEDURE|POEM|Peroral endoscopic myotomy (POEM) has recently been described as a new minimally invasive endoscopic myotomy technique intending a permanent cure from primary achalasia.
224219161|NCT02370966|DIETARY_SUPPLEMENT|Berry powder|Berry and gingivitis trial
224219162|NCT04586790|DRUG|Midodrine Oral Tablet|midodrine group will receive midodrine 10 mg PO q 8 hr with gradual weaning of IV nor-adrenaline after receiving 4 doses of oral midodrine .
224219163|NCT04586790|DRUG|Minirin oral tablet|Minirin group will receive minirin 60 µg PO q 8 hr with gradual weaning of IV nor-adrenaline after receiving 4 doses of oral minirin .
223630454|NCT06229444|BEHAVIORAL|No Intervention|Participants will not receive predictive alerts or reactive content after reporting symptoms or proactive IILI-related health educational content
223630455|NCT02420847|DRUG|Doxorubicin Hydrochloride|Given IV
223630456|NCT02420847|DRUG|Gemcitabine Hydrochloride|Given IV
223630457|NCT02420847|DRUG|Ixazomib Citrate|Given PO
223630458|NCT06195748|OTHER|Kinesiotaping|According to the manufacturer, the controllable variables in KT application included degree of pre-stretch applied to the tape (75-100%), the location and treatment goals. The subject will be asked to lie supine, with the ankle of the dominant side in neutral position. A Y shaped KT strip will be applied from the heel to lateral and medial femoral condyles. A I shaped KT strip will be applied from medial malleolus to lateral malleolus, passing under the heel. Another I shaped KT strip will be applied from slightly above the medial malleolus to slightly above the lateral malleolus, crossing on the instep at the malleoli level.
224219164|NCT04586790|DRUG|Nor-Adrenaline|control group will receive IV nor-adrenaline and is gradually weaning from it according to routine hospital care without adding oral midodrine or oral minirin .
224219165|NCT01945099|DEVICE|ePID closed loop system|Insulin pump controlled by closed loop unit and algorithm
224219166|NCT01945099|DRUG|hyaluronidase|
224219167|NCT01945099|DRUG|Lispro-PH20|
224219168|NCT02517359|DRUG|RV6153 single dose|Safety and tolerability of single doses
224219169|NCT02517359|DRUG|RV6153 matching placebo single dose|Safety and tolerability of single doses
224219170|NCT02517359|DRUG|RV6153 14 day repeat dose|Safety and tolerability of repeat doses
224219171|NCT02517359|DRUG|RV6153 matching placebo 14 day repeat dose|Safety and tolerability of repeat doses
224219172|NCT02517359|DRUG|RV6153 28 day repeat dose|Safety and tolerability of repeat doses
224219173|NCT02517359|DRUG|RV6153 matching placebo 28 day repeat dose|Safety and tolerability of repeat doses
224219174|NCT03825952|DEVICE|MERM - medication event reminder monitor|The MERM will help measure adherence to ART in routine clinical care.
224219175|NCT01557270|DRUG|dexmedetomidine|ropivacaine 100 mg + 150 mcg dexmedetomidine, single shot perineural application
223630459|NCT06195748|OTHER|Placebo kinesiotaping|The same tape will be used for the interventional application with 0 tension.
223630460|NCT03518086|DRUG|Mirikizumab|Administered IV
223630461|NCT03518086|DRUG|Placebo|Administered IV
223630462|NCT06066788|OTHER|CHAMPS|Cognitive Orientation to daily Occupational Performance is a performance-based treatment approach for children and adults who experience difficulties performing the skills they want to, need to or are expected to perform. Cognitive Orientation to daily Occupational Performance is a specifically tailored, active client-centered approach that engages the individual at the meta-cognitive level to solve performance problems. Focused on enabling success, the Cognitive Orientation to daily Occupational Performance Approach employs collaborative goal setting, dynamic performance analysis, cognitive strategy use, guided discovery, and enabling principles. These elements, all considered essential to the Cognitive Orientation to daily Occupational Performance Approach, are situated within a structured intervention format, and with parent/significant other involvement as appropriate.
223630463|NCT05967260|DEVICE|DailyDose Smart Snack app|A decision support tool that predicts the likelihood of overnight low blood sugar based on current CGM and inputted exercise. App will recommend a snack at bedtime based on the minimum low glucose predicted and the time of the low glucose.
223630464|NCT05967260|DEVICE|Dexcom G6 CGM|A commercially available Continuous Glucose Monitoring system that utilizes a transmitter and sensor to measure sensor glucose levels that transmit to a smart phone app.
223630465|NCT03064802|DEVICE|BioBurst Fluid, Burst Allograft|BioBurst Fluid or Burst Allograft used to augment spinal fusion
223630466|NCT02437916|DRUG|AMG 228|AMG 228 will be administered intravenously
223630467|NCT01673529|DRUG|SB705498|1%, 3% and 5% (w/w) of SB705498 will be used in part A of the study. One dose will then be selected based on criteria explained in the protocol for use in Part B of the study.
223630468|NCT01673529|DRUG|Placebo|Placebo to match SB705498 will be used in both Part A and Part B of the study.
223630469|NCT06589375|DIAGNOSTIC_TEST|Sniffin'Sticks|The Sniffin' Sticks test, a validated method to evaluate olfactory functions, utilizes pen-like devices to dispense scents for testing identification, discrimination, and detection of odors. In this study, participants' responses to various scents are recorded. EEG (Electroencephalography) captures electrical activity in the brain during exposure to these odors by using an EEG cap fitted with electrodes on the scalp. This allows for the monitoring of brain wave patterns in response to olfactory stimuli. Both the Sniffin' Sticks test and EEG recordings are conducted simultaneously, providing a dual assessment of behavioral reactions and brain activity to odors. The goal of the study is to compare brain wave patterns and olfactory function in normosmic (normal smell), hyposmic (reduced smell), and tinnitus patients with and without olfactory impairments, delivering comprehensive insights into the neural basis of olfactory perception.
223630470|NCT06999083|DRUG|HB0043|HB0043 Drug Product
223630471|NCT06999083|DRUG|Placebo|Placebo
223630472|NCT06999733|BIOLOGICAL|KB801|Ophthalmic suspension of replication-defective, non-integrating herpes simplex virus type 1 (HSV-1)-based vector delivering functional, full-length human nerve growth factor (NGF)
223630473|NCT06999733|DRUG|Placebo|Vehicle
223630474|NCT06999421|DEVICE|Robot with interactive animations, gesture recognition, and touch/voice-based input|A humanoid educational robot that provides GDM-related content using animated videos, emotional facial expressions, gesture movements, and voice/touch-based interaction. Designed to increase engagement, reduce anxiety, and improve health literacy among pregnant women.
223630475|NCT06999421|DEVICE|Standard tablet (video playback only).|A standard touchscreen tablet used to deliver pre-recorded educational videos on GDM. This intervention provides passive viewing without any robot interaction or feedback.
223630476|NCT06617312|DRUG|Cytisinicline|Targets α4β2 nicotinic acetylcholine receptors
223630477|NCT06617312|DRUG|Placebo Oral Capsule|Matched to active drug, cytisinicline
223630478|NCT06589739|DEVICE|Virtual Reality Headset|A virtual reality headset will be placed on patients\&#39; head before and during chest drain insertion
223630479|NCT04752618|BEHAVIORAL|P-STAIR|PCIT+ STAIR
223630480|NCT04752618|BEHAVIORAL|Supportive Counseling|Non-trauma focused psychotherapy
223630481|NCT04093297|PROCEDURE|Tricuspid Annuloplasty|Patients will undergo repair of tricuspid regurgitation
223630482|NCT06236893|OTHER|VH-01 vaginal suppository tablet|Participants will be instructed to take VH-01 Days 1, 4, 7, 14, and 21 of Month 1 and Days 1 and 14 of Months 2 and 3.
223630483|NCT06236893|OTHER|Placebo vaginal suppository tablet|Participants will be instructed to take the placebo on Days 1, 4, 7, 14, and 21 of Month 1 and Days 1 and 14 of Months 2 and 3.
223630484|NCT06589752|DRUG|TARPEYO 4 MG Delayed Release Oral Capsule|TARPEYO dispensing claim for any dose is exposure
223630485|NCT06589752|DRUG|RAS inhibitor|RASi dispensing claim for any dose is reference
223630486|NCT06599489|PROCEDURE|surgery ..operation|sleeve gastrectomy with cruroplasty with or without ligamentum teres wrapping
223630487|NCT06592716|DIAGNOSTIC_TEST|Liquid biopsy|The intervention is a liquid biopsy as a blood sample taken in a peripheral vein. The blood samples are analyzed for cell free HPV-DNA.
224219176|NCT01557270|DRUG|saline|ropivacaine + saline placebo, single shot perineural application
224219177|NCT04340232|DRUG|Baricitinib|Subjects will receive a 2 mg oral dose of baricitinib.
223630488|NCT06869252|BIOLOGICAL|Autologous Adipose Cells Therapy|Participants will receive Autologous Adipose Cells therapy treatment, and the safety and efficacy of the treatment will be monitored by the primary investigator up to 25 weeks.
223630489|NCT06595225|BEHAVIORAL|Nutrition education sessions|Participants received nutrition education each month, covering topics ranging from general nutrition knowledge, nutrition knowledge related to their diagnosis of living with HIV infection whether during the acute or chronic phase. In addition, specific information was shared about other comorbidities the participant could be living with, finally information was shared on ways to improve mental health and enhance physical activity levels.
224219178|NCT03063632|BIOLOGICAL|Interferon Gamma-1b|Given SC
224219179|NCT03063632|OTHER|Laboratory Biomarker Analysis|Ancillary studies
224219180|NCT03063632|BIOLOGICAL|Pembrolizumab|Given IV
224219181|NCT00927888|DRUG|Bupivacaine Block|Bupivacaine local anesthesia block prior to start of FESS procedure.
224219182|NCT00927888|DRUG|Placebo|placebo is identical in appearance in comparison to active drug.
224317800|NCT02895100|DRUG|PTG-100|Daily dosing of PTG-100 by subject for a 12 week treatment period.
223630490|NCT01360697|OTHER|JADE|"1. The nurse will complete the CA using standardized protocol including blood \& urine tests, eye \& feet examination.~2. Whenever feasible, the nurse will arrange 2-4 hours of diabetes education in groups or on an individual basis as appropriate.~3. Between each follow-up (FU) visit, the nurse or HCA will contact the patient by phone or email to remind them to attend visits, adhere to medications \& healthy lifestyles, perform self blood glucose monitoring as appropriate.~4. At each FU visit, the patients will first see the nurse or HCA for record of blood pressure, body weight \& blood glucose (or A1c) measurement as appropriate. Compliance will also be checked using the 4-item questionnaire.~5. After the FU visit, the patients will see the nurse or HCA again to clarify any issues \& concerns, reinforce compliance \& record any changes in medications.~6. After each FU visit, the HCA will generate summary reports to be given to patients \& doctors to promote sharing of information."
223630491|NCT01360697|OTHER|Non-JADE|Patients will receive a comprehensive assessments at baseline and again after 12 months. In the interim between these two time points patients will be managed according to 'usual care' procedures.
223630492|NCT06276322|OTHER|Low back pain group|The low back pain group will be evaluated the kinematics of all spine segments in 3 planes while performing the tasks that patients with chronic low back pain often describe as painful in their daily lives such as walking, stepping up, standing up, bending and lifting. Using Inertial Measurement Sensors that provide valid and reliable will evaluate the kinematics of all spine
223630493|NCT06276322|OTHER|Healthy group|Low back pain kinematics compare them with asymptomatic kontrols
223630494|NCT05943834|OTHER|Series of cognitive tasks during a semi-automated call|"Tasks:~* Verbal learning recall (immediate) or Story Recall task (immediate)~* Narrative Storytelling /free speech~* Verbal fluency task~* Verbal learning recall (delayed) or Story Recall task (delayed)"
223630495|NCT06705777|DRUG|Combinations|Aesculus hippocastanum, Polygonum acre, Smilax Pepyracea, and Rutin combination
223630496|NCT06706180|OTHER|Exercise for Mood video|As per arm of the same name
223630497|NCT06706180|OTHER|Exercise for Fitness video|As per arm of the same name
224219183|NCT00686478|DRUG|interferon alpha 2b|1 million IU of interferon alpha 2b (Intron A) subcutaneously once a day for 7 days, then 3 million IU of interferon alpha 2b (Intron A) subcutaneously three times a week for 23 weeks.
224219184|NCT00062556|DRUG|Niacin Extended Release and Lovastatin Tablets|
224219185|NCT00373685|DRUG|Celecoxib|open-label
224219186|NCT00373685|DRUG|Any commercially available NSAID with the indication for osteoarthritis|dosing as per USPI label related to the chosen commercially marketed NSAID
224219187|NCT00048971|GENETIC|mutation analysis|
224219188|NCT00048971|GENETIC|polymorphic microsatellite marker analysis|
224219189|NCT04656015|DEVICE|MRI|"cMRI will be done only to patients presented with signs of HF, with raised cardiac biomarkers and echocardiographic signs of myocardial injury~The Lake Louise diagnostic criteria for CMR in myocarditis:~CMR findings are consistent with myocardial inflammation if at least two of the following criteria are present:~* Regional or global myocardial signal intensity increase in T2-weighted images~* Increased global myocardial early gadolinium enhancement ratio between myocardium and skeletal muscle in gadolinium-enhanced T1-weighted images~* There is at least one focal lesion with non-ischemic regional distribution on late gadolinium enhancement Presence of left ventricular dysfunction or pericardial effusion provides additional, supportive evidence for myocarditis 6. Carotid du"
224219190|NCT00794326|DRUG|Solution for Peritoneal Dialysis|Treatment with one bag per day during 6 months
224219191|NCT02570165|DRUG|Batefenterol|Batefenterol will be provided as dry white powder for inhalation via a DPI with 30 doses (2 strips with 30 blisters per strip). First strip will contain lactose and the second strip will contain batefenterol blended with lactose with a unit dose strength of 37.5 mcg, 75 mcg, 150 mcg, 300 mcg, or 600 mcg per blister
223630498|NCT06704438|DIAGNOSTIC_TEST|D-Lactate|D-Lactate and SCUBE-1 can be used as early diagnosis and mortality indicators in critically ill patients.
223630499|NCT06706531|PROCEDURE|Standard treatment|All participants received up to six treatment sessions at a frequency of twice per week over a 3-week period i.e. ultrasound (0.5 W/cm² of 3 MHz for 5 minutes over plantar aspect of foot), stretching exercises and strengthening exercises. The exercise pro
224219192|NCT02570165|DRUG|Umeclidinium/ Vilanterol|Umeclidinium/Vilanterol will be provided as dry white powder for inhalation via a DPI with 30 doses (2 strips with 30 blisters per strip). First strip will contain umeclidinium blended with lactose and magnesium stearate with a unit dose strength of 62.5 mcg per blister and the second strip will contain vilanterol blended with lactose and magnesium stearate with a unit dose strength of 25 mcg per blister
224219193|NCT02570165|DRUG|Placebo|Placebo will be provided as dry white powder for inhalation via a DPI with 30 doses (2 strips with 30 blisters per strip) containing lactose
224219194|NCT00248339|DRUG|Peginterferon-alpha-2b (PEG-Intron)|"PEG-interferon-alpha-2b 1.5 μg/kg QW plus ribavirin \~13.3 mg/kg QD~PEG-interferon-alpha-2b 1.5 μg/kg QW plus standard dose ribavirin, \~13.3 mg/kg QD, plus erythropoetin (PROCRIT®) 40,000 U/week.~PEG-interferon-alpha-2b 1.5 μg/kg QW plus high dose ribavirin, \~15.2 mg/kg QD, plus erythropoetin (PROCRIT®) 40,000 U/week."
224219195|NCT00248339|DRUG|Ribavirin|"PEG-interferon-alpha-2b 1.5 μg/kg QW plus ribavirin \~13.3 mg/kg QD~PEG-interferon-alpha-2b 1.5 μg/kg QW plus standard dose ribavirin, \~13.3 mg/kg QD, plus erythropoetin (PROCRIT®) 40,000 U/week.~PEG-interferon-alpha-2b 1.5 μg/kg QW plus high dose ribavirin, \~15.2 mg/kg QD, plus erythropoetin (PROCRIT®) 40,000 U/week."
224219196|NCT00248339|DRUG|Epoetin-alpha (Procrit)|"PEG-interferon-alpha-2b 1.5 μg/kg QW plus standard dose ribavirin, \~13.3 mg/kg QD, plus erythropoetin (PROCRIT®) 40,000 U/week.~PEG-interferon-alpha-2b 1.5 μg/kg QW plus high dose ribavirin, \~15.2 mg/kg QD, plus erythropoetin (PROCRIT®) 40,000 U/week."
224219197|NCT03774979|DRUG|SHR-1701|Subjects will receive an intravenous infusion of SHR-1701 in a pre-set dose escalation until confirmed progression, unaccepted toxicity, or any criterion for withdrawal from the trial.
224219198|NCT01789281|DRUG|Everolimus|Everolimus was provided by the investigator in 2.5 mg, 5 mg or 10 mg tablets for daily oral administration. The starting dose of everolimus was the same as the last dose that was given in the parent study. Dose modification thereafter was done at the discretion of the Investigator based upon what is in the subject's best interest.
224219199|NCT01789281|DRUG|Sandostatin LAR Depot|Sandostatin LAR Depot was provided by Novartis or by the investigational site considering local regulations. The dose and frequency of Sandostatin LAR Intramuscular injections was the same as the last dose that was given in the parent study.
223630500|NCT06706531|PROCEDURE|Sham Dry needling|The sham dry needling group will also receive 6 sessions of sham dry needling on soleus, quadratus plantae, flexor digitorum brevis, and abductor halluces muscles for 5 minutes.Sterilized disposable stainless steel acupuncture needles of 0.25mm x 30mm will be used with depth of 20-55mm.The plantar and medial surface of the foot and ankle will be cleaned with alcohol. The sham dry needling will be performed for 5 minutes.
224219200|NCT01963819|OTHER|Endometrial biopsy|The endometrial biopsy will be done in the luteal phase (cycle day 18-22) prior to the treatment cycle (antagonist)
224219201|NCT05957718|DRUG|TKTX cream|TKTX cream was used in several studies on Tatto and laser
224317801|NCT02895100|DRUG|Placebo|Daily dosing of Placebo capsules by subject for a 12 week treatment period.
224219202|NCT03988725|DIETARY_SUPPLEMENT|Vitamin E|Vitamin E 800 IU once daily
224219203|NCT06259110|DIAGNOSTIC_TEST|Multiplex PCR|multiplex PCR is a molecular biology technique that detect multiple respiratory pathogens including both bacteria and viruses from a single respiratory tract sample
224219204|NCT00097123|DRUG|Misoprostol|
224219205|NCT05131503|OTHER|Survey Research|Non-applicable. There is no intervention. This study is descriptive research.
224219206|NCT03704779|BEHAVIORAL|Multimodal mindfulness activity program|"This program will provide the opportunity for participants to engage in in-person and online activities. The in-person activities will be held from 12:00 pm to 12:45 pm in the Georgian Physical Therapy Lab (and offered twice per week). The online activities will be available at all times during the study at convenience. There are one 40-minute in-person and four 10-minute online mindfulness activities per week (combined time of 1 hour and 20 minutes per week).~In-person activities will consist of mindfulness activities including guided imagery meditation, yoga, Tai Chi, progressive muscle relaxation, creating a Zen garden, aromatherapy, journaling, self-massage, and pet therapy. Online materials will additionally include guided and unguided meditations."
224219207|NCT06539299|PROCEDURE|Socket Preservation|After extracting a tooth, the alveolar socket is cleaned. A bone replacement material (Bio-Oss Collagen) is then placed into the socket and sutured with a collagen membrane (Mucograft-Seal). Patients will receive Antibiotics (Augmentin 875mg/125mg OR Dalacin C 300mg) and pain medication (Seractil forte 400 mg). Patients will be advised to carefully rinse with Chlorhexamed forte for one week. Sutures will be removed after two weeks.
224219208|NCT03121781|OTHER|respiratory support- interface|change interface to RAM cannula
224219209|NCT03121781|OTHER|respiratory support- interface|change interface to binasal prongs
224219210|NCT01885637|OTHER|Transition program|Accelerated transition program from oncological treatment to continuous specialized palliative care and psychological intervention at home for incurable cancer patients
224219211|NCT05796622|BEHAVIORAL|HIVST-Chatbot (HIV self-testing services with counseling provided by a Chatbot)|Promote and implement HIVST-Chatbot
224317802|NCT04319783|DRUG|Darolutamide|Darolutamide alone
224317803|NCT04319783|RADIATION|Radiotherapy|Darolutamide + Consolidation Radiotherapy
223630501|NCT06706531|PROCEDURE|Dry needling|The dry needling group will receive 6 sessions of dry needling using a standardized trigger point protocol on soleus, quadratus plantae, flexor digitorum brevis, and abductor halluces muscles for 5 minutes. Sterilized disposable stainless steel acupuncture needles of 0.25mm x 30mm will be used with depth of 20-55mm. The calf, plantar and medial surface of the foot and ankle will be cleaned with alcohol. Following insertion, needles will be manipulated bi-directionally to elicit a sensation of aching, tingling, deep pressure, heaviness or warmth. The needles will then left in situ for 5 minutes.
223630502|NCT06705049|RADIATION|MRI|On MRI, some lesions present as linear enhancement, while others exhibit nodular enhancement
224219212|NCT05796622|BEHAVIORAL|HIVST-OIC (HIV self-testing services with counseling provided by administrators)|Promote and implement HIVST-OIC
224219213|NCT03366285|DIAGNOSTIC_TEST|Attachment story completion taks (ASCT)|Bonding quality
224219214|NCT01830556|DRUG|Cetuximab|Group A:Day 1 Cetuximab 400 mg/m2 iv 120 minutes Day 8 and 15 Cetuximab 250 mg/m2 iv 60 minutes Day 1 Cisplatin 100mg/m2 or Carboplatin AUC 5 day 1-4 5-Fluorouracil 1000 mg/m2 iv 24 h Group B day 1 Cetuximab 400 mg/m2 iv 120 minutes Day 8 and 15 Cetuximab 250 mg/m2 iv 60 minutes day 1 Paclitaxel 175 mg/m2 day 1 Carboplatin AUC 5 treatment for 6 cycles thereafter day 1 Cetuximab 500 mg/m2 every second week treatment until progress or unacceptable toxicity
224219215|NCT06263309|DIAGNOSTIC_TEST|Femoral neck shortening measurement|We examine femoral neck shortening in patients with femoral neck fractures.
224219216|NCT03639272|PROCEDURE|open reduction and internal fixation (ORIF).|Depending on the fracture location, a single anteromedial or anterolateral approach was carried out. The fracture site was cleaned to make it visible, allowing anatomical reduction. Subsequently, fixation of provisional fragments was achieved using temporary Kirschner wires under radiographic guidance. Having obtained satisfactory reduction as seen with the radiographic intensifier, definitive fixation of the main bone fragments was carried out using two or more 3.5 mm titanium cannulated screws or 4.0 mm lag screws, placed anteriorly to posteriorly. Fractures complicated by severe comminution necessitated 3.5 mm cortical screws in order to avoid shortening, translation or angulation of the fragments.
224219217|NCT04767490|PROCEDURE|Standard Duodenal Switch|
224219218|NCT04767490|PROCEDURE|Single Anastomosis Duodenal Switch|
224317804|NCT00593151|OTHER|Locteron (controlled-release interferon alpha 2b)|biological+device, bi-weekly subcutaneous injections for 4-12 weeks, 160 mcg per injection
224317805|NCT00593151|BIOLOGICAL|pegylated IFNa2b|biological, weekly subcutaneous injections for 4-12 weeks, 1.5 mcg/kg
224317806|NCT06040775|DEVICE|Theta Burst Transcranial magnetic Stimulation using real MCF-B65 coil|"Site of stimulation will be predetermined at Dorsolateral prefrontal cortex of non-dominant side using the BeamF3 method.1 burst will be - 3 pulses at 50 Hz, burst will be set at 5Hz i.e. interburst interval 200ms .~At100% of resting motor threshold of dominant side - 5 trains (each 40sec on and 20 sec off) will be given at each session with a pause of 1 minute in between 2 trains Standard therapy with Applied Behavior Analysis and sensory integration would continue"
224317807|NCT06040775|DEVICE|Sham magnetic stimulation using sham MCF-B65 coil|"Similar set parameters using a sham coil which simulates sound and tactile effect of real coil but no electromagnetic induction is produced.~Standard therapy with Applied Behavior Analysis and sensory integration would continue"
224317808|NCT05119153|DIETARY_SUPPLEMENT|Placebo Comparator|Placebo designed to mimic coffee color.
224317809|NCT05119153|DIETARY_SUPPLEMENT|Light Roasted Coffee|12 oz light roast coffee
223630503|NCT06706388|DRUG|nL-ATN1-002|Personalized antisense oligonucleotide
223630504|NCT06705244|PROCEDURE|Trans-nasal sphenopalatine nerve block|"The patient was placed supine with shoulders slightly elevated to flex the neck and extend the head.~Then anterior nares were inspected for polyps, tumors, or significant septal deviation.~Long cotton-tipped applicators saturated with lidocaine 2% were inserted into each naris, until properly seated in the posterior nasopharynx.~These were left in place for 10 minutes to lubricate and anesthetize the mucous membrane, making the procedure more comfortable.~Then a mixture of 3 mL of 2 mL lidocaine 2% plus 1 mL dexamethasone 4 mg were injected through the applicators in the sphenopalatine area in each nostril.~Then the patient was positioned sitting and pain assessments were recorded."
223630505|NCT06705244|PROCEDURE|Greater and lesser occipital nerve block|"The back of the head was sterilized with an antiseptic solution and the landmarks at the base of the skull were identified while the patient in the prone position.~The landmarks were located on the medial third of a line drawn from occipital protuberance to mastoid process. At this level, the greater and lesser occipital nerves lie along the superior nuchal line medial to the occipital artery, halfway between the occipital protuberance and mastoid process.~Under Ultrasound guidance, the skin was infiltrated with 1-2 mL of lidocaine 2%, using a 25-gauge needle. Then the block was performed in this area with a mixture of 3 mL of 2 mL lidocaine 2% plus 1 mL dexamethasone 4 mg to block greater and lesser occipital nerves. Then the procedure was repeated on the other side.~After the procedure, the presence of bilateral occipital numbness was confirmed after 30 minutes. The patient was then positioned sitting and pain scoring was assessed."
223630506|NCT06705556|PROCEDURE|Active cycle of breathing technique, incentive spirometer, percussion, 3-minute of walking|"The intervention group:~patients were asked to perform Active cycle of breathing technique as add on to routine chest physical therapy such as Incentive spirometer, percussion, 3-minute of walking 3 days before surgery and five days postoperative.~* Incentive spirometry, 3 sessions per day, 10 repetitions~* Percussions, 3 sessions per day, 20 repetitions~* 3-minutes walking, 2 sessions per day~* ACBT, 3 sessions per day the following were included postoperatively:~* Nebulization, 3 sessions per day~* ACBT, 3 sessions per day"
223630507|NCT06705556|PROCEDURE|incentive spirometer, percussion, 3-minute of walking|"The control group The routine CPT was performed 3 days before surgery at the preoperative bay and 5 days after surgery in the ICU with 3 sessions each day.~Preoperative chest physical therapy sessions were followed as:~* Incentive spirometry, 3 sessions per day, 10 repetitions.~* Percussions, 3 sessions per day, 20 repetitions.~* 3-minutes walking, 2 sessions per day The preoperative chest physiotherapy treatment plan was continued after CABG surgery. In addition to these, the following were included postoperatively:~* Nebulization, 3 sessions per day~* 3-minutes walking, 2 sessions per day"
224219219|NCT02485496|DEVICE|Endovascular abdominal repair|
224219220|NCT00004843|PROCEDURE|parathyroidectomy|Standard parathyroidectomy with a bilateral approach
223630508|NCT06706037|OTHER|Exercise|A 6 week reformer pilates exercise program
223630509|NCT05262075|OTHER|Online Mindfulness Resiliency Program|An approximate 20 minute online mindfulness resiliency program offered 3/wk x 4 weeks.
224219221|NCT00004843|OTHER|Observation|Usual care
224219222|NCT06546683|OTHER|Short-Chain Fatty Acids|Colon-delivery capsules of Short-Chain Fatty Acids will be administered in a ratio of 60:20:20, thus 150 mmol of acetate, 50 mmol of propionate and 50 mmol of butyrate equivalent to 20g of fibers, once daily, one week
224219223|NCT06546683|OTHER|Placebo|Microcrystalline Cellulose will be used as placebo, one daily, one week
223630510|NCT03082690|DRUG|DuoGel|1% IQP-0528 in gel formulation
223630511|NCT02914158|DRUG|Goserelin|
223630512|NCT02914158|DRUG|Tamoxifen|
223630513|NCT02914158|DRUG|Aromatase Inhibitors|
223630514|NCT02914158|DRUG|Leuprolide|
224219224|NCT00198081|DRUG|COX-2 Inhibitor 6-8 weeks prior to surgery|400 mg BID 6-8 weeks prior to surgery
224219225|NCT00198081|DRUG|COX-2 Inhibitor for 6 months prior to follow-up EUS or ERCP|400 mg BID for 6 months prior to follow-up EUS or ERCP
224219226|NCT05195554|OTHER|Psycho-educational intervention|Psycho-educational intervention will consist of between 10 and 12 people led by two professionals.
224219227|NCT03057288|DEVICE|fiducial markers placement|The main objective of this study is to evaluate the feasibility of fiducial markers placement under EUS guidance for patients with esophageal or rectal cancer with an indication of radiotherapy
224219228|NCT03679845|DRUG|Sarilumab|Sarilumab is an IL-6 monoclonal antibody that has shown to be potentially important in the creation of sclerosis in SSc.
224219229|NCT04630366|DRUG|NST-1024|NST-1024
224219230|NCT04630366|DRUG|Placebo|Matching placebo to NST-1024
224219231|NCT03060031|DRUG|Oxytocin|Oxytocin intranasal administration, 40 IU, 5 puffs per nostril at 4 IU per puff delivered approximately 45 minutes prior to pain tasks.
224219232|NCT03060031|DRUG|Placebo|Placebo intranasal administration, 5 puffs per nostril delivered approximately 45 minutes prior to pain tasks
224219233|NCT02606682|DRUG|NPT200-11|Single doses of NPT200-11capsules, orally administered
224219234|NCT02606682|DRUG|Placebo|Single doses of microcrystalline cellulose capsules, orally administered
224219235|NCT04979065|DIETARY_SUPPLEMENT|Probiotics, Vitamin D|Combination of two supplement that given separately
224219236|NCT04979065|OTHER|Placebo|Placebo with inactive ingredient
224219237|NCT04413669|PROCEDURE|white light bronchoscopy & autofluorescence bronchoscopy|White light bronchoscopy and autofluorescence bronchoscopy were carried out，and Take a biopsy for abnormal bronchial mucosa
224219238|NCT04953481|OTHER|survey|The general information, home care status and functional status of ALS patients and family caregivers were collected.
224219239|NCT06249217|BEHAVIORAL|Good Nights Sleep Program|The Good Nights Sleep Program arm adapts established evidence-based motivational practices to change child and family sleep environments and sleep hygiene practices. At Week 0, participants will provide a comprehensive assessment of sleep environment and sleep hygiene practices and will be issued a Fitbit watch to wear for the duration of the study. At Week 2, participants will receive information about the benefits of good sleep, feedback about their sleep environment and sleep hygiene practices based on the Week 0 assessment data to implement at home, and sleep environment modification items based on participant-identified areas of need (e.g., a fan, sound machine, bedding). At Week 4, families in the Good Nights Sleep Program arm will provide post-intervention assessment data and feedback on the intervention and families in the Waitlist-Control arm can elect to receive the intervention if they choose to.
223630515|NCT05480449|BIOLOGICAL|Autologous Humanized CD19-Directed Chimeric Antigen Receptor T-Cells (huCART19)|The investigational agent in this protocol is humanized CART19 cells (huCART19). Autologous T cells will be engineered to express an extracellular single chain antibody (scFv) with specificity for CD19. This will be expected to redirect specificity of the transduced T cells for cells that express CD19, a molecule that is restricted in expression on the surface of the malignant cells and on normal B cells.
223630516|NCT03307109|OTHER|Quality of life|Patients will complete two EQ-5D-5L and EQ-5D-3L quality of life questionnaires and will complete an analog visual scale during each of their follow-up visits to the Infectious and Tropical Diseases Department of Croix-Rousse hospital. No visits will be added to complete the questionnaires.
224219240|NCT00738010|DEVICE|Kneehab|Program of NMES 3 times per day, five days per week for 12 weeks.
223630517|NCT06938048|OTHER|short stretch bendage (Lohmann e Raucher)|extensibility between 10% to 100% of the lenght
223630518|NCT06938048|OTHER|high stretch bandage (Coban)|extensibility above 100% of the lenght
223630519|NCT02017197|DRUG|Marevan®|Branded warfarin sodium tablets (manufacturer União Química Farmacêutica Nacional S/A, Brazil) by mouth; dose adjusted according to INR and medical judgement.
223630520|NCT02017197|DRUG|generic warfarin #1|Generic warfarin sodium tablets, manufacturer (União Química Farmacêutica Nacional S/A, Brazil), by mouth; dose adjusted according to INR and medical judgement.
223764178|NCT06418386|PROCEDURE|manual sodium hypochlorite IC|"* adjacent rubber dam will be disinfected with tincture of iodine solution~* . All carious tissue will be removed by hight speed hand piece~* distal cannel of mandibular primary molars and palatal cannel of maxillary primary molars will be chosen for sampling procedure.~* A sterile broach will be inserted to obtain root cannel content then sterile paper point inserted to root canal and will be left for 1 min 19 The paper point will be removed with sterilized tweezer which will immediately transferred to tube containing transport medium (eppendrof of containing 200 μl nutrient broth medium).~* using manual file and irrigation with 1% sodium hypochlorite~* Post irrigation sample and pre-preparation sample will be transferred to microbiological laboratory Canals will be filed with obturation material(Metapex)then crown will be restored with glass inomar and stainless steel crown"
224219241|NCT00738010|DEVICE|Poli-Stim|Poli-Stim is standard NMES which the patients used for 20 minutes, 3 times per day, 5 days per week for 12 weeks.
224219242|NCT00738010|BEHAVIORAL|Control|Voluntary quadriceps muscle contractions.
224317810|NCT05119153|DIETARY_SUPPLEMENT|Medium Roasted Coffee|12 oz medium roast coffee
224317811|NCT05119153|DIETARY_SUPPLEMENT|Dark Roasted Coffee|12 oz dark roast coffee
224219243|NCT01384864|DRUG|proflavine|2-6 ml of 0.01% proflavine
224219244|NCT05012085|OTHER|Investigation of Global Interest in Global Surgery|"The investigators searched the terms global surgery and global health on Google Trends (Google Inc., CA, USA) from January 2004 to May 2021. The investigators identified time trends and compared the two search terms using SPSS v26 (IBM, WA, USA) to run summary descriptive analyses and Wilcoxon rank-sum tests."
224219245|NCT00112515|DRUG|modafinil|
224219246|NCT00112515|PROCEDURE|cognitive assessment|
224219247|NCT00112515|PROCEDURE|psychosocial assessment and care|
224219248|NCT00112515|PROCEDURE|quality-of-life assessment|
224219249|NCT04336488|DRUG|Matrix Metalloproteinase Inhibitors (Orochem)|topical application of MMP inhibitors for 3 weeks to evaluate its effectiveness in treating oral lichen planus
224317812|NCT01816659|DRUG|Metformin ER|500 mg by mouth once daily, beginning the day after colonoscopy for one week, and then escalation to 1000 mg/day. The duration of the trial will be from the preoperative endoscopy till the surgery, and should be not less than 10 days and not more than 30 days.
224317813|NCT02547090|PROCEDURE|The use of two attending surgeons during posterior spinal fusion|Patients in the experimental group received posterior spinal fusion with two attending surgeons. Patients in the control group received posterior spinal fusion with one attending surgeon and one first assist, which could be a resident, PA, or nurse.
224317814|NCT00339144|DRUG|Dasatinib|tablets, Oral, 100 mg, once daily for 4 weeks
224317815|NCT00339144|DRUG|Dasatinib|tablets, Oral, 150 mg, once daily, 4 weeks
224317816|NCT00339144|DRUG|Dasatinib|tablets, Oral, 200 mg, once daily for 4 weeks
224317817|NCT00004378|PROCEDURE|Stem Cell Transplantation|
224317818|NCT06236841|DRUG|XH-S004 tablet|XH-S004 tablets will be administered orally as per assigned treatment regimen on schedualed days.
224317819|NCT06236841|DRUG|XH-S004 placebo tablet|XH-S004 placebo tablet (matched) will be administered orally as per assigned treatment regimen on schedualed days.
224317820|NCT00555841|DRUG|ALC and Placebo|ALC and Placebo
223630521|NCT02017197|DRUG|generic warfarin #2|Generic warfarin sodium tablets, manufacturer (Laboratório Teuto Brasileiro S/A, Brazil), by mouth; dose adjusted according to INR and medical judgement.
223630522|NCT03593746|OTHER|Physical training|Type 2 diabetic patients will be subjected to different types of physical training (high intensity interval training or combined training).
223630523|NCT03593746|OTHER|Light-Emitting Diode (LED) therapy|Type 2 diabetic patients will be subjected to Light-Emitting Diode (LED) therapy (active or sham).
223630524|NCT03059134|DRUG|Mirabegron 25mg|We compared the therapeutic effects and adverse events (AEs) in overactive bladder (OAB) patients receiving different combination of mirabegron and solifenacin.
223630525|NCT02299596|OTHER|Physical activity|The intervention will take place both pre- and postoperatively. During the hospital stay both groups will be treated in the same manner.
223630526|NCT04948216|OTHER|No intervention|No intervention
223630527|NCT02994108|BEHAVIORAL|txt2protect|Text messages sharing HIV/STI prevention information with a focus on HPV infection and vaccination.
223630528|NCT02994108|BEHAVIORAL|Sexual Health Control|Text messages sharing HIV/STI prevention and healthy relationship building information, including information about HPV infection and vaccination.
223630529|NCT00000827|DRUG|Anti-HIV Immune Serum Globulin (Human)|
223630530|NCT00170586|DEVICE|Underglove coating (skin barrier)|
223630531|NCT03889808|DIAGNOSTIC_TEST|Determination of serum anti-toxin Abs for C. difficile|
223630532|NCT02558959|DRUG|Irinotecan|
223630533|NCT02558959|DRUG|Capecitabine|
223630534|NCT02081677|DEVICE|ACUVUE 2|worn in a daily wear modality; lenses will be replaced after 2 weeks
223630535|NCT02081677|DEVICE|Prototype E1|worn in a daily wear modality; lenses will be replaced after 2 weeks
223630536|NCT02081677|DEVICE|Prototype E2|worn in a daily wear modality; lenses will be replaced after 2 weeks
223630537|NCT02081677|DEVICE|Prototype E3|worn in a daily wear modality; lenses will be replaced after 2 weeks
223630538|NCT05602246|PROCEDURE|Transobturator cystocele repair|Novel transvaginal surgical reconstruction of anterior compartment pelvic organ prolapse.
223630539|NCT05602246|PROCEDURE|Anterior colporrhaphy|The traditional transvaginal surgery for cystocele treatment used as a comparator in the study
224219250|NCT04336488|DRUG|Kenacort A,|topical application of both drugs 3 times daily for 3 weeks as an active control
224219251|NCT01416207|DRUG|Avonex|4 weekly injections of Avonex (IM)
224219252|NCT00973856|OTHER|PURELL VF481|One (1) pump of test product (approximately 1.5ml) is applied to a wooden applicator and gently rubbed into the wart, then covered with a latex free adhesive bandage (it is not necessary to wait until dry) each night before bed
224219253|NCT00973856|OTHER|Placebo Solution|One (1) pump of product (approximately 1.5ml) is applied to a wooden applicator and gently rubbed into the wart, then covered with a latex free adhesive bandage (it is not necessary to wait until dry) each night before bed
224317821|NCT06393517|DRUG|PF-06954522 IR (Formulation 1)|Participants to receive a single dose (Dose Level 1 and 2) of PF-06954522 Formulation 1 by mouth
224317822|NCT06393517|DRUG|PF-06954522 MR (Formulation 2)|Participants to receive a single dose (Dose Level 1 and 2) of PF-06954522 Formulation 2 by mouth.
224317823|NCT06393517|DRUG|PF-06954522 MR (Formulation 3)|Participants to receive a single dose (Dose Level 1 and 2) of PF-06954522 Formulation 3 by mouth
223630540|NCT01097668|BIOLOGICAL|ATX-MS-1467|Disease specific immune modulating treatment for multiple sclerosis
224219254|NCT01652261|DRUG|ABVD + FDG-PET/CT Scan treatment adaptation|
224317824|NCT00912613|OTHER|ICU Diary|ICU Diary containing daily information of patients condition and treatment with appropriate photographs
224317825|NCT06398119|OTHER|Traditional Treatment Program|Traditional Treatment Program for improving hand function
224219255|NCT01652261|DRUG|BEACOPPesc|
224219256|NCT01353105|PROCEDURE|Ex vivo lung transplantation|Evaluation and reconditioning of lungs following lung transplantation
224219257|NCT03956667|OTHER|Live Music|Musicians from Cascade Music will provide recruited participants in the experimental arm with high-quality calming, distracting music during their Emergency Department procedure.
224317826|NCT06398119|OTHER|Virtual Reality Program|Virtual Reality Program for improving hand function
224317827|NCT01890434|DRUG|Gadobutrol (Gadavist, Gadovist, BAY86-4875)|Participants received gadobutrol at the total approved standard dose of 0.1 millimole per kilogram body weight (mmol/kg BW) in 2 separate bolus injections: 0.05 mmol/kg BW at peak pharmacologic stress and 0.05 mmol/kg BW at rest via a power injector.
224317828|NCT02365116|BEHAVIORAL|Peer mentorship|Patients who are working with a peer specialist will have their sessions audio taped and reviewed by research staff for training purposes and to ensure that peer specialists are following protocol.
224317829|NCT02365116|BEHAVIORAL|Enhanced Usual Care|The enhancement to usual care will occur at the 3 and 6 month follow-up assessments, where participants will be assessed to determine whether they require any additional referral information for follow-up care. If referral information is indicated, the patient will be provided a list of mental health treatment providers in their area.
224317830|NCT04900519|BIOLOGICAL|STI-6643|Anti-CD47 human monoclonal antibody
223630541|NCT04432935|DIETARY_SUPPLEMENT|Bovine Lactoferrin|Lactoferrin is a nutritional supplement which was first discovered in bovine milk which was later isolated in human milk as the second most abundant protein; with high levels found in colostrum. The use of bovine Lactoferrin in children is generally recognized as safe by the US Food and Drug Administration.
223630542|NCT04432935|OTHER|Placebo Glucon D|This group will be given 100mg Glucon-D (99.4% glucose) which will be similar in shape, color to the bLF.
223630543|NCT03481088|PROCEDURE|Functional appliance therapy|"All records, including MRI scans will be collected at three stages and will be traced for various angular and linear measurements to document the alterations within the condyle glenoid fossa complex.~1. Stage- I (pre-treatment),~2. Stage- II (after pre-functional therapy)~3. Stage-III (After 6-8 months of functional appliance therapy that is after correction to Class I molar relation)"
223630544|NCT04521790|OTHER|support treatment, cardiac medical treatment, aetiology-specific treatment, device implant, arrhythmia ablation|Treatment will be patient-tailored, integrating international guidelines recommendation and the experience of the center where enrollment takes place.
223630545|NCT02088008|DRUG|cinidipine, valsartan|
223630546|NCT00278343|DRUG|cediranib maleate|30mg given PO, daily
223630547|NCT00278343|OTHER|laboratory biomarker analysis|Correlative studies
223630548|NCT00000385|DRUG|Lithium|Lithium 600 mg to 2700 mg per day
223630549|NCT00000385|DRUG|Placebo|Matching placebo
223630550|NCT05165771|DRUG|GS-5718|Tablets administered orally
223630551|NCT05165771|DRUG|GS-5718|Tablets administered orally
223630552|NCT05165771|DRUG|Placebo to match GS-5718|Tablets administered orally
223630553|NCT05165771|DRUG|Tofacitinib 5 mg|Tablets administered orally
223630554|NCT05165771|DRUG|Placebo to match Tofacitinib|Tablets administered orally
223630555|NCT00796939|DEVICE|Green light mask|Participants will receive approximately 10,000 lux from green light-emitting diodes.
223630556|NCT00796939|DEVICE|Red Light Mask|Participants will receive approximately 0.5 lux from white light-emitting diodes covered by a red gel.
223630557|NCT00646165|DRUG|Forodesine|
224219258|NCT02688101|DRUG|DpC|iron chelator
224219259|NCT00913588|DRUG|Fluoxetine HCl 20 mg Capsules Under Fasting Conditions (Geneva Pharmaceutical, Inc.)|
224219260|NCT00913588|DRUG|Fluoxetine HCl 20 mg Capsules Under Fed Conditions (Geneva Pharmaceutical, Inc.)|
224219261|NCT00913588|DRUG|Prozac Fluoxetine HCl 20 mg Capsules Under Fed Conditions (Dista)|
224317831|NCT00055042|DRUG|Vitamin E|
224317832|NCT01751737|PROCEDURE|Prostate Cancer Imaging|After imaging is completed, subjects will be scheduled for a prostate biopsy performed as part of their clinical care. If the imaging has identified suspicious lesions in the prostate, these regions will be made visible for the Urologist to be targeted for additional biopsies. These additional biopsies will undergo histological evaluation and further metabolomic testing to better understand metabolic differences between various grades of prostate cancer lesions.
224219262|NCT02746705|DEVICE|Transcranial Direct Current Stimulation (tDCS)|tDCS is a therapeutic development that utilizes low amplitude direct currents to induce changes in cortical excitability. tDCS is expected to produce neuronal polarization of less than one mV (millivolt) 9. tDCS produces relatively diffuse current flow, as demonstrated by imaging studies and computational models
224219263|NCT02746705|DEVICE|Sham Transcranial Direct Current Stimulation|During a sham session, the device is programmed to ramp up to the desired intensity (target 2.0 mA) and ramp down for the initial 60 seconds, with no current delivery during the session, and then again at the end of the session. These brief periods of stimulation serve to mimic the effects of a true stimulation session.
223630558|NCT01213888|DRUG|Trientine Hydrochloride|All participating subjects will all receive PRP (pan-retinal photocoagulation) according to present standards of care; however, subjects randomized the intervention group (trientine hydrochloride) will be on a 10-day course of oral Trientine at 1500mg administered for 7-days prior to and 3 days after the PRP sessions.
223630559|NCT01213888|DRUG|Oral placebo capsules|All participating subjects will all receive PRP (pan-retinal photocoagulation) according to present standards of care; however, subjects randomized the placebo group will be on a 10-day course of oral placebo capsules at 1500mg administered for 7-days prior to and 3 days after the PRP sessions
224219264|NCT02746705|BEHAVIORAL|Cognitive Training Program|
224219265|NCT00646087|DRUG|Ketamine|0.5 mg/kg of ketamine every other day for 12 days (days 1, 3, 5, 7, 9, 11)
224219266|NCT00646087|DRUG|Ketamine/Saline|0.5 mg/kg of ketamine on days 1 and 7, placebo (saline) on days 3, 5, 9, 11
224219267|NCT06221345|DRUG|Systane HYDRATION® Preservative-Free Lubricant Eye Drops|The HPG/HA group will receive Systane HYDRATION® Preservative-Free Lubricant Eye Drops and standard of care, i.e., prednisolone acetate (Pred forte®) and levofloxacin (Cravit®), at the dosage of 1-2 drops 4 times daily for 3 weeks from Weeks 1 to 4 post-op
224219268|NCT06221345|DRUG|Optive Fusion® Lubricant Eye Drops (Unit Dose)|The CMC/HA group will receive Optive Fusion® Lubricant Eye Drops (Unit Dose) and standard of care, i.e., prednisolone acetate (Pred forte®) and levofloxacin (Cravit®), at the dosage of 1-2 drops 4 times daily for 3 weeks from Weeks 1 to 4 post-op
224219269|NCT04267016|DIAGNOSTIC_TEST|TruGraf Testing - Peripheral blood gene expression profiling|5 mL collection PAXgene blood sample
224219270|NCT00479401|DRUG|Pramipexol Extended Release|
224219271|NCT00479401|DRUG|Pramipexol Immediate Release|
224219272|NCT00479401|DRUG|Placebo|
224219273|NCT03545737|OTHER|Measurement|The distances between the midpoint of the thyroid cartilage to suprasternal notch base on body surface measurement add the distance between suprasternal notch to carina of trachea according to chest CT
224219274|NCT03545737|OTHER|Formula|The formula base on patient's height as a guide for the intubation of a Left-sided Double-lumen tube
224219275|NCT06543160|OTHER|Immediate SSC and early breastfeeding during CS|Upon birth, the neonate is promptly placed prone on the mother's chest, with their head turned to one side for optimal skin contact. The drying process begins within 5 seconds and is completed within 20 to 30 seconds while the neonate remains on the mother's chest. Delayed cord clamping is practiced, with the cord clamped approximately 1-3 minutes after birth. Breastfeeding cues such as tongue movements or head turning are monitored, and the obstetric nurse assists the mother in initiating breastfeeding as soon as possible. SSC continues throughout the cesarean procedure, and upon completion, the newborn is temporarily separated from the mother for safety during transfer to the surgical cart. SSC is resumed immediately post-transfer and continues for a cumulative duration of at least 90 minutes. The neonate's skin color, breathing, and feeding responses are continuously observed.
224219276|NCT06543160|OTHER|Delayed SSC and breastfeeding after CS|The neonate is dried within 20-30 seconds after birth, the cord is clamped after 1-3 minutes, and then the neonate is sent to the ward to wait for the mother to complete the surgery. Immediate SSC is initiated within one hour after birth and maintained with the mother for at least 90 minutes post-surgery, during which the neonate's skin color and breathing are continuously monitored. The obstetric nurse supports the mother in initiating breastfeeding at the earliest opportunity.
224219277|NCT06543160|OTHER|Routine newborn care|Newborn eye care, vitamin K1 administration, immunizations, weighing, and standard examinations are conducted before the neonate is transferred to the ward.
224219278|NCT04998773|DEVICE|Theta Burst Transcranial Magnetic Bilateral Stimulation|TMS protocol of 22 sessions of bilateral active 1800 pulses.
224219279|NCT04998773|DEVICE|Theta Burst Transcranial Magnetic Sham Stimulation|TMS protocol of 22 sessions of sham bilateral 1800 pulses.
224219280|NCT04998773|DEVICE|Theta Burst Transcranial Magnetic Unilateral Stimulation|TMS protocol of 22 sessions of left active 1800 pulses and right sham 1800 pulses.
224219281|NCT02777931|DRUG|NFC-1|NFC-1 is supplied as size 2 hard gelatin capsules.
224219282|NCT02777931|DRUG|Placebo|Matching placebo capsules
224219283|NCT01004120|DIETARY_SUPPLEMENT|Bimuno|5.5g daily intake
223630560|NCT05632159|DRUG|Mg sulphate|Induction of anesthesia will be done by injecting fentanyl 2 μg/kg, propofol1.5-2.5 mg/kg and atracurium 0.5 mg/kg for muscle relaxation. With extra administration of intraoperative Magnesium sulphate 30 mg /kg as loading dose over 10 min then 10 mg /kg/ has maintenance dose
224219284|NCT01004120|DIETARY_SUPPLEMENT|Maltodextrin|5.5g daily intake
224219285|NCT00368238|DRUG|Recombinant human erythropoietin alfa (drug)|
223630561|NCT05632159|DRUG|conventional anaesthesia|Induction of anesthesia will be done by injecting fentanyl 2 μg/kg, propofol1.5-2.5 mg/kg and atracurium 0.5 mg/kg for muscle relaxation.
223630562|NCT03572517|PROCEDURE|Subarachnoid block|Balanced general anesthesia (Induction of anesthesia: Propofol, fentanyl and rocuronium. Maintenance: Desflurane /remifentanil) associated with subarachnoid block (bupivacaine and morphine)
223630563|NCT03572517|PROCEDURE|Spinal morphine|Balanced general anesthesia (Induction of anesthesia: Propofol, fentanyl and rocuronium. Maintenance: Desflurane /remifentanil) and spinal analgesia with morphine
223630564|NCT00257413|PROCEDURE|Transplantation of autologous endothelial progenitor cells|
224219286|NCT00368238|DRUG|Aspirin (drug)|
224219287|NCT00368238|DRUG|Clopidogrel (drug)|
224219288|NCT02759211|OTHER|Backwards Walking|The Backwards Walking Group will perform backwards walking for the entire treatment intervention.
224219289|NCT02759211|OTHER|Forwards Walking|The Forwards Walking Group will perform forwards walking for the entire treatment intervention.
223630565|NCT02821234|OTHER|MRI|
223630566|NCT01556022|DEVICE|ADRCs processed by the Celution System|Subjects will undergo liposuction under anesthesia. Lipoaspirate will be processed in the Celution System to isolate and concentrate ADRCs. When randomized to ADRCs, intramyocardial injections of ADRCs will be administered via the MYOSTAR injection catheter.
223630567|NCT01556022|DEVICE|Placebo Comparator: Lactated Ringer's and Subject's Blood|Subjects will undergo liposuction under anesthesia. Lipoaspirate will be processed in the Celution System to isolate and concentrate ADRCs. When randomized to Placebo, intramyocardial injections of Placebo will be administered via the MYOSTAR injection catheter.
223630568|NCT02759614|DRUG|Bevacizumab|Bevacizumab15mg/kg by intravenous drip infusion on day 1 of a 21-day (within 3 days) cycle and Erlotinib orally once daily at 150mg/day
223630569|NCT02759614|DRUG|Erlotinib|Erlotinib 150mg, orally once a day
223630570|NCT05834634|DEVICE|Ultrasound|The patients and controls will be scanned at the Neurophysiology unit of the Department of Neurology, Neurology, psychiatry and Neurosurgery hospital, Assiut university hospital. The acquisition of ultrasound images was performed using a Philips HD11XE imaging system with an L12-8 linear array probe. Cross-sectional area (CSA) of the right and left Vagus nerves in each subject, perimeter, echogenicity, and fascicular structure will be assessed and measured by tracing the nerve just inside its hyperechoic rim. The nerve will be seen on ultrasound B-mode near the bifurcation of the carotid artery, dorsal to the internal and common carotid arteries, as a structure that is hypoechogenic in the centre and more hyperechogenic on the periphery (24, 25). Both the carotid artery and the internal jugular vein served as anatomical landmarks (25). Two separate CSA measurements, with the probe repositioned for each measurement, will be taken and they will be averaged.
223630571|NCT04494841|DEVICE|Duotherm VibraCool Back Device|Low back plate belt with mechanicothermal and pressure intervention options.
223630572|NCT00202280|DRUG|Folic Acid 5mg, Vitamin B12 0.4mg and B6 50mg|
223630573|NCT00135031|DRUG|Bifidobacterium infantis 35624|
223630574|NCT01703195|PROCEDURE|Magnetic Resonance Imaging (MRI)|Magnetic Resonance Imaging (MRI) obtained pre-treatment and 4-6 weeks post-treatment.
224219290|NCT05717088|OTHER|24% Sucrose solution|"Infants will either receive oral sucrose (24%) 2 minutes before the procedure LUS scan. The dose will be 0.2 mL, 0.5 mL and 1 mL for infants with current weight \< 1500g, 1500-2500g, and \> 2500g respectively."
224219291|NCT03918395|DIETARY_SUPPLEMENT|Placebo beverage|A placebo beverage will be consumed both post-exercise and pre-bed
223630575|NCT01703195|PROCEDURE|Diffusion Weighted Magnetic Resonance Imaging (DWMR)|Diffusion Weighted Magnetic Resonance Imaging (DWMR) obtained pre-treatment and 4-6 weeks post-treatment.
223630576|NCT02783534|DEVICE|Verum acupuncture|"Participants allocated to VA group will receive traditional acupuncture treatment on the Guanyuan(RN 4), bilateral Sanyinjiao(SP 6), bilateral Zigong(EX-CA1), bilateral Xuehai(SP 10). Additional points will be chosen according to TCM syndrome differentiation constitution of patients. If patients with deficient syndrome, bilateral Zusanli (ST 36) will be included. If patients with sufficiency syndrome, bilateral Diji (SP 8) will be included. The NO.16 special type of acupuncture needle (0.30 x 30 mm) produced by German asia-med company will be applied.The needles will be inserted into the skin of acupuncture points and manipulated manually by using the techniques such as lifting, thrusting, and twirling, until the internal compound sensation known as deqi."
223630577|NCT02783534|DEVICE|Sham acupuncture|We use a non-insertive sham control produced by Asia-med Company in Germany-the streitberger placebo-needle. Sham points are described as follows: 1) 5 inch lateral to the seventh thoracic spine; 2) 5 inch lateral to the eighth thoracic spine; 3) 5 inch lateral to the ninth thoracic spine; and 4) 5 inch lateral to the tenth thoracic spine.
223630578|NCT02783534|BEHAVIORAL|Usual care|Patients in usual care group will not receive acupuncture treatment but enhance usual care by providing them with detailed information via propaganda booklets or the internet in the form of health education.
223630579|NCT05260736|PROCEDURE|Infraclavicular brachial plexus block|Named after the anatomical site; patients will be applied infraclavicular brachial plexus block with costoclavicular lateral, costoclavicular medial or lateral sagittal approach.
224219292|NCT03918395|DIETARY_SUPPLEMENT|Protein-polyphenol beverage|A protein-polyphenol beverage will be consumed both post-exercise and pre-bed
224219293|NCT01493726|DRUG|ALKS 9072, Low dose|IM injection, given monthly
224219294|NCT01493726|DRUG|ALKS 9072, Med dose|IM injection, given monthly
224219295|NCT01493726|DRUG|ALKS 9072, High dose|IM injection, given monthly
224219296|NCT01493726|DRUG|Placebo|Dosed matched placebo IM injection, given monthly
224219297|NCT01430104|DRUG|Teriparatide|Administered subcutaneously during the Treatment Period
224219298|NCT01430104|DRUG|Aspara-CA 600 mg|Administered orally throughout the study
224219299|NCT01430104|DRUG|Alfarol 1.0 µg|Administered orally throughout the study
224219300|NCT02124746|DRUG|Momelotinib|Momelotinib tablets administered orally once daily
223630580|NCT00551317|DRUG|Darapladib (SB480848)|
223630581|NCT01870349|PROCEDURE|Gingival Crevicular Fluid Sampling|Gingival crevicular fluids will be sampled from single implant restorations that have been in function for at least 6 months
223630582|NCT03938233|BEHAVIORAL|A low-cost DSME program and scalable delivery model for roll-out within the Thai primary care system|The intervention will be based on behaviour-change and social support theories, delivered in monthly group meetings by lay health workers or nurses, and aided by a suite of short films to introduce key topics and stimulate discussion.
223630583|NCT04312178|OTHER|cash incentive|cash incentive (20€ gift card)
223630584|NCT04312178|OTHER|no intervention|no intervention
224219301|NCT05941468|DEVICE|AR Dental Care Training System|AR dental care training system is the first training system used in tooth clean skill learning (including Bass method of brushing and inter-dental toothbrush brushing technique) the world, it has been used to training elementary school children and dental hygiene student. And we are the first study to use this system to learn oral cleaning skill in hospital for patient with T2DM.
224219302|NCT03180346|DEVICE|PICO|Single Use Negative Pressure Dressing
224219303|NCT03180346|DEVICE|Aquacel|Occlusive surgical dressing infused with ionized silver
224219304|NCT02226939|DRUG|BILN 2061 ZW|
224219305|NCT02226939|DRUG|Placebo|
224219306|NCT03039374|OTHER|Magnetic resonance imaging|The extent of obstetric anal sphincter injury will be evaluated using MRI, endoanal ultrasound and anal manometry
223630585|NCT04312178|OTHER|return vaginal self-swab kit in person|hand-delivered to a health care professional to encourage discussion of cervical cancer prevention
223630586|NCT04484077|BIOLOGICAL|hCT-MSC|2x10\^6 hCT-MSC/kg suspended in plasmalyte-A, 5% HSA, and residual DMSO/dextran administered intravenously over 30-60 minutes via syringe pump
223630587|NCT03429335|BEHAVIORAL|Teaching session|The cardiology nurse (RN) will have an hour long one-on-one teaching session prior to their pediatric cardiology clinic visit. The RN will go over the youth's cardiac history including the chronic heart disease diagnoses, names and dates of cardiac surgical procedures and cardiac catheterizations, and current cardiac medications and doses. She will also discuss transitioning from pediatric to adult care and healthy lifestyle choices.
223630588|NCT03429335|BEHAVIORAL|Just TRAC It!|Just TRAC It! (Transitioning Responsibly to Adult Care) is a mobile health intervention that encourages youth to use existing functions on their personal phones to track their health information. The use of Just TRAC It! allows youth to electronically document all medical information that would previously be printed on their MyHealth Passport, but may offer additional functionality in terms of learning to manage their health.
223630589|NCT03429335|BEHAVIORAL|MyHealth Passport|"MyHealth Passport is a customized, wallet-size card that includes the youth's important medical information. The RN will help the youth create a MyHealth Passport online, and print out the card for them.~The same educational intervention will be completed by cardiology nurse using a MyHealth Passport to track their medical information instead of the electronic Just TRAC It!"
223630590|NCT05924243|DRUG|RO7486967|For up to approximately 28 days
223630591|NCT05924243|DRUG|Placebo|For up to approximately 28 days
223630592|NCT04896866|BEHAVIORAL|Antimicrobial stewardship prospective audit and feedback|Audits are performed on weekdays, less statutory holidays, by members of the antimicrobial stewardship team consisting of infectious disease or antimicrobial stewardship physicians or pharmacists. Verbal and written feedback will be provided in real-time. Initial prospective audit and feedback (PAF) will occur on the day of enrolment. Follow-up PAF will occur weekly (+/-3 days to account for weekends or statuary holidays) and ad-hoc if a new antibacterial is prescribed, until the primary end-point. Appropriateness will be assessed based on local clinical practice guidelines. Only antibacterials will be audited. Prescriptions will be excluded from PAF if they are single doses or discontinued prior to PAF. Prescriptions will be also be excluded from PAF and the final analysis if being used for surgical or medical prophylaxis.
223630593|NCT04346745|BEHAVIORAL|Peer Mentoring Program|The Peer Mentoring Program (PMP) is a 3-month intervention to provide one-on-one mentoring support via phone calls to reduce the stress of Chinese dementia caregivers. The PMP will address the following topics: cultural beliefs about dementia and family caregiving, culturally effective coping strategies, and culturally appropriate social support.
223630594|NCT04607668|DRUG|Trilaciclib|Trilaciclib diluted in dextrose 5% in water or normal saline (sodium chloride solution 0.9%) administered by IV infusion over approximately 30 (±10) minutes no more than 4 hours prior to each Day 1 chemotherapy administration. Second dose of trilaciclib was administered on Day 2.
223630595|NCT04607668|DRUG|Placebo|Dextrose 5% in water or normal saline (sodium chloride solution 0.9%) administered by IV infusion over 30 (±10) minutes no more than 4 hours prior to each Day 1 chemotherapy administration. Second dose of placebo was administered on Day 2.
223630596|NCT05625113|DEVICE|neuroprosthesis|Use at least one time every day the gripping neuroprosthesis in daily life activities.
223630597|NCT04434482|DRUG|IMP4297(senaparib)|The dose levels will be escalated following a modified 3+3 dose escalation scheme.
224219307|NCT00091182|DRUG|oxaliplatin|Given IV
224219308|NCT03627182|DRUG|CKD-501 0.5mg|CKD-501 0.5mg, orally, 1 tablet once a day for 24weeks or 52weeks(if extension study) with D150 and D745
224219309|NCT03627182|DRUG|Placebo|"Placebo, orally, 1 tablet once a day for 24weeks with D150 and D745.~CKD-501 placebo will be changed to CKD-501 from extension stydy to EOS(end of study)."
224219310|NCT02205866|OTHER|Endometrial Receptivity Array analysis of endometrial biopsy|A biopsy of endometrium is peformed and Endometrial Receptivity Array analysis is carried out, as well as analysis of fat distribution and risk factors of Metabolic Syndrome.
224219311|NCT05279326|BEHAVIORAL|Virtual SMAs|18 weeks lifestyle approach for type 2 diabetes program: Session 1 (week 0): Introduction; Session 2 (week 3): Behaviour change process; Session 3 (week 6): Medical nutrition therapy recommendations - Part 1; Session 4 (week 9): Medical nutrition therapy recommendations - Part 2; Session 5 (week 12): Medical physical Activity recommendations; Session 6 (week 15): Smoking cessation: tobacco and E-cigarettes; Session 7 (week 18): Diabetes distress.
224219312|NCT06485492|PROCEDURE|Implant an aneurysm embolization system|The product uses minimally invasive interventional method to treat intracranial aneurysms approved for application. The study physician selects the appropriate size and/or shape of the aneurysm based on the size and shape of the intracranial arterioma. The aneurysm embolization system device is inserted into the arterioma through a compatible neurovascular microcatheter.
223630598|NCT06742931|OTHER|Discontinuation of antiplatelet agent group|In this group, antiplatelet monotherapy will be discontinued at the time of randomization. Randomization will be performed at 1 year from the index procedure using DCB angioplasty, standard duration of DAPT (1-3 months), and maintenance of antiplatelet monotherapy at least 1 year from the index procedure in patients with HBR and chronic coronary syndrome. In patients who are still under DAPT at 1 year from index DCB angioplasty, all antiplatelet agents will be discontinued after randomization.
224219313|NCT00821457|DRUG|Juvista|250ng
224219314|NCT00821457|DRUG|Placebo|Powder for solution for injection
224219315|NCT00821457|DRUG|Juvista|500ng
224219316|NCT03000868|PROCEDURE|Cold endoscopic mucosal resection|Cold endoscopic mucosal resection (EMR) means removing small colorectal polyps (\<1cm) with snare without the use of electocautery after injection of normal saline into the submucosa.
224219317|NCT03000868|PROCEDURE|Hot endoscopic mucosal resection|Hot endoscopic mucosal resection (EMR) means removing small colorectalpolyps (\<1cm) with snare without the use of electocautery after injection of normal saline into the submucosa.
224219318|NCT02487173|DEVICE|Respirio Flu Test|The Respirio Flu Test is a rapid test for the detection of influenza A or influenza B in nasal secretions. The Respirio Flu Test is designed to be simple to use and generates a result within 20 minutes.
224317833|NCT00766779|PROCEDURE|hematopoietic cell transplantation|low dose total body irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donors
223630599|NCT06742931|OTHER|Continuation of antiplatelet agent group|In this group, lifelong antiplatelet monotherapy will be continued after the time of randomization. Randomization will be performed at 1 year from the index procedure using DCB angioplasty, standard duration of DAPT (1-3 months), and maintenance of antiplatelet monotherapy at least 1 year from the index procedure in patients with HBR and chronic coronary syndrome. In patients who are still under DAPT at 1 year from index DCB angioplasty, DAPT will be changed to single antiplatelet therapy (aspirin or clopidogrel). The choice between aspirin or clopidogrel will be determined by the physician's discretion.
223630600|NCT03376438|OTHER|Prospective observational cohorts|Patients with AF or SVT that is significant enough to consider prenatal treatment are eligible for enrollment. Management decisions are made at each patient encounter by the primary physician based on clinical findings and may include: 1) no antiarrhythmic treatment; 2) transplacental antiarrhythmic treatment; 3) direct fetal antiarrhythmic treatment; 4) delivery. Patients enrolled in the FAST Registry will be followed from the time of enrollment until the baby is discharged after birth.
223630601|NCT04623788|DIAGNOSTIC_TEST|Cardiac MRI|Cardiac MRI with contrast
223630602|NCT05657340|DIAGNOSTIC_TEST|Video-head impulse testing|Video-head impulse testing is a recent diagnostic bed-side test for evaluation of semi-circular canal function.
224219319|NCT02487173|DEVICE|Reverse Transcriptase Polymerase Chain Reaction (RT-PCR)|Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) is a molecular diagnostic technique for the detection and identification of influenza viruses, both for clinical samples and isolates. The reverse-transcriptase polymerase chain reaction (RT-PCR) allows template viral RNA to be reverse transcribed producing complementary DNA (cDNA) which can then be amplified and detected.
224219320|NCT02487173|DEVICE|Sofia® Influenza A+B Fluorescent Immunoassay (FIA)|Sofia® Influenza A+B Fluorescent Immunoassay (FIA) employs immunofluorescence to detect influenza A and influenza B viral nucleoprotein antigens in nasal swab, nasopharyngeal swab, and nasopharyngeal aspirate/wash samples taken directly from symptomatic patients.
224219321|NCT05641272|BIOLOGICAL|3,000 MM09|Allergoid (Dermatophagoides pteronyssinus and Dermatophagoides farinae)-mannan conjugates (MM09) at 3.000 UTm/mL for sublingual immunotherapy.
224219322|NCT05641272|BIOLOGICAL|9,000 MM09|Allergoid (Dermatophagoides pteronyssinus and Dermatophagoides farinae)-mannan conjugates (MM09) at 9.000 UTm/mL for sublingual immunotherapy.
224219323|NCT05641272|OTHER|Placebo sublingual|The same solution, presentation, method of administration, frequency, and duration as the active treatment, but without active ingredients.
224219324|NCT01535846|BEHAVIORAL|Conscious food tasting intervention|Six weekly 2-hour workshops
224219325|NCT01785186|DRUG|SQ109|SQ109 300 mg
224219326|NCT01785186|DRUG|Rifampicin|Rifampicin 10 to 35 mg/kg
224219327|NCT01785186|DRUG|Moxifloxacin|Moxifloxacin 400mg
224219328|NCT01785186|DRUG|isoniazid|isoniazid 75 mg
224219329|NCT01785186|DRUG|pyrazinamide|pyrazinamide 400 mg
224219330|NCT01785186|DRUG|ethambutol|ethambutol 275 mg
224219331|NCT01785186|DIETARY_SUPPLEMENT|pyridoxine|pyridoxine 25 mg
224219332|NCT00571922|DRUG|Acamprosate|2 gr/day (333 mg, TID)
224219333|NCT00571922|DRUG|placebo|matching placebo
224219334|NCT04484922|DRUG|Dexmedetomidine|continuous infusion of dexmedetomidine during the surgery
224219335|NCT04484922|DRUG|Normal saline|continuous infusion of normal saline during the surgery
224219336|NCT03768219|BIOLOGICAL|APVO210|APVO210
224219337|NCT03768219|BIOLOGICAL|Placebo|Placebo is saline based IV infusion, and is identical in appearance to active study drug.
224219338|NCT00624403|DEVICE|Laryngeal mask insertion (LMA ProSeal)|Laryngeal mask insertion
224219339|NCT00624403|DEVICE|Laryngeal mask insertion (I-Gel)|Laryngeal mask insertion
224219340|NCT03459781|BEHAVIORAL|Cognitively-Based Compassion Training|CBCT® was designed at Emory University by Lobsang Tenzin Negi. CBCT® is a secular adaptation of techniques derived from traditional Tibetan Buddhist methods for cultivating compassion known as lo-jong. Over the course of 8 weeks there will a total of 8 CBCT® sessions, one session per week, led by the CBCT® instructor. Dyads will attend the weekly CBCT® classes together. Each weekly session will last for 90 minutes and will begin with brief meditation to focus attention. The instructor will then articulate content and goals of the current week, after which a group discussion led by the instructor will take place. A session will end with a 20-30 minute meditation. Dyads will be encouraged to practice a minimum of 10 minutes per day at home, and together as a dyad if possible.
224219341|NCT03459781|BEHAVIORAL|CHE (Cancer Health Education)|The cancer health education (CHE) intervention is an adaptation of the in-person program called Health Discussion, a protocol used by our group previously. The CHE will focus on relevant topics to health and cancer including 1) cancer advocacy, 2) health and cancer biology, 3) nutrition, 4) lifestyle interventions such as physical activity and goals for physical activity, 5) the importance of good sleep, 6) the impact of stress, and 7) mental health and social support. CHE will also discuss current events related to cancer. Over the course of 8 weeks there will be a total of 8 sessions, one session per week. Each session will last for approximately 90 minutes.
224219342|NCT04714099|DRUG|Topical Cyclosporine A|In our study we used 0.05% CsA prepared in castor oil by transferring (20ml ) of sterile castor oil in a sterile glass vial under laminar flow, removing a volume (400ul)of oil with micropipette (sterile tips), and replacing this volume with an equal volume of alcoholic CsA solution \[200mg cyclosporine in 8 ml ethanol (96%)\] under laminar flow.
224219343|NCT04714099|DRUG|Placebo|Placebo
224317834|NCT00766779|DRUG|Non-Transplant treatment approach for consolidation|Patients will receive the treatment that would be otherwise applied at the local institution. The consolidation or maintenance therapy is according to the study group protocol.
224317835|NCT01154361|DRUG|Icatibant (subcutaneous) and plazebo (intravenous)|
223630603|NCT03063177|PROCEDURE|Spinal manipulative therapy|A SMT will be delivered by contacting the transverse processes of T7 through our apparatus. Each participant will receive one SMT per session for 3 sessions.
224219344|NCT04393805|DRUG|Low Molecular Weight Heparin|Thromboprophylaxis with Low Molecular Weight Heparin, mostly enoxaparin
224219345|NCT01823315|DRUG|MTX 1|MTX 0.4mg/(kg·d) intramuscularly (IM) on days 1-5
224219346|NCT01823315|DRUG|MTX 2|MTX 100mg/m(2), IV, on day1 (after Act-d); MTX 200mg/m(2), IVgtt, on day1 (after MTX, 500ml NS, \>4h)
224219347|NCT01823315|BIOLOGICAL|Act-d|Act-d 0.6mg/m(2), IV, on day1,2
224317836|NCT01154361|DRUG|Cortisone + Clemastin (intravenous) and plazebo (subcutaneous)|
223630604|NCT00474487|BIOLOGICAL|Meningococcal ACWY Polysaccharide Vaccine|One dose of the licensed meningococcal ACWY polysaccharide vaccine was administered by subcutaneous injection.
223630605|NCT00474487|BIOLOGICAL|MenACWY CRM (19 to 55 years)|One dose of the Novartis meningococcal ACWY conjugate vaccine was administered by intramuscular injection to subjects 19 years to 55 years of age.
223630606|NCT00474487|BIOLOGICAL|Meningococcal ACWY Conjugate Vaccine|One dose of the licensed meningococcal ACWY polysaccharide-protein conjugate vaccine was administered by intramuscular injection.
223630607|NCT00474487|BIOLOGICAL|Novartis MenACWY Vaccine (56 to 65 Years)|One dose of the Novartis meningococcal ACWY conjugate vaccine was administered by intramuscular injection administered to subjects 56 years to 65 years of age.
223630608|NCT02260687|DRUG|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|Administration by intravitreal injection
223630609|NCT00751582|DIETARY_SUPPLEMENT|Food supplementation and nutrition education|Food supplementation and nutrition education for three months
223630610|NCT00751582|BEHAVIORAL|Nutrition education|Nutrition education for children for three months
223630611|NCT00751582|OTHER|Control Group|No Nutrition Education
223630612|NCT03773224|PROCEDURE|Irrigation|upon closure of the peritoneum gentamicin-saline solution (160 mg of gentamicin in 400 ml of normal saline 0.9%) will be used for irrigation of every layer of the wound before its closure
223630613|NCT02336152|DEVICE|Anaesthesia, Teles Pro, Body suit|
223630614|NCT01428258|OTHER|GMP Diet/GMP Medical Foods|The intervention consists of a low-phenylalanine (Phe) diet in combination with medical foods made with the peptide GMP supplemented with limiting indispensable amino acids, as provided by Cambrooke Therapeutics, LLC. The diet is formulated to replace the protein equivalents provided by AA medical foods with GMP medical foods, keeping other dietary components constant. The GMP dietary treatment period consists of all subjects following the GMP diet for 3-wks at home. The GMP diet intervention is administered in differing orders, GMP Diet/AA Diet or AA diet/GMP Diet.
223630615|NCT01428258|OTHER|AA Diet/AA Medical Foods|The intervention consists of a low-Phe diet in combination with commercial AA medical foods as consumed in each subject's usual diet. A total of 15 different commercial AA medical foods were consumed by subjects in the study. The diet is formulated to provide each subject with their typical daily intake of protein equivalents from AA medical foods. The AA dietary treatment period consists of all subjects following the AA diet for 3-wks at home. The AA Diet comparator intervention is administered in differing orders, GMP Diet/AA Diet or AA diet/GMP Diet.
223630616|NCT05093855|DRUG|BDB-001 Injection|Multiple IV infusions of BDB-001 Injection diluted in sodium chloride
223630617|NCT04763395|OTHER|No intervention|No intervention
223630618|NCT01672385|OTHER|Telemonitoring plus self-management support|Patients in the intervention group receive automated telephone calls that ask about their health and self-care along with tailored health-related feedback. The patient's CarePartner receives health update reports about the patient and how they can help via e-mail. Urgent health problems are reported to the patient's health care team via fax or e-mail.
223630619|NCT01831024|DEVICE|Dignicap System|The DigniCap™ System consists of the digitized system for controlled scalp cooling (Digni C3) in conjunction with the soft, tight-fitting silicon cap (DigniCap™), the neoprene outer cap (DigniTherm™), and the liquid coolant (DigniCool). DIGNISTICK™ is prepared to log data from a treatment when inserted in the slot. DIGNICARD™ is a key card which has to be inserted in order to start a treatment.
223630620|NCT05024539|OTHER|nonintervention|
223630621|NCT02132962|DIETARY_SUPPLEMENT|Amino acid infusion|
223630622|NCT02132962|OTHER|Bloodsamples, Biopsies.|
223630623|NCT01128374|PROCEDURE|Periodontal Scaling and root planing|Participants will be instructed to brush their teeth using the modified Bass toothbrushing technique; the use of interproximal hygiene aids such as proximal brush or dental floss will be included. A full mouth scaling and root planning will be performed in 2 appointments (2 hours each) with the use of local anesthesia (typically 2% lidocaine with 1:100,000 epinephrine). In the control group, this treatment will be performed after all the data and samples have been collected and will encompass the last 2visits. Periodontal scaling and root planning treatment has been defined by The American Academy of Periodontology (AAP) as the standard of care for patients with periodontal disease. An ultrasonic instrument, scalers and curettes will be utilized to remove calculus and obtain a smooth root surface. The experimental subjects will be appointed 1 week later to complete the scaling and root planning procedure
224219348|NCT00188695|PROCEDURE|MRI contrast agent Combidex (ferumoxtran-10)|Combidex as an MR-lymph node contrast agent for the detection of small lymph nodes and lymph metastases.
224219349|NCT06231797|DIAGNOSTIC_TEST|AI algorithm conducted on 12-lead ECG and transthoracic echocardiography|12-lead ECG is performed for each patient. For 12-lead ECG, AITIALVSD (AI algorithm) analysis will be performed through a separate server.
224219350|NCT05447585|DEVICE|Coronary atherectomy system of Shanghai MicroPort Rhythm|Coronary Atherectomy System utilizes a diamond-coated eccentric crown to expand the lumen diameter via centrifugal forces while rotating over an atherectomy guide wire.
224219351|NCT05447585|DEVICE|Rotablator Rotational Atherectomy System|The Rotablator Rotational Atherectomy System is comprised of a Rotablator RotaGlide, a Rotablator RotaLink Plus/RotaWire/Console
223630624|NCT06356454|OTHER|Questionnaire on knowledge, attitudes and practices of paediatric cardiologists about cardiac rehabilitation in children with congenital heart disease|"Creating the questionnaire: The self-administered questionnaire was designed based on literature review. The questions of the questionnaire were based on the 3 main components of the World Health Organisation's Knowledge, Attitude and Practice framework. The questions were evaluated by experts in the field such as cardiologists working in paediatric cardiology. The questionnaire, which was finalised with the questions updated according to expert opinions, has 5 sections:~* Section 1: Socio-demographic questions~* Section 2: Questions on the level of knowledge about CR~* Section 3: Questions on attitudes about CR~* Section 4: Questions on Practices about CR"
223630625|NCT03248908|DIAGNOSTIC_TEST|Pupillary dilation reflex|Perioperative pupillary dilation reflex assessment is executed every 10 minutes from start sedation until extubation in patients allocated to study arm Intervention 1 and Intervention 3
223630626|NCT03248908|OTHER|Standard of care|Perioperative opioid administration based on the attending anesthesiologist decision (mainly including assessment of heart rate, blood pressure, and limb movement)
223630627|NCT02303496|BIOLOGICAL|Platelet Rich Plasma Cream|Cream Containing Platelet Rich Plasma and Oleaginous Base
223630628|NCT02303496|BIOLOGICAL|Placebo - Sterile Water Cream|Cream Containing Sterile Water and Oleaginous Base
223630629|NCT04016935|OTHER|Observational|Observational
223630630|NCT04336774|DEVICE|Caption AI|Software program that guides the investigator or any other non-sonographer to take the best possible pictures of the heart.
223630631|NCT05108259|DRUG|PBP1502|40 mg/0.4 mL single SC injection via PFS
223630632|NCT05108259|DRUG|EU-licensed Humira|40 mg/0.4 mL single SC injection via PFS
223630633|NCT05108259|DRUG|US-licensed Humira|40 mg/0.4 mL single SC injection via PFS
223630634|NCT05330481|OTHER|Moderate-intensity (relative) exercise with glucose ingestion|120 minutes of cycling at 95% of lactate threshold ingesting 90 g/h of glucose
223630635|NCT05330481|OTHER|Moderate-intensity (absolute) exercise with glucose ingestion|120 minutes of cycling at a power matched to participant in the \<70 kg body mass group, ingesting 90 g/h of glucose
223630636|NCT06796361|DRUG|Ketanserin 40mg plus Psilocybin 40mg|40mg Ketanserin oral will be administered followed by 40mg Psilocybin.
223630637|NCT06796361|DRUG|40mg Psilocybin|Placebo oral followed by 40mg Psilocybin one hour later.
223630638|NCT06796361|DRUG|20mg Psilocybin|Placebo oral followed by 20mg Psilocybin one hour later.
224219352|NCT02103647|DRUG|Immediate release capsule(lyrica 150mg * 2/day)|Immediate release capsule
224219353|NCT02103647|DRUG|sustained release tablet|sustained release tablet
224219354|NCT04783259|OTHER|Structured approach|Structured approach with a narrow learning objective. The structured approach concerns a pre-escape room lecture and post-escape room debriefing
224219355|NCT04136197|DIAGNOSTIC_TEST|Manual palpation for incidence determination|The patients are positioned in a sitting and prone lying posture. Trigger points are discrete, local, hypersensitive spots located in a taut band of muscles. Palpation of the trigger point will cause elicitation pain over the affected area and radiation of pain toward a zone of reference and a local twitch response.
224219356|NCT04465383|DEVICE|Aqua© 30 on Oncomfort SedakitTM|Digital Sedation session consists in a virtual reality software (Aqua© 30 Version 3.0, Oncomfort SA, Waver, Belgium) including a clinical hypnosis script.Patients in the intervention group will undergo a 30-minute Digital Sedation program through a VR headset and headphones. This medical device called Oncomfort SedakitTM has been created to reduce anxiety and pain during medical/ surgical interventions
224219357|NCT04465383|DRUG|Propofol|Standard sedation starting doses of 1 µg/ml to 6 µg/ml depending on patient's reaction and titrated incrementally by 0.5µg/ml. Doses are adapted according to the level of comfort and needs of the patient.
224219358|NCT00350857|DRUG|Extended-Release Carbamazepine|
224219359|NCT00868582|OTHER|PET scanning in cancer|Collection of institutional practice PET imaging data
224219360|NCT04302428|BIOLOGICAL|Serum Zn|The investigators will obtain an additional 2 mL of blood in an extra tube. This will be collected at the same time blood is collected for the participant's yearly CF screening labs so as to minimize additional needle sticks.
224219361|NCT04302428|BIOLOGICAL|Red Blood Cell Zn|If the participant is greater or equal than 5 kg, an additional 2 mL of blood will be obtained in an extra tube. This will be collected at the same time blood is collected for the participant's yearly CF screening labs so as to minimize additional needle sticks.
223630639|NCT06796361|DRUG|10mg Psilocybin|Placebo oral followed by 10mg Psilocybin oral one hour later.
223630640|NCT06796361|DRUG|5mg Psilocybin|Placebo oral followed by 5mg Psilocybin one hour later
223630641|NCT06796361|OTHER|Placebo|Oral Placebo followed by oral Placebo one hour later
223630642|NCT06825260|DRUG|Senna|Senna, oral, 8.6mg, 2 tablets daily (up to 4 tablets twice a day) for 7 days
223630643|NCT06825260|DRUG|Polyethylene glycol 3350|Polyethylene Glycol 3350, oral, 17g, daily for 7 days
223630644|NCT05515484|OTHER|prone position with airbags|prone position with airbags
223630645|NCT05515484|OTHER|prone position without airbags|prone position without airbags
223630646|NCT06228482|DRUG|[68Ga]Ga DOTA-5G and [177Lu]Lu DOTA-ABM-5G.|Patients will be undergo \[68Ga\]Ga DOTA-5G PET/CT scans to confirm eligibility for the \[177Lu\]Lu DOTA-ABM-5G therapy. Patients with sufficient lesion uptake of \[68Ga\]Ga DOTA-5G PET/CT will be offered therapy. Patients will undergo a follow up \[68Ga\]Ga DOTA-5G PET/CT scans to assess tretament efficacy.
223630647|NCT04841447|OTHER|Study sample collection|Peripheral blood draws and bone marrow aspiration will be done during clinic visit and hospital stay.
223630648|NCT01274793|DRUG|Mosapride Citrate tablet|Orally administered 5 mg mosapride citrate tablet s three times a day for 4 continuous weeks if no severe adverse effects were found.
223630649|NCT01274793|DEVICE|Low-dose acupuncture|In this low current intensity group, the current applied would be relatively weak,it was clearly perceived by the participants
223630650|NCT01274793|DEVICE|High-dose acupuncture|In this group,the current was strong enough to reach the patients'tolerance threshold value.
223630651|NCT00434317|DRUG|Zoledronic acid|
223630652|NCT02179697|OTHER|Patient's Choice|Patient chooses between surgery plus bracing or bracing alone. The patient will be followed according to the same schedule as Group 1.
223630653|NCT02179697|PROCEDURE|Surgery + Bracing vs. Bracing Alone|Surgery + Bracing vs. Bracing Alone
224317837|NCT04149652|DIAGNOSTIC_TEST|Lung Elastosonography|Bedside lung ultrasound integrated with lung elastosonography, performed by using the convex probe of an Esaote Mylab Seven ultrasound system (Esaote, Genova, Italy), equipped with the strain elastography module ElaXto©.
223630654|NCT06394050|DIAGNOSTIC_TEST|Diagnostic Test|there is no intervention
223630655|NCT03207971|PROCEDURE|Root coverage treatment with subepithelial connective tissue graft|Periodontal plastic surgery aiming root coverage by palatal tissue graft removed from an area with predominance of lamina propria and predominance of submucosa.
223630656|NCT04277897|DRUG|Hepenofovir Fumarate Tablets Single Dose|Oral Tablet; Subjects will receive either a single dose of Hepenofovir Fumarate Tablets on Day 1 only (SAD), once daily dosing of HTS starting on Day 1 through Day 7 (MAD).
223630657|NCT04277897|DRUG|Placebo|Placebo to match Hepenofovir Fumarate Tablets
223630658|NCT04277897|DRUG|Hepenofovir Fumarate Tablets Dose4|Oral Tabet; Subjects will receive Hepenofovir Fumarate Tablets Dose4 on Day 1 in fast condition, then receive Hepenofovir Fumarate Tablets Dose4 on Day 8 in fed condition.
224317838|NCT02768831|OTHER|CPAP|Sealing the airway by holding CPAP of 20 cmH2O in the anesthesia circuit and slowly inflating the cuff until no air leak is heard with a stethoscope placed in the suprasternal notch.
223630659|NCT02946138|RADIATION|carbon-ion radiotherapy|Hypofractionated carbon-ion radiotherapy was prescribed at a dose of 40Gy RBE in 5 fractions
223630660|NCT02766023|BIOLOGICAL|Lactobacillus crispatus CTV-05|LACTIN-V is an intravaginal live biotherapeutic product composed of Lactobacillus crispatus CTV-05 (LACTIN-V, Osel Inc) in a vaginal applicator. Subjects receive 2x10\^9 cfu/dose applied vaginally daily x 5 days then twice weekly x 10 weeks.
223630661|NCT02766023|DRUG|Metronidazole|Metronidazole is a nitroimidazole. Metronidazole gel (MetroGel) is applied vaginally 7.5 mg/gm daily for 5 days
223630662|NCT02766023|OTHER|Placebo|Placebo formulation applied vaginally, daily x 5 days then twice weekly x 10 weeks.
223630663|NCT00408057|OTHER|no intervention|no intervenion
223630664|NCT06085625|BEHAVIORAL|Pre-Surgery Survey|Participants will be asked to complete a survey 3 times (before surgery, after surgery, and 2 weeks after surgery). You will be monitored for up to 1 month after your surgery, where you may be contacted by a study provider virtually or in person to ask you about medication usage and heath care needs.
223630665|NCT06085625|BEHAVIORAL|Post-Surgery Surveys|"After surgery, Participants will complete the same survey as in the pre-surgery visit about 1 day and then 2 weeks after surgery. These surveys will be completed electronically through the MyChart system. They will take about 5-10 minutes to complete and must be done within 24 hours after receiving the survey.~Participants will be monitored for 1 month after your surgery, including your standard-of-care postoperative visit at about 2 weeks. You may be contacted by a provider for a phone or in person visit at the 1-month time point to ask how you are doing."
223630666|NCT06387264|DEVICE|Medical Adhesive|Medical Adhesive (produced by Beijing Compont Medical Devices Co., Ltd.) For varicose veins in the main saphenous vein, use 0.1 ml glue for every 3 cm of blood vessels.
223630667|NCT06387264|DEVICE|ClosureFast Endovenous Radiofrequency Ablation(RFA) Catheter|ClosureFast Endovenous Radiofrequency Ablation (RFA) Catheter (produced by America Medtronic Inc.) The ClosureFast catheter precisely heats a 7 cm vein segment in one 20-second interval.
223630668|NCT05250284|BEHAVIORAL|WellBQ|National Institue for Occupational Safety and Health Worker Well-Being Questionnaire is comprised of 21 scales (multiple items assessing a single construct) and 31 single items that cover worker well-being. Domains include (i) work evaluation and experience, (ii) workplace policies and culture, (iii) workplace physical environment and safety climate, (iv) health status, and (v) home, community, and society.
223630669|NCT05250284|BEHAVIORAL|PROMIS|Patient-Reported Outcomes Measurement Information System is a set of person-centered measures that evaluates and monitors physical, mental, and social health in adults and children.
223630670|NCT04552652|BEHAVIORAL|High-Intensity Interval Training|Remotely monitored exercises will be performed at home. The high-intensity interval group warms-up for 5 minutes at moderate intensity (65-75% of maximal heart rate). After warm-up exercise, will continue in 4 minutes intervals at high-intensity to reach the target zone (85-95% of maximal heart rate) Each interval will be separated by 3 minutes of active recoveries (at 65-75% of maximal heart rate). The session ends with a 3-minute cool-down phase. Overall training exercise time will be 33 minutes - isocaloric compared to moderate-intensity continous training group. All participants will train using a heart rate monitor during each workout.
223630671|NCT04552652|BEHAVIORAL|Moderate-intensity continuous training|Remotely monitored exercises will be performed at home. Patients in the moderate-intensity continuous training group will perform a 41-minute constant workout with an intensity of 65-75% of maximum heart rate, representing the same total training load as the high-intensity aerobic exercise group. All participants will train using a heart rate monitor during each workout.
223630672|NCT05703945|OTHER|Progressive training program|The intervention consists of progressive training program : toe plantar flexion isometric at 30° of dorsal flexion of the metatarsophalangeal joint (0° is considered the anatomical position). The training will be performed in the same customized device used for the measurement. Each session consists of four sets at 80% of the maximal voluntary contraction performed until task failure. Between the sets, 2 minutes of rest will be allowed. Maximal voluntary contraction estimate will be updated every session of training, testing it before the start. The test is considered part of the training intervention. The total impulse performed during the single session will be recorded. Participants will train twice a week for 8 weeks. Training will be performed with both the feet.
224219362|NCT03473847|DEVICE|ArcScan Insight 100 very high-frequency digital ultrasound|The ArcScan Insight 100 VHF digital ultrasound scanner can measure individual layers within the cornea with very high precision, as well as being able to image the interior of the eye including the chamber between the iris and the cornea, the lens and other structures behind the iris. The ArcScan Insight 100 device is a digital ultrasound scanner, meaning that it uses ultrasound waves to measure parameters of the eye. The Insight examination involves the patient sitting in front of the ultrasound unit and looking through a disposable goggle-like eyepiece at a light source. Warm sterile balanced saline solution (like natural tears) are used to fill the space between the light source and the eye, to allow ultrasound transmission. There is no contact between the instrument and the eye other than being immersed in this water bath.
224219363|NCT03473847|DEVICE|Carl Zeiss Meditec Cirrus HD OCT 5000|The Cirrus HD OCT 5000 uses high definition spectral domain optical coherence tomography (OCT) to measure anatomical structures of the eye. OCT is non-contact and uses light, rather than ultrasound, to obtain cross-sectional images. An OCT scan involves the patient sitting in front of the device, placing their chin on a chin-rest and fixating on a light source. Nothing comes into contact with the eye and the patient is only aware of the instrument rotating in front of them.
223630673|NCT05703945|OTHER|Control group|The control group will not perform the progressive training program after visit 2 and will continue all of their daily activities during the 8-week intervention period.
223630674|NCT05820035|DEVICE|Pulsed Field Ablation Device and CF-Sensing Pulsed Field Ablation Catheter|All subjects will be ablated using the pulsed field ablation device and CF-sensing pulsed field ablation catheter in the management of their paroxysmal supraventricular tachycardia
223630675|NCT06129240|COMBINATION_PRODUCT|LIQ861|trepostinil inhalation powder
223630676|NCT06309628|DIAGNOSTIC_TEST|Breathe sample|Patients will provide two breathe sample into the Breathe device to see if their VOC patterns can be used to diagnose lung transplant rejection.
223630677|NCT06563700|OTHER|spectacle lens|one of ZEISS BD spectacle lens designs 1 to 5
223630678|NCT06563700|OTHER|single vision lens|single vision lens
223630679|NCT04839406|BEHAVIORAL|Structured support of caregivers at the ICU|Structured support of caregivers at the ICU provided by a trained group of 10-15 ICU nurses
223630680|NCT05794620|OTHER|Stool sample|Stool sample
223630681|NCT01488045|DRUG|Fentanyl|Fentanyl will be administered IV according to standard procedure for colonoscopy. Initial dose will consist of no more than 50µg of Fentanyl. Patient response will be monitored for 30-60 seconds of observation before deciding to administer more Fentanyl in no more than 50µg increments. increments.
223630682|NCT01488045|DRUG|Propofol|Propofol will be administered IV according to standard procedure for colonoscopy. The initial bolus of propofol will be up to 60 mg IV. Patient response will be monitored for 30-60 seconds of observation before deciding to administer more sedation in 10-20 mg boluses.
223630683|NCT01488045|DRUG|Midazolam|Midazolam will be administered IV according to standard procedure for colonoscopy. Initial dose will consist of no more than 2 mg of Midazolam. Patient response will be monitored for 30-60 seconds of observation before deciding to administer more Midazolam in no more than 2 mg increments.
223764179|NCT06418386|PROCEDURE|rotary saline IIA|"* shaping and cleaning done with using AF baby fanta files open file:#17 taper 08,then #20 taper 04 ,yellow then #25 taper 04 red , then #30 taper 04 blue . the files activated with torque 2 and speed 350 . Irrigation with normal saline~* Post irrigation sample and pre-preparation sample will be transferred to microbiological laboratory Canals will be filed with obturation material(Metapex)then restored with glass inomar and stainless steel crown"
224219364|NCT03473847|DEVICE|Optovue RTVue OCT|The Optovue RTVue OCT uses high definition Fourier/spectral domain optical coherence tomography (OCT) to measure anatomical structures of the eye. OCT is non-contact and uses light, rather than ultrasound, to obtain cross-sectional images. An OCT scan involves the patient sitting in front of the device, placing their chin on a chin-rest and fixating on a light source. Nothing comes into contact with the eye and the patient is only aware of the instrument rotating in front of them.
224219365|NCT03473847|DEVICE|CSO MS-39 OCT|"The CSO MS-39 OCT uses high definition Fourier domain optical coherence tomography (OCT) to measure anatomical structures of the eye. OCT is non-contact and uses light, rather than ultrasound, to obtain cross-sectional images. The MS-39 also includes a Placido topographer within the device to simultaneously obtain a measurement of the shape (curvature) of the front surface of the cornea, which is then combined with the OCT thickness measurement to generate the shape of the back surface of the cornea.~An OCT scan involves the patient sitting in front of the device, placing their chin on a chin-rest and fixating on a light source. Nothing comes into contact with the eye and the patient is only aware of the instrument rotating in front of them."
224219366|NCT05054166|OTHER|No intervention, it was a retrospective study.|This study aimed to retrospectively investigate the efficacy of the everolimus-containing chemotherapy in metastatic breast cancer patients with PI3K/AKT/mTOR mutations.There was no intervention.
224219367|NCT01999387|DIETARY_SUPPLEMENT|Allergenic food|
224219368|NCT03571854|DEVICE|Group PCV-VG|Pressure controlled ventilation-volume guaranteed
224219369|NCT03571854|DEVICE|Group VCV|Volume controlled ventilation
224219370|NCT00012584|DRUG|methylphenidate|
224219371|NCT00012584|DRUG|fluvoxamine|
224219372|NCT04582097|DRUG|Ramipril|angiotensin-converting enzyme inhibitor
224219373|NCT04582097|DRUG|placebo|same odor, color and size as the drug but without the active ingredient
224219374|NCT04510220|DRUG|Ofatumumab|Ofatumumab (OMB157) is a fully human anti-CD20 monoclonal antibody (mAb) self-administered by a once-monthly subcutaneous injection that is in development for MS. Ofatumumab drug product (also referred as OMB157) is formulated as 20 mg/0.4 mL (50 mg/mL) solution for injection, provided in autoinjectors, for subcutaneous administration. The autoinjectors contain a small overfill to allow for a complete withdrawal of the labeled amount (20 mg) of ofatumumab.
224219375|NCT04510220|DRUG|[F-18]PBR06|PET radiopharmaceutical. Subjects will undergo \[F-18\]PBR06-PET (microglial activation).
224219376|NCT01004484|OTHER|A probiotic yogurt with inulin|A 4 oz. cup with a probiotic yogurt containing Streptococcus thermophilus and Lactobacillus bulgaricus (at least 1x10\^8 cfu/g); the probiotic bacteria Bifidobacterium lactis (Bb12) (5x10\^7 cfu/g; 5x10\^9 cfu/serving) and Inulin (3gr/serving), once daily.
224219377|NCT01004484|OTHER|Acidified dairy snack|A 4 oz. cup of acidified dairy snack, once daily.
224219378|NCT06528223|DIAGNOSTIC_TEST|biopsy or operation|To obtain a biopsy pathology or surgical pathology according to the clinical process of PDAC.
224219379|NCT01575119|BEHAVIORAL|Decision Aid|Decision Aid tool is presented by respiratory therapist, prompting a discussion with the provider (physician or physician assistant)about smoking around time of surgery
224219380|NCT01575119|BEHAVIORAL|Control intervention|Standard of care information, including distributing patent education brochure, to provide information regarding perioperative smoking
224219381|NCT01575119|BEHAVIORAL|Decision Aid|Decision Aid tool is presented by respiratory therapist, prompting a discussion with the provider (physician or physician assistant)about smoking around time of surgery
224219382|NCT01575119|BEHAVIORAL|Control|Standard of care information, including distributing patient education brochure, to provide information regarding perioperative smoking
223630684|NCT05043363|DEVICE|LumenEye X1 digital rectoscope|The LumenEye X1 is a novel digital rectoscope that introduces digital HD imaging and improved ergonomics to conventional rigid sigmoidoscopy.
223630685|NCT01958996|DRUG|idarubicin|
223630686|NCT05365217|DRUG|Nonacog beta pegol|Nonacog beta pegol is administered as intravenous injections. Participants will receive nonacog beta pegol as prophylaxis, as on-demand for treatment of bleeding episodes and in relation to surgery.
223630687|NCT00989911|DRUG|Bosentan|Bosentan 62.5 mg tablet taken orally twice daily for one month, followed by Bosentan 125 mg tablet taken orally twice daily for three months.
223630688|NCT06066177|DIAGNOSTIC_TEST|Triglyceride glucose index TyG|Triglyceride glucose index is an indicator of insulin resistance
223630689|NCT00890734|DRUG|CYT003-QbG10|subcutaneous injection
223630690|NCT00890734|DRUG|Placebo|subcutaneous injection
224219383|NCT03349918|BEHAVIORAL|Mobile Health Monitoring|Use of mobile health application to monitor blood pressure and mood.
224219384|NCT03256175|PROCEDURE|Percutaneous Coronary Intervention|PCI technique (e.g. pre-dilatation vs. direct stenting and stent choice) was left to operator discretion. Stent post dilatation was permitted as per individual operator practice
223630691|NCT03864783|DIETARY_SUPPLEMENT|Curcumin (Meriva®)|"Experimental drug:~Meriva® 500 mg tablet (contains 1 mg curcumin)"
223630692|NCT03864783|DRUG|Placebo Oral Tablet|"Placebo:~Contains same ingredients as Meriva®, apart from curcumin. Similar in appearance to Meriva®."
223630693|NCT05746611|BIOLOGICAL|Recombinant Mycobacterium tuberculosis fusion protein for injection|For the suction test, EC0.1ml was injected into the palmar skin of the forearm by the Mondu's method
224219385|NCT06009900|DEVICE|Low intensity laser treatment|Low intensity laser treatment: Both patients and doctors wear goggles during the irradiation process. Using 810nm (infrared)/658nm (red) dual wavelength output for direct skin contact point irradiation, the maximum output power is 100mW (red)/60mW (infrared). Select the treatment site based on the patient's anatomical positioning (muscle and tendon attachment points, nerve distribution aggregation points) and/or pain points, and perform spot laser irradiation. Low intensity laser treatment process: Treat once a day for 15 minutes each time, with 5 consecutive days of treatment and 2 days of rest per week. The patient received a total of 3 weeks (15 times) of low intensity laser treatment.
224219386|NCT06009900|DRUG|Non-steroidal drug (Celecoxib) group|Oral Celecoxib 200mg/time, twice a day, for three consecutive weeks.
224219387|NCT02544633|DRUG|MGCD265|MGCD265 is a small molecule multi-targeted receptor tyrosine kinase inhibitor
224219388|NCT01977352|DRUG|Liposomal bupivacaine|liposomal bupivacaine (EXPAREL®; 88 mg in 20 cc)
224219389|NCT01977352|DRUG|Bupivacaine 0.25%|20 cc of bupivacaine 0.25%
224219390|NCT02270983|DRUG|Linaclotide 145 micrograms|
224219391|NCT02270983|DRUG|Linaclotide 290 micrograms|
223630694|NCT05746611|BIOLOGICAL|TB-PPD was injected|For the aspiration test, 0.1ml TB-PPD was injected into the palmar skin of the forearm by the Mondu's method
223630695|NCT02210572|DIETARY_SUPPLEMENT|Bimuno Galacto-oligosaccharide 1.37 g/d|Prebiotic versus low-FODMAPs diet
223630696|NCT02210572|DIETARY_SUPPLEMENT|Low- FODMAPs diet|
223630697|NCT01809938|OTHER|Black tea|300ml of tea without milk
223630698|NCT01809938|OTHER|Tea with milk|250ml of black tea with 50ml of full fat milk
224219392|NCT02270983|DRUG|Placebo|Matching placebo
224219393|NCT04317729|DEVICE|Fujirebio INNOTEST® HCV Ab IV assay|Enzyme Immunoassay
224219394|NCT02957786|DRUG|Cytisine|Cytisine tablets
224219395|NCT02957786|BEHAVIORAL|Behavioural support|Withdrawal-orientated cessation support
224219396|NCT02957786|DRUG|Varenicline|Varenicline tablets
224219397|NCT00124176|DRUG|Racemic albuterol (R+S albuterol)|20mg/hr continuous racemic albuterol
224219398|NCT00124176|DRUG|Levalbuterol (R albuterol)|10mg/hr continuous nebulized levalbuterol
224219399|NCT00226694|DRUG|Citalopram|Subjects receive provocative tests with citalopram, dexamethasone/corticotropin-releasing hormone and placebo on 3 separate, counterbalanced occasions at monthly intervals.
224219400|NCT00226694|OTHER|Placebo|Subjects receive provocative tests with citalopram, dexamethasone/corticotropin-releasing hormone and placebo on 3 separate, counterbalanced occasions at monthly intervals.
224219401|NCT02926391|DEVICE|UNiD 3D VBR|Corpectomy of one or several vertebral body(ies) followed by vertebral body(ies) replacement and fusion
223514341|NCT01414647|DIETARY_SUPPLEMENT|400 g of bilberry|Equivalent amount to 400 g of fresh bilberries were consumed as 40 g of dried bilberries and as 200 g of frozen bilberries. Restriction of use of strawberries, raspberries and cloudberries were set.
223514342|NCT01414647|OTHER|Control diet|Control diet, ie. habitual diet with restriction of berry consumption was consumed for eight weeks
223514343|NCT02369939|RADIATION|Irradiation|Radiotherapy 55,8 Gy - 59,4 Gy
223514344|NCT02369939|DRUG|Mitomycin C|MMC w1, w5
223514345|NCT02369939|DRUG|5-Fluorouracil|5-FU w1, w5
223514346|NCT02369939|PROCEDURE|Hyperthermia|6x deep regional hyperthermia
223514347|NCT05816161|DIAGNOSTIC_TEST|Integrated Neuromuscular Inhibition Technique|Exercises
223514348|NCT05816161|DIAGNOSTIC_TEST|Myofascial Release|Exercises
223514349|NCT05019963|BEHAVIORAL|NexJ Connected Wellness|NexJ Connected Wellness is an electronic case management platform with a patient-facing smart phone application and a clinician-facing web dashboard.
223514350|NCT05019963|OTHER|Usual Care|Participants will receive a treatment plan as decided on with their clinician(s).
223514351|NCT00160368|BEHAVIORAL|Potassium supplementation|
223514352|NCT02264821|DRUG|ropivacaine infiltration|wound infiltration
223514353|NCT02264821|DRUG|intrathecal morphine|100 µg added to the spinal anaesthesia
223514354|NCT02264821|DRUG|placebo|placebo in spinal anaesthesia and in wound infiltration
223514355|NCT00527631|RADIATION|whole abdomen irradiation using IMRT|Whole abdomen irradiation as consolidation therapy using intensity modulated radiation therapy (IMRT) to a total dose of 30 Gy in 1.5 Gy fractions
223514356|NCT01830465|DRUG|Bortezomib (VELCADE)|1,3 mg/m2, intravenous bolus (over 3-5 seconds) on days 1, 4, 8, 11 of each 21 day cycle. Number of Cycles: 6.
223514357|NCT01830465|DRUG|Rituximab|375 mg/m2 as intravenous infusion on day 1 of cycle III, IV, V, VI. Two additional doses will be administered at week + 3 and week + 6 after cycle VI.
223514358|NCT00983801|DRUG|Ixabepilone|Vial, Injection, Intravenous (IV), 40 mg/m\^2, Every 21 days, Up to 8 cycles or until disease progression or intolerable toxicity. Additional treatment was given in agreement by both the investigator and sponsor. Ixabepilone 40 mg/m\^2 was administered as a 3-hour IV infusion on Day 1 of each 21-day (3 week) cycle provided the participant met the retreatment criteria.
223514359|NCT05545059|DRUG|Sacubitril/valsartan|In sacubitril/valsartan group, patients will receive amlodipine 10mg, hydrochlorothiazide 25 mg, spironolactone 20 mg, sacubitril/valsartan 200mg to treat. The initial dose of sacubitril/valsartan will be 100mg per day and will be doubled to 200mg per day after 2 weeks then maintain until the end of the 8-week treatment period.
223514360|NCT05545059|DRUG|valsartan|In valsartan group, patients will receive amlodipine 10mg, hydrochlorothiazide 25 mg, spironolactone 20 mg and valsartan 160mg. The initial dose of valsartan will be 80mg per day and will be doubled to 160mg per day 2 weeks later and then maintain until the end of the 8-week treatment period.
223514361|NCT01251055|DRUG|GlyT-1 inhibitor-1|GlyT-1 inhibitor-1(500) 4# BID
223514362|NCT01251055|DRUG|Placebo|starch
223514363|NCT06547359|DRUG|Obicetrapib 10mg|tablets
223514364|NCT06547359|DRUG|Ezetimibe 10mg|tablets
223630699|NCT05559177|BIOLOGICAL|Chimeric exosomal tumor vaccines|Tumor cells (lesion site) were isolated from bladder cancer patients, and bladder cancer nuclei were extracted. Monocytes were isolated from peripheral blood of this patient and induced in vitro to obtain APC (DC or macrophage). Apc-tumor chimeric cells were constructed and stimulated with immune stimulator. Chimeric exosomal vaccines were extracted from cell supernatants by differential and hypervelocity centrifugation
223630700|NCT06150612|BEHAVIORAL|Unwinding Anxiety|In the Unwinding Anxiety arm, participants will receive 6 weeks of an educational app and weekly facilitated mindfulness groups.
223630701|NCT03446872|DRUG|ONIVYDE|irinotecan liposome injection
223630702|NCT03446872|DRUG|5-fluorouracil|a nucleoside metabolic inhibitor
223630703|NCT03446872|DRUG|Leucovorin|an active metabolite of folic acid
223630704|NCT05033197|BEHAVIORAL|CBBS intervention|The CBBS intervention group received the 16-week intervention, including 16 CBBS lessons in basketball unit (two 40-minute lessons/week, 8 weeks) and 16 CBBS lessons in soccer unit (two 40-minute lessons/week, 8 weeks) during the 2018-2019 school year.
223630705|NCT00736541|DRUG|N-acetylcysteine|The patients in the NAC group will receive a loading dose of 140 mg/kg IV of NAC over one hour at the start of the surgery. Thereafter, NAC will be repeated every 4 hours at a dose of 70 mg/kg IV, for a total of 13 doses
223630706|NCT05494840|BEHAVIORAL|Haptonomy|Haptonomy, as a field dealing with emotional contact through touch, describe the relationship between parents and the unborn baby.
223630707|NCT02043756|DRUG|Mitoxantrone Hydrochloride Liposome|6-16mg/m2, IV ,one time of each 28 day cycle,3 cycles
223630708|NCT02043756|DRUG|Mitoxantrone|10mg/m2, IV ,on day 1 of each 28 day,3 cycles
224219402|NCT00854620|DRUG|Sorafenib|Sorafenib administered in escalating 28-days cycles (400, 600 and 800 mg BID)
224219403|NCT03058939|DRUG|Paclitaxel|Administered to all patients for a minimum of 8 doses with a possible maximum of 16 doses.
224219404|NCT03058939|DRUG|Perjeta|Only administered to patients with HER2-positive disease.
224219405|NCT03058939|DRUG|Herceptin SC|Only administered to patients with HER2-positive disease.
223630709|NCT00656513|DRUG|Pilocarpine|5mg by mouth 3 times a day for 12 weeks
223630710|NCT00656513|PROCEDURE|ALTENS|Acupuncture-like transcutaneous electrical nerve stimulation (ALTENS) twice weekly for 12 weeks via a Codetron unit
223630711|NCT03670823|DEVICE|SIEMENS PRISMA MRI|Collect data on brain activation from different methods
224219406|NCT03058939|DRUG|Tamoxifen|Only administered to hormone-receptor positive patients. Patients will receive tamoxifen or letrozole.
223630712|NCT03651310|OTHER|Music Listening Group|Waiting in preoperative area with music listening.
224219407|NCT03058939|DRUG|Letrozole|Only administered to hormone-receptor positive patients. Patients will receive tamoxifen or letrozole.
224219408|NCT03058939|DRUG|LHRH agonist|Administered to all premenopausal patients.
223630713|NCT01969136|DRUG|Drug: EVP-6124|
223630714|NCT01969136|DRUG|Placebo|
223630715|NCT00801957|DRUG|tacrolimus ointment 0.03%|topical application
223630716|NCT00801957|DRUG|hydrocortisone acetate ointment 1%|topical application
223630717|NCT00801957|DRUG|hydrocortisone butyrate ointment 0.1%|topical application
223630718|NCT00801957|BIOLOGICAL|Meningitec|im injection
223630719|NCT00801957|BIOLOGICAL|AC VAX|im injection
223630720|NCT03160638|DRUG|Azithromycin 250 mg|Patients will be treated with azithromycin 250 mg once daily for 28 days. An azithromycin loading dose of 500 mg (two tablets of 250 mg) will be administered on day 1
223630721|NCT04429711|DRUG|Ivermectin Oral Product|3mg Capsules, 12-15mg/ day for 3 days
223630722|NCT04182516|DRUG|NMS-03305293|All patients will receive NMS-03305293 administered orally on Days 1-21 (schedule A) or Days 1-28 (schedule B) in repeated 4-week cycles.
223630723|NCT06052579|PROCEDURE|new hand-held retractor systems-assisted WiltseTLIF surgery|patients were included in study group underwent the new hand-held retractors assisted Wiltse TLIF surgery
223630724|NCT03405792|DRUG|Temozolomide (TMZ)|Patients will begin treatment with adjuvant TMZ at least 4 weeks but no more than 6 weeks from last dose of concomitant temozolomide or radiation therapy (the latter of the two). A minimum of 6 and maximum of 12 cycles of adjuvant TMZ will be given depending on tolerability and toxicity.
223630725|NCT03405792|DEVICE|Optune System|Patients will undergo 24-months of planned treatment with Optune therapy.
223630726|NCT03405792|DRUG|Pembrolizumab|Pembrolizumab will be given intravenously every 3 weeks beginning on Day 1 of Cycle 2 of adjuvant TMZ. Treatment with pembrolizumab every 3 weeks until first disease progression or unacceptable toxicities or 2 years, whichever comes first.
224219409|NCT03058939|DRUG|FEC|Only administered to patients who received paclitaxel and carboplatin, and were assessed as having poor response (defined as stable disease or progressive disease or partial response inoperable).
224219410|NCT03058939|DRUG|Carboplatin|Only administered to patients who receive paclitaxel and were assessed as having poor response (defined as stable disease or progressive disease or partial response inoperable).
224219411|NCT05559216|OTHER|Plyometric Training|Plyometric training exercises are being given to the participants to see the changes after the 8 week period
224219412|NCT02468479|OTHER|No relevant intervention.|No relevant intervention.
224219413|NCT06172010|DRUG|Clindamycin|antimicrobial treatment in oral treatment phase of staphylococcal prosthetic joint infection
224219414|NCT06172010|DRUG|Rifampicin and levofloxacin|antimicrobial treatment in oral treatment phase of staphylococcal prosthetic joint infection
224219415|NCT00208910|BEHAVIORAL|Odorant Cue|
224219416|NCT00928252|DRUG|IV fluorine-18 labeled methylcholine before PET/CT|Intervention at pre-treatment, and at two timepoints post treatment intiation.
224219417|NCT03695133|BEHAVIORAL|Group-based interventions|"1. Group-based interventions Elderly women will have a walk for physical activity for 12 weeks, three days a week. It is planned that each of the sightseeing, picnic, theater and cinema activities will be done twice. The topics that elderly women need most for group educations will be determined. Group educations will be held once every four weeks approximately three hours.~2. Individual interventions After the pre-tests are applied to the women in the intervention group, the home environment and the individual's health problems will be assessed, interventions will be implemented and the results will be evaluated during home visits at online. During the home visit to the elderly women and twelve-week intervention period, each woman will meet four times and initiatives will be implemented."
223630727|NCT06070883|PROCEDURE|Amniotic membrane transplantation|Amniotic membrane (AM) is the innermost layer of the placenta, which consists of a single layer of meta-bolically active epithelium, a thick basement membrane, and an avascular stromal matrix. It has been shown to exhibit a wide array of biological properties, including wound healing, anti-inflammatory, antimicrobial, and anti-angiogenic properties, amongst others. Amniotic membrane transplantation will be performed in eye OT under aseptic conditions. The necrotic tissues at the base of the ulcer will be debrided and sent for culture and sensitivity. The rolledup edge of the ulcer or the loosely adhered epithelium adjacent to the ulcer will also be removed. The amniotic membrane will be trimmed to fit the shape of the ulcer and placed with its epithelial side up. Then the amniotic membrane will be secured with 10-0 nylon suture (5 cases with interrupted and 25 cases with continuous suture) with the suture knots buried.
223630728|NCT04670588|DIAGNOSTIC_TEST|Circulating tumor DNA(ctDNA) level measurement|The ctDNA level will be measured using the Signatera platform developed by Natera, Inc. Signatera is a patient-specific, tumor informed custom-built ctDNA monitoring assay.
223630729|NCT06208969|BEHAVIORAL|intensive nutrition counseling|individualized regular nutrition education
223630730|NCT05405062|DEVICE|Carboxytherapy, short pulsed 1064 Nd Yag laser and subcision|Carboxytherapy is involves the injection of carbon dioxide into the subcutaneous tissue, with the goal of affecting the adipose tissue and circulation. Its mechanism of action is through an increase in capillary blood flow induced by hypercapnia and a decrease in cutaneous oxygen consumption (Pianez et al., 2016).
223630731|NCT05338684|DEVICE|Colour doppler,MSCT,MRI|ultrasound/color duplex at Jugular veins \& carotid and vertebral arteries first ,then MSCT/CTA mainly with relation of neck \& Bain arteries to the bone of the skull in 6 mm cuts and/or MRI/MRA/MRV by standardized multi-parametric MR protocol will be implemented for all patients. All sequences will be acquired on a 1.5T MR scanner.
223630732|NCT05720182|DEVICE|Compremium Compressibility Measurement|"CPM#1 measurements:~Step 1: Manual investigation to identify the compartment for compressibility measurements~Step 2: Marking the location for compressibility measurements~Step 3 - Examination with CPM#1~* Place the probe on the target area~* Identify correct landmark~* Compress the compartment~* Increase steadily the pressure applied by the CP probe to 80 mmHg."
223630733|NCT05720182|PROCEDURE|Treadmill Running|"Exercise:~Step 1: Participants will walk on a treadmill with standardized walking speed (5.0 km/hour) and slope (15%) for 5 minutes.~Step 2: Immediate, one minute, and five minutes post-exercise CPM#1 measurements will be performed at one leg.~Exercise and post-exercise CPM#1 measurements will be repeated for the other leg."
223630734|NCT05720182|OTHER|Questionnaire|"Questionnaires NIAPS questionnaire: Baseline NIAPS questionnaire with one additional question about leg dominance.~Experience questionnaire: Scores 1-5, questioning the intensity, how painful, the nuisance, the duration of the study and the non-invasive pressure measurements."
223630735|NCT04282486|OTHER|Telephone interview|"Primary objective: potentially inappropriate medication prevalence~Secondary objective:~Number and type of medication Polypharmacy prevalence Medication regimen complexity using Medication Regimen Complexity Index Anticholinergic and sedative exposure using Drug Burden Index~A telephone interview will be conducted with patients in order to collect medication data from medical prescriptions."
223630736|NCT05134584|DRUG|Linaclotide|290μg once daily, 4 weeks
223630737|NCT05134584|DRUG|Lactulose|20mL once daily, 4 weeks
223630738|NCT05134584|DRUG|Omeprazol|20mg twice daily for the first 10 days
223630739|NCT05134584|DRUG|Itopride|50mg three times daily for the first 10 days
223764180|NCT06418386|PROCEDURE|rotary neem IIB|"* The procedural tooth is anesthetized and isolated with rubber dam as mentioned~* All carious tissue will be removed by high speed hand piece ,distal cannel of mandibular primary molars and palatal cannel of maxillary primary molars will be chosen for sampling procedure.~* A sterile broach will be inserted to obtain root cannel content then sterile paper point inserted to root canal and will be left for 1 min The paper point will be removed with sterilized tweezer which will immediately transferred to tube containing transport medium (eppendrof of containing 200 μl nutrient broth medium).~* using AF baby fanta files SAME AS METION BEFORE ,and irrigation with 100%neem extract~* Post irrigation sample and pre-preparation sample will be transferred to microbiological laboratory Canals will be filed with obturation material(Metapex)then crown will be restored with glass inomar and stainless steel crown"
223630740|NCT00770263|DRUG|Erlotinib|
223630741|NCT00770263|DRUG|Temsirolimus|
223630742|NCT00941746|BIOLOGICAL|PG110|Single, slow intravenous infusion
223630743|NCT00941746|BIOLOGICAL|PG110|Single, slow intravenous infusion
223630744|NCT00941746|BIOLOGICAL|PG110|Single, slow intravenous infusion
223630745|NCT00941746|BIOLOGICAL|PG110|Single, slow intravenous infusion
223630746|NCT00941746|BIOLOGICAL|PG110|Single, slow intravenous infusion
223630747|NCT00941746|BIOLOGICAL|PG110|Single, slow intravenous infusion
223630748|NCT00941746|BIOLOGICAL|PG110|Single, slow intravenous infusion
223630749|NCT00941746|BIOLOGICAL|PG110|Single, slow intravenous infusion
223630750|NCT00941746|BIOLOGICAL|Placebo|Single, slow intravenous infusion that matches PG110 in appearance
223630751|NCT01735422|DRUG|r-hFSH|Daily r-hFSH treatment will be administered subcutaneously at a starting dose according to the site's standard practice from Day 3-5 of menstrual cycle up to follicular development or 28 days. Dose can be altered according to ovarian response (reduced to 75 IU/day; increased to 225 IU/day).
223630752|NCT01735422|DRUG|r-hLH|Ovulation triggering will be performed using a single injection of r-hLH injection subcutaneously at a dose of 825 or 2750 or 5500 or 11,000 or 22,000 IU as soon as follicles satisfy the criteria for follicular development, that is at least 1 follicle with diameter \>= 18 mm, not more than 5 follicles with diameter \>= 15 mm and with E2 levels less than 9000 picomoles per liter (pmol/L).
223630753|NCT01735422|DRUG|u-hCG|Ovulation triggering will be performed using a single injection of 5000 IU of u-hCG as soon as follicles satisfy the criteria for follicular development, that is at least 1 follicle with diameter \>= 18 mm, not more than 5 follicles with diameter \>= 15 mm and with E2 levels less than 9000 picomoles per liter (pmol/L).
224219418|NCT06205199|DRUG|Hydromorphone was injected into the subarachnoid space|The dose of hydromorphone is 50 micrograms
224219419|NCT06401200|OTHER|bar retained implant overdenture|use of bar attachment in completely edentulous patient
224219420|NCT04047212|DIAGNOSTIC_TEST|biopsy for oral cancer|surgical biopsy is to be taken for diagnosis of oral cancer or premalignant lesions
224219421|NCT04047212|DIAGNOSTIC_TEST|periodontal examination|Periodontal clinical examination to all by periodontal charting
224219422|NCT00526695|DRUG|Sevoflurane (Preconditioning)|Inhalation of sub-anesthetic doses of sevoflurane
224219423|NCT04543981|DIAGNOSTIC_TEST|Diagnostic Criteria for Tempro-mandibular Disorders(DC/TMD)|diagnostic sheet include questions to be answered by the patients and others include examinations will be done by the investigator
224219424|NCT02609737|DEVICE|PET/CT Imaging|
223630754|NCT06069193|BEHAVIORAL|Touch Intervention|"The participants will be examined, with various areas in the neck and upper back being palpated. Subsequently, the exercises to be performed at home will be demonstrated by the experimenter. The experimenter will ensure correct execution by touching specific areas in the neck and upper back of the participants. Finally, the participants will be provided with a cream to be applied to the affected regions.~Placebo cream:~The participants receive an inert placebo cream, which is a standard basic cream infused with lemon oil, produced by a local pharmacy. Participants are informed that they are about to receive an effective analgesic cream.~Placebo exercises:~Participants are assigned a series of five core exercises, with an optional supplementary exercise available in case any of the core exercises proves ineffective for the participants. Participants are led to believe that these exercises are expected to have therapeutic effects."
223630755|NCT06069193|BEHAVIORAL|Control|"The participants will be examined, and they will be asked to describe as accurately as possible the regions where they experience pain. Subsequently, the experimenter will demonstrate the exercises to be performed at home. Finally, the participants will be provided with a cream to be applied to the affected regions.~Placebo cream:~The participants receive an inert placebo cream, which is a standard basic cream infused with lemon oil, produced by a local pharmacy. Participants are informed that they are about to receive an effective analgesic cream.~Placebo exercises:~Participants are assigned a series of five core exercises, with an optional supplementary exercise available in case any of the core exercises proves ineffective for the participants. Participants are led to believe that these exercises are expected to have therapeutic effects."
223630756|NCT05173558|BEHAVIORAL|Uninterrupted motionless standing|Participants remained 20 minutes of uninterrupted motionless standing
223630757|NCT05173558|BEHAVIORAL|Uninterrupted motionless sitting|Participants remained 20 minutes of uninterrupted motionless sitting
223630758|NCT05173558|BEHAVIORAL|Sit-to-stand transitions|20 minutes of sit-to-stand transitions (1 minute sitting with 1 minute standing)
223630759|NCT00653510|DRUG|Actrapid (human insulin)|On day one the patients will receive glucose and insulin in order to reach a blood sugar around 18 and 20 mmol/L and on day two the patients will receive glucose and insulin in order to have a blood sugar around 5 and 7 mmol/L. On both days amino acid, lipid and glucose metabolism will be assessed by means of whole body isotope dilution.
223630760|NCT00944853|DIETARY_SUPPLEMENT|Liquid zinc syrup|Liquid zinc syrup containing 5 mg zinc as zinc sulfate
223630761|NCT00944853|DIETARY_SUPPLEMENT|Zinc tablet|Dispersible zinc tablet containing 5 mg zinc
223630762|NCT00944853|DIETARY_SUPPLEMENT|Liquid placebo supplement|Liquid placebo supplement containing 0 mg zinc
223630763|NCT01209871|BIOLOGICAL|Autologous Lymphoma Immunoglobulin-derived scFv-chemokine DNA Vaccine|Given ID
224219425|NCT02609737|RADIATION|68Ga-DOTA-JR11|
224219426|NCT02609737|RADIATION|177Lu-DOTA-JR11|
223630764|NCT01209871|OTHER|Laboratory Biomarker Analysis|Correlative studies
223630765|NCT03905018|DRUG|Tadalafil 20 MG|tadalafil 20 mg orally ,after a single administration
223630766|NCT00004217|BIOLOGICAL|filgrastim|5 μg/kg/day IV or SC
223630767|NCT00004217|BIOLOGICAL|sargramostim|5 μg/kg/day IV or SC starting d 15
223630768|NCT00004217|DRUG|cytarabine|Ara-C continuous IV: Hours 2.5 - 170.5 before PSC-833
223630769|NCT00004217|DRUG|daunorubicin hydrochloride|continuous IV: Hours 2 - 74 before PSC-833
223630770|NCT00004217|DRUG|valspodar|2 mg/kg load IV over 2 hrs (loading); 10 mg/kg/day Continuous hours 0 - 96
224219427|NCT06215781|PROCEDURE|Fully digital workflow of prosthetic fixed dental crown|The intervention that was administered was a full digital workflow. It includes an initial digital planning, an optical impression with intraoral scanner and a CAD-CAM milled zirconia crown. No analog materials were used.
224219428|NCT06215781|PROCEDURE|Combined digital and conventional workflows of prosthetic fixed dental crown|The intervention that was administered was a combined digital and traditional workflow. The initial planning was digital, then the impression was performed with analog impression material (silicones) and the final zirconia crown was CAD-CAM milled, with a digital procedure.
224219429|NCT06215781|PROCEDURE|Fully conventional workflow of prosthetic fixed dental crown|The intervention that was administered was a conventional workflow that doesn't provide any digital step. The impression was taken with analog material (silicones) and the final prosthesis was a metal-ceramic crown, realized on plaster cast.
224219430|NCT01605461|DRUG|BI 207127 NA|Single oral solution dose of BI 207127 NA combined with \[14C\]-BI 207127 NA
224219431|NCT04296383|DRUG|Azithromycin plus Xiyanping injection|Azithromycin for injection is 10mg / (kg • d), the maximum dose does not exceed 0.5g / d;Xiyanping injection intravenously, 0.4mL / (kg.d) daily, Qd
224219432|NCT04296383|DRUG|Azithromycin|Azithromycin for injection is 10mg / (kg • d), the maximum dose does not exceed 0.5g / d
224219433|NCT05730777|DRUG|Bifidobacterium Bifidum Oral Capsule|Bifidobacterium Bifidum Oral Capsule for 6 months in addition to conventional treatment
224219434|NCT05730777|DRUG|Cisplatin|Patients in the control group will receive conventional antitumor treatment only.
224219435|NCT05730777|DRUG|Carboplatin|Patients in the control group will receive conventional antitumor treatment only.
224219436|NCT05730777|DRUG|Paclitaxel|Patients in the control group will receive conventional antitumor treatment only.
224219437|NCT05730777|DRUG|Atlizumab|Patients in the control group will receive conventional antitumor treatment only.
224219438|NCT00530400|DRUG|cefuroxime|preoperative intravenous 1.5g cefuroxime
224219439|NCT00530400|DRUG|placebo|preoperative intravenous placebo
224219440|NCT01226147|DRUG|Tamibarotene|4mg/day for 24 weeks.
224219441|NCT05611268|DRUG|Pentoxifylline|Oral Pentoxifylline 400 mg/day for 30 days, followed by 800 mg/day for 150 days
224219442|NCT06090747|BEHAVIORAL|Hybrid lifestyle educational multidisciplinary intervention.|"Participants will receive a standardized educational healthy lifestyle intervention. The information will be shared via digital tools such as mail, WhatsApp, zoom workshops, educational videos, Joven, Fuerte y Saludable webpage, Joven, Fuerte y Saludable mobile app, and face-to-face educational sessions."
224219443|NCT06090747|BEHAVIORAL|Hybrid lifestyle personalized multidisciplinary intervention.|"Participants will receive a standardized educational healthy lifestyle intervention and personalized lifestyle intervention based on their clinical evaluation. Based on clinical records participants will be sent to nutritional, psychological, rehabilitation, and Mindfulness intervention. Educational and motivational strategies include digital tools such as mail, WhatsApp, zoom workshops, educational videos, the Joven, Fuerte y Saludable webpage, and the Joven, Fuerte y Saludable mobile app. And individualized follow-up through Mobile apps such as AVENA"
224219444|NCT02024698|DEVICE|omafilcon A|contact lens
224219445|NCT02024698|DEVICE|etafilcon A|contact lens
224219446|NCT05610605|OTHER|Health intervention programme: FRAGSALUD|The FRAGSALUD Program consists in two parts, a first part of health education that will be taught in a group in four sessions, and a second part of individual treatment and follow-up, individual consultations will have a bimonthly periodicity until reaching one year, at which time that the program ends and a final evaluation will be carried out to assess whether the changes are maintained 15 months after the start.
224219447|NCT06383377|DEVICE|Tooth extraction and bone graft procedure|"The subject will receive a flash dose of 2 gr of amoxicillin or 600 mg of Clindamycin 1 hour before the surgery.~Tooth will be extracted using gentle techniques to guarantee an atraumatic extraction. If the socket presents insufficient bleeding, the clinician must use an appropriate procedure to induce bleeding. The extraction site must be carefully cleaned. Extraction socket will then be filled with WHA or Bio-Oss previously hydrated with saline solution (0.9%). Extraction socket packed with the graft will be covered with a collagen sponge (Geistlich Mucograft® Seal) and sutured (cross suture, Vicryl rapide 4.0).~If required, a limited connective tissue graft can be placed in the vestibular region.~A CBCT scan will be performed after the bone graft procedure, i.e., after the extraction socket and the biomaterial placement, to measure the initial bone width.~The safety of the investigational device will be evaluated."
224219448|NCT06147219|PROCEDURE|interlocking intramedullary tibial nail|primary dynamization versus standard interlocking intramedullary tibial nail
224219449|NCT04712006|DRUG|JNJ-64304500|Participants will be administered with JNJ-64304500 SC (Dose 1 or 2) injection on Day 1.
224219450|NCT00645775|DIETARY_SUPPLEMENT|IGOB131|Comparison of 250 mg per day of Irvingia gabonensis to placebo
224219451|NCT00143754|PROCEDURE|Hydration|
224219452|NCT05079854|DRUG|Intraocular Instillation Solution|Intracameral Moxifloxacin 0.5%
224219453|NCT05079854|DRUG|Moxifloxacin Ophthalmic|Topical Moxifloxacin 0.5%
224219454|NCT04836156|DRUG|neoadjuvant chemotherapy upon in vitro PTC drug sensitivity screening for triple negative breast cancer|The choice of chemotherapy is based on the PTC drug sensitivity results.
224219455|NCT04836156|DRUG|neoadjuvant chemotherapy upon in vitro PTC drug sensitivity screening for luminal like breast cancer|The choice of chemotherapy is based on the PTC drug sensitivity results.
224219456|NCT05427565|OTHER|caffeine|The investigators will ask participant to only intake 200 mg of caffeine one hour before the experiment (no other caffeine intake since the wake-up) or avoid caffeine intake at all before the experiment
224219457|NCT05427565|OTHER|Experimental time|The investigators will ask participant to attend the experiment in the morning or afternoon
224219458|NCT02855190|OTHER|68Ga-citrate and 18F-FDG PET scans|68Ga-citrate and 18F-FDG PET/CT or PET/MR scans before operations
224219459|NCT04158856|DRUG|Pyrotinib|400mg po every day
224219460|NCT04158856|DRUG|Trastuzumab|Trastuzumab is administered at a loading dose of 8 mg/kg IV followed by 6 mg/kg every 21 days
224219461|NCT03397628|OTHER|FIFA 11 for health|
224219462|NCT00275028|DRUG|cediranib maleate|Given orally
223514365|NCT02719730|BEHAVIORAL|Reimbursement for whole grain purchases|All participants will receive education about whole grain foods. Those in the experimental arm will have a monthly financial incentive for purchases of specific whole grain foods foods during the 12-week study period, whereas the control group will not have a financial incentive for whole grain purchases during the study period.
223514366|NCT05960435|OTHER|Proprioceptive Neuromuscular Facilitation|PNF, a method used to increase the range of motion of the joint and strengthen the muscles in the newly gained range, is a holistic approach and is based on motor learning principles. PNF stretching involves isometric contraction of the target muscle in addition to static stretching.
223514367|NCT05960435|OTHER|Control Group Exercise|The control group will include static stretching, capsule stretching, progressive ROM exercises and strengthening exercises.
223514368|NCT03184675|OTHER|Functional action observation training|the Four Square Step Test (FSST) performance video for enhancing the dynamic balance and the video including participants' daily activities to increase the gait ability such as walking in a corridor, walking around the hospital, walking to the therapy room, coming out of the ward after opening and closing the door of it, coming in and out of toilet, shifting their blue plate. and bringing something from a refrigerator were produced and watched.
223514369|NCT03184675|OTHER|General action observation training|step 1, looking at the front, while walking comfortably; step 2, looking left and right, while walking; step 3, looking up and down, while walking; step 4, looking at the front, left and right, up and down while walking. After 15 minutes of watching the video, the exercise program with a therapist was conducted to increase the gait ability, for 15 minutes.
223514370|NCT05313256|DRUG|Lidocaine epinephrine buffered with sodium bicarbonate|When an extremely urgent fetal extraction by caesarean section is decided, the patient will be randomized. An epidural top-up will then be performed with Lidocaine epinephrine buffered with sodium bicarbonate.
223514371|NCT05313256|DRUG|Lidocaine epinephrine|When an extremely urgent fetal extraction by caesarean section is decided, the patient will be randomized. An epidural top-up will then be performed with Lidocaine epinephrine.
223514372|NCT06640322|OTHER|Reliability and validity|Reliability and validity of Craniocervical Dysfunction Index in Turkish Patients With Non-specific Neck Pain
223514373|NCT05882006|OTHER|gallstones|fellow up if the patients have gallstones
223630771|NCT04271878|OTHER|RespirAct™ system (Thornhill Research Inc., Toronto, Canada)|"1. HUTT with Normal Breathing in Room Air (No gas interventions will be applied)~2. HUTT with Normal Breathing and ETCO2 clamped at baseline levels~3. HUTT with Normal Breathing and Mild Hypercapnia (the ETCO2 will be clamped at 45mmHg )~4. HUTT with Normal Breathing and High Hypercapnia (the ETCO2 will be clamped at 55mmHg)~5. HUTT with Fast, Deep Breathing and resultant Hypocapnia Participant will be coached to breath around 15 breath per min.No gas interventions will be applied~6. HUTT with Fast, Deep Breathing and ETCO2 clamped at baseline levels. Participant will be coached to breath around 15 breath per min, with ETCO2 clamped to baseline levels."
223630772|NCT04232722|DRUG|Arsenicals|As4 S4
223630773|NCT05293769|OTHER|questionnaire|questionnaire will be filled in by all participants
223630774|NCT05910684|DIAGNOSTIC_TEST|Aegis CDM Test and Educational Materials|The Aegis CDM diagnostic test will be given to intervention participants to use on their patients. The participants will receive the results of the test through a web portal. Investigators will analyze the differences in quality of care between the control arm and the intervention arm.
223630775|NCT03962491|BEHAVIORAL|Daily Self-Monitoring Surveys + Contingency Management|Asked to complete a brief (5-minute) survey with questions related to pain experience and related measures every day for 28 days using the DynamiCare smartphone app, with the opportunity for monetary rewards for completing daily surveys.
223630776|NCT03962491|BEHAVIORAL|Daily Self-Monitoring Surveys|Asked to complete a brief (5-minute) survey with questions related to pain experience and related measures every day for 28 days using the DynamiCare smartphone app.
223630777|NCT03614182|DEVICE|physical training concurrent with cognitive training|The P+C group will undertake standing balance, stepping, and treadmill walking training while concurrently perform cognitive tasks.
223630778|NCT03614182|DEVICE|physical training followed by cognitive training|The P-then-C group will train the same set of standing balance, stepping, and treadmill walking activities as the P+C group while followed by cognitive training later.
223630779|NCT03614182|DEVICE|physical training without cognitive training|The P group will only train the same set of standing balance, stepping, and treadmill walking activities as the other two groups.
223630780|NCT00512889|BIOLOGICAL|therapeutic autologous lymphocytes|Autologous CTL generated from peripheral blood following culture with MART1/Melan-A peptide pulsed aAPC.
224219463|NCT04966897|DIETARY_SUPPLEMENT|GlycosBio Nutritional Supplement + PERT placebo|"The lipid (fat) in the GlycosBio Nutritional Supplement (GBNS) was provided in the form of a re-structured lipid monoacylglyceride (MAG) produced by the study sponsor. MAGs are readily absorbed by enterocytes without the need of digestion by pancreatic lipases. The MAG oil is produced enzymatically from almond oil. The product also contains essential amino acids, carbohydrates as simple sugars and fat-soluble vitamins and minerals. The GBNS to be administered in a volume sufficient to supply 0.5 g of MAG per kg of body weight"
224219464|NCT04966897|DIETARY_SUPPLEMENT|Standard Nutritional Supplement + PERT|A 5.9% fat triacylglycerol-based commercially available nutritional supplement (Boost Plus®, Nestlé Health Science, Bridgewater, NJ) in a volume sufficient to supply 0.5 g of TAG per kg of body weight over the same time period and PERT capsules (24,000 iu/capsule) at a dose of 2,500 iu of lipase activity per gram of fat ingested.
224219465|NCT05640310|DEVICE|Norbert Device|The Norbert Device (ND) is a contactless, noninvasive device that provides measurements of body temperature, oxygen saturation (SpO2), and pulse rate.
224219466|NCT00740727|DRUG|Human recombinant hyaluronidase (HRH)|150u HRH administered via EASI access line, prior to infusion of 250 D5W (5% dextrose in water)
224219467|NCT00740727|PROCEDURE|Enzymatically Augmented Subcutaneous Infusion (EASI) line placement|Subjects will under placement of an EASI line. This entails placement of a small (20-gauge) catheter in the upper back, in the subcutaneous space.
224219468|NCT01360957|DIETARY_SUPPLEMENT|Black cumin water extract as a traditional medicine|to be given orally in a dosage of 30 ml trice daily for 60 days
224219469|NCT04364165|BEHAVIORAL|Standard invitation to free HIV testing at mobile clinic|Participants receive standard invitation to same day HIV testing at mobile clinic.
224219470|NCT04364165|BEHAVIORAL|U=U messaging and invitation to free HIV testing at mobile clinic|Participants receive messaging about being undetectable equals untransmittable (U=U) and invitation to same day HIV testing at mobile clinic.
224219471|NCT01080027|DRUG|Rebif® New Formulation|The recommended dose of Rebif® is 22 or 44 μg administered three times per week by subcutaneous injection.
224219472|NCT06484192|DRUG|Naproxen 500 Mg|participants will receive Naproxen (500 mg) to take for 7 days after surgery as needed
223630781|NCT00512889|GENETIC|Use of an artificial antigen presenting cell (aAPC) to generate CTL|A genetically modified artificial antigen presenting cell (aAPC) is used in the generation of anti-tumor CTL.
223630782|NCT00512889|DRUG|GM-CSF|GM-CSF will be used as an immune activator and combined with the infusion of MART1/Melan-A specific CTL.
223630783|NCT00512889|RADIATION|Irradiation of cutaneous tumor lesion|Irradiation of cutaneous melanoma lesion will be combined with the infusion of MART1/Melan-A specific CTL.
224219473|NCT06484192|DRUG|Ketorolac|participants will receive Ketorolac (15 mg) immediately after surgery
224219474|NCT06484192|DRUG|OxyCODONE 5 mg Oral Tablet|participants will receive OxyCODONE (5 mg) to take for 7 days after surgery as needed
224219475|NCT06484192|DRUG|Metaxalone 800 MG|participants will receive Metaxalone (800 MG) to take for 7 days after surgery as needed
224317839|NCT02768831|OTHER|Tidal volume|The ratio of the inspired to expired tidal volume will be determined using the following formula: (TVinspired - TV¬expired)/TVinspired. The peak inflating pressure (PIP) required to achieve the set TV will be noted. The air in the cuff will then be increased or decreased as needed to achieve a set delivered ratio of 0.9-1.0.
223630784|NCT03581279|DEVICE|T2Lyme Panel testing|The T2Lyme Panel is an investigational use in vitro diagnostic (IVD) designed to qualitatively detect and identify the major causative agents of Lyme disease (Borrelia burgdorferi, Borrelia afzelii, Borrelia garinii, as well as an inclusive Borrelia spp. detection channel) from K2EDTA human whole blood samples.
223630785|NCT05164003|DRUG|CORETOX®|Up to a total of 360U of the IP was allowed to be injected at three flexors; wrist, elbow and finger.
223630786|NCT05164003|DRUG|BOTOX®|Up to a total of 360U of the comparator was allowed to be injected at three flexors; wrist, elbow and finger.
224317840|NCT01141205|BIOLOGICAL|AFO-18|18 peptides representing CD8 and CD4 epitopes mainly on HIV-1 in an adjuvants (CAF01)
224317841|NCT01141205|DRUG|Saline|1.2 ml saline intramuscularly
224219476|NCT05403021|BEHAVIORAL|GETCare Intervention|This 5-week intervention was administered remotely and individually to caregivers utilizing phone, email, and a secure online platform. The GETCare program was mostly self-led and included five weekly module education topics: basics of stroke, caregiver skills, caregiver changes, meaningful participation, and community resources. Each module incorporated (1) individualized education, (2) goal setting, (3) skills training, and (4) community resource recommendations. The program was led by a licensed occupational therapist who is a certified stroke rehabilitation specialist. The occupational therapist conducted weekly check-ins via email or phone focused on answering questions, tracking goal progress, and assisting in problem solving.
224219477|NCT02370784|DRUG|atorvastatin|Atorvastatin is an oral cholesterol-lowering medication commonly referred to as statin therapy.
224219478|NCT02370784|DRUG|Placebo|oral drug of similar appearance to atorvastatin
224219479|NCT00331630|DRUG|lapatinib ditosylate|Oral lapatinib is taken once daily on days 1-21 of each treatment cycle. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
224219480|NCT00331630|DRUG|paclitaxel albumin-stabilized nanoparticle formulation|30 patients receive Abraxane IV over 30 minutes on day 1 each of each treatment cycle. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
224219481|NCT06382779|PROCEDURE|reverse shoulder arthroplasty|resection of proximal humeral tumors and reconstruction with reverse shoulder arthroplasty
224219482|NCT04366388|DEVICE|ActivPAL3 VT (PAL Technologies Ltd).|. The ActivPAL will be fitted by a trained research assistant on the mid-thigh of the participants' dominant leg. ActivPALs have an inclinometer that detects the joint angle of the thigh to capture lying, sitting, standing, and stepping activities.
224219483|NCT03100253|DRUG|Tocilizumab|8 mg/kg i.v. every 4 weeks OR 162 mg s.c every seven days
224219484|NCT03100253|DRUG|Etanercept|a. Etanercept if initial failure to monoclonal antibodies: infliximab, adalimumab, golimumab or certolizumab
224219485|NCT03100253|DRUG|Infliximab|infliximab if initial failure to the receptor fusion protein, etanercept.
224219486|NCT03100253|DRUG|Adalimumab|adalimumab if initial failure to the receptor fusion protein, etanercept.
224219487|NCT03100253|DRUG|Golimumab|golimumab if initial failure to the receptor fusion protein, etanercept.
224219488|NCT03100253|DRUG|Certolizumab Pegol|Certolizumab Pegol if initial failure to the receptor fusion protein, etanercept.
224219489|NCT03645083|BEHAVIORAL|Telephone call|Participants in the intervention group receive a one-time telephone call reminder to attend follow-up treatment at the acupuncture clinic
224219490|NCT03645083|BEHAVIORAL|Text message|Participants in the intervention group receive a one-time text messaging reminder to attend follow-up treatment at the acupuncture clinic
224219491|NCT03639597|DEVICE|VytronUS Ablation System|
224219492|NCT05091606|PROCEDURE|Perfusion İndex in Patients with Spinal Anesthesia|Comparison of lower and upper extremity perfusion index values
223514374|NCT05292287|DEVICE|Polar Ignite Wearable Activity Monitor|A wearable activity monitor capable of monitoring outcomes relating to physical activity sedentary time, heart rate, and sleep quality. The watch synchronises to a corresponding mobile app called Polar Flow- Sync and Analyze or to the Polar FlowSync data transfer software on a computer.
223514375|NCT04218682|BEHAVIORAL|Shadow's Edge Mobile Application Gameplay|6 weeks of individual, interactive game play of the Shadow's Edge mobile app.
223514376|NCT05659251|COMBINATION_PRODUCT|Serplulimab, Albumin paclitaxel, carboplatin AUC=5, neoadjuvant therapy|Serplulimab 4.5mg/kg, IV, Day 1; Albumin paclitaxel 260mg/m2, Day 1; carboplatin AUC=5, Day 1; Preoperative neoadjuvant therapy for 3 cycles, one cycle every 21 days.
223514377|NCT05659251|PROCEDURE|Esophagectomy|"Prior to each surgical procedure, the department engaged in comprehensive discussions and deliberations to ascertain and establish the most suitable course of action. Minimally invasive Ivor-Lewis (intrathoracic anastomosis) or McKeown (neck anastomosis) esophagectomy, including two field extensive lymphadenectomies, was performed according to the tumor location. The resection length should be at least 5cm from the tumor origin according to prechemotherapy by endoscopy.~The surgeries will be performed by surgeons with rich experience. Minimally invasive esophagectomy, can be performed using the da Vinci surgical robot, thoracoscope, or laparoscope, or by using an open approach, as judged appropriate by the surgeon."
223514378|NCT05659251|OTHER|sample|"Blood, Tumour will be Collected from participant. Fate of sample is Destruction after use.~5 ml of peripheral blood was collected the day before each of the immunotherapy sessions and after surgery.~Tumour sample will be collected before neoadjuvant therapy and after surgery."
223514379|NCT05635409|BIOLOGICAL|STEM-PD|STEM-PD is a cryopreserved cell product, consisting of ventral midbrain dopaminergic progenitor cells derived from the clinical-grade hESC line RC17. STEM-PD will be administered using a non-CE marked class III neurosurgical medical device, the Rehncrona-Legradi device, bilaterally in one surgical session to the putamen.
223514380|NCT05974111|DIAGNOSTIC_TEST|blood sampling|At 5 time points (D0 (T0),morning after (T0B),D3 (T1),D5 (T2),D7(T3)) blood samples will be drawn next to blood sampling in context of standard of clinical care. A full coagulation and inflammation profile will be obtained as well as cell free DNA methylation
223514381|NCT02662582|DRUG|Reldesemtiv|Oral tablet
223514382|NCT02662582|DRUG|Placebo|Oral tablet
223514383|NCT06169579|DRUG|ND-003 tablets|ND-003 tablets will be administered orally and observe 4 days, and followed by over continuous 28-days cycles.
223514384|NCT06169579|DRUG|ND-003 tablets|ND-003 tablets will be administered orally and observe 4 days, and followed by over continuous 28-days cycles.
223514385|NCT06169579|DRUG|ND-003 tablets|ND-003 tablets will be administered orally and observe 4 days, and followed by over continuous 28-days cycles.
223514386|NCT06169579|DRUG|ND-003 tablets|ND-003 tablets will be administered orally and observe 4 days, and followed by over continuous 28-days cycles.
223514387|NCT06169579|DRUG|ND-003 tablets|ND-003 tablets will be administered orally and observe 4 days, and followed by over continuous 28-days cycles.
223514388|NCT06169579|DRUG|ND-003 tablets|ND-003 tablets will be administered orally and observe 4 days, and followed by over continuous 28-days cycles.
223514389|NCT06169579|DRUG|ND-003 tablets|ND-003 tablets will be administered orally over continuous 28-days cycles.
223514390|NCT06169579|DRUG|ND-003 tablets|ND-003 tablets will be administered orally over continuous 28-days cycles.
223630787|NCT03882021|PROCEDURE|A specific electrophysiology mapping protocol is applicable with the GRID catheter.|The procedure will be done according to a standard ablation approach. During the electrophysiology study, additional mapping data will be collected to support the study endpoints using the GRID catheter.
223630788|NCT02485873|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|As prescribed by treating physicians
223630789|NCT02485873|DRUG|Vitamin K antagonists|As prescribed by treating physicians
224219493|NCT01063478|DRUG|RAD001 (in addition to standard radiation and chemotherapy)|Standard radiation and chemotherapy (cisplatin and pemetrexed) + RAD001
224219494|NCT04126057|DEVICE|SightGlass Vision DOT Spectacle Lenses|Subjects randomized to test vs control, left eyes and right eyes
223630790|NCT05018000|BEHAVIORAL|Financial navigation|The CAFÉ intervention is a financial navigation intervention. During the Intervention, a CAFÉ financial navigator will provide information support and resources to people with cancer after diagnosis. CAFÉ intervention components include: (1) proactive assessment of patient financial questions and concerns (e.g., acute financial need or inability to pay for household expenses; deciding between care options depending on cost; uncertainty around planning for out of pocket costs and/or when patients will need to pay), (2) proactive, personalized support and referrals.
224219495|NCT04963465|DIAGNOSTIC_TEST|Ferning on microscopy|Amniotic fluid ferning will be assessed in the cohort before known rupture of membranes and after known rupture of membranes
224219496|NCT03072836|OTHER|analysing microbiota|16SRNA gene sequencing of feces
224219497|NCT00242762|DRUG|ZD1839 (IRESSA™)|
224219498|NCT00242762|DRUG|Docetaxel|
224219499|NCT00242762|DRUG|Cisplatin|
224219500|NCT03876574|PROCEDURE|DSA-guided implantation of hepatic artery infusion pump|Implant the infusion catheter and injection port (Celsite, B. Braun, Chasseneuil, France) under DSA-guiding. The proximal end of the infusion catheter was connected to the injection port and the device was implanted in a subcutaneous pocket in the right inner thigh; the distal end of the infusion catheter guarantee uni-direction infusion to liver.
223630791|NCT05018000|BEHAVIORAL|Enhanced usual care|The financial resource sheet lists and describes existing internal and community resources available to KP members
223630792|NCT02967991|DEVICE|EUS-guided liver biopsy|Endoscopic ultrasound guided liver biopsy
223630793|NCT05255679|DEVICE|Early FES|FES cycling starting 14-21 days post SCI for 6 months, 3 sessions/week, with gradually increasing duration (15-60 minutes), cadence (20-45 RPM) and resistance; surface stimulation of 3-5 muscle groups per leg; with RT300 Supine or SLSA FES cycle (Restorative Therapies, Inc, Baltimore, MD)
223630794|NCT05255679|DEVICE|Delayed FES|FES cycling starting 3 months (+ 14-21 days) post SCI, for 3 months, 3 sessions/week, with gradually increasing duration (15-60 minutes), cadence (20-45 RPM) and resistance; surface stimulation of 3-5 muscle groups per leg; with RT300 Supine or SLSA FES cycle (Restorative Therapies, Inc, Baltimore, MD)
223630795|NCT04151212|DRUG|BAT5906 injection|Signal dose escalation starting from 0.3mg. Route of administration: intravitreal injection
223630796|NCT00270881|PROCEDURE|Cord blood transplantation|unrelated cord blood transplantation
223630797|NCT00270881|RADIATION|TBI|Total body irradiation (TBI) 12Gy
223630798|NCT00270881|DRUG|cyclophosphamide|cyclophosphamide 120mg/kg
223630799|NCT00270881|DRUG|cytarabine|cytarabine 3g/m2x4
223630800|NCT02251262|DEVICE|Whole-body 18FDG-PET-CT scan|18FDG-PET-CT exam will be performed in patients, with suspicion of pacing or defibrillation lead infection, hospitalized in cardiology unit.
223630801|NCT03732573|BEHAVIORAL|Text messages|Text messages conveying 3 specific behaviour change techniques
223630802|NCT00939549|DRUG|Cyclophosphamide/Glatiramer acetate|Cyclophosphamide 50 mg/kg IV each day for four consecutive days. Glatiramer acetate 20 mg SC daily for 1 year.
223630803|NCT04100083|DRUG|Spironolactone 50 MG|"Study visit timeline: initial visit \[consent and enrollment followed by baseline exam (0 months), 3 months, 6 months, and follow up at 7 months, with optional treatment extension period for up to one year of total treatment during which patients will follow up every 3 months~The drug will be taken via oral tablets once daily for a duration of 6 months. Patients will be instructed to continue any current treatment regimen for hidradenitis suppurativa that was initiated at least 4 weeks prior to their enrollment in the study. Patients will be instructed to avoid potassium supplements and foods containing high levels of potassium, including salt substitutes, which could potentially lead to hyperkalemia. They will be instructed to avoid medications listed in the exclusion criteria."
223630804|NCT04100083|DRUG|Spironolactone 100mg|"Study visit timeline: initial visit \[consent and enrollment followed by baseline exam (0 months), 3 months, 6 months, and follow up at 7 months, with optional treatment extension period for up to one year of total treatment during which patients will follow up every 3 months~The drug will be taken via oral tablets once daily for a duration of 6 months. Patients will be instructed to continue any current treatment regimen for hidradenitis suppurativa that was initiated at least 4 weeks prior to their enrollment in the study. Patients will be instructed to avoid potassium supplements and foods containing high levels of potassium, including salt substitutes, which could potentially lead to hyperkalemia. They will be instructed to avoid medications listed in the exclusion criteria."
224219501|NCT03876574|DRUG|Gemcitabine|Given intra-arterially for 30 minutes
224219502|NCT03876574|DRUG|Floxuridine|Given intra-arterially continuously for 14 days
224219503|NCT03876574|DRUG|dexamethasone|Given intra-arterially continuously with 5-FUDR
224219504|NCT01773512|DRUG|Rosuvastatin|All patients will be using rosuvastatin 40 mg
224219505|NCT00171496|DRUG|Cyclosporine microemulsion|
224219506|NCT00171496|DRUG|Tacrolimus|
224219507|NCT00680576|BEHAVIORAL|CBT, Cognitive Behavioral Therapy|Eight weekly sessions of individual Cognitive Behavioral Therapy, to develop skills enabling adolescents stop or reduce their drug use.
224219508|NCT00680576|BEHAVIORAL|FFT, Family Functional Therapy|Eight weekly sessions of Functional Family Therapy designed to strengthen family relationships and build skills to help the adolescent stop or reduce his/her drug use.
224219509|NCT02658682|BEHAVIORAL|Attention Bias Modification|Computer based Attention Bias Modification
224219510|NCT02658682|BEHAVIORAL|Sham Attention Bias Modification|Computer based Sham Attention Bias Modification
224219511|NCT01536691|DRUG|ramosetron|ramosetron 0.3 mg iv D1 aprepitant 125 mg po D1, 80 mg po D2, 80 mg po D3 dexamethasone 12 mg po D1, 8 mg po D2-4
224219512|NCT01536691|DRUG|ondansetron|ondansetron 16 mg iv D1 aprepitant 125 mg po D1, 80 mg po D2, 80 mg po D3 dexamethasone 12 mg po D1, 8 mg po D2-4
223630805|NCT04100083|DRUG|Spironolactone 200 mg|"Study visit timeline: initial visit \[consent and enrollment followed by baseline exam (0 months), 3 months, 6 months, and follow up at 7 months, with optional treatment extension period for up to one year of total treatment during which patients will follow up every 3 months~The drug will be taken via oral tablets once daily for a duration of 6 months. Patients will be instructed to continue any current treatment regimen for hidradenitis suppurativa that was initiated at least 4 weeks prior to their enrollment in the study. Patients will be instructed to avoid potassium supplements and foods containing high levels of potassium, including salt substitutes, which could potentially lead to hyperkalemia. They will be instructed to avoid medications listed in the exclusion criteria."
223630806|NCT01440959|DRUG|dovitinib|TKI258 at 500 mg/day on a 5 days on/2 days off dosing schedule
223630807|NCT03889184|OTHER|rehabilitating meals-on-wheels service|the meals-on-wheels service will be specifically targeted for old people discharged from hospital, receiving exercise rehabilitation in the municipality or already receiving meals-on-wheels
223630808|NCT03796728|DEVICE|Juvéderm® VOLIFT™ with Lidocaine|Injectable gel that is a sterile, biodegradable, non-pyrogenic, viscoelastic, clear, colorless, homogeneous gel implant (dermal filler).
223630809|NCT02682953|DRUG|Neupogen|Pharmacological agents often used for stem cell mobilization will be utilized in this study.
223630810|NCT02682953|PROCEDURE|Hyperbaric oxygen therapy|Exposure to oxygen at 2.4 atmospheres absolute for 90 minutes/day for 3 to 5 days
223630811|NCT02682953|DRUG|Plerixafor|Pharmacological agents often used for stem cell mobilization will be utilized in this study.
223630812|NCT05873049|DEVICE|MolecuLight|MolecuLight is a handheld fluorescence imaging device that is utilized to help real-time visualize clinically undetectable fluorescent bacteria in wounds. It emits a 405 nm wavelength of safe violet light, which interacts with the wound tissue and bacteria causing certain bacteria to emit red or cyan fluorescence. The fluorescence signals were then captured by MolecuLight and those with bacteria at levels of ≥ 10\^4 colony forming units per gram (CFU/g) will be detected and displayed on the screen.
223630813|NCT00971659|DRUG|insulin glargine + exenatide + preexisting metformin|insulin glargine once daily subcutaneously over 4 weeks, dose adjustment according to a treat-to-target algorithm, exenatide 5ug twice daily subcutaneously for 2 weeks, then 10ug twice daily for 2 weeks, continuation of preexisting metformin
223630814|NCT00971659|DRUG|insulin glargine + sitagliptin + preexisting metformin|insulin glargine once daily subcutaneously over 4 weeks, dose adjustment according to a treat-to-target algorithm, sitagliptin 100 mg once daily in the morning over 4 weeks, continuation of preexisting metformin
223630815|NCT00971659|DRUG|insulin glargine + preexisting metformin|insulin glargine once daily subcutaneously over 4 weeks, continuation of preexisting metformin
223630816|NCT00333775|DRUG|Docetaxel|Docetaxel was supplied in 2 vials, 1 containing docetaxel and 1 containing a solvent, for intravenous infusion.
223630817|NCT00333775|DRUG|Placebo to bevacizumab|Placebo to bevacizumab was supplied as a sterile liquid for intravenous infusion in single-use vials.
223630818|NCT00333775|DRUG|Bevacizumab|Bevacizumab was supplied as a sterile liquid for intravenous infusion in single-use vials.
223630819|NCT03011268|OTHER|Discontinuation of anti-TNF treatment|Discontinuation of treatment with Infliximab, Adalimumab, and Golimumab in order to record time to relapse occurrences
223630820|NCT03011268|OTHER|Continuation of anti-TNF treatment|Continuation of treatment with Infliximab, Adalimumab, and Golimumab for 2 years after randomization, then discontinue
223630821|NCT04244448|DRUG|receive dissolved form of BIKTARVY®|The healthy volunteers will receive dissolved form of BIKTARVY® Pharmacokinetic samples will be taken at the following times: 0 hour (right before taking Biktarvy®); 0.5 hour; 1 hour; 1.5 hours; 2 hours; 2.5 hours; 3 hours; 4 hours; 8 hours; 12 hours; 24 hours; 36 hours; 48 hours and 72 hours (after Biktarvy®).
223630822|NCT04244448|DRUG|receive crushed form of BIKTARVY®|The healthy volunteers will receive crushed form of BIKTARVY® Pharmacokinetic samples will be taken at the following times: 0 hour (right before taking Biktarvy®); 0.5 hour; 1 hour; 1.5 hours; 2 hours; 2.5 hours; 3 hours; 4 hours; 8 hours; 12 hours; 24 hours; 36 hours; 48 hours and 72 hours (after Biktarvy®).
223630823|NCT04244448|DRUG|receive solid form of BIKTARVY®|The healthy volunteers will receive solid form of BIKTARVY® Pharmacokinetic samples will be taken at the following times: 0 hour (right before taking Biktarvy®); 0.5 hour; 1 hour; 1.5 hours; 2 hours; 2.5 hours; 3 hours; 4 hours; 8 hours; 12 hours; 24 hours; 36 hours; 48 hours and 72 hours (after Biktarvy®).
223630824|NCT00601224|BEHAVIORAL|Social cognition and interaction training (SCIT)|SCIT is a group-based treatment that has the goal of improving social cognition and social functioning for individuals with psychotic disorders. SCIT is composed of three phases: emotion training, figuring out situations, and integration. SCIT will be delivered by two therapists in 20 weekly sessions over 5 months.
223630825|NCT00601224|BEHAVIORAL|Treatment as usual (TAU)|TAU will involve routine care and meeting with case-managers and healthcare providers on an as-needed basis.
223630826|NCT04162288|OTHER|Online Training - Shared Decision Making in Prenatal Screening|TThe intervention consisted of an online self-study training program lasting 3 hours which aims to engage SDM in a prenatal screening context. The training was divided into four main modules: 1)SDM, 2)DS prenatal screening, 3)Decision aid and 4)Communication between healthcare professionals and patients. In each module, the targeted learning objectives and the work to be carried out (e.g. readings to be made, video to be viewed, evaluation to be carried out, etc.) are presented. Various teaching methods and medias are used during this training: videos, interviews, narrated capsule, readings, links to scientific articles and complementary websites. Videos are done with experts on SDM, ethics of prenatal testing. A simulation in the end is done to put participants in context of an actual consultation with a pregnant woman and her partner. This training was designed to adapt to the learning pace of the user, is hosted on University Laval platform and needs an identification code to enter.
224219513|NCT01092520|DRUG|Gabapentin|Day 1 - 5mg/kg/dose per os at bedtime then 5mg/kg/dose PO b.i.d x 1 day (Day 2) then on Day 3, 5mg/kg/dose PO t.i.d . x 19 days; after 7 days, if not at maximal effect may increase over 3 days to 10mg/kg/dose (Day 8: 5 mg/kg/dose q.am and midday, Day 9: 10mg/kg/dose b.i.d. + 5mg/kg/dose midday, Day 10: 10mg/kg/dose t.i.d.) Doses may be reduced if patient experiences intolerable side effects.
224219514|NCT00826631|PROCEDURE|Fast food arm|Doubling of regular caloric intake based on fast food, no exercise allowed
224219515|NCT02999373|OTHER|Autologous Umbilical Cord Blood Mononuclear Cells Therapy|Autologous Umbilical Cord Blood Mononuclear Cells Therapy in preterm for prevention of infection
223630827|NCT04162288|OTHER|Online Training - Online Training on Prenatal Screening|The control intervention consisted of an online self-study training program lasting 3 hours which aims to provides knowledge for prenatal screening. The training has four main modules: 1)Context and history of prenatal screening(new), 2)DS prenatal screening(existing), 3)Consent in prenatal screening(new) and 4)Communication between healthcare professionals and patients(existing). In each module, the targeted learning objectives and the work to be carried out are presented. Various teaching methods and medias are used during this training: videos, interviews, narrated capsule, readings, links to scientific articles and complementary websites. Videos are done with experts on SDM, ethics of prenatal testing. For the 2 new modules, narrated capsules and reports have replaced videos of experts. There is no simulation at the end. This training was designed to adapt to the learning pace of the user, is hosted on University Laval platform and needs an identification code to enter.
223630828|NCT03926208|PROCEDURE|Soak and Scrub|Betadine soak and scrub in addition to standard clorhexadine scrub (standard of care).
224317842|NCT01772485|BEHAVIORAL|Cognitive Training|The training comprises a suite of 26 engaging, performance-adaptive, and rewarding training modules that provide 30 hours of rigorous neuroplasticity-based cognitive training for children with ADHD addressing deficits in core cognitive domains of alertness, selective attention and working memory of goal-relevant information, control of impulsive actions and suppression of distracting information.
223630829|NCT03926208|PROCEDURE|Clorhexadine scrub|Clorhexadine scrub (standard of care).
223630830|NCT02968134|DRUG|Posaconazole|A single dose of 300mg intravenous posaconazole will be administered and blood samples will be taken prior to start of infusion, at 15,45,75minutes, 3,5,8,12,18,24,30,36 and 48 hours.
224219516|NCT03763331|DEVICE|Control/Sham Treatment|Thermoneutral water will be circulated through water-circulating trousers to maintain skin temperature at baselines levels daily for 90 minutes for 8 weeks.
224219517|NCT03763331|DEVICE|Heat Therapy|Water at 110 degrees F will be circulated through water-circulating trousers daily for 90 minutes for 8 weeks.
224219518|NCT02958540|BIOLOGICAL|SynGEM|Prime / boost vaccination in each group
224219519|NCT02958540|OTHER|placebo|prime /boost vaccination
224219520|NCT06541392|OTHER|breakfast 6.30 am|This group will have breakfast time from 6.30 to 7.30 am
224219521|NCT06541392|OTHER|breakfast 7.31 am|This group will have breakfast time from 7.31 to 8.31 am
224219522|NCT05482672|DRUG|Fisetin|Fisetin is a plant flavanol senolytic found in strawberries, persimmons, and cucumbers. This naturally derived senolytic has few side effects and previous animal models of both osteoarthritis and rheumatoid arthritis have demonstrated that the senolytic supplement fisetin reduces inflammation and slows cartilage breakdown.
224219523|NCT05482672|BEHAVIORAL|GetHealthy-OA mind-body program|The GetHealthy-OA mind-body program emphasizes increased physical activity, healthy diet and sleep habits to lessen osteoarthritis and depressive symptoms
224219524|NCT05482672|DRUG|Placebo oral capsule|The oral placebo will consist of corn starch and gelatin capsules
224219525|NCT05482672|BEHAVIORAL|Health education booklet|The booklet will containing brief summarized information that reflects the active intervention topics including the trajectory of pain and recovery for those with knee osteoarthritis, the role of relaxation strategies to manage pain, and the importance of returning to engagement in activities of daily living
224219526|NCT03953781|DRUG|Effect of valporate on Reproductive Functions in Newly Diagnosed Epileptic Males|
224317843|NCT01772485|BEHAVIORAL|Active Control|Participants will engage in any 4 of 13 suite games (visual tiled puzzles, word games etc.) from the Hoyle Puzzle and Board games program. Suite games are randomly assigned in each session.
224219527|NCT03953781|DRUG|Effect of levetiracetam on epileptic males reproductive function|
224219528|NCT03654534|DIETARY_SUPPLEMENT|NutrenOpimum|NutrenOpimum administration was recommended with a dosage of 400 kcal/400 ml per day within 7 days postoperatively and was continued for 3 months postoperatively.
224219529|NCT01312779|DEVICE|Implantation of CEP Magna Mitral Model 7000TFX|Heart valve surgery: CEP Magna Mitral Model 7000 TFX
224219530|NCT04741503|OTHER|Breast Cancer Screening Decision Support Tool|-Provides a description of screening mammography, current screening recommendations, benefits and downsides, narratives, and questions for the participant's physician.
224219531|NCT04741503|OTHER|National Cancer Institute Breast Cancer Screening PDQ|-Provides current information about breast cancer screening and is meant to inform and help patients
224219532|NCT05703555|DRUG|Tusamitamab ravtansine|Eligible subjects will receive Tusamitamab ravtansine (100mg/m2 IV Q2W). Subjects without evidence of disease progression or drug related toxicity can continue treatment with Tusamitamab ravtansine (100 mg/m2 IV Q2W) until disease progression, unacceptable toxicity occurs, or the participant's or Investigator's decision to stop the treatment.
224219533|NCT02241681|DIETARY_SUPPLEMENT|Peptamen 1.5|Peptamen will be given twice at the dose of 250 mL, with an interval of 4 hours.
224219534|NCT05658614|BIOLOGICAL|Sm14 recombinant vaccine+ GLA-SE adjuvant|rSm14 - recombinant protein (GMP produced) - 50ug / injection GLA-SE- synthetic Glucopyranosyl lipid A in stable emulsion: 2.5ug / injection
224219535|NCT00674219|DRUG|Memantine|Namenda 10mg BID for 12 weeks
224219536|NCT05480618|BEHAVIORAL|Slow Breathing|"On two separate visits (on Day 1 and between Day 7 and 9 of their self-practice) the subject will be coached on yoga breathing techniques.~The breathing techniques will be varied in:~1. frequency (between 0.25 and 0.1 Hz)~2. Inspiratory:Expiratory (I:E) ratio or 'Duty Cycle'~3. with and without ujjayi (yogic throat restriction)~4. with and without inspiratory/expiratory breath holding~At the end of the first coaching visit the subject will be given a diary to record their own practice of the breathing techniques they were coached on."
224219537|NCT03096613|DRUG|Levothyroxine|Levothyroxine is used to normalize the thyroid hormone level of patients allocated to levothyroxine.
223630831|NCT05665634|DEVICE|Concurrent transcranial magnetic stimulation and electroencephalogram|Single and paired-pulse TMS will be applied to 5 different brain regions during simultaneous recording of EEG. Paired-pulse stimulations will have either 3 ms or 11 ms between pulses, to stimulate cortical inhibition and excitation respectively. Stimulation intensity for single-pulse stimulation blocks will be 120% of the resting motor threshold (RMT). For paired-pulse blocks, the conditioning (first) pulse will be delivered at a stimulation intensity of 80% RMT, and the test (second) pulse will be delivered at 120% RMT. Each test block will consist of 60 TMS trials and will last for 5 minutes. Order of test blocks will be pseudo-randomized across participants. Out of 5 stimulation sites, 3 will be determined based on individual's own brain anatomy and resting state connectivity. These 3 regions will be stimulated using all 3 TMS protocols. The other two regions will be determined based on the literature and only be targeted using the single pulse TMS protocol.
223630832|NCT00217984|OTHER|Usual Care|Referral to smoking cessation clinic
223630833|NCT00217984|BEHAVIORAL|Extended cognitive behavior therapy|16 sessions of cognitive behavior therapy over 6 months
223630834|NCT02443467|OTHER|No intervention|
223630835|NCT03866122|DEVICE|NTM Monitoring|NTM and a patient monitor will continuously collect temperature for up to 72 hours. Additionally, Bempu and Thermospot may monitor temperature for up to 72 hours.
223630836|NCT05298579|OTHER|Yoga exercises|Yoga-based exercise training includes a warm-up and cool-down period for beginners
223630837|NCT02065830|DEVICE|EKSO|"The subjects will undergo inpatient rehabilitation consisting of a treatment cycle of 30/40 training section using the robot EKSO system device, according to individually tailored exercise scheduling.~The practice will include robot-assisted walking at variable speeds for 45/60 min and balance training."
223630838|NCT00754962|DRUG|protriptyline|10 mg tablet
224317844|NCT05810428|PROCEDURE|GKRS-VR training|One month after radiosurgery, GKRS-VR subjects will receive neuromodulation treatment twice a week (30' per time), for 8 consecutive weeks followed by 9 months of remote rehabilitation. GKRS-VR group will perform neuromodulation based on VR sensorimotor rehabilitation using an immersive system developed ad-hoc. Treatments will include voluntary mimic movements reinforced by VR augmented feedback, consisting in the reflection of a real-time avatar animation, multiplied when needed, associated with different targets to reach based on specific facial gestures. The execution of motion multiplier on avatar will be allowed in order to personalize treatments, emphasizing a graded exposure to pain perception. In addition, the investigators will develop a dedicated mobile-application for remote rehabilitation with the aim of prescribing VR augmented feedback home exercises and immersive VR pain neuromodulation.
224317845|NCT05810428|PROCEDURE|Control Group|Control Group will undergo only radiosurgery with no rehabilitation and they will perform only clinical evaluation at study entry, after three months and one year.
224317846|NCT04052334|DRUG|TIL|Participants will receive an infusion of Tumor-infiltrating lymphocytes (TIL) after tumor resection and TIL product is generated.
224317847|NCT04052334|DRUG|Interleukin-2|Participants will receive Interleukin-2 (IL-2) 600 000 IU/kg intravenously (IV) bolus (about 15 minutes) every 8 to 16 hours for up to 15 doses, beginning approximately 8 to 16 hours after T-cell infusion.
224317848|NCT04052334|DRUG|Fludarabine|Participants will receive an intravenously (IV) infusion of Fludarabine 25 mg/m2 for approximately 30 minutes for 5 days, prior to T-Cell infusion
224317849|NCT04052334|DRUG|Cyclophosphamide|Participants will receive Cyclophosphamide 60 mg/kg/day intravenously (IV) in 250 mL normal saline (NS) over approximately 2 hours, 7 days prior to T-Cell infusion
224317850|NCT04664933|DRUG|Intra-arterial administration of neuroprotective agents|Intra-arterial administration of 3-n-butylphthalide for 16 to 24 hours during and after the operation at 17.36 to 26.04 ug/min
224317851|NCT06159491|DRUG|Pacritinib|Participants will take Pacritinib 100 mg - 200mg BID for each 28 day cycle
223630839|NCT06242132|DRUG|Clopidogrel tablet|Efficacy and safety of a 300mg loading dose of clopidogrel administered within 24 hours of first-ever ischemic stroke followed by 75mg daily for 3 months will be assessed through NIHSS, mRS, duration of hospital stay, new ischemic stroke, and possible adverse effects.
223630840|NCT06242132|DRUG|Cilostazol 100 MG|Efficacy and safety of 200 mg cilostazole followed by 100 mg twice daily for 3 months will be assessed through NIHSS, mRS, duration of hospital stay, new ischemic stroke, and possible adverse effects.
224317852|NCT06159491|DRUG|Azacitidine|Azacitidine 75mg/m\^2 will be administered IV or SQ QD D1-7 of each 28 day cycle
223630841|NCT02476617|DRUG|ombitasvir/paritaprevir/ritonavir|ombitasvir/ABT-450/ritonavir tablets
223630842|NCT02476617|DRUG|dasabuvir|dasabuvir tablets
223630843|NCT02476617|DRUG|ribavirin|ribavirin tablets
223630844|NCT02661321|OTHER|No intervention was used in this study, this was an observational study|
223630845|NCT02241616|DRUG|Entecavir+Fuzheng Huayu+TCM Granule|The subjects will be taking 1 Entecavir tablet per day, 4 Fuzheng Huayu tablets three times a day and specific Traditional Chinese Medicine granule for 48 weeks.
223630846|NCT05933317|DIAGNOSTIC_TEST|Functional lung MRI|Functional lung MRI
223630847|NCT03987269|BEHAVIORAL|Embodied Virtual Reality|"The video will be formatted for viewing within a standard virtual reality headset. Once the video begins, subjects will follow the movements of the new body they are inhabiting in synchronicity to the video. Movement and haptic input include~1. Mimicking the hand gestures at the beginning in order to establish the body transfer illusion.~2. Shaking someone's hand~3. Someone holding the hand and elbow to assist them in standing, taking a few steps and returning to a seated position.~4. Shaking hands~5. Having their blood pressure taken~6. Having their pulse taken~7. Fill a pill organizer~8. Color a picture~All of the above interactions will be facilitated by the two Co-PI's (Blatter, Ware). Blatter and Ware have been creating and performing similar Virtual Reality Embodiments with haptics for the past year, and to date, have performed hundreds of them for demos, colleagues, students and the public."
223630848|NCT03987269|BEHAVIORAL|Narrative Video|The video will be formatted for a standard flat screen television. Participants will watch the video alone in a standard School of the Arts classroom.
223630849|NCT00635206|DEVICE|BiPap auto with Fi Flex|"* MinEPAP = 4 cmH2O for prescribed CPAP ≤ 10 cmH2O (use 6 cmH2O for prescribed CPAP \> 10 cmH2O)~* MaxIPAP = 25 cm H2O~* MinPS = 2 cm H2O (cannot be adjusted)~* MaxPS = 8 cm H2O~* Bi-Flex setting of 3"
224317853|NCT06250036|DRUG|Single agent zimberelimab|Single agent zimberelimab (PD-1 inhibitor) Q3W
224317854|NCT06250036|DRUG|Combination zimberelimab + domvanalimab|Combination zimberelimab + domvanalimab (TIGIT inhibitor) Q3W
223630850|NCT00635206|DEVICE|Standard CPAP|CPAP ≤ 10 cmH2O (use 6 cmH2O for prescribed CPAP \> 10 cmH2O)
223630851|NCT05661643|DRUG|Temozolomide capsule|Temozolomide 200 mg/m2 is administered orally for 1-5 days of each cycle, and then canceled for 23 days (a total of 28 days is 1 cycle)
223630852|NCT03916133|DIAGNOSTIC_TEST|Intervention group|6s PBV mapping will be conducted
223630853|NCT02505607|OTHER|Overactive Bladder Care Plan counseling|"Use of a printed Overactive Bladder Plan of Care information sheet."
223630854|NCT03486912|DRUG|BMS-986036|Specified dose on specified days.
223630855|NCT03486912|OTHER|Placebo|Specified dose on specified days.
223630856|NCT04020549|BEHAVIORAL|Growth, Gratitude, & Positive Activities|Reading and writing activities based on growth (designed to instill the belief that people can change), gratitude (noticing and appreciating good things in life), and behavioral activation (identifying and scheduling positive activities).
223630857|NCT04020549|BEHAVIORAL|Study Skills Control|Reading and writing activities designed to teach evidence-based study strategies.
223630858|NCT03518853|RADIATION|Short-course Hypofractionated Once-weekly Radiation Therapy|Eligible patients will be treated with a radiation regimen of 35 Gy in 5 fractions delivered at one fraction per week at 7 day intervals. The dose of radiotherapy is based on the consensus alpha beta ratio of 1.5.
223764181|NCT06418386|PROCEDURE|rotary sodoium hypochlorite IIC|"* The procedural tooth is anesthetized and isolated with rubber dam as mentioned~* All carious tissue will be removed by hight speed hand piece,distal cannel of mandibular primary molars and palatal cannel of maxillary primary molars will be chosen for sampling procedure.~* A sterile broach will be inserted to obtain root cannel content then sterile paper point inserted to root canal and will be left for 1 min The paper point will be removed with sterilized tweezer which will immediately transferred to tube containing transport medium (eppendrof of containing 200 μl nutrient broth medium).~* using AF baby fanta files SAME AS MENTION BEFORE , and irrigation with 1% sodium hypochlorite~* Post irrigation sample and pre-preparation sample will be transferred to microbiological laboratory Canals will be filed with obturation material(Metapex)then crown will be restored with glass inomar and stainless steel crown"
224219538|NCT02280421|DRUG|ASP2151 400mg + 100mg ciclosporin|
224219539|NCT02280421|DRUG|ASP2151 1200mg + 100mg ciclosporin|
224219540|NCT02797964|DRUG|SRA737|SRA737 will be administered orally on each day of a 28-day cycle. Subjects will receive a single dose of SRA737 between 4 to 7 days prior to starting the first cycle for PK profiling. Subjects can continue taking SRA737 if they are receiving clinical benefit and able to safely take the drug and follow the requirements of the study.
224219541|NCT03501784|DEVICE|Nobio particles incorporated within Novidia Dental Bonding|Nobio particles incorporated within Novidia Dental Bonding and Flow
224219542|NCT03501784|DEVICE|Filtek bond and flow composite|standard of care class V composite restoration performed with Filtek and 3M
224219543|NCT02367079|DEVICE|Diathermy|Sham diathermy vs switched on diathermy effect on pain where assessed
224219544|NCT04022070|OTHER|Dynamic Tape® (Tape)|To evaluate the evolution of this symptomatology prior to and thereafter the application of Dynamic Tape® bandage affected by plantar fasciitis during a week the Outcome Measure, pain is evaluate with a VAS (visual pain scale).
224219545|NCT04733352|OTHER|acupuncture|to conduct acupuncture on different acupoints
224219546|NCT04262375|BIOLOGICAL|Durvalumab|Durvalumab is a human immunoglobulin G (IgG)1 kappa monoclonal antibody directed against human PD-L1. Durvalumab selectively binds human PD-L1 with high affinity and blocks its ability to bind to PD-1 and cluster of differentiation (CD)80. The fragment crystallizable (Fc) domain of durvalumab contains a triple mutation in the constant domain of the IgG1 heavy chain that reduces binding to the complement component C1q and the Fc gamma receptors responsible for mediating antibody dependent cell mediated cytotoxicity.
224219547|NCT04262375|BIOLOGICAL|Oleclumab|Oleclumab is a human immunoglobulin G1 lambda monoclonal antibody (mAb) with a triple mutation in the heavy chain constant region for reduced effector function. Oleclumab selectively binds to cluster of differentiation 73 (ecto-5'-nucleotidase) (CD73) and inhibits CD73-associated ectonucleotidase activity, thereby inhibiting the CD73-mediated production of immunosuppressive adenosine. Extracellular adenosine contributes to the immunosuppressive effects of both regulatory T cells and myeloid derived suppressor cells, among others. This, in turn, leads to increased antitumor immunity.
224219548|NCT00840359|PROCEDURE|Photodynamic therapy|Application of Metvix 16% cream followed by exposure to daylight for 2.5 hours
223630859|NCT06351228|OTHER|Conization plus nodal evaluation|Conization plus nodal evaluation
223630860|NCT05831033|BIOLOGICAL|BEN101|"Lymphodepletion regimen：Cyclophosphamide 250mg/ m2/day x 3 days (day -4, -3，-2) , Fludarabine 25mg/ m2/day x 2 days (day-4, -3) , Paclitaxel 100mg/ m2/day -3. The lymphodepletion regimen could be adjusted by the treating physician according to patient's disease condition.~BEN101 infusion： Single dose level between 1x10\^9 to 1x 10\^11，not lower than 1×10\^9 cells, final dose is affected by the starting amount of TILs cells isolated from the tumor tissue sample.~IL-2：Administer 8-16 hr after TIL infusion. 600,000 IU/kg intravenously over 15-20 mins every 12 hours. It is recommended to start with high dose; and de-escalate based on tolerability, up to 5 days. IL-2 administration will be terminated if unacceptable toxicities occur."
223630861|NCT01495949|DRUG|etomidate|During induction, after 3 mcg/kg of fentanyl and 0.05 mg/kg of midazolam given, small doses 2-4 mg (1-2 ml) of etomidate will be given by titration (the syringe pump and extension and three way stopcock are covered to blind the study drug) until the patients are unconscious.
223630862|NCT01495949|DRUG|thiopentone|During induction, after 3 mcg/kg of fentanyl and 0.05 mg/kg of midazolam given, small doses 25-50 mg (1-2 ml) of thiopentone will be given by titration (the syringe pump and extension and three way stopcock are covered to blind the study drug) until the patients are unconscious
224219549|NCT00840359|PROCEDURE|Cryotherapy|Cryotherapy for 2 times 20 sec
224219550|NCT02057952|BEHAVIORAL|Education and exercise|The active groups will meet twice a week for 75 minutes over six months. They will be followed for an addition six months to monitor maintenance.
224219551|NCT04868409|DRUG|Suxamethonium|1 mg/kg for tracheal intubation after 60 seconds
223630863|NCT02491684|DRUG|Interferon beta-1a Nebuliser solution 48 μg/mL|Interferon beta-1a, 0,5 ml (24 μg, metered dose) once daily inhalation for 14 days
224219552|NCT04868409|DRUG|Rocuronium|1 mg/kg for tracheal intubation after 60 seconds
224317855|NCT05326412|DRUG|Itepekimab SAR440340|Pharmaceutical form: solution for injection in pre-filled syringe; Route of administration: subcutaneous
223630864|NCT02491684|DRUG|Placebo|Placebo solution for once daily inhalation for 14 days
223630865|NCT04665453|DIAGNOSTIC_TEST|Electroencephalography|Recording of the brain electrical activity during sleep; background activity and sleep phases will be evaluated
223630866|NCT04665453|DIAGNOSTIC_TEST|Monitoring of vital functions|Measuring of respiratory rate, heart rate, SpO2, every 10 minutes after the medicine is given to the patient for the duration of EEG, and after 120 minutes. Blood pressure is measured at the time of application of the medicine, at the end of EEG and after 120 minutes.
223630867|NCT04665453|DRUG|Melatonin 0,1mg/kg oral syrup|Melatonine in the form of syrup will be given orally to child.
223630868|NCT04665453|DRUG|Dexmedetomidine 3 mcg/kg sublingually|Dexmedetomidine in the form of a solution will be given to child sublingually.
223630869|NCT04665453|DRUG|Dexmedetomidine 3 mcg/kg intranasally|Dexmedetomidine in the form of nasal spray will be given to child intranasally.
223630870|NCT00005975|DRUG|Megestrol Acetate 20mg/day|Double blinded Megestrol Acetate 20 mg/day
224219553|NCT02888769|BEHAVIORAL|Text Messaging|Patients will receive regular semi-personalized text messages for 6 months. Each participants will receive 6 text messages per week, which will be sent at random times of the day (9.00am, 12noon, 4.00pm). Non-smokers will receive two general messages, two hypertension messages, one medication adherence message and one physical activity message per week. Smokers will receive one general message, two hypertension messages, one medication adherence message, one physical activity message and one smoking cessation message per week. Prior to study commencement, a bank of 280 messages have been developed based on guidelines and behavior change theory (BCT), and have underwent multidisciplinary expert review and qualitative review process.
224219554|NCT03246568|PROCEDURE|Renal Nerve Denervation|Bilateral renal denervation using a multi-polar radiofrequency ablation catheter (Symplicity™ Spyral Cather, Medtronic) in the right and left main, branch, and accessory renal arteries in vessels ranging in diameter between 3 and 8 mm.
224219555|NCT03246568|PROCEDURE|Pulmonary vein isolation|PVI by cryo-balloon ablation without linear ablation
224317856|NCT06298513|OTHER|Cardiac rehabilitation|Six weeks of cardiac rehabilitation with physical training
223630871|NCT00005975|DRUG|Megestrol Acetate 40 mg/day|Double blinded Megestrol Acetate 40 mg/day
223630872|NCT00005975|DRUG|Megestrol Acetate Placebo 20 mg/day|Megestrol Acetate Placebo 20 mg/day
223630873|NCT00005975|DRUG|Megestrol Acetate Placebo 40 mg/day|Megestrol Acetate Placebo 40 mg/day
223630874|NCT00368407|DEVICE|308-nm excimer laser|
223630875|NCT04137068|BEHAVIORAL|Reduced Activity|Participants reduce their activity level to \<5,000 steps/day and \<50 % of baseline steps.
223630876|NCT01419964|DRUG|Group 01|ACH24
223630877|NCT01419964|DRUG|Group 02|Placebo
223630878|NCT03983707|DEVICE|Purastat®|Use of Purastat®
223630879|NCT06027580|DEVICE|SPIO® Core-MAX® Expedition thoracolumbosacral orthosis|SPIO® Core-MAX® Expedition thoracolumbosacral orthosis use 2 hours per day for 6 months
223630880|NCT06027580|OTHER|Standard Care Therapy option|Standard of care Therapy without the use of trunk orthosis
223630881|NCT05906953|DRUG|HG004|Low dose Medium dose High dose
223630882|NCT06337799|BEHAVIORAL|Research Pharmacist|The goal of this intervention is to determine if allied health professionals will improve blood pressure in new mothers.
223630883|NCT06582901|BEHAVIORAL|Cognitive training (CT) plus the neuropsychological educational approach to cognitive remediation (NEAR) model and an Enhanced - Treatment as Usual (E-TAU)|Psychosocial interactions computer-based cognitive training (CT) administered in a group setting that includes the Neuropsychological Educational Approach to Cognitive Remediation (NEAR) model:
223630884|NCT06582901|BEHAVIORAL|Enhanced - Treatment as Usual|The Enhanced-Treatment as Usual (E-TAU) sessions are delivered in a group therapy format and guided by the principles of Cognitive Behavioral Therapy (CBT). Participants learn to develop coping skills and are educated on how to improve distortions to reduce anxiety and depression.
223630885|NCT05467007|DIAGNOSTIC_TEST|BioFire® Respiratory Panel 2.1-EZ|BioFire RP2.1-EZ Panel uses a syndromic approach to quickly identify SARS-CoV-2, along with 18 additional viral and bacterial pathogens in patients suspected of SARS-CoV-2. This PCR test provides results in about 45 minutes.
223630886|NCT05941546|DIAGNOSTIC_TEST|anti-TBEV serology|we will measure by ELISA in microplates the anti-TBEV IgG as well as the anti-TBEV IgM on the sera + in TBEV IgG. We will then send a patient questionnaire with an information note to document the context of this TBEV seropositivity and to eliminate false-positivities (vaccination). Finally, we will perform PCR on CSF if serum positive and CSF available
223630887|NCT05585788|DEVICE|Addinex Device (ADX-27)|"The device operates without the use of any electronics, wireless or firmware requirements. This is achieved through its mechanical system which uses a different randomized passcode for each dose that is loaded into a circular drum inside the device. The passcodes are provided by an online server through either a mobile app, web app, text service or call in service. The online server provides passcodes on a request basis, while following instructions set by the treating physicians."
223630888|NCT04197700|OTHER|Target MAP Management|Target MAP Management
223630889|NCT05818254|BEHAVIORAL|HOP-STEP (Healthy Outcomes in Pregnancy with SLE Through Education of Providers) Intervention|The HOP-STEP Intervention is simple with 3-steps: (1) ascertain and document current pregnancy intention and contraceptive use, (2) patient and provider collaboratively arrive at her optimal contraceptive and/or pregnancy plan using a Decision Guide directed conversation, and (3) create a warm handoff with a patient-specific SLE risk assessment and guideline-aligned recommendations.
223630890|NCT05818254|BEHAVIORAL|Routine Care|Providers will continue to provide reproductive healthcare in their current manner.
224219556|NCT02878291|BIOLOGICAL|Meningococcal ACYW135 Polysaccharide Conjugate Vaccine|Group 1:3/2/1 dose(s) according to age of subjects. Single intramuscular dose contains 10 µg each of Serogroup A, C, Y, and W135 polysaccharide conjugated to Tetanus Toxoids.
224219557|NCT02878291|BIOLOGICAL|Meningococcal ACYW135 Polysaccharide Conjugate Vaccine|Group 2:3/2/1 dose(s) according to age of subjects. Single intramuscular dose contains 5 µg each of Serogroup A, C, Y, and W135 polysaccharide conjugated to Tetanus Toxoids.
223630891|NCT01263769|DRUG|Axitinib|Starting dose: 5 mg by mouth twice each day for 12 weeks.
224317857|NCT05814822|BEHAVIORAL|Cognitive Behavioral Therapy for insomnia (CBTi-CB-TM)|Participants randomized to CBTi-CB-TM will participate in 6 individual telemedicine sessions delivered by a trained therapist to learn cognitive and behavioral strategies for insomnia.
223630892|NCT05984121|DRUG|Local ozon injections|"Local ozone therapy is approximately 2-3 cc of medical ozone, ozone-resistant is realised by injecting subcutaneously or intramuscularly with injectors. Local ozone injection group at 0., 2. and 4. weeks with ultrasound guided medial Firstly 1.5 cc with a 25 gauge needle into the plantar fascia insertion in the plantar region 02 lidocaine injection in a sterile way and then (according to the weeks 3 cc ozone injection of 10, 15 and 20 pyg/ml will be made respectively."
223630893|NCT05984121|DRUG|Local dextroz prolotherapy injections|Dextrose prolotherapy injection group under ultrasound guidance at weeks 0, 2 and 4 1.5 cc 30% dextrose solution and 1.5 cc 2 lidocaine mixture with a 25 gauge needle into the medial plantar region cc 2 lidocaine mixture will be made sterile with 3 cc 15% dextrose.
223630894|NCT05984121|OTHER|Exercise Group|Patients will receive a conventional therapy program consisting of exercises
223630895|NCT05518253|BIOLOGICAL|CD70 CAR-T cells|Administration method: intravenous infusion； Subjects will be treated with Fludarabine and Cyclophosphamide before cell infusion.
223630896|NCT05518253|BIOLOGICAL|CD70 CAR-T cells|Administration method: intraperitoneal injection； Subjects will be treated with Fludarabine and Cyclophosphamide before cell infusion.
224219558|NCT02764489|BIOLOGICAL|FEIBA|Anti-inhibitor Coagulant Complex Nanofiltered (activated prothrombin complex concentrate \[APCC\]), FEIBA NF.
224219559|NCT01110980|OTHER|Swallow therapy in combination with individual dietary counselling|Weekly swallowing therapy (by speech language therapist) from start of (chemo)radiation until 6 months after last (chemo)radiation. Weekly Individual dietary counselling (by dietician) form the start of (chemo) radiotherapy until 6 months after last (chemo)radiation. With close interaction between the both interventions.
224219560|NCT01110980|OTHER|Individual dietary counselling|Weekly Individual dietary counselling form the start of (chemo) radiotherapy until 6 months after last (chemo)radiation.
224219561|NCT03526367|DRUG|hydration plus rosuvastatin therapy|In experimental group,a loading dose of rosuvastatin 20mg then 10 mg daily followed for at least 7 days and hydration（3ml/kg/h）last 12 hours after randomized
224219562|NCT03526367|DRUG|Standard therapy|Prohibition of use any statins from randomized to 12 hours after procedure; The hydration or not is determined by physicians but 1 ml/kg/h at most.
224219563|NCT06064981|BEHAVIORAL|Text message nudges|"Fourteen text message nudges, tailored to address specific barriers and concerns regarding naloxone acquisition and carrying. These barriers were identified using qualitative interviews conducted by the authors in prior studies. Examples included: optimism bias (e.g., beliefs that participants were unlikely to encounter someone who had overdosed in their daily lives), and identity bias (e.g., beliefs that participants were not the type of people who could save a life)."
224219564|NCT06064981|BEHAVIORAL|Commitment contract|"In addition to the training, participants in the third arm were asked to sign commitment contracts, which had language in which they committed to carrying/acquiring naloxone."
224219565|NCT02706002|DEVICE|fluoroscopy|in active group femural stem of hip prosthesis will implanted under fluoroscopy guidance during operation till maximum rasp size reached that fills the medullary canal. ordinary 3-5 sequences per operation
224219566|NCT02706002|PROCEDURE|hip prosthesis|all patients in the study will undergo hip prosthesis
224219567|NCT00929903|DRUG|pazopanib hydrochloride|Given orally
224219568|NCT00929903|OTHER|pharmacological study|Correlative studies
224219569|NCT05816733|DRUG|Dapagliflozin|Patients randomized in this arm will receive dapagliflozin at a target dose of 10mg once daily and routine treatment.
224219570|NCT05816733|DRUG|Placebo|Patients randomized in this arm will receive placebo at a target dose of 10mg once daily and routine treatment.
224219571|NCT04813900|OTHER|Lung ultrasound|Lung ultrasound in order to calculate lung ultrasound score
224219572|NCT00293670|DRUG|Goserelin (Zoladex)|
224219573|NCT05153356|DEVICE|Personal Kinetigraph, Kinesia 360|10 patients will be assigned to each technology with a crossover at 3 months for a total of 20 patients over 6 months, 6 timepoints with data collected every 2 weeks.
223630897|NCT06088823|OTHER|Heart surgery|Adult cardiac surgery
223630898|NCT05235009|DIAGNOSTIC_TEST|Combined free GAGome MCED test|The combined free GAGome MCED test aggregates measurements of plasma and urine GAGomes (the exhaustive human glycosaminoglycan profile) into a diagnostic score, the combined free GAGome MCED score. The measurements are performed using MIRAM MCED Kits (Elypta AB) and the scores are computed using Elypta SKY Software (Elypta AB)
223630899|NCT03659266|OTHER|Robotic walking rehabilitation by Lokomat®|Lokomat sessions / week for 2 weeks. Each session lasts 45 minutes including 30 minutes of effective work of the march and 15 minutes of setting up.
223630900|NCT03659266|OTHER|Conventional walking rehabilitation|5 physiotherapy sessions / week for 2 weeks. Each session lasts 45 minutes including 30 minutes of walking and 15 minutes of stretching
223630901|NCT01874639|DEVICE|standard bipolar coagulation|
223630902|NCT01874639|DEVICE|Aquamantys® probe for liver hemostasis|
223630903|NCT04717037|BIOLOGICAL|Olive Oil Massage|olive oil massage application.
223630904|NCT03255603|OTHER|Resistant Starch Type 4 Supplementation|Ten participants will supplement their normal dietary intake with RS4 daily for four consecutive weeks, with each week the amount of RS4 provided being increased (10 g, 20 g, 35 g and 50 g/day).
223630905|NCT03255603|OTHER|Resistant Starch Type 4 Supplementation|Ten participants will supplement their normal dietary intake with RS4 daily for four consecutive weeks, with each week the amount of RS4 provided being increased (10 g, 20 g, 35 g and 50 g/day).
223630906|NCT03255603|OTHER|Resistant Starch Type 4 Supplementation|Ten participants will supplement their normal dietary intake with RS4 daily for four consecutive weeks, with each week the amount of RS4 provided being increased (10 g, 20 g, 35 g and 50 g/day).
224219574|NCT06402747|DRUG|Clopidogrel|Clopidogrel 75mg once daily
224219575|NCT06402747|DRUG|Cilostazol|Cilostazol 200mg per day
224317858|NCT05814822|BEHAVIORAL|Sleep Hygiene Education (SHE-TM)|Participants randomized to SHE-TM will participate in 6 individual telemedicine sessions delivered by a trained therapist to learn sleep hygiene and educational strategies for insomnia.
224317859|NCT06383182|PROCEDURE|endovascular treatment|all patients with anterior circulation large vessel occlusion will receive endovascular treatment.
224317860|NCT05405660|BIOLOGICAL|barzolvolimab|Subcutaneous Administration
224317861|NCT05405660|DRUG|Matching Placebo|Subcutaneous Administration
224317862|NCT06470295|OTHER|Saline|Normal saline will be infused during insulin-induced hypoglycemia
224219576|NCT03358394|BEHAVIORAL|A human-interventional study|"The intervention was developed by Ahmed et al. (2017) and was adapted by the investigators for parents of children with T1D. The researcher has received permission form the author to use the script but, not the audio recordings. As a result, we contacted Saab et al. (2016) to get the permission to use the Arabic audio recording of Mindfulness exercises (i.e., introduction to mindfulness practice and mindfulness breathing).~The mindfulness script to be used in the current study is based on MBPT. In this study, we will be using the MBPT programme, but tailored to the needs of parents of children with T1D. One of the main changes in our study is that it will be delivered via the Internet. Participants in the original MBPT programme attended in-person sessions however, Rayan et al. (2016) delivered only the first two sessions in person and the rest via telephone"
224219577|NCT01768962|DRUG|Once Daily Application of TFV RG 1% Gel - Vaginal|Vaginal application
224219578|NCT01768962|DRUG|Once Daily Application of TFV RG 1% gel - Rectal|Rectal application
224219579|NCT01768962|DRUG|Once Daily Application of TFV RG 1% gel - Rectal|Rectal application
224219580|NCT01768962|DRUG|Once Daily Application of TFV RG 1% Gel - Vaginal|Vaginal application
224219581|NCT04398394|DEVICE|Cellularis version 1 imaging|Using a new modality for retinal cell imaging, we aim at comparing qualitatively and quantitatively, the morphology of the deepest layer of the retina, the retinal pigment epithelium (RPE) by imaging the people with a prototype instrument (Cellularis version 1).
224219582|NCT01858246|DEVICE|Bonebridge|
224219583|NCT01858246|DEVICE|Bone Anchored Hearing Aid|
223630907|NCT03255603|OTHER|Digestible Starch Supplementation|Ten participants will supplement their normal dietary intake with digestible starch daily for four consecutive weeks, with each week the amount of starch provided being increased.
223630908|NCT05960097|BIOLOGICAL|CV0701 Bivalent High dose|Study vaccine is administered as a single intramuscular injection in the deltoid area on Day 1.
223764182|NCT04954742|DRUG|Riociguat|Treatment will be initiated and individually adjusted according to systolic blood pressure and tolerability. During the titration phase, each patient will be asked to measure their peripheral systolic blood pressure and the heart rate at home three times per day and document the values in the patient diary. The results will be examined by the investigator during each visit/phone call-visit. Provided that the systolic blood pressure is ≥ 95 mmHg measured at trough before intake of each dose and the patient has no signs or symptoms of hypotension, the dose of study medication will be titrated by +0.5 mg tid every 2 weeks until maximal tolerated dosage (maximal permitted dose: of 2.5 mg tid). After the titration period, blood pressure should be measured upon signs or symptoms of hypotension. Maintenance dose: The established individual dose should be maintained unless signs and symptoms of hypotension occur.
224219584|NCT04202302|PROCEDURE|IVF/ICSI|ovarian stimulation ，vaginal disinfection of flushing
224317863|NCT06470295|BIOLOGICAL|C-peptide|C-peptide will be infused during insulin-induced hypoglycemia
224317864|NCT05595408|DRUG|Adjuvant chemotherapy|cisplatin/carboplatin-gemcitabine 4-6 cycles
224317865|NCT05595408|DRUG|adjuvant immunotherapy|immunotherapy for one year
224219585|NCT03641118|DIAGNOSTIC_TEST|Cardiopulmonary exercise test|The CPET test involves cycling on an exercise bike for 8-12 minutes. Starting with a very low resistance on the pedals the patient will pedal at 60 revolutions per minute. After 3 minutes of cycling, the resistance will gradually increase until the patient can no longer turn the pedals at the required speed. The test will be thoroughly explained to the patient beforehand and trained staff will make the experience as comfortable as possible. CPETs will be stopped early by the study researcher/doctor in the presence of any adverse events. Each CPET appointment will last approximately one hour.
224219586|NCT05760079|DIETARY_SUPPLEMENT|Lactoferrin|750mg of Jarrow formulas taken three times daily for 30 days
224317866|NCT04714983|BIOLOGICAL|DNX-2440|DNX-2440 is a replication competent oncolytic adenovirus expressing human OX40 ligand.
224317867|NCT03430388|BIOLOGICAL|Yellow Fever vaccine (17D)|Vaccination against Yellow Fever, fractional dose (0,1mL) of 17D vaccine
224317868|NCT02257385|DRUG|UMEC/VI|ELLIPTA DPI will be supplied with 30 doses (2 strips with 30 blisters per strip) where first strip contains Umeclidinium bromide (unit dose strengths 62.5 mcg per blister) blended with lactose monohydrate and magnesium stearate 0.6% weight/weight (w/w) of total drug product and second strip contains Vilanterol (unit dose strengths 25 mcg per blister) blended with lactose monohydrate and magnesium stearate 1.0% w/w of total drug product
224317869|NCT02257385|DRUG|UMEC/VI matching placebo|ELLIPTA DPI will be supplied with 30 doses (2 strips with 30 blisters per strip) where first strip contains lactose monohydrate and magnesium stearate 0.6% w/w of total drug product and second strip contains lactose monohydrate and magnesium stearate 1.0% w/w of total drug product
224317870|NCT02257385|DRUG|Tiotropium|Tiotropium (as bromide monohydrate) inhalation capsules 18 mcg per dose will be supplied along with HANDIHALER inhalers manufactured by Boehringer Ingelheim
224317871|NCT02257385|DRUG|Tiotropium matching placebo|Tiotropium matching placebo capsules manufactured by GSK, will contain lactose and will be supplied along with HANDIHALER inhalers
224317872|NCT02257385|DRUG|Indacaterol|Indacaterol inhalation capsules 150 mcg per dose will be supplied by GSK along with BREEZHALER inhalers manufactured by Novartis
224317873|NCT02257385|DRUG|Indacaterol matching placebo|Indacaterol matching placebo capsules manufactured by GSK, will contain lactose and will be supplied along with BREEZHALER inhalers manufactured by Novartis
223630909|NCT05960097|BIOLOGICAL|CV0701 Bivalent Medium dose|Study vaccine is administered as a single intramuscular injection in the deltoid area on Day 1.
223630910|NCT05960097|BIOLOGICAL|CV0701 Bivalent Low dose|Study vaccine is administered as a single intramuscular injection in the deltoid area on Day 1.
223630911|NCT05960097|BIOLOGICAL|CV0601 Monovalent High dose|Study vaccine is administered as a single intramuscular injection in the deltoid area on Day 1.
223630912|NCT05960097|BIOLOGICAL|Control vaccine|Study vaccine is administered as a single intramuscular injection in the deltoid area on Day 1.
223630913|NCT05960097|BIOLOGICAL|CV0801 Monovalent|Study vaccine is administered as a single intramuscular injection in the deltoid area on Day 1.
223630914|NCT06144307|PROCEDURE|plane block|injection of local anesthetic to the myofascial plane
223630915|NCT01500733|DRUG|PCI 32765|420 mg daily
223764183|NCT06017089|DEVICE|AI-based Advisor system|Tandem t:slim X2 with Control-IQ and t:connect mobile application and Dexcom G6 or G7 system, connected to UVA cloud-based Physician Dashboard with insulin pump parameters driven by an AI-based Advisor system.
223630916|NCT06521723|OTHER|Daily acute intermittent hypoxia|Each participant will be exposed to 16 sessions of daily acute intermittent hypoxia via air generators over the span of four weeks. The generator will fill reservoir bags attached to a non-rebreathing facemask. Each session will consist of 15 episodes which include intervals of 1.5 minute hypoxia (FIO2=0.10±0.02, i.e. 10% O2) and 1 minute normoxia (FIO2=0.21±0.02).
223630917|NCT06521723|DEVICE|Walking + tSTIM|Individuals will participate in 45 minutes of gait training while having transcutaneous spinal cord stimulation. Stimulation intensity will be 80% involuntary motor threshold.
224219587|NCT00693784|BIOLOGICAL|Biostat® Disc Augmentation System|Delivery of Biostat BIOLOGX® Fibrin Sealant with the Biostat Delivery Device
224219588|NCT00860106|OTHER|ED, DDimers and phone follow up|ED score, DDimers level and phone questionnary
224219589|NCT01508585|BEHAVIORAL|Telephone Based Cognitive Behavioral Therapy|6 sessions of Cognitive Behavioral Therapy (CBT), lasting approximately 60 minutes each.
223630918|NCT05632653|PROCEDURE|CTO-PCI|Percutaneous coronary intervention (PCI) of a coronary chronic total occlusion (CTO) (CTO-PCI) in patients with systolic heart failure (LVEF \<50%).
223630919|NCT04332822|DRUG|R-pola-mini-CHP|"* Rituximab 375 mg/m2 iv, day 1, cycle 1. 1400 mg s c OR 375 mg/m2 iv cycles 2-6~* Cyclophosphamide 400 mg/m2 iv, day 1, cycles 1-6~* Doxorubicin 25 mg/m2 iv , day 1, cycles 1-6~* Prednisone, 40 mg/m2 po, days 1-5, cycles 1-6 - round up to nearest 25 mg~* Polatuzumab vedotin 1.8 mg/kg iv day 1 cycles 1-6"
223630920|NCT04332822|DRUG|R-mini-CHOP|"* Rituximab 375 mg/m2 i.v., day 1, cycle 1. 1400 mg s c OR 375 mg/m2 i. v. cycles 2-6~* Cyclophosphamide 400 mg/m2 i.v., day 1, cycles 1-6~* Doxorubicin 25 mg/m2 i.v., day 1, cycles 1-6~* Vincristine 1 mg i.v. (total dose), day 1, cycles 1-6~* Prednisone, 40 mg/m2 p.o, days 1-5, , cycles 1-6"
224219590|NCT04182932|BIOLOGICAL|CJ-40010 EV71 vaccine A dose|Inactivated vaccine against EV71, three doses, 28 days interval
224219591|NCT04182932|BIOLOGICAL|CJ-40010 EV71 vaccine B dose|Inactivated vaccine against EV71, three doses, 28 days interval
224219592|NCT04182932|BIOLOGICAL|CJ-40010 CVA16 vaccine C dose|Inactivated vaccine against CVA16, three doses, 28 days interval
224219593|NCT04182932|BIOLOGICAL|CJ-40010 CVA16 vaccine D dose|Inactivated vaccine against CVA16, three doses, 28 days interval
224219594|NCT04182932|BIOLOGICAL|CJ-40010 Bivalent vaccine E dose|Inactivated vaccine against EV71/CVA16, three doses, 28 days interval
224219595|NCT04182932|BIOLOGICAL|CJ-40010 Bivalent vaccine high dose|Inactivated vaccine against EV71/CVA16, three doses, 28 days interval
224219596|NCT04182932|BIOLOGICAL|Placebo|Placebo, three doses, 28 days interval
224219597|NCT02751333|PROCEDURE|FCSEMS with Endostitch (ES)|The fixation of FCSEMS using endostitch (ES) with the OverStitchTM system to prevent migration.
224219598|NCT02751333|PROCEDURE|FCSEMS with No Suturing (NS)|The insertion of FCSEMS with no suturing.
223630921|NCT04578769|PROCEDURE|conventional myotomy|"1. Initial mucosal incision. After submucosal injection, a reverse T entry incision is made at approximately 10 cm proximal to the gastroesophageal junction (GEJ).~2. Submucosal tunnel establishment. A submucosal tunnel is created to 2-3 cm distal to the GEJ.~3. Endoscopic myotomy. A selective circular muscle myotomy is carried out in a proximal to distal direction, from 2 cm distal to the mucosal entry down to 2 cm distal to the GEJ.~4. Zippered closure of mucosal entry. The mucosal incision is closed using hemostatic clips."
223630922|NCT04578769|PROCEDURE|short myotomy|"1. Initial mucosal incision. After submucosal injection, a reverse T entry incision is made at approximately 6 cm proximal to the gastroesophageal junction (GEJ).~2. Submucosal tunnel establishment. A submucosal tunnel is created to 2-3 cm distal to the GEJ.~3. Endoscopic myotomy. A selective circular muscle myotomy is carried out in a proximal to distal direction, from 2 cm distal to the mucosal entry down to 2 cm distal to the GEJ.~4. Zippered closure of mucosal entry. The mucosal incision is closed using hemostatic clips."
224219599|NCT02751333|DEVICE|Fully Covered Self-Expanding Metal Stents (FCSEMS)|This is the stent that will be used to treat the esophageal pathology in both groups
223764184|NCT06477029|DEVICE|tFUS|tFUS is a brief stimulation of a part of the brain called the ventral striatum with low-intensity sound waves that pass through the scalp and skull safely.
223764185|NCT06477029|DEVICE|Sham tFUS|Sham tFUS goes through the motions of applying tFUS to the brain. Participants will know that one session will be a sham, but they will be blinded to which session is the sham
223764186|NCT06329102|PROCEDURE|Surgical access|Complications by Clavien Dindo Number of lymph nodes. Disease free and Overall survival
224219600|NCT02751333|DEVICE|EndoStitch (ES) with the OverStitchTM system|This is the device used to apply the stitches to the stent in participants randomized to stent suturing.
224219601|NCT01072032|DEVICE|Anklebot (Ankle Robot)|Impedance controlled ankle robot provides assistance as needed for participants to perform ankle movements while playing a video game, is used to assist stroke patients to enhance motor recovery
224219602|NCT02062606|DEVICE|MESA Rail™ Deformity System|MESA Rail™ (cross-sectioned rod) with MESA pedicle screws compared to traditional rod use in the literature
224219603|NCT03336632|DRUG|Chidamide|20 mg orally, twice weekly from D-7 to D+14
224219604|NCT03336632|DRUG|Cyclophosphamide|50 mg/Kg intravenously D+3, +4
224219605|NCT03336632|DRUG|cyclosporine A|3 mg/Kg intravenously then orally from D+5 to D+100 if no acute graft-versus-host disease
224219606|NCT01331785|DRUG|Midodrine|Midodrine 2.5 mg to 10 mg three times a day to increase systolic BP above 100 mmHgor by 10 mmHg
224219607|NCT05141578|BEHAVIORAL|Luci Coach Assisted Intervention|"The Luci intervention is a personalized behaviour change program delivered via an interactive mobile platform with the online support of a coach. It targets 3 lifestyle domains: physical activity, healthy diet and cognitive engagement.~Participants in this group will be encouraged to adopt a healthy lifestyle, as a means for cognitive decline/dementia risk reduction. This will be achieved by providing educational materials, practical tips and strategies, and by assisting participants outlining goals to progressively adopt and maintain a healthier lifestyle.~Coaching sessions will be held on a weekly basis from week 1 to 12, and every 2 weeks from week 13 to 24."
224219608|NCT00326885|DRUG|catumaxomab|Catumaxomab is administered intraperitoneally via an indwelling catheter (or port) as a 3-hour infusion 4 times (Days 0, 3, 7, and 10) in ascending doses (10 mcg, 20 mcg, 50 mcg, and 150 mcg, respectively).
224219609|NCT03649737|BEHAVIORAL|Exercise Intervention|Attend supervised and unsupervised exercise sessions
224219610|NCT03649737|OTHER|Survey Administration|Ancillary studies
224219611|NCT03649737|OTHER|Quality-of-Life Assessment|Ancillary studies
223630923|NCT04578769|PROCEDURE|full-thickness myotomy|"1. Initial mucosal incision. After submucosal injection, a reverse T entry incision is made at approximately 10 cm proximal to the gastroesophageal junction (GEJ).~2. Submucosal tunnel establishment. A submucosal tunnel is created to 2-3 cm distal to the GEJ.~3. Endoscopic myotomy. A selective circular muscle myotomy is carried out in a proximal to distal direction, from 2 cm distal to the mucosal entry down to 4 cm proximal to the GEJ, and a full-thickness muscle myotomy is continually carried out from 4cm proximal to the GEJ down to 2 cm distal to the GEJ.~4. Zippered closure of mucosal entry. The mucosal incision is closed using hemostatic clips."
223630924|NCT04578769|PROCEDURE|tailored myotomy|"1. Initial mucosal incision. After submucosal injection, a reverse T entry incision is made at approximately 2 cm proximal to the spastic segment within the esophageal body, which is identified based on information gained from high-resolution manometry (HRM).~2. Submucosal tunnel establishment. A submucosal tunnel is created to 2-3 cm distal to the GEJ.~3. Endoscopic myotomy. A selective circular muscle myotomy is carried out in a proximal to distal direction, from 2 cm distal to the mucosal entry down to 2 cm distal to the GEJ.~4. Zippered closure of mucosal entry. The mucosal incision is closed using hemostatic clips."
223630925|NCT05772390|RADIATION|Partial breast re-irradiation|partial breast re-irradiation
223630926|NCT05379179|DRUG|Ketamine|This study will compare patient-reported pain scores after receiving either ketamine or fentanyl for the treatment of acute pain due to a rattlesnake bite.
223630927|NCT05379179|DRUG|Fentanyl|This study will compare patient-reported pain scores after receiving either ketamine or fentanyl for the treatment of acute pain due to a rattlesnake bite.
223630928|NCT02411630|DRUG|Emtricitabine/tenofovir disoproxil|"ATN 123 participants will not be administered Emtricitabine /Tenofovir disoproxil fumarate (Truvada®) as part of the ATN 123 study, but as part of the parent studies, ATN 110 or ATN 113. In order to be eligible for ATN 123, all participants must be co-enrolled in ATN 110 or ATN 113.~The only intervention for ATN 123 is the administration of the Interactive Questionnaire System (iQS), which is a new method to collect data on adherence. It will be utilized to collect adherence data across a variety of devices (i.e., computer/laptop, smartphone, tablet, etc.). Accuracy of this method will be determined; preference for this mode of data collection compared to other methods for adherence reporting used in the parent studies will be assessed."
223630929|NCT05039749|DEVICE|Human Centric Lights|Bright light is emitted during the day from 06:00, then auto-dimmed light is used at night, beginning 19:00.
223630930|NCT02972775|OTHER|no interventions. observational study|
223630931|NCT00028067|DRUG|Atazanavir|
223630932|NCT00028067|DRUG|Nelfinavir mesylate|
223630933|NCT04842747|DRUG|VERU-111|Subjects in the VERU-111 treatment groups will receive standard of care, plus oral daily VERU-111 9mg for 21 days or until released from hospital.
223630934|NCT05049590|BIOLOGICAL|Acute normovolemic hemodilution (ANH)|A blood conservation technique that removes whole blood (\~8-10cc/kg) from a patient in the operating room prior to incision.
223630935|NCT02082496|DRUG|Liraglutide|S.c. liraglutide 3.0mg once daily
223630936|NCT02559622|DRUG|Secukinumab|300 mg secukinumab
223630937|NCT02559622|OTHER|Placebo|Placebo followed by 300 mg secukinumab
223630938|NCT02559622|OTHER|Placebo|Placebo followed by 150 mg secukinumab
223630939|NCT02559622|DRUG|Secukinumab|150 mg secukinumab
223630940|NCT01950416|DRUG|Ticagrelor 180mg loading dose and 90mg bid maintenance dose|
223630941|NCT01950416|DRUG|Clopidogrel 600mg loading dose and 150mg maintenance dose|
223630942|NCT04836052|DRUG|Omega 3 fatty acid|omega-3-oil 2 gm twice daily PO/NGT/OGT for 28 days or ICU discharge or death.
223630943|NCT05329246|DEVICE|AI-assisted Clinical Assistant PMcardio|PMcardio is an AI-powered clinical assistant in the form of a mobile application empowering non-cardiologist healthcare workers with advanced cardiovascular diagnostic capabilities, recommending patient-specific suggestions for referral and facilitating remote consultations with specialized cardiologists.
223630944|NCT04643808|DEVICE|transcutaneous auricular vagus nerve stimulation|Microcurrent stimulation delivered to the left tragus, with stimulation 'on' during sucking from a bottle, and 'off' at rest during bottle feeding
223630945|NCT02424773|DEVICE|High Flow Nasal Canula (HFNC)|
224219612|NCT00736528|DRUG|PF-04447943|05 mg BID for 14 days
224219613|NCT00736528|DRUG|PF-04447943|15 mg BID for 14 days
224219614|NCT00736528|DRUG|PF-04447943|45mg BID for 14 days
224219615|NCT00736528|DRUG|Placebo|Placebo for 14 days
224219616|NCT03651661|DRUG|human insulin|human insulin administered as nasal spray
224219617|NCT03651661|DRUG|placebo|placebo administered as nasal spray
224219618|NCT03651661|DIAGNOSTIC_TEST|Pupillography|Autonomic tone will be adressed by pupillography using the F2D2 (Amtech Germany) device.
224219619|NCT01706198|DRUG|fluticasone furoate + vilanterol|once daily via a Novel Dry Powder Inhaler
224219620|NCT01706198|DRUG|inhaled corticosteroid with or without a long acting beta2-agonist|ICS alone or in combination with a long acting bronchodilator
224219621|NCT06524778|RADIATION|brachytherapy|Patients with locally unresectable giant osteosarcoma masses who meet the criteria are enrolled in the experimental group, and all patients receive a single dose of 10Gy of implantable brachytherapy. Record treatment-related acute events during and after treatment. Follow up on survival and local control after treatment ends, marking the end of the trial treatment.
223630946|NCT02424773|DEVICE|Venturi mask|
223630947|NCT02424773|DRUG|Oxygen|
223630948|NCT06352580|OTHER|Survey|26 survey questions were administered face to face to parents, which they could answer in a short time.
223630949|NCT05945784|OTHER|Use of Rare Beauty makeup products|Participants will be provided with a selection of beauty products items including foundation, concealer, blush, highlighter, and lipstick, specifically chosen for their potential accessibility features. They will have a specified trial period during which they can use the products as part of their regular beauty routines.
223630950|NCT05400291|DIAGNOSTIC_TEST|Chondroitin Sulfate Staining|Staining of histopathological slides
223630951|NCT03071120|BEHAVIORAL|Parent-Mediated Intervention|Children with ASD will participate in a 6-month parent-mediated intervention that will include direct intervention and parent education.
224219622|NCT02052128|DRUG|onapristone|
224219623|NCT03294083|BIOLOGICAL|Pexastimogene Devacirepvec (Pexa-Vec)|Pexa-Vec is a vaccinia virus based oncolytic immunotherapy designed to stimulate the immune system following infection and replication within tumor cells
223764187|NCT05994716|OTHER|Telemonitoring|"A) Monthly completion data on the web platform: 1) SCCAI for Ulcerative colitis and Harvey-Bradshaw index for Crohn disease. 2) IBD disk questionnaire to evaluate disease dynamics. 3) General blood test.~B) Possibility of online consultation with a gastroenterologist upon request via chat or phone call.~C) Access to educational information about IBD, necessary lifestyle changes, dietary recommendations;~D) monthly phone call will be made to each patient from the intervention group to answer any questions or concerns they may have and to interview them according to the checklist."
223764188|NCT03400033|DRUG|Daprodustat tablets|Round, biconvex, white, film-coated tablet in unit dose strengths 2 and 4 milligrams (7 millimeter tablets), 6, 8 and 10 milligrams (9 millimeter tablets) administered by the oral route.
224219624|NCT03294083|BIOLOGICAL|Cemiplimab|Cemiplimab is a monoclonal antibody to Programmed Death-1 (PD-1)
224219625|NCT05127811|DRUG|ZN-d5|BION design
224219626|NCT00950183|DEVICE|Iceman® Cold Therapy unit (djOrtho)|postoperative cold therapy
224219627|NCT00950183|OTHER|Ice|postoperative cold therapy
224219628|NCT05565183|DIAGNOSTIC_TEST|MRI (with injection of contrast product)|All patients included in the study will undergo two MRI examinations (with injection of contrast product) before and after the ablation procedure.
224219629|NCT02287454|OTHER|cognitive remediation program: REHACOP|Specifically, REHACOP group remediation with MS patients consisted of: four weeks training attention (sustained, selective, alternating and divided attention); three weeks focused on learning and memory (the stimulation of verbal and visual memory was combined with learning and compensatory strategies, working memory was also trained); three weeks exercising executive functioning (development, planning and attainment of objectives); three weeks focused on language (verbal fluency, syntax, grammar, vocabulary and comprehension); and one week training social cognition (social reasoning, theory of mind and moral dilemmas).
224219630|NCT00613847|RADIATION|PET Imaging with Ga-68 Labeled F(ab') 2- Trastuzumab|Pt will undergo one PET study following the i.v. administration of 10mCi of 68Ga-F(ab')2-trastuzumab fragments (HERScan). The PET study will be performed within 4 weeks of the patient's most recent imaging studies. A subset of 10 patients who have evidence of tumor uptake and localization with the 68Ga-F(ab')2-trastuzumab fragments will be asked to undergo follow-up PET scans (up to a maximum of 3) to examine the time course of HER-2 expression. These follow-up PET scans will be performed concurrently with the patient's standard imaging studies to evaluate response to their current therapy as per their treating physicians.
224219631|NCT00613847|RADIATION|PET Imaging with Ga-68 Labeled F(ab') 2- Trastuzumab|Once safety and feasibility has been established in this group, then enrollment to the HER2 1+ cohort will commence. Pt will undergo one PET study following the i.v. administration of 10mCi of 68Ga-F(ab')2-trastuzumab fragments (HERScan). The PET study will be performed within 4 weeks of the patient's most recent imaging studies. A subset of 10 patients who have evidence of tumor uptake and localization with the 68Ga-F(ab')2-trastuzumab fragments will be asked to undergo follow-up PET scans (up to a maximum of 3) to examine the time course of HER-2 expression. These follow-up PET scans will be performed concurrently with the patient's standard imaging studies to evaluate response to their current therapy as per their treating physicians.
224219632|NCT02309554|OTHER|SILCS diaphragm used with ContraGel|SILCS Diaphragm (branded as CAYA countoured diaphragm) is a single-size vaginal barrier method of contraception used with each sex act, made of silicone membrane with a nylon spring. ContraGel is a clear, water soluble greaseless gel packed in a metal tube.
224219633|NCT02309554|OTHER|SILCS diaphragm used with 3% Nonoxynol-9|SILCS Diaphragm (branded as CAYA countoured diaphragm) is a single-size vaginal barrier method of contraception used with each sex act, made of silicone membrane with a nylon spring. 3% Nonoxynol-9 (branded as Gynol II) is clear, unscented water soluble greaseless gel packed in plastic tubes with a vaginal applicator.
224219634|NCT02309554|OTHER|SILCS diaphragm|SILCS Diaphragm (branded as CAYA countoured diaphragm) is a single-size vaginal barrier method of contraception used with each sex act, made of silicone membrane with a nylon spring
224219635|NCT04313283|BEHAVIORAL|Parents Taking Action|A peer-led intervention, Parents Taking Action is the psychoeducational and child behavior management intervention led by trained Parent Leaders.
224219636|NCT04014998|OTHER|Virtual Reality|Virtual reality group will have virtual reality for 20 minutes in addition to motor control exercises for 20 minutes. Virtual reality will apply using Oculus Go. On the other hand control group will have only exercise for 40 minutes. Exercises will include same exercises in both groups, but exercise group will perform exercises twice compared to virtual reality group.
224317874|NCT02257385|DRUG|Albuterol/salbutamol Metered Dose Inhaler (MDI)|Albuterol/salbutamol MDI or nebules for as needed use will be issued throughout the study. Albuterol/salbutamol will be sourced from local commercial stock. If not available locally, GSK will source centrally
224317875|NCT03259438|BEHAVIORAL|Qigong|Qigong is a form of gentle mind-body movement that originates in China and has traditionally been used for healing purposes. It has been reported to improve energy levels, as well as strength and endurance and mental clarity and equanimity. This study will assess how a 10-week qigong intervention compares to an exercise-nutrition intervention in improving fatigue and vitality in female cancer survivors. On a secondary level, we will asses changes in underlying brain, heart, and peripheral dynamics that occur as a result of the qigong practice to develop a mechanistic understanding of qigong's efficacy.
224317876|NCT03259438|BEHAVIORAL|Healthy Living (CHIP + Pre-Train)|The Healthy Living active comparator intervention includes two components: plant based nutrition counseling via the Comprehensive Health Improvement Program (CHIP) and core strengthening exercises and light aerobic activity via the Pre-Train exercise program.
224317877|NCT03017703|DRUG|Eplerenone|
224317878|NCT05228938|PROCEDURE|VNOTES|vaginal Natural Orifice Transluminal Endoscopic Surgery approach for Elective bilateral salpingectomy or Salpingo-oophorectomy
224317879|NCT05228938|PROCEDURE|laparoscopic|laparoscopic Surgery approach for Elective bilateral salpingectomy or Salpingo-oophorectomy
224317880|NCT01242722|DEVICE|CRT-D|Cardiac pacing via a pulse generator and implanted intracardiac leads
223764189|NCT03400033|DRUG|Matching placebo tablets|Matching placebo to daprodustat tablets supplied as round, biconvex, white, film-coated tablet in unit dose strengths 2 and 4 milligrams (7 millimeter tablets), 6, 8 and 10 milligrams (9 millimeter tablets) administered by the oral route.
223630952|NCT02662673|DEVICE|Focal High Intensity Focused Ultrasound (HIFU) treatment|Focal High Intensity Focused Ultrasound (HIFU) treatment for localized prostate cancer (maximum two foci). HIFU treatment is using high energy ultrasound focused at the focal point to achieve precise tissue destruction. This mini-invasive therapy is using an endo-rectal approach to deliver the treatment, using a probe composed of a combined imaging and treatment transducer. The treatment is monitored by real-time ultrasound. The treatment planning is performed by the urologist, contouring the area to be treated (MRI target + security margins around the tumor) and the treatment phase is automatically performed by the robotic device.
223630953|NCT02395458|DRUG|Sequential therapy|Patient receive Omeprazole plus amoxicillin during 5 days and then omeprazole plus clarithromycin and metronidazole during another 5 days
223630954|NCT02395458|DRUG|Triple therapy|Patient receive Omeprazole plus amoxicillin and Clarithromycin during 14 days
223630955|NCT01365923|DRUG|remifentanil|remifentanil effect site-TCI 2-4ng/ml
223630956|NCT01365923|DRUG|dexmedetomidine with remifentanil|remifentanil effect site-TCI 2-4ng/ml with dexmedetomidine 0.5mcg/kg
223630957|NCT01063049|DRUG|Gatorade/Miralax|Gatorade 64 oz (1/2 gallon), Miralax 306 g to be consumed the day before your colonoscopy as follows: Miralax 51 g at 12 noon. Gatorade 64 oz mixed with Miralax 255 g from about 5 PM to 9 PM.
223764190|NCT03400033|DRUG|Epoetin alfa vials|Single-dose, preservative-free vials in unit dose strengths of 2000, 3000, 4000 and 10,000 Units/milliliter administered by the IV route.
223764191|NCT03400033|DRUG|Saline vials or bags|0.9% sodium chloride saline vials or bags administered by the IV route.
224219637|NCT00653497|BEHAVIORAL|Aquatic exercise|"Arthritis Foundation Aquatics Program~* community-based aquatic exercise program~* participants asked to attend 2 classes per week for 20 weeks~* each class 45-60 minutes in duration"
224219638|NCT00655005|OTHER|questionnaire administration|Newly diagnosed HNC patients
224317881|NCT00818688|PROCEDURE|compression ultrasonography at 3 months|A three-month follow-up prospective study was performed in the subgroup of patients with symptomatic ST but without deep-vein thrombosis on compression ultrasonography or documented symptomatic pulmonary embolism at inclusion, a group defined as patients with 'isolated ST'.
224317882|NCT06522633|DRUG|The intervention involves the discontinuation of the opioid.|Patients with dysphagia and esophageal manometry indicating opioid-induced esophageal dysfunction (OIED) will have the opioid discontinued, and esophageal manometry will be repeated.
224317883|NCT05127915|DEVICE|Adient absorbable filter + best practice VTE prophylaxis|Adient absorbable filter helps prevent PE during an 8 week protection period then gradually breaks down into carbon dioxide and water within 6 to 8 months. The absorbable filter does not require removal.
223630958|NCT01063049|DRUG|NuLytely|Nulytely (or Trilyte) 128 oz (1 gallon) to be consumed from about 5 PM to 9 PM the night before the colonoscopy.
223630959|NCT01063049|DRUG|Bisacodyl|Bisacodyl 10 mg (two 5 mg pills) to be consumed the day before the colonoscopy at 12 noon.
223630960|NCT01063049|DRUG|Placebo|Placebo (two 0.4 mg folic acid pills) to be consumed the day before the colonoscopy
223764192|NCT03367377|DRUG|LY3209590|Administered SC
223764193|NCT03367377|DRUG|Insulin Glargine|Administered SC
223764194|NCT00368589|DRUG|atorvastatin|
223764195|NCT03903666|OTHER|Nocturnal gaz exchanges measurement|Nocturnal gaz exchanges at patient's home BRIEF neuropsychological questionnaire VINELAND-II neuropsychological questionnaire Clinical OSA assessment Dysautonomia assessment
223630961|NCT05951400|DRUG|Dydrogesterone Tablets|used for pituitary suppression in ICSI cycle
223630962|NCT05951400|DRUG|Cetrorelix|GnRH antagonist for pituitary suppression
223630963|NCT01821079|DRUG|PF-05175157|Single 200 mg dose of PF-05175157 administered as powder in capsule (2x100 mg)
223630964|NCT01821079|DRUG|PF-05175157|Single 200 mg dose of PF-05175157 administered as tablet formulation (2x100 mg)
223764196|NCT02340533|PROCEDURE|hysteroscopic endo-myometrial biopsy|
223764197|NCT02340533|DEVICE|ultrasound|two dimensional trans-vaginal ultrasonography
223764198|NCT00755066|DRUG|Fluticasone propionate|200 µg intranasal, 4 weeks, od.
223764199|NCT00755066|DRUG|Placebo|Placebo intranasal spray
223630965|NCT01821079|DRUG|PF-05175157|Single 200 mg dose of PF-05175157 administered as tablet formulation (2x100 mg)
223630966|NCT01821079|DRUG|PF-05175157|Single 200 mg dose of PF-05175157 administered as tablet formulation (2x100 mg)
223630967|NCT01740167|BEHAVIORAL|health promotion lifestyle program|Individual counseling, once a month, total 3 times.
223630968|NCT02521506|DEVICE|Verio Pattern Alert® activated|
223630969|NCT02521506|DEVICE|Verio Pattern Alert® deactivated|
223630970|NCT02641925|PROCEDURE|Omentum preserving|The minimum volume of omentum (within 3cm from gastroepiploic vessel) will be removed during gastrectomy with lymph node dissection.
223764200|NCT02112825|BEHAVIORAL|Exercise|Blended supervised-home based walking exercise 3-4 times per week for 30-45 minutes
223764201|NCT03320681|DEVICE|Electrical Stimulation|Percutaneous electrical nerve stimulation
223764202|NCT03320681|OTHER|Dry Needling Stimulation|Percutaneous nerve stimulation
223764203|NCT04130295|OTHER|Wearable intensive nerve stimulator|The wearable device consists of 2 leads that provide biphasic, with alternating lead phase, asymmetrical rectangular current at a pulse duration of 0.28 msec, a randomly varying pulse frequency between 60-100 Hz, with a maximum intensity of 100mA.
223764204|NCT01437228|DRUG|povidone- iodine solution.|%10 Polivinilpirolidon iyot (Polividon- iyot
223764205|NCT01437228|DRUG|placebo|NO İNTERVENTİON
223764206|NCT04165668|OTHER|Exposure: First on scene|To be first on scene for resuscitation at the suspected out-of hospital cardiac arrest, before EMS and first responders (fire and police services)
224219639|NCT00655005|PROCEDURE|quality-of-life assessment|following treatment
224219640|NCT00411047|DRUG|gefitinib|oral drug taken daily around the same time
224219641|NCT00903890|OTHER|Survey|Survey asking questions regarding the subjects cardiac and general health.
224219642|NCT05731102|DIAGNOSTIC_TEST|Electronic version of the Composite International Diagnostic Interview 5th version (E-CIDI 5.0)|Observational study assessing prevalence of mental and substance use disorders among college and university students
224219643|NCT01374399|BEHAVIORAL|exercise and relaxation|resistance and endurance exercise, 3-5 times per week
223630971|NCT02641925|PROCEDURE|Total omentectomy|Whole omentum will be removed during gastrectomy with lymph node dissection.
223630972|NCT01384981|PROCEDURE|pulmonary rehabilitation|
224219644|NCT04295460|DRUG|Randomize|Randomize to naive-treatment HIV-infected patients to receive dual o triple therapy as initial antiretroviral treatment
224219645|NCT03742674|OTHER|Follow up|No intervention
223630973|NCT05072639|BEHAVIORAL|Guided Meditation|23 minute audio recording
223630974|NCT04011540|BEHAVIORAL|Digital data|Receiving digital data prior to a scheduled mental health session
224219646|NCT00919958|BIOLOGICAL|PLX-PAD IM injection|Single treatment; multiple injections
224219647|NCT02274467|DEVICE|Trans-catheter electric stimulation test|
223630975|NCT02676414|BEHAVIORAL|Interactive hypertension education program of the DHL©|
224219648|NCT04044846|BEHAVIORAL|Physical activity program for homebound older adults faciliated by Personal Support Workers|The intervention is an evidence- informed, theory-driven mobility intervention for community-dwelling OAs who are moderately and severely frail according to the clinical frailty scale (Rockwood et al., 2005). The intervention, entitled Promoting Movement in OAs (ProMO), will be implementable with frail OAs in partnership with any care provider in the home. Investigators will focus the study on the two main providers of care- personal support workers (PSWs) and family caregivers. OAs, PSWs, and caregivers will co-create ProMO with us. ProMO will be distinct from existing home-based exercise programs (Johnson et al., 2003) (Giangregorio et al., 2018) because it will optimize natural opportunities for mobilization during care (e.g., bathing and dressing) and will be embedded in facilitated activities of daily living.
224317884|NCT05127915|DEVICE|best practice VTE prophylaxis|Best practice VTE prophylaxis includes sequential compression machines, compression stockings, and anticoagulants (blood thinners) when indicated.
224317885|NCT03388489|BEHAVIORAL|Mind-Body Walking|walking, breathing, and mindfulness
224317886|NCT06393946|DRUG|Dupilumab|This study will not administer any treatment, only observe the treatment as prescribed in real world-clinical practice.
223630976|NCT01256268|DRUG|Ridaforolimus|Phase 1A: Ridaforolimus 20-40 mg will be administered daily for 5 days per week (days 2-5, days 8-12, days 15-19) in the first cycle of therapy and for further cycles on days 1-5, days 8-12, days 15-19 throughout the remainder of therapy. On the day of coadministration of ridaforolimus with paclitaxel 175mg/m\^2 IV and carboplatin AUC 5-6mg/ml/min on day 1 of each 3 week cycle, ridaforolimus will be dosed at the time of initiation of paclitaxel infusion. Phase 1B: as outlined in Treatment Arms.
223630977|NCT01256268|DRUG|Paclitaxel|Phase 1A: Paclitaxel 175mg/m2 IV. Phase 1B: As outlined in Treatment Arms.
223630978|NCT01256268|DRUG|carboplatin|Phase 1A: Carboplatin AUC 5-6mg/ml/min on day 1 of each 3 week cycle. Phase 1B: As outlined in Treatment Arms.
223630979|NCT05883501|BEHAVIORAL|Self-affirmation versus back massage|"Self-affirmation is non-pharmacological intervention which represents structured sentences to convey to the subconscious mind to help in reprogramming negative thoughts into positive ones.~Massage is defined as systematic touch of soft tissues for therapeutic purposes, such as pain relief, increased comfort and patient's relaxation"
223630980|NCT03998540|DIAGNOSTIC_TEST|Western blot|Western-blot analysis of a giant protein, with specific antibodies directed against C-ter and N-Ter of the protein
223630981|NCT03998540|OTHER|Protein interaction studies|Analyses of several interacting proteins by specific Western-blot and in-vitro tests.
223630982|NCT03998540|OTHER|Mass Spectometry|samples previously used for western blotting will be subjected to mass spectrometry analysis
223630983|NCT03998540|OTHER|RNA seq|analyze muscle gene expression in patients with titinopathies in our cohort by RNAseq
223630984|NCT06026384|OTHER|text in non-narrative form|Participants will be asked to read a text and give feedback afterwards
223630985|NCT06026384|OTHER|text in narrative form|Participants will be asked to read a text and give feedback afterwards
224317887|NCT03147755|OTHER|No intervention|No intervention
224317888|NCT02875964|DEVICE|electroencephalogram|Implanting electrode to measure brain activity
224317889|NCT02875964|DEVICE|magnetoencephalogram|Implanting electrode to measure brain activity
224317890|NCT00424918|BEHAVIORAL|Physical Activity, reduced sedentary behavior|
223630986|NCT06026384|OTHER|animated video in non-narrative form|Participants will be asked to watch a video and give feedback afterwards
223630987|NCT06026384|OTHER|animated video in narrative form|Participants will be asked to watch a video and give feedback afterwards
223630988|NCT00774371|BEHAVIORAL|Cognitive behavioral therapy CBT) for weight loss|The intervention program emphasizes regular physical activity, healthy eating, and psychological components within the structure of CBT for obesity. The physical activity component emphasizes planned aerobic exercise, increased physical activity and strength training. A deficit of 500-1000 kcal/day is the recommended level of dietary modification to promote weight loss and maintenance. Group sessions are held weekly for 4 months, every other week for two months, and monthly sessions through 18 months. Data are collected at baseline, 6 months, and 18 months. Wait-list group subjects will receive general contact without specific reference to weight management topics through a 24-month period of data collection and will then be provided intervention materials in a seminar format.
224219649|NCT01473758|DRUG|Roflumilast|500 µg tablet, od, oral administration in the morning after breakfast
224219650|NCT01473758|DRUG|Placebo|tablet, od, oral administration in the morning after breakfast
224219651|NCT04497324|BIOLOGICAL|Convalescent plasma|Administration of 1 to 2 units of convalescent plasma (200 ml to 250 ml, each), within 48 hours, plus standard of care.
224219652|NCT04749186|DEVICE|Compuflo Epidural Training Instrument|The intervention will consist of a Structured Didactic Model. It will include the following: two standardized video lessons (anatomy and technique), construction of a 3D epidural plastic module, practical training by using an epidural simulator with the CompuFlo Trainer instrument, and practical training with the eye-tracking assisted technique.
224219653|NCT02517710|PROCEDURE|Stratafix synthetic barbed suture|hysterotomy closure in Cesarian section
224317891|NCT05199090|DRUG|MBL949|subcutaneous injections administered for 14 weeks
224317892|NCT05199090|DRUG|Placebo|Placebo Comparator to MLB949
224317893|NCT01990482|DIETARY_SUPPLEMENT|caffe|
224317894|NCT01990482|DIETARY_SUPPLEMENT|Water|
224317895|NCT06237439|BEHAVIORAL|Move with HaRT|Move with HaRT is a group-based, manualized mind-body intervention.
224317896|NCT03414086|OTHER|Healthy Control|Ten healthy adult patients evaluating serum, PBMC's, and RNA.
223630989|NCT05694390|OTHER|Use of sterile transparent film dressing|The nurses in the unit were trained by the charge nurse of the clinic on catheter-related complications (infiltration, extravasation, phlebitis, and occlusion), the scales used in the study, and the use of sterile transparent film dressing. In the experimental group, a sterile transparent film dressing was used to fix the catheter and was monitored hourly until the catheter was removed. The infiltration scale for infants, , the criteria of extravasation (Redness accompanied by a vesicle, tissue necrosis, and ulcer), and The Phlebitis Scale were used to evaluate the catheter site.
223630990|NCT03730909|DRUG|Sodium Lactate|IV infusion
223630991|NCT03730909|DRUG|Sodium chloride|IV infusion
223630992|NCT05892224|PROCEDURE|Laparoscopic sleeve gastrectomy|Obese patients of different subtypes were all expected to undergo bariatric surgery
224219654|NCT05517512|DIAGNOSTIC_TEST|Estimation of Protein 13|"Serum biomarkers' levels were measured using enzyme-linked immunosorbent assay (ELISA) kits according to the manufacturer's instructions and were read using a 96 well microplate ELISA reader (Dynatech. MR 7000)~1. Human placental growth factor (PLGF) was measured with the enzyme-linked immunoassay (ELISA) kit (catalog no. DPG00 SPG00 PDPG00, R\&D Systems Inc., Minneapolis, USA) by quantitative sandwich enzyme immunoassay technique (20).~2. Human soluble fms-like tyrosine kinase-1 (sFlt-1) was measured with the enzyme-linked immunoassay (ELISA) kit (catalog no. MBS601616, MyBioSource, Inc., California, San Diego, USA) by quantitative sandwich enzyme immunoassay technique (21).~3. Human pregnancy protein 13 was measured with the enzyme-linked immunoassay (ELISA) kit (catalog no. ab100553, Abcam Inc., Cambridge, USA) by quantitative sandwich enzyme immunoassay technique (22)."
224219655|NCT02763579|DRUG|Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody|Atezolizumab intravenous infusion was administered at a dose of 1200 mg on Day 1 of each 21-day cycle during the induction phase (Cycles 1-4) and maintenance phase (Cycle 5 onward).
224219656|NCT02763579|DRUG|Carboplatin|Carboplatin intravenous infusion to achieve an initial target AUC of 5 mg/mL/min was administered on Day 1 of each 21-day cycle during the induction phase (Cycles 1-4).
224219657|NCT02763579|DRUG|Etoposide|Etoposide intravenous infusion was administered at a dose of 100 mg/m\^2 on Days 1, 2, and 3 of each 21-day cycle during the induction phase (Cycles 1-4).
223630993|NCT00623948|DEVICE|A fully implanted gluteal stimulation (GSTIM) system|A fully implanted gluteal stimulation system
223630994|NCT03249636|DIAGNOSTIC_TEST|Flow cytometric analysis|Level of expression of the markers and the correlation between the markers with each other and with the clinical presentation and impact on patients with ALL.
223630995|NCT03019406|DRUG|Avalglucosidase alfa (GZ402666)|"Pharmaceutical form: powder for concentrate for solution for infusion,~Route of administration: IV"
223630996|NCT03019406|DRUG|Alglucosidase alfa (GZ419829)|"Pharmaceutical form: powder for concentrate for solution for infusion,~Route of administration: IV"
223630997|NCT00988494|DRUG|DE-105 ophthalmic solution|Topical ocular application
223630998|NCT00988494|DRUG|DE-105 ophthalmic solution|Topical ocular application
223630999|NCT00988494|DRUG|Placebo ophthalmic solution|Topical ocular application
223631000|NCT00382486|PROCEDURE|Reduce the risk of allograft rejection|
223631001|NCT03710187|DRUG|Hydrocortisone|Hydrocortisone 50 mg IV Q6h
223631002|NCT02608190|BEHAVIORAL|Working memory training|See protocol
223631003|NCT06525298|DRUG|EIS-12656|EIS-12656 tablets given daily
223631004|NCT06525298|DRUG|Olaparib|as per USPI/SmPC
224219658|NCT02763579|DRUG|Placebo|Placebo intravenous infusion was administered on Day 1 of each 21-day cycle during the induction phase (Cycles 1-4) and maintenance phase (Cycle 5 onward).
223631005|NCT06525298|DRUG|Trastuzumab deruxtecan|as per USPI/SmPC
223631006|NCT00468169|DRUG|Cetuximab|250mg/m2(day 1, weekly x 10);
224219659|NCT03760133|DRUG|Duolac|Participants included in this group will be taken probiotics for 1 month after bowel preparation for colonoscopy.
224219660|NCT02269202|DRUG|Midazolam, tablet|
224219661|NCT02269202|DRUG|Crobenetine, i.v. infusion|
224219662|NCT02269202|DRUG|Placebo|
223631007|NCT00468169|DRUG|5-FU|600 mg/m2/day; days 0-5 (120 h total) every other week x 5
223631008|NCT00468169|DRUG|Hydroxyurea|500 mg PO BID, days 0-5 every other week x 5
223631009|NCT00468169|RADIATION|Twice-daily radiation|150 cGy per fraction, days 1-5, every other week x 5 (total duration 10 weeks)
223631010|NCT00468169|DRUG|Cisplatin|100 mg/m2, week 1 and 4 on day 1 (or 2)
223631011|NCT00468169|RADIATION|Accelerated fraction radiotherapy with concomitant boost|72 Gy/42 F/6 W (3-D or IMRT based). Total duration 7 weeks.
223631012|NCT00231816|BIOLOGICAL|ZOSTAVAX™ (concomitant)|a single administration of 0.65 mL subcutaneous injection of zoster vaccine live on Day 1 and placebo at Week 4
223631013|NCT00231816|BIOLOGICAL|Comparator: Influenza Vaccine|a single administration of 0.5 mL intramuscular injection of influenza vaccine (inactivated) at Day 1
223631014|NCT00231816|BIOLOGICAL|ZOSTAVAX™ (Nonconcomitant)|Placebo injection on Day 1 and a single administration of 0.65 mL subcutaneous injection of zoster vaccine live at Week 4
223631015|NCT03735303|DIETARY_SUPPLEMENT|VD3 group|VD3 50000 IU/ week for 8 weeks
223631016|NCT03735303|DIETARY_SUPPLEMENT|omega 3 FA group|omega 3 FA group 300 mg once daily for 8 weeks
223631017|NCT03735303|DIETARY_SUPPLEMENT|VD3 and omega- 3FA group|50000 IU VD3/week for 8 weeks and 300 mg of omega- 3 FA once daily for 8 weeks
223631018|NCT03735303|OTHER|control group|no intervention was given
223631019|NCT02011906|DIETARY_SUPPLEMENT|omega 3|
223631020|NCT02011906|DIETARY_SUPPLEMENT|vitamin E|
223631021|NCT02011906|DIETARY_SUPPLEMENT|placebo of omega 3|
223631022|NCT02011906|DIETARY_SUPPLEMENT|placebo of vitamin E|
223631023|NCT05588336|DRUG|Morphine|In the literature, intrathecal morphine doses were applied according to the patients' actual body weight and there is no study comparing intrathecal morphine dose in thoracic surgery patients.
223631024|NCT05975827|DEVICE|Sterile Wound Care Liquid Dressing|Sterile wound care liquid dressing is used in the wound treatment
223631025|NCT04372017|DRUG|Hydroxychloroquine|Participants randomized to hydroxychloroquine will take 800mg on day 1 followed by 400mg on days 2-5.
223631026|NCT04372017|DIETARY_SUPPLEMENT|Vitamin D|Participants randomized to placebo will take IU1600 on day 1 and IU 800 on days 2-5.
223631027|NCT04562922|DIETARY_SUPPLEMENT|Lifemel|
223631028|NCT02890797|RADIATION|radiology|The investigators propose to performed a chest ultrasound in infants (\<24 months) admitted for bronchiolitis with an available chest X-ray
223631029|NCT05403606|DEVICE|GASPARD®|Spinal cord injured patient with the connected electronic seat pressure measurement device (GASPARD®), a traditional follow-up and having received therapeutic education at the end of the treatment
223631030|NCT01126749|DRUG|Gemcitabine|Gemcitabine
223631031|NCT01126749|DRUG|E7389|E7389
223631032|NCT01126749|DRUG|Cisplatin|Cisplatin
223631033|NCT05559450|DRUG|Blinatumomab|Blinatumomab will be bridged to conventional BUCY conditioning regimen.
223631034|NCT05559450|OTHER|Conventional therapy|Control group will be given conventional BUCY conditioning regimen.
223631035|NCT04357743|OTHER|Chin supported Arm ergometry with pursed lip breathing|"The participants sat in chin support position for 10 minutes followed by arm ergometry with pursed lip breathing for 10 minutes. The participants again sat in chin support position for 10 minutes.~The treatment was provided for one week"
223631036|NCT04357743|OTHER|Arm ergometry with pursed lip breathing|"The participants sat in normal position for 10 minutes followed by arm ergometry with pursed lip breathing for 10 minutes; the participants again sat in sitting position for 10 minutes.~The treatment was provided for one week."
223631037|NCT00688116|DRUG|STA 9090 (ganetespib)|This is a dose-escalation study. The first cohort will consist of three patients who will receive 2 mg/m2 of STA 9090 (ganetespib) during a 1-hour infusion 2 times per week (e.g., \[Monday, Thursday\] or \[Tuesday, Friday\]) for three consecutive weeks followed by a 1 week dose-free interval. Subsequent cohorts will receive 4, 7, 10, 14, 19, 25, 33, 40 and 48 mg/m2 provided that the previous dose was well tolerated during cycle 1 (week 1 - 4). Further dose increments will be approximately 20% over the previous dose level, until the maximum tolerated dose (MTD) is determined.
223631038|NCT05211947|DRUG|BI 425809|BI 425809
223631039|NCT01623102|DRUG|cisplatin and gemcitabine combination with Bevacizumab|Patients receive gemcitabine and cisplatin chemotherapy combined with Bevacizumab every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Gemcitabine 1250mg/m2 d1, d8, cisplatin 75mg/m2 d1, Bevacizumab 7.5 mg / kg every 21 days.
224219663|NCT02455700|DEVICE|Interproximal Enamel Reduction|removal of enamel between lower incisor teeth as part of orthodontic treatment plan to achieve the aims of treatment
224219664|NCT00774332|DRUG|CODOX-M|Cytoxan,Mesna,Adriamycin,Vincristine,Methotrexate,Leucovorin,Cytarabine
224219665|NCT00493753|PROCEDURE|Acupuncture|
224219666|NCT04927754|BEHAVIORAL|Behavioral guidance|Conventional behavior guidance technique was used in one of the different treatment sessions with intervals of two weeks for both groups, and the cartoon-assisted distraction technique was used in the other. As a result, the effect of the cartoon-assisted distraction technique during dental treatment on behavior in pediatric patients was evaluated.
224219667|NCT04927754|OTHER|Pain assessment|Conventional behavior guidance technique was used in one of the different treatment sessions with intervals of two weeks for both groups, and the cartoon-assisted distraction technique was used in the other. It was assessed the effect of the cartoon-assisted audio/visual distraction technique usage on paediatric patient's pain during dental care.
224219668|NCT04927754|OTHER|Dental anxiety assessment|Conventional behavior guidance technique was used in one of the different treatment sessions with intervals of two weeks for both groups, and the cartoon-assisted distraction technique was used in the other. It was evaluated the effect of the cartoon-assisted audio/visual distraction technique usage on paediatric patient's dental anxiety during treatment sessions.
223631040|NCT01623102|DRUG|Gemcitabine combined with cisplatin chemotherapy|Patients receive gemcitabine combined with cisplatin chemotherapy every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Gemcitabine 1250mg/m2 d1, d8, + cisplatin 75mg/m2 d1.
223631041|NCT02475538|DEVICE|Electroacupuncture|"Gradual Tapering Benzodiazepines will be tapered off over four weeks. The subjects will be told by a blinded researcher to reduce their daily dose by 25% in the 1st and 2nd week. For the remaining 50%, subjects will be asked to reduce the dose by 12.5% each time for 3-4 days in the 3rd and 4th week. Subjects who are unable to taper according to the suggested plan can reduce dose at a slower pace.~Electroacupuncture The subjects will be treated with electroacupuncture at bilateral Sishencong (EX-HN1), Anmian, Shuaigu (GB8), Touwei (ST8), Taiyang (EX-HN5), Toulinqi (GB15), Neiguan (PC6), Shenmen (HT7), Sanyinjiao (SP6), Taichong (LV3), and unilateral Yintang (EX-HN3), Shenting (GV24), and Baihui (GV20). De qi is achieved if possible. The intensity of electric-stimulation will be adjusted up to a level the subject can tolerate without undue discomfort. The needles will be left for 30 min."
223631042|NCT02475538|DEVICE|Placebo acupuncture|"Gradual Tapering The gradual tapering procedure will be the same as in the Electroacupuncture combined with gradual tapering group.~Placebo acupuncture Placebo needles designed by Streitberger will be used. The placebo needles are inserted to the site 1 inch beside the acupoints of the electroacupuncture group in order to avoid acupressure effect. The needles are held by surgical tape or hair pin to imitate the procedure of acupuncture. The needles are connected to an electric-stimulator with zero frequency and amplitude. The number, duration and frequency of treatment session will be the same as in the Electroacupuncture combined with gradual tapering group."
223631043|NCT05732467|DEVICE|visual function training software|Experimental group: If there is a refractive problem, first correct the refraction, wear corrective glasses, and then use visual function training therapy software (model: SJ-JRS2021) for treatment.
224219669|NCT05885230|PROCEDURE|pecto intercostal fascial block using bupivacaine 0.25%|patients will receive bilateral ultrasound-guided pecto-intercostal fascial block using 20 ml of bupivacaine 0.25% for each side.
224219670|NCT05885230|DRUG|lidocaine infusion|1.5 mg/kg lidocaine will be administered after induction of anesthesia, then 2mg/kg/h lidocaine will be administered with continuous intravenous infusion until the end of the surgery.
224219671|NCT03807323|BEHAVIORAL|Lifestyle counselling and exercise|"The program consists of:~1. Instructor-led training twice a week,~2. One individual nutritionist counselling session of followed by three group based two-hour nutritionist counselling focusing on practical food purchase and preparation and~3. Three two-hour psychologist-led group counselling sessions based on implementation intentions theory and practical help to make if-then plans focusing on changing food and activity habits."
224219672|NCT00654706|DRUG|Sertindole|Once daily oral dose. Day 1-20: 4-16 mg/day (titration period). Day 21-84: 12, 16 or 20 mg/day (flexible treatment period).
223631044|NCT05732467|OTHER|occlusion therapy|Control group: If there is a refractive problem, correct the refraction first, wear corrective glasses combined with occlusion therapy, and cover the fellow eye for 2 hours a day.
223631045|NCT05732467|OTHER|corrective glasses|corrective glasses
223631046|NCT02183675|DRUG|Telmisartan/Amlodipine|Telmisartan/Amlodipine fixed-dose combination
223631047|NCT02183675|DRUG|Telmisartan/Amlodipine/HCTZ|Telmisartan/Amlodipine/HCTZ fixed-dose combination
223631048|NCT02183675|DRUG|Telmisartan/HCTZ|Telmisartan/HCTZ fixed-dose combination
223631049|NCT00437112|DRUG|Human Insulin Inhalation Powder|patient specific dose, inhaled, before meals, 24 weeks
223631050|NCT00437112|DRUG|Insulin Glargine|patient specific dose, injectable, before meals, 24 weeks
223631051|NCT03593902|DRUG|Rituximab|Monoclonal antibody therapy used to treat certain autoimmune diseases and types of cancer
224219673|NCT00654706|DRUG|Quetiapine|Twice daily oral dose. Day 1-20: 50-500 mg/day (titration period). Day 21-84: 400, 500 or 600 mg/day (flexible treatment period).
224219674|NCT04709900|DIAGNOSTIC_TEST|CT angiography, FFR-CT and stress CT myocardial perfusion|The study intervention team consists of a specialist in Cardiac CT imaging, an invasive cardiologist, a thoracic surgeon and a cardiology nurse specialist. Treatment strategy defined by the study team based on CT findings involve referral for percutaneous coronary intervention, Coronary Artery Bypass surgery and/or initiation of optimal medical therapy, in addition to potential supplementary diagnostic procedures.
224219675|NCT01730677|DRUG|Lapatinib|lapatinib 1000mg, once daily
224219676|NCT01730677|DRUG|Vinorelbine|Vinorelbine 20mg/m2, D1 and D8, every 3 weeks
224219677|NCT05923164|DIAGNOSTIC_TEST|MAP-BC (Myofascial Adhesions in Patients after Breast Cancer) Evaluation Tool|It's a tool to evaluate scar tissues that occured after breast cancer treatment. It quantitatively measures myofascial adhesions. The degree of adhesion is scored for each area at 3 different depth levels (skin, superficial, deep) as a 4-point scale (0: no adhesion - 3: severe adhesion). Axillary scar, breast/mastectomy scar, m. pectoralis region, frontal chest wall, lateral chest wall, axilla and inframammary fold are evaluated separately. Sum of the scores from three levels of each area gives the total score. The minimal total score is: 0 and the maximum total score is 63.
224219678|NCT05923164|DIAGNOSTIC_TEST|Patient And Observer Scar Assessment Scale ( Observer Subscale)|This assesment tool consists of two different scales evaluated by the observer and the patient.The observer scale rates five variables, which include vascularity, pigmentation, thickness, relief, pliability and surface area, between 1-10 points (1:normal skin). The total score ranges from 5 to 50.
224317897|NCT03414086|OTHER|Myositis in Remission|Ten patients (four who have polymyositis, six dermatomyositis) from our database who are followed in the Myositis Center. We will collect serum, PBMC's, and RNA samples will be obtained at baseline and at six months. Remission is defined as a global myositis disease activity score less than or equal to 1 on the MDAAT assessments with no new immunosuppressive drug or glucocorticoid use and no increase in dose of either in the preceding year.
224317898|NCT01857843|DEVICE|Zotalolimus Eluting Stent|"Permuted block randomization into 4 groups according to the type of drug and stent will be carried out in a ratio of 1:1:1:1(i.e.,Vytorin-ZES, Vytorin-EES, mevalotin-ZES, or mevalotin-EES) for balanced randomization.~Patients with native coronary arteries who fulfill all enrollment criteria for OCT study will be randomized to receive either ZES (Endeavor®-Sprint or Resolute-integrity) or EES (Xience®) in a ratio of 1:1."
224219679|NCT03411590|OTHER|Fortified milk Powder|Toddlers will be allocated to the 200 ml group and will receive on a daily basis 32g of growing up milk powder respectively, in doses of 16 g, which can be reconstituted with 180 ml water to a final volume of about 200 ml of milk. The intervention period will last for 6 months. For the 200 ml test group, this translates into 32 g of growing up milk powder supply as one dose per day (in the morning)
224317899|NCT01857843|DEVICE|Everolimus eluting stent|"Permuted block randomization into 4 groups according to the type of drug and stent will be carried out in a ratio of 1:1:1:1(i.e.,Vytorin-ZES, Vytorin-EES, mevalotin-ZES, or mevalotin-EES) for balanced randomization.~Patients with native coronary arteries who fulfill all enrollment criteria for OCT study will be randomized to receive either ZES (Endeavor®-Sprint or resolute-integrity) or EES (Xience®) in a ratio of 1:1."
224317900|NCT01857843|DRUG|Ezetimibe 10mg & Simvastatin 40mg|"Permuted block randomization into 4 groups according to the type of drug and stent will be carried out in a ratio of 1:1:1:1(i.e.,Vytorin-ZES, Vytorin-EES, mevalotin-ZES, or mevalotin-EES) for balanced randomization.~Patients will be randomized in a ratio of 1:1 according to the two different types of lipid lowering treatment.~1. Ezetimibe 10mg/Simvastatin 40mg (Vytorin®, MSD)~2. Pravastatin 20mg (mevalotin®, BMS)"
224317901|NCT01857843|DRUG|Pravastatin 20mg|"Permuted block randomization into 4 groups according to the type of drug and stent will be carried out in a ratio of 1:1:1:1(i.e.,Vytorin-ZES, Vytorin-EES, mevalotin-ZES, or mevalotin-EES) for balanced randomization.~Patients will be randomized in a ratio of 1:1 according to the two different types of lipid lowering treatment.~1. Ezetimibe 10mg/Simvastatin 40mg (Vytorin®, MSD)~2. Pravastatin 20mg (mevalotin®, BMS)"
224317902|NCT05833698|DIAGNOSTIC_TEST|Elevation of NLR|Blood test
223631052|NCT03593902|DRUG|Fludarabine|A chemotherapy medication commonly used in the treatment of leukemia and lymphoma
223631053|NCT03593902|DRUG|Cyclophosphamide|A medication used as chemotherapy and to suppress the immune system
223631054|NCT03593902|DRUG|Mesna|A medication used in those taking cyclophosphamide or ifosfamide to decrease the risk of bleeding from the bladder
223631055|NCT03593902|DRUG|rATG|A rabbit polyclonal antibody to lymphocytes
223631056|NCT03593902|DRUG|Methylprednisolone|A corticosteroid medication used to suppress the immune system and decrease inflammation
223631057|NCT03593902|DRUG|G-CSF|A glycoprotein that stimulates the bone marrow to produce granulocytes and stem cells and release them into the bloodstream
223631058|NCT03593902|BIOLOGICAL|IVIg|Pooled immunoglobulin (IgG) from thousands of plasma donors that has immunomodulatory and anti-inflammatory effects
223631059|NCT03593902|BIOLOGICAL|Autologous Stem Cells|Infusion of patient's own stem cells
223631060|NCT05301660|DRUG|Nicotine transdermal patch|14 mg / tablet, one tablet a day, attached to the patient's back for 8 weeks
223631061|NCT05328102|BIOLOGICAL|Plamotamab|Biological
223631062|NCT05328102|BIOLOGICAL|Tafasitamab|Biological
223631063|NCT05328102|DRUG|Lenalidomide|Drug
223631064|NCT04308122|DEVICE|Cervical Orthosis (CO)|Immediately following surgery patients in the CO group will be fitted with a Philadelphia collar prior to being transferred to the recovery room. On the patient ward a physiotherapist will fit the patient with a Cervimax/Aspen/Miami J collar which will be worn at all times for 6 weeks according the standard of care.
223631065|NCT04308122|DEVICE|No Orthosis|The NO group will have no specific precautions applied to their neck range of motion.
223631066|NCT03138369|DEVICE|Vestibular nerve stimulator|Battery powered headset that can be recharged when not being used.
223631067|NCT03138369|DEVICE|Sham vestibular stimulation|Identical in external appearance to the vestibular nerve stimulation device, this device is also powered by a battery and needs to be periodically recharge when not being used. However it discharges into an internal resistor and does not stimulate the vestibular nerve.
223631068|NCT03812731|DRUG|Ropivacaine|Intraoperatively after induction of anaesthesia caudal epidural block will be administered with 0.2% ropivacaine 1-ml/kg
224219680|NCT04105790|BEHAVIORAL|Cognitive Behavioural Therapy with Mindfulness classes|The standard CBTm protocol is comprised of four 90-minute classes offered virtually via videoconferencing once a week for four consecutive weeks. The classes cover topics including mindfulness, cognitive therapy principles, behaviour therapy principles, managing anger, assertiveness, problem solving, goal setting, and evidence-based self-help resources. They are lecture-based but also involve experiential elements, such as mindfulness activities and practice of cognitive therapy strategies. Participants are assigned daily homework between each class to practice the strategies taught in session.
224219681|NCT04317573|DEVICE|Personalised card|An individualised card containing the patient's eye drops regime was printed for the patient after his/consult with the physician to be brought home.
224219682|NCT05353374|DRUG|Sodium Fusidate 2 % Topical Ointment|Sodium fusidate 2% topical ointment was applied twice daily on the wound after cauterization for 14 days.
224317903|NCT00575887|DRUG|Temozolomide|100 mg/m2/day, (PO) orally, on days between 1 and 21 of each 28 day cycles. Number of cycles: Until progression or unacceptable toxicity
224317904|NCT00620087|PROCEDURE|Molecular Breast Imaging|Molecular breast Imaging is a new nuclear medicine technique for imaging the breast. It uses small filed of view semiconductor-based gamma cameras that use Cadmium Zinc Telluride detectors. These have superior spatial and energy resolution to conventional sodium iodide detectors.
224317905|NCT00620087|PROCEDURE|Screening Mammography|A screening mammogram is used to look for signs of breast cancer in women who don't have any breast symptoms or problems. X-ray pictures of each breast are taken from 2 different angles.
224317906|NCT03276078|DRUG|Aclidinium Bromide/Formoterol Fumarate 400/12μg BID|Aclidinium bromide/formoterol fumarate 400/12μg administered by inhalation via the Genuair® multidose dry powder inhaler, twice daily (morning and evening) for 5 days
224317907|NCT05151354|OTHER|Psychotherapy|Patients receive 8 weeks of inpatient psychotherapeutic treatment. Treatment consists of individual and group psychodynamic psychotherapy, as well as an individual combination of art, music, body-oriented and relaxation therapies, which are also carried out in group settings. Treatments is provided by an interdisciplinary team of psychotherapists with a medical or psychology degree, art of music therapists, social workers, physiotherapists and specialist nurses.
223631069|NCT03812731|DRUG|Fentanyl Citrate|Intraoperatively after induction of anaesthesia fentanyl 1-mcg/kg/hour will be administered
223631070|NCT01269203|DRUG|Curcumin|1000 mg per day
223631071|NCT01269203|OTHER|Placebo|Administered daily same as Curcumin.
223631072|NCT04716764|OTHER|3-Day Food Intake Record|Collecting clinical and socio-demographic information, nutritional status, food consumption (dietary intake of advanced glycation end products, dietary total antioxidant capacity, dietary inflammatory index), anthropometric measurements (body weight, height, body composition, handgrip strength, upper-middle arm circumference, waist circumference, hip circumference, triceps skinfold thickness), quality of life, biochemical biomarkers (serum carboxymethyl lysine, advanced glycation end products receptor, the soluble receptor of advanced glycation end products, TNF-α, IL-1β, IL-6, malondialdehyde, 2,4-dinitrophenyl hydrazine, 8-hydroxy-2'-deoxyguanosine, total antioxidant capacity)
223631073|NCT00001986|DRUG|1-Octanol|
223631074|NCT01942928|OTHER|Usual NHS Care|Usual NHS care is provided by a health visitor who will diagnose excessively crying infants/infants with colic in the first instance. Parents usually will then have the opportunity to consult their health visitor when needed. The health visitor will provide support and advice on how to manage the condition within their professional remit.
223631075|NCT01942928|OTHER|Osteopathic Manipulative Therapy|Osteopathic treatment will be provided by experienced osteopaths once a week for up to four weeks, depending on needs. Treatment will be individualised, according to clinical findings, and involves using standard cranial osteopathic techniques. All parents will be able to ask questions.
223631076|NCT02405689|DRUG|Remifentanil|
223631077|NCT02405689|DRUG|Dexmedetomidine|
223631078|NCT02405689|DRUG|Sevoflurane|
223631079|NCT01614249|DIETARY_SUPPLEMENT|Soybean oil soft gels|Each participant will receive OmegaVia soybean oil soft gels to take orally, one soft gel taken three times per day in the morning, mid-day and in the evening after meals for a period of 8 weeks
224219683|NCT05353374|DRUG|Petrolatum ointment|Petrolatum ointment was applied twice daily on the wound after cauterization for 14 days.
224219684|NCT05575960|BEHAVIORAL|Interpersonal Psychotherapy for Adolescents (IPT-A)|Interpersonal Psychotherapy (IPT) is a psychotherapeutic treatment originally developed for treating depression in adults. It is a brief, structured treatment based on the idea of mobilizing the patient's social network, increasing his/her capacity to accept and seek support from others, and to process interpersonal difficulties, in order to improve depressive symptoms. Interpersonal psychotherapy for adolescents (IPT-A) is a version of IPT designed for young people between the age of 12-18 years with depression (Mufson, 2004), and is in many respects similar to IPT although with some modifications (e.g., a few scheduled meetings with parents during the course of treatment).
224219685|NCT00277680|PROCEDURE|Laparoscopic bilateral occlusion of uterine artery|
224219686|NCT00277680|PROCEDURE|Radiological embolization (UFE)|
224219687|NCT02965820|DEVICE|Opti-Free® PureMoist® contact lens solution|
224219688|NCT02965820|DEVICE|Habitual Multi-Purpose Contact Lens Solution|
224219689|NCT02965820|DEVICE|Habitual Contact Lenses|Subject's habitual contact lens brand worn in a daily wear modality for 30 days.
223631080|NCT01614249|DIETARY_SUPPLEMENT|Fish oil omega-3 EPA-rich soft gels|A total of 3.0g of OmegaVia fish oil omega-3 EPA-rich soft gels will be taken orally per day as one soft gel in the morning, mid-day and evening after meals for 8 weeks with bi-weekly follow-up visits.
223631081|NCT04004234|DRUG|Manganese Chloride|Administered by inhalation at 0.2 or 0.4mg/kg/d once daily in a 3-week cycle
224219690|NCT02229240|DRUG|Albiglutide|Albiglutide is intended for self-administration as a SC injection. It is provided as a fixed dose of 30 mg of albiglutide or 50 mg of albiglutide in a 0.5 mL injection volume, fully disposable pen injector
224219691|NCT02229240|DRUG|Matching albiglutide placebo|Matching albiglutide placebo will be provided as 0.5-mL injection, fully disposable pen injector system
224219692|NCT00567281|DEVICE|Magstim Rapid 2 system triggering Magstim Super Rapid system|Week 1 treatment includes rTMS for 5 sessions to either to left or right Wernicke's area (BA22) synchronous with rTMS to opposite hemisphere middle temporal cortex (BA21). Week 2 treatment includes rTMS given for 5 sessions with positions reversed (e.g., if Wernicke's stimulation was on the left during Week 1, position of rTMS will switch to the right side during Week 2 and vice-versa). As in Week 1, active rTMS will also be given synchronously to the opposite hemisphere middle temporal cortex. Weeks 3 and 4 include 10 stimulation sessions to the configuration of sites producing greater improvement in comparing results of Week 1 and Week 2. rTMS for each stimulation session will be given at 1-Hertz (once per second) for 16 minutes without interruption.
224219693|NCT00567281|DEVICE|Magstim Rapid-2 system triggering Magstim Super Rapid system|Week 1 includes repetitive rTMS for 5 sessions to either to left or right Wernicke's area (BA22) synchronous with sham rTMS to opposite hemisphere middle temporal cortex (BA21). Week 2 includes rTMS given for 5 sessions with positions reversed (e.g., if Wernicke's stimulation was on the left during Week 1, position of rTMS will switch to the right side during Week 2 and vice-versa). As in Week 1, sham rTMS will also be given synchronously to the opposite hemisphere middle temporal cortex. Weeks 3 and 4 include 10 stimulation sessions to the configuration of sites producing greater improvement in comparing results of Week 1 and Week 2. rTMS for each stimulation session will be given at 1-Hertz (once per second) for 16 minutes without interruption.
224219694|NCT03182608|DIAGNOSTIC_TEST|Noninvasive ultrasound assessment|An investigator evaluate the L4-5 interspinous level using anatomic landmarks in turn, then another independent investigator assess the consistency of the landmarks-guided interspinous level with the actual one by noninvasive ultrasound assessment.
224219695|NCT01891513|BEHAVIORAL|Exercise|All participants will take part in 3 days/week of structured aerobic, stretching, and balance training for weeks 1-12. For weeks, 13-24, training will be reduced to 2 days/week and a resistance training component added. Participants will also be expected to engage in 2 bouts of 30 minutes of home-based walking per week.
224219696|NCT01891513|DRUG|ACE inhibitor + exercise|In addition to exercise training, participants will receive an initial perindopril dose of 2 mg/day which will be titrated to 4 mg/day.
223631082|NCT04004234|DRUG|nab-paclitaxel|Administered intravenously, 125mg/m2/d on day1 and day8 in a 3-week cycle
223631083|NCT04004234|DRUG|Gemcitabine|Administered intravenously, 1g/m2/d on day1 and day8 in a 3-week cycle
223631084|NCT04004234|DRUG|anti-PD-1 antibody|Administered intravenously, 2-4mg/kg on day 3 in a 3-week cycle
223631085|NCT05498649|DEVICE|DT1fA|DT1fA contact lenses
223631086|NCT04524949|DRUG|IMCY-0098 450 μg|Small synthetic peptide for SC admin. Solvent: alum hydroxide
223631087|NCT04524949|DRUG|IMCY-0098 1350 μg|Small synthetic peptide for SC admin. Solvent: alum hydroxide
223631088|NCT04524949|DRUG|Placebo|Solvent: alum hydroxide
223631089|NCT00412334|DRUG|Copegus|1200-1600mg/day po
223631090|NCT00412334|DRUG|Copegus|1000-1200mg/day po
223764207|NCT01565135|BEHAVIORAL|Multimodal Vaccine Program|"Efforts will be made to collaborate with private ob/gyn offices to develop a multimodal intervention to improve patients'immunization rates. As part of the overall intervention, intervention practices will agree to 1) purchase, stock, and administer influenza, HPV, and Tdap vaccines, if not already doing so and 2) track patients' vaccination status. In addition, intervention strategies adopted by intervention settings to improve immunization rates may include:~* Patient education regarding the importance of vaccination, including encouragement of vaccination for family members~* Practice-based reminder/recall~* Seek to decrease missed opportunities for immunization by using either or both of the following: provider prompts and/or provider education and feedback"
223764208|NCT01254799|DRUG|Doxycycline|100 mg Doxycycline capsules twice daily for 5 days
223764209|NCT01254799|DRUG|Placebo|Placebo capsules twice daily for 5 days
223764210|NCT00220025|DEVICE|Phototherapy|The patient begins total body NBUVB that day at a dose that is 50% of the MED. Patients are treated 3-7 times per week, with increasing doses at every treatment if no burning occurs. This is continued until clearance of disease or maximum efficacy.
223764211|NCT02153866|BIOLOGICAL|rotavirus vaccine|3ml/dose, oral
223764212|NCT02153866|BIOLOGICAL|measles-rubella vaccine|0.5ml per dose, subcutaneous injection
223764213|NCT02153866|BIOLOGICAL|measles-mumps-rubella vaccine|0.5ml per dose, subcutaneous injection
223764214|NCT05599178|OTHER|Ultrasound examination in early labor|Combined trans-abdominal and trans-perineal ultrasound examination
224219697|NCT01891513|DRUG|Thiazide diuretic + exercise|In addition to exercise training, participants will receive an initial hydrochlorothiazide dose of 12.5 mg/day which will be titrated to 25 mg/day.
224219698|NCT01891513|DRUG|Angiotensin receptor blocker + exercise|In addition to exercise training, participants will receive an initial losartan dose of 50 mg/day which will be titrated to 100 mg/day.
224219699|NCT04739449|BEHAVIORAL|Coaching, Cleaning, Communication, Collaboration|"1. Coaching staff~2. Cleaning protocols, standardized~3. Communication with staff and leadership~4. Collaboration with local expertise"
224219700|NCT00309075|DRUG|Gadopentetate dimeglumine (Magnevist)|Gadopentetate dimeglumine (Magnevist Injection), approximately 0.1mmol/kg body weight, single intravenous administration on the study day
224219701|NCT01694615|PROCEDURE|Cryoprobe biopsy|
224219702|NCT01694615|PROCEDURE|Forceps Biopsy|
224219703|NCT00914433|DRUG|TPI 1100|1 dose only increasing dose
224317908|NCT03476733|OTHER|Detection of drug related problem in inpatient|Detection of drug related problem in inpatient
224317909|NCT00418002|DRUG|AQW051|
224317910|NCT02552732|DEVICE|NHF with or without Oxygen|NHF using myAIRVO™ 2 will be set at 25L/min at 37°C. However, all participants are able to lower the delivered temperature to 34°C.
223631091|NCT00412334|DRUG|peginterferon alfa-2a [Pegasys]|360 micrograms sc weekly
223631092|NCT00412334|DRUG|peginterferon alfa-2a [Pegasys]|180 micrograms sc twice weekly
223631093|NCT03371667|DRUG|Methotrexate|"Methotrexate 5 mg/m2 will be given once week for 4 weeks, then 3 mg/m2 every two weeks for 12 weeks. Body surface area will be capped at 2 m2.~Methotrexate will be given as an IV infusion over 15 minutes. All patients will received prednisone 2 mg/kg.day PO (or methylprednisolone 1.6 mg/Kg/day) for 3 days.~For responding patients between day 4 and 28, the dose of prednisone must be at least 0.25 mg/kg/day prednisone (or 0.2 mg/kg/day methylprednisolone).~All patients should receive a folinic acid supplementation 24 hours after each MTX/placebo administration.~Lederfoldin 10 mg po or iv will be administered on days 2, 9, 16 and 23. Lederfoldin 10 mg po or iv will be administered on days 37, 51, 65, 79, 93 and 103."
223631094|NCT03371667|DRUG|Placebo|"Placebo 5 mg/m2 will be given once week for 4 weeks, then 3 mg/m2 every two weeks for 12 weeks. Body surface area will be capped at 2 m2.~Placebo will be given as an IV infusion over 15 minutes. All patients will received prednisone 2 mg/kg.day PO (or methylprednisolone 1.6 mg/Kg/day) for 3 days.~For responding patients between day 4 and 28, the dose of prednisone must be at least 0.25 mg/kg/day prednisone (or 0.2 mg/kg/day methylprednisolone).~All patients should receive a folinic acid supplementation 24 hours after each MTX/placebo administration.~Lederfoldin 10 mg po or iv will be administered on days 2, 9, 16 and 23. Lederfoldin 10 mg po or iv will be administered on days 37, 51, 65, 79, 93 and 103."
223631095|NCT06340295|OTHER||
223631096|NCT00568022|DRUG|Ixabepilone|Ixabepilone: Intravenous (IV) Solution, IV, 32(40)mg/m\^2, once every 3 weeks, up to 6 cycles
223631097|NCT00568022|DRUG|Capecitabine|Capecitabine: Tablets, Oral, 1650(2000)mg/m\^2, twice daily for 2 weeks, one week off, up to 6 cycles
224219704|NCT03929939|BEHAVIORAL|Exercise training and healthy eating (overseen by IEEM research team)|"Exercise Training: A personalized training program will be developed for participants. Based on maximal steady state heart rate and resting heart rate, three training zones (recovery, base pace, and maximal steady state) will be determined. The target heart rate for each training zone will be set for each patient. The majority of training sessions during the early phase of the program will be prescribed as base pace with target heart rate equivalent to about 75% of maximal. Initially, patients will train 3 times per week for 20-30 minutes per session by walking, jogging or swimming. As the patients become relatively fit, the duration of the base training sessions will be prolonged, and subsequently sessions of increased intensity (i.e., maximal steady state) will be added.~Healthy Eating: Participants will be provided with dietary advice consistent with the American Heart Association guidelines (D.A.S.H. diet eating plan)."
224219705|NCT06486363|DRUG|Aspirin combined with clopidogrel|Participants in this group shall take Aspirin (100 mg/day) + clopidogrel (75 mg/day) for at least 5 days before receiving stent-assisted coil embolization, and take same medication for 6 months after endovascular treatment
224219706|NCT06486363|DRUG|Aspirin combined with half-dose ticagrelor|Participants in this group shall take Aspirin (100 mg/day) + half dose of ticagrelor (45 mg, 12 hours/time), at least for 3 days before receiving stent-assisted coil embolization, and take same medication for 6 months after endovascular treatment
224219707|NCT03567720|BIOLOGICAL|tavokinogene telseplasmid|Intratumoral tavokinogene telseplasmid delivered by electroporation every 6 weeks
224219708|NCT03567720|BIOLOGICAL|Pembrolizumab|Intravenous 3 weekly treatments
224219709|NCT03567720|DEVICE|Immunopulse|Device that administers electroporation
224219710|NCT03567720|DRUG|nab paclitaxel|intravenous on days 1, 8 and 15 of each 28 day cycle
224219711|NCT03567720|DRUG|gemcitabine plus carboplatin|intravenous on days 1 and 8 of every 21 days
223631098|NCT02234882|DRUG|Rosuvastatin|
223631099|NCT02234882|DRUG|BMS-663068|
223631100|NCT04169035|DEVICE|The BD Odon DeviceTM is a new device for AVB that has been designed by a team of midwives, doctors and engineers.|The BD Odon DeviceTM works by placing a cuff of air attached to a plastic sleeve, around the baby's head. The doctor then gently pulls on this sleeve and air cuff to assist the birth of the baby.
223631101|NCT04169035|PROCEDURE|forceps or ventouse|"The woman is unable to have an Odon assisted birth as no Odon trained practitioner is available to assist the birth.~Forceps is a metal instrument with two handles used to encircle a baby's head and assist in birth.~Ventouse is a device used to help a baby be born by putting it over the baby's head and using suction (= removing air) to pull the baby out of the mother's body."
223631102|NCT01239199|OTHER|Measure of the exhaled NO|The exhaled NO will be measure by chemiluminescence in current ventilation by an indirect method (off-line)
223631103|NCT02946580|DRUG|MOVANTIK™ (naloxegol)|
223631104|NCT02946580|DRUG|Sugar Pill|
223631105|NCT01164514|BIOLOGICAL|CPG 7909|CPG 7909 is a synthetic oligodeoxynucleotide used as an adjuvant and administered at 2 different dosages: 250 mcg and 500 mcg.
223631106|NCT01164514|BIOLOGICAL|J5-OMP Vaccine|J5-OMP vaccine 10 mcg to be administered with and without CpG 7909 adjuvant 250 or 500 mcg, intramuscularly on Days 0, 29 and 59.
223631107|NCT01164514|DRUG|Placebo|Normal saline.
223631108|NCT06207331|DRUG|Dexmedetomidine 0.5 μg/kg|Participants inhale the atomized 0.5 μg/kg dexmedetomidine in 2 ml of 0.9% saline.
223631109|NCT06207331|DRUG|Dexmedetomidine 1 μg/kg|Participants inhale the atomized 1 μg/kg dexmedetomidine in 2 ml of 0.9% saline.
223631110|NCT06207331|DRUG|Saline|Participants inhale atomized 2 ml 0.9% saline.
223631111|NCT02265458|BEHAVIORAL|Musical intervention and sensory isolation|30 minutes musical intervention during NIV will be administrated, along with sensory isolation (mask obscuring the eyes)
224219712|NCT01573091|PROCEDURE|Cardiac Resynchronization Therapy|Any commercially available Cardiac Resynchronization Therapy devices with or without defibrillation backup (CRT-D/CRT-P) can be used upon discretion of the investigator according to current guidelines
224219713|NCT02472392|DRUG|Rabbit anti-thymocyte globulin|Active treatment
224219714|NCT02472392|DRUG|Busulfan|comparitor
224219715|NCT02472392|DRUG|Melphalan|comparitor
224219716|NCT02472392|DRUG|Fludarabine|comparitor
224219717|NCT02472392|DRUG|Cyclophosphamide|comparitor
223631112|NCT00459459|PROCEDURE|Fine needle aspiration of the thyroid|
223631113|NCT00904449|DRUG|Oxymorphone ER|10mg, 20mg, and 40mg PO
224219718|NCT04082962|DRUG|Dexamethasone intravitreal implant|Ozurdex™ is an intravitreal implant containing dexamethasone 0.7 mg in the NOVADUR® solid polymer drug delivery system (NOVADUR™ system contains poly (D,L-lactide-co-glycolide) PLGA intravitreal polymer matrix, which slowly degrades to lactic acid and glycolic acid.). Ozurdex™ is preservative-free. It is supplied in a foil pouch with a single-use plastic applicator.
224219719|NCT02718495|DRUG|PTI-428|
224219720|NCT02718495|DRUG|Placebo|
224219721|NCT04249089|BEHAVIORAL|Relaxation video and pamplet|This group will be asked to watch a video and perform relaxation techniques twice a day following surgery
224219722|NCT02079948|DRUG|Methotrexate + Folic Acid|"Participants in the methotrexate + folic acid condition will have a~* Blood draw at each monthly visit~* Cognitive performance testing to assess memory performance~* Physical function testing to assess walking speed and measure muscle endurance~* Pain assessment testing to assess the presence and location of daily pain~* Self-reported function and quality of life to measure disability and mobility limitations, and~* Depression assessment testing to assess participants' level of depression."
224219723|NCT02079948|DRUG|Placebo + Folic Acid|"Participants in the placebo + folic acid condition will have a~* Blood draw at each monthly visit~* Cognitive performance testing to assess memory performance~* Physical function testing to assess walking speed and measure muscle endurance~* Pain assessment testing to assess the presence and location of daily pain~* Self-reported function and quality of life to measure disability and mobility limitations, and~* Depression assessment testing to assess participants' level of depression"
224219724|NCT02079948|PROCEDURE|Functional MRI Experimental Tasks|Participants who are randomly assigned to the fMRI scan wil receive their study drugs at the the Baseline fMRI visit. Participants who are randomly assigned to the fMRI will also attend complete their last visit at the 6 month period.
224219725|NCT02079948|PROCEDURE|Muscle Biopsy|Participants who are randomly assigned to the muscle biopsy assessment of the study will receive their study drugs at the Baseline muscle biopsy visit. Participants who are randomly assigned to the muscle biopsy portion of the study will also complete their last visit at the 6 month period.
224219726|NCT00372827|DRUG|Brinzolamide 1% added to Travoprost 0.004%|
224219727|NCT03207360|BEHAVIORAL|Pain Coping Skills|Participants will be trained in pain coping skills and meaning-centered psychotherapy. The intervention will consist of 4 weekly videoconference-delivered sessions that will last between 45 and 60 minutes.
224219728|NCT01967888|DRUG|Reparixin|Solution for intravenous (IV) infusion; 2.772 mg/kg body weight/hour administered at 0.25 mL/kg/hour
223631114|NCT01751529|PROCEDURE|Contrast-enhanced Ultrasound|All patients will undergo a contrast-enhanced ultrasound prior to planned resection or ablative therapy or as part of routine screening for kidney cancer.
223631115|NCT01751529|DRUG|Perflutren lipid|All patients will receive a contrast-enhanced ultrasound using microbubble contrast agent (perflutren lipid; Definity®) prior to planned resection or ablative therapy or as part of routine screening for kidney cancer.
223631116|NCT03733717|DRUG|Isatuximab SAR650984|"Pharmaceutical form: Concentrate for solution~Route of administration: Intravenous"
223631117|NCT03690193|BEHAVIORAL|Ketogenic Diet|All participants will be assigned to the 3-month 1:1 ketogenic diet intervention (approximately 70% fat, \<10% carbohydrate, and 20% protein).
223631118|NCT05682430|BEHAVIORAL|Heart rate based HIIT|Week1,90% HRmax long duration HIIT + 90% HRmax long duration HIIT. Week2,90% HRmax long duration HIIT + 90% long duration HRmax HIIT. Week3,90% HRmax long duration HIIT + 90% HRmax long duration HIIT. Week4,90% HRmax long duration HIIT + 90% HRmax long duration HIIT. Week5,90% HRmax short duration HIIT + 90～95% HRmax long duration HIIT. Week6,90% HRmax short duration HIIT + 90～95% HRmax long duration HIIT. Week7,90% HRmax short duration HIIT + 90～95% HRmax long duration HIIT. Week8,90% HRmax short duration HIIT + 90～95% HRmax long duration HIIT. Week9,90～95% HRmax short duration HIIT + 90～95% HRmax short duration HIIT. Week10,90～95% HRmax short duration HIIT + 90～95% HRmax short duration HIIT. Week11,90～95% HRmax short duration HIIT + 90～95% HRmax short duration HIIT. Week12,90～95% HRmax short duration HIIT + 90～95% HRmax short duration HIIT.
223764215|NCT04623333|DRUG|TQB2450|TQB2450 1200mg administered intravenously (IV) on Day 1 of each 21-day cycle.
223764216|NCT01941446|DRUG|Eravacyline, Moxifloxacin, and placebo|
224219729|NCT01967888|DRUG|Placebo|Physiologic solution administered at 0.25 mL/kg/hour
224219730|NCT05904015|DRUG|Envafolimab combined with concurrent chemoradiotherapy (Hypofractionated radiotherapy)|"Envafolimab: 300mg SC d1,Q3W,2 cycles Cisplatin/carboplatin: Cisplatin: 75 mg/m2 IV d1,Q3W ,2 cycles or Carboplatin:AUC=5/6 IV d1,Q3W,2cycles Etoposide: 100mg/m2 IV d1,Q3W ,2 cycles Radiotherapy: Provide a prescription dose of 45Gy at a 95% PTV dose, with a single split dose of 3Gy, once a day, 5 times a week, for a total of 15 times.~Envafolimab maintenance: 300mg,SC, d1. Q3W, up to 2 years or until PD or intolerable."
224219731|NCT05904015|DRUG|Envafolimab combined with concurrent chemoradiotherapy (Conventional Radiotherapy)|"Envafolimab: 300mg SC d1,Q3W,2 cycles Cisplatin/carboplatin:Cisplatin:75 mg/m2 IV d1,Q3W ,2 cycles or Carboplatin:AUC=5/6 IV d1,Q3W,2cycles Etoposide: 100mg/m2 IV d1,Q3W ,2 cycles Radiotherapy: Provide a prescription dose of 60Gy at a 95% PTV dose, with a single split dose of 2Gy, once per day, 5 times per week, for a total of 30 times.~Envafolimab maintenance: 300mg,SC, d1. Q3W, up to 2 years or until PD or intolerable."
224219732|NCT02505100|OTHER|Touching relaxant|
224219733|NCT02505100|OTHER|Hypnoses|
224219734|NCT05105139|OTHER|Allantoin/ Coal Tar/ Clioquinol|Pharmaceutical Form: Shampoo Dosage: Allantoin 0.2 g/ Coal Tar 5.0 g/ Clioquinol 3.0 g Administration way: For scalp use
224219735|NCT05105139|OTHER|Allantoin/ Coal Tar/ Clioquinol/ Triclosan|Pharmaceutical Form: Shampoo Dosage: Allantoin 0.2 g/ Coal Tar 3.0 g/ Clioquinol 3.0 g/ Triclosan 0.3 g. Administration way: For scalp us
223631119|NCT05682430|BEHAVIORAL|VIFT speed-based HIIT with mechanical work|Week1,Wednesday 65% VIFT HIIT, saturday 65% VIFT HIIT. Week2,Wednesday 65% VIFT HIIT, saturday 65% VIFT HIIT. Week3,Wednesday 67.5% VIFT HIIT, saturday 67.5% VIFT HIIT. Week4,Wednesday 67.5% VIFT HIIT, saturday 67.5% VIFT HIIT. Week5,Wednesday 70% VIFT HIIT, saturday 90% VIFT HIIT. Week6,Wednesday 70% VIFT HIIT, saturday 90% VIFT HIIT. Week7,Wednesday 72.5% VIFT HIIT, saturday 92.5% VIFT HIIT. Week8,Wednesday 72.5% VIFT HIIT, saturday 92.5% VIFT HIIT. Week9,Wednesday 92.5% VIFT HIIT, saturday 100% VIFT HIIT. Week10,Wednesday 92.5% VIFT HIIT, saturday 100% VIFT HIIT. Week11,Wednesday 95% VIFT HIIT, saturday 105% VIFT HIIT. Week12,Wednesday 95% VIFT HIIT, saturday 105% VIFT HIIT.
223631120|NCT05684536|DEVICE|liagsure device|the vessel sealing device ( ligasure covidien ) which seals vessels by fusing the inner layers of the vessel wall, with dissection around ligament of berry and inferior thyroidal artery
223631121|NCT02677441|PROCEDURE|Conservative management|Specific standardized rehabilitation protocol under Cote et al (2010)
223631122|NCT02677441|PROCEDURE|Surgery|Coracoclavicular and acromioclavicular fixation as described ly Lädermann et al (2011), followed by specific standardized rehabilitation protocol under Cote et al (2010).
223631123|NCT02680249|DRUG|CTP-656|
224219736|NCT00553540|DEVICE|Back supports|The spinal / back supports are made of polymer shield covered by fabric and foam to be used externally to relieve back pain and offer spinal support. They are to be placed in the chair used in workstation related jobs.
224219737|NCT05805475|OTHER|Endotracheal suctioning with expiratory pause|Perform closed endotracheal suctioning with an expiratory pause of 5 seconds
223631124|NCT03075787|DEVICE|standard 24-h ambulatory polysomnography|A standard 24-h ambulatory ad libitum polysomnography including EEG, electro-oculography (EOG), electromyography (EMG), EKG, was performed by a standard clinical.
223631125|NCT05916183|BEHAVIORAL|Fluid loss and consumption|Upon 5% body mass loss, rehydration of fluid lost to sweating throughout a 2 hour recovery period
223631126|NCT03525236|OTHER|Tasting of flavours|"* Each patient will taste 5 products, in sequential-monadic test, randomized, one by one.~* Patients will take few sips of each study product, ideally in isolation (avoid influence of other patients)~* For each product tasted the subjects will be asked to answer a questionnaire including 1 question on the palatability of the product using a 10-point hedonic scale and a more detailed organoleptic evaluation of the product.~* Between product tastings, participants will have a 10 minutes break to rinse their mouth and fill in a questionnaire assessing sensory changes"
223631127|NCT02761330|DRUG|Ketamine|Ketamine will be used to induce general anesthesia with or without subsequent ECT. Within a single patient, the dose will remain consistent throughout the study and is estimated to be 2 mg/kg.
223631128|NCT02761330|PROCEDURE|Electroconvulsive Therapy|Dose of the ECT charge will be determined during titration session prior to randomization.
223631129|NCT05280340|DRUG|Anakinra|Anakinra will be given to enrolled infants starting in the first 24hrs of life for the first 3 weeks of life.
223631130|NCT03135600|PROCEDURE|Procedure|Once participants are eligible, they will undergo the experimental procedure. Before data collection, they will walk on a treadmill in barefoot for ten minutes to adapt the condition. The a gait analysis system will collect the data while they walk/run on the treadmill in barefoot at 4/6km/h.
223631131|NCT03020251|OTHER|preoperative chest physiotherapy|preoperative chest physiotherapy : 5 sessions per week during 3 weeks
223631132|NCT03020251|OTHER|preoperative rehabilitation program|exercise training at home : 5 sessions per week during 3 weeks
223631133|NCT03638453|OTHER|PediCARE|PediCARE provides support for groceries (using an online grocery delivery service called Instacart) and transportation to and from the hospital (using rides through RideHealth).
223631134|NCT03638453|OTHER|Usual Care|Standard care per hospital guidelines.
223631135|NCT06223893|DEVICE|CirrhoCare management system|"This is a UKCA-marked, digital-therapeutic system consisting of:~* clinical-grade, cirrhosis monitoring sensors and a smartphone app,~* a clinical team-facing, decision-facilitating dashboard, and~* CyberLiver's platform incorporating hepatic algorithms.~The CirrhoCare kit consists of: - Apple watch - iPhone with an in-built CirrhoCare app - a digital Bluetooth-linked system comprised of: \~Wellue BP monitor, \~Wellue weighing scale \~Bluetooth thermometer.~The CirrhoCare management system also includes:~* The clinician dashboard: All participant data collected through the app will be reviewed by the clinical team via the clinician dashboard.~* The CirrhoCare algorithm: This algorithm will advise the clinical team if the participant is at high, medium, or low risk of developing a particular outcome event, based on monitoring data collected each day from the participant which is compared to the baseline values and average values collected over the first week of monitoring."
223631136|NCT04291781|BIOLOGICAL|RC18 160mg|subcutaneous injection on the upper arm, abdomen, or upper thigh outside;
223631137|NCT04291781|BIOLOGICAL|RC18 240mg|subcutaneous injection on the upper arm, abdomen, or upper thigh outside;
223631138|NCT04291781|BIOLOGICAL|placebo|subcutaneous injection on the upper arm, abdomen, or upper thigh outside;
223631139|NCT03041740|DRUG|Perfluorooctyl Bromide|Subjects in the PFOB group will receive PFOB partial liquid ventilation instilled via side port of endotracheal tube (2.5 mL/kg/day) across 10 treatment days.
223631140|NCT06443762|DRUG|[68Ga] MDM2/MDMX Peptide|"Utilizing a peptide with high affinity to MDM2/MDMX as the targeting moiety for radiopharmaceuticals, this study explores the diagnostic efficacy of \[68Ga\] MDM2/MDMX Peptide in patients with malignant tumors exhibiting high MDM2/MDMX expression. This approach not only provides a basis for the early diagnosis of malignant tumors but also facilitates the formulation of effective precision therapy strategies tailored to the tumor's MDM2/MDMX expression profile, particularly for patients with recurrent and metastatic disease.~\[68Ga\] MDM2/MDMX Peptide, a novel MDM2/MDMX-targeted molecular probe labeled with 68Ga, utilizes DOTA as a bifunctional chelator for complexing with 68Ga3+. The labeling process is straightforward, allowing for direct use without purification, and demonstrates high in vivo stability."
223631141|NCT06384079|PROCEDURE|Antegrade and retrograde pyelogram|Participation in the study will guarantee that participants will receive this procedure.
223631142|NCT05656859|BEHAVIORAL|Single group|Survey
223631143|NCT03043313|DRUG|Trastuzumab|Given intravenously (into the vein; IV)
223631144|NCT03043313|DRUG|Tucatinib|Given orally
224219738|NCT05805475|OTHER|Endotracheal suctioning without expiratory pause|Perform closed endotracheal suctioning without expiratory pause
224219739|NCT06021977|DRUG|Zanubrutinib|Zanubrutinib was specifically designed to deliver complete and sustained inhibition of the BTK protein by optimizing bioavailability, half-life, and selectivity.
224219740|NCT06087393|DEVICE|CONVIVO|Any clinical adverse event (AE), laboratory abnormality, or other medical condition or situation occurs such that continued participation in the study would not be in the best interest of the participant. The participant meets an exclusion criterion (either newly developed or not previously recognized) that precludes further study participation.
224219741|NCT04193059|DRUG|Paclitaxel|paclitaxel 80 mg/m\^2 ivgtt d1, d8, d15, 28 days per cycle, 6 cycles.
224219742|NCT04193059|DRUG|Carboplatin|carboplatin AUC=2 ivgtt d1, d8, d15, 28 days per cycle, 6 cycles.
224219743|NCT04193059|DRUG|Epirubicin|epirubicin 90 mg/m\^2 ivgtt d1, 21 days per cycle, 4 cycles.
224219744|NCT04193059|DRUG|Cyclophosphamide|cyclophosphamide 600 mg/m\^2 iv d1, 21 days per cycle, 4 cycles.
224219745|NCT04193059|DRUG|Trastuzumab|trastuzumab 6 mg/kg (loading dose 8mg/kg) ivgtt d1, 21 days per cycle with chemotherapy; or trastuzumab 2 mg/kg (loading dose 4mg/kg, w1) ivgtt d1, d8, d15, d22, 28 days per cycle with chemotherapy. After chemotherapy, patient will continue to complete 1 year of adjuvant trastuzumab (6 mg/kg ivgtt every 3 weeks).
224219746|NCT04193059|DRUG|Pertuzumab|pertuzumab 420mg (loading dose 840mg) ivgtt d1, 21 days per cycle with chemotherapy. After chemotherapy, patient will continue to complete 1 year of adjuvant pertuzumab (420mg ivgtt every 3 weeks).
224219747|NCT04193059|DRUG|Docetaxel|docetaxel 100 mg/m\^2 ivgtt d1, 21 days per cycle, 4 cycles.
224219748|NCT05386745|BEHAVIORAL|physical activity|A series of 10 weekly psychoeducational modules including information on psychosocial determinants of physical activity engagement, adherence and maintenance, as well as a number of other behaviour change tools, like reflection activities.
224219749|NCT02622074|BIOLOGICAL|Pembrolizumab|200 mg administered Q3W as an IV infusion.
224219750|NCT02622074|DRUG|Nab-paclitaxel|125 mg/m\^2 or 100 mg/m\^2 administered weekly as an IV infusion, according to allocation.
224219751|NCT02622074|DRUG|Anthracycline (doxorubicin)|60 mg/m\^2 administered Q3W as an IV injection.
224219752|NCT02622074|DRUG|Cyclophosphamide|600 mg/m\^2 administered Q3W as an IV infusion.
224219753|NCT02622074|DRUG|Carboplatin|AUC 6 or AUC5 administered Q3W as an IV infusion, or AUC2 administered weekly as an IV infusion, according to allocation.
224219754|NCT02622074|DRUG|Paclitaxel|80 mg/m\^2 or 70 mg/m\^2 administered weekly as an IV infusion, according to allocation.
224219755|NCT03770871|DRUG|Indirect pulp treatment using Dycal (TM)|Partial caries removal and protection of the dental pulp with biocompatible material
224219756|NCT03770871|DRUG|Indirect pulp treatment using Vitrebond (TM )|Partial caries removal and protection of the dental pulp with biocompatible material
224219757|NCT04622384|OTHER|Dialysis weaning|Dialysis weaning as planned by the attending ICU-physician.
224219758|NCT02114931|BIOLOGICAL|ABP 501|Solution for subcutaneous injection in a syringe containing 40 mg/0.8 mL ABP 501
224219759|NCT00454974|DEVICE|Wearable artificial kidney|
224219760|NCT00590356|DEVICE|StarClose®|Closure device for femoral artery suture site occlusion
224219761|NCT00590356|DEVICE|AngioSeal®|Closure device for femoral artery suture site occlusion
224219762|NCT03555370|BEHAVIORAL|Vestibular Exercise Intervention|The vestibular exercise intervention group will complete behavioral management activities, and prescribed in--office/at home vestibular exercises from four groups: 1) gaze stability training (integrated eye and head movements on fixed target), 2) visual motion training (integrated eye and head movements on moving target), 3) standing balance (standing with eyes closed in different stances), and 4) dynamic gait (walking with head turns and eye movements). Participants will be prescribed to one of four levels of these exercise groups based on presentation of symptoms/impairment as indicated on VOMS. Progression through the levels will be based on symptom tolerance and successful completion of all exercises at the current level.
224219763|NCT03555370|BEHAVIORAL|Standard of Care|The standard of care consists of standardized in office/at home behavioral management including sleep, hydration, nutrition, and stress management interventions.
223631145|NCT05296473|DEVICE|ADHD Therapy|investigational game-play therapy
223631146|NCT05296473|DEVICE|Control Therapy|control game-play therapy
223764217|NCT03242681|PROCEDURE|Endoscopy Assisted Probing procedure|The patency of the system will be tested by irrigation with 1 ml normal saline. A cannula was introduced via the upper or lower canaliculus as far as the lacrimal sac and fluid injected through the system from a 5 ml syringe. Nasal endoscopy and irrigation will be performed simultaneously and free flow of fluid from the lacrimal sac to the nose will confirm anatomical patency of the system
224219764|NCT04572620|DRUG|Rituximab|375 mg/m2 as 4 weekly consecutive i.v. infusions with subsequent infusions of 375 mg/m2 performed every 3 months for 12 months.
224219765|NCT04572620|DRUG|Abatacept|10 mg/kg i.v. every 2 weeks twice, then every 4 weeks for 12 months.
224219766|NCT05394142|DRUG|Placebo|Comparator arm with placebo
224219767|NCT05394142|DRUG|Pioglitazone|Pioglitazone 7.5 mg/day
224219768|NCT05394142|DRUG|Spironolactone|Spironolactone 50 mg/day
224219769|NCT05394142|DRUG|Metformin|Metformin 850 mg/day
224219770|NCT03592381|PROCEDURE|Ridge Expansion by ossedensification|Osseodensification is a new concept facilitated by Densah® Burs which are a multi- fluted osteotome like drilling instrumentsThe idea behind the technique is using a non-subtractive drilling mode that preserves bone and increases its density along the osteotomy walls instead of cutting it away (Huwais and Meyer 2015)
223631147|NCT06583668|OTHER|Therapeutic Story|Listening and watching the therapeutic story in digital media
223631154|NCT02657889|DRUG|niraparib|
223631155|NCT02657889|BIOLOGICAL|pembrolizumab|
223764218|NCT00712296|DRUG|ASHMI 4|4 capsules orally twice a day
224219771|NCT03592381|PROCEDURE|ridge expansion by ridge splitting|using the piezotome,Piezoelectric ridge splitting allows exact, clean, and smooth even curved cutting of the bone tissue, with proper visibility.
224219772|NCT05593406|DEVICE|Vibration Group|Whole body vibration for 15 minutes in squat and lunge position.
223631156|NCT06110013|DEVICE|Electrical cardiometry|"All included patients will be connected to Electrical cardiometry device. The electrodes will be placed over the bare skin of patients at the following sites:~A. on the left neck below the ear B. directly superior to the midpoint of the left clavicle C. along the left mid-axillary line at the level of the xiphoid process D. two inches below the third electrode. High frequency signals pass through 2 acting electrodes, the other 2 measuring electrodes detect changes in bioimpedance resistance to allow continuous hemodynamic monitoring, then data will be analysed to give comprehensive picture of the hemodynamic circulatory system, allowing differential diagnosis for a patient management"
223631157|NCT04214340|OTHER|evaluation of practices|Study of the management and follow-up of patients presenting with appendicitis in France.
223631158|NCT04643275|DEVICE|BTL-899|Treatment with study device.
223631159|NCT02306330|DEVICE|Malditof|Malditof MS system is applied for Malditof group for identifying pathogens. It takes 20 minutes to give the results.
223764219|NCT00712296|DRUG|ASHMI 12|12 capsules orally twice a day
224219773|NCT05593406|OTHER|Control Group|NDT treatment 2 sessions per week
224219774|NCT01691755|DRUG|Placebo|oral doses once a day for 26 weeks
224219775|NCT01691755|DRUG|aleglitazar|150 mcg orally once a day for 26 weeks
224219776|NCT04706975|DRUG|difelikefalin 2.0 mg|Oral difelikefalin 2.0 mg administered twice daily
224219777|NCT04706975|DRUG|Placebo|Oral Placebo administered twice daily
224219778|NCT02578732|DRUG|FOLFOXA|"Schema:~1 cycle = 14 days \*\*It will not be considered a deviation if a cycle or pre-cycle assessment must be adjusted to accommodate scheduling or holidays. Adjustment must be documented with reason to BrUOG\*\*~Abraxane ®: 150mg/m2 IV over 30 minutes, day 1 (administered first) every 14 days.~Oxaliplatin: 85mg/m2, IV over 2 hours, day 1 every 14 days Leucovorin: 400mg/m2, IV over 2 hours, day 1 every 14 days 5-FU infusion:1200mg/m2/day, as a continuous IV infusion over 2 days, day 1 and day 2 (for a total dose of 2400mg/m2 over 46 hours.)~* It is at the discretion of the treating physician to give Neulasta, 6 mg sq x 1 post treatment~* Antiemetics will be administered as per standard institutional policy."
224219779|NCT02115191|DEVICE|2-octylcyanoacrylate|After sedation with midazolam (0.5 mg/kg orally) a Foley catheterization with a 10 Fr gauge siliconized catheter will be placed, with the balloon inflated with 1.5 ml water to prevent bladder spasm. After this we will apply the adhesive by using dissecting forceps to approximate the edges of the UCF, and then apply it several thin layers of OCA.
224219780|NCT02115191|PROCEDURE|Surgical reintervention|The reoperation will consist on mobilizing dartos flaps and closing the defect in layers with absorbable sutures. Urinary bladder drainage will be provided with a 10 Fr silicone Foley catheter, with the balloon inflated with 1.5 ml water to prevent bladder spasm.
224219781|NCT04411459|OTHER|Invasive mechanical ventilation|Invasive mechanical ventilation for respiratory failure associated to COVID-19 pneumonia
224219782|NCT04670757|DRUG|CPL409116|IMP administration, tablets contain CPL409116 as an active ingredient
224219783|NCT04670757|DRUG|Placebo|Placebo comparator
224219784|NCT02875171|DRUG|Anthracycline administration|Patients suffering from lymphoma or acute leukemia and requiring anthracycline administration were included
224219785|NCT03911609|OTHER|Exercise|Subjects will perform isometric (static) handgrip exercise at submaximal intensity for four minutes. The exercise will be performed while the subject is seated, and the elbow bent at around 90° and unsupported. Subjects will be asked to rate their pain using numerical pain rating scale that ranges from 0 (no pain) to 10 (worst pain), perceived exertion (RPE) from 0 (Nothing at all) to 10 (extremely strong), and perceived stress from 0 (not stressed at all) to 10 (extremely stressed). The ratings of pain intensity, RPE and perceived stress will be provided before, at the middle and at the end of the exercise.
224219786|NCT03911609|OTHER|Cognitive Task|The mental math task, which is also known as serial subtraction test, will be performed for four minutes. Subjects will be asked to rate their pain intensity and perceived stress before, at the middle and at the end of the mental math task.
224219787|NCT00535509|RADIATION|Cisplatin-Docetaxel ± Trastuzumab|Chemo \& RT
223764220|NCT00712296|DRUG|Placebo|Placebo 6 capsules twice a day
223764221|NCT05605665|DRUG|low-dose interleukin-2|low dose interleukin-2 injected subcutaneously, at a dose of 1 x 10\~6 IU once twice a week, for 12 weeks.
224219788|NCT00535509|OTHER|Cisplatin-Docetaxel ± Trastuzumab|Chemo \& RT
224219789|NCT00535509|DRUG|Cisplatin-Docetaxel ± Trastuzumab|Chemo \& RT
224219790|NCT06150378|DRUG|Corticosteroid|Patients that receive an injection with corticosteroid
224219791|NCT06150378|BIOLOGICAL|Plathet rich plasma|Patients that receive an injection with Plathet-rich plasma
224219792|NCT03565211|DRUG|Progesterone vaginal ring|A flexible, non-degradable PVR containing progesterone in micronized formulation and dispersed evenly throughout the ring.
223631160|NCT02306330|OTHER|Routine clinical microbiology|Pathogens will be identified by the routine clinical microbiology of the hospital.
223631161|NCT02028806|DRUG|mFOLFIRINOX|Patients will receive mFOLFIRINOX every 2 weeks: Oxaliplatin 65 mg/m2 IV over 3 hours on Day 1; Irinotecan 150 mg/m2 IV over 90 minutes on Day 1; Leucovorin(l-LV) 200 mg/m2 IV over 2 hours on Day 1; followed by 5-Fluorouracil 2.4 g/m2 for 46 hours continuous infusion.
223631162|NCT00670423|DRUG|Tacrolimus|Tacrolimus as a continuous IV infusion will begin on day -3. (Levels will be monitored at least every 3 days to target 5-10 ng/mL)
223631163|NCT00670423|DRUG|Sirolimus|Sirolimus oral loading dose on day -3, followed by oral daily dose. (Levels will be monitored at least every 3 days to target 3-12 ng/mL)
223631164|NCT00670423|DRUG|Bortezomib|"Administered intravenously on day 0 (a minimum of 6 hours post-infusion of PBSC), and on day +3. The following dose levels will be used:~Cohort 1 (3-6 pts): 1 mg/m2 on days 0 and +3~Cohort 2 (3-6 pts): 1.3 mg/m2 on days 0 and +3~Cohort 3 (3-10 pts): 1.6 mg/m2 on days 0 and +3"
223764222|NCT05605665|DRUG|rapamycin|Rapamycin 0.5ml was taken orally once per day
223764223|NCT03904706|OTHER|Audits only|Formalized audit teams with monthly meetings at each facility.
224219793|NCT01859325|BIOLOGICAL|rVSV|Attenuated recombinant vesicular stomatitis virus containing HIV-1 gag gene
224219794|NCT01859325|BIOLOGICAL|IL-12 pDNA adjuvant|plasmid DNA containing human IL-12 gene
224219795|NCT01859325|BIOLOGICAL|HIV-Mag pDNA|plasmid DNA vaccine containing genes encoding multiple HIV-1 proteins
224219796|NCT01859325|DRUG|Placebo|
223631165|NCT06251557|OTHER|Lumbopelvic Massage|10 minutes abdominal massage and 10 minutes lower back massage will be applied in each session. It will take 20 minutes in total.
223631166|NCT06251557|OTHER|Exercise Training|Exercise training will last approximately 10 minutes in each session. In the exercise training, lumbopelvic stabilization exercises (bridge, cat-and-cow and squatting exercises) will be performed for 10 repetitions, lumbopelvic flexibility exercises (child position, happy baby position, adductor muscle stretching, psoas muscle stretching) will be performed for 20 seconds and 5 repetitions, and diaphragmatic breathing exercises will be performed for 5 repetitions in supine, side lying and sitting positions.
224219797|NCT03335020|DEVICE|Shear Wave Elastography|The subject will be asked to lay on a hospital bed for ultrasound imaging of the arteries. The subject will have an automatic blood pressure cuff put on to measure blood pressure. The subject will also have a three-lead ECG taken during the experiment. The artery will be visualized using ultrasound imaging, and the depth of the arterial wall will be noted. The focal depth on the device will be set to measure shear wave propagation in the walls of the artery. Measurements will be made at multiple locations along the artery's length and at different phases of the cardiac cycle determined by ECG gating. Either or both the Verasonics or GE Logiq systems will be used for measurements. Measurements made with these systems use acoustic output within the FDA regulatory limits of diagnostic imaging.
224219798|NCT03335020|DEVICE|Pulse Wave Imaging|Researchers will use the Verasonics device to acquire data for measurement of wave velocity in the tissue of interest (arterial walls and surrounding tissue) due to the pressure pulse from ejection of blood by the heart into the systemic circulation. Using ECG gating we can regulate the timing of the individual acquisitions. In each acquisition, high frame rate ultrasound imaging is used to acquire data to measure the motion of the propagating waves. Multiple measurements on different heartbeats are made with varying delays to obtain measurements throughout the heart cycle assuming at that the behavior during consecutive heartbeats is similar. Multiple measurements will be made in a given artery and multiple locations in the arterial wall.
224219799|NCT03335020|DRUG|Contrast-Enhanced Ultrasound|Will be done using Lumason (Bracco Diagnostics, Inc) administered intravenously via slow hand infusion. Real-time contrast-enhanced carotid cine-loop (longitudinal and short axis) images obtained at least 3 seconds before and 5 minutes after the appearance of the contrast effect in the lumen of the determined artery will be acquired and digitally stored for off line analysis. Up to two vials will be used for a study.
224219800|NCT03335020|OTHER|Strain Imaging|Measurements will be performed offline on the workstation using Echo PAC software (GE Healthcare Inc., Princeton, NJ). The media-adventitia interface of the arterial wall will be manually traced from a still frame image. The circumferential and radial strain curves will be automatically obtained. Measurements of the peak radial and circumferential strain, strain rate will be obtained. If arterial plaque is identified: A region of interest will be placed at the plaque in 3 different regions: 2 shoulder regions and the fibrous cap top, the measurement results of the peak longitudinal, radial and circumferential strain, strain rate will be acquired by the software.
224219801|NCT03335020|DEVICE|3-D Volume Ultrasound|When generating a 3D volume the ultrasound data can be collected in 4 common ways. Freehand, which involves tilting the probe and capturing a series of ultrasound images and recording the transducer orientation for each slice. Mechanically, where the internal linear probe tilt is handled by a motor inside the probe. Using an endoprobe, which generates the volume by inserting a probe and then removing the transducer in a controlled manner. The fourth technology is the matrix array transducer that uses beam steering to sample points throughout a pyramid shaped volume
224219802|NCT03811197|BEHAVIORAL|Dietary counseling via face to face meeting|All subjects received individual MNT and individual dietary recommendations based on DASH (Dietary Approaches to Stop Hypertension) diet plan for 6 months (Part A). Dietary counseling is provided by a trained dietitian. Months 9 and 12 - follow up (Part B).
224219803|NCT03811197|BEHAVIORAL|Telemedicine|All subjects received an additional dietary counseling for 6 months (via internet, messenger or telephone) two weeks after each standard visit will be added to the counseling (Part A). Standard and additional dietary counseling (T) are provided by a trained dietitian. Months 9 and 12 - follow up (Part B).
224219804|NCT03811197|BEHAVIORAL|Hypnotic Suggestions|"All subjects received individual hypnotic suggestion (HS) for 6 months as a supplementary method for dietary counseling. HS will be adapted to the small steps method used in the management of obesity. During the visit, HS will be recorded and the individual will listen to it every day (Part A). HS will be provided by a physician, qualified in the field of hypnotherapy. Months 9 and 12 - follow up (Part B)."
224219805|NCT03845179|OTHER|Placebo|Saline infusion
224219806|NCT03845179|OTHER|GIP receptor antagonist|Used for infusion on study days
224219807|NCT03845179|DRUG|DPP-4 inhibitor|Oral administration of DPP-4 inhibitor in active treatment period
224219808|NCT03845179|OTHER|Placebo tablet|Oral administration of placebo tablet in placebo treatment period
223631167|NCT06251557|DEVICE|Pelvic Floor Electromyography (EMG) Biofeedback Therapy|Biofeedback therapy will be applied for 20 minutes in each session. During the application, adhesive surface electrodes will be placed on the perineum at 4 o'clock and 8 o'clock for each child. Through these electrodes, the activity signals of the muscles in that area will be recorded superficially. By monitoring the regional muscle activity, feedback is provided to increase and/or decrease the activity according to the activity pattern. As a result, pelvic floor biofeedback therapy will teach the child the correct use of the pelvic floor muscles. During the session, pelvic floor awareness and relaxation exercises specific to the child will be practiced with visual animations.
223631168|NCT06251557|BEHAVIORAL|Standard Urotherapy|The anatomy of the urinary system and related structures, the causes of voiding dysfunction and symptoms will be explained to the family and the child with visuals. A written form including timed voiding during the day, appropriate fluid intake, correct toilet posture, adequate and balanced nutrition will be given.
223631169|NCT04215224|DIAGNOSTIC_TEST|Histopathology images based survival prediction for glioma patients|Histopathology images based survival prediction of glioma patients in the frame of molecular pathology by leveraging AI
223631170|NCT01271777|DRUG|GFT505 80mg|hard gelatin capsules dosed at 20mg, oral administration, 4 capsules per day before breakfast
223631171|NCT01271777|DRUG|Placebo|hard gelatin capsules, oral administration, 4 capsules per day before breakfast
223631172|NCT01576341|DRUG|HX575 epoetin alfa (Sandoz)|Eligible patients are scheduled to receive HX575 (INN: Epoetin alfa) as a solution for injection in order to achieve or maintain the correction of renal anemia.
223631173|NCT02121223|DEVICE|post-dilatation with a Quantum Maverick balloon|post-dilatation with a Quantum Maverick balloon at high pressure (\>=16atm) for at least 15 seconds.
223631174|NCT02121223|DEVICE|manual thrombus aspiration + Promus Element stent implant|manual thrombus aspiration followed by Promus Element stent implantation at normal pressure
223631175|NCT05196763|BEHAVIORAL|the Supplemental Nutrition Assistance Program-Education|The Supplemental Nutrition Assistance Program-Education is federal nutrition education provided in all U.S. states to the SNAP-eligible population.
223631176|NCT02211794|OTHER|data collection|
223631177|NCT02356822|OTHER|Patient registry|Oncology data registry
223764224|NCT03904706|OTHER|Audits with community feedback|This intervention will implement the audits as described in arm 1; however, key community representatives (approximately 3-5 members) will be identified to attend monthly follow-up meetings with audit team leaders to discuss the community aspects (phase one and two-delays) that could have prevented the death, near miss or severe adverse outcome. Information regarding the cause(s) of death in the community will be collected by the LHW or CMW, who reports to the health facility on a monthly basis.
224219809|NCT02981797|OTHER|Blood Collection During Standard of Care Treatment|Blood collection for baseline CTC numeration and H2AX assay. Circulating prostate cancer cell analysis requires blood draw of 7.5 ml (about 1 ½ teaspoons) of blood, to be performed at the screening, 1-2 hours before the third and sixth dose of radium 223 and 24 hours after the first, third, sixth dose of Radium 223. Standard of care Radium 223 treatment is given every 4 weeks for a total of 6 treatments and post Radium 223 follow up at week 24 is also considered standard of care. Other than these standard clinic visits and treatments, the study only requires 3 extra trips to the cancer center for blood draw at 24 hours after the first, third, sixth dose of Radium 223. Blood draws other than circulating tumor cell analysis is considered standard of care and doesn't require extra visits.
224219810|NCT01894984|DRUG|Risperidone|This is an observational study. Risperidone will be administered as intramuscular injection at a starting dose of either 25 milligram (mg) or 37.5 mg or 50 mg (starting dose will be decided on the basis of the disease severity), every two weeks, up to Week 24, wherein after Week 8, dose may be increased or decreased at physician discretion. For first three weeks, previous oral antipsychotic drug (Benzodiazepines or Selective serotonin reuptake inhibitor \[SSRI\]) will be maintained and will cease at Week 3.
224219811|NCT01894984|DRUG|Oral atypical anti-psychotic|This is an observational study. Oral atypical anti-psychotic for example, olanzapine, risperidone, quetiapine etc will be administered as per Investigator's discretion.
224219812|NCT01584336|PROCEDURE|LATG|"1. After laparoscopic observation, the surgeon must check the possibility of laparoscopic surgery (without the serosal invasion of cancer or peritoneal metastasis or lymph node metastasis to splenic hilum). If the gastric cancer with serosal invasion or grossly lymph node metastasis to splenic hilum, operator must convert the operation method to open gastrectomy~2. The operator undergoes the laparoscopic total gastrectomy with lymph node dissection(including the status of lymph nodes - No #1,2,3,4sa,4sb,4d,5,6,7,8a,9,11p and 11d, and/or 12a).~3. The operator can choose any reconstruction method of esophagojejunostomy according to surgeon's preference.~4. After then, the operator performs the jejunojejunostomy."
224219813|NCT01791283|PROCEDURE|Arterial waveform analysis, esofageal doppler, transthoracal cardiac ultrasound, Cardiac magnetic resonance imaging.|
224219814|NCT02499185|DEVICE|Nephro Check Test|Urine sample
224219815|NCT02499185|OTHER|serum creatinine measurement|Blood sample
224219816|NCT00406432|DRUG|Paroxetine Controlled Release Tablet|Eligible subjects will receive paroxetine controlled release tablet with dose of 25 milligrams.
224219817|NCT02264457|DEVICE|T-flex Aspheric Toric IOL|
224219818|NCT02264457|DEVICE|AT TORBI toric IOL|
223631178|NCT03264586|DRUG|Lidocaine-prilocaine cream|"5gm dose of cream applied to the intact surface of the perineum and area covered with an occlusive dressing to facilitate penetration~\- EMLA cream was applied, 1 hour before the expected time of birth."
223764225|NCT02696356|BIOLOGICAL|GRN-1201|GRN-1201 is a vaccine comprised of 4 peptides
223764226|NCT05411796|DEVICE|Tampax menstrual cup|regular flow size
223764227|NCT05411796|DEVICE|Other menstrual cup|size 1
223764228|NCT04568252|DEVICE|Wristband with millimeter wave emission.|Wristband treatment with millimeter wave emission twice a day for 3 months.
223631179|NCT03264586|DRUG|mepivacaine infiltration group|"10 ml of 1% mepivacaine solution was injected slowly when the fetal head was crowned with frequent aspiration to avoid intravascular injection.~* In the mepivacaine group, if an episiotomy was indicated, it was performed after infiltration of perineal tissue with 10 ml of 1% mepivacaine solution.~* The suture procedure was delayed 10 minutes after the injection of the aneathetic"
223631180|NCT03264586|PROCEDURE|mediolateral episiotomy|"Episiotomy repair a loose, continous, non locking suture to close the vaginal mucosa and the muscular layer of the perineum using vicryl Number zero (0).~* At the end of the vaginal mucosal repair care is taken to align the edges of the episiotomy wound~* At the point where perineal skin begins; the suture is then passed beneath the vaginal mucosa, and repair of perineal muscle begins. The deep layer of muscles is closed first, ensuring no dead space one left behind~* The skin was closed with the same continuous suture to approximate the subcutinuous tissue."
223631181|NCT04357535|DRUG|Angiotensin-Converting Enzyme Inhibitors (ACE-I) and Angiotensin II Receptor Blockers (ARB)|ACE-I and ARB are a class of blood pressure lowering medications used to manage hypertension.
223631182|NCT04567069|BIOLOGICAL|DC vaccine|"Blood samples will be collected twice, 60-120ml/ time. The 1st collection will occur 5 days before the 1st DC vaccine injection, the 2nd collection will occur 15 days after the 1st injection.~Six subcutaneous(ih) injections of DC vaccine will be given at days 1, 8, 15, 21, 28, 35; 1-3×106 cells/time.~Injection site: inguinal lymph nodes."
223631183|NCT04567069|BIOLOGICAL|CTL|Four intravenous (iv) drip injections of CTL will be given at days 7, 9, 27, 29; 1-2×109 cells/time.
223631184|NCT04567069|DRUG|Sintilimab Injection|The Sintilimab Injection (3mg/kg) will be administered by intravenous (iv) drip injection at days 0, 20。
223631185|NCT01280006|OTHER|Intermittent hypoxia|The subjects will receive five days of drug intervention: either non-selective cyclooxygenase (Indomethacin) or selective cyclooxygenase-2 inhibition (Celecoxib) or placebo. On the testing day, the subjects will undergo an acute intermittent hypoxia testing before and six hours of hypoxic chamber exposure mimicking obstructive sleep apnea syndrome.
223631186|NCT01280006|DRUG|Indomethacin|"The subjects will receive five days of drug intervention: either non-selective cyclooxygenase (Indomethacin) or selective cyclooxygenase-2 inhibition (Celecoxib) or placebo. Then they will be tested with an exposure of intermittent hypoxia.~Indomethacin: 50 mg, Oral, three times per day for five days."
223631187|NCT01280006|DRUG|Celecoxib|"The subjects will receive five days of drug intervention: either non-selective cyclooxygenase (Indomethacin) or selective cyclooxygenase-2 inhibition (Celecoxib) or placebo. Then they will be tested with an exposure of intermittent hypoxia.~Celecoxib: 200 mg, Oral, two times per day for five days with a visually matching sequential placebo in between of two doses."
223631188|NCT01280006|DRUG|Placebo|"The subjects will receive five days of drug intervention: either non-selective cyclooxygenase (Indomethacin) or selective cyclooxygenase-2 inhibition (Celecoxib) or placebo. Then they will be tested with an exposure of intermittent hypoxia.~Placebo: Oral, three times per day for five days."
223631189|NCT05460104|DEVICE|Experimental|Virtual reality sessions with a psychologist (30 minutes per session) once a week for 10 weeks. Work of the psychologist on a virtual environment created for the protocol in partnership with the company.
223631190|NCT05460104|OTHER|Control|Standard care is medical follow-up, no specific psychological care.
223631191|NCT01779765|DIETARY_SUPPLEMENT|PHGG|
223631192|NCT01779765|DIETARY_SUPPLEMENT|Maltodextrin|
223631193|NCT01242423|DEVICE|extracorporeal shockwave therapy|ESWT is administered as a one-off treatment on the wound surfaces within 24 hours of a 2nd degree burn trauma and immediately after an intraoperative skin graft excision procedure. A defocused sound head is orthogradely applied to the burn wound or the donor site. 100 impulses/cm² is administered at 20 seconds per cm². The defocused sound head is placed on the wound along with a sterile gel (Lavaseptgel®, Octenidingel®) and a sterile protection foil. The shockwaves deployed are not at an energy density that is painful. This single application of ESWT is followed by routine dressing using Mepitel® in combination with Polyhexanid/Octenidin®.
223631194|NCT03341299|BIOLOGICAL|LY900014|Administered SC
223631195|NCT03341299|BIOLOGICAL|Insulin Lispro|Administered SC
223631196|NCT00647517|DRUG|Ultracet|"For the treatment arm: Tramadol 37.5 mg/APAP 325 mg combination tablets (Ultracet®) one tablet twice a day plus aceclofenac tablet per oral 100 mg twice a day.~For the control group: Placebo plus aceclofenac tablet per oral 100 mg twice a day."
223631197|NCT03636555|DRUG|Oxytocin|Oxytocin will be given in an intranasal spray (Syntocinon Spray) twice daily (10 insufflations, 1.0 mL, 40 IU/dose) for 12 weeks
223631198|NCT03636555|DRUG|Placebo|Placebo solution (contained all the ingredients in Syntocinon Spray except for oxytocin) will be given as an intranasal spray twice daily (10 insufflations, 1.0 mL/dose) for 12 weeks
223631199|NCT01235897|DRUG|MK-2206|Different dose levels of MK-2206 will studied, and co-administered with paclitaxel and trastuzumab. MK-2206 will be given orally with a starting dose of 135 mg weekly
223631200|NCT01235897|DRUG|Paclitaxel|80 mg/m2 weekly - paclitaxel
223631201|NCT01235897|DRUG|Trastuzumab|2 mg/kg weekly after a 1-time loading dose of 4 mg/kg - trastuzumab
223631202|NCT03083925|DEVICE|TIPS|Transjugular Intrahepatic Portosystemic Shunt
223631203|NCT02257398|DRUG|GSK2140944|GSK2140944 is available in dose strength 1000 mg and 1800 mg for single IV dose over 2 hours administration as a pale yellow to greyish yellow cake for reconstitution
223631204|NCT02257398|DRUG|GSK2140944 placebo|GSK2140944 placebo is 0.9% sodium chloride available for single IV dose over 2 hours administration.
223631205|NCT02257398|DRUG|Moxifloxacin|Moxifloxacin is available as pinkish red tablet with dose strength 400 mg for single oral dose to be administered in the morning in the fasted state with approximately 240 mL of water.
223631206|NCT02257398|DRUG|Moxifloxacin placebo|Moxifloxacin placebo is available as white, film-coated tablet. containing nonactive material for single oral dose to be administered in the morning in the fasted state with approximately 240 mL of water.
223631207|NCT00791934|DEVICE|Stratus Microflow Ethmoid Spacer|The Spacer is inserted surgically into the ethmoid complex through the use of a sinus access system. Triamcinolone acetonide will be administered into the Spacer for this investigational study. The Spacer will be left in the ethmoid sinus for a period of 28 days. At the end of the implant period, the device is removed with standard instrumentation, during a follow-up office visit.
223631208|NCT04771494|OTHER|Power and execution speed as a function of instability experience|"Each subject performed 3 repetitions for the light load (40% RM; VMP \> 1.0 m/s), with 1 minute rest; 2 repetitions for the medium load (60% RM; 0.65 m/s ≤ VMP ≤ 1.0 m/s) with 2 minutes rest and 1 repetition for the heavy load (80% RM; VMP \< 0.65 m/s) with 4 minutes rest. A metronome was used for the start countdown and to time the eccentric and concentric portions of the exercise.~Subjects began the bench press with their elbows fully extended, maintaining a grip distance slightly greater than shoulder width. The bar was then lowered to their chest and then applying as much thrust as possible until full elbow extension on a 2-1-0 count. The timing sequence involved 2 seconds for the eccentric phase, a 1 second hold (to minimise the contribution of the rebound effect and allow for more reproducible and consistent measurements) and for the concentric up phase the highest possible execution speed, until the bar returned to the starting position."
223631209|NCT00829738|DRUG|Pantoprazole|This was an observational study. Therefore, the physician decided about dosage according to individual needs (20 or 40 mg pantoprazole).
223631210|NCT06121102|PROCEDURE|Supervoltage pulsed radiofrequency glossopharyngeal nerve block|Stimulation will be done using baylis generator both sensory at 50 HZ and 0.5-1.0 V (patient felt tingling at base of tongue, throat, ear and side of upper neck) and motor at 2 HZ and 1-2 V (contraction of stylopharyngeus muscle will be felt). After injecting 1 ml lidocaine 2% plus 1 ml (4 mg) Betamethasone (Diprofos) to augment analgesia and to lower impedance (usually it was 200-300 ohm due to bony proximity).Super voltage pulsed RF(60-75 volt according to patient tolerability will be done for 8 minutes with pulse width = 5 millisecond and pulse frequency of 2 HZ.
223764229|NCT04568252|DEVICE|Placebo of wristband with millimeter wave emission.|Treatment with a millimeter wave emission wristband placebo twice a day for 3 months.
223764230|NCT04212468|OTHER|no intervention|no intervention
224219819|NCT00033631|RADIATION|70.2 Gy 3D-CRT/IMRT|Radiation will be delivered via 3D conformal radiation therapy (3D-CRT) or intensity modulated radiation therapy (IMRT) in 1.8 Gy minimum dose fractions to a total of 70.2 Gy in 39 Fractions. All fields treated once daily, five fractions per week. No more than 2% of the planning target volume and none of the clinical target volume may receive less than 70.2 Gy.
224219820|NCT00033631|RADIATION|79.2 Gy 3D-CRT/IMRT|Radiation will be delivered via 3D conformal radiation therapy (3D-CRT) or intensity modulated radiation therapy (IMRT) in 1.8 Gy minimum dose fractions to a total of 79.2 Gy in 44 fractions. All fields treated once daily, five fractions per week. No more than 2% of the planning target volume and none of the clinical target volume may receive less than 79.2 Gy.
223631211|NCT06121102|PROCEDURE|Standard voltage pulsed radiofrequency glossopharyngeal nerve block|Stimulation will be done using baylis generator both sensory at 50 HZ and 0.5-1.0 V (patient felt tingling at base of tongue, throat, ear and side of upper neck) and motor at 2 HZ and 1-2 V (contraction of stylopharyngeus muscle will be felt). After injecting 1 ml lidocaine 2% plus 1 ml (4 mg) Betamethasone (Diprofos) to augment analgesia and to lower impedance (usually it was 200-300 ohm due to bony proximity).Super voltage8 pulsed RF will be done for 8 minutes with pulse width = 5 millisecond and pulse frequency of 2 HZ.
223631212|NCT03545555|DIETARY_SUPPLEMENT|"Kale Preparation Kale Powder"|Effect of kale preparation kale powder on lipid status
223631213|NCT03545555|DIETARY_SUPPLEMENT|"Kale Preparation Kale Extract"|Effect of kale preparation kale extract on lipid status
223631214|NCT03545555|DIETARY_SUPPLEMENT|"Kale Preparation Flavonoid Extract"|Effect of kale preparation flavonoid extract on lipid status
223631215|NCT03545555|DIETARY_SUPPLEMENT|Placebo|Effect of placebo on lipid status
223631216|NCT05023733|DEVICE|CONDUIT™ Interbody Platform composed of the EIT (Emerging Implant Technologies) Cellular Titanium®|Patients undergoing 1-2 contiguous levels of interbody fixation from a transforaminal approach for spinal segments L2-S1
224219821|NCT04438629|DRUG|COVID-19 treatment|COVID-19 affected patients treated with hydroxicloroquine or antiviral therapy (lopinavir/ritonavir) as single agents or in combination (hydroxicloroquine plus antiviral therapy) according to clinical features. Other concomitant treatments (i.e. off-label therapy) will be provided at the discretion of clinicians. Supportive therapy, such as antibiotic prophylaxis and anticoagulant treatment, will be provided at the discretion of the clinicians.
224219822|NCT04293640|DIAGNOSTIC_TEST|Parasternal electromyogram measurement|Three electrodes are applied to the chest (two to parasternal muscles, one reference electrode to clavicle). Measurements of EMG signals are recorded on appropriate software.
224219823|NCT00109135|DRUG|taranabant|
224219824|NCT04537819|DRUG|Imupret in addition to local NAID|Additional prescription of Imupret oral drops to conventional therapy with local NAID (Benzydamine hydrochloridy), elimination of irritating factors in the diet and acetaminophen (if necessary)
224219825|NCT04537819|DRUG|Local NAID (Benzydamin)|(Benzydamine hydrochloridy) and acetaminophen (if necessary), elimination of irritating factors in the diet
224219826|NCT00956683|PROCEDURE|Ultrasound Guided Infraclavicular Nerve Block|Use of Ultrasound to help guide needle placement and local anesthetic injection during infraclavicular nerve block.
224219827|NCT00956683|PROCEDURE|Dual-Endpoint nerve stimulation|Use of dual-endpoint nerve stimulation to guide needle placement and local anesthetic injection during infraclavicular nerve block.
224219828|NCT00139490|BEHAVIORAL|Health Education Program|The augmented intervention will consist of just-in-time nurse, patient and physician information and feedback during the post-acute period, plus transition to an ongoing Home-Based HTN Support Program within approximately 30 days after the patient's admission to home health care. The augmented intervention adds an HTN Nurse Specialist (advanced practice nurse) and a lay community health worker, who will be responsible for assuring a patient's smooth transition to the Home-Based HTN Support Program and for delivering the main components of that intervention, backed up by the project physician.
224317911|NCT06359288|OTHER|Group receiving QR code supported training|During the training process, QR codes were integrated into the sections related to the care of the newborn in the guide to provide mothers with the opportunity to watch the video simultaneously while reading the guide in practices requiring skills related to hygienic care of the newborn and nutrition / communication / sleep, and to allow them to watch it repeatedly as long as they feel the need. In these videos, the application steps were shown one by one. When the code is scanned with a smartphone, it automatically redirects the user to the specified URL. The QR codes in the Implementation Guide on the Care of the Newborn consist of eight videos) that allow mothers to watch the hygienic care of the newborn in practice. After the end of this phase of the training, the questionnaires were re-administered to the mothers in both groups one month after discharge.
224219829|NCT00139490|BEHAVIORAL|Basic Group|"The basic information and referral intervention will deliver key just-in-time information to nurses, patients and patients' physicians while the patient is receiving post-acute home care services. The basic intervention relies on care provided by home health nurses during the routine home health stay."
224317912|NCT06625632|DRUG|Antiemetic Drug|All participants in the two groups will receive antiemetic drugs (ondansetron 4 mg) every 12 hours, for 5 days.
224317913|NCT06625632|DIETARY_SUPPLEMENT|Vitamin B6|All participants in the two groups will receive vitamin B6 (50 mg), once daily, for 5 days.
224317914|NCT06625632|OTHER|Home care advice|All participants in both groups will be advised to eat small portions of food, drink plenty of liquids, and avoid fatty and fried foods. Additionally, they should steer clear of highly spiced foods, foods and beverages with strong odors, caffeine, and consume neither very hot nor very cold foods and liquids.
223631217|NCT05685628|OTHER|Cinnamon dressing|"Use of CINESTEAM® as a non-occlusive secondary dressing~CE marked medical device class I, secondary, absorbent, non-adhesive and composed of:~* Anti-odor upper part, adsorbent containing cinnamon powder.~* Weakly absorbent lower part intended to absorb excess exudates."
223631218|NCT05685628|OTHER|Charcoal dressing|Use of a secondary non-occlusive activated charcoal dressing (brand of your choice)
223631219|NCT02977663|OTHER|Magnetic Resonance Imaging (MRI)|"* Chest MRI during the MRI cerebral~* 2 tubes of blood taken during the medical visit"
223631220|NCT02599571|OTHER|Very low nicotine content cigarettes|Cigarettes containing a reduced amount of nicotine
223631221|NCT02599571|OTHER|Conventional nicotine content cigarettes|Cigarettes containing a normal amount of nicotine
223631222|NCT02018562|DEVICE|Portex Blueline Ultra Suctionaid Tracheostomy Tube|
223631223|NCT06679686|OTHER|Role Playing|The group will analyse the instant cases given by the researchers using the role-play method.
224219830|NCT00139490|BEHAVIORAL|Control Group|Usual Care
223631224|NCT06679686|OTHER|Digital Storytelling|The group will analyse the ethical analysis of the cases containing ethical problems written by themselves by using digital storytelling
223631225|NCT04467736|DEVICE|Gengigel Forte©|Gengigel (hyaluronic acid) will be administered by the patient 3 times per day during 7 days following alveolar ridge preservation
223631226|NCT00001711|PROCEDURE|MRI|scan of healthy volunteers.
223631227|NCT05194124|DRUG|Setmelanotide 2 mg|Administered as SC injection
223631228|NCT05194124|DRUG|Setmelanotide 2.5 mg|Administered as SC injection
223631229|NCT05194124|DRUG|Setmelanotide 3 mg|Administered as SC injection
223631230|NCT05194124|DRUG|Setmelanotide 20 mg|Administered as SC injection
223631231|NCT05194124|DRUG|Setmelanotide 25 mg|Administered as SC injection
223631232|NCT05194124|DRUG|Setmelanotide 30 mg|Administered as SC injection
224317915|NCT06625632|OTHER|Kinesiotaping|It will be applied for all participants in the experimental group only for 5 days. The participant will be asked to stand in erect position, her hands beside her body then applying the kinesiotape from origin (from top to bottom where the stomach is placed on the abdominal region) to insertion (alongside the gastric curvature) with tension 25% for 5 days.
223631233|NCT06676735|DEVICE|Inflatable warming system|Inflatable warming system, including a forced air warming system (IOB, WU505) and forced air warming blanket (IOB-001, IOB-006, IOB-011), is employed for prewarming before anesthesia initiation and for maintaining body temperature throughout the operation. During the surgery, the insulation blanket will be applied to non surgical areas, and the host temperature will be adjusted to 38 ℃ for warming. If the temperature of the patient is lower than 36 ℃, the temperature of the system can be adjusted to 43 ℃; if the temperature of the patient is higher than 37 ℃, the temperature of the system can be adjusted to 32 ℃. After the patient\&#39;s temperature is normal, it can be adjusted back to 38 ℃.
223631234|NCT06676735|DIAGNOSTIC_TEST|Prediction of intraoperative hypothermia risk|According to the Intelligent Care For The Elderly (ICE, an optimized model based on the existing prediction model of our research group after dynamic incremental training), patients are divided into intraoperative hypothermia lowrisk group and intraoperative hypothermia high risk group.
223631235|NCT06676735|OTHER|The difference between axillary temperatature and core temperature in elderly patients|Previous studies have shown that the difference and standard deviation between esophageal temperature and axillary temperature are core 0.05 ℃ and 0.26 ℃, respectively. In light of 10% dropout rate, a integer sample size of 400 achieves 95% power to detect a mean of paired differences of 0.05 with an estimated standard deviation of paired differences of 0.26 and with a significance level (alpha) of 0.05 using a two-sided paired t-test. So 400 patients in the Model optimization group need to undergo core temperature (esophageal temperature or nasopharyngeal temperature).
223631236|NCT06676735|OTHER|Measurement of tympanic membrane temperature|As a intraoperative core temperature reference (measure every 15 minutes) for patients without esophageal temperature or nasopharyngeal temperature monitoring.
223631237|NCT03642873|DRUG|Humibid®|Humibid® 1200 mg (single extended release) tablet
224219831|NCT01779908|DIETARY_SUPPLEMENT|Vitamin D|
224317916|NCT02686138|DRUG|Tenapanor|
223631238|NCT03642873|DRUG|Hydrocodone Bitartrate|Hydrocodone Bitartrate (3.33 mg q4h X 3)
223631239|NCT03642873|DRUG|Humibid® and Hydrocodone Bitartrate tablet|Humibid® 1200 mg (single extended release) tablet and Hydrocodone bitartrate (3.33 mg q4h X 3)
223631240|NCT05690269|DEVICE|SpO2 and SaO2 comparison|Several pulse oximeter will be place on patients fingers a few minutes before arterial blood gases. SpO2 will be recorded during that time and up to 10 minutes.
224219832|NCT01779908|OTHER|Placebo|
224219833|NCT05956171|OTHER|Intra-articular corticosteroid injection|5 ml blind intra-articular corticosteroid injection
224219834|NCT05956171|OTHER|Ultrasound Guided Hydrodilatation with corticosteroid injection|15 ml intra-articular injection to shoulder via anterior approach under ultrasound guidance
224219835|NCT02605083|DRUG|eFT508|Will be given orally once or twice daily. Each treatment cycle = 21 days.
224219836|NCT05612737|PROCEDURE|Horizontal bone augmentation|"After taking six 9 mL tubes of blood from the patient, advanced (A-PRF) and liquid (S-PRF) PRFs were prepared. A-PRF was chopped, added to the xenogeneic bone substitute (THE Graft; Purgo Biologics Inc.), and then impregnated with the liquid S-PRF, which enabled the particulate bone substitute to become moldable and turned into a block (sticky bone). After local anesthesia, a midcrestal incision was made with one vertical releasing incision at the flap's mesial end. After full-thickness flap elevation, a periosteal releasing incision was made at the flap's apical portion. The alveolar bone was decorticalized on the buccal aspect with surgical burs. Next, the prepared bonded graft matrix was adapted to the ridge. Then, tenting screws (Pro-fix; Osteogenics) were placed to maintain the periosteum in an elevated and tension-free position The bone augmentation material was covered with A-PRF membranes. Finally, tension-free wound closure was performed."
224219837|NCT02455583|BEHAVIORAL|Project AIM (Adult Identity Mentoring)|Project AIM consists of 14 sessions that are delivered twice a week. Each session is 40 minutes long.
224317917|NCT02686138|DRUG|Placebo|
224317918|NCT04635293|PROCEDURE|preoperative infusion of levosimendan|the study group will consist of patients who have received a continuous infusion of levosimendan 0.1 μg/kg/min for 24 hours before cardiac surgery
224317919|NCT04635293|PROCEDURE|no preoperative infusion of levosimendan|the control group will consist of patients who proceeded to the cardiac operation without any infusion for 24 hours preoperatively
224317920|NCT04988087|DRUG|MHV370|MHV370 for 24 weeks
224317921|NCT04988087|DRUG|Placebo|Placebo for 24 weeks
223631241|NCT00010036|DRUG|carboplatin|
223631242|NCT00010036|DRUG|irinotecan hydrochloride|
223631243|NCT00010036|RADIATION|radiation therapy|
223631244|NCT04531085|PROCEDURE|Operative treatment|Surgery
223631245|NCT04531085|PROCEDURE|Long arm cast|cast immobilization
223631246|NCT04760782|DRUG|Abaloparatide|Abaloparatide 80 mcg by subcutaneous, self-administered injection once per day (8 weeks)
223631247|NCT04760782|DEVICE|Hard collar immobilization|Hard collar immobilization of the cervical spine for 12 weeks
223764231|NCT03929835|DRUG|Cannabis oil|T1/C20 CBD
223764232|NCT03929835|DRUG|Placebo|Olive oil with chlorophyl
223631248|NCT05757128|BEHAVIORAL|Optimal Health Program|The OHP intervention will comprise a psychosocial management program that will be adapted to the CHR population and will be accompanied by a structured workbook. Sessions are approximately 1 hour in duration and held weekly for 6 weeks, and every two weeks for the remaining 6 weeks. The OHP has three components: 1) assessment and engagement; 2) therapy sessions, and 3) maintenance integration.
223631249|NCT06444568|OTHER|Dietary Intervention|The intervention includes the application and follow-up of different diet therapies to individuals (Ketogenic diet and MIND).
223631250|NCT01407510|DRUG|Mapracorat|Application of the investigational product on the affected skin areas
223631251|NCT01739166|OTHER|Practice-tailored intervention to increase rates of targeted services|"Over a 6 month period, the Practice Facilitator (PF), offers individualized suggestions, strategies and tools for streamlining processes and incorporating new ideas into the flow of a practice's work day to increase their rates of delivery of the 3 targeted services of lead screening, obesity detection and dental decay prevention.~During the intervention visits the PF reviews a small number of recent well-visit charts. This allows for rapid feedback to a practice on their progress as they work toward reaching outcome measures. It also provides 'real time' feedback regarding the degree to which suggested interventions are working, allowing the PF to change the approach as needed."
223631252|NCT03538418|OTHER|WAT|The WAT intervention consists of 12 weekly WAT-based exercise sessions and 7 sessions of support for BCTs and technical issues.
223631253|NCT03525379|DRUG|Resveratrol|"Subject participation will be approximately 10 weeks in duration. Participants will be randomized to receive one treatment: either resveratrol for 8 weeks OR placebo for 8 weeks. There will be a 2-week run-in period prior to the treatment period.~The schedule for the study is:~Week 0 Screening and randomization Weeks 1-2 Run-in; no treatment Weeks 3-10 Treatment Phase (resveratrol or placebo)"
223631254|NCT03525379|DRUG|Placebo|Participants will be randomized to receive one treatment: either resveratrol for 8 weeks OR placebo for 8 weeks. There will be a 2-week run-in period prior to the treatment period.
223631255|NCT05933746|BEHAVIORAL|Sleep Hygiene Intervention|This 1-hour on-line intervention presents three sleep hygiene modules, selected randomly from among these six: establishing a bedtime routine, optimizing sleep environment, implementing a sleep schedule, bedtime relaxation, nutrition choices, and exercise habits.
223631256|NCT05933746|BEHAVIORAL|Non-behavioral Sleep Education|1-hour on-line set of three modules that cover non-skill (non-hygiene) educational topics (sleep research, sleep stages, dreams). This control condition equates for engagement rationale.
223631257|NCT03321357|DIAGNOSTIC_TEST|five-repetition sit-to-stand test|"An armless chair with a hard seat was stabilised by placing it against a wall. Seated participants were asked to come forward on the chair seat until the feet were flat on the floor and to fold their upper limbs across the chest. Participants were then instructed to stand up all the way and sit down once without using the upper limbs. For those unable to complete the initial manoeuvre or who required assistance, the test was terminated. If successful on the initial sit to stand, participants were then asked to stand up all the way and sit down landing firmly, as fast as possible, five times without using the arms. Timing with a stopwatch was started on the command 'go' and stopped at the end of the completed fifth stand; the time taken was recorded as the participant's score.~(1) Jones et al."
224219838|NCT02122211|DRUG|Betaine supplement|
224219839|NCT01052805|PROCEDURE|harvest nerve|harvest nerve from cadaveric donor and patients receiving nerve graft operation
224219840|NCT03124797|DEVICE|RD DCI Sensor|Noninvasive pulse oximeter sensor
224317922|NCT00827437|OTHER|Parent Interview|To include the PI, Nursing Research Specialist,Clinical Research Associate or Clinical Nurse Specialist
223631258|NCT04467749|OTHER|Suspension Wheel|Participants will be given a pair of Spinergy or Loopwheels to use during the 12-week intervention period. The Spinergy wheels consist of a lightweight carbon fiber material with natural shock absorbing properties. Loopwheels offer a rigid rim, a mid-wheel shock absorbing hub and three in-wheel loops that work as a self-correcting system when encountering uneven ground.
223631259|NCT00002649|BIOLOGICAL|aldesleukin|Given IV
223631260|NCT00002649|BIOLOGICAL|filgrastim|Given SC or IV
223631261|NCT00002649|DRUG|cyclophosphamide|Given IV
223631262|NCT00002649|DRUG|etoposide|Given IV
223631263|NCT00002649|RADIATION|radiation therapy|Undergo radiation therapy
224219841|NCT01827371|BIOLOGICAL|MVA Smallpox Vaccine|Subjects receive two dose regimen of IMVAMUNE® (1x10\^8 TCID50/0.5 mL per dose) via the SC route using either a syringe and needle or the Stratis™ system. Arm A receives doses via syringe and needle on days 1 and 29; Arm B receives doses via syringe and needle on days 1 and 15, Arm C receives doses via syringe and needle on days 1 and 22, Arm D receives doses via Stratis on days 1 and 29.
224219842|NCT03575182|OTHER|Gait retraining program|Supervised gait retraining with verbal and real-time visual feedback.
224317923|NCT00087282|DRUG|alvocidib|
223631264|NCT00002649|PROCEDURE|peripheral blood stem cell transplantation|Undergo autologous peripheral blood stem cell transplant
224219843|NCT01081483|DRUG|ABT-072|See arm description for more information
224219844|NCT01081483|DRUG|Placebo|See arm description for more information
224219845|NCT00618631|DRUG|Nicotine|
224219846|NCT00618631|DRUG|Carfentanil|
224219847|NCT02887482|BIOLOGICAL|GLS-5700|GLS 5700 at 2 mg DNA/dose
224219848|NCT02887482|BIOLOGICAL|Placebo|
224219849|NCT03320473|DEVICE|IC-8 IOL|The AcuFocus IC-8 intraocular lens (IC-8 IOL) is a one-piece hydrophobic acrylic posterior chamber IOL into which a circular mask with a small 1.36 mm central aperture has been embedded. The IOL mask works by extending the depth of focus and its design is based on the KAMRA corneal inlay, which operates under the principle of small aperture optics.
224219850|NCT03773094|DRUG|Guava leaves extract|"Natural product : The leaves of the guava tree are full of antioxidants, anti-inflammatory agents, antibacterials, and even tannins that can have significant health benefits, from treating stomach troubles to chronic diseases like cancer~•"
224317924|NCT00087282|DRUG|irinotecan hydrochloride|
224317925|NCT00925366|OTHER|Imaging Procedure|CT Arthroscopy of the Shoulder - MR Arthroscopy of the Shoulder - MR of the shoulder
224317926|NCT04939194|BEHAVIORAL|Fast Track Protocol|We will apply 22 items of ERAS society
224317927|NCT06634238|OTHER|Incremental shuttle walk test|Participants were recommended to wear comfortable clothing and appropriate shoes for the test. To minimize variability, one masked and one unmasked ISWT was performed on the same participant at the same time of day, one day apart
224317928|NCT06423807|DRUG|Ondansetron lozenge|Patients will receive ondansetron lozenge 4 mg (Ondalenz ©), 2 hours before surgery.
223631265|NCT00002649|PROCEDURE|bone marrow ablation with stem cell support|Undergo bone marrow ablation with stem cell support
223631266|NCT03433651|DRUG|Creatine monohydrate|Subjects will take by mouth 5 grams a day of creatine monohydrate powder.
223631267|NCT03433651|DRUG|Placebo|Subjects will take by mouth 5 grams a day of placebo powder.
223631268|NCT04570930|BEHAVIORAL|Just-in-time adaptive intervention (JITAI)|JITAI is an emerging intervention that incorporates passive mobile sensor data feedback (sleep and activity \[step\] data from a Fitbit ®), and real-time self-reporting of HRQOL via a study specific app called CareQOL to provide personalized feedback via app alert.
223631269|NCT04570930|BEHAVIORAL|Control|Participants will wear the Fitbit® and provide daily reports of HRQOL over a six-month (180 day) period.
223631270|NCT02515747|PROCEDURE|percutaneous coronary intervention|elective percutaneous coronary balloon angioplasty and/or stenting
223631271|NCT02515747|PROCEDURE|coronary artery bypass grafting|elective surgical myocardial revascularisation
223631272|NCT01662167|DRUG|Single|In the single dose regimen, 50 mg/m2 intramuscular methotrexate was given on day one and hCG level was measured on days four and seven. If the hCG level did not decrease by 15% between day four and seven, a second dose of methotrexate was injected on day seven, hCG level was measured weekly until a level of 15 mlU/ml or less was achieved
223631273|NCT01662167|DRUG|Multipe|In the multiple dose regimen, 1 mg/kg/day intramuscular methotrexate was given on days one, three, five and seven and 0.1 mg/kg/day intramuscular Citrovoram factor was administered on days two, four, six and eight until serum hCG level decreased 15% in 48 hours or four doses of methotrexate was given weekly until serum hCG level of 15 mlU/ml or less was obtained
224219851|NCT03773094|DRUG|Chlorhexidine|chemical agent used as a mouthwash against cariogenic bacteria. considered the gold standard
224219852|NCT04433845|DRUG|Psilocybin|Open-label
224219853|NCT01864473|OTHER|Kshar Sutra|The Kshar Sutra is a standard medicated thread smeared with Kshar of Apamarga (Achyranthus Aspera), Shnuhi (Euforbia Nerrifolia) which has quality of cutting and Haridra (Curcuma longa) which is used as a antiseptic. This combination of medicine on the thread helps in debridement and simultaneously healing of track. After conformation of vaginal fistula the track was cleaned with betadine and Hydrogen peroxide. The Kshar Sutra was tied covering the entire underlying track for simultaneous cutting and healing under all aseptic precaution. The patient was discharged on the next day of procedure. Patient was advice for Sitz bath with lukewarm water. The Kshar Sutra was changed weekly.
224219854|NCT00248820|PROCEDURE|Contrast-enhanced ultrasound|Contrast enhanced ultrasound using Sonovue / 2.4 ml per injection - one or two injections (maximum of 9.6 ml).
224317929|NCT05382585|OTHER|Next generation Sequencing|Next generation sequencing for 161 genes
224317930|NCT02600533|PROCEDURE|Video viewing group|First, participants will complete a brief electronic survey measuring their opinions on clinical trials. Next, participants in the video viewing group will watch the 10-minute DVD video on tablet devices using headphones in the clinic. Participants in this groups will be informed that a team member will call him/her in approximately 1 week to ask him/her the (same) questions about clinical research.
224219855|NCT00240864|DRUG|placebo|
224219856|NCT00240864|DRUG|acetaminophen|
224219857|NCT00240864|DRUG|ibuprofen|
224317931|NCT00564330|DRUG|Esomeprazole|20mg bid
224317932|NCT00564330|DRUG|Placebo|Placebo bid
223514391|NCT06199882|DRUG|SBRT Sequential Surufatinib Combined With Immunotherapy|"1. SBRT :~   Bioequivalent total dose \> 75Gy, completed within 2 weeks (once daily, 5 times a week).~2. Drug treatment (every 3 weeks is a treatment cycle) :~1\) Surufatinib: 200 mg, po, qd, taken continuously; 2) Carrelizumab: 200 mg/ time, intravenous drip on the first day of each cycle."
223514392|NCT06551961|DIETARY_SUPPLEMENT|methylcellulose|2.5 and 5 gm Methylcelllose heated to create a gel
223514393|NCT06551961|DIETARY_SUPPLEMENT|inulin|2.5 and 5 gm inulin powder dissolved in water
223514394|NCT06551961|DIETARY_SUPPLEMENT|maltodextrin|2.5 and 5gm maltodextrin dissolved in water
223514395|NCT06059248|OTHER|"the head in the sniffing position "|"Intubation was performed with the head in the  elevation  position"
223514396|NCT04635280|DEVICE|any closed-loop automatic insulin delivery system (or artificial pancreas) European Conformity (CE)-marking|A closed-loop automatic insulin delivery system includes a combination of an insulin pump, a continuous glucose monitoring system and an algorithm.
223514397|NCT06640608|BEHAVIORAL|ICBT - Internet Based Cognitive Behavioral Therapy|The study (intervention) group received 6 consecutive sessions utilizing ICBT techniques to overcome Fear of childbirth
223514398|NCT06641505|BEHAVIORAL|Guiding rehydration|Preoperative fluid rehydration was performed according to 421 fluid rehydration principles
223631274|NCT04973124|DRUG|Dexmedetomidine|These participants will receive intraoperative dexmedetomidine.
224219858|NCT03474289|DRUG|SHR-1316|Monotherapy
224219859|NCT04399902|DEVICE|Thermal Blanket|Ready-Heat 6-Panel Blanket (Military style, manufactured by Techtrade LLC). The 6-panel military-style blanket (86cm x 152 cm, 1.13kg) warms to 40˚C in approximately 15-20 minutes and maintains this temperature for 10 hours.
224219860|NCT03108391|DEVICE|Ambu AuraGain|
224219861|NCT03108391|DEVICE|LMA Supreme|
224219862|NCT02100566|BEHAVIORAL|Counseling (Care giver burden focus)|An advance directive (AD) document is provided to the patient along with counseling that focuses on care giver burden as the reason for adoption of the AD.
224219863|NCT02100566|BEHAVIORAL|Counseling (patient autonomy focus)|An advance directive (AD) document is provided to the patient along with counseling that focuses on patient autonomy (control) as the reason for adoption of the AD.
224317933|NCT00655343|DRUG|ATG-Fresenius S|"20 mg rabbit immunoglobulin (IgG) in 1 ml of sterile solution~20 mg/kg body weight per day diluted in 500 ml physiological saline, slow intravenous infusion at days -3, -2, -1 prior to transplantation"
224317934|NCT02495623|DRUG|SYN-010 21 mg|
224317935|NCT02495623|DRUG|SYN-010 42 mg|
224317936|NCT02495623|DRUG|Placebo|
224317937|NCT02800642|DRUG|Aflibercept (Eylea, BAY86-5321)|The recommended dose for intravitreal aflibercept was 2 mg equivalent to 50 μL. Study treatment was administered at baseline and at monthly intervals until stabilization of disease. When stability was achieved, the treatment interval could be extended based on visual and anatomic outcomes as judged by the treating investigator.
223631275|NCT04973124|DRUG|Placebo|These participants will not receive intraoperative dexmedetomidine.
223631276|NCT06295185|OTHER|application MARO|It is a mental healthcare application aim to improve mental health.
223631277|NCT06295185|OTHER|Sham application|It is a sham application in order to control spill over bias.
223631278|NCT05460754|BEHAVIORAL|Conventional-fed beef|Participants in the conventional-fed treatment of the study will consume a conventional-fed steak meal for breakfast one morning.
223631279|NCT05460754|BEHAVIORAL|Organic grass-fed beef|Participants in the organic grass-fed treatment of the study will consume a organic grass-fed steak meal for breakfast one morning.
223631280|NCT03589859|DIAGNOSTIC_TEST|VOR Test|Video-oculography is used to record the vestibulo-ocular reflex during active and passive turns of the head.
223631281|NCT03589859|OTHER|Computer Game|Participants play a custom computer game that is designed to produce motor learning in the vestibulo-ocular reflex
223631282|NCT03589859|OTHER|Nausea Scale|Participants asked to rate their subjective nausea on a numeric scale after playing units of the computer game
223631283|NCT05538741|DRUG|Bolus of remimazolam|0.19-0.25 mg/kg for 60-80 years old 0.14-0.19 mg/kg for \>80 years old
223631284|NCT05538741|DRUG|Continuous infusion of remimazolam|12 mg/kg/hr until loss of consciousness
223631285|NCT06466746|OTHER|Raising the Pulse faba bean-enriched bread|100 g of white bread produced using 40% faba bean enriched flour and 60% wheat flour will be provided in the breakfast meal with stork margarine, chocolate spread, a glass of orange juice and a glass of water containing the iron-57 stable isotope. An ad-libitum lunch consisting of pasta and a tomato sauce will be provide 6 hours after the breakfast.
223631286|NCT06466746|OTHER|Conventional White Bread|100 g of white bread produced using 100% wheat flour will be provided in the breakfast meal with stork margarine, chocolate spread, a glass of orange juice and a glass of water containing the iron-57 stable isotope. An ad-libitum lunch consisting of pasta and a tomato sauce will be provide 6 hours after the breakfast.
223631287|NCT04161950|OTHER|Assessment of the safety and validity of echoendoscope|"1. Ultrasonic and endoscopic image quality assessment~2. Device controllability assessment~3. System safety assessment~4. System stability assessment"
223631288|NCT01568177|BEHAVIORAL|Mental Stress Testing|Mental stress testing is used to test the mechanistic pathways through which biobehavioral variables are involved in the pathogenesis of MCD in women.
223631289|NCT01568177|OTHER|Peripheral Arterial Tonometry (PAT) Testing|PAT measurements will be used to predict ischemia in patients with MCD. PAT will be measured by Endo PAT 2000 (Itamar® Medical Ltd).
223631290|NCT01568177|OTHER|Heart Rate Variability (HRV)|Holter monitor will be used to measure heart rate and rhythm for approximately 24 hours.
223631291|NCT01568177|OTHER|RESPeRATE Breathing Trial|RESPeRATE Breathing will test whether a controlled breathing relaxation technique using an FDA-approved paced breathing device, RESPeRATE, helps with chest pain and shortness of breath and will test to see if this form of biofeedback or relaxation technique helps with heart rate variability during mental stress.
223631292|NCT01568177|PROCEDURE|SPECT cardiac scan with 123I-mIBG and Myoview|Single Photon Emission Computed Tomography (SPECT) cardiac scan with 123I-mIBG and Myoview will be used to measure cardiac sympathetic activity.
223631293|NCT03562273|RADIATION|Quality Of Life Sizing Nomogram|"If the participant meets the eligibility criteria of the study, and participant chooses to take part, they will receive the tumor bed boost in 8 Gy in 1 fraction just prior to starting whole breast radiation after joining the study. Treatment to the whole breast will begin within 7-8 days from the TB boost (GammaPodTM) treatment.~The radiation therapy will take approximately 6 weeks to complete. Follow-up visits specifically for this study will continue for one year, although the physician will continue to follow as part of routine care."
223631294|NCT02203903|BIOLOGICAL|Tumor associated antigen lymphocytes (TAA-T)|TAA-T may be generated from donors or recipients and will be tested for specificity to 3 tumor antigens commonly found in hematological malignancies (WT1, PRAME, and SURVIVIN,). The goal of this cell infusion will be to initiate an immune response to residual leukemia or lymphoma that includes multiple antigens and may prevent tumor evasion (through decreased expression of a single antigen).
223631295|NCT05010707|DRUG|Transdermal patch|Participants will be prescribed the medication and dosed based on their hormonal profile. Goal is achieve estradiol level between 100-200 pg/mL and to suppress testosterone to cisgender female levels
223631296|NCT05010707|DIAGNOSTIC_TEST|Pro-thrombotic markers|Once participants are started on gender affirming hormone therapy, pro-thombotic markers will be checked at baseline and every 6 months. Pro-thrombotic markers will include: Factor II, Factor IX, Factor XI, Von Willebrand factor, Protein C, Protein S, activated Protein C resistance.
223631297|NCT05010707|DIAGNOSTIC_TEST|Metabolic markers|Once participants are started on gender affirming hormone therapy, metabolic markers will be checked at baseline and every 6 months. Markers will include: Insulin level, fasting glucose, body mass index, waist circumference.
223631298|NCT05010707|DIAGNOSTIC_TEST|Hormone Profile|Once participants are started on gender affirming hormone therapy, hormonal levels will be checked every 4 weeks until estradiol and testosterone levels are within goal as established by standard of care.
223631299|NCT05010707|DRUG|Daily Sublingual Tablet|Participants will be prescribed the medication and dosed based on their hormonal profile. Participants will take dose as once daily medication. Goal is achieve estradiol level between 100-200 pg/mL and to suppress testosterone to cisgender female levels
223631300|NCT05010707|DRUG|BID Sublingual Tablet|Participants will be prescribed the medication and dosed based on their hormonal profile. Participants will take dose as twice daily medication. Goal is achieve estradiol level between 100-200 pg/mL and to suppress testosterone to cisgender female levels
223631301|NCT05010707|DRUG|Spironolactone|All patients will also receive spironolactone. Spironolactone will be started at 50 mg daily and will increase to standard dose.
223631302|NCT04086927|DEVICE|Unna Boot|The unna boot is a zinc coated compression dressing
223631303|NCT06597903|DRUG|NRL994|"In the afternoon/evening before colonoscopy: 1 litre solution plus 0.5 litre clear fluid.~Day of colonoscopy: 1 litre solution plus at least up to 1 litre clear liquid."
224219864|NCT02857725|DRUG|BAY 987517|Single dose application of two (2) mg/cm² of test product. Each 50 cm² test site area requires 100 mg of a product to obtain a standard 2 mg/cm² test application.
224219865|NCT02857725|DRUG|SPF 15 Control|Single dose application of two (2) mg/cm² of test product. Each 50 cm² test site area requires 100 mg of a product to obtain a standard 2 mg/cm² test application.
224219866|NCT05319340|OTHER|prescribing anticoagulant therapy|Patients who need anticoagulants were consulted by a cardiologist with subsequent recommendations
224219867|NCT03413865|OTHER|Visits conducted via Telemedicine|Patients will be followed via telemedicine with visits lead by a Pharmacist and a Nurse
224219868|NCT04874766|OTHER|Wingate exercise test and on-ice testing while wearing a face mask|Power output during 2 x 20s Wingate cycle tests and total distance during an on-ice skating test while wearing a face mask
224219869|NCT04874766|OTHER|Wingate exercise test and on-ice testing while wearing a sham face mask|Power output during 2 x 20s Wingate cycle tests and total distance during an on-ice skating test while wearing a face mask
224219870|NCT06547203|DRUG|Cetuximab|Cetuximab: 500 mg/m², intravenous infusion, once every 2 weeks
224219871|NCT06547203|DRUG|Toripalimab|Toripalimab: 3 mg/kg, intravenous infusion, once every 2 weeks.
224219872|NCT06547203|DRUG|Irinotecan|Irinotecan: 150 mg/m², intravenous infusion, once every 2 weeks.
224219873|NCT01222806|DEVICE|Repetitive Transcranial Magnetic Stimulation|
224219874|NCT00218621|PROCEDURE|Buprenorphine / methadone|Parallel study to double blind, double dummy study evaluating safety and efficacy of buprenorphine vs methadone treatment for pregnant opioid dependent women
224219875|NCT03698318|DIETARY_SUPPLEMENT|Tested product n°1|1 capsule (26% of gingerol/shogaol in 100 mg) to consume one time for each subject, at one experimental session (random assignment), with 250 mL of water (consumption at T0 time-point of the kinetic)
224219876|NCT03698318|DIETARY_SUPPLEMENT|Tested product n°2|1 capsule (38.6% of gingerol/shogaol in 74.9 mg) to consume one time for each subject, at one experimental session (random assignment), with 250 mL of water (consumption at T0 time-point of the kinetic)
224219877|NCT03698318|DIETARY_SUPPLEMENT|Tested product n°3|2 capsules (6.8% of gingerol/shogaol in 424.3 mg) to consume one time for each subject, at one experimental session (random assignment), with 250 mL of water (consumption at T0 time-point of the kinetic)
224219878|NCT03698318|DIETARY_SUPPLEMENT|Tested product n°4|1 capsule (27% of gingerol/shogaol in 104.9 mg) to consume one time for each subject, at one experimental session (random assignment), with 250 mL of water (consumption at T0 time-point of the kinetic)
224219879|NCT03698318|DIETARY_SUPPLEMENT|Tested product n°5|6 capsules (1.6% of gingerol/shogaol in 1806.25 mg) to consume one time for each subject, at one experimental session (random assignment), with 250 mL of water (consumption at T0 time-point of the kinetic)
224219880|NCT01481831|DRUG|Palonosetron Hydrochloride|0.25 mg IV\*1 dose on day 1, 30 minutes prior to the administration of the major chemotherapeutic agent.
224219881|NCT01481831|DRUG|Palonosetron Hydrochloride|0.25mg IV\*3 doses on days 1,3 and 5,30 minutes prior to the administration of the major chemotherapeutic agent.
224219882|NCT03803085|BEHAVIORAL|Control condition|Participants in the control group only saw their own daily walking steps using the WeChat. They did not use WeChat to see other group members' daily steps and did not contact other group members. The participants were asked to use the app every day. A message (through WeChat) was sent to remind them to use the application if they had not done so within three days.
224219883|NCT03803085|BEHAVIORAL|Treatment condition|Participants in the experimental condition used WeChat for 4 weeks to see their own and other's walking steps and also were able to contact other group members. The participants were asked to use the application every day. A message (through the group chat) was sent to remind them to use the application if they have not done so within three days.
224219884|NCT02118753|DRUG|Eplerenone|eplerenone administered ex vivo (to the organ bath in which human atrial tissue is exposed)
223631304|NCT06595472|DIETARY_SUPPLEMENT|Palm Oil Enriched with Plant Sterols|The enriched palm oil contained 52 mg/L of phytosterols, to reach the estimated intake of plant sterols in the treatment group at the level of around 2 g/day \[22\]. The phytosterols used was Vegapure 95 FF® derived from soybean derivatives containing campesterol, stigmasterol and beta-sitosterol. The oil is consumed by respondents as cooking oil.
223631305|NCT06595472|DIETARY_SUPPLEMENT|Palm oil|The type, composition, and physical appearance of the oil is the same as those of the intervention arm, except that it was not added plant sterol. The oil is consumed by respondents as cooking oil.
223631306|NCT06593171|BEHAVIORAL|Mentoring program|This three-session mentoring program is based on experiential learning and has been validated and adapted to our country. The mentors, professionals with lived experience in mental health, will provide knowledge and experiences to the students through direct contact sessions in the classroom, focusing especially on the processes of recovery and self-determination.
223631307|NCT06593171|BEHAVIORAL|Control (placebo) group|This group will not receive any intervention. However, they will be invited to participate in stigma education after the study is completed.
223631308|NCT02360579|BIOLOGICAL|Lifileucel|A tumor sample is resected from each patient and cultured ex vivo to expand the population of tumor infiltrating lymphocytes. After lymphodepletion, patients are infused with Lifileucel followed by IL-2.
223631309|NCT06999746|OTHER|Control|Sleep hygiene education
223631310|NCT06999746|DEVICE|Oropharyngeal Exercise|Device-monitoring oropharyngeal exercise, 1-5 days a week for three months
223631311|NCT06999746|DEVICE|Continuous positive airway pressure|Continuous positive airway pressure, 1-5 days a week for three months
223631312|NCT06999746|DEVICE|Continuous positive airway pressure and oropharyngeal exercise|Continuous positive airway pressure and device-monitoring oropharyngeal exercise, 1-5 days a week for three months
223631313|NCT06998212|BEHAVIORAL|Offer to record encounter|Patient will be given the option to record their clinical encounter on their personal smartphone
224219885|NCT06536842|OTHER|Postoperative Drain Placement|These drains will be placed with the intention to decrease the incidence of postoperative hematoma
224219886|NCT06536842|OTHER|No Postoperative Drain Placement|Participant will undergo lumbar spine fusion surgery and will not receive a postoperative drain
224219887|NCT00540709|DRUG|Insulin Glargine|
224219888|NCT05297071|DEVICE|Orascopic HDL 3.0 Loupes|The loupes will be used during the surgical procedure on half of the subjects. The other half will be performed with a microscope.
224219889|NCT05297071|DEVICE|Semorr DOM3000D Operation Microscope|The microscope will be used during the surgical procedure on half of the subjects. The other half will be performed with loupes.
224219890|NCT03997331|OTHER|CRx Health|CRx Health is a connected health solution comprised of connected devices (InsulCheck, a Bluetooth-enabled pill bottle cap, and a Bluetooth-enabled glucometer) paired to a mobile smartphone app (CRx Health).
223631314|NCT06999668|DEVICE|Virtual reality cognitive function training|"Participants will receive VR-based cognitive training over 4-5 days prior to surgery, with three daily 30-minute sessions (8:00-10:00 AM, 12:00-2:00 PM, and 5:00-7:00 PM), ensuring a total preoperative training duration ≥6 hours.~The intervention utilizes an immersive VR environment that simulates real-world scenarios and tasks. Training modules target multiple cognitive domains, including memory, executive function, calculation, and abstract reasoning, designed as engaging, game-like activities with a gradual learning curve.~Each participant's regimen is personalized based on baseline cognitive assessments or physician prescriptions, adhering to the 6-hour rule for standardized efficacy evaluation. The system incorporates adaptive difficulty adjustment, dynamically modifying task complexity in response to real-time performance."
223631315|NCT06999668|DEVICE|Virtual scene intervention|The control group will receive non-interactive VR exposure using identical equipment and session duration as the training group (3×30-minute daily sessions for 4-5 days, totaling ≥6 hours), with all interactive functions disabled to eliminate potential media-related biases (e.g., 2D/3D cognitive load differences from tablet-based interventions) and ensure between-group differences stem solely from interactive training while maintaining blinding integrity through equivalent hardware deployment.
223631316|NCT06998186|BEHAVIORAL|Discharge Education And Telephone Counseling|"Providing training on discharge education to parents of cardiac surgery patients.~Providing telephone counseling for 6 months"
223631317|NCT06998823|COMBINATION_PRODUCT|Probiotics|Participants will intake 90days Probiotics
223631318|NCT06998693|DRUG|5-ASA (5-Aminosalicylate)|Specialist doctors decide the administration method of 5-ASA based on the patient's condition (all groups), mainly including topical therapy, or oral therapy (2-4 gram/day).
223631319|NCT06998693|PROCEDURE|Colon Endoscopy Procedure|Participants in all groups will receive a standard Colon Endoscopy Procedure at 48-week.
223631320|NCT06998693|DIAGNOSTIC_TEST|Blood Routine Test at 4-week|Participants in will receive a standard Blood Routine Test at 4-week.
223764233|NCT02986204|PROCEDURE|removal of ENG implant|"the researcher(s) will ask you to: Visit 1 - SCREENING VISIT~* questions about your medical/contraception history~* Review medical record~* physical examination~* urine sample for pregnancy test~Visit 2a - Radiology~* Have an ultrasound of your arm~* The radiologist will mark your arm at the location of the implant.~Visit 2b~* ultrasound of your arm to locate the implant. This is done by feeling the area.~* Have your ENG implant removed through a numbed small cut. The researcher will apply a pressure bandage to the site(s). This will reduce bleeding/decrease swelling.~* Have the removal procedure video recorded.~Visit 3 - FOLLOW UP VISIT approximately 2 weeks after Visit 2:~* Provide a urine sample for pregnancy test~* Have the implant removal site examined"
224219891|NCT03997331|OTHER|Chronicare|Chronicare is a disease management program comprising self-management data from the CRx Health solution syncing to an automated support system (Intervention Engine) and a remote care application (CRx Care) used by a team of clinicians to remotely monitor and support patients.
223631321|NCT06998693|DIAGNOSTIC_TEST|Blood Routine Test at 8-week|Participants in will receive a standard Blood Routine Test at 8-week.
223764234|NCT02986204|PROCEDURE|continuation of ING implant|"the researcher(s) will ask you to:~* To answer questions about your medical and contraception history~* Review your medical record~* Have a physical examination by the researcher~* Provide a urine sample for pregnancy test~* Have an ultrasound of your arm"
223764235|NCT05687019|COMBINATION_PRODUCT|Intravesical instillations of Ialuril® Prefill|5 injections of Ialuril® Prefill on D0 or D1, D7, D14, D21 and D28 after Holmium laser surgery for prostate adenoma
224219892|NCT05798858|DIAGNOSTIC_TEST|NIPT|universal nipt in group a, NIPT for intermediate risk in Group B
224219893|NCT03615456|PROCEDURE|Conventional thyroidectomy|Thyroid vessels are ligated with sutures and divided
224219894|NCT03615456|PROCEDURE|Harmonic scalpel thyroidectomy|Thyroid vessels are sealed using harmonic scalpel device
224219895|NCT04922398|BIOLOGICAL|platelet rich plasma|blood will be withdrawn from the patient then separation of the platelet rich layer and then injection in the ovary
224219896|NCT04922398|DRUG|Normal saline|0.9% normal saline will be injected in each ovary
224219897|NCT03348046|DRUG|Biosimilar Infliximab|A vial containing powder for concentrate for solution for infusion. Each vial contains: Infliximab 100 mg
224219898|NCT05953922|OTHER|core stability exersises|core stability exercises and transcutaneous electrical nerve stimulation for four week three session per week
223631322|NCT06998693|DIAGNOSTIC_TEST|Blood Routine Test at 12-week|Participants in will receive a standard Blood Routine Test at 12-week.
223631323|NCT06998693|DIAGNOSTIC_TEST|Stool Routine Test at 4-week|Participants in will receive a standard Stool Routine Test at 4-week.
223631324|NCT06998693|DIAGNOSTIC_TEST|Stool Routine Test at 8-week|Participants in will receive a standard Stool Routine Test at 8-week.
223631325|NCT06998693|DIAGNOSTIC_TEST|Stool Routine Test at 12-week|Participants in will receive a standard Stool Routine Test at 12-week.
223631326|NCT06998693|DIAGNOSTIC_TEST|Erythrocyte Sedimentation Rate Test at 4-week|Participants in will receive a standard Erythrocyte Sedimentation Rate Test at 4-week.
223631327|NCT06998693|DIAGNOSTIC_TEST|Erythrocyte Sedimentation Rate Test at 8-week|Participants in will receive a standard Erythrocyte Sedimentation Rate Test at 8-week.
223631328|NCT06998693|DIAGNOSTIC_TEST|Erythrocyte Sedimentation Rate Test at 12-week|Participants in will receive a standard Erythrocyte Sedimentation Rate Test at 12-week.
223631329|NCT06998693|DIAGNOSTIC_TEST|C-reactive Protein Test at 4-week|Participants in will receive a standard C-reactive Protein Test at 4-week.
224219899|NCT04148183|DRUG|Metformin group|We add treatment with Metformin (850 mg/day), treatment was administered for 8 weeks
224219900|NCT04148183|DRUG|Rosiglitazone group|we add Rosiglitazone (4 mg/day), treatment was administered for 8 weeks
224219901|NCT04148183|DRUG|Placebo oral tablet|We add Placebo, treatment was administered for 8 weeks
224219902|NCT01042496|DRUG|Lamotrigine|12 week open trial: 25mg/day for 2 weeks, 50mg/day for 2 weeks, 100mg/day for 2 weeks, 200mg/day for 6 weeks. Flexible titration for early response and/or side effects.
224219903|NCT01042496|PROCEDURE|1H-MR|Proton magnetic resonance spectroscopy (1H-MR) evaluation of medial anterior cingulate cortex (MACC) and left dorsal lateral prefrontal cortex (LDLPC).
224219904|NCT01427803|DRUG|Naproxen Sodium ER (BAYH6689)|BAYH6689; oral tablet used as needed upon incidence of pain
224219905|NCT00417599|BEHAVIORAL|Lifestyle Intervention|lifestyle intervention .
223631330|NCT06998693|DIAGNOSTIC_TEST|C-reactive Protein Test at 8-week|Participants in will receive a standard C-reactive Protein Test at 8-week.
223631331|NCT06998693|DIAGNOSTIC_TEST|C-reactive Protein Test at 12-week|Participants in will receive a standard C-reactive Protein Test at 12-week.
223631332|NCT06998693|DIAGNOSTIC_TEST|Liver Function Test at 4-week|Participants in will receive a standard Liver Function Test at 4-week.
224219906|NCT00417599|OTHER|control group|waiting list control group
224219907|NCT01484990|DRUG|Levodopa-Carbidopa|Intestinal Gel
224219908|NCT04727346|RADIATION|CBCT|Cone Beam Computed Tomography
224219909|NCT04727346|PROCEDURE|DISE|Drug Induced Sleep Endoscopy
224219910|NCT05578573|DEVICE|KARAHOC device|After leaving a mark on the part where the puncture is to be performed using a pen, sterilization dressing are performed, local anesthesia is performed aseptic then ascites paracentesis by KARAHOC device.
223631333|NCT06998693|DIAGNOSTIC_TEST|Liver Function Test at 8-week|Participants in will receive a standard Liver Function Test at 8-week.
223631334|NCT06998693|DIAGNOSTIC_TEST|Liver Function Test at 12-week|Participants in will receive a standard Liver Function Test at 12-week.
223631335|NCT06998693|DIAGNOSTIC_TEST|Kidney Function Test at 4-week|Participants in will receive a standard Kidney Function Test at 4-week.
223631336|NCT06998693|DIAGNOSTIC_TEST|Kidney Function Test at 8-week|Participants in will receive a standard Kidney Function Test at 8-week.
223631337|NCT06998693|DIAGNOSTIC_TEST|Kidney Function Test at 12-week|Participants in will receive a standard Kidney Function Test at 12-week.
223631338|NCT06263010|DRUG|Allopregnanolone|Allopregnanolone is a neurosteroid ( 3α,5α-tetrahydroprogesterone, 3α-hydroxy-5α-pregnan-20-one) and by-product of the metabolism of the hormone progesterone.
223631339|NCT03300128|BEHAVIORAL|Incredible Years - ASD|The IY-ASD intervention is designed for parents of children with autism spectrum disorder. The programs uses a mix of videos, collaborative brainstorming sessions, and role plays to deliver content on child-directed play and positive discipline practices.
223631340|NCT03300128|OTHER|Circle of Parents|"Circle of Parents is an open parent support group led by a parent leader. Participants are encouraged to share resources and other support both during groups, and between meetings."
223764236|NCT06391879|GENETIC|Single cell sequencing, whole genome and metabolomic sequencing|The blood specimen of subjects in this cohort would be collected to conduct single cell sequencing, whole genome and metabolomic sequencing.
223764237|NCT05958212|BEHAVIORAL|Gait training program|"Gait training program at PolyU is a supervised rehabilitation program performed on the dual-belt treadmill. It consists of forward walking at increased speed over the affected leg and retro walking (backward walking) at individual's own pace (5 minutes/set for three sets, with rest periods in each session). This program also consists of a standardized set of warm-up and cool-down exercises at each training session.~Participants will also receive conventional physiotherapy treatment in the outpatient physiotherapy clinic."
223764238|NCT05958212|BEHAVIORAL|Conventional training only|Conventional physiotherapy treatment in the outpatient physiotherapy clinic.
223764239|NCT02741115|DRUG|Udenafil|Active drug
223631341|NCT05342961|PROCEDURE|spinous balloon dilatation catheter (Plastic-Blade)|To treat Coronary artery disease
223631342|NCT05342961|PROCEDURE|spinous balloon dilatation catheter(lacrosse NSE)|To treat Coronary artery disease
223631343|NCT06871683|DEVICE|ClotTriever® Thrombectomy System|ClotTriever® Thrombectomy System use for treatment of patients with deep vein thrombosis with acute severe symptoms.
223631344|NCT06284005|DEVICE|WRL ATP|evaluation of functionality, degree of safety and reliability of the lower limb prosthesis prototype
223631345|NCT00380055|BEHAVIORAL|Navigation Services|Navigators (community health workers) identify and assist in overcoming barriers to appropriate cancer care.
223631346|NCT00380055|BEHAVIORAL|Cancer education|Community health workers provide cancer education appropriate for Medicare participants.
223764240|NCT02741115|DRUG|Placebo|Matching Placebo
223764241|NCT04912921|DIETARY_SUPPLEMENT|palmitoylethanolamide|4 tablets taken daily (2 in the am and 2 in the pm)
223764242|NCT04912921|DIETARY_SUPPLEMENT|Placebo|4 tablets taken daily (2 in am and 2 in pm)
224219911|NCT05578573|DEVICE|Angiocatheter|After leaving a mark on the part where the puncture is to be performed using a pen, sterilization dressing are performed, local anesthesia is performed aseptic then ascites paracentesis by angiocatheter
224219912|NCT01919957|OTHER|No intervention|
224219913|NCT04351282|RADIATION|SBRT|SBRT for oligometastatic lesions will be assigned to those who got PR,SD after systemic treatment.
224219914|NCT01445132|DRUG|Allogeneic Cell Therapy w/ Tumor-derived Lypho|
224219915|NCT02445170|PROCEDURE|Amputation|Transmetatarsal or below-knee amputation
224219916|NCT04390139|DRUG|XCEL-UMC-BETA|Administration on top of the standard administered treatment
223631347|NCT06700824|DEVICE|OTR4132|OTR4132 is a new ReGeneraTing Agent (RGTA®) which is a polymer of glucose (α-1,6 bounds, i.e. dextran backbone) engineered to mimic heparan sulphate (HS) in all three mechanical functions (extracellular matrix scaffold element, protector of matrix pro-teins and cellular communication peptides storage sites) but differ from HS by their resistance to glycanases. OTR4132 allows a restoration of the matrix architecture which secondarily facilitates cell survival and recovery at the site of injury.
223631348|NCT06700824|DEVICE|Placebo|saline solution
223764243|NCT04912921|DIETARY_SUPPLEMENT|Curcumin|500 mg HydroCurc® twice a day
224219917|NCT04390139|OTHER|Placebo|Administration on top of the standard administered treatment
224219918|NCT03229031|DRUG|ES135|ES135 will be administered via intrathecal
224219919|NCT04647344|DRUG|AK104 plus Carboplatin and Pemetrexed|Subjects receive AK104 15mg/kg intravenously (IV) plus pemetrexed 500 mg/m\^2 IV and carboplatin area under the curve (AUC) 5 IV on Day 1 of every 3-week cycle (Q3W) for 4 cycles followed by AK104 15mg/kg IV plus pemetrexed 500 mg/m\^2 IV Q3W until progression.
224219920|NCT04647344|DRUG|AK104 plus Carboplatin and paclitaxel|Subjects receive AK104 15mg/kg intravenously (IV) plus paclitaxel 175 mg/m\^2 IV and carboplatin area under the curve (AUC) 5 IV on Day 1 of every 3-week cycle (Q3W) for 4 cycles followed by AK104 15mg/kg IV IV Q3W until progression.
224219921|NCT02545413|DRUG|Probiotic VSL#3|
224219922|NCT02545413|DRUG|Placebo|
223631349|NCT05856422|DEVICE|Respiratory rate measure based on PPG|"Testing was conducted under normal office environment conditions. Each subject was connected to the reference EtCO2 monitor (GE Datex-Ohmeda) and the Device Under Test, the Gabi SmartCare Gabi Band. A waveform collected from an EtCO2 measurement was used to determine performance of respiratory rate metrics. Each subject was given a nasal cannula that allowed for measurement of the EtCO2 respiratory rate.~The reference respiratory rate was measured simultaneously with the Device Under Test. Data was marked for stable quiet periods that were useable for analysis."
223631350|NCT06702319|OTHER|Exercise|Home exercises and home exercises with internal focus exercises or external focus exercises
223631351|NCT06704529|BEHAVIORAL|pitching motion|participants pitch fastball to the strike zone
223631352|NCT06704308|BEHAVIORAL|Web Application|A web application for vaccine-hesitant parents and their teens with brief, 90-second narrative videos and tailored, motivational content
223631353|NCT06704308|BEHAVIORAL|Provider Elaborated Prompts|A component for providers that suggests elaborated prompts to be used with parents that align with the content of the web application, are tailored to parent concerns, and are motivational in nature
223631354|NCT04104854|DEVICE|drug coated balloon|Balloon/vessel diameter ratio 0.8-1.0, 8-12 ATM (atmosphere), lasting for \>30 seconds
223764244|NCT04912921|DIETARY_SUPPLEMENT|Control (microcrystalline cellulose)|2 tablets taken daily
224219923|NCT06035783|DEVICE|Orbital Atherectomy|The Diamondback 360° Coronary orbital atherectomy system (OAS) is a device dedicated to debulk severely calcified coronary lesions to facilitate stent delivery and enable stent expansion with optimal results. The OAS's main mechanism is the synergistic rotation of the crown around its axis and simultaneously its endoluminal orbital motion. This effect allows blood to flow continuously and it facilitates heat dispersion which results in reduced heat damage to the arterial walls and subsequently to less myocardial damage, at the same time it softens the plaques tissue. It also appears that the microparticles created from sanding the artery plaques do not create any agglomeration to the branching arteries
224219924|NCT02687204|DRUG|Twice daily enoxaparin prophylaxis|Patients will have peak and trough steady state anti-Xa levels drawn. For patients with out of range peak levels, real time enoxaparin dose adjustment using a clinical protocol will be performed. Repeat steady state levels will be checked.
224219925|NCT02687204|DRUG|Real time dose adjustment|Patients will have peak and trough steady state anti-Xa levels drawn. For patients with out of range peak levels, real time enoxaparin dose adjustment using a clinical protocol will be performed. Repeat steady state levels will be checked.
223631355|NCT06706375|PROCEDURE|Using ultrasound for penile nerve block|30% of men over the age of fifteen worldwide have had a circumcision according to a World Health Organization report. (1) This operation is common and should not be trivialized. A certain number of surgical complications should be considered, including pain, infections, excessive bleeding or hematomas. (1,2) Today, the use of opioids as intra- and postoperative analgesics in pediatric urological surgery remains predominant (3) but is the subject of increasing controversies. Indeed, the recent opioid crisis challenges us about their use and highlights their multiple side effects. First of all, their use involves significant risks, (4) including opioid-induced hyperalgesia and potential long-term effects. An increase in pain sensitivity within the 24 postoperative hours being proportional to intraoperative administration of high doses of opioids can be observed. (5) Long-term addiction is also questioned. Then, opioids don't appear to be the most effective per- and postoperative analgesi
223631356|NCT06706375|PROCEDURE|Dorsal Penile Block Anesthesia using landmarks|Dorsal penile nerve block (DPNB) is LRA technique of choice for circumcisions and aims to anesthetize both dorsal penile nerves. (10-12) The name DPNB is used for blocks performed by determining precise dorsal anatomical landmarks and doing two distinct injections.
223631357|NCT06705920|DRUG|topical oxygen gel|In the study group the gel will be applied over the suture and the patients will be instructed to apply the gel to the wound area and to the suture thread using a cotton swab
223631358|NCT06704360|DEVICE|immersive VR pathfinding training|Pathfinding training with immersive VR.
223631359|NCT06704360|OTHER|Occupational therapy|Only receive conventional cognitive training group
223631360|NCT06704425|OTHER|For observational studies, participants are not assigned an intervention as part of the study.|For observational studies, participants are not assigned an intervention as part of the study.
223631361|NCT06705985|DEVICE|Implantation of lateral meniscus prosthesis|Implantation of a lateral meniscus prosthesis after meniscectomy.
223631362|NCT03253393|DEVICE|Smart Touch Technology packaging|hioxifilcon A contact lens in Smart Touch Technology (hydrogel, no EDTA) midafilcon A contact lens in Smart Touch Technology (silicone hydrogel, with EDTA)
223631363|NCT03253393|DEVICE|Conventional lens packaging|hioxifilcon A contact lens in conventional lens packaging (hydrogel, no EDTA) midafilcon A contact lens in conventional lens packaging (silicone hydrogel, with EDTA)
223631364|NCT03253393|DEVICE|EDTA|hioxifilcon A contact lens in Smart Touch Technology (hydrogel, with EDTA) midafilcon A contact lens in Smart Touch Technology (silicone hydrogel, no EDTA)
223764245|NCT04106479|DEVICE|NIRS evaluation|NIRS will be used for measurement of cerebral and renal saturation.
224219926|NCT04825509|DEVICE|Ultrasound|"Diaphragm ultrasound will be done while patient is supine on T-piece during SBT 30 minutes after disconnecting mechanical ventilation. The measurements will be done by placing the transducer in the eighth or ninth intercostal space, between the anterior axillary and the mid-axillary lines.~Diaphragmatic excursion (DE) will be measured in M-mode using a 1- to 5- Megahertz (MHz) ultrasound curved transducer during maximal breathing. The amplitude of diaphragmatic excursion will be measured as the point of maximal height of the diaphragm to the base line.~Diaphragmatic thickness (DT) will be measured at both end of maximal inspiration and end of maximal expiration using a high frequency 7-11 MHz ultrasound linear transducer in M-mode. The diaphragm thickness will be measured from the middle of the pleural line to the middle of the peritoneal line."
224219927|NCT03881579|BEHAVIORAL|nurse-led supportive care assessment|Trained project nurses will conduct systematic assessment and provide coaching to patients in the experimental arm
224219928|NCT04495465|OTHER|Radial Shock Wave Therapy|2000 shots of extracorporeal radial shock waves therapy on neck muscles at 4bars and 10 Hertzs
224219929|NCT04495465|OTHER|Manual Therapy|25 minute massage to neck muscles
224219930|NCT04495465|OTHER|placebo shock waves|3 minutes of placebo extracorporeal radial shock waves therapy on painful points of neck muscles.
223631365|NCT06736457|PROCEDURE|AdvanCore bone grafting|AdvanCore medical device is implanted making sure that is in direct contact with all surfaces of the defect area.
223631366|NCT00189722|DRUG|Tacrolimus|
223631367|NCT03712696|DEVICE|DIGNICAP™|Scalp cooling to prevent chemotherapy-induced alopecia
223631368|NCT05684835|PROCEDURE|Excision|All patients underwent surgery under general anesthesia and intraoperative neuromonitoring according to the preoperatively predicted NO. Using an anterior cervical approach, the tumor was delineated after identifying the relationships among the great vessels, nerves, and tumors. The NO was confirmed intraoperatively. Sharp dissection was performed meticulously to enucleate the tumor from the NO to preserve most nerve fibers.
223631369|NCT02137746|BIOLOGICAL|Dendritic Cells DCVAC/PCa|DCVAC/PCa Experimental therapy
223631370|NCT03140241|PROCEDURE|PDR measurement|"PDR measurement at two standardized times perioperatively:~1. : anesthetized subject by propofol sedation until sedation depth monitor NeuroSense® (NeuroWave Systems Inc, Cleveland, OH) between 40-50~2. : administration of remifentanil via effect site target concentration (Minto-model) at 5 ng/ml, in the absence of adjustments in sedation depth"
223631371|NCT05781542|BIOLOGICAL|sD-NP-GT8 DNA|0.4 mg or 1.6 mg
223631372|NCT05781542|BIOLOGICAL|IL-12 DNA|0.1 mg or 0.4 mg
223631373|NCT05781542|BIOLOGICAL|Trimer 4571|100 mcg
223631374|NCT05781542|BIOLOGICAL|3M-052-AF|5 mcg
223631375|NCT05781542|DRUG|Alum|500 mcg
223631376|NCT02435953|PROCEDURE|TACE|TACE will be done according to the current method in our center. We use intra-injection of lipiodol mixed with pirarubicin,mitomycin and lobaplatin when the catheter was placed in the superselective location very close to the tumor. Gelfoam sponge was then injected to temporarily occlude the arterial blood flow.
223631377|NCT02435953|PROCEDURE|RFA|For RFA, we used two commercially available system (Cool-Tip, Valleylab，USA) and (Octopus RF Systema，Starmed,Korea）with needle electrode with a 17-gauge internally cooled electrode.
223631378|NCT04143035|OTHER|No Intervention|No Intervention
223631379|NCT04301960|OTHER|Single task training|The single task group includes balance gaining and cognitive training. The single task group will have 30-40 minutes of single-task training for 3 sessions per week for 8 weeks.
223631380|NCT04301960|OTHER|Dual task training|The dual-task group includes CSRT Mat training. The dual-task group will have CSRT Mat training for 30-40 minutes of dual-task training for 3 sessions per week for 8 weeks.
223631381|NCT02231112|RADIATION|Whole breast RT on prone position|
223631382|NCT00002534|BIOLOGICAL|anti-thymocyte globulin|
223631383|NCT00002534|DRUG|cyclophosphamide|
223631384|NCT00002534|DRUG|cytarabine|
223631385|NCT00002534|DRUG|methylprednisolone|
223631386|NCT00002534|DRUG|thiotepa|
223631387|NCT00002534|PROCEDURE|allogeneic bone marrow transplantation|
223631388|NCT00002534|PROCEDURE|in vitro-treated bone marrow transplantation|
223631389|NCT00002534|RADIATION|low-LET electron therapy|
223631390|NCT00002534|RADIATION|low-LET photon therapy|
223631391|NCT00003127|DRUG|amifostine trihydrate|740 mg/m2 IV, Day 1, q 28 days X 6 cycles
223631392|NCT00003127|DRUG|carboplatin|target AUC=6, IV Day 1, q 28 days X 6 cycles
223631393|NCT00003127|DRUG|paclitaxel|175 mg/m2, IV, Day 1 q 28 days X 6 cycles
223631394|NCT03524846|DRUG|Ascorbic Acid 300 MG|Ascorbic acid 300 mg was administered intravenously for 5 minutes after each dialysis session, three times per week for 12 weeks.
223631395|NCT03524846|DRUG|Ascorbic Acid 600 MG|Ascorbic acid 600 mg was administered intravenously for 5 minutes after each dialysis session, three times per week for 12 weeks.
224219931|NCT01571635|DRUG|SOTATERCEPT (ACE-011)|0.1 mg/kg to 1.5mg/kg Sotatercept will be administered as a subcutaneous injection once every 21 days during the treatment period.
223631396|NCT03524846|DRUG|Normal saline|Normal saline was administered intravenously for 5 minutes after each dialysis session, three times per week for 12 weeks.
223631397|NCT04188743|BIOLOGICAL|Allogenic FMT|Transplantation of fecal microbiota from a donor into a recipient
223631398|NCT04188743|BIOLOGICAL|Autologous FMT|Transplantation of autologous fecal microbiota
223631399|NCT02786849|OTHER|neuromuscular electrical stimulation of high frequency and intensity|"Training with neuromuscular electrical stimulation isometric form in lateral and medial bilaterally vast, three times a week, lasting an hour, the first two hours of dialysis.~Will be applied using portable stimulators with 4 channels. The parameters are: frequency of 50 Hz, pulse width 400ms, rise time and 2s descent, stimulus mode on-off starting with a ratio of 1: 2 in the first week (stimulus time of 10 seconds and rest time of 20s, aiming at adaptation and mitigation of the effects of muscle fatigue), evolving from the second week to a ratio of 1:1 (stimulation time of 10 seconds and rest time of 10s).~The current intensity is adjusted individually for the first application and gradually increased as the tolerance of patients.~In each session there will be a warm-up period, training and slowdown. The intensity will be the maximum tolerated by the patient in order increments every session, this being monitored for further evolutionary calculating."
223631400|NCT02786849|OTHER|neuromuscular electrical stimulation of low frequency and intensity|"Training with neuromuscular electrical stimulation isometric form in lateral and medial bilaterally vast, three times a week, lasting an hour, the first two hours of dialysis.~Will be applied using portable stimulators with 4 channels. The parameters are: 5 Hz frequency, time on: off 1: 3 with a pulse duration of 100ms.~The current intensity is adjusted individually for the first application and it was the least noticeable by the patient.~In each session there will be a warm-up period, training and slowdown."
223631401|NCT03630289|PROCEDURE|Tissue autograft of pedicled temporoparietal fascial (TPF) or pericranial flap to bypass the blood brain barrier (BBB)|Surgical tissue autograft of pedicled temporoparietal fascial (TPF) or pericranial flap into the resection cavity of newly diagnosed glioblastoma multiforme (GBM) patients.
223631402|NCT01485029|PROCEDURE|Nasopharyngeal (NP) aspirate|Nasopharyngeal (NP) aspirate with a small flexible canule to obtain NP swabs
223631403|NCT04230629|DEVICE|Vivinex XY1|Implantation of an intraocular lens Hoya Vivinex XY1
223631404|NCT04230629|DEVICE|Vivinex XY1A|Implantation of an intraocular lens Hoya Vivinex XY1A
223631405|NCT00248625|DRUG|N-acetylcysteine|The study drug is administered as a continuous infusion at a dose of 150 mg/kg/day for up to 7 days following entry into the study. The infusion is discontinued at the time of death, liver transplant or discharge.
223631406|NCT00248625|DRUG|Placebo|Eligible children were adaptively allocated within strata defined by age (less than 2 years of age or at least 2 years old) and hepatic encephalopathy (grade 0-1 or 2-4) to receive N-acetylcysteine (150 mg/kg/d) in 5% dextrose (D5W) and water or placebo consisting of an equal volume of D5W alone. Volumes were adjusted for small children. Study medications were infused over 24 hours for up to 7 consecutive days in a dedicated line without other medications. Treatment was stopped earlier than 7 days in the case of hospital discharge, liver transplantation, or death within 7 days of randomization.
223631407|NCT02464540|PROCEDURE|Laminate veneers luted with light-cured resin cement|After the use of light-cured luting agent the color of laminate venners will be performed with visual evaluation based on Vita and 3D Master scales and with a spectrophotometer Vita Easyshade (Vita Zahnfabrik / Bad Saeckingen, Germany) based on CIEL\*a\* b system. Data collected will be evaluated for translucency parameter (TP) and color variation (ΔE) according to luting agent, thickness and color of the LVs as well as color of dental substrate. Additionally, the color obtained with visual evaluation and with spectrophotometer will be compared to evaluate the level of agreement between the color observed by the operator and the color named by the spectrophotometer.
223631408|NCT02464540|PROCEDURE|Laminate veneers luted with light-cured flowable composite|After the use of light-cured luting agent the color of laminate veneers will be performed with visual evaluation based on Vita and 3D Master scales and with a spectrophotometer Vita Easyshade (Vita Zahnfabrik / Bad Saeckingen, Germany) based on CIEL\*a\* b system. Data collected will be evaluated for translucency parameter (TP) and color variation (ΔE) according to luting agent, thickness and color of the LVs as well as color of dental substrate. Additionally, the color obtained with visual evaluation and with spectrophotometer will be compared to evaluate the level of agreement between the color observed by the operator and the color named by the spectrophotometer.
223631409|NCT05240820|PROCEDURE|multi-layer wound closure|We prospectively analyze clinical outcome data from 30 subjects who perform multi-layer wound closure using polyglactin 910 and polypropylene, and polydioxanone and combination of 2-octyl cyanoacrylate and polyester mesh following excision of giant benign tumors.
223631410|NCT03432676|DRUG|Epacadostat|Given PO
223631411|NCT03432676|BIOLOGICAL|Pembrolizumab|Given IV
224219932|NCT03865524|DEVICE|Total knee arthroplasty implanted with GPS navigation system|Obese patients undergoing Total Knee Arthroplasty, GPS achieved alignment
224219933|NCT03865524|DEVICE|Total knee arthroplasty implanted with standard guides.|Obese patients undergoing Total Knee Arthroplasty, alignment achieved by using standard guides
224219934|NCT01457131|DRUG|Fludarabine|50 mg/m2, IV(in the vein)on day 5 of each 25 day cycle
224219935|NCT01457131|DRUG|Cyclophosphamide|60 mg/kg/day X 2 days IV in 250 ml D5W with mesna 15 mg/kg/day X 2 days
224219936|NCT01457131|OTHER|IL-12 &amp; Anti-NY ESO1 TCR PBL|10(7) cells to 3 X 10(10) cells
224219937|NCT03574246|DRUG|chlorhexidine gluconate %0,12 benzydamine hydrochloride %0,15|chlorhexidine gluconate + benzydamine hydrochloride oral rinse
224219938|NCT03574246|OTHER|%0.9 NaCl Solution|isotonic sodium chloride
224219939|NCT01741480|OTHER|Early warning system monitoring.|General hospital ward patients will be monitored 24/7 for clinical deterioration using the early warning system monitoring developed at Washington University.
224219940|NCT01741480|OTHER|routine care|
224219941|NCT04486183|OTHER|capillary blood samples|The patient's finger was wiped with alcohol, left to dry, and the first and second blood drops were read The patient was asked to wash their hands, their finger was perforated with a strip, and the first and second blood drops were read The finger of the patient whose hands had been washed was wiped with alcohol, left to dry, and the first and second blood drops were read Venous blood was collected for blood sugar measurement 2 hours after the patient had a beverage containing 75 gr sugar for OGTT The patient was ensured to wash their hands, their finger was wiped with alcohol, and the first and second blood drop glucose values were measured and recorded
224219942|NCT01449058|DRUG|BYL719|taken orally
223631412|NCT00293098|DRUG|deferiprone|oral administration of 75 mg/kg/day in three divided doses, usually in combination with deferoxamine therapy
223631413|NCT04009408|DEVICE|Expiratory muscle strength therapy (EMST150, Aspire LLC)|Active therapy calibrated to the participant's maximum expiratory pressure
223631414|NCT03519035|OTHER|To pass different questionnaires|Patients will have to pass different questionnaires (DIB-R, DES II, THQ, PCL-S, PSAS, qualitative questionnaire) in order to compare the characteristics between BDL patients with and without hallucinations.
223631415|NCT00730717|DRUG|Humira|Will receive 80 mg of Humira injection at week 0 followed by 40 mg weekly Humira injection from Week 1 to Week 23
223631416|NCT00730717|DRUG|Humira|Will receive 40 mg Humira injection every other week from Week 0 to Week 23
224219943|NCT01449058|DRUG|MEK162|taken orally
223631417|NCT06429917|OTHER|Subgingival instrumentation|All the participants will undergo subgingival instrumentation with hand scalers, curettes and ultrasonic scaler. Parameters will be recorded at baseline and two, three and six months of time points after subgingival instrumentation.
224219944|NCT06286566|DEVICE|Implant placement with soi surface in diabetic subjects|Implants placement with SOI surface in subjects with diabetes who have lost at least one tooth element and need of a prosthetic implant-supported rehabilitation. After osseointegration implants will receive definitive prosthesis.
224219945|NCT06286566|DEVICE|Implant placement with soi surface in healthy subjects|Implants placement with SOI surface in subjects without diabetes who have lost at least one tooth element and need of a prosthetic implant-supported rehabilitation. After osseointegration implants will receive definitive prosthesis.
224219946|NCT00769015|BEHAVIORAL|BA-LVR|Low vision clinic-based optometry plus 6 in-home occupational therapy visits
224219947|NCT00769015|BEHAVIORAL|ST-LVR|Clinic-based low vision optometry plus 6 in-home sessions of Supportive Therapy
224219948|NCT05658289|PROCEDURE|Coracoid Transfer|For patients randomized to the active comparator group, the coracoid process and conjoined tendon will be cut and transferred to the anterior rim of the glenoid through an incision in the subscapularis muscle.
224219949|NCT05658289|PROCEDURE|Distal Tibia Allograft with Bankart repair|For the experimental group, a distal tibia allograft will be prepped, cut (20mm x 10mm x 15mm), and inserted into the anterior aspect of the shoulder through a far medial portal. The distal tibia allograft will be attached to the anterior glenoid using cannulated screws. A soft tissue repair, Bankart repair, is performed above the graft.
224219950|NCT05073263|OTHER|Physical Therapy|Patient is randomized to the weightbearing group the day after surgery.
223631418|NCT05856721|DIAGNOSTIC_TEST|stool analysis|"Detection of prevalence and pattern of intestinal parasitic infection in cirrhotic patients and the difference between cirrhotic patients and non-cirrhotic patients with no comorbidity.~To determine the most common risk factors of intestinal parasitic infection in cirrhotic patients."
223631419|NCT02365025|OTHER|Meetings guides by experts in sleeping disorders.|meetings guides by experts in sleeping disorders. In those meeting the parents will be exposed to sleep disturbances, the importance of sleep habits and the influence of electronic media on sleep and learning.
223631420|NCT04162418|DEVICE|Temporary Spur Stent System|Treatment of qualifying infrapopliteal lesions with Temporary Spur Stent System and a commercially available, limus-base drug-coated balloon
223631421|NCT05330559|OTHER|Fluid MAX group|to evaluate and compare with the histopathological analysis the various margin-assessment systems, including ultrasound, florescence, brightfield vision, new optical filters and microscope image post-processing systems, for the treatment of High Grade Gliomas (HGGs)
223764246|NCT06476587|OTHER|Assessment of postural stability and active motion perception|"This assessment, designed to evaluate the impact of the vestibular deficit on everyday tasks, will include questionnaires and standardised clinical tests.~The questionnaires are the Fall Efficacy Scale; the Dizziness Handicap Inventory; the Oscillopsia Severity Questionnaire; the Hospital Anxiety and Depression Scale; the Hamilton Anxiety Scale; the Global Physical Activity Questionnaire; the Motion Sickness Susceptibility Questionnaire part B; and the Cambridge Depersonalization Scale.~In addition, three standardised clinical tests will be carried out: Five Times Sit to Stand Test; Tandem walking test; and Fukuda step test (50 steps).~Five specific clinical tests will also be carried out: Sit-to-stand-with-walk-and-turn; Perception of active body rotation; Perception of walking distance; Triangle Completion Task; and Gait assessment."
223764247|NCT06476587|OTHER|Cognitive tests|Four cognitive tests from the French Focus Group on Executive Functions Assessment (GREFEX) battery will be carried out: the Stroop test; the Trail Making Test; the Baddeley's dual task; and a test of Corsi's Blocks.
223764248|NCT06476587|OTHER|Eccentric axis rotation|This test, also known as the unilateral centrifugation test, provides a quantitative assessment of unilateral utricular otolith function, whereas the tests currently used (vestibular evoked myogenic potential, VEMP) only provide a qualitative assessment.
224219951|NCT04150588|DRUG|Efrin drops|The amount that the eyelid rise after Erin drops before surgery
224219952|NCT04380571|DEVICE|Biofeedback|Biofeedback therapy in addition to the conventional measures done in the control Group. It was performed in the same position used for baseline manometry. The used protocol included strength and sensory training, twice weekly for 3 months. Strength training was performed by a double-lumen rectal PVC balloon clothed catheter (MMS U-72210).
224219953|NCT04380571|DEVICE|Electrical stimulation|A positive auto adhesive electrode was applied above the medial malleolus over the S3 dermatome. A second negative electrode was applied just below the same malleolus. Both electrodes were linked to an electrical stimulation device ( EMS physio Ltd, OX129 F, England) with a low frequency current (10 Hz), and adjustable intensity.
224219954|NCT04380571|OTHER|Traditional treatment|Conventional treatment through Kegal exercises and dietetic regulation where they had received bulky food including vegetables, fruits bran and cereals. Fast foods, spicy drinks and caffeine should be limited in child's diet. Local hygiene and zinc oxide application to the perianal skin were advised to prevent skin excoriation.
224219955|NCT02758093|BEHAVIORAL|Speed of Processing Training|These are specific computerized exercises that are designed to increase the rate in which people can process visual information.
224219956|NCT02758093|OTHER|Internet Navigational|This is a sham condition in which participants will receive the same amount of social and computer contact as those randomized to receive the 10 hours of speed of processing training. In this condition, participants will learn how to do various activities on the internet.
223631422|NCT02443688|DRUG|CTX-4430|
223764249|NCT06476587|OTHER|Osteodensitometry|To assess the participants' bone mineral density, the reference technique of densitometry using two-photon absorptiometry will be used.
223764250|NCT06476587|OTHER|Posturography|Participants' ability to maintain their balance will be assessed using measurements taken on the Synapsys platform. To standardise their position, they will have to stand on the platform with their feet apart, arms at their sides and look straight ahead. Volunteers will be asked to sit down between each trial. The surface area and length of the centre of pressure will be measured under open-eye balance conditions with and without image reading/exploration and dynamics. During this test, 9 balance assessment situations lasting approximately 1 minute each will be performed.
224219957|NCT01341522|PROCEDURE|MRI exam|MRI exam
224219958|NCT01341522|PROCEDURE|control|waiting room
224219959|NCT06024863|DIAGNOSTIC_TEST|Screening stress test on a bicycle ergometer (usual practise)|
224219960|NCT04304950|DRUG|Evening Group|Participants will take their IBD medication (either azathioprine or 6-mercaptopurine) between 6:00 pm and 11:00 pm.
224219961|NCT04304950|DRUG|Morning Group|Participants will take their IBD medication (either azathioprine or 6-mercaptopurine) between 6:00 am and 11:00 am.
224219962|NCT04049695|BEHAVIORAL|Exercise|This intervention is based on Control Theory and Social Cognitive Theory and includes: 1) weekly emails with tips and tools to set personalized exercise goals and to increase exercise; 2) Health coaching phone sessions; 3) wrist worn monitor such as a Fitbit to track activity
224219963|NCT04049695|BEHAVIORAL|Control|This intervention includes: 1) weekly emails with tips and tools to support health and wellness such as brain health, stress management, nutrition; 2) Health coaching phone sessions
224219964|NCT00140556|RADIATION|Chemoradiotherapy|External beam radiation daily (M-F)
224219965|NCT00140556|DRUG|Cisplatin|Cisplatin week 1 and 5 of radiation
224219966|NCT00140556|DRUG|Bevacizumab|Bevacizumab (Avastin) day 1 of weeks 1, 3, and 5 of radiation
224219967|NCT00140556|DRUG|Erlotinib|Erlotinib daily during radiation
224219968|NCT00072033|DRUG|Cisplatin and Docetaxel|cisplatin and docetaxel chemo- and radiochemotherapy
224317938|NCT03368456|BEHAVIORAL|S4E|S4E application was developed in collaboration with youth in Southeast Michigan. S4E aims to prevent and reduce HIV/STI risk behaviors, including drug use and sexual risk behaviors, and increase HIV/STI testing among youth. Content produced for the application is based on scientific prevention principles in conjunction with youth input. To date, we have developed modules focused on youth alcohol \& drug use, HIV \& STIs and a forthcoming module on tobacco prevention and cessation.
223631423|NCT02443688|DRUG|Placebo|
223631424|NCT01852877|BEHAVIORAL|Corrections case management|Corrections case management is a long-term (18-24 months) program that seeks to improve the linkage of HIV-positive persons recently released from jail or prison to community-based HIV care, retain them in care, and reduce recidivism. Compared to the long-standing Ryan White case management program, corrections case management has greater access to housing and a greater emphasis on employment. Clients completing the program are then linked to the Ryan White case management program.
223631425|NCT01094236|BEHAVIORAL|On the Playground behavior management program|Treatment school playground supervisors were show the CD intervention. Control school playground supervisors were given a video on playground equipment safety. All school staff subjects were assessed before the intervention and 75 days following the supervisor intervention. Students were assessed before the intervention, and then 45 days and 75 days following the supervisor intervention. School Administrators were assessed before the intervention, and then 30 and 60 days after the supervisor intervention - school administrators at treatment schools had access to a treatment binder with CDs and worksheets, while the control school administrators did not.
223631426|NCT03182374|DEVICE|nSTRIDE APS|Intra-articular injection
224219969|NCT06547853|BEHAVIORAL|Physical exercise|Groups will be enrolled in a 12-week exercise program. The intervention will be carried out in a highly complex oncology center in Maceió-AL, using the FITT components of the prescription: frequency (4 days a week), intensity (aerobic part through musical beats, subjective perception scale and resistance exercises through a number of maximum repetitions), the time of each session will be 45 minutes, the type of activity offered will be combined exercise training and aerobic exercise training (i.e., walking).
224219970|NCT05091814|RADIATION|radiotherapy|patients who recieved radiotherapy after surgical removal of the tumor
224219971|NCT02158910|DRUG|Aricept|5 mg Aricept increasing dose to 10 mg Aricept, or 10 mg Aricept increasing dose to 23 mg Aricept
224219972|NCT03495700|PROCEDURE|L-PRF block|The use of the L-PRF block as graft material for sinus augmentation procedure will be analysed
224219973|NCT03495700|PROCEDURE|DBBM|The use of bovine xenograft will be analysed
224219974|NCT02590978|PROCEDURE|Early cholecystectomy|Cholecystectomy + intraoperative cholangiography within the first 72 hours of admission.
224219975|NCT02590978|PROCEDURE|Control (Delayed cholecystectomy)|Standard care arm. Cholecystectomy + intraoperative cholangiography is delayed once complete resolution of abdominal tenderness, oral feeding and trending down in pancreatic laboratory is achieved
224219976|NCT01439841|DIETARY_SUPPLEMENT|Multi-strain probiotic|The product consists of Lactobacillus rhamnosus GG, Lactobacillus acidophilus La-5 and Bifidobacterium animalis subsp. lactis Bb-12 added to fermented skimmed milk
224219977|NCT01439841|DIETARY_SUPPLEMENT|Placebo|Fermented and subsequently heat-treated, sterile skimmed milk
224219978|NCT01315301|OTHER|Comparison of different treatment strategies|600 mg efavirenz based HAART initiated one week after starting rifampicin based short course anti tuberculosis treatment.
224219979|NCT01315301|OTHER|Comparison of different treatment strategies|600 mg efavirenz based HAART initiated four weeks after starting rifampicin based short course anti tuberculosis treatment
224219980|NCT01315301|OTHER|Comparison of different treatment strategies|600 mg efavirenz based HAART initiated eight weeks after starting rifampicin based short course anti tuberculosis treatment.
223764251|NCT06476587|OTHER|Vestibulo-sympathetic regulation test|"Participants will be seated on a rotating chair in the dark. Using a virtual reality headset, three visual stimuli will be presented: (A) no visual stimulus (darkness), (B) visual stimulus corresponding to a displacement of the participant along a cylindrical trajectory, (C) visual stimulus corresponding to a displacement of the participant along a conical trajectory. These 3 types of visual stimuli will be presented alone or during an Off-Vertical Axis Rotation (OVAR) with the chair axis inclined at an angle of 10° to the vertical and a rotation speed of 60°/s.~During each sequence, blood pressure, heart rate and end-tidal carbon dioxide (CO2) will be continuously recorded using standard medical equipment."
224219981|NCT03185299|OTHER|Video|Patients randomized to the intervention arm will be contacted 48-72h before their procedure via telephone using a standardized script and will be provided a link to a website allowing posting of videos for public viewing
224219982|NCT03185299|OTHER|Standard preparation instructions|The control arm will receive written instruction on preparing for a colonoscopy per standard of care
224219983|NCT01692418|DRUG|Ferric carboxymaltose|1000mg of ferric carboxymaltose will be administered as an i.v. infusion (100ml normal saline)
224219984|NCT01692418|DRUG|Normal saline|Normal saline will be administered as an i.v. infusion (100ml normal saline)
223631427|NCT03182374|DEVICE|Synvisc-One|Intra-articular injection
223764252|NCT06476587|OTHER|Sleep quality assessment|"Participants will have to complete five standardised clinical questionnaires: Pittsburgh Sleep Quality Index; Spiegel questionnaire assessing sleep quality; Morningness-Eveningness questionnaire; Insomnia Severity Scale; and Epworth Sleepiness Scale.~Moreover, the activity/rest rhythm will be measured continuously by actimetry over a period of 11 days.~The volunteer will also have to wear a Somno-Art® bracelet all night long during the eleven days of monitoring to collect the volunteer's actimetry and heart rate in order to specify which sleep stage the volunteer is in and thus monitor changes in sleep stages over the course of the night.~Finally, participants will have to complete a sleep diary."
224219985|NCT05882968|DIAGNOSTIC_TEST|kidney function tests|using GFR test according to kdigo guide lines
224219986|NCT03805178|DRUG|Belatacept|"Initial phase: 10 mg/kg on days 0 and 4, and again at weeks 2 and 4. Maintenance phase: 10 mg/kg every month beginning 4 weeks after completion of the initial phase.~No dosage adjustments required for renal or hepatic impairment. No known drug interactions for usual post-transplant medication regimen."
224219987|NCT03805178|DRUG|Carfilzomib|20mg/m2 Plasmapheresis
224219988|NCT06150131|OTHER|Exercise|Aerobic and strength exercise.
224219989|NCT06150131|OTHER|Exercise|Aerobic and strength exercise.
224219990|NCT01080105|BEHAVIORAL|AIM Web based intervention + surveillance|The web based intervention will include 12 weeks of Internet-based cognitive behavioral therapy combined with brief telephone and email support from a coach. Surveillance will consist of monthly screening of depression symptoms and outreach from the coach should there be an increase in symptoms.
224219991|NCT01080105|BEHAVIORAL|AIM web based intervention|The web based intervention will include 12 weeks of Internet-based cognitive behavioral therapy combined with brief telephone and email support from a coach.
223631428|NCT04228523|OTHER|Therapeutic education workshop|"Workshop on Parkinson disease drug has several educative sequences (lasting 4hours).~* A first round table is organized to know the needs and issues related to drug management of patients.~* The 1st educative sequence consists in knowing the different class of dopaminergic drugs and their action.~* The 2nd educative sequence leads patients to understand their prescription and be aware of the needs to take pills regularly.~* The 3rd educative sequence consists in learning and identifying potentials adverse effects and finds effective strategies to prevent them.~At the end, one patient explains its tips and tricks about its drug management"
223631429|NCT04228523|OTHER|Speaking Therapy|Speaking group is leaded by a psychologist from Centre Expert Parkinson (lasting 2 hours). This specific time is an exchange between patients with Parkinson disease who feel free to come. It is about sharing its own experience. It is a very special moment, confidential and kindly where patients don't judge themselves and speak only if they want to.
223631430|NCT05077202|DEVICE|ultra sound|chest ultrasound
223631431|NCT04103138|DEVICE|Sedline EEG sensor placement|Patients will have Sedline EEG sensor placed before or immediately after induction.
223631432|NCT04103138|DEVICE|Sedline EEG monitoring|Anaesthesia depth will be guided by EEG characteristics in addition to routine clinical parameters
223631433|NCT04790617|BEHAVIORAL|Community Health Navigator Program|Patients will be matched to a community health navigator (CHN) who will conduct a needs assessment to determine the frequency of meetings. A CHN may perform any of the following: providing information to a patient's health care provider, translation, advocating for the patient, connecting the patient with resources (e.g., social, financial, insurance), helping patients set health-related goals, facilitating health care referrals and appointments, and monitoring appointments. These activities may require the CHN to be physically present at appointments or have direct contact with the patient's health care provider. Goal setting and support will be provided in-person or over the telephone using motivational interviewing principles.
223631434|NCT02360254|DRUG|Insulin degludec|Once daily injection of insulin degludec
223631435|NCT01148368|DRUG|fimasartan|single administration of fimasartan 120mg
223631436|NCT04231578|BEHAVIORAL|Couple HOPES Guided, Internet-Delivered, Self-Help Intervention|Couple HOPES is a guided self-help intervention for individuals with PTSD and their partners based on Cognitive-Behavioral Conjoint Therapy for PTSD (Monson \& Fredman, 2012). This intervention consists of text and video-based content across seven intervention modules and phone and online-based coaching sessions with a paraprofessional. Participants are able to complete these modules in their own home or private location of their choosing. The primary outcomes are PTSD symptoms, relationship satisfaction, and the mental health and wellbeing of partners of those with PTSD.
223631437|NCT02629718|DRUG|NACT (Paclitaxel + Cisplatin or carboplatin)|Paclitaxel 150mg/m2 over 3 hours + Cisplatin 70mg/m2 or carboplatin AUC = 6, repeat per 21 days, 3 cycles.
223631438|NCT02629718|PROCEDURE|radical surgery|Radical hysterectomy (Piver Type III or Type IV hysterectomy) plus bilateral pelvic lymph node dissection and para-aortic lymph node dissection or sampling
223764253|NCT06476587|OTHER|Representation of space and time assessment|"* Classic geometric illusions (inverted T, Mueller-Lyer, Ponzo, Poggendorff, Zoellner, Hering) which generate systematic distortions will be used.~* Time perception task: Participants will wear a virtual reality headset in which instructions will appear for 6 consecutive tasks each repeated 10 times with different durations.~* Perception of rotation amplitude and duration: Participants will be seated on a rotating chair, in complete darkness with noise-cancelling headphones. Participant will have to estimate the duration and the amplitude of rotations of the chair.~* Perceptual time constant: Participants will be seated on a rotating chair, in complete darkness, with a mask over their eyes and noise-cancelling headphones. After each chair rotation, participants will have to turn a crank every time the chair stops and reproduce their sensation of rotation in terms of direction (left or right) and intensity."
224219992|NCT01080105|BEHAVIORAL|Educational website|Participants will receive access to a static educational website for 12 weeks.
223631439|NCT03085095|DRUG|Relugolix|Relugolix 120-mg tablet administered orally once daily following an oral loading dose of 360 mg (3 x 120-mg tablets) on Day 1
223631440|NCT03085095|DRUG|Leuprolide Acetate|Leuprolide acetate depot suspension, 22.5 mg (or 11.25 mg in Japan, Taiwan, and China), every 3 months by subcutaneous injection
223631441|NCT00894816|DIETARY_SUPPLEMENT|Lactobacillus F19|Infant cereals with the addition of Lactobacillus paracasei subsp. paracasei strain F19 (LF19)10E8 CFU per serving
223631442|NCT00894816|DIETARY_SUPPLEMENT|Placebo|Infant cereals without any addition
223631443|NCT06380491|DRUG|Melatonin 3 MG Oral Tablet|Participants with OSA and nocturnal non-dipping Blood Pressure will be randomly assigned to a treatment with melatonin 3mg/d or to receive only the usual care.
224219993|NCT02475967|OTHER|Intervention group|The intervention group patients have access to the eLearning platform in addition to conventional cardiac care.The content of platform will be gathered from a multidisciplinary input of both medics (e.g. cardiologists) and paramedics (e.g. psychologists). Patients will also contribute to platform content.
224219994|NCT02475967|OTHER|Control group|The control group patients receive conventional cardiac care alone.
224219995|NCT01618773|DRUG|0.1% adapalene / 2.5% benzoyl peroxide|topical application
224219996|NCT00057018|PROCEDURE|Constraint-induced movement therapy|
224219997|NCT03938298|OTHER|ENDS (vaporizer/e-cig) and smoking cessation counseling|"Participants in the intervention group will receive an ENDS and nicotine-containing e-liquids, which they will be allowed to use ad libitum. Additionally, they will receive standards of care, i.e. smoking cessation counseling and encouragement to use NRT. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date and again at week 1, 2, 4 and 8 after the target quit date. All participants will be followed over a 6-month period. After 6 months, participants will be asked to come to a final clinical visit.~PFT and MBW will be performed at baseline and after the 6 months follow-up period in all participants of the substudy."
223631444|NCT02572102|DIETARY_SUPPLEMENT|Energy Drink|Energy Drink, two 16oz containers consumed in 45 minutes
223631445|NCT02572102|DIETARY_SUPPLEMENT|Panax Ginseng|Panax Ginseng, lime juice, water and cherry flavoring
223631446|NCT02572102|OTHER|Placebo|Lime juice, water and cherry flavoring
223631447|NCT00408317|DRUG|Ultrase® MT20|Ultrase® MT 20 capsules containing enteric-coated minitablets orally daily at a dose stabilized during the first stabilization period (4 days), as per investigator's discretion, for 6 to 7 days in either first intervention period or second intervention period.
223631448|NCT00408317|DRUG|Placebo|Placebo matched to Ultrase® MT 20 capsules orally daily for 6 to 7 days in either first intervention period or second intervention period.
223631449|NCT05649215|OTHER|No intervention will be applied.|This is a questionnaire study.
223631450|NCT00813241|DRUG|celecoxib reference formulation|200 mg single oral dose of celecoxib tablets
223631451|NCT00813241|DRUG|celecoxib test formulation A1|150 mg single oral dose of celecoxib A1 formulation tablets
223631452|NCT00813241|DRUG|celecoxib test formulation B2|150 mg single oral dose of celecoxib B2 formulation tablets
223631453|NCT00813241|DRUG|celecoxib test formulation C1|150 mg single oral dose of celecoxib Cl formulation tablets
223631454|NCT02545985|DEVICE|Prolim stent deployment|Prolim stent was implanted in patients who signed the informed consent and met the exclusion and inclusion criteria.
223631455|NCT05771987|PROCEDURE|pace maker implant guided by acute hemodynamic testing|To evaluate the ability of acute hemodynamic testing to optimize pacing therapy and to predict the response of HOCM to pacing
223631456|NCT01110902|DRUG|Agomelatine (AGO178C)|
223631457|NCT01110902|DRUG|Placebo|
223631458|NCT01334177|DRUG|TLR8 agonist VTX-2337|Given SC
223631459|NCT01334177|BIOLOGICAL|cetuximab|Given IV
223764254|NCT06476587|OTHER|Influence of vestibular information on the bodily self-consciousness|"Participants will wear a virtual reality headset which allows them to be immersed in a virtual room similar in appearance to the one they are in. They will sit on a stool and hold a joystick in their hand. An avatar seen from behind, also sitting on a stool, will be presented in the centre of the virtual room approximately 2 m from them. The experimenter will touch several areas of the participant's back, over his clothes, with the end of the joystick. This movement will be reproduced by the virtual joystick in contact with the avatar's back, in two conditions: the synchronous condition, and the asynchronous condition.~After 2 min of stimulation, participants will perform a mental imagery task: a ball in the background of the virtual scene will roll towards them. After 3'', a black screen will appear and participants will have to imagine that the ball keeps moving towards them at the same speed. They will have to press the trigger when they think the ball has reached their level."
224317939|NCT03368456|BEHAVIORAL|Usual Care|Participants in Usual Care (i.e., Control Condition) will not receive the S4E intervention from the study staff. The Clinic's usual care includes a standard risk behaviors intake form, pamphlets highlighting resources, and reproductive and healthcare services.
224317940|NCT06223776|PROCEDURE|Sleep restriction|Participants will experience a night of acute sleep restriction. During this night, they will sleep 3 hours less than usual.
224317941|NCT07135128|DRUG|225Ac-FAPI-XT|Patients will receive \[225Ac\]Ac-FAPI-XT(XT117) administration at an interval of 6 weeks between each dose.
224317942|NCT07133698|DEVICE|High Flow nasal Cannula|"Eligible subjects successfully passing a SBT will be extubated and immediately randomized (1:1:1) to receive one of the following post-extubation respiratory supports for ≥24 hours:~HVNI Arm: High-Velocity Nasal Insufflation (Flow: 40-60 L/min, FiO₂ titrated to SpO₂ ≥92%)."
223631460|NCT01334177|OTHER|laboratory biomarker analysis|Correlative studies
223631461|NCT01334177|OTHER|pharmacogenomic studies|Correlative studies
223631462|NCT03694886|DRUG|Caffeine Anhydrous with small sucrose pill|caffeine anhydrous that has been weighed out to 90 mg per dose presented with a 1 mm sucrose pillule
223631463|NCT03694886|OTHER|Placebo - large sucrose pill|sucrose pillules of 5 mm diameter will be given to all participants in the large pill groups
223631464|NCT03694886|DRUG|Caffeine Anhydrous with large sucrose pill|caffeine anhydrous that has been weighed out to 90 mg per dose presented with a 5 mm sucrose pillule
223631465|NCT03694886|OTHER|Placebo - small sucrose pill|sucrose pillules of 1 mm diameter will be given to all participants in the small pill groups
223631466|NCT05100550|DIETARY_SUPPLEMENT|Zinc|Zinc is given as written in the arm description, two hours after lunch
223631467|NCT05100550|OTHER|Control|This group will not receive zinc
224317943|NCT07133698|DEVICE|High velocity nasal insufflation|HFNC Arm: High-Flow Nasal Cannula (Flow: 50-60 L/min, FiO₂ titrated to SpO₂ ≥92%).
223631468|NCT05642403|DRUG|XW001|Inhaled XW001
223631469|NCT05642403|DRUG|Placebo|Matched inhaled placebo
223631470|NCT05765916|BEHAVIORAL|Online mindfulness and acceptance intervention|"Session 1 aims to encourage participants to share their experiences; and introduce the purpose, content, delivery mode, duration, and frequency of the intervention.~Session 2 aims to explain how negative illness perceptions lead to fear of cancer recurrence; and introduce the signs, screening, treatment and prognosis of breast cancer, ways to reduce the risk of recurrence, and symptom management.~Session 3 aims to guide the participants to practice body scan and seated meditation.~Session 4 aims to guide the participants to practice detached mindfulness, promoting reflection on the negative effect of indulging in unhelpful thoughts.~In session 5, participants will receive several forms covering work, health, parenting style, intimate relationships, self-development and so on. Participant will be asked to choose one or two forms and set action plans.~In session 6, the facilitator will invite participants to recall positive experiences and practice the Self-care exercise."
223631471|NCT04461717|DEVICE|MicroNet covered stent implantation in the increased risk arterial lesions beyond the carotid bifurcation|Implantation of the MicroNet covered stent in the increased risk arterial lesions beyond the carotid bifurcation as per Vascular Team recommendation
223631472|NCT03822117|DRUG|Pemigatinib|Pemigatinib administered orally once daily (QD).
223631473|NCT02279914|DRUG|Misoprostol 400 mcg 3 hours prior to procedure|Misoprostol 400 mcg 3 hours prior to D\&E procedure
223631474|NCT02279914|DRUG|Misoprostol 600 mcg 90 minutes prior to procedure|Misoprostol 600 mcg 90 minutes prior to D\&E procedure
223631475|NCT04317287|DIETARY_SUPPLEMENT|Cardio formulation|Tomato-based formulation with dietary supplement softgels
223631476|NCT04317287|DIETARY_SUPPLEMENT|Placebo|Placebo softgels
223631477|NCT04144608|DRUG|Toripalimab|Nab-paclitaxel/pem +cisplatin +PD-1(Nab-paclitaxel260mg/m2 D1 Cisplatin 75mg/m2 D1 or carboplatin,determined by the investigator AUC)PD-1 200mg D1
224317944|NCT07133698|DEVICE|Noninvasive ventilation|NIV Arm: Non-Invasive Ventilation (Mode: \[e.g., PSV\], IPAP: \[e.g., 8-12 cmH₂O\], EPAP: \[e.g., 4-6 cmH₂O\], FiO₂ titrated to SpO₂ ≥92%) delivered via \[e.g., oronasal mask\] for ≥16 hours/day initially, with weaning per protocol.
224317945|NCT07133555|OTHER|Healthcare counseling service|Using peer health navigators to support linkage to HIV prevention and treatment resources among Black MSM in online spaces following mobile testing.
223631478|NCT00445042|DRUG|Sorafenib|The initial dose of Sorafenib will be administered orally with a dose of 400 mg twice a day, daily. Intrapatient dose escalation will occur as defined in the protocol, providing no dose limiting toxicity (Grade 3 or 4) is observed.
223631479|NCT01074502|DRUG|apremilast|apremilast 20 mgs orally twice a day for 12 weeks
223631480|NCT03117010|DRUG|Steroids|High dose dexamethasone 20 mg PO or IV
223631481|NCT03117010|DRUG|Etoposide|Etoposide 150mg/BSA
223631482|NCT03874338|DRUG|Colchicine Pill|Participants in the main CLEAR SYNERGY trial are randomized to colchicine/spironolactone versus placebo in a 2x2 factorial design. The substudy is interested in the evaluation of biospecimens obtained from patients in the colchicine vs placebo group.
223631483|NCT01708200|OTHER|Memory Intervention|A comparison of two type of memory intervention protocols; a psychoeducational/intervention protocol versus a computerized memory protocol in a population of individuals with mental illness.
223631484|NCT04506229|GENETIC|Whole exome sequencing|MoCA survey to evaluate cognitive function in COVID-19 positive cases with vs without neurological symptoms
223631485|NCT03198715|DRUG|DS1040b|DS-1040b in solution for intravenous infusion
223631486|NCT03198715|DRUG|Placebo|Saline solution for intravenous infusion
223631487|NCT02040324|DEVICE|Laryngeal mask with gastric access|
223631488|NCT02040324|DEVICE|Endotracheal tube|
223631489|NCT00615303|DRUG|Simethicone|2 dosages of either 45 ml of sodium phosphate plus 240 mg of simethicone tablets or 45 ml of sodium phosphate plus placebo in the evening before and in the morning of the procedure day. The colonoscopic examination was recorded
223631490|NCT00615303|DRUG|Placebo|2 dosages of either 45 ml of sodium phosphate plus 240 mg of simethicone tablets or 45 ml of sodium phosphate plus placebo in the evening before and in the morning of the procedure day
223764255|NCT06476587|OTHER|3 Tesla MRI|"The imaging evaluation will include an acquisition of anatomical images of the brain in its entirety and centred on the hippocampus.; and T2\*-weighted images sensitive to the blood-oxygen-level-dependent (BOLD) effect to assess functional brain activation during cognitive tasks and functional brain connectivity during rest.~For the functional activation sequences, three activation tasks will be performed, each lasting approximately 5 minutes: a mental rotation task, a time estimation task, and a prediction task.~These acquisitions will be combined with a collection of cardiorespiratory variables: respiratory movements and plethysmography. These signals will be used in the pre-processing of the functional MRI to remove physiological noise from the BOLD signal."
223764256|NCT06425458|BEHAVIORAL|Co-Designed Strengths-Based Leadership Program|Please see arm description.
224219998|NCT03938298|OTHER|Smoking cessation counseling|"Participants in the control group will receive standard of care only, i.e. i.e. smoking cessation counseling and encouragement to use NRT. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date and again at week 1, 2, 4 and 8 after the target quit date. All participants will be followed over a 6-month period. After 6 months, participants will be asked to come to a final clinical visit.~PFT and MBW will be performed at baseline and after the 6 months follow-up period in all participants of the substudy."
224219999|NCT01412073|DRUG|oxytocin|group I : oxytocin 5 IU bolus over 3 minutes after delivery of the baby group II : oxytocin 5 IU bolus over 3 minutes after delivery of the baby and oxytocin infusion in 500 ml 0.9% saline over 4 hours
224220000|NCT01412073|DRUG|Misoprostol|misoprostol intrauterine 800 microgram placed intrauterine after delivery of the baby \& the placenta
223631491|NCT02628288|DEVICE|Coronary Bifurcation PCI|In one group, the coronary bifurcation lesion will be treated (Coronary bifurcation PCI) with the Axxess device + Absorb BVS. In the other group, the coronary bifurcation lesions will be treated(Coronary bifurcation PCI) by modified T stenting using Absorb BVS.
223631492|NCT06514625|DEVICE|splint|ready night splints
223631493|NCT04699617|DEVICE|Dolphin 2.0|The Dolphin 2.0 is a platform that runs an immersive virtual reality software, based on an oceanic environment, where players control simulated creatures.
223631494|NCT04105036|OTHER|Data Collection|Telephone interview questionnaire, in-home face-to-face interview, and data from the Collection Site
223631495|NCT03182049|PROCEDURE|Airway assessment|Airway Specialist (Otolaryngology, Pulmonology, Thoracic Surgery), assess clinical location and degree of airway compromise, glottic mobility, and sinonasal disease.
223631496|NCT03182049|PROCEDURE|Rheumatology assessment|Clinically assess systemic function (renal/pulmonary ect), biochemical profile (routine labs), neurocognitive function, and completing entry BVAS tool.
223631497|NCT00520182|BEHAVIORAL|MUFA diet|Patients were advised to consume 23 cal/kg/day. The diet contained sodium (up to 3000mg/day), potassium (more than 3000 mg/day), calcium (around 1300 mg/day) and magnesium (more than 800 mg/day). MUFA diet included only low glycemic index carbohydrates. The diet consisted of 35% carbohydrates and 45% fat (50% of them were mono-unsaturated fatty acids \[MUFA\]). Participants were advised to eat 4-6 meals per day according to their lifestyle and to participate in 30-45 min of aerobic activity at least 3 days a week.
223631498|NCT00520182|BEHAVIORAL|ADA 2003|Patients were advised to consume 23 cal/kg/day. The diet contained sodium (up to 3000mg/day), potassium (more than 3000 mg/day), calcium (around 1300 mg/day) and magnesium (more than 800 mg/day). The carbohydrates are with mixed glycemic index. The diet contains 50-55% carbohydrates, 30% fat and 15-20% protein. Participants were advised to eat 4-6 meals per day according to their lifestyle and to participate in 30-45 min of aerobic activity at least 3 days a week.
223631499|NCT00520182|BEHAVIORAL|Low Glycemic index (LGI) diet|Patients were advised to consume 23 cal/kg/day. The diet contained sodium (up to 3000mg/day), potassium (more than 3000 mg/day), calcium (around 1300 mg/day) and magnesium (more than 800 mg/day). LGI diet included only low glycemic index carbohydrates. The diet consisted of 50-55% carbohydrates, 30% fat and 20%. protein. Participants were advised to eat 4-6 meals per day according to their lifestyle and to participate in 30-45 min of aerobic activity at least 3 days a week.
224220001|NCT06538974|DEVICE|Hands-free exoskeleton|During the one-year intervention period, participants will complete at least one exoskeleton session per week (≥36 sessions) with the Atalante X. The additional voluntary year follows the same design. During sessions with the exoskeleton, the patients will perform ambulatory exercises with the device, with a gradual increase of intensity through the sessions.
224220002|NCT02754180|DRUG|Gemcitabine|gemcitabine 1g/m2 iv d1, 8, 15, q4wks. 6 cycles
224317946|NCT07135050|GENETIC|MZ-1866|AAV-9 gene therapy delivered by intracerebroventricular injection
223631500|NCT05085938|PROCEDURE|gonadal vein embolization|"GVE was performed under local anesthesia with 5.0-10.0 mL of 0.5% lidocaine solution with a patient under intravenous sedation. For the left GV embolization, the transfemoral approach was used, while for the right or both GV embolization, the transjugular approach was used. The 5F multipurpose angiographic catheters (Cordis; USA), standard 'moving core' J .035 guidewire, and an angled hydrophilic guidewire (Radiofocus; Terumo Corp., Japan) were used. For the GV occlusion, the pushable 0.035 standard stainless steel coils (Gianturco; William Cook, Bjæverskov, Denmark) and 0.035 coils made of Inconel with interwoven long collagen fibrils (MReye; Cook Medical Inc., Bloomington, USA) were used. The diameter of coils was 8-12 mm, and the length was 10-20 cm."
223631501|NCT04764071|PROCEDURE|percutaneous nephrolithotomy|percutaneous access of the desired calyx is achieved under fluoroscopic guidance with the use of an 18-gauge needle and a guidewire passage. Tract dilation is accomplished by using Amplatz dilators up to 30F.
223631502|NCT04764071|PROCEDURE|ultra-mini percutaneous nephrolithotomy|percutaneous access of the desired calyx is achieved under fluoroscopic guidance with the use of an 18-gauge needle and a guidewire passage. Tract dilation is accomplished by using Amplatz dilators up to 12-14 F fascial dilator was used to dilate the nephrostomy tract to pass the 13 F semi-rigid plastic sheath.
223631503|NCT06956612|DIETARY_SUPPLEMENT|Control (Placebo comparator)|The control group will consume a placebo supplement, entirely free of nitrate, in the form of juice (70 ml) for four weeks while maintaining their habitual diet.
223631504|NCT06956612|DIETARY_SUPPLEMENT|Juice (Active comparator)|The juice group will consume a beetroot supplement enriched with \~400 mg of nitrate in juice form (70 ml) for four weeks while maintaining their habitual diet.
223631505|NCT06956612|DIETARY_SUPPLEMENT|Crystals (Experimental)|The crystals group will consume a beetroot supplement enriched with \~400 mg of nitrate in crystals form (20g) for four weeks while maintaining their habitual diet.
223631506|NCT00616759|PROCEDURE|electroconvulsive therapy|electroconvulsive therapy as usual
223631507|NCT00616759|PROCEDURE|electroconvulsive therapy plus propofol|electroconvulsive therapy identical to the comparator group except that propofol 0.5 mg/kg is given intravenously 15 seconds after the electrical stimulation at each treatment in order to terminate the ECT-induced seizure
223631508|NCT00616759|DRUG|propofol|Propofol 0.5 mg/kg intravenously given 15 seconds following electrical stimulation
223631509|NCT04754048|DEVICE|Avance Solo NPWT System|Wound treatment with Avance Solo NPWT System for up to 28 days.
223631510|NCT04334967|DRUG|Hydroxychloroquine|Treatment arm medication will be administered on an outpatient basis. Due to the emergent health crisis, study drug will be delivered to patients by institution staff or contract courier using a non-contact protocol.
223631511|NCT04334967|DIETARY_SUPPLEMENT|Vitamin C|Control arm supplement will be administered on an outpatient basis. Due to the emergent health crisis, study supplies will be delivered to patients by institution staff or contract courier using a non-contact protocol.
223631512|NCT03553693|OTHER|RAPID-VL study intervention|"* Viral load (VL) ordering flowsheet with periodic health facility performance feedback~* Rapid near-point-of-care VL testing and telephone delivery of results~* Structured VL counseling package"
223631513|NCT01605708|DRUG|REGN846|Dose 1
223631514|NCT04254380|BIOLOGICAL|Gan & Lee Insulin Lispro Injection|Route of administration: subcutaneous injection
223631515|NCT04254380|BIOLOGICAL|Humalog|Route of administration: subcutaneous injection
224220003|NCT02754180|RADIATION|TS-1 with radiation|gemcitabine 1g/m2 iv d1, 8, 15, q4wks. 6 cycles. Followed by TS-1 based chemoradiation. TS-1 40mg/m2 bid, 5 days/week, with radiation.
224317947|NCT07133282|BEHAVIORAL|Group exercise programme|12-week group exercise programme
224317948|NCT07134595|OTHER|C-CAPD Prescription|The prescription for the M-CAPD therapy is the C-CAPD with an additional 1 to 2 short, low-volume, 15 to 30-minute dwells per exchange before instilling the computed full dwell volume.
223631516|NCT01591200|BIOLOGICAL|Allogeneic Mesenchymal Stem Cells|High dose of Bone Marrow Derived Allogeneic Mesenchymal Stem Cells will be administered through the hepatic artery
223631517|NCT01591200|BIOLOGICAL|Allogeneic Mesenchymal Stem Cells|Intermediate dose of Bone Marrow Derived Allogeneic Mesenchymal Stem Cells will be administered through the hepatic artery
223631518|NCT01591200|BIOLOGICAL|Allogeneic Mesenchymal Stem Cells|Low dose of Bone Marrow Derived Allogeneic Mesenchymal Stem Cells will be administered through the hepatic artery
223631519|NCT04154072|DRUG|NLY01|exenatide and polyethylene glycol (PEG)
223631520|NCT04154072|DRUG|Vehicle|Saline (Sodium Chloride)
223631521|NCT02784886|BIOLOGICAL|Women at high risk of MAP|Blood sample
223631522|NCT03906019|PROCEDURE|ESP Block|Erector spinae plane block performed with 0,25% bupivacaine (0,5 mL/kg-max 20mL), under general anesthesia before the start of the surgery.
223631523|NCT03906019|DIAGNOSTIC_TEST|FLACC score|For up to 7 years old patients, Face, Legs, Activity, Cry and Consolability (FLACC) scores during postoperative 24h period.
224220004|NCT03634488|DRUG|hydroxyurea (20mg/kg/day)|Treatment of severe malnutrition in children with SCA in northern Nigeria
224220005|NCT03634488|DIETARY_SUPPLEMENT|Ready-to-use therapeutic food|Treatment of severe malnutrition in children with and without SCA in northern Nigeria with an additional 500-1000 calories from ready-to-use-therapeutic food
224220006|NCT05103488|OTHER|Comprehensive palliative care|CPC is multidisciplinary inpatient care that aims to respond to patients' suffering in many aspects: physical, psychological, social, and spiritual. It is basically a standard palliative care service in Vietnam with additional psychosocial and spiritual support with a multidisciplinary approach.
224317949|NCT07134595|OTHER|M-CAPD Prescription|The prescription for the M-CAPD therapy is the C-CAPD with an additional 1 to 2 short, low-volume, 15 to 30-minute dwells per exchange before instilling the computed full dwell volume.
224317950|NCT07133334|OTHER|Selenium disulfide|1% SeS2
224317951|NCT07133334|OTHER|Piroctone olamine|0.5% piroctone olamine
224317952|NCT07133542|BEHAVIORAL|Dynamic Matrix Management for Weight Control (DMM-WC)|Precision weight management using a two-dimensional grid model. Participants undergo bi-weekly positioning on a waist risk-body fat matrix (9 grids), receiving tiered interventions (e.g., high-intensity exercise + dietary control for high-risk grids; maintenance plans for low-risk grids). Real-time progress feedback via visual spatial migration maps promotes adherence. Comparator group receives standardized aerobic prescription without dynamic adjustments.
223631524|NCT03906019|DIAGNOSTIC_TEST|NRS score|Patients older than 7 years, NRS scores during postoperative 24h period.
223631525|NCT04306276|DRUG|Dienogest 2 MG|Three-month treatment with DNG (2 mg daily; Visanne, Bayer Pharma, Germany) before IVF
223631526|NCT00976183|DRUG|Vorinostat|Vorinostat will start at 200 mg QD on weeks 1 and 3, and escalating to 300 mg QD after safety has been evaluated following 2 cycles of treatment. If safety is acceptable, then the following patients could be treated at 400 mg QD on weeks 1 and 3.
223631527|NCT00976183|DRUG|Vorinostat|Vorinostat will be given as a lead-in dose escalation starting at 200 mg QD.
224220007|NCT05103488|OTHER|Standard of care|Patients who are randomized to the control group will receive the standard palliative care in Vietnam. They can assess to the same palliative care for their physical symptoms as patients in the intervention group do. They can also access psychosocial and spiritual support from the resources that available for them before entering to the study. If they request for social or financial support, their care team can reach out to the social work departments. Patients who are in need can receive mental health care from psychiatrists from the psychiatrist unit at UMC.
223631528|NCT05728437|PROCEDURE|Resistance exercise|The program will consist of seven exercises: triceps press, biceps curl, lat pull down, calf raise, leg press, leg extension and sit-ups using dumbbells and sand bags. Each session will last approximately 45 minutes and consist of a 5-minute warm-up with stretching following by resistance exercise that will be done as a cir¬cuit, ending with 5-minute cool down. The 1 repetition maximum (1RM) is measured at baseline and follow¬ing the intervention. Initially, participants will do two circuits using 50% of their 1RM and repeat them 10 times for the first and second weeks, progressing to two circuits, using 60% of their 1RM and repeat 10 times for the third and fourth weeks. In fifth and sixth weeks, participants will do three circuits using 60% of their 1RM and repeat 10 times. In the last two weeks, patients will do three circuits using 70% of their 1RM and repeat 10 times. A 90-second rest will be allowed between sets of exercises.
223631529|NCT01417806|DRUG|Topotecan and Pasireotide|Topotecan 1.5mg/m2 dailyx5 days and Pasireotide 60 mg IM every 28 days
224220008|NCT06539065|DEVICE|VR interactive games|The experimental group received a twelve-week intervention of 36 sessions using VR interactive games in their exercise prescription,
224220009|NCT03182686|BIOLOGICAL|4 mL injection of Ampion|4 mL injection of Ampion
224220010|NCT03182686|DRUG|4 mL Injection of Placebo|4 mL Injection of Placebo
224220011|NCT00817466|DRUG|Racemic adrenaline|"For inhalation.~Dosing (as in previous study):~1\) 0,1ml\<5kg, 0,15ml 5-6,9kg, 0,20ml 7-9,9kg, 0,25ml \>10kg of racemic adrenaline 20mg/ml diluted in 2ml NaCl 9mg/ml.3~Maximum 12 inhalations/24 hours. One bottle (10ml) per patient. The bottles will be marked with the name of the study and a randomisation number."
224220012|NCT00817466|DRUG|Isotonic saline|2ml NaCl 9mg/ml.
224220013|NCT06521606|PROCEDURE|Primary open reduction and internal fixation|The percutaneous pin was used to manipulate the fragment to achieve reduction; then, a lag screw fixation was done by antegrade technique through a stab incision posteriorly and directly over the fragment. The medial fragment was fixed after the reconstruction of the tibial articular surface to facilitate the anatomic reduction of joint fragments. Again, an image intensifier was used to check the reduction and fixation and to avoid errors of penetration of the joint by screws, malalignment, and inadequate reconstruction of the articular surface; then, the necessary changes were adjusted and made. Wide bone defects in six cases of the primary ORIF cohort and eight cases of the two-stage cohort were packed by corticocancellous iliac bone grafts.
224220014|NCT06521606|PROCEDURE|Temporary external fixator|). Schanz screws with a 6 mm diameter were used to simulate the gripping points on the tibial crest at the proximal metaphyseal or diaphyseal level and on the medial side of the heel bone. This latter pin was carefully inserted medial to lateral, ensuring the starting point is two cm anterior and proximal to the posteroinferior aspect of the calcaneal tuberosity to avoid injury to the medial neurovascular bundle and prevent injury iatrogenic fracture. Such posterior pin placement better balances the deforming forces of the powerful triceps surae muscles. To prevent equinus contracture and provide additional stability. Medial and lateral side rods were then connected to the pins. Manual traction was applied to the exoskeleton base during ligamentotaxis to distract the joint and realign the fracture; this distraction was then kept in place by tightening the clamps.
224220015|NCT06355960|DRUG|GROUP Dexmedetomidine|Dexmedetomidine (Precedex) loadings of 1 μg/kg , then continuously at a rate of 0.2 μg/(kg/h) till the end of the operation .
224220016|NCT06355960|DRUG|GROUP B|Dexmedetomidine (Precedex) loadings of 0.5 μg/kg , then continuously at a rate of 0.2 μg/(kg/h) till the end of the operation .
224220017|NCT06355960|DRUG|GROUP C|Dexmedetomidine (Precedex) loadings of 0.25 μg/kg, then continuously at a rate of 0.2 μg/(kg/h) till the end of the operation .
224220018|NCT03909568|PROCEDURE|Third molar surgery|Comparing complete removal of third molar with removal of crown only on contralateral side
223631530|NCT00834977|DRUG|Amlodipine-benazepril 10 mg-20 mg capsules|1 x 10-20 mg
223631531|NCT00834977|DRUG|Lotrel® 10 mg-20 mg capsule|1 x 10-20 mg
223631532|NCT03376880|OTHER|1 year follow-up testing|The approach of the study is not in studying the effectiveness of the intervention stimulus, the dose response of diet and exercise, or the rate of weight loss but only the response to 1) weight loss and regular exercise or 2) continued weight gain.
223631533|NCT05650606|OTHER|High Intensity Gait Training|Physical therapy intervention for improving gait in patients post Cerebral Vascular Accident.
224220019|NCT04721756|DRUG|18F-LY3546117 Injection|370 megabecquerel (MBq) intravenous injection
224220020|NCT04721756|PROCEDURE|PET Scan|positron emission tomography (PET) scan
224220021|NCT04005105|BEHAVIORAL|Intensive management|Management based on premorbid MAP and MPP
223631534|NCT05650606|OTHER|Conventional Therapy|Standard inpatient rehabilitation physical therapy treatments for Cerebral Vascular Accident.
223631535|NCT06392165|OTHER|self-adhesive device|Test device which is self-adhesive
223631536|NCT01283841|DRUG|Mycophenolate Mofetil|Mycophenolate Mofetil 500 mg tablets
223631537|NCT03119987|DIAGNOSTIC_TEST|Red cell distribution widths|Measured value of Red cell distribution widths in initial laboratory result of blood cell counts at emergency department
223631538|NCT03585881|DEVICE|3DPrinted Windowed Bracket- Positioning tray|3 D printed tray with windows for accurate positioning of brackets
223631539|NCT05533606|DRUG|Beta-Lactam Drugs|During hospitalization，patients used Beta-Lactam drugs.
223631540|NCT00169416|DRUG|valaciclovir HCl granules|
223631541|NCT00726063|DEVICE|Nanotite dental implant|Nanotite root form titanium dental implant
223631542|NCT00726063|DEVICE|Osseotite dental implant|Osseotite Root form titanium dental implant
223631543|NCT05479877|DRUG|sterile medicated collagen particles, Biofil-AB ,Eucare Pharmaceuticals Pvt. Ltd, Chennai, India|Collagen based pulpotomy will be applied (sterile medicated collagen particles, Biofil-AB ,Eucare Pharmaceuticals Pvt. Ltd, Chennai, India)according to the manufacturer's instructions and gently placed over the pulp stumps to a thickness of 2 mm
223631544|NCT05479877|DRUG|Biodentine (Septodont, Saint-Maur-des-Fossés, France)|Biodentine (Septodont, Saint-Maur-des-Fossés, France) will be applied according to the manufacturer's instructions and placed over the radicular pulp with the help of a suitable sterile amalgam carrier. Gentle condensation of the mix will be done in the pulp chamber with a moistened cotton pellet.
223631545|NCT02007096|DRUG|Transabdominal Plane Block|0.25% bupivacaine injection in 6 different locations in abdomen. Weight \<100kg: 50ml total; weight \>100kg: 60ml total
223631546|NCT02007096|DRUG|Non Transabdominal Plane Block|Saline injection in 6 different locations in abdomen. Weight \<100kg: 50ml; weight \>100kg: 60ml
223631547|NCT01529892|DRUG|A single oral 5 mg of duterium labeled methamphetamine|
223631548|NCT03041519|PROCEDURE|Zero-fluoroscopy ablation|Catheter ablation will be performed under the guidance of Ensite NavX and without fluoroscopy.
223631549|NCT03041519|PROCEDURE|Conventional fluoroscopy ablation|Catheter ablation will be performed under the guidance of fluoroscopy pllus Ensite NavX.
223631550|NCT04501523|DRUG|Tislelizumab|200mg, q3w, for 1 year
223631551|NCT04501523|DRUG|capecitabine|600-750 mg/m2 PO Bid，continuous, for 1 year
223631552|NCT06293599|OTHER|scapular stabilization exercises|the patients will receive scapular stabilization exercises in the form of scapular orientation exercises,Forward/Backward Bear Crawls,Lateral Bear Crawls and assisted stretch for pectoralis minor
223631553|NCT06293599|OTHER|virtual reality exercises|"The exercises described were done in a consistent manner, emphasizing low intensity, and using lightweight dumbbells (range, 3 to 30 pounds). The weight of the dumbbell was individually selected by the subject for each exercise.~1. elevation of the arm in the sagittal plane (shoulder flexion~2. elevation of the arm in the scapular plane with humeral external rotation (shoulder scaption~3. elevation of the arm in the coronal plane (shoulder abduction)~4. rowing~5. horizontal shoulder abduction~6. horizontal abduction with humeral external rotation~7. push-up with hands apart~8. push-up with a plus-normal push-up adding maximum shoulder and scapular protraction with elbows fully extended~9. dumbbell bench press~10. dumbbell military press~11. shoulder shrug~12. deceleration exercise-simulating the pitching followthrough~13. shoulder extension prone~14. shoulder internal rotation~15. shoulder external rotation~16. press-up"
223631554|NCT06293599|OTHER|regular routine exercises|the patients will receive routine exercises in the form of Sleeper Stretch: Posterior Capsular Stretch, Push up, Wall slides, Kettlebell High Pull,
223631555|NCT00006461|DRUG|cisplatin|Given IV
224220022|NCT06542848|OTHER|Physiotherapy and Rehabilitation Practices|The treatment program consisted of 3 sessions per week, each lasting 45 minutes. The rehabilitation program included 30 minutes of conventional TENS application to the wrist extensor muscles and quadriceps muscle, upper and lower extremity exercises, balance and coordination exercises, and weight transfer exercises. The upper extremity exercises consisted of range of motion exercises for the shoulder joint, while the lower extremity exercises included range of motion exercises for the hip, knee, and ankle joints. Balance exercises included forward, backward, and lateral leaning exercises, as well as weight transfer and stepping exercises in all directions. The treatment duration was planned to be a total of 24 sessions over 8 weeks. Evaluations were conducted before and after the treatment program.
224220023|NCT01696474|DRUG|Bortezomib|
224220024|NCT01783925|DRUG|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|Patients in daily life clinical practice treatment receiving EYLEA according to indication on the label.
224220025|NCT00475111|BEHAVIORAL|Cognitive Behavior Therapy for Pain (CBT-P)|
224220026|NCT00475111|BEHAVIORAL|Mindfulness Meditation for Emotion Regulation (MM-ER)|
224220027|NCT00475111|BEHAVIORAL|Rheumatoid arthritis education|
224220028|NCT00415961|DEVICE|CoStar Paclitaxel Drug-Eluting Coronary Stent System|CoStar Paclitaxel Drug-Eluting Coronary Stent System
224220029|NCT05053178|BEHAVIORAL|Mindfulness-based mandala activity|Mindfulness-based mandala activity was applied to the intervention group via the zoom online program. Students will be divided into groups of 6-10 and mandala activities will be carried out. 3 weeks of mandala activity, breathing exercises, affirmations, etc. a therapeutic application program was created and implemented
224220030|NCT01154127|DRUG|NVA237|50 μg via NEOHALER inhaler device single dose dry powder inhaler (SDDPI) once daily
223631556|NCT00006461|DRUG|cyclophosphamide|Given IV
223631557|NCT00006461|DRUG|vincristine sulfate|Given IV
223631558|NCT00006461|DRUG|etoposide|Given PO
223631559|NCT00006461|PROCEDURE|therapeutic conventional surgery|Undergo surgery
223631560|NCT00006461|RADIATION|3-dimensional conformal radiation therapy|Undergo 3-dimensional conformal radiation therapy
223631561|NCT03740451|OTHER|Active mobilization of soft tissues|This study will compare the effects of joint passive mobilization with the effects of soft tissue active mobilization on heart rate variability (as an indicator of autonomous regulation), psychological well-being (measured by the Ryff scale) and pain in patients with fibromyalgia.
223631562|NCT03740451|OTHER|Passive mobilization|This study will compare the effects of joint passive mobilization with the effects of soft tissue active mobilization on heart rate variability (as an indicator of autonomous regulation), psychological well-being (measured by the Ryff scale) and pain in patients with fibromyalgia.
223631563|NCT03633032|DIAGNOSTIC_TEST|Acquiring of ultrashort echo time (UTE) MRI sequences|Modern MRI sequences (ultrashort echo time (UTE)) for a better depiction of bone anatomy
223631564|NCT00006086|DRUG|BMS-188797|
223631565|NCT00006086|DRUG|carboplatin|
223631566|NCT05517252|OTHER|Tele - Yoga|Telehealth interventions with Yoga are called Tele-yoga. Tele-Yoga aims to provide Yoga support to patients at low cost with the same quality and safety as face-to-face
223631567|NCT05517252|OTHER|Thoracic Expansion Exercise|Thoracic expansion exercises are deep breathing exercises that focus on inspiration and help to loosen secretions on the lungs. Inspiration is active and usually combined with a three-second, end-inspiratory hold before a passive, relaxed and unforced expiration.
223631568|NCT05030337|DEVICE|Closed-loop automated oxygen control (Oxygenie, SLE 6000)|The OxyGenie closed-loop oxygen saturation monitoring software (SLE) uses oxygen saturations from the SpO2 probe attached to the neonate, fed into an algorithm, to automatically adjust the percentage of inspired oxygen to maintain oxygen saturations within the target range. Manual adjustments including the percentage of FiO2 will be allowed at any point during the study if deemed appropriate by the clinical team.
223631569|NCT04595656|OTHER|verbal autopsy interview|The study involves filling of verbal autopsies for deaths in SEACTN villages. This is an observational study being conducted as a substudy of rural febrile project of SEACTN program.
223631570|NCT05690308|OTHER|Visual perturbation treadmill training|12 sessions of (max 30 minutes) walking at comfortable speed on an instrumented treadmill in a virtual reality environment (Gait Real-time Analysis Interactive Lab system, MOTEK) with projected visual perturbations.
223631571|NCT05690308|OTHER|Regular treadmill training|12 sessions of (max 30 minutes) walking at comfortable speed on an instrumented treadmill
223631572|NCT05003505|OTHER|Follow up|Participants will be followed up at 6, 12 and 24 months with the test of enous blood, vaginal secretions, faeces, and cervical exfoliated cells.
223631573|NCT05284773|OTHER|Caretaker MUAC screening - training by health workers|Study personnel will train caregivers to conduct weekly AM screening using the color-coded MUAC tape. AM screening will involve identifying the midpoint of the child's right arm, wrapping the tape around the mid-point, inserting one end of the tape through the slit at the other end, pulling the tape secure, and reading the measurement based on the color bands. Caregivers will be trained to refer children with yellow or red readings to the nearest CSPS and will be provided with a referral slip to do so. Caregivers will be informed of the signs, symptoms, and consequences of malnutrition as well as the available nutritional programs. Study personnel will conduct monthly supervision visits including brief refresher trainings. In all study communities, standard of care screening for AM will continue. This includes biannual community-based screening by community health workers as well as weekly malnutrition days led by the CSPS.
223631574|NCT05284773|OTHER|Caretaker MUAC screening - training by caregivers|Study personnel will train a group of caregivers to perform AM training of all caregivers living in their communities. they will instruct caregivers to conduct weekly AM screening. Training will include the same information as the communities receiving training by Health workers: MUAC training and how to interpret MUAC as well as key concepts of malnutrition. Caregivers will be trained to refer children with yellow or red readings to the nearest CSPS and will be. In all study communities, standard of care screening for AM will continue. This includes biannual community-based screening by community health workers as well as weekly malnutrition days led by the CSPS.
223631575|NCT05719311|DRUG|adrulipase|Enteric microgranule formulation of adrulipase.
223631576|NCT05176314|DRUG|Rosuvastatin|Administered Orally.
223631577|NCT05176314|DRUG|Pirtobrutinib|Administered Orally.
224220031|NCT01154127|DRUG|Placebo|Matching placebo via NEOHALER inhaler device single dose dry powder inhaler (SDDPI) once daily
223631579|NCT06389019|OTHER|Deep learning system for prognostication prediction in bladder cancer|develop and validate a deep learning system for prognostication prediction in bladder cancer based on CT radiomics and whole slide images.
224220032|NCT00863369|BIOLOGICAL|rituximab|Given IV
223631580|NCT04922944|DRUG|COVID-19 vaccine|Two-dose COVID-19 vaccine
223631581|NCT06956469|OTHER|Identification of types of anti-HLA-specific memory LBs|Using blood sample, it will be perform single cell RNA sequencing of sorted anti-HLA B cells, identified with HLA tetramers, of five groups of patients based on their immunization histories. It will be further perform a phenotypic characterization of the tetramer+ anti-HLA B cells using spectral cytometry to study their nature and identify novel markers of memory subgroups.
223631582|NCT01231984|DEVICE|4 mm x 32G Pen Needle|During the 12 week study period, subjects use this pen needle with their own pen device for all daily insulin injections they usually administered themselves with a pen device. Subjects follow their usual insulin regimen and there is no upper limit on total daily insulin dosage or number of injections. Subjects are advised to inject straight in when using the 4mm PN, with no pinch up.
224220033|NCT00863369|DRUG|bortezomib|Given IV
224220034|NCT00863369|DRUG|gemcitabine hydrochloride|Given IV
224317953|NCT07133542|BEHAVIORAL|Standard Aerobic Prescription|Personalized progressive aerobic exercise program. Participants receive baseline-adjusted intensity prescriptions (40-90% heart rate reserve), with adherence monitored via wearable devices. NO dynamic adjustments, tiered strategies, or visual feedback are provided throughout the 8-week intervention.
224220035|NCT00863369|OTHER|questionnaire administration|Ancillary studies
224220036|NCT00189345|BIOLOGICAL|anti-EpCAM x anti-CD3 (removab)|
224220037|NCT05209061|OTHER|Biopsy|Participants included in the study, will have a full thickness biopsy of the middle of the appendix taken, after the resected bowel has been removed during surgery.
224220038|NCT03074279|OTHER|Interview with a psychologist and self-reported questionnaires|The family members or patients who decide to participate in the study will be asked to complete an interview with a psychologist (semistructured interview, standard form, questionnaires) and self-reported questionnaires
224220039|NCT01581762|PROCEDURE|EUS-guided FNA|EUS-guided FNA with two types of needles - conventional 22G needle (Sham control) and Procore needle (active comparator)
224220040|NCT02151396|BEHAVIORAL|Working memory training|
224220041|NCT02151396|DEVICE|Functional magnetic resonance imaging (fMRI)|
224220042|NCT03883971|OTHER|3D printed model|Same as previously reported in arm descriptions
224317954|NCT07133659|DRUG|Avatrombopag 20 mg Oral Tablet|Description: Patients will start on avatrombopag 20 mg every other day for a week then the dose will be readjusted according to the platelet count.
224317955|NCT02602600|DRUG|Liraglutide|"* Liraglutide up to 3 mg daily injected subcutaneously (minimum 1.2 mg daily) for 12 weeks.~* Weight maintenance diet for 2 weeks"
224317956|NCT01004003|DRUG|Sorafenib|
224317957|NCT01004003|DRUG|BIBF 1120|Dose escalated in phase I until MTD or adjusted by investigator, dose in phase II part based on phase I data
224317958|NCT01188278|DRUG|Imatinib|Drug being observed but not provided
224317959|NCT00351975|DRUG|Belinostat|Given IV
223631583|NCT01231984|DEVICE|8mm x 31G Pen Needle|During the 12 week study period, subjects will use this pen needle with their own pen device for all daily insulin injections they usually administered themselves with a pen device. Subjects follow their usual insulin regimen and there is no upper limit on total daily insulin dosage or number of injections. Subjects are directed to use pinch-up when injecting in the abdomen or thigh with the 8mm PN, and no pinch-up at other injection sites.
223631584|NCT01231984|DEVICE|12.7mm x 29G Pen Needle|During the 12 week study period, subjects will use this pen needle with their own pen device for all daily insulin injections they usually administered themselves with a pen device. Subjects follow their usual insulin regimen and there is no upper limit on total daily insulin dosage or number of injections. When using the 12.7mm PN, subjects are instructed to insert either at an angle of 45 degrees, or to pinch up and hold the pen device at a 90 degree angle (straight in).
223631585|NCT04445753|OTHER|Tai Chi exercise|Individuals in the intervention group will perform a 12-week Tai Chi exercise in company with a researcher.Following the warm-up movements (Qi-gong), the training protocol of the Tai Chi movements, which includes the 10-form Yang style, will continue for 12 weeks, with two sessions per week determined by the researchers.The first and second weeks of the exercise protocol will include introducing the Tai Chi philosophy and teaching 10 forms of Yang style to patients. For 12 weeks, individuals will practice 10 forms of Tai Chi exercises with a researcher in each session. Each session will be planned as one hour.
224220043|NCT03883971|OTHER|Placebo|nothing other than the ultrasound
224220044|NCT01335152|BEHAVIORAL|Coping with Breast Cancer web-based workbook|10 chapter web-based workbook that teaches stress management, cognitive behavioral coping skills and relaxation training.
224220045|NCT00577954|PROCEDURE|Multimodal MRI|Multimodal MRI
224220046|NCT02390219|DRUG|Lumacaftor|
224317960|NCT00351975|DRUG|Azacitidine|Given SC
224317961|NCT00351975|OTHER|Laboratory Biomarker Analysis|Correlative studies
224317962|NCT00517556|DRUG|CCOCP|(CCOCP) continuous treatment with Monophasic oral gestodene/ethinyl estradiol
223631586|NCT04445753|BEHAVIORAL|Education (control group)|Individuals in the control group will also be trained on heart failure, which will be applied to individuals in the intervention group. The only attempt to be made to the control group will be education.
223631587|NCT05021354|DEVICE|Dry needling|dry needling, stretching and eccentric exercise
224220047|NCT02390219|DRUG|Ivacaftor|
224220048|NCT02623309|BIOLOGICAL|Allogeneic (Allo) hematopoietic stem cell transplantation|
224220049|NCT05564702|OTHER|traditional drug treatment|The patients in this arm will be given doctor specified dosage.
224220050|NCT05564702|OTHER|Opt-IVF predicted dosage|The patients in this arm will be given dosage predicted by Opt-IVF.
224220051|NCT01169844|BIOLOGICAL|AIN457A|
224220052|NCT01169844|OTHER|Other|
224220053|NCT02662322|OTHER|Hypnotic communication|hypnotic communication during peripheral intravenous catheterization
224317963|NCT00517556|DRUG|Traditional OCP|(traditional OCP) (21 active days/7 inactive days) treatment regimen
224317964|NCT03108053|PROCEDURE|Semirigid Ureteroscopy (URS) With Guide Wire|Semirigid URS is the operations used for ureteral stone disease. In routine practice it is most commonly done with the use of a guide wire. It is conducted with ureteroscope and stone is disintegrated most commonly with lasers.
224317965|NCT03108053|DEVICE|Semirigid Ureteroscopy (URS) Without Guide Wire|Semirigid URS is the operations used for ureteral stone disease . It is conducted with ureteroscope and stone is disintegrated most commonly with lasers.
224317966|NCT02064985|DRUG|"Inhibition of Platelet Aggregation by Brilinta(Ticagrelor)"|To determine the Inhibition of Platelet Aggregation (IPA) profiles of single and multiple doses of ticagrelor 45, 60, and 90 mg in Chinese patients with stable coronary heart disease (CHD) on chronic low dose ASA (75-100mg daily).
223631588|NCT05021354|DEVICE|Topical gel|aplication of topical gel to the epicondyle
223631589|NCT05021354|DRUG|NSAIDs|oral intake of NSAIDs
223631590|NCT03988309|DIAGNOSTIC_TEST|Cxbladder|"The Cxbladder Triage test result will be provided to physicians for all low risk subjects on the test arm. If a low risk subject has a Cxbladder Triage negative test result then the indication is to rule out the subject without further assessment. The decision to rule-out or further evaluate is solely that of the physician and subject. If the low risk subjects are not Cxbladder Triage negative then a Cxbladder Detect test result will also be provided. The indication is further evaluation as per standard of care. Not low risk patients will be evaluated as per standard of care."
223631591|NCT05716958|RADIATION|Digital Breast Tomosynthesis|Digital Breast Tomosynthesis (DBT) is a type of 3D mammography that creates detailed images of the breast tissue. It uses X-rays to take multiple images at different angles and combines them to create a clear, layered view of the breast tissue. DBT is used for breast cancer screening and diagnosis and provides a more accurate view of the breast tissue compared to traditional 2D mammography.
223631592|NCT02818972|DEVICE|RelayPro|Endovascular treatment with investigational device.
224220054|NCT02662322|OTHER|negative connotation communication|negative connotation communication during peripheral intravenous catheterization
224220055|NCT02662322|OTHER|neutral connotation communication|neutral connotation communication during peripheral intravenous catheterization
224220056|NCT02662322|OTHER|peripheral intravenous catheterization|peripheral intravenous catheterization
224220057|NCT06271421|DEVICE|NanoTherm therapy|Cyclic hyperthermia in patients with recurrent glioblastoma multiforme, who underwent implantation of iron oxide nanoparticles.
224220058|NCT06271421|PROCEDURE|Glioma Resection|Removal of brain tumor - gross total ressection
224220059|NCT06271421|RADIATION|radiotherapy according to Stupp protocol|The total dose according to the Stupp protocol is 60 Gy and is administered in fractions of 2 Gy per day for 5 days (Monday to Friday) for 6 weeks.
224220060|NCT06271421|DRUG|chemotherapy according to Stupp protocol|Temozolomide is used during radiotherapy: 75 mg/m2 of body surface area per day for 7 days a week. After the completion of radiotherapy, temozolomide is used as adjuvant therapy - 6 cycles of 150-200 mg/m2 of body surface area for 5 days every 28 days.
224220061|NCT00201929|PROCEDURE|Standard Decision Board|
224317967|NCT04142112|DEVICE|Ohana IVF Sperm Preparation Kit (OHB035)|The Ohana IVF Sperm Preparation Kit (OHB035) contains media for processing sperm through a series of timed steps prior to insemination with oocytes.
223631593|NCT02070575|OTHER|blood draw|Venous blood will be collected in an EDTA Vacutainer tubeup to 10 mL and will be immediately put on ice. This sample may be drawn as a stand-alone blood draw. Samples will be centrifuged at 1900g (3000-3200 RPM) for 15 Minutes and the serum aliquoted into freezer vials and stored at -80°C until analysis. In addition patients who have not received treatment for biochemical recurrence after their first draw are eligible for subsequent draws to determine the reproducibility of the test over time.
223631594|NCT01968447|OTHER|hypocapnia|Hyperventilation to the level of hypocapnia
223631595|NCT01968447|OTHER|normocapnia|Normal ventilation to the level of nromocapnia
223631596|NCT03090360|DIETARY_SUPPLEMENT|Infant formula (CF)|Formula-fed infants will be randomly assigned to receive one of the study formulas (CF or EF) orally, ad libitum, each day from Study Day 1 until Study Day 180, for a treatment duration of approximately 180 days.
223631597|NCT03090360|DIETARY_SUPPLEMENT|Infant Formula (EF)|Formula-fed infants will be randomly assigned to receive one of the study formulas (CF or EF) orally, ad libitum, each day from Study Day 1 until Study Day 180, for a treatment duration of approximately 180 days.
223631598|NCT00131768|DEVICE|Synvisc (hylan G-F 20)|
223631599|NCT06182137|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|A randomised controlled trial (RCT) of 60 subjects will be conducted to evaluate the effectiveness of transmodalistic therapy with a combination of rTMS and Cognitive Behavioral Therapy (CBT) for online gambling disorder.
223631600|NCT06381765|PROCEDURE|ultrasound guided Serratus plane bock and pectointercostal block|ultrasound guided serratus plane block (20 ml 0,25 %bupivacaine) will perform at the midaxillary 5.th rib and pectointercostal plane block (0,25% bupivacaine 15 ml) will perform at 4-5.th intercostal space. Both 2 blocks will perform bilaterally
223764257|NCT05483790|BEHAVIORAL|the multimodal intervention|"The in-person training course included 25 minutescognitive training activities were conducted for , followed by a 15-minute healthy lifestyle education. After a 10-minute break, physical exercise training was administered for 15 minutes. Finally, 15 minutes wrap-up session.~The cognitive training encompassed memory-related training and attention-related training. The physical exercise included finger exercises, elastic band exercises, Tai Chi/ Baduanjin with guidance. The healthy lifestyle education included guidance on nutrition, sleep, stress management, and mood adjustment by teaching problem-solving skills. Additionally, the intervention provided information and support to facilitate lifestyle changes and included discussions and practical exercises, such as tools for assessing dietary behavior."
224220062|NCT00201929|PROCEDURE|Computer Decision Board|
224317968|NCT04142112|DEVICE|Standard IVF Preparation Kit (OHB037)|The Standard IVF Sperm Preparation Kit (OHB037) contains media for processing sperm per the traditional steps prior to insemination with oocytes.
224317969|NCT05450601|DRUG|HCP2102-1|Take once daily for 2 weeks orally
223631601|NCT06381765|PROCEDURE|ultrasound guided Serratus plane bock|ultrasound guided serratus plane block (20 ml 0,25 %bupivacaine) will perform at the midaxillary 5.th rib to the all patients
223631602|NCT03454763|DRUG|PRRT every 5 weeks|PRRT (radiolabelled somatostatin analogues) every 5 weeks for 5 cycles
223631603|NCT03454763|DRUG|PRRT every 8-10 weeks|PRRT (radiolabelled somatostatin analogues) every 8-10 weeks for 5 cycles
223631604|NCT05989009|OTHER|Breastfeeding|Mothers will breastfeed their newborns
223631605|NCT05132907|BIOLOGICAL|HDT-301|HDT-301 Investigational Vaccine (a Nanoparticle Carrier-Formulated Replicon RNA (repRNA-CoV2S))
223631606|NCT05788510|OTHER|Pneumococcal vaccine|Investigation of vaccination status, for Pneumococcal vaccine , of patients who received anti-TNF alpha therapy
224220063|NCT00201929|PROCEDURE|Paper Decision Board|
224220064|NCT02683733|DIETARY_SUPPLEMENT|Bio-enhanced Curcumin Soft Gelatin Capsule|Each capsule is a bio-enhanced modification of curcumin (diferuloylmethane), which is a derivative of curcuma longa (rhizome extract)
223631607|NCT05891704|PROCEDURE|Hand therapy Rehabilitation intervention program that incorporate cultural reference|The intervention will provide a conventional hand therapy rehabilitation intervention program that incorporates cultural reference based on Focused Acceptance and commitment Therapy ( FACT).
223631608|NCT05891704|PROCEDURE|Conventional Hand therapy Rehabilitation intervention program|The intervention will provide a conventional hand therapy rehabilitation intervention program
223631609|NCT01827137|BIOLOGICAL|Galinpepimut-S|Galinpepimut-S admixed with the adjuvant Montanide following specified schedule
223631610|NCT01827137|BIOLOGICAL|GM-CSF|subcutaneous injection
223631611|NCT01827137|OTHER|Montanide|adjuvant
223631612|NCT01827137|DRUG|lenalidomide|optional post-ASCT therapy
223764258|NCT03723655|DRUG|mavacamten|mavacamten capsules
223764259|NCT03233594|OTHER|Chiropractic Group|Participants will receive approximately 8 weeks of chiropractic care.
224220065|NCT02683733|DRUG|5-Aminosalicylic acid|Dosage is as instructed by patient's physician
224220066|NCT04736979|DRUG|amoxicillin clavulanate|dosage according to Shariff score and creatinine clearance
223631613|NCT01827137|DRUG|bortezomib|optional post-ASCT therapy
223631614|NCT04882735|DRUG|Acoramidis|TTR stabilizer administered orally twice daily (BID)
224220067|NCT00754195|OTHER|Thoracic epidural catheter|Comparison of 3 insertion distances (3,5 and 7 cm) for a thoracic epidural catheter in the context of thoracic surgery.
224220068|NCT00271804|DRUG|bortezomib|
224220069|NCT03876158|DEVICE|Prometra II Programmable Pump system(Flowonix Medical)|This valve gated Prometra II Programmable Pump system will be replacing prior peristaltic Synchromed II pump
224317970|NCT05450601|DRUG|HPP2104-1|Placebo drug. Take once daily for 2 weeks orally
224317971|NCT05450601|DRUG|HCP2102-2|Take once daily for 6 weeks orally
224317972|NCT05450601|DRUG|HPP2104-2|Placebo drug. Take once daily for 6 weeks orally
224317973|NCT05450601|DRUG|RLD2106-1|Take once daily for 2 weeks orally
224317974|NCT05450601|DRUG|HPP2103-1|Placebo drug. Take once daily for 2 weeks orally
224317975|NCT05450601|DRUG|RLD2106-2|Take once daily for 6 weeks orally
224317976|NCT05450601|DRUG|HPP2103-2|Placebo drug. Take once daily for 6 weeks orally
223631615|NCT04092504|OTHER|gero-erat|"The intervention is a standardize Care Plan which will be developed based on the evidence of caring for elderly patients in a trauma setting. The Care Plan will have its base in, the concept of ERAS and CGA. Also, patient experience will be taken in consideration and complement the care pathway.~Patients admitted to the trauma unit will be given the care and asked to be a part of the study witch include to fill out surveys at baseline, six months and 1 year."
223631616|NCT03095495|DEVICE|Heated Humidified High Flow Nasal Cannula|HHHFNC therapy is a simple to use system that delivers warm and moist air/oxygen mixture at high flow rates that generate positive airway pressure
223631617|NCT03095495|DEVICE|Standard Therapy (Low Flow Nasal Cannula)|will be used only if the patient needs oxygenation and Rescue HHHFNC will be used if the patient needs PICU
223631618|NCT05274815|BIOLOGICAL|Tezepelumab|Tezepelumab subcutaneous injection
223631619|NCT05499065|PROCEDURE|Fluorescence guided detection of tumor positive margins|To test if the fluorescence can guide the location for fresh frozen section sampling intra-operatively
223631620|NCT05499065|DRUG|Cetuximab-IRDye800|Administrate 75mg cetuximab + 15mg cetuximab-800CW for fluorescence visualization
223631621|NCT01565200|DRUG|T-DM1|3.6 mg/kg iv every 3 weeks
223764260|NCT03233594|OTHER|Healthy Control Group|Participants will not receive any interventions.
224220070|NCT01183845|PROCEDURE|Colon Capsule Endoscopy|Ileocolonic endoscopy scheduled; then colon capsule endoscopy performed.
224220071|NCT00472706|PROCEDURE|excision|excision 3 mm margin
224220072|NCT00472706|PROCEDURE|Photodynamic therapy|Photodynamic therapy
224220073|NCT06097611|DRUG|Tranexamic Acid administration|Tranexamic Acid administration to compare mortality and blood transfusion amounts among severely polytraumatized pediatrics who did or did not receive tranexamic acid within 3 h of injury
224220074|NCT01888328|DRUG|Isotretinoin|Isotretinoin Capsules,40 mg
224220075|NCT05514028|OTHER|Salivary samples|"For patients with a benign ovarian cyst, 1 saliva sample taken at 3 times (concomitant with a visit performed in routine care):~* During the inclusion visit,~* At the postoperative visit,~* At the 6-month follow-up visit~For patients with ovarian cancer, 1 saliva sample taken at different times (concomitant with a visit performed in routine care):~* At the inclusion visit,~* During the postoperative visit,~* At the follow-up visits (6 months post-surgery and then every 6 months until 24 months)~For patients with a borderline ovarian tumor, 1 saliva sample taken at different times (concomitant with a visit performed in routine care):~* At the inclusion visit,~* During the postoperative visit,~* During pre- and post-chemotherapy visits (before and after each cycle)~* During follow-up visits (every 4 months until 24 months)"
224220076|NCT03418077|DIETARY_SUPPLEMENT|Energy Drink|Participants will consume a randomly assigned single 24 oz can of an original flavor energy drink within a 30-minute period. Baseline ECG, HR, BP, blood sample and body weight will be obtained. Then perform a continuous, progressive treadmill or bicycle ergometry test until volitional exhaustion. ECG will be monitored continuously during exercise, rating of perceived exertion (RPE) will be recorded every minute of each workload increase. After completion of exercise, subject will remain standing on treadmill (or seated on ergometer) for 10 minutes while ECG, BP, HR and blood samples are obtained. Subsequent ECG measures will be obtained at 1,4,7 and 10 minutes. After 10 minutes, the subjects will be free to sit, stand or move quietly in the lab. During the 2-hour post exercise monitoring period, subject's ECG, HR, BP will be recorded at 30-minute intervals. Blood samples will be collected immediate upon cessation of exercise, at 1 and 2 hours post exercise
224220077|NCT03418077|DIETARY_SUPPLEMENT|Placebo-control|Participants will consume a randomly assigned single 24 oz can of control drink within a 30-minute period. Baseline ECG, HR, BP, blood sample and body weight will be obtained. Then perform a continuous, progressive treadmill or bicycle ergometry test until volitional exhaustion. ECG will be monitored continuously during exercise, rating of perceived exertion (RPE) will be recorded every minute of each workload increase. After completion of exercise, subject will remain standing on treadmill (or seated on ergometer) for 10 minutes while ECG, BP, HR and blood samples are obtained. Subsequent ECG measures will be obtained at 1,4,7 and 10 minutes. After 10 minutes, the subjects will be free to sit, stand or move quietly in the lab. During the 2-hour post exercise monitoring period, subject's ECG, HR, BP will be recorded at 30-minute intervals. Blood samples will be collected immediate upon cessation of exercise, at 1 and 2 hours post exercise
224220078|NCT02115737|BEHAVIORAL|Dialectical Behavior Therapy Skills Group|
224220079|NCT02115737|BEHAVIORAL|Psychoeducation group treatment|
224220080|NCT00165854|DRUG|E7070|
223631622|NCT01565200|PROCEDURE|89Zr-trastuzumab|Injection of 89Zr-trastuzumab for HER2 imaging
223631623|NCT05705024|BIOLOGICAL|Mesenchymal Stromal Cells|Subconjunctival Injection of Allogeneic Mesenchymal Stromal Cellsmasked clinical trial, patients with non-resolving corneal epithelial disease (i.e., refractory to standard treatments for at least two weeks) will receive a single subconjunctival injection of bone marrow-derived allogeneic MSCs or vehicle (CS5 freezing media, BioLife Solutions Inc, Bothell, WA, USA), with continued follow-up for up to 90 days.
223631624|NCT05705024|OTHER|Control Solution|For the control group, 150 µL of injectable normal saline (0.9% NaCl). will be injected.
223631625|NCT06187896|DRUG|remimazolam|in this group,patients are treated with remimazolam and remifentanil for reduced sedation.
223631626|NCT06187896|DRUG|Propofol|in this group,patients are treated with propofol and remifentanil for reduced sedation.
223631627|NCT06580444|DRUG|Brexanolone|The participant will receive either a placebo, or 90, 60, or 30 mcg/kg/hr of Brexanolone over a 20-hour period intravenous infusion.
223764261|NCT06855160|BIOLOGICAL|Candidate varicella vaccine|Investigational varicella vaccine administered intramuscularly.
223764262|NCT06855160|BIOLOGICAL|Marketed varicella vaccine|Marketed varicella vaccine administered subcutaneously.
223764263|NCT06855160|BIOLOGICAL|MMR vaccine|MMR vaccine administered subcutaneously or intramuscularly.
223764264|NCT06855160|BIOLOGICAL|Hepatitis A vaccine|Hepatitis A vaccine co-administered intramuscularly.
223764265|NCT06855160|BIOLOGICAL|PCV (pneumococcal conjugate vaccine) 13|The 13-valent pneumococcal conjugate vaccine co-administered intramuscularly. In some countries PCV will only be administered depending on the availability, country's registration status and national recommendations for pneumococcal vaccination at the time of study conduct.
223631628|NCT06581016|DEVICE|Ambu aScope Gastro|CE-marked single-use gastroscopes from Ambu are used in the single-use group.
223631629|NCT06581016|DEVICE|Ambu aScope Gastro Large|CE-marked single-use gastroscopes from Ambu are used in the single-use group.
223631630|NCT06581016|DEVICE|Diagnostic gastroscopes, Olympus|Reusable gastroscopes from Olympus are used in the reusable group.
223631631|NCT06581016|DEVICE|Therapeutic gastroscopes, Olympus|Reusable gastroscopes from Olympus are used in the reusable group.
223631632|NCT05265429|GENETIC|Data and Specimen Collection|"* Provide research team access to relevant medical records~* Answer two (2) short questionnaires at time of consent~* Provide up to 5 tubes (37 ml) of blood at or near the time of consent, and/or saliva sample~* Consider consenting to other optional parts of the research such as:~  * Providing additional blood or tissue samples in the future (optional)~ * Providing permission for obtainment of stored tissue specimens from lung cancer surgeries or biopsies from the pathology departments where they have been stored (optional)"
223631633|NCT05156047|DRUG|Open-label pitolisant|"Pitolisant 4.45 mg tablets: white, round, plain, biconvex film-coated tablet, 3.7 mm in diameter. Each tablet contains 5 mg of pitolisant hydrochloride equivalent to 4.45 mg of pitolisant.~Pitolisant 17.8 mg tablets: white, round, plain, biconvex film-coated tablet, 7.5 mm in diameter. Each tablet contains 20 mg of pitolisant hydrochloride equivalent to 17.8 mg of pitolisant."
224220081|NCT03299530|OTHER|patients with corneal astigmatism|The total corneal astigmatism, anterior chamber depth, will be measured by a Scheimpflug tomographer. Pupil size will be measured by itrace device and MONCV3 device. Residual astigmatism will be tested by subjective refraction.
223631634|NCT05156047|DRUG|Double-blind placebo|Matching placebo tablets will be provided for each strength of active pitolisant film-coated tablets.
223631635|NCT05156047|DRUG|Double-blind pitolisant|"Pitolisant 4.45 mg tablets: white, round, plain, biconvex film-coated tablet, 3.7 mm in diameter. Each tablet contains 5 mg of pitolisant hydrochloride equivalent to 4.45 mg of pitolisant.~Pitolisant 17.8 mg tablets: white, round, plain, biconvex film-coated tablet, 7.5 mm in diameter. Each tablet contains 20 mg of pitolisant hydrochloride equivalent to 17.8 mg of pitolisant."
223631636|NCT02887820|DEVICE|Thromboelastograph|A thromboelastograph flowchart will be followed in addition to traditional laboratory tests to manage blood transfusion and coagulation decisions
223764266|NCT06855160|BIOLOGICAL|PCV 20|The 20-valent pneumococcal conjugate vaccine co-administered intramuscularly. In some countries PCV will only be administered depending on the availability, country's registration status and national recommendations for pneumococcal vaccination at the time of study conduct.
224220082|NCT02964728|DRUG|Botulinum Neurotoxin Type A|topical injection
224220083|NCT02964728|OTHER|Normal saline|topical injection
224220084|NCT03755700|DRUG|Vitamin E|As a gel capsule of vitamin E 800 IU orally 2 hours before intervention and 400 IU orally 4 hours after intervention
224220085|NCT03755700|DRUG|N-acetyl cysteine|As an effervescent tablets of NAC 1200 mg orally 2 hours before intervention and 1200 mg orally 4 hours after intervention
224220086|NCT03755700|DRUG|Placebo oral capsule|The placebo of vitamin E as a soft gel capsule with the consumption order similar to vitamin e group
224220087|NCT03755700|DRUG|Placebos|The placebo of n-acetylcysteine as a tablet with the consumption order similar to n-acetylcysteine group
224220088|NCT03755700|DRUG|Normal Saline Flush, 0.9% Injectable Solution|Normal saline 0.9% infusions (1 mL/kg) for 12 hours prior to and after coronary catheterization
224317977|NCT02394704|OTHER|Sensory attention training|"Participants will be instructed to attend to sensory stimuli and to press a button as quickly and accurately as possible while ruminating. Stimuli will consist of vibration via a wearable subwoofer or non-painful electrical muscle stimulation (10Hz biphasic current with a pulse width of 200us with rectangular 2 electrodes placed on the back near the shoulders) or vibratory stimulation with a vibroacoustic element placed on the back near the shoulders. Up to four sessions will be approximately 45 minutes, over the course of two weeks."
224317978|NCT01141855|DRUG|Champix|"Standard MIMS dosage (including period of titration) will be used. 0.5mg daily for 3 days 0.5mg b.d. for 4 days~1mb b.d. for 70 days (full course 3 months)"
224317979|NCT01141855|BEHAVIORAL|Counselling alone|Quit SA 5A counselling over the phone. Maximum 8 calls over a 3 month period
223764267|NCT06855160|BIOLOGICAL|Vaxneuvance|The Vaxneuvance (15-valent pneumococcal conjugate vaccine) co-administered intramuscularly. In some countries Vaxneuvancewill only be administered depending on the availability, country's registration status and national recommendations for pneumococcal vaccination at the time of study conduct.
223764268|NCT04761185|DRUG|Raltitrexed|The RTX-HIPEC protocol used a modified Fibonacci dose escalation method with 7 dose levels (3, 4, 5, 6, 7, 8, 9 mg/m2)
223764269|NCT06981234|DRUG|Acetazolamide|Acetazolamide is a potent carbonic anhydrase inhibitor that acts on the renal proximal tubule. Through this mechanism, it inhibits proximal tubule sodium reabsorption.
224220089|NCT01289938|DRUG|Diphenhydramine|Diphenhydramine 50 mg oral once
224220090|NCT01289938|DRUG|Metoclopramide|10 mg i.v. metoclopramide once
224220091|NCT02588131|DRUG|tremelimumab plus MEDI4736|tremelimumab1 mg/kg i.v over 60 minutes plus MEDI 4736 20 mg/kg i.v every four weeks for 4 doses, then MEDI4736 20 mg/kg IV every four weeks for additional 9 doses.
224220092|NCT01773278|DRUG|Antioxidants|Patients will be prescribed the drug DEKAS plus at a dose based on age and weight. The effects of the treatment will be monitored by serial ERG, ABR, oxysterol levels and clinical findings. Blood levels of 25-Oh vitamin D will be monitored to prevent toxicity.
224220093|NCT01773278|DRUG|Cholesterol|Patients with SLOS typically have cholesterol deficiency. They will be treated with cholesterol supplementation to keep cholesterol levels \> 100 mg/dl if possible
224220094|NCT02348970|DEVICE|ONIRIS®|sleeping test
224220095|NCT02348970|DEVICE|TALI|sleeping test
224220096|NCT00529568|DRUG|eltrombopag|double-blind active treatment daily oral administation at dose of 25, 50, 75, or 100 mg
223631637|NCT03535584|BEHAVIORAL|Exercise Program|Participants will be asked to complete 2 1-hour exercise sessions per week for 8 weeks (16 total sessions) under the supervision of a licensed respiratory therapist on non-dialysis days. The exercise program will be based on pulmonary rehabilitation and will follow guidelines established by the American Thoracic Society. Exercise sessions will include endurance (treadmill or cycle ergometer), strength (weight resistance), and flexibility training. Exercise sessions will be tailored to individual participants, and participant safety will be monitored during each session.
223631638|NCT04077801|DIAGNOSTIC_TEST|diagnostic test|diagnostic test
223631639|NCT04077801|DIAGNOSTIC_TEST|Postpartum pain|test
223631640|NCT04077801|OTHER|Visual analogue scale|test TMJ /pelvic angle/lumber angle
223631641|NCT04494672|PROCEDURE|Intramedullary nailing with ADAPT system|Stryker ADAPT®system (ADAPT, Stryker Leibinger GmbH \& Co. KG, Freiburg, Germany) is a computer navigation system which can reconstruct a 3D model of the femoral head from the positional information oriented by bidirectional fluoroscopic views. ADAPT shows the distance from the tip of the screw to the surface of the femoral head, tip-to-head-surface distance (TSD), and tip-apex distance (TAD) intraoperatively
223631642|NCT04494672|PROCEDURE|Intramedullary nailing without ADAPT system|Intramedullary nailing without ADAPT system
223631643|NCT06102954|OTHER|Falls prevention intervention including exercise and educational components|This includes five domains of exercise (strength, balance, flexibility, coordination, and endurance) and educational components to manage other falls risk factors (polypharmacy, nutrition, pain, orthostatic hypotension, poor vision and environmental hazard evaluations).
223631644|NCT05427344|OTHER|Water exercise group|Water exercise group where the Ai Chi technique was selected as the exercise method of choice. The activity will take place in a hydrotherapy pool approved by the Ministry of Health and will be led by a hydrotherapist who has been trained in Ai Chi.
224220097|NCT00529568|DRUG|placebo|double-blind matched placebo control daily oral administration
224220098|NCT04446832|OTHER|Vaccine immunogenicity|Evaluation of the vaccine immunogenicity by standard approved serological tests
224220099|NCT01201356|DRUG|Fingolimod|0.5 mg/day
224220100|NCT03483844|DIAGNOSTIC_TEST|GE CT 750 HD|Low-dose dual-energy CT imaging
224220101|NCT00524875|DRUG|Bevacizumab|One dose of bevacizumab (1.25 mg/0.05 cc) one to two weeks before pars plana vitrectomy for diabetic retinopathy
224220102|NCT03889457|OTHER|anticoagulation choice|Type of anticoagulant chosen by the patient (oral or injectable).
224220103|NCT04933669|DRUG|Imatinib|Imatinib neoadjuvant therapy
224220104|NCT02784717|DRUG|Rivaroxaban (Xarelto, BAY 59-7939)|Decision regarding dose and duration of treatment made at the discretion of the attending investigator.
224220105|NCT03010202|DRUG|Dexamethasone|Comparing the effect of Rituximab infusion With or without Dexamethasone
224220106|NCT03010202|DRUG|Rituximab|Comparing maintenance dose of 500mg Rituximab at week 1 and week 24 to Placebo
224220107|NCT02295683|DEVICE|Renal Denervation|
224220108|NCT03374137|BIOLOGICAL|obinutuzumab|Obinutuzumab 1000 mg solution used for infusion according to routine clinical practice.
224220109|NCT06284707|OTHER|swimming training|2 sessions per week of swimming training
224220110|NCT06284707|OTHER|rhythmic gymnastics training|2 training sessions of rhythmic gymnastics
224220111|NCT05217056|OTHER|measurements|All of the infants with high risk of cerebral palsy will be assessed from birth to 12 months age with the assessments of Prechtl's General movements (GMs) until 20 weeks of age. Also BAYLEY-III Infant and Toddler Development Assessment Scale (BAYLEY-III) will be performed at the 3rd, 6th, and 12th months for the cognitive development.
223631645|NCT05427344|OTHER|Land exercise group|Land exercise group who will perform the same Ai Chi movements on land in order to standardize the groups. The activity will take place in a hall and will be led by a physiotherapist who has been trained to teach Ai Chi on land.
223631646|NCT05427344|OTHER|Control group|Control group who will not perform additional physical activity or receive any extra treatments.
223764270|NCT06981234|DRUG|Placebo|Standard pharmaceutical filler will be capsulated and packaged identically to the acetazolamide.
223631647|NCT05732311|DEVICE|intermittend theta burst stimulation|intermittend theta burst stimulation
224220112|NCT03635684|DRUG|Acetaminophen|"Subcutaneous infusion of Acetaminophen over 20 to 30 minutes, with evaluation of:~* local side effects;~* pain and/or fever;~at time of infusion, after 30 minutes, 60 minutes and 180 minutes."
224220113|NCT00811070|DRUG|SKI-606 (Bosutinib)|"Formulation: 100 mg Capsule for Part 1, 100 mg tablet for Part1 and Part 2.~SKI-606 (Bosutinib) will be taken by mouth with water and food as continuous once-daily dosing."
224220114|NCT03667625|OTHER|Multidimensional Mobility Exercises|Multidimensional mobility exercises, combined with breathing exercise protocol was established by a committee of specialized physiotherapists and rheumatologist. Land-based and aquatic-based exercises were designed according to environmental features (gravity, buoyancy, viscosity etc).
224220115|NCT03667625|OTHER|Control group|A conventional home exercise programme was given by a specialized physiotherapist to control group. Patients were checked and encouraged to continue their programs by weekly phone calls for eight weeks
224220116|NCT04662684|DRUG|Rivaroxaban 10 MG|No intervention
224220117|NCT04070599|BIOLOGICAL|Collection of biological samples|A collection of biological samples will be carried out, with the remainders of the immunological samples taken on dry tube: the serum of the patients, taken at the initial diagnosis, will be kept frozen at -20 ° C.
224220118|NCT03371238|BEHAVIORAL|Floorball|The subjects in this group are set to play floorball three times pr. week for 39 weeks.
224220119|NCT04742725|DRUG|Placebo|Placebo
224220120|NCT04742725|DRUG|Prothione™ (6g)|Prothione is a pro-Glutathione compound includes free-form amino acids
224220121|NCT03917563|DEVICE|WATCHMAN LAA occluder|WATCHMAN LAA occluder
223631648|NCT06177080|OTHER|transperineal ultrasound|descent angle and head symphysis distances by transperineal ultrasound of active phase of labor women.
223631649|NCT05417542|OTHER|EEG|EEG recording during prematurity or around term
223764271|NCT06984861|DIAGNOSTIC_TEST|18F-FMISO PET/CT Scan|The 18F-FMISO PET/CT Scan Protocol consists first of an IV bolus injection of approximately 5-10 mCi of the radiotracer. Subjects will undergo 18F-FMISO scan (only 1 injection) occurs at 8-10 treatment days\* into chemoradiation. Each patient will have a baseline staging FDG PET scan which is used to localize the tumor at the primary site and all suspicious cervical neck nodes (\> 1 cm in short axis diameter with focal abnormal increased FDG avidity). These lesions are then assessed on the respective 18F-FMISO PET/CT.
224220122|NCT01921036|PROCEDURE|traditional cardiac rehabilitation|mutifactoral cardiac rehabilitation
224220123|NCT01921036|PROCEDURE|combined exercise|Moderate endurance and resistance exercise once a week over six months
224220124|NCT03271463|BEHAVIORAL|Selective Control Assessment of Lower Extremity (SCALE)|Inter- and intra-rater reliability Validity: correlation analysis with Fugl-Meyer Assessment - Lower Extremity Component (FMA-LE) and 10 meter walk test (see below)
224220125|NCT04079842|DEVICE|INVSENSOR00029|Noninvasive pulse oximeter sensor
224220126|NCT01025193|DRUG|Belimumab|Belimumab is a fully human monoclonal antibody that recognizes and inhibits BLyS ®. BLyS ® is a B-lymphocyte stimulator protein which plays a role in the development of B lymphocyte cells into plasma B cells, which then produce antibodies that can sensitize a potential transplant recipient. At the time of this trial, belimumab was not yet FDA approved and was being studied in clinical trials for the treatment of systemic lupus erythematosus. Until this trial, it had not yet been used in the transplant setting.
224220127|NCT02904200|DEVICE|Silicon adhesive dressing|Sterile soft silicon adhesive dressing
224220128|NCT02904200|DEVICE|Acrylic adhesive dressing|Sterile acrylic adhesive dressing
224220129|NCT03833453|BEHAVIORAL|EMDR|EMDR is a PTSD treatment that specifically addresses troubling memories of and the personal meaning of the traumatic event and consists of 12 to 18 sessions in a maximum of 6 months.
224220130|NCT03833453|BEHAVIORAL|DBT|DBT is a treatment for personality disorders (PD) focused on emotion regulation. It takes at least one group-session per week, and one individual coaching session every two weeks, for the duration of one year.
224220131|NCT02431884|PROCEDURE|collect body fluids/tissues & med history|collect tissues/fluids \& history
224220132|NCT06427330|DRUG|Inotuzumab ozogamicin|"1. st dose is given after D+60：inotuzumab 0.3mg/m2~2. nd dose is given after 1 month：inotuzumab 0.6mg/m2"
224220133|NCT05837598|BEHAVIORAL|Virtual Cancer and Mental Health Tumor Board|The Virtual Cancer and Mental Health Tumor Board intervention aims to increase access to psycho-oncology and oncology expertise, facilitate clinician communication, build understanding of the person's needs and strengths, and address barriers to care. Strategies include a proactive assessment of illness understanding, psychiatric history, and barriers to care followed by development of an integrated cancer and mental health treatment plan during the tumor board session that is framed in terms of patient values and addresses barriers to accessing psycho-oncology and specialty oncology expertise. These recommendations will be shared with treating oncologists, documented in the medical record, and shared with the patient. Patients will receive a transition phone call at 12 weeks.
224220134|NCT00185211|DRUG|Interferon beta-1b (Betaseron, BAY86-5046)|Initial Betaferon/Betaseron treatment (Interferon beta-1b, IFNB-1b), 250 ug administered s.c. (subcutaneous) every other day, continued in Follow-up phase
224220135|NCT00185211|DRUG|Interferon beta-1b (Betaseron, BAY86-5046)|Initial placebo treatment; Betaferon/Betaseron, 250 ug administered s.c. (subcutaneous) every other day offered in Follow-up phase (= this trial)
224220136|NCT04460599|OTHER|Observation|Observation of recorded neurological signs
224220137|NCT00176683|PROCEDURE|Capnography|device which measures carbon dioxide at intubation
224220138|NCT01067859|DRUG|Cinaciguat (BAY58-2667)|Infusion of 25 µg/h during 48 hours
224220139|NCT01067859|DRUG|Cinaciguat (BAY58-2667)|Infusion of 10 µg/h during 48 hours
224220140|NCT01067859|DRUG|Placebo|Infusion of placebo during 48 hours
224220141|NCT01538706|OTHER|Hospital-based home care|Low-intensive intravenous antibiotics b) intravenous low-toxic chemotherapy c) blood samples drawn from the central venous catheter or peripheral vein d) subcutaneous injections e) nutrition treatment f) pain management (e.g. controlling an intravenous morphine pump g) supportive care e.g. changing dressings.
224220142|NCT06700499|DRUG|AK120 300mg Q2W (JAK inhibitor users need to double the initial dose)|AK120 300mg Q2W SC until week 14(JAK inhibitor users need to receive a first dose of 600mg SC)
224317980|NCT05123183|OTHER|acupressure group|A suitable environment will be prepared for mothers in terms of warmth and light, where privacy can be protected. The application points will be determined with the acu-point device by choosing the most comfortable position of the mother, leaving the application points exposed. The most preferred points ST36 and CV17 were selected from the points reported to affect lactation by reviewing the literature on the points to be compressed. Acupressure will be applied to CV17 point (single point) and ST36 point (bidirectional, right and left) for 2 minutes for a total of 6 minutes. Light pressure will be applied with the thumb of the practitioner's hand. Immediately after applying pressure for 2 minutes for each point, it will be moved to the other point in the symmetrical region and the application will be made without interruption. While practicing, the researcher will control the time using a digital wrist watch with a stopwatch.
223631650|NCT05417542|OTHER|NIRS|NIRS recording during prematurity or around term
223631651|NCT05662410|DRUG|Three monthly injections of intravitreal aflibercept|Three monthly intravitreal injection of aflibercept (2.0mg / 0.05ml) after diagnosis of pathychoroid neovasculopathy.
223631652|NCT06638931|DRUG|Nivolumab|"The intervention consists of administering Nivolumab 480 mg intravenously every 4 weeks, with a +5 day window for postponement but not for advancement of treatment. Treatment will continue until limiting toxicity, disease progression, or for a maximum period of 12 months (13 cycles) as maintenance therapy, provided the patient maintains stable disease, a partial response, or a complete response. Patients who are off treatment for more than 56 days (2 cycles) due to Nivolumab-related toxicities or other clinical issues will be discontinued from the protocol.~After 12 months of treatment or in the event of study discontinuation for any reason, patients will be followed by the research team via telephone every 60 days, with a +/- 7 day window, until death."
223764272|NCT06984861|COMBINATION_PRODUCT|Chemoradiation|Patients will start with induction chemotherapy of carboplatin, paclitaxel and cetuximab for 6 weeks and when downstaged to T1-2 and \< N3, the patient is eligible to receive concurrent chemoradiation per protocol.A total radiation therapy of 30Gy will be delivered to the oropharynx and neck at 2Gy per fraction per day over 15 days for patients who exhibited no evidence of hypoxia on the intra-treatment 18F-FMISO PET/CT. Concurrent chemotherapy (2 cycles) will be given. After completion of chemotherapy and radiation therapy, a 4 month (+/- 4 weeks)
223764273|NCT06984861|OTHER|Questionnaires|EQ-5D-5L, MDADI-HN, COST-FACIT
223764274|NCT02620098|OTHER|Size Matters Handwriting Program|The Size Matters Handwriting Program (Moskowitz, 2009) (SMHP) program incorporates principles grounded in motor learning theory, cognitive theory, and motivation theory. Children learn the importance of letter size by learning size 1 (capital and tall letters), size 2 (small letters) and size 3 letters (those that dive below the baseline) at different stages (Moskowitz, 2009). The intervention group received a total of 30 sessions of the SMHP, completed twice weekly over a 16 week period. Sessions lasted 30 minutes, and were led by an occupational therapist with training in the Size Matters Handwriting Program. All interventions were provided within the existing support classrooms. Each child had their own SMHP workbook.
224220143|NCT05756413|BEHAVIORAL|Self-determination theory|"SDT is relatively unique among theories of motivation due to its focus on the quality, rather than the quantity, of motivation. Central to SDT is the distinction between selfdetermined or autonomous and non-self-determined or controlled forms of motivation. These types of motivation differ from one another based on the degree to which actions are (or are not) fully self-endorsed by the individual. Autonomous motivation reflects freely chosen and fully or whole-heartedly self-endorsed reasons for engaging in a behavior, such as because it is important and because it is enjoyable. In contrast, controlled motivation reflects reasons for acting that are not self-endorsed because one is pressured into doing them because of internal pressure, such as this is something I should do, even though I don't really want to, or because of environmental contingencies because I have to; it is required that I do this."
224220144|NCT05860712|OTHER|Irrigation|Cinnamon to be prepared were mixed with 50% ethanol and this suspension was placed on the magnetic stirrer for 4 hours.Whitman's filter paper was used to obtain the filtrate which was then dried to obtain the extract. The extract was dried to evaporate the solvent to prevent the influence of extracting agent (ethanol) on the final extract. Cinnamon extract was obtained using cinnamon bark which was pulverized into medium coarse granules. The extracting agent and the procedure to obtain the final extract.These extracts were stored in dark coloured bottles at 4 degree Celsius until use.
224220145|NCT00581594|PROCEDURE|Graft-augmented colporrhaphy|Patients will undergo randomized surgical procedure. Patients will be seen at 6 weeks for a pelvic exam and evaluation of the posterior wall. Points Ap and Bp will be recorded with values at 0.5cm intervals being on the posterior vaginal wall that is 3cm above the hymen. Point Bp is the most dependent portion of the posterior vaginal wall when the patient performs a Valsalva maneuver. Patients will be seen at 6 months for a pelvic exam evaluation of posterior wall support and completion of SF-36, PISQ and FISI. Patients will be given 60 minute Questionnaires on defecatory dysfunction, pelvic pain and/or symptoms of prolapse. Patients will be seen at 1 year and yearly intervals up to five years for a pelvic exam for evaluation of posterior wall support and the questionnaires.
224220146|NCT00581594|PROCEDURE|Traditional posterior colporrhaphy|Patients will undergo randomized surgical procedure. Patients will be seen at 2 weeks for routine post-op care and evaluation of any post-op complications. Patients will be seen at 6 weeks for a pelvic exam and evaluation of the posterior wall. Points Ap and Bp will be recorded with values at 0.5cm intervals being on the posterior vaginal wall that is 3cm above the hymen. Point Bp is the most dependent portion of the posterior vaginal wall when the patient performs a Valsalva maneuver. Patients will be seen at 6 months, for a pelvic exam evaluation of posterior wall support and completion of SF-36, PISQ and FISI. Patients will be given 60 minute Questionnaires on defecatory dysfunction, pelvic pain and/or symptoms of prolapse. Patients will be seen at 1 year and yearly intervals up to five years to have a pelvic exam for evaluation of posterior wall support and the questionnaires.
224220147|NCT03875183|DRUG|INL1|Capsules
224220148|NCT03875183|OTHER|Placebo|Capsules
224220149|NCT02462382|PROCEDURE|Arthroscopic Rotator Cuff Repair|During arthroscopic rotator cuff surgery, the surgeon inserts a small camera, called an arthroscope, into your shoulder joint. The camera displays pictures on a television screen, and your surgeon uses these images to guide miniature surgical instruments to repair the torn ligament.
224220150|NCT02462382|DRUG|Ropivacaine|The study group will receive a pump with study drug attached to a catheter placed into the shoulder area by the anesthesiologist.
224220151|NCT02462382|DRUG|Saline|The control group will receive a pump with saine attached to a catheter placed into the shoulder area by the anesthesiologist.
224220152|NCT04157270|DEVICE|Penumbra System|Penumbra System
224220153|NCT02477007|DRUG|Paracetamol|Paracetamol will be an oral solution of 30 mg/ml. The doses of paracetamol will be 15 mg/kg (maximum dose: 1g).
224220154|NCT02477007|DRUG|Ibuprofen|Ibuprofen will be an oral suspension of 20mg/ml. The doses of ibuprofen 10 mg/kg (maximum dose: 400 mg).
224220155|NCT02477007|DRUG|paracetamol + ibuprofen|Paracetamol will be an oral solution of 30 mg/ml. The doses of paracetamol will be 15 mg/kg (maximum dose: 1g) Ibuprofen will be an oral suspension of 20mg/ml. The doses of ibuprofen 10 mg/kg (maximum dose: 400 mg).
224317981|NCT05123183|OTHER|back massage group|The mother sits in the chair and leans forward, placing her arms on the table at her level and resting her head on her arms. The mother's breasts are naked and freely released. The researcher massages the mother from top to bottom on both sides of the spine between the scapula bones. At this time, his fists are clenched and the thumb is open. While pressing firmly with his fists, small circular friction movements are made with his thumb. From the neck to the scapula, both sides of the spine are rubbed at the same time for 3 minutes. While practicing, the researcher will control the time using a digital wrist watch with a stopwatch.
224317982|NCT05123183|OTHER|control group|No application will be made to the mothers in this group, and the amount of milk will be measured by weighing the baby before and after breastfeeding.
224317983|NCT05857852|DEVICE|Low-Intensity Focused Ultrasound|Low-Intensity Focused Ultrasound administration to right dorsal anterior insula, in one of two sessions
223764275|NCT00445328|DRUG|Dalteparin (Fragmin)|Dalteparin 5000 IU once daily subcutaneously for 6-14 days.
223764276|NCT00445328|DRUG|Unfractionated heparin|Unfractionated heparin 5000 IU thrice daily subcutaneously for 6-14 days.
223631653|NCT05339555|OTHER|Instructions for IUD Self-Removal Provided to Participant|The provider will offer any individual presenting for in-person IUD removal or exchange (removal-replacement) the option for self-removal. The participant will be provided a 'how to' instruction sheet with information on positioning and what to expect. The participant will first attempt removal with clean hands if desired, then utilizing non-sterile, clean gloves (not explicitly tested in prior studies) and if that fails, the use of a menstrual cup (a novel technique). If not successful, the provider will perform standard IUD removal in the clinic.
223631654|NCT02923726|DEVICE|Arm 1 (ATP+Shock)|Subjects will be randomized and device programmed to the respective arm.
223631655|NCT02923726|DEVICE|Arm 2 (shock only)|Subjects will be randomized and device programmed to the respective arm.
223631656|NCT05380466|OTHER|Quantum Touch|Quantum-Touch is one of the therapeutic touch techniques, a biofield therapy that uses life force energy to facilitate healing
223631657|NCT05011942|DEVICE|Irrisept Irrigation solution|ii. Irrigation (Irrisept vs control of normal saline) used after initial skin inicision prior to coming through fascia, after placement of instrumentation (screws, hooks), prior to placement of bone graft, and after fascial closure iii. Irrigation exposure/soak time to be 1 min for each irrigation time point. iv. 1 bottle (450 mL) Irrisept irrigation to be used during case with normal saline rinse to follow at each irrigation time point in study subjects v. Normal saline irrigation will be used alone in control subjects at the same time points.
223631658|NCT04144569|DRUG|PD-1 Combined With Pyrotinib|PD-1 Combined With Pyrotinib
224220156|NCT02477007|DRUG|Placebo|Placebo will have the closest flavour, smell and aspect to the active substances, respectively paracetamol and ibuprofen. Placebo will be prepared in bottles with a fake label of active substances for a better blinding both for the nurse and the patient. Labels will be hiding by a mask.
224220157|NCT02593188|BIOLOGICAL|HYQVIA|Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase
224220158|NCT02880215|BEHAVIORAL|Attention Bias Modification|Behavioral intervention designed to decrease negative attention bias.
224220159|NCT02880215|BEHAVIORAL|Cognitive Control Training|Behavioral intervention designed to improve sustained attention.
224220160|NCT04583488|DRUG|Intraperitoneal docetaxel|Up to 3 dose levels of intraperitoneal docetaxel will be studied (25mg/m2, 35 mg/m2, 45 mg/m2).
224220161|NCT06330428|BEHAVIORAL|Sexuality-Based Family Planning Education via Podcast|The training program is planned to consist of 5 modules. These trainings will be shared module by module on a daily basis through an application (Spotify) where podcasts are shared. These modules are as follows: 1. Sexual and Reproductive Health / Sexual Rights / Female-Male / Physiology of Sexual Functions, 2. Sexual Myths, 3. Contraceptive Methods-1, 4. Contraceptive Methods-2, 5. Sexually Transmitted Diseases / Safe Sexual Intercourse As a result of randomization, the links of the podcasts will be shared with the women in the experimental group one by one on a daily basis. Podcasts are planned to last an average of 10 minutes. This training content is planned for 5 days and the second tests will be applied by the researcher to the women who finish the podcasts. The 3rd tests will be applied 4 weeks after the second tests.
224220162|NCT03372083|DRUG|Deferasirox|Deferosirox was provided in tablet forms of 90, 180 and 360mg. Tablets were crushed in the home environment and administered by sprinkling the full dose on to soft food to be consumed immediately.
224220163|NCT03210233|PROCEDURE|Blood test, skin testing and challenge testing.|Skin Prick Testing (SPT) and Intradermal Testing (IDT). We will follow the STARD framework for reporting studies of diagnostic accuracy
223631659|NCT05659953|DRUG|LMT503|Subjects will receive one of several different oral doses of LMT503 once daily
223631660|NCT05659953|DRUG|Placebo|Subjects will receive one of several different oral doses of Placebo once daily
223631661|NCT03446235|BEHAVIORAL|Exercise instruction with motivational interview|An activity tracker and a heart rate monitor to track the participants activity and exercise records will be used. In addition to the basic instruction of exercise and nutrition, an exercise physiologist provides individualized exercise instruction with a motivational interviewing skill, which is a different style from traditional persuasive style of communication between the healthcare professionals and patients.
223631662|NCT03446235|BEHAVIORAL|Self-monitoring|An activity tracker and a heart rate monitor to track the participants activity and exercise records will be used. Basic instruction about exercise and nutrition is provided at the initial visit.
223631663|NCT03324607|DRUG|hyperpolarized 129Xe gas MRI|There will be MRI imaging before the treatment with Bevespi and another one 2 weeks after use Bevespi. Images obtained using 129Xe MRI will be compared with standard lung function tests that are used routinely in the clinic, 6 minute walk test that assesses walking ability and several questionnaires that assess shortness of breath and life quality.
223631664|NCT03324607|DRUG|Bevespi Aerosphere|There will be MRI imaging before the treatment with Bevespi and another one 2 weeks after use Bevespi.
223631665|NCT02648308|BEHAVIORAL|Obesity Management Workshop|Workshop provided to first year medical residents to improve confidence and skill when conducting weight management visits with patients
224220164|NCT06203691|DIETARY_SUPPLEMENT|Supplementation with Nirvana Super Pro Liquid Supplements|Intervention will measure strength pre \& post operatively. Intervention group will receive liquid supplements (3oz daily shots) pre (Prepare) and Post (Recover) operatively.
224220165|NCT06203691|DIETARY_SUPPLEMENT|Non-Supplementation Group|Intervention will measure strength pre \& post operatively. Intervention group will not receive liquid supplements.
224220166|NCT06011473|DEVICE|CGM (FreeStyle Libre 3)|"FreeStyle Libre 3 system consists of a sensor that measures interstitial glycemia every minute and a dedicated application on mobile phone. Measurements are transmitted via Bluetooth to a mobile phone, that collects the data in the mobile application. Moreover, the study subject's application is connected to the doctor's application which allows remote real-time glycemia monitoring on another device.~Other Name: continuous glucose monitoring, CGM, FreeStyle Libre 3"
224317984|NCT05857852|DEVICE|Sham LIFU device|Sham LIFU device administered in one of two sessions
224317985|NCT02520297|DRUG|TRV130|Drug
224317986|NCT01507766|DRUG|early enteral nutrition|The enteral nutrition was started within 48h after admission
224317987|NCT01507766|DRUG|Delayed enteral nutrition|The enteral nutrition was started at the 8th day after admission
224317988|NCT01326923|DRUG|Cetuximab|Single arm phase II study of chemotherapy
223631666|NCT05301959|DEVICE|low intensity percutaneous musculoskeletal electrolysis|An acupuncture needle (0.30mm X 25mm) will be introduced into the device's strut. With the equipment on and with a base intensity of 120µA, the acupuncture needle is introduced in a proximal-distal and postero-anterior direction, in the area of the Achilles tendon body. The position of the needle will be checked with ultrasound and once the point to be treated is reached, the working intensity will be increased up to 600 µA. The emission will be maintained until the participant reports a pain of 60/100 in VAS. At that moment, the emission will be paused completely until the participant reports a sensation of at least 20/100 in VAS. After this period the emission will be continued at 600 µA. This cycle will continue until the emission lasts for more than 120 sec, continuously. At this point, the needle will be repositioned to repeat the emission protocol a maximum of 3 times in total.
223631667|NCT05301959|DEVICE|Sham application|A modification will be made in a second equipment, closing the circuit with a 10kΩ resistor inside the equipment, in the output strand chip. Allowing the simulation of emission without emitting current to the participant and without being able to appreciate any type of alteration in the handling of the equipment, by the operators. Therefore, the same steps will be followed as in the experimental group.
223631668|NCT05301959|OTHER|Silbernagel protocol|The Silbernagel et al. protocol comprises several heel raising exercises with concentric and eccentric movements, performed on two legs and one leg. It is composed of 3 sets of 15 repetitions and that during the exercises allows pain to be present, but not being disabling. The exercises will be performed only once a day. The progression will be made by changing from standing exercises to monopodal support, moving from concentric-eccentric to purely eccentric loading, adding weight in a backpack (in steps of 5 kg when pain does not exceed 5 in the pain monitoring model) and finally using fast rebound exercises and plyometric exercises.
223631669|NCT03779256|PROCEDURE|2D transvaginal ultrasound|"Transvaginal ultrasound is part of routine pre-operative examination of the women before surgery is scheduled. Described surgical treatment interventions is standard practice used to alleviate patient symptoms.~Women recruited at Oslo university hospital, Norway will also have an MRI performed pre-operatively."
223631670|NCT00476125|BEHAVIORAL|Dietary manipulation ketogenic diet|Subjects will consume a ketogenic diet for 3 days.
223631671|NCT00476125|BEHAVIORAL|Dietary Manipulation - 12 day ketogenic diet|Subjects will consume a ketogenic diet for 12 days.
223631672|NCT00476125|BEHAVIORAL|16 Hour Fast|Subjects will fast for 16 hours.
223631673|NCT03291535|OTHER|Connected-device|This intervention will allow patients to upload blood pressure data automatically from a blood pressure cuff into the electronic health record.
223631674|NCT03291535|OTHER|Usual care|This intervention will consist of usual clinical care as determined by the clinical pharmacist.
223631675|NCT02626585|PROCEDURE|Postrhinoplasty taping|Postrhinoplasty taping is commonly applied by rhinoplasty surgeons. Following rhinoplasty the nose is generally taped and a (thermoplastic) nasal cast is applied on top of this to make sure the final form of the nose is protected. Postoperatively, this cast is removed at some point. After this, some of the surgeons prefer to tape the nose with nasal tapes such as Micropore (3M) etc. Postrhinoplasty taping is the term used for this. The nose is (generally) taped horizontally with 1/2 inch wide tapes. This is done superiorly from radix to inferiorly to nasal tip. The idea is to compress the nose and to cover it. The duration of postrhinoplasty taping differs according to the preference of the surgeon and the patient
223631676|NCT03297047|DEVICE|combi cast|upper arm or forearm combi cast
223631677|NCT02946086|BEHAVIORAL|HABIT-ILE with prismatic adaptation|Bimanual and locomotor intensive intervention for 90h including 8 hours of prismatic adaptation
223631678|NCT02946086|BEHAVIORAL|HABIT-ILE without prismatic adaptation|Bimanual and locomotor intensive intervention for 90h including 8 hours of prismatic adaptation wearing sham goggles.
224220167|NCT01528566|BEHAVIORAL|Tai Chi|The experimental group received three sessions of Sun Tai Chi (TC) a week for 20 weeks (20-to-40 minute exercise plus a 5-minute rest per session). Sun TC includes 6 basic and 6 advanced forms designed for all ages with arthritis seeking a joint-safe exercise routine.
224317989|NCT06470178|COMBINATION_PRODUCT|corhot1: chemotherapy combined with fruquintinib|"Chemotherapy Drugs: Selection based on clinical guidelines/indications and patient condition.For example, recommended chemotherapy regimens: mFOLFOX6 or CAPEOX.~Fruquintinib: 3mg (starting dose), PO (once daily). Dosing schedule and dosage can be adjusted based on concurrent chemotherapy and immune checkpoint inhibitors. Have received fruquintinib treatment for at least 2 cycles."
223631679|NCT03212911|BIOLOGICAL|Hepatitis B vaccine|Hepatitis B vaccine (20 mcg/ml) 1 ml intramuscular injection in 3 (at 0, 1, 6 months) or 4 doses (0, 1, 2, 6 months)
223631680|NCT05471765|DEVICE|Withdrawal of Continuous Positive Airway Pressure device|After completing one month of therapeutic management with The Continuous Positive Airway Pressure device and have controlled OSA defined as Apnea Hypopnea Index (AHI) of \< 5 while on treatment. At random, a group of participants will cease to use the Continuous Positive Airway Pressure. And they'll have weakly clinic visits where they will fill the Epworth Sleepiness Scale, check their blood pressure, heart rate and undergo Polysomnography for 4 weeks.
223631681|NCT05471765|DEVICE|Alternation usage of Continuous Positive Airway Pressure Device|After completing one month of therapeutic management with The Continuous Positive Airway Pressure device and have controlled OSA defined as Apnea Hypopnea Index (AHI) of \< 5 while on treatment. Randomly, these patients will alternatively use The Continuous Positive Airway Pressure device every other day (e.g. They will use the device 4 days and not use it for 3 days of the week) and they'll have weakly clinic visits where they will fill the Epworth Sleepiness Scale, check their blood pressure, heart rate and undergo Polysomnography for 4 weeks.
223631682|NCT02278510|DRUG|Topotecan|Topotecan is a chemotherapy that is approved by the FDA to treat cancers. It is normally given by an intravenous injection, and not directly into a tumor. That is why it is considered to be an investigational drug for this study
224220168|NCT01528566|BEHAVIORAL|Attention control|The attention control group participated in health education, culture related activities and other activities for a total of 20 weeks. The attention control protocol was standardized in terms of teaching content, materials and duration. The length and frequency of the activities carried out in this group closely matched those in the TC group.
223631683|NCT02278510|DRUG|Gadolinium DTPA|Gadolinium DTPA is a contrast agent which will be added to topotecan to allow the investigators to observe where topotecan goes in tumors. Gadolinium DTPA is approved by the FDA for intravenous injection during an MRI scan. It is not approved by the FDA for administration directly into a tumor.
223631684|NCT02278510|DEVICE|Cleveland Multiport Catheter|The Cleveland Multiport Catheter is a device that is not approved by the FDA and so it is classified as an investigational device. It has been designed to deliver drugs and other agents intended to treat cancers directly into the affected tissues. The Cleveland Multiport Catheter can be placed into a brain tumor only in the operating room. It is placed during an operation to perform a biopsy of brain tumors. Following the biopsy, a surgeon will place two catheters into the tumor with use of an image guided navigation system. Once each catheter has been placed, it will be secured into the scalp and the incision will be closed. The Cleveland Multiport Catheter will be left in place until the completion of the topotecan treatment.
223631685|NCT01004068|OTHER|SET-diet plus clomiphene|Two months of structured exercise program plus hypocaloric diet followed by 150 mg daily of clomiphene citrate
223631686|NCT01004068|DRUG|Clomiphene citrate|Clomiphene citrate at 150 mg daily for one cycle
223631687|NCT01004068|BEHAVIORAL|Structured exercise program plus hypocaloric diet|SET plus diet
223631688|NCT06352723|DRUG|Cenobamate|"Study Drug: Cenobamate 400mg x 1 NGT/G-tube (Day 1), 100mg (Day 2-14)~* Discontinued cenobamate upon cessation of seizures or RegiSCAR score 4-5 or at 14 days.~* Adjust cenobamate dose based on patient response; this may include discontinuation if seizures resolve, or increase in dose to 150mg or 200mg a day after Day 7"
223631689|NCT02731586|DRUG|Allogenic Mesenchymal stem cells|Allogenic mesenchymal stem cells are introduced during placement of dental implants.
223631690|NCT00269061|DRUG|pioglitazone|
224220169|NCT03281434|DIETARY_SUPPLEMENT|Collagen peptide|Low leucine content protein supplement to be consumed twice daily
224220170|NCT03281434|DIETARY_SUPPLEMENT|Whey protein isolate|High quality protein (DIAAS score), high leucine supplement, to be consumed twice daily
224220171|NCT06340542|OTHER|Thoracic Mobility exercises|Exercises which focus on improve the mobility of the spine especially thoracic region was administered to the patients in different position including quadruped and standing position.
224220172|NCT06340542|OTHER|Manual Release technique|Interventions include release the muscle tension, trigger point release and reducing stiffness of spine was administered
224220173|NCT03839888|DRUG|0.125% Atropine|patients used 0.125% atropine eyedrop per night before sleep for 7 days.
224220174|NCT01846247|OTHER|Standard Care + VEM|Patient will receive standard stroke unit care with earlier and additional physiotherapy and nursing sessions as per an intervention protocol.
224317990|NCT06470178|COMBINATION_PRODUCT|corhot2: chemotherapy combined with fruquintinib|"Chemotherapy Drugs: Selection based on clinical guidelines/indications and patient condition.For example, recommended chemotherapy regimens: mFOLFOX6 or CAPEOX.~Fruquintinib: 3mg (starting dose), PO (once daily). Dosing schedule and dosage can be adjusted based on concurrent chemotherapy and immune checkpoint inhibitors. Have received fruquintinib treatment for at least 2 cycles."
224220175|NCT01846247|OTHER|Standard care|
224220176|NCT04351191|DRUG|Hydroxychloroquine Sulfate Regular dose|Hydroxychloroquine administered based off of in-vitro pharmacokinetics study of optimal dosage for efficacy against SARS-CoV-2
224220177|NCT04351191|DRUG|Hydroxychloroquine Sulfate Loading Dose|Hydroxychloroquine administered as a loading dose only
224220178|NCT04351191|DRUG|Chloroquine|Chloroquine administered based off of in-vitro pharmacokinetics study of optimal dosage for efficacy against SARS-CoV-2
224317991|NCT03039114|DRUG|Parsaclisib|Parsaclisib at the protocol-defined starting dose administered once daily for 8 weeks followed by once weekly.
223631691|NCT03464734|DRUG|Pembrolizumab and Nanoparticle Albumin-bound Paclitaxel|At study entry, patients will receive 2 cycles of pembrolizumab at the dose of 200 mg, intravenously in 30 min, on day 1 and nab-paclitaxel 125 mg/m2 intravenously in 30-40 min, on day 1 and 8.
223631692|NCT04475978|DEVICE|IVUS-guide DCB PTCA|IVUS-guide DCB PTCA
223631693|NCT04475978|DEVICE|Angio-guide DCB PTCA|Angio-guide DCB PTCA
224317992|NCT03039114|DRUG|Hexal|Bendamustine 90 mg/m\^2 administered intravenously at protocol-defined timepoints.
224317993|NCT03039114|DRUG|Gazyvaro|Obinutuzumab 1000 mg by intravenous infusion at protocol-defined timepoints.
223631694|NCT04784325|DIAGNOSTIC_TEST|Blood draw through TAP II|Two self-administered blood draws through TAP II device
223631695|NCT04784325|DIAGNOSTIC_TEST|Blood draw through ADx cardT|One self-administered ADx card blood draw
223631696|NCT04784325|DIAGNOSTIC_TEST|Blood draw through standard venipuncture|One phlebotomist-performed standard venipuncture
223631697|NCT01449162|DRUG|Masitinib|6 mg/kg/day
223631698|NCT01449162|DRUG|Placebo|
223631699|NCT02197884|DRUG|JNJ-54861911, 25 mg|JNJ-54861911, 25 mg tablet orally on Day 1 and Day 9.
223631700|NCT02197884|DRUG|Itraconazole 200 mg|Itraconazole 200 mg (2\*100 mg capsule) orally once daily from Day 5 to Day 12.
223631701|NCT02197884|DRUG|Clarithromycin 500 mg|Clarithromycin 500 mg immediate release tablet orally twice daily from Day 5 to Day 12.
223631702|NCT05222334|PROCEDURE|Intrafascial interscalene brachial plexus block|"After sterilization of skin with povidone-iodine (betadine) and skin infiltration with 1-3ml lidocaine 1%, interscalene brachial plexus block will be performed using an ultrasound machine (Phillips Cx-50,Amsterdam, Netherlands) with a linear probe (L12-3 MHz) will be used in both groups. The US transducer will be placed under aseptic fashion on the lateral side of the neck at the cricoid cartilage level to view three hypoechoic structures, that represent the roots of the brachial plexus.~The two outermost nerve roots (C5 and C6) between the anterior and the middle scalene muscles will be identified and the local anesthetic (10 ml 0.5% bupivacaine) is then injected, so that spread will be seen immediately between the C5 and the C6 nerve roots."
224220179|NCT04351191|DRUG|Placebo|Standard of Care plus placebo
224220180|NCT01213355|DRUG|Placebo|Capsule, single dose, oral, 1 day
224220181|NCT01213355|DRUG|Scopolamine|injectable subcutaneous formulation, single dose, 1 day
224220182|NCT01213355|DRUG|PF-05212377|5 mg, PF-05212377, capsule, single dose, 1 day
224220183|NCT01213355|DRUG|Scopolamine|injectable subcutaneous formulation, single dose, 1 day
224220184|NCT01213355|DRUG|PF-05212377|20 mg, capsule PF-05212377, single dose, 1 day
224220185|NCT01213355|DRUG|scopolamine|injectable subcutaneous formulation, single dose, 1 day
223631703|NCT05222334|PROCEDURE|Extrafascial interscalene brachial plexus block group|Final needle tip position will be 4 mm lateral to the brachial plexus sheath, at a level equidistant between C5 and C6 roots. The distance of 4 mm is chosen according to the calculated success rate over 90% reported. the local anesthetic (10 ml 0.5% bupivacaine) is then injected
223631704|NCT05222334|DRUG|Bupivacaine|bupivacaine
223631705|NCT00579215|BEHAVIORAL|Enhance Care|EC will receive a decision aid with seven components: social support, anticipatory guidance, adhering to the patient's preference for participation in treatment decision making, a quality decision-making process tutorial, normalization (using a CD program), structured time with oncology professionals to discuss difficult decisions, and values clarification of 3 decisions throughout treatment. Self-report measures will be used for all participants in addition to probes for the taped interviews with EC. The outcome measures are quality decision making and decisional conflict. Two panels (decision making and lung cancer) will review the protocol twice. The plan will include serially screening the appointment roster. The decision aid will be administered during three clinic visits
223631706|NCT00579215|BEHAVIORAL|Usual Care|As an intentional control, the usual care group will receive standard care related to lung cancer and treatment; they will not receive any oral, written, or recorded information related to decision making. Usual care includes anticipatory guidance related to the disease and treatment (e.g., what to do about treatment side effects, signs of an infection, why a treatment would be changed or stopped) using patient education materials normally used in the MSKCC, TOS, Outpatient Clinic.
223631707|NCT02610296|DRUG|QPI-1002|IV injection
223631708|NCT02610296|OTHER|Placebo|isotonic saline
223631709|NCT06066034|DIAGNOSTIC_TEST|HOMA-IR，ESHRE/ASRM|Grouping based on HOMA-IR and the diagnostic criteria of the European Society for Human Reproduction and Embryology and American Society for Reproductive Medicine (ESHRE/ASRM) in Rotterdam in 2003
223631710|NCT03149679|DRUG|Cyclophosphamide|Chemotherapy
223631711|NCT03998410|DEVICE|Lung Doppler Signals|Recording Doppler ultrasound on the right chest wall
223631712|NCT01146769|OTHER|Pelvic floor exercise|Pelvic floor strengthening exercise
223631713|NCT03402217|BEHAVIORAL|Patient Centered Postpartum Contraception App|This is a theory-based smart phone-based application designed to provide immediate postpartum contraception information to young women aged 15-25.
223631714|NCT01277016|DRUG|BMDex|"BMDex:~cycles 1 and 2 = MDex with bortezomib (B) at 1.3 mg/m2 i.v. on days 1, 4, 8 and 11 of a 28 day cycle, cycles 3 - 8 = MDex with bortezomib at 1.3 mg/m2 i.v. on days 1, 8, 15 and 22 of a 35 day cycle."
224220186|NCT01213355|DRUG|PF-05212377|60 mg PF-05212377, capsule, single dose, 1 day
224220187|NCT01213355|DRUG|scopolamine|injectable sub cutaneous formulation, single dose, 1 day
224220188|NCT01213355|DRUG|Donepezil|Tablet, 10mg, single dose, 1 day
224220189|NCT01213355|DRUG|Scopolamine|injectable sub cutaneous formulation, single dose, 1 day
224220190|NCT00355069|BEHAVIORAL|electronic (computer based) provider feedback tool|All sites received a Basic Pediatric Chronic Care Model; 2x2 factorial design allocated the additional Medication Assessment Prompt and family education across the four sites as well.
224220191|NCT01321112|DRUG|conversion from CNI to MMF|After screening procedure mycophenolate mofetil will be started (week -4) at a dose of 500 mg twice a day for two weeks and then (week -2) increased to 1000 mg twice a day and CNI will be reduced at the 50% of the initial dose. After two weeks (week 0) CNI will be completely discontinued (complete IS conversion). The investigators will follow up patients every 4 weeks up to 48 weeks after the complete IS conversion.
224220192|NCT01681043|BEHAVIORAL|protocol 'Quiet in the room'|"Protocol 'Quite in the room' between 10 p.m. and 6 a.m.~* nurse nearby~* no visits after 10 p.m.~* decreased alarm sound in ventilator and monitor~* decreased light intensity~* no unnecessary conversations around the patient~* medication should be limited to max 1-2 times in this time period~* no unnecessary therapeutic or diagnostic procedures in this time period~* earplugs and sleep masks"
224220193|NCT05399719|OTHER||no intervention
224220194|NCT05704218|BIOLOGICAL|blood sample|the patient will have a blood sample in order to perform serology tests
224220195|NCT06496113|PROCEDURE|Minimally invasive liver resection|Patients underwent liver resection either by robotic or laparoscopic approach
224220196|NCT02266706|DRUG|Ceftolozane/Tazobactam 1000/500 mg|A fixed dose combination (FDC) of 1000 mg ceftolozane and 500 mg tazobactam as a 60 minute infusion.
224220197|NCT02266706|DRUG|Ceftolozane/Tazobactam 30/15 mg/kg|A FDC of 30 mg/kg of ceftolozane and 15 mg/kg of tazobactam as a 60 minute infusion.
224220198|NCT02266706|DRUG|Ceftolozane/Tazobactam 20/10 mg/kg|A FDC of 20 mg/kg of ceftolozane and 10 mg/kg of tazobactam as a 60 minute infusion.
224220199|NCT02266706|DRUG|Ceftolozane/Tazobactam 18/9 mg/kg|A FDC of 18 mg/kg of ceftolozane and 9 mg/kg of tazobactam as a 60 minute infusion.
224220200|NCT02266706|DRUG|Ceftolozane/Tazobactam 12/6 mg/kg|A FDC of 12 mg/kg of ceftolozane and 6 mg/kg of tazobactam as a 60 minute infusion.
224220201|NCT03673384|DEVICE|infrared-C ray irradiation|Infrared-C irradiation by hot compress with a powered heating compress
224220202|NCT03673384|DEVICE|eye mask|infrared-C irradiation by hot compress with a powered heating eye mask
224220203|NCT03673384|DRUG|Xyzal Oral Product|used to relieve allergy symptoms, It works by blocking histamine that body secretes during an allergic reaction.
224220204|NCT03673384|DRUG|Fluticasone Furoate|used to treat seasonal and perennial allergic rhinitis. It also helps to reduce the symptoms of seasonal allergic rhinitis.
223631715|NCT03715114|DRUG|GV-971|Oral GV-971
223631716|NCT03715114|DRUG|Placebo|Oral Placebo
223631717|NCT01680341|DRUG|insulin degludec/insulin aspart|Twice weekly self-titration at intervals of 3-4 days, based upon a single pre-breakfast and pre-dinner SMPG (self-measured plasma glucose) value. For subcutaneous (s.c., under the skin) administration.
223631718|NCT01680341|DRUG|insulin degludec/insulin aspart|Once weekly self-titration based upon the lowest of 3 pre-breakfast and 3 pre-dinner SMPG (self-measured plasma glucose) values. For subcutaneous (s.c., under the skin) administration.
223631719|NCT04351542|DIETARY_SUPPLEMENT|Ayurveda|Based on individual constitution (ayurveda based assessment) and symptoms an individual has, ayurveda herbal supplement and self managed practices were advised along with usual care recommendation.
223631720|NCT04351542|OTHER|Usual Care|Usual care recommended by National Health Services, self isolation, plenty fluid, rest and Paracetamol. During the Covid 19 outbreak, additional recommendation were followed given by health services.
223631721|NCT06419465|BEHAVIORAL|Peer-Led Health Protection and Promotion Training Program|Multiple teaching methods will be used throughout 12 weeks; interactive group trainings on health protection and promotion issues and health seeking behavior methods, demonstration and demonstration using Google Fit and E-Nabiz mobile applications and downloading the applications to their phones, establishing WhatsApp groups to interact with peers, encouraging physical activity using the Google Fit mobile application. In order to provide social interaction, walking with peer leaders, health protection and development issues, receiving questions and opinions and giving guidance by individual phone calls regarding E-Nabiz and Google Fit mobile applications, holding peer group meetings and any of the Health Protection and Development Training Program targets. It consists of interventions such as giving a success badge for the relevant behavior if it reaches someone. Individual phone calls are also included in the intervention program.
223631722|NCT06419465|BEHAVIORAL|Health Protection and Promotion Training Program under the Leadership of a Public Health Nurse|Multiple teaching methods will be used throughout 12 weeks; interactive group trainings on health protection and promotion issues and health seeking behavior methods, demonstration and demonstration using Google Fit and E-Nabiz mobile applications and downloading the applications to their phones, establishing WhatsApp groups to interact with nurses, encouraging physical activity using the Google Fit mobile application. To achieve any of the Health Protection and Development Training Program targets by walking with the nurse, taking individual phone calls regarding health protection and promotion issues, E-Nabiz and Google Fit mobile applications, receiving questions and opinions and giving guidance, holding group meetings in order to provide social interaction and social interaction. It consists of interventions such as giving a success badge for the relevant behavior. Individual phone calls are also included in the intervention program.
223631723|NCT05613569|DRUG|KLS-2031|KLS-2031 administered by transforaminal epidural injection
223631724|NCT01546103|DIETARY_SUPPLEMENT|Cholecalciferol|1000 IU by mouth, once daily for 3 months.
223631725|NCT01546103|DIETARY_SUPPLEMENT|Cholecalciferol|5000 IU by mouth, once daily for 3 months.
223631726|NCT02640586|DEVICE|three MR examination|Three MR examinations: first MRI taken within 1 week before preoperative chemo-radiotherapy; second MRI taken between 14-16days after the initiation of radio-chemotherapy; third MRI taken 7-9 weeks after the completion of preoperative chemo-radiotherapy.
223631727|NCT01426100|DRUG|CKD-828 40/2.5mg|Fixed dose combination of Telmisartan 40mg and S-Amlodipine 2.5mg
223631728|NCT01426100|DRUG|CKD-828 40/5mg|Fixed dose combination of Telmisartan 40mg and S-Amlidioine 5mg
223631729|NCT01426100|DRUG|Telmisartan 80mg|Telmisartan 80mg monotherapy
223631730|NCT03596034|OTHER|JUUL 5%, Virginia Tobacco, ENDS product|Subjects participate in a 15 day product use period during which subjects will be requested to predominantly use the JUUL 5% product ad libitum as their primary source of nicotine. Subjects will be asked to report their daily use of the JUUL 5% product and CPD throughout the 15 day product use period.
223631731|NCT00005942|DRUG|liposomal daunorubicin citrate|Given IV
223631732|NCT00005942|DRUG|semaxanib|Given IV
223631733|NCT00005942|OTHER|laboratory biomarker analysis|Correlative studies
223631734|NCT06567145|BEHAVIORAL|Narrative Enhancement Cognitive Therapy (NECT)|The Narrative Enhancement and Cognitive Therapy (NECT) consists of 20 group sessions divided into five parts: orientation (2 sessions), psychoeducation on stigma (3 sessions), cognitive restructuring (7 sessions), narrative enhancement (7 sessions), and a concluding reflection (1 session). The program helps participants challenge self-stigmatizing beliefs, develop coping skills, and create a new, positive narrative about themselves. Each session lasts about an hour, with a structured format of introduction, main discussion, and conclusion, encouraging active participation and reflection on personal experiences. The intervention ultimately fosters self-efficacy, control, and hope for the future.
223631735|NCT00481832|DRUG|Cyclophosphamide|4 gm /m² IV over 2 hours on day 8
223631736|NCT00481832|DRUG|BCNU|"The dose of BCNU will be based on actual body weight unless the actual body weight is more than 15 kg greater than the ideal body weight in which case the adjusted ideal body weight will be used:~Males IBW = 50 kg + 2.3 kg/inch over 5 feet Females IBW = 45.5 kg + 2.3 kg/inch over 5 feet Adjusted IBW = IBW + 50% (actual weight - IBW)"
223631737|NCT00481832|DRUG|Etoposide|60mg/kg, IV over 4 hours on day -4 pre-transplant and for preparative regimen. The dose of etoposide for mobilization is 2 gm/ m².
223631738|NCT00481832|DRUG|Filgrastim|10µg/kg sc qd starting day following cyclosphamide (or VP-16) until last day of apheresis
223631739|NCT00481832|DRUG|Antithymocyte globulin|1.5 mg/kg/d, IV from day -11 to -7
224220205|NCT06312085|DEVICE|Endofill|Endofill is intended for the permanent obturation of root canals following root canal preparation and disinfection.
223631740|NCT00481832|DRUG|Cyclosporine|5mg/kgbid,variable, po or IV
223631741|NCT00481832|DRUG|Mycophenolate mofetil|15 mg/kg po on day 0, at 5-10 hours after mobilized PBPC infusion is complete. Thereafter, beginning on day +1 MMF is taken at 15 mg/kg po b.i.d. (30 mg/kg/day) if transplantation was using a matched related donor and 15 mg/kg po t.i.d if from a matched unrelated donor or a one antigen mismatched donor. Doses will be rounded up to the nearest 250 mg (capsules are 250 mg). MMF will be stopped on day +28 for matched related donors. For one antigen mismatched related or unrelated donors, the taper will begin on day +40. MMF will be tapered by 10% weekly till off, typically by day +96. If there is nausea and vomiting at any time preventing the oral administration of MMF, MMF should be administered intravenously at an equal dose. MMF dosing is based on actual body weight.
223631742|NCT00481832|DRUG|Rituximab|375 mg/m2 IV (calculated based on actual body weight) on day 1 and day 7. Administered per current standard of care..
224220206|NCT02191956|BEHAVIORAL|Behavioral Parent Training|Weekly clinic session, mid-week call, home practice
224220207|NCT00612833|PROCEDURE|Vasectomy occlusion techniques|Cautery and excision with fascial interposition Cautery and excision without fascial interposition Ligation and excision with fascial interposition
224220208|NCT01071109|PROCEDURE|Therapeutic Massage|Therapeutic Massage--subjects randomized to this group will receive weekly, one-hour therapeutic massage
224220209|NCT05737888|OTHER|fMRI Neurofeedback|15 intervention sessions on a 3T MRI scanner.
224220210|NCT05737888|OTHER|EEG Neurofeedback|15 intervention sessions with a standard EEG-cap with 64 active electrodes.
224220211|NCT05737888|BEHAVIORAL|Cognitive Behavioral Therapy|10 intervention sessions of CBT group therapy, as per local university hospital standard of care.
223631743|NCT00481832|PROCEDURE|Autologous hematopoietic stem cell transplantation (auto-HSCT)|Auto-HCT involves an intravenous infusion of a participant's previously collected and frozen white blood cells collected after treatment with mobilizing agents
223631744|NCT00481832|PROCEDURE|Allogeneic hematopoietic stem cell transplantation (allo-HSCT)|Allo-HCT involves an intravenous infusion of a donor's white blood cells collected after treatment with mobilization with filgrastim (G-CSF)
223631745|NCT00481832|PROCEDURE|Total lymphoid irradiation|TLI is administered in 80cGy fractions on Days -11 to Day-7 relative to allo-HSCT
223631746|NCT00481832|DRUG|CD34+ Cells|2 x 10e6 CD34+ cells per kg actual body weight on Day 0
223631747|NCT00481832|DRUG|Solu-Medrol|1 mg/kg, Day-11 to Day-7
223631748|NCT04614363|DRUG|68Ga-PSMA|All subjects enrolled in the study will receive a single IV dose of 3-7 mCi of 68 Ga-PSMA (study drug) followed by PET/CT imaging for detection of tumor location.
223631749|NCT02558894|DRUG|MEDI4736 monotherapy|MEDI4736 via IV infusion.
223631750|NCT02558894|DRUG|tremelimumab+MEDI4736|tremelimumab+MEDI4736 via IV infusion.
223631751|NCT02992288|DRUG|Neladenoson bialanate (BAY1067197)|5 mg orally once daily for 20 weeks
223631752|NCT02992288|DRUG|Neladenoson bialanate (BAY1067197)|10 mg orally once daily for 20 weeks
223631753|NCT02992288|DRUG|Neladenoson bialanate (BAY1067197)|20 mg orally once daily for 20 weeks
223631754|NCT02992288|DRUG|Neladenoson bialanate (BAY1067197)|30 mg orally once daily for 20 weeks
223631755|NCT02992288|DRUG|Neladenoson bialanate (BAY1067197)|40 mg orally once daily for 20 weeks
223631756|NCT02992288|DRUG|Placebo|Orally once daily for 20 weeks
223631757|NCT06205277|PROCEDURE|Second TURBt|Second TURBt for pT1 NMIBC as per current EAU Guidelines.
223631758|NCT03416985|DEVICE|Oral B Healthy Clean Manual Toothbrush|Manual Toothbrush
223631759|NCT03416985|DEVICE|BURST Sonic Oral Care|Electric sonic toothbrush
223631760|NCT03416985|DEVICE|Philipps Sonicare DiamondClean 300 Series|Electric pulsating toothbrush
223631761|NCT05839964|DIETARY_SUPPLEMENT|CBN and CBD|CBN and CBD in Gummy Format
223631762|NCT05173194|OTHER|Exercise|Eight-week program of a remotely supervised resistance exercise. Frequency: three times per week. Duration: 60 minutes per session. Training program: warm-up and joint mobility; strength exercises for different muscle groups; and cool down (stretching and breathing exercises).
223631763|NCT02006472|DRUG|Pridopidine|22.5 mg and 45 mg capsules
223631764|NCT02006472|OTHER|Placebo|Capsules matching drug
223631765|NCT00499486|DRUG|sirolimus|Treatment with rapamycin will begin on Day 1 at a single flat dose level of 5 mg/day. Rapamycin will be administered continuously without interruption through all cycles in an outpatient setting. Each cycle will last 28 days.
223631766|NCT05639894|BIOLOGICAL|RSV vaccine candiate formulation 1|Pharmaceutical Form: Liquid frozen solution in a vial Route of Administration: Intramuscular injection
223631767|NCT05639894|BIOLOGICAL|RSV vaccine candidate formulation 2|Pharmaceutical Form: Liquid frozen solution in a vial Route of Administration: Intramuscular injection
223631768|NCT05639894|OTHER|Placebo|Pharmaceutical Form: Liquid Route of Administration: Intramuscular injection
223631769|NCT05128669|PROCEDURE|CPIP|CPIP is an innovative Child-Parent Individualized Psychotherapy, consisting of 25 sessions, designed by the PI and his clinical collaborators for children with internalizing disorders in the aftermath of childhood neglect. It is informed by Short-term Psychoanalytic Child Therapy, elements of psychoanalytic parent work, videofeedback and Child-Parent Psychotherapy (CPP) and. CPIP supports the child-caregiver relationship and helps the child to resolve rigid conflictual internal representations/working models and improve interpretative and mentalizing techniques.
223631770|NCT05128669|PROCEDURE|ECS|"Enhanced Caregiving Support (ECS) will serve as the control condition provided by the Allgemeine Sozialdienst (ASD - Community Social Services) of the two participating cities. According to German law (§ 27 SGB VIII), caregivers are entitled to receive caregiving support (CS; Hilfe zur Erziehung) in cases where the child's wellbeing is jeopardized. CS generally includes supportive work across all child-relevant systems (family, neighborhood, (pre-)school, peer group etc.). Appointed social workers and educators provide parenting counseling, family support, and intensive child support according to an individualized helping plan (Hilfeplan). In more severe cases, children are placed in (temporary) day-care centers, children's homes, foster families etc. Within the context of the trial, we will appoint an additional multi-systemic case manager to each case to enhance the quality of case coordination (enhanced CS; ECS). All children and families will receive ECS."
223631771|NCT01803009|BEHAVIORAL|Patient views NCI CRC RAT|
223631772|NCT01803009|BEHAVIORAL|View presentation regarding current chance of having an advanced adenoma|
223631773|NCT06389422|RADIATION|Moderate-dose Hypofractionated Intensity-modulated Radiotherapy|All lesions receive moderate-dose hypofractionated intensity-modulated radiotherapy, with a gross tumor dose of 25Gy/5f, and a maximum dose of 35Gy/5f at the tumor center.
223631774|NCT06389422|DRUG|Pembrolizumab|One week before or during the radiotherapy, patients receive concurrent Pembrolizumab at a dose of 200mg. Subsequently, Pembrolizumab is administered intravenously every 3 weeks. Follow-up examinations are conducted 1-3 months post-radiotherapy. Lenvatinib 4mg may be used for maintenance therapy with Pembrolizumab if there are no contraindications. Maintenance therapy is continued until disease progression or intolerance.
224220212|NCT06232356|DIAGNOSTIC_TEST|Mobile Web App|all participants will undergo an assessment of respiratory health by analyzing the sound of exhaled air recorded by the participant's mobile phone
223631775|NCT00169286|PROCEDURE|Telephone care management|
223631776|NCT00169286|PROCEDURE|peer-led chronic disease self-management workshop|
223631777|NCT00169286|PROCEDURE|professionally-led cognitive behavioral psychotherapy group|
223631778|NCT00002894|DRUG|carboplatin|
223631779|NCT00002894|DRUG|cisplatin|
223631780|NCT00002894|DRUG|paclitaxel|
223631781|NCT02856568|DRUG|Cisplatin|Given IV
223631782|NCT02856568|DRUG|Gemcitabine Hydrochloride|Given IV
223631783|NCT02856568|OTHER|Laboratory Biomarker Analysis|Correlative studies
223631784|NCT02856568|OTHER|Pharmacological Study|Correlative studies
223631785|NCT02856568|DRUG|Ricolinostat|Given PO
223631786|NCT00441909|DRUG|UC-781|0.1% UC-781 Vaginal Gel
223631787|NCT00441909|DRUG|UC-781 placebo|Vaginal Gel Placebo
224220213|NCT03405337|DRUG|FVIII products|Adynovate, Eloctate, Afstyla, Kovaltry
223631788|NCT00418678|DRUG|Cesamet|2 mg BID on Days 2-5.
223631789|NCT04257357|BEHAVIORAL|8-weeks supervised exercise program|Please refer to group description
223631790|NCT04257357|BEHAVIORAL|Active control|Please refer to group description
223631791|NCT05524025|DIAGNOSTIC_TEST|Salivary TTMV-HPV DNA Test|Mouthwash rinse
223631792|NCT05524025|DIAGNOSTIC_TEST|Blood TTMV-HPV DNA Test|Blood test
223631793|NCT00087152|DRUG|Capecitabine|1,000 mg/m\^2 by mouth twice daily Days 1-14 of each 21 day cycle
223631794|NCT00087152|DRUG|Imatinib mesylate|400 mg by mouth daily
223631795|NCT01708356|BEHAVIORAL|Cycling on a residential route|
223631796|NCT05632042|BEHAVIORAL|lifestyle modification (exercise and control of diet)|erectile dysfunction (ED) psoriatic men with metabolic syndrome that will receive lifestyle changes (12 weeks of low calorie diet and moderate-intensity walking on treadmill, the walking duration will be 40 minutes, the walking will be three times per week)
223631797|NCT02689427|PROCEDURE|Axillary Lymph Node Dissection|Undergo axillary lymph node dissection
223631798|NCT02689427|DRUG|Enzalutamide|Given PO
223631799|NCT02689427|OTHER|Laboratory Biomarker Analysis|Correlative studies
223631800|NCT02689427|PROCEDURE|Lymph Node Biopsy|Undergo lymph node biopsy
223631801|NCT02689427|DRUG|Paclitaxel|Given IV
223631802|NCT02689427|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgical resection of primary tumor
223631803|NCT05506384|BEHAVIORAL|Relaps Preventions Therapy|The treatment consists of three parts: 1) setting goals, 2) understanding and identifying high-risk situations and problem behaviors, and 3) consolidating the new activity schedule and identifying future high-risk behaviors. The first part is focused on examining the patient's undesirable behavior, his/her motivation for change, and establishing goals with the. The second part, drawing more from traditional Cognitive Behavioral Therapy (CBT) techniques, consists of exploring problematic situations, identifying high-risk situations and events, emotions and cognitions that induce the problematic gaming behavior or result in a relapse; managing game time with activity scheduling and practicing problem-solving skills. The final part consists of recognizing early warning signals that may indicate that the primary problem behavior is more likely to occur and consolidating the parts of the treatment that have been most helpful in maintaining the new activity schedule.
223631804|NCT05506384|BEHAVIORAL|Treatment as usual|This group will receive treatment as usual at their Child and Adolescent Psychiatry Clinic.
223631805|NCT00598338|DRUG|Prucalopride|4 mg o.d.
223631806|NCT00598338|OTHER|Placebo|o.d.
223631807|NCT06101212|OTHER|survey|After obtaining the informed consent form, a 10-15 minute questionnaire will be applied to the patients included in the study.
223631808|NCT02829424|DRUG|Methotrexate|Use of low dose methotrexate (MTX) in psoriasis patients receiving an anti TNF alpha agent
223631809|NCT02829424|DRUG|Methotrexate Placebo|Use of placebo- MTX in psoriasis patients receiving anti TNF alpha agent according to the approved indication
223631810|NCT03288675|DEVICE|aiTBS|In the active aiTBS arm, the patients will receive 100 cycli of thetaburst trains of 2s, separated by an inter-train-interval of 6 seconds, delivered on the left dorsolateral prefrontal cortex (DLPFC; i.e. 3000 pulses per session). On each stimulation day, a given patient will receive 5 sessions with a between-session interval of 15 minutes. The treatment protocol of in total 20 aiTBS sessions will be spread over 4 days (i.e. 60.000 pulses in total). The sham coil has been specifically developed to mimic the real one.
223631811|NCT03288675|BEHAVIORAL|CCT|By training working memory processing, the CCT aims at modulating similar prefrontal cortex regions as being stimulated previously by aiTBS, namely the DLPFC. thereby possibly stabilizing clinical effects of aiTBS over time. In total 20 sessions of CCT vs. control training (of approximately 25 minutes per session), will be spread over a period of 4 weeks.
223631812|NCT03288675|DRUG|SSRI|All patients will be prescribed antidepressant medication (SSRI) again when starting the CCT (vs. control training).
223631813|NCT02250846|DRUG|EGFR-TKI|egfr-TKI treatment
223631814|NCT01611714|OTHER|Audit-feedback|Clinicians will receive a short email educational message at regular intervals alerting them to the historic disparities in diagnostic workup for SAH in our department and reminding them of the increased risk of SAH among African-American patients.
223631815|NCT01611714|OTHER|Clinical Decision Support|"Clinicians receive an embedded real-time Best Practice Alert (BPA) of increased rates of SAH among African-Americans when they open the headache electronic charting template."
223631816|NCT06142058|DIAGNOSTIC_TEST|RecistTM criteria|RecistTM criteria and RECIST criteria were used to evaluate the efficacy of targeted therapy for NSCLC with positive driving gene.
223631817|NCT04218526|DEVICE|Vercise DBS System|Vercise Deep Brain Stimulation (DBS) System that consists of two bilateral directional DBS Cartesia electrodes implanted in the cuneiform nucleus and a Gevia generator implanted in the upper chest area just below the clavicle.
223631818|NCT06070454|DIAGNOSTIC_TEST|Vaginitis panel|vulvovaginal swab to test for the most common causes of vulvovaginitis - bacterial vaginosis (BV), trichomonas, and candida
223631819|NCT06644573|PROCEDURE|PROSOMNIA Sleep Therapy™ (PSTx)|PROSOMNIA Sleep Therapy (PSTx) is a novel intervention designed to manage homeostatic sleep pressure by leveraging an anesthesia-induced protocol. Using Diprivan/Propofol, PSTx rapidly induces REM sleep, clearing adenosine from the brain and reducing sleep pressure more efficiently than traditional methods. Monitored in real-time via EEG, this therapy personalizes sleep architecture optimization, ensuring deep restorative REM sleep. PSTx stands apart as a promising treatment for chronic insomnia, sleep deprivation, and REM sleep disorders, offering long-term improvement in sleep quality and overall health.
223631820|NCT06644573|PROCEDURE|Anesthesia-Induced Sleep Therapy|"1. Single-Arm, Non-Randomized Design: All eligible participants receive the same treatment PROSOMNIA Sleep Therapy(PSTx), ensuring consistency and homogeneity.~2. Targeted Use of Diprivan/Propofol: The PSTx involves the administration of Diprivan/Propofol, an FDA-approved anesthetic, delivered in a controlled environment under the supervision of an Anesthesiologist.~3. Monitored Anesthesia with Advanced Sleep Assessment: The procedure is monitored according to ASA (American Society of Anesthesiologists) standards, along with real-time EEG to track brain activity during REM sleep.~4. One (1) Hour PPSTx (60-120 minutes): A PSTx is designed to provide immediate results within a controlled timeframe of 60 to 120 minutes.~5. Follow-Up Protocol: Post-treatment follow-ups occur at 24 hours, 7 days, and 30 days after the session to measure outcomes and safety parameters.~6. Focus on Safety and Feasibility: A single-arm approach allows for a concentrated assessment of treatment efficacy."
224220214|NCT03405337|DRUG|Conventional FVIII replacement therapies|Advate, Kogenate FS, Helixate, Novoeight, Nuwiq, Recombinate, Xyntha
224220215|NCT04741685|DEVICE|TTSX2|Treatment with Tandem T Slim X2 with Basal IQ
224220216|NCT04741685|DEVICE|MM640G|Treatment with Medtronic Minimed 640G with Smartguard
224220217|NCT04933578|BEHAVIORAL|Dental anxiety scales|"* The Faces Version of Modified Child Dental Anxiety Scale (MCDASf), which is a psychometric dental anxiety scale for children with eight questions, was used to determine the dental anxiety levels of the children. The scores of each question are represented by varying cartoon faces according to emotions ranging from 1 'relaxed' to 5 'very anxious'. The total scores range from 8 to 40. The scores were categorized as not anxious (\>9), slightly anxious (9-16), fairly anxious (17-24), very anxious (25-32), and extremely anxious (33-40).~* the Modified Dental Anxiety Scale (MDAS) was administered to parents, differently from children. The MDAS has five questions. The scores of each question range from 1 'relaxed' to 5 'very anxious.' The total score ranges from 5 to 25."
224220218|NCT02115685|OTHER|Treadmill Training|Subjects will be randomized to a high intensity and low intensity group. The high intensity group will train at 70-80% of their HRR and the low intensity group will train at 30-40% of their HRR.
224220219|NCT00409188|BIOLOGICAL|Tecemotide (L-BLP25)|After receiving cyclophosphamide, participants will receive 8 consecutive weekly subcutaneous vaccinations with 806 microgram (mcg) of tecemotide (L-BLP25) at Weeks 0, 1, 2, 3, 4, 5, 6, and 7 followed by maintenance vaccinations with 806 mcg of tecemotide (L-BLP25) at 6-week intervals, commencing at Week 13, until disease progression is documented.
224220220|NCT00409188|DRUG|Single low dose cyclophosphamide|A single intravenous infusion of 300 milligram per square meter (mg/m\^2) (to a maximum 600 mg) of cyclophosphamide will be given 3 days before first tecemotide (L-BLP25) vaccination.
224220221|NCT00409188|DRUG|Placebo|A single infusion (IV) of 0.9% Saline solution instead of cyclophosphamide but in the same calculated dose will be given three days before first placebo vaccination. Subjects will then receive eight consecutive weekly subcutaneous vaccinations with placebo at weeks 0; 1; 2; 3; 4; 5; 6 and 7 followed by maintenance placebo vaccinations at 6-week intervals, commencing at week 13, until disease progression is documented.
223631821|NCT06644573|DRUG|Diprivan (propofol), Astra-Zeneca|Diprivan/Propofol is a short-acting intravenous anesthetic used in PROSOMNIA Sleep Therapy to induce rapid and controlled REM sleep. Unlike other sleep aids, Propofol works by potentiating GABA\_A receptor activity, leading to a deeper and faster transition into sleep. The administration is closely monitored in real-time using EEG to ensure optimal sleep stages are achieved. Propofol is distinct from traditional sedatives due to its precise control, rapid onset, and ability to clear adenosine from the brain, reducing sleep pressure effectively and safely.
223631822|NCT06644573|DEVICE|Continuous EEG Monitoring|Continuous EEG Monitoring is an essential component of PROSOMNIA Sleep Therapy, used to accurately track and optimize sleep architecture in real time. This device provides precise monitoring of brainwave activity, ensuring the patient achieves the necessary stages of REM sleep during therapy. Unlike other monitoring systems, this EEG is used to dynamically adjust the Diprivan/Propofol infusion, allowing for personalized sleep regulation. The continuous data collection helps maintain ideal sleep conditions, distinguishing it from standard sleep therapy interventions that lack real-time neurological insights.
223631823|NCT01436149|DRUG|SPD489 (Lisdexamfetamine dimesylate )|Antidepressant (either escitalopram oxalate, sertraline hydrochloride, venlafaxine hydrochloride extended release or duloxetine hydrochloride) oral, once daily + SPD489 (oral, 20, 30, 50 or 70 mg, once daily) for 8 weeks
223631824|NCT01436149|DRUG|Placebo|Antidepressant (either escitalopram oxalate, sertraline hydrochloride, venlafaxine hydrochloride extended release or duloxetine hydrochloride) oral, once daily + Placebo (oral, once daily) for 8 weeks
223631825|NCT05473988|OTHER|Admission to General Ward|Admission to General Ward
223631826|NCT05473988|OTHER|Admission to Intensive Care Unit|Admission to Intensive Care Unit
223631827|NCT05473988|OTHER|30 Day Mortality|30 Day Mortality
223631828|NCT05261386|DRUG|CBT-008|Treat MGD
223631829|NCT03893071|DRUG|Hydroxypropyl-β-cyclodextrin|HP-β-CD will be administered as Trappsol® Cyclo 25% (250mg/mL) by slow intravenous infusion over a period of 8 up to 9 hours.
224220222|NCT00003637|DRUG|cisplatin|
224220223|NCT00003637|DRUG|fluorouracil|
224220224|NCT00003637|RADIATION|radiation therapy|
224220225|NCT01260571|DRUG|Benzoyl peroxide and sulfur|topical cream, 5% benzoyl peroxide and 2% sulfur Frequency once to day Duration 24 hours
224220226|NCT05139654|OTHER|Arm elevation in the scapular plane|Lift the arm up in the scapular plane
224220227|NCT05139654|OTHER|Pull up with gymbar|Grasp the gymbar with both hands and pull up as high as the subject can
224220228|NCT05139654|OTHER|Pull up with fingerboard|The width of the fingerboar is 20 mm. Pull up with fingers on the fingerboard.
224220229|NCT04549909|OTHER|collect retrospectively data|Analyse the incidence of BPL in these populations
223631830|NCT05811936|BEHAVIORAL|Survivorship Needs Assessment Planning (SNAP) tool|"SNAP includes 2 educational survivorship modules for caregivers and survivors. There are 3 main elements: needs assessment, a tailored care plan and a mobile support app. SNAP uses pre-specified categories of needs, resources, and messaging behind the scenes to automate the identification, rating and management of high priority needs. Generated tailored care plans include referrals, messages and educational materials mapped to prioritized dyad-reported concerns addressing survivorship domains (diagnosis, treatment, follow-up care). Care plans and referrals are reviewed with an Advanced Practice Provider. Barriers to uptake are addressed, goal-oriented action planning is refined with brief mobile app training. Dyads receive a personalized binder with care plan, referrals, and an action plan. Dyads receive e-monitoring for 6 weeks to check in and identify barriers with algorithm-driven messaging to reinforce progress, provide further resources and encouragement."
223631831|NCT00002754|BIOLOGICAL|monoclonal antibody Me1-14 F(ab')2|
224220230|NCT02879747|DRUG|Genotropin|Children were randomized to either decreased dose by 50% or unchanged dose after 2-3 years of Catch-up growth
224220231|NCT00845754|DRUG|ketorolac|15mg IV every6 hours for 4doses
224220232|NCT00845754|DRUG|saline|15mg IV every 6hrs for 4 doses
224220233|NCT03066154|DRUG|oral docetaxel (ModraDoc/r)|Weekly once- or twice daily ModraDoc/r
224220234|NCT03066154|DRUG|androgen deprivation therapy|ADT according to the standard of care
224220235|NCT03066154|RADIATION|high-dose intensity-modulated radiation therapy|77 Gy in 35 fractions of 2.2 Gy, 5 fractions a week
223631832|NCT03151044|DRUG|High-dose Epirubicin Combined with CVP ± Rituximab|Experimental group shall be given high-dose Epirubicin (90mg/m2) combined with standard-dose Cyclophosphamide (750mg/m2), Vincristine (1.4mg/m2) and Prednisolone (100mg/m2) ± Rituximab
223631833|NCT03151044|DRUG|Standard-dose Epirubicin Combined with CVP ± Rituximab|Active comparator group shall be given standard-dose Epirubicin and standard-dose Cyclophosphamide (750mg/m2), Vincristine (1.4mg/m2) and Prednisolone (100mg/m2) ± Rituximab
223631834|NCT06347198|DRUG|Fruquintinib|Fruquintinib: 4 mg/d, qd po, administered continuously for 2 weeks, discontinued for 1 week;
223631835|NCT06347198|DRUG|Sintilimab|Sintilimab: 200 mg, i.v.gtt.D1, administered every 3 weeks;
224220236|NCT01950754|BEHAVIORAL|standing with both feet|
224220237|NCT01950754|BEHAVIORAL|descent of the platform|
224220238|NCT01950754|BEHAVIORAL|standing on the platform, feet together and always with simultaneous performance of a task of mental count|
224220239|NCT02103322|DRUG|Imatinib Mesylate Tablets, 400 mg|Brown, oval, scored, film coated, beveled edge tablet. Debossed with AN on scored side and 795 on the other side.
224220240|NCT02103322|DRUG|Imatinib Mesylate Tablets, 400 mg|"Very dark yellow to brownish orange, film-coated tablets, ovaloid, biconvex with bevelled edges, debossed with 400 on one side with score on the other side, and SL on each side of the score."
224220241|NCT05651529|DIETARY_SUPPLEMENT|exogenous ketone salt supplement|Dietary Supplement: Fasting water and with exogenous ketone salt supplement. Participants will have to take 1 doses of supplement 30 minutes before the scan.
224220242|NCT05651529|DIETARY_SUPPLEMENT|exogenous carbohydrate supplement|Dietary Supplement: Fasting water and with exogenous carbohydrate supplement. Participants will have to take 1 doses of supplement 30 minutes before the scan.
224220243|NCT00308373|DRUG|Metformin vs Thiazolidinedione (Pioglitazone)|
223631836|NCT06347198|DRUG|Inulin|Inulin: 5g/d, qd po in the first week, 10g/d, bid po from the second week onwards.
224220244|NCT01119976|BEHAVIORAL|Reduced calorie diet and exercise plan|Participants will receive written diet and exercise instructions to follow for the duration of the study.
224220245|NCT01119976|BEHAVIORAL|Different reduced calorie diet and exercise plan|Participants will receive written diet and exercise instructions to follow for the duration of the study.
224220246|NCT00677924|DRUG|Zalutumumab|Solution for infusion
224220247|NCT04859855|PROCEDURE|Restrictive transfusional strategy|Transfusion of Red Blood Concentrates (RBCs) if Hb ≤7,0g/dL with the aim of maintaining Hb levels between 7,0-9,0g/dL.
224220248|NCT04859855|PROCEDURE|Liberal transfusional strategy|Transfusion of RBC if Hb ≤9,0g/dL, with the aim of maintaining Hb levels between 9,0-10,0g/dL
224220249|NCT02872181|PROCEDURE|Supine|Placed in Supine position
224220250|NCT02872181|PROCEDURE|Left uterine displacement|Placed in 15 degrees left uterine displacement
223631837|NCT05062655|OTHER|Drug reconciliation|Drug reconciliation information transmission to pharmacist interview with the patient
224220251|NCT02495610|OTHER|Gait analysis and MRI:|"* Gait analysis: Treadmill with pressure sensors (FDM-THM-M-System; 'Zebris' medical GmbH), study-specific, but routine procedures.~* MRI: Performed in a scanner at the University Hospital with standard MRI compatibility procedures; study specific is only the additional MRI after the CSF release with spinal tap or drainage."
223631838|NCT01643668|DRUG|Busulfan|Busulfan as part of reduced intensity conditioning prior to allogeneic stem cell transplantation
223631839|NCT01643668|DRUG|Clofarabine|Clofarabine as part of reduced intensity conditioning prior to allogeneic stem cell transplantation
223631840|NCT01643668|PROCEDURE|Allogeneic Stem Cell Infusion|Allogeneic stem cell transplantation after reduced intensity conditioning with busulfan / clofarabine chemotherapy
223631841|NCT04281407|DIETARY_SUPPLEMENT|Visbiome|2 capsules of Visbiome, a probiotics supplement, twice a day (morning and evening) for 28 days
223631842|NCT00322881|DRUG|Paclitaxel|
224220252|NCT04401319|DEVICE|Sham Stimulation for Crossover Study|Stimulation will be delivered on the dorsolateral prefrontal cortex (DLPFC) or the angular cortex (AG) using a sham coil for 20 minutes with a frequency of 20Hz (train duration: 4s; inter-train interval: 26s; 3200 pulses at 80% of the resting motor threshold ) in one session. A single session will be conducted.
224220253|NCT04401319|DEVICE|DLPFC Stimulation for Crossover Study|Stimulation will be delivered on the left dorsolateral prefrontal cortex (DLPFC) using a real coil for 20 minutes with a frequency of 20Hz (train duration: 4s; inter-train interval: 26s; 3200 pulses at 80% of the resting motor threshold ) in one session. A single session will be conducted.
223631843|NCT00322881|DRUG|Carboplatin|
223631844|NCT00623272|OTHER|compare measurements of left ventricular volumes and LVEF (by Cardiac Magnetic Resonance and Echocardiography)|To compare measurements of left ventricular volumes and LVEF obtained by 2DE, 3DE, and CMR after a ST elevation myocardial infarction (STEMI) complicated by systolic left ventricular dysfunction.
223631845|NCT04836468|DIAGNOSTIC_TEST|Tape application|Magnetic Tape or Kinesiology tape will be applied randomly with both the examiner and the subjects blinded.
223631846|NCT03113851|RADIATION|Radiotherapy|One lesion received radiotherapy for 35 Gy in 10 fractions and rested for one week; then another metastatic lesion were treated with radiotherapy for 35 Gy in 10 fractions.
223631847|NCT03113851|DRUG|rhGM-CSF|Patients were injected subcutaneously rhGM-CSF 125mg/m2 per day from day1 to day 14, every three weeks, concurrent with radiotherapy
223631848|NCT00352508|BEHAVIORAL|Dietary advice|
223631849|NCT02779439|BIOLOGICAL|Virus specific CTLs|Virus specific CTLs will be given to patients with persistent or recurrent viral reactivation after 2 weeks of standard anti-viral therapy
223631850|NCT03549923|DEVICE|Simultaneous CRRT|The patients in the simultaneous CRRT group will receive CRRT within 24 hours after the initiation of ECMO support.
224220254|NCT04401319|DEVICE|AG Stimulation for Crossover Study|Stimulation will be delivered on the left angular cortex (AG) using a real coil for 20 minutes with a frequency of 20Hz (train duration: 4s; inter-train interval: 26s; 3200 pulses at 80% of the resting motor threshold ) in one session. A single session will be conducted.
224220255|NCT04401319|DEVICE|Sham Stimulation for Parallel Study|Stimulation will be delivered on the dorsolateral prefrontal cortex (DLPFC) or the angular cortex (AG) using a sham coil for 20 minutes with a frequency of 20Hz (train duration: 4s; inter-train interval: 26s; 3200 pulses at 80% of the resting motor threshold ) in one session. Twenty sessions will be conducted.
223631851|NCT03549923|DEVICE|Conventional-indication CRRT|The patients in the conventional-indication group will not receive CRRT until the patient demonstrates AKI and fulfills any one of the criteria of the conventional CRRT indication.
224220256|NCT04401319|DEVICE|DLPFC Stimulation for Parallel Study|Stimulation will be delivered on the left dorsolateral prefrontal cortex (DLPFC) using a real coil for 20 minutes with a frequency of 20Hz (train duration: 4s; inter-train interval: 26s; 3200 pulses at 80% of the resting motor threshold ) in one session. Twenty sessions will be conducted.
224220257|NCT04401319|DEVICE|AG Stimulation for Parallel Study|Stimulation will be delivered on the left angular cortex (AG) using a real coil for 20 minutes with a frequency of 20Hz (train duration: 4s; inter-train interval: 26s; 3200 pulses at 80% of the resting motor threshold ) in one session. Twenty sessions will be conducted.
224220258|NCT05697484|DEVICE|educational game|"Control group will be provided with usual care. Intervention group will be provided in addition to the usual care, an access to the mobile game after a simple training for game usage. Both groups will be followed for a period of 3 months.~The mobile game is planned to have the following design:~1. Game will be presented in Arabic language.~2. The game will consist of four levels. a. At the beginning of each level there will be an educational video that the patient must watch in order to be allowed to start the level."
223764277|NCT01356433|DRUG|oral vitamin C|"cross-over study,2 arms Arm 1(50cases): is given oral vitamin C 200mg per day in the first 3 months, then stop oral VitC for the next 3 months.~Arm 2(50cases): is not given vitamin C in the first 3 months, then switch to receive oral VitC 200mg per day in the next 3 months."
224220259|NCT02257632|DRUG|Ranibizumab 0.5 mg|Administered as an intravitreal injection
224220260|NCT02257632|DRUG|Aflibercept 2 mg|Administered as an intravitreal injection
224220261|NCT02330120|DRUG|propofol|
224220262|NCT02330120|DRUG|dexmedetomidine|
224220263|NCT01393990|DRUG|LY2228820|Administered orally
224220264|NCT01393990|DRUG|Midazolam|
224220265|NCT01393990|DRUG|Tamoxifen|
224220266|NCT01859390|DRUG|AquADEKs-2|AquADEKs-2 contains standard amounts of fat-soluble vitamins (A, D, E, K) that are contained in typical CF multivitamin supplements plus several antioxidants including beta-carotene, mixed tocopherols (different forms of vitamin E), coenzyme Q10 (CoQ10), mixed carotenoids (lutein, lycopene and zeaxanthin), and the minerals zinc and selenium.
224220267|NCT01859390|DIETARY_SUPPLEMENT|control multivitamin|The control multivitamin contains standard (standard for CF multivitamin supplements) amounts of vitamins A, B, D, E, and K without added antioxidants.
224220268|NCT02450942|DRUG|18F-FDS|18F-FDS were intravenously injected into the patients 1 h before the PET/CT scans
224220269|NCT01088152|BEHAVIORAL|Celiac school|Structured education of adult celiac patients at 10 sessions.
224220270|NCT01088152|BEHAVIORAL|Usual care of celiac disease women|Written information corresponding to that offered when seeking medical advice for well treated celiac disease in the primary care.
224220271|NCT05165251|DRUG|Amlodipine/Atorvastatin 5 Mg-10 Mg ORAL TABLET|Amlodipine/Atorvastatin 5 Mg-10 Mg ORAL TABLET QD
223631852|NCT03549923|DRUG|Esmolol|The patients in esmolol group will receive a continuous esmolol infusion in addition to the standard care.
223631853|NCT03549923|DRUG|Standard care|The patients in control group will not receive any beta-blockers, including esmolol, unless the doctor thinks there's a strong indication.
223631854|NCT01258777|DRUG|400 mg golimumab or placebo|Single dose of 400 mg subcutaneously
223631855|NCT01258777|DRUG|200 mg golimumab or placebo|Single dose of 200 mg subcutaneously
223631856|NCT03527849|BEHAVIORAL|Mindfulness-Based Stress Reduction|The intervention will be an MBSR course.
223764278|NCT01356433|DRUG|oral vitamin C|Arm 2(50cases): is not given vitamin C in the first 3 months, then switch to receive oral VitC 200mg per day in the next 3 months.
224220272|NCT05165251|DRUG|Amlodipine 5mg|amlodipine 5mg QD
224220273|NCT05165251|OTHER|Lifestyle intervention|Lifestyle intervention
224220274|NCT01567371|DEVICE|LiDCO rapid monitor|Technology which provides a continuous means of monitoring various hemodynamic parameters including cardiac output and pulse pressure variability.
224220275|NCT02604069|DEVICE|Continuous Glucose Monitor|
224220276|NCT04460989|PROCEDURE|arthroplasty|total knee replacement
224220277|NCT05874869|DRUG|Dihydroartemisinin-piperaquine|The drug will be administered once a day for three consecutive days for three months (March, April, and May)
224220278|NCT02982382|OTHER|Manipulative Therapy|Subjects will receive techniques of High Velocity and Low Amplitude (HVLA) or grade V manipulation to the lumbar region (lumbar roll), and pain education based on the biopsychosocial approach.
224220279|NCT02982382|OTHER|Pain Education|Individuals will receive pain education based in a biopsychosocial approach
224220280|NCT02982382|OTHER|Sham|The individuals will receive a simulation of spinal manipulation (sham) involving manual contact over lumbar region totaling 5 minutes.
224220281|NCT03575429|BEHAVIORAL|Engagement Intervention|"Family navigators will use MI to engage families to decrease resistance and build motivation and commitment to challenging behavior changes by eliciting and reflecting broader goals and values, linking those values to specific behavior change, and negotiating a menu of options for change based on individual preferences. PSE will be used by the Family Navigators to guide families in selecting an objective, measurable problem, then proceed through a series of steps that involve goal setting, brainstorming and evaluating solutions, choosing a solution, and action planning."
224220282|NCT03575429|BEHAVIORAL|Engagement + Coaching Intervention|ESI program planning entails identifying goals and objectives for the child and teaching strategies and supports for parents. Each session includes the following components: 1) setting the stage to develop that visit's agenda and gather updates; 2) intervention implementation that must include the following steps to coach the parent: a) review the objective, b) use modeling, guided/caregiver practice, or video review to teach the strategy, c) provide specific feedback to the parent, and d) problem solving and plan for next time; steps a-d are repeated for 3-5 activities per session; and 3) summarize plans for parent implementation between sessions. Families are invited to Autism Navigator How-To Guide for Families, a self-guided web-based course, with an online weekly group meeting.
224220283|NCT04618835|DIAGNOSTIC_TEST|40-Steps-test|40 steps performed on the spot
224220284|NCT02038634|DRUG|Betamethasone|
224220285|NCT02038634|DEVICE|Ultrasound|Ultrasound guided injection using GE Healthcare LOGIQ e Ultrasound
224220286|NCT05938452|DRUG|Glyceryl Tribenzoate|Oral Solution
223631857|NCT03527849|BEHAVIORAL|Health Enhancement Program|Propose to use an active control training, the Health Enhancement Program (HEP), an intervention designed to isolate mindfulness as a testable active ingredient. HEP and MBSR are structurally equivalent in that they share the same amount of in- and out-of class work time. The content of the HEP intervention meet the following criteria: (1) class activities match MBSR activities as closely as possible, (2) activities represent valid, active, therapeutic ingredients in their own right, and (3) these ingredients do not include mindfulness.
223631858|NCT04527952|BEHAVIORAL|Online handouts describing how to follow each diet for 1 week each|Participants will receive handouts via email about how to follow each diet
223631859|NCT00561652|BEHAVIORAL|Education & Exercise|Education \& Exercise
223631860|NCT00561652|PROCEDURE|Chiropractic treatment (plus Education & Exercise)|Chiropractic treatment (plus Education \& Exercise)
223631861|NCT03904394|OTHER|Exercise|Four sets of 7 minutes at 65% of VO2peak interspersed with 3 min of passive recovery
223631862|NCT04964635|DEVICE|TetraGrip II system|"This main aim of this whole research project is to evaluate the performance of the TetraGrip II system in improving the upper limb functions in people with C4-C7 tetraplegia i.e. people who have damaged their spinal cord in the neck resulting in loss of function in all four limbs. The Tetragrip system uses a technique called Functional Electrical Stimulation (FES) in which small electrical impulses are used to activate paralysed muscles and hence provide movement. The stimulation is controlled by sensors which measure the movement of the other shoulder and enable the person to regain the use of their hand via stimulating electrodes placed on the skin over the relevant muscles.~The feasibility of using this FES based system in restoring the upper arm functions will be evaluated by clinically trying the device on participants with C4-C7 tetraplegia."
223631863|NCT06333314|DRUG|Dostarlimab|Anti-PD-1 monoclonal antibody
223631864|NCT06333314|DRUG|Chemotherapy|"* mFOLFOX6 or FOLFIRI or XELOX regimen~* FOLFOX or XELOX or TFOX regimen~* FOLFIRINOX or gemcitabine-nab-paclitaxel or gemcitabine monotherapy.~* Cisplatin and gemcitabine cisplatin or CAPOX or mFOLFOX6.~* Etoposide-cisplatin-doxorubicin or mitotane~* Cisplatin and gemcitabine or carboplatin and paclitaxel~* Etoposide-cisplatin or etoposide-carboplatin~* Doxorubicin and ifosfamide or doxorubicin monotherapy or doxorubicin and trabectedin."
223631865|NCT04982653|OTHER|Quality-of-Life Assessment|Ancillary studies
223631866|NCT04982653|PROCEDURE|Surgical Procedure|Undergo hepatectomy using small bites fascial method for abdominal wall closure
223631867|NCT04982653|PROCEDURE|Surgical Procedure|Undergo hepatectomy using conventional fascial method for abdominal wall closure
223631868|NCT00573508|DRUG|Placebo|Oral Administration
223631869|NCT00573508|DRUG|Solifenacin Succinate|Oral Administration
223631870|NCT00010816|DRUG|Herbal remedies|
223631871|NCT04559568|DRUG|LY3522348|Administered orally.
223631872|NCT04559568|DRUG|Placebo|Administered orally.
223631873|NCT04559568|DRUG|Midazolam|Administered orally to some participants.
223631874|NCT02285855|DRUG|Metformin|Metformin treatment given at a dose of 2000 mg by mouth in divided dose daily (500 mg am, 1000 mg noon, 500 mg pm). To reduce GI toxicity, participants start Metformin at 1000 mg daily in a divided dose (500mg am, 500 mg pm) for 1 week.
223631875|NCT02285855|OTHER|Placebo|Placebo treatment given 3 weeks prior to SBRT treatment and for 1 week during SBRT treatment. Placebo administered by mouth three times a day.
223631876|NCT02285855|RADIATION|Stereotactic body Radiotherapy (SBRT)|SBRT delivered per standard of care practice as determined by participant's physician.
223631877|NCT04662385|DRUG|aloe vera toothpaste|aloe vera toothpaste have antimicrobial and other multipotential effects.
223631878|NCT04662385|DRUG|Colgate Total|Whitening toothpaste that removes and prevents new stains Fights bacteria on teeth, tongue, cheeks and gums for whole mouth healthy Mint toothpaste for long lasting fresh breath Helps prevent plaque, tartar, cavities \& gingivitis
223631879|NCT04443244|DRUG|Botulinum Toxin Type A Injection (Botulax®) 24Units|Experimental: Botulax® 24Units
223631880|NCT04443244|DRUG|Botulinum Toxin Type A Injection (Botulax®) 48Units|Experimental: Botulax® 48Units
223631881|NCT04443244|DRUG|Botulinum Toxin Type A Injection (Botulax®) 72Units|Experimental: Botulax® 72Units
223631882|NCT04443244|DRUG|Botulinum Toxin Type A Injection (Botulax®) 96Units|Experimental: Botulax® 96Units
223631883|NCT04443244|OTHER|Normal Saline|Placebo Comparator: Normal Saline
223631884|NCT00556569|OTHER|CHAM JAM|"CHAM JAM (previously known as Moving Smart (MS) program) is a daily, 10-minute classroom-based physical activity program led by teachers that integrates academic objectives with physical activity"
223631885|NCT02403557|BEHAVIORAL|Waitlist|Weekly check up.
223631886|NCT02403557|BEHAVIORAL|Tailored Internet-delivered CBT|Tailored Internet-delivered CBT during 8 weeks.
223631887|NCT02718898|DRUG|Ixekizumab|Administered SC
223631888|NCT02718898|DRUG|Placebo|Administered SC
223631889|NCT02659163|BEHAVIORAL|mHealth wristband|A wristband containing several sensors worn by participants to collect daily objective patient-generated health behavior data on physical activity, sleep, and screen time
223631890|NCT02659163|BEHAVIORAL|mHealth scale|A wireless scale used by participants to measure and record daily weight.
223631891|NCT02659163|BEHAVIORAL|EMA|Self-reported information on sugar sweetened beverage consumption collected via mobile messaging
223631892|NCT02659163|BEHAVIORAL|mHealth app|A mobile application that houses study data and provides two-way messaging between the study team and study participants.
223631893|NCT02659163|BEHAVIORAL|Health Behavior Feedback|Provide feedback on patient-generated health behaviors data, along with standard of care recommendations, for self-guided
223631894|NCT02659163|BEHAVIORAL|Integrated closed-loop feedback system|Daily feedback and weekly e-report cards on patient-generated longitudinal health behaviors along with clinical recommendations via mobile messaging
223631895|NCT00589225|GENETIC|Genetic Analysis|We will draw one tube of blood from your arm to obtain white blood cells. These white blood cells will be used as a source of DNA for genetic testing.
223631896|NCT03252769|OTHER|Self-sampling|
223631897|NCT01861808|OTHER|Lumbar puncture|The only intervention is the lumbar puncture on the patients to obtain a Cerebrospinal Fluid sample
223631898|NCT05976360|DRUG|Dupilumab (SAR231893)|Injection solution, subcutaneous
223631899|NCT05976360|DRUG|Dupilumab (SAR231893)|Injection solution, subcutaneous.
223631900|NCT01384175|PROCEDURE|intravenous analgesia|Patients received postoperative analgesia with intravenous infusion of fentanyl 10 µg/ml 3-8 mL/h
223631901|NCT01384175|PROCEDURE|epidural infusion|Postoperative analgesia was performed using continuous epidural infusion of ropivacaine 0.2% 3-8 mL/h and fentanyl 2 µg/mL
223631902|NCT01384175|PROCEDURE|patient-controlled epidural analgesia|Postoperative analgesia was performed by continuous epidural infusion of ropivacaine/fentanyl mixture combined with patient-controlled epidural analgesia with ropivacaine/fentanyl bolus 1 mL, lock-out interval 12 min.
223631903|NCT03458338|DIAGNOSTIC_TEST|estimated glomerular filtration rate and albuminuria|chronic kidney disease according to KDIGO
223631904|NCT04484961|DEVICE|Blood flow restriction (BFR)|The study group underwent normal ACL rehab modified by use of a tourniquet for blood flow restriction during selected exercises.
223631905|NCT04044950|BIOLOGICAL|E7 TCR|The injection will be approximately 3x10\^8 E7 TCR T cells, unless fewer cells are generated, at each site of organ involvement (i.e. primary tumor, palpable lymph node (s)) in approximately 1-2 mL of volume.
223631906|NCT04871906|OTHER|stretching exercises|Our interventions are home-based stretching exercises. The experimental group will receive 6 stretching exercises which stretch 20-30 seconds, relax for 10 seconds, and repeat 5 times for each side. It will take 25-30 minutes every day for continuous 8 weeks. Those include stretching of the deep front line, spiral line, superficial front line, lateral line, superficial back line, and plantar flexors. Designed concepts are the following three: 1) based on ''Anatomy- Train'' theory, 2) emphasize on movements of trunk and pelvis, and 3) stress on the stretching of lower extremities.
223631907|NCT01667900|DRUG|Dulaglutide|
223631908|NCT01667900|DRUG|Placebo|Administered SQ in the placebo arms and to maintain the blind in the dulaglutide arms.
223631909|NCT00253812|PROCEDURE|flexible sigmoidoscopy|
224220287|NCT01664052|DEVICE|ESS505 (Essure, BAY1454033)|Unilateral hysteroscopic placement of the permanent birth control system, Model ESS505 insert inclusive of polyethylene terephthalate (PET) fibers (investigational device model ESS505) followed by tubal occlusion evaluation by hysterosalpingogram (HSG) approximately 60 minutes following insert placement. A subsequent HSG was performed prior to the subjects' scheduled hysterectomy procedures at 30 (group 3), 60 (group 2) or 90 days (group 1) post insert placement. At the conclusion of the hysterectomy, the uterine cornua and fallopian tubes were sent to a pathology lab for histological preparation, and subsequent evaluation.
223631910|NCT04031599|DEVICE|Single-hormone closed-loop system|Every 10 minutes, the glucose levels as measured by the sensor will be transferred automatically to a LG Google Nexus Smartphone that the algorithm is running on, which will calculate the recommended doses and will send them wirelessly to the infusion pump.
223631911|NCT04031599|DEVICE|Insulin pump|Tandem Diabetes Care
223631912|NCT04031599|DEVICE|Continuous glucose monitoring system|Dexcom G6
223631913|NCT04031599|DRUG|Aspart or Lispro|Aspart or lispro will be infused with the infusion pump
223631914|NCT04031599|OTHER|Carbohydrate counting|Participants will be required to enter an estimate of the carbohydrate content of their meal into the phone. Insulin boluses will be calculated based on grams of carbohydrates and participant's insulin-to-carbohydrate ratio. Carbohydrate-matching full prandial bolus will be given 5 to 10 minutes before the meal.
224220288|NCT01664052|DEVICE|ESS305 (Essure, BAY1454032)|Unilateral hysteroscopic placement of the permanent birth control system, Model ESS505 insert inclusive of polyethylene terephthalate (PET) fibers (investigational device model ESS505) and contralateral placement of the current commercially approved Essure device, model ESS305 followed by tubal occlusion evaluation by hysterosalpingogram (HSG) approximately 60 minutes following insert placement. A subsequent HSG was performed prior to the subjects' scheduled hysterectomy procedures at 30 (group 3), 60 (group 2) or 90 days (group 1) post insert placement. At the conclusion of the hysterectomy, the uterine cornua and fallopian tubes were sent to a pathology lab for histological preparation, and subsequent evaluation.
224220289|NCT01664052|DEVICE|ESS505-A (Essure, BAY1454033)|Bilateral hysteroscopic placement of the permanent birth control system, Model ESS505 insert with minimal polyethylene terephthalate (PET) fibers (investigational device model ESS505-A) followed by tubal occlusion evaluation by hysterosalpingogram (HSG) approximately 60 minutes following insert placement. A subsequent HSG was performed prior to the subjects' scheduled hysterectomy procedures at 30 (group 3), 60 (group 2) or 90 days (group 1) post insert placement.
224220290|NCT03355378|PROCEDURE|gum chewing|chewing gum orally for 30 minutes
224317994|NCT06820190|OTHER|Multiple Mid-Transverse Process to Pleura (MTP) Block|Patients will receive multiple mid-transverse process to pleura (MTP) block after induction of anesthesia.
224317995|NCT06820190|DRUG|Morphine|Patients will receive IV-PCA. Morphine is generally administered as an initial loading dose of 0.05-0.1 mg/kg before the end of surgery, with PCA settings of a bolus dose of 0.01-0.03 mg/kg, a lockout interval of 6-10 min, and a background infusion of 0.01-0.02 mg/kg/h.
223631915|NCT04031599|OTHER|Simplified qualitative meal-size estimation strategy|A pre-meal partial prandial bolus will be given 5-10 minutes before the meal. The partial bolus will be based on the estimated meal size (small, regular, large and extra-large). The closed-loop system will give the remaining insulin needed based on the sensor readings. For this strategy, meal size will be defined as: small as any meal less than 30g, regular meal as any meal between 30g and 60g CHO, large meal as any meal between 60g and 90g CHO, extra-large meal for anything above 90g CHO.
224220291|NCT01369251|BEHAVIORAL|Hygiene|
224220292|NCT01369251|PROCEDURE|Usual alcohol care|
224220293|NCT01084005|DRUG|linagliptin|patients receive linagliptin 5 mg tablets once daily
224220294|NCT01084005|DRUG|placebo|patients receive placebo matching linagliptin 5 mg once daily
224220295|NCT02967198|DEVICE|CT/US fusion|Fusion of pre-procedure cross-sectional imaging (CT or MRI) and real-time USG using registration function of USG device.
224317996|NCT06824857|OTHER|Abdominal Massage Application|As part of the abdominal massage application, patient follow-up forms and checklists were prepared. Before starting the study, the abdominal massage practitioner participated in a certification program on this topic and received a competency certificate. Patients will be followed up for the first 3 days postoperatively using the prepared patient follow-up forms. Abdominal massage will be applied to each patient for 15 minutes according to a certain standard as stated in the literature
224317997|NCT00200044|DEVICE|Gatekeeper Reflux Repair System|The Gatekeeper System™ consists of a specialized 16-mm overtube assembly, a 2.4-mm diameter prosthesis delivery system (1-mm diameter needle, dilator, and 2.4-mm diameter sheath), a pushrod assembly and Gatekeeper Prosthesis. Up to 4 prostheses will be implanted at the initial procedure and retreatment with up to four more prostheses will be allowed at 3-months if the subject has a GERD HRQL score \>15.
224317998|NCT06858007|DEVICE|KOS® M|Delivery of medical device as injection
224317999|NCT05520125|BIOLOGICAL|Mesenchymal stem cells enriched by extracellular vesicles|Mesenchymal stem cells enriched by extracellular vesicles
224318000|NCT05520125|OTHER|Standard treatment of bone defects|Standard surgical treatment of bone defects
224318001|NCT06990256|DIETARY_SUPPLEMENT|Fisetin intervention|Participants assigned to this intervention take capsules containing a fixed dose of Fisetin daily after breakfast.
224318002|NCT06990256|DIETARY_SUPPLEMENT|Placebo|Participants assigned to this intervention take a capsule containing 500 mg of corn starch daily after breakfast.
224318003|NCT06990256|DIETARY_SUPPLEMENT|Urolithin A intervention|Participants assigned to this intervention take capsules containing a fixed dose of Urolithin A daily after breakfast.
223631916|NCT04031599|OTHER|3-week intervention|Glucose levels will be regulated by the single-hormone closed-loop system for 3 consecutive weeks.
223631917|NCT04031599|OTHER|1-hour postprandial exercise (sub-study)|60 minute exercise will be started one hour after the meal time.
223631918|NCT04031599|OTHER|2-hour postprandial exercise (sub-study)|60 minute exercise will be started two hours after meal time
223631919|NCT04031599|OTHER|Exercise announcement and meal bolus reduction (sub-study)|Meal bolus reduction of 33% at meal time and exercise announcement (increased target glucose from 6 to 9mmolL) to the CLS algorithm
223631920|NCT05414526|OTHER|InterCARE package|"The InterCARE package includes:~1. Healthcare Provider HTN/CVD Curriculum A new HTN curriculum will be developed in collaboration with local stakeholders using KITSO Master trainer program documents (Healthcare provider HIV curriculum), Primary Care Guidelines, HTN/CVD curriculum/protocols trialled in Kweneng District and the CDC Prevention Hypertension Management Curriculum.~2. Adaptation of HIV care EHR for HTN/CVD care EHR modifications will be done to enhance data collection around HTN/CVD care, with input from MoH.~3. Patient and treatment partner sessions Clinic staff will provide in-clinic education and counselling on HTN/CVD to all PLWHIV with a diagnosis of hypertension during their routine HIV clinic visit. All patients will be provided a take-home easy-to-read pamphlet on HTN/CVD risk factor management. All PLWHIV will be asked to bring a treatment partner from their social network at the 2nd study visit so that they can practice role-plays with each other."
224220296|NCT02967198|DEVICE|ultrasound shear wave elastography|ultrasound shear wave elastography is performed in S-shear wave scanner according to guidelines of ultrasound elastography.
224220297|NCT00549198|DRUG|Abacavir/lamivudine and efavirenz|
224220298|NCT00549198|DRUG|Tenofovir/Emtricitabine and efavirenz|
224318004|NCT04704570|OTHER|Exercise|Spinal stabilization exercise
224318005|NCT04704570|OTHER|Remotely and face to face evaluation of Functional Capacity Level|Quality of life assessment (SF-36), and cognitive assessment ((Montreal Cognitive Assessment Scale (MOCA)) will be administered face to face. Functional capacity assessment tests will be administered both face-to-face and remotely. All participants will be administered both remotely and face-to-face. The order of the remote and face-to-face evaluations will be determined by the closed envelope randomization method. The remote evaluation will be done by video interview method under the direction of the researcher. During the remote evaluation, the necessary equipment for the participant will be prepared in the unit in advance. There will be a 10-30 minute rest interval between each evaluation.This application will only be applied at the beginning of the exercise program.After the 8-week program, only face-to-face evaluation will be made.
224318006|NCT05645705|OTHER|Colgate Cavity Protection Toothpaste|Participants will use Colgate Cavity Protection Toothpaste for brushing teeth twice daily.
224318007|NCT05645705|OTHER|LISTERINE Cool Mint Antiseptic Mouthwash|Participants will use 20 mL of LISTERINE Cool Mint Antiseptic Mouthwash for 30 seconds after brushing twice daily.
224318008|NCT05645705|OTHER|Listerine Advanced Gum Alcohol|Participants will use 20 mL of Listerine Advanced Gum Alcohol Rinse for 30 seconds after brushing twice daily.
224318009|NCT05645705|OTHER|Listerine Advanced Gum Zero|Participants will use 20 mL of Listerine Advanced Gum Zero Rinse for 30 seconds after brushing twice daily.
224318010|NCT05645705|OTHER|LISTERINE ULTRACLEAN Tartar Control Antiseptic Mouthwash Cool Mint|Participants will use 20 mL of LISTERINE ULTRACLEAN Tartar Control Antiseptic Mouthwash Cool Mint Rinse for 30 seconds after brushing twice daily.
224318011|NCT06446128|BIOLOGICAL|CD19/CD20/BCMA CAR T cells|"Subjects will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of CD19/CD20/BCMA CAR T cells.~Cyclophosphamide and fludarabine will be given from day-5 to day-3 before the infusion for lymphodepletion. On day0 subjects will receive one dose treatment with CD19/CD20/BCMA CAR T cells by intravenous (IV) injection"
224318012|NCT02824471|OTHER|SCD Group|No Intervention. Use of discard blood/tissue
223631921|NCT00370058|PROCEDURE|ECT treatment|
224318013|NCT05671016|PROCEDURE|MRI scans and questionnaires|Extra baseline MRI scan performed and questionnaires (EORTC validated questionnaires involving EORTC QLQ C-30, EORTC BN20 and EORTC ELD14) to assess quality of life at baseline, 4 weeks and 8 weeks after treatment
224318014|NCT03633201|DEVICE|Cruciate Retaining|Zimmer Biomet's Personalized Knee system for knee osteoarthritis treatment. The standard insert.
223631922|NCT01740830|DEVICE|Transcranial Direct Current Stimulation (tDCS) (Neuroconn DC-stimulator)|The anode will be fixed over the primary motor cortex. The cathode will be fixed over the contralateral supraorbital region.
223631923|NCT00641771|DRUG|alendronate sodium (+) cholecalciferol|MK0217A, a tablet containing alendronate 70-mg and vitamin D3 2800 IU, once weekly for 4 weeks. All patients will be instructed to take the tablet fasting upon arising for the day with 6 to 8 oz. of plain water (i.e., tap), wait at least one-half hour while continuing to fast and before the first food, beverage (except water), or other medication. All patients must eat before lying down.
223631924|NCT00641771|DRUG|Comparator: Placebo (unspecified)|MK0217A, Pbo tablet, once weekly for 4 weeks. All patients will be instructed to take the tablet fasting upon arising for the day with 6 to 8 oz. of plain water (i.e., tap), wait at least one-half hour while continuing to fast and before the first food, beverage (except water), or other medication. All patients must eat before lying down.
223631925|NCT02438176|PROCEDURE|single trans-septal puncture|The investigators will compare bilateral groin puncture AF ablation and single groin puncture AF ablation with 1:2 randomization.
223631926|NCT02438176|PROCEDURE|conventional bilateral groin puncture|Bilateral groin puncture AF ablation is control procedure exactly same to routine AF ablation with double trans-septal puncture.
223631927|NCT02236286|BEHAVIORAL|Exercise|Agility Boot Camp (ABC) exercise intervention consisting of 18 sessions of group exercise led by an exercise trainer.
223631928|NCT00654667|DRUG|Placebo|Placebo, no active drug, take 5 capsules by mouth daily for one month
223631929|NCT00654667|DRUG|Resveratrol|
223631930|NCT01468558|DRUG|MAP0004|MAP0004 1.0mg via inhalation on Day 1 and Day 6 of Visit 2
223631931|NCT01468558|DRUG|IV DHE|IV DHE (Intravenous Dihydroergotamine Mesylate) administered at Visit 3
223631932|NCT01468558|DRUG|Ketoconazole|Ketoconazole 400 mg administered once a day on days 3-6 of Visit 2
223631933|NCT03449017|BEHAVIORAL|E-cig use|Self-administration of e-cig (10 puffs in 5 minutes) prior to lab task, self-administration of e-cig (10 puffs in 5 minutes) prior to ad lib alcohol, and ad lib e-cig use throughout ad lib alcohol paradigm.
223631934|NCT01761916|DRUG|CLONIDINE|Postpartum patients with very high blood pressure will be treated with oral clonidine (0,1mg)
223631935|NCT01761916|DRUG|CAPTOPRIL|Postpartum patients with very high blood pressure will be treated with oral captopril (25mg)
223631936|NCT02164253|DRUG|Deferiprone|30 mg/kg per day, oral use
223631937|NCT00812994|DRUG|Escitalopram|SSRI antidepressant
223631938|NCT00812994|DRUG|Placebo|
223631939|NCT00384345|DEVICE|Bright Light Therapy|
223631940|NCT00384345|BEHAVIORAL|Exercise|
223631941|NCT05518500|BIOLOGICAL|Flu Vaccine (Year 1)|Participants will receive Fluzone® Quadrivalent High-Dose in the 2022-2023 flu season.
223631942|NCT05518500|BIOLOGICAL|Flu Vaccine (Year 2)|Participants will receive FLUAD® Quadrivalent in the 2023-2024 flu season.
223631943|NCT05518500|BIOLOGICAL|Flu Vaccine (Year 3)|Participants will receive Flublok Quadrivalent in the 2024-2025 flu season.
223631944|NCT00298012|DRUG|Methotrexate|
223631945|NCT00976274|DIETARY_SUPPLEMENT|Korean red ginseng|5 capsules (300 mg/capsule) three times everyday for 12 weeks
223631946|NCT00976274|DIETARY_SUPPLEMENT|starch|5 capsules three times everyday for 12 weeks
223631947|NCT01318577|DEVICE|Investigational Cleaning & Disinfecting Solution|Contact lenses will be cleaned and stored daily in the cleaning, disinfecting and storage solution
223631948|NCT01318577|DEVICE|Clear Care Solution|Contact lenses will be cleaned and stored daily in the cleaning, disinfecting and storage solution
223631949|NCT00627393|DRUG|Standard antimicrobial therapy|Antimicrobial therapy is broadly defined as therapy within the standard of care for a particular infection and should be consistent within a given institution. Participants will undergo the recommended therapy for specific infections for 42 days.
223631950|NCT00627393|BIOLOGICAL|Granulocyte transfusions|Participants will receive one granulocyte transfusion per day until one of the following occurs: recovery from neutropenia, life-threatening toxicity, resolution or improvement of infection, or Day 42 after treatment. Granulocyte content of each transfusion is targeted to be at least 4 x 10\^10 per collection (or proportionately less for participants less than 30 kg in weight).
223631951|NCT00627393|DRUG|G-CSF/dexamethasone|Twelve hours before each donation, participants will be injected with G-CSF and will take one dose of dexamethasone by mouth.
223631952|NCT00627393|DEVICE|Apheresis machine|Participants will undergo a procedure using an apheresis machine for granulocyte collection. The procedure will last 3 to 4 hours and will involve the drawing of blood from each arm, the separation of granulocytes from the red cells and plasma in the machine, and the return of the red cells and plasma to the participants.
223631953|NCT05512897|PROCEDURE|erector spinea plane block|in assistance of ultrasound for visualization anesthetic injection point. 30-40 mL Ropivacaine 0.375% plus 2 mg Dexamethasone administered on each side will be administered between thoracic transversus process and longitudinal spine muscle
223631954|NCT03361800|DRUG|Entinostat|oral drug, 5mg tablet given once weekly x 2 doses
223631955|NCT02329444|PROCEDURE|Remote ischemic preconditioning|Appropriately sized sphygmomanometer cuff placed around right upper arm; where contraindicated, left arm, with inflation of the cuff up to 200mmHg for 5 minutes, followed by deflation of 5 minutes to allow reperfusion with cycle repeated 3 times.
223631956|NCT02329444|PROCEDURE|Sham ischemic preconditioning|Appropriately sized sphygmomanometer cuff placed around right upper arm; where contraindicated, left arm, with inflation of the cuff up to 50mmHg for 5 minutes, followed by deflation of 5 minutes to allow reperfusion with cycle repeated 3 times.
224220299|NCT04495777|OTHER|Fonseca Anamnestic Index|"Fonseca Anamnestic Index was developed to assess the severity of temporomandibular disorders, based on its signs and symptoms. It has been proposed as a low cost and easy to apply alternative and has been used in screening for TMD in a non-patient population5. It was created with 10 items with 3 options of answers (specific scores): yes (10 points), sometimes (5 points) and no (0 points). The final score of the instrument is determined by the sum of the scores of all items, allowing the following classifications: the absence of signs and symptoms of TMD (0-15 points), mild TMD (20-45 points), moderate TMD (50-65 points), and severe TMD (70-100 points) (19)."
224220300|NCT04161794|OTHER|multimodal|2 g EPA/DHA as fish oil, repeated dietary counselling and twice weekly 2 x exercises
223631957|NCT05616286|BEHAVIORAL|Mindfulness-SOS for Refugees|Mindfulness-SOS for Refugees is a brief internet-based mobile-supported intervention program which is a mobile health adaptation of MBTR-R, mindfulness- and compassion-based, trauma-sensitive, and socio-culturally adapted group intervention program designed for FDPs. Mindfulness-SOS for Refugees entails 8 brief sessions and 9 mindfulness meditation practice exercises - delivered via audio recordings using participants' smartphones. The Mindfulness-SOS for Refugees intervention program is specifically designed to mitigate acute stress and related mental health symptoms among FDPs.
223631958|NCT00004563|DRUG|Cyclophosphamide|Cyclophosphamide (Cytoxan, Bristol-Myers Squibb) was initiated with a dose of 1 mg per kilogram of body weight per day (to the nearest 25 mg). The doses were increased monthly by one capsule up to 2 mg per kilogram.
223631959|NCT00004563|DRUG|Placebo|Matching gelcaps 25 mgs
223631960|NCT03337308|COMBINATION_PRODUCT|Bempedoic Acid + Ezetimibe Fixed-Dose Combination|bempedoic acid + ezetimibe FDC 180 mg/10 mg tablet
223631961|NCT03337308|DRUG|Bempedoic Acid|bempedoic acid 180 mg tablet
223631962|NCT03337308|DRUG|Ezetimibe|ezetimibe 10 mg overencapsulated tablet
223631963|NCT03337308|DRUG|Placebos|placebo tablet or capsule to match bempedoic acid + ezetimibe fixed-dose combination (FDC) 180 mg/10 mg tablet, or bempedoic acid 180 mg tablet, or ezetimibe 10 mg capsule
223631964|NCT01762410|DRUG|P7170|Patients will receive study drug on a daily basis for twenty-one days according to the dose and schedule specified for a particular cohort of therapy. This 21 day administration will define a treatment cycle. Patients may receive consecutive treatment cycles until evidence of disease progression, intolerance of therapy, death or withdrawal from the protocol as specified.
223631965|NCT01056822|DRUG|1|Continue with same dose of MMF as patient was taking before randomisation
223631966|NCT01056822|DRUG|2|Increase MPS by 180mg every 12h based on investigator's judgement up to a maximum of 720 mg of MPS every 12 hours
223631967|NCT06005688|DRUG|Vepdegestrant|Participants will receive a single dose of Vepdegestrant by mouth in Period 1 and Period 2, with a washout period of at least 20 days between two doses of Vepdegestrant.
223631968|NCT06005688|DRUG|Carbamazepine|Participants will receive Carbamazepine by mouth once a day for 19 days in Period 2.
223631969|NCT06266481|DRUG|Topical dexamethasone|Patients were interviewed at 1 and 6 h after extubating for post-operative sore throat (POST). POST was assessed by a modified 4-point scale (0= no sore throat, 1= mild sore throat: complains of sore throat only on asking, 2 = moderate sore throat: complains of sore throat spontaneously, and 3 = severe sore throat: change of voice or hoarseness.
223631970|NCT06266481|DRUG|10% lidocaine was sprayed over the tube for the second group|Patients were interviewed at 1 and 6 h after extubating for post-operative sore throat (POST). POST was assessed by a modified 4-point scale (0= no sore throat, 1= mild sore throat: complains of sore throat only on asking, 2 = moderate sore throat: complains of sore throat spontaneously, and 3 = severe sore throat: change of voice or hoarseness.
223631971|NCT01569191|OTHER|Artificial Tear Supplement|artificial tear supplement (Hypromellose)
223631972|NCT01569191|DEVICE|Cold compress|Cold compress bag fill with temperature retention gel placed over closed eyes Sold by http://www.visiondirect.co.uk/vision-direct/eye-gel-mask-blue
223631973|NCT01569191|DRUG|Anti-allergic Medication|1 drop on single occasion after exposure to grass pollen
223631974|NCT00003149|BIOLOGICAL|recombinant interleukin-12|
223631975|NCT00691613|DRUG|Epoetin alpha|The dosage (60.000 I/U Epoetin alpha) will be diluted in 10 ml of 0.9% sodium chloride solution and injected in a single dose intravenously in the dominant forearm (the non-dominant forearm will be used as ischemic model).
223631976|NCT00691613|DRUG|NaCl|0.9% sodium chloride solution as placebo dosage is 10 ml, which will be administered in the same manner as the interventional medicinal product.
223631977|NCT04225195|DRUG|Amphotericin B cholesteryl sulfate complex for injection(ABCD)|"IC patients will only receive intravenous treatment with ABCD, with the longest course of treatment up to 42 days. ABCD will be administered once a day at a dose of 3-4 mg/kg. Visit plan: screening period (D-4 to D-1), baseline period (D1), treatment period and follow-up period (14±3days after the end of the last dose of ABCD).~IA patients will be treated with ABCD for 4 weeks first, followed by oral administration of voriconazole. The total course of treatment should be at least 6 to 12 weeks. ABCD dosing regimen will be the same as that for IC patients. Visiting plan: screening period (D-4to D-1), baseline period (D1), treatment period and follow-up period."
223631978|NCT04965701|DRUG|Osimertinib 80 MG|Osimertinib is administered according to clinical practice at the recommended dose of 80 mg, orally, once a day.
224220301|NCT04189276|BIOLOGICAL|ETV/TDF+T101 No.1|Patients will be injected with T101 once on Day1 (Week0), Day8 (Week1), Day15 (Week2), Day106 (Week15), Day113 (Week16), Day120 (Week17), Day211 (Week30), Day218 (Week31), Day225 (Week32), Day316 (Week45), Day323 (Week46), Day330 (Week47); ETV or TDF will be administrated once each day successively until Day420.
224318015|NCT03633201|DEVICE|Medial Congruent|Zimmer Biomet's Personalized Knee system for knee osteoarthritis treatment. The new anatomical congruent shaped insert.
224318016|NCT02567630|BEHAVIORAL|Soft Mitt Constraint Therapy for Sensory/Motor Impairment in Cerebral Palsy|The CIMT intervention includes 3 components: (1) placement of a removable soft constraint for ½ each day, with a non-invasive wear monitor (2) demonstration and prescribed home-use of a sensory kit (3) and a reach/grasp tool. The intervention lasts 4 weeks as has been published in older children as well as used in infant trial descriptions.
224318017|NCT07001319|DRUG|GS-3242|Administered orally
223631979|NCT05672758|BEHAVIORAL|Sprint training|One-year cycle including specific sprint-oriented athletic training
223631980|NCT05672758|BEHAVIORAL|Endurance training|One-year cycle including specific endurance-oriented athletic training
224220302|NCT04189276|BIOLOGICAL|ETV/TDF+T101 No.2|Patients will be injected with T101 once on Day1 (Week0), Day106 (Week15), Day211 (Week30), Day316 (Week45); ETV or TDF will be administrated once each day successively until Day420.
224220303|NCT04189276|BIOLOGICAL|ETV or TDF|Patients will be administrated ETV or TDF once each day successively until Day420.
224220304|NCT04189276|BIOLOGICAL|ETV/TDF+Peg-IFNα-2b|Patients will be administrated Peg-IFNα-2b successively once a week until Day330 (Week47); ETV or TDF will be administrated once each day successively until Day420.
224220305|NCT02911389|OTHER|Home PT via web-based platform|
224220306|NCT02911389|OTHER|Home PT via paper manual|
224220307|NCT02911389|OTHER|outpatient PT|
224318018|NCT07001319|DRUG|BVY|Administered orally
224318019|NCT07001319|DRUG|Standard of Care|Antiretroviral therapy, administered orally Non-NNRTIs, examples: ABC/ DTG/3TC; DTG plus (TAF or TDF) plus (FTC or 3TC)
224318020|NCT00497861|PROCEDURE|Activator Methods Chiropractic Technique|
224318021|NCT07134530|DEVICE|HPI-driven intraoperative hemodynamic management strategy|Hemodynamic management protocol based on information detected by Edwards HemoSphere monitor equipped with the Acumen Hypotension Prediction Index software (HPI)
223631981|NCT05672758|BEHAVIORAL|Recreational Training|One year of nonspecific recreational training
223631982|NCT04094558|DEVICE|Ingestible capsule|Participants will swallow capsules and collect in stool concurrent with stool samples
223631983|NCT04094558|PROCEDURE|Sedated EGD|Participants will undergo sedated esophagogastroduodenoscopy (EGD) for collection of small intestine aspirate and simultaneous saliva sample.
224318022|NCT07134530|DEVICE|GDT strategy|Current clinical hemodynamic care
223631984|NCT04094558|DIAGNOSTIC_TEST|Lactulose Breath Test|Hydrogen and methane breath test with lactulose substrate
223631985|NCT00273221|PROCEDURE|Glaucoma Implant Surgery|
223631986|NCT00273221|PROCEDURE|trabeculectomy|
223631987|NCT00273221|PROCEDURE|phacoemulsification|
223631988|NCT03566602|DEVICE|Dura Sealant Patch|Adjunctive bioresorbable patch
223631989|NCT06301490|OTHER|Myofascial Release|Myofascial release is a popular hands-on method manual therapy technique that uses carefully guided low load, long duration mechanical pressures to modify the myofascial complex (directly or indirectly), with the goal of restoring appropriate length, decreasing discomfort, and improving range of motion, muscle recovery, and physical performance in healthy persons.
223631990|NCT05096195|DRUG|Denosumab 60 mg/ml|Details described in intervention arm/group description section.
224220308|NCT05299229|DIAGNOSTIC_TEST|Echocardiogrpahy and non-invasive monitoring|Study participants will have echocardiography and non-invasive monitoring by chest/back sensors and a finger cuff.
224220309|NCT02415166|BIOLOGICAL|INFLUENZA VACCINE|THE PURPOSE OF THE STUDY IS TO EVALUATE THE EFFICACY OF THE SEASONAL INFLUENZA VACCINE IN PEOPLE WITH MAJOR DEPRESSIVE DISORDER
224220310|NCT02415166|OTHER|NaCl-saline placebo|placebo
224220311|NCT06238492|BEHAVIORAL|game-like computerized activities|Experimental
223631991|NCT05096195|OTHER|Calcium and vitamin D prophylaxis|Details described in intervention arm/group description section.
223631992|NCT05096195|DIAGNOSTIC_TEST|Monitoring of post-injection calcium and phosphate|Details described in intervention arm/group description section.
224220312|NCT06238492|BEHAVIORAL|Placebo|game-like computerized activities
224220313|NCT00463892|PROCEDURE|High-resolution contrast-enhanced MRI scan|High-resolution contrast-enhanced MRI scan of regional lymph nodes every 6 months on study
224220314|NCT03208348|OTHER|Pilot Virtual Reality|Exposure to a virtual reality vignette with anxiety rating to support exposure therapy
224318023|NCT07133503|OTHER|radiological evaluation|Using a line drawn through the midpoints of the teeth, parallel to their long axes, the anterior crest morphology was assessed. For maxillary central, lateral, and canine teeth, alveolar crest width and height, buccal bone thickness, and tooth-crest angle were measured separately. To determine buccal bone thickness, measurements were taken from the buccal crest apex, the midpoint of the root, and the apex of the tooth. The height of the alveolar crest was defined as the length of a line drawn parallel to the crest's long axis between the nasal fossa floor and the alveolar crest. The width of the alveolar crest was calculated by averaging measurements taken from the midpoints of three equal sections of the alveolar crest. The buccal undercut was determined as the point where the crest came closest to the root in the sagittal plane. Additionally, the angle between the tooth roots and the alveolar crest was measured to determine the root position in the radial plane
223631993|NCT03922100|DRUG|NMS-03592088|Route of administration: Oral
223631994|NCT06229626|OTHER|intensive reeducation|"* 1 group physiotherapy session per week at the ICM or by videoconference from home for 6 weeks~* 2 sessions per week at home with video support sent by e-mail for 6 weeks"
223631995|NCT01064388|DRUG|AZD9742|IV infusion, 15 days
223631996|NCT01064388|DRUG|Placebo|IV infusion, 15 days
223631997|NCT01263080|DRUG|mirtazapine|mirtazapine 30mg QD
223631998|NCT01263080|DRUG|folic acid placebo|folic acid placebo 1 tablet QD
223631999|NCT01263080|DRUG|mirtazapine placebo|mirtazapine placebo 1 tablet QD
224220315|NCT05028101|PROCEDURE|Delayed autologous breast reconstruction|SOC: Delayed autologous breast reconstruction
224220316|NCT05028101|BEHAVIORAL|Perioperative Functional Medicine (FM) Care|SOC plus FM: A food plan that encourages consumption of nutrient-dense whole foods. It provides adequate protein, balanced quality fats and foods which contain targeted nutrients essential to proper wound healing. Select dietary supplements will be provided as an adjunct to the food plan. Health coaching will support optimal sleep, adequate movement/exercise and stress reduction.
224220317|NCT02099968|BEHAVIORAL|Comprehensive Lifestyle Modification|"* Fasting (1st week), followed by:~* Vegetarian and modified DASH diet (plant-based, low-salt)~* Aerobic exercise~* Stress reduction techniques: progressive muscle relaxation, meditation, yoga"
224220318|NCT02099968|BEHAVIORAL|Standard Lifestyle Modification / modified DASH|"* Modified DASH (vegetarian focused, plant-based, low-salt)~* Aerobic exercise~* Stress reduction techniques: progressive muscle relaxation"
224220319|NCT02116686|DEVICE|ventilatory polygraphic recordings|Standard nocturnal in-home ventilatory polygraphic recordings were performed using an Embla device (Embla®, Broomfield, USA) and scored according to the AASM recommendations (RemLogic® software, Broomfield, USA).
224220320|NCT02480010|DRUG|Pertuzumab|Participants will receive pertuzumab on Day 1 of each 3-week cycle. In Cohort A, an 840-mg loading dose will be administered prior to the 420-mg IV infusion. In Cohort B, the 1050-mg IV infusion will be administered with no loading dose.
224220321|NCT05085314|PROCEDURE|Ngenuity digital 3D microscope|Cataract surgery under topical anesthesia with the Ngenuity digital 3D microscope, Alcon, Fort Worth, TX
224220322|NCT05085314|PROCEDURE|Conventional microscope|Cataract surgery under topical anesthesia with a conventional microscope
223632000|NCT01263080|DRUG|folic acid|folic acid 0.4mg QD
223632001|NCT05623124|OTHER|No intervention|No intervention
223632002|NCT00295555|DRUG|Effects of doxazosin on morning surge in diabetic patients|
223632003|NCT05577247|OTHER|functional magnetic resonance imaging|Patients treated with ketamine antidepressants will be tested with fMRI before or 24h after a single ketamine infusion administered in the clinical setting.
223632004|NCT04246684|DRUG|Oxaliplatin, 85 mg/m2|85 mg/m2,2h-civ, day 22, 36, 50, 64, 78, 92, 106, 120, and 134 of therapy
223632005|NCT04246684|DRUG|5FU; 2400 mg/m2|2400 mg/m2, 46h-civ, day 22, 36, 50, 64, 78, 92, 106, 120, 134 of therapy for Control arm
223632006|NCT04246684|DRUG|5FU, 250 mg/m2|250 mg/m2 per day, civ, on day 1-14, day 22-35 of radiotherapy;
224220323|NCT03826381|DIAGNOSTIC_TEST|Magnetic resonance (MR) spectroscopy of the liver|Magnetic resonance (MR) spectroscopy of the liver. Golden standard for non-invasive determination of NAFLD
224220324|NCT03826381|DIAGNOSTIC_TEST|Fibroscan|Transient Elastography for Measurement of liver fibrosis.
223632007|NCT04246684|DRUG|5FU, 2400 mg/m2|2400 mg/m2,46h-civ, d64, d78, d92, d106, d120, d134 of therapy
223632008|NCT04246684|DRUG|Oxaliplatin 50 mg/m2|50 mg/m2, 2h-civ, d1, d8, d21, d29 of radiotherapy and
223632009|NCT04246684|DRUG|Folinic Acid, 400 mg/m2|2h-civ day 22, 36, 50, 64, 78, 92, 106, 120, and 134 of therapyfor Control arm; 400 mg/m2, 2h-civ d 64, d78, d92, d106, d120, d134 of therapy for experimental arm
223632010|NCT04246684|RADIATION|Radiotherapy control, 5x5 Gy: 25 Gy|Control arm: 5x5 Gy (total: 25 Gy) 5 fractions
223632011|NCT04246684|DRUG|Capecitabine, 1000 mg/m2|1000 mg/m2 (twice daily) day1-14 every three weeks instead of 5FU optional
223632012|NCT04246684|DRUG|Oxaliplatin 85 mg/m2|85 mg/m2, 2h-civ, d64, d78, d92, d106, d120, d134 of therapy
223632013|NCT04246684|RADIATION|radiotherapy experimental, 30 x 1,8 Gy: 54 Gy|30 x 1.8 Gy (total: 54 Gy), 5 fractions per week
224220325|NCT03826381|DEVICE|Continuous glucose monitoring (CGM) for four days.|CGM is attached to the abdominal skin for four days. Afterwards data is converted and analysed in a computer program.
224220326|NCT03826381|RADIATION|Dual Energy X-ray Absorptiometry (DEXA) scan|DEXA-scan of the body composition.
224220327|NCT03826381|BIOLOGICAL|Blood samples|Immediately analyse of basic lab data. Later analyses for glucagon, amino acids, bile acids, lipidomics and metabolomics.
224220328|NCT03826381|OTHER|Clinical and demographic data|Measurements of blood pressure, pulse, height, weight.
224220329|NCT04998643|DIAGNOSTIC_TEST|Muscle ultrasound to estimate lean body mass|The investigators will perform serial muscle ultrasounds in the postoperative period to estimate lean body mass.
224220330|NCT00717210|DRUG|Temozolomide|200 mg/m2 body surface on days 1-5 every 28 days for 8 cycles; and again for another 4 cycles at primary progression
224220331|NCT00717210|RADIATION|Focal radiotherapy|54-60 Gy in 28-30 fractions over 6-7 weeks
224220332|NCT05088512|GENETIC|SNP analysis of the DNA|SNP analysis of the DNA obtained from peripheral blood sample
224220333|NCT00782236|DEVICE|Bone Graft Material|After screening and enrollment, subjects will undergo tooth extraction of a single tooth with placement of Straumann Bone Ceramic or Freeze Dried Allograft Bone (FDBA) with a resorbable collagen membrane (Bio-Gide) for preservation of the alveolar ridge following tooth extraction. Following 6 months of healing, a core of bone will be taken from the surgical site and a dental implant will be placed. The subjects will then be followed for 12 months following dental implant placement.
224220334|NCT05434208|OTHER|Nurse-led telephonic calls|active telephonic follow-up program by specialist nurses until end-of-treatment (28 days)
224220335|NCT04051138|OTHER|Voxx socks and sleeves|participants will be tested with a true device as well as with a placebo device
224220336|NCT02788123|DRUG|bismuth tripotassium dicitrate|oral
224220337|NCT02788123|DRUG|pantoprazole|oral
223632014|NCT04246684|DRUG|Capecitabine, 825 mg/m2|825 mg/m2 bid, per os, on day 1-14, 22-35 of RT instead of 5FU optional
223632015|NCT04246684|DRUG|Oxaliplatin, 130 mg/m2|day1every three weeks (optional)
223632016|NCT01854411|OTHER|analgesic measure|ibuprofen and ketoprofen measured into breast milk
223632017|NCT04503070|BEHAVIORAL|Motion capture participant|"Once participants have undergone appropriate calibration processes, they will perform listed swing progressions:~1. 15 dry swings with a wiffle bat at low, medium and high effort~2. 15 dry swings with a weighted bat at low, medium and high effort~3. 15 swings off of a tee at low, medium and high effort~4. 15 swings at an underhand toss at low, medium and high effort~5. 15 swings from a pitching machine at low, medium and high effort"
223632018|NCT04664491|BEHAVIORAL|Standardized COPD management|"In standardized management group, patients will receive a multifaceted and integrated disease management that follows recommendations in GOLD 2020 and China Guideline on COPD care. It contains the components below.~1. Maintenance therapy after initial treatment. In this study, patients' initial therapy is the prescribed inhalers at baseline. Maintenance therapy is the medications (LABA, LAMA, or ICS) prescribed for regular or long-term use after initial therapy.~2. Long-term follow-up and routine monitoring of symptoms measured by CAT, mMRC and SGRQ.~3. Regular pulmonary function testing for lung function monitoring~4. Strengthened COPD education~5. Behavioral modification, eg. encouragement of influenza/pneumococcal vaccination, providing smoking cessation counseling and pulmonary rehabilitation."
223632019|NCT04664491|OTHER|Routine COPD management|Patients will undergo usual care according to current clinical practice in study sites. Usual care is the routine care provided to patients. Prescription and dispense of medicine for COPD initial and maintenance therapy will be at the discretion of doctors.
223632020|NCT04614896|DIAGNOSTIC_TEST|Transoral ultrasound of tongue tumors|A transoral ultrasound scan of tongue tumors will be performed to assess the depth of invasion of the tumor
223632021|NCT00232063|DRUG|ciclosporin|
223632022|NCT04528641|BIOLOGICAL|GRAd-COV2|Single intramuscular administration.
223632023|NCT02010892|PROCEDURE|Stent Grafting (ESR)|
224220338|NCT04221555|DRUG|Docetaxel, Oxaliplatin, S-1 and Durvalumab|"1. Neoadjuvant treatment Durvalumab 1120 mg IV on day (D) 1, Docetaxel 50 mg/m2 intravenously (IV) on D1, oxaliplatin 100 mg/m2 IV on D1, S-1 40 mg/m2 bid orally on D1-14, will be administered every three weeks for three cycles.~2. Surgery~3. Adjuvant treatment After 4-6 weeks from surgery, S-1 40 mg/m2 bid orally on D1-28 plus durvalumab 1120 mg on D1 and D22 will be administered every 6 weeks for 12 months as an adjuvant treatment."
224220339|NCT04221555|DRUG|Durvalumab and Tremelimumab|"1. Neoadjuvant treatment Durvalumab 1500 mg IV and tremelimumab 75 mg IV on D1 will be administered every four weeks for three cycles.~2. Surgery~3. Adjuvant treatment After 4-6 weeks from surgery, durvalumab 1500 mg on D1 will be administered every 4 weeks for 12 months as an adjuvant treatment."
224220340|NCT01114113|DRUG|pancelipase/placebo|"ZenPep 20000 units of lipase will be provided for the participant to take with a trigger meal or an identical placebo. This will only be given to those participants willing to consume 2 more identical trigger meals and will not be given for the initial baseline non-trigger and baseline trigger meal. In both of these arms, patients will also be swallowing the SmartPill Capsule."
224220341|NCT01114113|DEVICE|SmartPill capsule|Measurement of a baseline, non-trigger meal intestinal transit by using the SmartPill capsule.
224220342|NCT01114113|DEVICE|SmartPill capsule|"Measurement of intestinal transit of a trigger meal baseline by using the SmartPill capsule"
224220343|NCT01114113|DEVICE|SmartPill capsule|SmartPill capsule
223632024|NCT02010892|PROCEDURE|Open Surgery (OSR)|
224220344|NCT04229303|DRUG|Voriconazole inhaled|"Part 1 (SAD): eligible subjects received a single ascending inhaled dose (5 mg, 10 mg, 20 mg, and 40 mg) of ZP-059 5mg capsules administered via dry powder inhaler (DPI) on the morning of Day 1.~Part 2 (MAD): eligible subjects received 2 (10mg twice daily \[BID\]) or 4 \[20mg BID\]) inhaled doses of ZP-059 5mg capsules administered via DPI BID for 9 days and once in the morning of Day 10, or 8 inhaled doses of ZP-059 5 mg capsules (40mg once daily \[QD\]) for 10 days. For QD dosing, subjects received QD doses of ZP-059 (at hour 0) on Days 1 to 10.~Part 3 (2-period crossover): eligible subjects received a 4 \[20mg BID\] inhaled doses of ZP-059 5mg capsules administered via DPI on the morning of Day 1 according to the crossover scheme of the study.~ZP-059 (inhaled voriconazole) was provided in clear, colorless size 3 hydroxypropylmethylcellulose hard capsules, which were individually and manually triggered by a breath actuated inhalation device (RS01 monodose inhaler)."
224220345|NCT04229303|DRUG|oral voriconazole|Part 3 (2-period crossover): eligible subjects received a single dose of oral voriconazole (200mg oral film-coated tablet, Vfend) on the morning of Day 1 according to the crossover scheme of the study.
224220346|NCT02705079|OTHER|EEG Monitoring|Value of EEG monitoring as adjunct to standard monitoring
224220347|NCT00606684|DRUG|GW642444 6.25|GW642444 6.25
224220348|NCT00606684|DRUG|GW642444 3mcg|once daily
224220349|NCT00606684|DRUG|GW642444 12.5mcg|GW642444 12.5mcg
224220350|NCT00606684|DRUG|GW642444 25mcg|GW642444 25mcg
224220351|NCT00606684|DRUG|GW642444 50mcg|GW642444 50mcg
224220352|NCT00606684|OTHER|placebo|placebo
224220353|NCT02254733|BEHAVIORAL|Cognitive Behavioral Social Skills Training (CBSST)|CBSST integrates CBT and SST techniques and neurocognitive compensatory aids. The treatment manual includes a patient workbook that describes the skills and includes homework assignment forms. Cognitive therapy is combined with role play practice of communication skills and problem-solving training. The ACT-adapted, team-delivered individual CBSST intervention will be delivered in 3 6-session modules (Cognitive Skills, Social Skills, and Problem Solving Skills) for a total of 18 weekly individual therapy sessions, but with participants completing the sequence of 3 modules twice, for a total of 36 sessions (9 months).
224220354|NCT02254733|OTHER|Assertive Community Treatment (ACT)|Assertive Community Treatment model is a evidence based practice model. ACT teams are multi-disciplinary and provide comprehensive services to individuals in their natural setting with small staff to recipient ratio. ACT teams use assertive engagement to proactively engage individuals in treatment providing services and support directly to individuals that are tailored to meet their specific goals and needs.
224220355|NCT02144259|DRUG|DMPA immediately postpartum|DMPA is an intramuscular injection of 150mg of depot medroxyprogesterone acetate.
224220356|NCT02144259|DRUG|Implanon immediately postpartum|Implanon ® is a subdermal implant that contains 68mg of etonogestrel.
224220357|NCT01178359|DRUG|nitrite|
224318024|NCT07134803|DEVICE|Bonding of the orthodontic brackets with dental loupe with Zumax Dental loupes DFK Angled Loupe with a magnification of x3.0 and focus depth of 42cm|Bonding of the orthodontic brackets on patients' teeth with dental loupe with Zumax Dental loupes DFK Angled Loupe with a magnification of x3.0 and focus depth of 42cm. Then the scanned for STL file and be superimposed with the gold standard created for the patient individually.
224318025|NCT07135180|DIETARY_SUPPLEMENT|Cordyceps cicadae|Cordyceps cicadae 500mg
224318026|NCT07135180|DIETARY_SUPPLEMENT|Blank control|Blank control
224318027|NCT07134296|RADIATION|MR-Guided Irradiation|MR-Guided Irradiation
224318028|NCT00400842|DRUG|SA-001|0.25 g of SA-001 pellets/capsule, 12 capsules/day for 7 days
224318029|NCT00400842|DRUG|SA-001|0.25 g of SA-001 pellets/capsule, 6 capsules/day for 7 days
224318030|NCT00400842|DRUG|Placebo|Placebo
224318031|NCT00315237|DRUG|vinflunine and best supportive care|solution for injection, IV, 280/320 mg/m2, every 3 wks variable duration
224318032|NCT05795647|DRUG|Pentoxifylline+Tocopherol|Treatment will consist of pentoxifylline LP 400 mg morning and evening, combined with tocopherol 500 mg morning and evening
224318033|NCT06867523|OTHER|Eye Mask|Participants in this group will wear an eye mask between 11:00 PM and 07:00 AM for three consecutive nights to assess its effects on delirium and pain levels in pediatric intensive care unit patients
223632025|NCT01431612|DRUG|Esmolol administration|50 µg/kg/min of the ß1-receptor-blocker esmolol was infused intravenous over 3 hours
224318034|NCT06867523|OTHER|Earplugs|Participants in this group will use earplugs between 11:00 PM and 07:00 AM for three consecutive nights to evaluate their effects on delirium incidence and pain levels.
224318035|NCT06874751|OTHER|No treatment given|No treatment given
224318036|NCT06874751|OTHER|No treatment given|No treatment given
224318037|NCT06230406|PROCEDURE|surgery for artherial and/or venous diseases|collection of vascular samples from surgery and blood samples
224318038|NCT05365724|BIOLOGICAL|Omicron COVID-19 Vaccine (Vero Cell), Inactivated|2 doses of vaccine according to the immunization schedule of 0, 21-28 days
224318039|NCT05645952|OTHER|Clinical follow up of hypertrophic cardiomyopathy|Patients diagnosed with hypertrophic cardiomyopathy during study period
224318040|NCT00002070|DRUG|Sargramostim|
224318041|NCT00002070|DRUG|Ganciclovir|
224318042|NCT03683771|DIAGNOSTIC_TEST|Transvaginal US with Doppler study|Transvaginal Ultrasound with doppler study on endometrium will be made
224318043|NCT03783429|DRUG|Digoxin|Digoxin tablets will be given orally
224318044|NCT03783429|DRUG|Placebos|Placebo tablets will be given orally
223632026|NCT01431612|DRUG|Phenylephrine infusion|0.01 µg/kg/min of the alpha-1-adrenergic receptor agonist phenylephrine
223632027|NCT01431612|DRUG|Lactated Ringer´s solution|Intravenous Infusion of 10 ml/h lactated Ringer's solution that contained no drug
223632028|NCT02337413|DRUG|Polyethylene glycol 3350|Patients will initially receive three days of high dose PEG3350 treatment (1.5gr/kg up to 100gr maximum) and then will be stepped down to 0.8gr/kg subsequently and tapered accoriding to stool consistency and frequency.
223632029|NCT02337413|BEHAVIORAL|Constipation behavioral therapy|Patients in the active group will receive dietary instruction as to fiber content, as well as behavioral therapy including active sitting on the toilet to attempt defaction following meals.
223632030|NCT02337413|BEHAVIORAL|Urotherapy|Patients will be guided for appropriate drinking and toilet habits, and will start with timed voiding.
223632031|NCT02015273|DEVICE|easypod™|Saizen® (Somatropin) as per Summary of Product Characteristics administered by easypod™
223632032|NCT04686461|DRUG|Nigella sativa seeds extract containing ointment intervention|Nigella sativa seeds extract containing ointment Nigella sativa seed extract, bee wax, white petrolatum, stearyl alcohol
223632033|NCT03380650|DEVICE|directional atherectomy and locol drug delivery|combined use of directional atherectomy and locol drug delivery for the treatment of femoralpopliteal disease
223632034|NCT03380650|DEVICE|drug-coated balloon dilation|use of drug-coated balloon dilation for the treatment of femoralpopliteal disease
223632035|NCT00173472|DRUG|Chemotherapy|
223632036|NCT01847521|DIETARY_SUPPLEMENT|Luteolin, Quercetin and Rutin combined in a capsule|
223632037|NCT01917058|DRUG|Abatacept|"This will be a randomized double blind placebo controlled study. Patients will be randomly assigned to abatacept or placebo in a 1:1 ratio based on a computer generated randomization list. The list will be generated prior to study initiation. Based on the randomization list, patients will be assigned to treatment vs. vehicle (provided by BMS) in the order in which they are enrolled. The assignment will be made by study personnel who are not involved in making clinical assessments or evaluations. The patient and the assessing physicians will remain blinded to the treatment assignment for the duration of the study.~Patients will be treated with abatacept 125mg SC self-administered each week. Treatment will be continued for 6 months to provide adequate time to assess the short-term efficacy and safety of abatacept in patients with alopecia areata. Patients will then be followed for an additional 6 months to assess the timing and incidence of relapse."
224220358|NCT02537132|OTHER|Adaptation and training to Non Invasive Ventilation (NIV)|Each person recruited after a respiratory evaluation (baseline spirometry and supine, maximal inspiratory and expiratory pressures (MIP / MEP) or sniff nasal inspiratory pressure (SNIP), 6 Minute Walking Test (6MWT) -if still ambulatory, arterial blood gas, nocturnal polygraphy) will be adapted to Non Invasive Ventilation (NIV). Moreover, the subject will be brought to the management of bronchial secretions (under the terms set out herein) during not less than five outpatient or house accesses, depending on who is randomly assigned to the experimental group or the control group. These accesses will take place weekly, for a period of two months, considering both the needs and the patient's clinical condition.
224220359|NCT02917200|DRUG|Moxifloxacin|Oral route
224318045|NCT07134179|OTHER|Experience of pain during caesarean delivery|We wish to investigate how women experience insufficient regional anesthesia during cesarean sections, in cases where the regional anesthesia was not converted to general anesthesia. The focus is on exploring the factors that contribute positively and negatively to the woman's experience in this situation
223632038|NCT01917058|DRUG|placebo|
223632039|NCT06009965|DRUG|CsA+ATG+Herombopag|CsA: 3-5 mg/kg/day, monitor trough concentration monthly, maintain trough concentration at 100-200 ng/ml.ATG: rabbit anti-thymocyte immunoglobulin (r-ATG) 3 mg/kg/d x 5 days or porcine anti-lymphocyte immunoglobulin ((p-ATG) 25 mg/kg/d x 5 days.TPO-RA: Heptapepto-Papa 7.5 mg qd to start. Monitor blood every 2 weeks and if ineffective, increase by 1 tablet every 2 weeks up to a maximum of 6 tablets (15mg) qd.
223632040|NCT06009965|DRUG|CsA+Herombopag|CsA: 3-5 mg/kg/day, monitor trough concentrations monthly, maintain trough concentrations at 100-200 ng/ml.TPO-RA: Start with Hetropoxyphene 7.5 mg qd, monitor blood every 2 weeks, and if ineffective, increase by 1 tablet every 2 weeks up to a maximum of 6 tablets (15 mg) qd.
224220360|NCT02917200|DEVICE|DAV132|Oral route
224220361|NCT02917200|OTHER|Negative control|Oral route
223632041|NCT05918601|OTHER|Health-risk behaviors|Participants will be asked about the priority they place on engagement in health-related lifestyles, such as quitting drugs, alcohol, smoking or exercising regularly.
223632042|NCT05918601|OTHER|Theory of planned behavior, Self-determination theory|The participants will be asked to quit drugs immediately or progressively with the ultimate goal of quitting drugs completely.
223632043|NCT05918601|OTHER|Assist them to adhere to their schedule of quitting drugs throughout the study period|The participants will receive instant messaging via WeChat or WhatsApp from peer supporters to assist them to adhere to their schedule of quitting drugs throughout the study period.
223632044|NCT05918601|OTHER|Assist them to adhere to their schedule of desirable health-related lifestyles/quitting drugs throughout the study period|The participants will receive instant messaging via WeChat or WhatsApp from peer supporters to assist them to adhere to their schedule of desirable health-related lifestyles/quitting drugs throughout the study period.
223632045|NCT05918601|OTHER|(AWARD) model|Participants receive a brief intervention using the Ask, Warn, Advise, Refer and Do-it-Again (AWARD) model
223764279|NCT04246970|OTHER|Prehabilitation|Supervised training program of 8-weeks and a frequency of 2 days/week. It includes interval aerobic exercise (5 cycles of 2 minutes at 70 percentage of Watts or heart rate of cardiopulmonary exercise testing (CEPT) and 3 minutes of active rest at 40 percentage; peripheral muscle training and balance exercises in a circuit of 10 phases, 10 to 15 repetitions, from 1 to 3 sets (the participants will work at moderate intensity, no more than 5-6/10 on the modified Borg scale); Inspiratory Muscle Training (IMT) through a threshold loading device \[2 sessions / day, 3 sets of 15 repetitions, at 60-70 percentage of the maximum inspiratory pressure (cmH2O)\]; ventilatory reeducation by an incentive inspirator based on the vital capacity evaluated in the initial spirometry. Both the aerobic modality and the resistance training, will increase the intensity of work (HR, Watts, Kg or cmH2O) between 2-5 percentage every 2 weeks complying with the principle of training overload.
223632046|NCT05918601|OTHER|Receive four independent 1-minute videos|The participants will receive four independent 1-minute videos which focus on the health risks associated with abusing drugs and the benefits of quitting drugs.
224220362|NCT04368052|DIAGNOSTIC_TEST|Mini Mental Test (MMT), S-100 beta, Neuron specific enolase and Glial fibrillary acidic protein|Patients undergoing liver transplantation (LTx) were measured using the Mini Mental Test (MMT) whereas simultaneous neuronal damage was evaluated through the measurement of S-100 beta (S100β), Neuron specific enolase (NSE) and Glial fibrillary acidic protein (GFAP) levels.
224318046|NCT04440670|BIOLOGICAL|autologous cord blood mononuclear cells|preterm neonates less than 28 weeks are assigned to receive intravenous autologous cord blood mononuclear cells infusion (5×107cells/kg) within 24 hours after birth
224318047|NCT04440670|BIOLOGICAL|normal saline|preterm neonates less than 28 weeks are assigned to receive normal saline within 24 hours after birth
224318048|NCT01833819|DRUG|Dexmedetomidine and lidocaine|
224318049|NCT01833819|DRUG|Remifentanil|
223632047|NCT05165667|OTHER|rehabilitation team|The meeting comprised physiotherapist, occupational therapist, rehabilitation nurse, speech and language therapists, social worker, nutritionist, psychologists under the team leader guidance by physiatrist. Respondents of both groups will be assessed to see the effects of treatment at 6 th weeks, 12 th weeks and 24 th weeks. Outcomes will be measured by FIM (Functional independence Measure) scores.
223632048|NCT04880980|DRUG|Terbinafine Pill|Double than usual dose of oral terbinafine pills will be used for treatment purpose in one group.
223632049|NCT04880980|DRUG|Itraconazole capsule|Double than usual dose of oral itraconazole capsules will be used for treatment purpose in second group.
223632050|NCT01413035|BIOLOGICAL|MSC|1.0E+6 MSC/kg, IV drop in Day 0 and repeat to apply in Day 90 if the effect of MSC is better.
223632051|NCT06365359|OTHER|Blood sample for analysis of plasma of organochlorine pesticides concentration|A 20 mL blood sample will be taken up to 6 months after inclusion of the patient for the analysis of chlordecone and the following organochlorine compounds: p,p'-DDE, βHCH, γHCH, PCB 153. This analysis will be carried out at the Institut Pasteur of Guadeloupe (IPG).
223632052|NCT06365359|OTHER|Blood sample for cell collection|"A 20 mL blood sample will be taken up to 6 months after inclusion of the patient for the cell collection which will be kept at the CeRBiM.~This collection will be used for subsequent studies on the immunotoxicity of chlordecone, by studying the cytokine, apoptotic and autoreactive functions of PBMC (Peripheral Blood Mononuclear Cells)."
223632053|NCT05899257|BEHAVIORAL|Immersive Training using EYME|Psychological assessment based on the RGT with EYME-Explore Your Meanings, a digital platform to explore the structure and content of personal identity with Virtual Reality.
223632054|NCT04366349|BIOLOGICAL|melrilimab (GSK3772847) 70 milligram (mg)|melrilimab (GSK3772837) will be available at a dose strength of 70 milligram per milliliter (mg/mL) in a 3 milliliter (mL) glass vial.
223632055|NCT04366349|BIOLOGICAL|melrilimab (GSK3772847) 140 milligram (mg)|Two doses of melrilimab (GSK3772837) 70 milligram per milliliter (mg/mL) will be administered to achieve a dose strength of 140 milligram per milliliter (mg/mL)
224220363|NCT00586300|OTHER|Physical training program|The physical training will be completed in two phases. In Phase 1, which will last 9 months, participants will complete the program under the supervision of an experienced trainer. Sessions will occur three times each week in a designated study facility. The program will include the following components: stretching and balance, flexibility and range of motion, muscle strengthening, and aerobics. The program will also emphasize the importance of individualizing exercise regimens according to each person's specific needs (function and fitness). In Phase 2, the primary objective will be to promote long-term exercise (for up to 24 months from the time of study entry) that incorporates the four modalities of exercise instruction introduced in Phase 1, but on an independent basis.
224220364|NCT00586300|BEHAVIORAL|Self-management training program|The self-management training program is designed to target primarily coping skills and self-efficacy. This will be accomplished by using a variety of educational and behavioral methods. The program will be delivered in two phases. The initial 9-month phase will consist of 12 weekly 60-minute classroom sessions, followed by 24 weeks of a structured telephone intervention program. Phase 2 will continue to incorporate the telephone intervention program, at less frequent intervals, for up to 24 months from the time of study entry.
224220365|NCT00586300|OTHER|Physical training and self-management training programs|"This multidimensional intervention will combine both the physical training and self-management training programs described for Groups 1 and 2."
224220366|NCT04014400|OTHER|Suprathel or Xeroform donor site application|The surgical procedure for recovery of a skin graft will be the same for all patients as follows. Once the patient is taken to the operating room, the selected donor site will be prepared and harvested with a Zimmer Dermatome set at 0.007 to 0.009 thousands of an inch for pediatric patients and 0.12 to 0.14 thousands for adult patients. After the harvesting procedure, the donor site will be covered with Telfa saturated with 1:10,000 epinephrine in normal saline until hemostasis is achieved. The Telfa will be irrigated off the donor site with the epinephrine saline solution. The surgeon will don a new pair of sterile gloves to handle the donor site dressing. The randomized dressing will be applied over the hemostatic donor site with an approximate 1-2cm border. Next, the wound will be dressed with 4x4 cotton gauze pads (fluffs), rolled gauze (Kerlix) and either Coban or BandNet.
224220367|NCT01882400|DRUG|Bisphosphonate treatment|Treatment with Calcium, vitamin D and a weekly bisphosphonate. Comparison of bone mass, fracture rate, pain intensity and scoliosis progression before and after treatment
224220368|NCT01998685|DRUG|Propofol|
224220369|NCT01998685|DRUG|remifentanyl|
224220370|NCT01998685|DRUG|Midazolam|
224220371|NCT01998685|DRUG|Fentanyl|
224220372|NCT01998685|DRUG|Sevoflurane|
224220373|NCT02684500|DEVICE|Ultrasound|Study measurements of the diameter and doppler flow velocity of the superior mesenteric artery (SMA) for a aneurysmal subarachnoid hemorrhage using abdominal ultrasound.
223632056|NCT04366349|OTHER|Placebo|Placebo to match melrilimab (GSK3772847) will be available in the form of solution for injection in a 3 milliliter (mL) glass vial.
223632057|NCT02475590|PROCEDURE|Laparoscopic sleeve gastrectomy|Laparoscopic sleeve gastrectomy
223632058|NCT02475590|PROCEDURE|Laparoscopic Roux-en-Y gastric bypass|Laparoscopic Roux-en-Y gastric bypass
223632059|NCT03377582|OTHER|Exercise|Both interventions uses exercises
223632060|NCT02560038|DRUG|Gemcitabine|1000 mg/m2 will be administered as an IV infusion over 10 mg/minute on Days 1 and 8 of each cycle (each cycle is 21 days).
223632061|NCT02560038|DRUG|Paclitaxel|175 mg/m2 will be administered as an IVPB over 3 hours on Day 2 of each cycle (each cycle is 21 days).
224220374|NCT03016585|OTHER|Tai Chi Training|Participants practiced, under supervised instruction, 10 forms from the classic Yang style of Tai Chi 3 times per wk for 12 weeks.The Tai Chi sessions lasted approximately 55 minutes and included a 10-minute warm up, 40 minutes of practice and exercise finalizing with a 5-minute cooldown period.
224220375|NCT01623661|OTHER|hypertonic saline|hypertonic saline 3.0 % (7 ml/kg)
224220376|NCT03753997|BEHAVIORAL|Treatment by a diabetes educated psychologist|Patients will meet a diabetes educated psychologist. There will be a minimum of 5 meetings during the first 3 months and then in the following 6 months there will be a minimum of 2 meetings. More meetings will be scheduled if needed.
223632062|NCT02560038|DRUG|Cisplatin|70 mg/m2 will be administered as an IVPB over 2 hours on Day 2 of each cycle (each cycle is 21 days).
223632063|NCT03542812|DRUG|L-Citrulline|The L-citrulline will be procured in powder form and will be solubilized in sterile water to achieve a concentration of 50 mg/ml. Therefore, 3 ml/kg of the solubilized L-citrulline (50 mg/ml) will be administered per dose for the single-dose groups and the dose administered to the steady-state group will be determined from results from the single-dose studies.
223632064|NCT02981147|DRUG|Phytus (Cisti, Thyme and Ivy Leaves)|Phytus is a medicinal herb containing Ivy leaves, Cisti and Thyme.
223632065|NCT00579033|OTHER|Tactile training + sham rTMS|tactile training for 2.5/hr/day for 15 days - this plus the sham rTMS
223632066|NCT00579033|OTHER|Tactile training + rTMS|tactile training 2.5/hr/day for 15 days plus daily 5Hz rTMS
223632067|NCT05919342|DIAGNOSTIC_TEST|NT-proBNP|Patients will undergo an NT-proBNP which will guide their future involvement within the study. Patients with an NT-proBNP of ≥125 pg/mL will undergo transthoracic echocardiogram along with a clinical assessment - any diagnosis of HF will result in patients undergoing referral for initiation of guideline directed medical therapy (for HF).
223632068|NCT02878499|OTHER|polysomnography|
224220377|NCT01451905|DRUG|Liraglutide|Victoza® is supplied in pens for injection containing 18 mg of the GLP-1 agonist liraglutide in 3 mL sterile water with disodiumphosphate and propylene glycol, and phenol for conservation (pH 8.15). Commercial pens will be used and the information given in the packaging will be applicable. The initial daily dose will be 0.6 mg for one week, 1.2 mg the following week and then 1.8 mg for the remaining treatment period. The injection is administered once daily in the morning. The maximal plasma concentration is reached 8-12 hours after subcutaneous injection. The half-life in plasma is approximately 13 hours. The duration of effect is 24 hours.
224220378|NCT01451905|DRUG|Placebo|The placebo pens contain saline and are administered in the same way and volume as Victoza. The placebo pens are specially prepared for this study and will be used in the study only
224220379|NCT04895618|DEVICE|Erchonia GVL|Single treatment with the Erchonia GVL to the neck and shoulders. The treatment applies 520 nanometers (nm) green diode light and 405 nm violet diode light simultaneously.
224220380|NCT05652920|BIOLOGICAL|Ori-C101|Hepatic arterial infusion
224220381|NCT03974594|DRUG|Trifluridine and Tipiracil Tablets|Trifluridine and Tipiracil Tablets given 20mg orally once under fasting or postprandial conditions per cycle
224220382|NCT03974594|DRUG|TAS-102|TAS-102 given 20mg orally once under fasting or postprandial conditions per cycle
223632069|NCT00299767|PROCEDURE|sequential cord blood transplantation|Infused on Day 0
223632070|NCT05421624|DEVICE|Digital music therapeutic|The digital music therapeutic is comprised of foot sensors, a smart phone with pre-installed proprietary software application, and headphones. The device obtains real-time walking data through movement sensors that communicate wirelessly with the smartphone application software. Music cues are tailored to the person's walking pattern, and are transmitted wirelessly to the headphones. Music cues are time-shifted to the user's baseline cadence and adjusted in real-time based on the user's walking performance metrics.
223632071|NCT05421624|BEHAVIORAL|Active-Control|The Active-Control intervention will implement a similarly structured community-based walking program as Amped-PD, with the only exception the digital music therapeutic.
224220383|NCT01900873|DEVICE|Inspiratory Muscle Strength Training|IMT will be performed using a variable flow resistive loading device (POWERbreathe®KH1, HaB International Ltd., Southam, UK). The device is able to store training parameters of up to 40 sessions. Most training sessions during this RCT will be performed by patients at their homes without supervision. The intervention group (strength IMT) will perform two daily sessions of 30 breaths. Measurements of Pi,max will be performed every week and training loads will be increased continuously to maintain at least 40-50% of the actual Pi,max values. Each week, one training session will be performed under supervision. Training load will be increased during this session.
224220384|NCT01900873|DEVICE|Inspiratory Muscle Endurance Training|IMT will be performed using a variable flow resistive loading device (POWERbreathe®KH1, HaB International Ltd., Southam, UK). The device is able to store training parameters of up to 40 sessions. Most training sessions during this RCT will be performed by patients at their homes without supervision. The sham group (endurance IMT) will perform three daily sessions of 30 breaths and will train at a constant inspiratory load of no more than 10% of their initial Pi,max. Each week, one training session will be performed under supervision.
223632072|NCT04523714|BEHAVIORAL|Online CBT-CP based program|Self-completed, online program in which participants complete eight, interactive sessions (approximately one per week) focused on training in one or more evidence-based pain coping skills
223632073|NCT04523714|BEHAVIORAL|Virtual coach-led CBT-CP based program|Live, coach-led program delivered by telephone or videoconference in which participants complete eight, interactive sessions (approximately one per week) focused on training in one or more evidence-based pain coping skills
223632074|NCT06007872|DEVICE|Intracardiac Echocardiography (ICE)|ICE will be used to guide trans-septal puncture and to guide device implant.
223632075|NCT02783690|RADIATION|Hypofractionation|40 Gy (RBE) in 15 daily fractions
223632076|NCT04706208|BEHAVIORAL|Cognitive Multisensory Therapy|Cognitive multisensory rehabilitation (CMR) is a type of physical therapy that incorporates conscious perception of body positions and movements during (multi)sensory discrimination exercises. The treating therapists will give 40 minutes of discrimination exercises embedded in functional movements followed by 5 minutes of applying the learned strategies during activities of daily living. CMR uses several types of discrimination exercises: Participants discriminated shapes, length, weight, distance, resistance, textures or compare kinesthetic information with visual information for integration of multisensory information. Solving the discrimination task is combined with reflection and a learning process, prompted by the therapist on how the limb (was) moved or was positioned.
223632077|NCT04706208|OTHER|Usual Care|Standard of care treatment for neuropathic pain after spinal cord injury
223632078|NCT04706208|BEHAVIORAL|Clinical Assessment|Clinical assessments are detailed below. Screening will include demographic and general health data; mini mental state evaluation (MMSE)-short version; Edinburgh handedness inventory; and the kinesthetic and visual imagery questionnaire (KVIQ).
223632079|NCT04706208|BEHAVIORAL|Magnetic Resonance Imaging (MRI)|The MRI scanning will include structural scans, resting-state functional MRI, and 4 task-based functional MRI.
223632080|NCT04706208|OTHER|OPTIONAL: blood draw|This part is OPTIONAL: 38ml of blood will be taken one time (for able body adults) or at 3 time points (for adults with spinal cord injury and neuropathic pain.
223632081|NCT06268704|DRUG|Dexamethasone|This is a non-particulate steroid commonly used to treat SI joint pain.
223632082|NCT06268704|DRUG|Methylprednisolone|This is a particulate steroid commonly used to treat SI joint pain.
223764280|NCT04246970|OTHER|Prehabilitation and posttransplant training program|Prehabilitation will be followed by a posttransplant training program. In this, the patient will perform supervised exercise (IIa interval aerobic exercise and resistance training) 2 days / week, and a physical exercise program at home until completing a total of 5 sessions / week in the aerobic modality. In the unsupervised phase (IIb), the patient will continue with the learned physical exercise program, but without supervision, 5 sessions / week (including a minimum of 2 non-consecutive sessions to perform resistance training).
224220385|NCT00410722|DIETARY_SUPPLEMENT|Whole wheat and bran muffin|
224220386|NCT00410722|DIETARY_SUPPLEMENT|Mixed tree nuts|
224220387|NCT06536712|BIOLOGICAL|Mesenchymal Stem Cells Derived Exosomes|Mesenchymal Stem Cells Derived Exosomes will be administered intraperitoneally to patients at the end of their surgery
224220388|NCT06536712|OTHER|Placebo|10 patients will receive intraperitoneal placebo at the end of their surgery
224220389|NCT00162383|DRUG|Debrisoquine|
224220390|NCT00162383|DRUG|Mephenytoin|
224220391|NCT00162383|DRUG|Dapsone|
224220392|NCT00162383|DRUG|Caffeine|
224220393|NCT06113523|BIOLOGICAL|monogenic obesity|The DNA samples will be sequenced for the 71 obesity genes especially for the study.
224220394|NCT03522584|BIOLOGICAL|Durvalumab|Given IV
224220395|NCT03522584|OTHER|Laboratory Biomarker Analysis|Correlative studies
224220396|NCT03522584|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
224220397|NCT03522584|BIOLOGICAL|Tremelimumab|Given IV
224220398|NCT03522584|PROCEDURE|Hypofractionated Image-Guided Radiation Therapy|Undergo HIGRT
224220399|NCT00910858|DRUG|Lenalidomide|Lenalidomide 5-mg capsules for oral administration
224220400|NCT00910858|DRUG|Recombinant human erythropoietin|Recombinant human erythropoietin (rhu-EPO) subcutaneous injection of 40,000 units.
224220401|NCT04625920|DEVICE|SootheVR: AppliedVR, Los Angeles, California|a head-mounted display
224220402|NCT02189694|DEVICE|Single-hormone closed-loop strategy|Variable subcutaneous insulin infusion rates will be used to regulate glucose levels. Insulin Aspart (Novorapid, Novo Nordisk) will be used.
224220403|NCT02189694|DEVICE|Dual-hormone closed-loop strategy|Variable subcutaneous insulin and glucagon infusion rates will be used to regulate glucose levels. Insulin Aspart (Novorapid, Novo Nordisk) and Glucagon (Eli Lilly and Company) will be used.
224220404|NCT02189694|DEVICE|Insulin pump therapy|Subjects will use conventional pump therapy to regulate glucose levels. Insulin Aspart (Novorapid, Novo Nordisk) will be used.
224220405|NCT04169282|DEVICE|nPEP (non-invasive positive expiratory pressure) mask|Positive end expiratory pressure (PEEP) mask
224220406|NCT02844374|OTHER|Functional stereotaxic exploration|Visual analysis : in order to define the level of cortical resections. Epileptogenic maps : calculated for each crisis and for all crisis in general. Connectivity maps : calculated for each site stimulated at low-frequency. Post-operative evaluation : in order to assess the extent of resection.
224220407|NCT00698022|DRUG|Risperidone|risperidone daily for 28 days
223632083|NCT06268704|DRUG|2% Lidocaine HCl Injection|Lidocaine is a local anesthetic used in SI joint injection procedures to numb the procedure site and helps to confirm SI joint dysfunction when injected with the steroid medication into the SI joint.
223632084|NCT00609102|DRUG|Placebo|one capsule BID
223632085|NCT00609102|DRUG|n-aceylcysteine|450 mgm BID
223632086|NCT06705725|DRUG|CBG002 CAR-T Cell Suspension|"Single dose of CAR+ T cells will be infused, and classic 3+3 dose escalation will be applied."
223632087|NCT05411562|DIAGNOSTIC_TEST|SARS-CoV-2 genomic sequencing|SARS-CoV-2 viral genomic sequencing and phylogenetic analyses
223632088|NCT06322160|OTHER|Interview|Interview with individual participant will take place via online videoconferencing MS Teams
223632089|NCT05910073|DEVICE|Lamina curved plate|Use of a Lamina Curved plate (Osteobiol® Laboratory) in the treatment of OAC
223632090|NCT04921241|OTHER|In Utero Exposure to SARS-CoV-2|Born to mother with SARS-CoV-2 infection during pregnancy
223632091|NCT05758116|DRUG|Tislelizumab|Tislelizumab: 200mg d1,q21d\*17
223632092|NCT03851523|OTHER|No intervention|No intervention
223764281|NCT04669457|DRUG|Intra-nasal Dexmedetomidine|Subjects will receive Dexmedetomidine intra-nasally in the preoperative area. It will be administered at a dose of 1 mcg/kg, approximately 15-25 minutes before entering the operating room.
224220408|NCT00698022|DRUG|Mifepristone|mifepristone daily for 28 days
224220409|NCT00698022|DRUG|Risperidone-matched placebo|risperidone-matched placebo daily for 28 days
224220410|NCT00698022|DRUG|Mifepristone-matched placebo|mifepristone-matched placebo daily for 28 days
224220411|NCT00621686|BIOLOGICAL|bevacizumab|
224220412|NCT00621686|DRUG|sorafenib tosylate|
224220413|NCT01703741|DRUG|Testosterone Gel (FE 999093)|
224220414|NCT04716114|DRUG|SKLB1028|SKLB1028 will be administered by oral capsules, 150 mg twice daily (BID).
224220415|NCT04716114|DRUG|Salvage Chemotherapy|Low-dose cytarabine (LoDAC); azacytidine; homoharringtonine (HHT), cytarabine and aclarubicin (HAA) or fludarabine, cytarabine and granulocyte colony-stimulating factor (FLAG) will be administered by subcutaneous (SC) and/or intravenous (IV) injections.
224220416|NCT01170364|DRUG|Sibutramine|1 week of active sibutramine (15mg)
224220417|NCT01170364|DRUG|Placebo|2 weeks of placebo
224220418|NCT01604213|DRUG|Metformin plus vildagliptin|Oral Metformin 850mg and vildagliptin 50mg, qd initially, up-titrated to BID if clinically necessary
224220419|NCT01604213|DRUG|Metformin only|Oral Metformin 850mg QD, up-titrated to 850mg TID is clinically indicated
224220420|NCT01381900|DRUG|Placebo|Form=capsule, route=oral administration. One capsule once daily for up to 18 weeks after completing a single-blind placebo run-in period (1 placebo capsule once daily for up to 2 weeks).
224220421|NCT01381900|DRUG|Canagliflozin 100mg|Type=1, unit=mg, number=100, form=capsule, route=oral use. One capsule once daily for up to 18 weeks after completing a single-blind placebo run-in period (1 placebo capsule once daily for up to 2 weeks).
224318050|NCT04262180|OTHER|Base intervention-Fitbit with EHR integration|Every subject will start with a base intervention - Fitbit activity tracker with EHR integration including messages delivered via the EHR's patient portal
224220422|NCT01381900|DRUG|Canagliflozin 300mg|Type=1, unit=mg, number=300, form=capsule, route=oral use. One capsule once daily for up to 18 weeks after completing a single-blind placebo run-in period (1 placebo capsule once daily for up to 2 weeks).
224220423|NCT01381900|DRUG|Metformin|The participant's stable dose of background therapy of metformin should be continued throughout the study.
224220424|NCT01381900|DRUG|Sulphonylurea|The participant's stable dose of background therapy of metformin plus sulphonylurea should be continued throughout the study.
224220425|NCT06358352|DIETARY_SUPPLEMENT|Lutein / Zeaxanthin|lutein extract from lutein oral capsules
224220426|NCT06358352|BIOLOGICAL|Platelet rich fibrin|platelet rich fibrin extracted from patient's blood after centrifuging
224220427|NCT00002806|DRUG|lomustine|
224220428|NCT00002806|DRUG|procarbazine hydrochloride|
224220429|NCT00002806|DRUG|vincristine sulfate|
224220430|NCT00002806|RADIATION|low-LET photon therapy|
224220431|NCT05947552|DRUG|Serum ferritin|Serum ferritin in CKD patients
224220432|NCT02222142|DRUG|Isoflurane|Comparison between isoflurane and propofol, Retrospective study
224220433|NCT02056899|DRUG|Gabapentin|
224220434|NCT02911883|DEVICE|Optical Coherence Tomography Angiography|
224220435|NCT01617733|DRUG|Pasireotide|4 Weeks pasireotide 0.6mg s/c injections twice daily followed by 24 weeks treatment with pasireotide LAR 60mg every 28 days with dose reductions if poor tolerability is encountered
224220436|NCT05661877|OTHER|DengueAid mobile application|•Education materials regarding dengue fever and self-care. The education section (My Dengue Knowledge) consists of seven modules (dengue essentials, risk, symptoms, aedes mosquito, self-care, prevention and interesting facts) with gamification properties. Each module contains a series of multiple-choice questions. After answering each question, the user would be instantly notified if they had answered the question correctly and be provided with some facts related to the question. A progress meter would allow users to keep track of each module answered. A medal would be awarded to users who have completed 100% of each module. The self-care section consists of basic information about dengue fever and points to look out for self-care. It contains information on dengue fever phases, signs of dengue, importance of keeping hydrated, complementary therapy, medicine to avoid and prevention practices.
224220437|NCT05661877|OTHER|MyHealth website|MyHealth is developed by Ministry of Health, Malaysia (http://www.myhealth.gov.my/en/dengue-fever/) to provide information on dengue.
224220438|NCT03189797|OTHER|tailored preventive program|In the study group they were given a preventive program as homecare program including tooth brushing 2/day with a fluoride toothpaste( 5000 ppm F) following the instructions in addition to fluoride mouth rinse. For the clinical approach motivational engagement was done by discussing with patients how to improve oral health behavior including amount of sugar, fibrous food and junk food. This in addition to pits and fissures sealant, F- varnish 2 times /year. and application of fluoride varnish every 6 months and dietary intake interventions.
224220439|NCT01137305|OTHER|VR- training|"Prospective randomization if 50 subjects to either three months of structured VR- training or no training; basic VR- skills assessment and a serial assessment of defined soft skills: self- efficacy, stress- coping and motivation prior to randomization; basic VR- skills measured within seven modules of the VR- simulator LapSim®: camera and instrument navigation, coordination, grasping, lifting and grasping, clip applying and diathermy cutting in different levels of difficulty- medium and hard referring to time to complete task, economy of instrument motion and tissue damage; intervention group: sessions of 45 minutes each twice a week for three months; control group: no training"
224220440|NCT02833402|DEVICE|InterStim Therapy|Sacral Neuromodulation, delivered by the InterStim® System, offers long-term control of bladder control and bowel control symptoms through modulation of the nerves that help control the pelvic floor and lower urinary tract.
224220441|NCT02041494|DEVICE|Ventralight|
224220442|NCT02041494|DEVICE|Strattice|
224220443|NCT04558216|DRUG|Vonoprazan|20 mg tablets administered orally
224220444|NCT04558216|DRUG|Rifampin|600 mg (Two 300 mg capsules)
224220445|NCT03599310|BEHAVIORAL|Advance care planning|The ACP guide is adapted from the Serious Illness Communication Guide and a culturally-sensitive ACP programme developed in the local context. The trained ACP facilitators will initiate the conversation by introducing the concepts of ACP with the support of the guide and assessing the patient's illness understanding and readiness to think about end-of-life care issues.
224220446|NCT03599310|BEHAVIORAL|Usual care|In the current practice, patients will have to take the initiative themselves if they would like to discuss their end-of-life care or make an advance directive.
224220447|NCT00005615|BIOLOGICAL|Interferon alfa|Interferon alfa as outlined in treatment arm.
223764282|NCT04669457|DRUG|Oral Midazolam|Subjects will receive Midazolam orally in the preoperative area. It will be administered at a dose of 0.5 mg/kg (with a maximum dose of 20 mg), approximately 10-15 minutes before entering the operating room.
223764283|NCT02710682|PROCEDURE|Mini-open surgery|"This treatment will be administered by an orthopedic surgeon specialized in upper limb surgery.~1. Skin disinfection; Local anesthesia (lidocaine 1%).~2. Skin incision, slightly anterior to lateral epicondyle.~3. Exposure of the plane between the tendon and fascia.~4. Extensor Carpi Radialis Longus (ECRL) tendon is lifted to expose the Extensor Carpi Radialis Brevis (ECRB) tendon.~5. Excision of diseased tissue of the ECRB tendon.~6. ECRL tendon is sutured back to the fascia. The skin is closed.~7. Patient is monitored for 30 minutes after procedure."
224220448|NCT00005615|RADIATION|Radiation therapy|Radiation therapy as outlined in treatment arm.
224220449|NCT03179683|DEVICE|Diode laser application|an 630-660 nm aluminum gallium indium phosphide (AlGalnP) laser device (Scorpion Dental Optima Model 405-7A; Optica Laser, Sofia, Bulgaria) was used immediately after surgery, third day, fifth day and seventh day only for one operation side. Treatment side were randomly selected by another surgeon who applied LLLT. Tissue was irradiated at 25mW power for total six minutes, two minutes for each point (buccal, palatal, crestal). 72J /cm2 energy density was deposited in one session.
224220450|NCT05334654|DRUG|Enoxaparin Sodium|Enoxaparin will be subcutaneously administered at a dosage from 4000 to 8000 twice daily according
224220451|NCT05334654|DRUG|Bivalirudin|Bivalirudin will be intravenously administered to obtain an activated prothrombin time (aPTT) of 1.5 fold of the normal values.
224220452|NCT00608205|DRUG|cisplatin|Given IV
224220453|NCT00608205|DRUG|fluorouracil|Given IV
223632093|NCT06255275|OTHER|neurocognitifs tests + pedestrian crossign whith virtual reality|Neurocognitive tests (attention, executive functions, reaction to difficulty). Assessment of anxiety and impulsivity + pedestrian crossign with virtual reality + post-crossing questionnaire
224220454|NCT00608205|RADIATION|radiation therapy|Patients undergo full-dose radiotherapy once or twice daily 5 days a week for up to 7 weeks
224220455|NCT00057447|DRUG|Interferon Gamma-1b|100 or 200 mcg, SQ, 3x per week
224220456|NCT00057447|DRUG|Rituximab|375 mg per square meters, IV, 1x per week
224220457|NCT01630200|DRUG|Roflumilast|Roflumilast coated tablet, 500µg oral application, once daily in the morning
224220458|NCT01630200|DRUG|Placebo|Placebo coated tablet (visually identical to 500µg Roflumilast tablet), oral application, once daily in the morning
224220459|NCT06240962|OTHER|Strength Training|They will receive the strength training only (6 weeks, 3 sessions/week) that feature training modifications to help control injury-related symptoms.
224220460|NCT06240962|OTHER|Mindfulness Exercise|They will receive mindfulness-exercise for 6-week mindfulness intervention in addition to the strength training protocol.
224220461|NCT05547230|OTHER|questionnaires|The same tests will be applied to all participants in an objective way.
224220462|NCT03828123|BIOLOGICAL|Suspension of human autologous MSC 3P in 1.5 ml|Intrathecal application of Autologous Multipotent Mesenchymal Stromal Cells 3P suspension
224220463|NCT01593527|DRUG|ACZ885|Canakinumab 150 mg s.c.
224220464|NCT01593527|DRUG|Triamcinelone acetonide|Triamcinelone acetonide 40 mg i.m.
224220465|NCT03215485|BEHAVIORAL|Nutrition lessons|Face-to-face interactive group lessons delivered in the classroom.
224220466|NCT03215485|BEHAVIORAL|Virtual world learning environment|Every participant has their own unique avatar in the virtual world learning environment named Rippleville. They can choose to complete quests, watch archived nutrition video lessons, explore, and socialize with other avatars. They receive rewards (Rippleville dollar and badges) for their efforts.
224220467|NCT03215485|OTHER|Newsletter|All participants in the intervention and comparison groups receive up to 10 professional newsletters on topics related to sports nutrition and performance, healthy eating and active living tips.
224220468|NCT04520035|DRUG|camrelizumab|Carilizumab 200 mg, every 3 weeks, 2 cycles.Paclitaxel 175 mg / m2, D1, every 3 weeks, 2 cycles
224220469|NCT04520035|DRUG|Paclitaxel|Cisplatin 75mg / m2 D1, conventional hydration for 3 days, every 3 weeks, 2 cycles
224220470|NCT04520035|DRUG|Neoadjuvant Chemotherapy|Neoadjuvant Chemotherapy
224220471|NCT03790085|DRUG|Risperidone|Risperidone tablet
224220472|NCT03790085|DRUG|Olanzapine|Olanzapine tablet
223632094|NCT02331056|OTHER|fluid loading|"Fluid loading at defined period~* 500ml colloid solution infusion at 20min after thorax open for 30min. 500ml colloid administration is a kind of routine procedure during pulmonary lobectomy in our hospital. We just control the fluid loading timing for hemodynamic parameter records."
223632095|NCT02331056|PROCEDURE|thoracoscopic pulmonary lobectomy|the patient group for scheduled thoracoscopic pulmonary lobectomy
223632096|NCT02331056|PROCEDURE|thoracotomy|the patient group for scheduled open pulmonary lobectomy
223632097|NCT03474588|BEHAVIORAL|Standard treatment (ST) PLUS web-based CBT4CBT|Participants will have access to the CBT4CBT website in Spanish as an add-on to treatment. In this treatment participants will work with a computerized program that teaches skills for stopping alcohol use and increasing coping skills, such as how to understand patterns of alcohol use, how to cope with cravings for alcohol, how to refuse offers of alcohol, and so on
223632098|NCT03474588|BEHAVIORAL|Standard Treatment (ST)|ST includes individual and group therapy sessions and regular urine monitoring. Sessions will generally last for 1 hour one time per week for 8 weeks
223632099|NCT01493206|RADIATION|intraoperative radiotherapy|intraoperative radiotherapy
224220473|NCT03790085|DRUG|Aripiprazole|Aripiprazole tablet
224220474|NCT02655172|OTHER|cognitive tasks + PANSS+ IQ|Patients will perform different tasks: reaction time (Alert TEA, Zimmermann and Fimm, 2005), Edinburgh laterality questionnaire (Oldfield,1971), IQ test (IQ: PM38, Raven, 1960), and the PANSS (Positive and Negative Syndrome Scale (Kay et al., 1987) + the experimental task (affordance task with graspable device)
224220475|NCT02655172|OTHER|cognitive tasks|Healthy volunteers will perform only Edinburgh laterality questionnaire (Oldfield, 1971) + the experimental task (affordance task with graspable device).
224220476|NCT03154320|OTHER|Same-Day Treatment|Treatment with ART or TB medication on day of HIV diagnosis
224220477|NCT03154320|OTHER|Standard treatment|Standard treatment
224220478|NCT01892774|PROCEDURE|Radiofrequency catheter ablation|Extended PVAI plus ablation of non-pulmonary vein (non-PV) triggers and complex fractionated electrograms (CAFÉ)
224220479|NCT04850638|DRUG|SHR4640 tablets and furosemide tablets|SHR4640 tablets and furosemide tablets
224220480|NCT01682174|OTHER|Control Drink|
224220481|NCT01682174|OTHER|Experimental Drink|
224220482|NCT01797120|DRUG|Fulvestrant|"Fulvestrant 500 mg Day 1 \& 15 of Cycle 1, then 500 mg Day 1 of all subsequent cycles (every 28 days for 12 cycles).~If no evidence of disease progression after 12 cycles, unblind and continue same dose and schedule until progression or unacceptable toxicity."
224220483|NCT01797120|DRUG|Everolimus|"Everolimus 10 mg (2 tablets) daily x 12 cycles.~If no evidence of disease progression after 12 cycles, unblind and continue same dose and schedule until progression or unacceptable toxicity."
224220484|NCT01797120|DRUG|Placebo|Placebo for Everolimus (2 tablets) daily x 12 cycles. Placebo manufactured to mimic everolimus tablet.
224318051|NCT04262180|OTHER|Coaching Calls|Non-responders to base intervention will be randomized to coaching calls.
224318052|NCT04262180|OTHER|Online Gym|Non-responders to base intervention will be randomized to online gym.
223632100|NCT05523674|OTHER|Warm-up exercise|The warm-up exercise will be performed on a treadmill.
223632101|NCT05523674|OTHER|Warm-up exercise with Blood Flow Restriction|The warm-up exercise will be performed on a treadmill and pressure cuffs will be used for the blood flow restriction technique.
223632102|NCT03902418|DRUG|emtricitabine/tenofovir|Women recruited at ante-natal clinics, counseled about PrEP, and provided medication and follow up if desired
223632103|NCT06338774|BEHAVIORAL|Cognitive training|Computerized cognitive training completed on any computer or tablet with internet
223632104|NCT06338774|BEHAVIORAL|Exercise|Aerobic exercise intervention with structured exercise sessions prescribed by a study exercise specialist
223632105|NCT03448926|OTHER|Treatment Recommendation Surveys|Treatment Recommendation Surveys are completed by the treating physicians before and after receiving results from the DCISionRT test, which is prognostic for risk of recurrence over 10 years and predictive for benefit from radiation therapy.
224220485|NCT05893212|BEHAVIORAL|Nature based facilitated group intervention|The Nature-group programme included learning more about local outdoor areas and nature itself, the biotopes visited were chosen to provide a various nature experience, including forests, farmland, lakes, and seashore. Accompanied by nature guides the group practiced simple sensorial exercises that enhance the contact with nature and its microbiome.
223632106|NCT03448926|DEVICE|7-gene biosignature|Ordering the 7-gene biosignature assay (DCISionRT) as a part of routine care for DCIS is a prerequisite (inclusion criterion) for the study. The study is not designed to determine the efficacy of the assay, rather it is designed to meausre the impact of the assay results on treatment decisions for patients with DCIS.
223632107|NCT06487988|DEVICE|direct conventional laryngoscopy|direct conventional laryngoscopy will be performed with N3 (for females) or N4 (for males) Macintosh laryngoscope blade.
223632108|NCT06487988|DEVICE|fiberoptic guided intubation|fiberoptic guided intubation will be performed.
224220486|NCT05893212|BEHAVIORAL|Exercise in group|The Sports-group participated in an exercise programme and met weekly in community sports facilities. Exercise we define as a planned, structured, repetitive, and purposeful form of physical activity that aims for improvement or maintenance of one or more components of physical fitness. The sports programme was planned and executed by professional sports leaders in cooperation with health professionals and included both aerobic and anaerobic exercise as well as team sports, content was planned according to current best practice and considered the participants physical ability.
224220487|NCT03689296|OTHER|Questionnaires (Phase 3)|"* CardioVascular Risk (CVR) questionnaire representation~* SF12~* Getting Better My Way~* My recovery plan~* Psycom~* Partner In Health scale"
224220488|NCT03689296|OTHER|Focus groups (Phase 2)|Focus group interviews conducted by two health sociologists in 4 distinct categories: caregivers, patients, primary health care professionals and psychiatric professionals.
224220489|NCT03689296|OTHER|semi-structured interviews (Phase 1)|Conduct of exploratory semi-directive interviews with users, caregivers, primary health care professionals and psychiatric professionals by a health sociologist
224220490|NCT05057195|RADIATION|Interstitial radiation therapy|From 30 to 50 Gy,
224220491|NCT05057195|RADIATION|Postoperative external beam therapy|50 Gy and locally on the tumor bed up to 10-26 Gy, depending on the status of the resection margin
224220492|NCT04634110|DRUG|Brigatinib|At day 1, all patients will be started on brigatinib 90 mg daily for 7 days, before escalating to 180 mg daily thereafter as tolerated.
224220493|NCT03308110|DRUG|PF-06650833|Two formulations of PF-006650833
224220494|NCT06521788|DEVICE|AI-assisted breast ultrasound|AI-assisted breast ultrasound in community-based breast cancer screening
223632109|NCT05203510|DRUG|Parenteral Treprostinil|Parenteral treprostinil will be administered per schedule specified in the arm description.
223632110|NCT05203510|DRUG|Oral Treprostinil|Oral treprostinil will be administered per schedule specified in the arm description.
223632111|NCT04398433|DRUG|INO-3107|INO-3107 administered by IM injection followed by EP using CELLECTRA™ 2000 device at Day 0, Week 3, 6, and 9.
224220495|NCT06521788|DEVICE|Routine breast ultrasound|Routine breast ultrasound conducted by primary care physicians
224220496|NCT05066087|BEHAVIORAL|DAHLIA treatment|6 weeks; CBT/ ACT/ process-based treatment; micro-learning format with 4 digital micro-sessions per week; exposure as the core process; guidance to be OPEN, AWARE, ACTIVE; weekly contact with therapist; booster sessions after 2- and 4 months;
224220497|NCT05066087|OTHER|Treatment as usual|Usual pain treatment; defined post-hoc based on what patients receive
223632112|NCT04398433|DEVICE|CELLECTRA™ 2000|CELLECTRA™ 2000 device used for EP following IM delivery of INO-3107.
223632113|NCT05110456|BEHAVIORAL|Telephone support|"Participants will receive 10 telephone counseling calls by trained coaches: 9 during pregnancy (one call/week) and 1 at 6 weeks postpartum. We have included individual telephone calls by a trained coaches aimed to :~1. encourage the use of online material;~2. identify strategies for overcoming obstacles;~3. help apply content to real-life settings; and~4. underscore the participants' success in using effective coping strategies"
223632114|NCT06091111|DEVICE|THD, THN|New hybrid absorbing incontinence product for day (THD) and night (THN) use. These are variants of the same product. The intervention product is a novel design that contains reusable elements allowing for a more sustainable product.
223632115|NCT04223115|BEHAVIORAL|Digitalized CBT with phone coaching|Digitally delivered CBT intervention with weekly phone coaching
223632116|NCT04223115|OTHER|Psychoeducation about depression|Psychoeducational material about depression in a digitalized form
223632117|NCT06264336|BEHAVIORAL|treadmill training|Participants will undergo 12 sessions (4 weeks, 3 sessions/week) of treadmill training. During each session, participants will walk for 40 min. with 5 min. of warmup and cooldown at 50% of maximal walking speed (tested each week) with 30 min. of training interposed. The type of training will be determined by the assigned treatment arm.
223632118|NCT04536909|OTHER|Non-surgical|We have constructed a training program with help from physiotherapists from Rikshospitalet in Oslo, tailored for kyphotic- and scoliotic patients.
223632119|NCT04536909|PROCEDURE|Surgical|Surgery for correction of kyphotic- or scoliotic deformity.
224220498|NCT04093973|DIAGNOSTIC_TEST|bicycle stress echocardiography|Study subjects will perform supine bicycle exercise with echocardiography performed before, during, and after exercise. Definity (perflutren microbubble contrast agent) will be used as needed to enhance echo images.
224220499|NCT00906685|DRUG|bevacizumab|Intravitreal injection of 1.25 mg bevacizumab
224220500|NCT00906685|DRUG|Sham bevacizumab injection|Sham intravitreal injection
224220501|NCT00271999|BEHAVIORAL|Nocturnal home hemodialysis|Six times per week nocturnal home hemodialysis
224220502|NCT00580333|DRUG|cisplatin|Preoperatively: Given intravenously on day one of the treatment cycle (once every 3 weeks) for four cycles
224318053|NCT06619626|DEVICE|alveolar recruitment strategy applied group|the effect of alveolar recruitment strategy on the mechanical parameters of the patients
224318054|NCT06619626|DRUG|group without alveolar recruitment strategy|effect on mechanical parameters of patients without alveolar recruitment strategy
223632120|NCT02598284|OTHER|Point of Care|Practice facilitators will work with practices to implement strategies to improve ABCS care during the patient encounter. Some examples of these types of quality improvement initiatives are electronic reminders and clinical decision support to prescribe aspirin or a statin at the time of a visit, improving how your practice collects blood pressure measures to increase clinicians' willingness to act on readings, or electronic reminders for nursing staff that there is no lipid panel in record and have a standing order to act on this.
223632121|NCT02598284|OTHER|Population Management|"Practice Facilitators will work with practices to both implement Point of Care strategies as well as population management strategies. These practices will use their EHR and/or receive training to use the popHealth software package, which works with data from the EHR, to generate lists of high-risk patients that need outreach for one of the ABCS domains (such as conducting outreach to patients who are not on aspirin who would benefit from this therapy).~Practices in this arm will receive the opportunity to link to community resources such as pharmacists who could assist patients with medication management or tobacco quit lines through the HealtheRx program."
224220503|NCT00580333|DRUG|bevacizumab|Preoperatively: Given intravenously on day 1 of the treatment cycle (once every three weeks) for three cycles Postoperatively: Intravenously for four 2-week cycles (once every two weeks) and after the 8 weeks (study doctor will determine course of treatment) for an additional four 2-week cycles with or with out paclitaxel
224220504|NCT00580333|DRUG|doxorubicin|Postoperative: Given intravenously for four 2-week cycles
224220505|NCT00580333|DRUG|cyclophosphamide|Postoperative: Given intravenously for four two-week cycles
224220506|NCT00580333|DRUG|paclitaxel|Postoperative: 8 weeks after postoperative chemotherapy regimen (study doctor will determine course of treatment) paclitaxel for four 2-week cycles (once every two weeks)
224220507|NCT01917188|BEHAVIORAL|Full simulation and education|
224220508|NCT01917188|BEHAVIORAL|See simulation room, usual education|
224220509|NCT05851482|DIAGNOSTIC_TEST|High resolution manometry|Standard chicago classification 4.0 HRM protocol
224220510|NCT00123058|BEHAVIORAL|Nurse administered|Subjects received a nurse administered behavioral intervention via telephone every 8 weeks for 24 months.
224220511|NCT00123058|DEVICE|BP Monitor|Subjects received a study provided home BP monitor and recorded home BP 3 times per week for 24 months.
224220512|NCT00000318|DRUG|Buprenorphine|"1. Experimental Maintenance treatment with daily medication~2. Experimental Maintenance treatment with thrice-weekly medication"
224220513|NCT05295251|OTHER|medical ,oncological and surgical treatment of cases of acute abdomen|medical treatment and surgical intervention during covid-19 pandemic
224220514|NCT06006351|OTHER|Physiotherapy|manual therapy stretching exercises strengthening exercises electrotherapy applications
224220515|NCT06006351|OTHER|Hypervolt Device|The painful area will be applied with a massage tool, and the frequency and mode of the tool will be adjusted in a way that does not disturb the patient.
224220516|NCT00293826|DRUG|AMG 108|50mg via SC (subcutaneous) injection every 4 weeks
224220517|NCT00293826|DRUG|AMG 108|250mg via SC (subcutaneous) injection every 4 weeks
224220518|NCT00293826|DRUG|AMG 108|125mg via SC (subcutaneous) injection every 4 weeks
224220519|NCT00293826|DRUG|Placebo|Placebo via SC (subcutaneous) injection every 4 weeks
224220520|NCT03458026|OTHER|Connected object use combined with SMS (text messages) of physical activity reminders|Watch connected used and receipt of SMS (text messages)
224220521|NCT03458026|OTHER|Without connected object|Any intervention except follow-up visit
224220522|NCT05792865|DRUG|paxlovid|Patients treated with PAXLOVID within 5 days of being diagnosed with covid-19 will be included in this group. Patients treated with PAXLOVID will be included in this group. This study is a non-interventional observational study, and no intervention measures were applied to the clinical diagnosis and treatment process of hospitalized COVID-19 patients. The use of Paxlovid is completely decided by the clinical doctors based on the patients' condition and clinical experience.
224220523|NCT05792865|DRUG|No paxlovid|Patients not treated with PAXLOVID will be included in this group. This study is a non-interventional observational study, and no intervention measures were applied to the clinical diagnosis and treatment process of hospitalized COVID-19 patients. The use of Paxlovid is completely decided by the clinical doctors based on the patients' condition and clinical experience.
224220524|NCT05792865|DRUG|Paxlovid|Patients treated with PAXLOVID outside of the initial 5 days after being diagnosed with covid-19 will be included in this group.
224220525|NCT04916860|BIOLOGICAL|Senl-T7|Patients will be treated with CD7 CAR-T cells
224220526|NCT01666925|BIOLOGICAL|ChAd63 ME-TRAP / MVA ME-TRAP prime-boost immunisation|ChAd63 ME-TRAP: 5 x 10\^10vp MVA ME-TRAP: 2 x 10\^8 pfu
224318055|NCT06803927|DEVICE|Barrett's Esophagus Test (LDT)|Barrett's Esophagus Test (LDT) will be performed on esophageal cells collected using the EndoSign Cell Collection Device (510(k) cleared) and compared to the results of standard of care EGD plus biopsies (if applicable)
224318056|NCT01321463|DRUG|PH-797804|6 mg oral tablet once daily for 12 weeks
224220527|NCT01666925|BIOLOGICAL|Rabies vaccine|2 x 2.5IU Verorab
224220528|NCT00827359|DRUG|Everolimus|Tablet form taken orally once a day
224220529|NCT05756868|BEHAVIORAL|Time restricted feeding|In the time-restricted nutrition intervention, the first meal is scheduled at 10:00 and the last meal at 18:00 (ad libitum). Eating for 8 hours and fasting for 16 hours are targeted.
224220530|NCT00844727|DRUG|Rofecoxib|
224220531|NCT00844727|DRUG|placebo|placebo pills
224220532|NCT00108901|BEHAVIORAL|Aerobic exercise program|Vigorous intermittent physical activity in group format conducted in research gymnasium after school by research staff. Heart rate monitors documented each child's average heart rate on a daily basis. Small incentives were offered for achieving goal of \>150 bpm average HR each day and attending at least 80% of sessions (4 days/week).
224318057|NCT01321463|DRUG|Placebo|Placebo oral tablet once daily for 12 weeks
224220533|NCT03840135|DRUG|Polyoxidonium 6 mg/ml|"Nasal and sublingual spray Polyoxidonium 6 mg/ml will be administered at a dose of 0,15 mg/kg daily for 7 days:~in children aged from 1 to 2 years - 1 spray sublingually 2 times a day (every 12 hours); in children aged from 2 to 5 years - 1 spray intranasally (in each nasal passage) 2 times a day (every 12 hours; in children aged from 5 to 8 years - 1 spray intranasally (in each nasal passage) 3 times a day (every 8 hours); in children aged from 8 to 12 years - 2 spray intranasally (in each nasal passage) 2 times a day (every 12 hours)."
224220534|NCT03840135|OTHER|Placebo|"Placebo nasal and sublingual spray will be administered for 7 days:~in children aged from 1 to 2 years - 1 spray sublingually 2 times a day (every 12 hours); in children aged from 2 to 5 years - 1 spray intranasally (in each nasal passage) 2 times a day (every 12 hours; in children aged from 5 to 8 years - 1 spray intranasally (in each nasal passage) 3 times a day (every 8 hours); in children aged from 8 to 12 years - 2 spray intranasally (in each nasal passage) 2 times a day (every 12 hours)."
224220535|NCT02506725|OTHER|prenatal care in groups|We will do prenatal care in groups using centering care pregnancy methodology
224220536|NCT01452113|DRUG|Vildagliptin|one 50 mg tablet per os
224220537|NCT01894113|PROCEDURE|transbronchial lung biopsy|
224220538|NCT05466513|OTHER|Facial tactile stimulation|Tactile stimulation was given around the face with soft tissue paper for two minutes.
224220539|NCT01695798|BIOLOGICAL|Injectable polio vaccine and Bivalent oral polio vaccine|"One dose of IPV given IM (arm, thigh) to infant aged 9-12 month after randomization.~There will be two groups Chronic Malnourished group and Non-Malnourished group. Each group has two arms, which were randomized on IPV+bOPV and bOPOV alone"
224220540|NCT00877266|PROCEDURE|perineural mepivicaine catheter placed via ultrasound or electrical stimulation|Patients will be randomized to one of two groups: catheter placement via ultrasound or nerve stimulation. Placement of the catheter will be timed by research staff and discomfort level asked after placement of catheter. If the catheter is not placed by the randomized method within 15 minutes, the practitioner my switch to the alternate method. Patients will be called the morning after surgery by research staff to assess discomfort levels.
224220541|NCT02662608|DRUG|Brontictuzumab|1.5 mg/Kg intravenously every three weeks.
224220542|NCT00164203|BEHAVIORAL|Cognitive Behavioral Therapy|12-session, weekly, school-based protocol based on cognitive restructuring, tailored to children Grades 3 to 6; comparison with activity control condition of equal duration.
224220543|NCT00164203|BEHAVIORAL|School-based CBT|12 sessions, weekly
224220544|NCT00164203|BEHAVIORAL|activity control condition|weekly games \& activities x 12 weeks
224220545|NCT05064202|DEVICE|Impella 5.5|temporary Mechanical Circulatory Support (tMCS)
224220546|NCT05064202|DRUG|Inotropes|Enoximone, Dobutamine, Dopamine, Milrinone
224220547|NCT02930109|DRUG|PTX-200|During the Phase I study, increasing dose levels of PTX-200 will be administered as an intravenous infusion on Day 1 each cycle. Triciribine will be infused over 1 hour on Day 1 of each 21 day cycle. The initial dose level will be 25 mg/m2 and each dose level will be increased by 10 mg/m2 to a maximum dose of 55 mg/m2
224220548|NCT02930109|DRUG|Cytarabine|Cytarabine will be given at a dose of 400 mg/m2 as a continuous IV infusion on days 3-7 of each cycle.
223632122|NCT00584948|DRUG|Memantine|Week 1: Take 5mg tab every morning. Week 2: Take 5mg tab every morning and evening. Week 3: Take 10mg tab in the morning and 5 mg in the evening. Week 4: Take 10 mg tab in the morning and evening, and remain on this dose through the remainder of the study.
224220549|NCT03596918|BIOLOGICAL|Bleomycin Sulfate|Given IV
224220550|NCT03596918|OTHER|Laboratory Biomarker Analysis|Correlative studies
224220551|NCT03596918|OTHER|Quality-of-Life Assessment|Ancillary studies
224220552|NCT03596918|OTHER|Questionnaire Administration|Ancillary studies
224220553|NCT03596918|DRUG|Vincristine Sulfate|Given IV
224220554|NCT03364985|DRUG|DWP16001|DWP16001 tablets
224220555|NCT03364985|DRUG|Placebo|DWP16001 placebo-matching tablets, Active control placebo-matching tablets
224220556|NCT03364985|DRUG|Dapagliflozin|Forxiga®
223632123|NCT00584948|DRUG|Placebo|Week 1: Take 5mg tab every morning. Week 2: Take 5mg tab every morning and evening. Week 3: Take 10mg tab in the morning and 5 mg in the evening. Week 4: Take 10 mg tab in the morning and evening, and remain on this dose through the remainder of the study.
224220557|NCT04598672|BEHAVIORAL|Cognitive behavioral therapy for insomnia (CBTi)|Patients will undergo a 7 sessions course in cognitive behavioral therapy for insomnia.
224220558|NCT05061667|PROCEDURE|Thoracic Paravertebral Block|Paravertebral block for postoperative analgesia in thoracic surgery
224220559|NCT05061667|PROCEDURE|Rhomboid Block|Rhomboid block for postoperative analgesia in thoracic surgery
224220560|NCT00509210|DRUG|telaprevir (VX-950)|
224220561|NCT00700284|DRUG|placebo vaginal ring|vaginal ring containing no TMC120 (dapivirine)
224220562|NCT00700284|DRUG|TMC120 (dapivirine) vaginal ring|vaginal ring containing 120 mg TMC120 (dapivirine)
224220563|NCT00459082|DRUG|Dexmedetomine|
224220564|NCT00839020|PROCEDURE|Navigated TKA with a minimally invasive approach|Navigated total knee arthroplasty with a minimally invasive approach
224220565|NCT00839020|PROCEDURE|Navigated TKA with a conventional approach|A navigated total knee arthroplasty is performed using the Orthopilot navigation system. A conventional approach is performed
224220566|NCT02751060|OTHER|No intervention|
224220567|NCT02372682|DEVICE|Shear wave sonoelastography|Sonoelastography is to be performed on the liver.
224220568|NCT00323674|DEVICE|Polysoft Mesh|Polysoft Mesh is used.
224220569|NCT00323674|DEVICE|Light Weight Mesh|Light Weight Mesh is used.
224220570|NCT00904059|DRUG|BMS-650032|Capsules, Oral, 600 mg, Q12h, Days 1-7
224220571|NCT00904059|DRUG|BMS-790052|Capsules, Oral, 60 mg, Q24h, Days 1-7
224220572|NCT00904059|DRUG|BMS-650032|Capsules, Oral, 200 mg, Q12h, Days 8-21
224220573|NCT00904059|DRUG|BMS-790052|Capsules, Oral, 30 mg, Q24h, Days 8-21
224220574|NCT05521490|OTHER|Usual Care Control|30 minutes of physical activity on each school day.
224220575|NCT05521490|BEHAVIORAL|Physical Activity Enhanced Curriculum|Additional 2.5 hours of physical activity per week in addition to the stipulated 30 minutes of daily physical activity.
224220576|NCT04073693|DIETARY_SUPPLEMENT|Branched chain amino acids (BRCA)|They were with BRCA during the day apart of following the standard recommendations
224220577|NCT02023502|OTHER|collection of urine and blood sample|
223632124|NCT05025787|DRUG|CNTX-6970|CNTX-6970, a novel potent antagonist of CCR2 with lesser effects on CCR5, is being developed as a new treatment for chronic pain, including painful osteoarthritis of the knee.
223632125|NCT05025787|DRUG|Placebo|BID
223632126|NCT00498940|DEVICE|Optimization Testing|Atrioventricular (AVD) and interventricular (VVD) delays and left ventricle lead site location were optimized after weaning off bypass (Phase I), after sternal closure (Phase II), and 12 to 24 hours (Phase III) after bypass. Intrinsic heart rate was also optimized in Phase III.
223632127|NCT00498940|DEVICE|Temporary Biventricular Pacing|Continuous temporary biventricular pacing for 24 hours at a heart rate of 90 bpm or 10 bpm above intrinsic heart rate.
224318058|NCT03564418|PROCEDURE|Ultrasound-Guided Thermocoagulation of Lumbar facet joints|"Prone position: Thanks to a high-resolution ultrasound and a 5 MHz curved probe, we will use the ultrasound technique described by Greher et al to reach the target points.~Then, in order to check the correct positioning of the needles, we will inject 1 ml of a solution of contrast medium (omnipaque® 300 mg / ml of Iohexol) to observe them using the standard Fluoroscopic method. Wrongly positioned needles will be correctly repositioned and these patients will be excluded from ODI and VAS scale statistics.~To ensure the effectiveness of the injury by thermocoagulation, sensory electrical stimulation is performed to confirm that the needle is close to the posterior ramus (50Hz, 0-3 volts) and another electrical stimulation is performed to confirm that there is no motor stimulation (2Hz, 0-3 volts). After injecting 1 ml of 2% linisol® through the needle, denervation of the facet will be performed with an electrode at 68 ° C for 90 seconds."
223764284|NCT02710682|DEVICE|Ultrasound-guided Tendon fenestration|"This treatment will be administered by a fellowship-trained MSK radiologist.~1. Patient's elbow at 70 degrees of flexion with the forearm pronated resting on an examination table.~2. Skin disinfection. Local anesthesia, skin, superficial fascia and tendon, with lidocaine 1%.~3. Using a 22 G needle under continuous ultrasound guidance, several passes (about 20-30) within the abnormal area of the tendon, contacting the bone, until the area softens.~4. Patient monitored for 30 minutes, before being discharged."
223764285|NCT06033638|OTHER|Score assessment|PBS Score
224220578|NCT06416137|DIAGNOSTIC_TEST|Neuropsychological tests|Participants will be assessed with neuropsychological tests and will be collected information about their lifestyle, clinical history and sociodemographic status. Special attention will be paid to the presence of modifiable risk factors for dementia (i.e., low education, hearing impairment, traumatic brain injury, excessive alcohol consumption, obesity, smoking, hypertension, depression, physical inactivity, diabetes, and social isolation).
224220579|NCT01987700|DEVICE|FLEX-HD|
224220580|NCT01987700|DEVICE|Strattice|
224220581|NCT02757300|DEVICE|Hypopharyngeal packing|After introduction and orotracheal intubation a hypopharyngeal packing soaked with Chlorhexidinbis (D-gluconat) is placed.
224220582|NCT02757300|DEVICE|Without Hypopharyngeal packing|After introduction and orotracheal intubation the patient will pass the operation without hypopharyngeal packing with a short tip coming out the mouth to imitate a packing.
224220583|NCT04056507|PROCEDURE|Immunolabeling|Immunolabeling of abnormalities observed by the cell study in flow cytometry.
224220584|NCT00492388|DRUG|PMI-150 (intranasal ketamine)|intranasal dosing
224220585|NCT00492388|DRUG|placebo|placebo
224220586|NCT00069407|PROCEDURE|Electroconvulsive Therapy|Electroconvulsive therapy
224220587|NCT01736137|OTHER|Six minute walk test|If patients meet the criteria of the study, their data will be collected and will be interviewed to fill the Minnesota Living with Heart Failure Questionnaire (MLHFQ). They then will be taken to the hallway to perform the six minute walk test monitored with a heart rate monitor (Polar RS800 CX). After the test there will be a break of 20 to 30 minutes before repeating the walk test. During rest time, the patient will answer the general health survey questionnaire: Medical Outcome Study 36-item Short-Form Health Survey (SF-36).
224220588|NCT01809314|DRUG|Epoetin beta|Treatment will be given according to standard of care and the Summary of Product Characteristics during the study.
224220589|NCT01682941|DIETARY_SUPPLEMENT|Arm I Soy Bread|On day 0 or day 70 pharmacokinetic study of isoflavones over 24 hours will follow after consumption of 2 slices of soy bread. Afterwards 2 slices of soy bread/day will be consumed for 56 days and isoflavone metabolites will be assessed in urine at days 0, 28, 56, 70, 98, and 126.
224220590|NCT01682941|DIETARY_SUPPLEMENT|Arm II Soy-Almond Bread|On day 0 or day 70 pharmacokinetic study of isoflavones over 24 hours will follow after consumption of 2 slices of soy-almond bread. Afterwards 2 slices of soy-almond bread/day will be consumed for 56 days and isoflavone metabolites will be assessed in urine at days 0, 28, 56, 70, 98, and 126.
224220591|NCT05743790|DIETARY_SUPPLEMENT|RS2-control-RS4|Group A: Treatment 1 = RS2 (Hi-Maize 260), Treatment 2 = Control (Amioca TF), Treatment 3 = RS4 (Versafibe 1490)
224220592|NCT05743790|DIETARY_SUPPLEMENT|RS4-control-RS2|Group B: Treatment 1 = RS4 (Versafibe 1490), Treatment 2 = Control (Amioca TF), Treatment 3 = RS2 (Hi-Maize 260)
223632128|NCT06396884|DEVICE|Oscillometric intermittent non-invasive blood pressure|The hemodynamic management followed liberal fluid therapy, as determined by the attending anesthetist's discretion
223632129|NCT06396884|DEVICE|ClearSight|The hemodynamic management will be conducted in accordance to a goal-directed fluid therapy (GDFT) utilizing the Clearsight system monitoring.
223632130|NCT05299307|DIAGNOSTIC_TEST|semen analysis and hormonal proflie|measure total prolactin and total testosterone and semen
223632131|NCT06060925|DIAGNOSTIC_TEST|Ultrasound imaging|B-mode, color Doppler, shear wave elastography
223632132|NCT06060925|DIAGNOSTIC_TEST|Bioimpedance spectroscopy|Multifrequency bioimpedance spectroscopy
223632133|NCT06060925|DIAGNOSTIC_TEST|Electromyography|High density electromyography
223632134|NCT06060925|DIAGNOSTIC_TEST|Physical examination|Comprehensive musculoskeletal physical examination, including range of motion, and quantitative sensory testing
224220593|NCT01407679|DRUG|Alitretinoin|1 capsule Alitretinoin 30 mg per day; optional reduction to 10 mg per day in case unacceptable adverse reactions to the higher dose occur
224220594|NCT02012179|OTHER|Low sodium diet|Low sodium diet (65 mmol or 1500 mg/day)
224220595|NCT04665479|OTHER|Web-based legacy-making intervention through digital storytelling|A child-parent dyad will participate in a nurse-delivered intervention that will guide children to create electronic digital storyboards about themselves during 6 sessions over 6 weeks.
223632135|NCT01832636|DIETARY_SUPPLEMENT|Alanyl-Glutamine|Alanyl-Glutamine and Glycine doses will be prepared immediately prior to administration by dissolving in formula, milk, or fruit juice. Administration of each dose will be directly observed by a study nurse or health agent.
223632136|NCT00832663|DRUG|NSAID|Effect of NSAID ingestion on muscle regeneration
223632137|NCT00832663|DRUG|placebo|receive placebo
223632138|NCT05468099|OTHER|Chlorhexidine mouthwash and Povidone-Iodine|Chlorhexidine mouth rinse which participants use for 20 seconds before procedure. Moreover, Povidone-Iodine nasal swabs are used to disinfect nostrils
223632139|NCT05468099|DEVICE|High volume evacuator|High volume evacuator held by assistant to capture dental spray
223632140|NCT05468099|DEVICE|High volume evactuator and saliva ejector|High volume evacuator and saliva ejector held by assistant to capture dental spray
223764286|NCT05114005|BEHAVIORAL|Rhythmic Auditory Stimulation|Rhythmically-entrained sensorimotor activity.
224220596|NCT04921683|DEVICE|BX Pulsar 1002 (LIFUP) Low intensity Focused Ultrasound Pulsation|"Administration of LIFUP will be performed at the bedside using frameless stereotaxy. Specifically, the LIFUP transducer will be fit to the patient's head employing adjustable straps, and will be positioned over the patient's left temporal bone, over the temporal window in order to minimize bone absorption and refraction. Accurate aiming will be ensured employing the BrainSight neuronavigation device, customized for tracking our LIFUP transducer (total \~10 min). Once satisfactory aiming is achieved, the LIFUP exposure will be initiated employing the settings described previously (which meet the FDA safety limits: ISPPA \<= 190W/cm2, ISPTA \<= 0.72W/cm2). Accurate aiming will be monitored in real-time throughout exposure using the Brain Sight Neuronavigation interface."
224220597|NCT01684722|DIETARY_SUPPLEMENT|Vitamin D|Vitamin D3 (cholecalciferol), 2000 IU per day.
224220598|NCT01684722|DRUG|Omega-3 fatty acids (fish oil)|Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid \[EPA\] and 375 mg of docosahexaenoic acid \[DHA\]).
224220599|NCT01684722|DIETARY_SUPPLEMENT|Vitamin D placebo|Vitamin D3 placebo
224220600|NCT01684722|DIETARY_SUPPLEMENT|Fish oil placebo|Fish oil placebo
224220601|NCT06417957|OTHER|cultural competence training|The peer students in the experimental group will be given a total of 16 hours of cultural competence training, two days a week, two lessons per day (60 min. + 60 min.) for four weeks.
223632141|NCT05468099|DEVICE|Local Exhaust System|Local exhaust system hovers above patient head to capture dental spray
223632142|NCT04834505|OTHER|Diagnostic imaging modalities for validation sample|Endoscopic ultrasound and other imaging modalities such as CT, MRI, or PET-CT are performed.
223764287|NCT05114005|BEHAVIORAL|Evidence-Based Exercise|This program consists of information on neuropathy and fall prevention combined with a schedule of 1 hour training (i.e., endurance, resistance, and sensorimotor) performed 2x per week
223764288|NCT06664333|OTHER|Semi-structured interviews|"The study consists of conducting two semi-structured interviews, with an estimated duration of 15 to 30 minutes, with siblings of children hospitalized in pediatric intensive care at Necker-Enfants Malades Hospital and Robert Debré Hospital.~The first interview will take place during the stay in intensive care, the second 1 month after discharge from pediatric intensive care."
223764289|NCT01852448|GENETIC|Blood or Saliva Sample Collection|A blood or saliva sample will be obtained for genotyping of TCF7L2 and approximately ten other genes implicated in type 2 diabetes.
223764290|NCT05514405|DRUG|Remimazolam (Byfavo)|Remimazolam is continuously infused based on bispectral index (within 40-60).
223764291|NCT05514405|DRUG|Propofol|Propofol is continuously infused based on bispectral index (within 40-60).
223764292|NCT02284503|DRUG|Rosuvastatin|The subjects will receive intensive Rosuvastatin before and after PCI
224220602|NCT06081725|BEHAVIORAL|Playful interactions in an online format|The activity is grounded in dramatic improvisation and comprises several games: a ball game, an association game, a mirror game, a movement story game. The intervention will be conducted by zoom
224220603|NCT06081725|BEHAVIORAL|An active control condition in a face-to-face format|The activity consisted of three parts: A structured conversation centered around hobbies. In the second part an exercise in words - singular plural. In the third part, participants will be engaged in a movement practice resembling an exercise class.
224220604|NCT06081725|BEHAVIORAL|An active control condition in an online format|The activity consisted of three parts: A structured conversation centered around hobbies. In the second part an exercise in words - singular plural. In the third part, participants will be engaged in a movement practice resembling an exercise class. The intervention will be conducted conducted by zoom
224220605|NCT06081725|BEHAVIORAL|Playful interactions in a face to face format|The activity is grounded in dramatic improvisation and comprises several games: a ball game, an association game, a mirror game, a movement story game.
224220606|NCT06527495|DRUG|Sorafenib|Sorafenib Tablets (200 -400 mg) twice daily
223764293|NCT06601309|DRUG|Serplulimab|Serplulimab (300 mg) administered intravenously on day 1 of each 21-day cycle for 2 cycles.
223764294|NCT06601309|DRUG|Paclitaxel+Cisplatin (Neoadjuvant Chemotherapy)|Paclitaxel (175 mg/m²) and Cisplatin (75 mg/m²) administered intravenously on day 1 of each 21-day cycle for 2 cycles as part of neoadjuvant chemotherapy.
223764295|NCT06601309|DRUG|Paclitaxel+Cisplatin(Concurrent Chemoradiotherapy)|Paclitaxel (50 mg/m²) and Cisplatin (25 mg/m²) administered intravenously on days 1, 8, 15, and 22 of a 4-week cycle as part of concurrent chemoradiotherapy.
223632143|NCT04834505|OTHER|EUS for derivation sample|Endoscopic ultrasound was performed.
223632144|NCT00626106|DRUG|AMG 479|AMG 479 administered with exemestane or fulvestrant
223632145|NCT00626106|DRUG|Placebo|Placebo administered with either exemestane or fulvestrant
223632146|NCT05510583|OTHER|Control group|Retrospective study on pregnant women (≥18 years) with gestational diabetes who gave birth between 01/01/2013 and 30/06/2015. Patients received traditional paper-based blood glucose monitoring.
223632147|NCT05510583|OTHER|Treated group|Retrospective study on pregnant women (≥18 years) with gestational diabetes who gave birth between 01/01/2021 and 31/12/2021. Patients received remote monitoring with myDiabby Healthcare
223632148|NCT05417438|BEHAVIORAL|Wearable device deployment|Participants will receive a Fitbit to be synced with a smartphone app (MyDataHelps). Participants will receive push notifications to complete surveys via the MyDataHelps app. The Fitbit will sync with the app for data collection.
223632149|NCT03426670|DEVICE|OraQuick HIV Self-Test|OraQuick® HIV Self-Test is an in-vitro diagnostic medical device that is used for self-testing of antibodies for HIV-1 and HIV-2 in oral fluid. This test is intended as an aid to detect antibodies to HIV-1 and HIV-2 from infected individuals.
223632150|NCT06594536|DIETARY_SUPPLEMENT|Sulforaphane|taken once a day (one to three capsules a day depending on the patient's weight) for 8 weeks of Sulforaphane
223632151|NCT06594536|OTHER|Placebo|taken once a day (one to three capsules a day depending on the patient's weight) for 8 weeks of placebo
224318059|NCT03564418|PROCEDURE|Fluoroscopy-Guided Thermocoagulation of Lumbar facet joints|"Prone position: We will use the standard fluoroscopic method to reach the target points. (maximum three levels, same side). Then, in order to check the correct positioning of the needles, we will inject 1 ml of a solution of contrast medium (omnipaque® 300 mg / ml of Iohexol). The correct location being the superolateral edge of the lateral facet and the diffusion of the contrast material at the level of the medial branch observed thanks to an anteroposterior radioscopic view. Then the location of the needles is confirmed by a lateral radioscopic view.~To ensure the effectiveness of the injury by thermocoagulation, sensory electrical stimulation is performed to confirm that it is close to the posterior ramus (50Hz, 0-3 volts) and another electrical stimulation is performed to confirm that there is no motor stimulation (2Hz, 0-3 volts). After injecting 1 ml of 2% linisol® through the needle, denervation of the facet will be performed with an electrode at 68 ° C for 90 seconds."
224220607|NCT02168075|DRUG|0.25g/kgof 20% mannitol|When the neurosurgeon starts the drilling of skull, 0.25g/kg of 20% mannitol administered through the IV catheter with fulldrip. Neurosurgeon evaluate the degree of brain relaxation after dura opening in 4 point scale ( 1=bulging brain, 2=firm brain, 3-satisfactorily relaxed, 4=perfectly relaxed).
224220608|NCT02168075|DRUG|0.5g/kg of 20% mannitol|When the neurosurgeon starts the drilling of skull, 0.5g/kg of 20% mannitol administered through the IV catheter with fulldrip. Neurosurgeon evaluate the degree of brain relaxation after dura opening in 4 point scale ( 1=bulging brain, 2=firm brain, 3-satisfactorily relaxed, 4=perfectly relaxed).
224220609|NCT02168075|DRUG|1.0g/kg of 20% mannitol|When the neurosurgeon starts the drilling of skull, 1.0g/kg of 20% mannitol administered through the IV catheter with fulldrip. Neurosurgeon evaluate the degree of brain relaxation after dura opening in 4 point scale ( 1=bulging brain, 2=firm brain, 3-satisfactorily relaxed, 4=perfectly relaxed).
224318060|NCT01179698|PROCEDURE|Navigation surgery|In en bloc resection, the osteotomy sites were determined by navigation guidance. For curettage, we monitored curette in real-time with navigation.
224318061|NCT01179698|PROCEDURE|Navigation system|In en bloc resection, the osteotomy sites were determined by navigation guidance. For curettage, we monitored curette in real-time with navigation.
223632152|NCT06603194|DIETARY_SUPPLEMENT|Bovine or Marine Collagen|Bovine or Marine Collagen
223632153|NCT06593301|OTHER|Flipped classroom model Blood and Gore Based on FCM Products Transfusion Training|Distance Learning; study papers, flowcharts, clinical guides, voiced ppt presentations, skill videos etc. (10 days after face-to-face training before) Theoretical Training Based on FCM; Face to Face In-Class Education (student-centered learning activities, group work, case study, discussion, question answer, etc.)
223632154|NCT06655571|PROCEDURE|Ultrasound guided caudal Block|caudal block using Ultrasound
223632155|NCT06655571|PROCEDURE|Conventionel|Caudal Block based on anatomical landmarks
223632156|NCT04053036|DRUG|MDMA|Participants will be given 1.5mg/kg of MDMA
223632157|NCT04053036|DRUG|Placebo oral tablet|Participants will be given a placebo capsule that will only contain lactose.
223632158|NCT02702492|DRUG|KPT-9274|
223632159|NCT02702492|DRUG|Niacin ER|
223632160|NCT02702492|DRUG|Nivolumab|
223632161|NCT06589921|DRUG|Pirfenidone Modified-Release Tablets|take the tablet under fed condition, 1 tablet at a time, once a day.
223632162|NCT06589921|DRUG|Pirfenidone Tablets|ake the tablet under fed condition, 1 tablet at a time, three times a day.
223632163|NCT06599177|OTHER|Informational leaflet|"An informational leaflet describing:~* Information on benefits to which they are entitled and how to receive them.~* Information and linkage to support services in the community.~* Information on how to obtain health care materials (insured, uninsured).~* Information on relevant support associations/voluntary groups in the community.~* Information on employment programs.~* Activation of patient\&#39;s supportive social network/or referral to home help programs if they are a lonely person or in need of support.~* Individualized assessment of the patient\&#39;s needs.~* Design of a plan for individualised psychosocial intervention (focus personal intervention).~* Patient education about existing social support networks in the community and how to find them.~* Educate patients about available resources in the community (benefits, services).~* Patient referral/advocacy to community services."
223632164|NCT06586073|OTHER|cosmetic products|All patients enrolled were prescribed four cosmetic products (Ontherapy® by Dermophisiologique) for skin treatment: a cleansing cream, a soothing and nourishing cream, an anti-desquamation cream with urea 5%, and an emollient mixture. Patients were instructed to use each product at home for 45 days, following a specific protocol: in the morning, apply the affinity cleansing cream during skin cleansing, followed by the anti-desquamation cream, while in the evening, apply affinity cleansing cream followed by the application of the emollient mixture and then the soothing and nourishing cream.
223632165|NCT06596720|OTHER|Aerobic Exercise|After the initial assessments of the individuals in the study group were completed, the exercise program was implemented. The exercise program consisted of 30 minutes of submaximal cycling using the Karvonen formula. The aerobic exercise program was structured with a 5-minute warm-up, a 5-minute cool-down, and the remaining time dedicated to the exercise phase. Since our study included only a single exercise session, a moderate-intensity training program was applied to the participants.
223632166|NCT06592573|OTHER|CBT_ONLINE|10-12 sessions of cognitive behavioural therapy conducted online
223632167|NCT06592573|OTHER|CBT_IN PERSON|10-12 sessions of cognitive behavioural therapy conducted in-person.
223632168|NCT06588335|DRUG|BTLA inhibitor (JS004)|BTLA inhibitor (JS004):200mg, intravenous infusion , d1, Q3W;
223632169|NCT06588335|DRUG|Toripalimab|Toripalimab:240mg,intravenous infusion, d1, Q3W;
223632170|NCT06588335|DRUG|Paclitaxel, Cisplatin|Paclitaxel, 175mg/m2, intravenous infusion, d1, Q3W; Cisplatin, 75mg/m2, intravenous infusion, d1, Q3W;
223632171|NCT06598826|DEVICE|Graston technique (IASTM)|Group A includes 26 patients post ND who received Graston technique (IASTM) , in additional to traditional treatment (ROM exercise, strengthening exercise, and stretching exercise) for 1 month
223632172|NCT06598826|OTHER|Kinesio taping|Group B includes 26 patients who received Kinesiotaping, in addition to traditional treatment (ROM exercise, strengthening exercise, and stretching exercises) for 1 month
223632173|NCT06588075|PROCEDURE|Reduction and fixation of zygomatico- Maxillary complex fracture using a full digital work flow|All surgeries will be carried out under general anesthesia the fracture lines will be exposed then For the study group: following the exposure of all fracture lines , anatomically seated bone-supported predictive holes surgical guides will be inserted on the bone segments with intimate contact. Each segment hole will be drilled according to the predesigned predictive holes guide. The fractured segments will then be reduced and fixed using titanium miniplates customized for the patient and screws at least two screws for each fracture segment. then closure in layers will be performed using absorbable vicryl for deep layers and intraoral sutures and non-absorbable polyproline for skin closure.
224220610|NCT02168075|DRUG|1.5g/kg of 20% mannitol|When the neurosurgeon starts the drilling of skull,1.5g/kg of 20% mannitol administered through the IV catheter with fulldrip. Neurosurgeon evaluate the degree of brain relaxation after dura opening in 4 point scale ( 1=bulging brain, 2=firm brain, 3-satisfactorily relaxed, 4=perfectly relaxed).
224220611|NCT03037684|DIAGNOSTIC_TEST|neurophysiology|electrophysiologic measurements of peripheral nerves
224220612|NCT06422611|DEVICE|Impression methods|Both digital and conventional impressions were taken from same patients
224220613|NCT04490083|PROCEDURE|Extra corporeal shock wave lithotripsy|ESWL will be performed with a third generation electromagnetic lithotripter (Delta Compact, Dornier Med Tech, Germany) This has both fluoroscopy and ultrasound imaging facility. Radio opaque calculi will be targeted directly while a naso pancreatic tube (NPT) was placed for all radiolucent calculi and contrast was passed through this to localize the calculi. Between 5000 and 6000 shocks were delivered per session with frequency of 90 shocks per minute. The aim will be to fragment the calculi to \<3 mm or demonstrate a decrease in heterogeneity or density of the calculi in the main pancreatic duct. Shocks will be delivered on consecutive days till fragmentation is achieved. If there is no fragmentation after four sessions of ESWL the procedure will be labeled as unsuccessful and patient will be advised surgery. Procedures will be performed under epidural anesthesia.
224220614|NCT03256383|DEVICE|Lead testing|Fingerstick
224220615|NCT04423653|BEHAVIORAL|Telehealth home exercise program|The intervention will include videos of exercises and also live coaching using telehealth system.
224220616|NCT04656951|DRUG|Daratumumab|Daratumumab added to induction regimen of bortezomib, cyclophosphamide and dexamethasone (VCD), to bortezomib and dexamethasone during maintenance and to lenalidomide and dexamethasone at progression/relapse.
224220617|NCT03031457|DIAGNOSTIC_TEST|Duplex ultrasound|Duplex ultrasound of lower extremity venous system
224220618|NCT01559974|DRUG|Placebo|Placebo to 45'000 units of Cholecalciferol per month for 3 months
224220619|NCT01559974|DRUG|Cholecalciferol|45'000 units of cholecalciferol per month for 3 months
224220620|NCT04302766|DRUG|Remdesivir|Remdesivir (RDV,GS-5734) is a monophosphoramidate prodrug of an adenosine analog with potent activity against an array of RNA virus families including Filoviridae, Paramyxoviridae, Pneumoviridae, and Orthocoronavirinae, through the targeting of the viral RNA dependent RNA polymerase (RdRp).
224220621|NCT01634022|PROCEDURE|Acupuncture|5 specific body acupoints (HT-7 and LI-4 on the hands bilaterally, and ST-36, SP-6, and LR-3 on the legs bilaterally) with gentle manual tonification every 10 min. Two acupoints along the midline of the head, GV-20 and GV-24.5 (Yintang), were also used with a 2 Hz current applied from GV-20 (-) to GV24.5 (+).
224220622|NCT05077306|OTHER|music therapy group|individual bedside single session of receptive music therapy (RMT) by a certified Music therapist- GIM fellow in presence. STAI Y-1 was administered 5 min. before session (STAI Y-1 PRE) and 15 min. after session (STAI Y-1 POST) in paper form. HR and O2Sat were recorded from the bedside monitor 3 times: start session (T0), 10 min. (T1), end session (T2).Participants i were asked to fill in an optional open-ended question concerning their experience with music therapy.
224220623|NCT02098356|OTHER|Low Bicarbonate|Low bicarbonate hemodialysis - 30 mEq/L dialysate bicarbonate
224220624|NCT00325494|DRUG|MORAb-009|Each dose of investigational product will be given as a continuous infusion ranging from 12.5 mg/m\^2 up to 400 mg/m\^2.
224220625|NCT01814137|DRUG|insulin degludec/insulin aspart|For subcutaneous (s.c., under the skin) administration twice daily in combination with up to 2 oral antidiabetic drugs (OADs- dose and dosing frequency of OAD should remain unchanged).
224220626|NCT01814137|DRUG|insulin degludec|For subcutaneous (s.c., under the skin) administration once daily in combination with up to 2 oral antidiabetic drugs (OADs- dose and dosing frequency of OAD should remain unchanged).
224220627|NCT01814137|DRUG|insulin aspart|For subcutaneous (s.c., under the skin) administration once daily. Dose of IDegAsp and IAsp are individually adjusted.
224220628|NCT01814137|DRUG|insulin aspart|For subcutaneous (s.c., under the skin) administration three times a day. Dose of IDeg and IAsp are individually adjusted.
224220629|NCT02856867|DRUG|Nintedanib|
224220630|NCT02856867|DRUG|Fluorouracil|
223764296|NCT06601309|RADIATION|Radiotherapy|Radiotherapy at a dose of 40 Gy, delivered in 20 fractions over 4 weeks.
223764297|NCT04961034|PROCEDURE|kasai portoenterostomy|surgical creation of stoma between porta hepatis and jejunal loop
224220631|NCT02856867|DRUG|Leucovorin|
224220632|NCT02856867|DRUG|Oxaliplatin|
224220633|NCT02856867|DRUG|Placebo|
224220634|NCT00219557|DRUG|Gemcitabine|Gemcitabine 1000 mg/m\^2 30 minutes IV infusion on Day 1, 8 and 15 of each cycle, in cycles of 4 weeks
224220635|NCT00219557|DRUG|AG-013736|Axitinib (AG-013736) 5 mg tablet orally BID starting from Day 1 of Cycle 1, in cycles of 4 weeks.
224220636|NCT00219557|DRUG|Gemcitabine|Gemcitabine 1000 mg/m\^2 30 minutes IV infusion on Day 1, 8 and 15 of each cycle, in cycles of 4 weeks.
224220637|NCT04848350|OTHER|Lavender essential oil|Aromatherapy agents were added to the nebulizer at a rate of 2% (120 ml of water).The nebulizer was prepared and operated on in the SWL room before the procedure, The patients were taken to the room 5 minutes before the procedure and the nebulizer was operated on during the procedure
224220638|NCT00654043|DRUG|Torsemide|tablets, 20 Mg, single-dose
224220639|NCT00654043|DRUG|Demadex|Tablets, 20 mg, single-dose
224220640|NCT02711150|DEVICE|PLL Length Measured through US|The PLL will be measured for each allocated position: EPD or Flexed Position
223632174|NCT06588075|PROCEDURE|Reduction and fixation of zygomatico- maxillary complex fracture using a conventional free hand protocol|For the control group: all cases will be treated under general anesthesia and the fracture lines will be exposed then the conventional protocol of treatment depend mainly on visualization of the fracture line and tactile sensation of the operator intra-operative during reduction procedure and the fixation of fractured segments will be done using titanium miniplates and screws then closure in layers will be performed.
223632175|NCT06603909|OTHER|group 1: Use AI to assist nutrition management|group1：AI-assisted nutrition management. group 2：Traditional nutrition management（through the hospital dietitian）.group 3:control.
223632176|NCT06603909|OTHER|group 2：Traditional nutrition management（through the hospital dietitian）|group 2：Traditional nutrition management（through the hospital dietitian）
223632177|NCT06600334|DIAGNOSTIC_TEST|dexa scan|Bone density scans
223632178|NCT06595056|BEHAVIORAL|Multi-technology MVPA intervention|Participants will receive a one-on-one counseling session and access to an individually tailored multi-media website. Key intervention components will be reinforced through text messaging to aid goal setting, a physical activity tracker (Fitbit) to set goals, track and log activity, and access to a study Instagram account to reinforce exposure to web content.
224220641|NCT05684250|BEHAVIORAL|Auditory biofeedback training|For the auditory biofeedback training, subjects are provided with two tones while fixating a target, one tone related to their accommodative response and the second to the target distance. Their task is to match these tones.
224220642|NCT03205514|DIAGNOSTIC_TEST|NSTE-ACS with intermediate stenosis and negative FFR|Patients will undergo intracoronary imaging evaluation with IVUS-NIRS and OCT, endothelial function and inflammatory state evaluation.
224220643|NCT00833781|BIOLOGICAL|mRNA-transfected autologous dendritic cells|Injections will be administered intradermally at weeks 0, 2, 6 and 10.
224220644|NCT00833781|BIOLOGICAL|autologous dendritic cells with no mRNA transfection|Injections will be administered intradermally at weeks 0, 2, 6 and 10.
224220645|NCT00912470|PROCEDURE|ocular blood flow measurement|"Retinal blood flow (with scanning laser Doppler flowmetry, laser Doppler velocimetry + retinal vessel analyzer) each measurement once on the study eye~Choroidal blood flow (with laser Doppler flowmetry, laser interferometry, pneumotonometry)~Frequency distribution of alleles of genetic markers for NOS3, more precisely eNOS -786CC polymorphism and of ET-1 (EDN1), and the receptors ETA (EDNRA), more precisely EDN1/+138/ex1 del/ins, EDN1/K198N, EDNRA/C+1222T, EDNRA/C+70G polymorphisms"
224220646|NCT02531828|DEVICE|Application of dressings for surgical correction.|Dressing for surgical correction
223632179|NCT06596109|BEHAVIORAL|honey intake and lifestyle changes|Twenty fatty liver (non-alcoholic from) patients with obesity are included as 20 patients who will receive natural unprocessed honey intake (orally, as a daily total dose of 2 g/kg, this dose will be divided to three equal subdoses, every dose will be administered before meal), low calorie diet, and treadmill walking (40 minutes per session, three times per week) for 12 weeks.
223764298|NCT05742451|OTHER|kids yoga|"The kids yoga was applied to the intervention group for 8 weeks, once a week (8 sessions), 40 minutes per session, by a yoga instructor occupational therapist.~Kids yoga training included: 5-minute warm-up consisting of jogging, jumping, stretching, relaxation exercises; 20 minutes of asanas (positions) consisting of standing, sitting, prone, supine postures and pranayamas (breathing exercises) consisting of vigorous inspiration and expiration, slow and rhythmic alternating nostril breathing; 10-minute yogic games about balance, reaction time and agility; meditation with focus for 5 minutes with resuscitation techniques."
224220647|NCT02531828|DEVICE|POLYSHAFT®|
224220648|NCT05871697|OTHER|Measurement of multifidus and gastrocnemius muscle thickness with Ultrasound|To measure multifidus and gastrocnemius muscle thickness using ultrasound imaging, the following steps are typically followed. First, the patient is positioned appropriately to allow access to the muscles to be imaged. For example, the patient may lie prone for imaging of the lumbar multifidus or sit with the leg extended for imaging of the gastrocnemius. Next, a trained clinician or technician places an ultrasound probe on the skin over the target muscle and adjusts the settings on the ultrasound machine to optimize the image quality. The probe is then moved around to obtain different views of the muscle, and the images are stored for later analysis. To measure muscle thickness, the clinician or technician identifies the muscle fascia on the ultrasound image and measures the distance between the fascia and the underlying bone or tissue. This measurement provides an estimate of the muscle thickness.
224220649|NCT05871697|OTHER|Berg Balance Scale|The Berg Balance Scale is a clinical assessment tool used to measure an individual's ability to maintain balance during various functional tasks. The test includes 14 items, such as standing unsupported, reaching forward, turning, and standing on one leg. Each item is scored on a 5-point scale, ranging from 0 (unable to perform the task) to 4 (able to perform the task independently and safely). The scores for each item are summed to provide a total score, with a maximum possible score of 56.
224220650|NCT00863057|DRUG|Duloxetine|During each treatment period, participants will take duloxetine in the following doses. On Days 1 to 5, participants will take one 30-mg capsule orally, once daily. On Days 6 to 28, participants will take two 30-mg capsules orally, once daily. During days 29 to 31 dosage will be reduced to one capsule daily and then discontinued on Day 32.
224220651|NCT00863057|DRUG|Duloxetine placebo|During each treatment period, participants will take duloxetine placebo in the following doses. On Days 1 to 5, participants will take one 30-mg capsule orally, once daily. On Days 6 to 28, participants will take two 30-mg capsules orally, once daily. During days 29 to 31 dosage will be reduced to one capsule daily and then discontinued on Day 32.
224318062|NCT04252898|BEHAVIORAL|Front-of-pack nutrition label Nutri-Score|The intervention consists of displaying the Nutri-Score on dishes and pre-packed foods.
224318063|NCT04450576|DIAGNOSTIC_TEST|Glycosylated hemoglobin|Glycosylated hemoglobin levels associated with correlative measures of diastolic cardiac function
223632180|NCT06596109|BEHAVIORAL|lifestyle changes|Twenty fatty liver (non-alcoholic from) patients with obesity are included as 20 patients who will receive low calorie diet and treadmill walking (40 minutes per session, three times per week) for 12 weeks.
223632181|NCT06989320|DIETARY_SUPPLEMENT|Low-oxalate diet and glycolate dosing|Low-oxalate diet 4 days of fixed eucaloric diet with low oxalate (\<60 mg/day), normal calcium content (600-1000 mg/day)
223632182|NCT06989320|DIETARY_SUPPLEMENT|Oral glycolate dosing|Oral 13C-glycolate dosing (0.5 mg/kg)
223632183|NCT06989320|DIETARY_SUPPLEMENT|Oral 13C- ascorbic acid dosing|Oral 13C- ascorbic acid dosing (0.75 mg/kg)
224318064|NCT03038594|DRUG|Somatropin|
223632184|NCT06585995|DRUG|vitamin D (cholecalciferol) supplementation|"This pilot clinical study administered and compared daily and bolus vitamin D dosing regimens to achieve and maintain optimal serum 25(OH)D levels in patients with COVID-19. The daily dose group received constant cholecalciferol supplementation (vitamin D supplementation), aimed at achieving more stable and non-peak 25(OH)D levels. In contrast, the bolus group received a one-month cumulative monthly dose, divided into 4 doses, administered on 4 consecutive days, which could result in rapid increases followed by gradual decreases in 25(OH)D levels. The daily dose of cholecalciferol was calculated using the following formula: Daily dose of cholecalciferol = \[Weight (kg) × desired increase in 25(OH)D (ng/ml) × 2.5\] - 10 .~Bolus dose = (daily dose)(30 days)/4 doses"
223632185|NCT06704230|DEVICE|video googles|Patients undergoing surgery use video googles and a headphone to distract from surgery
223632186|NCT06702644|DEVICE|Remote ischemic conditioning|Remote ischemic conditioning: Remote ischemic conditioning (RIC) is induced by 5 cycles of 5 min of bilateral upper limbs ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflations of a blood pressure cuff to 200 mmHg.
223632187|NCT06702644|DEVICE|Sham remote ischemic conditioning|Sham remote ischemic conditioning (RIC) is induced by 5 cycles of 5 min of bilateral upper limbs ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflations of a blood pressure cuff to 60 mmHg.
223632188|NCT06704282|BEHAVIORAL|VR Mindfulness Meditation Program|A 15-minute guided mindfulness meditation session conducted in a virtual reality environment to enhance stress reduction and mindfulness.
223764299|NCT03621137|OTHER|No study-specific intervention|Treatment of atopic eczema with phototherapy or systemic immunomodulating therapy according to usual clinical practice
223764300|NCT00864773|PROCEDURE|intravitreal injection with anterior paracentesis|0.1cc Aqueous humor samples were taken each time an intravitreal injection of bevacizumab (2.5 mg in 0.1 ml)
224220652|NCT00863057|DRUG|Methadone|During each treatment period, participants will take methadone in the following doses. On Days 1 to 5, participants will take one 5-mg capsule orally, twice daily. On Days 6 to 10, participants will take one 5-mg capsule orally, three times daily. On Days 11 to 28, participants will take two 5-mg capsules orally, three times daily. On Days 29 to 31, dosage will be one 5-mg capsule orally, three times daily. On Days 32 to 34, dosage will be decreased to one 5-mg capsule, twice daily and ultimately discontinued on Day 35.
224220653|NCT00863057|DRUG|Methadone placebo|During each treatment period, participants will take methadone placebo in the following doses. On Days 1 to 5, participants will take one 5-mg capsule orally, twice daily. On Days 6 to 10, participants will take one 5-mg capsule orally, three times daily. On Days 11 to 28, participants will take two 5-mg capsules orally, three times daily. On Days 29 to 31, dosage will be one 5-mg capsule orally, three times daily. On Days 32 to 34, dosage will be decreased to one 5-mg capsule, twice daily and ultimately discontinued on Day 35.
224220654|NCT02345486|OTHER|0.9% sodium chloride|
224220655|NCT02345486|OTHER|Physiologically balanced fluid|
224220656|NCT04400695|DRUG|RC48-ADC|RC48-ADC 2.0mg / kg, intravenous drip, once every 2 weeks
224220657|NCT04400695|DRUG|Paclitaxel Injection|Administered according to label, as one option for Physician's Choice (determined before randomization)
224220658|NCT04400695|DRUG|Docetaxel Injection|Administered according to label, as one option for Physician's Choice (determined before randomization)
224220659|NCT04400695|DRUG|Vinorelbine Tartrate Injection|Administered according to label, as one option for Physician's Choice (determined before randomization)
224220660|NCT04400695|DRUG|Capecitabine Tablets|Administered according to label, as one option for Physician's Choice (determined before randomization)
224220661|NCT00410566|DRUG|rhASM|Single dose of 0.03mg/kg body weight IV
224220662|NCT00410566|DRUG|rhASM|Single dose of 0.1mg/kg body weight IV
224220663|NCT00410566|DRUG|rhASM|Single dose of 0.3mg/kg body weight IV
224220664|NCT00410566|DRUG|rhASM|Single dose of 0.6mg/kg body weight IV
224318065|NCT03038594|DRUG|0.09% Saline Solution|
224220665|NCT00410566|DRUG|rhASM|Single dose of 1.0mg/kg body weight IV
223764301|NCT03331692|OTHER|monitoring of the proper level of general anesthesia|The monitoring of the adequate level of general anesthesia was performed both clinically and instrumentally.
224220666|NCT03163095|DEVICE|Open Abdomen Management with ANPPT dressing|"The abdominal fascia will not be closed, but a temporally abdominal closure (TAC) dressing, such as AbThera dressing, will be placed to protect the viscera with active Negative Pressure Peritoneal Therapy.~The time that the TAC dressing will be changed will be left to the discretion of the attending surgeon, but practice guidelines mandate either formal abdominal closure or dressing change at 24-72 hours from placement.~Blood samples and peritoneal fluid will be drawn up to 72 hours after enrollment."
224318066|NCT02906241|BEHAVIORAL|Patients: Questions to Ask Your Doctor: A Workbook for Patient-Doctor Teams|This booklet encourages patients to view themselves as members of the patient-doctor team and to participate actively during clinical interactions by asking questions and stating concerns.
224318067|NCT02906241|BEHAVIORAL|Physicians: Educational Module|Physicians will participate in an educational module and receive email prompts to encourage them to discuss trials with all patients who are eligible for a clinical trial, using patient-centered communication
224318068|NCT05157906|BEHAVIORAL|Education based|The interventional materials will be provided digitally for 12 weeks, with the monthly theme featured from the educational Grow Happy book and related tips and videos that will be released weekly.
224318069|NCT05157906|BEHAVIORAL|Control|At enrollment, subject will be provided with the Mother and Child booklet, which is the Indonesian standard of care for parenting guidance.
224318070|NCT03790150|OTHER|Evidence-based practices|Implementation of evidence-based practices
224318071|NCT03492827|DRUG|chlorhexidine acetate gargle|observe whether it can achieve the effect of preventing postoperative infection
224318072|NCT01656538|DRUG|Paclitaxel|
224318073|NCT01656538|DRUG|Reolysin|
224318074|NCT01045213|OTHER|Integrated Care|Study looking at the efficacy of a combination of Guideline-based COPD education, self-management training, remote telemonitoring and enhanced communication with a coordinator.
224318075|NCT01914627|DRUG|Dimethicone|The treatment will be carried out once daily (in the evening) onto all scaling areas of the scalp over a period of 2 weeks, with the last application of investigational products being applied one day prior to the final visit.
223632189|NCT06705127|DRUG|TORIPALIMAB INJECTION(JS001 )|"Drug A: 240mg intravenous infusion of Toripalimab, once every 3 weeks, the first dosing date was C1D1, followed by the first day of each course for 18 cycles, a total of 1 year.~Drugs B and C: Epirubicin was administered intravenously after the dosage was calculated at 90mg/m2 body surface area, cyclophosphamide was calculated at 600mg/m2 body surface area by intravenous micropump, both drugs were administered every 3 weeks, the first administration date was C1D1, and then the first day of each course was administered for 4 cycles.~Drug D:albumin paclitaxel was given intravenatically at a dose of 125mg/m2 body surface area, once a week, with the first administration date of C5D1, and then on the first day of each course for 12 cycles."
224220667|NCT03163095|OTHER|Closed Abdomen Management|"Primary closure of the abdominal fascia with placement of an intra-peritoneal drain (such as a Jackson-Pratt drain).~This strategy will allow drainage of intra-peritoneal fluid for both clinical reasons and to facilitate intra-peritoneal fluid testing. Closure or not of the skin will be left to the attending surgeons discretion. Any decision to perform a relaparotomy (Relaparotomy on Demand) will be at the discretion of the treating critical care teams, and in no way mandated by this recruitment.~Blood samples and peritoneal fluid (if available) will be drawn up to 72 hours after enrollment."
224220668|NCT04317833|DRUG|SSS17|SSS17 is a novel small molecule compound which stimulates erythropoiesis through inhibition of hypoxia-inducible factor- prolyl hydroxylases( HIF-PH). It is being developed for the treatment of anemia in patients with chronic kidney disease.
224220669|NCT04317833|DRUG|Placebo|matched placebo
224220670|NCT05507554|DRUG|Opioid|"Drug: intravenous injection Tramadol 50 mg and then oral capsule Tramadol 50 mg, once patient starts taking orally.~Designated coated 14 days supply of pain medication (oral capsule Tramadol 50 mg) will be given to the patients on discharge. For Pain control oral capsule Tramadol 50 mg is administered 2 times per day until the stent will be removed in clinic 2 weeks later."
224220671|NCT05507554|DRUG|Non-Opioid Analgesic|"Drug: intravenous injection Paracetamol 1 Gram and then oral Tablet Paracetamol 1 Gram, once patient starts taking orally.~Designated coated 14 days supply of pain medication (oral Tablet Paracetamol 1 Gram) will be given to the patients on discharge. For Pain control oral Paracetamol 1 Gram is administered 3 times per day until the stent will be removed in clinic 2 weeks later."
224220672|NCT05507554|DRUG|Non-Opioid|"Drug: intra muscular injection Diclofenac Sodium 50 mg and then oral Tablet Diclofenac Sodium 50 mg, once patient starts taking orally.~Designated coated 14 days supply of pain medication (oral Tablet Diclofenac Sodium 50 mg) will be given to the patients on discharge. For Pain control oral Diclofenac Sodium 50 mg is administered 2 times per day until the stent will be removed in clinic 2 weeks later."
224220673|NCT03082391|DEVICE|Heavy weight Mesh|Patients will undergo ventral hernia repair with heavy weight mesh.
224220674|NCT03082391|DEVICE|Medium weight Mesh|Patients will undergo ventral hernia repair with medium weight mesh.
224220675|NCT00428194|DRUG|cisplatin|40 mg/m\^2 every 7 days during radiation
224220676|NCT00428194|DRUG|erlotinib hydrochloride|Erlotinib escalating dose per schedule - 100, 125 and 150 mg/m\^2 by mouth once a day beginning day 1.
224220677|NCT00428194|PROCEDURE|radiation therapy|standard (fixed) doses of pelvic irradiation (as determined by their radiation oncologist)
224220678|NCT03875391|DRUG|Oxytocin|Drug: Oxytocin nasal spray
224220679|NCT03875391|DRUG|Placebo|Drug: Placebo nasal spray
224220680|NCT02048397|OTHER|Pulmonary Rehabilitation|
223632190|NCT06705127|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|Local radiotherapy: Subjects received stereotactic radiotherapy for the primary breast cancer lesion at 8Gy each time for 3 consecutive days, once a day, 2 weeks before the start of systemic therapy
223632191|NCT06704555|RADIATION|radiation therapy|received radiation (dose:18～24Gy)
223632192|NCT06704555|DRUG|Tiselizumab|200 mg iv day 1
223632193|NCT06704555|DRUG|Rituximab|375 mg/m2 intravenous \[IV\] day 2
224220681|NCT02048397|DIETARY_SUPPLEMENT|Hyperproteic oral nutritional supplement enriched with beta-hydroxy-beta-methylbutyrate|
224220682|NCT03908983|DEVICE|Kalios Implant|KALIOS is an adjustable annuloplasty ring, to be implanted by open surgery, having a hollow structure that comprises a flat rigid ring surrounding a deformable cage. The unique feature of KALIOS is that its annular shape and dimension can be finely adjusted percutaneously by an external actuator (three-balloon catheter) independently in the three areas corresponding to P1, P2 and P3
224220683|NCT03335943|DRUG|CDA-2 (Cell Differentiation Agent 2)|CDA-2 will be given intravenously, with 200 ml each day for 14 consecutive days in every four weeks (one cycle). The treatment will be repeated at least for 3 cycles.
224220684|NCT03111979|DIETARY_SUPPLEMENT|beta-alanine|
224220685|NCT03111979|DIETARY_SUPPLEMENT|Placebo|
224220686|NCT02447484|BEHAVIORAL|Mujer Segura Siempre|Participants receive personalized text messages twice a day, five days per week. Messages are designed to encourage women to maintain positive behavioral changes they have made in response to the baseline safer-sex training that is delivered to all participants regardless of intervention assignment. Message content is based upon theoretical constructs of behavior-change maintenance as articulated by Voils et al. (Health Education \& Behavior, 2013). Personalization elements include participant's name, times of day when she prefers to receive messages, and specific motivators of behavior change she expressed in the baseline interview.
224220687|NCT02447484|BEHAVIORAL|General Health Message Texts|Participants receive generic health-promotion text messages twice a day, five days per week.
224220688|NCT01279642|DEVICE|ultrasound|Doppler vascular ultrasound guidance to PICC insertion in children -
224220689|NCT01279642|OTHER|traditional puncture|traditional approach of PICC insertion by visualization and inspection of insertion site
224220690|NCT03295799|OTHER|Patient Self-Management|Patient will manage their own warfarin therapy.
224220691|NCT05511285|BEHAVIORAL|Digital Cognitive Behavioural Therapy for Insomnia|6-10 weeks of digital cognitive behavioural therapy for insomnia (Sleepio) delivered online, in addition to usual care.
223632194|NCT06704555|DRUG|Cyclophosphamide|750 mg/m2 IV day 3
223632195|NCT06704555|DRUG|Doxorubicin|50 mg/m2 IV day 3
223632196|NCT06704555|DRUG|Vincristine|1.4 mg/m2 \[maximum 2.0 mg total\] IV day 3
223632197|NCT06704555|DRUG|Prednisone|100 mg oral days 3-7
224220692|NCT00299585|PROCEDURE|"using PD VitalOs Cement with dental implants"|supporting dental implants with Vitalos bone cement
224220693|NCT00676585|DRUG|Normal Saline|Normal Saline
224220694|NCT00676585|DRUG|Hydrocortisone|Hydrocortisone 100mg
223764302|NCT06670625|BEHAVIORAL|IDAC+|Diet and physical activity counselling at baseline, 6, 12 and 24 months visit.
224220695|NCT02439242|DRUG|fluid challenge of saline|250 ml of saline
224220696|NCT01405170|DRUG|methylprednisolone|constituted powder for oral suspension 4 mg/mL single dose at 32 mg
224220697|NCT01405170|DRUG|methylprednisolone|tablets 32 mg single dose
224220698|NCT03551678|DEVICE|Active feedback gait retraining|The device measures pressure/force under the lateral side of the foot and activates vibration if loading crosses a set threshold. The location of the vibration is customized for each subject to achieve maximal sensitivity.
224220699|NCT02741271|DRUG|MF MDI 100 mcg BID (Open Label)|Eligible participants will receive open-label MF MDI 100 mcg BID during a 2-week run-in period.
224220700|NCT02741271|DRUG|MF/F MDI 100/10 mcg BID|After a 2 week run-in on open-label MF MDI 100 mcg BID, eligible participants will receive double-blinded treatment with MF/F MDI 100/10 mcg BID.
224220701|NCT02741271|DRUG|MF MDI 100 mcg BID|After a 2 week run-in on open-label MF MDI 100 mcg BID, eligible participants will receive double-blinded treatment with MF MDI 100 mcg BID.
224220702|NCT02741271|DRUG|Albuterol/Salbutamol PRN|Participants may use study-provided short-acting beta agonist (SABA), albuterol/salbutamol, as needed (PRN) for the relief of asthma symptoms.
224220703|NCT02741271|DRUG|Prednisone/Prednisolone|Participants may use a systemic corticosteroid (prednisone/prednisolone) for acute asthma worsening per investigator discretion.
224220704|NCT06090578|OTHER|TabCAT Brain Health Assessment Clinical Pathway|Primary care providers concerned that their patients are exhibiting signs of cognitive decline will refer them to clinical associates who will then perform the TabCAT-BHA tablet-based test. The TabCAT-BHA paradigm comprises 7-10 minutes of tablet-based testing and an optional 3-minute self-administered informant survey captures behavioral symptoms and change from baseline. The results are available to the PCP in the EMR along with turnkey guidance to evaluate for reversible causes, identify and involve a care partner, make and disclose diagnosis, provide community and educational resources, and make medical referrals as appropriate. Nursing support is available to support the PCP in making the diagnosis and to consult to the family via telephone post-diagnosis to address immediate care needs.
224220705|NCT03652961|DRUG|Abatacept|Abatacept for reconstitution and dilution prior to intravenous (IV) administration. Each single-use vial of Abatacept for injection provides 250-mg Abatacept, maltose (500 mg), monobasic sodium phosphate (17.2 mg), and sodium chloride (14.6 mg) for administration.
224220706|NCT03652961|DRUG|DMARDs|Patients will receive methotrexate or remain on pre-existing conventional synthetic disease-modifying anti-rheumatic drug (DMARD) if already prescribed.
223764303|NCT06997445|OTHER|Interventional group: Jacobson's progressive muscle relaxation technique with aerobic exercise|Jacobaon's progressive muscle relaxation technique for 15 minutes Total duration: 45 minutes
224220707|NCT03506009|DRUG|Argatroban combined with rt-PA|Argatroban as a 100-ug/kg bolus over 3 to 5 minutes was administered intravenously within 1 hour of the tPA bolus followed by a continuous Argatroban infusion of 1.0 ug/kg per minute for 48 hours adjusted to a target activated partial thromboplastin time of 1.75 X baseline (about 10%).
224220708|NCT03506009|DRUG|rt-PA|Intravenous throbolysis with 0.9mg/kg rtPA.
224220709|NCT01612156|DRUG|2% lidocaine gel|2% lidocaine gel will be used to coat the urethral catheters and cotton tipped swab before use during the examination.
224220710|NCT01612156|DRUG|Water based lubricant|Water based lubricant will be applied to all urethral catheters and cotton tipped swabs before use in the pelvic floor examination.
224220711|NCT01856985|DRUG|Misoprostol|
224220712|NCT01856985|DRUG|Mifepristone|
224220713|NCT04778527|DRUG|Dual Prevention Pill|a single over-encapsulated DPP containing a PrEP tablet and a COC
224220714|NCT04778527|DRUG|PrEP tablet and a COC as two separate tablets|PrEP tablet and a COC as two separate tablets
224220715|NCT01151787|DRUG|cyclobenzaprine hydrochloride|15mg daily for 3 months
224220716|NCT01151787|DRUG|placebo|placebo
224220717|NCT03725787|DEVICE|CuroCell S.A.M. ® pro mattress|During 30 days, participants will use the static air mattress.
224220718|NCT03799978|DRUG|ACT-541468|ACT-541468 50 mg film-coated tablets
224220719|NCT02109926|OTHER|Phone interview and blood test|Subjects will be interviewed about environmental, domestic and occupational exposures during several periods of life Two blood samples will be collected at enrollment to study genetic polymorphisms
224220720|NCT03989960|PROCEDURE|LISA+SNIPPV|The LISA+SNIPPV group receives PS by the way of invasive surfactant administration technique and selects nasal synchronized intermittent positive pressure ventilation.
224220721|NCT03989960|PROCEDURE|traditional InSurE|The traditional InSurE group receives intubation-surfactant- extubation technique and selects CPAP ventilation.
224220722|NCT00922792|DRUG|activated recombinant human factor VII, long acting|Single dose of 0,2 mg/kg LA-rFVIIa injected i.v. (intravenous) of 2 minutes duration
224220723|NCT00922792|DRUG|activated recombinant human factor VII, long acting|Multiple doses of 100 mg/kg LA-rFVIIa injected i.v. (intravenous) of 2 minutes duration every 48 hours
224220724|NCT02831530|DRUG|Abemaciclib|
224220725|NCT00665522|DRUG|fentanyl iontophoretic transdermal system (40mcg) No Placebo|40 mcg per dose, maximum of 6 doses/hour
224220726|NCT00665522|DRUG|IV PCA with standard of care opioid analgesia|total maximum 80 doses/24 hours
224220727|NCT03086239|DRUG|Rovalpituzumab tesirine|Intravenous
224220728|NCT04915586|DRUG|Intra-pleural Alteplase 16mg with Pulmozyme (DNase) 5mg|Intra-pleural Alteplase 16mg with Pulmozyme (DNase) 5mg for total 3 doses within 24 hours
224220729|NCT04638855|DEVICE|Medicurtain®|Anti-adhesion barrier (Medicurtain® 5ml prefilled syringe after hysteroscopy surgery)
224220730|NCT04638855|DEVICE|Placebo|No device after hysteroscopy surgery
224220731|NCT01712412|DRUG|IW-9179|
224220732|NCT01712412|DRUG|Placebo|
224220733|NCT03276910|DRUG|EPREX|6 doses at 50 IU/kg or 20 IU/kg in subcutaneous use
224220734|NCT03276910|DRUG|sodium chloride AGUETTANT 0.9%|6 injections at 1ml in subcutaneous use
224220735|NCT00410410|DRUG|abatacept (ABA)|"Dextrose 5% in water, IV. Placebo on days IP-1, IP-15,IP-29, IP-57; 3 mg/kg on days IP-1, IP-15,IP-29, IP-57; 10 mg/kg on days IP-1, IP-15,IP-29, IP-57; or 30 mg/kg on days IP-1,IP-15 and \~10 mg/kg on days IP-29, IP-57 (ABA 30/\~10 mg/kg Group).~Induction Period 3 months~Maintenance Period 12 months"
224220736|NCT00410410|DRUG|placebo|"Normal saline, IV, 0 mg/kg, every 28 days.~Induction Period 3 months~Maintenance Period 12 months"
224318076|NCT01914627|DRUG|Salicylic Acid|The treatment will be carried out once daily (in the evening) onto all scaling areas of the scalp over a period of 2 weeks, with the last application of investigational products being applied one day prior to the final visit.
223632198|NCT06704789|DEVICE|Measurement of brain activity (fNIRS, EEG)|Brain activity assessments are conducted as a single session lasting approximately 60 minutes
223632199|NCT06706011|OTHER|Virtual Patient|Interactive Educational Activity
223632200|NCT06879678|BEHAVIORAL|Web-Based Exercise Program|Web-Based Exercise Program + standard protocol
223632201|NCT04045535|OTHER|Physical Activity Program|Usual Care and a nurse-led physical activity program once a week for 8 weeks. Each session last for 60 minutes, 15 for warming-up and 45 for different exercises.
223632202|NCT04045535|OTHER|Usual care|Usual clinical care based on current clinical practice guidelines.
223632203|NCT05860946|DEVICE|Remote ischemic conditioning|The RIC intervention included five cycles of 5 min inflating tourniquets with the pressure of 200 mmHg and 5 min deflating with pressure of 0 mmHg alternately
224220737|NCT00410410|DRUG|abatacept|"\~10 mg/kg, once monthly~Open- Label Extension Period until the drug is marketed for UC or the UC development program for abatacept is discontinued"
224220738|NCT04497610|DIAGNOSTIC_TEST|Breath sample|Patient will blow into a tube 5 times.
224220739|NCT01783496|DEVICE|Thermage CPT|Treatment with Thermage patterned, total, or framed tip
223632204|NCT02081781|PROCEDURE|Probing|"A punctal dilator was used for dilating the punctum. The nasolacrimal system was irrigated through either the lower or upper punctum with a hollow 23-gauge irrigating cannula attached to a syringe. A #0 (or #00) Bowman probe was passed through either the lower or upper canaliculus into the lacrimal sac and then directed downward through the nasolacrimal duct into nasal cavity. A Hard resistance could be felt as the probe touched the end of the nasolacrimal duct. A Pop tactile sensation might be noted while the probe passing through an obstruction at the valve of Hasner."
223632205|NCT02609919|DRUG|Gadoteric Acid|MRI Contrast Agent
224220740|NCT01072019|OTHER|Instrument|Randomization to instrumentation to be used for primary total knee replacement; either standard knee cutting guides or MRI generated patient specific custom cutting guides.
224220741|NCT01232257|DRUG|N-acetylcysteine|4 gifts of N-acetylcysteine 600 mg BID
224220742|NCT03114189|PROCEDURE|footbath|
224220743|NCT03114189|BEHAVIORAL|care of sleep|
223632206|NCT02874872|BEHAVIORAL|OASIS Collaborative|OASIS (Optimizing Antibiotic Stewardship in Skilled Nursing Facilities) is a system redesign of skilled nursing facility work systems
223632207|NCT00727467|DEVICE|Auditory Cueing Device|Each participant will be given an iPod containing an auditory cue in the form of a continuous metronome beat, individualised to the patient's walking frequency (less 10%).Participants will be instructed to listen to the cueing when they are performing any mobility related tasks.
224220744|NCT01692171|DRUG|Heparin, Low-Molecular-Weight|single intravenous administration of 3mg/Kg of the test drug and the comparator drug, according to randomization, in a crossover design, each administration separated by 6 days of washout.
224220745|NCT03666182|OTHER|No Intervention|No Intervention
224220746|NCT01720940|DRUG|continuous vancomycin infusion|24-hour continuous infusion of vancomycin
224220747|NCT01720940|DRUG|intermittent vancomycin infusion|
224220748|NCT01023269|DEVICE|InterStim Therapy|Neuromodulation therapy which delivers low level electrical stimulation to bladder wall for the treatment of overactive bladder with urinary incontinence.
224220749|NCT02357550|DRUG|ketone|3-OHB is infused intravenously.
224220750|NCT02357550|DRUG|placebo|Saline infusion.
224220751|NCT05030857|DRUG|GLPG4716|From Day 3 to Day 14, participants will receive GLPG4716 tablets once daily in fasted state. On Day 8 GLPG4716 will be administered in fed state.
223632208|NCT01212835|PROCEDURE|Sham Comparator: no ring|Open roux-en-Y gastric bypass not banded
223632209|NCT01212835|PROCEDURE|RYGBP-RING|Vertical Roux-en-Y banded gastric bypass
223632210|NCT00509054|PROCEDURE|Prophylactic mesh|A low weigth partly absorbable mesh in a subaly posistion
223632211|NCT02886819|OTHER|vibration|Whole body vibration
223632212|NCT00018148|DRUG|nortriptyline|Dose titrated to 75 mg daily as tolerated combined with transdermal nicotine 21 mg
223632213|NCT00018148|DRUG|transdermal nicotine|Transdermal nicotine 21 mg, titrated down plus placebo
223632214|NCT00641433|DEVICE|oxidized regenerated cellulose collagen-silver|Wound dressed daily with oxidized regenerated cellulose collagen-silver matrix.
223632215|NCT00641433|DRUG|topical silver sulfadiazine cream|Cream will be applied to nailbed daily and dressed with a bandage until healing occurs.
223632216|NCT01156662|DEVICE|Endeavor resolute or Resolute integrity (Medtronic)|PCI without thrombus aspiration
223632217|NCT01156662|DEVICE|Export Aspiration Catheter, Endeavor resolute or Resolute integrity (Medtronic)|PCI after thrombus aspiration
224220752|NCT05030857|DRUG|Midazolam|On Days 1, 3 and 13, participants will receive a single oral dose of MDZ as an oral solution in fasted state.
224220753|NCT02561312|OTHER|Rapid manual partial exchange transfusion|The first four participants will receive peripheral red blood cells via rapid manual partial exchange transfusions every month for 6 months. There is a pre-study washout for 3 months then there is a 3 month test period (data collection) before the participant is transferred to ST treatment.
224220754|NCT02561312|OTHER|Simple Transfusion|The second group of four participants will receive peripheral red blood cells via simple transfusion every month for 6 months. There is a pre-study washout period for 3 months then there is a 3 month test period (data collection) before the participant is transferred to RMPET treatment.
224220755|NCT05340556|GENETIC|Blood sample|Blood sample of 12 ml EDTA plasma.
224220756|NCT05340556|GENETIC|Swap test|receive swab tests for collecting cells from the oral mucosa
224220757|NCT00585091|DRUG|phenylephrine|All patients undergo repeated phenylephrine infusions during standard up-titration and maintenance of carvedilol treatment.
224318077|NCT00732576|DIETARY_SUPPLEMENT|menaquinone-7|capsule consisting of 10, 20 or 45 µg menaquinone-7 per day during 8 weeks
224318078|NCT00732576|DIETARY_SUPPLEMENT|fish oil|9 fish oil capsules equivalent to 3 gram per day of n-3 polyunsaturated fatty acids during 12 weeks
223632218|NCT00781768|DRUG|Standard PO (Zofran + Dexamethason)|Dexamethasone 10 mg (dose blinded) in 50 ml D5W IVPB over 15 minutes daily + ondansetron 8mg PO q 8 hours - repeated qd of the preparative regimen and for 1 day after completion. A placebo capsule will be given daily on each day of the preparative regimen plus 3 days after. Antiemetic therapy will start a minimum of 30 minutes prior to and continued for 24 hours after completion of the preparative regimen.
224220758|NCT06168955|OTHER|skin biopsy|skin biopsy for cell culture and N-homocysteinylation study
224220759|NCT04275219|DRUG|Tongfu capsules|Tongfu capsules include 5 herbals
224220760|NCT04275219|DRUG|The Placebo of Tongfu capsules|The Placebo of Tongfu capsules are made from dextrin, starch and so on.
224220761|NCT00182221|PROCEDURE|MDA D-Dimer Testing|
224220762|NCT03611114|DIETARY_SUPPLEMENT|Blood orange juice|
224220763|NCT03611114|DIETARY_SUPPLEMENT|Control drink|
224220764|NCT02758002|PROCEDURE|Firm ablation for transitional AF rotors|Transitional AF rotors will be mapped and ablated as part of this study. All subjects will undergo this ablation after standard PVI and Firm ablation for sustained rotors.
223632219|NCT00781768|DRUG|Aprepitant (MK-869) + Standard PO|Dexamethasone 7.5 mg (dose blinded) in 50 ml D5W IVPB over 15 min daily + ondansetron 8mg PO q 8 hours - repeated QD of the preparative regimen and for 1 day after completion. Aprepitant 125mg PO \[blinded\] will be given a minimum of 30 minutes prior to the preparative regimen on day 1. MK-Aprepitant 80mg PO \[blinded\] will be given will be given approximately 24 hours later starting on day 2 then each day of the preparative regimen plus 3 days after. Antiemetic therapy will start a minimum of 30 minutes prior to and continued for 24 hours after completion of the preparative regimen.
223632220|NCT01395797|DRUG|PIO|0, 15, and 45 mg per day.
223632221|NCT01395797|DRUG|Placebo|Placebo
223764304|NCT06997445|OTHER|Aerobic Exercise|"Participants in this group will only be provided aerobic exercise for 4 weeks supervised by physiotherapist.~Aerobic Exercise include the following:~* Warm up exercises for 5 minutes.~* Brisk walking on treadmill for 25 minutes which include warm up period for 10 minutes then 14 minutes brisk walk and cool down period included 1 minute walk.~* Stepper for 5 minutes.~* Static cycling for 5 minutes.~* Cool down for 5 minutes.~Week 03 and Week 04:~Frequency: 5 days per week Intensity: 60-80% Target heart rate Time: 45 minutes~Week 01 and Week 02:~Frequency: 5 days per week Intensity: 50-60 % Target heart rate Time: 45 minutes"
223764305|NCT06434649|PROCEDURE|Extrafascial robotic assisted radical prostatectomy via posterior approach|Extrafascial robotic assisted radical prostatectomy via posterior approach will be applied in the intermediate or high risk patients.
224220765|NCT05686733|DEVICE|SEAL Device|Endovascular treatment of target aneurysm using the Saccular Endovascular Aneurysm Lattice (SEAL) device.
224220766|NCT05171803|OTHER|No intervention|No intervention, prospective, cohort study.
224220767|NCT04466449|DIAGNOSTIC_TEST|stool sample|A stool sample will be collected from each patient for diagnosis of Entamoeba
224220768|NCT06370299|OTHER|(exposure of) MDR carriage|The difference in exposure between the two groups is the carriage or non-carriage of multidrug resistant gram negative bacilli.
224220769|NCT01215123|DRUG|Bevacizumab|Participants received bevacizumab according to routine clinical practice until disease progression, unacceptable toxicity or withdrawal, along with taxane-based chemotherapy or in combination with other chemotherapy as prescribed.
224220770|NCT02457624|BEHAVIORAL|Education and feedback|Experienced endoscopists will receive education on Kimura-Takemoto classification and feedback for their answers for classification tests.
224220771|NCT01833949|PROCEDURE|Unilateral laparoscopic drilling|Unilateral laparoscopic drilling with diathermy adjusted to ovarian volume
224220772|NCT01833949|PROCEDURE|Bilateral laparoscopic drilling|Bilateral laparoscopic drilling with fixed doses energy
224220773|NCT03634670|OTHER|Interdisciplinary multimodal pain therapy (IMPT)|The IMPT-program is provided in a specialized day-clinic setting over a period of 20 treatment days. There are two different treatment programs with either 5 days per week over a period of 4 weeks or 3 days per week over a period of 7 weeks. IMPT comprises individual pharmacotherapy evaluated in regular consultations with a physician as well as a structured physiotherapy and psychotherapy programs on group level and individual level. Group physiotherapy comprises exercise therapy, movement experience and relaxation techniques. Additionally individual physiotherapy is provided in two extra sessions focusing on the individual needs and problems of the patient. Group psychotherapy comprises educational contents (e.g. pathophysiology and biopsychosocial aspects of pain) as well as cognitive-behavioral-interventions e.g. regarding stress-management. Additionally individual psychotherapy is provided in four extra sessions focusing on the individual needs and problems of the patient.
224220774|NCT00947011|DRUG|Placebo|1 tablet 100 mg once a day
224220775|NCT00947011|DRUG|Januvia|1 tablet 100 mg once a day
224220776|NCT02166242|DRUG|ethaselen|ethaselen is a specific thioredoxin reductase inhibitor, which has finished phase 1a study in China, phase 1 study of ethaselen showed that 600 mg ethaselen bid could be well tolerated
224220777|NCT01527539|DRUG|biphasic insulin aspart 30|Dose individually adjusted. Injected twice daily immediately before breakfast and dinner. Administrated subcutaneously (s.c., under the skin)
224220778|NCT00022425|DRUG|perillyl alcohol|
223632222|NCT04567628|OTHER|No Intervention|As this was an observational study, no intervention was administered.
223632223|NCT02025686|DRUG|Hyperbaric Oxygen|Subjects will breathe oxygen (FIO2 = 1.0) at 2.4 ATA in a hyperbaric chamber after the tonic heat stimulations. The duration of oxygen exposure is 90 min.
223632224|NCT02025686|OTHER|Normal ambient conditions|Normal ambient conditions (1 ATA, FIO2 = 0.21)
224220779|NCT02922114|OTHER|Ultrasonography|B-mode and power Doppler ultrasonography examination.Ultrasonography assessments includes wrists, metacarpophalangeal, proximal interphalangeal, elbows, shoulders, knees, ankles, metatarsophalangeal and twenty six tendons (wrist extensors, finger flectors and tendons of the ankles).
224220780|NCT04013256|OTHER|Cigarette Smoke|Cigarette smoke, generated by a smoking machine and aged is used to reproduce exposure to secondhand and thirdhand cigarette smoke.
224220781|NCT04013256|OTHER|Clean Air and Clean Clothing/Sham exposure|"Clean air, created by high-efficiency particulate air (HEPA) and charcoal filtration and temperature and humidity control.~Clean cotton clothing."
224220782|NCT03090009|DRUG|Flurbiprofen|100 mg twice a day for 14 days
224220783|NCT03090009|DRUG|Placebo Oral Tablet|placebo group
224220784|NCT01993420|DRUG|DRM02|
224220785|NCT01993420|OTHER|Vehicle|
224220786|NCT05806359|DRUG|Danicamtiv|Specified dose on specified days
223632225|NCT05882591|PROCEDURE|Posteromedial Tibiofemoral Incongruence (PMTFI) Treatment by the means of published technique (reference nr 1).|Posteromedial Tibiofemoral Incongruence (PMTFI) Treatment by the means of published technique (reference nr 1).
223632226|NCT00079417|DRUG|Carboplatin|Given IV
223632227|NCT00079417|PROCEDURE|Cryosurgery|
224220787|NCT05806359|DRUG|Placebo|Specified dose on specified days
224220788|NCT01939600|OTHER|Starch-free breakfast|Starch-free breakfast alone
224220789|NCT01939600|OTHER|Hi-Maize 260|Starch-free breakfast plus 55.3g Hi-Maize 260
223632228|NCT00079417|PROCEDURE|Infrared Laser Therapy|
223632229|NCT00079417|RADIATION|Iodine I-125|Undergo radioactive therapy
223632230|NCT00079417|RADIATION|Radiation Therapy|Undergo radioactive therapy
223632231|NCT00079417|RADIATION|Ruthenium Ru-106|Undergo radioactive therapy
223632232|NCT00079417|DRUG|Vincristine Sulfate|Given IV
223632233|NCT00896896|OTHER|immunologic technique|Sera from head and neck cancer or colorectal cancer patients who were treated with cetuximab will be obtained from Tumor Tissue Repository
223632234|NCT00896896|OTHER|laboratory biomarker analysis|Sera from head and neck cancer or colorectal cancer patients who were treated with cetuximab will be obtained from Tumor Tissue Repository
223632235|NCT04004741|PROCEDURE|Osteopathic Manipulative Treatment|"The purpose of this research is to investigate the effect of osteopathic manipulative treatment (OMT) focused on somatic dysfunctions commonly associated with arrhythmias on the amount of quantifiable arrhythmias as recorded on a diagnostic device.~It is known that OMT has a stabilizing effect on the autonomic nervous system, which plays a key role in regulating heart rate and blood pressure. This increases parasympathetic tone and decreases sympathetic tone, which generally stabilizes the heart with an antiarrhythmic effect.~Previous work has been done showing that osteopathic treatment is a beneficial adjunctive therapy for paroxysmal atrial fibrillation and decreased symptoms, though has not been proven to be helpful for patients with heart failure.~While the effect of OMT on the neurology has been studied, we would like to further research the effect OMT specifically has on arrhythmias using more quantifiable data from implanted devices."
223632236|NCT04004741|PROCEDURE|Light Touch Therapy|The physician will contact various areas of the body for 120 seconds each to expose the subject to a similar environment as the interventional group, without stimulating the autonomic nervous system.
223632237|NCT02027155|DRUG|AR09 solution|moderate levels of sedation
223632238|NCT02027155|DRUG|placebo|Sterile Saline, USP
223632239|NCT02458313|DRUG|DMXB-A|150 mg DMXB-A (3-(2,4-dimethoxybenzylidene anabaseine) b.i.d. for 12 weeks.
223632240|NCT02458313|OTHER|Placebo|Placebo capsules b.i.d. for 12 weeks
223632241|NCT05684237|PROCEDURE|HiSMILE treatment option|The non-CE labeled VisuMax treatment option HiSMILE is able to modify the lenticule shape in a way that should lead to a change in spherical aberration postoperatively.
223632242|NCT04017052|DRUG|FSME-IMMUN Vaccine|Booster with TBE vaccine (i.m.) FSME Immun
224220790|NCT01939600|OTHER|Hylon VII|Starch-free breakfast plus 56.9g Hylon VII
224220791|NCT01939600|OTHER|Amioca|Starch-free breakfast plus 56.4g amioca starch
224220792|NCT00814658|DRUG|Galantamine|Galantamine 8 mg/day for one month, followed by 4 weeks of galantamine 16 mg/day. If necessary and well tolerated, dosage of galantamine will be increased to 24 mg/day.
224220793|NCT00814658|DRUG|Nimodipine|Nimodipine 30 mg 3 times a day (tid).
224220794|NCT00814658|DRUG|Placebo|Matching placebo three times a day (tid).
224220795|NCT01741857|BIOLOGICAL|human umbilical cord derived MSC transplantation for SLE|
224220796|NCT05266456|BIOLOGICAL|24 valent pneumococcal conjugate vaccine|0.5 ml dose of VAX-24 will be administered into the deltoid muscle at Day 1
224220797|NCT05266456|BIOLOGICAL|20 valent pneumococcal conjugate vaccine|0.5 ml dose of PCV20 will be administered into the deltoid muscle at Day 1
223632243|NCT04174417|PROCEDURE|systolic blood pressure (SBP)|"Systolic blood pressure (SBP) 80-90 mmHg remifentanil infusion was applied to Group 1 patients. In addition to remifentanil infusion, 0.002 μg.kg of glycerol trinitrate (Perlinganit) was administered as an intermittent bolus in patients who needed to achieve target blood pressure. All patients received 5-8 ml / kg / h IV infusion of balanced electrolyte solution (Isolyte-S) during the operation.~Hemodynamic parameters (HR, SBP, OCD), BIS, SpO2 and NIRS were recorded at 5 minute intervals. At the end of the operation, 3 ml of blood was taken from the untreated arm of all patients to the HIF1a, TAS and TOS values and sent to the biochemistry laboratory"
223632244|NCT04174417|PROCEDURE|mean blood pressure (MBP)|"For group 2, remifentanil infusion was performed with a mean blood pressure (OCD) of 50-65 mmHg. In addition to remifentanil infusion, 0.002 μg.kg of glycerol trinitrate (Perlinganit) was administered as an intermittent bolus in patients who needed to achieve target blood pressure. All patients received 5-8 ml / kg / h IV infusion of balanced electrolyte solution (Isolyte-S) during the operation.~Hemodynamic parameters (HR, SBP, OCD), BIS, SpO2 and NIRS were recorded at 5 minute intervals. At the end of the operation, 3 ml of blood was taken from the untreated arm of all patients to the HIF1a, TAS and TOS values and sent to the biochemistry laboratory."
223764306|NCT06434649|PROCEDURE|Extrafascial robotic assisted radical prostatectomy via anterior approach|Extrafascial robotic assisted radical prostatectomy via anterior approach will be applied in the intermediate or high risk patients.
223764307|NCT06672523|DRUG|BMS-986504|Specified dose on specified days
223764308|NCT06672523|DRUG|[14C]-BMS-986504|Specified dose on specified days
224220798|NCT03356587|DRUG|Abemaciclib|Patients will be instructed to take Abemaciclib orally at a dose of 200mg bid with a glass of water twice daily, in a fasting state or with a light fat-free meal, and as close as possible to the same time each day
224220799|NCT01141283|DRUG|Buprenorphine transdermal patch|Buprenorphine transdermal patch 5 mcg/h applied for 7-day wear
224220800|NCT01141283|DRUG|Buprenorphine transdermal patch|Buprenorphine transdermal patch 10 mcg/h applied for 7-day wear
224220801|NCT01141283|DRUG|Buprenorphine transdermal patch|Buprenorphine transdermal patch 20 mcg/h applied for 7-day wear
224220802|NCT01720628|OTHER|serum levels of angiogenin, bFGF, VEGF|Behçet's patients
224220803|NCT05252806|DIAGNOSTIC_TEST|MRI examination of the prostate|Participants will undergo one MRI examination of approximately 45 minutes including an intramuscular injection with an antispasmodic agent to minimize bowel movement
224220804|NCT01787474|DRUG|Cytarabine|Given IV
224220805|NCT01787474|BIOLOGICAL|Filgrastim|Given SC
223632245|NCT00904969|DEVICE|The AMS Male Transobturator Sling System|The AMS Male Transobturator Sling System was developed to treat urinary stress incontinence in men resulting from intrinsic sphincter deficiency (ISD) secondary to radical prostatectomy. The Male Transobturator Sling System procedure is minimally invasive and consists of using two single-use needle passers and passing them through two small incisions over the obturator foramen. The needles are pushed in an arc through the tissue and exited at a perineal incision. Once the passers are through the perineal incision, the Sling System mesh arms are attached to the needles which are then pulled back through the needle track to their points of origin over the obturator foramen. The Sling System is subsequently tensioned and all incisions are closed.
223632246|NCT00904969|DEVICE|AdVance Male Sling|A transobturator sling for the treatment of post-prostatectomy incontinence
223632247|NCT03502928|OTHER|Motor Control|Neck Motor Control
223632248|NCT03502928|OTHER|Manual Therapy|Massage + Joint Mobilizations
223632249|NCT03502928|OTHER|Dry Needling|Dry Needling in Neck Muscles
223632250|NCT04267354|OTHER|Arm cycling|The arm cycle will be placed on table with height adjusted to be the same as the acromion (highest point on shoulder). Participants will start arm cycling at a low intensity and increase as per tolerance. They will exercise for a maximum of two minutes at a time, followed by a rest period for 30 seconds. In this manner 5 cycles of exercise and rest will be performed. The exercise sessions are anticipated to last a maximum of 20 minutes, depending on the patient's abilities.
223632251|NCT02947321|PROCEDURE|Genicular Nerve RFA|Under fluoroscopic guidance, the target locations based on boney landmarks of the superior lateral (SL), superior medial (SM), and inferior medial (IL) branches of the genicular nerve will be determined. RFA probes will be placed and connected to the RFA generator and the generator is activated. The RFA is performed.
223632252|NCT02947321|PROCEDURE|Sham Genicular Nerve RFA|Under fluoroscopic guidance, the target locations based on boney landmarks of the superior lateral (SL), superior medial (SM), and inferior medial (IL) branches of the genicular nerve will be determined. The RFA probes for the control group will not be connected to the RFA generator (no neurotomy); however, the generator will still be activated to mimic the RFA group.
224220806|NCT01787474|BIOLOGICAL|Filgrastim-sndz|Given SC
224220807|NCT01787474|DRUG|Fludarabine Phosphate|Given IV
224220808|NCT01787474|OTHER|Laboratory Biomarker Analysis|Correlative studies
224220809|NCT01787474|BIOLOGICAL|Membrane-bound Interleukin-21-Expanded Haploidentical Natural Killer Cells|Given IV
224220810|NCT00831727|BEHAVIORAL|Expressive Writing|Participants will write about their experienced trauma for 20 minutes on each of three consecutive days using techniques associated with expressive writing
224220811|NCT00831727|BEHAVIORAL|Control|Participants will write as factually as possible about an assigned trivial topic for 20 minutes on each of three consecutive days
224220812|NCT06007573|DRUG|The control group received oral nimodipine tablets|The control group received oral nimodipine tablets
224220813|NCT04829409|PROCEDURE|Paravertebral block|Patients receive ultrasound-guided paravertebral block
224220814|NCT04829409|PROCEDURE|ESP block|Patients receive ultrasound-guided erector spinae plane (ESP) block
223632253|NCT01843829|DRUG|Oxaliplatin|
223632254|NCT01843829|DRUG|Capecitabine|
223632255|NCT01843829|DRUG|Carboplatin|
223632256|NCT01843829|DRUG|Paclitaxel|
224220815|NCT04829409|PROCEDURE|MTP block|Patients receive ultrasound-guided mid-point transverse process to pleura (MTP) block
224220816|NCT05272098|OTHER|Group A will receive myofascial release therapy + conventional physical therapy|myofascial release therapy (4 sessions per week). It soft, deep and non-manipulative form of treatment that involves the application of gentle pressure while stretching the body's connective tissue. A specialized form of touch, somatic sense, and specific body movement protocols are the three steps involved in the myofascial release therapy + hot pack (15min) + back care advice and postural modification. A total of 45 min session four times a week.
224220817|NCT05272098|OTHER|Group B will receive endurance training of the trunk extensor muscles + conventional physical therapy|It will be treated with endurance training of trunk extensor muscles. Erector spinae and latissimus dorsi will be included. The exercise protocol will be in four levels Bilateral shoulder left in prone position+ contralateral arm and leg lift in prone position+ both hands behind head and bilateral shoulder lift +bilateral shoulder lift with arm fully elevated + Hot pack (10 min) + back care advice and postural modification. A total of 45 min sessions four times a week.
224220818|NCT02436395|PROCEDURE|Group A (povidone-iodine wash the surgical incision)|Gastric cancer patients underwent conventional open D2 total or subtotal gastrectomy and with povidone-iodine wash the surgical incision
224220819|NCT02436395|PROCEDURE|Group B (normal saline wash the surgical incision)|Gastric cancer patients underwent conventional open D2 total or subtotal gastrectomy and with normal saline wash the surgical incision
224220820|NCT00253097|BEHAVIORAL|Intervention|Patients allocated to the intervention group have 4 visits by a study nurse. She will measure patient's blood pressure (BP) by standardized meathods, inform the patient about the target BP, stress the importance of lowering the BP and in case of elevated BP she advices the patient to go the the GP for further control. She advises about smoking cessation, reduction of alcohol consumption, loss of excess body weigt and stresses the importance of physical activity as appropriate
224220821|NCT03084978|PROCEDURE|General Anesthesia|General anesthesia by standard endotracheal intubation.
224220822|NCT03084978|PROCEDURE|Conscious Sedation|Conscious sedation
223632257|NCT01843829|RADIATION|Radiotherapy|
223764309|NCT06868277|BIOLOGICAL|Rilvegostomig|Administered intravenously (IV) on Day 1 of each 21-day cycle
224220823|NCT02451969|BIOLOGICAL|investigational 23-valent PPV|The investigational vaccine was manufactured by Sinovac Biotech Co., Ltd.
224220824|NCT02451969|BIOLOGICAL|control 23-valent PPV|The control vaccine was manufactured by Chengdu Institute of Biological products Co., Ltd.
224220825|NCT04745325|BEHAVIORAL|SMAART Canada smartphone app|a smartphone app designed to promote reductions in alcohol consumption among people who drink in a hazardous fashion
224220826|NCT04007588|DRUG|Nivolumab|Nivolumab is a types of immunotherapy. Immunotherapy works by encouraging the body's own immune system to attack the cancer cells. Nivolumab work by stopping various molecules on cancer cells and body cells from working against the immune system's natural fight against cancer
223632258|NCT01843829|PROCEDURE|Surgery|Patients will have their tumour surgically removed by two-phase oesophagectomy and two-field lymphadenectomy.
223632259|NCT04396756|DRUG|PLN-74809|PLN-74809
223632260|NCT04396756|DRUG|Placebo|Placebo
223632261|NCT02405078|DRUG|Chemotherapy|Given standard salvage chemotherapy
223632262|NCT02405078|PROCEDURE|Computed Tomography|Undergo FDG-PET/CT scan
223632263|NCT02405078|DRUG|Fludeoxyglucose F-18|Undergo FDG-PET/CT scan
223632264|NCT02405078|PROCEDURE|Positron Emission Tomography|Undergo FDG-PET/CT scan
223632265|NCT04363008|DIAGNOSTIC_TEST|serum inflammatory biomarkers|Serum biomarkers measured (IL-1 beta, IL-2, IL-6, IL-10, TNF alpha)
223632266|NCT00199381|DRUG|Istradefylline|Oral istradefylline (KW-6002) 20 or 40 mg once daily.
223632267|NCT03828825|OTHER|Patent Foramen Ovale closure|"The Patent Foramen Ovale closure is realized under trans-thoracic echocardiography control. If necessary, the operator will use trans-esophageal echocardiography to implant the prosthesis. One day after the procedure, a clinical assessment and an electrocardiogram are performed. At 3 months the consultation corresponds to a trans-thoracic echocardiography validation of the closure accompanied by a bubble test (Valsalva maneuver) and a clinical assessment. At 12 months, the visit corresponds to a consultation with a clinical assessment and an electrocardiogram. At 36-months and 60-months, the visits will be done following the on-site visits provided for in the usual care or during a telephone call from the attending cardiologist to retrieve the results of the clinical examination, electrocardiogram and MACCE (major cardiac and cerebral vascular events). A consultation dedicated to the study may be proposed to patients according to what is provided in the usual care."
223632268|NCT00485979|DRUG|larotaxel (XRP9881)|intravenous administration
223632269|NCT00485979|DRUG|docetaxel|intravenous administration
223632270|NCT00485979|DRUG|trastuzumab|intravenous administration
223632271|NCT03074136|DEVICE|Photodinamic therapy|Dentin sealant (HELBO® Endo Seal, Bredent, Senden, Germany) will be applied over the crown area and light cured. The root canals will be filled with the phenothiazine chloride (HELBO® Endo Blue, Bredent, Senden, Germany), agitated with a size 15K-file and left in the canal for 2 min. After this time, the root canals will be rinsed with distilled water to remove the excess of the photosensitizer, dried with paper points. The disposable 450 µm fiberoptic tip (3D HELBO® Endo Probe, Bredent, Senden, Germany) will be placed in the apical portion of the root canal at the point where resistance to the fiber will be felt, and root canal will be irradiated with HELBO® TheraLite Laser (λ = 660 nm, power = 100 mW) for 60 s (total energy, 6 J) in a continuous wave mode.
223632272|NCT03074136|DEVICE|Diode laser|High-power diode laser therapy will be applied by using Epic diode laser (Biolase® Technology, Inc., San Clemente, CA, USA) with settings determined in laboratory researches (λ = 940 nm, maximal power 10W).
223632273|NCT03074136|DRUG|0.5% Sodium hypochlorite|Chemomechanical preparation will be completed by hand instruments, with minimal instrumentation, and usage of sodium hypochlorite with minimal bactericidal concentration (0.5%, pH 12), on room temperature (21 degrees Celsius).
223632274|NCT00603408|DRUG|Cisplatin|
223632275|NCT00603408|RADIATION|Radiation Therapy|
224220827|NCT04007588|DRUG|BMS-986205|BMS-986205 is a types of immunotherapy. Immunotherapy works by encouraging the body's own immune system to attack the cancer cells. BMS-986205 work by stopping various molecules on cancer cells and body cells from working against the immune system's natural fight against cancer
223632276|NCT00603408|PROCEDURE|Mastectomy|(RECOMMENDED BUT NOT REQUIRED)
223632277|NCT05949736|DEVICE|The Online intervention platform|Music Therapy (MT) is known to have a calming effect on individuals by using relaxing and soothing music, gradually inducing a state of relaxation. Moreover, it can effectively regulate individual psychological emotions through its influence on specific brain regions such as the cerebral cortex, hypothalamus, and limbic system. This regulation of emotional responses can lead to an improvement in daily mood, reducing feelings of tension and anxiety.
223632278|NCT03520829|DEVICE|Intuitive Plan|dosimetric planning software
223632279|NCT00385671|DRUG|duloxetine hydrochloride|Duloxetine (DLX) once daily (QD), orally (PO)
223632280|NCT00385671|DRUG|pregabalin|Pregabalin (PGB) orally (PO)
223632281|NCT00385671|DRUG|gabapentin|Stable Gabapentin (GAB) (participants will remain on the same dose of gabapentin at which they entered the study)
223764310|NCT06868277|BIOLOGICAL|Pembrolizumab|Administered intravenously (IV) on Day 1 of each 21-day cycle
224220828|NCT04007588|DRUG|Ipilimumab|Ipilimumab is a types of immunotherapy. Immunotherapy works by encouraging the body's own immune system to attack the cancer cells. Ipilimumab work by stopping various molecules on cancer cells and body cells from working against the immune system's natural fight against cancer
223632282|NCT06403397|OTHER|Experimental group: CEASE Care Package and Remember Me Tool|"Before the intervention, the intervention group will first undergo the 'Nurse Identification Form' and the 'Alarm Fatigue Scale'. The current root cause analysis of monitor alarms in the clinical setting will be conducted through the 'CEASE Care Package' and the 'Current Situation Analysis Form'. Each patient monitor in the intensive care unit will be observed and recorded by two observers for a period of 24 hours.The Monitor Alarm Control Tool - Remember Me will be attached beneath each monitor to facilitate easier monitoring by nurses. Nurses are expected to use the tool for a period of 15 days. After intervention; Two observers will conduct a re-evaluation using the CEASE Care Package and the Current Status Analysis Form. Monitor alarms will be continuously assessed and recorded for 24 hours. Following the completion of this stage, the Alarm Fatigue Scale will be reapplied to the intervention group."
223764311|NCT03377712|DEVICE|optoelectronic plethysmography|Evaluates the thoracoabdominal kinematics and the ventilatory pattern of the patient through the filming with cameras, simple and non-invasive examinations
224318079|NCT00732576|DIETARY_SUPPLEMENT|krill oil|9 krill oil capsules, equivalent to 1,5 gram per day of n-3 polyunsaturated fatty acids (PUFA) during 12 weeks
224318080|NCT01203020|DRUG|Busulfan|Busulfex 130 mg/m2 intravenous piggy back (IVPB) for 4 days (Day -6 to -3) pharmacokinetic (PK) samples for Busulfex dose adjustment drawn on Day -6
224318081|NCT01203020|DRUG|Fludarabine|Fludarabine 40 mg/m2 IVPB for 4 days (Day -6 to -3)
223764312|NCT03377712|DEVICE|diaphragmatic ultrasound|Evaluates the diaphragmatic mobility through images, simple and non-invasive use
223764313|NCT03377712|DEVICE|Postural evaluation|Evaluates the patient's posture through photos and filming, rapid examination, simple and non-invasive
223764314|NCT03377712|DEVICE|Pain evaluation|by means of questionnaires
223632283|NCT00698763|DRUG|Levosimendan|from 0.125 mg to 2 mg in escalating doses
223632284|NCT00698763|DRUG|Placebo|Placebo capsules are identical in appearance to active capsules
224220829|NCT05097378|DRUG|Encorafenib + Binimetinib|"Encorafenib is a potent and highly selective ATP-competitive small molecule RAF kinase inhibitor, which suppresses the RAF/MEK/ERK pathway in tumour cells expressing several mutated forms of BRAF kinase (V600E, D and K).~Binimetinib is an ATP-uncompetitive, reversible inhibitor of the kinase activity of mitogen-activated extracellular signal regulated kinase 1 (MEK1) and MEK2. Binimetinib inhibits activation of MEK by BRAF and inhibits MEK kinase activity"
224220830|NCT05097378|DRUG|Standard Adjuvant Treatment|Standard Adjuvant Treatment
224220831|NCT01019005|DEVICE|Catheter|Catheter inserted into either perineural tibial nerve or wound
224220832|NCT02825472|BEHAVIORAL|exercise training|3 times per week 30 minutes of exercise training in the target heart rate zone
224220833|NCT04280393|DEVICE|Colonoscopy procedure with endocuff|Colonoscopy procedure with the use of ENDOCUFF VISION
224220834|NCT01316588|OTHER|Plastic adesive drape|Plastic adhesive drape intraoperatively on patients skin around the surgical wound on the chest and bare skin on the leg
224220835|NCT01316588|OTHER|Microbial Sealant|Microbial sealant intraoperatively on patients skin around the surgical wound on the leg and bare skin on the chest
224220836|NCT01068873|DRUG|lopinavir/ritonavir plus maraviroc|Lopinavir/ritonavir 400 mg/100 mg two tablets twice daily with Maraviroc 150 mg one tablet twice daily will be administered for 48 weeks to participants meeting entry criteria.
224220837|NCT00141531|DRUG|Apaziquone|"Apaziquone (EOquinTM) 4 mg/40 mL was administered by intravesical instillation once a week for 6 consecutive weeks.~In addition, patients with CIS were to receive further maintenance therapy of 3 weekly apaziquone (EOquinTM) instillations at 3, 6, and 12 months from the date of histological diagnosis."
224220838|NCT06243081|OTHER|intervention group (Flipped Teaching Method Group)|"Students will be given skill training with the Flipped Teaching method, which consists of outside and in-class applications.~Out-of-Class Practice: A Learning Management System-Web-Based Distance Education System will be created for the Flipped Teaching method. Theoretical course topics and skill training videos will be uploaded to the system 7 days before the course day. Students will be able to watch the video tutorials in the number and frequency they want until the day of the lesson. At the end of the lesson, the mini-exam will be uploaded to the system.~In-class practice: The researcher will come to the lesson prepared for classroom activities such as question and answer. Theoretical lectures and skill demonstrations will not be made by the researcher. The researcher will only guide the students. Then, the students will be provided to perform the skill under the guidance of the researcher in the clinical skills laboratory."
224220839|NCT04811222|DIAGNOSTIC_TEST|Ga-DOTATATE PETMRI scan|Patients with AAA with minimum 2 years surveillance will have one time Ga-DOTATATE PETMRI scan
224220840|NCT04069104|BEHAVIORAL|ABCD Information|The intervention condition includes exposure to a message emphasizing the ABCD strategy to identify malignant melanoma.
224318082|NCT05393843|DIETARY_SUPPLEMENT|omega-3 fatty acids, anthocyanins and alpha-cyclodextrins|administration for 12 weeks
224318083|NCT05393843|BEHAVIORAL|diet|12 weeks of personalized diet according to the Mediterranean standard diet referrals, the Healthy Eating Plate recommendations of Harvard University School of Public Health, and the reference intake levels of nutrients and energy for the Italian population (LARN) for pregnant women
223632285|NCT04785313|BIOLOGICAL|Retrievable Inferior Vena Cava Filters (IVCF)|Analysis anatomopathology of Retrievable Inferior Vena Cava Filters (IVCF) (ALN CF model).
223764315|NCT03377712|DEVICE|Evaluation of the function|through questionnaires
224220841|NCT04069104|BEHAVIORAL|UDS information|The intervention condition includes exposure to a message emphasizing the UDS strategy to identify malignant melanoma.
224220842|NCT04069104|BEHAVIORAL|Standard (clinical) feedback|Feedback on mole identification task provided by a dermatologist.
224220843|NCT04069104|BEHAVIORAL|Motivational feedback|Feedback on mole identification task provided by a dermatologist plus exposure to a motivational fear appeal message designed to increase skin self exam intentions.
224220844|NCT01436669|DEVICE|Home Telemonitoring System (The Zodiac, Philips Health care)|Full blood count (FBC) home tele-monitoring system which will allow cancer patients receiving chemotherapy to test their blood count at home (haemoglobin, haematocrit, white cell count and neutrophil count).
224220845|NCT00807625|DRUG|Depo Provera|Depo Provera administered by injection at randomization visit and the 12-week study visit.
224318084|NCT05393843|OTHER|placebo|sunflower oil as placebo for Omega3 fatty acids; isomaltulosio as placebo for Anthocyanins and Alpha-cyclodextrins; administration for 12 weeks
223632286|NCT04785313|OTHER|Demographics data collection|Demographics data : age, gender, thromboembolic risk factors, Retrievable Inferior Vena Cava Filters (IVCF) (indication, dates of insertion and removal), and anticoagulant management during the period with filter.
223632287|NCT03763084|DRUG|Acetaminophen|For patients in the acetaminophen group, oral acetaminophen supplemented dexmedetomidine sedation will be provided after surgery.
223632288|NCT03763084|DRUG|Sufentanil|For patients in the control group, sufentanil supplemented dexmedetomidine sedation will be provided after surgery.
223632289|NCT00087841|BEHAVIORAL|Self-hypnotic relaxation|
223632290|NCT04602663|DEVICE|Esophageal Variceal Band ligation|Band ligation of OV
224318085|NCT02368951|DRUG|BAY1187982|A dose of 0.1 mg BAY 1187982 per kilogram (kg) body weight (BW) was chosen as the starting dose based on toxicology data. The investigational drug will be administered as a 1-hour IV infusion once every 21 days at the trial site (Day 1 of each 21-day Cycle). The maximum possible dose escalation will be 2-fold and not more than 0.5 mg/kg BW until maximum tolerated dose is selected
224318086|NCT02976987|DRUG|Cidofovir|
224318087|NCT00929279|DRUG|bolus+infusion|Abciximab bolus of 0.25mg /Kg, followed by a 12-h infusion 0.125 microg/Kg/min (to a maximum of 10 µg/min) and immediate clopidogrel at 300 mg loading regimen
224318088|NCT00929279|DRUG|abciximab bolus only regimen|Abciximab bolus of 0.25mg /Kg followed by placebo infusion and immediate clopidogrel at 600 mg loading dose
224318089|NCT02317289|DEVICE|Detection of freezing|single wireless inertial sensor placed on the patients's lower limbs to detect freezing of gaitin Parkinsonian patients
224318090|NCT02445976|DRUG|Seviteronel: given orally once daily in 28-day cycles|Oral Seviteronel given once daily, in continuous 28-day cycles at the recommended Phase 2 dose
223632291|NCT02928887|OTHER|Blue light|Exposure to high illuminance (1000 lux), blue spectrum (480 nm) light for a 24-hour photoperiod immediately before surgery and a 24-hour photoperiod immediately after surgery
223632292|NCT00303069|BIOLOGICAL|V710|Single dose of V710 (at dosages of 5 μg, 30 μg, or 90 μg) intramuscularly
223632293|NCT00303069|BIOLOGICAL|Comparator: Placebo|Single dose of saline placebo intramuscularly
224220846|NCT00807625|DEVICE|Copper T Intrauterine contraception device|IUCD inserted upon randomization to this study arm
224220847|NCT00879424|DIETARY_SUPPLEMENT|cholecalciferol (vitamin D)|"1000 IU once daily x 1 month~Experimental group will receive Ddrops (Toronto, Canada). Placebo group will receive placebo drops."
224220848|NCT00879424|DIETARY_SUPPLEMENT|Placebo|"1000 IU once daily x 1 month~Experimental group will receive Ddrops (Toronto, Canada). Placebo group will receive placebo drops."
224220849|NCT03472833|DRUG|High-dose|Patients will receive a high dose - 180.000 I.U. (1 drop equals 400 I.U.) of Vitamin D3 orally on day 1, and then 4000 I.U. for 60 days
224220850|NCT03472833|DRUG|Standard dose|Patients will receive a standard dose - 800 I.U. (equals 2 drops) of Vitamin D3 orally for 60 days
224220851|NCT00003985|DRUG|KRN7000|
224220852|NCT00059514|BEHAVIORAL|Modified Project Toward No Tobacco Use|
224220853|NCT02868281|DRUG|ACT guided Routine Treatment|The ACT is a validated, short, easy to use, and self-administered instrument used to assess asthma control. Subjects in this group received routine treatment as per ACT score.
224220854|NCT02868281|DRUG|Routine Treatment|Subjects in the controlled treatment group will receive usual care of asthma. This treatment was monitored and adjusted as usual by the patient's general practitioner.
224318091|NCT00798876|DIETARY_SUPPLEMENT|Fish Oil|Subjects will be asked to take 10 grams of fish oil per day for 4 weeks.
223632294|NCT01632696|DRUG|I-124 PGN650 for PET/CT|I-124 PGN650 for PET/CT Day 1, Day 2 and 3.
223632295|NCT01183806|DRUG|Rivastigmine|All patients start on a 5-cm2 rivastigmine transdermal patch and their dose is progressively increased
224220855|NCT01313000|PROCEDURE|Autologous fat transfer|Autologous fat transfer from abdomen to upper arms
224220856|NCT01462500|DRUG|Miltefosine|Children (2-12 years of age) and adults (18-60 years of age) will receive Miltefosine PO at a dose of 1.8-2.5 mg/kg/day for 28 days.
224220857|NCT03545529|OTHER|Innovativ supported|addition of connected tools and stronger accompaniment to prevent falls
224220858|NCT01722266|DRUG|Liraglutide|"Patients randomized to 1.2 mg of liraglutide : They will start liraglutide 0.6 mg sc once daily for one week and will increase the dose to 1.2 mg sc once daily thereafter.~Patients randomized to 1.8 mg of liraglutide: They will start liraglutide 0.6 mg sc once daily for one week; will increase to 1.2 mg sc once daily for second week and will stay on 1.8 mg of liraglutide from third week onwards."
224220859|NCT01722266|DRUG|Placebo|"Patients randomized to 1.2 mg of placebo: They will start placebo 0.6 mg sc once daily for one week and then increase to 1.2 mg once daily thereafter.~Patients randomized to 1.8 mg of placebo: They will start placebo 0.6 mg sc once daily for one week; increase to 1.2 mg sc once daily for second week and then to 1.8 mg sc once daily from third week onwards."
224220860|NCT05472285|DIETARY_SUPPLEMENT|Verum|After randomization (visit V1), subjects will consume orally 2 capsules per day, during the breakfast, for 8 weeks (from visit V1 to visit V3).
224220861|NCT05472285|DIETARY_SUPPLEMENT|Placebo|After randomization (visit V1), subjects will consume orally 2 capsules per day, during the breakfast, for 8 weeks (from visit V1 to visit V3).
224220862|NCT00047489|DRUG|ABT-751|
224220863|NCT03582293|DRUG|Tranexamic Acid 500Mg Tablet|orally twice daily for 28 days
224220864|NCT03582293|DRUG|Placebo oral capsule|Oral placebo capsule two times a day for a total of 28 days
224220865|NCT02501109|DRUG|Aripiprazole|Healthy volunteers will receive Aripiprazole Oral Soluble Fim(OSF) 10mg orally a single of dose within 28 days
224220866|NCT00055874|BIOLOGICAL|recombinant interferon alfa|
223632296|NCT01183806|OTHER|Exercise training program|Exercise training program
223632297|NCT00751296|DRUG|Lenalidomide|Subjects will receive lenalidomide, starting at 2.5 mg daily x 3 weeks (days 1-21) and escalating up to a target dose of 10 mg daily X 3 weeks (days 1-21) followed by 1 week off therapy (days 22-28) on a 28 day cycle.Patients will be treated with lenalidomide until disease progression or 2 cycles past CR. (no maximum of cycles).
223632298|NCT03077971|BEHAVIORAL|ACT Self-Help|Self-Help Intervention Workbook using an Acceptance and Commitment Therapy approach
223632299|NCT03077971|BEHAVIORAL|ACT Self-Help with Telephone Support|Self-Help Intervention Workbook using an Acceptance and Commitment Therapy approach alongside weekly telephone support calls
223632300|NCT01775501|DRUG|Leucovorin|200mg/m2 administered IV on Days 1 and 15 of a 28 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
223632301|NCT01775501|DRUG|Fluorouracil|5-FU continuous infusion: 2400mg/m2 total (1200mg/m2/d on day 1 and 2) to start on Day 1 and Day 15 of each 28 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
224220867|NCT00055874|DRUG|cytarabine|
224220868|NCT00055874|DRUG|hydroxyurea|
224220869|NCT00055874|DRUG|imatinib mesylate|
224220870|NCT00055874|PROCEDURE|allogeneic bone marrow transplantation|
224220871|NCT00055874|PROCEDURE|autologous bone marrow transplantation|
224220872|NCT00055874|PROCEDURE|peripheral blood stem cell transplantation|
224220873|NCT00650559|PROCEDURE|Chest wall enlargement|Widening sternotomy
223632302|NCT01775501|DRUG|Oxaliplatin|85 mg/m2 IV on Days 1 and 15 of each 28 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
223632303|NCT01775501|DRUG|Sorafenib|400mg po BID continuously for a 2 week lead-in phase and then Days 1-28 of each 28 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
224220874|NCT03874806|DRUG|Ropivacaine 0.25%-NaCl 0.9% Injectable Solution|0.25% ropivacaine administered through a nerve catheter
224318092|NCT00798876|DIETARY_SUPPLEMENT|Vitamin E supplement|Subjects will be asked to take 800 International Units per day of Vitamin E for 4 weeks.
224318093|NCT00798876|DIETARY_SUPPLEMENT|Western Diet|Subjects will be provided with a standard western diet, food and beverages, to consume during their 4 week participation in this study.
224318094|NCT00798876|DIETARY_SUPPLEMENT|Low-Fat Diet|Subjects will be provided with a low-fat diet (food and beverages) for their 4 week participation in this study.
223632304|NCT06462937|BEHAVIORAL|Exercise with supervision|Remote exercise will be administered with digital supervision. The Exercise group will receive a personalised program with individual adaptations aiming to perform 3 exercise sessions per week including HIIT, strength exercise and moderate intensive aerobic exercise. Participants will consult their rheumatologist parallel to the SPARK trial.
223632305|NCT06462937|BEHAVIORAL|Exercise without supervision|Remote exercise will be administered without digital supervision. Participants will receive a standard exercise program fulfilling the exercise protocol requirements, the exercise program will progress. But there will be no direct contact between the participant and the coach. Participants will consult their rheumatologist parallel to the SPARK trial.
224220875|NCT03874806|DRUG|Ropivacaine 0.2%-NaCl 0.9% Injectable Solution|0.2% ropivacaine administered through a nerve catheter
224220876|NCT00002777|DRUG|exemestane|
224220877|NCT00002777|DRUG|tamoxifen citrate|
224220878|NCT05037682|OTHER|Dissemination and Implementation Research|The study will employ a research and implementation design that attempts to balance scientific rigor, research good practices, primary care implementation preferences and numerous limitations related to the study context. A waitlist-controlled, staggered implementation study will be conducted with three groups of 15 practices introduced to the intervention in 3-month intervals, each baseline overlapping with interim measurements of care quality and process outcomes in concurrent groups in every 3 months, followed by a final data collection at the end of the intervention in months 16 and 17, including baseline measures plus semi-structured interviews. The groups and their sequence will not be randomized, but practice characteristics will be used to distribute them among the three groups based on location, type, size and patient mix to maximize the balance of practices among the groups.
224220879|NCT04821882|DRUG|Dextrose|10% dextrose: 2 mL of 50% dextrose in 10 mL normal saline and injected by 11 sub urothelial injections
224220880|NCT00773526|DRUG|RO5126766|Administered orally daily for 28 days, at escalating doses (with a starting dose of 0.1mg) (Part 1). Optimal biological dose or maximum tolerated dose administered orally, daily (Part 2).
224220881|NCT06545058|PROCEDURE|Penile block|Penile block with local anesthetics
224220882|NCT04360603|DEVICE|27G|using 27G vitrectomy system to perform standard transconjunctival sutureless vitrectomy
224318095|NCT00798876|OTHER|Medical Examination|Subjects will have a routine medical exam.
224318096|NCT00798876|OTHER|Dietary Interview|Subjects will meet with the study nutritionist and have their current diet evaluated. Subjects will also undergo a test (bioimpedance) to estimate their body fat, lean weight, and the rate at which their body burns fat.
223632306|NCT04841122|DEVICE|Camera observation|Supplemental camera observation directly linked to the nurse's phone
223632307|NCT02325102|OTHER|No intervention|As this is an observational study, no intervention was conducted.
223632308|NCT06472518|DEVICE|pharmaco mechanical thrombolysis|arm with the pharmaco mechanical thrombolysis intervention combined with anticoagulant treatment with direct oral anticoagulants
223632309|NCT05115331|RADIATION|Experimental Radiation Dose|16 Gy in 2 fractions
223632310|NCT05115331|RADIATION|Conventional Radiation Dose|8 Gy in a single fraction
223632311|NCT00830882|DRUG|levosalbutamol|2 puffs four times a day for 2 weeks
223632312|NCT00830882|DRUG|racemic salbutamol|2 puffs four times a day for 2 weeks
223632313|NCT00830882|DRUG|placebo|2 puffs four times a day for 2 weeks
223632314|NCT05479695|DEVICE|Spinal Orthoses and Insoles|Evaluation of scoliosis treatment in people using spinal orthoses and insoles
223632315|NCT05479695|DEVICE|Spinal Orthoses|Evaluation of scoliosis treatment in people using spinal orthoses
223632316|NCT04086901|RADIATION|Radiotherapy dose escalation|Flour-Deoxy-Glucose /Positron Emissions Tomografi (FDG-PET) scans will be used to identify and delineate the tumour sub-volumes with the highest tracer uptake to guide the dose-escalation. The dose to the Gross tumor volume (GTV) will be escalated to a high dose while clinical target volume (CTV) and planning target volume (PTV) will be treated with standard dose.
224220883|NCT04360603|DEVICE|25G|using 25G vitrectomy system to perform standard transconjunctival sutureless vitrectomy
224220884|NCT04525157|DRUG|Afamelanotide|
224220885|NCT04525157|DRUG|Placebo|
223632317|NCT03818646|DIAGNOSTIC_TEST|Functional Respiratory Imaging|Functional Respiratory Imaging (FRI) is a novel image based functional diagnostic tool that combines high-resolution CT scans (HRCT) at TLC and FRC with flow simulations (computational fluid dynamics - CFD) providing a 3D visualization and quantification of lung structure and function.
223632318|NCT02166346|DRUG|Dalfampridine|Dalfampridine 10 mg twice daily for 8 weeks
223632319|NCT02166346|DRUG|Placebo|Placebo pill 1 tablet twice daily for 8 weeks
223632320|NCT01432041|BEHAVIORAL|tailored health education|Health Information via a computer kiosk in the pediatric emergency department
224220886|NCT02827513|DRUG|CTN SR1|
223632321|NCT05739721|BEHAVIORAL|Attractiveness|Visual attractiveness scale 0-7
223632322|NCT05739721|BEHAVIORAL|Self-Esteem|Self Esteem scale
223632323|NCT05739721|BEHAVIORAL|Trustworthiness|Trustworthiness scale 0-7
224220887|NCT02827513|DRUG|CTN XR1|
224220888|NCT02827513|DRUG|CTN XR2|
224318097|NCT00798876|OTHER|Blood Draw|40 mL of blood will be drawn from subjects to measure PSA, fatty acids, insulin and various hormones.
224318098|NCT00798876|PROCEDURE|Radical Prostatectomy|Subjects will undergo a radical prostatectomy as part of their standard of care.
224318099|NCT00563576|DRUG|Femring®|"Estrogen vaginal ring (100 mcg) placed for the first 90 days of Depo-Provera use.~Femring® (estradiol acetate vaginal ring) is a flexible off-white ring designed for vaginal insertion with measurements that include an outer diameter of 56 mm, cross-sectional diameter of 7.6 mm, and core diameter of 2 mm. Femring® 0.1 mg/day has a central core containing 24.8 mg of estradiol acetate which releases at a rate equivalent to 0.1 mg of estradiol per day for 3 months."
224318100|NCT00563576|DRUG|DepoProvera ®|Medroxyprogesterone intramuscular injection comes as a suspension (liquid) to be injected into the buttocks or upper arm. It is usually given once every 3 months (13 weeks), and the recommended dose is 150 mg.
224318101|NCT00315731|BIOLOGICAL|Follicular Lymphoma|For subjects with previously untreated or relapsed follicular or transformed follicular non-Hodgkin's
224318102|NCT06457165|DEVICE|Difficult Intubation|Noted for each patient.
224318103|NCT06457165|DEVICE|Not Difficult Intubation|Noted for each patient.
224318104|NCT00521040|DRUG|Levocetirizine dihydrochloride|
223632324|NCT06292260|DEVICE|mHealth app|The eSkinHealth app is a tablet application that can be used as a portable patient chart for dermatological conditions in areas with poor internet connectivity, and for teledermatology when in need.
223632325|NCT00311675|BIOLOGICAL|Inactivated Influenza A/H5N1 Vaccine (sanofi pasteur)|Monovalent subvirion H5N1 vaccine (HA of A/Vietnam/1203/04) provided in single-dose vials containing 90-mcg/mL A/H5N1 HA. Dosage is two 90 mcg doses administered intramuscularly separated by approximately 28 days.
224220889|NCT02827513|DRUG|CTN XR3|
224220890|NCT01604382|DRUG|General Anesthesia|General Anesthesia as described above
224220891|NCT01604382|DRUG|Neuraxial anesthesia|Neuraxial anesthesia as described above
224220892|NCT01001871|DIETARY_SUPPLEMENT|Sprinkles®|powdered vitamin/mineral fortificant WITH iron sprinkled onto food once a day for 5 months
224220893|NCT01001871|DIETARY_SUPPLEMENT|vitamin/mineral fortificant without iron|powdered vitamin/mineral fortificant WITHOUT iron sprinkled onto food once a day for 5 months
224220894|NCT02801591|PROCEDURE|Conventional ovarian stimulation proctol without rhGH|
224220895|NCT03437460|DRUG|Ibuprofen 600 mg|The investigators administer one single 600 mg dose of ibuprofen immediately before lunch. Participants are then asked to complete the cold pressor task, flower stringing sessions, and cognitive tasks.
224220896|NCT03437460|DIETARY_SUPPLEMENT|Prenatal vitamins|The investigators administer one single prenatal multivitamin immediately before lunch. Participants are then asked to complete the cold pressor task, flower stringing sessions, and cognitive tasks.
224220897|NCT01936168|DEVICE|Mechanochemical Endovenous Ablation (MOCA)|Mechanochemical Endovenous Ablation (MOCA)for treatment of great saphenous vein incompetence
224220898|NCT01936168|PROCEDURE|Radiofrequency ablation (RFA)|Radiofrequency ablation (RFA)for treatment of great saphenous vein incompetence
224220899|NCT02678221|DRUG|Sildenafil citrate|
224220900|NCT02678221|DRUG|Aspirin|
224220901|NCT01324245|DRUG|Fenoldopam|Intravenous infusion at 0.5 mics/Kg/min for three hours
224220902|NCT01190306|DEVICE|The VEGA UV-A Illumination System|This is a portable electronic device designed to deliver a dose of UV-A light to the treatment area
224220903|NCT01190306|DRUG|Riboflavin|Riboflavin is a solution that will be delivered to the treatment area
224318105|NCT05934240|OTHER|Manual therapy group|Manual therapy will be applied to the diaphragm and thoracic region.
224318106|NCT05934240|OTHER|Sham-manual therapy|Sham-manual therapy will be applied to the diaphragm and thoracic region.
224318107|NCT01525264|BEHAVIORAL|KIM-CHI|The intervention is based on cultural characteristics and context and focuses on changing (1) beliefs about breast cancer and screening, (2) knowledge of breast cancer and screening, (3) self-efficacy of confidence in one's ability to complete all the steps necessary for obtaining a mammogram including requesting a referral for mammogram from a physician. The KIM-CHI program also incorporates strategies for enhancing spousal support (perceived support received from husband). To standardize delivery of culture-relevant health behavior change information related to breast cancer screening to groups of women and their husbands separately, the KIM-CHI program uses a DVD with Korean role models, native Korean language, and male physician authentication as well as inclusion of spouses.
224220904|NCT02883829|BEHAVIORAL|Peer-Based Web-Based Health Information|The intervention will be a brief vignette to present educational content about alcohol use risks for Type 1 Diabetes; framed and delivered from a peer-based source. The content for the intervention will be drawn on existing theories of behavior change, including the concepts of 'consciousness raising', 'self-reevaluation' and 'helping relationships'. The intervention will comprise of PowerPoint slides for final implementation as a narrated video that can be posted to a website for participant viewing.
224220905|NCT02883829|BEHAVIORAL|Provider-Based Web-Based Health Information|The intervention will be a brief vignette to present educational content about alcohol use risks for Type 1 Diabetes; framed and delivered from a provider-based source. The content for the intervention will be drawn on existing theories of behavior change, including the concepts of 'consciousness raising', 'self-reevaluation' and 'helping relationships'. The intervention will comprise of PowerPoint slides for final implementation as a narrated video that can be posted to a website for participant viewing.
224220906|NCT05454423|OTHER|the Aquatic exercises +Traditional physical therapy programs +anti-hyperuricemia medication|"-Aquatic exercises: At the beginning of the exercises, aquatic exercises technique was educated to the participants out of water. Then, the aquatic exercises were conducted in a chest warm pool (28-30°C) for 30 minutes, three sessions a week for eight weeks.~-Traditional physical therapy programs : which included using hot packs (20 minutes), ultrasound (5 minutes), and electrotherapy using TENS (15 minutes) in addition to stretching exercises for the calf, hamstring muscles and big toes and strengthening exercises for the quadriceps muscles for 30 minutes. The stretching exercises were performed in 3 weekly sessions over 8 weeks, each with a 30 second holding and a 30-second relaxation repeated three times. One group of strengthening exercises consisted of 10 repeats with a 5 second holding"
224220907|NCT05454423|OTHER|traditional physical therapy + anti-hyperuricemia medication|"traditional physical therapy programs, which included using hot packs (20 minutes), ultrasound (5 minutes), and electrotherapy using TENS (15 minutes) in addition to stretching exercises for the calf, hamstring muscles and big toes and strengthening exercises for the quadriceps muscles for 30 minutes. The stretching exercises were performed in 3 weekly sessions over 8 weeks, each with a 30 second holding and a 30 second relaxation repeated three times. One group of strengthening exercises consisted of 10 repeats with a 5 second holding17."
224318108|NCT01525264|BEHAVIORAL|Healthy Wife Control Group|Intervention group of couples who received education about importance of Healthy diet
224318109|NCT06633731|OTHER|Biocellulose Mask|Immediately after treatment, a Biocellulose Mask was applied to the subjects global face for 8 to 10 minutes.
224318110|NCT06633731|OTHER|Post Procedure Cream|Immediately after treatment and after Biocellulose Mask removal, the Post-Procedure Cream was applied to the subjects global face. Subjects were instructed to apply to the global face from days 1 - 3 post treatment.
224318111|NCT06633731|OTHER|Gentle Cleanser|Subjects were instructed to wash their face with the Gentle Foaming Cleanser twice daily for 12 weeks.
223632326|NCT02323789|DRUG|Mesenchymal stromal cells|TC-MSC: a cell product containing mesenchymal stromal cells. Mesenchymal stromal cells are adherent non-haematopoietic multipotent cells that are expanded from bone marrow from healthy donors, using platelet lysate as source of growth factor.
223632327|NCT04422184|DRUG|Sensodyne Repair and Protect|Dentifricie with NOVAMIN technology
223632328|NCT04422184|DRUG|Dentalclean Daily Regenerator|Dentifricie with Refix technology
224220908|NCT04396470|DEVICE|tVNS|Participants will be randomized to either the tVNS treatment condition or the sham tVNS (placebo) condition. An identical non-invasive tVNS device will be used in both groups. In the active condition, the device is placed on the external earlobe (tragus), which directly stimulates the vagus nerve. In the sham condition, the device is placed on the external earlobe, providing the same sensations as in the treatment condition, but no stimulation to the vagus nerve. Intervention period: Participants will use the device 1-hr per day for 12 weeks per manufacturer's instructions.
224220909|NCT06080984|DRUG|Oncolytic Virus SDJ001|"Patients in the study receive intratumoral treatment with SDJ001 at two dose levels: 5x10\^11 and 1x10\^12 pfu per person. At the current dose levels, intratumoral injection is administered on the first day of each treatment cycle. Each treatment cycle consists of three weeks, continuing until tumor growth is observed following injection or until the patient experiences intolerable toxic effects.~Ultrasound-guided injection may be used when necessary (2.0 mL for tumors with a diameter \>2.5 cm, 1.0 mL for diameters of 1.5-2.5 cm, 0.5 mL for diameters of 0.5-1.5 cm, and 0.1 mL for diameters \<0.5 cm, with a maximum of 4 mL)."
224220910|NCT06080984|DRUG|Oncolytic Virus YD06-1|Patients in the study receive intratumoral treatment with a novel oncolytic virus YD06-1 at a concentration of 10\^6 pfu/mL to 10\^8 pfu/ml following a dose escalation plan. Each subject receives only one injection at the corresponding concentration, with the dose determined based on the size of the tumor mass. (Diameter ≤1.5 cm, maximum of 1 mL; diameter 1.5-2.5 cm, maximum of 2 mL; diameter greater than 2.5 cm, maximum of 4 mL). The second dose is administered three weeks after the first dose, followed by subsequent doses at two-week intervals.
224220911|NCT03279484|DEVICE|NAVIGO 4LV lead implant|All patients will be attempted to implant or implanted with NAVIGO 4LV lead
224220912|NCT02522754|BIOLOGICAL|Placebo Protesomal Vaccine|Intranasal vaccine Protesomal Vaccine
224220913|NCT02522754|BIOLOGICAL|Experimental: Protesomal Vaccine 1 x 30 µg|Experimental: Protesomal Vaccine 1 x 30 µg
224220914|NCT02522754|BIOLOGICAL|Experimental: Protesomal Vaccine 2 x 30 µg|Experimental: Protesomal Vaccine 2 x 30 µg
224220915|NCT02522754|BIOLOGICAL|Experimental: Protesomal Vaccine 2 x 15 µg|Experimental: Protesomal Vaccine 2 x 15 µg
224220916|NCT02862535|DRUG|Andecaliximab|Administered via intravenous (IV) infusion (approximately 30 minutes)
224220917|NCT02862535|DRUG|S-1|Administered orally
224318112|NCT06633731|OTHER|Facial Moisturizer|Subjects were instructed to apply the facial moisturizer twice daily to the global face from day 3 after treatment until next study visit.
224318113|NCT06633731|OTHER|sunscreen|Subjects were instructed to apply the bland sunscreen to the global face once daily in the morning, with re-application with extended sun exposure per FDA guidelines.
224318114|NCT01945073|BEHAVIORAL|Educational Booklet (BK)|The information booklet provides age appropriate explanation about SCD: inheritance patterns for the trait and common sickle cell disorders in the Jamaican population. It includes manifestations, complications and the necessary preventive and treatment advice. In addition, issues that are common to adolescents including sexual activity, contraceptive use, drug usage, career advice and developmental changes common to persons with the disease are also discussed.
224318115|NCT01945073|OTHER|Formal Counselling (CB)|The study coordinator will have a face to face counselling session, lasting about 30 minutes, with the adolescent and/or caregiver. This will include the use of the educational booklet as an education tool, as well as a thorough discussion on the disease process; its manifestations, effects, and specific concerns during the adolescent period; as well as clarification of common myths and misconceptions about the disease.
224318116|NCT04769063|OTHER|Kinesio Tape|Gluteus medius facilitation and knee spiral taping techniques will be applied to treat dynamic knee valgus
224220918|NCT02862535|DRUG|Cisplatin|Administered via IV infusion on Day 8 of every 5 weeks
224220919|NCT02862535|DRUG|Oxaliplatin|Administered via IV infusion for over 2 hours on Day 1 of each 21-day cycle
224220920|NCT02862535|DRUG|Nivolumab|Administered via IV infusion (approximately 60 minutes) every 2 weeks
224220921|NCT01675869|BEHAVIORAL|Executive Training of Attention and Metacognition (ETAM)|ETAM is an 8-week intervention involving weekly concurrent child (n=\~6 per group) and parent intervention groups. The ETAM groups will be 1 hour in length (except for the first session which will be 2 hours).
224318117|NCT03735069|PROCEDURE|IPT (Indirect pulp treatment)|Indirect pulp treatment involves complete caries excavation from the dentin-enamel junction using a round bur. Caries near the pulp is removed with caution using spoon excavator until the remaining dentine shows increased resistance to manual instrumentation. A layer of resin-modified glass ionomer (RMGI) dressing material is placed, followed by resin-modified glass ionomer (RMGI) build-up material, and the final restoration; a preformed Stainless Steel Crown (SSC).
224318118|NCT03735069|PROCEDURE|Cvek/partial pulpotomy|Cvek/partial pulpotomy involves removal of inflamed pulp tissue to depth until healthy pulp tissue is reached (depth of 2-4 mm), as indicated by healthy bleeding and arrest of hemorrhage upon pressure with a cotton pellet moistened with 2.5% NaOCl for 2-5 minutes and repeated for two times if required. Gray MTA will be placed in the pulp chamber in 2-3 mm thickness, moist cotton pellet will be placed to ensure setting and the tooth will be temporized with IRM, the patient will be reviewed after 1 week. If the tooth is asymptomatic, final restoration with RMGIC and stainless steel crown will be placed , and a post-operative radiograph will be taken.
223632329|NCT04422184|DRUG|Dentalclean Daily Regenerator with potassium citrate|Dentifricie with Refix technology+ potassium citrate
223632330|NCT00901836|RADIATION|Preoperative proton therapy|28 daily fractions of 1.8 cobalt gray equivalent(CGE)/fx for total of 50.4 CGE over 5.5 weeks.
223632331|NCT00901836|PROCEDURE|Surgery|Standard of care surgery will be performed 4-6 weeks after completion of radiation.
223632332|NCT05417646|OTHER|Hyperglycaemic clamp|Three-hour, three-step glucose clamp with plasma glucose targets 10, 14 and 18 mmol/l (each one hour)
223632333|NCT05417646|DRUG|Placebo|Placebo comparator to empagliflozin
224220922|NCT01675869|BEHAVIORAL|Attention Control|Attention Control is an 8-week intervention involving weekly concurrent child (n=\~6 per group) and parent groups that control for the effects of attention. The groups will be 1 hour in length (except for the first session which will be 2 hours).
223632334|NCT05417646|DRUG|Empagliflozin|Single-dose, 25 mg, two hours before clamp
223632335|NCT05600634|PROCEDURE|Skin allotransplantation|Sentinel skin grafts from the same donor source will be carried on in the meantime of kidney transplantation for assisting to detect acute renal rejection.
223632336|NCT04424134|DRUG|Bromhexine and Spironolactone|Bromhexine 8 mg x 4 times a day x 10 days Spironolactone 50 mg x once a day x 10 days
224220923|NCT00947765|BIOLOGICAL|Autologous blood injection|Patients were infiltrated with injection of 2 ml autologous blood drawn from contra lateral upper limb vein mixed with 1 ml 0.5% bupivacaine, at the lateral epicondyle according to the standard technique.
223632337|NCT04424134|DRUG|Base therapy|Therapy currently recommended by Ministry of Health of Russian Federation for COVID 19 treatment
223632338|NCT02364700|DEVICE|Hand of Hope (HOH)|"Subjects will receive arm training 3x/week for 6 weeks, each session is anticipated to last approximately 60 minutes. Sessions will be scheduled for Monday, Wednesday, and Friday whenever possible to provide a rest period between sessions. Each session will consist of the following:~* warm up-passive stretch of hand in flexion and extension (5 minutes);~* setting the EMG threshold parameters for the device;~* active practicing of opening the hand (Desperate Bee, Hungry Bird, Sun Archer games; 10 min)~* active practice of closing then hand (UFO Catcher game; 10 min)~* open and closing the hand (Ball and Basket game; 10 min)~* open and closing the hand while incorporating reach ( for subjects with adequate ability to reach with shoulder/elbow; 10 min)~* cool down-passive stretch of hand in flexion and extension (5 minutes)"
223632339|NCT03123692|DRUG|Emeramide|Lipophilic, membrane passing Metal chelator and anti oxidant
223632340|NCT03123692|DRUG|Placebo|14 days treatment with placebo
223632341|NCT01323114|PROCEDURE|Laparoscopic duodenal exclusion|Laparoscopically-performed Roux-en Y intestinal bypass of the duodenum and proximal jejunum; stomach remains normal size and proximal division performed just distal to pylorus.
223632342|NCT01323114|OTHER|Conventional Medical Treatment|Standard of care medical treatment for type 2 diabetes to include medications and dietary management under the monitoring of the study endocrinologist.
223764316|NCT03377712|DEVICE|Functional capacity assessment|Evaluated through the six-minute walk test, where the patient walks along a 30-meter corridor, simple, fast and safe assessment
224220924|NCT00947765|DRUG|Local corticosteroid injection|Patients were infiltrated with 2 milliliters of local corticosteroid (Methyl prednisolone acetate 80mg) mixed with 1 milliliters 0.5% Bupivacaine, at the lateral epicondyle according to the standard technique
224220925|NCT04388033|BIOLOGICAL|Dendritic Cell/Tumor Fusion Vaccine|Vaccine is derived from the participants dendritic cells and tumor cells.
223632343|NCT05348538|OTHER|Medication review with follow up or MaJ? for the acronym in french|"MaJ? service will involve a pharmacist-patient face-to-face consultation with a 6-months interval during the study, it includes:~1. Educational training: pharmacists will attend a half a day course. They will inform pharmacy technicians of their tasks. They will also have available an online version of the training about the service and data collection.~2. Service provision: before the pharmacist-patient consultation (pharmacy technicians review the medication to identify the prescribed medication included in the treatment plan and to remove expired or medications non taken by the patient), during (pharmacist assess potential drug related problem) and after the consultation (to send a medication management plan to patients and doctors).~3. Practice change facilitation to support pharmacists: pharmacists will be follow-up by the research team during the study (1st, 2nd, 3rd, 6th, 12th and 15th months of the study) to support them through the delivery of the service."
224220926|NCT04388033|DRUG|Interleukin-12|Given subcutaneously at dose of 6ug twice for interval of one hour.
224220927|NCT04388033|DRUG|Temozolomide|Following concomitant radiation (2 Gy/day x 30 days) and TMZ-chemotherapy (75 mg/m2/ day x 42 days) , maintenance chemotherapy with TMZ will be administered at 150-200 mg/m2/day for 5 days in each 28-day cycle.
224220928|NCT03501342|OTHER|Virtual reality group|"Immersive virtual reality training protocol consisted of Football and Guillotine games."
224220929|NCT03501342|OTHER|Dynamic Balance Training|Dynamic balance training protocol consisted of holding the ball and running away from the ball with a physiotherapist.
224220930|NCT03929224|DRUG|Medicinal honey|Treat healing surgical site with medicinal honey
223632344|NCT02289586|PROCEDURE|invasive ventilation|
223632345|NCT02289586|PROCEDURE|interventional bronchoscopy|
223632346|NCT02289586|DEVICE|noninvasive ventilation|
223632347|NCT02289586|DRUG|sedation(dezocine and midazolam)|
223632348|NCT02289586|DRUG|general anesthesia(midazolam, fentanyl，rocuronium，propofol and Remifentanil）|
223632349|NCT02273934|BEHAVIORAL|Reablement|The intervention deals with improving function in daily activities the person defines as important in the areas of self-care, productivity and leisure.
223632350|NCT02273934|BEHAVIORAL|Standard treatment|The control intervention is standard home-based treatment/care in Norway.
223632351|NCT02558088|DRUG|Salmeterol|
223632352|NCT05277415|BIOLOGICAL|Ghrelin|Ghrelin infusion
223632353|NCT05277415|BIOLOGICAL|Placebo|Placebo
223764317|NCT03377712|DEVICE|Quality of life assessment|through questionnaire
223764318|NCT04413929|DRUG|Ergoferon|Oral administration
223764319|NCT07009665|OTHER|Personalized SV-guided resuscitation|Participants will receive an IV fluid bolus directly after inclusion. Next, measurement of the cardiac output change in response to the fluid bolus by the Starling SV will be used to determine fluid responsiveness. Vital parameters and fluid responsiveness will be used to guide hemodynamic resuscitation, consisting of IV fluids and/or vasopressors, during the first 3 hours.
223764320|NCT07009665|OTHER|Standard Care Resuscitation|In the control group, IV fluid and vasopressor administration will be determined at the discretion of the physician and in accordance with currently available guidelines (e.g. Sepsis Surviving Campaign).
223764321|NCT02782949|DRUG|Curcumin|Given PO
224220931|NCT03929224|DRUG|Bacitracin|Treat healing surgical site with bacitracin
223632354|NCT00222612|OTHER|Reduced intensification|Deletion of one 7 week treatment block containing dexamethasone, vincristine, doxorubicin, Peg-asparaginase, intrathecal methotrexate, cyclophosphamide, cytarabine.
223632355|NCT00222612|DRUG|Standard childhood UK ALL protocol|No additional treatment to standard protocol.
223764322|NCT02782949|OTHER|Laboratory Biomarker Analysis|Correlative studies
224220932|NCT00046371|DRUG|THERATOPE® vaccine|
224220933|NCT04238780|PROCEDURE|Erector Spinae Plane Block|The transducer was placed vertically 3cm lateral to the midline to visualize the muscles of the back, transverse process and the pleura in between the two transverse processes. After local infiltration of the needle insertion site with 2-3 ml of 2% lidocaine needle was inserted in cranial-caudal direction towards the transvers process using in plane technique until the needle cross all the muscles then interfascial injection of 20ml local anesthetics is done after ensuring negative aspiration, the procedure was repeated following the same steps on the other side of the back.
224220934|NCT04238780|PROCEDURE|Intravenous fentanyl patient control device|24-hour fentanyl consumption will be recorded.
224220935|NCT00303381|DRUG|Interferon-beta-1a, 44 microgram|Interferon-beta-1a will be administered subcutaneously at a dose of 44 mcg, three times a week up to Week 8.
224220936|NCT00303381|DRUG|Placebo|Matching Placebo will be administered subcutaneously, three times a week up to Week 8.
224220937|NCT00303381|DRUG|Interferon-beta-1a, 66 microgram|Interferon-beta-1a will be administered subcutaneously at a dose of 66 mcg, three times a week up to Week 8.
224220938|NCT02276911|DRUG|Ibuprofen|
224220939|NCT02276911|OTHER|normal saline|
223632356|NCT00222612|DRUG|Intensified treatment including Capizzi maintenance|Augmented consolidation: vincristine, Peg-asparaginase. Capizzi maintenance: iv methotrexate and peg-asparaginase
223632357|NCT01280903|BEHAVIORAL|STAR Intervention|The 24-week modified Staying Active with Arthritis (STAR) intervention, guided by self-efficacy theory and modified to address comorbid hypertension, consists of 6 weekly individual face-to-face exercise sessions by a licensed physical therapist, 9 biweekly telephone counseling sessions by a registered nurse to continue the use of self-efficacy strategies, and lower extremity exercise and fitness walking being carried out at home between sessions. There will be no contact with participants during weeks 7, 9, 11, 13, 15, 17, 19, 21, and 23. During the 6-month follow-up period, the participants will be contacted briefly by telephone by a registered nurse at weeks 30, 36, and 48 for a general check-up.
224220940|NCT03549663|DRUG|Tacrolimus|Tacrolimus capsules: 0.5mg/pill, 50 pills/box, AstellasPharma (China) Co., Ltd.; Tacrolimus capsules: 1mg/pill, 50 pills/box, Hangzhou ZhongmeiHuadong Pharmacy Co., Ltd. Start to administer on the randomized grouping day (D0) with an initial dose by weight: initial dose of 0.05-0.075mg/kg/d (bid) following a strict administration interval of 12 hours or fasting or 2 hours after meal. Adjust TAC dose according to 24-hour urine protein, plasma concentration and eGFR changes. It is recommended that plasma trough concentration should be remained at 5-8ng/ml and TAC dose during the whole therapy stage should not be lower than 0.5mg/d. Drugs should be stopped if the 6-month therapy is ineffective. After 6-month therapy, for those whose urine protein achieved complete remission (CR) or partial remission (PR), TAC dose should be reduced gradually with a total therapy duration of 48 weeks.
223764323|NCT02782949|OTHER|Placebo Administration|Given PO
224220941|NCT03549663|DRUG|Prednisone|Glucocorticoid (prednisone): 5mg/pill, 100 pills/bottle: Shanghai Sine Pharmaceutical Factory Co., Ltd. The initial dose of prednisone should be 0.5mg/kg/d orally (maximum dose of 40mg/d) and administration should be continued for 8-12 weeks; then reduced by the monthly decreased amount of 0.1mg/kg/d till to 0.2mg/kg/d (5-10mg) to maintain. Prednisone should be stopped after administration for the entire 48 weeks.
224220942|NCT02850445|DRUG|Olanzapine|All patients with schizophrenia were under medication treatment at the baseline. Individualized plan of antipsychotic medication for the patients were determined by psychiatrist who were blind to the group allocation. Medications could be changed at any time during the course of the study if the change was clinically warranted, the drug can also be any other antipsychotic medication.
224220943|NCT02850445|OTHER|Cognitive behavior therapy|Patients with schizophrenia allocated to the Integrated Treatment(IT) group received Cognitive behavioral therapy.
223764324|NCT02782949|OTHER|Quality-of-Life Assessment|Ancillary studies
224220944|NCT02850445|OTHER|Rehabilitation treatment|Rehabilitation treatment include three modules: medication management, symptom management, and social kill training. Patients with schizophrenia allocated to the Integrated Treatment(IT) group received Rehabilitation treatment therapy.
224220945|NCT02850445|OTHER|Case management|Patients with schizophrenia allocated to the Integrated Treatment(IT) group received Case management.
224220946|NCT03338270|DIAGNOSTIC_TEST|MRI|MRI sequence without intravenous contrast
224220947|NCT05140018|PROCEDURE|Kidney Transplantation|All participants will receive a kidney transplantation from a living donor or deceased donor
224220948|NCT05140018|COMBINATION_PRODUCT|Immunosuppression|All participants will receive immunosuppresive drugs to prevent rejection of de kidney transplant graft.
223764325|NCT07009132|DEVICE|Dual cholate clearance assay|Study participants are administered labeled oral and intravenous cholate, and then two blood samples are taken over 60-minutes. Serum cholate levels are measured by blood draws.
223764326|NCT07009132|RADIATION|MRI|Unsedated non contrast cardiac magnetic resonance imaging (MRI)
223764327|NCT07133178|BIOLOGICAL|VLA1553|Single intramuscular vaccination on Day 1 with VLA1553 full dose, a lyophilized live-attenuated Chikungunya vaccine
223764328|NCT07133178|BIOLOGICAL|Control|Single intramuscular vaccination on Day 1 with Nimenrix (Men ACWY vaccine), a conjugate vaccine indicated for the active immunization
223764329|NCT07008118|DRUG|INCA035784|INCA035784 will be administered at protocol defined dose.
223764330|NCT05871008|OTHER|Assessment tool IA3-CP with SDoH|Each patient randomly assigned to IA3-CP with SDoH study arm will complete a pre-visit assessment tool including SDoH. Feedback is provided to provider and patient.
223632358|NCT01280903|BEHAVIORAL|Attention-Control|Attention-Control is a 24-week general health education program for older adults that consists of 6 weekly telephone sessions by a registered nurse followed by 9 biweekly telephone sessions by a registered nurse. There will be no contact with participants during weeks 7, 9, 11, 13, 15, 17, 19, 21, and 23. Topics include cancer screenings; immunizations; osteoporosis; low vision; hearing loss; talking with your primary care provider; eating healthy (two parts); sleep and aging; injury prevention (two parts: balance problems and falls); oral health; foot care; and mental health (depression). During the 6-month follow-up period, the participants will be contacted briefly by telephone by a registered nurse at weeks 30, 36, and 48 for a general check-up.
223632359|NCT03453164|RADIATION|Radiotherapy|Radiotherapy of 22.5 Gy/5 fractions/5 days was given to a symptomatic lesion or the largest asymptomatic lesion suitable for irradiation from Day 1.
223632360|NCT03453164|DRUG|Nivolumab|Nivolumab was administered intravenously starting on Day 15-22 at a dose of 3 mg/kg (body weight) or 240 mg/body every 2 weeks to a total of 6 courses of administration.
223632361|NCT05683353|OTHER|None intervention|None intervention.
223632362|NCT05134038|DIAGNOSTIC_TEST|anthropomorphic measurements|anthropomorphic measurements + FES questionnaire + demographic data and medications
223632363|NCT04183660|DEVICE|MOBYBOX System|extracorporeal cardiopulmonary support
223632364|NCT06520501|DIETARY_SUPPLEMENT|Herbal Medicine Sambiloto|Jamu Sambiloto is herbal medicine obtained through products that already have a distribution permit and have a distribution permit registration number, with a consumption dose of 1 capul / day or 350 grams for 7 consecutive days.
223632365|NCT06520501|BEHAVIORAL|Brisk Walking|Moderate activity that uses brisk walking techniques for 30 minutes at an average speed of up to 5 km/h or 100 steps per minute.
224220949|NCT05140018|PROCEDURE|Nephrectomy (kidney donation)|All kidney donors will receive a nephrectomy for kidney donation
224220950|NCT03629847|DRUG|Everolimus|Drug: Everolimus will be administrated in combination with the intravenous radiolabelled Lu-177 DOTATATE therapy.
224220951|NCT06160674|OTHER|COPD|A vowel segmentation data set consisting of information from COPD and HC groups will be used to experiment with the classification performance of several Machine Learning techniques on different segments of a vowel recording.
224220952|NCT00235833|BIOLOGICAL|adalimumab|40 mg every other week (eow), subcutaneous (sc)
224318119|NCT03735069|PROCEDURE|Cervical pulpotomy|Cervical pulpotomy involves removal of inflamed pulp tissue from all pulp chamber as indicated by healthy bleeding and arrest of hemorrhage upon pressure with a cotton pellet moistened with 2.5% NaOCl for 6 minutes and repeated for two times if required. Gray MTA will be placed in the pulp chamber (2-3mm) thickness, moist cotton pellet will be placed to ensure setting and the tooth will be temporized with IRM, the patient will be reviewed after 1 week. If the tooth is asymptomatic, final restoration with RMGIC and stainless steel crown will be placed , and a post-operative radiograph will be taken.
223632366|NCT06520501|COMBINATION_PRODUCT|Brisk Walking and Herbal Medicine Sambiloto|Moderate activity that uses brisk walking techniques for 30 minutes at an average speed of up to 5 km/h or 100 steps per minute. Jamu Sambiloto is herbal medicine obtained through products that already have a distribution permit and have a distribution permit registration number, with a consumption dose of 1 capul / day or 350 grams for 7 consecutive days
224220953|NCT03348982|BEHAVIORAL|Jogging program|The intervention is a 12-week jogging program consisting of 24 sessions (two sessions per week, 30 min per session).
224220954|NCT05578222|DRUG|Pembrolizumab|Pembrolizumab, 200mg i.v. gtt,D1,Q3W,
224220955|NCT04220034|BIOLOGICAL|Blood sample|Blood sample will be collected to determine development or increase level frequencies of different types of autoantibodies in patients receiving ICI for the first time
224220956|NCT05729100|OTHER|Oral carbohydrate-electrolyte solution|Oral solution containing 10% glucose and electrolyte (in every 300 ml of fluid (contains 30 gr dextrose, 150 mg Natrium chloride, 366 mg Kalium chloride)
224220957|NCT05729100|OTHER|Control|Standard clear fluid (water)
224220958|NCT02472977|DRUG|Ulocuplumab|
224220959|NCT02472977|DRUG|Nivolumab|
224220960|NCT04525690|BEHAVIORAL|Nudge|Clinicians will receive a default order upon entering the the admission order set. They will have the opportunity to opt-out and not order screening. Clinicians will receive the nudge each time they enter the admission order set for a new, eligible patient.
224220961|NCT03654807|BEHAVIORAL|High Intensity Walking|70-80% HRmax
224220962|NCT03654807|BEHAVIORAL|Casual Speed Walking|Self selected pace
223632367|NCT04003467|DRUG|EBP05|tablets
223632368|NCT04003467|DRUG|Placebo of EBP05|tablets
223632369|NCT01125592|DEVICE|IonCLeanse Footbath|Application of an ionic footbath for 30 minutes per week for 4 weeks
223632370|NCT04718077|OTHER|Intraosseus|IO dexamethasone injection Dexamethasone 4 mg
223632371|NCT04718077|OTHER|Submucoal|SM dexamethasone injection Dexamethasone 4 mg
224220963|NCT01893866|DRUG|1 x 30 mg/mL pegvisomant|Subcutaneous injection, 30 mg, single dose.
224220964|NCT01893866|DRUG|2 x 15 mg/mL pegvisomant|Subcutaneous injection, 2 injections of 15 mg, single dose.
224318120|NCT00147602|DRUG|atorvastatin|
224220965|NCT05826769|DIETARY_SUPPLEMENT|Energy- Protein Enriched Nutritional Formula|EN volume will start at 1 mL/kg/h and then increase by 1 mL/kg every 6 hours if tolerated, until reaching 130 mL/kg/d.
224220966|NCT05459168|OTHER|Calm Meditation Smartphone App Feedback|Advisory committee members will be asked to use the current Calm meditation app platform for a full week and to keep an informal journal prior to participating in focus groups in which they will provide feedback about the app.
224220967|NCT05459168|OTHER|Cancer-Specific Meditation App Prototype Design|Findings from Aim 1 will inform the development of a cancer-specific meditation app prototype to be tested in Aim 3.
224220968|NCT05459168|DEVICE|Cancer-Specific Meditation App Prototype|Recruited cancer patients/survivors will be asked to beta-test the cancer-specific app prototype for four weeks. The prototype will be developed in Aim 2 and informed by qualitative findings of Aim 1.
224220969|NCT05879900|OTHER|Functional physical exercises|Functional physical exercises lasting approximately 15 minutes, for 12 weeks or 24 sessions. The exercises take place during physical education classes taught by the physical education teachers in charge of the classes. The place of intervention takes place in full-time schools in the rural area.
223632372|NCT04880278|DRUG|Nabilone|Half of the participants (30 individuals) will receive nabilone 1mg. Nabilone will be placed in opaque capsules with dextrose filler and administered by mouth only once (around 120 minutes prior to fMRI scanning).
223632373|NCT04880278|DRUG|Placebo|Half of the participants (30 individuals) will receive placebo capsules that are opaque and contain only dextrose. Placebo capsules will be administered by mouth only once (around 120 minutes prior to fMRI scanning).
223632374|NCT00707083|DRUG|dexamethasone|Given oral
223632375|NCT00707083|DRUG|mercaptopurine|Given orally
223632376|NCT00707083|DRUG|methotrexate|Given orally
223632377|NCT00707083|DRUG|vincristine sulfate|Given IV
223632378|NCT05991635|BEHAVIORAL|Gatekeeper training (e-learning)|"The gatekeeper training consists of an interactive e-learning (min. 1h, max. 3h) which includes theoretical knowledge, tips, exercises and relevant examples and cases. The main topics included in the e-learning are:~* Background information on suicide in Flanders (rates)~* Definitions and theoretical background (suicidal process, integrative explanatory model of suicide)~* Debunking existing myths about suicide~* The role of the pharmacist in suicide prevention~* Signal Recognition~* Talking about suicide and suicidal thoughts (start the conversation)~* How and to whom to refer as pharmacist or FTA~* Medication management and medication in the context of suicide~* Rights and obligations of a pharmacist/PTA in the context of suicide prevention~* Self-care"
223632379|NCT02706977|DRUG|Low Dose Sinemet CR|Sinemet CR (25 mg carbidopa/100 mg levodopa) will be taken by mouth twice daily for two weeks.
223632380|NCT02706977|DRUG|High Dose Sinemet CR|Sinemet CR (50 mg carbidopa/200 mg levodopa) will be taken by mouth twice daily for two weeks.
223632381|NCT02706977|DEVICE|RETeval Electroretinogram (ERG) Testing|ERG testing consists of sitting in the dark for 15 minutes. During the procedure, participants will have a single-use adhesive sensor strip placed on the skin near the eye. A hand-held device, called the RETeval, will be placed in front of the eye and a series of flashes and flickering lights presented. The light intensity level is typically not uncomfortable. When right eye imaging is complete, the procedure will be repeated on the left eye. Both eyes will be evaluated in less than 5 minutes for most participants. Electroretinogram (ERG) testing will be completed at baseline, day 1, week 2, and week 4.
223632382|NCT02706977|OTHER|Contrast Sensitivity Testing|Contrast sensitivity testing consists of looking at a series of moving lines on a tablet device. The lines will change from white to grey to black. Participants will be asked to determine when they can no longer distinguish between the lines. Contrast sensitivity testing will be completed at baseline, day 1, week 2, and week 4.
224220970|NCT05879900|OTHER|Physical Education classes|Physical Education classes according their previously planned contents.
224220971|NCT02584205|DEVICE|Powerbreathe|"In this intervention we will use an equipment called powerbreathe classic light. It provides us to choose resistance levels with an adjustable load setting range: 1 to 9 and it's ideal for beginners. In this research we will use it on the intervention group to improve the strength of inspiratory muscle training and evaluate the results in the functional capacity of the subjects with obstructive sleep apnea."
224220972|NCT00738920|BEHAVIORAL|Self Administered Cognitive Behavior Therapy|This 4 session treatment is aimed at controlling symptoms by changing specific behaviors found to aggravate IBS
224220973|NCT00738920|BEHAVIORAL|Therapist Administered Cognitive Behavior Therapy|This 10 session treatment is aimed at controlling symptoms by changing specific behaviors found to aggravate IBS
224318121|NCT03320421|RADIATION|Radiation therapy|"Radiation to the whole breast: 43.5 Gy in 15 fractions in 3 weeks. Simultaneous radiation to the surgical cavity: 49.5 Gy in 15 fractions in 3 weeks.~Intensity modulated radiation treatment is used."
224318122|NCT06010849|DIAGNOSTIC_TEST|Trunk control|Trunk control
223632383|NCT02706977|OTHER|Visual Acuity Testing|Participants will be asked to look at an eye chart with letters or symbols that become smaller as they move from top to bottom of the chart. Visual acuity testing will be completed at baseline, day 1, week 2, and week 4.
223632384|NCT02581813|BEHAVIORAL|I.D.E.A.L. for Adolescents Study - Higher Dairy|12 weeks diet and exercise intervention characterized by higher dairy consumption (4 servings per day) and exercise 3 times per week
223632385|NCT02581813|BEHAVIORAL|I.D.E.A.L. for Adolescents Study - Lower Dairy|12 weeks diet and exercise intervention characterized by lower dairy consumption (0-1 serving per day) and exercise 3 times per week
224220974|NCT00738920|BEHAVIORAL|Behavioral Education and Supportive Therapy|This 4 session treatment aims at controlling symptoms through support and the provision of information about IBS symptoms, how it is diagnosed, its causes, and treatment options and a collaborative, relationship between the patient and doctor
224318123|NCT05819203|DEVICE|Healsea Babykids|7-day-treatment period (14 intakes ) up to 10 days (20 intakes) .
223632386|NCT00003403|DRUG|GPX-100|
223632387|NCT00190918|DRUG|Pemetrexed|
223632388|NCT00874510|BEHAVIORAL|Mandatory Naps|As above, interns on extended duty overnight call shifts will be required to transfer cell phones and cross-coverage responsibilities to night float residents for a 5 hour period each night they are on call. For Year 2, interns will nap in shifts, instead of concurrently, with the first nap shift between 12am-3am and the second shift between 3am-6am
224318124|NCT05819203|DEVICE|Placebo|7-day-treatment period (14 intakes ) up to 10 days (20 intakes) .
224318125|NCT01170013|BEHAVIORAL|Family Check-up|Two session motivational intervention to improve parent monitoring and communication with respect to adolescent risk behavior especially substance use
224318126|NCT01170013|BEHAVIORAL|Parent psychoeducation|Two sessions of psychoeducation for parents regarding adolescent risk behaviors. especially substance use
224318127|NCT03033966|DEVICE|NIRS based Cerebral Oximetry|Cerebral Oximetric measurement before and after decompressive craniectomy
224318128|NCT00527306|DIETARY_SUPPLEMENT|multivitamin|Subject will be asked to take a multivitamin capsule or a placebo (inactive pill) once a day for one year. There will be an equal chance of getting the multivitamin or the placebo.
223632389|NCT04675593|BEHAVIORAL|iTAB-CV|Individualized Texting for Adherence Building - Cardiovascular (iTAB-CV): a personalized patient-centered text message-based adherence intervention
223632390|NCT04675593|BEHAVIORAL|Self-Monitoring|The Self-Monitoring (control) group will monitor their medication adherence, take their blood pressure weekly with a home blood pressure monitor provided by the study after being trained by the study staff, and rate their mood weekly in response to a text reminder.
223632391|NCT06954077|DRUG|BL-M09D1|Administration by intravenous infusion for a cycle of 3 weeks.
223632392|NCT04970134|OTHER|Immunohistochemistry (IHC)|VENTANA pan-TRK technique (EPR17341) Assay, with Optiview DAB-detection kit and Optiview amplification kit. Using FFPE slices
223632393|NCT04970134|OTHER|Fluorescence In-Situ Hybridization (FISH)|FISH using FFPE slices for genes: Neurotrophic tyrosin kinase 1 (NTRK1), Neurotrophic tyrosin kinase 3 (NTRK3) and rearranged during transfection (RET)
223632394|NCT04970134|OTHER|Oncomine Focus Assay Platform with 52 genes|Oncomine Focus Assay Platform with 52 genes (35 Hotspot genes, 19 Copy number variants and 23 Gene fusions). Using FFPE slices
223632395|NCT04293406|OTHER|Decision Navigation Intervention (DNI)|This study will develop and test the acceptability and feasibility of a decision navigation intervention (DNI) for AA or H/L men with prostate cancer through consideration of the role of partners and family members in the decision-making process. In the decision navigation intervention (DNI), participants will meet with the navigator in person or via phone, prior to their specialist treatment consultation. At the end of the DNI visit, participants will receive a personalized list of prioritized questions. At the end of the decision navigation appointment, all navigated patients will complete a five-item navigation rating scale evaluating the intervention and its impact on their preparation for the consultation visit.
223632396|NCT05833763|DRUG|Glofitamab|Glofitamab is provided as liquid concentrate for IV infusion. Each vial contains 10mg of glofitamab.
223632397|NCT05833763|DRUG|Pirtobrutinib|Pirtobrutinib is supplied as immediate release film-coated tablets containing 50 mg, or 100 mg of active compound. Tablets are supplied in labelled, HDPE bottles and sealed with child-resistant closures.
223632398|NCT05833763|DRUG|Obinutuzumab|Obinutuzumab is provided as a single dose 1000 mg liquid concentrate for infusion containing of 25 mg/mL obinutuzumab.
223632399|NCT05833763|DRUG|Tocilizumab|Tocilizumab is provided as a liquid concentrate for IV infusion. Each vial contains 200mg/10mL concentrate solution
223632400|NCT04879589|DRUG|Abiraterone Acetate|ATRS-2002
223632401|NCT00262340|OTHER|Non invasive measurement of airway inflammation|Airway inflammation will be assessed non-invasively using induced sputum and exhaled nitric oxide. In the active group the results of these tests will be used to determine if asthma treatment should be changed. In the comparator group treatment changes will be based according to conventional symptom based management
223764331|NCT05871008|OTHER|Assessment tool IA3-CP without SDoH|Each patient randomly assigned to IA3-CP only study arm will complete a pre-visit assessment tool excluding SDoH. Feedback is provided to provider and patient.
224220975|NCT05244382|OTHER|Overcome|Multimodal program individualized and supervised 12 weeks duration (three months), with two sessions weekly face-to-face. This program will combine aerobic exercise in unloading through the use of the TRAG (AlterG® Anti-Gravity Treadmill®), functional recovery of motor control with feedback ultrasound and occupational therapy. Physical activity will be measured in parallel with the test. Likewise, the patients will be monitored by means of a heart rate sensor.
224220976|NCT01130805|DRUG|Pazopanib in combination with capecitabine and oxaliplatin|Capecitabine 850 mg/m2 bid on day 1-14, Oxaliplatin 130 mg/m2 IV on day 1 and Pazopanib 800 mg once in a day on day 1-21, every 3 weeks
224220977|NCT02225028|BEHAVIORAL|Physical Activity Counseling|Participants in the physical activity counseling group will be mailed a home exercise toolkit that may include an activity monitor, exercise resistance bands, and exercise DVDs made for people with paraplegia or tetraplegia.
224220978|NCT02543736|DEVICE|Instrumented Treadmill System|Patients will perform twice a gait and a balance analysis on an instrumented treadmill system combined to a photoelectric cell system while controls will only perform once.
224220979|NCT01122472|DRUG|Lenalidomide|Daily for 3 weeks every 4 weeks for 24 months
224220980|NCT01122472|DRUG|Placebo|Daily for 3 weeks every 4 weeks for 24 months
224220981|NCT00802750|DEVICE|LoFric POBE|"LoFric POBE, Nelaton 40 cm, CH 12 with new solvent. Each subject will use the reference catheter LoFric POBE, Nelaton 40 cm, CH 12 with current solvent before being catheterized with the test catheters."
224318129|NCT01064752|DRUG|Minocycline|100 mg po bid for 8 weeks
223632402|NCT05740072|OTHER|Drying before wrapping|Immediately after birth, the infant's body will be dried before wrapping in a plastic bag
223632403|NCT05740072|OTHER|No drying before wrapping|Immediately after birth, the infant will be put in a plastic bag without wrapping
223632404|NCT01444612|DRUG|dalteparin|An injectable anticoagulant medication for the prevention of VTE related to cancer surgery. Patients received dalteparin during one day prior to or two days after cancer-related surgery during the hospitalization.
223632405|NCT01444612|DRUG|enoxaparin|An injectable anticoagulant medication for the prevention of VTE related to cancer surgery. Patients received enoxaparin during one day prior to or two days after cancer-related surgery during the hospitalization.
223632406|NCT01444612|DRUG|fondaparinux|An injectable anticoagulant medication for the prevention of VTE related to cancer surgery. Patients received fondaparinux during one day prior to or two days after cancer-related surgery during the hospitalization.
224220982|NCT00802750|DEVICE|LoFric POBE|"Unsalted LoFric POBE Hydro-Kit II, Nelaton 40 cm, CH 12 with new solvent Each subject will use the reference catheter LoFric POBE, Nelaton 40 cm, CH 12 with current solvent before being catheterized with the test catheters."
224318130|NCT03232632|DRUG|PET with 18 F-Flutemetamol|PET with 18 F-Flutemetamol (Vizamyl ®)
224318131|NCT03058432|RADIATION|Radiotherapy alone|
223632407|NCT01444612|DRUG|unfractionated heparin|An injectable anticoagulant medication for the prevention of VTE related to cancer surgery. Patients unfractionated heparin received during one day prior to or two days after cancer-related surgery during the hospitalization.
223764332|NCT04850612|OTHER|Survey|Delphi Survey on core outcomes, CSDH definition and data elements
223764333|NCT06619457|OTHER|Mitopure (Urolithin A) Cream|cosmetic cream to be applied topically on face and forearms twice/daily using split/face design
223764334|NCT06619457|OTHER|Placebo Cream|cosmetic cream to be applied topically on face and forearms twice/daily using split/face design
224220983|NCT01224756|DRUG|Tinoridine HCl|Tinoridine HCl 50 mg, orally, 2 capsules three times daily for up to 4 days.
224220984|NCT01224756|DRUG|Placebo|Tinoridine placebo-matching capsules, orally, 2 capsules three times daily for up to 4 days.
224220985|NCT03570580|OTHER|OSA scoring|OSA scoring (four scores: STOP-Bang, P-SAP, OSA50, DES-OSA were performed by several scorers on each patients, after what agreement between scores will be evaluated).
224220986|NCT03967483|DRUG|Indometacin|patient who are taken indomatacin for headaches and migraine
223632408|NCT01630369|DRUG|insulin human (HR1799)|Pharmaceutical form: solution for injection Route of administration: subcutaneous
223632409|NCT03007966|PROCEDURE|Ilioinguinal / Iliohypogastric Block|Patients randomized to this arm will receive 25cc's of Bupivacaine 0.25% + Epinephrine 1:200k + Clonidine 1.66mcg/cc administered via an ultrasound guided ilioinguinal / iliohypogastric block technique.
223632410|NCT03007966|PROCEDURE|Quadratus Lumborum Block|Patients randomized to this arm will receive 25cc's of Bupivacaine 0.25% + Epinephrine 1:200k + Clonidine 1.66mcg/cc administered via an ultrasound guided quadratus lumborum block technique.
223764335|NCT06504251|DIAGNOSTIC_TEST|Delirium Diagnostic Tool-Provisional ( DDT-Pro )|The Delirium Diagnostic Tool-Provisional (DDT-Pro) is another tool created to assist in the diagnosis of delirium. It does not require specialist expertise. It can assess the main symptoms of acute confusion, including cognitive ability (Cognition), higher-level thinking skills (Higher level thinking), and the sleep-wake cycle (Sleep-wake cycle).
224220987|NCT05464290|PROCEDURE|NANOfat grafting|The nanofat in a 10 cc syringe connected with a 23 gauge needle is then used to create a lot of tunnels in the plane of the sclerotic tissues and the nanofat is delivered into the tunnels. During injection the area is massaged to achieve complete releasing of fibrous tissue that was feel under the fingers.
224220988|NCT01725945|BEHAVIORAL|Dietary Approaches to Stop Hypertension dietary pattern|The intervention will employ a series of small group and individual sessions, followed by periodic telephone contacts, to help participants make appropriate dietary changes and develop the skills to maintain these changes over the long term. The initial 3 months of intensive intervention will involve 8 group and 3 individual sessions for 45-60 minutes each. During the next 3 months, participants will receive counseling phone calls once per month for 20-30 minutes each call. Group session sizes may range from 8-15 participants.
224220989|NCT02123056|DRUG|Metoprolol|the daily dose range is 25mg twice a day to a maximum of 100mg twice a day
224220990|NCT02123056|DRUG|Matching Placebo|the daily dose range is 25mg twice a day to a maximum of 100mg twice a day
224220991|NCT00405977|DRUG|Physiologic saline|Intravenous infusion of the study solution, 1 ml per kg bodyweight, corresponding to MgSO4 60 mg kg-1 in the magnesium group and 1 ml per kg physiological saline. The infusion will be given with during 15 minutes.
224220992|NCT00405977|DRUG|Magnesium sulphate|Intravenous infusion of the study solution, 1 ml per kg bodyweight, corresponding to MgSO4 60 mg kg-1 in the magnesium group. The infusion will be given during 15 minutes.
224220993|NCT01167855|OTHER|Asthma Education Sessions|Comprehensive asthma education sessions delivered via telemedicine.
224220994|NCT01167855|OTHER|Asthma Health Assessment via Telemonitoring|Each intervention participant will undergo assessment of asthma via school-based telemonitoring to measure lung function and provide a self-report of asthma symptoms.
224220995|NCT01167855|OTHER|Provider Treatment Prompt|A treatment prompt will be mailed to the primary care provider at baseline and 3 months.
224220996|NCT01167855|OTHER|School Absenteeism|Absenteeism before and after the intervention will be compared in the intervention group and also will be compared to absentee rates of the usual care group.
224220997|NCT01167855|OTHER|Prescription Filling Profile|Study personnel will monitor participants' prescription profiles.
224220998|NCT05821712|DRUG|0.2% zinc lactate, 0.17% amine fluoride and 0.0275% sodium fluoride Mouthwash|mouthwash
224220999|NCT05821712|DRUG|0.057% sodium fluoride Mouthwash|mouthwash
224318132|NCT03058432|RADIATION|Concurrent chemoradiotherapy|
224318133|NCT02748967|DRUG|ExPEC4V|Participant will receive single dose 0.5 ml of ExPEC4V as intramuscular injection on Day 1.
224318134|NCT02748967|DRUG|Placebo|Participant will receive single dose of Placebo on Day 1.
224318135|NCT05503810|BEHAVIORAL|Social support|Contact ones a week with Informal caregiver or peer support
224318136|NCT06102083|DRUG|TDI01 suspension|"Experimental group 1:~Drug: TDI01 suspension Administration: TDI01 suspension once daily.~Experimental group 2:~Drug: TDI01 suspension Administration: TDI01 suspension once daily.~Control group:~Drug: Placebo Administration: Placebo once daily."
224318137|NCT05535153|OTHER|functional movement screen|The volunteer subjects had to perform the FMS test at the request of the investigator, which is made up of seven movements: the squat, the crossing of the hurdle, the line lunge, the active elevation with the straight leg, a movement concerning the mobility of the shoulders, a rotational stability assessment movement and a core stability assessment movement.
224318138|NCT01840865|DEVICE|brain stimulation|oscillating direct current brain stimulation
224221000|NCT05164549|DRUG|Buprenorphine Injectable Product|Investigational Medicinal Product
224221001|NCT05164549|DRUG|Methadone|Standard of Care
224318139|NCT01840865|DEVICE|no stimulation|sham Stimulation
224318140|NCT02365194|BEHAVIORAL|Prehabilitation|information included in arm description
224318141|NCT02365194|BEHAVIORAL|Standard counseling|information included in arm description
223632411|NCT03007966|DRUG|Bupivacaine 0.25%|Administered as part of the local anesthetic mixture
223632412|NCT03007966|DRUG|Epinephrine 1:200k|Administered as part of the local anesthetic mixture
223632413|NCT03007966|DRUG|Clonidine 1.66mcg/cc|Administered as part of the local anesthetic mixture
223632414|NCT02963246|BEHAVIORAL|Mindfulness|"Mindfulness-based therapy has been used effectively to treat a variety of physical and psychological disorders, including depression, anxiety, and chronic pain. Recently, several lines of research have explored the potential for mindfulness-therapy in treating somatization disorders, including fibromyalgia, chronic fatigue syndrome, and irritable bowel syndrome. Mindfulness-based therapies (MBT) are a clinical application involving the key element of nonjudgmental acceptance of physical pain or psychological distress, thereby reducing the tendency to ruminate over and catastrophise these experiences.~In the present study, we propose a mindfulness intervention of 12 months, with sessions either personalized or online."
223632415|NCT02655120|PROCEDURE|Drilling|
223632416|NCT02655120|BIOLOGICAL|Bone Marrow +BMP7|
223764336|NCT06120283|DRUG|BGB-43395|Planned doses administered orally.
223764337|NCT06120283|DRUG|Fulvestrant|Standard dose administered via intramuscular injection.
223764338|NCT06120283|DRUG|Letrozole|Standard dose administered orally as a tablet.
223632417|NCT01181063|DRUG|Budesonide/formoterol 320/9 μg and 400/12 μg inhalers|Budesonide/formoterol 320/9 μg and 400/12 μg in different kind of inhalers and Symbicort Turbuhaler forte 320/9 μg. Ech subject will be randomly allocation to 4 of 5 products, a single dose administration of each product
223632418|NCT04062786|OTHER|Pmsf-PVC gradient measurement|implementation of standard standard hemodynamic monitorin
223632419|NCT04866784|DEVICE|Transcutaneous Electrical Nerve Stimulation (TENS)|Transcutaneous electrical nerve stimulation (TENS) is a non-pharmacologic intervention for acute and chronic pain. This treatment involves the application of electric current through the skin; it is safe, easy to use, and inexpensive
223632420|NCT03459079|DRUG|Lanifibranor|The film-coated tablet contains 400 mg of the active ingredient lanifibranor (IVA337) for an immediate release formulation. Participants receive 800mg/ day
223632421|NCT03459079|OTHER|Placebo|Film-coated tablets with a core containing 900 mg of a physical mixture of lactose monohydrate, microcrystalline cellulose, pre-gelatinized starch and magnesium stearate serve as placebo.
223632422|NCT02437344|DRUG|CI-581aa|92 minute infusion of CI-581aa
223632423|NCT02437344|DRUG|Naltrexone titration and XR-NTX initiation|participants will be provided a titration of naltrexone that culminates in the injection of XR-NTX
223632424|NCT05539625|DIETARY_SUPPLEMENT|MitoQ|"MitoQ in inflammation: In the experimental setting, MitoQ has been extensively studied with clear mode of action on inflammatory mechanisms relevant to IBD:~MitoQ can limit the damage to mitochondria caused by mitochondrial ROS and thereby reducing the leak and oxidisation of mtDNA that are critical to its pro-inflammatory actions within the cell.~MitoQ reduces the inflammatory potential of mitochondrial DNA which have escaped or released from dying inflammatory cells.~MitoQ can influence how the immune cells generate their energy, diverting it away from a more inflammatory type of metabolism (glycolysis) MitoQ can induce autophagy, a cellular recycling mechanism that removes damaged mitochondria. Defective autophagy is heavily implicated in the pathogenesis of IBD.~Hence collectively, MitoQ acts upstream of several pro-inflammatory mechanisms with the net effect to promote resolution of inflammation and mucosal healing."
224221002|NCT05164549|DRUG|Buprenorphine|Standard of Care
224221003|NCT02720952|DRUG|Infacort®|dry granule formulation of hydrocortisone
224221004|NCT04289220|BIOLOGICAL|Anti-CD19 CAR-T Cells Injection|Dosage form：injection Dosage:1-2.5x10\^6 cells/kg, 100ml/time, The CAR-T cells will be administered by i.v. injection over 20-30 minutes, Frequency: total one time
224221005|NCT05558722|DRUG|Anlotinib|Anlotinib (12 mg qd, d1-14; 21 days per cycle; total 5 cycles) Combined TAC×6 cycles: albumin-bound paclitaxel (200mg/m2, 1d Q3W) + pirarubicin （50mg/m2, 1d Q3W) + cyclophosphamide (500mg/m2, 1d Q3W);
224221006|NCT01995617|BIOLOGICAL|Placebo|normal saline, 0.5 mL per dose
224221007|NCT01995617|BIOLOGICAL|GEN-004 Low Dose|The GEN-004 Low Dose contains 10µg of each of the three antigens.
224221008|NCT01995617|BIOLOGICAL|GEN-004 Low Dose + Adjuvant|The GEN-004 Low Dose contains 10µg of each of the three antigens in combination with 350µg of aluminum hydroxide adjuvant.
224221009|NCT01995617|BIOLOGICAL|GEN-004 Mid Dose|The GEN-004 Mid Dose contains 30µg of each of the three antigens.
224221010|NCT01995617|BIOLOGICAL|GEN-004 Mid Dose + Adjuvant|The GEN-004 Mid Dose contains 30µg of each of the three antigens in combination with 350µg of aluminum hydroxide adjuvant.
224221011|NCT01995617|BIOLOGICAL|GEN-004 High Dose|The GEN-004 High Dose contains 100µg of each of the three antigens.
224221012|NCT01995617|BIOLOGICAL|GEN-004 High Dose + Adjuvant|The GEN-004 High Dose contains 100µg of each of the three antigens in combination with 350µg of aluminum hydroxide adjuvant.
224318142|NCT03865368|OTHER|Whole Body Vibration Training|Whole Body Vibration Training (WBVT) method has been used as an alternative to conventional strengthening exercises. In this method, the patient stands on the platform of the WBVT device in a static position or performs dynamic exercises, the mechanical vibration produced by the device is transferred to the body
223632425|NCT05539625|OTHER|Placebo|Placebo
223632426|NCT02118584|DRUG|Etrolizumab|Participants will receive etrolizumab 105 milligrams (mg), administered subcutaneously (SC) every 4 weeks for up to 9 years or until either commercial availability or the Sponsor's decision to terminate the study.
223632427|NCT06845761|BEHAVIORAL|Self-Guided Cognitive Behavioral Therapy|Computer Based Training for Cognitive Behavioral Therapy (CBT4CBT) is a set of seven modules that consist of different skills trainings that can be accessed by devices with an internet connection. The version of CBT4CBT that will be provided is the alcohol-based CBT4CBT.
223632428|NCT04018755|BIOLOGICAL|anakinra|anakinra single-use prefilled glass syringes
223632429|NCT05946057|DIAGNOSTIC_TEST|Molecular genetic testing and audiometry|Genetic testing and audiometry are the interventions of interest
223764339|NCT06120283|DRUG|Elacestrant|Standard dose administered orally as a tablet.
223764340|NCT07010705|DEVICE|ActiGraph LEAP|The ActiGraph LEAP has received 510(k) clearance from the US FDA and offers extensive sensor collections, providing continuous digital measures of activity, sleep, mobility, and additional vital signs, including heart rate and variability, oxygen saturation, and skin temperature, in a single fit-for-purpose device.
224221013|NCT04352413|DRUG|PLM60|Administration: Intravenous infusion
224318143|NCT00094406|PROCEDURE|Bronchoscopy|
224318144|NCT00094406|PROCEDURE|Bronchoalveolar lavage|
224318145|NCT00094406|DRUG|Endotoxin|
224318146|NCT00094406|DRUG|Carbon Monoxide|
224221014|NCT01193621|DRUG|haloperidol, PET|"1. Biodistribution study Intravenous 18F haloperidol(10 mCi) Dose injection two times before whole body PET scan~2. D2-receptor occupancy study Group Doses No. of subjects 1 0.5 mg 4 2 1 mg 4 3 3 mg 4~above doses will be administrated orally every 24 hours for 7 days."
224221015|NCT04862390|DEVICE|Continuous glucose monitoring|Home continuous glucose monitoring to be installed for two weeks during fasting Ramadan
224221016|NCT05871879|DIAGNOSTIC_TEST|The 5-item modified frailty index|The mFI-5 contains five items, including hypertension, diabetes, congestive heart failure (CHF), chronic obstructive lung disease (COPD), and physical function status, with each item attributing 1 point. Patients with an mFI-5 score greater than or equal to 2 were considered frail, while those with an mFI-5 score of 0 or 1 were considered nonfrail.
224221017|NCT05971121|DRUG|ciprofol|Ciprofol were used for sedation in ICU hypotensive patients
224318147|NCT04784533|DRUG|CTP-543|Oral dosing
224318148|NCT04784533|DRUG|Placebo|Oral dosing
223632430|NCT05967585|DEVICE|Behavioral: Quitting Program (TIQ)|"Implementation processes developed in Phase 1 to develop assessment of vaping behaviors and referral to an evidence-based program for vaping cessation (TIQ) will be tested in Phase 2.~TIQ program is a mHealth, text messaging based intervention. Users who enroll in this program will receive 1 to 2 messages per day with 3 messages sent on their quit date. Messages are tailored to users' age, enrollment date or quit date, and the vape product they use.~Those not ready to quit receive 4 weeks of messages focused on building skills and confidence. Users who set a quit date receive messages for up to 6 weeks preceding the date and up to 8 weeks after that include encouragement, support, skill- and efficacy- building exercises, coping strategies, etc. Keywords such as COPE, STRESS, SLIP, and MORE can be used to request on-demand support."
223632431|NCT06407726|OTHER|virtual reality training group|Participants will receive 40-minute sessions five days per week for six weeks of Virtual Reality intervention and conventional therapy.
223632432|NCT06407726|OTHER|vestibular exercise group|Participants will receive 40-minute sessions five days per week for six weeks of Vestibular Exercises and conventional therapy.
223632433|NCT06296953|DEVICE|PERIsign examination|Patients will be examined with the new device, PERIsign
223632434|NCT02210117|BIOLOGICAL|Bevacizumab|Given IV
223632435|NCT02210117|PROCEDURE|Biopsy|Undergo biopsy
223632436|NCT02210117|BIOLOGICAL|Ipilimumab|Given IV
223632437|NCT02210117|OTHER|Laboratory Biomarker Analysis|Correlative studies
223632438|NCT02210117|PROCEDURE|Metastasectomy|Undergo metastasectomy
223632439|NCT02210117|BIOLOGICAL|Nivolumab|Given IV
223632440|NCT02210117|PROCEDURE|Therapeutic Conventional Surgery|Undergo nephrectomy
223632441|NCT03557294|DRUG|1.0mg Varenicline b.i.d.|Varenicline is classified as a selective nicotine receptor partial agonist (SNRPA) that works both to stimulate the nicotine receptor and block smoking reward at the α4β2 nicotinic receptor subtype.
223632442|NCT03557294|DRUG|0.5mg Varenicline b.i.d.|Varenicline is classified as a selective nicotine receptor partial agonist (SNRPA) that works both to stimulate the nicotine receptor and block smoking reward at the α4β2 nicotinic receptor subtype.
223632443|NCT03557294|DRUG|0.0mg placebo Varenicline b.i.d.|Product that looks like active varenicline, but contains no active ingredient
223632444|NCT04026113|DRUG|Linaclotide|Oral capsule (For participants who do not wish to take the dose as a capsule, a sprinkled dose may be prepared)
223632445|NCT04026113|DRUG|Placebo|Matching placebo
223632446|NCT05562882|DRUG|Daratumumab Injection|intravenous daratumumab administration
223632447|NCT05398757|BEHAVIORAL|Mini mental state exame (MMSE)|Before the operation, and on the 1st, 3rd and 5th day after the operation, the Mini mental state exam (MMSE) score will be measured
223632448|NCT05398757|BEHAVIORAL|Digit Symbol Substitution Test (DSST)|Before the operation, and on the 1st, 3rd and 5th day after the operation, the Digit Symbol Substitution Test (DSST) score will be measured
223632449|NCT05398757|DIAGNOSTIC_TEST|Numeric rating Scale (NRS)|4h, 8h, 12h and 24h after surgery, pain in all patients will be assessed by the NRS scale.
223632450|NCT05398757|DIAGNOSTIC_TEST|Postoperative inflammation|All patients included in the study will have their blood taken for laboratory analysis of red blood cells, leukocytes, CRP, PCT, ChE and IL-6. Analyzes will be performed before the procedure, on the 1st, 3rd and 5th postoperative day.
223764341|NCT07010705|DEVICE|Axivity AX6|The Axivity AX6 is a data logger capable of recording raw data from a suite of integrated sensors. It features a state of the art 6-Axis movement sensor measuring linear acceleration and angular velocity at high precision. All sensor locations and Orientations are identical to the AX3 for maximum compatibility. All data is stored in its raw, unaltered format on the embedded flash memory.
223764342|NCT01592968|OTHER|Cognitive Assessment|Ancillary studies
223764343|NCT01592968|OTHER|Quality-of-Life Assessment|Ancillary studies
223764344|NCT01592968|RADIATION|Stereotactic Radiosurgery|Undergo SRS
223764345|NCT01592968|RADIATION|Whole-Brain Radiotherapy|Undergo WBRT
223632451|NCT05398757|DRUG|Midazolam|For sedation during surgery, patients in midazolam group will receive i.v. midazolam in dose 0.05 - 0.07 mg/kg after spinal anesthesia.
223632452|NCT05398757|DRUG|Propofol|For sedation during surgery, patients in propofol group will receive i.v. propofol in dose 25-27 mcg/kg/min.
223632453|NCT05398757|DRUG|Dexmedetomidin|For sedation during surgery, patients in dexmedetomidin gropu will receive i.v. dexmedetomidin in dose 0.5 mcg/kg/h
223632454|NCT04613362|BEHAVIORAL|TENACITY Telehealth Cognitive Behavioral Therapy for Migraine|Clinical health psychology therapy delivered via telehealth
223632455|NCT04613362|BEHAVIORAL|Behavioral Usual Care|Behavioral usual care may include outpatient clinic-based health psychology in the VA or Community Care, or mindfulness sessions with LCSW.
223680797|NCT01264627|BEHAVIORAL|Usual Care (UC) Control Condition|"This control intervention is designed to account for the effects of nonspecific factors such as enrollment in a study to enhance health with the associated expectancy effects, staff attention, and measurement procedures including the monitoring of PetCO2 and (Blood Pressure) BP, and completion of questionnaires. Participants who are randomly assigned to the Usual Care condition will receive care as usual for the management of their prehypertensive condition. UC participants will receive their usual care and have access to all Kaiser Permanente (KP) health education resources, such as KP's interactive healthcare guide, and online Healthy Lifestyle Programs. We will assess the extent to which participants in both MB and UC used these resources."
223764346|NCT07018765|BEHAVIORAL|Mindfulness-Based Stress Reduction (MBSR)|The MBSR program consists of eight weekly sessions, each lasting 60-90 minutes. The first session will be delivered face-to-face in the hospital, and the remaining sessions will be conducted online via Zoom. The program content includes mindful breathing, body scanning, stress management, emotional regulation, and interpersonal mindfulness exercises.
224221018|NCT03811379|DRUG|Toripalimab|Drug: Toripalimab, 240mg, every 3 weeks until disease progress or intolerable toxicity
224221019|NCT04371484|OTHER|ICD-10|A collection of ICD-10 codes used within the PMSI that relate to physical abuse.
224221020|NCT03739359|OTHER|nasal cannula gas flow|High flow nasal cannula (HFNC) is a relatively new oxygen device, which provides warmed and humidified oxygen for patients. When patients need to inhale aerosolized medication during HFNC, the nebulizer will be placed in-line in order to provide both treatments. This study will investigate the influence of three flow settings (50 L/min, GF:IF=1, GF:IF=0.5) on the clinical effects of nebulization.
223632456|NCT06221280|PROCEDURE|Nerve block|"Group E: While performing the erector spina plan block; Patients are placed in the lateral decubitus position, aseptic conditions are provided, the spinous process in the midline is determined under ultrasonography guidance, and the transverse process is determined 3 cm laterally from the T11 level. 100 mm 22G block needle erector.~Group T: The lumbar petit region will be determined and placed on the lateral abdominal wall at the mid-axillary line, between the iliac crest and the lower costal arch, via a linear probe (12-15 MHz probe). After determining the internal oblique muscle as the thickest muscle and the transversus abdominis muscle as the thinnest muscle, a 100 mm 22 G needle will be placed in the same plane as the USG probe (in-plane or long axis technique). The progress of the needle will be observed on ultrasound along with the facial click sensation. After the second click sensation is felt between the internal oblique and transversalis fascia."
223632457|NCT03790332|DRUG|Ibrutinib|Ibrutinib capsule, tablet, or suspension administered orally once daily
223632458|NCT06239883|OTHER|Voiding diary|The patients with diagnosed OSA will be asked to fill in the voiding diary.
224221021|NCT03895099|DRUG|Desogestrel early follicular phase|Start of ovarian stimulation in early follicular phase
224221022|NCT03895099|DRUG|Desogestrel medium follicular phase|Start of ovarian stimulation in medium follicular phase
224221023|NCT03895099|DRUG|Desogestrel ovulatory phase|Start of ovarian stimulation in ate follicular phase
224221024|NCT03895099|DRUG|Desogestrel late follicular phase|Start of ovarian stimulation in ovulatory Phase
224221025|NCT03895099|DRUG|Desogestrel luteal phase|Start of ovarian stimulation in luteal phase
224221026|NCT02257359|DRUG|Epelsiban|Epelsiban will be supplied as a 25 mg white to off-white round direct compression oral tablet.
224221027|NCT03089632|OTHER|Gluten-free diet|One-month gluten-free diet
224221028|NCT02680795|DRUG|Belinostat IV|"Cohort A:~Belinostat 1000mg will be administered once daily on days 1 through 5 of one 21-day cycle via 30-minute IV infusion.~Cohort B:~Belinostat 1000mg will be administered once daily on days 1 through 5 of one 21-day cycle via 30-minute IV infusion.~Cohort C:~Belinostat 750mg will be administered once daily on days 1 through 5 of one 21-day cycle via 30-minute IV infusion."
224221029|NCT01044147|BEHAVIORAL|VLM-S|Online program for weight loss - standard
224221030|NCT01044147|BEHAVIORAL|VLM-M|Online program for weight loss - modulated
224221031|NCT01044147|BEHAVIORAL|OGR|Online program for weight loss - resources
224221032|NCT06177678|DRUG|TFC-003|1 drop of TFC-003 ophthalmic solution twice a day for 4 weeks.
224221033|NCT06177678|DRUG|COSOPT ophthalmic solution|1 drop of TFC-003 ophthalmic solution twice a day for 4 weeks.
224221034|NCT00720798|DRUG|Tocilizumab|For participants weighing \> 100 kg, the maximum dose of tocilizumab was 800 mg. Tocilizumab was supplied as a sterile solution in vials.
224221035|NCT00720798|DRUG|Disease-modifying anti-rheumatic drugs|Disease-modifying anti-rheumatic drugs included methotrexate, chloroquine, hydroxychloroquine, parenteral gold, sulfasalazine, azathioprine, and leflunomide. These drugs could be used alone or in combination, except for the combination of methotrexate and leflunomide, which was not allowed.
224221036|NCT00720798|DRUG|Non-steroidal anti-inflammatory drugs|Participants could be treated with non-steroidal anti-inflammatory drugs up to the maximum recommended dose throughout the study. The choice and doses of non-steroidal anti-inflammatory drugs were at the discretion of the investigator.
224221037|NCT00720798|DRUG|Oral corticosteroids|Oral corticosteroids (≤ 10 mg/day) were permitted during the study.
224318149|NCT04339283|DIETARY_SUPPLEMENT|Standardized Hibiscus sabdariffa tea|Daily consumption of Standardized Hibiscus sabdariffa tea
224221038|NCT00778947|PROCEDURE|Harmonic Synergy Dissecting Hook (Harmonic Scalpel)|Harmonic Synergy Dissecting Hook (Harmonic Scalpel) uses ultrasound waves to coagulate and cut in surgery. It is available on the market, holds a CE mark and is coded as a Class IIb medical device.
224221039|NCT00778947|PROCEDURE|Electrocautery Diathermy|Electrosurgery uses high temperatures (150-400oC) and causes obliterative coagulation. Diathermy is the use of high frequency electric current to produce heat. In surgery it is used to cut or destroy tissue and/or to produce coagulation. The electrical frequency produced in diathermy is in the range of 300kHz to 3MHz.
224221040|NCT03057587|DEVICE|NIRS Monitoring|NIRS data will be collected throughout the surgery
224221041|NCT00892398|DRUG|ranibizumab|Two ranibizumab subconjunctival injections (0.5 mg ∕ 0.05 mL). The first injection at the end of the surgery (intraoperative) and the second two weeks post-operatively.
224221042|NCT00892398|PROCEDURE|standard care|standard post-operative care after trabeculectomy with mitomycin C
224221043|NCT05461820|DRUG|Methimazole|Methimazole used in this study was produced by Merck, Germany, and its trade name is Thyrozol. The specification of this drug is 10mg/ tablet, and its validity period is 36 months. It was approved by FDA in 2009 and listed in China in 2011.
224221044|NCT05235594|DEVICE|Wearable sensor|The patients will be asked to wear a smart shirt. The shirt is designed with multiple sensors and electrodes fully embedded which engender 6 different measurement flows continuously. The smart t-shirt system is washable, and patients can wash and dry this t-shirt anytime, thus the shirt can be worn repeatedly.
224221045|NCT01455558|DRUG|Pletaal|"Part 1: a single dose of the SR (200mg x 1 tablet, QD) and IR (100mg x 2 tablets, BID) formulation of cilostazol orally 7 days apart in a fasted state~Part 2: a single dose of the SR (200mg x 1 tablet, QD) formulation of cilostazol 7 days apart in a fasted and a fed state~Part 3: multiple doses of the two formulations for eight consecutive days 21 days apart"
224221046|NCT00433381|BIOLOGICAL|Bevacizumab|Given IV
224221047|NCT00433381|DRUG|Irinotecan Hydrochloride|Given IV
224221048|NCT00433381|DRUG|Temozolomide|Given orally
224221049|NCT01438723|DRUG|Metformin|prior to CAGB surgery 3 day treatment with metformin 500 mg three times a day
223632459|NCT02271919|DRUG|Nicotine Lozenge|Given PO
223632460|NCT02271919|DRUG|Nicotine Patch|Given via patch
223632461|NCT02271919|OTHER|Placebo|Given PO or via patch
223632462|NCT02271919|OTHER|Tobacco Cessation Counseling|Receive behavioral smoking cessation counseling
223632463|NCT02271919|DRUG|Varenicline|Given PO
223680798|NCT03767803|OTHER|Non-interventional study|This is an observational, non-interventional study.
224221050|NCT01438723|DRUG|Placebo|prior to CABG surgery 3 day treatment with placebo capsules three times a day
223632464|NCT02218372|DRUG|Fidaxomicin oral suspension|Participants from birth to \< 6 years of age received weight based doses of fidaxomicin oral suspension (32 mg/kg/day with a maximum dose of 400 mg/day divided in 2 doses) 2 times daily for 10 days.
224221051|NCT04117308|PROCEDURE|Classic information|The team delivers to each patient a unique and standardized information brochure including a definition of fetal active movements, and the need to consult if the patient perceives less the movements of her fetus.
224221052|NCT04117308|PROCEDURE|Information by detailed brochure on the fetal active movements account|Delayed single and standardized explanatory card on fetal movements (definition, interests of their follow-up, technique of movements on fetuses, table to fill during the follow-up noting the number of active movements physical feelings at 3 times of the day, managing the decrease in the number of active fetal movements).
224221053|NCT01014390|DEVICE|WallFlex Biliary RX Fully Covered Stent System|Temporary placement of a biliary stent as a treatment of biliary obstruction resulting from benign bile duct strictures. The stent is fully covered with a silicone polymer to reduce the potential of tissue ingrowth into the stent. The stent is removed after 5 months (±1 month) after stent placement in Post-Liver Transplant patients and after 11 months (±1 month) in Chronic Pancreatitis and Post-Abdominal Surgery patients.
224221054|NCT05186610|PROCEDURE|FDG PET/CT guided metabolic core needle biopsy|The target lesion to be biopsied was chosen based on accessibility and the highest metabolic activity (Highest standardized uptake value) on FDG PET/CT imaging. The final needle course was based on the anatomic location of the lesion, FDG avidity, and its relation with vital organs. The procedures were performed under full aseptic precautions and under adequate local anesthesia. The biopsy needle was placed to the target lesion using an automated robotic arm (ARA) workstation (ROBIO-EX, Perfint healthcare Pvt Ltd, Chennai, India).
224221055|NCT01519609|DRUG|bowel prep before endoscopy|bowel prep before colonoscopy
224221056|NCT00501761|BEHAVIORAL|Personalized Exercise Program|Walking up to thirty minutes on most days of the week.
224221057|NCT00501761|BEHAVIORAL|Questionnaire|Questionnaires regarding physical activity, exercise, and quality of life.
224221058|NCT00501761|BEHAVIORAL|Suggested Exercise Program|Exercise program performed over 7 days.
224221059|NCT05381259|BEHAVIORAL|hortitherapy in people living with Alzheimer's taking place in three different day care|"6 users benefiting from the horticultural workshop and 6 others from a usual workshop (control group) This control group will benefit from its usual workshop while the other group will participate in the horticultural workshop.~If it is impossible to carry out the workshops outdoors (rain or high heat), the day reception centers will provide a room to allow the workshops to be carried out. They will be adapted in terms of activities and materials."
224221060|NCT04921033|DIETARY_SUPPLEMENT|EEN (Nestle Modulen®)|35kcal/kg/day for every patient
224221061|NCT04921033|DRUG|Standart of care|"* Budesonide 9mg/day for mild disease~* Prednisolone 1mg/kg, maximum 40mg/day in decreasing doses (40mg for 4 weeks followed by a fixed taper for 6 weeks) for moderate-to-severe disease for 12 weeks.~* Patients with moderate to severe disease in the steroid group will also receive 2mg/kg azathioprine. The dose of azathioprine will be adjusted according to abnormalities of white blood cell (WBC) count, platelet count, liver function tests (LFTs; i.e. alanine transaminase \[ALT\], aspartate transaminase \[AST\], alkaline phosphatase), lipase, blood urea nitrogen (BUN), and serum creatinine."
224221062|NCT00000695|DRUG|Interferon beta-1b|
224221063|NCT00000695|DRUG|Zidovudine|
224221064|NCT04177069|DIETARY_SUPPLEMENT|Visucomplex Plus|capsule contains: Lutein, Zeaxanthin, alphalipoic acid MATRIX, Vitamine E, Zinc, Maquibright® (Aristotelian chilensis berry standardized, containing Anthocyanin and delphinidin extracts), Vitamin D and cupper.
224221065|NCT00133718|DRUG|Combined lifestyle intervention and optimisation of pharmacological treatment|"1. 6 months non-pharmacological treatment, 18 months with polypharmacy for glucose control (metformin, repaglinide/glimepiride, pioglitazone or insulin)~2. standard care"
224221066|NCT01060774|DRUG|Lidocaine|Up to 5 capsules of 2% lidocaine with epinephrine as a reinforcement drug post-operatively
224221067|NCT01060774|DRUG|Bupivacaine|Up to 5 capsules of 0.5% Bupivacaine with epinephrine given post-operatively.
224221068|NCT00598559|DRUG|IV Acetaminophen|Arm 1: 1 g IV Acetaminophen every 6 hours administered for five days. Arm 2: 650 mg IV Acetaminophen every 4 hours administered for five days. Arm 3: The standard of care treatments were defined as any medication the investigator deemed appropriate to treat the subject, including products containing acetaminophen but excluding IV acetaminophen.
224318150|NCT04475783|COMBINATION_PRODUCT|Percutaneous Transluminal Angioplasty (PTA)|PTA with an drug-coated balloon catheter (DCB) in the femoropopliteal artery
224221069|NCT03064542|DRUG|carbimazole (CMZ) or thiamazole (TMZ)|CMZ or TMZ will be used to treat the hyperthyroidism till the FT4/TSH is in normal range.
224221070|NCT05561309|DRUG|HR18034;Ropivacaine Hydrochloride Injection|"Drug: HR18034~Drug: Ropivacaine Hydrochloride Injection~Local nerve block of Ropivacaine Hydrochloride Injection to produce anesthesia for surgery and analgesia in postoperative pain management.~Other Name: Ropivacaine Hydrochloride Injection, 0.5% Injectable Solution"
224221071|NCT05636878|OTHER|Mobile Intervention Team in Perinatal Psychiatry (EMPPer)|The Mobile Intervention Team in Perinatal Psychiatry consists in going towards the most excluded patients, changing the organization of care compared to the current practice and facilitating access to care for the most vulnerable populations
224221072|NCT05924711|OTHER|Retrospective analysis of demographic and radiographic data previously obtained from the patient.|The patient's demographic data obtained previously by anamnesis and clinical examination will be retrospectively analyzsed. On the other hand, a radiographic evaluation including analysis of the implants, adjacent teeth and maxillary sinuses/sinus membranes shall be performed using computer software.
224221073|NCT01059071|DRUG|DFMO|"Escalating doses of DFMO in a 3 +3 cohort design.~DFMO at current cohort Dose Level orally each day for 21 day cycles~Dose level 1: 500 mg/m2 PO BID Dose level 2: 750 mg/m2 PO BID Dose level 3:1000 mg/m2 PO BID Dose level 4:1500 mg/m2 PO BID"
224318151|NCT02632461|BEHAVIORAL|Podcasts|Participants will receive twice weekly podcasts that will cover topics related to weight loss.
224318152|NCT02632461|BEHAVIORAL|Mobile Diet Application|Participants will use a mobile application on their smartphone to track their diet.
223632465|NCT02218372|DRUG|Fidaxomicin tablets|Participants aged ≥ 6 years to \< 18 years of age received a 200 mg fidaxomicin tablet 2 times daily for 10 days.
223632466|NCT02218372|DRUG|Vancomycin oral liquid|Participants from birth to \< 6 years of age received weight based doses of vancomycin oral liquid (40 mg/kg/day with a maximum dose of 500 mg/day divided in 4 doses) 4 times daily for 10 days.
224221074|NCT01059071|DRUG|Etoposide|Starting with Cycle 2, etoposide will be given at 50mg/m2/dose PO daily for the first 14 days of each 21 day cycle. Capsules will be rounded to closest 50 mg.
224221075|NCT05963256|DEVICE|Twitch Electrode Array|Monitor train-of-four (TOF) count and percentage
224221076|NCT00198497|DRUG|Placebo|
224221077|NCT00198497|DRUG|Vitrase|Hyaluronidase 55 IU in saline solution
224221078|NCT00198497|DRUG|Vitrase|Hyaluronidase 75 IU in saline solution
224221079|NCT00466297|BEHAVIORAL|Face-to-face communication interactions|
224221080|NCT03496870|DRUG|Opicapone|catechol-O-methyltransferase (COMT) inhibitor
224221081|NCT03496870|DRUG|Carbidopa Levodopa|Levodopa: dopamine precursor Carbidopa: DOPA decarboxylase inhibitor
224221082|NCT06105281|BEHAVIORAL|The consultation with a pain specialist nurse|When the participant receives a consultation with the pain specialist nurse ,there will be assessed if the patient knows what the procedure involves and what they can expect of it. To meet de expectations of the patient the nurse will explain the procedure and what they can expect. Further there will be an short education about what pain is and the physiology of chronic pain. Because chronic pain has a lot of influencing factors the nurse will explain the main factors.
224221083|NCT02036281|DRUG|Substance P-Saporin|
224221084|NCT04529148|DRUG|Ginkgo biloba dropping pills，best western medicine treatment|oral
224221085|NCT04529148|DRUG|Mimetic drug of ginkgo biloba dropping pills，best western medicine treatment|oral
224221086|NCT05760703|DRUG|STSG-0002 Injection|Intravenous infusion
224221087|NCT02270879|PROCEDURE|Phacoemulsification cataract surgery|Phacoemulsification of cataract (opacified lens) using clear corneal approach. Implantation of a intra-ocular lens in the capsular bag
224221088|NCT02371798|DRUG|Gadopentetate dimeglumine|IV administration of 0.2 mmol/kg of Gd-DTPA
224221089|NCT02673164|BIOLOGICAL|CSCC_ASC|The stem cells will be injected directly into the myocardium using the NOGA XP system (BDS, US)
224221090|NCT04816097|DRUG|Dexamethasone phosphate|4 doses of dexamethasone 6mg IM 48h before elective CS.
224221091|NCT00325403|DRUG|Oral treprostinil (UT-15C) Sustained Release Tablets|Sustained release oral tablet, twice daily
224318153|NCT02632461|BEHAVIORAL|Bite Counter|Participants will use a wrist-worn Bite Counter to track the number of bites in their diet per day.
223632467|NCT02218372|DRUG|Vancomycin capsules|Participants aged ≥ 6 years to \< 18 years of age received a 125 mg vancomycin capsule 4 times daily for 10 days.
224221092|NCT00325403|OTHER|Placebo|Placebo oral tablet twice daily
224221093|NCT05930574|PROCEDURE|Abdominal surgery|surgical interventions by gastrointestinal emergencies, hepatobiliary emergencies and trauma
224221094|NCT05177757|OTHER|Yoga Intervention|The yoga exercise program will be conducted at the Marquette campus and will consist of one session per week for 12 weeks. The duration of each session will be approximately one hour. The program the investigators will use is the Mindful Resilience for Trauma Recovery Program (https://www.veteransyogaproject.org/), an evidence-informed practice adapted for veterans with PTSD based on clinical and neuroscientific knowledge. This program is a 12-week protocol developed by a licensed clinical psychologist and is publicly available. All yoga sessions will be standardized based on the resilience program guidelines.
224221095|NCT02909725|OTHER|Limit accumulation of sedentary time|"Participants in this group receive a Fitbit Alta activity monitor, worn on the wrist for the entire intervention. The Alta is a fitness tracker designed to help individuals track their sedentary and physical activity behaviors when paired with an external device (e.g. iPhone, computer). The Sensewear armband and ActivPAL are not worn as part of the intervention; they are assessment tools used at the beginning and end of the study.~Each participant will have a Fitbit account set up with a Blossom Project username code to ensure privacy of the participant's identity. Participants will be asked to achieve a goal of 250 steps/hour. Using the reminder to move function, if a participant has not reached the hourly goal at 50 minutes, the Alta will vibrate, cueing the participant to walk."
224221096|NCT02909725|OTHER|Walk|"Participants in this group receive a Fitbit Charge activity monitor. There is no reminder to move function on this band. The Charge, worn on the wrist for the entire intervention is a fitness tracker designed to help individuals track their physical activity when paired with an external device. The Sensewear armband and ActivPAL are not worn as part of the intervention; they are assessment tools used at the beginning and end of the study.~Each participant will have a Fitbit account set up with a Blossom Project username code to ensure privacy of the participant's identity. Participants will be asked to meet current pregnancy physical activity recommendations; walking 30 minutes, most days of the week (150 minutes/week). Participants can use the app to view their active minutes."
224221097|NCT02909725|OTHER|Normal daily routine; Usual Care|Participants in this group will not be provided with a Fitbit Charge activity monitor, as participants will be asked to simply continue on with their normal daily routine. The Sensewear armband and ActivPAL are not worn as part of the intervention; they are assessment tools used at the beginning and end of the study.
223632468|NCT04816825|DEVICE|Alkit eSence|Home-based rehabilitation program including computer games and supervised by a physiotherapist.
223632469|NCT04816825|OTHER|Standard rehabilitation|Standard rehabilitation program at the COPD-Center
223632470|NCT06513910|BEHAVIORAL|Music|Participants in dyads will be positioned across from each other while listening to various types of music (i.e. music that is harmonically-intact and music in which the harmonic content has been randomly scrambled).
223632471|NCT05136560|DRUG|Dexamethasone|Intervention drugs would be administered for 1 or 2 days.
223680799|NCT04131218|DRUG|Sugammadex|Each patient received a single dose administration of sugammadex 2mg/kg according to the ideal body weight (IBW) at reappearance of the second twitch of the train-of-four (TOF).
223680800|NCT05607836|DEVICE|IntuBrite intubation|Use of new laryngoscope IntuBrite for intubation in patients with cardiopulmonary arrest and during resuscitation
223680801|NCT05607836|DEVICE|Macintosh laryngoscope|Use of standard Macintosh blade laryngoscope for intubation in patients with cardiac arrest and requiring cardiopulmonary resuscitation
223632472|NCT05484102|DIETARY_SUPPLEMENT|milk fermented with lactobacillus paracasei CBA L74|milk fermented with lactobacillus paracasei CBA L74 will be administered daily for 3 months to 100 children. Participants were supplied with the milk product in powder form, by Heinz Italia SpA, Segrate, Italy. The study products were provided in tins containing 400 g of powder, and the packaging was similar and the tins were stored at room temperature in a dry environment. The family pediatricians instructed parents about the daily amount of the assigned study product and the method of preparation. All subjects received 7 g/day of study products diluted in a maximum of 150 mL of cow's milk or water. After dilution, the look and the taste were the same for all of the study products.
223632473|NCT05484102|DIETARY_SUPPLEMENT|placebo milk formula|placebo milk formula containing maltodextrins will be administered daily for 3 months to 100 children. The study products were provided in tins containing 400 g of powder, and the packaging was similar and the tins were stored at room temperature in a dry environment. The family pediatricians instructed parents about the daily amount of the assigned study product and the method of preparation. All subjects received 7 g/day of study products diluted in a maximum of 150 mL of cow's milk or water. After dilution, the look and the taste were the same for all of the study products.
223632474|NCT05629988|DEVICE|IA with TheraSorb ® column|IA cycle is 5 days, repeat cycles will be given to responders at months 3 and 6
223632475|NCT06415175|DRUG|Dupilumab|This study will not administer any treatment, only observe the treatment as prescribed in real world-clinical practice.
223632476|NCT04146051|DRUG|Descartes-08|Autogolous T-cells expressing a chimeric antigen receptor directed to BCMA
223632477|NCT04733768|DIAGNOSTIC_TEST|18F-PSMA-1007|18f-PSMA-1007 PET/CT scan
223632478|NCT02753283|DRUG|denosumab|Semi-annual dose: 60 mg injection; Vitamin D 800-1000 IU/daily and Calcium approximately 1200 mg/daily (dietary + supplement)
223632479|NCT02753283|DRUG|Placebo|Semi-annual saline injection
223632480|NCT02753283|DIETARY_SUPPLEMENT|Calcium and Vitamin D|Dietary supplement: Vitamin D 800-1000 IU/daily and Calcium approximately 1200 mg/daily (dietary + supplement)
223632481|NCT05007405|OTHER|Groups/Cohortes|Retrospective study on medical file of patients with osteoarticular infections diagnose (date of the positive bacteriological sample) between January 1, 2010 and December 31, 2020
223632482|NCT04474080|BEHAVIORAL|Virtual Peer Support Platform|The intervention program will consist of 6 virtual 30-minute sessions delivered across three months. Sessions will follow a structured format including: check-in, issue identification \& context, facilitated discussion, environmental strategies, occupational strategies, experiential component, as well as summary and sign-out. Meetings will finish with a stress relieving activity, to be performed together on the web-based platform. The facilitated discussions will follow important themes including focus on self, patients, and external stressors.
223632483|NCT04474080|BEHAVIORAL|Control Period|The control period will be the time prior to randomization and commencement of the intervention, whereby residents will continue with their regular academic day activities during the allotted intervention time
223632484|NCT04386291|BEHAVIORAL|Anxiety Reduction Training|Educational material will be provided every two weeks that address different aspects of anxiety and cognitive-behavioral approaches to reduce anxiety and stress.
223632485|NCT04386291|BEHAVIORAL|Kundalini Yoga and Anxiety Reduction Training|Daily practice of Kundalini Yoga (light stretching, breathing exercises, and meditation) guided by on-line video instruction, as well as the biweekly anxiety reduction psychoeducation.
223632486|NCT04386291|BEHAVIORAL|Meditation and Anxiety Reduction Training|Daily practice of meditation (muscle relaxation, breathing, and meditation) guided by on-line video instruction, as well as the biweekly anxiety reduction psychoeducation.
223632487|NCT03158844|OTHER|Standard of care|Routine standard of care per Ministry of Health protocol, including blood draws and examinations.
223632488|NCT06206824|DRUG|Leucettinib-21|See arm's description.
223632489|NCT01300754|PROCEDURE|Dextrose Injection|12.5 Dextrose in 1% Lidocaine injected monthly for 3 months with a 27 gauge needle on painful areas of the tibial tuberosity, under the patellar tendon.
223632490|NCT01300754|PROCEDURE|Lidocaine Injection|1% Lidocaine injected monthly for 3 months with a 27 gauge needle on painful areas of the tibial tuberosity, under the patellar tendon.
223632491|NCT01300754|OTHER|Usual Care|Therapist supervised exercises that are standard of care for Osgood-Schatter Disease as well as relative rest and gradual resumption of pain-limited sport.
223632492|NCT05817656|DRUG|Sucralfate|3g of sucralfate powder through colonoscopy will be sprayed precisely on the polypectomy wound in the intervention group
223632493|NCT04331587|DEVICE|BF-P190 4 mm thin bronchoscope|"* EVIS EXERA III Bronchofiberviedoscopes~* Olympus"
223632494|NCT04331587|DEVICE|BF-MP190F 3 mm ultrathin bronchoscope|"* EVIS EXERA III Bronchofiberviedoscopes~* Olympus"
223632495|NCT04331587|DEVICE|Radial ultrasound probe (UM S20-17S)|-Olympus
223632496|NCT04331587|DEVICE|PeriView FLEX 21G Single Use Aspiration Needle|"* NA-403D-2021~* Gyrus ACMI, Inc."
223632497|NCT03015766|OTHER|auricular acupressure therapy|Auricular acupressure, is a therapeutic method in which specific acupoints on the ear are stimulated to treat various disorders of the body. This practice is based on the theory that there are specific points on the auricle which correspond to major organs or systems of the body; and therapeutic effect on the corresponding target organ or system can be exerted by manipulating auricular acupoints. Auricular acupressure applies stimulation through pressure on specific acupoints by the imbedded beads, usually Semen Vaccaria (Wang Bu Liu Xing) or stainless steel beads. This therapeutic method is non-invasive and can be self-manipulated by the recipients at times required.
223632498|NCT03015766|OTHER|sham auricular acupressure therapy|The intervention is the same as that in the experimental group only when the points are five Helix points (HX 5-9). These points are clearly remote from the inner ear area and have no evidence for insomnia treatment.
223680802|NCT04686487|PROCEDURE|stereotactic ablative radiotherapy|stereotactic ablative radiotherapy by targeting high energy heavy ion beams at a specific area of the body
223680803|NCT06074601|DIAGNOSTIC_TEST|Mirvie Predictive Test for Adverse Pregnancy Outcomes|This is a proprietary biomarker and clinical factor-based algorithm for predicting which pregnancies are at greatest risk of developing a variety of adverse pregnancy outcomes (e.g., preterm birth, preeclampsia)
224318154|NCT07047781|OTHER|Assessment|Individuals between the ages of 7 and 14 who are receiving primary education and meet the inclusion criteria will be included in this study planned to evaluate the relationship between smartphone addiction and thoracic hyperkyphosis in children with thoracic hyperkyphosis.
223632499|NCT02674035|PROCEDURE|Correction of diastasis of the rectus abdominis muscles|Thirty women with similar abdominal deformities, who had had at least one pregnancy, were randomized into three groups to undergo abdominoplasty. Plication of the anterior rectus sheath was performed in two layers with 2-0 monofilament nylon suture (control group) or in a single layer with either a continuous 2-0 monofilament nylon suture (group I) or using a continuous barbed suture (group II). Operative time was recorded. All patients underwent ultrasound examination preoperatively and at 3 weeks and 6 months postoperatively to monitor for diastasis recurrence. The force required to bring the anterior rectus sheath to the midline was measured at the supraumbilical and infraumbilical levels.
224221098|NCT02681965|BEHAVIORAL|LEAN book/videos|The intervention focuses on achieving long lasting lifestyle changes to achieve weight loss and maintenance. Women randomized to the weight loss program will receive the LEAN book, as well as a CD and flash drive with the LEAN videos (and internet link), a pedometer and the Log Book for recording their food intake and physical activity.
223632500|NCT04366414|OTHER|hook breathing removing nose-clip|"Participants will perform 3 days per week of usual training, involving intense exercise 8 submaximes-dynamic apnoeas with 3-minute recovery between each one per session, and continuous training of free style swimming at moderate effort over 30 minutes, including warm-up, recovery between intervals and cool down.~The experimental breathing protocol consisted on to remove nose-clip previous to surface and then perform hook breathing during 20 seconds."
223632501|NCT04366414|OTHER|usual breathing (UB)|Participants will perform 3 days per week of usual training, involving intense exercise 8 submaximes-dynamic apnoeas with 3-minute recovery between each one per session, and continuous training of free style swimming at moderate effort over 30 minutes, including warm-up, recovery between intervals and cool down.
223632502|NCT05172128|DIETARY_SUPPLEMENT|lyophilized blueberry supplement|lyophilized blueberry supplement bid
223632503|NCT00074711|DRUG|Calcium carbonate|Participants will receive teriparatide and vitamin D during the course of the 12-month study. They will also receive calcium carbonate.
223632504|NCT00074711|DRUG|Calcium Phosphate|Participants will receive teriparatide and vitamin D during the course of the 12-month study. They will also receive calcium phosphate.
223632505|NCT02340793|DIETARY_SUPPLEMENT|Counterweight Plus|A non-surgical, nutritionally replete weight management programme comprising a Total Diet Replacement Plan (TDR) of 800+ calories/day to produce a weight loss of \>15kg over 12-20 weeks; followed by a structured Food Reintroduction phase for 6-8 weeks and a Weight Loss Maintenance phase; total intervention period 2 years.
223632506|NCT00671658|DRUG|Rituximab|375 mg/m2 by vein
223632507|NCT00671658|DRUG|Cyclophosphamide (CTX)|300 mg/m2 by vein
223632508|NCT00671658|DRUG|Doxorubicin|50 mg/m2 by vein
223632509|NCT00671658|DRUG|Vincristine|2 mg by vein
223632510|NCT00671658|DRUG|Dexamethasone|40 mg by vein or by mouth (P.O.)
223632511|NCT00671658|DRUG|Methotrexate (MTX)|"12 mg intrathecally (6 mg if via Ommaya reservoir) for Courses 1,3,5,7~200 mg/m2 by vein followed by 800 mg/m2 for Courses 2,4,6,8"
223632512|NCT00671658|DRUG|Cytarabine|"100 mg intrathecal for Courses 1,3,5,7~3 gm/m2 by vein for Courses 2,4,6,8"
223632513|NCT00671658|DRUG|G-CSF|10 ug/kg subcutaneous injection
223632514|NCT00671658|DRUG|Mesna|600 mg/m2 a day by vein
223632515|NCT00671658|DRUG|Pegylated asparaginase|2000 International units/m2 by vein
223632516|NCT00671658|DRUG|Pegfilgrastim|6 mg (flat dose) within 72 hrs after completion of chemotherapy
224221099|NCT00406757|DRUG|Nelarabine injection 400mg/m2|"Cycle 1: Nelarabine 400mg/m2 will be administered once a day from Day 1 to Day 5.~Cycle 2 and subsequent Cycles: Nelarabine 650mg/m2 will be administered once daily from Day 1 to DAy 5."
224221100|NCT00406757|DRUG|Nelarabine injection 650mg/m2|Nelarabine 650mg/m2 will be administered once a day from Day 1 to Day 5.
224221101|NCT00406757|DRUG|Nelarabine injection 1000mg/m2|"Cycle 1: Nelarabine 1000mg/m2 will be administered once a day on Days 1, 3 and 5.~Cycle 2 and subsequent Cycles: Nelarabine 1500mg/m2 will be administered once a day on Days 1, 3 and 5."
224221102|NCT00406757|DRUG|Nelarabine injection 1500mg/m2|Nelarabine 1500mg/m2 will be administered once a day on Days 1, 3 and 5.
224221103|NCT05647486|OTHER|30-day postoperative outcome|The 30-day postoperative outcome after elective EVAR and the role of possible predictors among patients' baseline characteristics were assessed
224221104|NCT00465686|DEVICE|ergonomic chair and desk (Q-Learn Classic Chair and Q-Learn Desk)|ergonomic school chair and desk adjusted to fit the child user as per the manufacturer's instructions
223632517|NCT00671658|DRUG|Solumedrol|40 mg by vein for Courses 2,4,6,8
223632518|NCT03696160|DRUG|Biktarvy|Integrase inhibitor used to treat HIV-1 infection
224221105|NCT00465686|DEVICE|ergonomic desk and chair (Q-Learn Desk)|child sits on chair and desk for 5 minutes, then provides handwriting sample at one desk, then repeats this for the other desk
224318155|NCT05189444|DRUG|Vonoprazan|20mg bid
224318156|NCT05189444|DRUG|Amoxicillin|0.75g tid
223632519|NCT03696160|DRUG|Symtuza|Protease inhibitor used to treat HIV-1 infection
223632520|NCT06420804|DEVICE|ZIIP Acne Treatment Device|Evaluation of the Safety and Efficacy of a ZIIP Acne Treatment Device
223632521|NCT01921205|DRUG|Lacosamide|"Subjects \<30 kg (LCM oral solution): 4 mg/kg - 6 mg/kg BID ( 8mg/kg/day - 12 mg/kg/day)~Subjects ≥30 kg to \<50 kg (LCM oral solution): 3 mg/kg - 4 mg/kg BID (6 mg/kg/day - 8 mg/kg/day)~Subjects ≥50 kg (LCM tablets): 150 mg - 200 mg BID (300 mg/day - 400 mg/day)"
223632522|NCT01921205|OTHER|Placebo|"Subjects \<30 kg (placebo oral solution): 4 mg/kg - 6 mg/kg BID (8 mg/kg/day - 12 mg/kg/day)~Subjects ≥30 kg to \<50 kg (placebo oral solution): 3 mg/kg - 4 mg/kg BID (6 mg/kg/day - 8 mg/kg/day)~Subjects ≥50 kg (placebo tablets): 150 mg - 200 mg BID (300 mg/day - 400 mg/day)"
223632523|NCT05766397|DRUG|Methoxyflurane|Methoxyflurane belongs to the fluorinated hydrocarbon group of volatile anesthetic gases
223632524|NCT01007903|BEHAVIORAL|Tai Chi exercise|12-week tai chi exercise class
223632525|NCT02049775|PROCEDURE|NBI|
223680804|NCT01816841|PROCEDURE|fluorescence imaging|Undergo DVFE
223680805|NCT01816841|PROCEDURE|biopsy|Undergo scalpel biopsy
223680806|NCT01816841|PROCEDURE|examination|Undergo COE
223680807|NCT01816841|PROCEDURE|Comparison of surgical margins by COE vs. DVFE|Surgical margin determination using DVFE
224318157|NCT05189444|DRUG|Esomeprazole|20mg bid
224318158|NCT05189444|DRUG|Amoxicillin|1.0g bid
224318159|NCT05189444|DRUG|Clarithromycin|0.5g bid
223632526|NCT05608603|DIAGNOSTIC_TEST|"Portable cardiac monitor CardioQvark"|"Record an electrocardiogram (ECG) in one lead with an assessment of the pulse wave using a portable cardiac monitor CardioQvark (Russia, LLC L Card , RU No. RZN 2019/8124 dated February 15, 2019) once. Devices automatically transfer data to the A\&D Connect app paired with it (link). When transferring data, they are completely protected. The data obtained using the application must be sent to the specialists of the research group in a depersonalized form."
223632527|NCT05608603|DIAGNOSTIC_TEST|Cardiorespiratory stress test|Cardiorespiratory stress testing with gas analysis using the Quark CPET diagnostic system (COSMED, Italy). The study protocol will consist of 4 phases: rest, warm-up, exercise and recovery. During the load phase, a ramp protocol will be used with a stepped load from 10 to 25 W/min. The increase in power will be calculated individually before the start of the study so that the test lasts 8-12 minutes until complete muscle failure.
223632528|NCT05608603|DIAGNOSTIC_TEST|Analysis of exhaled air using the Compact PTR-MS proton mass spectrometer|The analysis of exhaled air will be performed using the Compact PTR-MS proton mass spectrometer manufactured by Ionicon (Austria)
223632529|NCT01657383|PROCEDURE|HPB Surgery|Hepatopancreatico Biliary Surgery
223632530|NCT01612338|BEHAVIORAL|Targeted|Targeted letter and booklet
223632531|NCT01612338|BEHAVIORAL|Enhanced Tailored|Tailored letter and booklet, enhanced family communication and support brochure
223632532|NCT04413500|BEHAVIORAL|Reminder|A reminder to take the anti-hypertension medication with adjustable frequency.
223632533|NCT04413500|BEHAVIORAL|Educational message|An educational message to increase the knowledge about various facts around hypertension. The short messages are supposed to be sent based on the patient's needs.
223632534|NCT04413500|BEHAVIORAL|Motivational messages|The motivational short messages to increase the motivational levels.
223632535|NCT04413500|BEHAVIORAL|showing trends|Short messages contain different trends of medication intake rate, BP, physical activity rate, and so on.
223632536|NCT02359318|PROCEDURE|Resin infiltration|Resin infiltration is done according to manufactures´ instructions after de-bonding of old brackets and prior bonding of new brackets.
223632537|NCT02359318|PROCEDURE|Bonding and debonding of brackets.|Brackets (Gemini metal brackets (3M Unitek) are bonded and de-bonded by one clinician (Roberto Vogel) and using the same bonding and de-bonding techniques and materials for all patients. All brackets were finally de-bonded at the end of the treatment, with silicon impressions taken before adhesive removal.
223632538|NCT01779830|DRUG|LY2624803 - Capsules|Administered orally as capsules.
223632539|NCT01779830|DRUG|Zolpidem - Tablets|Administered orally as tablets.
224221106|NCT00936884|DRUG|Methylnaltrexone|"Subjects received 0.6 mL (12 mg) every other day if weight ≥ 62kg; 0.4 mL (8 mg) every other day if weight between 38 and \< 62 kg; or 0.0075 mL/kg (0.15 mg/kg) every other day if weight between 27 and \<38 kg.~Study duration: 2 weeks double-blind period (MNTX treatments) followed by 12 weeks open-label extension period (MNTX treatments)."
223764347|NCT07173894|PROCEDURE|Shoulder Field Block by Orthopedic Surgeon|"For Shoulder Field Block intervention:~This intervention involves a regional anesthesia technique targeting the sensory nerves of the shoulder surgical field: the suprascapular, axillary, and lateral pectoral nerves. The block is performed intraoperatively by the orthopedic surgeon using anatomical landmarks after induction of general anesthesia. A mixture of lidocaine with epinephrine, bupivacaine, and saline is injected into the shoulder area to provide local anesthesia and prolonged postoperative analgesia. This technique aims to spare the phrenic nerve, potentially reducing respiratory complications associated with traditional blocks."
224221107|NCT00936884|DRUG|Placebo|"Subjects received matching placebo injections.~Study duration: 2 weeks double-blind period (placebo treatments) followed by 12 weeks open-label extension period (MNTX treatments)."
224221108|NCT00217412|DRUG|vorinostat|Given orally
224221109|NCT00217412|DRUG|isotretinoin|Given orally
224221110|NCT03250650|DEVICE|TTNS|Transcutaneous tibial electric stimulation
224221111|NCT03250650|DEVICE|ES+TTNS|Transvaginal electric stimulation
224318160|NCT05189444|DRUG|Bismuth potassium citrate|0.22g bid
224318161|NCT05567263|PROCEDURE|Bulk-fill resin composite, (3M, ESPE)|Teeth will be restored with Bulk-fill resin composite, (3M, ESPE)
223632540|NCT01779830|DRUG|Placebo - Capsules|Administered orally as capsules.
223632541|NCT01779830|DRUG|Placebo - Tablets|Administered orally as tablets.
223632542|NCT03481478|DIAGNOSTIC_TEST|CT and MRI|For such patients, using CT and/or MRI to find if existing humeral surgical neck fractures.
223632543|NCT00186576|PROCEDURE|nonmyeloablative allogeneic hematopoietic cell transplant|
224221112|NCT03432299|PROCEDURE|RFA for PTMC|Radiofequency ablation for papillary thyroid microcarcinoma will be performed using the system including radiofrequency generator and internally cooled electrode.
224221113|NCT04881526|DIETARY_SUPPLEMENT|D-beta-hydroxybutyrate|Drink containing D-beta-hydroxybutyrate administered at a dose of 395 mg/kg.
224221114|NCT04881526|DIETARY_SUPPLEMENT|Placebo|Isocaloric flavored water with medium-chain triglyceride oil.
224221115|NCT04591418|DEVICE|Rotary handpieces|Dental Caries removal
224318162|NCT05567263|PROCEDURE|Surefil one™ Self-Adhesive Composite Hybrid|teeth will be restored with Surefil one™ Self-Adhesive Composite Hybrid
223632544|NCT01578447|DRUG|DepoSubQ Provera 104 in Uniject|DepoSubQ Provera 104 in Uniject
223632545|NCT01578447|DRUG|Intramuscular DMPA|Intramuscular DMPA
223632546|NCT00683436|DRUG|Adipiplon|bilayer tablets 6 mg
223632547|NCT00683436|DRUG|Placebo|Placebo
223632548|NCT00683436|DRUG|Ambien CR|Ambien CR 12.5 mg
223632549|NCT00683436|DRUG|Adipiplon|bilayer tablets 9 mg
223632550|NCT02678949|DRUG|Inhaled Fluticasone 50 mcg/twice day|After 7 days washout period, patients with mild asthma (group 2) will come to visit 2 where carried out a baseline spirometry and MBW test, subsequently will indicate them start treatment with inhaled fluticasone 50 mcg/twice a day, for a period of 4 weeks. At the end of the 4 weeks of treatment patients will come to Visit 3 and perform again spirometry and MBW test.
224221116|NCT04591418|DEVICE|Er:YAG laser|Dental Caries removal
224221117|NCT02429154|OTHER|Normocapnia|Normoventilation in order to have an end-tidal carbon dioxide (ETCO2) of 5.5 kiloPascal (kPa)
224221118|NCT02429154|OTHER|Mild Hypercapnia|Decrease in minute ventilation in order to increase ETCO2 to 6.5 kPa
224318163|NCT03993730|DEVICE|ICD|Insertion of ICD in patients with LVEF \<45% and LGE on CMR.
223632551|NCT02678949|DRUG|Inhaled Fluticasone 100 mcg/twice day|After 7 days washout period, patients with moderate asthma (group 3) will come to visit 2 where carried out a baseline spirometry and MBW test, subsequently will indicate them start treatment with inhaled fluticasone of 100 mcg/twice a day, for 4 weeks period. At the end of the 4 weeks of treatment patients will come to Visit 3 and perform again spirometry and MBW test.
223632552|NCT02678949|DRUG|Inhaled Albuterol|The patients in Group 2 and group 3 performing a baseline spirometry and MBW test, after which one dose of 400 mcg of inhaled albuterol will be administered. Twenty minutes after inhaling the dose of albuterol, spirometry and MBW test will be measured again in both groups.
224221119|NCT03601247|DEVICE|silicone gel|"Patients who have consented to the study will receive two tubes labeled only left and right, corresponding to the side of the face to which the tube contents will be applied. One tube will contain silicone gel and the other tube will contain aquaphor. Neither the patient nor the surgeon will know what side will receive which treatment. These tubes will be given to patients at post-operative week 1 visit. Patients will be instructed to rub the solution into their eyelid incisions gently with their fingers for 2-3 minutes twice a day"
224221120|NCT03293927|DRUG|Fentanyl|The patient will receive IV fentanyl
224221121|NCT03293927|DRUG|Dexmedetomidine|The patient will receive IV dexemedetomidine
224221122|NCT05644691|OTHER|Lipikar Baume AP+M|application of Lipikar Baume AP+M twice daily for 3 months in parallel with the corticosteroid treatment
224221123|NCT05644691|OTHER|Usual emollient|application of the usual emollient twice daily for 3 months in parallel with the corticosteroid treatment
224221124|NCT03103581|DRUG|BLI4700|BLI4700 Bowel Preparation (Investigational Regimen)
224221125|NCT04134975|PROCEDURE|Spine surgery|surgery with pedicle screw placement between L1 and S1
224221126|NCT02245776|BIOLOGICAL|Stem Cell|Intrathecal autologous bone marrow mononuclear cell transplantation
224221127|NCT05574582|PROCEDURE|Graft reconstruction and internal fixation with compression screw|Patients suffering from scaphoid nonunion are treated surgically by debridement, graft reconstruction and internal fixation with compression screw
224221128|NCT01753531|DEVICE|Flu Symptoms|
224221129|NCT01483976|OTHER|Oral medical nutritional supplement|orally over a three hour period
224221130|NCT01483976|OTHER|Experimental oral medical nutritional supplement with AN777|orally over a three hour period
224221131|NCT04544891|OTHER|blood sampling|Blood will be collected every 3 days until Day 28, discharge, or death
224221132|NCT00732329|BEHAVIORAL|Occupational Therapy|"optimized home Based Occupational Therapy including:~* diagnostic assessment~* patient-centered definition of targets involving the care giver~* occupational therapy"
224221133|NCT01211574|BEHAVIORAL|peer coach|Participants will receive behavioral weight loss treatment and be coached by a peer between treatment visits.
224221134|NCT01211574|BEHAVIORAL|mentor|Participants will receive behavioral weight loss treatment and be coached by a mentor between treatment visits.
224221135|NCT01211574|BEHAVIORAL|Professional|Participants will receive behavioral weight loss treatment and be coached by a behavioral weight loss interventionist between treatment visits.
224221136|NCT02223026|DRUG|Linagliptin/metformin FDC|
224221137|NCT02223026|OTHER|high-fat, high caloric meal|
224221138|NCT00249548|BEHAVIORAL|Contingency management|
224221139|NCT04033939|DRUG|HSK3486|
224221140|NCT04033939|DRUG|Propofol|
224221141|NCT04033939|DRUG|Placebo|
223632553|NCT03910634|DRUG|Fluorouracil|1.33g/body surface QW1, continuous intravenous infusion for 72 hours, repeated for 4 weeks
223632554|NCT03910634|RADIATION|Intensity modulated radiation therapy|Radiotherapy for 5-6 weeks，50-60Gy
223632555|NCT03910634|DRUG|carboplatin|Carboplatin (AUC 2), QW1, intravenous drip, repeat for 4 weeks
224221142|NCT04755322|DRUG|Hydroxychloroquine|Hydroxychloroquine 400 mg at start of pregnancy
224221143|NCT04755322|DRUG|Folic acid|5 mg
224221144|NCT04755322|DRUG|Low-dose aspirin|75 mg
224221145|NCT06503744|PROCEDURE|ablation|ablation
224221146|NCT05271201|OTHER|treadmill exercise (mild)|mild intensity treadmill training.
224221147|NCT05271201|OTHER|treadmill exercise (moderate)|moderate-intensity treadmill training
224221148|NCT00200395|DRUG|Tarceva|OSI-774 will be supplied as 25 mg (non -film coated) 100 and 150 mg (film coated) tablets in separate bottles, containing 30 tablets respectively.
224221149|NCT01117064|DEVICE|Neuromodulation Therapy Device (NMTD)|Subjects will have an overnight PSG using CPAP (as previously titrated) for half of the night and NMTD the other half (this order will be randomized). we will monitor NMTD's influence on Apnea Hypopnea Index (AHI), sleep architecture, arousal index, and sleep efficiency compared to the same variables during CPAP use
224221150|NCT01117064|DEVICE|Neuromodulation Therapy Device (NMTD)|Subjects will have an overnight PSG using the NMTD. This device detects reduced airflow via a polymer sensor. When such event is detected, a short burst of sound is administered via earphones. We will determine NMTD's operating characteristics for treatment of OSA. The optimal duration of a detected apnea/hypopnea event before NMTD responds must first be determined. Additional adjustable features include sensitivity of respiratory event sensor, as well as pulse duration, frequency, and intensity of the delivered auditory tone. Since independent adjustment of each of the 4 parameters is not feasible, our screening analysis will test two variables at a time to identify which variables most effectively reduce AHI.
224221151|NCT01117064|DEVICE|Neuromodulation Therapy Device (NMTD)|Subjects will undergo two sequential nights of PSG with NMTD to evaluate if there is any stimulus-response extinction over time.
224221152|NCT02189616|BEHAVIORAL|SMS reminder|send weekly mobile phone short message reminders to the intervention group
224221153|NCT02189616|OTHER|SMS consultation|told patients to consult qualified asthma nurses by SMS when they need
224221154|NCT02189616|OTHER|regular care|patients are asked to fill in their paper asthma diary daily for 3 months
224221155|NCT06044558|DRUG|Combined with voriconazole|Renal transplant patients taking tacrolimus-based triple immunotherapy and voriconazole drug combination.
224221156|NCT06044558|DRUG|Combined with caspofungin|Renal transplant patients taking a combination of tacrolimus-based triple immunotherapy and caspofungin drugs.
223632556|NCT01082861|BIOLOGICAL|Cervarix|Cervarix, HPV vaccin
223632557|NCT01082861|BIOLOGICAL|Engerix-B|Engerix-B, HBV vaccin
223632558|NCT01225874|DRUG|SC-PEG E. coli L-asparaginase|Given IM
223632559|NCT01225874|DRUG|cytarabine|Given IT
223632560|NCT01225874|DRUG|daunorubicin hydrochloride|Given IV
223632561|NCT01225874|DRUG|dexamethasone|Given orally
223632562|NCT01225874|DRUG|methotrexate|Given IT
223632563|NCT01225874|DRUG|pegaspargase|Given IM
223632564|NCT01225874|DRUG|prednisone|Given orally
223632565|NCT01225874|DRUG|vincristine sulfate|Given IV
223632566|NCT04645355|DRUG|Guselkumab|All subjects will initially be treated with guselkumab 100 mg SQ at weeks 0, 4, and then every 8 weeks thereafter until week 44
223632567|NCT03802006|DIAGNOSTIC_TEST|Ultrasound assessment of gastric content|Ultrasound assessment of gastric body is performed
223632568|NCT01527149|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous HDC-ASCT
224221157|NCT06044558|DRUG|Tacrolimus-alone treatment|Renal transplant patients treated with tacrolimus-based triple immunotherapy alone
224221158|NCT01810796|DRUG|Ranolazine|Ranolazine versus placebo
224221159|NCT03596996|DIETARY_SUPPLEMENT|Ferrous Sulfate|Ferrous sulfate dosed by WHO guidelines by age for the prevention of iron deficiency and anemia.
224221160|NCT03596996|DIETARY_SUPPLEMENT|Placebo|Placebo with identical appearance comparison intervention arm
224221161|NCT04960696|DIAGNOSTIC_TEST|OSDI|Change of OSDI in distance education
224221162|NCT04960696|DIAGNOSTIC_TEST|tear break up time|Change of tear break up time in distance education
224221163|NCT04960696|DIAGNOSTIC_TEST|schirmer|Change of schirmer in distance education
224221164|NCT01132716|DRUG|Valacyclovir Hydrochloride|1000 mg caplet
224221165|NCT04532541|OTHER|Monogenic lupus screening|This is an observational study, and there is no intervention. This study intends to obtain the incidence of monogenic lupus in childhood onset SLE through gene test and bioinformatic analysis.
224221166|NCT03569319|BEHAVIORAL|"THINK-MED resource (baseline)"|"The THINK-MED resource contains an information booklet, recipe books, menu plan cards, shopping list cards and goal setting cards. Participants will receive this resource on one occasion at baseline."
224221167|NCT03569319|BEHAVIORAL|"THINK-MED resource (staged)"|"This group of participants will receive the THINK-MED resource at monthly intervals for 5 months accompanied by telephone feedback from the research dietitian"
224221168|NCT03569319|BEHAVIORAL|Control|"Participants will receive the THINK-MED resource after their final 6 month study visit (i.e. delayed intervention)."
224221169|NCT04605419|PROCEDURE|Calcium electroporation|Areas with Barrett's esophagus high-grade dysplasia will get an injection of calcium chloride in submucosa through an endoscopic system before getting electroporation
224221170|NCT05485181|BEHAVIORAL|Spiritual Intervention|The Intervention is a CBT- based psychotherapeutic process that occurs in a group setting with two cohorts of 8 subjects each. It will occur in an introductory 3-hour session followed by 9 weekly 1 ½ hour sessions. In this process, self-worth (self-confidence, self-esteem, self-competence) and dignity (reason, compassion, courage) as operationally defined are strengthened through an interpersonal, psychological process including mindful self-awareness training, attitude transformation with self-compassion, forgiveness, and self-acceptance, and opens to a new level of awareness. This awareness opens to spiritual / numinous features of connectedness, vitality, wholeness, meaning, and serenity that are predicted to be associated with greater well-being and relief of anxiety and depression symptoms.
224221171|NCT04634721|DRUG|bupivacaine|In one arm the TAP infiltration will contain 10 mL of 0.25 % bupivacaine injected . This will then be repeated on the contralateral side.
223632569|NCT01527149|DRUG|Cyclophosphamide|Given IV
223632570|NCT01527149|DRUG|Cytarabine|Given IV
223632571|NCT01527149|DRUG|Dexamethasone|Given IV or PO
223632572|NCT01527149|DRUG|Doxorubicin Hydrochloride|Given IV
223632573|NCT01527149|OTHER|Laboratory Biomarker Analysis|Correlative studies
223632574|NCT01527149|DRUG|Methotrexate|Given IV
223632575|NCT01527149|BIOLOGICAL|Ofatumumab|Given IV
224221172|NCT03015142|DEVICE|New image-guidance software|Patients in this group had spine surgery with new image-guidance software application
224221173|NCT02739815|DRUG|Normal Saline containing a prophylactic Antibiotic 1 g|500 ml of normal saline containing a prophylactic Antibiotic 1 g.
224221174|NCT02739815|DRUG|Tranexamic Acid|Tranexamic acid
224318164|NCT03993730|DEVICE|ILR|Insertion of ILR in patients with LVEF \<45% and LGE on CMR.
223632576|NCT01527149|DRUG|Vincristine Sulfate|Given IV
223632577|NCT02472821|BEHAVIORAL|Interactive youth educational program|Participation in a community-based face-to-face interactive youth educational program focusing on hearing health (i.e., noise hazards, risk of noise-induced hearing loss, mechanism of injury to the internal ear, and preventive measures)
223632578|NCT02472821|BEHAVIORAL|Internet-based educational booster|Visit to an educational Web site focused on hearing health
223632579|NCT05625308|DIETARY_SUPPLEMENT|Epigallocatechin gallate, Folic acid, Vitamin B12, and Hyaluronic Acid|One tablet per day containing 200 mg of EGCG, 400 mcg of Folic Acid, 1 mg of Vitamin B12 and 50 mg of Hyaluronic Acid.
223632580|NCT01586546|BEHAVIORAL|Face-to-Face MBM Skills Group|Mind Body Medicine (MBM) Skills Groups provide a means for study participants to learn skills for taking care of themselves in a supportive small group setting. Participants will learn and practice a variety of specific MBM skills. These MBM skills will enable a participant to change the way she/he deals with the wide range of stressors at different stages of her/his cancer journey. Some of these MBM skills are meditation, guided imagery, biofeedback, writing, and drawing. These groups are designed to assist a participant in coming to know themselves better and in learning and using these tools that will help the participant to deal with the distress as only a small percentage of cancer patients in distress receive appropriate support.
223632581|NCT01586546|OTHER|Waitlist Control I|No intervention offered during study period. Intervention is offered after completion of study.
223632582|NCT01586546|OTHER|Waitlist Control II|No intervention offered during study period. Intervention is offered after completion of study.
223680808|NCT02809261|PROCEDURE|Ultrasound-guided perineural injection with 5% dextrose|Ultrasound-guided perineural injection with 5% dextrose (3cc) between proximal carpal tunnel and surrounding median nerve with hydrodissection.
224318165|NCT06027385|DIAGNOSTIC_TEST|molecular-based screening|Test for three mutations in the CTNS gene and one mutation in the SMA1 gene.
223632583|NCT01586546|BEHAVIORAL|Online MBM Skills Group|Mind Body Medicine (MBM) Skills Groups provide a means for study participants to learn skills for taking care of themselves in a supportive small group setting. Participants will learn and practice a variety of specific MBM skills. These MBM skills will enable a participant to change the way she/he deals with the wide range of stressors at different stages of her/his cancer journey. Some of these MBM skills are meditation, guided imagery, biofeedback, writing, and drawing. These groups are designed to assist a participant in coming to know themselves better and in learning and using these tools that will help the participant to deal with the distress as only a small percentage of cancer patients in distress receive appropriate support.
223632584|NCT01519908|DEVICE|CRT-D (Medtronic)|Biventricular implantable cardioverter defibrillator, post marketing release
223632585|NCT02496286|DRUG|Intraperitoneal Bevacizumab|Bevacizumab 200mg diluted in 250 ml of normal saline
223632586|NCT03572504|OTHER|critically ill children|Compare a series of measurement or size estimation techniques to the WHO standard to identify the most reliable method (s) of pediatric resuscitation.
223632587|NCT03889496|RADIATION|indium-111-exendin SPECT/CT|SPECT/CT imaging after injection with In-111-DTPA-exendin-4
223632588|NCT03082521|BEHAVIORAL|Improving the antibiotic prescribing quality|The goal is to improve the antibiotic prescribing quality of GPs in a GPC by setting up a participatory action research. The interventions will be co-designed with the GPs.
223632589|NCT04389281|COMBINATION_PRODUCT|X-PACT|X-PACT is comprised of a phosphor device, the drug methoxsalen sterile solution and X-ray energy. The dose of methoxsalen sterile solution per injection will vary per patient and will remained fixed across injections within each patient as it is based on the applicable tumor volume at baseline. Immediately after each injection of the combination product, patients will be exposed to an X-ray beam delivered via a LINAC (and thus targeted at the tumor) at a fixed dose to activate the combination product.
223632590|NCT05943691|DRUG|hetrombopag 5mg po qd|hetrombopag 5mg po qd for 8 weeks, combining with dexamethasone 40 mg qd for 4 days
223632591|NCT05943691|DRUG|High-dose Dexamethasone|dexamethasone 40 mg qd for 4 days
224221175|NCT02967133|DRUG|Nivolumab|"Arm A: Nivolumab 240 mg via intravenous infusion (IV) over 30 minutes day 1 of each 14 day cycle until disease progression or not tolerated.~Arm B: Nivolumab 360 mg via intravenous infusion (IV) over 30 minutes day 1 of every 21 day treatment cycle until progression or not tolerated."
224221176|NCT02967133|DRUG|nab-paclitaxel|Patients in arm B receive nab-paclitaxel at a dose of 100 mg/m2 over intravenous infusion on Days 1 and 8 of each 21 day cycle.
224221177|NCT05431309|DIAGNOSTIC_TEST|Coronary Computed Tomography Angiography|Intervention strategies were selected according to CCTA results
224221178|NCT05431309|OTHER|Standard Treatment|Traditional cardiovascular disease prevention strategy based on Chinese guideline
224221179|NCT01518452|BEHAVIORAL|Cogmed JM working memory training|daily training for 5 weeks on a computerized program for training working memory; a total of 25 training sessions. Program: Cogmed JM - preschool version of program: 15-20 minutes training per day
224221180|NCT01518452|BEHAVIORAL|Cogmed JM working memory training after waiting|Waiting after baseline testing for 8 weeks. Daily training on a computerized program for training working memory for 5 weeks. 25 training sessions in total. Program: Cogmed JM - preschool version of program: 15-20 minutes training per day
224221181|NCT01034137|DRUG|methotrexate|orally weekly in ascending dosages, starting at 10mg/week
224221182|NCT01034137|DRUG|placebo MTX|orally weekly
224221183|NCT01034137|DRUG|placebo TCZ|iv every 4 weeks
224221184|NCT01034137|DRUG|tocilizumab [RoActemra/Actemra]|8mg/kg iv every 4 weeks
224221185|NCT00005583|DRUG|cisplatin|
223632592|NCT04308421|DEVICE|Red light|Low irradiation 650 nm +/- 5 nm red light
223632593|NCT01532596|BEHAVIORAL|Mindfulness-Based Stress Reduction|8-week standardized mindfulness meditation training program
224221186|NCT00005583|DRUG|doxorubicin hydrochloride|
224221187|NCT00005583|DRUG|epirubicin hydrochloride|
223632594|NCT05118945|DEVICE|Insulin pump Tandem: t:slim X2|"Insulin pump with Hybrid-Closed Loop - Modus. The insulin pump t:slim X2 from the manufacturer Tandem, in cooperation with the glucose sensor DexCom G6, has the option of using an algorithm called control IQ, which controls the insulin delivery semi-automatically by means of an MPC algorithm. For this purpose, the insulin basal delivery can be increased or decreased by the system. Furthermore, automatic bolus deliveries, which are possible in the amount of up to 60% of a manual correction, can be delivered."
223632595|NCT03868514|DEVICE|TiLOOP® Bra Pocket|Primary or secondary breast reconstruction following mastectomy with titanised polypropylene mesh TiLOOP® Bra Pocket
223632596|NCT02904681|OTHER|No intervention. Observational and descriptive study|
223632597|NCT05104138|DRUG|Eplerenone|The patients underwent eplerenone treatment for 6 months
223632598|NCT05104138|DEVICE|The patients underwent half fluence photodynamic therapy for 6 months|Half fluence photodynamic therapy for 6 months
223632599|NCT03125395|DRUG|LUM/IVA|Participants received LUM/IVA every q12h.
224221188|NCT00005583|PROCEDURE|adjuvant therapy|
224221189|NCT00005583|PROCEDURE|conventional surgery|
224221190|NCT00005583|RADIATION|radiation therapy|
224221191|NCT01718054|DIETARY_SUPPLEMENT|Vascular ready-to-use supplementary food|Daily vascular ready-to-use supplementary food containing protein, energy and fortified with 1 x recommended daily allowance(RDA) of vitamins and minerals except for folic acid = 1mg and with no iron fortificant included and fortified with arginine and citrulline amino acids
224221192|NCT01718054|DIETARY_SUPPLEMENT|Regular Ready-to-use supplementary food|Daily ready-to-use supplementary food containing protein, energy and fortified with 1 x RDA vitamins and minerals except for folic acid = 1mg and with no iron fortificant included.
224221193|NCT01718054|DRUG|Chloroquine|
224221194|NCT01764854|DRUG|AZD1722 (in-patient)|doses between 5 and 60 mg BID may be administered based on tolerability in a CPU setting
224221195|NCT01764854|DRUG|Placebo (in-patient)|Placebo, size and color matched to experimental drug administered in a CPU
224221196|NCT01764854|DRUG|AZD1722 (out-patient)|doses between 5 and 45 mg BID
224221197|NCT01764854|DRUG|Placebo|Placebo, size and color matched to experimental drug
224221198|NCT00936377|DRUG|Dexmedetomidine|Dexmedetomidine at 0.4 or 1.2 µg/kg per hour is administered for a maximum duration of five days
224221199|NCT00936377|OTHER|Placebo|Normal saline for five days.
223632600|NCT03817216|DEVICE|Prostatic Urethral Lift (PUL)|PUL/ UroLift® is an FDA-approved device for the treatment of obstructive symptoms due to benign prostatic hyperplasia (BPH). This study evaluates UroLift's efficacy participants with obstructive symptoms who are candidates for radiotherapy or those who developed obstructive symptoms after radiotherapy.
223764348|NCT07173894|PROCEDURE|Interscalene brachial plexus block and superficial cervical plexus block|This intervention involves a standard interscalene brachial plexus block performed preoperatively by an anesthesiologist under ultrasound guidance. It anesthetizes the upper roots (C5-C7) of the brachial plexus to provide effective analgesia for shoulder surgery. While effective, it carries risks such as hemi-diaphragmatic paralysis, Horner's syndrome, and motor weakness of the ipsilateral arm due to spread to adjacent nerves.
223764349|NCT07174349|DRUG|Uroselective alpha-1-adrenergic receptor antagonist|Subjects will receive Tamsulosin (0.4 mg daily) beginning 5 days prior to surgery and for the duration of the postoperative hospital stay (approximately 8-12 days)
224221200|NCT00521898|PROCEDURE|Descemet Membrane Endothelial Keratoplasty (DMEK)|
224221201|NCT03391297|BEHAVIORAL|Prolonged Exposure Therapy|PE consists of 10-15 treatment sessions. Treatment includes psychoeducation, in vivo exposure (i.e., confronting trauma-related situations and objects that are being avoided), imaginal exposure (i.e., revisiting and recounting traumatic memory) followed by processing (discussing the experience of revisiting the trauma memory, with a focus on new learning and changed beliefs or perspectives).
224221202|NCT04372498|DRUG|Senicapoc (synonyms: ICA-17043; 2,2-bis-(4-fluorophenyl)-2-phenylacetamide)|This study is conducted as open label, with each patient's response determined with an adaptive Bayesian model based on historical and baseline values for the primary endpoints of the trial. 3 monthly dose escalation steps will assess the efficacy of senicapoc in a dose range (10-40 mg/day) which has been used in prior trials for other indications.
224221203|NCT03509298|BIOLOGICAL|Activated CIK and CD3-MUC1 Bispecific Antibody in Treating Pancreatic Cancer|CIK cells was activated by PD-1 inhibitor and bispecific antibody of anti-CD3/MUC1
224221204|NCT03509298|PROCEDURE|cryotherapy|the maximum tumor length≥2 cm，cool down the lesion,result in degeneration, necrosis or loss of the lesion.
224221205|NCT00406198|PROCEDURE|venovenous hemofiltration|
224221206|NCT04211298|DRUG|Dexmedetomidine|Dexmedetomidine will be used for sedation during bronchoscopy
224221207|NCT04211298|DRUG|Propofol|Propofol
224221208|NCT05044442|BEHAVIORAL|moderate intensity continous training|Participants will complete 6 sessions of moderate intensity continous training during a 2 week intervention period. Participants will be asked to complete 30 minutes of continuous exercise.
224318166|NCT06400277|OTHER|Edentulous maxilla final impression for complete denture|Final impressions of edentulous maxilla separated in two groups. In physical impression group stock and individual trays and physical impression materials used.
224318167|NCT02185053|DRUG|CPC-201|
224318168|NCT02505308|OTHER|Glucose-Potentiated Arginine-Induced Insulin Secretion|Intravenous catheters are inserted into antecubital veins in both arms. One arm is used for infusion of glucose/amino acid (Arginine). The other arm is used for intermittent sampling.
224318169|NCT06536959|DRUG|PD-1 inhibitor, Venetoclax, Decitabine, Azacytidine|"For AML patients: PD-1 inhibitor was given at a dose of 200mg on day 21 of the treatment. Venetoclax was given at a dose of 400 mg/day for 28 days per cycle. Decitabine was given at a dose of 20 mg/m2/day for 5 days or azacytidine was given at a dose of 75 mg/m2/day for 7 days at the discretion of the treating physician.~For MDS patients: PD-1 inhibitor was given at a dose of 200mg on day 21 of the treatment. Venetoclax was given at a dose of 400 mg/day for 14 days per cycle. Decitabine was given at a dose of 20 mg/m2/day for 5 days or azacytidine was given at a dose of 75 mg/m2/day for 7 days at the discretion of the treating physician.~The venetoclax starting dose is 100 mg on the first day, ramping up to 200 mg on the second day and finally 400 mg once daily. The steady daily dose (after ramp-up phase) should be reduced to 100 mg (coadministered with moderate CYP3A inhibitors or P-gp inhibitors) and 70 mg (coadministered with strong CYP3A4 inhibitors)."
224318170|NCT05200000|BIOLOGICAL|SygeLIX-Coll-T|Reconstituted suspension made of Trehalose and chemically treated, grinded, freeze-dried and sterilized Wharton's Jelly used by the patient as eye drops.
224318171|NCT01844232|DRUG|arbaclofen|Arbaclofen ER tablets, 20 mg, 30 mg and 40 mg
223632601|NCT01875653|BIOLOGICAL|Autologous Dendritic Cell-Tumor Cell Immunotherapy (DC-TC)|Comparison of a cancer treatment containing patient specific irradiated tumor cells mixed with antigen presenting immune cells suspended in an immune system stimulant vs. a cancer treatment containing patient specific immune cells suspended in an immune system stimulant
223632602|NCT01875653|BIOLOGICAL|Autologous PBMCs in GM-CSF (MC)|Comparison of a cancer treatment containing patient specific irradiated tumor cells mixed with antigen presenting immune cells suspended in an immune system stimulant vs. a cancer treatment containing patient specific immune cells suspended in an immune system stimulant
224318172|NCT04332887|BEHAVIORAL|Multidimensional Exercise Program|Patients in the experimental group will receive a 12-week multidimensional exercise program; patients in the control group will maintain their usual life activities.
224318173|NCT02521376|DRUG|Entospletinib|Entospletinib 100 mg tablet administered orally
223764350|NCT07174349|OTHER|Placebo|Subjects will receive placebo beginning 5 days prior to surgery and for the duration of the postoperative hospital stay (approximately 8-12 days)
224221209|NCT05044442|BEHAVIORAL|high intensity interval training|Participants will complete 6 sessions of high intensity interval training during a 2 week intervention period. The programme involves repeated 1 minute bouts of simple on the spot movements interspersed with 1 minute of rest.
224221210|NCT04497480|BEHAVIORAL|Motor-Assisted and Active Resistive Upper/Lower Extremities Rehabilitation Training System|The Passive, Motor-Assisted and Active Resistive Upper/Lower Extremities Rehabilitation Training System is designed for patients conﬁned to bed at the long-term care facilities hospitals, in early rehabilitation. This system can induce a natural movements of the upper/lower limb with safe motorized passive movement, as well as motor-assisted and active resistive muscle training to stimulate nerves, increase blood circulation of aﬀected tissue, cell metabolism and improve joint mobility, in promoting upper/lower extremities motor recovery.
224221211|NCT02311426|OTHER|Observational study|Function, health related quality of life and rehabilitation needs will be analysed in the two country region groups
224221212|NCT06545240|DIAGNOSTIC_TEST|Mid-upper arm circumference|Mid-upper arm circumference was taken using non-stretchable band SECA 202
223632603|NCT02322632|DRUG|Paricalcitol Capsules, 4 mcg|Paricalcitol Capsules, 4 mcg of Dr. Reddy's Laboratories Limited
223632604|NCT01780506|DRUG|E/C/F/TAF|150/150/200/10 mg FDC tablet administered orally once daily
223632605|NCT01780506|DRUG|E/C/F/TDF|150/150/200/300 mg FDC tablet administered orally once daily
223632606|NCT01780506|DRUG|E/C/F/TDF Placebo|Tablet administered orally once daily
224221213|NCT02165579|OTHER|1 cohort, standard care, observational|This is one cohort standard care observational study. 40 diabetic patients admitted to Parkland hospital with a foot infection. We will enroll a representative cross section of subjects with diabetic foot infection. Patient will be consented and will receive therapy based on standard protocols. Currently patients with suspected osteomyelitis have bone biopsies to identify bacterial pathogens and verify MRI diagnosis. Repeat bone biopsies are performed at the end of therapy to verify that osteomyelitis has been successfully treated. Serum to measure procalcitonin will be obtained at baseline, week 3 and week 6. Tissue samples will be obtained at Baseline, Week 3 and Week 6 for tissue culture.
224221214|NCT04430270|BEHAVIORAL|Survey|Sequential Assignment
224221215|NCT05101499|PROCEDURE|AKIN osteotomy with screw fixation|"A simple skin speck is made on the medial aspect of the hallux, in the metaphyseal area, using a 3 mm beaver blade. The tissue is lifted from the bone using an elevator medially and dorsally on the phalanx. A Shannon 2x12 mm burr is then positioned transversely by making the osteotomy which must preserve a lateral hinge, a guarantee of stability in the event of non-fixation.~Fixation with a screw will be effected by another skin speckle allowing access to the infero-medial area of the phalangeal base. A pre-hole can be made with the same bur to facilitate the introduction of the guide wire for osteosynthesis, which is not specific."
224221216|NCT05101499|PROCEDURE|AKIN osteotomy without screw fixation|This is the same procedure as the procedure under study, without the fixation by a target: a simple skin speck is performed on the medial face of the hallux, in the metaphyseal area using a beaver blade. of 3 mm. The tissue is lifted from the bone using an elevator medially and dorsally on the phalanx. A Shannon 2x12 mm burr is then positioned transversely by making the osteotomy which must preserve a lateral hinge, a guarantee of stability in the event of non-fixation.
224221217|NCT03377556|OTHER|Laboratory Biomarker Analysis|Correlative studies
224221218|NCT03377556|OTHER|Pharmacological Study|Correlative studies
224221219|NCT03377556|DRUG|Talazoparib|Given PO
224221220|NCT04580056|PROCEDURE|Uterine fundus endometrial incision during hysteroscopy|Uterine fundus endometrial scratching during hysteroscopy by incision
224221221|NCT02477761|DIETARY_SUPPLEMENT|Nutrient preload|Ingestion of a small mixed protein and lipid meal 30 minutes before glucose
224221222|NCT02025309|DEVICE|Neuromuscular monitorisation|
224221223|NCT04038151|DEVICE|Hybrid Leg|The Hybrid Knee uses an actively variable transmission in combination of a passive spring/damper system. This allows the motor torque output to be adapted to the requirements of active dynamic tasks - changing the effective transmission ration from zero (fully passive) for level ground walking to a maximum value (fully active) for sit-to-stand transfers. This provides physiological knee torque and speed with a small motor and primary transmission system while also maximizing electrical efficiency, which minimized battery weight. The knee prototype weights 1.7kg. The Semi-active ankle can actively reposition during non-weight bearing phases of gait and uses a non back driveable transmission to maintain its set point during weight bearing activities.
224221224|NCT04038151|DEVICE|Prescribed Passive Prosthesis|Participants will participate in training sessions of community skills and advanced ambulation training for their home, prescribed passive prosthesis.
224221225|NCT03830047|DEVICE|nd yag laser|nd yag laser will be applied on the vulval warts
224221226|NCT04360421|DRUG|Liposomal bupivacaine|"Patient's undergoing major extremity amputation and enrolled in the study as part of the experimental arm will, during their amputation operation, receive liposomal bupivicaine per recommended manufacturing dosing and administration in a field block for long-acting local anesthesia."
224221227|NCT04027010|OTHER|"Healthy U tablet application"|"There are seven modules in Healthy U: Puberty, Birth Control, Teen Pregnancy, HIV, STDs, Healthy Relationships, and Condom Negotiation. Each module has six sections: Introduction and Review, Narrative Teen Portrait, Information Film, Activity/Game, Dramatic Film, and Imagination Challenge. The Introduction and Review has videos lasting 1-2 minutes where the Healthy U host introduces each module. In the Narrative Teen Portrait for each module, a different teen discusses their experience with the topic for 1-3 minutes. The Information Film lasts 5-18 minutes per module and provides factual information. For each module, the Activity/Game includes multiple choice, true/false, or other games. The Dramatic Film lasts 5-17 minutes for each module and shows a fictional account of a teen experiencing the topic. Finally, the Imagination Challenge asks the youth to imagine a scenario, such as going to a health clinic to obtain free condoms."
223632607|NCT01780506|DRUG|E/C/F/TAF Placebo|Tablet administered orally once daily
223632608|NCT02527811|DRUG|Ulinastatin|Ulinastatin will be diluted into saline solution and administered intravenously in the intraoperative and postoperative
223632609|NCT05936073|DIAGNOSTIC_TEST|Patients co-infected HBV/HDV|Step 1: collection of SNDS data from 2016 to 2020 Snapshot of the prescription of the Delta tests and the tests usually prescribed simultaneously (HBV but also HIV and HCV) in one year. The investigator will collect the number of tests performed once for a given patient: anti-HDV, HDV RNA, HBsAg, anti-HCV, anti-HIV, and for each test, the description of the profile and the geographical distribution of prescribers in the metropolitan area; the description of age and sex of the patients screened. Step 2: collection of anti-HDV and RNA tests performed in French private and Public laboratories over the year 2019 Anti-HDV and HDV RNA are subcontracted by most private laboratories to two specialized biology companies. Number of HDV tests prescribed, technique used, number of positive tests and name of the requesting laboratory will be collected. The investigator will then go back to the prescriber of the positive tests, identify the patient, his epidemiological profile and his medical care.
223632610|NCT03324087|DIAGNOSTIC_TEST|HRQoL|use SF-36 and ITP-PAQ questionnaires to assess the HRQoL in patients with ITP in the real world, and analyze the influencing factors of HRQoL so as to provide a sufficient basis for clinical decision making.
223632611|NCT06078254|DEVICE|ULTRASOUND|Ultrasound and CT chest for all patients
223632612|NCT03550599|OTHER|Patients accessing to Radiotherapy Unit|No intervention; information about patient and disease characteristics will be recorded as well as information about pain and analgesic treatment
223632613|NCT03159429|BEHAVIORAL|Standard rehabilitation|The patient will participate in a therapeutic education programme consisting of 4 visits (days 1 +- 14, 21 +- 14, 61 +- 14 and 90 +-14) representing usual procedures, which include: maintaining a diary, breathing coordination excercises, voluntary control of breathing rate, releasing contracted muscles, posture harmonization, a six minute walking test, and walking up four flights of stairs.
223632614|NCT03159429|BEHAVIORAL|Nasal breathing rehabilitation|The patient will participate in a therapeutic education programme consisting of 4 visits (days 1 +- 14, 21 +- 14, 61 +- 14 and 90 +-14) representing the experimental procedures, which include: maintaining a diary, evaluating nasal breathing by the nostril-alternating technique according to Anuloma Viloma Pranayama Yoga, releasing contracted muscles, posture harmonization, a six minute walking test, and walking up four flights of stairs.
223632615|NCT02684825|DEVICE|Reveal LINQTM- LNQ11 Internal Loop Recorder plus standard cardiac monitoring|Reveal LINQTM- LNQ11 continuously monitors cardiac electric activity for up to three years.
224221228|NCT00472446|DRUG|bilateral superficial cervical block|10 ml of 5% bupivacaine (Carbostesin®) was used for each side. Along the cranial dorsal edge of the sternocleidomastoid muscle, three deposits of approximately 2.5 ml were injected to anaesthetize the cervical plexus with its nervus transversus colli. To anaesthetize the region of the planned skin incision, the remaining 2·5 ml was injected subcutaneously on each side.
224221229|NCT00472446|DRUG|placebo bilateral superficial cervical block|"10 ml of saline (the carrier of bupivacaine in the experimental treatment) was used for each side.~Along the cranial dorsal edge of the sternocleidomastoid muscle, three deposits of approximately 2.5 ml were injected to anaesthetize the cervical plexus with its nervus transversus colli. To anaesthetize the region of the planned skin incision, the remaining 2·5 ml was injected subcutaneously on each side."
224221230|NCT00270374|DRUG|nesiritide|
224221231|NCT05824182|DEVICE|FACE self-help App|The FACE self-help app was developed based on well-established non-invasive psychological principles that have been used in other web-based self-help interventions. The app consists of two component, emotion regulation and social information processing/social skills with four modules each. Each module includes readings describing scientific knowledge about ACEs and ACEs related topics, as well as exercises to encourage participants to actively reflect on what was learned in the readings and to apply their knowledge and practice skills. Each module is divided in several submodules that include readings and exercises.
224221232|NCT00827827|OTHER|Exercise- Strength Training|3x per week lower-extremity ST lasting approximately 45 minutes to 1 hour.
224221233|NCT00827827|OTHER|Exercise- Stretching Control|3x per week upper and lower body stretching mixed with active and passive range of motion exercises
224318174|NCT04105127|DEVICE|orthodontic - Anterior resin builds-ups|After lower brackets placement, resin builds-ups are added on the palatal aspect of the upper central incisors. Both central incisors are customarily bonded to broadly distribute the occlusal forces. Builds-ups are removed when the overbite was considered adequate to prevent lower brackets detachment.
224318175|NCT04105127|DEVICE|orthodontic - Posterior resin builds-ups|After lower brackets placement, resin builds-ups are added on the supporting cusps of first or second upper/lower molars. Builds-ups are removed when the overbite was considered adequate to prevent lower brackets detachment.
224318176|NCT02391129|PROCEDURE|Operation for Periprosthetic fractures of the hip with stem loosening|
223632616|NCT02788552|DRUG|Thiamine Hydrochloride|Administered Intravenously in 100ml bag of normal saline (0.9%) infused over 30 mins.
223632617|NCT00192985|DEVICE|Nitrofuranzone coated bladder catheter|
223632618|NCT03774732|RADIATION|Radiotherapy|Irradiation technique (3D-CRT or SABR) will be at physician discretion.
223632619|NCT03774732|DRUG|Pembrolizumab|pembrolizumab will be administered as per standard of care every 3 weeks until progression or toxicity
223764351|NCT07172659|DRUG|Dovramilast|Dovramilast
223764352|NCT07172659|DRUG|Prednisolone|Standard of care
224221234|NCT01532882|DRUG|Diosmin|tablet, 600mg, PO, 1 tab per day during 28 days
224221235|NCT01532882|DRUG|Placebo|tablet, PO, 1 per day during 28 days
224221236|NCT05653791|DIAGNOSTIC_TEST|Intestinal ultrasound|Ulcerative colitis patients treated with filgotinib will undergo intestinal transabdominal ultrasound at baseline, week 4 and at the time of the follow-up endoscopy (week 10-16)
224221237|NCT00000992|DRUG|Itraconazole|
224221238|NCT03690479|DEVICE|Florida Probe Straight Tip Probe|Twenty (20) consecutive adult patients with a diagnosis of periodontal disease (varying degrees, from slight to severe) will be selected to undergo full-mouth periodontal probing. . One half (upper or lower jaw) of the mouth will be probed using the current, standard probe tip.
224221239|NCT03690479|DEVICE|Ball Tip Probe|Twenty (20) consecutive patients meeting the inclusion criteria will be selected to undergo full-mouth periodontal probing. The opposing jaw will be probed using the new trial tip. At a second visit, prior to treatment, the mouth will be probed once again, alternating the jaws from the first visit.
224221240|NCT01521728|OTHER|Resistance Exercise|Resistance will be administered using a series of adjustable cuff weights for the upper limbs and hip flexion. Knee flexion and extension will be administered with a weight bench using a leg exercise attachment and free weights.
224221241|NCT01521728|OTHER|Endurance Exercise|Endurance will be administered using a minicycle. It can be used from a sitting position (chair or wheelchair) for lower limb exercise and then placed on a tabletop for upper limb use.
224221242|NCT01521728|OTHER|Stretching/Range-of-Motion|"Stretching and range of motion exercise is widely accepted as a standard of care for ALS management."
224221243|NCT01275313|DEVICE|Lightweight wheelchair|Seating and wheeled mobility assessment and fitting of a lightweight wheelchair
224221244|NCT01275313|DEVICE|Skin Protection Cushion|Seating assessment and provision of a cushion meeting CMS code for Skin Protection wheelchair cushion
224221245|NCT01165684|DRUG|insulin aspart|"Insulin aspart added stepwise according to the largest meal following an evaluation of HbA1c.~Doses individually adjusted."
224318177|NCT00729573|DRUG|Emtricitabine/tenofovir disoproxil fumarate|200 mg/300 mg tabletas a part of MTN-003
224318178|NCT00729573|DRUG|Emtricitabine/tenofovir disoproxil fumarate placebo|placebo tablet as a part of MTN-003
224318179|NCT00729573|DRUG|Tenofovir disoproxil fumarate|300 mg tablet as a part of MTN-003
223632620|NCT03774732|DRUG|Chemotherapy|for squamous NSCLC carboplatin AUC6, paclitaxel 200 mg/m² every 3 weeks for 4 cycles; for non-squamous NSCLC carboplatin AUC5 or cisplatin 75 mg/m² every 3 weeks for 4 cycles, and pemetrexed 500 mg/m² every 3 weeks until progression or toxicity
223632621|NCT04577521|DEVICE|BioVisc Ortho Single|BioVisc Ortho Single consisted of a prefilled syringe containing 90 mg/3 mL of IA-HA and is an injectable-grade HA from a biofermentation origin. Biovisc ortho single prefilled syringes are intended for single-use only, and the entire content of the syringe was injected into the target joint.
223632622|NCT00200369|DEVICE|MEMS cap|
223632623|NCT04467684|DRUG|CB-0406 100 mg|Single oral dose
223632624|NCT04467684|DRUG|CB-0406 200 mg|Single oral dose
224221246|NCT01165684|DRUG|insulin aspart|Insulin aspart added before each main meal. Doses individually adjusted.
224221247|NCT01165684|DRUG|insulin detemir|Insulin detemir as basal insulin, adminstered once daily. Doses individually adjusted.
224221248|NCT03135379|DEVICE|Heated ultrasound gel|"Gel stored in Thermasonic Gel Warmer (Model 82-03 LED, 120V) set to medium setting (102 degree fahrenheit)."
224221249|NCT03135379|DEVICE|Room temperature gel|Gel stored in Thermasonic Gel Warmer (Model 82-03 LED, 120V) turned off.
224221250|NCT00671879|DRUG|Carisoprodol SR 700 mg|700 mg twice daily tablet
224221251|NCT00671879|DRUG|Carisoprodol SR 500 mg|carisoprodol SR 500 mg tablet
224221252|NCT00671879|DRUG|Placebo|placebo tablet
224318180|NCT00729573|DRUG|Tenofovir disoproxil fumarate placebo|placebo tablet as a part of MTN-003
224318181|NCT00277173|BEHAVIORAL|Adoption of Crew Resource Management approach|
224221253|NCT01081184|BIOLOGICAL|blood sample|blood sample for determination of seric and lymphocytic NT profile will be added to a standard biological analysis done for pSS follow- up
223632625|NCT04467684|DRUG|CB-0406 400 mg|Single oral dose
223632626|NCT04467684|DRUG|CB-0406 800 mg|Single oral dose
223632627|NCT04467684|DRUG|CB-0406 1,000 mg|Single oral dose
223632628|NCT04467684|DRUG|Matched placebo|Color and size matched placebo
223632629|NCT03967977|DRUG|Tislelizumab|200 mg administered Intravenously (IV) as specified in the treatment arm
223632630|NCT03967977|DRUG|Placebo|Tislelizumab placebo to match
223632631|NCT03967977|DRUG|Cisplatin|70 mg/m2 administered IV as specified in the treatment arm
223632632|NCT03967977|DRUG|Gemcitabine Hydrochloride|1000 mg/m2 administered IV as specified in the treatment arm
223632633|NCT03967977|DRUG|Carboplatin|Area Under the Curve (AUC) 4.5 administered IV as specified in the treatment arm
223632634|NCT02281916|DRUG|P28GST|3 injections of 100 µg of P28GST within 3 months (one injection per month)
223632635|NCT02418572|DRUG|Testosterone gel|"Patients will receive once daily application of 0.55 gr testosterone gel-TTG (GROUP A) (Testosterone gel 1%; Laboratories Besins International, Paris, France) with a 5.5 mg/d nominal delivery rate of testosterone starting from day 1 or 2 of the following menstrual cycle, for approximately 65 days.~The application will be administered in the morning by the patient onto clean dry healthy skin over external surface of the thighs. The gel will be simply spread on the skin gently as a thin layer.~TTG will start on the day of enrollment and will continue until patients' menstruation (28-30 days). Daily administration of TTG or placebo will continue for 35 days (21days until the initial of downregulation with triptorelin and for 14 more days until the initiation of ovarian stimulation with HP-hMG). Ovarian stimulation will commence the day after last testosterone gel application. (GROUP A)"
224221254|NCT04633837|DEVICE|Extracellular Matrix Graft Injectable Implant|The extracellular matrix injectable implant will serve as the intervention in this study.
224221255|NCT05043532|PROCEDURE|2 passes during EUS-guided fine needle biopsy|Once the pancreatic mass has been visualized on endoscopic ultrasound, a total of two passes will be performed and placed in 10% formalin for processing for molecular profiling. Onsite evaluation will be performed using a part of the sample from the first pass in order to establish onsite diagnostic adequacy in all patients.
224221256|NCT05043532|PROCEDURE|3 passes during EUS-guided fine needle biopsy|Once the pancreatic mass has been visualized on endoscopic ultrasound, a total of three passes will be performed and placed in 10% formalin for processing for molecular profiling. Onsite evaluation will be performed using a part of the sample from the first pass in order to establish onsite diagnostic adequacy in all patients.
224221257|NCT00901628|DRUG|ropivacaine|300mg (0.75%, 40cc) intraoperative periarticular injection
224221258|NCT00901628|DRUG|morphine sulfate|10mg intraoperative periarticular injection
224221259|NCT00901628|DRUG|ketorolac|30 mg intraoperative periarticular injection
224221260|NCT00901628|DRUG|epinephrine|300 microgram (1:1000) intraoperative periarticular injection
224221261|NCT00901628|DRUG|cefuroxime|750mg intraoperative periarticular injection
224221262|NCT02203747|OTHER|Administration of patient self-assessment|
224221263|NCT03965312|DEVICE|Continuous temperature monitor|Temperature will be measured using a novel temperature monitor continuously for up to 72 hours. Accuracy (as compared to a commercially available patient monitor) will be evaluated.
224221264|NCT03965312|DEVICE|Neonatal Incubator|Infants at risk for hypothermia will be placed in a neonatal incubator. Their temperature will be monitored as they are treated. The infant will be treated until the infant is transitioned to skin-to-skin care, discharged, or no longer at risk for hypothermia.
224221265|NCT03965312|DEVICE|Patient monitor|Temperature will be measured using a commercially available patient monitor.
224221266|NCT00427986|DRUG|Galactose, intravenous|
224318182|NCT01197144|DRUG|adalimumab|Subcutaneous, 40 mg every other week for 4 weeks
224318183|NCT01197144|DRUG|Placebo|Subcutaneous, every other week for 4 weeks
224318184|NCT03844386|BIOLOGICAL|MVA.tHIVconsv3|viral-vector, MVA, expressing immunogens derived from conserved yet immunogenic regions of HIV-1
224318185|NCT03844386|BIOLOGICAL|MVA.tHIVconsv4|viral-vector, MVA, expressing immunogens derived from conserved yet immunogenic regions of HIV-1
224318186|NCT03844386|OTHER|Placebo|The appropriate amount of Sodium Chloride for Injection USP, 0.9% will be drawn into a syringe.
224318187|NCT05228535|DIETARY_SUPPLEMENT|Human milk fortifier|Human milk fortifier added to human breast milk at day 1 vs day 8 of feeds
224221267|NCT00185419|DRUG|Yasmin|30 µg ethinylestradiol, 3mg drospirenone
224221268|NCT00185419|DRUG|Marvelon|30 µg ethinylestradiol, 150 µg desogestrel
224221269|NCT02462421|DRUG|Canagliflozin|A single dose of canagliflozin (300 mg, p.o.) will be administered prior to assessing pharmacodynamic response.
224221270|NCT02856256|DIETARY_SUPPLEMENT|RedBull® energy drink|Subjects consume 25 mL of RedBull® energy drink
224221271|NCT05915052|PROCEDURE|B-type suture ileostomy|Type B suture stoma group：2-0 stitched sutures were placed in the center of the incision, from the anterior rectus sheath on the left side of the incision → the posterior rectus sheath on the left side of the incision → through the avascular area below the vascular arch at the mesenteric border of the ileum to the contralateral side → the posterior rectus sheath on the right side of the incision → the anterior rectus sheath on the right side of the incision→ the posterior rectus sheath on the right side of the incision → through the avascular area below the vascular arch at the mesenteric border of the ileum to the contralateral side → the posterior rectus sheath on the left side of the incision →the anterior rectus sheath on the left side of the incision sutures were sewn through in the sequence, tightened and knotted .
224221272|NCT05915052|PROCEDURE|the traditional ileostomy|Then take the right lower abdominal incision to cut a circular incision of 3 cm in diameter, round excision of subcutaneous fat, cross incision of rectus sheath and peritoneum, enter the abdomen, raise the marked ileum out of the body, interrupt suture of ileum with peritoneum and posterior sheath of rectus abdominis for one week, then interrupt suture of ileum with anterior sheath of rectus abdominis for one week, transverse incision of 2 cm in diameter, interrupted with 3-0 absorbable thread, The ileocecal incision and the skin of the right lower abdominal circular incision were sutured for one week to complete the double-lumen stoma at the end of the ileum.
224221273|NCT02117193|OTHER|Alcohol intake|The subjects will be drink beer (with or without alcohol) before sleep intervention (normal sleep and sleep deprivation).
224221274|NCT02117193|OTHER|Sleep deprivation|One night of sleep deprivation or one night of normal sleep.
224221275|NCT00051428|PROCEDURE|Reiki (distant and direct-contact)|
224221276|NCT00886665|DRUG|placebo|placebo, 4 g, powder, oral, 3 times a day
224221277|NCT00886665|DRUG|JWHGWT|JWHGWT, 4 g, powder, oral, 3 times a day
224221278|NCT01895920|OTHER|Blood sample|
224221279|NCT01909466|DRUG|Aripiprazole, OPC-14597|5 monthly applications of 400 mg of aripiprazole IM depot, where the first application is in the gluteal or deltoid muscle followed by 4 monthly administrations to the deltoid muscle
224221280|NCT01720186|DEVICE|PET/CT 4D imaging in a synchronized mode centered on the thorax.|
224221281|NCT03622502|DRUG|Dexmedetomidine|Dexmedetomidine 0.5mcg/kg was infused over 10 min before end of the surgery
224221282|NCT03622502|DRUG|Remifentanil|Remifentanil was maintained at predetermined effect-site concentration during the periextubation period (initial concentration: 2.0 ng/ml)
224318188|NCT04960033|BEHAVIORAL|FRAX|The 10-year MOF probability and the 10-year HF probability were calculated using the FRAXs of different regions (mainland China, Hong Kong, Taiwan, and Asia-America). Subjects were deemed as high-risk for osteoporotic fracture if the 10-year probability of MOF was ≥20% or the 10-year probability of HF was ≥3%.
224318189|NCT04243083|DRUG|TLL018 tablet, placebo|Oral QD
224318190|NCT04502420|DIAGNOSTIC_TEST|Lung function before and after surgery|A diagnostic test
224318191|NCT01566227|OTHER|Questionnaire|3 surveys with 10 questions each: one before, during and after treatment
224318192|NCT00676780|DRUG|Polyphenon E (EGCG)|4 capsules daily with a meal for the duration of the study
224318193|NCT01613313|DRUG|Collagenase Clostridium Histolyticum|This is a dose escalation study in which subjects will sequentially receive single injections of 0.058 mg, 0.15 mg, 0.29 mg, 0.44 mg.
224318194|NCT00096837|DRUG|Motexafin Gadolinium Injection|
223764353|NCT07172659|DRUG|Thalidomide|Standard of care (US only)
223764354|NCT07172945|OTHER|Blood, fecal, saliva|Blood, fecal and saliva samples
224221283|NCT03622502|DRUG|Normal saline|Normal saline was infused over 10 min before end of the surgery
224221284|NCT00365612|DRUG|Efavirenz (EFV), Emtricitabine (FTC), Tenofovir DF (TDF)|
224221285|NCT01339910|DRUG|Fludarabine and Busulfan|"(Flu/Bu)~* Fludarabine: 30 mg/m\^2/day on Days -6 to -2 (total dose of 150 mg/m\^2)~* Busulfan: 4 mg/kg/day PO or 3.2 mg/kg/day (total dose of 8 mg/kg or 6.4 mg/kg, respectively) on Days -5 to -4"
224221286|NCT01339910|DRUG|Fludarabine and Melphalan|"(Flu/Mel)~* Fludarabine: 30 mg/m\^2/day on Days -5 to -2 (total dose of 120 mg/m\^2)~* Melphalan: 140 mg/m\^2 on Day -2"
224221287|NCT01339910|DRUG|Busulfan and Fludarabine|"(Bu/Flu)~* Busulfan: 4 mg/kg/day PO, 3.2 mg/kg/day IV or mg/m\^2/day with Bu Css 900±100 ng/mL (total dose of 16 mg/kg, 12.8 mg/kg or 520 mg/m\^2, respectively) on Days -5 to -2~* Fludarabine: 30 mg/m\^2/day on Days -5 to -2: Flu (total dose of 120 mg/m\^2)"
224221288|NCT01339910|DRUG|Busulfan and Cyclophosphamide|"(Bu/Cy)~* Busulfan: 4 mg/kg/day PO, 3.2 mg/kg/day IV or 130 mg/m\^2/day with Bu Css 900 ± 100 ng/mL (total dose of 16 mg/kg or 12.8 mg/kg or 520 mg/m\^2, respectively) on Days -7 to -4~* Cyclophosphamide: 60 mg/kg/day on Days -3 to -2 (total dose of 120 mg/kg)"
224221289|NCT01339910|DRUG|Cyclophosphamide and Total Body Irradiation|"(Cy/TBI)~* TBI: 1200-1420 cGy on Days -7 to -4~* Cyclophosphamide: 60 mg/kg/day on Days -3 to -2 (total dose of 120 mg/kg)"
224318195|NCT00340678|DRUG|Losartan|Treatment with losartan began at 50 mg daily, with the dose increasing to 100 mg daily after 1 week if symptomatic hypotension did not develop.
224318196|NCT00340678|DRUG|Placebo|Treatment with placebo corresponding to each dose of losartan.
224318197|NCT01790477|PROCEDURE|Auricular Acupuncture|Application of auricular acupuncture to 5 points on the ear
224318198|NCT04244383|DIAGNOSTIC_TEST|interleukin IL-1beta and interleukin IL-18|pro-inflammatory cytokines measured in the serum
224318199|NCT01795911|BIOLOGICAL|Pegylated Interferon Lambda|
224318200|NCT01795911|DRUG|Ribasphere|
224318201|NCT01795911|DRUG|Daclatasvir|
224318202|NCT03295682|DEVICE|Endovascular thoracoabdominal aneurysm repair|Endovascular treatment of patients with thoracoabdominal aneurysm using a multibranch stent graft tailored to the patient´s anatomy in combination with peripheral covered stents to bridge the visceral arteries
224318203|NCT00212680|DRUG|ONO-1101|
224318204|NCT03532373|OTHER|Preference Elicitation tool|A preference elicitation tool for carpal tunnel syndrome
223632636|NCT02418572|DRUG|Placebo gel|"Patients will receive once daily application of 0.55 gr of placebo gel from day 1 or 2 of the following menstrual cycle, for approximately 65 days.~The application will be administered in the morning by the patient onto clean dry healthy skin over external surface of the thighs. The gel will be simply spread on the skin gently as a thin layer.~Placebo gel will start on the day of enrollment and will continue until patients' menstruation (28-30 days). Daily administration of placebo gel will continue for 35 days (21 days until the initial of downregulation with triptorelin and for 14 more days until the initiation of ovarian stimulation with HP-hMG"
224221290|NCT04999514|BEHAVIORAL|Mindful Parenting, Tuning in to Kids|The Mindful Parenting program consists of 8 weekly 2.5-hour group sessions and 3 weekly individual telephone interview sessions (each lasts for around 15-20 minutes). Program materials are translated into Chinese by local partners of the program developer. The Tuning in to Kids program consists of 8 weekly sessions, each lasting for 2.5 hours. Program materials are translated into Chinese.
224221291|NCT00164879|PROCEDURE|Endoscopic stenting followed by elective laparoscopic resection|
224221292|NCT03150979|OTHER|Provision of a cane|The participants will receive a single-point cane and will be instructed to use it all the time during locomotion. Weekly, they will receive a phone call, to ensure that they are using the cane and to clarify any doubts. A home visit may be conducted, if necessary.
224221293|NCT03150979|OTHER|Control|The control group will be instructed to to perform stretching of the lower limb muscles daily and keep their daily activities, without the use of a cane. They will also receive weekly phone calls, to ensure similar level of attention to that of the the participants in the experimental group.
224221294|NCT04732299|OTHER|MRI examination|Magnetic resonance thrombography is used to determine the location of thrombus, quantify the thrombus and determine its stage.
224221295|NCT03187652|DIAGNOSTIC_TEST|CT Perfusion Study|Brain and cardiac CT perfusion scan
224221296|NCT03187652|DIAGNOSTIC_TEST|Echocardiogram|Speckle tracking Echocardiography
224221297|NCT03187652|DIAGNOSTIC_TEST|neuro-cognitive assessment|Cambridge Brain Sciences neuro-cognitive assessment
224221298|NCT03187652|DIAGNOSTIC_TEST|MRI|MRI to assess white matter changes
224221299|NCT06404593|DIAGNOSTIC_TEST|Blood sampling|Evaluating the value of dynamic monitoring of a colorectal cancer liver metastasis cohort after receiving multipoint ctDNA detecting in predicting recurrence prognosis and guiding adjuvant chemotherapy treatment.
224221300|NCT05676333|DRUG|Secukinumab|
224318205|NCT00467324|DEVICE|Aspire Medical Advance System|The treatment includes a device that is surgically implanted in the tongue and lower jaw. The purpose of the implant is to prevent obstruction of the upper airway thereby improving breathing during sleep.
224318206|NCT06434623|OTHER|patient record|using patient record to construct AI models
224318207|NCT00338312|DRUG|Testosterone Transdermal System|testosterone patch (300 mcg/day) patch changed 2 times/week, for one year
224318208|NCT00338312|DRUG|Placebo patch|placebo patch changed twice a week for one year
224318209|NCT02987452|OTHER|aerobic exercise|Aerobic exercise (EA): activity on a treadmill lasting 45 minutes with intensity of 50-60% of maximum heart rate (HR) obtained from ergometer test
224221301|NCT03513354|OTHER|Soil group|Exercises in soil.
224221302|NCT03513354|OTHER|Pool group|Exercises in pool.
224221303|NCT01095757|DRUG|Plerixafor|240 µg/kg subcutaneous injection on the day that the absolute neutrophil count (ANC) is \> 1500/mm3 and on each day of apheresis for a total of 4 aphereses or the target CD34 cell dose has been reached.
224318210|NCT02987452|OTHER|resistance exercise|resistance exercise (RE): 4 series of 12 repetitions of resistance exercises at moderate intensity (until moderate fatigue), for 45 minutes
224318211|NCT02987452|OTHER|combined exercise|combined exercise (CE): EA (25 minutes) + ER (20 minutes), with an interval of 2 minutes between sessions totalizing 45 minutes
224318212|NCT03925259|BEHAVIORAL|Acceptance and Commitment Therapy|Acceptance and commitment therapy (ACT) is a 'third wave' behaviour therapy delivered on a one to one basis.
224318213|NCT06089200|PROCEDURE|Transversus Abdominal Plane Block|20 cc of bupivacaine 0.2% was given to the transversus abdominis plane
224318214|NCT06089200|PROCEDURE|Spinal Morphine|100 µg was administered intrathecally preoperatively
224318215|NCT04234659|DEVICE|Clinical placement of a temporary IMPELLA® mechanical circulatory support device.|Surgical placement of the IMPELLA® device for life threatening cardiogenic shock not responsive to other medical treatment.
224318216|NCT03629197|BEHAVIORAL|Communication skills training|Intervention components include an 8-10 minute instructional video, a pocket card and pamphlet, and 2 standardized patient visits with role-play and feedback by the standardized patient
223632637|NCT00209911|PROCEDURE|cardioversion|
224221304|NCT04363125|DIAGNOSTIC_TEST|Pathology result|Pathology result of rectal biopsy
224221305|NCT05107440|OTHER|BREATHE|A virtual, multidisciplinary, patient-centred self-management program for long COVID. The BREATHE program provides education on Breathing, Rest/recovery, Education, Activity management, Thinking/cognition, Healthy voice strategies, and Eating/nutrition.
224221306|NCT03836781|DRUG|Ketorolac|Ketorolac 3% topical subgingival irrigation was put into the periodontal pocket using an insulin syringe
224221307|NCT03836781|DRUG|Chlorhexidine 2%|Chlorhexidine 2% topical subgingival irrigation was put into the periodontal pocket using an insulin syringe
224221308|NCT01567306|BIOLOGICAL|Allergovac Depot|Increasing dosages till the maintenance dose of 0.25 SPT is reached. Afterwards, 3 maintenance doses are given at 4-weekly intervals.
224221309|NCT01567306|BIOLOGICAL|Allergovac Depot|Increasing dosages till the maintenance dose of 0.5 SPT is reached. Afterwards, 3 maintenance doses are given at 4-weekly intervals.
224318217|NCT03629197|OTHER|Attention control|Physician will review materials based on CDC opioid prescribing guidelines.
224318218|NCT05102227|DEVICE|Left bundle branch area pacing|A dual-chamber DF-1 defibrillator is implanted. Left bundle branch area pacing is performed for cardiac resynchronization therapy.
223632638|NCT01941810|DIETARY_SUPPLEMENT|bovine lactoferrin supplement|Given PO
223632639|NCT01941810|OTHER|questionnaire administration|Ancillary studies
224221310|NCT01567306|BIOLOGICAL|Allergovac Depot|Increasing dosages till the maintenance dose of 1SPT is reached. Afterwards, 3 maintenance doses are given at 4-weekly intervals.
223632640|NCT01941810|PROCEDURE|quality-of-life assessment|Ancillary studies
223632641|NCT01941810|OTHER|laboratory biomarker analysis|Correlative studies
224221311|NCT01567306|BIOLOGICAL|Allergovac Depot|Increasing dosages till the maintenance dose of 2 SPT is reached. Afterwards, 3 maintenance doses are given at 4-weekly intervals.
224221312|NCT01567306|BIOLOGICAL|Allergovac Depot|Increasing dosages till the maintenance dose of 4SPT is reached. Afterwards, 3 maintenance doses are given at 4-weekly intervals.
224221313|NCT01567306|BIOLOGICAL|Placebo|Increasing volumes of placebo. Afterwards, 3 maintenance doses are given at 4-weekly intervals.
224221314|NCT00208949|DRUG|G-CSF|G-CSF, solution given subcutaneously twice per day, total dosage varies by weight.
224221315|NCT00208949|DRUG|GM-CSF|GM-CSF, solution given subcutaneously twice per day, total dosage varies by weight.
224221316|NCT04072718|RADIATION|Radiotherapy|34 Gy/10#/2wk to the PTV and 40Gy/10#/2 Wk to the PTV SIB with IGRT using Rapid arc technique.
224221317|NCT01684566|DEVICE|episil(R)|episil® is a lipid-based liquid that spreads onto mucosal surfaces and transforms into a protective, strongly bioadhesive FluidCrystal® film after intraoral administration.
224318219|NCT01352780|BEHAVIORAL|Motivational interviewing|"Motivational interviewing technique will be used to improve patient adherence to multiple health behaviour changes and support patients with psoriasis to self- manage effectively. The intervention will discuss on four main topics: diet, physical activity, stress management and psoriasis treatment.~Motivational interviewing is a patient centered directive counselling technique that focuses on assisting patients to identify their problems and involves exploring ambivalence in an empathic manner. A key goal in motivational interviewing is to increase the importance of change from the client's perspective. This is accomplished by using specific types of open ended questions, selective reflections and reflective listening."
224318220|NCT03183167|OTHER|No intervention|
223632642|NCT04942574|OTHER|Total sleep deprivation|Participants will perform repeatedly : task of reading with voice acquisition before each MSLT, KSS, VAS-Anxiety, VAS-Fatigue and PVT during the day after a night of total sleep deprivation.
223764355|NCT07172945|OTHER|intestinal content samples and biopsies|intestinal content samples and biopsies obtained per upper or lower gastrointestinal tract endoscopy
224221318|NCT01684566|OTHER|Oral hygiene procedures|Oral hygiene by using toothbrush, toothpaste, lip balm and dental floss (if available)
224221319|NCT03761836|DEVICE|ShangRing|The ShangRing™ is a device for male circumcision that was invented by Jian Zhong Shang and has been on the Chinese market since 2005. It consists of a sterile device with two concentric medical grade plastic rings: an inner ring with a silicone band and an outer, hinged ring. The inner ring fits inside the outer ring which will lock when snapped together. It currently holds a European Conformity (CE) mark, an EN ISO certificate, and is FDA approved. Clinical data from ShangRing studies in Africa were reviewed by the WHO Technical Advisory Group (TAG) on Innovations in Male Circumcision in January 2013 and were found to meet its clinical requirements. The ShangRing manufacturer was accepted by the WHO Prequalification Programme for Male Circumcision Devices in 2015.
224221320|NCT02999464|OTHER|Qigong|The experimental group will be required to practice a total of 50 minutes of qigong training 3 times per week and for 16 weeks
224221321|NCT02999464|OTHER|Fitness exercise|Active control group will be required to practice a total of 50 minutes of fitness training 3 times per week and for 16 weeks
224221322|NCT02849821|OTHER|hypobaric pressure chamber|hypobaric chamber: ascent within 10 minutes, 3 hour exposure to hypoxic conditions simulating an altitude of 4,000 m.a.s.l., afterwards controlled descent under continuous pulsoximetric control
224221323|NCT02849821|OTHER|Sigmoidoscopy|To retrieve biopsies from the colon during the course of the study 3 sigmoidoscopies were performed. The first sigmoidoscopy was performed 1 day before the stay in the hypobaric chamber. The second sigmoidoscopy was performed directly after the hypobaric chamber and the third sigmoidoscopy was performed 1 week after the hypobaric chamber. During each sigmoidoscopy 6 biopsies were taken with standard size forceps (2.4 mm). One biopsy was analysed by real-time quantitative polymerase chain reaction (PCR), one biopsy was analysed by Western blotting and another biopsy was analysed for gene gene-expression by in situ hybridisation. Two biopsies were analysed by immunohistochemistry (IHC) and one biopsy was stained with hematoxylin and eosin (H\&E).
224221324|NCT05306379|DRUG|Simvastatin|Oral dose 40 mg
224221325|NCT05306379|DRUG|Voclosporin|Oral dose 23.7 mg twice daily
224221326|NCT00138359|DRUG|Niclosamide|
223632643|NCT04942574|OTHER|Normal sleep|Participants will perform repeatedly : task of reading with voice acquisition before each MSLT, KSS, VAS-Anxiety, VAS-Fatigue and PVT during the day after a night of normal sleep.
223764356|NCT07164742|BEHAVIORAL|8 week (short arm) Intervention - pulmonary rehabilitation|8 weeks (short arm) of a pulmonary rehabilitation (PR) program, administered during TB treatment, comprising of exercise training, counselling and education, and airway clearance techniques.
223764357|NCT07164742|BEHAVIORAL|24 week (long arm) Intervention - pulmonary rehabilitation|24 weeks (extended arm) of a pulmonary rehabilitation (PR) program, administered during TB treatment, comprising of exercise training, counselling and education, and airway clearance techniques.
224221327|NCT01936779|DIETARY_SUPPLEMENT|Dietary supplement: fatty acid|Consumption of n-3 fatty acids for 8 weeks
224221328|NCT01936779|DIETARY_SUPPLEMENT|Dietary supplement: fatty acid|Consumption of olive oil for 8 weeks.
224221329|NCT00004659|PROCEDURE|irradiation|
224221330|NCT00004659|PROCEDURE|radiosurgery|
224221331|NCT04091542|DEVICE|Optiflow/Ventilator|Participants will have 2 days with optiflow, 2 days with ventilator.
224221332|NCT03468036|OTHER|none, does not apply|none: does not apply
224221333|NCT01334788|OTHER|sleep deprivation|Sleep restriction
223632644|NCT05236270|BEHAVIORAL|Text Message|Participants will be randomized to receive or not receive a text message encouraging COVID-19 vaccine uptake.
223632645|NCT05236270|BEHAVIORAL|Motivational Interviewing|Participants will be randomized to receive either motivational interviewing when receiving SARS-CoV-2 antibody test results or standard interpretation of antibody results.
223632646|NCT05236270|BEHAVIORAL|Electronic Educational Message with Tailored Questions/Prompts|Participants will be randomized to receive either an electronic educational message tailored to their COVID-19 vaccine concerns and vaccine status or an attention control message about overall healthy choices.
223632647|NCT03255122|BEHAVIORAL|I-CALM|Families receiving I-CALM will immediately receive a videoconferencing-based, Internet-delivered format of an evidence-based CBT treatment for early child social anxiety disorder (Coaching Approach behavior and Leading by Modeling, or the CALM Program; Puliafico, Comer, \& Albano, 2013) in which therapists and families meet in real-time via videoconferencing and parent-child interactions are broadcast from the family's home via a webcam while therapists provide bug-in-the-ear coaching from a remote site. Parents are taught and guided in how to coach their young anxious child to engage in brave, approach behavior.
223632648|NCT03255122|BEHAVIORAL|Delayed I-CALM|Families receiving Delayed I-CALM will participate in a waitlist period, and then will complete the I-CALM treatment program.
223632649|NCT06342258|DRUG|Ultradent Ultra Seal XT Plus|Each child who has erupted, bilateral permanent molars that qualify for the study and agree to participate will have a side (right or left side) of their mouth randomized for bond that will be cured prior to sealant placement. Daily flossing and oral hygiene instructions will be taught to patients of all study groups. Sealant will be placed using a dental suction isolation system, such as DryShield isolation after prophy cup polish with pumice. No enameloplasty will be conducted.
224221334|NCT01334788|OTHER|Normal sleep|These are subjects who are randomized to sleep normally.
224221335|NCT00672971|OTHER|4% dimethicone foam|The dimethicone foam is applied to dry hair and left on the hair for approximately 15 minutes. The product is then removed by washing the hair with baby shampoo. The foam is applied two time, separated by an interval of 7-9 days.
224221336|NCT00672971|OTHER|1% permethrin|Nix® Cream Rinse is applied as indicated on the product labeling. The cream rinse is applied to wet hair and left on the hair for 10 minutes. The hair is then rinsed with tepid water to remove the product, toweled dry, and combed with a detangling comb. The product is applied two times, separated by an interval of 7-9 days.
224221337|NCT02523911|DRUG|Simethicone|Patients will be randomized to receive either simethicone or placebo in addition to oral sodium sulfate/potassium sulfate/magnesium sulfate solution (Suprep), and will be blinded to whether they are in the simethicone arm or the placebo arm of the trial. Simethicone and placebo will be prepared as identically-appearing liquid solution (2.4 mL) with the assistance of a pharmacist. The simethicone or placebo solution will then be assigned to patients according to the randomization scheme and samples will be labeled with patient information prior to distribution. Only the pharmacist will participate in the labeling process and know which patients receive simethicone or placebo; administering staff, nurses, physicians, and patients will be blinded to this.
224221338|NCT02523911|DRUG|Placebo|Patients will be randomized to receive either simethicone or placebo in addition to oral sodium sulfate/potassium sulfate/magnesium sulfate solution (Suprep), and will be blinded to whether they are in the simethicone arm or the placebo arm of the trial. Simethicone and placebo will be prepared as identically-appearing liquid solution (2.4 mL) with the assistance of a pharmacist. The simethicone or placebo solution will then be assigned to patients according to the randomization scheme and samples will be labeled with patient information prior to distribution. Only the pharmacist will participate in the labeling process and know which patients receive simethicone or placebo; administering staff, nurses, physicians, and patients will be blinded to this.
224221339|NCT02523911|DRUG|sodium sulfate/potassium sulfate/magnesium sulfate solution|Both arms will receive sodium sulfate/potassium sulfate/magnesium sulfate solution for bowel preparation
224221340|NCT05465915|DEVICE|Electroconvulsive therapy|Patients are treated with ECT.
224221341|NCT01153061|DEVICE|Fistula closure with Gore Helex Septal Occluder|The occluder will be released at the tracheoesophageal fistoulous traject through endoscopic procedures
224221342|NCT01153061|DEVICE|Gore Helex Septal Occluder|Fistula closure with endoscopic release of occluder in the fistula traject.
224221343|NCT00505609|BEHAVIORAL|Standard Days Method|The Standard Days Method is a fertility awareness-based method of family planning. Users avoid unprotected intercourse during cycle days 8 to 19. Study participants were for up to 13 cycles of method use.
224221344|NCT00738673|DRUG|degarelix|Starting dose of 240 mg (40 mg/mL). Maintenance doses of 80 mg (20 mg/mL).
224318221|NCT04948892|OTHER|Prescence of the father during cesarean section in general anesthesia|The father is now present in the OR during cesarean section category 1, instead of waiting outside
224318222|NCT00208273|DRUG|Letrozole - Concomitant|
224318223|NCT00208273|DRUG|Letrozole - Sequential|
224318224|NCT03316547|OTHER|SENSE Program|Specific amounts of auditory, tactile, vestibular, kinesthetic, and visual exposure conducted daily through hospitalization. This includes specifically timed and set amounts of reading/talking/singing, cycled lighting, skin-to-skin (kangaroo) care or gentle human touch, rocking, and therapeutic exercises \[passive range of motion (PROM), gentle stretching\]. The intervention plan is intended to be implemented by parents when available, and by surrogates when the parents are unable to be present in the hospital. Specific amounts and timing of interventions will be tailored to the current medical status and age of each infant.
224318225|NCT05772247|DIAGNOSTIC_TEST|Lung ultrasound|Lung ultrasound score was calculated by the results of lung ultrasound examination
224318226|NCT02939053|DEVICE|SOZO|The SOZO device is a bioimpedance spectroscopy device that measures bioimpedance parameters.
223632650|NCT05920590|OTHER|PNF|"The protocol will be individualized and will last 45 minutes. The following techniques will be applied:~* Application of the hold - relax technique to increase the range of motion of knee flexion.~* Rhythmic initiation with the application of diagonal trunk and lower limb shapes.~* Application of stabilizing reversals from a sitting and standing position.~* Application of dynamic reversals from a standing position.~* Rhythmic stabilization.~* Combination of isotonics.~* Gait retraining."
223632651|NCT05920590|OTHER|PNF plus Tendon Vibration|Participants in this group will be given the same exercise program as Group 1 combined with the application of tendon vibration. Tendon vibration will be applied on both quadriceps' tendons in three weekly sessions (not on the same day as the exercise program). To implement the protocol, 100 Hz frequency mechanical stimulation will be applied.
223632652|NCT05920590|OTHER|Control|Participants in this group will be given an exercise leaflet for home-based exercises and will be instructed to perform these exercises three times a week for the same period as the other two groups (6 weeks). They will also be given recommendations to maintain and increase their physical activity.
223632653|NCT00131222|PROCEDURE|Food supplement: fortified spread|
224221345|NCT03858881|BEHAVIORAL|PROJECT PERSONALITY|"PROJECT PERSONALITY is self-administered by youth via Qualtrics and is 30 minutes in duration. The intervention includes five elements: 1. An introduction to the brain, including a lesson on neuroplasticity (how and why our behaviors are controlled by thoughts and feelings in the brains, which have potential for change); 2. Testimonials from older youths who describe their views that people's traits are malleable, given the brain's plasticity; 3. Additional vignettes written by older youths, describing times when they used growth mindsets to persevere through social and emotional setbacks; 4. A summary of selected scientific studies suggesting that personality can, and often does, change in positive ways over time; and 5. An exercise in which the participants write notes to younger students, drawing on scientific information to describe the malleability of people's personal traits"
224221346|NCT03858881|BEHAVIORAL|VR PERSONALITY PROJECT|The VR PERSONALITY PROJECT contains similar elements as PROJECT PERSONALITY, including a lesson on neuroplasticity; testimonials from older youths; information about research on the malleability of personal traits; and an exercise wherein the participant provides advice to a student in the VR environment who has experienced a peer-related setback. Content is delivered by characters in the VR environment (hired/filmed actors) who guide youths through the program, providing scientific information and personal stories. Completion time is 30-40 minutes. The key difference between the VR and web-based mindset intervention is the delivery system, and by extension the level of immersion each program offers. The VR program is designed to be immersive, fun and interactive; youth choose to speak to various scientists and students within the VR environment and navigate themselves from scene to scene. In the online program, participants automatically view a series of text-based activities.
224221347|NCT03858881|BEHAVIORAL|SHARING FEELINGS PROGRAM|The web-based supportive therapy (ST) intervention, called the Sharing Feelings Program, is delivered via Qualtrics, self-administered by youth, and 30 minutes in duration. It aims to encourage youths to identify and express feelings to close others and does not teach specific skills or beliefs. It is designed to control for nonspecific aspects of intervention, including engagement in a technology-based program. It mirrors the web-based growth mindset intervention as closely as possible, including vignettes written by older youths who describe times when they benefited from sharing their feelings with friends or family.
224221348|NCT06074471|PROCEDURE|ultrasound guided supraclavicular brachial plexus block|"Block will be performed in semi-sitting position with head tilted to the opposite side of injection site. linear probe (4-12MHz) (Mindray Digital Ultrasonic Model DP-10 SN 6N-49005130 2014-09. SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO.LTD) will be placed parallel to the clavicle in the supraclavicular fossa visualizing the subclavian artery is seen beating above the first rib. A volume of 2 mL lignocaine 2% will be infiltrated subcutaneous before the block. A 20-gauge needle will be advanced in plane aiming to the corner pocket towards the deeper portion of the brachial plexus at the angle between the first rib and the subclavian artery, 10 mL of drug will be injected. Then, the needle will be retracted and advanced at a shallower angle, aiming toward the superficial plexus after negative aspiration another 10 ml will be injected, total drug injected 20 ml (18 mL of drug will be injected with addition to 8mg dexamethasone (2ml))"
224318227|NCT04269473|PROCEDURE|Telehealth Gait Retraining|Telehealth gait retraining is a novel approach to train participants to adopt a non-rearfoot foot strike pattern during running via telecommunications. During telehealth gait retraining, video of a participant's running form are sent to clinicians over a mobile device app and running form feedback is given. This process is repeated once a week for four weeks and then every other week until week 8.
224221349|NCT01924871|DRUG|Desflurane with remifentanil|During the emergence from anesthesia,extubation was performed under 1.0 MAC desflurane with 1.0ng/ml remifentanil
224221350|NCT01924871|DRUG|Desflurane|During the emergence from anesthesia,extubation was performed under 1.5 MAC desflurane
224221351|NCT02736227|DRUG|Tacrolimus Withdrawal and Everolimus Monotherapy|During the first month post-transplant, the subject receives everolimus (about 5-8 ng/mL) and tacrolimus with or without mycophenolic acid as part of standard of care procedures. At one month post-transplant, mycophenolic acid will be stopped and tacrolimus dosage will be reduced while continuing the dosage of everolimus. At three months post-transplant, tacrolimus dosage will be reduced by 50% of the daily dose each week. At four months post-transplant, tacrolimus will be discontinued.
224221352|NCT00431262|DRUG|antabuse (disulfiram)|
224318228|NCT04269473|PROCEDURE|Standard Physical Therapy Treatment|Participants receiving standard Physical Therapy will visit the Physical Therapy Clinic every 2 to 3 weeks to be treated by a Physical Therapist.
224318229|NCT04269473|PROCEDURE|Return to Running Protocol|The Return to Running protocol is a six-phase running volume progression to re-introduce running slowly and safely after experiencing a running-related injury.
224318230|NCT04269473|PROCEDURE|At Home Exercise Program|The At Home Exercise Program consists of 4 lower leg and foot exercises that participants can perform on their own time.
223632654|NCT00131222|PROCEDURE|Food supplement: maize and soy flour|
223632655|NCT06208124|DRUG|IMM-6-415|Twice daily, oral tablet administered in 21-day cycles until treatment discontinuation criteria are met.
223632656|NCT06346717|BEHAVIORAL|"Knee Prosthesis-M mobile application service"|"In the early phase of mobile application development, qualitative interviews will be conducted with patients with total knee arthroplasty (TKA) experience regarding their own surgery experiences. A training booklet for Knee prosthesis-M will be created, taking into account the literature and patient feedback. Then, the Knee prosthesis-M application design will be completed. One day before surgery; Written consent will be obtained from patients who meet the criteria via an Informed Consent Form. Patients in the intervention group will access the Knee Prosthesis-M application from their smartphones and will be asked to use it actively for 6 weeks, starting from the 1st day of the surgery. Mobile application-supported care will be provided to the patients by sending information, warning and reminder messages to the patients for 6 weeks."
223632657|NCT00406250|DRUG|intravitreal injection|1.25 mg in 0.05 cc of bevacizumab
223632658|NCT00406250|DRUG|intravitreal injection|1.25 mg of bevacizumab intravitreally injected in a steril field
223632659|NCT01023763|OTHER|A structured training program|A structured training program in nursing homes in the intravenous treatment of dehydration and infections.
223632660|NCT03636074|PROCEDURE|Hypothermia during Extracorporeal Circulation|Normothermia during Extracorporeal Circulation
224221353|NCT01765985|DEVICE|PSORIAMED|"V0 : Selection: Information of the patient, control of inclusion and non inclusion criteria.~V1 : Control of inclusion and non inclusion criteria (treatment against psoriasis have to be discontinued for at least 3 weeks and 3 months for anti-IL12/23). Clinical scores and photographs. Explanation of the functioning of the device, then the treatment is followed at home, twice a day 5 minutes. 10% salicylic acid ointment will be applied after each session.~V2 : End of the treatment (12 weeks after V1). Clinical scores and photographs. V3 : End of the follow-up (24 weeks after V1). Clinical scores and photographs."
224221354|NCT01765985|DEVICE|PLACEBO|"V0 : Selection: Information of the patient, control of inclusion and non inclusion criteria.~V1 : Control of inclusion and non inclusion criteria (treatment against psoriasis have to be discontinued for at least 3 weeks and 3 months for anti-IL12/23). Clinical scores and photographs. Explanation of the functioning of the device, then the treatment is followed at home, twice a day 5 minutes. 10% salicylic acid ointment will be applied after each session.~V2 : End of the treatment (12 weeks after V1). Clinical scores and photographs. V3 : End of the follow-up (24 weeks after V1). Clinical scores and photographs."
224221355|NCT01188733|DRUG|Long acting octreotide 10mg|Comparison of different doses
224221356|NCT01188733|DRUG|Long acting Octreotide 30mg|Comparison of drug doses
224318231|NCT04007991|DRUG|Ecopipam|Ecopipam HCI tablets administered PO to establish 2 mg/kg/day
224221357|NCT01188733|DRUG|Saline|Comparison of drug doses
224221358|NCT04531033|DIETARY_SUPPLEMENT|Lactobacillus acidophilus MPH734|After supplementing with oral probiotics, it has been suggested that select probiotics capable of expressing Beta-glucosidase enzyme activity may likewise be effective treatment for lactose intolerance.
224221359|NCT04531033|DIETARY_SUPPLEMENT|Placebo|placebo made to match dietary supplement being tested.
224221360|NCT04120194|BIOLOGICAL|NanoFlu|Investigational quadrivalent seasonal influenza vaccine for the 2019-20 Northern hemisphere influenza season.
224221361|NCT04120194|BIOLOGICAL|Fluzone Quadrivalent|Licensed quadrivalent seasonal influenza vaccine for the 2019-20 Northern hemisphere influenza season.
224221362|NCT04481971|DRUG|Prednisolone|Tablets
224221363|NCT04481971|DRUG|lactose in capsules gelatin|Tablets
224221364|NCT05448144|OTHER|Collect stool and blood samples from patients|Collect stool and blood samples from patients
224318232|NCT04007991|DRUG|Placebo|Matching Placebo
224318233|NCT07133347|DEVICE|Brain computer interface controlled functional electrical stimulation therapy integrated with social media|The investigators created an app interface (FlickTok) to have brain computer interface (g.tech gel 16 channel EEG headset) controlled functional electrical stimulation (NeuroTrac Electrical Stimulator) integrated with social media (Instagram reels or YouTube Shorts)
224318234|NCT02713269|PROCEDURE|Computed Tomography|Undergo CT scan
224318235|NCT02713269|OTHER|Quality-of-Life Assessment|Ancillary studies
223632661|NCT03260946|OTHER|Complementary medicine use|The prevalence of complementary medicine use
223632662|NCT00460161|PROCEDURE|acupuncture|2 treatments/week for 4 weeks
223632663|NCT00460161|OTHER|placebo/sham acupuncture|2 treatments/week for 4 weeks
223632664|NCT00159393|OTHER|registry and database|data collection
223632665|NCT05310240|PROCEDURE|Hip arthroscopy|Arthroscopic surgery of the hip
224221365|NCT00300092|DRUG|Cepahlexin (drug)|Cephalexin 50 mg/kg divided 3 times daily for 7 days
224318236|NCT02713269|OTHER|Questionnaire Administration|Ancillary studies
224318237|NCT02713269|RADIATION|Stereotactic Radiosurgery|Undergo CT-guided SSRS
224318238|NCT02713269|PROCEDURE|Thermal Ablation Therapy|Undergo thermal ablation therapy
224221366|NCT00613678|BEHAVIORAL|Activity Strategy Training|The AST component will involve training in specific behavioral and environmental strategies to facilitate performance in daily activities and routines. The activity strategy training group sessions will use education, group discussion, and demonstration and practice of techniques to facilitate activity performance. Homework assignments will be given after many of the sessions to practice and reinforce concepts learned.
223632666|NCT03725397|BEHAVIORAL|Outpatient|The offered (studied) intervention will be allowing the women with a transcervical Foley catheter in place to spend the night at home.
223632667|NCT03725397|BEHAVIORAL|Inpatient|"Women with a transcervical Foley catheter to be admitted to the hospital overnight which has been a standard of care."
223632668|NCT02922244|OTHER|Control|Apply moisture cream to the treatment skin everyday after radiation therapy
223632669|NCT02922244|OTHER|Cucumber cream|Apply cucumber cream to the treatment skin everyday after radiation therapy
223632670|NCT02922244|OTHER|Centella cream|Apply centella cream to the treatment skin everyday after radiation therapy
223632671|NCT02922244|OTHER|Thunbergia cream|Apply thunbergia cream to the treatment skin everyday after radiation therapy
223632672|NCT04730453|PROCEDURE|ENB-guided ablation therapy combined with VATS|After receiving multidisciplinary assessments, Lesion A will receive ENB-guided ablation therapy and Lesion B will receive VATS at the same time.
223632673|NCT05829694|OTHER|Parental Status|The aim of the study is to assess the impact parenthood has on health outcomes.
223632674|NCT00530478|DRUG|Donepezil|
223632675|NCT00101179|DRUG|Azacitidine|Given SC
223632676|NCT00101179|DRUG|Entinostat|Given orally
223632677|NCT03536208|DRUG|Warfarin|5 different doses of warfarin will be assigned, ranging from 1mg to 5 mg.
223764358|NCT07174128|OTHER|Fluid Therapy|Patients would receive the second round of fluid loading if the Plethysmographic Variability Index (PVI) was 14%.
224221367|NCT00613678|BEHAVIORAL|Education|The health education program is based on educational materials from the Arthritis Foundation.
224318239|NCT06840314|DEVICE|Pelvic floor therapy|Once randomized to either the vibrating pelvic floor massage arm or the traditional vaginal dilator arm, they will receive instructions on frequency of device use and will use manufacturer's instructions for specifics of device use. We will not dictate more specific instructions on use, nor is this standard of care, as every patient is unique and will need to retain autonomy in terms of how quickly they progress in the use of the product. They will then complete a survey at 4 weeks which includes measures of sexual function and pelvic pain, as well of global impressions of improvement in their symptoms.
224318240|NCT07134140|DIETARY_SUPPLEMENT|Omega-3|Participants will take three capsules per day (a total of 1,500 mg EPA and 750 mg DHA). They will take 1 g with each main meal (breakfast, lunch, and dinner).
224318241|NCT07134140|DIETARY_SUPPLEMENT|Placebo comparator|Participants will take 3 g of olive oil. They will take 1 g with each main meal (breakfast, lunch, and dinner).
223632678|NCT01499940|DRUG|Vitamin D3|Vitamin D3 will be administered at a dose of 2000 IU orally daily starting on day 1 of the first cycle of oxaliplatin. The vitamin will be continued at this dose and schedule for approximately 6 months if the patient is receiving oxaliplatin in the adjuvant setting and neither dosage nor interval has been modified for neurological toxicity. The duration of therapy if oxaliplatin is given for metastatic disease will vary. Nonetheless, the study vitamin will be continued using the same criteria as in the adjuvant setting.
223632679|NCT03743168|OTHER|Intermittent stretching protocol|Intermittent stretching protocol of five sets of 1 minute and15 second rest
223632680|NCT03743168|OTHER|Continuous stretch|2 minutes continuous stretch
224221368|NCT02469974|DRUG|RUXOLITINIB / INC 424|Administered orally 5-20 mg twice daily x 16 weeks of therapy prior to attempted peripheral blood stem cells (PBSC) collection, during the collection and rest period and 3 months of therapy after high dose chemotherapy (HDC).
224221369|NCT02469974|DRUG|Filgrastim|Peripheral blood stem cells (PBSC) will be mobilized with filgrastim 10 mcg/kg/day IV
224221370|NCT02469974|DRUG|Busulfan|Conditioning for autologous Hematopoeitic Stem Cell Transplantation (HSCT) will consist of IV busulfan 2.0 mg/KBW once daily x 4 for days -5 to -2
224221371|NCT03297359|BIOLOGICAL|Dalteparin|daily subcutaneous injection of weight-adjusted dalteparin
224221372|NCT05140161|DEVICE|collagen|use of hemostatic device in order to reduce bleeding in nail surgery
224221373|NCT04790305|DRUG|Huaier Granule|The subjects in the experimental group will be treated with Huaier Granule continuously for 2 years or until the disease progressed, intolerable toxicity, withdrawal of informed consent form or died for any reason.
224221374|NCT03455023|OTHER|pharmaceutical care|Patients receive pharmaceutical care including individualized evaluation and intervention of adherence, efficacy and safety in cancer pain treatment.
224221375|NCT03701620|DIAGNOSTIC_TEST|HRV monitoring|HRV monitoring derived from electrocardiogram
224221376|NCT04399720|PROCEDURE|Root canal treatment|Root canal treatment using a standard manual k file instrumentation and carrier-based root canal filling technique
224221377|NCT01340950|DRUG|zidovudine-lamivudine-nevirapine|96 weeks of zidovudine 300 mg orally twice daily, lamivudine 300 mg orally daily, nevirapine 200 mg orally daily for the first 14 days then 200 mg orally twice daily
224221378|NCT01340950|DRUG|tenofovir-lamivudine-efavirenz|96 weeks of tenofovir disoproxil fumarate 300 mg orally daily, lamivudine 300 mg orally daily, efavirenz 600 mg orally daily
224221379|NCT01802840|DIETARY_SUPPLEMENT|biscuits supplemented with soy fiber|Thirty nine overweight and obese college adults (19-39 y of age) were randomly assigned to consume control biscuits or biscuits supplemented with soy fiber for 12 wk (approximately 100g/d).
224221380|NCT02343016|DEVICE|Near-InfraRed Spectroscopy (NIRS)|NIRS is a non invasive monitoring system that enables assessment of tissue oxygenation through a quantitative estimation of haemoglobin oxygen-saturation within tissues.
224221381|NCT01159769|DRUG|Olopatadine hydrochloride ophthalmic solution, 0.2% (Pataday®)|Commercially marketed ophthalmic solution for the treatment of ocular itching associated with allergic conjunctivitis
224221382|NCT02555618|BIOLOGICAL|TAK-850|TAK-850 subcutaneous injection
224221383|NCT02555618|BIOLOGICAL|Influenza HA vaccine|Influenza HA vaccine subcutaneous injection
224221384|NCT03076671|BEHAVIORAL|Palliative Care|Palliative care training for community neurologists and use of telemedicine for team-based support of patients
224221385|NCT01584726|DRUG|Magnesium Sulfate|single dose of magnesium sulfate nebulization
223764359|NCT07174128|OTHER|Fluid Therapy|Patients would receive the second round of fluid loading if the Plethysmographic Variability Index (PVI) was 20%.
224221386|NCT02063698|DRUG|auranofin|Given PO
224221387|NCT02063698|OTHER|placebo|Given PO
224221388|NCT02063698|OTHER|questionnaire administration|Ancillary studies
224221389|NCT02734615|DRUG|LSZ102|LSZ102
224221390|NCT02734615|DRUG|LEE011|LEE011
224221391|NCT02734615|DRUG|BYL719|BYL719
223680809|NCT02809261|PROCEDURE|Ultrasound-guided perineural injection with normal saline|Ultrasound-guided perineural injection with normal saline (3cc) between proximal carpal tunnel and surrounding median nerve with hydrodissection.
223680810|NCT02809261|DRUG|Normal Saline|Normal saline is safe for perineural injection.
223680811|NCT02809261|DRUG|5% Dextrose|5% Dextrose could decrease the release of CGRP and substance P to reduce the nerve inflamation.
223680812|NCT00000203|DRUG|Buprenorphine|
223680813|NCT01541345|DEVICE|Autogenous bone graft|Bone augmentation will be performed using autogenous bone from the retromolar or chin area followed by a fixation with titanium screws at the recipients site; filled with deproteinized bovine bone mineral (DBBM) particles (Bio-Oss®, Geistlich Pharma AG, Wolhusen, Switzerland) and covered with a collagen membrane (Bio-Gide®, Geistlich Pharma AG, Switzerland)
224221392|NCT02896868|DRUG|LY3041658|Administered IV.
224221393|NCT02896868|DRUG|Placebo|Administered IV.
224221394|NCT03560622|DEVICE|multi-modality neuroimaging|multi-modality neuroimaging consists of structural imaging, diffusion tensor imaging (DTI), task-based functional MRI (t-fMRI), and resting state functional MRI (rs-fMRI).
224221395|NCT01005550|DRUG|6 mg of ropivacaine|6 mg of ropivacaine are used for the spinal anaesthesia
223632681|NCT06409533|OTHER|Rate control|Patients diagnosed with atrial fibrillation due to moderate to severe rheumatic mitral stenosis (AF-RMS) and undergoing treatment will receive care in accordance with the PERKI (Indonesian Heart Association) guidelines for Atrial Fibrillation. The selection and titration of rate control medications, including β-blockers, digoxin, or their combination, will be managed by the attending cardiologists (care providers) to achieve the target rate control.
223632682|NCT04166643|BEHAVIORAL|WHHIP PLUS|Worksite health promotion and occupational health and safety (total worker health)
223632683|NCT04166643|BEHAVIORAL|Education only control|Education at the start of the project
223632684|NCT04488679|OTHER|direct pulp capping|teeth with exposed pulp during caries removal will be capped either with PRF followed by mta or mta alone directly on exposed pulp, in both groups restoration will be placed over mta
224221396|NCT01005550|DRUG|8 mg of ropivacaine|8 mg of ropivacaine are used for the spinal anaesthesia
224221397|NCT01005550|DRUG|10 mg of ropivacaine|10 mg of ropivacaine for the spinal anaesthesia
224221398|NCT01005550|DRUG|12 mg of ropivacaine|12 mg of ropivacaine for the spinal anaesthesia
224221399|NCT03952156|GENETIC|HMI-102|HMI-102 is an AAVHSC15 vector containing a functional copy of the human PAH gene
224221400|NCT03952156|GENETIC|HMI-102|"Control subjects will generally have the same assessments as treated subjects.~Control subjects will undergo pre-baseline procedures to confirm that they are eligible to receive treatment with HMI-102. Once eligible control subjects are dosed with HMI-102, they will initiate the same post-dose procedures as subjects who received HMI-102."
224221401|NCT02818556|DRUG|Restalyne Silk|
224221402|NCT02818556|DRUG|Belotero Balance|
224221403|NCT03892681|OTHER|hepatocyte-specific contrast agent, extracellular contrast agent|The type of contrast agent for the 1st MRI will be performed using hepatocyte-specific contrast agent (Primovist). The participant will undergo the 2nd MRI using extracellular contrast agent (Gadovist).
224221404|NCT04340414|DEVICE|Low flow ECMO driving by CVVH machine|With aim to clear CO2 and improve oxygenation, a low flow ECMO treatment(using oxgyenator membrane of kid type ) driving by CVVH machine will be performed in the NCP with severe ARDS
224221405|NCT01893502|BEHAVIORAL|Telephone counselling from Quitline|
224221406|NCT03342508|DEVICE|Fetal Pillow|see arm description
224221407|NCT06483672|DRUG|Furmonertinib|Furmonertinib 80mg, once daily, orally
224221408|NCT06483672|DRUG|Anlotinib|Anlotinib 12mg, once daily (days 1-14, 21 days per cycle), orally
224221409|NCT00988234|PROCEDURE|SGPP|ultrasound guided posterior lumbar plexus block and subgluteal sciatic nerve block under prone position
224221410|NCT00988234|PROCEDURE|SGTPP|ultrasound guided posterior lumbar plexus block and sub-greater trochanter approach under prone position
224318242|NCT07134517|OTHER|Pilates exercise|The principles of centering, concentration, breathing, control, flow, and precision in the Pilates method will be explained to participants. Pelvic floor activity and lateral breathing will be taught and practiced, along with neutral spine alignment. The first and last 5 minutes of each session will consist of stretching exercises. Stretching exercises will begin with 3-5 repetitions, while strengthening and stabilization exercises will start with 6-8 repetitions, with the number of repetitions increasing each week based on participants' tolerance. Springs are attached according to the purpose and difficulty level of the exercises. Stretching exercises are performed with lighter resistance springs, while strengthening and stabilization exercises are performed with higher resistance springs. All movements will be demonstrated and explained to ensure the exercises are performed correctly. Verbal cues will be given for breath control and centering.
224221411|NCT00988234|PROCEDURE|SGLP|ultrasound guided posterior lumbar plexus block and subgluteal sciatic nerve block under lateral decubitus position
224221412|NCT00988234|PROCEDURE|SGTLP|ultrasound guided posterior lumbar plexus block and sub-greater trochanter approach under lateral decubitus position
224221413|NCT03535883|DRUG|Novel Oral Anti-Coagulants|Novel Oral Anti-Coagulant (NOAC) medications (i.e. Eliquis, Plavix, Xarelto etc.)
223632685|NCT06075082|DEVICE|LEFT smartwatch app|The LEFT smartwatch app is an app on the Apple Watch which measures body sleep position and gently vibrates when the body is in the right lateral decubitus position. In this way, patients with nocturnal gastroesophageal reflux symptoms learn to avoid the right lateral sleep position as they will avoid the annoying vibrations. Measurements while using the smartwatch app will be compared to measurements at baseline.
223632686|NCT06379529|OTHER|NuvoAir clinical service|Patients with COPD receiving usual care plus NuvoAir clinical services.
224221414|NCT01953783|DRUG|IXAZOMIB|"Part A: Ixazomib 4.1 mg containing approximately 500-nCi \[14C\]-ixazomib, solution, orally on Day 1 and ixazomib 4 mg, capsule, orally on Days 14 and 21.~Part B: Ixazomib 4 mg, capsule, orally, once weekly, on Days 1, 8 and 15 in 28-day cycles until disease progression or unacceptable toxicity."
224221415|NCT03553277|OTHER|transfluthrin|passive emanator with formulated transfluthrin
224221416|NCT03553277|OTHER|placebo|passive emanator with formulated inert ingredients
224221417|NCT02627014|OTHER|Manual therapy|"6 treatments: 2 treatments for week~1 treatment = 30 minutes"
224221418|NCT02627014|OTHER|Home physical therapy|once a day: 15 minutes
224221419|NCT02627014|OTHER|Manual therapy in cervical region|"6 treatments: 2 treatments for week~1 treatment = 30 minutes"
224221420|NCT02627014|OTHER|Home physical therapy in cervical region|once a day: 15 minutes
224221421|NCT04800055|OTHER|Attractive Targeted Sugar Bait|ATSBs will be installed on all structures of consenting households in intervention areas for six months according to instructions from the manufacturer. Monitoring assistants will be responsible for providing individual level household orientation for the ATSB and seeking informed consent. Prior to ATSB deployment, community sensitization activities will be conducted to prepare communities for the intervention and research activities. Where appropriate, local media may be used to disseminate messages to sensitize the community to the intervention and the research.
224221422|NCT03231618|DIETARY_SUPPLEMENT|1. Low-fat and high-carbohydrate diet; 2. High-fat and low-carbohydrate diet; 3. High-protein and low-fat diet|Every participate was provided with 3 types of diets in random order
224221423|NCT02361021|OTHER|- Weaning from mechanical ventilation|
224221424|NCT05007691|DEVICE|Occlusal splint|Occlusal splints are hard, made of polymer biocompatible material using digital additive technology.
224221425|NCT00686920|DRUG|Rifaximin|Oral
223632687|NCT06094322|OTHER|MR prostate exam|Subjects will lie in supine position. The systematic use of a headset will reduce the acoustic noise inherent to the machine. We are going to carry out the standard MR prostate protocol which patients usually benefit from in clinical routine. This protocol consists of morphological sequences (T2 weighting with spin echo readout), Diffusion MR and dynamic contrast-enhanced sequences. We will then perform an additional faster enhanced T2-weighting SE and DWI sequences combined with Deep Learning reconstruction
224318243|NCT07133841|DIAGNOSTIC_TEST|Pre-Season Assessments|Pre-Season Assessments including performance based tests and thermal imaging.
223632688|NCT05960890|BEHAVIORAL|Remote monitoring assisted by community physicians|"Patients upload data such as wristband data, blood pressure, weight through their mobile phones, while physicians can check the data on the platform. Upon detecting alerts, community physicians review participant-related medical information, conduct structured symptom assessments via StarNet Home platform/phone within 2 hours, and initiate protocol-guided interventions (e.g., diuretic adjustment for fluid overload)."
223764360|NCT07170332|DEVICE|ZIPPER™ Stent-Graft Trial for Aortic Arch Dissection|The ZIPPER aortic arch stentgraft system consists of the arch mainbody stentgraft system, the branch artery stentgraft system and the thoracic extension stentgraft system.
224221426|NCT02832908|OTHER|Change from semi-seated position to supine|from semi-seated position (30°) to lying position
224221427|NCT04597606|OTHER|Exercise with spontaneous ventilation.|"Patients will perform 10 minutes, constant load, exercise in a cycloergometer. To set the load, a baseline incremental effort test will be performed previously (VISIT 1).~Then, in a separate day (VISIT 2), the subject will perform 10 minutes cycling at the 75% load of that determined as maximum in VISIT 1, at a constant rate of 30 to 35 pedal revolutions per minute, in spontaneous breathing, with low flow oxygen through conventional nasal cannula adjusted to achieve SpO2 between 92to 94%"
224221428|NCT04597606|DEVICE|Exercise with NIV|VISIT 2 Non invasive mask ventilation: parameters will be titrated during a free cycling period at the end of the spontaneous breathing exercise. Then, in a separate day (VISIT 3), with the same constant load, cycling cadence and under NIV, the patient will perform 10 min of cycling.
224221429|NCT04597606|DEVICE|Exercise with HFNC|With constant flows of 50 lpm and with FiO2 adjusted according to SPO2, to obtain a constant saturation between 92 and 94%. The same pedaling load and frequency will be maintained, with similar variables collected.
224221430|NCT04735237|PROCEDURE|Autogenous fat injection|Done under general anesthesia. Fat is to be harvested from the abdomen using manual liposuction. Small aliquots of fat are to be injected into the philtral column (and in the vermilion and any other area of volume insufficiency if needed).
224221431|NCT04735237|PROCEDURE|Surgical revision with orbicularis oris muscle reconstruction.|Surgical repair done under general anesthesia. The original scar will be marked on the skin with methylene blue. The skin will be incised along the designed line with scar removal. The orbicularis oris muscle stump will be dissected medially and laterally and approximated by means of 4-0 inverted horizontal mattress sutures.
224221432|NCT04271150|DEVICE|Self-etch|Universal adhesive with self-etch mode
224318244|NCT02512718|DRUG|Omegaven|Comparison of FOLE vs. SOLE
224221433|NCT04271150|DEVICE|Total-etch|Universal adhesive with total-etch mode
223632689|NCT06194864|DRUG|Itraconazole|itraconazole 200 mg QD Days 6 to 16
223632690|NCT06194864|DRUG|rifampicin|rifampicin 600 mg QD Days 6 to 20
223632691|NCT06194864|DRUG|Ecopipam|89.6 mg on Days 1 and 9 for Part 1 or 179.2 mg on Days 1 and 13 for Part 2
223632692|NCT04007692|PROCEDURE|Esophageal stent placement|Exposure of interest is standard of care esophageal stent placement
223632693|NCT03745508|OTHER|Instant Coffee|Instant coffee prepared at different caffeine concentrations
223632694|NCT03365414|BIOLOGICAL|Albumin (Human) 5%, USP|Albumin (Human) 5%, USP. Intravenous Solution. Plasma Substitute/Blood Derivative
223632695|NCT03365414|DRUG|Normal Saline 0.9% Infusion Solution Bag|Placebo Normal Saline 0.9% Infusion Solution Bag.
223764361|NCT07174167|DRUG|Genicular nerve block with prilocaine|ultrasound guided genicular nerve block (GNB) injecting 6 mL of 2% prilocaine to the genicular nerves
223764362|NCT07174167|DRUG|genicular nerve block with prilocaine and triamcinolone|ultrasound guided genicular nerve block (GNB) injecting 5 mL of 2% prilocaine in combination with 1 mL/40 mg of triamcinolone to the genicular nerves
223764363|NCT07174167|DRUG|Sham injection|placebo injection using 6 mL of 0.9% saline to knee region other than genicular nerves
223764364|NCT07174141|OTHER|Ophthalmological examination|at inclusion, at 3 months and 6 months; OCT-A retina
224221434|NCT00012155|BIOLOGICAL|NV1020|
224221435|NCT03999281|OTHER|Human Allograft (Theraskin)|Biologically active cryopreserved human skin allograft (Theraskin) was used on both cohorts, both diabetic foot ulcer and venous leg ulcer.
224221436|NCT06321237|DEVICE|Vagus nerve stimulation for 8 weeks|The vagus nerve at the position of the ear nail was stimulated by an ear nail stimulator with pulse width of 200μs and frequency of 30Hz in patients with IBS for 8 weeks
224221437|NCT06321237|DEVICE|Vagus nerve stimulation for the first 4 weeks|The vagus nerve at the position of the ear nail was stimulated by an ear nail stimulator with pulse width of 200μs and frequency of 30Hz in patients with IBS for the first 4 weeks
224221438|NCT06321237|DEVICE|Vagus nerve stimulation for the last 4 weeks|The vagus nerve at the position of the ear nail was stimulated by an ear nail stimulator with pulse width of 200μs and frequency of 30Hz in patients with IBS for the last 4 weeks
224221439|NCT06321237|DEVICE|Pseudostimulus|The patient is given some electrical stimulation but not vagus nerve stimulation
224221440|NCT04343911|DEVICE|Pink Pad ® (Xodus Medical Inc., New Kensington, PA)|a non-sliding foam mattress
224221441|NCT01888471|PROCEDURE|Blood sample|Blood sample will be obtained from enrolled mothers at delivery(either immediately before or after delivery) Both original blood sample and cord blood sample will be obtained for serology.
224318245|NCT02512718|DRUG|Soybean oil lipid emulsion|Comparison of FOLE vs. SOLE
224318246|NCT01810302|DRUG|Nicardipine hydrochloride|Nicardipine hydrochloride 4mg by intrathecal administration twice a day until post-hemorrhage day 10.
224318247|NCT01810302|DRUG|Preservative-free normal saline|Preservative-free normal saline 1.6 mL by intrathecal administration twice a day until post-hemorrhage day 10.
224318248|NCT01711515|DRUG|Cisplatin|Given IV
224318249|NCT01711515|RADIATION|External Beam Radiation Therapy|Undergo external beam radiation therapy
223632696|NCT05520203|OTHER|Care provided by the Nurse Practitioner|Introduction of a Nurse Practitioner in the interdisciplinary care team
223632697|NCT00074165|DRUG|Rituxan|Total dose: 375mg/m2 infused IV; Every 4 weeks for up to one year.
223632698|NCT00074165|DRUG|Cyclophosphamide|Dose 330mg/m2 x 2 days infused IV; Every 4 weeks for up to 1 year
223632699|NCT00074165|DRUG|Etoposide|Dose 200mg/m2 x 2 days infused IV; Every 4 weeks for up to one year. Etoposide phosphate may be given instead.
223632700|NCT00074165|DRUG|Etoposide phosphate|Dose 200mg/m2 infused IV x 2 days; Every 4 weeks for up to one year. Etoposide may be given instead.
223632701|NCT00074165|DRUG|Carboplatin|Dose: 200mg/m2 x 2 days infused IA with BBBD; Every 4 weeks for up to one year.
223632702|NCT00074165|DRUG|Sodium thiosulfate|"Dose: 4 hrs post carboplatin = 20gm/m2;~Dose: 8 hrs post carboplatin = 16gm/m2~Infused IV x 2 days"
223632703|NCT00074165|DRUG|Neupogen|48 hours after chemotherapy, QD x 7-10 days until WBC greater than 5000. Neulasta (Pegfilgrastim) may be given instead.
223632704|NCT00074165|DRUG|Neulasta|Dose: 6mg, 24-72 hours after chemotherapy. Neupogen may be given instead.
223632705|NCT00074165|DRUG|Cytarabine|Dose: 40mg on Day 14 following chemotherapy
223632706|NCT05855798|DRUG|Bupivacain|Bupivacaine is a local anesthetic agent commonly used in ESP block.
223632707|NCT05855798|DRUG|Magnesium sulfate|Magnesium is an adjuvant agent that can be added to the local anesthetic agent to increase analgesic effectiveness..
224221442|NCT01888471|OTHER|Vaginal swab sample|Vaginal swab will be collected at delivery from a pre-defined subset of enrolled mothers for the identification of controls, for determining GBS maternal colonization status and serotype.
224221443|NCT01768078|PROCEDURE|Intravitreal injection of Betamethasone + antibiotics|
224221444|NCT01768078|PROCEDURE|Intravitreal injection of antibiotics|
223632708|NCT05855798|DRUG|Ketamine Hydrochloride|Ketamine Hydrochloride is an also adjuvant agent that can be added to the local anesthetic to increase analgesic effectiveness.
223632709|NCT04080661|PROCEDURE|Venapuncture|Blood samples will be collected to determine the serum trough levels and anti-drug antibodies of secukinumab.
223632710|NCT04080661|OTHER|Patient questionnaires|The study participants will complete the Dermatology Quality of Life (DLQI) and EQ-5D-5L questionnaire at each study visit.
223632711|NCT03136744|BEHAVIORAL|Sit Less with MS|The Sit Less with MS intervention has a total duration of 16 weeks and consists of two stages: sit less and move more stages. During the first stage (sit less), we will conduct coaching sessions with participants every week and the focus will be on interrupting their sitting time every 30 minutes. Facebook and Twitter will be also used to provide information and supplement coaching sessions. During the second stage, the focus will be on encouraging the participants to move more by replacing sitting with light intensity activities frequently throughout waking hours.
223632712|NCT06416566|DRUG|Subcutaneous Enoxaparin|Selected patients will receive subcutaneous low dose enoxaparin once a week for 6 weeks.The level of serum heparinase enzyme will be measured before and after treatment
223632713|NCT05379088|BEHAVIORAL|Phone/zoom calls|Participants will complete weekly follow-up phone/zoom calls with a member of the research team. The phone/zoom calls will typically last 30-60 minutes. Participants will discuss barriers to activity and goals for upcoming weeks.
223632714|NCT05214001|DRUG|Almotriptan 12.5 Mg Oral Tablet|Treatment for an acute, moderate to severe migraine attack
223632715|NCT05214001|DRUG|Ubrogepant 50Mg Tab|Treatment for an acute, moderate to severe migraine attack
223632716|NCT03279081|DRUG|Cx601|Cx601 eASCs intralesional injection.
223632717|NCT03279081|OTHER|Placebo|Cx601 placebo-matching eASCs intralesional injection.
224318250|NCT01711515|RADIATION|Internal Radiation Therapy|Undergo intracavitary brachytherapy
223632718|NCT03521570|RADIATION|IMRT|Undergo intensity-modulated radiation therapy
223632719|NCT03521570|BIOLOGICAL|Nivolumab|Given IV
223632720|NCT03304561|OTHER|Traditional rehabilitation|traditional ACL rehabilitation program
223632721|NCT03304561|OTHER|Cross-over training|Cross-over training addition to the traditional rehabilidation
223632722|NCT04771455|BEHAVIORAL|Behavioral weight loss|Participants will receive behavioral weight loss intervention
223632723|NCT04771455|BEHAVIORAL|Intervention component: Decrease overvaluation of weight and shape|Participants will receive an intervention component to decrease overvaluation of weight and shape
223632724|NCT04771455|BEHAVIORAL|Intervention component: Decrease unhealthy weight control practices|Participants will receive an intervention component to decrease unhealthy weight control practices
223632725|NCT04771455|BEHAVIORAL|Intervention component: Decrease negative affect|Participants will receive an intervention component to decrease negative affect
223632726|NCT06301230|DEVICE|Portable Laparoscopic Trainer (PLET)|"The PLET trainer is light and easy to transport packed in a bag and consists of a foldable plastic box, which can be assembled in less than 30 seconds by means of simple handles. There are three accesses for the surgical instruments (ports) as well as a central recess over which a tablet with an integrated camera can be placed.~Each participant received a previously prepared opaque envelope containing a black or white USB stick from the Principal Investigator with the assignments on it as part of the randomization process. The outcome assessors were blinded to the allocation."
223632727|NCT02575534|DRUG|Procainamide|the procainamide will be infused at 12mcg/kg up to a max of 1 gram at a rate of 20mg/min which will take up to 1 hour to infuse
223764365|NCT07174141|BIOLOGICAL|Blood sample|Collection of a 2 mL blood sample at inclusion
223764366|NCT07171983|DRUG|BMS-986454|Specified dose on specified days
224221445|NCT02005354|DEVICE|Trans-cutaneous Electrical Nerve Stimulation (TENS)|Patients in whom a bone marrow biopsy is planned will be randomised to one of two groups - a Placebo Comparator group where the TENS machine will be set at the lowest sensory threshold and an Active Comparator group where the TENS machine will be set at a recognised analgesic level (\>50Hz and below the pain threshold for the patient).
224318251|NCT01711515|BIOLOGICAL|Ipilimumab|Given IV
224318252|NCT01711515|OTHER|Laboratory Biomarker Analysis|Correlative studies
224318253|NCT03584087|DRUG|Normal Saline|TG 0 (0Hr)
224318254|NCT03584087|DRUG|Terlipressin|Duration of Terlipressin after EVL
224318255|NCT03659929|DRUG|Amphetamine Sulfate|active experimental AR19
224318256|NCT03659929|DRUG|Placebo|Matching placebo
223632728|NCT04895839|BEHAVIORAL|Patient Empowerment Program|"The 6 months at home program focuses on aerobic and strength training, pelvic floor muscle exercises, meditation, social connection, and overall healthy lifestyle practices supported with daily text message/email reminders. The aerobic (5 times/week) and strength (2 times/week) program will comprise of a single 30-minute session daily and will be individualized to each participant. Pelvic floor muscle training will include three, 10-minute sessions and mediation for 10 minutes daily. Intimacy and Connection component of PC-PEP consists of engaging in at least one form of intimacy practice prescribed, per day. Social connection will be fostered by pairing participants up with peers from the study. To encourage program compliance, study participants will receive 3 daily reminders to do their pelvic floor muscle exercises per day plus an additional motivational email daily containing helpful tips."
223632729|NCT03664297|DRUG|SHR1459|SHR1459 will be administered continually till disease progression or unacceptable toxicity.
223632730|NCT00000211|DRUG|Buprenorphine|
223632731|NCT04076696|DEVICE|Scatter corrected s-DCT|All patients will have a breath held s-DCT scan in an anterior-posterior direction
223632732|NCT04042558|DRUG|Carboplatin + Pemetrexed + Atezolizumab + Bevacizumab|4 cycles of induction every 3 weeks of cisplatine,pemetrexed, atezolizumab + bevacizumab and patients without disease progression, treatment will be followed by maintenance therapy by Atezolizumab + Pemetrexed +/- Bevacizumab administered at the same dosage on 3-week cycles
223632733|NCT04042558|DRUG|Carboplatin + Pemetrexed + Atezolizumab|Carboplatin + Pemetrexed + Atezolizumab
223632734|NCT00500123|PROCEDURE|Alpha-1 Antitrypsin Genotype|Home fingerstick testing for alpha-1 antitrypsin genotype
223632735|NCT03496844|DIAGNOSTIC_TEST|F-18 fluciclovine-PET/CT scan|PET/CT imaging with F-18 fluciclovine
223632736|NCT02495428|PROCEDURE|Kinesio Tape Method|
223632737|NCT01025908|BEHAVIORAL|Psychotherapy|Cognitive Behavioral Therapy
223632738|NCT01025908|BEHAVIORAL|Supportative psychotherapy|Supportative psychotherapy
224221446|NCT02005354|DRUG|Standard pain relief (ie. local anaesthetic with or without inhaled nitrous oxide)|All patients will receive standard pain relief (ie. local anaesthetic with or without inhaled nitrous oxide)
224221447|NCT00591253|DRUG|Azilsartan medoxomil|Azilsartan medoxomil 40 mg, tablets, orally, once daily for up to 6 weeks.
223632739|NCT04079439|BEHAVIORAL|Physical activity with tailored e-health support|The planned e-health intervention will contain several elements: A motivating smartphone app registers indoor- and outdoor activity as well as activity from the use of an ergometer-bike. For recording of outdoor activity commercial wrist-born accelerometers will be used. The app-solution will be motivating and result in a reward after a predefined level of activity.
223632740|NCT03797651|DRUG|Standard DAPT|Patient will continue standard treatment (aspirin plus ticagrelor) for 1 year. Dosage of ticagrelor would be 90 mg twice a day, and 100 mg of aspirin will be prescribed once a day.
223632741|NCT03797651|DRUG|Very-short DAPT less than 1 month after PCI|Patient will stop aspirin (ticagrelor monotherapy) after discharge or within 1 month. Dosage of ticagrelor would be 90 mg twice a day, and 100 mg of aspirin will be prescribed once a day (during hospitalization).
223632742|NCT03962465|DRUG|Inotuzumab ozogamicin|By IV, given on days 12 and 19 Inotuzumab ozogamicin is approved as a single-agent in this population (patients with B-ALL) but adding it to these drug combinations has not been tested in humans
223632743|NCT03962465|DRUG|Prednisone Pill|Taken daily days 1-28 by mouth
223632744|NCT03962465|DRUG|Daunorubicin|By IV, given on days 1, 8, 15, and 22
223632745|NCT03962465|DRUG|Vincristine|By IV, given on days 1, 8, 15, and 22
223632746|NCT03962465|DRUG|Cytarabine|Intrathecal, administered on day 1 only
223632747|NCT03962465|DRUG|Methotrexate|Intrathecal, administered on days 8 and 29
223632748|NCT03962465|DRUG|Pegaspargase|By IV, given on day 4
223632749|NCT06010654|DEVICE|Software as a Medical device|The test device is a software medical device designed for the purpose of treating generalized anxiety disorder that provides self-talk training based on acceptance and commitment therapy (ACT). Use 2 sets per day for 10 weeks with generalized treatment of standard treatment method.
223632750|NCT04181359|DRUG|Nitric Oxide|Inhaled nitric oxide, which consists of breathing medical grade air (21% O2) with 40 parts per million of nitric oxide.
223632751|NCT04181359|DRUG|Placebo|Inhaled placebo, which consists of breathing medical grade air (21% O2).
223632752|NCT02663492|DEVICE|TEAS|The patients will be treated by their assigned acupuncture stimulation in 7 days. The surface electrical stimulation devices and application parameter are: G6805-II pulse acupuncture treatment instrument from Shanghai Medical Technology Company, Ltd (Shanghai, China); sparse-dense wave stimulation (sparse wave 30Hz; dense wave 100Hz) with an intensity of 6-15 V; and the corresponding parts of the body experienced a slight quiver, with a duration 20 minutes each time.
223632753|NCT02663492|DRUG|Sanguisorba officinalis L.|Sanguisorba officinalis L., a Leukogenic medication, named Diyu Shengbai Pian (Chengdu Diao Tianfu Pharmaceutical Group Co., Ltd., China) will be taken 0.4g each time by 3 times per day.
223632754|NCT01250808|DRUG|Bortezomib/Dexamethasone/Melphalan|"Induction therapy: The treatment will continue for 3-4 cycles and each cycle will be last 21 days.~Bortezomib 1.3mg/m2, twice weekly for two weeks (days 1, 4, 8, and 11) of each cycle + Dexamethasone 20mg/m2, on days 1-4 of each cycle.~Bortezomib 1.0mg/m2, twice weekly for two weeks (days 1, 4, 8, and 11) of each cycle + Dexamethasone 20mg/m2, on days 1-4 of each cycle.~Bortezomib 1.6mg/m2, once weekly for two weeks (days 1, 8) of each cycle + Dexamethasone 20mg/m2, on days 1-4 of each cycle and on days 9-12 of the first and second cycles.~ASCT therapy:~Melphalan 200mg/m2 +Bortezomib 1.0mg/m2 for four times. Melphalan 200mg/m2 +Bortezomib 1.0mg/m2 for two times."
223632755|NCT03253796|BIOLOGICAL|Golimumab|Injections of 50 mg golimumab. At the investigator's discretion, participants with a body weight of more than 100 kg could receive 100 mg injections with golimumab.
223632756|NCT03253796|BIOLOGICAL|Placebo|Injections of matching placebo for golimumab.
223632757|NCT00181896|DRUG|bupropion SR|Open-label prescription of Bupropion SR for 8 weeks.
223764367|NCT07171983|OTHER|Placebo|Specified dose on specified days
224221448|NCT00591253|DRUG|Azilsartan medoxomil|Azilsartan medoxomil 80 mg, tablets, orally, once daily for up to 6 weeks.
224221449|NCT00591253|DRUG|Placebo|Azilsartan medoxomil placebo-matching tablets, orally, once daily for up to 6 weeks.
223632758|NCT01581801|PROCEDURE|Gastric Bypass|"Roux-en-Y Gastric Bypass This laparoscopic operation includes the division of the stomach in two parts. A proximal, smaller pouch (20-25 cc volume), is connected to the rest of the gastrointestinal tract through a gastro-jejunal anastomosis, whereas the distal gastric pouch is left behind but excluded from the transit of food.~An entero-entero anastomosis, with a Roux-en-Y type of reconstruction, allows the bile and pancreatic juices to mix with the nutrients at about 100-150 cm from the gastro-jejunal connection."
223632759|NCT01581801|PROCEDURE|Sleeve Gastrectomy|Sleeve gastrectomy Laparoscopic SG involves a longitudinal resection of the stomach on the greater curvature from the antrum starting opposite of the nerve of Latarjet up to the angle of His The final gastric volume is about 100 mL.
223632760|NCT04504500|BEHAVIORAL|HSOG guidelines application|In their practice, as regards the mode of delivery, obstetricians are encouraged to conform to the three guidelines and two consent forms published by the Hellenic Society of Obstetrics and Gynecology (HSOG). The members of the appointed Steering Committee and/or local opinion leaders will discuss and disseminate these guidelines among the professional staff in the respective maternity units, providing them with the opportunity to identify specific barriers, overcome them, and develop an implementation timetable.
224221450|NCT05338554|DEVICE|Repetitive transcranial magnetic stimulation|Magnetic stimulation was performed using a figure-eight coil connected to a Magstim Rapid2 system, All patients seat in a comfortable reclining chair and delivered pcTBS protocol using repetitive transcranial magnetic stimulation . The stimulation intensity was set to 80% of the resting motor threshold, which is measured as the minimal intensity of stimulation evoking an electromyographic response ≥50µV on the first dorsal interosseus muscle of the hand contralateral to the stimulated hemisphere in at least 5 out of 10 trials. For this measurement, a figure-of-eight coil is positioned over the hand motor hotspot and oriented perpendicular to the central sulcus (parallel to the hemispheric midline).
224221451|NCT05338554|DEVICE|Repetitive transcranial magnetic stimulation|Magnetic stimulation was performed using a figure-eight coil connected to a Magstim Rapid2 system, All patients seat in a comfortable reclining chair and delivered 10HZ protocol using repetitive transcranial magnetic stimulation . The stimulation intensity was set to 80% of the resting motor threshold, which is measured as the minimal intensity of stimulation evoking an electromyographic response ≥50µV on the first dorsal interosseus muscle of the hand contralateral to the stimulated hemisphere in at least 5 out of 10 trials. For this measurement, a figure-of-eight coil is positioned over the hand motor hotspot and oriented perpendicular to the central sulcus (45° away from the hemispheric midline).
224221452|NCT03986749|PROCEDURE|Doppler ultrasonography after bursa augmentation|Dynamic ultrasound examination with Grading of blood vessels using the modified Ohberg Score in the longitudinal scan in dynamic ultrasound of the rotator cuff tendon - primary to surgery and 3 weeks later.
224221453|NCT03428659|OTHER|Data acquisition of functional abilities in sub-acute stroke|MRI data, motor evoked potentials, gait function and behavior data acquisition
224221454|NCT03811249|DEVICE|VisAbility™ Micro Insert|No (new) intervention will be administered during the course of this long term follow-up study. Subjects that previously participated in the VIS-2014 clinical trial that had VisAbility™ Micro Inserts surgically implanted in the eye(s) will be followed prospectively.
224221455|NCT04964622|DRUG|nurofen|tablet
224221456|NCT03124381|DEVICE|Cleanser, Acne Mask|A facial cleanser will be used twice daily (morning and evening). The light therapy mask will be used for 10 minutes in the evening after washing/drying the face.
224221457|NCT03124381|DEVICE|Cleanser, Gel-Cream, Acne Mask|A facial cleanser will be used twice daily (morning and evening). In the evening after cleansing, the gel-cream will be applied full face and allowed to dry before the light therapy mask is used for 10 minutes.
224221458|NCT04192617|DRUG|SM03|SM03: 600 mg intravenous (IV)
224221459|NCT04192617|DRUG|Placebo|Placebo: 600 mg intravenous (IV)
224221460|NCT04192617|DRUG|Methotrexate|methotrexate: 7.5-20 mg/week oral
223632761|NCT04504500|BEHAVIORAL|Interactive workshops and courses|The workshops and courses will give instruction in indications for cesarean section and clinical scenarios, physiology-based cardiotocography (CTG) interpretation, obstetric emergencies (with topics including breech delivery, trial of labor after cesarean, delivery of twins, induction and augmentation of labor), organization of the labor ward, as well as launching of regular cesarean section and CTG meetings with review of the patient notes. The workshops will last four days and will be conducted by experienced trainers. The expectation is that the obstetricians will gain very considerable knowledge and skills, which will enable them to subsequently follow these practices safely and competently.
223632762|NCT04504500|BEHAVIORAL|Feedback through follow-up meetings|Regular follow-up meetings with members of the steering committee and local opinion leaders throughout the intervention period will enhance compliance with the guidelines. Feedback with positive phrasing will be incorporated to meet local needs.
223632763|NCT04504500|BEHAVIORAL|Robson criteria usage|Obstetricians are set to a routine to enable them to use the Robson 10-group classification criteria for cesarean sections and obtain feedback on the unit's cesarean section rates monthly. They thus know which category is higher and can be reduced further.
224221461|NCT05951517|DRUG|MMF|MMF treat refractory gastrointestinal Henoch-Schönlein purpura
224221462|NCT04684784|DEVICE|Intervention-Dry Needling|Deep Dry Needling into the site of the latent TriggerPoint of the upper trapezius muscle. 1 session in upper trapezius muscle moving the needle up and down ten times.
223632764|NCT04504500|BEHAVIORAL|Access to live real-time statistics|Live real-time statistics provided by an online platform, on a regular basis, is expected to improve adherence, through regular feedback. Each unit will see other units' statistics by means of an anonymous reporting system. This repetition will create silent signals that will remind the participating obstetricians to remain on task.
223680814|NCT01541345|DRUG|InductOs|CE-marked medical device Bio-Oss Spongiosa Block® (xenogenic bone) loaded with InductOs® (1.5 mg Dibotermin alfa / ml) covered with Bio-Gide® (collagen membrane). One time application at augmentation surgery.
223680815|NCT01541345|PROCEDURE|Augmentation surgery|CE-marked medical device Bio-Oss Spongiosa Block® (xenogenic bone) loaded with InductOs® (1.5 mg Dibotermin alfa / ml) covered with Bio-Gide® (collagen membrane)
224221463|NCT04684784|DEVICE|Control-Dry Needling|Sham Dry Needling into the site of the latent Trigger Point of the upper trapezius muscle with non-penetrating needles
223632765|NCT04504500|BEHAVIORAL|Attendance of local cesarean section meetings|Local cesarean section meetings will be held weekly, in each unit. The members of the steering committee or local opinion leaders may actively participate in these meetings. Local obstetricians learn to judiciously adapt standard medical practices, thereby avoiding unnecessary medical interventions. This is a way to further enhance compliance, as during the discussions the behavior expected of the obstetricians is clearly stated by the participating opinion leaders.
223632766|NCT04504500|BEHAVIORAL|Attendance of local CTG interpretation meetings|"Local CTG interpretation meetings will be held weekly, in each unit, during which all abnormal CTG cases that led to cesarean section will be reviewed and discussed. Members of the Steering Committee or local opinion leaders may actively participate in these meetings. Obstetricians are encouraged to reflect on their medical practice through judicious physiology-based CTG interpretation."
223632767|NCT04504500|BEHAVIORAL|Reminders of proper clinical practice|Effective and reliable reminders concerning optimal obstetric practice will be placed in labor wards, staff rooms, patient notes, vaginal birth packages and above theater hand washers. There will be short messages with positive phrasing regarding the benefits of vaginal birth, thus reminding birth attendants to reduce unnecessary cesarean sections. Relevant SMS (short message service) will be sent to the participating obstetricians' mobiles on a regular basis, so as to motivate them via non-verbal signals.
223632768|NCT04504500|OTHER|HSOG guidelines implementation|There will be application in daily practice of three guidelines and two consent forms pertaining to the mode of delivery published by HSOG. Obstetricians are informed on evidence-based medicine in obstetrics and provided with a structured and safe approach to labor management. The members of the appointed Steering Committee and/or local opinion leaders discuss and disseminate the guidelines among the professional staff at the respective maternity units, answer questions, and make available their knowledge and experience. Adoption of guidelines by the participating unit helps to establish clear, consistent rules that are direct and simple, and obstetricians are asked to embrace fully justified medical practice.
223632769|NCT04504500|OTHER|Interactive workshops and courses training|The workshops and courses will provide instruction in indications for cesarean section and case scenarios, physiology-based CTG interpretation, obstetric emergencies (with topics including breech delivery, trial of labor after cesarean, delivery of twins, induction and augmentation of labor), organization of labor ward and launching of cesarean section and CTG meetings. This type of formal training provides problem-solving strategies, using mnemonics, that are critical in emergencies and that also aid in learning and retaining the skills being taught. Functional and social skills that directly affect decision-making and effectiveness are addressed. Thus, units adopt a continuous educational procedure for their staff, enhancing their confidence when dealing with labor emergencies and redesigning labor management plans, so as to ensure high-level obstetric services.
223632770|NCT04504500|OTHER|Implementation of Robson criteria classification|Use will be implemented of an online application embedded in the REDCap electronic database questionnaire with Robson 10-group classification criteria and feedback on the unit's cesarean section rates monthly, so as to know which category is higher and can be reduced further. This change in the unit's practice will introduce a new medical reporting and audit system that can detect unjustified medical procedures much more easily.
223632771|NCT04504500|OTHER|Live real-time statistics online platform|Live real-time statistics provided on a regular basis by an online platform will provide feedback and essential information. Each unit will see other units' statistics using an anonymous reporting system. This information can trigger self-generative learning strategies and help obstetricians to become more effective learners.
223680816|NCT00943553|DRUG|decitabine Induction Chemotherapy|Arm A - 12 days (5 days of intravenous (IV) decitabine 20 mg/m\^2 followed by 7 days of induction chemotherapy with IV daunorubicin 45 mg/m\^2 and cytarabine 100 mg/m\^2/day)
223680817|NCT00943553|DRUG|Induction Chemotherapy|Arm B - 7 days (7 days of induction chemotherapy with IV daunorubicin 45 mg/m\^2 and cytarabine 100 mg/m\^2/day only)
224221464|NCT04809779|DRUG|Sintilimab|The PD-1 inhibitor Sintilimab 200mg for intravenous (IV) administration will be given together with three-week epirubincin, cyclophosphamide (EC) × 4 treatments from the second cycle followed by weekly nab-paclitaxel x12 treatments or three-week nab-paclitaxel x4 treatments.
224221465|NCT05881200|DEVICE|Magnetic mitohormesis|"The BIXEPS machine employs gentle pulsed magnetic signals specifically tuned to activate the natural powerhouse (mitochondria) within muscle. Brief 10-minute MM sessions with the device recreate similar biological and metabolic effects as exercise, but without physical stress or strain. It is intended to improve the strength and function of users, promoting overall fitness and well-being. Just like exercise, these effects accumulate with time.~Subjects will receive 12 sessions of 10 minute treatments"
224221466|NCT00592020|PROCEDURE|Short Transverse Incision|Short Transverse Incision for kidney transplantation
224318257|NCT02764346|BEHAVIORAL|iCanCope app|"In addition to standard medical care, adolescents in the experimental group will receive access to the iCanCope smartphone app for 8 weeks. The app consists of daily pain symptom tracking (pain intensity, sleep, mood, physical activity, and fatigue), goal setting, in-the moment coping strategies, as well as a social community component."
224318258|NCT02764346|BEHAVIORAL|iCanCope attention control app|"The control group is designed to control for the potential effects on outcomes of time, attention, and smartphone use during the intervention. In addition to standard medical care, adolescents in the attention control group will receive access to the iCanCope control app, with limited functionality."
224318259|NCT03281018|BEHAVIORAL|Caregiver Accompaniment Time (CAT) + preoperative hypnosis session|The hypnosis session is performed by a nurse trained in medical hypnosis; this interview lasts approximately one hour and is carried out 5 to 15 days before the hospitalisation. During the hypnosis session, the patient is free to choose what issues she wants to address. The patient will then go from a state of ordinary consciousness to a modified state of consciousness. This state will allow her to activate her own resources to handle difficulties, especially anxiety. Using a post-hypnotic suggestion, the patient will be able to revisit her work at any time she needs
224318260|NCT01153100|DRUG|Glargine|Glargine 0.25 units per kg body weight given every 24 hours while patients are receiving intravenous (IV) standard insulin drip therapy
223680818|NCT04243421|DEVICE|Implantation|Soft tissue aesthetics, marginal bone level on CBCT
223680819|NCT03607643|DRUG|Cannabidiol|"* Sublingual dose of 1 mL (0.910 g) of BRCX014 in the morning, prior to the first meal of the day~* Sublingual dose of 1 mL (0.910 g) of BRCX014 in the afternoon, prior to the evening meal"
223632772|NCT04504500|OTHER|Local cesarean section meetings|Local cesarean section meetings will be held weekly in each unit. The members of the Steering Committee or local opinion leaders may actively participate in these meetings. The unit's staff can hear about both justified and unnecessary surgical procedures and draw informed conclusions as to the optimal procedure in similar cases. They will also have the opportunity to actively participate in an elaborative problem-solving discussion. These meetings when routinely conducted, provide feedback and audit resources to help improve performance and further enhance compliance.
223632773|NCT04504500|OTHER|Local CTG interpretation meetings|"Local CTG interpretation meetings will be held weekly, in each unit during which all abnormal CTG cases that led to cesarean section will be reviewed and discussed. Members of the Steering Committee or local opinion leaders may actively participate in these meetings offering coaching and counseling services in decision-making. Through elaborative discussion the staff will improve their knowledge and skills in correct CTG interpretation, thus preventing unnecessary interventions, such as cesarean sections."
223632774|NCT04504500|OTHER|Follow-up meetings|Regular follow-up meetings of the participating obstetricians with members of the steering committee and local opinion leaders throughout the intervention period will enhance compliance with the guidelines. Establishment of commonly accepted practice augments the homogeneity of clinical action plans and team work in the unit.
223632775|NCT01161940|DRUG|Nizatidine|Nizatidine Capsules 300 mg of Dr.Reddy's Laboratories Limited
223632776|NCT01161940|DRUG|Axid|Axid 300 mg Capsules of Reliant Pharmaceuticals, US
223632777|NCT03784443|DRUG|Iluvien 0.19 MG Drug Implant|Fluocinolone Acetonide Sustained Release Intravitreal Implant at Baseline Visit
223764368|NCT07173907|PROCEDURE|CuRV CXL|A two-part transepithelial isotonic riboflavin system (ParaCel™ Part 1 and Part 2) was used. Part 1 was applied with a surgical spear and repeated drops, followed by Part 2 instillation for 6 minutes. After rinsing with balanced salt solution, UVA irradiation was performed using the Mosaic® device with Boost Goggles™ delivering supplemental oxygen. Pulsed UVA (365 nm, 30 mW/cm²) was applied in a personalized, three-zone pattern (15 J/cm² to the cone apex, 10 J/cm² to an intermediate annulus, and 7.2 J/cm² to the periphery), guided by Pentacam tomography. A bandage contact lens was placed at the end of the procedure.
223764369|NCT07173907|PROCEDURE|Accelerated CXL Procedure (aCXL)|The subjects underwent the aCXL procedure was performed under topical anesthesia after tailored epithelial removal, leaving a small island over the thinnest corneal area. Riboflavin-dextran solution was applied for 30 minutes, followed by UVA irradiation (9 mW/cm², total 5.4 J/cm²) using the KXL device. The cornea was rinsed with Ringer's solution during treatment, and a bandage contact lens was placed afterward.
223764370|NCT07172139|COMBINATION_PRODUCT|Active rTMS + Pinaverium Bromide|A figure-of-eight coil is used to apply active low-frequency (1 Hz) rTMS to the corresponding representation area of the prefrontal cortex (mPFC). The treatment is administered for 20 minutes daily for a total of 2 weeks.
223764371|NCT07172139|COMBINATION_PRODUCT|Active rTMS + Bifidobacterium|Bifidobacterium animalis subsp. lactis BB-12, provided in capsule form. Each capsule contains a minimum of 5 billion colony-forming units (CFU). Administered orally at a dosage of one capsule twice per day, with meals, for a duration of 2 weeks. The product will be stored refrigerated as per manufacturer's instructions.
223764372|NCT07172139|COMBINATION_PRODUCT|Sham Comparator: Sham rTMS + Pinaverium Bromide|Pinaverium Bromide 50 mg film-coated tablets. Administered orally at a dosage of 50 mg (one tablet) three times daily, 30 minutes before meals, for a duration of 2 weeks.
223764373|NCT07172139|COMBINATION_PRODUCT|Placebo Comparator: Sham rTMS + Bifidobacterium|Description: Sham stimulation is delivered using a placebo coil that mimics the sound and sensation of active rTMS but does not deliver the full magnetic field. Parameters identical to active arm.
223632778|NCT03784443|DRUG|Ranibizumab Injection [Lucentis]|Monthly PRN intravitreal injections
223632779|NCT03784443|PROCEDURE|Sham Intravitreal Injection|Sham injection without penetrating needle and without drug delivery at baseline visit.
223632780|NCT01243164|OTHER|Wheelchair Skills Training Program|The Wheelchair Skills Training Program will be administered in 2, 1 hour sessions.
223632781|NCT03173885|DIAGNOSTIC_TEST|Preimplantation Genetic Screening|"* laser assisted hatching~* trophectoderm biopsy~* next generation sequencing"
223632782|NCT04228471|PROCEDURE|spontaneous breathing activity during APRV|Allowing spontaneous breathing activity with APRV throughout the first 48 hours.
223632783|NCT04228471|PROCEDURE|No spontaneous breathing activity|No spontaneous breathing activity will be allowed with pressure controlled ventilation throughout the first 48 hours.
223632784|NCT01378364|DRUG|AbGn-168H|single very low dose of AbGn-168H i.v.
223632785|NCT01378364|DRUG|AbGn-168H|single low dose of AbGn-168H i.v.
223632786|NCT01378364|DRUG|Placebo|single dose of Placebo i.v.
223632787|NCT01378364|DRUG|Placebo|single dose of Placebo i.v.
223632788|NCT01378364|DRUG|Placebo|single dose of Placebo i.v.
223632789|NCT01378364|DRUG|Placebo|single dose of Placebo i.v.
223764374|NCT07171827|DRUG|Brentuximab Vedotin + Doxorubicin, Vinblastine, and Dacarbazine|Patients received Brentuximab Vedotin (BV)+ Doxorubicin, Vinblastine, and Dacarbazine (AVD) drug regimen by intravenous infusion on Days 1 and 15 of each 28-day cycle.
224221467|NCT00592020|PROCEDURE|Hockey Stick Incision|Hockey Stick Incision for kidney transplantation
224221468|NCT00371488|DRUG|GW572016 oral tablets|Tablets contain 405mg of lapatinib ditosylate monohydrate, equivalent to 250mg lapatinib free base per tablet. Oval, orange, film-coated tablets.
224221469|NCT00798083|DRUG|topical amitriptyline 2%, ketamine 1%, and lidocaine 5% in pluronic lecitine organogel(AKL in PLO gel)|Subjects will be taught to apply topical 2%amitriptyline, 1% ketamine and 5% lidocaine(AKL) in PLO gel to the sites of maximum neuropathic pain three times per day for up to 2 weeks after completion of radiotherapy.
224221470|NCT04911920|OTHER|Questionnaire Patient Rated Tennis Elbow Evaluation|Participants are asked to complete questionnaires at three measurement time points.
224221471|NCT03242382|DRUG|Palbociclib|Treatment will continue until disease progression, development of unacceptable toxicity, non-compliance, withdrawal of consent by the patient or investigator decision
224221472|NCT01562431|OTHER|Feed-back|Counselors will receive the results of the completed Signal-checklist completed by participants in the intervention group
224221473|NCT04559620|OTHER|Maternal voice|Maternal voice (song/ words) played in the incubator for 30mins x4/day x 7 days
223632790|NCT01378364|DRUG|AbGn-168H|single medium dose of AbGn-168H i.v.
223632791|NCT01378364|DRUG|AbGn-168H|single high dose of AbGn-168H i.v.
223632792|NCT01378364|DRUG|AbGn-168H|single low dose of AbGn-168H s.c.
223632793|NCT01378364|DRUG|Placebo|single dose of Placebo s.c.
224221474|NCT00334620|PROCEDURE|15 radon(+CO2) baths vs 15 CO2 baths; beside rehabilitation|
223632794|NCT01378364|DRUG|Placebo|single dose of Placebo s.c.
223632795|NCT01378364|DRUG|AbGn-168H|single medium dose of AbGn-168H s.c.
223632796|NCT03594513|PROCEDURE|MCAF|Periodontal surgical technique to treat gingival recessions.
223632797|NCT03594513|PROCEDURE|PR|Restorative procedure to treat tooth structure loss.
223632798|NCT03594513|PROCEDURE|CTG|Autogenous graft harvested from palate placed in the surgical site.
223632799|NCT03594513|PROCEDURE|XMD(Mucoderm®)|Xenogenous graft placed in the surgical site.
223632800|NCT03594513|DRUG|Sodium dipyrone|All participants were instructed to take 500 mg sodium dipyrone just in case of pain.
223632801|NCT03594513|DRUG|chlorhexidine rinse|All participants were instructed to perform 0.12% chlorhexidine rinse after the surgical procedures.
223764375|NCT07171827|DRUG|Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine|Patients received Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine (ABVD) drug regimen by intravenous infusion on Days 1 and 15 of each 28-day cycle.
224221475|NCT06527729|DRUG|sildenafil-loaded liposomes|Topical 1% sildenafil-loaded liposomes was applied twice daily for a period of 8 weeks over patchy alopecia areata of the scalp.
224318261|NCT03015987|OTHER|diode laser activated irrigation|diode laser became the most common and affordable type of laser used in endodontics for many uses , its disinfection effect is an important issue which not discussed in clinical trial before , So this study is assigned to study that
223632802|NCT05057611|OTHER|CRT-targeted strategy associated with a clinical hemodynamic phenotyping to personalize initial resuscitation in septic shock patients|A combination of combine a CRT-targeted strategy with a clinical hemodynamic phenotyping that may aid to personalize initial resuscitation with potential additional fluid-sparing effects.
223632803|NCT05057611|OTHER|Usual care (UC)|\- Patients allocated to the UC group will be managed by the clinical staff according to usual practice at their sites including decisions about hemodynamic and perfusion monitoring, and all treatments, but should follow general recommendations of the Surviving Sepsis Campaign to avoid extremes of clinical practice. This includes basic hemodynamic targets such as a MAP \>65 mmHg, heart rate (HR) \<120 beats per minute (BPM), arterial oxygen saturation (SaO2) \>94%, Hb \> 7 gr/dl, and the use of NE as the first vasopressor and crystalloids as the fluid of choice.
223632804|NCT02236026|DRUG|Supratherapuetic dose of Nestorone|
223632805|NCT02236026|DRUG|Placebo|
223632806|NCT02236026|DRUG|Moxifloxacin|
223632807|NCT01964508|OTHER|Fine needle aspiration|
223632808|NCT01205217|DRUG|Lapatinib|Lapatinib 1000 mg orally once daily continuously
223632809|NCT01205217|DRUG|Trastuzumab|Part II (Week 13-24) Trastuzumab 4 mg/kg IV load followed by 2 mg/kg IV Day 1 of each week
224221476|NCT06527729|DRUG|minoxidil gel|Topical 5% minoxidil gel was applied twice daily for a period of 8 weeks.
224221477|NCT00096369|DRUG|tamoxifen citrate|
224221478|NCT00567944|DEVICE|BrainPort Balance Device|The BrainPort balance device, is a non-invasive medical device that provides head and body position information to a person via their tongue.
224221479|NCT06363201|DIETARY_SUPPLEMENT|Ocoxin Oral solution|Patients will receive one vial of Ocoxin® orally daily, preferably at the same time each day. The duration of treatment will depend on the chemotherapy schedule the patient will receive. Treatment with Ocoxin® will be from the start of oncospecific therapy until two weeks after the end of therapy.
223632810|NCT01205217|DRUG|Epirubicin|Part I (Week 1-12) Epirubicin 90 mg/m2 by IV infusion on Day 1 every 21 days
223632811|NCT01205217|DRUG|Cyclophosphamide|Part I (Week 1-12) Cyclophosphamide 600 mg/m2 by IV infusion on Day 1 every 21 days
223632812|NCT01205217|DRUG|Paclitaxel|Part II (Week 13-24) Paclitaxel 80 mg/m2 by IV infusion on Day 1 of each week
223632813|NCT00791349|DRUG|Immediate release (IR) Paliperidone|
223632814|NCT02673372|DRUG|Morphine|intravenous Morphine given at 0.1 mg/kg as intravenous infusion (10 min) with a maximum dose of 10 mg. The device is the Care Fusion Alaris PC.
223632815|NCT02673372|DRUG|Ketamine|Ketamine administered in sub-dissociative doses 0.3 mg/kg as a intravenous infusion (10 min). The device is the Care Fusion Alaris PC.
223632816|NCT01259063|DRUG|Everolimus and Intravesical Gemcitabine|Phase I: Everolimus will be adm as follows: Dose level 1: 5 mg every other day, Dose level 2: 5 mg daily, Dose level 3: 10 mg daily Phase II: Everolimus will be adm at 10 mg daily the dose determined in Phase I. Pts will receive a dose of 2000 mg of intravesical gemcitabine twice a week (72-96 +8 hours between doses) for 3 weeks for a total of 6 treatments in course 1. After 1 week of rest from intravesical gemcitabine, course 2 will be administered, provided the treating physician notes acceptable pt tolerance. The total number of intravesical instillations will be 12. There will be no dose modifications to gemcitabine; however, pts will be allowed to skip gemcitabine doses if needed, per the treating physician's discretion. Missed or skipped doses of gemcitabine will not be repeated. The pt will receive as many instillations as tolerable up to the maximum of 12 instillations.
223632817|NCT05544526|BIOLOGICAL|GD2 CAR T cells|Infusion with: GD2 CAR T-cells
223632818|NCT05207774|DRUG|Oxytocin|8 weeks intranasal oxytocin 24 units per day. 8 units prior each meal. 4units/0.1 ml per puff
223632819|NCT05207774|DRUG|placebo|8 weeks intranasal placebo 0.6 ml per day. . 0.1 ml per puff
224221480|NCT04021901|DEVICE|balloon dilatation|"The balloon catheter (BD U30) was placed through narrow ureter along the guide wire, and the balloon was pressurized to 25 atm until the bee waist sign disappeared on the balloon or the narrow section was seen under the endoscope. Dilation, expansion for 10 min, and then through the endoscope to observe the stenosis of the stenosis (stenosis of the stenosis of the visible adipose tissue)"
224221481|NCT00609895|DRUG|INSULIN GLARGINE|
224221482|NCT00425659|DEVICE|home sleep study|different in algorithm arrangement for diagnosing sleep apnea
224221483|NCT00425659|DEVICE|home CPAP titration (Autoset)|continuous positive airway pressure device for treatment of sleep apnea
224221484|NCT00425659|DEVICE|CPAP|usual practice
224221485|NCT03305432|COMBINATION_PRODUCT|sleeve + preoperative PPI|sleeve + preoperative PPI
223632820|NCT04768738|DEVICE|Auricular Vagus Nerve Stimulation Level Of Above Threshold|Biphasic current was applied as follows; frequency 10 Hz, in Modulation mode (Modulation mode is a combination of pulse rate and pulse width modulation. The pulse rate and width are automatically varied in a cycle pattern. The pulse width is reduced by 50% from its original setting in 0.5 second, then the pulse rate is reduced by 50% from its original setting in 0.5 second. Total cycle time is 1 second.), the pulse width was 300 μs. The current intensity was kept constant where the participant felt the current comfortably and applied for 5 minutes.
223632821|NCT04768738|DEVICE|Auricular Vagus Nerve Stimulation Level Of Subthreshold|biphasic current was applied as follows; frequency 10 Hz, in Modulation mode (Modulation mode is a combination of pulse rate and pulse width modulation. The pulse rate and width are automatically varied in a cycle pattern. The pulse width is reduced by 50% from its original setting in 0.5 second, then the pulse rate is reduced by 50% from its original setting in 0.5 second. Total cycle time is 1 second.), the pulse width was 300 μs. The parameters were the same with Above Threshold Group but the current was reduced to where the participant did not feel the current after the threshold value was reached and again applied for 5 minutes.
223632822|NCT04768738|DEVICE|Auricular Vagus Nerve Stimulation Sham Method|Participants were shown that the device was working, but no current was given.
223632823|NCT04768738|DIAGNOSTIC_TEST|5 Minutes Bicycle Exercise|Participants in this group were asked to perform bicycle exercise with maximum performance under 50 watts for 5 minutes.
223632824|NCT03497936|BEHAVIORAL|Women's Stories|Women's Stories is a brief, HPV vaccination promotion intervention. It presents vaccine information and videos of HPV vaccine decision making. It also includes follow up vaccine reminder text messages.
224221486|NCT03305432|COMBINATION_PRODUCT|sleeve + preoperative Placebo|sleeve + preoperative Placebo
223632825|NCT03889223|PROCEDURE|Anatomical intervention with USG and comfort evaluation with NRS|The anatomical evaluation of the two neuraxial positioning techniques sonographically and comparison of comfort with the 7-point NRS
223632826|NCT01075243|DRUG|Paracetamol 1000 mg|Paracetamol 1000mg
223632827|NCT01075243|DRUG|Paracetamol 650 mg|Paracetamol 650 mg
223632828|NCT01075243|DRUG|Placebo|Placebo
223632829|NCT04927546|BEHAVIORAL|Exercise|Thirty minutes of aerobic exercise in a treadmill.
223632830|NCT05587270|OTHER|Web based surveys|A web-based survey will explain the purpose, aims, and ethical rights, as well as how to complete the questionnaire online. Further, information about, and an invitation to participate in the DXA-scan will be included with this information. Upon electronic consent by both parent and athlete (or just athlete if of consenting age (15 y o a)), access to the multi-section questionnaire will be granted. Contact details of the researchers will be available in case of difficulties comprehending the questions. Following completion, the participants' data will be sent to a secure database for analysis. Participants will be ensured of the confidentiality of the study and will be free to withdraw from the study. Parents will also be asked to provide their consent if participants age is under 14.
223632831|NCT05587270|RADIATION|DXA|All participants will be invited to complete a DXA scan at baseline. DXA is to date the most reliable way of examining the long-term physical consequences of RED-S.
223632832|NCT04805502|BEHAVIORAL|Exercise Modes|Moderate intensity aerobic exercise, moderate intensity resistance exercise, moderate intensity combination exercise
224221487|NCT05127603|BEHAVIORAL|Cognitive behavioral intervention|Individually tailored physiotherapy that fits within the guideline non-specific neck pain (KNGF, 2016) with a focus on influencing dysfunctional illness perceptions and dysfunctional movement/ pain behavior, by means of communication, body awareness exercises, functional movements and exposure techniques. Tools are supplied to create an appropriate explanatory model for the pain, for functional movement behavior and active coping in a patient's daily lives.
223632833|NCT04943952|DRUG|Asparaginase Erwinia Chrysanthemi (recombinant)|Participants will receive JZP458 via intramuscular injection.
223632834|NCT00347022|DRUG|Xenetix|300 mg of iodine/ml
223632835|NCT00347022|DRUG|Visipaque|270 mg of iodine/ml
224221488|NCT01841359|DRUG|Pramlintide|See description above (arm description).
223632836|NCT00541372|DEVICE|insulin injection needle size|The intervention in this study is a specific needle with a length of 5 mm and 8 mm to be used with an insulin pen.
223632837|NCT06375161|BIOLOGICAL|anti-CD19-CAR-T cells|"Before cell infusion, Investigator may decide, based on necessity, whether to administer prophylactic medication, which may include options such as acetaminophen and diphenhydramine, or H1 antihistamines, among others.~Subjects are allowed to receive adequate supportive care after anti-CD19-CAR-T cell infusion, including blood transfusions and blood products, antibiotic therapy, antiemetics, antidiarrheals, analgesics, etc."
223680820|NCT03607643|DRUG|Bortezomib|Standard of care (SOC) chemotherapy for multiple myeloma will include a bortezomib-based regimen given at 1.3 mg/m2 on days 1, 4, 8 \& 11 schedule to be repeated every 21 days.
223680821|NCT03607643|DRUG|Leucovorin|Standard of care chemotherapy for Stage IV colon or rectal cancer, will include leucovorin 350 mg/m2 IV over 2 hours Day 1, 5-FU 400 mg/m2 IV bolus followed 2400 mg/m2 IV over 46 hours, oxaliplatin 100 mg/m2 IV Day 1, bevacizumab 5 mg/kg IV day1. Irinotecan can be substituted for oxaliplatin.
223680822|NCT03607643|DRUG|5-FU|Standard of care chemotherapy for Stage IV colon or rectal cancer, will include leucovorin 350 mg/m2 IV over 2 hours Day 1, 5-FU 400 mg/m2 IV bolus followed 2400 mg/m2 IV over 46 hours, oxaliplatin 100 mg/m2 IV Day 1, bevacizumab 5 mg/kg IV day1. Irinotecan can be substituted for oxaliplatin.
223680823|NCT03607643|DRUG|Oxaliplatin|Standard of care chemotherapy for Stage IV colon or rectal cancer, will include leucovorin 350 mg/m2 IV over 2 hours Day 1, 5-FU 400 mg/m2 IV bolus followed 2400 mg/m2 IV over 46 hours, oxaliplatin 100 mg/m2 IV Day 1, bevacizumab 5 mg/kg IV day1. Irinotecan can be substituted for oxaliplatin.
223680824|NCT03607643|DRUG|Bevacizumab|Standard of care chemotherapy for Stage IV colon or rectal cancer, will include leucovorin 350 mg/m2 IV over 2 hours Day 1, 5-FU 400 mg/m2 IV bolus followed 2400 mg/m2 IV over 46 hours, oxaliplatin 100 mg/m2 IV Day 1, bevacizumab 5 mg/kg IV day1. Irinotecan can be substituted for oxaliplatin.
223680825|NCT03607643|DRUG|Irinotecan|Standard of care chemotherapy for Stage IV colon or rectal cancer, will include leucovorin 350 mg/m2 IV over 2 hours Day 1, 5-FU 400 mg/m2 IV bolus followed 2400 mg/m2 IV over 46 hours, oxaliplatin 100 mg/m2 IV Day 1, bevacizumab 5 mg/kg IV day1. Irinotecan can be substituted for oxaliplatin.
223680826|NCT03607643|DRUG|Gemcitabine|Stage IV pancreatic cancer will include a gemcitabine-based regiment at 1000 mg/m2 day 1, 7, 15 of a 21-day cycle.
223632838|NCT04917172|DIAGNOSTIC_TEST|postoperative acute pancreatitis evaluation|Surgical resection and reconstruction will be carried out according to the Institutional standards. After the surgical procedure, serum pancreatic amylase and lipase activity will be systematically measured two hours after surgery on postoperative day (POD) 0 and every day at 7 a.m. until POD 5 according to our institutional policy. At our institution, the upper limit of normal for serum pancreatic amylase is 52 U/L and for serum lipase is 60 U/L. Postoperative protocols included the routine measurement of inflammatory markers (white blood cell \[WBC\] count and C-Reactive Protein \[CRP\]). A urine trypsinogen strip test will be done on POD 1. A trypsinogen-2 concentration of more than 50 µg/l is considered a positive test. As routine clinical practice, a post-operative imaging will be scheduled to check for potential surgical morbidity. Abdominal magnetic resonance imaging (MRI) will be assessed on POD 3.
223632839|NCT04398771|DRUG|Rosuvastatin/Valsartan|Rovatitan QD for 12 weeks
223632840|NCT04382950|COMBINATION_PRODUCT|Recombinant Bacterial ACE2 receptors -like enzyme of B38-CAP (rbACE2) plus Aerosolized 13 cis retinoic acid|In this study, the experimental group will receive 0.4 mg/kg rbACE2 IV plus Aerosolized 13 cis retinoic acid in gradual in 2 divided doses increases froms 0.2 mg/kg/day to 4 mg/kg/day as inhaled 13 cis retinoic acid therapy for 14 days
223632841|NCT04324034|DEVICE|vNOTES|vaginal Natural Orifice Transluminal Endoscopic Surgery (vNOTES) is vaginal surgery with a natural approach. The GelPOINT V-path transvaginal access platform is used. It is a device designed to be placed transvaginally to establish a pathway for the insertion of minimally invasive instruments while maintaining insufflation to perform diagnostic or operative procedures. This device also allows a passage for the extraction of operating parts.
223632842|NCT04324034|PROCEDURE|laparoscopy|The surgery by conventional laparoscopy is used
223632843|NCT04100486|OTHER|Standing-Squatting-Standing Test|The participant will begin by actively standing for one minute, followed by a transition to a squat for one minute, and one last transition to one minute of standing.
223632844|NCT04100486|OTHER|Deep Breathing Test|The participant will be asked to lay down for seven minutes and take long, controlled breaths at a rate within 4 to 10 breaths per minute.
223632845|NCT04100486|OTHER|Cold Pressor Test|The participant will be asked to immerse their hand into ice water (1- 10°C) for up to three minutes, followed by removal of the hand from the bath and continuation for recording for a further three to five minutes. The participant will be informed that he or she can remove his or her hand at any point if there is discomfort.
223632846|NCT04100486|OTHER|Cold Face Test|The cold stimulus will be applied with refrigerated gel-filled compresses places on the forehead and cheeks of the participant for one minute.
224221489|NCT01132287|OTHER|FID 112903|lubricant eye drop FID 112903
224221490|NCT04368585|DRUG|Tebipenem pivoxil hydrobromide (TBPM-PI-HBr)|Tebipenem pivoxil hydrobromide (TBPM-PI-HBr) 600 mg single-dose given orally.
224221491|NCT04368585|DRUG|20 mL aluminum hydroxide/magnesium hydroxide/simethicone (400 mg aluminum hydroxide/400 mg magnesium hydroxide/40 mg simethicone per 5 mL)|20 mL aluminum hydroxide/magnesium hydroxide/simethicone (400 mg aluminum hydroxide/400 mg magnesium hydroxide/40 mg simethicone per 5 mL) oral suspension.
223632847|NCT04100486|OTHER|Valsalva Maneuver|The participant will be asked to inhale deeply, pinch his or her nose, close his or her mouth, and forcibly exhale, while bearing down with tight chest and stomach muscles, for approximately 10 to 15 seconds. The sensors will continue recording as the participant recovers to normal breathing over the next one minute.
224221492|NCT04368585|DRUG|Omeprazole|40 mg (1 x 40 mg capsule) omeprazole administered QD
224221493|NCT05093283|DEVICE|Virtual Reality Glasses|Virtual Reality Glasses
223632848|NCT04100486|DEVICE|Transcutaneous Auricular Vagus Nerve Stimulation (taVNS)|The participant will receive electrical stimulation applied to their ear for five minutes. The threshold for stimulation will be determined before the test begins at a level that may elicit sensation (tickling, vibrating, pricking), but no pain. There is a possibility that the participant will receive sham stimulation, or inactive stimulation, for this test.
223632849|NCT06118021|DRUG|HS-20094|Administered SC
224221494|NCT02151461|DRUG|Low Metformin|1100 mg L Leucine in combination with 125 mg of Metformin BID
224221495|NCT02151461|DRUG|Metformin|500 mg metformin BID until day 14 with dose escalation at day 14 to 850 mg metformin BID
223632850|NCT06118021|DRUG|Placebo|Administered SC
223680827|NCT03607643|DRUG|Temozolomide|Standard of care chemotherapy for patients with glioblastoma multiforme includes concurrent radiation therapy (2 Gy per day for a total of 60 Gy) and temozolomide (75 mg per square meter of body-surface area per day, 7 days per week from the first to the last day of radiotherapy), followed by six cycles of adjuvant temozolomide (150 to 200 mg per square meter for 5 days during each 28-day cycle).
223680828|NCT05420363|OTHER|different walking surfaces|different surfaces materials and textures as sand ,grass, air mattress , foam mattress ,gravels and Rollator
223680829|NCT05420363|OTHER|traditional gait training over hard surface only|The children will receive gait training over hard surface and even ground only and bare feet without wearing any foot ware or orthosis
224221496|NCT02151461|DRUG|Mid Metformin|1100 mg of Leucine in combination with 250 mg Metformin BID
224221497|NCT02151461|DRUG|High Metformin|1100 mg of Leucine in combination with 500 mg Metformin BID
224221498|NCT05846828|OTHER|Stanford Binet IQ test|"The Fourth Edition Stanford-Binet test which is based upon a four-factor model of intelligence, and its 15 subtests are partitioned into :~1. Verbal ability.~2. Abstract/Visual ability.~3. Quantaitive potential.~4. Short-Term Memory Scales"
224221499|NCT03392961|DRUG|IN-105 (Insulin Tregopil)|15 mg strength tablets for oral use used at a dose of 30 mg
224221500|NCT03392961|OTHER|Placebo comparator|Placebo tablet for oral use
224221501|NCT04496089|DIAGNOSTIC_TEST|89Zr-girentuximab|A single dose of 37 MBq (±10%) is administered. The dose per dose is equivalent to girentuximab 10 mg (±10%).
224221502|NCT00740467|BIOLOGICAL|anti-thymocyte globulin|
224221503|NCT00740467|DRUG|busulfan|
224221504|NCT00740467|DRUG|cyclophosphamide|
224221505|NCT00740467|DRUG|cyclosporine|
224221506|NCT00740467|DRUG|fludarabine phosphate|
224221507|NCT00740467|DRUG|mycophenolate mofetil|
224221508|NCT00740467|PROCEDURE|nonmyeloablative allogeneic hematopoietic stem cell transplantation|
224221509|NCT01783769|BEHAVIORAL|"Low O.R. Traffic"|"Low OR Traffic protocol will restrict personnel movement thru the operating room to a bare minimum of personnel traffic."
224221510|NCT02168270|DIETARY_SUPPLEMENT|ascorbic acid|Given IV
224221511|NCT02168270|DRUG|temozolomide|Given PO
224318262|NCT05204706|OTHER|MyManis app|The women will receive a brochure outlining the app features and step guide on how to download the app which will be available in both Bahasa Melayu and English languages. A link to download the app via text message will also be sent to participants for convenience. Once the app has been downloaded, participants will be invited to set up an account. Once completed this will give them full access to the MyManis app. The key component of MyManis app content presented under six main tabs which are homepage, information, diet, exercise, wellbeing and GDM monitoring. The women will be invited to join group peer support through WhatsApp facilitated by a dietitian trained in motivational interviewing. The women will be notified via text message if an update of the app is required. If there's women who have not accessed the app for over a two-week period will be flagged and a notification will be sent via the app to motivate app engagement.
223764376|NCT05241223|OTHER|Behavior change intervention|This is an online intervention based on the transtheoretical model, along with self-determination theory strategies. This intervention will take place weekly summing up 12 online individual and/or group sessions of approximately 20 minutes. The sessions will be made through a platform and/or application that makes video calls privately. Each session will address a topic. In addition, in all sessions, the patients gain during the previous week will be recognized, as well as new goals will be set for the next week. The goals will always be individualized, realistic and achievable, based on the identification of each person's capacity and motivation. A Fitbit Zip will be used to propose objective goals aimed at increasing physical activity and reduce sedentary behavior. Additionally, a complex practice environment will be created around this device, such as the visualization of the number of steps evolution and competitions/games with other participants, among others.
224221512|NCT02168270|OTHER|quality-of-life assessment|Ancillary studies
224221513|NCT02168270|OTHER|laboratory biomarker analysis|Correlative studies
224221514|NCT04780737|PROCEDURE|Cholecystectomy|Laparoscopic or laparotomic cholecystectomy
224221515|NCT02248532|BIOLOGICAL|Stem cell therapy|Bone marrow cells will be mobilized into peripheral blood by daily subcutaneous injections of G-CSF (10 µg/kg daily) and collected by leukapheresis. Positive immunomagnetic selection of CD34+ cells will be performed. Electroanatomic mapping of the left ventricle will be performed using the Biosense NOGA system (Biosense-Webster®, Diamond Bar, CA). The target area for cell delivery will be defined as the myocardial segments with unipolar voltage potentials ≥8.3 mV, bipolar amplitudes \>1.9 mV, and linear shortening \<6%. Intramyocardial delivery of cell suspension will be performed with the MyoStar (BiosenseWebster®, Diamond Bar, CA) injection catheter. Each patient will receive 20 injections (0.3 mL each; total volume of 6 mL). All the procedures will be repeated 6 months after baseline.
224221516|NCT05012137|PROCEDURE|Ultrasound-guided Supra-anterior Superior Iliac Spine Fascia Iliaca Compartment Block (SASIS-FICB) with 0.5% ropivacaine|all the patients received Ultrasound-guided Supra-anterior Superior Iliac Spine Fascia Iliaca Compartment Block (SASIS-FICB)
224221517|NCT05012137|DRUG|different volume of 0.5% ropivacaine|According to the subject's response to the injection dose, the next subject will be injected with a different volume of the drug according to the preset rules
224318263|NCT03827889|PROCEDURE|WMP of fluoride varnish|Application of fluoride varnish (drug of the intervention - Duraphat, Colgate) on all teeth, regardless of the lesions found
224318264|NCT03827889|PROCEDURE|TWLP of fluoride varnish|application of the fluoride varnish (drug of the intervention - Duraphat, Colgate) only on the teeth with active initial caries lesions detected through visual examination after prophylaxis
224318265|NCT03827889|BEHAVIORAL|DHP (educational intervention)|The control group will receive diet and hygiene guidance (educational intervention) through verbal explanations and teeth brushing practices
224318266|NCT02116270|BIOLOGICAL|Blood sample|3 tubes of 5 ml tubes and 4 of 7 ml for biological assays at t0.
224318267|NCT03928483|BEHAVIORAL|Modified WW Food program|Participants will receive a structured, holistic, behavioral weight management program that encourages development of healthy habits to help individuals eat healthier, move more, and shift to a more helpful mindset.
224318268|NCT02968602|DRUG|Minocycline|Minocycline capsules taken twice daily for two weeks.
224318269|NCT02968602|OTHER|Placebo|Placebo capsules taken twice daily for two weeks.
224318270|NCT02522689|PROCEDURE|Endoscopic kidney stone surgery|Ultra-mini PCNL will be performed.
224221518|NCT04571957|OTHER|No Intervention|No Intervention
224221519|NCT05031481|DRUG|Venus 20 + 0,064|Venus vaginal cream 20 + 0,064, single-dose.
224221520|NCT05031481|DRUG|Venus 20 + 1|Venus vaginal cream 20 + 1, single-dose.
224221521|NCT05031481|DRUG|Venus 20 + 4|Venus vaginal cream 20 + 4, single-dose.
224221522|NCT05031481|DRUG|Butoconazole nitrate|Butoconazole nitrate vaginal cream, 100 mg single-dose.
224318271|NCT02522689|PROCEDURE|Endoscopic kidney stone surgery|Micro PCNL will be performed.
224318272|NCT00129883|BEHAVIORAL|Professional education|
224318273|NCT00129883|BEHAVIORAL|Implementation of a Critical Care Pathway|
224318274|NCT00129883|BEHAVIORAL|Professional audit and feedback|
224318275|NCT00129883|BEHAVIORAL|Process analysis and redesign|
224318276|NCT03849911|DIAGNOSTIC_TEST|Neurophysiological Prognosis|SEP and EEG evaluation for Neurological Prognosis of Cardiac Arrest
224318277|NCT03849911|DIAGNOSTIC_TEST|Multimodal Prognosis for poor early neurological outcome|Brain CT, SEP and EEG evaluation
224318278|NCT06057948|BIOLOGICAL|OPT-821 (QS-21)|Comprised of the immunological adjuvant OPT-821 (QS-21)
224221523|NCT06307808|DRUG|Tacrolimus|Immunosuppressive drug: main immunosuppressant is a calcineurin inhibitor (CNI), namely tacrolimus
224318279|NCT06057948|DIETARY_SUPPLEMENT|oral β-glucan|Participants will be randomized to receive this agent in two different schedules
224318280|NCT04447313|OTHER|Survey Administration|Ancillary studies
224318281|NCT04447313|BEHAVIORAL|Telephone-Based Intervention|Receive ACT telephone coaching
224318282|NCT04447313|BEHAVIORAL|Telephone-Based Intervention|Receive SBT telephone coaching
224318283|NCT06286696|DIAGNOSTIC_TEST|Optic Nerve Sheath Diameter|Point of care ultrasonography of the optic nerve sheath diameter
224318284|NCT03675230|DEVICE|Tomotherapy HD|Patients with Medulloblastoma receiving Tomotherapy
224318285|NCT03675230|DEVICE|3DCRT|Patients with Medulloblastoma receiving Three-Dimensional Conformal Radiation Therapy
223632851|NCT04298047|OTHER|participatory art-based activity|The intervention is a 3-month cycle of weekly guided tours carried out at the MMFA. Each visit will be performed with a group of 8 participants and a trained guide. They will meet at the museum once per week for a 45 min museum guided tour during a 3-month period. Each visit will be different and supervised by a museum guide. Regardless the topic of the visits, each visit will be standardized and separated in two consecutive phases: (1) Presentation of the objectives of the activity and (2) tour with a guide. Guided tours will target visual art (i.e., painting). They will be tailor-made and based on emotions and interactions in front of painting. The levels of information given to participants will regularly (i.e., each month) increase during the 3-month cycle of museum guided tours. The participants will be separated in 8 groups of 8 individuals per week. The same guide will manage each group of 8 participants during the 12 planned visits.
224221524|NCT06307808|DRUG|Belatacept|Immunosuppressive drug: main immunosuppressant is a costimulation inhibitor, namely belatacept
223632852|NCT03094416|DRUG|levothyroxine sodium capsule|after the run-in period, patients will be switched to levothyroxine sodium capsule at the same dose used during run-in
223632853|NCT03094416|DRUG|Proton pump inhibitor (PPI)|for the whole study duration all subjects will keep taking their proton pump inhibitor medication, as per prescription and as before inclusion
223632854|NCT03094416|DRUG|Levothyroxine Sodium (LT4) Tablets|during the run-in period, subjects will continue taking their levothyroxine sodium tablet medication as per prescription and as before inclusion
224221525|NCT02533999|DEVICE|PEAK® Plasma System|Surgical method for tonsillectomy and adenoidectomy.
223632855|NCT05230134|PROCEDURE|Cervical sympathetic block|All participants will get the cervical sympathetic block and catheter under ultrasound guidance.
223632856|NCT01542047|DRUG|Carboplatin|Carboplatin will be administered intravenously over approximately 30 minutes on day 1 of each cycle. The dosage used will be 5 AUC for the first 5 cycles, and will be increased to 6 AUC for the sixth cycle.
223632857|NCT01542047|DRUG|Pazopanib|Pazopanib will be administered orally at 200 to 800 mg/kg2. It will be given either on days 1 through 21 of each 3-week cycle, or if needed, it will be given on days 3 through 19.
223632858|NCT04916990|BEHAVIORAL|CARES Intervention|Nurse navigators and masters levels counselors will meet with participants up to 10 times each (10 navigation and 10 counseling) over a 6 month period. The number of sessions will be determined by the length of the patient's treatment. The timing of each session will be guided by a regular assessment to reduce the time from diagnosis to initiation of treatment and the time between subsequent treatments. Sessions will occur at key transition points during treatment to target the factors associated with treatment delays, reduced Quality of Care and poor Patient Reported Outcomes
223632859|NCT01668784|BIOLOGICAL|Nivolumab|
224221526|NCT02533999|DEVICE|Electrosurgery|Surgical method for tonsillectomy and adenoidectomy.
224221527|NCT04797715|DRUG|AXS-05|AXS-05 tablets, taken twice daily
224318286|NCT03011138|PROCEDURE|Gait velocity|Once participants are eligible, they will undergo the experimental procedure. Before data collection, they will walk on a treadmill in barefoot for ten minutes to adapt the condition. The a gait analysis system will collect the data while they walk on the treadmill in barefoot at selected gait speed.
224318287|NCT04237337|OTHER|Exposure to MS drugs|Exposure in ICSRs to MS drugs (dichotomous, exposed/not exposed), for each individual MS drug
224318288|NCT05642845|DRUG|Atorvastatin film-coated tablet 40 mg|Atorvastatin is manufactured by Pharmtechnology LLC, Republic of Belarus. Each tablet contains 40 mg of atorvastatin.
224318289|NCT05642845|DRUG|Liprimar® film-coated tablet 40 mg|"Liprimar® is manufactured by Pfizer Pharmaceuticals LLC, Puerto Rico, LLC Polysan Scientific and Technological Pharmaceutical Firm; RU holder: Pfizer Inc, USA. Each tablet contains 40 mg of atorvastatin."
224318290|NCT03734939|OTHER|None intervention is planned.|None intervention is planned, just a survey.
223632860|NCT01668784|DRUG|Everolimus|
223632861|NCT04609943|DRUG|BAY1211163|Participants will receive one of the drug doses of BAY1211163 solution three times per day (TID) by inhalation for seven days.
223632862|NCT00210496|DRUG|topiramate; almotriptan malate|
223632863|NCT04412863|DRUG|VIR-2218|VIR-2218 given by subcutaneous injection
224221528|NCT04797715|DRUG|Placebo|Placebo tablets, taken twice daily
224221529|NCT01102777|BEHAVIORAL|automated internet-mediated walking program|intervention participants are encouraged to walk daily to their step-count goal while wearing a pedometer provided by the study that will measure their daily step-counts. They are also encouraged to log into their personally tailored website to upload their step counts and obtain other information about the study and progress
224221530|NCT01102777|OTHER|Usual Care|Control group, instructed to wear the pedometer but not provided with walking goals or instruction.
224221531|NCT01875445|DRUG|Inositol|Taken as 2g of powder TID for 2 weeks, then 4g of powder TID for 2 weeks and then 6g of powder TID for the remainder of the study.
224221532|NCT01875445|DRUG|Placebo|Taken as 2g of powder TID for 2 weeks, then 4g of powder TID for 2 weeks and then 6g of powder TID for the remainder of the study.
224221533|NCT05354245|DIETARY_SUPPLEMENT|Fibre supplement (potato-pectin)|Fibre supplement
224221534|NCT05354245|DIETARY_SUPPLEMENT|Placebo|Maltodextrin
224318291|NCT00237965|BEHAVIORAL|Mole Mapping Diagram|
224318292|NCT02462291|OTHER|Ecological Environmental therapy|The program of EET consist of the physical interaction (visual, tactile, olfactory) between natural ecological elements such as flowers, trees, grass, and the patients with AD.
224318293|NCT06140446|DEVICE|FeverApp|The (self-management) FeverApp contains evidence-based information about fever and how to deal with it, tailored (phase-oriented) fever advices, and the option to monitor the health status of the child during a fever episode. All information and advices are based on the clinical expertise of paediatricians and the most recent international literature on fever, and complement the Dutch national fever guidelines. It is expected that by letting the body fight the infection on its own in a safe way, less ABs are needed, and the immune system will get stronger leading to less future infections as well.
224221535|NCT05354245|DIETARY_SUPPLEMENT|High-protein diet|High-protein diet
224221536|NCT05837559|OTHER|Korle-Bu Modified WHO Partograph for Uncomplicated Labour|Monitoring of labour using the Korle-Bu Modified WHO Partograph for Uncomplicated Labour
224221537|NCT06531096|BEHAVIORAL|v-DOT|Video directly observed therapy
224221538|NCT03974984|PROCEDURE|Colon Resection|All patients undergo laparoscopic colon cancer resection.
224221539|NCT03974984|PROCEDURE|Epidural anesthesia|Epidural inserted preoperatively and kept for 1 day postoperatively
224221540|NCT03974984|DRUG|NSAID|NSAID administered according to standard operating procedure postoperatively
224221541|NCT00706706|DRUG|Sunitinib Malate (SU011248)|Subjects will receive treatment with sunitinib in repeated 6-week cycles (4 weeks on, 2 weeks off), at a starting dose of 50 mg.
224221542|NCT05017493|COMBINATION_PRODUCT|Xagrotin|A group of patients were treated with Xagrotin with or without standard of care, the control group received stadard of care
224221543|NCT01943461|DRUG|Avelumab 3 mg/kg|Participants received intravenous infusion of Avelumab over 1 hour duration at a dose of 3 milligrams per kilogram (mg/kg) once every 2 weeks in the dose- escalation cohort until disease progression, unacceptable toxicity or withdrawal from the study or study drug occurred.
224221544|NCT01943461|DRUG|Avelumab 10 mg/kg|Participants received intravenous infusion of Avelumab over 1 hour duration at a dose of 10 mg/kg once every 2 weeks in the dose- escalation cohort and expansion cohort until disease progression, unacceptable toxicity or withdrawal from the study or study drug occurred.
224221545|NCT01943461|DRUG|Avelumab 20 mg/kg|Participants received intravenous infusion of Avelumab over 1 hour duration at a dose of 20 mg/kg once every 2 weeks in the dose- escalation cohort until disease progression, unacceptable toxicity or withdrawal from the study or study drug occurred.
224221546|NCT02232451|DEVICE|ERCP with loop tip wire|Endoscopic retrograde cholangio-pancreatography with guide wire (loop-tip) for CBD cannulation
224221547|NCT02232451|DEVICE|ERCP for cannulation|Endoscopic retrograde cholangio-pancreatography with traditional technique for CBD cannulation
224221548|NCT02807766|BEHAVIORAL|Behavior modification|Each group has 30 subjects and experiences six months' training.
224221549|NCT02807766|BEHAVIORAL|Behavior modification and sensory integration training|Each group has 30 subjects and experiences six months' training.
224221550|NCT02807766|BEHAVIORAL|Behavior modification and applied behavioral analysis|Each group has 30 subjects and experiences six months' training.
224221551|NCT02807766|BEHAVIORAL|Behavior modification and TEACCH|Each group has 30 subjects and experiences six months' training.
224221552|NCT04405206|DRUG|Oxaliplatin|OXA 130mg/m2
223632864|NCT04412863|DRUG|pegylated interferon-alfa 2a|pegylated interferon-alfa 2a given by subcutaneous injection
224221553|NCT04405206|DRUG|Capecitabine|Cape 1000mg/m2
224221554|NCT04405206|RADIATION|intensity modulated radiotherapy|IMRT 50.4Gy/22f
224221555|NCT04405206|PROCEDURE|DRE-Endoscopy-MRI-CEA|examination process in follow up
224221556|NCT04405206|PROCEDURE|Nonoperative Management|Watch and Wait
224221557|NCT04405206|PROCEDURE|Local excision|For ymriT1N0 and near-cCR patients，LE is optional.
224221558|NCT04405206|PROCEDURE|Total Mesorectal Excision|Standard TME surgery openly or laporoscopically
224221559|NCT04405206|BEHAVIORAL|Quality of Life Questionnaires|QLQ C30 and QLQ CR29
223632865|NCT06453746|OTHER|Home-based cognitive training exercises|"The subjects received (i) education on lifestyle modification, (ii) home-based cognitive training exercises with physiotherapist/ physiatrist contact when needed and (iii) a physical training exercises conducted at hospital under the supervision of physiotherapist/ physiatrist (3 weekly session for 12 weeks).~This arm has a duration of 12 weeks."
223632866|NCT06453746|OTHER|Supervised cognitive training exercises|"The subjects received (i) education on lifestyle modification, (ii) supervised cognitive training exercises at hospital (1 weekly session for 12 weeks) and (iii) a physical training exercises conducted in a hospital under the supervision of physiotherapist/ physiatrist (3 weekly session for 12 weeks).~This arm has a duration of 12 weeks."
224221560|NCT02122094|BEHAVIORAL|Sexual Health Promotion Intervention|The seven core modules are 1) the Importance of Sexual Health, 2) Sexual Diversity, 3) HIV and other STIs, 4) Behavioral Risk and Risk Reduction, 5) Alcohol and Drugs, 6) Stigma and 7) Health Seeking Practices. The five optional modules are 1) HIV Treatment and Adherence, 2) Stress Reduction, 3) HIV Status Disclosure, 4) MSM/Gay Disclosure, and 5) Other Sexual Health Concerns
224221561|NCT00557973|DRUG|XP19986 SR1, 10 mg BID|XP19986 Sustained Release (SR) 10 mg tablet dosed orally, twice a day (BID), for approximately 26 days with titration and taper periods
224221562|NCT00557973|DRUG|XP19986 SR1, 20 mg BID|XP19986 Sustained Release (SR) 20 mg tablet dosed orally, twice a day (BID), for approximately 26 days with titration and taper periods
224221563|NCT00557973|DRUG|XP19986 SR1, 30 mg BID|XP19986 Sustained Release (SR) 30 mg tablet dosed orally, twice a day (BID), for approximately 26 days with titration and taper periods
224221564|NCT00557973|DRUG|Placebo|Placebo tablets to match active intervention, taken twice a day (BID) for approximately 26 days with titration and taper periods. Also taken during placebo washout periods.
224221565|NCT01708876|DRUG|Artesunate-mefloquine|
224221566|NCT01708876|DRUG|Chloroquine|
224221567|NCT01708876|DRUG|Primaquine|Given to P. vivax patients only. Delayed administration at day 28; 0.5mg/kg for children or 45mg for adults; normal G6PD activity (once daily administration for 14 days); moderate G6PD deficiency (once weekly for 8 weeks); severe G6PD deficiency (contraindicated / not given).
224221568|NCT00564369|OTHER|CDC HIV testing recommendations|Current vs. prior CDC recommendations
224221569|NCT02082613|PROCEDURE|Lord´s procedure|
224221570|NCT02082613|PROCEDURE|Sclerotherapy|
224221571|NCT06175195|BEHAVIORAL|Psychoeducational Inervention|Psychoeducational Program would be used as an intervention stratégie for cancer patients to provide understanding and insight to the patients about the problems. Further, this program would address treatment refusal and illness denial, depressive symptoms, and treatment related irrational fears and anxiety. Moreover, this program will improve patients' motivation and attitude toward changing health, and quality of life.
224221572|NCT04657510|OTHER|COVID-19|Patients affected versus not affected by COVID-19, with the same starting condition (proximal femur fracture)
224221573|NCT01478503|DRUG|mirabegron OCAS|oral
224221574|NCT01478503|DRUG|Placebo|oral
224221575|NCT01913730|DRUG|Bortezomib|
224221576|NCT01913730|DRUG|Dexamethasone|
224221577|NCT04158830|DRUG|Aspirin 81 mg Enteric Coated Tab - 1 tablet|take one (1) 81 mg tablet each evening
224221578|NCT04158830|DRUG|Aspirin 81 mg Enteric Coated Tab - 2 tablets|take two (2) 81 mg tablets each evening
224221579|NCT01708928|DEVICE|Ulthera System Treatment|Focused ultrasound energy delivered below the surface of the skin
223632867|NCT01702207|DRUG|Once Daily Tacrolimus|Subjects switched from the tacrolimus twice daily (Prograf®) to the once daily formulation (Advagraf®) to maintain a trough tacrolimus level of 5-8.
223632868|NCT01702207|DRUG|Twice Daily Tacrolimus|Subjects are kept on Prograf® which is the Twice Daily Tacrolimus
223632869|NCT01862289|OTHER|Diagnostic of chronic hyperventilation syndrome|Nijmegen questionnaire, Hyperventilation challenge and blood gases
223764377|NCT05241223|OTHER|Educational program|The educational program will be delivered similarly to both groups through videos and booklets, which will be sent in all weekdays during de first week after the initial assessment. Later, one educational material will be sent every two weeks until de 11th week. In the first day, patients will receive a quick welcome video call, in which information will be provided on how this program will work. In the subsequent days, the material will be sent daily and the participants will be able to ask questions, if they want to. The program will cover information regarding the respiratory system, pathophysiology of asthma, asthma treatment, prevention strategies and medication instructions. It will also be briefly addressed the subjects: understanding physical activity and sedentarism, as well as the importance and benefits of being physically active and less sedentary.
224221580|NCT01525706|DRUG|Ethanol and Paclitaxel Injection|Endoscopic ultrasound will be used to locate and assess the pancreatic cyst. The fluid contents will be aspirated using a fine needle and sent for tumor marker analysis and cytology. With the needle maintained in the same position, 99% ethanol will be injected into the cyst. After 3-5 minutes of lavage, the entire volume of fluid will be removed from the cyst. The same volume of paclitaxel minus 1 mL \[3mg/ml diluted in normal saline from original concentration of 6mg/mL\] will be injected and left in the cyst. The needle is then retracted and the procedure completed. Patients will receive oral prophylactic antibiotics for 5 days after the procedure. Clinical follow up with MRI imaging with be done at 6, 12, 18, and 24 months. For those with a persistent cyst at 12 months, a repeat EUS FNI procedure will be done.
224221581|NCT03807154|BEHAVIORAL|ICBT|A nine week long ICBT-programme with therapist guidance. Based on cognitive and behavioral techniques that have been tailored to address loneliness.
224221582|NCT03807154|BEHAVIORAL|IPT|A nine week long internet-based IPT-programme with therapist guidance. Contains three distinct phases: assessment phase (three weeks), focus phase (five weeks, during which the participants will choose from one of four primary problem areas during the three latter weeks), and end phase (one week).
224221583|NCT01154153|DRUG|Placebo nasal spray|1 spray/nostril, once daily in the morning, for 8 to 24 days during the screening phase.
224221584|NCT01154153|DRUG|Triamcinolone acetonide aqueous (TAA-AQ) nasal spray (NASACORT AQ)|"Treatment assignment was randomized with stratification by sex and age group (\>=2 to \<6, \>=6 to \<12 years old).~* For children who were \>=2 to \<6 years old, 1 spray/nostril (110 µg TAA-AQ), once daily in the morning, for 6 weeks, during the double-blind treatment phase.~* For children who were \>=6 yrs to \<12 years old, either 1 spray/nostril (110 µg TAA-AQ) or 2 sprays/nostril (220 µg TAA-AQ), once daily in the morning, for 6 weeks, during the double-blind treatment phase."
224221585|NCT01154153|DRUG|Placebo nasal spray|"Treatment assignment was randomized with stratification by sex and age group (\>=2 to \<6, \>=6 to \<12 years old).~* For children who were \>=2 to \<6 years old, 1 spray/nostril, once daily in the morning, for 6 weeks, during the double-blind treatment phase.~* For children who were \>= 6 yrs to \<12 years old, either 1 spray/nostril or 2 sprays/nostril, once daily in the morning, for 6 weeks, during the double-blind treatment phase."
224221586|NCT01154153|DRUG|Claritin® Syrup|Children's Claritin® Syrup \[5 mg of loratadine per 5 mL\] could be taken orally for the relief of AR symptoms throughout the study on an as needed basis, according to the Food and Drug Administration-approved manufacturer's label.
224221587|NCT04109157|DIAGNOSTIC_TEST|20-minute pad test|Our 20-minute modified pad test was described previously proposed first by Hahn and Fall and modified by Sand and Ostergard. Each patient's bladder was emptied with a transurethral catheter and filled to the SD amount of sterile water for test. The catheter was removed, and then the patient returned to a standing position with a pre-weighed perineal pad placed on the underwear. The patient was asked to cough 10 times, bear down 10 times, do 10 deep knee bends, jump up and down on the spot 10 times, wash her hands under cold water for 1 minute, walk up and down five stairs 10 times, walk in the hall for 10 minute, and then return for removal of the pad. The pad was then weighed and the net weight was calculated by subtracting from the original dry weight to achieve a measure of the total urine loss during the 20 minute exercise. The pad weight was measured in grams and the accuracy of the scale was 1 gram. The positive pad weight result was defined as more than 1 gram of leakage.
224221588|NCT04499456|OTHER|Personalised Normative Feedback|The Personalised Normative Feedback provides information on 1) alcohol consumption (the number of drinks consumed, alcohol-pattern use, binge drinking); 2) normative comparisons; 3) alcohol-related consequences; 4) practical costs of alcohol consumption (money spent and calories consumed); 5) strategies to avoid or risks associated with alcohol use.
224221589|NCT01665053|DEVICE|PROMUS Element Plus|A drug eluting coronary stent system
223764378|NCT05586399|BEHAVIORAL|Maximal strength training in COPD|Participate in a rehabilitation program for 4 weeks, with exercise 5 times a week. Supervised maximal strength training in a leg press machine for a total of 20 exercise sessions. Patients will participate in rehabilitation in one of two rehabilitations centers in Trondheim, Norway.
224221590|NCT01665053|DEVICE|SYNERGY|A drug eluting coronary stent system
224221591|NCT06107088|DIETARY_SUPPLEMENT|Active 1|lactase enzyme
224221592|NCT06107088|DIETARY_SUPPLEMENT|Active 2|lactase-bacterial strain combination
224221593|NCT06107088|DIETARY_SUPPLEMENT|Active 3|bacterial strain alone
224221594|NCT06107088|DIETARY_SUPPLEMENT|Placebo|placebo
223632870|NCT04853758|DRUG|Sacubitril / Valsartan Oral Tablet [Entresto]|100 consecutive participants randomized independently at the Heart Institute - School of Medicine of the University of São Paulo (InCor),will receive sacubitril/valsartan for 6 months.
223632871|NCT04853758|DRUG|Enalapril|100 consecutive participants randomized independently at the Heart Institute - School of Medicine of the University of São Paulo (InCor),will receive enalapril for 6 months.
223632872|NCT03926286|DRUG|FMP-30|FMP-30 containing frozen human fecal microbiota administered as (3) units of FMP30 enema on Day 0 and Week1
223632873|NCT05552846|RADIATION|thoracic radiotherapy|Four courses of carboplatin/etoposide/anti-PD-1/PD-L1 every 3 weeks All the enrolled patients will be patients with ES-SCLC who did not have PD (determined as per the RECIST v1.1) after 6 cycle of platinum-based chemotherapy in combination with an anti-PD-1/L1. Then, thoracic radiotherapy of 45 Gy/15 fractions. PD-1/PD-L1 maintenance therapy concurrently and after thoracic radiotherapy at least more than 6 months, or until intolerable toxicity, progressive disease leading to a need for other treatment, or until the patient no longer wishes to continue treatment.
223632874|NCT05068258|PROCEDURE|Lymphovenous bypass, including lymphaticovenular anastomosis/implantation|Lymphovenous bypass (LVB) is a supermicrosurgical technique by diverting lymphatic drainage into venous system. Simultaneously, we performed LVB at ipsilateral foot dorsum and debride the VLUs and resurface the wound primarily or by skin graft depending on defect size.
223632875|NCT01891253|DEVICE|non-invasive determination of cardiac output|
223764379|NCT03063359|DRUG|Intranasal fentanyl + Oral Placebo|Administration of intranasal fentanyl (1.5µg/kg) and Oral placebo (NaCl 0.9%) in children with acute pain in traumatic context on arrival in emergency pediatric department.
224221595|NCT04804332|PROCEDURE|Operative hysteroscopy|Operative hysteroscopy is performed without or under local, regional or general anesthesia according to the local protocol preferably within 2 to 3 weeks after randomization. In case of highly vascularized RPOC, a repeat sonogram is performed 2 to 4 weeks after randomization to check for persistence of vascularity and to optimize operative timing. Operative hysteroscopy is then performed within 2 to 3 weeks after the repeat sonogram. Removal of the RPOC is performed by an experienced gynecologist using hysteroscopic morcellation (TruClearTM Hysteroscopic Tissue Removal System (Medtronic, Minneapolis, MN, USA)) and according to the local protocol.
224221596|NCT04804332|OTHER|Expectant management|No treatment will be offered. Patients will be given telephone numbers to contact a doctor. In case of severe complaints, defined as heavy uterine bleeding and/or severe abdominal pain, not responding to conservative treatment, an emergency curettage or operative hysteroscopy may be performed.
224221597|NCT00771901|DRUG|tauroursodeoxycholic acid|1750 mg/day for four weeks. Seven pills daily, 2 with breakfast, 2 with lunch, and 3 with dinner.
224221598|NCT00771901|OTHER|placebo|7 pills daily for 4 weeks
224221599|NCT00771901|DRUG|sodium phenylbutyrate|20g/day for four weeks.
224221600|NCT00001144|DRUG|Modified bone marrow stem cell transplantation|
224221601|NCT03902756|OTHER|Endotracheal cuff inflation|Endotracheal cuff inflation is putting the air in to the endotracheal tube cuff to make the proper sealing.
224221602|NCT01740856|OTHER|Rest three hours|Intervention group (IG), will maintain bed rest supine for two hours after the digital compression. After this period prescribed, patients sit in bed with the head elevated at 45 degrees for 50 minutes and then walk within the unit hemodynamic for about 10 minutes. Afterwards patients remain sitting out of bed in hemodynamics unit, until they are five hours, then they will be discharge.
224221603|NCT01740856|OTHER|Rest five hours|Control group (CG) maintain bed rest supine for four hours after the digital compression. After this period, the patients sit in bed with the head elevated at 45 degrees for 50 minutes and then walk into the unit hemodynamic for 10 minutes. After that patients receive discharge.
223632876|NCT01400308|DRUG|Mupirocin + Chlorhexidin|"Treatment after protocol described in the Consensus document and GEIH-SEIMC SEMPSPH Version 31/10/07. It is a protocol of 5 days (nasal mupirocin and chlorhexidine, potentially plus systemic antibiotics and 7 days)"
223632877|NCT01400308|DEVICE|Prontoderm MRSA Kit|"Treatment after protocol established for Prontoderm® for five days and eventually plus systemic antibiotics.~Prontoderm® is a Class III medical device"
223632878|NCT00467688|DEVICE|Real time access to current glucose values during CGMS|One arm gets real time access to current measured glucose values and hypoglycemic or hyperglycemic alerts are elicited, The second arm get´s a retrospective analysis of glucose values
223632879|NCT02717234|OTHER|Oral Nutrition Supplement|Oral nutrition supplement intended for consumption at 3 servings per day
223632880|NCT01516905|DRUG|NM404|injection of either 2.0mCi or 5.0mCi I-124 NM404
223764380|NCT03063359|DRUG|Oral Morphine + Intranasal Placebo|Administration of oral morphine (0,4mg/kg) and intranasal placebo (NaCl 0.9%) in children with acute pain in traumatic context on arrival in emergency pediatric department.
223764381|NCT02800044|DEVICE|Wearing a non-invasive glucose sensor|Glucose readings will be obtained from both a glucometer (fingerstick readings) and from the non-invasive glucose sensor at the following four timepoints: fasting, 1.5 to 2 hours after consuming a meal, and before and after 15-30 minutes of moderate exercise on a stationary bicycle.
223764382|NCT03440970|DRUG|Lysine Chloride|Patients will receive the study drug thrice daily for 5 days.
224221604|NCT03036033|DEVICE|SaeboGlove|All participants are given a Saebo glove to use during their stroke recovery.
224221605|NCT06479304|DRUG|Hydroxychloroquine Oral Tablet|Hydroxychloroquine is taken at the dose of 0.1g / dose, twice a day for 1 year, regardless of food intake.
224221606|NCT06479304|DRUG|Prednisone tablet|Prednisone is given at the dose of 1mg/kg every morning after meals for 2 weeks ( if platelet count does not recover higher than 30×10\^9/L after 2 weeks, prednisone will be given at the dose for 2 more weeks ), then tapering off.
223632881|NCT04696432|BIOLOGICAL|Prizloncabtagene autoleucel|Autologous 2nd generation CD19/CD20-directed CAR-T cells, single infusion intravenously
223632882|NCT02867436|OTHER|Gluten-free diet|
223632883|NCT06032871|PROCEDURE|high frequency chest wall oscillation|Patients receive airway clearance by high frequency chest wall oscillation for 30 minutes twice a day.
223632884|NCT06032871|PROCEDURE|Chest physiotherapy|Participants received chest physiotherapy twice a day
223632885|NCT05101902|OTHER|Pre-Screening|No intervention given
223632886|NCT03280719|DEVICE|Prone Radiotherapy|Prone positioning for regional nodal irradiation using the crawl breast couch.
223764383|NCT03440970|OTHER|Placebo|Patients will receive the placebo thrice daily for 5 days.
223764384|NCT05492773|DEVICE|Micro-osteoperforations Technique|Micro-Osteoperforations Technique (MOPs) Surgery will be performed to the lower anterior bony segment of the lower jaw in order to accelerate tooth movement.
223764385|NCT05492773|DEVICE|Active comparater|Active Comparator: Traditional treatment The patients in this group will be receive treatment with the traditional clear aligners technique without any surgical procedure.
223764386|NCT05709002|BEHAVIORAL|MASP+|mHealth (mobile app) for smoking cessation
223632887|NCT03280719|RADIATION|Acceleration|Accelerated irradiation in 5 fractions over 12 days with simultaneously integrated boost
224221607|NCT03348215|OTHER|Enhanced Treadmill Training|6 week programme of treadmill training with addition of an immersive environment (virtual reality projection), body weight support, orthotics and functional electrical stimulation
224221608|NCT03922659|COMBINATION_PRODUCT|Transcranial magnetic stimulation and Cognitive behavioral therapy|Transcranial magnetic stimulation on different side with/without cognitive behavioral therapy
223764387|NCT05709002|BEHAVIORAL|Control|A mobile app designed to assist the general population with smoking cessation.
224221609|NCT04800445|DIAGNOSTIC_TEST|Salivary CRP|Salivary C reactive protein in neonatal sepsis
224221610|NCT01742325|BEHAVIORAL|walking|two 20-minute sessions of walking around the nurse's station daily, five days a cycle
223632888|NCT03280719|DEVICE|Supine Radiotherapy|Supine positioning for regional nodal irradiation using breastboard.
223632889|NCT03280719|RADIATION|Hypofractionation|Moderate hypofractionation in 15 fractions over 3 weeks with simultaneously integrated boost
223764388|NCT06783361|DEVICE|Transcranial Magnetic Stimulation with figure-eight coil|A total of 50 sessions will be applied for 2 weeks, 5 sessions a day, 5 days a week. There will be at least 30 minutes rest time between each session. It includes first an intermittent theta burst (iTBS) protocol at a frequency of 5 Hz with 1800 pulses to the left DLPFC at 90% motor threshold, followed by a continuous theta burst (cTBS) protocol at a frequency of 5 Hz with 600 pulses to the right DLPFC at 80% motor threshold.
223764389|NCT06783361|DEVICE|Transcranial Magnetic Stimulation with figure-eight coil|A total of 50 sessions will be applied for 2 weeks, 5 sessions a day, 5 days a week. There will be at least 30 minutes rest time between each session. One session will consist of a high frequency (5 Hz) intermittent theta burst (iTBS) of 1800 pulses at 90% motor threshold to the left DLPFC followed by a pseudo continuous theta burst (cTBS) of 600 pulses at 5 Hz frequency at 80% motor threshold to the right DLPFC. The sham cTBS treatment will be applied by placing the coil at a 45-degree angle to the application site.
224221611|NCT00728559|DRUG|bupivacain 0.5%|trocar site injection
224221612|NCT00067158|DRUG|nicotine transdermal system|
224221613|NCT01548950|DRUG|Sildenafil singly or in association with Bosentan|Sildenafil, 1-4 mg/Kg/day (6-hour intervals) preoperatively, until development of pulmonary congestion (generally 1-4 weeks) or preoperatively, for 10-12 months, in association with bosentan (15.6-62.5 mg b.i.d.) if pulmonary congestion does not develop. Surgery will be performed at 1-4 weeks (short-term treatment) or at 10-12 months (medium-term treatment) if operability criteria are met (catheterization). In both cases (short and medium-term treatments), the drug or drugs will be kept for 6 months postoperatively, when final catheterization will be performed for efficacy testing.
224221614|NCT00249457|BEHAVIORAL|Contingency management|Invited to attend the Therapeutic Workplace 3 hr per day, Monday through Friday. Each day when a participant reported to the workplace, she was required to provide a urine sample. If the sample tested negative for opiates and cocaine, she was allowed to work that day. Participants who gained entrance to the workplace participated in basic skills education and job skills training throughout each 3-hr work shift.
224221615|NCT05642559|OTHER|questionnaire|Assessment of refractory chronic cough (RCC) or unexplained chronic cough (UCC) impact on HRQoL of the explored population and relationship with clinical variables. Development of a web application of the questionnaire.
224221616|NCT04976049|PROCEDURE|Imaging using 5-Aminolevulinic Acid (5-ALA) during surgery|Patients will be administered FDA approved oral 5-ALA and imaged by a FDA approved surgical fluorescence imaging device (Spy Elite) which is 0.5 meter away from the subject.
224221617|NCT05723627|DRUG|Remimazolam besylate|Patients in this group receives 0.1mg/kg of remimazolam to induce sedation prior to endoscope insertion.
223632890|NCT05159440|DRUG|TORL-2-307-MAB|monoclonal antibody
224221618|NCT05723627|DRUG|Propofol|Patients in this group receives 0.5mg/kg of propofol to induce sedation prior to endoscope insertion.
224221619|NCT01815411|DIETARY_SUPPLEMENT|Mushroom extract|The mushroom extract (Andosan) is given orally in doses 30 m x 2 daily for 21 days
224221620|NCT00194818|DRUG|Asacol (mesalamine)|Available in 400mg delayed release tablet. Randomized to either 6 tablets BID (4.8 g/day) or 4 tablets TID (4.8 g/day) for a total of 12 weeks.
224318294|NCT06140446|DEVICE|DMT App|The (self-care) DMT App is a decision making tool (DMT) that can be used by parents to choose a safe and effective herbal medicine (HM) product to reduce symptoms of mild, acute uncomplicated URTIs in their child. The advices that the DMT App provides, are based on a systematic review (SR) of SRs on effectiveness of HM for URTIs, a SR on working mechanisms of the most promising herbs, a prescription rates study of HM for URTIs in 6 European countries, and current EMA status of the included herbs. No prescription from a doctor is needed for these products.
223632891|NCT03264859|DIAGNOSTIC_TEST|NGAL levels early and post STEMI|NGAL levels early and post ST elevation MI (STEMI)
223632892|NCT05800873|DRUG|EVER001|A highly selective, oral, reversable, covalent Bruton tyrosine kinase (BTK) inhibitor with high selectivity over other kinases.
223632893|NCT05800873|DRUG|EVER001|A highly selective, oral, reversable, covalent Bruton tyrosine kinase (BTK) inhibitor with high selectivity over other kinases.
223632894|NCT03685760|OTHER|Reiki therapy|Reiki, a complementary health approach where trained practitioners place their hands lightly on or just above a person, in discrete positions, with the goal of facilitating the person's own healing response. Reiki therapists will administer the Reiki intervention (i.e., a 30-minute treatment in which the subject is lightly touched for 3 minutes at each of 10 standardized Reiki hand positions).
223632895|NCT03685760|OTHER|Sham Reiki|Sham (pretend) Reiki therapists will administer the sham Reiki intervention (i.e., a 30-minute treatment in which the subject is lightly touched for 3 minutes at each of 10 standardized Reiki hand positions). Sham providers do not have Reiki training.
223764390|NCT06529705|DEVICE|EkiYou V2|Use of a mobile application that help users to evaluate their daily bolus and basal insulin needs, and that adjusts at weekly basis their insulin to carb ratios, correction factor and basal dose.
223764391|NCT05825469|BEHAVIORAL|Nutrition Algorithm|A technology-based platform for a person-centered nutrition program, providing suggested foods and recipes from dietitians.
223632896|NCT04515615|DRUG|Camrelizumab|Camrelizumab, 200 mg IV for 30-60 min in first day every 3 weeks. Repeated every 21 days. 21 days for a cycle.
224221621|NCT03357432|OTHER|gelatin, collagen, gummy dose|The study is aimed at determining if the same dose of gelatin, hydrolyzed collagen (administered in a beverage form) or a mixture gelatin/hydrolyzed collagen (administered in a gummy form) with a standard dose of vitamin C (50 mg) has a similar effect a marker of collagen synthesis (PINP). In a randomized, crossover design subjects consume 3 different nutritional supplements: (a) 15 of gelatin, (b) 15 hydrolyzed collagen (administered in a beverage form) or (c) 15 g of gelatin/hydrolyzed collagen mixture all with a standard dose of vitamin C (50 mg) 1 hour prior to exercise stimulus (6 minutes of jump rope). A baseline assessment with only the jump rope and no intervention will also be conducted prior to the interventions. Each intervention will be separated by a \>24 hr washout. Following completion of exercise, subjects will remain in the lab in a rested state for the subsequent 4 hours. After 4 hours blood samples will be collected. Blood samples will be used for PINP analysis.
224221622|NCT01965652|DRUG|Naldemedine|Naldemedine 0.2 mg tablet taken orally once a day
224221623|NCT01965652|DRUG|Placebo|Placebo tablet taken orally once a day
224221624|NCT00424606|DRUG|Docetaxel|Docetaxel at the dose of 75 mg/m2 intravenously (IV) every 3 weeks for 4 consecutive cycles
224221625|NCT00424606|DRUG|Epirubicin|Epirubicin at the dose of 90 mg/m2 IV every 3 weeks for 4 consecutive cycles
224221626|NCT00424606|DRUG|Epirubicin|Epirubicin at the dose of 75 mg/m2 IV every 3 weeks for 6 consecutive cycles
224221627|NCT00424606|DRUG|Docetaxel|Docetaxel at the dose of 75 mg/m2 IV every 3 weeks for 6 consecutive cycles
224221628|NCT05073900|PROCEDURE|Rhomboid intercostal block|two regional anesthesia block techniques are applied
223632897|NCT04515615|DRUG|Oxaliplatin|Oxaliplatin: 130 mg/m\^2 IV for 2-6 hour in first day which will be administered at least 30 min after completion of camrelizumab administration, every 3 weeks. Repeated every 21 days, 21 days for a cycle.
223632898|NCT04515615|DRUG|Tegafur gimeracil oteracil potassium capsule|Tegafur gimeracil oteracil potassium capsule: 80 mg/m\^2 twice daily (BID) by continuous oral administration for 14 days, followed by a recovery period of 7 days. Repeated every 21 days. 21 days for a cycle.
223632899|NCT04414748|DRUG|GnRH antagonist|GnRH antagonist (Cetrorelix 0.25mg) once subcutaneously daily from day 6 of COH till the day of the ovulation trigger
223632900|NCT04414748|DRUG|oral Duphaston|oral Duphaston 10mg bd from Day 3 of COH till the day of ovulation trigger.
223632901|NCT04723992|OTHER|retrospective analysis|The investigators retrospectively analyzed the outcome and possible prognostic factors in polytrauma patients.
223632902|NCT02167490|PROCEDURE|Arm 1: sentinel node biopsy|Sentinel node biopsy policy
223632903|NCT04069689|DRUG|EPX-100 (Clemizole Hydrochloride)|EPX-100 (Clemizole Hydrochloride)
223632904|NCT04069689|DRUG|Placebos|Placebo to match EPX-100
223764392|NCT06520566|BEHAVIORAL|Holistic care partner perinatal nurse navigation|The nurse navigators assess patient medical, social, and structural needs at enrollment, 20-, 28-, and 36-weeks gestation; and at 1-week, and 3, 6, and 9 months postpartum. They provide coordination, support, and referrals, and enhanced communication with or escalate concerns to the primary physician as indicated. The nurse navigator tailors additional visits to the individual needs of the patients (for example, managing comorbidities, social isolation, breastfeeding support). Participants also have access to a Black woman-led support group during pregnancy and the first postpartum year, and access to Black woman-led childbirth and lactation classes.
223764393|NCT05782686|PROCEDURE|Margin shaving|In both cohorts, an intraoperative study of the margins will be carried out, and enlargement of those margins that are affected will be carried out as indicated by the pathologist. Subsequently, shaving is performed in case of being randomized to the study group or surgery is completed in the control group.
223764394|NCT01433263|DRUG|BYM338 active drug|
224221629|NCT03564899|BEHAVIORAL|Lighter intensity physical activity intervention|Prescription of 300 minutes/week of physical activity at an intensity of 40-60% of heart rate reserve
224221630|NCT03564899|BEHAVIORAL|Higher intensity physical activity intervention|Prescription of 150 minutes/week of physical activity at an intensity of 60-80% of heart rate reserve
224221631|NCT02524106|DRUG|Bococizumab|PF-04950615 is a humanized monoclonal antibody against the proprotein convertase subtilisin kexin type 9 (PCSK9) enzyme responsible for the degradation of the low-density lipoprotein receptor (LDLR), being developed by Pfizer, Inc for the treatment of primary hyperlipidemia and mixed dyslipidemia.
224221632|NCT02524106|DRUG|Placebo|placebo
224221633|NCT02799316|OTHER|HBV core antibodies testing. • Real time PCR testing.|"* HBV core antibodies testing in HBV surface antigen negative patients.~* Real time PCR testing for those having positive HBc antibodies."
224221634|NCT02922803|DRUG|1 combination tablet of Vitamin D3/calcium per day|Combination tablet of Cholecalciferol (800 IU or 20 ug) and calcium carbonate (500 mg)
224221635|NCT02922803|DRUG|2 combination tablets of Vitamin D3/calcium per day|Combination tablets of Cholecalciferol (800 IU or 20 ug) and calcium carbonate (500 mg)
224221636|NCT01121900|DRUG|Trazodone HCl|"Dosage form: Extended-release caplets containing 300 mg trazodone HCl~Dose: 300 mg trazodone HCl extended-release caplets (one caplet) at 23:30 on Day 1 of the test product treatment period following a fasting period of at least 4 hours."
223632905|NCT04827264|DIAGNOSTIC_TEST|Safe Return to Play Following ACL Reconstruction Checklist|"All participants who have undergone primary ACL reconstruction will receive PT evaluation using our Return to Play Checklist at 7 months post-op, prior to return to sports"
223632906|NCT04523194|OTHER|Optical Coherence Tomography (OCT) and Computed Tomography Angiography (CTA)|Subjects underwent CTA, then OCT during cardiac catheterization as part of their standard clinical care.
223632907|NCT03747549|OTHER|Acupuncture and Home Exercise|Acupuncture (needles will be placed at BL 60, BL 61, KI 3, KI 4 with needles directed into the Achilles tendon. Needles inserted until a firm catch of the needle entering the tendon was appreciated. Energy (a small electrical current) is placed from KI 3(-) KI 4(+) and BL 61 (-) BL 60(+) at 30 Hz for 15min) plus the prescribed home exercise program
223632908|NCT03747549|OTHER|Home Exercise Alone|The prescribed home exercise program alone.
223764395|NCT01433263|DRUG|Placebo|
223764396|NCT03827486|OTHER|Standard of care (exercise)|Exercise program according to the standard of care
223764397|NCT03827486|OTHER|Domicilary exercise program|Domicilary exercise program according to protocol (evidence based medicine)
223632909|NCT04156087|DRUG|Durvalumab 50 MG/ML|"Combination of Durvalumab (fixed dose of 1500 mg) and Tremelimumab (fixed dose of 75 mg) will be given 2 weeks before surgery.~Minimally invasive surgical microwave ablation (MIS-MWA) of the pancreatic tumor will be performed two weeks after the first dose of Durvalumab and Tremelimumab After 4 doses of Durvalumab and Tremelimumab, only Durvalumab 1500mg is provided q4w until disease progression.~Systemic gemcitabine will be started 6 weeks after MIS-MWA. Gemcitabine will be given at a dose of 1000 mg /m² body surface, once a week for 3 weeks, followed with a week of rest."
223632910|NCT04156087|DRUG|Tremelimumab|"Combination of Durvalumab (fixed dose of 1500 mg) and Tremelimumab (fixed dose of 75 mg) will be given 2 weeks before surgery.~Minimally invasive surgical microwave ablation (MIS-MWA) of the pancreatic tumor will be performed two weeks after the first dose of Durvalumab and Tremelimumab After 4 doses of Durvalumab and Tremelimumab, only Durvalumab 1500mg is provided q4w until disease progression.~Systemic gemcitabine will be started 6 weeks after MIS-MWA. Gemcitabine will be given at a dose of 1000 mg /m² body surface, once a week for 3 weeks, followed with a week of rest."
223632911|NCT04156087|DRUG|Gemcitabine|"Combination of Durvalumab (fixed dose of 1500 mg) and Tremelimumab (fixed dose of 75 mg) will be given 2 weeks before surgery.~Minimally invasive surgical microwave ablation (MIS-MWA) of the pancreatic tumor will be performed two weeks after the first dose of Durvalumab and Tremelimumab After 4 doses of Durvalumab and Tremelimumab, only Durvalumab 1500mg is provided q4w until disease progression.~Systemic gemcitabine will be started 6 weeks after MIS-MWA. Gemcitabine will be given at a dose of 1000 mg /m² body surface, once a week for 3 weeks, followed with a week of rest."
223632912|NCT04156087|PROCEDURE|Minimally Invasive Surgical Microwave Ablation (MIS-MWA)|Minimally invasive surgical microwave ablation (MIS-MWA) of the pancreatic tumor will be performed two weeks after the first dose of Durvalumab and Tremelimumab
223632913|NCT05178173|OTHER|Placebo Comparator: Sterile Water|Sterile Water Placebo Comparator
223632914|NCT05178173|OTHER|27% Ethanol plus essential oils|Over-the-counter antiseptic mouth rinse
223632915|NCT05178173|OTHER|0.075% Cetylpyridinium Chloride|Over-the-counter antiseptic mouth rinse
223632916|NCT04144153|COMBINATION_PRODUCT|Opioid Free Total Intravenous Anesthesia|Total intravenous anesthesia with propofol and dexmedetomidine hydrochloride and ketamine hydrochloride
223632917|NCT04144153|COMBINATION_PRODUCT|Total Intravenous anesthesia with opioid|Total Intravenous anesthesia with opioid
223632918|NCT04732520|DEVICE|Pulsed electric field treatment using the Aliya System|pulsed electric field treatment of a single NSCLC tumor
223632919|NCT05037240|DIETARY_SUPPLEMENT|Quercetin|Quercetin (500 mg), 2 times a day for 3 months
223632920|NCT05037240|COMBINATION_PRODUCT|Placebo|500 mg, 2 times a day for 3 months
223632921|NCT01748747|DRUG|Montanide ISA 51 VG|Given SC
223632922|NCT01748747|BIOLOGICAL|MART-1 antigen|Given SC
223764398|NCT06394570|DRUG|Enfortumab vedotin|Enfortumab Vedotin administered 1.25mg/kg (max 125mg) IV on Day 1 and Day 8 of each 21 day cycle x 3 cycles
223764399|NCT05351255|DEVICE|Transcranial Magnetic Stimulation (TMS)|Aim 2 of the study includes an intervention where participants receive a repetitive TMS protocol called theta burst stimulation (TBS) to study its effect on motor learning behavior.
223764400|NCT01400594|DRUG|HTU-520 Patch|Terbinafine hydrochloride patch
223632923|NCT01748747|OTHER|laboratory biomarker analysis|Correlative studies
223632924|NCT01748747|BIOLOGICAL|Gag:267-274 peptide vaccine|Given SC
223632925|NCT01748747|DRUG|resiquimod|Applied topically
223632926|NCT00519441|OTHER|pH study|All patients will have 48 hour pH study
223764401|NCT01400594|OTHER|Placebo Patch|Treatment with Placebo Patch
223764402|NCT00256659|BEHAVIORAL|Early assessment and referral to ancillary care services vs. standard care|
223764403|NCT03736421|PROCEDURE|Peripheral Intravenous Analysis (PIVA)|Non-invasive measurement of peripheral intravenous waveform analysis (PIVA) obtained by connecting an Edwards standard transducer to a universal adaptor or stopcock on a peripheral IV
223764404|NCT03736421|PROCEDURE|Non-invasive fluid response measure|To measure the stroke volume and changes in stroke volume in response to a passive leg raise (PLR) maneuver and fluid administration.
223764405|NCT03736421|DIAGNOSTIC_TEST|Passive leg raise (PLR)|Test to predict cardiac output and fluid responsiveness
223764406|NCT06029322|PROCEDURE|Socket seal after alveolar ridge preservation|Socket seal is performed after ARP. Using a collagen matrix or membrane the socket is sealed, at the control (membrane) site a small pouch is made at the buccal and lingual aspect. Monofilament sutures are used to secure the respective material in place.
224318295|NCT05228431|DRUG|XELOX|Starting from the first day of radiotherapy (set as day 0), the patient received a total of 4 courses of XELOX chemotherapy on days -42, -21, 42, and 63, including oxaliplatin 130 mg/m2, intravenous administration, d1, repeat every 3 weeks; and capecitabine 1000mg/m2, twice daily, d1-d14, repeat every 3 weeks.
224318296|NCT05228431|DRUG|Capecitabine monotherapy|During radiotherapy (Monday to Friday), capecitabine was administered at 1650 mg/m2/d, twice a day.
224318297|NCT05228431|RADIATION|Radiation|The TV is expanded by 6-7mm to form PTV1, and the CTV is expanded by 6-7mm to form PTV2. The dose of PTV1 was 50Gy/25 times/35 days, and the dose of PTV2 was 45Gy/25 times/35 days, 5 times/week for a total of 5 weeks.
223632927|NCT00236223|DRUG|Gabapentin + dexamethasone + ketamine|Comparing analgesic effect of gabapentin 1200 mg + dexamethasone 8 mg + ketamine 0.15 mg/kg
223764407|NCT05341544|DEVICE|Parasym device|The study will utilize the Parasym device (Parasym Health, London, United Kingdom) paired with compatible electrodes to administer the transcutaneous LLTS.
223632928|NCT00236223|DRUG|Placebo|Matching placebo
223632929|NCT01723384|DRUG|Intermittent Oral Naltrexone|
223632930|NCT01723384|DRUG|Placebo|
223632931|NCT00671736|DRUG|Moli1901|2,5 ml inhalation solution, 8 weeks treatment period
223632932|NCT00671736|DRUG|Moli1901 placebo|2,5 ml placebo solution, 8 weeks treatment period
223632933|NCT05927818|DIAGNOSTIC_TEST|Sentinel lymph node biopsy (using sterile charcoal stain) in early ovarian cancer|Described in previous sections
224318298|NCT03624920|DRUG|THN102 Dosage A|THN102 Dosages A: placebo
224318299|NCT03624920|DRUG|THN102 Dosage B|THN102 Dosage B : 200mg/2mg
224318300|NCT03624920|DRUG|THN102 Dosage C|THN102 Dosage C: 200mg/18mg
224318301|NCT04905628|DEVICE|Dexcom CGM System|Dexcom CGM System
224318302|NCT05009017|DRUG|Bevacizumab|Patients with colorectal cancer or lung cancer who use originator or biosimilar of bevacizumab
224221637|NCT01121900|DRUG|Trazodone HCl|"Dosage form: Immediate-release tablets containing 100 mg trazodone HCl~Dose: 100 mg trazodone HCl immediate-release tablets (one tablet per dosing time) at 23:30 on Day 1, at 07:30 and 15:30 on Day 2 of the reference product treatment period."
223632934|NCT05642728|OTHER|Case management follow-up program|The case manager will monitor asthma control (asthma control test, ACT) and adherence to treatment with questionnaires (inhaler adherence test, TAI) and electronic prescription withdrawal (e-prescription). The case manager will make decisions based on these results and according to pre-designed medical instructions. In addition, the patient will be able to contact the case manager for advice during periods of worsening symptoms. The patient will contact the case manager via a mobile app with messaging and video call option, as well as a contact phone number and email for consultations.
223632935|NCT02784080|OTHER|HLA-alloantibodies exposure|"Following analyzes will be done:~LABScreen® Single Antigen, One Lambda, CA~C1qScren™, One Lambda, CA (planned for later study)~PE-conjugated IgG3 antibody (planned for later study)~LABScreen® Mixed, One Lambda, CA (never analysed in the study)"
223632936|NCT03804528|BEHAVIORAL|Aerobic Exercise|"Participants will be fitted with a heart rate monitor and will be instructed to walk (or trot) to maintain 55-64% of maximal heart rate (determined by exercise test) for the first 4-weeks of exercise or to maintain 65-90% of maximal heart rate (determined by exercise test) for the second 4-weeks of exercise during each session. Participants are provided the option to participate remotely due to COVID-19 pandemic, as detailed below. Both options are designed to be equivalent in intervention and outcome measures.~Option A: Current, IRB-approved, in-person methods pending appropriateness based on current University of Miami recommendations and standard operating procedures as it relates to the COVID-19 pandemic.~Option B: Remote option of current methods to maximize recruitment. This will be the only option until the study team obtains approval to resume Option A (as per University's safety guidelines)."
223632937|NCT06822062|OTHER|Meal A|Vegetable soup prepared with dried intrinsically labeled T.molitor (isotopic iron 57, native chitin content = 1g)
223632938|NCT06822062|OTHER|Meal B|Vegetable soup prepared with dried intrinsically labeled T.molitor (isotopic iron 57) + 2g of extrinsically added chitin
223632939|NCT06822062|OTHER|Meal C|Vegetable soup prepared with dried intrinsically labeled T.molitor (isotopic iron 57) + ascorbic acid (4:1 ascorbic acid to iron molar ratio)
223632940|NCT06822062|OTHER|Meal D|Vegetable soup without insects with extrinsic addition of FeSO4 (isotopic iron 58)
223632941|NCT06822062|OTHER|Meal E|Vegetable soup without insects with extrinsic addition of FeSO4 (isotopic iron 58) + 1g of extrinsically added chitin
224221638|NCT00591422|DRUG|ZIO-101-C (Darinaparsin)|Capsule, Dose escalation study from 100 mg to 1000 mg (or Maximum Tolerated Dose). 3 times weekly (\>36 hours between doses) for 3 weeks with 1 week rest.
224318303|NCT01125371|BEHAVIORAL|Computerized brief alcohol intervention + IVR booster calls|1\) Computerized brief alcohol intervention + IVR booster calls: Clinic-based computerized brief alcohol intervention (delivered once) followed by three booster phone calls using interactive voice response technology + text messages
224318304|NCT01125371|BEHAVIORAL|Computerized brief alcohol intervention|Computerized brief alcohol intervention: Clinic based computer delivered brief alcohol intervention delivered one time
224318305|NCT01125371|BEHAVIORAL|Attention Control|Attention Control: 20 minute attention control condition focused on dental hygiene delivered once
223632942|NCT06822062|OTHER|Meal F|Vegetable soup without insects with extrinsic addition of FeSO4 (isotopic iron 58) + 3g of extrinsically added chitin
223764408|NCT05341544|DEVICE|Sham device|Sham device
224318306|NCT00029029|PROCEDURE|pain therapy|
224318307|NCT00029029|PROCEDURE|radiofrequency ablation|
224318308|NCT05938608|DRUG|Regimen 1 (Oral primaquine)|Primaquine 15 mg base orally once
223632943|NCT06822062|OTHER|Meal G|Vegetable soup without insects with extrinsic addition of FeSO4 (isotopic iron 54) + ascorbic acid (4:1 ascorbic acid to iron molar ratio)
223632944|NCT04747964|DRUG|STSP-0601 for Injection|Subjects will receive one single lowest dose of STSP-0601 for Injection following protocol requirements
223764409|NCT02685774|DRUG|Duvie Tab. 0.5mg, Glucophage XR Tab. 500mg|Duvie Tab. 0.5mg 1T, Glucophage XR Tab. 500mg 2T oral administration
224221639|NCT03872271|PROCEDURE|ileal pouch-anal anastomosis with diverting loop ileastomy|Defunctioning ileostomy has demonstrated its benefits (rate and seriousness of anastomotic leakage) in cancer for low colorectal and coloanal anastomoses, whereas there are no such good quality evidences in case of ileal pouch-anal anastomosis (IPAA) performed for inflammatory bowel disease (IBD). However, most surgical teams do protect systematically IPAA by an ileostomy.
224318309|NCT05938608|DRUG|Regimen 2 (IV primaquine phosphate)|Primaquine 7.5 mg base in normal saline 500 mL infused over 30 minutes intravenously
223632945|NCT04747964|DRUG|STSP-0601 for Injection|Subjects will receive one single low dose of STSP-0601 for Injection following protocol requirements
223632946|NCT04747964|DRUG|STSP-0601 for Injection|Subjects will receive one single low-intermediate dose of STSP-0601 for Injection following protocol requirements
223632947|NCT04747964|DRUG|STSP-0601 for Injection|Subjects will receive one single intermediate dose of STSP-0601 for Injection following protocol requirements
224221640|NCT03872271|PROCEDURE|ileal pouch-anal anastomosis with diverting loop ileastomy|Defunctioning ileostomy has demonstrated its benefits (rate and seriousness of anastomotic leakage) in cancer for low colorectal and coloanal anastomoses, whereas there are no such good quality evidences in case of ileal pouch-anal anastomosis (IPAA) performed for inflammatory bowel disease (IBD). However, most surgical teams do protect systematically IPAA by an ileostomy.
224221641|NCT02583620|GENETIC|blood sample|A blood test is realized on the subject
224318310|NCT05938608|DRUG|Regimen 3 (IV carboxyprimaquine)|Carboxyprimaquine 7.93 mg base in normal saline 500 mL infused over 30 minutes intravenously
224318311|NCT00316095|DRUG|telmisartan|
223632948|NCT04747964|DRUG|STSP-0601 for Injection|Subjects will receive one single high dose of STSP-0601 for Injection following protocol requirements
223632949|NCT04747964|DRUG|STSP-0601 for Injection|Subjects will receive one single highest dose of STSP-0601 for Injection following protocol requirements
223632950|NCT04607005|DRUG|Mepolizumab|Mepolizumab will be available as a clear to opalescent, colorless solution for SC injection in a single-use, safety syringe at a unit dose strength of 100 mg/milliliters (mL).
223764410|NCT02685774|DRUG|CKD-395 0.25/500mg|CKD-395 0.25/500mg 2T oral administration
223764411|NCT01368575|PROCEDURE|CABG|CABG
223632951|NCT04607005|DRUG|Placebo|Placebo will be available as a clear to opalescent, colorless sterile solution for SC injection in a single-use, safety syringe
223632952|NCT04607005|DRUG|Standard of care|Participants will continue to receive Standard of care as they are used to before entry in the study.
223632953|NCT02142699|DRUG|Heme arginate|
223632954|NCT06585111|OTHER|Intervention|"In the first motivational interview, the HAPA Model Prenatal Motivation Interview Questionnaire, the first part of the Personal Information Form, the Prenatal Breastfeeding Self-Efficacy Scale, and the Breastfeeding Intention Scale for Pregnant Women Expecting Twins were applied. A brochure on breastfeeding twin babies prepared by the researcher was distributed to women. In the second interview, the HAPA Model Postpartum Motivation Interview Scale, the second part of which was the Personal Information Form, Breastfeeding Follow-up Form, Breastfeeding Motivation Scale and Postpartum Breastfeeding Self-Efficacy Scale were applied. In the third meeting, the Breastfeeding Follow-up Form was applied. Breastfeeding Motivation Scale, Postpartum Breastfeeding Self-Efficacy Scale and Breastfeeding Follow-up Form were applied in the fourth and fifth interviews, and Breastfeeding Follow-up Form was applied in the sixth interview."
223632955|NCT04495218|BIOLOGICAL|Blood samples|Performed a 10 ml blood sample (2 unnamed samples of 5ml) in each of the 100 patients included.
223764412|NCT01368575|PROCEDURE|CABG combined with MV repair with remodeling annuloplasty rigid ring|CABG combined with MV repair with remodeling annuloplasty rigid ring
223764413|NCT01368575|PROCEDURE|CABG combined with MV repair with remodeling annuloplasty rigid ring|CABG combined with MV repair with remodeling annuloplasty rigid ring
224221642|NCT03370484|DIETARY_SUPPLEMENT|Control|Water with 80 mg sucralose
224221643|NCT03370484|DIETARY_SUPPLEMENT|Milk mineral supplement|Water with milk mineral supplement (1000 mg calcium), plus 80 mg sucralose
224221644|NCT00648856|DRUG|Sertraline Hydrochloride Tablets 100 mg|100mg, single dose fed
224221645|NCT00648856|DRUG|Zoloft® Tablets 100 mg|100mg, single dose fed
223764414|NCT01368575|PROCEDURE|CABG combined with MV repair with remodeling annuloplasty rigid ring and endoventricularplasty of subvalvular apparatus|CABG combined with MV repair with remodeling annuloplasty
224221646|NCT02528578|DEVICE|thermal stimulation delivered by a thermode.|Empathetic context (neutral, empathetic, non-empathetic) when thermal stimulation
224221647|NCT02528578|OTHER|functional MRI|MRI realised with thermal stimulations and empathetic context (neutral, empathetic, non-empathetic) when thermal stimulation
224221648|NCT04053478|DRUG|Ephedrine|Ephedrine in solution, at applicable concentrations based on literature
224221649|NCT04053478|DRUG|Phenylephrine|Phenylephrine, at applicable concentrations based on literature
224221650|NCT04053478|DRUG|Norepinephrine|Norepinephrine, at applicable concentrations based on literature
224221651|NCT04053478|DRUG|Vasopressin|Vasopressin, at applicable concentrations based on literature
224221652|NCT04759495|DEVICE|Continuous Glucose Monitoring Dexcom G5 and G6 system (real-time continuous glucose monitoring)|rtCGM is used in Type 1 diabetic patients to improve glucose control and to minimize or avoid severe hypoglycaemia.
224221653|NCT04759495|DEVICE|Continuous Glucose Monitoring FreeStyle Libre Flash system (flash glucose monitoring)|FGM is used in Type 1 diabetic patients to improve glucose control and to minimize or avoid severe hypoglycaemia.
224221654|NCT01328054|DRUG|lapatinib|lapatinib commercial tablet, 2000mg, will be given as three separate doses (8 tablets/dose) given 12 hours apart over a 2 day period
224221655|NCT01328054|DRUG|placebo matching lapatinib|placebo matching lapatinib will be given as three separate doses (8 tablets/dose) given 12 hours apart over a 2 day period
223632956|NCT05343182|OTHER|Modified Technique|This operation is performed using modified anesthesia care/deep sedation (MAC) for anesthesia. The vestibule is removed to the boundary of Harts line. The surgical flap for this procedure is the Hymen plus 1 cm of the vagina.
223764415|NCT01368575|PROCEDURE|CABG and MV replacement|coronary artery bypass grafting and mitral valve replacement
223764416|NCT01394575|RADIATION|IMRT with an simultaneous integrated boost|IMRT in 25 fractions delivering 45Gy to the whole breast and 60Gy to the tumor bed
224221656|NCT02182960|DRUG|Ibuprofen syrup|
224221657|NCT02182960|DRUG|Brufen syrup|
224221658|NCT03496532|DEVICE|biphasic stimulation|Fixed 70Hz symmetrical biphasic pulses
224221659|NCT03496532|DEVICE|standard stimulation|Fixed 70Hz pseudo-monophasic pulses
224221660|NCT03496532|DEVICE|Uniform distribution|Uniform distribution 70Hz Biphasic pulses
224221661|NCT03496532|DEVICE|Poisson distribution|Poisson distribution 70Hz Biphasic pulses
224221662|NCT03496532|DEVICE|Recordings of LFP oscillations|"Two minutes of recordings of LFP oscillations will be performed from the contacts of the implanted electrode.~Recordings of the depth of anaesthesia (BIS) all along the measurements performed under general anaesthesia.The correlation between the depth of anaesthesia and the cerebral oscillations recorded at the site of subthalamic nucleus will be studied."
224221663|NCT00180869|PROCEDURE|transfusion of allogeneic red blood cell concentrate|
224221664|NCT00180869|PROCEDURE|transfusion of leuko-reduced red blood cell concentrate|
224221665|NCT05500495|OTHER|no intervention|no intervention
224221666|NCT06424678|OTHER|Only data collection in the Utstein template|The intervention that we will carry out in both groups will consist of collecting data from the patient (age, sex and race), on cardiopulmonary arrest, cardiopulmonary resuscitation, and the results of cardiopulmonary resuscitation.
224221667|NCT01051622|OTHER|Labeling Ceretec|Technetium-99m is used to radiolabel cells of interest i.e PBMC's
224221668|NCT02022371|PROCEDURE|Targeted biopsies of the prostate|Multiple biopsies from a MRI lesion for analysis of intratumour heterogeneity
224221669|NCT03760510|DEVICE|Tube Fastener|Endotrachel tube secured with tube fastener
224221670|NCT03760510|DEVICE|Adhesive Tape|Endotracheal tube secured with adhesive tape.
224221671|NCT03170505|PROCEDURE|repairing fistula|A tailored piece of Acellular Dermal Matrix or Conchal Cartilage will be placed between the oral and nasal layers for repair of a Cleft Palate.
224221672|NCT04249206|PROCEDURE|Root Canal Treatment|
224221673|NCT06182683|DIAGNOSTIC_TEST|optical coherence tomography and fractional flow reserve|The assessment of pre-procedural lesions and optimization status of implanted stents will involve both intracoronary imaging and physiological indices.
224318312|NCT00316095|DRUG|simvastatin|
224221674|NCT06182683|DIAGNOSTIC_TEST|Coronary angiography|The assessment of pre-procedural lesions and optimization status of implanted stents will be determined by conventional coronary angiography
223632957|NCT05343182|OTHER|Traditional Technique|This operation is performed using an Laryngeal Mask Airway (LAM), (modified anesthesia care/deep sedation) for anesthesia. The vestibule is removed 0.5 to 1 cm beyond the boundary of the Hart's line. The Hymen plus 1 cm of the vagina is excised.
223632958|NCT05518812|DRUG|Carboprost Tromethamine|During myomectomy, low-dose carboprost will be injected at the base of the fibroid and repeated as necessary. The efficacy of low-dose carboprost is being assessed, and the total dose administered will not exceed single vial for other indications.
223764417|NCT06840782|RADIATION|Radical local treatment|"RLT of all metastatic sites. The possible RLT options will be SBRT, interventional radiology and/or minimally invasive surgery. Depending on the metastatic site, access and patient condition, the best RLT should be initially discussed in a case-to-case basis at the local multidisciplinary board (MTB).~The primary tumour and initially invaded lymph nodes should be treated during the maintenance phase. Curative-intent approach modalities (e.g. hypofractionated intensity-modulated thoracic radiation therapy or surgery) should be discussed at the local MTB."
224221675|NCT00000531|DEVICE|defibrillators, implantable|
224221676|NCT00000531|DRUG|amiodarone amiodarone|
224221677|NCT00000531|DRUG|sotalol|
224221678|NCT03080194|DRUG|paliperidone palmitate|Subjects in experimental group will be injected with 150mg eq and 100mg eq paliperidone palmitate in the deltoid at the 1st and 8th day, and afterwards a flexible dose of paliperidone palmitate from 75 to 150mg eq will be administrated monthly according to clinical judgement. Previous oral antipsychotics could be continued or withdrawn in 2-4 weeks after first paliperidone palmitate administration according to doctors' clinical judgement.
224221679|NCT03080194|DRUG|control group|Subject in control group will be applied with oral antipsychotics or other conventional medication.
223764418|NCT06840782|DRUG|SoC-based immunotherapy (+/- chemotherapy)|"Current French SoC will be used. Main SoC-based immunotherapy includes:~* Platinum-based chemotherapy combined with an anti PD-1 immunotherapy (pembrolizumab). Pemetrexed-platinum combinations may be used in non- squamous carcinoma, while paclitaxel-platinum combination is favoured in squamous carcinoma.~* Anti PD-1 monotherapy if PD-L1 ≥ 50% is a possible alternative (pembrolizumab or atezolizumab or cemiplimab).~Other alternatives include nivolumab-ipilimumab-chemotherapy or durvalumab-tremelimumab-chemotherapy association. Bevacizumab is not allowed given possible interactions with RLT.~Maintenance/Immunotherapy alone will be pursued at the investigator's discretion according to the standard procedures (toxicity, progression, choice of the patient...)."
223764419|NCT04709237|DEVICE|omafilcon A control lens|Participants were randomized to wear omafilcon A control soft contact lens for 10 days.
223764420|NCT04709237|DEVICE|omafilcon A test lens 1|Participants were randomized to wear omafilcon A test soft contact lens 1 for 10 days.
224221680|NCT05559294|BEHAVIORAL|Professional Development of Early Childhood Education and Care Staff for Science|A nine-month program consisting of three e-learning modules and three group workshops
224221681|NCT05559294|BEHAVIORAL|Education and care as Usual (ECAU)|Active control
224221682|NCT04341818|OTHER|Strength Training and Vitamin D monthly|For 4 wks 50.000 IU vitamin D is given as a monthly dose together with daily 400mg of calcium. Both as a supplement, followed by a 10 weeks resistance training (progressive strength training in a fitness center is applied; the intensity is adjusted continuously in order to obtain a sufficient training stimulus). During the training period the vitamin D and calcium intake remain.
224221683|NCT04341818|OTHER|Strength Training and Vitamin D daily|For 4 wks 800 IU vitamin D is given as a daily dose together with daily 400mg of calcium. Both as a supplement, followed by a 10 weeks resistance training (progressive strength training in a fitness center is applied; the intensity is adjusted continuously in order to obtain a sufficient training stimulus). During the training period the vitamin D and calcium intake remain.
224221684|NCT04341818|OTHER|Strength Training and no Vitamin D|For 4 wks no vitamin D is administered, followed by a 10 weeks resistance training (progressive strength training in a fitness center is applied; the intensity is adjusted continuously in order to obtain a sufficient training stimulus). During the training period the also no vitamin D is given. Over the whole study period participants get 400 mg calcium/day.
224221685|NCT06219382|DEVICE|Neurorehabilitation ecosystem|Over a period of six weeks, the participants will integrate the NEST system into their daily routines, running parallel to their regular neurorehabilitation treatment.
224221686|NCT04566783|DIAGNOSTIC_TEST|Psychological/psychiatric examination|Thorough diagnostic and (neuro)psychological assessment using standardized clinical interviews (e.g. MINI, SOMS) as well as questionnaires assessing sexual function (e.g. SIS/SES), depression and anxiety (HADS), childhood trauma (CTQ) and life quality (WHOQOL-BREF). In a semi-structured interview sociodemographic data, drug history and sexual characteristics are captured.
224221687|NCT04566783|DIAGNOSTIC_TEST|Neurological examination|Standardized clinical neurological examination as well as neurophysiological measurements (Pudenus-SEP, ENoG, clinical EEG).
224221688|NCT04566783|DIAGNOSTIC_TEST|Gynecological/urological examination|Standard clinical investigation including ultrasound of the genital organs will be conducted to look for any somatic pathology (e.g. varices, tumors).
224318313|NCT05823324|BEHAVIORAL|Therapeutic play group|The dramatization method with teddy bear, one of the TP methods, was applied during the PIVC intervention
223632959|NCT02331134|DRUG|Filgrastim|Patients will receive 10 μg/kg/day of filgrastim subcutaneously in a 4-day mobilization schedule
223632960|NCT04671901|DRUG|Romiplostim|Participants will receive weekly doses of romiplostim, beginning with cycle 4. The initial romiplostim dose will be 10 mcg/kg, and subsequent doses w ill vary based on chemotherapy regimen for a target of platelet count \> 75,000- 200,000/mcL. Participants will continue romiplostim until completion of MAP or D9803, as defined above. Maximum romiplostim dose is 10 mcg/kg. Participants will be followed until 6 months after the last dose of romiplostim.
223764421|NCT04709237|DEVICE|omafilcon A test lens 2|Participants were randomized to wear omafilcon A test soft contact lens 2 for 10 days.
223632961|NCT06041737|OTHER|consultation|nephrology consultation during 2020
223632962|NCT04825574|DRUG|Avapritinib|avapritinib tablet
224318314|NCT02111603|DRUG|Colesevelam|Subjects will receive 1875 mg of Colesevelam orally twice daily for 10 days
223632963|NCT04049032|BEHAVIORAL|In-Person Perinatal OUD Treatment|Participants were seen weekly for four weeks, every two weeks for four weeks and monthly thereafter and provided relapse-prevention therapy and buprenorphine as part of standard of care.
223632964|NCT04049032|BEHAVIORAL|Perinatal OUD Treatment via Telemedicine|Participants were seen weekly for four weeks, every two weeks for four weeks and monthly thereafter and provided relapse-prevention therapy and buprenorphine as part of standard of care..
223632965|NCT06143852|BEHAVIORAL|Mindfulness|12 minute daily guided meditation
224221689|NCT04566783|DIAGNOSTIC_TEST|Laboratory assessment|Blood sample will be analyzed to evaluate (epi-)genetic markers of increased central excitability or decreased inhibition including specific parameters of the serotonin-, dopamine- and endocannabinoid system.
224221690|NCT04566783|DIAGNOSTIC_TEST|Structural and Functional Magnetic Resonance Imaging|"1. Structural MRI of the pelvis is conducted to rule out any anatomical pathologies underlying PGAD (e.g. varices).~2. Structural MRI of the lumbosacral spinal cord to look for any pathologies on the spinal level, especially spinal level S2-4 (e.g. Tarlov cysts).~3. High-resolution structural MRI (T1) including brain stem will be applied to all participants in order to explore alterations in gray matter volume or density.~4. Structural differences in white matter will be assessed using a high-resolution DTI sequence. In addition to standard voxel-wise comparison of DTI derived parameters for white matter microstructural integrity, a tractography-based analysis will test for alterations in structural connectivity.~5. Resting-state functional MRI including brain stem scans will evaluate abnormal brain circuitry at rest (resting-state functional connectivity, RSFC).~6. Functional MRI to assess brain response towards sexual cue reactivity."
224221691|NCT00987987|PROCEDURE|donor lymphocyte infusion|regulatory T cells depletion
223632966|NCT06143852|BEHAVIORAL|Social Media Reduction + Exercise|Reduce social media use at least 30 minutes daily and exercise instead
223632967|NCT03564275|RADIATION|Proton Boost|13-15 treatments with proton therapy given as a boost to standard of care photon therapy
223632968|NCT02624596|DRUG|Ketamine|OCD patients in this arm will receive 0.5mg/kg of ketamine - one single infusion
223632969|NCT02624596|DRUG|Midazolam|OCD patients in this arm will receive 0.045mg/kg of midazolam - one single infusion
224221692|NCT04898725|DIETARY_SUPPLEMENT|Vitamin D3|Vitamin D3 4800IU daily
224221693|NCT02112903|DRUG|Encapsulated vortioxetine IR tablet, 20 mg|
223764422|NCT02984176|DRUG|Simethicone Tab 40 mg|3 tablets of Simethicone Tab 40 mg (one tablet after each meal) and to fast overnight the day before the operation.
224221694|NCT02112903|DRUG|Vortioxetine MR capsule 20 mg (pH 5.5)|
224221695|NCT02112903|DRUG|Vortioxetine MR capsule 20 mg (pH 6.0)|
224221696|NCT02112903|DRUG|Vortioxetine MR capsule 20 mg (pH 7.0)|
224221697|NCT01344395|DRUG|ropivacaine and ketorolac|The RK-group receives four intra-articular injections via catheter with a total volume of 40 ml (380 mg ropivacaine and 60 mg ketorolac) combined with 4 intravenous injections of saline during 24 hours postoperatively
224221698|NCT01344395|DRUG|Ketorolac|The K-group receives four intra-articular injections via catheter with a total volume of 40 ml saline combined with 4 intravenous injections of ketorolac (total 60 mg) during 24 hours postoperatively
224221699|NCT00887627|DRUG|conivaptan hydrochloride|intravenous
223632970|NCT04507412|DRUG|dexamethasone|perioperatively 9 mg i.v subministration
223632971|NCT03482726|BEHAVIORAL|Cycling Cadence Modulation|6-week high intensity training (HIIT) indoor cycling program, described later, at their prescribed cadence (FCC or EOC), using cadence meters.
223632972|NCT05391503|BEHAVIORAL|Light therapy|Morning bright light for 60 minutes after awakening
223764423|NCT02984176|DRUG|Placebo Tablets|3 tablets of Placebo Tablets (one tablet after each meal) and to fast overnight the day before the operation.
224221700|NCT05478603|DRUG|PF-07081532|PF-07081532 20 milligrams (mg), 1 tablet orally, once on Day 1
224221701|NCT06319391|OTHER|CYP3A5*1*、CYP3A5*1*3|2ml of venous blood was drawn and placed in an EDTA anticoagulant tube. Peripheral blood genomic DNA was extracted according to the instructions of the DNA extraction kit.The reaction system was prepared by polymerase chain reaction (PCR) according to the instructions of PCR amplification system. After 25g/L agarose gel electrophoresis, the bands of amplified products were observed under UV lamp. The PCR products were purified by enzymolysis. The purified product was prepared according to sequencing PCR amplification system. After 1min predenaturation at 96℃, denaturation at 96℃ for 30s, annealing at 56 ℃ for 30s and extension at 72℃ for 1 cycle. A total of 25 cycles were performed for sequencing PCR amplification. The amplified products were purified by ethanol precipitation method.
224221702|NCT06319391|OTHER|CYP3A5*3*3|2ml of venous blood was drawn and placed in an EDTA anticoagulant tube. Peripheral blood genomic DNA was extracted according to the instructions of the DNA extraction kit.The reaction system was prepared by polymerase chain reaction (PCR) according to the instructions of PCR amplification system.After 25g/L agarose gel electrophoresis, the bands of amplified products were observed under UV lamp. The PCR products were purified by enzymolysis. The purified product was prepared according to sequencing PCR amplification system. After 1min predenaturation at 96℃, denaturation at 96℃ for 30s, annealing at 56 ℃ for 30s and extension at 72℃ for 1 cycle. A total of 25 cycles were performed for sequencing PCR amplification. The amplified products were purified by ethanol precipitation method.
224221703|NCT00139204|PROCEDURE|C11 Methionine PET scan|
224221704|NCT05512325|DRUG|Gene evolution and molecular response under Bevacizumab treatment|Patients with glioma were routinely treated with temozolomide chemotherapy from the 4th week after operation, for 5 days continuously, once every 4 weeks, with a single dose as follows: Single dose = BSA (body surface area) \* 150mg/m2/day BSA(Body Surface Area)=\[weight (kg)\* height (cm)/3600\]2, According to the molecular pathological grade (WHO CNS5 grade), it is decided whether to combine radiotherapy (GBM combined with radiotherapy) and temozolomide combined with bevacizumab (600mg) in the course of tumor progression, Recording image changes
223764424|NCT04048460|DEVICE|Delivery of hearing healthcare through eAudiology application|Participants will receive bilateral, behind-the-ear hearing aids as part of this study. The intervention will involve e-Audiology sessions following the initial hearing aid fitting and orientation. E-Audiology sessions will consist of hearing aid follow-up programming, troubleshooting, HAT assistance, and general help with hearing devices. E-Audiology sessions will take place over the course of approximately 6 weeks.
223632973|NCT05391503|BEHAVIORAL|Placebo light therapy|Placebo morning bright light for 60 minutes after awakening
223632974|NCT04906122|OTHER|The grandmothers in the intervention group will be given breastfeeding counseling before discharge. Home monitoring will be performed in the 2nd week, 3rd and 6th months after the counseling.|The research was planned as a randomized controlled study. Voluntary postpartum primiparous mothers who have recently given birth and their accompanying grandmothers will be randomly assigned to the intervention and control group. The grandmothers in the intervention group will be given breastfeeding counseling before discharge. Home monitoring will be performed in the 2nd week, 3rd and 6th months after the counseling. In each follow-up, breastfeeding knowledge and attitudes of the grandmothers, breastfeeding success of mothers, attitude towards breastfeeding, perception of postpartum support and newborn growth parameters will be determined. As a result of the research, the effect of breastfeeding training given to grandmothers will be evaluated breastfeeding status of the first 6 months, self-efficacy, attitude, social support perceptions, breastfeeding continuity and newborn growth parameters of primiparous mothers who have just given birth.
223632975|NCT06653972|DRUG|Pegylated Liposomal Doxorubicin + vinorelbine,every cycle is 14d.|Pegylated Liposomal Doxorubicin 25mg/m2 ivgtt d1 + vinorelbine25mg/m2 ivgtt d1/q14d.
223632976|NCT06654362|BEHAVIORAL|nutritional interventions include education and modifying company's restaurant menu|"* Reducing fried foods and replacing them with healthier alternatives.~* Decreasing the consumption of sweetened beverages such as soda and replacing them with yogurt.~* Reducing the intake of refined grains and substituting with whole grains.~* Increasing fruit intake.~* Increasing the intake of vegetables as much as possible.~* Organizing face-to-face educational sessions with the chef to train them and improve cooking methods, to reduce fat and oil intake."
223632977|NCT06654973|OTHER|GMP-produced SARS-CoV-2 Delta strain|The challenge virus used in Sing-CoV study is the same as that used in COVHIC002 study. It was originally obtained in mid 2021 from a nose-throat swab from an otherwise healthy young adult with mild COVID-19 in the community. The procedure for isolation, storage, preparation, and administration of challenge virus in this study (Sing-CoV and COVHIC002) is the same as used in the first SARS-CoV-2 human challenge study (COVHIC001) at Imperial College London and the same as used in the COV-CHIM01 (NCT04864548) SARS-CoV-2 human challenge study at University of Oxford.
223632978|NCT04199221|BEHAVIORAL|Stress Innoculation Training (SIT)|1 hour lecture that will cover the conceptualization phase and skills-training phase portions of stress inoculation training.
223632979|NCT04199221|BEHAVIORAL|Extra attempt|an extra attempt at intubating a mannequin configured at a difficulty level higher than will be used in the future scenarios
223632980|NCT03491059|DRUG|C-11 labeled nicotine|Participants will vape with e-cigarettes radio-labeled with C-11 nicotine.
223632981|NCT03491059|RADIATION|PET/CT imaging|After vaping with radio-labeled e-cigarettes, participants will be PET/CT imaged.
223632982|NCT02257593|OTHER|Dietary protein|"Persons were fed~Participants were randomized to one of three arms, each of which received 10%, 15% or 25% of total energy derived from protein"
223632983|NCT02845297|DRUG|pembrolizumab|Intravenous pembrolizumab
223632984|NCT02845297|DRUG|Azacitadine|Intravenous or subcutaneous
223632985|NCT06810960|OTHER|No Intervention|This is a non-interventional study.
223632986|NCT06599242|OTHER|Basic Body Awareness Therapy|Basic Body Awareness Therapy is an exercise approach belonging to physiotherapists
223632987|NCT06599242|OTHER|American football team training|American football team training
223632988|NCT06594913|OTHER|Eating disorder diagnosis group|This is an observational study, no active intervention is applied. Participants are assigned to an eating disorder diagnosis group based on their lifetime history of disordered eating behaviors and symptoms.
224221705|NCT01288833|DEVICE|Close focus HD NBI Colonoscopy System|Technically improved colonoscope with close focus high definition narrow band imaging. Optical specifications include a 2mm near field focal depth.
224221706|NCT00533520|DRUG|ranibizumab|Arm A: 0.5 mg ranibizumab on day 0 with retreatment based on defined criteria not to occur sooner than every 28 days Arm B: 1.0 mg ranibizumab on day 0 with retreatment based on defined criteria not to occur sooner than every 28 days Third Arm 2.0mg Arm with retreatment based on defined criteria not to occur sooner than every 28 days
224221707|NCT03275701|DRUG|Triumeq|Open Label, Switch to Triumeq (ABC/DTG/3TC)
224221708|NCT05621200|DEVICE|Transcranial stimulation over the cerebellar hemispheres|Single session of Transcranial stimulation over the cerebellar hemispheres
224221709|NCT06120010|DEVICE|MRI|To detect prevalence of anatomical variants of dural sinuses by MRV
224221710|NCT04875156|OTHER|measurement of range of motion and strength|measurement of range of motion (goniometer) and strength (dynamometer) of the metacarpophalangeal joint of the thumb
224221711|NCT02593890|DEVICE|THEYA Recovery Range|Post-operative Lingerie made from viscose derived bamboo
224221712|NCT00291330|DRUG|dabigatran etexilate 150 mg|twice daily
223632989|NCT06594250|DIAGNOSTIC_TEST|Nasal swab|Nasal swab to detect nasal carriage of S. aureus
223632990|NCT06594250|BIOLOGICAL|Venous sampling|Peripheral venous sampling to collect peripheral blood mononuclear cells.
223632991|NCT06594250|BIOLOGICAL|Antibiotic treatment|Antibiotic treatment for bacteremia (+/- 1 month), in all patients with S. aureus
223632992|NCT06594250|DEVICE|Nasal swab|A new nasal swab will be taken using the same technique, to see whether or not the carriage persists
223632993|NCT06594250|BIOLOGICAL|Intracellular reservoir test|In the event of positive carriage, a new intracellular reservoir test will be performed. A search for relapse (new S. aureus infection) or recurrence (S. aureus bacteremia if the 1st bacteremia was due to another pathogen) will be carried out.
223632994|NCT06601608|DRUG|Herbal therapy|rosemary extract gel is used for the first time as a local drug delivery as an adjunct to non-surgical periodontal therapy in management of stage III periodontitis patients.
223632995|NCT06601608|DRUG|Placebo Drug|a placebo gel will be applied in deep pockets (\&gt;5mm) in stage III periodontitis patients as an adjunct to non-surgical periodontal therapy
224221713|NCT00291330|DRUG|warfarin (INR 2-3)|prn to maintain INR (2-3)
224221714|NCT05884138|OTHER|exercise and nutritional support|resistance exercise and protein supplementation including branched chain amino acids for 12 weeks
224221715|NCT04309955|PROCEDURE|pigtail catheter|After inserting the chest tube, add a pigtail catheter into the posterior axillary lines of the 7th intercostal.
224221716|NCT03765944|DRUG|sirolimus|SIngle administration under fasted condition
223632996|NCT06589531|DEVICE|During TIPS operation, shunt diameter or diameter of covered stent|"Transjugular intrahepatic portosystemic shunt (TIPS) is an effective treatment strategy for managing portal hypertension-related variceal bleeding. However, the appropriate diameter of the covered stent during the TIPS procedure remains a subject of debate. To date, there is a lack of strong evidence regarding the most suitable covered stent diameter.~Due to the lack of a dedicated 6-mm covered stent, we first released a 6-mm diameter stent (SD Express; Boston Scientific Co., or Luminexx; Bard Medical Division) in the liver parenchymal segment of the shunt, and then released an 8-mm TIPS stent (Viatorr; WL Gore \&amp;amp; Associates) to create a final 6-mm shunt."
223632997|NCT06589531|DEVICE|During TIPS operation, shunt diameter or diameter of covered stent|After successful puncture, in the 8-mm shunt group, a balloon with a diameter of 6 mm was used to expand the shunt, and then an 8-mm covered stent was implanted (Viatorr; WL Gore \&amp; Associates, Inc.).
223632998|NCT06598839|DRUG|Thymosin Alpha1|subcutaneous injection of Tα1, 1.6mg each time, biw, for 3 months
223632999|NCT06600958|OTHER|SA brief descriptive name used to refer to the intervention(s) studied|Details that can be made public about the intervention
224221717|NCT05481060|OTHER|Screen-based simulation|In the research, training will be given to the experiment group on intimate partner violence against women through screen-based simulation.
224221718|NCT01877707|OTHER|home monitoring|Record daily - peak flow measurements, pulse rate, oxygen saturation levels, weight,activity and daily sputum samples.
224221719|NCT00492089|DRUG|bevacizumab|Given IV
224221720|NCT00492089|DRUG|placebo|Given IV
224221721|NCT00492089|PROCEDURE|magnetic resonance imaging|
224221722|NCT00492089|PROCEDURE|quality-of-life assessment|
224221723|NCT02631109|DRUG|Pegaspargase|2000U/m2 day5
224221724|NCT02631109|DRUG|doxorubicin|25mg/m2 day1
224221725|NCT02631109|DRUG|etoposide|100 mg/m2 was administered once on the first day of every week
224221726|NCT02631109|DRUG|methylprednisolone|15 mg/kg days 1 to 3, 0.75 mg/kg days 4 to 7
224221727|NCT01593150|DRUG|Pradaxa|Pradaxa for 3 weeks prior to DC
223633000|NCT06586996|OTHER|no intervention|no intervention
223633001|NCT06595654|OTHER|repetitive Transcranial Magnetic Stimulation|"* Patient is in a chair.~* Hearing protection will be implemented.~* The corresponding targeting method will be implemented.~* The stimulation coil will be set up according to the indications of the targeting method.~* A caregiver is present throughout the session.~* After the session, the patient is re-assessed clinically for possible adverse effects.~* If an adverse reaction is objectified, a doctor on site, is quickly mobilized."
223764425|NCT03977324|PROCEDURE|Chlorhexidine|Inflammatory tissue, excess cement or plaque deposits will be removed using titanium curettes and the implant surface will be cleaned by copious irrigation with sterile saline and surgical gauze soaked in chlorhexidine.
223764426|NCT03977324|PROCEDURE|Connective Tissue Graft|CTG will be positioned in the buccal aspect of the peri-implant tissue
224221728|NCT01593150|PROCEDURE|TEE|Transesophageal echo to exclude LAA thrombus, followed by early DC.
224221729|NCT01593150|OTHER|Compare TEE guided cardioversion to Dabigatran + DC cardioversion|compare the two groups, TEE followed by early DC cardioversion with Dabigatran for 3 weeks followed by DC cardioversion.
224221730|NCT00566709|PROCEDURE|Red blood cells transfusion|Patients will be transfused (one to one red blood cells unit transfusion)
224221731|NCT04890704|DRUG|Curcuminoid|Patients were stratified according to baseline eGFR and diabetes status with 1:1 assignment into curcuminoids and placebo group. Curcuminoids (250 mg capsules) were purchased from the Government Pharmaceutical Organization of Thailand (Anti-ox® registration number 1A 1/60(H)), which contained curcumin: demethoxycurcumin: bis-demothoxycurcumin at the ratio of 1:0.5:0.2.
224221732|NCT04890704|DRUG|Placebo|Identical capsules were used for the placebo from the same manufacturer.
224221733|NCT00757666|DEVICE|Rate adaptive pacemaker|Accelerometer sensor
224221734|NCT00757666|DEVICE|Rate adaptive pacemaker|Minute ventilation sensor
224221735|NCT04537325|DEVICE|RenalGuard system|Periprocedural intravenous hydration matched to urinary output.
224221736|NCT04582448|DRUG|Insulin icodec|A single dose of insulin icodec administered subcutaneously (s.c. - under the skin) Injection in the belly, upper arm and thigh on different occasions.
224221737|NCT02178449|DRUG|Dexamethasone acetate|
224221738|NCT02178449|DRUG|Placebo|
224221739|NCT02178449|DRUG|Ropivacaine|
224221740|NCT03443869|DRUG|Letermovir|LET 480mg (or 240 mg when administered concomitantly with cyclosporin A) once daily for 28 weeks
224221741|NCT03443869|DRUG|Valganciclovir|900 mg VGCV tablet orally, once daily for 28 weeks
224221742|NCT03443869|DRUG|Acyclovir (ACV)|400 mg over-encapsulated ACV tablet orally, every 12 hours for 28 weeks
224221743|NCT03443869|DRUG|Placebo to ACV|Over-encapsulated placebo tablet orally, every 12 hours for 28 weeks
224221744|NCT03443869|DRUG|Placebo to LET|Placebo to LET tablet orally, once daily for 28 weeks
224221745|NCT03443869|DRUG|Placebo to VGCV|Placebo to VGCV tablet orally, once daily for 28 weeks
224221746|NCT00299728|BIOLOGICAL|NY-ESO-1 Protein Vaccine|NY-ESO-1 recombinant protein mixed with CpG 7909 and Montanide ISA-51 VG
224221747|NCT04729218|BEHAVIORAL|movement imagery ability|Determining the movement imagery ability: internal visual, external visual and kinesthetic imagery
224221748|NCT02378506|BIOLOGICAL|etanercept|50mg subcutaneous, once weekly, 24 weeks
224221749|NCT01606137|DRUG|GW-1000-02|Contained delta-9-tetrahydrocannabinol (THC) (27 mg/ml) and cannabidiol (CBD) (25 mg/ml) as extract of Cannabis sativa L., with peppermint oil, 0.05% (v/v), in ethanol:propylene glycol (50:50) excipient. Each 100 μl actuation of the pump action spray delivered 2.7 mg THC and 2.5 mg CBD. A maximum daily exposure of 130 mg THC was specified by the UK regulatory authority authorisation.
224221750|NCT04522011|OTHER|intraoperative or postoperative hyperthermic intraperitoneal chemotherapy|Intraoperative hyperthermic intraperitoneal chemotherapy：Use docetaxel + oxaliplatin Intraoperately.(Docetaxel 30mg/m2 + oxaliplatin 30mg/m2), perfusion at 43 ℃ for 1 hour
224221751|NCT06208761|OTHER|Triphala capsule supplementation and high-intensity interval training|Triphala capsule supplementation is categorized in dietary supplement but and high-intensity interval training is included as other
224221752|NCT03165643|DIAGNOSTIC_TEST|OGTT|75 g glucose tolerance test was provided to all pregnant women during 24-28 weeks.
224221753|NCT05617820|DRUG|Estradiol|Vaginal Insert, 4 mcg tablet
223764427|NCT01302964|DRUG|Placebo|Subjects randomized to placebo will receive placebo for duration of the study
223764428|NCT01302964|DRUG|Mirtazapine|Subjects will receive 7.5 mg daily at the start of the trial. The dose will be increased by 7.5 mg per week for subjects weighing less than 50 kg and up to 15 mg per week for subjects weighing more than 50 kg depending on efficacy and tolerability.
223764429|NCT06445374|DRUG|Inhaled Epinephrine|"0.125 mg per inhalation.~The maximum proposed dose to be administered is 1.0 mg (consisting of 8 inhalations of 0.125 mg over 6 minutes)."
223764430|NCT04820283|BEHAVIORAL|Care manager intervention (nurse)|In this intervention, a primary care nurse provides the participant with self-management support to manage stress-related problems. The participant meets with the nurse face-to-face for typically 2 to 6 sessions.
224221754|NCT05617820|DRUG|Imvexxy|Estradiol 4 mcg Vaginal Insert
224221755|NCT05617820|DRUG|Placebo|Vehicle Vaginal Insert
224221756|NCT01574989|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|Subjects will either undergo (1) active low-frequency rTMS (1Hz continuous), (2) active high-frequency rTMS (10Hz, 2 second trains with inter-train interval of 28 seconds) or (3) sham rTMS (using a sham coil). Each session will last 20 minutes and will be conducted at 100% of the motor threshold.
224221757|NCT01574989|DEVICE|Transcranial Direct Current Stimulation (tDCS)|Subjects will either undergo (1) active anodal tDCS, (2) active cathodal tDCS or (3) sham tDCS. Each session will last 20 minutes and will be conducted using 1mA with 35\^2 electrodes.
224221758|NCT01368003|DRUG|STA9090|200 mg/m\^2 IV every week for 3 weeks on, 1 week off (days 1,8,15 on a 28-day cycle)
224221759|NCT01368003|DRUG|STA9090 with Dutasteride|Dutasteride 3.5 mg orally per day STA9090 200 mg/m\^2 IV every week for 3 weeks on, 1 week off (days 1,8,15 on a 28-day cycle)
224221760|NCT03572933|DRUG|ganaxolone|active drug
224221761|NCT03572933|DRUG|Placebo|inactive
224221762|NCT05958277|DRUG|Vitamin B3|Vitamin B3 upto 16 mg/day
224221763|NCT05958277|DRUG|Vitamin B12|Vit B12 upto 250 mcg per day
224221764|NCT04018144|DIAGNOSTIC_TEST|Gingiva Biopsy Sampling|Gingival samples of healthy individuals were collected by gingivectomy or crown lengthening procedure in the routine treatment protocol or before orthodontically indicated tooth extraction. Gingival samples of periodontitis patients were obtained during the scaling and root planning procedure. Posterior maxillary teeth (#4, #5, #6, and #7) were chosen for gingival sampling.
224221765|NCT01517724|DRUG|Bortezomib|1.3mg/sq m, subcutaneous injection, days 1, 8, 15 and 22 of 28 day cycle; maximum of 8 cycles
224221766|NCT04371614|BEHAVIORAL|Prime Time Sister Circle|The PTSC is a multi-faceted, facilitated, curriculum- and community-based, intensive, support group intervention with 25-30 mid-life African American women per group.
224221767|NCT02717975|PROCEDURE|Use of catheter valve before 'trial removal of catheter'|The investigators are comparing two groups of patients (Group A) Trial removal of urinary catheter in patients with urinary retention after applying catheter valve and closing it 3-4 hours before catheter removal.
224221768|NCT02717975|PROCEDURE|Trial removal of catheter in patients with urinary retention|The investigators are comparing two groups of patients (Group B) Trial removal of urinary catheter in patients with urinary retention without using catheter valve - 'Traditional method'
224221769|NCT03999437|DRUG|TERBINAFINE HYDROCHLORIDE (1%)|Topical liquid solution
224221770|NCT03999437|DRUG|BUTENAFINE HYDROCHLORIDE (1%)|Topical liquid solution
224221771|NCT03999437|DRUG|Vehicle Control|Topical liquid solution
224221772|NCT00673985|OTHER|Percutaneous Transluminal Angioplasty|Balloon Angioplasty
224221773|NCT00673985|DEVICE|LifeStent NT™ Self-Expanding Peripheral Stent|Balloon angioplasty plus stent
224221774|NCT01907737|OTHER|Active tDCS|Active tDCS will be applied with the anode positioned over the ipsilesional M1 and the cathode over the contralateral supraorbital region for 20 minutes (1mA).
224221775|NCT01907737|OTHER|Active PNS|Active PNS will be administered by 2 pairs of surface electrodes (cathode proximal). One pair will overly the median and ulnar nerves at the wrist, and the other pair will overly the radial nerve. Trains of electric stimulation will be delivered at 1 Hz by using isolation units connected to a square pulse stimulator.
224221776|NCT01907737|OTHER|Sham tDCS|In sham tDCS, no current will be delivered through the tDCS device.
223764431|NCT04820283|BEHAVIORAL|CBT|In this intervention, the participant receives therapist supported self-help CBT. The participant randomized to this arm can choose to receive the treatment via an online treatment platform or via bibliotherapy, i.e., a self-help book.The treatment is comprised of 12 modules or chapters, which entail information about stress management techniques including behavioral activation and exposure. The participant that chooses online CBT is guided by a therapist who provides feedback on homework assignments through written asynchronous text messages; the patient who chooses bibliotherapy is guided by a therapist in typically 2 to 5 face-to-face sessions at a primary care clinic.
224221777|NCT01907737|OTHER|Sham PNS|No current will be delivered to the radial, ulnar and median nerves.
224221778|NCT00851032|OTHER|Molecular Profiling Analyses|Molecular profiling analyses from advanced cancer participants' stored tissue bank samples.
224221779|NCT03775356|OTHER|Treatment of hypotension and/or reduction of anesthetics|The treatment of hypotension can be done by the responsible anesthetist according to the clinical standard operations including any accepted drug typically used in this hospital. The reduction of anesthetics can be done either by reducing the volatile end tidal anesthetics concentration (ETAC) or the infusion rate of propofol.
224221780|NCT03491878|PROCEDURE|Three dimensional laparoscopic|Three dimensional laparoscopic cholecystectomy including segments IVB and V
224221781|NCT03491878|PROCEDURE|Open|Open cholecystectomy including segments IVB and V
224221782|NCT00174733|DRUG|Ciclesonide (XRP1526)|
224318315|NCT01713452|PROCEDURE|Purse string closure|"1. An incision around the stoma will be made with 2-3 mm circumferential margins. This dissection along the mucocutaneous junction will then be made to the fascial defect. Re-establishment of bowel continuity will them be performed. If the circumferential incision does not provide adequate exposure, the incision can be converted to an elliptical one. Thereafter, it will be closed primarily with staples, similar to the primary closure group.~2. Following ostomy closure, the subcutaneous tissues will be irrigated. A 2-0 monocryl subcuticular purse string stitch will then be placed and cinched to a 1cm diameter. This opening will then be packed with Nu-Gauze as a wick dressing.~3. Diameter of the skin defect should then be measured.~4. A postoperative photo will then be taken."
223633002|NCT06596551|BEHAVIORAL|Pre-Post ARCH Intervention|Stroke dyads, consisting of a survivor and primary family caregiver, will engage in a 4 weekly, 1.5 hour experiential dyadic sessions, totalling 6 hours of participation. In Week 1, dyads acknowledge the losses occurring after the stroke to normalize feelings of grief and sadness and find comfort within the familial space. In Week 2, dyads interpret their post-stroke losses within the framework of their existing knowledge for managing adversities (strengths, resources, and values) and identify changes that are most meaningful to them. In Week 3, dyads set specific, measurable, and achievable goals to actualize the meaningful changes identified in Week 2. Finally in Week 4, dyads bring together their individually derived strengths from the previous sessions to culminate into strengthened dyadic bonds. The exercise will also encourage participants to expand beyond the dyadic space to seek support from their communities, social networks and care services that are available to them.
223633003|NCT06596239|DEVICE|lower-clear-plate-based intermaxillary traction (LCP-IMT)|The patient is instructed to apply elastics between the upper molar bands and the hooks on the lower clear plates.
223633004|NCT06596239|DEVICE|Removable mandibular retractor (RMR)|An appliance is worn on the upper jaw, which affects the lower jaw by using an inferiorly extended labial bow.
223633005|NCT06729658|DRUG|Madopar|Experimental group participants will receive Madopar 125mg for 6 days.
223764432|NCT06533969|PROCEDURE|Epidural Spinal Cord Stimulation|"This will be a one time surgery lasting no more than 2 hours where ESCS electrodes will be connected to an external stimulator approved for human research. Stimulation intensity and parameters will be configured before each session for optimal upper extremity motor function.~The ESCS approach will include surgical implantation of temporarily placed leads in the cervical epidural space and connection cables tunneled percutaneously through the skin for \<30 days"
224221783|NCT04756609|PROCEDURE|Systematic offer of nurse-driven SARS-CoV-2 screening combined with usual practice|"I- A SARS-CoV2 self-administered questionnaire about SARS-CoV2 symptoms, possibilities of close contacts, risk exposure situations and socio-demographic characteristics will be offered to patients included who are capable of filling it out.~* The patient will fill out the questionnaire and hand it in to the nurse caring for him/her.~* The nurse, regardless of the answers to the questionnaire, will offer the SARS-CoV2 screening.~* A nasopharyngeal swab for SARS-CoV2 will be carried out.~* A patient will be considered as symptomatic if he/she presents one or more symptoms listed in the questionnaire.~* For symptomatic patients, a SARS-CoV2 for multiplex PCR will be carried out. This analysis takes 75 minutes.~* For asymptomatic patients, a RT-LAMP test will be carried out. This analysis takes 5 to 15 minutes."
224221784|NCT04756609|OTHER|Usual emergency department practice with physician-directed diagnostic testing|The physician offers a SARS-CoV2 test according to current recommendations. The tests are prescribed as a means of diagnosis for patients presenting symptoms suggestive of Covid-19 or as a means of diagnosis for patients requiring hospitalisation for another cause, before their transfer to hospital. Patients will be cared for according to usual procedures of each hospital. Patients tested positive will be asked to fill out the DEPIST-COVID questionnaire. Patients who had not completed it will be contacted by phone to answer the questions over the phone.
224221785|NCT00752661|DRUG|Tramadol Hydrochloride; JNS013|
224221786|NCT00359853|DRUG|Oral norfloxacin|
224221787|NCT05869097|DRUG|Trifluridine/Tipiracil|TAS-102 35 mg/m²orally twice a day on days 1-5 and 8-12, every 28 days
224221788|NCT05869097|DRUG|Bevacizumab|Bevacizumab 5 mg /kg, intravenously on days 1,15,every 28 days
224221789|NCT02384681|OTHER|Exposure to auditory fatigue|12-hour auditory exposure
224221790|NCT05322564|OTHER|Standardized opiate prescription|The standardized prescription will include a single opiate, with a fixed dose and number of tablets. It will also include non-opiate adjuncts commonly prescribed at our institution, namely acetaminophen and an anti-inflammatory medication.
224221791|NCT02030574|DRUG|Gemcitabine and fractionated cisplatin (combination treatment)|1 Cycle = 21 days. GC x 4 cycles ----\> cystectomy Gemcitabine: 1000mg/m2, days 1 and 8 Cisplatin: 35mg/m2, days 1 and 8
223633006|NCT06729658|DRUG|Placebo|Control group participants will receive placebo for 6 days.
223633007|NCT03066869|DRUG|H.P. ACTHAR GEL|H.P. Acthar Gel is an adrenocorticotropic hormone (ACTH) analogue indicated for ophthalmic diseases.
223633008|NCT04272242|DRUG|Dolutegravir (DTG)|Administered orally
223633009|NCT04272242|DRUG|Isoniazid (INH)|Administered orally
223633010|NCT04272242|DRUG|Rifapentine (RPT)|Administered orally
223633011|NCT04272242|DRUG|Antiretroviral Therapy (ART)|Participants remained on DTG-based ARV treatment with 2 NRTIs (excluding TAF) during the study. NRTIs were not provided by the study. Arm 1 participants took non-study supply of DTG for morning doses, and study-supplied DTG for evening doses. For Arm 2 participants, DTG was to have come from non-study ARV supply.
223633012|NCT04272242|DIETARY_SUPPLEMENT|Pyridoxine (Vitamin B6)|Participants received 25 or 50 mg of pyridoxine (vitamin B6) with each dose of INH, based on the current local, national, or international dosing guidelines. Pyridoxine was not provided by the study.
223633013|NCT06595849|BEHAVIORAL|4-week feeling tone intervention program|Participants will take part in a 4-week mindfulness of feeling tone intervention program taught by a registered mindfulness teacher, who is also a registered clinical psychologist. The intervention program includes 4 sessions, with each session lasting for about 2 hours. The program is taught in Cantonese, in a group setting, live online (via Zoom). Participants will practice meditation practices during the session, explore themes of the week, review and explore their meditation experiences. They will also practice meditation practices daily for at least 30 minutes at home, with meditation audio recordings provided by the teacher.
223633014|NCT06591052|OTHER|Passive stretching|The physiotherapist positioned each muscle in its maximum lengthened state and held it there for 30 seconds. This process was repeated three times, with a 30-second rest interval between each stretch of the different muscle groups.
223633015|NCT06591052|OTHER|PNF stretching|The physiotherapist initially positioned each muscle in its most extended state, similar to the positions used in passive stretching. In this extended position, the participants performed an isometric contraction against maximal resistance in the antagonist direction for 5-8 seconds. Following the isometric contraction, participants were instructed to actively relax, and after a 5-second waiting period to ensure complete relaxation, the movement range was passively increased. The new end point of the extended range of motion was held for 30 seconds. This stretching protocol was repeated three times for each muscle group, with a 30-second rest period between each stretch.
224221792|NCT02363582|OTHER|formula|An infant formula contains prebiotics and lactoferrin
224221793|NCT01823549|OTHER|questionnaire administration|Ancillary studies
224221794|NCT05747079|OTHER|Rehabilitation|All patients complete rehabilitation under supervision of their own physiotherapist. The investigators will provide some guidelines and criteria, but it is the physiotherapist's choice how to implement these guidelines in clinical practice.
224221795|NCT05747079|PROCEDURE|Optional delayed anterior cruciate ligament reconstruction|"If a patient complains about persistent symptomatic instability of the knee or the inability to progress in rehabilitation, delayed surgery can be considered. ACL insufficiency induced instability in combination with a positive pivot shift and an additional MRI are needed to confirm the cause of instability.~This surgery will not be performed within the first 12 weeks after the ACL injury."
224221796|NCT05747079|PROCEDURE|Immediate anterior cruciate ligament reconstruction|"No guidelines on type of ACL reconstruction will be imposed to keep the trial pragmatic. The decision of graft type and surgery technique is a clinical decision made by the orthopaedic surgeons of the participating centra.~This surgery will be performed within 12 weeks after the ACL injury."
224221797|NCT00908752|DRUG|Brivanib|Tablets, Oral, 200 mg, once daily, until disease progression or toxicity
224221798|NCT00908752|OTHER|Brivanib Placebo|Tablets, Oral, 0 mg, once daily, until disease progression or toxicity
223633016|NCT06592950|OTHER|No treatment given|Online survey
224221799|NCT00908752|PROCEDURE|TACE Therapy|Trans-Arterial Chemo-Embolization Therapy
224221800|NCT02840656|OTHER|oropharyngeal swabbing|microbiological sampling will be performed on buccal mucosa with standard swab. only one sample will be done
224221801|NCT02840656|OTHER|rectal swabbing|same process as oropharyngeal swabbing will be used to collect rectal microbiological sample
224318316|NCT01713452|PROCEDURE|Primary closure|"1. An elliptical incision (extending transversely) will be made with 2-3 mm superior/inferior margins around the mucocutaneous junction. Dissection will then be made in a perpendicular fashion through the subcutaneous tissue with tapering near the fascial defect. Re-establishment of bowel continuity will then be performed.~2. Following ostomy closure, the subcutaneous tissue will be irrigated and the skin will be closed tight with staples placed at close intervals (\<1.5cm). No subcutaneous drains will be placed.~3. Length of the incision should be measured in centimeters.~4. A postoperative photo will then be taken."
224318317|NCT06548178|DRUG|T-DXd|T-DXd (5.4 mg/kg Q3W on Day 1) ×6 cycles.
224318318|NCT06548178|DRUG|THP|Docetaxel (75 mg/m2 Q3W on Day 1) concurrent with trastuzumab (8 mg/kg loading dose followed by 6 mg/kg Q3W on Day 1) and pertuzumab (840 mg loading dose followed by 420 mg Q3W on Day 1) × 6 cycles.
224318319|NCT02931929|DRUG|68Ga-NeoBOMB1, 2-vial kit|intravenous application of a radiopharmaceutical for Positron Emission tomography (PET)
224318320|NCT06551766|DEVICE|Photosensitive hydrogel|In the photosensitive hydrogel group, the anastomosis of the lacrimal cyst mucosal flap and the nasal mucoperiosteal flap was achieved by photosensitive hydrogel.
224318321|NCT06551766|DEVICE|6-0 absorbable stitches|In the suture fixation group, the anastomosis of the lacrimal cyst mucosal flap and the nasal mucoperiosteal flap was achieved by two stitches using 6-0 absorbable wire.
224318322|NCT02191644|DIETARY_SUPPLEMENT|Dietary intervention-refined rice|Subjects in the control group maintained the usual refined-rice diet.
224318323|NCT02191644|DIETARY_SUPPLEMENT|Dietary intervention-whole grains and legumes|Subjects in the whole-grain group replaced refined rice with a mix of 1/3 legumes, 1/3 barley, and 1/3 wild rice three times per day, and increased vegetable intake to at least 6 units (30-70 g/unit) per day for sufficient dietary fiber intake.
223633017|NCT06592950|OTHER|No treatment given|Interviews
223633018|NCT06592469|PROCEDURE|Ureteroscopy|URS is done to each group to reveal outcome of stone free rate in fresh versus recurrent cases of stone ureter
223633019|NCT06594666|DEVICE|VR/AR visual training group|Wear glasses for correction combined with VR/AR visual training in the first 6 months, and terminate the training for follow-up observation in the last 6 months. Regular follow-up every 3 months, with a total follow-up time of 1 year.
223633020|NCT06587711|PROCEDURE|acupuncture treatment|Patients in experimental group received acupuncture at specific acupoint on the face, patients in control group received sham acupuncture at non-acupoint on the face.
223633021|NCT06589193|OTHER|HOCl|10ml,twice a day
223633022|NCT06589193|OTHER|CHX|10ml,twice a day
224221802|NCT00520507|DRUG|Olanzapine|Olanzapine will be taken once daily at 6pm for 1 month. Dosing will be titrated up to 5mg and then changed as clinically indicated.
224221803|NCT00520507|DRUG|Placebo|An inactive form of the treatment will be taken once daily at 6pm for 1 month.
224221804|NCT05582733|OTHER|Cervical spine manipulation|hot pack for 10 minutes will be applied followed by cervical manipulation (chin hold kaltenborn) once and then stretching
224318324|NCT03179423|DRUG|GNbAC1|Monthly IV repeated dose
224318325|NCT03179423|DRUG|Placebo|Monthly IV repeated dose
224318326|NCT00775125|DRUG|Telaprevir; Darunavir; Ritonavir; Fosamprenavir|
223633023|NCT06842615|DIAGNOSTIC_TEST|Pantum detect test|epitope detection in monocyte (EDIM)
223633024|NCT06593145|BIOLOGICAL|FCTX-CL19-1 (Tarcidomgen Kimleucel)|"It will be administered only by Investigators during hospitalization. Each patient will receive one administration of IMP on Day 0:~* administration route - intravenous~* cell dose: 0,2 x 106 -2 x 106 CAR T cells per kilogram of patient body weight"
223764433|NCT06533969|DEVICE|Electrocorticographic|Neural activity during upper and/or lower extremity tasks will be recorded to characterize the changes that occur in the signals before, during, and after task performance. Observed characteristics of neural signals that are related to the initiation, continuation, or termination of movement will be used to derive control signals that can trigger or enable assistive devices.
224221805|NCT05582733|OTHER|traction|Hot pack will be applied followed by sustained pressure or MPR for 90 sec and then stretching.
224221806|NCT02699580|DEVICE|lateral rectus recession with biodegradable collagen implant|Exotropia was treated with bilateral lateral rectus recession procedure. Lateral rectus recession was done. After lateral rectus recession, no degradable collagen implant was placed in the area, where lateral rectus was original inserted. One eye was randomly selected for the comparison.
223764434|NCT06533969|DEVICE|Electroencephalographic|Neural activity during upper and/or lower extremity tasks will be recorded to characterize the changes that occur in the signals before, during, and after task performance. Observed characteristics of neural signals that are related to the initiation, continuation, or termination of movement will be used to derive control signals that can trigger or enable assistive devices.
223633026|NCT06998849|DIAGNOSTIC_TEST|Perfusion index|The perfusion index (PI) is defined as the ratio of pulsatile light absorption to continuous light absorption, denoted as AC/DC. Initially used as a quality signal indicator in pulse oximetry, PI has increasingly been recognized for its potential in non-invasive hemodynamic monitoring. Since PI changes with peripheral blood flow, it may reflect peripheral temperature gradients and, consequently, thermoregulatory responses like peripheral vasoconstriction. Studies have reported that the core-to-peripheral temperature difference correlates with peripheral PI. The findings suggest that both peripheral and core temperatures contribute to the threshold for shivering and that PI reflects the vasoconstriction induced by thermoregulatory responses that precede shivering
223633027|NCT07000019|BEHAVIORAL|CARAT: combined aphasia and robot-assisted arm therapy|Participants will receive 18 sessions of robot-assisted arm therapy combined with a standardized picture-word verification therapy task with the goal of improving language and arm movements.
223633028|NCT07000019|BEHAVIORAL|Robot-assisted arm therapy|Participants will receive 18 sessions of robot-assisted arm therapy with the goal of improving arm movements.
223633029|NCT06999408|DEVICE|Scalp tattoo|A micropigmentation scalp tattoo will be applied at baseline to mark consistent photographic sites.
223633030|NCT06999408|DEVICE|Canfield HairMetrix®|Canfield HairMetrix® imaging will be utilized to capture global and trichoscopic hair measurements.
223633031|NCT06999408|DEVICE|TargetCool|Boosting will be used to apply exosomes
223633032|NCT06999408|DEVICE|Microneedle-facilitated lidocaine application|Microneedling will be performed to a depth of 0.5 mm.
223633033|NCT06998342|RADIATION|Short course radiation|The radiation arm in this study involves Short Course Radiation Therapy (SCRT), which consists of 5 fractions delivered twice a week (either Monday/Thursday or Tuesday/Friday).
223633034|NCT06998342|OTHER|Active Surveillance|The Active Surveillance arm (Group M) aims to monitor participants with moderate-risk cutaneous squamous cell carcinoma (cSCC) after surgical resection, without immediate intervention unless disease progression occurs. Participants will undergo regular clinical evaluations, physical exams, and skin checks to detect new lesions or signs of recurrence. Imaging, including ultrasound and CT/MRI scans, will be performed every 6 months for up to 3 years to monitor for metastasis or progression. Blood samples will be collected for future biomarker analysis to identify indicators of disease recurrence. Participants will also complete quality of life assessments using the EORTC QLQ-C30 and Skin Cancer Index (SCI) to evaluate the impact of surveillance on their daily lives. If disease progression is detected, radiation therapy may be initiated. The study will track overall survival without initiating radiation, as well as disease progression and quality of life outcomes, to determine if active s
223633035|NCT06998745|BEHAVIORAL|Medication Therapy Management (MTM) model|MTM model comprising five core elements: Medication Therapy Review (MTR), Personal Medication Record (PMR), Medication-Related Action Plan (MAP), interventions \& referrals, and documentation \& follow-up
224221807|NCT02699580|PROCEDURE|Lateral rectus recession without biodegradable collagen implantation|Exotropia was treated with bilateral lateral rectus recession procedure. Lateral rectus recession was done in the other eye without placing biodegradable collagen implantation.
224221808|NCT04253431|DEVICE|Droplet lancing device (HTL-Strefa S.A.)|
224221809|NCT04253431|DEVICE|Microlet 2 lancing device (Bayer)|
224221810|NCT04253431|DEVICE|OneTouch Delicia lancing device (LifeScan)|
224221811|NCT04253431|DEVICE|ReliOn lancing device (ReliOn)|
224221812|NCT04253431|DEVICE|Accu-Chek Softclix lancing device (Roche)|
223633036|NCT05465174|DRUG|Tovorafenib|Given orally
223633037|NCT02711891|DRUG|Loperamide|Following lance one, 0.2 grams of loperamide 5% gel was applied from a sterile syringe to the participants previous lance site within an 8 mm diameter circular plastic mold. The loperamide gel was rubbed lightly on the skin surface for one minute using a gloved finger swirled into the mold site. The mold was removed and the site was covered with a transparent occlusive dressing for 30 minutes. At 30 minutes the gel was removed with gauze, the skin cleaned with an alcohol wipe and the second lance was done within the same location as the first. The loperamide gel was also swabbed to the forearm within the 8 mm mold and left in place for 30 minutes.
223633038|NCT02711891|DRUG|Drug, placebo gel|Following lance one, 0.2 grams of gel alone was applied to the participants previous lance site within an 8mm diameter circular plastic mold. The gel was rubbed lightly on the skin surface for one minute using a gloved finger swirled into the mold site. The mold was removed and the site was covered with a transparent occlusive dressing left in place for 30 minutes. At 30 minutes the gel was removed with gauze, the skin cleaned with an alcohol wipe and the second lance was done within the same location as the first. The placebo gel was also swabbed to the forearm within the 8 mm mold and left in place for 30 minutes.
223633039|NCT04883281|RADIATION|Intensity modulated radiation therapy (IMRT) with or without chemotherapy|Intensity modulated radiation therapy (IMRT) with or without chemotherapy (if given, either cisplatin, cetuximab, or carboplatin-paclitaxel)
223633040|NCT04883281|DRUG|cisplatin, cetuximab, or carboplatin-paclitaxel|chemotherapy (if given, either cisplatin, cetuximab, or carboplatin-paclitaxel)
223764435|NCT05576025|OTHER|Lifestyle intervention (cold exposure)|Participants will undergo two cold exposures with different shivering intensities. Mild shivering is defined as energy expenditure increased by 1.5-fold compared to the resting metabolic rate. Moderate shivering is 2.5-fold increase in metabolic rate.
223764436|NCT06062056|OTHER|EHR alert|An EHR alert will be fired if a behavioral health patient is missing a COVID-19 or influenza vaccine.
224221813|NCT04253431|DEVICE|BGStar lancing device (Sanofi Aventis)|
224221814|NCT04253431|DEVICE|Ultra-Fine 33G lancets (BD)|
224221815|NCT04253431|DEVICE|Droplet 33G lancets (HTL-Strefa S.A.)|
224221816|NCT04253431|DEVICE|OneTouch Delicia Extra Fine 33G lancets (LifeScan)|
224221817|NCT04253431|DEVICE|HaemoFine 33G lancets (HTL-Strefa S.A.)|
224221818|NCT04253431|DEVICE|Softclix 28 G lancets (Roche)|
224221819|NCT04253431|DEVICE|ReliOn Ultra-Thin Plus 33G lancets (ReliOn)|
224221820|NCT04253431|DEVICE|GlucoJect Dual S lancing device (Menarini)|
224221821|NCT04253431|DEVICE|Microlet 28G lancets (Bayer)|
223633041|NCT06602661|PROCEDURE|Fissureless Lobectomy with Reinforced Staple Lines|"This intervention involves performing a fissureless lobectomy, a type of lung surgery where the lobes of the lung are removed without dissecting the fissures between them. The procedure utilizes the ECHELON™ 3000 stapler equipped with the ENDOPATH™ stapler line reinforcement. The ENDOPATH™ device uses bioabsorbable buttress material made from Polyglactin and Polydioxanone, designed to enhance the durability and effectiveness of the staple line.~The reinforcement tool is a novel preloaded device with a click and go mechanism, making it easy to load and use during surgery.~The primary objective is to reduce the average duration of hospital length of stay (LOS) directly caused by prolonged air leak (PAL). Secondary objectives include improving intraoperative characteristics (such as duration and amount of blood loss) and postoperative outcomes (such as incidence and duration of PALs, number of chest tube days, and incidence of hospital."
223633042|NCT06602661|PROCEDURE|Fissureless Lobectomy with Non-Reinforced Staple Lines|"This intervention involves performing a fissureless lobectomy, a type of lung surgery where the lobes of the lung are removed without dissecting the fissures between them. The procedure utilizes the ECHELON™ 3000 stapler without any additional reinforcement. This means the staple lines are created using the standard stapler without the use of bioabsorbable buttress materials.~The ECHELON™ 3000 stapler is used to divide the lung parenchyma, pulmonary artery branches, veins, and bronchus without any reinforcement, relying solely on the standard stapling mechanism."
223633043|NCT03277482|DRUG|Durvalumab|Durvalumab is given by intravenous infusion every 4 weeks for a maximum of 13 doses over 52 weeks. One cycle is defined as every 4 weeks. Each infusion will take approximately 1 hour.
223764437|NCT06062056|BEHAVIORAL|Motivational Interviewing|In response to the alert and using support tools in the EHR, the behavioral health clinician will integrate motivational interviewing into the counseling session to discuss vaccine hesitancy (if it is deemed appropriate based on patient needs and clinical judgment).
224221822|NCT04253431|DEVICE|BGStar Ultra-Thin 33G lancets (Sanofi Aventis)|
224221823|NCT00045448|DRUG|alvocidib|
224221824|NCT00045448|DRUG|docetaxel|
224221825|NCT01508026|DRUG|Nebivolol and Valsartan 1|Fixed Dose Combination Nebivolol 5 mg and Valsartan 80 mg, oral administration, then dose doubled at Week 11 to Fixed Dose Combination Nebivolol 10 mg and Valsartan 160 mg, oral administration
224221826|NCT01508026|DRUG|Nebivolol and Valsartan 2|Fixed Dose Combination Nebivolol 5 mg and Valsartan 160 mg, oral administration then dose doubled at Week 11 to Fixed Dose Combination Nebivolol 10 mg and Valsartan 320 mg, oral administration
224221827|NCT01508026|DRUG|Nebivolol and Valsartan 3|Fixed Dose Combination Nebivolol 10 mg and Valsartan 160 mg, oral administration then dose doubled at Week 11 to Fixed Dose Combination Nebivolol 20 mg and Valsartan 320 mg, oral administration
224221828|NCT01508026|DRUG|Nebivolol 1|Nebivolol Monotherapy 5 mg, oral administration, then dose doubled to at Week 11 to Nebivolol Monotherapy 10 mg, oral administration
224221829|NCT01508026|DRUG|Nebivolol 2|Nebivolol Monotherapy 20 mg, oral administration, then dose doubled to at Week 11 to Nebivolol Monotherapy 40mg, oral administration
224221830|NCT01508026|DRUG|Valsartan 1|Valsartan Monotherapy 80 mg, oral administration, then dose doubled to at Week 11 to Valsartan Monotherapy, 160 mg, oral administration
224221831|NCT01508026|DRUG|Valsartan 2|Valsartan Monotherapy 160 mg, oral administration, then dose doubled to at Week 11 to Valsartan Monotherapy, 320 mg, oral administration
224221832|NCT01508026|DRUG|Placebo|Dose matched placebo, oral administration
224221833|NCT00678392|DRUG|Axitinib (AG-013736)|axitinib will be given at a starting dose of 5 mg twice daily \[BID\] with continuous dosing
224221834|NCT00678392|DRUG|Sorafenib|sorafenib will be given at a dose of 400 mg twice daily \[BID\] with continuous dosing
224221835|NCT05117099|BEHAVIORAL|Family Check-Up|This intervention includes access to the Family Check-Up Online website and telehealth coaching provided by trained mental health providers. A minimum of 5 coaching sessions will be offered.
224221836|NCT03603756|DRUG|SHR-1210|a novel anti-PD-1 antibody
224221837|NCT03603756|DRUG|Apatinib|a VEGFR-2 tyrosine kinase inhibitor
223764438|NCT06062056|BEHAVIORAL|Warm hand off to nurse|For patients interested in vaccination following motivational interviewing, the behavioral health clinician will do a warm hand off to a nurse for vaccination
223764439|NCT05684770|OTHER|4G tablet|Participants will receive for the whole period of study a 4G tablet in order to fill questionnaires, learn information about their drugs (patient education), have a remote consultation and evaluate treatment compliance.
224221838|NCT03603756|DRUG|Irinotecan Injection|cytotoxic agent that binds to topoisomerase I
224221839|NCT03603756|DRUG|Paclitaxel liposome|cytotoxic agent that prevent depolymerization of cellular microtubules
224221840|NCT03603756|DRUG|Nedaplatin|cytotoxic agent that cross-links and denatures strands of DNA
224221841|NCT03619252|BIOLOGICAL|Vaccination with pneumococcal conjugate vaccine (PCV13)|Vaccination with pneumococcal conjugate vaccine - PCV13 (Prevnar 13/Prevenar 13, Pfizer Inc) containing saccharides from serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F individually conjugated to nontoxic diphtheria cross-reactive material. Vaccination regimen: 3 doses monthly, with a booster dose 6 months later.
224221842|NCT03619252|DRUG|Standard Antibacterial Prophylaxis|Levofloxacin 500 mg once daily during the median four cycles of treatment by novel agents.
224221843|NCT03994588|PROCEDURE|Intraperitoneal Mesh hernia repair|The mesh will be inserted intraperitoneally for complex ventral hernia repair and fixed according the previously described ADMIR technique.
224221844|NCT03113058|COMBINATION_PRODUCT|Adoptive transfer of γδT cells|Patients are treated via intravenous infusion of in vitro-activated allogeneic γδ Tcells every two weeks, 12 times in total (6 months).
224221845|NCT06544798|GENETIC|AAV2-hAQP1|Administration of a prespecified concentration of AAV2-hAQP1 via Stensen's duct to each parotid gland
224221846|NCT01405820|DRUG|natalizumab IV|natalizumab for IV Infusion
224221847|NCT01405820|DRUG|natalizumab SC|natalizumab for Subcutaneous Injection
224221848|NCT01405820|DRUG|IV Placebo|Intravenous placebo to natalizumab
224221849|NCT01405820|DRUG|SC Placebo|Subcutaneous placebo to natalizumab
224318327|NCT03106987|DRUG|Active Comparator: Olaparib tablets|"Olaparib~300mg Olaparib tablets taken orally twice daily (except where this dose and formulation was previously not tolerated) until objective radiological disease progression as per RECIST 1.1 or as long as in the Investigator's opinion they are benefiting from treatment and they do not meet any other discontinuation criteria."
223633044|NCT03277482|DRUG|Tremelimumab|Tremelimumab is given by intravenous infusion every 4 weeks for a maximum of 4 doses over 16 weeks. One cycle is defined as every 4 weeks. If receiving both durvalumab and tremelimumab for the first 4 cycles, they will be given on the same day. Each infusion will take approximately 1 hour
223633045|NCT03277482|RADIATION|Radiation Therapy|Radiation treatment will begin on the same day as the first immunotherapy infusion or on the following day. The radiation treatment course is either 1 day or 5 days.
223633046|NCT06723106|DRUG|RAY121|Injection
224221850|NCT02925273|OTHER|palmar grasp without dorsal stimulation|"The patient will then be asked to keep the arms at 90 degrees and the researcher will slightly stroke palm and fingers of both hands of the patient simultaneously. After completion of each technique, the presence or absence of the response will be noted. In addition, the prominence of the response on the rating scale will be obtained as explained below.~The scaling of the grasp response is as followed:~1. Flexion at the distal interphalangeal joint of the hand~2. Flexion at the proximal interphalangeal joint of the hand~3. Flexion at the metacarpal-phalangeal joint of the hand"
224221851|NCT02925273|OTHER|standard palmar grasp test with dorsal stimulation|The patient will be asked to put their arms at 90 degrees and the researcher will hold one hand at the wrist and dorsum of the palm and lightly stroke the palm and fingers. The patient will be instructed to relax hands and not hold on while doing the grasp and see if the response persists. The same technique will be repeated for the patient's other hand.
224221852|NCT03421652|DRUG|Nivolumab|Patients receive nivolumab IV over 30 minutes on day 1. Treatment repeats every 14 days (2 weeks) for up to 14 courses (6 months) in the absence of disease progression or unacceptable toxicity. Beginning 3 days of course 1, patients undergo radiation therapy over 32-35 on weeks 1, 3, 5, 7 and 9.
224221853|NCT03421652|RADIATION|Radiation|Beginning 3 days of course 1, patients undergo radiation therapy over 32-35 on weeks 1, 3, 5, 7 and 9.
224318328|NCT03106987|DRUG|Placebo|"Placebo~300mg placebo tablets taken orally twice daily (except where this dose and formulation was previously not tolerated) until objective radiological disease progression as per RECIST 1.1 or as long as in the Investigator's opinion they are benefiting from treatment and they do not meet any other discontinuation criteria."
224318329|NCT04368351|DIETARY_SUPPLEMENT|SivoMixx (200 billion)|Composition of SivoMixx: Streptococcus thermophilus DSM322245, Bifidobacterium lactis DSM 32246, Bifidobacterium lactis DSM 32247, Lactobacillus acidophilus DSM 32241, Lactobacillus helveticus DSM 32242, Lactobacillus paracasei DSM 32243, Lactobacillus plantarum DSM 32244, Lactobacillus brevis DSM 27961 (NB: DSM n°... : bacterial strain identification code)
223633047|NCT06706466|OTHER|observational study|Non-interventional
223633048|NCT06705608|DRUG|Fingolimod|patients who received fingolimod for treating RRMS
223633049|NCT06705608|DRUG|Natalizumab|patients who received natalizumab for treating RRMS (active comparator)
223633050|NCT06705608|DRUG|Dimethyl fumarate (DMF)|patients who received dimethyl fumarate for treating RRMS (active comparator)
223633051|NCT06705608|DRUG|Alemtuzumab|patients who received alemtuzumab for treating RRMS (active comparator)
223633052|NCT06705608|DRUG|Teriflunomide|patients who received teriflunomide for treating RRMS (active comparator)
223633053|NCT06705231|BEHAVIORAL|The Aarhus-intervention|A multifactorial family-centered lifestyle intervention with a maximum duration of one year, corresponding to three-four visits. Participants were offered complimentary weekly supervised physical activity. The day-to-day intervention was managed by specialized nurses at local healthcare centers, at the participants' homes, or in a local clinic.
223633054|NCT06578039|BIOLOGICAL|umbilical cord-derived mesenchymal stem cell|allogeneic umbilical cord-derived mesenchymal stem cell
223633055|NCT03863795|OTHER|Survey Administration|Respond to SurveyGizmo survey online
223633056|NCT00150436|DRUG|Pregabalin|
223633057|NCT05527977|BEHAVIORAL|Compensation Incentives to improve Clinical Documentation|"The investigators have identified six Diagnoses of Interest for the initiative. For each Diagnosis of Interest, the investigators have specified a series of clinically significant diagnostic details. Each physician will receive a compensation bonus from a pool of $20,000 based on the absolute number of times that he or she appropriately documented a Diagnosis of Interest.~The investigators will use SQL Server Management Studio 18.0 to create an initial dataset using ICD-10 codes from office visits during which a Diagnosis of Interest was addressed. The investigators will compare documentation during the 12-week against a 6-week period prior to the intervention. The 6-week period will not be used to determine compensation bonuses. Two blinded research assistants will review H\&P's and progress notes from extracted visits to tabulate the number of times that clinical documentation met expectations."
223633058|NCT02473848|DRUG|ingenol mebutate 500 ucg|Ingenol mebutate gel, 0.05%, commercially supplied in a box of 2 single use, unit dose tubes for topical application for each 25cm2, four conjunctive 25cm2 areas (100cm2) will be treated. If the 100 cm2 area is not cleared at Day 57 (+/- 3 Days), a second treatment cycle will be initiated with commercially supplied drug in a box of 2 single use, unit dose tubes for topical application for each 25cm2 and four conjunctive 25cm2 areas (100cm2 ) will be treated. In total for the first cycle, 4 commercially supplied boxes (8 unit dose tubes) will be used, and for the second cycle an additional 4 commercially supplied boxes (8 unit dose tubes) will be used (in total 8 boxes, 16 unit dose tubes per patient).
223633059|NCT05864859|OTHER|Simulation|In the simulation session, while 2 participants (1 midwife, 1 pregnant) performed the roles in accordance with the clinical scenario, the performance was recorded in the control room. A Wearable Pregnancy Simulator was worn by the student performing the pregnant role. During the simulation, the participants were able to interact with the facilitators when they had questions. The application time did not exceed 10 minutes.
224221854|NCT05120011|DIETARY_SUPPLEMENT|L-carnitine|L-carnitine-L-tartrate
224221855|NCT05120011|DIETARY_SUPPLEMENT|L-leucine|L-leucine
224318330|NCT04368351|DRUG|Azithromycin|dose: 500mg 1 cp / day (alternatively lopinavir/ritonavir cps 200/50 mg, 2 cps x 2 / day or darunavir 800 mg 1 cp / day + ritonavir 100 mg 1 cp / day or darunavir/cobicistat 800/150 mg 1 cp / day)
224318331|NCT04368351|DRUG|hydroxychloroquine|dose: 200 mg, 1 cp x 2 / day
224318332|NCT05931653|OTHER|Multimodal Physical therapy|• Multimodal Physical therapy: Hot pack for 15 mins, TENS for 15 mins, Ultrasound at 1.5 W/cm2 intensity for 5 mins, Soft tissue release for \<5-15 mins as per need, HVLA, PA Glides (Central and Transverse mobilizations) (10 sec each) x5 sets, Lumbar facet gapping (LFG) in side lying (10 sec 3 sets) and Lumbar rotational facet gapping (LRFG) in side lying (10 sec 3 sets). 03 days/week for 06 weeks.
223633060|NCT00436696|OTHER|Laboratory Biomarker Analysis|Correlative studies
223633061|NCT00381901|BIOLOGICAL|trastuzumab|
223633062|NCT00381901|GENETIC|polymorphism analysis|
223633063|NCT00381901|PROCEDURE|adjuvant therapy|
223633064|NCT05609292|DEVICE|observational|Infants will get their temperature measured with the liquid crystal thermometer. We are not providing any interventions as they will be in the care of a healthcare team.
223633065|NCT01786005|DEVICE|Transcranial magnetic stimulation|
224221856|NCT06158061|DIAGNOSTIC_TEST|tryptase enzyme level|"In serum:~Three ml blood will be collected from all participants (patients and controls) by aseptic venipuncture into redtop plain glass tubes. Blood samples will be allowed to coagulate during 30-60 minutes. Serum will be obtained by centrifugation at t 1262 g for 10 minutes, aliquoted, and immediately frozen at -20°C until analyzed to determine serum tryptase level. Serum tryptase concentration will be assessed by a commercially available double antibody sandwich enzyme-linked immunosorbent assay (ELISA) kit.~In tissue:~Punch skin biopsies of 3mm depth will be taken under local anesthesia from back of Acne vulgaris patients and from matched sites of control subjects. Skin biopsies will be fixed in 10% formalin solution, and submitted to Pathology department in our institute for routine tissue processing by special stain for assessment of tissue tryptase level and number of mast cells tissue biopsy."
224221857|NCT00651456|DRUG|Standard Chemotherapy (Pemetrexed and Cisplatin)|"* Pemetrexed 500 mg/m² with previous Folic acid and vitamin B12 supplementation Day 1 (D1=D22, 6 cycles)~* Cisplatin 75 mg/m² Day 1 (D1=D22, 6 cycles)"
224221858|NCT00651456|DRUG|Standard Chemotherapy (Pemetrexed and Cisplatin) + Bevacizumab|"* Pemetrexed 500 mg/m² with previous Folic acid and vitamin B12 supplementation D1 (D1=D22, 6 cycles)~* Cisplatin 75 mg/m2 D1 (D1=D22, 6 cycles)~* Bevacizumab 15 mg/kg D1 (D1=D22, until progression)"
224221859|NCT02165670|DEVICE|Coronary stenting with CE-marked stent|
224221860|NCT02619799|DRUG|intrathecal magnesium sulphate,|comparision of effects of intrathecal magnesium sulphate with intrathecal midazolam when administered along with epidural 0.75% Ropivacaine
224221861|NCT02619799|DRUG|Intrathecal midazolam|comparision of effects of intrathecal magnesium sulphate with intrathecal midazolam when administered along with epidural 0.75% Ropivacaine
224221862|NCT02333409|PROCEDURE|Electroacupuncture|Electroacupuncture (EA) has been used as a part of Traditional Chinese Medicine (TCM) and the benefits and success of EA as a viable treatment option for acute and chronic pain of various origins have been well-recognised.electro-acupuncture (EA) is taken place as to give out the stimulation with fixed frequency, pulse width and current to acupuncture needle for further promotion of analgesics effects.
224221863|NCT05373875|DIAGNOSTIC_TEST|Doppler ultrasound|Doppler to listen and classify the arterial signal in the ankle and arm (Ankle brachial pressure index (ABPI))
224221864|NCT01142297|DEVICE|dental implant and modified dental implant|standard SLA surface and chemically modified surface
223633066|NCT01940952|DRUG|Zydena (Udenafil) 50mg + Donepezil 5mg or 10mg|
223633067|NCT01940952|DRUG|Placebo + Donepezil 5mg or 10mg|
223633068|NCT01940952|DRUG|Zydena (Udenafil) 100mg + Donepezil 5mg or 10mg|
223633069|NCT04944992|DRUG|Efinopegdutide 20 mg/mL|Subcutaneous injection in a dose-escalation administration of 2.4 mg, 5.0 mg, and 10.0 mg
224221865|NCT01635985|DRUG|AZD5423|solution for injection, administered as intravenous infusion Corr to total dose of 250 µg AZD5423
224221866|NCT01635985|DRUG|AZD5423|nebuliser suspension, inhaled via Spira, corr to approximately 300 µg lung deposited dose AZD5423
224221867|NCT01635985|DRUG|AZD5423|nebuliser suspension, inhaled via I-neb, corr to approximately 300 µg lung deposited dose AZD5423
224221868|NCT01635985|DRUG|AZD5423|nebuliser suspension to be administered orally, corr to a total dose of 1200 µg AZD5423
224221869|NCT01635985|DRUG|AZD5423|dry powder inhaled via Turbuhaler, corr to approximately 200 µg lung deposited dose AZD5423
224221870|NCT01635985|DRUG|AZD5423|dry powder inhaled via New Dry Powder Inhaler, corr to approximately 200 µg lung deposited dose AZD5423
223633070|NCT04944992|DRUG|Semaglutide 1.34 mg/mL|Subcutaneous injection in a dose-escalation administration of 0.25 mg, 0.5 mg, and 1.0 mg
223633071|NCT01295814|DRUG|Adalimumab|80 mg loading dose given subcutaneously followed by 40 mg dose given subcutaneously every two weeks over a twelve week period
223633072|NCT01295814|OTHER|inactive drug|80 mg loading dose given subcutaneously followed by 40 mg dose given subcutaneously every two weeks over a twelve week period
223633073|NCT05148468|DEVICE|Active spinal cord stimulation|Spinal cord stimulation is accomplished with surgically implanted epidural leads at Th3 - Th4 levels and a pulse generator implanted in subcutaneous fat. During active stimulation amplitude will be set to 90% paresthesia inducing threshold.
223633074|NCT05148468|DEVICE|Sham spinal cord stimulation|Spinal cord stimulation is accomplished with surgically implanted epidural leads at Th3 - Th4 levels and a pulse generator implanted in subcutaneous fat. During sham stimulation amplitude will be set to zero.
223633075|NCT02495506|OTHER|Cold stored platelets|Intervention: Leukoreduced platelet concentrates stored at 4 degrees C for treatment of bleeding after Cardiac surgery. Storage time for RCT platelet concentrates are up to 7 days.
223633076|NCT02495506|OTHER|Room temperature platelets|Intervention: Leukoreduced platelet concentrates stored at 22 degrees C for treatment of bleeding after Cardiac surgery. Storage time for RCT platelet concentrates are up to 7 days.
223633077|NCT01031212|DRUG|ASA404|Administered intravenously over 20 minutes weekly after chemotherapy
223633078|NCT01031212|DRUG|Cetuximab|Administered at 400mg/m2 over 120 minutes on day -7 and then 250mg/m2 over 60 minutes weekly thereafter
223633079|NCT01031212|DRUG|Carboplatin|Administered at fixed dose of AUC 6 intravenously on day 1 of each 3-week cycle
223633080|NCT01031212|DRUG|Paclitaxel|Administered over 3 hours at a fixed dose of 175mg/m2 intravenously on day 1 of each 3-week cycle
223764440|NCT05426174|BIOLOGICAL|mRNA NA vaccine|Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
223764441|NCT05426174|BIOLOGICAL|High Dose Quadrivalent Influenza Vaccine|Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
224221871|NCT02789007|OTHER|Assess the impact of parabolic flight|"MRI testing will be performed using a 3T MRI facility in Bordeaux close to Novespace (CHU Pellegrin).~Spatial cognition will be assessed using a battery of in-house virtual paradigms General cognitive performance testing will include a wide range of cognitive functions, and particularly executive control using the Cognition Battery Mental status will be assessed on a tablet computer using a visual analogue scale Vigilant attention will be determined using the 3-min Psychomotor Vigilance Test (PVT) Blood samples (5 mL per collection) will be collected prior to neuroimaging by venepuncture"
224318333|NCT05931653|OTHER|Proprioceptive training along with and Multimodal Physical therapy|"* Multimodal Physical Therapy: Hot pack-5 mins, TENS-5 mins, U.S (1.5 W/cm2)-5 mins, Soft tissue release-\<5-15 mins, HVLA, PA Glides (Central and Transverse)-10 sec each 5 sets, Lumbar facet gapping-10 sec 3 sets and Lumbar rotational facet gapping-10 sec 3 sets. 3 days/week for 6 weeks.~* Proprioceptive Training:1. Trunk Balance (15 mins). In sitting, kneeling, quadruped, and supine positions for 30 seconds to 2 minutes. Progression to more challenging. Each will be performed for 2-3 mins. In case of pain exercise will be interrupted and substituted with another one.~  2\. PNF Training (10-12 mins). Each PNF training-1 set of 15 reps with 30s rest between and 60s after 15 reps. Week 1-2 alternate full isometrics of trunk flexors and extensors for 10s in sitting. Week 3-4, 5s resisted concentric, 5s eccentric and 5s isometrics contractions in forward and backward bending. Week 5-6, alternate chop and lift movement patterns of upper extremities in diagonal and spiral directions for 10s."
224318334|NCT06633094|OTHER|Educational videos|Internet will be used to deliver educational videos to subjects enrolled in the home management arm of the study which will be available on the Carilion Clinic Orthopaedic Education YouTube Channel. This will consist of a prerecorded video made by the three pediatric orthopaedic surgeons on this study explaining the nature of buckle fractures and treatment. Participants will be sent a link to the video over email (an example of a similar video in clinical use at Carilion Orthopaedics and the script of the video can be found in the study document attached).
224318335|NCT00275574|PROCEDURE|acupuncture|acupuncture
224318336|NCT04495335|DEVICE|photobiomodulation|Laser treatment will complete using Gallium-Aluminum-Arsenide (GaA1As) diode laser and application will complete by laser energy immediately and three times a week for just 15 days after surgery.
223633081|NCT06245343|DEVICE|Functional inspiratory muscle training group|"Patients will be given fundamental inspiratory muscle training with the inspiratory muscle training device at 50% of the maximal inspiratory pressure 30 min/day, 3 days/week for 4 weeks online with a physiotherapist. On the other days of the week, the training will be used as a home program.~In the 5th week, the functional inspiratory muscle training program will be started. Before the program begins, patients will be shown the exercises in the functional inspiratory muscle training program. Patients will be given functional inspiratory muscle training with the inspiratory muscle training device at 50% of the maximal inspiratory pressure 30 min/day, 3 days/week for 4 weeks online with a physiotherapist. On the other days of the week, fundamental inspiratory muscle training will be used as a home program.~Pressure increases will be made weekly to 10 centimeters of water (cmH2O). Unsupervised training sessions will be followed by charts filled out by patients."
223633082|NCT06245343|DEVICE|Control group|The control group will not be given any training during the 8-week period. After the study, the treatment applied to the training group will also be applied to the control group in order to ensure that the patients in the control group are not ethically deprived of rehabilitation.
223633083|NCT04733469|BEHAVIORAL|Multimedia Psychoeducational Intervention|"The Multimedia Psychoeducational Intervention includes a multimedia educational video plus additional resources to reinforce the video content. The Multimedia Psychoeducational Intervention includes the following:~* A multimedia educational video about palliative care that is individually tailored to each patient's level of education and health literacy~* Take-home and online copies of the video for repeat viewing~* A video summary~* A question prompt list patients can use to ask clinicians more questions about palliative care~* Contact information and brochures for local palliative care programs"
223633084|NCT04733469|BEHAVIORAL|Enhanced Usual Care|"Enhanced Usual Care refers to usual care plus minor enhancement to improve quality and standardization. Enhanced Usual Care includes the following:~* Usual care~* A packet of flyers and handouts with general information on psychosocial oncology services derived from the American Society of Clinical Oncology (ASCO), Center to Advance Palliative Care (CAPC), and American Cancer Society (ACS)"
223633085|NCT02353208|OTHER|Sham Feeding of Bacon Bits|Bacon bits will be a commercially available produce which has been deemed safe for sale in Canada.
223633086|NCT02353208|OTHER|Placebo|Participants will not be asked to chew bacon bits
223633087|NCT01376258|DRUG|5ARI|dutasteride or finasteride
223633088|NCT03568214|OTHER|Exercise|The MICT will be prescribed according to two exercise intensity methods: individualized (i.e., VT1 and VT2) and standardized (i.e., HRR). The HIIT will be prescribed based on individual fitness (i.e., VO2max).
223633089|NCT03414983|BIOLOGICAL|Nivolumab|Specified dose on specified days
224221872|NCT02125188|DRUG|Desmopressin|Desmopressin 3ug/kg ivdrip before surgery
224221873|NCT02125188|DRUG|saline|saline 100ml ivdrip before surgery
224221874|NCT01614509|PROCEDURE|intravitreal bevacizumab monotherapy|The monotherapy group receive intravitreal injection of 1.25 mg/0.05 ml bevacizumab. The injections are performed using 0.5% proparacaine drops for topical anesthesia under sterile conditions. The bevacizumab is injected through the pars plana using a 30-gauge needle.
224318337|NCT02827695|BEHAVIORAL|SMASK|Medication adherence and BP monitoring
224318338|NCT02827695|BEHAVIORAL|EnhancedSC|Standard care without med reminder functions with healthy lifestyle texts
223633090|NCT03414983|DRUG|Oxaliplatin|Specified dose on specified days
223633091|NCT03414983|DRUG|Leucovorin|Specified dose on specified days
223633092|NCT03414983|DRUG|Fluorouracil|Specified dose on specified days
223633093|NCT03414983|DRUG|Bevacizumab|Specified dose on specified days
224318339|NCT00437918|DRUG|nateglinide|
224318340|NCT00437918|DRUG|acarbose|
224318341|NCT02392949|BEHAVIORAL|Passive mobilization|An anterior-posterior manual pressure act on the cervical spine of the subject
224318342|NCT02392949|OTHER|Placebo|The elbows will be put into a 90 deg elevated position and held for 5 secs, then back to resting position
224318343|NCT01867203|OTHER|Genotyping|DNA extraction from blood
223633094|NCT01254617|BIOLOGICAL|Cetuximab|Given IV
223633095|NCT01254617|OTHER|Laboratory Biomarker Analysis|Correlative studies
223633096|NCT01254617|DRUG|Lenalidomide|Given PO
224221875|NCT01614509|PROCEDURE|combined therapy of posterior subtenon triamcinolone acetonide and intravitreal bevacizumab injection|The combined group receive intravitreal injection of 1.25 mg/0.05 ml bevacizumab and posterior subtenon injection of 40 mg/1.0 ml triamcinolone acetonide. The injections are performed using 0.5% proparacaine drops for topical anesthesia under sterile conditions. The bevacizumab is injected through the pars plana using a 30-gauge needle and triamcinolone acetonide is injected through the posterior subtenon area (near macula) by using a 27-gauge needle at the same time.
224221876|NCT02336997|PROCEDURE|FAT-GRAFT|Liposuction will be performed and autologous fat graft will be harvest after washing with saline. Patients will receive autologous fat graft transplantation subdermally to expanded skin at the density of 0.1 ml/cm2.
224221877|NCT02336997|PROCEDURE|SVF-TRANSPLANTATION|Liposuction will be performed. SVF will be separated from autologous fat graft by collagenase digestion. Patients will receive resuspended SVF transplantation subdermally to expanded skin at the density of 1\*10e6 cells/cm2.
224221878|NCT02336997|PROCEDURE|PLACEBO|Saline will be injected into expanded skin.
224221879|NCT04468087|DRUG|Atazanavir|600 mg (2 capsules) twice daily on the first day and 300 mg (1 capsule) twice daily for the subsequent 9 days.
224221880|NCT04468087|DRUG|Daclatasvir 60 mg|initial dose of 120mg (2 capsules), followed by 60mg (1 capsule) once daily for 9 days.
224221881|NCT04468087|DRUG|Sofusbuvir + Daclastavir 60 mg|400 mg twice daily (2 capsules) on the first day and 400 mg (1 capsules) once daily for the subsequent 9 days (sofusbuvir) + initial dose of 120mg (2 capsules), followed by 60mg (1 capsule) once a day for 9 days (daclastavir)
224221882|NCT04468087|DRUG|Placebo Atazanavir|2 capsules twice daily on the first day and 1 capsule twice daily for the subsequent 9 days.
224221883|NCT04468087|DRUG|Placebo Daclatasvir 60 mg|2 capsules twice daily on the first day and 1 capsule twice daily for the subsequent 9 days.
224221884|NCT04468087|DRUG|Placebo Sofusbuvir + Daclatasvir 60 mg|2 capsules twice daily on the first day and 1 capsule twice daily for the subsequent 9 days.
224221885|NCT00813371|DEVICE|Airway Pressure Release Ventilation|Airway Pressure Release Ventilation (APRV) also known as Bi-Vent or Bi-Level ventilation is a time-cycled, pressure-limited mode of ventilation that allows spontaneous respiration throughout the ventilator cycle.
224221886|NCT00813371|DEVICE|ARDSnet protocol|ARDSnet protocol
224221887|NCT04988659|OTHER|Exposures|Exposures
224221888|NCT00570856|DRUG|Folic acid|Folic acid 5 mg/day
224221889|NCT00570856|DRUG|Placebo|Placebo similar to the folic acid tablets, 1/day
224221890|NCT05726773|PROCEDURE|Robot Assisted Therapy|In robotic rehabilitation, continuous passive range of motion (CPM), active assistive exercises and assistive continuous passive range of motion (CPM Plus) programs will be used.
224221891|NCT05726773|PROCEDURE|Conventional Therapy|In the Conventional Therapy group, an exercise program consisting of passive and active assistive range of motion exercises, strengthening exercises and task-oriented exercises for 30 minutes for both hands was planned, accompanied by a physiotherapist experienced in spinal cord injury rehabilitation for at least 5 years.
224221892|NCT04063618|PROCEDURE|Osteopathic Manipulative Therapy|The OMT practitioner, using a strong anatomic knowledge base, applies specific genital forces in the dysfunctional area, thus providing aid to the body's innate mechanisms of healing. During OMT, a patient's muscles, joints, and tissues are moved using techniques that include stretching, gentle pressure, and resistance.
224221893|NCT04063618|PROCEDURE|Standard of Care Concussion Treatment|Standard of care for concussion management is cognitive rest, meaning no stimulation (or as little as possible). This mean no TV/phones/music/school/homework generally for 24 hours. After that a return to academic work is typically started. Once patient is symptom free for 24 hours, then the return to play protocol is initiated (this takes 7 total days to complete at a minimum).
224221894|NCT00407459|DRUG|Bevacizumab, Pemetrexed, Carboplatin|"* Bevacizumab: 15 mg/kg intravenous infusion over 30 to 90 minutes, following chemotherapy, on Day 1 every 3 weeks~* Pemetrexed: 500 mg/m2 intravenous infusion over 10 minutes on Day 1 every 3 weeks~* Carboplatin: AUC 5 intravenous infusion over 1 hour on Day 1 every 3 weeks"
224221895|NCT01418352|DRUG|Aripiprazole|Aripiprazole tablets once weekly for 8 weeks.
224221896|NCT01418352|DRUG|Placebo|Aripiprazole matching-placebo once-weekly for 8 weeks.
224221897|NCT00619619|DRUG|Desvenlafaxine Succinate Sustained-Release Tablets (DVS SR)|DVS SR Tablets of 10mg, 25mg, 50mg, and 100mg. Assigned DVS SR daily doses of 10mg, 25mg, 50mg, 100mg, or 200mg for up to 8 weeks.
223633097|NCT00269217|DRUG|niacin (+) laropiprant (+) simvastatin|Duration of Treatment 12 Weeks
224221898|NCT02778568|BEHAVIORAL|Resistance training|Resistance training exercises
224221899|NCT02778568|BEHAVIORAL|Control|Stretching exercises
224318344|NCT04272749|BEHAVIORAL|Assess opinons on the milk beverages|Questionnaires and consumption behaviors of dairy and non-dairy milks, including whole, 2% fat, 1% fat, skim, unsweetened almond, sweetened almond, unsweetened coconut, sweetened coconut, unsweetened soy, sweetened soy, unsweetened rice, and sweetened rice.....
223633098|NCT00269217|DRUG|Comparator: niacin (+) laropiprant|Duration of Treatment 12 Weeks
223633099|NCT00269217|DRUG|Comparator: simvastatin|Duration of Treatment 12 Weeks
223633100|NCT00638677|DIETARY_SUPPLEMENT|Sorbitol|Sorbitol tablet delivered with a slow-release pacifier starting 1 mo after delivery and lasting max 2 years
223633101|NCT00638677|DIETARY_SUPPLEMENT|Xylitol + BB12|Xylitol + BB12 tablet delivered with a slow-release pacifier starting 1 mo after delivery and continuing max 2 years
223633102|NCT00638677|DIETARY_SUPPLEMENT|Xylitol|Xylitol+BB 12 delivery with a pacifier max until 2 years
223633103|NCT00092417|BIOLOGICAL|Comparator: Varicella Zoster Virus Vaccine|Single 0.65 mL subcutaneous injection of higher potency zoster vaccine (\~207,000 plaque-forming units \[PFU\]/0.65-mL dose)
223633104|NCT00092417|BIOLOGICAL|Comparator: Varicella Zoster Virus Vaccine|Single 0.65 mL subcutaneous injection of lower potency zoster vaccine (\~58,000 plaque-forming units \[PFU\]/0.65-mL dose)
223633105|NCT06472232|DRUG|Chloroprocaine|Selection of low concentration of chloroprocaine as local anesthetic for labor analgesia
223633106|NCT04664686|PROCEDURE|AF catheter ablation|Isolation of all four pulmonary veins and additional lesions, considered indicated by the operator
223633107|NCT04664686|PROCEDURE|AV node ablation|AV node ablation
223633108|NCT02647619|DRUG|Xiapex|Injection of collagenase of primary dupytren cord
223633109|NCT02647619|PROCEDURE|Needle aponeurotomy|26 G needle multiple perforation tecqnique with local anesthetic
223633110|NCT05984017|OTHER|No treatment is included in this study|No drug intervention or tissue sampling will be included in this study.
223633111|NCT04073173|PROCEDURE|INSURE|Patients will be intubated by endotracheal tube, exogenous surfactant (Poractant alfa) will be administered and then they will be extubated.
223633112|NCT04073173|PROCEDURE|LISA|Surfactant (Poractant alfa) will be directly delivered into the lungs via a fine bore catheter inserted into the trachea and then patients will be extubated.
223633113|NCT04073173|DRUG|Analgesic, Opioid|Remifentanil (0.5-2 micrograms/kg/dose)
223633114|NCT05557084|PROCEDURE|laparoscopic vertical clip gastroplasty (LVCG) with Bariclip.|The investigator performed laparoscopic vertical clip gastroplasty, This procedure consists of a nonadjustable clip that is vertically placed around the stomach, parallel to the lesser curvature, mimicking the effect of sleeve gastrectomy. The clip restricts oral intake, the anatomy of the stomach is not permanently changed, the small bowel remains untouched, the digestive pathway is not diverted, no stapling or resection are required and the magnitude of restriction is supposed to remain constant during the years. The vertical clip is thus placed without risks of staple line leak, malabsorption side effects, changes in anatomy, and is potentially reversible \[9\]. creating a 4-cm window to enter the lesser sac while lifting the stomach to create sufficient space to be able to suture. Plication of the antrum for 3-5 cm is performed. Fluid testing for patency is performed with methylene blue or normal saline and the procedure is terminate.
223633115|NCT00574197|DRUG|Mycophenolate Sodium|1440mg/day (720mg by mouth, twice a day)
223633116|NCT00007254|DRUG|Pain relief for pressure ulcers|
223633117|NCT03574584|DRUG|NNC0165-1562|Participants will receive NNC0165-1562 subcutaneous (s.c., under the skin) injection(s) once-weekly for 20 weeks. The dose will be escalated over 16 weeks to a final dose level that will be maintained for 4 weeks.
223633118|NCT03574584|DRUG|Semaglutide|Participants will receive semaglutide s.c. injection(s) once-weekly for 20 weeks. The dose will be escalated over 16 weeks to a final dose level that will be maintained for 4 weeks.
223633119|NCT03574584|DRUG|Placebo (NNC0165-1562)|Participants will receive placebo (NNC0165-1562) s.c. injection(s) once-weekly for 20 weeks.
224221900|NCT05103267|DEVICE|Tauropace|TauroPace™ contains disinfecting substances to eradicate environmental microbial contamination on the surface of cardiac implantable electronic devices (CIEDs). The surface of the CIED is moistened with TauroPace™ during the implantation procedure to create a hostile environment on the surface of the CIED.
223633120|NCT05535296|BEHAVIORAL|Risk profile|Compiliation of risk profile based on fitness, strength, mobility, balance, posture, physical activity level, weight and pain. Advice based on the above and support in goal-setting.
223633121|NCT01622166|BEHAVIORAL|psychodynamic art therapy|2 sessions à 1.5 hrs /week, intervention duration 6 weeks
223633122|NCT06070064|OTHER|Effect of music on the manifestation of strength|"After the first 1RM visit, described above, each participant will complete 2 additional randomised, counterbalanced visits, each with one condition: Music (MUS) and No Music (No-MUS). The participants will be instructed to attend the laboratory to perform the screening test in different environmental conditions that do not impact on their health status.~During the MUS session, participants will perform a back squat test and a CJM test while listening to music. The chosen songs will be at least 120 beats per minute (BPM) 15. The tempo of the music for each of the tracks will be calculated using bpm software (Tangerine!v.1.4). The music will be played using an iPhone X (Apple Inc., Cupertino, CA, USA) connected to a portable speaker (Sony MHC-V02, Sony Co., Tokyo, Japan). The sound intensity will be adjusted and standardised for all participants to 75 dB (at ear level) using the Decibel X-dBA sound level meter. Trap and reggaeton music will be played before, during and after the test."
224221901|NCT02787226|DRUG|Liposomal Bupivacaine Infiltration|Surgical wound infiltration of 266 mg of 1.3% liposomal bupivacaine suspension.
224221902|NCT02787226|DRUG|Continuous Perineural Ropivicaine Infusion|Indwelling interscalene catheter with a continuous infusion of 6ml per hour of 0.2% ropivacaine.
223633123|NCT03234322|OTHER|external validated risk prediction model|The risk prediction model will be integrated into a routine health check. The diabetes risk prediction model contains modifiable non-invasive risk factors and consists of eleven questions on age, height, waist circumference, hypertension, physical activity, smoking status, intake of whole-grain bread, intake of red meat, coffee consumption, and family history of diabetes (parents and siblings) to predict the five-year diabetes risk. The filled diabetes risk score will be used in the counseling interview with the PCP at the end of the health check as a practical guide to discuss individual tailored preventive strategies.
223764442|NCT06375798|PROCEDURE|radiotherapy|If the postoperative paraffin pathology of patients in the IORT group indicated positive axillary lymph nodes, the radiologist should determine whether to irradiate the whole milk and lymph nodes in the drainage area.If the postoperative pathology of patients in the WBI group indicated the need for chemotherapy, radiotherapy was initiated within 6 weeks after the end of chemotherapy, allowing both endocrine therapy and radiotherapy to be performed simultaneously. Clinical standard treatment plan (chemotherapy, endocrine therapy, etc.) was developed based on postoperative pathological and immunohistochemical reports.
223764443|NCT02489318|DRUG|Apalutamide|Participants will receive apalutamide 240 mg (4 x 60 mg) tablets orally once daily in each 28 day treatment cycles.
223764444|NCT02489318|DRUG|Placebo|Participants will receive Placebo orally once daily in each 28 day treatment cycles.
223764445|NCT02489318|DRUG|Androgen Deprivation Therapy (ADT)|All participants will receive and remain on a stable regimen of ADT (gonadotropin releasing hormone analog \[GnRHa\] or surgical castration). The choice of the GnRHa (agonist or antagonist) will be at discretion of the Investigator. Dosing (dose and frequency of administration) will be consistent with the prescribing information.
224221903|NCT02195960|DIETARY_SUPPLEMENT|Placebo|intake corn extract poor in anthocyanins: three daily stick packs containing water-soluble extract from corn cobs poor in anthocyanins
224318345|NCT00979199|OTHER|Non invasive cardiac imaging|Non invasive cardiac imaging consists of CTCA combined with one Stress Imaging Test
224318346|NCT02114385|BIOLOGICAL|V503|9-valent HPV \[Types 6, 11, 16, 18, 31, 33, 45, 52, and 58\] L1 virus-like particle vaccine, 0.5-mL intramuscular injection
223633124|NCT02958917|DRUG|Pirfenidone|This is a single-center, randomized, double-blind, placebo-controlled, efficacy and safety study of pirfenidone in subjects with FHP. Approximately 42-45 subjects will be randomized in a 2:1 ratio to receive pirfenidone 2403 mg/d or placebo for 52 weeks.
223764446|NCT03773900|DIETARY_SUPPLEMENT|Kiotransine (chitin-glucan from aspergillus niger)|The volunteers will take three times a day one bag of powder containing 1.5g of chitin-glucan fiber during three weeks. The powder will be diluted in water.
224221904|NCT02195960|DIETARY_SUPPLEMENT|intake anthocyanin-rich corn extract|intake anthocyanin-rich corn extract: three daily stick packs containing water-soluble extract from high-anthocyanin rich corn cobs
224221905|NCT00878449|DRUG|ABT-263|150mg of ABT-263 is taken daily for 3 out of 21 days. This is a dose escalation study, therefore the dose of ABT-263 will change throughout the study.
223764447|NCT03773900|DIETARY_SUPPLEMENT|Placebo|The volunteers will take three times a day one bag of powder containing placebo during three weeks. The powder will be diluted in water.
223764448|NCT06184516|PROCEDURE|Reproductive organ sparing radical cystectomy|"Participants on this arm will undergo a reproductive organ sparing radical cystectomy if they are classified as favorable based on the decision tool."
224221906|NCT00878449|DRUG|etoposide/cisplatin|etoposide = 100 mg/m2 Days 1-3 of each Cycle; Max duration 6 cycles. cisplatin = 75 mg/m2 Day 1 of each Cycle; Max duration 6 cycles
224221907|NCT01735591|DIETARY_SUPPLEMENT|Placebo|Placebo, 1 capsule a day from inclusion until the date of liver transplantation
224221908|NCT01735591|DIETARY_SUPPLEMENT|Probiotic|Capsules with 3x10\^9 colony forming units of: Lactococcus lactis PB 411 (50%), Lactobacillus casei PB 121 (25%), Lactobacillus acidophilus PB 111 (12,5%), Bifidobacterium bifidum PB 211 (12,5)
224221909|NCT02015923|PROCEDURE|Colonic resection|Colonic cancer resection, R0 No surgical intervention on metastasis
224221910|NCT02015923|DRUG|Chemotherapy- scheme|Chemotherapy, specified in each center with or without biological drugs
224221911|NCT00004871|DRUG|azacitidine|
224221912|NCT00004871|DRUG|sodium phenylbutyrate|
224221913|NCT03235583|DEVICE|MOTIONPODTM device validation|MOTIONPODTM validation in free-living conditions using gold standards, including the DLW method
224221914|NCT01186783|DRUG|ivabradine|"Patients in the ivabradine treatment arm receive an additional enteral preparation (orally, via nasogastric tube or percutaneous endoscopic gastrostomy-probe) of ivabradine for 4 days.~Day 1 and 2:~5,0 mg ivabradine b.i.d. if heart rate ≥60bpm (acute renal failure: ≥70bpm)~Day 3 and 4:~5,0 mg ivabradine b.i.d. if 60bpm≥heart rate\<90bpm (acute renal failure: 70bpm≥heart rate \<90bpm~7,5 mg ivabradine b.i.d. if heart rate ≥90bpm"
224221915|NCT00505505|DRUG|Insulin (Actrapid)|50 UI Actrapid diluted in 50 ml of saline
224221916|NCT03381066|DRUG|gefitinib, pemetrexed,cisplatin|"* Intercalation phase (Duration: 3weeks x 4 cycles = 12 weeks) Pemetrexed 500mg/m2 D1, Cisplatin 75mg/m2 D1, Gefitinib 250mg D5-18, every 3week~* Maintenance phase (Duration: 1 year) Gefitinib 250mg D1-2"
224221917|NCT03381066|DRUG|Vinorelbine, cisplatin|Duration: 3wks x 4 cycles = 12 weeks Vinorelbine 25mg/m2 D1,8, Cisplatin 75mg/m2 D1 q3week
224221918|NCT03628352|DRUG|Tricaprilin|Tricaprilin with flavoring agents added
224221919|NCT05035485|DRUG|Phenylephrine|A rescue phenylephrine (75μg) was given when postspinal anesthesia hypotension occurred within 30 minutes after spinal anesthesia
224318347|NCT02114385|BIOLOGICAL|GARDASIL|Quadrivalent HPV \[Types 6, 11, 16, and 18\] L1 virus-like particle vaccine, 0.5-mL intramuscular injection
223633125|NCT02958917|OTHER|Placebo controlled|This is a single-center, randomized, double-blind, placebo-controlled, efficacy and safety study of pirfenidone in subjects with FHP. Approximately 42-45 subjects will be randomized in a 2:1 ratio to receive pirfenidone 2403 mg/d or placebo for 52 weeks.
223633126|NCT06025773|DRUG|Lansoprazole 15 mg|AD-2121 (Lansoprazole 15 mg), Oral, Capsule
223633127|NCT06025773|DRUG|Lansoprazole 15mg/Calcium carbonate 600mg|AD-212-A (Lansoprazole 15mg/Calcium carbonate 600mg), Oral, Tablet
223633128|NCT00181168|DRUG|Euthyroid Group|Euthyroid Group: Received rhTSH to prepare for radioiodine therapy.
223764449|NCT06184516|PROCEDURE|Radical cystectomy|"Participants on this arm will undergo a radical cystectomy if they are classified as unfavorable based on the decision tool."
224221920|NCT05035485|DRUG|Norepinephrine|A rescue norepinephrine (6μg) was given when postspinal anesthesia hypotension occurred within 30 minutes after spinal anesthesia
224221921|NCT03786913|DIAGNOSTIC_TEST|Quantitative muscle ultrasound measurements|Quantitative ultrasound measurements will be performed to biceps, forearm flexors, quadriceps and tibialis anterior according to a standard protocol; for each muscle three consecutive measurements will be made to minimize variation in echo intensity during analysis .The captured images will be analyzed offline for echo intensity by means of computer-assisted grayscale histogram analysis.
224221922|NCT06240845|OTHER|High-level laser therapy|This group received High-level laser therapy along with conventional physiotherapy treatment 3 times per week for 6 weeks.
224221923|NCT06240845|OTHER|Low-level laser therapy|This group received Low-level laser therapy along with conventional physiotherapy treatment 3 times per week for 6 weeks.
224221924|NCT06321666|OTHER|WB-MRI|All patients will undergo a CT scan (neck/thorax/abdomen/pelvis) and a WB-MRI
224221925|NCT01092702|DRUG|Varenicline|During the first week varenicline will be started at a dose of 0.5 mg once daily for days 1-3; then 0.5 mg twice daily for days 4-7. Target quit date is set at day 8. Varenicline is then continued for weeks 2-12 at a dose of 1 mg twice daily.
224221926|NCT05678621|DRUG|trimethoprim-sulfamethoxazole (co-trimoxazole)|Doxycycline is an alternative for participants with hypersensitivity to co-trimoxazole.
224221927|NCT05678621|DRUG|amoxycillin/clavulanic acid and ciprofloxacin|clindamycin is an alternative to amoxycillin/clavulanic acid for participants with hypersensitivity to penicillin.
224221928|NCT05678621|DRUG|Immunoglobulins|Intravenous monthly immunoglobulin or subcutaneous weekly immunoglobulin
224221929|NCT01434459|DRUG|Gemcitabine with TheraSphere|Gemcitabine dose will be escalated and combined with therasphere.
224221930|NCT06180811|OTHER|Women's Health Delaware Food Farmacy|Participants will receive medically tailored groceries (10 meals per person in the household per week from enrollment to 4 weeks after delivery) high in micronutrients that are delivered to their homes weekly. They will also interact weekly with their assigned Community Health Worker to address social needs and patient-centered goals.
224221931|NCT06180811|OTHER|Usual Standard of Care|Participants will receive the usual standard of care.
224221932|NCT04283383|OTHER|Primary Care Clinical Ultrasound Classroom (AECAP)|A structured training process oriented to the clinical practice of the family physician, Primary Care Clinical Ultrasound Classroom (AECAP) will be carried out,
224221933|NCT04304326|OTHER|Resistence Exercise|"Underwent resistance exercise twice a week, for twelve weeks for the following muscles group: upper limbs, lower limbs and trunk.~It was carried out two exercises for major muscle groups and one exercise for small muscles. The exercises were divided in 3 sets of 12 repetitions for each muscle group. The intensity of the exercises was 60% of one-maximum repetition (1RM).~The exercise program involved pectoral exercises: crucifix and seat supine; biceps: alternated screw; triceps: triceps pulley; back: standing handsaw and pulled ahead; quadriceps: leg extensor and finally gluteus: standing hips extension."
224221934|NCT03804801|DIETARY_SUPPLEMENT|Hibiscus Sabdariffa|The extract of the plant Hibiscus Sabdariffa, also known as sour or red tea
224221935|NCT00384696|DRUG|Nicotine Replacement Therapy|4 Weeks of nicotine patch. Patch therapy for participants who smoke \>10 cigarettes/day consists of 2 weeks of 21 mg patches, 1 week of 14 mg patches, and 1 week of 7 mg patches. Patch therapy for participants who smoke 5-10 cigarettes/day consists of 2 weeks of 14 mg patches and 2 weeks of 7 mg patches.
224221936|NCT00384696|BEHAVIORAL|Questionnaire|Survey taking 1 and 1/2 hours at each study visit.
224221937|NCT02627365|BEHAVIORAL|Individualized, interactive short messaging intervention|An Individualized, interactive short messaging intervention reminding study participants to take antiretroviral medication and report any problems.
224221938|NCT05509634|DRUG|HR20013 for injection；dexamethasone|"HR20013 for injection；Drug for preventing nausea and vomiting caused by chemotherapy~dexamethasone: Drug for preventing nausea and vomiting caused by chemotherapy"
224221939|NCT05509634|DRUG|fosaprepitant dimeglumine for injection；palonosetron hydrochloride injection；dexamethasone|"fosaprepitant dimeglumine for injection: Drug for preventing nausea and vomiting caused by chemotherapy~palonosetron hydrochloride injection: Drug for preventing nausea and vomiting caused by chemotherapy~dexamethasone: Drug for preventing nausea and vomiting caused by chemotherapy"
224221940|NCT03263819|DIAGNOSTIC_TEST|Oral glucose tolerance test|75 grams of glucose
224221941|NCT05903599|OTHER|Anodal transcranial direct current stimulation|The size of both electrodes will be 5cm x 5cm placed on the head with the anode on the primary motor cortex M1 of the affected side while the cathode on the contralesional eye. The duration of the stimulation of anodal TDCS is 20 min and the intensity of current will be 2mA. The ramp up and down period will be 30se each. Treatment duration will be 5 times a week for 6 weeks for postural stability.
224221942|NCT05903599|OTHER|Sham Stimulation|"postural training by visual feedback and weight shifting towards the non-paretic side. This program will have two phases. Phase one have 4 stages; The first stage (sessions 1-7), second stage (sessions 8-14), third stage (sessions 15-22), fourth stage (sessions 23-30).~Next phase will include the exercises including balancing exercises."
224221943|NCT02514187|DRUG|Cyclotron-produced 99mTc|"Each research subject will serve as his/her own control, and will undergo imaging using both generator- and cyclotron-produced 99mTc. The study will follow the usual clinical procedure for routine imaging in the nuclear medicine department.~All subjects will be contacted by phone or in person the day following the injection of both generator and cyclotron-produced 99mTc to monitor for potential adverse events."
224221944|NCT02514187|DRUG|Generator-produced 99mTc|"Each research subject will serve as his/her own control, and will undergo imaging using both generator- and cyclotron-produced 99mTc. The study will follow the usual clinical procedure for routine imaging in the nuclear medicine department.~All subjects will be contacted by phone or in person the day following the injection of both generator and cyclotron-produced 99mTc to monitor for potential adverse events."
224221945|NCT00000606|PROCEDURE|Lung volume reduction surgery|
224221946|NCT01319071|OTHER|Blood sample|Extraction of blood sample from top-level athletes
224221947|NCT00125931|DRUG|Talwin Nx|Talwin NX 50mg po twice
224221948|NCT03269175|OTHER|Brain MRI|Brain MRI will be performed
223633129|NCT04672278|DIETARY_SUPPLEMENT|Shanzha Fruit drink or placebo drink|The dosage of Shanzha fruit drink or the placebo is 3 cans per day
223633130|NCT02656771|DEVICE|Echo Bi-Metric|The insertion of the Echo® Bi-Metric® THA stem
224221949|NCT03269175|OTHER|Blood sampling|Blood samples will be taken
223633131|NCT06350331|OTHER|mobile venous thromboembolism application (mVTEA)|mVTEA will assist in the management of patients during the post-hospitalization follow-up phase. The mVTEA's doctor terminal automatically sends VTE-related health education materials in different frequencies and contents based on the patient's knowledge of VTE prevention and treatment, as well as their risk of thrombosis and bleeding during follow-up. In addition, thrombosis physicians on the mVTEA's doctor terminal can deliver health education to patients based on their condition. This can be done through the mVTEA doctor-patient communication module, which includes text, photo, and voice interactions.
224221950|NCT05206136|DEVICE|Ultrasonography|Neck and Low back muscles will be evaluated by ultrasound.
224221951|NCT02749019|DRUG|68Ga-NOTA-BBN-RGD|68Ga-NOTA-BBN-RGD were injected into the patients before the PET/CT scans
224221952|NCT05452538|DEVICE|Transfusion|Data from patients who were transfused at the Centre Léon Bérard from the day of surgery to the 10th postoperative day will be analyzed.
224221953|NCT01691365|DIETARY_SUPPLEMENT|vitamins|a capsule of antioxidant vitamins 221mg of alpha tocopherol and 167mg of vitamin C and B-group vitamins (1.67 mg folic acid, 1.67mg vitamin B-2, 20 mg vitamin B-6, 0.134 mg vitamin B-12) or an identical placebo daily for 90 days
223633132|NCT06382038|OTHER|mobile venous thromboembolism application (mVTEA)|mVTEA will assist in the management of patients during the post-hospitalization follow-up phase. The mVTEA's doctor terminal automatically sends venous thromboembolism (VTE)-related health education materials in different frequencies and contents based on the patient's knowledge of VTE prevention and treatment, as well as their risk of thrombosis and bleeding during follow-up. In addition, thrombosis physicians on the mVTEA's doctor terminal can deliver health education to patients based on their condition. This can be done through the mVTEA doctor-patient communication module, which includes text, voice, and video communication.
223633133|NCT02170376|DRUG|BIA 9-1067|BIA 9-1067 25 mg and 50 mg
223633134|NCT02170376|DRUG|Entacapone|Entacapone (ENT), over-encapsulated tablet 200 mg
223633135|NCT02170376|DRUG|Placebo|PLC, placebo
223633136|NCT02170376|DRUG|Levodopa/carbidopa|Levodopa/carbidopa, tablet 100/25 mg
223633137|NCT05026593|DRUG|Carboplatin|Carboplatin will be administered after completion of Sintilimab by IV infusion to achieve an initial target AUC of 5 mg/mL/min on Day 1.
223633138|NCT05026593|DRUG|Cisplatin|Cisplatin 75 mg/m\^2 will be administered after completion of Sintilimab by IV infusion on Day 1.
223633139|NCT05026593|DRUG|Etoposide|Etoposide 100 mg/m\^2 will be administered by IV infusion following carboplatin or cisplatin administration, during the induction phase on Day 1 through 3 of each cycle. On Days 2 and 3, patients will receive etoposide alone.
223633140|NCT05026593|DRUG|Sintilimab|Sintilimab 200 mg will be administered by IV infusion following IBI110 on Day 1 of each 21-day .
223633141|NCT05026593|DRUG|IBI110|IBI110 RP2D will be administered by IV infusion on Day 1 of each 21-day .
223633142|NCT03975985|OTHER|Core stability exercises (CSE)|"CSE are exercises focused on trunk muscle strengthening, proprioception, selective movements of the trunk and pelvis muscle, and coordination, and will be carried out in supine, sitting on a stable surface and sitting on an unstable surface (physioball). The exercise involves changes in the position of the body without resistance, aiming to improve strength, endurance, proprioception and coordination.~\- TENS: Half of the patients assigned to CSE will also receive TENS (highfrequency TENS 100 Hz; 0.2 ms pulse width), administered via TENS stimulator with two disposable 0.9 mm diameter electrodes placed on the skin over the lumbar erector spinae (3 cm lateral to the L3 and L5 spinous process)."
223633143|NCT03975985|OTHER|Conventional Physiotherapy|The common feature of CP is that it consists of a management by the physiotherapist according to the CP may consist in a variety (or combination) of multiple components such as tone normalization, exercises for maintain range of motion, passive mobilization of hemiparetic side, postural control, gait re-education to walking/standing between parallel bars or with a therapist, rehabilitation of the activity of daily living, etc.
223633144|NCT03780244|DEVICE|Sculptra Aesthetic 8ml|Treatment of nasolabial folds
223633145|NCT03780244|DEVICE|Sculptra Aesthetic 5ml|Treatment of nasolabial folds
223633146|NCT03428984|DRUG|EXPAREL|EXAPREL 266 mg in 20 mL
223633147|NCT03659396|OTHER|individualized Tai Chi|individualized Tai Chi training exercise
223633148|NCT03659396|OTHER|Entire Tai Chi|the classical Yang style Tai Chi program
223633149|NCT03659396|OTHER|home-based program|Home-based exercise
223633150|NCT05996016|OTHER||
223633151|NCT04424095|DIAGNOSTIC_TEST|In-office vascular visit|The patient will be examined to search for signs or symptoms of chronic venous disease (teleangiectasia, reticular veins, varicose veins, skin changes, pain, itching, heavy legs, ankle edema)
223633152|NCT04424095|DIAGNOSTIC_TEST|Echo Duplex of lower limbs|The venous system of lower limbs will be checked in order to detect any vein dilation and reflux.
223633153|NCT01695226|DRUG|celecoxib|pre-operative celecoxib (400 mg) twice daily for two to three weeks
223633154|NCT01695226|DRUG|Placebo|pre-operative placebo twice daily for two to three weeks
223633155|NCT01853670|RADIATION|concurrent chemo + IGRT|
223633156|NCT01853670|RADIATION|neoadjuvant chemo + IGRT|
223633157|NCT06001047|PROCEDURE|Group A|Acupoint selection: The location of the vertigo-auditory area follows the positioning standard of Jiao Shunfa's Head Acupuncture. Operation: Electroacupuncture stimulation in the vertigo-auditory area of affected side. Pulse electrotherapy produced by Wujin Changcheng Medical Instrument. Sparse-dense waveforms are selected, with a voltage of 2-4V, a frequency of 60-80 times/min, and the intensity is determined by the patient's tolerance. The needle is in affected side for 30 minutes, and treatment is given once daily for a total of 5 days.
223633158|NCT06001047|DRUG|Group B|"The original text is related to a medication called Pitavastatin Calcium Tablets, commonly known as Minshilang in Chinese, produced by Weicai (China) Pharmaceutical Co., Ltd. The dosage is 12mg, three times a day (Tid) for four consecutive weeks. Compliance monitoring is conducted by counting the remaining tablets in the medication packaging box brought by patients during the 4-week follow-up period. Concurrent use of other medications that may affect the observation results, such as anti-anxiety drugs, vestibular suppressants, and anti-dizziness Chinese patent medicines, is considered a violation of the protocol."
223633159|NCT00628667|DRUG|Esomeprazole|40mg orally twice daily
223633160|NCT00628667|DRUG|Placebo|
224221954|NCT01691365|DRUG|Placebo|Placebo Capsule shell (Hydroxypropylmethyl cellulose, Hydroxypropylcellulose, Propylene glycol as stabilizer, Colour-Titanium dioxide)
224221955|NCT01566799|DRUG|Metformin|metformin 500 mg/day po for 24 weeks.
224221956|NCT02324985|DRUG|S-Ibuprofen Topical Gel 5%|S-Ibuprofen Topical Gel 5% applied every 6 hours
224221957|NCT02324985|DRUG|Vehicle Topical Gel|Vehicle Topical Gel applied every 6 hours
224318348|NCT03566615|DEVICE|CAP-straight|This study is to detect any differences in the detection rate of adenomas using straight caps that will be attached to the colonoscope and to compare it to the control method where no cap is used in the colonoscopy procedure.
223633161|NCT03629535|DEVICE|Non-invasive non-oscillometric blood pressure wristband device|The device is a band intended to be worn on the wrist for intermittent blood pressure measurements. The device applies no inflatable mechanics or moving parts. The wristband is watertight and can be worn as any type of bracelet.
223633162|NCT03629535|DEVICE|Invasive intra-arterial blood pressure monitors.|Because the subjects also have an intra-arterial blood pressure monitor in place, the subjects will serve as their own control
223633163|NCT04927195|DRUG|EDP1867|EDP1867 is an orally administered, pharmaceutical preparation of a single strain of bacteria
223633164|NCT04927195|DRUG|Placebo|Placebo oral capsule
223633165|NCT02722083|DRUG|Chlorpheniramine maleate (BAY X002134)|4 mg tablet, single dose, orally
223633166|NCT02722083|DRUG|Placebo|placebo tablet, single dose, orally
223633167|NCT00998686|DRUG|dutogliptin|400 mg
223633168|NCT00998686|DRUG|sitagliptin|100 mg
223633169|NCT03902444|DEVICE|Credo® Stent, NeuroSpeed® PTA balloon catheter|a self-expanding stent is used together with a PTA balloon catheter
223633170|NCT04645758|COMBINATION_PRODUCT|Dry needling and Extra corporeal Shock wave therapy|5 mins of dry needling and 1250 pulses of shockwave therapy on dominant forearm muscles
224318349|NCT03566615|DEVICE|CAP-daisy|This study is to detect any differences in the detection rate of adenomas using daisy caps that will be attached to the colonoscope and to compare it to the control method where no cap is used in the colonoscopy procedure.
223633171|NCT05642364|BEHAVIORAL|Joviality(TM)|5-week positive psychological intervention delivered using 3D virtual reality software that is immersive and uses a head-mounted display
223633172|NCT05642364|OTHER|Inert Virtual Reality|Participants randomized to the control arm will receive a rigorous placebo following clinical trial guidelines of VR-CORE, which consists of 2-dimensional (2D) non-immersive visual content displayed on the HMD. Footage of wildlife and nature-based settings are visually displayed as part of the Sham VR with inert music that does not promote high levels of relaxation or distraction.
223633173|NCT00809185|DRUG|everolimus|Patients will receive monotherapy with RAD001(everolimus)for 21 days within the 28 day cycle.
223633174|NCT00809185|OTHER|laboratory biomarker analysis|Laboratory correlates (cytotoxic t cell populations, S6K1 levels, GSTT-1 mutations, and the presence or absence of HLA-DR15) will be assessed to see if any of these correlates correspond to response.
223633175|NCT00809185|PROCEDURE|Bone marrow aspirate/biopsy|Bone marrow aspirate and biopsy with cytogenetics should be obtained within 4 weeks prior to starting drug and at week 33. A bone marrow aspirate and biopsy should also be obtained for patients going off study prior to week 33 (including cytogenetics). The percentage of blasts on the aspirate should be used to determine the IPSS score.
223633176|NCT01010880|DRUG|BKT140|BKT-140 drug substance is a highly selective CXCR4 antagonist. BKT140 will be injected S.C once at dose of 0.03, 0.1, 0.3, 0.9 mg/kg
223633177|NCT00394017|BEHAVIORAL|Reminder letters|3 mailed reminder letters
223633178|NCT05625126|OTHER|Rumination Intervention for individuals with PTSD|The intervention utilises evidence-based cognitive behavioural therapy (CBT) techniques.
224221958|NCT06546878|PROCEDURE|Cardiac Rehabilitation (Phase I) - nurse intervention|"The intervention consists of applying CR program (phase I ) following the Guidlines of American Association of Cardiovascular and Pulmonary Rehabilitation. The program was applied by adapting it to the patient, varying the intensity and frequency of the sessions, according to the FITT\_VP acronym.~This phase consists of functional respiratory rehabilitation and motor rehabilitation exercises. Each session is divided into three parts, starting with a warm-up with breathing and isometric exercises, then the so-called peak, which consists of specific endurance/aerobic exercises, and at the end, as a recovery phase, relaxation exercises with stretching are instructed.~Also, health education sessions for patients/caregiver."
224221959|NCT00002185|DRUG|Nelfinavir mesylate|
224221960|NCT06038188|BEHAVIORAL|SIT LESS Booster|"Patients allocated to the SIT LESS Booster group receive usual care in combination with the SIT LESS Booster program.~The SIT LESS Booster program consists of: 1) The use of the pocket-worn activity tracker (Activ8sit). The activity tracker can be connected to an app to track the daily sitting time. Besides, the device buzzes when a person sits more than 30 consective minutes a s a reminder to stand up and move; 2) Telephone consultation (TC1) during which the researcher and patients will reactivate knowledge on the detrimental health effects of SB, discuss patients' personal goals and motivation, and collaboratively set action plans for reducing SB in the upcoming week (±20 minutes); and 3) Weekly telephone calls (TC2 and TC3) to evaluate sedentery behaviour of the preceding week (±10 minutes).~The SIT LESS Booster will be delivered completely remote"
224221961|NCT05445115|DEVICE|Mollie device|medical device
223633179|NCT06029946|DIAGNOSTIC_TEST|elastography, ultrasound|First local anesthesia with lidocaine 2%, then 3 smears will be obtained for each nodule using a 20-22 gauge needle, multiple passes within the lesion will be made to obtain sufficient cells, the aspirate will be spread over a glass, fixed with ethanol 95% and submitted to the pathology department to be reported.
223633180|NCT04427267|OTHER|Personal protective equipment from biological hazard|Includes: isolation clothing, mask, eyewear, overshoes
223633181|NCT00804908|DRUG|temozolomide|temozolomide capsule administered orally once daily for 5 days every 28 days
223633182|NCT00804908|DRUG|ABT-888|ABT-888 capsule administered orally twice daily for 7 days every 28 days
223633183|NCT00804908|OTHER|Placebo|Placebo for ABT-888 capsule administered orally twice daily for 7 days every 28 days
223633184|NCT04550429|DEVICE|MyoSure Hysteroscopic Morcellator Device|This device is normally used for this procedure, but I included it as intervention because we will lower the pressure for one arm of the study (treatment) and keep the pressure in the other arm (control) as the standard of care.
223633185|NCT06956794|BEHAVIORAL|VirtualDONA Multimodal Program|A group-based behavioral intervention using immersive virtual reality without headsets. The 8-week program includes 16 sessions combining mindfulness, cognitive training, and physical exercises, designed to improve cognitive health and emotional well-being in older women living alone and at risk of poverty.
223633186|NCT02561884|DRUG|Olostar Tab.|
223633187|NCT02561884|DRUG|Co-administration of Olmetec and Crestor|
223633188|NCT04849247|DRUG|68Ga-DOTA-FAPI, 177Lu-DOTA-FAPI|PET imaging using 68Ga-DOTA-FAPI will be used to diagnose patients who are eligible for treatment with the 177Lu-DOTA-FAPI.
223633189|NCT06491277|OTHER|Flossband|The use of Flossband (Sanctband COMPRE Floss 5.1 cm × 3.5 m; Sanct Japan Co., Ltd.), made of natural rubber, was applied starting from 5 cm below the ankle joint line with a 50% stretch. The band tension was increased to 70-75% around 2 cm above the attachment point of the Achilles tendon.
223633190|NCT06491277|OTHER|Controlled Group|Cramer Tape Underwrap (7cm X 27m) foam bandage was applied starting 5 cm below the ankle joint line without tension. The control group received the same exercise protocol as the study group.
223633191|NCT03879733|BEHAVIORAL|Thrive by Three|"The intervention consists of the following components:~1. Measurement of daycare quality with CLASS (Classroom Assessment Scoring System) 3 times during the intervention period~2. Feedback to group staff on 8 CLASS-quality dimensions~3. Monthly supervision of staff on two levels: supervision of daycare staff, and supervision of supervisors~4. Competence building with all staff: 3 full training days, plus 2 extra training days for pedagogical leaders/supervisors~5. Written material to parents, supervisors, and staff~6. Web page for staff and parents: tf3.no"
223633192|NCT03879733|BEHAVIORAL|Treatment as usual (TAU)|The wait-list control group will continue with their daily activities and work in the childcare as usual. The wait list control group will have received general information about the study prior to consenting, however no materials or are provided by project. The child-care centers in the control conditions will receive a gift certificate of 3000 Norwegian Crones (NOK) by the end of the intervention period.
223764450|NCT05723770|DRUG|instillation of NOV03|This trial consists of 2 office visits over a period of approximately 2 weeks. At Visit 2, a designated clinical staff member or the investigator will instill 1 drop of NOV03 into each eye.
224221962|NCT03998228|DIAGNOSTIC_TEST|Dual X-ray absorptiometry (DMO) densitometry.|"Simple clinical examination with forearm inspection and palpation;~* Radiological examination of BMD;~* Calculation of the FRAX® score;~* Fact sheet on patients with dermatoporosis, proposal of a topical treatment (cosmetic cream) and completion of the questionnaire specific to dermatoporosis"
224221963|NCT00103870|PROCEDURE|Electrodermal stimulation|
224221964|NCT00103870|PROCEDURE|Music listening task|
224221965|NCT03845478|BEHAVIORAL|Control Group (CG)|The control group is subjected to follow a hypocaloric diet and receives information about the benefits of achieving 10,000 steps a day in weight loss and improved body composition.
224221966|NCT03845478|BEHAVIORAL|Intervention Group (IG)|This group in addition to fulfilling a hypocaloric diet identical to the control group, and receive identical information about physical activity that the control group, it has a system of prescription, monitoring and establishing an objective to achieve 10,000 steps a day.
224221967|NCT01047085|PROCEDURE|impedance pH measurement|Impedance pH measurement: Impedance-pH is a recently developed technique used to monitor all kinds of reflux (gas, liquid, acides and non-acides), reflux level and the clearance period of the esophagus.
224221968|NCT04758871|DRUG|Dydrogesterone 10 MG Oral Tablet|10 mg three times daily
224318350|NCT03566615|OTHER|water|using water instead of traditional air insufflation to help insertion
224318351|NCT02268578|DEVICE|Transcranial Direct Current Stimulation|2mA tDCS
224318352|NCT02268578|PROCEDURE|Sham Transcranial Direct Current Stimulation|Transcranial Direct Current Stimulation is administered but at 0mA
224318353|NCT01325844|PROCEDURE|Epidural anesthesia|0.5% ropivacaine infusion via epidural catheter at 5ml/hr during general anesthesia
223764451|NCT05556876|DIETARY_SUPPLEMENT|Protein omega-3|An oral supplement with a high content of protein and with essential fatty acids
223764454|NCT04992221|PROCEDURE|arterial line|arterial line inserted for invasice mointroing and sampling
223764455|NCT01659112|OTHER|Core Stabilization|A 6-week (3 days a week) exercise intervention including progressive core exercises was performed.
223764456|NCT01659112|OTHER|Traditional upper extremity rehabilitation|A 6-week (3 days a week) exercise intervention of the injured joint based on the recovery process was performed.
224221969|NCT04758871|DRUG|Micronized progesterone|2x 200 mg vaginal tablets two times daily
224221970|NCT00229112|DRUG|MK0826, ertapenem sodium / Duration of Treatment - 24 weeks|
224221971|NCT00229112|DRUG|Comparator: Piperacillin/Tazobactam / Duration of Treatment - 24 weeks|
224221972|NCT06481826|DRUG|Glofitamab|Glofitamab given in standard dosage
224221973|NCT06256250|PROCEDURE|pulpectomy treatment will be done using the adaptive xp endo shaper.|the patient will be anesthetized by local anesthesia. the rubber dam will be used for isolation. caries will be removed using high speed handpiece. determination of working length using apex locator. the canal patency will be checked with a # 10 K file, and gliding path until #15 K- file. the root canals of primary molars will be cleaned and shaped in pulpectomy treatment using the adaptive xp endo shaper. it is single file technique saves time and help with patient cooperation . the endomotor will be activated at aspeed of 800 rpm and 1 Ncm torque. the canals will be irrigated using 2.5% Nacol ending with 0.9% normal saline canal irrigation. the canals will be dried with paper points and obturated with Metapex. teeth will be restored by glass ionomer restoration than stainless steel crown.
224318354|NCT05296863|COMBINATION_PRODUCT|Non-concentrated adipose-derived stem cell conditioned media and 5% Minoxidil|"Non-concentrated ADSC-CM is given during week 0, 2, 4, and 6 on the left side of the scalp.~Minoxidil is applied twice using a spray, in the morning and at night."
224318355|NCT05296863|COMBINATION_PRODUCT|Concentrated adipose-derived stem cell conditioned media and 5% Minoxidil|Intervention is given during week 0, 2, 4, and 6 on the left side of the scalp. Minoxidil is applied twice using a spray, in the morning and at night.
224318356|NCT05296863|COMBINATION_PRODUCT|Placebo and 5% Minoxidil|"Intervention is given during week 0, 2, 4, and 6 on the right side of the scalp.~Minoxidil is applied twice using a spray, in the morning and at night."
224318357|NCT04204057|DRUG|Tenalisib|Tenalisib 800 mg BID, Orally
224318358|NCT02229474|BEHAVIORAL|CST Intervention|The CST intervention comprises 14 sessions lasting 1-2 hours across 7 weeks. The CST manual has been adapted for use in this setting by members of our study team. Each session has a theme. Activities include tasks aimed at engaging participants in cognitive and physical tasks designed to improve quality of life. Sessions will be led and facilitated by a study nurse or occupational therapist. The sessions will be held at a local health centre of village hall.
224318359|NCT01045330|BEHAVIORAL|a modified NTU-HELP|The intervention consists of a daily inpatient care protocol on three core intervention protocols on top of hospital routine care.
224318360|NCT02315274|OTHER|Frequent remote contact between clinic visits.|Subjects will upload diabetes device data onto websites. Website data will be reviewed by study team who will provide feedback to patients without clinic visits.
224318361|NCT05263310|BEHAVIORAL|Prepare for Your Diabetes Care|Educational video and Action Plan handout
224318362|NCT05263310|BEHAVIORAL|Usual Care|Control arm patients will continue with usual care
223764457|NCT06845891|DEVICE|CONNECTED SMART CAP|The intervention in this study consists of attaching a smart cap to the insulin pen of individuals with type 1 diabetes who use flash glucose monitoring and experience a time above range (TAR \>180 mg/dL) for more than 25% of the time. This metric has been associated with diabetes-related complications, and the objective of this study is to determine whether this simple device could help reduce this underexplored parameter.
223764458|NCT02150564|DEVICE|Sonowand|Initially a 2D acquisition will be performed and ultrasound parameters adjusted to obtain the best image resolution. Then anatomical landmarks will be identified if possible and the lesioncharacterized. Once the lesion is identified a rapid 3D-US acquisition will be performed. Tumor resection will proceed guided by the 3D US images using a trackable pointer to navigate. Repeat 3D US images will be obtained as many times as required during the surgery to update the information as tumor debulking proceeds. A final US will be obtained at the end of the procedure and after dural closure
224221974|NCT06256250|PROCEDURE|pulpectomy treatment will be done using FANTA AF baby files.|"the patient will be anesthetized by local anesthesia. the rubber dam will be used for isolation. caries will be removed using high speed handpiece. determination of working length using apex locator. The canal patency will be checked with a #10 K-file, and a glide path until #15 K-file will be created .the root canals of primary molars will be cleaned and shaped in pulpectomy treatment using FANTA AF baby files. it is pediatric rotary system consists of 4 files specialized for primary molars.Open file: #17, taper 08.~* BTF1: #20, taper 04, Yellow~* BTF2: #25, taper 04, Red~* BTF3: #30, taper 04, Blue The file will be activated at speed 350 rpm and torque 2 N until reaching the full working length. the canals will be irrigated using 2.5% Nacol ending with 0.9% normal saline canal irrigation. the canals will be dried with paper points and obturated with Metapex. teeth will be restored by glass ionomer restoration than stainless steel crown."
224221975|NCT06256250|PROCEDURE|pulpectomy treatment will be done using hand k files.|the patient will be anesthetized by local anesthesia. the rubber dam will be used for isolation. caries will be removed using high speed handpiece. determination of working length using apex locator. the root canals of primary molars will be cleaned and shaped in pulpectomy treatment using hand k files starting with #15 stainless steel hand K file. they are manual files, they are standard for root canal treatment (control group). the canals will be irrigated using 2.5% Nacol ending with 0.9% normal saline canal irrigation. the canals will be dried with paper points and obturated with Metapex. teeth will be restored by glass ionomer restoration than stainless steel crown.
224221976|NCT02449603|DRUG|Exenatide|
224221977|NCT02449603|DRUG|Biphasic insulin Aspart 30|
224221978|NCT04897971|DIAGNOSTIC_TEST|Medium enriched for newly synthesized antibodies in spine infection|Medium enriched for newly synthesized antibodies titers in patients with Staphylococcus aureus infections of orthopedic spine implants at baseline and in the post operative period
224221979|NCT02539563|OTHER|peanut shaped birthing ball|peanut ball will be utilized
224221980|NCT02752256|DRUG|Tissue Plasminogen Activator|
224221981|NCT03779399|OTHER|Assessment of percentage of Treg, Th17, NKT and serum level of HE4, CA125 and ROMA.|Treg, Th17, NKT cells in peripheral blood and ovarian tissue and serum level of HE4, CA125 and ROMA.
224221982|NCT00132431|DRUG|Sensipar|
224221983|NCT02159859|DRUG|Ertapenem|Subjects are hemodialysis patients who are admitted to Oakwood Hospital - Dearborn
224221984|NCT04788589|OTHER|Sedation and ventilator weaning protocol|Subjects randomized to this group will underwent sedation and ventilator weaning protocol as mentioned before.
224221985|NCT05092711|BEHAVIORAL|Observation|Using INTERASPIRE model to determine patients with established CHD whether the guidelines on cardiovascular disease prevention are being followed or not with incorporation of COVID 19 as a risk factor with the other classical risk factors to understand significance of the new pandemic virus in mortality and morbidity of CVD and coronary events in association with the other known classical risk factors .
224221986|NCT05092711|DRUG|Observation|Using INTERASPIRE model to determine patients with established CHD whether the guidelines on cardiovascular disease prevention are being followed or not with incorporation of COVID 19 as a risk factor with the other classical risk factors to understand significance of the new pandemic virus in mortality and morbidity of CVD and coronary events in association with the other known classical risk factors .
224221987|NCT06288165|DEVICE|Coronary Sinus Reducer Implantation|Coronary Sinus (CS) Reducer implantation to coronary sinus via the venous system. Coronary Sinus is a balloon-expandable, hourglass-shaped, scaffold implanted percutaneously into the coronary sinus creating a narrowing to delay blood outflow.
224221988|NCT01930084|OTHER|Point of care CD4+ after HIV diagnosis|Point of care (POC) CD4+ testing immediately following HIV diagnosis
224221989|NCT01930084|OTHER|Accelerated ART initiation|Accelerated ART initiation for eligible participants delivered by facility personnel
224221990|NCT01930084|BEHAVIORAL|SMS appointment reminders|Cellular appointment reminders delivered by study personnel
224221991|NCT01930084|OTHER|Non-cash Financial Incentives|Non-cash Financial Incentives
224221992|NCT02008110|DRUG|CA125 guided strategy|Up titration of loop diuretics according to plasma levels of CA125 in the active arm
224221993|NCT02008110|DRUG|CA125 guided strategy|Consider statins in all patients in the active arm
224221994|NCT02008110|DRUG|CA125 guided strategy|Consider omega-3 polyunsaturated fatty acids in the active arm
224221995|NCT02008110|OTHER|CA125 guided strategy|Frequency of monitoring according plasma evolution of CA125 in the active arm.
224221996|NCT02008110|DRUG|Standard treatment strategy|All patients should be treated following standard european guidelines regarding angiotensin converting enzyme inhibitors, angiotensin receptor blockers, beta-blockers, aldosterone antagonists, diuretics, ivabradine and other treatments such as (diet, anticoagulants, antiarrhythmics, statins, omega-3 polyunsaturated fatty acids, digoxin, nitrates and vasoactive group).
224221997|NCT02008110|DRUG|CA125 guided strategy|All patients should be treated following standard european guidelines regarding angiotensin converting enzyme inhibitors, angiotensin receptor blockers, beta-blockers, ivabradine and other treatments such as (diet, anticoagulants, antiarrhythmics, digoxin, nitrates and vasoactive group).
224221998|NCT01199406|DRUG|Levobupivacaine|0.125% levobupivacaine 80 mL (100 mg) intraoperative, 20 mL subcutaneously and 60 mL intraperitoneally
224221999|NCT03150836|DRUG|Durvalumab|All participants will receive durvalumab 1500 mg via IV infusion every 4 weeks for up to 13 doses.
224318363|NCT00972296|DEVICE|Carbon fiber ankle foot orthosis versus cast boot|Relief of ankle pain and normalizing of gait using either device.
224318364|NCT01174043|DRUG|Erlotinib|Erlotinib will be administered orally at 150 mg once a day, continuously. Each cycle will be 28 days and there will be no break between the cycles.
223633193|NCT04060498|BEHAVIORAL|Mindfulness intervention|MBI-p focuses on simplicity, for both facilitators and patients; and use acceptance and embracing attitude for fear and sadness. The ultimate aims are to help patients achieve a greater sense of peace and calmness, and facilitate participants in handling everyday stress and conflicts.
224222000|NCT03150836|DRUG|Tremelimumab|Participants receiving Regimen B (safety lead-in or expansion cohort) will be administered tremelimumab 75 mg via IV infusion every 4 weeks for 1 cycle or 2 cycles.
224222001|NCT03150836|RADIATION|Radiation Therapy|In all arms of the study, participants will receive 5 fractions of radiation. The radiation dose will either be 6.6 Gy for a total dose of 33 Gy, or 6.0 Gy for a total dose of 30 Gy.
223633194|NCT04060498|BEHAVIORAL|Psychoeducation intervention|Psychoeducation focuses on disseminating information about common mental disorders, psychosis (its causes, risk factors and trajectory), and methods of treatment for psychosis.
223633195|NCT02065037|DEVICE|room temperature air insufflation|control arm
224222002|NCT03654898|BEHAVIORAL|VITAL Start: Video-based pre-ART counseling|Patients in the experimental group will receive VITAL start pre-ARV counseling (approximately 27 minutes video followed by 10 minute guided Q \& A to reinforce key messages and provide an opening for individual counseling=approximately total 37 minutes). This will be delivered by study staff.
224222003|NCT03654898|BEHAVIORAL|Standard of Care|Patients randomized to the control arm will receive the usual standard of care (SOC) pre ARV initiation education with the National ARV Educational Flipchart
224222004|NCT01271933|DRUG|pregabalin|controlled release tablet; 165-495 mg/day; given once daily
224222005|NCT01271933|DRUG|placebo|matching placebo tablet; given once daily
224222006|NCT01513785|DRUG|Rabeprazole and Amoxicillin|Amoxicillin (Zhuhai United Laboratories Co., Zhuhai, China) 1g t.i.d and Rabeprazole (Misato Plant of Eisai Co., Ltd. Japan) 10 mg b.i.d.for 14 days.
224222007|NCT01513785|DRUG|Amoxicillin and Rabeprazole|Amoxicillin (Zhuhai United Laboratories Co., Zhuhai, China) 1 g t.i.d and Rabeprazole (Misato Plant of Eisai Co., Ltd. Japan) 20 mg b.i.d. for 14 days
224222008|NCT02067715|DRUG|Tooth bleaching|The bleaching agent will be used in a single-application of 45 minutes.
224222009|NCT00190307|DRUG|aspirin 75 mg/day|aspirin 75 mg/day
224222010|NCT00442585|DRUG|S(+)-ibuprofen|
224222011|NCT01424956|DEVICE|Automated Breast Ultrasound (ABUS)|Automated Breast Ultrasound (ABUS) as an adjunct to digital screening mammography.
224222012|NCT04497090|DEVICE|fixed-EPAP|In the fixed-EPAP mode, the device kept EPAP fixed at the prescribed value
224222013|NCT04497090|DEVICE|auto-EPAP|In the Auto-EPAP mode, the device automatically adjusted EPAP to the minimum level able to abolish tidal expiratory flow limitation.
224222014|NCT06276179|DRUG|Oxycodone|Patient will receive a bolus dose of 0.15 mg/kg plus 20 ml bupivacaine 0.25% followed by an infusion 0.03 mg/kg/h oxycodone plus 0.1 mL/Kg/h bupivacaine 0.125%.
224318365|NCT00261781|BEHAVIORAL|Treadmill training|Walking on a treadmill 3 times per week for 6 weeks
223633196|NCT02065037|DEVICE|warmed carbon dioxide insufflation|comparator arm
223633197|NCT03475095|OTHER|Tuina|Patients will receive Tuina therapies tiwce per week in one month.each time lasts about 20 minutes,a total of 4 weeks.
223633198|NCT04333563|DEVICE|CPAP|Continuous positive airway pressure
223633199|NCT04333563|DEVICE|NIV NAVA|Non-invasive neurally adjusted ventilatory assist
223764459|NCT02150564|PROCEDURE|Navigation|Routine microneurosurgical procedures would be adopted in all cases.Sonowand system will be used for navigation control arm as well as sononavigation experimental arm. Image registration (on the previously imported DICOM images) will be done on the system and after positioning, patient-toimage registration will be completed. The Registration accuracy will be documented.
224222015|NCT06276179|DRUG|Bupivacaine|Patient will receive a bolus 20 ml bupivacaine 0.25% followed by an infusion 0.1 mL/Kg/h bupivacaine 0.125%.
224222016|NCT06526767|DEVICE|Vibrabot capsules twice a week|Subjects in control group took Vibrabot capsules twice a week, one pill/time (on Monday and Thursday), for six weeks.
224222017|NCT06526767|DEVICE|Vibrabot capsules three times a week|Subjects in trial group 1 took Vibrabot capsules three times a week, one pill/time (Monday, Wednesday, and Friday) for six consecutive weeks.
224222018|NCT06526767|DEVICE|Vibrabot capsules five times a week|Subjects in trial group 2 took Vibrabot capsules five times a week, one pill/time (Monday, Tuesday, Wednesday, Friday, and Saturday), for six weeks.
224222019|NCT06526767|DEVICE|Vibrabot capsules loading dose|Subjects in trial group 3 took Vibrabot capsules one pill/time, five times a week (Monday, Tuesday, Wednesday, Friday, and Saturday) during the first two weeks, three times a week (Monday, Wednesday, and Friday) during the middle two weeks, and two times a week (Monday and Thursday) during the last two weeks.
224222020|NCT04009057|OTHER|B/F/TAF|B/F/TAF administered in accordance with the approved product monograph
224222021|NCT03856671|DRUG|Neomycin,metronidazole|Orally intake neomycin 1g and metronidazole 0.2g four times before surgery
224222022|NCT01433133|BIOLOGICAL|implantation|subcutaneous implantation of autologous dermis implant treated ex vivo with genetic vector carrying the gene for interferon alfa 2b
224222023|NCT00404586|DRUG|GW784568X|GW784568X will be delivered as a micronized suspension (50 or 100mcg/spray) via an aqueous nasal spray. Dose planned for treatment groups are 100, 200 and 400 mcg.
223633200|NCT05809557|OTHER|Chemotherapy toxicity tool|"CARG is an EMR based tool that informs medical oncologists visiting a patient for the first time of potential risk of chemotherapy toxicity. This intervention will make available a simple calculator which includes: Gender, Height and weight, Cancer Subtype, Hemoglobin, How is your hearing (with hearing aid, if needed)?, Number of falls in the past 6 months, Can you take your own medicines, Does your health limit you in walking one block., During the past 4 weeks, how much of the time has your physical health or emotional problems interfered with your social activities (like visiting with friends, relatives, etc.)? and Glomerular filtration rate.~The CARG chemotoxicity calculator will be built into the patient navigator and its use will be assessed on a monthly basis and used to inform iteration."
223633201|NCT05809557|OTHER|Oncology Consultation|Oncologists will consult new patient with a new diagnosis of cancer.
224222024|NCT00404586|DRUG|Fluticasone propionate|Fluticasone propionate will be delivered 50 mcg/spray and planned dose is 200 mcg.
224222025|NCT00404586|DRUG|Placebo|Matching Placebo to GW784568X as aqueous nasal spray.
224222026|NCT03062865|OTHER|No intervention|
224222027|NCT02059577|DIETARY_SUPPLEMENT|Nutritional and Dietary Interventions|Day 0: Vitamin/Mineral supplementation begins. Day 30: Essential Fatty Acid supplementation begins. Day 60: Epsom Salt baths begin (2x/week) Day 90: Carnitine supplementation begins Day 180 Digestive Enzyme supplementation begins; Day 210: Healthy, casein-free, gluten-free diet is begun.
224318366|NCT02049970|DRUG|dexmedetomidine|1 ml 100 mcg dexmedetomidine+ 15 ml 0.25 % bupivacaine are applied around brachial plexus
224318367|NCT02049970|DRUG|bupivacaine|30 ml 0.25 % bupivacaine is applied around brachial plexus
224222028|NCT05350683|PROCEDURE|Remote ischemic preconditioning|In the 12 hours prior to surgery, the principal investigator performed the remote ischemic preconditioning (RIPC) following the protocol: 4 cycles of inflation/deflation of a pneumatic arterial tourniquet on the non-dominant upper extremity. Considering inflated a pressure of 50mmHg above systolic blood pressure for 5 minutes, followed by 5 minutes of deflation. Patients included in the preconditioning group were randomized at a rate of 1:1 consecutively.
224222029|NCT06546436|DRUG|CARC-101C|Subjects enrolled in the project will received a one-dose injection of CARC-101C
224222030|NCT03110952|BIOLOGICAL|TDENV-PIV|Single-dose vial with pre-filled syringe, subcutaneous injection
224222031|NCT03110952|BIOLOGICAL|TDENV-F17|Single-dose vial with pre-filled syringe 0.5 mL administered intramuscularly
224222032|NCT03110952|OTHER|Placebo|0.5 mL vial
224222033|NCT02839356|DRUG|epinephrine|20-mL irrigation with epinephrine diluted to 0.02% in saline over the entire papilla
224222034|NCT02839356|DRUG|normal saline|20-mL irrigation with physiological saline over the entire papilla
224222035|NCT01138150|DRUG|Treximet|One tablet of sumatriptan 85 mg and naproxen sodium 500 mg will be given upon subject presentation with an acute migraine attack and after blood levels have been drawn.
224222036|NCT01138150|DRUG|Placebo|One tablet of a sugar pill will be given upon subject presentation with an acute migraine attack and after blood levels have been drawn.
224222037|NCT05496114|DEVICE|Checklist|A checklist is an aid that outlines assessments or actions systematically. In this study, the checklist outlines interventions to consider during management of a patient with tricyclic antidepressant poisoning. Each checklist will include indications, contra-indications and for medication, dose, route and rate of administration.
224222038|NCT01897597|DRUG|BI 144807 high dose|oral solution
224222039|NCT01897597|DRUG|BI 144807 intermediate dose|tablet
224222040|NCT01897597|DRUG|BI 144807 intermediate dose|tablet
224222041|NCT01897597|DRUG|BI 144807 intermediate dose|tablet
224222042|NCT01897597|DRUG|BI 144807 intermediate dose|tablet
224222043|NCT01897597|DRUG|BI 144807 intermediate dose|oral solution
224222044|NCT01897597|DRUG|BI 144807 high dose|tablet
224222045|NCT00819650|DRUG|Licartin (generic name,[131I]metuximab injection)|Licartin, radioiodination of Metuximab with Na\[131I\],with radiochemical purity above 95% and specific activity between 173.25-288.75 MBq/ml.All patients in the treatment group received Licartin 3 times at an interval of 28 days beginning from the 4th week after liver resection
224222046|NCT01620983|BEHAVIORAL|Pain Coping Skills Training|
224222047|NCT01620983|BEHAVIORAL|Arthritis Education|
224222048|NCT01620983|OTHER|Usual Care|
224222049|NCT05085054|DRUG|Osimertinib Mesylate|Participants will receive targeted therapy followed by salvage surgery
224222050|NCT04421885|DRUG|Tebipenem pivoxil hydrobromide (TBPM-PI-HBr) - Reference|600 mg (2 x 300 mg tablets) clinical study drug product batch TBPM-PI-HBr.
224222051|NCT04421885|DRUG|Tebipenem pivoxil hydrobromide (TBPM-PI-HBr) - Test|600 mg (2 x 300 mg tablets) registration drug product batch TBPM-PI-HBr.
224222052|NCT01713153|DRUG|Misoprostol|600 mcg misoprostol oral
224222053|NCT01713153|DEVICE|UnijectTM|10 IU oxytocin delivered intramuscularly with UnijectTM
224222054|NCT03944486|DEVICE|Feasibility of OnTrack|Patients to use digital application- study assessed the feasibility of the application for patients and therapists.
224222055|NCT03548376|OTHER|Hippotherapy|Hippotherapy is a therapeutic intervention that is typically conducted by a physical or occupational therapist and is aimed at improving impaired body function. Hippotherapy has been proposed as a technique to decrease the energy requirements and improve walking in patients with cerebral palsy. It is thought that the natural swaying motion of the horse induces a pelvic movement in the rider that simulates human ambulation. In addition, variations in the horse's movements can also prompt natural equilibrium movements in the rider.
224222056|NCT01566292|DRUG|BOTOX|Botulinum Toxin type A, 200-300 UI dilued in 6 ml of saline solution
224222057|NCT05200702|DEVICE|Knee-hip Powered Soft Exoskeleton (MyoSuit, MyoSwiss, Zurich, Switzerland)|Patients and healthy subjects will wear the movement assistance device to perform different standardised physical evaluations.
224222058|NCT06344442|DRUG|Arginine vasopressin|low-dose arginine-vasopressin supplementation group: Vasopressin will be administered by continuous infusion. AVP will be used to a final concentration of 0.12 U/ml. The vasopressor infusion will be titrated to maintain an MAP of at least 65 mmHg. The study-drug infusion will be started at 5 ml/h and increased by 2.5 ml/h to achieve a maximum target rate of 30 ml/h, so that AVP doses ranged from 0.01 to 0.06 U/min.
224222059|NCT06344442|DRUG|Norepinephrine|Norepinephrine will be administered by continuous infusion. Norepinephrine will be used with final concentrations of 120 microg/ml. The vasopressor infusion will be titrated to maintain an MAP of at least 65 mmHg. The study-drug infusion will be started at 5 ml/h and increased by 2.5 ml/h to achieve a maximum target rate of 30 ml/h, so that NE doses ranged from10 to 60 microg/min.
224222060|NCT02880904|OTHER|Photography|Photos will be taken of the vulvar lichen sclerosus lesions.
224222061|NCT03873519|OTHER|Chromatic Environment|Rooms where chemotherapy sessions are delivered will be modified to show warm/cold color temperature in walls and equipment.
224222062|NCT03873519|OTHER|Room Orientation|Room will be facing North or South
224222063|NCT01788722|DRUG|Dienogest (Visanne, BAY86-5258)|Patients in daily life clinical practice treatment receiving Visanne (dienogest 2mg) according to indication on the label.
224222064|NCT05085964|DRUG|RNA antisense oligonucleotide for intravitreal injection|"QR-421a will be first administered to the fellow eye (as defined in the preceding study), and will be repeated every 6 months.~Treatment of the study eye (as defined in the preceding study) can commence 3 months (9 months for subjects from study PQ-421a-001) after the treatment of the fellow eye has been initiated and will be repeated every 6 months as well.~Continued subject treatment in this study will be pursued provided that the benefit-risk balance is positive for the individual subject."
224222065|NCT03676023|DRUG|Tranexamic Acid|Inhalation of Transexamic acid in age adjusted dosing
224222066|NCT04841239|OTHER|Herbal topical formulation|
224222067|NCT05544747|OTHER|Action Observation Therapy|"following phases will be included in action observation therapy group:~1. upper limb active range of motion (AROM) exercises.~2. reaching movement or object manipulation.~3. upper limb functional tasks."
223633202|NCT02902458|OTHER|Individual interview with a qualified psychologist|Individual, recorded interview with a qualified psychologist to discuss any and all subjects related to the ICD implantation, or any other topics deemed relevant by the patient.
223633203|NCT04057950|OTHER|cosmetic product|Disulfure de sélénium versus placebo formula
223633204|NCT02271269|BEHAVIORAL|Value Pricing Subsidies|"* Usual care for glaucoma~* Subsidies granted to adherent patients for their glaucoma medications and physician visits, lowering the costs of treatment and providing a financial incentive for patients to take their medicines as prescribed.~* Subsidy (25 / 50%) granted based on meeting dose-rate adherence percentage targets (75 / 90%) at the month 3 and 6 assessment points."
223633205|NCT02306746|DIETARY_SUPPLEMENT|TARGET protocol EN 1.5 kcal/mL|Enteral feed 1.5 kcal/mL
223764460|NCT06843980|DEVICE|MISHA Knee System|The MISHA Knee System is an extra-capsular knee implant intended to reduce loads on the medial knee. The implant consists of an absorber located between bases fixed with locking screws to the medial cortices of the distal femur and proximal tibia. The implant shares the load with the medial knee joint and articulating ball-and-sockets allow the device to accommodate the natural motions of the knee.
223764461|NCT06843980|OTHER|Non-Surgical Treatment|The non-surgical arm includes assist devices, physical conditioning, prescription or nonprescription medications, creams, vitamins, or supplements, intra-articular Injections, physical therapy and weight loss.
223764462|NCT03323489|RADIATION|Celiac Plexus Radiosurgery|patients will receive a single radiation treatment of 25 Gy directed towards the celiac surgery, and at the physician's discretion also abutting tumor
223764463|NCT02871128|DIETARY_SUPPLEMENT|Natureheme-iron|An 12 week double-blinded randomized parallel study with 4 week follow-up period was performed in mild anemia subjects. Consenting eligible subjects were receive 2 capsules per day containing either 1000 mg Fe of similar appearance for 12 weeks. The subjects were required to visit at baseline, every 6 weeks during the intervention period (6 weeks), and at follow-up 4 weeks after treatment had ended. During each study visit, fasting blood samples were collected and anthropometric measurements were performed. Compliance was evaluated using a food diary and monitored with biweekly telephone calls.
224222068|NCT05544747|OTHER|Mirror Therapy|"following phases will be included in mirror therapy group:~1. AROM exercises),~2. reaching movement or object manipulation, and~3. functional task practice"
224222069|NCT01670461|BEHAVIORAL|FACE|FACE intervention goal is to facilitate conversations about EOL care between adolescents and their legal guardians/surrogates to increase congruence in treatment preferences, to decrease decisional conflict, while supporting plans and actions, psychological adjustment and quality of life. Three 60 to 90-minute sessions in a dyadic format with a trained/certified interviewer. Session 1. The Lyon Family Centered Advance Care Planning Survey©. Session 2. Respecting Choices® Family-Centered Cancer Specific ACP Interview. Session 3. Completion of Five Wishes©.
224222070|NCT01670461|BEHAVIORAL|Standard of Care (SOC) Control|"Standard of Care (SOC) control will be provided with written information that encourages conversation the treatment team. At Children's National the following represent hospital policy:  … regarding advance directives … to honor each non-minor patient's wishes … to encourage and assist patients in determining and expressing their preferences regarding treatment decisions for use in the event they subsequently become unable to make such decisions. Upon admission if they do not have an advance directive, they should be given the Advance Directive Information Booklet and the Advance Directive Checklist. If they already have one, the patient is asked to provide a current copy, and it is placed in the medical record."
224222071|NCT01040221|DRUG|Trichuris Suis Ova|TSO will be administered in vials prepared by Coronado Biosciences. Vials will be diluted with a commercial drink and given to subjects to ingest. Subjects will receive a dose of 2500 ova every two weeks for 12 weeks.
224222072|NCT02658409|BIOLOGICAL|GC3106(quadrivalent cell-culture based influenza vaccine)|GC3106(quadrivalent),0.5ml, intramuscular, a single dosing at Day 1
224222073|NCT02658409|BIOLOGICAL|Fluarix™tetra Syringe Inj.(quadrivalent influenza vaccine)|Fluarix™tetra Syringe Inj., 0.5ml, intramuscular, a single dosing at Day 1
224222074|NCT00545233|DRUG|peginterferon alfa-2a [Pegasys]|180 micrograms subcutaneous weekly for 48 weeks
224222075|NCT00545233|DRUG|ribavirin [Copegus]|1000-1600 mg day orally for 48 weeks.
224222076|NCT00545233|DRUG|Pioglitazone|30 mg daily for 8 weeks increasing to 45 mg daily for 64 weeks.
224222077|NCT04525742|OTHER|Difficulties lived by disabled children's parents in the period of COVID-19 pandemic|It will be a cross sectional study to obtain the information on difficulties lived by disabled children's parents during recent pandemic period
224222078|NCT02914366|DRUG|Ambroxol|
224222079|NCT02914366|OTHER|Placebo|
224222080|NCT00123305|DRUG|Microplasmin|1mg/kg bolus of microplasmin solution followed by 1,2 or 3mg/kg infusion of mircroplasmin solution.
224222081|NCT00123305|DRUG|Microplasmin|1mg/kg bolus of placebo solution followed by 1,2 or 3mg/kg infusion of placebo solution
224222082|NCT03503474|OTHER|No intervention|There is no intervention, this is observational only
223633206|NCT02306746|DIETARY_SUPPLEMENT|TARGET protocol EN 1.0 kcal/mL|Enteral feed 1.0 kcal/mL
223633207|NCT00000670|DRUG|Probenecid|
223633208|NCT00000670|DRUG|Zidovudine|
223633209|NCT06051201|OTHER|ReceptIVFity test (vaginal microbiome swab)|"A vaginal self-swab for determination of the vaginal microbiome is performed by the patient.~For women of European origin randomization in one of the following groups:~SDM group: Using Shared-Decision-Making according to the ReceptIVFity microbiome profile with its predicted chance of achieving a pregnancy in the current cycle.~Physician decision group: Postponing treatment until a switch to a favorable ReceptIVFity microbiome profile"
223633210|NCT00767988|DIETARY_SUPPLEMENT|Urex-cap-5 (2x10^9 cfu each of Lactobacillus reuteri RC-14 and Lactobacillus rhamnosus GR-1)|Capsules once daily at approximately the same time each day for 6 months.
223633211|NCT00767988|OTHER|Placebo|Capsule once daily at approximately the same time each day for 6 months.
224222083|NCT02394431|OTHER|Cardiac echography|Ejection fraction measured by Teicholz and planimetry, diastolic function, tissular doppler, myocardiac performance index, global longitudinal strain measured by speckle tracking, arterial pulmonary hypertension, left ventricular hypertrophy.
224222084|NCT02394431|OTHER|Biological parameters|Hemoglobin levels, red cells, hematocrit, iron, ferritin
224222085|NCT02394431|OTHER|Clinical parameters|Blood transfusion number, severity of the sickle cell disease damage, evolution duration of the sickness
224222086|NCT01408407|OTHER|Aveeno cream|Apply cream on irradiated area twice a day
224222087|NCT01408407|OTHER|Alkagin paste|Apply Alkagin paste three times a day.
224222088|NCT00390988|PROCEDURE|blood sampling|
224222089|NCT04539509|BEHAVIORAL|Exercise Prescription|A specific exercise prescription, based on the results of a treadmill test.
224222090|NCT04539509|BEHAVIORAL|Treadmill Test|A symptom-limited treadmill test, using the Buffalo Concussion Treadmill Test (BCTT) protocol.
224222091|NCT04539509|DEVICE|Monitoring|Activity monitoring using a Fitbit.
224222092|NCT01517568|DRUG|liraglutide [3H]|A single dose of 0.75 mg will be given as a subcutaneous injection
223633212|NCT03181932|DRUG|Vancomycin inhalation powder|100 participants are to be treated with double-blind vancomycin inhalation powder (75 subjects ≤21 years old, 25 subjects \>21 years old) for 24 weeks during Period 1.
223633213|NCT03181932|DRUG|Placebo inhalation powder|100 participants are to be treated with double-blind placebo (75 subjects ≤21 years old, 25 subjects \>21 years old) for 24 weeks during Period 1.
223633214|NCT03181932|DRUG|Vancomycin inhalation powder|In the 24-week Period 2, all participants are to be treated with open-label vancomycin inhalation powder.
223633215|NCT02576483|BEHAVIORAL|Questionnaire (QoV questionnaire)|Quality of vision and quality of life questionnaire
224222093|NCT04921150|OTHER|standardization management|Apply standardization management to improve the outcomes of pregnancy
223633216|NCT02214797|DEVICE|Etafilcon A, Lotrafilcon B , Senofilcon A|
223633217|NCT04698863|DEVICE|Oxygen reserve index|eveluating oxygen reserve in blood
223633218|NCT03276507|DIAGNOSTIC_TEST|Pulmonary function studies|
223633219|NCT03276507|DIAGNOSTIC_TEST|Echocardiogram|
223633220|NCT03276507|DIAGNOSTIC_TEST|Electrocardiogram|
223633221|NCT03276507|DIAGNOSTIC_TEST|Chest radiography|
224222094|NCT03863652|PROCEDURE|Percutaneous coronary intervention via snuffbox approach|After local anesthesia on left or right anatomical snuffbox with lidocaine hydrochloride using a 26 gauge needle, the puncture is performed using a 20 gauge needle with the through-and-through puncture technique or a 21 gauge open needle with anterior wall puncture technique. After successful puncture, 0.025-inch straight wire or 0.018-inch hair wire are inserted, followed by an insertion of the 5Fr. or 6Fr radial sheath (Prelude® Radial; Merit medical, UT, USA or Radifocus® Introducer II or Glidesheath Slender®; Terumo Corporation, Tokyo, Japan). The selection of puncture device is at physician discretion.
224222095|NCT01089049|DIETARY_SUPPLEMENT|FemMED Breast Health Formula|Two capsules daily, with meals. FemMED Breast Health Formula containing lignans.
224222096|NCT01334736|BEHAVIORAL|Usual care|After participants have completed the data collection portion of the SHIELD visit, the research assistant will provide the participant with an informational flyer regarding the risks of tobacco smoking and benefits of tobacco cessation. The participant will be provided the phone number for the Tobacco Quit Line in Maryland as well as a list of local tobacco cessation programs. Any questions will be answered by the research assistant. If the participant inquires about nicotine replacement therapy, they will be advised to contact their primary care provider to discuss potential therapeutic options. Spirometry results will be verbally disclosed to participants describing their lung function as a percent of predicted value. A handout with these results will be given to participants. At each follow-up visit, after obtaining CO and questionnaire data, spirometry results will be reviewed and participants will be offered the informational flyer and quit line number.
224222097|NCT01334736|BEHAVIORAL|Lung age|For individuals randomized to spirometric lung age intervention, after completion of data collection, CO level and acceptable spirometry, the participant will be verbally informed of spirometric results. It will be explained that lung function normally reduces with age and that smoking can damage lung as if they were aging more rapidly than normal using visual depictions. Their lung function estimates based on their chronological age and lung age will be provided. They will be informed that smoking cessation would slow the aging of their lungs. After questions are answered, the participant will receive a written report that includes enumeration of their lung age and chronological age. At initial and follow-up visits, the research assistant will provide the participant with the same informational flyer and Tobacco Quit Line in Maryland as the usual care intervention.
224222098|NCT01334736|BEHAVIORAL|Contingency Management|For individuals randomized to CM, after completion of data collection, it will be explained to the participant that they will receive monetary compensation for biological confirmation of tobacco cessation. At each visit, exhaled carbon monoxide levels will be checked. If the subject has a negative CO level, they will be compensated. If a participant has a CO consistent with recent tobacco use, (s)he will receive the payment for attending the visit, but no additional payment at that visit. Spirometry results will be verbally disclosed to participants describing their lung function as a percent of predicted value. A handout with these results will be given to participants. At each follow-up visit, after obtaining CO and questionnaire data, spirometry results will be reviewed and participants will be offered the informational flyer and quit line number.
224222099|NCT01334736|BEHAVIORAL|Lung age + Contingency Management|For individuals randomized to the combined contingency management + spirometric lung age intervention, after completion of data collection, CO level and acceptable spirometry, the participant will be described the process of contingency management as outlined above. Following this, the research assistant will then describe lung age to the participant as described above. At the end of this process, the participant will then receive the informational flyer, quit line and local tobacco cessation program information similar to the usual care intervention. At each follow-up visit, after obtaining CO level and questionnaire outcomes, appropriate CM payment, review of participant's baseline lung age and informational flyer will occur.
224222100|NCT02189395|DRUG|NPH and regular insulin|
224222101|NCT02189395|DRUG|glargine and humalog|
223633222|NCT03276507|DIAGNOSTIC_TEST|Blood test|
223633223|NCT03276507|BEHAVIORAL|Quality of life questionnaire|
223633224|NCT00904605|DRUG|Lidoderm|Eligible patients were randomly allocated to receive one of two treatments for 12 weeks: lidocaine patch 5% or celecoxib 200 mg daily. Lidocaine patch 5% (Lidoderm®, Endo Pharmaceuticals Inc.), 1⅓ patches applied topically to each affected knee every 24 hours (q24h
223633225|NCT00904605|DRUG|Celecoxib|Eligible patients were randomly allocated to receive one of two treatments for 12 weeks: lidocaine patch 5% or celecoxib 200 mg daily. Lidocaine patch 5% (Lidoderm®, Endo Pharmaceuticals Inc.), 1⅓ patches applied topically to each affected knee every 24 hours (q24h)
223633226|NCT01590719|DRUG|Placebo|Repeating intravenous dose until disease progression, unacceptable toxicity, or patient or physician decision to discontinue treatment
223633227|NCT01590719|DRUG|Onartuzumab (MetMAb)|Repeating intravenous dose until disease progression, unacceptable toxicity, or patient or physician decision to discontinue treatment
223633228|NCT01590719|DRUG|Oxaliplatin|Oxaliplatin 85 mg/m2 IV every 2 weeks until disease progression, unacceptable toxicity, or patient or physician decision to discontinue treatment
223633229|NCT01590719|DRUG|Folinic acid|Folinic acid 400 mg/m2 every 2 weeks until disease progression, unacceptable toxicity, or patient or physician decision to discontinue treatment
223633230|NCT01590719|DRUG|Levofolinic acid|If folinic acid is unavailable: levofolinic acid 200 mg/m2 every 2 weeks until disease progression, unacceptable toxicity, or patient or physician decision to discontinue treatment
223633231|NCT01590719|DRUG|5-Fluorouracil|5-Fluorouracil 400 mg/m2 IV followed by 2400 mg/m2 IV infusion every 2 weeks until disease progression, unacceptable toxicity, or patient or physician decision to discontinue treatment
223633232|NCT05902689|PROCEDURE|alveolar ridge preservation with bio-oss collagen|Alveolar ridge preservation with bio-oss collagen is a surgical method that reduces or limits the physiological resorption of alveolar bone after tooth extraction by implanting bio-oss collagen in the socket and covering the biological barrier membrane.
223633233|NCT05902689|PROCEDURE|alveolar ridge preservation with sticky bone|Alveolar ridge preservation with sticky bone is a surgical method that reduces or limits the physiological resorption of alveolar bone after tooth extraction by implanting sticky bone in the socket and covering the biological barrier membrane.
223633234|NCT01451112|BIOLOGICAL|Autologous cultured dermal and epidermal cells|A piece of occipital scalp is taken from the subject. The epidermal and dermal cells from this tissue are expanded in culture. The cells are then harvested and, for certain types of product, combined. These cells are then injected into the balding area of the scalp of the original subject.
223633235|NCT04631419|OTHER|Flapless laser corticotomy|The flapless laser corticotomy will be done by Er, Cr: YSGG laser as a series of circular holes will be made along with the planned position. The depth of laser cutting will be measured and controlled continuously during the operation by the periodontal probe with stopper read to each 3mm depth in addition to a few parts of a millimetre depth into the medullary bone to enhance bleeding. Canine retraction will be started after this procedure.
224222102|NCT01208402|DRUG|Esmolol|Infusion will be started at 50 mcg/kg/min for 4 minutes and titrated in increments of 50 mcg/kg/min up to a maximum of 300mcg/kg/min (maintenance dose) to maintain a heart rate between 60 and 80 beats per minute (bpm) while maintaining a minimum systolic blood pressure (SBP) of 95 mmHg during the length of surgery and up to 12 hours post-operatively.
224222103|NCT02077192|DRUG|Fostamatinib Disodium|Fostamatinib Disodium tablet 100 mg or 150 mg by mouth twice a day
224222104|NCT02197182|DRUG|LUXSOL copper containing cream|Active comparator arm
224222105|NCT02197182|DRUG|Metronidazole gel|Active comparator for treatment of bacterial vaginosis
224222106|NCT05649631|DIETARY_SUPPLEMENT|Sodium|50 IHA patients were randomized into two groups with low sodium (50mmol/d) and normal sodium (100mmol/d) without potassium supplement. A 14 days dietary intervention was performed respectively to compare the changes in blood pressure (BP) and serum potassium in two groups.
223633236|NCT04631419|OTHER|Canine retraction|canine retraction will be done on 17x25 stst archwire using coil spring adjusted to 150 gm, and miniscrews will be used as an indirect method of anchorage reinforcement
223633237|NCT00237302|DRUG|topiramate|
223633238|NCT02242604|OTHER|Multidimensional Geriatric Assessment (MGA)|"The MGA contains the following tests:~1. Barthel Katz Index (activity of daily living, ADL)~2. Mini Mental State Test (MMST)~3. DemTec (dementia detection test)~4. Clock Test~5. Geriatric Depression Scale (GDS)~6. Tinetti Test~7. TUG (timed up-and-go Test)~8. Esslinger Transfer Scale (ETS)~9. Handgrip Test~10. Mini Nutritional Assessment (MNA)"
223633239|NCT02770014|DRUG|Erlotinib|
223633240|NCT03925090|DRUG|Cisplatin+Toripalimab|chemotherapy and monoclonal antibody
223633241|NCT03925090|DRUG|Cisplatin+placebo|chemotherapy
223633242|NCT02172274|DRUG|[14C]-BI 10773 - oral solution|
224222107|NCT02106169|BEHAVIORAL|Therapeutic education group|
223633243|NCT00707889|DRUG|ABT-869|12.5 mg QD, tablets taken orally days 1-14 of every 14-day cycle
223633244|NCT00707889|DRUG|bevacizumab|10 mg/kg QD, IV on Day 1 of each 14-day cycle
223633245|NCT00707889|DRUG|oxaliplatin|85 mg/m2 IV, 120 minutes on Day 1 of each 14-day cycle
223633246|NCT00707889|DRUG|folinic acid|400 mg/m2 IV, 120 minutes on Day 1 of each 14-day cycle
223633247|NCT00707889|DRUG|fluorouracil|400 mg/m2 IV bolus on Day 1 of each 14-day cycle; followed by 2400 mg/m2 IV infusion 46-48 hours
223633248|NCT00707889|DRUG|ABT-869|7.5 mg QD tablets taken orally days 1-14 of every 14-day cycle
223633249|NCT06175806|DRUG|Ondansetron Oral Film|5-hydroxytryptamine (5-HT) receptor antagonist
224222108|NCT03559010|DRUG|Norgestrel 0.075 mg tablets|"All subjects enrolled in the use phase of this open-label study will be given the opportunity to purchase and take one Norgestrel 0.075 mg tablet daily up to 16 weeks.~Subjects will use the investigational product based on their understanding of the directions on the outer packaging called the Drug Facts Label and information inside the product packaging called the Consumer Information Leaflet."
224222109|NCT00384358|DRUG|rhBMP-2/CPM|one time injection of 3-5 mL test article at time of internal fracture fixation
223633250|NCT06175806|DRUG|Granisetron Oral Liquid Product|5-hydroxytryptamine (5-HT) receptor antagonist
223633251|NCT03341702|OTHER|penintetiary's incident reports collection|collection of clinical and penitentiary 's data
224222110|NCT00384358|DRUG|rhBMP-2/CPM|one time injection of 3-5 mL test article at time of internal fracture fixation
223633252|NCT00508794|BEHAVIORAL|Yoga Group|3 sessions of yoga each week for 6 weeks.
223633253|NCT00508794|BEHAVIORAL|Stretching Control Group|3 sessions of stretching each week for 6 weeks
223633254|NCT00508794|BEHAVIORAL|Waitlist Control Group|Option of participating in the yoga or stretching program after the study has ended.
223633255|NCT00508794|OTHER|Questionnaire|Questionnaire evaluating treatment-related symptoms during the middle of radiotherapy.
223633256|NCT02220920|DRUG|Canagliflozin (TA-7284)|The patients will receive Canagliflozin orally for 16 weeks
223633257|NCT02220920|DRUG|Placebo|The patients will receive Placebo orally for 16 weeks
223633258|NCT02220920|DRUG|Insulin|
223633259|NCT01792895|PROCEDURE|Manipulation|The Cervical Spine Manipulation is a manual therapy technique directed at the hypomobile and painful vertebral level. The subject was supine with the cervical spine in a neutral position. The index finger of the therapist applies contact over the posterolateral aspect of the zygapophyseal joint of the hypomobile vertebra. The therapist performs the technique taking account the most limited movement; lateral or rotational. A maximum of 2 attempts will performed on each subject regardless audible cavitation.
223633260|NCT01792895|PROCEDURE|Mobilization|The mobilization is a passive oscillatory technique, applied over cervical region in the hypomobile cervical level, the patient will be in prone and the therapist standing at the head of the patients with his thumbs in opposition placed at the level of the facet of the hypomobile cervical vertebra. A posteroanterior(PA) oscillatory pressure is applied, through the thumbs, over the process of the hypomobile vertebra. This oscillatory mobilization, is performed at a frequency of 2Hz (with metronome control/steps) for 2 minutes and repeated 3 times. The rest time between each mobilization was 1 minute.
223633261|NCT01792895|PROCEDURE|Mobilization with movement|"This is a manual therapy technique that consist of applied a sustain pressure over cervical hypomobile symptomatic level and request to patient a pain free movement.~For performs it, the therapist placed his thumbs on the articular process of that level. The patient sitting. Then, the subject had to perform actively the painful motion while the therapist guides the movement of that vertebra and resists it while returning to neutral. The strength applied was parallel to the plane of the joint, and the procedure was performed in 3 sets of 10 repetitions."
224222111|NCT00384358|OTHER|surgical intervention alone|surgical internal fixation of fracture defines the standard of care group
224222112|NCT06134739|OTHER|No intervention.|Observational study, no intervention.
224222113|NCT01335464|DRUG|placebo|placebo matching BIBF1120, BID
224222114|NCT01335464|DRUG|BIBF 1120|BIBF1120 BID (twice daily)
224222115|NCT00919139|OTHER|biologic sample preservation procedure|Blood and 3-4 cc bone marrow aspirate collected at same time (in association with treatment protocols on which patient is registered)
224318368|NCT02470845|DRUG|herbal patches of Tian Jiu group|The formula of herbal patch consists of BaiJieZi (Sinapis Semen), Yan Hu Suo（CorydulisRhizoma）、ZhiGan Sui (Kansui Radix)、Xi Xin (Asari Radix et rhizama) and Rengong She xiang(Moschus Artifactus) . The four herbs will be ground into powder, mixed thoroughlywith 20% BaiJieZi (Sinapis Semen), 25% Yan Hu Suo（CorydulisRhizoma), 15% ZhiGan Sui (Kansui Radix), and 40% Xi Xin (Asari Radix et rhizama), and the mixed powder will mix with fresh ginger juice in the ratio of 20g to 25 ml. The mixture will be made to a patch weighted as 2g and 1cm\*1cm round size. 0.02g artificial She Xiang (Moschus Artifactus) will be added on top of each patch. Each patch will be applied on one acupoint.
223633262|NCT03410277|OTHER|Experimental hypoglycemia|Experimental hypoglycemia with and without MRI
223633263|NCT04894266|DRUG|Apabetalone|Apabetalone 100mg BID
224318369|NCT02470845|DRUG|placebo patches of placebo-control group|The placebo patch consists of flour and edible pigments. These two ingredients will be mixed with water and made to patches weighted as 2g and 1cm\*1cm round size.Each patch will be applied on one acupoint.
223633264|NCT04894266|OTHER|Standard of care|Standard of Care
223764464|NCT02871128|DIETARY_SUPPLEMENT|Placebo|An 12 week double-blinded randomized parallel study with 4 week follow-up period was performed in mild anemia subjects. Consenting eligible subjects were receive 2 capsules per day containing either 1000 mg starch placebo of similar appearance for 12 weeks. The subjects were required to visit at baseline, every 6 weeks during the intervention period (6 weeks), and at follow-up 4 weeks after treatment had ended. During each study visit, fasting blood samples were collected and anthropometric measurements were performed. Compliance was evaluated using a food diary and monitored with biweekly telephone calls.
224222116|NCT01162395|DRUG|AZD3514|Patients will be given AZD3514 orally as a single dose, and then multiple once daily dosing following a 5-9 day washout.
224222117|NCT01595490|BEHAVIORAL|Mind-Body Skills Group|Teaching mind-body skills such as meditation, biofeedback, guided imagery, and meditation in a group setting
224222118|NCT03156270|DEVICE|Vivaer Stylus|Stylus used to deliver low-power, temperature-controlled, radiofrequency energy to the tissues of the internal nasal valve area
224318370|NCT00053183|PROCEDURE|conventional surgery|
224318371|NCT00053183|RADIATION|brachytherapy|
224318372|NCT00053183|RADIATION|radiation therapy|
224318373|NCT02646761|DEVICE|InterACTION|InterACTION guided home exercise program paired with standard of care physical therapy
224318374|NCT02646761|OTHER|Standard of Care Physical Therapy|Physical therapy rehabilitation program
224318375|NCT00448383|BIOLOGICAL|adalimumab|40mg every other week
223633265|NCT00896077|DRUG|Lisofylline|Lisofylline via i.v. administration vs Lisofylline vs s.c. administration
223633266|NCT01080079|DRUG|Terbinafine Hydrochloride|4% w/w Terbinafine Hydrochloride Gel
223633267|NCT01080079|OTHER|Purified Water|Purified Water
223633268|NCT00959855|OTHER|Pulmonary Rehabilitation|Sixteen, two hourly pulmonary rehabilitation sessions over an eight week period. The first hour will consist of an individualized exercise programme based on exercise field tests. The second hour will consist of an educational component. A home exercise programme of inspiratory muscle training (Threshold(R)IMT (respiratory muscle trainer re:HS730EU-001 single patient use) starting between 15% -30% of PiMax and progress weekly to 60% for 30 mins a day/ 5 dats a week with an inspiratory/expiratory ratio of 3:4. Patients will also be encouraged to walk or undertake an home exercise programme based on a Borg score of between 3 and 5 an additional 3 days a week.
224318376|NCT00302445|DRUG|Efalizumab|
224318377|NCT00302445|DEVICE|Narrow Band Phototherapy|
224318378|NCT02441660|DRUG|Capsaicin 8% Patch|Applied topically for 1 hour
224318379|NCT02441660|DRUG|Low Dose Capsaicin 0.025% Well Patch|
223633269|NCT00733018|BEHAVIORAL|"Western versus balanced macro nutrient diet composition"|Randomized crossover diet intervention. 6 days on solely one of two isocaloric diets, 8 days washout, and then the other diet for 6 days. Fasting blood sampling before and after each diet intervention period.
224222119|NCT05725278|BEHAVIORAL|Tiko Platform Behavioural cum mHealth Intervention|Tiko platform is a mix of social franchising and social marketing concepts to promote health behaviours through rewards to health promoters (pro agents), healthcare providers (doctors and pharmacies), Beneficiaries (women needing FP and/or ANC services), and shop keepers and life-style service providers where beneficiaries, providers and promoters could use their rewards points. The health promoters could purchase from wholesale retailers products such as sanitary napkins, condoms and then resale these at profit. Beneficiaries were given discounts and their rewards points can be used as cash to avail certain lifestyle services at participating locations, and so did the health care providers. Pro agents also got incentives for recruiting the beneficiaries and after beneficiaries reached certain service access/use milestones. All this was integrated on a mHealth platform using smart phones and smart cards (for those without access to Tiko card).
224222120|NCT05725278|OTHER|Standard of Care / Business as Usual|Non-Users of Tiko did not use Tiko platform but they could access any health care provider or pharmacy to avail same services related to Family planning, antenatal care, postnatal care
224318380|NCT03148665|DEVICE|OncAlert|A noninvasive point of care salivary rinse test performed as 1) a one-time test for control subjects, 2) at pretreatment and post treatment 3,6, 12, and 18 month time points in oral cavity/oropharynx cancer patients
224318381|NCT03486665|OTHER|Blood Sampling|Blood samples will be taken from all patients and healthy volunteers.
224318382|NCT03486665|OTHER|CSF Sampling|CSF sample will be taken from hospitalized newly diagnosed patients only.
224318383|NCT03002701|BEHAVIORAL|UNDERPIN-ICU program|UNDERPIN-ICU consists of standardized protocols focusing on several modifiable risk factors for delirium, including cognitive impairment, sleep deprivation, immobility and visual and hearing impairment.
224318384|NCT04283422|DIAGNOSTIC_TEST|Biofire filmarray|"Identification of microorganisms including:~1. Isolation of microorganisms:~   The sample will be cultured on blood agar, chocolate agar , MacConkeys agar and Sabouraud dextrose agar (SDA) plates,~2. Identification of the organism by Vitek2~3. Antibiotic sensitivity test of the organism by Vitek2~4. Identification of the organism by Biofire filmarray"
224318385|NCT03685422|OTHER|Virtual Reality|Before surgery, consented patients are given a Virtual Reality headset with pre-installed relaxation apps to choose a preferred scenario. Patient will be asked on their satisfaction on the VR experience after the intervention. Visual analog scale-anxiety (VAS-A), Spielberger State-Trait Anxiety Inventory (STAI) and EQ-5D-3L questionnaires will be conducted during this period.
224318386|NCT03399825|DEVICE|OCT-A|"optical coherence tomography angiography~Imaging with optical coherence tomography angiography"
224318387|NCT04600258|DIETARY_SUPPLEMENT|Dark Chocolate|The patients will receive 40g per day of dark chocolate for 2 months
224318388|NCT05489666|DIETARY_SUPPLEMENT|Nature Made Vitamin D3 5,000 IU, 125mcg|Taking a 5,000 IU oral supplement of Vitamin D3, daily, for 8 weeks, may improve strength performance in women who have and are continuing a resistance trained workout regimen. After blood vitamin D levels have been raised to an optimal range, a lower dosage may be assigned as needed from 5,000 IU per day to 1,000-2,000 IU per day.
223633270|NCT04490070|BEHAVIORAL|Cognitive Stimulation|The caregiver training program consisted of applying the cognitive stimulation model of the CUIDA-2 program. This application included theoretical training made up of three modules: 1) person-centered care, 2) communication strategies, and 3) mediated cognitive stimulation strategies. The training was given in two group sessions of two hours each, plus 50 hours of individual practice, either on the job (in the case of professional caregivers) or in the home (in the case of family caregivers), in both cases supervised by psychologists who were experts in the program. In these individual practice hours, the caregivers were required to keep a weekly log. Here they had to plan in advance the activities that they were going to carry out with the older adult, and once they had taken place, they had to record how they were done and how the older adult had responded.
223633271|NCT05681182|COMBINATION_PRODUCT|CardiaMend with the Addition of Amiodarone|The CardiaMend patch will be saturated with Amiodarone prior to being sutured into place.
223633272|NCT01112917|DEVICE|VenaTech Convertible Vena Cava Filter|Prevention of Pulmonary Embolism
223633273|NCT01112917|PROCEDURE|Vena Cava Filter Conversion|Conversion of VenaTech Convertible filter to open configuration.
223633274|NCT04681443|DRUG|Crystallized phenol application|Crystallized phenol application into the sinus tract
223633275|NCT00667199|DRUG|Radium-223 dichloride (BAY88-8223)|The required volume of study drug to be administered to a patient was calculated using the patient's body weight, the dose (5 , 25 , 50 or 100 kBq/kg b.w.)
223633276|NCT00003449|DRUG|dexamethasone|
223633277|NCT00003449|DRUG|gemcitabine hydrochloride|
223633278|NCT00003449|DRUG|paclitaxel|
223633279|NCT00887536|DRUG|bevacizumab|bevacizumab 15 mg/kg IV every 21 days for 6 cycles followed by bevacizumab 15 mg/kg IV every 21 days until 1 year following the first dose of bevacizumab
223633280|NCT00887536|DRUG|docetaxel|docetaxel 75 mg/m2 IV every 21 days for 6 cycles
223633281|NCT00887536|DRUG|doxorubicin|doxorubicin 50 mg/m2 IV every 21 days for 6 cycles
223633282|NCT00887536|DRUG|cyclophosphamide|"Group 1: cyclophosphamide 500 mg/m2 IV every 21 days for 6 cycles~Group 2 and 3: cyclophosphamide 600 mg/m2 IV every 21 days for 6 cycles"
223633283|NCT00887536|DRUG|pegfilgrastim|pegfilgrastim 6 mg subcutaneous (SC) Day 2 every 21 days for 6 cycles \[filgrastim (Neupogen®) 5 mcg/kg Days 2-10 may be given in lieu of pegfilgrastim (Neulasta®), but pegfilgrastim is preferred.\]
224318389|NCT05489666|DIETARY_SUPPLEMENT|Placebo|Resistance trained women may not improve their strength performance with low levels of vitamin D in the blood.
223633284|NCT03264677|COMBINATION_PRODUCT|Group 1|NTG Hydro Boost Gelee Milk Cleanser + NTG Hydro Boost Kiwi Water Gel
223633285|NCT03264677|COMBINATION_PRODUCT|Group 2|NTG Hydro Boost Gelee Milk Cleanser + NTG Hydro Boost Water Gel
223633286|NCT03264677|COMBINATION_PRODUCT|Group 3|NTG Hydro Boost Gelee Milk Cleanser + NTG Hydro Boost Extra Dry Emulsion
223633287|NCT00643747|BIOLOGICAL|tgAAG76 (rAAV 2/2.hRPE65p.hRPE65)|Single subretinal injection of vector suspension; up to 3x10e12 vector particles
223633288|NCT06322628|DRUG|VSA006|every 12 weeks, subcutaneous injections
223633289|NCT06322628|DRUG|Placebo|every 12 weeks, subcutaneous injections
223633290|NCT00898417|BIOLOGICAL|bevacizumab|
223633291|NCT00898417|DRUG|carboplatin|
223633292|NCT00898417|DRUG|paclitaxel|
223633293|NCT00898417|GENETIC|proteomic profiling|
223633294|NCT00898417|OTHER|laboratory biomarker analysis|
223633295|NCT00898417|OTHER|matrix-assisted laser desorption/ionization time of flight mass spectrometry|
224222121|NCT00644371|DRUG|Ibritumomab Tiuxetan (Zevalin)|"Conditioning Regimen~1. Rituximab, 250 mg/m2 on days -21 and -14.~2. Ibritumomab tiuxetan (Zevalin): 0.4 mCi/kg (14.8 MBq/kg). Maximum: 32 mCi on day -14.~Chemotherapy:~* Fludarabine 30 mg/m2/day on days -7, -6, -5, -4 and -3 as a 30-min infusion.~* Melphalan 70 mg/m2/day on days -3 and -2 as a 15-min infusion.~Chemotherapy for relapsing patients after autologous transplantation including melphalan over the last 6 months:~* Thiotepa 5 mg/kg over 4 hours every 12 hours on day -8.~* Fludarabine 30 mg/m2/day on days -7, -6, -5, -4 and -3 as a 30-min infusion.~* Melphalan 70 mg/m2/day on day -2 as a 15-min infusion."
224222122|NCT00002571|BIOLOGICAL|bleomycin sulfate|5u/m2 IV Q21days x 6 cycles
224222123|NCT00002571|BIOLOGICAL|filgrastim|5ug/kg SC, Days 9-20, Q 21 days x 6 cycles
224222124|NCT00002571|DRUG|cyclophosphamide|490 mg/m2 IV Q 21 days x 6 cycles
224222125|NCT00002571|DRUG|cytarabine|225 mg/m2 IV Q 21 days x 6 cycles
223633296|NCT04743843|DEVICE|Omnyx Dynamyx Software|Digital pathology image management and viewing software.
223633297|NCT02433418|PROCEDURE|Tubal flushing by Urografin®|Women will have tubal flushing through HSG using water soluble media (Urographin ®)
223633298|NCT02433418|DRUG|Diclofenac|Women will receive oral diclofenac 50 mg (voltaren ®) 1 hour before hysterosalpingography
223633299|NCT05630924|OTHER|SI! Program-NYC|SI! Program-NYC incorporates a comprehensive and integrated vision of CV health promotion that encompasses four (4) basic and interrelated components: body and heart, physical activity healthy diet; and emotional management.
223633300|NCT02177123|DEVICE|InnFocus MicroShunt implantation|Implantation will include the use of Mitomycin C applied with sponges.
223633301|NCT01112826|DRUG|Capecitabine|capecitabine 650 mg/m2 twice every day for 1 year.
224222126|NCT00002571|DRUG|doxorubicin hydrochloride|19 mg/m2 IV Q 21 days x 6 cycles
224222127|NCT00002571|DRUG|etoposide|90 mg/m2 IV Q 21 days x 6 cycles
224222128|NCT00002571|DRUG|leucovorin calcium|25 mg/m2 po 24 hours after methotrexate Q 6 hours x 4 doses for 6 cycles.
224222129|NCT00002571|DRUG|methotrexate|90 mg/m2 IV, Q 21 days x 6 cycles.
223633302|NCT05686902|OTHER|CLEANING SOLUTION|The difference in peristomal skin integrity between the groups will be examined.
223633303|NCT05753943|DRUG|QUALI|Medication 1 pill at night
223633304|NCT06525012|OTHER|Usual patient care for patients hospitalized for subarachnoid hemorrhage of aneurysmal origin|During hospitalization (2013-2021), patients were managed after multidisciplinary consultation in accordance with national recommendations between resuscitators, neurosurgeons and neuroradiologists, depending on the severity of the initial management and the patient's comorbidities, either by interventional radiology, neurosurgery or medical treatment.
223633305|NCT06450899|DRUG|Prochlorperazine Maleate|Currently, prochlorperazine maleate is approved by the FDA for the treatment of nausea and vomiting, and additionally used off-label as an acute migraine treatment. The FDA has approved the dose of 5-10 mg to be taken orally 3-4 times a day. The study intervention will be obtained from Belmar Pharma solutions. Individuals randomized into the study arm will receive generic prochlorperazine maleate 10 mg orally taken three times daily for one day. Participants will convene in the morning of the trial date at low altitude, where they will receive their first dose. They will then be driven to Summit Lake and break for lunch, where they will receive their second dose approximately 6 hours later. They will then hike to the summit and receive their final dose in the evening, approximately another 6 hours later.
223633306|NCT06450899|DRUG|Placebo|The placebo arm individuals will receive a non-identical inert generic placebo tablet containing microcrystalline cellulose provided by Belmar Pharma Solutions. Placebo tablets will be taken at the same time and frequency as the study intervention drug.
223633307|NCT03870945|BIOLOGICAL|MB-CART2019.1 Dose level 1|This is a prospective, multi-center, open phase I/II trial to evaluate feasibility, dosage, safety and toxicity as well as efficacy of ex vivo expanded autologous T cells genetically modified to express anti-CD20 and CD19 immunoreceptor (MBCART2019.1) in patients with relapsed or resistant aggressive CD20 and CD19 positive B-NHL/CLL/SLL.
224222130|NCT00002571|DRUG|prednisone|60 mg/m2 po QD x 14days for 6 cycles
224222131|NCT00002571|DRUG|trimethoprim-sulfamethoxazole|1 double throughout strength treatment tablet po on Monday, Wednesday, and Friday x 6, 21 day cycles
224222132|NCT00002571|DRUG|vincristine sulfate|1.4 mg/m2 IV Q 21 Days x 6 cycles
224222133|NCT00002571|RADIATION|radiation therapy|All patients achieving a CR or PR following systemic therapy and IT Ara-C, will receive 2,400 cGy in two hundred cGy fractions to the whole brain. Fields should adequately encompass all meningeal surfaces.
224222134|NCT00002571|DRUG|Intrathecal cytarabine|"If initial bone marrow positive:~Ara-C 30 mg/m2 IT per dose x 5 doses spaced evenly during the first two cycles of therapy. Ara-C 30 mg/m2 IT Day 1 of each subsequent cycle.~If initial CSF cytology positive:~Ara-C 30 mg/m2 IT per dose x 5 doses spaced evenly during the first cycle of therapy. If CSF negative after above, Ara-C 30 mg/m2 IT Day 1 of each subsequent cycle. If CSF positive after initial five doses of Ara-C, IT MTX 12 mg per dose x 5 doses should be given spaced evenly during the second cycle of therapy.~If initial bone marrow and CSF negative:~Ara-C 30 mg/m2 IT per dose x 5 doses to be given spaced evenly within 1 month of completion of systemic therapy."
224222135|NCT04708405|OTHER|Observation|Follow up and observe under standard of care given
224222136|NCT02971345|PROCEDURE|Stent and Iodine-125 seed strand implantation|The patent second-order branch of the intrahepatic portal vein was punctured with a 22-gauge Chiba needle under ultrasound guidance.Stent and Iodine-125 seed strand are implanted by two 0.035-inch,150-cm-long wire.
224222137|NCT02971345|DEVICE|Stent|Bare stent should be placed through a 7-F, 23-cm-long sheath over the wire.
223633308|NCT03870945|BIOLOGICAL|MB-CART2019.1 Dose level 2|This is a prospective, multi-center, open phase I/II trial to evaluate feasibility, dosage, safety and toxicity as well as efficacy of ex vivo expanded autologous T cells genetically modified to express anti-CD20 and CD19 immunoreceptor (MBCART2019.1) in patients with relapsed or resistant aggressive CD20 and CD19 positive B-NHL.
223633309|NCT06004999|OTHER|Whole body vibration|"All patients will be pedaling for 5 minutes, followed by a warm-up phase with 5 minutes of stretching for the hamstring, gastrocnemius, soleus, and quadriceps muscles.~Afterward, the following exercise program on the vibration platform will be applied to the 1st group.~* Lunge,~* Squat,~* Deep squat,~* Wide stance squat,~* Calves,~* Deep calves. The exercise time will be 6 minutes in the first week, and the exercise time will be increased in the following weeks, and the total exercise time will continue at 18 minutes in the last week."
223633310|NCT06004999|OTHER|The exercise program on flat ground without a vibration platform|"All patients will be pedaling for 5 minutes, followed by a warm-up phase with 5 minutes of stretching for the hamstring, gastrocnemius, soleus, and quadriceps muscles.~Afterward, the following exercise program will be applied to the group.~The exercise program will be applied to the 2nd group (controls) on flat ground without a vibration platform.~* Lunge,~* Squat,~* Deep squat,~* Wide stance squat,~* Calves,~* Deep calves. The exercise time will be 6 minutes in the first week, and the exercise time will be increased in the following weeks, and the total exercise time will continue at 18 minutes in the last week."
223633311|NCT04723056|DEVICE|Use of Zemedy Application|8 weeks of CBT via the Zemedy Application.
223633312|NCT05106894|BEHAVIORAL|smartphone application to promote nurturing care|see arm description
223633313|NCT05106894|BEHAVIORAL|printed caregiving materials|see arm description
223633314|NCT05941481|COMBINATION_PRODUCT|neoadjuvant chemo-hypofractionated radiotherapy plus PD-1 antibody (Tislelizumab)|"1. Immunotherapy combined with chemotherapy (2 cycles): Intravenous tislelizumab (200mg, d1, q21d) in combination with XELOX regimen (capecitabine 1000 mg/m2 bid\*14d + oxaliplatin 130mg/m2, d1, q21d);~2. Concurrent radiotherapy: Within one week after the first initiation of chemo-immunotherapy, concurrent hypofractionated radiotherapy will be started: intensity modulated radiotherapy was given for tumors, total dose:30Gy/12f, 2.5Gy/f."
223633315|NCT05697770|DRUG|Sodium bicarbonate|Sodium bicarbonate 8.4% will be continuously infused for a maximum of 5 hours. The infusion will start at 100 mL/hr and be kept at this rate until both pH and BE targets are achieved, following which, the infusion rate will be decreased to 25 mL/hr and kept constant at this rate until 5 hours has elapsed since the start of the infusion. At this point, the infusion will be stopped, independently, of the results of arterial blood gas analysis.
223633316|NCT05697770|DRUG|5% Dextrose|5% dextrose will be continuously infused for a maximum of 5 hours. The infusion will start at 100 mL/hr and be kept at this rate until both pH and BE targets are achieved, following which, the infusion rate will be decreased to 25 mL/hr and kept constant at this rate until 5 hours has elapsed since the start of the infusion. At this point, the infusion will be stopped, independently, of the results of arterial blood gas analysis.
223633317|NCT05236816|OTHER|Fatigue (physical exercise)|Subjects were evaluated before and after a fatiguing exercise of hip abductor muscles that consisted to repeat hip abduction with rate and range of motion until a target decrease of force is attempt
223633318|NCT05561920|DEVICE|High - speed video endoscopy (HSV)|Describe anatomical and morphological characteristics o phonatory movement of PEM in laryngectomy patients
223633319|NCT05561920|DEVICE|Acoustic voice analysis|acoustic program (lingWAVES - Voice and speech analyser) - measuring the values of acoustic parameters in voice recordings
223633320|NCT05561920|BEHAVIORAL|Quality of life questionnaire|Filling out questionnaires
223633321|NCT03776968|DRUG|HC1119|oral
223633322|NCT04050358|DIETARY_SUPPLEMENT|NRPT|Subjects randomly assigned to the active group will receive Nicotinamide Riboside and Pterostilbene (each capsule contains 125 mg NR and 25 mg PT, total daily dose is 2 capsules) for 3 weeks
223633323|NCT04050358|DIETARY_SUPPLEMENT|Placebo oral capsule|Subjects randomly assigned to the Placebo group will receive placebo oral capsules for 3 weeks
223633324|NCT03727217|DIAGNOSTIC_TEST|Pre and postoperative ultrasound|An ultrasound is performed in preoperative and in postoperative
223633325|NCT03956849|OTHER|Training COACH Conversationstarter|"After elaborating perceived barriers and facilitators via surveys and semi-structured focusgroups, a short training with the COACH Conversationstarter will be provided to a part of the participants. The COACH Conversationstarter will be provided to the participants attending the training, which they can use in the next couple of months. After a period of time all participants will be provided with a second questionnaire, and results of the group that received the COACH Conversationstarter will be compared with the group that didn't receive the COACH Conversationstarter. (A part of) the participants that used the COACH Conversationstarter will be interviewed about their experiences.~However, the study will have an observational design, since the decision if a professional is attending the training is not based on the investigator / protocol, but depending on the professional, for example logistic reasons. This is part of routine education."
223633326|NCT01596010|DRUG|2 mg estradiol / 1 mg norethisterone acetate (NETA)|A single dose of one tablet under fasting conditions separated by a wash-out period of 2 weeks (+0-2 days) between dosing visits. Administered orally.
223764465|NCT02871128|DRUG|supplement|An 12 week double-blinded randomized parallel study with 4 week follow-up period was performed in mild anemia subjects. Consenting eligible subjects were receive 1 capsule per day containing either 100 mg Fe of similar appearance for 12 weeks. The subjects were required to visit at baseline, every 6 weeks during the intervention period (6 weeks), and at follow-up 4 weeks after treatment had ended. During each study visit, fasting blood samples were collected and anthropometric measurements were performed. Compliance was evaluated using a food diary and monitored with biweekly telephone calls.
224222138|NCT02971345|DEVICE|Iodine-125 seed|The number of Iodine-125 seeds planned to be implanted was calculated by the following formula: N = length of obstructed main portal vein (mm)/4.5 + 4. These seeds were arranged linearly and sealed into a 4-F catheter continuously to construct a Iodine-125 seed strand.
224222139|NCT02971345|DRUG|Epirubicin|Epirubicin is a chemotherapy drug used in transarterial chemoembolization (TACE).Dosage: Epirubicin 30-60 mg per patient,depending on the situation of the patient.
224222140|NCT02971345|DRUG|Ultra-fluid lipiodol|Ultra-fluid lipiodol is a kind of embolization material used in TACE. Standard: 38% ultra-fluid lipiodol .
223764466|NCT01453842|DIETARY_SUPPLEMENT|Diet oil|Carrot and diet oil (containing 2-OG) and 1½ g of paracetamol
223764467|NCT01453842|DIETARY_SUPPLEMENT|Olive oil|Carrot and olive oil and 1½ g of paracetamol
223764468|NCT01453842|DIETARY_SUPPLEMENT|Carrot|Carrot and 1½ g of paracetamol
223764469|NCT06221696|DIETARY_SUPPLEMENT|Active Fiber Supplement Group|Three daily packets of active fiber supplement (each containing 1g of glucomannan, 1g of inulin, and 3g of psyllium), taken 30 minutes before each main meal. The supplement is provided by S.Lab (Soloways), LLC.
223764470|NCT06221696|OTHER|Placebo Group|Three daily packets of placebo powder, taken 30 minutes before each main meal.
223764471|NCT04076969|BEHAVIORAL|Integrated educational session|The educational session aimed to correct the pregnant women diatery habits and enhance the degree of compliance to the iron treatment and follow up instruction.
223514399|NCT06642233|DIAGNOSTIC_TEST|Socio-demographic survey|Socio-demographic survey includes: age, sex, time of symptoms, work activity, hours of work activity, work position, activities with loads, physical activity, household chores, missing teeth, dental splints, dentures, smoking, alcohol consumption, whether they can reproduce their symptoms, hours during which they perform focal distance tasks, whether they have visual problems, whether they take painkillers or anti-inflammatory drugs, presence of headaches and their frequency), whether you can reproduce your symptoms, hours during which you perform tasks at focal distance, whether you have visual problems, whether you take analgesics or anti-inflammatory drugs, presence and frequency of headaches.
223514400|NCT06642233|DIAGNOSTIC_TEST|Visual Analogue Scale|VAS scale - The subject must indicate with a horizontal line their perception of pain on a scale (not numbered) of 100 millimetres, with 0 being the absence of pain and 100 the worst pain imaginable. The patient will complete the VAS scale, responding to the average, maximum and minimum pain experienced throughout its duration.
223514401|NCT06642233|DIAGNOSTIC_TEST|The World Health Organization Quality-of-Life Scale-BREF questionnaire|The WHOQOL-BREF questionnaire is used to assess domains quality of life: physical, mental, social functioning and functioning in the environment. Responses are on a 5-point scale (score range 1-5). In each field you can get maximum 20 points. The results of individual areas are positive (the higher the number of points, the higher the quality of life).
223514402|NCT06642233|DIAGNOSTIC_TEST|The International Physical Activity Questionnaire|The International Physical Activity Questionnaire (IPAQ) is a self-reported questionnaire for assessing physical activity and sedentary behavior for adults aged 15-69 years, across a range of socio-economic settings.
223514403|NCT06642233|DIAGNOSTIC_TEST|The Neck Disability Index questionnaire|The NDI evaluates the effect of neck pain on activities of daily living and social relationships. It consists of 10 items with 6 response options that are scored from 0 to 5 points each for a total possible score of 50. The classification of disability is based on the total score obtained, with higher number indicating greater disability.
223514404|NCT06642233|DEVICE|Body composition analysis using TANITA device|"TANITA device - body composition analyzer, the proportion of muscle mass and fat in the upper limbs~* Body height will be determined using a SECA 217 stadimeter.~* General and segmental body composition using the eight-electrode body composition analyzer by TANITA."
223514405|NCT06642233|DIAGNOSTIC_TEST|Cervical spine AROM (Active range of motion)|"Measurement of cervical spine AROM can be performed using the CROM system (Performance Attainment Associates, Roseville, MN, USA). Flexion, extension, side bending to the right and left, and rotation to the right and left of the cervical spine are examined.~The CROM measuring equipment consists of a helmet-shaped structure with the shape of glasses. These glasses adjust to the nasal septum thanks to the velcro on the back to fit them on the head. Three inclinometers for measuring on 3 cardinal planes were placed in the plastic construction."
223514406|NCT06642233|DIAGNOSTIC_TEST|Sagittal plane UCS AROM (Upper cervical spine active range of motion)|Measurement of sagittal plane UCS AROM can be performed using the CROM system. Flexion and extension of the upper cervical spine are examined.
223514407|NCT06642233|DIAGNOSTIC_TEST|Flexion-Rotation Test|The flexion-rotation test can be performed using the CROM system. Rotation of the upper cervical spine is tested while the cervical spine is flexed.
223514408|NCT06642233|DIAGNOSTIC_TEST|Sidebending-Rotation Test|The sidebending-rotation test can be performed using the CROM system. Rotation of the upper cervical spine is tested while the cervical spine is in a lateral tilt.
223514409|NCT06642233|DIAGNOSTIC_TEST|Axial rotation test C0-C2|The Axial rotation test C0-C2 can be performed using the CROM system. Rotation of the C0-C2 is examined.
223514410|NCT06642233|DIAGNOSTIC_TEST|Tilting test C0-C1 and C2-C3|The Tilting test C0-C1 and C2-C3 can be performed using a goniometer. Lateral tilt of the C0-C1 and C2-C3 are examined.
223514411|NCT06642233|DIAGNOSTIC_TEST|Craniocervical flexion test|The test measures the level of activation of the deep neck flexors using a pressure biofeedback device, an air-filled manual pressure cuff (Stabilizer TM, Chattanooga Group, INC., USA).
223514412|NCT06642233|DIAGNOSTIC_TEST|Craniovertebral angle|The test measure the craniovertebral angle using a telephone placed on a tripod and a computer program. The CVA measurement is defined as the angle a horizontal line passing the neural spine of C7 in relation to the line connecting the tragus and the neural spine of C7.
223514413|NCT06643780|DRUG|Denosumab|60mg subcutaneous Denosumab (1mL solution) every 6 months and intravenous placebo (100mL normal saline) once yearly
223514414|NCT06643780|DRUG|Zolendronic Acid|5mg intravenous Zoledronic Acid (100mL solution) once yearly and subcutaneous placebo (1mL normal saline) every 6 months
223514415|NCT00511199|DRUG|NOMAC-E2|"Nomegestrol Acetate and Estradiol Tablets, 2.5 mg~NOMAC and 1.5 mg E2 taken once daily from Day 1 of menstrual period up to and including Day 28 for 13 consecutive 28-day menstrual cycles (1 year)."
223514416|NCT00511199|DRUG|DRSP-EE|Drospirenone and Ethinyl Estradiol Tablets, 3 mg DRSP and 30 mcg EE taken once daily from Day 1 of menstrual period up to and including Day 28 for 13 consecutive 28-day menstrual cycles (1 year).
223514417|NCT02449447|BEHAVIORAL|Cognitive behavioral therapy|CBT based on behavioral activation and cognitive therapy techniques including homework
223514418|NCT02449447|OTHER|Treatment as usual|Treatment as usual in primary care including antidepressants and counselling
223514419|NCT05671887|PROCEDURE|Double Lung Transplantation|To evaluate outcomes among patients who undergo lung transplantation for treatment of a select group of medically refractory cancers affecting the lungs alone without extrapulmonary nodal and distant metastasis.
223514420|NCT00048308|DRUG|pexelizumab|
223633327|NCT06177132|BEHAVIORAL|VIS-REHAB protocol|The VIS-REHAB protocol entails two essential components: postural stability (PS) and gaze stability (GS). Within the postural stability component of the VIS-REHAB protocol, there are static and dynamic balance exercises, along with general gross motor activities targeting core stability, agility, and bilateral coordination. The gaze stability part includes exercises enhancing oculomotor function such as smooth pursuit and saccadic movements, as well as VOR-exercises. Additionally, a general gross motor training program emphasises gaze stability by including exercises that improve eye-foot and eye-hand coordination. Furthermore, each session includes counselling and the provision of background information on the exercises.
223633328|NCT03431285|DRUG|Morphine Group|Patients will receive standard dose of morphine (0.1 mg/kg) in 100 ml normal saline infused over 30 min in addition to standard IV hydration.
223633329|NCT03431285|DRUG|Ketamine Group|Patients will receive low dose ketamine 0.3 mg/kg in 100ml N.S. infused over 30 min in addition to standard IV hydration
223633330|NCT03431285|OTHER|standard IV hydration|IV hydration as per our institutional protocol (Lactated Ringer's or NaCl 0.9% solution will be infused at a rate of 2-3 ml/kg/h)
223633331|NCT05902962|DRUG|VP-001|Phase 1 open-label, single arm dose escalation study of VP-001 in participants with genetically confirmed PRPF31 mutation-associated retinal dystrophy
223633332|NCT05040464|DRUG|AZA capsules|oral AZA capsules at a daily dose of 2.5 mg per kilogram,
223633333|NCT05040464|DRUG|MTX|MTX 25 mg SC once a week
223633334|NCT05040464|BIOLOGICAL|blood sample|The lab tests are: serum albumin, C-reactive protein, thrombocytosis and haemoglobin.
223633335|NCT06271993|DEVICE|ColActivePlus Collagen Matrix Dressing|The test product, positive control and negative control will be applied directly to the volar forearm skin of the subject. The sites will be a minimum of 2cm from each other to minimize cross contamination.
224222141|NCT02971345|OTHER|Gelatin sponge articles|Gelatin sponge articles embolization material used in TACE. Standard: 350-560 um in diameter.
223633336|NCT00335088|DRUG|Moxifloxacin and Povidone Iodine vs Povidone Iodine|
223633337|NCT02748083|DEVICE|tDCS|Electrodes for tDCS will have the anode placed over the left DLPFC (F3) and the cathode over the contralateral (right) supraorbital ridge. The exact location of electrodes will be determined by the 10/20 EEG method with EEG cap. Subjects will have tDCS sessions on consecutive days (weekends and holidays excluded). The tDCS group will have 10 active or sham tDCS sessions. The active group will be stimulated with a 2 mA current for 20 minutes.
223633338|NCT02748083|DEVICE|Sham tDCS|Electrodes for tDCS will have the anode placed over the left DLPFC (F3) and the cathode over the contralateral (right) supraorbital ridge. The exact location of electrodes will be determined by the 10/20 EEG method with EEG cap. Subjects will have tDCS sessions on consecutive days (weekends and holidays excluded). The sham tDCS group will have 10 active or sham tDCS sessions. The sham group will have stimulation lasting only 40 seconds though the electrodes will remain in place for 20 min.
223633339|NCT02614300|OTHER|Pulmonary Rehabilitation and Chest Physiotherapy|The patient will come 3 times per week during 12 weeks Each session 1h15min
224318390|NCT05086263|DEVICE|Pico G2 4k|"On this virtual reality headset, it will be loaded with an educational virtual reality mock MRI training titled Ready Teddy. This training explains the procedure to the viewer and addresses common questions that individuals often have regarding an MRI. Furthermore, using audio/visual cues, when the viewer moves their head too much in a MRI like setting they are reminded to stay still. Biofeedback training is aimed to mimic the experience of the MRI with real audio recordings of image acquisition, in order to adequately train the view to stay still in an MRI procedure."
223633340|NCT02614300|OTHER|Pulmonary Rehabilitation|The patient will come 3 times per week during 12 weeks Each session 45min
223633341|NCT02614300|OTHER|Chest Physiotherapy|The patient will come 3 times per week during 12 weeks Each session 30min
223633342|NCT03103542|BIOLOGICAL|Recombinant coagulation factor (rFVIIIFc)|"rFVIIIFc 200 IU/kg/day during ITI Period and thereafter adjusted according to the Investigator's judgement~administered intravenously."
223633343|NCT01719016|PROCEDURE|Cardiac PET, Coronary catheterization|"Patients would under go a Cardiac rest and stress PET scan and include the following drug administration:~1. N-13 Ammonia radionuclide - Two doses, 10 mCi for rest, 20 mCi for stress~2. Lexiscan - stress agent for PET scan~Patients would also undergo Coronary catheterization including the following drug administration and device usage:~1. Combowire to obtain pressure and flow readings on Combomap machine (Volcano Therapeutics, CA).~2. Adenosine - stress agent during catheterization, 140 ug/Kg/min"
223633344|NCT06242652|DRUG|608 Dose A|608 subcutaneous (SC) injection.
223633345|NCT06242652|DRUG|608 Dose B|608 subcutaneous (SC) injection.
223633346|NCT06242652|DRUG|608 Dose C|608 subcutaneous (SC) injection.
223633347|NCT06242652|DRUG|Adalimumab|Adalimumab subcutaneous (SC) injection.
223633348|NCT06242652|DRUG|Placebo|Placebo subcutaneous (SC) injection.
224222142|NCT05927805|OTHER|E-bibliotherapy|Participants in the intervention group will accept eight weekly sessions of e-bibliotherapy. The e-bibliotherapy will be delivered via the e-bibliotherapy app we develop and includes eight e-bibliotherapy sessions, each focusing on one active component that may affect a caregiver's mental well-being.
224222143|NCT05927805|OTHER|Control|The control group will give access to the same e-bibliotherapy app, but only be authorized to access general daily living knowledge that is different from the intervention contents. They will also be asked to finish a session each week for eight weeks.
224222144|NCT00446654|DRUG|CGC-11047|16.5 mg (3.3%) subconjunctival injection
223633349|NCT04721860|BEHAVIORAL|Backward Locomotion Treadmill Training (BLTT)|12-training sessions of reverse treadmill training (no bodyweight support) over four weeks.
224222145|NCT02175407|DRUG|ASP1707|oral
224222146|NCT02175407|DRUG|itraconazole|oral
224222147|NCT04826185|DRUG|IMB-1018972|Modified release (MR) oral tablet
224222148|NCT04826185|DRUG|Placebo|Matching oral tablet
224222149|NCT05478811|DEVICE|Er,Cr:YSSG laser|NaOCl, Er,Cr:YSSG will be activated by laser during the final irrigatio
224222150|NCT05478811|DEVICE|Control|Routine final irrigation procedure will be done, NaOCl will not be activated by any method)
224318391|NCT00582010|DRUG|inhaled nitric oxide|inhaled 80ppm for duration of surgery.
224318392|NCT00582010|DRUG|nitrogen gas|inhaled
223633350|NCT04721860|BEHAVIORAL|Forward Locomotion Treadmill Training (FLTT)|12-training sessions of forward treadmill training (no bodyweight support) over tfour weeks.
223633351|NCT04971161|BIOLOGICAL|allo-APZ2-CVU|Suspension of ABCB5-positive dermal mesenchymal stromal cells. One topical application with a syringe.
223633352|NCT04971161|DRUG|Placebo|One topical application with a syringe
223633353|NCT06329817|PROCEDURE|Incidence of regurgitation in two different position.|Preventing aspiration pneumonia in general anaesthesia in two different position supine v/s semi - Fowler
223633354|NCT03566511|DRUG|Diazoxide|Healthy and T2D participants will receive diazoxide at a dose of 4-7 mg/kg (based upon weight) between baseline MRI scan and second MRI scan.
223633355|NCT03566511|DRUG|Placebo|Healthy and T2D participants will receive placebo between baseline MRI scan and second MRI scan.
223633356|NCT04538989|DRUG|RZ358 Sequential Group Cohort 1|IV infusion for 8 weeks (3 mg/kg bi-weekly for 8 weeks)
223633357|NCT04538989|DRUG|RZ358 Sequential Group Cohort 2|IV infusion for 8 weeks (6 mg/kg bi-weekly for 8 weeks)
223633358|NCT04538989|DRUG|RZ358 Sequential Group Cohort 3|IV infusion for 8 weeks (9 mg/kg bi-weekly for 8 weeks)
224222151|NCT05086120|OTHER|eCARIBOU|A 16 week remote electronically deliver Integrated Care Pathway (ICP) for adolescents (13-18 years old) with Major Depressive Disorder (MDD).
224222152|NCT01712230|DRUG|GnRH agonist|"Drug: leuprolide acetate~Other Names:~Lupron 3.75 mg for depot suspension delivered by monthly intramuscular injection for 6 months"
224222153|NCT01712230|BEHAVIORAL|Supervised cardiovascular exercise|Supervised exercise, 4 days per week for 45 to 60 minutes per session for 6 months
224222154|NCT01712230|DRUG|Placebo|Placebo
224222155|NCT03047954|DRUG|Broncho-Vaxom|BV is an orally administered immunostimulating preparation, which consists of a lyophilised bacterial extract prepared from 8 bacterial species (Haemophilus influenzae, Streptococcus pneumoniae, Klebsiella pneumoniae and ozaenae, Staphylococcus aureus, Streptococcus pyogenes and viridans, Neisseria catarrhalis)
224222156|NCT03047954|DRUG|Placebo - Cap|Matching Placebo capsule administered
224318393|NCT03596138|OTHER|Evaluate the reliability and reproductibility of the automated angular measurement by the Gazelab|Compare the results of the Gazelab to the alternate occlusion by prism bar (standard gold) examiners.
223633359|NCT04538989|DRUG|RZ358 Sequential Group Cohort 4|IV infusion for 8 weeks (bi-weekly fixed dose-titration from 3 to 9 mg/kg for the first 4 weeks, followed by a fixed 9 mg/kg dose amount thereafter for the remaining 4 weeks)
223633360|NCT06366217|DEVICE|MydCombi Device|ophthalmic spray
223633361|NCT06366217|DRUG|MydCombi Drug|Tropicamide 1% and phenylephrine HCl 2.5%
223633362|NCT04196777|BEHAVIORAL|Audit-and-feedback|We will provide feedback both at baseline and at regular intervals to the 3 intervention sites. At first, we will schedule one-on-one conference calls with urology providers and the antimicrobial stewardship team at each of the 3 intervention sites. These conference calls will include a review of guidelines, a review of the facility's data on excessive post-procedural antimicrobial use for urologic patients, and an anonymous comparison to all other VHA sites. Next, we will prospectively monitor excessive post-procedural antimicrobial use at all 3 sites and the entire VHA for 1 year. Data on hospital-level excessive post-procedural antimicrobial use specific to urologic patients (primary outcome) will be sent electronically to urology providers and the antimicrobial stewardship team at the intervention site every other month via electronic mail.
223633363|NCT04691648|DRUG|Gilteritinib Exposure|Oral
224222157|NCT06021262|OTHER|exposure to organophosphates|organophosphates are esters of phosphoric acids or Thio phosphoric acids that exist in pesticides, where patients can be chronically or acutely exposed to such compounds.
223633364|NCT06132659|OTHER|Functional magnetic resonance imaging (fMRI) with Veritable-NF|Participants will have 4 visits (some can be done virtually). The baseline visit will include an interview and questionnaires. Eligible participants will have a practice session at visit 2, and may do a mock scanner if the visit is in person. Visit 3 will take place within 5 days of the practice session and participants will be asked to complete questionnaires and have an fMRI with the real neurofeedback. Visit 4 will take place one month after visit 3 and will include a follow-up interview with a trainer assessor as well as questionnaires. Additionally, 2 weeks after visit 3 participants will also complete some questionnaires online.
223633365|NCT06132659|OTHER|fMRI with Sham-NF|Participants will have 4 visits (some can be done virtually). The baseline visit will include an interview and questionnaires. Eligible participants will have a practice session at visit 2, and may do a mock scanner if the visit is in person. Visit 3 will take place within 5 days of the practice session and participants will be asked to complete questionnaires and have an fMRI with feedback that looks similar to real neurofeedback, but is computer generated. Visit 4 will take place 2 weeks after visit 3 and participants will complete more questionnaires.
223633366|NCT06224205|OTHER|Passive Digital Marker for screening for ADRD|Patients in the primary care clinics randomized to PDM+QDRS will have Electronic Health Record Data of their patients run through the PDM, a machine learning algorithm which can predict ADRD one year and three years prior to its onset. In addition, patients from these clinics will have their patients complete the QDRS, a validated patient reported outcome (PRO) tool. This combined approach will assess the value of early detection of ADRD and if the annual well visit can overcome the barriers related to early detection of ADRD.
223633367|NCT05371717|OTHER|Domiciliary use of Biorepair Total Protection + Biorepair Shock Treatment|Domiciliary use of Biorepair Total Protection twice a day for oral hygiene + Biorepair Shock Treatment application for 10 min once a day.
224222158|NCT01504867|DRUG|Aspirin|325mg loading dose once on study day 1, followed by 81mg dose once daily on study days 2-7. Administered by mouth or down nasal gastric tube.
224222159|NCT01504867|DRUG|Lactose powder|Matching lactose powder filled capsules will be administered on days 1-7.
224222160|NCT04182139|OTHER|Static Stretching Exercise|Each intervention group received a different duration and intensity of static stretching exercise protocol.
224318394|NCT00792350|DRUG|Sorafenib (Nexavar, BAY43-9006)|Treatment of Hepatocellular Carcinoma with Nexavar (HCC)
224318395|NCT05579002|OTHER|Questionnaires and tests|"Application of three questionnaires:~1. Canadian Occupational Performance Measure (CORM),~2. a version of the Disabilities of the Arm Shoulder and Hand (DASH) modified for the child~3. a questionnaire developed by CEREFAM~   * Two analytical and functional tests:~1\) the Action Research Arm Test (ARAT) 2) modified 400-point assessment."
224318396|NCT00601575|DRUG|Lithium|
223633368|NCT05371717|OTHER|Biorepair Total Protection|Domiciliary use of Biorepair Total Protection twice a day for oral hygiene + Biorepair Shock Treatment application for 10 min once a day.
223633369|NCT02939287|DRUG|o Aprepitant 125 mg orally one hour prior to chemotherapy on Day -1 and 80 mg orally on Days 0 and +1|Add aprepitant to anti-emetic regimen
223633370|NCT02939287|DRUG|Olanzapine10 mg orally daily on Days -1,0,+1 and +2|add olanzapine to anti-emetic regimen
223633371|NCT02939287|DRUG|Aprepitant plus Olanzapine|add aprepitant and olanzapine to anti-emetic regimen
223633372|NCT00981656|DRUG|cisplatin|60-minute intravenous (IV) infusion of 15 mg/m\^2 on days 1, 2, 3, 15, 16, 17, 29, 30, and 31 of radiation treatment.
223633373|NCT00981656|DRUG|5-fluorouracil|Continuous IV infusion of 500 mg/m\^2/24 hrs for 5 consecutive days during weeks 1 and 4 of radiation treatment.
223633374|NCT00981656|DRUG|Mitomycin|IV bolus dose of 12 mg/m\^2 on day 1 of radiation treatment.
223633375|NCT00981656|RADIATION|Three-Dimensional Conformal Radiation Therapy|Total dose to the gross bladder volume of 61.2 Gy as 34 daily fractions 5 days/week, for approximately 7 weeks.
224222161|NCT02332135|PROCEDURE|microwave ablation|First, the investigators detect the iPTH levels of all the patients in the investigators' blood purification center. The patients whose iPTH are between 300pg/ml and 800pg/ml and who have parathyroid nodular or diffuse hyperplasia demonstrated on ultrasound imaging or radioisotope scan are chosen to involve in this study. Patients are divided into 2 groups at random, the control group and the microwave ablation group. In the microwave ablation group, patients will accept microwave ablation. Oral medicines, if needed, will be taken according to the the suggestions in K/DOQI guideline.
224222162|NCT02332135|DRUG|active vitamin D|The control group will be treated by active vitamin D and other general treatment,such as dietary phosphate restriction and phosphate binders,according to the suggestions in K/DOQI guideline.
224222163|NCT06282796|DEVICE|Echocardiography|Two-dimensional, color Doppler, spectral Doppler, tissue Doppler and three-dimensional echocardiographic image recordings will be taken using a Philips Epiq 7C echocardiography device and X5-1 probe. Conventional parameters, additional parameters, and strain analyzes will be performed by TomTec AutoStrain Suite Software
224222164|NCT06527716|OTHER|Teaching Strategy|"Experimental group:~Get involved in the LINE digital media course learning platform.~1. LINE digital media course study period:~   Research subjects need to complete the aforementioned three pre-measurement forms before they can join the LINE digital media course. In this lesson plan design, at the end of a single class, there will be a summary of the key points of the class; after the end of a single class, there will be 5 to 10 questions accompanying the class. When the research subjects have finished answering, Regardless of whether the answer is correct or not, the system will display Problem Solution Analysis. The study time for this stage is 1 month.~2. WorkShop Learning~Control group:~Intervention in regular education course learning platform. The above-mentioned digital media courses will be placed on the educational platform of the college for research subjects to watch and learn."
223633376|NCT06513858|BEHAVIORAL|Communal Drumming|Communal drumming
223633377|NCT06513858|BEHAVIORAL|Communal drumming recordings|Recordings of drumming taken from the music made during a previous component of the study
223633378|NCT05620628|DRUG|Durvalumab|Durvalumab will be administered at 1500mg every 4 weeks from cycles 1 day 1.
223633379|NCT05620628|DRUG|Savolitinib|Savoritinib 600mg will be administered orally a day for 28 days as one cycle.
223633380|NCT00687596|DRUG|TAC-101|Participants were randomized to TAC 101 received TAC 101 20 mg (administered as 2 10 mg formulated tablets) PO daily with approximately 240 mL (8 oz) of water under fed conditions (no later than 1 hour after a meal) for 14 days followed by a 7 day recovery period. This cycle was repeated every 21 days.
223633381|NCT00687596|DRUG|Placebo|Participants randomized to placebo received 2 placebo tablets (identical in appearance to the TAC 101 tablets) administered PO daily with approximately 240 mL (8 oz) of water under fed conditions (no later than 1 hour after a meal) in a regimen identical to that for TAC 101.
223633382|NCT04861103|DRUG|Lovenox|Three times a day dosing and measuring Xa peak and trough levels
223633383|NCT06471244|OTHER|Finger tapping|The volunteer is tapping with his/her right hand index finger.
223633384|NCT06471244|OTHER|Median nerve stimulation|Electrical pulses are applied at the wrist to the median nerve.
223633385|NCT06471244|OTHER|Speech processing|German sentences are played to the volunteers and the volunteers have to fulfill a semantic task.
223633386|NCT05292794|DEVICE|CereGate Software; BSN cDBS Programmer; BSN Burst Programmer|"CereGate's objective is to, with a single DBS system implanted in the standard STN location for PD:~(i) deliver conventional tonic DBS stimulation of STN-to mitigate dopamine-responsive symptoms; and concurrently (ii) deliver bursting DBS-induced cueing stimulation-to mitigate FOG.~The sole function of CereGate Software is to guide the clinician through a systematic investigation of the stimulation parameter space to thereby configure / tune CereGate Therapy for each participant. CereGate Software proposes parameters for the clinician to evaluate and assists in documenting the response. It does not send commands to, nor control the output of, the DBS System."
223633387|NCT03406780|BIOLOGICAL|CAP-1002|The active pharmaceutical ingredient in CAP-1002 is Cardiosphere-Derived Cells (CDCs). CDCs are known to secrete numerous bioactive elements (growth factors, exosomes) which impact the therapeutic benefits of the cell-based therapy. The mechanism of action is the composite ability to be immunomodulatory, anti-fibrotic, anti-inflammatory, and pro-angiogenic.
223633388|NCT03406780|DRUG|Placebo|Placebo
223633389|NCT05450835|PROCEDURE|OGT group|In OGT group,the nasogastric tube was pulled out 3 cm from the oesophagal lumen to connect with the OGT. Meanwhile, the OGT was sleeved on anvil fork extracorporeally and the linear stapler was put into abdomen through trocar on the right side and then cartridge fork was inserted through jejunum opening towards the oral side of the lumen. Next, the anvil fork sleeved with OGT insert into the oesophageal mucosa canal by movement of the connection of fork -OGT -gastric tube.
223633390|NCT05450835|PROCEDURE|Overlap group|In overlap group, the oesophagojejunostomy was performed as reported by Inaba et al.
223633391|NCT04033926|DRUG|KZR-616|Subcutaneous 30 mg weekly for 2 weeks, then 45 mg weekly for 14 weeks
223633392|NCT04033926|DRUG|Placebo|Subcutaneous injection for 16 weeks
223633393|NCT00287105|DRUG|Standard chemotherapy + Imatinib|Patients receive Imatinib together with the standard chemotherapy regimen of phase IB and after each of three consecutive blocks of the standard chemotherapy in the consolidation phase
223633394|NCT03466658|DEVICE|JumpStart Antimicrobial Wound Dressing|A novel, wireless, low-level microcurrent-generating antimicrobial device (JumpStart) is a sterile single layer dressing consisting of a matrix of alternating silver (Ag) and zinc (Zn) dots that are held in positions on a polyester substrate with biocompatible binder. Dressing is then activated in the presence of a conductive fluid, which may come from wound exudate or exogenous fluids, such as saline. It has been observed, in vitro, to exhibit electricidal effect in the presence of antibiotic and multidrug resistant clinical wound isolates.
223633395|NCT06252181|OTHER|electromagnetic pulsed therapy|patients (20 elderly) with peripheral arterial disease who take their medications will receive one hour elliptical exercise ( exercise will be applied 3 times per the week for eight week) and 3 sessions per weeks of 8-week electromagnetic one-hour pulsed therapy
223633396|NCT06252181|OTHER|elliptical exercise|patients (20 elderly) with peripheral arterial disease who take their medications will receive one hour elliptical exercise (n=20 patients, exercise will be applied 3 times per the week for eight week)
223633397|NCT04956796|BEHAVIORAL|Airway Video Library Training|A video airway library consisting of real-life clinical videos of laryngoscopy and endotracheal intubation was developed by the study investigators. This library consists of video clips of normal and easy airways, pediatric airways as well as pathological or difficult airways that is devoid of patient identifying data. The participants of the study group will be exposed to the video library by two learning sessions. Each learning session consists of 1 hour of interactive \& immersive learning of 30 airway videos. At the end of the session, the participants will be oriented to the airway and identify key airway structures, learn to troubleshoot and navigate difficult anatomy, optimize visualization, and use accessory airway equipment.
224222165|NCT04190238|OTHER|Super inductive system (high frequency electromagnetic field)|Super inductive system (high frequency electromagnetic field)
224222166|NCT04190238|OTHER|Physical therapy|specific for spasticity
224222167|NCT05535517|OTHER|CeraVe SA Smoothing Cleanser|The CeraVe Salicylic Acid (SA) Smoothing Cleanser is formulated with salicylic acid to help exfoliate the skin and remove dirt and dead skin cells on the skin without compromising or striping moisture from the skin's natural barrier, leaving the skin feeling clean, smooth and hydrated. This salicylic acid cleanser is also formulated to include hyaluronic acid to hydrate and retain moisture and 3 essential ceramides to moisturise and help support the skin's barrier.
224222168|NCT05535517|OTHER|CeraVe SA Smoothing Cream|The CeraVe Salicylic Acid (SA) Smoothing Cream contains salicylic acid as well as hydrating hyaluronic acid and three essential ceramides.
224222169|NCT05535517|OTHER|Propaira 20% Lactic Acid Exfoliating Lotion|For smoothing rough skin.
224222170|NCT05535517|OTHER|Propaira 30% Urea Exfoliating Emollient|30% Urea, 7% Glycerin to smoothen rough skin.
224222171|NCT05535517|OTHER|KPAI|The proposed score, Keratosis Pilaris Area Index (KPAI), is a 5-point IGA score (0-4) of five main body areas: face, upper limbs, lower limbs, trunk, and buttocks, for a maximum of 20 in two main categories, activity (erythema, skin roughness and papulation) and damage (pigmentation and scarring). The final score will be a maximum of 100.
224222172|NCT05535517|OTHER|KP-IGA|A standard 5-point IGA score (0-4) defined specifically for KP
224222173|NCT02519972|DEVICE|low dose computed tomography|Participants will receive 3 round of low dose computed tomography screening every year
224222174|NCT05209490|PROCEDURE|Femoral nerve blockade under ultrasound control with a peripheral nerve stimulator|"Following the ultrasound visualization of the femoral nerve, a insulated injection needle was connected to the nerve stimulator . Under ultrasound visualization guidance, the needle of the electronic nerve stimulator was positioned at the sciatic nerve (in plane) from its lateral side at a slightly superior position . A marker for LA introduction was the visualization of the needle end near the nerve, and a positive muscular response . Subsequently, the introduction of LA solution was initiated.If LA was spreading from the lateral side down to the nerve, then the needle was replaced to the upper point of the nerve and the rest of LA was introduced, and vice versa . The presence of a complete and incomplete spread of LA along the entire circumference of the nerve was assessed. Correspondingly, if the anesthetic was spreading upwardly, the needle would be downwardly replaced.~In addition, a sciatic femoral nerve block is performed."
224222175|NCT05209490|PROCEDURE|femoral nerve blockade under ultrasound control without a peripheral nerve stimulator|"Under ultrasound visualization guidance, the needle owas positioned at the femoral nerve (in plane) from its lateral side at a slightly superior position . A marker for LA introduction was the visualization of the needle end near the nerve. Subsequently, the introduction of LA solution was initiated. The position of the needle was corrected 1-2 times according to the type of anesthetic spread. If LA was spreading from the lateral side down to the nerve, then the needle was replaced to the upper point of the nerve and the rest of LA was introduced, and vice versa . The presence of a complete and incomplete spread of LA along the entire circumference of the nerve was assessed. Correspondingly, if the anesthetic was spreading upwardly, the needle would be downwardly replaced.~In addition, a sciatic nerve block is performed."
224222176|NCT03525665|OTHER|Metabolic activity measured by FDG-PET|To evaluate whether metabolic activity measured by FDG-PET (SUV max) at time of relapse is predictive of patient's outcome.
224222177|NCT04072978|DEVICE|Intraocular lens implantation|Implantation of an intraocular lens using either an anterior chamber IOL or a scleral fixated IOL using the modified Yamane technique.
224222178|NCT01583751|PROCEDURE|videoendoscopic resection of pilonidal sinus|Resection of pilonidal sinus tissue with videoendoscopic approach.
224222179|NCT05881109|DRUG|Caspogunfin|No specific interventions were administrated. Participants receive interventions as part of routine medical care, where CAS was infused intravenously over 60 min at a loading dose of 70 mg/m2 on day 1, followed by a maintenance dose of 50 mg/m2 (maximum: 70 mg daily).
223633398|NCT04956796|BEHAVIORAL|Conventional Airway Training|The endotracheal intubation training Anesthesiology students currently receive routinely as part of their education.
223633399|NCT00754663|BEHAVIORAL|exercise training|walking training at least 3 times a week
223633400|NCT00129402|DRUG|ezetimibe with simvastatin|Ezetimibe 10 mg plus simvastatin 10 mg once a day for six weeks, or Ezetimibe 10 mg plus simvastatin 20 mg once a day for six weeks, or Ezetimibe 10 mg plus simvastatin 40 mg once a day for six weeks
223633401|NCT00129402|DRUG|simvastatin|Ezetimibe matching placebo plus simvastatin 10 mg once a day for six weeks, or Ezetimibe matching placebo plus simvastatin 20 mg once a day for six weeks, or Ezetimibe matching placebo plus simvastatin 40 mg once a day for six weeks
223633402|NCT02163239|DEVICE|Cannula and Blunt Obturator|The FloShield 10mm Endoscopic Cannula and Blunt Obturator will be used to maintain access to the peritoneal cavity during robot-assisted single site laparoscopic surgery
223633403|NCT01917617|DRUG|Gemcitabine , Cisplatin, Oral Rehydration Solution (ORS)|"Short hydration via oral rehydration solution (OS-1)~Cisplatin plus gemcitabine will be administered via infusion as follows; 500 ml of 0.9% saline including cisplatin (25 mg per square meter of body-surface area) over 1 hour followed by 250 ml of 0.9% saline including gemcitabine over 30 minutes. Before and after the infusion, each 500ml bottle of oral rehydration solution (OS-1) will be taken respectively."
223633404|NCT01917617|DRUG|Gemcitabine , Cisplatin|"Standard hydration via intravenous infusion~Cisplatin plus gemcitabine will be administered via usual infusion regimen by each hospital. In general, it is administered total 2 litters over 3 hours or more."
223633405|NCT02258737|BEHAVIORAL|Transitional Case Management|The case management activity deals with organizational and clinical aspects. The objective is to focus on network's expectations during hospitalization and at discharge, and ensure contacts between hospital and patient' social network. The aim is to support patient during the transition phase following discharge
223633406|NCT02258737|BEHAVIORAL|Standard Care|Routine hospitalization care is broadly defined as the usual level of care in the context of the adult department of psychiatry of the CHUV (Centre Hospitalier Universitaire Vaudois).
223633407|NCT00758017|OTHER|Acupuncture 1|Application of individualised acupuncture
224222180|NCT04949867|DRUG|Glucagon|Glucagon is filled in the pump and given automatically in case of hypoglycemia or pending hypoglycemia.
224222181|NCT04949867|DEVICE|Closed-loop System|Closed-loop system comprise of two DANA RS (R) insulin pumps (FiAsp-GlucaGen vs FiAsp-saline), one DexCom G6 sensor, and a smartphone for the control algorithm.
224222182|NCT06000189|PROCEDURE|Standardized skin surface biopsies (SSSB)|Skin samples will be obtained from four regions of the participants' faces, including the forehead, right cheek, left cheek, and the nose, before phototherapy and after 20 sessions of phototherapy. The SSSB will be performed as follows: a 1 cm² square will be drawn on a glass slide using a ruler. The skin areas to be sampled will be gently swabbed with a dry gauze to induce irritation by this way to obtain more mites. Then, one drop of cyanoacrylate adhesive will be dropped onto the marked area on the glass slide, and the adhesive surface of the slide will be pressed onto the skin surface for approximately one minute. Afterwards, the slide will be gently lifted, and the sampled area will be examined under a light microscope at x10 and x40 magnifications after applying immersion oil. The presence of more than five Demodex mites per square centimeter will be defined as increased Demodex density.
224222183|NCT00003633|DRUG|docetaxel|
224222184|NCT00003633|DRUG|estramustine phosphate sodium|
224222185|NCT00003633|DRUG|mitoxantrone hydrochloride|
223633408|NCT00758017|OTHER|Acupuncture 2|Application of standardised acupuncture
223633409|NCT01721135|DRUG|GSK2190915 100mg|Film coated oral tablet
223633410|NCT01721135|DRUG|GSK2190915 200mg|Film coated oral tablet
223633411|NCT01721135|DRUG|moxifloxacin 400mg|Film coated oral tablet
223633412|NCT01721135|DRUG|moxifloxacin placebo|Film coated oral tablet
223633413|NCT01721135|DRUG|GSK2190915 placebo|Film coated oral tablet
223633414|NCT01954498|DIETARY_SUPPLEMENT|Walnuts|
223633415|NCT01954498|DIETARY_SUPPLEMENT|OTC multivitamin|
223633416|NCT04734028|DRUG|Clopidogrel Tablets|DES-treated patients were treated with clopidogrel 75 mg daily and aspirin 100 mg daily
224222186|NCT00003633|DRUG|prednisone|
224222187|NCT04336267|DEVICE|Transcranial direct current stimulation (tDCS) group|Patients randomized to the tDCS group were treated with the following parameters: duration of stimulation of 20 minutes per session with a 2 mA intensity of anodal stimulation.
224222188|NCT04336267|DEVICE|Sham group|In the sham group, the stimulation setting was exactly the same but the stimulation intensity was set according to a ramping up/ramping down method and delivered only in the first and last 30 seconds of each session.
224222189|NCT05474612|OTHER|kinesiology taping with conventional therapy|Two pieces of the tape cutted in a Y-shape. Applied on deep cervical extensors and upper fibers of trapezius. Length of the tape may vary from person to person. Patient is instructed to keep the tape for at-least 2 days.
224222190|NCT05474612|OTHER|Instrument assisted soft tissue mobilization with conventional therapy|IASTM using tools over the length of targeted muscles (SCM, descending fiber of trapezius, suboccipitalis muscles) in a multidirectional stroking fashion applied to the skin at 30°- 60° for 5 minutes. Participants are in a comfortable position during treatment.
224222191|NCT00871169|DRUG|Irinotecan, oxaliplatin, and cetuximab|"Irinotecan at 90 mg/m2 intravenously every two weeks (administered over 60 minutes) + Oxaliplatin at 60 mg/m2 intravenously every two weeks(administered over 60 minutes) + Cetuximab at 250 mg/m2 intravenously every two weeks (administered over 90 minutes).~The treatment interval (one cycle) is every 14 days."
224222192|NCT05425108|DEVICE|Binocular CP1|Binocular active projection of defocused image in the peripheral visual field
224222193|NCT03724721|PROCEDURE|vacuum bottle|using vacuum bottle plus catheter for drainage of pneumothorax
224222194|NCT01040013|PROCEDURE|Laparoscopy|Laparoscopic Left-Colectomy
224222195|NCT01040013|PROCEDURE|left colectomy by laparotomy|PatientS will be operated by laparotomy
224222196|NCT03239275|PROCEDURE|Biocreative therapy|
224222197|NCT05531045|DIAGNOSTIC_TEST|PET/CT|FDG PET/CT assessed after 2 cycles of chemotherapy with PERCIST criteria
224222198|NCT01365845|RADIATION|Photon|50.4 Gy to the breast/chest wall and peripheral lymph nodes at 1.8 Gy per fraction
224222199|NCT01365845|RADIATION|3D-Proton/Conventional plan or 3D-proton only|50.4 Cobalt Gray Equivalent/Gray to the breast/chest wall and peripheral lymph nodes at 1.8 Cobalt Gray Equivalent/Gray per fraction
224222200|NCT06336889|PROCEDURE|Pelvic Angioembolization|Embolization is performed by placing a small catheter inside the blood vessels that supply the area that is bleeding. Carefully navigating the catheter, under image guidance, to the safest and farthest point, a variety of different materials can then be used to block the bleeding vessels.
224222201|NCT01993394|OTHER|hypergravity|1hr sitting rest followed by 10 min of hypergravity (2 centrifuge runs)
224222202|NCT01993394|OTHER|gas mixture|breathing air, 44.5%O2 or 100%O2
224222203|NCT05910710|GENETIC|Visium, Whole Genome Sequencing(WGS)/Whole Transcriptome Sequencing(WTS)|Visium : Spatial transcriptomics WGS/WTS : detection of somatic mutation
223633417|NCT01825460|OTHER|Manual Therapy Protocol|The manual therapy protocol consists in the application of the following techniques: stretching diaphragm, Inhibition for phrenic center, Neuromuscular technique, technique jones and balance technique functional.
223633418|NCT01825460|OTHER|Two manual techniques|The two manual techniques applied to control group are: inhibition for phrenic center and neuromuscular technique.
223633419|NCT00761423|BIOLOGICAL|PRP Injection with eccentric exercises|PRP Injection with eccentric exercises
223633420|NCT00761423|BIOLOGICAL|Placebo Injection with eccentric exercises|Placebo Injection with eccentric exercises
223633421|NCT00023777|BIOLOGICAL|filgrastim|induction: 5 mcg/kg/d IV or SC starting apx day 15
223633422|NCT00023777|BIOLOGICAL|sargramostim|induction: 250 mcg/m2/d IV or SC starting apx day 1
223633423|NCT00023777|DRUG|cytarabine|ind: 200 mg/m2/d continuous IV days 1-7 consol: 200 mg/m2/d continuous IV days 1-5
223633424|NCT00023777|DRUG|daunorubicin hydrochloride|ind and consol: 45 mg/m2/d continuous IV days 1-3
223633425|NCT00456846|DRUG|ABI-007|100 mg/m\^2 ABI-007 weekly for 3 weeks followed by 1 week rest
223633426|NCT03398317|OTHER|PICSI|sperm selection using PICSI dish for selecting sperm with lower DNA fragmentation index
223633427|NCT03398317|OTHER|MACS|sperm selection using MACS for selecting sperm with lower DNA fragmentation index
224318397|NCT04049136|DIAGNOSTIC_TEST|NT-proBNP|Measure levels of NT-proBNP in healthy pregnancy women across BMI categories.
223633428|NCT01241721|DEVICE|Positron Emission Mammography (PEM)|Phase 1 of the study will involve imaging the breast with cancer up to 3 times over 2 hours using one half (1/2) of the standard dose of the radioactive tracer, F18FDG, for PEM imaging. If this reduced dose is equivalent to the standard dose then one quarter (1/4) dose will be tested to find the lowest effective radiation dose of tracer to see breast cancer. Phase 2 of the study will involve imaging of both breasts several times over a shorter duration using the lowest effective dose of tracer identified in the first part of the study. This will allow us to examine the reliability of PEM to identify a second unsuspected abnormality in either breast. Patients will be offered biopsy by ultrasound, MRI or PEM as clinically appropriate of lesions suspected of being cancer prior to final surgical planning.
223633429|NCT00497614|DRUG|adalimumab|
223633430|NCT00811122|RADIATION|11C-PIB PET Scan|Participants will receive an 11C-PIB PET scan of the brain.
223633431|NCT00811122|RADIATION|FDG-PET Scan|Participants will receive an FDG-PET scan of the brain.
223633432|NCT00915252|DRUG|azacitidine|"Starting dose has been determined during run-in dose finding part of the study. Starting dose of the interventional drug is 75 mg/m²/d. Application form:~During induction therapy phase: i.v. on days -5--1 before standard chemotherapy for 1 or 2 cycles, During consolidation therapy: s.c. on days -5--1 before standard chemotherapy (2 cycles).~During maintenance therapy: s.c. on days 1-5 on a 28day cycle till maximum one year after start of first induction therapy."
223633433|NCT00915252|DRUG|standard chemotherapy (7+3 scheme): Daunorubicin, Cytarabine|"Induction therapy:~Daunorubicin 60mg/m²/d i.v.on days 3,4,5 AraC 100mg/m²/d i.v. on days 1-7~Consolidation therapy:~AraC 1g/m² twice a day on day 1,3,5"
223633434|NCT05944302|BEHAVIORAL|EMDR group|Eye Movement Desensitization and Reprocessing
223633435|NCT01185236|DRUG|simvastatin/ezetimibe|simvastatin/ezetimibe 10/20mg once daily for 12weeks
223633436|NCT01185236|DRUG|atorvastatin 20mg|atorvastatin 20mg once daily for 12weeks
223633437|NCT01328886|DRUG|Omalizumab|omalizumab lyophilized 150 mg injection
223633438|NCT01245556|DRUG|BMS-908662|Capsules, Oral, escalating doses starting at 25 mg, Q 12 h daily, Continuously
223633439|NCT01245556|DRUG|BMS-908662|Capsules, Oral, escalating doses starting at 25 mg Q 12 h daily for 3 weeks with 3 weeks interval for 4 cycles, then Q12 h daily for 3 weeks every 12 weeks, Continuously
223633440|NCT01245556|DRUG|Ipilimumab|Vial, IV, escalating doses starting at 3 mg/kg, Once every 3 weeks for 6 weeks, then once every 12 weeks, Continuously
223633441|NCT01245556|DRUG|Ipilimumab|Vial, IV, escalating doses starting at 3 mg/kg, Once every 6 weeks for 4 cycles, then once every 12 weeks, Continuously
223633442|NCT04323969|BEHAVIORAL|Specific Modification Target|Participants will be instructed to increase their baseline foot progression angle by 15 degrees. Visual feedback during practice will be delivered using a mirror and guideline (tape placed on mirror). Verbal feedback will be incorporated to encourage participants to perform the modified foot progression angle as accurately as possible.
223633443|NCT04323969|BEHAVIORAL|Self-directed Modification|Participants will be instructed to modify their foot progression angle as much as is comfortable. A mirror will be used during practice for visual feedback, but no specific target or guide will be provided.
223633444|NCT03044106|DEVICE|CLRT|CLRT is a novel method of laser stimulation on specific cranial reflex points that modulate muscle tone.
223633445|NCT01748292|DRUG|0.5 mg ranibizumab|Subject will receive drug (ranibizumab) via intravitreal injections (IVT) at every visit.
223633446|NCT01503203|OTHER|Strength Training|It will be does three times per week. The exercises are: squat, single leg squat, leg extension, leg curl, chair adductor, chair abductor and double plantar flexion.
223633447|NCT01503203|OTHER|Core training|Exercises for trunk stabilization. Will be lateral, front and back bridges. It will be does three times per week with three sets between fifteen and third seconds.
224222204|NCT00786110|DRUG|Sorafenib|Treatment scheme consisted of oral Sorafenib 400 mg p.o. bid until disease progression.
224318398|NCT04316793|OTHER|Dry needling|Intramuscular insertion of an OPTIMED 40mm x 0.3mm acupuncture needle in a trigger point of the infraspinatus muscle
224318399|NCT04316793|OTHER|Sham needling (SN)|Intradermal insertion of an OPTIMED 40mm x 0.3mm acupuncture needle over the infraspinatus region
223633448|NCT01503203|OTHER|Physical Virtual Training|The video game (Nintendo Wii and Wii Balance Board) will used for intervention. After strength and core training will be applied the physical virtual training during thirty minutes. Tho total time session for the Wii Group will be 110 minutes.
223633449|NCT01503203|OTHER|Strength Training|It will be does three times per week. The exercises are: squat, single leg squat, leg extension, leg curl, chair adductor, chair abductor and double plantar flexion.
223633450|NCT01503203|OTHER|Core Training|Exercises for trunk stabilization. Will be lateral, front and back bridges. It will be does three times per week with three sets between fifteen and third seconds.
223633451|NCT02147639|DIETARY_SUPPLEMENT|Sodium Nitrate|
224222205|NCT00786110|DRUG|Paclitaxel|Intravenous Paclitaxel 60 mg/mq/weekly i.v., until disease progression.
223633452|NCT02147639|DIETARY_SUPPLEMENT|Sodium Nitrate - double dose|
223633453|NCT02147639|DIETARY_SUPPLEMENT|Placebo|
223633454|NCT02147639|PROCEDURE|Increased exercise intensity|
223633455|NCT00400465|PROCEDURE|Normal dressing|Normal dressing
223633456|NCT00400465|PROCEDURE|Pressure dressing|Pressure dressing
223633457|NCT03379818|BEHAVIORAL|Shape training intervention|This intervention is based on on a study conducted by Smith and colleagues (2002), where they found that teaching typically developing infants to attend to shape by the end of the second year of life significantly enhances their word learning. Participants will be taught that the significant property they should focus in when learning and extending novel labels is shape. This will be done through play-like sessions.
223633458|NCT03379818|BEHAVIORAL|Specific word training|"In this intervention, participants will be taught the names of 28 real objects. The target words have been selected from the Wordbank database, which is an open database that lists the proportion of children that know a specific word at a specific age. Twenty-eight words that are understood by 80% of the total child population at 25 months were randomly selected as target words. Techniques such as focused stimulation and modelling target words, which have proved to be useful for word learning, will be used."
223633459|NCT00771277|BEHAVIORAL|Support Teams|Use of volunteers organized into teams with a coordinator to provide services to TBI family
223633460|NCT03199976|DRUG|Tiotropium Bromide|Tiotropium Bromide 2.5 µg/dose inhaled aerosol
223633461|NCT03199976|DRUG|Fluticasone Propionate|Fluticasone Propionate 125 µg/dose inhaled aerosol
223633462|NCT03199976|DRUG|Salbutamol|Salbutamol 0.1 mg/dose inhaled aerosol
223633463|NCT03249207|DRUG|IL-1Ra|Doses to be administered subcutaneously (SC) twice daily (12 hourly) starting within 72 hours of ictus (onset of symptoms) for a maximum of 21 days from ictus (or sooner if discharged from neurosurgical centre).
223633464|NCT03249207|DRUG|IL-1Ra Placebo|Doses to be administered subcutaneously (SC) twice daily (12 hourly) starting within 72 hours of ictus (onset of symptoms) for a maximum of 21 days from ictus (or sooner if discharged from neurosurgical centre).
223633465|NCT05761782|BEHAVIORAL|Education|To educate catchment area residents on modifiable risk factors for cancer (e.g., screening, behavior, vaccination) and the importance of participation in cancer research. Provide participants with educational materials on cancer prevention, screening, and vaccination.
223633466|NCT03505502|DRUG|IV tranexamic acid|in IV tranexamic acid group they received 1-gram tranexamic acid (10 ml) in 100 ml saline infusion or placebo (110 normal saline) by slow intravenous injection at an approximate rate of 1 mL per min.In topical tranexamic acid groupA gauze soaked with 2g tranexamic acid (20 ml) diluted in 100 ml of sodium chloride 0.9% or placebo (120ml of sodium chloride 0.9%.) used to compress the myoma bed for 5 minutes. To ensure a sufficiently high concentration, the tranexamic acid was diluted only to a volume sufficient to moisten a large wound surface. 20 ml moisten at least 1500 cm2.
224222206|NCT04482010|OTHER|Local community-based HIV care|"Compared to the classic HIV care, community-based HIV care includes:~* Individual interviews with a psychosocial agent;~* Support groups conducted by psychosocial agents;~* Culinary workshops gathering PLWHIV and healthcare professionals;~* Home visits by a community worker;~* Emergency relief based on a funding for patients with urgent needs~As in the classic HIV care, ARCAD Santé PLUS provides consultations with doctors, prescriptions and delivery of antiretroviral (ARV) treatment every 3 months, biological analyses for enrolment, and follow-up every 6 months. In addition, psychosocial agents from ARCAD Santé PLUS propose workshops on education and support for adherence to treatment."
224222207|NCT05063019|DIAGNOSTIC_TEST|MRI|Magnetic resonance imaging and enterography before surgery
224222208|NCT04664608|DEVICE|wearable EEG sensor|Wireless wearable EEG devices offer a new, non-invasive, and easy way of performing EEG monitoring.
224222209|NCT02110706|DRUG|Rituximab|Intervention (rituximab): The treatment group will receive a total of two cycles of rituximab separated by 6 months. Each cycle is defined as one infusion (375mg/m2 IV) per week for four consecutive weeks
224222210|NCT02110706|DRUG|Placebo|The placebo group will receive a vehicle control infusion
224222211|NCT03782649|DEVICE|Working Model 3.4NR|Investigational Medical Device collecting spectral Raman data from tissue
224222212|NCT03210259|DRUG|Humira®|Duration - 58 weeks
224222213|NCT03210259|DRUG|BI 695501|Duration - 58 weeks
224222214|NCT02087059|DRUG|Ruxolitinib|
224222215|NCT00252187|DRUG|B-type Natriuretic Peptide (BNP)|BNP hormone self-administered subcutaneously twice daily for 8 weeks at 10 mcg/kg.
224222216|NCT00252187|OTHER|Placebo|Placebo self-administered subcutaneously twice daily for 8 weeks.
223633467|NCT03913455|DRUG|Guadecitabine|Guadecitabine 30 mg/m2 subcutaneously Days 1-5
223633468|NCT03913455|DRUG|Carboplatin|Carboplatin AUC 4 IV Day 5
223633469|NCT04017663|OTHER|Application of questionnaires|Application of questionnaires to identify characteristics and main barriers of patients
223633470|NCT03463057|DRUG|Atezolizumab|Intervention Atezolizumab starts after 6 - 8 R-CHOP induction cycles (Rituximab, Cyclophosphamide, Hydroxo-doxorubicin, Vincristine and Prednisone (R-CHOP)); 18 cycles Atezolizumab followed by 12 months of observation
223633471|NCT06368635|DIAGNOSTIC_TEST|Coronary angiography|target vessel with intermediate coronary lesion (40-80% diameter stenosis and FFR(fractional flow reserve) ≥0.8； or severe stenosis（\>80%）after successful PCI(percutaneous coronary intervention) and FFR ≥0.8
223633472|NCT00005766|DRUG|Creatinine|
223633473|NCT03955198|COMBINATION_PRODUCT|Radiotherapy + durvalumab|Radiotherapy will be administered in combination with Durvalumab
223633474|NCT02241824|DEVICE|In-elastic lumbar brace|
223633475|NCT02241824|DEVICE|Elastic abdominal binder|
223633476|NCT05176288|DRUG|Axitinib|Taken Orally
223633477|NCT05176288|DRUG|Palbociclib|Taken Orally
223633478|NCT05176288|DRUG|Avelumab|Intravenous infusion
223633479|NCT01876836|DEVICE|i-gel|i-gel placed after induction
223633480|NCT01876836|DEVICE|C-LMA|placed after induction
223633481|NCT02940795|OTHER|Coke|Patients were given a 20 ounce bottle of Coke Cola.
223633482|NCT02940795|OTHER|Diet Rite|Patients were given a 12 ounce can of Diet Rite.
223633483|NCT05876442|DEVICE|Extracorporeal Shock Wave Therapy.|Patients will receive EPSW therapy at the area of the wrist for 5 minutes 1 time a week for 2 months.
223633484|NCT05876442|DEVICE|High Intensity Laser Therapy|High-intensity laser therapy at the area of the carpal bones for 5 minutes 2 times a week for two months..
223633485|NCT05876442|OTHER|Traditional Physical Therapy Exercise Program|30 minutes of stretching exercise for the wrist and carpal region with the fingers flexed and extended. Followed by strengthening exercises for the wrist flexors, extensors, and radial and ulnar deviation muscles. Mobilizing exercise, tendon gliding exercise, and instructed to wear a wrist splint at night for two months.
223633486|NCT03373123|PROCEDURE|Endoscopy|Endoscopy
223633487|NCT03373123|PROCEDURE|CTA|Radiomic features were extracted from CTA images.
223633488|NCT06413992|DRUG|Fluzoparib|During the maintenance phase of treatment. Oral administration of Fluzoparib capsules at a dose of 150mg（N=78 participants）, once in the morning and once in the evening until disease progression, intolerable toxicity, death, or up to a maximum of 2 years.
223633489|NCT06413992|DRUG|Camrelizumab|During the maintenance phase of treatment. Camrelizumab, 200 mg administered intravenously every 3 weeks until disease progression, intolerable toxicity, death, or up to 2 years.
223633490|NCT06413992|DRUG|paclitaxel (albumin bound)|Paclitaxel (albumin-bound) for injection, 260 mg/m\^2 administered intravenously in 3-week cycles for 6 cycles.
223633491|NCT06413992|DRUG|Carboplatin injection|AUC=5 Intravenous dosing is administered every 3 weeks for a total of 6 treatment cycles. Specific dosing cycles may be determined by the investigator
223633492|NCT06413992|DRUG|Carboplatin|AUC=5 Intravenous dosing is administered every 3 weeks for a total of 6 treatment cycles. Specific dosing cycles may be determined by the investigator
223633493|NCT06413992|RADIATION|External irradiation|Non-essential, decision to combine is made by the principal investigator based on the patient's condition.
224222217|NCT03465228|DEVICE|Training and LED group|The LED application will be performed before GTL training sessions and will be applied through the spot method with direct contact of the equipment over the irradiated site for 30 seconds. The application will be in four points in the lumbar region, above the gluteal region, with an angle of 90 ° in relation to the cutaneous surface. A wavelength of 660 to 850nm will be used with a frequency of 0 to 1500 Hz and energy irradiated of 0.9 J of each diode totaling 43.2J (48 diodes).
224222218|NCT03465228|DEVICE|Training group|The training sessions will be monitored based on the subjective perception of exertion of the session (PSESession) (FOSTER, 1998), and heart rate. There will be two types of training: continuous and interval training. The sessions of the training group (GT) and group training + LED (GL) will be preceded by a warm-up of 15 minutes. Participants in the two training groups will undergo weekly training twice weekly on non-consecutive days during four weeks. Continuous training will be 30 minutes at 70% to 80% of maximum heart rate, and interval training will be performed 30 minutes at 100% maximum heart rate of laced racing with fixation of an elastic tube in the floating vest, 30 seconds of intense running and 30 seconds interval. The LED off will be performed before training sessions.
223633494|NCT04030143|DRUG|Aripiprazole|Administered as an intramuscular (IM) depot injection.
223633495|NCT04030143|DRUG|Aripiprazole|Administered as an IM depot injection.
223633496|NCT02199184|DRUG|Cyclophosphamide|Given IV
223633497|NCT02199184|DRUG|Doxorubicin Hydrochloride|Given IV
223633498|NCT02199184|DRUG|Etoposide|Given IV
223633499|NCT02199184|BIOLOGICAL|Ofatumumab|Given IV
223633500|NCT02199184|DRUG|Prednisone|Given PO
223633501|NCT02199184|BIOLOGICAL|Rituximab|Given IV
223633502|NCT02199184|DRUG|Vincristine Sulfate|Given IV
223633503|NCT00412984|DRUG|warfarin|Oral tablets, 2.0 mg, adjusted to an INR of 2.5 (range 2.0 to 3.0)
223633504|NCT00412984|DRUG|apixaban|Oral tablets, 5.0 mg or 2.5 mg, twice daily
223633505|NCT05543603|DRUG|Lacer Clorhexidina Colutorio|15 ml 0,12% Chlorhexidine, one minute rinse
223633506|NCT05543603|DRUG|Lacer Clorhexidine 0.20% Colutorio|15 ml 0,2% Chlorhexidine, one minute rinse
223633507|NCT05543603|DRUG|Gingilacer Encías Delicadas Colutorio|15 ml 0,10% cymenol + 0,10% zinc chloride, one minute rinse
223633508|NCT05543603|DRUG|Distilled water|15 ml distilled water, one minute rinse
223633509|NCT02949336|RADIATION|Observational use of fluoroscopy|Minimal radiation exposure (0.17 mSv) for observational purpose
223633510|NCT00004688|DRUG|carmustine|
223633511|NCT00004688|DRUG|mercaptopurine|
223633512|NCT00004688|DRUG|streptozocin|
223633513|NCT00037843|DRUG|I-131 Iodocholesterol|
223633514|NCT05426499|DRUG|Patients requiring cefotaxime treatment|Dosage according to SmPC
223633515|NCT05426499|DRUG|Patients requiring meropenem treatment|Dosage according to SmPC
223633516|NCT05426499|DRUG|Patients requiring fluconazole treatment|Dosage according to SmPC
223633517|NCT05426499|DRUG|Patients requiring isavuconazole treatment|Dosage according to SmPC
223633518|NCT05426499|DRUG|Patients requiring anidulafungin treatment|Dosage according to SmPC
223633519|NCT01062958|OTHER|Neevo® (a medical food)|
223633520|NCT01062958|OTHER|Prenatal vitamins (≤1mg folic acid, 27 - 35mg iron, and ≤12mcg vitamin B12)|
223633521|NCT02383576|OTHER|No Intervention|No intervention administered in this study.
223633522|NCT06329830|DRUG|177Lu-PSMA-617|7.4 GBq (200 mCi) via IV infusion once every 6 weeks for 6 cycles
223633523|NCT06329830|DRUG|Niraparib abiraterone acetate|Dual action drug tablet that is taken orally by the participant once per day in one of the following dose combinations depending on the cohort assignment and number of dose-limiting toxicities: 200 mg/1000 mg, 150 mg/1000 mg, 100 mg/1000 mg, 50 mg/500 mg
223633524|NCT06329830|DRUG|Prednisone|5 mg orally twice per day
223633525|NCT06253442|PROCEDURE|Patients will receive Supra scapular nerve block and Axillary nerve block.|"Suprascapular nerve block will be done by posterior approach with the patient sitting up and leaning forward. The linear ultrasound probe will identify the suprascapular nerve, after that we will inject aliquots of Sunnypivacaine 0.5% 15 ml after negative aspiration of blood.~For the axillary nerve block, the ultrasound transducer will be placed in a sagittal plane over the humeral head on the posterior aspect of the arm to identify the deltoid muscle, neck of the humerus, the teres minor muscle, the circumflex humeral artery, and the triceps muscle. After the neurovascular quadrangular space identification and observing the deltoid muscle response to stimulation, a local anesthetic (10 ml 0.25% Sunnypivacaine) will be injected with the in-plain technique."
223633526|NCT06253442|PROCEDURE|Patients will receive Interscalene block.|Interscalene nerve block will be done ultrasound-guided using a linear array ultrasound transducer. While the patient is in the supine position, the head will be rotated to the contralateral side of the block. Ultrasound scanning will be performed in the transverse plane with long axis of the probe parallel to clavicle to visualize the brachial plexus between the anterior and middle scalene muscles. A 5-cm 22-gauge insulated needle will then be inserted in line with the probe in a lateral-to-medial needle orientation. Local anesthetic solution will then be injected in 15-ml aliquots Sunnypivacaine 0.5% after negative aspiration for blood to achieve spread posterior to or between the C5 and C6 nerve roots.
223633527|NCT04081493|OTHER|Low-load blood flow restricted exercise|"Leg press and knee extension exercise 3 times per week for 8 weeks. Repetition scheme: 30-15-15-until exhaustion interspaced by 30 sec rest. 5 min free-flow rest between exercises"
223633528|NCT04150614|DRUG|Granisetron Transdermal Patch|Antiemetic
223633529|NCT04150614|DRUG|Intravenous Dexamethasone|Antiemetic
223633530|NCT04150614|DRUG|Ondansetron|ondansetron
223633531|NCT03932344|DRUG|Anakinra|Anakinra according to prescription
223633532|NCT06329440|DIAGNOSTIC_TEST|Ultrasonographic measurement of diaphragm thickness|Lineer probe of the ultrasound machine will be placed sagitally on the level of 9th to 11th rib in order to observe diaphragmatic thickness change during a sniff. The thicknesses will be measured both in full expiration (Te) and full inspirium (Ti) in centimeters. The diaphragm thickness fraction will be calculated as follows: (Ti-Te)/Te
223633533|NCT04430452|BIOLOGICAL|Durvalumab|Given IV
223633534|NCT04430452|RADIATION|Hypofractionated Radiation Therapy|Undergo hypofractionated RT
223633535|NCT04430452|BIOLOGICAL|Tremelimumab|Given IV
223633536|NCT02854345|DEVICE|Tomoscintigraphic parathyroid imaging on a CZT camera|
223633537|NCT04218240|DRUG|Pregabalin 200 MG capsules|oral pregabalin 200 mg capsules given with a taper on day 5
223633538|NCT04218240|DRUG|Placebo oral tablet|oral Placebo
223633539|NCT04218240|DRUG|Lofexidine 0.18Mg Tab|lofexidine 0.18 tab given with a taper starting on day 5
223764472|NCT04347395|PROCEDURE|Respiratory Bundle & Prevention|The respiratory care bundle intervention comprised of: bed tilt, swallow screen, mouth wash and vaccinations. The bed tilt was a 30-degree whole bed-up positioning both day and night throughout the hospital stay and is shown in Figure 1. Swallow screen was undertaken within 48 hours of admission. Chlorhexidine mouth wash was prescribed initially four times daily. The protocol was amended to twice daily chlorhexidine mouth wash in August 2017 due to poor compliance with four times daily administration. Mouthwash administration was monitored in the intervention group only and deemed non-compliant if missed more than 3 times during the admission. Pneumococcal and influenza vaccination was offered at discharge or within 2-4 weeks post discharge, at no charge to the patient. Post discharge advice was to use pillows in bed to minimize the time the patient laid flat and to avoid lying down for an hour after meals.
223764473|NCT03535220|COMBINATION_PRODUCT|Protease Inhibitors|Nucleic Acid Synthesis Inhibitors,Hydroxyurea,Antineoplastic Agents
224222219|NCT03465228|OTHER|LED group|This group will be applied through the spot method with direct contact of the equipment over the irradiated site for 30 seconds. The application will be in four points in the lumbar region, above the gluteal region, with an angle of 90 ° in relation to the cutaneous surface. A wavelength of 660 to 850nm will be used with a frequency of 0 to 1500 Hz and energy irradiated of 0.9 J of each diode totaling 43.2J (48 diodes).
223764474|NCT01359592|BIOLOGICAL|rituximab|
224222220|NCT06251128|BEHAVIORAL|Stroke Self management Program|"Our educational and behavioral program includes an educational component, problem-solving to overcome barriers to a healthy lifestyle, activities of daily living, and management of medications.~No drugs or devices will be delivered to the participants"
224222221|NCT03334487|DRUG|Dexamethasone|Oral
224222222|NCT03334487|DRUG|Rovalpituzumab tesirine|Intravenous
224222223|NCT03764059|DEVICE|Filtek™ Bulk Fill Posterior Restorative|The subjects were assigned to either the investigational device (Filtek™ Bulk Fill Posterior Restorative) or the control device (Filtek™ Z350XT Universal Restorative) per web-based randomization system.
223633540|NCT04735575|BIOLOGICAL|EMB-06|EMB-06 is a FIT-Ig® bispecific antibody against BCMA and CD3.
223633541|NCT03160118|DRUG|Seasonal,quadrivalent,influenza vaccine|1 dose to be administered on Day 0, the first visit
223633542|NCT04664517|PROCEDURE|Flexible intramedullary nail (FIN)|Both bone FIN
223633543|NCT04664517|PROCEDURE|Reduction auder general anesthesia and long arm cast|Reduction and cast
223633544|NCT04005378|OTHER|CSC Step-down intervention|Web-based telemedicine and a smartphone app, to decrease disengagement likelihood
223633545|NCT04005378|OTHER|Usual Care|Usual Care provided by CSC center
223633546|NCT04914364|OTHER|Balance assessments|There is no formal intervention in this study. The investigators will only be completing balance assessments with no follow-up visit.
223633547|NCT06962592|BEHAVIORAL|MM+|Participants in both study arms will receive clinic-based HIV counseling, including urine tenofovir testing and biofeedback counseling on recent PrEP or ART use. Activities unique to women enrolled in the intervention arm include: Brief motivational interviewing sessions with a mentor mother focusing on 1) EtG testing and biofeedback on recent alcohol use, 2) counseling and mentorship on ways to reduce alcohol use.
223633548|NCT06962592|BEHAVIORAL|Enhanced HIV attention control (eSOC)|Participants in the enhanced HIV attention control arm (comparison group) will attend a similar number of study visits within the same time frame as intervention participants (5-6 sessions during 6-month timeframe including both pregnancy and postpartum). Control arm sessions will consist of one-on-one educational counseling on HIV risk, partner HIV testing modalities, as well as conducting PrEP/ART urine assay testing followed by real-time in-clinic adherence counseling delivered privately (different from study nurses delivering PrEP/ART biofeedback in MM+ intervention arm to avoid contamination), all coinciding with routine ANC visits.
223633549|NCT04097678|OTHER|Retained Surgical Sponge|A surgical sponge will be intentionally placed in the surgical field prior to final imaging and then removed. Postoperatively, images will be assessed for the presence or absence of a retained surgical sponge.
223764475|NCT01359592|DRUG|cyclophosphamide|
223764476|NCT01359592|DRUG|doxorubicin hydrochloride|
223633550|NCT03694678|BEHAVIORAL|Recovering Together|The intervention will teach resiliency skills (mindfulness, coping, interpersonal communication, etc) within 2 in person sessions at hospitalization and 4 live video sessions after discharge. Both patient and caregiver will participate in all sessions
223633551|NCT05874843|DIAGNOSTIC_TEST|Thromboelastography (TEG 6S)|The TEG 6s assays are performed in a microfluidic cartridge which only requires a small amount of a patient's blood be transferred to the cartridge for analysis. The vibration frequency of the blood meniscus at which resonance occurs is used to create a clot dynamics tracing.
223633552|NCT02435212|DRUG|Deferasirox granule formulation|Deferasirox granules will be provided as stick packs containing 90 mg, 180 mg and 360 mg granules for oral use and will be administered based on body weight.
223633553|NCT02435212|DRUG|Deferasirox DT formulation|Deferasirox DT will be provided as 125 mg, 250 mg and 500 mg dispersible tablets for oral use and will be administered based on body weight.
223633554|NCT02647099|DRUG|Acetylsalicylic acid|
224222224|NCT03764059|DEVICE|Filtek™ Z350XT Universal Restorative|The subjects were assigned to either the investigational device (Filtek™ Bulk Fill Posterior Restorative) or the control device (Filtek™ Z350XT Universal Restorative) per web-based randomization system.
224222225|NCT01901315|PROCEDURE|Online consultation|Patients in the online consultation (intervention) group have monthly consultation with their attending psychiatrist through videoconferencing during one year. After each consultation, the medication is sent to the patient through a home delivery program. For reasons of patient safety, consultations at baseline, and after 6 and 12 months will be realized in a face-to-face form at the Institute of Psychiatry (IPq).
224222226|NCT01901315|PROCEDURE|Face-to-face consultation|Patients in the face-to-face consultation (control) group have monthly face-to-face consultation with their attending psychiatrist during one year at the Institute of Psychiatry (IPq).
223633555|NCT02647099|DRUG|Placebo|
223633556|NCT05131308|OTHER|leak closure with either detachable embolization coils, vascular plugs/CSO, or RFA|All patients were evaluated and followed with imaging, and per investigators' respective clinical judgement, then proceeded to have an intervention for leak closure with either detachable embolization coils, vascular plugs/CSO, or RFA.
223633557|NCT05773937|DRUG|9MW2821|All subjects will receive a single intravenous (IV) infusion of 9MW2821 once weekly for the first 3 weeks of every 4 week cycle (i.e., on Days 1, 8 and 15).
223764477|NCT01359592|DRUG|prednisone|
223764478|NCT01359592|DRUG|vincristine sulfate|
223764479|NCT01359592|OTHER|R-CHOP regimen|
223764480|NCT01359592|OTHER|laboratory biomarker analysis|
223764481|NCT01359592|RADIATION|fludeoxyglucose F 18|
224222227|NCT00767689|DRUG|Vitamin B 6|vitamin b6 100 mg po daily
224222228|NCT00767689|DRUG|placebo|placebo is given in the placebo arm
224222229|NCT01608633|OTHER|Spray and stretch|Physiotherapeutic technique which consist in stretching the muscle while a cold spray is applied on the skin.
224222230|NCT02720315|PROCEDURE|Intensive cryotherapy|Application of ice inside a plastic bag wrapped to the patient's site of pain, and held in place for 20min.
224222231|NCT04111133|DRUG|Betablocker + ivabradine|Use of maximum tolerated dose of carvedilol and ivabradine to achieve therapeutic heart rate reduction (THR) to 55-65 beats per minute
223764482|NCT01359592|RADIATION|selective external radiation therapy|
224222232|NCT04111133|DRUG|Betablocker|Use of maximum tolerated dose of carvedilol to achieve targeted heart rate reduction (THR) to 55-65 beats per minute (responder) or inability to reach THR (non responder) with maximum dose of carvedilol, maintaining a minimum MAP of 70 mmHg.
224222233|NCT00001951|DRUG|TMTDS|
223633558|NCT05964842|BEHAVIORAL|SMS|Participants in this arm will receive three SMS reminders. The first SMS will be sent on day one after enrollment into the study. The second SMS will be sent once participant results are ready. If two days after the second SMS the patient has not returned to complete TB diagnosis, a third SMS will be sent. Messages will be automatically sent in either English or Luganda, the commonly spoken local language in the study area. The preferred language of the participant will be determined at enrollment.
223633559|NCT05964842|BEHAVIORAL|Phone call|Participants in this arm will receive three phone call reminders. The first phone call will be made on day one after enrollment into the study. The second phone call will be made once participant results are ready. If two days after the second phone call the patient has not returned to complete TB diagnosis, a third phone call will be made. Phone calls will be made in either English or Luganda, the commonly spoken local language in the study area. The preferred language of the participant will be determined at enrollment.
223633560|NCT05964842|BEHAVIORAL|Mobile money incentive|Once participants in the study arms with mobile money complete TB diagnosis by submitting a sputum sample and collecting back results, a money incentive worth 20,000/= (Twenty thousand shillings only) will be given as a transport refund sent via mobile money.
223633561|NCT05179785|DEVICE|Continuous Theta Burst Stimulation (cTBS)|cTBS is a brief stimulation of a part of the brain with a magnetic field that passes through the scalp and skull safely that can decrease the excitability of cortical neurons. It is FDA-approved as a treatment for psychological conditions including depression; however, this device is not approved for the treatment of adults with Bipolar Disorder I or for use in healthy adults. This research study is using the cTBS off label in all participants (those with and without Bipolar Disorder I) to examine research questions
223764483|NCT01359592|RADIATION|yttrium Y 90 ibritumomab tiuxetan|
223764484|NCT02881996|DRUG|IV tylenol|IV tylenol given scheduled in addition to standard PCA
223764485|NCT02881996|DRUG|No IV tylenol|No additional IV Tylenol given
223764486|NCT02881996|DRUG|Ketorolac|both groups receive as part of our standard postop pain protocol after all operations
223764487|NCT01422499|DRUG|zolinza/vorinostat|orally once per day (suspension of 50mg/ml or capsules of 100 mg vorinostat); starting dose will be 180 mg/m²/d; escalated with increments of 50 mg/m²/d every two weeks until dose limiting toxicity (grade 3 or 4 toxicity according to CTC) occurs or up to a maximum dose of 580 mg/m²/d; This dose will then be applied for 3 months. Patients without progression at first response evaluation will continue treatment for a maximum of 9 months.
223764488|NCT04262466|DRUG|Brenetafusp|Brenetafusp IV infusions
224222234|NCT05079893|OTHER|Case control study|Observational case control study
224222235|NCT04604483|DEVICE|PTNS|Patients meeting the criteria are treated with PTNS and are evaluated at 3 months and 1 year after end of treatment.
223633562|NCT05179785|DEVICE|Intermittent Theta Burst Stimulation (iTBS)|iTBS is a brief stimulation of a part of the brain with a magnetic field that passes through the scalp and skull safely to increase the excitability of cortical neurons. It is FDA-approved as a treatment for psychological conditions including depression; however, this device is not approved for the treatment of adults with Bipolar Disorder I or for use in healthy adults. This research study is using the cTBS off label in all participants (those with and without Bipolar Disorder I) to examine research questions.
223633563|NCT05153746|DEVICE|3D colonoscopy|3D colonoscopy is a new device to enhance endoscopic imaging.
223633564|NCT05966142|OTHER|Pharmacogenetic testing|Genetic testing of CYP2D6 and CYP2C19
223633565|NCT05966142|OTHER|Clinical decisions support|Prescribing recommendations to the provider based on the pharmacogenetic testing results
223633566|NCT04692233|BEHAVIORAL|Qigong Baduanjin|Qigong Baduanjin will comprise eight standardized movements. It is practiced as a combination of body movements, breath control, and mindful meditation, which is designed to improve qi function.
223633567|NCT04692233|BEHAVIORAL|Light flexibility exercise|Each session will include seated and standing stretches that target upper (neck, arms, upper back, shoulders, back, and chest) and lower body (quadriceps, hamstrings, calves, and hips), as well as trunk rotations.
223633568|NCT06379659|DRUG|Growh hormone|In this group, patients will receive growth hormone solution containing 1.99 milligrams of the drug dissolved in 1.5 milliliters of 0.9% saline solution (normal saline), in addition to standard hormonal therapy, starting from cycle day 10. Treatment sessions will be conducted at two-day intervals. In case of non-response to treatment (failure to reach a minimum endometrial thickness of 7 millimeters in the subsequent assessment), the patient will receive a maximum of 4 doses, and if response to treatment is observed, growth hormone infusion will be discontinued. All infusions will be administered intrauterinely via an Intrauterine Insemination (IUI) catheter.
224222236|NCT02693184|OTHER|Full length Block 2014 Food Frequency Questionnaire|The food and beverage list includes 127 items, plus additional questions to adjust for fat, protein, carbohydrate, sugar, and whole grain content.
224222237|NCT02693184|OTHER|Revised Calcium, Vitamin D and Protein Screener|The food list includes 29 food items and 5 supplements
224222238|NCT04938206|PROCEDURE|The Clinical Decision Rule|The Clinical Decision Rule will be applied to all patients included in the study at different times depending on the type of cancer: at H12-H24 of admission for patients with solid tumor; at H24-H48 for patients with hematological cancer. Patients classified as being at low risk of severe infection by the DRC were then randomized to a control group under standard management or to an experimental group with therapeutic relief. Treatment reduction for the experimental group was started immediately after randomization, in hospital. Discharge was proposed 24 hours later, with follow-up every two days, by telephone or in
223633569|NCT06379659|OTHER|Placebo|Similar to the intervention group, from cycle day 10, an equal volume of 0.9% saline solution (normal saline) will be administered in addition to standard hormonal therapy. Treatment sessions will be conducted at two-day intervals. In case of non-response to treatment (failure to reach a minimum endometrial thickness of 7 millimeters in the subsequent assessment), the patient will receive a maximum of 4 doses, and if response to treatment is observed, placebo infusion will be discontinued. All infusions will be administered intrauterinely via an Intrauterine Insemination (IUI) catheter.
223633570|NCT05699642|BEHAVIORAL|Tai chi + wearable|The tai chi intervention will be delivered remotely via Zoom Enterprise. Participants will access classes on a phone, tablet, laptop, or desktop computer. Participants will attend 3 classes/week (each lasting 60 min) during weeks 1-12, 2 classes/week during weeks 13-16, and then 1 class every other week during weeks 17-24. Classes include tai chi warm-up exercises, breathing exercises, review and practice of tai chi forms, and cool-down exercises. Participants will be asked to practice tai chi at home 3x per week during the 6 month intervention period using an instructional video provided to them. The Fitbit fitness tracker will be given to each participant along with instructions on how to use the tracker and the Fitbit app on their personal device.
223633571|NCT06218277|DIAGNOSTIC_TEST|ASTAR|Rapid AST with ASTAR
223764489|NCT04262466|DRUG|Brenetafusp and pembrolizumab|Brenetafusp and pembrolizumab IV infusions
224222239|NCT03534297|DRUG|dapansutrile capsules|Hard opaque capsules containing 100 mg of API.
224222240|NCT03534297|DRUG|Placebo capsules|Hard opaque capsules containing 0 mg of API.
224318400|NCT01159561|BIOLOGICAL|Western Equine Encephalitis Vaccine|Subject will be vaccinated with 0.5 mL of reconstituted WEE vaccine, inactivated, TSI-GSD 210 (Lot 3-1-92) subcutaneously in the upper outer aspect of the deltoid region.
224318401|NCT00333151|DRUG|liraglutide|
223633572|NCT05876689|DEVICE|DREAM OCT|Swept Source OCT (similar to Zeiss Plex Elite)
223633573|NCT04526340|DIAGNOSTIC_TEST|Blood sample|2 Blood samples at the beginning and end of the test to analyze; Haptoglobin phenotyping, Haptoglobin concemtration (μmol/l) (serum), Sodium (mmol/l) (serum), Osmolality (mOsm/kg) (serum), Urea (g/l) (serum), Creatinine (g/dl) (serum), Potassium (mmol/l) (serum).
223633574|NCT04526340|DIAGNOSTIC_TEST|Bio-impedance measurement (BIA)|for every 30 minutes for 4 hours
223764490|NCT04262466|DRUG|Brenetafusp and chemotherapy|Brenetafusp and chemotherapy IV infusions
223764491|NCT04262466|DRUG|Brenetafusp and monoclonal antibodies and chemotherapy|Brenetafusp and a monoclonal antibody therapy and chemotherapy
223764492|NCT04262466|DRUG|Brenetafusp and tebentafusp|Brenetafusp and tebentafusp IV infusions
223764493|NCT04262466|DRUG|Brenetafusp and bevacizumab|Brenetafusp and bevacizumab IV infusions
223764494|NCT04262466|DRUG|Brenetafusp and kinase inhibitors|Brenetafusp and oral kinase inhibitors
223764495|NCT03854916|OTHER|Caminemos Juntas App|A tailored mobile app that encourages Latinas and Hispanic women to walk together using location-based services.
223764496|NCT03854916|OTHER|World Walking App|A mobile app that encourages users to walk.
224222241|NCT02175966|DRUG|DCV/ASV/BMS-791325|
224222242|NCT02175966|DRUG|Ribavirin|
224222243|NCT02175966|DRUG|Sofosbuvir|
224222244|NCT02175966|DRUG|Peginterferon α-2a|
224222245|NCT03139747|DRUG|Lenvatinib|Lenvatinib is an anti-cancer drug for the treatment of certain kinds of thyroid cancer, and potentially for other cancers as well. It was developed by Eisai Co. and acts as a multiple kinase inhibitor against the VEGFR1, VEGFR2 and VEGFR3 kinases.
224318402|NCT00333151|DRUG|rosiglitazone|
224318403|NCT00333151|DRUG|metformin|
223633575|NCT04526340|DIETARY_SUPPLEMENT|Ingestion of testing nutrient/food capsules|The subjects will be tested in fasted and sober state in the morning. No food/drink 6 hours prior to the test. The subjects will be asked to take 2 different dosages of testing nutrient along with 500ml of water and only water for the control, on 3 different test days. The testing nutrients will be prepared in 1g capsules.
223633576|NCT04526340|DIAGNOSTIC_TEST|Urine sample|3 Urine samples at the beginning, after 2 hrs and at the end of the test to analyze: Total voided volume, Osmolality (mOsm/kg), Creatinine (g/dl), Sodium (mmol/l), Potassium (mmol/l), Urea (g/l)
223764497|NCT06424054|OTHER|eChemoCoach|the eChemoCoach is an electronic questionnaire which is accessible for patients via the secured electronic health portal (EHP) of the EHR, which is CE-certified. By utilizing the eChemoCoach, patients (for this project we focus on breast cancer patients) have the ability to complete a questionnaire on a daily basis, when experiencing side effects. The eChemoCoach has the potential to evaluate the severity of adverse effects based on the CTCAE criteria and triage them, mimicking the decision-making process of a HCP through computer adaptive testing (CAT). Upon completing the questionnaire, the eChemoCoach translates the responses for each specific side effect into corresponding CTCAE grades. The tool then promptly offers patients personalized advice, tailored to their individual condition.
224222246|NCT03139747|DRUG|Everolimus|It is currently used as an immunosuppressant to prevent rejection of organ transplants and in the treatment of renal cell cancer and other tumours. Much research has also been conducted on everolimus and other mTOR inhibitors as targeted therapy for use in a number of cancers.
223633577|NCT02933008|OTHER|aNMT Biofeedback|"aNMT utilizes well-established visual feedback strategies to promote efficient, rapid and robust learning of complex movements. Athletes can discover how to move to create the desired feedback, even without explicit, conscious knowledge of how their movements relate to the visual pattern. aNMT biofeedback is created by calculating kinematic and kinetic data in real-time from the athlete's own movements. These values determine real-time transformations of the stimulus shape the athlete views via augmented-reality (AR) glasses during movement performance. The athlete's task is to move so as to create (animate) a particular stimulus shape that corresponds to desired values of the biomechanical parameters targeted by the intervention."
223633578|NCT02933008|OTHER|Sham Biofeedback|Sham biofeedback provides a similar phenomenological experience to aNMT biofeedback for athletes-both groups experience a shape that changes with their movements-but the sham biofeedback will not provide usable information to modify movement parameters during critical movement phases.
223633579|NCT02933008|OTHER|Neuromuscular Training|Participants will complete a 12-session, pre-season training program, over 6 weeks.
223633580|NCT06011759|BEHAVIORAL|Academic Detailing (AD)|"The National Resource Center for Academic Detailing (NaRCAD) describes AD as an innovative, one-on-one outreach education technique that helps clinicians provide evidence-based care to their patients. Using an accurate, up-to-date synthesis of the best clinical evidence in an engaging format, academic detailers ignite clinician behavior change, ultimately improving patient health. A successful AD visit is highly interactive, always a dialogue, and assesses a clinician's individual needs, beliefs, attitudes, issues, and concerns in order to promote better \[practice\]."
223633581|NCT06011759|BEHAVIORAL|LEAP|Learn. Engage. Act. Process (LEAP) program is a structured 6-month core curriculum plus 6 monthly collaborative sessions. The LEAP quality improvement program engages frontline teams in sustained incremental improvements of EBPs over a six-month period, allowing space for busy clinicians to learn and immediately apply fundamental QI skills. LEAP encompasses: 1) a structured, accessible curriculum based on the Institute for Healthcare Improvement's (IHI) Model for Improvement and Plan-Do-Study-Act cycles of change; 2) team-based, hands-on learning, and 3) coaching support and a QI network to enhance learning and accountability.
223764498|NCT00152217|DRUG|TS-1 (S-1)|80 mg of oral S-1 per square meter of body-surface area per day was given for 4 weeks and no chemotherapy was given for the following 2 weeks
223764499|NCT00152217|PROCEDURE|Surgery|Stage II or III gastric cancer who underwent gastrectomy were assigned to surgery only
223764500|NCT05155969|DRUG|Esketamine|esketamine (0.3 mg/kg in 100 ml normal saline) is intravenously infused 40 minutes before anesthesia induction
223764501|NCT05155969|DRUG|Normal saline|Normal saline will be administrated intravenously at the dural opening, with a total dose of 0.5 ml/kg and continual infusion for 40 minutes.
223764502|NCT04080765|BEHAVIORAL|HIV-ASSIST|HIV-ASSIST is an online interactive patient-based tool that allows for individualized HIV treatment recommendations through the synthesis of patient-specific factors with existing guidelines and evidence.
224222247|NCT00006081|DRUG|Bryostatin-1|40 mcg/m2 one-hour infusion 24 hours after each dose of paclitaxel (i.e., day 2, 9, 16).
224222248|NCT00006081|DRUG|Paclitaxel (Taxol)|80 mg/m\^2 one-hour infusion weekly x 3 every 4 weeks
224222249|NCT04698122|OTHER|Biological sample collection|Collection of faeces, urine, saliva, and blood for biobanking, to evaluate the proteomic, metascriptomic, metabolomic, metagenomic, and metagenetic profile, and to perform routine screening
223764503|NCT04080765|BEHAVIORAL|DHHS guidelines|This is the Department of Health and Human Services HIV/AIDS Treatment Guidelines.
223764504|NCT02473068|DEVICE|CPAP|
223764505|NCT00595569|BEHAVIORAL|Flexible insulin therapy (FIT)|Flexible insulin therapy (FIT) courses consisting in 7 weekly ambulatory sessions lasting 90 minutes each
224222250|NCT04698122|OTHER|Questionnaire|Anamnestic questionnaire, 3-day food questionnaire, Food Frequency Questionnaire
224222251|NCT04698122|OTHER|Medical examination|Blood pressure measurement, abdominal and thoracic physical examination
224222252|NCT02152787|DRUG|Injection of propofol 1.0mg/kg|
224222253|NCT02152787|DRUG|propofol 0.5mg/kg|
224222254|NCT02152787|DRUG|normal saline|
224222255|NCT01203683|BEHAVIORAL|Active computer-based training|8 sessions across 4 weeks.
224222256|NCT01203683|BEHAVIORAL|Inert computer training|8 sessions across 4 weeks.
224222257|NCT02854683|DRUG|Normal Saline|1 liter of intravenous saline will be delivered over 1 hour
224222258|NCT02854683|DIETARY_SUPPLEMENT|Oral Rehydration Solution|1 liter of ORS solution given by mouth
224222259|NCT01033383|DIETARY_SUPPLEMENT|Placebo|36 milligram (mg) placebo capsule taken before quiet hours of sleep (qhs).
224222260|NCT01033383|DIETARY_SUPPLEMENT|Cranberry Capsule|36 milligram (mg) cranberry capsule, taken before quiet hours of sleep (qhs).
224222261|NCT03787745|PROCEDURE|Ischemic postconditioning|After 60 seconds of reperfusion, ischemic postconditioning with an adequately sized balloon (60 reperfusion/60 seconds re-occlusion, four cycles) will be performed
223633582|NCT03586102|DIETARY_SUPPLEMENT|High protein supplementation|To increase protein content of human milk, a fixed amount of commercially available hydrolyzed bovine protein will be added to fortified human milk. With this pragmatic approach, preterm infants assigned to the high protein supplementation group will receive \> 4.5 g/kg/day of enteral protein after establishment of full enteral feeding.
223633583|NCT03586102|DIETARY_SUPPLEMENT|Standard protein supplementation|Infants assigned to the standard protein supplementation group will receive fortified human milk (\< 4.5 g/kg/day of enteral protein)
223633584|NCT04548661|PROCEDURE|Intraoperative incisional wound irrigation with povidone-iodine solution|Participants randomized to the povidone-iodine irrigation group will have all incisions irrigated once with povidone-iodine diluted in 0.9% sterile normal saline (to a final concentration of 5% povidone-iodine (0.5% available iodine)) delivered through a bulb syringe. The povidone-iodine irrigation should be left on for 60 seconds and then dried with sterile gauze. Irrigation will be performed after any/all deep tissue layers are closed, prior to skin closure. The volume used will be left to the discretion of the clinician and irrigation will be administered until saturation is achieved.
224222262|NCT03787745|PROCEDURE|Conventional|State of the art primary PCI, however thrombectomy is not allowed
224222263|NCT02638857|PROCEDURE|TACE|lipiodol 10-20ml,MMC 8～10mg,EADM20～40mg. According to tumor area of maximum diameter,0.1～0.2ml/cm2 hepatic arterial infusion.Each cycle received one TACE treatment on day 13,34,55.
224222264|NCT02638857|BIOLOGICAL|Dendritic Cell|DC suspension (1×107 DC+ physiological saline + 0.25% human serum albumin) 1ml for each infusion, subcutaneous injection for each infusion 3 cycles, each cycle received two infusions on day 19, 20; 40, 41; 61, 62.
224222265|NCT02638857|DRUG|lipiodol|lipiodol 10-20ml,hepatic arterial infusion
224222266|NCT02638857|DRUG|Mitomycin (MMC)|MMC 8～10mg. According to tumor area of maximum diameter,0.1～0.2ml/cm※2, hepatic arterial infusion.
224222267|NCT02638857|DRUG|Epirubicin(EADM)|EADM20～40mg. According to tumor area of maximum diameter,0.1～0.2ml/cm※2 hepatic arterial infusion.
224222268|NCT02638857|BIOLOGICAL|Precision Multiple Antigen T Cell|PMAT cell suspension (1-6×109 PMAT + physiological saline + 0.25% human serum albumin) 300ml for each infusion, IV (in the vein) for each infusion 3 cycles, each cycle received one infusions on day 21, 42, 63.
224222269|NCT02376985|PROCEDURE|Oral management|
224222270|NCT02376985|DRUG|Everolimus|
224222271|NCT01261533|DEVICE|foldable capsular vitreous body(FCVB)|FCVB with silicone oil inside is tamponaded into the vitreous cavity
224222272|NCT00778557|DRUG|CEFPROZIL FOR ORAL SUSPENSION USP 250 mg/ 5 mL|
224222273|NCT05287659|DIETARY_SUPPLEMENT|meal replacements or supplementation with leucine|meal replacements or animal protein or supplementation with leucine
224222274|NCT00210626|DRUG|PROCRIT|40,000 IU/mL/week for max of 12 weeks
224222275|NCT00210626|DRUG|Placebo|40,000 IU/mL/week for max of 12 weeks
224222276|NCT01792258|PROCEDURE|Percutaneous tracheostomy|Percutaneous tracheostomies will be performed with the kit commercially available in the current clinical practice.
224222277|NCT04052100|OTHER|Usual care|The standard preoperative measures will consist of a recommendation for physical activity and advice on tobacco smoking cessation and reduction of alcohol intake. In addition, patients who suffer from iron deficient anemia will receive intravenous iron and those at risk of malnutrition (Malnutrition Universal Screening Tool ≥2 (www.bapen.org.uk/pdfs/must/must\_full.pdf)) or that require weight control for obesity (IMC≥30) will perform a nutrition intervention by a nutritionist.
223633585|NCT04548661|PROCEDURE|Intraoperative incisional wound irrigation with saline|Participants randomized to the saline irrigation group will have all incisions irrigated once with 0.9% sterile normal saline delivered through a bulb syringe. Irrigation will be performed after any/all deep tissue layers are closed, prior to skin closure. The volume used will be left to the discretion of the clinician and irrigation will be administered until saturation is achieved.
223633586|NCT06055868|OTHER|Group Meeting (Focus Group)|Focus Group Discussions (FDGs) will be recorded, transcribed, and coded.
223633587|NCT06055868|OTHER|Questionnaires|Given electronically or via phone by study team staff
223633588|NCT03292926|DRUG|Bupivacaine|Bupivacaine will help treat pain and sensation after ACL repair
224222278|NCT04052100|OTHER|Multimodal prehabilitation|"The experimental group will also carry out a prehabilitation program consisting in:~A. A motivational interview to reinforce the patient's motivation and generate a commitment in relation to the objectives of the program.~B. A physical activity promotion program to increase the number of daily steps of patients, measured by a wristband and a mobile App.~C. A supervised high-intensity exercise training program. D. An individualized nutritional optimization plan with dietary advice and protein supplementation (if necessary). Educational material and motivational messages will be sent through a mobile App.~F. Psychological support through weekly Mindfulness sessions (1.5 hours duration). Educational material and motivational messages will be sent through a mobile App.~E. A smoking cessation program consisting psycho-cognitive therapy combined with pharmacological treatment. Educational material and motivational messages will be sent through a mobile App."
224222279|NCT02629952|OTHER|Blueberry Tea|Blueberry Tea
224222280|NCT04452799|DRUG|Hesperidin and Diosmin mixture|Interventional Clinical Trial
224222281|NCT05140642|OTHER|Automated annotation of the left ventricle through deep learning|A semantic segmentation deep learning model will identify the left ventricle and label the left ventricle. The AI model will produce an assessment of LVEF using video based features.
224222282|NCT05140642|OTHER|Sonographer Measurement of LVEF|Standard practice sonographer measurement of left ventricle and assessment of LVEF
224222283|NCT00343850|DRUG|Asacol (mesalamine)|
224222284|NCT00738556|DEVICE|Drug-eluting stents (Cypher and Taxus)|Spot or full length stenting of a coronary lesion
224222285|NCT05206032|OTHER|Raman spectroscopy|Blood (serum or plasma) will be collected, processed and analysed through Raman spectroscopy. Data acquired will be normalized and treated for the creation of the classification model.
224222286|NCT01671787|DRUG|GS-7340|Subjects are randomized to receive one of four different doses of GS-7340 over 28 days of therapy.
224222287|NCT01671787|DRUG|Tenofovir disoproxil fumarate|Subjects will receive 300mg of Tenofovir disoproxil fumarate (TDF) over 28 days of therapy
223633589|NCT03292926|DEVICE|Ultrasound|Ultrasound will guide anesthesiologist in performing the different nerve blocks
223633590|NCT03292926|DRUG|Dexamethasone|Dexamethasone will be used to prolong block duration
223633591|NCT06510439|BEHAVIORAL|Need to Be Needed Intervention|Interventionist-supported volunteering intervention that targets opportunities creating social connections that matter through focus on kindness and gratitude throughout the intervention.
223633592|NCT06510439|OTHER|Active Control Group|Weekly non-directive listening support
223633593|NCT03350529|DEVICE|MRI guided transurethral HIFU ablation of prostatic tissue|The technology is developed to ablate targeted benign and malignant prostate tissue through transurethrally inserted probe that transmit ultrasound energy under MRI guidance and control. The therapeutic endpoint of this method is thermal coagulation of prostate tissue.
223633594|NCT02453737|RADIATION|Brachytherapy APBI|
223633595|NCT02453737|RADIATION|3D-CRT (photon) APBI|
223633596|NCT02453737|RADIATION|Proton APBI|
223633597|NCT04085926|DEVICE|Sealed therapeutic shoe|Off-the-shelf therapeutic shoe and custom-made insole
223633598|NCT04085926|DEVICE|Total contact cast|Custom-made total contact cast
223633599|NCT04954339|DRUG|Aatezolizumab plus Bevacizumab|Two cycles of naeoadjuvant atezolizumab (1200 mg) plus bevacizumab (15 mg/kg) prior to surgical resection and four cycles of adjuvant atezolizumab (1200 mg) plus bevacizumab (15 mg/kg) after the surgery will be administered.
223633600|NCT04913272|DRUG|US-APR2020|US-APR2020 capsules 45 billion CFUs of the LBT.
223633601|NCT04913272|DRUG|Placebo|Placebo
223633602|NCT04852302|BEHAVIORAL|Cancer and Living Meaningfully (CALM) Therapy|The Cancer and Living Meaningfully (CALM) intervention is a brief, individualized psychotherapeutic intervention established to meet an unmet need to address psychological distress and promote well-being in advanced cancer patients.
223633603|NCT06577896|DEVICE|Onyx family|Safety and Efficacy of 1-Month DAPT in Elderly Patients at High Risk of Ischemia and Bleeding After Percutaneous Coronary Intervention with Onyx Family Stents
223633604|NCT03042689|DRUG|Regorafenib|Regorafenib will be administered on a 28 day cycle Treatment will be administered on outpatient basis at a pre-determine dosage.
223633605|NCT06486987|OTHER|Constraint induced movement therapy delivered by televideo|In-home Constraint induced movement therapy delivered by a therapist participating by televideo
223633606|NCT04711850|DRUG|Imlifidase|Immunoglobulin G degrading enzyme of Streptococcus pyogenes
223633607|NCT03788213|RADIATION|3 week RT|40 Gy in 15 fractions over 3 weeks to the whole breast or chest wall. Patients undergoing breast conservation therapy will receive additional boost radiotherapy to the tumor bed. The supraclavicular fossa will be treated in patient with node positive disease or those receiving neoadjuvant chemotherapy. IMC and Axillary radiotherapy will be given as per the institutional policy. Boost Dose schedule for BCS patients will be 8 Gy delivered in 15 fractions simultaneously with tangential EBRT. In institutions planning for sequential boost, a dose of 12 Gy in 4 fractions will be delivered after whole breast EBRT.
223633608|NCT03788213|RADIATION|1 week RT|26 Gy in 5 fractions over 1 week to the whole breast or chest wall. Treatment volumes will be same as the control arm. Additional boost will be delivered to patients who have undergone breast conservation. Boost Dose schedule for BCS patients will be 6 Gy delivered in 5 fractions simultaneously with tangential EBRT. In institutions planning for sequential boost, a dose of 12 Gy in 4 fractions will be delivered after whole breast EBRT.
224222288|NCT01886456|DEVICE|Laser trabeculoplasty|
223633609|NCT03267277|DRUG|Sodium Thiosulfate|Sodium thiosulfate is a calcium chelator
224222289|NCT03951428|DIAGNOSTIC_TEST|Menstrual Blood Screening Test|The sponsor will be testing women's menstrual blood to investigate the feasibility and efficacy of assessing three early stage cancers via self-collected menstrual blood using FDA approved devices.
223633610|NCT06537193|DIAGNOSTIC_TEST|AMRI|The study subjects will receive intravenous injection of gadoxetic acid (0.025 mmol/kg, Primovist; Bayer, Berlin, Germany) in the waiting room and then proceed to the examination room for MRI testing 15-20 minutes later. The MRI examination will be conducted using a 3-Tesla MRI machine, and the MRI protocol consists of T2-weighted imaging,diffusion-weighted imaging (b value of 0, 50, and 500 s/mm2), and hepatobiliary phase imaging.
223633611|NCT06537193|DIAGNOSTIC_TEST|CT|CT will be performed by obtaining dynamic phases (precontrast phase, arterial phase, portal venous phase, and delayed phase images). Subjects will receive intravenous injection of iodine contrast media. Scan coverage was from the basal lung to the iliac crest or pelvis.
223633612|NCT06560372|PROCEDURE|Additional realization of a brain perfusion scan sequence which would allow the radiological diagnosis of CV|"Neurological monitoring by daily TCD will be carried out.~* If monitoring finds, between 3rd and 12th day of treatment, a neurological deterioration or an uncontrolled increase in intracranial pressure, a new cerebral CT scan will be performed, as recommended in such a case.~* As part of this research, a specific interventional act will be implemented: additional brain perfusion scan sequence which would allow the radiological diagnosis of CV.~* Interventions related to improving cerebral perfusion and reducing intracranial pressure recommended in head trauma patients will be implemented without modification of management linked to protocol.~The additional perfusion sequences will be analyzed independently and blindly by 2 experienced interventional neuroradiologists (double reading blinded to the patient's characteristics)."
224222290|NCT05808556|DEVICE|Sticker pads containing lavender and ylang ylang oil|The sticker pad group attached an sticker pad (0.3% lavender oil and 0.7% ylang ylang oil) to their shirt, close to the right side of the neck, for 14 days,
224222291|NCT05808556|DEVICE|Placebo|The placebo group attached a sticker pad without lavender and ylang ylang oil to their shirt, close to the right side of the neck, for 14 days.
224222292|NCT02060656|DRUG|Gemcitabine|1000mg/m2 IV D1, D8, D15 every 28 days
224222293|NCT02060656|DRUG|Methylprednisolone|1000mg/m2 IV or PO D1-5 every 28 days
224222294|NCT02060656|DRUG|Rituximab|375mg/m2 IV D1, D15 every 28 days
223633613|NCT04119986|DEVICE|drug coated balloon|Balloon/vessel diameter ratio 0.8-1.0, 8-12 ATM (atmosphere), lasting for \>30 seconds.
223633614|NCT04119986|DEVICE|drug eluted stent|with regular techniques
223764506|NCT06381921|BEHAVIORAL|IBS-PPSM intervention|IBS-PPSM intervention includes 10 video modules focused on IBS knowledge and self-management skills plus one-on-one consultation with a nurse for personalized advice about self-monitoring, diet, sleep, and goal setting.
224222295|NCT02060656|DRUG|Cisplatin|100mg/m2 IV D15 every 28 days
223633615|NCT03237624|DEVICE|Functional Chitosan Chewing Gum|Chitosan and chitosan-related preparations have been shown to have some antimicrobial properties, possibly in the disruption of bacterial colonization. It is thought that as a component of a functional chewing gum this will supplement in the removal of daily build up of dental plaque on tooth surfaces.
223633616|NCT03237624|DEVICE|Control Chewing Gum|Control chewing gum device does not have food additive chitosan in its composition.
223633617|NCT03237624|BEHAVIORAL|Oral hygiene measures|Patients will be given instructions on how to brush and floss routinely (twice per day)
223633618|NCT06527469|OTHER|PhysZou emPOWER: a strength, power, and gait intervention group physical therapy program for children with CP|Each session will include a 10-minute game-based warm-up, 45 minutes of gait interventions to include treadmill and overground walking as well as other aerobic activities, 45 minutes of resistance training (power and strength training as appropriate for their individual goals), and a 10-minute cool-down incorporating yoga and breathing activities. To ensure participants are exercising at the appropriate level of intensity, 1 repetition maximum measures will be used to determine the appropriate levels of resistance and heart rate monitors will be worn.
223633619|NCT06088992|GENETIC|HG004|Method of Administration: Once unilateralsubretinal injection; The duration of the study isabout 60 weeks for each subject including a 8-weekscreening period, enrollment/baseline visit,treatment visit, and 52 weeks follow-up period.
223633620|NCT06098755|BEHAVIORAL|Transcendence Research: Holistic Education|With informed consent the participant act as a partner to their health and acknowledges responsibility for self-help or self-care directed activities in a non-clinical setting. Transcendence in research involves actively exploring the best possible options or resources for a resolution or self-determination or hypotheses. To reinforce healthy activities, periodic forecast consist of one or more of the following variables: lectures, group discussions, team building exercises, faith-based initiatives, respite, support group, supportive care, natural food remedies, critical thinking questioning and tests.
223633621|NCT01379898|DRUG|Phenoxybenzamine|Starting dosage of phenoxybenzamine in hypertensive subjects:20 mg q.d. (=10 mg b.i.d.) and in normotensive subjects 10 mg q.d. (in the evening). Dose escalation until blood pressure targets are reached, with a maximum dose of 140 mg q.d. (=70 mg b.i.d.)
223633622|NCT01379898|DRUG|Doxazosin|Starting dosage of doxazosine in hypertensive subjects:8 mg q.d. (=4 mg b.i.d.)and in normotensive subjects starting dose 4 mg q.d. (in the evening). Dose escalation until blood pressure targets are reached, with a maximum dose of 48 mg q.d. .(=24 mg b.i.d.)
223633623|NCT02685969|PROCEDURE|18F-Flutemetamol & 18F-FDG|Characterization of cerebral amyloid deposition with 18F-Flutemetamol PET and glucose metabolism 18F-FDG PET.
223633624|NCT05164289|OTHER|Control group|Patients in the control group will have simple consultations on D15, D30, D45, D60 and D75
223633625|NCT05164289|OTHER|EMDR group|Patients in the EMDR group will have EMDR session on D15, D30, D45, D60 and D75
223633626|NCT04769479|DRUG|acoramidis|acoramidis
223633627|NCT03948971|PROCEDURE|Venogram|The 5 French (5F) diagnostic catheter will be navigated into the inferior then superior vena cava and then into the internal jugular bulb on the dominant venous side (as determined from the arteriographic images). Next, a 0.027 inch microcatheter will be navigated using fluoroscopic guidance into the superior sagittal sinus and a venogram will then performed by injecting a small dose of contrast. Next, the venous sinus pressure waveforms will be recorded as the catheter is withdrawn into the jugular bulb and then in the superior vena cava to obtain a central venous pressure. Once completed, the catheters will be removed and the sheaths will be removed. Manual pressure will be held at the venous access site for a few minutes. The arterial sheath will be closed based upon standard arteriogram protocol.
223633628|NCT01766609|DRUG|Triamcinolone Acetonide|
223633629|NCT05398653|DRUG|MIL62|An intravenous (IV) infusion of 600 mg of MIL62 will be administered at Week 1，Week 3.If the treatment is effective, MIL62 will continue be administered at W25，W27.
223633630|NCT05398653|DRUG|Cyclosporine|Participants will receive Cyclosporine at a starting oral dose 3.5 mg/kg/d, divided into 2 doses, try to give every 12 hours.The dose was adjusted according to the blood concentration of cyclosporine monitored every 2 weeks ±3 days until the target blood concentration of 125\~175 ng/ mL was reached.Cyclophosphamide will be maintained for 12 months, after which the dose was reduced by about 1/3 to 1/2 of the original dose each month, and discontinued after 2 months.
223633631|NCT03432598|DRUG|Tislelizumab|Administered 200 mg intravenously (IV) as specified in the treatment arm
223633632|NCT03432598|DRUG|Paclitaxel|Administered 175 mg/m² IV as specified in the treatment arm
223633633|NCT03432598|DRUG|Gemcitabine|Administered 1250 mg/m² IV as specified in the treatment arm
223633634|NCT03432598|DRUG|Etoposide|Administered 100 mg/m2 IV as specified in the treatment arm
223633635|NCT03432598|DRUG|Pemetrexed|Administered 500 mg/m² IV as specified in the treatment arm
223633636|NCT03432598|DRUG|Cisplatin|Administered 75 mg/m²/day IV as specified in the treatment arm
223633637|NCT03432598|DRUG|Carboplatin|Administered AUC 5 as specified in the treatment arm
223633638|NCT04849364|DRUG|Capecitabine|Capecitabine 1000 mg/m2 BID Orally 14 days on and 7 days off Cycle = 21 days; Total of 8 cycles
223633639|NCT04849364|DRUG|Talazoparib|Talazoparib Cycle 1: 0.75 mg then Cycle 2-8: 1 mg Cycle = 21 days; Total of 8 cycles
223633640|NCT04849364|DRUG|Pembrolizumab|Per standard of care.
223764507|NCT05194020|OTHER|Primary Services|Participants receive 16 hours of Father Factor curricula, 4 hours of The New Playbook curricula, 4 hours of Money Smart curricula over the course of five weeks. Participants also receive on-going job readiness support and post-employment support.
224222296|NCT02060656|DRUG|Lenalidomide|25mg PO D1-21 every 28 days
224222297|NCT00794261|DRUG|Injection of Pegfilgrastim|Single subcutaneous administration of Pegfilgrastim (Neulasta® - Laboratory AMGEN) 6 mg at D5
224222298|NCT00794261|DRUG|Injection of Filgrastim|Daily subcutaneous administration of Filgrastim (Neupogen® - Laboratory AMGEN) 5 µg/kg/day from D5 until recovery from aplasia (PNN \> 0.5 G/L)
224222299|NCT00200928|BIOLOGICAL|BCG|
224318404|NCT01161485|BEHAVIORAL|HIV Testing and Counseling|A manualized individual-level model consisting of two education and counseling sessions that structurally bracket confidential HIV antibody screening.
223633641|NCT04849364|DRUG|Inavolisib|Inavolisib Cycle 1: 6 mg then Cycle 2-8: 9mg Orally 21 days on Cycle = 21 days; Total of 8 cycles
224222300|NCT03500770|DEVICE|Transcranial Direct Current Stimulator|The tDCS device to be used will be an investigational, battery powered, custom-made stimulator able to deliver a biphasic alternate current. Active stimulation consists of 10 active tDCS sessions with current intensity fixed at 2mA for 20 minutes. It has been safely used in several other research studies. The side effects profile for this type of stimulation include tingling/itching at the site of stimulation, skin irritation/redness at the site of stimulation, headache or dizziness.
223633642|NCT03844997|DRUG|Palcociclib|"Palbociclib is an investigational (experimental) drug that works to induce early G1 arrest by inhibiting CDK4/6, which are two types of CDKs that are overexpressed in AML cell cancer lines. Palbociclib is experimental because it is not approved by the Food and Drug Administration (FDA).~Palbociclib will be supplied as capsules or tablets containing 125 mg equivalents of Palbociclib free base"
223633643|NCT03844997|DRUG|CPX-351|CPX-351 (daunorubicin and cytarabine) liposome for injection is a combination of daunorubicin and cytarabine in a 1:5 molar ratio encapsulated in liposomes for intravenous administration. CPX-351 is an investigational (experimental) drug that works as formulation of a fixed combination of the antineoplastic drugs cytarabine and daunorubicin. CPX-351 is experimental because it is not approved by the Food and Drug Administration (FDA).
223633644|NCT00135226|DRUG|Aspirin|
224222301|NCT02350530|DRUG|FOLFOXIRI + Bevacizumab|Bevacizumab 5mg/kg + irinotecan\* 165 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5-FU 2800 mg/m² cont. inf. 46h all on day 1 of each 2 weeks cycle until PD or resectability or to max. 12 cycles
224222302|NCT02350530|DRUG|FOLFOXIRI|Irinotecan\* 165 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5-FU 2800 mg/m² cont. inf. 46h all on day 1 of each 2 weeks cycle until PD or resectability or to max. 12 cycles
224222303|NCT03720756|OTHER|Nickel-free diet|Subjects follow a nickel-free diet. Lists of acceptable foods will be provided to subjects.
224222304|NCT02473510|BIOLOGICAL|Trivalent Influenza Vaccine|A single dose of 10\^(7.0 ± 0.5) FFU per strain of trivalent influenza vaccine will be administered as intranasal spray on Day 1.
224222305|NCT02473510|OTHER|Placebo|A single dose of placebo matched to trivalent influenza vaccine will be administered as intranasal spray on Day 1.
224222306|NCT01306253|BIOLOGICAL|Inflexal V|"Inflexal V influenza vaccine, formulated for the WHO requirements of the 2009-2010 season, containing per 0.5 mL dose:~* 15 µg hemagglutinin (HA) antigen of A/Brisbane/59/2007 (H1N1)-like virus~* 15 µg HA antigen of A/Brisbane/10/2007 (H3N2)-like virus~* 15 µg HA antigen of B/Brisbane/60/2008-like virus~Dose: intramuscular administration (M. deltoides) of a single dose of 0.5 mL on Day 1"
224222307|NCT02568995|DRUG|ropivacaine + ketorolac + adrenaline|A combination of drugs injected locally for postoperative pain management
224222308|NCT01690065|DRUG|Nilotinib+AD induction|"• Post-remission consolidation chemotherapy~* 4 courses of high-dose cytarabine will be given as post-remission therapy. Cytarabine 3 g/m2 will be administered in a 3-hour iv infusion every 12 hours on days 1, 3, and 5 (a total of six doses per course).~* Nilotinib 400mg bid PO will be administered continuously during consolidation chemotherapy and for 2 years after the consolidation therapy or until allogeneic hematopoietic stem cell transplantation"
224222309|NCT00003747|DRUG|carboplatin|
224222310|NCT00003747|DRUG|temozolomide|
224222311|NCT03736395|BEHAVIORAL|Idaho Rural Implementation Model|The Idaho Rural Implementation Model (I-RIM) includes several aspects to support implementation of schoolwide positive behavioral interventions and supports (SWPBIS). In the first year, schools will send a staff member to a coaching institute to build internal capacity. Schools will also receive technical assistance (on-site twice per year and virtual support as needed). Schools will also receive statewide professional learning opportunities, through one group meeting per year, and through access to an invitation-only professional learning community.
224222312|NCT03736395|BEHAVIORAL|Control|Schools in this condition will receive a four-day training session about SWPBIS.
224222313|NCT06537856|OTHER|Health Belief Model Based Cardiovascular Disease Risk Factor Prevention Education|"In line with the literature review, Health Belief Model-Based Cardiovascular Disease Risk Factor Prevention Training was created in order to increase the level of knowledge of firefighters regarding cardiovascular disease risk factors, improve their awareness and positively affect their quality of life. This training was given in 3 different sessions by meeting face-to-face with firefighters in the training hall of the fire stations. Each session lasted 40 minutes. Answers were given to the questions asked at the end of the session. The training was organized under the following main headings:~Perceived Sensitivity, Perceived Seriousness, Perceived Barriers, Perceived Self-Efficacy, Health Motivation/Activators"
223633645|NCT00135226|DRUG|Omega-3 Ethyl Esters|
223633646|NCT00135226|DRUG|Placebo Aspirin|
223633647|NCT00135226|DRUG|Placebo Omega-3 Ethyl Esters|
223633648|NCT06578364|DEVICE|Educational Program about Preconception Care|The educational program consisted of a single session, which included a lecture, pictures, videos, and discussions.
223633649|NCT04689139|DIAGNOSTIC_TEST|blood sample tests for determination of biomarkers levels|Using of proadrenomedullin, presepsin, NT-proBNP, Troponin I to determine the correlation of perioperative complications.
223633650|NCT05569044|OTHER|Control Group|No intervention
223633651|NCT05569044|OTHER|Oral Rehydration Solution|Participants will be administered ORS during one of the study visits
223633652|NCT05569044|OTHER|Water|Participants will be administered water during one of the study visits
223633653|NCT02647125|DRUG|Huachansu|Huachansu 20 ml/m2/d, intervenous infusion, once a day, 5 times per week, during the period of radiation.
223633654|NCT02647125|RADIATION|thoracic radiation|A total dose of 61.2 Gy will be delivered in 34 fractions at 1.8 Gy/fraction, 5 fractions per week in 6.8 weeks.
223633655|NCT05454033|DEVICE|JUVÉDERM® VOLITE™|Injection, intradermal
223633656|NCT05454033|OTHER|Control|No-treatment control
223764508|NCT04263818|PROCEDURE|Recording of endoscopist and endoscope motions right after the endoscopic exam the patient came for|"Carrying out the endoscopic procedure planned for the patient with the dedicated colonoscope which has magnetic coils over the entire length of the insertion tube. These magnetic coils generate a pulsed magnetic field at low frequency. These pulses are transmitted to an external receiver, refreshed at 15 images per second, then relayed to the processor to generate a 3D representation of the colonoscope next to it of the endoscopic image. There is no additional risk to the patient compared to current practice.~Recording of endoscopist and endoscope motions right after the endoscopic exam the patient came for."
224222314|NCT06537856|BEHAVIORAL|Reminder Short Messages|After the Health Belief Model-Based health education, 39 text messages were sent via WhatsApp application 3-4 times a week for 3 months to increase the effectiveness of the education and the motivation of firefighters in CVD prevention.
224222315|NCT05587101|DIAGNOSTIC_TEST|Urodynamic Study (Filling cystometry and pressure-flow study)|Under sterile conditions and at lithotomy position, an urethral and a rectal catheter will be inserted. Bladder will be filled by sterile saline slowly. The first feeling of urine, the first sensation of urination and the sensation of severe desire to urinate will be recorded step by step. Vesical, rectal and detrusor pressures will be monitorized during these period. After the strong desire to void sensation, filling cystometry phase will be completed. Sterile saline infusion is stopped. While the patient urinates the vesical, detrusor and rectal pressures, the maximum and average urine flow rates will be recorded.
224222316|NCT05587101|DIAGNOSTIC_TEST|Questionnaires|Bladder diary is an online application. Frequency, nocturia, functional bladder capacities will be reported. More than 8 urination during daytime will be recorded as overactive bladder. More than 1 interruption of sleep for urination at night is nocturia. Functional bladder capacity below 100 ml will be defined as decreased bladder capacity, while capacity over 400 ml will be reported as increased bladder capacity and compliance.
224222317|NCT05587101|DIAGNOSTIC_TEST|Uroflowmetry|Uroflowmetry test consists measuring the maximum urine flow rate, the average urine flow rate, the micturiated volume and postmictional urine volume. The maximum flow rate below 12 ml/sec in males and 18 ml/sec in females will be recorded as emptying phase disorder. Postvoid residual urine volume above 150 ml is a sign of incomplete emptying of bladder.
223633657|NCT02679313|DEVICE|Phoropter|Each subject will be tested on 3 separate occasions using either the manual phoropter (American Optical 11625), electronic phoropter (Topcon CV-5000) or the wearable adaptive refractor (VisionFit). Oculomotor measurements, i.e., heterophoria, vergence ranges, AC/A and accommodative findings will be measured at each session using the different devices. Each session will be separated by a minimum of 24 hours and a maximum of 14 days.
223633658|NCT04531410|DIETARY_SUPPLEMENT|linoleic acid supplementation|Oils given daily at morning meal with extra enzymes
223633659|NCT04531410|DIETARY_SUPPLEMENT|oleic acid supplementation|Oils given at morning meal with extra enzymes
224222318|NCT03312725|DEVICE|WEB aneurysm embolization system|The WEB aneurysm embolization system is a class III device and consists of an implantable embolization device attached to a delivery device. The WEB is a mesh composed of single layers of braided nitinol tubes with platinum cores. The braids are held together by proximal and distal platinum/iridium radiopaque markers.
223633660|NCT04552301|BEHAVIORAL|Cognitive Processing Therapy|Integrated CPT. CPT is based on a social cognitive theory of PTSD that focuses on how the traumatic event is construed and coped with by a person who is trying to regain a sense of mastery and control in his or her life. The asthma components that will be integrated into the intervention include psychoeducation about asthma, barriers to asthma self-care, asthma medication education, inhaler technique, and asthma self-management behaviors.
223764509|NCT00394030|DRUG|GSK716155 subcutaneous injections|GSK716155 will be available as lyophilize uniform cake in 10 milliliter (mL) clear glass vials with 20 millimeter (mm) closure. Subjects will administer dose of either 16mg or 64mg of GSK716155 via subcutaneous injection(s). For dose of 16 mg 1 injection of 0.62 mL will be administered and for dose of 64 mg 3 injections of 0.82 mL each will be administered.
223764510|NCT03794843|DRUG|Nimodipine Injection|Nimodipine injection (trade name: Nimotop) manufactured by Bayer Pharma AG was used as the reference preparation
223764511|NCT03794843|DRUG|Nimodipine Injection (II)|Nimodipine Injection (II) was supplied by Shenyang Dongxing Pharmaceutical Technology Co., Ltd
223764512|NCT02337244|DEVICE|Zimmer Persona Total Knee System|No Intervention
223764513|NCT01276314|DRUG|anti- TNF-a|25mg BIW, SC
223764514|NCT01276314|DRUG|Prednisolone|1-1.5 mg / kg / day
223764515|NCT02634138|DEVICE|Revitive IX|A foot plate Neuromuscular Electrical Stimulation Device
223764516|NCT01860261|BEHAVIORAL|Aerobic and Strength Training Intervention|The exercise intervention has three components: (1) aerobic exercise with a metabolic equivalent of task (MET) energy expenditure of at least 900 MET-minutes per week; (2) strength training consisting of 2 sets of 4 upper body exercises (bench press, seated row, shoulder press, and pull down), 3 sets of 3 leg exercises (leg press, extension, and flexion) and 2 sets each of abdominal crunches and back extensions. Weights for each exercise will be gradually increased as participants can complete 12 repetitions for each set on 2 consecutive sessions, with participants performing strength training twice per week total. Three workshops on using ChiWalking or ChiRunning technique for achievement of aerobic activity goals will be provided to participants in the experimental arm.
223633661|NCT04552301|BEHAVIORAL|Psychotherapy|The Study Interventionist will conduct generalized supportive psychotherapy with the participants to provide emotional support for both PTSD and general education for asthma.
223633662|NCT04552301|BEHAVIORAL|Targeted Asthma Education|The manualized 10-session program of asthma self-management
223633663|NCT04552301|BEHAVIORAL|General Asthma Education|A 10-session program of similar time
223633664|NCT05722860|DRUG|L-Citrulline, capsule|5g/daily dose for the duration of 1 week intervention
223633665|NCT01184898|DRUG|Sirolimus|Sirolimus, by mouth, will be given as a 12mg loading dose followed by 8 daily doses of 4mg/day.
223633666|NCT01184898|DRUG|Mitoxantrone|Mitoxantrone 8mg/m2/day IV
223633667|NCT01184898|DRUG|Etoposide|100 mg/m2/day IV
223633668|NCT01184898|DRUG|Cytarabine|1000mg/m2/day IV every 24 hours for 5 days
224222319|NCT01261325|DRUG|Placebo|Daily oral dose of two equal intakes of placebo in a double-blinded way for the 12-week treatment period
224222320|NCT01261325|DRUG|Brivaracetam|Daily oral dose of two equal intakes of Brivaracetam 100 mg/ day in a double-blinded way for the 12-week treatment period
224222321|NCT01261325|DRUG|Brivaracetam|Daily oral dose of two equal intakes of Brivaracetam 200 mg/ day in a double-blinded way for the 12-week treatment period.
224222322|NCT01261325|DRUG|Antiepileptic drugs with market authorization available per country|
224222323|NCT01001663|DEVICE|FemoSeal®|Closure device for femoral artery access closure
224222324|NCT01001663|OTHER|Manual compression|Conventional manual compression
224222325|NCT04242966|OTHER|Usual Care|Protein targets will be set using pre-ICU dry actual weight. For patients with BMI \>30, ideal body weight based on a BMI of 25 will be used. We will endorse the guidelines for energy targets set forth by ASPEN/SCCM, especially as it pertains to the obese patient.
224222326|NCT04242966|OTHER|Higher Protein/Amino Acid Group|Protein targets will be set using pre-ICU dry actual weight. For patients with BMI \>30, ideal body weight based on a BMI of 25 will be used. We will endorse the guidelines for energy targets set forth by ASPEN/SCCM, especially as it pertains to the obese patient.
224222327|NCT04242966|OTHER|Ultrasound measure|Patients will undergo the ultrasound measures at baseline (within 24 hours of randomization, day 10 days post randomization (if still in hospital) and just prior to hospital discharge. In the event that hospital discharge is prior to day 10, the day 10 measure will not be done.
224222328|NCT02170701|DRUG|BIBR 1048|Ascending doses (in mg) given twice daily
224222329|NCT01637025|DEVICE|Oxidized cellulose strip|Single use, intra-operative application to the target bleeding site
224222330|NCT01637025|DEVICE|Oxidized regenerated cellulose strip|A substance used to promote hemostasis (stops bleeding) based on oxidized regenerated cellulose
224222331|NCT03844568|DEVICE|nocturnal nasal continuous positive airway pressure|applying nasal continuous positive airway pressure at 7.5-10cmH2O for at least 4 hours during nighttime
224222332|NCT03089099|OTHER|Blood drawing|Blood drawing
224222333|NCT01906099|OTHER|nutritional intervention|
224222334|NCT01906099|OTHER|life style modification|
224222335|NCT02280356|RADIATION|external beam radiation therapy|
224222336|NCT02280356|RADIATION|brachytherapy|
224222337|NCT02280356|BEHAVIORAL|questionnaires|
224222338|NCT02611206|DEVICE|Active Repetitive Transcranial Magnetic Stimulation (rTMS): intensity 80% MT|"rTMS applies a pulsatile magnetic field to the scalp which painlessly induces electrical currents to the brain. Typically, rTMS is applied to the dorsolateral prefrontal cortex (DLPFC), a brain region that is hypoactive in depression. Whereas standard rTMS stimulates superficial (1cm depth) cortical areas, recent advances in rTMS coil technology support stimulation of deeper (5 cm depth) limbic structures that are also relevant to depression.~Other Name: Brainsway rTMS"
224222339|NCT02611206|DEVICE|Device: Active Repetitive Transcranial Magnetic Stimulation (rTMS); Stimulation intesity: 100% of MT|"rTMS applies a pulsatile magnetic field to the scalp which painlessly induces electrical currents to the brain. Typically, rTMS is applied to the dorsolateral prefrontal cortex (DLPFC), a brain region that is hypoactive in depression. Whereas standard rTMS stimulates superficial (1cm depth) cortical areas, recent advances in rTMS coil technology support stimulation of deeper (5 cm depth) limbic structures that are also relevant to depression.~Other Name: Brainsway rTMS"
224222340|NCT02611206|DEVICE|Device: Active Repetitive Transcranial Magnetic Stimulation (rTMS); Stimulation intesity: 120% of MT|"rTMS applies a pulsatile magnetic field to the scalp which painlessly induces electrical currents to the brain. Typically, rTMS is applied to the dorsolateral prefrontal cortex (DLPFC), a brain region that is hypoactive in depression. Whereas standard rTMS stimulates superficial (1cm depth) cortical areas, recent advances in rTMS coil technology support stimulation of deeper (5 cm depth) limbic structures that are also relevant to depression.~Other Name: Brainsway rTMS"
224222341|NCT04916886|BIOLOGICAL|Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) 0.5ml|Containing 0.5E10vp
224222342|NCT04916886|BIOLOGICAL|Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) 0.3ml|Containing 0.3E10vp
224222343|NCT01878656|DRUG|Sevoflurane|The investigators decrease to 1 minimal alveolar concentration(MAC) of anesthetic combination of sevoflurane and nitrous oxide, and maintain end-tidal concentration of anesthetic combination at 1 MAC until the end of surgery. At the end of surgery, sevoflurane and nitrous oxide are discontinued.
224222344|NCT01878656|DRUG|Desflurane|The investigators decrease to 1 MAC of anesthetic combination of desflurane and nitrous oxide, and maintain end-tidal concentration of anesthetic combination at 1 MAC until the end of surgery. At the end of surgery, desflurane and nitrous oxide are discontinued.
224222345|NCT00412815|BEHAVIORAL|Exercise training|
224222346|NCT02958878|DRUG|Tamsulosin|
224222347|NCT02958878|DRUG|Placebo Oral Capsule|
224222348|NCT03670407|PROCEDURE|Ovarian tissue fragmentation|Unilateral ovariectomy, ovarian tissue in vitro fragmentation and reimplantation.
224222349|NCT03785483|BEHAVIORAL|Motivation|8 weeks of either action planning or mindfulness in addition to a treatment as usual which is a physical activity program of 120 minutes per week.
224222350|NCT02577289|PROCEDURE|Evaluation of bone quantity in open sinus lift technique with simultaneous implantation ( Nano crystalline hydroxyapatite)|• The sinus cavity will be augmented with bone graft ( Nano crystalline hydroxyapatite)
224222351|NCT02577289|PROCEDURE|Evaluation of bone quantity in open sinus lift technique with simultaneous implantation (PRF)|platelet rich fibrin (PRF) as sole grafting material in created space (PRF)
224222352|NCT01017679|DRUG|Gefitinib 500mg/Gefitinib 250mg|Gefitinib 500mg or 250mg is Taken Orally everyday by Experimental and controlled Arms respectively
224222353|NCT02971514|BEHAVIORAL|Flossing before Brushing|
224222354|NCT02971514|BEHAVIORAL|Brushing before Flossing|
224222355|NCT00029185|DRUG|Dehydrex|
223633669|NCT05375617|OTHER|Observational|No intervention
223633670|NCT06383871|DRUG|HRS-7058 capsule/ HRS-7058 tablet|HRS-7058 capsule/ HRS-7058 tablet
224222356|NCT03718156|OTHER|PREPARED Trial Intervention|Nursing staff members will be trained to adjust the therapeutic nursing plans (TNP) for residents enrolled in the study, as follows: 1) by providing optimal stimulation (surveying the use of eyeglasses and hearing aids, the room lighting and space organization; orienting the resident to time and space; and stimulating the resident using familiar objects, photos, and life histories); and 2) by assessing the presence of 4 modifiable delirium risk factors (antipsychotic use, sensory impairment, restraint use, and dehydration) and taking specific actions once a given risk factor is identified. For instance, if physical restraints are used, the TNP will require that they are to be removed during care when a caregiver is present (nail care, feeding, and wound care).
223633671|NCT06075901|DEVICE|Tissue Flossing|Tissue Flossing ia a elastic band that when applied exerts an external pressure above or below a muscle or joint of the extremities.
223633672|NCT06075901|DEVICE|Blood Flow Restriction Cuff|Inflatable device that exerts an external pressure above a muscle or joint of the extremities.
223633673|NCT06075901|OTHER|Training Protocol|The lower limb resistance training protocol will follow that recommended in the study by Patterson et al. for resistance training, and will last 4 weeks, with 3 training sessions per week, with a day break between sessions.
223633674|NCT04304495|OTHER|Fall Prevention|The intervention arm participants will receive a physical therapy and pharmacy consults as well as Apple Watch training and an Apple Watch device to test memory and mobility during the ED visit and during our home visits.
223633675|NCT05323474|OTHER|Usual rehabilitation|"Usual rehabilitation according to the practice of the Haute Autorité de Santé (HAS)"
223633676|NCT05323474|OTHER|Rehabilitation optimized|Rehabilitation optimized according to the study protocol
223633677|NCT05734768|BEHAVIORAL|State-Trait Anxiety Inventory - Y ou STAI-Y|Questionnaire
224222357|NCT00692926|BIOLOGICAL|ALDHbr Umbilical Cord Blood Cells|ALDHbr sorted Umbilical Cord Blood Cells
224222358|NCT04521400|DRUG|High dose Interferon-beta 1a|High dose IFN-β1a (Recigen) (Subcutaneous injections of 88μg (24,000 IU) on days 1, 3, 6)
224222359|NCT04521400|DRUG|Lopinavir/Ritonavir|Lopinavir/Ritonavir (Kaletra) \[IFN-β1a group\] (400mg/100 mg twice a day for 10 days
224222360|NCT04521400|DRUG|Low dose Interferon-beta 1a|Low doseIFN-β1a (Recigen) (Subcutaneous injections of 44μg (12,000 IU) on days 1, 3, 6)
223633678|NCT00660725|DRUG|Vandetanib|Vandetanib is a pill that will be self-administered orally on Days 1-14 of each 14-day cycle. The dose of vandetanib each subject will receive will be determined by a dose escalation schedule (either 200 mg or 300 mg per day), which will be followed to determine the MTD of the study drug combination (vandetanib + GemOx). In the absence of disease progression, unacceptable toxicities, or other complications, the vandetanib and GemOx combination may continue per protocol for a maximum of 6 cycles, or 12 weeks. In subjects who show response or stable disease, vandetanib may be continued as a single agent beyond the 6 cycle maximum, at the investigator's discretion.
223633679|NCT00660725|DRUG|Gemcitabine|30-minute IV infusion of 1000 mg/m\^2 gemcitabine on Day 1 of each 14-day cycle.
223633680|NCT00660725|DRUG|Oxaliplatin|Immediately following gemcitabine IV: 2-hour IV infusion of 85 mg/m\^2 oxaliplatin on Day 1 of each 14-day cycle.
223633681|NCT06072794|DRUG|VL-PX10|VL-PX10 is a decellularized product consisting of proteins, lipids, and nucleic acids derived from human placenta mesenchymal stem cells.
223633682|NCT01422096|DRUG|Leuprolide|depot leuprolide 11.25 mg if less than or equal to 37.5 kg or 15 mg if \> 37.5 kg im once
223633683|NCT02799836|DEVICE|Blindfold|Study subjects will be blindfolded to create an environment of complete light deprivation which will be worn for 48 hours.
223633684|NCT04531176|OTHER|Weight Management Program (WMP)|Weight Management Program (WMP)
223633685|NCT04531176|OTHER|Traditional care|Traditional care
223633686|NCT04531176|DRUG|Phentermine / Topiramate Extended Release Oral Capsule|Medication for chronic weight management (Rx)
223633687|NCT04531176|DRUG|naltrexone/bupropion extended-release|Medication for chronic weight management (Rx)
223764517|NCT01570023|BEHAVIORAL|Isometric Progressive Resistance Oropharyngeal Therapy|Tongue press exercises consist of pressing the tongue against the sensors. Isometric exercises will focus on the anterior and posterior sensor. Subjects will be given a target pressure value for both the anterior and posterior sensor locations for which to aim when doing the exercises. Visual feedback on the display will signal the subject that they have attained their target pressure goal.
223764518|NCT01588002|DRUG|danoprevir|multiple oral doses
224222361|NCT02725970|OTHER|survey|Cross-sectional survey
223633688|NCT04531176|DRUG|liraglutide 3.0 mg|Medication for chronic weight management (Rx)
223633689|NCT04531176|DRUG|Orlistat|Medication for chronic weight management (Rx)
223633690|NCT06281587|PROCEDURE|penetrating keratoplasty|replacement of the affected tissue with healthy donor tissue in diseases that disrupt the shape or transparency of the cornea.
223633691|NCT04595071|DEVICE|Voice Activated Prosthetic Interface (VAPI) Controller|A device installed between a subjects socket quick disconnect wrist connection and multi-articulating hand which enables the use of voice as a control modality in addition to their standard two-site myoelectric control.
223633692|NCT06512584|DRUG|PJ009|subcutaneous injections, 0.05 mg/kg once daily
223633693|NCT06512584|DRUG|PJ009 Placebo|subcutaneous injections, once daily
224222362|NCT01609660|DIETARY_SUPPLEMENT|Saccharomyces boulardii|100mg daily for seven days prior to surgery
223633694|NCT06564571|DEVICE|Patients undergoing endoscopic ultrasound procedures|Patients will undergo endoscopic ultrasound procedures as planned. Abnormalities in the pancreas identified by the endoscopist during the endoscopic ultrasound examination will be correlated against those detected by the AI platform.
223633695|NCT03701958|DEVICE|Exalt Model D Single-Use Duodenoscope|Subjects will have a clinically indicated per standard of care ERCP procedure performed with the Exalt single use duodenoscope study device.
223633696|NCT00003122|PROCEDURE|surgical procedure|
223633697|NCT02943174|BEHAVIORAL|MIND programme for cancer patients|Psychotherapeutic programme based on Acceptance, Mindfulness and Compassion for cancer patients Other: Cancer Treatment as Usual
223633698|NCT02943174|OTHER|Treatment as Usual (TAU)|Standard personalized treatment of cancer
223633699|NCT02122016|DEVICE|SmartCare|Ventilator with a SmartCare module that is capable of performing a computer-driven weaning trial taking into account patients lung mechanics and exaled CO2.
223633700|NCT02122016|OTHER|Conventional weaning protocol|A conventional weaning protocol performed by physiotherapist with a daily weaning screen and a spontaneous breathing trial
223633701|NCT02916212|OTHER|Optimized alarm profiles|
223633702|NCT00528112|DRUG|LCS12|Intrauterine system (IUS) with Levonorgestrel, in vitro releasing rate 12 microg/24 h
223633703|NCT00528112|DRUG|LCS16|Intrauterine system (IUS) with Levonorgestrel, in vitro releasing rate 16 microg/24 h
223633704|NCT02227914|DRUG|Oprozomib|Study subjects will receive oprozomib tablets once a day on Days 1, 2, 8, 9, 15, 16, 22 and 23 of a 28 day cycle
223633705|NCT02227914|DRUG|Sorafenib|Study subjects will receive sorafenib tablets twice a day for Days 1-28
223633706|NCT03403803|DEVICE|Optune|"Optune is a wearable and portable, FDA-approved device that has been shown in clinical trials to safely deliver continuous therapy to the area of your brain where your GBM (Glioblastoma) tumor is located.~TMZ (Temozolomide) is an oral chemotherapy drug. It is an alkylating agent used as a treatment of some brain cancers; as a second-line treatment for astrocytoma and a first-line treatment for glioblastoma multiforme."
223633707|NCT04877626|DRUG|Artemeter plus lumefantrina vs artesunato plus amodiquina|"Group 1 received the combination AQ+AS (COARSUCAM®) which was administered orally at an initial dose of 2 tablets (200 mg AQ/540 mg AS) followed by 2 additional doses of 2 tablets at 24 and 48 hours (6 tablets in 48 hours).~Group 2 received the combination Artemeter+lumefantrina (COARTEM®) administered orally at an initial dose of 4 tablets (80 mg artemeter/480 mg lumefantrina) followed by 5 additional doses of 4 tablets at 8, 24, 36, 48, and 60 hours (24 tablets in 60 hours)"
223633708|NCT03526133|DIAGNOSTIC_TEST|Polysomnography (PSG) and wireless sensor Oxistar|Monitoring the apnea-hypopnea index (AHI) derived from PSG and the oxygen desaturation index (ODI) obtained by the Oxistar.
223633709|NCT05544162|DIETARY_SUPPLEMENT|Nutrition supplement - Ensure shakes|Ensure shakes will be take up to 3 times a day throughout hospitalization and for 4 weeks after discharge.
223633710|NCT03210948|DEVICE|RTE-guided EUS-FNA|Fine needle aspiration with 25 gauge needle under RTE-guidance
223633711|NCT03210948|DEVICE|Conventional EUS-FNA|Fine needle aspiration with no RTE guidance
223764519|NCT01588002|DRUG|efavirenz|multiple oral doses
224222363|NCT00306631|DRUG|MKC-1|Oral capsules, 30 mg and 100 mg capsule strengths; administered twice daily for 14 days in a 28 day cycle
224222364|NCT05682794|PROCEDURE|transanal total mesorectal excision|transanal TME
224222365|NCT00468923|DRUG|Candesartan/HCT|Candesartan 16 mg/HCT 12.5 once daily
224222366|NCT00468923|DRUG|Rosuvastatin|Rosuvastatin 10 mg once daily
223633712|NCT06331559|DRUG|SIM0501 Tablets|Every 28 days is one cycle. Multiple dose levels of SIM0501 will be explored in dose escalation, and determine the maximum tolerated dose.
223633713|NCT06331559|DRUG|SIM0501 Tablets|Every 28 days is one cycle.Patients will be administered a potential recommended dose of SIM0501 established from SIM0501 mono dose escalation.
223633714|NCT06331559|DRUG|SIM0501 in combination with olaparib|Every 28 days is one cycle.Multiple dose levels of SIM0501 and olaparib will be explored in dose escalation, and determine the maximum tolerated dose.
223633715|NCT06331559|DRUG|SIM0501 in combination with olaparib|Every 28 days is one cycle.Patients will be administered a potential recommended dose of SIM0501 combination with olaparib established from SIM0501 combination dose escalation.
223633716|NCT03118310|BEHAVIORAL|5:2 diet|Dietary intervention according to 5:2 diet during three months.
223633717|NCT03118310|BEHAVIORAL|LCHF|Dietary intervention according to LCHF diet during three months.
223633718|NCT03118310|BEHAVIORAL|Placebo diet|Placebo diet: normal dietary advice
223764520|NCT01588002|DRUG|ritonavir|multiple oral doses
223764521|NCT04230096|DEVICE|low level laser therapy|apply low level laser therapy on buccal surface of maxillary jaw on anterior segment for three minutes at every three weeks in fixed orthodontic patients in their regular follow up visits
223764522|NCT05418452|DRUG|Metformin|metformin (MF), an antidiabetic agent, has been successfully used as a local drug delivery agent in periodontitis patients. Literature has suggested that MF possesses the osteogenic potential and induces the growth of osteoblast precursor cells. Therefore, several human studies have reported the use of MF alone or combined with PRF in the treatment of bony defects
224222367|NCT00776633|DRUG|aspirin|6 weeks triple therapy with aspirin, clopidogrel and oral anticoagulation
224222368|NCT00776633|DRUG|clopidogrel|6 months triple therapy with aspirin, clopidogrel and oral anticoagulation
224222369|NCT00776633|DRUG|oral anticoagulation|
223633719|NCT02473081|BEHAVIORAL|Minimal psychological intervention|Minimal psychological intervention (MPI) was used to help adults with chronic illness to manage their psychological burden by breaking through a negative spiral between thoughts and behaviors.
223633720|NCT02473081|OTHER|Usual care|Usual care was given by their family physicians.
223633721|NCT02462694|BEHAVIORAL|Dialectical Behavior Therapy|Dialectical Behavior Therapy is an empirically validated treatment approach emphasizing the role of emotion regulation in the treatment of suicidal and self-destructive behaviors in BPD
223633722|NCT02462694|BEHAVIORAL|Treatment As Usual|TAU for these subjects involves close tracking by the Suicide Prevention Coordinator and treatment by their individual team of clinicians. Additionally, a support group with psychoeducation about suicide prevention will be offered as part of TAU
223764523|NCT05322187|DRUG|PD-1 inhibitor|Sequential PD-1/PD-L1 Inhibitor and LENvatinib treatment after chemotherapy resistance
224222370|NCT03853083|DEVICE|Hypoxi Equipment|Using the Hypoxi exercise equipment to try and improve lipedema fat tissue
224222371|NCT03853083|DEVICE|Recumbent Bicycle|Recumbent bike is a piece of exercise equipment used as the comparison group
224222372|NCT00293969|DRUG|Morphine 0.1mg/kg versus morphine 0.15 mg/kg|
223633723|NCT00611936|DRUG|Placebo|Placebo
223633724|NCT00611936|DRUG|Atomoxetine|20mg maximum of d-amphetamine
223633725|NCT04090918|DIAGNOSTIC_TEST|Cardiac examination programme 3 months after abdominal surgery|Blood- and urine sampling, electrocardiogram, wavECG (Myovista), transthoracic echocardiography, Finapres, cardiac magnetic resonance imaging
223764524|NCT00779675|BIOLOGICAL|Infliximab|Infliximab administered intravenously at a dose of 5 mg/kg body weight at Weeks 0, 2, 6 and then every 8 weeks (Weeks 14, 22, 30, 38, and 46 for the Treatment Period and Week 54, 62, 70, 78, 86, and 94 for the Extended Treatment Period) as per the product monograph (PM; Canada), summary of product characteristics (SPC; European Union), or local labeling (for all other countries).
223764525|NCT06210529|DEVICE|a high-intensity focused ultrasound tumor treatment system (Super Knife)|All participants will be randomly divided into groups A and B. Participants in group A will receive a high-intensity focused ultrasound tumor treatment (Super Knife) once, and participants in group B will receive treatment twice (4 weeks, one cycle).. Breast cancer surgery was performed at 3 months ± 1 week after the Super Knife treatment.
223764526|NCT00796965|DRUG|AZD7268|Solution/Capsule, Oral, once daily
223764527|NCT00796965|DRUG|Placebo|
223764528|NCT03949075|DRUG|Enalapril|Participants will be assigned to daily administration of ACE inhibitors (Initially 5 mg Corodil® 'Enalapril' daily followed by up to 20 mg daily dependent on the blood pressure response) combined with an 8-week training period.
223764529|NCT03949075|DRUG|Placebo|Participants will be assigned to daily administration of placebo (5-20 mg CaCO3) combined with an 8-week training period.
223764530|NCT01829932|DIETARY_SUPPLEMENT|Factor Altered Diet|
223764531|NCT02821962|BEHAVIORAL|Sedentary prompts from a VTAP device|
224222373|NCT03721848|BEHAVIORAL|Healthy community clinic NCD+MH|"NCD+MH Awareness Intervention Overview:~i. Patients are assigned, at minimum, one health awareness lecture per month with a total of 28 lectures possible ii. Patients attend lectures on specific topics given by MoH staff, mainly nurses.~iii. Topics tackled include: Diabetes, Hypertension, Asthma, Cardiovascular Disease, Reproductive Health, Healthy Nutrition, Smoking, Emotional Wellness, Stress Relief and Positive Coping.~iv. Group nutrition and physical fitness counselling are incorporated into most health awareness lectures"
224222374|NCT03721848|BEHAVIORAL|Healthy community clinic NCD|"i. Patients are assigned, at minimum, one health awareness lecture per month with a total of 24 lectures possible ii. Patients attend lectures on specific topics given by MoH staff, mainly nurses.~iii. Topics tackled include: Diabetes, Hypertension, Asthma, Cardiovascular Disease, Reproductive Health, Healthy Nutrition, and Smoking iv. Group nutrition and physical fitness counselling are incorporated into most health awareness lectures"
224222375|NCT03469271|DRUG|1,25 (OH)2 D3|0.25 micrograms, taken daily for eight weeks, orally
223633726|NCT00894803|DRUG|Eptifibatide|IV Eptifibatide is an approved drug by the Food and Drug Administration as a treatment for blood clots causing heart attack and chest pain.Eptifibatide inhibits platelet aggregation by blocking activated platelets from binding fibrinogen.
223633727|NCT00894803|DRUG|rt-PA|Intravenous recombinant tissue plasminogen activator (rt-PA) is the only approved acute stroke therapy.
223633728|NCT04160117|DRUG|Colchicine 0.6 mg|p.o. twice daily for 10 days after catheter ablation for atrial fibrillation
223633729|NCT04160117|DRUG|Matching placebo|p.o. twice daily for 10 days after catheter ablation for atrial fibrillation
223633730|NCT03743272|DEVICE|LiverMultiScan|Up to 6 separate 5-10 minute abdominal MRI scans. Each scan requires a short breath hold.
223633731|NCT05246046|DRUG|Tiotropium Bromide Monohydrate|In each period, subjects receive single dose of tiotropium consisting of 2 inhaled doses via Easyhaler or 2 Spiriva capsules inhaled via HandiHaler
223764532|NCT02399150|OTHER|No intervention as observational study|
223764533|NCT03237234|OTHER|Motor Skill Training|Motor skill training will consist of activities that will be performed while standing to promote upright control (the toe-tapping activity will be performed while seated). Participants will perform each of the 6 different activities for one minute each, until 4 cycles of the circuit have been completed (approximately 25 minutes total). Motor training activities will be performed at an intensity of 40-59% of heart rate reserve (HRR). Toe tapping will provide the opportunity for scheduled rest. During MT, all participants will wear a heart rate monitor to ensure that the optimal HR range is achieved. HRR will be calculated from resting and peak heart rate measures obtained during baseline testing via administration of a graded-exercise test.
223764534|NCT03237234|DEVICE|Transcranial direct current stimulation (tDCS)|The tDCS electrode placement is based on procedures shown to improve gait and balance in a single session when used in combination with gait training activities. tDCS electrodes can simultaneously activate the bilateral leg motor areas when placed at the midline of the scalp slightly anterior to the vertex (anode) and at the inion (cathode), with a current intensity of 2mA. The tDCS device is lightweight, and can be worn in a backpack during the MT activities. As reported previously, participants in the MT-only group will receive sham tDCS to maintain analogous study procedures.
223764535|NCT01569529|BEHAVIORAL|Online advertisement|Internet advertisement with messages tailored for young adult smoker's motivated to quit
223764536|NCT01813981|DIETARY_SUPPLEMENT|Low roast coffee|Instant coffee
223764537|NCT01813981|DIETARY_SUPPLEMENT|High roast coffee|Instant coffee
223764538|NCT01813981|DIETARY_SUPPLEMENT|Control (Caffeine dissolved in water)|Caffeine dissolved in water
224222376|NCT03469271|OTHER|Inspiratory isometric resistance training|A small hand-held reusable device to increase muscle strength and endurance through inhalation therapy. Participants will inhale through a valve which provides resistance that increases the work of breathing and exercises the respiratory muscles.Participants in the active groups will breathe against a resistance set to generate 30% of maximal inspiratory pressure (PImax).
224222377|NCT03469271|DRUG|Oral Placebo|Placebo will be created to mimic the appearance of the study drug
223633732|NCT05320952|DEVICE|WellO2|The WellO2 breathing training device performs back-pressure steam breathing training during the inhalation and exhalation phases.
223633733|NCT04837443|BEHAVIORAL|Rubber hand illusion|Tactile sensory threshold from quantitative sensory tests, two point discrimination from cortical senses, pressure pain threshold measured by algometer will be examined during and after the rubber hand burning, which causes changes in body perception.
223633734|NCT04325672|BIOLOGICAL|Convalescent Plasma|Anti-SARS-CoV-2 convalescent plasma obtained from patients identified as having recovered from COVID-19 with neutralizing antibody titers \>1:64.
223633735|NCT00329043|DRUG|LHRH Agonist|Intramuscular injection either monthly for 3 months or in a single 3-month dose.
223633736|NCT00329043|DRUG|Sunitinib Malate|25 to 37.5 mg/day once daily for 30 days (= 1 cycle), up to 3 cycles.
224222378|NCT03469271|OTHER|Sham Inspiratory Isometric Resistance Training|A small hand-held reusable device to increase muscle strength and endurance through inhalation therapy. Participants will inhale through a valve which provides resistance that increases the work of breathing and exercises the respiratory muscles. Participants in the sham group will train daily against a resistance set to only 15% PImax.
224222379|NCT03469271|DEVICE|Threshold Inspiratory Muscle Trainer (IMT)|A small hand-held reusable device to increase muscle strength and endurance through inhalation therapy. Participants will inhale through a valve which provides resistance that increases the work of breathing and exercises the respiratory muscles.
224222380|NCT02277821|DEVICE|Stendo pulsating suit System|The Stendo system, a multilayer pulsatile inflatable suit is applied to the lower limbs and the abdomen. This device induces a sequential compartmentalized compression synchronized with each diastolic phase of the cardiac cycle, each phase evolving centripetally (lower limbs to abdomen).
224222381|NCT02382978|OTHER|nurse-provided well child visit|
224222382|NCT01174641|OTHER|trans-cranial magnetic stimulation|1 Hz trans-cranial magnetic stimulation will be applied for 20min at 60% motor threshold over the vertex
224222383|NCT01174641|OTHER|trans-cranial magnetic stimulation|trans-cranial magnetic stimulation will be applied at 1Hz for 20 min over the ipsilesional posterior parietal cortex of stroke patients with unilateral neglect
224222384|NCT01011322|DRUG|LT-02|Comparison of different dosages of drug versus placebo. 4 times daily over 12 weeks
224222385|NCT01011322|DRUG|placebo|placebo
224222386|NCT01806883|BEHAVIORAL|WII Rehabilitation|"30 patients will receive Wii rehabilitation of 15 minutes (tennis, boxing and golf), in comparison with 10 healthy subjects."
224222387|NCT01806883|BEHAVIORAL|Traditional rehabilitation|30 patients will receive the traditional rehabilitation.
224222388|NCT05371301|DRUG|Paclitaxel, Carboplatin|Paclitaxel 175mg/m2 iv d1 followed by Carboplatin(AUC=5) iv d1
224222389|NCT05371301|PROCEDURE|debulking surgery|"Remove all visible tumors and any other tissues or organs where tumor may have spread, which may include:~Uterus Fallopian tubes Omentum (tissue that covers the stomach, large intestine and other abdominal organs) Lymph nodes Diaphragm Part of the large bowel Spleen Parts of the liver"
224222390|NCT02277795|DEVICE|AccuCirc|Circumcision with the use of the AccuCirc device.
224222391|NCT03841721|DRUG|Linezolid oral tablet 300 mg/day for 5 day|Linezolid oral tablet 300 mg/day for 5 day and blood sample were obtained by direct venipuncture at 0, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hour after drug administration in day 5
224222392|NCT05588830|DRUG|Belimumab|Belimumab, 10mg/kg, was administered intravenously on the 0, 14 and 28 days, and then once every 28 days until the 24th week
224222393|NCT05588830|DRUG|Telitacicept|Telitacicept is injected subcutaneously, 160mg/time, once a week, for a total of 24 weeks
224222394|NCT03786510|BEHAVIORAL|Active control|Control group received a personalized advice on lifestyle modification to prevent dementia and usual care of Community Center for Dementia.
224222395|NCT03786510|BEHAVIORAL|Intensive + Maintenance program|"Both intensive and maintenance program~1. Intensive program The 4-week group-based intensive program was comprised of eight sessions; each session consisted of (1) a 30-min review of the tasks, (2) a 50-min training period, and (3) a 10-min meeting to assign tasks on an individual basis. A study nurse-guided training for modification of vascular risk factors, diet, cognitive and social activity were conducted, And, a physiotherapist conducted an exercise training mainly composed of muscle strengthening and stretching.~2. Maintenance program The allocated study assistants monthly check-up whether participants adhere to the altered habits or not, based on the workbook"
224222396|NCT03786510|BEHAVIORAL|Intensive program only|"Only the intensive program was conducted.~The 4-week group-based intensive program was comprised of eight sessions; each session consisted of (1) a 30-min review of the tasks, (2) a 50-min training period, and (3) a 10-min meeting to assign tasks on an individual basis. A study nurse-guided training for modification of vascular risk factors, diet, cognitive and social activity were conducted, And, a physiotherapist conducted an exercise training mainly composed of muscle strengthening and stretching."
224222397|NCT03767673|DIAGNOSTIC_TEST|Initial Spirometry|Determination of Vital Capacity by spirometry before (within 30 minutes) spiroergometry. Measurements will be performed in both groups.
224222398|NCT03767673|DIAGNOSTIC_TEST|Final Spirometry|Determination of Vital Capacity by spirometry after (within 30 minutes) spiroergometry. Measurements will be performed in both groups.
224222399|NCT03767673|DIAGNOSTIC_TEST|Pulmonary microbiome (16S rDNA profiling)|Harvesting of deep induced sputum and determination of the airway microbiome by 16S ribosomal RNA (rRNA) pyrosequencing. Evaluation of alpha and beta diversity and relative bacterial abundance at the genus level. Measurements will be performed in both groups (samples will be harvested within 30 minutes after spiroergometry).
223633737|NCT00329043|PROCEDURE|Radical Prostatectomy|Radical prostatectomy after completion of Sunitinib and LHRH agonist.
223633738|NCT01345240|BIOLOGICAL|GlaxoSmithKline (GSK) Biologicals' candidate Plasmodium falciparum malaria vaccine 257049|Children enrolled in 9 groups will receive 3 doses of the candidate malaria vaccine (Lot 1, 2 and 3) by intramuscular injection.
223633739|NCT01345240|BIOLOGICAL|Engerix-B™ vaccine|Children enrolled in 2 groups will receive 4 doses of Engerix-B™ vaccine by intramuscular injection. Children enrolled in all other groups will receive one dose of Engerix-B vaccine by intramuscular injection.
223633740|NCT01345240|BIOLOGICAL|Infanrix/Hib™ vaccine|Children enrolled in all 11 groups will receive 4 doses of Infanrix/Hib™ vaccine by intramuscular injection
223633741|NCT01345240|BIOLOGICAL|Polio Sabin™ vaccine|Children enrolled in all 11 groups will receive 3 doses of Polio Sabin™ by intramuscular injection.
223633742|NCT01345240|BIOLOGICAL|Rotarix™ vaccine|Children enrolled in all 11 groups will receive 2 doses of oral Rotarix™ vaccine.
223633743|NCT01345240|BIOLOGICAL|Synflorix™ vaccine|Children enrolled in all 11 groups will receive 4 doses of Synflorix™ vaccine by intramuscular injection.
224318405|NCT01161485|BEHAVIORAL|Contingency Management|In voucher-based CM programs, drug users who submit urine samples that are negative for specified drugs are reinforced with vouchers. Based on operant conditioning, CM rewards those who comply with the targeted behavior and does not reward when compliance is not achieved. In this study a mid-value reinforcement CM schedule will be used in order to balance community cost concerns with the need to show comparative efficacy in reducing meth use and concomitant sex risk behaviors in a largely unstudied risk group. Participants in the CM arm will be asked to come to the study site three times a week to leave a urine sample, get the result, and will then be offered a voucher if their urine is clean and given brief verbal feedback.
223633744|NCT01345240|BIOLOGICAL|Measles vaccine|Children enrolled in all 11 groups will receive 1 dose of measles vaccine by intramuscular injection.
223633745|NCT01345240|BIOLOGICAL|Yellow fever vaccine|Children enrolled in all 11 groups will receive 1 dose of yellow fever vaccine by intramuscular injection.
223633746|NCT06360380|DEVICE|AquaPass System|a treatment session of up to 5 hours with the AquaPass system, evaluating net fluid removal for efficacy analysis and effect on vital signs for safety analysis
223633747|NCT05711810|DRUG|Nifedipine 30 MG|Due to initial availability of drugs and the intensities of the patient's symptoms, Nifedipine was used for initial intervention in preventing acute myocarditis from happening.
223633748|NCT05711810|DIAGNOSTIC_TEST|Kangzhu BPCB0A-3A|The diagnostic test has been used to confirm objective parameters to guide the intervention drug dosages and accessing the risks in sudden death and long term adverse effects.
223633749|NCT05711810|BEHAVIORAL|Low Mobility|The behavioral intervention aimed at reducing the risks of sudden and strong blood flows in the patient's system.
223764539|NCT03218722|DRUG|Pro-Thrombin Concentrate Complex|Patient at risk of massive hemorrhage will be managed with standard care with 1ml/kg PCC.
224222400|NCT03767673|DIAGNOSTIC_TEST|Maximum oxygen uptake|Determination of the maximum oxygen uptake (ml/kg/min) corrected for gender, age and body weight by bicycle spiroergometry. Measurements will be performed in both groups.
224222401|NCT03767673|DIAGNOSTIC_TEST|Maximum performance|Determination of the maximum performance (W/kg) corrected for body weight by bicycle spiroergometry. Measurements will be performed in both groups.
224222402|NCT03767673|DIAGNOSTIC_TEST|weight|Determined by Kilogram on a medical weight scale
224222403|NCT03767673|OTHER|age|Determination of age by patient's Report and past medical history
224222404|NCT04624022|DIAGNOSTIC_TEST|Anterior segment optical coherent tomography|Examination of the implanted perforated lacrimal plugs using anterior segment optical coherent tomography
224222405|NCT04456465|OTHER|Pain diabetic peripheral neuropathy|Neuropathic pain is the focus of current clinical research, clinical identification, and treatment. It is unique from nociceptive pain and requires evaluation of the relevance and utility of common pain measures created for other painful conditions.
224222406|NCT01016496|OTHER|action observation therapy|15 consecutive sessions of 18 minutes, plus repetition
224222407|NCT01016496|OTHER|repetition of gestures|15 consecutive session of visual games, plus repetition of gestures
224222408|NCT04976868|DRUG|Pimecrolimus 1% Top Cream|Elidel® as prescribed within routine clinical practice
224222409|NCT01437137|DEVICE|classic-laryngeal mask airway (c-LMA)|Insertion of c-LMA
224222410|NCT01437137|DEVICE|i-gel™|Insertion of I-gel
224222411|NCT04171388|DRUG|Azithromycin 500 mg|Azithromycin 500mg (Kern Pharma): 2g (4 tablets) at 2 time points during pregnancy: enrollment (\<=24 weeks gestation), and follow-up ANC at least 4 weeks later
224222412|NCT04171388|DIETARY_SUPPLEMENT|Multiple Micronutrient or Fortified Balanced Energy Protein Supplement|Daily multiple micronutrient (MMN) tablet (Contract Pharmacal Corp) for women with mid-upper arm circumference (MUAC) \>=23 cm, OR Daily fortified balanced energy protein (BEP) supplement (DSM South Africa; Faffa Food Products): Fortified corn-soy blend (784 kcal/day) for women with MUAC \<23 cm
224222413|NCT04171388|DRUG|Placebo oral tablet 500 mg|Placebo 500mg (Idifarma): 2g (4 tablets) at 2 time points during pregnancy; enrollment (\<24 weeks gestation), and follow up ANC at least 4 weeks later
224222414|NCT04171388|OTHER|Enhanced Infection Management Package (EIMP)|"ENROLLMENT VISIT: Screening for bacteriuria with urine culture, and antimicrobial susceptibility testing; Screening for chlamydia and gonorrhea with Cepheid GeneXpert; Presumptive deworming with albendazole 500mg.~FOLLOWUP TREATMENT VISIT: For women with identified urinary tract infection or asymptomatic bacteriuria, treatment with antibiotics based on antimicrobial susceptibility patterns. For women with identified chlamydia or gonorrhea, treatment of woman (and partner) with appropriate antibiotics. Test of cure sample and retreatment of infection.~Second deworming with albendazole at least 4 weeks after enrollment ANC visit."
224222415|NCT06458686|DRUG|Vit D|Vitamin D is a fat soluble vitamin used for the treatment of many diseases.
224222416|NCT06458686|OTHER|Placebo|Placebo is a non drug formulation
224222417|NCT06066307|OTHER|Olfactory training|Olfactory training will be performed by sniffing four specific essential oils twice daily for 30 seconds each. Participants are encouraged to visualize the item they are smelling, while they perform the procedure, in a quiet room, with their eyes closed. The odors will comprise four major odor categories: flowery (phenyl ethyl alcohol/rose), aromatic (eucalyptol), fruity (citronellal/lemon), and resinous (eugenol).
224222418|NCT02586545|OTHER|Shared care|
224222419|NCT00236327|DRUG|fentanyl|
224222420|NCT02761369|DEVICE|A multi-channel deep TMS device with an H-coil (Brainsway Ltd)|A 3-week long treatment (15 days). Treatment session consist of 300 rapidly occurring pairs of pulses over the dorsolateral prefrontal cortex (at a frequency of 10 Hz and intensity of 110% of individual's motor threshold), with a 5-seconds interval, for a duration of 1800 seconds in total.
224222421|NCT00000295|DRUG|Micronized Progesterone|
223633750|NCT05711810|DRUG|Enalapril Maleate 10Mg Tab|The intervention aims to reduce the vein flows in Diastolic Blood Pressure, and the risks in blood clot formation and internal vein scratch bleeding.
223764540|NCT03218722|DRUG|NaCl 0.9%|Patient at risk of massive hemorrhage will be managed with standard care with 1ml/kg Saline solution.
223764541|NCT00749775|DRUG|Selara|Treatment should be initiated at 25 mg once daily and titrated to the recommended dose of 50 mg once daily, preferably within 4 weeks as tolerated by the patient. Selara may be administered with or without food.
223633751|NCT05711810|DRUG|Lansoprazole 30Mg Ec Cap|The intervention aims to server the allergy-inducing proteins to induce renal hemodialysis.
223633752|NCT05711810|DRUG|Metoprolol Succinate|Metoprolol Succinate is used to control the cardiac artery flow amounts and stabilize the patient's heart rate.
223633753|NCT05711810|DIETARY_SUPPLEMENT|Coenzyme Q10|200 mg per day is used for supplement with the cardiac interventions.
223633754|NCT05711810|DIETARY_SUPPLEMENT|d-alpha tocopherol acetate|The 268 mg twice per day dietary healthcare is the patient's usual daily use.
223633755|NCT05711810|DIETARY_SUPPLEMENT|Omega-3|The 900 mg twice per day dietary healthcare is the patient's usual daily use.
223633756|NCT05711810|DRUG|Duloxetine Hydrochloride 20 MG Oral Capsule, Delayed Release|Duloxetine hydrochloride is used for the patient's neurodiverse conditions.
223764542|NCT01280773|DEVICE|NAVA|Neurally adjusted ventilatory assist (NAVA) was delivered by a SVi ventilator. NAVA utilizes EAdi, a reflection of the neural respiratory output to diaphragm, as its primary source to trigger and cycle-off assist in synchrony with neural inspiratory efforts.
224222422|NCT04976140|BIOLOGICAL|PN-101|"PN-101: Mitochondria isolated from Allogeneic Umbilical Cord-derived Mesenchymal Stem Cells.~3 or 6 subjects are enrolled in each dose group in line with the traditional 3+3 rule-based method, and the investigator intravenously administers a single-dose of the investigational product according to the planned dose."
224222423|NCT05252078|DRUG|Anlotinib hydrochloride|Anlotinib Hydrochloride is a capsule in the form of 8 mg ,10 mg and 12 mg, orally, once daily, 2 weeks on/1 week off.
224222424|NCT05252078|DRUG|TQB2450|TQB2450 is an injection in the form of 600 mg; 1200 mg, iv, D1.
224222425|NCT03493698|DRUG|Midazolam|Midazolam
224222426|NCT03493698|DRUG|Inarigivir|Inarigivir
224222427|NCT00990561|DRUG|Ultravate ointment twice daily + LacHydrin lotion twice daily|Topical corticosteroid
224222428|NCT00990561|DRUG|Ultravate ointment once daily + LacHydrin lotion twice daily|Topical corticosteroid
224222429|NCT03385187|DEVICE|NightOwl HSAT|Patient wears the NightOwl sensor device
224222430|NCT00408876|DRUG|Duloxetine|
224222431|NCT00408876|DRUG|Placebo|
224222432|NCT02006147|DRUG|TLC399|Dose-escalation Study from 100 mM PL (20 µL) with 0.24 mg DSP to 100 mM PL (20 µL) with0.36 mg DSP to 100 mM PL (20 µL) with 0.6 mg DSP to 50 mM PL (10 µL) with 0.6 mg DSP.
224222433|NCT03361956|DRUG|JNJ-56136379|Participants will receive JNJ-56136379 tablet orally.
224222434|NCT03361956|DRUG|Placebo|Participants will receive matching placebo tablet orally.
224222435|NCT03361956|DRUG|NA (ETV or TDF)|Participants will receive NA (ETV or TDF) tablet orally as per approved label.
224222436|NCT03605615|OTHER|vocalization|The vocalization will be taught in voice form exhaled / sung in grave tones with the vowels, A, O and U.
224222437|NCT03198988|DEVICE|smART Feeding Tube System|Replacing generic feeding tube with smART Feeding Tube System.
224222438|NCT05494554|DEVICE|Changing mechanical ventilation mode|On the 2nd day of intensive care hospitalization, while under deep sedation and in the controlled mode (VCV or PRVC) and in the supine position, the ventilator in the VCV mode was switched to PRVC mode for 60 minutes without changing any of the set ventilator settings (RR, PEEP, TV, I:E ratio). Likewise, if it is in PRVC mode, it is also switched to VCV mode for 60 minutes. MP values were calculated from the minute respiratory parameters of all patients with the MP formulas defined in the software.
223633757|NCT05711810|DRUG|Superoxide Dismutase|Superoxide Dismutase is used to substitute the missing of antiviral drugs.
223633758|NCT01502293|BIOLOGICAL|Tavokinogene Telseplasmid (tavo)|Patients received intratumoral injection(s) of tavo.
223633759|NCT01502293|DEVICE|OncoSec Medical System (OMS)|Electroporation via OMS was performed immediately following intratumoral injection of tavo. A sterile applicator containing 6 stainless steel electrodes arranged in a circle were placed around the tumor. The applicator was connected to the OMS power supply and six pulses were administered to each tumor lesion at the approximate point of tavo injection.
223633760|NCT01808755|DIETARY_SUPPLEMENT|D Mannose|1 gr. every 8 hours
223633761|NCT01808755|DRUG|trimethoprim/sulfamethoxazole|one cp b.i.d. for 5 days. Then one week of antibiotic every 4 weeks for the following 23 weeks
223633762|NCT04686474|DRUG|Azadirachta indica leaves extract containing ointment intervention.|Azadirachta indica leaves extract containing ointment, white petroleum, bee wax, stearyl alcohol
223633763|NCT03166917|PROCEDURE|3D printing implant|3D printing implants in bone defect
223633764|NCT03166917|PROCEDURE|autogenous bone grafting|3D printing implants in bone defect
223764543|NCT04300296|DRUG|secukinumab 300 mg Q4W|secukinumab 300 mg administered every four weeks (Q4W) via a pre-filled syringe.
223764544|NCT04300296|DRUG|secukinumab 300 mg Q2W|secukinumab 300 mg administered every two weeks (Q2W) via a pre-filled syringe.
223764545|NCT04300296|OTHER|Placebo|Matching placebo administered via a pre-filled syringe
223764546|NCT03499652|DIAGNOSTIC_TEST|neonatal bacterial meningitis risk score|In the validation cohort,according to the neonatal bacterial meningitis risk score, we will suggest neonates who reach certain score to take a lumbar puncture, but we will not interfere with clinicians' decision
224222439|NCT03111888|DEVICE|Silicone Stent Airway Implant|The Patient-Specific Tracheobronchial Stent is a silicone stent indicated for use in adults that have stenosis of the airway. The subject device takes a CT scan, thresholds out the airway from the other anatomy, and allows the physician to digitally build the stent to his/her desired dimensions. According to the physician's design, a patient-specific stent can be manufactured using rapid prototyping technology. The patient-specific stent is indicated for use with any rigid bronchoscopy/stent application system that fits the design envelope.
224222440|NCT06530485|DIETARY_SUPPLEMENT|Microbiota-directed food|MDF can modulate the gut microbiota and enhance host immunity, growth, and development in malnourished children. Each sachet of MDF (100 gm) provides approximately 500 kcal.
224222441|NCT06530485|DIETARY_SUPPLEMENT|Khichuri|Khichuri is a home-based nutritious food with high energy and protein. This arm also contains zinc (10 gm/day), micronutrient powder, and an egg daily.
224222442|NCT02767622|PROCEDURE|Liver transplantation|
224222443|NCT01491659|DIETARY_SUPPLEMENT|Idoform Plus|orally once daily
224222444|NCT01491659|DIETARY_SUPPLEMENT|Placebo|orally once daily
224222445|NCT01016860|DRUG|OSI-906|OSI-906 will be given orally in tablets for one dose starting on Cycle 1 Day-3 then on Cycle 1 Day 2-4, 8-10 and 15-17. Cycle is 21 days. Subsequent cycles, dosing will start be Day 1-3, 8-10 and 15-17
223633765|NCT00774046|DRUG|Ara-C|"Induction: 3000mg/m2 IV infusion for day 1 and day 5~Mobilization: within 2 weeks of end of induction therapy - 2000mg/m2 as 2 hour IV infusion once every 12 hours for 3 days (6 doses total)"
223633766|NCT00774046|DRUG|Mitoxantrone|Induction: 30mg/m2 after the end of HiDAC day 1 and day 5
224222446|NCT01016860|DRUG|irinotecan|Irinotecan will be administered IV over 90 minutes on Day 1 and 8 of a 21-day cycle
224222447|NCT04698057|DRUG|Placebo|The aim of the study is to validate the desescalation of the treatment to stop ciprofloxacin prescription that may not impact the outcome of the patients but add toxicity and antibiotics selection. Placebo will be administred in the experimental arm
224222448|NCT04698057|DRUG|Amoxicillin Clavulanate|Will be administred to all patients
224222449|NCT04698057|DRUG|Ciprofloxacin|Will be administred to patients in the standard of care arm
224222450|NCT00263978|DRUG|Defibrotide|
224222451|NCT03876756|OTHER|postpartum acute urinary retention|Collection of risk factors
224222452|NCT03876756|OTHER|no postpartum acute urinary retention|Collection of risk factors
224222453|NCT04649801|PROCEDURE|Atrial fibrillation ablation|Catheter ablation
224222454|NCT04157634|DIAGNOSTIC_TEST|Prognostication model|In a prospective cohort of children hospitalized in a PICU, developement a model based on biomarkers, HRV, and a computerized classifier output, to predict long-term neurological outcome after a moderate or severe TBI in children aged 0 to 18 years.
224222455|NCT05385029|DRUG|Thyroxine|treatment for hypothyroidism or hyperthyroidism
224222456|NCT03028194|PROCEDURE|Curettage|Postpartum uterine curettage with a sharp curette # 14 or #16, immediately after delivery of the placenta.
224222457|NCT03028194|PROCEDURE|Placebo|No procedure after delivery of the placenta
224222458|NCT01387308|DRUG|Fostamatinib|Oral tablets, 50 mg x 2, single dose
224222459|NCT01387308|DRUG|Fostamatinib|Oral tablets, 50 mg x 3, single dose
224222460|NCT01387308|DRUG|Fostamatinib|Oral tablets, 100 mg, single dose
224222461|NCT01387308|DRUG|Fostamatinib|Oral tablets, 150 mg, single dose
224222462|NCT01387308|DRUG|Fostamatinib|Oral tablets, 50 mg x 2, single dose
224222463|NCT01653197|BEHAVIORAL|Control|No scratch off element
224222464|NCT01653197|BEHAVIORAL|Curiosity|The recipient will be prompted to scratch off for answer to question.
224222465|NCT01653197|BEHAVIORAL|Curiosity linked to Action|The recipient will be prompted to scratch off for answer only after he/she makes an appointment.
224222466|NCT02355548|OTHER|Outpatient Treatment of Pulmonary Embolism|Patients who participate in the study will be treated for their pulmonary embolism in an outpatient setting instead of being hospitalized.
224222467|NCT04776174|DEVICE|Ultrasound using the telerobotic Melody system|The children will first have a telerobotic ultrasound abdominal, pulmonary or cardiac followed by a classical ultrasound.
224222468|NCT01754181|DRUG|Insulin|the intervention is applied only at the dose of insulin
224222469|NCT00001622|PROCEDURE|investigate the relationship between in vivo and in vitro vascular responses|
224222470|NCT05509322|OTHER|Subsidy for fertility consult|Some participants will receive a subsidy when they purchase the fertility consult.
224222471|NCT05509322|OTHER|Invitation to purchase fertility consult|Some participants will receive an invitation from their health center to purchase an at-home fertility consult.
224222472|NCT04755881|OTHER|Occurence of biphasic reaction following anaphylaxis|Prospective observation for biphasic reaction following anaphylaxis and subsequent analysis (comparison between usual care and the care that would have been suggested by the three proposed clinical decision rules).
224222473|NCT01951183|DRUG|Placebo|RO681135 placebo subcutaneously daily
224222474|NCT01951183|DRUG|RO6811135|Subcutaneously daily
224222475|NCT01626378|DRUG|TRx0237|TRx0237 100 mg tablet will be administered twice daily.
224222476|NCT01626378|DRUG|Placebo|Placebo tablets will be administered twice daily. The placebo tablets include 4 mg of TRx0237 as a urinary and fecal colorant to maintain blinding; hence, the placebo group will receive a total of 8 mg/day of TRx0237.
224222477|NCT00301106|BIOLOGICAL|adenovirus-mediated human interleukin-12|"The purified ADV-hIL12 is suspended in formulation buffer (10mM Tris, pH 7.5/~1mM MgCl2/ 150mM NaCl/ 10% glycerol) and aliquoted into 1ml cryovials. The filled vials are stored at or below -60 degC."
224222478|NCT06528028|DRUG|CAZ/AVI|continuous infusion is used
224222479|NCT06528028|DRUG|CAZ/AVI|2h-infusion is used
224222480|NCT00787670|OTHER|Diabetes Support and Education|The subjects will attend three educational/social support sessions for 1 year after enrollment. The educational sessions include informational sessions on diet/nutrition and exercise. These sessions are informational and do not teach behavioral self-regulation skills.
224222481|NCT00787670|PROCEDURE|gastric bypass surgery|gastric bypass surgery to induce weight loss in obese patients with type 2 diabetes
224222482|NCT00787670|OTHER|Tissue Control Group|During the abdominal surgery we would like to take 5 ml blood from the IV line and small pea-sized samples of the fat tissue just under the skin and around the stomach area. These samples will be stored so that we can compare these tissue with other patients.
224222483|NCT01503242|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic peripheral blood stem cell transplantation
224222484|NCT01503242|DRUG|Cyclosporine|Given PO
224222485|NCT01503242|DRUG|Fludarabine Phosphate|Given IV
224222486|NCT01503242|DRUG|Mycophenolate Mofetil|Given IV or PO
224222487|NCT01503242|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo allogeneic peripheral blood stem cell transplantation
224222488|NCT01503242|RADIATION|Total-Body Irradiation|Undergo TBI
224222489|NCT01503242|RADIATION|Yttrium Y 90 Anti-CD45 Monoclonal Antibody BC8|Given IV
224222490|NCT02972970|DEVICE|Aveera|Subjects will use the 3D crafted CPAP mask. All subjects will receive a mask to use
224222491|NCT04060472|DRUG|albumin-bound paclitaxel + oxaliplatin|Using albumin-bound paclitaxel (125 mg/m2, d1, 8, 15, ivgtt) + oxaliplatin (80 mg/m2, d1, 8, ivgtt) with or without other chemotherapeutic drugs, 28 days /cycle, until the disease progresses or patients can not tolerate toxicity. The investigators decide the follow-up treatment plan.
223633767|NCT00774046|DRUG|Etoposide|Mobilization: 30mg/kg over 6 doses given once every 12 hours for 3 days
223633768|NCT05722925|DRUG|Fluciclovine PET/CT|8 mCi (± 20%) of Fluciclovine administered as a bolus intravenous injection
223633769|NCT01783613|DIETARY_SUPPLEMENT|Docosahexaenoic acid administration: 50 mg/kg/day during 12 months|
223633770|NCT01783613|DIETARY_SUPPLEMENT|Placebo: 50 mg/kg/day during 12 months|
223633771|NCT03879512|DRUG|depletion of regulatory T cells|oral metronomic cyclophosphamide
223633772|NCT03879512|PROCEDURE|reoperation|resection of relapsed tumor in order to improve clinical condition of the patient and to acquire tumor tissue for vaccine generation
223633773|NCT03879512|BIOLOGICAL|cancer vaccine|4 weekly intradermal injections of lysate-loaded dendritic cells, followed by 3 monthly boost vaccines with tumor lysate and further boost vaccines every three months
223633774|NCT03879512|BIOLOGICAL|checkpoint blockade|Immediately one week after the DC-induction vaccines, patients will receive four applications of Nivolumab/Ipilimumab double checkpoint blockade in threeweekly intervals, followed by Nivolumab monotherapy every month for a total duration of one year.
223633775|NCT05655351|BIOLOGICAL|anti-SARS-Cov-2 vaccination|For the purposes of the study, 10 mL of venous blood will be collected from each patient.
223633776|NCT05764265|DRUG|LTP001|LTP001 will be administered orally once daily in the morning
223633777|NCT00464698|DRUG|Duloxetine|Participants received increasing amounts of Duloxetine for 7 weeks.
223633778|NCT02928679|DRUG|Liraglutide 3 mg (Saxenda)|
223633779|NCT02928679|DRUG|Liraglutide 3 mg placebo|
223633780|NCT03268772|DRUG|PLD and IFO|PLD 30 mg/m2, d1, plus IFO 1.8 g/m2, d1-5
223633781|NCT01091064|OTHER|Randomization early depart|Patients will be randomized to either an early depart or for being seen by a physician.
223633782|NCT02994563|DEVICE|Thrombectomy Device|The Amnis Thrombectomy Device is intended to restore blood flow by removing thrombus from intracranial vessels in patients experiencing ischemic stroke
224222492|NCT04528628|DRUG|SSRIs/SNRIs (Selective Serotonin Reuptake Inhibitors/ Serotonin and Norepinephrine Reuptake Inhibitors)|Patients will be treated with one kind of selective serotonin reuptake inhibitors/ serotonin and norepinephrine reuptake inhibitors. Dose is titrated to the minimum effective dose within 2 weeks. Benzodiazepines can be used for a short period lasting no more than 2 weeks.
224222493|NCT04528628|DRUG|Treatment as Usual|The research doctor discusses the treatment plan with the patient, and therapies and drugs are not limited.
224222494|NCT04528628|COMBINATION_PRODUCT|SSRIs/SNRIs (Selective Serotonin Reuptake Inhibitors/ Serotonin and Norepinephrine Reuptake Inhibitors) Combined with Magnetic Stimulations|Drug therapies are the same as the SSRIs/SNRIs monotherapy group. Patients will randomly receive one kind of magnetic stimulations including repetitive transcranial magnetic stimulation (rTMS), continuous theta burst stimulation(cTBS) and intermittent theta burst stimulation (iTBS) at a ratio of 1:1:1.
224222495|NCT03558997|DRUG|Dupilumab|Dupilumab was administered SC in a single-use, pre-filled glass syringe
224222496|NCT03558997|DRUG|Timothy Grass SCIT|Timothy grass extract was administered SC.
224222497|NCT03558997|DRUG|Placebo matching dupilumab|Placebo matching dupilumab was prepared in the same formulation without the addition of protein
224222498|NCT03558997|DRUG|Placebo matching SCIT|Placebo matching SCIT was prepared in the same formulation (SCIT diluent) without the addition of Timothy grass extract
224222499|NCT01306461|DRUG|Timolol and Tafluprost|"Preservative-free Timolol eye drops administered twice daily concomitantly with preservative-free Tafluprost eye drops administered once daily~Treatment period 6 months"
224222500|NCT01306461|DRUG|Fixed Dose Combination of tafluprost and timolol|"Preservative-free Fixed Dose Combination of tafluprost and timolol eye drops administered once daily.~For masking purposes also: vehicle for timolol administered twice daily~Treatment period 6 months"
224222501|NCT01645228|RADIATION|coronary calcium score measurement|
224222502|NCT01645228|BIOLOGICAL|high sensitivity C reactive protein measurement|
224222503|NCT01645228|PROCEDURE|ankle brachial index measurement|
223633783|NCT00240123|DRUG|Benadryl versus Placebo|
223633784|NCT04412759|OTHER|microbial cellulose|polymer dressing synthesized in abundance with Acetobacter Xylinum
223633785|NCT01007201|BIOLOGICAL|Influenza A (H1N1) 2009 monovalent vaccine, inactivated|
223633786|NCT02246530|PROCEDURE|PRP injection into PTRCT|"Day of procedure, 60 cc blood draw will be taken for processing and isolation of PRP. PRP sample will be injected peri-tendinous / intra-tendinous area at location of the PTRCT under ultrasound guidance to ensure accurate placement at site of injury.~PRP is an autologous blood product that is being re-injected into the same patient and is considered a non-invasive interventional procedure. PRP is classified as a procedure and not a drug."
223633787|NCT02246530|DRUG|Subacromial steroid bursal injection|Combination steroid (Celestone) and anesthetic drug (Lidocaine) will be injected into the patient's subacromial bursa via needle guidance of ultrasound
223633788|NCT00829569|DIETARY_SUPPLEMENT|Intralipid +/- Omegaven|"Intralipid®: the 500 ml 20% Intralipid will be infused during a hyperinsulinemic clamp. Infusion rate will increase from 50 to 100 ml/hour the first 30 min and then continue at 100 ml/hour for the next 210 min, infusion duration 240 min (4 hours) in all.~Intralipid® + Omegaven®: In the 500 ml 20% Intralipid 100 ml will be replaced by 100 ml 10% Omegaven and infused during the hyperinsulinemic clamp as described for Intralipid only. Heparin (0.4 U/kg/min) will be added to both lipid emulsions.~Content of marine n-3 fatty acids in 100 ml Omegaven will be 1.25-2.82 g EPA and 1.44-3.09 g DHA (seasoning variations of n-3 fatty acids in fish oil)."
223633789|NCT03945383|DEVICE|Treatment with IPL device|Treatment with IPL device
223633790|NCT01817153|DRUG|hydrocortison hemisuccinate|
223633791|NCT01817153|DRUG|placebo followed by hydrocortisone hemisuccinate|
223633792|NCT06054126|OTHER|Echocardiography|Cardiac function was evaluated by echocardiography at one year follow-up.
223633793|NCT03810677|DEVICE|ELVeS® Radial® 2ring slim fiber|Device for endovenous laser ablation manufactured by Biolitec AG company (ELVeS system) - diode laser with a wavelength of 1470 nm
223633794|NCT06474455|DRUG|SHR-9839 ；SHR-A2009|SHR-9839 combined with SHR-A2009
223633795|NCT06474455|DRUG|SHR-9839 ； SHR-A1921|SHR-9839 combined with SHR-A1921
224222504|NCT04101136|DRUG|Atorvastatin - placebo controlled clinical trial|The participants will get the medication supply every month along with the refill of antiretroviral drugs. The drug and placebo tablets will be administered to patients by a staff member who are privy to the treatment. In the end of every month, each participant should return the unused pills every month
223633796|NCT06474455|DRUG|SHR-9839 ； pemetrexed ；carboplatin|SHR-9839 combined with pemetrexed + carboplatin
223633797|NCT06474455|DRUG|SHR-9839 ； Almonertinib|SHR-9839 combined with Almonertinib
223633798|NCT01396304|DEVICE|Restore Calcium Alginate Dressing|Wound dressing appropriate for venous leg ulcers. Dressing to be changed minimally once per week.
223633799|NCT01396304|DEVICE|AquaCel Ag Wound Dressing|Wound dressing appropriate for venous leg ulcers. Dressing to be changed minimally once per week.
223633800|NCT01730599|OTHER|neurological exam|motor and cognitive functions
223633801|NCT04246788|OTHER|Intensive robotic rehabilitation|5 sessions per week of 30 minutes of robot-assisted rehabilitation with the G-EO system during two weeks
223633802|NCT04246788|OTHER|classical physiotherapy|3 sessions per week of 30 minutes of classical physiotherapy during two weeks
223633803|NCT00736021|DRUG|Escitalopram|Up to 40 mg oral dose in 10 or 20 mg tablets taken twice daily
223633804|NCT04440475|PROCEDURE|TAP block|"Tap block description:~The skin is prepped and draped in a sterile fashion for a lateral to posterior/lateral approach to the Transverse Abdominis Plane (TAP). The Anesthesiologists use ultrasound guidance for all TAP blocks and pre mix 60cc of 0.2% ropivicaine with 10mg of preservative free dexamethasone. After the plane is identified in approximately the mid axillary line, a 17g Tuohy needle is used under ultrasound guidance to enter the potential space from an anterior approach. The needle is visualized in-plane with the ultrasound probe, traversing the exterior and interior oblique muscles and penetrating through the posterior fascia of internal oblique into the transverse abdominal plane. Once the Tuohy is in place, the needle is aspirated and the plane is hydro-dissected using 0.2% Ropivicaine with 10mg of dexamethasone. The anesthesiologist will use 30ml of 0.2% Ropivicaine on each side."
223633805|NCT06552871|BEHAVIORAL|Forming Love around Autistic People to Prevent Suicide|Four-part virtual educational intervention
223633806|NCT02450370|BEHAVIORAL|Low FODMAP diet|Subjects in this group will follow a low FODMAP diet for up to 10 weeks. Foods that are high in oligosaccharides, disaccharides, monosaccharides and polyols will be avoided. They will receive 3 dietetic consultations at week 0,6 and 10. Dietary leaflets, including meal samples and Yes/No food lists will be provided.
223633807|NCT02450370|BEHAVIORAL|Conventional IBS diet group|Subjects in this group will follow a conventional diet for up to 10 weeks. They will receive 3 dietetic consultations at week 0,6 and 10. This diet will focus on small frequent meals, no skipping meals and dietary adjustments for bloatedness, diarrhea and constipation. Advice on intake of caffeine and alcohol will also be given. Dietary leaflets will be provided.
223633808|NCT01526447|PROCEDURE|Craniosacral Therapy|Standardized therapy protocol (according to Upledger): Still point technique, diaphragm release, compression-decompression and lift techniques of the cranial bones, facial balancing in the region of shoulder and pelvis and somato-emotional unwinding
223633809|NCT01526447|PROCEDURE|Sham Craniosacral Therapy|Standardized sham protocol: Placing hands on various parts of the clothed body for two minutes each time without therapeutic intention
224222505|NCT03421860|DRUG|"cardiac output changes with ephedrine"|measure cardiac output after giving a bolus of ephedrine intervention: will receive complementary doses of ephedrine to maintain systolic blood pressure above 80 % of baseline
224222506|NCT03421860|DRUG|"cardiac output changes with phenylephrine"|measure cardiac output after giving a bolus of phenylephrine intervention: will receive complementary doses of ephedrine to maintain systolic blood pressure above 80 % of baseline
224222507|NCT03421860|DRUG|"cardiac output changes with ondansetron"|measure cardiac output after giving a bolus of ondansetron intervention: will receive complementary doses of ephedrine to maintain systolic blood pressure above 80 % of baseline
223633810|NCT05138653|DRUG|CVL-354|Oral solution/suspension
224222508|NCT03421860|DRUG|"cardiac output changes with nor-epinephrine"|measure cardiac output after giving a bolus of nor-epinephrine intervention: will receive complementary doses of ephedrine to maintain systolic blood pressure above 80 % of baseline
224222509|NCT00174759|DRUG|Clopidogrel|
224222510|NCT02589769|OTHER|unsaturated fat for saturated fat|Substituting unsaturated fat for saturated fat
224222511|NCT02589769|OTHER|saturated fat|a control diet with whole fat dairy and meat with saturated fats that are not fat reduced
223633811|NCT05138653|DRUG|Placebo|Placebo matched to CVL-354
223633812|NCT05138653|DRUG|CVL-354|Capsule
223633813|NCT05220618|BEHAVIORAL|Autobiographical Memory Specificity and Savoring Training: PESCAR|An autobiographical memory specificity and savoring training has been developed by authors, based on previous training within the frame of Cognitive Bias Modification Interventions (CBM-I; Barry et al., 2019; Hitchcock et al., 2017) and savoring interventions (Bryant et al., 2005; Hanson et al., 2023). The training group will receive a self-guided intervention, which consists of an initial session (lasting 20 minutes approximately) and two-week training, conducted online. Participants will be provided with an online platform for following the intervention in a self-guided modality. The first session aims to give information about autobiographical memory functioning, to train in specificity recall through concrete processing steps and to explain the functioning of the self-guided modality. Then, during the next two weeks, participants will use the online platform once a day for practising the recall of autobiographical memories during 10-15 min approximately.
223633814|NCT05794321|DRUG|Intravenous TXA|Patients in the experimental group will receive a loading dose of tranexamic acid (TXA) at a concentration of 1g/10ml over a period of 10 minutes, administered immediately following anesthesia induction.
223633815|NCT04458402|RADIATION|Hypofractionated WPRT|Cohort 1: 41.25 Gy in 15 fx Cohort 1: 38 Gy in 10 fx
224222512|NCT05175079|DEVICE|Acupressure band|"acupressure band apply to P6 (nei guan) point which located three fingers below the skin wrinkles of the anterior wrist.~Acupressure band wear 3 times daily before breakfast, lunch and dinner for at least 10 minutes"
224222513|NCT05175079|OTHER|Standard treatment hospital protocol|Intravenous metaclopromide 10mg PRN Intravenous fluids as per protocol
224222514|NCT04960475|OTHER|Hospital Anxious and Depression(HADS)|The assessment content in the scale is divided into two parts: anxiety and depression. Anxiety is an unexplained state of restlessness, manifested as tension, fear, and panic all day long. Depression is manifested as depression, slow thinking, decreased volition and physical symptoms. The two parts are scored separately. A total score of 0-7 means normal, a total score of 8-10 means mild depression/anxiety, a total score of 11-14 means moderate depression/anxiety, and a total score of 15-21 means severe depression/ anxiety.
223633816|NCT05536635|BEHAVIORAL|breathing techniques|Intervention will be daily use of breathing techniques thought by the researcher as explained in detail in arm/group descriptions
223633817|NCT05598333|DRUG|AB-1002|Intracoronary Infusion of AB-1002 or placebo
223633818|NCT06650709|DRUG|Olaparib|Olaparib 300mg orally twice daily on a continuous dosing schedule for a maximum of 3 x 28-day cycles.
223633819|NCT06650709|DRUG|Bevacizumab|Bevacizumab 10mg/kg intravenously on Day 1 and 15 of the 28 day cycle for a maximum of 3 cycles (Cycle 3, Day 15 will be omitted).
223633820|NCT06650709|DRUG|Durvalumab|Durvalumab 1500mg intravenously on Day 1 of the 28 day cycle for a maximum of 3 cycles.
223633821|NCT06590766|OTHER|acupressure/relaxation with acupuncture|The acupressure/acupuncture points will be designated according to a protocol for each of the four leading concerns (pain, fatigue, emotional, and gastrointestinal), based on evidence-based research. For example, clinical guideline-based IO protocols for pain relief will include the following analgesia-related acupressure/acupuncture points: Liver-3, Taichong; Large-Intestine 4, Hegu; Stomach-36, Zusanli; Pericard-6, Neiguan; Spleen-6, Sanyinjiao; Yin tang; as well as battlefield ear acupuncture points. In both IO intervention groups, relaxation techniques will be tailored to the patient's main concern, with the option of including breathing and guided imagery modalities as well.
223633822|NCT06596174|PROCEDURE|Transcutaneous spinal cord stimulation (tSCS)|The subjects will undergo 20 minutes transcutaneous spinal cord stimulation (tSCS).
223633823|NCT06596174|PROCEDURE|Short-term Machine-Assisted Ankle Movement Training with tSCS|The subjects will undergo 30 minutes of machine-assisted ankle movement training combined with transcutaneous spinal cord stimulation (tSCS) at a time
223633824|NCT06596174|PROCEDURE|Long-term Effects of Machine-Assisted Ankle Movement Training with tSCS|"The subjects will undergo machine-assisted ankle movement training combined with transcutaneous spinal cord stimulation (tSCS).~Each session will last for 30 minutes, conducted three times per week, over a period of four weeks."
223633825|NCT06596122|DRUG|Vitamin D (Cholecalciferol )|In conjunction with the AC-T chemotherapy protocol, individuals in the intervention group who have a vitamin D deficiency will receive an oral loading dose of 50,000 IU weekly for eight weeks. Subsequently, they will be given 100,000 IU monthly until the completion of their chemotherapy treatment.
223633826|NCT06595186|DRUG|JK-1201I|JK-1201I will be administered.
224222515|NCT04960475|OTHER|Fear-Avoidance Belief Questionnaire (FABQ)|FABQ is a self-assessment questionnaire with 16 options. Each option has 7 levels of 0-6 points, representing totally disagree, uncertain, and totally agree; there are 2 subscales, and one subscale measures the fear-avoidance in physical activity, another subscale measures fear-avoidance of work. The final score of FABQ is the superposition of the value of each item. A high score indicates a high level of fear-avoidance beliefs.
224222516|NCT04960475|OTHER|The MOS 36-Item Short From Health Survey (SF-36)|The SF-36 is a multi-purpose survey designed to capture adult patients' perceptions of their own health and well-being. The SF-36 has 36 items grouped in 8 dimensions: physical functoning, physicial and emotional limitations, social functioning, bodily pain, general and mental health.
224222517|NCT06304870|BEHAVIORAL|Rehabilitation therapy|"Rehabilitation therapy includes Diet management: Avoiding consumption of irritant foods and beverages, such as spicy foods, caffeine, alcohol, and acidic foods. Controlling portion sizes and meal timing, and adopting smaller, more frequent meals.~Lifestyle adjustments: Avoiding lying down or bending immediately after meals, maintaining a sitting or upright position for at least 2 hours. Adjusting sleeping positions by elevating the head of the bed to reduce nighttime acid reflux. Avoiding excessive exertion and managing stress levels.~Rehabilitation training: Strengthening the control of esophageal and gastric muscles through rehabilitation exercises to improve the function of the gastroesophageal sphincter and prevent gastric fluid reflux."
224222518|NCT06304870|DRUG|Lidocaine|The patient lies supine without a pillow, turns the head to the contralateral side of the block, and at the midpoint of the line connecting the angle of the mandible with the mastoid process (the styloid process), the skin is disinfected, and a 22-gauge, 3.8 cm puncture needle is loaded onto a 5 mL syringe. The puncture needle is inserted perpendicularly to the skin surface at the styloid process, and advanced through the skin and subcutaneous tissue until it contacts the bone of the styloid process. The puncture needle is then retracted and advanced anteriorly beyond the styloid process by 0.5-1.0 cm. When no blood or cerebrospinal fluid is aspirated, the blocking drug can be injected \[20 g/L lidocaine injection\].
224222519|NCT06304870|PROCEDURE|Injection|The patient lies supine without a pillow, turns the head to the contralateral side of the block, and at the midpoint of the line connecting the angle of the mandible with the mastoid process (the styloid process), the skin is disinfected, and a 22-gauge, 3.8 cm puncture needle is loaded onto a 5 mL syringe. The puncture needle is inserted perpendicularly to the skin surface at the styloid process, and advanced through the skin and subcutaneous tissue until it contacts the bone of the styloid process.
223633827|NCT06595186|DRUG|Temozolomide (TMZ)|Temozolomide will be administered.
223633828|NCT06593158|BEHAVIORAL|Parent-delivered Hand-Arm Bimanual Intensive Therapy Including Lower Extremities (HABIT-ILE) for CP children at camp with the guidance and supervision of experts.|"* The caregivers delivering HABIT-ILE therapy at camp will follow the same principles as the usual HABIT-ILE. The therapy will take place in a rehabilitation center, and caregivers will provide therapy during the sessions, coached by trained supervisors on site~* The intervention day will then take place, lasting for 5 hours with the constant presence of supervisors. This will be divided into two sessions: a 3-hour intervention in the morning followed by a lunch break, and a 2-hour intervention in the afternoon."
223633829|NCT06593158|BEHAVIORAL|Parent-delivered Hand-Arm Bimanual Intensive Therapy Including Lower Extremities (HABIT-ILE) for CP children at home with the online guidance and supervision of experts.|"* The caregivers delivering HABIT-ILE therapy at home will follow the same principles as the usual HABIT-ILE. The therapy will take place at children's home, caregivers will provide therapy during the sessions, coached by trained supervisors online~* The intervention day will then take place, lasting for 5 hours with the supervisors through online setting. This will be divided into two sessions: a 3-hour intervention in the morning followed by a lunch break, and a 2-hour intervention in the afternoon."
223633830|NCT06588816|DEVICE|optical coherence tomography|"Optical coherence tomography (OCT) is a non-invasive imaging test . It uses light waves to take cross-section pictures of the retina .~With OCT, the ophthalmologist can see each of the retina's distinctive layers, and so we can use it to study the changes in pseudoexfoliation syndrome."
223633831|NCT06593613|BEHAVIORAL|RUBI-A|"The RUBI-A intervention includes 9 sessions covering Behavioral Principles, Prevention Strategies, Visual Supports, Reinforcement, Co-Regulation, Supporting Communication, Effective Instructions, Teaching Skills, and Generalization and Maintenance. RUBI teaches skills to help build a behavioral toolbox for challenging behaviors and adaptive skills. RUBI emphasizes: 1) tailoring the intervention to the specific individual; 2) identifying behavioral function instead of topography to inform behavioral strategy choice; 3) increasing appropriate behaviors; and 4) using positive behavioral supports,39,40 such as antecedent management (e.g., use of visual supports), reinforcement, and functional communication strategies to support independence, self-help, and safety skills."
223633832|NCT06593613|BEHAVIORAL|R-ISLEA|R-ISLEA training focuses on increasing core knowledge and understanding of autism, but it does not provide specific guidance on behavioral strategies for managing challenging behaviors. Developed by autism experts at Drexel University in collaboration with autistic self-advocates, ISLEA is a commercially available psychoeducation program designed for educators, direct support staff, families, caregivers, and autistic individuals. If English is not the language of care for a dyad, subtitles in the preferred language will be provided for the webinars, and interpreters will be available for the live sessions.
224222520|NCT01934374|BEHAVIORAL|Task-Oriented Lower Extremity Strengthening Training|"On the 30th day post stroke (D30), the experimental group will start to receive the TOLEST program for four weeks, one hour per session and three sessions per week. The TOLEST focuses on using task-specific circuit training combined with strengthening of bilateral lower limbs.~The control group will receive equal-dose exercises starting on D30, with the emphasis on stretching and non-functional movements of the affected lower extremity."
224222521|NCT00934037|PROCEDURE|320 Volume Detector Computed Tomography|Single Arm Study. All patients undergo Volume (Multidetector) CT.
224222522|NCT00934037|OTHER|Other: Multidetector Computed Tomography - 320 detectors|Multidetector computed tomography angiography
224222523|NCT02033876|DRUG|Ursodiol|
224222524|NCT03780933|DIETARY_SUPPLEMENT|vitamin c|vitamin c IV 10 G
224222525|NCT02711189|DRUG|Oxytocin|Oxytocin nasal spray given in dose 80
224222526|NCT02711189|OTHER|Placebo|
224222527|NCT01569503|DEVICE|vagus nerve stimulation (VNS)|VNS therapy consists of an implanted pacemaker-like device that delivers mild, intermittently pulsed signals to the patient's left vagus nerve. Roughly the size of a small pocket-watch and weighing less than one ounce, the pulse generator is implanted in the patient's left chest area. A thin thread-like wire, attached to the generator, runs under the skin to the left vagus nerve in the neck
224222528|NCT04779411|OTHER|Weekly Food Frequency Questionnaire|A purpose designed 91-item questionnaire to measure frequency of consumption of a selection of L/Z containing foods over the prior 7 days.
224222529|NCT04779411|OTHER|Monthly Food Frequency Questionnaire|A purpose designed 95-item questionnaire completed at visit 1 to measure frequency of consumption of a selection of L/Z containing foods over the prior month.
224222530|NCT04779411|OTHER|24-Hour Diet Recall|the diet recall via the online Automated Self-Administered 24-Hour Dietary Assessment Tool (ASA24®) takes approximately 25 minutes to complete, and investigates food and beverages consumed in the prior 24-hours.
224222531|NCT04779411|OTHER|Electronic Device Use Questionnaire|1\. The EDUQ: A 22-item questionnaire that takes 20 minutes to complete, and measures participant demographic information (weight, height, age, highest level of education, occupational status, post-code and country of residence), usual daily ED use from present up to 20 years ago, occupational influence to use, and differences to ED use between a weekend and weekday.
224222532|NCT04779411|OTHER|24-Hour Electronic Device Use Diary|Participants asked to record their electronic device use in hours and minutes over 24 hours.
224222533|NCT02144493|OTHER|The existence of periampullary diverticulum|Periampullary diverticulum has been postulated as risk factor of recurrent CBD stone.
224222534|NCT02144493|OTHER|CBD angle|Narrow CBD angle has been postulated as risk factor for the development of recurrent CBD stone
224222535|NCT01015911|DRUG|SGN-75|SGN-75 (IV) in 21- or 28-day cycles; dose range: 0.3-9 mg/kg
224222536|NCT02230085|OTHER|Administration of the questionnaire and monitoring of CPAP adherence|
224222537|NCT03793075|DRUG|Ketamine|ketamine 5 mcg/kg/min will be used as intravenous anesthetic infusion
224222538|NCT03793075|DRUG|Propofol|propofol 17 mcg /kg/min
224222539|NCT00137085|DRUG|ketamine|
224222540|NCT03479385|BEHAVIORAL|Integrative Medicine Intervention|Study participants will attend 14 sessions with an Integrative Medicine clinician over the course of 6 months, potentially followed by a 6 month maintenance phase.
224222541|NCT03479385|BEHAVIORAL|Health Education Intervention|Study participants will attend 14 sessions with a Health Educator over the course of 6 months.
224222542|NCT00897533|GENETIC|gene mapping|
224222543|NCT00897533|GENETIC|polymorphism analysis|
224222544|NCT00897533|OTHER|diagnostic laboratory biomarker analysis|
224222545|NCT00897533|OTHER|immunohistochemistry staining method|
224222546|NCT03268031|DIAGNOSTIC_TEST|Visual field and OCT tests|Visual field test and OCT are commonly used essential tests to make accurate diagnosis of glaucoma. Algorithms to classify Visual field and OCT tests would both be developed and verified.
224222547|NCT01920373|DRUG|Group A (corticosteroid injection group)|
224222548|NCT01920373|BIOLOGICAL|Group B (platelet rich plasma injection group)|
224222549|NCT00481962|DRUG|Tygacil|Initial dose of 100mg followed by 50mg every 12 hours for 5 to 14 days
224222550|NCT02340156|GENETIC|SGT-53|SGT-53, at 3.6 mg DNA per infusion, will be administered twice per week for 3 weeks (on Day 1, 4, 8, 11, 15 and 18 of each cycle) for 3 cycles. If SGT-53-related toxicity occurs, the dose of SGT-53 will be de-escalated to 2.4 or 1.2 mg DNA/infusion when appropriate.
224222551|NCT02340156|DRUG|Temozolomide|TMZ will be administered orally on days 9-13 of each cycle. In cycle 1, the dose of TMZ will be 150 mg/m². If the TMZ-related toxicities are tolerated in cycle 1, the dose of TMZ will be escalated to 200 mg/m² for cycle 2 and beyond. If TMZ-related toxicity occurs, the dose if TMZ will be de-escalated to 125 mg/m² (dose level -1), 100 mg/m² (dose level -2) or 75 mg/m² (dose level -3) when appropriate.
223633833|NCT06590636|PROCEDURE|Expressive touching|"Woman's anxiety level was measured with the State-Trait Anxiety Inventory scale Following these measurements, expressive touching that lasted 15-20 minutes was performed in the following manner.~The hands of the expressive touching performer warmed to body temperature (should not be cold).~The woman's hand close to the performer was placed between the hands of the expressive touching performer.~The woman's palm was gently grasped with the palms of the expressive touching performer.~The hand below was fixed and the upper part of the woman's hand was gently rubbed with the hand above.~Before and after massaging, the woman's arms and shoulders were touched at intervals.~During the procedure, the woman was called by her name, and verbal communication with the woman was continued by holding her hands firmly and sincerely as if a handshaking done.~Before the woman's discharge from the center, her anxiety level was measured with the State-Trait Anxiety Inventory scale"
223633834|NCT06604013|PROCEDURE|non-surgical full-mouth periodontal therapy without using adjunct disinfectants|Supragingival scaling was performed by Ultrasonic Scaler and manual scaling by sickle scaler . Subgingival scaling and root planing were accomplished with either universal or area specific Gracey curettes
223633835|NCT06604013|DIAGNOSTIC_TEST|GCF level of adiponectin and resistin|Gingival crevicular fluid (GCF) samples were gathered and relocated in phosphate buffer saline inside Eppendorf tube then t they were manipulated by commercially available enzyme-linked immuno-sorbent assay
224222552|NCT05715606|DRUG|Metabolically Armed CD19 CAR-T cells|Each subject receive metabolically armed CD19 CAR-T cells by intravenous infusion
224222553|NCT04504929|DEVICE|Sham tape|Use sham type on the pitching shoulder
223764547|NCT03676452|BEHAVIORAL|Active@Home exergame training|The Active@Home exergame is a multicomponent, motor-cognitive training for fall prevention in elderly adults. It mainly consists of three components; strength training, balance training and cognitive training. For strength training, Tai Chi-based movements are included. For balance training, dancing is included in the Active@Home exergame. Moreover, the Active@Home exergame explicitly targets specific attentional and executive functions. The Active@Home system set up is easy and consists of an HDMI dongle (to run the application) which must be plugged into the TV and four wearable sensors (to measure the movements).
223764548|NCT06408116|RADIATION|photon|radiation with 4-5 cm safte margin
223764549|NCT06408116|PROCEDURE|surgical therapy|surgery based on PET-CT/MRI staging
223764550|NCT06408116|DRUG|Chemotherapy|neoadjuvant chemotherapy
224222554|NCT04504929|DEVICE|Dynamic tape|Use dynamic type on the pitching shoulder for supporting internal rotation
224222555|NCT02247570|PROCEDURE|Vestibular Rehabilitation|Stimulation of the vestibular system by off axis rotational therapy, gaze stabilization, eye movement strategies, balance training
224222556|NCT01494220|DEVICE|Bispectral index monitoring (BIS)|BIS recording electrodes (Aspect Medical Systems. Inc., One Upland Road, Norwood, MA 02062 USA) were applied to the forehead of each patient according to the manufacturer recommendations. The BIS monitor was masked with opaque sheet and BIS data was recorded prior to induction of general anesthesia then continued throughout the procedure. All information obtained from the BIS monitor was continuously downloaded to a computer for offline analysis. The patient's management was not guided by the changes in BIS readings.
224222557|NCT05738564|DRUG|Epinephrine Inhalation Solution|epinephrine prepared solution mixed with lidocaine (EL) Otrivin adult nasal drops 0.1Otrivin adult nasal drops 0.1%, 10 ml of 1 mg/ml; Novartis Consumer Health, UK Ltd, 980 Great West Road, Brentford, Middlesex, TW8 9GS, UK) in each nostril in the pre-induction room just before the induction of anesthesia
224222558|NCT05602233|OTHER|Exercise|The training will be given for 6 weeks, 3 times a week for 20 minutes. This phased balance training program is based on the participant's ability to maintain a single limb posture while performing balance activities. The program includes: 1) hop to stabilization, 2) hop to stabilization and reach, 3) hop to stabilization box drill, 4) progressive single-limb stance balance activities with eyes open, and 5) progressive single-limb stance activities with eyes closed. Participants will be followed up with a physiotherapist and will be able to proceed to the next stage of the test after completing the previous level without errors.
224318406|NCT01161485|BEHAVIORAL|Strengths-based case management|Strengths-based case management (SBCM) is a specific type of case management that is based on the following principles: 1) clients are most successful when they identify and use their strengths, abilities, and assets; 2) goal-setting is guided by the clients' perceptions of their own needs; 3) the client-case manager relationship is promoted as essential; 4) a creative approach to the use of the community will lead to the discovery of needed resources; and 5) case management is conducted in the community. It differs from more traditional case management models that emphasize resource brokerage and client advocacy in its recognition that only the individual can change his/her behavior.
224318407|NCT05082740|OTHER|Notification of a revised breast cancer risk estimate|These women will be given the opportunity to learn of their revised breast cancer risk estimate which has been re-calculated with the inclusion of new strong independent risk factors. These women will be offered a clinical consultation to discuss their risk and will a subset will be asked to take part in a qualitative interview about their experiences.
224318408|NCT01009502|DRUG|sodium stibogluconate|Sodium stibogluconate 900 mg/m2/day will be given on Monday through Friday every other week for the first 16 weeks of the study (on the 1st, 3rd, 5th, 7th, 9th, 11th, 13th and 15th weeks). On the alternate weeks patients will not receive any study treatment.
224318409|NCT00294580|DRUG|Maloprim|
224318410|NCT03242525|DIAGNOSTIC_TEST|POCT and central laboratory blood analysis|In every participant blood analysis will be performed by POCT and central laboratory investigating the time advantage.
224318411|NCT02681510|DRUG|Varenicline|Standard FDA approved 12 weeks of treatment with Varenicline
224318412|NCT02681510|DRUG|Nicotine Transdermal Patch|Standard FDA approved 12 weeks of treatment with Nicotine Transdermal Patch
224318413|NCT02681510|DRUG|Nicotine Mini|Standard FDA approved 12 weeks of treatment with Nicotine Mini-Lozenge
224318414|NCT00079950|DRUG|Pegamotecan|
224318415|NCT03991676|BEHAVIORAL|Values-Based Behavioral Treatment|The values-based behavioral treatment will consist of a series of three, once-weekly weight loss workshops infused with techniques to elicit values clarification and awareness in moments of dietary decision-making, and to enhance autonomous motivation for behavior change.
224318416|NCT03005665|DRUG|Acetazolamide|
224318417|NCT03005665|DRUG|Normal Saline|
223633836|NCT06592898|BEHAVIORAL|straight leg raise|The patient was supine position, one knee angle was 90°, the foot was flatted on the ground. The ankle was flexed to contract the quadriceps on the other side. Then straighten the knee joint and the hip was 30° and lift the thigh, the heel was about 20cm away from the ground, and put down the lower limb after 2 seconds. Ten times are in a group, each practice has 5 groups, rest between the groups is 1 minute. Practice 5 times a week, practice on both sides, take uniform respiration without holding breath.
223633837|NCT06592898|BEHAVIORAL|wall squat|The subjects' upper body was upright, the distance between feet was same as width of shoulder, and hands were placed on each side of the body or above the thighs. Tiptoes were towards the front, and perpendicular to the wall. The distance between the wall and heel was about a foot long, and the back was close to the wall, squatted slowly.
224222559|NCT05602233|OTHER|STARS (Sensory-Targeted Ankle Rehabilitation Strategies)|STARS includes; joint mobilization, plantar massage and triceps surae stretching. The training will be given for 6 weeks, 3 times a week for 5 minutes.
224222560|NCT04624191|OTHER|Saturation at home|Clinical benefit of taking saturation at home in interstitial lung disease
224222561|NCT00323583|DRUG|paclitaxel|
224222562|NCT00323583|DRUG|oxaliplatin|
224222563|NCT00323583|DRUG|leucovorin|
224222564|NCT00323583|DRUG|5-fluorouracil|
224222565|NCT00323583|DRUG|glutathione|
224222566|NCT00323583|DRUG|calcium and magnesium|
224222567|NCT00323583|PROCEDURE|Chemotherapy|
224318418|NCT06501326|DRUG|Liraglutide|After randomization, the control group was treated with lifestyle intervention + orlistat until the end of follow-up. Trial group 1 was treated with lifestyle intervention + liraglutide. Trial group 2 was treated with lifestyle intervention + liraglutide + orlistat for a total treatment and follow-up period of 3 months.
223633838|NCT06592898|BEHAVIORAL|direct squat|The subjects stood on the flat ground, the upper body was upright, the distance between feet was same as width of shoulder, and tiptoes were towards the front. The trunk was adjusted forward according to the Angle of static squat. The specific method is to adjust the trunk position to the line of the shoulder joint and knee joint perpendicular to the ground. Knee joint can bend at a large angle. The center of gravity was between the feet, put hands in front of body.The angle was set at 30° for the first two weeks, increased to 45° after two weeks, and set at 60° for the last two weeks.
223633839|NCT06592898|BEHAVIORAL|wall squat assisted by elastic bands|Based on wall squat, subjects put elastic band of 20 pounds between the thighs, open thighs and feet at a low speed, so that the elastic bands were slightly deformed and sence of resistance was obvious on the outside of the thighs.The angle was set at 30° for the first two weeks, increased to 45° after two weeks, and set at 60° for the last two weeks.
223633840|NCT06601777|BEHAVIORAL|Immediate application of the Smart Homespital system|The Smart Homespital system can be applied for the first 3 months (12 weeks), and then the primary and secondary variables will be evaluated at 3, 6, 9months. While applying the Smart Homespital system, exercise three times a week, measure sleep twice a week, and questionnaire assessments (mMRC, CRQ, EQ-5D, K-CESD) are conducted once every two weeks.
223633841|NCT06601777|BEHAVIORAL|Delayed application of the Smart Homespital system after 3 months|The waiting list-control group will receive general medical services for the first 3 months and will receive a Smart Homespital system for 3-6 months. Primary and secondary variables will be monitored between 3, 6, and 9 months. While applying the Smart Homespital system, exercise three times a week, measure sleep twice a week, and questionnaire assessments (mMRC, CRQ, EQ-5D, K-CESD) are conducted once every two weeks.
223633842|NCT06590779|OTHER|Aminexil® active+ lotion|Aminexil® active+ lotion
223633843|NCT06590779|OTHER|Finasteride 1mg|Finasteride 1 mg
223633844|NCT06590103|BEHAVIORAL|Physically Active Lessons|Physically active learning: this type of intervention is carried out once a week for 1 hour outside the classroom. The teachers of the corresponding subject (with the support of the Physical Education teacher) are in charge of designing and delivering the physically active classes.
224222568|NCT00323583|PROCEDURE|Chemoprotection|
224222569|NCT00323583|PROCEDURE|Complementary and alternative therapy|
224222570|NCT05953285|OTHER|Sleep restriction|The proposed study will take the form of a within-subjects, randomized crossover experimental design. The data will be quantitative.
224222571|NCT02885935|OTHER|Recommended protein intake|Recommended protein intake diet contained 10% protein, 55% carbohydrate,and 35 % fat.
224222572|NCT02885935|OTHER|Elevated protein intake|Recommended protein intake diet contained 20% protein, 45% carbohydrate,and 35 % fat.
224222573|NCT05843838|PROCEDURE|Hypotension during spinal anesthesia for cesarean section|Hypotension, Mean Arterial Pressure\<65 mmHg, or Systolic arterial pressure \< 30% will be considered an initial value
224222574|NCT05843838|DIAGNOSTIC_TEST|Mini-mental test|"A Mini-Mental State test is a set of questions that doctors and other healthcare professionals commonly use to check for cognitive impairment (problems with thinking, communication, understanding and memory).~At the end of the research, the mental test scores of the two groups will be compared and the effect of hypotension will be evaluated."
224222575|NCT05843838|PROCEDURE|Spinal anesthesia|It is a neuraxial anesthesia technique in which local anesthetic is placed directly in the intrathecal space. Spinal anesthesia will be applied to both groups with heavy bupivacaine in usual doses.
224222576|NCT05843838|DIAGNOSTIC_TEST|The Bromage scale|"The Bromage scale is the accepted tool for motor block examination. The classification of these scores~1. complete block: unable to move feet or knees~2. almost complete: able to move feet only~3. partial: just able to flex knees; free movement of feet~4. no block: full movement of knees and feet"
224222577|NCT05843838|DRUG|Heavy Bupivacaine for spinal anesthesia|Routine clinical heavy bupivacaine doses
224222578|NCT04087083|OTHER|Technological intervention arm|Each session will include 30 minutes of traditional physical rehabilitation therapy followed by 20 minutes of robotic training (G-EO system, Reha Technology, Switzerland), an end-effector technology that simulates floor walking and stairs climbing (up and down)
224222579|NCT04087083|OTHER|Control arm|Each session will include 50 minutes of traditional physical rehabilitation therapy
224318419|NCT06501326|DRUG|Orlistat|After randomization, the control group was treated with lifestyle intervention + orlistat until the end of follow-up. Trial group 1 was treated with lifestyle intervention + liraglutide. Trial group 2 was treated with lifestyle intervention + liraglutide + orlistat for a total treatment and follow-up period of 3 months.
224318420|NCT01284010|GENETIC|DNA analysis|
224222580|NCT06325982|DRUG|Triethanolamine cream|"Triethanolamine cream retention enema was given once every night before going to bed during radiotherapy until the end of radiotherapy. Triethanolamine cream retention enema was given once before going to bed the day after radiotherapy for 3 months.~Preparation method: Pull out the syringe piston, add 15ml triethanolamine cream, add 30ml normal saline, gently pat, shake well.~Specific methods of retention enema: at night before going to bed, empty urine and feces, prepare enema liquid into the syringe, connect the special catheter, and insert the other end of the special catheter into the anus (the special catheter can be applied with lubricant such as tea oil before insertion). The patient remained prone and semi-seated. Use a special catheter, insert a special catheter about 15cm from the anus, and inject enteral liquid while withdrawing, so that the liquid is retained in the rectum; The above treatment was performed before bed and retained overnight."
223764551|NCT05728112|OTHER|Hydrogen Inhalation|The manufacturer will install a hydrogen inhalation machine (hydrogen inhalation or air inhalation) at the subject's home and explain the relevant operation methods. The research executor will pay attention to the LINE group on the first day of installation, and obtain the pre-test basic value data through the google form After (baseline data), continuous hydrogen inhalation was performed daily, and four post-test evaluations were performed before the inhalation and on the 1st, 3rd, 7th, and 14th days after the inhalation was started.
224222581|NCT00094783|PROCEDURE|MRI|
224222582|NCT04344054|BIOLOGICAL|RV3-BB|1.0 mL of the thawed rotavirus vaccine to be administered orally at birth, 6 weeks and 10 weeks of age
224222583|NCT04344054|BIOLOGICAL|Trivalent P2-VP8|0.5 mL of vaccine containing 90 μg of the TV P2-VP8 antigen; IM; at approximately 6, 10 and 14 weeks of age
224222584|NCT04344054|BIOLOGICAL|Rotarix|1.5 mL of the liquid vaccine containing the RIX4414 strain of human rotavirus vaccine to be administered orally at 6 weeks and 10 weeks of age.
224222585|NCT04344054|BIOLOGICAL|RV3-BB birth dose|1.0 mL of the thawed rotavirus vaccine to be administered orally at birth.
224222586|NCT04344054|BIOLOGICAL|Trivalent P2-VP8 Booster dose|0.5 mL of vaccine containing 90 μg of the TV P2-VP8 antigen; IM; at 14 weeks of age
224222587|NCT00967200|OTHER|laboratory biomarker analysis|laboratory biomarker analysis
224222588|NCT00967200|OTHER|pharmacogenomic studies|pharmacogenomic studies
224222589|NCT06432621|PROCEDURE|using of sugammadex and neostigmine for reversal from rocuronium and assessment of response using ultrasound and nerve stimulation|patients will be randomly divided into two groups using a computer generated random number chart. Group S will receive sugammadex for reversal of rocuronium, whereas Group N will receive neostigmine for reversal of rocuronium using nerve stimulation and ultrasound to asses recovery of respiratory muscle
224222590|NCT02386410|BEHAVIORAL|Group parent training for anxious parents|
224222591|NCT02386410|BEHAVIORAL|Internet delivered parent training for anxious parents|
224222592|NCT04967313|BEHAVIORAL|Behavioral Change Techniques|"Four behavioral changes techniques (BCTs) will be administered to participants in random order. The BCTs are defined as follows:~1. Goal setting: set or agree on a goal defined in terms of behavior to be achieved. Example: Set the goal of walking 2,000 steps more per day.~2. Action planning: prompt detailed planning of performance of behavior (must include a setting \[walking to the mailbox\], frequency, duration, and intensity. Example: Develop a plan to walk today.~3. Self-Monitoring of behavior: establish a method for person to monitor and record their number of steps based on their Fitbit. Example: Did you check your Fitbit and record daily total number of steps?~4. Feedback on behavior: Monitor and provide informative or evaluative feedback on performance of the behavior (e.g. form, frequency, duration, intensity). Example: You walked 6,000 steps today. This is 1,000 steps above your baseline."
224222593|NCT03167099|PROCEDURE|Full Weight Bearing|full weight bearing after fixation of a distal femur fracture
224222594|NCT05188040|OTHER|Virtual Reality Exercises|Hand Therapy Exercises utilizing Oculus Quest 2 VR system with augmented feedback for patient to perform active hand therapy. Specific interventions / games will be selected by the participants individual therapist.
224222595|NCT03350048|DIAGNOSTIC_TEST|Trans-Dot point-of-care test|"Training set participants will be recruited and receive investigations for TB. Blood samples will also be collected from them for performance of ELISAs and laboratory-based TransDot tests. These blood samples will be drawn at baseline, week 8 and week 24 at end of treatment for confirmed TB cases and at baseline for non-TB cases.~Test set participants will be recruited and receive investigations for TB. A POC TransDot test will be performed on fingerprick blood at baseline, and at week 8 and week 24 in participants on TB treatment, as well as a laboratory based TransDot test on serum at baseline. The week 8 and week 24 TransDot tests will be used to investigate the test's utility as an indicator of treatment response."
224222596|NCT06544083|DIAGNOSTIC_TEST|Proteomics|Proteomic is performed on all blood samples.
224222597|NCT02127047|DRUG|Sitagliptin|
224318421|NCT01284010|GENETIC|fluorescence in situ hybridization|
223764552|NCT05728112|OTHER|Ordinary Air Inhalation|The control group was inhaled with the same machine as the experimental group, but the gas was only ordinary air, which was used as a placebo control.
223764553|NCT04347486|DRUG|Sugammadex Injection 2mg/kg|Intravenous injection of 2mg/kg of sugammadex sodium on reappearance of T2
224222598|NCT02127047|DRUG|Exercise|
224318422|NCT01284010|GENETIC|gene expression analysis|
224318423|NCT01284010|GENETIC|microarray analysis|
224318424|NCT01284010|GENETIC|mutation analysis|
224318425|NCT01284010|GENETIC|polymerase chain reaction|
224318426|NCT01284010|OTHER|laboratory biomarker analysis|
224318427|NCT00741338|BIOLOGICAL|Laronidase|0.058 mg/kg - 0.58 mg/kg IV infusion weekly.
224318428|NCT00741338|DRUG|Cyclosporine A (CsA)|Orally three times daily.
224318429|NCT00741338|DRUG|Azathioprine (Aza)|Orally either every day for Cohort 1 or every other day for Cohort 2.
224318430|NCT02234076|BEHAVIORAL|VRET|
224318431|NCT02234076|BEHAVIORAL|TAU|Treatment as usual offered by the participating mental health care organisations
224318432|NCT05220644|PROCEDURE|Protocols for the management of end-of-life symptoms|Application of the care protocol and data collection
224318433|NCT00309686|DRUG|Paliperidone ER|
223633845|NCT06599112|OTHER|Densah Burs|Series of drilling burs inserted in the osteotomy with special design that have a large negative rake angle flute, a cutting chisel edge and a tapered shank, so as they enter deeper into the osteotomy and they have a progressively increasing diameter that controls the expansion process. These burs are used with a standard surgical engine and can densify bone by rotating in the noncutting direction (counterclockwise at 800-1,200 rotations per minute) or drill bone by rotating in the cutting direction (clockwise at 800-1,200 rotations per minute) with an in and out movement together with copious saline irrigation and increasing bone plasticity and ability to expand under rate dependent stress.
223633846|NCT06599112|OTHER|Osteotomes|The osteotomes kit are a series of tools that first designed by Summers in 1994. The concept was to maintain the existing bone by compressing trabecular bone laterally and apically with minimal trauma to improve the bone density. The condensed bone in this way will have to put in act a double repairing mechanism, from one side represented by the normal processes of osteointegration and on the other side from the processes of the reparation post fracture like that depends on BMU (bone modelling units) which create new spaces for the new vessels and afterwards filling all the gaps between the bone and the implant.
223633847|NCT06599112|OTHER|Conventional drilling|The implant drilling kit provided by the manufacturer will be used for the implant placement, using the pilot drill followed by consequent drills according to the size of the osteotomy needed.
223633848|NCT06592430|OTHER|Patients diagnosed with lung cancer use WeChat to communicate with healthcare providers|Patients diagnosed with lung cancer use WeChat to communicate with healthcare providers
223633849|NCT06592430|OTHER|Patients diagnosed with lung cancer don't use WeChat to communicate with healthcare providers|Patients diagnosed with lung cancer don't use WeChat to communicate with healthcare providers
223633850|NCT06603506|OTHER|tumour and blood samples|Tumour and blood samples
223633851|NCT06591104|DIAGNOSTIC_TEST|24 hour urinary protein|proteinuria and renal function impairment will be detected in patients of four groups
223633852|NCT06604676|PROCEDURE|guided soft tissue grafting|guided soft tissue grafting techniquea special digital guide was fabricated for one intervention non-guided soft tissue grafting technique receive the traditional technique without guide
223633853|NCT06604676|PROCEDURE|non-guided soft tissue grafting technique|the graft was taken with traditional technique without guide
223633854|NCT06312826|PROCEDURE|Abdominal US|The acquired images included B-mode images of the left hepatic lobe through transverse and longitudinal scans including images of the umbilical portion of the left portal vein, and images of the right hepatic lobe through subcostal and intercostal scans including images of the right hepatic dome, right portal vein, and right hepatic vein with additional images of the confluence of both portal vein and three hepatic veins. When a liver observation was seen, additional images were taken, and its diameter was measured on both transverse and longitudinal planes.
223633855|NCT06312826|PROCEDURE|AMRI|The study subjects receive intravenous injection of gadoxetic acid (0.025 mmol/kg, Primovist; Bayer, Berlin, Germany) in the waiting room and then proceed to the examination room for MRI testing 15-20 minutes later. The MRI examination is conducted using a 3T MRI machine, and the MRI protocol consists of T2-weighted imaging, diffusion-weighted imaging (b value of 0, 50, and 500 s/mm2), and hepatobiliary phase imaging.
223633856|NCT01824836|DRUG|anastrozole|Given PO
223633857|NCT03378869|PROCEDURE|esophagectomy|all the included participants had received esophagectomy, either Ivor Lewis or tri-incision, or more complex procedures.
223633858|NCT06594822|DIETARY_SUPPLEMENT|probiotic plus standard treatment|Bacillus clausii, 5ml ampule containing 2 billion spores, given orally once daily
223633859|NCT06594822|DRUG|standard treatment|diclofenac 50 mg twice a day, prednisone 5mg once daily, methotrexate 10mg once weekly or sulfasalazine 500 twice daily
223764554|NCT04347486|DRUG|Sugammadex Injection 4mg/kg|Intravenous injection of 4mg/kg of sugammadex sodium on reappearance of T2
224222599|NCT04593290|DEVICE|Oticon Opn S 1 miniRITE hearing aid|Everyone who participates in Part 1 (listening effort testing and cognitive testing) will be invited to participate in Part 2 (hearing aids). It is not a requirement to participate in the administration, 6-week use, and re-testing procedures involved in Part 2 of the study. All cognitively healthy participants will be invited to participate, only MCI patients with a live-in informant will be given this opportunity. After ear measurement and dome and wire length selection, Oticon Opn S 1 miniRITE hearing aid fitting will occur wirelessly using Genie software, followed by hearing aid use instructions. The fitting will use Open domes, the standard NAL-NL2 protocol, and will increase gain seven steps on top of Real Ear Unaided Gain (REUG) from 750 Hz to 6 kHz.
223764555|NCT04347486|DRUG|Sugammadex Injection 8mg/kg|Intravenous injection of 8mg/kg of sugammadex sodium on reappearance of T2
224222600|NCT00803959|OTHER|Office evaluation|Office evaluation
224222601|NCT00803959|OTHER|UDS|Urodynamics
224222602|NCT03213756|DEVICE|Isometric exercises using Hand grip and elastic bands|"* Isometric exercises using hand-grip. This exercise consists of two sets of 30 hand-grip contractions with the hand of the upper arm candidate for AVF (in case of doubts about the most appropriate arm for AVF the exercise will be performed with both arms). The patient will rest one minute every 10 contractions and 5 minutes between both sets. The patient will repeat this protocol twice a day, morning and night (Approximately 15 minutes each session). The contraction intensity will start with half of the maximum force obtained by dynamometry and will be increased or decreased to be placed on an effort intensity 2-3 in the Borg scale.~* Isometric exercise using elastic bands. At noon the patient will perform a slow contraction session using elastic band with 20 slow repetitions with the arm in flexion and 20 repetitions with the arm in extension. (Total duration: less than 10 minutes)"
223764556|NCT04347486|DRUG|Neuromuscular reversal agent injection|Intravenous injection of 0.02mg/kg of atropine and 0.03mg/kg of neostigmine
223764557|NCT00417183|DRUG|Arvekap 0.1 mg (Triptorelin, Ipsen, France)|
224222603|NCT04936971|DRUG|Switch from Mycophenolate Mofetil to Everolimus manteinance treatment in Active Comparator Arm|Switch from Mycophenolate Mofetil in Active comparator Arm if assymptomatic Cytomegalovirus viremia \>1000-\<5000 copies/mL observed
223764558|NCT00417183|DRUG|Ganirelix 0.25 (Orgalutran, Organon, The Netherlands)|
223633860|NCT06609174|DIAGNOSTIC_TEST|KardiaRx ECG Screening and AI interpretation of ECG|The Kardia 6-lead device is an ambulatory, wireless device that connects to a smartphone. The KardiaRx App processes the signal acquired from the Kardia device into a real-time ECG. ECG will be interpreted by an AI algorithm
223633861|NCT06991335|DEVICE|Deep Brain Stimulation|Medtronic Percept PC with SenSight Directional Leads will be implanted to control the shape and size of stimulation
223633862|NCT06993168|DRUG|DA-5222|single dose administration (DA-5222 one tablet once a day)
223633863|NCT06991244|BEHAVIORAL|EMDR 2.0 Group Protocol|A short-term trauma-focused group protocol adapted from EMDR 2.0, delivered in three sessions over one week, targeting PTSD, depression, and anxiety symptoms among earthquake survivors. The first session lasted 90 minutes, followed by two 60-minute sessions. The intervention was administered face-to-face in a container city in Malatya, Türkiye. All sessions were conducted by a certified EMDR therapist who had completed advanced EMDR 2.0 training.
223633864|NCT05998902|PROCEDURE|Trophic enteral feeding combined with supplemental parenteral nutrition|The caloric goal of the first day is one-third of caloric requirements, the second day is half of caloric requirements, the third day is 70-100% and sustained for 1 week. Patients will receive the trophic enteral feeding with a caloric target of 500kcal/d (20-35ml/h), and the remaining calories are supplemented by parenteral nutrition. Protein requirements are calculated at 1.2 to 1.5 g per kilogram of body weight per day.
224222604|NCT04936971|OTHER|no intervention|Manteinance of assigned Arm treatment even if assymptomatic Cytomegalovirus viremia \>1000-\<5000 copies/mL observed
224222605|NCT00548990|BEHAVIORAL|cardiovascular exercise training|
223633865|NCT05998902|PROCEDURE|Full enteral feeding|The caloric goal of the first day is one-third of caloric requirements, the second day is half of caloric requirements, the third day is 70-100% and sustained for 1 week. Protein requirements are calculated at 1.2 to 1.5 g per kilogram of body weight per day. Enteral nutrition is given through nasogastric tube or nasointestinal tube.
223633866|NCT03905707|DRUG|glepaglutide|Glucagon-Like Peptide-2 (GLP-2) analog
223633867|NCT03907735|OTHER|Myometrial tissue sample collection|Myometrial tissue samples by core needle biopsy under ultrasound guidance
223633868|NCT06997978|OTHER|Tele-rehabilitation|Patients at the Telerehabilitation group are contacted via laptops that have cameras, microphones, and a reliable internet connection. The therapist's laptop camera is positioned so the patient may watch the therapist while the therapist demonstrates the exercises. After the therapist performs the exercise on himself, the patient must see the therapist via a laptop camera and then perform the same activity again.
223633869|NCT06997978|OTHER|Hand rehabilitation program|"1. Free exercises:~   1\. Wrist flexion and extension 2. Wrist side movement 3. Thumb flexion and extension 4-Finger opposition 5. Palm up and down~2. Ball exercises:~   1. Ball grip~  2. Finger flexion~  3. Thumb extend~  4. The pinch exercise~  5. Opposition 6- Side squeeze~   7\. Extend out~3. Household exercises~   1. Roll movement~  2. Wrist curl~  3. Extending the wrist~4. Pen exercises~   1. Pinch and release~  2. Pen spine~5. Exercises with coins~   1. Coin drop~  2. Coin stacking"
223633870|NCT07000032|OTHER|No Intervention: Observational Cohort|This is an observational cohort
223633871|NCT06998771|DRUG|JSKN003|JSKN003 is administered by intravenous infusion.
223633872|NCT06998771|DRUG|KN026|KN026 is administered by intravenous infusion.
223633873|NCT06998771|DRUG|Capecitabine|Capecitabine is for oral administration.
223764559|NCT03142503|DIETARY_SUPPLEMENT|Diet + supplementation|Supplementation of 1g of fish oil, 3 time a day, and hypocaloric diet (-500 calories) for 12 weeks, to evaluate weight loss, antioxidant markers and disease activity.
223764560|NCT03142503|DIETARY_SUPPLEMENT|Diet + placebo|Supplementation of 1g of soybean oil, 3 times a day, and hypocaloric diet (-500 calories) for 12 weeks, to evaluate weight loss, antioxidant markers and disease activity.
223764561|NCT03142503|DIETARY_SUPPLEMENT|Placebo|Supplementation of 1g soybean oil, 3 times a day.
223764562|NCT02694224|DRUG|vismodegib|Smo inhibitor
224222606|NCT00548990|BEHAVIORAL|flexibility/balance control|
224222607|NCT00418782|DRUG|naproxen|
224222608|NCT00418782|DRUG|CE-224535|
224222609|NCT00418782|DRUG|placebo|
224222610|NCT05586620|PROCEDURE|3-snip punctoplasty|punctoplasty, more commonly known as watery eye surgery, is an ophthalmic surgical procedure performed to correct punctal stenosis (a condition that causes tears to overflow from the eyes) by widening the punctal opening to allow the tears to drain with ease.
224222611|NCT05586620|PROCEDURE|3-snip punctoplasty and Mitomycin C|"punctoplasty, more commonly known as watery eye surgery, is an ophthalmic surgical procedure performed to correct punctal stenosis (a condition that causes tears to overflow from the eyes) by widening the punctal opening to allow the tears to drain with ease.~Mitomycin C is a chemotherapeutic agent that acts by inhibiting DNA synthesis"
224222612|NCT01761526|DRUG|Rotigotine transdermal patch|Rotigotine transdermal patch, single-dose application over 24 hours 2 mg /24 hours (10 cm2)
224222613|NCT04579497|OTHER|38°C warm water footbath|A ten-minute pre-intervention rest period followed by a 30-minute footbath with 16 l of warm water at a constant temperature of 38°C, followed by a ten-minute post-intervention rest period.
224222614|NCT04579497|OTHER|40°C warm water footbath|A ten-minute pre-intervention rest period followed by a 30-minute footbath with 16 l of warm water at a constant temperature of 40°C, followed by a ten-minute post-intervention rest period.
224222615|NCT04579497|OTHER|42°C warm water footbath|A ten-minute pre-intervention rest period followed by a 30-minute footbath with 16 l of warm water at a constant temperature of 42°C, followed by a ten-minute post-intervention rest period.
224222616|NCT04579497|OTHER|38-42°C rising temperature footbath|A ten-minute pre-intervention rest period followed by a 30-minute footbath with 16 l of warm water. Water temperature starts at 38°C and is increased by 1°C every 6 minutes, resulting in 42°C after 30 minutes. The footbath is followed by a ten-minute post-intervention rest period.
224222617|NCT05992545|DEVICE|Mobile application 'DangDang Care' under usual care|"The application incorporates a behavioral activation program to provide psychological support and enhance diabetes self-management for people with type 2 diabetes experiencing depressive symptoms, alongside conventional medical therapy.~The intervention group receives the mobile application with usual care."
224222618|NCT06104930|OTHER|Explorative biomarker study|Analysis of blood biomarker
224222619|NCT01405950|DRUG|Zanaflex Capsules|0.025 mg/kg
224222620|NCT01405950|DRUG|Zanaflex Capsules|0.05 mg/kg
224222621|NCT01405950|DRUG|Zanaflex Capsules|0.075 mg/kg
223633874|NCT06998771|DRUG|Enlonstobart|Enlonstobart is administered by intravenous infusion.
223633875|NCT06998771|DRUG|Oxaliplatin|Oxaliplatin is administered by intravenous infusion.
223633876|NCT06998771|DRUG|Trastuzumab|Trastuzumab is administered by intravenous infusion.
223633877|NCT06998771|DRUG|Pembolizumab|Pembolizumab is administered by intravenous infusion.
223633878|NCT06999395|BEHAVIORAL|Virtual online pelvic health program|The program offers a multimodal approach to self-guided treatment for PVD. Its multimodal approach is exemplified by pain education focusing on pelvic health and neuroplasticity to provide the foundation for strategies strengthening the mind-body connection to the pelvis; mindful breathing and relaxation exercises to reduce nervous system overactivation and enhance mood; and gradual progression of exercises encouraging awareness, stretching, and strengthening to promote relaxation of the pelvic floor muscles and reduction of accessory muscle tension resulting from protective guarding. The program uses 3 separate yet interconnected modules: Learn (20 modules of pain science education and skills), Rewire (11 modules featuring mindfulness and relaxation), and Move (45 pelvic and other exercises).
223633879|NCT01243190|DRUG|Ofatumumab|Loading first dose 300 mg by vein on Day 1 of Cycle 1; and full dose 1000 mg over 4 hours 1 time each week for 7 additional weekly doses (8 doses).
223633880|NCT06998836|BEHAVIORAL|Dementia prevention education|Dementia prevention education:A structured dementia prevention education program developed based on qualitative focus group findings. The program includes multiple interactive sessions covering dementia knowledge, health beliefs, risk reduction strategies, and motivation for preventive actions.
223633881|NCT06998836|OTHER|General Health Education Leaflet|Participants received printed general health education leaflets not specifically related to dementia. The content included general wellness and health maintenance advice.
223633882|NCT06998394|DRUG|AK104 - Chemotherapy|AK104 (10mg/kg, q3w) + cisplatin weekly or every 3 weeks + radiotherapy (pelvic external beam radiotherapy + brachytherapy) until disease progression, intolerable toxicity, or the investigator judgment that the participant can no longer benefit, participant withdrawal of consent, or completion of 2 years of AK104 treatment.
223633883|NCT06587698|DRUG|Sitagliptin|100 mg QD for 3 month
224222622|NCT01405950|DRUG|Zanaflex Capsules|0.1 mg/kg
223633884|NCT06587698|DRUG|BeiDouGen|60 mg BID for 3 month
223633885|NCT06587698|DRUG|Sitagliptin+BeiDouGen|100 mg Sitagliptin QD plus BeiDouGen 60 mg BID for 3 month
223633886|NCT06998303|OTHER|Bipolar DBS stimulation|All participants will receive bipolar DBS through stimulation contacts 3 (most dorsal GP contact) and contact 2 (adjacent to contact 3) as specified by the device manufacturer. Bipolar stimulation through contacts 3 and 2 may be different from the settings used by the participant for optimal clinical improvement, as determined by their DBS care provider
223633887|NCT05020977|OTHER|Blood pressure, physical activity, health|Observational study of work environment, leisure time, blood pressure, physical activity and health
223633888|NCT04802707|COMBINATION_PRODUCT|deoxycytidine and deoxythymidine|The Investigational Product (IP) dC/dT100-400 will be administered orally every day (QD) and the dose is divided over trid or bid for the daily dose of 100 mg/kg from Day 1-7, 200 mg/kg from Day 8-14, 300 mg/kg from Day 15- 21 and 400 mg/kg from Day 22 to 1825. Doses was chosen according to the safety and efficacy doses used in the literature.
223633889|NCT05878418|DEVICE|Thoracolumbosacral Spinal Orthosis (TLSO)|In the TE, PR, PC + spinal orthosis group, in addition to the control group program, a thoracolumbosacral spinal orthosis (TLSO) designed specifically for the child will be used for 8 hours a day for 8 weeks, every day of the week.
223764563|NCT02694224|DRUG|Paclitaxel|Paclitaxel (80 mg/m2) weekly x 12 doses followed by sequential dose dense Epirubicin (90 mg/m2) plus Cyclophosphamide (600 mg/m2) each 2 weeks x 4 doses with granulocyte macrophage colony stimulating factors (GM-CSF) support
224222623|NCT04485000|BEHAVIORAL|Online 1-Day Cognitive Behavioural Therapy (CBT)-Based Workshop|The workshop is a day-long intervention delivered in 4 modules based on Cognitive Behavioural Therapy (CBT). The workshop covers PPD etiology, modifiable cognitive risk factors, cognitive skills, behavioural skills, problem solving, goal setting and action planning. Each participant is given a professionally designed manual to facilitate learning. Weekly reminder emails are sent for 6 weeks after the workshop completion to encourage practice. A list of PPD resources and a copy of the Canadian Treatment Guidelines for Postpartum Depression are provided.
224222624|NCT02410252|DEVICE|iThermonitor|The device is a continuous temperature monitoring tool for home monitoring of temperature. Participants are asked to use this device for two weeks.
224222625|NCT01753479|OTHER|Spectroscopy device|Spectrum data are collected using spectroscopy device via an instrumental channel of endoscope. Then spectrum data is analyzed. Numerical features (spectral slope and width of spectrum) are used for statistical analysis.
224222626|NCT01336010|DRUG|Peginterferon alfa-2a|PEG-IFN 180 mcg in 0.5 ml (prefilled syringes) administered subcutaneously (SC) once weekly
224222627|NCT01336010|DRUG|Ribavirin|Genotype 1: 1000mg or 1200mg p.o. daily in split doses (1000mg for patients weighing \<75kg and 1200mg for patients weighing ≥ 75kg) Genotypes 2/3: 800mg daily p.o. daily in split doses for genotype 2 and 3 patients
224222628|NCT03877055|DRUG|Copanlisib|Treatment will be with intravenous copanlisib on days 1, 8, 15 of 28 day cycles.
224222629|NCT03877055|DRUG|Ibrutinib|Oral ibrutinib daily in 28 day cycles. A cycle is defined as 28 days of therapy.
224222630|NCT01125995|RADIATION|early CCRT|"1. patients will be received with 4 cycles of etoposide 100mg/m2 D1-3 \& Cisplatin 70mg/m2 D1.~2. radiotherapy start from day 1 of 1st chemotherapy cycle and complete 5250cGy/25fraction (daily one fraction, 210cGy)."
224222631|NCT01125995|RADIATION|late CCRT|"1. patients will be received with 4 cycles of etoposide 100mg/m2 D1-3 \& Cisplatin 70mg/m2 D1.~2. radiotherapy start from day 1 of the third cycle of EP chemotherapy and complete 5250cGy/25fraction (daily one fraction, 210cGy)."
223633890|NCT05878418|OTHER|Trunk Exercise (TE), Pulmonary Rehabilitation(PR) and Pulmonary Care (PC)|The active control group will receive a TE, PR and PC program in the outpatient clinic once a week for 8 weeks, 7 days a week, once a day, 50-60 minutes per session, for 8 weeks.
223633891|NCT06879431|BEHAVIORAL|cognitive-behavioral intervention|After enrollment in the experimental group, the guardians were asked to fill out a sleep diary every day before surgery to self-report the children's sleep, and to wear a somatic movement recorder to monitor sleep (non-dominant arm) (wGT3x-BT accelerometer, ActiGraph) during the preoperative hospitalization period, except during surgery, and then to wear it to record the sleep-related parameters until 7 days after surgery or before discharge from the hospital.Preoperative daily cognitive-behavioral interventions (developmental trials were guided with WeChat applets), including cognitive change, sleep hygiene, sleep restriction, stimulus control, and relaxation training
223633892|NCT06705738|DIETARY_SUPPLEMENT|SUPOL|Supplement containing Olive Oil Polyphenol with the main substance being Oleocanthal (SUPOL), 2 capsules twice a day (4 capsules total) for 12 months.
223633893|NCT06705738|OTHER|Dietary Pattern: MeDi|Adherance to Mediterranean dietary pattern to be followed for 12 months.
223633894|NCT06705309|BEHAVIORAL|Web-Based Education|The Effect of a Web-Based Education Program and Educational Booklet Developed on Cervıcal Cancer on Women's Prevention Methods
223633895|NCT06705296|DEVICE|Open Label Deep Brain Stimulation|Patients will receive open label deep brain stimulation
223633896|NCT06705296|DEVICE|Double blinded Deep Brain Stimulation|Patients will receive double blinded deep brain stimulation
223633897|NCT06705296|BEHAVIORAL|Prolonged exposure therapy|Patients will receive prolonged exposure therapy
223633898|NCT06705296|DEVICE|Closed loop Deep brain stimulation|Patients will receive closed loop deep brain stimulation
223633899|NCT06706713|DRUG|BEBT-109 Capsule|Take orally before breakfast and dinner each day, with a minimum interval of 9 hours between doses, 120mg each time, twice a day,and 28 days as a treatment cycle.
223633900|NCT04051996|DRUG|Glasdegib|Glasdegib will be administered at the starting dose of 100 mg orally once daily.
223633901|NCT04051996|DRUG|Decitabine|Decitabine will be administered per local label and will be administered by IV infusion at a dose of 20 mg/m2/day for either 5 days or 10 days as determined by randomization. Each cycle will be every 28 days.
223633902|NCT06704958|OTHER|AMPERE EMA app|AMPERE EMA smartphone app using MyCap
223633903|NCT06704711|DIETARY_SUPPLEMENT|Caffeine 300 MG|They will rinse the solution containing a total of 400 mg of caffeine (20 mL, 2% density) in the mouth for 20 seconds and try to continue the exercise against increasing resistance until exhaustion.
223633904|NCT06704711|COMBINATION_PRODUCT|Exercise|The exercise test will be performed on a bicycle ergometer (Ergometer Exercise Bike SANA 500, Germany) (where the pedaling speed is kept constant at 60 rpm, with an initial load of 50 Watts and a load increase of 25 watts per minute, gradually increasing until the participants become exhausted. To be able to determine the degree of difficulty perceived during the test and The Borg Scale will be used to end the test when the athlete reaches the point of exhaustion.
223633905|NCT06704711|OTHER|Placebo|They will rinse 20 mL of distilled water in their mouth for 20 seconds.
223633906|NCT05148364|BEHAVIORAL|interview|"A spiritual consultant and a psychologist will interview the participants about their experiences of chronic low back pain, how they interpret their pain experience and how they cope with the persistent pain. Each participant will be interviewed individually.~Questions related to the following three aspects will be asked:~1. Attributes: describe the changes in your personality, mood, and general happiness you have observed after you starting having chronic low back pain.~2. Pain resilience: How would you describe this persisting pain experience? How do you arrange your daily activity? What do you do to deal with this persistent pain?~3. Spirituality: As a person with chronic low back pain, how do you interpret this pain experience? Do you seek connections with higher powers (such as powers from religion) when you are desperate because of pain? Since the pain is chronic and persistent, it might not go away, how would you define your life?"
223633907|NCT06739746|OTHER|No intervention measures|No intervention measures
223633908|NCT06756880|DIAGNOSTIC_TEST|Pulmonary function test|Pulmonary function test results performed closest to the date of surgery and considered successful according to American Thoracic Society standards
223633909|NCT00846976|DRUG|Bicalutamide|200mg daily
223633910|NCT01141517|BEHAVIORAL|Not-On-Tobacco smoking cessation program|Adolescent quit-smoking program; Not-On-Tobacco
223633911|NCT00570830|DEVICE|Retisert (fluocinolone acetonide implant)|Patients with intermediate, posterior or pan-uveitis underwent simultaneous fluocinolone acetonide implantation (0.59 mg or 2.1 mg) and phacoemulsification and intraocular lens.
223633912|NCT02608684|DRUG|Pembrolizumab|Pembrolizumab IV solution
223633913|NCT02608684|DRUG|Gemcitabine|Gemcitabine IV solution
223633914|NCT02608684|DRUG|Cisplatin|Cisplatin IV solution
223633915|NCT01924338|DEVICE|MRI scan|Acquisition of a high-resolution MRI scan (0.15 x 0.15 x 1.0 mm³) aligned with the AC-PC (anterior commissure-posterior commissure) line
223633916|NCT01924338|DEVICE|Laser scan|A near-infrared laser scan of the subject's forehead is acquired
223633917|NCT01924338|PROCEDURE|Dental cast creation|A dental cast made of PMMA (polymethyl methacrylate) of the subject's maxilla is created
223764564|NCT02694224|DRUG|Epirubicin|dose dense Epirubicin (90 mg/m2) plus Cyclophosphamide each 2 weeks x 4 doses with GMCSF after Paclitaxel
223764565|NCT02694224|DRUG|Cyclophosphamide|dose dense Cyclophosphamide (600 mg/m2) together with Epirubicin each 2 weeks x 4 doses with GMCSF after Paclitaxel
224222632|NCT00387712|OTHER|Velocity based treadmill training|6 month of progressive treadmill walking with a safety harness and hand rail support to prevent falls. Treadmill speed is gradually progressed to meet the training heart rate goals for moderate aerobic exercise, when hemiparetic gait velocity can no longer be progressed, incline is added to achieve heart rate training goals. Progression is also based on participant's tolerance, abilities and safety.
224222633|NCT00387712|OTHER|Duration based treadmill training|6 month of progressive treadmill walking with a safety harness and hand rail support to prevent falls. Treadmill duration is gradually progressed to meet the endurance goals for low aerobic intensity exercise, gait velocity and incline do not progress. Progression is based on participant's tolerance, abilities and safety.
224222634|NCT01783106|DRUG|Ciprofloxacin|experimental
224222635|NCT01783106|DRUG|Doxycycline|experimental
224222636|NCT01783106|DRUG|Hydroxychloroquine|oral
223633918|NCT01105481|DRUG|Amisulpride add-on|At the beginning of the treatment phase (day 1), subjects in the combination treatment group will be started with adjunctive amisulpride, with a starting dose of 200 mg per day. Amisulpride is planned to increase to 400 mg/day on day 8, 600mg/day on day 15 and 800 mg/day on day 22, according to the subjects' responses and tolerability. All of the add-on amisulpride will be provided to subjects at night. To permit dose adjustment and ensure double-blind procedure, 200mg amisulpride is packed in capsules identical to those used for the placebo.
223633919|NCT01105481|DRUG|Placebo add-on|For subjects randomly allocated to the placebo treatment group, they will be added with one capsule of placebo from Day 1. On Day 8, Day 15 and Day 22, the placebo will be increased to 2, 3 and 4 capsules, respectively. and adjunctive amisulpride, with a starting dose of 200 mg per day. Amisulpride is planned to increase to 400 mg/day on day 8, 600mg/day on day 15 and 800 mg/day on day 22, according to the subjects' responses and tolerability. To permit dose adjustment and ensure double-blind procedure, 200mg amisulpride is packed in capsules identical to those used for the placebo.
224222637|NCT01783106|DRUG|Budesonide|active comparator
224222638|NCT06541470|PROCEDURE|Cutting needle biopsy|Effectivity, reliability and safety of pleural needle biopsy in histopathological diagnosis of pleural diseases.
224222639|NCT06541470|PROCEDURE|Abrams needle biopsy|Effectivity, reliability and safety of pleural needle biopsy in histopathological diagnosis of pleural diseases.
224222640|NCT03119532|OTHER|Receive metric feedback email|If the provider received an email about the participants performance metrics
224222641|NCT00171509|DRUG|Cyclosporine microemulsion|
223633920|NCT02209714|DRUG|BIIF 1149 BS|
223633921|NCT02209714|DRUG|Placebo|
223633922|NCT01883258|OTHER|High intensity aerobic interval training|Supervised aerobic interval training will be performed on bicycles 4 times per week for 8 weeks. Each training session will last 40 minutes and will consist of 10-minute warm up at 70% of maximal heart rate (HRmax), four 4-minute intervals at 90% of HRmax with 3-min active recovery at 70% of HRmax and 5-minute cool down at 70% of HRmax.
223633923|NCT01883258|OTHER|Continuous moderate intensity exercise|Supervised exercise training will be performed on bicycles 4 times per week for 8 weeks. Each training session will last 47 minutes and will consist of continuous moderate intensity cycling at 70% of HRmax.
224222642|NCT00322309|OTHER|Placebo|Placebo for days 1-4 Placebo for days 5-9 Placebo for days10-78 Placebo for days 79-81 Placebo for days 82-84
224222643|NCT00322309|DRUG|Mirtazapine|Days 1-4 15mg Days 5-9 30 mg Days 10-78 45mg Days 79-81 30mg Days 82-84 15mg
224222644|NCT03818737|BIOLOGICAL|Bone Marrow Derived MSCs|Autologous bone marrow concentrate (BMAC) is a standard orthobiologic injection for knee osteoarthritis. The procedure involves harvesting of bone marrow aspirate (BMA) from the posterior superior iliac spine (PSIS) and then following centrifugation in an FDA approved device (EmCyte GenesisCS Pure BMAC®-60 ml) will be injected back into the knee joint. All injections will be made via ultrasound guidance using a standard approach.
224318434|NCT03632018|BEHAVIORAL|HEART-PLAY|Participants assigned to the HEART-PLAY intervention will receive standard CR. Additionally, they will receive pedometers, group education, and educational materials introduced by peer Health Coaches for 12 months. Before or after their regularly scheduled CR appointments, they will meet at the clinic as a group twice per week to receive Health Tips and participate in discussions. At 8 weeks in to the 12-week CR, they will begin to discuss with their peer Health Coaches the transition from the formal CR setting into community-based exercise. As part of this transition, peer Health Coaches will slowly introduce group community walks and train participants in the proper use of resistance bands. Health Coaches will have talk with their assigned participants about relapse prevention and sustaining exercise following the termination of formal CR.
224318435|NCT03632018|BEHAVIORAL|Standard Cardiac Rehabilitation|During the 12-week intervention period, the STANDARD intervention participants will receive standard of care by attending the 36 sessions of standard CR as prescribed by his/her physician and administered by the Step Clinic.
224318436|NCT03423719|DIETARY_SUPPLEMENT|Fiit-ns®|Fiit-ns® is a blend of polyphenol-rich extracts from grapefruit, grape, green tea, guarana and black carrot. It also provides Vitamin B3. Daily dosage is 900 mg in two 450 mg-capsules for 16 weeks.
223633924|NCT03506152|DIAGNOSTIC_TEST|Serum Procalcitonin|Seven ml of blood was drawn in gel separator tubes within 24 hours of admission in ICU for Procalcitonin determination
223633925|NCT02984813|DRUG|GlaucoHealth|Containing alpha lipoic acid, citicoline, Co-enzyme Q10, Ginkgo biloba extract, grape seed extract, N-acetyl-cysteine, curcumin, and green tea extract
223633926|NCT02984813|DRUG|GlaucoSelect|Containing curcumin, bilberry extract, and grape seed extract
224222645|NCT03818737|BIOLOGICAL|Adipose-derived MSCs|Adipose-derived Stromal Vascular Fraction (SVF) will be obtained from a mini lipoaspirate. The lipoaspirate will then be enzymatically digested to produce a SVF that will be injected into the knee joint. All injections will be made via ultrasound guidance using a standard approach.
224222646|NCT03818737|BIOLOGICAL|Umbilical Cord Tissue (UCT) MSCs|Cryopreserved doses of umbilical cord tissue MSCs will be used. These MSCs were cryopreserved at P2 culture in plasmalyte A + 5% human serum albumin in 5 finger cryobags containing 20 million cells in 4 mL and stored under liquid nitrogen until shipment. Cells will be transported in a dry shipper and thawed at the study sites. The dose of MSCs will be aspirated from the cryobag into a sterile syringe and directly injected into the knee. All injections will be made via ultrasound guidance using a standard approach.
224222647|NCT03818737|DRUG|Corticosteroid injection|The corticosteroid injection is prepared by mixing 1cc of 40mg/dL depomedrol and 6cc of normal saline in a 10cc syringe will be made into the knee joint. All injections will be made via ultrasound guidance using a standard approach.
224222648|NCT03929211|DRUG|CPI-613|Given intravenously, CPI-613 dose will be 2,000 mg/m² and will not escalate.
224222649|NCT03929211|DRUG|Hydroxychloroquine|Given by mouth, hydroxychloroquine will be dose escalated from 600 mg to 1,200 mg orally given 2 hours before the CPI-613 infusion on days 1-5 of every 28 day cycle in a 3+3 dose escalation design.
224318437|NCT03423719|DIETARY_SUPPLEMENT|Placebo|Placebo product is 100% maltodextrin. Daily dosage is 900 mg in two 450 mg-capsules of identical appearance than the supplement capsule for 16 weeks.
224318438|NCT02501018|BIOLOGICAL|CLBS12|Intramuscular transfusion of CLBS12.
223633927|NCT02984813|DRUG|Placebo|No active ingredients
223633928|NCT03010449|DEVICE|Intra-bronchial valve and blood|Intra-bronchial valve implantation in combination with autologous blood instillation
224222650|NCT02405611|BEHAVIORAL|behavioral|The intervention package contains behavior change techniques targeting outcome expectancy, self-efficacy, action planning, coping planning, and self-monitoring. The active control group receives an information sheet regarding recommendations on fruit and vegetable intake. There will be 3 assessment points in time, with 1 month and six months in between. All the intervention materials and information sheets will be handed to participants after the baseline assessment. The self-monitoring calendar will be collected at time 2 assessment.
223633929|NCT05165134|OTHER|Kinesiotape|Elastic tape used for mechanical correction of the deformity in study group and placebo in control group
223633930|NCT06311487|BEHAVIORAL|Fasted-AM|Participants will engage in aerobic exercise within 4 hours of waking up, following a \>10h overnight fast across the 4d run-in and exercise metabolism assessment day. Energy and macronutrient-controlled meals will be consumed at \~08:00, \~13:00, and \~19:00. Plasma metabolite samples will be drawn immediately pre- and post- exercise.
223633931|NCT06311487|BEHAVIORAL|Fed-AM|Participants will engage in exercise within 4 hours of waking up, approximately 1h after consuming breakfast across the 4d run-in and exercise metabolism assessment day. Energy and macronutrient-controlled meals will be consumed at \~07:00, \~12:00, and \~18:00. Plasma metabolite samples will be drawn immediately pre- and post-exercise.
224222651|NCT02405611|BEHAVIORAL|behavioral|The intervention package contains behavior change techniques targeting outcome expectancy, self-efficacy, action planning, coping planning, and self-monitoring. The active control group receives an information sheet regarding recommendations on fruit and vegetable intake. There will be 3 assessment points in time, with 1 month and six months in between. All the intervention materials and information sheets will be handed to participants after the baseline assessment. The self-monitoring calendar will be collected at time 2 assessment.
224222652|NCT02405611|BEHAVIORAL|primary eduction|The intervention package contains behavior change techniques targeting outcome expectancy, self-efficacy, action planning, coping planning, and self-monitoring. The active control group receives an information sheet regarding recommendations on fruit and vegetable intake. There will be 3 assessment points in time, with 1 1 month and six months in between. All the intervention materials and information sheets will be handed to participants after the baseline assessment. The self-monitoring calendar will be collected at time 2 assessment.
224222653|NCT03104153|PROCEDURE|Early-drain removal|Drain removal at hospital discharge
224318439|NCT02501018|DRUG|SOC|Standard of care (SOC) is defined as pharmacotherapy with approved drugs (e.g., antiplatelets, anticoagulants, and vasodilators including prostanoids).
224318440|NCT05870618|BIOLOGICAL|vaccinate with DTap|vaccinate with DTap
224318441|NCT05870618|BIOLOGICAL|vaccinate with DT|vaccinate with DT
224318442|NCT01749202|DIETARY_SUPPLEMENT|Sunflower Oil Softgels|3 x 500 mg softgel capsules/day
224318443|NCT01749202|DIETARY_SUPPLEMENT|EPA softgels|3 x 500 mg softgel capsules/day
224318444|NCT01749202|OTHER|Sunflower Oil Food|3 servings/day
224318445|NCT01749202|OTHER|SDA soybean Oil Food|3 servings/day
223633932|NCT06311487|BEHAVIORAL|Fasted-PM|Participants will engage in exercise between 8-12 hours after waking up, following a \~10h fast across the 4d run-in and exercise metabolism assessment day. Energy and macronutrient-controlled meals will be consumed at \~07:00 and \~18:00. Plasma metabolite samples will be drawn immediately pre- and post-exercise.
223633933|NCT06311487|BEHAVIORAL|Fed-PM|Participants will engage in exercise between 8-12 hours after waking up, approximately 1h after consuming dinner across the 4d run-in and exercise metabolism assessment day. Energy and macronutrient-controlled meals will be consumed at \~07:00, \~12:00, and \~18:00. Plasma metabolite samples will be drawn immediately pre- and post-exercise.
223633934|NCT02403128|DRUG|aflibercept|Intravitreal injection of 2.0 mg aflibercept at baseline, and repeated no sooner than two months from the previous injection for persistent macular edema as defined in the protocol.
223633935|NCT03819192|DIAGNOSTIC_TEST|microbiome analysis|"From all full age pregnant women with PPROM enrolled in this study vaginal smear samples will be taken at three time points:~1. directly after hospitalization~2. 5-7 days after beginning of antibiotic treatment~3. 24 h before birth~The microbiome of the neonates of these women will be analysed out of pharyngeal and rectal swabs and umbilical cord blood taken directly after birth and additionally out of the first Meconium."
223633936|NCT03819192|DIAGNOSTIC_TEST|Conventional cultures|For every sample taken for microbiome analysis, a conventional culture is taken as control.
223633937|NCT03819192|DIAGNOSTIC_TEST|CAAP48 measurement|CAAP48 is an identified sepsis marker in adult patients. The samples are taken dependent on clinical monitoring to compare CAAP48 with established inflammation markers (CRP, IL-6, White blood cell count, Procalcitonin).
223633938|NCT00136396|DRUG|Rituximab|Given once weekly for 4 weeks followed by a 4 week observation therapy.
223633939|NCT03544684|BEHAVIORAL|Effects of the type of exercise on blood glucose concentrations|glucose concentrations were assessed over the 24 hour periods following no exercise, a single bout of high intensity interval training and a single bout of moderate intensity continuous training
223633940|NCT01972217|DRUG|Olaparib|Olaparib bid
223633941|NCT01972217|DRUG|Placebo|Placebo bid
223633942|NCT01972217|DRUG|Abiraterone|Abiraterone 1000 mg
223633943|NCT01972217|DRUG|Prednisone or prednisolone|Prednisone or prednisolone 5 mg bid will be co-administered with the abiraterone in this study.
223633944|NCT02799446|DRUG|Reslizumab|Reslizumab 3mg/kg intravenous (IV)
223633945|NCT02799446|DRUG|Placebo|Matching Placebo intravenous (IV)
223633946|NCT00117351|DRUG|VELCADE|
223633947|NCT06120374|RADIATION|Radiotherapy|"For participants eligible for enrollment, radiotherapy was started within 4-6 weeks after surgery. Rotational intensity-modulated radiotherapy (VMAT) with daily image-guided radiotherapy (Daily IGRT) technique was used.~Range of irradiation (patients were randomized into two groups - expanded field irradiation group and involved field irradiation group)"
223764566|NCT04187365|OTHER|Duration of Indwelling Catheter|Foley catheter
223764567|NCT00701129|BIOLOGICAL|Alglucosidase Alfa|Administered as IV infusion.
224318446|NCT02995408|BEHAVIORAL|Relaxation Response Resiliency Program for Parents of Children with ASD|
224318447|NCT04931121|DRUG|Viscosupplements|Synovial fluid is collected as part of a conventional injection of viscosupplement
223633948|NCT06120374|DRUG|Chemotherapy|For patients eligible for enrollment, postoperative adjuvant chemotherapy was initiated at about 4-6 weeks after surgery, for a total of 4 cycles, with the chemotherapy regimen of gemcitabine + cisplatin. Administration: Gemcitabine 1,000 mg/m2 on days 1 and 8 (completed within 30-60 minutes), cisplatin 70 mg/m2 on day 1.
223633949|NCT06120374|DRUG|Immunotherapy|For patients eligible for enrollment, sequential adjuvant immuotherapy was initiated at about 4-6 weeks after surgery, Immunotherapeutic agents include (PD-1/PD-L1) to be used every 21 days postoperatively for one year.
223633950|NCT04318873|OTHER|Packed Promise Demonstration Benefits|Monthly: Home-delivered food box, nutrition education handout, and $15 monthly voucher for fruits and vegetables
223633951|NCT03247647|BEHAVIORAL|Enhanced Intervention|Participants will complete a personal values task immediately before viewing feedback from eCheckUpToGo.
223633952|NCT03247647|BEHAVIORAL|Standard Intervention|Participants will write about the food they have eaten in the last 48 hours.
223633953|NCT02670317|DRUG|Obinutuzumab|Patients will receive a maximum of 6 courses of G-CHOP-21 followed by 2 doses of Obinutuzumab in combination with Ibrutinib.
223633954|NCT02670317|DRUG|Ibrutinib|Patients will receive a maximum of 6 courses of G-CHOP-21 followed by 2 doses of Obinutuzumab in combination with Ibrutinib.
223633955|NCT02670317|DRUG|CHOP|Patients will receive a maximum of 6 courses of CHOP-21 in combination with Obinutuzumab (G) followed by 2 doses of Obinutuzumab in combination with Ibrutinib.
223633956|NCT00689858|DRUG|Cilostazol, Ginkgo biloba and placebo|dosing time
223633957|NCT06327269|DRUG|Lenvatinib 10 mg|Lenvatinib would be used on patients with advanced liver cancer after Liver transplantation as an adjuvant treatment.
223764568|NCT00701129|DRUG|Methotrexate|Administered subcutaneously.
224222654|NCT04155697|DRUG|2% Chlorohexidine Gluconate soap|Participants will wash hands for 30 seconds with 2% Chlorohexidine Gluconate soap.
224222655|NCT04155697|DRUG|62% ethyl alcohol-based hand sanitizer|Participants will apply 62% ethyl alcohol-based hand sanitizer for 30 seconds
224222656|NCT00682383|DRUG|Cisplatin; Etoposide; Radiation therapy; Docetaxel; Neulasta|"Cisplatin 75 mg/m2 day 1 and 22~Etoposide 80mg/m2 days 1-3, 22-24~Radiation therapy: (initial fields 1.8gy/day (5 weeks) to 45Gy, then boost 2.0Gy/day (8 days) to a total of 61Gy) beginning day 1 (Total elapsed time: approximately 6 weeks, 3 days)~Filgrastim 5µg/kg\* SQ injection days 4-13 and days 25-34~Docetaxel 75mg/m2 Q 3 Weeks X 3 Cycles~Pegfilgrastim 6 mg SQ injection day 2 of each cycle"
224222657|NCT01772368|DRUG|Fp MDPI|"Fp MDPI is an inhalation-driven multidose dry powder inhaler (MDPI) containing fluticasone propionate dispersed in a lactose monohydrate excipient and contained within a reservoir. A metered dose of drug is delivered to a dose cup via an air pulse activated when the cap is opened.~Fp at 100 mcg was an active comparator (single dose). Further, participants were instructed to administer two inhalations of Fp MDPI 50 mcg twice daily (100 mcg total dose) during the Run-in (to replace the participant's current inhaled corticosteroid) and Washout Periods between treatments."
224222658|NCT01772368|DRUG|FS MDPI|FS MDPI is an inhalation-driven multidose dry powder inhaler (MDPI) containing fluticasone propionate and salmeterol xinafoate dispersed in a lactose monohydrate excipient and contained within a reservoir. A metered dose of drug is delivered to a dose cup via an air pulse activated when the cap is opened. The fluticasone propionate component was a fixed dose of 100 mcg. The salmeterol xinofoate dosage varied: 6.25, 12.5, 25 or 50 mcg.
224222659|NCT01772368|DRUG|Advair Diskus|ADVAIR DISKUS (100/50 mcg fluticasone propionate/salmeterol xinafoate) consists of a dry powder formulation of fluticasone propionate and salmeterol xinafoate in a lactose excipient. The dry powder is contained within individual blisters on a double foil strip within the device. Activation of the device opens a single blister of medication which is then dispersed into the air-stream by patient inhalation.
224318448|NCT01065402|DIETARY_SUPPLEMENT|PPB-R-203-Based Meal|PPB-R-203 is manufacture by Pharma Power Biotec Co., Ltd. The composition of PPB-R-203 is resistant starch (RS). Resistant starch can be regarded as a component of dietary fiber. Some forms of RS are present naturally in many foods, and average global consumption is estimated at 3-10 g/day. PPB-R-203-Based is the diet equivalent to daily energy needs as judged by indirect calorimetry and of the same macronutrient composition.
223633958|NCT04495244|DIAGNOSTIC_TEST|Syantra DX Breast Cancer|Blood test for detecting the presence of breast cancer.
223633959|NCT01487798|DRUG|biphasic human insulin 30|Administrated s.c. (subcutaneously, under the skin) for 16 weeks in treatment period 1 followed by 16 weeks in treatment period 2
223633960|NCT01487798|DRUG|biphasic insulin aspart 30|Administrated s.c. (subcutaneously, under the skin) for 16 weeks in treatment period 1 followed by 16 weeks in treatment period 2
223633961|NCT00948376|GENETIC|IFT80 screening|Natural History
223764569|NCT00701129|DRUG|Rituximab|Administered as IV infusion.
223764570|NCT02412631|DRUG|lorcaserin|lorcaserin is an FDA-approved weight loss medication for overweight and obese patients
223764571|NCT02412631|DRUG|Varenicline|Chantix is an FDA approved medication for smoking cessation
223764572|NCT02412631|DRUG|Placebo|Placebo for lorcaserin
223764573|NCT01204866|BIOLOGICAL|Valortim and selected Components|"* Valortim (Lot #10-08-001, 25 mg/mL) will be filtered through a 0.22 µm syringe filter and diluted 1:1000, 1:100, 1:10, and 1:1 in saline.~* Polysorbate 80 will be diluted in saline to the following concentrations: 0.06 mg/mL, 0.2 mg/mL, and 0.6 mg/mL.~* Mannitol (30 mg/mL) will be diluted in saline to the following concentrations: 1:1000, 1:100, 1:10, and 1:1~* Histamine (1 mg/mL), positive control~* Saline (0.9%), negative control"
224222660|NCT01772368|DRUG|Albuterol|Albuterol (Pro-Air) hydrofluoroalkane (HFA) metered dose inhaler (MDI), was provided to be used as needed for the relief of asthma symptoms during both the run-in and treatment periods (to replace the subject's current rescue medication).
224222661|NCT01452529|DRUG|Hydrocodone bitartrate q24h film-coated tablets|Hydrocodone bitartrate q24h film-coated tablets 20 - 120 mg once daily
224222662|NCT01452529|DRUG|Placebo to match hydrocodone bitartrate q24h tablets|Placebo to match hydrocodone bitartrate q24h film coated tablets 20 - 120 mg once daily
224222663|NCT02449291|DRUG|APD421|
224222664|NCT02449291|DRUG|Placebo|
224222665|NCT00227825|BEHAVIORAL|Motivational interviewing|
224222666|NCT05325892|COMBINATION_PRODUCT|This is an observational study|This is an observational study
223633962|NCT03258385|DIETARY_SUPPLEMENT|Vitamin B12 fortified UHT milk|Daily intake of 200 mL of UHT milk fortified with 100 µg vitamin B12
223633963|NCT03258385|DIETARY_SUPPLEMENT|Plain UHT milk|Daily intake of 200 mL of plain UHT milk
223633964|NCT00670254|DRUG|Placebo|Application is identical to experimental arm
223633965|NCT00670254|DRUG|Hydrocortisone|50 mg loading dose, continuous infusion of 200 mg/d for 5 d, 100 mg/d for 2d, 50 mg/d for 2 d, and 25 mg/d for 2 d.
223633966|NCT01470521|BIOLOGICAL|Hookworm larvae|Hookworm larvae solution is pipetted onto a plaster dressing which is then placed on the upper forearm for 24 hours. This is administered only once.
224222667|NCT06178146|DRUG|Thymosin Alpha1|Based on the conventional treatment, subcutaneous injection of Tα-1 (1.6 mg, qd) in Week 1; and in Week 2, subcutaneous injection of thymalfasin 1.6 mg, 3 times a week, followed by twice a week for 1 month since Week 3.
224222668|NCT06178146|DRUG|Immunosuppressant|Grade 2 irAEs: corticosteroid alone Grade 3 and above irAEs: corticosteroids combined with other immunosuppressants Steroid-refractory irAE: After 48-72 hours of systemic steroid therapy, the symptoms do not improve or worsen, and the second-line immunosuppressant therapy is adopted.
224222669|NCT03833596|DRUG|Prednisone|All 3 arms will receive Prednisone - 2 will be standard course treatment, 1 will be short course and rapidly-tapered
224222670|NCT03833596|DIETARY_SUPPLEMENT|Exclusive Enteral Nutrition|2 arms will receive EEN, in concurrence with either regular-course or short course and rapidly-tapered CS.
224222671|NCT00403286|DRUG|Fluticasone Propionate/Formoterol Fumarate|Inhalation suspension for nebulization 1000/20 mcg bid for 2 weeks
224222672|NCT00403286|DRUG|Fluticasone Propionate/Formoterol Fumarate|Inhalation Suspension for nebulization 1000/10 mcg bid for 2 weeks
224222673|NCT00403286|DRUG|Fluticasone Propionate/Formoterol Fumarate|Inhalation Suspension for nebulization 500/20 mcg bid for 2 weeks
224222674|NCT00403286|DRUG|Fluticasone Propionate/Formoterol Fumarate|Inhalation Suspension for nebulization 500/10 mcg bid for 2 weeks
224222675|NCT00403286|DRUG|Fluticasone Propionate|Inhalation Suspension for nebulization 1000 mcg bid for 2 weeks
224222676|NCT00403286|DRUG|Formoterol Fumarate|Inhalation Solution for nebulization 20 mcg bid for 2 weeks
224222677|NCT00403286|DRUG|Fluticasone Propionate/Salmeterol Xinafoate|Inhalation Powder delivered by Diskus device 250/50 mcg bid for 2 weeks
224222678|NCT00403286|DRUG|Placebo|Inhalation Solution for nebulization 2 mL bid for 2 weeks
224222679|NCT01981486|DRUG|Placebo Tablets|BID modified-release tablets
223633967|NCT01470521|BIOLOGICAL|Placebo|Pharmacopoeial grade water is pipetted onto a plaster dressing which is then placed on the upper forearm for 24 hours. This is administered only once.
224222680|NCT01981486|DRUG|PF-05180999 Tablets|BID modified-release tablets (20 to 240 mg BID)
224222681|NCT02363010|BEHAVIORAL|Gold Standard Behavior Therapy for Weight Loss|Group- based behavioral treatment for weight loss and weight loss maintenance, with a standard emphasis on diet (65% of session) and physical activity goals (25% of session). Other weight loss behaviors such as self monitoring will be covered in the remaining time (10% of session).
224222682|NCT02363010|BEHAVIORAL|Behavior Therapy for Weight Loss with Physical Activity Emphasis|Group-based behavioral treatment for weight loss and weight loss maintenance, with a larger emphasis on physical activity goals (65% of session) than eating-related goals (25% of session).Other weight loss behaviors such as self monitoring will be covered in the remaining time (10% of session).
224222683|NCT02363010|BEHAVIORAL|Acceptance-based Behavior Therapy for Weight Loss with PA emphasis|Group-based, acceptance-based behavioral treatment for weight loss and weight loss maintenance, with a larger emphasis on physical activity goals (65% of session) than eating-related goals (25% of session).Other weight loss behaviors such as self monitoring will be covered in the remaining time (10% of session).
224222684|NCT01617564|DRUG|bipuvacain|PCB with 20ml bupivakain or sodium cloride 9mg/ml will be administered one hour following misorpostol administration (first dose).
224222685|NCT01617564|OTHER|NaCl|PCB with 20ml sodium chloride (9mg/ml) inactive (sham) comparator
224222686|NCT00472550|DRUG|esomeprazole 20 mg|
224222687|NCT01093079|PROCEDURE|Laparoscopic partial nephrectomy|Laparoscopic partial nephrectomy
224222688|NCT01093079|PROCEDURE|Open partial nephrectomy|Open partial nephrectomy
224222689|NCT03347695|PROCEDURE|Left Atrial Geometric Volume Reduction, Pulmonary Vein Island Isolation and Left Appendage Base Closure(selected patients)|Left Atrial Geometric Volume Reduction, Pulmonary Vein Island Isolation and Left Appendage Base Closure
224222690|NCT03347695|PROCEDURE|Left Atrial Geometric Volume Reduction, Pulmonary Vein Island Isolation and Left Appendage Base Closure|Left Atrial Geometric Volume Reduction, Pulmonary Vein Island Isolation and Left Appendage Base Closure
224222691|NCT02477566|DRUG|Long-acting Triptorelin|Pituitary down-regulation with Long-acting Triptorelin 1.875mg during the luteal phase
224222692|NCT02477566|DRUG|Short-acting Triptorelin|Pituitary down-regulation with Short-acting Triptorelin 0.1mg/d,x10d, then 0.05mg/d until E2\<40pg/ml in serum, was initiated during the luteal phase
223633968|NCT04818853|OTHER|Observation to monitor patients for these infections|We will be receiving discarded specimens weekly. From these we are going to identify these various potential infections.
223633969|NCT00752349|PROCEDURE|Ultrasound|To evaluate oral phase swallowing function using submental ultrasound
223633970|NCT02318706|DRUG|DS-5565|
223633971|NCT02318706|DRUG|placebo|
223633972|NCT02461641|OTHER|NuShield|NuShield is a sterilized dehydrated amnion chorion membrane patch.
223633973|NCT02461641|OTHER|Affinity|Affinity is a aseptically produced hypothermically stored amniotic membrane patch.
223633974|NCT02461641|OTHER|Standard of Care|Standard of Care for this study is defined as sharp debridement, moist wound dressing and offloading of the area using a DARCO shoe.
224222693|NCT00996866|DRUG|Vitamin D3|Vitamin D supplementation will follow an algorithm for initial vitamin D dosing and for dose changes. Subjects will receive 100 ug/day of vitamin D3 if their 25(OH)D level is less than 50nmol/L and 50 ug/day if their 25(OH)D level is between 50 and 80 ug/day.
224222694|NCT00996866|DRUG|placebo|The placebo group will receive sugar pills appearing similar to the vitamin D capsules.
224222695|NCT04948190|BEHAVIORAL|Testing with medical detection dogs|Participants will be screened by medical detection dogs. In phase 2, participants may be asked to wear clothing samples collected in phase 1, as part of dog training procedures. In subsequent study parts, participants will wear their own clothing.
223633975|NCT04400201|DRUG|Remimazolam Tosilate|Intravenous injection at a dose of 0.3mg/kg for sedation induction and continuous intravenous infusion at an initiative dose of 1 mg/kg/h for sedation maintenance.
223633976|NCT04400201|DRUG|Propofol|Intravenous injection at a dose of 1.5\~2.5mg/kg for sedation induction and continuous intravenous infusion at the dose of 0\~12 mg/kg/h for sedation maintenance
223633977|NCT02824653|BIOLOGICAL|Mesenchymal Stem Cells|Allogenic Human Bone Marrow Mesenchymal Stem Cells (ex-vivo expanded in pooled human platelet lysate)
223633978|NCT02556385|DEVICE|High frequency rTMS|Most activated area from fNIRS findings: Perileisional Broca's area, High frequency rTMS (10Hz), Number of total stimuli: 800, Location: perilesional Broca's area, Intensity: 100% of resting motor threshold, Coil orientation: tangential to scalp, in combination with speech therapy(35-40min) after each rTMS session, Daily 10 treatment session
223633979|NCT02556385|DEVICE|Low frequency rTMS|Most activated area from fNIRS findings: Contralesional homologs of Broca's area, Low frequency rTMS (1Hz), Number of total stimuli: 1200, Location: Contralesional homologs of Broca's area (Pars triangularis), Intensity: 90% of resting motor threshold, Coil orientation: tangential to scalp, in combination with speech therapy(35-40min) after each rTMS session, Daily 10 treatment session
223633980|NCT06009211|OTHER|QueaseEase|Study participants will participate in one week with aromatherapy treatment and one week without aromatherapy treatment (randomly ordered) to serve as their own control.
223633981|NCT06289790|PROCEDURE|Erector Spinae Plane (ESP) block|Erector Spinae Plane (ESP) block with bupivacaine and for pain management in VATS procedure
223633982|NCT06289790|DRUG|Lignocaine|Lignocaine bolus and infusion for pain management in VATS procedure
223633983|NCT06289790|DRUG|Bupivacaine|Bupivicaine with adrenaline will be used to perform the ESP block
223633984|NCT02018718|DEVICE|Magnetic Resonance Imaging (MRI)|
223633985|NCT04859738|DRUG|Lidocaine Spray|"Individuals who met the research criteria and signed the informed consent form were numbered according to the order in which they came to the hospital. Later, the numbered individuals were assigned to the study groups according to the randomization list created in the computer environment.~Lidocaine Spray was applied 60 seconds before to the area where the peripheral intravenous catheter application of the patients in the Experiment I Group (Lidocaine Spray) will be performed. After waiting 60 seconds, peripheral intravenous catheter application was performed.~The nurse responsible for data collection measured blood pressure, pulse rate and peripheral oxygen saturation values 5 minutes before and just after the application with a finger-type pulse oximeter.~After performing peripheral intravenous catheterization, the pain level felt by the individual during the procedure and the injection satisfaction level values were taken and recorded on the Case Report Form by the nurse."
223633986|NCT04859738|DRUG|Benzokain Sprey|"Individuals who met the research criteria and signed the informed consent form were numbered according to the order in which they came to the hospital. Later, the numbered individuals were assigned to the study groups according to the randomization list created in the computer environment.~Benzocaine Spray was applied 60 seconds before to the area where the peripheral intravenous catheter will be applied to the patients in the Experiment II Group (Benzocaine Spray). After waiting 60 seconds, peripheral intravenous catheter application was performed.~The nurse responsible for data collection measured blood pressure, pulse rate and peripheral oxygen saturation values 5 minutes before and just after the application with a finger-type pulse oximeter.~After performing peripheral intravenous catheterization, the pain level felt by the individual during the procedure and the injection satisfaction level values were taken and recorded on the Case Report Form by the nurse."
223633987|NCT04859738|OTHER|Alcohol|"Individuals who met the research criteria and signed the informed consent form were numbered according to the order in which they came to the hospital. Later, the numbered individuals were assigned to the study groups according to the randomization list created in the computer environment.~In patients in the placebo group, alcohol was sprayed 60 seconds before the area where the peripheral intravenous catheter will be applied. After waiting 60 seconds, peripheral intravenous catheter application was performed.~The nurse responsible for data collection measured blood pressure, pulse rate and peripheral oxygen saturation values 5 minutes before and just after the application with a finger-type pulse oximeter.~After performing peripheral intravenous catheterization, the pain level felt by the individual during the procedure and the injection satisfaction level values were taken and recorded on the Case Report Form by the nurse."
223633988|NCT03921957|RADIATION|stereotactic radiotherapy|first level : W1 : 3 fractions - W2 : 2 fractions - W3 : 3 fractions second level : W1 3 fractions - W2 : 3 fractions - W3 : 3 fractions Third level : W1 : 4 fractions - W2 : 2 fractions - W3 : 2 fractions Fourth level : W1 : 4 fractions - W2 : 4 fractions
223633989|NCT01921595|OTHER|Valanced salt colloid|Maximum dose : 30ml/kg, IV, The infusion of valanced salt colloid is started at bleeding and continued until reach at maximum dose
223633990|NCT01921595|OTHER|Valanced salt crystalloid group|Maximum dose : 30ml/kg, IV, The infusion of valanced salt crystalloid is started at bleeding and continued until reach at maximum dose
224222696|NCT03154879|DEVICE|Amplitude integrated electroencephalography|Frontal Amplitude-integrated Electroencephalogram in Early Prognostication After Cardiac Arrest
224318449|NCT01065402|DIETARY_SUPPLEMENT|TK9-Based Meal|TK9, Taikeng 9, is one commercially available rice manufacture by Yeedon Enterprise Co., Ltd. TK9-Based Meal is a diet equivalent to daily energy needs as judged by indirect calorimetry and of the same macronutrient composition.
223633991|NCT02151864|DRUG|LDE225|LDE225 will be administered orally, on a continuous once daily dosing schedule at a dose determined by the cohort the patient is enrolled in until progression or unacceptable toxicity develops
224222697|NCT00330421|DRUG|sorafenib tosylate|Given PO
224222698|NCT00330421|PROCEDURE|therapeutic conventional surgery|Undergo surgery
224222699|NCT00330421|OTHER|laboratory biomarker analysis|Correlative studies
224222700|NCT00330421|OTHER|pharmacological study|Correlative studies
224222701|NCT00330421|PROCEDURE|computed tomography|Correlative studies
224222702|NCT00330421|PROCEDURE|dynamic contrast-enhanced magnetic resonance imaging|Correlative studies
224318450|NCT02234102|DEVICE|Endoscopically guided laser ablation HeartLight system|
224318451|NCT03511599|DRUG|Cycloserine|Cycloserine 100mg
224318452|NCT03511599|DEVICE|Transcranial Magnetic Stimulation|Single-pulse transcranial magnetic stimulation and theta-burst stimulation
224318453|NCT03511599|DRUG|Placebo Oral Tablet|Placebo tablet matched to cycloserine tab
223633992|NCT05096403|DRUG|Pegcetacoplan|Pegcetacoplan taken twice weekly as subcutaneous injection
223633993|NCT04936945|PROCEDURE|Temporomandibular joint arthroscopy plus intra-articular injection|patients with TMJ degenerative joint diseases Wilkes stages IV, V not responding to conservative treatment will undergo operative diagnostic arthroscopic treatment then at the end of the procedure intra-articular injection of platelet rich plasma or hyaluronic acid will be done.
223633994|NCT00451360|DRUG|diacerein|
223633995|NCT00755183|DRUG|testosterone ophthalmic solution|testosterone ophthalmic solution for 128 days
223633996|NCT00755183|DRUG|vehicle of testosterone ophthalmic solution|vehicle of testosterone ophthalmic solution for 128 days
223633997|NCT02869152|OTHER|Endoscopic injection of 99mTc-sulfur colloid|Radiotracer injection around the rectal tumor for SLN mapping with gamma probe
223633998|NCT02869152|OTHER|Endoscopic injection of ICG|Dye injection around the rectal tumor for SLN mapping with NIR imaging.
223633999|NCT02869152|OTHER|Endoscopic injection of Spot|Dye injection for tattooing rectal tumor prior to surgical resection.
223764574|NCT01204866|DRUG|Valortim and Selected Components|"• It is anticipated that up to 4 subjects that received Valortim in a previous study (#0036-08-05) will participate in Stage II of the study; two of these subjects experienced adverse events while being dosed with Valortim. Subjects will each be tested percutaneously with Valortim, polysorbate 80, mannitol, histamine, and saline.~* Only one subject will be skin tested in a single day.~* The appropriate dilution for Valortim, mannitol, and polysorbate 80 will be based on the results from Stage I of this study. As was done in Stage I, Valortim will be filtered through a 0.22 µm syringe filter. Histamine (1 mg/mL) and saline (0.9%) will be used as the positive and negative controls, respectively"
223764575|NCT05035069|DRUG|Ciprofol|Ciprofol infusion, starting with 0.8 \~ 1mg/kg/h until BIS value below 60 (including 60), and then 0.2 \~ 0.6mg/kg/h until the end of the operation, ciprofol infusion was adjusted to keep the BIS value between 40-60.
224222703|NCT03854084|OTHER|The cranial osteopathic techniques|Technique of the temporal bones in favor of the free movement. Ear Pull technique: the hands of the osteopath holds the auricle of the individual with the thumb, index and the middle finger in a tweezer shape and with the elbows resting over the stretcher. Ruddy technique: The osteopath puts the thumbs on the eyelid of each eyeball.
224222704|NCT03854084|OTHER|Control group|Simulation of the techniques was used in the interventional group
224222705|NCT00318552|DRUG|Meropenem|
224222706|NCT04549259|BEHAVIORAL|Group-Based Social Support|This intervention involves weekly support group calls facilitated by a licensed counselor or therapist for 8 consecutive weeks. The calls will last approximately 90 minutes and will include 5-8 individuals per group. Groups will follow pre-determined topic areas, with participants encouraged to explore their feelings about the difficulties associated with normal aging, being HIV-positive, and living with HIV/AIDS as an older adult. Therapists will facilitate mutual support among group members, encourage greater openness and emotional expressiveness, and help participants to improve their social and family support and enhance their quality of life. This intervention is an adaptation of Telephone Supportive-Expressive Group Therapy (Heckman et al., 2013).
224222707|NCT04549259|BEHAVIORAL|HIV Stigma Reduction|"This intervention involves weekly support group calls facilitated by a licensed counselor or therapist for 6 consecutive weeks. The calls will last approximately 60-90 minutes and will include 5-8 individuals per group. This intervention is grounded in minority stress theory and will use cognitive-behavioral strategies to help empower participants to cope with stressful and stigmatizing experiences. Intervention components may include minimizing self-stigmatizing attitudes, reducing engulfment, developing a sense of future and hope, and developing and pursuing meaningful life goals. This intervention is an adaptation of Ending Self Stigma (Lucksted et al., 2011)."
224318454|NCT06622642|PROCEDURE|Transoral technique for mandibular angle fracture reduction|In transoral technique approach inferior alveolar nerve block and buccal nerve block will be given by 2% xylocaine with 1:100000 adrenaline. Incision will be made with surgical blade no 15 from gingival crevices of molars to ascending ramus. Fracture segments will be reduced alongwith MMF. A 5-hole 2mm miniplate with 2 holes anterior and 2 holes posterior to fracture line will be screwed to external oblique ridge and MMF will be removed and incision line will be closed.
223634000|NCT02869152|PROCEDURE|Flexible sigmoidoscopy|Flexible sigmoidoscopy prior to surgery to facilitate endoscopic injections of radiotracer and dyes.
223634001|NCT02869152|PROCEDURE|Endoscopic NIR imaging and gamma probe|Endoscopic near infrared (NIR) imaging of ICG and detection of radiotracer with gamma probe after standard removal of rectal neoplasm.
223634002|NCT02869152|PROCEDURE|Dissection of sentinel lymph node(s)|Surgical removal of identified lymph nodes in the rectum.
223634003|NCT03584477|DEVICE|Robot InMotion 2.0|Repetitive work of large numbers of targeted alternative movements with or without assistance. The passage between with and without assistance taking place according to the evolution of performance judged by the investigator therapist. Note that the duration of the training using the assisted mode should be at least 3 weeks, i.e. half of the total duration of treatment.
223634004|NCT03584477|OTHER|Conventional rehabilitation|Conventional rehabilitation implemented by an occupational therapist, involving stretching movements in submaximal passive amplitude, inhibition postures (Bobath), active efforts assisted of varied difficulty, exercises of direction of the arm towards a target with or without elbow support and grasping tasks, adapted to the capacities of the paretic upper limb.
223634005|NCT00497094|DEVICE|carotid artery stenting|Using retrograde transfemoral access an overview aortic angiogram is established. A stiff wire is then placed in the external carotid or distal common carotid artery to introduce a long hydrophilic sheath into the common carotid artery. The stenosis is then crossed with a Filter wire. For stent implantation Monorail Carotid Wallstents or the Monorail Nitinol Stent of Boston Scientific are used. Road map or overlay technique with a magnification of 20 to 28 inch is used to localize the stenosis during the procedure. Finally a control angiogram is performed to ensure correct placement of the stent. After successful completion of the procedure, the arterial access site is closed using a standard closure device.
223634006|NCT00648609|OTHER|Palliative home care in advanced COPD|Interdisciplinary palliative care team on community based self care management of advanced COPD.
223634007|NCT00648609|OTHER|Standard of care|Usual care for COPD patients
223764576|NCT05035069|DRUG|Propofol|Propofol infusion, starting with 4 \~ 5mg/kg/h until BIS value below 60 (including 60), and then 1 \~ 3mg/kg/h until the end of the operation, propofol infusion was adjusted to keep the BIS value between 40-60.
224318455|NCT06622642|PROCEDURE|Transbuccal technique for mandibular angle fracture reduction|In transbuccal technique inferior alveolar nerve block and buccal nerve block will be given by 2% xylocaine with 1:100000 adrenaline. Incision will be made with surgical blade no 15 from gingival crevices of molars to ascending ramus. Fracture segments will be reduced alongwith MMF. extraorally a stab incision will be made with scalpel blade parallel to relaxed resting skin tension lines through which the cannula with a trocar will be inserted through facial tissue down to bone. Transbuccal instrument system will cionsist of transbuccal guide, mountable retractor, drill sleeve, drill guide, and 2mm drill bit. A 2mm titanium miniplate will be placed along buccal cortex and screwed through trocar system. MMF will be removed and incision line closed
224318456|NCT01630070|DEVICE|Self-expandable drug eluting stent|Self-Expanding Paclitaxel-Eluting stent
223634008|NCT03016728|BEHAVIORAL|Physical Activity|Participants will receive a 12-week home-based physical activity program that has been individualized using their baseline assessment results. The program will be comprised of aerobic training (2 days/week) and resistance training (2 days/week). The aerobic training will be performed unsupervised. The resistance training will be performed under the supervision of a study team member (who will visit participants homes) for the first 6 weeks to ensure proper form and safety.
223634009|NCT00148317|DRUG|Bortezomib|During Induction Phase (6 cycles): Bortezomib 1.3 mg/m2 on days 1, 4, 8, and 11 During 21-day mobilization cycle (1 cycle): Bortezomib 1.3 mg/m2 on days 1, 4, 8, and 11
223634010|NCT00148317|DRUG|dexamethasone|During Induction Phase (6 cycles): dexamethasone 40 mg on days 1-4, 8-11, and 15-18
224222708|NCT04549259|BEHAVIORAL|Strengths-Based Case Management (SBCM)|The investigators have adapted an individually-tailored strengths-based case management (SBCM) intervention to help address the multiple structural barriers faced by rural older PLH. The adapted intervention, delivered by trained research staff, will include two 60-minute telephone-based SBCM counseling sessions with shorter follow-up phone calls to check-in on progress and help patients navigate identified barriers. The case manager will provide tailored sessions based on individually-identified needs and proximal life stressors. Capitalizing on participants' personal strengths, case managers will help empower participants to navigate issues related to employment, insurance, mental health, housing, or transportation. This may include assistance understanding, applying for, and accessing benefits or programs.
224222709|NCT04549259|BEHAVIORAL|Personalized Technology Detailing|Participants will be called by a technology-fluent study staff member, who will assess the current state of their technology literacy, access, and use. Detailing will focus on advancing the participant along the technology use cascade (using the internet, possessing a device and service to access internet at home, using the internet to access their electronic health record and pharmacy services, seeking HIV-related information, and finding social support). Each participant will be provided with personalized assistance based on their local and personal circumstances. Because of the individualized advice provided, there will be a range of contacts between 1 and 5, at customized intervals. Detailing protocols include the option of providing the participant with a tablet including cellular service (for 3 months) when in-home internet service is not available or is cost prohibitive.
224222710|NCT03958279|DIAGNOSTIC_TEST|Ultrasound measurement of residual volume in the urinary bladder|Aim of this study is to asses post voiding residual volume by ultrasound scan 3th day after delivery with consecutive scan after 6 weeks, and determination of data dispersion among the population of primiparas.
224222711|NCT03958279|DIAGNOSTIC_TEST|Questionnaire|Simple questionaire concerning voiding problems, infectious complications, medicaments and breastfeeding during puerperium period (6weeks)
224318457|NCT02352870|BEHAVIORAL|Computerised Cognitive Behavioural Therapy|Online treatment sessions are scheduled to last approximately one hour, completed independently by the participant on a weekly basis
224318458|NCT02352870|BEHAVIORAL|Telephone support|Telephone support calls are scheduled to last 30 minutes and and are received fortnightly at weeks: 2, 4 and 6.
223634011|NCT00148317|DRUG|liposomal doxorubicin|If patients achieve less then a PR during the induction phase after 2 cycles, or less then a CR after 4 cycles: Liposomal doxorubicin was added at 30 mg/m2 on day 4 for the remaining cycles
223634012|NCT00148317|DRUG|cyclophoshamide|During the 21 day mobilization phase (1 cycle): cyclophosphamide at 3 g/m2 on day 8
223634013|NCT00148317|DRUG|filgrastim|During the 21 day mobilization phase (1 cycle): 10 μg/kg/day for 10 consecutive days starting 24 hours after cyclophosphamide administration on day 9
223634014|NCT02700061|PROCEDURE|Robotic occupational therapy|Robotic Occupational Therapy three times a week for twelve weeks.
223634015|NCT02700061|PROCEDURE|Induced Constraint Therapy - ICT|Standard Occupational Therapy two times a week for ten weeks, followed by two whole weeks of Induced Constraint Therapy.
223634016|NCT04693819|DIAGNOSTIC_TEST|Somatic modulation|"Type of modulations: 3 jaw and 6 cervical spine modulations, 1 control movement (i.e. without any expected somatic modulation effect) Jaw modulations: laterotrusion to the left, laterotrusion to the right and protrusion Cervical spine modulations: isometric flexion, extension and left and right lateroflexion of the head against resistance of the investigator's hand, compression and traction of the cervical spine in sitting position.~Control movement: the investigator's hand rests against the patient's forehead without any force application"
223764577|NCT06364124|DRUG|evolocumab|Preoperative subcutaneous injection of Evolocumab (420mg)，Atorvastatin 40mg per day
223764578|NCT06364124|PROCEDURE|standard post-treatment for STEMI|standard post-treatment for STEMI
223764579|NCT03626116|PROCEDURE|silicone metacarpophalangeal arthroplasty (SMPA)|Replacement of the metacarpophalangeal (MCP) joint using a silicone arthroplasty
223634017|NCT06118632|OTHER|Observational|Observational
223634018|NCT06271577|DEVICE|AliveCor 12-lead ECG|The primary objective of this study is to determine if the AliveCor 12-lead Smartphone ECG is an acceptable substitute for a standard 12-lead ECG in the identification of STEMI and NSTEMI.
223764580|NCT00958776|DRUG|Peramivir+SOC|"* Adults (≥ 18 years): Peramivir (BCX-1812) 600 mg, administered intravenously, once daily (every 24 hrs) for 5 days (5 doses) in addition to institution's standard of care.~* Adolescents (12-17 years): Peramivir (BCX-1812) 10 mg/kg (not to exceed a maximum dose of 600 mg), administered intravenously, once daily (every 24 hrs) for 5 days (5 doses) in addition to institution's standard of care."
223764581|NCT00958776|DRUG|Placebo+SOC|Placebo Peramivir (BCX1812) administered intravenously, once daily (every 24 hrs) for 5 days (5 doses) in addition to institution's standard of care.
223634019|NCT00473239|DRUG|cholecalciferol.|100,000 IU of Vitamin D
223634020|NCT04398927|DRUG|Folfirinox|Systemic Chemotherapy (Oxaliplatin，5-fluorouracil and Irinotecan)
223634021|NCT04398927|DRUG|Sintilimab|Sintilimab
223634022|NCT03762811|DEVICE|NanoFUSE® Bioactive Matrix|NanoFUSE® is placed into bony voids or gaps of the skeletal system that are not intrinsic to the stability of the bony structure.
223634023|NCT04949997|OTHER|diagnose|HF was divided into HF with preserved ejection fraction, HF with median ejection fraction and HF with reduced ejection fraction.
223764582|NCT00480636|DRUG|Fragmin (dalteparin sodium )|Month 1: dalteparin 200 IU/kg SC once daily. Months 2-6: dalteparin 150 IU/kg SC, once daily.
223764583|NCT02093637|OTHER|Placebo acupuncture|Placebo Comparator
223764584|NCT02093637|OTHER|Battlefield Acupuncture|Experimental
224222712|NCT01765556|DRUG|ketoconazole|multiple doses of ketoconazole in Period B and C
224222713|NCT01765556|DRUG|vemurafenib|single dose of vemurafenib in Period A and C
224222714|NCT01988311|DRUG|psilocybin|dose manipulation as described in the protocol
224222715|NCT02600728|BEHAVIORAL|Experimental Training|"The ET consisted of 3 phases being that the first one (Phase 1) was done only in the first session.~Phase 1: patients received a short and simple explanation about the deficiency in automatic movement resulting from PD. Following explanation, the patient memorized a sequence of declarative cues. Phase 2: the patient organized a sequence of cues using cards illustrating the subcomponent movements (key movement) involved in taking steps.~Phase 3: the patient had to train using declarative cues as a gait performance aid through 8 sets follow the instruction Walk in your ordinary speed. Use the key movements and going to saying each of them while you make them. The declarative cues had to be evoked verbally by the patients themselves, during gait, triggering the corresponding movement."
224222716|NCT02600728|BEHAVIORAL|Control Training|"The CT consisted of 3 phases, being the first one (Phase 1) was done only in the first session of training, and the other two (Phase 2 and 3) were repeated at each of the 8 sessions.~Phase 1: Patients received a short and simple explanation about the deficiency in automatic movement resulting from PD.~Phase 2: Patients received a general verbal attentional instruction of pay attention to your steps and try to walk as better as you can, before starting the walk.~Phase 3: motor training of gait, where the patient had to perform 8 sets, following the instruction Walk in your ordinary speed, paying attention to your steps in the identical trajectories of ET. Additional instructions or cues were not provided."
224222717|NCT02509728|DIETARY_SUPPLEMENT|choline supplementation|in addition to standard nutrition: enteral supplementation with 30mg/kg choline chloride for 10 days
224222718|NCT02509728|DIETARY_SUPPLEMENT|DHA supplementation|in addition to standard nutrition: enteral supplementation with 60mg/kg DHA for 10 days
224222719|NCT02509728|DIETARY_SUPPLEMENT|standard nutrition|standard nutrition
224222720|NCT06303583|DRUG|paclitaxel|paclitaxel, 50 mg/m2, QW\*5
224222721|NCT06303583|DRUG|carboplatin|area under the curve of2mg/mL/min, QW\*5
224222722|NCT06303583|DRUG|tislelizumab|200mg Q3W, 2cycles
224222723|NCT06303583|RADIATION|radiotherapy|41.4Gy in 23 fractions
224222724|NCT02326428|DEVICE|Stent retriever endovascular device for thrombectomy|Thrombectomy by selected stent retrievers (TREVO, Solitaire, pREset, in special cases all stent retrievers) as additional therapy in major artery occlusion in patients fulfilling criteria for and receiving intravenous thrombolysis
224222725|NCT02326428|DRUG|Intravenous thrombolysis by alteplase (Actilyse) (optional)|Stroke thrombolysis with Alteplase (Boeringer-Ingelheim, ATC-code B01AD02; a fibrinolytic drug) according to conventional guidelines (0.9 mg/kg, not exceeding 90 mg, given intravenously)
224222726|NCT03216733|DEVICE|COMBO|PCI with COMBO stent
224222727|NCT03216733|DEVICE|ORSIRO|PCI with ORSIRO stent
224222728|NCT02519426|PROCEDURE|Mandibular third molar surgery|Mandibular third molar surgery is a mandibular wisdom tooth removal procedure in which surgical access is required to completely remove a tooth. Even if the tooth is visible in the mouth without surgically exposing it, surgical techniques may be necessary to remove the tooth. This includes sectioning the tooth into two or more pieces, corticotomy, and removal with forceps and elevators, whether or not a soft tissue incision is made.
224222729|NCT00356720|DRUG|Azithromycin|
224222730|NCT02233179|DEVICE|Removable cast walker|Offloading device that can be removed by patients.
224222731|NCT02233179|DEVICE|Irremovable cast walker|Offloading device that cannot be removed by patients.
224222732|NCT03646981|DEVICE|Leishmania Ab Rapid Test (CTK, Biotech)|Rapid diagnostic tests to detect antibodies anti-Leishmania
224222733|NCT02447536|BIOLOGICAL|BCG-Denmark 1331 (Statens Serum Institute)|See above
224222734|NCT02447536|BIOLOGICAL|BCG-Russia-I (Serum Institute of India)|See above
224222735|NCT01549288|BEHAVIORAL|modified Atkins diet|Carbohydrate restricted to 10 g/day (18-36 months) and 5 g/day (9-18 months), fat intake encouraged, proteins unrestricted
224222736|NCT01549288|OTHER|no dietetic input|continuation of anti-epileptic medication without any dietetic input
224222737|NCT04156269|BIOLOGICAL|BCMA-CS1 cCAR T cells|BCMA-CS1 cCAR T cells administered to patients, will be either fresh or thawed CAR T cells by IV injection after receiving lymphodepleting chemotherapy.
224222738|NCT00909727|DRUG|Ivacaftor|150-mg tablet given orally q12h for up to 48 weeks
224222739|NCT00909727|DRUG|Placebo|Tablet given orally q12h for up to 48 weeks
224222740|NCT02033265|PROCEDURE|Brachial plexus block|Ultrasound guided axillary brachial plexus block
224222741|NCT01136226|DRUG|Eligard (TM)|Eligard (TM) 22.5 mg administered at baseline and Month 3
224222742|NCT04120220|OTHER|Heavy Cream|Participants will receive a meal in the form of a fruit-containing shake containing 30 g of fat prepared with heavy cream.
224222743|NCT04120220|OTHER|Soybean Oil|Participants will receive a meal in the form of a fruit-containing shake containing 30 g of fat prepared with soybean oil.
224222744|NCT02553239|DEVICE|CoolLoop®|Cryoablation of Atrial Fibrillation Using the CoolLoop Cryoablation System
224222745|NCT01103557|PROCEDURE|prophylactic selective lateral neck dissection|Level II, III, IV lymph node dissection
224222746|NCT05042635|DRUG|Ixekizumab+Jueyin Granules|"Ixekizumab：160mg was injected subcutaneously at week 0 (80mg twice), then 80mg at week 2 and 4 (once).~Jueyin Granules：Put each bag of daily dose into the same container, pour about 50ml warm water into it, stir until the particles are basically dissolved, then add proper amount of boiling water to dilute it, take it warm in two times."
223634024|NCT04618536|OTHER|Inorganic sunscreen|Inorganic sunscreen will be applied evenly to 2 areas on the back of the subject with a 1 cc syringe and gloved finger in an amount of 2 mg / cm2. In the first session, one area will be irradiated 20 minutes after sunscreen application. In the second session, the other area will be irradiated after the subject has swam for 1.5 hours.
223634025|NCT04618536|OTHER|Organic sunscreen|Organic sunscreen will be applied evenly to 2 areas on the back of the subject with a 1 cc syringe and gloved finger in an amount of 2 mg / cm2. In the first session, one area will be irradiated 20 minutes after sunscreen application. In the second session, the other area will be irradiated after the subject has swam for 1.5 hours.
223634026|NCT03831152|DRUG|ADV7103|Single group assignment
224222747|NCT05042635|DRUG|Ixekizumab+Jueyin placebo Granules|"Ixekizumab：160mg was injected subcutaneously at week 0 (80mg twice), then 80mg at week 2 and 4 (once).~Jueyin placebo Granules：Put each bag of daily dose into the same container, pour about 50ml warm water into it, stir until the particles are basically dissolved, then add proper amount of boiling water to dilute it, take it warm in two times."
224222748|NCT02971410|OTHER|Laboratory Biomarker Analysis|Correlative studies
224222749|NCT02971410|OTHER|Quality-of-Life Assessment|Ancillary studies
224222750|NCT02971410|DRUG|Simvastatin|Given PO
224222751|NCT03004521|DRUG|Quetiapine|Quetipatine prescribed in addition to the patient's existing antidepressant treatment.
224222752|NCT03004521|DRUG|Lithium|Lithium prescribed in addition to the patient's existing antidepressant treatment.
224222753|NCT05825118|DIAGNOSTIC_TEST|Neutrophil/Lymphocyte ratio and lactate/ albumin ratio will be measured in all patients.|Blood will be drawn from peripheral vein, arterial or a central catheter for evaluation of whole blood count, serum lactate and serum albumin.
224222754|NCT02775890|BEHAVIORAL|Eating wild game shot with lead bullets|Participants will eat meat harvested with lead bullets, prepare mince meat and eat at least a standard serving (\>85 grams).
224222755|NCT00287287|DRUG|Lenalidomide|Initial dose is 25 mg/day dose will be adjusted accordingly as needed. Dose range for the study is 5 to 25 mg/day
224222756|NCT00225199|DRUG|Visanne (BAY86-5258, SH T00660AA)|orally once daily
224222757|NCT00225199|DRUG|Placebo|orally once daily
224222758|NCT03316859|DRUG|Naloxegol 25 MG|Naloxegol 25 mg administered 1 hour pre-operatively
224318459|NCT01181570|DRUG|Adalimumab|Patients receive adalimumab 80 mg followed by 40 mg at week 1 and 40 mg every other week (EOW) thereafter.
224318460|NCT01181570|DRUG|Placebo|Patients will receive 2 injections of placebo at week 0, one injection at week 1 and one injection every other week (EOW) thereafter.
224318461|NCT03305367|DIETARY_SUPPLEMENT|Hydrolyzed pine nut oil|Randomized cros-over intervention of 3 OGTT with no oil, low dose or high dose.
223634027|NCT04799834|OTHER|Questionnaire administration,blood sampling and genetic analyses.|"Adults (≥18 years) living in Bergamo and in all the towns of its territory shall be invited to voluntarily complete a questionnaire, with their personal data and information on SARS-CoV-2 clinical history (swab test and serologic test results, clinical symptoms, treatments, hospital care) and other previous conditions. Subjects considered fit for the genetic study will be asked to report to the Daccò Clinical Center for an interview, during which the data entered in the questionnaire will be reviewed and implemented, the informed consent for participation in the genetic investigations will be collected and blood sampling will be carried out.~Genetic: Exome sequencing and genotyping of host genome of individuals infected with SARS-CoV-2 and showing severe disease (cases), or infected with SARS-CoV-2 and showing mild disease or remaining asymptomatic, and in individuals without evidence of infection with SARS-CoV-2 (negative sierology)."
223634028|NCT03819439|OTHER|Microbiome and Autism Questionnaire|The questionnaire will be administered to collect demographic data (i.e. sex, age, race, and ethnicity) of the volunteers. Additionally, it will ask for the volunteers to identify whether or not they have autism spectrum disorder and what other medical conditions they have and what medications (e.g. prescribed, over the counter, herbal; etc.) that they take.
223634029|NCT01798043|OTHER|Cardiac MRI with pacemaker stimulation|Patient is undergoing a Cardiac MRI at enrollment and 12 months later
223634030|NCT01798043|OTHER|Cardiac MRI with and without pacemaker stimulation|Patient is undergoing a Cardiac MRI at enrollment and 12 months later
223634031|NCT01678235|DRUG|Insulin glulisine|
223634032|NCT01678235|DRUG|Insulin aspart|
223634033|NCT04273737|DRUG|Amantadine Hydrochloride|6-week long daily regimen of amantadine, twice a day, while documenting perceived effects in a diary.
223634034|NCT00045760|DRUG|Drotrecogin alfa (activated)|
223634035|NCT00967746|DRUG|Etonogestrel-releasing IUS|Low dose; treatment duration of 6 months with a possible extension to 12 months
224222759|NCT03316859|OTHER|Placebo pill|Placebo pill administered 1 hour pre-operatively
224222760|NCT00671671|DRUG|Small Molecule Agent (PF-868554)|Study drug will be administered 700mg BID in the fed state for three days.
224222761|NCT00671671|DRUG|Small Molecule Agent (PF-868554)|Study drug will be given 450mg BID for a duration of 10 days.
224318462|NCT02688660|OTHER|MRI Scans|
224318463|NCT04649944|DIAGNOSTIC_TEST|Serological test and phone interview|"Families are interviewed by telephone to gather information about the family cluster (i.e. age and number of cohabitants, their symptoms and swab results, if performed), the subject who tested positive (i.e.sex, age, course of the disease, symptoms suggestive of COVID-19) and children aged between 4 and 16 y.o. (i.e. sex, age, drug therapy and/or chronic diseases, symptoms suggestive of COVID-19).~Children, young adults and the cohabitant who previously tested positive to the swab undergo a serological test for the detection of IgG and IgM antibodies for Sars-Cov-2."
224222762|NCT04485988|DRUG|Beta blocker|Duration of medication
224222763|NCT00819728|DRUG|Docetaxel|35mg/m2 IV each week for 4 weeks
224222764|NCT00819728|DRUG|Irinotecan|50mg/m2 IV each week for 4 weeks
224222765|NCT02903433|OTHER|High-intake avocados|Families will receive 14 avocados on a weekly basis.
224222766|NCT02903433|OTHER|Low-intake avocados|Families will receive 3 avocados on a weekly basis.
224318464|NCT00313989|PROCEDURE|Evaluation of the success rate of implants|Evaluation of the success rate of implants
224318465|NCT00425763|DRUG|AQAS|AQAS dosed by body weight, on days 0, 1, 2
224318466|NCT03066258|GENETIC|RGX-314|RGX-314 is a recombinant adeno-associated virus (AAV) gene therapy vector carrying a coding sequence for a soluble anti-VEGF protein
224318467|NCT03892018|DRUG|Oraxol|Oraxol will be supplied as paclitaxel capsules and HM30181AK-US tablets.
223634036|NCT00967746|DRUG|Etonogestrel-releasing IUS|Intermediate dose; treatment duration of 6 months with a possible extension to 12 months
223634037|NCT00967746|DRUG|Etonogestrel-releasing IUS|High dose; treatment duration of 6 months with a possible extension to 12 months
223634038|NCT00967746|DEVICE|Multiload-cu 375®|Duration of 6 months with a possible extension to 12 months
223634039|NCT01029275|DRUG|Pre-treatment with octreotide|Pre-treatment with octreotide
223634040|NCT02798627|DRUG|NS2359|NS2359 is a small molecule which inhibits the reuptake of dopamine, norepinephrine and serotonin with equal affinity.
223634041|NCT02798627|DRUG|placebo|Placebo pills identical in appearance to the NS2359 will be provided
223634042|NCT00385359|PROCEDURE|aerosol drug deposition strategies|
223634043|NCT00385359|DRUG|Albuterol|
223634044|NCT05036863|BEHAVIORAL|Weekly questionnaires|Patients will complete weekly symptom monitoring PROMs. If a symptom exceeds the thresholds for clinical importance, a registered nurse will contact the patient, confirm the symptoms and coordinate the further clinical procedure in line with standard practice.
223634045|NCT05336162|OTHER|Self etch giomer based fissure sealant (BeautiSealant, Shoufu, USA)|A fissure sealant providing a physical barrier that inhibits microorganisms and food particles accumulation, preventing caries initiation, and arresting caries progression
223634046|NCT04395976|OTHER|Ayurveda|The Ayurveda intervention is multimodal and following the principles of Ayurveda as a whole medical system, each participants will be treated with individualised care. From the range of proven Ayurvedic Herbs, combination will be decided based on individual participants, his symptoms and his personality.
223764585|NCT01800292|DRUG|sildenafil|Subjects will be started on sildenafil at 20 mg PO TID at the baseline visit. Each individual will serve as his/her own control. Subjects will be evaluated at 3 months, with participation completed at that time.
223634047|NCT04448535|DIETARY_SUPPLEMENT|Gingko Biloba|oral intake of Gingko Biloba, 240mg/day for 4 weeks
223634048|NCT03821402|BIOLOGICAL|DAXI for injection 250 U|DaxibotulinumtoxinA for injection is a sterile, white to off-white lyophilized product containing the active ingredient, daxibotulinumtoxinA, and inactive ingredients to be reconstituted with sterile, non-preserved, 0.9% sodium chloride solution saline
223634049|NCT03821402|BIOLOGICAL|DAXI for injection 375 U|DaxibotulinumtoxinA for injection is a sterile, white to off-white lyophilized product containing the active ingredient, daxibotulinumtoxinA, and inactive ingredients to be reconstituted with sterile, non-preserved, 0.9% sodium chloride solution saline.
223634050|NCT03821402|BIOLOGICAL|DAXI for injection 500 U|DaxibotulinumtoxinA for injection is a sterile, white to off-white lyophilized product containing the active ingredient, daxibotulinumtoxinA, and inactive ingredients to be reconstituted with sterile, non-preserved, 0.9% sodium chloride solution saline
223634051|NCT03821402|OTHER|Placebo|Placebo is a sterile lyophilized product consisting of inactive ingredients without the neurotoxin to be reconstituted with sterile, non-preserved 0.9% sodium chloride solution.
223634052|NCT00992108|DRUG|lidocaine|1cc 1%
223634053|NCT00992108|DRUG|chemodenervation|botulinum toxin
223634054|NCT00390143|BIOLOGICAL|Meningococcal vaccine 134612|One intramuscular dose during the primary study
223634055|NCT00390143|BIOLOGICAL|Mencevax™ ACWY|One subcutaneous dose during the primary study
223634056|NCT00535639|DRUG|Betula Verrucosa allergen extract|
223764586|NCT05195320|BEHAVIORAL|Reinvention with MS|A manualized group therapy to build self-efficacy among people living with multiple sclerosis.
223764587|NCT04948138|DIETARY_SUPPLEMENT|Glutamine oral supplementation|Oral supplementation with 10-15 g/day of glutamine (adjusted for weight and plasma concentrations).
224222767|NCT02903433|BEHAVIORAL|Diet tips|Diet tips will come from educational materials including culturally appropriate dietary and nutritional education materials, and personalized recommendations taken from http://www.choosemyplate.gov.
224222768|NCT02903433|BEHAVIORAL|Avocado consumption advice|Recipe book with healthy recipe suggestions that include avocado.
223634057|NCT03755258|DRUG|GCK 100 mg + Placebo 200 mg|GCK 100 mg + Placebo 200 mg, oral, 12 weeks
223634058|NCT03755258|DRUG|GCK 200 mg + Placebo 100 mg|GCK 200 mg + Placebo 100 mg, oral, 12 weeks
223634059|NCT03755258|DRUG|GCK 300 mg|GCK 300 mg, oral, 12 weeks
223634060|NCT03755258|DRUG|Placebo 300mg|Placebo 300mg, oral, 12 weeks
223634061|NCT04639245|DRUG|Atezolizumab|Given IV
223634062|NCT04639245|DRUG|Cyclophosphamide|Given IV
223634063|NCT04639245|DRUG|Fludarabine|Given IV
223634064|NCT04639245|BIOLOGICAL|MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells|Given IV
223634065|NCT04639245|BIOLOGICAL|PD1 Inhibitor|Given IV
223764588|NCT00326911|BIOLOGICAL|cetuximab|I.V. infusion of 400 mg/m2 (over 120 minutes) on day 1 of cycle 1
223764589|NCT00326911|BIOLOGICAL|bevacizumab|10 mg/kg (over 60 minutes) on day 1 and repeated every 2 weeks.
223764590|NCT00326911|DRUG|gemcitabine|1000 mg/m2 administered intravenously at 10 mg/m2/minute over 100 minutes weekly x 3 of 4 weeks.
223764591|NCT00326911|BIOLOGICAL|cetuximab|I.V.infusions of 250 mg/m2 (over 60 minutes) weekly
223764592|NCT01530126|BIOLOGICAL|B-TCP + 0.3 mg/ml rhPDGF-BB in buffer|B-TCP mixed with sodium acetate buffer and 0.3 mg/ml rhPDGF-BB and placed into osseous defect once at baseline visit.
223764593|NCT01530126|BIOLOGICAL|B-TCP + 1.0 mg/ml rhPDGF-BB in buffer|B-TCP mixed with sodium acetate buffer and 1.0 mg/ml rhPDGF-BB and placed into osseous defect once at baseline visit.
223764594|NCT01530126|BIOLOGICAL|B-TCP +buffer|B-TCP mixed with sodium acetate buffer and placed into osseous defect once at baseline visit.
224222769|NCT01843283|BEHAVIORAL|Daily Enhancement Meaningful Activity (DEMA)|
224222770|NCT01843283|BEHAVIORAL|Information Support (IS)|
224222771|NCT02563483|BEHAVIORAL|yoga and compassion meditation program|25 min of physical exercise, holding each pose (stretching exercise) for an average of 1 min and 30 s; 25 min of breathing exercises and 25 min of meditation.
224222772|NCT02716883|PROCEDURE|AMT|"The AM was trimmed in two layers to fit the corneal ulcer and was placed with its epithelium (basement membrane) side up, secured with 10/0 nylon sutures, supported by a therapeutic contact lens. The operated eye was patched for 2 h, and then administration of the medical treatment agents was resumed.~In patients in the case group AMT was performed during days 2-5 of antibiotic therapy when initial clinical response to the treatment was observed."
224222773|NCT00295854|DRUG|MN-001 BID|Eligible patients received 500 mg MN-001 bid
223634066|NCT02083900|DEVICE|Banana Leaf Dressing|Banana leaf dressing will be prepared by cutting the mid rib of the leaf cutting the leaf into standard size of 12 x 12 inches to facilitate packing. The leaves are rolled and packed in polypropelene bags and subject to gamma irradiation or packed in paper bags for autoclaving. The Banana Leaf Dressing site will receive a single layer of banana leaf without any topical antibiotic applied to the wound followed by a layer of dry gauze for absorption of exudates. The dressing is secured with cling wrap to maintain an occlusive environment. This is then covered by rolled gauze and elastic bandage.
223634067|NCT02083900|DRUG|Hydrocolloid Dressing (DuoDERM CGF)|The donor under HCD was covered with hydrocolloid (DuoDERM CGF). The hydrocolloid dressing was cut to the size of the donor site with an overlap of at least 2 centimeter around the wound edge. After pulling off the adhesive backing, care was taken to ensure that the adhesive was in direct contact with the raw surface. This was likewise covered with a top dressing of gauze for absorption of exudates and an elastic bandage to secure dressing.
223634068|NCT01702311|DRUG|Bedtime insulin Aspart (Novolog)|Bedtime insulin aspart supplementation based on blood glucose value in the bedtime supplementation arm.
223634069|NCT04985279|DEVICE|Position and Angle Marking System|Position and Angular Marking System (PAMS) attaches on to the ultrasound probe. When the desired insertion site is identified by ultrasound, the doctor gently presses PAMS into the patient's back to create skin indentations demarcating the needle insertion point. These indentations are not affected by skin sterilisation, and may improve accuracy and reduce the time taken to perform the epidural procedure. Next, the angle between the ultrasound probe and the patient's back can be measured using PAMS, and this angle can be maintained using a needle guide during the epidural procedure.
223634070|NCT04985279|DEVICE|Standard clinical practice|When the desired insertion site is identified by ultrasound, the doctor demarcate the needle insertion point using marker pens.
223634071|NCT00690508|PROCEDURE|Supra-Sternal Tube-Tip Palpation (SSTTP)|The supra-sternal palpation of the tube after tracheal intubation.
223634072|NCT05133388|GENETIC|ARMS PCR|ARMS PCR using primer pairs that only amplify individual alleles
223634073|NCT01167075|DIETARY_SUPPLEMENT|Fresubin Original|
223634074|NCT01167075|DIETARY_SUPPLEMENT|Intestamin plus Fresubin Original|
223634075|NCT03271658|BEHAVIORAL|Web based life support patient decision aid|The web-based life support decision aid (eLSDA) was adapted from a print-based decision aid. The eLSDA includes information on the pros and cons of both life support and comfort care. The eLSDA lays out the decision about life support for an individual patient/family in a logical stepwise fashion to permit discussion, ask questions, and permit reflection on each step. At the end of the eLSDA, unmet decision-making needs are identified to seek support from the healthcare team.
223634076|NCT03271658|BEHAVIORAL|Decision coaching|During the interactive process of using the eLSDA, the study nurse provides decision coaching for patient/family, specifically a facilitated values clarification exercise.
223634077|NCT06210568|OTHER|no intervention|no intervention
223634078|NCT03079622|PROCEDURE|Electric Vacuum Aspiration|
223634079|NCT03079622|PROCEDURE|Manual Vacuum Aspiration|
223634080|NCT02404935|DRUG|Cetuximab|
223634081|NCT02404935|DRUG|FOLFIRI and cetuximab|
223634082|NCT03527459|BEHAVIORAL|SPARC B|SPARC B includes all aspects of the SPARC A clinical program, as well as targeting negative cognitions of perceived burdensomeness.
223634083|NCT03527459|BEHAVIORAL|SPARC A|SPARC A is an existing clinical program with a general focus on negative cognitions.
223634084|NCT04642027|RADIATION|Conventional sEBRT|A total dose of70 Gy in 35 daily fractions of 2 Gy during 7 weeks
223764595|NCT04605575|DRUG|Pyrotinib 320mg + Vinorelbine|pyrotinib 320mg tablets administered daily by mouth, vinorelbine(po) 80 mg/m2 weekly (following a first cycle at 60 mg/m2) administered on day 1 and day 8 of 21 day cycle. Treatment lasts for two cycles
224222774|NCT00295854|DRUG|MN-001|Eligible patients received 500 mg MN-001 once daily (qd)
224222775|NCT00295854|DRUG|Placebo|Eligible patients received placebo
224222776|NCT00035633|DRUG|Entecavir|
224222777|NCT00772577|DRUG|Aliskiren Hydrochlorothiazide|Aliskiren HCTZ 150/12.5 mg: 1 week; Aliskiren HCTZ 300/25 mg: 7 weeks
224222778|NCT00772577|DRUG|Ramipril|Ramipril 5mg: 1 week; Ramipril 10 mg: 7 weeks
223634085|NCT04642027|RADIATION|Hypofractionated sEBRT|A total dose of 60 Gy in 20 daily fractions of 3 Gy during 4 weeks
223634086|NCT01314313|DEVICE|TAVR Implantation with SAPIEN XT|Operable Group with SAPIEN XT
223634087|NCT01314313|DEVICE|SAVR Implantation|Control Group
223634088|NCT03902431|BEHAVIORAL|ABCS training|Clinicians and patients will be given information regarding the ABCS (Aspirin, Blood Pressure control,Cholesterol control, and Smoking Cessation) and for reducing CVD risk among HIV patients.
223634089|NCT00441077|BEHAVIORAL|Education|
223634090|NCT00495313|DRUG|doxycycline|COL-101, QD plus metronidazole
223634091|NCT00495313|DRUG|doxycycline|40 mg with metronidazole QD
223634092|NCT01178047|DRUG|Rasagiline|Rasagiline: 1 mg/d p.o. or Placebo one tablet p.o. once daily
223634093|NCT03916770|DEVICE|Sham vibrator|The Sham control group will have WBV the same time,in the same position with the same frequency but 99.5% weakened amplitude.
223634094|NCT03916770|DEVICE|Real vibrator|The intervention group will have WBV(frequency:30Hz,amplitude:2,2mm,at upright position
223764596|NCT04605575|DRUG|Pyrotinib 400mg + Vinorelbine|pyrotinib 400mg tablets administered daily by mouth, vinorelbine(po) 80 mg/m2 weekly (following a first cycle at 60 mg/m2) administered on day 1 and day 8 of 21 day cycle. Treatment lasts for two cycles
224222779|NCT05986877|DRUG|STSA-1201 Subcutaneous injection|Subcutaneous injection
224222780|NCT05986877|DRUG|Placebo|Subcutaneous injection
224222781|NCT00672620|DRUG|Vortioxetine|Encapsulated vortioxetine immediate-release tablets
224222782|NCT00672620|DRUG|Duloxetine|Duloxetine capsules
224222783|NCT00672620|DRUG|Placebo|Placebo-matching capsules
224222784|NCT03211156|DRUG|Amoxicillin|Amoxicillin is an aminopenicillin antibiotic
224222785|NCT03211156|OTHER|Placebo|Placebo
224222786|NCT00048360|DRUG|Extended-release bupropion hydrochloride|
224222787|NCT05671289|DIAGNOSTIC_TEST|analysis of urine volatile organic compounds|gas chromatography - mass spectrometry will be used to assess the composition of VOCs in urine samples of all participants.
224318468|NCT02784795|DRUG|LY3039478|Administered orally
224318469|NCT02784795|DRUG|Taladegib|Administered orally
224318470|NCT02784795|DRUG|Abemaciclib|Administered orally
223634095|NCT02723708|OTHER|Real-Time functional Magnetic Resonance Imaging Feedback (RTFF)|During the Activate trials, the thermometer will display the weighted average of VTA BOLD activation, dynamically updated every second. This continuously updated thermometer is the primary feedback mechanism.
223634096|NCT04254458|DIAGNOSTIC_TEST|Corneal densitometry|Corneal density values were measured by densitometry software of Pentacam HR-Scheimpflug corneal topography
223634097|NCT04035460|DEVICE|Helmet|The helmet encloses the head and neck of the patient, has a rigid ring and is secured by 2 armpit braces. A soft collar adheres to the neck and ensures a sealed connection once the helmet is inflated.
223634098|NCT04035460|DEVICE|High Flow Nasal Oxygen|Large-bore nasal prongs through which oxygen is delivered at high flow rates
223634099|NCT04291547|DEVICE|BALM|An online Behavioural Activation programme for young people with mild to moderate low mood/depression. The programme comprises 10 treatment sessions lasting 30 to 45 minutes
223634100|NCT03878563|DEVICE|Cellvisio 100 Series (fibered confocal microscopic system)|"This system is intended to allow confocal laser imaging of the internal microstructure of tissues within or adjacent to anatomical tracts, i.e. Gastrointestinal accessed trough an endoscope.~An 488-nm wavelength laser system is used, images are steamed at a frame rate of 12 frames per second, obtaining real time videos of the mucosa. In this trial we will use the Confocal miniprobe ColoFlex UHD and GastroFlex UHD."
224222788|NCT02051127|OTHER|Exercise|Physical training Duration: 45-60 minutes Frequency: 3 times per week Intensity: mean heart rate \> 75% of maximum heart rate determined by exercise test before start of the intervention
223634101|NCT00578539|DRUG|ARA C|Ara C (3000 mg/m2) IV every 12 hours for 6 doses (days -8 to -5)
223634102|NCT00578539|DRUG|Cyclophosphamide|Cyclophosphamide (45mg/kg) IV once daily on day -7 and day -6
224222789|NCT02123927|DRUG|TAK-438|TAK-438 tablets
224222790|NCT02123927|DRUG|Placebo|TAK-438 placebo-matching tablets
224222791|NCT00527189|BEHAVIORAL|Balance Exercises|Home based balance exercises based on Otago Exercise programme
224222792|NCT05813782|BEHAVIORAL|Baby Massage|Baby massage training (30 minutes) was given to primiparous mothers before they were discharged from the hospital. Baby massage training consists of sections that explain the importance of massage, preparation for massage, stages of baby massage and situations that need attention. Primiparous mothers were told to do this massage to their babies in the postpartum period. Baby massage video CD, brochure and baby oil were given to primiparous mothers for an effective baby massage.
224222793|NCT03204591|OTHER|No intervention|No intervention
224222794|NCT04893148|DRUG|IGlarLixi|Changing to iGlarLixi from insulin glargine
224222795|NCT04893148|DRUG|Dulaglutide|Add dulaglutide to insulin glargine
224222796|NCT04604665|OTHER|High frequency postural change|"Repositioning of patients hospitalized in bed in intensive care units will be carried out with a frequency interval that we call high-frequency to be performed on each patient between an interval between less than or equal to every 2 hours in a full day (24 hours) (minimum goal of 8-10 in 24 hours subtracting 2 or 4 at night and not alter the circadian cycle). The position must be modified in each postural change to right lateral, supine, left lateral, or prone to supine if the position changes every 2 hrs."
224222797|NCT04604665|OTHER|Conventional care|Repositioning of patients hospitalized will be performed in the current way it is commonly applied to patients.
224222798|NCT02598648|OTHER|FXR|FXR could elevate the transcription of RIPK3, a key protein in necroptosis, and play important role in bile aicd induced alveolar epithelial cell(AEC) necroptosis. FXR were measured in neonate with ALI、ARDS and control
224222799|NCT02598648|OTHER|RIPK3|FXR(farnesoid-X-receptor) could elevate the transcription of RIPK3, a key protein in necroptosis, and play important role in bile aicd induced alveolar epithelial cell(AEC) necroptosis. RIPK3 were measured in neonate with ALI、ARDS and control.
223634103|NCT00578539|DRUG|MESNA|MESNA (45mg/kg; divided into 5 doses) will be administered 15 minutes prior to each dose of Cyclophosphamide and 3, 6, 9, and 12 hours after each dose of Cyclophosphamide.
223634104|NCT00578539|RADIATION|Total Body Irradiation (TBI)|TBI: total dose 14.0 Gy, will be delivered in 8 fractions of 1.75 Gy in two fractions on day -4, day -3, day -2, and day -1
223634105|NCT00578539|BIOLOGICAL|Campath-1h|CAMPATH (3 mg IV for patients between 5 and 15 kg; 5 mg for patients between 16 and 30 kg; and 10 mg for patients greater than 30 kg) will be given on day -4, day -3, day -2 and day-1.
223634106|NCT00578539|PROCEDURE|Stem Cell Infusion|Stem cells are infused on day 0
224222800|NCT00448955|DRUG|ARD-0403|ARD-0403
224222801|NCT00815490|DEVICE|Desaturation|Reduction in blood oxygen saturation by sequential reduction in inspired gas composition. Steps are of 6 minutes duration with reduction in pulse oximeter oxygen saturation from 100 to 70%.
224222802|NCT04648579|DEVICE|Hillrom|Hillrom Connecta solution will record vital signs in an automated way, without the need for human intervention, and activate TRR activation when at least one criteria is met. The frequency of monitoring vital signs will be defined based on the MEWS score.
224222803|NCT04648579|OTHER|Control|Hospital usual care regarding vital signs collection and TRR activation.
224222804|NCT01616303|DRUG|Carboplatin|carboplatin (area under the curve (AUC) 6, administered intravenously in a single day for 6 cycles every three weeks \[21 days\])
224222805|NCT01616303|DRUG|Paclitaxel|Paclitaxel (175 mg / square meter, intravenously over three hours in one day to be repeated for 6 cycles every three weeks \[21 days\])
224222806|NCT01616303|BIOLOGICAL|oregovomab|oregovomab (2 mg infused intravenously jointly during the 1st, 3rd and 5th chemotherapy cycle and 12 weeks after the 5th cycle).
224318471|NCT02784795|DRUG|Cisplatin|Administered IV
224318472|NCT02784795|DRUG|Gemcitabine|Administered IV
224318473|NCT02784795|DRUG|Carboplatin|Administered IV
224318474|NCT02784795|DRUG|LY3023414|Administered orally
224318475|NCT02352688|PROCEDURE|Enhanced Colorectal Geriatric Care|
224318476|NCT00652561|DRUG|S-1|All patients will receive S-1 orally at a dose of 30 mg/m2 twice daily (BID) for 14 days followed by a 1-week recovery period, repeated every 3 weeks. The study may go to the second stage only if the stage 2 criteria are met, where 3/30 (10%) or more patients must have achieved a confirmed response (CR or PR) in stage 1.The study may go to the third stage only if at least 8/50 patients (16%) must have achieved a confirmed response in stage 2
224318477|NCT00626561|DRUG|Bevacizumab|10 mg/kg IV twice weekly on days 1 and 15.
224318478|NCT00626561|DRUG|Paclitaxel|60 mg/m\^2 IV weekly on days 1, 8, 15, and 22.
224318479|NCT00595309|BIOLOGICAL|IC51|IC51, 6 mcg, intramuscular (i.m.) booster vaccination 15 months after the primary immunization
224318480|NCT00002528|DRUG|tamoxifen citrate|20 mg daily beginning within 6 weeks of surgery for 5 years or until relapse, whichever occurs first.
224318481|NCT00002528|PROCEDURE|conventional surgery|Either total mastectomy or, optionally if the tumor was smaller than 5 cm, a breast conserving procedure (lumpectomy or quadrantectomy).
223634107|NCT05327348|DRUG|Intravenous Ascorbate|Intravenous ascorbic acid 1 gram 8 hourly (3 grams per day) over 15 minutes for 7 days since pre-operative day 1 until post-operative day 5.
223634108|NCT05327348|DRUG|Normal Saline 10 mL Injection|Intravenous 0.9% normal saline 8 hourly bolus infusion over 15 minutes for 7 days since pre-operative day 1 until post-operative day 5.
223634109|NCT04652752|DEVICE|CONNETTIVINA HI TECH patch|It is a medical device for topical application in the form of a patch with adhesive transparent polyurethane edge and a central pad impregnated with a solution of hyaluronic acid sodium salt, able to create a hydrating environment, such as to favor the natural healing process of tissue repair in case of bruises, abrasions, small cuts, superficial wounds, burns
223634110|NCT01829620|BEHAVIORAL|TAU|This is standard outpatient mental health care that is routinely provided in study site outpatient clinics.
223634111|NCT01829620|BEHAVIORAL|CCVT+TAU|"Participants in the CCVT + TAU condition will receive caring texts at 1 day, 1 week, 1, 2, 3, 4, 6, 8, 10, \& 12 months, and on their birthday. Text messages will indicate a general concern for the individual and a link to a website with general resources including behavioral health and crisis services.~Participants in both conditions will continue to receive usual behavioral health care according to standard operating procedures."
223634112|NCT04938154|DEVICE|DBS ON|The DBS system will be turned on and the patient will be left on their best setting for 3 months.
223634113|NCT04938154|DEVICE|DBS OFF|The DBS system will be turned off, and will be left off for 3 months.
223634114|NCT04106557|DRUG|Gaboxadol|OV101 versus placebo once daily at bedtime for 12 weeks
223634115|NCT04106557|DRUG|Placebo|Matching placebo capsules to OV101 capsules.
223634116|NCT04665167|BEHAVIORAL|Body image exposure|Exposure therapy is a key element of evidence-based cognitive behaviour therapy for eating disorders . Body image exposure intervention involves deliberate, planned, and systematic exposure to the body image. Participants will be asked to stand so that they can see their whole body - far enough back. Participants will be asked to look at their bodies on screen. Participants will be continually encouraged by the facilitator for looking at and talking about the body parts.
223634117|NCT04665167|BEHAVIORAL|Self-compassion|The self-compassion intervention condition consists of Neff's self-compassion exercises. These exercises are part of the self-compassion intervention condition. Meditation text used in this study is obtained from the following link https://self-compassion.org/category/exercises/.
223634118|NCT02388308|DEVICE|Clarity ultrasound|Ultrasound imaging data will be recorded only. Treatment will not be altered as a result of this study.
223634119|NCT03925285|DRUG|Bevacizumab-800CW|Two to four days prior to surgery bevacizumab-800CW will be administered intravenously
223634120|NCT01209689|DRUG|Tocilizumab|
223634121|NCT01209689|DRUG|Placebo|
223634122|NCT04812392|DEVICE|Continuous Glucose Monitoring System|Subjects will wear a continuous glucose monitoring system for 3 days during the 3 day reduced physical activity phase.
223634123|NCT03175367|DRUG|Evinacumab|SC or IV administration
223634124|NCT03175367|DRUG|Matching placebo|SC or IV administration
223634125|NCT03175367|OTHER|Background Lipid Modifying Therapy (LMT)|All participants should be on a stable, maximally tolerated statin throughout the duration of the study. The dose of statin and of PCSK9 inhibitor, such as alirocumab or evolocumab, as well as other LMT (if applicable), should remain stable throughout the study duration, from screening through the end of study (EOS) visit.
223634126|NCT00433420|BIOLOGICAL|pegfilgrastim|
223634127|NCT00433420|DRUG|cyclophosphamide|
223634128|NCT00433420|DRUG|epirubicin hydrochloride|
223634129|NCT00433420|DRUG|fluorouracil|
223634130|NCT00433420|DRUG|paclitaxel|
224222807|NCT04892459|BIOLOGICAL|Recombinant SARS-CoV-2 Ad5 vectored vaccine|This vaccine contains 5×10\^10 virus particles of recombinant replication defective human type 5 adenovirus expressing SARS-CoV-2 S protein, which is produced by CanSino Biologics Inc. It is a liquid dosage form, 0.5 ml / bottle.
224222808|NCT04892459|BIOLOGICAL|Inactive SARS-CoV-2 vaccine (Vero cell)|This vaccine contains 600 SU of SARS-CoV-2 antigen, which is produced by Sinovac Research \& Development Co., Ltd. 0.5 ml / bottle.
224222809|NCT02028000|PROCEDURE|Insorb staples skin closure|Patients will be randomized to Insorb staples skin closure and compared to Monocryl and Vicryl group.
224222810|NCT02028000|PROCEDURE|Monocryl skin closure|Patients will be randomized to Monocryl skin closure and compared to Insorb skin closure and Vicryl skin closure.
224222811|NCT02028000|PROCEDURE|Vicryl skin closure|Patients will be randomized to Vicryl skin closure and compared to Insorb and Monocryl skin closure groups.
223634131|NCT00433420|PROCEDURE|adjuvant therapy|
224222812|NCT03804099|DRUG|Aflibercept Injection [Eylea]|After instillation of topical anesthetic, sterilization of the eyelid, and instillation of 1.25% povidone-iodine drops, 2.0 mg/0.05 mL of aflibercept (Eylea) is injected into the vitreous cavity through a standard pars plana approach (3.5 mm posterior to the limbus) under sterile conditions
224318482|NCT00002528|RADIATION|radiation therapy|No radiotherapy is to be given after mastectomy. Radiotherapy is optional after breast conserving surgery according to prospectively determined guidelines within each institution. It should be given to the breast only and not to the draining node areas.
224318483|NCT00002528|PROCEDURE|Axillary clearance|Axillary node dissection.
224318484|NCT02451761|BIOLOGICAL|Blood sampling|
223634132|NCT02254135|DRUG|BEA 2180 BR - rising dose|
223634133|NCT02254135|DRUG|Placebo|
223764597|NCT04605575|DRUG|Pyrotinib plus Vinorelbine|pyrotinib administered daily by mouth（MTD）, vinorelbine(po) 80 mg/m2 weekly (following a first cycle at 60 mg/m2) administered on day 1 and day 8 of 21 day cycle, or vinorelbine(iv) 25 mg/m2 on day 1 and day 8 of 21 day cycle. Treatments will lasts until disease progression (as assessed by the investigator) or unmanageable toxicity.
223634134|NCT04909996|DEVICE|Sentinox--Group A|"GROUP A: Sentinox treatment performed 3 times/day for 5 days (as addon to the standard therapy) at 8am, 2pm and 8pm;~The application of IP on should be performed in accordance to the following indication:~The treatment is administered in a dose of 0.5 ml into each nostril (5 sprays) per the number of times per day according the trial group assigned according the randomization procedure (i.e., GROUP A: 3 times/day; GROUP B: 5 times/day; GROUP C: no IP treatment)."
223634135|NCT04909996|DEVICE|Sentinox--Group B|"GROUP B: Sentinox treatment performed 5 times/day for 5 days (as addon to the standard therapy) at 8am, 11am, 2pm, 5pm and 8pm;~The application of IP on should be performed in accordance to the following indication:~The treatment is administered in a dose of 0.5 ml into each nostril (5 sprays) per the number of times per day according the trial group assigned according the randomization procedure (i.e., GROUP A: 3 times/day; GROUP B: 5 times/day; GROUP C: no IP treatment)."
223634136|NCT06036745|DRUG|Pembrolizumab + SOX|Pembrolizumab 200mg, ivdrip, q3w; Oxaliplatin 135mg/m2, ivdrip，q3w; Trastuzumab 40 mg/m2，po bid，d1\~d14，q21d. Each cycle consists of three weeks, totaling eight cycles
223634137|NCT00732030|DEVICE|Toric IOL (SN60T3)|Each enrolled eye implanted with the AcrySof Toric Model SN60T3 intraocular lens (IOL) for the treatment of cataract.
223634138|NCT04383600|PROCEDURE|Micro-osteoperforation|three flapless micro-osteoperforations was performed distal to the maxillary canine before starting retraction.
223634139|NCT02887677|DRUG|Dapagliflozin|Administration of dapagliflozin (film-coated tablet of 10mg, per os, q24h, 12 weeks)
223634140|NCT02887677|DRUG|Placebo|Administration of placebo (film-coated tablet of same color and texture with dapagliflozin, 10mg, per os, q24h, 12 weeks).
223634141|NCT06473857|BEHAVIORAL|Mental health literacy intervention|Online interventions for adolescents and young adults on mental health literacy, 3 modalities : webconferences, build battle, serious games
223634142|NCT06473857|BEHAVIORAL|Non mental health intervention|Online interventions for adolescents and young adults on other topics, 3 modalities : webconferences, build battle, serious games
223634143|NCT01411046|DIAGNOSTIC_TEST|Synacthen test|250 microg Synacthen test, performed fasting, in the morning, starting between 08·00 and 10·30 h, after an overnight fast and a prednisolone pause of approximately 48 hours (depending on normal dose administration time).
224222813|NCT01454700|DEVICE|Insulin pump therapy (CSII) plus continuous glucose monitoring (CGM)|Randomization to 12 months with CSII plus CGM
224222814|NCT01454700|OTHER|Multiple daily insulin injections (MDI)|Randomization12 months therapy with MDI
224222815|NCT04568447|DEVICE|IMOOVE|Imoove® is a device dedicated to rehabilitation and fitness and has the capacity to increase muscle tenfold.
223634144|NCT01136161|BIOLOGICAL|RUTI|dose:5 micrograms of FCMtb (Fragmented cells of M. tuberculosis); given subcutaneously twice, on days 28 and 56.
223634145|NCT01136161|BIOLOGICAL|RUTI|dose:25 micrograms of FCMtb (Fragmented cells of M. tuberculosis); given subcutaneously twice, on days 28 and 56.
223634146|NCT01136161|BIOLOGICAL|RUTI|dose:50 micrograms of FCMtb (Fragmented cells of M. tuberculosis); given subcutaneously twice, on days 28 and 56.
223634147|NCT01136161|BIOLOGICAL|RUTI Matching Placebo|Placebo of the vaccine RUTI; given subcutaneously twice, on days 28 and 56.
223634148|NCT02151058|DRUG|Colgate® Regular Cavity Protection|Brushing twice daily with an ADA - Accepted fluoride - containing dentifrice (Colgate Cavity Protection)
223634149|NCT02151058|DRUG|Experimental Mouth Rinse|Brushing twice daily with an ADA - Accepted containing toothpaste, followed by rinsing with 10 mL for 60 seconds with the investigational product.
223634150|NCT02151058|OTHER|Crest® 3D White Multi-Care Whitening Rinse, Glamorous White, Fresh Mint|Brushing twice daily with an ADA - Accepted containing toothpaste, followed by rinsing with 15 mL for 60 seconds with the active comparator.
223634151|NCT02181777|BEHAVIORAL|GRASP|GRoup trAining for Social skills in Psychosis
223634152|NCT02181777|BEHAVIORAL|Standard care|Treatment as usual
223634153|NCT06210997|BEHAVIORAL|Questionaires|The questionnaire was done online by the participants from second to fifth-year medical students.
223634154|NCT04179669|DRUG|IBI306|Administered by subcutaneous injection
223634155|NCT04179669|DRUG|placebo|Administered by subcutaneous injection
224222816|NCT03104790|BIOLOGICAL|Fluenz Tetra (The two groups are defined by immunisation history, all receive the same intervention in the study)|live attenuated influenza vaccine (LAIV)
224222817|NCT01352650|DRUG|plerixafor|Cohort 1 will receive plerixafor at a dose of 320 mcg/kg, cohort 2 will receive plerixafor at a dose of 540 mcg/kg and cohort 3 will receive plerixafor at a dose of 810 mcg/kg. Schedule A will receive plerixafor on the 2nd and 4th cycles and Schedule B will receive plerixafor on the 1st and 3rd cycles of treatment.
224222818|NCT01352650|DRUG|decitabine|decitabine will be given to all cohorts/schedules at 20 mg/m2 IV daily for a 1-hour infusion on days 1-10 for all cycles
224222819|NCT00281294|DRUG|Fontolizumab|
224222820|NCT02203565|DRUG|Dakin's solution|Applied topically
224222821|NCT02203565|RADIATION|radiation therapy|Undergo radiation therapy
224222822|NCT02203565|OTHER|questionnaire administration|Ancillary studies
224222823|NCT02203565|OTHER|laboratory biomarker analysis|Optional correlative studies
224222824|NCT02688894|OTHER|No treatment is included in this protocol.|"Tumor tissues (fresh or archival) will be analyzed using NGS-based cancer panel, nanostring CNV, immunohistochemistry and/or FISH.~Specific methods of each molecular tests will be defined with standard laboratory manual developed by pathologists."
224222825|NCT06541366|OTHER|case-control study|physical examination and Survey Form
224222826|NCT00535522|DRUG|TAK-285 Dose Escalation Cohorts|TAK-285 50 mg tablet, orally, once or twice daily for three weeks, followed by seven days off. Dose escalation to maximum tolerated dose, with possibility of continuous dosing per cycle (daily dosing for four weeks without a break between cycles).
224222827|NCT00535522|DRUG|TAK-285 Recommended Phase 2 Dosing Cohort|Expanded cohort with dose and regimen dependent upon the safety profile of the maximally tolerated dose and schedule determined in the dose escalation phase of the study.
224222828|NCT02757586|GENETIC|shRNA|Using shRNA interfered the expression of the gene of CLL
223764598|NCT02105077|DRUG|Anesthesia with inhalative application of xenon gas|
223634156|NCT04349397|BEHAVIORAL|Medication Tracking Form|Parents will complete medication tracking form for 5 days after child's surgery. They will track medications administered, pain scores, nausea and vomiting
223634157|NCT04377893|DEVICE|Eye gaze AT intervention|"The eye-gaze AT intervention includes eye-gaze AT and service delivery to support the participants using this technology in daily life. The Tobii PCEye Mini (Tobii, Danderyd, Sweden) and specialized software are applied with adaptation to meet each child's individual needs.~To ensure the consistency of service delivery, two-day courses are conducted before the intervention. The participant's teachers or parents are invited as the main interventionist to facilitate the child's usage of eye-gaze AT in daily life under team support. The service delivery involves parents in joint goal-setting, planning, and jointly review the progress of the usage of eye-gaze AT as a family-centered practice. Individual meetings and individual supports are provided during intervention periods. The collaborative team will perform biweekly follow-up contacts during intervention periods.~The researcher will conduct the fidelity checklist every month to determine the extent of treatment integrity."
223634158|NCT03673800|OTHER|Experimental Group|Cognitive web-based training : 2 up to 30 minutes sessions a week during 6 weeks. Optional debriefing by a neuropsychologist up to 15 minutes twice a week
223634159|NCT03673800|OTHER|Control Group|Sensorial web-based training : 2 up to 30 minutes sessions a week during 6 weeks. Optional debriefing by a neuropsychologist up to 15 minutes twice a week
223634160|NCT01949818|DRUG|Yangzhengxiaoji capsule combined with CHOP regimen|Yangzhengxiaoji capsule combined with CHOP regimen(Yangzhengxiaoji capsule,Cyclophosphamide,Vincristine,Doxorubicin,Prednisone)Yangzhengxiaoji capsule ,1.56g,Tid,p.o,d7-21, Cyclophosphamide 750mg/d,ivgtt, d1;Vincristine,1.4g/m2,ivgtt, d1;Doxorubicin,50mg/m2,ivgtt,d1;Prednisone 60mg/m2,p.o, d1-5.
223634161|NCT01949818|DRUG|CHOP regimen|CHOP regimen(Cyclophosphamide,Vincristine,Doxorubicin,Prednisone) Cyclophosphamide 750mg/d,ivgtt, d1;Vincristine,1.4g/m2,ivgtt, d1;Doxorubicin,50mg/m2,ivgtt,d1;Prednisone 60mg/m2,p.o, d1-5
223634162|NCT01398709|OTHER|Slow rewarming strategy|Rewarming rate:0.24 degrees C/min.
223634163|NCT01398709|OTHER|Fast rewarming strategy|Rewarming rate:0.5 degrees C/min.
223634164|NCT02668562|PROCEDURE|Early CABG (Day 2-3 after ticagrelor discontinuation)|Timing for CABG after ticagrelor discontinuation
223634165|NCT02668562|PROCEDURE|Delayed CABG (Day 5-7 after ticagrelor discontinuation)|Timing for CABG after ticagrelor discontinuation
223634166|NCT05511233|DIETARY_SUPPLEMENT|feeding with breastmilk within 48 hours after surgery|Electronic health records of babies who feed and not fed with breastmilk within 48 hours after surgery
223634167|NCT03829228|DIETARY_SUPPLEMENT|Proglucamune|Following screening and enrollment, participants were treated with 2 tablets of Proglucamune per day for a total duration of 8 weeks. Each Proglucamune tablet contained \~100 mg ß-glucan derived from Baker's Yeast extract (Saccharomyces cerevisiae, cell wall), Reishi mushroom powder (Ganoderma lucidum), and Shitake mushroom powder (Lentinula edodes).
223634168|NCT03337477|DRUG|Placebo|Suspension administered orally for a treatment period of 24h. 2 sachets administered up to three times over 10h (at 0, 4 and 10h).
223634169|NCT03337477|DRUG|Sodium Zirconium Cyclosilicate(ZS)|Suspension administered orally for a treatment period of 24h. Single dose contains 2 sachets of ZS 5g. 10g administered up to three times over 10h (at 0, 4 and 10h).
223634170|NCT03337477|DRUG|Insulin|Insulin 0.1 units/kg administered as a bolus or for up to 30 minutes.
223634171|NCT03337477|DRUG|Glucose|Glucose 25g administered IV \<15 minutes before the insulin.
223764601|NCT05552040|BEHAVIORAL|START NOW Group|START NOW psychotherapy is a CBT, DBT and skills-based intervention
223764602|NCT04181346|DRUG|Pregabalin|antipsychotic
223764603|NCT04181346|DRUG|Placebo|Placebo
223634172|NCT03337477|DRUG|Insulin|Insulin 0.1 units/kg administered as a bolus or for up to 30 minutes.
223634173|NCT03337477|DRUG|Glucose|Glucose 25g administered IV \<15 minutes before the insulin.
223634174|NCT01896167|OTHER|Hypoxia|Inhalation of hypoxic air (8-12% oxygen content)
223634175|NCT01896167|OTHER|Placebo|Inhalation of atmospheric air
223634176|NCT05259189|DRUG|NBL-012 Injection|a single subcutaneous injection
223634177|NCT05259189|DRUG|Placebo|a single subcutaneous injection
223634178|NCT03593369|DEVICE|KLOX BioPhotonic System (single treatment)+SOC|"KLOX BioPhotonic system (composed of LumiHeal Gel and KT-L Lamp). In this study arm one treatment will be assessed - two visits per week.~Standard of Care (SOC) for wound healing will be administered during the treatment and follow-up periods (20 weeks)."
223634179|NCT03593369|DEVICE|KLOX BioPhotonic System (consecutive treatments)+SOC|"In this study arm, two consecutive treatments during the same visit will be evaluated- two visits for the first two weeks, then one visit per week.~Standard of Care (SOC) for wound healing will be administered during the treatment and follow-up periods (20 weeks)."
223764604|NCT01948375|DEVICE|real needle- placebo needle|All acupoints were needled through the pad but just pressed against the skin without penetration by pragmatic placebo needle, while through the pad and into the skin 15 mm by real needle. For each intervention, LI4 and RN12 are needled first in a supine position for 15 minutes; BL36 and BL25 are needled secondly in a prone position for another 15 minutes. After withdrawal of the needle, participants were asked to give answers on perception of skin penetration, needle sensation and acupuncture pain. Acupuncture was given every other day, three sessions for one kind of needle, six sessions in total for each subject. There was a two-day interval between the applications of two kinds of needles.
223764605|NCT01948375|DEVICE|placebo needle - real needle|All acupoints were needled through the pad but just pressed against the skin without penetration by pragmatic placebo needle, while through the pad and into the skin 15 mm by real needle. For each intervention, LI4 and RN12 are needled first in a supine position for 15 minutes; BL36 and BL25 are needled secondly in a prone position for another 15 minutes. After withdrawal of the needle, participants were asked to give answers on perception of skin penetration, needle sensation and acupuncture pain. Acupuncture was given every other day, three sessions for one kind of needle, six sessions in total for each subject. There was a two-day interval between the applications of two kinds of needles.
223764606|NCT00006475|DRUG|imatinib mesylate|
223634180|NCT03593369|OTHER|Standard of Care (SOC)|Standard of Care (SOC) for wound healing will be administered during the treatment and follow-up periods (20 weeks).
223634181|NCT06262815|PROCEDURE|Nasogastric tube placement|Conventional nasogastric tube placement done for decompression of small bowel obstruction
223634182|NCT06262815|DIAGNOSTIC_TEST|Clinical Frailty Scale|The scale described by Rockwood et al. categorizing patients \&gt;65 years of age on a 9 item scale depending on the frailty.
223634183|NCT01887327|PROCEDURE|Phototherapy|Phototherapy starts within 30 minutes before or after injection
223634184|NCT01887327|DRUG|Stannsoporfin|Stannsoporfin (3.0 or 4.5 mg/kg) administered by intramuscular (IM) injection (a shot in the muscle)
223634185|NCT01887327|DRUG|Placebo|Matching placebo administered by IM injection
223634186|NCT03027609|DRUG|AR-105|monoclonal antibody
223634187|NCT03027609|DRUG|Placebo|matching placebo (+ SOC antibiotics)
223634188|NCT04238923|DRUG|Topical vancomycin paste (1g vancomycin powder + 4mL sterile saline) and Collatamp G gentamicin-eluting sponge (Azralez Pharmaceuticals; 2.0mg gentamicin sulphate/cm2 to cover wound)|Topical vancomycin paste and gentamicin-eluting collagen sponge will be applied directly to the deep layers of the wound following reconstruction, prior to closure.
223634189|NCT00346580|DRUG|Nelfinavir|
223634190|NCT01049022|DRUG|Moxifloxacin (Avelox, BAY12-8039)|Single intravenous (IV) infusion of moxifloxacin administered over 60 minutes, at an initial dosage of 5 milligram per kilogram per body weight (mg/kg/BW) with dose escalation to 6 mg/kg in subjects of age 6 years (yrs) to less than or equal to (\<=) 14 years.
223634191|NCT01049022|DRUG|Moxifloxacin (Avelox, BAY12-8039)|Single IV infusion of moxifloxacin administered over 60 minutes, at a dosage of 7 mg/kg/BW with dose escalation to 8 mg/kg in subjects of age 2 years to less than (\<) 6 years; dose escalation was based on evaluations of the pharmacokinetic (PK) and safety data from the subjects in a preceding cohort.
223634192|NCT01049022|DRUG|Moxifloxacin (Avelox, BAY12-8039)|Single IV infusion of moxifloxacin administered over 60 minutes, at a dosage of 9 mg/kg/BW with dose escalation to 10 mg/kg in subjects of age 3 months to \< 2 years; dose escalation was based on evaluations of the PK and safety data from the subjects in a preceding cohort.
224222829|NCT03487796|BEHAVIORAL|MySTYLE|Youth and parents will receive two secure texts or emails to their cell phone or preferred device weekly (for eight weeks). Each text/email will contain a link to new media content designed to (1) improve sexual health knowledge surrounding HIV/AIDs and sexually transmitted infections, (2) increase acceptance of young Black men of all backgrounds (sexual, economic, and family), and (3) improve parent and adolescent relationships and communication.
224222830|NCT03487796|OTHER|Waitlist Control|Youth and parents will not receive intervention materials for the first four months of participation. At the completion of the 4-month follow-up assessment, youth and parents will be eligible to receive two secure texts or emails to their cell phone or preferred device weekly (for eight weeks). Each text/email will contain a link to new media content designed to (1) improve sexual health knowledge surrounding HIV/AIDs and sexually transmitted infections, (2) increase acceptance of young Black men of all backgrounds (sexual, economic, and family), and (3) improve parent and adolescent relationships and communication.
224222831|NCT04057781|PROCEDURE|Dry Needling (DN)|One to three filament needles (similar to an acupuncture needle) with no medication will be inserted into the trigger point(s) of the muscle. The needles will be repositioned a few times to make the muscle twitch (local twitch response). After several twitches occur, the researcher will leave the needles as they are, and the subject will lie on a treatment table without moving arms or head, for 10 minutes. After 10 minutes the needles are removed and discarded.
224222832|NCT04057781|PROCEDURE|Dry needling with Intramuscular electrical stimulation (DNES)|One to three filament needles (similar to an acupuncture needle) with no medication will be inserted into the trigger point(s) of the muscle. The needles will be repositioned a few times to make the muscle twitch (local twitch response). After several twitches occur, the researcher will leave the needles as they are, and attach alligator clips to the needles to provide electrical stimulus for 10 minutes while the subject lies on a treatment table without moving arms or head. After 10 minutes, the electrical stimulus will be turned off and detached, and the needles removed and discarded.
223634193|NCT02187419|OTHER|Hypnosis|"Hypnosis is a promising, but under-studied non-pharmacological treatment option for poor sleep during the menopausal transition. Hypnosis is a mind-body therapy that may be defined as a deeply relaxed state involving mental imagery and suggestion. The hypnotic state has been described variously as being an altered state of consciousness, focused attention, imaginative involvement, and role assumption.~However, it is generally agreed that hypnosis is a state or condition, which occurs when appropriate suggestions elicit distortions of perception, memory, or mood. Research has shown that most people are hypnotizable. Hypnosis intervention for managing chronic symptoms usually involves a hypnotic induction, instruction in self-hypnosis and practice using audio recordings."
223634194|NCT01434615|DEVICE|CRT|Patients who meet CRT device implantation guidelines (i.e., meet CRT indication and on optimal medical therapy) and receive CRT-P or CRT-D device
223634195|NCT01434615|OTHER|No-CRT|Patients who meet CRT device implantation guidelines (i.e., meet CRT indication and on optimal medical therapy) but who do not get a CRT-P or CRT-D device implanted
223634196|NCT05430399|DRUG|utidelone|Eligible patients will receive treatment with utidelone(40 mg/ m2 /day, D1-5,Q3W) , treated until disease progression, unacceptable toxicity or patient request for withdrawal, whichever occurs first. Each cycle is 3 weeks in duration.
223634197|NCT05430399|DRUG|docetaxel|Eligible patients will receive treatment with docetaxel (75mg/ m2/day, D1, Q3W) , treated until disease progression, unacceptable toxicity or patient request for withdrawal, whichever occurs first. Each cycle is 3 weeks in duration.
223634198|NCT00499070|GENETIC|polymerase chain reaction|
223634199|NCT00499070|OTHER|flow cytometry|For analyzing GPI deficient clones full blood will be analyzed by phenotyping using flowcytometry. For that purpose CD14, CD16 and CD24 expression will be evaluated in CD45 positive cells. Erythroid cells will be evaluated for CD55 and CD59 expression searching for clear populations with a lack of GPI-linked molecules. In addition, immunophenotyping using flowcytometry will be performed to evaluate which differentiation stages of the major hematopoietic lineages in BM and PB are associated with TCRVβ repertoire skewing. Comparison between BM and PB will identify which is the optimal compartment to analyze the responsible hematopoietic clones.
223634200|NCT00499070|OTHER|immunologic technique|
223634201|NCT00499070|PROCEDURE|biopsy|
223634202|NCT01462370|DRUG|Etoricoxib|Etoricoxib 120 mg tablet given orally for one dose.
223634203|NCT01462370|DRUG|Ibuprofen|Ibuprofen 600 mg (three 200-mg capsules) given orally up to four times a day as needed, for a maximum of 2400 mg/day.
223634204|NCT01462370|DRUG|Placebo to etoricoxib|Placebo to etoricoxib, one tablet.
223634205|NCT01462370|DRUG|Placebo to ibuprofen|Placebo to ibuprofen, up to four 3-capsule doses.
223634206|NCT01462370|DRUG|Acetaminophen 250 mg, isopropylantipyrine 150 mg and anhydrous caffeine 50 mg|Provided to participants as rescue medication. Participants may take 2 tablets at a time and up to 3 doses within 24 hours for rescue purposes.
223764607|NCT03004534|DRUG|darolutamide|Oral 300 mg tablets; 600 mg (2 x 300 mg tablets) taken twice per day, to a daily dose of 1200 mg.
223764608|NCT02440880|DRUG|Dexamethasone in addition to TAP block in dose of 4 mg|Dexamethasone in addition to TAP block in dose of 4 mg
223634207|NCT00941213|DEVICE|ultrasound scissors - Harmonic ACE|preparation with ultrasound scissors during operation
223634208|NCT00941213|DEVICE|electroscalpel (Erbe Vio 300; Aesculap AG)|preparation with electroscalpel during operation
224222833|NCT04833712|RADIATION|Stereotactic Radioablation|Stereotactic Radioablation targets on the pulmonary vein ostium aiming to achieve PVI
224318485|NCT01598194|DEVICE|Novel 22-gauge Core Biopsy Needle + Standard Biopsy Needle|Two passes performed with the standard 22-gauge or 25-gauge straight hollow core needle and two passes will be performed using the 22-gauge EchoTip® Procore™ needle. All passes will be taken from a single lesion and from the same endoscopic location.
224318486|NCT02910804|DRUG|68Ga-BBN-IRDye800CW|
223634209|NCT03036202|DRUG|Epinephrine|This is truly an observational study to determine T1/2 for epinephrine and time to peak concentration following a single dose of epinephrine in a cardiac arrest setting
223634210|NCT02224807|BEHAVIORAL|Active Comparator: Progressive Resistance Training (PRT) and a healthy diet|no additional information; see arm description
223634211|NCT02224807|BEHAVIORAL|Experimental: PRT and a healthy diet, plus weight loss|no additional information, see arm description
223634212|NCT01834989|DRUG|Insulin-like growth factor I|
223634213|NCT01834989|DRUG|Placebo|
223634214|NCT03011918|OTHER|Data Collection prior to first fall for all fallers|Weight history. Descriptive analysis of weight history in single event fallers compared to multiple event fallers. Information on use of any nutrition supplementation exposure will also be collected
223634215|NCT03011918|OTHER|Hgb value|Hgb decline. Descriptive analysis of single event fallers compared to multiple event fallers will be analyzed. Use of nutrition supplement exposure will be collected
223634216|NCT03011918|OTHER|Vitamin D|Descriptive analysis of vitamin D status of single event fallers compared to multiple event fallers will be analyzed. Use of nutrition supplement exposure will be collected..
223634217|NCT03011918|OTHER|C-Reactive Protein|Descriptive analysis of C-RP value status of single event fallers as compared to multiple event fallers will be analyzed. Use of nutrition supplement exposure data will be collected.
223634218|NCT05249556|DRUG|Ganaxolone|Ganaxolone
223634219|NCT05249556|DRUG|Placebo|Placebo (for ganaxolone)
223634220|NCT05329948|OTHER|Haptonomy application|Feeling the fetus by touching the mother's womb with meditation
223764609|NCT02440880|DRUG|Dexamethasone in combination with TAP block in dose of 8 mg|Dexamethasone in combination with TAP block in dose of 8 mg
223764610|NCT02440880|DRUG|Dexamethasone intravenous 4mg+ TAP block|Dexamethasone intravenous in addition to TAP block in dose of 4 mg
223764611|NCT02440880|DRUG|Dexamethasone intravenous in addition to TAP block in dose of 8 mg|Dexamethasone intravenous + TAP block in dose of 8 mg
224222834|NCT03252795|PROCEDURE|uterus transplantation|transplantation of a uterus from a deceased donor
224222835|NCT02129023|DEVICE|Xbox 360|For each participant in the experimental arm, two Xbox 360 exercise items were randomly selected from the nine items, which are related to user health. Each participant takes the two exercise items in turn.
224318487|NCT02910804|DEVICE|PET/NIRF|
224318488|NCT02910804|PROCEDURE|PET/NIR fluorescent imaging-guided surgery|
223634221|NCT01703143|PROCEDURE|Laser ablation|Laser ablation of focal lesions in patients with medically refractory partial epilepsy.
223634222|NCT00853307|DRUG|Alisertib|Alisertib capsules
223634223|NCT01939613|DRUG|colloids|TMMU group allows for administration of colloids early,while Parkland group infuse colloids 24 h after burn injury.
223634224|NCT00473564|PROCEDURE|da Vinci® Robotic System|Head and Neck Surgery using the da Vinci® Robotic System
223634225|NCT00674817|DRUG|400 microgrammes GSK961081|Inhaled GSK961081 administered via Dry Powder Inhaler.
223634226|NCT00674817|DRUG|1200 microgrammes GSK961081|Inhaled GSK961081 adminisntered via dry powder inhaler.
223764612|NCT02440880|OTHER|control|TAP block without Dexamethasone neither intravenous nor in combination with the block
223764613|NCT00343317|DRUG|Intrapartum Cefoxitin (2g) vs. placebo|
223764614|NCT01043796|OTHER|Insecticide treated nets and wall liners|Participants will be provided a long-lasting insecticide treated net recommended by the WHO Pesticide Evaluation Scheme. Households where participants reside will be fitted with insecticide treated wall liners.
223764615|NCT01043796|OTHER|Insecticide treated nets alone|Participants will be provided with a long-lasting insecticide treated net recommended by the WHO Pesticide Evaluation Scheme
223764616|NCT05941039|DEVICE|Vestibular training using VR followed by Control|A cross-over design will be used with group one receiving the training intervention for 6 days, a 4-day washout period, and a 6-day no-training period.
224222836|NCT02949323|OTHER|urinary stone|patients of group one have urinary stones
224222837|NCT00030108|DRUG|ixabepilone|
224222838|NCT01871779|OTHER|Standard Treadmill Exercise|Standard treadmill exercise to the point of pain twice weekly for 35-45 minutes for 12 weeks
224222839|NCT01871779|OTHER|Intermittent treadmill & resistance training|Combination of standard treadmill training and resistance training with weights twice weekly for 12 weeks
224318489|NCT01804972|OTHER|Verbal and written information|Patients will receive verbal information supplied by the attending doctor and also written information in the form of patient information leaflets
224318490|NCT01804972|OTHER|Verbal and electronic information|Patients will receive verbal information by the attending doctor and also be provided with a web address to access electronic patient information.
223634227|NCT04046913|BEHAVIORAL|Dietary education|Intervention: Low food additive diet. Control: Habitual food additive diet
223634228|NCT03040544|PROCEDURE|LTB-Curriculum|The Lübeck Toolbox (LTB) curriculum has a structured training program, in which the laparoscopic basic skills are to be learned in six consecutive exercises. In doing so, the curriculum has precise targets for each of the six exercises based on the abilities of 15 MIS experts as a benchmark. The LTB curriculum is thus a structured training program with clear objectives that enable the technical learning of MIS basic skills comparable to the expert level.
223634229|NCT03040544|PROCEDURE|Laparoscopic cholecystectomy|Performing Laparoscopic cholecystectomy by surgical residents without previous experience in MIS
223634230|NCT04169217|BEHAVIORAL|Prehabilitation|"A combination of a one off workshop and mentored prehabilitation.~Covid Pandemic amendment: The workshop was originally a group based face to face patient workshop. This intervention is now (since the first national lockdown in March 2020) a virtual workshop using a the Bluejeans platform."
223634231|NCT05021185|OTHER|Interactive Mobile Doctor (iMD)|Video educational tool
223634232|NCT04441138|DRUG|Durvalumab|Adjuvant Durvalumab in Poor Risk and/or Elderly Patients With Newly Diagnosed Stage III Non-small Cell Lung Cancer who have completed concurrent, split course chemoradiation without progression of disease
223634233|NCT01076478|DRUG|Cilostazol|100 mg, 200mg tablet Cilostazol
223634234|NCT02559453|PROCEDURE|Debridement|Removing dead tissue from infected wounds.
223634235|NCT03692624|BEHAVIORAL|Biofeedback|Heart Rate Variability Biofeedback
223634236|NCT04730700|PROCEDURE|Radiofrequency Ablation with MEE|RFA will be performed in the usual fashion utilizing the MEE instead of the RFA needles routinely used at each institution.
224318491|NCT05972369|OTHER|12-Week Tailored Exercise Intervention|12-week individually tailored exercise therapy program based on patient presentation. Supervised physiotherapy plus home exercise
224318492|NCT05034016|DEVICE|High Myopic Posterior Scleral Fixation System|Implant HM into the eye through posterior scleral reinforcement
223634237|NCT04730700|BEHAVIORAL|Conventional Medical Management|Conventional medical management (CMM), which may include physical therapy, home exercise programs, pain medication, and other conservative therapies such as back brace, walking aid, and chiropractic care.
223634238|NCT06175767|DRUG|MT101-5|Tablet
223634239|NCT00837434|DRUG|Etanercept|50 mg dose of etanercept by subcutaneous injection
223634240|NCT00837434|DRUG|Adalimumab|40 mg dose of adalimumab by subcutaneous injection
223634241|NCT00758732|DRUG|Docetaxel|Docetaxel at the dose of 75mg/m2 over a 60 min intravenous infusion every 3 weeks for a maximum of 6 consecutive cycles
223634242|NCT00758732|DRUG|Carboplatin|Carboplatin 5 AUC over a 90 min intravenous infusion every 3 weeks for a maximum of 6 consecutive cycles
223634243|NCT00758732|DRUG|Docetaxel|Docetaxel at the dose of 40mg/m2 over a 60 min intravenous infusion every 2 weeks in 28 days cycle for a maximum of 6 consecutive cycles.
223634244|NCT00758732|DRUG|Liposomal doxorubicin|Liposomal doxorubicin at the dose of 20 mg/m2 over a 90 min intravenous infusion every 2 weeks in 28 days cycle for a maximum of 6 consecutive cycles.
223634245|NCT02195765|DRUG|enamel matrix derivative|Open flap debridement associated with enamel matrix derivative
223634246|NCT02195765|PROCEDURE|Open flap debridement|Open flap debridement
223634247|NCT03350997|BEHAVIORAL|Trial 2 Exercise|During the exercise session, subjects will exercise at 65% of VO2peak. One hour after the exercise session, participants will eat a standardized dinner which will NOT include the energy expended from their exercise session (- 350 kcal).
223634248|NCT03350997|BEHAVIORAL|Trial 1 Exercise|During the exercise session, subjects will use a mouthpiece and nose clip (which will allow all of their expired air to pass through the metabolic cart for analysis of oxygen consumption and carbon dioxide production) for \~5 min at the beginning, middle and toward the end of exercise to verify they are exercising at 65% of VO2peak. This will allow us to accurately measure energy expenditure (kcal) during exercise. One hour after the exercise session, participants will eat a standardized dinner which includes the energy expended from their exercise session (+ 350 kcal).
223634249|NCT05549960|DEVICE|The medical device used in this study is a 980 nm wavelength diode laser with maximum output of 30 W (EUFOTON Laser Spectrum).|"EUS will be performed with a FUJIFILM EG- 580UT linear endoscope. LA will be performed with a 980 nm laser light (EUFOTON Laser Spectrum) guided by a 300 μm optical fiber (EUFOTON). AN EUS-21 gauge needle (Boston Scientific Expect Slimline) will be used for the optical fiber placement.~The protrusion of the fiber end from the needle tip should be 5 mm. After the correct placement of the fiber inside the tumor, the ablation treatment can start. Once inside the lesion, the needle will be slightly retracted, and the fiber will be gently pushed out of the needle tip by a length of 5 mm. The fiber will be placed at the top of the lesion, and the laser will be turned on. The laser settings estimated by the mathematical model will be used. The total number of ablations will depend on the radiological characteristics of the lesion and location. Special attention must be paid to have 1 cm between the fiber tip, the walls of the main vessels, and any metal stents that may be present."
223634250|NCT03732417|OTHER|Secondary prevention of cardiovascular risk factors|Intervention group (n=35) Control group (n=35)
223764617|NCT05941039|DEVICE|Control followed by Vestibular training using VR|Group two will follow the reverse sequence.
223764618|NCT04537806|DRUG|Brexanolone|Administered as IV infusion.
223764619|NCT04537806|DRUG|Placebo|Administered as IV infusion.
223764620|NCT02111486|OTHER|breakfast|
223764621|NCT03019627|DRUG|NGF|Eye Drop 20 μg/mL
223764622|NCT03019627|OTHER|Vehicle|Vehicle Eye Drop
224222840|NCT01492270|PROCEDURE|Prostate HistoScanning|Advanced Ultrasound assessment of the prostate
224222841|NCT01492270|PROCEDURE|Multi-parametric MRI|Multi-sequence Magnetic resonance imaging of the prostate
224222842|NCT01492270|PROCEDURE|Transperineal prostate mapping biopsy|Needle biopsy of the perineum via the transperineal route at 5mm intervals guided by the use of ultrasound.
224222843|NCT01492270|PROCEDURE|Image guided biopsies|Biopsies targeted to lesions seen at a) Prostate HistoScanning and b) mp-MRI. In men with an MRI lesion further MRI/US registration biopsies will be obtained
224222844|NCT04272775|DRUG|Ixazomib|Ixazomib capsules.
224222845|NCT04272775|DRUG|Lenalidomide|Lenalidomide capsules.
223764623|NCT04226079|DIAGNOSTIC_TEST|Collection of exhaled breath|Collection of exhaled breath will be analyzed for specific volatile organic compounds which show different distribution between groups
223634251|NCT00459316|BIOLOGICAL|Quadrivalent meningococcal conjugate vaccine|MCV4 vaccine (4 µg each of meningococcal A, C, Y, and W-135 polysaccharides conjugated to approximately 48 µg of diphtheria toxoid protein carrier ) was given by injection intramuscularly at least once and no more than three times for each participant, depending on adverse reactions.
223634252|NCT02286349|DEVICE|Transcranial magnetic stimulation (Neurosoft®)|Repetitive transcranial magnetic stimulation
223634253|NCT02286349|DEVICE|Transcranial direct current stimulation (Soterix, USA)|Transcranial direct current stimulation
223634254|NCT03922386|DEVICE|XFINE leads|Pacemaker subjects with at least one XFINE passive lead
223634255|NCT03837223|DRUG|GnRH agonist|In High Responder patients (HR) (more than 18 follicles with diameter ≥ 12mm at ovulation induction), the trigger was obtained with triptorelin 0.2 mg sc. In this cohort if less of 18 oocytes were retrieved, patients were considered at intermediate risk of OHSS and fresh transfer was performed. An adequate support of the luteal phase was initiated: HCG 1500 IU / sc the day of the pick up + estradiol 4 mg + vaginal progesterone 400 mg daily (Rescue protocol).
223634256|NCT01614886|DRUG|Active Comparator|1-step titration group begin treatment with a rivastigmine patch 9 mg/day for 4 weeks, followed by a dose increase to 18 mg/day.
223634257|NCT01614886|DRUG|ENA713|-3-step titration group will begin treatment with a rivastigmine patch 4.5 mg/day for 4 weeks, followed by a further dose increase of 4.5 mg/day at 4-week intervals up to the maintenance dose of 18 mg/day.
223634258|NCT01750151|DIETARY_SUPPLEMENT|Glucose Beverage|
223634259|NCT01750151|BEHAVIORAL|Video Game Playing|
224318493|NCT02995863|DEVICE|Rigid Rocker Sole Footwear|
223634260|NCT01750151|DIETARY_SUPPLEMENT|Control Beverage|
223634261|NCT01239953|DEVICE|Coronary angioplasty using the paclitaxel-eluting balloon|Balloon angioplasty
223634262|NCT01239953|DEVICE|Coronary angioplasty using the everolimus-eluting stent|Stent implantation
223634263|NCT03848325|BEHAVIORAL|Sleep deprivation|Eight hour opportunity for sleep followed by 24 hours of sleep deprivation.
223634264|NCT01207414|DRUG|iloperidone|Iloperidone tablets supplied at doses of 1 mg, 2 mg, 4 mg, 6 mg, 8 mg, 10 mg and 12 mg to achieve a target dose of 12-24 mg/day for 12 weeks.
223634265|NCT00761995|DRUG|Azopt|topical eye drop dosed 1 drop 3 times daily
223634266|NCT00761995|DRUG|Cosopt|topical eye drop dosed 1 drop 2 times daily
223634267|NCT04959994|DEVICE|Novel Motorized Spiral Enteroscopy|All the patients with suspected small bowel disease and an indication to undergo total enteroscopy and satisfying inclusion criteria will undergo novel motorized spiral enteroscopy
223634268|NCT01654354|DRUG|NEOVIST 370 INJ.(Iopromide 768.86mg)|
223764624|NCT04871919|DRUG|Filgotinib|Tablets are administered in accordance with the product label
223764625|NCT02904811|OTHER|Testing for Ct infection immediately|Self-taken vaginal samples will be immediately tested for Ct infection at the National Reference Centre (CNR) at University of Bordeaux, using a commercially available CE marketed real-time PCR assay.
224222846|NCT04272775|DRUG|Dexamethasone|Dexamethasone tablets.
224222847|NCT04999332|DRUG|leucovorin, oxaliplatin, docetaxel, S-1|Perioperative chemotherapy with LOTS
224222848|NCT01530685|DIETARY_SUPPLEMENT|Glycabiane|2 gelule per day for 4 months
224222849|NCT01530685|DIETARY_SUPPLEMENT|placebo|2 gelules per day for 4 months
224318494|NCT02995863|DEVICE|Therapeutic Footwear|
224318495|NCT02514902|DEVICE|Lateral Flow Device|A drop of whole blood from a finger stick is placed on the lateral flow device at two different time points to indicate the presence of a neuronal specific biomarker. The results will also be correlated to severity of clinical and radiographic injury. Separate drops are evaluated similarly for serum levels. The objective is to determine feasibility of a diagnostic tool for stroke (ischemic and hemorrhagic and traumatic brain injury (TBI). No diagnostic results or resulting treatments will be applied to any subject.
223634269|NCT01654354|DRUG|Ultravist 370 INJ.(Iopromide 768.86mg)|
223634270|NCT01008020|DIETARY_SUPPLEMENT|tea catechin extracts|Tea catechin extracts 540 mg/day, are consumed for 5 months.
223634271|NCT03520998|DRUG|GRF6019|GRF6019 for IV infusion
223634272|NCT03997188|DEVICE|Hepilor|ZLC oral suspension and placebo were both started on Day 1 of RT-HeT and ended when RT was completed or at the onset of dysphagia.
223634273|NCT02032017|PROCEDURE|Ceramic on ceramic couple|All patients will get a standard total hip replacement (cementless hydroxyapatite coated cup and a titanium plasmasprayed stem) with a ceramic on ceramic (third generation biolox delta) couple. Preoperative leg length and offset are marked to reconstruct the preoperative leg length and to obtain the optimal offset.
223634274|NCT02032017|PROCEDURE|Percutaneous assisted approach|
223634275|NCT02032017|PROCEDURE|Anterolateral approach|
223634276|NCT02032017|OTHER|Usual care|Both groups will receive usual care (UC) after surgery. This includes standard physiotherapy care consisting of mobilizing and strengthening techniques. All patients will receive a booklet containing information about the surgery, weight bearing after the surgery, and rehabilitation in general.
224222850|NCT02507206|DRUG|DAR 0-100A|15 mg DAR 0100A is dissolved in 150 cc NS administered over 30 minutes intravenously.
224222851|NCT02507206|DRUG|Placebo|15 mg DAR placebo is dissolved in 150 cc NS administered over 30 minutes intravenously.
224222852|NCT05166993|DEVICE|MostCareUp|Pressure transducers have been connected to the MostCareUp and the hemodynamic parameters compared as follows: no filter, electronic filter, no electronic filter plus Accudynamic (our reference system). Invasive pressure values have been then compared with the non-invasive ones.
224222853|NCT02197533|OTHER|Written List|Written list of seven management strategies for OAB to be produced during verbal discussion about management.
224222854|NCT00124020|DRUG|Telavancin|Telavancin 10 mg/kg/day IV for up to 21 days
224222855|NCT00124020|DRUG|Vancomycin|Vancomycin 1 Gm administered every 12 hrs IV for up to 21 days
224222856|NCT03650582|DRUG|Glucagon|Intranasal glucagon
224222857|NCT03650582|DRUG|Placebo|Intranasal placebo
224222858|NCT00418873|DRUG|Zotepine|Oral
224222859|NCT00418873|DRUG|Risperidone|Oral
224222860|NCT04665674|OTHER|Standard of care|Standard of car of pulmonary Langerhans cell histiocytosis (PLCH)
224222861|NCT03872037|PROCEDURE|Selective removal of carious tissue and restoration with Maxxion|Molars subjected to selective removal and restored with Maxxion
223634277|NCT05073874|OTHER|Functional Near-Infrared Spectroscopy (fNIRS)|The hemodynamic response in prefrontal cortex will be measured using an Octomon+ system (Artinis). Eight emission and two detector probes will be arranged on the participant's forehead.
223634278|NCT05738642|DRUG|4 factor Prothrombin Complex Concentrates|Cluster 4 f - PCC by intravenous infusion (boya 4 f - PCC, a bottle of 400 IU) : 25 IU/kg dose infusion time: as soon as possible after admission infusion, at the latest within 2 hours after admission to infusion infusion method: Sodium chloride injection 5% glucose injection was diluted into 50 ml per bottle, and then intravenous infusion was carried out with a blood transfusion device with a mesh device. The infusion was finished in 60-120 minutes
223634279|NCT03071588|DEVICE|Mechanical rotary burs|A rotary drill made of steel or diamond impregnated materials attached to a steel shank, available in varying degree of sharpness, lengths and sizes used conventionally in preparation of teeth to receive a dental restoration.
223634280|NCT03071588|DEVICE|Carisolv gel|A chemical gel made of a combination of amino acids and sodium hypochlorite used with hand instruments to soften and remove the decay to prepare the tooth to receive a dental restoration.
223634281|NCT01459211|DRUG|Lenalidomide & Dexamethasone|"Subjects with relapsed or refractory CLL will receive twelve 28-day cycles of treatment. Each cycle will consist of:~1. Oral Dexamethasone (20mg daily, days 1-4),~2. Oral Lenalidomide on days 1-28 of each cycle, starting at 5mg per day in cycle 1 in patients with creatinine clearance ≥ 60ml/min calculated by Cockcroft-Gault. The dose will be increased to 10mg per day with cycles 2-12 unless there is evidence of disease progression or unacceptable drug toxicity"
223634282|NCT04514185|DEVICE|Passive industrial exoskeleton for the upper limb|The goal is to compare the human response to the simulated industrial tasks
223634283|NCT04514185|OTHER|The protocol will be performed without exoskeleton|The protocol will be performed without exoskeleton
223634284|NCT03826303|OTHER|E-cigarette liquid with ethanol, 1 puff|E-cigarette liquid with ethanol, 1 puff
223634285|NCT03826303|OTHER|E-cigarette liquid without ethanol, 1 puff|E-cigarette liquid without ethanol, 1 puff
223634286|NCT03826303|OTHER|E-cigarette liquid with ethanol, 10 puffs|E-cigarette liquid with ethanol, 10 puffs
223634287|NCT03826303|OTHER|E-cigarette liquid without ethanol, 10 puffs|E-cigarette liquid without ethanol, 10 puffs
223634288|NCT03466814|OTHER|Non-Interventional|Non-Interventional
223634289|NCT00043316|DRUG|interferon gamma-1b|500 or 1000 mcg, inhalation, 3x per week
223634290|NCT03697252|DRUG|Xanomeline and Trospium Chloride Capsules|Xanomeline 50 mg/trospium 20 mg BID on days 1-2 followed by xanomeline 100 mg/trospium 20 mg BID on days 3-7. The dose is increased to xanomeline 125 mg/trospium 30 mg BID on days 8-34 unless the subject is experiencing adverse events from the xanomeline 100 mg/trospium 20 mg dose. Subjects who were increased to xanomeline 125 mg/trospium 30 mg will have the option to return to xanomeline 100 mg/trospium 20 mg depending on clinical response and tolerability. Dosing must not change after Visit 7 of the study (at 21 ± 2 days of dosing) and may be decreased for tolerability reasons no more than once during the study.
223634291|NCT03697252|DRUG|Placebo Capsules|Placebo Capsules
223634292|NCT01713920|DRUG|SEVIKAR|
223634293|NCT02928042|OTHER|Lactobacillus bacteria|Antimicrobial effects of Lactobacillus bacteria (LAB) and nisin bacteriocin on pathogen bacteria and commercial strains of the same bacteria's growth rate will be investigated.
223634294|NCT05879185|BIOLOGICAL|XmAb23104|XmAb23104 (10 mg/kg) intravenously on days 1 and 15 of each 28-day cycle. XmAb23104 will be administered by IV infusion at a constant rate over 1 hour.
223634295|NCT00403520|DRUG|Experimental 1|Drug: Donepezil Hydrochloride 10 mg orally for 12 months
223634296|NCT00403520|DRUG|Placebo Comparator|Drug: Placebo Matching placebo orally for 12 months
223634297|NCT06296069|OTHER|exergame-based cognitive-motor training on an unstable surface|"The intervention group will receive an exergame-based cognitive-sensorimotor intervention on an unstable surface (by placing the exergame device (Senso) on an unstable surface).~The Senso is a platform for the dynamic recording of steps, weight shifts and other body movements producing forces. For the labile condition, the Senso is mounted on steel balls, allowing the platform to swing freely along the horizontal plane. There is no movement induced by the platform itself. Sway is only induced when the participant steps and shifts the center of pressure. The degree of instability and movement of the platform can be adjusted by inducing a dampening. The dampening can be set manually, either to on or off. When damping is on, the movement can be reduced by predefined percentages. The maximum displacement of the platform is thereby 100 mm to each side."
223764626|NCT02904811|OTHER|Testing for Ct infection at the end of the study|Self-taken vaginal samples will be tested for Ct infection at the end of the study (M18).
223764627|NCT01433224|GENETIC|DNA methylation analysis|
223764628|NCT01433224|GENETIC|RNA analysis|
223764629|NCT01433224|GENETIC|mutation analysis|
223764630|NCT01433224|GENETIC|nucleic acid sequencing|
223764631|NCT01433224|GENETIC|polymerase chain reaction|
223764632|NCT01433224|GENETIC|polymorphism analysis|
223764633|NCT01433224|OTHER|laboratory biomarker analysis|
224222862|NCT03872037|PROCEDURE|Control|Molars subjected to selective removal and restored with Ketac Molar Easymix
224222863|NCT04701697|DRUG|Recombinant Human Albumin Injection|Participants will receive Recombinant Human Albumin Injection of intravenous infusion
224222864|NCT04701697|DRUG|HumanAlbumin|Participants will receive HumanAlbumin of intravenous infusion
224222865|NCT01051609|OTHER|History and Physical Exam|The physical exam includes vital signs and ECOG performance status.
224222866|NCT01051609|OTHER|Grip Strength Measurement|A hand grip strength test will be used to measure and compare baseline and post-AI treatment forearm muscle strength in each hand.
224222867|NCT01051609|BEHAVIORAL|Surveys|Self-administered surveys including Health Assessment Questionnaire Disability Index, CES-D, FACIT-F, PSQI, GAD7, number of minutes of morning stiffness, and questions pertaining to vasomotor symptoms will be used in this study to assess for presence, severity, characteristics, and associations of AI-associated musculoskeletal symptoms.
224318496|NCT04812808|DRUG|Bazedoxifene 20 mg|"Bazedoxifene will be administered during the duration of the study in the experimental arm together with chemotherapy.~Prophylactic rivaroxaban (Xarelto®) 10 mg per day orally will be added to avoid thromboembolic events."
224222868|NCT01051609|OTHER|Blood Collection|A set of blood markers will be assayed at baseline, 6 months, and 12 months.
223634298|NCT06296069|OTHER|exergame-based cognitive-motor training on an stable surface|"The control group will receive an exergame-based cognitive-motor intervention on an stable surface using the exergame device Senso.~The Senso is a platform for the dynamic recording of steps, weight shifts and other body movements producing forces."
223634299|NCT04111380|DRUG|cisplatin and nab-paclitaxel|Nab-paclitaxel, 130mg/m2, d1,d8, Cisplatin, 20mg/m2, d1-3 ,3week, 4-6 cycles.
223634300|NCT04031105|DEVICE|Theta-burst stimulation (TBS)|"intermittent (iTBS) and continuous (cTBS) will be applied at an intensity of 70% or 100%\* resting motor threshold (RMT) on the dorsolateral prefrontal cortex, position F3 (EEG 10-20 international system)~\*The optimal %RMT will be evaluated in a pilot study before commencement of the main study"
223634301|NCT05683028|BEHAVIORAL|Cognitive Control Training|Cognitive Control Training (CCT) makes use of a very basic cognitive task that strongly loads on working memory and cognitive control processes, namely the adaptive Paced Auditory Serial Addition Task (aPASAT) where participants are given a number every 3 seconds and are asked to add the number they just heard with the number they heard before. Task difficulty is modified based on the participants current task performance, allowing training of cognitive control. Participants in the intervention group will start the CCT training after completion of ECT with a maximum time interval of 7 days. Training sessions will be performed on a tablet or computer and participants will complete five sessions per week (20 minutes per session) for a period of two weeks.
223634302|NCT05683028|BEHAVIORAL|Active Control|Participants in the active control group will start placebo training after completion of ECT with a maximum time interval of 7 days. The placebo task consists of a task similar to the experimental condition but that does not train cognitive control. Prior research confirmed that this condition controls for non-specific effects of the training and motivational issues. Participants will perform the sessions on a tablet or computer and complete five sessions per week (20 minutes per session) for a period of two weeks.
223634303|NCT06371612|OTHER|Standard Care|Parental Presence
223634304|NCT06371612|OTHER|Adhesive Remover Spray|Parental Presence + an alcohol-free silicone-based aresol spray for medical use
223634305|NCT06371612|BEHAVIORAL|Ball Squeezing + Adhesive Remover Spray|Parental Presence + an alcohol-free silicone-based aresol spray for medical use + squeezing the stress ball
224222869|NCT01051609|PROCEDURE|Ultrasound of Hand/Wrist|An inflammatory arthritis ultrasound scoring method similar to the RAMRIS scoring system used in rheumatoid arthritis, will evaluate joints in the most affected hand and wrist at 6 months.
224222870|NCT02043366|DRUG|Normal Saline|Normal Saline is intravenously administrated before anesthesia induction
224222871|NCT02043366|DRUG|Butorphanol|Butorphanol is intravenously administrated
223634306|NCT01341834|DRUG|LBH589 and RAD001|Dose escalation of LBH589 tablets (5 and 10 mg) and RAD001 tablets (2.5, 5 mg and 10mg)
223634307|NCT05246592|PROCEDURE|Branches Sparing|The patients will undergo axillary lymph node dissection with preserved axillary vein branches
224222872|NCT02043366|DRUG|Flurbiprofen axetil|Flurbiprofen axetil is intravenously administrated
224222873|NCT02043366|DRUG|Remifentanil|Remifentanil is intravenously administrated
224222874|NCT02043366|DRUG|Sufentanil|Sufentanil is intravenously administrated
223634308|NCT05246592|PROCEDURE|None Branches Sparing|The patients will undergo axillary lymph node dissection without preserved axillary vein branches
223634309|NCT02340026|OTHER|Dynamic Supported Mobility|Dynamic weight support; Child-directed; No assistive devices, limited use of orthoses, no treadmill; Encourage high degree of error with reduced physical assistance; Encourage frequent variability in motor tasks (no redirection when moving from one activity to another); Physical therapist expertise is focused on designing a salient and challenging environment for the child's specific interests and ability level to encourage engagement, variability, challenge, and error experience, and on determining the appropriate amount of weight assistance
223634310|NCT02340026|OTHER|Conventional Therapy|"No or static weight support; Therapist-directed (therapist initiates); Traditional early gait training methods: use of assistive devices/orthoses and may use treadmill; Focus on producing typical movement patterns with extensive manual guidance/correction from therapist, prevention of falls; Therapy activities grouped into blocks of practice (i.e. repeated floor to stand practice followed by gait training); Physical therapist expertise is focused on designing and directing the specific practice activities each session, tailored to the individual child"
223634311|NCT05199337|DRUG|ZN-d5|ZN-d5 will be administered orally
223634312|NCT06772376|DIAGNOSTIC_TEST|SERS sensor based on CHA reaction|1\. Screening interested participants should sign the appropriate informed consent (ICF) prior to completion any study procedures. 2. The investigator will review symptoms, risk factors, and other non-invasive inclusion and exclusion criteria. 3. The following is the general sequence of events during the 3 months evaluation period: 4. Completion of baseline procedures Participants were assessed for 3 months and completed all safety monitoring.
223634313|NCT05911984|DRUG|9MW3811 Injection|Intravenous injection
223634314|NCT06312150|OTHER|Analysis of peripheral blood (control group)|Peripheral blood sample will be acquired in excess to the last scheduled control sample according to clinical practice.
224222875|NCT06542965|OTHER|Non-Interventional Research|Non-Interventional Research
224222876|NCT02079792|PROCEDURE|Lying Head Back Position|Subjects randomized to the LHB position will be instructed to lay supine on the clinical table, with their head hanging over the edge of the bed as far as possible without discomfort.
224222877|NCT02079792|PROCEDURE|Head Down and Forward Position|Subjects randomized to the HDF position will be instructed to kneel down, placing the top of their head on the ground and forehead close to the knees with the nostrils facing upwards.
224222878|NCT00521248|DRUG|buprenorphine|sublingual buprenorphine administered every 8 hours, titrated to control of abstinence symptoms
224222879|NCT00521248|DRUG|Oral morphine solution|0.4 mg/kg/day morphine every 4 hours
224222880|NCT04572568|OTHER|Multi-disciplinary assessment|"1. Comprehensive evaluation by multidisciplinary experts;~2. Preoperative multi-modal imaging examination was applied to determine the angioarchitecture, functional fiber bundle, and hemodynamics."
224222881|NCT01127581|DRUG|MVI 200|Dose reservoir of 200 mcg of misoprostol in a hydrogel polymer vaginal insert within a retrieval system. The MVI 200 will be kept in place for up to 24 hours or will be removed earlier if one of the following occur: onset of active labor, intrapartum adverse event necessitating discontinuation of the study drug, other reasons including maternal request.
223634315|NCT06312150|OTHER|Analysis of biological sample (Substudy-solid neoplasms)|peripheral blood sample, bone marrow aspirate and fresh or paraffin biopsia tissutale will be collected for the substudy
223634316|NCT06312150|OTHER|Analysis of biological sample (substudy-leukaemia patients)|sample of peripheral blood and bone marrow blood for the substudy, derived from paediatric or young adult leukaemia patients
223634317|NCT05582434|DRUG|Adapalene Gel|Single topical treatment arm topical to be applied daily to area affected
223634318|NCT05582434|DRUG|Adapalene Gel and the clindamycin phosphate/benzoyl peroxide gel|Two topical treatments will be dispensed and instructions to apply daily to affected area
223634319|NCT05582434|DRUG|adapalene, benzoyl peroxide gel, and clindamycin phosphate gel every day.|Three topical treatments will be dispensed and instructions to apply daily to affected area arm.
223764634|NCT01433224|OTHER|medical chart review|
223634320|NCT01058980|PROCEDURE|Additional ablation until elimination of dormant conduction|Additional RF energy will be delivered at sites of re-conduction on the circular mapping catheter in each PV. Abolition of the dormant conduction will then be assessed by repeated injections of adenosine using the same doses previously used to reveal dormant conduction. Additional ablation as described will be performed until re-injection of adenosine shows no re-conduction in any of the PV.
224222882|NCT01127581|DRUG|Dinoprostone Vaginal Insert (DVI)|Dose reservoir of 10 mg of dinoprostone in a hydrogel polymer vaginal insert within a retrieval system. The DVI will be kept in place for up to 24 hours or will be removed earlier if one of the following occur: onset of active labor, intrapartum adverse event necessitating discontinuation of the study drug, other reasons including maternal request.
224222883|NCT00772564|DRUG|Atorvastatin|Oral Atorvastatin
224222884|NCT02727036|DIETARY_SUPPLEMENT|Pumpkin seed oil|1 gram capsule of Pumpkin seed oil.
224222885|NCT02727036|DIETARY_SUPPLEMENT|Pumpkin seeds|4.1 grams (1½ teaspoons/\~0.15ounces) of pumpkin seeds
224222886|NCT01313390|DRUG|docetaxel|
224222887|NCT01313390|DRUG|everolimus|
224222888|NCT01313390|OTHER|laboratory biomarker analysis|
224222889|NCT01313390|OTHER|pharmacological study|
224222890|NCT01567215|PROCEDURE|silver nitrate|Application 1 - 2 times a week for 3 - 4 weeks
224222891|NCT01567215|DRUG|Steroids|Dermovate creme group IV steroid. Application 2 times a day for 3 weeks or less if the granuloma disappears.
224222892|NCT01567215|PROCEDURE|alcohol|Alcohol swabs 82% ethanol. Application 6 - 8 times a day, each time the parents change the diaper. Treatment for 3 weeks or less if the granuloma disappears.
224222893|NCT00891774|DEVICE|EVOLENCE®|Single injection of material into the mid-dermis of the wrinkle - Second 'touch-up' injection is permitted approximately 14-Days later if needed to achieve satisfactory results
224222894|NCT05488184|DIETARY_SUPPLEMENT|Flavoured Oral Nutritional Supplement (ONS)|Sensory analysis of different ONS of sweet (pineapple, tropical, brownie) and acid flavoured (tomato, ham)
224222895|NCT00004143|DRUG|Campath, Chemo and/or TBI Allo SCT|Allogeneic PBSC/marrow will be collected/harvested from the donor after granulocyte colony-stimulating factor (G-CSF) priming. The allogeneic PBSCs will be infused as per current institutional practice.
223634321|NCT01058980|PROCEDURE|No additional ablation|Presence of dormant PV conduction, no additional ablation.
223634322|NCT01058980|PROCEDURE|Registry group|Among those who will be found not to have the presence of dormant conduction, and within each site, three-quarters of the patients will be randomly selected to be included in the registry group.
223634323|NCT01058980|PROCEDURE|Usual medical care|Clinical follow-up will be performed according to the regular follow-up after AF ablation procedures in each of the participating centers. No data will be collected after discharge.One-fourth of the patients will be randomly selected to be included in the usual medical care group.
223634324|NCT05614531|GENETIC|EXG001-307 injection|non-replicating, rAAV vector based on AAV9 containing cDNA encoding the human SMN protein.
223764635|NCT02424240|OTHER|IGF-1/IGFBP-3 ratio|IGF-1/IGFBP-3 ratio for the diagnosis of GHD Vs. IGF-1, IGFBP-3 and IGF-1 \& IGFBP-3 combination
223764636|NCT00934206|BEHAVIORAL|Endurance training|running / walking at 60 % heart rate reserve 4 times per week for 4 weeks
224222896|NCT05045209|OTHER|Virtual rehabilitation|Patient who are assigned to this group will receive virtual rehabilitation
224222897|NCT03175120|DRUG|Insulin degludec/liraglutide|Administered subcutaneously (s.c., under the skin) once daily in combination with metformin for the treatment duration of 26 weeks.
224318497|NCT05224609|DRUG|Lorlatinib|Single 100mg oral dose anti-cancer agent
223634325|NCT04854174|DRUG|ZN-d5|Oral agent; 25 mg formulation
223634327|NCT02380573|DRUG|Methylene Blue|
223634328|NCT02380573|DRUG|FD&C Blue # 2|
223634329|NCT02380573|DRUG|Phenazopyridine hydrochloride|
224222898|NCT03175120|DRUG|Insulin degludec|Administered subcutaneously (s.c., under the skin) once daily in combination with metformin for the treatment duration of 26 weeks.
224222899|NCT01140074|DRUG|Zinc Sulfate|Zinc Sulfate in sugar sirup will be given orally in dosis of 10-20 mg per day for 10 days
224222900|NCT01977092|BEHAVIORAL|Motivational interviewing case management|
224222901|NCT01977092|BEHAVIORAL|Resource referrals|
224222902|NCT00954967|BEHAVIORAL|Lifestyle Counseling|The intervention is based on lifestyle advice, motivational interviewing and the use of medications, using the Clinical Practice Guidelines of the Catalan Institute of Health. Health professionals in the intervention group receive a training on the abovementioned techniques.
224222903|NCT00477828|DEVICE|Continuous positive airway pressure|
224222904|NCT02099279|DEVICE|echocardiography examination|patients underwent echocardiography examination
224222905|NCT03038113|DRUG|RO7062931|Administered subcutaneously in Parts 1 and 2. Part 1 will be administered in single-ascending doses after 0.1 mg/kg starting dose. Subsequent doses of 0.3, 1, 2 and 4 mg/kg may be administered based upon tolerability. In Part 2a, participants will receive two monthly doses of either 0.4, 0.8, 1.2 times the saturation dose or placebo. In Part 2b, a dose selected from Part 2a will be administered to participants randomized into 4 cohorts QW or Q2W. In Part 2c, participants will receive RO7062831 QW on top of another therapy for up to 24 or 48 weeks.
223634330|NCT04797585|OTHER|Laparoscopic supracervical hysterectomy|Laparoscopic supracervical hysterectomy
223634331|NCT04797585|OTHER|Vaginal hysterectomy|Vaginal hysterectomy
223634332|NCT02738801|DRUG|GLPG1690 600 mg QD|GLPG1690 capsules, administered at a dose of 600 mg, orally QD
223634333|NCT02738801|DRUG|Placebo QD|Matching placebo capsules, administered orally QD
223634334|NCT02516696|DRUG|Clarithromycin|500mg PO twice daily on days 1-28 for a 28-day cycle.
223634335|NCT02516696|DRUG|Lenalidomide|25 mg PO days 1-21 followed by a 7 day rest period for each 28-day cycle
223634336|NCT02516696|DRUG|Dexamethasone|20 mg PO on Days 1, 8, 15, and 22 for each cycle for subjects 75 years and younger.
223634337|NCT04990024|OTHER|Dietary Intervention Med Diet|The diet will consist of a calorie-restricted Med diet, with 500 Kcal/d energy restriction. The intervention consists of individual and reinforcement sessions on Med diet. During these sessions, the RA will go over the benefits of Med diet, what composition it should have, and how to make appropriate choices for meal planning, in addition to providing food lists, by season. The individual sessions with subjects will also allow to individualize the diet plan.
224222906|NCT03038113|DRUG|Placebo|Part 1 cohorts: active drug vs placebo 4:1. Part 2a 4 parallel cohorts of 3 active drug doses and placebo in 1:1:1:1. Part 2b active drug vs placebo in 3:1 in 2 parallel cohorts.
224222907|NCT03038113|DRUG|Immune Modulator|Participants in Part 2c will receive an immune modulator subcutaneously QW for up to 48 weeks.
224222908|NCT01461200|OTHER|Swab of vestibule and middle meatus of nose|Swabs of vestibule and middle meatus of nose will be taken prior to and during the grass/tree allergy season
224222909|NCT03258359|BIOLOGICAL|PACTN|To treat patients with MDS who have failed treatment with hypomethylating agents or have relapsed after treatment with hypomethylating agents or have declined hypomethylating therapy.
224222910|NCT06136052|OTHER|Forms|All participants filled out a case evaluation form including demographic information, information about headache complaints, and scores of the questionnaire results. Participants completed the Tampa Kinesiophobia Scale (TKS) for kinesiophobia assessment. The International Fall Efficacy Scale (IFES) used in our study is a questionnaire consisting of 16 questions that provide information about the level of fear of falling during daily life activities. In our study, the visual analog scale (VAS), one of the most commonly used, oldest, and best validated scales, was used to measure pain intensity. The short form of the International Physical Activity Questionnaire (IPAQ)- consisting of seven questions- was used in our study. The Quality of Life Scale for Children (QoLSC) is a general quality of life scale that is widely used in research and evaluates the physical and psychosocial experiences of children between the ages of 2 and 18.
224222911|NCT05817799|DRUG|L-Carnitine 500Mg thrice daily|L-Carnitine 500mg oral thrice daily
224222912|NCT05817799|DRUG|1g L-Carnitine IV three times a week|1g IV L-Carnitine three times a week
224222913|NCT01235052|RADIATION|Positon Emission Tomography using 18F-FMISO|We will introduce a pretherapy \[18F\]-FMISO PET-CT in the treatment planning of patients suffering of head and neck cancer and eligible to a radical treatment with curative intent, consisting of conformational radiotherapy with or without chemotherapy or associated targeted therapy. \[18F\]-FMISO PET-CT results will not be taken into account for the patients' management. We will test different acquisition protocols and use a wild panel of quantification parameters issued from published studies and originals 'one developed by our team enable to describe \[18F\]-FMISO uptake. Patients will be followed clinically and para-clinically during two years after the end of the treatment according to the edited recommendations of these tumours type and grade to analyze outcome.
223634338|NCT04990024|OTHER|Dietary Intervention HP/LC Diet|This is a non-ketogenic diet consisting of ad libitum intake of proteins, fat, and vegetables, with restriction of daily carbohydrates to \<130 g/d. The intervention consists of individual and reinforcement educational sessions on HP/LC, same as with Med diet (above). The individual sessions with subjects will also allow to individualize the diet plan.
224222914|NCT00514137|DRUG|sunitinib malate|Oral 37.5 mg each day of the 6-week cycle (continuous dosing).
224222915|NCT00170885|DRUG|Everolimus|
224222916|NCT02307409|OTHER|Sonoclot/TEG test|The Sonoclot/TEG test will be done at the study time points. Within 12 hours of presentation in the emergency department, at 72 hours, and at 7 days, or when the patient meets the study criteria for suspected or proven sepsis
223634339|NCT00352768|DRUG|Fluvoxamine maleate|Test product: Fluvoxamine maleate 25mg tablet. In case that the daily dose is one tablet, the study medication will orally be administered once daily, at bedtime. In case that the daily dose is two tablets or higher (maximam:6 tablets), the study mmedica
223634340|NCT00352768|DRUG|Placebo|Placebo
223634341|NCT03715556|DRUG|Amiodarone|Administration of the drug will be blinded within the first 48 hours for the principal investigator. Amiodarone (5 mg / kg EV in 30 minutes) will be the drug of choice in the Restricted group blinded to the principal investigator. If there is no reversal / control and there is no adverse event, a further dose of the same previously administered medicinal product will be performed within 30 minutes, amiodarone 3 mg / kg. After the second dose, continuous infusion of amiodarone at a dose of 900 mg in 24 hours will be initiated.
223634342|NCT03715556|DRUG|0.9% physiological solution|Administration of 0.9% physiological solution.
223634343|NCT00647764|DRUG|SNX-5422 Mesylate Hsp90 inhibitor|dose escalated, tablets twice a week; undetermined duration until disease progression
223634344|NCT00593346|RADIATION|brachytherapy|brachytherapy (radioactive implants)
223634345|NCT04069234|DRUG|Ticagrelor|ticagrelor 60 mg BID for 30 days
223634346|NCT04069234|DRUG|Clopidogrel|clopidogrel 75mg OD for 30 Days
223634347|NCT01282034|PROCEDURE|Marrow stimulation - Drilling or Microfractures|"Subchondral drilling consists in penetration of the subchondral bone endplate and creation of holes, and it is mostly indicated for the treatment of osteochodral lesion.~Microfractures (MF), according to Steadman's technique, are one of the most used first-line treatment for cartilage injuries, and commonly considered safe and effective."
224222917|NCT01698320|DRUG|Placebo MDPI|Placebo MDPI (multi-dose dry powder inhaler) to match the active intervention.
224222918|NCT01698320|DRUG|Albuterol MDPI|Albuterol MDPI (multi-dose dry powder inhaler or Spiromax®) 90 mcg/inhalation.
224222919|NCT01952574|DRUG|Erenumab|Administered by study site staff once a month (QM) as a subcutaneous injection
224222920|NCT01952574|DRUG|Placebo|Administered by study site staff once a month (QM) as a subcutaneous injection
223634348|NCT01282034|DEVICE|MaioRegen Surgery|MaioRegen® (is a bioceramic, multi-layered scaffold, in a single gradient structure, consisting of deantigenated Type I equine collagen and Magnesium enriched-Hydroxyapatite, able to mime the entire osteocartilaginous section. MaioRegen® is able to promote the tissue regeneration in case of severe and large chondral/osteochondral lesions.
223634349|NCT02731469|BIOLOGICAL|BCD-131|
223634350|NCT02731469|BIOLOGICAL|Mircera®|
223634351|NCT02731469|BIOLOGICAL|Aranesp®|
223634352|NCT03696836|DEVICE|Trammpolin® meniscus prosthesis|Trammpolin® meniscus prosthesis is an anatomically shaped, synthetic medial meniscus replacement
224318498|NCT05467787|BEHAVIORAL|Message-based psychotherapy (MBP)|Message-Based Psychotherapy (MBP) allows patients to chat with an assigned licensed therapist as frequently as they wish. After consumers complete an intake and select a therapist, the consumer can begin chatting with their therapist right away, and as often as they wish. Therapists respond to text within 15 minutes to an hour during office hours, and within 14 hours outside of office hours. Thus, MBP is not fully synchronous. This enables therapists to deliver care to a larger number of patients than is possible under synchronous methods by disentangling the therapist's time from the patient's time to respond. It also has the potential to improve quality as it gives the therapist time to think through the most effective response and intervention. MBP will be based on CBT, PST or IPT intervention strategies.
224318499|NCT05467787|BEHAVIORAL|Video-chat Psychotherapy (VCP)|Video Chat Only (VCP) consists of weekly psychotherapy appointments that last between 30-45 minutes. These sessions are conducted using Agora, a secure, HIPAA-compliant video conferencing service that is seamlessly integrated into the Talkspace platform application. Therapists will provide evidence-based treatments for depression and anxiety.
223634353|NCT02364375|DEVICE|Menai mask (full face)|Prototype mask system (full face variant) with novel vent and humidification system
223634354|NCT02364375|DEVICE|Menai Standard mask (full face)|Prototype mask system (full face variant) with conventional vent and humidification system
223634355|NCT02364375|DEVICE|Menai mask (nasal)|Prototype mask system (nasal variant) with novel vent and humidification system
223634356|NCT02364375|DEVICE|Menai Standard mask (nasal)|Prototype mask system (nasal variant) with conventional vent and humidification system
223634357|NCT02364375|DEVICE|Menai mask (pillows)|Prototype mask system (pillows variant) with conventional vent and humidification system
223634358|NCT02364375|DEVICE|Menai Standard mask (pillows)|Prototype mask system (pillows variant) with conventional vent and humidification system
223634359|NCT01670344|PROCEDURE|Treatment with investigational method (virtual implant positioning system)|
223634360|NCT01670344|PROCEDURE|Treatment with surgical standard of care|
223634361|NCT05310955|OTHER|daily rehabilitation interventions|including Naikan therapy, Morita therapy, group art therapy, group painting therapy
223634362|NCT05310955|OTHER|shen-based Qigong exercise|a 12-week intervention of shen-based Qigong exercise : exercise 5 days a week, about 30 minutes a day
223634363|NCT03481400|DRUG|Calcitonin Gene-Related Peptide|Calcitonin gene-related peptide intravenous infusion (1.5 micrograms/min for 20 mins)
223634364|NCT03481400|OTHER|Placebo|Isotonic saline
223634365|NCT04663763|DRUG|PD-1 antibody|Sintilimab is a humanized IgG4 monoclonal antibody against the programmed death-1 (PD-1) receptor. Usage: 200mg ivgtt d1 q3w.
223634366|NCT04663763|DRUG|Capecitabine|Usage: 1000mg/m2 d1-14 q3w
223634367|NCT04663763|DRUG|Oxaliplatin|Usage: 130mg/m2 d1 q3w
223634368|NCT02302599|BIOLOGICAL|Umbilical cord mesenchymal stem cells|Infusion treatment
223634369|NCT02302599|BIOLOGICAL|Controlled suspension liquid|Infusion treatment
223634370|NCT04049786|PROCEDURE|Digestive biopsy|All patients with indication for RYGB bariatric surgery undergo to endoscopy before and after the surgery as standard protocol. Digestive biopsy are being performed in obese and post-RYGB patients for transcriptomic analysis
223634371|NCT04049786|DRUG|Carvedilol 25mg|Single-dose of carvedilol 25 mg are being administrated orally.
223634372|NCT04049786|PROCEDURE|Serial blood sampling for PK analysis|Serial blood samples are being collected at times 0, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 15, 18 and 24 hours after drug administration for PK evaluation .
223634373|NCT04049786|DRUG|Metoprolol 100 mg for CYP2D6 phenotyping|Metoprolol is being used as probe drug to evaluate CYP2D6 activity. Single-dose of metoprolol 100 mg are being administrated orally.
223634374|NCT04049786|DRUG|Simvastatin 40mg|Single-dose of simvastatin 40 mg are being administrated orally.
223634375|NCT04049786|DRUG|Midazolam 2 mg for CYP3A4 phenotyping|Midazolam is being used as probe drug to evaluate CYP3A4 activity. Single-dose of midazolam 2 mg are being administrated intravenous.
223634376|NCT04049786|OTHER|Genotyping|Patients are being genotyped for the main SNP on CYP2C9, ABCB1, SLCO1B1 and CYP2D6 genes using blood samples
223634377|NCT05324462|DRUG|IDegLira|Collecting data reported in medical records of patients with T2D, who had initiated treatment with commercially available IDegLira according to the routine clinical practice and local label at the discretion of the treating physician
223634378|NCT04964180|DRUG|Indomethacin suppository|two 100 mg indomethacin rectal suppositories 2 hours prior to surgery
223634379|NCT04964180|DRUG|Lidocaine 2% Injectable Solution|200 ml saline containing 200 mg 2%lidocaine intraperitoneal insilltation
223634380|NCT00888134|DRUG|Selumetinib|Given PO
223634381|NCT03183869|DRUG|Fecal microbiota|fecal microbial transplantation
223634382|NCT06500390|DIAGNOSTIC_TEST|Examination of temporomandibular joint and masticator muscles|The TMJ and the masticatory muscles were evaluated by the same clinician. Patients described symptoms such as preauricular pain, limited mouth opening, deviation or deflection during mouth opening, and joint sounds. All patients were assessed using Okeson's Muscle and temporomandibular joint examination and treatment outcome form. This form records (for both TMJ) tenderness and pain in the masseter, temporalis, lateral pterygoid, medial pterygoid, sternocleidomastoid, trapezius, splenius capitis, and digastric muscles, as well as maximum interincisal distance, restriction of laterotrusion and protrusive movements, joint sounds, deviation or deflection during mouth opening, and the visual analogue score (VAS) for pain in the TMJ.
223634383|NCT04827407|DEVICE|Efferon LPS hemoperfusion|Hemoperfusion using continuous extracorporeal LPS adsorption with Efferon LPS therapeutic device during a period of 24h immediately following admission to the intensive care unit
223634384|NCT06400758|OTHER|questionary|"A questionnaire, based on the main sexual health topics frequently discussed, was given to students by the school management prior to an intervention.~The preventive intervention consisted of comprehensive prevention on the emotional and sexual lives of adolescents. It was carried out by health professionals and was based on questions from the students, who were able to leave their questions anonymously in a box in the school infirmary for several months.~These questions were collected and used to identify several themes for discussion:~emotional life, with notions of affection, love, friendship and the notion of normality, as well as consent and sexual violence physical and sexual aspects, with reminders of the menstrual cycle, contraception, sexually transmitted infections, pregnancy and abortion.~The same questionnaire was given to students after the intervention, to check whether the prevention intervention had improved their general knowledge."
224222921|NCT01952574|DRUG|Erenumab PFS|Erenumab supplied in a single-use prefilled syringe for self-administration in the CHU substudy
223634385|NCT05633602|DRUG|Chemotherapy|Receive standard of care chemotherapy
223634386|NCT05633602|BIOLOGICAL|Pembrolizumab|Given IV
223634387|NCT05633602|BIOLOGICAL|Ramucirumab|Given IV
223634388|NCT05928936|DRUG|Sodium Bicarbonate|Participants take 650-1300 mg of sodium bicarbonate orally twice daily. Serum bicarbonate levels are measured at baseline and then every 2-4 weeks throughout the trial. Doses will be adjusted or held to avoid metabolic alkalosis.
223634389|NCT05928936|BEHAVIORAL|Exercise Training|"Exercise training consists of progressive, interval-based Spin exercise on stationary bicycles three times per week for 12 weeks, led by a certified exercise physiologist. The duration of each session begins at 20 minutes and is increased by 1 to 2 minutes as tolerated to a goal of 45 minutes per session. Exercise intensity begins at low levels (50% of maximal heart rate reserve (HRR)) and increases by 5% every week to a goal of 75% maximal HRR. Each session includes a 5-min warm up, then an interval-based, work-out phase that includes steady up-tempo cadences, sprints, and climbs, followed by a 5-minute cool down."
223634390|NCT05928936|DRUG|Placebo|Participants take placebo pills to match 650-1300 mg of sodium bicarbonate orally twice daily.
223634391|NCT06008795|DRUG|Pterygopalatine Fossa Nerve Block with Ropivacaine and Dexamethasone|Each PPF-active nerve block will consist of 20mg (4ml) ropivacaine plus 4mg (1ml) dexamethasone
224222922|NCT01952574|DRUG|Erenumab AI/Pen|Erenumab supplied in a single-use autoinjector/pen for self-administration in the CHU substudy
223634392|NCT06008795|PROCEDURE|Placebo Pteryogpalatine Fossa Injection|Each placebo PPF-injection will consist of 5ml normal saline
224222923|NCT05158491|DRUG|JK-1201I|JK-1201I will be given every 3 weeks, maximum of 4 treatment cycle.
223634393|NCT06092450|OTHER|develop and validate a deep learning radiomics model based on preoperative enhanced CT image|develop and validate a deep learning radiomics model based on preoperative enhanced CT to predict postoperative survival in MIBC
223634394|NCT05085353|PROCEDURE|non-obstetric acute general surgical disease|non-obstetric acute general surgical disease
223634395|NCT03728465|BIOLOGICAL|Nivolumab|In the induction phase of this study nivolumab is administered as a IV infusion in combination with ipilimumab at a dose of 1 mg/kg for 4 cycles at three weeks interval and in a maintenance phase alone at a dose of 3 mg/kg every two weeks.
223634396|NCT03728465|BIOLOGICAL|Ipilimumab|In the induction phase of this study ipilimumab is administered as a IV infusion in combination with nivolumab at a dose of 3 mg/kg for 4 cycles at three weeks interval.
223634397|NCT02425410|OTHER|Collect of data on viral environment of T1D patients|Questionnaires on viral events during mother's pregnancy and patient's childhood, health book copies, addresses' geolocation, quantification of viral exposures using Sentinel Network data
223634398|NCT02425410|GENETIC|Collect of blood samples for DNA extraction and genetic characterization (GWAS)|Collect of blood samples for DNA extraction and genetic characterization (GWAS) on Illumina platform (Centre National de Genotypage)
223773665|NCT06983262|OTHER|Milled PEEK Stent|A CBCT will be performed to assess the anatomy of the subnasal area and plan the position, size, shape and thickness of the PEEK Stent. These data will be transferred to a 3D planning software to generate a digital model. Eventually, the PEEK stents will be milled in a milling machine and sterilized in ethylene oxide before the surgery. Local anesthesia will be administered into the vestibular mucosa along the extension of the anterior maxilla. VISTA technique begins with a vestibular access incision in the midline frenum and 2 bilateral incisions at premolar area. A periosteal elevator will be introduced through the incision and inserted between the bone and periosteum to elevate the tissue, creating a subperiosteal tunnel, extending distally based on the dynamic of the smile. The PEEK stent will be in one piece. They will be placed onto the bone and stabilized with 2 bone graft screw for each side. The midline incision and the lateral incisions will be sutured primarily.
224222924|NCT01189240|DRUG|gamma-secretase/Notch signalling pathway inhibitor RO4929097|Given orally
223634399|NCT04202848|DIAGNOSTIC_TEST|Flora analysis|diversity and abundance of bacteria in patients who received malignant tumors
224222925|NCT01189240|BIOLOGICAL|bevacizumab|Given IV
224222926|NCT01189240|OTHER|laboratory biomarker analysis|Correlative studies
224222927|NCT01189240|OTHER|pharmacological study|Correlative studies
224222928|NCT02692430|OTHER|No intervention is studied|
224222929|NCT03522740|OTHER|Decision Aid for Renal Therapy|DART is a web-based decision aid that informs older adults with advanced kidney disease of kidney disease treatment options and prompts them to consider their preferences and raise questions to discuss with their kidney disease providers.
224222930|NCT01264211|DRUG|Diacerein|Week 0 to Week 4: Diacerein 50 mg daily for 4 weeks Week 4 to Week 24: Diacerein 100 mg daily for 20 weeks
224222931|NCT01264211|DRUG|Placebo|Week 0 to Week 4: Diacerein 50 mg daily for 4 weeks Week 4 to Week 24: Diacerein 100 mg daily for 20 weeks
224222932|NCT04726917|BEHAVIORAL|Pulmonary rehabilitation|Patients qualified for rehabilitation were assessed for stress levels as well as symptoms of anxiety and depression before rehabilitation began
224222933|NCT03107351|DEVICE|Cardiac contractility assessments with Kino-cardiograph|Cardiac contractility will be assessed with Kino-cardiograph device. Echocardiography will also be used for the experimental arm
223634400|NCT05776940|DRUG|Live Combined Bacillus Subtilis and Enterococcus Faecium Enteric-coated Capsules combined with Bortezomib+Dexamethasone/Bortezomib+Dexamethasone+Daratumumab/single Daratumumab|Naive al amyloidosis patients receive Bortezomib+Dexamethasone, Bortezomib+Dexamethasone+Daratumumab or single Daratumumab therapy combined with Live Combined Bacillus Subtilis and Enterococcus Faecium Enteric-coated Capsules(250mg/time, bid,up to 3 months).
223634401|NCT05776940|DRUG|Bortezomib+Dexamethasone/Bortezomib+Dexamethasone+Daratumumab/single Daratumumab|Naive al amyloidosis patients receive Bortezomib+Dexamethasone, Bortezomib+Dexamethasone+Daratumumab or single Daratumumab therapy without any probiotics (Blank Control).
223634402|NCT03293108|DRUG|Denosumab|Denosumab 60 mg is subcutaneously administered to osteoporotic patients at baseline, month 6 and month 12.
224222934|NCT03107351|DEVICE|Cardiac assessment repeatability with Kino-cardiograph|Cardiac contractility will be assessed with Kino-cardiograph device only, at different times of the day to assess the repeatability of the measures.
223634403|NCT03293108|DIETARY_SUPPLEMENT|calcium|All women will receive daily supplements containing at least 1000 mg of elemental calcium (divided in two doses), during 18 month of the study.
224222935|NCT04585555|DEVICE|Accuryn Monitoring System|The Accuryn Monitoring System is a novel Foley catheter and monitoring device capable of detecting physiologic changes in vital signs via sensors within the catheter system. These data are captured non-invasively, continuously, and at a high frequency.
224222936|NCT05733650|BIOLOGICAL|Epcoritamab|Eligible patients will receive epcoritamab (28-day cycle) that will be administered as subcutaneous (SC) injections until disease progression, or one or more of the treatment discontinuation criteria are met.
224222937|NCT01916564|OTHER|Split-dose|"2 tablets of bisacodyl 5 mg at 8 p.m. two days before colonoscopy~Low fibre diet and 2 tablets of bisacodyl 5 mg at 8 p.m. on the day before colonoscopy~1-L PEG-ELS between 8 p.m. and 8.30 p.m. on the day before and 1-L PEG-ELS between 5.30 a.m. and 6 a.m. on the day of colonoscopy"
224222938|NCT01916564|OTHER|Same-morning whole-dose|"2 tablets of bisacodyl 5 mg at 8 p.m. two days before colonoscopy~Low fibre diet and 2 tablets of bisacodyl 5 mg at 8 p.m. on the day before colonoscopy~2-L PEG-ELS between 5 a.m. and 6 a.m. on the day of colonoscopy"
224318500|NCT05991869|BEHAVIORAL|Point-of-care decision support intervention|"PCPs notified by EHR messages if they had an upcoming in-person or video visit with an eligible patient who had a predicted risk of incident HIV diagnosis of 0.2% or higher. Study team members manually sent messages marked as high priority one business day prior to scheduled visits, alerting PCPs that a patient may be at increased risk for acquiring HIV and may benefit from a conversation about PrEP. Additional information was provided about the study, the prediction model, clinical indications for PrEP, strategies for initiating discussions about HIV prevention and PrEP, and how to refer patients to KPSF's PrEP program. Messages did not include the numeric predicted HIV risk from the model. PCPs received a maximum of two messages per day; with the two patients with the highest predicted risk were selected. Patient with multiple visits were flagged no more than once monthly."
223634404|NCT03293108|DIETARY_SUPPLEMENT|vitamin D|All women will receive daily supplements containing at least 400 IU vitamin D daily during 18 month of the study.
223634405|NCT02233777|DRUG|Pregabalin capsules 150 mg of Dexa Medica|Each capsule contains 150 mg of pregabalin. Test product was given as a single dose, under the procedure as described in the Section: Detailed description of the study.
223634406|NCT02233777|DRUG|Pregabalin capsules 150 mg of Pfizer Manufacturing Deutschland|Each capsule contains 150 mg of pregabalin. Reference product was given as a single dose, under the procedure as described in the Section: Detailed description of the study.
224222939|NCT00386724|DEVICE|Precision Spinal Cord Stimulation System|Precision System aids in the management of chronic intractable pain of the trunk and/or limbs, including unilateral or bilateral pain associated with the following: failed back surgery syndrome, intractable back pain, and leg pain.
224222940|NCT00386724|DEVICE|Artisan Surgical Lead|Artisan paddle electrode is a 2 x 8 surgical lead approved for use as part of the Precision System.
224222941|NCT03564925|PROCEDURE|Wide area circumferential ablation|Wide area circumferential ablation with contact force catheter will be performed in Patients allocated in this group,the induction of atrial fibrillation by isoproterenol or programmed stimulation and burst pacing will be performed. If frequent atrial premature beats are found beyond pulmonary vein, activation mapping will be performed for eliminating the triggers. If atrial tachycardias(ATs)are induced, activation mapping the ATs and ablation will be performed. Electrical isolation of pulmonary veins and elimination the triggers and ATs induced by isoproterenol or programmed stimulation and burst pacing are the endpoints of ablation
224222942|NCT03564925|PROCEDURE|Cryoballoon ablation|In the cryoballoon procedures, pulmonary vein isolation (PVI) was achieved using fluoroscopic guidance to position the cryoballoon catheter. Once PV-to-balloon occlusion was confirmed by retrograde radiopaque contrast agent retention, circumferential ablation was performed by freezing with a single-shot delivery of coolant to the balloon.
224222943|NCT00502541|DRUG|fluocinolone acetonide|fluocinolone acetonide 0.59 mg intravitreal implant
224222944|NCT00502541|PROCEDURE|Standard of Care|Repeat macular grid laser or observation
224222945|NCT02477904|OTHER|Ketogenic Diet|Dietary
224222946|NCT02501239|BEHAVIORAL|Accept Yourself!|
224222947|NCT02501239|BEHAVIORAL|Weight Watchers|
224222948|NCT02232503|GENETIC|Studied cohort|For the purpose of DNA isolation prior to genetic analysis of patients two samples of peripheral blood will be taken; first in the volume of 3.5 ml and second in the volume of 9 ml from each patient included into the study.
224222949|NCT06123403|DIAGNOSTIC_TEST|blood methotrexate level and Cystatin C level|blood methotrexate level and Cystatin C level
224222950|NCT01475188|DRUG|Allergovit|commercially available grass pollen allergoid (100%), concentration A (1000 TU/ml, therapeutic units/ml)concentration B (10000 TU/ml).Patients were given subcutaneous injections with initial dose of 0.1 ml (concentration A) was increased once a 7 (+7) days until the highest tolerated dose (0.6, concentration B) was reached and SIT was continued with injections once every 4 - 6 weeks up to two years.
224222951|NCT01475188|OTHER|placebo|placebo administered with the same scheme and doses as specific subcutaneous immunotherapy
224318501|NCT01666769|DRUG|Micafungin|4 mg/kg/day
224318502|NCT01666769|DRUG|Micafungin|8 mg/kg/day
224318503|NCT01666769|DRUG|Micafungin|Standard of care Dosing
224318504|NCT05291338|DRUG|Doxorubicin|no optimal dosage of doxorubicin in TACE procedures (ranging from 30 to 75 mg/m2 up to a maximum of 150 mg/m2 ) according to tumor size
223764637|NCT06133543|PROCEDURE|Robot-assisted ICG-guided sentinel lymph node biopsy|The robot-assisted ICG-guided sentinel node (SN) biopsy is conducted as follows: At the start of the operation, indocyanine green (ICG) solution is transscrotally injected into the testicular parenchyma. The patient is positioned in the nephrectomy posture. After port placement and docking of the robotic system, the sentinel node(s) should be visible with the fluorescence camera. The SN is removed and sent for immediate frozen section biopsy evaluation. The inguinal orchiectomy is performed subsequently until the biopsy results are available. If the biopsy is negative, the procedure concludes. If the biopsy shows viable tumor, indicating clinical stage IIA and the indication for systematic unilateral retroperitoneal lymph node dissection. The patient was informed about the potential expansion of the procedure upon study enrollment. After the procedure, all patients are placed under observation and do not receive adjuvant systemic treatment. The follow-up period extends to 2 years.
223764638|NCT00479908|DRUG|Sildenafil citrate|
223764639|NCT00479908|DRUG|Glyceryl trinitrate|
223634407|NCT06140589|DRUG|Cadonilimab|The intravenous dose of Cadonilimab was 10mg/kg, and every 3 weeks was a course of treatment; Or 6mg/kg, every 2 weeks for a course of treatment
223634408|NCT06256406|OTHER|in the field of rehabilitation and neonatal care: the combination of Kangaroo care method and music therapy|Kangaroo care is a practice involving skin-to-skin contact between the infant and a caregiver,. Music therapy is a therapeutic approach that utilizes the expressive and emotional qualities of music to address physical, emotional, cognitive needs of individuals.
223634409|NCT01488890|BIOLOGICAL|Live, attenuated, recombinant dengue serotypes 1, 2, 3, and 4 virus|0.5 mL, Subcutaneous
223634410|NCT01488890|BIOLOGICAL|Live, attenuated, recombinant dengue serotypes 1, 2, 3, and 4 virus|0.5 mL, Subcutaneous
223634411|NCT01488890|BIOLOGICAL|Live, attenuated, recombinant dengue serotypes 1, 2, 3, and 4 virus|0.5 mL, Subcutaneous
223634412|NCT01488890|BIOLOGICAL|Yellow Fever|0.5 mL, Subcutaneous
223634413|NCT06417424|DEVICE|gastrointestinal external stimulation|We used the device Gastrointestinal multifunctional therapeutic instrument. The positive pole was placed 1 to 2cm above the umbilicus, and the negative pole was placed 4 to 10 cm to the right of the midpoint between the xiphoid process and the umbilicus.
223634414|NCT05712460|DRUG|sisunatovir|Sisunatovir is an orally administered RSV F-protein inhibitor being developed to target viral-host cell fusion for the treatment of adult and pediatric patients with RSV
223764640|NCT03009240|DRUG|Decitabine|Given IV
223764641|NCT03009240|OTHER|Laboratory Biomarker Analysis|Correlative studies
223764642|NCT03009240|DRUG|Pevonedistat|Given IV
223634415|NCT05712460|DRUG|Placebo|Placebo for sisunatovir
223764643|NCT03009240|OTHER|Pharmacological Study|Correlative studies
223764644|NCT04606693|OTHER|Treatment of SAHS|Patients diagnosed with SAHS will be treated in the Pneumology Service according to usual practice (dietary hygienic measures, CPAP, etc.).
223764645|NCT03366350|PROCEDURE|Allogeneic hematological stem cell transplantation|Patients receive allogeneic hematological stem cell transplantation after they achieve MRD- CR through CAR-T therapy.
223764646|NCT00807781|BIOLOGICAL|Mammaglobin-A DNA vaccine|
223764647|NCT05114291|OTHER|Explorations are planned as part of the one-day hospitalization|"* Clinical parameters : Interrogation, physical examination, morphological data measurements (weight, height, waist circumference, hip circumference) and impedencemetry (body composition).~* Biological samples : Blood and urine exam, fasting urine sample (urinary osmolarity)~* Standardized blood pressure measurement :~  * After 5 to 10 minutes of rest, with automated measurements at 1 minute intervals : un-attended, then attended~* Hemodynamic parameters :~  * Sphygmocor® : measure of the central blood pressure and pulse wave velocity~ * MESI® tool : measure of the Systolic Pressure Index (PSI or IPS)~ * pOpmetre® : Calculation of the speed of the pulse wave by the pOpmetre® device~* Others : if indicated (echocardiography, ABPM)"
223764648|NCT02953821|DRUG|Acthar Gel|1 mL (80 Units) given by a shot under the skin (via subcutaneous injection)
223634416|NCT05376150|DRUG|XEN1101 10 mg|XEN1101 oral capsule
223634417|NCT05376150|DRUG|XEN1101 20 mg|XEN1101 oral capsule
223634418|NCT05376150|DRUG|Placebo|Placebo capsule
223634419|NCT05077215|DRUG|EG-007|A Repurposed Drug
223634420|NCT05077215|DRUG|Pembrolizumab 100 mg/ 4 ml (25 mg/ml) Injection|Pembrolizumab will be provided as a sterile, preservative-free, clear to slightly opalescent, colorless to slightly yellow solution that requires dilution for intravenous infusion. Each vial contains 100 mg of pembrolizumab in 4 mL of solution.
223634421|NCT05077215|DRUG|Lenvatinib Capsules|Lenvatinib will be provided as 4-mg and 10-mg capsules. Lenvatinib is formulated with calcium carbonate, mannitol, microcrystalline cellulose, hydroxypropylcellulose, low-substituted hydroxypropylcellulose, and talc.
223634422|NCT02233686|DRUG|XEN-D0501|
223764649|NCT02953821|DRUG|Placebo Gel|1 mL (0 Units) given by a shot under the skin (via subcutaneous injection)
223764650|NCT00484302|BEHAVIORAL|Cognitive behavioral therapy with motivational interviewing|Individual and group therapy, education of family and case-manager.
223764651|NCT00484302|BEHAVIORAL|Non-manualized standard treatment|Treatment by case-manager
223764652|NCT04884152|PROCEDURE|Home Exercise Group|Educational training program about bruxism and the other oral parafunctional activities in patients with myofascial temporomandibular disorders.
223764653|NCT04884152|PROCEDURE|Telerehabilitation Group|Telerehabilitation program combined with educational training program about bruxism and the other oral parafunctional activities in patients with myofascial temporomandibular disorders.
223764654|NCT06158802|OTHER|Questionnaire|"Questionnaire on human papillomavirus vaccine status of girls and young women and modalities of the vaccination or reason of the non-vaccination.~The questionnaire is completed by the patient."
223773666|NCT06983262|PROCEDURE|Lip repositioning surgery|Profound anaesthesia will be achieved. A marking pencil§ will be used to outline the apical, coronal, and lateral boundaries of the elliptical incision. The coronal boundary will be at the mucogingival junction and will be used as a reference point to mark the apical boundary at two times the amount of gingival display. The coronal and apical incisions will be parallel to each other, and the apical incision gradually angled downward to meet the coronal incision. A partial thickness dissection will be made. The epithelium will be excised, exposing the underlying connective tissue. The mucosal flap will be advanced and sutured at the mucogingival junction.
223634423|NCT02233686|DRUG|Placebo|
223634424|NCT06185725|OTHER|Modified Perichondral Approach Thoracoabdominal Nerve Block|M-TAPA block will be performed to Group M-TAPA at the end of the surgery, using US (Vivid Q) while the patient is in the supine position After providing aseptic conditions, the high frequency linear US probe (11-12 MHz, Vivid Q) will be covered with a sterile sheath, and an 80 mm block needle (Braun 360°) will be used. The US probe will be placed in the sagittal plane where the midclavicular line intersects with the costal cartilage corresponding to the costochondral angle. Using the In Plane technique, the probe is gently pushed to visualize the lower part of the costochondral angle at the central level, advancing the block needle in the caudal-cranio direction, 5 ml of saline will be injected into the layer between the transverse abdominal muscle and the lower plane of the costal cartilage, and the block location will be confirmed. After the block location is confirmed, a total of 20 ml + 20 ml of 0.25% bupivacaine (total 40 ml for both sides) will be injected bilaterally
223634425|NCT06185725|OTHER|Transversus Abdominal Plane Block|TAP block will be performed to Group TAP at the end of the surgery, using US (Vivid Q) while the patient is in the supine position. After providing aseptic conditions, the high frequency linear US probe (11-12 MHz, Vivid Q) will be covered with a sterile sheath, and an 80 mm block needle (Braun 360°) will be used. USG will be placed transversely on the mid-axillary line between the iliac crest and subcostal planes. Using the In Plane technique, the block needle will be advanced into the fascial plane between the internal oblique and transversus abdominis muscles and the location will be confirmed by administering 5 ml of saline. The block needle will be advanced into the fascial plane between the internal oblique and transversus abdominis muscles and the location will be confirmed by administering 5 ml of saline.and than 20 ml of 0.25% bupivacaine (total 40 ml for both sides) will be injected bilaterally
223634426|NCT01539824|BIOLOGICAL|Mycobacterium obuense|IMM-101 is a suspension of heat-killed whole cell M. obuense in borate-buffered saline.
224222952|NCT01409356|BEHAVIORAL|Diet + exercise|Program of dietary counselling by dietists, who will periodically follow-up the patient to achieve weight loss; moreover a fitness professional will instruct and train the patients twice a week to enhance their physical activity. A step counter will be also given to all participants and daily step count will be recorded. The duration of diet+exercise is 4 months from baseline HVPG measurement.
223634427|NCT01539824|RADIATION|SBRT|The CyberKnife system is normally used for the treatment of cancerous tumours in cases where the type and position of the tumour and the condition of the patient indicate that treatment may be curative. In this study, the CyberKnife is being used in an experimental way to deliver a targeted dose of stereotactic body radiation with extreme accuracy in order to damage a single tumour growth (metastasis) in the liver.
223634428|NCT06265233|OTHER|Group Improv sessions|Therapist-led 90-minute exposure and response prevention (ERP) combined with improv sessions.
223634429|NCT06265233|BEHAVIORAL|Group Exposure and Response Prevention (ERP) Therapy|Therapist-led 90-minute exposure and response prevention (ERP) combined with improv sessions.
223634431|NCT01213680|DRUG|Monofer (iron isomaltoside 1000)|1000 mg iron isomaltoside administered as a infusion over 15 minutes
223634432|NCT01213680|DRUG|Monofer|500 mg iron isomaltoside 1000 given as bolus injection over 2 minutes
223634433|NCT05900167|BEHAVIORAL|enteral nutrition|The nutritional status of the patient is assessed by the physician to determine the need for enteral nutrition
223634434|NCT02735863|DRUG|ABX464|50 mg or 150mg once daily for 28 days
223634435|NCT02735863|DRUG|Placebo|ABX464 matching placebo
223634436|NCT02375854|OTHER|Observation|
223634437|NCT00829426|DRUG|Alprazolam Extended-Release 3 mg Tablets|1 x 3 mg, single dose fasting
223634438|NCT00829426|DRUG|Alprazolam Extended-Release 3 mg Tablets|1 x 3 mg, single dose fasting
223634439|NCT04421677|DRUG|Phenylbutyrate Oral Tablet|Phenylbutyrate, an orally active chemical chaperone approved by the US Food and Drug Administration for treatment of urea cycle disorders, mimics the function of intracellular molecular chaperones in preventing protein aggregation and oligomerization.
224222953|NCT00305370|DRUG|Aripiprazole|
223634440|NCT02333435|DIETARY_SUPPLEMENT|EPA|3g/day of purified EPA , capsules, taken once daily, for 14 months
223634441|NCT02333435|DIETARY_SUPPLEMENT|Placebo|3g/day of placebo (high oleic sunflower oil) , capsules, taken once daily, for 14 months
224222954|NCT05208411|BEHAVIORAL|Project ImPACT: Improving Parents As Communication Teachers|"Project ImPACT (Improving Parents As Communication Teachers, Ingersoll \& Dvortcsak, 2019) is a promising evidence-based parent-mediated intervention that is part of a class of naturalistic, developmental, behavioral interventions (NBDIs). NBDIs involve the use of behavioral principles of learning to teach skills chosen from a developmental sequence in naturalistic play-setting and using natural rewards. Skills selected as relevant for intervention are those that allow the child to participate more fully within reciprocal interactions with the adult. In recent years the program has been adapted for use with infants and toddlers at elevated likelihood of ASD. These adaptations have made this program appropriate for younger children and children who are experiencing social communication delays but do not have an ASD diagnosis."
224222955|NCT01172353|DRUG|sodium bicarbonate|hydration with sodium bicarbonate 1ml/Kg/h for 6 hours
224222956|NCT01172353|DRUG|saline|hydration with saline 1ml/Kg/h for 6 hours
224222957|NCT03877874|DRUG|Aironyl syrup(Terbutaline sulfate) + Epidrone syrup(Dexamethone)|Aironyl syrup(Terbutaline sulfate ................. 1.5mg) 0.075-0.29 mg/ kg body weight 3 times daily Apidone syrup(Dexamethone) (0.02 to 0.3 mg per kilogram (kg) of body weight per day, divided and taken 3 or 4 times a day)
224222958|NCT01991587|BIOLOGICAL|Low dose of quadrivalent VLP vaccine|A single low dose of quadrivalent VLP vaccine
224222959|NCT01991587|BIOLOGICAL|Medium dose of quadrivalent VLP vaccine|A single medium dose of quadrivalent VLP vaccine
223634442|NCT05446649|OTHER|dry needling|the patient will be in comfortable position .and clean the area over upper trapezius and sub occipital muscles. detect the trigger point then Perpendicular needling into the bulk of the muscle is the safest technique for this area.
224318505|NCT05291338|DRUG|Lipiodol|Lipiodol dose should be over 5 ml if tumor diameter is less than 5 cm, and the maximum dose will be 10 ml when the tumor develops to more than 5 cm in diameter.
224222960|NCT01991587|BIOLOGICAL|High dose of quadrivalent VLP vaccine|A single high dose of quadrivalent VLP vaccine
224222961|NCT01991587|BIOLOGICAL|Placebo|A single dose of placebo
223634443|NCT05446649|OTHER|instrumented assisted soft tissue mobilization|the patients will be in sitting position. The appropriate IASTM technique instrument will be selected to scan, and then treat the affected area for 30 to 60 seconds per treated area. The procedure will be applied to the superficial cervical fascia and investing the layers of deep cervical fascia that surround all the structures in the neck. Strokes will be applied on the sub occipital and upper fibers of trapezius muscle. The IASTM technique will be applied at a 45° angle in a direction parallel to the treated muscle fibers for 20 seconds, followed immediately by an additional 20 seconds application at a 45° angle in a perpendicular direction to the muscle fibers, resulting in a total treatment time of approximately 40 seconds. The patients will be advised that they might be sore, bruised, or have small red dots called petechiae, on the treated area. Ice will be applied for 15 to 20 min after the treatment if there will be a massive soreness.
223634444|NCT05446649|OTHER|conventional therapy|patients will be received traditional physiotherapy (stretching and strengthening cervical muscles and postural correction exercise)
223634445|NCT05611151|DIAGNOSTIC_TEST|Computer Aided Detection (CADe)|Computer-aided detection (CADe) devices are used in conjunction with colonoscopy to aid in the detection of lesions in the gastrointestinal tract.
223634446|NCT02780648|RADIATION|Stereotactic Body Radiation|
223634447|NCT05495815|DRUG|6 months of SAT|6 months of oral suppressive antibiotic therapy
223634448|NCT05495815|DRUG|12 months of SAT|12 months of oral suppressive antibiotic therapy
223634449|NCT05495815|DRUG|Indefinite SAT|Indefinite oral suppressive antibiotic therapy
223634450|NCT05560425|BEHAVIORAL|Koru Mindfulness (KM) Training|The Koru Basic curriculum consists of four weekly interactive 75-minute classes delivered online through Zoom. Each class consists of an overview of 2-3 skills, group practice of the skills, and group reflection. Topics discussed during each training visit include: belly breathing, dynamic breathing, body scan (week 1); walking meditation, gatha (week 2); guided imagery, labeling thoughts (week 3); eating meditation, and labeling feelings (week 4). Participants are instructed to practice a skill for 10 minutes/day and log any reflection on that practice using the Koru phone application.
223764655|NCT03362840|BEHAVIORAL|Early Start Denver Model|The ESDM is a manualized comprehensive treatment model for young children (12-48 months). In the preschool based ESDM, learning objectives are guided by the ESDM curriculum checklist, which includes developmental skills in language, play, motor skills, personal independence, imitation and cognition. The objectives are monitored for progress during each session The sessions are conducted according to ESDM principles, and include weekly parent-coaching session, in which parents observe the therapist interact with the child while applying various teaching techniques, and then implement these techniques during the interaction with their child. Additionally, parents get acquainted with the daily objective sheet and are encouraged to work on these objectives at home as well. Finally, in this model, therapist adherence to the ESDM practices are monitored according to the ESDM fidelity rating system
223764656|NCT03362840|BEHAVIORAL|Eclectic preschool intervention|"The eclectic approach consists of a combination of methods from several treatment-models. Individualized educational plans are based on multi-disciplinary assessment, and include objectives in several domains - communication, social-skills, play, emotional adjustment, adaptive daily skills, motor skills and cognition. They are presented to parents at the beginning of the year and are reviewed by the staff three times a year.~Parents attend by-weekly counseling-sessions with a professional in order to receive input regarding their child's progress, and discuss issues concerning their child's functioning. All staff members receive supervision at various intensities. However, these usually do not adhere to a single structure and are not guided by official fidelity criteria."
224222962|NCT02684695|OTHER|MRI scan (adolescent spine protocol)|MRI scan of the lumbar spine and sacroiliac joints
224222963|NCT02684695|OTHER|MRI scan (whole body protocol)|MRI scan of multiple joints ('whole body')
224222964|NCT02232048|OTHER|Transthoracic Echocardiogram|
224222965|NCT00240357|PROCEDURE|Lifestyle Regulation|
224222966|NCT00770991|DRUG|Black raspberry (BRB) Slurry|20 grams BRB Slurry
224222967|NCT00770991|DRUG|Black Raspberry (BRB) Suppositories|Two, 730 mg BRB suppositories QHS
224222968|NCT00770991|DRUG|Black Raspberry (BRB) Placebo Slurry|20 grams BRB placebo slurry
224222969|NCT03985501|OTHER|SCD newborn screening with the MS/MS method from Zentech|The analysis of the SCD newborn screening with the MS/MS method from Zentech will be realized after achievement and biological validation of the SCD newborn screening in the usual care pathway. The results will be compared with the method used at the Lille Academic Hospital (CHU Lille) (sub-contractor for SCD newborn screening of Lyon)
224222970|NCT03563950|DRUG|Rifampin|Specified dose on specified days
224222971|NCT03563950|DRUG|BMS-986224|Specified dose on specified days
224222972|NCT02275988|DRUG|K-877|
224222973|NCT02275988|DRUG|Clarithromycin|
224222974|NCT01126515|PROCEDURE|Magnetic Resonance Imaging|Imaging of the brain without gadolinium will be performed with a 3 Tesla magnetic resonance (MR) System (Intera Achieva 3T; Philips Medical Systems). The protocol will include anatomical sequences, a diffusion tensor imaging sequence with fiber tracking, and auditory, visual, and motor functional magnetic resonance imaging (MRI).
224222975|NCT01126515|PROCEDURE|Computed Tomography Angiography|Computed tomography angiography (CTA) with intravenous (IV) contrast will be performed on a 320 head computed tomography (CT) scanner, assessing brain perfusion.
224222976|NCT00132509|DRUG|DFIL|Alteplase : 0.8mg/kg over 90 minutes
224222977|NCT00132509|DRUG|NINDS|Alteplase : 0.9mg/kg over 60 minutes
224222978|NCT02129374|PROCEDURE|Direct repair of pars defect|Direct repair at pars defect was performed with 4.5mm cortical screw in young spondylolytic patients.
224222979|NCT03801733|DRUG|Vadadustat|Oral dose of 600 mg QD
224222980|NCT03801733|DRUG|Simvastatin|Oral Simvastatin
224222981|NCT03801733|DRUG|Rosuvastatin|Oral Rosuvastatin
224222982|NCT03801733|DRUG|Atorvastatin|Oral Atorvastatin
224222983|NCT03801733|DRUG|Pravastatin|Oral Pravastatin
224222984|NCT03801733|DRUG|Sulfasalazine|Oral Sulfasalazine
224222985|NCT02045628|BEHAVIORAL|Investment intervention|Those in the investment group will complete carefully framed questions designed to raise the salience of the investment they have made in their procedure at baseline and 3 months follow up. The content of this intervention will be tailored to the recent experiences of the patient (ie pre or post surgery).
224222986|NCT00310778|DRUG|high sodium diet|high sodium diet
224222987|NCT00310778|DRUG|low sodium diet|low sodium diet
223634451|NCT05560425|BEHAVIORAL|Navigating College (NC) Training|With topics discussed from the Freshman Survival Guide book, this training provides a closely matched active control group for KM Training. The training consists of four weekly 75-minute classes delivered online through Zoom. Each class consists of lecture and group discussions on topics related to navigating college. Topics discussed during each training visit include: habits, roommate issues, homesickness, the internet (week 1); strategies when sinking, study skills, getting involved, habit formation (week 2); HALT, gateway habit (week 3); and academic success tips, taking notes, and procrastination (week 4). Participants are instructed to journal about learned information and skills for 10 minutes/day.
223634452|NCT05499910|BEHAVIORAL|NSBAA|The Neuro Strengths-Based Approach to Autism is an approach that teaches people how the autistic brain works and the best practices for providing intervention.
223634453|NCT04945746|PROCEDURE|AF ablation|"AF ablation using the Volta Medical VX1 CE marked software and a new criteria to establish a priority of the dispersed zones according to the stability of the core algorithm's response (thanks to the new software module under study named stability)."
223634454|NCT06222905|OTHER|non interventional|non interventional
223634455|NCT06399900|DEVICE|Far red light therapy|All participants will receive one far red light device per leg. Participants will be asked to use their two light devices daily, exposing their bare legs to the devices for 10 minutes twice per day. An unblinded study coordinator will deliver the light devices to each participant's home, positioning the devices 15 cm behind the participant's heels, using tape on the floor to mark where the light and feet should be positioned. Twice each day, the participant flips a switch on the device to begin each session. A timer will turn off the device after 10 minutes. A power meter will measure the total time that the device was turned on. Participants will also record use of the light in a log.
223634456|NCT06399900|DEVICE|Sham light therapy|All participants will receive one sham device per leg. Participants will be asked to use their two light devices daily, exposing their bare legs to the devices for 10 minutes twice per day. An unblinded study coordinator will deliver the light devices to each participant's home, positioning the devices 15 cm behind the participant's heels, using tape on the floor to mark where the light and feet should be positioned. Twice each day, the participant flips a switch on the device to begin each session. A timer will turn off the device after 10 minutes. A power meter will measure the total time that the device was turned on. Participants will also record use of the light in a log.
223764657|NCT02720913|DEVICE|COR-KNOT|The COR-KNOT device was developed to make suture fixation faster and save operative time. With a single squeeze of the lever, the device remotely and automatically secures sutures with a titanium fastener, while also simultaneously trimming excess suture tails.
224222988|NCT00310778|DRUG|ramipril 10 mg|ramipril 10 mg
224222989|NCT00310778|DRUG|valsartan 160 mg|valsartan 160 mg
224222990|NCT00310778|DRUG|candesartan 8 mg|candesartan 8 mg
223764658|NCT02720913|PROCEDURE|Standard Suture Tying|Standard Suture Tying
223764659|NCT05740722|DIETARY_SUPPLEMENT|Nicotinamid riboside|500 mg x 2 po
223764660|NCT05740722|DIETARY_SUPPLEMENT|Placebo|Placebo tablets
224222991|NCT00310778|DRUG|atenolol 50 mg|atenolol 50 mg
224222992|NCT02733237|DRUG|oxytocin treatment|intranasal administration of oxytocin (40 IU)
224222993|NCT02733237|DRUG|placebo treatment|intranasal administration of placebo (40 IU)
224222994|NCT05267574|DRUG|REN001|Once daily dosing
224222995|NCT03212196|PROCEDURE|Pancreaticogastrostomy with external drain|"Pancreatico-enteric anastomosis is provided according to the Bassi technique, pancreatic remnant is pushed into the gastric cavity through a posterior gastrotomy. An externalized drain is placed into the main pancreatic duct."
224222996|NCT03212196|PROCEDURE|Pancreaticojejunostomy with transanastomotic drain|Pancreatico-enteric anastomosis is provided through a double-layer, duct-to-mucosa anastomosis with a transanastomotic externalized drain.
224222997|NCT06011421|DEVICE|Local Anaesthetic Wound Catheter Insertion|Use of the Local Anaesthetic Wound Catheter Insertion during kidney transplant
224222998|NCT01534975|DIAGNOSTIC_TEST|contrast agent|we are randomizing patients to different contrast agents.
224222999|NCT02448628|DRUG|CS-3150|
224223000|NCT00168337|DRUG|Dexamethasone|350 µg or 700 µg dexamethasone posterior segment drug delivery system - injection into the vitreous cavity not less than every 6 months for up to 36 months.
224223001|NCT00168337|OTHER|Sham|Sham posterior segment drug delivery system-needle-less drug delivery system without study medication not less than every 6 months for up to 36 months.
224223002|NCT02748005|DIETARY_SUPPLEMENT|Fenugreek seeds extract 500 mg|one cap once a day
224223003|NCT05447429|PROCEDURE|Transversus abdominis plane block|TAP block will be performed by a needle which is punctured at the midaxillary line between subcostal margin and iliac crest, once tip of the needle had detected just above the peritoneum the syringe pulled back.
224223004|NCT05447429|DRUG|Placebo|20 ml saline solution will be injected by a needle which is punctured at the midaxillary line between subcostal margin and iliac crest, once tip of the needle had detected just above the peritoneum the syringe pulled back.
224223005|NCT01488019|DRUG|Perforomist-Placebo|Placebo vehicle, 2mL, twice daily for 52 weeks
224223006|NCT01488019|DRUG|Perforomist, nebulization, COPD|Perforomist, 20 mcg/2 mL, twice daily for 52 weeks
224223007|NCT02758054|BEHAVIORAL|Patient Navigation|Patient navigated reminder calls containing information about screening appointments, reminders, hints to facilitate communication with physicians, and smoking cessation.
224223008|NCT03158428|OTHER|CSD170202AA|A moist snuff product
224223009|NCT03158428|OTHER|CSD170202AB|A moist snuff product
224223010|NCT00871728|DRUG|Itraconazole|Itraconazole (ICZ) capsule will be administered in 3 cycles (Week 1, Week 5 and Week 9) and each cycle will consist of taking 2 capsules of 100 milligram (mg) each, orally twice daily, continuously for 1 week and then not taking medication for next 3 weeks. Total duration of treatment will be 49 weeks.
224223011|NCT02561390|PROCEDURE|Skin prick test|skin prick test to American cockroach, dog, cat, dust mite and mold allergen extracts are performed
224223012|NCT02561390|OTHER|specific IgE measurement|measure specific IgE of American cockroach, dog, cat, dust mite and mold
224223013|NCT06214026|DEVICE|META-Arc foot locked|Participants are provided with the META-Arc from WIllowWood Global, and a locking mechanism prevents side-to-side motion.
224223014|NCT06214026|DEVICE|META-Arc foot unlocked|Participants are provided with the META-Arc from WIllowWood Global allowing side-to-side motion.
224223015|NCT02400710|BEHAVIORAL|Clinician-Supported PTSD Coach|Brief primary care-based intervention provided by a mental health clinician who is located in primary care.
223634457|NCT06399900|BEHAVIORAL|Home-based walking exercise|This study involves a 16 week intervention where participants will walk at home for exercise with guidance from a study coach. Participants will have 4 in-person visits in the first four weeks and then have weekly phone calls in the last 12 weeks of the intervention with their coach.
223634458|NCT05206708|BEHAVIORAL|Personalized psychotherapy|Strategy including personalized psychotherapy
223634459|NCT05206708|BEHAVIORAL|Standard of care|Strategy based standard intregrative psychodynamic therapy
223634460|NCT06320054|BEHAVIORAL|Maternal Health Management Program|Program participants will receive 10 fresh, local meals each week, delivered to their homes, health coaching including cooking and physical activity, biometrics screenings, and educational support to enable sustainable lifestyle change.
223634461|NCT05584410|OTHER|Patient information|Patient education according to national guidelines, with information about e.g. disease progression, symptoms, treatment, exercise, self-care techniques and dietary information
223634462|NCT05584410|OTHER|Smart phone application based exercises|Individually based exercise programs individualized exercises where instructions are given through real-time video or pictures in combination with written descriptions.
223634463|NCT05584410|OTHER|Web based exercises|Generic osteoarthritis exercise, including about 20 different exercises, provided by real-time videos and written description
223634464|NCT05584410|OTHER|Group based information|Osteoarthritis specific information at three different group meeting (physical or digital) led by a physiotherapist, an occupational therapist and / or dietitian (each rehab clinic makes its own arrangement).
223634465|NCT05584410|OTHER|Supervised rehabilitation|The patient is offered to regularly exercise at the clinic, individually or in a group under supervision from a physiotherapist.
223764661|NCT05196412|DEVICE|PulseOn Arrhythmia Monitor device|Wearing of the wrist device for a period of two weeks
223764662|NCT00251394|DRUG|Rituxan|Given intravenously once weekly for four weeks.
223764663|NCT00251394|DRUG|1018 ISS|Given as an injection under the skin after the 2nd, 3rd and 4th rituxan infusion. One week after the last rituxan infusion is given, a fourth and final 1018ISS injection will be given.
223764664|NCT03219333|DRUG|Enfortumab vedotin|Intravenous (IV) infusion on days 1, 8 and 15 every 28 days
223764665|NCT00723606|DRUG|Intramuscular ziprasidone mesylate|The recommended dose is 10 to 20 mg administered as required up to a maximum dose of 40 mg per day. Doses of 10 mg may be administered every two hours; doses of 20 mg may be administered every four hours up to a maximum of 40 mg/day for 3 days.
224223016|NCT02400710|BEHAVIORAL|Self-Managed PTSD Coach|One 10 minute session explaining how to use the PTSD Coach mobile app.
223634466|NCT05584410|OTHER|Self-monitoring|Patients will be followed by validated questionnaires and function tests (30 sec Chair-to-stand test) every six months until three years after the start of treatment. The patients will get a report of the results and a research coordinator will contact the patients if their symptoms/function has worsen and discuss further treatment
223634467|NCT05584410|BEHAVIORAL|Motivational notifications|Automatic and daily reminders and / or motivational notifications
223634468|NCT05584410|OTHER|Home based rehabilitation|Individualized exercises that the patient performs on their own, i.e. at home or at a gym.
223634469|NCT00535314|DRUG|RTA 402 Dose1|
223634470|NCT00535314|DRUG|RTA 402 Dose2|
223634471|NCT02637245|OTHER|No intervention|No intervention
223634472|NCT06235775|DRUG|GV1001 Placebo|0.9% normal saline
223634473|NCT06235775|DRUG|GV1001 1.12mg|Lyophilized peptide from hTERT
223634474|NCT05135767|BEHAVIORAL|Brief Motivational Interviewing with Personalized Feedback|A brief motivational interviewing (MI) intervention will target drinking. The intervention will leverage in-depth personalized feedback to identify areas of progress and barriers to change. The personalized feedback will include results of laboratory diagnostic tests, summary reports of timeline followback interviews, and graphical depictions of self-monitoring reports collected on smartphones in daily life. The brief intervention will include an initial 60-minute videoconference session, two brief, 5-10 minute phone-call check-ins completed one and two weeks after the initial intervention, and a 30-minute videoconference booster session completed three weeks after the initial intervention.
223634475|NCT04943744|DEVICE|Entero-tracker|Esophageal STRING test (Entero-tracker)
223634476|NCT04943744|BIOLOGICAL|omalizumab|Used in the parent study
223634477|NCT04943744|BIOLOGICAL|dupliumab|Used in the parent study
223634478|NCT03475004|DRUG|Pembrolizumab|An intravenous, potent and highly selective humanized monoclonal antibody of the immunoglobulin G4 (IgG4)/kappa isotype designed to directly block the interaction between PD-1 and its ligands, PD-L1 and PD-L2.
223634479|NCT03475004|DRUG|Bevacizumab|The pharmacokinetics of bevacizumab are characterized by a slow CL, long half-life, and a volume of distribution consistent with limited extravascular distribution.
223634480|NCT03475004|DRUG|Binimetinib|Binimetinib (MEK162/ARRY-438162) is an orally bioavailable, small molecule selective and potent mitogen-activated protein kinase (MEK) 1 and MEK 2 inhibitor.
223764666|NCT00723606|DRUG|Intramuscular haloperidol|The haloperidol group will receive an initial intramuscular injection of haloperidol 5mg, following on which 5mg haloperidol may be repeated every 4-8 hours to a maximum of 20 mg /day for 3 days.
223764667|NCT01947530|PROCEDURE|Navigational Bronchoscopy|
224223017|NCT00657878|DRUG|stealth liposomal doxorubicin|stealth liposomal doxorubicin 40 mg/m2 IV day 1 every 28 days
224223018|NCT00657878|DRUG|carboplatin|carboplatin AUC 5 IV day 1 every 21 days
224223019|NCT00657878|DRUG|paclitaxel|paclitaxel 175 mg/m2 IV day 1 every 21 days
224223020|NCT00657878|DRUG|Topotecan|dosing and schedule according to Institutional guidelines
224223021|NCT00657878|DRUG|Gemcitabine|1000 mg/m2 on days 1,8,15 every 28 days
224223022|NCT02546284|DRUG|lenzilumab|
224223023|NCT04346290|DRUG|Dexmedetomidine|Initial infusion dose of dexmedetomidine is 0.4 mcg/kg/min, maintenance infusion dose is 0.1-0.7 mcg/kg/min
224223024|NCT04204486|BEHAVIORAL|Exercise|Functional strength training, 1 hour, 3 times a week.
224223025|NCT03920436|DIETARY_SUPPLEMENT|infrared water group|This group takes 1,8 L of drinking water using a tumbler that emits far infrared rays at room temperature.
224223026|NCT03920436|DIETARY_SUPPLEMENT|sham group|This group takes 1,8 L of drinking water using a tumbler at room temperature.
224223027|NCT04147715|DRUG|S-648414|Tablet for oral administration
223634481|NCT02376634|BEHAVIORAL|Hypnosis|Patients will be taught self-hypnosis.
223634482|NCT05133297|DRUG|TLL-018|Oral tablets administered at dose1 BID daily for 24 weeks.
223634483|NCT05133297|DRUG|TLL-018|Oral tablets administered at dose2 BID daily for 24 weeks.
223634484|NCT05133297|DRUG|TLL-018|Oral tablets administered at dose3 BID daily for 24 weeks.
223634485|NCT05133297|DRUG|Tofacitinib|Oral tablets administered at 5 mg BID daily for 24 weeks.
223634486|NCT04936607|PROCEDURE|Personalized hydration strategy|In the experimental group, NS infusion rate will be adjusted based on LVEDP for the whole duration of the procedure (\<13 mmHg: 5 ml/kg/h; 13-18 mmHg: 3 ml/kg/h; \>18 mmHg: 1.5 ml/kg/h), or for one hour, whichever is the longest. After the procedure, and for a duration of 4 hours, the hydration rate will be adjusted based on the (contrast volume:estimated glomerular filtration rate (eGFR)) ratio, according to the following scheme: 1.5 ml/kg/h if contrast volume/eGFR ratio \<2.0; 3 ml/kg/h for contrast volume/eGFR ratio 2.0-2.9; 5 ml/kg/h for contrast volume/eGFR ratio ≥3.0.
223634487|NCT04936607|PROCEDURE|Standard of care|In the control group, infusion rate will be of 1.5 ml/kg/h during the procedure, and for the 4 following hours.
223634488|NCT00311766|DRUG|Thymosin Beta 4|Topical administration, 0.01%, 0.03%, and 0.1% Thymosin Beta 4 gel, qd up to 56 days
223634489|NCT00311766|DRUG|Placebo|Topical administration, 0.00% Thymosin Beta 4 gel qd up to 56 days
223634490|NCT02260934|BIOLOGICAL|Rituximab|Rituximab 1000mg intravenously (IV) at week 0 and week 2
223634491|NCT02260934|DRUG|Cyclophosphamide|Cyclophosphamide (750 mg) intravenously (IV) at week 0 and week 2.
223634492|NCT02260934|DRUG|Prednisone|"* Week 0 and Week 2: Prednisone (40 mg/day; taper to 10 mg/day by week 12)~* Continue prednisone 10 mg/day to week 96"
223634493|NCT02260934|DRUG|Methylprednisolone|"Week 0 and Week 2:~Solumedrol (100 mg) IV"
223634494|NCT02260934|DRUG|Diphenhydramine|Diphenhydramine (50 mg, or equivalent dose of similar antihistamine) will be given orally 1 hour (plus or minus 15 minutes) before each infusion of rituximab.
223634495|NCT02260934|DRUG|Acetaminophen|Acetaminophen (650 mg) will be given orally 1 hour (plus or minus 15 minutes) before each infusion of rituximab.
223634496|NCT02260934|BIOLOGICAL|Rituximab|Rituximab 1000mg intravenously (IV) at week 0 and week 2.
223634497|NCT02260934|DRUG|Cyclophosphamide|Cyclophosphamide (750 mg) intravenously (IV) at week 0 and week 2.
223634498|NCT02260934|DRUG|Prednisone|"* Week 0 and Week 2: Prednisone (40 mg/day; taper to 10 mg/day by week 12)~* Continue prednisone 10 mg/day to week 96"
223634499|NCT02260934|DRUG|Methylprednisolone|Week 0 and Week 2: Solumedrol (100 mg) IV
223634500|NCT02260934|DRUG|Diphenhydramine|Diphenhydramine (50 mg, or equivalent dose of similar antihistamine) will be given orally 1 hour (plus or minus 15 minutes) before each infusion of rituximab.
223634501|NCT02260934|DRUG|Acetaminophen|Acetaminophen (650 mg) will be given orally 1 hour (plus or minus 15 minutes) before each infusion of rituximab.
223634502|NCT02260934|BIOLOGICAL|Belimumab|The RCB Group will receive IV belimumab 10mg/kg at weeks 4, 6, 8, and then every 4 weeks through week 48
223634503|NCT01931540|BEHAVIORAL|Exercise Training|Three times a week, for four months.
223634504|NCT05231226|PROCEDURE|Immediately CR|Immediately opening non-IRA after emergency opening IRA in STEMI patients with MVD
223634505|NCT05231226|PROCEDURE|Staged (within 45 days) CR|Staged opening non-IRA after emergency opening IRA in STEMI patients with MVD
223634506|NCT01436526|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Single oral dose of rivaroxaban administered under fasting conditions 2\*5 mg tablet in first intervention period and 1\*10 mg tablet in second intervention period (after washout period)
223634507|NCT01436526|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Single oral dose of rivaroxaban administered under fasting conditions 1\*10 mg tablet in first intervention period and 2\*5 mg tablet in second intervention period (after washout period)
223634508|NCT05829070|BEHAVIORAL|CHAT-S|The CHAT-S intervention will include 4 videoconference sessions over a 2-month time period that is delivered by a patient navigator. Session 1 will include content to educate participants about survivorship care and common types of follow-up care required for their specific cancer, as well as, basic insurance terms and concepts. Session 2 will teach participants about their own insurance plan (e.g., coverage, benefits, breakdown of bills, and explanation of benefits) so they can better navigate both the medical and insurance systems. Session 3 reviews health insurance laws (e.g., ACA, FMLA, No Surprises Act) and how to proceed with an appeals process. Session 4 explains how to manage the costs through budgeting and cost-of-care conversations with their medical providers.
223634509|NCT05829070|BEHAVIORAL|Usual Care|Usual care will consist of a resource list that describes organizational and community resources available on insurance, financial burden, and survivorship care. Further, we will track whether participants were referred or engaged in services using the follow-up surveys and via the EHR/claims data.
223634510|NCT01648712|DEVICE|Balance surface, Carmeda heparin-coated surface|"This study compares the influence of a Balance - coated CPB system in pediatric use versus the Carmeda TM heparin-coated system in platelet function preservation and hemostatic activation.~Balance arm group recieved like intervention a Balance circuit"
223634511|NCT01648712|DEVICE|non -heparin extracorporeal pediatric device for operation|The carmeda arm group received like intervention the Carmeda circuit
223634512|NCT03605667|DRUG|troriluzole|Oral BHV-4157 will be given daily for up to 48 weeks
223634513|NCT03605667|DRUG|Placebo oral capsule|Oral matching placebo will be given daily for up to 48 weeks
223764668|NCT01947530|PROCEDURE|Standard Bronchoscopy|
224223028|NCT04147715|DRUG|Placebo|Tablet for oral administration
224223029|NCT04147715|DRUG|Midazolam|Solution for oral administration
224223030|NCT04147715|DRUG|Dolutegravir|Tablet for oral administration
224223031|NCT03404206|DRUG|Naproxen Sodium (Aleve, BAY117031)|220 mg x 2 tablets, oral, single dose
224223032|NCT03404206|DRUG|Ibuprofen (Advil)|200 mg x 2 tablets, oral, single dose
224223033|NCT03404206|DRUG|Placebo|Matching placebo, 2 tablets, oral, single dose
224223034|NCT01248312|DEVICE|Sentec monitoring device|Sentec monitor applied transcutaneously to forehead
224223035|NCT01248312|DEVICE|sentec monitor|transcutaneous monitoring
224223036|NCT02756000|PROCEDURE|PCI|percutaneous angioplasty and stent implantation in coronary artery with significant atherosclerosis and stenosis
224223037|NCT02756000|PROCEDURE|dobutamine stress echocardiography|Echocardiographic stress test of provoked myocardial ischemia using dobutamine
224223038|NCT02024828|OTHER|Early/Slow|
223634514|NCT04939766|DEVICE|Activation of a closed loop device in an insulin pump device with GCM|After a run-in period of 20 days to co,firm eligibility, the closed loop is activated and patients are followed for 6 months by their diabetologists.
223634515|NCT06372626|BIOLOGICAL|ZG005|"ZG005 for dose escalations are set as 10mg/kg, 20mg/kg, and the other doses after discussion. intravenous infusion, once every 3 weeks.~ZG005 for dose expansion will commence after the Recommended Phase 2 Dose (RP2D) is determined during the dose-escalation stage."
223634516|NCT06372626|DRUG|Etoposide|IV infusion
223634517|NCT06372626|DRUG|Cisplatin|IV infusion
223634518|NCT06372626|DRUG|Placebo|0.9% Sodium Chloride Injection
223634519|NCT04854343|DIAGNOSTIC_TEST|Secretory leukocyte protease inhibitor (SLPI) in prostate cancer|"7 ml of peripheral blood and a urine sample for the determination of SLPI concentration. Blood samples will be promptly processed to obtain sera; both sera and urine will be stored at -80°C in the laboratory. The levels of SLPI in the serum and in the urine will be quantitated by an ELISA assay by using the Human SLPI Quantikine ELISA Kit. SLPI level will be measured at diagnosis and during the follow-up (3, 9, 15 months and in case of progression).~Immunohistochemistry protocol for SLPI immunostaining to investigate SLPI levels prostate tissue"
223634520|NCT04854343|DIAGNOSTIC_TEST|Determination of molecular alterations|The presence of ETS translocation (or of ETS overexpression) will be tested on bioptic samples in each patient as for routine diagnostic procedures. First, ERG overexpression will be investigated by ERG immunostaining. The samples negative for ERG immunostaining will be studied for TMPRSS2-ERG translocation either by in situ FISH or by a translocation-specific RT-PCR. Next, the biopsies negative for TMPRSS2-ERG will be tested for the overexpression of other ETS proteins (ETV1, ETV4, ETV5 and for others rarely occurring ETS). When possible, it will be determined the status of pTEN gene, the tumor suppressor most frequently lost in prostate patients. The patients negative for the overexpression of the ETS proteins will be tested for SPINK1.
223634521|NCT04854343|DIAGNOSTIC_TEST|Secretory leukocyte protease inhibitor (SLPI) Healthy|"SLPI level will be measured also in the serum and in the urine from controls (patients with BPH and healthy subjects).~7 ml of peripheral blood and a urine sample for the determination of SLPI concentration. Blood samples will be promptly processed to obtain sera; both sera and urine will be stored at -80°C in the laboratory. The levels of SLPI in the serum and in the urine will be quantitated by an ELISA assay by using the Human SLPI Quantikine ELISA Kit."
223634522|NCT00768417|BEHAVIORAL|10 chews|Participants were required to chew 55g grams of almonds per day for four days in 11, 5 gram portions. Almonds were to be chewed 10 times before swallowing.
223634523|NCT00768417|BEHAVIORAL|25 Chews|Participants were required to chew 55g grams of almonds per day for four days in 11, 5 gram portions. Almonds were to be chewed 25 times before swallowing.
223634524|NCT00768417|BEHAVIORAL|40 Chews|Participants were required to chew 55g grams of almonds per day for four days in 11, 5 gram portions. Almonds were to be chewed 40 times before swallowing.
223634525|NCT06125834|DRUG|Trastuzumab Emtansine (T-DM1)|Enrolled patients will receive Trastuzumab Emtansine (T-DM1) treatment (3.6mg/kg, d1/21, IVD) until progressive diseases or intolerable adverse effects occurs.
223634526|NCT06156020|PROCEDURE|Endoscopic endonasal surgery|Endoscopic endonasal transsphenoidal approach for resection of pituitary adenomas
223634527|NCT01780311|DRUG|antiarrhythmic drugs (Flecainide or Propafenone or Sotalol)|
223634528|NCT01780311|PROCEDURE|Catheter Ablation|
223634529|NCT03659188|PROCEDURE|Cortico-alveolar perforations|Mechanical drills will be used on a handpiece
223634530|NCT03659188|PROCEDURE|Traditional Corticotomy|Piezo-surgery will be employed following flaps' elevation.
223634531|NCT00537134|DEVICE|Embolization, coiling|Endovascular embolization with platinum coils
223634532|NCT00006016|DRUG|thalidomide|Given orally
223634533|NCT00006016|DRUG|doxorubicin hydrochloride|Given transarterially (chemoembolization)
223634534|NCT00006016|OTHER|laboratory biomarker analysis|Correlative studies
223634535|NCT03597347|DRUG|Molgramostim nebulizer solution|300 µg / dose molgramostim (recombinant human GM-CSF) for inhalation
223634536|NCT03597347|DEVICE|PARI eFlow nebulizer system|PARI eFlow nebulizer system
223634537|NCT02569385|OTHER|Spontaneous breathing trial|
223634538|NCT05418179|DIETARY_SUPPLEMENT|Probiotic|Probiotic (Bifidobacterium animalis subsp. Lactis, Bifidobacterium breve, Bifidobacterium longum, Lactobacillus gasseri, Lactobacillus casei, Lactobacillus rhamnosus) - 1 capsule/day
223634539|NCT05418179|DIETARY_SUPPLEMENT|Placebo|Maltodextrin (1 capsule/day)
223634540|NCT00107653|DRUG|Ribavirin|1000-1200mg po daily for 48 weeks
223634541|NCT00107653|DRUG|Peginterferon alfa-2a|180 micrograms sc/week for 48 weeks
223634542|NCT00107653|DRUG|Ribavirin|1000-1200mg po daily for 48 weeks
224223039|NCT02024828|OTHER|Early/Fast|
223634543|NCT00107653|DRUG|Peginterferon alfa-2a|180 micrograms sc/week for 48 weeks
223634544|NCT04144686|OTHER|Physiotherapy Rehabilitation|Participants will be randomly allocated, using a random number generator, to a 12-week supervised customised exercise group incorporating VRT programme without (Group A) or with cognitive DT exercises (Group B).
224223040|NCT02024828|OTHER|Late/Slow|
224223041|NCT02024828|OTHER|Late/Fast|
224223042|NCT05621642|OTHER|Breathing exercises|In the sitting position, the patient does 15 diaphragm breathing and 15 huffing exercises.
224223043|NCT05621642|OTHER|Core stabilization exercises|This intervention includes bridging exercise and abdominal exercises.
224223044|NCT05621642|OTHER|Balance and strengthening exercises|It includes sitting and standing on the chair 15 times and turning around the chair.
224223045|NCT01004081|DRUG|BIIB021|BID orally for 28 days
224223046|NCT01004081|DRUG|BIIB021|TIW orally for 28 days
224223047|NCT01004081|DRUG|exemestane (Aromasin)|Daily in tablet form for 28 days
223634545|NCT06210646|DRUG|Citicoline 2000|The citicoline arm consists of 400 patients who received 2000 mg citicoline once daily for 12 months, and an open-label double antiplatelet in the form of 75 mg aspirin, and 75 mg clopidogrel for three weeks, followed by a single antiplatelet in the form of 75 mg clopidogrel for the rest of our trial.
223634546|NCT06210646|DRUG|citocoline 1000|The placebo arm consists of 400 patients who received a citicoline 1000 mg once daily for 12 months, an open-label double antiplatelet in the form of 75 mg aspirin, and 75 mg clopidogrel for three weeks, followed by a single antiplatelet in the form of 75 mg clopidogrel for the rest of our trial.
223634547|NCT06334432|DRUG|NUV-1511|Novel small molecule
223634548|NCT02800668|DEVICE|DJBL (Duodenal jejunal bypass liner, EndoBarrier)|Implantation of EndoBarrier after medical and patient's decision, Duration of treatment 12 months in maximum, follow up for 4 weeks after Explantation, follow up during treatment by physical examination, ECG control, sampling and analysis of blood parameters, mixed meal tolerance tests only for diagnostic purposes to assess gut hormonal changes and metabolic parameters
223634549|NCT02401165|OTHER|Blood test|blood test
224223048|NCT03032497|DEVICE|EEG-based BCI analysis of fear avoidance|Scalp EEG signals that are acquired and recorded from experiment 1 and 2 are analysed for healthy controls, participants with low back pain and participants with lower limb pain. Comparisons of signal patterns are made between groups. Assuming unique signal patterns are obtained for each groups, these signals are further analysed and used to develop a feedback brain training system to better manage pain and ideally reduce fear-avoidant behaviors towards pain.
224223049|NCT04596449|OTHER|study intervention|"The sleep structure of healthy volunteers will be recorded (9 Electroencephalograms (EEG), 2 Electrooculograms (EOG), 2 Electromyograms (EMG) and 2 Electrocardiograms (ECG)) during 1 night. The characteristics of the spindle (density, frequency and amplitude) will be automatically analyzed from purified EEG during Non Rapid Eye Movement sleep (NREM).~Volunteers will completed a neuropsychological evaluation that will evaluate Sustained attention (simple reaction time test), Vigilance (TAP Vigilance), Sustained and selective attention (CPT II), Inhibition (Stroop test), Mental flexibility (TAP flexibility) , Executive operation (Tower of London), Short-term memory (Wechsler code test).~Driving performance will be analyzed as part of a complex scenario involving attentional and high-level functions on a driving simulator."
224223050|NCT03187080|PROCEDURE|Paravertebral block procedure using either local anesthetic (0.25% bupivacaine) or sterile saline|Paravertebral block (PVB) will be performed in the standard fashion using an out-of-plane ultrasound approach by an anesthesiologist with appropriate training in regional anesthesia. Landmarks on the patient will be identified. The skin will be sterilized. The intended target (paravertebral space) will be located using an ultrasound. A Pajunk UniPlex NanoLine needle will be inserted. A syringe filled with sterile saline (used for hydrodissection) connected to a syringe of 0.25% bupivacaine with 2.5 mcg/mL of epinephrine will be connected to the Pajunk needle and used for injection. The needle will be advanced toward and through the superior costotransverse ligament or internal intercostal membrane. Once through the ligament, the pleura will be seen deflecting anteriorly with the hydrodissection. Negative aspiration will be confirmed, and the local anesthetic will be injected into the paravertebral space.
224223051|NCT03187080|OTHER|Enhanced recovery after breast surgery (ERABS) strategies|"For comparing ERABS strategies to current standard of care, the following perioperative strategies will be utilized:~* Standardized written information given preoperatively.~* Allow clear liquids for up to 2 hours prior to arrival at the surgery center.~* Use paravertebral block to augment postoperative pain control.~* Standardized multimodal analgesic regimen~* Antiemetics~* Easily accessible call-in or walk-in postop care/support~The proposed strategies differ from standard of care in the following ways:~* PVB is less commonly used in elective surgery.~* Patients do not eat or drink after midnight.~* There is no standardized preoperative information packet.~* Anesthetic/intraoperative analgesic and antiemetic regimen varies between providers."
223634550|NCT02920632|BEHAVIORAL|Online cognitive training 1|Eight-week online cognitive training program, three times a week for 45 minutes. The training contains several games that are designed to train cognitive functions.
223634551|NCT02920632|BEHAVIORAL|Online cognitive training 2|Eight-week online active comparator program, three times a week for 45 minutes. The training contains several games.
223634552|NCT05917899|BEHAVIORAL|Virtual Family-Centered Rounds|The care team will use a computer with a speaker camera, mounted on a stand with wheels to launch telehealth visits using the application ExtendedCare. This platform meets HIPAA security rules and launches from the patient's electronic health record. From within this telehealth visit, a care team member will send a message (via text or email) to the parent(s) that includes a link that can be clicked to open a browser that allows the parent to join the telehealth visit. Parent do not need to download or use an application. The care team will invite the video interpreter to join the visit if a parent is present. Family-centered rounds will then proceed in usual fashion with the care team and \[if in attendance\] parent(s). Parents can participate in virtual family-centered rounds as much, or as little, as they choose.
223634553|NCT02532517|DEVICE|CODMAN ENTERPRISE® Vascular Reconstruction Device and Delivery System|
223634554|NCT03935984|DRUG|Calcitonin|Treatment with calcitonin to lower high calcium levels prior to reimaging exam
223634555|NCT04746391|DEVICE|Dialyzer type|Fiber blocking and dialyzer clearance is calculated in two different commercially available dialyzers
223634556|NCT04746391|OTHER|Dialysis duration|Fiber blocking and dialyzer clearance is calculated for three different dialysis durations
223764669|NCT05908097|DEVICE|Virtual Reality Avatar Intervention|In the Virtual Reality Avatar Intervention experience, participants will see an avatar resembling themselves in a park setting.
223634557|NCT03312231|DRUG|AS03|Oil-in-water emulsion based adjuvant system.
223634558|NCT03312231|BIOLOGICAL|Inactivated influenza H7N9 vaccine|Monovalent 2017 H7N9 inactivated influenza vaccine
223634559|NCT03312231|OTHER|Phosphate Buffered Saline (PBS) diluent|Diluent for 2017 Monovalent Inactivated Influenza A/H7N9 virus vaccine (2017 H7N9 IIV)
223634560|NCT00471055|DRUG|"0.0125% Capsaicin gel CAPSIKA gel"|
223634561|NCT00471055|DRUG|Placebo|Placebo
223764670|NCT05908097|DEVICE|Virtual Reality Empty Park|The Virtual Reality Empty Park experience is a habituation experience that does not contain avatars.
223764671|NCT05107128|DRUG|SAGE-718|Oral capsules.
223764672|NCT05107128|DRUG|Placebo|SAGE-718-matching oral capsules.
223634562|NCT03214601|DEVICE|penetrating atherosclerotic ulcer, aorta branch cardiovascular implant|The Relay Branch System is intended to provide an option for patients with arch and proximal descending chronic thoracic aortic pathologies.
223634563|NCT00886002|DRUG|Fentanyl; Buprenorphine; Naloxone|
224223052|NCT03187080|PROCEDURE|Sham paravertebral block using saline|Paravertebral block (PVB) will be performed in the standard fashion using an out-of-plane ultrasound approach by an anesthesiologist with appropriate training in regional anesthesia. Landmarks on the patient will be identified. The skin will be sterilized. The intended target (paravertebral space) will be located using an ultrasound. A Pajunk UniPlex NanoLine needle will be inserted. A syringe filled with sterile saline (used for hydrodissection) connected to a syringe of sterile saline will be connected to the Pajunk needle and used for injection. The needle will be advanced toward and through the superior costotransverse ligament or internal intercostal membrane. Once through the ligament, the pleura will be seen deflecting anteriorly with the hydrodissection. Negative aspiration will be confirmed, and the local anesthetic will be injected into the paravertebral space.
223634564|NCT00723736|DRUG|Desloratadine|2.5 ml (1.25 mg) once daily
223634565|NCT03694353|DRUG|Pegvaliase|40-60mg/day
223634566|NCT03670680|DEVICE|Use of the Lina LibrataTM|Use of the Lina LibrataTM
223634567|NCT04552951|DRUG|Cholecalciferol|Single doe of 100.000 IU
223634568|NCT05831228|DIETARY_SUPPLEMENT|Ketogenic food products|Participants will be given a ketogenic food product prior to the hyperbaric oxygen exposure.
223634569|NCT05831228|DIETARY_SUPPLEMENT|Control: Placebo|Participants will be given a dietary supplement comparator prior to the hyperbaric oxygen exposure.
223634570|NCT05306899|DRUG|Ketamine|Bolus of IV Ketamine 1 mg.kg-1 (= 0.1 ml.kg-1) followed by Infusion of Ketamine 1 mg.kg-1.hour-1 (= 0.5 mL.kg-1.hour-1) for 6 hours. All patients will receive IV midazolam 0.04 mg.kg-1 (maximum 3 mg) and subsequently 0.01-0.02 mg.kg-1 every hour to keep participants in a sedated but arousable state (Ramsay Sedation Scale score 3 or 4) to blind the participants and assessors to group allocation. Ondansetron 8 mg and 8 mg of dexamethasone will be administered to prevent nausea, 5000 units of heparin will be given subcutaneously to prevent thrombo-embolic events.
223634571|NCT05306899|OTHER|0.9% Saline|Bolus of IV Saline 0.9% of 0.1 ml.kg-1 followed by Infusion of Saline 0.9% of 0.5 mL.kg-1.hour-1 for 6 hours. All patients will receive IV midazolam 0.04 mg.kg-1 (maximum 3 mg) and subsequently 0.01-0.02 mg.kg-1 every hour to keep participants in a sedated but arousable state (Ramsay Sedation Scale score 3 or 4) to blind the participants and assessors to group allocation. Ondansetron 8 mg and 8 mg of dexamethasone will be administered to prevent nausea, 5000 units of heparin will be given subcutaneously to prevent thrombo-embolic events.
223634572|NCT05720897|OTHER|Auditory Alone|Participants randomized to this arm will receive earphones to listen to an 8 minute guided brief relaxation recording, focusing on breathing and a body scan. Participants will listen to the recording prior to their dental procedure.
223634573|NCT05720897|DEVICE|Relaxation Virtual Reality|Participants randomized to this arm will receive will receive virtual reality goggles and choose a scene of their liking to experience. Participants will choose from 11 different themed environments (such as savannah, beach, meadow, or space), and will experience the chosen virtual reality environment for 8 minutes. Participants will complete the virtual reality intervention prior to their dental procedure.
223634574|NCT02320084|DRUG|Nitisinone|Nitisinone according to prescription
223634575|NCT00400179|DRUG|S-1/Cisplatin|"In Arm A, S-1 25 mg/m2 was taken orally two times daily for 21 days followed by a 7-day recovery period. The patient was instructed to have nothing by mouth (NPO 1 hour prior to and 1 hour after S-1 administration. S-1 was taken with approximately 8 ounces of water and prior to cisplatin infusion on Day 1.~Cisplatin 75 mg/m2 was administered as a 1- to 3-hour IV infusion after the morning dose of S-1 on Day 1 of each cycle. This regimen was repeated every 4 weeks with a maximum of 6 cycles of treatment for cisplatin."
223764673|NCT04488276|OTHER|In-depth interviews|In-depth interviews will be conducted to understand how smoking partners of pregnant women perceive risks and behaviors related to SHS exposure and how can it be altered to decrease exposure of pregnant women to SHS. These will be conducted in peri-urban slums and rural settings of Rawalpindi district with expectant or new father who smoke and pregnant or new mothers exposed to SHS. Interview guide will be developed deductively as a result of the systematic review and will be piloted before its actual use. Trained interviewer will conduct in-depth interview using semi-structured interview guide and will record it with consent from respondents. This data will be transcribed and translated and coded by team of two researchers.
223764674|NCT04930029|OTHER|Ten year evaluation|Clinical, biological and endoscopic evaluation
224223053|NCT03187080|DRUG|Paravertebral block using local anesthetic|Use of local anesthetic (0.25% bupivacaine) that is \*NOT\* an experimental drug but will be used as part of the paravertebral block to provide local anesthetic. This will not be given to those in the sham block groups.
224223054|NCT00014521|DRUG|karenitecin|
224223055|NCT06039670|PROCEDURE|biliary biopsy|biliary biopsy through a percutaneous approach during a percutaneous biliary drainage
224223056|NCT00729235|DEVICE|Ovatio CRT 6750|"Slow VT zone programmed as a Monitoring zone (Monitoring arm)"
224223057|NCT00729235|DEVICE|Ovatio CRT 6750|Slow VT zone programmed with ATP therapies (therapy arm).
223634576|NCT00400179|DRUG|5-FU/cisplatin|In Arm B, 5-FU 1000 mg/m2/24 hours was administered CIV on Days 1 through 5 following cisplatin 100 mg/m2 administered IV as a 1- to 3-hour infusion on Day 1. This regimen was repeated every 4 weeks with a maximum of 6 cycles of treatment for cisplatin.
223634577|NCT06541938|DIETARY_SUPPLEMENT|low FODMAP diet|You consume low FODMAP diet for 24 hours before taking the FODMAP challenge
223634578|NCT06541938|DIETARY_SUPPLEMENT|Lactose Sachet|"You will engage in a 4-week study to document responses to 4 Fermentable Carbohydrates(FCHOs): Lactose(25g), Fructose(25g), Sorbitol(10g), and Inulin(10g). Each FCHO, dissolved in 250ml of lukewarm water, is taken after a 24-hour low FODMAP diet to clear residual FCHOs. Exhaled H2 and CH4 are measured before and 60 minutes after the first and last meal of the low FODMAP period. Each morning, after a baseline breath test, you will consume one FCHO challenge and record breath tests for three hours at 15-minute intervals. Following each challenge, there is a 6-day washout period with your typical diet. This 24-hour low FODMAP diet, FCHO challenge, and washout cycle is repeated until all FCHOs are tested. The order of FCHO challenges is randomized and consistent among all, who remain blinded to the order to minimize confounding factors.~25g sachet having lactose roughly equal to amount of lactose present in 1 large glass of milk"
223634579|NCT06541938|DIETARY_SUPPLEMENT|Fructose Sachet|"You will engage in a 4-week study to document responses to 4 Fermentable Carbohydrates(FCHOs): Lactose(25g), Fructose(25g), Sorbitol(10g), and Inulin(10g). Each FCHO, dissolved in 250ml of lukewarm water, is taken after a 24-hour low FODMAP diet to clear residual FCHOs. Exhaled H2 and CH4 are measured before and 60 minutes after the first and last meal of the low FODMAP period. Each morning, after a baseline breath test, you consume one FCHO challenge and record breath tests for three hours at 15-minute intervals. Following each challenge, there is a 6-day washout period with your typical diet. This 24-hour low FODMAP diet, FCHO challenge, and washout cycle is repeated until all FCHOs are tested. The order of FCHO challenges is randomized and consistent among all, who remain blinded to the order to minimize confounding factors.~25g sachet having fructose roughly equal to the amount of fructose present in 2 large apples"
223764675|NCT03977571|PROCEDURE|Cytoreductive nephrectomy|Partial or complete nephrectomy by open, laparoscopic, or robotic approach.
223764676|NCT03977571|OTHER|Tissue sampling|Tumor biopsies, blood, and stool specimens for translational biomarker research will be sampled at baseline and after 3 or 6 months.
224223058|NCT02439606|DEVICE|Glide Rite Rigid Stylet group|Intubation with the GlideScope® video-laryngoscope and styletted the tracheal tube using manufacturer's GlideRite Rigid Stylet (GRS) (GVL - ST1; Verathon Medical Inc., Bothell, WA, USA). Time till successful intubation of the patient is calculated.
224223059|NCT02439606|DEVICE|Parker Flex-It directional stylet group|Intubated with the GlideScope® video-laryngoscope and styletted the tracheal tube using Parker-Flex-It directional Stylet (Parker Medical, Colorado, USA) (Flexi-Stylet). Time till successful intubation of the patient is calculated.
224223060|NCT03140306|DIAGNOSTIC_TEST|Patients who have had split dose CT|Computed tomography
224223061|NCT02602340|BEHAVIORAL|Behavioral Activation therapy|Behavioral Activation therapy
224223062|NCT00163410|DRUG|Ciclesonide|
224223063|NCT04188925|DEVICE|Laser Acupuncture|"The LA is using a gallium aluminum arsenide LaserPen (maximal power, 150 mW; wavelength, 810nm; area of probe, 0.03cm2; power density, 5W/cm2; pulsed wave; RJ-Laser, Reimers \& Janssen GmbH, Waldkirch, Germany). The LA treatment will be applied to EX-LE5, ST35, and BL40 for 80 seconds, under power 150mW, to deliver a total treatment dose of 6 Joule/ cm2.~The EA is the combination of acupuncture and transcutaneous electrical nerve stimulator. The transcutaneous electrical nerve stimulator is produced by Ching Ming Medical Device Company. This machine is verified by Department of Health in Taiwan, with the ID number 001147. We perform acupuncture on GB33, GB34, SP9, SP10, and ST36."
224223064|NCT04188925|DEVICE|Sham Laser Acupuncture|Sham LA is using the same appearance of LaserPen without energy output to perform the same acupoint as above description. Both of the LaserPen in two groups are labeled with A and B, one of them is revised by the company to become the sham LA. The outward of both LaserPen are the same and our physician does not know which one is the real.
224223065|NCT04829695|DRUG|Artesunate-amodiaquine drug combination|Artesunate-amodiaquine is co-packaged as artesunate 50 mg and amodiaquine hydrochloride USP equivalent to amodiaquine base of 153.1 mg. Each child shall be given one, two or three tablets depending on the weight.
224223066|NCT04829695|DRUG|Artemether-lumefantrine drug combination|Artemether-lumefantrine is formulated as tablets and will be provided in blister packs. Each tablet contains 20 mg artemether and 120 mg lumefantrine. Every pack has a picture showing how the drug should be given and contains two blisters for each day with one, two or three tablets depending on the weight of the child.
224223067|NCT01270022|OTHER|Implementation|
224223068|NCT01270022|OTHER|dissemination|
224223069|NCT02541656|PROCEDURE|Study of preload dependence indices after volume expansion in laparoscopy with Saldinger technique.|The measurements of pulse pressure variation, plethysmographic waveform of pulse oximetry variation and stroke volume variation will be performed before pneumoperitoneum at the beginning of the surgery, and will be repeated after pneumoperitoneum insufflation applying each time modification of preload conditions (applying reverse Trendelenburg position followed by Trendelenburg position). The responses will be appreciated by the measurements of the stroke volume.
224223070|NCT02893852|BEHAVIORAL|standard CO-OP Approach|The CO-OP protocol originally developed by Mandich and Polatajko (2004) comprises 12 sessions. The therapist teaches the participants a global cognitive strategy: GOAL - PLAN - DO - CHECK. The participants use the global strategy and cooperate to learn specific strategies to solve each task performance breakdown identified through Dynamic Performance Analyses (DPA). The therapist uses DPA at pre-intervention and throughout the sessions and mediational techniques to guide participants to use GOAL-PLAN-DO-CHECK to discover specific strategies to solve performance problems and to support generalization and transfer of skills.
224223071|NCT02893852|BEHAVIORAL|standard CO-OP Approach plus coaching parents|CO-OP Approach with parents coaching groups will include an addition of four extra coaching groups sessions for parents to provide additional information to supplement their knowledge on CO-OP (how to use GOAL-PLAN-DO-CHECK at home; how to use dynamic performance analysis to support their children's' performance solutions; to talk about their experiences with their children at home).
224223072|NCT04237571|BEHAVIORAL|CANE Meal Program|Participants will be encouraged to pick up a healthy meal from the Community Agriculture Nutritional Experience (CANE) Kitchen in Whitesburg, Kentucky once a week for five weeks. The meals will consist of at least one serving of a fruit or a vegetable. At each meal, education materials will be distributed, including the recipe for the healthy meals and nutrition handouts that are linked to the recipes. Additional information about the ways the nutrients in the meal may help protect from the negative effects of environmental pollutants will be included.
224223073|NCT01829295|DRUG|Mycophenolate mofetil|For the first two weeks, an introductory dose of 500 mg twice a day (BID) orally. After two weeks, the dose will be increased to 1.5 g BID.
223764677|NCT06447116|DEVICE|CGuard Prime™ Carotid Stent System|CGuard Prime™ Carotid Stent System
223634580|NCT06541938|DIETARY_SUPPLEMENT|Sorbitol Sachet|"You will engage in a 4-week study to document responses to 4 Fermentable Carbohydrates(FCHOs): Lactose(25g), Fructose(25g), Sorbitol(10g), and Inulin(10g). Each FCHO, dissolved in 250ml of lukewarm water, is taken after a 24-hour low FODMAP diet to clear residual FCHOs. Exhaled H2 and CH4 are measured before and 60 minutes after the first and last meal of the low FODMAP period. Each morning, after a baseline breath test, you consume one FCHO challenge and record breath tests for three hours at 15-minute intervals. Following each challenge, there is a 6-day washout period with your typical diet. This 24-hour low FODMAP diet, FCHO challenge, and washout cycle is repeated until all FCHOs are tested. The order of FCHO challenges is randomized and consistent among all, who remain blinded to the order to minimize confounding factors.~10g sachet of sorbitol is roughly equal to the amount of sorbitol present in 3 pears or 1 prune"
223634581|NCT06541938|DIETARY_SUPPLEMENT|Inulin Sachet|"You will engage in a 4-week study to document responses to 4 Fermentable Carbohydrates(FCHOs): Lactose(25g), Fructose(25g), Sorbitol(10g), and Inulin(10g). Each FCHO, dissolved in 250ml of lukewarm water, is taken after a 24-hour low FODMAP diet to clear residual FCHOs. Exhaled H2 and CH4 are measured before and 60 minutes after the first and last meal of the low FODMAP period. Each morning, after a baseline breath test, you consume one FCHO challenge and record breath tests for three hours at 15-minute intervals. Following each challenge, there is a 6-day washout period with your typical diet. This 24-hour low FODMAP diet, FCHO challenge, and washout cycle is repeated until all FCHOs are tested. The order of FCHO challenges is randomized and consistent among all, who remain blinded to the order to minimize confounding factors.~A 10g sachet of inulin is roughly equal to the amount of inulin present in 1 head of garlic"
223634582|NCT06541938|DEVICE|AIRE-2 Portable breath analyzer|The AIRE-2 breath analyzer will capture hydrogen and methane at baseline and after every fodmap challenge
223634583|NCT04780061|DRUG|Vitamin D3 50,000 IU|This is a loading dose of Vitamin D. Vitamin D (cholecalciferol \[vitamin D3\]) is a fat-soluble vitamin that is synthesized following ultraviolet radiation to the skin, naturally occurs in a few dietary sources and is available as a dietary supplement.
223634584|NCT04780061|DIETARY_SUPPLEMENT|Vitamin C/Zinc|This is a combination of Vitamin C and Zinc. Vitamin C (ascorbic acid, ascorbate) is a water-soluble vitamin that naturally occurs in many foods and is sold as a dietary supplement. It is required for the functioning of several enzymes and is important for the immune system. Zinc is one of the most abundant essential trace elements in the human body and is required for the function of several hundred enzymes and transcription factors.
223634585|NCT04780061|DIETARY_SUPPLEMENT|Vitamin K2/D|This is a combination of Vitamin K2 (menaquinone-7) and vitamin D. Vitamin K (menaquinone-7 \[vitamin K2\]) is a fat-soluble vitamin found in foods and sold as a dietary supplement. Vitamin K plays a large role in synthesizing coagulation factors in the blood, and vitamin K deficiency has been associated with uncontrolled bleeding. Vitamin K1 (phylloquinone) is an alternate form of vitamin K found in foods and supplements; however, vitamin K2 has a better absorption profile50 and additionally plays a role in bone metabolism controlling the binding of calcium, especially in older adults, where it attenuates the rate of bone loss
223634586|NCT04780061|OTHER|Microcrystalline Cellulose Capsule|Placebo equivalent of Vitamin C/Zinc and Vitamin D3.
223634587|NCT04780061|OTHER|Medium Chain Triglyceride Oil|Placebo equivalent of Vitamin K2/D
223634588|NCT03090230|DEVICE|Relay Pro Thoracic Stent-Graft System|RelayPro Thoracic Stent-Grafts are designed for the management of patients with aneurysms and penetrating ulcers within the descending thoracic aorta (DTA). The device is designed specifically for use in the thoracic aorta.
223634589|NCT02753270|PROCEDURE|Short catheter|Ultrasound Guided Foam Sclerotherapy in Great Saphenous Vein, measuring from 6 to 10 mm, with Short Catheter.
223634590|NCT02753270|PROCEDURE|Long catheter preceded by tumescence|Ultrasound Guided Foam Sclerotherapy Transcatheter in Great Saphenous Vein, measuring from 6 to 10 mm, Preceded by Tumescence.
223634591|NCT00635414|DRUG|Esomeprazole|40mg oral
223634592|NCT00635414|DRUG|Esomeprazole|15 minute intravenous infusion
223634593|NCT04236427|DRUG|Angong Niuhuang Wan|Angong Niuhuang Wan 3g
223634594|NCT04236427|DRUG|Angong Niuhuang Wan Placebo|Angong Niuhuang Wan Placebo 3g
223634595|NCT00114569|DRUG|lorazepam|
224223074|NCT01829295|DRUG|Methotrexate|For the first two weeks, an introductory dose of 15 mg/week (7.5mg BID once a week) orally. After two weeks, the dose will be increased to 25 mg/week (12.5mg BID once a week)
224223075|NCT01829295|DRUG|Prednisone|All patients enrolled in the study will be initially taking concomitant oral corticosteroids at 1 mg/kg or 60 mg daily, whichever is less. Initial corticosteroid dose will be continued for 2 to 4 weeks at which point prednisone will be gradually tapered. Prednisone will be tapered to and held at 7.5 mg/day for the first 6 months of the study.
224223076|NCT05766215|BEHAVIORAL|Therapeutic Education|It consists of four structured phases: 1. Welcome nurse visit, 2. Diabetologic education course adapted to the detected needs, 3. Individualized follow-up through alternating quarterly appointments between nurses and endocrine physician, 4. Evaluation and discharge of the program
224223077|NCT00242775|DRUG|Budesonide/formoterol Turbuhaler|
224223078|NCT00242775|DRUG|Salmeterol/fluticasone Diskus|
224223079|NCT00039507|PROCEDURE|conventional surgery|
223634596|NCT03880097|PROCEDURE|Research Biopsy|"The Research Biopsy is a biopsy in addition to the standard of care biopsies that the patient will have to inform their diagnosis. The actual procedure is not any different to the standard per-cutaneous biopsy, this is just an additional procedure, solely for research purposes."
223634597|NCT05910996|PROCEDURE|Conversion from vv-ECMO to va-ECMO|Conversion from vv-ECMO to va-ECMO
223634598|NCT00509977|PROCEDURE|Light Treatment|Light treatment applied to half of the face at each study visit
224223080|NCT00039507|PROCEDURE|radiofrequency ablation|
224223081|NCT01626859|DRUG|MP-214 3mg|Patients who meet eligibility criteria will be administered a once daily oral 3mg of MP-214 for twelve weeks.
223634599|NCT00509977|PROCEDURE|Laser Treatment|Laser treatment applied to half of the face at each study visit
223634600|NCT05670093|DEVICE|Neural Pressure Support (mode of mechanical ventilation)|Nasogastric tube will be removed and replaced by a Esophageal catheter and Electrical Diaphragm activity catheter and mechanical ventilation in mode Neural Pressure Support
223634601|NCT06061991|BEHAVIORAL|Mobile instant messaging-based lifestyle intervention|Nurse-led personalised lifestyle intervention grounded in social cognitive theory via WhatsApp or WeChat from baseline to the 28th gestational week, which aims to maintain optimal gestational weight gain using dietary and exercise advice and behavioural change techniques.
223634602|NCT06061991|BEHAVIORAL|Text messaging reminders|Follow-up reminders via text messaging as attention control.
223634603|NCT06061991|BEHAVIORAL|Brief advice on GDM prevention|Brief advice on GDM prevention aided by an A4-sized, half-fold leaflet, which covered the risk factors and complications of GDM, optimal gestational weight gain targets, and advice on dietary and exercise during pregnancy
223634604|NCT06061991|BEHAVIORAL|Usual care|Usual care provided by the prenatal clinic.
223634605|NCT05907785|BEHAVIORAL|Educational intervention|The intervention will consist of recommendations to improve physical activity (PA) and dietary habits. It is based on the PAIDO Programme (www.programapaido.es), an outpatient family-based multidisciplinary programme that combines PA, education on nutrition, and behavioural therapy. It will last 6 months and improvement of metabolic health and body weight loss is expected, particularly in the groups with overweight and obesity. The dietary intervention will be focused on the promotion of the Mediterranean diet, with follow-up and advice from a dietitian-nutritionist. Participants will be encouraged in reducing sedentary behaviour (watching television, playing computer games, playing board games). Performance of aerobic and strength physical exercises will be scheduled, progressively increasing the intensity. Volunteers and their parents will participate in monthly sessions to follow-up on adherence to the PA and dietary recommendations and give personalized advice.
223634606|NCT03548532|DEVICE|G210 incubator|very stable culture temperature, up to 0.1°C, in both arms
223634607|NCT04327154|DEVICE|TISSIUM™ Nerve Coaptation Device|Placement of the TISSIUM™ Nerve Coaptation Device on repair site to achieve an end-to-end nerve coaptation.
223634608|NCT05317403|DRUG|Venetoclax|"Dose Level 0: Day 1 60 mg/m2 PO x1, Days 2-14 120 mg/m2/dose PO once daily (Max: 200 mg/day)~Dose level 1: Day 1 120 mg/m2 PO x1, Days 2-14 240 mg/m2/dose PO once daily (Max: 400 mg/day)~Dose level 2: Day 1 180 mg/m2 PO x1, Days 2-14 360 mg/m2/dose PO once daily (Max: 600 mg/day)"
223634609|NCT05317403|DRUG|Azacitadine|75 mg/m2/dose IV once daily over 15 minutes
223634610|NCT05317403|DRUG|Vorinostat|"1 year to 17.99 years old: 180 mg/m2/dose PO once daily~≥18 years old 200 mg PO BID. Doses should be separated by 12 hr (±4 hr)"
223634611|NCT05317403|DRUG|Cytarabine|"2000 mg/m2/dose IV once daily over 3 hours~IT Cytarabine:~1. \- 1.99 years old: 30 mg~2. \- 2.99 years old: 50 mg~   * 3 years old: 70 mg"
224223082|NCT01626859|DRUG|MP-214 6mg|Patients who meet eligibility criteria will be administered a once daily oral 6mg of MP-214 for twelve weeks.
224223083|NCT01626859|DRUG|MP-214 9mg|Patients who meet eligibility criteria will be administered a once daily oral 9mg of MP-214 for twelve weeks.
224223084|NCT04025619|DEVICE|tape|Sports tape
224318506|NCT02335697|BEHAVIORAL|Attitude change towards female circumcision|The intervention comprises of a series of meetings between newly arrived Somalis and established Somalis. At each meeting, a pre-determined topic relating to FC will be discussed. The topics include culture, religion, health, children's rights, and Swedish laws. Different experts, chosen to match the specific topic of the meeting will be invited to each meeting to facilitate the interactive discussions between the participants. Somalis who are both familiar with the Swedish and Somali culture will facilitate the meetings. The intervention spans over a time period of six months. The intervention meetings will be held during the first five months of the intervention period; one meeting scheduled per month. Thereafter, there will be a 'wash-out' period of one month to allow for reflections and to minimize the risk of courtesy bias.
223634612|NCT05317403|DRUG|Fludarabine|30 mg/m2/dose IV once daily over 30 minutes
223634613|NCT05317403|DRUG|Filgrastim|5 microgram/kg/dose subcutaneous (or IV over 15-30 min) once daily
223634614|NCT06212856|OTHER|Plyometric training|"The group will receive plyometric exercises in a controlled environment. Following, Plyometrics would be performed.~1. Leg hops~2. Tuck jumps~3. Vertical jumps~4. Explosive push-ups~5. Jumping spider~6. Lateral/ diagonal and broad jumps~7. Clapping push-ups~8. Medicine ball presses~9. Rotational throws~10. Vertical and obstacle jumps~11. Box shuffles~12. Chest passes~13. Box jumps~14. Drop jumps~15. Overarm throws"
223634615|NCT06212856|OTHER|Conventional|"The group will receive conventional exercises in a controlled environment. Following, conventional exercises would be performed.~1. Pushups.~2. Situps.~3. Lunges~4. Squats~5. 500m running"
223634616|NCT05142787|DEVICE|Magseed Pro(R) and Sentimag(R) Gen3 by Endomagnetics|placement of Magseed Pro \& localisation with Sentimag Gen3 in axillary lymph nodes and/or breast lesions
223764678|NCT01452308|BIOLOGICAL|Simtuzumab|
223764679|NCT01679275|OTHER|measuring cerebral oxygenation|
223764680|NCT01470469|DRUG|SPD503 (extended-release Guanfacine hydrochloride)|Once-daily oral dosing of SPD503 in the evening ranging from 1-6 mg for 12 weeks (6 week dose optimization and 6 week dose maintenance).
224223085|NCT01340274|BEHAVIORAL|CRAFT treatment|Clients will receive 12 sessions of CRAFT delivered over a 12 week period. There will be 1 session per week.
224223086|NCT01340274|BEHAVIORAL|Treatment as Usual|Clients will receive Treatment as Usual delivered over 12 session. There will be 1 session per week.
224223087|NCT02629965|DRUG|tiotropium|fixed dose combination
224223088|NCT02629965|DRUG|olodaterol|fixed dose combination
224223089|NCT02629965|DRUG|tiotropium|
224223090|NCT05426252|DRUG|Abatacept|Abatacept, co-stimulation blockade, to be given for GVHD prophylaxis in combination with sirolimus post allogeneic hematopoietic stem cell transplantation.
224223091|NCT05426252|DRUG|Sirolimus|Sirolimus, mTOR inhibitor, to be given for GVHD prophylaxis in combination with abatacept post allogeneic hematopoietic stem cell transplantation.
224223092|NCT00141284|DRUG|nelfinavir 1,250 mg twice daily|
224223093|NCT00141284|DRUG|Zidovudine 300 mg twice daily|
224223094|NCT00141284|DRUG|Lamivudine 150 mg twice daily|
224318507|NCT02335697|OTHER|No intervention|
223764681|NCT01470469|DRUG|Placebo|Once-daily oral dosing in the evening for 12 weeks.
223634617|NCT04060303|PROCEDURE|Perioperative surgical care|The ENRICH-US Protocol includes perioperative counseling and education, maintaining euvolumia through limited perioperative fasting and limited intraoperative fluid resuscitation, early enteral intake and mobilization, limited use of opioids, and non-routine use of surgical drains and tubes. Elements span the pre-, intra-, and post-operative experience for patients and involve care coordination among surgery, anesthesia, and nursing providers. Though individually simple, the concomitant implementation of the combined elements results in a markedly improved patient care experience that mitigates the physiologic stress of surgery and hastens recovery.
223634618|NCT06069128|DEVICE|Neurotrigger Basic. eye blinking stimulator|NeuroTrigger Basic is intended to stimulate healthy muscles in order to improve or facilitate muscle performance for maintaining/increasing muscle range of motion and for the prevention or retardation of disuse atrophy.
223634619|NCT00517387|DRUG|Quetiapine XR|All patients will receive Quetiapine XR at an initial dose of 50mg/day to be increased incrementally (dose of 50mg/day 2 and 150mg/day 3) to achieve a target dose of 300 mg/day by day 4. Tablets will be self-administered early each night.
223634620|NCT06332495|OTHER|Questioning the patient during hygiene care|The study examines how patients and caregivers feel when using the bedpan. Over the course of a day, collecting all this information would take just under 7 minutes. Over the duration of patient participation (2 days), we estimate that it would take a total of 15 minutes per patient to collect this information. The objectives are focused on pain and discomfort, and on the alteration of the (patient's) skin condition through objective observation of redness or stage I pressure sores by the caregiver.
223634621|NCT03007732|DRUG|Pembrolizumab|200 mg IV every 21 days for up to 13 doses (Arms 1 and 2)
223634622|NCT03007732|DRUG|SD-101|5 mg will be delivered to the dominant prostatic tumor lesion at time of fiducial marker placement (1-5 weeks prior to Cycle 1, Day 1) and and 1-3 weeks after Cycle 1 Day 1
223634623|NCT03007732|DRUG|Leuprolide acetate|22.5 mg will be given intramuscularly (IM). First injection 3 months prior to Cycle 1 Day 1. Intermittent androgen deprivation therapy will be given every 3 months starting Cycle 1, Day 1 for 3 additional doses.
223634624|NCT03007732|DRUG|Abiraterone Acetate|1000 mg oral dosage will be given daily for 3 months prior to Cycle 1, Day 1 and daily for 9 months starting Cycle 1, Day 1.
223634625|NCT03007732|DRUG|Prednisone|5 mg oral dosage will be given daily for 3 months prior to Cycle 1 Day 1 and daily for 9 months starting Cycle 1, Day 1.
223634626|NCT03007732|RADIATION|Stereotactic Body Radiation Therapy|7 Gy x 5 fractions (35 Gy total) 1-2 weeks after fiducial marker placement and simulation over 10-14 days.
223634627|NCT06202365|DEVICE|Whole body Vibration|A vibrating platform (WBV) will be used in this study with 6 training exercises for 4 minutes, 2 times /week for 6 weeks. Feet should be parallel at shoulder width apart and knees hold constant. WBV sessions were conducted from low to medium-vibration mode
223634628|NCT06202365|OTHER|Sham Whole body vibration|They will receive the same intervention while the device turned off for 4 minutes, 2 times /week for 6 weeks.
223764682|NCT05916586|DRUG|Prednisone|Prednisone 40 mg orally once a day for 7 days
224223095|NCT02189083|DRUG|TSD|"TSD is composed of 15 individual Chinese medicines: Astragalus Membranaceus, Semen Coicis, Poria, Curcuma longa L, and Fritillaria Thunbergii Miq, Cassia twig, Pollen typhae, Resina draconis, Lithospermum erythrorhizon, Halloysitum Rubrum, Rhizoma Corydalis processed with vinegar, Hirudo, Calcined corrugated sub , Oyster Shell and Laminaria Japonica Aresch.~High dose (127g) or Low dose (69g) TSD decoction boiled as 200ml per bag; 2 bags per day, 6 days per week; Orally in-take one bag of TSD decoction in morning and another in evening after meal; The whole treatment lasts for 16 weeks."
224223096|NCT00035165|DRUG|epothilone b|intravenous 2.5 mg/m2 as a 5 minutes bolus infusion once every week for three weeks followed by one week off
224223097|NCT04270669|BIOLOGICAL|intravitreal injection of RC28-E 0.5mg|The patient received one treatment of RC28-E 0.5mg in the test group
224223098|NCT04270669|BIOLOGICAL|intravitreal injection of RC28-E 1.0mg|The patient received one treatment of RC28-E 1.0mg in the test group
224223099|NCT04270669|BIOLOGICAL|intravitreal injection of RC28-E2.0mg|The patient received one treatment of RC28-E 2.0mg in the test group
224318508|NCT01654315|DEVICE|Myomo Robotic Arm|"Patients are administered rehabilitative therapy (repetitive task specific therapy,, also known as RTP' in this study) using only the Myomo robotic device targeting their affected arms on 3 days/week during a 8 week period. These patients engage in RTP, which consists of a battery of activities that emphasize use of their affected arms repetitively, with the device providing assistance as needed with movement through the arm's range of motion."
224318509|NCT01654315|BEHAVIORAL|RTP Standard Therapy|Active Comparator: RTP Group Patients are administered rehabilitative therapy using only RTP that is targeting their affected arms on 3 days/week during a 8 week period. In this condition, patients engage in activities that emphasize use of their affected arms repetitively, with the therapist providing assistance as needed with movement through the arm's range of motion. As patients progress, the amount of assistance provided by the therapist during the activities is reduced.
224318510|NCT05491486|BEHAVIORAL|Mindfulness-based Group Therapy|see above
224318511|NCT03094637|DRUG|Azacitidine|Given IV
224318512|NCT03094637|BIOLOGICAL|Pembrolizumab|Given IV
224318513|NCT06316011|DEVICE|Magnetocardiography|Magnetocardiography
223764683|NCT06421142|PROCEDURE|imaging examinations:FAPI PET/MRI, FDG PET/MRI, MRI|"FAPI PET/MRI and FDG PET/MRI examination Data acquisition was performed using a GE Healthcare SIGNA PET/MR instrument. Enrolled patients were injected intravenously with 68Ga-FAPI or 18F-FDG tracer and underwent simultaneous PET and MRI scanning approximately 30-60 minutes after intravenous administration of the tracer at a dose of 1.85-3.7 MBq/kg.~MRI examination MRI examination was performed using a Skyra 3.0T MRI scanner from Siemens, Germany, with a 16-channel phased-array surface coil, and the scanning range was from the superior margin of the iliac wing to the inferior margin of the pubic symphysis."
223764684|NCT05459129|DRUG|Atezolizumab|Atezolizumab will be administered intravenously at a fixed dose of 1200 mg on Day 1 of each 21-day cycle.
224223100|NCT00918697|PROCEDURE|Mechanical debridement|For mechanical epithelial removal, an 8.0-mm optical zone marker was applied to the cornea, centering over the entrance pupil. A hockey spatula was used to remove the central corneal epithelium.
223764685|NCT05459129|DRUG|Tiragolumab|Tiragolumab will be administered intravenously at a fixed dose of 600 mg on Day 1 of each 21-day cycle.
224223101|NCT00918697|PROCEDURE|Alcohol-assisted debridement|For alcohol-assisted debridement, 20% ethyl-alcohol solution was instilled into an 8.0-mm well and kept in contact with epithelium for 20 seconds (being careful to avoid spillage over the areas not being treated). It then absorbed using a dry cellulose sponge followed by copious irrigation with BSS. The epithelium of the central cornea was removed using a blunt spatula.
224223102|NCT02330081|DEVICE|Mirasol treatment of whole blood|"Subject will be infused with two products at the same time:~1. radio-labeled platelets derived from subject's stored whole blood which has been treated with Mirasol.~2. radio-labeled platelets derived from subject's untreated fresh whole blood."
224223103|NCT00700869|PROCEDURE|mechanical ventilation|mechanical ventilation
224223104|NCT04052399|DEVICE|anodal transcranial direct current stimulation|"Anodal tDCS of the lateral hypothalamus-cognitive or medial hypothalamus-cognitive network.~The total injected current will never go beyond 4 milliamp, which will be split among the different stimulation electrodes."
224223105|NCT04052399|DEVICE|cathodal transcranial direct current stimulation|"Cathodal tDCS of the lateral hypothalamus-cognitive or medial hypothalamus-cognitive network.~The total injected current will never go beyond 4 milliamp, which will be split among the different stimulation electrodes."
224223106|NCT04052399|DEVICE|transcranial direct current stimulation|Single blind sham stimulation (ramp-up ramp-down stimulation will be applied for 30 seconds)
224223107|NCT04916171|OTHER|incidence|It is aimed to determine the incidence of endometriosis and/or adenomyosis in patients diagnosed with polycystic ovary syndrome, or to determine the incidence of polycystic ovary syndrome in patients diagnosed with endometriosis and/or adenomyosis.
224223108|NCT01718210|DRUG|GM-CSF medium|incubation of IVF embryos with a specific medium containing GM-CSF
224223109|NCT01718210|DRUG|CONTROL|group of controls treated with a standard IVF medium
224223110|NCT00002189|DRUG|Paclitaxel|
224223111|NCT03016559|OTHER|releasing muscle|At baseline, hip and knee angles were measured. The quadratus lumborum muscle was released. After that, the hip and knee angles were re-measured.
224223112|NCT05455970|OTHER|Rhythmic auditory stimulation (RAS)|A therapeutic application of pulsed rhythmic or musical stimulation in order to improve gait or movement
224223113|NCT01572961|DRUG|acetylsalicilic acids (Aspirin)|single oral dose of 1g.
224223114|NCT01572961|DRUG|Placebo|
224223115|NCT04269278|DRUG|0 ul of dexmedetomidine|Venous blood is taken from 11 healthy volunteers and divided into four specimen bottles, which were added with different doses (0 ul) using dexmedetomidine
224223116|NCT04269278|DRUG|0.25 ul of dexmedetomidine|Venous blood is taken from 11 healthy volunteers and divided into four specimen bottles, which were added with different doses (0.25 ul) using dexmedetomidine
224223117|NCT04269278|DRUG|0.5 ul of dexmedetomidine|Venous blood is taken from 11 healthy volunteers and divided into four specimen bottles, which were added with different doses (0.5 ul) using dexmedetomidine
223764686|NCT05459129|DRUG|Carboplatin|Carboplatin will be administered intravenously at a dose of area under the concentration-time curve (AUC) 5 mg/mL/min on Day 1 of each 21 day cycle.
224223118|NCT04269278|DRUG|0.75 ul of dexmedetomidine|Venous blood is taken from 11 healthy volunteers and divided into four specimen bottles, which were added with different doses (0.75 ul) using dexmedetomidine
224318514|NCT05725551|DEVICE|ShotBlocker|"Before the procedure, the protruding surface of the vehicle was placed on the injection site in contact with the skin and used by holding it during injection. The level of pain and fear experienced by the child during and 5 minutes after the injection was evaluated with the Facial Expressions Pain Scale and Visual Comparison Scale, and the level of fear was evaluated with the Child Fear Scale by the child, the parent accompanying the child, and the observer."
223764687|NCT05459129|DRUG|Paclitaxel|Paclitaxel will be administered intravenously at a dose of 175 mg/m2 on Day 1 of each 21 day cycle.
223764688|NCT03816358|BIOLOGICAL|Anetumab Ravtansine|Given IV
223764689|NCT03816358|PROCEDURE|Biopsy Procedure|Undergo biopsy
223764690|NCT03816358|PROCEDURE|Biospecimen Collection|Undergo collection of blood
223764691|NCT03816358|DRUG|Gemcitabine Hydrochloride|Given IV
223764692|NCT03816358|BIOLOGICAL|Ipilimumab|Given IV
223764693|NCT03816358|BIOLOGICAL|Nivolumab|Given IV
223764694|NCT06285981|DEVICE|Chimaera Long Nail|The CHIMAERATM, is an internal fixation system intended intended for insertion into the medullary canal of a femur in individuals suffering from stable and unstable pertrochanteric, intertrochanteric and subtrochanteric fractures of the femur alone or when these fractures occur in combination with shaft fractures extending distally to a point approximately 10cm proximal to the intercondylar notch.
224223119|NCT00654303|DRUG|Rosuvastatin|
224223120|NCT02778178|DRUG|ropivacaine plus clonidine|20 mL ropivacaine 3.75 mg/ml + 75 µg clonidine, per side
224223121|NCT02778178|DRUG|Placebo|20 mL saline 0.9%, per side
224223122|NCT02778178|DEVICE|ultrasound|
224223123|NCT03210675|DIAGNOSTIC_TEST|Polysomnography (PSG)|PSG will be perfomed every 6 months in the Study group from the age of 6 months to 3 years
224223124|NCT03474705|DEVICE|Eccentric Training Protocol|A custom-built dynamic shoulder dynamometer (Aalborg University, Aalborg, Denmark) will be used. Participants will be seated with back support and no feet support. The maximal voluntary contraction (MVC) of the painful side will be assessed. Sessions will start with a 5-min warm-up. After that, participants will sit in the dynamometer, and the range of shoulder elevation (highest and lowest vertical position) will be measured for the affected side. During training, subjects will have to counteract a dynamometer vertical force from the highest to the lowest shoulder position at a force equal to 60% (training sessions 1-3), 70% (training sessions 4-6), and 80% (training sessions 7-10) of the MVC recorded during baseline. Three bouts of 10 repetitions (sessions 1-3), 8 repetitions (sessions 4-6) and 6 repetitions (sessions 7-10) will be performed, with a 3-second rest between contractions and a 2-minute break between bouts.
224223125|NCT06359678|DEVICE|NorthStar|Throughout the real-time MRI-guided ablation procedure, the operator will assess the precision of the NorthStar 3D navigation software. Before commencing the actual ablation, the operator will confirm the alignment of the 3D anatomical shell, generated in NorthStar through specific electrical signals. Post the ablation procedure, a secondary alignment verification will be conducted to detect any potential drift or shift.
223634629|NCT06359015|DRUG|Metformin|"Oral Metformin schedule:~Day 1: 500 milligrams in morning Day 2: 500 milligrams two times a day Day 3: 1000 milligrams in morning, 500 milligrams in evening Day 4 onwards: 1000 milligrams two times a day based on individual tolerance~Oral Esomeprazole schedule:~40 milligrams Oral Esomeprazole daily until delivery which can be tapered down to 20 milligrams daily based on individual tolerance."
223634630|NCT06359015|DRUG|Esomeprazole|40 milligrams Oral Esomeprazole daily until delivery which can be tapered down to 20 milligrams daily based on individual tolerance.
223764695|NCT03924492|DRUG|ZULRESSO (brexanolone) injection|ZULRESSO
223764696|NCT04140149|BEHAVIORAL|Living with Hope|12-week, CBT-based, psychoeducational skills class
224223126|NCT04076306|OTHER|iSTEP exercise testing|iSTEP 10 minute step test, up and down on a commercial standard 3-height adjustable step Undertaking the 10m-MSWT 20-30 minutes Procedure takes place on testing track at Great Ormond Street Hospital; a 5 minute walk from the Haemophilia Centre. One of the research team accompanies the family with child to the track and will accompany them back to the Centre once testing is finished. Muscle Myometry 10 minutes, carried out by one of the research team at the end of the physiotherapy clinical assessment in the Haemophilia Centre. Wearing of accelerometer (activity/ step counter)7 days Device will be set up and provided at the end of the testing on the day of attendance at clinic. They will be instructed to wear this throughout the week at home when they are awake (at least 8 hours). Haemophilia Joint Health Score (HJHS) - a standardised outcome measure of joint health in people with Haemophilia, undertaken by the Clinical Specialist Physiotherapists in Haemophilia.
224223127|NCT01811797|DEVICE|Low Intensity Shockwave by Renova|
224223128|NCT01811797|DEVICE|Sham treatment|Sham treatment that looks, sounds and feels like the real LISW treatment.
224223129|NCT04846556|OTHER|data collection|data collection : gender, weight, biological data (platelets, hemoglobin, creatinine, liver function tests), performance status, type of Venous Thromboembolic Event (VTE) and cancer, anticancer and anticoagulant therapy, adverse events (bleeding, recurrence of Venous Thromboembolic Event (VTE), death) up to 6 months after their Venous Thromboembolic Event (VTE).
224223130|NCT03958981|DRUG|Castor Oil|The intervention group will be given 60 mL of castor oil in 140 mL of orange juice
224223131|NCT03958981|DRUG|placebo|the control group will be given a sunflower oil as a placebo with a similar texture to castor oil
224223132|NCT02531230|DEVICE|VascuFlex Multi-LOC®|Multi-LOC® peripheral stent system for bailout stenting after Plain Old Balloon Angioplasty (POBA) or Drug Coated Balloon (DCB) Angioplasty
224223133|NCT02826603|DRUG|Secukinumab|300mg, s.c. at randomization, Weeks 1, 2 and 3 and thereafter 4-weekly till Week 48
224223134|NCT02826603|DRUG|Ustekinumab|Per approved label, 45 mg or 90 mg s.c. based on subject weight (at randomization visit) to be administered at randomization, Week 4, 16, 28 and 40. At other timepoints subjects will receive placebo injections.
224223135|NCT02707432|BEHAVIORAL|Heart Matters|"Heart Matters is an intervention adapted from PREMIER, an evidence-based, comprehensive lifestyle intervention that focuses on blood pressure as the primary outcome. To assess the feasibility and efficacy of adapting PREMIER for rural African Americans, Heart Matters will be delivered to multiple intervention groups, but at two different stages."
224223136|NCT03221946|DRUG|Diclofenac Sodium|tablet of 50mg,
224223137|NCT03221946|DRUG|Diclofenac sodium|Transdermal patch 100 mg
224223138|NCT03221946|DRUG|Diclofenac|intra muscular injection 100mg
224223139|NCT01269983|OTHER|Fascial Manipulation|8 treatment session in 4 weeks: every week both fascial manipulation and standard physiotherapy
224223140|NCT04887545|DIAGNOSTIC_TEST|Proteomics analysis of pleural effusion|Pleural effusion removed as part of standard care is fractionized and analyzed by mass spectrometry
224223141|NCT03654209|DEVICE|Argon Plasma Coagulation|APC will be applied to the perimeter of the resection site
224223142|NCT03654209|DEVICE|Snare Tip Soft Coagulation|STSC will be applied to the perimeter of the resection site
224223143|NCT03681106|DEVICE|Kinesio Tex|Kinesio Tex tape on the operated limb
224223144|NCT01337050|DRUG|PF-03446962|PF 03446962 given by a 1 hour IV infusion. Each patient will initially receive the first dose on Cycle 1 Day 1 with a 28 day observation period. Cycle 2 will start on Day 29. The dosing interval will be 14 days for Cycle 2 and subsequent cycles.
224223145|NCT00003102|BIOLOGICAL|Iodine-131 radiolabeled chimeric monoclonal antibody G250 (131I-cG250)|cG250 is an IgG1 chimeric monoclonal antibody. It was supplied as a sterile solution at a concentration of 1.0 mg/mL in either a 2 mL or a 5 mL vial. cG250 was radiolabeled with Iodine-131 prior to use.
224223146|NCT01273103|DRUG|200mg [14C]- GSK2248761|single oral suspension dose of \[14C\]- GSK2248761 200 mg
224223147|NCT00583596|DEVICE|Device closure with AMPLATZER Duct Occluder|Device closure with AMPLATZER Duct Occluder
224223148|NCT00583596|OTHER|Objective Performance Criteria|Compare results of device closure to objective performance criteria
224223149|NCT00088777|BEHAVIORAL|Behavioral coping skills training plus physical therapy|10 hours coping sessions, 6 hours activating physical therapy, 4 hours physical therapy education
224223150|NCT00088777|BEHAVIORAL|Stress management education plus physical therapy|10 hours stress management education, 6 hours activating physical therapy, 4 hours physical therapy education
224223151|NCT04523415|OTHER|without intervention, just retrospectively review the data about patients|without intervention
224223152|NCT02934828|DRUG|Neoadjuvant Chemotherapy|Neoadjuvant Chemotherapy: TNBC:paclitaxel (PTX) 175mg/m2 d1, Carboplatin area under the curve（AUC4） d2, q14d\*6. HER-2 Positive BC: PTX 175mg/m2 d1, Carboplatin AUC4 d2, q14d\*6, and plus Herceptin 2mg/kg qw, 6mg/kg q3w after chemotherapy until 1 year.
224223153|NCT02934828|DRUG|postoperative chemotherapy|postoperative chemotherapy: EC-P/D±H, paclitaxel and Carboplatin plus Herceptin(TCH）, EC/TC±H, and so on.
224318515|NCT05725551|OTHER|Finger Puppet group|"During the interaction between the finger puppet and the child, an intramuscular injection was made. The level of pain experienced by the child during the injection and 5 minutes after the injection was evaluated by the child, the parent and the observer through the Facial Expressions Pain Scale and the Visual Comparison Scale, and the fear level by the Child Fear Scale."
223764697|NCT03739775|PROCEDURE|Blood sampling|Patients will have a blood draw at each visit to the hospital and at least 6 months (+/- 1 month) intervals.
223764698|NCT06631287|DRUG|Baricitinib|4mg encapsulated, pre-formed tablet PO once daily for 24 weeks.
223764699|NCT06631287|OTHER|Placebo|Matched placebo capsule, PO once daily for 24 weeks.
224318516|NCT05725551|OTHER|Balloon group|"An intramuscular injection was given when the child began to inflate the balloon. The level of pain experienced by the child during the injection and 5 minutes after the injection was evaluated by the child, the parent and the observer through the Facial Expressions Pain Scale and the Visual Comparison Scale, and the fear level by the Child Fear Scale."
224318517|NCT02268877|OTHER|Emergency Medicine Physician Ultrasound|An ultrasound will be performed by an emergency medicine resident or attending physician
224318518|NCT02268877|DEVICE|Ultrasound|An ultrasound will be performed by a radiology department technician
224318519|NCT00699426|DRUG|nexium|40 mg once daily is tested together with Yoghurt
224318520|NCT00699426|DRUG|nexium|nexium and placebo are tested
224223154|NCT01955603|DRUG|NNC0215-0384|A total of seven once-weekly doses of NNC0215-0384 or placebo will be administered subcutaneously (s.c., under the skin) at one of three ascending dose levels. Each cohort will consist of eight subjects randomised to either active (6 subjects) or placebo (2 subjects) treatment. Each subject will participate in one cohort only. Dose-escalation to the next dose level will be initiated when the safety data has been evaluated and if considered safe.
224223155|NCT01955603|DRUG|placebo|Placebo administered corresponding to NNC0215-0384 treatment
224223156|NCT02874963|PROCEDURE|Surgical Periodontal Treatment|In the patient's with periodontal disease at least one tooth extraction will be performed.
224318521|NCT00699426|DIETARY_SUPPLEMENT|Yoghurt|Yoghurt
223634631|NCT05880134|PROCEDURE|conventional posterior nerve neurectomy|"A vertical incision is made behind the posterior fontanelle. The posterior end of the posterior fontanelle is identified by palpation with an elevator. .~The mucoperiosteum is raised gently using a Cottle elevator or a suction freer elevator, after making the initial incision. Care must be taken not to injure the sphenopalatine vessel during flap elevation.~The peripheral part of the posterior nasal nerve can usually be identified just behind the incision, about 4-5 mm inferior to the sphenopalatine artery or crista ethmoidalis.~I After identifying the nerve fibres, it is cauterised using monopolar suction cautery and cut using microscissors. It is essential to carry out this procedure on both sides for effective results."
224223157|NCT02874963|DEVICE|Non Surgical Periodontal Treatment includes scaling root planing with UDS-J Ultrasonic Scaler.|Previous to surgery procedures, in particular in the two groups with an adjunctive non surgical periodontal treatment such as full mouth tooth cleaning will be included: full-mouth scaling and root planing (FM-SRP) with ultrasonic device (UDS-J Ultrasonic Scaler, Guilin Woodpecker Medical Instrument) and periodontal curets for mechanical debridement of the supra- and sub-gingival plaque and calculus.
224223158|NCT02874963|DRUG|Non Surgical Periodontal Treatment includes post operative mouth wash with Listerine® (ethanol 21.6%, methyl salicylate 0.06%, menthol 0.042%, thymol 0.064% and eucalyptol 0.092%)|Previous to surgery procedures, in particular in the two groups with an adjunctive non surgical periodontal treatment such as full mouth tooth cleaning will be included mouth wash with Listerine® (ethanol 21.6%, methyl salicylate 0.06%, menthol 0.042%, thymol 0.064% and eucalyptol 0.092%) for the 3 weeks after tooth extraction and cleaning.
223634632|NCT05880134|PROCEDURE|cartilage graft reinforcement after posterior nerve neurectomy|"A vertical incision is made behind the posterior fontanelle. The posterior end of the posterior fontanelle is identified by palpation with an elevator. .~The mucoperiosteum is raised gently using a Cottle elevator or a suction freer elevator, after making the initial incision. Care must be taken not to injure the sphenopalatine vessel during flap elevation.~The peripheral part of the posterior nasal nerve can usually be identified just behind the incision, about 4-5 mm inferior to the sphenopalatine artery or crista ethmoidalis.~I After identifying the nerve fibres, it is cauterised using monopolar suction cautery and cut using microscissors. It is essential to carry out this procedure on both sides for effective results.~then harvest cartilage from nasal septum and refashion it around sphenopalatine bundle to prevent nerve re-innervation~The mucoperiosteal flaps are repositioned . No nasal packing is required. Patients are discharged on the same day"
223634633|NCT06604273|DIAGNOSTIC_TEST|Fibroblast Activation Protein Inhibitor|PET CT imaging using the fibroblast activation protein inhibitor tracer
223634634|NCT06596824|BEHAVIORAL|Training intervention|Personalized digital training intervention aims to correct pathological knee movement and loading patterns and reduce inflammation in pre-stage knee osteoarthritis.
223634635|NCT06589817|DRUG|Hydrochloride Carliprazine capsules|Oral administration, once daily, with a total treatment duration of 6 weeks after successful screening.
224223159|NCT04939974|DIETARY_SUPPLEMENT|probiotic|The probiotic preparation selected for this study will contain use three species of probiotic bacterias namely Lactobacillus rhamnosus - ATCC 21052, Lactobacillus plantarum - ATCC 8014 and Bifidobacterium longum subsp. Infantis-ATCC 15707 at the dose of one billion (10 9 ) CFU/g of product (Total 3x10 9 CFU/g).
224223160|NCT06194097|PROCEDURE|adenoidectomy versus endoscopic sinus surgery with adenoidectomy|adenoidectomy versus endoscopic sinus surgery
224223161|NCT03502421|DRUG|Ketamine|Low dose continuous infusion of ketamine 0.3 to 0.5 mg/kg per hour
224318522|NCT00699426|DRUG|placebo+placebo|placebo and placebo are tested.
224318523|NCT00953966|OTHER|Genetically modified potatoes|Starch from genetically modified potatoes
223634636|NCT06589817|DRUG|Aripiprazole tablets|Oral administration, once daily, with a total treatment duration of 6 weeks after successful screening.
223634637|NCT06601036|DRUG|Sevoflurane|Patients will undergo fiberoptic intubation under sevoflurane sedation.
223764700|NCT06106373|DEVICE|iotaSOFT Insertion System|robotic assistive technology for cochlear implant electrode insertion
224318524|NCT01883466|OTHER|Forearm venous occlusion plethysmography study|Measurement of forearm blood flow during unilateral intrabrachial infusion of four vasodilator drugs in incremental doses separated with 20-min washout periods. Bradykinin (endothelial-dependent vasodilator that releases t-PA) was infused at 100, 300 and 1000 pmol/min; acetylcholine (endothelial independent vasodilator that does not release t-PA) was infused at 5, 10 and 20 mcg/min; sodium nitroprusside (endothelial independent vasodilator that does not release t-PA) was infused at 2, 4 and 8 mcg/min and verapamil (endothelial independent and NO independent vasodilator that does not release t-PA) was infused at 10, 30 and 100 mcg/min. Bradykinin, acetylcholine and sodium nitroprusside were given in random order and verapamil was administered last due to its long acting effects.
224223162|NCT03338465|DEVICE|Duolith SD1, STORZ Medical, Switzerland with F-SW applicator|The procedure will be performed with the patient in lateral positioning of the decubitus. The treatment area will be prepared with a coupling ultrasound gel to minimize the loss of shockwave energy at the interface between the tip of the applicator and the skin. The inline ultrasonic guide will be used to concentrate the shockwaves on the pain area in the trochanteric region. No local anesthesia will be applied.
223634638|NCT06601036|DRUG|2% Xylocaine (2 ml )|Patients will undergo fiberoptic intubation with bilateral Superior Laryngeal Nerve block and Recurrent laryngeal nerve block.
223634639|NCT06603727|DEVICE|Computerized Gaming Rehabilitation Program 1|Brain training games displayed on a large screen paired with physical exercise component. The program involves movements such as reaching, stepping, or stretching in place.
224223163|NCT03496454|OTHER|PfSPZ Challenge|The administration of an injection PfSPZ Challenge in Gambian adults
224223164|NCT00656019|DRUG|Vitamin D|0, 2000, 4000, and 6000 IU per day orally
224223165|NCT02407756|DRUG|Dupilumab|
224223166|NCT00054119|DRUG|Cositecan|Given IV
224223167|NCT00054119|OTHER|Pharmacological Study|Correlative studies
224223168|NCT03860519|BEHAVIORAL|Electronic Medication Monitors on ICS and SABA - Active Mode|"The patients in the intervention group will have sensors that are active, so that these patients receive reminders about when to use their inhalers medications."
224223169|NCT03860519|BEHAVIORAL|Electronic Medication Monitors on ICS and SABA - Silent Mode|"The patients in the control group will have sensors that are silent, so that these patients do not receive reminders about when to use their inhalers medications."
224223170|NCT03860519|BEHAVIORAL|Asthma App Tracking of ICS/SABA Usage - Active Mode|Patients in the intervention group will have access to their medication usage information (as collected by their sensors) via their Propeller Health applications.
224223171|NCT03860519|BEHAVIORAL|Asthma App Tracking of ICS/SABA Usage - Silent Mode|Patients in the control group will not have access to their medication usage information (as collected by their sensors) via their Propeller Health applications.
224223172|NCT03860519|BEHAVIORAL|NorthShore Connect Real Time ICS and SABA Usage Feedback - Yes|Patients in the intervention will receive feedback from the Research Nurse about their medication use and asthma control status.
224223173|NCT03860519|BEHAVIORAL|NorthShore Connect Real Time ICS and SABA Usage Feedback - No|Patients in the intervention will not receive feedback from the Research Nurse about their medication use and asthma control status.
224223174|NCT03860519|BEHAVIORAL|Asthma Nurse Monthly Phone Calls for ICS/SABA Usage Feedback - Yes|Patients in the intervention group will receive monthly calls from the Research Nurse to obtain feedback information about the Propeller Health Platform.
224223175|NCT03860519|BEHAVIORAL|Asthma Nurse Monthly Phone Calls for ICS/SABA Usage Feedback - No|Patients in the control group will not receive monthly calls from the Research Nurse to obtain feedback information about the Propeller Health Platform.
224223176|NCT02808806|OTHER|real-time audio-visual feedback|real-time audio-visual feedback to caregivers on TSD (i.e. displaying time, a colour code which will provide an easy-view visualization on whether or not pre-set median time delays between locations are exceeded, and auditory signals indicating the elapsed time), displayed through handhelds and on pre-mounted tablets through the whole trajectory of acute stroke care
224223177|NCT01674842|RADIATION|Radiation Therapy|Once daily, Monday - Friday for six weeks
224223178|NCT01674842|DRUG|Cisplatin|Intravenously, once weekly for six weeks
223634640|NCT06603727|DEVICE|Computerized Gaming Rehabilitation Program 2|Brain training games displayed on a tablet device paired with physical exercise component. The program involves movements such as reaching, stepping, or stretching.
223634641|NCT06590701|OTHER|Early dart throwing motion-mobilization|We compare two different mobilisations in the rehabilitation of patients following scapholunate ligament reconstruction
223634642|NCT06604572|PROCEDURE|Transabdominal preperitoneal approach|The enrolled patients underwent either open tension-free hernia repair or Transabdominal preperitoneal approach
223764701|NCT05013554|DRUG|SAR443216 IV|Pharmaceutical form: Powder for solution; Route of administration: IV infusion
224223179|NCT06320899|DEVICE|SpineShape System IV straight rod elastic|Implantation of SpineShape System IV straight rod elastic
224223180|NCT06320899|DEVICE|SpineShape System IV straight rod medium|Implantation of SpineShape System IV straight rod medium (mid-flex)
223634643|NCT06592417|DRUG|JSKN016 injection|JSKN016 is a bispecific antibody drug conjugate targeting HER3 and TROP2.
223764702|NCT05013554|DRUG|SAR443216 SC|Pharmaceutical form: Powder for solution; Route of administration: SC injection
223764703|NCT04446260|DRUG|SHR-A1811|be administered via intravenous (IV) infusion
224223181|NCT06320899|DEVICE|SpineShape System IV straight rod stiff|Implantation of SpineShape System IV straight rod stiff (low-flex)
224223182|NCT06407895|OTHER|Lower Limb Fitness Program|the stability of the core area can help to improve dynamic balance, coordinate the upper and lower trunk muscles, and reduce muscles' damage and abnormalities. Physiotherapy had a role in programming training for Down Syndrome children, for example, using squat to stand training that seemed to improving lower extremity muscle power. Squat-to-stand training will stimulate the proprioceptive stimulation on the trunk and lower extremity
224223183|NCT06407895|OTHER|Routine Therapy|In control group routine therapy will be given 3 times a week for 6 weeks with session conducting 45 minutes per sessions which involve standing balance exercises, sitting from chair to stand, heal to toe stand will be performed.
224223184|NCT00096486|DRUG|everolimus|
224223185|NCT00096486|DRUG|gefitinib|
224223186|NCT00895583|DRUG|Tacrolimus|During the screening phase, tacrolimus is provided by the investigator (not the Sponsor) and is dosed to achieve a target trough level determined by the investigator. Therefore, the dosage form, dosage, and frequency are determined by the investigator. Duration of treatment is from transplantation until randomization (from 90 to 150 days).
224223187|NCT00895583|DRUG|Sirolimus|Following randomization, sirolimus is provided by the Sponsor in 1 and 2 mg oral tablets. Sirolimus is dosed once daily to achieve a target trough level of 7 to 15 ng/mL in the 1st year post-transplant and 5 - 15 ng/mL in the 2nd year post-transplant. Duration of treatment is from randomization through 2 years post-transplant (19 to 21 months).
224223188|NCT00895583|DRUG|Tacrolimus|During the study, tacrolimus is provided by the investigator (not the Sponsor) and is dosed to achieve a target trough level determined by the investigator. Therefore, the dosage form, dosage, and frequency are determined by the investigator. Duration of treatment is 2 years post-transplant.
223634644|NCT06654635|DRUG|Rhomboid intercostal plane block|The patients in this group will receive ultrasound -guided rhomboid intercostal plane block after induction of general anesthesia. The rhomboid intercostal block will be performed at the T6 levels, bilaterally.
223634645|NCT06654635|OTHER|Erector spinae plane block|The patients in this group will receive ultrasound -guided Erector spinae plane block after induction of general anesthesia. Erector spinae plane block will be performed at the level of T9 bilaterally.
223634646|NCT06654635|OTHER|Control group|No block will be performed, and patient will receive general anesthesia (GA) only.
224223189|NCT04163692|OTHER|Progressive relaxation exercises|"Following intructions have been performed by patients:~* Punch your hands and contract your forearm~* Punch your hands, push your elbow towards the seat~* Bend your elbows~* Push your shoulders back~* Press your knee down and pull your toes towards you~* Pull your knees towards you and push your feet down~* Tighten your hips~* Push your head back~* Lift your eyebrows~* Make wrinkles on your nose~* Tighten your teeth~* Push your chin down~* Close your eyes and think of good things."
224223190|NCT03333525|OTHER|Calculation of insulin dosages for different meals|Calculation of insulin dosages For CARB counting meals using insulin-carbohydrate ratio for dosing mealtime boluses. For fat protein counting meal ICR and additionally fat-protein unit were used for dosing of mealtime boluses.
224223191|NCT04593680|DRUG|Emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg (F/TDF) and emtricitabine 200 mg/tenofovir alafenamide 25 mg (F/TAF)|The first full PK measurement of MHT will be performed starting at week 4 and end at week 6 to assess the steady-state plasma PK of testosterone in the absence of PrEP. The second PK measurement of MHT will be performed starting at week 12 and end at week 14 to assess plasma PK of testosterone in the presence of both MHT and PrEP. The first full PK measurement of PrEP will be performed at week 12 to assess the steady-state plasma PK of FTC, TFV, and TAF; and intracellular PBMC FTC-TP and TFV-DP in the presence of both MHT and PrEP. The second measurement of PrEP will be performed at week 16 to assess plasma PK of FTC, TFV, and TAF; and intracellular PBMC FTC-TP and TFV-DP in the absence of MHT.
224223192|NCT04120168|GENETIC|Laboratory Tests|"* Acid Alpha IgGlucosidase alpha enzyme test for Late Onset Pompe Disease and gene sequencing test from the same sample in samples with low enzyme activity~* Genetic Analysis for DMD (only in boys): Detection of dystrophin gene for duplication and deletion with MLPA (Multiplex-ligation dependent probe amplification) and re-screening for other mutations by gene sequencing in patients without MLPA deletion / duplication."
224223193|NCT03509051|BIOLOGICAL|B vaccination|One intramuscular injection of Bexsero (multicomponent B vaccine) from 6 months after transplant. A second similar dose will be given 2 months later.
224223194|NCT00924066|DRUG|Ixempra (Ixabepilone (BMS-247550) )|Participants received Ixabepilone 6mg/m\^2 for a total of 30mg/m\^2 inpatient or outpatient intravenously over an hour on the first five days of each 21 day cycle.
224223195|NCT04453566|OTHER|Online Survey|Online Survey
224223196|NCT02540148|DEVICE|Nova Oculus™ Micro-current electrical stimulation|Active treatment with transpalpebral micro-current electrical stimulation device, 3 sessions within 5 days of the 1st treatment. 1 session during weeks 2, 14 and 26.
224223197|NCT02540148|DEVICE|Nova Oculus™ Micro-current electrical stimulation - Sham treatment|Non-active treatment with transpalpebral micro-current electrical stimulation SHAM device, 3 sessions within 5 days of the 1st treatment. 1 session during weeks 2, 14 and 26.
224223198|NCT02260375|BIOLOGICAL|Mesenchymal Stromal Cells|
224223199|NCT01152281|BEHAVIORAL|Maximal Control|30 min video with stories of people with HIV. Content describes general health and emotional benefits of counseling.
224223200|NCT01152281|BEHAVIORAL|Instrumental and Empowering|Mix of Instrumental and empowering messages with stories of people living with HIV
224223201|NCT01152281|BEHAVIORAL|Minimal Control|Control messages to increase awareness of HIV risk
224223202|NCT01152281|BEHAVIORAL|Instrumental|Instrumental messages with stories of people living with HIV
224223203|NCT01152281|BEHAVIORAL|Empowering|Empowering messages with stories of people living with HIV
223634647|NCT06988410|BEHAVIORAL|Work opportunities|Individuals in the treated arms of the study will be offered work opportunities (sewing bags) to earn cash. The timing of these opportunities and knowledge of the amount and timing varies by experimental arm.
223634648|NCT06592066|DEVICE|Digital Impression by using Intraoral Scanning of Scan Bodies|intraoral scanning will be used to capture the positions of full-arch mandibular implants with the aid of scan bodies.
223634649|NCT06592066|DEVICE|Digital Impression by using Intraoral Scanning of Scan Bodies with Prefabricated Landmarks|intraoral scanning will be used to capture the positions of full-arch mandibular implants with the aid of scan bodies with prefabricated landmarks in place.
223634650|NCT06592066|DEVICE|Splinted Open Top Tay Conventional Impression Technique|Splinted open-top tray conventional impression technique will be preformed by using medium body silicone impression material.
223634651|NCT06602557|DRUG|Amikacin|Patients included in the inhaled amikacin group will receive inhaled antibiotic therapy by nebulization of amikacin at a dose of 25 mg/kg in 1 daily dose (+/- 3 hours apart), within 6 hours of randomization and for a total duration of 5 days.
223634652|NCT06602557|DRUG|Standard of care|Patients included in the standard of care group will not receive any nebulization. They will receive Standard care alone.
223634653|NCT06596070|OTHER|No intervention was carried out|This study is an observational study and no intervention was performed on the patients.
223634654|NCT06993285|OTHER|Protologic and LAnguage adaptation rehabilitation|Each patient will receive a maximum of 34 weeks of Protologic and LAnguage adaptation rehabilitation by a speech therapist at a rate of one or two speech therapy sessions per week, for a total of 30 sessions maximum. All sessions are filmed and at posteriori analysed with the help of ELAN© software
223634655|NCT06591208|DEVICE|pulsed dye laser|PDL (Cynosure - Chelmsford, MA-USA) wavelength 585 nm at a fluence 2.5-5 J/cm2, pulse duration of 0.5 ms and spot size 7 -10 mm
223634656|NCT06591208|DEVICE|Carboxytherapy|"carboxytherapy (Carbo - Programmable automatic carbon dioxide therapy apparatus, MA-USA) that was automatically calibrated to adjust the flow rate, through regulation of infusion pressure and the dosage of CO2 in ml. the infusion velocity consequently was adjusted to a flow rate of 1 cc/. The injection performed slowly, subcutaneously, by tilting the needle at 15 degree using a sterile disposable insulin needle, with the depth adjusted at 2 mm. the gas volume per injection spot is 2ml with 1.5 cm spacing between each injection point. End point was skin distension with the gas giving the characteristic popcorn appearance."
223634657|NCT06588114|OTHER|Antistress Ball|Hemodialysis patients will be asked to look away by giving an antistress ball to the non-arteriovenous fistula hand and squeezing and then loosening the ball during the arteriovenous fistula intervention
224223204|NCT05830448|BEHAVIORAL|Cognitive Behavioral Therapy|The trial was planned to have a three-month announcement and an eight-week intervention period. Personal information form, Perceived Stress Scale, Coping with Stress Scale, Connor-Davidson Resilience Scale, Quality of Life Scale for Employees will be used in the pre-test phase of data collection. Participants meeting the inclusion criteria will be randomly assigned to the intervention and control groups. In order to support nurses in the intervention group to gain awareness of stress and anxiety and develop positive coping skills, 8 sessions of 40 minutes were planned, including interaction steps based on education and cognitive approach. As of the second week, homework will be given to individuals and they will be asked to submit these assignments to the researcher 2 days before the next interview. Participants who do not submit the assignments given in this study to the researcher on time will be excluded from the study even if they have completed the training.
224223205|NCT05830448|BEHAVIORAL|T.R. Mobile Mental Health Support System produced by the Ministry of Health|No intervention will be applied to the individuals assigned to the control group by the researcher. Participants will be informed about the Mobile Mental Health Support System created by the Turkish Ministry of Health and will be directed to this application.
224223206|NCT05062109|BEHAVIORAL|Multimodal geriatric prehabilitation|"Multimodal prehabilitation will be carried out over a period of 6 weeks in a day admission (once a week) and at home, and will include:~* Muscle rehabilitation developed with a physiotherapist or physical activity monitor~* Nutritional support (dietitian at the 1st, 3rd, and 6th day admission (DA))~* Cognitive and physical stimulation Exergame~* Psychological support by a psychologist~* Information in the form of videos on the main risks and important points to know and prepare before and after surgery~* Assessment of patient satisfaction, any limitations encountered, the possible performance of exercises at home and the occurrence of any adverse effects.~* One session of adapted physical activity at home of one hour per week by a physical trainer from the Siel Bleu association"
224223207|NCT02328261|DRUG|Icotinib|Icotinib (125 mg tablet) is orally administered three times daily until disease progression or unaccepted toxicity.
224223208|NCT03640936|BEHAVIORAL|Induced Sputum|Total IgE and Specific IgE to Dermatophagoides pteronyssinus in Induced Sputum
223634658|NCT06588114|OTHER|The Valsalva maneuver|The Valsalva maneuver is a breathing method that can slow down a heart with a very fast pulse rate. In this maneuver, the individual breathes strongly through his mouth while his nose is tightly closed, and while holding his breath, a strong tension occurs. This maneuver allows the heart to react and return to a normal rhythm.
223634659|NCT06588114|OTHER|Skin cooling|Hemodialysis patients will be provided with lowering of skin temperature with a skin cooling device by the researcher for 10 minutes before arteriovenous fistula intervention is made to hemodialysis patients
223634660|NCT05523089|DRUG|Saline placebo|Sterile normal saline for injection
223634661|NCT05523089|COMBINATION_PRODUCT|CD388|CD388 liquid for injection
223634662|NCT06993103|DIETARY_SUPPLEMENT|Standard care Cow's milk based formula|Standard hospital care would be given as as per local unit policy at the site.
223634663|NCT06993103|DIETARY_SUPPLEMENT|Dietary Supplement: PDHM Pasteurised Donor Human Milk|PDHM will be given to infants randomised to the intervention group
223634664|NCT06369909|PROCEDURE|EUS-FNA|For patients with pancreatic masses, EUS-FNA is performed to confirm pathological diagnosis, and pancreatic biopsy samples and duodenal mucosal biopsy samples are collected.
223634665|NCT06414369|OTHER|Diathermy|A DT equipment (CET 400 VA - RET 130 Watts - Winback, France), with a frequency of 500 kHz and intensity at 40% will be used. It will be applied utilizing a flat capacitive head 4 cm in diameter. It will be applied using longitudinal and transverse movements and a conductive cream for DT. DT will be used over the TP of the right and left trochanteric prominence. The settings will be calibrated so that patients fell no more than mild warmth during the treatment.
223634666|NCT06414369|OTHER|Simulated Diathermy|This same intervention that has been given to the experimental group, will be simulated as placebo in the control group; the DT will not be activated during administration.
223634667|NCT02681523|DRUG|Eribulin|
223634668|NCT03928132|BEHAVIORAL|CPD Workshop on Depression and Diabetes|2 parallel face-to-face onsite workshops on diabetes and depression in primary care given by experts in French (control and experimental) using Powerpoint presentations.
223634669|NCT06600555|PROCEDURE|metabolic surgery with SLEEVE technique|metabolic surgery with SLEEVE technique
223634670|NCT06600555|PROCEDURE|metabolic surgery with BY-PASS technique|metabolic surgery with BY-PASS technique
223634671|NCT06998758|DRUG|Megestrol Acetate|Oral megestrol acetate at 625 mg/day is given from the beginning to the end of neoadjuvant chemotherapy.
223634672|NCT06998108|DRUG|BEBT-209 capsules|Oral, 75 mg per dose, twice daily, in a 28-day cycle. Continuous dosing from day 1 to day 21, followed by a rest period from day 22 to day 28.
224223209|NCT00548353|DRUG|MK3207|M3207 (20 mg); patients will be administered a single dose of 100 mg of MK3207 (i.e., 5 x20-mg tablets).
224223210|NCT00548353|DRUG|Comparator: Placebo (unspecified)|M3207 (20 mg) Pbo; patients will be administered a single dose of 100 mg of MK3207 Pbo (i.e., 5 x20-mg tablets).
224223211|NCT01164423|DEVICE|Space TGC|Space TGC with incorporated eMPC algorithm to establish glycaemic control with a blood glucose target range of 80-150 mg/dL (4.4-8.3 mM)
224223212|NCT05752305|DRUG|Dexamethasone 4 Mg/mL Injectable Solution|Preoperative submucosal administration of 8mg of dexamethasone or 40mg of methylprednisolone.
224223213|NCT05752305|DRUG|MethylPREDNISolone 40 Mg/mL Injectable Suspension|Preoperative submucosal administration of 8mg of dexamethasone or 40mg of methylprednisolone.
223634673|NCT06998108|DRUG|BEBT-209 Placebo capluses|Oral, 75 mg per dose, twice daily, in a 28-day cycle. Continuous dosing from day 1 to day 21, followed by a rest period from day 22 to day 28.
223634674|NCT06998108|DRUG|Fulvestrant Injection|500 mg intramuscular injection, with a 28-day treatment cycle. Administration on day 1 and day 15 of the first cycle, and then on day 1 of each subsequent cycle.
223634675|NCT06589557|OTHER|Virtual Reality (VR) and Standard Rehabilitation|"VR Rehabilitation:~The VR therapy includes exercises designed to improve the range of motion, coordination, and spatial awareness of the cervical spine. Each patient will complete 15 training sessions over three weeks (5 sessions per week, 2 hours per session), with an additional 30 minutes of daily VR exercises.~Standard Rehabilitation Program:~Manual Therapy: Mobilization and manipulation techniques are applied to enhance the mobility of the cervical spine joints.~Proprioceptive Exercises: These exercises focus on improving body position awareness, movement, and balance.~Strengthening and Stretching Exercises: Individually tailored exercises are provided to strengthen and stretch the neck muscles."
223634676|NCT06589557|OTHER|Standard Rehabilitation|"Patients in this group will participate solely in the standard rehabilitation program.~Standard Rehabilitation Program:~Number of Sessions: Each patient will complete 15 training sessions, held 5 times per week for 3 weeks, with each session lasting 2 hours.~Program Components:~Manual Therapy: Mobilization and manipulation techniques will be applied to improve the mobility of the cervical spine joints.~Proprioceptive Exercises: These exercises aim to enhance body position awareness, movement control, and balance.~Strengthening and Stretching Exercises: Customized exercises will be provided to strengthen and stretch the neck muscles, tailored to individual needs."
223634677|NCT06604585|BEHAVIORAL|Parenthood - a journey together. Digital tool to increase security in parenthood, a way to promote public health..|"The project involved the development of an internet-based parental support program to be delivered via the national Support and Treatment (Sob) platform and used in primary care to enhance traditional parental support within child healthcare, as needed. The innovation has been developed in collaboration with the Innovation Fund in Västra Götaland. The aim is to increase the experience of parental competence and a sense of security in parenting by reflecting on attitudes and approaches in interaction with the child through an interactive, digital parental support program. The four themes in the parental support program, Parenthood a journey together, are named: Being a good enough parent, understanding one's child, interacting with one's child, and meeting daily challenges as a parent regarding food, sleep, play, screen time, and physical activity. The four modules will include explanatory and psychoeducational texts, written exercises, videos, and homework."
223634678|NCT06602609|OTHER|Remote Patient Monitoring Strategy|Continuous remote monitoring with the SmartCardia device includes continuous heart rate and cardiac conduction rhythm tracking through a 7-lead ECG enhanced by machine learning. This system can detect cardiac rhythm disturbances, measure breathing and heart rate, and provide live-alert notifications. Daily 12-lead ECG will be collected from each patient for 7 days after discharge; patients are instructed to perform a daily 12-lead ECG on the SHL device, along with recording blood pressure and oxygen saturation levels. Each ECG is interpreted by the trial team, and a cardiologist\&#39;s interpretation is confirmed, and patients will undergo remote consultations with a cardiologist or research nurse each day if needed. During the initial 30 days of patient recruitment, if the individual exhibits potential cardiac symptoms, they can activate a remote consultation by performing an extra 12-lead ECG and recording blood pressure and oxygen saturation levels.
223634679|NCT06602609|OTHER|Standard Medical Therapy|No intervention is required. Patients in this arm will fill out a self-reported anxiety report (SHAI form) and provide recent admission information
223634680|NCT06992856|PROCEDURE|Conventional colonoscope passage|Use conventional colonoscope passage through the sigmoid colon
223634681|NCT06992856|PROCEDURE|left colon water exchange colonoscope passage|Use left colon water exchange colonoscope passage through the sigmoid colon
223634682|NCT06992856|PROCEDURE|cap-assisted left colon water exchange colonoscope passage|Use cap-assisted left colon water exchange colonoscope passage through sigmoid colon
223634683|NCT06998160|OTHER|glycine subgingival sandblasting group and erythritol subgingival sandblasting group|Given glycine subgingival sandblasting group glycine subgingival sandblasting group. Swiss EMS ultrasonic therapy instrument and EMS glycine sandblasting were used. Before the operation, both parties should wear safety glasses and place the mouth opener after the patient gargled. The location of sandblasting was selected to be 1-2 mm below the gingiva. During the operation, the time of sandblasting in the planting area should be controlled within 10 minutes, and then the time of sandblasting at other sites with the same amount of water and power should be controlled within 5s. After sandblasting, the patient's mouth was continuously rinsed with normal saline for 20s. After the operation, the patient was informed of the precautions after the operation, and the patient was instructed to master the correct oral maintenance method, pay attention to maintaining the cleanliness around the implant, and adhere to regular periodontal maintenance.
223764704|NCT05286034|BEHAVIORAL|Decision aid tailored to women with lower educational attainment,accessible via artificial intelligence-based Chatbot platforms|"Non-compliant women those that have not been screened for more than 4 years and living in the disadvantaged areas will be sent screening reminder letters to perform HPV self-sampling (HPVss) test, with access to decision aid tailored to women with lower education attainment and available via Chatbot platforms.~ChatBot will deliver information in a responsive, conversational way via text and spoken language in multiple languages through multiple mobile channels."
224223214|NCT04049552|DRUG|Rapamycin 8% Ointment|A compounded ointment containing 8% rapamycin
224223215|NCT04049552|DRUG|Placebo|Petrolatum ointment placebo
224223216|NCT00333333|PROCEDURE|Cord blood|Cord blood will be obtained at the time of delivery.
224223217|NCT05707429|OTHER|The Arabic version of The International Index of Erectile Function (IIEF-5)|The Arabic version of The International Index of Erectile Function A self-administered questionnaire that assesses 5 dimensions of sexual function over the most recent 4 weeks. It consists of five questions, including vaginal penetration, maintenance of erection, completion of intercourse, sexual satisfaction, and self-confidence of the patient's sexual arousal and maintenance of an erection. A total score of \< 22 is defined as ED .
224223218|NCT05707429|OTHER|The Sexual Quality of Life Questionnaire Male/Female (SQoL M/F)|was developed by Symonds et al.,(14) which assesses subjects' feelings toward their sexuality (ranging from 0% to 100%, with higher scores indicating higher SQoL). The SQoL M/F was developed as a condition-specific QoL questionnaire to test the relationship between sexual symptoms and other aspects of general health and sexual QoL.
223634684|NCT06998160|OTHER|control group|The control group was given ultrasonic subgingival curettage. With Swiss EMS ultrasonic therapy instrument, both the operator and the patient should wear safety goggles before operation. After the operator guides the patient to gargle, the mouth opener should be placed to perform ultrasonic subgingival curetting. The debridement time of the implant area should be controlled within 6 minutes, and the debridement time of other sites should be 5 s.
223634685|NCT06999889|DIAGNOSTIC_TEST|Recording of Periodontal Parameters.|Periodontal Parameters recording in terms of various indices,measurements and radiographs.
223634686|NCT06999902|DRUG|20mg/day PRAX-628 for 6 weeks then 30mg/day PRAX-628 for remaining 6 weeks|Once daily oral
224223219|NCT05707429|OTHER|Assessment of depression and anxiety|Arabic version of Hamilton depression and anxiety rating scale (15): used to measure the severity of anxiety and depressive symptoms, and is widely used in both clinical and research settings.
224223220|NCT05707429|OTHER|The Fatigue assessment scale (16)|It is a 10-item self-report scale evaluating symptoms of fatigue. The FAS treats fatigue as a unidimensional construct and does not separate its measurement into different factors. However, in order to ensure that the scale evaluates all aspects of fatigue, it measures both physical and mental symptoms. The total score ranges from 10 to 50, with a higher score indicating more severe fatigue.
224223221|NCT05707429|OTHER|• Quality of life assessment|Health related quality of life (HRQoL measure): using the Short Inflammatory Bowel Disease Questionnaire (SIBDQ) (17), which assesses physical, social, and emotional domains of IBD patients' lives (scores range from 10-70, with higher scores indicating better HRQoL) The SIBDQ reflects relevant clinical changes in both CD and UC.
224223222|NCT05707429|OTHER|The Female Sexual Function Index (FSFI)|The FSFI includes such parameters as desire, arousal, lubrication, orgasm, satisfaction, and pain. The optimal cutoff score of the FSFI is 26.55, which means that a score at or below this value is defined as female SD.
224223223|NCT02523365|PROCEDURE|interventional therapy|cervical carcinoma patients received HepaSphere interventional therapy using the digital subtraction angiography（DSA）
224223224|NCT00790075|DRUG|risperidone|liquid risperidone was administered on a mg/kg basis to a child needing seclusion. 0.015mg/kg was the start dose. Dose was increased to 0.02mg/kg if duration of episode was \>30 minutes.
224223225|NCT04323007|DIAGNOSTIC_TEST|Nephrotic patients|Laboratory measures will include Blood sugar Urine analysis with 24hrs protein in urine Complete blood count Liver function tests Kidney functions test Plasma lipid levels Thyroid functions test Abdominal ultrasound Antithyrperoxidase Renal biopsy
224223226|NCT00922337|DEVICE|MGuard Coronary Stent system|MGuard Coronary Stent system implanted within a PCI
224223227|NCT00931853|DRUG|SENNA+CASSIA(Naturetti)|Daily administration (oral) of one spoon (5g) of Naturetti (SENNA+CASSIA) jelly sugar free at bedtime, during 30 days
224223228|NCT01986790|BEHAVIORAL|Plain Language|
224223229|NCT01986790|BEHAVIORAL|Plain Language + Visuals|
224223230|NCT01986790|BEHAVIORAL|Plain Language + Narratives|
224223231|NCT01677442|PROCEDURE|no-intubated thoracic epidural anesthesia|VATS under no-intubated thoracic epidural anesthesia
224223232|NCT01677442|PROCEDURE|double-lumen endotracheal intubated anesthesia|VATS under double-lumen endotracheal intubated anesthesia
224223233|NCT01491490|DRUG|GWP42003 : GWP42004 (40:1)|Capsules taken once a day for 6 weeks
224223234|NCT01491490|DRUG|Placebo|Capsules taken once a day for 6 weeks
224223235|NCT01968616|DRUG|Ranibizumab, 0.5mg, Intravitreal|
224223236|NCT01360632|DRUG|OPC-34712 + ADT|Tablets, Oral, 1 or 3 mg OPC-34712 and FDA Approved Antidepressant Therapy (ADT)
224223237|NCT01360632|DRUG|Placebo + ADT|Placebo + FDA Approved Antidepressant (ADT)
224223238|NCT01360632|DRUG|Placebo + ADT|Placebo + FDA Approved Antidepressant (ADT)
224223239|NCT00125567|DRUG|Stalevo (levodopa/carbidopa/entacapone)|Oral, 50-150 mg levodopa four times daily, for up to 2 years
224223240|NCT00125567|DRUG|Levodopa/carbidopa|Oral capsules, 50-150 mg levodopa four times daily, for up to 2 years
224223241|NCT01315483|OTHER|Weight Loss Dietary Pattern|Diet-physical activity program creating a weekly negative energy balance equivalent to 3500 kcal. Intervention groups receive PA protocol promoting the Physical Activity Guidelines and translated in step recommendations, but one of two diets with divergent dietary patterns (opposing fat and CHO content) that do not overlap \>+5% in CHO and fat content. Macronutrient values reflect a 'pattern' or ratio within (LC 3:2 ratio for F:CHO; HC 1:4 ratio for F:CHO ) and between diets (LC:HC 3:1 for fat; LC:HC 1:2 for CHO). Six-week meal plans for five calorie levels available and incorporate educational material, supporting program components (e.g. self monitoring tools) and core competencies reinforcing weight loss behaviors in order to promote high levels of dietary adherence.
224223242|NCT00196222|PROCEDURE|RF-ablation|RF ablation/modulation of the slow pathway in AV nodal reentrant tachycardia
224223243|NCT00196222|PROCEDURE|cryo ablation|Cryo ablation/modulation of the slow pathway in AV nodal reentrant tachycardia
224223244|NCT04591769|DEVICE|Different tracheal tube cuff design|Comparison of effect between 2 different designs of tracheal tube cuff
224223245|NCT00280774|DRUG|Memantine|
223634687|NCT06999902|DRUG|Placebo|Once daily oral
223634688|NCT06998810|DEVICE|cerebellar rTMS|Non-invasive magnetic stimulation targeting the cerebellum using a figure of eight coil
223634689|NCT06999369|OTHER|MedChef App|Once patients have been randomized to the MedChefs arm, they will be contacted by the research team and sent an email link to use the MedChefs app. The research team will contact the patient based on their preferred contact method and will walk through how to use the app and share education on its use.
223634690|NCT06999369|OTHER|MedChefs and Instacart food voucher|Once patients have been randomized to the MedChefs arm and voucher arm, they will be contacted by the research team and sent an email link to use the MedChefs app. The research team will contact the patient based on their preferred contact method and will walk through how to use the app and share education on its use and use of Instacart food vouchers. Patients will also be given a $100 voucher to buy food recommended by the app. Vouchers will be provided once a month for the 6 months of the study
223634691|NCT06998316|OTHER|Screening questionnaire|Every patient will answer the 2 screening questionnaires given to them, once at baseline and a second time after 1 month.
224223246|NCT02672774|PROCEDURE|Magnification endoscopy with narrow band imaging|Magnification endoscopy with narrow band imaging is an optically enhanced endoscopic imaging technique used for better characterization of lesions as compared to white light endoscopy alone. With only a push of a button optical filters are applied to reduce the illuminating light to 415 nm (blue) and 540 nm (green) wavelengths, which are selectively absorbed by haemoglobin. As a result the superficial vascular networks are highlighted and morphological changes in capillary patterns can be described for different gastrointestinal lesions.
224223247|NCT02672774|DEVICE|Probe based confocal laser endomicroscopy|Confocal laser endomicroscopy enables in vivo microscopic analysis during ongoing endoscopy and has shown good accuracy for predicting the histopathological diagnosis in lesions of both the upper and lower GI tract. During the examination fluorescein is administered intravenously as a contrast agent, highlighting the vessels and surrounding epithelial structures. The probe based confocal laser endomicroscopy system can be easily integrated into the imaging protocol as it uses flexible catheter probes that can be passed through the working channels of the endoscopes once the area of interest has been identified.
224223248|NCT03101423|DRUG|Interleukin-2|On +60 day after transplantation,check patients with STR more than or equal to 90%. transplantat interleukin-2 treatment per month
224223249|NCT03101423|DRUG|Donor Regulatory T-Lymphocytes|On +60 day after transplantation,check patients with STR less than 90%. Donor Regulatory T-Lymphocytes infusion (DLI) treatment per month
224223250|NCT02173301|DRUG|XP23829 400 mg QD|active dose 1
224223251|NCT02173301|DRUG|XP 23829 800 mg QD|active dose 2
223634692|NCT06999967|DIAGNOSTIC_TEST|Electroencephalogram (EEG)|All study subjects will undergo monitoring via a portable electroencephalogram (pEEG), the CGX EEG system (a Research-grade 2-Channel EEG device) to measure the brainwaves of patients admitted to Stanford Medical Center. Investigators will then use the Lucidify software to allow for the interpretation of obtained brainwaves for the detection of delirium .
223634693|NCT06998121|OTHER|Intrarectal ıce application|Patients included in the study group will receive intrarectal ice application by researchers (E.K.D. and M.B.) in addition to the outpatient clinic's routine treatment and care practices. For each patient, a new glove (size 8) will be filled with water and frozen to obtain the cold application material. Immediately before the procedure, the lubricated ice will be inserted into the patient's rectum and held in place for 5 minutes (Caliskan and Mutlu, 2015).
224223252|NCT02173301|DRUG|XP23829 400 mg BID|active dose 3
224223253|NCT02173301|DRUG|Placebo|control
224223254|NCT02717286|PROCEDURE|restorative|It was performed direct restoration using two kinds of adhesive system (total-etching adhesive and self-etching adhesive)
224223255|NCT04548895|DEVICE|Observational measurement of biometric data. No change to health care provided.|"Emfit devices will be installed once after enrollment under each participant's mattress and left to record automatically without further intervention. The participants will wear their Biostrap wristbands consistently, ideally 24 hours a day, 7 days a week, for 2 months.~A virus panel will be upon enrollment (baseline) and then every two weeks (± 3 days, or on the closest convenient sampling day if the LTCF is testing all residents on the same day) for a maximum of 5 times during the two-month period. Using polymerase chain reaction or next generation sequencing, the virus panel will detect COVID-19 and 12 other common respiratory viruses that may cause similar symptoms and similar biometric signatures. These include influenza A and B, parainfluenza types 1 through 4, respiratory syncytial virus, non-COVID coronavirus, rhinovirus, adenovirus, bocavirus and metapneumovirus."
224223256|NCT03980795|OTHER|Exercise Program|Participants met with an exercise physiologist at their monthly center appointment over a 3-month period (4 meetings). The consultations took place either together or separate from or with the dietitian's consultation (depending on appointment logistics). In addition the Exercise Physiologists telephone called each intervention participant on a weekly basis.
224223257|NCT03655210|DRUG|HL151|HL151(1Tab) once a day for 4 weeks of treatments
224223258|NCT03655210|DRUG|placebo|HL151 placebo(1Tab, Placebo of Bepostatine salicylate) once a day for 4 weeks of treatments
224223259|NCT01226875|PROCEDURE|SWL: Shock Wave Lithotripsy Intervention|Shock wave lithotripsy (SWL) is the most common treatment modality for kidney stones. It is a safe and non-invasive treatment performed on patients under intravenous sedation (light anesthesia) on an out-patient basis, whereby shock waves are generated by a source external to the patient's body and are then propagated into the body and focused on a kidney stone. The unique quality of SWL is in its exploitation of shock wave focusing. The Storz lithotripter is an electromagnetic lithotripter with a unique design that allows for a dual focus system with the option of either a narrow (6x28 mm) or wide (9x50 mm) focal zone, depending on the clinical situation. This is the first lithotripter on the market to allow for two different focal zones for shock wave targeting.
224223260|NCT03016078|DEVICE|Mepilex Border Post-Op Ag|To investigate if there was any skin damage under the dressing from operation day to last visit.
224223261|NCT01710306|BEHAVIORAL|Nurse Care Manager (NCM)|Nurse care manager interventions with telephone implemented shared decision making protocol compared to outreach as usual OEF/OIF/OND outreach.
224223262|NCT03287479|PROCEDURE|Gavi® Vitrification|A closed, semi-automated vitrification system
224223263|NCT03287479|PROCEDURE|Cryotop® Vitrification|An open, manual vitrification system
223634694|NCT05270759|DIAGNOSTIC_TEST|Estimated absolute blood volume|Baseline absolute blood volume will be inferred based on the change in relative blood volume (RBV) after a single 240mL replacement fluid infusion and then monitored throughout the session via the RBV value.
223634695|NCT05270759|DIAGNOSTIC_TEST|Modified VExUS evaluation|The presence of at least 2/3 abnormal venous Doppler waveforms at the following sites: Portal vein, hepatic vein, and femoral vein.
224223264|NCT01247688|DRUG|Cytoxan|50 mg/kg/dose will be given IV on day -5,-4, -3, -2 over 1 hour. The total dose to be given over 4 days is 200 mg/kg.
224223265|NCT01247688|DRUG|Fludarabine|40mg/m2/day will be given IV over 1 hour on day -4, -3, -2
224223266|NCT01247688|RADIATION|Total Body Irradiation (TBI)|1.75Gy/fraction will be given on day -9, -8, -7, -6
224223267|NCT01247688|PROCEDURE|Cord Blood Stem Cell Infusion|The cord blood stem cells will be infused on day 0
224318525|NCT05439967|OTHER|Augmented and Virtual Reality Gait and balanceTraining|C-Mill VR+ device used for training. The training was carried out 3 days a week for 6 weeks, with each exercise session lasting approximately 1.5 hours, accompanied by a physiotherapist. Training started with conventional exercises, continued with C-Mill VR+ training, and ended with stretching and relaxation exercises. The patients in the intervention group were applied the exercises with the same principles with conventional training, except the exercises performed in standing and walking. Patients performed 10 exercises in AR and VR gait training for 4 minutes and resting the individuals by sitting for 1 minute between exercises.
224318526|NCT05439967|OTHER|Conventional Training|Conventional training was applied to the patients in the control group. Conventional training was planned taking into account the following goals: increasing mobility by improving the impaired kinesthetic sensation; improving axial rotation, coordination, flexibility of soft tissues, mobility in and out of bed; increasing body image perception by improving upright and proper posture; and improving balance and gait. The training was applied 3 days a week for 6 weeks, with each exercise session lasting 40-50 minutes, accompanied by a physiotherapist. Each of the exercises was done in 2 sets of 10 repetitions. In gait training, each exercise was performed for 4 minutes.
224318527|NCT05273346|BEHAVIORAL|Traditional Chinese medicinal ointment|The Group1 will be treated using the Comprehensive Conservative TCM Treatment Group protocol.The special TCM ointment will be applied to the waist, and then Tuina, in order to play the comprehensive therapeutic role of Tuina and medicine, promoting blood circulation and removing stasis, warming and dispersing cold, strengthening tendons and strengthening bones, regulating qi and blood. The method of ointment is generally used with rubbing method, rubbing method, flat pushing method and kneading method. Treatment time: 7 minutes.
224318528|NCT05273346|BEHAVIORAL|Acupotomy|It is in the special acupoints or Ashixue for cutting, stripping and other different stimulation, in order to reduce the tension of soft tissue outside the spinal canal, reduce the trend of dynamic and static spinal canal stenosis, to achieve the purpose of relieving pain and removing disease, opening points and collaterals. Acupotomy can separate the adhesive tissue, which can improve the blood circulation of the local tissue and promote the absorption of inflammation. Most acupotomy points are tenderness points or induration points, such as yaojiaji and Shenshu. Treatment time: 3 minutes.
224318529|NCT05273346|BEHAVIORAL|Cupping therapy with bamboo cup|Put the bamboo cup with the thickness of the thumb into the cup and boil it, then find the meridian and select the acupoint, Pierce the skin with a needle at the appropriate acupoint, and remove the heated bamboo cup from the cup while it is hot. When the temperature of the steam in the bamboo cup is reduced, steam will condense into water quickly, which produces strong negative pressure. Through the medicinal force, heat and the suction of the bamboo cup, the blood stasis in the affected area is smoothly discharged, so that qi and blood can be unblocked and pain can be eliminated. Treatment time: 20 minutes.
224318530|NCT05273346|OTHER|Oral Chinese medicine granules|Oral Chinese medicine granules use to nourish liver and kidney, improve qi and blood. Patients voluntarily take it when they think it is necessary.
224318531|NCT05273346|BEHAVIORAL|Epidural Steroid Injections (ESIs)|The Group2 will be treated using the Modern Medicine Conservative Treatment Program Group protocol.All Epidural Steroid Injections(ESIs) will be performed by a physician in an outpatient surgical setting(a sterile operating room),the patient will be in prone position,while monitored the vital signs. After aseptic treatment, 1mg non-granular betamethasone plus 5mL 0.9% sodium chloride solution will be injected. Patients will repeat ESIs up to four times within three months after randomization, depending on the response to the previous ESIs, when the degree of pain increases or the degree of relief is less than 50%.
224318532|NCT05273346|BEHAVIORAL|Interferential current therapy|The 30-50cm padded electrode will be properly fixed on the left and right sides of the lumbar spinal stenosis, and the two groups of current will be crossed at the lesion. Constant frequency output 90Hz, frequency conversion output 90-100Hz, the current intensity is generally suitable for patient tolerance, each treatment for 10min, a total of 20 minutes. Twice a week for 3 months.
223634696|NCT06597864|BEHAVIORAL|Seven-step phenomenological psychotherapy for self-disorders|Phenomenological exploration of anomalous self-experiences, meaning attributions and behavioral consequences. Psychoeducation. Dialogical approach focusing on self-narratives, searching for new meaning and understanding of self-disorders
224223268|NCT03700710|BEHAVIORAL|Self-Guided Approach|"For a 12-week period, patients will be asked to access the web platform (Evolve, formerly BMIQ), review educational materials, and enter dietary information.~From January 2019 to February 2021, participants used an earlier version of the platform, which was used in tandem with LoseIt (www.loseit.com), a meal-logging app that integrated with the platform.~In February 2021, a platform update occurred (Evolve) where the core tenets of the program remained the same and included the dietary data entry directly on the platform."
224223269|NCT03700710|BEHAVIORAL|Dietitian-led Approach|"For a 12-week period, patients will be asked to access the web platform (Evolve, formerly BMIQ), review educational materials, and enter dietary information.~From January 2019 to February 2021, participants used an earlier version of the platform, which was used in tandem with LoseIt (www.loseit.com), a meal-logging app that integrated with the platform.~In February 2021, a platform update occurred (Evolve) where the core tenets of the program remained the same and included the dietary data entry directly on the platform.~Dietitians will access the web platform and provided personalized motivational interview phone calls on a weekly basis."
224223270|NCT02479828|DRUG|Fascia iliaca compartment block|40 ml ropivacaine 0,5% injected under fascia iliaca using ultrasound
224223271|NCT02479828|DRUG|Ropivacaine|
224223272|NCT02479828|DEVICE|ultrasound|
224223273|NCT02479828|DRUG|Placebo|
224223274|NCT02123459|DRUG|Cephalexin|Administered orally
223634697|NCT06600230|OTHER|Education and exercise|Training including information on pelvic floor and dysmenorrhea and exercise practices were given both theoretically and practically by physiotherapists.
223634698|NCT06600230|OTHER|Self-method like resting or heat|Classical self-methods such as rest and heat application were applied.
223634699|NCT06593535|OTHER|Placebo (Placebo trial)|The Placebo capsule supplement was taken for 4 days (7 capsules per day)
223634700|NCT06593535|OTHER|Astaxanthin (AST trial)|The AST capsule supplement was taken for 4 days, with a daily dosage of 28 mg of AST (equivalent to 7 capsules per day, each containing 4 mg of AST).
223634701|NCT06602700|BEHAVIORAL|HIIT|high-intensity interval training
223634702|NCT06602700|BEHAVIORAL|MICT|moderate-intensity continuous training
223634703|NCT06599645|OTHER|CST+BFR+Tai Chi+Education|"1. Core Stability Training: It includes core activation exercises (feed-forward control)(Libenson,2006). Each set will consist of 10 repetitions of this exercise with a 10-second hold. There will be a 30-second rest between repetitions and a 60-second rest after each set.~2. Tai Chi: The first 10 Tai Chi movements from the 24-simplified Tai Chi form. Three qualified teachers will lead the training sessions.~3. Blood Flow Restriction: The professional physical therapist puts on the cuff pneumatic tourniquet system(Kaastu Master) on the proximal end of the left lower limb of the subjects and gives a certain pressure through the Kaastu Master. The pressure needs to ensure that the venous return of the particapants is restricted to perfect ground, while the artery still has some blood flow.~4. Education: After enrollment, patients will receive face-to-face education sessions at baseline, 30-45 min each time. Guided education by the same experienced professional physiotherapist."
223634704|NCT06599645|OTHER|CST+BFR+Education|"1. Core Stability Training: It includes core activation exercises (feed-forward control)(Libenson,2006). Each set will consist of 10 repetitions of this exercise with a 10-second hold. There will be a 30-second rest between repetitions and a 60-second rest after each set.~2. Blood Flow Restriction: The professional physical therapist puts on the cuff pneumatic tourniquet system(Kaastu Master) on the proximal end of the left lower limb of the subjects and gives a certain pressure through the Kaastu Master. The pressure needs to ensure that the venous return of the particapants is restricted to perfect ground, while the artery still has some blood flow.~3. Education: After enrollment, patients will receive face-to-face education sessions at baseline, 30-45 min each time. Guided education by the same experienced professional physiotherapist."
223634705|NCT06599645|OTHER|Tai Chi +BFR+Education|"1. Tai Chi: The first 10 Tai Chi movements from the 24-simplified Tai Chi form. Three qualified teachers will lead the training sessions.~2. Blood Flow Restriction: The professional physical therapist puts on the cuff pneumatic tourniquet system(Kaastu Master) on the proximal end of the left lower limb of the subjects and gives a certain pressure through the Kaastu Master. The pressure needs to ensure that the venous return of the particapants is restricted to perfect ground, while the artery still has some blood flow.~3. Education: After enrollment, patients will receive face-to-face education sessions at baseline, 30-45 min each time. Guided education by the same experienced professional physiotherapist."
223634706|NCT06599645|OTHER|CST+Education|"1. Core Stability Training: It includes core activation exercises (feed-forward control)(Libenson,2006). Each set will consist of 10 repetitions of this exercise with a 10-second hold. There will be a 30-second rest between repetitions and a 60-second rest after each set.~2. Education: After enrollment, patients will receive face-to-face education sessions at baseline, 30-45 min each time. Guided education by the same experienced professional physiotherapist."
223634707|NCT04276870|BIOLOGICAL|Murine CART19|CART19 cells transduced with a lentiviral vector to express anti-CD19 scFv:41-BB:TCRζ, administered by IV injection with a planned dose of 5x106 CART19 cells/kg on day 0 with possible reinfusion/retreatment
223634708|NCT06089668|OTHER|Observational Study|None, this is a non-interventional trial
223634709|NCT06998290|OTHER|Blue-Line home telemonitoring program|"* A dedicated telemonitoring team with nurses and pediatric cardiologist~* A dedicated therapeutic patient education programme~* A home telemonitoring medical device with a dedicated platform"
223634710|NCT06601582|DEVICE|Use of a operative blood salvage system|The surgical team will use a operative blood salvage system
223634711|NCT06603714|OTHER|Instrument assisted soft tissue mobilization|We will perform instrument assisted soft tissue mobilization on calf muscles. The intervention will last 9 min. For the first minute of treatment light pressure will be applied for tissue preparation. Afterwards, four different strokes will be applied by maintaining the tool at a 30° of inclination for one minute. This will be repeated for a second set, with a tool inclination of 45°.
224223275|NCT05009628|PROCEDURE|automated oxygenation with a sitting patient position in the ICU|Oxygenation will be done with the Free O2 device via oxygen goggles or a face mask and with an O2 prescription to obtain a SpO2\> 94%. The patient's position in the ICU will be a sitting position with the chest raised at an angle greater than 45°.
224223276|NCT05009628|PROCEDURE|Automated oxygenation with the patient lying down in the ICU|Oxygenation will be done with the Free O2 device via oxygen goggles or a face mask and with an O2 prescription to obtain a SpO2\> 94%. The patient's position in the ICU will be a recumbent position with the head elevated to a maximum of 10
224223277|NCT05009628|PROCEDURE|Oxygenation is controlled with the patient in a sitting position in the ICU.|ICU. Oxygenation will be done via the same interface in manual mode where the post-interventional monitoring room nurse modifies the flow to maintain oxygen saturation above 94%. The patient's position in the ICU will be a sitting position with the chest raised at an angle greater than 45°.
224223278|NCT06526897|PROCEDURE|Biopsy|Undergo biopsy
224223279|NCT06526897|PROCEDURE|Chest Computed Tomography|Undergo chest CT
224223280|NCT06526897|PROCEDURE|Chest Radiography|Undergo CXR
224223281|NCT06526897|OTHER|Quality-of-Life Assessment|Ancillary studies
224223282|NCT06526897|OTHER|Questionnaire Administration|Ancillary studies
224223283|NCT03553784|OTHER|Group delivered Low Intensity Cognitive Behavioural Therapy|The intervention is group-delivered, low-intensity CBT similar to that used in IAPT (Improving Access to Psychological Therapies) Services in England. This intervention is already being offered as part of standard care at the Intervention site, and will not be altered by the study protocol, other than the requirement to complete a few more questionnaires. The intervention group meets weekly for eight weeks, and is facilitated by a clinical psychologist, a psychological well-being practitioner and a clinical nurse specialist from the medical oncology team. Content of the intervention is broad CBT, combining aspects of second-wave CBT, with elements of Narrative Therapy and ACT.
224223284|NCT00643110|DRUG|D50 glucose|D50 glucose would be administered, if necessary.
224223285|NCT03658278|DIETARY_SUPPLEMENT|Juven|Nutritional supplement (Juven) will be consumed daily per manufacturer recommendations
224223286|NCT06527053|DEVICE|obturator|special maxillofacial device to close hollow defects
224318533|NCT05273346|BEHAVIORAL|Thermal therapy|After the interferential current therapy, the patient will receive Bohm light for 5 minutes at the site of lumbar spinal stenosis and massage for 5 minutes at low back. Twice a week for 3 months.
224318534|NCT05273346|OTHER|Oral painkillers|NSAID drugs, if necessary.
224223287|NCT05163002|BEHAVIORAL|Nutritional education & carbohydrate counting|Nutrition Education with a multidisciplinary team
224223288|NCT01191255|DRUG|ferric citrate, ca acetate, sevelamer carbonate, placebo|All intervention doses will be based on serum phosphorus levels and/or drug label requirements
224223289|NCT05555082|OTHER|Massage|10 times of 30 minutes Swedish classical Massage will be given monthly during one year. The massage will be give by a cerified masseur
224223290|NCT00036777|DRUG|carboplatin|Given IV
224223291|NCT00036777|DRUG|7-hydroxystaurosporine|Given IV
224223292|NCT00036777|OTHER|pharmacological study|Correlative studies
224223293|NCT06525441|OTHER|Plant-based Diet|Participants assigned to the plant-based diet group will be provided three meals daily for 3 weeks. Of the energy of each meal, 60% is from carbohydrates, 15% from plant protein, and 25% from fat. The main dietary sources of plant protein will be soybeans, flat beans, nuts, grains, and algae.
224223294|NCT06525441|OTHER|Animal-based Diet|Participants assigned to the animal-based diet group will be provided three meals daily for 3 weeks. Of the energy of each meal, 60% is from carbohydrates, 15% from animal protein, and 25% from fat. The main dietary sources of animal protein will be chicken, beef, pork, fish, eggs, and dairy products.
224223295|NCT00920335|OTHER|tumoral sample|Ependymoma tumoral sample
224223296|NCT05744661|OTHER|Mechanical Method|Use of Rotary Master Apical file for the removal of Calcium Hydroxide Medicament from Root Canal System
224223297|NCT05744661|OTHER|Chemomechanical Method|Sonic Activation of Endodontic irrigants for the removal of Calcium Hydroxide from Root Canal System
224223298|NCT02196506|DRUG|Placebo + ADT|Placebo + ADT Placebo + FDA Approved Antidepressant (ADT)
224223299|NCT02196506|DRUG|Brexpiprazole +ADT|Brexpiprazole + ADT Tablet, Oral, 2mg brexpiprazole and FDA Approved Antidepressant (ADT)
224223300|NCT01396759|PROCEDURE|Bubble continuous positive airway pressure|All children will be monitored for by pulse oximetry for arterial O2 saturation, respiratory rate, lower chest wall in-drawing, intercostal retraction, head nodding, cyanosis, tracheal tug, heart failure (defined by the presence of tachypnea, tachycardia, gallop rhythm, hepatomegaly, pedal oedema, basal crackles). Arterial or capillary blood gas analyses will be done for children failing to maintain saturation (\>90% with allocated treatment), or if there is concern about hypercarbia or acidosis.
224223301|NCT01396759|PROCEDURE|Humidified high flow air / O2 mix at 2 l/kg/min|Humidified high flow air / O2 mix at 2 l/kg/min through nasal canula. All children will be monitored for by pulse oximetry for arterial O2 saturation, respiratory rate, lower chest wall in-drawing, intercostal retraction, head nodding, cyanosis, tracheal tug, heart failure (defined by the presence of tachypnea, tachycardia, gallop rhythm, hepatomegaly, pedal oedema, basal crackles). Arterial or capillary blood gas analyses will be done for children failing to maintain saturation (\>90% with allocated treatment), or if there is concern about hypercarbia or acidosis.
224223302|NCT01396759|PROCEDURE|Standard O2 supplementation by nasal cannula at 0.5 - 2 l/min|Standard O2 supplementation will be given by nasal cannula at 0.5 - 2 l/min. All children will be monitored for by pulse oximetry for arterial O2 saturation, respiratory rate, lower chest wall in-drawing, intercostal retraction, head nodding, cyanosis, tracheal tug, heart failure (defined by the presence of tachypnea, tachycardia, gallop rhythm, hepatomegaly, pedal oedema, basal crackles). Arterial or capillary blood gas analyses will be done for children failing to maintain saturation (\>90% with allocated treatment), or if there is concern about hypercarbia or acidosis.
224223303|NCT00202553|DRUG|Perindopril|
224223304|NCT00368329|DRUG|Capecitabine (Xeloda)|PO bid daily on RT days: 500mg \& 150mg tabs for dose 825mg/m2 bid AM/PM (total daily dose 1650mg/m2)
224223305|NCT00368329|DRUG|[18-F] Fluorodeoxyglucose (FDG)|5-10 mCi IV administration
224223306|NCT00368329|DRUG|5-Fluorouracil (5-FU)|200mg/m2 continuous venous infusion
224223307|NCT00368329|DRUG|Carboplatin|AUC 2, based onCalvert formula IV infusion
224223308|NCT00681408|DRUG|Omega 3 Fish Oil supplements|Subjects in this arm will receive 3 grams daily Omega 3 fish oil supplements
224223309|NCT00681408|DRUG|Placebo|Fish oil placebo pills
224223310|NCT00254397|DRUG|Leuprolide|A 3-month 11.25 mg sustained-release formulation will be administrated intramuscularly at time 0, and approximately 12 weeks (2 injections).
224223311|NCT00254397|BIOLOGICAL|GP100: 209-217(210M) Peptide|1.0 ml subcutaneous injection in extremities.
224223312|NCT00254397|BIOLOGICAL|MAGE-3 Peptide|1.0 ml subcutaneous injection in extremities.
224223313|NCT02926183|DRUG|Neoadjuvant chemotherapy of gemcitabine plus nab-paclitaxel|Enrolled patients were administered a 30-min intravenous infusion of nab-paclitaxel at a dose of 125 mg/m2, followed by a 30-min intravenous infusion of gemcitabine at a dose of 1000 mg/m2, on day 1, 8, and 15 evey 4 weeks as one cycle of regimen.
224223314|NCT00973037|DRUG|Tamoxifen|Tamoxifen 20mg qd
223634712|NCT05950035|BEHAVIORAL|Written Exposure Therapy (WET)|WET is a trauma-focused intervention in which individuals write about their worst traumatic experience following scripted instruction from the therapist.
224223315|NCT06344702|DEVICE|CPAP|70% of nights use CPAP for more than 4 hours
224223316|NCT00528437|DRUG|temozolomide, thiotepa, carboplatin, 13-cis-retinoic acid|13-cis-retinoic acid, when absorbed, may be subject to first-pass metabolism and subsequent plasma (and tumor) concentrations will depend on the rate of metabolism to the inactive 4-oxo metabolite.
224223317|NCT04181996|DRUG|Colchicine Oral Product|Patients will be randomized to receive either placebo or colchicine
223634713|NCT05950035|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia (CBTi)|CBTi focuses on stimulus control, eliminating maladaptive coping habits, reducing arousal, and challenging maladaptive thoughts about sleep in an effort to reduce time to fall asleep and time awake during the night.
224223318|NCT04181996|DRUG|Placebo oral capsule|Patents will be randomized to receive either placebo or colchicine
224223319|NCT03242993|DRUG|[18F]-AzaFol|\[18F\]-AzaFol is a radiotracer produced at ETH Hönggerberg in a radiopharmaceutical GMP facility. The drug product is provided as sterile solution for intravenous injection in a glass vial containing 6 mL of formulated product, the maximal applicable dose being 600 MBq.
224223320|NCT03242993|DRUG|folarell|"For the purpose of this study only 1 mg folic acid (corresponding to 0.2 mL Folarell®) will be injected 5 min prior to \[18F\]-AzaFol. Due to this low dose of a single injection of folic acid it is unlikely that adverse events would occur.~Folarell® is a folic acid preparation for intravenous or intramuscular injection"
224223321|NCT03727464|BEHAVIORAL|Abstract priming|Patients were primed with a list of abstract during their general anesthesia
223634714|NCT05950035|BEHAVIORAL|Cognitive Behavioral Therapy for Nightmares (CBTn)|CBTn involves writing about a distressing or frequent nightmare, rewriting the narrative of the nightmare to target trauma-related themes, and reading the rescripted nightmare narrative.
223634715|NCT05950035|BEHAVIORAL|Waitlist|Waitlist for delayed intervention.
223634716|NCT06690359|COMBINATION_PRODUCT|IM19 chimeric antigen receptor T cell injection|"IgA nephropathy:~The investigators plan to recruit IgA nephropathy subjects with urinary protein and renal dysfunction who meet the inclusion and exclusion criteria. They will receive Beijing Zaimiao Biological IM19 CAR-T cell infusion therapy at doses of 0.5 × 10 \^ 8 and 1 × 10 \^ 8 CAR-T cells, with 3 subjects enrolled at each dose~Primary membranous nephropathy:~The investigators plan to recruit primary membranous nephropathy subjects who meet the inclusion and exclusion criteria and receive IM19CAR-T cell infusion therapy at doses of 0.5 × 10 \^ 8 and 1 × 10 \^ 8 CAR-T cells, with 3 subjects enrolled at each dose"
223634717|NCT06382597|OTHER|Nordic hamstring exercise|Nordic Hamstring Exercise involves a controlled descent of the upright torso from a vertical kneeling position forward towards the ground (parallel to the ground) and returning to the starting position. The ankle joints are stabilized by the other person's grip during a series of exercises.
223634718|NCT06872996|DIAGNOSTIC_TEST|Prick-test|"Several foods may be tested for the same participant depending on the number of food allergies the patient has. PT are performed using the prick-to-prick method with lancets, in a single session per patient, using fresh and preserved native foods. Simultaneously, a positive control and a negative control are performed. The PT are performed and read by nursing or medical staff trained in the technique.~Participants' clinical follow-up is performed continuously for 30 minutes from the performance of the prick-tests and under the responsibility of the allergologist doctor, whose presence is mandatory during the performance of these tests.~For meat, fruit, vegetable, leguminous plant, milk, seafood and fish tests will be performed with fresh products and with products preserved for 3 months as well as with products preserved for 6 months \[-15 days; +15 days\].~For dry foods (nuts and peanuts), tests will be performed with products harvested over 3 separate and consecutive seasons."
224223322|NCT03727464|BEHAVIORAL|Concrete priming|Patients were primed with a list of concrete during their general anesthesia
224223323|NCT03727464|BEHAVIORAL|Controls|Patients did not receive any specific stimulation with words during their general anesthesia
224223324|NCT03727464|DRUG|Propofol|Propofol general anesthesia
224223325|NCT03727464|DRUG|Sevoflurane|Sevoflurane general anesthesia
224223326|NCT06481553|DRUG|first line treatment|Paclitaxel liposome in combination with trastuzumab (or trastuzumab biosimilar, or pyrotinib) ± pertuzumab ± other chemotherapy drugs (such as capecitabine, carboplatin, gemcitabine) may be used for HER-2 positive patients, with the addition of endocrine therapy for triple-positive patients.
224223327|NCT02116491|DEVICE|Visual Sputum Suctioning System|All ES procedures were performed on indication by RICU nurses and according to protocol, according to which Closed suction system was performed which the patient remained connected to the ventilator. The double-lumen catheter of the Visual Sputum Suctioning System integrated with a 0.9-mm micro-imaging fiber was inserted into the endotracheal tube until resistance was met and withdrawn 0.5 cm. A negative pressure of maximum 150mmHg was set, and the catheter was withdrawn while gently rotating. The procedure lasted for a total of 10 seconds. Nonsterile gloves were to be used during all procedures.
224223328|NCT03644602|DIETARY_SUPPLEMENT|low FODMAPs diet|Low FODMAPs diet was a diet containing low amount of poorly absorbed short-chain carbohydrates (Fermentable, Oligo-, Di-, Mono-saccharides And Polyols)
224223329|NCT04953585|PROCEDURE|radical gastrectomy|According to the size and location of the tumor, the appropriate surgical method was selected for radical gastrectomy
224223330|NCT01035320|DRUG|Ezetimibe|After a placebo only run-in period patients (two groups) are treated with simvastatin + ezetimibe and simvastatin + placebo in a cross-over trial. Ezetimibe effects on top of simvastatin will be evaluated as the primary aim; simvastatin effects compared to run-in on placebo will be evaluated as a secondary aim.
224223331|NCT03994094|OTHER|Telephone interview|Structured, directive, telephone interview, in order to collect the outcome measures in addition to the patients electronic health record.
224223332|NCT05898282|OTHER|observation|since this is a cross sectional observational study any form of intervention was not applicable
224223333|NCT00344630|DEVICE|TAXUS Stent and Cypher Stent|
224223334|NCT03501550|DRUG|CDI-31244|investigational drug
224223335|NCT03501550|DRUG|SOF/VEL|sofosbuvir and velpatasvir fixed dose combination
223634719|NCT06596057|BIOLOGICAL|CAR-T/CAR-NK cells|One to two days after completion of eluvial chemotherapy, CAR-T/CAR-NK cells were transfused in subjects assessed by the investigators as eligible for infusion. The CAR-T/CAR-NK dose is calculated according to the patient's body weight, and the total number of cells transfused is about 1-2x106 /kg. Single intravenous infusion
223764705|NCT03328273|DRUG|Ceralasertib|An ATP competitive, orally bioavailable inhibitor of the Serine/Threonine protein kinase Ataxia Telangiectasia and Rad3 related (ATR).
223764706|NCT03328273|DRUG|Acalabrutinib|An experimental anti-cancer drug and Bruton's tyrosine kinase (BTK) inhibitor.
223764707|NCT04083976|DRUG|Erdafitinib|Participants will receive erdafitinib oral tablets.
223764708|NCT06637371|DRUG|AMG 691|Subcutaneous (SC) injection
223764709|NCT06637371|DRUG|Placebo|SC injection
224223336|NCT04158479|DEVICE|ECMO|ECMO for circulatory and/or respiratory support
224223337|NCT01724970|DEVICE|ProSeal|Patients will be ventilated with PLMA
224223338|NCT01724970|DEVICE|Supreme LMA|Patients will be ventilated with SLMA
224223339|NCT01386879|DRUG|methylene blue|A dilute solution of methylene blue (5 ml of 1 % methylene blue solution in saline, 1:1 dilution) will be gently delivered into the hypopharynx using a flexible suction catheter approximately once per hour until trachea is extubated.
224223340|NCT03903484|OTHER|Deprescribing toolbox and intervention|Pharmacist-led deprescribing plan with the patient which will include the patient's deprescribing goals. The intervention advocates for deprescribing according to recognized algorithms and guidelines which will be included in a resource toolbox/website.
224223341|NCT01743677|DRUG|CP-690,550|Single dose 100 mg (5 x 20 mg tablets)
224223342|NCT01743677|DRUG|Placebo|Single dose placebo tablets (5 tablets)
224223343|NCT01743677|DRUG|Moxifloxacin|Single dose Avelox 400 mg tablet
224223344|NCT06680089|DRUG|[18F]RCCB6|Enrolled patients will receive 0.05-0.1mCi/kg of \[18F\]RCCB6. ImmunoPET/CT imaging will be acquired 1-2 hours after \[18F\]RCCB6 injection.
224223345|NCT01715415|DRUG|ABT-450/r/ABT-267, ABT-333|Tablet; ABT-450 coformulated with ritonavir and ABT-267, ABT-333 tablet
224223346|NCT01715415|DRUG|Ribavirin|Capsule (double-blind treatment period), tablet (open-label treatment period)
224223347|NCT01715415|DRUG|Placebo for ABT-450/r/ABT-267|Tablet
224223348|NCT01715415|DRUG|Placebo for ABT-333|Tablet
224223349|NCT01715415|DRUG|Placebo for ribavirin|Capsule
224223350|NCT01015612|DEVICE|Medtronic CoreValve® System|The Medtronic CoreValve® System device is designed to replace the native aortic valve without the requirement for open heart surgery and without concomitant surgical removal of the failed native valve in patients with symptomatic severe aortic stenosis who have an elevated surgical risk
224223351|NCT00563303|DRUG|hydrocortisone|200mg/jour (solution of 48mL), Day 1 to Day 4 100mg/jour (solution of 48mL), Day 5 50mg/jour (solution of 48mL), Day 6
224223352|NCT00563303|DRUG|NaCl|48mL from Day 1 to Day 6
224223353|NCT01244607|DRUG|Placebo|single i.v. administration
224318535|NCT05434169|BIOLOGICAL|Arterial Blood Gas|The procedure of arterial blood collection will be conducted in a seated position for all three groups. The patient is in a supine position, with the forearm comfortably placed on a small table. The needle used for blood collection is a 25 gauge needle without local anesthetic. This method of sampling is identical to the one used in daily practice in the Emergency department of Fribourg
223634720|NCT05030597|DRUG|68Ga-DOTA-FAPI|Intravenous access is pre-established. Quality control is carried out to confirm the radiochemical purity of 68Ga-DOTA-FAPI by HPLC. Intravenous administration of 68Ga-DOTA-FAPI according to 1.85-3.7 MBq/kg body weight (0.05-0.1 mCi/kg), rinsed with 0.9% saline, and hydrated after drinking more water.
223634721|NCT05030597|DEVICE|PET/CT|Each subject undergoes PET/CT imaging within 20-30 minutes after injection.
223634722|NCT05030597|DIAGNOSTIC_TEST|Participants receive baseline paired FDG and FAPI PET/CT. For resectable locally advanced cases receiving neoadjuvant therapy undergo follow-up FAPI PET imaging.|"This observational study evaluates the application of paired FDG and FAPI PET/CT in oral cancer.~1. Baseline phase: All participants undergo baseline FDG and FAPI PET/CT scans.~2. Post-neoadjuvant phase: For patients with resectable locally advanced disease receiving neoadjuvant therapy (as per clinician decision), a second FAPI PET/CT scan is performed after 2 cycles of treatment to assess treatment response.~3. Purpose: To explore the utility of FAPI PET in (a) initial staging, (b) treatment response evaluation, and (c) prognostic value in oral cancer."
223764710|NCT05141058|BIOLOGICAL|Coronavirus-specific T cell (CST)|Participants will receive donor-derived CSTs for prevention of SARS-CoV-2 infection after HSCT (≥28 days and \<4 months after hematopoietic stem cell transplantation (HSCT).
223764711|NCT05448846|PROCEDURE|Enhanced Recovery After Surgery|ERAS protocol includes preoperative counselling, optimization of nutrition, standardized analgesic and anesthetic regimens and early mobilization.
224223354|NCT01244607|DRUG|NI-0801|single i.v. administration
224223355|NCT00066807|DRUG|chemotherapy|Planned duration of chemotherapy: 2 months if an anthracycline is included (e.g., 4 cycles of EC or AC) or 4 months if no anthracycline is given (e.g., 6 cycles of CMF) is recommended. Unless medically contraindicated, an anthracycline-containing regimen using epirubicin should be given.
224223356|NCT00066807|DRUG|exemestane|Exemestane 25 mg orally daily for until 5 years from date of randomization, unless relapse or intolerance should occur earlier.
224223357|NCT00066807|DRUG|tamoxifen|Tamoxifen 20 mg orally daily until 5 years from date of randomization, unless relapse or intolerance should occur earlier.
224223358|NCT00066807|DRUG|triptorelin|Triptorelin (GnRH analogue) 3.75 mg by intramuscular injection every 28 days for 5 years from randomization, unless relapse or intolerance should occur earlier or surgical oophorectomy or ovarian irradiation is subsequently performed.
224223359|NCT00066807|PROCEDURE|oophorectomy|Bilateral surgical oophorectomy via laparotomy or laparoscopy.
224223360|NCT00066807|PROCEDURE|ovarian irradiation|Bilateral ovarian irradiation.
224223361|NCT02818478|OTHER|Reporting of patient reported outcome measures|Electronic reporting of patient reported outcome measures from home, compared to reporting of patient reported outcome measures at the outpatient clinic
224223362|NCT01418729|DRUG|Pravastatin|"Treatment:~Patients will be randomized in two groups, A and B:~* Control Group (A ≡ 1): Patients will receive treatment with sorafenib 400 mg/12 h + placebo/24 h.~* Experimental Group (B ≡ 2): The treatment received will be sorafenib 400 mg/12 h + pravastatin 40 mg/24 h."
224223363|NCT05463458|OTHER|nutrition|Standard of nutrition Care plus adjusted and calculated dose of omega-3 polyunsaturated fatty acids (PUFA) anti-oxidants.
224223364|NCT06012175|DIETARY_SUPPLEMENT|Melatonin|One 3 mg melatonin tablet every night before bedtime for 12 weeks
224318536|NCT05547217|DEVICE|Hand Therapy using the MyHand System|The MyHandTM System is a smart-mechatronic device programmed with proprietary hand function training regiments (protocols) based on deep research in neuroplasticity. It provides a highly unique and targeted approach to hand function rehabilitation with the help of the aforementioned protocols delivered with gamified training techniques. The gamified format of the protocols allows for better patient engagement, thus allowing for more effective and efficient therapy. Participants will undergo a 2-hour training session, 2-3 days per week, over 12 weeks, for a total of 30 sessions. Hand function therapy will be administered in a specific and gamified manner to enhance rehabilitation of the hand and provide participants with greater opportunity to regain hand function over the course of the study.
224223365|NCT06012175|DIETARY_SUPPLEMENT|Placebo|One placebo tablet, having an identical appearance to the melatonin tablet, every night before bedtime for 12 weeks
224223366|NCT06702540|DEVICE|Biosensor chip|An electronic platform measuring the impedance variation between microelectrodes is used upon capturing the target biomolecule by a selective bioprobe previously grafted over the biosensor surface. The required sensitivity will be achieved by operating the biosensor in lock-in mode, which ensures the highest resolution in tracking amplitude and phase variations of impedance signals.
224223367|NCT01438333|DIETARY_SUPPLEMENT|lactobacillus brevis tablets|5 tablets a day for 6 weeks
224223368|NCT01438333|DIETARY_SUPPLEMENT|PLACEBO|5 tablets a day for 6 weeks
224223369|NCT00990119|DEVICE|Vapotherm High Flow Therapy|use of high flow nasal cannula to support oxygenation and CO2 removal by flushing the nasopharynx with warmed, humidified respiratory gas at flow rates that exceed a patient's inspiratory flow rate
223634723|NCT04935372|OTHER|Observational|"Cross sectional analyses The two main variables for the analysis will be: Values of biomarker concentrations in blood and their correlations with CSF biomarkers and the development of prodromal AD for the cognitively unimpaired SCD population. Other variables of interest for the study are, among others, risk factors, cognitive status, measurements of brain structure and function, mental health, chronic diseases, environmental exposures, age and sex.~Longitudinal analyses Longitudinal analyses will estimate the association between the intensity of the subjective complaint and the rate of progression between the diagnostic categories; The association of biomarkers, risk factors and other clinical variables with the rate of progression between the diagnostic categories; The association of cognitive and neuroimaging variables with the rate of progression between the diagnostic categories; The evolution of the complaint itself and its relation to the other variables described."
223634724|NCT06599775|DRUG|Adebrelimab injection|Experimental group：Adebrelimab is an innovative PD-L1 inhibitor, monotherapy can improve pathological complete response rates with tolerable safety
224223370|NCT00990119|DEVICE|Non-invasive positive pressure ventilation|Patients will be fit with an oronasal mask using a fitting gauge that will be applied by a respiratory therapist or other clinician skilled in management of NIPPV. Initial pressures will be at low end of suggested range but can be increased as rapidly as necessary to alleviate respiratory distress.
224223371|NCT05185687|BEHAVIORAL|First Come, First Served|"Respondents will view the following description of the plan: Tests will be sent out in the order they are requested. People who request tests the quickest will get them first, no matter where they live. People who request tests later may not get any. This strategy is also known as 'First Come, First Served.'"
224223372|NCT05185687|BEHAVIORAL|Random|"Respondents will view the following description of the plan: People who request tests will be entered into a random drawing, like a sweepstakes or lottery. Everyone who is in the drawing has the same chance of getting tests, no matter where they live, but some people may not get any tests."
224223373|NCT05185687|BEHAVIORAL|Disadvantaged Priority & Random|"Respondents will view the following description of the plan: Because COVID-19 has hit people living in disadvantaged areas of the country harder, a proportion of tests will be sent exclusively to people in these zip codes. Planners will allocate 80% of the tests using a random drawing, like a sweepstakes or lottery. Everyone who is in the drawing has the same chance of getting tests, no matter where they live. The remaining 20% are set aside exclusively for the most disadvantaged areas, again allocated with a random drawing. Some people may not get any tests. But people living in disadvantaged areas are more likely to get them."
224223374|NCT06418087|DRUG|Durvalumab 50 MG/1 ML Intravenous Solution [IMFINZI]|"Intravenous infusion of durvalumab 1500 mg on day 1 (induction phase) with carboplatin (AUC 5 on day 1), etoposide (100 mg/sqm on days 1-3) every 3 weeks, and durvalumab (1500 mg on day 1) administered every three weeks for up to 4 cycles (induction phase) or until progression of disease, unacceptable toxicity, patient refusal or loss of clinical benefit (for durvalumab).~Treatment with intravenous durvalumab (1500 mg on day 1) every 4 weeks ± 3 days (maintenance phase) will continue until completion of 24 courses (for a total of 28 courses, including the 4 courses of induction phase) or 2 years of treatment whichever occurs first, disease progression, unacceptable toxicity, patient refusal or loss of clinical benefit."
224223375|NCT03177356|PROCEDURE|extraction,implant placement,PRF|Surgical extraction of mandibular molar using periotome and forceps followed by implant placement in inter-septal bone. Then a blood sample is withdrawn from patient and placed in the centrifuge. Then Platelet-Rich fibrin is placed in the extraction socket as space filling material
224223376|NCT03177356|PROCEDURE|Exctraction,Implant placement,Bone graft|Surgical extraction of mandibular molar using extraction forceps and periotome followed by implant placement in interseptal bone. De-proteinized bovine bone graft material is placed as space filling material
224223377|NCT05028751|DRUG|Lanraplenib|Orally via tablets
224223378|NCT05028751|DRUG|Gilteritinib|Orally via tablets
224223379|NCT05787977|OTHER|Visual Feedback and Rhythmic Auditory Cue|Patients were trained five times per week for eight weeks. After eight weeks of training the gait pattern and balance was evaluated by the gait parameters, 6min Walk test, Pediatric Balance Scale and Berg balance scale.
224223380|NCT03092089|DRUG|Definity, (Lipid Microspheres) Intravenous Suspension|Sonothrombolysis (High Impulse therapeutic ultrasound with infusion of ultrasound contrast agent Definity) will be applied before and after standard of care reperfusion therapy with PPCI
224223381|NCT03092089|DEVICE|Myocardial Contrast Echocardiography|Myocardial contrast echocardiography will be applied before standard of care reperfusion therapy as well as prior to discharge and at 3 month follow up
224223382|NCT03092089|PROCEDURE|Repurfusion therapy with PPCI|Patients will receive reperfusion therapy with PPCI as standard of care
224223383|NCT05550558|DRUG|Anlotinib + Camrelizumab|Anlotinib PO plus Camrelizumab IV
224223384|NCT03586830|DRUG|JNJ-64565111 Dose Level 1|Participants will receive JNJ-64565111 Dose Level 1 SC once-weekly until Week 12.
224223385|NCT03586830|DRUG|JNJ-64565111 Dose Level 2|Participants will receive JNJ-64565111 Dose Level 2 SC once-weekly until Week 12.
224223386|NCT03586830|DRUG|JNJ-64565111 Dose Level 3|Participants will receive JNJ-64565111 Dose Level 3 SC once-weekly until Week 12.
223634725|NCT06599775|DRUG|Albumin-Bound Paclitaxel|Experimental group：combined with Adebrelimab（PD-L1 inhibitor）,and carboplatin followed by endoscopic resection and subsequent simultaneous radiotherapy combined with albumin-bound paclitaxel and carboplatin
224223387|NCT03586830|DRUG|Placebo|Participants will receive matching placebo to JNJ-64565111 SC once-weekly until Week 12.
224223388|NCT00764998|BIOLOGICAL|Fluviral|
224223389|NCT04578548|DRUG|GLPG2737|Capsules administered orally
224223390|NCT04578548|DRUG|Placebo|Matching placebo capsules administered orally
223634726|NCT06599775|DRUG|Carboplatin injection|Experimental group：combined with Adebrelimab（PD-L1 inhibitor），and albumin-bound paclitaxel followed by endoscopic resection and subsequent simultaneous radiotherapy combined with albumin-bound paclitaxel and carboplatin
223634727|NCT06704737|DEVICE|AR training|Dichoptic augmented reality training with dual-pathway (parvocellular pathway and magnocellular pathway) and interocular push-pull paradigms developed based on neural deficits in adults with unilateral amblyopia
224223391|NCT06346054|DIAGNOSTIC_TEST|Breath analysis|Detection of proteins and volatile organic compounds (oncometabolites) in the exhaled breath
224223392|NCT06346054|DIAGNOSTIC_TEST|Blood analysis|Detection of proteins and circulating tumor DNA (oncometabolites) in the peripheral blood
223634728|NCT06704737|DEVICE|Patching|Conventional patching therapy.
223634729|NCT06706050|BIOLOGICAL|Microbiome Therapeutic LP-51|Microbiome therapeutics LP-51 was applied on the individuals suffering from xerosis
223634730|NCT06706050|OTHER|placebo cream (M23004-03)|placebo cream (M23004-03) was applied on the participants
223634731|NCT06704490|OTHER|Cesarean section|Observational study without intervention
223634732|NCT06704828|DRUG|SHR-4602|SHR-4602
223634733|NCT02677493|BIOLOGICAL|IL-YANG Quadrivalent Influenza Vaccine|A single 0.5mL dose administrated as an intramuscular injection.
223634734|NCT02677493|BIOLOGICAL|IL-YANG Flu Vaccine Prefilled Syringe|A single 0.5mL dose administrated as an intramuscular injection.
223634735|NCT02677493|BIOLOGICAL|IL-YANG Trivalent Influenza Vaccine|A single 0.5mL dose administrated as an intramuscular injection.
223634736|NCT06705322|DRUG|Cnidium Monnieri Detoxification Formula|"Drug composition of Cnidium Monnieri Detoxification Formula: snake seed 9g, Tuckaia 30g, Matrine 9g, snake berry 30g, white Ying 30g. Based on the Cnidium Monnieri Detoxification Formula, the other symptoms were treated with syndrome differentiation and flavor. The traditional Chinese medicine decoction is provided by the Pharmacy of Yueyang Hospital of Integrated Traditional Chinese and Western Medicine Affiliated to Shanghai University of Traditional Chinese Medicine, with 1 dose per day, decocted into 300ml by a medicine decocter, packed in 2 vacuum bags, taken orally after meals, twice a day, one bag each time. Do not stop taking decoction during menstruation. 1 month is a course of treatment, at least 3 courses of treatment, no more than 6 courses of treatment.~Baseline HPV clearance, improvement in clinical symptoms and quality of life, and drug safety were assessed at 3 months, 6 months, and 12 months after initiation of treatment."
223634737|NCT01203202|DRUG|Clomipramine|15mg and 30mg on demand
223634738|NCT06225453|OTHER|Individualized perioperative blood pressure management strategy|In this group, perioperative mean arterial pressure and systolic blood pressure are maintained at no less than -20% of the baseline values of each patient.
223634739|NCT06225453|OTHER|Conventional perioperative blood pressure management strategy|In this group, perioperative mean arterial pressure and systolic blood pressure are maintained at ≥65 mmHg and ≥90 mmHg, respectively, in all patients.
223634740|NCT00312429|PROCEDURE|Stem Cell Transplantation|Allogeneic umbilical cord blood stem cell transplant
223634741|NCT04833582|DRUG|ZN-c3|ZN-c3 is an investigational drug.
223634742|NCT04833582|DRUG|Gemcitabine|Gemcitabine is an approved drug
224223393|NCT00288171|DRUG|Placebo|placebo capsule twice daily for one month
224223394|NCT00288171|DRUG|Allopurinol|Allopurinol 200mg twice daily for one month
224223395|NCT02248285|DEVICE|FilmArray™ Gastrointestinal (GI) Panel|BioFire Diagnostics, LLC (BioFire) has developed a polymerase chain reaction (PCR), high-resolution melting analysis instrument called the FilmArray™ and an associated reagent pouch that together are capable of simultaneously detecting multiple microorganisms in a single sample. The FilmArray™ Gastrointestinal (GI) Panel pouch contains freeze-dried reagents to perform nucleic acid purification and nested, multiplex PCR for the identification of common bacterial, viral, and parasite microorganisms responsible for infectious gastroenteritis. The test was made available for sale in the US and EU following FDA clearance and CE marking in May, 2014
223634743|NCT00072709|DRUG|TCH346|
224223396|NCT06421623|OTHER|Program Including Various Workshops aiming to preserve elderly's autonomy through foot health|Combination of minimalist footwear, foot massages, and workshops to re-learn walking and posture
224223397|NCT05452577|DRUG|Suanzaoren Decoction and Huanglian Wendan Decoction|Twice daily. Chinese herbal medicine includes: includes: 25 grams of Suanzaoren, 10 grams of chuanxiong, 30 grams of fushen, 10 grams of Polygala tenuifolia, 10 grams of Pinellia ternata, 12 grams of tangerine peel, 15 grams of Zhuru, 30 grams of forged keel, 30 grams of forged oyster,10 grams of aurantii fructus, 6 grams of coptis chinensis, 30 grams of Albizzia bark.Add or subtract Chinese herbal medicine according to the different clinical manifestations of each patient.
224223398|NCT05452577|DRUG|Estazolam 1Mg Tab|1mg tablet once daily
224223399|NCT00395083|BEHAVIORAL|COPD Self-management Education|The comprehensive self-management intervention incorporates self-management education, development of an action plan, and case management. The intervention is designed using the social cognitive theory with the Precede-Proceed Model which has guided other successful patient education programs.
224223400|NCT03608072|DRUG|BI 690517|3 sequential dose groups
224223401|NCT03608072|DRUG|Placebo|3 sequential dose groups
224223402|NCT00972153|DEVICE|Air Barrier System Device|Device is deployed adjacent to the surgery site and activated so that the filtered air emits over the surgery site.
224223403|NCT00972153|DEVICE|Sham Air Barrier System device|Device is deployed to the surgery site, but the airflow is not activated. This intervention is used to determine any effects that the presence of the device alone may have.
224223404|NCT01078415|DEVICE|Ablation with the NanoKnife Low Energy Direct Current (LEDC) System|90 pulses of 70 microseconds each in duration will be administered per electrode pair.
224318537|NCT06581458|DRUG|tDCS|The immediate intervention group will continue to receive five tDCS treatments per week for 6 months. The late intervention group will receive five sham treatments per week for 3 months and then begin receiving five weekly tDCS treatments for an additional 3 months.
223634744|NCT05270720|BIOLOGICAL|dendritic cell|"Biological: Dendritic Cell Immunotherapy Adult patients with histopathologically diagnosed Ovarian Cancer will be eligible for this novel, personalized dendritic cell vaccine during course of standard of care chemotherapy.~If unacceptable side effects are observed at a total dose of 5x106, as detailed in the study protocol, then a cohort of 3-6 enrolled patients will receive a de-escalated total dendritic cell dose of 2.5x106.~If no unacceptable side effects are identified at a total dose of 5x106, as detailed in the study protocol, then a cohort of 3-6 enrolled patients will receive an escalated total dendritic cell dose of 1X107."
223634745|NCT01108016|BEHAVIORAL|Videoconferencing support group|
223634746|NCT02746653|DEVICE|TroClose1200(TM)|Creation of access port and closure it by the same device, TroClose1200(TM)
223634747|NCT02252003|OTHER|Pain scales testing|
223634748|NCT05176405|BEHAVIORAL|You-Tube Video: Elissa's EE song|Watch You-Tube video utilizing Entertainment-Education communication strategy.
223634749|NCT05176405|BEHAVIORAL|Active Comparator: Standard of Care|Reading materials containing information about early breast cancer screening in the form of infographics. Information is adopted from the Saudi Ministry of Health (MOH).
223634750|NCT05251168|PROCEDURE|PET Guided Bone Marrow Biopsy|"The results of PET/CT images were discussed with the referring physician. PET/CT targeted metabolic marrow biopsy was planned two hours after the whole body diagnostic imaging or on a subsequent day one hour after injecting 2-3 mCi of FDG to minimize the radiation exposure burden to the interventionist.~Society of Interventional Consensus guidelines was followed for image-guided biopsy.~The bone marrow biopsy was done under the PET/CT guidance using the same PET/CT scanner with the help of an automated robotic arm (ARA) workstation"
223634751|NCT05251168|PROCEDURE|Trephine Bone Marrow Biopsy|All the participants underwent trephine bone marrow biopsies from the bilateral posterior superior iliac spine before treatment planning.
223634752|NCT02168244|OTHER|Heating Pack|Application of heat to skin for 2-3 minutes prior to injection of biologic drug
223764712|NCT05448846|BEHAVIORAL|Home-based multicomponent exercise program (EXE)|"Home-based multicomponent exercise program:~A) Strength and balance (20 to 40 minutes, 2 days/week):~* Chair sit to stand exercise \| 1 to 3 sets completing repetitions until rating 5 to 8 in the Rated of Perceived Exertion, 0-10 scale (RPE).~* Seated curl to press exercise \| 1 to 3 sets completing repetitions until rating 5 to 8 RPE.~* Monopodal balance \| 1 to 3 sets with progressive time targets up to 60-second for each leg.~B) Gait (at least 30 minutes at an intensity that allows for comfortable conversation, 2 days/week on separate days from strength and balance exercise)~C) Inspiratory Muscle Training: 30 inspirations at 40% of maximal inspiratory pressure through a Power Breathe device, 2 times per day)"
223764713|NCT06189092|DRUG|Bleomycin|Using electroporation to infuse bleomycin in the lesion
224223405|NCT00482313|DRUG|PR OROS Methylphenidate|PR OROS Methylphenidate given orally once daily for 5 weeks. The dosage was as follows: 36 mg per day from day 1-3, 54 mg per day from day 4-7 and 72 mg per day from day 8 until end of 5th week.
224223406|NCT00482313|DRUG|Placebo|Sugar pill
224223407|NCT00644605|DRUG|sildenafil|sildenafil 40 mg by mouth three times daily (TID), with doses at least 6 hours apart, for 12 weeks
224223408|NCT00644605|DRUG|sildenafil|sildenafil 80 mg by mouth three times daily (TID), with doses at least 6 hours apart, for 12 weeks; initially, patients received 40mg TID for one week and were then up-titrated to 80mg TID
224223409|NCT00644605|DRUG|placebo|placebo by mouth three times daily (TID), with doses at least 6 hours apart, for 12 weeks
224223410|NCT00644605|DRUG|sildenafil|sildenafil 20 mg by mouth three times daily (TID), with doses at least 6 hours apart, for 12 weeks
224318538|NCT05387343|DIAGNOSTIC_TEST|Coronavirus (COVID-19) SARS-CoV-2 inSIGHT™ T Cell Immunity Test|Boosters will be given after month 3 after transplant, and the 2nd booster will be given 3 months after the first.
223764714|NCT05980676|BEHAVIORAL|Personalized Two-Week Email-Based Program|Both intervention groups will complete an activity that will guide the creation of a habitual instigation implementation intention (e.g., When I finish eating lunch at work, then I will put on my walking shoes and go outside) and receive a 2-week long personalized email campaign. The Coached group will be able to reply to the emails to give feedback, ask questions, and receive additional support.
224223411|NCT05576909|DRUG|Donafenib|"0.2g BID for downstaging treatment;~0.1g BID for adjuvant therapy"
224223412|NCT05576909|PROCEDURE|TACE|For downstaging treatment
224223413|NCT02204215|DEVICE|electric acupuncture|Electric acupuncture therapy was made on LI4, LI11, ST36, and ST41 on four limbs for each patient, 30 min for each time, twice per day. Starting from the beginning of mechanical ventilation, to the weaning of the mechanical ventilation.
224223414|NCT02204215|OTHER|conservative|General treatment, without electric acupuncture, include passive range-of-motion exercise，q2H turning，minimizing the use of sedation, etc.
224223415|NCT05273398|DRUG|nasal diazepam|Nasal administration of diazepam
224223416|NCT00002594|BIOLOGICAL|Sargramostim|Given IV
224223417|NCT00002594|DRUG|cyclophosphamide|Given IV
223634753|NCT02168244|OTHER|Ice pack|Application of cold to skin for 2-3 minutes prior to injection of biologic drug
223634754|NCT04011046|DEVICE|Stent|
223634755|NCT00157677|PROCEDURE|D-dimer testing|Uniform D-dimer use
224223418|NCT00002594|DRUG|melphalan|Given IV
223634756|NCT00157677|PROCEDURE|D-dimer testing|Selective D-Dimer use
223634757|NCT05360004|DRUG|Chinese herbal medicine|CHM is in the form of granules (9 g/sachet), which is comprised of 10 commonly used medicinal herbs: Codonopsis Radix, Astragali Radix, Lonicerae Japonicae Flos, Saposhnikovia Radix, Schizonepetae Herba, Mori Folium, Poria, Atractylodis Rhizoma, Atractylodis Macrocephala Rhizoma, Glycyrrhizae Radix et Rhizoma.
224223419|NCT00002594|PROCEDURE|autologous bone marrow transplantation|
224223420|NCT00002594|PROCEDURE|bone marrow ablation with stem cell support|
224223421|NCT00002594|PROCEDURE|peripheral blood stem cell transplantation|
224223422|NCT03354156|DRUG|statin treatment|The patients with elevated LDL receive statin treatment in the context of normal patient care (so this is NOT an intervention of the study)
224223423|NCT03904498|DRUG|Tolcapone|Tolcapone 100 mg tablets
224223424|NCT03904498|DRUG|Placebo|Placebo tablets
224223425|NCT06394921|PROCEDURE|2 day cardiopulmonary exercise test|Consecutive day 2 day CPET and follow up for 7 days for subjective feelings/fatigue.
224223426|NCT04136626|DEVICE|Perspectives OCD|The app-delivered cognitive behavioral therapy (CBT) in this project includes modules such as cognitive skills (e.g., cognitive restructuring, core belief work) and behavioral skills (e.g., exposure and response prevention).
224318539|NCT00704132|DRUG|Comparator: sitagliptin phosphate|Sitagliptin tablet 100 mg, administered once daily before the morning meal.
224318540|NCT00704132|DRUG|Comparator: placebo (unspecified)|Matching placebo tablet, administered once daily before the morning meal.
224318541|NCT01618565|PROCEDURE|Hands-On Training|one-time, 30 minute hands-on training
224318542|NCT01618565|PROCEDURE|Demonstration|30 minutes passive training
224223427|NCT04136626|DEVICE|The Health and Well-Being Program|The website includes 12 modules related to general health and well-being (e.g., sleep and nutrition). Each module contains educational information and questions about an indvidual's experience with the given topic.
224223428|NCT02817854|PROCEDURE|Measure PCT, CRP and WBC at admission|Measure PCT, CRP and WBC at admission after diagnosis of acute diverticulitis with CT scan has been done
224223429|NCT02817854|PROCEDURE|Measure PCT, CRP and WBC 1 day after admission|Measure PCT, CRP and WBC at one day after admission for acute diverticulitis
223634758|NCT04295720|DEVICE|Transcranial magnetic stimulation (TMS)|"Subjects will undergo testing at baseline prior to TMS treatments and once more at the end of the 2-week intervention.After the conclusion of baseline data acquisition, the research team will analyze each participant's unique structural and functional connectivity patterns to determine stimulation site for TMS in future study sessions.~The subjects will receive 10-sessions (1 session per day, M-F over 2 consecutive weeks).~The treatment itself lasts approximately only 190 seconds."
223634759|NCT05642052|DIETARY_SUPPLEMENT|low carb diet|low carb meals will be 50% less carbs than the regular meals
223634760|NCT05642052|DIETARY_SUPPLEMENT|Regular diet|Regular diet
223634761|NCT05552937|DRUG|Tafasitamab and Lenalidomide|"Tafasitamab will be administered intravenously in 28-day cycles. During Cycles 1 through 3, tafasitamab will be administered weekly on Days 1, 8, 15, and 22; an additional loading dose will be administered on Cycle 1 Day 4. Starting with Cycle 4, tafasitamab will be administered on Days 1 and 15 of each cycle.~Participants will self-administer lenalidomide capsules orally on Days 1-21 of each 28-day cycle, up to 12 cycles."
223634762|NCT03018652|DRUG|Intravenous immunoglobulin|IVIG 0.5 g/kg, up to maximum of 80 grams will be given on the day of randomization and then every 4 ± 1 weeks for 44 weeks (Total 48 weeks)
223634763|NCT03018652|DRUG|Normal Saline|5 mL/kg, up to maximum of 800 mL will be given on the day of randomization (this will match the volume of 0.5g/kg of IVIG product) and then every 4 ± 1 weeks for 44 weeks (Total 48 weeks)
223634764|NCT01407432|DRUG|Folic acid|Taking of folic acid 15 mg per day by hanging oral route during 3 at 4 months
223634765|NCT01407432|DRUG|placebo of folic acid|Taking of placebo of folic acid by hanging oral route during 3 at 4 months
223634766|NCT05458115|PROCEDURE|Liver resection|Patient underwent hepatic R0 resection within a week
224223430|NCT02817854|PROCEDURE|Measure PCT, CRP and WBC 2 days after admission|Measure PCT, CRP and WBC at 2 days after admission for acute diverticulitis
224223431|NCT00628745|OTHER|None. Observational Study.|
223634767|NCT04176471|OTHER|Therapeutic Hypothermia|Therapeutic hypothermia involves use of a servo-controlled device and blanket to lower the core body temperature by 3°C for 72 hours followed by a period of re-warming in which the temperature is increased by 0.5°C per hour for 6 hours until normothermia is achieved.
223634768|NCT04176471|OTHER|Normothermia|Normothermia will be achieved using the same servo-controlled device and blanket to assure normothermia of the control arm. The goal temperature for normothermia is 36.5-37.3°C for 72 hours.
223634769|NCT03598686|DIAGNOSTIC_TEST|OraQuick|Most trials assessing oral HIVST make use of OraQuick® (OraQuick ADVANCE HIV I/II test kits, packaged for self-use), an oral-fluid rapid self-test. OraQuick® is a 2nd generation serology assay with a sensitivity of 99.3% (95%CI; 98.4%, 99.7%) and a specificity of 99.8% (95%CI; 99.6%, 99.9%). In a pilot study with 59 participants conducted in Lesotho in 2015 more than 90% of the participants found utilization of OraQuick® easy, and trusted the results of the self-test kit. The WHO recently has announced that OraQuick becomes the first prequalified HIV self-test, in order to improve diagnosis in low-resourced health systems and in countries where stigma prevents people from getting tested. Therefore, OraQuick® is now available in Lesotho for as little as 2 USD per test kit.
224223432|NCT06384365|BEHAVIORAL|Physical activity|The control and the athletic group differ in the degree of physical acitvity
224223433|NCT03805204|PROCEDURE|Open reduction and internal fixation (ORIF)|ORIF with a forearm plate
224223434|NCT00982410|BEHAVIORAL|cognitive-behavioral treatment|cognitive-behavioral treatment (CBT) interventions to manage pain and decrease substance use abuse/misuse
224223435|NCT00982410|BEHAVIORAL|educational supportive group|A control condition providing social support and education about pain and/or drug use.
224223436|NCT03522779|DIETARY_SUPPLEMENT|Tart cherry Juice|Tart cherry juice will be used to compare antioxidant and oxidative stress levels in human plasma following a high fat meal.
224223437|NCT03522779|OTHER|High-fat meal|A high fat meal will be given to elicit postprandial oxidative stress.
224223438|NCT03522779|OTHER|Exercise|The exercise will consist of 30 minutes of treadmill running at 70% of each participants' calculated heart rate reserve.
224223439|NCT02687282|OTHER|Evaluate upper airway changes|Evaluate upper airway changes at several point of time before and after cesarean delivery
224223440|NCT03322462|DRUG|Flortaucipir F18|370 megabecquerel (MBq) IV single-dose
224223441|NCT03322462|PROCEDURE|Brain PET Scan|positron emission tomography (PET) scan of the brain
224223442|NCT03574155|BEHAVIORAL|Pre-operative Counseling and Education|"Group control Pre-operative Orientation Routine Application of the questionnaire (ESAS) and (HADS) Post-operative Immediate (1 OP) Application of the Questionnaire to assess HADS and ESAS Anxiety (Patient)~Experimental Group Pre-operative Counseling and Education Application of the questionnaire (ESAS) and (HADS)~Late postoperative (2 - 4 weeks) Questioning the patient and companion evaluating the degree of satisfaction regarding the preoperative guidelines."
224223443|NCT00770003|DRUG|AZD8848|nasal spray solution; 30 or 60 µg administered intranasally once weekly for one month
223634770|NCT00000197|DRUG|Propranolol|
223634771|NCT04214938|OTHER|Intranasal solutions application were done including one solution for per patient before nasoendoscopy procedure according to randomization|Hypertonic sea water, Vemcaine, Otrivine, and a placebo were applied by intranasal before the nasoendoscopy procedure for improving the field of view of clinician and reducing the patient discomfort.
223634772|NCT00512915|DEVICE|pacemaker implantation|St. Jude Medical Dual Chamber Pacemaker model Identity (ADx) DR, Victory DR, or newer
224223444|NCT00770003|DRUG|Placebo|nasal spray solution. Once weekly intranasal administrations for one month.
224223445|NCT04190654|DRUG|KW-6356|Single oral dose of KW-6356
224223446|NCT01271114|DRUG|Hypertonic Saline and Terlipressin|Hypertonic saline 3% 7mL/Kg (with a maximum 500 mL)triggered by either Systolic Volume Variation or Pulse Pressure Variation more than 10%; Terlipressin infusion (dilution 1mg in 100mL) triggered by MAP below 70 mmHg for a goal MAP above 70 mmHg
224223447|NCT01271114|DRUG|Normal saline and norepinephrine|Normal saline IV bolus 7mL/kg (with a maximum 500 mL)triggered by either Systolic Volume Variation or Pulse Pressure Variation above 10%; Norepinephrine drip (80 micrograms/mL) to keep MAP at least 70 mmHg
224223448|NCT02004847|DEVICE|PSO-CT02|The PSO-CT02 device is a non CE marked investigational medical device that is worn on the affected skin area where it irradiates the Psoriasis plaque for 30 minutes with blue light.
223634773|NCT04301375|DRUG|Pertuzumab and trastuzumab FDC subcutaneous|Pertuzumab and trastuzumab FDC subcutaneous, A loading dose of 1200 mg pertuzumab and 600 mg trastuzumab followed by a maintenance dose of 600 mg pertuzumab and 600 mg; day 1 of each 3 week cycle during 5 neoadjuvant cycles and 13 adjuvant cycles if complete response
223634774|NCT04301375|DRUG|Paclitaxel|80 mg/m2, day 1,8,15 of each 3 week cycle during 4 cycles
223634775|NCT04301375|DRUG|TDM1|3,6 mg/kg, 14 adjuvant cycles if not complete response
223634776|NCT04301375|DRUG|Endocrine therapy|Adjuvant endocrine therapy will be administered as per local practice and according to recognized clinical practice guidelines
223634777|NCT04301375|PROCEDURE|Omission surgery|Omission of surgery and sentinel lymph node dissection in patients with HER2-E and ERBB2 high breast cancer who achieving a complete response following standard anti-HER2-based neoadjuvant therapy with paclitaxel/trastuzumab/pertuzumab
223634778|NCT01456039|DRUG|Romidepsin|Intravenous dosing for 4 hours on Days 1, 8, and 15 of each 28-day cycle
223634779|NCT03614650|BIOLOGICAL|engineered immune cells|Engineered immune effector cells (EIE)
223634780|NCT01547078|BIOLOGICAL|Lyophilized Plasma|Licensed plasma that has been lyophilized.
223634781|NCT01547078|BIOLOGICAL|Licensed Plasma|Plasma that has been authorized for transfusion.
223634782|NCT00755664|DIETARY_SUPPLEMENT|Low-dose complex B-vitamins|The complex B vitamins supplement has been made as capsule and packaging 31 capsules in 1 bottle with a pre-determined code number on its cover. The main content contains either vitamin C 50mg alone or combination with folate 0.4 mg, vitamin B6 2mg, vitamin B12 10μg and vitamin C 50 mg. Two kinds of the supplements could not be discriminated by appearance, smell, taste, size and package.volunteers in either arms are required to take 1 capsule per day and last for 48 weeks.
223634783|NCT00335777|DRUG|Migranal nasal spray at 1 hour|Migranal® 4 mg. will be self administered by each subject in the following manner: one spray in each nostril, wait 15 minutes then follow with one spray in each nostril. This will deliver the desired 4 mg. dose.
223634784|NCT00335777|DRUG|Migranal nasal spray at 4 hour|Migranal® 4 mg. will be self administered by each subject in the following manner: one spray in each nostril, wait 15 minutes then follow with one spray in each nostril. This will deliver the desired 4 mg. dose.
224223449|NCT02946957|BEHAVIORAL|Cognitive Behavior Therapy for Insomnia|Six telephone sessions that last 20-30 minutes presenting cognitive behavioral therapy for insomnia.
224223450|NCT02946957|BEHAVIORAL|Education Only Control|Six telephone sessions that last 20-30 minutes presenting sleep and osteoarthritis education.
224223451|NCT04261257|OTHER|Cardiac scanner|"As part of the usual care of patients hospitalized for stroke, the following examinations are carried out: a trans-thoracic cardiac ultrasound, a transesophageal cardiac ultrasound according to the needs of patient's care, an echo-doppler of the supraaortic trunks, a CT angiography of the supraaortic trunks, a transcranial doppler, a biological assessment, a 24-hour holter or long-term holter.~The additional examination, specific to the research, corresponds to a cardiac scanner, which does not require the additional injection of contrast medium, carried out during the cerebral artery scanner within 36 hours of discovering the stroke. Within 3 days after inclusion, a trans-thoracic cardiac ultrasound, and a transesophageal cardiac ultrasound according to the needs of patient's care are carried out."
224223452|NCT01144910|OTHER|methacholine challenge test|"2 ml of liquid-dissolved methacholine in concentration of 16 mg/ml dosed in 5 steps of 0.01 mg, 0.1 mg, 0.4 mg, 0.8 mg, and 1.6 mg. 2 minutes after each step up an impulse oscillometry (IOS) and spirometry will be performed.~the challenge will be stopped in case of a ≥ 20% decrease from baseline in FEV1 (PD20) and 0,2 mg Salbutamol will be given."
223634785|NCT00562224|DRUG|PCI-24781|"Up to 7 cohorts will receive PCI-24781 orally at doses starting at 30 mg/m2 three times a day approximately 4 hours apart (TID), up to 90 mg/m2, administered 5 days/week during the first 21 days of each 28 day cycle until MTD is reached. If a dose limiting toxicity (DLT) occurs, then the next cohort will receive PCI-24781 twice a day approximately 4 hours apart (BID). If a DLT occurs on the BID schedule, the subsequent cohort will receive PCI-24781 BID for 7 days every other week (2 times in a 28 day cycle). If a DLT occurs on this dosing schedule, then the next cohort will receive PCI-24781 BID for 5 days/week every other week (2 times in a 28 day cycle) until the maximum tolerated dose is reached."
223634786|NCT03682419|PROCEDURE|VKA Patients|Venepuncture and capillary blood collection from Patients receiving Warfarin Therapy
223634787|NCT03682419|PROCEDURE|Non-VKA Patients|Venepuncture and capillary blood collection from Patients not receiving Warfarin Therapy
223634788|NCT00533208|DRUG|MK0524|
223634789|NCT02271204|DRUG|Ibandronic acid|As prescribed by physician
223634790|NCT05371626|PROCEDURE|Suture-less surgical procedure|Suture-less technique will be used in treatment for cicatricial upper eyelid entropion
223634791|NCT06314802|OTHER|no intervention|No intervention
223634792|NCT04446884|BIOLOGICAL|Autologous adipose-derived mesenchymal stem cells|Autologous adipose-derived mesenchymal stem cells mixed with collagen solution
223634793|NCT04446884|OTHER|Standard treatment according to the Clinical protocols|Standard treatment according to the Clinical protocols
223634794|NCT05669911|DEVICE|Teal Health Self-Collection Device Group|Participants will use the Instructions for Use to perform self-collection of cervicovaginal cells using the Teal Health Self-Collection Device, and will fill out a usability survey and a satisfaction and needs survey. A Pap smear will be performed by a clinician before or after self-collection.
223634795|NCT00471939|DRUG|I-020502|1 mcg/mL TG-PDGF.AB
223634796|NCT04214158|OTHER|Assessment|Assessment
223634797|NCT02389296|OTHER|Questionnaire|Questionnaires will be distributed to nursing staff
223634798|NCT00714727|PROCEDURE|acupuncture|8 weeks of acupuncture, starting with twice a week for 4 weeks, followed by once a week for 4 weeks, using 8 standardized, bilateral acupuncture points.
223634799|NCT02670811|DIETARY_SUPPLEMENT|Fermented milk|150 mL daily of fermented milk with Lactococcus lactis NRRL-B50571
223634800|NCT02670811|DIETARY_SUPPLEMENT|Acidified milk|150 mL daily of artificially acidified milk
223634801|NCT02946723|PROCEDURE|ultrasound|Lead implantation surgery for SNM using ultrasound guided technique
223634802|NCT02946723|PROCEDURE|X-ray|Lead implantation surgery for SNM using X-ray technique
224223453|NCT01144910|OTHER|methacholine challenge test|"2 ml of liquid-dissolved methacholine in concentration of 16 mg/ml dosed in 5 steps of 0.01 mg, 0.1 mg, 0.4 mg, 0.8 mg, and 1.6 mg. 2 minutes after each step up an impulse oscillometry (IOS) and spirometry will be performed.~the challenge will be stopped in case of a ≥ 20% decrease from baseline in FEV1 (PD20) and 0,2 mg Salbutamol will be given."
224318543|NCT06582420|DRUG|Fibrinogen concentrate|Patients will be randomly assigned to receive either standard trauma care or standard trauma care plus administration of FC. The standard of care is determined by national guidelines on trauma, elaborated by the National Institute of Medical Emergency and taught to prehospital physicians and nurses at the time of enrollment in prehospital teams to ensure consistency in the treatment of trauma patients nationwide. The patients assigned to the intervention arm will receive the administration of a fixed dose of 4g fibrinogen, as per previous studies.
223634803|NCT00224575|OTHER|diagnosis reassessment|Strategy of diagnosis reassessment following a decision tree.
223634804|NCT00224575|OTHER|Diagnosis strategy and subsequent therapeutic reassessment|Performed by geriatricians, following a decision tree, based on medical history, electrocardiogram, cardiac echotomography and stress scintigraphy
223634805|NCT00371150|DRUG|Entecavir|Tablets, Oral, 0.5 mg, once daily, up to 52 weeks
223634806|NCT02426021|DRUG|MLN1202|Subcutaneous administration of MLN1202
223634807|NCT02426021|DRUG|MLN1202 Placebo|Subcutaneous administration of MLN1202 placebo
223634808|NCT03176706|OTHER|no intervention|this is a completely observational study, NO INTERVENTION
223634809|NCT03081117|DRUG|Insulin, intranasal|Regular insulin administered by specialized, non-commercial intranasal drug delivery device
223634810|NCT03081117|DRUG|Placebo, intranasal|Saline solution administered by specialized, non-commercial intranasal drug delivery device
223634811|NCT05800080|DRUG|Penpulimab combined with Anlotinib Hydrochloride Capsules and chemotherapy;Cadonilimab combined with Anlotinib Hydrochloride Capsules and chemotherapy|one group receives peri operative treatment of Penpulimab combined with Anlotinib Hydrochloride Capsules and chemotherapy, and the other group receives peri operative treatment of Cadonilimab combined with Anlotinib Hydrochloride Capsules and chemotherapy.After receiving corresponding neoadjuvant treatment for 3 cycles according to the established treatment plan, surgical treatment shall be carried out within 3-6 weeks after drug withdrawal
223634812|NCT01742026|PROCEDURE|Aspergillus PCR technique|Aspergillus DNA PCR technique
223634813|NCT01742026|PROCEDURE|Aspergillus AGA technique|Aspergillus AGA technique
223634814|NCT00125177|BEHAVIORAL|Knack therapy|
223634815|NCT01747395|OTHER|Exercise training|The heart failure patients are subjected to differents protocols of physical training
223634816|NCT01303016|DIETARY_SUPPLEMENT|Chispuditos|Daily dose per child is 1 heaping Tablespoon of Chispuditos (using the appropriate measuring spoon provided to each participant), 1 teaspoon of sugar if desired (using appropriate measuring spoon provided to each participant), mixed with 8 ounces of water or milk. The mixture is stirred over a heat source (fire or stove) until the mixture boils for 8 minutes.
224223454|NCT03616834|DRUG|Tomivosertib (eFT-508)|Tomivosertib (eFT-508) is a novel, small-molecule investigational drug being developed by eFFECTOR Therapeutics, as an antitumor therapy that acts by selectively inhibiting mitogen-activated protein kinase (MAPK)-interacting serine/threonine kinase (MNK)1 and MNK 2.
224223455|NCT02034799|BIOLOGICAL|Bioseal Fibrin Sealant|
223634817|NCT03474419|PROCEDURE|laser surgery|laser surgery
223634818|NCT00275912|DRUG|Oxcarbazepine|
223634819|NCT00124943|DRUG|Nanoparticle Paclitaxel|Nanoparticle albumin-bound paclitaxel, administered via intracoronary catheter.
223634820|NCT00321620|DRUG|zoledronic acid|Q4W 4 mg zoledronic acid IV over minimum 15 minutes and 120 mg denosumab placebo SC
223634821|NCT00321620|BIOLOGICAL|denosumab|Q4W 120 mg denosumab SC and 4 mg zoledronic acid placebo IV over a minimum of 15 minutes
223634822|NCT01287962|DRUG|apatinib|750 mg，po，QD； 28 days every cycle
224318544|NCT06582420|DRUG|Standard trauma care|Patients will be randomly assigned to receive either standard trauma care or standard trauma care plus administration of FC. The standard of care is determined by national guidelines on trauma, elaborated by the National Institute of Medical Emergency and taught to prehospital physicians and nurses at the time of enrollment in prehospital teams to ensure consistency in the treatment of trauma patients nationwide. The patients assigned to the intervention arm will receive the administration of a fixed dose of 4g fibrinogen, as per previous studies.
223634823|NCT01287962|DRUG|placebo|po，QD； 28 days every cycle
223634824|NCT00905944|OTHER|Endurance exercise|The patients carry out an exercise program (walking on a treadmill) three times weekly for 12 weeks at a speed corresponding with an intensity of 70% of VO2max.
224318545|NCT05351931|DIETARY_SUPPLEMENT|Salovum and SPC-flakes or corresponding placebo|Salovum and SPC-flakes are foods approved for specific medical purposes.
223634825|NCT02490098|OTHER|6-day intervention with sensor-augmented pump therapy|One day prior to the intervention, participants will have to install a glucose sensor and the study insulin pump. Participants will adjust their insulin delivery as per their standard practice; including temporary basal and correction boluses. Participants will have access to their finger-stick glucose measurements and will be advised to measure their glucose level as per their standard practice. Participants will be asked to install a new infusion set every 2 days. Participants will be allowed to eat whatever they want and allowed to drink alcohol. Participants will use sensor-augmented pump therapy for 6 days.
223634826|NCT02490098|OTHER|6-day intervention with single-hormone closed-loop strategy|One day prior to the intervention, participants will have to install a glucose sensor and the study insulin pump. On the first day of the intervention, participants will be admitted to the clinical research facility in the morning. A team member will review with the participant how to use study devices. Competency on the use of study devices will be assessed by a team member. Only participants demonstrating competency on use of study devices will be allowed to continue to the home study phase. Participants will be allowed to go home in the afternoon. They will be advised to continue with study intervention at home for the next 5 days. Participants will be asked to install a new infusion set every 2 days. Participants will be allowed to eat whatever they want and allowed to drink alcohol.
224223456|NCT02034799|OTHER|Standard of Care (SoC)|
224318546|NCT03610230|DRUG|Iron Isomaltoside|Iron Isomaltoside 1000 (Monofer®) consists of iron with a tighter binding to its carbohydrate moiety with less free iron
223634827|NCT02490098|OTHER|6-day intervention with dual-hormone closed-loop strategy|One day prior to the intervention, participants will have to install a glucose sensor and the study insulin pump. On the first day of the intervention, participants will be admitted to the clinical research facility in the morning. Participants will have to install a second pump containing glucagon. A team member will review with the participant how to use study devices. Competency on the use of study devices will be assessed by a team member. Only participants demonstrating competency on use of study devices will be allowed to continue to the home study phase. Participants will be allowed to go home in the afternoon. They will be advised to continue with study intervention at home for the next 5 days. Participants will be asked to install a new infusion set every 2 days. Participants will be allowed to eat whatever they want and allowed to drink alcohol.
223634828|NCT02490098|DRUG|Insulin|Participant's usual fast-acting insulin analog will be used: Lispro (Humalog), Aspart (NovoRapid) or Glulisine (Apidra)
223634829|NCT02490098|DRUG|Glucagon|Glucagon (Eli Lilly) will be used during dual-hormone closed-loop strategy.
223634830|NCT02490098|DEVICE|Continuous Glucose Monitoring System Enlite sensor®, Medtronic|Enlite sensor®, Medtronic
223634831|NCT02490098|DEVICE|Insulin pump MiniMed® Paradigm® Veo™, Medtronic|MiniMed® Paradigm® Veo™, Medtronic
223634832|NCT02962414|DRUG|everolimus|everolimus, 2mg dispersible tablets
223634833|NCT00807508|DIETARY_SUPPLEMENT|placebo|wheat meal capsules with each main meal
223634834|NCT00807508|DIETARY_SUPPLEMENT|leucine|daily leucine capsules with each main meal
223634835|NCT06371092|DRUG|UltraEZ|General examination with bite-wings. Dental prophylaxis (dental scaling and polishing with an abrasive paste). Alginate impressions of both arches. Creation of individualized bleaching trays and a position-finder tray of both arches. Application of the UltraEZ gel in the bleaching trays for 30 minutes. Application of the bleaching gel in the bleaching trays during 6-8 hours
224223457|NCT06546241|BEHAVIORAL|Celebrandome|This intervention is based on existing cognitive dissonance body confidence programs for youth such as Amazing Me, Free Being Me, and Body Project. Consistent with these programs, workshops are entirely experiential getting you to discuss appearance ideals and why they are problematic, pressures they experience to conform to appearance ideals, ways to combat pressures, they compare pictures that are normal versus digitally altered and discuss ways this is problematic, they discuss body talk statements they hear all the time and how this promotes appearance ideals, they practice ways to combat body talk statements. They develop positive affirmation statements. In addition and unique to this curriculum, all activities highlight cultural ideals and how youth can receive different messages related to different appearance ideals and they unique stress and pressures this creates.
224223458|NCT04857307|DRUG|Alprazolam|"* Pharmaceutical form: Inhalation powder.~* Study participants will receive Staccato alprazolam at prespecified time-points."
224223459|NCT05321810|DRUG|Apixaban|This is observational study and the patients in the apixaban cohort include those who are exposed to apixaban in the real world settings.
224223460|NCT05321810|DRUG|Warfarin|This is observational study and the patients in the warfarin cohort include those who are exposed to warfarin in the real world settings.
224223461|NCT01976390|DRUG|Everolimus|0.75mg twice a day, Orally, starting on day of transplant
224223462|NCT01976390|DRUG|Sirolimus|5mg, Orally, starting on day of transplant; decreasing to 3mg
224223463|NCT00830674|DRUG|Placebo|single dose IV or SC administration
224223464|NCT00830674|DRUG|KRN23|Single IV administration on day 1: 0.003, 0.01, 0.03, 0.1 and 0.3 mg/kg and Single SC administration on day 1: 0.1, 0.3, 0.6 and 1.0 mg/kg
223634836|NCT06371092|DRUG|Placebo|General examination with bite-wings. Dental prophylaxis (dental scaling and polishing with an abrasive paste). Alginate impressions of both arches. Creation of individualized bleaching trays and a position-finder tray of both arches. Application of the placebo gel in the bleaching trays for 30 minutes. Application of the bleaching gel in the bleaching trays during 6-8 hours
224223465|NCT00916890|DRUG|Morphine|After a titration phase with fast-release oral morphine, once the optimal dosage (no side effects and less than two rescue doses per day) is reached, an equipotent dose of oral sustained-release morphine will be randomly assigned to a patient.
224223466|NCT00916890|DRUG|Oxycodone|After a titration phase with fast-release oral morphine, once the optimal dosage (no side effects and less than two rescue doses per day) is reached, an equipotent dose of oral extended-release oxycodone will be randomly assigned to a patient.
224223467|NCT00916890|DRUG|Fentanyl|After a titration phase with fast-release oral morphine, once the optimal dosage (no side effects and less than two rescue doses per day) is reached, an equipotent dosage of transdermal fentanyl will be randomly assigned to a patient.
224223468|NCT00916890|DRUG|Buprenorphine|After a titration phase with fast-release oral morphine, once the optimal dosage (no side effects and less than two rescue doses per day) is reached, an equipotent dosage of transdermal buprenorphine will be randomly assigned to a patient.
224223469|NCT06544551|DRUG|Peginterferon Alfacon-2|Peginterferon Alfacon-2 injection will be weekly subcutaneous injected for 48 weeks. Tenofovir alafenamide Fumarate Tablets(TAF) will be take orally for at least 48 weeks, not more than 72 weeks. Peg-interferon Alfacon-2 and TAF will discontinue when HBsAg levels is less than 0.05 IU/mL and HBV DNA is below 10 IU/mL during 48-72 weeks.
224223470|NCT06544551|DRUG|Peginterferon Alfacon-2 placebo|Peginterferon Alfacon-2 placebo injection will be weekly subcutaneous injected for 48 weeks. Tenofovir alafenamide Fumarate Tablets(TAF) will be take orally for at least 48 weeks, not more than 72 weeks. Peg-interferon Alfacon-2 and TAF will discontinue when HBsAg levels is less than 0.05 IU/mL and HBV DNA is below 10 IU/mL during 48-72 weeks.
224223471|NCT02265848|OTHER|High frequency stimulation|Implanted pulse generator of a spinal cord stimulator will programmed to deliver high frequency stimulation for pain relief. For our purposes, high frequency stimulation will be defined as 1000 hertz.
223634837|NCT06834295|DRUG|Vapendavir|Single oral dose of \[14C\]vapendavir
223634838|NCT06228170|BEHAVIORAL|Rehabilitation therapy|The study lasted 20d for each patient. During the treatment, All the participants were provided with the rehabilitation therapy, which included routine rehabilitation, cognitive training, swallowing function training and nutrition support.
224223472|NCT02265848|OTHER|Low frequency stimulation|Implanted pulse generator of a spinal cord stimulator will programmed to deliver low frequency stimulation for pain relief. Low frequency stimulation will be defined as conventional stimulation pulse generator programming.
223634839|NCT06228170|PROCEDURE|Stellate ganglion block|Based on the invention above, the patients in the observation group were provided with Stellate ganglion block , using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate ganglion block . The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
223634840|NCT00150085|DRUG|cyclosporine micro-emulsion|
224223473|NCT03321058|BEHAVIORAL|Assessment|Assessment of patients' medication organisation and comprehension of generics
224223474|NCT05126381|BEHAVIORAL|Smoking|The Study contains patients who are allowed to smoke
224223475|NCT05126381|BEHAVIORAL|non-somking|The Study contains patients who are not allowed to smoke
224223476|NCT02874495|BEHAVIORAL|Psychological tests|Related to affective and cognitive dimensions of pain.
224223477|NCT02874495|DEVICE|Magnetic Resonance Imaging|"With a certain or uncertain anticipation phase of distension (warning light) followed or not by a rectal distension at the pain threshold previously determined, and then a retrospective quotation of pain during distension and the fear of pain induced by anticipation. Structural MRI and rest of functional connectivity measure MRI.~With measure of heart rate variability."
224223478|NCT02874495|BEHAVIORAL|Heart Rate Variability|During MRI session, from the electrocardiographic signal. (measure of variations on R-R interval in milliseconds ms).
224223479|NCT01704664|DIETARY_SUPPLEMENT|Early postoperative enteral nutrition, based on standard elementary diet (Peptisorb)|Early postoperative enteral nutrition with standard elementary diet (Peptisorb), will start 20 hours post-surgery. The initial flow rate will be 8 ml/h, which will increase gradually, with the volume doubled every 24 hours, up to 100 ml/h. The enteral nutrition wil be continued for six days. During the initial five days post-surgery, the patients will be additionally supplemented parenterally via peripheral veins (commercially available two-chamber bag for peripheral access with 480 kcal of energetic value and 5.7g of N contained in standard amino acids).
224223480|NCT01704664|DRUG|glutamine|The nutritional therapy of group II patients will start post-surgery. It will be based on early enteral nutrition with elementary diet (Peptisorb) with simultaneous parenteral nutrition with two-chamber bag with 480 kcal energetic value and 5.7g of N contained in standard amino acids administered via peripheral veins. Additionally, glutamine (100 ml of Dipeptiven) will be added to the two-chamber bag. The parenteral nutrition will be administered for five days.
224223481|NCT01704664|DIETARY_SUPPLEMENT|oral diet enriched with arginine (Cubitan)|Preoperatively, group III patients will be given commercially available oral diet enriched with arginine (Cubitan, 1 package 3 times per day). Additionally, they were administered commercially available two-chamber bag with 480 kcal energetic value and 5.7g of N in standard amino acids via peripheral access. The duration of pre-operative preparatory phase ranged between 5 and 10 days (8 days on average). Enteral nutrition with commercially available arginine-containing diet (Cubison) will start 20 hours post-surgery at an 8 ml/h flow rate; the rate will increase gradually, with the volume doubled every 24 hours, up to 100 ml/h and continued for six days. Simultaneously, commercially available two-chamber bags for peripheral access with composition identical to that used preoperatively will be administered via peripheral veins for five days.
224223482|NCT01704664|DRUG|Perioperative parenteral immunonutrition (Dipeptiven, Omegaven)|Nutritional therapy of group IV will based on intravenous preparations. Two-chamber bags with 480 kcal energetic value and 5.7 g of N in standard amino acids were administered preoperatively. A solution of glutamine (Dipeptiven, 100 ml) and ω3-fatty acids (Omegaven, 100 ml) will be added to the bags. The duration of pre-operative preparatory phase ranged between 5 and 10 days (8 days on average). Enteral nutrition with elementary commercially available diet (Peptisorb) will be begun 20 hours post-surgery; it will start at an 8 ml/h flow rate and increased gradually, with the volume doubled every 24 hours, up to 100 ml/h. The enteral nutrition was continued for six days. During the initial five days post-surgery, the patients will be additionally supplemented parenterally via peripheral veins; similarly to the preoperative period, the content of two-chamber bag for peripheral access enriched with glutamine and ω3-fatty acids will be administered for five days.
224223483|NCT02660411|DRUG|Sevoflurane|Sevoflurane will be administered by inhalation for anesthesia maintenance. The concentration of inhaled sevoflurane will be adjusted to maintain the BIS value between 40 and 60. Sevoflurane inhalational concentration will be decreased towards the end of surgery. Sevoflurane inhalation will be stopped at the end of surgery.
224223484|NCT02660411|DRUG|Propofol|Propofol will be administered by intravenous infusion for anesthesia maintenance. The infusion rate of propofol will be adjusted to maintain the BIS value between 40 and 60. Propofol infusion rate will be decreased towards the end of surgery. Propofol infusion will be stopped at the end of surgery.
224223485|NCT01025856|OTHER|Rich in MUFA diet -PA|The patients will follow a rich in MUFA diet without a physical activity program.
224318547|NCT03610230|DRUG|Iron sucrose|the currently most widely used intravenous iron preparation with good safety profile
224318548|NCT00442962|DRUG|Efavirenz|600-mg tablet taken orally daily
223634841|NCT02844569|DEVICE|Xenograft bone substitute|Subjects requiring tooth extraction will have the hopeless tooth extracted. The extraction socket will be treated with xenograft bone substitute. At 6 months post-extraction a dental implant will be placed at the extraction site.
223634842|NCT02844569|DEVICE|Collagen dressing|Subjects requiring tooth extraction will have the hopeless tooth extracted. The extraction socket treated with xenograft bone substitute will receive a collagen dressing to cover the surgical site.
223634843|NCT02844569|DEVICE|3D-collagen matrix|Subjects requiring tooth extraction will have the hopeless tooth extracted. The extraction socket treated with xenograft bone substitute will receive a 3D collagen matrix to cover the surgical site.
223634844|NCT03304626|DRUG|Budesonide 3Mg Capsule|Budesonide capsule in place of prednisone (standard of care)
223634845|NCT03304626|DRUG|Standard of Care Prednisone|Prednisone taper (Standard of Care)
223634846|NCT01816035|OTHER|Laboratory Biomarker Analysis|Correlative studies
223634847|NCT01816035|OTHER|Pharmacological Study|Correlative studies
223634848|NCT01816035|BIOLOGICAL|Trastuzumab Emtansine|Given IV
223634849|NCT00027534|BIOLOGICAL|TRICOM-CEA(6D)|dendritic cells loaded with TRICOM-CEA(6D)
223634850|NCT01501565|PROCEDURE|Postoperative transverse abdominal plain (TAP) blockade|Bupivacaine 0.25%. Maximum 150 mg. A maximum of 75 mg bupivacaine is administered in each side (posterior and subcostal TAP) in a single puncture.
223634851|NCT02809482|OTHER|Eucaloric feeding|3 days of a diet designed to maintain energy balance
223634852|NCT02809482|OTHER|Overfeeding|3 days of a diet designed to induce a 40% positive energy balance
223634853|NCT05828147|DRUG|Rituximab|Rituximab will be administered as two IV infusions of 1000 mg each, given two weeks apart at Day 0 and Week 2. All subjects will receive 40 mg of prednisone orally the night before and morning of each infusion with diphenhydramine and acetaminophen orally thirty to sixty minutes prior to each infusion of rituximab. Subjects will remain on their baseline standard medical regimen.
223634854|NCT02341183|DEVICE|tPAD|7% NaCl administered continuously for 8 hours, overnight, via the tPAD device
223634855|NCT02341183|DEVICE|7% hypertonic saline (510K approved as a device)|Subjects will receive overnight treatments of 7% HS via the tPAD device in both comparators, but in a randomly assigned order as described.
223634856|NCT01213563|DRUG|Actrapid insulin+Gloucose|On admission to hospital all pre-operative oral antidiabetic agents and insulin are stopped and glucose monitoring is carried out every four hours at the same time as routine observations. Actrapid insulin+ Glucose is administered as per standard sliding scale (Appendix A). Just prior to discharge, total insulin administered over the previous 24 hour post-operative period is calculated. Based on the results of ward based glucose monitoring, post-operative patients can be divided in two broad categories.
223634857|NCT01213563|DRUG|Actrapid insulin|On admission to hospital all pre-operative oral antidiabetic agents and insulin are stopped and glucose monitoring is carried out every four hours at the same time as routine observations. Actrapid insulin is administered as per standard sliding scales (appendix A). Just prior to discharge, total insulin administered over the previous 24 hour post-operative period is calculated. Based on the results of ward based glucose monitoring patients are discharged home on metformin 1000mg BID and/or the equivalent amount of Glargine insulin requirement in previous 24 hours prior to discharge.
223634858|NCT05784896|DIAGNOSTIC_TEST|v/Q scanning & CT pulmonary angiography & Echocardiography|"Echocardiography ( comparative follow up of the RVSF PASP TAPSE IVC).~CT pulmonary angiography with assessment of the following parameters :~Intravascular web. dilated bronchail arteries. Arterial retraction. dilated pulmonary arteries. RV/LV diameter more than 1. Flattening of interventricular septum. V/Q scanning Following ESC/ERS Guideline recommendations, V/Q is the preferred and recommended test for CTEPH. It has a sensitivity of \>96% and normal V/Q scan can rule out CTEPH . V/Q lung scintigraphy was interpreted as positive for CTEPH if there was at least one segmental or two sub-segmental mismatched perfusion defects, as proposed by the European Association of Nuclear Medicine (EANM) guidelines for the diagnosis of acute PE."
223634859|NCT04642092|BEHAVIORAL|PsicAP protocol|The intervention will include: psychoeducation, relaxation and breathing techniques, thought management, tips to improve quality of life and relapse prevention. All of these activities will be based on scientific evidence and many of these aspects will be supported by mobile devices.
223634860|NCT04642092|BEHAVIORAL|Conventional treatment|Typical treatment that is currently given to patients with emotional disorders in Dominican primary care units.
224223486|NCT01025856|OTHER|high fiber/low glycemic index diet + pa|patients will follow for two months a high fibre/ low glycemic index diet with a physical activity program.
224223487|NCT01025856|OTHER|Rich in MUFA diet+PA|Patients will follow for two months a rich in MUFA diet with a physical activity program.
224223488|NCT01025856|OTHER|High fibre/low glycemic index diet-PA|Patients will follow for two months a high fibre/low glycemic index diet without a physical activity program.
223634861|NCT03806361|PROCEDURE|Fat grafts supplemented with ADRC|Isolation of ADRC from fat aspirates and its use for supplementation of fat grafts.
223634862|NCT03806361|PROCEDURE|Structural fat grafting|Fat grafts without supplementation of ADRC
223634863|NCT04155762|OTHER|Pin Suspension System (a prosthetic suspension system)|Participants used the PSS for three months following fabrication and adjustment of the prosthesis, and a prosthetic training period.
223634864|NCT04155762|OTHER|Vacuum-Assisted Suspension System (a prosthetic suspension system)|After PSS, participants employed the VASS for three months after a similar training period.
224223489|NCT05073653|DIAGNOSTIC_TEST|68Ga-PSMA PET/CT|Exploratory, Single-institution Study, Comparing 68Ga-GRP PET/CT Versus 68Ga-PSMA PET/CT in Patients Diagnosed With Prostate Cancer of Low and Intermediate Risk for Radical Prostatectomy
224223490|NCT05073653|DIAGNOSTIC_TEST|68Ga-GRP PET/CT|Exploratory, Single-institution Study, Comparing 68Ga-GRP PET/CT Versus 68Ga-PSMA PET/CT in Patients Diagnosed With Prostate Cancer of Low and Intermediate Risk for Radical Prostatectomy
224223491|NCT01817348|PROCEDURE|Lidocaine group|"* Patient position: prone position with arm under the abdomen and the elbow flexed to a right angle~* Injection with a 25-gauge, 1.5-inch long needle fitted with 3ml syringe filled with 3ml 1% lidocaine."
224223492|NCT01817348|OTHER|Physiotherapy (PT)|\- Include electric therapy, hot pack, followed by stretch exercise and joint mobilization
224223493|NCT05207215|OTHER|Home Base Exercises|The study developed 3 approaches that innovate beyond the existing delivery modes of the SAFE programme, by developing means for providing an intervention that is functionally equivalent to the SAFE programme but can be implemented in a patient's home. These home approaches include: (a) video conferencing; (b) gamification; and (3) self-guided home exercise programme. The investigators' task is to focus on developing these 3 modes and evaluating each in a pilot context for participants upon discharge from the hospital.
224223494|NCT01580761|BEHAVIORAL|Sleep restriction|14 days of sleep restriction, 4 hours of sleep per day.
224223495|NCT00434161|DRUG|Palifermin before only|One bolus IV injection at 60 μg/kg/day, on Days 6, 5 \& 4 days before-high dose chemotherapy and one bolus IV injection at 60 μg/kg/day of matched placebo on days 0, 1 \& 2 days after-high dose chemotherapy. Minimum of 4 days between before-chemotherapy and after-transplantation dosing.
224223496|NCT00434161|DRUG|Placebo|"One bolus IV injection at 60 μg/kg/day of matched placebo on Days 6, 5 \& 4 (before-high dose chemotherapy) and on Days 0, 1 \& 2 (after-high dose chemotherapy).~Minimum of 4 days between pre-chemotherapy and post-transplantation dosing."
224223497|NCT00434161|DRUG|Palifermin before and after|"One bolus IV injection at 60 μg/kg/day, on Days 6, 5 \& 4 (before-high dose chemotherapy) and on Days 0, 1 \& 2 (after-high dose chemotherapy).~Minimum of 4 days between before-chemotherapy and after-transplantation dosing."
224223498|NCT03342898|BIOLOGICAL|YF-17D|YF-17D SC injection.
224223499|NCT03342898|BIOLOGICAL|TDV|TDV SC injection.
224223500|NCT03342898|DRUG|Placebo|Normal Saline (0.9% NaCl) SC injection.
224223501|NCT00311818|DRUG|Insulin glargine|
224223502|NCT00000654|DRUG|Fialuridine|
224223503|NCT00043706|DRUG|Human Anti-Transforming Growth Factor Beta-1 Monoclonal Antibody|
224223504|NCT01903577|OTHER|Robotic Task Performance|Subjects will perform FLS tasks on the robotic platform while EMG data is being collected. Task performance and NASA task load index will be assessed. Experts in robotic surgery will also perform operative cases while EMG is being collected.
224223505|NCT01903577|OTHER|Laparoscopic Task Performance|Subjects will perform FLS tasks on the laparoscopic platform while EMG data is being collected. Task performance and NASA task load index will be assessed. Experts in laparoscopic surgery will also perform operative cases while EMG is being collected.
224223506|NCT04320459|DIAGNOSTIC_TEST|Bath Ankylosing Spondylitis Metrology Index (BASMI)|It characterises the spinal mobility of patients with ankylosing spondylitis. Cervical rotation, tragus-wall distance, lateral lumbar flexion, anterior lumbar flexion (modified schober), intermalleolar distance were measured. The total score of the 5 measurements was taken, the score range was 0-10, the low score meant that the spinal movement was better.
224223507|NCT04320459|DIAGNOSTIC_TEST|Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)|It assess the disease activity. It was evaluated with a 6-question questionnaire. After taking the answer of each question out of 10, the total of the points was calculated by dividing the number of questions.
224223508|NCT04320459|DIAGNOSTIC_TEST|Bath Ankylosing Spondylitis Functional Index (BASFI)|It assess functional status. It was evaluated with a 10-question questionnaire. After taking the answer of each question out of 10, the total of the points was calculated by dividing the number of questions.
224223509|NCT04320459|DIAGNOSTIC_TEST|Ankylosing Spondylitis Quality of Life Questionnaire (ASQoL)|"It evaluates quality of life. Each statement on the ASQoL (18-item) is given a score of 1 or 0. A score of 1 is given where the item is affirmed, indicating adverse QoL. All item scores are summed to give a total score or index. Scores can range from 0 (good QoL) to 18 (poor QoL)."
224223510|NCT04320459|DIAGNOSTIC_TEST|Toronto Alexithymia Scale-20 (TAS-20)|It assess alexithymia. It is a 20 item questionnaire and each item is evaluated in a Likert type scale with five intervals (1= strongly disagree, 5=strongly agree). The total alexithymia score is the sum of responses to all 20 items, while the score for each subscale factor is the sum of the responses to that subscale. The TAS-20 uses cutoff scoring: equal to or less than 51 = non-alexithymia, equal to or greater than 61 = alexithymia. Scores of 52 to 60 = possible alexithymia.
224223511|NCT04320459|DIAGNOSTIC_TEST|Beck's Depression Inventory (BDI)|It assess depression status. It is a 21-question multiple-choice self-report inventory, each set is ranked in terms of severity and scored from 0 to 3 with a total summed score range of 0-63. Higher scores indicate greater depressive severity. Conventional cutoffs are 0-9 for normal range, 10-18 for mild to moderate depression, 19-29 for moderate to severe depression, and 30-63 for severe depression.
224223512|NCT05710185|DRUG|Deucravacitinib|See arm/group description
224223513|NCT03049683|OTHER|Vestibular evoked myogenic potentials (VEMPs)|The c- and oVEMPs will be assessed in three different sessions including conventional sequential recordings and two different simultaneous recording methods, i.e., unilateral simultaneous recording of cVEMPs and oVEMPs during monaural stimulation (Figure 1A) and bilateral simultaneous recording of each VEMP during binaural stimulation (Figure 1B).
224223514|NCT00821392|DRUG|Febuxostat|
224223515|NCT05503004|BEHAVIORAL|Prehabilitation|10 min exercise, 5 min respiratory mindfulness, and preoperative nutrition assessment.
224223516|NCT05503004|BEHAVIORAL|Standard care|Standard care before surgery
224223517|NCT01489722|DRUG|AZD1208|Daily oral doses of AZD1208 for 28 day cycles until progression or unacceptable toxicity develops. Starting dose will be 120 mg and will be escalated in successive cohorts until an MTD is established.
224223518|NCT01267266|DRUG|saracatinib|Given orally
224223519|NCT01267266|OTHER|hydrocortisone/placebo|Given orally
224223520|NCT00306969|DRUG|bexarotene|
224223521|NCT00306969|DEVICE|photopheresis|
224223522|NCT02501850|DRUG|Liraglutide|Treatment with liraglutide, exenatide or lixisenatide
224223523|NCT02501850|DRUG|metformin|Treatment with metformin and/or sulphonilurea
224223524|NCT03974152|OTHER|Subox Mini C with Avail 18 mg nicotine salt (protonated)|Participants will be instructed to take one puff of the Subox Mini C with Avail 18 mg nicotine salt (protonated) liquid every 30 seconds for 5 minutes followed by a 2nd blood draw. Next, participants will be given 90 minutes to use the product ad lib, i.e., as much as desired.
224223525|NCT03974152|OTHER|Subox Mini C with Avail 18 mg nicotine (unprotonated)|Participants will be instructed to take one puff of the Subox Mini C with Avail 18 mg nicotine (unprotonated) liquid every 30 seconds for 5 minutes followed by a 2nd blood draw. Next, participants will be given 90 minutes to use the product ad lib, i.e., as much as desired.
224223526|NCT03974152|OTHER|Own brand cigarette|Participants will be instructed to take one puff of a cigarette matching their typical brand every 30 seconds for 5 minutes followed by a 2nd blood draw. Next, participants will be given 90 minutes to use the product ad lib, i.e., as much as desired.
224223527|NCT00711906|DRUG|Cotrimoxazole|Cotrimoxazole
224223528|NCT00711906|DRUG|Sulfadoxine-pyrimethamine|Sulfadoxine-pyrimethamine
224223529|NCT01414946|OTHER|Intravenous nutrition with glucose and amino acids|Glucose and amino acids intravenously starting 20 hours before the operation until the second postoperative day. Glucose provides 50% and amino acids 20% of each patient's measured resting energy expenditure.
224223530|NCT01414946|OTHER|Intravenous nutrition with amino acids|Amino acids intravenously starting 20 hours before the operation until the second postoperative day. Amino acids providing 20% of each patient's measured resting energy expenditure.
224223531|NCT00739479|DIETARY_SUPPLEMENT|Weight Loss|Participants will reduce their total dietary intake by \~800 kcal/day. \~100 kcal will be replaced by either the PHWP of PHG protein supplement, resulting in a total energy restriction of \~700 kcal/day.
224223532|NCT00004110|BIOLOGICAL|monoclonal antibody 3F8|
224223533|NCT00004110|DRUG|etoposide|
224223534|NCT00004110|DRUG|isotretinoin|
224223535|NCT01847573|DRUG|HT-100|May be administered in either fed or fasted state
224223536|NCT02625766|PROCEDURE|LC fracture surgical fixation|
223764715|NCT05149950|BEHAVIORAL|Active internet treatment|The patient gets access to the internet treatment via a secure login to 1177 The care guide e-services on 1177.se. The treatment lasts for six months and includes 12 treatment modules. The patient works with each module for two weeks. The modules have different numbers of sections, but most have 4-5 sections. The modules consist mainly of text but also films and pictures are included. It is also possible to listen to the text. The modules end with one or more exercises to be performed before the next module is activated for the patient. Participants receive feedback on the information from therapists via the email function in the treatment program. The therapist provides individual feedback on completed exercises and answers questions that the patient has.
224223537|NCT02625766|PROCEDURE|LC fracture non-operative management|
224223538|NCT05737329|DRUG|Transdermal estradiol gel 0.1% 1.5mg/ day|Estradiol gel 0.1% 1.5mg/ daily + Micronized Progesterone 200mg
224223539|NCT05737329|DRUG|Transdermal estradiol gel 0.1% 2.0mg/ day|Estradiol gel 0.1% 2.0mg/ daily + Micronized Progesterone 200mg
224223540|NCT04443322|DRUG|Durvalumab Injection|Anti-PD-L1 Monoclonal Antibody
224223541|NCT04443322|DRUG|Lenvatinib 4 MG|Lenvatinib (Lenvima, Eisai China) is a novel angiogenesis inhibitor which targets vascular endothelial growth factor 1-3, fibroblast growth factor receptor 1-4, platelet-derived growth factor receptor β etc.
224223542|NCT02413073|PROCEDURE|Whole Body Vibration|We wil use vibration in patients with kidney disease
224223543|NCT03164863|DIAGNOSTIC_TEST|Onco4D Biodynamic Chemotherapy Selection Assay|The Onco4D Biodynamic Chemotherapy Selection Assay uses Motility Contrast Tomography (MCT) to measure ex-vivo fresh tumor biopsy response when challenged by an array of chemotherapeutic agents. A machine learning algorithm uses the MCT datastream to predict in vivo tumor response or non response to chemotherapy.
224223544|NCT01466686|RADIATION|Low Dose Fractionated Radiation Therapy (LDFRT)|All patients will receive 0.5 Gy of radiation therapy twice daily. This study will include a safety run-in component. If \> 33% of patients in the initial cohort of 6 experience grade 3 or greater hematologic toxicity according to the NCI Common Toxicity Criteria version 4, then a dose reduction will occur following the schedule listed below.
224223545|NCT01466686|DRUG|Temozolomide|All patients will receive temozolomide (150 to 200 mg per square meter for 5 days during each 28 day cycle) for a total of 1 year or until the time of disease progression.
224223546|NCT02714686|BEHAVIORAL|Radio Mass Media Family Planning Campaign|Short daily spots, weekly interactive shows, testimonies, and interviews with experts and community leaders on contraception and family planning
224223547|NCT03575039|DEVICE|VitaFlow II Transcatheter Aortic Valve System|VitaFlow II Transcatheter Aortic Valve System contains a Valve stent -VitaFlow Aortic Valve, a Delivery system-VitaFlow II Delivery System and a Introducer set
224223548|NCT01467063|DIETARY_SUPPLEMENT|Glutamine|Participants will keep a diary of food intake and activity as well as wear an accelerometer (to measure overall movement) for 2-3 days prior to the admission. Subject will come to the Clinical Research Center for approximately 24 hours. They will receive a drink containing Glutamine (0.25 g/kg/dose). Afterwards they will have an afternoon exercise session consisting of 15-min bouts of exercise, interspersed with 5-min rest periods in between for a total of 75min. Blood glucose will be checked during rest intervals. They will be served a controlled dinner. Before bedtime another dose of the same drink will be given. Overnight blood glucose will be monitored closely. In the morning, another dose of the same drink will be given. Subjects will have two isotope infusions (non-radioactive) running concomitantly and a hyperinsulinemic-euglycemic clamp will be performed. Afterwards lunch will be served and subject discharged home.
224223549|NCT01467063|DIETARY_SUPPLEMENT|Placebo|Participants will keep a diary of food intake and activity as well as wear an accelerometer (to measure overall movement) for 2-3 days prior to the admission. Subject will come to the Clinical Research Center for approximately 24 hours. They will receive a PLACEBO drink. Afterwards they will have an afternoon exercise session consisting of 15-min bouts of exercise, interspersed with 5-min rest periods in between for a total of 75min. Blood glucose will be checked during rest intervals. They will be served a controlled dinner. Before bedtime another dose of the same drink will be given. Overnight blood glucose will be monitored closely. In the morning, another dose of the same drink will be given. Subjects will have two isotope infusions (non-radioactive) running concomitantly and a hyperinsulinemic-euglycemic clamp will be performed. Afterwards lunch will be served and subject discharged home.
224223550|NCT05472610|BIOLOGICAL|BZ019|A treatment program will include lymphodepleting chemotherapy with fludarabine and cyclophosphamide (flu/cy) followed by single-dose of BZ019 administered intravenously (IV).
224223551|NCT05717881|DIETARY_SUPPLEMENT|Propolis|"Propolis supplements were packaged in marine capsules and consisted of poplar propolis powder (propolis concentrate, carob powder, magnesium stearate and silicon dioxide), concentrated to 30% total polyphenols.~Each supplementation period lasted 3 months, with a 2-week wash-out period, to allow total excretion of polyphenols by the body and do not interfere with the new supplementation phase.~The subjects in this study were submitted to five visits, allowing the tracking of biological parameters (clinical examination, fasting blood samples, HGPO) during the study. During the supplementation phases, follow-up by telephone call was performed."
224223552|NCT05717881|DIETARY_SUPPLEMENT|Placebo|"Placebo powder capsules (maltodextrin, fatty acids, magnesium salts and silicon dioxide) are presented in the same packaging to have an identical appearance and taste. Patients in the propolis group were dosed with propolis to reach 6 mg total polyphenols/kg body weight, based on the results of a previous preclinical study in mice.~Each supplementation period lasted 3 months, with a 2-week wash-out period, to allow total excretion of polyphenols by the body and do not interfere with the new supplementation phase.~The subjects in this study were submitted to five visits, allowing the tracking of biological parameters (clinical examination, fasting blood samples, HGPO) during the study. During the supplementation phases, follow-up by telephone call was performed."
224223553|NCT02850523|OTHER|Cognitive Behavioural Therapy for Perinatal Anxiety|The treatment consists of cognitive and behavioural strategies for treating anxiety, tailored specifically to a perinatal/postpartum population.
224318549|NCT00442962|DRUG|Emtricitabine/Tenofovir disoproxil fumarate|200-mg emtricitabine/300-mg tenofovir disoproxil fumarate tablet taken orally once daily
224318550|NCT01144429|BIOLOGICAL|Allergoid, allergenic extract of 100% Birch|Subcutaneous injections Build-up = 1 day: 0,1mL + 0,2mL + 0,2mL s.c. in intervals on 30 minutes; Maintenance = 5 x single injection of 0,5 mL s.c. every 4 weeks
223764716|NCT06504719|DRUG|Antibody-Drug Conjugates|Patients with advanced breast cancer treated with ADCs
224223554|NCT03306108|DEVICE|NRT|NRTratio is based on each individual electrode's ECAP threshold and can identify the intracochlear electrode array position in perimodiolar electrodes. The NRT-ratio showed a good reliability for the determination of the intracochlear electrode array position compared to the radiologic control intraoperatively Calculation of the NRT-ratio is done by dividing the arithmetic average of the t-NRT values from the apical electrodes 16 to 18 divided by the arithmetic average of the basal t-NRT from electrodes 5 to 7. With a NRT-ratio above 1.05, a high chance of a scalar change was rather likely, and a NRT-ratio below 1.05 was associated with a high chance of an electrode array position within the scala tympani.
224223555|NCT01271764|OTHER|no drug|The role of G9a protein in patients with endometrial cancer
224223556|NCT03978702|OTHER|Blood sampling|20 mL will be collected at each time point (day-1,day 0, day 1, day 3, day 7, 1 year after pancreatectomy)
224223557|NCT03389984|DIAGNOSTIC_TEST|cutaneous|SKIN BIOPSY
224223558|NCT06177379|OTHER|healthy volunteer|Volunteers age between 50 and 75 years
224223559|NCT00763984|BEHAVIORAL|Usual Care|This group will receive routine care, however, it is possible that that control condition participants will receive Pelvic Floor Muscle Training (PFMT) instruction from their health care providers. We will monitor control women's knowledge, adoption and maintaining of PFMT.
224223560|NCT00763984|BEHAVIORAL|Bladder Health class|Modeled on our intervention with older women, Bladder Health Class (BH Class) will include Pelvic floor muscle training (PFMT), defined by the International Continence Society as repetitive selective voluntary contraction and relaxation of specific pelvic floor muscles, and bladder training (BT), defined as a program of scheduled voiding with gradually progressive voiding intervals. The BT instructions will be modified for this pregnant group. We will monitor control women's knowledge, adoption and maintaining of PFMT and BT.
224223561|NCT04517006|BEHAVIORAL|Self-focused acts|Completion of daily acts for personal enjoyment.
224223562|NCT04517006|BEHAVIORAL|Prosocial acts|Completion of daily acts for the benefit of others.
224223563|NCT01486706|DRUG|Gabapentin|100mg/capsule initially one capsule once a day then titrate according to the symptoms of the patient upto maximum dose of 1500mg/day
224223564|NCT01486706|DRUG|Solifenacin Succinate|5mg/tablet initially 1 tablet once a day then titrate up to maximum dose of 10mg/tab
224223565|NCT01486706|DRUG|Placebo drugs|will titrate medications similar to the active drug group
224223566|NCT05896059|DRUG|Tislelizumab|Tislelizumab，200mg，D1, intravenous，Q3W；
224223567|NCT05896059|DRUG|Anlotinib|Anlotinib，12mg，oral administration，QD.
224223568|NCT01464359|DRUG|Allopurinol|On Day 8 pre-transplant, start hydration with allopurinol per standard of care.
224223569|NCT01464359|DRUG|Fludarabine|On Days 7, 6 and 5 pre-transplant, 25 mg/m\^2 intravenously over 1 hour.
224223570|NCT01464359|RADIATION|Total body irradiation|On Days 5, 4, 3, and 2 pre-transplant, 165 cGy times 2 (330 cGy daily, 1320 total dose) according to the University Of Minnesota Blood and Marrow Transplant Program total body irradiation (TBI) guidelines.
224223571|NCT01464359|DRUG|Cyclophosphamide|"On Days 7 and 6 pre-transplant, 60 mg/kg intravenously (IV) over 2 hours with a high volume fluid flush and mesna per institutional guidelines.~Alternate Preparative Therapy For Patients Not Able To Receive TBI: Days 5, 4, 3 and 2 pre-transplant; 50 mg/kg/day IV over 2 hours."
224223572|NCT01464359|DRUG|Levetiracetam|Alternate Preparative Therapy for Patients Not Able to Receive Total Body Irradiation (TBI): Hydration therapy on Day 10 pre-transplant.
224223573|NCT01464359|DRUG|Busulfan|Alternate Preparative Therapy For Patients Not Able To Receive TBI: Days 9, 8, 7 and 6 pre-transplant; 0.8 mg/kg (1.1 mg/kg if \<12 kg) intravenously every 6 hours
224223574|NCT01464359|BIOLOGICAL|Umbilical Cord Blood Transplantation|Day 0: Two UCB units will compose the graft. The infusion of the first UCB unit should begin within 15 minutes, and no later than 30 minutes after arrival on the Unit. The UCB unit without IL-2 activation will be infused first, followed by the IL-2 activated unit. Both cords will be infused within 30-60 minutes of each other as deemed clinically safe by the BMT attending.
224223575|NCT01464359|BIOLOGICAL|Interleukin-2|"First Course of IL-2 (begin day +3) post-transplant: For patients ≥ 45 kg, IL-2 will be given at 9 million units every other day for a total of 6 doses subcutaneously. Patients weighing less than 45 kilograms, the IL-2 will be dosed at 5 million units/m\^2 every other day for a total of 6 doses.~Second Course of IL-2 (day +60):~Patients will receive a second course of IL-2 beginning on Day +60 post transplant to expand and educate the NK cells derived from the UCB graft source."
224223576|NCT03453359|DEVICE|BIS monitor|The investigators will place on the forehead of all patients the sensor BIS quatroTM, that connects with this monitor, and they will guide sedation and will record the values obtained.
224223577|NCT03453359|DEVICE|Ramsay scale|In this group, sedation is guided by the Ramsay monitoring scale. The investigators will talk with the patients and will determine the corresponding level of sedation.
224223578|NCT01556685|OTHER|clinical and neurological evaluation|The day of the usual IFN beta 1a IM injection
224223579|NCT01556685|OTHER|Blood Sample|For evaluation of interferon-related Nab
224223580|NCT01556685|GENETIC|Blood Sample|genetic evaluation - predisposition to Nab generation
224223581|NCT00195806|DRUG|divalproex sodium|
224223582|NCT01907087|BIOLOGICAL|BMN 190|30-300 mg ICV infusion administered every other week for at least 48 weeks.
224223583|NCT01317732|DEVICE|MOTIONPOD (TM) measures|It is a study with a single arm. The MOTIONPOD TM measures are compared with simultaneous estimations obtained with the criteria measure (indirect calorimeter) and with existing activity monitors (heart rate monitor POLAR; different accelerometers - rT3 et Actigraph GT3X-, Actiheart, Sensewear Pro2 Armband) After physical fitness evaluation, different activity monitors are set up and the subjects perform a series of standardised activity tasks of different intensities, and well as a 30-min free activity period. Physical activity energy expenditure is measured at the end of each task using a metabolic gas analyser
223764717|NCT06232629|DEVICE|TUS Active|Bilateral GPis will be sonicated using NeuroFUS device for either two minutes (5Hz protocol) or 40 seconds (10 Hz protocol) per hemisphere and with 30 W/cm2 Isppa
223764718|NCT06232629|DEVICE|TUS Sham|"Passive sham: Bilateral GPis will be sonicated using NeuroFUS device for two minutes (5Hz protocol) or 40 seconds (10 Hz protocol) per hemisphere and 0 W/cm2 Isppa~Active sham: Bilateral occipital cortices will be sonicated using NeuroFUS device for two minutes (5Hz protocol) or 40 seconds (10 Hz protocol) per hemisphere and 30 W/cm2 Isppa"
224318551|NCT06025240|DIAGNOSTIC_TEST|cf-DNA|In addition to the standard of care tests, participants will have an additional blood sample (dd-cf DNA). A cohort study patients who have undergone high immunological risk kidney transplant at our centre defined as a re-transplant, where the cRF is \>20% or where there is a level 4 HLA-mismatch. We will take a single plasma sample for dd-cfDNA testing at 6-12 months post-transplant and pair this with an assessment of renal function (creatinine, eGFR), MSU, BK and CMV PCR, single antigen bead (SAB) monitoring of HLA-specific antibodies and allograft USS.
224318552|NCT06025240|DIAGNOSTIC_TEST|Immunological Events following renal transplant in older age|Determine the overall frequency of immunological events and de novo HLA specific antibody formation in the \<60 and \>60 age population. Standard of care test taken at the different time intervals for routine storage. We will use those samples for HLA testing (either screening alone or screening and single antigen bead testing if screening yields a positive result).
224318553|NCT06025240|OTHER|Determining Predictive Models for Post-transplant HLA-specific Antibody Formation|A machine learning model will be developed in Python using a range of pre- and post-transplant variables to determine a predictive model for de novo HLA-specific antibody following renal transplant.
223634865|NCT04286984|OTHER|unified protocol of Patient Blood Management measure|upPBM description: After performing a laboratory work-up 2 to 4 weeks before surgery, preoperative iron supplementation in case of iron deficiency anemia at least 7 days before surgery was recommended. Preoperative anemia was defined by a Hb level \< 13 g/dL for both sexes. In anemic patients, iron status study was recommended and iron supplementation with intravenous iron was indicated if Hb\<12g/dL and/or ferritin \<300 mg/l. Intravenous iron (ferric sucrose or carboxymaltose) was administrated with the goal of recovering iron deficit, calculated using the Ganzoni formula or by the simplified strategy, only available for ferric carboxymaltose. Recommended transfusion triggers were: Hb \< 9 g/dL for patients with risk factors and/or anemia symptoms; and Hb \< 7 g/dL for the rest of patients in absence of active bleeding.
223634866|NCT03187392|DRUG|Lidocaine Injectable Product|3 cm of Lidocaine- will be injected subcutaneous for 5 minutes before insertion of subcutaneous birth control implant
223634867|NCT03187392|DRUG|Lidocaine Topical Cream [LMX]|3 mg of Lidocaine- will be applied to skin for 5 minutes before insertion of subcutaneous birth control implant
223764719|NCT06322771|BEHAVIORAL|Questionnaire|Questionnaire about acceptance
223764720|NCT06322771|BEHAVIORAL|Questionnaire|Questionnaire about refusal
224223584|NCT00647049|DRUG|methotrexate|8000mg/m2 i.v., max. 2 cycles
224223585|NCT00647049|DRUG|Rituximab|375mg/m2, max. 8 times
224223586|NCT00647049|DRUG|Cytarabine|3000mg/m2 die i.v., 2 days (max. 2 cycles)
224223587|NCT00647049|DRUG|Thiotepa|40mg/m2 i.v. (max. 2 cycles) 2 x 5mg/kg/die i.v. for 2 days
223634868|NCT04470154|DRUG|Stage I:HSK21542 0.05 μg/kg|Following the principle of dose escalation and starting from the low dose of 0.05 μg/kg to the high dose 0.80 μg/kg
223764721|NCT04528446|RADIATION|Dual-energy X-ray absorptiometry|DXA whole body, hip, spine, and radius at baseline, and 12-month visit.
224223588|NCT00647049|DRUG|Carmustin|400mg/m2 i.v. for 1 day
224223589|NCT05216978|BEHAVIORAL|Positive Psychology Intervention|Weekly phone calls with the study interventionist and positive psychology exercises over an 9-week period. The positive psychology program exercises include three modules: gratitude-based activities, strength-based activities, and meaning-based activities.
223634869|NCT04470154|DRUG|Stage I:HSK21542 0.15 μg/kg|Following the principle of dose escalation and starting from the low dose of 0.05 μg/kg to the high dose 0.80 μg/kg
223764722|NCT04528446|RADIATION|High Resolution Peripheral Quantitative Computed Tomography (HR-pQCT)|HR-pQCT of the radius and tibia at baseline, and 12-month visit.
224318554|NCT05175040|PROCEDURE|Prophylactic manual rotation|Prophylactic manual rotation, performed in the experimental arm, involves a vaginal examination performed with an obstetric provider's hands to turn the baby from a position in which the baby's face is looking up in the direction of the ceiling (occiput posterior) or to the side (occiput transverse) to a position in which the baby's face is looking down in the direction of the mother's spine (occiput anterior). Prophylactic manual rotation will occur at the initiation of pushing once the individual achieves complete cervical dilation, performed by a trained study investigator (M.D. or midwife) to maintain blinding of the patient's primary obstetrician.
223634870|NCT04470154|DRUG|Stage I:HSK21542 0.30 μg/kg|Following the principle of dose escalation and starting from the low dose of 0.05 μg/kg to the high dose 0.80 μg/kg
223634871|NCT04470154|DRUG|Stage I:HSK21542 0.80 μg/kg|Following the principle of dose escalation and starting from the low dose of 0.05 μg/kg to the high dose 0.80 μg/kg
223634872|NCT04470154|DRUG|Stage II:HSK21542 0.3 μg/kg|Randomized to HSK21542 0.3 μg/kg or 0.6 μg/kg or the corresponding placebo group
223634873|NCT04470154|DRUG|Stage II:HSK21542 0.6 μg/kg|Randomized to HSK21542 0.3 μg/kg or 0.6 μg/kg or the corresponding placebo group
223634874|NCT02052258|DRUG|Oxytocin|
223764723|NCT04528446|OTHER|Blood draw and Urine collection|The blood draw can be completed +/- 3 weeks from baseline or 12-month visit.
223764724|NCT04528446|OTHER|Questionnaires|Questionnaires regarding fracture history, physical activity and dietary intake at baseline, and 12-month visit.
223764725|NCT04011878|PROCEDURE|Combined trabeculotomy trabeculectomy with mitomycin C|Combined trabeculotomy trabeculectomy with mitomycin C with histopathological examination of the peripheral iris tissue specimen of all cases
223764726|NCT05552313|PROCEDURE|kinesio tape|kinesio tape will be applied while patient is in sitting position. Y strip will be applied along C1 till T1.while patient's cervical spine is in contalateral side bending and rotation. same will be performed on the other side. on top of it, an I strip will be applied horizontly along C1 to C4. Both strips will be applied with 15% to 20% stretch.
224223590|NCT04705909|DRUG|Pitavastatin|Pitavastatin 2 mg oral tablets daily will be given to the patients concomitantly with the intended chemotherapy protocol for the treatment period prior to surgery.
224223591|NCT04705909|DRUG|placebo|patients in this group will receive placebo tablets concomitantly with the intended chemotherapy for the treatment period prior to surgery.
223634875|NCT05114954|DEVICE|CardioPulsesTM pulsed field ablation system|Using pulsed field ablation (PFA) catheter, steerable sheath and pulsed field generator to treat atria fibrillation.
223634876|NCT01081652|DRUG|Micronised Progesterone|Micronised progesterone administered intravaginally once daily from the day of ET. If pregnancy was confirmed on day 14 of progesterone administration, progesterone was continued for another 45 days.
223764727|NCT05552313|PROCEDURE|standard therapy|Thoracic manipulation along with conventional including Tens, stretching and strengthening exercises of entire neck musculature
224223592|NCT03232528|OTHER|Herb-partitioned moxibustion|Patients receive herb-partition moxibustion 3 times a week, once a day for 30 minutes, for a total of 12 weeks.
224223593|NCT03232528|OTHER|Sham herb-partitioned moxibustion|Patients receive sham herb-partition moxibustion 3 times a week, once a day for 30 minutes, for a total of 12 weeks.
224223594|NCT00840983|PROCEDURE|delayed cord clamping|cord clamping was delayed for 30 to 45 seconds and infant was held lower than the level of the placenta
224223595|NCT01877928|DEVICE|Boussignac CPAP device|Is a continuous positive airway pressure (CPAP) system marketed in Canada and the US for the treatment of Obstructive Sleep Apnea. The main difference is that this system is portable wheres the standard hospital CPAP is not. This allows for the application immediately post-extubation.
224223596|NCT01877928|DEVICE|standard CPAP|Standard of care postoperative treatment for OSA.
224223597|NCT00217854|PROCEDURE|Bronchoscopic|Bronchoscopic procedure
224223598|NCT04484597|DIAGNOSTIC_TEST|Rt PCR|positive COVID-19 by PCR and tested for other ancillary tests and CT chest to compare them and analyse which is the most sensitive in both moderate and severe clinical condition
224223599|NCT01129154|DRUG|infusions of Panitumumab|Patients will receive six infusions of Panitumumab 6 mg/kg every 2 weeks or until progression if earlier.
224223600|NCT00437151|OTHER|More frequent than normal office visits|Mode of patient reminder
224223601|NCT00437151|OTHER|Electronic reminders (voice, e-mail, text messages)|Mode of patient reminder
224223602|NCT00437151|OTHER|Parenteral involvement / intervention reminders|Mode of patient reminder
224223603|NCT00437151|OTHER|No intervention or reminders|Mode of patient reminder
224223604|NCT03093545|BIOLOGICAL|Equine Rabies Immunoglobulin|40 IU per kg of body weight of ERIG at Day 0
224223605|NCT03093545|BIOLOGICAL|Purified chick-embryo cell rabies vaccine|1 ml of PCEC Rabies vaccine on days 0, 3, 7, 14 and 28.
224223606|NCT02429869|DRUG|everolimus|
224223607|NCT03238768|OTHER|Enhanced Intravenous Nutrition|Increased macronutrients for first 7 days
223634877|NCT01081652|DRUG|Progesterone|Progesterone 60 mg administered intramuscular once daily from the day of ET. If pregnancy was confirmed on day 14 of progesterone administration, progesterone was continued for another 45 days.
223634878|NCT00078585|BIOLOGICAL|PROSTVAC®-VF/TRICOM™|
223634879|NCT02206633|DEVICE|Hydration Monitor|Measurement of the ultrasound velocity with the Hydration Monitor for specific anatomic locations. Triplicate measurements will be made for each time-point. All subjects will also be measured for bioelectrical impedance analysis (BIA) and estimation of total body water using a leg-to-leg BIA machine.
223634880|NCT06166732|BEHAVIORAL|Music-based Mindfulness|The participants will receive a single 20-minute music-based mindfulness session in person. The participants will listen to instrumental music during the session.
223634881|NCT06166732|BEHAVIORAL|Control Group|The participants will receive a single 20-minute information session in person. The information session will introduce the definition, history, basic concepts, and benefits of mindfulness practice.
223634882|NCT04385277|PROCEDURE|Biospecimen Collection|Correlative studies
223634883|NCT04385277|PROCEDURE|Bone Marrow Aspiration|Undergo BM aspiration
223634884|NCT04385277|PROCEDURE|Bone Marrow Biopsy|Undergo BM biopsy
223634885|NCT04385277|PROCEDURE|Computed Tomography|Undergo CT
223634886|NCT04385277|BIOLOGICAL|Dinutuximab|Given IV
223634887|NCT04385277|PROCEDURE|FDG-Positron Emission Tomography|Undergo FDG-PET
223634888|NCT04385277|RADIATION|Iobenguane I-123|Undergo 123I-MIBG
223634889|NCT04385277|DRUG|Irinotecan|Given IV
224223608|NCT03238768|OTHER|Standard Intravenous Nutrition|Standard macronutrients for first 7 days
224223609|NCT00658320|DRUG|Everolimus|0.75 mg twice daily, trough level adjusting between 3 and 8 ng/ml.
224223610|NCT00658320|DRUG|Mycophenolate mofetil (MMF)|The initial dose of 2 gm/day Mycophenolate mofetil was started within 24-36 hours from reperfusion after transplantation. MMF was administered daily for 12 months in the core study and 12 months in the extension study.
224223611|NCT00658320|DRUG|Basiliximab|Patients received first dose of basiliximab (20 mg) 2 hours prior to transplantation and 20 mg at Day 4 or according to local practice
224223612|NCT00658320|DRUG|Cyclosporine A|The cyclosporine was initiated either pre-transplant or within 24 hours after transplantation following local regime. Standard dose of cyclosporine was administered with MMF. The Reduced dose of cyclosporine was administered with everolimus.
223634890|NCT04385277|DRUG|Isotretinoin|Given PO
223634891|NCT04385277|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223634892|NCT04385277|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
223634893|NCT04385277|BIOLOGICAL|Sargramostim|Given SC or IV
223634894|NCT04385277|DRUG|Temozolomide|Given PO or via enteral tube
223764728|NCT05544344|BEHAVIORAL|Healthy ReStart|In addition to receiving mental health services as usual, subjects receive services from health coaches over a four-month period to assist them in creating a Restart plan and attaining related life goals.
224223613|NCT00658320|DRUG|Corticosteroid|Corticosteroid was administered according to local practice during the trial but at a dose not less than 5mg per day for 12 months of the study
224223614|NCT04093180|PROCEDURE|Intensive Neurophysiological Rehabilitation System|Intensive Neurophysiological Rehabilitation System (INRS) is a multicomponent approach that consists of different treatment modalities.
224223615|NCT04093180|PROCEDURE|Activity and care as usual|Control group continues usual activity and care while staying in the waiting list.
224223616|NCT06405776|DRUG|lidocaine|Patients in the lidocaine group, lidocaine 1.5mg/kg/h is continuously infused (using ideal body weight) during the whole procedure, postoperative analgesia pump with lidocaine (lidocaine 50mg/kg, sufentanil 2ug/kg, glassetron 12mg) diluted to 200ml with saline until 72h after surgery.
223634895|NCT02988466|BIOLOGICAL|Haplo HCT <55 years old|"* Fludarabine (Flu)~* Cyclophosphamide (Cy)~* Melphalan (Mel)~* Total body irradiation (TBI)~* Non-T-cell depleted donor bone marrow stem cell infusion Day 0"
223634896|NCT02988466|BIOLOGICAL|Haplo HCT ≥55 years old|"* Fludarabine (Flu)~* Cyclophosphamide (Cy)~* Melphalan (Mel): Dose reduction by 30%~* Total body irradiation (TBI)~* Non-T-cell depleted donor bone marrow stem cell infusion"
223634897|NCT02988466|DRUG|GVHD Prophylaxis|"* Cyclophosphamide (Cy)~* Tacrolimus (Tac)~* Mycophenolate mofetil (MMF)"
223634898|NCT02988466|BIOLOGICAL|Haplo HCT ≥55 and < 65 years old|"* Fludarabine (Flu)~* Cyclophosphamide (Cy)~* Melphalan (Mel)~* Total body irradiation (TBI)~* non-T-cell depleted donor bone marrow stem cells"
223764729|NCT05544344|OTHER|Services as Usual|Subjects receive mental health services as usual.
224223617|NCT06405776|DRUG|Placebo|In the placebo group, the same volume of normal saline will be administered during anesthesia. The postoperative PCIA device will contain sufentanil 2μg/kg, granisetron 12mg diluted to 200 mL in 0.9% normal saline solution with a total volume of 200 mL.
224223618|NCT00652873|DRUG|Cabergoline|Tablets 0.5 mg (2 x 0.5 mg dose), fed
224223619|NCT00652873|DRUG|Dostinex|Tablets, 0.5 mg (2 X 0.5 mg dose), fed
224223620|NCT06462157|OTHER|Compassionate Mind Training|Participants will attend 6 x 90-minute online CMT sessions. CMT is delivered by combining taught information, exercises, and practices. It is effective, so the aim is to explore its use with menopausal women.
224223621|NCT00093639|DRUG|everolimus|
224223622|NCT00093639|DRUG|imatinib mesylate|
224223623|NCT03712969|DRUG|Shenlingcao Oral Liquid|Patients receive Shenlingcao oral liquid combined with conventional adjuvant chemotherapy, which take 4 courses, 30 days per course, one bottle per day.
224223624|NCT02727140|BEHAVIORAL|Yoga with Asana (yoga postures)|Yoga intervention consisting of asana, breathing and relaxation, meditation
224223625|NCT02727140|BEHAVIORAL|Yoga without Asana (yoga postures)|Yoga intervention without asanas, consisting only of breathing, relaxation and meditation
224223626|NCT00736619|OTHER|Cetuximab, IMRT, Albumin-bound paclitaxel (Abraxane®)|"All patients will receive standard treatment with definitive radiation therapy (IMRT, intensity-modulated radiation therapy) administered concurrently with cetuximab (400 mg/m2 intravenous loading dose one week prior to radiation therapy, followed by 250 mg/m2 weekly intravenous infusions). To explore different dose levels of nanoparticle albumin-bound paclitaxel (Abraxane®) given intravenously weekly with the standard regimen of weekly cetuximab + daily radiation therapy.~The total number of planned cetuximab infusions is 8 (loading dose, plus 7 weekly infusions concurrent with radiation therapy). The total number of planned albumin-bound paclitaxel infusions is 7 (all concurrent with radiotherapy). Five dose levels of weekly intravenous (IV) albumin-bound paclitaxel will be explored."
224223627|NCT02210884|DIETARY_SUPPLEMENT|Vitamin D|Weekly oral supplementation with 15,000 IU vitamin D
224223628|NCT06529263|OTHER|newborn massage|Newborn massage is one of the complementary treatment methods that support the treatment and contribute to the development of the baby
224223629|NCT01396941|BEHAVIORAL|Sleep restriction|Sleep restriction will consist of 5 nights, sleeping 4 hours per night Normal sleep will consist of 5 nights, sleeping 9 hours per night
224223630|NCT02224521|DRUG|GSK2190915 Solution.|Aqueous Solution, 10mg/mL.
224223631|NCT02224521|DRUG|GSK2190915 Granule Capsule (A)|GSK2190915A granule filled in to Gelatin capsules
224223632|NCT02224521|DRUG|GSK2190915 Semi-solid Lipid Capsule (B)|GSK2190915A dispersed in a lipid vehicle and filled in to HPMC capsules
224223633|NCT02224521|DRUG|GSK2190915 Liquid Lipid Capsule (C)|GSK2190915A dissolved in lipid vehicle milled and filled in to Gelatin capsules
224223634|NCT02224521|DRUG|GSK2190915 Milled Tablet|GSK2190915A granule is blended, compressed into tablets and aqueous film coated
224223635|NCT02224521|DRUG|GSK2190915 Micronised Tablet|GSK2190915A granule is blended, compressed into tablets and aqueous film coated
224223636|NCT00631670|RADIATION|Stereotactic Body Radiation Therapy|15 Gy in one treatment
224223637|NCT00631670|RADIATION|Stereotactic Body Radiation Therapy|Dose: 70 Gy at 2.8 Gy/treatment
224223638|NCT03943342|DRUG|Ibrutinib|Given PO
224223639|NCT03943342|DRUG|Venetoclax|Given PO
224223640|NCT04675983|DRUG|Sintilimab|Administered IV
223634899|NCT02988466|BIOLOGICAL|Haplo HCT ≥65 and ≤75 years old|"* Fludarabine (Flu)~* Cyclophosphamide (Cy)~* Total body irradiation (TBI)"
223634900|NCT02903771|DRUG|Part A: Dose Escalation of Cantrixil|"Cantrixil will be administered via the intraperitoneal route only. The dose of study drug that each participant will receive will depend on how far the study has progressed when the participant enrols. There are 9 potential doses of Cantrixil, they are 0.06, 0.12, 0.24 (starting dose), 0.6, 1.25, 2.5, 5, 10, or 20 mg/kg. The dose each participant receives will remain the same during the study, unless it needs to be reduced for safety reasons. The dose will not be increased.~Each participant will receive the study drug once a week during the first two cycles; each cycle is 21-days (three weeks); the MTD will be determined during Cycle 1 only. If after two cycles of monotherapy, the patient tolerates Cantrixil adequately, they may continue to receive Cantrixil once a week and will also begin combination chemotherapy for another 6 cycles. Participants will receive no more than 8 cycles of study drug."
223634901|NCT02903771|DRUG|Part B: Expansion Cohort of Cantrixil|Once the MTD has been established, an expansion cohort will be recruited at the MTD. An additional 12 patients will be recruited in this cohort on top of those recruited in Part A at the MTD. These patients will be subjected to the same intervention described in Part A with 2 cycles of monotherapy followed by up to 6 cycles of combination therapy.
223634902|NCT06268236|OTHER|Electroacupuncture|Electro-acupuncture at Shuigou and Yintang.
223634903|NCT06268236|OTHER|Sham electroacupuncture|Sham-EA at sham-Shuigou and sham-Yintang.
223634904|NCT04231773|DRUG|Nitric Oxide|40 parts per million dosage
223764730|NCT05049785|OTHER|Counseling|Attend nutrition counseling sessions
223764731|NCT05049785|BEHAVIORAL|Exercise Intervention|Complete PA sessions
223764732|NCT05049785|OTHER|Informational Intervention|Receive nutrition handouts
224223641|NCT04675983|DRUG|Ramucirumab|Administered IV
224223642|NCT04675983|DRUG|Cisplatin|Administered IV
224223643|NCT04675983|DRUG|5-fluorouracil|Administered IV
224223644|NCT04675983|DRUG|Oxaliplatin|Administered IV
224223645|NCT04675983|DRUG|Capecitabine|Administered orally
223634905|NCT04231773|DRUG|Placebo|Inhaled placebo. Device connected to same delivery system, but does not deliver nitric oxide.
223634906|NCT03884829|DRUG|CYC140|CYC140 single agent
223634907|NCT03299556|OTHER|WHT|Incorporating WHT into treatment for chronic pain. WHT includes patient and provider tracking of patient-reported pain, pain management, medication usage, functionality, depression, activity and sleep (measured by 3 axis actigraph); as well as prompts to subjects to engage in self-care, including non-pharmaceutical pain management therapies consistent with MPP training.
223634908|NCT05994612|BEHAVIORAL|Cognitive Therapy for Suicide Prevention|10 sessions of cognitive therapy for suicide prevention plus 9 optional booster sessions
223634909|NCT05994612|BEHAVIORAL|Services as Usual|Participants will receive services that they would normally receive in the community.
223634910|NCT01122238|DRUG|Nicotine Patch|"If randomized to only the Nicotine Patch condition (and not the Nicotine Gum):~Participants randomized to this condition will receive a 6-week supply of 14 mg patches at the initial visit. Participant will be instructed to use one patch daily for 6 weeks."
223634911|NCT01122238|DRUG|Nicotine Gum|"If randomized to only the Nicotine Gum condition (and not the Nicotine Patch):~Participants randomized to this condition will receive a 6-week supply of 2 mg gum at the initial visit. Participants will be instructed to use 10 pieces of gum daily for 6 weeks."
224223646|NCT03867591|OTHER|Gastro-AD®|"The product under study is Gastro-AD® fermented soy powder in the form of orodispersible flavored powder packed in non-transparent sachets.~Content: 1 g of Gastro-AD® powder per sachet + flavoring agents."
223634912|NCT01122238|BEHAVIORAL|Motivational Interviewing|"Participants randomized to this condition will receive an initial MI counseling session during the in-person clinic visit followed by three counseling phone calls over the 6-week intervention period (a total of four intervention contacts). The phone counseling sessions will occur during weeks 2, 4, and 6. Case managers will engage the participant in a series of motivation building exercises such as reviewing feelings and thoughts about the pros and cons of quitting and smoking, reinforcing the positives of quitting, helping to dispel myths and concerns about the negatives of quitting, and posing questions about the good aspects of smoking."
223634913|NCT01122238|BEHAVIORAL|Smoking Reduction|Participants randomized to Smoking Reduction will receive an initial counseling session during the in-person visit followed by 6 weekly phone counseling sessions over the 6-week intervention period. During the initial session, participants will be told that the goal is to reduce cigarette consumption by 50% over the course of the intervention (approximately 10% reduction per week). During the initial meeting and subsequent counseling calls, case managers will work with participants to problem-solve strategies for reduction (e.g., increasing time between cigarettes, delaying smoking, or eliminating smoking in specific situations). Participants will be asked to record information in a provided smoking log to help keep track of daily smoking patterns and as a feedback mechanism for identifying successes and challenges.
223634914|NCT01122238|OTHER|No Intervention|No Intervention
223634915|NCT01122238|DRUG|Nicotine Patch + Nicotine Gum|"If randomized to both the Nicotine Patch and the Nicotine Gum conditions:~Participants randomized to this condition will receive a 6-week supply of 14 mg patches and a 6-week supply of 2 mg gum at the initial visit. Participant will be instructed to use one patch daily and to use 10 pieces of gum daily for 6 weeks."
223634916|NCT00683527|DRUG|Elemental iron|Iron in the dose of 3-4 mg/kg/day (of elemental iron) PO once daily mixed with expressed breast milk from 14 days of life till the end of study period
223634917|NCT01537666|DRUG|AeroVanc|Vancomycin hydrochloride dry powder for inhalation
223634918|NCT01537666|DRUG|IV vancomycin hydrochloride|Vancomycin hydrochloride solution for intravenous administration
223634919|NCT03041038|DRUG|Secukinumab|Anti IL-17A antibody
223634920|NCT03041038|DRUG|Placebo|
223764733|NCT05049785|DIETARY_SUPPLEMENT|Nutritional Intervention|Attend tasting sessions
223764734|NCT05049785|OTHER|Questionnaire Administration|Ancillary studies
223764735|NCT06322121|OTHER|MRI|Assessment of vascular reactivity and CAA/SVD MRI markers
223764736|NCT06836180|DEVICE|Near infrared light therapy|Once a day, once 30 minutes of near-infrared light treatment, 6 times a week for 96 weeks
224223647|NCT03867591|OTHER|Placebo|The placebo product will have very similar appearance, color, texture and taste as the Gastro-AD® flavored sachet. The placebo sachets contain the respective amount of maltodextrin (1 g) and exactly the same flavoring and coloring agents as Gastro-AD® powder flavored sachets.
224223648|NCT06286839|DIETARY_SUPPLEMENT|Cannabidiol (CBD)|Cannabidiol (CBD), a non-psychoactive component of Cannabis sativa L.
224223649|NCT02596997|DRUG|Brincidofovir|Up to 100mg Brincidofovir twice weekly, not to exceed a total dose of 200mg each week
224223650|NCT02668783|DRUG|Etonogestrel (ENG) 125 μg + 17β-estradiol (E2) 300 μg vaginal ring|Up to 4 cycles (or 6 cycles if also participating in the extension) of ENG-E2 125 μg/300 μg administered intravaginally. Each cycle will consist of 21 days of vaginal ring use followed by 7 ring-free days.
224223651|NCT02668783|DRUG|Placebo vaginal ring|Up to 4 cycles (or 6 cycles if also participating in the extension) of placebo administered intravaginally. Each cycle will consist of 21 days of placebo vaginal ring use followed by 7 ring-free days.
224223652|NCT02668783|DRUG|Ibuprofen|Ibuprofen tablets, to be taken orally, will be provided for use as rescue medication for dysmenorrhea treatment throughout the study. Participants may take 400 mg every 4 hours as needed for pelvic pain/cramping, or as instructed by their physician according to local labeling for relief of menstrual pain.
224223653|NCT00046423|DRUG|ABI-007|
224223654|NCT06524791|OTHER|bacteriophage detection|bacteriophage detection
224223655|NCT04746014|DIAGNOSTIC_TEST|Clearblue Pregnancy Test|Urine Pregnancy Test
224223656|NCT02884206|DRUG|LCZ696|LCZ696 50, 100, and 200 mg tablets taken orally twice daily with matching placebo for valsartan
224223657|NCT02884206|DRUG|Valsartan|Valsartan 40, 80, and 160 mg tablets taken orally twice daily with matching placebo for LCZ696
224223658|NCT02884206|DRUG|Placebo of LCZ696|Placebo to match LCZ696 50 mg, 100 mg, and 200 mg tablets
224223659|NCT02884206|DRUG|Placebo of Valsartan|Placebo to match valsartan 40 mg, 80 mg, and 160 mg tablets
224223660|NCT01492582|BIOLOGICAL|quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine or nonavalent human papillomavirus vaccine (HPV 6, 11, 16, 18, 31, 33, 45, 52, 58)|Given IM
224223661|NCT01492582|OTHER|laboratory biomarker analysis|Correlative studies
224223662|NCT01492582|OTHER|survey administration|Ancillary studies
224223663|NCT01492582|OTHER|medical chart review|Ancillary studies
224223664|NCT06349720|BEHAVIORAL|respiratory rehabilitation|"Emote respiratory rehabilitation:Patients wear monitoring devices and upload real-time monitoring data such as vital signs through the FREE rehabilitation app installed on their personal phones. Medical staff monitor changes in patients' vital signs in real time through the FREE rehabilitation app on the medical end, and adjust respiratory rehabilitation plans based on their phone or video guidance.~Outpatient respiratory rehabilitation:Traditional outpatient respiratory rehabilitation is based on a group approach, with individualized intensity determined based on baseline assessment results, and is conducted under supervision twice a week for a period of 12 weeks."
224223665|NCT00892827|DRUG|Rituximab (Mabthera) , FFP (Fresh Frozen Plasma)|Rituximab (375 mg/m2) with FFP will be given every two weeks
224223666|NCT05117892|OTHER|Training, certification and marketing scheme|The 12hr training will address the vendors (i) knowledge on hygienic handling of milk, preservation and low-cost methods for testing milk safety; (ii) business skills in record keeping, access and management of credit; (iii) milk marketing. On completion of the training and successfully passing an evaluation, vendors will be given a written certificate using a format suitable to be displayed in their premises (i.e. A4 poster, a hat or badge) indicating they have completed the training. The certification will not have legal value. Two quarterly unannounced visits will be conducted to collect a milk sample from the vendors and report back the results of microbiological quality. Vendors will have access to various milk marketing and communication items to be used in their daily operations. The materials will promote milk consumption through marketing focused on messages to consumers related to (i) good milk hygiene practices, (ii) good child nutrition practices, and (iii) household diets
224223667|NCT00112489|DRUG|carboplatin|
223634921|NCT02574624|PROCEDURE|Intraocular assistance|Intraocular assistance with help of surgical assistants during vitreous surgery (VISIA) in patients who require vitreous surgeries as part of standard of care procedure for conditions like retinal detachments, dislocated intraocular lens and glaucoma patients requiring endophotocoagulation.
223634922|NCT05908916|DRUG|AtezoBev with combined radiotherapy|Atezolizumab (1200mg) and Bevacizumab (15mg/kg) are administered to patients once for each cycle with 3-week intervals, and additional radiotherapy (iGTV 50-60 Gy, CTV 40Gy, PTV 30Gy / 10Fx) for the mass or portal vein tumor thrombosis is performed before second cycle of AtezoBev.
223634923|NCT02352025|DRUG|S-equol|S-equol should be administered orally, twice daily (12 hours apart), preferably on an empty stomach with a glass of water. Tablets should be swallowed whole.
223634924|NCT03480581|BEHAVIORAL|Forward First ICARE Training|Participants will engage in 12-sessions in forward direction, followed by 12-sessions in the reverse direction. Sessions will be scheduled 3 times/week with training parameters adjusted to progressively increase challenge as tolerated.
223634925|NCT03480581|BEHAVIORAL|Reverse First ICARE Training|Participants will engage in 12-sessions in reverse direction, followed by 12-sessions in the forward direction. Sessions will be scheduled 3 times/week with training parameters adjusted to progressively increase challenge as tolerated.
223634926|NCT03331315|DRUG|Celecoxib|
223634927|NCT03331315|DRUG|Ketorolac|
223634928|NCT01709721|DRUG|Hydromorphone Hydrochloride|Opioid for chronic pain
223634929|NCT01709721|DEVICE|Programmable Implantable pump|Programmable Implantable pump delivering intrathecal hydromorphone
223634930|NCT02121158|DEVICE|Implantable Cardioverter Defibrillator|The ICD and lead(s) will be FDA-approved.
223634931|NCT02121158|OTHER|Optimal Medical Therapy|Guidance on lifestyle modification, exercise training, and disease management including review of American Heart Association (AHA) Guidelines for Primary Prevention of Cardiovascular Disease and Stroke.
223634932|NCT06139276|PROCEDURE|Small Needle-Knife|"The small needle-knife therapy originated from the ancient Chinese acupuncture instrument known as the Pi needle from the Nine Needles, which resembled a sword, had two sharp edges, and was originally used for abscess drainage. It is currently widely applied in treating conditions such as myofascial adhesions, chronic pain, or nerve compression.~The small needle-knife features a flat and rounded tip design, with its handle made of solid steel. This construction provides excellent toughness and flexibility, minimizing tissue damage, and facilitating microadhesiolysis, an intervention aimed at releasing adhesions."
223634933|NCT06139276|OTHER|Standard treatment|Standard treatment
223634934|NCT04420234|DRUG|narfurine hydrochloride orally disintegrating tablets|Subjects swallowed 2 tablets of test drug (2.5 µg/tablet) with saliva at about 8:00 AM on D1; swallowed 2 tablets of test drug (2.5 µg/tablet) with saliva at about 8:00 AM starting on D4. Dosing for 7 consecutive days (D10 last dose in the morning).
223764737|NCT03567213|DEVICE|Surgical implantation of CortiCom system|Implantation of Cortical communication system, consisting of one or two Electrocorticography (ECoG) grids connected to a transcutaneous patient pedestal.
224223668|NCT00112489|DRUG|paclitaxel|
223634935|NCT00360230|BIOLOGICAL|GSK Biologicals' candidate Plasmodium falciparum malaria vaccine 257049|2 different formulations are tested. For each formulation, 3 different dosing schedules are tested
223634936|NCT00360230|BIOLOGICAL|Rabipur|3-dose intramuscular injection.
223634937|NCT05564468|OTHER|Best Practice|Receive standard of care
223634938|NCT05564468|OTHER|Internet-Based Intervention|Receive Peacefully's end-of-life planning program
223634939|NCT05564468|OTHER|Questionnaire Administration|Ancillary studies
223634940|NCT00581308|DEVICE|GORE® HELEX® Septal Occluder|Percutaneous transcatheter closure of ostium secundum atrial septal defects (ASDs)
223634941|NCT02042417|DEVICE|INRatio2 and CoaguChek|
223634942|NCT05889104|OTHER|Randomization Program|The subjects in the Control Group will undergo twelve weeks of low impact Aerobics Training along with a health awareness program
223764738|NCT05922332|DIETARY_SUPPLEMENT|Rich medium chain fatty acid milk powder group|In intervention group,there are 32 infants.They will be fed with rich medium chain fatty acid milk powder, formula with MCT content of 39%, total energy of 68kcal/100ml, and feeding frequency at a 3-hour interval
223764739|NCT05922332|DIETARY_SUPPLEMENT|Regular milk powder group|In control group,there are 32 infants.They will be fed regular milk powder,formula with MCT content of less than 30%, total energy of 67kcal/100ml, and feeding frequency at a 3 hours interval
223764740|NCT05516628|PROCEDURE|Surgical Resection|Resection of Primary Hepatocellular Cancer Tumour.
223634943|NCT05889104|OTHER|Progressive Loading Protocol (PLP):|he subjects in the Progressive Loading Group will undergo 4-7 days of moderate to high impact loading activities per week.
223634944|NCT00006396|DRUG|Nevirapine|
223634945|NCT00006396|DRUG|Zidovudine|
223634946|NCT01479296|BIOLOGICAL|VRC rAd5 vaccine (rAd5 gag-pol/env A/B/C)|Given intramuscularly
223634947|NCT01479296|BIOLOGICAL|rAd5 env A|Given intramuscularly
223634948|NCT01479296|BIOLOGICAL|rAd5 env B|Given intramuscularly
223634949|NCT01479296|BIOLOGICAL|rAd5 env C|Given intramuscularly
223634950|NCT01479296|BIOLOGICAL|rAd5 gag-pol|Given intramuscularly
223634951|NCT01479296|BIOLOGICAL|Placebo Vaccine|Given intramuscularly
224223669|NCT03035838|DRUG|Fosaprepitant|Within 24 hours from injury, IVAMEND (the intravenous formulation of the NK-1 antagonist fosaprepitant) will be administered at a dose of 300 mg, intravenously over 1 hour.
224223670|NCT04744844|PROCEDURE|blastocoel fluid biopsy|In the present study, blastocoel fluid biopsy (BF-biopsy) and collapse will be performed using a microinjection pipette similar to that used to perform ICSI. The pipette will be pushed gently through the zona pellucida and TE, and up to 90% of the BF will be aspirated.
224223671|NCT03136991|DRUG|AZD4831|Participants will receive AZD4831 once daily, orally, for a period of 10 days. Note: Additional doses (for cohorts 2,3\&4) are provisional and could be adjusted based on the emerging data after the review of all available safety or other pertinent data from the previous dose by the Safety Review Committee (SRC).
223634952|NCT05068297|OTHER|Incrediwear Germanium-Embedded Knee Brace following ACL reconstruction|Germanium-Embedded Knee Brace will be applied to the effected limb following ACL reconstruction
223634953|NCT05068297|OTHER|Replica Knee Brace|Replica Knee brace will be applied to the effected limb following ACL reconstruction
223634954|NCT02309346|DRUG|Clindamycin|Use of Clindamycin 2700mg+gentamicin 240mg+ 250ml sterile saline solution i.v. once a day or Gentamcin 240mg i.v once a day, plus clindamycin 900mg i.v. 8/8 h diluted in 250ml of sterile saline solution
223634955|NCT03219723|DRUG|Vonoprazan|Vonoprazan tablets
223634956|NCT03219723|DRUG|Amoxicillin hydrate|Amoxicillin hydrate (potency)
223634957|NCT03219723|DRUG|Clarithromycin|Clarithromycin (potency)
223634958|NCT03219723|DRUG|Metronidazole|Metronidazole
223634959|NCT06020820|OTHER|Cervical Rehabilitation program (Intervention Group) Group A|"(Positional release technique on trapezius muscle): the therapist locate and apply pressure along the tender points in the upper fibers of the trapezius. Lateral flexion of subject's head toward the side of a tender point held for 90 seconds.~(Suboccipital muscle release): The therapist places both his palms under the sub occipital region of the subject with his curled-up fingers and places an upward pressure causing a stretch and distraction for 30 seconds,This technique was performed 3 times in one session.~Stretching of pectoralis muscle:~Pectoralis muscle stretch were performed once daily, completing three repetitions on each side with a 30-second hold. Stretching with repetition of five, three times a day for 1week neck and soulder ROMs"
223634960|NCT06020820|OTHER|control group group B|"1. Relax shoulders and neck sufficiently~2. look down~3. turn face to the right~4. turn face to the left~5. incline head to the right~6. incline head to the left~7. turn shoulders round and round~8. slowly raise hands fully then lower them. patients were asked to perform five repetitions of each stretching exercise, three times per day (morning, afternoon, and evening)."
223634961|NCT05122338|DRUG|Normal saline|Before the induction of anesthesia, normal saline is used for bilateral transversus abdominis plane block in a volume of 20 mL of each side
223634962|NCT05122338|DRUG|Ropivacaine|Before the induction of anesthesia, 0.375% ropivacaine is used for bilateral transversus abdominis plane block in a volume of 20 mL of each side
223634963|NCT05122338|DRUG|Compound lidocaine|Before the induction of anesthesia, 0.4% compound lidocaine is used for bilateral transversus abdominis plane block in a volume of 20 mL of each side
223634964|NCT05122338|DRUG|Esketamine|Before the induction of anesthesia, 0.4mg/kg esketamine is used for bilateral transversus abdominis plane block
223634965|NCT00430014|DRUG|Atiprimod|Starting Dose of 60 mg/day orally for 14 days of 28 day cycle.
223634966|NCT04815941|OTHER|Soft ball tissue release exercises|"Exercise program were given to patients with low back pain secondary to hip muscle tightness using soft balls, i.e. tennis balls plus core stability exercises.~3 days a week for four weeks."
223634967|NCT03537989|DRUG|Saline|To reduce the volume of saline administered during surgery of the colon and the rectum
223634968|NCT05074992|DRUG|Ipilimumab|Ipilimumab is a monoclonal antibody medication that works to activate the immune system by targeting CTLA-4, a protein receptor that downregulates the immune system.
223764741|NCT05516628|DRUG|Adjuvant Atezolizumab-Bevacizumab Therapy|Patient receives adjuvant Atezolizumab plus Bevacizumab every 3-weekly for two years following resection of hepatocellular carcinoma tumour.
223764742|NCT02504372|BIOLOGICAL|Pembrolizumab|IV infusion
224223672|NCT03136991|DRUG|Placebo|Participants will receive placebo matching the AZD4831 dose, once daily, orally, for a period of 10 days.
223634969|NCT06009133|PROCEDURE|Conservative treatment|"Micronized purified flavonoid fraction, which is routinely used within indications in hemorrhoidal disease and recommended in ESCP and ASCRS guidelines, and licensed for use in hemorrhoidal disease by the Ministry of Health in our country, was given 2 g/day for one month.~Also, Conservative methods (fiber foods, warm shower, regulation of toilet habits, laxatives and nonsteroidal anti-inflammatory drugs) were recommended."
223634970|NCT06009133|PROCEDURE|Surgical Treatment|While the patient was in the Jack-knife position, both hips were pulled laterally with tapes, appropriate visualization was obtained, the external thrombosed pack was excised under local anesthesia, and the wound was left to heal with secondary intention.Conservative methods were recommended in the surgical group as well as in the medical group.
223634971|NCT01722617|OTHER|Questionnaire|Patients in groups 2 and 3 will be asked to fill in questionnaires FLARE.
223634972|NCT02116036|DRUG|Rivaroxaban|
223634973|NCT01682434|PROCEDURE|Laser in situ keratomileusis (LASIK)|Wavefront guided treatment in one eye, conventional in the other.
224223673|NCT03341286|DRUG|TK3|Tryptophan and thiamine as on oral supplement
224223674|NCT02867904|DRUG|Methylprednisolone (40 mg depomedrol, 1ml, injection)|Experimental Drug
224223675|NCT02867904|DRUG|Marcaine (4ml 0.5%, injection)|Control
224223676|NCT06191367|OTHER|Aerobic Exercises|Aerobic Exercises
223634974|NCT00842114|BIOLOGICAL|R+CVP+IFN|Immunochemotherapy
224223677|NCT06191367|DEVICE|Incentive Spirometer Device|is a handheld medical device used to help patients improve the functioning of their lungs. By training patients to take slow and deep breaths, this simplified spirometer facilitates lung expansion and strengthening. Patients inhale through a mouthpiece, which causes a piston inside the device to rise. This visual feedback helps them monitor their inspiratory effort. Incentive spirometers are commonly used after surgery or other illnesses to prevent pulmonary complications.
223634975|NCT02191111|BEHAVIORAL|Task-focused facilitation|An external, task-focused facilitation, informed by an evaluation of contextual factors using the Alberta Context Tool (ACT), will be applied to train community pharmacies to develop alternative team processes that enable a greater number of medication management services to be provided to patients with diabetes, hypertension, and/or dyslipidemia.
223634976|NCT05778604|BEHAVIORAL|Physio-feedback|"The researcher presents the BTrackS software to display the participant's BBS score (s) with interpretations including: (1) baseline, post-baseline, percent of changes; (2) comparison to sex and age group; and (3) levels of fall risk. The researcher will categorize participants into four groups (irrational \| incongruent \| congruent \| rational) based on the fall risk appraisal (FRA) matrix and plots the position on one of the four quadrants in the FRA matrix chart. The researcher will provide physio-feedback to participants at baseline and week 9."
223634977|NCT05778604|BEHAVIORAL|Cognitive reframing|Cognitive reframing will be based on the fall risk appraisal (FRA) matrix. We will present the FRA matrix and activities will be tailored based on the quadrant that participant fits. Quadrant 1 (Irrational) focus on increasing balance confidence and maintaining exercise. Quadrant 2 (Incongruent) focus on individual fall risk factors from the CDC fall risk checklist, enhance fall risk awareness, and participate in the exercise. Quadrant 3 (Congruent) focus on individual fall risk factors from the CDC fall checklist and participate in the exercise. Quadrant 4 (Rational) encourage to maintain exercise.
223634978|NCT05778604|BEHAVIORAL|Peer-led exercises|The peer-led exercise is focused on balance, strength training, and incorporating exercises into daily activities. A trained peer coach (PC) will lead the group-based exercises for 60 mins (8-10/group). Exercise training consists of four sets: a) warm-up (seated), b) strength for upper and lower body (seated and standing), c) balance (standing and moving), and d) stretching of the lower and upper body. We will provide an exercise booklet (English/Spanish version) with illustrations that highlight steps for each set of exercises and a wide variety of exercises to integrate into daily activities (e.g., cooking). Participants will be instructed to complete a weekly exercise log to record types and duration of activity performed at home.
223634979|NCT05778604|BEHAVIORAL|CDC older adults fall prevention|Participants will receive an information pamphlet about falls (English or Spanish version) developed by the CDC (Stopping Elderly Accidents, Deaths, and Injuries (STEADI)-Older Adult Fall Prevention). The pamphlet contains information on fall risk, how to prevent falls, check for safety, postural hypotension and chair rise exercise including what you can do to prevent falls. The participants will be encouraged to discuss fall prevention with a primary care provider and continue normal activities (treatment-as-usual) for 6 months. Participants will receive monthly follow-up phone calls from the study team to record a monthly fall incidence log.
223634980|NCT05163080|BIOLOGICAL|SurVaxM|Consists of a synthetic peptide conjugate that stimulates immune responses capable of killing cancer cells that express the survivin molecule. Multiple copies of the multiplied peptide (SVN53-67/M57) are conjugated to Keyhole Limpet Hemocyanin (KLH) yielding a molecule designated as SVN53-67/M57-KLH. The SVN53-67/M57-KLH conjugate (SurVaxM)produces immune responses in mice and humans that are cross-reactive to the wild-type survivin molecule expressed by tumor cells. The survivin peptide in SurVaxM is a defined antigenic peptide comprised of 15 amino acids that encompass multiple epitopes capable of binding human MHC Class I and murine H2-Kb molecules. SurVaxM also contains a core antigenic epitope that has been modified by substitution of methionine for cysteine at amino acid position 57 (i.e., M57).
223634981|NCT01527370|BIOLOGICAL|Zoster Vaccine Live|One approximately 0.65 mL injection subcutaneously on Day 1
223634982|NCT02057250|DRUG|Sarilumab|Pharmaceutical form: Solution Route of administration: Subcutaneous
223634983|NCT02057250|DEVICE|Auto-Injector Device (AID)|
223634984|NCT02057250|DEVICE|Pre-filled Syringe (PFS)|
223634985|NCT02057250|DRUG|Methotrexate|Dispensed according to local practice.
223634986|NCT02057250|DRUG|Sulfasalazine|Dispensed according to local practice.
223634987|NCT02057250|DRUG|Leflunomide|Dispensed according to local practice.
223634988|NCT02057250|DRUG|Hydroxychloroquine|Dispensed according to local practice.
223634989|NCT05895188|DEVICE|Virtual Reality Glasses|From the beginning to the end of the procedure, women will watch the selected nature video.
223764743|NCT02504372|OTHER|Placebo|IV infusion
224223678|NCT06191367|OTHER|Traditional Chest Physiotherapy|"1. Breathing exercise.~2. Postural drainage.~3. Percussion.~4. Coughing.~5. Vibration."
224223679|NCT01003886|DRUG|Doxazosin mesylate GITS|Doxazosin mesylate GITS 4mg to 8mg once daily
224223680|NCT04806984|OTHER|Participant outreach|Participants in the experimental arms will receive a call center phone call or MyChart message to remind them to schedule their appointments.
223634990|NCT00497484|DRUG|recombinant human somatotropin|
223634991|NCT04172181|PROCEDURE|cord blood stem cell transplantation|Unrelated cord blood stem cell selection； Reduced intensity conditioning； GVHD prevention； Infection prevention.
223634992|NCT04843007|DRUG|Pemetrexed|Alvopem® was administered every 3 weeks with a dose of 500 mg/m\^2
223634993|NCT00349518|DRUG|Dasatinib|
223634994|NCT03177317|DRUG|Dexamethasone|"Dexamethasone 8mg IV before chemotherapy on cycle 1 day 1~Once the complete response is achieved, the dose of dexamethasone will be reduced by 2 mg in the next cycle."
223634995|NCT03772886|DEVICE|Peanut Ball|A peanut shaped exercise ball.
223634996|NCT03959514|BIOLOGICAL|NovoRapid|Rapid acting prandial insulin aspart
223634997|NCT03959514|BIOLOGICAL|Fiasp|Fast acting prandial insulin aspart
223634998|NCT03959514|BIOLOGICAL|AT247|Ultra rapid acting prandial insulin aspart
223764744|NCT05620940|DRUG|Vivitrol Injectable Product|Naltrexone Long-Acting Injection
223764745|NCT05620940|DRUG|IVL3004|Naltrexone Long-Acting Injection
223764746|NCT05620940|DRUG|IVL4002|Naltrexone Long-Acting Injection
224223681|NCT02979379|OTHER|Pain|
223634999|NCT03324269|DEVICE|NOL|"After tracheal intubation, a Tetanus test (60 mAmp,100 Hz) is done during 30 sec at remifentanil level Ce of 4 ng/ml (with starting NOL value \<10). According to the NOL response: increment of 1 ng/ml of RemiCe if NOL gradient ≥ 20 / decrement of 1 ng/ml of remifentanil Ce NOL gradient \< 10. During the testing period propofol Ce is fixed at the concentration associated with BIS levels between 45-60 during the first calibration.~Upon the incision and 2 minutes after skin incision, Propofol TCI (Schnider model) is adjusted to BIS between 45-60 and remifentanil Ce at which the variation of NOL index variation is less than10 units at a NOL starting value \<10. MAP (mean arterial pressure), HR (heart rhythm) and NIBP (non-invasive blood pressure) will be measured.~The formula derived from the calibration phase will be tested during a single tetanic stimulation at remifentanil Ce of 4 ng/ml during the validation phase."
223635000|NCT03924050|DRUG|TORIPALIMAB INJECTION(JS001 )|TORIPALIMAB INJECTION(JS001 ) or Placebo, 240mg/6ml/vial, Q3W,up to 2 years of treatment.
223635001|NCT01473888|DRUG|T89(Dantonic)|capsule, 225mg B.I.D.
223635002|NCT05207488|DIETARY_SUPPLEMENT|Fructooligosaccharides (FOS)|FOS (NUTRAFLORA® P-95, Ingredion) supplements (10g/day) will be consumed daily mixed with water.
223635003|NCT05207488|BEHAVIORAL|Exercise|During the intervention period, all participants will perform 6 weeks of supervised progressive multi-component exercise training consisting of moderate to vigorous aerobic and strength-based exercises (3x/wk.).
223635004|NCT05207488|DIETARY_SUPPLEMENT|Placebo|Maltodextrin (Globe 18DE Maltodextrin, Ingredion) supplements (10g/day) will be consumed daily mixed with water.
223635005|NCT04961775|DRUG|Perflubutane Microspheres for Injection|16 µL as perflubutane microbubbles (1 vial) is reconstituted with 2 mL of attached water for injection; usually, once for an adult, 0.015 mL/kg as dispersion is administered intravenously.
224223682|NCT02437214|OTHER|Use of music for anxiety in children|"The Baby Go to Sleep CD played a combination of the sound of an actual human heartbeat and children's songs. The concept behind the Baby Go to Sleep CD is to blend heart beat sounds, which are known to be calming to infants and children, with children's music. The basic principles of relaxation were incorporated in the arrangements of heartbeat and children's songs, ie: simplicity, repetition, predictability, and simple symmetry (short repeated patterns). The adult human heart in the Baby Go to Sleep CD was recorded from the chest and set in consistent tempos for each song ranging from 62 to 78 beats per minute(BPM). The sound of the heartbeat continued between and during songs. Tempo changes occurred between each song."
224223683|NCT06014450|RADIATION|Prophylactic Cranial Irradiation for experiment arm|Prophylactic Cranial Irradiation DT30Gy/10f
224223684|NCT01499914|BIOLOGICAL|influenza vaccination|Influenza vaccination in patients with cystic fibrosis
224223685|NCT02444312|BEHAVIORAL|Benefit-finding Writing Activity|Caregivers will be instructed to write about the benefits of caring, considering things such as improved social relationship, appreciation of life and loved ones, and the positive consequences with respect to these.
223635006|NCT01434212|DRUG|Interferon Alfa-2b, Ribavirin|"Interferon:dosage,5 million units/person;frequency,every other day (qod);duration,48 weeks;Subcutaneous injection.~Ribavirin: dosage,15mg/kg/day;frequency,three times a day (t.i.d);duration,48 weeks;take orally."
223635007|NCT06319014|BEHAVIORAL|Exercise Modes|Moderate intensity aerobic exercise Moderate intensity resistance exercise Moderate intensity combination exercise
223635008|NCT01988155|OTHER|Eccentric Exercise|Subjects in the eccentric exercise group will be instructed to perform the modified Alfredson eccentric protocol for insertional Achilles tendinopathy. To perform the eccentric exercise, subjects will be instructed to stand upright with one hand on the wall or a chair for support as needed. A heel raise exercise is then performed with the non-painful leg. Once in the elevated position, subjects are instructed to transfer all of their body weight to the painful leg and slowly lower their heel to the floor while keeping their knee extended. The eccentric exercise program will consist of 3 sets of 15 repetitions performed per session. Subjects will perform 2 sessions per day for a total of 12 weeks and a log will be kept to monitor compliance. In order to partially control for the effect of regular contact with a therapist, subjects in the control group will be contacted by telephone one time per week to discuss their progress with the program and address any questions they may have.
223635009|NCT01988155|OTHER|Astym|In addition to performing the same eccentric protocol as the eccentric exercise group, subjects in the Astym group will also be seen in the clinic two times per week. Astym treatment will be performed per the foot, ankle, and knee protocol as described in the Astym clinical manual. During the first visit each week, the eccentric exercise protocol will be orally reviewed to match the one time per week phone education received by the eccentric only group. Astym treatment will continue for up to six weeks but may be discontinued early if a subject scores 90 or above on the VISA-A. Subjects in the Astym group will be required to continue with the eccentric exercise protocol for the full 12 weeks even in Astym is discontinued early.
224223686|NCT02444312|BEHAVIORAL|Neutral Writing Activity|The control group will be instructed to write number of things about the weather that day. Although the sentences can be as long or as short as they like, they will be encouraged to try and aim for about 3 or 4 sentences at least.
224223687|NCT03824210|OTHER|App|Mobile phone app
224223688|NCT00027469|PROCEDURE|MRI|
224223689|NCT00484523|PROCEDURE|SPET, PET and MRI|60 healthy subjects after a a consultation with a neurologist for wich 4 examinations will be programmed in two days ( 1 cerebral MRI, 1pet scan, 1 spet, 1 datascan
224223690|NCT04212702|DRUG|Hormonal therapy-based treatments|Hormonal therapy-based treatments, ex. HT single agent, HT plus other targeted therapy, HT plus everolimus, HT plus metronomic oral chemotherapy or oral chemotherapy only
224223691|NCT05291143|BEHAVIORAL|Short videos on blood pressure monitoring|Short videos on blood pressure monitoring
224223692|NCT03666637|PROCEDURE|dynamic hip screw (DHS) and cannulated screw (CS)|A preformed case report form was used to collect the data which included the demographic profile of the patients (age, gender), comorbidities, smoking history, mode of injury (high or low energy), presence of multiple trauma, garden classification, side of injury, time to fixation (in hours), type of reduction, type of implant used, RUSH score (healing), start of weight bearing, development of AVN, and final outcome (whether varus, valgus, displaced or healed).
224223693|NCT01200056|DRUG|Atorvastatin 10mg versus 40mg.|2 arms comparing atorvastatin 10mg daily for 6 months to atorvastatin 40mg daily for 6 months. The primary endpoint would be the 6 months VH-IVUS findings and clinical outcomes.
224223694|NCT02613637|OTHER|Registry|
223635010|NCT06132672|BEHAVIORAL|Navigators (peer navigator) training|The Navigators training will be designed to increase knowledge and skills to help others (i.e., social network members). Navigators in the intervention group will be trained and supported for 12 months of implementation across years 3 and 4
223635011|NCT06132672|BEHAVIORAL|delayed-intervention|Those in the delayed-intervention group will be trained in year 5
223635012|NCT02578069|DEVICE|NOVA Intracranial Sirolimus Eluting Stent System|A sirolimus eluting intracranial stent system with polylactic-co-glycolic acid (PLGA) biodegradable drug carrier and electro-grated polybutyl methacrylate (PBMA) base coating. The stent platform is made of 316L stainless steel.
223635013|NCT02578069|DEVICE|Apollo Intracranial Stent System|A 316L stainless steel balloon-expandable intracranial stent system
223635014|NCT01435382|BIOLOGICAL|PF-04950615 (RN316)|Dose A - single-dose intravenous infusion
223635015|NCT01435382|BIOLOGICAL|PF-04950615 (RN316)|Dose B - single-dose subcutaneous injection
223635016|NCT01435382|BIOLOGICAL|PF-04950615 (RN316)|Dose C - single-dose subcutaneous injection
223635017|NCT01435382|BIOLOGICAL|PF-04950615 (RN316)|Dose D - single-dose subcutaneous injection
224223695|NCT06031311|DIAGNOSTIC_TEST|Echocardiography and HRCT|Echocardiography:is non invasive and easily accessible tool in the diagnosis of any patient with suspected PH.HRCT: is a non-invasive and easily accessible tool to detect pulmonary hypertension in COPD patients.
224223696|NCT00716183|BIOLOGICAL|Lactobacillus salivarius HN6|9 log colony-forming units, capsules, daily, four weeks
224223697|NCT00716183|BIOLOGICAL|Lactobacillus reuteri CR20|9 log colony-forming units, capsules, daily, four weeks
224223698|NCT00716183|BIOLOGICAL|Lactobacillus fermentum LC40|9 log colony-forming units, capsules, daily, four weeks
224223699|NCT00716183|DRUG|Beta-lactam antibiotic|Use of amoxicillin, cloxacillin or amoxicillin/clavulanic acid(500-750 mg), orally, every 8-12 h, for 2-3 weeks (as prescribed by the physician responsible for the clinical diagnosis of lactational mastitis)
224223700|NCT03418883|OTHER|Mirror therapy|
224223701|NCT02691897|DRUG|Melatonin|Melatonin 3mg once daily at bedtime
224223702|NCT02691897|DRUG|Placebo|Placebo 1 tablet once daily at bedtime
224223703|NCT04467697|DRUG|SOV2012-F1|Oral preparation of testosterone undecanoate (TU). Strengths of 100 mg TU, 150 mg TU and 200 mg TU
224223704|NCT02506790|DRUG|metformin|
224223705|NCT02506790|DRUG|Melatonin|
224223706|NCT02506790|DRUG|Toremifene|
224223707|NCT04523558|DEVICE|Implantation of LuxSmart hydrophobic IOLs (Bausch + Lomb) in both eyes|Extended depth of field intraocular lens made form hydrophobic material
224223708|NCT05218863|OTHER|No intervention|No intervention
224223709|NCT01172600|OTHER|Entonox|Those randomized to Entonox will inhale the gas through a mouthpiece throughout the procedure and also continue to receive it for a total of 4 hours in the recovery.
224223710|NCT01172600|OTHER|Oxygen|Those randomized to oxygen will inhale it through a mouthpiece throughout the procedure and also continue to receive it for a total of 4 hours in the recovery.
224223711|NCT01056757|DRUG|Ribavirin|1000 mg bid, po, q28days
224223712|NCT05571527|BIOLOGICAL|Platelet Rich Plasma treatment|Patients receive platelet-rich plasma via injection into the vaginal area.
224223713|NCT05571527|DRUG|Vaginal Hyaluronic Acid supplement|Patients receive Vaginal Hyaluronic Acid supplement for 10 days, then once a week for 3 months.
223635018|NCT04859907|DEVICE|Clamp-like system|Craniotomy closure
223635019|NCT04859907|DEVICE|Plates and screws|Craniotomy closure
223635020|NCT04592302|DIAGNOSTIC_TEST|Blood Draw|2-4 weeks before surgery a blood draw will be taken to test for nicotine levels in the body
223635021|NCT00600262|DRUG|intravitreal bevacizumab|
223635022|NCT02435992|DRUG|RPC1063|
223635023|NCT02435992|DRUG|Placebo|
223635024|NCT05216549|OTHER|Water-based exercise|8 weeks x 2 times per week for 45 min
223635025|NCT05216549|OTHER|Land-based exercise|8 weeks x 2 times per week for 45 min
223635026|NCT00566319|BEHAVIORAL|PREPARE with pedometer|Structured educational programme with pedometer use
223635027|NCT00566319|BEHAVIORAL|PREPARE|Structured educational programme
223635028|NCT00260533|DRUG|atomoxetine|Flexible dose, up to 50 mg per day
223635029|NCT00260533|DRUG|placebo|placebo (matching to atomoxetine)
223635030|NCT05512884|BEHAVIORAL|Speeded anomia therapy|The speeded anomia therapy was introduced as RISP (Repeated, Increasingly Speeded Production) by Conroy et al. (2018). Participants are asked to name the picture presented to them before an auditory stimulus ('beep' sound) at the end of item presentation. In each session the allotted response time is gradually reduced. After an incorrect response, participants are asked to repeat the word three times.
223635031|NCT01761877|DRUG|Sulindac|
223635032|NCT04106492|DRUG|SQ3370|SQ3370 consists of 2 components: SQL70, a protodrug-activating biopolymer, and SQP33, a protodrug of Doxorubicin
223635033|NCT02891499|PROCEDURE|Low-level laser therapy|"1. Immediate post-operative period (implantation day) Red emission (660 nm) Energy density: 4 J/cm2 Power: 0.1W Irradiation area: 0,5 cm2 One application, 10 seconds of non-contact irradiation (01 point at the area surrounding the miniscrew) at a distance of 15,5 mm.~2. Mediate post-operative period (after implantation day) Infrared emission (808 nm) Energy density: 8 J/cm2 Power: 0.1W Irradiation area: 0,5 cm2 6 applications every 48 hours after the day of implantation, 20 seconds of non-contact irradiation (01 point on the area surrounding the miniscrew) at a distance of 15,5 mm."
223635034|NCT02891499|PROCEDURE|Mediate force application|Mediate force application protocol: orthodontic force application (150 gF) 4 weeks after the day of the implantation.
223635035|NCT05087706|DRUG|Pyrotinib|Pyrotinib 400mg qd po
224223714|NCT04676191|DEVICE|Sleepiz One+|Simultaneous sleep study with polysomnography and Sleepiz One+
224223715|NCT04676191|DEVICE|Polysomnography|Simultaneous sleep study with polysomnography and Sleepiz One+
224223716|NCT05751629|DRUG|Dostarlimab|Dostarlimab was administered.
224223717|NCT05751629|DRUG|Bevacizumab|Bevacizumab was administered.
224223718|NCT05751629|DRUG|Niraparib|Niraparib was administered.
224223719|NCT04866589|BEHAVIORAL|Distribution of free face masks|"Corona hosts will be placed at the entrance of the intervention stores, and hand out face masks to customers entering the store."
224223720|NCT01764620|OTHER|Elastic taping applied with tension|
224223721|NCT01764620|OTHER|Elastic taping applied without tension|
224223722|NCT01764620|OTHER|Fatigue protocol|
223635036|NCT05087706|DRUG|Bicalutamide|Bicalutamide was administered orally at a daily dose of 50 mg
223635037|NCT05087706|DRUG|Leuprorelin|Leuprorelin acetate was administered subcutaneously at a dose of 3.75 mg every 4 weeks
223635038|NCT03530215|DRUG|Antineoplastic and Immunomodulating Agents|Antineoplastic agents, endocrine therapy, immunostimulants and immunosuppressants drugs included in the ATC classification L
223635039|NCT03542877|DRUG|Oral Tablet: Cabozantinib|Patients will take 60mg cabozantinib, by mouth, once daily, every day for 12 weeks. This medication should be taken on an empty stomach. Patients should not eat 2 hours before or 1 hour after taking cabozantinib. Only water is permitted during this 3 hour time frame.
223635040|NCT04965818|DRUG|Futibatinib and Binimetinib|Patients will receive futibatinib once daily in combination with binimetinib twice daily by oral administration on a 21-day cycle
224223723|NCT04228510|PROCEDURE|2D speckle tracking echocardiography|"Global and segmental strain and strain rate in longitudinal and circumferential directions will be detected after PPCI; before discharge. The LV circumferential strains and strain rates will be determined from the short-axis views at the basal, middle, and apical levels, and longitudinal strains and strain rates will be determined from the apical 2-, 3-, and 4-chamber views of the LV.~Segmental longitudinal strains equal to -15% or closer to 0 will be considered abnormal (injured segments). The average segmental longitudinal strain and strain rate of the abnormal segments is defined as the injury longitudinal strain (InjLS) and injury longitudinal systolic strain rate (InjLSRs)."
224223724|NCT02231710|BIOLOGICAL|BPX-501 and Rimiducid|Single administration of BPX-501 T cells post partially-mismatched, related T cell depleted HCT followed by Rimiducid infusion on day 7
224223725|NCT04081337|DRUG|Tirzepatide|Administered SC
224223726|NCT04081337|DRUG|Placebo|Administered SC
224223727|NCT04463433|BEHAVIORAL|Cognitive and behavioral intervention.|Two hours group sessions including mindfulness and emotion regulation. The practice of mindfulness is taught to parents to become aware of their thoughts and emotion on the present moment. The behavioral intervention has parents develop an Positive Time-out for dealing with conflict and negativity, using strategies to down-regulate their own negative emotions.
224223728|NCT04463433|BEHAVIORAL|Problem-solving and relationship improvement intervention.|Two hours group sessions including problem-solving and improving marital relationship . In the problem-solving part, the knowledge and techniques of problem-solving are taught to couple. relationship improvement part which promote the couple relationship by being aware of their own and their partner's deep-seated needs and communicating in a congruent way.
224223729|NCT04577274|DIETARY_SUPPLEMENT|smoothie with regular formulas (SM)|Participants were given 300 kcal of smoothie drink within 3-5 minutes and blood collection after drinking at 30, 60, 90, 120, 180 and 240 minutes. Participants have one week wash out period before try-out other formulas.
224223730|NCT04577274|DIETARY_SUPPLEMENT|smoothie with low carbohydrate formulas (SMLS)|Participants were given 300 kcal of smoothie drink within 3-5 minutes and blood collection after drinking at 30, 60, 90, 120, 180 and 240 minutes. Participants have one week wash out period before try-out other formulas.
224223731|NCT04577274|DIETARY_SUPPLEMENT|conventional diabetic enteral drinks (Glucerna)|Participants were given 300 kcal of smoothie drink within 3-5 minutes and blood collection after drinking at 30, 60, 90, 120, 180 and 240 minutes. Participants have one week wash out period before try-out other formulas.
224223732|NCT04435613|OTHER|protective mechanical ventilation strategies|1\. Reduce tidal volume from 7 ml/kg to 5 ml/kg. 2 Set end-inspiratory pausa. 3 respiratory rate reduction until 20% of the basal condition
224223733|NCT01234779|DRUG|bitopertin [RO4917838]|10 mg orally daily, 4 weeks
224223734|NCT01234779|DRUG|bitopertin [RO4917838]|30 mg orally daily, 4 weeks
224223735|NCT01234779|DRUG|olanzapine|15 mg orally daily, 4 weeks
224223736|NCT01234779|DRUG|placebo|orally daily, 4 weeks
224223737|NCT06203899|BEHAVIORAL|Op Volle Kracht|This is a preventive group training based on cognitive behavioural therapy for depression.
224223738|NCT06203899|BEHAVIORAL|Gatekeeperstraining|This is a training for teachers to detect and address depressive symptoms and suicidality in their students .
224223739|NCT01338428|BEHAVIORAL|Enhanced AAA Sexual Assault Resistance Education|Resistance Program: 4x3-hour units. Unit 1 (Assess) accurate assessment of sexual assault risk. Provides: empirically-based information on situational and (male) behavioural danger cues; practice identifying risk and counteracting it. Unit 2 'Acknowledge\[ment\]' of risk when present. Includes: women's sexual rights; emotional barriers; tactics used by coercive men; practice. Unit 3 (Act) includes: assessing whether or not an escape is possible; research evidence on the effectiveness of resistance strategies; physical self-defense training. Unit 4 applies content to longer term relationships covering: comfort talking about sexuality, identification of sexual values, practices beyond intercourse, and articulation of relationship goals.
223635041|NCT01424384|DRUG|Citalopram|Neurophysiological testing.
223635042|NCT01424384|DRUG|GSK424887|Neurophysiological testing
223635043|NCT01424384|DRUG|Plactebo To Match|Neurophysiological testing
223635044|NCT01310777|DRUG|Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension|
223635045|NCT01310777|DRUG|Brinzolamide 1% ophthalmic suspension|
223635046|NCT01310777|DRUG|Brimonidine tartrate 0.2% ophthalmic solution|
223635047|NCT02195102|DEVICE|Transcatheter aortic valve Replacement|
223635048|NCT03857854|DRUG|Pirfenidone|treatment group
223635049|NCT03857854|DRUG|Placebos|placebo group
223635050|NCT01795677|DRUG|Ruxolotinib|Ruxolotinib doses calculated with platelets count and P450 cytochrome inhibitor HSCT for patients with donor
223635051|NCT04337645|PROCEDURE|surgical treatment of peri-implantitis|resective surgical treatment of peri-implantitis
223635052|NCT05962060|OTHER|Proprioceptive neuromuscular facilition|PNF Proprioceptive Neuromuscular Facilitation (PNF) is a more advanced form of flexibility training. PNF involves both stretching and contracting (activation) of the muscle group being targeted in order to achieve maximum static flexibility.
223635053|NCT05962060|OTHER|Electrical muscle stimulator|Electrical Muscle Stimulation (EMS), also known as neuromuscular electrical stimulation (NMES) or electromyo stimulation, is a protocol that elicits a muscle contraction using electrical impulses that directly stimulate your motor neurons.
223635054|NCT06430970|DEVICE|endoscopy|upper and lower endoscopy
223635055|NCT00994513|DIETARY_SUPPLEMENT|Alpha Lipoic Acid|1200 mg/day
223635056|NCT00994513|DIETARY_SUPPLEMENT|Placebo|1200 mg/day
223635057|NCT02203396|DRUG|rabbit ATG, Cyclosporine, Levamisole|rATG is administered at a dose of 1.97 mg/kg/day for 9 days CSA is administered orally at a dose of 3 mg/kg qod Levamisole is administered orally at a dose of 2.5 mg/kg qod. The CSA and LMS is designed to alternately every other day.
223635058|NCT06522646|DEVICE|SPCM|During a period of 4-6 weeks, patients will live in their usual environment with the SPCM prosthesis
223635059|NCT06522646|DEVICE|Usual Prothesis|During a period of 4-6 weeks, patients will live in their usual environment with their usual microprocessor prosthesis
223635060|NCT03171649|DEVICE|RETRAINER-S1|"It consists of the execution of different exercises with the affected arm supported by the RETRAINER-S1 device. The subject is actively involved in the exercises and the system provides two types of support: weight relief and FES. The following exercises can be performed:~* anterior reaching (in a plane or in the space)~* lateral elevation of the arm~* hand to mouth movements with or without an object in the hand~* moving objects on a plane or in the space. A subset of exercises is defined based on the patient's capability and the training time is equally shared between the selected exercises. The different training sessions can include different exercises and a different number of repetition for each exercise."
223635061|NCT03171649|OTHER|Conventional therapy|"It consists of a combination of different treatment modalities among the following, based on the petient's specific needs:~* Upper limb passive motion~* Arm Cycle ergometer with or without FES~* Neuro Muscular Electrical Stimulation~* Upper limb exercises using augmented or virtual reality environment~* Occupational therapy exercises~* Constraint induced movement therapy~* Upper limb active movement (reaching, grasping, elevation, spatial orientation)~* Repetitive task training~* Mirror therapy~* Writing training~* Chemodenervation Therapy"
223635062|NCT02878031|DRUG|Oral amoxicillin for CI pneumonia|"CHW management of chest indrawing (CI) pneumonia in children 2-59 months old using oral amoxicillin, given in the following age specific dosage:~2 months ≤ children age \<12 months (4 - \<10kg): one (1) tablet 250mg dispersible amoxicillin twice daily (morning and evening) for 5 days.~12 months≥ children age \<3 years (10 kg - \<14 kg): two (2) tablets 250mg dispersible amoxycillin taken twice daily (morning and evening) for 5 days.~≥ 3 years of age children \<5 years (14kg - 19kg): three (3) tablets 250mg dispersible amoxycillin taken twice daily (morning and evening) for 5 days."
223635063|NCT00488371|BIOLOGICAL|Pneumococcal Conjugated Vaccine (Prevnar®)|
223635064|NCT02396576|BEHAVIORAL|Telehealth Intervention|The telehealth model will integrate developmental, behavioral, (DB) and mental health services (MH) into pediatric primary care using videoconferencing that will be tested with children in low-income, urban communities.
223635065|NCT01099722|DRUG|Flutiform|inhaler 2 puffs bd daily
224223740|NCT01338428|BEHAVIORAL|Brochure|Current 'standard of care' at Canadian universities. Invitation to take and read brochures on sexual assault selected from those available on their Canadian university campus. All sites' brochures include general information on sexual assault and 'date-rape' drugs and post-rape legal and medical advice. The research assistant (RA) will ask the participants to take brochures, read them over, and to ask any questions they may have. Questions will be answered in a group setting and the participant will take home any brochures that she selected. Interaction between participants and the RA on the topic will be limited to 10-15 minutes and will be audio recorded for verification.
224223741|NCT00815451|DIETARY_SUPPLEMENT|placebo|polyphenol-free dark chocolate 20g to be distributed throughout the day for 4 weeks
224223742|NCT00815451|DIETARY_SUPPLEMENT|Acticoa polyphenol-rich dark chocolate|20g to be distributed throughout the day for 4 weeks
224318555|NCT05175040|PROCEDURE|Sham rotation|Sham rotation, performed in the comparator arm, involves a vaginal exam that obstetric providers commonly do with their hands to assess cervical dilation and fetal position during routine labor, and will occur at the initiation of pushing once the individual achieves complete cervical dilation. Duration of the vaginal exam for sham rotation will be consistent with that used for prophylactic manual rotation and will be performed by a trained study investigator (M.D. or midwife) to maintain blinding of the patient's primary obstetrician.
223635066|NCT01099722|DRUG|Symbicort Turbohaler|2 puffs bd daily
223635067|NCT00425776|DEVICE|acupuncture|
223635068|NCT00425776|DEVICE|Sham acupuncture|
223635069|NCT00643864|BEHAVIORAL|mirror training|"Training will be performed one-on-one by an investigator in a quiet room, one hour a day, five days a week, for four weeks. Attendance will be recorded. The mirror-box apparatus consists of an 18 x 24 vertical mirror secured in the center of a wooden platform. During training, the mirror-box will be placed on a table in front of the subject so that the mirror is perpendicular to the chest, slightly lateral of midline. Subjects will be asked to attend to the mirror reflection of their unaffected hand performing a series of tasks, while keeping their affected limb still. At the end of the four week training period, posttests will be administered by the same Occupational Therapist who performed the pretests."
223635070|NCT04665947|DRUG|[68Ga]Ga DOTA-5G and [177Lu]Lu DOTA-ABM-5G.|PET imaging using \[68Ga\]Ga DOTA-5G will be used to diagnose patients who are eligible for treatment with the \[177Lu\]Lu DOTA-ABM-5G.
223764747|NCT06829017|OTHER|Postoperative Hypothermia Management Care Bundle|"The postoperative hypothermia care bundle consists of three main parameters, Diagnose hypothermia, Maintain/maintain normothermia and Monitor body temperature at regular intervals, and eight sub-parameters of these parameters. For this purpose, this study evaluates the pilot implementation and effectiveness of the postoperative hypothermia management care bundle developed within the scope of the research."
223764748|NCT06559995|DIETARY_SUPPLEMENT|"ketone supplement D-beta-hydroxybutryric acid and R-1,3 butanediol 12g of ketones,"|ketone supplement
224223743|NCT00829413|DRUG|SonoVue®|SonoVue (2.4 mL)
224223744|NCT06422117|DRUG|HSK16149 20mg-40mg BID|Oral, 20mg, BID, adjustable to 40mg, BID based on tolerability and efficacy;
224223745|NCT06422117|DRUG|Placebo|Placebo, oral, 2 capsules twice daily
224223746|NCT01414465|DRUG|Orlistat|Obese women were treated with orlistat 120mg 3 times a day for 4 months, compared with basal data and with normal weight women that didn´t receive orlistat
223635071|NCT03835195|OTHER|Diabetes Disease Management Program|The attention is carried out in a single physical place, in the city of Medellin. The scheme of intervention in the comprehensive Diabetes Clinic is based on the concept of disease management. The intervention is composed of 5 phases, which apply to all the patients cared for in the institution (access, reception, entry, clinical consultation, management plan, education, pharmaceutical care). The healthcare team consists of 5 endocrinologists, an endocrinologist pediatrician, 7 general practitioners trained in diabetes, 5 pharmacists trained in diabetes and certified in education for patients with diabetes and 3 nutritionists.
223635072|NCT03835195|OTHER|Usual Care Process|The patients are treated in the cardiovascular risk clinic (general practitioners) of their Primary Healthcare Provider Institution or by specialists in internal medicine, pediatrics or endocrinology in the different Provider Institutions of Health Services of the insurance service network of health or in private doctors' offices assigned to the insurer. In some cases there is assisted consultation (general practitioner - specialist). There is no defined periodicity for follow-up; Appointments are assigned to need, according to the criteria of the treating physicians. In some cases there is remission to educational activities, not necessarily focused on type 1 diabetes.
223635073|NCT01697917|OTHER|Total Gastrectomy or Proximal Gastrectomy|
223635074|NCT02124837|BEHAVIORAL|Park walk during lunch break|
223635075|NCT02124837|BEHAVIORAL|Relaxation during lunch break|
223635076|NCT04128852|DEVICE|MagnetOs Putty|MagnetOs Putty has a CE-mark (2115660CE01) as well as FDA 510(k) clearance (K171563/K181958).
223635077|NCT02461758|BIOLOGICAL|Standard dose Influenza vaccine (SDIV)|
223635078|NCT02461758|BIOLOGICAL|High dose influenza vaccine (HDIV)|
223635079|NCT04690660|OTHER|Data collection for parameters of organ damage (cardiac and renal blood markers)|Blood results will be taken out of next routine venipuncture. Routinely collected standard parameters are a blood count, chemistry panel including renal parameters and electrolytes, lipid profile and a HbA1c as well as albumin/creatinine and protein/creatinine ratio in urine.
223635080|NCT04690660|OTHER|Data collection for blood pressure (BP)|Clinic blood pressure and 24hour BP Measurements
223635081|NCT04690660|OTHER|Home-based blood pressure management (substudy)|Subjects participating in home-based blood pressure management via telemonitoring will receive a free HekaHealth application (App) for the structured assessment of HBPM.
223635082|NCT04690660|OTHER|Biomarker Profiles (substudy)|Substudy where possible cardiac, renal and pregnancy related biomarkers will be additionally analyzed. The following biomarkers will be analyzed: N terminal (NT)-proBNP, Troponin, elevated mid-regional pro-atrial natriuretic peptide (ANP), elevated mid-regional pro adrenomedullin (ADM), soluble fms-like tyrosine kinase (sFlt-1), and placenta growth factor (PlGF).
223635083|NCT04690660|OTHER|Data collection on patient reported outcomes|Data collection on patient reported outcomes (Questionnaire EQ-5D, Questionnaire for App based monitoring )
223635084|NCT06553703|OTHER|Acceptance and commitment therapy based group psychoeducation|Acceptance and commitment therapy-based group psychoeducation aimed at increasing nursing students' psychological flexibility and reducing their somatic symptoms.
223635085|NCT04138940|BEHAVIORAL|Script Training|Participant uses a computer program to practice scripts with a virtual therapist.
224223747|NCT04871217|DIAGNOSTIC_TEST|68Ga-NODAGA-RGD PET-imaging|Patients will undergo cardiac 68Ga-NODAGA-RGD PET in order to detect myocardial αVβ3 integrin expression 3-14 days after an acute myocardial infarction or within 4 weeks before and 2 weeks after re-opening of chronic coronary occlusion. Echocardiography of cardiac function will be performed at the time of PET imaging and repeated 6 months later.
224223748|NCT01831063|BEHAVIORAL|Simulation|The experimental group received a simulation based seizure teaching session in addition to the traditional seizure teaching
224223749|NCT01578707|DRUG|ofatumumab|"The ofatumumab (IV) dosage and schedule is 12 doses administered over 24 weeks or until disease progression, unacceptable toxicity.~Week 1: 300 mg initial dose Week 2 through 8: 2,000 mg (once weekly) Week 12, 16, 20 and 24: 2,000 mg (every 4 weeks)"
224223750|NCT01578707|DRUG|ibrutinib|ibrutinib 420 mg (3 x 140-mg capsules) will be administered orally once daily until disease progression or unacceptable toxicity
224223751|NCT04887883|BEHAVIORAL|Resistance exercise|Participants performed 8 weeks of resistance training and muscle biopsies were taken before and 24 h before and after the program.
224223752|NCT00719381|DRUG|Pioglitazone|Treatment of pioglitazone will consist of 15 mg once daily for 28 days followed by 30 mg once daily for 28 days (N=12)
224223753|NCT02587702|OTHER|β-Palmitate Content|
224223754|NCT02587702|OTHER|Placebo|
224223755|NCT02587702|OTHER|β-Palmitate Content Naturely in Human Milk|
224223756|NCT01799590|DRUG|Topiramate|Topiramate tablets will be administered orally in the dose range of 50 to100 milligram per day (mg/day). Dose will be increased or decreased as per Investigator's discretion. Maximum daily dose limit will be 200 mg.
224223757|NCT05865509|OTHER|Escape room|Students were given training on stress response using the escape room method.
224223758|NCT05865509|OTHER|Storytelling|Students were given training on stress response using the storytelling method.
224223759|NCT04299997|OTHER|Assessment of the accuracy of the PI-RADS v2.1 score for predicting the presence of ISUP ≥2 prostate cancer at subsequent biopsy in the dataset of the 171 MRIs for 21 different readers.|"1. Ass of targeted suspect lesions~   On each mpMRI,radiologist will contour lesions that were targeted at subsequent biopsy based on reports. Contours will be disclosed to readers who will assess,for each lesion:~  * Likert score(gut feelingie subjective ass of the likelihood that lesion is clinically significant prostate cancer(5-level scale))~  * PI-RADSv2, PI-RADSv2.1 score(by strictly applying the published PI-RADS criteria)~  * EPE score(ie the likelihood of extraprostatic extension;5-level subjective scale without predefined criteria)~  * Max diameter~2. Def of add suspect lesions Readers could define suspectadditional targets(AT);for each AT,they will provide the same criteria. It is expected that, for these suspect AT,at least one score is≥3~3. Ass of lobes Scores of prostate lobes will be automatically calculated based on 2 previous steps of reading. However,in lobes with no suspect lesion,readers could define whether same criteria are1or2,in peripheral zone and transition zone"
224318556|NCT00323050|BIOLOGICAL|Haemophilus influenzae type b- and meningococcal (vaccine)|
224318557|NCT02228850|DRUG|Alprostadil|
224318558|NCT02228850|OTHER|Placebo|
224318559|NCT03633825|BEHAVIORAL|Brief help-seeking barrier reduction intervention|The BRI was designed to overcome common concerns and misconceptions (i.e., barriers) related to using crisis services. It works by first asking the user about what potential barriers may keep them from using the crisis service referrals, and then, based on the user's response, by providing information intended to help the user overcome the potential barrier(s) they selected. By exploring the menu of barriers, users could read brief messages designed to dispel common misconceptions or concerns related to each barrier. For example, a common concern among Koko users was that calls to lifelines invariably result in visits by the police or other emergency services. Users who feared this possibility could tap on the associated button and learn that active rescues such as these are extremely rare, and occur in less than one percent of all cases. Whenever possible, we used language throughout the intervention to help validate the experiences of the users.
223635086|NCT03165617|BIOLOGICAL|QIVc|Cell-derived Quadrivalent Influenza Vaccine for intramuscular use containing each of the 2 influenza type A strains and each of the 2 influenza type B strains
223635087|NCT03165617|BIOLOGICAL|Non-influenza Comparator Vaccine|Non-influenza comparator vaccine for intramuscular use
223635088|NCT03435250|DRUG|AG-270|AG-270, orally, once or twice daily, on Days 1 through 28 of each 28-day cycle, until disease progression or unacceptable toxicity.
223635089|NCT03435250|DRUG|AG-270|AG-270, orally, once or twice daily, for 1 week prior to the first dose of docetaxel. Thereafter, AG-270 continues to be given daily, on Days 1 through 21 of each 21-day cycle, until disease progression or unacceptable toxicity.
223635090|NCT03435250|DRUG|AG-270|AG-270, orally, once or twice daily for 1 week prior to the first doses of nab-paclitaxel and gemcitabine. Thereafter, AG-270 continues to be given daily on Days 1 through 28 of each 28-day cycle, until disease progression or unacceptable toxicity.
223635091|NCT03435250|DRUG|docetaxel|Docetaxel, IV, once during each 21-day cycle, until disease progression or unacceptable toxicity.
223635092|NCT03435250|DRUG|nab-paclitaxel|Nab-paclitaxel, IV, on Days 1, 8, and 15 of each 28-day cycle, until disease progression or unacceptable toxicity.
223635093|NCT03435250|DRUG|gemcitabine|Gemcitabine, IV, on Days 1, 8, and 15 of each 28-day cycle, until disease progression or unacceptable toxicity.
223635094|NCT02585856|DEVICE|PDT|"Patients with unresectable CCA are performed PDT with ERCP after porfimer sodium （chongqing ray high medical instrument co., LTD，Chongqing, China) i.v. at a dose of 2 mg/kg at 48 h.~PDT procedure: for light distribution, flexible cylindrical diffuser probes mounted on 400-mm quartz fibres with an active distal tip length of 2 cm （chongqing ray high medical instrument co., LTD，Chongqing, China) is used. The light source was a diode laser system with a maximum power output of 2 Wand a wavelength of 633.3 nm. The power emitted by the diffuser tip was calibrated to 400 mW/cm before PDT was administered using an integrating sphere power meter. The mean irradiation time was 452 s (range: 400-600 s), using a power density of 300-400 mW/cm and an energy dose of 180-200 J/cm (of diffuser length)."
223635095|NCT02585856|DEVICE|stent|Patients with unresectable CCA are performed with ERCP, one or several plastic biliary stents (Boston Scientific Corporation, MA,USA) are inserted to ensure adequate decompression and bile drainage.
223635096|NCT03635281|PROCEDURE|Recruitment manoeuvers|"Recruitment manoeuvers will be performed as follow Recruitment manoeuvers~1. set FIO2 at 1.0~2. Ppeak limit at 45 cmH2O~3. Respiratory rate set at 6~4. I:E set at 1:1~5. Raise the VT at step of 2 ml/kg PBW until the Pplat is between 30-40 cmH2O~6. If the maximum VT is set without rasing the Pplat, raise PEEP~7. Allow three respiratory cycles with Pplat between 30 and 40 cmH2O~8. End of RM~The recruitment manouvers will be performed after 20 minutes of OLV. At the end of the RM, the VT will be set back to 5 ml/kg while the PEEP will be chosen according to the best static compliance with a decremental trial (from 16 cmH2O, lowering PEEP with steps of 2 cmH2O each until the best compliance is reached)."
223635097|NCT03635281|PROCEDURE|incremental PEEP|In this group the a PEEP level will be added after 20 minutes from OLV. PEEP values will be chosen according to the best static compliance with an incremental trial (i.e. starting from ZEEP, the PEEP values will be increased in step of 2 cmH2O each until the best compliance is reached
223635098|NCT04963010|DIAGNOSTIC_TEST|second forward view|second forward view examination of the proximal colon
223635099|NCT06035159|BEHAVIORAL|online psychotherapy|6 modules
223635100|NCT03316924|PROCEDURE|Foreskin resection|During the pediatric surgery consultation, the doctor will decide between Foreskin resection, orchidopexie or inguinal hernia repair.
223635101|NCT04848298|BEHAVIORAL|mHealth Intervention|"The Mobile Health Arm will receive standard of care including tailored prescription of physical activity as well as the mobile health intervention, which will have the following features:~* Goal setting for frequency and duration of exercise sessions~* Graphic feedback and reinforcement with educational and motivational messages tailored to user's exercise adherence.~* Problem-solving support~* Library with educational tips and information regarding physical exercise."
223635102|NCT06560489|DRUG|Subjects will be randomly assigned to receive 1.25 mg, 2.5 mg, 5 mg, or 10 mg of LP-98.|This study consisted of 4 cohorts with 10 subjects in each group, who were randomly assigned to receive LP-98 treatment of 1.25 mg, 2.5 mg, 5 mg, and 10 mg. The method of administration was subcutaneous injection, and the interval of administration was 14 days, a total of 4 doses.
223635103|NCT06513871|BEHAVIORAL|Social perception tasks|social perception tasks
223635104|NCT06629376|DRUG|Pegylated Recombinant Candida Utilis Uricase for Injection|According to the dosage requirements of each experimental group, intravenous infusion should be administered for at least 2 hours each time
223764749|NCT06559995|DIAGNOSTIC_TEST|magnetic resonance imaging session|1.5 hour magnetic resonance imaging session
223635105|NCT05557916|OTHER|Standard rehab|Standard rehab protocol including knee orthosis following meniscal repair
223635106|NCT05557916|OTHER|accelerated rehab group|accelerated rehab group, no orthosis
223635107|NCT04819126|OTHER|Nintendo Wii Virtual Reality Application|The training group was trained with games from different categories such as balance and aerobic exercises with a Nintendo Wii virtual reality device 2 times a week for a period of 6 weeks, with 1 session lasting for 30 minutes.
223764750|NCT06559995|DIETARY_SUPPLEMENT|Placebo beverage|Placebo beverage, visually matched, three times a day before meals, by mouth for 4 days plus 1 dose on day 5 for magnetic resonance imaging session visit.
223764751|NCT02102256|DEVICE|Auditory Brainstem Implant|
223635108|NCT02698215|DRUG|Varenicline|Varenicline 1 mg twice daily
223635109|NCT02698215|DRUG|Varenicline plus Naltrexone|Varenicline 1 mg twice daily plus Naltrexone 50 mg once daily
223635110|NCT04971746|DRUG|Pirfenidone|On Days 1 and 13, participants will receive an oral dose of pirfenidone.
223635111|NCT04971746|DRUG|GLPG4716|From Day 3 to Day 14, participants will receive GLPG4716 daily.
223635112|NCT04971746|DRUG|Nintedanib|On Days 1 and 13, participants will receive an oral dose of nintedanib.
223635113|NCT06261320|DRUG|Mesotherapy with mesocaine, thiocolchicoside, amitriptyline, magnesium pidolate|4 sessions of mesotherapy (mesocaine, thiocolchicoside, amitriptyline, magnesium pidolate), with intra-epidermal and intra-hypodermal technics.
223635114|NCT04393935|BEHAVIORAL|Pharmacy Delivered PrEP Intervention|Pharmacy client participants who are eligible and agree to the HIV test will be provided with a pre-packaged kit of a self-administered test for HIV and directed back to the private area of the pharmacy to perform their screening. Pharmacy client participants who test HIV negative will be provided with their results and be given a 30-day prescription for PrEP, culturally appropriate PrEP counseling and a follow-up appointment with a PrEP prescribing physician. Pharmacy client participants will be contacted after 3 months to determine whether they continued PrEP use.
223635115|NCT05542641|DEVICE|repetitive transcranial magnetic stimulation (rTMS)|real versus sham rTMS
223635116|NCT05179135|OTHER|Postprandial exercise of different modalities|Physical exercise performed 60 minutes after a standardized meal, of different modalities (4 different modalities will be examined, as described in the Arms)
223635117|NCT01210313|OTHER|Physical exercise|Defined exercise program
223635118|NCT03501082|OTHER|L Reuteri PB-W1 Strain|L. Reuteri PB-W1 strain will be prepared in accordance to the standardized operating procedures to prepare Limosilactobacillus reuteri in food grade conditions
223635119|NCT03501082|OTHER|L. Reuteri DSM20016T Strain|L. Reuteri DSM20016T strain will be prepared in accordance to the standardized operating procedures to prepare Limosilactobacillus reuteri in food grade conditions
224223760|NCT04277611|PROCEDURE|Subcostal Oblique Quadratus Lumborum Block and Erector Spinae Plain Block.|patients undergo general anesthesia,will be put in prone position.In case of Quadratus Lumborum block 1-3 mL of normal saline is injected to produce hydro-dissection and spread cranially between the QL and kidney. The corresponding ultrasonographic sign is a lunar-shaped hypo-echoic fluid collection observed between the long axis of the kidney and QL muscle. 20 ml Bupivacaine 0.5%, 10 ml Lidocaine 2%, and 10 ml normal saline is administered. In case of the ESPB The location of the needle tip is confirmed by hydro-dissection and after visualizing the fluid spread lifting the Erector Spinae off the transverse process, 20 ml bupivacaine 0.5%, 10 ml Lidocaine 2%, and 10 ml normal saline is injected.
223635120|NCT03501082|OTHER|Placebo|2 g of maltodextrin will be dissolved in 50 ml water in food grade conditions
223635121|NCT03501082|OTHER|Non-Industrialized-Type Diet|Non-industrialized-type diet will be prepared in a metabolic kitchen, with all meals and snacks provided to participants for three weeks.
223635122|NCT03193840|PROCEDURE|posterior wall osteotomy|posterior wall osteotomy is conducted through Kocher-Langenbeck approach.
224223761|NCT02231190|DRUG|GSK1278863|GSK1278863 will be supplied as oral tablet of strength 100mg, 5mg(5mg if a low dose is elected for subjects enrolled after interim analysis) to be administered with 240 mL of water after end of eccentric exercise
224223762|NCT02231190|DRUG|Placebo|GSK1278863 matching placebo will be supplied as oral tablets for administration with 240 mL of water after end of eccentric exercise
224223763|NCT05819567|DEVICE|Newly Developed Ankle Brace|The ankle brace is made of gripping tissue and includes two straps and one latex wedge. The purpose of this brace is to lift up the plantar arch.
224223764|NCT00352495|DRUG|carboplatin|
224223765|NCT00352495|DRUG|vinblastine sulfate|
224223766|NCT02320279|DEVICE|Fetal Heart Rate Monitor|Use of a system that monitors fetal heart rate through use of fetal EKG read using abdominal electrodes
224223767|NCT01489956|BIOLOGICAL|Immucothel Alone (Part A)|100 ug at day 0 (priming dose) and day 9(booster dose)
223635123|NCT02958995|OTHER|No Intervention|
223635124|NCT00355108|DRUG|tranexamic acid|2 3-month-periods in cross-over: placebo or 3g/day of tranexamic acid
223635125|NCT01488604|DEVICE|Polymeric Nasal Spray|Experimental nasal spray
223635126|NCT01488604|DEVICE|Sham Nasal Spray|Sham nasal spray
223635127|NCT01338441|DRUG|Erythromycin|4mg/Kg, IV during 20 min once
223635128|NCT01338441|DRUG|Placebo|4mg/Kg, IV during 20 min once
223635129|NCT05620667|DIETARY_SUPPLEMENT|immature ponkan (Citrus reticulate) extract|Drink 25mL for once, and once a day.
224223768|NCT01489956|BIOLOGICAL|Immucothel+Montanide (Part A)|100 ug SQ Immucothel plus Montanide at day 0 (priming dose) and day 9 (booster dose)
224223769|NCT01489956|BIOLOGICAL|Immucothel Alone or Immucothel+Montanide (Part B)|50 mg of native KLH on days 0-4 and 10-14 (total of 500 mg). Immunization on days 26 and 35.
223635130|NCT05620667|DIETARY_SUPPLEMENT|placebo|Drink 25mL for once, and once a day.
223635131|NCT05620667|BEHAVIORAL|time restricted feeding|Controlling a shortened period of time for eating within 8 hour each day.
224223770|NCT03502629|BIOLOGICAL|GB226|3mg/kg treat every 2 weeks
224223771|NCT02162329|BEHAVIORAL|Questionnaires|"Participants fill out several questionnaires asking questions about memory and concentration, mood, fatigue, how they have been feeling, and general quality of life. The questionnaires should take about 30 minutes to complete.~Meditation Group and Wait-List Group also complete questionnaires at follow up visit."
223635132|NCT04006288|DRUG|Clopidogrel|Patients on aspirin and plavix will be randomized to either continue with aspirin and plavix or to switch to aspirin and rivaroxaban
223635133|NCT04006288|DRUG|Prasugrel|Patients on aspirin and prasugrel will be randomized to either continue with aspirin and prasugrel or to switch to aspirin and rivaroxaban
223635134|NCT04006288|DRUG|ticagrelor|Patients on aspirin and ticagrelor will be randomized to either continue with aspirin and ticagrelor or to switch to aspirin and rivaroxaban
223635135|NCT04006288|DRUG|aspirin|all patients will remain on aspirin
223635136|NCT04006288|DRUG|rivaroxaban|Patients on DAPT will be randomized to either continue with DAPT or to switch to aspirin and rivaroxaban
223635137|NCT01796145|OTHER|Fibroscan|
224223772|NCT02162329|PROCEDURE|Electroencephalography (EEG)|"Meditation Group and Wait-List Group: Electroencephalography (EEG) performed at baseline and at follow up visit. During EEG, 3 tests to check attention, short-term memory, and levels of emotions.~Healthy Control Group: Electroencephalography (EEG) performed at study visit. During EEG, 3 tests to check attention, short-term memory, and levels of emotions."
224223773|NCT02162329|PROCEDURE|Magnetic Resonance Imaging (fMRI|"Healthy Control Group: Magnetic resonance imaging (fMRI) scan performed.~Meditation Group and Wait-List Group: Magnetic resonance imaging (fMRI) scan of brain performed at baseline and at follow up visit."
224223774|NCT02162329|BEHAVIORAL|Meditation Classes|Participants take part in up to 16 meditation classes for a total of 8 weeks. All sessions videotaped.
224223775|NCT02383147|DEVICE|Tomographic Neurofeedback|EEG-Electrodes are placed on the patients head to record the brain activity, EEG-recordings are processed by the standardized Low Resolution Brain Electromagnetic Tomography algorithm (sLORETA) to calculate the frequency spectrum in the auditory cortex and deliver feedback for the patient
224223776|NCT02383147|DEVICE|Non Tomographic Neurofeedback|EEG-electrodes are placed on the patients head, but only 4 electrodes (Fc1, Fc2, F3 and F4 of a 10-10 EEG-system) record the surface activity and generate the feedback for the patient.
224223777|NCT01174056|DRUG|Zileuton|600 mg tablets po QID for 5 days prior to endotoxin, stopping 24 hours after endotoxin instillation
224223778|NCT01174056|DRUG|Pioglitazone placebo|Lactose filled gelatin capsule, size 00, 1 tablet po bid x 2 weeks prior to endotoxin instillation until 24 hours after endotoxin.
224223779|NCT01174056|DRUG|Zileuton placebo|Placebo tablets provided by manufacturer of Zyflo CR (Cornerstone Therapeutics), 2 tablets po bid x 5 days prior to endotoxin instillation until 24 hours after endotoxin.
224223780|NCT01174056|DRUG|Pioglitazone|PPAR-gamma agonist
224223781|NCT06483607|OTHER|M-TAPA block with bupivacaine 25%|Following sterile conditions for bilateral M-TAPA block application, the transducer will be inserted on the chondrium in the sagittal plane at the 9-10th rib level. Subsequently, a deep angle will be created with the probe for visualization of the underside of the costochondrium. The sonovisible needle tip will be placed just below the chondrium and saline (5 ml) will be injected for site confirmation. After the confirmation, 20 ml of 0.25% bupivacaine will be administered for each group for a total of 40 ml of local anesthetic. Blocks will be applied using an 80 mm sonovisible needle with a 6-10 MHz linear probe under the guidance of a portable ultrasound. M-TAPA block with the same standard technique and drug dose will be applied to the contralateral side for each group of M-TAPA patients.
224223782|NCT06483607|OTHER|TAP block with bupivacaine 25%|After the necessary sterilization conditions established, the linear ultrasound probe will be placed in the middle of the iliac crest with the end limit of the ribs. Starting with skin, the layers in descending order, subcutaneous adipose tissue, external oblique muscle, internal oblique muscle, transversus abdominis muscle, and peritoneum will be identified. As the tip of the 80 mm sonovisible needle passes through the muscular layers and fascia, the needle will be advanced in a controlled manner. After receiving the click sensation (passage of the fascia of the internal oblique muscle), the location of the needle will be fixed and 20 ml of 0.25% bupivacaine will be injected between internal oblique and transversus abdominis muscles. Same procedure will be performed to the other site. (40 ml local anesthetics in total)
224223783|NCT03777475|PROCEDURE|transarterial infusion|transarterial infusion
224318560|NCT05973968|DRUG|Surufatinib|Taking 28 days as a treatment cycle, the tumor was evaluated by imaging method every 8 weeks (±7 days) in the first 52 weeks, and then every 12 weeks (±7 days) until the disease progression (RECIST1.1) or death (during the treatment of the patient). The treatment and survival status of the tumor after disease progression were recorded.
223635138|NCT01710345|DRUG|Sufentanil NanoTab 20 mcg|
223635139|NCT01710345|DRUG|Sufentanil NanoTab 30 mcg|
223764752|NCT04519528|OTHER|DENVER scale (under 2 years old) or Pediatric Cerebral Performance Category (PCPC) score (over 2 years old)|"The DENVER II is a measure of developmental problems in young children. It was designed to assess child performance on various age-appropriate tasks and compares a given child's performance to the performance of other children the same age. The instrument consists of 125 tasks, which broadly reflect the following areas: personal-social, fine motor-adaptive, language, and gross motor.~The target population corresponds to infants and pre-school age children.~The POPC and PCPC are global scales based on observer impressions. Scores include 1 for good, 2 for mild disability, 3 for moderate disability, 4 for severe disability, and 5 for vegetative state or coma (6 indicates death)."
223773668|NCT06593704|OTHER|PROSPERA-program|"The PROSPERA-program consists of the following components:~1. Health care provider training and education about U-Prevent and cardiovascular risk communication.~2. Risk stratification: proactive selection of cardiovascular patients through the PROSPERA-empanelment procedure - for the population with increased cardiovascular risk, prior to consultation.~3. Decision support tools: use of the Lifestylecheck and the U-Prevent clinical decision support tool to guide motivated shared decision making towards appropriate care matched to the care complexity of the patient - for the individual patient, during consultation."
224223784|NCT02236533|DIETARY_SUPPLEMENT|whole grain pasta|Volunteers were fed with probiotic fortified pasta or control pasta once a day for 12 weeks.
224318561|NCT01938495|DEVICE|NeuRx® Diaphragm Pacing System™ (DPS)|The NeuRx® Diaphragm Pacing System™ (DPS) is a four channel, implanted percutaneous diaphragm muscle stimulation system. Pictures of the device are provided in the Clinician's Manual for the NeuRx® DPS procedure and technique guide from the manufacture Synapse Biomedical, Inc. Under general anesthesia, the intramuscular electrodes are laparoscopically implanted in the diaphragm. The ends of the implanted electrodes are tunneled subcutaneously to an exit site on the chest or abdominal wall and connected to an external stimulator.
223635140|NCT01710345|DRUG|Placebo NanoTab|
223635141|NCT01650506|DRUG|Metformin|Due to frequent GI upset in patients starting metformin the dose will be titrated up to the assigned dose level. The first metformin dose level will be 850 mg twice daily and be escalated to its maximum FDA approved dose of 850 mg three times daily. Dose escalation will follow the standard 3 + 3 design. Dose limiting toxicities will be determined during the first 5 weeks of therapy.
223635142|NCT01650506|DRUG|Erlotinib|Erlotinib dosing will start and remain at 150 mg daily.
223635143|NCT04475081|BIOLOGICAL|MMR vaccine|Merck MMR-II vaccine
223635144|NCT01766440|DRUG|Calcitriol 3 mcg/g ointment|Topical ointment; twice daily application
223635145|NCT03563339|BEHAVIORAL|P-POD|. P-POD will include seven 30-minute online, educational, interactive modules that teach at-risk pregnant women skills derived from the gold standard, empirically supported cognitive-behavioral treatment for anxiety disorders and OCD. Additionally, P-POD will include three modules for fathers, to help them support their partners during the postpartum period. We will modify P-POD from an already existing in-person prevention program for postpartum OCD (developed by Co-Investigator Kiara Timpano). The m-health foundation of P-POD will be an already existing Internet-delivered treatment infrastructure (OurRelationship.com, developed by Co-Investigator Brian Doss).
223635146|NCT05062785|DRUG|Intranasal insulin|"This will be given intranasally at differing doses depending on study day. A total of 11 possible doses will be tested, ranging from 0 to 1000 U insulin. Each volunteer will come for 5 visits.~On the first treatment day participants will receive placebo (sterile water) in each nostril followed by a 4-hour observation period. After this observation period participants will receive the initial dose of insulin squirted in each nostril followed by a a 4 hour observation period. Participants will have at least 7 days in between the other 4 visits. Subsequent visits will include increased doses of insulin (depending on how this is tolerated) and will take approximately 4 hours at these visits."
223635147|NCT05996575|OTHER|fNIRS measurement|Kernel Flow2 measurements.
223635148|NCT04554784|OTHER|Conventional|Patients' condition will be continue managed by pain specialists with regular follow-ups and continue patients' active concurrent pain treatment such as taking analgesics, physiotherapy, massage, chiropractor.
223635149|NCT04554784|PROCEDURE|Bowen|"Patients will be referred to Occupational therapist for Bowen Therapy. There will be a week washout period before the start of Bowen Therapy. During a week washout period and study period, patients can continue taking analgesia, but advised to stop the concurrent treatments which can affect the deep tissue such as massage, physiotherapy, and chiropractic to minimize the counteracting effect on the Bowen's action.~During a Bowen Therapy session, patients will lie relaxed on the examination couch wearing loosely fitting clothing or only the affected area being exposed. The therapist applies a series of gentle movements across the body. The gentle movements focus on a body of muscle, tendon or nerve and release tension through the nerve within the area. Each session will last for 30 minutes to an hour. After each session, the next appointment will be given to patients. The first four sessions will be scheduled on weekly basis, and the remaining four on biweekly session."
223635150|NCT05491265|BEHAVIORAL|Intermittent Kangaroo mother care|Skin to skin contact between mother and preterm newborn between gestational age 28 weeks to 36+6 weeks for three sessions per day ,each contact session of two hours .
223635151|NCT04298697|DRUG|Tenofovir disoproxil fumarate/emtricitabine (TDF/FTC)|TDF/FTC is a combination anti-HIV medication that contains the drugs tenofovir disoproxil fumarate (300 mg) and emtricitabine (200 mg). Participants will take 2 pills on the first day of the week and one pill per day on the second and third days of the week, according to the dosing schedule of the study arm they are in. Participants will have biologic specimens collected at specific time points until 28 days after the last dose.
223635152|NCT00449696|DEVICE|Gel-200|Single intra-articular injection
224223785|NCT00730522|DRUG|CPP-109 vigabatrin|tablets, bid for 12 weeks
224223786|NCT00730522|DRUG|Matching Placebo|tablets, bid, 12 weeks
224318562|NCT04102917|DIAGNOSTIC_TEST|QFR assessment|The quantitative flow ratio (QFR) is a novel angiography-based method for noninvasive functional assessment of intermediate coronary lesions.
223635153|NCT00449696|DEVICE|Placebo|Single intra-articular injection
223635154|NCT00057200|PROCEDURE|Telephone, videophone care|
223635155|NCT01392144|PROCEDURE|Nitric oxide breath test|Breathe out into a device (nitric oxide breath analyzer) for 10 seconds; repeated 3 times. Done prior to start of radiation therapy, 1 week before completion of radiation therapy, at completion of radiation therapy, then at each follow-up visit for 6 months.
224223787|NCT02775968|DRUG|Cephalosporins and Macrolide Antibiotics|The intervention drugs are prescribed by treating caregiver.
224223788|NCT03341507|DEVICE|classical laryngoscopy|the laryngoscopy with the McIntosh laryngoscope performed prior the use of rigid tube and the Cormack-Lehane glottis visualisation noted.
224223789|NCT03341507|DEVICE|rigid tube for laryngoscopy|the view of glottis achieved with the rigid tub for laryngoscopy and tracheal intubation with an elastic gum bougie performed
224318563|NCT04151680|DRUG|Intermittent administration of dabigatran, rivaroxaban, apixaban, or edoxaban|Patients will receive intermittent treatment with a novel oral anticoagulant drug
223635156|NCT01392144|BEHAVIORAL|Questionnaires|On day of each breathing test, completion of a breathing and symptom questionnaire, approximately 10 minutes.
223635157|NCT05075265|DRUG|Methadone|Standard dose of 0.2 ug/kg before Cardiopulmonary Bypass.
223635158|NCT01707342|DRUG|Simeprevir (TMC435)|Treatment A: Simeprevir (TMC435) 50 mg; and Treatment B: Simeprevir (TMC435) 150 mg; will be followed 5 hours later by a single 10 minute intravenous infusion of \[3H\]-TMC435 (100 microcurie) 100 microgram in Period 1 and Period 2, respectively.
223635159|NCT04638088|OTHER|assessment of urinary function and erectil function before and after prostatectomy|assessment of urinary function and erectil function before and after prostatectomy performed by robot assisted or conventional laparoscopy or laparotomy will complete
223635160|NCT02543684|OTHER|ready to eat mixed meal 1|wild greens pie providing 50g of carbohydrates
223635161|NCT02543684|OTHER|ready to eat mixed meal 2|chicken burgers with boiled broccoli and cauliflower providing 50g of carbohydrates
223635162|NCT02543684|OTHER|ready to eat mixed meal 3|vegetable moussaka providing 50g of carbohydrates
223635163|NCT02543684|OTHER|oral glucose load|glucose load providing 50g of carbohydrates
223635164|NCT00927108|OTHER|Progenitor Stem Cell Culture|
223635165|NCT00274586|DRUG|Aggrenox® modified release capsules|
223635166|NCT00274586|DRUG|Aggrenox® modified release capsules matching placebo|
223635167|NCT04263623|DRUG|Dexmecamylamine HCl|Investigational drug
223635168|NCT04263623|OTHER|Placebo|Oral tablet containing no active drug.
223635169|NCT01054014|DRUG|JNJ-40346527/Placebo|Single oral dose of JNJ-40346527 (either 10, 50, 150, 300, 600, or 1000mg) or Placebo
223635170|NCT01054014|DRUG|JNJ-40346527/Placebo|JNJ-40346527 once daily oral dose for 14 days (either 50, 150, 300, 500 or 750mg) or Placebo
223635171|NCT01054014|DRUG|JNJ-40346527|JNJ-40346527 150mg one dose, either fasting (or with food), then after 7 days off treatment, JNJ-40346527 150mg either with food (or fasting)
223635172|NCT02474316|DRUG|Peginterferon alfa-2a|Peginterferon alfa-2a 180ug/wk s.c for 48 weeks
223635173|NCT02474316|DRUG|nucleos(t)ide analgoue|nucleos(t)ide analgoue (NA) 1 piece p.o for 48 weeks
223635174|NCT03773640|DEVICE|Radio frequency currents|Study group (I) consist of patients who were treated with the occlusal splints and radio frequency currents. In the case of application of radiation to the muscle area, the energy was 20 J and 15 J to the area of the masticatory muscles, the frequency was 3 MHz, bipolar technique, the duration of the procedure was 10 minutes, the coupling substance was a gel for ultrasound examinations.
223764753|NCT04519528|OTHER|Pediatric Quality of Life Inventory™ (PedsQL)|"The PedsQL questionnaire is a modular approach to measuring health-related quality of life in healthy children and adolescents and those with acute and chronic health conditions. The PedsQL Measurement Model integrates seamlessly both generic core scales and disease-specific modules into one measurement system. Twenty-three items divided into different functional areas are evaluated: physical (8 items), emotional (5 items), social (5 items) and school (5 items over 4 years old; 3 items before 4 y.o).~Child self-report and parent proxy report formats of the questionnaire allows self-assessment of child over 5 years old and parents' evaluations. Items can be reverse and linearly transformed to a 0-100 scale (0=100, 1=75, 2=50, 3=25, 4=0) with higher scores indicating better quality of life."
224223790|NCT02927847|DRUG|Nicotine Patch|Both groups will receive nicotine patches (21 mg/d) to wear for 1 month prior to the quit date. After the quit date, both groups will wear the nicotine patch for 8 weeks (21 mg/d for 4 weeks, 14 mg/d for 2 weeks, and 7 mg/d for 2 weeks).
224223791|NCT02927847|DRUG|SPECTRUM Nicotine Research Cigarettes (.03 mg)|For 1 month prior to their quit date, participants will switch to smoking SPECTRUM Nicotine Research Cigarettes instead of their usual brand.
224223792|NCT02927847|BEHAVIORAL|Behavioral Activation|Participants in the BA+VLNC group will undergo 8 60-minute behavioral sessions (4 pre-quit, 1 on quit day, and 3 post-quit) including 15 min of standard smoking cessation counseling and 45 minutes of behavioral activation treatment. BA components will include activity monitoring, values assessment, activity scheduling, and social contracts.
224223793|NCT02927847|BEHAVIORAL|Supportive Counseling|Participants in the VLNC Only group will undergo 8 60-minute behavioral sessions (4 pre-quit, 1 on quit day, and 3 post-quit) including 15 min of standard smoking cessation counseling and 45 minutes of supportive counseling and health education. Supportive counseling and health education will include empathic listening as well as informational content on topics of exercise, nutrition, sleep and relaxation.
224223794|NCT04138459|OTHER|Not an interventional study. This is a qualitative, explorative study of recovery orientation of community mental health services|"Explore recovery orientation of mental health services in a municipality through:~1. Qualitative, in-depth interviews with service users and mental health professionals and~2. Observational fieldwork"
224223795|NCT01501942|DRUG|AIM-102, D-cyclohexylalanine-D-glutamic-glycine tripeptide|AIM-102 is supplied as an oral solution. Dose is 15 mg of AIM-102 per kg of patient weight measured on Treatment Day 1 of each treatment phase The study drug will be administered for 4 consecutive days with at least a 2 week wash-out period prior to crossing over to the alternative treatment for 4 days.
224223796|NCT01501942|DRUG|Buffered Saline|The matching placebo is an oral solution of phosphate buffered saline
224223797|NCT00723554|DRUG|Iloprost PD-6|Period 1 (PD-6): study period defined as the 14 days prior to the first dose of study iloprost inhalation with PD-15. Commercial iloprost inhalation solution delivered using the Power Disc-6 with the I-neb® Adaptive Aerosol Delivery (AAD®) system administered 6 to 9 times per day
223635175|NCT03773640|DRUG|Sonophoresis|The control group ( II) consisted of 20 patients treated with occlusion splints and sonophoresis procedures. For the area of mastication muscles 0.9 W/cm² treatments were applied, the duty factor was 80%, the treatment time was 10 minutes, and the medical substance was 25%Voltaren gel.
223635176|NCT05459363|OTHER|I-THINC|Improved Training Happens with Integrated Neuromuscular and Cognitive Challenge (I-THINC) is an injury prevention program. It will be used to integrate cognitive tasks with traditional sports injury prevention approaches that focus on balance, agility, and neuromuscular control.
223635177|NCT05188859|DRUG|Sintilimab+Anlotinib+Pemetrexed+Cisplatin|Sintilimab 200mg+Anlotinib 12mg+Pemetrexed 500mg/m²+Cisplatin 75mg/m2
223764754|NCT06288867|PROCEDURE|Arthroscopic Labral Repair|Patients with Hip Labral tears will be treated with labral repair
223764755|NCT06288867|PROCEDURE|Arthroscopic Labral Debridement|Patients with Hip Labral tears will be treated with labral debridement
224223798|NCT00723554|DRUG|Iloprost PD-15|"Period 2 (PD-15): study period between the administration of the first dose with PD-15 on Day 1 until Day 28 inclusive.~Period 3 (PD-15): study period from Day 29 until discontinuation of the PD-15. Commercial iloprost inhalation solution delivered using the Power Disc-15 with the I-neb® Adaptive Aerosol Delivery (AAD®) system administered 6 to 9 times per day"
224223799|NCT00672022|DRUG|Zavesca (Miglustat)|
224223800|NCT00698178|OTHER|Anthropometric measurements|All patients undergo anthropometric measurements to record body weight, body height and waist circumference on the day of enrollment
224223801|NCT00593138|DRUG|dex-methylphenidate|The drug is administered as a capsule by mouth. Participants are assigned to receive either 20, 30 or 40 mg doses before each scan visit.
224223802|NCT00938652|DRUG|gemcitabine/carboplatin|"Gemcitabine 1000 mg/m2 intravenous infusion (30 ± 10 minutes)~Carboplatin AUC 2 intravenous infusion (30 ± 10 minutes or 60 ± 10 minutes)"
224223803|NCT00938652|DRUG|Iniparib|"Body weight adjusted dose~intravenous infusion (60 ± 10 minutes)"
224223804|NCT05106933|OTHER|Plain water|Measure gastric residual volume during upper endoscopic, after given plain water and carborie 2 hours prior upper endoscopy
224223805|NCT05106933|OTHER|Carborie|carbohydrate drink
224223806|NCT04787406|DEVICE|Transcranial direct current stimulation|"Transcranial electrical stimulation device. A weak direct electrical current, up to 2 mA, is passed between two electrodes placed on the scalp. Electrodes are housed in 35 cm2 sponges saturated with 4 ml of saline solution (0.9 % NaCl) per side, per pad.~Stimulation is phased in with a 30 second ramp up period prior to the specified stimulation period and phased-out with a ramp down of the current following the specified stimulation period. For sham stimulation, the ramp-up and ramp-down periods are retained, but stimulation is switched off for during the specified stimulation period."
224318564|NCT04151680|DRUG|Chronic administration of dabigatran, rivaroxaban, apixaban, or edoxaban|Patients will receive chronic treatment with a novel oral anticoagulant drug
223635178|NCT00740038|BEHAVIORAL|Stress Management training|Self-administered stress management training comprising 10 minute introduction by staff, \& provision of DVD, CD,brochure, and workbook. Materials provide overview of sources of stress during chemotherapy, and instruction in cognitive-behavioral stress management techniques (paced abdominal breathing, progressive muscle relaxation with guided imagery, and use of coping self-statements). Daily use is encouraged over 13-14 weeks of the study.
223635179|NCT00740038|BEHAVIORAL|Exercise Training|Home-based exercise (walking) program: brief introduction by staff (10 minutes) and provision of packet with DVD, brochure, workbook, pedometer (electronic step counter) along with instructions on initiating and maintaining a walking program. Dose Recommendations: 3-5 exercise session per week for at least 20-30 minutes at maximum intensity of 50 to 75% of their estimated heart rate reserve (RPE of 11-13) which is calculated based on their age and resting pulse.
223635180|NCT00740038|BEHAVIORAL|Usual care|Usual psychosocial care and provision of NCI booklet, Chemotherapy and You (NCI, 1999) which gives general feedback about fitness testing, exercise and stress management during chemotherapy. Recommended to read booklet at least once.
224223807|NCT01664195|DRUG|Epoetin Alfa|Intravenous single-dose administration of 100 IU/kg of the test drug (Eritromax) in the first period and intravenous single-dose administration of 100 IU/kg of the comparator drug (Eprex) in the second period, after 23-30 days of washout, or vice-versa.
224223808|NCT01319682|DRUG|Intravenous lidocaine injection|Patients in Group I (intravenous lidocaine injection group) received an intravenous bolus injection of 1.5 mg/kg lidocaine followed by a continuous lidocaine infusion of 2 mg/kg/hr.
224223809|NCT01319682|DRUG|Intravenous normal saline injection|The patients in Group C (placebo control group) received normal saline intravenous injection
224223810|NCT05124431|DRUG|Anlotinib hydrochloride|Anlotinib hydrochloride is a multi-target receptor tyrosine kinase inhibitor.
224223811|NCT05124431|DRUG|everolimus|5mg po，qd
224223812|NCT02038985|OTHER|Participants will receive ICG Dye|Participants will receive ICG Dye preoperatively for use in the Visual Diagnosis of Endometriosis
224223813|NCT03255031|OTHER|Ketogenic Diet (KD)|For each meal at breakfast, lunch and dinner, the diets will consist of ketogenic diet (KD) meal. Compliance tests are done twice a week with a blood test measuring ketone levels.
224223814|NCT03255031|OTHER|Standard American (SA) Meals and Shakes|For each meal at breakfast, lunch and dinner, the diets will consist of SA meal (carbohydrate rich) KD meal. Compliance tests are done twice a week with a blood test measuring ketone levels.
224223815|NCT01228396|DRUG|Hyperimmune caprine serum against HIV lysate|1.0ml solution for subcutaneous injection (4.5mg total protein / ml) twice weekly for 4 weeks
224223816|NCT03151499|DRUG|BI 409306|Reference and Test Treatment
224223817|NCT03151499|DRUG|Rifampicin|Test Treatment
224223818|NCT04448691|DIAGNOSTIC_TEST|CCTA|requested follow up CCTA
224223819|NCT01689974|DRUG|Ipilimumab|Ipilimumab will be administered alone on day 4, 25, 46 and 67.
224223820|NCT01689974|RADIATION|Radiation Therapy|Radiation is given over one week interval On the fourth day of radiation (day 4)Ipilimumab is administered and repeated on Days 25, 46 and 67.
224223821|NCT00229450|DRUG|Estrogen|0.625 mg/day of conjugated Estrogen
223635181|NCT00740038|BEHAVIORAL|Combined stress management and exercise training|Home-based, self-administered stress management and exercise (walking) program: brief introduction by staff and provision of DVD, CD, brochure, pedometer, workbook. Dose Recommendations: walking/exercise program (3-5 times per week for at least 20-30 minutes) and use of CD (progressive muscle relaxation with guided imagery) and coping statements once per day.
223764756|NCT03912753|BEHAVIORAL|Comunică|Comunică is based on the Information-Motivation-Behavioral Skills (IMB) model of health behavior change, which postulates that individuals must possess the requisite information for enacting sexual health, motivation to change their HIV risk and alcohol use, and behavioral skills necessary for reducing their risk. Therefore, Comunică includes MI to provide accurate information about HIV transmission, alcohol abuse, and local GBM-affirmative health resources and build motivation to improve behavioral skills (via CBST). CBST is a therapeutic approach used in the treatment of various behavioral problems, such as alcohol abuse and depression and more recently HIV risk. CBST can help modify cognitions driving unhealthy behaviors, promote awareness of contextual triggers and unhealthy behavioral patterns, and teach coping skills to improve health. Comunică also draws upon minority stress theory recognizing that stigmatizing societal contexts compromise health behavior.
224223822|NCT03334565|DEVICE|Low efficiency air filtration systems|Subjects were exposed to low-efficiency filtered air.
224223823|NCT03334565|DEVICE|High efficiency air filtration systems|Subjects were exposed to high-efficiency filtered air.
224223824|NCT03334565|DEVICE|Air filtration systems without filters (sham)|Subjects were exposed to unfiltered air.
224223825|NCT05228119|BIOLOGICAL|Oncolytic Virus Injection(RT-01)|Intravenous injection with or without intratumoral injection of a single dose of RT-01 and intravenous infusion of Nivolumab
224223826|NCT03563027|BEHAVIORAL|Social Incentive Gamification|Game-based intervention with points and levels
224223827|NCT03563027|BEHAVIORAL|Support Sponsor|Participants select a support sponsor to receive weekly updates on progress in the game
224223828|NCT03563027|BEHAVIORAL|Financial Incentive|Participants receive a loss-framed financial incentive allocated upfront each week and financial incentives taken away each day the goal is not met
224223829|NCT05360433|DRUG|Oxycodone oral capsule|Reduced initial prescription of oxycodone for postoperative pain management following cesarean section.
224223830|NCT00000452|DRUG|naltrexone (Revia)|
224223831|NCT00000452|BEHAVIORAL|Compliance Enhancement Tech.|
224223832|NCT00000452|BEHAVIORAL|Cognitive Behavior Therapy|
224223833|NCT00415532|DRUG|Medical Standard of Care for ITP|
224223834|NCT00415532|BIOLOGICAL|Romiplostim|
224223835|NCT00135642|BIOLOGICAL|Subcutaneous Alutard SQ grass pollen (Phleum pratense)|
224223836|NCT00135642|PROCEDURE|Venepuncture: 20 ml blood sample taken on 2 separate visits|
224223837|NCT04121000|PROCEDURE|VIDEO ASSISTED THOTACOSOPIC SURGERY|VATS
224223838|NCT04878406|DRUG|NNC0480-0389|A single dose of subcutaneous NNC0480-0389. The study will last for a maximum of 72 days.
224223839|NCT04878406|DRUG|Placebo (NNC0480-0389)|A single dose of subcutaneous placebo (NNC0480-0389) The study will last for a maximum of 72 days.
224223840|NCT04878406|DRUG|Semaglutide|A single dose of subcutaneous Semaglutide 0.5 mg The study will last for a maximum of 72 days.
223635182|NCT05798494|BEHAVIORAL|Weight loss intervention|Subjects will receive dietary counseling by a dietitian from 3 months post-partum of the 1st child until birth of the 2nd child. The mother (and father if overweight, BMI ≥25 kg/m\^2) will receive advice to provide a moderate caloric restriction (-500 to 1000 kcal/d) and power walk 2-4 times a week for a half an hour and attend physical activity sessions every 2nd week to attain a minimum weight loss of approximately 0,5-1,0 kg/week. The weight loss will last until a 10% weight loss (according to pre-pregnancy weight) has been achieved or until 1-year post-partum. If the subject has not achieved a weight loss of 10%, she or he will receive Very low-calorie diet (VLCD) until target weight loss is reached, though no longer than 8 weeks. After weight loss subjects will receive counseling to maintain weight loss and healthy weight gain during pregnancy until birth of the 2nd child.
223635183|NCT04032964|DRUG|L19TNF|L19TNF 13 µg/kg i.v. will be administered on day 1, 3 and 5 of each 21-day cycle
223635184|NCT04032964|DRUG|DOXORUBICIN|Doxorubicin 75 mg/m2 will be administered on day 1 of each 21-day cycle
223635185|NCT06514950|BEHAVIORAL|Ujjayi Yogic Breathing|Participants will undergo 6 weeks of resistive yogic breathing (Ujjayi) upon exhalation (first three weeks) and upon inhalation and exhalation (second three weeks).
223635186|NCT04777799|DEVICE|URGOnight|"URGOnight is a daytime brain training solution (CE marked) aim at improve the quality of sleep. The device consists of an electroencephalographic (EEG) measuring strip connected to a mobile application. The latter is available free of charge on Android and iOS in various mobile application stores (Google Play Store and App Store).~URGOnight is a wireless device, it connects via Bluetooth® Low Energy (BLE) to the URGOnight mobile application running on a smartphone. The EEG data is broadcast via a BLE protocol, and the standard Bluetooth® operating distance has a range of 10 meters.~To use the URGOnight solution, the user must authorize the application to access his phone's memory to store his usage data and must also authorize the geolocation of his phone to enable BLE connection. This data is not recorded but is necessary for the proper functioning of the solution."
223635187|NCT02826070|DRUG|Telbivudine|Telbivudine, 600mg, oral, daily
223635188|NCT02826070|DRUG|Adefovir dipivoxil|Adefovir dipivoxil 10mg, oral, daily
223635189|NCT02826070|OTHER|off-treatment follow-up|
223635190|NCT01171859|DRUG|Doxycycline + Tauroursodeoxycholic acid|doxycycline 100 mg twice a day for 12 months; tauroursodeoxycholic acid 250 mg three times a day for 12 months
224223841|NCT04878406|DRUG|Placebo (Semaglutide)|A single dose of subcutaneous placebo (semaglutide) The study will last for a maximum of 72 days.
223635191|NCT06100653|DRUG|BCG for therapeutic use|The 10 patients were infused with BCG 120mg dissolved in 40 \~ 50 mL normal saline once a week for 6 times, then once every 2 weeks for 3 times, and then once a month (30 days) for 10 times, with a total of 19 times.
223635192|NCT04115774|DRUG|bisphosphonates|Since this is an observational study, the investigators collect general information on bisphosphonates treatment/impact
223635193|NCT00278577|BIOLOGICAL|Immune Ablation and Hematopoietic Stem Cell Support|Autologous Hematopoietic Stem Cell Transplant
223635194|NCT01903460|DRUG|LUM001|
223635195|NCT01903460|DRUG|Placebo|
223635196|NCT05269914|OTHER|Autologous anti-CD19 CAR-T cell injection|"According to preclinical research, existing preliminary clinical data and similar approved therapeutic products (kte-c19 of Kate company, the trade name is yescarta ®） According to the clinical trial results, three doses (the number of cells per unit body weight) were selected as the therapeutic dose of this study. Among the patients who increased the dose according to the 3 + 3 design, the number of target cells in each dose group was: (1) the first dose group was 1.00 × 106 Car + T cells / kg, 20% dose error is allowed. (2) the second dose group is 3.00 × 106 Car + T cells / kg, 20% dose error is allowed. (3) the third dose group is 9.00 × 106 Car + T cells / kg, 20% dose error is allowed."
224223842|NCT05048732|DRUG|18F-FluorApoTrace|-The dose of 18F-FluorApoTrace to be given is 5 mCi
224223843|NCT05863988|OTHER|Functional Electrical Stimulation|The group A will receive functional electrical stimulation 30-45 min session 5 days per week for 8 weeks.
224223844|NCT05863988|OTHER|Upper Limb Loading Exercises|The group B will receive Upper Limb Loading Exercises 30-45 min session 5 days per week for 8 weeks.
224223845|NCT06010056|DRUG|Ketamine-Morphine|PCA ketamine (Ketamine HCl, Pfizer Inc., US) 0.5 mg plus morphine 0.5 mg ml-1 (ratio 1:1)
224223846|NCT06010056|DRUG|Morphine|PCA morphine (Pfizer Inc., US) 1 mg ml-1
224223847|NCT04155788|BEHAVIORAL|Food Exposure|Participants will complete a meal exposure using one of their feared foods.
224223848|NCT00894985|BIOLOGICAL|heparin sodium - blausiegel|heparin sodium 5.000UI
224223849|NCT00894985|BIOLOGICAL|heparin sodium - APP|heparin sodium 5.000 USP - APP
224223850|NCT03058978|DEVICE|Etonogestrel Implant|Ovarian function will be assessed with weekly serum progesterone levels. Participants will undergo weekly venipuncture for a total of four draws over a 30 day period. Participants will also complete a bleeding diary to assess daily bleeding patterns for the 30 day study period.
224223851|NCT03765671|DRUG|Elafibranor|120mg oral single dose
224223852|NCT05954078|DRUG|mFOLFIRINOX adjuvant chemotherapy|mFOLFIRINOX (oxaliplatin 85 mg/m2, irinotecan 180 mg/m2, and folinic acid 400 mg/m2 followed by 5-fluorouracil 2400mg/m2 as a 46-hour continuous infusion on day 1) for 6 cycles
224223853|NCT05954078|DRUG|mFOLFOX6/XELOX adjuvant chemotherapy|mFOLFOX6 (oxaliplatin 85 mg/m2, and folinic acid 400 mg/m2 followed by 5-fluorouracil 400mg/m2 infusion, and 2400mg/m2 as a 46-hour continuous infusion on day 1) for 12 cycles or XELOX (oxaliplatin 130mg/m2, ivgtt, Q3w; capecitabine 1000mg/m2, p.o, Q3w) for 8 cycles
224223854|NCT01584778|OTHER|eosinophil cationic protein|Serum eosinophil cationic protein levels
224223855|NCT03409185|DEVICE|Alcon 1 piece SA60AT lens|Optic Diameter: 6.0 mm, Overall length: 13.0 mm, Material: Ultraviolet-absorbing Acrylate/Methacrylate Copolymer
224223856|NCT03409185|DEVICE|AMO 1-piece AABOO lens|Optic Diameter: 6.0 mm, Overall length: 13.0 mm, Material: Ultraviolet-blocking hydrophobic acrylic
224223857|NCT06528678|DEVICE|Intraocular lens|Lens exchange with an intraocular lens
224223858|NCT00421785|DRUG|Oral N-Acetylcysteine 1200 mg x 2/day for 4 weeks.|
224223859|NCT04290078|DEVICE|Kaia Back Pain Study App|Kaia Back Pain is an integrated solution for self-management of low-back pain that digitizes multidisciplinary rehabilitation into a smartphone application.
223635197|NCT03866746|DRUG|Aflibercept Injection|Group A;Under complete aseptic conditions; intravitreal aflibercept injections with dose of 2 mg/0.05 mL per injection was given for the patients. Patients were scheduled to receive 3 loading injections at monthly interval. At the 3rd month; further treatment was planned pro re nata (PRN) according to the response. Injections were discontinued when the CMT reached 250 µm or less. If there was no change in the CMT after two consecutive injections; patients shifted to other line of treatment. Reinjection was continued for the other eyes with re-evaluation of the response every month.In group B Patients received the initial 3 monthly loading doses of IVI of aflibercept followed by MPL therapy (within one week after the 3rd injection). Patients were scheduled for follow-up monthly. Injection followed by MPL was then repeated according to the response as in group A.
224223860|NCT04290078|OTHER|Usual Care|Participants in the control arm will be provided with online links to educational materials about home exercises and pain management and asked to continue their usual care. On-line resources will include links to Web MD, the National Library of Medicine (Medline), and OnHealth
224223861|NCT04050332|BEHAVIORAL|Stair Walking|Walking up and down stairs for four minutes at a comfortable pace
224223862|NCT00359970|DRUG|Azithromycin 500 mg|A single 500 mg dose at the start of treatment
224223863|NCT00359970|DRUG|Azithromycin 1000 mg|A single 1000 mg dose at the start of treatment
224223864|NCT00359970|DRUG|Loperamide|A single 4 mg loading dose at the start of treatment and then 2 mg after each loose stool
224223865|NCT00359970|OTHER|Placebo|A single loading dose at the start of treatment and then a dose after each loose stool
224223866|NCT06527482|PROCEDURE|Autologous Osteoperiosteal Transplantation|After full exposure of the lesion, the center of the cystic lesion was determined and drilled perpendicularly using a 2-mm pin. Then, a 4.5-mm cannulated bore was used to drill the lesion until the cyst was reached, and a small bone socket was created. A harvester tube matching the diameter of the cyst was used to enlarge the bone socket with care to avoid damage to the adjacent normal cartilage. The cystic lesion was debrided thoroughly, and the sclerotic wall of the cyst was freshened using a curette. The harvester tube with a matched diameter was driven in to a depth of 15 to 20 mm at the 2-cm proximal part of the anterior superior iliac spine perpendicularly without violation of the lateral wall of the crest. When necessary, small pieces of cancellous bone were also harvested from the iliac crest using a bone curette then grafted into the peripheral area of the cyst to fill up the remaining space of the cyst around the bone socket in the talus.
224223867|NCT03119064|DRUG|Nanoliposomal Irinotecan|Three patients will be accrued to level 1. If no dose limiting toxicities are observed following completion of 4 weeks (2 cycles) of treatment then accrual to dose level 2 will proceed (patients must be evaluated prior to their cycle 3 treatment and this will be used to confirm DLTs). If a DLT is observed in one of the first 3 patients in a dose level, then accrual for that level will be expanded to 6 patients. Accrual will continue in this way until the MTD of nanoliposomal irinotecan with temozolomide 50mg/m2/day is determined. Two or more instances of DLT in a cohort of 6 patients will result in the preceding dose level being defined as the MTD. If two or more instances of DLT in a cohort of 6 patients occurs in dose level 1 then dose level -1 of nanoliposomal irinotecan will be investigated. After determination of the MTD, the final cohort will be expanded so that a total of 25 patients are treated on study. The final cohort will be treated at the MTD.
224223868|NCT03119064|DRUG|Temozolomide|Three patients will be accrued to level 1. If no dose limiting toxicities are observed following completion of 4 weeks (2 cycles) of treatment then accrual to dose level 2 will proceed (patients must be evaluated prior to their cycle 3 treatment and this will be used to confirm DLTs). If a DLT is observed in one of the first 3 patients in a dose level, then accrual for that level will be expanded to 6 patients. Accrual will continue in this way until the MTD of nanoliposomal irinotecan with temozolomide 50mg/m2/day is determined. Two or more instances of DLT in a cohort of 6 patients will result in the preceding dose level being defined as the MTD. If two or more instances of DLT in a cohort of 6 patients occurs in dose level 1 then dose level -1 of nanoliposomal irinotecan will be investigated. After determination of the MTD, the final cohort will be expanded so that a total of 25 patients are treated on study. The final cohort will be treated at the MTD.
224223869|NCT06544486|PROCEDURE|Caries Removal|The cavity preparation and restoration were performed by a single operator. Infected dentin tissue was selectively removed. The differentiation between infected and affected dentin was determined by the clinician through the visual-tactile method.Isolation was achieved with cotton rolls and suction.
224223870|NCT06544486|PROCEDURE|Filling|Sectional matrix systems and interdental wedges were used to achieve an anatomical contour and contact. Then, the selected materials were placed in the cavity according to the manufacturers' recommendations.
224223871|NCT02555709|DRUG|VTP-43742|VTP-43742 administered as an oral capsule once daily
224223872|NCT02555709|DRUG|Placebo 1|Placebo 1 matching VTP-43742 administered as an oral capsule once daily
223635198|NCT03866746|OTHER|micropulsed yellow laser|Micropulse yellow IQ 577nm laser (Iridex Corporation, Mountain View, CA, USA) was employed. The Area Centralis lens (laser spot size magnification 0.94) was utilized with 400 mw power, 200μm spot size and 200 ms pulse duration with 5% duty cycle after micropulse mode activation. Laser was applied on clinically visible thickened macula with different number of confluent non- spacing shots in 7x7 grids. Care was taken to begin treatment outside the foveal avascular zone and not to treat the fovea when there was no visible reaction. If there was any visible reaction; treatment was stopped and the power was reduced until there was no visible reaction.
224223873|NCT02555709|DRUG|Placebo 2|Placebo 2 matching VTP-43742 administered as an oral capsule once daily
224223874|NCT01687309|DRUG|GSK2586184 800mg single and repeat dose|GSK2586184 800mg single dose and then twice daily dosing for 13 days
224223875|NCT01687309|DRUG|Placebo-to-match GSK2586184|Placebo-to-match GSK2586184
224223876|NCT01687309|OTHER|GSK2586184 single dose taken with food|GSK2586184 single dose taken with FDA approved high fat, high calorie breakfast
224223877|NCT01687309|OTHER|GSK2586184 single dose taken without food|GSK2586184 single dose taken in a fasted state
224223878|NCT02957409|DRUG|sacubitril/valsartan|This study is designed as an observational, naturalistic, multicenter study in patients being treated with sacubitril/valsartan as per the Canadian product label. Treatment initiation with sacubitril/valsartan must be within the last 3 months. Sacubitril/valsartan will be used as commercially available supplies which are available as Film coated tablets in 3 dosage: 1) 24 mg sacubitril / 26 mg valsartan, 2) 49 mg sacubitril / 51 mg valsartan and 3) 97 mg sacubitril / 103 mg valsartan.
224223879|NCT05431283|DRUG|Tofacitinib|This study aims to assess the effectiveness of TOFA
224223880|NCT06547723|OTHER|MBSR and physiotherapy|"In experimental group in the first session, the research program and plans for outcome assessment will be introduced. They will sign the research agreement form and will be interviewed to obtain information about their pain, their medication(s), and demographics. This will be followed by the first 70-80-minute physiotherapy session. During each session, the physiotherapist will administer the Transcutaneous electrical nerve stimulation (TENS), low-level laser therapy (LLLT), and ultrasound therapy to the painful body region. In addition, they will engage in 20 minutes of exercise during each session.~After that, participants will be received their 8 MBSR session with a trained therapist. They will be given their assignments for the week, consisting of the content of that MBSR session.~Finally, three months after the last study session, they will be asked to return to the clinic for the follow-up assessment to complete patient-reported outcome measures."
223635199|NCT06253988|DRUG|Probiotic Formula|intra-pocket formula (local delivery drug)
223635200|NCT06253988|DRUG|placebo formula|intra-pocket formula (local delivery drug)
223635201|NCT04299373|DRUG|Alcohol: Oral administration|Patients who plan to undergo bariatric surgery will consume a controlled dose of alcohol orally.
223635202|NCT04299373|DRUG|Alcohol: Intravenous administration|Patients who plan to undergo bariatric surgery will be infused with alcohol intravenously.
223635203|NCT06002412|OTHER|Image quality control|The investigators identify the region of interest in the relevant section to give a conclusion on whether the image is standard or not, guiding clinicians to standardize the operation, and reducing the rate of misdiagnosis and underdiagnosis.
224223881|NCT06547723|OTHER|physiotherapy|In control group in the first session, the research program and plans for outcome assessment will be introduced. The participants then will sign the research agreement form and will be interviewed to obtain information about their pain (i.e., duration, location, and course), their medication(s), and demographics. This will be followed by the first 70-80-minute physiotherapy session. During each session, the physiotherapist will administer the Transcutaneous electrical nerve stimulation (TENS), low-level laser therapy (LLLT), and ultrasound therapy to the painful body region. In addition, they will engage in 20 minutes of exercise during each session.
224223882|NCT00859625|PROCEDURE|nurse observation during colonoscope withdrawal|nurse observation during colonoscope withdrawal
224223883|NCT00696358|RADIATION|308nm excimer lamp|50 mJ/cm² below the MED (minimal erythemal dose) and progressive increase Twice a week for 12 weeks
224223884|NCT00696358|RADIATION|308nm excimer laser|50 mJ/cm² below the MED (minimal erythemal dose) and progressive increase Twice a week for 12 weeks (same doses will be used between the 2 arms)
224223885|NCT04450303|BEHAVIORAL|Telehealth CBT|The Coordinated Anxiety Learning and Management (CALM) program is an evidence-based, computer-assisted protocol for cognitive behavioral therapy (CBT) for anxiety, depression, and/or post-traumatic stress. CALM will be implemented via secure and HIPAA compliant video-conferencing software (enterprise Zoom), following modifications to address obstacles associated with physical distancing and the tele-health medium.
224223886|NCT03605706|DRUG|SHR-1210|Subjects receive SHR-1210 intravenous at the dose 3mg/kg on Day 1 every 2 weeks
224223887|NCT03605706|DRUG|FOLFOX4|Subjects receive FOLFOX4 treatment on D1-D2 of every 2 weeks
224223888|NCT03605706|DRUG|Placebo|Subjects receive placebo of SHR-1210 intravenous at the dose 3mg/kg on Day 1 every 2 weeks
224223889|NCT01405976|DEVICE|life style modification, noninvasive ventilation, CPAP|life style modification, noninvasive ventilation, CPAP
224223890|NCT04741360|OTHER|Modified Story Memory Technique|10-session computerized program to improve new learning and memory
223635204|NCT06448143|DRUG|Indigotindisulfonate sodium 0.8% injection|Experimental contrast dye for diagnostic procedures, commonly used as a visualization aid in pelvic and abdominal surgeries, as well as for evaluating ureteral patency.
224223891|NCT03291457|DRUG|Tocilizumab|For intravenous (IV) tocilizumab, the recommended dosage is 8 milligrams per kilogram (mg/kg) once every 4 weeks. For subcutaneous (SC) tocilizumab, the recommended dosage is 162 milligrams (mg) once weekly. However, because of the observational nature of the study, dosing and treatment duration is at the discretion of the physician in accordance with local clinical practice and local labeling.
224223892|NCT03291457|DRUG|Glucocorticoid Agent|Because of the observational nature of the study, the choice of glucocorticoid agent, as well as dosing and treatment duration, is at the discretion of the physician in accordance with local clinical practice and local labeling.
223635205|NCT00102466|DRUG|vildagliptin|
223635206|NCT00102466|DRUG|Gliclazide|
223635207|NCT00102466|DRUG|Metformin|
223635208|NCT00358475|DRUG|GW685698|
223635209|NCT03572946|PROCEDURE|Targeted prostate biopsy|MRI-guided targeted prostate biopsy
223635210|NCT03572946|PROCEDURE|Standard biopsy|Transperineal ultrasound guided prostate biopsy(SB).
223635211|NCT01814111|PROCEDURE|renal sympathetic denervation|The ablation catheter was maneuvered within the renal artery to allow energy delivery in a circumferential, longitudinally staggered manner to minimize the chance of renal artery stenosis.
223635212|NCT03330925|DEVICE|ElastiMed's SACS|A wearable medical device that improve circulation using smart materials
223635213|NCT03186300|DEVICE|PEPPER system|In the phase 1 participants will use PEPPER safety system (with the CBR algorithm enabled) and in the phase 2 participants will use whole PEPPER system (with the CBR algorithm integrated).
223635214|NCT05322707|DRUG|Budesonide 80 μg and Formoterol Fumarate Dihydrate 4.5 μg|Inhalation aerosol, 2 actuations orally inhaled twice daily
223635215|NCT05322707|DRUG|Symbicort, 80 Mcg-4.5 Mcg/Inh Inhalation Aerosol|Inhalation aerosol, 2 actuations orally inhaled twice daily
223635216|NCT05322707|DRUG|Placebo|Inhalation aerosol, 2 actuations orally inhaled twice daily
223635217|NCT04973449|BIOLOGICAL|AZD1222|10 mM histidine/histidine hydrochloride, 7.5% (w/v) sucrose, 35 mM sodium chloride, 1 mM magnesium chloride, 0.1% (w/v) polysorbate 80, 0.1 mM edetate disodium, 0.5% (w/v) ethanol, at pH 6.6.
223635218|NCT04973449|BIOLOGICAL|AZD2816|10 mM histidine/histidine hydrochloride, 7.5% (w/v) sucrose, 35 mM sodium chloride, 1 mM magnesium chloride, 0.1% (w/v) polysorbate 80, 0.1 mM edetate disodium, 0.5% (w/v) ethanol, at pH 6.6.
223635219|NCT05495789|OTHER|Virtual Reality|A relaxing video will be watched with virtual reality glasses.
223635220|NCT05495789|OTHER|Music|Relaxing music will be played by wearing headphones.
223635221|NCT00521079|DEVICE|Therapy ON|Intermittent, programmable, intra-abdominal vagal blocking device that delivers therapy (Therapy ON)
223635222|NCT00521079|DEVICE|Therapy OFF|Active intra-abdominal placebo device that delivers no therapy (Therapy OFF)
223635223|NCT05020951|OTHER|Medidata RAVE|Data collection done exclusively through Medidata Rave. Medidata Rave is a clinical data management system being used for data collection for this trial/study. Access to the trial in Rave is controlled through the CTEP-IAM system and role assignments.
223635224|NCT02524327|OTHER|Toolbox: Automated group|A dedicated algorithm controls the infusion rate of drugs depending on the magnitude of variation of the bispectral index
223635225|NCT02524327|OTHER|Manual group|The anesthesiologist controls the infusion rate of drugs depending of the magnitude of variation of the bispectral index
223635226|NCT00629980|DRUG|AzaSite®|ophthalmic solution; 1 drop in each eye BID for two days, then 1 drop in each eye QD for \~26 days
223635227|NCT03586765|OTHER|Female urinary incontinence|Assess prevalence of urinary functional disorders in women of 40 and more, visiting a general practitioner, occupational medicine or health examination center in Puy-de-Dôme. Study conducted for a month using a self-filled survey distributed by secretaries or nurses.
223635228|NCT03816696|DRUG|GSK3640254|GSK3640254 will be available as 100 mg capsules. Subjects will be administered GSK3640254 200 mg QD via the oral route.
223635229|NCT03816696|DRUG|DTG|DTG will be available as 50 mg tablets. Subjects will be administered DTG 50 mg QD via the oral route.
223635230|NCT02916186|BIOLOGICAL|Acellular Dermal Matrix|Puros Dermis is a collagenous membrane derived from solvent preserved,human dermis, works as biological scaffold for the new formation of vasculated connective tissue.
223635231|NCT02916186|PROCEDURE|Tunnel technique with the subepithelial connective tissue graft|Tunnel prepared with the placement of subepithelial connective tissue graft harvested from the palate
224223893|NCT06441981|BEHAVIORAL|Education|Educational material brochures will be given to 800 respondents. Educational material is provided via WhatsApp chatbot. After being educated, respondents were given a test to determine the increase in understanding of the material.
224223894|NCT06230471|DRUG|Pembrolizumab,Lenvatinib and Gemox Chemotherapy（Gemcitabine and Oxaliplatin）|Drug: Pembrolizumab Pembrolizumab 200 mg will be administered intravenously once every three weeks, with intravenous infusion on Day 1 of each cycle. Drug: Lenvatinib Oral Product The dose of lenvatinib is 12mg/day for patients with a body weight of ≥60 kg, and 8mg/day for patients with a body weight of \<60 kg, taken once daily. Drug: Chemotherapy GEMOX regimen: Gemcitabine 1000mg/m2 will be administered intravenously over 30 minutes on Day 1 and Day 8; Oxaliplatin 100mg/m2 will be administered intravenously over 2 hours on Day 1, and the cycle will be repeated every 3 weeks.
224223895|NCT06230471|DRUG|Pembrolizumab and Lenvatinib|Pembrolizumab and Lenvatinib
224223896|NCT06230471|DRUG|Pembrolizumab and Gemox Chemotherapy（Gemcitabine and Oxaliplatin）|Pembrolizumab and Gemox Chemotherapy（Gemcitabine and Oxaliplatin）
224223897|NCT04630197|BEHAVIORAL|e-CBT|The description is provided in the treatment arm description.
224223898|NCT04665505|BEHAVIORAL|Educational Workshop|The intervention consists of providing educational content for all ICU care providers concerning building staff knowledge surrounding methods to facilitate cost-effective and evidence-based decision-making about patient care (including tests, treatments, and procedures). The first intervention is an educational workshop to increase staffs' awareness of the current Choosing Wisely Canada Critical Care strategies and recommendations to facilitate cost-effective and evidence-based decision-making about patient care (including tests, treatments, and procedures).
223635232|NCT01506596|DRUG|pazopanib|Pazopanib 800 mg orally once daily will be started on Cycle 1 Day 1 and will be administered continuously for a 28-day cycle. Study treatment may continue until disease progression or unacceptable toxicity.
223635233|NCT03863886|PROCEDURE|Endoscopic ultrasound catheter (UM-2R/3R, Olympus)|A miniprobe ultrasound catheter (UM-2R/3R, Olympus) will be passed into the colonoscope's accessory channel at the time of colonoscopy to measure the thickness of the different colon wall layers (mucosa, submucosa, muscular propria, and total wall thickness) in the cecum and rectum.
223635234|NCT06315712|OTHER|inspiratory exercise|The training consisted of 6 sets of 30 breaths per day, divided into 2 sessions per day. A one-minute rest interval between each set. Training was prescribed 5 days a week for 8 weeks
223635235|NCT06315712|OTHER|Pulmonary rehabilitation|Four resistive exercises, aerobic exercise, and deep breathing exercises, five sessions per week for 8 weeks
223635236|NCT01314183|OTHER|Exercise|The program starts with a 10 minute aerobic exercise warm-up (treadmill walking or stationary cycling). Subjects then perform a series of strengthening, stretching, and neuromuscular control activities which are core exercises for the program and mandatory. In addition to the above core exercises, therapists have the option to select additional optional exercise activities, based on the initial examination findings. These exercises will address strength or flexibility in the hip, and ankle if impairments are identified in the initial examination.
223635237|NCT01314183|OTHER|manual therapy|The manual therapy (MT)techniques are maneuvers that are applied with manual force from the treating therapist. The MT techniques will include a series of accessory motion techniques, manual stretching , and soft tissue manipulation (deep massage to muscles and connective tissues associated with knee function). Core techniques include anterior-posterior and posterior-anterior tibiofemoral translations, superior-inferior and medial-lateral patellofemoral mobilizations, knee flexion and extension mobilizations that may be combined with varus-valgus stresses,medial-lateral tibial rotations, manual stretching of the quadriceps, rectus femoris, hamstring, and gastrocnemius muscles, and soft tissue manipulations of the quadriceps, peri-patellar tissues, hamstring, hip adductors, and gastroc-soleus muscle groups. There are optional MT techniques for the hip, and foot and ankle joints that can be selected by the therapist based on initial examination findings.
223635238|NCT02873858|OTHER|smell and taste tests|
223764757|NCT03912753|OTHER|Education Attention Control|The EAC condition consists of eight self-administered modularized topics, content-matched with the Comunică sessions, which we have generated based on our HIV-prevention education with GBM in the US and Romania.
223764758|NCT04009330|DIAGNOSTIC_TEST|POC Assay|"Interventions:~Blood Baseline - up to 40ml Day 3 - up to 40ml~Urine Baseline - 10ml Day 3 - 10ml~Study population:~Adults (18 plus) in ICU units diagnosed with ARDS."
223764759|NCT06528405|DRUG|dapagliflozin|Sodium-glucose cotransporter 2 inhibitor for 90 days during the acute kidney disease period.
223635239|NCT05657002|OTHER|patient A with accurate problem list|A problem list that contains a diagnosis code that is contraindicated with a type of medication (Y). Also, all other relevant diagnoses and medical history for the patient are up-to-date on the problem list, which was defined according to the problem list policy at our institution (i.e. all current active problems and relevant medical history should be documented on the problem list). Additionally, the problem list is included in eight out of thirteen notes using so-called smart phrases that can automatically import a (part of a) problem list. One note includes the problem list with the diagnosis relevant for the question asked.
223635240|NCT05657002|OTHER|patient B with inaccurate problem list|"A problem list that does not contain the diagnosis code and corresponding details explaining medical history of this diagnosis caused by a type of medication (Y). Additionally, the problem list is included in three out of thirteen notes using so-called smart phrases that can automatically import a (part of a) problem list. The relevant diagnosis is not documented on the problem list and hence is not included in the imported problem list in the notes.~The expert panel provided and anonymized two real-world representative examples of hematology patient records that included inaccurate problem lists and that had many free-text notes. An 'inaccurate problem list' is defined as a problem list where diagnoses are missing resulting in missed trigger medication or order-alerts, where diagnoses are 'active' although they should be closed or removed and/or where the problem list contained duplicated diagnoses."
223635241|NCT05657002|OTHER|patient A with inaccurate problem list|"A problem list that does not contain the diagnosis code that is contraindicated with the type of medication (Y). Additionally, the problem list is included in eight out of thirteen notes using so-called smart phrases that can automatically import a (part of a) problem list. The relevant diagnosis is not documented on the problem list and hence is not included in the imported problem list in the notes.~The expert panel provided and anonymized two real-world representative examples of hematology patient records that included inaccurate problem lists and that had many free-text notes. An 'inaccurate problem list' is defined as a problem list where diagnoses are missing resulting in missed trigger medication or order-alerts, where diagnoses are 'active' although they should be closed or removed and/or where the problem list contained duplicated diagnoses."
223635242|NCT05657002|OTHER|patient B with accurate problem list|A problem list that contains the diagnosis code and corresponding details explaining medical history of this diagnosis caused by a type of medication (Y). Also, all other relevant diagnoses and medical history for the patient are up-to-date on the problem list, which was defined according to the problem list policy at our institution (i.e. all current active problems and relevant medical history should be documented on the problem list). Additionally, the problem list is included in three out of thirteen notes using so-called smart phrases that can automatically import a (part of a) problem list. One note includes the problem list with the diagnosis and details relevant for the question asked.
223635243|NCT05430178|OTHER|Oral sugar tolerance test|Measurement of glucose and insulin for calculation of insulin sensitivity
223635244|NCT05430178|OTHER|De novo lipogenesis test|Oral consumption of deuterated water to measure incorporation of label into lipids
223635245|NCT05430178|OTHER|Gluconeogenesis test|Oral consumption of 13C-labeled glycerol to measure incorporation into glucose
223635246|NCT02586181|DIETARY_SUPPLEMENT|Vitamin D and Calcium|"a combination of dietary supplement including all 1200 IE Vitamin D3 plus 800 mg Calcium Carbonate~1200 IE Vitamin D3 plus 800 mg Calcium Carbonate~Arm: Experimental: Vitamin D, Calcium, Vitamins B9, B6, B12~1200 IE Vitamin D3 plus 800 mg Calcium Carbonate plus 0,5mg Folic acid, 50 mg B6, 0,5 mg B12"
223635247|NCT02586181|DIETARY_SUPPLEMENT|Vitamin D, Calcium, Vitamins B9, B6, B12|"a combination of dietary supplement including all 1200 IE Vitamin D3 plus 800 mg Calcium Carbonate plus 0,5mg Folic acid, 50 mg B6, 0,5 mg B12"
223635248|NCT00888173|DRUG|Brivanib Alaninate|Given PO
223635249|NCT00888173|OTHER|Laboratory Biomarker Analysis|Correlative studies
223635250|NCT04065269|DRUG|Ceralasertib|ATR inhibitor
223635251|NCT04065269|DRUG|Olaparib|PARP inhibitor
224223899|NCT04665505|BEHAVIORAL|Optimizing Staff Scheduling|This initiative will focus solely on the nurse subgroup and concerns schedule optimization to ensure the presence of the appropriate number of nurses per shift, thereby reducing stress, burnout and limiting the need for overtime.
224223900|NCT02631928|DRUG|human biphasic insulin|investigational insulin, biosimilar human insulin suspension of 30% normal insulin and 70% basal protamined insulin
224223901|NCT02631928|DRUG|human biphasic insulin, reference|marketed product, human insulin suspension of 30% normal insulin and 70% basal (NPH) insulin
224223902|NCT02040766|DRUG|Beclomethasone dipropionate BAI|Beclomethasone dipropionate (BDP), was delivered by a single inhalation using a breath-actuated inhaler (BAI) at levels of 40 mcg or 80 mcg per inhalation, twice each day.
224223903|NCT02040766|DRUG|Placebo BAI|Placebo was delivered by a single inhalation using a breath-actuated inhaler (BAI) twice each day.
224223904|NCT02040766|DRUG|albuterol/salbutamol 90 mcg|Rescue medication (albuterol/salbutamol hydrofluoroalkane (HFA) MDI \[90 mcg ex-actuator\] or equivalent) for use on an as-needed basis for the immediate relief of asthma symptoms throughout the treatment period.
224223905|NCT02040766|DRUG|Beclomethasone dipropionate MDI|Beclomethasone dipropionate (BDP), was delivered by a single inhalation using a metered-dose inhaler (MDI) at levels of 40 mcg or 80 mcg per inhalation, twice each day.
224223906|NCT02040766|DRUG|Placebo MDI|Placebo was delivered by a single inhalation using a metered-dose inhaler (MDI) twice each day.
224223907|NCT02974114|DRUG|Paracetamol and caffeine|Test product containing 500 mg paracetamol and 65 mg caffeine
224223908|NCT02974114|DRUG|Paracetamol|Test product containing 500 mg paracetamol
224223909|NCT02974114|OTHER|Placebo|Placebo to match paracetamol 665mg sustained release tablets
224223910|NCT00914888|DRUG|Tigecycline|"Subject with cIAI:~Dosing information for subjects 8 to 11 years old is currently under investigation and will be determined later. Subjects 12 to 17 years old will receive tigecycline 50 mg IV every 12 hours, metronidazole placebo IV will be administered every 8 hours. In addition, at the discretion of the investigator, an aminoglycoside placebo IV may also be administered."
223635252|NCT04065269|DRUG|Durvalumab|Anti-PD-L1 immunotherapy
223635253|NCT06281132|DRUG|CKD-341, D956|A single dose of 1 tablet under fasting condition
223635254|NCT05045586|DEVICE|The tunnel technique for root coverage with CTG without Cross-linked Hyaluronic Acid|The tunnel technique for root coverage with CTG without Cross-linked Hyaluronic Acid
223635255|NCT05045586|DEVICE|The tunnel technique for root coverage with CTG andCross-linked Hyaluronic Acid|The tunnel technique for root coverage with CTG andCross-linked Hyaluronic Acid
223635256|NCT01564160|DIETARY_SUPPLEMENT|Fish Oil|Source of omega-3 fatty acids.
223635257|NCT01564160|DIETARY_SUPPLEMENT|PCSO-524|Extract of Greenshell Mussel
223635258|NCT06294626|OTHER|Group 1|21 cases with scaphocephaly diagnoses were included. Neuromotor development was evaluated with the Denver-II Developmental Screening Test and Alberta Infant Motor Scale.
223635259|NCT05962528|DEVICE|Soft lens|Patients were randomly fitted with five different designs of soft lenses
223635260|NCT05215431|PROCEDURE|periodontal examination&amp;#39;s, determination of salivary antioxidants and cytokine levels (VEGF, TGF-β, Il-17) in gingival crevicular fluid, Non-surgical therapy of periodontitis|Periodontal parameters has been recorded on six sites of each tooth using a manual periodontal probe. Activity of antioxidants in unstimulated saliva (GPX, SOD, UA) has been determined using the colorimetric method and commercial kits. Total cytokine levels (VEGF, TGF-β, Il-17) in gingival crevicular fluid were determined using commercial ELISA (enzyme-linked immunosorbent assay) kits . The therapeutic procedure begun with ultrasonic scaling (MiniPiezon, EMS Electro Medical Systems, Switzerland), along with education and motivation of subjects to maintain oral hygiene properly. Periodontal debridement was carried out under local anesthesia, by quadrants, starting from the upper right quadrant at 7-day intervals until the completion of therapy. Instrumentation of all periodontal pockets was processed manually using specialized curettes.
223635261|NCT05215431|DIAGNOSTIC_TEST|Activity of antioxidants in unstimulated saliva (GPX, SOD, UA)|Activity of antioxidants in unstimulated saliva (GPX, SOD, UA) has been determined using the colorimetric method and commercial kits.
223635262|NCT05215431|DIAGNOSTIC_TEST|Total cytokine levels (VEGF, TGF-β, Il-17) in gingival crevicular fluid|Total cytokine levels (VEGF, TGF-β, Il-17) in gingival crevicular fluid were determined using commercial ELISA (enzyme-linked immunosorbent assay) kits .
223635263|NCT05215431|PROCEDURE|Periodontal treatment|The therapeutic procedure begun with ultrasonic scaling (MiniPiezon, EMS Electro Medical Systems, Switzerland), along with education and motivation of subjects to maintain oral hygiene properly. Periodontal debridement was carried out under local anesthesia, by quadrants, starting from the upper right quadrant at 7-day intervals until the completion of therapy. Instrumentation of all periodontal pockets was processed manually using specialized curettes.
223635264|NCT00522093|DRUG|TJ-100|TJ-100 2.5g three times per day for 6 weeks
223635265|NCT04008472|OTHER|Telemedecine|Initiation of tele-medical consultation with the resident, a caregiver for the nursing home, the referring physician and geriatrician téléexpert. After a overall geriatric assessment in nursing homes by UPSAV the first teleconsultation is organized within 10 days. Subsequent visits are scheduled every 3 months for 12 months. Spontaneous visits can be requested at the initiative of the referring physician.
223764760|NCT06528405|OTHER|Other anti-diabetic drug or no anti-diabetic drug|"Other anti-diabetic drug or no anti-diabetic drug for 90 days during the acute kidney disease period.~Other anti-diabetic drug includes metformin, sulfonylureas, meglitinides, dipeptidyl peptidase-4 inhibitor, insulin, α-glucosidase inhibitors, thiazolidinediones, and glucagon-like peptide-1 receptor agonist."
224223911|NCT00914888|DRUG|Tigecycline|"Subject with CAP:~IV therapy period: Dosing information for subjects 8 to 11 years old is currently under investigation and will be determined later. Subjects 12 to 17 years old will receive tigecycline 50 mg IV every 12h. At the discretion of the investigator oral clarithromycin placebo may be given every 12h.~Oral therapy period: If oral switch criteria are met, on or after Day 4 amoxicillin/clavulanate may be prescribed (40 mg/kg per day divided into 3 equal doses, maximum of 500 mg/dose to subjects weighing less than 40 kg and 500 mg every 8h to subjects weighing 40 kg or greater). In addition, if oral clarithromycin or placebo had been given during the IV period, oral clarithromycin may be given every 12h (7.5 mg/kg, maximum dose 500 mg for subjects 8 to 11 years old, 500 mg for subjects 12 to 17 years old)."
223635266|NCT03606902|PROCEDURE|Group f : Epidural catheter insertion|Infiltrate the skin with local anesthetic lidocaine approximately 1 cm lateral to the inferior aspect of the targeted spinous process , epidural needle tip is midline at the junction of the lamina and spinous process . The needle is withdrawn and advanced with the same medial angle but in small increments cephalad to the same depth. Either bone or ligamentum flavum is contacted. If bone is contacted, the needle is redirected cephalad and advanced. If bone is no longer contacted and the depth exceeds the depth previously noted, the epidural needle stilette is removed. loss-of-resistance syringe is attached to the needle Once attained, stabilize the epidural needle and thread the catheter. Secure the catheter using a sterile locking device and adherent dressings.
223635267|NCT03606902|DRUG|Group F: Continous epidural infusion of bupivacaine plus fentanyl|Epidural injection of bolus of 15 ml total Volume of 0.0625%bupivacaine with 1 µg /Kg Fentanyl initial bolus, then from the 1st hour continuous epidural infusion of 0.0625% bupivacaine with µ/Kg/h Fentanyl fixed for the next 5 hour during operation and in the recovery room after recovery of general anesthesia then stop epidural infusion. (Total infusion time 6 hours=maximum hours needed for nephrectomy surgery)
223635268|NCT03606902|DRUG|Group LF :Continous epidural infusion of decreasing doses of fentanyl plus pubivacaine|Epidural injection of bolus of 15 ml total Volume of 0.0625%bupivacaine with 1 µg/Kg Fentanyl initial bolus, then continuous IV infusion of 0.0625%bupivacaine with 1 µg/Kg/h Fentanyl for the 1st hour then continuous epidural infusion of 0.0625%bupivacaine with 0.5 µg/Kg/h Fentanyl during the 2nd hour, then 0.0625%bupivacaine with 0.25 µ g/Kg/h Fentanyl for the 3rd hour then continue the same infusion volume and dose (0.0625%bupivacaine with 0.25Mg/Kg/h Fentanyl) for the next 3 hours during operation and in the recovery room after recovery of general anesthesia then stop epidural infusion. (Total infusion time 6 hours=maximum hours needed for nephrectomy surgery)
223764761|NCT06528405|DRUG|empagliflozin|Sodium-glucose cotransporter 2 inhibitor for 90 days during the acute kidney disease period.
223764762|NCT06528405|DRUG|canagliflozin|Sodium-glucose cotransporter 2 inhibitor for 90 days during the acute kidney disease period.
223635269|NCT03606902|PROCEDURE|Group L f : Epidural catheter insertion|Infiltrate the skin with local anesthetic lidocaine approximately 1 cm lateral to the inferior aspect of the targeted spinous process , epidural needle tip is midline at the junction of the lamina and spinous process . The needle is withdrawn and advanced with the same medial angle but in small increments cephalad to the same depth. Either bone or ligamentum flavum is contacted. If bone is contacted, the needle is redirected cephalad and advanced. If bone is no longer contacted and the depth exceeds the depth previously noted, the epidural needle stilette is removed. loss-of-resistance syringe is attached to the needle Once attained, stabilize the epidural needle and thread the catheter. Secure the catheter using a sterile locking device and adherent dressings.
223635270|NCT00140452|DRUG|Thalidomide|Thalidomide will start at a dose of 100mg/day, dose escalated every 2 weeks by 100mg/day to a target dose of 400mg/day.
223635271|NCT04124809|DEVICE|laser assisted collapse|Apply 1-2 pulses of laser using the Saturn between 2 adjacent trophectoderm cells away from the inner cell mass in the blastocysts
223635272|NCT05810740|DRUG|Binimetinib 15 MG|Binimetinib 15 mg tablet
223635273|NCT05810740|DRUG|Binimetinib 45 MG|Binimetinib 45 mg tablet
224223912|NCT00914888|DRUG|cIAI: Ceftriaxone with metronidazole, plus if applicable aminoglycoside|"Subject with cIAI:~Subjects will receive ceftriaxone 35 mg/kg (maximum of 1 g/dose) IV every 12 hours, metronidazole 10 mg/kg (maximum of 1 g/dose) IV will be administered every 8 hours.~In addition, at the discretion of the investigator, an aminoglycoside IV (adjusted dose if necessary) may also be given."
224223913|NCT00914888|DRUG|CAP: Ceftriaxone, plus if applicable oral clarithromycin|"Subject with CAP:~IV therapy period: Subjects will receive ceftriaxone 35 mg/kg (maximum of 1 g/dose) IV every 12h. At the discretion of the investigator, oral clarithromycin may be given every 12h (7.5 mg/kg, maximum dose 500 mg for subjects 8 to 11 years old, 500 mg for subjects 12 to 17 years old).~Oral therapy period: If oral switch criteria are met, on or after Day 4 amoxicillin/clavulanate may be prescribed (40 mg/kg per day divided into 3 equal doses, maximum of 500 mg/dose to subjects weighing less than 40 kg and 500 mg every 8h to subjects weighing 40 kg or greater). In addition, if oral clarithromycin or placebo had been given during the IV period, oral clarithromycin may be given every 12h (7.5 mg/kg, maximum dose 500 mg for subjects 8 to 11 years old, 500 mg for subjects 12 to 17 years old)."
224223914|NCT03720483|DRUG|N-acetyl cysteine then Placebo|Subject will receive N-acetyl cysteine first followed by Placebo
224223915|NCT03720483|DRUG|Placebo then N-acetyl cysteine|Subject will receive Placebo first followed by N-acetyl cysteine
224223916|NCT04051632|DEVICE|Medtronic 670G insulin pump|"* percent of patients who continue to use Medtronic 670G over time~* impact of 670G on glycemic control: hemoglobin A1c, time in range"
224223917|NCT03543033|DRUG|Corticosteroid injection|These subjects will first receive a topical anesthesia to the skin and underlying tissue in a maximum amount of 5 ml of 1% Lidocaine. Following this application, an 18-20 gauge epidural needle will be used to inject a solution containing 80 mg Depo-Medrol in 1 ml of 1% PF Lidocaine and 5ml of sterile PF saline
224223918|NCT05238506|DRUG|Intravenous lidocaine|Intraoperative intravenous lidocaine infusion.
224223919|NCT05238506|DRUG|Normal saline infusion|Intraoperative intravenous normal saline infusion.
224223920|NCT05887830|DRUG|Nivolumab|Single administration of Nivolumab on the third day of revascularization after acute anterior ST segment elevation myocardial infarction. The active drug Nivolumab will be administered at a standard dose (5mg/kg) dissolved in 100ml 0.9%NaCl solution. Nivolumab was given at a rate of 15-25 drops per minute, and the intravenous infusion time exceeded 1 hour.
224223921|NCT05887830|OTHER|Placebo|Single administration of Placebo on the third day of revascularization after acute anterior ST segment elevation myocardial infarction. Patients assigned to the placebo treatment group will receive an intravenous infusion of 100 ml 0.9% NaCl solution at a rate of 15-25 drops/min for an IV infusion duration of more than 1 hour.
224223922|NCT05070520|DRUG|Artemether-lumefantrine|Efficacy of artemether lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in three sentinel sites in Niger (Agadez, Gaya and Tessaoua) in 2020
223635274|NCT03613441|BEHAVIORAL|Mindful Awareness Practices (MAPs)|Please refer to arm description
223635275|NCT03310138|DEVICE|Real Transcranial Magnetic Stimulation|Transcranial magnetic stimulation (TMS) is a minimally invasive brain stimulation technology that can focally stimulate the brain of an awake individual. A localized pulsed magnetic field transmitted through a figure-8 coil (lasting only microseconds) is able to focally stimulate the cortex by depolarizing superficial neurons, which induces electrical currents in the brain. TMS pulses that are delivered repetitively and rhythmically are referred to as repetitive TMS (rTMS). In this study TMS is being delivered with the MagVenture MagPro B60 coil.
223635276|NCT03310138|DEVICE|Sham Transcranial Magnetic Stimulation|The MagVenture MagPro system has an integrated active sham that passes current through two surface electrodes placed on the skin beneath the B60 coil.
223635277|NCT00048425|DRUG|Levosimendan|
224223923|NCT03282435|BIOLOGICAL|CIK cells with PD-1 blocking|CIK cellular therapy with PD-1 blocking
224223924|NCT03282435|OTHER|standard lung cancer treament|standard non-small cell lung cancer treatment: surgery, chemotherapy
224223925|NCT03282435|BIOLOGICAL|CIK cells without PD-1 blocking|CIK cellular therapy without PD-1 blocking
224223926|NCT04652921|DIETARY_SUPPLEMENT|Creatine-guanidinoacetic acid|A dietary supplement provided as powder dissolved in a glass of water
224223927|NCT04652921|OTHER|Inulin|A dietary supplement provided as powder dissolved in a glass of water
224223928|NCT01580020|BIOLOGICAL|RFB002|0.5 mg/0.05 mL solution to be injected intravitreally. Ranibizumab was formulated as a sterile solution aseptically filled in a sterile glass vial. Each vial contained ranibizumab in an aqueous solution (pH 5.5) with histidine, trehalose and polysorbate 20.
224223929|NCT01580020|DRUG|Dexamethasone|Ozurdex (Dexamethasone): intravitreal implant as per commercial label (700 µg Dexamethasone; Dexamethasone was formulated as a rod shaped implant to be inserted into the eye by an applicator. The implant as well as the respective applicator were suitable for single use only. Dexamethasone had to be stored according to label instructions and it had to be kept in a secure locked facility
224223930|NCT00075894|DRUG|L-alanosine|
224223931|NCT03834584|DRUG|AG-636|AG-636 will be administered orally intermittently in 28-day cycles.
224223932|NCT03238950|OTHER|Porcine model|participants to conduct training on porcine model
224223933|NCT03238950|OTHER|Synthetic model|participants to conduct training on synthetic model
223635278|NCT05382845|DIAGNOSTIC_TEST|Manual pain provocation tests|Validated and empirical pain provocation tests of the pelvic joints will be performed, both to exclude ongoing symptoms, and to diagnose one or several dysfunctions. The participants will be asked questions regarding previous symptoms, traumas, type of profession etc.
223635279|NCT06442319|BIOLOGICAL|Platelet-rich plasma|Platelet-rich plasma intra-articular injection in patients after anterior cruciate ligament reconstruction
223635280|NCT02784756|DEVICE|Quantiferon-CMV assay|
223635281|NCT05679388|DRUG|Relugolix Pill|A medication used to treat prostate cancer. Relugolix comes as a tablet to take by mouth. It is usually taken with or without food once daily.
223635282|NCT05679388|DRUG|Ritonavir|HIV antiviral It can treat HIV infection, which causes AIDS. It does not cure HIV or AIDS, but combinations of drugs may slow the progress of the disease and prolong life.
223635283|NCT05679388|DRUG|Itraconazole|A drug used to treat fungal infections.
224223934|NCT04482114|RADIATION|ULD CT|All the examinations are part of the routine care. Addition of the ULD CT protocol does not require injection of contrast agent and does not extend the duration of the examination.
224223935|NCT01724359|DRUG|Paliperidone ER|The recommended Paliperidone extended-release (ER) dose will be 6 mg/day. Some patients may benefit from higher or lower doses, in the range of 3 to 12 mg/day. Paliperidone ER will be administered orally once daily. Adjustment of the dosage will be done at the investigator's discretion.
224223936|NCT00224250|PROCEDURE|One- versus two-layer hysterotomy closure|
224223937|NCT04694040|DEVICE|Modjaw® device|Analysis of mandibular kinematics with Modjaw® device
224223938|NCT06014632|OTHER|Rehabilitation|The study group will be given motor control exercises in addition to the program given to the control group.
224223939|NCT06014632|OTHER|Control|The control group will receive stretching, strengthening, core stabilization and educational content as usual care.
223635284|NCT04632680|DEVICE|PVI followed by targeting of drivers|Patients will undergo intraprocedural ECG-I mapping. The pulmonary veins will be isolated followed by targeting of drivers aiming to terminate AF.
223635285|NCT04699864|DIAGNOSTIC_TEST|Screening of DR and DME with artificial intelligence using NeoRetina|Macula-centered eye color fundus photos will be acquired by DIAGNOS team using a non-mydriatic digital camera (without pupil dilation). After a numerical treatment, retinal images will be analyzed by NeoRetina artificial intelligence (AI) algorithm in order to find eye lesions characteristics of diabetic retinopathy (DR) and diabetic macular edema (DME). The severity of DR and DME will be graded by NeoRetina according to the ''Early Treatment Diabetic Retinopathy Study'' (ETDRS) international classification standards.
223635286|NCT04699864|DIAGNOSTIC_TEST|Routine ophthalmological evaluation of DR and DME|Standard of care eye examination (blind assessment) will be performed by an ophthalmologist of the CHUM in order to find lesions characteristics of diabetic retinopathy (DR) and diabetic macular edema (DME). The severity of DR and DME will be graded by the doctor according to the ''Early Treatment Diabetic Retinopathy Study'' (ETDRS) international classification standards.
223635287|NCT04699864|DIAGNOSTIC_TEST|Manual grading of DR and DME by CHUM ophthalmologists based on retinal photographies acquired by Diagnos|Ophthalmologists of the CHUM will revise the macula-centered eye color photos acquired by DIAGNOS in order to find lesions characteristics of diabetic retinopathy (DR) and diabetic macular edema (DME). The severity of DR and DME will be graded (blind assessment) according to the ''Early Treatment Diabetic Retinopathy Study'' (ETDRS) international classification standards.
224223940|NCT03626610|BEHAVIORAL|Exercise prehabilitation during chemotherapy before surgery|Monitored exercise training in patients with a new diagnosis of oesophageal adenocarcinoma
224223941|NCT06432205|PROCEDURE|surgery|any forms of surgery, such as all tumor resection, partial tumor resection and palliative tumor resection surgery
224223942|NCT04246190|DRUG|CKD-501 and D759|Reference drug, CKD-501 1T and D759 1T, QD, PO
224223943|NCT04246190|DRUG|CKD-396|Reference drug, CKD-396 1T, QD, PO
224223944|NCT03096574|OTHER|Questionnaire|The participants will be approached by a member of the study team and, following recruitment, participants will be asked to fill in a short paper or online questionnaire. Our estimated time for completion is 5-10 minutes, and this time will be stated at the start of the questionnaire. Having completed the questionnaire they will be free to leave without further follow up, and given the contact details of the investigators/research governance office whom they can contact if they have further questions or concerns.
224223945|NCT06326268|DEVICE|Phototherapy system CareMin650TM|"* As part of preventive treatment: Photobiomodulation sessions will be carried out at a dose of 3 joules for 1 minute 51 seconds, 3 times a week (for a maximum duration of 4 to 6 weeks).~* As part of curative treatment (i.e. for patients developing mucositis, from grade I): photobiomodulation will be carried out at a curative dose of 6 joules daily (for a maximum duration of 4 to 6 weeks ) for 3 minutes 34 seconds."
224223946|NCT02291107|DEVICE|Lokomat (Hocoma, Zurich, Switzerland)|Patients allocated to the Experimental group performed a Robotic Assisted Gait Training by means of the Lokomat. The Lokomat is robotic device set up as an exoskeleton on the lower limbs of the patient. The system uses a dynamic body weight-support system to support he participant above a motorized treadmill synchronized with the Lokomat.
224223947|NCT02291107|OTHER|Conventional Physiotherapy|Patients allocated to the Control Group performed a general exercise program and a conventional gait training. The same trained therapist treated all the patients in this group and standardized the duration of each part of the treatment.
224223948|NCT00078468|DRUG|PELITREXOL/AG-2037|
224223949|NCT03099967|DEVICE|Transcatheter closure of an atrial septal defect or patent foramen ovale.|In a prospective study in adults troponin T (TnT) serum concentrations were determined before and the day after transcatheter closure of an atrial septal defect (ASD) or patent foramen ovale (PFO).
224223950|NCT00503126|DRUG|bivalirudin|anticoagulation
224223951|NCT02963298|PROCEDURE|Continuous renal replacement therapy|
224223952|NCT00707915|DRUG|Drug: Benzodiazepine (listed out below)|"The benzodiazepine (BZD) dose will be discontinued in 4 weeks by a weekly 25% reduction. BZD-derivative hypnotics will include brotizolam, flunitrazepam, etizolam, quazepam, estazolam, nitrazepam, flurazepam, and diazepam.~All psychotropic agents other than the BZD-derivative hypnotics will be kept constant throughout the study. In addition, the use of trazodone (25-100 mg/day) will be allowed anytime throughout the study period. Subjects will be observed for 8 weeks."
223635288|NCT02649166|DEVICE|Deep brain stimulation|The deep brain stimulation system includes an implantable neurostimulator, thalamic leads to be implanted in the ventral intermediate nucleus (Vim), and subdural cortical strips. The deep brain stimulation system will be set to provide continuous stimulation for the 6 months following surgery. Subjects will be seen monthly for evaluation as a part of normal clinical care for deep brain stimulation. At 6 months, the investigators will determine whether or not the subject is a candidate for closed-loop deep brain stimulation. Qualifying subjects will have the option to have their settings changed in order to participate in the RBS stimulation intervention. These subjects will been seen every 6 months for evaluation as part of normal clinical care for deep brain stimulation.
223635289|NCT02649166|DEVICE|Closed-loop deep brain stimulation|The deep brain stimulation system includes an implantable neurostimulator, Vim thalamic leads, and subdural strips. Six months post-surgery, the deep brain stimulation system will be set to provide responsive stimulation for the duration of the study. Subjects will be seen every 6 months for evaluation as a part of normal clinical care for deep brain stimulation. Data gathered from the subject during the first 6 months will be used to determine if this intervention is applicable for each individual subject. Subjects who do not qualify will continue to receive the other study intervention.
223635290|NCT03645122|OTHER|Paired corticospinal-motoneuronal stimulation (PCMS)|Synapses in the spinal cord that transmit voluntary movement commands from the brain to hand muscles will be activated by noninvasive stimulation in a particular sequence and interval that has been shown to strengthen connectivity.
223635291|NCT03645122|OTHER|Sham stimulation|Synapses in the spinal cord that transmit voluntary movement commands from the brain to hand muscles will not be activated by noninvasive stimulation in a particular sequence and interval that has been shown to strengthen connectivity.
223635292|NCT02402816|DEVICE|MultiPoint Pacing ON|MultiPoint Pacing ON
223635293|NCT02402816|DEVICE|Implantable cardioverter-defibrillator (ICD)|Implantable cardioverter-defibrillator (ICD)
223635294|NCT00446979|DRUG|Placebo gel|HEC (hydroxyethyl cellulose) Control Gel applied vaginally twice daily for two weeks
224223953|NCT00360867|DRUG|AMG 706|The dose of AMG 706 will be administered at the same dose level and schedule received at the conclusion of the previous study but will be no greater than 125 mg QD or 75 mg BID.
224223954|NCT04988945|PROCEDURE|TACE|Procedure of TACE will be standardized.
224223955|NCT04988945|RADIATION|SBRT|SBRT screening and planning will be performed by radiation therapists, medical physicists, and oncologists.
224223956|NCT04988945|DRUG|Durvalumab|1500mg Durvalumab administered IV over 60 minutes on Day 1 of each immunotherapy treatment every 4 weeks until disease progression (PD)
224223957|NCT04988945|DRUG|Tremelimumab|300mg Tremelimumab administered over 60 minutes on Day 1 of cycle 1.
224223958|NCT01082198|BIOLOGICAL|HLA-A1-binding MAGE-1/MAGE-3 multipeptide-pulsed autologous dendritic cell vaccine|
224223959|NCT01082198|BIOLOGICAL|HLA-A2-binding TYR/MART-1/gp100 multipeptide-pulsed autologous dendritic cell vaccine|
224223960|NCT01082198|BIOLOGICAL|autologous melanoma lysate-pulsed autologous dendritic cell vaccine|
224223961|NCT01082198|BIOLOGICAL|autologous melanoma lysate/KLH-pulsed autologous dendritic cell vaccine|
224223962|NCT01082198|BIOLOGICAL|dendritic cell-idiotype-keyhole limpet hemocyanin vaccine|
224223963|NCT01082198|OTHER|flow cytometry|
224223964|NCT01082198|PROCEDURE|adjuvant therapy|
224223965|NCT00231049|DRUG|AG-707|
224223966|NCT03900611|DEVICE|peripheral electrical stimulation|The subjects will undergo 8-week home-based peripheral electrical simulation on the median nerve. The peripheral electrical simulation will be performed once a day for 30 minutes. The stimulation will be active or sham depend on the group assignment.
224223967|NCT02765828|OTHER|Observational study|The following exams will be done in all cohorts: tongue manual muscle testing (MMT), tongue quantitative muscle testing, tongue ultrasound measurements
224223968|NCT01207128|DRUG|Voriconazole, micafungin|Patients will receive either IV micafungin 100 mg or placebo equivalent daily. Intravenous (IV)Voriconazole will be administered at a loading dose of 6 mg/kg every 12 hours for the first 24 hours followed by a maintenance dose of 4 mg/kg every 12 hours. Patients may be switched to oral voriconazole 200 mg BID provided aspergillosis response is achieved and gastrointestinal functions are intact.
224223969|NCT00001728|DRUG|Fosamax (Alendronate)|
224223970|NCT05625711|DEVICE|The endovascular interventional surgical instrument control system|The endovascular interventional surgical instrument control system is based on the analysis of the operation behavior of doctors and their assistants in the process of manual intervention. It simulates the coordinated movement of four manipulators, completes the advance and retreat of the catheter and guide wire cavity, and realizes the different actions of wire feeding along the tube, wire feeding along the wire, wire twisting coordination, wire replacement, stent release, etc.
224223971|NCT03286647|PROCEDURE|Oral hygiene instruction|the participants will receive instructions to perform a satisfatory oral hygiene
224223972|NCT04362033|DIAGNOSTIC_TEST|Passive Leg Raising (PLR) and PEEP increment (PEEP)|PLR: Fluid responsiveness maneuver which patient is positioned from 45 grade of semi-recumbent position to dorsal decubitus and the legs are raised at 45 grades; PEEP increment: Fluid responsiveness maneuver which consisted in increased the PEEP level 5 cmH2O above the mean airway pressure, patient is positioned in 45 grade of semi-recumbent position
224223973|NCT03343106|BEHAVIORAL|ACT plus ERP|16 twice-weekly sessions of 120-minute individual psychotherapy consisting of Acceptance and Commitment Therapy plus Exposure and Response Prevention (ACT plus ERP).
224223974|NCT03343106|BEHAVIORAL|ERP alone|16 twice-weekly sessions of 120-minute individual psychotherapy consisting of Exposure and Response Prevention (ERP alone) monotherapy.
224223975|NCT00593333|DEVICE|Antegrade Intramedullary Nail|Use of an antegrade intramedullary nail implanted through the Piriformis fossa of the femur. The use of these nails has yielded a union rate of 97 - 99%, and has clearly become the most commonly utilized implant for femur fractures.
224223976|NCT00593333|DEVICE|Trigen Trochanteric Femoral Nail|Antegrade intramedullary nails developed with a proximal lateral bend that allows implantation through the greater trochanter rather than the piriformis fossa. This start portal is remarkably easier to locate and may be associated with decreased risk of abductor muscle weakness and pain.
223635295|NCT00446979|DRUG|UC 781|UC 781 0.1% or UC 781 0.25%, applied vaginally twice daily for two intermenstrual weeks
224223977|NCT05909306|OTHER|Education Group|Two online meetings were planned with the education group. In the first meeting, an average of 35-minute-long live lecturing was performed on filling out the data forms and using the partograph e-learning tool through e-learning tool created in the first interview. The researcher held the second interview one week after the first one. In the second interview, a live lecture lasting 30 minutes was given to talk about and solve the problems that students experienced with the partograph e-learning tool and answer the questions. The partograph e-learning tool was kept open for one month for the students in the education group. At the end of the one-month education, the students were asked to fill out the post-test (Academic Achievement Test) defined in the system. After the post-test was completed, the system was closed to the access of the students in the education group and made available to the students in the control group.
224223978|NCT01752920|DRUG|Derazantinib low dose range|Derazantinib was administered orally at dose levels from 25 mg QOD - 200 mg QD on a 28-day schedule.
224223979|NCT01752920|DRUG|Derazantinib middle dose range|Derazantinib was administered orally at dose levels from 250 mg QD - 325 mg QD on a 28-day schedule.
224223980|NCT01752920|DRUG|Derazantinib high dose range|Derazantinib was administered orally at dose levels from 400 mg QD - 425 mg QD on a 28-day schedule.
223635296|NCT03059849|DRUG|Adalimumab|Dose of adalimumab will be increased by 40mg every 2 weeks.
223635297|NCT00142155|DRUG|Rituximab|
223635298|NCT00142155|DRUG|monoclonal antibodies|
223635299|NCT04235608|DRUG|Inhaled sedation with sevoflurane|Inhaled sedation with sevoflurane using the Anesthesia Conserving Device (AnaConDa-S, Sedana Medical, Danderyd, Sweden).
223635300|NCT04235608|DRUG|intravenous sedation with propofol|intravenous sedation with propofol, as already routinely used in participating ICUs.
223635301|NCT06061926|DRUG|Celery Seed|Celery seed capsules (Apium graveolens L.) 150 mg twice times at day, one capsule with 75 mg before breakfast and one capsule with 75 mg before dinner during 12 weeks. Homologated to the other intervention. Oral administration.
223635302|NCT06061926|DRUG|Placebo|Placebo capsules (calcined magnesia) twice times at day, one capsule before breakfast and one capsule before dinner during 12 weeks. Homologated to the other intervention. Oral administration.
223635303|NCT05065060|OTHER|Observation|Observation
224318565|NCT04932421|BEHAVIORAL|Emotion Detectives: Unified protocol for transdiagnostic treatment of emotional disorders in children (UP-C)|"UP-C is a transdiagnostic and emotion-focused cognitive-behavioral group intervention for children aged 6-13 years old with emotions disorders (i.e., anxious and/or mood disorders) and their parents. UP-C unifies cognitive-behavioral, contextual (eg. mindfulness) and parental training techniques aiming to reduce the intensity and frequency of children's clinical symptomatology.~The intervention consists of 15 weekly group sessions (90 minutes per session; 5-8 children and parents per group) conducted by at least two clinical psychologists trained in the UP-C. The sessions start with the parents and children together (15 minutes); then, one psychologist conduct the session with the group of children while the other psychologist conduct the session with the group of parents, simultaneously (60 minutes); finally, the session ends with the group together (15 minutes). This is a structured and manualized intervention with a manual for the therapist and a workbook for the child and parents."
223635304|NCT05737069|DRUG|Ibuprofen arginine granules 400 mg|Experimental- Ibuprofen arginine granules 400 mg, one sachet administration containing 400 mg ibuprofen granules.
223635305|NCT05737069|DRUG|Ibuprofen arginine granules 400 mg (Spedifen)|Marketed drug- Ibuprofen arginine granules 400 mg (Spedifen), one sachet administration containing 400 mg ibuprofen granules.
223635306|NCT00002009|DRUG|Sargramostim|
223635307|NCT03951103|OTHER|rFVIIIFc|Drug according to prescription
223635308|NCT05400967|DRUG|68Ga-FAPI for PET / CT scan and 177Lu-EB-FAPI for therapy|Patients with positive results were screened with 68Ga-FAPI PET / CT, and 2.22GBq(60mci) 177Lu-EB-FAPI was injected intravenously for therapy after contraindications were excluded and informed consent was signed.
223635309|NCT02825498|DEVICE|Contact force guided RFA|Contact force guided RFA during Atrial Flutter ablation procedure.
223635310|NCT00877500|OTHER|Best Practice|Receive standard of care
223635311|NCT00877500|DRUG|Ixabepilone|Given IV
223635312|NCT04610346|BEHAVIORAL|Persons with Aphasia Training Dogs Program|Participants will learn and apply positive reinforcement training techniques for working with dogs to train them in basic obedience behaviors (e.g., SIT, STAY).
223635313|NCT05415761|BEHAVIORAL|iCanQuit|iCanQuit is a smoking cessation smart phone application that uses acceptance and commitment therapy (ACT) approach, a cognitive behavioral treatment
223635314|NCT05415761|BEHAVIORAL|iCanQuit+Motiv8|iCanQuit + Motiv8 is a integrated version of iCanQuit (Cognitive Behavioral Therapy smoking cessation therapy application) with Motiv8 (a contingency management program that rewards decreased smoking determined by measuring CO levels of participant)
223635315|NCT05415761|BEHAVIORAL|Florida quit line|An evidence-based, existing smoking cessation healthcare option recommended by the U.S. clinical practice that connects active smokers to trained quit coaches via referral by their providers.
223764763|NCT03944499|DRUG|FS-1502|"Dose-Escalation Phase (Phase 1a)： FS-1502 dose-escalation will be proceeded on standard 3+3 design with starting dose of 0.1 mg/kg, IV, once per 28 days, 28 days as a cycle in the V1.2 and V2.0 regimens; IV, once per 21 days, 21 days as a cycle in the V3.0 regimens..~Dose level 1: 0.1 mg/kg; Dose level 2: 0.2 mg/kg; Dose level 3: 0.4 mg/kg; Dose level 4: 0.6 mg/kg; Dose level 5: 0.8 mg/kg; Dose level 6: 1.0 mg/kg; Dose level 7: 1.3 mg/kg. If 1.3mg/kg is still tolerated safely and in line with linear kinetic characteristics, and combined with the results of PK, PD, safety and effectiveness, a comprehensive assessment is made to determine whether to continue the dose escalating. The subsequent dose increase ratio is 33% (the dose increase ratio can be adjusted according to the previous data results) until MTD or RP2D.~Dose-expansion Phase (Phase 1b) : RP2D determined in phase 1a, IV."
223635316|NCT04309396|DEVICE|Hydrogen content recording|Eligible participants will eat participants' normal, typical diets during the first week of the study. Participants will use the AIRE machine to measure exhaled H2 content before and after two meals each day - the first meal of the day and the last meal of the day. Participants will breathe into the AIRE machine before eating to obtain a baseline value. Once participants have finished eating, participants will breathe into the AIRE machine 30 minutes, 60 minutes, and 90 minutes postprandially. The participants will record participants' food intake and symptoms directly into participants' smartphone via an app that comes with the AIRE device.
223635317|NCT00651742|DRUG|S-1|All participants received S-1 orally at a dose of 30 mg/m2 BID for 14 days followed by a 1-week recovery period, repeated every 3 weeks. The trial was planned to proceed to the second stage only if sufficient efficacy was demonstrated in Stage 1.
223635318|NCT05106647|BEHAVIORAL|Reduce screen time|The intervention is information provided via email on how to set up an automated response to emails received during their weekend off, reduce screen time for duration of leisure time, and uninstall work applications from their mobile device.
224223981|NCT01752920|DRUG|Derazantinib at recommended phase 2 dose (RP2D)|Derazantinib was administered orally at the recommended phase 2 dose of 300 mg QD on a 28-day schedule.
223635319|NCT06313736|BEHAVIORAL|Action Brings Change Project (15-minute adult version)|The ABC Project is a self-guided online single-session intervention based on principles of behavioral activation. In a slightly different form intended for adolescents, it has demonstrated efficacy in several studies. Its adult version has also shown some efficacy.
223635320|NCT06313736|BEHAVIORAL|Action Brings Change Project (10-minute adult version)|This is a 10-minute shortened version of the 15-minute adult version of the ABC Project. The research team created it and pilot-tested it.
223635321|NCT06313736|BEHAVIORAL|Action Brings Change Project (6-minute adult version)|This is a 6-minute shortened version of the 15-minute adult version of the ABC Project. The research team created it and pilot-tested it.
223635322|NCT06313736|BEHAVIORAL|Action Brings Change Project (2-minute adult version)|This is a 2-minute shortened version of the 15-minute adult version of the ABC Project. The research team created it and pilot-tested it.
223635323|NCT06115642|DRUG|HLX43|HLX43 is an anti-PD-L1 monoclonal antibody conjugated with a novel high potency DNA topoisomerase I (topo I) inhibitor, with a drug-antibody-ratio (DAR) of 8.
223635324|NCT04097938|DRUG|GLPG3667 oral suspension|GLPG3667 oral suspension
223635325|NCT04097938|DRUG|Placebos|Placebo oral suspension
223635326|NCT04097938|DRUG|GLPG3667 capsules|GLPG3667 capsules
223635327|NCT06540742|DIAGNOSTIC_TEST|Artificial intelligence identifies liver hydatids|Artificial neural network was constructed to automatically identify liver hydatid by using deep learning technology
223635328|NCT05995210|PROCEDURE|Kinesio taping|A corrective kinesio taping was applied to the patellofemoral joint for the knee. In addition, exercise therapy was taken.
223635329|NCT05995210|PROCEDURE|Orthosis|They were asked to use a knee orthosis for a minimum of 6 hours a day. They also received exercise therapy.
224223982|NCT00384891|DEVICE|Synergo + MMC|Combined bladder wall hyperthermia and intravesical instillation with cooled Mitomycin-C
223635330|NCT05995210|PROCEDURE|Control|An exercise program focused on the knee and hip muscles was given two days a week.
223635331|NCT04347798|OTHER|Hydroxychloroquine/Chloroquine|Prospective evaluation of development of Covid-19 in inflammatory arthritis patients on biologics with anti-malarials compared to inflammatory arthritis patients on biologics without anti-malarial exposure
223635332|NCT04042441|DRUG|Insulin Degludec/Insulin Aspart|Insulin Degludec/Insulin Aspart (Ryzodeg®) as prescribed by the patient's treating physician. The decision to initiate or switch into treatment with commercially available Ryzodeg® has been made before, and independently from, the decision to include the patient in this study.
223635333|NCT05376917|DEVICE|Zeiss CT Asphina / Zeiss CT Asphina|Monovision with refractive target of -1.50D on the dominated eye
223635334|NCT05376917|DEVICE|Zeiss AT Lara/ Zeiss AT Lisa Tri|Zeiss AT Lara (dominant eye) / Zeiss AT Lisa Tri (non-dominant eye)
223635335|NCT05376917|DEVICE|Zeiss CT Asphina/ Zeiss AT Lara|Zeiss CT Asphina/ Zeiss AT Lara (non-dominant eye)
224223983|NCT00384891|DRUG|Bacillus Calmette-Guérin|Intravesical instillation with BCG (Bacillus Calmette-Guérin)
224223984|NCT03483181|DRUG|Xarelto (rivaroxaban)|An oral anticoagulant medication for the prevention of VTE (Venous thromboembolism) related to orthopedic surgery. Patients received rivaroxaban during one day prior to or two days after orthopedic surgery during the hospitalization.
224223985|NCT03483181|DRUG|Lovenox (enoxaparin)|An injectable anticoagulant medication for the prevention of VTE (Venous thromboembolism) related to orthopedic surgery. Patients received enoxaparin during one day prior to or two days after orthopedic surgeries during the hospitalization.
224223986|NCT02500017|DIETARY_SUPPLEMENT|Melatonin|5mg rapid release melatonin capsule
224223987|NCT02500017|OTHER|Placebo|matching placebo capsule
224223988|NCT03603236|DIAGNOSTIC_TEST|preeclampsia|liver function tests, kidney function tests and platelets measures the ratio of protein to creatinine
224223989|NCT03603236|DIAGNOSTIC_TEST|control|liver function tests, kidney function tests and platelets measures the ratio of protein to creatinine
224223990|NCT03286413|PROCEDURE|microwave ablation|Microwave ablation and cryoablation are both thermal ablation techniques for minimally invasive treatment of breast tumor. They are performed percutaneously by ultrasound guidance.The tumor can be completely killed without injurying adjacent tissue.
224223991|NCT00604656|DRUG|insulin aspart|
224223992|NCT02595333|DRUG|Group SF1|primary cesarean section+postoperative analgesia with sufentanil plus flurbiprofen axetil group
224223993|NCT02595333|DRUG|Group S1|sufentanil was administered for analgesia in primary cesarean section
224223994|NCT02595333|DRUG|Group SF2|sufentanil and flurbiprofen was administered for analgesia in repeated cesarean section
223635336|NCT05376917|DEVICE|Zeiss AT Lara / Zeiss AT Lara|Micromonovision with refractive target of -0.75D on the non-dominant eye
223635337|NCT04930445|DRUG|Oxbryta® (voxelotor) 500mg Tablets|Participants will receive treatment with Oxbryta as prescribed by their physician, as part of their usual care. Participants will be treated and evaluated per standard of care (SOC) and at the physician's discretion. There are no pre-defined treatment requirements.
224223995|NCT02595333|DRUG|Group S2|sufentanil was administered for analgesia in repeated cesarean section
224318566|NCT04932421|OTHER|ABC of Emotions|"ABC of Emotions is a psychoeducational group intervention for children with anxiety and/or mood disorders, aged between 6 to 13 years. ABC of Emotions consists of 5 group psychoeducation sessions (about 90 minutes per session; 5-8 children per group). This is a structured and manualized intervention, with a manual for the therapist and a workbook for the child.~The contents of the sessions were developed by the researchers of this study and are based on classic psychoeducational cognitive-behavioral therapies (CBT) strategies. Since anxiety disorders are more frequent in childhood than mood disorders (e.g., Merikangas et al., 2009), this program is essentially based on psychoeducation materials focused on emotions such as anxiety and fear. However, the same materials are available in an attachment, adapted for use with children to whom the main emotion is not fear/anxiety, but sadness (as in mood disorders)."
224318567|NCT02263287|OTHER|LeSCoD scale|LeSCoD is a clinical scale
224318568|NCT01187056|BEHAVIORAL|Training programme|2 x 2 hours of training (workshops)
223635338|NCT05913882|DEVICE|Respiratory Muscle Strength Training (LVR+EMST)|Combined respiratory muscle strength training regimen that will be completed daily for 5 weeks.
224223996|NCT02916381|PROCEDURE|PEC block + General anaesthesia|Patients will receive an ultrasound-guided PEC block after the induction of general anaesthesia.
224223997|NCT02916381|PROCEDURE|General anaesthesia|
224223998|NCT03164590|DRUG|Ketamine|patients receive local anesthetic wound infiltration with 1 mg /kg ketamine
224223999|NCT03164590|DRUG|dexmedetomidine|patients receive local anesthetic wound infiltration with 1µg/kg dexmedetomidine
224224000|NCT03164590|DRUG|bupivacaine|patients receive local anesthetic wound infiltration with bupivacaine 0.5 % diluted in 20 ml saline
224224001|NCT03201471|DRUG|Chidamide + R-CHOP regimen|Patients will receive 2 courses of Chidamide+ R-CHOP regimen, the way of administration and dosage of the medicine used in the trial is as follows: Rituximab 375mg//m2, ivgtt,d1;CTX 750mg/m2, ivgtt,d2;EPI 70mg/m2, ivgtt,d2;VCR 1.4 mg/m2, ivgtt, d2; Pred 60 mg/m2,PO, d2-6; Chidamide 20mg/d,d1、4、8、11、14、18;one cycle every 21 days;
224224002|NCT02347878|DRUG|Aprepitant|use aprepitant 1 hour before lumbar puncture and intrathecal treatment
224224003|NCT05278377|BEHAVIORAL|"Apprenti en Action program"|"The Apprenti en Action program aims to teach students how to read and follow recipes, prepare and cook various foods using various culinary techniques, and apply food safety practices. Students are also taught the basics of healthy food, nutrition, and cooking."
224224004|NCT02775253|OTHER|Chronic cold acclimation|
224224005|NCT00887003|DRUG|Bupivacaine|Low Volume, Low Dose (5cc, 5mg plain Bupivacaine)
224224006|NCT00887003|DRUG|Bupivacaine|Low Volume, High Dose (5cc, 10mg plain Bupivacaine)
224224007|NCT00887003|DRUG|Bupivacaine|High Volume, Low Dose (10cc, 5mg plain Bupivacaine)
224224008|NCT00887003|DRUG|Bupivacaine|High Volume, High Dose (10cc, 10mg plain Bupivacaine)
224224009|NCT00887003|DRUG|Depo-Medrol|80mg Depo-Medrol
224224010|NCT02682290|OTHER|Expectoration and measurement of sputum rheological properties|
224224011|NCT03183466|PROCEDURE|arthroscopic repair|
224224012|NCT03183466|PROCEDURE|arthroscopic debridement|
224224013|NCT02006966|DRUG|Systemic intravenous lidocaine infusion|In group L, intravenous lidocaine infusion(0.1mg/kg) for 10minutes after induction of anesthesia. After 10 minutes, lidocaine infusion continued at rate of 3mg/kg/hr during operation, and discontinued before move the patients to PACU.
223635339|NCT04050553|DRUG|Tirzepatide|Administered SC
224224014|NCT02006966|DRUG|Normal saline infusion|In group C, the patients receive same volume of normal saline
223635340|NCT04050553|DRUG|Placebo|Administered SC
223635341|NCT05824650|OTHER|Observational|Individuals will be evaluated observationally in a 45-minute period in one day.
224224015|NCT04283578|DRUG|OT|One group will receive OT for 4 weeks, then placebo or OT for 8 weeks
224224016|NCT04283578|DRUG|Placebo comparator|One group will receive Placebo for 4 weeks, then Placebo or OT for 8 weeks.
224224017|NCT03677778|PROCEDURE|Normal saline injected via interscalene nerve catheter|With the catheter covered, treatment group patients will receive a normal saline (NS) bolus regimen (30cc 0.9% NS) via their interscalene nerve block catheter.
224224018|NCT03677778|OTHER|Placebo|With the catheter covered, placebo group patients will go through the same steps as the treatment group, but no solution will be injected into the interscalene nerve block catheter.
224224019|NCT01186978|RADIATION|Radiation Therapy|1.5-2 Gy per fraction to a total dose of 19.8-20 Gy with radiation given 5 days/week
224224020|NCT03822962|DRUG|Ibuprofen 600Mg Tablet|ibuprofen 600 mg by mouth every 8 hours scheduled in addition to standard tylenol regimen.
224224021|NCT03822962|OTHER|"Standard Regimen | Tylenol"|Tylenol 1000 mg by mouth every 6 hours scheduled and a rescue prescription of oxycodone 5 mg tablets by mouth every 6 hours as needed for pain. Ten total oxycodone tablets will be prescribed.
224224022|NCT01227668|DRUG|Aripiprazole|Tablets, Oral, 2-15 mg, once daily, 13-42 weeks
224224023|NCT01227668|DRUG|Placebo|Tablets, Oral, 0 mg, once daily, 16 weeks
224224024|NCT03979209|DRUG|Nasal Mometasone Rinse|Nasal irrigation twice a day (BID) of assigned dose.
224318569|NCT00017095|BIOLOGICAL|filgrastim|
224318570|NCT00017095|DRUG|cyclophosphamide|
224318571|NCT00017095|DRUG|docetaxel|
224318572|NCT00017095|DRUG|epirubicin hydrochloride|
224318573|NCT00017095|DRUG|fluorouracil|
224318574|NCT00017095|GENETIC|microarray analysis|
224318575|NCT00017095|OTHER|immunohistochemistry staining method|
224318576|NCT00017095|OTHER|laboratory biomarker analysis|
223635342|NCT06081296|PROCEDURE|Control group|Control Group (Ctl): alveolus closure with total flap elevation and simple suture; and socket sealing with mixed free gingival tissue graft.
223635343|NCT06081296|PROCEDURE|Mixed free gingival graft group|closure of the alveolus without flap elevation, and placement of a free gingival tissue graft removed from the individual's own palate, which will be properly sutured. This graft is a combination of epithelialized-subepithelial connective tissue graft, which will be taken from the hard palate of the regions.
223635344|NCT06081296|PROCEDURE|Bone+ mixed free gingival graft group|closure of the socket without flap elevation, placement of a freeze-dried bone graft and sealing of the socket with a mixed free gingival tissue graft.
224318577|NCT00017095|PROCEDURE|biopsy|
224318578|NCT00017095|PROCEDURE|conventional surgery|
224318579|NCT00017095|PROCEDURE|neoadjuvant therapy|
223635345|NCT06081296|PROCEDURE|Bone + Titanium Seal group|socket closure without flap elevation, placement of lyophilized bone graft, socket sealing by installing a non-absorbable titanium membrane.
223635346|NCT06006208|DEVICE|Hamilton C1 ventilator during transport to the ICU|Instead of AMBU bag manual ventilation during transport to the ICU, intervention is using Hamilton C1 ventilator during transport to the ICU
223635347|NCT04046497|OTHER|Smartphone App|artificial intelligence (AI) smartphone app to provide support for medication adherence
223635348|NCT04046497|OTHER|Usual Care|Usual Care provided by CSC clinic
223635349|NCT06591143|PROCEDURE|ART|Caries excavation with hand instruments only and restoration with glass ionomer filling
223635350|NCT06591143|PROCEDURE|Hall technique|Stainless steel crown placement without tooth preparation
223635351|NCT06586060|OTHER|lung ultrasound guided fluid balance strategy|"Lung ultrasound (LUS) guided fluid management based on B-Line score assessment using LUS within 24 hours of icu admission and daily thereafter until icu discharge or for up to 14 days after randomization which ever comes first~In patients with BLS = 0-14, a zero fluid balance (FB) will be targeted if no signs of shock are present. In patients with BLS ≥ 15, a daily negative FB of -250 to -1000 mL will be targeted until BLS drops under 15. To reach daily targeted FB, furosemide-induced diuresis and RRT will be used In case of shocked patients with BLS \&amp;amp;lt; 15: they will receive fluid boluses and packed RBCs to achieve a Hb of 10 and a MAP of \&amp;amp;gt;65 mmHg.~In case of shocked patients with BLS ≥ 15: they will start norepinephrine infusion to reach a MAP of \&amp;amp;gt;65 mmHg."
223635352|NCT06586060|OTHER|usual care guided fluid balance strategy|fluid balance management will be guided to maintain an adequate intravascular volume while minimising weight gain within 24 hours of icu admission and daily thereafter until icu discharge or for up to 14 days after randomization which ever comes first. Various parameters will be used to attain this goal based on case-by-case clinical judgment: lung sounds, heart rate, blood pressure, temperature, urine output, lactate, haemoglobin, haematocrit, serum urea, creatinine, sodium, potassium, chloride, and bicarbonate values To reach daily targeted fluid balance, furosemide-induced diuresis and RRT will be used
224224025|NCT03208283|DIAGNOSTIC_TEST|Water method group|During the insertion phase of the initial 30 FS procedures, sterile water will be infused by a standard endoscopy water pump into the distal colon to allow passage of endoscope to ≥ 50cm above anal verge (including rectum, sigmoid colon and part of descending colon), or to the limit of patient tolerance of an unsedated procedure. Air insufflation will not be used during the insertion phase. Trainees will be allowed 10 minutes for the insertion phase. The unassisted portion of the examination would be terminated if reasonable progress is not being attained, excessive patient discomfort observed, or the supervising endoscopist believes that patient safety may be compromised. During the withdrawal phase, air insufflation will be used in standard fashion for examination of the colonic mucosa.
224224026|NCT03208283|DIAGNOSTIC_TEST|Air insufflation group|During the insertion phase of the initial 30 FS procedures, air insufflation will be used to allow passage of endoscope to at least 50cm above anal verge (including rectum, sigmoid colon and part of descending colon), or to the limit of patient tolerance of an unsedated procedure. Trainees will be allowed 10 minutes for the insertion phase. The unassisted portion of the examination would be terminated if reasonable progress is not being attained, excessive patient discomfort observed, or the supervising endoscopist believes that patient safety may be compromised. During the withdrawal phase, air insufflation will be used in standard fashion for examination of the colonic mucosa.
224224027|NCT04998253|DRUG|Effects in oxygenation and hypoxic pulmonary vasoconstriction|"Determination of the anti-inflammatory effect. The anti-inflammatory effect is assessed with serum measurement of interleukin 6 (IL-6), C-reactive protein (CRP), ferritin, DHL (lactic dehydrogenase), taken by venipuncture on admission, at 24 and 48 hours.~The following measurements will be performed: pulmonary artery systolic and diastolic pressure (PASP, PADP respectively), central venous pressure (CVP), pulmonary artery occlusion pressure (PAOP), pulmonary vascular resistance (PVR), systemic vascular resistance (SVR), right ventricular stroke work (RVSW) and left ventricular work (LVSW). Stroke volume (and cardiac output) will be computed using the thermodilution technique averaging three consecutive injections with 10 ml of 0.9% saline solution."
224224028|NCT02925767|DEVICE|311-nm Ti:Sapphire laser|Pallas, LaserOptek, South Korea
224224029|NCT02925767|DEVICE|308-nm excimer laser|XTRAC, PhotoMedex, US
224224030|NCT03871400|PROCEDURE|Anterior cervical discectomy and fusion|primary, 2-level, contiguous
224224031|NCT01033864|DRUG|MMF|1 g per day b.i.d. p.o. for at least 1 month
224224032|NCT01033864|DRUG|EC-MPS|720 mg b.i.d. p.o. for at least 1 month
224224033|NCT01033864|DRUG|Prednisone|5 mg per day p.o.
224224034|NCT03491605|OTHER|peripheral EBV-DNA load|No intervention
224224035|NCT04556669|BIOLOGICAL|Autologous aPD-L1 armored anti-CD22 CAR T cells|Autologous aPD-L1 armored CD22-targeting CAR T cells
224224036|NCT06302712|BEHAVIORAL|Traditional Islamically Integrated Psychotherapy|Traditional Islamically Integrated Psychotherapy for OCD. We will be using the culturally adapted module of TIIP that is translated into the Urdu language for Pakistan Muslims with OCD. The treatment module is mainly based on four domains Nafs (Behavior), Ihsas (Emotions), Aql (Thought), and Ruh (Spirituality). The session will be conducted in an individual format, with eight sessions, and the intervention will be conducted by a certified therapist in TIIP.
224224037|NCT01709383|DEVICE|Transcranial Direct Current Stimulation|The tDCS treatments will be applied bilaterally, with the anodal electrode placed on the left temple and the cathodal electrode placed on the right temple. The tDCS will be applied at the beginning of 60-minute speech-language treatment sessions for five days across a one-week period.
224224038|NCT01709383|DEVICE|Sham Stimulation|The sham tDCS will be applied at the beginning of 60-minute speech-language treatment sessions for five days across a one-week period.
224224039|NCT02245191|DRUG|Ephedrine|5mg after Spinal Anesthesia
223635353|NCT06591273|BIOLOGICAL|Infliximab-dyyb Biosimilar (Remsima)|Subcutaneous injections of Infliximab-dyyb Biosimilar (Remsima) were injected weekly for 4 weeks and then fortnightly for 24 weeks
223635354|NCT00837382|BEHAVIORAL|MEDVAMC Nightmare Treatment|Veteran Nightmare Treatment Using Imagery Rescripting
224224040|NCT02245191|DRUG|Phenylephrine|100mcg after Spinal Anesthesia
224224041|NCT02245191|DRUG|Metaraminol|200mcg Metaraminol after Spinal Anesthesia
224318580|NCT00017095|RADIATION|radiation therapy|
224318581|NCT00491712|PROCEDURE|Glaucoma drainage implant with/without triamcinolone|
223635355|NCT00837382|BEHAVIORAL|Telepsychiatry Nightmare Treatment|Veteran Nightmare Treatment Using Imagery Rescripting Through Videoconferencing
224224042|NCT01109459|OTHER|Pediatric blood pressure screening|Website presenting case-based education with tailoring based on knowledge and interactive with responses collected on line. Has a tool box for office materials to promote and encourage guideline based performance.
224224043|NCT01109459|OTHER|Pediatric vision screening|Website presenting case-based education about amblyopia and strabismus with tailoring based on knowledge and interactive with responses collected on line. Has a tool box for office materials to promote and encourage guideline based performance.
224224044|NCT00119977|PROCEDURE|1 Periacetabular osteotomy|pelvic osteotomy to increase acetabular coverage
224224045|NCT04402554|BEHAVIORAL|Cannabis questionnaire|The effectiveness and use of cannabis in the management of chronic pain has been well known for many years, but has so far been illegal and therefore largely unacknowledged. We hypothesize that the use of cannabis in this population of patients with chronic joint or spinal pain is not anecdotal and responds to a need to further improve the overall management of patients. The objective of our anonymous questionnaire is to estimate the prevalence of cannabis use in patients with chronic inflammatory rheumatism.
224224046|NCT02136732|OTHER|Active self-management intervention|Participants will set health goals at baseline. They will then receive, at minimum, a visit or a phone call to assess how progress and coaching toward meeting goals on a monthly basis from a nurse and/or social worker. The frequency and exact activities associated with the intervention are dependent on each participant's unique health goals.
224224047|NCT02136732|OTHER|Attention control phone calls|Participants will be called by a social service aide at 2, 4, 6, 8, 10, and 12 months.
224224048|NCT05634187|DEVICE|Functional endoscopy|Transnasal endoscopy by an ultrathin video endoscope
224224049|NCT01038583|DRUG|100 mg enteric-coated aspirin|100 mg enteric-coated aspirin, taken daily
224224050|NCT01038583|DRUG|Placebo|100 mg enteric-coated placebo
224224051|NCT03264066|DRUG|Cobimetinib|Participants will receive cobimetinib 60 mg (3 tablets of 20 mg each) orally once a day on Days 1-21 of each 28-day cycle.
224318582|NCT00214383|BEHAVIORAL|CHESS Internet telehealth|CHESS Internet telehealth
224318583|NCT00862732|BEHAVIORAL|Cognitive behavioural therapy|Will receive a series of sessions of cognitive behaviour therapy. Delivery of CBT will be by three therapists; PI and two other Medical Officers. Each session will last for 30- 45 minutes and they will be delivered at the participant's residence (or at an alternative place of participant's choice) at two weeks intervals. They will be followed-up for three months from the cessation of CBT sessions.
224318584|NCT00862732|OTHER|Treatment as usual|Will be referred to the MO(MH). They also will be followed-up for an equal length of time period as of the participants in the intervention group.
224318585|NCT00879411|DRUG|Micardis|
223635356|NCT06585800|OTHER|sample collection|blood and/or tissue collection
223635357|NCT06604247|BEHAVIORAL|Cognitive Behavioral therapy for insomnia (CBT-I)|Cognitive Behavioral Therapy for Insomnia includes evaluation and orientation; data acquisition and delivery of sleep restriction therapy \&amp; stimulus control instructions; review of sleep hygiene; cognitive therapy \[decatastrophization\]; managing nonadherence and relapse prevention), and, finally, the final sessions will be largely focused on time-in-bed titration.
224224052|NCT03264066|DRUG|Atezolizumab|Atezolizumab will be given at a fixed dose of 840 mg by intravenous (IV) infusion on Days 1 and 15 of each 28-day cycle.
224224053|NCT03264066|DRUG|Atezolizumab Cohort 7|Only for participants in cohort 7, the first dose of atezolizumab of 840 mg will be given by IV infusion on Day 15 of Cycle 1; thereafter, they will receive atezolizumab 840 mg IV infusion Q2W on Days 1 and 15 of Cycle 2 and all subsequent cycles.
224224054|NCT02793063|OTHER|Web-based Survey|This study will occur online. Participants will be asked to complete multiple surveys one time. Participants may receive study reminder emails to complete surveys. Participants will be able to complete the surveys all at once or in multiple sessions. Participants will have approximately 3 months to complete the surveys after consenting.
224224055|NCT00382330|DRUG|Ciclopirox|
224318586|NCT03157479|DRUG|Intravenous anesthetic|Anaesthesia induction will be obtained with i.v. 2-3 mg/kg propofol, 0,6-0,8 mcg/kg fentanyl, and 0.9-1,2 mg/kg rocuronium. Anaesthesia will be maintained with i.v. propofol continuous infusion, with a dose titrated to achieve a bi-spectral index value between 40 and 50
224318587|NCT03157479|DRUG|Crystalloid Solutions|Balanced crystalloids will be administered to patients in both groups as a standard rate of 3-5 ml/kg/h. Treatment of eventual hemodynamic instability will be left to the attending physician
224318588|NCT03157479|DIAGNOSTIC_TEST|Esophageal pressure measurement|A nasogastric polyfunctional tube (Nutrivent, Sidam, Italy) will be placed after anaesthesia induction in all enrolled patients to measure esophageal pressure, estimate pleural pressure and compute transpulmonary pressure
223635358|NCT06590831|DRUG|Lactoferrin|to compare between efficacy of lactoferrin alone and lactoferrin with iron for treatment of iron deficiency anemia during 3rd trimester of pregnancy
224318589|NCT03157479|DIAGNOSTIC_TEST|Lung volume measurement with the nitrogen washin-washout technique|Lung volume will be measured through nitrogen wash-in wash-out technique and low-flow Pressure-volume curve will be recorded to estimate differences in alveolar recruitment between the two study groups.
224318590|NCT02244814|BEHAVIORAL|Low Carbohydrate/Conventional|Lower-carbohydrate/conventional diet (usual care)
224318591|NCT02244814|BEHAVIORAL|Choosing Healthy Options in Carbohydrate Energy|Choosing Healthy Options in Carbohydrate Energy
223635359|NCT05624632|OTHER|Remote cognitive testing|Remote cognitive testing
223635360|NCT06604052|PROCEDURE|Reduced-Port Fusion Surgery|(1) The Joint Trocar/Stoma Zone will be delineated by the stoma therapist. (2) The placement of the fusion point will involve collaboration between the surgeon and stoma therapist. This will be based on the surgeon\&#39;s trocar placement plan and the stoma therapist\&#39;s positioning principles. (3) Follow the principles of modified stomal positioning. (4) The surgeon will insert the main trocar based on the preoperative positioning point. During stoma creation, the 12 mm main trocar incision will be extended to 25-30 mm to create an ileostomy.
224318592|NCT05342779|PROCEDURE|stripping of great saphenous vein|"I will make 2 or 3 small cuts in your leg. The cuts are near the top, middle, and bottom of your damaged vein. One is in your groin. The other will be farther down your leg, either in your calf or ankle.~I will then thread a thin, flexible plastic wire into the vein through your groin and guide the wire through the vein toward the other cut farther down your leg.~The wire is then tied to the vein and pulled out through the lower cut, which pulls the vein out with it.~I will close the cuts with stitches. Patient will wear bandages and compression stockings on leg after the procedure."
223635361|NCT06604052|PROCEDURE|Traditional surgery|(1) The stoma therapists perform stoma positioning using traditional stoma positioning method. The surgeon will determine the primary trocar location, ensuring it does not overlap with the stoma site. (2) The surgeon will insert the primary trocar based on the preoperative positioning point and conduct the surgery. During stoma creation, the surgeons create ileal stoma according to the preoperative stoma positioning point.
223635362|NCT06590805|PROCEDURE|Electrotherapy using Chattanooga stimulation unit|Electroacupoint stimulation using the Chattanooga intellect transport 2-channel electrotherapy stimulation unit 2783. It uses the influences energy flows by needling the acupuncture points which lie along the body meridians to achieve a harmonious balance between physical, emotional, and spiritual states. The same effect can be achieved without the use of needles. These needleless stimulations are noninvasive and nontraumatic and are useful for individuals who are scared of needles. They are also associated with decreased risk of infection or bruise.
223635363|NCT06590805|DIETARY_SUPPLEMENT|Balanced Diet using domperidone drug, iron, and folic acid supplementation.|"Postnatal care diet in form of balanced diet using domperidone drug, iron, and folic acid supplementation. Additionally, drinking sufficient clean water and routine postnatal care.~It was performed by asking the participant to take ten mg domperidone three times a day after meals. Iron and folic acid supplementation were also continue for three months after birth."
223635364|NCT05919875|BEHAVIORAL|Unguided Mindfulness-Based Cognitive Therapy|"The unguided iMBCT intervention is divided into six sessions. The sessions are an online adaptation of the regular MBCT. Subsequent sessions are unlocked gradually, once a week. The training consists of audio/video recordings and a workbook. Materials are recorded by a certified MBCT teacher and represent topics raised during regular courses:~1. Awareness and automatic pilot~2. Living in our heads~3. Being present in the body~4. Recognizing aversion~5. Allowing / Letting be~6. How can I best take care of myself?~The intervention requires daily commitment of about 30-40 minutes."
223635365|NCT05919875|BEHAVIORAL|Guided Mindfulness-Based Cognitive Therapy|"The guided iMBCT intervention consists of six online meetings in groups of maximum 25 participants. The weekly meetings will be led by an experienced and certified MBCT teacher. The course of the meeting will represent thematically the unguided condition according to the agenda:~* Introduction to the topic~* Guided meditation~* Brief inquiry and discussion~* Setting tasks for the upcoming week~To reduce the number of differences between the conditions as much as possible and narrow it down to the active participation of the teacher, the meetings will be modified version of MBCT and will last maximum 90 minutes. Between the meetings participants will be ask to practice daily 30-40 minutes mindfulness exercises."
223635366|NCT06991426|DIETARY_SUPPLEMENT|CreaSafe® creatine|Will receive CreaSafe® creatine (0.03 g/kg/day) for 90 days, orally administered diluted in water, every morning (between 7:00 and 9:00 a.m.)
223635367|NCT06991426|COMBINATION_PRODUCT|Placebo 0.03 g/kg/day|will receive a placebo (microcrystalline cellulose; 0.03 g/kg/day) for 90 days, orally administered diluted in water, every morning (between 7:00 and 9:00 a.m.)
223635368|NCT06996418|OTHER|Intergenerational mealtime (intervention + follow-up)|Intergenerational lunchtime at an intentional intergenerational dining room 4 days a week for 8 weeks. Once this period is over, this group will move on to a follow-up phase that will last for another 8 weeks, during which they will eat 5 days a week in different dining rooms with their generational peers, as they had been doing up to the time of the intervention. Finally, they will undergo a last follow-up period of about 2 weeks.
224224056|NCT04305223|PROCEDURE|Dry Needling|Dry Needling is a treatment technique whereby a sterile, single-use, fine filament needle is inserted into the muscle to assist with decreasing pain and improving function through the release of myofascial trigger points (knots in the muscle).
224224057|NCT04305223|OTHER|Upper extremity stretching program|A standard home exercise program consisting of strengthening and stretching exercises for the upper quarter
224318593|NCT00737152|OTHER|RAS 130 with diet and exercise|Entire population, which will also include existing patients, will be treated with RAS 130 along with diet and exercise. By the end of 6 months: 3 months of study and 3 months of follow-up, the entire population will be divided into two groups which will be determined through endpoints. The first group will be subjects with diet and exercise and the second group will be subjects without diet and exercise. The endpoints for the division of the groups are given in the design of the study.
223635369|NCT06996418|OTHER|Intergenerational mealtime (wait + intervention)|Waiting period consisting of 8 weeks (while Intervention Group #1 is using the intergenerational dining room). During this period toddlers and older people will eat lunch 5 days a week with their generational peers in separate dining rooms as they have been doing before the intervention. They will then move to eating together lunch 4 days a week for 8 weeks in the intergenerational dining room. Once this period is over they will enter a final follow-up phase for about 2 weeks during which they will go back to eat in generationally separate dining rooms.
223635370|NCT06672120|BEHAVIORAL|Exercise training|Combined, home-based, supervised, video- assisted, endurance and resistance training
224224058|NCT00949130|DRUG|NXL103|BID for 7-14 days
224224059|NCT00949130|DRUG|Linezolid|BID for 7-14 days
224224060|NCT00686803|DRUG|PL3994|Study drug
224224061|NCT00686803|DRUG|Placebo|Placebo
224224062|NCT01272557|DRUG|Doxorubicin|Doxorubicin 60 mg/m2 i.v. on day 1 every 21 days Sorafenib 400 mg bid (oral) from day 3-19 every 21 days. Maximum accumulative dose of doxorubicin: 360 mg/m2 (thereafter sorafenib monotherapy continuously until progression or unacceptable toxicity).
224224063|NCT01272557|DRUG|Sorafenib|Sorafenib 400 mg bid (oral) continuously
224318594|NCT00003577|DRUG|CMF regimen|
224318595|NCT00003577|DRUG|cyclophosphamide|
224318596|NCT00003577|DRUG|epirubicin hydrochloride|
224318597|NCT00003577|DRUG|fluorouracil|
224318598|NCT00003577|DRUG|methotrexate|
224318599|NCT00003577|PROCEDURE|adjuvant therapy|
224318600|NCT00003577|RADIATION|radiation therapy|
223635371|NCT05730933|BEHAVIORAL|Intervention|Subjects will receive a behavioral intervention with additional education in combination with more frequent follow up and patient reminders
223635372|NCT06999538|OTHER|Radiologist interpretation|two interpretations (with and without Liflow, oncology imaging tool).
223635373|NCT03914443|BIOLOGICAL|Nivolumab|240 mg or 360 mg
223635374|NCT03914443|DRUG|5-FU|750 or 800 mg\^2
223635375|NCT03914443|DRUG|CDDP|70 or 80 mg/m\^2
223764764|NCT06350513|OTHER|Animation movie, story book|"Animation movie: For this study, an animated film (Professor bumblebee animation) prepared for newly diagnosed children with type 1 diabetes will be shown in the experimental group. This is an approximately 10 minute film produced by Life for a children's center in New South Wales (DIABETES AUSTRALIA). The animated film will be translated into Turkish and sent to experts (specialists in the field of Children and Diabetes) for expert opinion. It will be shown to children after all permissions have been obtained following expert opinions. This animated movie is a guide to diabetes for children. Additionally, the storybook will be given as a gift for the children in the experimental group to read.~Story Book: It is an educational booklet version of the Professor Bumblebee animation translated into Turkish and illustrated. The aim here is to serve as an auxiliary tool for newly diagnosed T1D children to look at later and where they are confused."
224224064|NCT06220461|DIETARY_SUPPLEMENT|Folic acid|Infants allocated to the intervention group will receive folic acid (50 mcg flat dose/day) starting at 14 days of age.
224224065|NCT03872700|DRUG|Intranasal fentanyl|Fentanyl Citrate
224224066|NCT03872700|DRUG|Placebo|Sterile Water Up to 5Cc
224224067|NCT05205785|DIETARY_SUPPLEMENT|Human Milk Oligosaccharide Mix|Subjects takes 5.5 g of powder mixed in water once a day for 12 weeks.
224224068|NCT05205785|OTHER|Placebo|The placebo to be used in this trial is 5.5 g of powdered dextrose powder in a single-serve stick pack. The participants will be instructed to mix the product in a 4-6 oz glass of water and consume in the morning once a day for 12 weeks.
224224069|NCT01193517|DRUG|Azacitidine|Starting dose level 75 mg/m2/day subcutaneously on Days 1-5 of a 21 day cycle.
224224070|NCT01193517|DRUG|Capecitabine|1500 mg/m2/day by mouth twice daily in divided doses on Days 1-14 of a 21 day cycle.
224224071|NCT01193517|DRUG|Oxaliplatin|Starting dose level 90 mg/m2 by vein on Day 2 of a 21 day cycle.
224224072|NCT01193517|DRUG|Azacitidine MTD|Highest tolerable dose of combination azacitidine with CAPOX found in Phase I.
224224073|NCT02208583|DRUG|Docetaxel & Prednisone|Docetaxel \& Prednisone: Docetaxel 75mg/m2，d1;Prednisone 5mg，bid，d1-21
224224074|NCT02208583|DRUG|DP & Targeted drugs|Docetaxel 75mg/m2，d1; Prednisone 5mg，bid，d1-21;Targeted drugs for PO. Participants with EGFR gene mutation will receive a drug called Gefitinib; Participants with BRAF gene mutations will receive a drug called Vemurafenib; Participants with AKT1 gene mutations will receive a drug called Celecoxib; Participants who have ERBB2 gene mutation will receive a drug called lapatinib; Participants with PDGFRA gene mutations will receive a drug called sunitinib; Participants with PIK3CA gene mutations will receive a drug called Everolimus
223635376|NCT03914443|DRUG|DTX|70 mg/m\^2
223764765|NCT05263947|DRUG|Bevacizumab and Icotinib|Bevacizumab15mg/kg by intravenous drip infusion on day 1 of a 21-day (within 3 days) cycle; Icotinib orally twice daily at 250mg/day
223764766|NCT05441332|OTHER|EOS Radiation|One EOS exam of lower extremities
223764767|NCT05441332|BEHAVIORAL|Semi-structured interview|Semi-structured interview to identify factors influencing patient adherence behavior for a sub-group of 15 patients. By phone, between 1 to 3 months after inclusion.
223764768|NCT04530552|DRUG|Apalutamide|Given PO
223764769|NCT04530552|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
223764770|NCT04530552|OTHER|Quality-of-Life Assessment|Ancillary studies
223764771|NCT04198116|DRUG|Varenicline|Varenicline 2mg/day
223764772|NCT04198116|DRUG|Guanfacine ER|Guanfacine Extended Release (6mg/day ER)
224224075|NCT02208583|DRUG|cisplatin & Etoposide|cisplatin \& Etoposide:cisplatin 25mg/m2，d1-3; Etoposide 100 mg/m2，d1-3
224224076|NCT02208583|DRUG|EP & Targeted drugs|cisplatin 25mg/m2，d1-3; Etoposide 100 mg/m2，d1-3; Targeted drugs for po. Participants with EGFR gene mutation will receive a drug called Gefitinib; Participants with BRAF gene mutations will receive a drug called Vemurafenib; Participants with AKT1 gene mutations will receive a drug called Celecoxib; Participants who have ERBB2 gene mutation will receive a drug called lapatinib; Participants with PDGFRA gene mutations will receive a drug called sunitinib; Participants with PIK3CA gene mutations will receive a drug called Everolimus
224224077|NCT04888650|OTHER|questionnaire|electronic questionnaire
223635377|NCT06999759|DEVICE|cute serum box|After the children in the intervention group were made to draw pictures, they were glued to the designed cute serum box and chemotherapy drug serum was hidden and they were provided to receive their treatment.
223635378|NCT06999759|OTHER|coloring book and coloring pencils|Children in the intervention group were provided with a coloring book and coloring pencils to make a picture to hang on the picture box.
223764773|NCT06095947|BIOLOGICAL|Influenza Vaccine (Split Virion), Inactivated, Quadrivalent|A total of 652326 healthy children with immunization history and no immunization history aged 3-8 years who met the program requirements received two doses of normally commercially available quadrivalent influenza vaccine according to the 0,30-day procedure.
224224078|NCT00790374|DRUG|BN83495 (Cohort 1)|20 mg daily BN83495 for 28 days
224224079|NCT00790374|DRUG|BN83495 (Cohort 2)|40 mg daily BN83495 for 28 days
224224080|NCT00790374|DRUG|BN83495 (Cohort 3)|60 mg daily BN83495 for 28 days
224224081|NCT03717389|OTHER|presence of soft tissue calcification in head and neck|soft tissue calcifications of the head and neck region in the Egyptian population
224224082|NCT02115256|DRUG|Intravenous Terbutaline|0.25 mL of Intravenous Terbutaline. This will be followed 3 minutes later by an injection of 0.25 mL IV of normal saline.
224224083|NCT02115256|DRUG|Intravenous Nitroglycerine|The dose of IV nitroglycerine will be 100 micrograms three minutes before beginning the procedure, and because of it's short half-life (approximately 3 minutes) will be followed by a second dose 3 minutes later just after the start of the procedure for a total of 200 micrograms.
223635379|NCT06999200|DRUG|neural therapy|This prospective study will be conducted with mothers who underwent general anesthesia for labor or elective cesarean delivery and local anesthesia for postoperative pain management during a one-year period following ethical approval.
223635380|NCT06604403|OTHER|Massage|After the hemodialysis, the patients will receive a 15-20 minute hand and foot massage. This application will be applied to the patients in two weekly dialysis sessions for a total of 8 sessions for four weeks. Before starting the massage applications, the patient's hands and feet will be washed and dried thoroughly. The patients will be given a semi-sitting or lying position that they can feel comfortable in. Before starting the hand and foot massage, the researcher will gently rub and warm their hands and wrists. The massages will start with a hand massage. A foot massage will be performed after the hand massage. 3-5 drops of baby oil applied at room temperature will be used to reduce friction during the massage. Effleurage, petrissage and friction styles of the massage will be applied.
223635381|NCT06998654|BEHAVIORAL|Muli-app|The Muli-app is designed after a traffic-light model, indicating different levels of severity of emotional distress and need for help. Green parts represent self-management measures that can be taken to try to regulate themselves (coping plan, write notes for their next appointment , and exercises to reduce emotional distress.) Yellow parts represent contact-based measures when the patient needs someone to talk to outside office hours, to de-escalate emotional distress and to avoid further crisis. This function connects study participants with mental health professionals at the local psychiatric hospital outside office hours (chat, phone or videocall). When the patient activates this function, the staff at the local hospital have 30 minutes to reply. The red part also activates contact with the local psychiatric hospital, but with a need of acute response, activating acute measures stated in the coping plan, such as access to an open bed in the municipality.
223635382|NCT06998511|OTHER|interdisciplinary collaborative care and family empowerment (ICCM-FE) intervention|The observation group received interdisciplinary collaborative care and family empowerment (ICCM-FE) intervention based on the COM-B model on the basis of routine care.
223635383|NCT06998511|OTHER|routine nursing intervention|The control group received routine nursing intervention, including basic drug treatment, diet and exercise guidance, psychological counseling, etc.
223635384|NCT06587620|DRUG|Tranexamic acid|Start IV infusion of a loading dose of tranexamic acid 10 mg/kg completed to 50 ml saline over 10 min before induction of anesthesia. IV infusion of tranexamic acid at a dose of 1 mg/kg/h immediately after induction till 15 min before the end of surgery.
223635385|NCT06587620|DRUG|Dexmedetomidine|Start IV infusion of a loading dose of dexmedetomidine 1ug/kg completed to 50 ml saline over 10 min before induction of anesthesia. IV infusion of dexmedetomidine 0.3-0.7 µg/kg/h immediately after induction to maintain Mean Arterial Pressure (MAP) between 60-70 mmHg till 15 min before the end of surgery.
223635386|NCT06587620|OTHER|Saline (NaCl 0,9 %) (placebo)|IV infusion of 50 ml saline over 10 min before induction of anesthesia. IV saline infusion immediately after induction till 15 min before the end of surgery.
224224084|NCT03058510|PROCEDURE|Frequency domain optical coherence tomography|OCT is an established medical imaging technique that uses light to capture high-resolution, three-dimensional images of blood vessels
223764774|NCT06028932|DRUG|Sacituzumab govitecan|Sacituzumab govitecan will be administered at 10 mg/kg weekly as an infusion for 2 consecutive weeks (2 weekly doses plus 1 week without treatment represents a single 3 week cycle). Treatment can be continued without a rest period in the absence of progression of disease or unacceptable toxicity.
224224085|NCT00617435|DIETARY_SUPPLEMENT|vaccenic acid enriched diet|"The experimental milk fat, entitled vaccenic acid enriched milk fat (VAMF), has been obtained by feeding cows with a diet containing sunflower oil."
224224086|NCT00617435|DIETARY_SUPPLEMENT|Elaidic acid enriched diet|Mixture of vegetable oils (including partially hydrogenated oils)
224224087|NCT00617435|DIETARY_SUPPLEMENT|control diet|Mixed of different oil
224224088|NCT00577759|OTHER|Active Intervention|Quality improvement activities, including monthly teleconferences and chart audit with feedback, to help practices refer to community resources
224224089|NCT00577759|OTHER|Passive Intervention|Provision of tools to help with referrals to community resources
224224090|NCT00577759|OTHER|No intervention|No intervention
224224091|NCT06126042|DRUG|Test Product|DRL\_AB, Pre Filled Syringe; Solution for injection
224224092|NCT06126042|DRUG|Reference product|USA licenced ORENCIA®, Pre Filled Syringe; Solution for injection
224224093|NCT06126042|DRUG|Reference Medicinal Product|EU approved ORENCIA®, Pre Filled Syringe; Solution for injection
224224094|NCT06358378|DEVICE|Aktiia SA Bracelet|The Aktiia device is a wearable blood pressure monitor developed by the company Aktiia SA. It is designed to monitor at blood pressure frequent intervals throughout the day and night without the need for inflatable cuffs. Instead, it contains optical sensors which collect photoplethysmography signals from arteries in the patient's wrist and uses these to estimate blood pressure. The device only takes measurements when it perceived optimal conditions for doing so, corresponding to minimal arm movement (i.e. a resting state) for at least five minutes and good quality signal detection. This device is commercially available and validated for use in adults aged 85 and younger.
224224095|NCT03849794|OTHER|Experimental Group|"Chiropractic Care A chiropractor will see participants in the experimental group about 3 times per week using a pragmatic approach for 4 weeks, and each session will be approximately 15-20 minutes in duration. The spinal adjustments performed in this study will be high-velocity, low-amplitude thrusts to the spine, pelvic joints, extremities or instrument-assisted adjustments~Physiotherapy:~Physiotherapists will see participants in each group 3 times per week for four weeks. Each session will be approximately 40 minutes in duration. Physiotherapy interventions are likely to include stretches and exercises, massage and mobilization as required."
224224096|NCT03849794|OTHER|Control group|The control group will receive the same physiotherapy intervention as the experimental group at the same frequency of care. The control group will also attend three passive movement sessions with the chiropractor each week, primarily to minimise the psychological effect of the interaction with the chiropractor, but also to act as a physiological control. These passive movement sessions will be 15 minutes in duration.
224224097|NCT01545219|DIETARY_SUPPLEMENT|Prebiotic|8g/day xylo-oligosaccharide
224224098|NCT01545219|DIETARY_SUPPLEMENT|Bi-07|10\^9 CFU B. lactis / day
224224099|NCT01545219|DIETARY_SUPPLEMENT|Synbiotic|8g/day xylo-oligosaccharide + 10\^9 CFU Bi-07
224224100|NCT01545219|DIETARY_SUPPLEMENT|Placebo|8g/day maltodextrin
224318601|NCT03259386|DEVICE|Microelectrode array|Microelectrode array implanted in area of amputation of either transradial or transhumeral amputees. This device is not designed to collect data on safety and effectiveness but rather, the device is a tool to assist in the sensory and motor properties of peripheral nerve stump fibers in amputees and is considered basic physiological research. This study was determined to be IDE exempt by the FDA; the study is considered basic physiological research.
224318602|NCT04871672|OTHER|Pilates Exercises|basic five pilates intermediate workout based on the principles of Pilates
224318603|NCT04871672|OTHER|Home Exercise program|home exercise
224318604|NCT05085444|BIOLOGICAL|Assigned Interventions CD19/BCMA CAR T-cells|Drug: CD19/BCMA CAR T-cells Each subject receive CD19/BCMA CAR T-cells by intravenous infusion Other Name: CD19/BCMA CAR T-cells injection
223635387|NCT06593795|PROCEDURE|ultrasound|"before ECV procedure, an ultrasound will be performed to evaluate~* fetal biometry (BPD, HC, AC, FL, EFW);~* Occiput position (right, left);~* Back position (anterior, posterior, right, left);~* Breech variant (footling, frank, complete);~* Fetal leg posture (extended, flexed)~* Placental localization;~* Amniotic Fluid Index (AFI);~* Fore-bag of amniotic fluid;~* Eventual presence of nuchal cords;~* Fetal head ballottement (yes, no);~* Occiput-spine angle These parameters will be compared to find predictive factors for successful ECV"
223635388|NCT06999876|DEVICE|The AscenZ-VIII Stimulator (Investigational Medical Device)|Sham tPCS current will be delivered through Channel 1, while active TENS treatment delivered through Channel 2, 3 and 4 of The AscenZ-VIII Stimulator via surface electrodes. The placement of electrodes will be exactly the same as the active tPCS montage.
223635389|NCT06999876|DEVICE|The AscenZ-VIII Stimulator (Investigational Medical Device)|This group will receive active TENS treatment delivered through Channel 2, 3 and 4 of The AscenZ-VIII Stimulator via 6\*9cm Silica gel electrodes on top of the tPCS that is delivered through Channel 1. The placement of the electrodes will be on the part of the spinal segment innervating the lower limbs (L1-L5), the adductor muscles and the gastrocnemius muscles.
223635390|NCT06998901|OTHER|FIFA 11+ Kids training program|Participants in this arm will receive the FIFA 11+ Kids training program in addition to their regular basketball practice. The program consists of structured neuromuscular warm-up exercises designed to improve balance, coordination, strength, and overall movement control. It will be implemented over a period of 7 weeks, with sessions conducted four times per week, each lasting approximately 15-20 minutes. The exercises are age-appropriate and follow a progressive format to enhance athletic performance and reduce injury risk in youth athletes.
223635391|NCT06998940|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223635392|NCT06998940|PROCEDURE|Computed Tomography|Undergo CT scan
223635393|NCT06998940|DRUG|Fluorouracil|Given IV
223635394|NCT06998940|DRUG|Gemcitabine|Given IV
224224101|NCT02103738|OTHER|0.5 mg Ranibizumab intravitreal injections|All eligible patients will initially be treated in a fixed loading phase, consisting of one intravitreal injection of Ranibizumab 0.5 mg per month for 3 consecutive months (Day 1, Month 1, and Month 2). After the loading phase, patients will be treated according to the treatment arm to which they have been assigned, either a continued once monthly dosing regimen, or an extended schedule of Ranibizumab intravitreal injections as described below. The planned duration of total treatment is 24 months.
224224102|NCT05738109|OTHER|Self-Talk Journals|Participants randomized to the intervention group will receive a physical copy of the 91-day self-talk journal during the baseline meeting. Participants will also be introduced the purpose of the journal and its intended usage (i.e., daily journaling). Intervention participants will not be offered guidance or feedback on the journal after these initial instructions, in order to emulate an ad libitum usage. Control group participants will not receive any contact with the researchers outside of the planned questionnaires and to receive their journal at the three-month timepoint.
224224103|NCT00722111|DEVICE|lingual press|lingual press (high-intensity, oral, non-swallowing)
224224104|NCT00722111|BEHAVIORAL|effortful swallowing|effortful swallowing (high-intensity swallowing)
224224105|NCT00722111|BEHAVIORAL|natural swallowing|natural swallowing (high frequency, low intensity swallowing)
224224106|NCT00722111|BEHAVIORAL|non-oral sham (control) exercise|non-oral sham (control) exercise
224224107|NCT00111189|DRUG|Placebo|Placebo every 4 wk up to 24 mo
224224108|NCT00111189|DRUG|Paliperidone Palmitate|25, 50, 75 or 100 mg eq every 4 wk for up to 24 mo
224224109|NCT04117152|OTHER|Latent class mixed modeling|To identify CAV trajectories after heart transplantation using a contemporary unsupervised trajectory-based approach known as latent class mixed modeling
224224110|NCT03682783|DIAGNOSTIC_TEST|Fundus Image|Fundus image of optic nerve
224318605|NCT06254612|DRUG|SP-624|Once daily oral administration of two capsules totaling 20 mg/day
224318606|NCT06254612|DRUG|Placebo|Once daily oral administration of two matching placebo capsules
224318607|NCT06299839|DRUG|PAS-004 Capsules|A mitogen-activated protein kinase/extracellular signal-regulated kinase kinase (MAPK/ERK kinase, or MEK) 1/2 inhibitor presented in 1 mg, 4mg, and 10 mg strength capsules, intended for oral administration once daily.
224318608|NCT06299839|DRUG|PAS-004 Tablets|A mitogen-activated protein kinase/extracellular signal-regulated kinase kinase (MAPK/ERK kinase, or MEK) 1/2 inhibitor presented in 4mg strength tablets, intended for oral administration once daily.
224318609|NCT01898221|DRUG|Ethanol|We enter the CS with a sheath advanced from the right internal jugular vein. A sub-selector catheter with a \~90° angle at the tip (typically, a left internal mammary artery angioplasty guide catheter) is advanced through the CS sheath with its tip pointing superiorly and posteriorly.
223635395|NCT06998940|DRUG|Irinotecan|Given IV
223635396|NCT06998940|DRUG|Irinotecan Sucrosofate|Given IV
223635397|NCT06998940|DRUG|Leucovorin|Given IV
223764775|NCT06484855|DRUG|IBI355|IBI355 IV. Q4W
223635398|NCT06998940|DRUG|Nab-paclitaxel|Given IV
223635399|NCT06998940|BIOLOGICAL|Panitumumab|Given IV
223635400|NCT06998940|OTHER|Questionnaire Administration|Ancillary studies
223635401|NCT06999070|DRUG|Dexamethasone 0.1mg/kg|On incidence of Shivering after spinal anaethesia
223635402|NCT06999070|DRUG|Dexamethasone 0.3mg/kg|On incidence of Shivering after spinal anaethesia
223635403|NCT06999551|DRUG|switch NPH to glargin|Switch of patients with type 2 diabetes mellitus from NPH insulin to insulin glargine
223635404|NCT06999343|DRUG|Metformin 850Mg Tab|Tolerance phase dose: 850mg/24h for 2 weeks. Treatment dose: 1700 mg twice daily.
223635405|NCT06999343|OTHER|Placebo|Tolerance phase dose: One tablet/24h for 2 weeks. Treatment dose: Two tablets twice daily.
223635406|NCT04167657|DRUG|Sintilimab|"Sintilimab 200mg IV, every 3 weeks, until progressive disease (PD), intolerable toxicity, or at a maximum of 24 months.~Before enrollment, patient should undergo radiation no less than dose 30Gy( 6 Gy × 5, or other ), or the planned dose could reach 30 Gy. Sintilimab shall be started no later than 3 weeks after radiation. Radiotherapy can be performed on the same day as sintilimab."
223635407|NCT06999031|BIOLOGICAL|BCMA-Targeted Chimeric Antigen Receptor Autologous T-cell|Chimeric Antigen Receptor Autologous T-cell
223635408|NCT06871267|BEHAVIORAL|General Healthy Diet|Participants will follow the quarter-quarter-half plate diet as per the Malaysian Healthy Plate guideline.
224318610|NCT01898221|PROCEDURE|Ablation|The doctor will perform only the standard procedure. Throughout the procedure, the researchers will document the following information for ALL patients: measurements such as whether the treatment was successful or unsuccessful, X-ray exposure time, procedure time, whether there were any complications, and other general procedural measurements.
223635409|NCT06871267|BEHAVIORAL|Crohn's Disease Exclusion Diet (CDED)|Participants will follow the Crohn's Disease Exclusion Diet (CDED), which consists of three phases with specific dietary restrictions.
223635410|NCT05229887|PROCEDURE|Nostril-Tragus-Length|"Endotracheal tube depth is determined by measuring the newborn's nasal septum-tragus length (NTL) and adding 1cm.~The NTL is described as the distance from the base of the nasal septum to the tragus of the ear."
223635411|NCT05229887|PROCEDURE|Vocal cord marking|The endotracheal tube has markings on the tube, which are called vocal cord markings, which will be used to provide a guidance to how deep to place the ETT into the trachea.
223635412|NCT06586697|RADIATION|Thoracic Radiotherapy|Thoracic Radiotherapy (45Gy /1.5Gy/bid/3w)
223635413|NCT06630598|BEHAVIORAL|Online Family Violence Education Resource|"The VEGA Family Violence Education Resources (© 2020 VEGA Project, McMaster University) is an on-line suite of educational resources that target professionals who are likely to encounter survivors of family violence in professional and clinical settings. The resources provide information about family violence, appropriate clinical responses, legal obligations, and more. The resources are broken down into several training modules and include three interactive learning scenarios. The training modules include:~Know About Family Violence in Canada Creating Safety Recognizing and Responding Safely to Child Maltreatment Recognizing and Responding Safely to Intimate Partner Violence Voices of those with Lived Experiences of Family Violence"
223635414|NCT04351711|OTHER|Immunological profiling|The immune activation phenotype will be assessed using a standardized panel of soluble and membrane immune activation markers
223635415|NCT04351711|OTHER|Immunological profiling|The immune activation phenotype will be assessed using a standardized panel of soluble and membrane immune activation markers
223635416|NCT05884645|PROCEDURE|Video-directed endotracheal intubation|There will be no intervention in this prospective observational cohort study. Endotracheal intubation is already used to secure the airway by placing an endotracheal tube into the trachea via the oral or nasal route. Indications include the need for airway control during general anaesthesia, mechanical ventilation, resuscitation, and various forms of acute respiratory distress.
223635417|NCT04998331|OTHER|No Intervention|This is a non-interventional study.
223635418|NCT03600233|DRUG|CVM-1118|"Patients will initially receive CVM-1118 orally twice daily at 200 mg per dose (400 mg total daily dose).~Patients who tolerate this dose for at least 2 Cycles will have the option of increasing the dose of CVM-1118 to 300 mg BID (600 mg total daily dose) if specific criteria are met."
223635419|NCT04887116|BEHAVIORAL|Virtual Reality Exposure Therapy|Ten ninety minute sessions of Virtual Reality Exposure Therapy twice a week for five weeks, either remotely or in person.
223635420|NCT06701864|DIAGNOSTIC_TEST|Palpation|Identification of the cricothyroid membrane using PALPATION, a procedure used to prepare for front of neck airway access
223635421|NCT06701864|DIAGNOSTIC_TEST|Ultrasound|"Identification of the cricothyroid membrane, using ULTRASONOGRAPHY with either the String of pearls or TACA aproach as chosen by the participant , a procedure used to prepare for front of neck airway access"
223635422|NCT06700135|OTHER|sensorimotor stimulation program sessions|The study group, consisting of 15 neonates, received traditional medical treatment along with sensorimotor stimulation program sessions. These sessions included oral stimulation protocol, Tactile/Kinesthetic (T/K) intervention, feeding position, and oral support.
223764776|NCT06484855|DRUG|IBI355 placebo|IBI355 placebo IV. Q4W
224224111|NCT04809428|PROCEDURE|vNOTES salpingectomy|Surgical removal of both salpinx by vNOTES with using a 3-cm of posterior colpotomy and either glove port or Gel point V path. Colpotomy will be closed with using 2.0 rapid vicryl.
224224112|NCT04809428|PROCEDURE|Laparoscopic salpingectomy|Surgical removal of both salpinx by conventional laparoscopy in a standardised fashion: with using one 10-mm umbilical and two 5-mm lateral ports.
224224113|NCT00657956|DEVICE|Advance Biofoam porous metal backed tibial component with or without screw augmentation|total knee arthroplasty tibial component that has a backing of porous titanium metal to facilitate bone in-growth
224224114|NCT00007241|DEVICE|Isometric exercise|
224224115|NCT00005091|DRUG|exatecan mesylate|
224224116|NCT00636428|DRUG|Midazolam|oral midazolam, was prepared into a final solution (2.5 mg/mL) from injectable midazolam hydrochloride and a orange flavored syrup. For preparation, midazolam injection (5 mg/mL) was diluted 1:1 with the flavored syrup.
224224117|NCT02059733|DRUG|18F-DTBZ|"During this study, subjects will receive a single i.v. administration of approximately 10 mCi 18F-DTBZ immediately prior to imaging.~The proposed dose for this study is based on our phase I study. At the proposed human dose of 10 mCi, the whole body effective dose (ED) will be approximately 680 mrem. The estimated human ED is expected to be comparable to or below the range of other approved brain imaging agents, such as 18F-FDG."
224318611|NCT06648967|DIETARY_SUPPLEMENT|Supplementation with a multi-ingredient whey supplement|Malabsorption of two different fructose boluses at baseline and after 3 and 5 weeks of multi-ingredient whey supplementation.
224318612|NCT05101369|DRUG|INCB086550|INCB086550 will be administered orally, followed approximately 10 minutes later by an oral dose solution of radio labeled INCB086550.
223635423|NCT06632639|OTHER|Corrective exercise protocol|The program requires 60 minutes consisting of a ten-minute warm-up, a forty-minute Thera-band exercise, and a ten-minute cool-down. Thera-band exercises are to improve the external rotators, and the extensors and for strengthening the quadriceps and the gluteus. A set consists of 15 reps, each of the exercise methods consisted of three sets.
223635424|NCT06632639|OTHER|Lateral wedged insoles with subtalar strapping|A silicon rubber 10 mm lateral wedge has a 10 mm lateral elevation and a 75 mm width, which has an approximately 7.6 inclination. This silicon rubber material is usually used for cosmetic remodeling and has a natural form-fit to the skin. The 75 mm width silicon rubber is scaphoid shaped and it is suitable for attachment to a barefoot of all of the subjects. The rational for using this inclination is that 7.6 is approximately the median between 5 and 10. Patients will be instructed to use the wedge in an appropriate shoe (not high heels or narrow-toed shoes), 1 h a day during the first week. The duration of use gradually will be increased to the minimum of 8 h a day.
223635425|NCT05801120|DIETARY_SUPPLEMENT|Ketogenic food products|Participants will be given a ketogenic food product prior to the hyperbaric oxygen exposure.
223635426|NCT06700304|DEVICE|N1 Implant|The N1 Implant is a type of implantable brain-computer interface.
223635427|NCT06700304|DEVICE|R1 Robot|The R1 Robot is a robotic electrode thread inserter that implants the N1 Implant.
223635428|NCT06700473|OTHER|reiki|Before the intervention, when their cervical dilatation is 4-5 cm, EC-1, EC-2 and EC-3 will be applied to pregnant women in all groups. After the initial data collection, the researcher TC will apply reiki for approximately 15-20 minutes to pregnant women in the reiki group with cervical dilatation of 4-5 cm. Immediately after the first intervention, the second EC-2 and EC-3 measurements will be performed. The third EC-2 and EC-3 measurements will be performed when the cervical dilatation is 6-7 cm and then the fourth EC-2 and EC-3 measurements will be performed after 15 minutes of reiki application. The fifth EC-2 and EC-3 measurements will be performed when the cervical dilatation is 8-9 cm, followed by 15 minutes of reiki and the sixth EC-2 and EC-3 measurements. The final data will be collected one hour after delivery of the placenta with a seventh VAS measurement and administration of the EC-4. The EC-4 will also be reassessed by the researchers online at six weeks postpartum
223635429|NCT06879626|OTHER|Pecan|2 oz of whole raw pecans
223635430|NCT06879626|OTHER|Pretzel|3.5 oz of pretzel snacks daily
223635431|NCT06704893|DRUG|ASA injection 40 mg group|Participants will receive intra-articular knee injections under ultrasound guidance with AMNIOGEN® 40mg (HCT Regenerative, New Taipei, Taiwan) diluted in 3.0 mL of sterile normal saline.
223635432|NCT06704893|DRUG|ASA injection 20 mg group|Participants will receive intra-articular knee injections under ultrasound guidance with AMNIOGEN® 20mg (HCT Regenerative, New Taipei, Taiwan) diluted in 3.0 mL of sterile normal saline.
223635433|NCT06704893|DRUG|HA injection group|Participants will receive intra-articular knee injections under ultrasound guidance with 3 ml of HyLink (SEIKAGAKU CORPORATION, Tokyo, Japan).
223635434|NCT06704893|DRUG|Normal saline injection group|Participants will receive intra-articular knee injections under ultrasound guidance with 3 ml of sterile normal saline.
223635435|NCT06705361|DEVICE|Transparent Radial Artery Band (Screw-Type)|The researcher will randomly assign patients undergoing radial arterial line removal after open heart surgery into four groups: ice-bag pressure, transparent radial band compression device (screw type), transparent radial band compression device (air type), and control group. The researcher will assign specific card colors to each group: white for the control group, yellow for the ice-bag pressure group, pink for the Transparent Radial Band Compression Device - Screw Type group, and green for the Transparent Radial Band Compression Device - Air Type group. The researcher will place all these cards in a container, allowing the participant to select their preferred color, and then apply the intervention separately to each group.
223635436|NCT06706193|PROCEDURE|Total hip arthroplasty using CPE|
223635437|NCT06706193|PROCEDURE|Total hip arthroplasty using HXLPE|
223635438|NCT06706297|OTHER|pranayama breathing exercise|Normal breathing, focusing on breathing, Alternative Nose Breathing, Cooling Breath, Bee Buzzing Sound, A breathing exercise of 20 minutes in total, consisting of 5 stages: normal breathing and focusing on breathing.
223764777|NCT05480956|BEHAVIORAL|SIRI Checklist|A standardized checklist of clinical items to review by the attending hospitalist with participants.
224224118|NCT04928911|BIOLOGICAL|COVID-19 vaccine|Adults about to receive a COVID-19 vaccine fill out a questionnaire of potential predictors of side effect occurrence
224224119|NCT00905489|DRUG|Nevirapine Immediate Release (IR)|200 mg Tablet or 50 mg / 5 ml oral suspension
224224120|NCT00905489|DRUG|Nevirapine Extended Release (XR)|200 mg, 300 mg or 400 mg Tablet formulation
224224121|NCT06503042|DRUG|Chemotherapy combined with immunotherapy|Patients in the chemotherapy combined with immunotherapy group use any chemotherapy drug in combination with any immunotherapy drug. The premise is that the treatment regimen for patients is consistent with the diagnostic and treatment protocols.
224224122|NCT06503042|DRUG|Chemotherapy only|Patients in the chemotherapy alone group use any chemotherapy drug. The premise is that the treatment regimen for patients is consistent with the diagnostic and treatment protocols.
224224123|NCT05935800|BEHAVIORAL|COVID Patients who Underwent pre-transplant frailty assessment (PFA) at MDMC|This is a single-center, retrospective study that uses de-identified, anonymized patient data. Data from 369 liver transplant candidates who underwent pre-transplant frailty assessments at the Liver Institute at Methodist Dallas from April 1, 2018 to February 28, 2022. The study data will be divided into cohorts: pre-COVID and COVID. Specifically, the pre-COVID period will consist of the dates between April 1st, 2018 and March 12, 2020, while the COVID period will consist of the dates between March 13, 2020 and February 28th, 2022.
224224124|NCT01957657|DRUG|BI 207127|oral administration
224224125|NCT01957657|DRUG|faldaprevir|oral administration
224224126|NCT01957657|DRUG|BI 207127|oral administration
224224127|NCT01957657|DRUG|BI 207127|oral administration
224224128|NCT01957657|DRUG|BI 207127|oral administration
224224129|NCT01957657|DRUG|faldaprevir|oral administration
224224130|NCT01957657|DRUG|faldaprevir|oral administration
224224131|NCT01957657|DRUG|faldaprevir|oral administration
224224132|NCT03331965|DRUG|Metoclopramide 5 MG/ML Injectable Solution|A one-time dose of promotility agent (metoclopramide 10 mg in 10 mL saline IV) will be administered at the time of GJ placement.
224224133|NCT03331965|DRUG|Saline|A one-time dose of a placebo (10 mL saline IV) will be administered at the time of GJ placement.
223635439|NCT06706583|BEHAVIORAL|Telematic educational interviews + standard training|"Physicians attending at healthcare centers in the experimental arm will receive periodic telematic educational interviews in which an Infectious Diseases consultant will provide practical training on the appropriate use of antibiotics through the review of one of the physician´s randomly chosen antibiotic prescription, according to a structured brief interview.~In addition to this, each of these centres will continue carrying out the already established activities of the Regional ASP (PIRASOA)."
223635440|NCT06706583|BEHAVIORAL|Standard training|Primary Care Health Centers assigned to the control group will receive standard educational activities designated by the current Regional ASP (PIRASOA).
223635441|NCT06880341|OTHER|Standard of Care|Standard of care treatment of Transient Neurologic Events (TNEs) as needed
224224134|NCT02668302|COMBINATION_PRODUCT|Steroid-eluting sinus implant|PROPEL (Intersect ENT, Inc., Menlo Park, CA), containing 370μg of mometasone furoate gradually released over 30 days
224224135|NCT02668302|OTHER|Post-op standard of care|Post-op standard of care including debridement, irrigation, and/or topical steroids
224224136|NCT00217256|DEVICE|Percutaneous Coronary Stenting|Endeavor Drug Eluting Stent
224224137|NCT00217256|DEVICE|Percutaneous Coronary Stenting|Cypher Drug Eluting Stent
224224138|NCT01581983|BEHAVIORAL|Internet Mindfulness Meditation|one hour session each week for six weeks
224224139|NCT01581983|BEHAVIORAL|Individual Mindfulness Meditation|one hour session each week for six weeks
224224140|NCT03207659|PROCEDURE|Basketing in RIRS|Treament of renal stones by fragmentation of stone under direct vision through a flexible ureteroscope and then actively extracting them using a basket
224224141|NCT03207659|PROCEDURE|Dusting in RIRS|Treament of renal stones by dusting the stone under direct vision through a scope and then leaving them to pass spontaneously
224224142|NCT03561948|PROCEDURE|Experimental group|After performing the surgical intervention, the patient will undergo intraoperative intra-abdominal chemotherapy with mitomycin C. Further, lavage of the abdominal cavity will be repeated, followed by immunological examination.
224224143|NCT03561948|PROCEDURE|Control group|In the control group (40 patients), after laparotomy and revision, peritoneal lavage will also be performed with subsequent immunological examination. Patients of this group will not receive intraperitoneal chemotherapy. After performing the surgical intervention, the patient will be irrigation of the abdominal cavity with physiological saline. Further, lavage of the abdominal cavity will be repeated, followed by immunological examination.
224224144|NCT02185781|OTHER|Autologous NK cells infusions|"Each patient will receive repeated intravenous (IV) infusions of escalating doses of expanded autologous NK cells.~The initial dose will be 1 x 106/kg of recipient body weight (BW), followed by half log increments of the dose level for each infusion, to a maximum of 1 x 108/kg of recipient BW or until they experience any toxicity, for a maximum of 5 infusions. The minimum interval between each infusion will be 28 days. No conditioning therapies will be administered before the infusion of the expanded NK cells. Patients may receive TKI maintenance."
224224145|NCT03775681|PROCEDURE|Endoscopic Retrograde Cholangiopancreatography|Undergo standard of care ERCP
223635442|NCT06704581|DRUG|5 mg BGM0504 injection|5mg BGM0504 injection administered subcutaneously (SC) once a week.
224224146|NCT03775681|OTHER|Interview|Ancillary studies
223635443|NCT06704581|DRUG|10 mg BGM0504 injection administered subcutaneously (SC) once a week|10mg BGM0504 injection administered subcutaneously (SC) once a week.
223635444|NCT06704581|DRUG|15 mg BGM0504 injection|15mg BGM0504 injection administered subcutaneously (SC) once a week.
223635445|NCT06704581|DRUG|BGM0504 placebo|BGM0504 placebo administered SC once a week.
223764778|NCT05480956|BEHAVIORAL|Enhanced Peer Recovery Coach|Participants will receive the addiction medicine standard of care plus peer recovery coaching beginning while hospitalized and continuing for up to 1 month after randomization. As part of this study, Peer recovery coaches will initiate contact with patients weekly in person during the hospitalization and at the time of hospital discharge. The enhanced part of the peer coach is the post-hospital follow-up. Following discharge, contact will continue weekly in person, by phone, and/or via text messaging based on the participant's preferences for 1 month.
224224147|NCT03775681|DEVICE|Laryngeal Mask Airway|Wear LMA
224224148|NCT03151239|DIETARY_SUPPLEMENT|NMN supplement|Intervention will last at least 8 weeks in the form of two capsules (250 mg total).
224224149|NCT03151239|OTHER|Placebo|Intervention will last at least 8 weeks in the form of two capsules.
224224150|NCT01063530|DEVICE|DIammine SIlver fluoride|Application of Diammine SIlver Fluoride in cervical lesions
224224151|NCT01063530|DEVICE|DIstilled water|Application of distilled water in cervical lesions
224224152|NCT01030276|OTHER|Bright light therapy|Bright light therapy
224224153|NCT01030276|OTHER|"Inactive placebo-light"|In this arm, patients will not get any bright-light therapy in a double-blind setting
224224154|NCT02783742|BEHAVIORAL|Communication coaching|Study coaches will conduct tailored individual sessions with participating providers to teach and improve communication techniques. Coaches will then shadow or audio-record patient encounters and deliver feedback to providers on their communication during these encounters.
224224155|NCT02535052|BIOLOGICAL|Seasonal influenza and pneumococcal polysaccharide vaccines|Vaccination
224224156|NCT06537895|OTHER|EDCRN questionnaires|Participants will complete questionnaires and have blood and other physical tests as specified in the EDCRN dataset.
224224157|NCT00616928|BIOLOGICAL|Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted|Two intramuscular injections at Days 0 and 21.
223635446|NCT05949047|BEHAVIORAL|Cognitive Emotion Regulation Training via Psychological Distancing|The project will randomly assign Alzheimer's Disease or related dementia (AD/ADRD) unpaid primary caregivers to receive a brief course of reappraisal training using either psychological distancing or reinterpretation, or to a no regulation natural history control condition. In the Psychological Distancing group, participants will be asked to down-regulate negative emotion by reappraising an emotional stimulus as an objective, impartial observer.
224224158|NCT00616928|BIOLOGICAL|Placebo|Two intramuscular injections at Days 0 and 21.
224224159|NCT04624269|DRUG|Hydroxychloroquine Sulfate Tablets|Hydroxychloroquine Sulfate Tablets ,0.1mg，bid po
224224160|NCT01149616|DRUG|Dexamethasone 8mg iv x1|Dexamethasone 8mg iv x1
224224161|NCT01149616|DRUG|placebo|2 ml normal saline IV x1
224224162|NCT05351385|PROCEDURE|Hematolgy and Chemistry analysis|Samples will be collected at Day 0, Day 5, Day 10 and Day 15
223635447|NCT05949047|BEHAVIORAL|Cognitive Emotion Regulation Training via Reinterpretation|The project will randomly assign Alzheimer's Disease or related dementia (AD/ADRD) unpaid primary caregivers to receive a brief course of reappraisal training using either psychological distancing or reinterpretation, or to a no regulation natural history control condition. In the Reinterpretation group, participants will be asked to down-regulate negative emotion by imagining a better outcome (when engaging with an emotional stimulus) than what initially seemed apparent.
223635448|NCT05926297|PROCEDURE|Application NaOCl gel + HA gel|First step: application of NaOCl gel Second step: NSMD Third step: application of HA gel
223635449|NCT05926297|PROCEDURE|Non-surgical mechanical debridement|Only mechanical debridement with curettes ans scaler tips
223635450|NCT06705283|PROCEDURE|yoga and home exercise|"The intervention period for the study was determined as 6 weeks. It has been decided that yoga practice will be done 3 times a week for 45 minutes.~Poses to be practiced in the yoga group:~1. Tadasana (mountain pose)~2. Utkatasana (chair pose)~3. Trikonasana (triangle pose)~4. Malasana (squat pose):~5. Viparita Karani Variation (legs up the wall pose)~6. Salamba Set Bandhasana (supported bridge pose)~7. Supta Baddha Konasana (reclining bound angle pose)~8. Savasana (dead pose)"
223635451|NCT06705283|PROCEDURE|whole body vibration training and home exercise|A total of 40-45 minutes of training was planned for WBVT, including warm-up (10 minutes), active phase (25-30 minutes) and cooling phase (5 minutes).
224224163|NCT05351385|PROCEDURE|Real Time PCR|Samples will be collected at Day 0, Day 5, Day 10 and Day 15
224224164|NCT05351385|PROCEDURE|PROS assay COVID+|Samples will be collected at Day 0, Day 5, Day 10 and Day 15
224224165|NCT05351385|PROCEDURE|Sflt1 assay COVID+|Samples will be collected at Day 0 and Day 10
224224166|NCT05351385|PROCEDURE|PROS assay CONTROL|Samples will be collected at Day 0 (+5)
224224167|NCT05351385|PROCEDURE|Sflt1 assay CONTROL|Samples will be collected at Day 0 (+5)
224224168|NCT00900809|BIOLOGICAL|Neukoplast™ (NK-92)|The Neukoplast™ (NK-92) cells will be administered intravenously over 60 minutes. The starting dose of Neukoplast™ (NK-92) cells will be 1 x 10e9 ZRx-101 cells/m2 (The 3 dose levels are: 1 x 10e9 cells/m2, 3 x 10e9 cells/m2 and 5 x 10e9 cells/m2). The second infusion will only be administered after 24 hours if no unacceptable or dose limiting toxicities side effects due to the infusion of Neukoplast™ were encountered after the first infusion.
224224169|NCT05491564|DEVICE|SoftStitch™|The SoftStitch™ meniscal repair system includes a unique knotless all-inside meniscal repair implant with all suture fixation, eliminating the traditional hard plastic PEEK anchors used in the previous devices.
224224170|NCT05585502|OTHER|Training (minute oscillation stretching)|The training session involves the use of an elastic band that the subjects will use to induce passive ankle flexion /extensions (with a frequency of 1 Hz): 10 repetitions will be performed with 60 s exercise and 30 s of pause in-between. At the end of the session, the subjects will fill a diary with data of perceived intensity of exercise and localized ankle pain. The telemedicine session will be conducted by trained personnel.
224224171|NCT05608590|DRUG|Lipiodol UltraFluid|The investigational product is an oil-based contrast medium, Lipiodol® (Guerbet). Lipiodol® is a solution of ethyl esters of iodized fatty acids of poppy seed oil equivalent to 480mg I /ml and is a licensed contrast agent in the Netherlands (RVG 02806, see SmPC D2). The maximum amount of Lipiodol® per HSG procedure is 15 ml.
224224172|NCT06410937|PROCEDURE|thyroidectomy without drain|thyroidectomy without subcutaneous suction drain
224224173|NCT06410937|PROCEDURE|thyroidectomy with drain|hyroidectomy with subcutaneous suction drain
224224174|NCT03621085|DRUG|Ketamine Hydrochloride|A total of 20 mg of Ketamine Hydrochloride will be administered intravenously
224224175|NCT03621085|OTHER|Placebo|Subjects will receive placebo
224224176|NCT04109378|PROCEDURE|Surgical procedures( conventional laparoscopic and NOSE technique) for the treatment of colorectal DIE|For conventional laparoscopic and NOSE techniques a 4-port approach is used. The rectum is skeletonized. The distal rectum is closed using an endoscopic linear stapler. The mobilized rectum with the specimen is retrieved through a small suprapubic incision. The anvil of a conventional circular stapler is introduced in the proximal colon after placement of a purse string suture. A circular stapled colorectal anastomosis is fired. In case of NOSE, both the proximal sigmoid colon and the proximal rectum are tied off laparoscopically with a nonabsorbable suture. A transverse colotomy is performed in healthy tissue using a harmonic scalpel to deliver the anvil from a circular stapler introduced through the anus. The specimen is extracted transrectally in a specimen retrieval bag. Proximal part of the anastomosis is completed by suturing the anvil in place with a laparoscopic suture. The distal rectum is closed using a linear stapler. End-to-end anastomosis is made using the circular stapler
224224177|NCT04967716|OTHER|basic information|Demographic data registration, medical history inquiry, physical examination; electromyography, nerve conduction velocity examination; CMT nerve function score;
224224178|NCT04967716|OTHER|venous blood test|The specific method is as follows: 12ml of peripheral blood is drawn from the peripheral vein, and EDTA is used for anticoagulation. No fasting is required before blood draw, and there is no time limit. Part of the specimens submitted for inspection are sent to a qualified genetic testing company for examination, and the fees are charged in accordance with the corresponding charging standards set by the hospital. The remaining part of the sample will be stored or accumulated for a period of time, and the DNA will be extracted and stored in the sample library.
223635452|NCT06705283|PROCEDURE|home exercise group|Pelvic floor muscle training will be done in the home exercise group. This training will be done in the form of slow and fast contractions of the pelvic floor muscles in supine, chin up, sitting, squat and standing positions.
223635453|NCT04668690|DRUG|Mitoxantrone Hydrochloride Liposome Injection|Drug: Liposomal mitoxantrone hydrochloride (20 mg/m2) administered as an intravenous infusion on day 1 of each 28-day cycle.
223635454|NCT04668690|DRUG|Chidamide|Drug: Chidamide tablet (30 mg) is given to the patients p.o. 30 minutes after breakfast, twice per week with 3-day intervals.
224224179|NCT01512979|DRUG|metformin|1000 mg to 2000 mg per day
224224180|NCT01512979|DRUG|linagliptin|5 mg daily
224224181|NCT01512979|DRUG|metformin placebo|0 to 2 tablets daily
224224182|NCT01512979|DRUG|metformin placebo|4 tablets daily
224318613|NCT03652558|DEVICE|Ozone application with the Ozonytron XL device|An ozone generator (Ozonytron; Bionix, Munchen, Germany) with an KPX probe (CA Probe; Ozonytron, Bionix, Munchen, Germany) was used for OT. Topical gaseous ozone was applied into the periodontal pocket twice a week for 2 weeks based on the manufacturer's instructions. Ozone applications were at 75% power for 30 seconds (75 µg/ml). Ozone applications were performed by an experienced investigator. Ozone applications in the control side were simulated without starting the ozone generator
223635455|NCT06730126|DRUG|Soquelitinib|Soquelitinib is an ITK inhibitor in clinical development for treating relapsed/refractory T-cell lymphoma.
224318614|NCT00858481|DRUG|Spinosad Creme Rinse - Vehicle Control|One or two, 10-minute topical applications (7 days apart)
224318615|NCT00858481|DRUG|Spinosad Creme Rinse|0.5% Spinosad Creme Rinse: one or two, 10-minute topical applications (7 days apart)
223635456|NCT06845644|OTHER|Quantitative neuromuscular MRI|Quantitative neuromuscular MRI is used to quantify a number of biomarkers associated with these pathophysiological processes
223635457|NCT06845644|OTHER|Neuromuscular ultrasound|Neuromuscular ultrasound is used to quantified nerve diameter variation
223635458|NCT06847217|OTHER|Mouth moisturization|This intervention will include mouth cleaning with water and gauze to remove plaque and debris. Water-based hydrating gels (bioXtra Dry Mouth Oral Gel, Lifestream Pharma N.V., Seneffe, Belgium) will be then applied to all oral structures, including the lips, tongue, palate, and cheeks, using gloved fingers or a small toothbrush. In the presence of dried secretions, the gels will be massaged into these areas and left to act for a few minutes to facilitate removal and reduce patient discomfort.
223635459|NCT06847217|OTHER|Mechanical oral hygiene care|Patients with natural teeth will be treated using a soft toothbrush and a sodium lauryl sulfate-free fluoride toothpaste (meridol® toothpaste, Colgate-Palmolive Company, Belgium). The teeth will be brushed using the modified BASS technique. Subsequently, the tongue will be cleaned with either a scraper. For participants wearing dentures, the dentures will be cleaned using a denture brush and soap.
223635460|NCT06847217|OTHER|Combined care|Patients will receive a comprehensive oral hygiene intervention incorporating mouth cleaning, mechanical oral hygiene, and moisturization. The procedure will begin with oral cleaning using water and gauze, followed by mechanical oral hygiene, and conclude with the application of the hydrating gel.
224318616|NCT00858481|DRUG|Spinosad Creme Rinse|1.0% Spinosad Creme Rinse: one or two, 10-minute topical applications (7 days apart)
224318617|NCT00858481|DRUG|Spinosad Creme Rinse|2.0% Spinosad Creme Rinse - one or two, 10-minute topical applications (7 days apart)
223635461|NCT06848439|DRUG|benmelstobart-Anlotinib-Chemo|"Neoadjuvant Treatment Regimen :~Benmelstobart: 1200mg, Day 1, IV (21 days per cycle); Anlotinib: 10mg, Days 1-14, orally (21 days per cycle); Cisplatin: 60mg/m², Day 1, IV (21 days per cycle); Albumin-bound Paclitaxel: 260mg/m², IV infusion, Day 1 (21 days per cycle). Total of 3 cycles.~Surgery is performed within 2 weeks after completing neoadjuvant therapy. Postoperative adjuvant treatment is selected based on pathological grading:~Group A (pCR): Postoperative RT alone: 40Gy/5 weeks. Group B (MPR): Postoperative RT alone: 50Gy/5 weeks. Group C (partial pathological response/no pathological response) : low and intermediate-risk patients: RT: 60Gy/6w; High-risk patients: CCRT: 60-66Gy/6-6.6w + cisplatin: 60mg/m2 Q3W, 2-3 cycles.~All patients also received adjuvant Benmelstobart 3-4 weeks after surgery, as well as maintenance Benmelstobart for a total duration of 1 year."
223635462|NCT06239493|DIAGNOSTIC_TEST|IVUS Guided|Those already undergoing an IVUS guided percutaneous vascular intervention
224318618|NCT01267994|DRUG|Anakinra|100mg of anakinra administered by a subcutaneous injection for 84 consecutive days.
224224183|NCT05363124|OTHER|PEWS calculation by parents using AI-based smartphone app|After patient registration, the patient will be installed in the nursing office with one of his parents . After screening a potential life-threatening patient for which treatment would be started first of all, the nurse will collect the signed parental consent for participating to the study. Explanations will be given to the parents regarding the use of the application and the way to calculate the PEWS through a very brief and standardized education. Parents should then proceed to the calculation of PEWS, as far as possible before the intervention of the nurse, using the Caducy® appl with a smartphone dedicated to the study .
224224184|NCT05363124|OTHER|PEWS calculation by nurse using conventional procedure|After patient registration, the patient will be installed in the nursing office with one of his parents . After screening a potential life-threatening patient for which treatment would be started first of all, the nurse will collect the signed parental consent for participating to the study. the nurse proceed to the calculation of PEWS in blind of parents and to triage process by priorityzing patient in 5 level of gravity (from 1-vital emergency to 5-nonurgent patient). If the medical examination was not proceeded directly after the triage process, nurses were asked to proceed a new triage if the optimal delay of the medical examination was passed.
224224185|NCT02100449|OTHER|Lung ultrasound and Doppler (Day 0)|In patients presenting a consolidation of suspected atelectatic nature, a lung ultrasound examination using pulsed-wave Doppler will be performed on Day 0.
224224186|NCT02100449|OTHER|Lung ultrasound and Doppler (Day 0)|In patients presenting a consolidation of suspected infectious nature, a lung ultrasound examination using pulsed-wave Doppler will be performed on Day 0. A bronchoalveolar lavage will also be performed on Day 0.
224224187|NCT03266549|PROCEDURE|botulinum toxin augmented surgery|unilateral recess-resect procedure, or bilateral rectus muscle recession plus intraoperative injection of 2.5 to 5 units of botulinum toxin A into the recessed muscle.
224224188|NCT03266549|PROCEDURE|conventional surgery|unilateral recess-resect procedure, bilateral rectus muscle recession, or 3 horizontal rectus muscle surgery according to the type of strabismus and the presence or absence of deep amblyopia. The standard correction tables will be used as a guide for the amount of muscle recession and, or resection.
224318619|NCT00004180|DRUG|rosiglitazone maleate|
224318620|NCT03837743|DRUG|DUR-928 Topical Solution|Topical solution containing active drug
224318621|NCT03837743|DRUG|Vehicle Topical Solution|Topical solution containing no active drug
224318622|NCT04791514|DRUG|Treprostinil Palmitil|Administered by oral inhalation using a Plastiape capsule-based dry powder inhaler
224318623|NCT01316302|DRUG|Pristiq|Flexible dose, 50-100mg QD, for 12 weeks.
224318624|NCT01316302|DRUG|Placebo|Matching placebo, taken QD for 12 weeks.
224318625|NCT03052296|DEVICE|Passeo-18 Lux DCB|The endovascular procedure is conducted as per the local standard practice and device instruction for use
223764779|NCT05480956|BEHAVIORAL|SIRI Checklist + Enhanced Peer Recovery Coach|A standardized checklist of clinical items to review by the attending hospitalist with participants. Participants will receive the addiction medicine standard of care plus peer recovery coaching beginning while hospitalized and continuing for up to 1 month after randomization. As part of this study, Peer recovery coaches will initiate contact with patients weekly in person during the hospitalization and at the time of hospital discharge. The enhanced part of the peer coach is the post-hospital follow-up. Following discharge, contact will continue weekly in person, by phone, and/or via text messaging based on the participant's preferences for 1 month.
223764780|NCT06345742|OTHER|No parental participation|"1. Before collecting data, Preterm Infant information form will be filled out.~2. The Premature Infant Comfort Scale will be evaluated before the procedure.~3. Diaper care will be performed by the primary nurse.~4. Premature Infant Comfort Scale will be evaluated during and after the diaper care application."
223764781|NCT06345742|OTHER|Mother participation|"1. Before collecting data, Preterm Infant information form will be filled out.~2. The Premature Infant Comfort Scale will be evaluated before the procedure.~3. Mothers' stress level will be determined using the Neonatal Intensive Care Unit Parent Stress Scale~4. Mothers will be given practical diaper care training on the infant model doll.~5. Diaper care will be provided by the mothers of the infants~6. Premature Infant Comfort Scale will be evaluated during and after the application."
224224189|NCT05497011|DEVICE|PiCSO Impulse System|After blood flow restoration, the subjects meeting all eligibility criteria will be enrolled into the study and randomized either to PiCSO Group or Control Group. If the subject is randomized to PiCSO Group, the coronary sinus (CS) will be cannulated through the femoral vein and the PiCSO Impulse Catheter will be placed in the CS. Once PiCSO Impulse Catheter is placed into CS, PiCSO treatment is started followed by stenting. The physician shall target a PiCSO treatment of 45 minutes whereas the treatment should be continued during and post stent insertion. At the end of the PiCSO treatment, the PiCSO Impulse Console is stopped and the PiCSO Impulse Catheter is removed.
224224190|NCT03031522|RADIATION|18F-IRS|According to experiment, 18F-IRS was non-toxic and stable in serum.
224224191|NCT05250349|DIAGNOSTIC_TEST|Echocardiography|Transthoracic echocardiography with standard measurements
224224192|NCT05250349|DIAGNOSTIC_TEST|Doppler sonography|Transcarotid and transcranial Doppler sonography
224224193|NCT05250349|DIAGNOSTIC_TEST|Neuropsychological tests|Mini Mental State Examination (MMSE) and Montreal Cognitive Assessment (MoCA)
224224194|NCT04413747|BEHAVIORAL|morning Yoga-based breathing support|Low and deep inspiration and phonetic syllable OM laryngeal vibration ( OM technique) as expiratory exercises, sitting in easy pose. The length of more than 5 -8 sec. and frequency between 20 and 23 breaths /min. Conscious breath number (n°) of 15 respiratory acts (RAc) and OM technique n° of 5 RAc and Bhramari pranayama n° of 5 RAc.
224224195|NCT04413747|BEHAVIORAL|pre_lunch Yoga-based breathing support|Low and deep inspiration and OM technique as expiratory exercises, sitting in easy pose.The length of more than 5 -8 sec. and frequency between 20 and 23 breaths /min. Conscious breath number (n°) of 15 respiratory acts (RAc) and OM technique n° of 5 RAc and Surya Bheda pranayama n° of 5 RAc.
224224196|NCT04413747|BEHAVIORAL|pre_dinner Yoga-based breathing support|Low and deep inspiration and OM technique as expiratory exercises, sitting in easy pose.The length of more than 5 -8 sec. and frequency between 20 and 23 breaths /min. Conscious breath number (n°) of 15 respiratory acts (RAc) and OM technique n° of 5 RAc and Nadi Shodhana pranayama n° of 5 RAc.
224224197|NCT02161952|DRUG|Pirfenidone|Pirfenidone was supplied orally in 400 mg gel capsules three times daily (every 8 hours) for a full dosage of 1200 mg daily during 24 months.
224224198|NCT02161952|DRUG|Matched equivalent placebo|
224224199|NCT03776409|DRUG|vancomycin plus piperacillin/tazobactam|Patients in intensive care unit who received the combination of VAN(vancomycin) and PTZ (piperacillin/tazobactam) for at least 48 hours, had a serum creatinine level measured in the 24-hour of hospital admission.The dosage and frequency of VAN and PTZ was adjusted based on clinical practice and patient characteristics.
224224200|NCT03776409|DRUG|vancomycin plus other beta-lactams|Patients in intensive care unit who received the combination of VAN (vancomycin) and other beta-lactams (cefoperazone/sulbactam, meropenem, imipenem/siastatin, ceftriaxone, ceftazidime, et al) for at least 48 hours, had a baseline serum creatinine (Scr) concentration value within 24 hours of hospital admission.The dosage and frequency of VAN and other beta-lactams were adjusted based on clinical practice and patient characteristics.
224224201|NCT03799887|BEHAVIORAL|0% unweighed BWSTT|"30 minutes conventional rehabilitation program (CRP) including range of motion, stretching and strengthening exercises for upper and lower extremities, balance and mobility exercises.~After CRP, participants were provided 30 minutes 0% unweighed BWSTT sessions including a 5 minutes warm - up and cool - down period for each session, 5 days a week, for 6 weeks (totally, 30 sessions)."
224224202|NCT03799887|BEHAVIORAL|10% unweighed BWSTT|"30 minutes conventional rehabilitation program (CRP) including range of motion, stretching and strengthening exercises for upper and lower extremities, balance and mobility exercises.~After CRP, participants were provided 30 minutes 10% unweighed BWSTT sessions including a 5 minutes warm - up and cool - down period for each session, 5 days a week, for 6 weeks (totally, 30 sessions)."
224224203|NCT03799887|BEHAVIORAL|20% unweighed BWSTT|"30 minutes conventional rehabilitation program (CRP) including range of motion, stretching and strengthening exercises for upper and lower extremities, balance and mobility exercises.~After CRP, participants were provided 30 minutes 20% unweighed BWSTT sessions including a 5 minutes warm - up and cool - down period for each session, 5 days a week, for 6 weeks (totally, 30 sessions)."
224224204|NCT04082975|DRUG|NVP-1203|Oral dose for 7 days
224224205|NCT04082975|DRUG|NVP-1203-R|Oral dose for 7 days
224224206|NCT04082975|DRUG|NVP-1203 placebo|Oral dose for 7 days
224224207|NCT04082975|DRUG|NVP-1203-R placebo|Oral dose for 7 days
224224208|NCT04841278|DEVICE|EUS/ERCP|EUS with possible interventions, including liver biopsy and/or cholangiography, and possible ERCP. No new experimental procedures are proposed, only new protocol for diagnosis and treatment of liver graft dysfunction.
224224209|NCT03475732|DRUG|XueBiJing injection|100mL XueBiJing injection (dissolved with 100 mL of 0.9% normal saline),intravenous infusion for 1.25 h, q12h for 5 days
224224210|NCT04185831|DRUG|Atezolizumab|PD-L1 inhibitor
224224211|NCT04185831|DRUG|Everolimus|MTOR inhibitor
224224212|NCT04185831|DRUG|Cobimetinib|MEK inhibitor
224224213|NCT04185831|DRUG|Niraparib|PARP inhibitor
223635463|NCT06812819|DIAGNOSTIC_TEST|Cryostimulation is a form of cooling the body using low temperatures without causing tissue damage. The stimulus effect is achieved at temperatures below - 110⁰C, in a short time of 1-3 minutes. The p|PBC protocol involved the participant being in a JUKA cryosauna (model 0104-1), for 3 minutes at - 140 ° C± - 20 ° C with the lid at shoulder height and the head over the chamber. The cryosauna was cooled with liquid nitrogen, and the temperature was monitored by a computer. Participants entered the cabin wearing clogs, wool socks, shorts, gloves, caps, and disposable PP non-woven masks to protect against inhalation of nitrogen fumes. The temperature inside the cryosauna was recorded at 30-second intervals using a sensor placed on the bottom of the cabin. The temperature of the room where the cryosauna was located was 21.0 ± 0.9° C, and the humidity of the air during the treatment was 35 ± 2, 0 % monitored with a QUIGG type LE 2014.14 moisture absorber.
223635464|NCT01350258|DRUG|Fludarabine|Part of the conditioning regimen
223635465|NCT01350258|DRUG|Thiotepa|Part of the conditioning regimen
223635466|NCT01350258|RADIATION|Total Body Irradiation (TBI)|There is one fraction of total body irradiation (2Gy) as part of the conditioning regimen.
223635467|NCT01350258|BIOLOGICAL|Donor Lymphocyte Infusion (DLI)|Immediately following the conditioning regimen of fludarabine, thiotepa, and TBI, the patient receives a set dose of their donor's T cells (DLI), After the DLI, the donor's T cells will react with the remaining parts of the recipients immune system.
223635468|NCT01350258|DRUG|Melphalan|Two days after the DLI, Melphalan will be given to eliminate the reacting T cells to avoid graft versus host disease. Non-activated T cells should not be affected by the Melphalan and remain to help fight infection.
224224214|NCT01893151|DRUG|Iguratimod|Iguratimod placebo:25 mg/tablet, taken orally, 2 tablets/day (bid),52week
224224215|NCT01893151|DRUG|Iguratimod placebo|Iguratimod placebo:25 mg/tablet, taken orally, 2 tablets/day (bid),24week; Iguratimod:25 mg/tablet, taken orally, 2 tablets/day (bid),28week.
224224216|NCT04633759|OTHER|Blood Flow Restriction Exercise|Following a 5-minute low intensity warm-up, the BFR cuff will be placed at the most proximal portion of the leg and dosed following standard BFR guidelines: 1 set of 30 reps, then 3 sets of 15 reps at 20-30% 1RM with up to 80% limb occlusion. Exercises will target bilateral 1) knee and hip extension, 2) hip abduction, and 3) ankle plantarflexion, as these muscles are important for functional mobility in people with MS.
224224217|NCT00162786|DRUG|Rupatadine|
224224218|NCT00162786|DRUG|Hydroxyzine|
224224219|NCT00162786|DRUG|Placebo|
224224220|NCT01488266|DRUG|Aripiprazole|patients who are randomly assigned to adjunctive aripiprazole are treated with a starting dose of 2.5 (or 5) mg/day of aripiprazole, which can be increased weekly in 2.5\~5mg/day increments to a maximum dose of 15 mg/day based on assessment of tolerability and clinical response. Doses can be decreased at any visit, based on tolerability; They continue to receive the same fixed-dose of the previously used antidepressant throughout the study period when patient is assigned to aripiprazole augmentation group.
224224221|NCT01488266|DRUG|switching to different class of antidepressant|Patients randomly assigned to switching to different antidepressant have to discontinue the previously used antidepressant and receive different antidepressant within flexible therapeutic doses as indication label information (as based on clinicians' preference and experience). Dose increase is permitted until the first 2 weeks of the study.
224224222|NCT02746159|DEVICE|Lutonix 035 Drug Coated Balloon PTA Catheter, Model 9004|
224224223|NCT05448703|OTHER|Blood Samples for Biomarkers|blood sample to be taken at baseline, during radiotherapy, and after radiotherapy
224224224|NCT01363609|DRUG|Liraglutide treatment 12 weeks|liraglutide will be started with a titration period of 2 weeks: week 1 0.6mg once daily, week 2 1.2mg once daily. If well tolerated, treatment will be continued for 10 more weeks in dosage of 1.8mg once daily
224224225|NCT01363609|DRUG|insulin glargine treatment|Insulin glargine treatment consist a treatment period of 12 weeks. Treatment will start with a dosage of 10 IU once daily. Patient will self-titrate the insulin glargine dosage based on self-monitored fasting blood glucose (FBG) concentrations for the previous 3 days using the following guideline: If FBG levels are above 5.6 mmol/L (100-153 mg/dL) on 3 consecutive mornings, the daily dose is to be increased by 2 IU/day. If hypoglycemia documented by glucose concentration \< 3.3 mmol/L (60 mg/dL) or requiring assistance occurs without an easily identifiable reason (skipped meal, excessive physical activity), the daily dose is to be downregulated, with -2 IU/day
224224226|NCT01363609|DRUG|GLP-1 receptor antagonist|Exendin 9-39 will be infused intravenously at doses of 600 pM/kg • min. This will only be during one of the visit for the healthy lean controls and the T2DM group, and during two visits in the group with obesity planned for gastric bypass surgery
224318626|NCT04730037|DRUG|Edoxaban|\- Edoxaban 30 mg/60 mg tablet according to body weight. 60 kg or less: 30 mg once daily, over 60 kg: 60 mg once daily, reduced to 30 mg once daily depending on renal function and concomitant medications
224318627|NCT04730037|DRUG|Warfarin Potassium|\- Warfarin K 1 mg tablets once daily (Dose adjusted with target PT-INR of 1.5-2.5)
224318628|NCT04730037|DRUG|Warfarin Potassium placebo|\- Warfarin K 1 mg placebo tablets once daily
224318629|NCT04730037|DRUG|Edoxaban placebo|\- Edoxaban 30 mg/60 mg placebo tablet according to body weight. 60 kg or less: 30 mg once daily, over 60 kg: 60 mg once daily, reduced to 30 mg once daily depending on renal function and concomitant medications
224318630|NCT04547842|DRUG|Mirtazapine 30 MG|mirtazapine is given in arm M to prevent PONV
223635469|NCT01350258|DEVICE|Hematopoietic stem cell transplantation (HSCT)|"One day after the Melphalan ends, the patient will receive their donor's stem cells. This is the actual day of transplant.~The CliniMACS® Plus Instrument will be used for the selection of human CD34+ hematopoietic stem and progenitor cells in human allogeneic hematopoietic stem cell transplantation."
223635470|NCT02153632|DRUG|amantadine HCl ER|Subjects are given either 240 mg amantadine HCl ER tablet or 320 mg amantadine HCl ER tablet
223635471|NCT02153632|DRUG|Placebo|subjects are given an identical placebo tablet
224318631|NCT04547842|DRUG|Dexamethasone|Dexamethasone is given in arm D to prevent PONV
224318632|NCT01210612|DEVICE|Unilateral CAI|five-toed socks usage
224318633|NCT01920022|DRUG|Mifepristone|Day one of medical abortion
224318634|NCT01920022|DRUG|etonorgestrel|
224318635|NCT02558439|DRUG|CNTX-4975|
224318636|NCT02558439|OTHER|Placebo|
224318637|NCT03287843|PROCEDURE|Total mesorectal excision before 56 days (4-8 weeks)|Low anterior resection or abdominoperineal resection
223635472|NCT06903637|OTHER|Hierarchical Cluster Analysis|The complexity of clinical follow-up stems from the wide range of variables involved, such as physical performance, mobility, pain, psychological well-being, and prosthetic functionality. Therefore, developing methods to identify the most relevant and interrelated clinical variables is critical for enhancing patient management. To address this need, Hierarchical Cluster Analysis (HCA) offers a powerful multivariate statistical approach for detecting relationships among clinical variables.
223635473|NCT06878547|DEVICE|Ultrasound|Non-invasive breast imaging using VisR ultrasound
223635474|NCT04323124|DRUG|PF-07059013|Participants will recieve PF-07059013
223635475|NCT04323124|DRUG|Placebo|Participants will recieve placebo
223635476|NCT04074044|BEHAVIORAL|BHmApp|Use of BHmApp for bladder education and training in pregnancy
223635477|NCT00489307|DRUG|Dexamethasone|4 mg PO (by mouth) twice daily x 14 days
223635478|NCT00489307|DRUG|Placebo|Placebo PO twice daily x 14 days
223635479|NCT06645457|OTHER|stress ball|Patients squeeze the stress ball
223635480|NCT06645457|OTHER|4-7-8 breathing technique|breathing in quietly through the nose for 4 seconds. holding the breath for a count of 7 seconds. exhaling forcefully through the mouth for 8 seconds.
223635481|NCT05888038|DEVICE|virtual reality|virtual reality
223635482|NCT06904586|OTHER|Thyromental distance|Distance between the chin and thyroid cartilage with a tape measure when the patient is in a neutral position
223635483|NCT06904586|OTHER|Neck circumference|Measurement of neck circumference with a tape measure when the patient is in a neutral position
223635484|NCT06904586|OTHER|Mouth opening distance|Distance between the upper and lower teeth at the point where the mouth opening is maximum when the patient is in a neutral position.
224224227|NCT03944785|DRUG|XADAGO (safinamide)|XADAGO (safinamide) is a monoamine oxidase type B (MAO-B) inhibitor indicated as adjunctive treatment to levodopa/carbidopa in patients with Parkinson's disease experiencing off episodes.
223635485|NCT06904586|OTHER|Distance from jawbone to hyoid bone with neck in neutral position|Distance from mentum to hyoid bone with neck in neutral position by ultrasonography
223635486|NCT06904586|OTHER|Distance from jawbone to hyoid bone with neck in extension|Ultrasound measurement of distance from mentum to hyoid bone with neck in extension
223635487|NCT06904586|OTHER|Distance between skin and trachea|Ultrasound measurement of distance between skin and trachea
223635488|NCT06904586|OTHER|Distance between skin and epiglottis|Distance between skin and epiglottis measured by ultrasonography
223635489|NCT06904586|OTHER|Distance between skin and anterior commissure of vocal cord:|Distance between skin and anterior commissure of vocal cord measured by ultrasonography
223635490|NCT06904586|OTHER|Distance between skin and hyoid bone|Distance between skin and hyoid bone measured by ultrasonography
223635491|NCT06904586|OTHER|Maximum Tongue Thickness|Measurement of Maximal Tongue Thickness by Ultrasonography
223635492|NCT03894124|DRUG|Doravirine|Non-nucleoside reverse transcriptase inhibitor. Administered as film coated tablet.
223635493|NCT06653387|DEVICE|CGuard Prime 80cm stent system|This study is single arm looking at the technical success of the CGuard Prime 80cm stent system when used in conjunction with the FDA-cleared ENROUTE NPS during a TCAR procedure.
223635494|NCT04965623|DEVICE|Atrial Shunt|Transcatheter treatment of symptomatic left heart failure patients
223635495|NCT03204188|DRUG|Ibrutinib|Ibrutinib will be administered daily by mouth starting cycle -3 at 420 mg until end study or disease progression or intolerable side effects occur.
223635496|NCT03204188|DRUG|Fludarabine|Fludarabine will be administered intravenously only on cycle -2 at 25mg/m\^2 x5 days.
223635497|NCT03204188|DRUG|Pembrolizumab|Pembrolizumab will be administered intravenously every 3 weeks at 200 mg starting from cycle 1 through cycle 17 or 1 year of immunotherapy phase.
223635498|NCT06924697|DRUG|Application of GLP-1RAs drugs|The pharmacological intervention will be given as an add-on to the standardised psychosocial T2DM treatment paradigm. Patients self-inject Semaglutide once a week or use other GLP-1RAs
223635499|NCT06924697|DRUG|DPP-4i group|The pharmacological intervention will be given as an add-on to the standardised psychosocial T2DM treatment paradigm. Patients took the DPP-4i according to their actual needs.
223764782|NCT06345742|OTHER|Father participation|"1. Before collecting data, Preterm Infant information form will be filled out.~2. The Premature Infant Comfort Scale will be evaluated before the procedure.~3. Fathers' stress level will be determined using the Neonatal Intensive Care Unit Parent Stress Scale~4. Fathers will be given practical diaper care training on the infant model doll.~5. Diaper care will be provided by the fathers of the infants~6. Premature Infant Comfort Scale will be evaluated during and after the application."
224224228|NCT04605952|DIAGNOSTIC_TEST|Repeat SARS-CoV-2 IgG antibodies at 45-65 days|All cases who initially tested positive for SARS-CoV-2 IgG antibodies would undergo a repeat test at 45-65 days
224224229|NCT03201783|OTHER|immediate frozen-thawed embryo transfer|Frozen-thawed embryo transfer will be performed in the first cycle following the stimulated IVF cycle
224224230|NCT03201783|OTHER|delayed frozen-thawed embryo transfer|Frozen-thawed embryo transfer will be performed at least in the second cycle following the stimulated IVF cycle
223635500|NCT03904849|DRUG|Cannabidiol|Cannabidiol oral solution
223635501|NCT03904849|DRUG|Placebo|Placebo oral solution
223635502|NCT06932991|BEHAVIORAL|Cognitive Remediation|cognitive remediation
223635503|NCT03651752|DRUG|Diphenylcyclopropenone (DPCP) Ointment|All subjects will be administered a sensitization dose of 0.05 mL 0.4% DPCP ointment formulation topically in the inner aspect of the upper right arm at Day -16, and 0.05 mL of four concentrations (0.1, .05, 0.01, 0.005%), prepared through dilutions in the ointment vehicle, topically on the inner aspect of the left thigh at Day -2. The weakest strength that may cause a minimal reaction (DTH skin reaction score of 1+) after two days will be chosen, and 0.75-1 g of that concentration will be applied to the scalp starting at Week 1 and administered subsequently twice a week for 18 weeks
223635504|NCT06944106|DRUG|AK112|All enrolled subjects will receive Ivonescimab（AK112，a PD-1/VEGF bispecific antibody，20mg/kg Q3W) in combination with gemcitabine and nab-paclitaxel
223635505|NCT06844383|DRUG|Talazoparib with enzalutamide|Talazoparib (0.5 mg PO QD) and enzalutamide (160 mg PO QD) will be administered in continuous 28-day cycles.
224224231|NCT05368142|DRUG|Nocardia rubra Cell Wall Skeleton|Nocardia rubra cell wall skeleton for external application
224224232|NCT05368142|DRUG|Silver ions dressing|Silver ions dressing for external application
223635506|NCT06844383|DRUG|Talazoparib|Talazoparib (1 mg PO QD) will be administered in continuous 28-day cycles.
224224233|NCT06223581|OTHER|ECHO in sever asthma patient|Evaluation of cardiac burden in patients with sever bronchial asthma
224224234|NCT06483152|OTHER|Metro Transit Pass|A transit pass that enables riders to use the Minneapolis Metro Transit system that will paid for by the study for 6 months
224224235|NCT06483152|OTHER|Standard of Care|The current standard of care for Ryan White eligible clients is to receive two $10 bus cards a month from a case manager
224224236|NCT02347930|OTHER|kidney ultrasound|kidney ultrasound
224224237|NCT05720481|OTHER|Full mouth Scaling and root planing|patients were treated with full mouth Scaling and root planing
224224238|NCT05720481|OTHER|Quadrant Scaling and root planing|patients were treated with quadrant Scaling and root planing
224224239|NCT00526890|DIETARY_SUPPLEMENT|selenomethionine|Oral Twice daily
224224240|NCT00526890|DRUG|carboplatin|Weekly IV
224224241|NCT00526890|DRUG|paclitaxel|Weekly IV
224224242|NCT00526890|OTHER|laboratory biomarker analysis|Correlative Study
223635507|NCT04433065|DEVICE|Intrepid™ TTVR System|Device: Intrepid™ TTVR System
223635508|NCT06955546|DRUG|Toothpaste Product|"Patients have to use the Curasept Prevent Toothpaste daily, during their domiciliar oral hygiene maneuvers.~Link at: https://curaseptspa.it/prodotti/curasept-prevent-dentifricio/"
224224243|NCT00526890|RADIATION|radiation therapy|Undergoing radiation Therapy
224224244|NCT04003870|DEVICE|CASO|Customized arch support orthoses (CASO)
224224245|NCT04003870|DEVICE|HL|Orthotic Heel Lift (HL)
224224246|NCT00328874|DRUG|Coenzyme Q10|
224224247|NCT04706871|DEVICE|taVNS|"taVNS was applied using a Huatuo stimulator (SDZ-IIB) developed by Suzhou manufacture of Medical Device and Material. Stimulation parameters was 1 mA of electrical current at a frequency of 30 Hz with pulse duration ≤ 1 ms, for 30min, administered twice daily.~The two electrodes were placed on the cymba conchae and concha around the left ear."
224224248|NCT04706871|DEVICE|tnVNS|"tnVNS was applied using a Huatuo stimulator (SDZ-IIB) developed by Suzhou manufacture of Medical Device and Material. Stimulation parameters was 1 mA of electrical current at a frequency of 30 Hz with pulse duration ≤ 1 ms, for 30min, administered twice daily.~The two electrodes were placed on the antihelix around the left ear."
224224249|NCT03529955|DRUG|Apremilast 30mg|Patients with refractory cutaneous dermatomyositis will be started on apremilast 30 mg twice a day in addition to a stable dose of their treatment regimen (including steroids and steroid sparing agents).
224224250|NCT03740685|DIAGNOSTIC_TEST|High sesitive C reactive protien|High sesitive C reactive protien will be evaluated at admission time and after 36 hours
224224251|NCT05168059|DRUG|Clevidipine 0.5 MG/ML Intravenous Emulsion|Effectiveness and safety of clevidipine
223764783|NCT04355000|PROCEDURE|Hall technique|SS Crown will be cemented on primary carious molar which satisfy the inclusion criterion without any carious removal, without any tooth preperation, without any local anaesthesia.
223764784|NCT04355000|PROCEDURE|RMGIC restoration|Complete removal of caries and filling will be done with RMGIC material
224224252|NCT00580983|RADIATION|IMRT|
224224253|NCT00580983|DRUG|Paclitaxel|
224224254|NCT00580983|DRUG|Carboplatin|
224224255|NCT00580983|DRUG|Cisplatin|
224224256|NCT00580983|DRUG|5-Fluorouracil|
224224257|NCT02746458|OTHER|Blood Flow Restriction|Brief and intermittent blood flow restriction via a Delfi PTSII Tourniquet System will be used during physical therapy.
224224258|NCT02746458|DEVICE|Delfi PTSII Tourniquet System|
223635509|NCT06955546|DRUG|Mouthwash Product|"Patients have to use the Curasept Prevent Mouthwash daily, during their domiciliar oral hygiene maneuvers.~Link at: https://curaseptspa.it/prodotti/curasept-prevent-collutorio/"
223635510|NCT06955546|DIETARY_SUPPLEMENT|Probiotic|Patients received a daily tablet of Curasept Prevent Probiotics. Link at: https://curaseptspa.it/prodotti/curasept-prevent-probiotico-integratore-alimentare/
223635511|NCT06955546|OTHER|Placebo|Patients received a placebo toothpaste, mouthwash and probiotics. Their appearance was kept identical to mimic the real products containing effective substances, in order to dissuade the patient to drop out.
224224259|NCT03363282|PROCEDURE|Pterygium Excision|Pterygium excision is the first step for repair
224224260|NCT04437069|OTHER|Decision Aid|Participants will view a Decision Aid (delivered as an app) that provides them with information regarding congenital heart disease, as described in the literature. The DA is tailored to the specific diagnosis of the fetus/neonate, so that participants are only viewing information about their baby's specific CHD diagnosis (and not other types of CHD). This is shown using videos and diagrams to clearly explain the defect, what their treatment options are (surgical intervention, comfort care, or termination), and personal stories from other parents who have dealt with the same diagnosis before (including both positive and negative outcomes). The DA was developed according to the International Patient Decision Aid Standards (see http://ipdas.ohri.ca/) (IRS# 14-13332).
224224261|NCT04437069|OTHER|Values Clarification Exercise|The Values Clarification Exercise is a process that aids patients in clarifying their values and goals to improve alignment of their preferences with their chosen treatment. It was developed according to the International Patient Decision Aid Standards. It includes ten values that were chosen based on feedback from the parent investigators and clinicians. The ten values are: 1) discomfort to the child, 2) time in the hospital, 3) risk that the child will have impairments, 4) need to provide home medical care, 5) chronic medical care/decisions, 6) financial issues, 7) life in adulthood, 8) impact on the family, 9) beliefs about doing everything medically possible, \& 10) life expectancy. Each value has a sliding scale where the user can compare 2 treatment options at a time. They are asked which described situation feels better for them and their family.
224224262|NCT01986842|DIETARY_SUPPLEMENT|Protein diet|Subjects will receive either a low protein or a high protein diet for 14 days. High protein will be realized with protein supplements.
224224263|NCT04825080|DIAGNOSTIC_TEST|duplex ultrasound and computed tomography angiography|Identification of carotid artery stenosis \> 60% NASCET criteria
224224264|NCT05738356|COMBINATION_PRODUCT|Adhesive bonding systems|Three different adhesive bonding systems were used; one system per group
224224265|NCT03786666|PROCEDURE|Carotid artery recanalization CEA or carotid artery stenting|Carotid artery recanalization CEA or carotid artery stenting
224318638|NCT03287843|PROCEDURE|Total mesorectal excision after 56 days (8-12 weeks)|Low anterior resection or abdominoperineal resection
223635512|NCT05118022|OTHER|Artificial Intelligence identified Dyskalemia using Electrocardiogram (AIDE) system|Once the AIDE indicates high risk of dyskalemia, an obvious message by scarlet letter was appeared in the HIS operation interface to corresponding physicians. To avoid the alert fatigue, we selected the cut-off points with expected positive predictive values of ≥40% according to previous data, which was the consensus of enrolled physicians before the trial considering the clinical loading. The physicians received the AIDE alerts as long as they were operating HIS logged in by their account, even if they were caring other patients. Physicians can review the AIDE predictions of patients in the intervention group. Therefore, this was a single-blind study since HIS presented different information for patients in intervention and control groups. The participated physicians understood the likelihood of dyskalemia and cardiac risk for those patients with ECG-dyskalemia, and provided suitable medical care according to patients' conditions.
224224266|NCT06210412|BEHAVIORAL|health education and yoga intervention group|"Health education program based on the Penderin Health Promotion Model; It consists of 10 sessions as a program focused on the management of menopause (increasing the quality of life by teaching physical, psychological and social coping methods in menopause, yoga practices and their importance). In the first week, introduction, first tests (Sociodemographic data form, MÖYKÖ), and general introduction of the program will be made. It is a program in which active education methods (question and answer, role play, demonstration, etc.) are used, with each session planned to last approximately 30 minutes. Final tests will be performed at the end of 12 weeks.~Yoga practice will be carried out as 45-minute sessions 2 days a week, which will last for 12 weeks, following the health education program.12. At the end of the week, MOQÖ and Yoga Transformation Impact Scale will be applied to those who have completed 10 weeks."
224224267|NCT02468557|DRUG|Idelalisib|Tablets administered orally twice daily
224224268|NCT02468557|DRUG|Nab-paclitaxel|125 mg/m\^2 administered intravenously on Days 1, 8 and 15 of each 28 day cycle
224224269|NCT02468557|DRUG|mFOLFOX6|mFOLFOX6 will be administered intravenously on Days 1 and 15 of each 28 day cycle. This regimen consists of levoleucovorin 200 milligram/meter per square (mg/m\^2) or racemic leucovorin 400 mg/m\^2, oxaliplatin 85 mg/m\^2, bolus 5-fluorouracil 400 mg/m\^2, and a 46 hour infusion of 5-fluorouracil 2, 400 mg/m\^2.
223635513|NCT03493152|DRUG|Everolimus|mTOR inhibitor
223635514|NCT05527015|DEVICE|Bifocal Spectacles|Bifocals with a +3.00 Diopter flat top 35
223635515|NCT05527015|DEVICE|Single Vision Lenses|Single vision lens as prescribed by provider
224224270|NCT00519012|DRUG|Sertraline to Paroxetine|For subjects enrolled in this arm, sertraline will be initiated at 25mg, increased to 50mg on day 3, and maintained until day 14. If subjects show an early response (i.e. a 20% improvement in the MADRS total score from baseline) at week 2, sertraline will be continued and titrated at 50 - 100mg based on clinical judgment. On the other hand, if subjects fail to show an early response at week 2, they will be randomly divided into two groups. In one group, sertraline will be continued and titrated at 50 - 100mg, whereas in the other group sertraline will be switched to paroxetine. In this switching group, paroxetine will be started at 10mg on days 15 and 16, increased to 20mg on day 17, and further increased to 40mg by a weekly 10mg increase, while sertraline will be dosed at 25mg on day 15 and terminated on day 16.
224224271|NCT00519012|DRUG|Paroxetine to Sertraline|Paroxetine will be initiated at 10mg, increased to 20mg on day 3, and maintained until day 14. If subjects show an early response (i.e. a 20% improvement in the MADRS total score from baseline) at week 2, paroxetine will be continued and titrated at 20 - 40mg based on clinical judgment. On the other hand, if subjects fail to show an early response at week 2, they will be randomly divided into two groups. In one group, paroxetine will be continued and titrated at 20 - 40mg, whereas in the other group paroxetine will be switched to sertraline. In this switching group, sertraline will be started at 25mg on days 15 and 16, increased to 50mg on day 17, and further increased to 100mg by a weekly 25mg increase, while paroxetine will be dosed at 10mg on day 15 and terminated on day 16.
224224272|NCT03316079|OTHER|Chest physiotherapy techniques|Respiratory manual CPT
224224273|NCT03316079|DEVICE|Mechanical insufflation-exsufflation|CPT + MI-E (4 series of 5 inspiratory-expiratory cycles at +/- 40 cmH2O, 3 seconds of inspiratory time, 2 seconds of expiratory time and 1 second pause between cycles).
224224274|NCT01093742|DRUG|HM10560A|Subcutaneously administrate at 0 hour on Day 1
224224275|NCT01093742|DRUG|Placebo|Placebo
224224276|NCT01280799|BEHAVIORAL|Acceptance-based separated family treatment|Family treatment that combines Acceptance and Commitment Therapy (ACT) for the adolescent with Parent Skills Training for caregivers. The treatment package is designed to increase willingness to experience difficult thoughts, feelings, and bodily sensations in order to engage in effective behavior. To facilitate this, caregivers are provided with psychoeducation on eating disorders and skills in behavior management, self-regulation, and emotion regulation.
223635516|NCT02103387|BEHAVIORAL|Cognitive Behavioral Training|Cognitive Behavioral Training \[CBT\] (stress awareness, cognitive restructuring, coping skills training, interpersonal skills training)
223635517|NCT02103387|BEHAVIORAL|Relaxation Training|Relaxation Training \[RT\] (muscle relaxation, deep breathing, guided imagery, meditation)
223635518|NCT02103387|BEHAVIORAL|Health Education Control|Health Education control condition (information about breast cancer diagnosis and treatment, side-effect management, recurrence, physical activity and nutrition, and life after breast cancer)
223635519|NCT03493165|DRUG|Everolimus|mTOR inhibitor
223635520|NCT02693366|OTHER|Bone marrow stem cell|Endovascular infusion of bone marrow derived cells in both renal arteries.
223635521|NCT05790720|DRUG|Propofol|Patients older than 65 years of age will receive an intravenous infusion of Propofol with prespecified plasma targets. During its administration, registration of BIS values, frontal electroencephalography, and clinical signs of consciousness will be performed.
223635522|NCT03215056|DRUG|Methoxyflurane|PENTHROX 3mL inhalation vapour, liquid
223635523|NCT03215056|DRUG|Normal saline|Placebo
223635524|NCT04029636|OTHER|Inhaled Hyperpolarized Xenon-129|How hyperpolarized 129Xe MRI measurements of lung structure and function change over time in a population at high risk for LONIPC related to their transplant
223635525|NCT03290066|DEVICE|kinesiotape|For the Kinesio taping group, a piece of Kinesio tape 5 cm in width and 7-8 cm in length will be applied right from below the navel and will reach to where the pubic hair begins, and another piece of tape 10 cm in length will be applied to make a cross shape with the first piece. A tape of 20cm in length will be placed horizontally to the lower back.
223635526|NCT03290066|OTHER|Usual care|Participants will note the usual self-care used to relief pain (NSAIDs, heat, massage therapy.....).
224224277|NCT04388059|PROCEDURE|Laparoscopic sleeve gastrectomy|Laparoscopic sleeve gastrectomy at 2 and 5 cm from the pylorus on the postoperative weight loss, GLP1 levels and the glycemic control in morbid obese diabetic adolescents.
224224278|NCT01016652|DEVICE|etafilcon A multifocal contact lens|low-add multifocal contact lens
224224279|NCT01016652|DEVICE|etafilcon A Contact Lens|standard sphere contact lens
224224280|NCT02060461|DEVICE|FS200 femtosecond laser LASIK|
224224281|NCT02060461|DEVICE|IntraLase femtosecond laser LASIK|
224224282|NCT03822052|OTHER|Lactated ringers|IV fluid
224224283|NCT03822052|OTHER|5% dextrose lactated ringers|IV fluid
224224284|NCT00845585|DEVICE|Below Knee Arterial Reconstruction|Patency, Reinterventions, Amputations, mortality
224224285|NCT00845585|DEVICE|Below Knee Arterial Reconstruction|Patency, Reinterventions, Amputations, mortality
224224286|NCT00876278|DEVICE|*AT.Smart 46LC|Primary implantation of \*AT.Smart 46 LC into the eye's capsular bag for the visual correction of aphakia in persons in whom the cataractous lens has been removed by phacoemulsification extracapsular cataract extraction. The IOL is intended to be placed only in an intact capsular bag. When implanted, the \*AT.Smart 46LC replaces the natural lens of the eye and functions as a refracting medium in the correction of aphakia.
224224287|NCT04892966|DIAGNOSTIC_TEST|TXI Light Imaging|Standard Colonoscopy using TXI imaging
224224288|NCT04892966|DIAGNOSTIC_TEST|WLI Imaging|Standard Colonoscopy using White Light Imaging
224224289|NCT04142346|BEHAVIORAL|Sitting + moderate intensity breaks|Participants will be followed in a randomized crossover trial undertaken at Faculty of Human Kinetics between April and August 2019. Participants will attend to the laboratory on twelve separate occasions: visit 1 (day 1), baseline assessments for body composition; visit 2 (day 2), cardiorespiratory fitness assessment; visit 3 (day 3), OGTT and the first randomized experimental protocol; visit 4 (day 4), follow-up OGTT; visit 5 (4-6 days after the first experimental protocol), OGTT and the remaining experimental protocol; visit 6 (day following the previous experimental protocol), follow-up OGTT. An additional 6 visits will be performed following the same rational, after a 2-week period of detraining, where participants will be instructed to refrain from structured exercise. The follow-up assessments for body composition and cardiorespiratory fitness will be accomplished after the protocols.
224224290|NCT04812509|DRUG|MW032|The active ingredient of MW032 is a recombinant human anti-RANKL monoclonal antibody ,subcutaneous injection of 120 mg (1.7ml)every 4 weeks for a maximum of 13 consecutive doses throughout the trial.
224224291|NCT04812509|DRUG|Xgeva|The active ingredient of Xgeva® is denosumab,subcutaneous injection of 120 mg (1.7ml)every 4 weeks for a maximum of 13 consecutive doses throughout the trial.
224224292|NCT04459663|DRUG|Toripalimab injection combine with Axitinib|The patients in the group will be infused intravenously with fixed dose of 240mg JS001 on the first day of each cycle. Oral Axitinib 5mg bid (recommended interval of about 12 hours) was given daily from the second day of the initial cycle
224224293|NCT04133181|DEVICE|3D guide|Use of a 3D guide in endodontic surgery
224224294|NCT04133181|DEVICE|Mock guide|Use of a mock guide in endodontic surgery
224224295|NCT03308448|DRUG|Recombinant human erythropoietin|Intravenous administration of recombinant human erythropoietin (4000 u/vial) with different dosage for each group
224224296|NCT00759148|DRUG|Moxifloxacin Alternative Formulation (AF) Ophthalmic Solution 0.5%|Eye drops
224224297|NCT00759148|OTHER|Moxifloxacin AF Vehicle|Inactive ingredients used as a placebo for masking purposes
224224298|NCT03381248|DEVICE|Cooled Radiofrequency|Delivery of energy to ablate sensory nerves via cooled radiofrequency probe.
224224299|NCT03381248|OTHER|Hyaluronic Acid Injection|Delivery of hyaluronic acid into knee by injection with needle to reduce knee pain.
224224300|NCT03381248|OTHER|Crossover from Hyaluronic Acid Injection to Cooled Radiofrequency|Delivery of hyaluronic acid into knee by injection with needle to reduce knee pain. After 6 months, qualifying subjects in this group will have the option to crossover to receive cooled radiofrequency treatment.
224318639|NCT00387556|DRUG|Ondansetron|ondansetron (0.15 mg/kg/dose; maximum dose 4 mg)
223635527|NCT04524780|DEVICE|intracardiac echocardiography|30 patients use intracardiac echocardiography to guide left atrial appendage occluder device, 30 patients use radiography to guide left atrial appendage occluder device.
223635528|NCT01520506|DEVICE|Covidien OneShot™ System|Placed percutaneously, the OneShot™ balloon catheter is advanced into the renal artery using a routine femoral approach in a cardiac catheterization laboratory setting. RF is applied with pre-programmed time and intensity in each of the renal arteries.
223764785|NCT06297122|OTHER|Collection of data from the patient's medical file|Collection of data from the patient's medical file (electronic health record). The identification of eligible cases will be conducted through an examination of the hospital's electronic microbiology database. Subsequently, the complete hospital record(s) of each patient will be used to extract a pre-defined set of variables required for data analysis.
223764786|NCT03916146|BEHAVIORAL|Parent Training Intervention|Adapted version of the Family Check-Up/Everyday Parenting intervention
224224301|NCT06430879|DEVICE|VICTORY PATCH|Drug- free, non-invasive patch (VICTORY Patch) with haptic vibrotactile trigger technology (VTT)
224224302|NCT06430879|DEVICE|Sham Patch without VTT|Sham Patch without haptic vibrotactile trigger technology (VTT)
224224303|NCT02954679|OTHER|Online self-administrated and anonymous survey questionnaire|The study will be conducted during a period of 3 years, between September 2016 and September 2019, according to a standardized methodology identical in every school involved and a procedure based on an online self-administrated and anonymous survey questionnaire. The questionnaire, elaborated on Limesurvey®, will be available for two successive academic years for all students aged more than 18 years old.
224318640|NCT02847988|DEVICE|Neuromuscular electrical Stimulation (NMES)|Electrical stimulation of lower extremities will be applied using an electrotherapy stimulator device (Vectra® Neo). The intensity of stimulation will be titrated based on maximal tolerable muscle contraction
224318641|NCT02847988|DEVICE|Sham Stimulation|Sham stimulation of lower extremities will be applied using an electrotherapy stimulator device (Vectra® Neo).
224318642|NCT03391726|OTHER|CART-19 cells|CART-19 cells treat
224318643|NCT00086281|DRUG|Xyrem (X)|Xyrem (Sodium Oxybate) Oral Solution
224318644|NCT00086281|DRUG|Zolpidem (Z)|Zolpidem 10 mg oral tablets
223635529|NCT00425269|BEHAVIORAL|lifestyle intervention (diet and physical activity)|The intervention will include a combination of individual counselling group sessions. The intervention groups will be divided into subgroups of 10-12 subjects. Each group will have 10 group sessions on diet/lifestyle in the 6 months the intervention period lasts, and will additionally have the possibility to join a culturally adapted exercise program of low intensity twice a week.
223635530|NCT03997344|BEHAVIORAL|Group nature hikes|Six group nature hikes will be offered once every other week. Total duration of intervention is 12 weeks. Hikes will be co-lead by two experienced hike leaders.
223635531|NCT03997344|BEHAVIORAL|Group urban hikes|Six group urban hikes will be offered once every other week. Total duration of intervention is 12 weeks. Hikes will be co-lead by two experienced hike leaders.
223635532|NCT03549936|OTHER|Low lactose or regular formula|"If infant is not breast feeding and parents plan to formula feed, following written informed consent, infant is randomized to receive low lactose formula or regular formula which arrives from milk lab blinded and labeled as formula A or formula B."
223635533|NCT00758667|DRUG|Mesna|B. Mesna will be used to aid in the removal of the capsule when capsulectomy is performed
223635534|NCT01546610|OTHER|insoles intervention|EVA insole with arch support and bar retrocapital
223635535|NCT01546610|OTHER|placebo insole|EVA insole flat
223635536|NCT03886896|DRUG|Lidocaine|Lidocaine infusion during surgery
224224304|NCT01133821|DRUG|IPSRT plus placebo (IPSRT-PLA)|"Subjects will be seen approximately weekly/biweekly during the 20 week acute phase. All subjects will return at weeks 36 and 52 for follow-up assessments to evaluate the enduring effects of treatment.~The therapist will administer IPSRT and the psychiatrist will administer medication management procedures (quetiapine or placebo).~Medication Dosing~The research pharmacy will dispense medication in the following unit-dose packs:~Dose A (50 mg of QUE or PLA) Dose B (100 mg of QUE or PLA) Dose C (separate packs of 50 mg and 100 mg QUE capsules or PLA) Dose D (200 mg of QUE or PLA) Dose E (separate packs of 50 mg and 200 mg QUE capsules or PLA) Dose F (separate packs of 100mg and 200mg QUE capsules or PLA)"
224224305|NCT01133821|DRUG|IPSRT plus quetiapine|"Subjects will be seen approximately weekly/biweekly during the 20 week acute phase. All subjects will return at weeks 36 and 52 for follow-up assessments to evaluate the enduring effects of treatment.~The therapist will administer IPSRT and the psychiatrist will administer medication management procedures (quetiapine or placebo).~Medication Dosing~The research pharmacy will dispense medication in the following unit-dose packs:~Dose A (50 mg of QUE or PLA) Dose B (100 mg of QUE or PLA) Dose C (separate packs of 50 mg and 100 mg QUE capsules or PLA) Dose D (200 mg of QUE or PLA) Dose E (separate packs of 50 mg and 200 mg QUE capsules or PLA) Dose F (separate packs of 100mg and 200mg QUE capsules or PLA)"
224224306|NCT00846378|PROCEDURE|Post conditioning|after 30 seconds of re-established coronary flow following the therapeutic balloon dilatation and deflation, the same balloon will be re-inflated for 30 seconds and then again deflated for 30 seconds. This procedure of balloon inflation/deflation will be performed a total of 3 to 4 times.
224224307|NCT00846378|PROCEDURE|Usual Care for STEMI|Usual care for treatment of TIMI 0 to TIMI 1 flow in occluded infarct related artery. Usual care includes reperfusion of the artery per operator discretion, i.e. primary stenting, thrombectomy, balloon inflation/deflation without timed intervals.
224224308|NCT03803709|DIETARY_SUPPLEMENT|inulin|inulin given at different dosis from day 3 to day 20
224224309|NCT03803709|DIETARY_SUPPLEMENT|placebo|maltodextrine given at different dosis from day 3 to day 20
224224310|NCT00861783|DRUG|irinotecan and ON 01910.Na|"ON 01910.Na will be administered by IV infusion over 24 hours once per week in a 6-week cycle (6 doses per cycle). The dose of ON 01910.Na will start at 250 mg/m2 and will proceed to higher levels based on safety of the combination regimen in the previous cohort.~Irinotecan 180 mg/m2 will initially be administered by IV infusion over 90 minutes q2 weeks of a 6-week cycle (3 doses per cycle). Dose modifications due to toxicity will be instituted according to approved labelling."
224224311|NCT00861783|DRUG|oxaliplatin and ON 01910.Na|"ON 01910.Na will be administered by IV infusion over 24 hours once per week in a 6-week cycle (6 doses per cycle). The dose of ON 01910.Na will start at 250 mg/m2 and will proceed to higher levels based on safety of the combination regimen in the previous cohort.~Oxaliplatin 85 mg/m2 will initially be administered by IV infusion over 120 minutes every 2 weeks of a 6-week cycle (3 doses per cycle). Dose modifications due to toxicity will be instituted according to approved labeling."
224224312|NCT05409911|DRUG|S-217622|Tablet for oral administration
224224313|NCT05133128|OTHER|blood samples|blood samples
224224314|NCT05293028|DRUG|F527|0.001、0.01、0.1、0.3、1、3 and10 mg/kg QW
224318645|NCT00086281|DRUG|Modafinil (M)|Modafinil Oral Tablets
224318646|NCT00086281|DRUG|Placebo (P)|Placebo Oral Solution
223635537|NCT01980563|PROCEDURE|ultrasound|
223635538|NCT01980563|PROCEDURE|combined monitoring|
223635539|NCT04953858|OTHER|Social network strategy (SNS)|SNS utilizes peers to reach and recruit their network members into HIV services, therefore having the advantage that recruiters with different behavioral risks and HIV statuses are likely to have access to a wide variety of HIV at risk populations
223635540|NCT02762916|OTHER|Selfmanage with the help of telemedicine program|"The intervention group patients were not followed by the usual protocol, but it used the program CONTECI (and test different directions) to guide the patient monitoring.~Both groups used antiplatelets and statines as usual protocol (these were not the interventions) We did not use drugs or device for the intervention, only a Telemedicine programme"
223635541|NCT03521284|OTHER|Parental educational program|Behavior: psychotherapy, life hygiene advice
224318647|NCT00487968|DRUG|eltrombopag|
224318648|NCT04942743|DIAGNOSTIC_TEST|MRI|MRI OF TMJ
223635542|NCT03521284|OTHER|Questionnaires|knowledge questionnaire + parental anxiety questionnaire
224318649|NCT04543890|RADIATION|Hyperfractionated radiotherapy|Thoracic radiotherapy (45 Gy/30 fractions) for the Hyperfractionated Arm and prophylactic cranial irradiation (25 Gy/10 fractions).
224318650|NCT04543890|RADIATION|Hypofractionated radiotherapy|Thoracic radiotherapy (45 Gy/15 fractions) for the Hypofractionated Arm and prophylactic cranial irradiation (25 Gy/10 fractions).
224318651|NCT04543890|DRUG|Etoposide|Etoposide will be administered IV 100mg/m2 on days 1-3, 22-24, 43-45 and 64-66.
224318652|NCT04543890|DRUG|Cisplatin|Cisplatin will be administered IV 80mg/m2 on days 1, 22, 43 and 64.
223635543|NCT06097715|DIAGNOSTIC_TEST|upper gastrointestinal endoscopy|Upper gastrointestinal endoscopy to asses present of esophageal varices and will be done to all patient group
224224315|NCT05866146|OTHER|Interprofessional rehabilitation program|The interprofessional rehabilitation program includes a comprehensive assessment, intensified physical activities and exercises, pain education, psychotherapy, occupational therapy, ergonomic interventions, and psychosocial counselling in addition to the current treatment standards. The interprofessional rehabilitation program will be delivered in a combination of individual (one-to-one) and group sessions (in groups of 6 - 10 patients). Care providers will apply a combination of lectures and discussions, individual exercises, and group-based exercises and education. All sessions will be delivered face-to-face (in person). The intervention will be provided by a team of healthcare providers with different professional backgrounds and training. The interprofessional team may include experienced physicians (GPs), neurosurgeons, physiotherapists, nurses, occupational therapists, and clinical psychologists.
224224316|NCT05866146|OTHER|Usual standard care|Participants in this group will receive the usual care currently implemented mainly pharmacological treatment (pain medication), and back pain advice. The usual care in rare occasions may also include physical therapy such as exercise and massage.
224224317|NCT01387282|DRUG|Anamorelin HCl|Anamorelin HCL 100 mg will be orally administered daily at least 1 hour prior to meal
224224318|NCT01387282|DRUG|Placebo|Placebo tablets identical in appearance to active tablets; oral administration QD for 12 weeks, at least 1 hour prior to meal before the first meal of the day.
224224319|NCT03565549|BEHAVIORAL|Mnemonic|A mnemonic used as a memory aid
224224320|NCT03565549|BEHAVIORAL|CCHR rule|A list of the CCHR items
224224321|NCT03165565|BEHAVIORAL|Motivational Interviewing (MI) and Acceptance and Commitment Therapy (ACT)|Participants will receive Motivational Interviewing (MI) and Acceptance and Commitment Therapy (ACT).
224224322|NCT03165565|BEHAVIORAL|Conventional Care|Conventional care from the hospital for NICU mothers who test positive for drug use, which includes visits and resources from hospital social workers.
224224323|NCT03715595|OTHER|SSDM group|The patients can perform self-evaluation, including DAS28, morning stiffness duration (MSD) and HAQ, and input medical records (including medication and laboratory test results) every month.
224224324|NCT02419859|DEVICE|PaQ® Insulin Delivery Device|PaQ is a 3 day insulin delivery device which delivers U 100 rapid-acting insulin. Provides basal insulin at preset basal doses and bolus insulin (in 2 unit increments) with a push of a button.
224224325|NCT02419859|DRUG|Insulin, Asp(B28)-|a fast-acting analog of human insulin
224224326|NCT00580359|DRUG|S-1, capecitabine|S-1 40mg/m2 orally twice daily on days 1(evening) - 15 (morning)every 3 weeks, until disease progression, Capecitabine 1250mg/m2 orally twice daily on days 1 (evening) - 15 (morning)every 3 weeks, until disease progression
224224327|NCT02200133|OTHER|Individualized Survivorship Care Plan (SCP)|The individualized SCP incorporates patient specific treatment exposures and provides a framework for long term followup based on those exposures and subsequent risks for late complications.
224224328|NCT06081751|BEHAVIORAL|Pretest|"Internet usage time, How many hours do you use the Internet per day? and What is your weekly internet usage frequency? will be questioned using questions.~Child Perceived Stress Scale was developed by Snoeren-Hoefnagels (2014) and adapted to Turkish by Oral and Ersan in 2017. The scale consists of 9 items. It is a 4-point Likert type scale. It consists of a single sub-dimension. The answer never gets one point, and the answer always gets 4 points. In the scale that does not contain reverse items, the minimum score is 9 and the maximum score is 36. High scores from the scale questions mean that the individual's stress level is high.~I"
224224329|NCT06081751|BEHAVIORAL|Posttest|"Internet usage time, How many hours do you use the Internet per day? and What is your weekly internet usage frequency? will be questioned using questions.~Child Perceived Stress Scale was developed by Snoeren-Hoefnagels (2014) and adapted to Turkish by Oral and Ersan in 2017. The scale consists of 9 items. It is a 4-point Likert type scale. It consists of a single sub-dimension. The answer never gets one point, and the answer always gets 4 points. In the scale that does not contain reverse items, the minimum score is 9 and the maximum score is 36. High scores from the scale questions mean that the individual's stress level is high.~I"
224224330|NCT04538963|DEVICE|Orthodontic Band affixed with Glass Ionomer Cement|Glass ionomer cement utilized to affix a blank orthodontic band to the tooth; the mechanical retention of the band will also help retain cement in contact with the tooth- the hypothesis is that the fluoride release from the cement will aid in remineralization of tooth structure.
224224331|NCT06544304|DEVICE|PMMA|PMMA 30%
224224332|NCT00977925|BIOLOGICAL|Fibrin Pad|Fibrin Pad is a sterile bio-absorbable combination product consisting of two constituent parts- a flexible matrix and a coating of two biological components (Human Fibrinogen and Human Thrombin).
224224333|NCT00977925|PROCEDURE|Standard of Care|Standard of Care is a composite of techniques/methods typically used by the surgeon to control severe bleeding.
223635544|NCT06097715|DIAGNOSTIC_TEST|1- Complete blood count 2- Coagulation profile|cmplete blood count to detect thrombocytopenia, liver function test to detect if they are elevated,and any impaired coagulation profile
224224334|NCT04544176|OTHER|Observational|There will be no interventions in this study, it is purely observational using data already collected.
224224335|NCT00352157|BEHAVIORAL|Revival Soy Dietary Supplement|
224318653|NCT06552156|DIETARY_SUPPLEMENT|Dietary Emulsifier|Intervention was delivered by supplying dietary emulsifiers or placebo through 3 brownies a day that participants had to consume.
224318654|NCT04069338|PROCEDURE|Lithotripter|Patients receive standard of care treatment for their urolithiasis using one of two lithotripter machines
224318655|NCT03912545|DIAGNOSTIC_TEST|Quantra System|Diagnostic device to monitor coagulation properties of a whole blood sample at the point-of-care.
223635545|NCT03531112|BEHAVIORAL|Appetite Awareness Treatment + Lifestyle Modification|The AAT + LM intervention includes 16 60-90 minute group sessions to enable participants to be able to relearn their stomach's hunger signals and begin to obey and monitor functions of satiety. All sessions involve didactic training, review of self-monitoring of eating episodes, interactive activities, and homework assignments to enable participants to practice learned skills. Participants will be provided a workbook, which will include session content, and self-monitoring forms.
223635546|NCT03544749|DEVICE|Ambu® AuraGain™|After induction of anesthesia, Ambu® AuraGain™ will be inserted for the mechanical ventilation.
224224336|NCT05533346|BEHAVIORAL|with WISE (Walking Instruction based on Self-Efficacy)|Will be provided with walking health education leaflets and exercise measurement wristbands for exercise monitoring. Only the experimental group will be additionally given the interventional treatment of the WISE program: walk three times a week for at least 30 minutes each time, with a pace between 100-130 steps/min, and then increase the number or time weekly according to your personal ability, and remind you if the monitoring heart rate is higher than 170 times/min or the blood oxygen concentration is lower than 95%, and if the body feels any discomfort, it is necessary to stop taking a rest, and an educational strategy for improving self-efficacy of walking for 12 weeks is also provided.
223635547|NCT03544749|DEVICE|I-gel|After induction of anesthesia, I-gel will be inserted for the mechanical ventilation.
223635548|NCT01423175|DRUG|Clofarabine, ara-C|
223635549|NCT01423175|DRUG|FLAMSA|
223635550|NCT01084655|DRUG|TAK-700|TAK-700 with docetaxel and prednisone on a continuous schedule.
223635551|NCT01084655|DRUG|Docetaxel|TAK-700 with docetaxel and prednisone on a continuous schedule.
223635552|NCT01084655|DRUG|Prednisone|TAK-700 with docetaxel and prednisone on a continuous schedule.
223635553|NCT01999881|BEHAVIORAL|exercise intervention|Receive aerobic and exercise intervention
223635554|NCT01999881|PROCEDURE|standard follow-up care|Receive usual care
223635555|NCT01999881|PROCEDURE|quality-of-life assessment|Ancillary studies
223635556|NCT01999881|OTHER|laboratory biomarker analysis|Correlative studies
223635557|NCT02931877|DRUG|sevoflurane|
223635558|NCT02931877|DRUG|propofol|
223635559|NCT02037971|PROCEDURE|Aerobic Exercise|From 1st week up to and including 4th week, subjects will do: 5 minutes warm-up, then 15-30 minutes low to moderate (55-65% VO2) exercise, then 15 minutes stretching. From 5th week up to and including 16th week, subjects will do: 5 minutes warm-up, then intermittent training for between 30-40 minutes, then 10 minutes stretching.
223635560|NCT02037971|OTHER|Control Group|The control group will have monthly meetings to learn about: good sleep habits, Systemic Lupus Erythematosus (their disease) and general good health.
223635561|NCT05894915|PROCEDURE|open surgery|Open surgery is a traditional surgery method.
223635562|NCT05894915|PROCEDURE|laparoscopic surgery|Laparoscopic surgery is a newly developed minimally invasive method.
224224337|NCT05533346|BEHAVIORAL|without WISE (Walking Instruction based on Self-Efficacy)|The procedure of the control group was the same as that of the experimental group, both of which will be provided with walking health education leaflets and exercise measurement wristbands for exercise monitoring.
223635563|NCT04428853|BEHAVIORAL|iyengar yoga|different yoga postures including warm up, cool down and meditation that incorporate 75 minutes of training
223635564|NCT00535496|DRUG|sugammadex|Participants will receive an intubating dose of 0.6 mg/kg rocuronium, followed by one or more maintenance doses of 0.15 mg/kg rocuronium, if necessary. Fifteen minutes after the last dose of rocuronium, 1.0 or 4.0 mg/kg sugammadex will be randomly administered by intravenous (IV) bolus dose based on actual body weight.
223635565|NCT01841099|DRUG|Mesalamine|Mesalamine granules
223635566|NCT01841099|DRUG|Placebo granules|Provided by Ferring Pharma
223635567|NCT02671708|DRUG|Idarubicin（IDA）|Idarubicin was administered at 15mg/m2/day on days -12 and -10.
224224338|NCT04155164|DRUG|Metformin|Participants will receive Metformin at 1000mg for 12 months.
223635568|NCT02671708|DRUG|Busulfan (BU)|Busulfan was administered at 3.2 mg/kg/day on days -7 to -4.
223635569|NCT02671708|DRUG|Cyclophosphamide (CY)|Cyclophosphamide was administered at 60 mg/kg/day on days -3 to -2.
223635570|NCT03013803|DIETARY_SUPPLEMENT|Nutricomp Drink Plus Fibre|
223635571|NCT01391078|DEVICE|Sensimed Triggerfish Sensor|IOP will be monitored for 24 hours
223635572|NCT01391078|DEVICE|Goldmann Applanation Tonometry, Perkins Tonometry|IOP will be measured every two hours within 24 hours
223635573|NCT02667795|OTHER|Monitored walking based exercise|Monitored walking based exercise
223635574|NCT00586378|DEVICE|Ovatio DR and Ovatio VR|implantable cardioverter defibrillator
223635575|NCT05024032|DRUG|Tirzepatide|Administered SC
223635576|NCT05024032|DRUG|Placebo|Administered SC
223635577|NCT00000817|DRUG|Amitriptyline hydrochloride|75 mg oral tablet taken daily
223635578|NCT00000817|DRUG|Amitriptyline hydrochloride placebo|Oral placebo tablet taken daily
223635579|NCT00000817|PROCEDURE|Point acupuncture|Standardized or alternate acupuncture procedure
223635580|NCT02231086|PROCEDURE|Adjuvant HIPEC (open/laparoscopic)|Adjuvant HIPEC procedure: access to the abdominal cavity by laparoscopy or laparotomy under general anaesthesia, adhesiolysis if necessary, complete staging of the intra-abdominal cavity, positioning of in- and outflow catheters, perfusion with a minimum of 2l isotonic dialysis fluid at a flow rate of 1-2l/min and an inflow temperature of 42-43˚C. Before the beginning of HIPEC, 5-fluorouracil 400 mg/m2 and leucovorin 20 mg/m2 will be administered intravenously to potentiate oxaliplatin activity. Oxaliplatin (460 mg/m2) is added to the perfusate after attaining at least 42 degrees inflow temperature with a total of 30 minutes perfusion time.
223635581|NCT02231086|DRUG|Standard adjuvant systemic chemotherapy|Colon cancer patients with a high risk of developing PC, but do not have (yet) proven macroscopic peritoneal metastasis, are standardly treated with adjuvant systemic chemotherapy. Standard adjuvant systemic chemotherapy consists in the Netherlands of a capecitabine and oxaliplatin (CAPOX) or 5-FU and oxaliplatin (FOLFOX) for a total of 6 months.
223635582|NCT02231086|PROCEDURE|Diagnostic laparoscopy|Presence or absence of peritoneal recurrence will be evaluated by laparoscopy in case of negative routine examination (CEA and CT thorax/abdomen) at 18 months postoperatively in both study arms.
223635583|NCT05939882|DRUG|low concentration atropine (0.01%)|low concentration atropine (0.01%)
223635584|NCT05939882|DRUG|low concentration atropine (0.02%)|low concentration atropine (0.02%)
223635585|NCT05939882|DRUG|low concentration atropine (0.04%)|low concentration atropine (0.04%)
223635586|NCT05939882|DRUG|Placebo|Placebo eye drop
223635587|NCT03529032|DRUG|Methadone|methadone for control postoperative pain
223635588|NCT04495595|OTHER|No intervention|There is no intervention due to the observational, cross-sectional design of the study
223635589|NCT00000982|DRUG|Zidovudine|
223635590|NCT00000982|DRUG|Didanosine|
223764787|NCT05624112|DRUG|Dupilumab|Dupilumab solution in a pre-filled syringe for Subcutaneous injection
223635591|NCT02695108|OTHER|classical approach for neck pain|Patients with mechanical neck pain were instructed to do cervical exercise
223514421|NCT04601493|BEHAVIORAL|Choice Architecture Nudge|"During the choice architecture nudge intervention, Primary Care Providers (PCPs) will be sent alerts in the Electronic Health Record (EHR) system when they initiate an opioid order for a patient who has not had an opioid prescription within the past six months. The alert provides guidance language about opioid prescribing and prompts the PCP to open the SmartSet to order non-opioid treatment alternatives. PCPs can choose to ignore this, but opening the SmartSet is the default option. When the SmartSet is opened, PCPs can choose to click on a variety of treatment order options, including both non-opioid pharmacological options and non-pharmacological options (e.g., referral to physical therapy or pain clinic)."
223514422|NCT04601493|BEHAVIORAL|PMP Integration & Nudge|During the Prescription Drug Monitoring Program (PMP) integration \& nudge intervention, Primary Care Providers (PCPs) will have integrated access to the PMP embedded within the EHR. All clinicians can already access the PMP to look up a patient's prior opioid prescriptions and prescription fills. However, this process involves signing in to the separate PMP website and can be complicated and time-consuming within typical clinical workflow. The integrated PMP tool makes it much easier and faster for a PCP to access the PMP information for a given patient.
223514423|NCT03255200|DEVICE|ReActiv8 Implantable Stimulation System|Implantable electrical stimulation system.
223514424|NCT00790660|DRUG|ASP1941|Oral
223514425|NCT00790660|DRUG|Placebo|Oral
223514426|NCT04281576|DEVICE|NovoTTF-100L(P)|Patients receive continuous TTFields treatment using the NovoTTF-100L(P) device. TTFields treatment will consist of wearing four electrically insulated electrode arrays on the abdomen. The treatment enables the patient to maintain regular daily routine.
223514427|NCT04281576|DRUG|Oxaliplatin|Oxaliplatin 130 mg/m\^2 intravenous infusion will be administered once every 3 weeks
223514428|NCT04281576|DRUG|Capecitabine|Capecitabine 1000mg/m\^2 taken by mouth, twice daily on day 1-14, 3 weeks per cycle
223514429|NCT04281576|DRUG|Trastuzumab|Trastuzumab (HER-2 positive patients only) intravenous infusion will be administered once every 3 weeks on Day 1 of each cycle. First dose is 8mg/kg, followed by 6 mg/kg.
223514430|NCT04834388|DRUG|Anakinra|Anakinra treatment is started within 8 hours of symptom onset
223514431|NCT06510231|OTHER|Inspiratory Muscle Training|Inspiratory muscle training (IMT) targets the inspiratory muscles and is used to improve inspiratory muscle strength.
223514432|NCT04163770|DEVICE|caliberation of pacemaker|evaluation of ventricular impedence, ventricular sensing, ventricular capture threshold
223514433|NCT04163770|DEVICE|caliberation of pacemaker|evaluation of ventricular impedence, ventricular sensing, ventricular capture threshold
223514434|NCT00948207|BEHAVIORAL|My Living Story|"Components include:~1\. Life Review Interview by phone (questions based on Chochinov, 2002 dignity enhancing interview);~2\) Edited transcript is delivered in a word format on...;~3\) miLivingStory, a personal social network, where participants can manage content, design and layer; invite and manage their fiends and family.~4\) miStory, a life review education website and portal to websites for: cancer information, databases to do your own research, social support, interactive planning tools, and a page to add their own weblinks."
223514435|NCT00948207|BEHAVIORAL|My Own Resources|"miOwnResources is a personalized, password-protected web portal to high quality websites that provide cancer information, cancer research databases for do your own research, social support, and interactive planning tools. miOwnResources also has a page for participants to add their own weblinks."
223514436|NCT01774539|OTHER|Diffusion MRI|Each subject will undergo one diffusion MRI scan to identify characteristics of their physes
223514437|NCT01953354|BIOLOGICAL|Trichuris suis ova (TSO)|Six doses of TSO orally over a ten-week period (e.g., every 2 weeks x 10 weeks for a total of 6 total doses)
223514438|NCT01953354|BIOLOGICAL|Placebo|Six doses of TSO placebo orally over a ten-week period (e.g., every 2 weeks x 10 weeks for a total of 6 total doses)
223514439|NCT03951415|DRUG|PARP inhibitor and Anti-PD-L1|olaparib tablets 300mg twice daily orally and durvalumab 1500mg by IV infusion every 4 weeks
223514440|NCT06235970|DEVICE|Transcranial electrical stimulation (tES) including SHAM|Transcranial electrical stimulation, known as tES, refers to a family of devices that utilize low-cost technologies and involve low-intensity currents which are safe for humans, and carry minimal risk of side effects or adverse events. Conventional approaches, which utilize fixed direct currents (tDCS) or alternating currents at a fixed oscillatory frequency (tACS), have been widely used as both a basic research tool and as a clinical intervention. In the current project, we use a custom-built device that enables near real-time current modulation triggered digitally, via software control, to allow for stimulation protocols guided by whole-brain individualized neural modeling.
223514441|NCT01570192|DRUG|IV meropenem|Subjects assigned to this group will receive IV meropenem (2 g infused over 3 hrs q 8 hr).
223514442|NCT01570192|DRUG|I.V. Meropenem|"Subjects assigned to this group will receive IV meropenem (2 g infused over 3 hrs q 8 hr).~Linezolid or vancomycin (per institutional guidelines) will be available for MRSA coverage"
223514443|NCT01570192|DRUG|Parenteral aminoglycoside; tobramycin for injection USP OR gentamicin sulfate injection solution concentrate 5mg.kg IV q24h; amikacin sulfate injection USP 20 mg/kg IV q24h|a parenteral aminoglycoside (tobramycin or gentamicin-5mg/kg IV Q24h or amikacin 20 mg/kg IV Q24h)
223514444|NCT01570192|DRUG|Linezolid or Vancomycin (per institutional guidelines) will be available for MRSA coverage.|Linezolid or vancomycin (per institutional guidelines) will be available for MRSA coverage.
223514445|NCT01570192|DEVICE|tobramycin nebulization|tobramycin nebulization 600mg/day
223514446|NCT01696214|DRUG|Fluticasone 250 mg/salmeterol 50 mg|Drug: Fluticasone 250 mg/salmeterol 50 mg Participants will be assigned to a 24 week treatment with inhaled fluticasone/salmeterol or matching placebo
223635592|NCT02695108|OTHER|scapular exercise on neck pain|Patients with mechanical neck pain were instructed to do scapular stabilization and cervical exercise
223635593|NCT02334904|DRUG|Aripiprazole|To be prescribed and monitored by participant's attending physician (not given to participants as a part of the study)
224224339|NCT04155164|DRUG|Placebos|Placebo group will take Placebo at 1000mg for 12 months.
224224340|NCT00147381|DRUG|Alemtuzumab|"Day 0: Campath-1H 20 mg IV infusion over 3-6 hours~Day 1: Campath-1H 20 mg IV infusion over 3-6 hours"
223635594|NCT02334904|DRUG|Risperidone|To be prescribed and monitored by participant's attending physician (not given to participants as a part of the study).
224224341|NCT00147381|DRUG|Tacrolimus|"Day 0: Tacrolimus will be given pre-operatively or immediately post transplant surgery. The recommended initial daily starting dose is 0,1 mg/kg/d orally (0,05 mg/kg/bid) to aim at a whole blood level of 8-12 ng/ml.~till Month 6: Aim at blood level of 8-12 ng/ml (try to prevent the Tacrolimus trough level falling below 10 ng/ml in the first 3 months).~Month 7-12: Maintain the Tacrolimus blood level at 5-8 ng/ml after 6 months."
224224342|NCT00147381|DRUG|Alemtuzumab|"Day 0: Campath-1H 30 mg IV infusion over 3-6 hours~Day 1: Campath-1H 30 mg IV infusion over 3-6 hours"
224224343|NCT06092606|DRUG|Control group:DH001 placebo|Dosage: DH001 placebo (8 tablets)
224318656|NCT03145389|PROCEDURE|Epidural catheter placement|After explaining about the procedure an 18 Gauge epidural catheter was inserted into thoracic 11-12 inter vertebral space under strict asepsis. Before inserting the epidural needle same space was infiltrated with adequate amount of 2% Lignocaine with Adrenaline (1: 200,000) to make the procedure pain free. Epidural space was confirmed by loss of resistance technique.
224224344|NCT06092606|DRUG|Trial group: DH001 low-dose group|Dosage: DH001 200mg (4 tablets) + DH001 placebo (4 tablets)
224224345|NCT06092606|DRUG|Trial group: DH001 high-dose group|Dosage: DH001 400mg (8 tablets).
224224346|NCT05426122|OTHER|Barley rice protein concentrate shake|At one out of three test days barley rice protein concentrate powder will be mixed with water to obtain a shake, representing a 20g protein load.
224224347|NCT05426122|OTHER|Pea protein concentrate shake|At one out of three test days pea protein concentrate powder will be mixed with water to obtain a shake, representing a 20g protein load.
224318657|NCT03277924|DRUG|Sunitinib 37.5 MG, Sunitinib 25 MG [Sutent]|Treatment will continue until disease progression, development of unacceptable toxicity, non-compliance, withdrawal of consent by the patient or investigator decision.
223514447|NCT01696214|DRUG|Montelukast 10mg|Participants will be assigned to montelukast once a day for 24 weeks.
223514448|NCT01696214|DRUG|Theophylline 400 mg|Participants will be assigned to theophylline once a day for 24 weeks
223514449|NCT01696214|DRUG|ipratropium|Participants will be assigned to ipratropium 2.5 mL of 0.02% solution via mini nebulizer 3 times a day day for 24 weeks.
223514450|NCT00806026|DRUG|placebo and pregabalin|following 3 months placebo treatment, subjects are to be re-distributed to pregabalin 300 mg per day for 9 months. Both placebo and pregabalin are to be administered orally once a day, 1-3 hours before bedtime.
223514451|NCT00806026|DRUG|pramipexol|following 3 months placebo treatment, subjects are to be re-distributed to pramipexol 0.25mg per day for 9 months. Both placebo and pramipexol are to be administered orally once a day, 1-3 hours before bedtime.
223514452|NCT00806026|DRUG|pramipexol|following 3 months placebo treatment, subjects are to be re-distributed to pramipexol 0.5mg per day for 9 months. Both placebo and pramipexol are to be administered orally once a day, 1-3 hours before bedtime.
223514453|NCT00806026|DRUG|Pregabalin|pregabalin 300 mg, orally administered once a day, 1- 3 hours before the bedtime for 12 months
223514454|NCT00806026|DRUG|pramipexol|pramipexol 0.25 mg, orally administered once a day, 1- 3 hours before the bedtime for 12 months
223514455|NCT00806026|DRUG|pramipexol|pramipexol 0.5 mg, orally administered once a day, 1- 3 hours before the bedtime for 12 months
223514456|NCT03180138|BEHAVIORAL|Reminders alone|Automated reminders (text and /or voice in local language) for upcoming vaccination visit(s) will be provided via cell-phone to the subject (mother / caregiver) or pregnant woman.
223514457|NCT03180138|BEHAVIORAL|Compliance-linked incentives|Automated compliance-linked incentives (as cell-phone minutes) will be provided via cell-phone to the subject (mother / caregiver) or pregnant woman.
223514458|NCT03600103|BEHAVIORAL|Tech2Check|The intervention uses behaviors to improve HIV adherence and self-care. Investigators will use the Center for Disease Control (CDC) Partnership for Health (PfH) Medication Adherence.The CHN will administer PfH at all home/venue-based encounters, using communication styles that are more receptive to adolescents and young adults. Resources will be provided. At the end of the session, the participant will be able to state/demonstrate: goals of HIV care and adherence, meaning of CD4 and Viral Load (VL) measurements and the significance of their own measurements,signs of complications or problems for which participants need to seek additional care,understanding of optimal self-care.Further, CHNs will also provide tips to stay on schedule with taking their ART and problem-solve adherence barriers.
223514459|NCT01775410|DEVICE|Wolverine System to perform atherectomy|
223514460|NCT02768246|DEVICE|BVGA|The BVGA enables the direct connection of a bag valve device to a guedel, eliminating the need for a face mask during ventilation
223514461|NCT02768246|DEVICE|Face Mask|Classic face mask
223514462|NCT05856461|PROCEDURE|Pulmonary vein isolation|Circumferential pulmonary vein isolation procedure using 3D navigation systems with entrance and exit block verification
223514463|NCT05856461|PROCEDURE|Sham pulmonary artery denervation|Sham pulmonary artery denervation procedure includes 3D reconstruction of the right ventricular outflow tract, main, left and right pulmonary arteries with creation of the false ablation points. No true ablation lesions will be performed in the pulmonary artery
223514464|NCT05856461|PROCEDURE|Pulmonary artery denervation|Pulmonary artery denervation procedure includes 3D reconstruction of the right ventricular outflow tract, main, left and right pulmonary arteries and 3 circles of ablation lesions (bifurcation of the main pulmonary artery, left and right pulmonary arteries)
223514465|NCT02557919|OTHER|Motivational Interviewing Training|1.5 day training on Motivational Interviewing (MI) techniques plus 2 booster sessions to address real experiences using MI with families.
223514466|NCT02557919|OTHER|Usual Best Practice|.5 day training on tobacco control and emerging products.
223514467|NCT02572687|DRUG|Ramucirumab|Administered IV
223514468|NCT02572687|DRUG|MEDI4736|Administered IV
223514469|NCT06523153|BIOLOGICAL|VYD2311|Monoclonal antibody
223514470|NCT06523153|OTHER|Placebo|Matching Placebo
223514471|NCT02338557|DEVICE|motor relearning programme|MRP exercises for training of Wrist Extensors, Extension of wrist and holding objects, training of supination of forearm, opposition of thumb, cupping of hand and training of manipulation of the objects
223635595|NCT01449968|OTHER|home visit|home visit of UMG
223635596|NCT01449968|OTHER|telephone management|telephone management of the situation reported by the patient's GP
224318658|NCT03277924|DRUG|Nivolumab 100 MG/10 ML [Opdivo]|Treatment will continue until disease progression, development of unacceptable toxicity, non-compliance, withdrawal of consent by the patient or investigator decision.
223635597|NCT00379964|DRUG|caspofungin acetate|Cancidas 50 mg dose followed by 70 mg load on day 1 was administered in Indian adults with persistent fever and neutropenia for a maximum duration of empirical treatment from 28 days ((for patients without documented infection) to 90 days (for patients with documented baseline or emergent fungal infection). Patients were treated until the resolution of neutropenia (ANC\>500/mm3), and for up to 72 hours later.
223635598|NCT03461614|OTHER|Exercise group|Exercise group mainly conducted the 5 core stabilization exercises as described by McGill. These include the curl-up, side bridge, trunk extension, double leg lifts and bird-dog exercises that support respiratory functions. In other words, every single training session consisted of frontal, dorsal, and lateral core exercise. In general, participants always exercised in group so that for integration and motivation. During training weeks 1-2, participants exercises with 3 sets per exercise and 10 s contraction time and 10 repetitions. During training weeks 3-4, contraction times and repetitions were increased to 15 s and 15 repetitions. Additionally, increasing the complexity of exercises, adding opposite limb movements and increasing the lever arm of the exercises were done.
223635599|NCT03461614|OTHER|Control group|In addition to the service routine rehabilitation program mentioned above, participants in the Control group participated in leisure activities such as table tennis/basketball under service staff supervision for 45-60 minutes, 2 times a week, 6 weeks similar time period of Exercise group.
223635600|NCT00438009|DRUG|Coxsackievirus A21|Two doses of drug, separated by 48 hours
223635601|NCT03714672|DRUG|Tramadol/Diclofenac 50/50|Each dose comprised 1 fixed-dose combination tablet and 3 placebo tablets or capsules matching the other active treatment groups. Doses were taken 8 hours apart.
223635602|NCT03714672|DRUG|Tramadol/Diclofenac 25/25|Each dose comprised 1 fixed-dose combination tablet and 3 placebo tablets or capsules matching the other active treatment groups. Doses were taken 8 hours apart.
223635603|NCT03714672|DRUG|Tramadol 50|Each dose comprised 1 capsule containing 50 mg tramadol hydrochloride and 3 placebo tablets matching the other active treatment groups. Doses were taken 8 hours apart.
223635604|NCT03714672|DRUG|Diclofenac 50|Each dose comprised 1 tablet containing 50 mg diclofenac sodium and 3 placebo tablets or capsules matching the other active treatment groups. Doses were taken 8 hours apart.
223635605|NCT05189717|DRUG|HRS-8080 tablets、SHR 6390 tablets、Abemaciclib、Everolimus|During HRS-8080 monotherapy period, the dose of HRS-8080 would be increasing. In the combination therapy period, HRS-8080 will be administered at flat dose of RP2D-1 and RP2D.
223635606|NCT02345070|DRUG|SAR156597|Pharmaceutical form: solution for injection Route of administration: subcutaneous
223635607|NCT02345070|DRUG|placebo|Pharmaceutical form: solution for injection Route of administration: subcutaneous
223635608|NCT01245530|DRUG|Aricept|Aricept Comparator Intervention: Drug: Aricept 5\~10 mg orally every day for 24weeks
223635609|NCT01245530|DRUG|INM-176|INM-176: Experimental Intervention: Drug:INM-176 600\~1200 mg orally every day for 24weeks
224224348|NCT05426122|OTHER|Whey protein concentrate shake|At one out of three test days whey protein concentrate powder will be mixed with water to obtain a shake, representing a 20g protein load.
224224349|NCT06234046|DRUG|Rifaximin 550Mg Tab|group (1) received Rifaximin as 550 mg twice daily dosage for six months.
224224350|NCT06234046|DRUG|Ciprofloxacin 750 MG|group (2) received Ciprofloxacin 750 mg tab mg once weekly dosage for six months.
224224351|NCT06234046|DIAGNOSTIC_TEST|ascitic fluid sample|aspiration of ascitic fluid sample and analysis for differential cell count
224224352|NCT04596501|OTHER|Early and late postmenopausal women|The intervention involves supervised team sports 1 h 3 x/week for 16 weeks.
223635610|NCT03408093|DRUG|Interferon beta-1b (Betaseron, BAY86-5046)|Interferon beta-1b (INFb-1b) was used at the standard dose of 250 mg/ml.
224224353|NCT02943681|BIOLOGICAL|Measles vaccine|
224224354|NCT04767269|DRUG|Cuminum Cyminum|Cuminum Cyminum mouthwash in chronic gingivitis patients
224224355|NCT04767269|DRUG|herbal Mouthwash|herbal mouthwash in chronic gingivitis patients
224224356|NCT03500939|DRUG|Medical oxygen|inhalation of 100% oxygen at high flow via a sealed non-rebreather face-mask with reservoir
224224357|NCT03500939|OTHER|Standard of care|e.g. thrombectomy, thrombolysis
224224358|NCT03129737|PROCEDURE|Mitral valve surgery|Mitral valve repair is preferred whenever technically feasible over valve replacement. Annuloplasty may be used as sole therapy or in conjunction with other repair maneuvers to support the reconstruction and reinforce the annulus as well as prevent future annular dilatation. The mitral regurgitation secondary to myxomatous degeneration is prolapse of the middle scallop of the posterior leaflet result from chordal rupture or chordal elongation. Quadrangular resection of the involved middle scallop of the posterior leaflet combined with a posterior mitral annuloplasty is the best way to handle this situation. Chordae replacement could be used also to treat flail/prolapse of the anterior leaflet. Annuloplasty is always doing in mitral valve repair to stabilize and reshape the annulus.
224224359|NCT03129737|PROCEDURE|Tricuspid valve annuloplasty|Depending on the extent of the valve disease, there is the possibility to perform valve repair. In mitral valve reference center the rate of repair will reach 100%. In many patients with mitral valve regurgitation, tricuspid valve will be insufficient or the annulus dilated. Tricuspid annuloplasty ring will be helpful to treat dilation by reshaping, or to treat the regurgitant diseases. The ring will be secured and sutured to the native annulus by U-stitches.
223635611|NCT00828776|BIOLOGICAL|Heparin sodic - Cristália|5000UI/mL
223635612|NCT00828776|BIOLOGICAL|heparin - Liquemine (Roche)|5000UI/mL
223635613|NCT05742542|OTHER|Exercise training|Two weeks of high intensity interval training with high or low time spent near VO2max.
223635614|NCT00193661|DRUG|Testosterone Gel (1%)|
224224360|NCT02089828|OTHER|autologous purified CD34+ cells|
224224361|NCT02089828|OTHER|autologous peripheral blood mononuclear cells|
224224362|NCT01501383|DRUG|VX-765 Part A|Tablets of VX-765 given at different doses based on treatment group in Part A
224224363|NCT01501383|DRUG|Placebo|Matching placebo
224224364|NCT01501383|DRUG|VX-765 Part B|Tablets of VX-765 given at different doses based on patients who meet the study eligibility criteria for Part B
224224365|NCT00003833|GENETIC|DNA stability analysis|
224224366|NCT00003833|GENETIC|gene mapping|
224318659|NCT03277924|DRUG|Epirubicin|Treatment will continue until disease progression, development of unacceptable toxicity, non-compliance, withdrawal of consent by the patient or investigator decision.
224318660|NCT03277924|DRUG|Ifosfamide|Treatment will continue until disease progression, development of unacceptable toxicity, non-compliance, withdrawal of consent by the patient or investigator decision.
224318661|NCT03277924|DRUG|Doxorubicin|Treatment will continue until disease progression, development of unacceptable toxicity, non-compliance, withdrawal of consent by the patient or investigator decision.
224318662|NCT03277924|DRUG|Dacarbazine|Treatment will continue until disease progression, development of unacceptable toxicity, non-compliance, withdrawal of consent by the patient or investigator decision.
224318663|NCT03277924|DRUG|Cisplatin|Treatment will continue until disease progression, development of unacceptable toxicity, non-compliance, withdrawal of consent by the patient or investigator decision.
224318664|NCT03277924|DRUG|Methotrexate|Treatment will continue until disease progression, development of unacceptable toxicity, non-compliance, withdrawal of consent by the patient or investigator decision.
223514472|NCT02338557|DEVICE|MIRROR THERAPY|Mirror therapy in which patient was seated close to the table in front of mirror (35x35 cm). The involved hand was placed behind the mirror. : the practice consisted of intransitive exercises as Hand opening, Wrist extension and flexion, Forearm pronation and supination, Hand sliding on a flat surface. During the session patient were asked to try to do the same movement with the paretic hand while they were moving the non-paretic hand.In both the groups total treatment was given for 1 hour/day for 6 days/week
224224367|NCT01527448|DRUG|Quetiapine XR (seroquel)|During the study period, subjects will be receiving a treatment with Quetiapine XR. The starting dose of quetiapine that subjects will receive is 50mg. The response to the treatment of quetiapine will determine whether the study doctor will increase the dosage of the subject's quetiapine. If the study doctor increases the quetiapine during the study, the maximum dosage allowable during the study is 300mg.
224224368|NCT00064181|DRUG|FOLFIRI regimen|
224318665|NCT02122692|DRUG|Lu AE58054 30 mg|Lu AE58054 encapsulated film-coated tablets, once daily, Day 1-5, orally
224318666|NCT02122692|DRUG|Lu AE58054 30 mg + itraconazole 200 mg|Lu AE58054 encapsulated film-coated tablets, once daily, Day 6-11, orally + itraconazole capsules, once daily, Day 6-11, orally
223514473|NCT05984992|DRUG|SRN-001|siRNA therapeutics, Self Assembled Micelle inhibitory RNA platform utilized
223514474|NCT05984992|DRUG|Placebo|0.9% Sodium Chloride(Normal saline)
223514475|NCT00134498|DRUG|torcetrapib/atorvastatin|
223514476|NCT00134498|DRUG|atorvastatin|
223514477|NCT00452530|DRUG|Enoxaparin|40 mg, administered once daily by subcutaneous injection, for 12 days
223514478|NCT00452530|DRUG|Apixaban|2.5 mg, administered twice daily as tablets, for 12 days
223514479|NCT00452530|DRUG|Enoxaparin-matching placebo|Administered once daily by subcutaneous injection
223514480|NCT00452530|DRUG|Apixaban-matching placebo|Oral tablet administered twice daily
223514481|NCT02349828|DRUG|Acyclovir|
223514482|NCT02375256|BIOLOGICAL|AERAS-402|Live recombinant serotype 35 replication deficient adenovirus vector expressing a fusion protein of 3 Mycobacterium tuberculosis antigens (Ag85A, Ag85B, and TB10.4).
223514483|NCT02375256|BIOLOGICAL|Placebo|Identical buffer solution in which AERAS-402 is formulated.
223514484|NCT02375256|BIOLOGICAL|BCG (1-8 x105 cfu ID)|BCG given to all participants at day -84 prior to a boost with either Aeras-402 or placebo.
224318667|NCT02122692|DRUG|Itraconazole|Itraconazole capsules, once daily, Day 12-13, orally
224318668|NCT00933647|DIETARY_SUPPLEMENT|Yerba Mate Tea|Before and after 8 weeks, serum lipids, C-reactive protein and fibrinogen will be measured. They will also be tested for glycemia, insulin, aminotransferases, bilirubin. Anthropometric measurements will be also performed at week 0 and 8. The subjects will receive instructions to maintain their usual dietary intake and normal physical activity.
224318669|NCT00933647|DIETARY_SUPPLEMENT|Green tea|Before and after 8 weeks, serum lipids, C-reactive protein and fibrinogen will be measured. They will also be tested for glycemia, insulin, aminotransferases, bilirubin. Anthropometric measurements will be also performed at week 0 and 8. The subjects will receive instructions to maintain their usual dietary intake and normal physical activity.
224318670|NCT00933647|DIETARY_SUPPLEMENT|Apple tea|Before and after 8 weeks, serum lipids, C-reactive protein and fibrinogen will be measured. They will also be tested for glycemia, insulin, aminotransferases, bilirubin. Anthropometric measurements will be also performed at week 0 and 8. The subjects will receive instructions to maintain their usual dietary intake and normal physical activity.
224318671|NCT02175901|DRUG|Lansoprazole|antisecretory drug of each quadruple therapy
224318672|NCT02175901|DRUG|Bismuth Potassium Citrate|one component of each quadruple therapy
223514485|NCT02100644|DRUG|Lamotrigine tablets 25/100 mg|Lamotrigine (LTG) is administered according to the package insert: that is, 25 mg of LTG will be orally administered once every other day for the first 2 weeks and then once daily for the next 2 weeks. Thereafter, the dose will be gradually escalated by 25-50 mg every 1-2 week for once or twice daily administration. During the VPA reduction phase and LTG\&amp;VPA maintenance phase, as specified in the information of package insert, maintenance dose of LTG will be administered twice daily.
224224369|NCT00064181|DRUG|capecitabine|
224224370|NCT00064181|DRUG|celecoxib|
224224371|NCT00064181|DRUG|fluorouracil|
224224372|NCT00064181|DRUG|irinotecan hydrochloride|
224224373|NCT00064181|DRUG|leucovorin calcium|
224224374|NCT05399810|OTHER|Computer Application (ICOGNI) Training|Participants will be given App-based training under supervision for 40 sessions, which will include multiple games with multiple levels along with routine physiotherapy.
224318673|NCT02175901|DRUG|Amoxicillin|antibiotic of each quadruple therapy
224318674|NCT02175901|DRUG|Metronidazole|antibiotic of the amoxicillin/metronidazole-based quadruple therapy
224318675|NCT02175901|DRUG|Clarithromycin|antibiotic of the amoxicillin/clarithromycin-based quadruple therapy
223514486|NCT06570057|BEHAVIORAL|Participatory, learning and Action (PLA) Based intervention|An PLA based intervention would be carried out to prepare the Diabetes Mellitus type II patients. The intervention would be carried out for a tentative time of 2 to 3 hours to educate the type II diabetes mellitus. The study participants would be evaluated after completion of 18 months of the intervention. A structured, validated and literature-based assessment checklist will be devised to assess the effectiveness and feasibility of the intervention.
224224375|NCT06417606|DRUG|Lenvatinib|Lenvatinib（oral，12mg once daily if body weight ≥60Kg; Body weight \< 60Kg, 8mg/ day）； Adebrelimab（intravenous drip，1200mg once every 3 weeks）； GEMOX（intravenous drip，Gemcitabine 1000mg/m2, 2 times every 3 weeks d1+d8; intravenous drip，Oxaliplatin, 100mg/m2, was given every 3 weeks）
224224376|NCT03273387|DRUG|Trimetazidine|The participant will received trimetazidine 35 mg bid for 3 months on top of their regular PAH specific therapy.
223635615|NCT04379856|DRUG|NM-002|NM-002 is a fusion protein, of which the pharmacological active portion is the glucagon-like peptide-1 (GLP-1) analog domain with the same amino acid sequence as the active pharmaceutical ingredient (exenatide)
223635616|NCT02379728|DEVICE|PrenaBelt|"The PrenaBelt (PB) is a belt-like, positional therapy (PT) device designed for pregnant women. While the PB does not prevent the user from lying on her back during sleep, it is expected to significantly decrease the amount of time a user spends supine via the mechanism of PT. PT is a simple, non-invasive, inexpensive, long-established, safe, and effective intervention for preventing people with positional-dependent snoring or obstructive sleep apnea from sleeping on their back - a position that exacerbates their condition.~The PB is worn at the level of the waist or thorax. By design, the PB affects subtle pressure points on the user's back while supine, activating her body's natural mechanism to reposition itself to relieve discomfort, thereby reducing the amount of time spent supine."
223635617|NCT02379728|DEVICE|Body Position Sensor|The Body Position Sensor (BPS) is for research purposes only. The BPS can be securely integrated into a pocket on the PrenaBelt (PrenaBelt with BPS Arm) or sham-PrenaBelt (Control with BPS Arm). The BPS is a small, electronic data acquisition device. The BPS uses a three axes accelerometer to detect orientation of the PrenaBelt, and thus the user (right, left, prone, supine), in three-dimensional space. The accelerometer data is collected continually with time stamping and stored on the BPS hard drive and can be accessed via connecting it to a computer. The BPS is not expected to affect the body position of the user.
223635618|NCT02379728|DEVICE|sham-PrenaBelt|The PrenaBelt can be easily converted into a sham-PrenaBelt for research purposes by removing the hard balls from its pockets or exchanging these hard balls for soft balls so it cannot provide pressure points, i.e., positional therapy function. The sham-PrenaBelt looks, fits, and feels like the PrenaBelt but cannot provide positional therapy.
224224377|NCT03273387|DRUG|Placebo oral capsule|The participant will received placebo oral capsule bid for 3 months on top of their regular PAH specific therapy.
224224378|NCT02049359|OTHER|Texting|Bidirectional texting once weekly for 12 weeks
224224379|NCT04843085|OTHER|Proteomic analysis|: Proteomic analysis in the 3 subgroups of oligodendrogliomas (O1, O2 and O3) and in the comparator groups of IDH-mutant astrocytomas, IDH-wildtype glioblastomas and normal brain samples
224224380|NCT02345278|DRUG|SUBLIVAC FIX Mite mixture|Study medication will be taken sublingually once a day. Patients will start with one drop and increase the dose by one drop each consecutive day until the maintenance dose (5 drops/day) is reached. Drops should be kept under the tongue for 2-3 minutes before swallowing. After reaching the maintenance dose patients will be treated up to 1 month.
223635619|NCT05295095|PROCEDURE|positive pressure during extubation procedure|positive pressure during extubation procedure
223635620|NCT03656159|BEHAVIORAL|Cognitive-Behavioral group therapy|Intervention will consist of eight weekly sessions of two hours each with a break of 15 minutes. The CBT will be delivered by a clinical psychologist and a clinical neuropsychologist previously trained in this therapeutic approach.
224224381|NCT02345278|OTHER|Placebo|Study medication will be taken sublingually once a day. Patients will start with one drop and increase the dose by one drop each consecutive day until the maintenance dose (5 drops/day) is reached. Drops should be kept under the tongue for 2-3 minutes before swallowing. After reaching the maintenance dose patients will be treated up to 1 month.
224224382|NCT03273985|OTHER|Dry needling|Trigger point deep dry needling
224224383|NCT03273985|OTHER|Ischemic compression|Trigger point ischemic compression
224224384|NCT04108377|DRUG|Roflumilast|Roflumilast capsule
224224385|NCT04108377|DRUG|Placebo|Sugar pill manufactured to mimic look of Roflumilast capsule
224224386|NCT04511351|DRUG|Chidamide|chidamide administration during radiation and chemotherapy phase in the study group
223635621|NCT03656159|BEHAVIORAL|Non directive support Group|Intervention will consist of eight weekly sessions of two hours each with a break of 15 minutes. The support group will be delivered by Ph.D. students having no experience with CBT.
223635622|NCT05101122|DRUG|Dosing 1: Atomoxetine|Oral administration at bedtime
223635623|NCT05101122|DRUG|AD313|Escalating dose of AD313; Oral administration at bedtime
224224387|NCT00594633|OTHER|donepezil and questionaires|Patients will undergo a brief cognitive evaluation prior to (baseline/Time 1), Cognitive Re-Evaluation (about 12 weeks after Time 1), Cognitive Re-Evaluation (about 12 weeks after Time 2) ,Cognitive Re-Evaluation (about 6 months after discontinuation of Donepezil). Then pt will be tx with donepezil, an acetylcholinesterase inhibitor. They will undergo a four-week dose titration (i.e., 5mg QD during weeks 1-4) to reach a final dose of 10mg QD of oral donepezil there after for a maximum of 24 weeks.
224224388|NCT02557945|DRUG|Gabapentin|Subjects will be treated with 400mg pills of gabapentin , titrating up to 3600mg per day, or 9 tablets (3 tabs tid)
224224389|NCT02557945|DRUG|Placebo|Subjects will be treated with 400mg pills of placebo, titrating up to 3600mg per day, or 9 tablets (3 tabs tid)
224224390|NCT03392597|BEHAVIORAL|Brothers as Allies|Strengths-based group approach to promote boys' and young men's safe and healthy passage through the pre-teen and adolescent years.
223635624|NCT04135417|BIOLOGICAL|HAV|Surgical implantation of the HAV and subsequent use of the implanted vascular conduit for hemodialysis vascular access.
223635625|NCT05131737|PROCEDURE|High altitude exposure|Exposure to 2500m of altitude
223635626|NCT05131737|PROCEDURE|Low altitude exposure|Exposure to 490 m
224224391|NCT03392597|BEHAVIORAL|Programming-as-Usual|Usual afterschool programming.
224224392|NCT06262698|BEHAVIORAL|Experiment group|The experimental group will receive six weeks of HBM-based training.
224224393|NCT06262698|OTHER|Pre-post test|The TCM Attitude Scale (CACMAS), Medication Health Belief Scale
224224394|NCT02831062|OTHER|low protein diet + ketosteril|Patients will follow a diet containing 0.6 g protein/kg per day, phosphorus 5-10 mg/kg/day, Ketosteril 1 capsule per 5 kg body weight/day divided over three doses (max 8 capsules per dose).
224224395|NCT00131989|DRUG|sorafenib tosylate|Given orally
224224396|NCT00131989|OTHER|pharmacological study|Correlative studies
224224397|NCT00131989|OTHER|laboratory biomarker analysis|Correlative studies
224224398|NCT02956720|DEVICE|UltraShape Power|non-invasive body contouring procedure
224224399|NCT01923246|BEHAVIORAL|Single WEB intervention|Brief WEB intervention recieved once
224224400|NCT01923246|BEHAVIORAL|Repeated WEB intervention|WEB intervention recieved twice.
224224401|NCT01923246|BEHAVIORAL|Single IVR intervention|IVR intervention recieved once
224224402|NCT01923246|BEHAVIORAL|Repeated IVR intervention|IVR intervention recieved twice
224224403|NCT05868057|DRUG|SHR7280 tablets|SHR7280 tablets 1 time
223514487|NCT05245175|OTHER|Sodium chloride particles|Patients are exposed to sodium chloride particles alone for 4 hours in the Fraunhofer Allergen Challenge Chamber.
223514488|NCT05245175|OTHER|Lactose particles|Patients are exposed to lactose particles alone for 4 hours in the Fraunhofer Allergen Challenge Chamber.
223514489|NCT05245175|OTHER|Clean air|Patients are exposed to clean air for 4 hours in the Fraunhofer Allergen Challenge Chamber.
223514490|NCT05245175|OTHER|Sodium chloride particles with house dust mite|Patients are exposed to sodium chloride particles coupled with D. pteronyssinus for 4 hours in the Fraunhofer Allergen Challenge Chamber.
223514491|NCT05245175|OTHER|Lactose particles with house dust mite|Patients are exposed to lactose particles coupled with D. pteronyssinus for 4 hours in the Fraunhofer Allergen Challenge Chamber.
223514492|NCT00000853|BIOLOGICAL|rgp120/HIV-1MN|
223514493|NCT00728182|DRUG|NA-1|single intravenous dose of 2.6 mg/kg of NA-1 administered as a 10-minute infusion
223514494|NCT00728182|DRUG|Placebo|single intravenous dose of 2.6 mg/kg of placebo administered as a 10-minute infusion
223514495|NCT02236767|DEVICE|Neurostar Transcranial Magnetic Stimulation Therapy System|Treatment will entail daily (5 days/week) sessions of repetitive transcranial magnetic stimulation for 6 weeks employing right-sided, low frequency stimulation (1 Hz, 900 pulses/session for 30 sessions, 27,000 total pulses, intensity at 90% of the passive motor threshold) to the dorsolateral prefrontal cortex (DLPFC).
223514496|NCT01513928|DRUG|Pf-04937319|Formulation A) Pf-04937319 50 mg - administered as tablet
223514497|NCT01513928|DRUG|Pf-04937319|Formulation B) Pf-04937319 50 mg - administered as capsule
223514498|NCT01513928|DRUG|Pf-04937319|Formulation C) Pf-04937319 50 mg - administered as capsule
223514499|NCT01898091|DRUG|Neem Mouthrinse|10ml dose of assigned study mouthrinse, three times per day, for approximately 7 weeks during radiation therapy.
223514500|NCT01898091|DRUG|Placebo Mouthrinse|10ml dose of assigned study mouthrinse, three times per day, for approximately 7 weeks during radiation therapy.
223514501|NCT01187875|DIETARY_SUPPLEMENT|Placebo- Fiber free control|Dextrin control administered in a muffin treatment.
223514502|NCT01187875|DIETARY_SUPPLEMENT|Hi-maize resistant starch 9g|9g Hi-maize resistant starch administered in a muffin treatment.
223514503|NCT01187875|DIETARY_SUPPLEMENT|Novalose 330 resistant starch 9g|9g Novalose 330 resistant starch administered in a muffin treatment.
223514504|NCT01187875|DIETARY_SUPPLEMENT|4.5g Hi-maize resistant starch and 4.5g Novalose 330|4.5g Hi-maize and 4.5g Novalose 330 in a muffin treatment.
223514505|NCT05129384|DIETARY_SUPPLEMENT|B. infantis EVC001 or Lactose Placebo|Infant probiotic
223514506|NCT02831036|OTHER|training program|subjects in the trial group will follow a training program which includes 3 times a week running on a treadmill.
223514507|NCT02831036|OTHER|VO2max test|each subject will perform 4 times VO2max test according to BRUCE protocol in order to evaluate his aerobic fitness.
223514508|NCT02831036|OTHER|spatial orientation test|each subject will undergo 4 spatial orientation tests during the trial (month between 2 tests), each test is composed of 5 following days in which the subject will wear virtual reality glasses (Oculus Rift DK2) and attempt to arrive different destinations in a virtual maze tasks (using xbox one controller). each day will be given 3 attempts, the duration of each attempt is 2 min.
223514509|NCT03830411|DRUG|Sintilimab|Sintilimab will be administered intravenously at a fixed dose of 200 milligrams (mg) on Day 1 of each 21-day cycle.
223514510|NCT03830411|DRUG|Docetaxel|Docetaxel 75 milligrams per square meter (mg/m\^2) will be administered intravenously on Day 1 of each 21-day cycle.
223514511|NCT03830411|DRUG|Pemetrexed|Pemetrexed 500 mg/m\^2 will be administered intravenously on Day 1 of each 21-day cycle.
223514512|NCT01512173|DRUG|propranolol gel|Topical administration twice daily
223514513|NCT01512173|DRUG|Placebo|Topical administration twice daily
224224404|NCT05868057|DRUG|SHR7280 dry suspension|SHR7280 dry suspension 1 time
224224405|NCT00003235|DRUG|carboplatin|
223514514|NCT00492674|DEVICE|APOS biomechanical gait system|
223514515|NCT00492674|PROCEDURE|Physical Therapy|
223514516|NCT01276418|DEVICE|CO2 laser|Ablation and coagulation of soft tissue
223514517|NCT01618708|DEVICE|Synvisc-One (hylan G-F 20)|6-mL IA injection
223514518|NCT01618708|DEVICE|Placebo|6 mL injection of phosphate buffered saline
223514519|NCT05686252|OTHER|Held Position|Change in angle of held position during kangaroo mother care to alternative angle
223514520|NCT01573793|BEHAVIORAL|Parenting Education|Will receive parenting educational materials hypothesized to enhance emotional and cognitive development
223514521|NCT01573793|BEHAVIORAL|Control Group - Safety Materials|Will receive safety and dental hygiene materials that have no bearing on emotional and cognitive development
223514522|NCT03531567|BEHAVIORAL|Virtual Reality Mystic Isle Game|8 week virtual reality based exercise program
223514523|NCT03531567|BEHAVIORAL|Standard Home Exercise Program|8 week standard occupational therapy home exercise program
223635627|NCT05357001|OTHER|Connective tissue manipulation|to remove muscle spasticity
223635628|NCT05357001|OTHER|stretching exercises|to remove muscle spasticity
224224406|NCT00003235|DRUG|paclitaxel|
224224407|NCT00003235|RADIATION|radiation therapy|
224224408|NCT04361019|OTHER|On-Line Survey|A survey has been sent by email to the students of the participating universities
224224409|NCT01169090|DRUG|SK-0403|SK-0403
224224410|NCT01169090|DRUG|Placebo|Placebo
224224411|NCT01169090|DRUG|Sitagliptin|Sitagliptin
224224412|NCT06045481|DRUG|administration of single dose of doxycycline|Postexposure prophylaxis with Single Dose doxycycline
224224413|NCT02577081|OTHER|CAT scan (CT scan)|all patients will pass a CAT scan of ths pelvis and the 2 femurs. No other interventions are required.
223635629|NCT06201780|DIAGNOSTIC_TEST|serum levels of Janus Kinase 1and 2|assessment of serum levels of Janus Kinase 1and 2 by ELISA
223635630|NCT04163952|BIOLOGICAL|Panitumumab|Given IV
223635631|NCT04163952|BIOLOGICAL|Talimogene Laherparepvec|Given IM
223635632|NCT02146066|BIOLOGICAL|DCVax-L|Autologous Dendritic Cells Pulsed with Tumor Lysate Antigen
223635633|NCT04374942|DRUG|Hydroxychloroquine|Oral Hydroxychloroquine, 400 mg taken once daily, for three months as pre-exposure prophylaxis to prevent COVID-19 in health care workers in the emergency department.
224224414|NCT02229006|RADIATION|18F-NaF PET-CT|
224224415|NCT01429402|DRUG|Botulinum Toxin Type A|1-2U/kg, at 25U/mL, into the bilateral aberrant oriented orbicularis ocuris muscle via 4 superficial injection site; only once after surgery. No additional injection is needed
224224416|NCT01429402|DRUG|Botulinum Type A|b. Study group II: For revision lip surgery, immediately after revision lip surgery 3 injection of 2.5U of botulinum toxin with a distance of 0.5 cm from each injection and operative wound are injected over both sides of upper lip in a adult on the operation room just after surgery. (total dosage injected 15U)
224224417|NCT01429402|DRUG|Normal Saline|Similar amount (in C.C.) of normal saline as group I will be injected after primary lip surgery at 3 months of age.
224224418|NCT01429402|DRUG|Normal Saline|Similar amount (in C.C.) of normal saline as study group II will be injected after revision lip surgery (secondary cleft lip repair).
223635634|NCT04374942|DRUG|Placebo oral tablet|Placebo pill (same formula as Hydroxychloroquine without active ingredient) taken once daily, for three months.
223635635|NCT02194335|DRUG|BIBN 4096 BS - in single rising doses|
224224419|NCT06543602|DIAGNOSTIC_TEST|multi-model monitoring and alert|All agitated critically illed patients are monitored by manual and multi-model monitoring and alert system
224224420|NCT01371513|OTHER|continuous screening|practice patterns for screening prostate cancer
224224421|NCT05261113|PROCEDURE|CE-IOUS|Use of contrast-enhanced intraoperative ultrasound during liver surgery
224224422|NCT02171936|OTHER|Questionnaire EPICES (Evaluation of the Precariousness and the Disparities of Health for the Centers of Examination of Health).|
223635636|NCT02194335|DRUG|Placebo|
223635637|NCT04945733|DRUG|Amivantamab|Amivantamab will be administered intravenously.
223635638|NCT05208060|BIOLOGICAL|MV130|Treatment administered sublingually
223635639|NCT05208060|OTHER|Placebo|Treatment administered sublingually
223635640|NCT00207077|DRUG|Cetuximab + Erlotinib|IV solution + tablet, IV+ oral, ERB 100 mg/m2, 200 mg/m2, 250 mg/m2 IV + Erl 150 mg tablet, ERB weekly/ Erl once daily, Until disease progression.
223635641|NCT05626621|DRUG|Azelastine (137 mcg/spray) Nasal Spray and Mometasone (50 mcg/spray) Nasal Spray|Participants will follow this medication regimen for 6 months.
223635642|NCT05626621|DRUG|Mometasone Nasal Irrigation (1 mg capsule)|Participants will follow this medication regimen for 6 months.
223635643|NCT05626621|DRUG|Mometasone (1 mg) and Azelastine (1 mg) Nasal Irrigation|Participants will follow this medication regimen for 6 months.
224224423|NCT05585359|OTHER|injectable platelet rich fibrin augmented with Vitamin C|According to the amount of the injectable platelet rich fibrin that will be obtained after the centrifugation of blood, the amount of Vitamin C will be calculated to be; for each 1 ml of injectable platelet rich fibrin, 250 μg of Vitamin C will be mixed with the i-PRF and injected inside the canals using a plastic syringe with a 25-gauge needle that was placed 1mm short of the working length and will be withdrawn gradually while injecting till reaching the canal orifice
224224424|NCT01373606|DRUG|Terlipressin|
224224425|NCT02960815|BIOLOGICAL|Intanza|
224224426|NCT02960815|BIOLOGICAL|Mutagrip|
224224427|NCT02960815|DRUG|Aldara|
224224428|NCT05849428|DEVICE|Freestyle Libre 3|Freestyle Libre 3 consists of a sensor that is applied to the back of the upper arm. The sensor is a penny-sized flexible filament placed beneath the skin surface to measure interstitial fluid. This sensor is applied utilizing a sensor applicator provided in the packaging. The sensor will continuously read interstitial glucose readings every minute and syncs with the Freestyle View app. At the completion of the study, the sensor is discarded per protocol.
224224429|NCT02011594|DRUG|Nimotuzumab|400mg Q2W intravenously
224224430|NCT02011594|DRUG|Placebo|Normal saline
223635644|NCT04053777|DEVICE|non-invasive ventilation|Noninvasive positive pressure ventilation used assist/control mode to treat chronic respiratory disease.
223635645|NCT03666754|PROCEDURE|Standard therapy arm|Multilayer elastic compression bandaging/ stockings with the deferred treatment of superficial reflux (usually once the ulcer has healed)
223635646|NCT03666754|PROCEDURE|Early endovenous glue embolization arm|Early endovenous glue embolization of superficial venous reflux within 2 weeks in addition to standard compression therapy
223635647|NCT02897323|OTHER|description|
223635648|NCT03580811|DEVICE|Dental Implant &ADMG|A dental implant will be placed and the buccal soft tissue will be grafted using ADMG .
223635649|NCT03580811|DEVICE|Dental implant & ADMG & BDX|Dental Implant will be placed with ADMG that covers the BDX
223635650|NCT01392105|DRUG|Mesenchymal stem cell|Route : intracoronary injection Frequency : single dose of autologous bone-marrow derived mesenchymal stem cells Dosage : 1x1000000 cells/kg Duration : mean injection duration approximately 4 weeks after primary percutaneous coronary intervention
223635651|NCT01392105|DRUG|Control group|No additional treatment of mesenchymal stem cells
223635652|NCT03095859|OTHER|Physical rehabilitation.|Early mobility, aerobic exercise, upper and lower limb strength and flexibility training, trunk mobility and core strengthening, inclusive of respiratory therapy and education.
223635653|NCT06130488|BEHAVIORAL|KMC|KMC implementation as per protocol
224224431|NCT04528095|DRUG|Clozapine|Clozapine 400 \~ 600mg/d or plasma concentration \>350ng/ml Amisulpride 200-800mg/d Gingke biloba 120-360mg/d
224224432|NCT04528095|DEVICE|MECT|MECT:The treatment lasted for 4 months,16 times in total MST:The treatment lasted for 4 months,16 times in total
224224433|NCT04528095|DEVICE|DBS|Two electrode emplacement groups (target nucleus accumbens and hippocampus respectively)
224224434|NCT05336279|DRUG|famitinib malate T(5 mg*4)、famitinib malate R(20 mg)|TR Group: famitinib malate T on day 1, famitinib malate R on day 13.
224224435|NCT05336279|DRUG|famitinib malate T(5 mg*4)、famitinib malate R(20 mg)|RT Group: famitinib malate R on day 1, famitinib malate T on day 13.
223635654|NCT01841411|DRUG|N-Acetyl cysteine|N-Acetyl cysteine is a pharmaceutical drug and nutritional supplement,it is a derivative of the natural amino acid cysteine, from which it differs by virtue of the introduction of an acetyl group on the nitrogen atom of the amino terminal.It is used mainly as a mucolytic and in management of paracetamol overdose. It has been observed that N-acetyl cysteine has shown good properties in terms of combating bacterial infections. In particular, it has been observed that NAC presents good activity in terms of inhibiting bacterial adhesion and in dissolving the biofilm matrix.
223635655|NCT01841411|DRUG|Metronidazole + N-Acetyl cysteine|Metronidazole is an antibiotic effective against anaerobic bacteria and certain parasites.It can be used in treatment of vaginal infections such as trichomoniasis and bacterial vaginosis N-Acetyl cysteine is a pharmaceutical drug and nutritional supplement, It is used mainly as a mucolytic and in management of paracetamol overdose. It has been observed that N-acetyl cysteine has antibacterial and antibiofilm activities
223635656|NCT01841411|DRUG|metronidazole|Metronidazole is an antibiotic effective against anaerobic bacteria and certain parasites.It can be used in treatment of vaginal infections such as trichomoniasis and bacterial vaginosis in treatment of bacterial vaginosis, it can be used in treatment of bacterial vaginosis either in a dose of 500 mg twice daily or 250 mg three times daily for seven days
223635657|NCT00286247|GENETIC|INGN 201|
224224436|NCT01583387|OTHER|1-Increased water intake regimen|Arm 1-Intervention
224224437|NCT01583387|OTHER|2-Non-modified water intake regimen|Arm 2-Control
224224438|NCT04316858|DRUG|Sodium phosphate|90ml of sodium phosphate will be added to 800ml of solvent( water or zero calorie carbonated drink) and taken in divided doses one day prior to procedure. Whole solution will be finished 3 -4 hours before colonoscopy.
224224439|NCT04316858|DIETARY_SUPPLEMENT|Water|800 ml of water will be added to 90 ml of sodium phosphate to facilitate its intake by the patients preparatory to colonoscopy
224318676|NCT03223701|COMBINATION_PRODUCT|Solum IV, Bone Marrow Concentrate with general fluid concentrate (GFC) in Transforaminal Lumbar Interbody Fusion|The bone marrow aspirate (BMA) will be taken from the iliac crest of the enrolled subjects. The BMA will be transferred to a processor that will use ART BMC Plus (Celling Biosciences, Austin, TX) platform technology to obtain the BMC preparation. The plasma component that remains as a by-product of generating the BMC will then be concentrated by the ART BMC Plus device to create a concentrated plasma/general fluid concentrate (GFC). The enrolled subjects' BMC and GFC will be provided to the principle investigator who will combine the two together with Solum IV using the Graft Delivery Kit (Celling Biosciences) and perform a TLIF procedure. (See Appendix B for Graft Delivery Kit). All subjects will be assigned to receive lumbar interbody fusion via a TLIF approach with Solum IV bone graft and BMC with GFC in the interbody space of a TLIF using cynch bullet cage (@SpineSmith) and Stryker based pedicle screw system (Xia 3 system).
224318677|NCT05835908|OTHER|Phone questionnaire|Patients will be contacted by the investigator to collect information regarding follow-up from the initial call to the Emergency call center until the patient is taken care of in the health care facility to which he/she has been admitted.
224318678|NCT06443723|DIAGNOSTIC_TEST|USG, blood tests, waist, hip, height and blood pressure measurements|"MAFLD is defined as hepatic steatosis entity in addition to the presence of overweight or obesity, DM, or evidence of metabolic dysfunction.~Metabolic dysfunction (two or more of the following)~1. waist circumference ≥ 90 cm in men and 88 cm in women,~2. blood pressure ≥ 130/85 mmHg or on specific drug treatment,~3. plasma triglycerides (TG) ≥ 150 mg/dl or on specific drug treatment,~4. plasma high-density lipoprotein cholesterol (HDL-C) \< 40 mg/dl for men and 50 mg/dl for women or on specific drug treatment,~5. prediabetes (FBS 100 to 125 mg/dl or HbA1c 5.7 to 6.4%),~6. homeostasis model assessment of insulin resistance (HOMA-IR) score ≥ 2.5."
224318679|NCT01616355|OTHER|Sodium hypochlorite immersion|Dentures daily immersion in a 0.5% sodium hypochlorite solution for 3 minutes.
223514524|NCT04381559|BEHAVIORAL|Cognitive Behavioural Therapy|In sessions 1-2, the participant's sexual history and goals regarding social anxiety reduction and HIV risk reduction will be discussed, including reducing CAS, and considering use of PrEP to reduce HIV risk. In sessions 3-4, the role of social anxiety and substances in social avoidance and HIV risk will be discussed, and a fear hierarchy of the participant's social fears will be created. In sessions 5-7, cognitive restructuring and coping skills for anxiety reduction will be discussed. In sessions 8-9, participants will face their fears via exposures to feared situations using their new cognitive coping skills. In sessions 10-11, exposures are continued with a focus on (a) situations higher in the fear hierarchy and (b) the role of substance use as a barrier to personal goals. In session 12, relapse prevention and goals for progress regarding social anxiety, substance use, and HIV risk reduction beyond the end of therapy will be discussed.
223635658|NCT03431207|OTHER|Standardized video recording for behaviors|"A standardized apparatus, scenario, and procedure was applied to record all the behavioral phenotypes with minimized background interference and stimulation.~For each standardized procedure, the guardian sits in the chair, holding the infant facing the stage. Each infant is given a few minutes to adapt to the surroundings and to be calm before recording. No hints or simulations are permitted during the entire process. The recording process lasted for over 5 minutes to ensure that behavioral phenotypes could be completely recorded."
223635659|NCT00524836|DRUG|levocetirizine dihydrochloride|
224224440|NCT04316858|DIETARY_SUPPLEMENT|Zero calorie carbonated drink|800 ml of zero calorie diet cola will be added to 90 ml of sodium phosphate to facilitate its intake by the patients preparatory to colonoscopy
224224441|NCT00225082|DRUG|Nucleoside analogue switch|stavudine switched to tenofovir
224224442|NCT03779191|DRUG|Alectinib|Alectinib dosed 600 mg twice a day (BID) with meals until disease progression, unacceptable toxicity, or other reasons specified in the protocol
224224443|NCT03779191|DRUG|Bevacizumab|Bevacizumab 15 mg/kg intravenously every 3 weeks until disease progression, unacceptable toxicity, or other reasons specified in the protocol
224224444|NCT05661929|OTHER|Questionnaire CMQ|The questionnaire is used to diagnose cognitive distortions. It includes 50 items to identify 10 the most common cognitive biases.
224224445|NCT00557882|DEVICE|synthetic polypropylene mesh|Mesh used will be synthetic monofilament polypropylene. In this trial, patients in the experimental group will undergo interpositional multi-armed mesh placement using trocars for transobturator +/- ischioanal fossa placement at the level of the ischial spine.
224224446|NCT06021548|OTHER|Blood sample|Finger stick blood spots will be collected at V0 and M12
223635660|NCT02047032|PROCEDURE|acupuncture|For BL33, the needle (75mm) will be inserted at the point upper and outside of BL33. Insert the needle with a 30-45°angle to a depth of 50-60 mm. The needle will be manipulated with an even lifting, thrusting and twisting method and the sense of soreness and distention will radiate to the perineal region or the anus. For BL35, the needle will be inserted upward and outward slightly with an even lifting, thrusting and twisting method. The sense of soreness and distention will radiate to the perineal region or the anus. The electric stimulator will be put on the two pair of points with a spare-dense wave, 10/50 Hz, 0.1-5.0 mA. The current intensity will be increased until the participant can not stand.
223635661|NCT02047032|DRUG|solifenacin|Solifenacin used in this trial is produced by Astellas Pharma Europe B.V.(Country medicine accurate character No. J20090109 )
223635662|NCT02047032|PROCEDURE|PFMT|Intensity of the PFMT exercises will conform to the guideline of National Institute for Health and Clinical Excellence (NICE).
223635663|NCT05660577|DEVICE|new silicone hydrogel daily disposable multifocal contact lens, the Bausch + Lomb (kalifilcon A) Daily Disposable Multifocal Contact Lens|new silicone hydrogel daily disposable multifocal contact lens, the Bausch + Lomb (kalifilcon A) Daily Disposable Multifocal Contact Lens
223635664|NCT02796599|DEVICE|Non invasive ventilation during exercise with facial or nasal mask.|Every patients will achieve 3 constant work load test (CWLT) at 75% Wpic. The first CWLT will be realized without any ventilatory support. The 2 others CWLT will be achieved with non-invasive ventilation support using facial or nasal interface in a randomized order.
223635665|NCT04295447|OTHER|Standard of care|"1. Observation only or~2. An optional adjuvant radiation of the prostate bed in case of positive surgical margin"
223635666|NCT04295447|DRUG|Apalutamide 60Mg Tab|(4 x 60 mg) once daily on days 1-28 of a 28-day cycle
223635667|NCT05198596|BIOLOGICAL|MVC-COV1901|Approximately125 participants will receive 2 doses of MVC-COV1901(S-2P protein with adjuvant) at Day 1 and Day 29 via intramuscular (IM) injection in the deltoid region
223635668|NCT05198596|BIOLOGICAL|AZD1222|Approximately 125 participants will receive 2 doses of AZD1222 at Day 1 and Day 29 via intramuscular (IM) injection in the deltoid region
223635669|NCT04758572|OTHER|Manual Therapy|Mobilization, massage and stretching
223635670|NCT04758572|OTHER|Massage muscle chain|Massage very soft following the directions of the muscle chains, massage and stretching
223635671|NCT06107608|PROCEDURE|FAPI PET/CT|The radiopharmaceutical 68Gallium-FAPI-46 (FAPI) is injected intravenously for molecular imaging of FAP expression with FAPI PET/CT.
223635672|NCT06156488|PROCEDURE|Maxillary sinus floor augmentation|Maxillary sinus floor augmentation through a lateral window grafted with anorganic bovine bone + polynucleotides and hyaluronic acid
223635673|NCT06156488|PROCEDURE|Maxillary sinus floor augmentation|Maxillary sinus floor augmentation through a lateral window grafted with anorganic bovine bone
224224447|NCT06021548|OTHER|Saliva sample|Saliva sample will be collected at V0
223635674|NCT04794634|DIAGNOSTIC_TEST|Optical coherence tomography (OCT)|to make a complete ophthalmological and neurological examination, an OCT to AD and to compare their results with LD and controls subjects
223635675|NCT04794634|DIAGNOSTIC_TEST|Optical coherence tomograpohy angiography (OCTA)|to make a complete ophthalmological and neurological examination, an OCT and OCTA, to AD and to compare their results with LD and controls subjects
223635676|NCT05753449|DEVICE|Baseline (or standard of care) DBS programming|Baseline (or standard of care) DBS programming.
223635677|NCT05753449|DEVICE|Burst-type DBS electrical stimulation programming|Burst-type DBS is defined as a novel stimulation protocol in which intermittent bursts of traditional high-frequency rectangular wave stimulation are delivered.
223635678|NCT02479399|DRUG|ipragliflozin|Tablets
223635679|NCT06254638|BEHAVIORAL|Multicomponent school-based intervention.|"Physically active learning: this type of intervention is carried out once a week for 1 hour outside the classroom. The teachers of the corresponding subject (with the support of the research team) are in charge of the physically active classes.~Active break: the intervention consists of 2 active pauses per day. The development of each pause is carried out through a specific digital platform in which students follow the instructions of an avatar, who is in charge of guiding the realization of the active break. Each active break takes a total of 4 minutes, in which two sets of 20 seconds of work and 10 seconds of rest of four different exercises are performed.~Active break: The intervention consists of a daily active break, every school day of the week. The design and supervision of each active break will be carried out by the support technician and the teaching staff based on the students' tastes."
223635680|NCT04822337|DRUG|Carfilzomib, Lenalidomide, Dexamethasone, Belantamab Mafodotin|Phase I - Chemotherapy multiple agents systemic Phase II - Maximum Tolerated Dose from Phase I
224224448|NCT06021548|OTHER|Hair sample|Hair sample will be collected at V0 (optional)
224224449|NCT04834557|DRUG|Placebo|Placebo will be administered to the control group for 24 weeks as an add-on treatment to the current DMARDs treatments for rheumatoid arthritis.
224224450|NCT04834557|DRUG|Digoxin 0.25 mg|All subjects will receive digoxin administered at 0.25 mg every other day for 24 weeks as an add-on treatment to the current DMARDs treatments for rheumatoid arthritis.
223635681|NCT06584318|OTHER|Intermittent hypoxia intervention|The intermittent hypoxia protocol refers to 6 cycles of 10 minutes hypoxia inhaling interval by 5 minutes normoxia, which is performed twice a day (at least 6 hours apart) in 7 days.
224224451|NCT04834557|DRUG|Ursodeoxycholic acid (UDCA) 500 mg|All subjects will receive Ursodeoxycholic acid (UDCA) administered at 500 mg/day for 24 weeks as an add-on treatment to the current DMARDs treatments for rheumatoid arthritis.
224224452|NCT04894422|OTHER|Observational intervention|Voluntarily (not) wearing a face mask (cotton or surgical) for 4 hours, following the government's guidelines during the COVID-19 pandemic.
223635682|NCT04804384|DEVICE|Prehension neuroprosthesis|"The experimental condition corresponds to patients in the condition where the prehension neuroprosthesis is active, which means that the extensor muscles of the fingers and thumb will be stimulated by the prehension neuroprosthesis to ensure the opening of the hand. The prehension neuroprosthesis designates a functional electrical stimulation device controlled by the patient which will itself trigger the stimulation of the extensor muscles of the fingers (closed-loop control), according to stimuli which it controls voluntarily. The goal is to restore an opening of the fingers to capture objects.~The control condition corresponds to the patients in the condition where the prehension neuroprosthesis is inactive."
223635683|NCT03363841|DRUG|SCY-078|Oral SCY-078
223635684|NCT02020265|DEVICE|EEG neurofeedback|
224224453|NCT05539573|DEVICE|Planned TAVI with the ACURATE neo2™ aortic bioprosthesis and ACURATE neo2™ transfemoral delivery system.|"The study will collect data from patients treated with the ACURATE neo2™ and its transfemoral delivery system following standard TAVI practice at each participating center. All patients will be followed to 12 months after the implant procedure. The study is divided into three periods:~1. Screening period: from screening to enrollment if study criteria are met.~2. Implantation procedure: immediately pre-implant to 24 hours post-procedure.~3. Follow-up period: at hospital discharge, at 30 days and at 12 months post-procedure."
224224454|NCT00969839|DEVICE|NovaLign Intramedullary Fixation System|Intramedullary fixation of broken humerus
224318680|NCT05210010|DEVICE|CA-4F|"The study intervention is the CA-4F algorithm developed by Ensho Health.~The algorithm is a process for converting input parameters to a CA-4F Risk Score intended to facilitate clinical prioritization of patients suitable for follow-up investigation for ATTR-CM.~The algorithm is applied using the CA-4F Likelihood Estimator which encodes it in software and records its outputs. The CA-4F Likelihood Estimator is controlled through a graphical user interface called the CA-4F Controller.~The CA-4F Likelihood Estimator and its Controller are Class I medical devices in Canada registered under the Medical Device Establishment License of Ensho Health (license 16208)."
223514525|NCT04381559|BEHAVIORAL|Applied Relaxation|12 sessions of AR will serve as our second, control arm. In AR, patients are trained in progressive muscle relaxation, and then taught to practice using relaxation when facing feared situations, as a new coping response.86 AR involves noticing early signs of anxiety, learning relaxation skills, and applying relaxation at the first sign of anxiety.87 This therapy is chosen because it does not involve the cognitive and exposure focused techniques that are used in the experimental condition.88 Reviews of psychological treatments show that AR does not statistically differ from cognitive restructuring with exposure in its effects on social anxiety.87 However, AR is an appropriate control arm for the present study because it is credible and can be time-matched to CBT, but has no theoretical or empirical support for substance use management or HIV risk behaviour reduction, the latter of which is the primary outcome of the present study.
223514526|NCT03339765|BEHAVIORAL|Strong Together serious game|The Strong Together serious game program is an interactive, immersive education program in which participants quickly learn the behaviors of self-advocacy and the potential consequences of self-advocating or not. Participants will receive weekly game sessions to play at home for three months.
223514527|NCT03509480|PROCEDURE|Surgical Curettage for benign bone lesion|Surgical curettage for benign bone lesion, created defects will be filled with one of two types of graft material Vitoss versus Prodense, there are no other devices or drugs used
223514528|NCT04698447|DIETARY_SUPPLEMENT|Natural supplement containing nanovesicles delivered from Citrus Limon (L.) juice_MetS|20 eligible subjects with the metabolic syndrome (MetS) will take natural supplement containing a spray-dried formulation of citraVes™, directly in the mouth, without water, to be dissolved preferably under the tongue, at a stable dose of one sachet a day (1000 mg/day) for 6 months and as add-on therapy to the ongoing treatment, maintained at fixed doses for the entire study.
223514529|NCT04698447|DIETARY_SUPPLEMENT|Placebo (without any active ingredients)|20 eligible subjects with the metabolic syndrome will take placebo in a spray-dried formulation (without any active ingredients) directly in the mouth, without water, to be dissolved preferably under the tongue, at a stable dose of one sachet a day for 6 months, as add-on therapy to the ongoing treatment, maintained at fixed doses for the entire study.
223514530|NCT04698447|DIETARY_SUPPLEMENT|Natural supplement containing nanovesicles delivered from Citrus Limon (L.) juice_HS|20 eligible healthy subjects (HS) will take natural supplement containing a spray-dried formulation of citraVes™, directly in the mouth, without water, to be dissolved preferably under the tongue, at a stable dose of one sachet a day (1000 mg/day) for 6 months, maintained at fixed doses for the entire study.
223514531|NCT01401205|OTHER|upper airway ultrasonographic examination|upper airway ultrasonographic examination and cuff leak test
223514532|NCT03729141|DIETARY_SUPPLEMENT|Added Cholesterol|Participants assigned to the added cholesterol group will receive snacks containing added cholesterol (1g/day) for 3 weeks prior to surgery.
223514533|NCT03729141|OTHER|No Added Cholesterol|Participants assigned to the no added cholesterol group will receive snacks containing no added cholesterol for 3 weeks prior to surgery.
223635685|NCT05358665|OTHER|mask use|long term mask use
223635686|NCT02624076|OTHER|Acupuncture|semi-fixed protocol will be used including four local core points; conception vessel (CV) 3, CV 6, and stomach (ST) 29 bilaterally and four in the leg/feet; spleen (SP) 6, and SP 9 bilaterally. The core points CV 3, CV 6, ST 29, SP 6, and SP 9 are thereafter connected to electrical stimulator (Hwoto, China) and stimulated with low-frequency, 2Hz, 0.5 ms
223635687|NCT02624076|OTHER|expectant management|one initial counselling session, an information leaflet on timed intercourse, access to a telephone helpline for queries and ad hoc support on demand from the fertility clinic over a period of 4 months post randomization.
224224455|NCT00820235|DEVICE|OsseoSpeed™|OsseoSpeed™ implant
224224456|NCT00820235|DEVICE|NobelSpeedy™ Replace®|NobelSpeedy™ Replace® implant
224224457|NCT00820235|DEVICE|NanoTite™ Certain® PREVAIL®|NanoTite™ Certain® PREVAIL® implant
224224458|NCT01433900|DRUG|Tafluprost|1 drop of tafluprost to eligible eye(s) once daily (at 9 pm)
224224459|NCT01433900|DRUG|Latanoprost|1 drop of tafluprost to eligible eye(s) once daily (at 9 pm)
224318681|NCT04759768|DRUG|Nalmefene Hydrochloride|3mg nasal spray
224318682|NCT04759768|DRUG|Nalmefene|1mg intramuscular injection
224318683|NCT01858272|DRUG|H5.020CMV.PDGF-b and limb compression bandage|
223635688|NCT05378750|OTHER|Diuretic algorithm|Implementing diuretic algorithm
224224460|NCT00891683|DRUG|AEG33773 oral dosing|AEG33773 capsules: subjects will receive a daily dose of either 100 mg, 200 mg, or 400 mg AEG33773. Placebo capsules: subjects will receive a daily dose of placebo (matching test product). Capsules will be taken by mouth, over 28 consecutive days
224224461|NCT01890083|BEHAVIORAL|Exercise|
223635689|NCT02309242|BEHAVIORAL|Neuropsychological assessment, MRI|All subjects will be imaged (MRI) on the same 3T Philips scanner with a 32-channel phased-array head coil, located in the radiology department at UZ Leuven. For the neuropsychological assessment we will implement an extended neuropsychological assessment battery: ANT, CMS, Rey, BRIEF, WISC III, PedsQL, STAI, BDi, achenbach questionnaires
224224462|NCT01890083|BEHAVIORAL|Health Education|
223635690|NCT00635297|PROCEDURE|Percutaneous vertebroplasty|PMMA injection 3-10 milliliter in each treated vertebrae
224224463|NCT03551730|COMBINATION_PRODUCT|PRT064445/Enoxaparin|
224224464|NCT03551730|COMBINATION_PRODUCT|Placebo/Enoxaparin|
224224465|NCT03551730|DRUG|Placebo|
224224466|NCT02095847|PROCEDURE|High-Resolution Microendoscopy Imaging|Once the cervix has been dilated, a hysteroscope will be introduced in the uterine cavity to evaluate for presence of tumor. Location and size of tumor documented. White-light images obtained using the HRME camera introduced through the hysteroscope. Once completed; the hysteroscope will be removed and the uterine cavity will be infused with 10 mL of proflavine (an acridine dye) (0.01% Proflavine (10ml)). A resectoscope will then be introduced in the uterine cavity and fluorescent images obtained using the HRME camera.
223514534|NCT00979615|DRUG|Olopatadine HCL (Patanase) Nasal Spray, 0.6%|2 sprays/ nostril BID
223514535|NCT00979615|DRUG|Azelastine HCl (Astelin) Nasal Spray, 137 mcg|2 sprays/ nostril BID
223514536|NCT02438085|OTHER|prospective collection of data and follow-up|prospective collection of data and follow-up of all patients admitted to hospital for ACS
223514537|NCT01630811|DRUG|Nuedexta|Nuedexta (Dextromethorphan hydrobromide 20 mg and quinidine sulfate 10 mg) will be given once daily for 7 days. If well-tolerated, it will be given every 12 hours for the next 7 weeks.
223514538|NCT01630811|OTHER|Placebo|Placebo will be given once daily for 7 days.
223514539|NCT06535737|DRUG|Cabozantinib|Cabozantinib (Cabometyx) 60, 40 and 20 mg
223514540|NCT02872688|OTHER|GanedenBC30|
223514541|NCT04518657|BEHAVIORAL|Behavioral Intervention for Physical Activity in MS (BIPAMS)|A behavioral intervention that involves an internet website and one-on-one video coaching calls for increasing physical activity in people with MS.
223514542|NCT04518657|BEHAVIORAL|Wellness for MS (WellMS)|A behavioral intervention that involves an internet website and one-on-one video coaching calls for increasing wellness in people with MS.
223514543|NCT05393908|PROCEDURE|TAP Block Group|Participants will receive a surgeon administered TAP block.
223514544|NCT04873856|DIETARY_SUPPLEMENT|Intervention|"The four dimensions of MINDNUT are described below:~Nutritional plan: is conducted in collaboration with the participant based on nutritional registration and information about routines and habits to reach a daily protein target of 1.5 g/kg/day. The nutritional plan is adjusted at the regular contact, and nutritional supplementation will be handed out to the participant.~Friendly reminder/informal caregiver: is a friendly reminder that encourage the participant to follow the nutritional plan and to ask for support (a note to hang on the refrigerator). The informal caregiver is a person with close contact to the participant.~Regular contacts: The participant will be contacted on regular basis (with an interval of 7-14 days) via phone and besides nutritional plan, this conversation will be used to talk about well-being, compliance and potential side-effects.~Weight diary: participants is instructed in keeping a weight diary which include registration of a daily weight."
223514545|NCT03430973|BEHAVIORAL|Videos|Videos depicting various aggressive driving and road rage behaviors.
223514546|NCT03430973|BEHAVIORAL|Bumper stickers|Bumper stickers hypothesized to increase or decrease aggressive driving.
223514547|NCT03430973|BEHAVIORAL|Alcohol-related cues|Case of beer or water on passenger seat.
223514548|NCT03430973|BEHAVIORAL|Music|Lyrics and tempo of music will be manipulated to increase or decrease aggressive driving.
223514549|NCT03430973|BEHAVIORAL|Roadside vegetation|The roadside will contain trash to increase aggressive driving, or vegetation to decrease aggressive driving. There is also a control group.
223514550|NCT03430973|BEHAVIORAL|Video game|Participants will play a racing or neutral video game before driving in the simulator.
223514551|NCT04276701|BIOLOGICAL|blood sample|35 ml whole blood for Peripheral blood mononuclear cell (PBMC), serum and plasma
223514552|NCT04276701|OTHER|Ultrasonography assessment|assessment of atherosclerotic plaques and measurement of carotid intima-media thickness (cIMT)
223514553|NCT04276701|BEHAVIORAL|questionnaires|Food and exercise questionnaires validated by the American heart Association
223514554|NCT06432452|DRUG|Endothelin Receptor Antagonist|Oral capsules twice daily
223514555|NCT06432452|OTHER|Placebo control|Oral capsules twice daily
223514556|NCT05284513|BEHAVIORAL|FH diagnosis program|Uptake of screening, diagnosis, and initiation of care management for FH
223514557|NCT05284513|BEHAVIORAL|Implementation strategy package: Develop and implement tools for quality monitoring|EHR tools to order labs, record results, and document FH care
223514558|NCT05284513|BEHAVIORAL|Implementation strategy package: Develop educational materials|Education regarding guidelines for identification and treatment of FH
223514559|NCT05284513|BEHAVIORAL|Implementation strategy package: Conduct educational outreach visits|Continuing medical education (CME) material for FH that is presented to
223514560|NCT05284513|BEHAVIORAL|Implementation strategy package: Intervene with clinicians and patients to enhance|Notify patients simultaneously with clinicians about the need for screening
223514561|NCT05284513|BEHAVIORAL|Behavioral (e.g., Psychotherapy, Lifestyle Counseling) Implementation strategy package: Identify and prepare champions Clinical lipid champions|Clinical lipid champions
223514562|NCT05284513|BEHAVIORAL|Implementation strategy package: Audit and provide feedback|Provide aggregate level feedback to clinics on diagnosing FH
223514563|NCT05284513|BEHAVIORAL|Implementation strategy package: Stage implementation scale up|Develop the timeline for the stepped-wedge rollout to primary care
223514564|NCT01725308|DRUG|FK949E|Taken by mouth (orally).
224224467|NCT02095847|DRUG|Proflavine|After hysteroscopy with HRME camera, uterine cavity infused with 10 mL of Proflavine.
224224468|NCT02318498|PROCEDURE|CMR|Intervention performed 2-4 days after admission to hospital with the latest CMR technique including sensitive oedema sequences using T1 mapping
224224469|NCT02490423|OTHER|Nudges Intervention|The intervention arm will employ standard cardiovascular clinical care plus the combination of the MoBe Maps Patient Activation Platform with the Intermountain Risk Score to personalize and deliver motivational nudges to each participant.
224224470|NCT03554421|PROCEDURE|Percutaneous tibial nerve stimulation|A 20Hz electrical current is given via an electrode inserted through the skin over the posterior tibial nerve above the medial malleolus of the foot and the nerve is stimulated until a motor reflex of the big toe is acheived. Treatment is then continued for 30 minutes at this level. The treatment is then repeated for a total of 10 sessions within a 2 week period.
224224471|NCT03907280|DRUG|BI 1265162 (T1)|oral solution
224224472|NCT03907280|DRUG|BI 1265162 (T2)|Solution for inhalation
224224473|NCT03907280|DRUG|BI 1265162 (R)|concentrate for i.v. solution
224224474|NCT03907280|DRUG|BI 1265162 (T3)|Solution for inhalation
224224475|NCT04854720|DEVICE|Fuji® II LC CAPSULE|"Fuji® II LC is a resin modified glass ionomer contained, fluoride releasing and light-cured material. Since the product is tolerant to moisture and saliva, it's used for fissure sealant of newly erupted teeth.~Test 1 newly erupted first permanent molars were cleaned with a pumice paste using a bristle brush and isolated with cotton rolls. Then, 20% cavity conditioner was applied to all surfaces of the tooth for 10 seconds.The tooth surface was rinsed with water and dried. Thereafter, Fuji® II LC was applied to the pits and fissures on the tooth surface using a brush. Then, the varnish was applied and cured according to the manufacturer's instructions."
224224476|NCT04854720|DEVICE|Clinpro™ XT Varnish|"Clinpro™ XT Varnish is a resin modified glass ionomer containing, fluoride-releasing, light-cured varnish. Since the product is tolerant to moisture and saliva, it is used for fissure sealant of newly erupted teeth. The product can be recharged with fluoride using fluoride-containing products.~Test 2 newly erupted first permanent molars were cleaned with a pumice paste using a bristle brush and isolated with cotton rolls. Then, 35% phosphoric acid was applied to all surfaces of the tooth for 15 seconds.Then the tooth surface was rinsed with water and dried. Thereafter, Clinpro™ XT Varnish was applied in compliance with the manufacturers' instructions."
224224477|NCT04854720|DEVICE|Beautifil Flow|"Beautiful Flow is a Giomer contained, fluoride releasing and light cured material. The product contains pre-reacted glass ionomer particles (PRG). It is a high water resistant material. It is used for fissure sealant.~Test 3 newly erupted first permanent molars were cleaned with a pumice paste using a bristle brush and isolated with cotton rolls. Then, 7% phosphoric acid was applied to all surfaces of the tooth for 10 seconds. Then the tooth surface was rinsed with water and dried. Afterwards, a two-stage self-etch adhesive system was applied. Thereafter, Beautiful Flow was applied in compliance with the manufacturers' instructions."
224224478|NCT04854720|DEVICE|Fuji Triage® CAPSULE|"Fuji Triage® is a new generation glass ionomer containing with low viscosity, high fluoride content and light curing materials. Since the product is tolerant of moisture and saliva, it is used for fissure sealant of newly erupted teeth.~Control newly erupted first permanent molars were cleaned with a pumice paste using a bristle brush and isolated with cotton rolls. Then, 20% cavity conditioner was applied to all surfaces of the tooth for 10 seconds.Then the tooth surface was rinsed with water and dried. Thereafter,Fuji Triage® was applied to the pits and fissures on the tooth surface using a brush. Thereafter, the varnish was applied and cured according to the manufacturer's instructions."
224224479|NCT03801629|DRUG|High Morphine Dose|Subjects will receive an intramuscular morphine injection (0.07mg/kg) in the non-dominant deltoid muscle. Metoclopramide (10mg; oral) will be administered PRN to reduce nausea.
224224480|NCT03801629|DRUG|Low Morphine Dose|Subjects will receive an intramuscular morphine injection (0.04mg/kg) in the non-dominant deltoid muscle. Metoclopramide (10mg; oral) will be administered PRN to reduce nausea.
224224481|NCT04113395|OTHER|sequences T1 FE|T1 TSE and T1 TFE sequences with a duration of 6 minutes are added to the imaging protocol.
224318684|NCT06469203|DRUG|Oxytocin|"Women undergoing dilation and curettage, who meet the eligibility criteria for the study, will be divided into two groups. They will receive the assigned medication at the beginning of the procedure, after cervical dilation but before using suction curettage.~Group 1: Participants will receive 100 ml of saline alone. Group 2: Participants will receive an intravenous infusion of 8 units of oxytocin diluted in 100 ml of saline."
223635691|NCT06225414|OTHER|Usual Care|The usual care includes a provider flag in electronic medical record (EMR) on patients' eligibility for LCS if their smoking history is complete.
224224482|NCT03540810|DRUG|Hydroxychloroquine|The patients will additionally receive this drug with their usual treatment to evaluate its efficiency to prevent new thrombotic events in primary antiphospholipid syndrome patients
224224483|NCT03540810|DRUG|Placebo|The patients will receive placebo with their usual treatment
224224484|NCT01385410|BEHAVIORAL|Peer mother support for continued exclusive breastfeeding|Peer counselling on breastfeeding beginning in third trimester and continuing until 3 months postpartum
224224485|NCT00525109|OTHER|No Intervention|No intervention
224224486|NCT02491788|DRUG|Suvorexant|
224224487|NCT02491788|DRUG|Placebo|
224224488|NCT04537676|OTHER|No intervention, this is an observational study|No intervention
224224489|NCT03065127|BEHAVIORAL|Cognitive Training|Training the cognitive domain may be accomplished by training various cognitive and executive functions with guided practice focusing on specific skills (e.g. visuospatial processing, executive function, memory, language, and attention). Cognitive training has been demonstrated to be efficacious in several studies in individuals with PD. Given the potential cognitive contribution to FOG episodes, this type of therapy may alleviate FOG by potentially improving upon planning, set-shifting, and/or response inhibition.
224318685|NCT06469203|DRUG|Sodium Chloride 0.9% Inj|"Women undergoing dilation and curettage, who meet the eligibility criteria for the study, will be divided into two groups. They will receive the assigned medication at the beginning of the procedure, after cervical dilation but before using suction curettage.~Group 1: Participants will receive 100 ml of saline alone. Group 2: Participants will receive an intravenous infusion of 8 units of oxytocin diluted in 100 ml of saline."
223635692|NCT06225414|BEHAVIORAL|Brief Patient Education|Brief one-page education material on lung cancer screening benefits and risk
224318686|NCT02996487|DRUG|Vancomycin|
223635693|NCT06225414|BEHAVIORAL|Patient education|Patients will be sent information (in preferred language) on lung cancer risk, lung cancer screening (LCS) benefits, harms, false positive rates, recommendations of follow-up for positive results, and exam insurance coverage.
223635694|NCT06225414|BEHAVIORAL|Referral to financial navigation resources|Patients who self-report needing help with health-related social risks at baseline will be sent a brochure (in preferred language) from patient advocate foundation (PAF), a national non-profit financial navigation organization, where patients can self-refer.
223635695|NCT06225414|BEHAVIORAL|Patient Reminders|within 2 weeks prior to appointment, patients will receive a text message or a phone call (if not having a phone that receives text messaging) encouraging patients to discuss lung cancer screening with their provider.
223635696|NCT06225414|BEHAVIORAL|Provider Reminders|Within 2 weeks prior to primary care appointment, providers will be notified of their patient's eligibility for lung cancer screening and their reported barriers.
224224490|NCT03065127|BEHAVIORAL|Cognitive Behavioural Therapy|CBT has been demonstrated to be effective in the remediation of anxiety in individuals with PD. This may be beneficial to individuals experiencing FOG, given the evidence that anxiety may provoke FOG. During periods of elevated anxiety (e.g. walking in a threatening environment), freezers will be able to more efficiently process this limbic load resulting in greater resources available for movement control.
224224491|NCT03065127|BEHAVIORAL|Proprioceptive Training|Currently, studies investigating proprioceptive training as a treatment in PD are limited. However, this type of training has potential by improving proprioceptive processing. It would be expected that due to this training, when sensorimotor processing is challenged during locomotion (e.g. by removing visual feedback and preventing compensation of proprioception deficits), freezers would experience less decrements to gait due to an enhanced ability to process sensorimotor demands.
224224492|NCT03140592|PROCEDURE|Biopsy|Two extra EUS guided pancreatic biopsies collected for only research purposes.
224224493|NCT00389506|BIOLOGICAL|LMB-2 immunotoxin|
224224494|NCT00389506|DRUG|cyclophosphamide|
224224495|NCT00389506|DRUG|fludarabine phosphate|
224224496|NCT00389506|OTHER|pharmacological study|
224224497|NCT04272359|DRUG|Sulfa-zero: possible benefits of the treatment of new generation hypoglycaemic drugs compared to sulphonylureas|"Substitution of sulfonylureas with other classes of new hypoglycaemic drugs. In every group, it will be evaluated:~* efficacy in terms of glycometabolic compensation (glycemia, HbA1c, lipid profile);~* effects on BMI, blood pressure monitoring and hypoglycemic risk;~* changes in renal function and microalbuminuria;~* tolerability and side effects of the new therapeutic regimes;~* therapeutic adherence;~* post-prandial glycemic excursion, determined by a 6-point glycemic diary (pre- and 2h post-prandial glucose values) to be performed at home in the week before the scheduled follow-up visit;~* effects on chronic complications of diabetes and cardiovascular safety."
224224498|NCT00673361|DRUG|Concurrent decrescendo biochemotherapy regimen|"* Temozolomide: 200mg/m\^2, daily, PO, days 1-4~* Vinblastine: 1.5mg/m\^2, daily, IV, days 1-4~* Cisplatin: 20mg/m\^2, daily IV, days 1-4~* IL (interleukin)-2: - 18 milli-International unit (MIU)/m\^2, IVCI (intravenous continual infusion), day 1~* 9 MIU/m\^2, IVCI, day 2~* 4.5 MIU/m\^2, IVCI, days 3 \& 4~* Interferon (IFN) alpha: 5 MIU/m\^2, daily, SC (subcutaneously), days 1-5~* 5-day inpatient regimen, to be repeated every 21 days"
224224499|NCT00673361|DRUG|Low-dose Temozolomide plus Sorafenib|Temozolomide: 75mg/m\^2, PO, QD (quaque die), 6 weeks on/2 weeks off Sorafenib: 400mg, PO, BID, 8 weeks
224224500|NCT01464827|DRUG|ABT-450|ABT-450 tablets
224224501|NCT01464827|DRUG|ABT-333|ABT-333 tablets
224224502|NCT01464827|DRUG|ABT-267|ABT-267 tablets
224224503|NCT01464827|DRUG|Ribavirin|Ribavirin tablets administered at a weight-based dose, between 1,000 to 1,200 mg daily (divided).
224224504|NCT01464827|DRUG|Ritonavir|Ritonavir capsules
224224505|NCT05721144|DRUG|Nitric Oxide Gas|Inspired NO/N2 will be delivered at 80 parts per million (ppm) after anesthesia induction and intubation and lasted until the end of surgery and leave the operating room.
224224506|NCT03175237|OTHER|Mirror Therapy|
224224507|NCT00000275|DRUG|Flupenthixol|
224224508|NCT01945632|DEVICE|conventional gracey curettes|
224224509|NCT01945632|DEVICE|Vertically oscillating ultrasonic device|
224224510|NCT01945632|DEVICE|piezoelectric ultrasonic scraper|
224224511|NCT05487456|OTHER|P4M3 CA35|Ad libitum use of P4M3 with CA35 cartridges
224224512|NCT05487456|OTHER|P4M3 CM35|Ad libitum use of P4M3 with CM35 cartridges
224224513|NCT05487456|OTHER|CIG|Ad libitum use of subject's own preferred brand of cigarettes
224224514|NCT05487456|OTHER|Smoking Abstinence|Abstention from cigarette smoking
223635697|NCT01202097|DRUG|Salmeterol/Fluticasone|
223635698|NCT01202097|DRUG|Seretide|
223635699|NCT05670951|DRUG|ELGN-2112|Human insulin \[rDNA\]
223635700|NCT05670951|DRUG|Placebo|Placebo
223635701|NCT06238544|DRUG|HRS-5965 tablets|HRS-5965 tablets until the end of study treatment
223635702|NCT06238544|DRUG|HRS-5965 Capsules|HRS-5965 capsules.
224224515|NCT02780778|DRUG|Apatinib|Targeted therapy Apatinib：500 mg，po，qd
223635703|NCT03787511|OTHER|Cough assessment|Cough assessment with cough visual analog scale (VAS), and Leicester Cough Questionnaire (LCQ) for Diabetic patients with chronic cough and Diabetic patients without chronic cough
223635704|NCT03787511|OTHER|Neurological tests and cardiovascular tests|Neurological tests : electromyography, thermotest, QSAR + cardiovascular test for Diabetic patients with chronic cough and Diabetic patients without chronic cough
223635705|NCT03787511|OTHER|Skin biopsy|Skin biopsy to evaluate small fiber neuropathy for Diabetic patients with chronic cough and Diabetic patients without chronic cough
223635706|NCT04971499|DRUG|Dapansutrile|500 mg tablet
223635707|NCT04971499|DRUG|Pembrolizumab|Single-use vial containing 100 mg/4 mL of pembrolizumab
224224516|NCT02780778|DRUG|Docetaxel|chemotherapy Docetaxel：60mg/m²，vein input 1hour，every 3w
224224517|NCT00688285|OTHER|automated clinical alerts|automated clinical alerts in the electronic medical record
224224518|NCT00688285|OTHER|provider education|PCP education session on CKD
224224519|NCT04561128|DRUG|SHR-1819|SHR-1819 will be subcutaneously administered with different dose levels
224224520|NCT04561128|DRUG|Placebo|Placebo will be subcutaneously administered with different dose levels
224318687|NCT02996487|OTHER|Placebo|
224224521|NCT00981253|BEHAVIORAL|SMT-enhanced Cardiac Rehabilitation|Standard exercise-based cardiac rehabilitation, three times per week, enhanced with weekly stress management training for 12 weeks.
224224522|NCT00981253|BEHAVIORAL|Standard Cardiac Rehabilitation|Supervised exercise, three times per week, for 12 weeks.
224224523|NCT03706638|DIETARY_SUPPLEMENT|Ferrous Sulfate|Patients would be randomized to either taking ferrous sulfate daily or every other day (on non consecutive days).
224224524|NCT05072301|BEHAVIORAL|Contingency Management|The treatment group will receive a onetime offer of $80 (a reactive carrot) to forego all abstinence (contingency management) reward payments in the future.
224224525|NCT05072301|BEHAVIORAL|Control|The control group will receive contingency management payments and other monetary benefits for completing the trial.
224224526|NCT04689477|DEVICE|Vascular occlusion test|The ischemic challenge will consist in a standardized Vascular Occlusion Test (VOT), as previously described in the literature. Briefly, a blood pressure cuff will be placed proximal to the forearm, and rapidly inflated at 40 mmHg above systolic pressure, and kept inflated during three minutes. Then the cuff will be rapidly deflated. The resulting deoxygenation (DeO2) and reoxygenation (ReO2) slopes will be reported as change in O2 saturation over time.
224224527|NCT03882047|DRUG|Mometasone furoate|Mometasone furoate nasal spray, 200 mg once daily
224224528|NCT03882047|DRUG|Fluticasone propionate|Fluticasone propionate nasal spray, 200 mg once daily
224224529|NCT03882047|DRUG|Mometasone furoate placebo|Mometasone furoate placebo matching nasal spray, once daily
224224530|NCT03882047|DRUG|Fluticasone propionate placebo|Fluticasone propionate placebo matching nasal spray, once daily
224224531|NCT00218309|DRUG|Hydromorphone|
224224532|NCT03761433|DEVICE|SPI group|All patients applied surgical pleth index at the time of surgical incision, under End tidal Sevoflurane 3%
224224533|NCT04690777|PROCEDURE|Experimental: VESTIBULAR EXERCISE|OCULAR AND MOVEMENT EXERCISES
224224534|NCT04690777|PROCEDURE|MULTICOMPONENT EXERCISE|exercises includes strengthening, cardiovascular training, flexibility and balance
224224535|NCT04206852|PROCEDURE|Balloon pulmonary angioplasty|Balloon pulmonary angioplasty is an interventional technique where a balloon catheter is used to recanalize affected segments of pulmonary arteries identified during angiography.
224224536|NCT05113225|PROCEDURE|Micro-swim up technique|processing and selection of the sperm for ICSI in the same dish
224224537|NCT02152020|BEHAVIORAL|Survey|
224224538|NCT04109911|DIETARY_SUPPLEMENT|Fermented oyster extract|Fermented oyster extract 1,200 mg/day for 12 weeks
224224539|NCT04109911|DIETARY_SUPPLEMENT|Placebo|Placebo
223514565|NCT01725308|DRUG|Placebo|Taken by mouth (orally).
223514566|NCT06393985|DRUG|Decitabine, venetoclax and blinatumomab|"Cycle1 and cycle3： Decitabine monotherapy,20 mg/m2 qd, d1-5,intravenous infusion;~Cycle2 and cycle4:~Venetoclax 200mg qd, d1-14, orally; Blinatumomab d4-17(Weight ≥45 kg, 9ug d4-6, 28ug d7-17; Weight \<45 kg, 5ug/m2 d4-6, 15ug/m2 d7-17;continuous intravenous infusion)"
223514567|NCT05358639|DRUG|Olaparib tablet|Olaparib tablet will be administered alone for 14 days at a starting dose of 200 mg twice daily. Subsequently olaparib will be administered continuously over 28 days at a fixed dose and the dose of navitoclax will be escalated.
223514568|NCT05358639|DRUG|Navitoclax|For navitoclax, a lead-in of 7 days at 150 mg PO will be used prior to dose escalation. The DLT period for dose levels above DL 3 will include the 14-day olaparib alone lead-in, the 7 days combination with navitoclax at 150 mg and the first 28 day cycle of the combination of olaparib and navitoclax cycle at the full dose level dosing (49 days).
223514569|NCT05094102|DEVICE|OnLume Imaging System|for fluorescence-guided surgery with ICG dye
223514570|NCT05094102|DRUG|Indocyanine green|Indocyanine green is a cyanine dye used in medical diagnostics
223514571|NCT01340118|DRUG|Budesonide|once daily inhalation with 400 µg budesonide (dry powder)during 6 weeks
223514572|NCT05269940|DRUG|ZX-101A|oral dosing, once daily
223514573|NCT06015165|DRUG|Analgesia plan for Anes. Group|For Anes. Group, hydromorphone intravenous pump (PCIA) with 0.04mg/hr and 0.2mg/hr bolus controlled administration. Rescue opioids will be given as sufentanil 5μg/hr, depending on the time of the last intraoperative administration. NSAIDs such as flurbiprofen axetil or ibuprofen will be administered as a complementary treatment option.
223514574|NCT06015165|DRUG|Analgesia plan for Surg. Group|For Surg. Group, hydromorphone intravenous pump is set with the same analgesic formula as in Anes. Group. Routine prescriptions for rescue opioids (tramadol) and NSAIDs according to pain level recommended by the pharmacy department will be administered.
223514575|NCT06015165|PROCEDURE|Multi-modal analgesia during the surgery|Multi-modal analgesia, including intraoperative long-acting local anesthetics (ropivacaine and methylene blue), perioperative narcotic analgesics, and postoperative laxative and antibiotics. PCIA with the same analgesic formula will be applied in both groups.
223514576|NCT04870554|BEHAVIORAL|Enteric feeding|All subjects will be given nutrition enterally, corresponding to their calculated nutritional needs.
223514577|NCT05811637|OTHER|Pilates Exercise|The program will be applied with the Pilates exercises every week. All patients were evaluated before and after the treatment (6 weeks).
223514578|NCT05811637|OTHER|Supervised Rehabilitation|The program will be applied with the progression of the supervised rehabilitation in the 4th week
223514579|NCT02364271|OTHER|Thrombolysis in myocardial infarction score|An English- and Cantonese-speaking research nurse obtained the TIMI scores which consists of seven variables from each eligible patient.
223514580|NCT02364271|BIOLOGICAL|routine blood test for hs-cTnT|Patient had routine venipuncture blood taking for hs-cTnT measurement in the central laboratory of the hospital. Normal level of hs-cTnT is below 14ng/L.
223514581|NCT02364271|OTHER|HEART score|The modified HEART score of each patient was determined retrospectively by a research assistant.
223514582|NCT06483828|BEHAVIORAL|Dental Anxiety Coping Module|Dental tour where participants will be introduced to the dental clinic setting while Expressive Art Therapy, participants will engage with activity of making collage and finger painting.
223514583|NCT04584320|OTHER|Stool sample|Stools samples taken daily to test for present of Clostridium butyricum and Clostridium neonatale
223514584|NCT05950659|DEVICE|Orpyx Sensory Insole System|The Orpyx Sensory Insoles System uses Orpyx Sensory Technology: a powered limb overload warning technology intended for monitoring physiologic parameters, such as plantar pressure, temperature, motion, and adherence, and providing real-time cues for pressure offloading
223764788|NCT03413423|BEHAVIORAL|BAT-CS|All participants will receive one hour standard smoking cessation counseling during their hospitalization for an acute coronary syndrome. Participants will be randomized 1 week after discharge. Those assigned to BAT-CS condition will receive 5 more counseling sessions over the 12 weeks after discharge. The first will be up to one hour and will be conducted in person. The next 4 sessions will occur by phone and will take about 30 minutes. Post-discharge sessions will be focused on smoking cessation and mood management using behavioral activation techniques. Participants will be offered the nicotine patch if medically cleared.
224224540|NCT06484023|OTHER|Survey|quality of life questionnaire
224224541|NCT04931420|DRUG|Standard of Care Chemotherapy|"* If you have cancer of the stomach or food pipe (esophagus): the preferred chemotherapy regimen includes two or three medications. These drugs include Cisplatin or Oxaliplatin and 5-fluorouracil (5 FU) in combination with Docetaxel.~* If you have cancer of the pancreas or ampulla: the preferred chemotherapy medicines include Gemcitabine or a three-drug combination chemotherapy called FOLFIRINOX, which includes 5FU, Leucovorin, Irinotecan, and Oxaliplatin.~* If you have bile duct cancers: a combination of Gemcitabine, platinum agents, or fluoropyrimidine will be considered."
224224542|NCT04931420|PROCEDURE|Video-Assisted Thoracic Surgery (VATS)|If you have lung cancer, you may receive video-assisted thoracic surgery (VATS): a type of minimally invasive thoracic surgery of the chest, performed with a thoracoscope (small videoscope) using small incisions and special instruments to minimize trauma.
224318688|NCT04898530|OTHER|NO INTERVENTION|There is no intervention for this study.
224224543|NCT04931420|PROCEDURE|Lobectomy|"If you have lung cancer, you may receive a lobectomy:~A major/invasive surgical procedure where an entire lobe of your lung is removed."
224318689|NCT04492592|BEHAVIORAL|Workshop|Workshop
224318690|NCT04492592|BEHAVIORAL|SMS/Texting|SMS/Texting
224318691|NCT00812448|DIETARY_SUPPLEMENT|tea catechin extracts|catechins are composed of tea catechin extracts available in grren tea supplements
224318692|NCT02027428|DRUG|Abraxane (Induction)|100 mg/m2 IV infusion over 30 minutes on Days 1 and 8 and 15 of each 21-day cycle, administered as standard of care
224318693|NCT02027428|DRUG|Carboplatin (Induction)|6 mg/min/mL IV on Day 1 of each 21-day cycle after completion of nab-paclitaxel infusion
224318694|NCT02027428|DRUG|Abraxane (Maintenance)|100 mg/m2 IV infusion over 30 minutes on Days 1 and 8 of each 21-day cycle, administered as standard of care
223514585|NCT03959904|PROCEDURE|Small stitch|Wound closure will be using small stiches or larger spaced stitches
223514586|NCT03959904|OTHER|Blood sample|A blood sample to look for biological markers of Hernia formation will be taken
223514587|NCT03959904|OTHER|Tissue Sample|A tissue sample will be taken to measure markers of wound healing.
223514588|NCT03959904|OTHER|Pain Score|A pain score will be recorded following the surgical procedure.
223514589|NCT03959904|OTHER|Quality of Life Score|A Quality of Life Score will be recorded at 1 month 6 months and 12 months post surgery
223514590|NCT05867940|BEHAVIORAL|Physical activity on prescription|"Physical activity on prescription (PAP) is a well-established method to enhance physical activity in adults in primary care. The prescribed activity should lead to moderate increase of the pulse, such as walking, cycling, swimming, or gardening, and should be performed over a longer period of time in order to achieve a change towards a more active lifestyle. The activity may be prescribed by a physiotherapist, physician, nurse, or other health professional. PAP has shown to be feasible to increase participation in physical activity and to reduce sedentary behaviour in children with cerebral palsy.~Motivational interviewing is used for our PAP with participants with disabilities. During PAP-period, the participants are asked to fill in an activity logbook."
223514591|NCT00000738|DRUG|Nimodipine|
223514592|NCT00000738|DRUG|Zidovudine|
223514593|NCT05377671|DIAGNOSTIC_TEST|IRM multimodale a ultra-haute camp|The MRI includes, in addition to structural task sequences, diffusion imaging and resting state fMRI.
223514594|NCT01637571|DRUG|Dexilant|60mg of Dexilant QD for 12 weeks
223514595|NCT01637571|DRUG|Dexilant Placebo|60mg of Dexilant placebo QD for 12 weeks
223514596|NCT06393426|DRUG|Chinese Herb|Chinese herbal medicine
223514597|NCT01206270|DRUG|Testosterone undecanoate|Testosterone undecanoate 1000mg (in 4 ml of castor oil injections) at baseline (0-week), 6-week, 18-week, 30-week
223514598|NCT01206270|DRUG|Castor Oil|4 ml of Castor Oil injected at baseline (0-week), 6-week, 18-week, 30-week.
223514599|NCT02936271|OTHER|Vasculera|"Vasculera is a specially formulated prescription medical food product. This study compares Vasculera to placebo at reducing post procedural pain, bruising and edema for patients requiring an intervention for lower extremity venous disease.~Patient will be randomized to receive Active Vasculera or Vasculera Placebo. The study product will be taken for two weeks prior to the patient's planned procedure and continued for four weeks after their procedure. If multiple procedures are required the patient will be instructed to use the product throughout treatment."
223514600|NCT02936271|OTHER|Placebo|
223514601|NCT06466252|BEHAVIORAL|Psychometric Group|There are no interventions
223514602|NCT03511209|BEHAVIORAL|CBTI plus taper method A|This intervention includes CBTI plus the novel hypnotic tapering method.
223514603|NCT03511209|BEHAVIORAL|CBTI plus taper method B|This intervention includes CBTI plus the usual hypnotic tapering method used by the VA.
223514604|NCT06069271|OTHER|Kettlebell swing|The intervention group completed two-handed Russian KBSs using an interval training protocol outlined by Jay et al.10 involving 30 seconds of work followed by 30 seconds of rest for 10 total intervals. Prior to completing the intervention, participants completed a general warmup consisting of 10 non-weighted squats, 10 non-weighted dead-lifts, and 10 dowel rod shoulder flexion repetitions. Participants were instructed to perform all warm-up activities at an intensity of 70% of maximal effort using a Rate of Perceived Exertion scale(RPE).
223514605|NCT01743703|OTHER|diagnostic whole body MRI|diagnostic whole body MRI, both STIR and diffusion weighted
223514606|NCT05810311|DRUG|Roxadustat|"The group will receive Roxadustat (Evrenzo) three times weekly at an initial dose of 70mg (for body weight \<100.0 kg) or 100 mg (for body weight weight ≥100.0 kg). The dosage for both arms will be adjusted to keep Hb at the recommended levels between 11-12g/dl.~The aim is to investigate the effects of systemic administration of Evrenzo (Roxadustat \[RD\]) or Aranesp (darbepoetin alpha \[DA\]) on the levels of renal oxygenation in patients with diabetic nephropathy and associated anemia."
223635708|NCT03708614|OTHER|Controlled energy diet with elevated protein intake|Participants will be counseled to elevate protein and control energy intake for ten consecutive weeks. Protein intake will be increased in the range of 20-30% of total daily caloric intake. Each participant's diet will also be modified to implement controlled energy intake. Controlled energy intake will be defined as being isocaloric with the participant's current dietary intake.
223635709|NCT05101070|DRUG|S-531011|Administered by intravenous infusion
224224544|NCT04931420|RADIATION|Consolidative Radiation|A type of radiation treatment used to kill any cancer cells that may be left in the body. It may also include a stem cell transplant or treatment with drugs that kill cancer cells.
224224545|NCT04931420|RADIATION|Ablation Treatment|"Depending on the location of you cancer and the state of your cancer after chemotherapy, you may receive on the the following ablation treatments:~-Microwave or Radiofrequency Ablation: Radiofrequency ablation (RFA) and microwave ablation (MWA) are treatments that remove liver tumors by placing a needle through the skin into the tumor. In RFA, high-frequency electrical currents are passed through an electrode in the needle, creating a small region of heat. In MWA, microwaves are created from the needle to create a small region of heat. The heat destroys the liver cancer cells.~-General Tumor Ablation Treatment: a minimally invasive surgical method to treat solid cancers. Special probes are used to burn or freeze cancers without the usual surgery. Doctors use images of your tumor to guide where they place the needle. This requires only a tiny hole, usually less than 3 mm via which the probe is introduced."
224224546|NCT04931420|PROCEDURE|Resection or Excision|Depending on the type of GI cancer you have and the state of your cancer after chemotherapy, you may receive a resection or excision: a surgical procedure that focuses on removing all or part of a tumor/organ/body using a sharp knife (scalpel) or other cutting instrument.
224318695|NCT02027428|OTHER|Best Supportive Care (Maintenance)|The best palliative care per investigator (including but not limited to: antibiotics, analgesics, antiemetics, thoracentesis, pleurodesis, blood transfusions, nutritional support, and/or focal external-beam radiation for control of pain, cough, dyspnea, or hemoptysis), excluding antineoplastic agents
223635710|NCT05101070|DRUG|Pembrolizumab|Administered by intravenous infusion
223635711|NCT04882514|BIOLOGICAL|p*17-K4S2|Administer p\*17-K4S2 25 μg vaccine at 0, 3, and 6 weeks and evaluate the safety and antibody levels for a total of 6 months after the last injection. All vaccines will be administered intramuscularly
223635712|NCT04882514|BIOLOGICAL|J8-K4S2|Administer a vaccination schedule of J8-K4S2 50μg vaccine at 0, 3, and 6 weeks and evaluate the safety and antibody levels for a total of 6 months after the last injection. All vaccines will be administered intramuscularly
223635713|NCT04882514|BIOLOGICAL|Rabavert vaccine|Administer the standard Rabavert vaccine at 0, 3, and 6 weeks and evaluate the safety and antibody levels for a total of 6 months after the last injection. All vaccines will be administered intramuscularly. The Rabavert vaccine will be used as a control comparator as it has a similar approved dosing schedule to the investigational vaccines.
223635714|NCT02595125|DEVICE|IUD|copper IUD or levonogestrel IUD insert by the conventional technique or by direct technique
223635715|NCT00002022|DRUG|Epoetin alfa|
223635716|NCT03181022|BEHAVIORAL|Motivational Interviewing|HIV care providers will be asked to attend an MI training workshop lasting a total of 12 hours. The workshop will be conducted by members of the MI Network of Trainers. MI training relies on experiential activities and cooperative learning methods. After the training, study staff will monitor MI fidelity, or how providers are using the MI skills, using the MI Coach Rating Scale. This will occur 3 times prior to the training, 3 times during the practice period, and then quarterly. They will be asked to complete an audiotaped standardized patient interaction (approximately 30 minutes) with one of the study staff. These will be coded and providers will be informed of their competency level for all but the pre-training role plays. Coaching will be provided for all participants during the practice period. For the quarterly role plays, no coaching occurs unless their score indicates they need additional coaching (an additional 45 minute session with an MI trainer).
223635717|NCT04986072|DRUG|Sodium Nitroprusside|Half of participants will receive Intravenous Sodium Nitroprusside (0.5 μg/kg/min) for 4 hours.
223635718|NCT04986072|DRUG|5% Dextrose solution|Half of participants will receive intravenous 5% Dextrose solution for 4 hours.
223635719|NCT02584686|DRUG|Botulinum Toxin Type A|The treatment group will be injected intracavernously with a trimix solution (20 ug alprostadil + 1 mg phentolamine + 30 mg papaverine) for colour Doppler assessment, followed next day by 50 units of BTX-A.
223635720|NCT02584686|DRUG|Normal Saline|The control group, 12 patients, will be injected with a trimix solution during penile colour Doppler assessment followed next day with a normal saline injection.
224224547|NCT04931420|PROCEDURE|Peritonectomy|Peritonectomy is a surgery used to remove peritoneal tumors (tumors in the lining of the abdomen/stomach) from a patient. Following surgery, a heated chemotherapy bath (HIPEC) is commonly administered.
224318696|NCT02027428|DRUG|Abraxane (Induction)|100 mg/m2 IV infusion over 30 minutes on Days 1 and 8 and 15 of each 21-day cycle, administered as standard of care
223635721|NCT03891134|DIETARY_SUPPLEMENT|Branched Chain Amino Acid|Participants were purposively sampled to receive one sachet enriched BCAA twice a day(7.2g) for 5 weeks.
223635722|NCT00620451|DRUG|larazotide acetate|gelatin capsule
223635723|NCT00620451|DRUG|placebo|gelatin capsule
223635724|NCT04119115|DEVICE|CT-V|CT-V is a newer computed tomography scan which is more comprehensive and tracks movement of the lungs.
223635725|NCT04119115|OTHER|Metabolites|Metabolites are compounds which can be measured in biospecimens and may indicate a disease or biological process.
223635726|NCT04897997|PROCEDURE|coronarography and angioplasty|selective angiography of the coronaries and angioplasty of significant culprit lesion(s)
223635727|NCT01781936|DRUG|Fluocinolone Acetonide|
224318697|NCT02027428|DRUG|Carboplatin (Induction)|6 mg/min/mL IV on Day 1 of each 21-day cycle after completion of nab-paclitaxel infusion, administered as standard of care
224318698|NCT02027428|OTHER|Best Supportive Care (Maintenance)|The best palliative care per investigator (including but not limited to: antibiotics, analgesics, antiemetics, thoracentesis, pleurodesis, blood transfusions, nutritional support, and/or focal external-beam radiation for control of pain, cough, dyspnea, or hemoptysis), excluding antineoplastic agents
224318699|NCT05937737|BEHAVIORAL|Type 2 Diabetes Diet Modification|A 12-week dietary intervention model was prescribed to the patients in accordance with their needs.
224318700|NCT04082156|DEVICE|electrical stimulation|electrical stimulation
223764789|NCT03413423|BEHAVIORAL|Smoking Cessation and Health & Wellness|All participants will receive one hour of standard smoking cessation counseling during their hospitalization for an acute coronary syndrome. Participants will be randomized 1 week after discharge. Those assigned to the Smoking Cessation plus Health and Wellness condition will receive 5 more counseling sessions over the 12 weeks after hospital discharge. The first will be up to one hour and will be conducted in person. The next 4 sessions will occur over the phone and will take about 30 minutes. Post-discharge sessions will be focused on smoking cessation and didactic health and wellness education. Participants will be offered the nicotine patch if medically cleared.
223635728|NCT03817359|COMBINATION_PRODUCT|Remifentanil-propofol mixture|Participants receive total intravenous anesthesia with remifentanil-propofol mixture by single TCI pump in intervention group. All TCI target concentration adjustments or extra bolus of propofol or remifentanil during operation were based on BIS and ANI monitor.
223764790|NCT05552716|OTHER|School safety tactics and policies|A list of school safety tactics and policies (such as metal detectors, armed security guards, active shooter drills) that were in place at the school at the time of shooting.
223764791|NCT04771208|BEHAVIORAL|"I kua na'u Let Me Carry Out Your Last Wishes"|A combination of Native Hawaiian advance care planning video decision support tool and personalized video declarations shared with providers and family members.
223764792|NCT03456336|OTHER|Active Treatment|Infants assigned to the active treatment group will receive indomethacin or ibuprofen per their local site usual care dosing and schedule if the infant has a sPDA. The choice of indomethacin or ibuprofen will be left to the center, however, infants may only receive one or the other. If the infant receives both, it will be considered a protocol violation.
224224548|NCT04931420|OTHER|Transarterial Radioembolization|"If you have cancer in your biliary tract (gallbladder, pancreas or liver), you may receive transarterial radioembolization known as TARE.~TARE allows doctors to deliver radiation treatment directly to the liver using a minimally invasive technique that is designed to cause few side effects. TARE allows doctors to thread a catheter through a small incision in the participant's upper thigh through the artery that goes directly to the liver."
224224549|NCT01522352|PROCEDURE|Aortic valve replacement by bioprosthesis|Comparison of short and mid-term hemodynamic performance between three types of stented pericardial aortic valves: Trifecta aortic valve (St. Jude Medical), Mitroflow aortic valve (Sorin Group), Magna Ease (Edwards Lifesciences)
224224550|NCT01743365|DRUG|Cisplatin-5FU-Afatinib|
224224551|NCT04480203|OTHER|Stressproffen cognitive based stress management|The participants will download an app (Stressproffen 2A) with cognitive based stress management.
224224552|NCT04480203|OTHER|Stressproffen mindfulness based intervention|The participants will download an app (Stressproffen 2B) with mindfulness based intervention.
223514607|NCT05810311|DRUG|Darbepoietin Alfa|"The control group will receive darbepoietin alpha (Aranesp) s.c. 0.45mg/kg once a week. The dosage for both arms will be adjusted to keep Hb at the recommended levels between 11-12g/dl.~The aim is to investigate the effects of systemic administration of Evrenzo (Roxadustat \[RD\]) or Aranesp (darbepoetin alpha \[DA\]) on the levels of renal oxygenation in patients with diabetic nephropathy and associated anemia."
223514608|NCT00829478|BEHAVIORAL|Decision Aid for Atrial Fibrillation|Single contact educational session
223635729|NCT02675465|DRUG|ATB200|
223635730|NCT02675465|DRUG|AT2221|
223635731|NCT02587676|OTHER|Evatouch Super|The deterioration of RDLs may differ between in vitro conditions and the conditions encountered in denture wearers. We conducted an in vivo study to investigate how resilient denture liners (RDLs) changed in hardness when embedded in complete maxillary dentures worn by patients for one month in a clinical setting. We hypothesized that the hardness one month after application of the RDLs would be affected by the age, the condition of the saliva, the occlusal force, type of denture used, the patients habits related to smoking, drinking, wearing dentures while sleeping, and using a denture cleanser.
223635732|NCT04627402|DRUG|Conbercept and TA|Intravitreous injection of Conbercept and TA
223635733|NCT04627402|DRUG|Conbercept|Intravitreous injection of Conbercept
223635734|NCT03576586|BEHAVIORAL|Brief computerized intervention|"Brief computerized intervention (computer game Tetris) plus usual care in the maternity department"
224224553|NCT04480203|OTHER|Control|The participants will receive no app. (They will be able to download it after the end of the 3 year study).
224224554|NCT00881270|DRUG|LACTIC ACID(ND)|Dermacyd Infantile (LACTIC ACID)
224224555|NCT00441584|BIOLOGICAL|PegIntron (peginterferon alfa-2b)|Powder for injection in vial or Redipen (50, 80, 100, 120, and 150 microgram strengths), subcutaneous, dose of 1.5 micrograms/kg, weekly for up to 48 weeks
223514609|NCT00829478|OTHER|Usual Care|Usual Care
223514610|NCT01505426|DRUG|ASP1941|oral
223635735|NCT03576586|BEHAVIORAL|Attention placebo control|Brief cognitive task plus usual care in the maternity department
223635736|NCT00886379|DIETARY_SUPPLEMENT|Mongolian milk without vitamin D|710ml per day for 49 days
223635737|NCT00886379|DIETARY_SUPPLEMENT|Mongolian milk with vitamin D|710ml per day for 49 days. A total of 13,700 IU of vitamin D over the intervention period.
223635738|NCT00886379|DIETARY_SUPPLEMENT|UHT milk|710ml per day for 49 days. A total of 13,700 IU of vitamin D over the intervention period.
223635739|NCT00886379|DIETARY_SUPPLEMENT|Milk Substitute|710ml per day for 49 days. A total of 13,700 IU of vitamin D over the intervention period.
223635740|NCT00886379|DIETARY_SUPPLEMENT|Seasonal D supplement|Deliver dosage of 13,700 IU vitamin D over 7 days
223635741|NCT00886379|DIETARY_SUPPLEMENT|Daily D supplement|Deliver dosage of 13,700 IU vitamin D in vitamin capsules over 49 days.
224224556|NCT00441584|DRUG|Rebetol (ribavirin)|200 mg capsules, oral, weight based dose of 800-1400 mg, daily for up to 48 weeks
224224557|NCT00678067|DIETARY_SUPPLEMENT|Docosahexaenoic acid|Soft capsules 500 mg/each; 1 capsule/day for 4 months
224224558|NCT00678067|DIETARY_SUPPLEMENT|Docosahexaenoic acid (DHA)+ Eicosapentaenoic acid (EPA)|Soft capsules, 228 mg DHA + 208 mg EPA /each; 1 capsule/day for 4 months
224224559|NCT00678067|DIETARY_SUPPLEMENT|Germ oil|Soft capsules, 275 mg linoleic acid + 35 mg linolenic acid + 65 mg oleic acid /each; 1 capsule/day for 4 months
224224560|NCT00678067|OTHER|National Cholesterol Education Program (NCEP) Step I Diet|Dietary counselling aimed at achieving NCEP Dietary Guidelines: Total fat intake \<30% of total calories, Saturated fat intake \<10% of total calories, Polyunsaturated fat intake up to 10% of total calories, monounsaturated fat intake 10-15% of total calories
224224561|NCT04296864|DRUG|Dupilumab|monoclonal antibody
224224562|NCT04560764|DEVICE|Virtual Reality|"Participants in both groups will attend 10 sessions of approximately 30 minutes each three times a week. Each session contemplates the execution of a single repetition of two minutes of each of the four exercises.~There are four exercises:~1. Reaching: the participant is requested to reach a target in front of him with the paretic hand; the target will appear in a different place every time;~2. Reaching and grasping: the participant is requested to grab a wooden cube with the paretic hand and place it into a bowl positioned in front of him; the cube will appear in a different place every time;~3. Goalkeeper: the participant is requested to block a ball coming towards him with the paretic hand; the ball will appear in a different place every time;~4. Occupational task: the participant is requested to grab four cans, one at time, with the paretic hand and place them on four targets placed on a hemispherical arch.~Each exercise provides six levels of increasing difficulty."
224224563|NCT04560764|DEVICE|Action Observation Therapy|"Before the execution of the exercises described in the intervention Virtual Reality, the participants in the experimental group will see a video demonstrating the same exercise (according to the level of difficulty selected) he will be later asked to perform for two minutes."
224224564|NCT04560764|DEVICE|Landscape video|"Before the execution of the exercises described in the intervention Virtual Reality, the participants in the sham comparator group will see a video of a natural landscape for two minutes."
224224565|NCT04560764|OTHER|Standard treatment|Participants in both groups will receive the standard treatment, one hour a day for three days a week.
224224566|NCT01584609|DEVICE|Penumbra System with Separator 3D|The Separator 3D is an additional Separator with a new tip configuration for the Penumbra System.
224224567|NCT01584609|DEVICE|Penumbra System alone|The Penumbra System® is a new generation of neuro-embolectomy devices specifically designed to remove thrombus through aspiration.The treatment paradigm of this System involves the introduction of the Reperfusion Catheter through a guide catheter into the intracranial vasculature, and guided over an appropriate guidewire to the site of primary occlusion. The Reperfusion Catheter is used in parallel with the Separator and an aspiration source (Aspiration Pump) to separate the thrombus and aspirate it from the occluded vessel.
224224568|NCT05698381|DIETARY_SUPPLEMENT|Liquid vinegar|2 tablespoons consumed twice daily with meals
224224569|NCT05698381|DIETARY_SUPPLEMENT|Vinegar pill|2 pills consumed upon waking
224224570|NCT04615676|OTHER|Follow-up phone call|Follow-up phone call after month to detect which patient have been hospitalized
224224571|NCT02307474|RADIATION|Stereotactic Radiosurgery|3 fractions of 16 Gy per fraction to a total dose of 48 Gy on non-consecutive day within a 10 day time span
224224572|NCT02307474|DRUG|Pazopanib Hydrochloride|Given PO starting at 800mg to be systematically altered following drug related toxicities.
224224573|NCT05394558|DRUG|AsiDNA|Administration of AsiDNA followed by radiotherapy
224224574|NCT04050800|DRUG|Carbon 11 Butanol|Two sequential administrations of a PET tracer
224224575|NCT00002119|DRUG|WF10|
224224576|NCT03670979|PROCEDURE|bone swaging|osseous wall pedicle was placed to treat the infrabony defect by autogrnous bone
224224577|NCT00147264|DRUG|Telmisartan (Micardis®) vs. Placebo|
224224578|NCT00147264|BEHAVIORAL|Low-Glycemic Index Diet vs. Control Diet|
224224579|NCT06253468|OTHER|tested product|application twice a day of the tested product (in the morning and evening) and a sunscreen (in the morning and at midday) to the face for 3 months
224318701|NCT04082156|DEVICE|Sham|no stimulation
223514611|NCT01505426|DRUG|metformin|oral, concomitant use
224224580|NCT00945425|DRUG|AZD7325|oral capsule, once or twice daily, 7 days
224224581|NCT00945425|DRUG|Placebo|oral capsule, once or twice daily, 7 days
224224582|NCT03294161|DRUG|Immucillin DI4G|Immucillin DI4G was administered by topical use at 2% concentration once a day for 20 days associated with Meglumine antimoniate administered by intravenous route at a dosage of 20mg/kg/day, during 20 days.
224224583|NCT03294161|DRUG|Meglumine antimoniate|Placebo for topical use once a day at the ulcer for 20 days associated with Meglumine antimoniate administered as the standard treatment for cutaneous leishmaniasis by intravenous route at a dosage of 20mg/kg/day, during 20 days.
224224584|NCT01767441|PROCEDURE|Roux-en-Y-gastric bypass|Gastric bypass consisted of creation of a 15-20 ml gastric pouch, a 150 cm Roux limb, and a 50 cm biliopancreatic limb
224224585|NCT01767441|PROCEDURE|laparoscopic adjustable gastric banding|Gastric banding functions by limiting food intake after the placement of an inflatable tube around the stomach just below the gastroesophageal junction, which allows for adjustment of the size of the outlet via the addition or removal of saline through a subcutaneous port.
224224586|NCT01767441|PROCEDURE|laparoscopic sleeve gastrectomy|Sleeve gastrectomy involved a gastric reduction of 75 to 80% by resecting the stomach alongside a 30-French endoscope beginning 3 cm from pylorus and ending at the angle of His
224318702|NCT00613652|DRUG|AZD4877|10 mg IV (3 weeks treatment 1 week rest)
223514612|NCT01505426|DRUG|Placebo|oral
223514613|NCT06565936|RADIATION|PET scan with tracer injection [18F] DPA-714 or [18F]F-FDG|Brain PET/MRI imaging will be conducted following the administration of \[18F\] DPA-714 or \[18F\]F-FDG. The radiopharmaceuticals are given intravenously in doses that are safe for the human body, with minimal quantities to reduce potential effects. Additionally, the irradiation levels are kept low, ensuring the procedure is safe and reliable for patients.
223514614|NCT04947865|OTHER|Peripheral nerve stimulation|Electrical stimulation of peripheral nerves to measure resulting gait kinematics and surface muscle activity
223514615|NCT04947865|DEVICE|Commercial knee brace|Knee brace used to limit knee mobility in healthy individuals to imitate stroke survivors and measure resulting gait kinematics and surface muscle activity.
223514616|NCT00447369|DRUG|Pregabalin|
223514617|NCT00447369|DRUG|sodium valproate|
223514618|NCT06323473|DIETARY_SUPPLEMENT|Black Maitake Prothera|Mushroom extract; liquid
224318703|NCT04220970|OTHER|BIA-ALCL|Observational : no intervention
224318704|NCT03212248|DIAGNOSTIC_TEST|Thoracic Ultrasound (TUS)|
224318705|NCT01403857|OTHER|Whole grain foods|Eight commonly consumed whole grain products that meet the consumers Dietary Guidelines recommendations for a period of six weeks.
224318706|NCT01403857|OTHER|Refined grains|Eight commonly consumed refined grain products given in amounts that fulfill the consumer's Dietary Guidelines for Americans recommendation over the course of six weeks.
223764793|NCT03456336|OTHER|Expectant Management|Infants assigned to the expectant management group will receive indomethacin or ibuprofen if cardiopulmonary compromise occurs.
224224587|NCT01767441|OTHER|diet treatment|Hypocaloric diet providing a 1000 Kcal/d deficit from total energy expenditure assessed by indirect calorimetry and physical activity determination
224224588|NCT01638936|DRUG|BT062 , intravenous administration|Dose escalation to determine dose limiting toxicities (DLTs) and/or the maximum tolerated dose (MTD)/recommended Phase II dose (RPTD) of BT062 in combination with lenalidomide/dexamethasone
224224589|NCT01333033|DRUG|Oxaliplatin|Given IV
224224590|NCT01333033|DRUG|Leucovorin Calcium|Given IV
224224591|NCT01333033|DRUG|Fluorouracil|Given IV
224224592|NCT01333033|DRUG|Carboplatin|Given IV
224224593|NCT01333033|DRUG|Paclitaxel|Given IV
224224594|NCT01333033|PROCEDURE|Positron Emission Tomography|Undergo PET/CT scan
224224595|NCT01333033|PROCEDURE|Computed Tomography|Undergo PET/CT scan
224224596|NCT01333033|RADIATION|Radiation Therapy|Undergo RT
224224597|NCT03693690|PROCEDURE|Vaginal laser thermotherapy|Laser thermotherapy can increase the stiffness of vaginal wall. It has been reported that vaginal laser therapy can be used to treat stress urinary incontinence.
224224598|NCT02323906|DRUG|CC-122|Investigational new drug
224224599|NCT02323906|DRUG|Sorafenib|Kinase inhibitor
223514619|NCT04257513|DIAGNOSTIC_TEST|Brain MRI|Neurological and Cognitive evaluation; Brain MRI
223514620|NCT06063031|DIETARY_SUPPLEMENT|Active|Active nutritional supplement plus telerehabilitation
223514621|NCT06063031|OTHER|Placebo|Placebo nutritional supplement plus telerehabilitation
223514622|NCT06106984|DEVICE|Graded motor imagery mobile app|The Graded Motor Imagery mobile app is a mobile app designed for intervention in phantom limb pain.
223514623|NCT05532657|OTHER|Hearing intervention|The hearing intervention is best practices hearing rehabilitation treatment program, consisting of fitting with hearing aids and other hearing assistive technologies along with comprehensive, individualized hearing rehabilitation sessions with a study audiologist spaced over the 2-3 months post-fitting designed to provide all the active components of the intervention. Participants also received semi-annual booster sessions with the study audiologist for 3 years and will continue to receive hearing healthcare from the study audiologist and complete semi-annual sessions for 3 additional years.
223514624|NCT05532657|OTHER|Successful aging/delayed hearing intervention|The successful aging health education program follows the protocol and materials developed for the 10 Keys to Healthy Aging program. The program involved individualized sessions with a study health educator, with initial sessions spaced over the 2-3 months post-randomization and semi-annual sessions for 3 years. Upon completion of the ACHIEVE trial, these participants are offered the best practices hearing rehabilitative treatment program with comprehensive, individualized sessions post-fitting and will receive semi-annual booster sessions with the study audiologist for 3 years.
223514625|NCT05445323|GENETIC|Low dose LX2006|Adeno-associated viral vector encoding the FXN gene (AAVrh.10hFXN)
223514626|NCT05445323|GENETIC|Mid Dose LX2006|Adeno-associated viral vector encoding the FXN gene (AAVrh.10hFXN)
223514627|NCT05445323|GENETIC|High Dose LX2006|Adeno-associated viral vector encoding the FXN gene (AAVrh.10hFXN)
223514628|NCT06013800|OTHER|Measurement of sodium levels|Patients will get measurements of sodium levels daily in the first 48 hours, then daily or every other day until normal sodium levels (\>135mEq/L).
223514629|NCT01137760|DIETARY_SUPPLEMENT|Sucrose|5 g of sucrose daily for 8 weeks
223514630|NCT01137760|DIETARY_SUPPLEMENT|Galactooligosaccharide|2.5 g galactooligosaccharide plus 2.5 g sucrose daily for 8 weeks
223764794|NCT05379166|DRUG|Azacitidine|Given IV
223764795|NCT05379166|OTHER|Quality-of-Life Assessment|Ancillary studies
223764796|NCT05379166|OTHER|Questionnaire Administration|Ancillary studies
223764797|NCT05379166|DRUG|Venetoclax|Given PO
223764798|NCT01351896|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223764799|NCT01351896|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
223764800|NCT01351896|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
223764801|NCT01351896|PROCEDURE|Computed Tomography|Undergo CT
224224600|NCT03483285|DEVICE|airtraq|airtraq videolaryngoscope
224224601|NCT03483285|DEVICE|storz|storz videolaryngoscope
224224602|NCT00500409|DRUG|Osteoform|Administer Osteoform 20 µg daily subcutaneously and 1000 mg calcium and 500 IU vitamin D orally for 180 days
224224603|NCT00500409|DRUG|SHELCAL|Administer calcium and vitamin D (1000 mg calcium and 500 IU vitamin D) orally for 180 days
224224604|NCT01280370|PROCEDURE|Abdominal surgery|intraoperative mesh implantation
224224605|NCT01891591|PROCEDURE|Roux-en-Y gastric bypass (RYGP)|
224224606|NCT03687125|DRUG|Tinostamustine|Participants received tinostamustine IV injection.
224224607|NCT03687125|PROCEDURE|Autologous Stem Cell Transplant (ASCT)|Undergo autologous stem cell transplant
224224608|NCT03216330|OTHER|No Intervention|There is no treatment intervention. We are assigning measurement tools such as the Electronic Thimble Algometer for QST and questionnaires to both groups.
224224609|NCT02648373|BEHAVIORAL|Patient Education|An educational video was watched based on Consumer Reports Choosing Wisely patient education supporting the recommendation that imaging is not helpful early for low back pain and the best strategy is to remain as active as possible. Key themes were discussed with a physical therapist and the patient's questions were answered.
224224610|NCT02648373|OTHER|Control|Patients receive no additional intervention. They will begin physical therapy and receive care at the therapist's discretion.
224224611|NCT04037566|GENETIC|XYF19 CAR-T cell|Autologous T cells engineered to specify CD19 transduced with a lentiviral vector and electroporated with CRISPR guide RNA to disrupt expression of endogenous HPK1 administered by IV injection.
224224612|NCT04037566|DRUG|Cyclophosphamide|A cytotoxic chemotherapy agent used for lymphodepletion prior to XYF19 CAR-T cells.
224224613|NCT04037566|DRUG|Fludarabine|A chemotherapy agent used for lymphodepletion prior to XYF19 CAR-T cells.
224224614|NCT01992107|BIOLOGICAL|QIVc|Novartis Investigational Quadrivalent Vaccine
224224615|NCT01992107|BIOLOGICAL|TIV1c|Licensed Influenza Vaccine
224224616|NCT01992107|BIOLOGICAL|TIV2c|Novartis Investigational Vaccine
224224617|NCT00804609|DRUG|DepoDur following epidural lidocaine|"All participant underwent cesarean delivery. An epidural top-up anesthetic consisting of 2% lidocaine with epinephrine 1:200,000 and sodium bicarbonate (1 meq per 10 mL lidocaine) was given. The lidocaine solution was administered in 5 mL increments every 2.5 minutes until a T6 sensory level to touch was attained. Patients also received a 100 mcg dose of fentanyl epidurally after the lidocaine solution had been administered.~Provided delivery had occurred at least 60 minutes after the initial lidocaine administration, patients received EREM 8 mg (DepoDur™) administered through the epidural catheter. A 2 mL epidural saline flush was administered before and after drug administration."
223514631|NCT01137760|DIETARY_SUPPLEMENT|Galactooligosaccharide|5.0 g galactooligosaccharide daily for 8 weeks
223514632|NCT02058277|DRUG|bosutinib or bosutinib + aprepitant|Single dose of bosutinib (500 mg) or single dose of bosutinib (500 mg) and aprepitant (125 mg)
223514633|NCT04006756|BEHAVIORAL|Online cognitive training 1|Eight-week online cognitive training program, three times a week for 45 minutes. The training contains several games that are designed to train cognitive functions.
223514634|NCT04006756|BEHAVIORAL|Online cognitive training 2|Eight-week online active comparator program, three times a week for 45 minutes. The training contains several games.
223514635|NCT02167360|DRUG|CTL019|A dose of CTL019 transduced cells will consist of a single infusion of 2 to 10 x 108 CTL019 transduced cells.
223514636|NCT03406975|DEVICE|Overstitch Endoscopic Suture System|Endoscopic Sleeve Gastroplasty (ESG), an endoscopic minimally-invasive weight loss procedure, utilizing a suturing device to reduce the stomach volume by 80% through the creation of sleeve. This is accomplished by a series of endoscopically placed stitches through the stomach wall.
223514637|NCT03406975|BEHAVIORAL|Lifestyle Intervention|Standard low-calorie diet plan and moderate intensity life-style intervention of 150 minutes of aerobic exercise per week for 12 months.
223514638|NCT04877639|DRUG|Esmketamine,Dexmedetomidine|Two different drugs were given to observe which of the two drugs was more suitable for DISE detection
223514639|NCT03709095|OTHER|Sprint interval training|Participants utilized the arm ergometer for improving aerobic exercise capacity
223514640|NCT03709095|OTHER|moderate intensity continuous training|Participants utilized the arm ergometer for improving aerobic exercise capacity
223514641|NCT03056430|BEHAVIORAL|Training|
223514642|NCT00220714|DRUG|atypical antipsychotics:oral vs. long-acting route|
223514643|NCT00220714|BEHAVIORAL|Family Psychoeducation|
223514644|NCT00401830|DRUG|Lacosamide|Tablet 400mg daily (200mg twice daily) during 8-week maintenance phase following 4-week titration phase starting at 100mg/day and increasing to 400mg/day at weekly intervals of 100mg
223514645|NCT00401830|OTHER|Placebo|Matching placebo tablet administered twice daily
223514646|NCT02425488|BEHAVIORAL|Nursing therapeutics education|"Educational intervention will focus on~1. Appropriate lifestyles~2. Early recognition of signs/prodromal symptoms of HF~3. Early recognition of signs of inflammation of the ICD-pocket~4. Good management of the device~1\) Therapy, body weight, diet, smoking, alcohol, rest, exercise, job and sex 2) Dyspnea, edema and fovea, rapid weight gain, loss of appetite, fatigue, asthenia, insomnia, mental confusion 3) Signs and symptoms of inflammation: hyperpyrexia, rubor, dolor, calor and tumor 4) Identification tag, vibration, metal detectors, air travel, use of electronic devices, diagnostic PET and MRI"
223514647|NCT01837095|DRUG|POL6326|POL6326 will be given by i.v. infusion over 2 hours. Treatment will occur on days prior to, on the day of and on days after treatment with eribulin
223514648|NCT03120923|DRUG|Lidocaine 3 cc|
223514649|NCT03120923|DRUG|Lidocaine 9 cc|9mL of 1% lidocaine plus 1mL of 40mg triamcinolone acetonide
223514650|NCT03120923|DRUG|Triamcinolone Acetonide|
223514651|NCT02623439|DRUG|Cyclophosphamide 50 mg/kg IV Days 3 and 4 post transplant|Cyclophosphamide 50 mg/kg IV Days 3 and 4 post transplant
223514652|NCT04679818|DRUG|Routine opioid management|Clinical judgement will be according to their standard practice and may include interpretation of blood pressure, heart rate, diaphoresis, tearing, and pupil size. Boluses of fentanyl 1 µg/kg actual body weight (ABW), up to a maximum dose of 100 µg per bolus, can be given per clinical judgement.
223514653|NCT04679818|DEVICE|PMD-200 Nol-guided opioid administration|PMD-200 Nociception level (NOL) values exceeding 25 for more than 30 seconds will typically be treated with boluses of fentanyl 1µg/kg ABW, up to a maximum of 100 µg per boluses, 5-minute intervals. Towards the end of the surgery (approximately 30-45 minutes before end of surgery, based on clinical judgment), the boluses of fentanyl will be reduced to 0.5 µg/kg ABW, up to a maximum of 50 µg per boluses, 5 minutes intervals. The target of a PMD-200 NOL score below 25 will be maintained until surgery ends
223514654|NCT00971503|PROCEDURE|autologous bone marrow implantation|Filgrastim treatment before bone marrow aspiration that will then be implanted via pancreatic artery
223514655|NCT00971503|OTHER|Saline injection|Injection of saline solution for 5 days
223514656|NCT02655809|RADIATION|Fluoroscopic examination|
223514657|NCT05156814|DRUG|Femoston® 1, Femoston® 2|Femoston® 1 (1 mg estradiol / 10 mg dydrogesterone), Femoston® 2 (2 mg estradiol / 10 mg dydrogesterone)
223514658|NCT05156814|DRUG|Duphaston|Duphaston®, 10 mg
223514659|NCT05156814|DRUG|Klimadynon|Cimicifuga racemosa rhizomatum extract
223514660|NCT05156814|DRUG|Divigel|Divigel, 0.1%
223514661|NCT03802357|PROCEDURE|Exercise training|Patients perform an exercise Training program of 3 weeks Duration including endurance Training, resistance Training and squat Training. This program is part of an inpatient pulmonary Rehabilitation.
223514662|NCT03024632|PROCEDURE|Trial of labor|trial of labor after 3 or more previous cesarean deliveries
223514663|NCT02480361|DEVICE|acupuncture|Acupuncture treatment after gastric cancer surgery during 5 postoperative days
223514664|NCT03378635|DRUG|Dasiglucagon|Glucagon analog
223514665|NCT03378635|DRUG|GlucaGen|Native glucagon
223514666|NCT03378635|DRUG|Placebo|Placebo for dasiglucagon
223514667|NCT05752331|BEHAVIORAL|Physical activity behavioural modification|8-week intervention consisting motivational interview, individualised action plan and weekly consultations regarding activities of daily living and symptom management.
223635742|NCT03515486|OTHER|Post stroke mood disorders evaluation|Each patient will be assessed by a clinical evaluation, will have a standardized psychological evaluation, will perform a brain MRI and will be given a smartphone and an actimeter for a one-week period for the purpose of ecological evaluations
223764802|NCT01351896|DRUG|Lenalidomide|Given PO
224224618|NCT00804609|DRUG|DepoDur following spinal anesthetic|"Participants underwent an elective cesarean delivery with a combined spinal/epidural. All patients received 12 mg hyperbaric bupivacaine with 20 mcg fentanyl administered intrathecally. No local anesthetic was administered through the catheter. The combined spinal-epidural was performed at the L2/L3 or L3/L4 interspace and the intrathecal dose was injected over 5-10 s. A multiple orifice epidural catheter was threaded 5 cm into the epidural space.~Provided delivery had occurred 60 minutes after the intrathecal dose patients received EREM 8 mg (DepoDur™) through the epidural catheter. A 2 mL epidural saline flush was administered before and after drug."
224224619|NCT01723956|PROCEDURE|Cryotherapy|This is involves freezing the lesions with a cryo gun using Nitrous Oxide for 3 minutes-- wait 5 minutes and then refreezing for 3 more minutes. This procedure uses the Wallach cryogun
224224620|NCT01723956|PROCEDURE|LEEP|The cervix is anaesthetized with lidocaine and then a electric loop is applied to the cervical lesion which is cut with one pass. The LEEP machine used is the automatic Finesse Machine.
224224621|NCT02022007|DRUG|Metformin XR|"Start 2 pills (2 pills of 500 mg =1000mg XR) for 3 weeks~Increase to 4 pills as tolerated (4 pills of 500 mg XR =2000 mg XR) for remainder of study"
224224622|NCT02022007|DRUG|Saxagliptin|"Start 1 pill (5 mg)) for 3 weeks~Remain at 1 pill (5mg dose) for remainder of study"
223514668|NCT00689286|DEVICE|BION|"They will be divided into three groups. Two groups of experimental subjects will receive stimulation using BIONs. The first group will have a stimulation paradigm like that used in a previous feasibility study that preceded the proposed trial, using low-frequency (1-5 PPS) twitch stimulation. The second group will have a stimulation paradigm in which tetanic-frequency stimulation (25-50 PPS) is used to produce fused muscle contractions. A third group of experimental subjects will have a standardized program of voluntary exercise.~In Groups 1 and 2, the femoral nerve will be stimulated electrically according to the assigned protocol during the 12 week experimental period after implantation of the devices. Individuals assigned to Group 3, receiving conventional exercise therapy for 12 weeks, will be allowed to receive BIONs at the end of the trial, providing they request BION therapy and they have been at least minimally compliant with the exercises."
223514669|NCT03688113|BEHAVIORAL|Tinnitus application|Use of tinnitus application
223514670|NCT05389800|OTHER|Upper Extremity Aerobic Exercise|Using a cycle-ergometer (Monark 881E)
223514671|NCT01496703|OTHER|no intervention, this is an observational retrospective trial|no intervention, this is an observational retrospective trial
223514672|NCT02297035|BEHAVIORAL|Behavioural testing|
223514673|NCT02297035|OTHER|Brain imaging|MRI, PET
223514674|NCT02297035|GENETIC|Genetic screening|APOE, Progranulin
223514675|NCT01098578|DRUG|Floseal|Received 1 syringe of Floseal as treatment for posterior epistaxis.
223514676|NCT02403778|DRUG|VESANOID|All-trans retinoic acid (ATRA) is a vitamin A derivative that binds the retinoic acid receptor on MDSCs and differentiates immature monocytes into more mature dendritic cells (12). VESANOID is a standard treatment for patients with acute promyelocytic leukemia (APL).
223514677|NCT02403778|DRUG|Ipilimumab|Ipilimumab is current standard of care treatment for melanoma.
223514678|NCT01316900|DRUG|GSK573719/GW642444 125/25|125/25 mcg once-daily
223514679|NCT01316900|DRUG|GSK573719/GW642444 62.5/25|62.5/26 mcg once-daily
223514680|NCT01316900|DRUG|GW642444|25 mcg once-daily
223514681|NCT01316900|DRUG|tiotropium bromide|18 mcg once-daily
223514682|NCT05612607|DRUG|Immunoglobulin replacement therapy (IGRT)|IGRT discontinuation will be dependent on participant's SMB levels. If SMB cells are ≥ 2%, IGRT will be discontinued. If SMB cells are \< 2%, the patient will remain on IGRT and a maximum of 40 mL of blood will be drawn again in 3-6 months to reassess SMB levels and eligibility for IGRT discontinuation.
223514683|NCT05047887|PROCEDURE|Modified socket shield technique with autogenous dentin graft material (in one side)|The crown of the hopeless tooth will be decoronated, the root will then be sectioned, the lingual root fragment will be carefully retrieved, the remaining buccal root fragment will be thinned and concaved, The coronal part of this shield will be beveled to make a lingual slope then Tooth particles will be demineralized using 2% HNO3 (El-Gomhouria CO. Egypt) for 20 minutes to expose the dentin organic matrix.
223514684|NCT05047887|PROCEDURE|Modified socket shield technique with alloplast graft material (in contralateral side)|The crown of the hopeless tooth will be decoronated, the root will then be sectioned, the lingual root fragment will be carefully retrieved, the remaining buccal root fragment will be thinned and concaved, The coronal part of this shield will be beveled to make a lingual slope then alloplast graft will be used
223514685|NCT03109925|DEVICE|DC Lumi Bead, BTG|Embolic agent which is radio-opaque
223514686|NCT01796444|PROCEDURE|Sentinel Lymph Node Biopsy|Sentinel lymph nodes are identified with the combining use of intraoperative gamma detector and/or blue dye.
223514687|NCT01796444|PROCEDURE|Intraoperative Pathological Examination|touch imprint cytology and/or frozen section and/or OSNA
223514688|NCT01796444|PROCEDURE|Axillary Lymph Node Dissection|Axillary lymph node dissection involving removal of at least level I and II nodes.
223514689|NCT01796444|PROCEDURE|Pathological Evaluation|H\&E and IHC
223635743|NCT05387200|DRUG|Masibone S|The investigators will evaluate the change of bone mineral density at lumbar spine measured by DEXA after 48 weeks of alendronate sodium trihydrate 70mg (oral solution) 1 bottle weekly and cholecalciferol 1000U/calcium 100mg 1T daily use.
223635744|NCT05387200|DRUG|Fosamax|The investigators will evaluate the change of bone mineral density at lumbar spine measured by DEXA after 48 weeks of alendronate sodium 70mg (oral tablet) 1T weekly and cholecalciferol 1000U/calcium 100mg 1T daily use.
223635745|NCT03496311|DIAGNOSTIC_TEST|Acid - Base characterization|Samples of cerebrospinal fluid and arterial blood will be collected anaerobically to measure acid-base variables, electrolytes, albumin, progesterone and copeptin levels
223764803|NCT01351896|BIOLOGICAL|Pneumococcal Polyvalent Vaccine|Given IM (concurrently or sequentially)
224224623|NCT02022007|DRUG|Saxagliptin-Metformin XR|"Start 1 pill (2.5 mg/ 1000mg XR) for 3 weeks~Increase to 2 pills as tolerated (5mg/2000 mg XR) for remainder of study"
224224624|NCT05877820|BIOLOGICAL|Tislelizumab|Intravenous infusion
224224625|NCT05877820|DRUG|Lenvatinib|Oral tablet
223514690|NCT01796444|DRUG|Adjuvant Systemic Therapy|Adjuvant systemic therapy was determined by the treating physician according to the recently NCCN.
223514691|NCT01796444|RADIATION|Radiation Therapy|Whole-breast opposing tangential-field radiation therapy.
223514692|NCT06279403|DRUG|Toripalimab|Preoperative Treatment with Toripalimab: Administer 240mg of Toripalimab via intravenous infusion every 3 weeks for a total of 4 cycles.
223514693|NCT06279403|PROCEDURE|Cytoreductive Nephrectomy|"Radical Nephrectomy: Complete resection of the tumor and affected kidney within the renal fascia.~Partial Nephrectomy: Complete resection of the tumor while preserving maximal kidney function.~Lymph Node Dissection: For patients with evident enlargement of retroperitoneal lymph nodes preoperatively, perform lymph node dissection at the renal hilum, along the ipsilateral major vessels, and anterior to the ipsilateral major vessels. Lymph node dissection is not required for patients without evident enlargement of retroperitoneal lymph nodes preoperatively."
223514694|NCT06279403|DRUG|Axitinib|Preoperative Treatment with Axitinib: Administer 5mg of axitinib orally twice daily for a duration of 3 months.
223514695|NCT03409146|DEVICE|Monica Novii Wireless Patch System|The Monica Novii Wireless Patch System is a transabdominal fetal/maternal recorder that provides fetal heart rate, maternal heart rate and maternal uterine activity contractions.
223514696|NCT03879577|DRUG|Docetaxel|Administered to all patients for a minimum of 4 cycles for 12 weeks.
223514697|NCT03879577|DRUG|Herceptin|Administered for 18 cycles every three weeks (52 weeks) for each patient starting at the first day of treatment with docetaxel.
223514698|NCT03879577|DRUG|FEC|Only administered to patients who received docetaxel and herceptin and were assessed as having poor response (defined as stable disease or progressive disease or partial response inoperable).
223514699|NCT03879577|DRUG|Tamoxifen|Only administered to hormone-receptor positive patients. Patients will receive tamoxifen or letrozole.
223514700|NCT03879577|DRUG|Letrozole|Only administered to hormone-receptor positive patients. Patients will receive tamoxifen or letrozole.
223514701|NCT03879577|DRUG|LHRH agonist|Administered to all premenopausal patients.
223514702|NCT03927755|OTHER|Education|Physicians will undergo training on how to rapidly obtain appropriate images.
223514703|NCT01684033|DEVICE|Opti-Free® PureMoist® MPDS|
223514704|NCT01684033|DEVICE|Biotrue™ MPS|
223514705|NCT01684033|DEVICE|Habitual contact lenses|Silicone hydrogel contact lenses per participant's habitual brand, prescription, and replacement schedule worn on a daily wear basis for at least 8 hours a day, 5 days a week for the duration of the study. During the washout period, the contact lenses were worn on a daily disposable basis.
223514706|NCT05152095|OTHER|Vaccaria seed (Wang Bu Liu Xing) pre-attached to adhesive tape used for auricular acupressure|Apply on auricular acupoints, Shenmen and Occiput, apply pressure for 3 minutes, 5 times per day, at the interval of 2 \~ 3 hours, for 5 days.
223514707|NCT05152095|OTHER|Plain ear adhesive tape|Apply on Shenmen and Occiput without applying pressure for 5 days.
223514708|NCT02783963|DEVICE|OCT and CMR imaging|"OCT: Imaging for the presence and vulnerability of coronary plaque as well as plaque disruption.~CMR: Imaging for identification of myocardial injury (late gadolinium enhancement and myocardial edema) as well as other concomitant findings."
223514709|NCT02948075|DRUG|Quisinostat|
223514710|NCT02948075|DRUG|Paclitaxel|
223514711|NCT02948075|DRUG|Carboplatin|
223514712|NCT04674904|OTHER|Dry Needling|Dry needling on Upper trapezius, Levator Scapulae, Sternocledomastoid , Pectorals major and minor and rhomboids for 10 min
223514713|NCT04674904|OTHER|Hot pack , TENS , Stretching|"Treatments are~1. Hot Pack for 15 minutes~2. TENS for 10 minutes~3. Stretching~The third treatment which is Stretching will be given one time on each muscle (tight upper trap, Levator Scapulae, Sternocledomastoid , Pectorals major and minor and rhomboids) of upper spine"
223514714|NCT04147741|DIETARY_SUPPLEMENT|Pre-Workout Supplement|"One week familiarisation, one-week training, two weeks washout period and one-week training.~15 Minutes before every training, the Pre-Workout Arm (PRE-W) will take a Supplement shake, consisting of some ingredients (Multi-Ingredient, explained before) and the Placebo Comparator Arm (CHO) will drink a Placebo shake, consisting of Maltodextrin."
223514715|NCT04147741|OTHER|Resistance Training|-Resistance Training days (Monday-Wednesday-Friday): Before training starts, Tensiomyography and Energy Feeling will be assessed (Energy Level, Fatigue Level, Feeling of Alertness, and Feeling of Focus on the task). Immediately after finishing, Tensiomyography and Performance (Vertical Jump, Overhead Medicine Ball Throw, and Maximal Mid-Tigh Pull Isometric Strength) will be assessed. Training Protocol: 10 minutes of standardized warm-up, Strength Circuit training using free weights (Parallel Squat; Bench Press; Alternate Box Set-Ups; Shoulder Press; Alternate Lunges; Up-right Row; Hip-Thrust; Squat on Isoinertial Fly-Wheel or Drop Jump). The participants will have to perform 16 repetitions of each exercise, with 30 seconds rest and 3 minutes rest after every set. If they can complete 16 repetitions easily, 2,5 to 5 kg will be added for the next set. Also, whole-body Perceptual Response will be assessed using the 0-10 OMNI-RES Scale, after every set and 15 minutes after finishing.
223514716|NCT04147741|OTHER|Endurance Training|\- Endurance Training days (Tuesday-Thursday): Energy Feeling Questionnaire will be implemented before training. The training will consist of 30 minutes cycling at their Fatmax Intensity (\~60% Vo2max) on a Cycloergometer (estimated during familiarisation week). Also, the Heart Rate will be recorded during the whole training. Besides, Perception of Effort will be assessed using the 6-20 version of the Borg Scale every 5 minutes during training and 15 minutes after it has been completed.
223514717|NCT02289014|OTHER|online stress Management program|Active treatment group
223764804|NCT06124976|DRUG|ST-02|ST-02 drug instillation into the upper urinary tract (renal pelvis)
223514718|NCT01018771|PROCEDURE|Actifuse ABX|bone graft to be used in posterolateral instrumented lumbar fusion
223514719|NCT01018771|PROCEDURE|INFUSE, plus Mastergraft granules|bone graft to be used in posterolateral instrumented lumbar fusion
223514720|NCT04902482|DEVICE|iCycle Mark 3|The iCycle Mark 3 is a cycle ergometer, designed to be used by people with SCI while they are seated in their own wheelchairs. The purpose of iCycle is to stimulate the leg muscles in the correct phase for cycling while motivating the person with a Virtual Reality cycling event, perhaps a race, to try to use their muscles.
223514721|NCT03397719|BEHAVIORAL|Treatment Condition|This group will receive three hours of parent coaching per week, one hour per week will involve feedback on parent usage of coached strategies based on parent recorded interactions with their children.
224224626|NCT06482970|OTHER|Neuromuscular exercise plus pain neuroscience education|"The exercises follow neuromuscular principles, which aim to improve sensorimotor control and achieve compensatory functional stability (also called dynamic stability).~Pain neuroscience education will take an active, person-centered approach through their own fear-avoidance beliefs."
224224627|NCT06482970|OTHER|Neuromuscular exercise|The exercises follow neuromuscular principles, which aim to improve sensorimotor control and achieve compensatory functional stability (also called dynamic stability).
224224628|NCT06482593|DRUG|Zinc-Oxide Eugenol Sealer|Zinc oxide-eugenol sealers have a slow setting time, shrinkage while setting, solubility, and can discolour tooth structure. This sealer group has an advantage in terms of antibacterial activity.It will absorb if extruded into the periradicular tissues.
224224629|NCT06482593|DRUG|AH-Plus Epoxy Resin Sealer|Dentsply AH Plus Root Canal Sealing Material is a two-component paste/paste root canal sealer based on epoxy-amine resin. The AH Plus sealer shows extremely low shrinkage making it a suitable choice of material to seal the root canal.
224224630|NCT06482593|DRUG|Bio-C Sealer|Bio-C® Sealer is a ready-to-use, bioceramic root canal sealer with biologically active ingredients to seal and heal the root canal space. Bio-C Sealer's mechanical and physical properties make it easy to manipulate and seal the canals, while its biological properties and high pH ensure safety and treatment success.
224224631|NCT05778279|DIAGNOSTIC_TEST|High-resolution ultrasonography|High-resolution ultrasonography to detect fetal CNS anomalies
223514722|NCT03397719|BEHAVIORAL|Control Group|This group will receive in-vivo parent coaching three hours per week.
223514723|NCT05157789|OTHER|SMS|In the study, text message will be sent to relatives of the patients for informing and the effect will be determine on the level of anxiety during cardiovascular surgery.
223514724|NCT02956863|PROCEDURE|Osteopathic manipulative treatment|Osteopathic manipulative treatment delivered on pragmatic way.
223514725|NCT02956863|PROCEDURE|Exercises|Exercise for stretching and strength for neck muscles
223514726|NCT02446288|DEVICE|TMJ Next Generation|
223514727|NCT02446288|DEVICE|DSG Relaxer|
223514728|NCT02496156|BEHAVIORAL|Usual Clinical Practice|Diabetes management and education related to insulin pump or continuous glucose monitor as currently practiced at the enrolling site.
223514729|NCT02496156|BEHAVIORAL|Shared Medical Decision Making|Access to and use of multimedia decision aid websites to facilitate adolescent and parent decision making about incorporating these devices into the diabetes management regimen.
223514730|NCT01005979|DRUG|Lenalidomide, Rituximab, and Cyclophosphamide|"COHORT 1: Cyclophosphamide 250 mg/m2 day 1, 2 and 3, Rituximab 500 mg/m2 i.v. day 1, Lenalidomide 2.5 mg/day starting day 8-28 of Cycle 1 and then daily on Days 1-28 of subsequent cycles~COHORT 2: Cyclophosphamide 250mg/m2 day 1, 2 and 3. Rituximab 500 mg.m2 i.v. daY Lenalidomide 5 mg/day starting day 8 -28 of Cycle 1 and then daily on Days 1-28 of subsequent cycles~COHORT 3: Cyclophosphamide 250mg/m2 day 1, 2 and 3, Rituximab 500 mg.m2 i.v. day 1, Lenalidomide 10 mg/day starting day 8 -28 of Cycle 1 and then daily on Days 1-28 of subsequent cycles~COHORT 4: Cyclophosphamide 250mg/m2 day 1, 2 and 3, Rituximab 500 mg.m2 i.v. day 1, Lenalidomide 15 mg/day starting day 8 -28 of Cycle 1 and then daily on Days 1-28 of subsequent cycles~Patients will receive a total of 6-8 cycles."
223514731|NCT00089583|DRUG|LEXIVA (GW433908)|Fosamprenavir suspension or tablet bid
223514732|NCT00089583|DRUG|Ritonavir|Ritonavir solution bid
223514733|NCT03778697|PROCEDURE|Endoscopic Sleeve Gastroplasty|Endoscopic full-thickness suture system to plicate the greater curvature of the stomach
223514734|NCT05918770|DIAGNOSTIC_TEST|systematic screening and early treatment|in case of positive screening, the online app will alert and the patient will be referred to the corresponding area for diagnosis and early treatment (Rehabilitation, Psycho-oncology, Sexual health and Nutrition
223514735|NCT06481072|OTHER|Digital patient education|This educative intervention includes both medical and psychological explanations, as well as basic strategies to manage pediatric FAPD. The medical information spans the topics of pain, functional abdominal pain and general advice in terms of child health, and the psychological information is based on cognitive-behavioural and pain management theoretical approaches. The intervention consists of six short, animated films with a total run-time of approximately 30 minutes. The films each cover one of the following topics; Why and how do we feel pain? What is functional abdominal pain? How to help: general advice, Thoughts, feelings and behaviour, Goals and strategies. The films are accessed by the patient via 1177.se and maintained on the SoB (Stöd- och behandling) platform that is recognised by the care provider as meeting current safety criteria and standards.
223514736|NCT06481072|OTHER|Digital patient education and iCBT|This includes the educative intervention and a fully digital, four session version of the Aim to Decrease Anxiety and Pain Treatment (ADAPT), a CBT treatment program for FAPD. The treatment focuses on pain-management through the following core elements; The Pain-Gate Theory, breathing and relaxation strategies, calming statements, activity pacing, problem solving and behavior activation. This intervention is also accessed by the patient via 1177.se and maintained on the SoB (Stöd- och behandling) platform.
223514737|NCT01229202|DRUG|Bevacizumab|single bevacizumab subtenon injection of 1.25 mg. at end of trabeculectomy surgery
223635746|NCT04558125|DRUG|TNKase|Tenecteplase (0.25 mg/kg) supplied by Genentech, Inc. as a sterile, lyophilized powder, diluted with 10mL sterile water.
223635747|NCT04558125|DRUG|Placebo|Placebo to match supplied by Genentech, Inc. as a sterile, lyophilized powder, diluted with 10mL sterile water.
223635748|NCT04558125|DRUG|Enoxaparin|All participants must also receive standard of care anticoagulation therapy.
223635749|NCT05311709|DRUG|sotorasib|single group, all patients receive sotorasib
223635750|NCT03137381|DRUG|CTP-543|Administered as tablets.
223635751|NCT03137381|DRUG|CTP-543 matching placebo|Administered as tablets.
223635752|NCT01684917|BEHAVIORAL|Metabolomic and Energy Intake Restriction|Metabolomic inquiry followed by a 12 week energy intake restriction. This study is part of a very large European study called EPIC. Only the results by Lee et al. 2016 have been presented here. The results of the study published by Cheung 2017 are from a different study. therefore the entries for the results are correct. For this particular study, participants were not randomly assigned to one of five different diets; red meat, fish, poultry, processed meat or a supplement and vegetarian option. In summary, both studies (lee and cheung) are considered as separate trials and results of the first phase where participants were assigned to one of five different diets, are reported separately. Unfortunately no different NCT number is available.
223635753|NCT03146923|OTHER|Current Low Phosphorus Diet Prescription|"Routine / Standard Care: Routine dietary intervention is currently provided by one-to-one counselling to the subject and his/her relevant family members or carers, by a state registered dietitian regarding a diet which provides \<15mg Phosphorus /g Protein (over the day). This is equivalent to approximately 1000mg P / day. This is based on the 'Eating Well with Kidney Disease' dietsheet produced by the Renal Interest Group (RIG) of the Irish Nutrition \& Dietetic Institute (INDI) in 2010 and includes following main components:~* Restricting protein intake to requirements (1-1.2g/kg Ideal Body Weight)~* Restricting dairy intake (1-1.5 portions per day)~* Avoiding foods high in phosphate~* Avoiding foods with phosphate additives"
224224632|NCT02896465|OTHER|Oral rehydration solution|
224224633|NCT02896465|OTHER|Zinc|
224224634|NCT02896465|OTHER|Human milk oligosaccharides|
224224635|NCT02896465|OTHER|Breastfeeding|
223514738|NCT05538650|BEHAVIORAL|Mindfulness-Based Social Work and Self Care (MBSWSC)|MBSWSC is a unique mindfulness-based programme for social work and self-care which has been specifically developed for online delivery. The MBSWSC programme is embedded within key cognitive and emotion regulation, and stress coping theory. This programme combines mindfulness practices with psychoeducation with the aim of allowing participants to reduce any negative thinking about the past and future by learning skills that will allow them to focus on the present. It will also focus on how to effectively apply these newly acquired mindfulness skills in social work practice. The programme has been the subject of an initial RCT, which has helped to inform the current programme content and structure. The MBSWSC programme comprises 6x1.5 hour sessions, delivered weekly, over a 6 week period. Homework, in the form of mindfulness practices, is given each week. This will take approximately 20-30 minutes to complete, on 6 out of 7 days, each week.
223514739|NCT05538650|BEHAVIORAL|Mindfulness-Based Self-Care (MBSC)|MBSC is a modified, condensed Mindfulness Based Intervention; with a key focus on self-compassion/self-care. Key practices in this condensed programme were chosen for their relevance and utility to social workers. The MBSC programme comprises 3x1 hour sessions delivered over a 6 week period, with one session every two weeks. Homework, in the form of mindfulness practices, is given each week. This will take approximately 20-30 minutes to complete, on 6 out of 7 days, each week.
223514740|NCT03288831|DIETARY_SUPPLEMENT|Gluten|Six grams of gluten will be mixed with water and Tang flavoring. Subjects will drink the mixture one time.
223514741|NCT03288831|DIETARY_SUPPLEMENT|Placebo|Subjects will drink a mixture of rice water and Tang flavoring one time.
223514742|NCT00507507|DRUG|Tenofovir DF|Tenofovir disoproxil fumarate (tenofovir DF) 300 mg tablet taken orally once daily
223514743|NCT00507507|DRUG|FTC|Emtricitabine (FTC) 200 mg capsule taken orally once daily
223514744|NCT00507507|DRUG|Placebo|Placebo to match FTC taken once daily
223514745|NCT05287100|DRUG|Midodrine Oral Tablet|Midodrine starting at 0.25mg/kg/day in 2-3 divided doses, increased to 0.5mg/kg/day after 7 days if MAP does not increase by \>10% ; Midodrine dosage will be decreased by 25% in case of arterial hypertension (\>95th centile BP for the age). Also Standard medical therapy as per departmental protocol will be continued
223514746|NCT05287100|OTHER|Standard Medical Treatment|"Albumin infusion 1g/kg/day - maximum 20gm/day and repeat till serum albumin reaches 2.8g/dl If serum albumin is \< 2.8g/dl SBP - Day 1 and Day 3~For Ascites :~Restriction of sodium to \< 2meq/kg/day A combination of a distal-acting diuretic (spironolactone, 3-6 mg/ kg/day) and loop-acting diuretic (furosemide,0.5- 2 mg/kg per day) was given with dose escalation by one step at a time if there is no decrease in weight (by ≥ 0.5 %/day) after 5-7 days Therapeutic paracentesis (\>50ml/kg) with infusion of albumin (8 g/L) performed for tense, symptomatic ascites~For Spontaneous Bacterial Peritonitis :~IV antibiotics for 7 days Albumin Infusion on Day 1 and Day 3"
223514747|NCT02916433|DRUG|Octreotide|
223514748|NCT03760666|DRUG|Brequinar/Brequinar + Ribavirin|The first 14 participants had brequinar monotherapy; the final 3 subjects were also exposed to a combination of brequinar + ribavirin.
223514749|NCT05847335|BEHAVIORAL|Survey work|Childhood Trauma scale, Personality Beliefs questionnaire, Emotional Intelligence scale
223514750|NCT00693732|DRUG|Escitalopram treatment|On study inclusion at Visit 2, patients will be successively randomised using a computer generated randomisation list to either placebo or escitalopram (Lundbeck Export A/S, Singapore) 10mg given at bedtime in the first 2 weeks, followed by 20mg in the next 6 weeks. The treatments will be identical in appearance and will be administered in double-blind fashion. Treatment with any anticoagulants, antidiabetics, antimigraine drugs, antispasmodics, analgesics, psychoactive agents including antidepressants, Zelmac®, TCM or acupuncture for IBS and any drugs affecting nociception as judged by investigator are prohibited during the entire study.
223514751|NCT00693732|BEHAVIORAL|Quantitative sensory testing|Rectal Distention Stimulation
223514752|NCT01623154|OTHER|Pranactin citric solution|All patients were required to drink the pranactic citric solution to diagnose H.pylori.
223514753|NCT00890097|DRUG|AL-8309B Ophthalmic Solution|
223514754|NCT00890097|DRUG|AL-8309B Vehicle|Inactive ingredients used as placebo comparator
223514755|NCT04784871|BEHAVIORAL|5waysA Intervention|Web-based 10 week intervention, encouraging participants engaging in five potential health promoting activities: 1. Be active, 2. Take notice, 3. Keep learning, 4. Connect and 5. Give.
224224636|NCT00655421|OTHER|Unaided Visual Inspection|Simple unaided visual inspection of the oral cavity with a bright white light source by trained Primary Health Care Worker
224224637|NCT00655421|DEVICE|VelScope|Examination of the oral cavity through a VelScope by trained Primary Health Care Worker
224224638|NCT00655421|OTHER|Toluidine Blue Assisted Oral Examination|Examination of the oral cavity after the local application of Toluidine Blue dye by trained Primary Health Care Worker
224224639|NCT03198299|DEVICE|MEI BIN insoles|wearing insoles for 12 weeks
224224640|NCT00799006|DRUG|Placebo|Subjects will be given placebo or PF-04620110
224224641|NCT00799006|DRUG|PF-04620110|A single oral dose of PF-04620110 will be given. The specific dose will depend on the cohort to which the subject is assigned and the period of the cross-over for that cohort. Initial planned doses are 0.3-30 mg but may be modified based on emerging PK and safety data.
224224642|NCT03508895|OTHER|Whole hemp seed protein|The intervention was provided in the form of a smoothie.
224224643|NCT03508895|OTHER|Whole hemp seed protein plus bioactive peptides|The intervention was provided in the form of a smoothie.
224224644|NCT03508895|OTHER|Casein protein|The intervention was provided in the form of a smoothie.
223764805|NCT05752955|OTHER|SMARThealth Pregnancy|"At each visit, the CHW will:~* Update history and contact details~* Check haemoglobin with a point of care device.~* Check BP~* Check iron folic acid (IFA) supply and compliance~* Brief screen for mental health problems~An electronic decision support platform will provide advice if referral is needed. At the Primary Health Centre, doctor/s will be issued a tablet computer with a version of the SMARThealth Pregnancy App to:~* Generate an automated list of all patients in the community who require review, with the dates of testing and referral, and with two-way communication back to the CHW.~* Suggest management based on current Indian guidelines for the diagnosis and management of anaemia, hypertension and diabetes in pregnant and non-pregnant adults."
224224645|NCT02862639|DEVICE|Experimental group|patient receive intra articular injection (hip joint) of viscosupplementation in combination with corticosteroid
224224646|NCT02862639|DEVICE|control group|patient receive intra articular injection (hip joint) of corticosteroid alone
224224647|NCT02087046|DEVICE|ANS Totally Implantable Deep Brain Stimulation System|ANS Totally Implantable Deep Brain Stimulation System will be implanted in the VIM nucleus of the thalamus
224224648|NCT00362986|DRUG|sunscreen|
224224649|NCT00362986|OTHER|placebo|
224224650|NCT06207825|DIAGNOSTIC_TEST|Test images and videos|A set of test images and videos will be collected prospectively from other subjects, according to the eligibility criteria, followed by random allocation of computer-generated sequence.
224224651|NCT04951050|DEVICE|Rapamycin target eluting stent|Rapamycin target eluting stent
224224652|NCT04427696|BEHAVIORAL|Aerobic walking intervention|Walking exercise is self-controlled and tracked by daily dairy. All of the participants are obligated to record the start and end time of walking every day. And pedometers will be used for tracking walking steps including heart rate and calories. We plan to use pedometer in our study, which was reported the most accurate pedometer and suitable for scientific research. For the ones who are in the control group, they have to keep sedentary lifestyle, and no regular walking exercise, and they are agree to be in the comparable members in our study.
224318707|NCT04965077|DRUG|Recombinant Humanized Monoclonal Antibody MIL97 for Injection|"Dose escalation phase: The patients confirming to the eligibility criteria will be assigned to the 6 dose groups (0.01mg/kg, 0.03mg/kg, 0.1mg/kg, 0.2mg/kg, 0.3mg/kg 0.45mg/kg, respectively) based on the sequence of inclusion. Each patient will receive an intravenous infusion of MIL97 every 3 week on Day 1 of each cycle. Additional 1 or 2 dose cohorts will receive an intravenous infusion of MIL97 every 2 week on Day 1 of each cycle after last patient finishes DLT observation period.~Dose expansion phase: One or two recommended expansion doses (either Q3W or Q2W) will be selected from 6 dose groups (0.01mg/kg, 0.03mg/kg, 0.1mg/kg, 0.2mg/kg, 0.3mg/kg 0.45mg/kg) based on results of dose escalation phase. MIL97 will be administered via intravenous infusion for 60 to 90 minutes on Day 1 of each cycle."
224318708|NCT00747032|DRUG|NYC 0462 Ointment|To assess the efficacy of NYC 0462 Ointment versus Placebo in the treatment of Plaque Psoriasis
224318709|NCT00747032|DRUG|Placebo|To assess the efficacy of NYC 0462 Ointment versus Placebo in the treatment of Plaque Psoriasis
224318710|NCT05509075|DIETARY_SUPPLEMENT|nutraceuticals|antioxidants
223514756|NCT04784871|BEHAVIORAL|5waysA Active wait-list control|Writing activity log in the waiting time. Then, after five months and the writing of activity log, the participants get the web-based intervention and SMS massages, which encourage the participants to engage in five potential health promoting activities: 1. Be active, 2. Take notice, 3. Keep learning, 4. Connect and 5. Give.
223514757|NCT04784871|BEHAVIORAL|5waysA Inactive wait-list control|No activity while the participants wait. After five months of waiting, the participants get the web-based intervention and SMS messages, which encourage participants engage in five potential health promoting activities: 1. Be active, 2. Take notice, 3. Keep learning, 4. Connect and 5. Give.
223514758|NCT05858151|BEHAVIORAL|Food system and demand generation|The Global Alliance for Improved Nutrition (GAIN) will implement the Transforming Food Systems to Improve Diet Quality and Resilience for the Most Vulnerable program, which will use a market-based approach to improving diets through food systems. The set of interventions proposed is based on characteristics and challenges of the food environments of bottom of pyramid consumers in Mozambique. GAIN will focus on elements of the food environment related to accessibility, affordability, and desirability of animal source foods (ASFs) in Mozambique.
223514759|NCT05151419|PROCEDURE|bronchoscpe|bronchoscopic biopsy from lung mass using cryobiopsy and forceps
223514760|NCT03721367|OTHER|Diagnostic Ultrasound|All individuals will undergo a blood draw for measurement of biomarkers of liver disease and an ultrasound with shear-wave elastography.
223514761|NCT06105892|DEVICE|Virtual Eye Rotation Vision Exercise (VERVE)|VERVE utilizes a virtual reality (VR) headset with integrated eye-tracking where the patient makes specific vergence eye movements by playing a VR game controlled by eye movements. Participants will be making convergence and divergence eye movements as steps and ramps.
223514762|NCT06105892|DEVICE|Sham VR Therapy|VERVE game without changes in eye movement demands. Maximizing gameplay with no intervention.
223514763|NCT04056429|COMBINATION_PRODUCT|BHA|BHA active ingredients include beta-tricalcium phosphate and a blood-derived component. It is applied directly to the bone fracture and nearby viable bone at the time of wound closure.
223514764|NCT01163877|DIETARY_SUPPLEMENT|Fe-57 orally, Fe-58 intravenously|Subjects will receive a test drink containing 3 mg Fe-57 in the form of labelled FeSO4 followed by 1 ml of an aqueous solution containing 50 μg Fe-58 as iron citrate.
223514765|NCT05792254|DRUG|Huaier granule|Oral Huai Er granules, 20 g once, 3 times a day, continued to progress or intolerance toxicity.
223514766|NCT00398450|BIOLOGICAL|recombinant interferon alfa-2b|
223514767|NCT00398450|DRUG|azacitidine|
223514768|NCT02037880|PROCEDURE|Lumbar puncture|
223514769|NCT02037880|DEVICE|Magnetic Resonance Imaging (MRI) of the brain|
223514770|NCT04576221|DEVICE|stacked breathing exercise|"• Breath stacking was done using a bag which is a simple device used to give artificial breaths..~* It is best done in a sitting position but can be done reclining or lying flat whichever position is used, try to avoid slouching. If sitting: rest against the back of a chair and keep the shoulders, arms and hands relaxed.~* If using the mouthpiece, place the lips tightly around the mouthpiece to create a tight seal."
223514771|NCT04576221|DEVICE|NIV by CPAP mask|provides pressurized air through a mask to help push air into your lungs and help you breathe
223514772|NCT04197323|DRUG|Alprostadil liposomes for injection|40ug,once a day,continuous administration for 2 weeks
223764806|NCT05053503|DEVICE|Sparrow Ascent Therapy System|Transcutaneous auricular neurostimulation (tAN)
223764807|NCT05053503|DRUG|Lofexidine|Participants will receive 3 lofexidine 0.18 mg/tablets four times per day (daily dose of 2.16 mg) for 7 days.
224224653|NCT01107535|BIOLOGICAL|Synagis (palivizumab), monoclonal antibody for passive immunoprophylaxis against severe RSV disease administered according to usual clinical practice.|Synagis (palivizumab) administered according to usual clinical practice. After the enrollment visit, subjects will have monthly visits until they have received the complete Synagis immunization regimen of their hospital, then they will have 2 follow up visits, one of them 30 days after the fifth dose of Synagis and the other visit at one year of age.
224224654|NCT01214603|DRUG|LY2090314|Administered intravenously
224224655|NCT00471406|PROCEDURE|Photodynamic Therapy with Verteporfin|
224224656|NCT03100578|DEVICE|WOPN TRANSMURAL DRAINAGE: PLASTIC STENT|"Endoscopic ultrasound-guided transmural drainage of walled-off pancreatic necrosis:~The pancreatic collection will be located with the linear echoendoscope, and we will proceed to choose an optimal area to perform the puncture guided by EUS; with the absence of intervening vessels.~This collection will be punctured with a 19 G needle or with an electrocautery device directly. Guidance will be advanced through the needle and the ostomy will proceed according to the routine of the experienced endoscopist.~Placement of a plastic double pigtail, 5-10 cm in length, diameters 7-8,5-10 Fr. Minimum one 10 Fr prosthesis.~Arm associated: PLASTIC STENT"
224224657|NCT03100578|DEVICE|WOPN TRANSMURAL DRAINAGE: METALLIC STENT|"Endoscopic ultrasound-guided transmural drainage of walled-off pancreatic necrosis:~The pancreatic collection will be located with the linear echoendoscope, and we will proceed to choose an optimal area to perform the puncture guided by EUS; with the absence of intervening vessels.~This collection will be punctured with a 19 G needle or with an electrocautery device directly. Guidance will be advanced through the needle and the ostomy will proceed according to the routine of the experienced endoscopist.~Placement of a metal self-expanding fully covered luminal apposition stent: 10, 15 or 20 mm diameter.~Arm associated: SELF EXPANDABLE METALLIC STENT"
224224658|NCT03673189|DEVICE|sensors|Acquisition and transmission of exploitable recordings in the public targeted by the DS, that is to say which allow to draw clinical information in relation to the objectives of the DS (detection of the cardiac rhythm): data without artefact (saturation), in a good signal to noise ratio.
224224659|NCT05851235|OTHER|Prehabilitation course|During prehabilitation course, patients will follow a nutritional programme, a cardiovascular and motor programme and a psychological programme.
224224660|NCT01388647|DRUG|eribulin|During Phase I, the eribulin dose will be assigned upon study enrollment. The maximum tolerated dose (MTD) determined in Phase I will be the dose used for Phase II. Eribulin will be administered intravenously (IV) over 2 to 5 minutes on Days 1 and 8 of each cycle.
224224661|NCT01388647|DRUG|carboplatin|Carboplatin area under the curve (AUC) 6 will be administered IV over 15 to 30 minutes on Day 1 of each cycle.
224224662|NCT01388647|DRUG|trastuzumab|Trastuzumab will be administered as an IV infusion on Day 1 of each cycle. A loading dose of 8 mg/kg of trastuzumab will be administered over 90 minutes on Cycle 1 Day 1. Then, a maintenance dose of 6 mg/kg of trastuzumab will be administered over 30 to 90 minutes on Day 1 of Cycles 2 - 6.
224224663|NCT02444533|DRUG|Liposomal Bupivacaine|Injection of 8 ml of liposomal bupivacaine total in the tonsillar fossae after tonsillectomy.
224224664|NCT00425529|DEVICE|Module AOX (attached to Sondalis ISO)|
224224665|NCT04455568|DEVICE|use EKG Wisdom bracelet|Non-invasive Wearable Device (use EKG Wisdom bracelet)
224224666|NCT04087668|PROCEDURE|Monitored Anesthesia Care|MAC was induced and maintained via the continuous infusion of propofol AND remifentanil using a target-controlled infusion (TCI) pump. The appropriate level of sedation was 65 to 80 points on BIS. The adjunctive sedatives (eg, fentanyl, midazolam) was at the discretion of the anesthesia team.
224224667|NCT04087668|PROCEDURE|General Anesthesia|Induction was done with propofol (2 mg/kg) , cis-atracurium (0.15 mg/kg) , and fentanyl (5μg/kg). After orotracheal intubation, general anesthesia was maintained with sevoflurane (1-1.3MAC) , propofol (3mg/kg/h), remifentanil (0.05-0.2 ug/kg/min) and repetitive doses of 0.1mg atracurium per kilogram were administered. After the procedure was completed, neostigmine mixed with atropine was used as a reversal agent for the neuromuscular blockade, and the patient was extubated when the recovery from anesthesia was confirmed.The BIS was 45 to 60 points .
224318711|NCT02892552|RADIATION|Cone Beam Computed Tomography (CBCT)|Patients had an additional Cone Beam Computed Tomography, after the usual MDCT
223514773|NCT04920994|PROCEDURE|M-TAPA block|A high-frequency linear ultrasound probe will be used, probe will be placed on the costochondral angle in the sagittal plane and angled deeply to view the lower aspect of the chondrium in the midline, then using in-plane approach, a 22 Gauge Tuohy needle will be introduced into the lower aspect of the chondrium. The same procedure will be repeated on the contralateral side.
223514774|NCT04920994|PROCEDURE|SCTAP block|A high-frequency linear ultrasound probe will be placed obliquely on the upper abdominal wall, along the subcostal margin near the midline. After identifying the rectus abdominis muscle, the ultrasound probe will be gradually moved laterally along the subcostal margin until the transversus abdominis muscle will be identified lying posterior to the rectus muscle, then using in-plane approach, a 22 Gauge Tuohy needle will be introduced medially and directed towards the transversus abdominis plane until its tip reaches the fascia between the rectus abdominis and the transverse abdominis muscles on entering the neurofascial plane. The same procedure will be repeated on the contralateral side.
223514775|NCT04920994|DRUG|Bupivacaine Hydrochloride|20 ml 0.25% bupivacaine will be injected after the negative aspiration test.
223514776|NCT01941628|DRUG|Rocuronium|Rocuronium 0.6 mg/kg will be used as muscle relaxant to allow intubation during induction into general anesthesia and to induce deep neuromuscular blockade for the surgery. Deep neuromuscular blockade will be maintained until the suture of fascia of musculus rectus abdominis.
223514777|NCT01941628|DRUG|Succinylcholine|Standard induction into general anesthesia with succinylcholine 1 mg/kg will be performed. No other muscle relaxant will be administered during the Caesarean section until surgeon would request it. In that case, according to general standards, dose of atracurium 0.25 mg/kg will be administered.
223514778|NCT05740826|DEVICE|Algometer|The algometer head was applied to the trigger point of selected muscles at an angle of 90° and, increasing the pressure at a speed of about 100g/s, three measurements were made. Each measurement stoped at the first sensation of pain
223635754|NCT03146923|OTHER|Modified Low Phosphorus Diet Prescription|"Modified Low Phosphorus Diet Prescription: The new prescription recommends five changes to current management~* Introduction of some plant protein in the form of pulses and nuts where the phosphorus is largely bound by phytate~* Increased focus on avoiding additives~* Introduction of more whole grains e.g. wholemeal sliced pan/ pasta/rice .~* Avoiding over-prescription of protein which carries an obligatory phosphorus load.~* Focus on high protein foods with a low phosphorus to protein ratio"
223635755|NCT02143804|BIOLOGICAL|oncolytic adenovirus expressing GMCSF|Treatment once weekly by intravesical route. Use of DDM to first remove the GAG layer of the bladder and to improve virus transduction. Installation of 100 ml. of CG0070 at 10e12 viral particles for 45 minutes inside bladder.
223635756|NCT04690686|DEVICE|LW-02 device immunopheresis combined with atezolizumab|The LW-02 device comprises an immunoadsorption affinity column, employing a proprietary human recombinant protein, single chain TNF-α ligand, covalently linked to a bead resin, that both enhances the capture efficiency of sTNF-Rs while avoiding complications from column leaching. Reduced sTNF-R plasma levels may lead to objective tumor responses. In combined treatment arm the immunopheresis procedure is combined with standard dose immunotherapy (atezolizumab) to potentially enhancing its cytotoxic effect.
223635757|NCT04690686|DEVICE|LW-02 device immunopheresis combined with weekly paclitaxel|The LW-02 device comprises an immunoadsorption affinity column, employing a proprietary human recombinant protein, single chain TNF-α ligand, covalently linked to a bead resin, that both enhances the capture efficiency of sTNF-Rs while avoiding complications from column leaching. Reduced sTNF-R plasma levels may lead to objective tumor responses. In combined treatment arm the immunopheresis procedure is combined with low dose chemotherapy to potentially enhancing its cytotoxic effect.
223764808|NCT05053503|DRUG|Extended-release injectable naltrexone|Participants will receive extended-release injectable naltrexone based on the clinical site's standard of care.
223764809|NCT04522024|PROCEDURE|Epicardial focal cryoablation|Epicardial focal cryoablation on the left atrium around right upper pulmonary vein area
223764810|NCT04522024|PROCEDURE|Mei Mini Maze procedure|Unilateral thoracoscopic epicardial ablation by radiofrequency energy from left side
223764811|NCT06007014|DRUG|Chiglitazar sodium|tablets 48mg/ day administered for 18 weeks
223764812|NCT06007014|DRUG|Chiglitazar placebo|tablets 48mg/ day administered for 18 weeks
224224668|NCT04087668|PROCEDURE|Induction Without Neuromuscular Blockade|Anaesthesia was induced with propofol (2 mg/kg), remifentanil(3 ug/kg) and 2% lidocaine (1 mg/kg). Nasotracheal intubation was performed 60 s after the administration. After intubation, general anesthesia was sevoflurane (1-1.3MAC) , propofol (3mg/kg/h), remifentanil (0.05-0.2 ug/kg/min). After the procedure was completed, the patient was extubated when the recovery from anesthesia was confirmed.The BIS was 45 to 60 points .
224318712|NCT02892552|RADIATION|Multiple Detector Computed Tomography (MDCT)|Patients had a usual MDCT, before having an additional Cone Beam Computed Tomography
224318713|NCT05532033|DEVICE|High flow nasal cannula|A device able to delivery high flow oxygen therapy
224318714|NCT05532033|DEVICE|Facial mask|standard oxygen therapy
224318715|NCT00282451|DRUG|biphasic insulin aspart|
224318716|NCT00282451|DRUG|insulin aspart|
224318717|NCT01267487|DRUG|Heparin fixed doses|"Fixed doses of 400 units/ kg of patient's body weight before CPB to achieve an ACT \> 480 sec. Supplemental doses of 50mg of heparin if ACT \<480 sec during CPB.~Reversal doses of protamine in a 1:1 ratio (1mg of protamine for every mg of heparin administered), plus 0.8mg/kg of protamine at the end of the surgery."
224318718|NCT01267487|DRUG|PO continuous infusion of Protamine|25mg/hour in IV continuous infusion during first 6 PO hours
223514779|NCT02999360|BEHAVIORAL|Language therapy|There will be three blocks of treatment, ideally three times a week 100 minutes per day. Treatment will target impairment-directed speech language therapy (SLT) approaches or compensatory-directed SLT in each of the three treatment blocks. Half of the participants will receive the impairment-directed SLT. Half of the participants, will receive treatment that will target compensatory-directed speech language therapy approaches that are focused on functional communication skills in the conversational context. Methods of treatment will include PACE (Promoting Aphasics Communicative Effectiveness (Davis, 2005), conversational coaching (Hopper et al., 2002), and supported conversation (Kagan et al., 2001). The clinician will model and encourage all (verbal and non verbal) modalities of communication.
223514780|NCT02999360|BEHAVIORAL|Background Music|30 minutes background music only
223514781|NCT02999360|BEHAVIORAL|Aerobic Exercise|There will be three blocks of treatment and the AE will take place for all participants during one or two treatment blocks (randomly assigned), threetimes a week (sessions are three times a week prior to speech therapy but may be one or two times a week if a session is missed or may be up to four or five times a week if one or two sessions are missed and rescheduled due to weather or other circumstances).
223514782|NCT06222736|OTHER|Rocabado Exercises|Patients trained by Rocabado Exercises
223514783|NCT06222736|OTHER|Servical Core Exercises|Servical Core Exercises
223514784|NCT04200209|OTHER|Implementation of a quality indicator feedback mechanism|"1. Audit and feedback: A summary of clinical performance and hospital safety culture over a specified period of time.~2. Benchmarking Achievable: benchmarks are calculated from the performance of all members of a peer group and represents a realistic standard of excellence attained by the top performers in that group (i.e. comparing to the top 10% of peers).~3. Educational outreach: A trained independent person or investigator will meet with health professionals or managers in their practice setting to provide information (e.g. feedback of quality indicators).~4. Action planning: The purpose of action planning is to support quality improvement efforts by identifying opportunities for improvement, strategies and steps to accomplish the work."
223514785|NCT02656173|DRUG|Mirabegron|Oral tablet
223514786|NCT02656173|DRUG|Placebo|Oral tablet
223514787|NCT02656173|DRUG|Tamsulosin|Oral tablet
223514788|NCT01064622|DRUG|Gemcitabine Hydrochloride|Given IV
223514789|NCT01064622|OTHER|Hydrocortisone/Placebo|Given PO
223514790|NCT01064622|DRUG|Vismodegib|Given PO
223514791|NCT06684678|OTHER|individualized automatic coaching message for glycemic management and depressive symptom|For 12 weeks, the intervention group will receive weekly personalized coaching messages for glycemic management based on data from continuous glucose monitoring and bi-weekly personalized coaching messages for depression symptoms based on depression questionnaires, instead of non-face-to-face diabetes management.
223635758|NCT04690686|DEVICE|LW-02 device immunopheresis|The LW-02 device comprises an immunoadsorption affinity column, employing a proprietary human recombinant protein, single chain TNF-α ligand, covalently linked to a bead resin, that both enhances the capture efficiency of sTNF-Rs while avoiding complications from column leaching. Reduced sTNF-R plasma levels may lead to objective tumor responses.
223635759|NCT03566290|DRUG|GTx-024|Study drug is an opaque, white to off-white, size 5, oval Softgel capsule containing the active ingredient GTx-024. Subjects will be required to take one 3 mg Softgel capsule per day.
223635760|NCT05929963|OTHER|HCV infection status|Divided into 3 groups based on HCVAb and HCVRNA status
223635761|NCT03730753|DEVICE|Programmed intermittent epidural bolus|Programmed intermittent epidural bolus added to patient controlled epidural analgesia
223635762|NCT03730753|DEVICE|Continuous infusion|Continuous infusion added to patient controlled epidural analgesia
223635763|NCT01106612|PROCEDURE|Coronary CT angiography|EKG-gated, computed tomography angiography of the coronary arteries during heart rate control
223635764|NCT01106612|PROCEDURE|Myocardial perfusion imaging|Stress radionuclide myocardial perfusion imaging
223635765|NCT03401346|COMBINATION_PRODUCT|INP104|Dihydroergotamine Mesylate (DHE) administered via I123 Precision Olfactory Delivery (POD) Device
223635766|NCT03401346|DRUG|Dihydroergotamine Mesylate (DHE)|Dihydroergotamine Mesylate (DHE) injection (intravenous)
223635767|NCT03401346|COMBINATION_PRODUCT|Migranal Nasal Spray|Dihydroergotamine Mesylate (DHE) delivered via Migranal Nasal Spray pump
223635768|NCT01980017|BEHAVIORAL|Ottawa Model for Smoking Cessation|
224224669|NCT05265026|BEHAVIORAL|High Intensity Interval Training|A training session consists of 40 minutes as follows: 4x4 minutes at \> 85% of heart rate maximum (HRmax) alternated by 3x3 minutes active recovery at (50-70% of HRmax) and a 10-min-warm-up (60-79% of HRmax) and 5- minute cool-down at \~ warm up intensity. HRmax was determined during the VO2max test at baseline visit. Minutes spent in the different heart rate zones is monitored during the session (zone 1: 60-69%, zone 2: 70-74%, zone 3: 75-79%, zone 4: 80-84%, zone 5: \>85% of HRmax).
223764813|NCT02983071|DRUG|G1T38|
224318719|NCT01267487|DRUG|Heparin and protamine titration|"Titrated doses of heparin during CPB were manually calculated using Bull´s dose-response curve, which was based in periodic assessment of Activated-Coagulation Times (ACT)- baseline ACT, after 2mg/kg of heparin at cannulation and every 15 to 30 minutes during CPB.~Reversal doses of protamine were calculated as a 1:1 ratio of the actual estimated heparin concentration (in mg/kg) at the end of CPB, using the Bull´s dose response curve."
224318720|NCT03500380|DRUG|RC48-ADC|RC48-ADC 2.0 mg/kg IV every 14 days
223635769|NCT03733015|DEVICE|repetitive transcranial magnetic stimulation|Repetitive transcranial Magnetic Stimulation (rTMS) can be used to temporary modify the brain activity.
223635770|NCT06061796|PROCEDURE|prone position|"patient kept in prone position until the following criteria have been reach for 4 consecutive hours:~* ratio P/F \> 150 mm Hg~* FiO2 \< 60%~* PEEP ≤ 10 cm d'H2O"
223635771|NCT03104127|DEVICE|Alter G Bionic Leg|Participants are randomized to a 10 week, community-based bionic leg programme. Participants must use the leg for a minimum of 1 hour per day and continue to have active physical therapy sessions.
223635772|NCT03104127|OTHER|Normal therapy (physiotherapy)|Participants are randomized to a normal therapy (physiotherapy) only program. Participants are also advised to undertake 1 hour a day of physical activity and have active physical therapy (physiotherapy) sessions.
223635773|NCT05993858|DRUG|3cycles (Toripalimab + cetuximab)|"Toripalimab by intravenous (IV) infusion every 3 weeks (Q3W), 3 preoperative and 17 consolidated doses.~The preoperative starting dose of cetuximab is 400 mg/m\^2 by IV infusion over 120 minutes for 1 week, subsequently followed by 250 mg/m\^2 IV infusion over 60 minutes, from week 2 to 9."
223635774|NCT05993858|PROCEDURE|Surgery|After neoadjuvant therapy, patients would accept surgery within 11-13 weeks.
223635775|NCT05993858|RADIATION|Radiotherapy or chemoradiotherapy|Adjuvant radiotherapy was given 4 weeks after surgery. Patients with positive intraoperative pathological margins/extra lymph node envelope invasion are treated with an additional cisplatin synchronous chemotherapy.
223635776|NCT02604394|PROCEDURE|Rheolytic Thrombectomy|"RT will be performed with the The AngioJet rheolytic thrombectomy system (Medrad Interventional/Possis, Minneapolis, Minnesota).~The RT system includes three units: disposable catheter, disposable pump set and a reusable drive unit:~1. The single-use catheter has two lumens; one allows for the in-flow of high velocity saline jets through the catheter tip, and the other allows for the evacuation of thrombotic debris and passage of a guidewire.~2. The disposable pump connects to a bag of heparinized saline.~3. The drive unit pumps pressurized heparinized saline at 10,000 psi at the tip of the catheter,"
223635777|NCT02604394|PROCEDURE|Conventional PCI|In patients in the conventional PCI group, antegrade flow in the culprit vessel will be established with conventional PCI with preference of direct stenting and use of manual thrombus aspiration when deemed necessary by the operator.
223635778|NCT02372955|DRUG|dapagliflozin|subjects will be randomly assigned to receive dapagliflozin 10 mg daily
223635779|NCT02372955|DRUG|glimpiride|subjects will be randomly assigned to receive glimpiride 4 mg daily
223635780|NCT00649038|DRUG|Benazepril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg|20/25mg, single dose fed
223635781|NCT00649038|DRUG|Lotensin HCT® Tablets 20 mg/25 mg|20/25mg, single dose fed
223764814|NCT02983071|DRUG|Fulvestrant|
223764815|NCT06184750|PROCEDURE|Biopsy Procedure|Undergo biopsy
223635782|NCT03854175|DRUG|sildenafil citrate|25mg vaginally every 6 hours (a half of 50 mg tablet is crushed and dissolved in 2cc of distilled water and injected in to vagina) starting from day 2-14 of the cycle
223764816|NCT06184750|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
223764817|NCT06184750|PROCEDURE|Mammography|Undergo mammography
223764818|NCT06184750|OTHER|Questionnaire Administration|Ancillary studies
223764819|NCT06184750|DRUG|Tamoxifen|Given PO
223764820|NCT00015275|BEHAVIORAL|Cocaine-Related Disorders|
223764821|NCT05385939|OTHER|Observational|This was an observational study which involved collection of stool samples and environmental samples at 1 week and 4 weeks of life.
223764822|NCT03909009|DEVICE|rTMS + Neuronavigation|Repetitive Transcranial Magnetic Stimulation (Neuro-MS/D) + Neural Navigator
223764823|NCT04590885|BEHAVIORAL|Couple Communication Skills Training|Participants attend six 60-minute sessions consisting of education and skills training to enhance cancer-related communication.
223635783|NCT03854175|DRUG|Estradiol Valerate 2 MG|2mg 6-8 hourly from the day 2-14 of the cycle to prepare the endometrium
223635784|NCT06071247|OTHER|3D printed models|3D printed simulation models of the stomach, duodenum, common bile duct, and pancreatic duct structures using a combination of soft and hard materials
223635785|NCT00416910|BIOLOGICAL|Filgrastim|
223635786|NCT00416910|DRUG|Fludarabine|
223635787|NCT00416910|DRUG|Cyclophosphamide|
223635788|NCT00416910|DRUG|Mitoxantrone|
224224670|NCT04409366|OTHER|Conventional Crown Lengthening (CCL)|Using the surgical guide, submarginal internal bevel incisions were performed on the buccal aspect of the affected teeth. A full-thickness flap was raised up to the mucogingival junction (Dominguez et al., 2020). Ostectomy and osteoplasty were carried out by means of rotatory instruments and surgical chisels, as necessary, to achieve the necessary space between the bone crest and the restorative margin according to the presurgical plan. The CEJ was not the reference point since, in many cases, the position of the final margin of the restoration was planned apical to the actual position of the CEJ. Exposed root surfaces were carefully instrumented manually with curettes and, finally, vertical internal mattress sutures were placed to position the gingival margin at the level of the margin of the planned restoration. Sutures were removed after 7 days
224224671|NCT04409366|OTHER|Two-stage Crown Lengthening (SCL)|In the first surgical intervention, intrasulcular incisions were performed and a full thickness flap was raised up to the mucogingival junction. Ostectomy and osteoplasty were performed to establish the space for supracrestal tissue attachment, following the restorative plan and using the presurgical blueprint as the reference to determine the final position of the restoration margin, instead of the CEJ (Lee, 2004). Then the flaps were repositioned and secured with internal mattress sutures, placing the gingival margin at the original level. Sutures were removed at 7 days. In the second stage, after 3-4 months, minor gingival recontouring was performed, if necessary, to attain the desired gingival margin position according to the presurgical plan.
224224672|NCT05635825|OTHER|Observational Survey|Collection of a 4-day food record
224224673|NCT06187922|DRUG|Pregabalin 75mg|Group pregabalin will receive cap pregabalin 75mg as premedication and will continue as B.D dose for 72 Hrs.
224224674|NCT06187922|PROCEDURE|adductor canal block|Both group will receive ultrasound guided Adductor canal block with bupivacaine 0.2% 20-30ml and dexmedetomidine 1mcg/Kg
224224675|NCT00260325|DRUG|valdecoxib|
223514792|NCT06691503|PROCEDURE|mediastinoscopic-assisted transhiatal laparoscopic esophagectomy (MATLE)|mediastinoscopic-assisted transhiatal laparoscopic esophagectomy (MATLE)
223514793|NCT06687551|DRUG|Baricitinib (LY3009104) 4 mg|"Treatment with baricitinib 4 mg daily~* Step 1 (after randomization): baricitinib 2mg daily~* Step 2 (in case of CDAI≤ 10 AND CRP level below the laboratory standard; 6 months after starting step1): baricitinib 2mg every other day"
223514794|NCT06687551|DRUG|filgotinib 200mg/day|"Treatment with filgotinib 200 mg daily~* Step 1 (after randomisation): filgotinib 100 mg daily~* Step 2 (in case of CDAI≤ 10 AND CRP level below the laboratory standard; 6 months after starting step1): filgotinib 100mg every other day"
223514795|NCT06687551|DRUG|Tofacitinib 5 mg twice daily|"Treatment with tofacitinib 5 mg twice daily or tofacitinib 11mg daily~* Step 1 (after randomisation): tofacitinib 5 mg once daily~* Step 2 (in case of CDAI≤ 10 AND CRP level below the laboratory standard; 6 months after starting step1): tofacitinib 5 mg every other day"
223514796|NCT06687551|DRUG|Upadacitinib 15 MG|"Treatment with upadacitinib 15 mg daily~* Step 1 (after randomisation): upadacitinib 15 mg every other day~* Step 2 (in case of CDAI≤ 10 AND CRP level below the laboratory standard; 6 months after starting step1): upadacitinib 15 mg every 4 days"
223514797|NCT06687551|DRUG|Baricitinib (LY3009104) 4 mg|use of JAK inhibitor at full dose until the end of the protocol
223514798|NCT06687551|DRUG|filgotinib 200mg/day|use of JAK inhibitor at full dose until the end of the protocol
223514799|NCT06687551|DRUG|Tofacitinib 5 mg twice daily|use of JAK inhibitor at full dose until the end of the protocol
223514800|NCT06687551|DRUG|Upadacitinib 15 MG|use of JAK inhibitor at full dose until the end of the protocol
223514801|NCT06691802|DRUG|Shu Fei Tie|Optimize the extraction process and matrix formulation, and combine the use of traditional Chinese medicine volatile oil and chemical transdermal enhancers to develop adermal patch（Shu Fei Tie）
223514802|NCT06691802|DRUG|Shu Fei Tie placebo|Shu Fei Tie Placebos are made using substances without active drug ingredients, following the same preparation procedures
223514803|NCT06688812|OTHER|Perceptual Motor Training|"8 set of exercises~1. Balance training and related exercises~2. Tones of awareness training, body parts' role and related exercises~3. Space awareness training and related exercises~4. Perception of shape training and related exercises~5. Visual perception training and related exercise.~6. Kinesthetic-tactile perception training and related exercises~7. Auditory perception training and related exercises~8. Eye and hand coordination, ﬁne motor movements and related Exercises"
223514804|NCT06688812|OTHER|Repetitive Facilitation Exercises|"Eight set of exercises:~1. Shoulder Flexion with 90° Elbow Flexion (Supine).~2. Shoulder Horizontal Extension/Flexion with Elbow flexion (supine).~3. Complex Shoulder and Upper Limb Movements (Supine)~4. Shoulder Flexion/Abduction/External Rotation with Elbow and Forearm Supination (Supine)~5. Forearm Supination/Pronation with 90° Elbow Flexion (Sitting)~6. Wrist Extension and Forearm Pronation with Finger Extension (Supine)~7. Finger Extension with Wrist Flexion (Supine)~8. Finger Extension/Flexion with Wrist Flexion (Sitting) • Therapist facilitate the movement by rubbing, tapping and gentle stretching."
223635789|NCT01921309|DEVICE|Trinity CoC Total Hip System|total hip replacement with a ceramic femoral head which moves on a ceramic acetabular cup liner
223635790|NCT01921309|DEVICE|Trinity Ceramic-on-Poly THR|total hip replacement with a ceramic femoral head which moves on a highly cross-linked ultra high molecular weight polyethylene acetabular cup liner
223635791|NCT02948127|BIOLOGICAL|RSV LID cp ΔM2-2 Vaccine|10\^5 plaque-forming units (PFUs); administered as nose drops
223635792|NCT02948127|BIOLOGICAL|Placebo|Administered as nose drops
223635793|NCT00910650|BIOLOGICAL|F5 TCR transgenic cells and MART-1 peptide pulsed dendritic cells|After chemotherapy, patients receive up to 1 x 10(9) MART-1 F5 TCR transgenic T cells infused i.v., 1 x 10(7) MART-1 peptide pulsed dendritic cells intradermally, and low dose IL-2 500,000 IU/m2 s.c. twice daily for 14 days.
223764824|NCT04590885|BEHAVIORAL|Healthy Lifestyle Information|Participants attend attend six 60-minute sessions consisting of information and support across a range of cancer-related topics.
223635794|NCT00910650|DRUG|non-myeloablative conditioning chemotherapy|Patients receive non-myeloablative conditioning chemotherapy with Cyclophosphamide 60 mg/kg/day x 2 days and Fludarabine 25 mg/m2/day i.v. over 30 minutes for 4 days
223635795|NCT03367793|DEVICE|Spectacles - Clinically Derived|Prescription spectacle lenses determined by clinically derived techniques. The specific techniques employed for each subject are left up to the masked examiner and are dependent upon the information needed for refraction determination, as well as ability of the participant to cooperate for testing. Measures may include autorefraction obtained pre or post dilation, retinoscopy obtained pre or post dilation, and subjective refraction obtained pre or post dilation.
223635796|NCT03367793|DEVICE|Spectacles - Metric Technique #1 Derived|Prescription spectacle lenses determined by metric-derived objective technique #1. For this method, wavefront error will be measured with the COAS (complete ophthalmic analysis system) wavefront aberrometer post-dilation with the goal of obtaining 3 to 5 high quality captures per eye. Wavefront measures will be re-sized to the patient's habitual pupil diameter and averaged. Post-measurement analysis will then be performed using a computer algorithm to identify the refractive correction predicted to produce the best image quality, as measured by maximization of the image quality metric Visual Strehl ratio in the spatial domain (VSX). The refractive correction determined from this analysis will be produced in prescription spectacle lenses and dispensed to the patient as the Intervention: Spectacles - Metric Technique #1 Derived.
223635797|NCT03367793|DEVICE|Spectacles - Metric Technique #2 Derived|Prescription spectacle lenses determined by metric-derived objective technique #2. For this method, wavefront error will be measured with the COAS (complete ophthalmic analysis system) wavefront aberrometer post-dilation with the goal of obtaining 3 to 5 high quality captures per eye. Wavefront measures will be re-sized to the patient's habitual pupil diameter and averaged. Post-measurement analysis will then be performed using a computer algorithm to identify the refractive correction predicted to produce the best image quality, as measured by maximization of the image quality metric Pupil Fraction tessellated (PFSt). The refractive correction determined from this analysis will be produced in prescription spectacle lenses and dispensed to the patient as the Intervention: Spectacles - Metric Technique #2 Derived.
223635798|NCT00423579|DRUG|Ezetimibe/Simvastatin 10/20 mg|1 tablet containing 10 mg of ezetimibe and 20 mg of simvastatin per day for 6 weeks
223635799|NCT00423579|DRUG|simvastatin 40 mg|1 tablet containing 40 mg of simvastatin per day for 6 weeks
223635800|NCT05647317|OTHER|A combination of a provider-facing desktop and mobile application with a patient-facing mobile application|A combination of a provider-facing desktop and mobile application with a patient-facing mobile application that is integrated with a remote blood pressure cuff, heart rate monitor, and scale.
223635801|NCT02392637|DRUG|Cisplatin|Given IV
223635802|NCT02392637|DRUG|Gemcitabine Hydrochloride|Given IV
224224676|NCT04777630|DIAGNOSTIC_TEST|None, neuroimaging|Observation only to observe differences in neuroimaging
224224677|NCT02064426|DRUG|Molidustat (BAY85-3934)|Subjects will continue with the same treatment they were receiving in the parent study (16208). BAY85-3934 will be administered daily as oral tablets. Dose assessments will be made every 4 (± 1) weeks. At the scheduled visits, the dose may be titrated on an individualized basis taking into account the subject's Hb response and the tolerability of the previous dose. Total treatment time is up to 36 months. Planned doses include 15, 25, 50, 75, 100, and 150 mg once daily.
224224678|NCT02064426|BIOLOGICAL|Epoetin alfa/beta|Subjects will continue with the same treatment they were receiving in the parent study (16208). Epoetin alfa / beta will be administered as intravenous (IV) or subcutaneous (SC) injections per individual subject regimen according to the local label. Dose assessments will be made every 4 (± 1) weeks. At the scheduled visits,dose may be titrated on an individualized basis taking into account the subject's Hb response and the tolerability of the previous dose.Total treatment time is up to 36 months.
224224679|NCT03567057|DRUG|ADS-5102, 274 mg|Oral capsules
224224680|NCT01480856|PROCEDURE|Cobedding|Newborn twins are settled in a singe bed: this is cobedding
224224681|NCT01480856|PROCEDURE|Single-bedding|Newborn twins are settled in two single beds : this is single-bedding
224224682|NCT01745978|PROCEDURE|Precut papillotomy|
224224683|NCT04217278|DRUG|Vyxeos|Vyxeos administered by intravenous infusion
224224684|NCT04217278|DRUG|Fludarabine|Fludarabine administered by intravenous infusion
224224685|NCT04217278|DRUG|Busulphan|Busulphan administered by intravenous infusion
224224686|NCT04217278|DRUG|Thiotepa|Thiotepa administered by intravenous infusion
224224687|NCT04217278|DRUG|Cytarabine|Cytarabine administered by intravenous infusion
224224688|NCT01760278|DRUG|recombinant Follicle Stimulating Hormone (rFSH)|"There are two arms of the study. The Study arm and the Control arm. In each arm, subjects, after randomization, will be stimulated with rFSH 225IU/day.~On day 6, Cetrorelix 0.25mg/day to be added till the day of Ovitrell. Thereafter, ovum pick-up and embryo transfer to be done. Six weeks after transfer clinical pregnancy identified which will be the end-point of the study."
223514805|NCT06691373|OTHER|Static Stretching|"Static stretching of the quadriceps and hamstrings which was performed in the dominant limb, and held in a position where the participants referred discomfort:~* Quadriceps - participants were in the standing position, with one hand holding the back of a chair to maintain the balance, and were instructed to pull the ankle of the lower limb to be stretched, pressing the heel towards the buttocks and, at the same time, extending the thigh;~* Hamstrings - participants were also in the standing position, with the heel resting on a chair. They were then instructed to lean the body forward keeping the spine erect and the pelvis in anteversion, to obtain a stretch over the knee and hip."
223514806|NCT06689644|DIETARY_SUPPLEMENT|Nootropics (ginkgo biloba, nicergoline, piracetam, or others)|Commercially available product: Mind lab pro
223514807|NCT06689644|DIETARY_SUPPLEMENT|Placebo|A cellulose commonly used as a bulking agent in supplement products
223514808|NCT06689644|BEHAVIORAL|Perceptual decision-making performance|A computerised cognitive task involving rapid visual categorisation of images
224224689|NCT01159327|DRUG|Sorafenib|Sorafenib 400mg, bid(800mg/day), daily, PO
224224690|NCT02320474|DRUG|Aflibercept|
224224691|NCT00708331|DEVICE|2 HEMA Hydrophilic Acrylic Intraocular Lens|2 HEMA Hydrophilic Acrylic Intraocular Lens implanted into the posterior capsule following cataract surgery for patient life duration.
224318721|NCT03500380|DRUG|Lapatinib|Lapatinib 1250 mg orally once daily during each 21-day cycle.
224318722|NCT03500380|DRUG|Capecitabine|Capecitabine 2000 mg/m\^2 orally daily on Days 1-14 of each 21-day treatment cycle.
224318723|NCT04274712|DIAGNOSTIC_TEST|INNOGRAFT Heart Suite|Liquid biopsy to identify acute rejection
224318724|NCT02234492|DRUG|Rosuvastatin|Comparison of rosuvastatin to no rosuvastatin
224318725|NCT06327152|DRUG|Caffeine|"Infants randomized to receive caffeine will continue to receive caffeine at the current weight-based dose (which is the standard of care maintenance dose of 10-15 mg/kg/day) given every 24 hours. The weight-based dose calculated using the weight at the time of enrollment will be the weight-based dose used for the duration of the study. The dose will be weight adjusted every 7 days, starting on the day of enrollment. Caffeine will be given enterally, via nasogastric tube or by mouth.~The study drug (caffeine) will be administered for a maximum of 4 weeks. The study drug will be discontinued after 4 weeks or when the infant reaches Step 4 of our institution's oral feeding protocol (oral feeding 6 times per day), whichever comes first. The study drug will also be discontinued if the open-label maintenance caffeine is started by the clinical team based on clinical indications."
224318726|NCT06327152|OTHER|Sterile Water Placebo|"Infants randomized to the placebo group will be given sterile water at an equivalent volume to the volume if caffeine were to be given, using the previous weight-based caffeine dose. The placebo will be given every 24 hours. The dose/volume will be weight adjusted every 7 days, starting on the day of enrollment. The placebo will be given enterally, via nasogastric tube or by mouth.~The placebo will be administered for a maximum of 4 weeks. The placebo will be discontinued after 4 weeks or when the infant reaches Step 4 of our institution's oral feeding protocol (oral feeding 6 times per day), whichever comes first. The placebo will also be discontinued if the open-label maintenance caffeine is started by the clinical team based on clinical indications."
224318727|NCT02425566|DRUG|Trimethaphan|Trimethaphan is a Nn-nicotinic receptor antagonist that blocks sympathetic and parasympathetic transmission at the level of the autonomic ganglia. It will be administered as an acute intravenous infusion with doses ranging from 0.5 to 5.0 mg/min.
223635803|NCT02392637|OTHER|Laboratory Biomarker Analysis|Correlative studies
224224692|NCT06143735|DRUG|Efgbemalenograstim alfa|Efbemalenograstim alfa Injection is a recombinant fusion protein composed of the double molecules of human granulocyte colony-stimulating factor (G-CSF) and the Fc fragment of human immunoglobulin (hIgG2). It is used for adult patients with non-myeloid malignancies undergoing myelosuppressive anticancer therapy that is associated with a high risk of febrile neutropenia, to reduce the incidence of infections manifested by febrile neutropenia.
224224693|NCT02131896|OTHER|Interventional arm-Mediterranean diet|
224224694|NCT02131896|OTHER|Control Arm- regular nutritional instructions in accordance with the accepted nutritional guidelines|
224224695|NCT02801058|OTHER|Osteopathic manipulative treatment|Osteopathic manipulative techniques on thoracic diaphragm
223514809|NCT06689644|DEVICE|Electroencephalography|Brain signals are recorded from a 64 channel EEG system during the cognitive task
223514810|NCT06690762|OTHER|Education|It consists of nutrition, physical activity, stress management, relaxation exercises and defecation training.
223514811|NCT06689982|DRUG|Tofacitinib tablets|All patients should be closely monitored for signs and symptoms of infection during and after treatment with tofacitinib tablets. If a patient develops a severe infection, opportunistic infection, or sepsis, medication should be discontinued. During treatment, patients with lymphocyte counts \< 500 cells/mm\^3 or ANC \< 500 cells/mm\^3 confirmed by repeated testing should be stopped. When 500≤ANC≤1000 cells/mm\^3, administration should be interrupted, and if ANC returns to more than 1000 cells/mm\^3, administration should be resumed. When hemoglobin \< 8 g/dL or decreases by more than 2 g/dL, administration should be interrupted until hemoglobin values return to normal.
224224696|NCT04811261|DRUG|Intravenous Infusion of UCLSCs|The first 3 subjects will be administered 50 x 10\^6 ULSCs reconstituted in PBS with 1% human serum albumin in a volume of 250 ml, and monitored for adverse events or toxicities, immediately following dosing, and again at 30 days.
224224697|NCT00490061|DRUG|Lapatinib|1500 mg po daily orally
224224698|NCT00490061|PROCEDURE|Radiotherapy (radiation)|Standard of Care
224224699|NCT00490061|DEVICE|G.E. Healthcare 1.5T MR, systems revision 12.0 M5|Standard of Care, used to deliver IMRT
224224700|NCT00490061|DEVICE|DCE-MRI|A subset of patients received imaging before and after Lapatinib loading, prior to starting radiotherapy.
224224701|NCT01433835|DRUG|MBX-400|Capsule(s) for oral administration as a single dose. Planned doses include: 35, 100, 350, 700, 1000 and 1350 mg.
224224702|NCT01433835|OTHER|Placebo|Capsule(s) for oral administration as a single dose. Planned doses include: 35, 100, 350, 700, 1000 and 1350 mg.
224224703|NCT00735683|DRUG|ATHX-105 phosphate|includes diet, physical activity, and lifestyle modification
224318728|NCT02425566|DRUG|Nitroglycerin|Sublingual nitroglycerin (0.3-0.6 mg) will be given after baseline measurements.
223514812|NCT06689865|DEVICE|HA-HCP|Prescription hearing aid fit by a hearing healthcare professional using audiology best practices.
223514813|NCT06689865|DEVICE|OTC-HCP|Over-the-counter hearing aids fit by a hearing care professional using audiology best practices.
223514814|NCT06689865|DEVICE|OTC-R|OTC fit to an individual using some best practices via remote consultation.
223514815|NCT06689865|DEVICE|OTC-SF|Self-fit OTC hearing aids without any clinical support from HCPs.
223514816|NCT06688500|PROCEDURE|Bowel function post Holmium Laser Enucleation of the Prostate|Observing post operative bowel functions among participants who have undergone a HoLEP procedure.
223514817|NCT06687317|OTHER|Behavioral|KNAP
223514818|NCT06690580|OTHER|Motivational interviewing based on the knowledge motivation behavior skills model|Breastfeeding education that includes motivational interviews based on the knowledge motivation behavior skills model
223514819|NCT06691542|DRUG|platelet-rich plasma|platelet-rich plasma, metformin and cryotherapy in treatment of non-genital warts
223514820|NCT06691542|DRUG|Metformin|platelet-rich plasma, metformin and cryotherapy in treatment of non-genital warts
223514821|NCT06691542|OTHER|cryotherapy|platelet-rich plasma, metformin and cryotherapy in treatment of non-genital warts
223635804|NCT02392637|DRUG|Nab-paclitaxel|Given IV
223635805|NCT03763838|OTHER|Acupressure|Six weeks of daily self-administered relaxing acupressure. Instructions will be provided for how to perform acupressure on self. A tool (AcuWand) will be provided to help participants apply the right amount of pressure on the appropriate points on their bodies. These are points that are recognized as effective in Traditional Chinese Medicine (TCM).
223635806|NCT03763838|OTHER|Sham acupressure|Six weeks of daily self-administered sham acupressure. Instructions will be provided for how to perform acupressure on self. A tool (AcuWand) will be provided to help participants apply the right amount of pressure; however, the points that participants are instructed to use are not known to have any effect on the body.
223635807|NCT03763838|OTHER|Standard of Care|Fatigue management provided by participants' health care providers.
223635808|NCT01875796|BEHAVIORAL|Cognitive-Behavioral Therapy|
223635809|NCT01875796|BEHAVIORAL|Motivation Enhancement Therapy|
223635810|NCT01875796|BEHAVIORAL|Integrated Cannabis and Anxiety Reduction Treatment|
223635811|NCT01875796|BEHAVIORAL|False Safety Behavior Elimination Therapy|
223635812|NCT01048619|DRUG|ON 01910.Na|In Part I, the bioavailability and tolerability of ON 01910.Na as single, oral, escalating doses in a fasting state (defined as no less than 30 min before next meal) is studied. Three patients get 70mg dose the 1st week. In the absence of drug-related grade 2 toxicity or higher, doses will escalate in each patient weekly (wk) to 140mg (wk 2), 280mg (wk 3), 560mg (wk 4) and 700mg (wk 5). At end of Part I all patients will be eligible for Part II. Part II proceeds if drug is measured in plasma and DLT not observed at 70mg dose in Part I. The maximum tolerated dose of oral ON 01910.Na administered in a fasting state (defined as no less than 30 min before next meal) twice a day for 14 days will be determined following an adaptive design at doses between 70 and 700mg.
223635813|NCT03367663|DRUG|Prednisone 20 Mg|Each participant will be randomly assigned to one of two treatment groups, low dose of Prednisone 20mg/d (n=10) and high dose of Prednisone 40 mg/d (n=10). During the experimental periods, the subjects will take either one or two 20mg tablet of Prednisone, according to their assigned group. Subjects will be instructed to take the tablets at home in the mornings after a meal each day for 5 consecutive days. At the baseline visit, a medical history will be documented and a physical examination will be performed. Subjects will be asked to come to the research unit on days 1,2,5 after a 14h fasting where two blood samples (5ml each) will be taken, immediately centrifuged, one for biochemical analysis (Lipid profile, Liver function tests, Glucose, Electrolytes and Renal function tests) and the second will be aliquoted, and stored at -20°C until later analyses.
224318729|NCT01550029|BEHAVIORAL|Counseling/Healthy Lifestyle|"A trained counselor will meet with subjects for approximately 60 minutes each week during the 12-week treatment period to provide support for quitting and to help develop knowledge and skills for quitting. Also, the National Cancer Institute's Clearing the Air guide to smoking cessation will be given to subjects. Some specific areas of focus for this intervention are developing a better understanding of reasons for smoking and the consequences of tobacco use and identifying ways for establishing a healthier lifestyle."
224318730|NCT01550029|BEHAVIORAL|Counseling/Managing Mood|"A trained counselor will meet with subjects for approximately 60 minutes each week during the 12-week treatment period to provide support for quitting smoking and to help develop knowledge and skills for quitting. Also, subjects will receive the National Cancer Institute's Clearing the Air guide to smoking cessation. Some specific areas of focus for this intervention are managing negative moods without smoking and overcoming other obstacles to quitting."
224318731|NCT00802932|DEVICE|Non-contrast Computed Tomography (CT) Scans (Metallic Markers)|Non-contrast CT Scans prior to start of radiation therapy, and during weeks 2, 4, 6.
223635814|NCT03367663|DRUG|Prednisone 40 Mg|Each participant will be randomly assigned to one of two treatment groups, low dose of Prednisone 20mg/d (n=10) and high dose of Prednisone 40 mg/d (n=10). During the experimental periods, the subjects will take either one or two 20mg tablet of Prednisone, according to their assigned group. Subjects will be instructed to take the tablets at home in the mornings after a meal each day for 5 consecutive days. At the baseline visit, a medical history will be documented and a physical examination will be performed. Subjects will be asked to come to the research unit on days 1,2,5 after a 14h fasting where two blood samples (5ml each) will be taken, immediately centrifuged, one for biochemical analysis (Lipid profile, Liver function tests, Glucose, Electrolytes and Renal function tests) and the second will be aliquoted, and stored at -20°C until later analyses.
223635815|NCT02835378|OTHER|No intervention|
223635816|NCT05281302|DEVICE|Neck muscle vibration|Patient will receive neck muscle vibration during the first 15 minutes of occupational therapy. Vibratory stimulators will be fixed bilaterally on the skin over the belly of the trapezius muscles and fastened with straps. Only the left vibrator will be activated.
224318732|NCT00802932|DEVICE|Non-contrast CT Scans (Metallic Markers)|Non-contrast CT Scans prior to start of radiation therapy and on Day 5.
223635817|NCT05281302|DEVICE|Neck muscle vibration + sham-tDCS|"Patient will receive neck muscle vibration during the first 15 minutes of occupational therapy.. Vibratory stimulators will be fixed bilaterally on the skin over the belly of the trapezius muscles and fastened with straps. Only the left vibrator will be activated.~Moreover, tDCS will be applied using an electrical stimulator (DC-STIMULATOR®, NeuroCare, Illmenau, Germany) through large saline-soaked sponge surface electrodes placed as follows: anode over the right (ipsilesional) posterior parietal cortex (P4 according to the International 10-20 EEG electrode placement system) and cathode over the left supraorbital region. The tDCS will be automatically turned off after 20 seconds. This allows the reproduction of the initial mild itching sensation at the beginning of active tDCS, thus ensuring that the patient stays blind to the activation status of the device."
223764825|NCT06168526|BEHAVIORAL|Acute physical activity|Regarding the first aim, participants will go through five different conditions using a within-participants cross-over design in a randomized order: control group (quietly sitting), light intensity (40% VO2max), moderate intensity (63% VO2max), or vigorous intensity (100% VO2max) exercise. All conditions will last 16 minutes and 15 seconds. The exercise conditions will be organized following an interval protocol, which includes 22 bouts of 30 seconds running at the established intensity with 15 seconds of passive rest between bouts. In addition, to achieve the second aim, the active break will be designed taking into account the intensity of physical activity that proves to have the greatest benefits on cognition and well-being.
224318733|NCT07134842|BIOLOGICAL|Ipilimumab (3 mg/kg)|All participants will be treated with ipilimumab (3mg/kg) for up to 2 cycles. Each cycle will last 21 days with participants receiving ipilimumab on the 1st day of the cycle.
224318734|NCT07133997|DRUG|Asparaginase Erwinia chrysanthemi|Given IM
223635818|NCT05281302|DEVICE|Neck muscle vibration + anodal-tDCS|"Patient will receive neck muscle vibration during the first 15 minutes of occupational therapy. Vibratory stimulators will be fixed bilaterally on the skin over the belly of the trapezius muscles and fastened with straps. Only the left vibrator will be activated.~Moreover, tDCS will be applied using an electrical stimulator (DC-STIMULATOR®, NeuroCare, Illmenau, Germany) through large saline-soaked sponge surface electrodes placed as follows: anode over the right (ipsilesional) posterior parietal cortex (P4 according to the International 10-20 EEG electrode placement system) and cathode over the left supraorbital region. A continuous 2 mA current will be delivered for 20 minutes simultaneously to NMV stimulation. The stimulation will begin 5 minutes before the beginning of occupational therapy."
223635819|NCT03013231|BEHAVIORAL|Brief Resilience Scale|6 months post-op, patients will complete the BRS survey as a method of evaluating resilience.
223635820|NCT00427453|BIOLOGICAL|MVA85A|
223635821|NCT02192489|DRUG|CC-220 0.3 mg Daily|
223635822|NCT02192489|DRUG|CC-220 0.6mg Daily|
223635823|NCT02192489|DRUG|Placebo|
223635824|NCT01412502|OTHER|IES-R and HDAS scores|The Impact of Event Scale and Hospital Depression and Anxiety Score questionnaires are administered to participants.
223635825|NCT02660151|DEVICE|Hyper-CL™ lens|
223635826|NCT02660151|DEVICE|Regular soft contact lens|
223635827|NCT02660151|DRUG|Salt solution|
223635828|NCT03279744|DRUG|Radion™-pdt|The Radion™-pdt will be applied topically to the lesion. The Radion™-pdt applied dosage is about 0.1 mL/cm\^2 and properly cover the entire lesion.
224224704|NCT00735683|DRUG|Placebo|includes diet, physical activity, and lifestyle modification
224224705|NCT03931083|DIAGNOSTIC_TEST|Screening for CIN2+/HSIL|The investigators will compare three different screening methods: visual assessment with portable magnification device , visual inspection after application of acetic acid, screening for high risk variants of HPV. All patients will receive cervical biopsies and histopathological examination.
224224706|NCT00631111|DRUG|effervescent ibuprofen tablets|
224224707|NCT00631111|DRUG|effervescent Aspirin plus Vitamin C tablets|
224224708|NCT00631111|DRUG|ibuprofen tablets|
224224709|NCT00631111|DRUG|placebo|
223635829|NCT01577992|DRUG|Levodopa test|Each patients with PD and MSA will be evaluated in two conditions : OFF (without dopaminergic treatment since 12h) and ON condition (after a L-DOPA dose. This dose will be 150% of the DOPA morning dose. The healthy volunteers will be evaluated in only one condition (without L-DOPA administration)
223635830|NCT01577992|PROCEDURE|determination of objective and subjective pain threshold|Test without levodopa intake
223635831|NCT06387693|DIAGNOSTIC_TEST|Holter monitoring, intracoronary ECG|Holter monitoring device to track ECG abnormalities during spontaneous chest pain in the outpatient setting. Intracoronary ECG to evaluate perprocedural ECG responses
223635832|NCT04976400|PROCEDURE|semi-individualized total knee replacement treatment with a gender-specific design|Patients in the experimental group received a semi-individualized total knee replacement treatment with a gender-specific design.
223635833|NCT04976400|PROCEDURE|Zimmer total knee replacement prostheses (Zimmer, Warsaw, IN, USA)|Patients in the control group received imported Zimmer total knee replacement prostheses (Zimmer, Warsaw, IN, USA).
223635834|NCT05182593|OTHER|Diet moderate/high in FODMAPs|The subjects will obtain meal boxes prepared in the hospital kitchen with a moderately high FODMAP content (23 grams/day)
224224710|NCT00843453|OTHER|blood collection|blood collection
224224711|NCT00843453|DRUG|treatment (cyanocobalamin nasal spray)|cyanocobalamin nasal spray -- 500 mcg q week for eight weeks
224224712|NCT06364605|DEVICE|Rehabilitation with the iReach novel multisensory medical device|From the results of Phases 1,2 and 3, in Phase 4 a medical device for spatial and sensorimotor rehabilitation in infants aged 3 to 36 months will be tested and developed.
224318735|NCT07133997|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223635835|NCT05182593|OTHER|Diet low in FODMAPs|The subjects will obtain meal boxes prepared in the hospital kitchen with a low FODMAP content (\<5 grams/day)
223635836|NCT05900596|DIAGNOSTIC_TEST|Fetal blood sampling|Fetal scalp blood sampling and analysis
223635837|NCT00240513|DRUG|Minocycline|100 mg capsules OD for 3 months
223635838|NCT00240513|DRUG|Minocycline plus tretinoin|100mg OD Minocycline for 12 weeks plus OD Topical tretinoin 0.01% for 12 weeks Followed by topical tretinoin 0.01% OD for 12 weeks alone
223635839|NCT00597220|DIETARY_SUPPLEMENT|Omega 3 (n-3 PUFA)|1 gram of n-3 PUFA containing DHA and EPA
223635840|NCT00597220|DRUG|Placebo|Placebo
223635841|NCT00106704|DRUG|Comparator: Sitagliptin|sitagliptin 10 mg tablet, once daily for 54 weeks
223635842|NCT00106704|DRUG|Comparator: Placebo|Placebo oral tablet once daily for 24 weeks
223635843|NCT00106704|DRUG|Comparator: Pioglitazone|Pioglitazone 30 mg tablet once daily for 30 weeks
223635844|NCT04591613|OTHER|Questionnaire|Quality of life and chronic disease impact scales will be completed at inclusion and follow-up visits.
223764826|NCT05658562|DRUG|MT-2111|i.v. infusion
224224713|NCT01155583|DRUG|azacitidine|Given by subcutaneous injection (SC)
224224714|NCT01155583|DRUG|lenalidomide|Given orally
224224715|NCT01155583|DRUG|dexamethasone|Given orally
224224716|NCT01155583|OTHER|DNA methylation analysis|Correlative studies
224224717|NCT01155583|OTHER|gene expression analysis|Correlative studies
224224718|NCT01155583|OTHER|bone marrow aspiration|Correlative studies
224224719|NCT01155583|OTHER|immunohistochemistry staining method|Correlative studies
224224720|NCT01155583|OTHER|reverse transcriptase-polymerase chain reaction|Correlative studies
224224721|NCT01155583|OTHER|flow cytometry|Correlative studies
224224722|NCT00471835|PROCEDURE|computed tomography|
224224723|NCT00471835|PROCEDURE|positron emission tomography|
224224724|NCT00471835|RADIATION|stereotactic body radiation therapy|
224224725|NCT03179618|DRUG|Anti-Platelet Drugs|Including aspirin and clopidogrel, etc.
224224726|NCT03179618|DRUG|Lipid Regulating Drugs|Mainly including statins
224224727|NCT03179618|DRUG|Coronary Vasodilator|Mainly including nitrates
224224728|NCT03179618|DRUG|Xuefu Zhuyu Decoction|Mainly including Peach Kernel, Safflower, Angelica, Bupleurum etc.
224224729|NCT02641613|PROCEDURE|retroclavicular block|retroclavicular block for forearm or hand surgery
223635845|NCT04591613|OTHER|Biocollection|Total serum, plasma samples will be collected
223635846|NCT04591613|OTHER|Follow-up visit|All patients will make an inclusion visit (IV), then a clinical follow-up will be organized for the study at M4, M6, M12 from the day of the onset of the 1st symptoms of COVID.
224224730|NCT02641613|PROCEDURE|supraclavicular block|supraclavicular block for forearm or hand surgery
224224731|NCT03316313|DIAGNOSTIC_TEST|Hepatitis C Antibody|Patients who received a blood test to screen for the Hepatitis C virus.
224224732|NCT05085613|BEHAVIORAL|Corrective message framing and humor|The main content of the messages will be the same. Experimental conditions (arms 2-4) will additionally include consequent framing as a result of getting vaccinated (e.g. economic recovery for arm 2 and freedom for arm 3) and humor for arm 4. Participants will be randomized to view one of the four messages.
224224733|NCT02242513|DEVICE|Pulsed radiofrequency (PRF)|Pulsed radiofrequency (PRF) treatment, a relative novel pain intervention at recent decade, was found to be able to alleviate pain by delivering an electrical field and heat bursts at a temperature less than 42°C to neural tissue in the absence of neural injury.
224224734|NCT02242513|DRUG|Xylocaine|
224224735|NCT00952484|BIOLOGICAL|asfotase alfa|2 mg/kg subcutaneous injection three times per week for 6 months.
224224736|NCT00952484|BIOLOGICAL|asfotase alfa|3 mg/kg subcutaneous injection three times per week for 6 months.
224224737|NCT01638702|OTHER|Follow up of complications|Follow up for complications leading or not to removal (occlusion, accidental removal, infection, catheter related thrombosis, leaking, pain...)
224224738|NCT04852536|DEVICE|Neurostimulation (High Definition - transcranial Direct Current Stimulation) HD-tDCS|5 consecutive sessions lasting 20 minutes of HD-tDCS4x1, based on previous publications (VILLAMAR et al., 2013). A list will be provided current of 2 mA, placing a central electrode (anode) on the M1 contralateral to the painful limb and the four return electrodes within a radius of 7.5 cm around, corresponding approximately to Cz, F3, T7 and P3 if the stimulation is on the side left, and Cz, F4, T8 and P4 if it is on the right, according to the International 10/20 System.
224318736|NCT07133997|BIOLOGICAL|Blinatumomab|Given CIV
223635847|NCT01107054|DRUG|PF-00610355|An orally inhaled dose of PF-00610355 450 µg on days 1 to 4
223635848|NCT01107054|DRUG|PF-00610355|An orally inhaled dose of PF-00610355 1200 µg on days 1 to 4
223635849|NCT01107054|DRUG|moxifloxacin|A single oral dose of moxifloxacin 400 mg on Day 4.
223635850|NCT01107054|DRUG|placebo|A single oral dose of non-matched placebo on Day 4.
223635851|NCT00003153|BIOLOGICAL|therapeutic allogeneic lymphocytes|
223635852|NCT01574729|DRUG|Surgery combined with rAd-p53 gene therapy|Surgery combined with rAd-p53 gene therapy during surgery plus post-surgery chemotherapy
223635853|NCT01574729|PROCEDURE|Surgery|Surgery plus post-surgery chemotherapy
223635854|NCT02224560|DRUG|GWP42003-P|GWP42003-P was presented as an oral solution containing 100 mg/milliliter (mL) cannabidiol (CBD) in the excipients sesame oil and anhydrous ethanol (79 mg/mL) with added sweetener (0.5 mg/mL sucralose) and strawberry flavoring (0.2 mg/mL). Participants were randomly assigned to receive either 10 or 20 mg/kg/day.
223635855|NCT02224560|DRUG|Placebo control|Placebo was presented as an oral solution containing 0 mg/mL CBD in the excipients sesame oil and anhydrous ethanol (79 mg/mL) with added sweetener (0.5 mg/mL sucralose) and strawberry flavoring (0.2 mg/mL).
223635856|NCT01161277|DRUG|Aripiprazole|Dose: 5-10 mg depending on subject weight
223635857|NCT01161277|DRUG|Haloperidol|Dose: 1-2 mg depending on subject weight
223635858|NCT01161277|DRUG|Placebo sugar pill|Dose: 1-2 pills depending on subject weight
223635859|NCT02481674|DRUG|VX15/2503|VX15/2503 (pepinemab) is a humanized IgG4 monoclonal antibody and will be administered intravenously at a dose of 20 mg/kg. The antibody is formulated at 20 mg/mL in 20 mM Sodium Acetate buffer, pH 5.4, containing 130 mM Sodium Chloride and 0.02% Polysorbate 80.
223635860|NCT02481674|DRUG|Placebo|Placebo consists of formulation buffer only which is 20 mM Sodium Acetate buffer, pH 5.4, containing 130 mM Sodium Chloride and 0.02% Polysorbate 80.
224224739|NCT00927459|DRUG|PRO-040201|Single dose IV infusion
224224740|NCT00927459|DRUG|Placebo|placebo
224224741|NCT06188390|PROCEDURE|Ultrasound guided median nerve hydrodissection injection with Hyaluronic acid|Hyaluronic acid was injected under ultrasound guidance around median nerve at the wrist
224224742|NCT06188390|PROCEDURE|Ultrasound guided median nerve hydrodissection injection with Dextrose water|Dextrose water was injected under ultrasound guidance around median nerve at the wrist
224224743|NCT04402749|OTHER|Nephrectomy|Patients underwent nephrectomy
224224744|NCT02916979|DRUG|Fludarabine|Fludarabine: 30 mg/m2 daily for 5 days
224224745|NCT02916979|DRUG|Busulfan|Busulfan: 100 mg/m2 daily for 4 days
224224746|NCT02916979|BIOLOGICAL|Rabbit ATG|"Rabbit ATG:~Related donors: 1.5 mg/kg daily x 2 days (on days -6 and -5) Unrelated donors: 1.5 mg/kg on day - 6 2 mg/kg on day -5 2.5 mg/kg on day -4"
224224747|NCT02916979|DRUG|Methotrexate|"Methotrexate:~Related donors: 5 mg/m2 on days 1, 3 and 6 Unrelated donors: 5 mg/m2 on days 1, 3, 6 and 11"
224224748|NCT00734864|DRUG|enzyme-inducing anti-epileptic drugs|Subjects taking EIAEDs (CYP3A enzyme-inducing anti-epileptic drugs Phenytoin/Dilantin, Fosphenytoin/Cerebyx, Phenobarbital, Primidone/Mysoline, Oxcarbazepine/Trileptal, Carbamazepine/Tegretol).
224224749|NCT00734864|DRUG|enzyme-inducing anti-epileptic drugs|Subjects NOT taking EIAEDs (CYP-3A enzyme-inducing anti-epileptic drugs Phenytoin/Dilantin, Fosphenytoin/Cerebyx, Phenobarbital, Primidone/Mysoline, Oxcarbazepine/Trileptal, Carbamazepine/Tegretol).
224224750|NCT01375933|BIOLOGICAL|NicVAX Vaccine|NicVAX Vaccine given 6 times over 6 months
224224751|NCT00621179|DRUG|Leuprolide acetate in depot suspension|Leuprolide acetate in depot suspension 3.75 mg intramuscularly every 28 days x 3
224224752|NCT00621179|OTHER|No intervention|
224224753|NCT03672500|DRUG|Bupivacaine 0.5%+Epinephrine 50mc|Local infiltration of the perineum with Bupivacaine 0.5%+Epinephrine 50mc
224224754|NCT03672500|OTHER|Sham injection|Sham injection of the perineum
224224755|NCT02988752|DEVICE|Electronic Mobile Device|Measure C/D Ratio With An Equipment Attached To A Ophthalmoscope That Will Determine C/D Ratio Without Touching Patient's Eyes. To Perform It We Need Mydriatic Conditions.
224318737|NCT07133997|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration and biopsy
224318738|NCT07133997|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow aspiration and biopsy
223635861|NCT06002880|DEVICE|Optibond Universal|OBU™ will be used used for the cementation of indirect restorations (ceramic restorations, composite, zirconia and metal crowns) and pretreatment for indirect restoration, according to manufacturer's Instruction For Use in self-etch and total-etch modes.
223635862|NCT03691376|BIOLOGICAL|Aldesleukin|Given SC
223635863|NCT03691376|BIOLOGICAL|Autologous NY-ESO-1-specific CD8-positive T Lymphocytes|Given IV
224224756|NCT02988752|DEVICE|Optical Coherence Tomography|Measure C/D Ratio With OCT, Considered Gold Standard Equipment
224224757|NCT00192699|DEVICE|Bimetric femoral stem|Cemented Bi-Metric femoral stem
224224758|NCT01413399|DRUG|4 degree chilled saline|4 degree chilled saline up to 2L in the prehospital setting
224224759|NCT01292200|BEHAVIORAL|watch DVD and small group discussion|Women in the small-group discussion mode will be called by their community educators to determine possible dates, times, and places for group meetings. The small group sessions will be conducted near the participants' homes. Each small-group will consist of 5-10 participants who will first view a 20-minute video together and then discuss the content of the video as well as their barriers to screening for about 30 minutes. A community educator and an RA at the study site will facilitate the discussion in Chinese languages according to a structured guide.
224224760|NCT01292200|BEHAVIORAL|watch DVD|Women in the single video mode will receive a cultural video along with an information sheet on local free and low-cost screening programs by mail.
224224761|NCT02246842|BIOLOGICAL|D-Gam® (human anti-D immunoglobulin)|
224224762|NCT02246842|BIOLOGICAL|Rhophylac® (human anti-D immunoglobulin)|
224224763|NCT04615442|DEVICE|Epihunter|Subjects wear epihunter during routine video EEG
224224764|NCT00886483|DEVICE|Active Neurofeedback|A comparison of active neurofeedback to sham neurofeedback and of two treatment schedules: twice weekly vs. three times a week, with the same amount of total treatment over 40 sessions, varying only in frequency.
224224765|NCT00886483|DEVICE|Sham neurofeedback|Active neurofeedback vs. sham neurofeedback for 40 treatments, either twice or three times per week.
224224766|NCT00650156|BIOLOGICAL|adalimumab|40 mg single sc dose
224224767|NCT00650156|BIOLOGICAL|adalimumab|80 mg single sc dose
224224768|NCT02160197|DEVICE|Aircast XP Walker boot|Ankle boot allowing weight bearing as tolerated
224224769|NCT02160197|DEVICE|Plaster Immobilisation|Plaster immobilisation with no weight bearing allowed.
224224770|NCT05233683|DRUG|Caudal block|Caudal block will be performed in lateral position with 0.25% bupivacaine in the dose of 0.75 ml/kg containing 1 mic/kg dexmedetomidine. The patients will be turned back to the supine position after the block placement and the head of the patient will be placed in the neutral position. Paracetamol suppository will also be inserted per rectum in the dose of 15 mg/kg before the start of surgery. The surgery will be started 10 minutes after block placement to allow adequate time for the block to be effective.
224224771|NCT05233683|DRUG|Dorsal penile nerve block plus ring block|"It will be performed with the child in the supine position. Following skin preparation and palpation of the arch of the lower border of the symphysis pubis, the base of the penis will be gently pulled down, and a 25-G needle will be inserted at 10 and 2.0 O clock position to a depth of 0.25-0.5 cm (under Bucks' fascia) and 1 ml + 0.1ml X weight of the patient) of local anesthetic (0.25% bupivacaine) will be injected at each point after negative aspiration and then RB will be done in the form of a circumferential subcutaneous ring at the level of the base of the penis. Paracetamol suppository will also be inserted per rectum in the dose of 15 mg/kg before the start of surgery. The surgery will be started 10 minutes after block placement to allow adequate time for the block to be effective."
223635864|NCT03691376|OTHER|Cellular Therapy|Given autologous NY-ESO-1 CD4-TCR CD34+ HSC IV
224224772|NCT05233683|PROCEDURE|Circumcision with Plastibell|Circumcision with Plastibell
223635865|NCT03691376|DRUG|Melphalan|Given IV
223635866|NCT05521607|DEVICE|Picterus Jaundice Pro (JP)|Use Picterus Jaundice Pro, a smartphone app that is used to take photo of the newborns skin, where the Picterus calibration card is place.
223635867|NCT06300697|OTHER|Data and biospecimen collection|Enrolled participants will have health-related information and blood specimens collected.
223635868|NCT06300697|OTHER|Skin biopsies|Participants will be asked to provide one or two skin biopsies (days 1 and 2) from the forearm, unless the participant is a healthy child (no food allergy and no atopic dermatitis), in which case there will be no skin biopsy.
223764827|NCT00006279|DRUG|Nevirapine|
223764828|NCT05063396|PROCEDURE|opioid free anesthesia|Instead of use of large amount of opioids for intraoperative stress response and postoperative pain controlling, during the whole perioperative period patients received no opioid at all. intravenous local anesthetics and thoracic epidural were used.
224224773|NCT05233683|PROCEDURE|Conventional Dissection Method|Conventional Dissection Method
224224774|NCT00548977|OTHER|Drawing blood to study genetic polymorphism|
224224775|NCT01982383|DEVICE|Micropulse Laser Treatment|
224224776|NCT01982383|OTHER|No treatment|
224224777|NCT04347447|OTHER|Exercise training|All groups will complete a supervised 12-week resistance training protocol, 3 days per week.
224224778|NCT01725477|DRUG|methylen blue &normal saline|Washing after dye injection
224224779|NCT01725477|DRUG|methylene blue|
224224780|NCT01725477|DRUG|metheylne blue with normal saline|
224224781|NCT02033525|DRUG|XCEL-M-ALPHA and standard rehabilitation|Intraarticular infusion of autologous bone marrow derived ex vivo expanded mesenchymal stromal cells produced at Xcelia (Advanced Therapies Division of the Blood and Tissue Bank)
224224782|NCT02033525|OTHER|Rehabilitation|Standard rehabilitation program
224224783|NCT04192825|PROCEDURE|surgical treatment|surgical drainage and/or surgical reconstruction procedures to anoperineal suppurations according to the doctor's decision
224224784|NCT03077997|BEHAVIORAL|Space from Diabetes|Space from Diabetes is an internet-delivered cognitive behaviour therapy-based programme for symptoms of depression, anxiety, \& diabetes distress in people with type 2 diabetes mellitus.
224224785|NCT01117961|BEHAVIORAL|Lifestyle|Behavioral lifestyle intervention targeting diet and physical activity to reduce excessive gestational weight gain
223764829|NCT05063396|PROCEDURE|Opioid-sparing anesthesia|patients will receive opioid-sparing anesthesia protocol with minimal intraoperative sufentanil, remifentanil and epidural hydromorphone.
223764830|NCT03551470|PROCEDURE|Robotic one-stage colorectal and liver resection|
223764831|NCT02538926|DRUG|Asparaginase|Given IM or IV
223635869|NCT06300697|OTHER|Oral Food Challenge (OFC) procedures|Participants will have the choice of consenting to an OFC (approximately 2-4 hours) to peanut, tree nut, egg, milk, or sesame. If there is no allergy history, the study team will conduct an oral food challenge to one of the choices. The OFC will occur in the clinical research area. and done the same as a clinical care OFC. A transepidermal water loss monitor will be applied to participant's arm with a sticky pad and will stay on the arm for the challenge. Food doses will be given in small amounts that increase in size up to a defined single serving of the food based upon the participants age/size. The OFC will proceed until a full dose is consumed without symptoms, or until anaphylaxis occurs. Depending upon the participant's reaction to the oral food challenge, the participant may be requested to return the next day for a research visit that would take less than an hour. The 24-hour post oral food challenge visit will include an interview to assess condition and a blood sample.
223635870|NCT04680585|OTHER|Enhanced Usual Care|A standardized handout with information on what treatment options might be useful to start with based on EPDS score and stage of pregnancy or postpartum.
223635871|NCT04680585|OTHER|MOVIN Care Platform|Virtual collaborative care intervention with a stepped care approach in which a care coordinator directs participants to one or more evidence-based virtual interventions as appropriate.
223635872|NCT02374242|DRUG|Nivolumab|Nivolumab is a fully human monoclonal antibody directed against the negative immunoregulatory human cell surface receptor PD-1 (programmed death-1 or programmed cell death-1/PCD-1) with immunopotentiation activity.
223635873|NCT02374242|DRUG|Ipilimumab|Ipilimumab is a recombinant, human monoclonal antibody that binds to the cytotoxic T lymphocyte-associated antigen 4 (CTLA-4). CTLA-4 is a negative regulator of T-cell activation. Ipilimumab binds to CTLA-4 and blocks the interaction of CTLA-4 with its ligands, CD80/CD86. Blockade of CTLA-4 has been shown to augment T-cell activation and proliferation. The mechanism of action of ipilimumab's effect in patients with melanoma is indirect, possibly through T-cell mediated anti-tumour immune responses.
223635874|NCT00596414|PROCEDURE|transjugular liver biopsy|liver biopsy through the transjugular route with hepatic-venous pressure gradient measurement
223635875|NCT00596414|DRUG|placebo|
224224786|NCT00192296|BIOLOGICAL|MEDI-528 0.3 mg/kg|MEDI-528 (0.3 mg/kg) administered as a single, intravenous (IV) dose
224224787|NCT00192296|BIOLOGICAL|MEDI-528 1 mg/kg|MEDI-528 (1 mg/kg) administered as a single, IV dose
224224788|NCT00192296|BIOLOGICAL|MEDI-528 3 mg/kg|MEDI-528 (3 mg/kg) administered as a single, IV dose
224224789|NCT00192296|BIOLOGICAL|MEDI-528 9 mg/kg|MEDI-528 (9 mg/kg) administered as a single, IV dose
224224790|NCT04805684|DEVICE|LUS Twelve area|Application of 12 areas (2 posterior, 2 lateral, and 2 anterior)lung ultrasonography protocol using the convex ultrasound probe (2-6 MHz)
224224791|NCT04805684|DEVICE|LUS Fourteen area|Application of 14 areas (3 posterior, 2 lateral, and 2 anterior) lung ultrasonography protocol using the convex ultrasound probe (2-6 MHz)
224224792|NCT00735241|DEVICE|SIR-Spheres microspheres|SIR-Spheres yttrium-90 microspheres
223635876|NCT00596414|DRUG|midazolam|
223635877|NCT00596414|DRUG|midazolam + pethidine|
223635878|NCT02798666|OTHER|High intensity exercise training|Exercise training using sprint interval exercise
223635879|NCT02798666|OTHER|Continuous exercise training|Exercise training using continuous exercise at constant heart rate
223764832|NCT02538926|DRUG|Cyclophosphamide|Given IV
223764833|NCT02538926|DRUG|Doxorubicin Hydrochloride|Given IV
224224793|NCT00735241|DRUG|FOLFOX6 cycles 1-3|Oxaliplatin 60 mg/m2, IV infusion, q 2 weeks Leucovorin 200 mg/m2, IV infusion, q 2 weeks 5-Fluorouracil 400 mg/m2, IV bolus, q 2 weeks 5-Fluorouracil 2.4 g/m2, IV infusion, q 2 weeks
224224794|NCT00735241|DRUG|FOLFOX6 cycles 4 onwards|Oxaliplatin 85 mg/m2 given, IV infusion, q 2 weeks Leucovorin 200 mg/m2 given, IV infusion, q 2 weeks 5-Fluorouracil 400 mg/m2, IV bolus, q 2 weeks 5-Fluorouracil 2.4 g/m2, IV infusion, q 2 weeks
224224795|NCT00735241|DRUG|Bevacizumab cycles 3 onwards|Bevacizumab 10 mg/m2, IV infusion, q 2 weeks commencing with the third cycle of chemotherapy
224224796|NCT00962299|DRUG|Beclomethasone|Beclometasone 100 ug b.i.d. by metered dose inhaler with spacer for 6 months
224224797|NCT00962299|DRUG|Placebo|Placebo once a day by metered dose inhaler with spacer for 6 months
223635880|NCT04421053|BEHAVIORAL|prenatal care for women with GDM|we conduct prenatal care for GDM pregnancies through both prenatal clinic and app.
223635881|NCT04308759|OTHER|Experimental Smoking Cessation Program|Participate in Quitbot experimental cessation program
223635882|NCT04308759|OTHER|Control Smoking Cessation Program|Participate in Quitbot control cessation program
223635883|NCT02325934|DRUG|Stribild|Elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil
223764834|NCT02538926|DRUG|Etoposide|Given IV
223764835|NCT02538926|DRUG|Imatinib Mesylate|Given PO
223764836|NCT02538926|OTHER|Laboratory Biomarker Analysis|Correlative studies
224224798|NCT05783583|DEVICE|Remote Digital Slit Lamp|Slit Lamp Examination
223635884|NCT02325934|DRUG|Stribild, crushed|Crushed Stribild tablet
223635885|NCT05356897|BIOLOGICAL|Trastuzumab|Given IV
223635886|NCT05356897|DRUG|Trifluridine and Tipiracil Hydrochloride|Given PO
223635887|NCT05356897|DRUG|Tucatinib|Given PO
223635888|NCT02226367|DRUG|prazosin hydrochloride|study drug arm prazosin
223764837|NCT02538926|DRUG|Prednisone|Given PO
223764838|NCT02538926|BIOLOGICAL|Rituximab|Given IV
223764839|NCT02538926|DRUG|Vincristine Sulfate|Given IV
223764840|NCT01263574|DRUG|70% ethanol|Administration of the lock solution will occur between cycles of parenteral nutrition. Lock solutions will be administered three days per week. The pre-measured volume of lock solution will then be injected into the catheter for 4 hours. Prior to the next instillation of medications into the catheter, the lock solution will be aspirated and discarded. Another 5mL flush of saline will then be instilled into the catheter prior to medication or parenteral nutrition administration. Volume of lock solution administered will be determined by catheter size.
224224799|NCT03465891|DRUG|atezolizumab|1200mg IV on day 1 of a 21-day cycle for a planned total of 17 cycles of therapy (1 year).
224224800|NCT03465891|RADIATION|Low- Dose, Local Radiotherapy|4Gy will be administered in 2 fractions to a single nodal site amenable to radiation as identified by the radiation oncologist on day 2 and day 3 of Cycle 1 (over the two days following to the first dose of atezolizumab ).
224318739|NCT07133997|DRUG|Cyclophosphamide|Given cyclophosphamide
223635889|NCT02226367|DRUG|placebo|study drug arm placebo
224224801|NCT02387320|OTHER|Self-Care Toolkit|The self-care toolkit was designed and created for individuals undergoing surgery and/or invasive medical procedures. It provides individuals with guided instruction to learn several evidence-informed mind-body skills (e.g., breathing, relaxation, meditation, guided imagery) and tools (e.g., acupressure wristbands, journal) in order to regulate their own physiologic and emotional reactions to stressful situations and to lessen symptoms associated with surgery (principally pain, anxiety, nausea, fatigue, sleep disturbance).
223635890|NCT05829551|DRUG|RAY1216 dose 1|RAY1216 dose 1 or Placebo
223635891|NCT05829551|DRUG|RAY1216 dose 2|RAY1216 dose 2 or Placebo
223635892|NCT05829551|DRUG|RAY1216 dose 3|RAY1216 dose 3 or Placebo
223635893|NCT05829551|DRUG|RAY1216 dose 4 &ritonavir|RAY1216 dose 4 \&ritonavir or Placebo
223635894|NCT05829551|DRUG|RAY1216 dose 5|RAY1216 dose 5 or Placebo
223635895|NCT05829551|DRUG|RAY1216 dose 6|RAY1216 dose 6 or Placebo
223635896|NCT05829551|DRUG|RAY1216 dose 7|RAY1216 dose 7 or Placebo
223635897|NCT05829551|DRUG|RAY1216 dose 8|RAY1216 dose 8 or Placebo
223635898|NCT05829551|DRUG|RAY1216 dose 9|RAY1216 dose 9 or Placebo with high fat meal
223635899|NCT05829551|DRUG|RAY1216 dose 10|RAY1216 dose 10 or Placebo with high fat meal
223635900|NCT05965258|DIAGNOSTIC_TEST|Cardiac magnetic resonance (CMR)|Cardiac magnetic resonance (CMR) at 6 months. If referred to MitraClip, CMR will be performed at 6 months from the procedure.
224224802|NCT01841320|OTHER|Integrated methadone and antiretroviral therapy (iMART) clinic|
224224803|NCT00614159|DRUG|Ketamine|Weight based dosage for Peds subjects, used for duration of the endoscopy.
224224804|NCT00614159|DRUG|Propofol|Weight based dosage for Peds subjects, used for duration of the endoscopy.
223635901|NCT04405791|PROCEDURE|Active stimulation group Sham stimluation group|"Participants are randomly assigned to either treatment group or sham group for application of transcranial low intensity focused ultrasound stimulation. For sham group, transducer is surrounded by rubber band in order to block the transmission of ultrasonic wave.~Before initiating transcranial low intensity focused ultrasonic stimulation, in order to identify anatomical structure of the brain, Brain Magnetic Resonance Image(MRI) and Computer Tomography(CT) will be taken. For image coordination, multi-modal stick(fiducial marker, PinPoint) will be attached to the participant.~With acquired brain images of the participant, researchers identify participant's dorsolateral prefrontal cortex(DLPFC) region, and design focused ultrasound focus targeting, image-guidance method.~The treatment is started by targeting left DLPFC region according to assigned groups. Both the treatment and sham group will be under procedure for 2 weeks, 3 times a week."
224318740|NCT07133997|PROCEDURE|Echocardiography Test|Undergo ECHO
223635902|NCT05573633|PROCEDURE|ECG|the POAF will be diagnosed using a 12-lead ECG and according to the usual monitoring protocols for patients in the cardiac surgery department of Amiens University Hospital.
223635903|NCT05573633|PROCEDURE|scanwatch|POAF will be diagnosed with a Withings SM (ScanWatch). FAPO diagnosed by the SW will have to be confirmed by a 12-lead ECG.
223635904|NCT04240210|DRUG|Symtuza|The study is a prospective cohort analysis of change in adherence, tolerability and safety of subjects who reports poor adherence to ART due to intolerance/side effects from integrase inhibitor containing regimens when they are switched to DRV/COB/FTC/TAF and monitored for 4 months.
223635905|NCT03773978|DRUG|Baricitinib|Administered orally.
223635906|NCT03773978|DRUG|Placebo|Administered orally.
223635907|NCT05678608|PROCEDURE|surgical excision|posterior midline approach and total excision for spinal cord tumors
223635908|NCT02577172|BEHAVIORAL|Exercise group|The intervention will be conducted during chemotherapy and tailored for each patient. The program will include 1) weight bearing aerobic exercises to maintain the oxygen transport and thereby reduce the decline in VO2max during chemotherapy and 2) strength training exercises to maintain muscle mass and muscle strength. The intervention will last for 9 or 12 weeks, depending on the number of BEP/EP cycles received. The program will consist of two-three one-hour exercise sessions per week, of which most supervised by a personal trainer. The intensity of each exercise sessions will varies from easy (warm-up: 60-70 % of peak heart rate) to moderate/high (between aerobic intervals 60-70% of peak heart rate and during aerobic intervals 85-95 %).
223635909|NCT02577172|BEHAVIORAL|Control group|The control group will receive one individual lifestyle counseling session during the first chemotherapy cycle and can perform all activities that they have planned to do during chemotherapy.
223635910|NCT03244878|BEHAVIORAL|Thrive|A interactive computerized program using structured content of cognitive behavior therapy
223635911|NCT01237756|DEVICE|measurement of left and right lung ventilation|Patients are ventilated after endotracheal tube placement and left and right lung ventilation if determined using electrical impedance tomography
223635912|NCT03986970|DRUG|Tenofovir|Pre-exposure prophylaxis
223635913|NCT06507254|DIETARY_SUPPLEMENT|Polyphenol Supplement|Dietary supplement taken twice daily for 12 months.
223635914|NCT06507254|DIETARY_SUPPLEMENT|Placebo Supplement|Dietary supplement taken twice daily for 12 months.
223635915|NCT04603846|DRUG|anti-PD-L1 antibody|Patients will receive 16 cycles of anti-PD-L1 antibody 5mg/kg IV on day 1 every 3 weeks.
223635916|NCT04603846|DRUG|albumin bound paclitaxel|Patients will receive 6 cycles of albumin bound paclitaxel 260mg/m2 on days 1 every 3 weeks .
223635917|NCT02706756|OTHER|Manual therapy|Hip joint and spine manual therapy techniques applied toward the impairments of the subject.
223635918|NCT02706756|OTHER|Exercise|Prescriptive exercise program of self-mobilization and/or strengthening program to address impairments of the subject.
223635919|NCT02706756|OTHER|Education and advice|All three groups will receive standardized education on the current state of FAI interventions (with both conservative and surgical care).
223635920|NCT02706756|OTHER|Supervised neglect|Monitoring of group without formal intervention.
223635921|NCT06569901|BEHAVIORAL|Hope Intervention|"Group meetings after hospital discharge reflecting on themes that may have an impact on hope.~The Hope Intervention consists of four group meetings and two individual conversations during a four week period."
223635922|NCT02439723|DRUG|Regorafenib|
223635923|NCT06244628|DRUG|Iguratimod|Oral administration of Iguratimod, 25mg twice daily
223635924|NCT01245309|PROCEDURE|scratching|endometrial scratching before COH in IVF
223635925|NCT01245309|PROCEDURE|A PLACEBO PROCEDURE|A PLACEBO PROCEDURE
224224805|NCT03109990|DRUG|Dexmedetomidine|Patients in the experimental group will receive Dexmedetomidine during surgery.
224224806|NCT03109990|DRUG|Saline|Patients in the control group will receive saline but not Dexmedetomidine during surgery.
224224807|NCT01001169|BIOLOGICAL|GSK Biologicals' Pandemic influenza (H1N1) candidate vaccine (GSK2340274A)|Two intramuscular injections
224224808|NCT01545635|DRUG|Fibrinogen concentrate, Prothrombin complex concentrate and FXIII concentrate|"Fibrinogen concentrate Dose: 50 mg/kg BW fibrinogen concentrate if FIBTEM A10\<7mm Kind of application: Intravenously Frequency and rate of administration: Single-dose or repeated, each single vial (1g) over 5 min~Prothrombin complex concentrate Dose: 20IE/kg BW PCC if EXTEM CT \>90sec and FIBTEM A10\>7mm Kind of application: Intravenously Frequency and rate of administration: Single-dose or repeated, each single dose over 10 min~FXIII concentrate Dose: 20 IU/kg BW Fibrogammin® P will be administered with the second dose of fibrinogen concentrate (=100 mg/kg) and if FXIII decreases below 60% as detected by laboratory measurements.~Kind of application: Intravenously Frequency and rate of administration: Single-dose or repeated, each single dose over 10 min"
224224809|NCT01545635|DRUG|Fresh Frozen Plasma blood type 0, A, B and AB|Fresh Frozen Plasma Dose: 15ml/kg BW if FibTEM A10 \<7mm and/or ExTEM CT\>90sec. Kind of application: Intravenously Frequency and rate of administration: Single-dose or repeated, each single U (200mL) over 5 min
224224810|NCT05872074|DIAGNOSTIC_TEST|Coronary angiography plus percutenous coronary intervention|"1. wire both branches, MV and SB, with two coronary guide wires.~2. Main branch pre-dilation~3. Side branch pre-dilation using (ordinary balloon in group A and Drug coated balloon in group B for the side branch)~4. Main vessel stenting~5. Proximal optimization technique (POT) of the main vessel stent"
224224811|NCT01945138|DEVICE|Closed Loop Insulin|The Closed Loop Insulin system is an automated insulin delivery system based on body blood glucose. It consists of an Insulin pump, continuous glucose monitor, and a control device (laptop with algorithms).
224224812|NCT00645489|BEHAVIORAL|psychoeducational|Psychoeducation intervention includes information about self-care of heart failure, and a communication training intervention for patients and family members
224224813|NCT00645489|OTHER|wait list|Wait list
224224814|NCT01608295|DRUG|Vilazodone; Viibryd|Subjects randomized to receive vilazodone blindly will have incremental dose titration of 10mg per day for the 1st week; 20mg per day the 2nd week; 40mg per day for the 3rd-12th week. Doses of the drugs will be adjusted according to individual tolerability and safety.
224318741|NCT07133997|PROCEDURE|Lumbar Puncture|Undergo lumbar puncture
224318742|NCT07133997|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
224318743|NCT07133997|DRUG|Venetoclax|Given PO
223514822|NCT06072261|OTHER|kinesio tape application|"Before the standard rehabilitation program, kinesio taping was applied to both upper extremities in the form of a Y tape from the medial epicondyle to the wrist flexors, with 15-20% tension, to the patients hospitalized in the orthopedic service after lower extremity surgery. The tape should remain on the patient's arm throughout the hospital stay"
223514823|NCT06695364|OTHER|survey study|Not all classes were included in the study
223514824|NCT06695793|PROCEDURE|Interrupted Sutures|The first layer of uterine incision will be closed using individual, separate sutures placed at regular intervals along the incision line. Each suture will be tied independently, ensuring adequate apposition of uterine tissue, followed by a second layer of running continuous sutures.
223514825|NCT06695793|PROCEDURE|Locked Sutures|The first layer of uterine incision will be closed using continuous sutures placed along the uterine incision, incorporating a locking technique at specified intervals to prevent unraveling. The knots will be securely tied to maintain tissue approximation, followed by a second layer of running continuous sutures.
223514826|NCT06695793|BIOLOGICAL|Running Continuous Sutures|Double layer closure of uterine incision using running continuous suture used to close the uterine incision without interruption, providing seamless tissue approximation throughout the incision length.
223514827|NCT06693947|OTHER|Alpine dairy products|The intervention group will be instructed to eat three portions of alpine dairy products daily. The proposed three portions represent an estimated mean consummation in the study population, taking into consideration the national statistics.
223514828|NCT06694324|DRUG|Liposomal Doxorubicin (Doxil)|30 mg/m2, d1, IV
223514829|NCT06694324|DRUG|Apatinib|250 mg, qd
223514830|NCT06694324|DRUG|Camrelizumab|200 mg, d1, IV
223514831|NCT06687902|DIAGNOSTIC_TEST|Digital breast tomosynthesis|In digital breast tomosynthesis (DBT), images are acquired using a specialized X-ray tube that moves in an arc around the breast. This technique captures multiple low-dose images from various angles, typically within a 15° to 60° range. These images are then reconstructed into 1-mm slices to create a 3D representation of the breast, allowing for detailed layer-by-layer evaluation. The number of images acquired varies depending on the size of the breast and the specifications of the equipment but generally ranges from 10 to 25 projections, captured within a few seconds.
223514832|NCT06691399|OTHER|Oral care|Oral care done twice daily with chlorhexidine oral care solution (concentration 1.2%)
223514833|NCT06688617|OTHER|Swedish Hand Massage|Swedish technique hand massage: Effleurage-petrissage-friction-tapotement,-vibration-effleurage
223514834|NCT04448912|PROCEDURE|Damage control surgery|Surgery for non-traumatic abdominal emergencies using the damage control approach
223514835|NCT04448912|PROCEDURE|Conventional surgery|Conventional surgery for non-traumatic abdominal emergencies
223514836|NCT06694610|PROCEDURE|non-pulmonary vein ablation group|In the non-pulmonary vein ablation group, pulmonary vein isolation was not allowed, but the left atrial low-voltage area was treated first, and then the ablation route that terminated the reentry ring was treated.
223514837|NCT06694610|PROCEDURE|only pulmonary vein ablation group|In the group treated with only pulmonary vein ablation route, only potential isolation of pulmonary vein was performed, and bidirectional block was the end point.
223514838|NCT06686277|OTHER|Gong's Mobilization Technique|The therapist will push the scapula of the affected side in a posterior to anterior direction with one hand, and pushed the humeral head in an anterior to posterior direction parallel to joint plane with the other hand.
223514839|NCT06686277|OTHER|Mulligan Mobilization Technique|Mulligan Mobilization Technique
223514840|NCT06691633|DRUG|Preoperative Methadone|patient receives a one-time preoperative dose of 10 mg of methadone
223514841|NCT06691633|DRUG|Preoperative Oxycodone|patient receives a one-time preoperative dose of 10 mg of oral oxycodone
224224815|NCT01608295|DRUG|Paroxetine; Paxil|Subjects randomized to receive paroxetine blindly will have incremental dose titration of paroxetine 10mg per day for the 1st week; 20mg per day for the 2nd week; and 30mg per day for the 3rd-12 week. Doses of the drugs will be adjusted according to individual tolerability and safety.
224224816|NCT04418141|DRUG|CN1|Participants will receive CN1 by IV infusion on Day 1 of each cycle (every 3 weeks). The 5 planned dose levels are 0.03 mg/kg, 0.3 mg/kg, 1 mg/kg, 3 mg/kg and 10 mg/kg.
224224817|NCT03564548|DRUG|PPP001|Group assigned to PPP001
224224818|NCT03564548|DRUG|Morphine sulfate or Hydromorphone or Oxycodone|Group assigned to morphine sulfate or hydromorphone or oxycodone
224224819|NCT05418348|DRUG|GTX-104|new formulation of nimodipine injection for IV infusion
224224820|NCT05418348|DRUG|Nimodipine Capsules|Nimodipine capsules (reference formulation)
224224821|NCT01249105|DRUG|MK-2206|Taken orally once a week
224224822|NCT00635388|OTHER|Placebo|oral, placebo, once/day for 12 weeks
224224823|NCT00635388|OTHER|Lactobacillus (Probiotic 1)|oral, Lactobacillus, once/day for 12 weeks
224318744|NCT07133997|DRUG|Vincristine|Given vincristine
223514842|NCT05289453|PROCEDURE|lens extraction by phacoemulsification|lens extraction by phacoemulsification
223514843|NCT06686498|BEHAVIORAL|Illness Management and Recovery adapted to suicidal behavior (IMR-ACS)|"Illness Management and Recovery adapted to suicidal behavior (IMR-ACS) is a protocolized clinical intervention in a brief group format aimed at people at risk of suicide. Specifically, people who have had more than two attempts in their lifetime are called repeaters. For its construction, we relied on the Spanish version of the Illness Management and Recovery IMR, developed by the Spanish Nursing Association, adapted to the field of suicidal behavior, taking as a reference the model of personal recovery from suicide attempt proposed by Sokol et al.~The goals of IMR-ACS are to 1) know the warning signs of a suicidal crisis, 2) implement strategies to manage the suicidal crisis, 3) foster social support among peers, 4) formulate goals for recovery from a suicidal crisis, and 5) seek help and make informed decisions in the event of a suicidal crisis.~IMR-ACS is a complementary intervention to the usual treatments."
223514844|NCT04009135|BEHAVIORAL|internet delivered cognitive behavioural therapy (iCBT)|The intervention comprises 7 weekly online modules available through Therapist Assisted Online (TAO), including: 1) psychoeducation about chronic pain and depression; 2) thoughts and feelings; 3) understanding stress and relaxation; 4) unhealthy and healthy thoughts; 5) layers of thinking; 6) core beliefs; and 7) relationship, lifestyle, problem solving, and relapse prevention. Online content is supplemented with weekly coaching sessions performed via video-conference with doctoral students of Clinical Psychology.
223514845|NCT04009135|BEHAVIORAL|online delivered acceptance and commitment therapy (iACT)|The intervention comprises 7 weekly online modules available through Therapist Assisted Online (TAO), including: 1) psychoeducation about chronic pain and depression; 2) introduction to ACT; 3) cognitive fusion and defusion; 4) thinking mind versus observing mind \& acceptance; 5) mindfulness; 6) values; and 7) taking action. Online content is supplemented with weekly coaching sessions performed via video-conference with doctoral students of Clinical Psychology.
223514846|NCT04009135|OTHER|Attention Control (AC)|1-module of psychoeducation about chronic pain and major depression. Weekly contact to complete measures of symptomatology and well-being.
223514847|NCT06691763|BEHAVIORAL|Pythagorean Self-Awareness Intervention for stress management and health promotion|Pythagorean Self-Awareness is a holistic stress magement program that combines cognitive reconstruction and the implementation of the 6 pillars of life-style medicine depending on the targeted population.
223514848|NCT00468000|BIOLOGICAL|Ixmyelocel-T|IM injection
223514849|NCT00468000|BIOLOGICAL|Placebo|IM Injection
223514850|NCT03449147|DRUG|Placebo|Placebo tablet administered orally BID
223514851|NCT03449147|DRUG|Gefapixant 15 mg BID|Gefapixant 15 mg tablet administered orally BID
223514852|NCT03449147|DRUG|Gefapixant 45 mg BID|Gefapixant 45 mg tablet administered orally BID
223514853|NCT05924230|OTHER|RL 10ml/kg|Inferior vena cava collapsibility index of all patients will be calculated by ultrasonography and if it is \>50%, then patients of this group (Group 1) will receive Ringer's lactate 10ml/kg before induction in the receiving area
223514854|NCT05924230|OTHER|RL 15ml/kg|Inferior vena cava collapsibility index of all patients will be calculated by ultrasonography and if it is \>50%, then patients of this group (Group 2) will receive Ringer's lactate 15ml/kg before induction in the receiving area
223514855|NCT01942512|DEVICE|Endovascular treatment of intracranial aneurysm|
223514856|NCT05583058|OTHER|Hormone Overdose and Misuse|This is an observational study. Hormone Overdose and Misuse is an exposure.
223514857|NCT02099591|DRUG|Naloxegol|Opioid Antagonist
223514858|NCT02286791|BEHAVIORAL|Mindful Awareness Program|For Mindful Awareness Program, 40-minutes weekly sessions for 12 weeks, followed by 40-minutes monthly for 6 months. The mindful awareness practice techniques to be taught to the elderly include: (1) mindfulness of the senses practice; (2) the body scan practice; (3) walking meditation practice; (4) 'movement nature meant' practice; and (5) visuo-motor limb tasks
223635926|NCT05219851|RADIATION|Cancer patients underwent thoracic intensity-modulated radiotherapy|Cancer patients underwent thoracic intensity-modulated radiotherapy, previously received ICIs
223635927|NCT01082770|DEVICE|TEGO|A bung that can be attached to the end of dialysis lines that can be directly attached to the dialysis machine with minimal handling
223635928|NCT01082770|DEVICE|Standard|Patients in this group will have a normal 'bung' placed at the end of their dialysis line, which will need to be removed by nursing staff prior to initiation of dialysis
223635929|NCT01033019|DRUG|LDE225 0.75%|0.75% cream
223635930|NCT01033019|DRUG|Vehicle|matching placebo cream to 0.75% LDE225 cream
223635931|NCT04659863|DRUG|Inclisiran|Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL solution for subcutaneous injection
223635932|NCT04659863|DRUG|Placebo|Sterile normal saline (0.9% sodium chloride in water for injection) for subcutaneous injection
223635933|NCT06054490|BEHAVIORAL|Self-management|It is based on the premise that cognition, the process of acquiring knowledge and forming beliefs, is a primary determinant of mood and behavior. The therapy uses self-management techniques to identify, correct and prevent behaviors or situations capable of altering the subject's state. In addition, relaxation techniques, sleep hygiene, diet modification, thermotherapy, encouragement to practice social and aerobic activities, and how to prevent risk factors and bad habits.
223635934|NCT06054490|OTHER|Home exercises|It is based on home self-exercise routine. Basic exercise therapy includes mobilization, stretching, and muscle strengthening exercises
223635935|NCT02683512|OTHER|No intervention|This is an observational study that consists of data abstraction from patient medical records.
223635936|NCT03162146|OTHER|Deaths in intensive care unit|Assessment of the influence of team familiarity among the members of medical and nursing staffs on risk of patient death
223635937|NCT01932593|PROCEDURE|Infusion of autologous bone marrow|Bone marrow harvest under general anaesthetic and intravenous infusion of filtered but otherwise unselected autologous bone marrow
223635938|NCT02105740|BEHAVIORAL|Hypnosis|The hypnosis intervention consists of two 40-minute sessions, with an interval of 7 days between them, emphasizing the pain blocking, the well-being of the patient and the reduction of the symptoms of anxiety and depression of the same.
223635939|NCT02105740|BEHAVIORAL|Control|The control and experimental groups respond in 3 different moments to Visual Analogue Scale (VAS) for the evaluation of pain, and to Hospital Anxiety and Depression Scale (HADS) to evaluate depression and the anxiety. The first meeting will be made before the hypnosis. In the second meeting, within an interval of 7 days, the scales will be applied in all patients. Before applying the scales, the hypnosis group will be submitted to the session. The third meeting will occur two weeks later, where the scales will be only applied to compare the groups.
223635940|NCT04423666|BEHAVIORAL|Walking using a wireless pedometer|See arm/group
224224824|NCT00635388|OTHER|Lactobacillus and Bifidobacterium (Probiotic 2)|oral, Lactobacillus and Bifidobacterium, once/day for 12 weeks
223635941|NCT04046367|BEHAVIORAL|Prehabilitation|Prehabilitation: The intervention of a physiotherapist will be added to the components of the control group. Patients will receive practical instructions on aerobic and resistance physical activity, as well as training of their inspiratory muscles.
224224825|NCT04495491|OTHER|pupillary block group|According to the configurations of angle closure, the pupillary block group is defined as the iris bombe.
224224826|NCT04495491|OTHER|plateau iris group|According to the configurations of angle closure, the plateau iris group is defined as the thickness of the peripheral iris.
223635942|NCT04046367|BEHAVIORAL|Control|Standard group intervention. Educational program and cognitive-behavioral intervention. The patient receives training in nutrition and cognitive-behavioral therapy, as well as standard instructions to increase physical activity.
223635943|NCT02554292|DEVICE|Drug Coated Balloon Angioplasty, Scoring Balloon Dilatation|Percutaneous Coronary Intervention
223635944|NCT03982121|DRUG|FOLFOX regimen|Oxaliplatin 85 mg/m² Leucovorin (LV) levogyre form (LLV) 200 mg/m² or dextro-levogyre (DL-LV) racemic mixture 400 mg/m²) Fluorouracil 2400 mg/m²
224224827|NCT04495491|OTHER|mixing mechanism group|According to the configurations of angle closure, the mixing mechanism group is defined as the iris bombe plus thickening of the peripheral iris.
223635945|NCT03982121|DRUG|Nivolumab|Nivolumab 240 mg
223635946|NCT03982121|DRUG|Ipilimumab|Ipilimumab 5 or 10 or 25 mg
223635947|NCT03982121|DRUG|GLA-SE|GLA-SE 1 or 2 or 5 or 10 or 20 μg
223635948|NCT05623878|DRUG|68Ga-labeled NY108|Patients will receive a tracer (20-40mcg, IV) dose of 68Ga (2-5mCi) labelled NY108.
223635949|NCT05041413|BEHAVIORAL|Moms Quit|Participants will receive text messages tailored on (1) current smoking status and (2) intention to quit/remain quit. Message content includes supportive messaging for child and self-care, relapse prevention, and smoking cessation. Women who are ready to quit will receive messages from the SmokeFreeText library.
223635950|NCT05041413|BEHAVIORAL|Text4Baby|Text4Baby is a free, publicly available text messaging program that provides information about nutrition, safe sleep tips, baby's milestones, signs and symptoms of labor, doctor visit and appointment reminders, breastfeeding advice, car seat safety, information on health insurance, urgent health alerts, and resource hotlines and websites.
223635951|NCT00079469|BEHAVIORAL|smoking cessation intervention|
223635952|NCT00079469|DRUG|bupropion hydrochloride|
223635953|NCT05354596|PROCEDURE|STRICT LUNG|Stereotactic body radiation therapy: Centrally located tumors are treated on standard-linacs with daily CBCT image-guidance and plan adaptation.
223635954|NCT05354596|PROCEDURE|STAR LUNG|Stereotactic body radiation therapy: Ultra-centrally tumors are treated on MR-linacs with daily MR-guided plan-adaptation.
223635955|NCT02700321|DEVICE|OPTIFLOW/ AIRVO|"Patients randomized in HFNC group will received a four minutes preoxygenation period with Nasal High Flow Therapy (HFT) Optiflow ®/AIRVO® (60 l/mn FIO2 = 1) before orotracheal intubation under laryngoscopy after crash induction."
223635956|NCT02700321|PROCEDURE|STANDARD Face Mask|"Patients randomized in STANDARD Face Mask group will received a four minutes preoxygenation period with a standard face mask (15 l/mn) before orotracheal intubation under laryngoscopy after crash induction."
224224828|NCT04777773|OTHER|dual-task training|dual-task training
224224829|NCT02448459|DRUG|COOL-COS|"Controlled ovarian stimulation will start on the second or third day of a menstrual cycle: Oral clomiphene citrate: 100 mg/day until the day of the triggering. Oral letrozole: 7.5 mg/day during the first 5 days of the controlled ovarian stimulation.~Corifollitropin Alfa: 100 mcg on the 3rd day of the controlled ovarian stimulation.~The triggering will be performed using leuprorelin 1 mg (subcutaneous)."
223635957|NCT00174408|DRUG|Genotropin|
223635958|NCT05584514|OTHER|Sentence Stimulus|"The sentences are designed such that a specific target word is either (a) Plausible (normal), (b) a semantic pragmatic violation, or (c) a morpho-syntactic violation. Example: e.g., Every morning at breakfast, the boys would (A: EAT)/ (B.PLANT )/ (C. EATS ) eggs..."
223635959|NCT05584514|OTHER|Auditory Noise|The sentences will be presented either A) in quiet, or B) with speech- shaped stationary background noise presented 3dB below the speech.
223635960|NCT03153592|PROCEDURE|Transpulmonary pressure driven ventilation strategy|Patients will receive volume controlled ventilation set with a tidal volume at 6-8 ml/kg of ideal body weight, an inspiratory transpulmonary pressure less than 20 cmH2O, and an expiratory transpulmonary pressure (PLexp) equal or greater than 0. At PLexp increasing from 0 up to 10 cmH2O, inspired fraction of oxygen would also be increased from 40% to 100%. Respiratory rate will be set to obtain an arterial partial pressure of carbon dioxide between 35 and 45 mmHg and to ensure a physiological pH. Whenever the clinician will deem it appropriate, an alveolar recruitment maneuver as previously described
224224830|NCT04086706|PROCEDURE|Retroflexion in the Right Colon|Prospective evaluation of an every day technique (retroflexion) used in our department for many years. The protocol of ascending colon examination encompassed 2 phases: A first phase (1) divided in Forward view (1a) videlicet insertion from the right flexure to the caecum followed by a second forward view (1b) namely withdrawal till the right flexure and reinsertion to the caecum maintaining the endoscope straight and a second phase (2, Retroflexion) with U-turn of the colonoscope in the caecum till the right flexure and then redressing to the forward view and reinsertion to the caecum.
224224831|NCT06201624|DRUG|Isotretinoin|Patients will receive 1mg/kg/day for 3 months
224224832|NCT06201624|DRUG|Triple combination formula|Patients are instructed to apply the triple combination formula at night daily for 3 months
224224833|NCT00751374|DRUG|gentamicin|topical gentamicin cream on daily basis
224224834|NCT00751374|DRUG|gentamicin cream alternating with mupirocin cream|topical gentamicin cream alternating with mupirocin cream at monthly basis
224224835|NCT04638686|DRUG|Dolutegravir 50 MG|The subjects started their antiretroviral treatment containing dolutegravir once a day.
224224836|NCT04638686|DRUG|Lamivudine 300 MG|The subjects started their antiretroviral treatment containing lamivudine once a day
224224837|NCT00798889|DRUG|Sunitinib|Sunitinib dose varies according to the doses allowed in previous protocol. It is given once a day, orally with various schedules depending on the parent protocol
224224838|NCT01641744|BEHAVIORAL|Systematic Training for Effective Parenting (STEP)|Parenting skills training class, 1x/week, 12 weeks
224224839|NCT01641744|BEHAVIORAL|Group Attachment Based Intervention (GABI)|Parent-child group, 3x/week, 26 weeks
224224840|NCT04111237|BEHAVIORAL|Two Finger technique|two finger method for chest compression provuision
224224841|NCT04111237|BEHAVIORAL|Two Thumb Technique|Two thumb technique
224224842|NCT00188370|PROCEDURE|high frequency ultrasound imaging|
224224843|NCT03674164|OTHER|Ovarian Cryopreservation|Surgical ovarian removal and vitrification
224224844|NCT00617461|DRUG|GEn 1200mg/day|1200mg/day gabapentin enacarbil
224224845|NCT00617461|DRUG|GEn 3600mg/day|3600mg/day gabapentin enacarbil
224224846|NCT04657484|DRUG|Medium dose prednisolone|Same as arm description
224224847|NCT04657484|DRUG|Low dose prednisolone|Same as arm description
224224848|NCT04944602|BIOLOGICAL|SYN008|injection of 300 mg
223514859|NCT02286791|BEHAVIORAL|Health Education Program|"For the Health Education Program, weekly sessions of 40 minutes for 12 weeks, followed by monthly sessions of 40 minutes for 6 months.~Week 1: Diabetes Mellitus Week 2: Hypertension Week 3: Home Safety Week 4: Medications Week 5: Diet Week 6: Depression Week 7: Dementia Week 8: Anxiety Week 9: Sleep Week 10: Exercise Week 11: Coping with bereavement Week 12: Social support"
223514860|NCT01801969|OTHER|Rehabilitation service|"* Centralized/ decentralized hospital based rehabilitation defined as hospital based rehabilitation in a single or in multiple locations, respectively.~* Size of the municipality responsible for providing rehabilitation services after discharge from hospital"
223514861|NCT03305211|OTHER|sample|Participation in NephroMIC involves additional blood samples of 5 tubes (35 mL) and an additional sample of fresh urine.
223514862|NCT02571855|DRUG|ACT-541468 (hydrochloride salt)|Hard-gelatin capsules (strength: 5 mg and 25 mg)
223514863|NCT02571855|DRUG|ACT-541468 (free base)|Soft capsules (strength: 25 mg)
223514864|NCT02571855|DRUG|Placebo|Placebo capsules matching the ACT-541468 formulations
223514865|NCT03338686|PROCEDURE|Free Gingival Graft (FGG)|Free Gingival Graft (FGG) was performed on all study sites in this arm.
223514866|NCT03338686|PROCEDURE|Connective Tissue Graft followed by Laser Gingivoplasty|Connective Tissue Graft followed by Laser Gingivoplasty one month later on all study sites in this arm.
223514867|NCT02842671|OTHER|Assigned Ambassador|If assigned to the intervention group, participants will be contacted by the assigned medical student ambassador at least 1 day prior to the procedure. A brief discussion will take place to review the child's history and survey results. The family will be met by the Ambassador at the hospital and stay with the family until the patient is in the post anesthesia recovery unit. The ambassador is expected to make accommodations for the child as determined by the accommodations survey results. The family will be required to allow the Ambassador to stay through check-in and the procedure.
223764841|NCT05168319|DEVICE|Repetitive transcranial magnetic stimulation|Participants received 10HZ rTMS protocol consisted of 5 sessions over 5 consecutive workdays
223764842|NCT05168319|DEVICE|Repetitive transcranial magnetic stimulation|Participants received pcTBS protocol consisted of 5 sessions over 5 consecutive workdays
224224849|NCT04944602|BIOLOGICAL|Omalizumab for injection|injection of 300 mg
223764843|NCT05168319|DEVICE|Sham stimulation|Participants received Sham rTMS stimulations consisted of 5 sessions over 5 consecutive workdays
223764844|NCT05142683|OTHER|Treatment As Usual|Various typical interventions for adolescents with depression.
223514868|NCT03556878|BEHAVIORAL|Fitted Transdiagnostic Sleep and Circadian intervention|Fitted TranS-C is an adapted version is designed to improve the fit with community needs and resources.
223514869|NCT01981993|BIOLOGICAL|Urinary proteomic analysis|
223514870|NCT00974233|DRUG|Bendamustine|90 mg/m2/day IV days 1 and 2 every 28 days for 6 cycles
223514871|NCT00974233|DRUG|Rituximab|375 mg/m2 Day 1 every 28 days for 6 cycles
223514872|NCT00974233|DRUG|Lenalidomide|5 mg/day days 1-28 of each 28 day cycle, up to 12 cycles maximum. Dose escalation to 10 mg/day allowed after one cycle as defined in the protocol.
223514873|NCT01691092|DRUG|Ketamine|All subjects will receive ketamine to induce glutamate release in the brain
223514874|NCT05042687|DRUG|Tc99m sestamibi|Given by IV
223764845|NCT05142683|OTHER|CARIBOU-2|Integrated Care Pathway intervention for adolescents with depression.
224224850|NCT03833388|DRUG|TOP1630 0.1% Ophthalmic Solution TID OU|Bilateral ocular drug administration
224224851|NCT03833388|DRUG|Placebo to TOP1630 0.1% Ophthalmic Solution TID OU|Bilateral ocular drug administration
224318745|NCT07133724|OTHER|AI-Based Smart Assessment and Rehabilitation Training|Through the integration of wireless inertial sensors and smartphone imaging, the system can monitor pelvic and lumbar movements in real time, generate a digital twin model, and deliver instant feedback to guide patients in performing correct exercises.
223635961|NCT03153592|PROCEDURE|Conventional ventilation strategy|13 patients will undergo volume controlled ventilation set with a tidal volume between 6-8 ml/kg of ideal body weight, positive end-expiratory pressure and fraction of inspired oxygen set to obtain a peripheral saturation in oxygen equal or greater than 94% and a plateau pressure \<28 cmH2O Respiratory rate will be set to obtain an arterial partial pressure of carbon dioxide between 35 and 45 mmHg and in any case to ensure a physiological pH. In addition, whenever the clinician will deem it appropriate, an alveolar recruitment maneuver will be performed as previously described
223764846|NCT02082717|DRUG|potassium chloride replacement|
223764847|NCT02082717|DRUG|Experimental - 4% Sodium Bicarbonate|
223514875|NCT01539889|RADIATION|99mTC-PulmoBind|DFH-12 (PulmoBind) is a peptide derived from human adrenomedullin (hAMI-52). Adrenomedullin (AM) is a 52-amino acid peptide produced by many tissues in the body, including the vascular endothelium. 3 radiolabeled doses of PulmoBind will be used in this study (5mCi, 10mCi and 15mCi) 5 healthy subjects per dose for the 5 mci and the 10 mci groups but 10 subjects will be used for the 15 mci group.
223514876|NCT01657942|DEVICE|ExAblate MR Guided Focused Ultrasound|ExAblate MR Guided Focused Ultrasound - Local treatment of prostate lesions using Magnetic Resonance Imaging guided endorectally applied focused ultrasound energy.
223514877|NCT06926361|BEHAVIORAL|Mindfulness for Life|Behavioral: Mindfulness for Life (MBCT-L) MBCT-L is an 8-week program consisting of mindfulness practices and cognitive-behavioral techniques with 8 sessions (2 hours and 15 minutes per session) and one-day retreat that can provide participants with an extended period to deepen their personal mindfulness practices.
223514878|NCT06926361|BEHAVIORAL|Positive education training|Positive Education program is an 8-week course consisting of theories and activities of positive psychology to enhance teachers' skills to support students' learning and wellbeing using a strength-based approach.
223514879|NCT04225819|DIETARY_SUPPLEMENT|Vitamin D3|Softgel capsules containing 5,000 IU cholecalciferol (Vitamin D3), sunflower oil, beef gelatin, glycerin, water
223514880|NCT04225819|OTHER|Placebo|Sfotgel capsules containing sunflower oil, beef gelatin, glycerin, water
223514881|NCT05171205|DEVICE|Spinal cord stimulation|Spinal cord stimulation (SCS) is a very thin electrode implanted in the dorsal epidural space of the spinal cord to improve the patient's symptoms by stimulating the spinal nerves with pulsed electrical currents, which attenuate or enhance the flow of nerve impulses from the periphery to the central system, i.e., stimulating thick fibers to achieve therapeutic results. SCS system consists of three components: an electrode implanted in the epidural space of the patient's spinal cord, a stimulator implanted subcutaneously in the abdomen or buttocks that delivers electrical impulses, and an extension cord that connects the two.
223514882|NCT06932744|DRUG|MY008211A tablets|Participants will receive MY008211A at a dose of 400 mg orally b.i.d for 24 weeks
223514883|NCT06932744|DRUG|Eculizumab Injection|Eculizumab Injection for 24 weeks
223514884|NCT05529953|DIETARY_SUPPLEMENT|Oleanolic acid (CAS no. 598-02-1; PubChem CID 10494)|Postprandial study of bioavailability of Oleanolic acid, formulated as functional olive oil, in healthy subjects
223514885|NCT05529953|DIETARY_SUPPLEMENT|Control commercial olive oil|Postprandial study of Oleanolic acid bioavailability in healthy subjects
223514886|NCT00002431|DRUG|Chlorhexidine gluconate|
223514887|NCT02795962|OTHER|Direct transfer to an Endovascular Center|Cluster randomized controlled study: allocation to active or no intervention arm will be performed accordingly to a pre-established temporal sequence
223514888|NCT03087149|DIETARY_SUPPLEMENT|monitored vit D supplementation|The vit D supplementation dose start from dose 500IU from 7th day of age and is modified based on vit D measurement at 4 week of age for infants born \<30 GA, at 8 week of age for infants born \<26 GA at 35+/-2 weeks PMA(postmenstrual age), +/-at 40+/-2 weeks PMA according to the protocol.
223514889|NCT03087149|DIETARY_SUPPLEMENT|standard vit D supplementation|The vitamin D supplementation dose is 500IU from 7th day of age.
223514890|NCT00963885|DRUG|Copegus|1000 or 1200mg po daily for 24 or 48 weeks
223514891|NCT00963885|DRUG|Pegasys|180micrograms sc weekly for 24 or 48 weeks
223514892|NCT00963885|DRUG|Placebo|po for 12 weeks
223514893|NCT00963885|DRUG|Placebo|po for 24 weeks
223514894|NCT00963885|DRUG|RO5190591 (Danoprevir)|300mg po q8h for 12 weeks
223514895|NCT00963885|DRUG|RO5190591 (Danoprevir)|600mg po q12h for 12 weeks
223514896|NCT00963885|DRUG|RO5190591 (Danoprevir)|900mg po q12h for 12 weeks
223514897|NCT00963885|DRUG|RO5190591 (Danoprevir)|300mg po q8h or 600mg po q12h or 900po q12h for 24 weeks
223514898|NCT05476731|DIAGNOSTIC_TEST|culture and antifungal sensitivity and molecular detection|"Samples will be cultured on Modified Dixon media for 10 days at temperature between 32-34°C.Molecular detection of malassezia species by Restriction Fragment Length Polymorphism (RFLP) .~Antifungal susceptibility testing of the isolates will be performed using the following antifungals Fluconazole, AmphotericinB and Fluocytosine"
223514899|NCT04636580|BEHAVIORAL|parent accompanying the child during treatment|After the parents were divided into two groups, anxious and non-anxious, the groups were equally divided randomly and the parents accompanied their children during the treatment
223514900|NCT00185614|PROCEDURE|Autologous hematopoietic cell transplant (Auto-HCT)|The target cell dose is 2.6 x 10e6 CD34+ cells/kg
223514901|NCT00185614|PROCEDURE|Allogeneic hematopoietic cell transplant (Allo-HCT)|The target cell dose is 5 x 10e6 CD34 cells/kg
223514902|NCT00185614|DRUG|Cyclophosphamide|Cyclophosphamide administered intravenously (IV) at 4 mg /m² mobilize peripheral blood progenitor cells (PBPC) for autologous re-infusion
223514903|NCT00185614|DRUG|Filgrastim|"* Filgrastim 10 µg/kg/day to mobilize peripheral blood progenitor cells (PBPC) for autologous re-infusion (Auto-HCT)~* Filgrastim 5 µg/kg/day starting 6 days after melphalan (Day 4 after Auto-HCT)~* Filgrastim 16 µg/kg/day to mobilize donor peripheral blood progenitor cells (PBPC) for allogeneic transplant (Allo-HCT)"
223514904|NCT00185614|DRUG|Melphalan|Melphalan 200 mg/m2 (high-dose) intravenously as conditioning for Auto-HCT
223514905|NCT00185614|RADIATION|Total body irradiation (TBI)|200 centigray (cGy) total body irradiation delivered on Day 0
223514906|NCT00185614|PROCEDURE|Cyclosporine (CSP)|Cyclosporine administered twice-daily by mouth at a dose of 6.25 mg/kg from Day -3 through Day 56
223514907|NCT00185614|DRUG|Mycophenolate Mofetil (MMF)|Mycophenolate mofetil will begin at 15 mg/kg twice-daily by mouth from Day 0 to Day 27
224318746|NCT07135167|COMBINATION_PRODUCT|Epi-ON corneal cross-linking (CXL)|"Corneal cross-linking involves the following steps:~* applying riboflavin (Vitamin B2 eye drops) to the eye, then~* exposing the eye to ultraviolet (UV-A) light for 20 minutes."
224318747|NCT07134335|DRUG|UBT251|Subcutaneous injection once weekly
224318748|NCT07134335|DRUG|UBT251|Subcutaneous injection once weekly
224318749|NCT07134335|DRUG|UBT251|Subcutaneous injection once weekly
224318750|NCT07133256|BEHAVIORAL|Resistance Exercise|Structured machine-based resistance exercise protocol performed under supervision, targeting osteogenic loading to improve bone mineral density and alter bone metabolism markers in CKD stage 3-4 patients.
223514908|NCT01048359|BEHAVIORAL|Brief advice|The American College of Surgeons (ACS) recently mandated standards of care for all level I trauma centers and currently defined standards of care at the collaborating institution requires that assessment and referral are included in treatment as usual. Therefore, our treatment as usual, or BA, consists of an initial interview conducted by study staff, a recommendation to abstain from drug use, provision of educational material supporting that recommendation, referral to hospital or community treatment resources most likely to be beneficial to the patient and information about relevant community health care agencies.
223514909|NCT01048359|BEHAVIORAL|Brief Intervention plus Booster|A brief drug use intervention based on motivational interviewing is provided to participants at baseline and a booster session incorporating personalized feedback is provided at one month
223514910|NCT01048359|BEHAVIORAL|Brief Intervention|A brief drug use intervention based on motivational interviewing is provided to participants at baseline
223514911|NCT06002698|PROCEDURE|Root canal treatment (Control)|Root canal treatment - Removal of the inflamed pulp tissues from the whole root canals of the tooth.
223514912|NCT06002698|PROCEDURE|Full pulpotomy (Experimental)|Full pulpotomy - Removal of the inflamed coronal pulp tissues from the crown of the tooth.
223514913|NCT00536705|DRUG|montelukast|montelukast 5-mg chewable tablet with matching placebo once daily in the evening at bedtime.The study consisted of a 2-week, single-blind placebo baseline period and a 12-week double-blind, active treatment period
223514914|NCT01215162|RADIATION|Intra-operative radiation to tumor bed|IOERT is given to the tumor bed. Applicator selection should allow treatment of the tumor bed plus 1-2 cm margin. The surgical incision may need to be enlarged slightly to allow the placement of the appropriate applicator. The use of more than 1 treatment field is discouraged. In order to encompass the entire tumor bed in 1 treatment field, it may be necessary to suture the mammary parenchyma loosely so that the lateral margins of the tumor bed are brought into apposition. Electron energy used for the treatment. If the tumor bed can be flattened and encompassed by an applicator, 6 MeV electron is recommended. Use of bolus material may be considered to increase the surface dose. If the mammary parenchyma has been brought into apposition by sutures, a higher electron energy may be necessary to allow adequate dose coverage to a depth of 1.0-2.0 cm into the tumor bed. The dose of IOERT is 1000 cGy, prescribed to the 90% isodose line.
223514915|NCT01931826|PROCEDURE|Endoscopic treatment|The presence of gastroesophageal varices was confirmed by fiberoptic esophagogastroduodenoscopy (EGD). In view of the experience of our service and local circumstances at the time of the study, the endoscopic treatment of choice was sclerotherapy, performed with a Teflon-sheathed metal needle. The sclerosing agent was 2.5% monoethanolamine oleate. Esophageal varices visible on EGD in the pre- and post-treatment period were classified as small, medium or large on the basis of criteria proposed by Paquet. All complications attributable to sclerotherapy were recorded.
223514916|NCT01931826|PROCEDURE|Total EGDS+ endoscopy|Esophagogastric devascularization with splenectomy followed by endoscopic sclerotherapy of esophageal varices 2 months postoperatively.
223514917|NCT03024411|OTHER|iPod (Music/video games)|Experimental patients will be given an iPod to enjoy music/video games during induction of labor.
223514918|NCT04680208|PROCEDURE|Surgical procedure under anesthesia|Different varieties of surgical procedures done under anesthesia
223514919|NCT04488887|DIAGNOSTIC_TEST|Optical coherence tomography angiography|patients in all groups will be examined with optical coherence tomography angiography, for every eye 3 macular and 3 papillary scans will be performed by two different OCTA machines, analysis will be carried out to evaluate the repeatability and reproducibility of the test
223514920|NCT03160573|DRUG|ClōSYS® Unflavored Rinse|
223514921|NCT03160573|DRUG|ClōSYS® Flavored Rinse|
223514922|NCT03160573|OTHER|Placebo-Flavored Oral Rinse|Flavor-matched placebo rinse
223514923|NCT03160573|OTHER|Placebo-Unflavored Oral Rinse|Unflavored-matched placebo rinse
223514924|NCT05818007|DRUG|Hyaluronic acid|The main function of HA appears to be in tissue healing, by activating and modulating inflammatory responses, stimulating cellular proliferation, migration, and angiogenesis, inducing basal keratinocyte proliferation and re-epithelization by reducing collagen deposition and scarring
223514925|NCT05818007|DRUG|Sodium bicarbonate|sodium bicarbonate solution
223514926|NCT05856942|OTHER|Health service - home-based PrEP monitoring|Home-based PrEP care
223514927|NCT05982379|OTHER|Technology Based Motivation Program|"A 10-week Technology Based Motivation Program was given to the intervention group. The website and four training modules were used with the children in the intervention group. Nine coaching interviews with each child (once a week) were conducted over WhatsApp. The children were encouraged to do progressive relaxation and breathing exercises at least twice a week, and eight therapeutic stories (once a week) were sent to the child's phone in the form of animation.~Three training modules were used with the primary caregivers, and coaching interviews were conducted on WhatsApp twice during the program. Primary caregivers practiced progressive relaxation and breathing exercises at least twice a week. In addition, eight motivation messages were sent to the child and primary caregiver, and 24/7 consultancy was provided."
223514928|NCT05533437|DEVICE|dry needling|the dry needle inserted to area of pain
223514929|NCT05533437|OTHER|kinesio taping|kinesio taping
223514930|NCT06313346|DIETARY_SUPPLEMENT|Probiotic|Probiotic capsules
223514931|NCT06313346|DIETARY_SUPPLEMENT|Placebo|Placebo capsules
224318751|NCT07133256|BEHAVIORAL|Aerobic Training|"Participants in this arm performed supervised aerobic exercise (treadmill walking) three times per week for six months. Each session included:~5-minute warm-up~30-minute treadmill walking at 60%-80% of age-predicted maximum heart rate (HRmax = 220 - age)~10-minute cool-down Exercise sessions were supervised by trained exercise professionals and tailored to maintain target heart rate zones."
223635962|NCT04772001|DRUG|Hydrochloride anlotinib|Hydrochloride anlotinib is a small molecular anti-angiogenesis drug with multiple targets. It will be taken at a starting dose of 12 mg for 14 days. Then participants will rest for 7 days and start a new cycles. At most of 3 cycles will be administrated. If intolerable toxicity happen, dosage of 10mg or 8mg will be taken.
223635963|NCT04772001|DRUG|cis Platinum/carboplatin|Concurrent chemotherapy will be administrated weekly during radiation for a total of 5-6 doses. Cisplatin of 40mg/m2 will be the most preferred regime. For patients with intolerable toxicity of cisplatin, carboplatin of AUC 2 will be the alternative drug.
223635964|NCT04772001|RADIATION|External beam radiotherapy and brachytherapy|Radiation will be given by external beam of 45Gy total dose and 3D-brachytherapy of 30Gy/5F or 28Gy/4F. Duration of radiotherapy will be no more than 8 weeks.
223635965|NCT04636268|BIOLOGICAL|FIB Grifols|"FIB Grifols is the IP and will be administered via slow intravenous (IV) infusion at a rate not to exceed 5 mL/minute.~Dosing will be individually calculated for each subject based on the target plasma fibrinogen level according to the type of bleeding, measured actual plasma fibrinogen level before infusion, and body weight. The IP will be administered according to the nominal potency of the product."
223635966|NCT02964689|DRUG|Binimetinib|Binimetinib will be administered in combination with pemetrexed and cisplatin (induction therapy), and with pemetrexed only (maintenance therapy), during the first 2 weeks of each cycle. Cycles will be repeated every 21 days.
223635967|NCT02964689|DRUG|Pemetrexed|Pemetrexed 500 mg/m2 i.v. is applied on day 1 of each cycle, before cisplatin administration
223635968|NCT02964689|DRUG|Cisplatin|Cisplatin 75 mg/m2 i.v. is applied on day 1 of each induction therapy cycle. The drug must be administered after pemetrexed infusion
223635969|NCT00006445|PROCEDURE|Ultrasound|
224224852|NCT02381821|OTHER|3 D ultrasound and Doppler examination|Endometrial thickness was measured in the longitudinal plane at the widest anteroposterior diameter with a trans-vaginal 2D ultrasound, and then 3D mode was then activated with power Doppler setting for this study standardized using a frequency at 4-9 MHZ pulse repetition frequency at 0.5KHz gain at-3.0 and wall motion filter at 1. The sub-endometrial region was considered to be within 3 mm of the originally defined myometrial-endometrial contour. The endometrial volume (EV) and 3D power Doppler indices below the endometrium were measured using the automated VOCAL™ for the 3D power Doppler histogram analysis
224224853|NCT02381821|DRUG|GnRH agonist|All women received daily subcutaneous 0.1 mg triptorelin injection started from day 21) of the cycle preceding stimulation. Downregulation of the pituitary gonadotropins was confirmed after 12 days , gonadotropin (Gn) induction was started using Human menopausal gonadotropins for ovarian stimulation. The starting dose was 225 to 300 IU . Ultrasound Folliculometry was done every other day . When two or more follicles reached a minimum mean diameter of 18 mm, triggering of ovulation trigger was done using Human chorionic gonadotropin (hCG) 10,000 IU and ovum pick up was scheduled 36 hours later
224224854|NCT02116283|BEHAVIORAL|48 hour smoking abstinence|Participants will maintain smoking abstinence for 48 hours
224224855|NCT02116283|OTHER|Smartphone|Participants will use an Android-based smartphone as their own for one month
223635970|NCT00006445|PROCEDURE|Serum screen|
223635971|NCT06494644|DRUG|AZD6793|Participants will receive single dose of AZD6793 on Day 1 in Period 1 and on Day 8 in combination with itraconazole in Period 3.
223635972|NCT06494644|DRUG|Itraconazole|Participants will receive 2 doses of itraconazole on Day 4 and single dose from Day 5 to Day 7 in Period 2. On Day 8 participants will receive single dose of itraconazole combined with AZD6793 and then single dose of itraconazole from Day 9 to Day 10 in Period 3.
223635973|NCT06494644|DRUG|AZD6793+ Itraconazole|Participants will receive a combined dose of AZD6793 and itraconazole on Day 8 in Period 3.
223635974|NCT06359951|BEHAVIORAL|Project YES|Digital SSI
223635975|NCT00863278|PROCEDURE|pulsed dye laser treatment|On one side of the face according to Arm placement.
223635976|NCT00863278|DRUG|Kligman's Trio|The combination of hydroquinone, retinoic acid and steroids combined in topical daily application.
223635977|NCT03224819|DRUG|Emerfetamab|Administered by intravenous (IV) infusion.
223635978|NCT03536572|BEHAVIORAL|Sleep Apnea Self-Management Program|Protocol-based sleep apnea and CPAP education and support
224224856|NCT05895370|BIOLOGICAL|HPV-T|Participant will receive HPV-T iv on day 0. One time of cell infusion constitute a cycle, each participant receives up to four cycles of treatment
224224857|NCT05895370|DRUG|Interleukin-2|500,000IU/m\^2 SC, after each cell infusion, IL-2 will start within 24 hours and every 8-12 hours for up to 6 doses.
224224858|NCT04414501|BEHAVIORAL|Separation Anxiety|Perioperative anxiety is a common, undesirable outcome in pediatric surgical patients and has been associated with adverse outcomes.
224224859|NCT03314766|DEVICE|IC-8 IOL|Patients previously implanted with an IC-8 IOL contralaterally or bilaterally will be evaluated for their long-term visual functions and overall satisfaction at least 12 months post-implantation
224224860|NCT05259111|OTHER|Home hospital|Acute care provided at home, including nurse/paramedic visits, physician visits, laboratory testing, imaging, continuous monitoring, 24/7 urgent visits, and specialty consultation.
223635979|NCT00286728|BEHAVIORAL|Intensive referral to dual-focused self-help|4 group sessions to introduce patients to dual focused groups
223635980|NCT03662867|BEHAVIORAL|Family-based mindfulness intervention|"For the parent program of family-based mindfulness intervention, the content includes: guide body scan practice; guide stretching exercise and mindful breathing; guide practice of mindfulness to breath and body; teach three-minute breathing exercise; guide joint session and let parents practice mindfulness with children; guide mindfulness practice of exploring difficulties; and teach loving-kindness practice.~For the child program, the content includes: guide mindful breathing exercise; guide mindful movement exercises; use stories of animal characters to guide body scan exercise; guide mindful eating and mindful walking exercise; tell stories about different emotions and guide discussion; guide the imagination exercise about different emotions; and guide loving-kindness practice."
224224861|NCT00455663|BEHAVIORAL|Cognitive Adaptation Training|Environmental supports for all independent living skills
224224862|NCT00455663|BEHAVIORAL|Pharm-Cognitive Adaptation Training|Environmental supports for medication and appointment adherence
224224863|NCT00455663|OTHER|Treatment as usual|Medication follow-up and limited case management provided by local community mental health authority
224224864|NCT00358826|DRUG|VIA-2291|oral dosing, 1 time daily for 12 or 24 weeks
223635981|NCT03662867|OTHER|Wait-list|No intervention is given between T1 and T2. Family-based mindfulness intervention would be received after posttest of intervention groups.
223635982|NCT04649112|GENETIC|PBCAR19B|Single dose of Allogeneic Anti-CD19 CAR T cells will be injected/infused
223635983|NCT00011596|PROCEDURE|Gait Training|
223635984|NCT01017185|DRUG|HF10|
224224865|NCT00358826|DRUG|Placebo|oral dosing, 1 time daily for 12 or 24 weeks
224224866|NCT03289975|OTHER|pulmonary ultrasound|Collect the aeration profile for each lung quadrant: profile A, profile B1, profile B2, profile C. Calculate the aeration score from O to 36 (LUS (Lung ultrasound) score).
223635985|NCT04735263|DRUG|Atorvastatin 80mg|Patient will be receiving 80mg of Atorvastatin, if they are able to tolerate it from the start to the end of the study.
223635986|NCT03038061|OTHER|Patients undergoing Laparoscopic Surgery|Data are to be obtained at three phases at supine horizontal position (during spontaneous breathing, at mechanically ventilated patient under general anesthesia with muscle relaxation and at mechanically ventilated patient under general anesthesia with muscle relaxation during insufflation of carbon dioxide into the peritoneal cavity to achieve exposure during laparoscopic surgery).
223635987|NCT06532578|BIOLOGICAL|CPX101 or placebo 120mg Q2W|Subcutaneous injection of CPX101 or placebo
223635988|NCT06532578|BIOLOGICAL|CPX101 or placebo 160mg Q4W|Subcutaneous injection of CPX101 or placebo
223635989|NCT06532578|BIOLOGICAL|CPX101 or placebo 160mg Q2W|Subcutaneous injection of CPX101 or placebo
223635990|NCT06532578|BIOLOGICAL|CPX101 or placebo 240mg Q4W|Subcutaneous injection of CPX101 or placebo
223635991|NCT06532578|BIOLOGICAL|CPX101 or placebo 240mg Q2W|Subcutaneous injection of CPX101 or placebo
223635992|NCT06532578|BIOLOGICAL|CPX101 or placebo 360mg Q2W|CPX101 or placebo 360mg Q2W
223635993|NCT06532578|BIOLOGICAL|CPX101 or placebo 360mg Q4W|CPX101 or placebo 360mg Q4W
223635994|NCT05452486|DIAGNOSTIC_TEST|English APD assessment|Materials presented in English
223635995|NCT05452486|DIAGNOSTIC_TEST|Spanish APD assessment|Materials presented in Spanish
223635996|NCT01402752|BIOLOGICAL|Blood flow to the tracheo-bronchial mucosa|Measurement of blood flow to the tracheo-bronchial mucosa via differential absorption of diluted dimethyl ether tracer gas.
224224867|NCT00638170|BIOLOGICAL|Cranberry juice|5 ml/kg up to 300 ml, 1-2 doses daily for six months
224224868|NCT00638170|BIOLOGICAL|Placebo juice|5 ml/kg up to 300 ml, 1-2 doses daily for six months
223635997|NCT03698071|BIOLOGICAL|blood sample|30 ml whole blood for Peripheral blood mononuclear cell (PBMC) and monocytes isolation
223635998|NCT03698071|BIOLOGICAL|urine sample|6 ml
223635999|NCT01249352|DRUG|Nimotuzumab|200 mg, IV Weekly IV dose for up to 26 weeks.
223636000|NCT01249352|DRUG|Cisplatin|75 mg/m2, IV dose on D1 of each chemotherapy cycle, for 4 cycles, always after nimotuzumab.
223636001|NCT01249352|DRUG|Fluorouracil|1,000 mg/m2, IV dose in a 24-hour continuous infusion, from D1 to D4, every chemotherapy cycle, for 4 cycles.
223636002|NCT01249352|RADIATION|Radiotherapy|Radiotherapy 50.4 Gy, fractions of 1.8 Gy/day
223636003|NCT05120180|PROCEDURE|axillary lymph node dissection with vein branches reservation|Spare the vein branches when ALND being performed
223636004|NCT05120180|PROCEDURE|axillary lymph node dissection without vein branches reservation|Don't spare the vein branches when ALND being performed
223636005|NCT04088149|DRUG|GXNPC1|Autologous ADSCs
223636006|NCT03762590|OTHER|Doxy.me genetic education +/- Color Genomics genetic education|"Doxy.me is a HIPAA compliant telemedicine platform that allows clinicians to provide education to remote patients.~Genetic education via Doxy.me will consist of a pre-recorded genetic education video and a live interactive video conferencing session with a GENERATE genetic counselor.~Genetic education via Color Genomics will consist of both written information and an educational video on the Color Genomics website."
223636007|NCT03762590|OTHER|Color Genomics genetic education|Genetic education via Color Genomics will consist of both written information and an educational video on the Color Genomics website.
223636008|NCT05109364|DRUG|Terazosin therapy|Primary procedures in this study are MIBG scan, DAT scan, NM-MRI, and terazosin titration. Subjects will return for research visits and imaging every six months for three years. The investigators hypothesize that the rate of decline in DAT scan123I-Ioflupane uptake will be slower in subjects who have received the a1- Adrenergic Receptor Antagonist Terazosin, resulting in a decreased clinical conversion rate to parkinsonism.
223636009|NCT06172959|BEHAVIORAL|Vocal Intonation Therapy (VIT)|Participants will receive 12 individual sessions, four times a week (i.e., any four days of seven days) over three weeks. Each session will be held virtually for 30-minutes. Vocal Intonation Therapy is a music therapy technique consisting of breathing and vocal exercises to target respiratory function and vocal quality.
223636010|NCT06172959|BEHAVIORAL|Therapeutic Singing (TS)|Participants will receive 12 individual sessions, four times a week (i.e., any four days of seven days) over three weeks. Each session will be held virtually for 30-minutes. Therapeutic Singing is a music therapy technique used to work on the rehabilitation of vocal and respiratory function.
223636011|NCT04033796|DIETARY_SUPPLEMENT|25,000 IU|Vitamin-D3 supplementation providing 25,000 IU administered orally every two months (equivalent to \~400 IU/d);
223636012|NCT04033796|DIETARY_SUPPLEMENT|50,000 IU|Vitamin-D3 supplementation providing 50,000 IU administered orally every two months (equivalent to \~800 IU/d);
223636013|NCT04033796|DIETARY_SUPPLEMENT|Placebo|A placebo (administered orally every two months) supplementation control group.
224224869|NCT00903383|DRUG|LX3305 low dose|A low dose of LX3305; daily oral intake for 12 weeks
224224870|NCT00903383|DRUG|LX3305 mid dose|A mid dose of LX3305; daily oral intake for 12 weeks
224224871|NCT00903383|DRUG|LX3305 high dose|A high dose of LX3305; daily oral intake for 12 weeks
224224872|NCT00903383|DRUG|Placebo|Matching placebo dosing with daily oral intake for 12 weeks
224224873|NCT01195922|DRUG|Sirolimus|21 evaluable subjects will take rapamycin (sirolimus) orally once per day for 21 days. Before and after dosing tumor assessments to include: photographs, CT \& amp; PET scans will be done for tumor measurement.
224224874|NCT04687163|DRUG|HAIC of 130 mg/m² Oxaliplatin, and 5-fu|Hepatic arterial infusion of 130 mg/m² oxaliplatin,leucovorin and 2400 mg/m² 5-FU
224224875|NCT04687163|DRUG|HAIC of 85 mg/m² Oxaliplatin, and 5-fu|Hepatic arterial infusion of 85 mg/m² oxaliplatin,leucovorin and 2400 mg/m² 5-FU
224224876|NCT04687163|DRUG|TKI|sorafenib 400mg bid or lenvatinib 12 mg/day (for bodyweight ≥60 kg) or 8 mg/day (for bodyweight \<60 kg)
224224877|NCT00997581|DRUG|apremilast|apremilast 20 mg taken twice daily by mouth
224224878|NCT00997581|DRUG|indomethacin SR|indomethacin SR 75 mg taken twice daily by mouth
224224879|NCT01727479|OTHER|Ribose|After each of the 3km time trial (3 in total), participants will be asked to drink the experimental product (or placebo) incorporated in a sports drink.
224224880|NCT01727479|OTHER|Placebo|
224224881|NCT00743067|DRUG|GSK1363089 (formerly XL880)|GSK1363089 will be available as solid capsules with dose unit of 20, 100 and 200 mg. Subjects will administer GSK1363089 capsules orally
224224882|NCT01110681|DEVICE|Solesta (Dextranomer in gel of stabilized non-animal hyaluronate)|
224224883|NCT05128409|DRUG|XKH001 Injection|0.5mg/kg: 3Subjects,1Sentinel Participants 1.67mg/kg: 6Subjects, ,1Sentinel Participants 3.34mg/kg: 6Subjects,1Sentinel Participants 5.0mg/kg: 6Subjects, ,1Sentinel Participants 10.0mg/kg: 6Subjects,1Sentinel Participants
224224884|NCT05128409|DRUG|XKH001Placebo Injection|1.67mg/kg: 2Subjects,1Sentinel Participants 3.34mg/kg: 2Subjects,1Sentinel Participants 5.0mg/kg: 2Subjects,1Sentinel Participants 10.0mg/kg: 2Subjects, 1Sentinel Participants
224224885|NCT01821625|DRUG|Eltrombopag|Study patients will be provided eltrombopag to raise platelet levels before anti-hepatitis C drugs are initiated, and will continue eltrombopag throughout the study.
224224886|NCT03868449|OTHER|Question Prompt List|Question prompt list
224224887|NCT03868449|OTHER|3 questions|3 questions from the AskShareKnow model
224224888|NCT04170166|PROCEDURE|Anterolateral subacromial steroid injection|Applying to the anterolateral approach arm, this group will receive their subacromial steroid injection via an anterolateral approach
224224889|NCT04170166|PROCEDURE|Posterior subacromial steroid injection|Applying to the posterior approach arm, this group will receive their subacromial steroid injection via an posterior approach
224224890|NCT02837978|DRUG|Tacrolimus|Tacrolimus capsule: 0.5mg to 1mg, po, twice per day (Bid)，adjusted by its concentration in blood or due to patient response. Then may titer down until the endpoint.
224224891|NCT02837978|DRUG|MTX|MTX：5mg to 15mg, po, once per week (Qw) until the endpoint or adjusted due to unacceptable toxicity develops.
224224892|NCT03019393|OTHER|Beef|200 g beef topside which is fully cooked will be provided to participant after overnight fast. The intervention is one time only.
224224893|NCT02388178|DRUG|Control toothpaste containing no anti-cavity ingredients|Brush whole mouth with study toothpaste 2x/day for the 2 week test period. Each brushing routine is 1 minute whole mouth brushing with oral retainer in mouth, spit out toothpaste residue and wait for 1 minute before rinsing with water.
224224894|NCT02388178|DRUG|Experimental toothpaste containing fluoride and amino acid (arginine)|Brush whole mouth with study toothpaste 2x/day for the 2 week test period. Each brushing routine is 1 minute whole mouth brushing with oral retainer in mouth, spit out toothpaste residue and wait for 1 minute before rinsing with water.
224224895|NCT02388178|DRUG|Fluoride toothpaste containing fluoride as the anti-cavity ingredient|Brush whole mouth with study toothpaste 2x/day for the 2 week test period. Each brushing routine is 1 minute whole mouth brushing with oral retainer in mouth, spit out toothpaste residue and wait for 1 minute before rinsing with water.
224224896|NCT05029323|DIAGNOSTIC_TEST|Fast HUTT|Fast HUTT protocol stabilization phase of 5 min in the supine position; passive phase of 10 min at a tilt angle of 60 degrees; provocation phase of further 10 min after 300 micrograms NTG sublingual spray.
224224897|NCT05029323|DIAGNOSTIC_TEST|Conventional HUTT|Conventional HUTT protocol stabilization phase of 5 min in the supine position; passive phase of 20 min at a tilt angle of 60 degrees; provocation phase of further 15 min after 300 micrograms NTG sublingual spray.
223514932|NCT06501248|DRUG|Triticum Aestivum|The intervention period will be 120 days, searching for effects on insulin sensitivity and metabolic control.
223514933|NCT06501248|DRUG|Placebo (calcined magnesia)|The intervention period will be 120 days, searching for effects on insulin sensitivity and metabolic control.
223514934|NCT00926900|DRUG|D-cycloserine|50 mg at approximately 1.5 hours prior to cue-exposure training sessions
223514935|NCT00926900|DRUG|Placebo|Placebo
223514936|NCT04575298|DIETARY_SUPPLEMENT|Acceptability, tolerance study for an infant formula with human milk oligosaccharides|Prospective study
223514937|NCT03150888|DRUG|Antihypertensive Agents|Single or combination therapy with five type of antihypertensive agents, such as Ca channel blockers, ACE inhibitors, ARBs, diuretics, or beta-blockers.
223514938|NCT03150888|OTHER|Cardiovascular risk factors|Different level of cardiovascular risk factors associated with genetics, environments and lifestyles.
223514939|NCT04652999|BEHAVIORAL|Muscle Relaxation with Guided Imagery|Relaxation intervention session begins with diaphragmatic breathing, followed by Jacobson's progressive muscle relaxation, which involves the contraction and subsequent relaxation of the 16 muscle groups of the body (forearm, arm, upper forehead, eye, mouth, jaw and throat, neck, shoulder, chest, stomach, thigh, leg and foot). The contraction is performed for 7 seconds while the relaxation lasts for about 40 to 50 seconds. The relaxation of the foot muscle group is only performed on the healthy foot, because dressing and bandages may bandage the foot with the DFU, which together with the typical joint stiffness of the diabetic foot, make it difficult to perform. After muscle relaxation, begins the guided imagery focused on DFU healing. The patient is instructed to think about his/her current state of health and to imagine the DFU as a dark area and the healing relaxation as a light associated to pleasant sensations, which will focus on the foot with DFU to heal it.
223514940|NCT04652999|BEHAVIORAL|Neutral Guided Imagery|This placebo consists on neutral guided imagery focused on themes of the patient's daily life before having DFU. Each session has a theme associated with the patient's life - family, work, friends and leisure. Initially, the patient is asked to think about an event related to the theme of the session of his/her choice, be it positive or negative, which occurred before patient has the current DFU. Then, questions are asked which allow a more detailed reconstruction of the event and the patient is asked to imagine according only to the instructions given. When the whole episode is remembered, the patient is asked to tell what he or she imagined/remembered in each of the questions given.
223514941|NCT03167658|BEHAVIORAL|Workplace wellness program|Multi-prong workplace wellness program, with components such as nutrition counseling, fitness challenges, and stress management workshops, including supports and incentives.
224224898|NCT06536933|DIAGNOSTIC_TEST|Abdominal Ultrasound|Diagnostic non invasive Abdomibal Ultrasound will be done to quantify hepatic steatosis
224224899|NCT01928654|DEVICE|Micropulse laser treatment|Device for subthreshold treatment of the retina, by decomposing a continuos wave of laser in micropulses, with 5% duty cycle, 200 milliseconds, 100 microns, and power adjusted according to patient's diopter transparency and pigmentation.
224224900|NCT01928654|DEVICE|Laser modified ETDRS|Device for visible treatment of the retina, with direct treatment of microaneurysms or grid pattern covering the area of retinal edema.
224224901|NCT00320593|DEVICE|Progressive Addition Lenses (PALs)|Varilux Ellipse progressive addition lenses (PALs) with a +2.00 D addition
224224902|NCT00320593|DEVICE|Single Vision Lenses (SVLs)|Single vision lenses
224224903|NCT02950753|DRUG|Lactated Ringer Solution|Fluid bolus of Lactated Ringer solution (30ml/kg).
224224904|NCT02950753|DRUG|Normal Saline|Fluid bolus or Normal Saline (30ml/kg).
224224905|NCT00097071|DRUG|insulin lispro|
224224906|NCT00097071|DRUG|insulin aspart|
224224907|NCT03485131|DEVICE|Transcranial direct-current stimulation (tDCS)|Stimulation sessions will be conducted twice a day on 5 consecutive weekdays. The twice daily sessions will be separated by at least 3 hours (one in the morning and the other one in the PM). The duration of treatment will be 4 weeks
224224908|NCT03485131|DEVICE|Placebo|Placebo/sham stimulation: After 40 seconds of real stimulation of 2 mAmp to simulate the tDCS induced skin sensation, only a small current pulse is delivered every 550 msec (110 mAmp over 15 msec) through the remainder of the 20-minute period
224224909|NCT01234428|PROCEDURE|Laparoscopic surgery|Gastric banding
224224910|NCT01234428|PROCEDURE|gastric banding|laparoscopic gastric banding
224224911|NCT06282588|DRUG|Darolutamide|2x300 mg tablets twice daily, for up to 96 weeks
224224912|NCT06282588|DRUG|Darolutamide matched placebo|2x300 mg tablets twice daily, for up to 96 weeks
224224913|NCT06282588|RADIATION|Radiotherapy|Preferred regimens: 60 to 62 Gy delivered in 20 fractions of 3.0 to 3.1Gy per fraction; 36.25 Gy delivered in 5 fractions of 7.25 Gy per fraction, 2-3 fractions per week
224224914|NCT06282588|DRUG|Zoladex 3.6Mg Implant|3.6 mg, subcutaneous use
223514942|NCT03614832|DRUG|Ticagrelor 90 mg|half-dose ticagrelor treatment (90 mg loading dose, then 90 mg once daily) for 1 week.
224224915|NCT06282588|DRUG|Zoladex LA|10.8 mg, subcutaneous use
224224916|NCT06282588|DRUG|Decapeptyl sustained release 22.5 mg|22.5 mg, intramusculair injection
224224917|NCT06282588|DRUG|Decapeptyl sustained release 11.25 mg|11.25 mg, intramusculair injection
224224918|NCT06282588|DRUG|Depo-Eligard 45 mg|45 mg, subcutaneous use
224224919|NCT06282588|DRUG|Depo-Eligard 22.5 mg|22.5 mg, subcutaneous use
224224920|NCT06282588|DRUG|Depo-Eligard 7.5 mg|7.5 mg, subcutaneous use
223514943|NCT03614832|DRUG|Clopidogrel 150 mg|double standard-dose clopidogrel treatment (150 mg loading dose, then 150 mg once daily) for 1 week.
223514944|NCT01157494|OTHER|classification of hand manipulation function|To determine the criterion validity of the classification of the pattern of manipulation proposed by Ferrari et al. we correlated hand manipulation classes with both the scores of the two standard criteria chosen (AHA and Melbourne Assessment).
224224921|NCT06282588|DRUG|Firmagon 120 MG Injection|120 mg, subcutaneous use
224224922|NCT06282588|DRUG|Firmagon 80 MG Injection|80 mg, subcutaneous use
224224923|NCT06282588|DRUG|Docetaxel|75 mg per square m, IV infusion
224224924|NCT03086668|PROCEDURE|Conventional Jaw thrust Group|a video-stylet assisted nasotracheal intubation and facilitate by conventional jaw thrust technique
224224925|NCT03086668|PROCEDURE|Fingers hook Group|a video-stylet assisted nasotracheal intubation and facilitate by fingers-hook technique
224224926|NCT02118701|OTHER|Shared Decision-Making educational training|
223514945|NCT01883375|BEHAVIORAL|Dignity Talk|Patient and family member participants will be given the Dignity Talk framework questions and asked to use them in conversation with each other. Research nurse will return at day 4-6 to confirm both participants have covered all items they wish to discuss. 4-6 months after the death of patient, family members will be contacted in order to collect data pertaining to their bereavement experiences and distress. Will also be asked to complete evaluative feedback on Dignity Talk.
223514946|NCT01883375|BEHAVIORAL|The Dignity Talk Communication Topics|There have not been any non-completers - this arm not being used currently
223514947|NCT06421454|DRUG|Melatonin|Pressure Ulcer will be treated with a melatonin cream daily
223514948|NCT06421454|DRUG|Hydrogel|Pressure ulcer will be treated with hydrogel daily as a comparator
223514949|NCT03638180|DRUG|BLU-5937|BLU-5937 oral tablet
223514950|NCT03638180|DRUG|Placebo|Matching placebo to BLU-5937
223514951|NCT06160778|DRUG|Ketorolac Tromethamine|Intravenous ketorolac given at 0.5 mg/kg of body weight up to a maximum of 30 mg in a single dose.
223514952|NCT06160778|DRUG|Morphine Sulfate|Intravenous morphine given at 0.1 mg/kg of body weight up to a maximum of 5 mg in a single dose.
224224927|NCT01217203|DRUG|IPH2101 combined to lenalidomide|"Dose level 1 : 0.2 mg/kg IPH2101(with Lenalidomide 10 mg/day) Dose level 2 : 0.2 mg/kg IPH2101(with Lenalidomide 25 mg/day) Dose level 3 : 1 mg/kg IPH2101(with Lenalidomide 25 mg/day) Dose level 4 : 2 mg/kg IPH2101(with Lenalidomide 25 mg/day)~Extension cohort: 6 patients at the Maximum Tolerated Dose (MTD)"
224224928|NCT00662714|DRUG|Repaglinide|oral; initial dose: 3x 0.5mg/d; 2 years
224224929|NCT00662714|DRUG|short-acting Insulin (Actrapid)|initial dose: 3x 0.05E/kg/d, injected; 2 years
224224930|NCT00457665|DRUG|Nelfinavir|
224224931|NCT00457665|DRUG|Efavirenz|
224224932|NCT00003054|DRUG|paclitaxel|
224224933|NCT02755545|DRUG|Product A|Product A applied topically to the entire face or other affected area of the skin once daily
224224934|NCT02755545|DRUG|Product B|Product B applied topically to affected area of the skin 1 to 3 times daily
224224935|NCT01716754|DRUG|QGE031|QGE031 was supplied as 120 mg liquid in vial per 1 mL
224224936|NCT01716754|DRUG|Omalizumab|Omalizumab was supplied as 150 mg lyophilisate in vial
224224937|NCT01716754|DRUG|Placebo|Placebo to QGE031 and Omalizumab was supplied as QGE031 0 mg in vial per 1 mL
224224938|NCT00481247|DRUG|Dasatinib|Tablets, oral, dasatinib 50-140 mg once daily (QD)
224224939|NCT00481247|DRUG|Imatinib|Tablets, oral, imatinib 200-800 mg, QD
224224940|NCT00376142|BEHAVIORAL|Psychological theory-based behaviour change interventions|
223636014|NCT05720286|DEVICE|Arthroscopic rotator cuff repair|Arthroscopic transosseous reinsertion of the rotator cuff is the most widely used arthroscopic technique. The tendons are repositioned on the greater and lesser tuberosities of the humerus with specific anchors. These anchors, placed in the humeral bone, are attached to sutures which are in turn tied to the tendon.
223636015|NCT01570413|PROCEDURE|No Pelvic Exam|Will not receive pelvic examination.
223636016|NCT01570413|PROCEDURE|Pelvic Examination|Pelvic examination will be performed.
223636017|NCT01088568|PROCEDURE|the implantation of toric implantable collamer lens|perform the implantation of toric implantable collamer lens for both eyes
223636018|NCT01088568|PROCEDURE|customized laser-assisted in situ keratomileusis|perform Q-factor customized laser-assisted in situ keratomileusis for both eyes
223636019|NCT00693407|PROCEDURE|gastric capsaicin with heterotopic stimulation/ distraction|The subjects are randomized to swallow either a capsaicin 0.50mg capsule or an identical placebo capsule with 100ml of water If after 15 minutes pain scores do not reach a minimum level of 30, a further double-blinded capsule of the same content will be swallowed with 100ml of water. This is repeated to a maximum of 8 capusles until pain with VAS \>30 is reported.
223636020|NCT01535040|DRUG|memantine hydrochloride|Estimate participation, accrual, adherence, and retention of cancer survivors who smoke and are randomized to receive memantine (10 mg twice daily) or a matching placebo for 12 weeks.
223636021|NCT01535040|DRUG|placebo|Placebo by mouth through completion of 12 weeks.
223636022|NCT03479814|RADIATION|IMRT-SIB plus sequential IG-RT boost|
223636023|NCT02086175|DRUG|Imprime PGG|
223636024|NCT02086175|DRUG|Rituximab|
223636025|NCT01074970|DRUG|Cisplatin|Cisplatin 75 mg/m2 IV infusion over 60 minutes, D1 every 21 days for 4 cycles
223636026|NCT01074970|DRUG|Rucaparib|Rucaparib 24mg C1,30mg C2-4, D1,2,3 every 21 days for 4 cycles
223636027|NCT01074970|DRUG|Cisplatin|Cisplatin 75 mg/m2 IV infusion over 60 minutes, D1 every 21 days for 4 cycles
223636028|NCT00734149|DRUG|Bortezomib|
223636029|NCT00734149|DRUG|Melphalan|
223636030|NCT00734149|DRUG|Prednisone|
224224941|NCT02587156|DIETARY_SUPPLEMENT|Meal serving at high dietary protein|Participants are habituated to a high level of dietary protein intake for 21 days.
223636031|NCT02734875|OTHER|Intervention|The intervention arm offers primary care providers additional information on patient risks and benefits as well as an offer of assistance with managing a patient's anticoagulation from a respected service at BWH.
223636032|NCT05430854|BIOLOGICAL|Daxdilimab|Daxdilimab will be administered subcutaneously as two injections for each dose.
223636033|NCT04314284|BEHAVIORAL|I Can PIC|-Online decision tool that explains health insurance terms and health insurance terms, provides tips on lowering health care costs, advises patient to discuss costs with provider and insurance, and provides financial resources for patient.
223636034|NCT04314284|OTHER|Historical control survey|-31 questions including overall experience with cancer care provider, previous discussions with care team regarding health care costs, preferences for discussing health care costs with physician, confidence level on discussing health care costs with physician, feelings about current financial situation, delays or avoidance of medical care in the past 12 months, confidence in health care choices and health insurance choices, current health conditions, and demographic data.
223636035|NCT04314284|OTHER|Post-intervention survey (I Can PIC participants)|-31 questions including overall experience with cancer care provider, previous discussions with care team regarding health care costs, preferences for discussing health care costs with physician, confidence level on discussing health care costs with physician, feelings about current financial situation, delays or avoidance of medical care in the past 12 months, confidence in health care choices and health insurance choices, current health conditions, and demographic data.
223636036|NCT04314284|OTHER|Follow-Up survey (I Can PIC participants)|-19 questions including overall experience with cancer care provider, discussion with care team regarding health care costs, preferences for discussing health care costs with physician, confidence level on discussing health care costs with physician, feelings about current financial situation, delays or avoidance of medical care in the past 12 months, and confidence in health care choices and health insurance choices.
223636037|NCT00161759|DRUG|Sheet skin grafts affixed with Fibrin Sealant (lyophilized) with 4 IU/mL Thrombin|
223636038|NCT06521125|DIAGNOSTIC_TEST|High resolution Computed Tomography (HRCT) scans of the Chest|A chest high-resolution computed tomography (HRCT) scan will be performed
223636039|NCT06521125|DIAGNOSTIC_TEST|Pulmonary Function Testing (PFTs)|Spirometry and diffusing capacity of the lung for carbon monoxide (DLCO) measurements will be performed
223636040|NCT06521125|DIAGNOSTIC_TEST|Digital lung sounds auscultation|Lung sounds will be recorded using a manual approach with a digital stethoscope
223636041|NCT06521125|DIAGNOSTIC_TEST|Laboratory Assessments|Clinical laboratory tests will be collected from each participant
223636042|NCT06521125|GENETIC|DNA sequencing|A sample of genomic DNA from peripheral blood lymphocytes will be collected for DNA sequencing
223636043|NCT00938704|DRUG|carboxymethylcellulose 0.5% +glycerin 0.9%|To open, twist and pull tab to remove. Instill study medication as needed, but at least one drop 3 times a day as instructed in the protocol and then discard the container.
223636044|NCT00938704|DRUG|sodium hyaluronate 0.18%|To open, twist and pull tab to remove. Instill study medication as needed, but at least one drop 3 times a day as instructed in the protocol and then discard the container.
223636045|NCT06114238|DRUG|Itepekimab AI|Pharmaceutical form:Solution for injection; Route of administration: Subcutaneous AI
223764848|NCT05132127|DRUG|sutimlimab|Pharmaceutical form: solution for injection Route of administration: intravenous (IV)
223764849|NCT05220397|BIOLOGICAL|Janssen Ad26.CoV2.S Vaccine|Single dose vaccine of 0.5 mL administered via intramuscular injection, typically in the deltoid muscle
224224942|NCT02587156|DIETARY_SUPPLEMENT|Meal serving at low dietary protein|Participants are habituated to a low level of dietary protein intake for 21 days.
224224943|NCT02587156|DIETARY_SUPPLEMENT|Meal serving|To investigate impact of habituated protein level
224224944|NCT02535000|DRUG|Duloxetine|duloxetine 60 mg
224224945|NCT02535000|DRUG|Placebo|placebo
224224946|NCT00565370|DRUG|Capecitabine, Cisplatin, Sorafenib|Capecitabine ( ) mg/m2 bid D1-D15 Cisplatin 80 mg/m2 D1 Sorafenib ( ) mg bid PO daily every 3 weeks
224224947|NCT05771311|DEVICE|KTP|split-side, 1 -5 sessions at intervals of 6 - 8 weeks
224224948|NCT05771311|DEVICE|PDL|split-side, 1 -5 sessions at intervals of 6 - 8 weeks
223514953|NCT06160778|DRUG|normal saline|Intravenous normal saline placebo (labelled as morphine) given at 0.1 mg/kg of body weight up to a maximum of 5 mg in a single dose.
223514954|NCT06160778|DRUG|Normal saline|Intravenous normal saline placebo (labelled as ketorolac) given at 0.5 mg/kg of body weight up to a maximum of 30 mg in a single dose.
223514955|NCT01283945|DRUG|Lucitanib|"Oral administration, once daily (qd), in fasting conditions.~Dose escalation - continuous schedule~Dose expansion - continuous or intermittent dosing schedules (i.e. 5 days on/2days off or 21 days on/7 days off)~Dosage form: hard gelatin capsules for oral administration (2.5, 5, 10, 30 and 50 mg strengths)"
223514956|NCT01946269|OTHER|Goal-directed Resuscitation Therapy (GDT)|"* A target value of a cardiac index (CI) greater than 2.5 L/min/m2 and a mean arterial pressure of 70 mmHg will be sought.~* The first step will be fluid resuscitation with 200ml aliquots of Lactated Ringer's solution plus human albumin 20% 50 mL whenever the CI is lower than 2.5 L/min/m2. The fluid challenge will be stopped if the CVP rises by more than 4 mmHg during the infusion period or CI increases less than 10%.~* When the CI is lower than or equal to 2.5L/min/m2 despite of fluid challenge, dobutamine will be initiated with increasing doses up to 20mcg/kg/min.~* The final step will be red blood transfusion to reach a hematocrit higher than 28%.~* If necessary, norepinephrine infusion will be used to maintain a mean arterial pressure above 70 mmHg."
223514957|NCT01946269|OTHER|Standard protocol|The control group will be managed by the surgical ICU staff in the postoperative period according to institutional protocol of hemodynamic monitoring.
223514958|NCT06327165|OTHER|observation|The ANI monitor calculates heart rate variability mediated by changes in the parasympathetic nervous system.
223514959|NCT05522400|BEHAVIORAL|Virtual Reality (VR) and human computer interaction system|The experimental group used VR technology and human-computer interaction system for exercise, while the control group used traditional exercise program
223514960|NCT05390320|PROCEDURE|PAOO|Periodontally accelerated osteogenic orthodontics will be applied to treat patients with moderate crowding.
223514961|NCT05390320|OTHER|Fixed appliance|Fixed appliances will be applied to treat patients with moderate crowding without any acceleration methods.
223514962|NCT04739215|DRUG|Dapagliflozin 10 MG [Farxiga]|Dapagliflozin 10 mg / day oral
223514963|NCT04739215|DRUG|Placebo|One Placebo capsule daily oral
223514964|NCT00000397|BEHAVIORAL|Behavioral insomnia therapy|
223514965|NCT04878926|PROCEDURE|IV midazolam and propofol-based sedation combined with ultrasound-guided, left side TAP block|IV midazolam and propofol-based sedation combined with ultrasound-guided, left side TAP block
223514966|NCT04878926|PROCEDURE|IV midazolam and propofol-based sedation with Local Anesthetic infiltration|IV midazolam and propofol-based sedation with Local Anesthetic infiltration
223514967|NCT05950997|DRUG|Acalabrutinib|100 mg capsules administered by mouth once daily (28-day cycles)
223514968|NCT05950997|DRUG|Obinutuzumab|100 mg administered intravenously on Day 1 and 900 mg administered intravenously on Day 2, 1000 mg administered intravenously on Day 8 and 15 of cycle 2 and 1000 mg on Day 1 of subsequent cycles for a total of 6 cycles (28-day cycles)
223514969|NCT02144337|BEHAVIORAL|Steps To Active Kids (STAK) programme|Intervention described in Arm/Group Description.
223514970|NCT00235625|DRUG|Curcuminoids C3 Complex®|
223514971|NCT04419987|GENETIC|draw blood|search for new genetic variations (when the diagnostic exploration will have been non informative) by sequencing exons.
223514972|NCT01872000|PROCEDURE|Cataract surgery|
223514973|NCT04973293|DRUG|sintilimab|Sintilimab 200 mg, 4 cycles of treatment before surgery
223514974|NCT04973293|DRUG|bevacizumab|bevacizumab 15 mg/kg, 4 cycles of treatment before surgery
223514975|NCT02163863|DEVICE|Femoropopliteal stenting|
223514976|NCT01013337|PROCEDURE|acupuncture therapy|
223514977|NCT01013337|PROCEDURE|sham intervention|Placebo acupuncture
223514978|NCT03221335|DEVICE|EUS-guided RFA|All patients would undergo EUS with a linear array echoendoscope. The location and size of the lesion would be assessed for suitability of treatment. After locating the lesion, the RFA needle would be inserted to the centre of the lesion. RFA would then be initiated and hyperechoic interferences would be observed around the electrode signifying heating of the tissue. The duration of ablation would be according to the size of the lesion.
223514979|NCT03066180|DEVICE|Viveve SUI treatment|Non-ablative radiofrequency treatment with surface cooling
223514980|NCT00968630|OTHER|Laboratory Biomarker Analysis|Correlative studies
223514981|NCT00968630|PROCEDURE|Leukapheresis|Undergo leukapheresis
223514982|NCT01435642|OTHER|No treatment given|Subject will fill out a questionnaire when entering the non-interventional study
223514983|NCT02743312|DEVICE|Torso Weights|Following assessment of an individual's directional instability, small weights are applied to a vest-like garment to correct balance loss.
224224949|NCT01918709|DRUG|Sequence 1 : Period 1(V) Period 2(R) Period 3(V+R)|Valsartan = Antihypertensive drug / Rosuvastatin = Antihyperlipidemic drug
224224950|NCT01918709|DRUG|Sequence 2 : Period 1(V+R) Period 2(V) Period 3(R)|Valsartan = Antihypertensive drug / Rosuvastatin = Antihyperlipidemic drug
224224951|NCT01918709|DRUG|Sequence 3 : Period 1(R) Period 2(V+R) Period 3(V)|Valsartan = Antihypertensive drug / Rosuvastatin = Antihyperlipidemic drug
224224952|NCT01918709|DRUG|Sequence 4 : Period 1(V+R) Period 2(R) Period 3(V)|Valsartan = Antihypertensive drug / Rosuvastatin = Antihyperlipidemic drug
224224953|NCT01918709|DRUG|Sequence 5 : Period 1(R) Period 2(V) Period 3(V+R)|Valsartan = Antihypertensive drug / Rosuvastatin = Antihyperlipidemic drug
224224954|NCT01918709|DRUG|Sequence 6 : Period 1(V) Period 2(V+R) Period 3(R)|Valsartan = Antihypertensive drug / Rosuvastatin = Antihyperlipidemic drug
224224955|NCT04317781|BIOLOGICAL|Tagraxofusp-erzs|Given IV
224224956|NCT06462001|BIOLOGICAL|Bacillus Calmette-Guerin Vaccine Intravesical|BCG (Oncotice) is administered intravesically as per usual standard of care
224224957|NCT06462001|DRUG|Mitomycin|MMC is administered intravesically as per usual standard of care
224224958|NCT01620489|DRUG|liraglutide|1.8 mg administered once daily subcutaneously (s.c., under the skin) as add-on to the subject's stable pre-trial oral antidiabetic drug (OAD) and/or insulin regimen.
224224959|NCT01620489|DRUG|placebo|Administered once daily subcutaneously (s.c., under the skin) as add-on to the subject's stable pre-trial oral antidiabetic drug (OAD) and/or insulin regimen.
223636046|NCT06114238|DRUG|Itepekimab PFS|Pharmaceutical form:Solution for injection; Route of administration: Subcutaneous PFS
224224960|NCT03705884|OTHER|18F-FDG|Hybrid 18F-FDG PET/MR imaging for observational diagnostic purposes.
224224961|NCT03705884|DRUG|Prednisolone|Oral course of Prednisolone for treatment of sarcoidosis (patient cohort) or as control (healthy volunteer cohort)
224224962|NCT03378349|BEHAVIORAL|Internet-delivered cognitive behavior therapy|The intervention lasts for 10 weeks and include: Education, Interoceptive exposure, exposure in-vivo, combining in-vivo exposure with interoceptive exposure, behavioral activation and relapse prevention. Include the guidance of a minimum weekly contact with a CBT psychologist.
224224963|NCT03378349|BEHAVIORAL|Treatment as usual|Consist of standardized AF information that emphasizes that an active physical and social lifestyle is necessary to maintain good health, without the guidance of a psychologist or any CBT interventions.
224224964|NCT04127591|OTHER|exosome|Collect exosomes in peripheral blood of patients and extract miRNAs from them.
224224965|NCT02649231|DRUG|Ketamine|0.8 mg/kg ketamine
224224966|NCT02649231|DRUG|Placebo|0.9% saline
224224967|NCT02649231|BEHAVIORAL|Psychological Therapy|Manualised relapse prevention based CBT
224224968|NCT02649231|BEHAVIORAL|Alcohol Education|Simple education about alcohol effects
224224969|NCT06252194|DRUG|Metformin and doxycycline|Metformin 500 mg tablet twice daily
224224970|NCT00280787|DRUG|Paclitaxel|175 mg/m2 administered on Day 1, of a 21 day cycle. Subjects will receive 2 cycles
224224971|NCT00280787|DRUG|Carboplatin|Area Under the Curve(AUC)=5 administered on Day 1 of a 21 day cycle. Subjects will receive 2 cycles.
224224972|NCT00280787|DRUG|CPT-11|100 mg/m2 administered on Day 1 of each 21 day cycle. Subjects will receive 2 cycles.
224224973|NCT00280787|DRUG|Pegfilgrastim|6 mg administered on Day 2 each each 21 day cylce. Subjects will receive 2 cycles of treatment.
224224974|NCT00280787|RADIATION|Conformal radiotherapy|Radiation therapy will be administered with standard daily fractionation of 2.0 Gy per fraction, 5 days per week.The total dose of radiotherapy will be 74 Gy
224224975|NCT06163833|DRUG|Mesenchymal stromal cell low dosage-80*10^6 cells|"MSCs have to be administered at the dosage of 80\*10\^6. MSCs have to be administered by intravenous infusion via an in situ venous catheter within 15 minutes from the preparation and within 48 hours from TBI.~They have to be diluted 1:2 in a saline solution for a total of 36mL."
224318752|NCT07134465|DRUG|HSK31858 Tablets and Itraconazole Capsules|"HSK31858 Tablets On the morning of Day 1, a single dose of HSK31858 tablets 40 mg will be administered.~Itraconazole capsules After a 10-day washout period, Take Itraconazole capsules 200mg in the morning and 200mg in the evening on D11 . A single dose of Itraconazole capsules 200 mg will be administered every morning from Day 12 to Day 14. On the morning of Day 15, take a single dose of itraconazole capsules 200mg, followed by a single dose of HSK31858 tablets 40 mg 1 hour later,"
224318753|NCT07134088|DRUG|Blinatumomab|Blinatumomab will be administered as a SC injection for up to 5 cycles (each cycle will be 35 days).
224318754|NCT07134413|DRUG|QL1706 plus bevacizumab with or without chemotherapy|"QL1706(iparomlimab and Tuvonralimab) was generated by using MabPair, a new technological platform that enables the production of two antibodies close to their natural forms from a single host cell line and is manufactured as one product. QL1706 contains a mixture of anti-PD-1 IgG4 and anti-CTLA-4 IgG1 that were produced together in a fixed ratio. Each antibody was individually optimized to achieve desirable target coverage and antibody effector functions.~Bevacizumab is a monoclonal antibody medication used to treat various cancers and a specific eye disease. It works by blocking a protein called VEGF, which helps tumors form new blood vessels, thus starving the tumor of nutrients and oxygen.~Chemotherapy (nab-paclitaxel, pemetrexed, or docetaxel) Nab-paclitaxel, also known as nanoparticle albumin-bound paclitaxel, is a chemotherapy drug used to treat certain cancers. It's a form of paclitaxel that's bound to albumin nanoparticles, which improves its solubility and delivery to cance"
223514984|NCT02743312|DEVICE|Sham Weights|Following assessment of an individual's directional instability, small weights are applied to a vest-like garment to correct balance loss. The garment is then taken by another investigator and the actual weights are replaced with sham weights.
223514985|NCT02743312|DEVICE|Fitbit Flex|Potential effect on participants' physical activity to see their own step count using this wrist-worn remote monitoring device.
223514986|NCT05874011|OTHER|understanding of prosody|The inverse correlation test consists of having the same word heard twice, and asking which of the two sounds the most like a question. The exercise will be repeated several times, for a task that will take a total of about thirty minutes
223514987|NCT01728896|OTHER|Patient-controlled oral refeeding|
224224976|NCT06163833|DRUG|Mesenchymal stromal cell low dosage-160*10^6 cells|"MSCs have to be administered at the dosage of 160\*10\^6. MSCs have to be administered by intravenous infusion via an in situ venous catheter within 15 minutes from the preparation and within 48 hours from TBI.~They have to be diluted 1:2 in a saline solution for a total of 36mL."
223514988|NCT01730729|DRUG|cabergoline|Given orally
223514989|NCT03397641|DRUG|HBI-3000|Small molecule, multi-ion channel blocker
223514990|NCT03397641|OTHER|Placebo|Normal Saline
223514991|NCT04872647|BEHAVIORAL|Phone-Based Health Coaching Utilizing Lifestyle Action Plans|Culturally sensitive health coaches trained in motivational interviewing provide 10-20 minutes of weekly phone-based health coaching. They not only guide the patient in creating a SMART goal, but assess and build off of the previous weeks' goal and problem-solve with the patient. During the week, the coach and patient text regarding daily blood glucose monitoring with real-time feedback and coaching about the implementation of the patients' goal.
223514992|NCT04332770|OTHER|levothyroxine withdrawal|All participants of this study are decided to get radioactive iodine therapy using levothyroxine withdrawal or human recombinant TSH injection prior to the study enrollment. That decision is independent with this study protocol. This study just collect continuous bio signals using wearable devices in the patients undergoing two different preparation methods for radioactive iodine therapy. That is why this study is an observational cohort study.
223636047|NCT05650749|BIOLOGICAL|GPC2 CAR T cells|The GPC2 CAR T investigational product is comprised of autologous human T cells that have been genetically modified to express a GPC2-targeting chimeric antigen receptor (CAR) transgene.
223636048|NCT04638231|OTHER|Supportive messages|Daily supportive messages via SMS or email
223636049|NCT01710982|DRUG|TZP-101|
223636050|NCT01710982|OTHER|Placebo|
223636051|NCT05375461|DRUG|TQB3616 capsules|The dose of TQB3616 capsules is 180mg, taken orally on an empty stomach, once a day for 28 consecutive days as one treatment cycle.
223636052|NCT05375461|DRUG|TQB3616-matching placebo|The dose of placebo is 180mg, taken orally on an empty stomach, once a day for 28 consecutive days as one treatment cycle.
223636053|NCT05375461|DRUG|Fluvestrin injection|Fluvestrin injection was given at a fixed dose of 500mg on day 1, day 15 of the first treatment cycle and day 1 of each subsequent treatment cycle, and a treatment cycle of 28 days.
223636054|NCT05177965|OTHER|Exposure to shift work|Detailed questionnaire adapted from the Standard Shiftwork Index, measured at inclusion
223636055|NCT06204757|OTHER|questionary|questionary relating to birth trauma are completed by midwives and patients
223636056|NCT05083741|DEVICE|Chitogel|post-operative dressing within standard of care
223636057|NCT05083741|DEVICE|Nexfoam|post-operative dressing within standard of care
223636058|NCT05672784|PROCEDURE|GNB plus standard analgesia|When patients are in supine position with a pillow under the popliteal fossa, we will target points next to superior medial, superior lateral, and inferior medial genicular arteries to block the superior medial, superior lateral, and inferior medial branches of genicular nerve. For identification, we will use color Doppler near the periosteal areas (the junctions of the epicondyle with the shafts of the femur and tibia, accordingly). using a 12 MHz linear transducer (XarioTM SSA-660A, Toshiba Medical Systems Corporation, Otawara, Japan) positioned parallel to the shaft of the long bones in the legs, the needle will be inserted ( in plane technique in the long-axis view) and a 2.5 mL of bupivacaine (5%) will be injected at each target points.standard analgesia will be given post-operativelly (paracetamol 1 gm/ three times a daily and meloxicam (15 mg)once a day)
223636059|NCT05672784|PROCEDURE|GNB plus IPACK block plus standard analgesia|IPACK block will be done when the patients in supine position with the knee flexed in 45 degree. using a low frequency transducer at a depth of 3.5-4 cm positioned transversely, 2-3 cm above the patella and over the medial aspect of the knee, we will identify the distal part of the shaft of the femur and the popliteal artery with sliding the transducer proximally and distally (If the two femoral condyles appear first, proximal sliding of the probe, so the humps of the femoral condyles will disappeared and the flat metaphysis will appeared). With advancement of the needle in plane toward the space between the popliteal artery and the femur, 15 ml of bupivacaine 0.5% will be injected. The genicular nerve block will be done as in group G and standard analgesia will be given post-operative as in group G
223636060|NCT05672784|DRUG|standard analgesia (paracetamol and meloxicam)|(paracetamol 1 gm 3 times a daily and meloxicam (15 mg) once aday.
223636061|NCT06033222|DIETARY_SUPPLEMENT|Ricinoleic Acid 750 mg|750 mg administered orally
223636062|NCT06033222|DIETARY_SUPPLEMENT|Ricinoleic Acid 1500 mg|1500 mg administered orally
223636063|NCT06033222|DIETARY_SUPPLEMENT|Ricinoleic Acid 3000 mg|3000 mg administered orally
223764850|NCT05220397|OTHER|Reduction in Immunosuppression Medication|Reduction in immunosuppression medication dosage
224318755|NCT07134699|OTHER|Participants are not assigned an intervention|For observational studies, participants are not assigned an intervention as part of the study.
224318756|NCT06828224|DEVICE|KOS® L|Delivery of medical device as injection
224318757|NCT06599216|DRUG|Adebrelimab+Dalpciclib+Standard Endocrine Therapy|Adebrelimab: 1200mg, intravenously, Q4w Dalpiciclib: 150mg once a day for 3 weeks, stop for 1 week, Q4w Standard Endocrine Therapy: Choice of endocrine therapy is according to guidelines and centre policy by investigator
224318758|NCT06983080|DRUG|Trazodone 25 mg|Trazodone 25 mg at bedtime, which can be increased to 50 mg after 14 days of treatment.
224318759|NCT06982456|OTHER|Manual Therapy on the Upper Trapezius with or without Passive Stretching|The intervention consists of manual therapy techniques applied to the upper fibers of the trapezius muscle, including superficial massage, deep massage, and pressure release technique. In one of the experimental groups, this treatment is followed by passive stretching. The control group receives no intervention. Algometric measurements (pressure pain threshold) are taken before and after the intervention, and at one-week and two-week follow-up points to assess the effectiveness and persistence of the treatment.
224318760|NCT00000591|PROCEDURE|lymphocyte depletion|
223764851|NCT05220397|OTHER|Maintenance in Immunosuppression Medication|Maintain current immunosuppression medication dosage
223764852|NCT05418556|DRUG|aspirin|DAPT strategy
223764853|NCT01332942|DRUG|BAY85-3934|Subjects received an oral single dose of placebo tablet matched to the molidustat dose (BAY85-3934) on Day 1 followed by a washout day and once daily multipledose over 12 days (from Day 3 to Day 14).
224318761|NCT04798131|OTHER|Active neurofeedback procedure|Patients will perform 5 fMRI sessions. Four consecutive fMRI runs (1/ day) during which they will continuously receive visual feedback computed from the fMRI signal analyzed with the hallucinations decoder. Patients will be trained to maintain the brain state associated with the no-hallucination state using appropriate coping strategies. A 5th fMRI scan will be performed at 1 month post-treatment.
223764854|NCT01332942|DRUG|BAY85-3934|Subjects received an oral single dose of 5 mg of molidustat IR tablet on Day 1 followed by a washout day and once daily multiple-dose over 12 days (from Day 3 to Day 14).
224318762|NCT04798131|OTHER|Sham neurofeedback procedure|Patients will perform 5 fMRI sessions. Four consecutive fMRI runs (1/ day) during which they will receive a random feedback and a 5th run at 1 month post-treatment.
223636064|NCT06033222|DRUG|Placebo|Contains no active ingredient.
223636065|NCT06585098|OTHER|game based learning|"The students in the intervention group were informed by the researcher, and the students who met the research participation criteria and volunteered to participate in the research filled out the Informed Consent Form (Annex 1) and downloaded the prepared game-based virtual reality application by entering the prepared website and using their username and password for a period of 1 week. They were asked to play with. After one week, students in the intervention group were invited to a simulation-based training application in groups of seven. In addition, the game was played at least once by the students in the intervention group under the supervision of the researcher."
223636066|NCT06584968|OTHER|training with visual feedback|Training with visual feedback by comparing the value of the monofilament with the pressure value of the monofilament applied on the precision scale in grams.
223636067|NCT06584968|OTHER|classical learning|Study of the test with practical applications on the researcher who plays the role of the patient
224224977|NCT06163833|OTHER|Placebo-storage solution|Placebo has to be administered by intravenous infusion via an in situ venous catheter within 15 minutes from the preparation and within 48 hours from TBI. It has to be diluted 1:2 in a saline solution for a total of 36mL.
224224978|NCT01871987|DRUG|FK949E|oral
224224979|NCT01283633|DEVICE|Neuromodulation|Neuromodulation as directed via remote presence robotic and experienced clinician for those with neuromodulation systems implanted to treat movement disorders and chronic pain
224224980|NCT03622333|GENETIC|Research of constitutional genetic alterations|Tumor DNA extraction Blood sample and constitutional DNA extraction CGH-array, Exome sequencing Bio-informatic analysis
224224981|NCT00648453|DRUG|Clopidogrel (Plavix)|
224224982|NCT02327520|OTHER|Colitis with CDI treatment|All patients will be treated with standard treatment
224224983|NCT01448031|DRUG|Capsule ASA 81mg/esomeprazole 20mg|Multiple doses administered on Day 1 to 5
224224984|NCT01448031|DRUG|Acetylsalicylzuur Apotex Cardio|Multiple doses administered on Day 1 to 5
224224985|NCT04236310|DRUG|SHR6390|SHR6390 150 mg, orally once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment for 4 cycles
224224986|NCT04236310|DRUG|Anastrozole|Anastrozole 1md, orally once daily for 16 weeks (For premenopausal women, ovarian suppression may be considered)
224224987|NCT04236310|DRUG|Pyrotinib|Pyrotinib 400mg once daily for 16 weeks
224224988|NCT04236310|DRUG|Trastuzumab|Trastuzumab 6mg/kg (loading dose, 8mg/kg), infusion once every 3-week cycle for 5 cycles.
224224989|NCT01738581|DEVICE|Repetitive Transcranial Magnetic Stimulation|Applied to the premotor cortex at 1 Hz at 90% resting motor threshold for 1200 pulses.
223636068|NCT06584695|DRUG|Transversus abdominis plane block|Patients will receive transversus abdominis plane block with an oblique subcostal approach in the supine position. The anesthesiologist will place the linear ultrasound transducer obliquely on the upper abdominal wall along the subcostal margin near the xiphisternum of the sternum in the midline of the abdomen. The anesthesiologist will direct a 22G, 80 mm needle toward the transversus abdominis fascia and inject 25 mL of 0.25% bupivacaine between the rectus abdominis and transversus abdominis muscles along the subcostal line.
223636069|NCT06584695|DRUG|External Oblique Intercostal Plane Block|Patients will receive external oblique intercostal block the patient will be in the supine position with their ipsilateral arm abducted, A linear ultrasound transducer will be placed in the sagittal plane between the midclavicular and anterior axillary lines at the level of sixth rib, with the orientation marker directed cranially. The skin will be sterilized, and the probe will be placed over the sixth rib medial to the anterior axillary line in a parasagittal orientation the in-plane technique with a 22G, 80 mm block needle will be used to inject 25 ml of 0.25% bupivacaine into the external oblique intercostal plane.
224224990|NCT01738581|BEHAVIORAL|Sensorimotor Retraining|For sensorimotor retraining, a subset of the Learning-based Sensorimotor Training program was followed
224224991|NCT01738581|BEHAVIORAL|Non-specific Therapy|A non-specific massage and stretching program directed to the hand, wrist and forearm
224224992|NCT06460428|BEHAVIORAL|Interactive video usage|The implementation of the research was carried out in two stages. In the first stage, interactive videos were created, in the second stage, the experimental group was trained with interactive videos, and no intervention was made to the control group.
224224993|NCT02157233|BEHAVIORAL|Rest|
223636070|NCT06584695|DRUG|Control group|"Patients will receive IV morphine 0.1mg/kg after induction of general anesthesia.~General anesthesia induction will be performed with fentanyl 1-2 μg/kg, propofol 2-3 mg/kg, and rocuronium 0.6 mg/kg and maintained with sevoflurane."
223764855|NCT01332942|DRUG|BAY85-3934|Subjects received an oral single dose of 10 mg of molidustat ( 2x 5mg IR tablets) on Day 1 followed by a washout day and once daily multipledose over 12 days (from Day 3 to Day 14).
224224994|NCT02157233|BEHAVIORAL|Exercise|
224224995|NCT06503796|DRUG|Lamivudine|4mg/kg/d, oral
224224996|NCT06503796|DRUG|Interferon|Use only in children who remain positive for HBV-DNA and/or HBsAg after 1 year of age. Regular interferon (3 million U/m2 body surface area, intramuscular or subcutaneous, every other day, adjusted during treatment according to the child's specific tolerance) for 52 weeks.
224224997|NCT00696709|BIOLOGICAL|Comparator: V212|0.65 mL subcutaneous injection of heat-treated Varicella zoster virus (VZV) vaccine or alternative inactivation method VZV vaccine A, B, C; 4-dose regimen administered \~30 days apart
224224998|NCT00696709|BIOLOGICAL|Comparator: Placebo|Placebo; 4-dose regimen administered \~30 days apart.
224224999|NCT05343949|OTHER|HIIT exercise program ABC|Delivery of 3 different exercise programs to patients with COPD to determine which program gives least breathlessness with the same exercise benefits
224225000|NCT05343949|OTHER|HIIT exercise program CAB|Delivery of 3 different exercise programs to patients with COPD to determine which program gives least breathlessness with the same exercise benefits
224225001|NCT05343949|OTHER|HIIT exercise program BCA|Delivery of 3 different exercise programs to patients with COPD to determine which program gives least breathlessness with the same exercise benefits
224225002|NCT01810926|BIOLOGICAL|polyclonal antibody|iv at a dose of 5 mg/kg within 8 hours on day -4,-3,-2 (total dose 15 mg/kg)
224225003|NCT01810926|DRUG|Rituximab|single infusion of200 mg/m2 on day -1
224225004|NCT01810926|DRUG|Treosulfan|iv at a dose of 14 g/m² within 120 minutes on day -7, - 6, -5 (total dose of 42 g/m²)
224225005|NCT01810926|DRUG|Fludarabine|iv at a dose of 30 mg/ m² within 30 minutes on day -7, -6, -5,-4,-3 after treosulfan
224225006|NCT01810926|DRUG|Thiotepa|iv at a dose of 8 mg/kg on day - 3 divided into 2 infusions at 12 hrs intervals
224225007|NCT01810926|DRUG|Cyclosporine A|iv at a dose of 3 mg/kg/day starting from day -1 and a dose adjustment will be done to obtain plasma levels of 150-250 ng/mL
224225008|NCT01810926|DRUG|Methotrexate|iv at a dose of 15 mg/m2 on day +1, at a dose of 10 mg/m2 on day + 3 and + 6
224225009|NCT01810926|DRUG|Methotrexate|iv at a dose of 15 mg/m2 on day +1, at a dose of 10 mg/m2 on day + 3 and + 6 and at a dose of 10 mg/m2 on day +11
223514993|NCT03752372|PROCEDURE|hematopoietic stem cell transplantation|"1. Reduced intensity conditioning(RIC) chemotherapy regimen before transplantation~2. All patients were cared for in single rooms ventilated with a highly effective particulate air filtration system. All patients received intravenous immunoglobulin and antimicrobial prophylaxis, which included antiviral, antifungal, and Pneumocystis jirovecii prophylaxis with ganciclovir and micafungin, as per routine clinical practice before transplantation.~3. Umbilical cord blood transplantation"
224225010|NCT02947113|DRUG|Cisplatin|Cisplatin will be administrated in a 3-weekly scheme for 2 courses combined with pemetrexed (non-squamous cell lung cancer) or etoposide (squamous cell lung cancer)
224225011|NCT02947113|RADIATION|hypofractionated radiotherapy|Hypofractionated radiotherapy of 24 x 2.75 Gy will be given combined with a 3-weekly scheme of cisplatin and pemetrexed/etoposide
224225012|NCT02947113|DRUG|Pemetrexed|Pemetrexed will be administrated in a combination with cisplatin and hypofractionated radiotherapy (for non-squamous cell lung cancer)
224225013|NCT02947113|DRUG|Etoposide|etoposide will be administrated in a combination with cisplatin and hypofractionated radiotherapy (for squamous cell lung cancer)
224225014|NCT01873768|DRUG|Tranexamic Acid (TXA)|1g in 250cc of saline given over 30 minutes just prior to raising the tourniquet and making the initial incision. A second 1g in 250cc of saline will be infused over 30 minutes beginning at the time of wound closure.
224225015|NCT01873768|DRUG|ε-Aminocaproic Acid (EACA)|7g in 250cc of saline given over 30 minutes just prior to raising the tourniquet and making the initial incision. A second 7g of EACA in 250cc saline will be infused over 30 minutes beginning at the time of wound closure.
224225016|NCT03999125|DRUG|Aflibercept,|Primary therapy will be with Aflibercept. If the edema does not respond to the intervention, the patient will be treated with Ranibizumab, Dexamethasone Implant or Laser.
224225017|NCT03999125|DRUG|Ranibizumab Injection|Primary therapy will be with ranibizumab. If the edema does not respond to the intervention, the patient will be treated with Alfibercept, Dexamethasone Implant or Laser.
223514994|NCT06310694|COMBINATION_PRODUCT|intervention group (Elastane circular dressing on sterile transparent dressing)|A circular dressing made of elastane material was placed on the patients in the intervention group on a sterile transparent dressing to provide additional fixation on the peripheral intravenous catheter.
223514995|NCT04127110|DRUG|Lorlatinib|Lorlatinib is administered orally at the daily dose of 100 mg (four tablets of 25 mg).
223514996|NCT01834378|BEHAVIORAL|Low intensity intervention|We administer, a pedometer and the participants receive a prescription on physical exercise.
223514997|NCT01834378|BEHAVIORAL|High intensity intervention.|We schedule group sessions for changes in behavior e.g. type of physical activity to prefer, barriers for change of life style etc.
223514998|NCT06207019|DEVICE|Hyflex EDM , The XP-endo Shaper, Primary WaveOne Gold|rotary single files
223514999|NCT06569420|OTHER|Drug: Foritinib Succinate|SAF-189s: 160 mg QD, 21 days a cycle
223515000|NCT06569420|OTHER|Drug: Crizotinib|Crizotinib: 250 mg BID, 21 days a cycle
223515001|NCT06569966|BEHAVIORAL|preoperative prehabilitation treatment of ileostomy contents filtrate reinfusion through distal ileocolon or retention of enema colon|The contents of the ileostomy were collected and placed in a wide mouth container, mixed with 500mL normal temperature saline, and placed in a funnel with double layer medical gauze. The filtrate of the ileal contents was collected and placed into an enema for use. The catheter was placed into the ileal output end of the ostomy through anterograde enema or transanal retention enema, and slowly infused for 15-20 minutes, 2-3 times a day for 4 weeks. The adverse reactions such as abdominal pain, abdominal distension and fever were observed. The number, time, antegrade/retrograde prehabilitation operation, adverse reactions during the operation and other special conditions were recorded every day, and the weight of the patient was recorded
223515002|NCT06571318|OTHER|Destress and Perform Capsule-U001|Two Capsules in sequence daily after meal for 60 days.
223515003|NCT06571318|OTHER|Destress and Perform Capsule-I001|Two Capsules in sequence daily after meal for 60 days.
223515004|NCT06571318|OTHER|Placebo capsules 002|Two Capsules in sequence daily after meal for 60 days
223515005|NCT06569888|DEVICE|LIPUS stimulation|Low Intensity Pulsed Ultrasound stimulation of the gut at the pre-clinically optimized conditions and energy dosage
223515006|NCT06571929|OTHER|INTERACT|INTERACT is an individualized, task-specific training program that includes environmental enrichment, natural and augmented realities, and active training.
223515007|NCT06570668|DRUG|CDD-2101|All subjects will receive 4 sachets of CDD-2101 and/or placebo at a time based on the computer-generated randomization. An unblinded pharmacist will mix the assigned dose of CDD-2101 and/or placebo with 400 mL of water at 70-80°C, cool it to a comfortable temperature and keep it at room temperature for not longer than 1 h. A blinded study nurse or investigator will dispense the suspension to the assigned subject. The subject will drink it under supervision within 15 minutes.
223515008|NCT02532907|PROCEDURE|Liver Biopsy|patients will get a research liver biopsy pre-DAA treatment and either 4 or the standard 12 week time point. The liver biopsy is performed using standard protocol with ultrasound guidance.
223515009|NCT06571825|DRUG|Venetoclax|The consolidation therapy involves a regimen of intermediate-dose cytarabine (Ara-C) combined with Ven, specifically Ara-C at 1.0 g/m²/day for 3 days (days 1-3) and Ven at 400 mg/day for 10 to 14 days (days 1-10 to 14), with each cycle lasting 4 to 6 weeks, for a total of 3 consolidation cycles. This is followed by maintenance therapy with azacitidine (AZA) at 50 mg/m²/day for 5 days (days 1-5), with each cycle lasting 4 weeks, for a total of 6 maintenance cycles.
223636071|NCT01652235|DEVICE|Zenith® p-Branch® or Zenith® Fenestrated AAA Endovascular Graft|Instead of making a large incision in the chest, the physician makes a small incision near each hip to insert, and guides the study device(s) into place in the aorta.
223764856|NCT01332942|DRUG|BAY85-3934|Subjects received an oral single dose of 25 mg of molidustat (1 x 20 mg IR tablet and 1 x 5 mg IR tablet) on Day 1 followed by a washout day and once daily multiple-dose over 12 days (from Day 3 to Day 14).
223636072|NCT06065670|DRUG|Clemastine Fumarate|12 or 8 mg Clemastine tablet. Clemastine fumarate was approved by the Food and Drug Administration (FDA) for the treatment of allergic rhinitis (seasonal allergies) in 1977 and was approved for over-the-counter marketing in 1992. Clemastine is not FDA approved as a remyelinating therapy
223636073|NCT06065670|DRUG|Placebo|Matched sugar tablet
223636074|NCT04718415|DRUG|sintilimab, paclitaxel, carboplatin|Patients receive sintilimab IV on day 1, paclitaxel IV on day 1 and carboplatin IV on day 1 . Treatment repeats every 21 days for up to 2 - 4 courses in the absence of disease progression or unacceptable toxicity.
223636075|NCT04718415|PROCEDURE|Surgical resection|Surgical therapy will be at the discretion of the treating surgeon per standard of care.
223636076|NCT06313515|DEVICE|Transcutaneous Spinal Cord Stimulation|Non-invasive electrical stimulation of the spinal cord over the skin
223636077|NCT06313515|BEHAVIORAL|Arm-crank bike exercise|Exercise using an arm-bike to target cardiovascular functioning.
223636078|NCT06313515|OTHER|Sham Stimulation|Non-invasive electrical stimulation of a lower extremity muscle group over the skin.
224225018|NCT03999125|DRUG|Ozurdex Drug Implant Product|Primary therapy will be with Ozurdex. If the edema does not respond to the intervention, the patient will be treated with Alfibercept, Ranibizumab or Laser
224225019|NCT00670878|DRUG|3 x FEC 3 x DOC / Gemcitabine|3 cycles of 5-Fluorouracil 500 mg/m² i.v. body surface area and Epirubicin 100 mg/m² i.v. and Cyclophosphamide 500 mg/m² i.v., (FEC100), each administered on day 1, repeated on day 22, subsequently followed by 3 cycles of Docetaxel 75 mg/m² body surface area i.v. (D), and Gemcitabine 1000 mg/m² i.v. (30 min infusion) (G), administered on day 1, followed by Gemcitabine 1000 mg/m² i.v. (30 min infusion) on day 8, repeated on day 22
224225020|NCT00670878|DRUG|3 x FEC 3 x DOC|3 cycles of 5-Fluorouracil 500 mg/m² i.v. body surface area and Epirubicin 100 mg/m² i.v. and Cyclophosphamide 500 mg/m² i.v., (FEC100), each administered on day 1, repeated on day 22, subsequently followed by 3 cycles of Docetaxel 100 mg/m² body surface area i.v. (D), administered on day 1, repeated on day 22
224225021|NCT02141178|DRUG|Bupivacaine|
224225022|NCT02141178|DRUG|Exparel|
224225023|NCT00321711|DRUG|Placebo|Subjects in the control group will receive a placebo subcutaneous injection on a weekly basis during the 4 cycle treatment period.
224225024|NCT00321711|BIOLOGICAL|AMG 531 (Romiplostim)|AMG 531 (Romiplostim) will be administered weekly by subcutaneous injection at a dose of 500 or 750 μg during Part A and 750 μg during Part B for the 4 cycle treatment period, depending on randomization.
223636079|NCT04205227|DRUG|ENB003|ENB003 is selective Endothelin B Receptor Antagonist
223636080|NCT04205227|DRUG|Pembrolizumab|anti-PD1
223636081|NCT06547684|DEVICE|fESWT|"Shock wave therapy will be applied with Duolith SD1 device (Storz Medical, Tagerwilen, Switzerland). Therapy will be administered in the gastrocnemius medial and lateral and in the soleus muscles.~Parameters: 0.15mJ/mm2, 4-5 Hz, 1500 shoots/muscle."
223636082|NCT03205709|OTHER|Computerized Cognitive Training|Computerized online cognitive training will be used to target specific cognitive abilities and neural networks to potentially improve cognitive functioning through neuroplasticity.
223636083|NCT03205709|OTHER|Crossword Puzzles|These are intended to mimic crossword puzzles in newspapers.
223636084|NCT06177483|DIETARY_SUPPLEMENT|95% curcumin extract powder|95% curcumin extract powder
223636085|NCT06177483|DIETARY_SUPPLEMENT|curQ+ curcumin formulation|curQ+ curcumin formulation
223636086|NCT02023086|PROCEDURE|Contrast sensitivity measurement|Contrast sensitivity test is made with targets alternating black and white lines. The larger the lines are, easier it is to see them. Targets are distributed in 5 rows, each oriented at a different angle. Contrast sensitivity level is determined by the smallest target seen by the participant, line by line. This test is done under dim lightning with the habitual visual correction worn.
224225025|NCT00321711|DRUG|Azacitidine|hypomethylating agent
224225026|NCT00321711|DRUG|Decitabine|hypomethylating agent
224225027|NCT00005042|DRUG|semaxanib|
224225028|NCT01696864|DEVICE|Hand tutor rehabilitation device|A rehabilitation device for the hand
224225029|NCT01696864|DEVICE|Arm tutor rehabilitation device|A rehabilitation device for the arm
224225030|NCT06546280|DRUG|Camrelizumab|Camrelizumab 200 mg will be administered by IV infusion on Day 1 of each 21-day cycle.
224225031|NCT06546280|DRUG|Apatinib|Apatinib 250 mg will be taken orally once daily.
224225032|NCT00377026|BEHAVIORAL|lifestyle intervention|Lifestyle modification including individual sessions with an interventionist to discuss dietary intake and exercise. Group sessions with other participants randomized to the lifestyle intervention to discuss lifestyle modification and group exercise.
224225033|NCT00005782|DRUG|Granulocyte colony-stimulating factor|
224225034|NCT00005782|PROCEDURE|Leukapheresis|
224225035|NCT00133302|DRUG|Standard CHOP|
224225036|NCT00133302|DRUG|Bi-CHOP (dose intensified CHOP)|
224225037|NCT00522288|DEVICE|Soft contact lenses|Daily wear soft contact lenses disposed of daily or biweekly
223764857|NCT01332942|DRUG|BAY85-3934|Subjects received an oral single dose of 50 mg) of molidustat (2 x 20 mg IR tablets and 2 x 5 mg IR tablets) on Day 1 followed by a washout day and once daily multiple-dose over 12 days (from Day 3 to Day 14).
224225038|NCT00522288|DEVICE|Spectacle|Spectacles for the treatment of myopia
224225039|NCT01040325|BIOLOGICAL|TD Vaccine System|TD Vaccine System containing heat labile enterotoxin of E. coli (LT)
224225040|NCT01040325|BIOLOGICAL|TD Vaccine System|TD Vaccine System Containing Placebo Product
224225041|NCT00058357|DRUG|lidocaine|
224225042|NCT00058357|OTHER|placebo|
224225043|NCT05081674|DRUG|Alectinib|600mg 1OD
224225044|NCT05081674|DRUG|Pembrolizumab|200mg every 21 days
224225045|NCT05081674|DRUG|Nivolumab|6mg/kg every 4 weeks
224225046|NCT05081674|DRUG|Erlotinib|150mg
223636087|NCT02023086|PROCEDURE|Slit Lamp assessment and intra-ocular pressure measurement|Slit lamp is used to assess the presence of significant lens opacities known as Fabry cataracts. In fact, these opacities can induced a bias on the contrast sensitivity measurement and can increase the symptoms felt by the patient. A grade 2 (CFDI grading chart) of lens opacities is considered clinically significant and this will become an exclusion criteria for the following of the study. Intra-ocular pressure will be measured with a non contact tonometer (air pulsed) (Ocular Response Analyser, Reichert Instrumentation.)
223636088|NCT02023086|PROCEDURE|Visual field testing|"Visual field will be assessed with an automated perimeter (Humphrey, Texas) using a threshold strategy. This implies that the subject has to identify not only if he perceives the visual stimulus but the minimal level of this stimulus (in decibels), to be seen, is also recorded. Visual field will be tested up to 30 degrees from the central point of fixation.~In order to measure immediate variability of the visual testing among Fabry subjects, this test will be done at the beginning of the testing session (in the morning) and another time 1h00 later."
223636089|NCT02023086|PROCEDURE|Oxygen flow at the optic nerve head measurement|"Pupils will be dilated with 1 drop of 1% tropicamide. The procedure is similar to the one used for taking a photo of the retina. Each measurement session represents a continuous recording of 20 simultaneous functions of reflectometry from the optic nerve area during 10 seconds.~During all recording sessions, the systemic arterial oxygen saturation will be also monitored at the right index finger using a pulse oximeter (Escort M10, Invivo, Orlando, USA). Arterial blood pressure will be also monitored before and after the testing using a manual sphygmomanometer."
223636090|NCT02023086|DRUG|Tropicamide|Used to dilate patient's pupil during testing
223636091|NCT02023086|DEVICE|OSOME|The OSOME system is the only technology able to perform on line and real time capillaries blood oxygenation measurement in the eye. The system operates with 1200 discreet wavelengths between 400 nm to 700 nm with 500 millisecond integration times. It is not invasive, functioning just like a fundus camera.
223636092|NCT03657628|OTHER|Exercise Intervention|Strength training and moderate-intensity, aerobic exercise
223636093|NCT06585397|OTHER|Grup 1|Within the framework of ICF, the Modified Ashworth Scale, the Manual Ability Classification System and the Functional Independence Measure for Children will be applied to 20 quadriparetic children with CP.
223636094|NCT05819138|DRUG|Semaglutide Pen Injector|Semaglutide injection
223636095|NCT05819138|DRUG|Placebo|Semaglutide placebo injection
224225047|NCT02325700|PROCEDURE|Aortic repair|Aortic bypass
223636096|NCT04971642|DEVICE|Intraoral ultrasound|Intraoral ultrasound scanning of the periodontium complex
223515010|NCT06571825|DRUG|Allogeneic transplant|"The consolidation therapy involves allo-HSCT, with the choice of conditioning regimens typically using reduced-intensity conditioning such as the Fludarabine+Busulfan (FluBu) or Fludarabine+Melphalan (FluMel) regimens commonly used by centers, which can also include Ven.~FluBu regimen: Flu 30 mg/m²/day from day -10 to day -5, Bu 3.2 mg/kg/day from day -6 to day -5 or day -7 to day -5, antithymocyte globulin (ATG) (e.g., rabbit ATG at a total dose of 6-7.5 mg/kg, administered from day -4 to day -1), and Ven from day -10 to day -4.~FluMel regimen: Flu 30 mg/m²/day from day -10 to day -5, Mel 50-70 mg/m²/day from day -4 to day -3, ATG and Ven from day -10 to day -4.~12 weeks (±4 weeks) post-HSCT maintenance begins with AZA at 32 mg/m²/day for 5 days (days 1-5), with each lasting 6 weeks, for a total of 6 cycles. Donor lymphocyte infusion is allowed in cases of minimal residual disease (MRD) positivity."
223636097|NCT03030586|OTHER|volumetric MRI|
223636098|NCT05005429|DRUG|Bintrafusp alfa|"Bintrafusp alfa (M7824) is a bifunctional fusion protein composed of the extracellular domain of the transforming growth factor β (TGF-β) receptor II (a TGF-β trap) fused to a human immunoglobulin G1 antibody blocking programmed death-ligand 1 (PD-L1).~Day 1 of week 1 of treatment will start within 1-5 days from enrollment. Cycles will be administered every 2 weeks (±3 days) until progression or other reason to discontinue. If a pseudoprogression is suspected patient is allowed to continue treatment until loss of clinical benefit as judged by principal investigator and after the permission from the trial chair is granted.~On Day 1 of each cycle (QW2), all eligible patients will receive:~Bintrafusp alfa (M7824): 1200mg, IV infusion over 60 minutes Current experience revealed that IRRs to bintrafusp alfa occur seldomly and are generally mild to moderate in severity. Therefore, administration of a premedication is generally not required."
224225048|NCT05157607|BEHAVIORAL|Family Connections Protocol for Relatives of Patients with SBD.|Family Connections is a Dialectical Behavioral Therapy. All the modules include practice exercises, video viewing, and homework assignments. In addition, throughout the program, with the aim of increasing social support, the FC-SBD program provides a forum where participants can stay in touch and share common problems and solutions.
224225049|NCT05157607|BEHAVIORAL|Treatment as Usual Optimized Protocol (TAU-O)|Participants will receive the usual treatment in their mental health service and will also receive a psychoeducation session of approximately 3 hours where the predictive and protective factors of suicidal behavior will be explained.
224225050|NCT04487756|DRUG|Atezolizumab 1200 mg in 20 ML Injection|"\- Induction (4 cycles, every 3 weeks): Atezolizumab, 1200 mg administered intravenously every 3 weeks on day 1 of each cycle)~\- Maintenance (only patients without PD after 4 induction cycles, up to PD): Atezolizumab iv (1200 mg/IV on day 1 every 3 weeks)"
224225051|NCT04487756|BIOLOGICAL|ADC Vaccine|\- Maintenance (only patients without PD after 4 induction cycles, up to PD): DCV intradermally (max. 6 doses) on weeks 1, 3, 6, 9, 21, 33.
224225052|NCT04487756|DRUG|Carboplatin|\- Induction (4 cycles, every 3 weeks): Carboplatin AUC 5 (5 mg per milliliter per minute, administered intravenously on day 1 of each cycle) and etoposide (100 mg per square meter of body-surface area, administered intravenously on days 1 through 3 of each cycle)
223515011|NCT06570330|DIETARY_SUPPLEMENT|SuperHMO|Super HMO Prebiotic Mix: five major types of human milk oligosaccharides including 2'-Fucosyllactose (2'-FL), Lacto-N-tetraose (LNT), Lacto-N-neotetraose (LNnT), 6'-Sialyllactose (6'SL), and 3'-Sialyllactose (3'SL)
224225053|NCT03846271|DRUG|intranasal oxytocin|24 IU of oxytocin nasal spray will be applied to each subject.
224225054|NCT03846271|DRUG|intranasal placebo|an identical amount of placebo nasal spray will be applied to each subject.
224225055|NCT05882981|OTHER|Sit and reach test|It will be used to measure the flexibility of the participants.
224225056|NCT05882981|OTHER|Hand grip strength measurement|Grip strength will be evaluated with a hand dynamometer in the position recommended by the American Association of Hand Therapists.
223636099|NCT04764799|PROCEDURE|Rapid sequence induction|Rapid sequence induction starts with the administration of rapid acting intravenous narcotics, opioids and neuromuscular blockage and avoids whenever possible positive-pressure ventilation after induction of anesthesia.
223636100|NCT05929274|DEVICE|tDCS|Direct current was applied by a battery-driven constant current stimulator using saline-soaked surface sponge electrodes (7 3 5 cm) with the anode positioned over the left dorsolateral prefrontal cortex (F3 according to the 10-20 international system for EEG placement) and the cathode placed over the right supraorbital region. During real tDCS, the current was increased to 2 milliampere (mA) from the onset of stimulation and applied for 20 minutes.
223636101|NCT05929274|DEVICE|sham tDCS|For the sham condition (sham tDCS), the same electrode placement was used as in the stimulation condition, but the current was applied for only 5 seconds, and was then ramped down.
223636102|NCT06060899|PROCEDURE|Pneumoperitoneum 14mmHg|Performing surgery in 14mmHg pneumoperitoneum pressure
223636103|NCT06060899|PROCEDURE|Pneumoperitoneum 10mmHg|Performing surgery in 10mmHg pneumoperitoneum pressure
223636104|NCT06651541|DRUG|BZ371A|Formulation with the active ingredient
223636105|NCT06651541|DRUG|Placebo|Formulation without the active ingredient
223636106|NCT03096743|DIAGNOSTIC_TEST|MR elastography|MR elastography image acquisition will be conducted on the Compact 3T MRI scanner using a modified single-shot spin-echo echo-planar imaging pulse sequence.
223636107|NCT03096743|DIAGNOSTIC_TEST|MRI structural brain imaging|MRI structural brain imaging will be done on the Compact 3T MRI at the same time as MR elastography.
224225057|NCT05882981|OTHER|Back-leg-chest muscle strength measurement|An analog Back Leg-Chest dynamometer will be used to evaluate general muscle strength.
224225058|NCT05882981|OTHER|Functional performance|Single-leg and double-leg horizontal jump test will be used to evaluate lower extremity functional performance. The tests will be carried out according to the Eurofit test battery (Council of Europe, 1988).
224225059|NCT05882981|OTHER|Functional capacity|Functional capacity will be evaluated with six minute walk test according to the ATS criteria.
223636108|NCT03096743|PROCEDURE|Lumbar puncture|All patients with papilledema will get lumbar punctures with opening pressure as part of their work-up for papilledema. A small number of patients without increased intracranial pressure will receive a lumbar puncture.
223636109|NCT03096743|DIAGNOSTIC_TEST|Optical Coherence Tomography (OCT) imaging|Optical Coherence Tomography (OCT) imaging will measure the peripapillary retinal nerve fiber layer (RNFL) thickness measurements The images with enhanced depth imaging will be obtained to measure the Bruch's membrane orientation.
223636110|NCT03096743|DIAGNOSTIC_TEST|Optic nerve B-scan ultrasound|Ultrasound will be used to measure the optic nerve sheath diameter 3 mm posterior to the posterior scleral surface.
223636111|NCT06494267|BEHAVIORAL|Experimental (Video-Assisted Self-Assessment on Nasogastric Tube Insertion)|Students in the experimental group will be videotaped while practicing and students will make self-evaluations.
223636112|NCT02700607|DRUG|Intravenous Crystalloid|crystalloid is administered to maintain stroke volume variation \< 15 during volume controlled ventilation (8 ml/kg tidal volume) of O2/air mixture
223636113|NCT02700607|DRUG|Intravenous HES|HES is administered to maintain stroke volume variation \< 15 during volume controlled ventilation (8 ml/kg tidal volume) of O2/air mixture
223636114|NCT05507138|DEVICE|AKL-T01|AKL-T01 is an iPad-based video game designed to improve executive dysfunction and depression symptoms by targeting executive skills (multitasking) and ECN abnormalities.
223636115|NCT05507138|BEHAVIORAL|Metacognitive Strategy Training|Metacognitive Strategy Training involves working with a clinician (neuropsychologist or occupational therapist) to learn strategies to manage cognitive difficulties
223636116|NCT05743335|BIOLOGICAL|JCXH-221|Participants will be randomized to either placebo or JCXH-221 for Phase 1. For Phase 2, participants will either be randomized to JCXH-221 or a FDA approved Active comparator.
223636117|NCT05743335|OTHER|Placebo|Participants will be randomized in Phase 1 to either JCXH-221 or placebo
223636118|NCT03581487|BIOLOGICAL|Durvalumab|Given IV
223636119|NCT03581487|DRUG|Selumetinib|Given PO
223636120|NCT03581487|BIOLOGICAL|Tremelimumab|Given IV
223636121|NCT00558584|DEVICE|protein A immunoadsorption|protein-A immunoadsorption and i.v. IgG substitution
223636122|NCT00558584|DEVICE|pseudo-immunoadsorption|pseudo-immunoadsorption followed by an intravenous infusion without IgG
223636123|NCT05048134|DRUG|HRS2300|HRS2300 monotherapy
223636124|NCT05048134|DRUG|HRS2300、 SHR-1316|HRS2300 combined with SHR-1316
223636125|NCT05048134|DRUG|HRS2300、SHR-1701|HRS2300 combined with SHR-1701
223636126|NCT05048134|DRUG|HRS2300、trametinib|HRS2300 combined with trametinib
223636127|NCT05048134|DRUG|HRS2300、Almonertinib|HRS2300 combined with Almonertinib
223636128|NCT05640830|DRUG|trastuzumab, bevacizumab with paclitaxel (triple combination)|Trastuzumab 4 mg/kg Day 1, 15 Bevacizumab 5 mg/kg Day 1, 15 Paclitaxel 80 mg/m2 Day 1, 8, 15 every 4 weeks
223636129|NCT01244841|PROCEDURE|fast post MI care|All post MI investigations, treatment, start of medication, information are performed within 3 days after admittance.
223636130|NCT03255408|DRUG|Drug Lowering Cerebral Blood Flow (CBF) and Normoxia Sleep|The study participants will take Cerebral Blood Flow (CBF) lowering drug and sleep under Normoxia Exposure
224225060|NCT01684449|DRUG|Gemcitabine + Rapamycin|"Gemcitabine + rapamycin at recommended dose of Phase 1. Recommended dose is defined as, the dose one level below of the (MTD). Being MTD, the dose of the cohort in which a maximum of one patient of 6 has presented dose-limiting toxicity (DLT).~Every three weeks until disease progression or unacceptable toxicity. The treatment will last for 6 cycles if there is not progression or intolerable toxicity.~Additionally, there will be a pharmacokinetic study in a minimum of 9 patients treated with the drug combination."
224225061|NCT02801448|DRUG|sulforaphane|sulforaphane-containing broccoli sprout extracts
224225062|NCT02801448|DRUG|Placebo|Maltodextrine-based placebo without sulforaphane
223636131|NCT03255408|DRUG|Drug Lowering CBF and Intermittent Hypoxia Sleep|The study participants will take Cerebral Blood Flow (CBF) lowering drug and sleep under Intermittent Hypoxia (IH) Exposure
223636132|NCT03255408|DRUG|Placebo and Normoxia Sleep|The study participants will take Placebo and sleep under Normoxia Exposure
223636133|NCT03255408|DRUG|Placebo and Intermittent Hypoxia Sleep|The study participants will take Placebo and sleep under Intermittent Hypoxia (IH) Exposure
223636134|NCT01343394|BIOLOGICAL|Autologous Human Umbilical Cord Blood|6 million cells/kg will be administered intravenously at one treatment time point.
223636135|NCT06477055|DRUG|Osimertinib|Osimertinib, 80mg, po, qd.
223636136|NCT05380427|DRUG|CU-40101|CU-40101，0.0025% CU-40101，0.005% CU-40101，0.01% CU-40101，0.02%
223636137|NCT03996824|OTHER|Peroperative collect of inner ear cells|"After obtaining an informed consent during the preoperative medical visit, and if a non-conservative approach (translabyrinthine or transotic) is decided, the collect of inner ear cells will be performed during surgical approach.~The sample will be collect in a sterile tube, and carried to the laboratory were it will be placed bon cell culture."
223636138|NCT06621264|BEHAVIORAL|EXERCISE TRAINING WITH OR WITHOUT MEDICATION|Patients enrolled in this group will receive a detailed 6-month exercise prescription aimed at providing in-home low fatiguing walking training (at light-moderate intensity, or 2-3 out of 10 of the CR10 Borg\&#39;s scale). The program consists of a two daily 10-minute interval walking sessions (1 minute walking : 1 minute resting) at a prescribed speed controlled by a digital metronome (https://www.youtube.com/watch?v=ki8YX\_t-0jA). The training speed will be set up according to the patients baseline walking capacity (approximately 50% lower than the habitual gait speed) and will be weekly increased until reaching the habitual gait speed. The training time will be maintained constant throughout the entire program. Exercise prescription will be updated during two intermediate hospital visits at the 1st and 3rd months. Patients will be provided with a digital application properly developed to keep pacing and to record the correct training execution.
223636139|NCT06621264|OTHER|Control (Standard treatment)|Patients enrolled in the Co group will receive standard CKD-PAD care, including optimal medical therapy and nutritional advices
223636140|NCT04249245|OTHER|Nasal Swab|All
223636141|NCT06652243|BIOLOGICAL|SN301A|"SN301A is an investigational off-the-shelf CAR NK cell therapy, armed with calibrated release (cr)IL15, designed to selectively target and treat GPC3 expressing advanced hepatocellular carcinoma.~Subjects will receive lymphodepletion pretreatment (Fludarabine/Cyclophosphamide), three SN301A intravenous infusions in a cycle (D0, D7, D14), with each subject receiving a maximum of 3 cycles."
223636142|NCT05878665|DIAGNOSTIC_TEST|Weight-adjusted low-dose contrast media paired with low-radiation dose abdomen CT|The investigators are aiming for a 10% reduction in iodine dosage at 10 kVp reduction in CT radiation. Routine iodine dosing is 0.521 g I/kg at 120 kVp. Therefore, at 90 kVp, a 30% reduction in iodine dosing is expected, which is 0.365 g I/kg. At 100 kVp, the iodine dosage is reduced to 0.417 g I/kg, which is a 20% reduction. The kVp value is automatically selected by the CT device according to the body habitus, which is a clinical routine.
223636143|NCT06978335|OTHER|Acupoint Stimulation|This intervention involves acupoint stimulation and auricular acupressure. Stimulation of selected body acupoints is administered by trained personnel following a standardized protocol. The intervention is provided once daily for three consecutive days, beginning post-surgery. For auricular acupressure, additional auricular points are chosen based on the involved abdominal organ and its corresponding viscera-meridian locations on the auricle. Vaccaria seeds are applied to the selected points with adhesive patches, and patients are instructed to apply pressure to the points regularly throughout the day.
224225063|NCT03270137|DEVICE|repetitive transcranial magnetic stimulation- IDLPFC|Repetitive transcranial magnetic stimulation (rTMS) at 5Hz administered over left dorsolateral prefrontal cortex (lDLPFC). Repetitive transcranial magnetic stimulation (rTMS) at 5Hz administered over left dorsolateral prefrontal cortex (lDLPFC) compared to six regions protocol, divided in two sub-conditions: day 1 (Broca area, Wernicke area and lDLPFC) alternated by day 2 (left and right parietal association cortex, and right dorsolateral prefrontal cortex \[rDLPFC\]). Main outcomes will be evaluated at ending of 15 rTMS sessions and 4 weeks after.
224225064|NCT03270137|DEVICE|repetitive transcranial magnetic stimulation - Six regions|Repetitive transcranial magnetic stimulation (rTMS) at 5Hz administered on six regions protocol, divided in two sub-conditions: day 1 (Broca area, Wernicke area and lDLPFC) alternated by day 2 (left and right parietal association cortex, and right dorsolateral prefrontal cortex \[rDLPFC\]). Main outcomes will be evaluated at ending of 15 rTMS sessions and 4 weeks after.
224225065|NCT03985033|OTHER|leucocyte and platelet-rich fibrin (L-PRF)|The blood collected from each patient will be centrifuged immediately at 2700 rpm for 12 min to separate L-PRF.
223636144|NCT06978335|OTHER|Sham Acupoint Stimulation|Participants in this group will receive a sham acupoint stimulation procedure. Acupoint stimulation will be using identical procedures to the experimental group, without applying pressure. No stimulation or manipulation was performed. The frequency and timing of the sham intervention matched that of the experimental group.
223636145|NCT04713644|DRUG|Standardized Propofol Administration|Intravenous bolus propofol administration of 0.5 mg/Kg dose, plus 0.5 mg/Kg extra if necessary
224225066|NCT02351128|DRUG|Lanreotide|
224225067|NCT03110393|DEVICE|Ambu AuraGain|Insert and intubation of an Ambu® AuraGain™ laryngeal mask
224225068|NCT03110393|DEVICE|Intersurgical i-gel|Insert and intubation of an Intersurgical i-gel®
224225069|NCT02956824|OTHER|Standard care|Current care
224225070|NCT06016933|DRUG|spirulina gel|Patient were received spirulina gel in diseased sites. The process will be repeated at 7, 14, 21 days.
224225071|NCT06016933|PROCEDURE|SRP of all teeth|Patients received oral hygiene instructions and SRP of all teeth.
224225072|NCT01754090|BEHAVIORAL|Online screening and feedback|An online single session screening procedure including individualized normative feedback.
224225073|NCT01754090|BEHAVIORAL|Online booklet.|An online booklet that covers general information about alcohol, its effect on the brain and the body, potential risks and harms of drinking, and an account of the threshold values of sensible drinking
223636146|NCT06976541|BEHAVIORAL|Portrait + Therapeutics Letter - EARLY|In the context of audit and feedback interventions, the prescribing Portrait is a document produced by the Therapeutics Initiative that provides personalized prescribing feedback for clinicians in British Columbia. Portraits are used as a practice resource tool for reflection on prescribing or test-ordering patterns. Each Portrait topic provides data of individual prescriber's ordering of HbA1c tests within 90 days of a previous test along with evidence-based benchmarks or targets. Prescribers are also given access to a succinct review of the best available evidence on the topic and recommendations for future action in the Therapeutics Letter, a stand-alone publication that details the evidence for the recommended practice in a brief and practical manner. Therapeutics Letters include a systematic literature review on a clinical topic, and provide references for the data presented in the prescribing Portraits.
223636147|NCT06976541|BEHAVIORAL|Portrait + Therapeutics Letter - DELAYED|In the context of audit and feedback interventions, the prescribing Portrait is a document produced by the Therapeutics Initiative that provides personalized prescribing feedback for clinicians in British Columbia. Portraits are used as a practice resource tool for reflection on prescribing or test-ordering patterns. Each Portrait topic provides data of individual prescriber's ordering of HbA1c tests within 90 days of a previous test along with evidence-based benchmarks or targets. Prescribers are also given access to a succinct review of the best available evidence on the topic and recommendations for future action in the Therapeutics Letter, a stand-alone publication that details the evidence for the recommended practice in a brief and practical manner. Therapeutics Letters include a systematic literature review on a clinical topic, and provide references for the data presented in the prescribing Portraits.
223636148|NCT05498883|OTHER|Score completion|completion of the SRI score
223636149|NCT06555120|BIOLOGICAL|blood sample|A 5-ml blood sample in a dry tube (or 500-µl cone) is taken and sent to the biochemistry laboratory for lipid analysis.
223636150|NCT06584604|OTHER|There is no intervention|There is no intervention
223636151|NCT04855552|BEHAVIORAL|Behavioral Weight-loss Program Via Telehealth|Investigators will use a manual based on the DPP, as adapted previously for the endometrial cancer population and now adapted for breast cancer survivors. Dr.Courtney McCuen-Wurst, has extensive experience in working with persons with overweight and obesity with medical comorbidities. She also has experience leading group interventions at our Center via telehealth. The content of the sessions addresses the domains associated with behavioral weight management including nutrition, exercise, stress and emotion management, and lifestyle modification strategies (to improve adherence to the diet and activity plan). Participants will monitor energy intake and physical activity daily to help them achieve recommended calorie and activity goals. Self-monitoring will be encouraged online with MyFitnessPal.com, which will be shared with the study staff to increase accountability and provide opportunity for feedback to participants.
223764858|NCT01332942|DRUG|BAY85-3934|Subjects received an oral single dose of 75 mg of molidustat (3 x 20 mg IR tablets and 3 x 5 mg IR tablets) on Day 1 followed by a washout day and once daily multiple-dose over 12 days (from Day 3 to Day 14).
223764859|NCT04677491|DRUG|Ospemifene 60 mg|Ospemifene vs placebo
224225074|NCT01754090|BEHAVIORAL|Online multi session follow-up|"An online multi session follow-up program (i.e., Balance). The central concept of Balance is to support continued self-regulation throughout the behavior change process. There are four key aspects of the program, the first is focus on goal setting and tracking of alcohol consumption on a day-to-day basis. The second on relapse prevention - for example, when clients report drinking more than their target, they receive individualized content aimed at preventing a full blown relapse. The third is emotion regulation, where content and assignments from positive psychology and from cognitive behavioral therapy are used. Finally, intervention covers alcohol education (i.e. the same topics as in the booklet provided to the control group)."
224225075|NCT04749524|DIAGNOSTIC_TEST|Medial-Olivocochlear Reflex (MOCR) Strength Measurement|Otoacoustic emissions (OAE) will be recorded using an ear probe with and without an efferent Medial-Olivocochlear Reflex (MOCR) elicitor.
224225076|NCT02305368|OTHER|Chimio-oncogramme|Cells fragment are cultured for 7 days. The effects of chemotherapy are studied on these cells through chimio-oncogramme.
224225077|NCT04182750|OTHER|Pharmacist consultation|"The intervention is a patient-centered consultation that will last about 15 minutes. The intervention is defined as A planned, individualized, and structured conversation with the purpose to relieve pregnant women for any concern and answer questions she may have regarding self-care ailments and medication use in pregnancy. Specifically, the consultation will:~* Answer any questions the participants may have within pharmaceutical care.~* Improve pregnant women's understanding of common pregnancy-related ailments and hence contribute to better management of the ailments.~* Raise awareness, provide confidence, and give information about safe medications options in pregnancy~* Focus on preventative measures for NVP.~* Contribute to better adherence for needed/chronic medication throughout the pregnancy.~The pharmacists will beforehand have access to the women´s answers from the baseline questionnaire Q1, including information about her medical conditions and medication use."
224225078|NCT04139174|PROCEDURE|first premolar extraction and complete canine retraction.|measurements on panoramic radiograph will be done after first premolar extraction and complete canine retraction.
224225079|NCT02724137|BEHAVIORAL|Fitbit®|Participants can read how many steps/day they walked on the Fitbit® daily. The treating physical therapist reviews Fitbit® recorded steps from the previous week and together with the patient sets a new step goal. The physical therapist discusses barriers to meeting step goals are discussed. Self-reward for meeting step/goal is set weekly. Participants in this group will also receive 1-month phone calls for 6-months after completing physical therapy rehabilitation to discuss physical activity, set monthly step count goal, barriers to overcoming goal and to continue to develop a reward system for when the participant achieves their step count goal.
223636152|NCT04855552|BEHAVIORAL|Behavioral Weight-Loss Program Via Telehealth - Weight Measures|Each participant will also be mailed a digital scale (Eat Smart) so they can weigh themselves each week and report their weight to the group leader; patients will be encouraged to take a picture of their weight on the scale after they step off (the number remains for 3-seconds) and send the picture to Dr. McCuen-Wurst. Participants will be encouraged to start with at least 1-minutes of moderately vigorous physical activity (e.g. brisk walking, swimming), at least five days per week, building up to at least 30-minutes per day (150-minutes per week) by week-6.
224318763|NCT05245318|OTHER|Standard Clinical care|The standard care treatment comprises 12 face-to-face individual physiotherapy sessions at a ratio of 1 session a week. Every patient in the control group will be treated in a tailored manner according to their results on the baseline measurements. The multimodal treatment program will consist of exercises to increase strength, endurance and coordination of the cervical spine and shoulder stabilising muscles, exercises to increase mobility and improve posture. In case of jaw complaints stretching exercises of the masticatory muscles are added to the program. In addition, manual mobilisations and manual techniques to decrease muscle tension in neck and jaw muscles can be added to the exercise program if necessary. Patients will receive counselling to learn about their neck/jaw complaints but no tinnitus counselling. Patients will be motivated to perform the exercise program at home on a daily basis. Patients will be evaluated weekly.
223636153|NCT04855552|BEHAVIORAL|Validated Surveys of Patient-Reported Outcomes|"The following surveys will be completed by participants pre- and post-intervention:~* COH-QOL Instrument - Breast Cancer Patient (QOL-BC)~* International Physical Activity Questionnaire (IPAQ) Short Form~* Patient Health Questionnaire (PHQ-9) (Depression)~* Acceptability of Intervention Measure~The following survey will be completed post-intervention~• Exit interview regarding acceptability of the program.~The following measurements/clinical tests results will be collected and compared pre- and post-intervention:~* Anthropometric measurements: height (self-report); weight (as measured on scale provided by study)~* Mammographic breast density estimated in annual clinical mammogram"
223636154|NCT03472885|DRUG|Danicopan|Participants received a daily oral dose of danicopan TID during the treatment period.
224225080|NCT02724137|OTHER|Physical Therapy Rehab|Standard of care physical therapy after total knee replacement. The goals of physical therapy are to increase knee range of motion and strength, improve balance and agility, and increase daily walking. Physical therapy appointment times range from 45-60 minutes with appointments occurring 2 times a week for 6-8 weeks.
224225081|NCT03294512|BEHAVIORAL|MAWDS data entry on app|Utilize the smartphone app to enter their MAWDS (Medication, Activity, Weight, Diet, Symptoms) data
224225082|NCT05092334|OTHER|proprioceptive exercises|proprioception exercises included (a)Head relocation it involve the practice of relocating head back to natural head posture and to predetermined positions in range first with eyes open using feedback from a laser attached to their head and then with closed all active movement of cervical flexion extension lateral flexion and rotations were used.(b)Gaze stability oculomotor exercises commencing with eyes movement with the head stationary ,progressing to movement of head with visual fixation on a target. (c) Eye head coordination exercises, commenced with rotation of eyes and head to the same side in both right and left directions. Then progressed with both eyes and head move in opposite direction
224318764|NCT05245318|DEVICE|Blended physiotherapy program|The experimental group will receive a blended physiotherapy program consisting of six physiotherapy treatments over a period of 12 weeks, meaning one treatment session every two weeks. In addition, a smartphone application will offer the patients a daily exercise program, based upon the standard physiotherapy treatment, and psychological counselling. Before the start of the program, the exercises will be tailored to the area, type and degree of the patient's dysfunctions. During the six physiotherapy treatment sessions patients will (if needed), receive additional manual mobilisations to increase mobility of the neck and/or temporomandibular joints or manual techniques to decrease muscle tension in neck and jaw muscles. Additional counselling on knowledge about neck and jaw pain and advice about good posture and movement habits will also be provided by the physiotherapist during these six treatment sessions.
224318765|NCT00000116|DIETARY_SUPPLEMENT|Vitamin A|15000 IU/d as retinyl palmitate
223636155|NCT03472885|DRUG|Eculizumab|Participants received intravenous eculizumab administered at the participant's usual dose and schedule.
223636156|NCT04380740|DRUG|Placebo|During the extended dosing of abatacept, those randomized to receive 4 doses will receive a placebo consisting of an equal volume of normal saline solution.
223636157|NCT04380740|DRUG|Abatacept|Investigational prophylaxis with extended-dosing abatacept, a calcineurin inhibitor and methotrexate.
223636158|NCT03390686|DRUG|Bevacizumab|15 mg/kg IV every 3 weeks on Day 1
223636159|NCT03390686|DRUG|HD204|15 mg/kg IV every 3 weeks on Day 1
223636160|NCT03390686|DRUG|Carboplatin|Carboplatin AUC 6 IV every 3 weeks on Day 1 for 4-6 cycles
223636161|NCT03390686|DRUG|Paclitaxel|Paclitaxel 200 mg/m2 IV every 3 weeks on Day 1 for 4-6 cycles
223636162|NCT05653492|DRUG|Sulforaphane|Dosing study one to four 30 mg/d tablets depending on weight
223636163|NCT06466200|DIAGNOSTIC_TEST|Schiff Test|Use of an air syringe positioned perpendicular to the tooth surface at a distance of 1 cm. A scale to determine the intensity of DH was created, with the SASS (Shiff Analog Sensitivity Scale) ranging from 0 to 3 (0 being the absence of pain felt by the patient and 3 being pain considered intolerable). If the pain is greater than 1 then the patient is considered hypersensitive.
223636164|NCT06466200|OTHER|GOHAI questionnaire|Oral health-related quality of life assessment by questionnaire
223636165|NCT06466200|OTHER|OHIP questionnaire|Oral health-related quality of life assessment by questionnaire
223636166|NCT06466200|OTHER|DHEQ fr questionnaire|dentin hypersensitivity and oral health-related quality of life assessment by questionnaire
223636167|NCT05978193|RADIATION|LDRT+CFRT|"LDRT: Primary tumor and all visible metastatic lesions, DT: 2Gy/2fx, d1-2, Q3W × 4 cycles~; CFRT: Primary tumor, DT:40-50Gy/20-25fx, starting from the 5th immunotherapy cycle"
224225083|NCT05092334|OTHER|Strengthening exercise|strengthening exercises which are performed with prone and supine position by placing a towel under head, press towel for 5 seconds with 10-12 repetitions ,one set in a week for six weeks for cervical muscles
224225084|NCT05055791|DRUG|SYHX1903|SYHX1903 tablets, orally, qd
224225085|NCT01484028|DEVICE|etafilcon A control lens (1DM)|A marketed daily disposable contact lens
224225086|NCT01484028|DEVICE|etafilcon A with print and PVP for light eyes (EALE)|A daily disposable contact lens
223636168|NCT05978193|DRUG|Immunotherapy|PD-1 inhibitor 200mg, Q3W, until disease progression or unacceptable toxicity or treatment reaches 2 years
223636169|NCT05978193|DRUG|Chemotherapy|Paclitaxel+ Cisplatin, Q3W × 4cycles or Paclitaxel+ Carboplatin, Q3W × 4 cycles
223636170|NCT06812442|OTHER|Reminiscence therapy|Intervention group will receive two RT sessions per week for 13 weeks. RT sessions will last approximately 50 minutes and will be developed according to the following structure: · Welcome to the patient and reality orientation therapy (7 minutes)· Conducting the main activity of reminiscence (40 minutes) · Closure, thank you for the participation and farewell until the next session (3 minutes). RT sessions will have an individual format and will be conducted by a therapist previously trained in the protocol and the principles of RT. The Reminiscence activities of each session will be carried out following the protocol proposed in the Book of the Past and the Present.
223636171|NCT06970236|OTHER|Exercise|Daily session during hospitalization. To carry out the training session, elastic bands (TheraBand CLX Consecutive Loops; TheraBand, Akron, OH) with resistance graded from very low to very high (i.e, yellow, red, green, blue, black, silver and gold) will be used. On each day, each exercise will start with 3 sets of two repetitions as a warm-up and to calculate the appropriate intensity. The intensity will be that at which the patient reports a perceived exertion of 5-6 of 10 at the Borg CR10 scale after two repetitions. For each exercise, one set will be completed until task failure is achieved.If in any of the exercises the patient perceives this intensity only with the weight of his own limb or body weight, the exercise will be performed without elastic bands.
223636172|NCT06654479|OTHER|In the newborns in the study, changes in body temperatures during routine nursing interventions of the nurses of the clinic were examined.|The study is an observational study. The newborns were not intervened by the researcher. Body temperature changes were observed during routine practices of nurses in the clinic.
223636173|NCT06654869|BEHAVIORAL|lauhgter yoga|include laughter yoga effects on cancer patients' symptom management
223636174|NCT06654921|DEVICE|Remote ischemic conditioning|RIC is a non-invasive therapy that performed by an electric auto-control device with cuff placed on arm. RIC procedures consist of five cycles of 5-min inflation (200 mmHg) and 5-min deflation of cuff on bilateral arm. The procedure will be performed twice daily for consecutive 6 months after enrollment.
223636175|NCT06654921|DEVICE|Sham remote ischemic conditioning|Sham RIC will be performed by the same electric auto-control device with cuff placed on arm. Sham RIC procedures consist of five cycles of 5-min inflation (60 mmHg) and 5-min deflation of cuff on bilateral arm. The procedure will be performed twice daily for consecutive 6 months after enrollment.
223636176|NCT06654921|DRUG|Standard medication therapy|Standard medication therapy will be performed according to the national and international guidelines.
223764860|NCT04677491|BEHAVIORAL|fMRI experiments|Participants will see sexually explicit video clips that alternate with non-sexual clips and neutral color projection and b) smell alternate pheromones with clear air and pine aroma.
223764861|NCT04953923|DRUG|Cedazuridine|Tablet for oral administration
223764862|NCT04953923|DRUG|Placebo|Capsule for oral administration
224225087|NCT01484028|DEVICE|etafilcon A with print and PVP for dark eyes (EADE)|A daily disposable contact lens
224225088|NCT02414425|PROCEDURE|Rectoscopy|A rectoscopy will be performed for Botulinum toxin A or physiologic serum injection
224225089|NCT02414425|PROCEDURE|Anorectal manometry|Anorectal manometry will be performed to evaluate efficacy of Botulinum toxin A or physiologic serum rectal injection
224225090|NCT02414425|DRUG|Botulinum toxin A or physiologic serum injection|Botulinum toxin A or physiologic serum injection is performed during rectoscopy
224225091|NCT04495387|DRUG|Chemotherapy|standard adjuvat chemotherapy for reast and colo cancer
224225092|NCT05562336|DEVICE|Optical coherence tomography angiography|Optical coherence tomography (OCT) is a noninvasive imaging method that uses reflected light to create pictures of the back of your eye
224225093|NCT01956227|BEHAVIORAL|Home-based exercise|exercise to look at balance and lower limb strength record in diary
223764863|NCT04953923|DRUG|Moxifloxacin|Tablet for oral administration
224225094|NCT01956227|BEHAVIORAL|Education|sessions to discuss self-management ideas to modify risk of falling
224225095|NCT01956227|BEHAVIORAL|Exercise plus Education|combination of exercise sessions with education sessions to modify fall risk
224225096|NCT00047242|DRUG|7-hydroxystaurosporine|
224225097|NCT00047242|DRUG|irinotecan hydrochloride|
224225098|NCT01165814|DRUG|Naproxen Tramadol|
224225099|NCT03500965|BEHAVIORAL|text-only PWL|control condition (no image)
224225100|NCT03500965|BEHAVIORAL|graphic PWL|pictorial warning
224225101|NCT03500965|BEHAVIORAL|absolute risk|Percentage risk information for smoking-related diseases for smokers
224225102|NCT03500965|BEHAVIORAL|relative risk|Percentage risk information for smoking-related diseases for smokers and non-smokers
224225103|NCT01308281|PROCEDURE|PCI with IVUS guidance|Patients will be randomized in a two-by-two factorial manner according to the use of IVUS guidance (IVUS guidance vs. no IVUS guidance) for the PCI and the duration of dual anti-platelet therapy (100 mg/day aspirin and 75mg/day clopidogrel for 6 months vs. 12 months) after PCI. Each randomization of the enrolled subjects will be done 1:1.
224225104|NCT01308281|PROCEDURE|PCI without IVUS guidance|Patients will be randomized in a two-by-two factorial manner according to the use of IVUS guidance (IVUS guidance vs. no IVUS guidance) for the PCI and the duration of dual anti-platelet therapy (100 mg/day aspirin and 75mg/day clopidogrel for 6 months vs. 12 months) after PCI. Each randomization of the enrolled subjects will be done 1:1.
224318766|NCT00000116|DIETARY_SUPPLEMENT|Docosahexaenoic acid|1200 mg/d
224225105|NCT04235647|OTHER|Nurse led tutorial on lifestyle management and pedometer hand-out|Individual 10-minute nurse-led tutorial with distributed handouts on the health benefits of regular physical activity and pedometer hand-out
224225106|NCT04235647|OTHER|Steps goal setting and supporting phone calls|A goal of minimum 7000 steps per day, phone calls to assess the goal meeting and to support goal achievement every 2 weeks
224318767|NCT00000116|DIETARY_SUPPLEMENT|Control fatty acid|
224318768|NCT04085055|DIAGNOSTIC_TEST|Solid pancreatic mass lesion biopsy|The needle will be used to puncture the lesion and remove a piece of tissue from the mass for histological diagnosis.
224318769|NCT00743418|DEVICE|GPS modem and RFID|The participant will take the GPS kit with him/her everywhere during the whole day for a period of 4 weeks. The GPS tracking kit consists of a GPS receiver with a GSM modem, an RF transmitter contained in a wrist-watch and a monitoring unit located in the home that enables researchers to know whenever the tracked person leaves home. The waterproof RF transmitter will allow researchers to know whether or not research subjects leave home with the GPS device and if they are carrying the device or not at a given moment.
224318770|NCT05104190|OTHER|Stabilization of teeth during debonding using fingure pressure and elastic wafer|To control pain during debonding in one group , teeth were stabilized with finger pressure with cotton between finger and teeth and then debonding using open mouth technique was done. In second group teeth were stabilized using a plastic wafer between maxillary and mandibular teeth and then debonding was done using closed mouth technique. In order to reduce biasness, all of the patients were debonded with same plier and with wires still ligated to brackets. With the help of VAS, pain score was measured after debonding. A single operator performed complete procedure of debonding and pain recording.
223636177|NCT06655103|OTHER|Educational movie|There are three groups in this research. The 1st group will be shown an educational movie about intrathecal chemotherapy treatment before intrathecal chemotherapy treatment, the 2nd group will be shown a cartoon movie before intrathecal chemotherapy treatment, and the 3rd group will not receive any intervention before intrathecal chemotherapy treatment. In all groups, measurements will be made in parallel; fear and pain scales as well as electrodermal activity, pulse, respiration and O2 saturation values 30 minutes before IT chemotherapy treatment, in the second measurement; In the second measurement, electrodermal activity, pulse, respiration and O2 saturation values along with fear and pain scales 15 minutes before IT chemotherapy, and in the third measurement, electrodermal activity, pulse, respiration and O2 saturation values along with fear and pain scales will be evaluated within 30-60 minutes after IT chemotherapy treatment (when the sedation effect is over).
223636178|NCT06653998|OTHER|Early mobilization and rehabilitation|"In the initial assessment will be applied the ICU Mobility Scale, with the objective of establishing the patient\&#39;s current level of function and determining the most appropriate type, intensity and duration of activity.~The sessions, which will be conducted by a physiotherapist, will include therapeutic strategies such as bed exercises (both active and passive), electrical stimulation, use of an in-bed cycloergometer (for upper and lower limbs), sitting on the edge of the bed, bed transfers, bedside transfers from bed to chair, out-of-bed exercises, standing, and walking. The latter two activities are considered to be the most complex. Each session will last approximately 20 to 30 minutes and will be conducted once a day, on a daily basis throughout the patient\&#39;s ICU stay. The last session wil be prior to discharge of the patient.~During each session, the Borg Perception of Exertion Scale will be assessed in order to adjust the intensity of physical activity."
223636179|NCT06654492|PROCEDURE|The dimension of the window for lateral window maxillary sinus elevation surgery|The window size for a single implant site should not exceed 25 square millimeters, while the window size for consecutive multiple implant sites should not exceed 40 square millimeters.
223636180|NCT06655116|BEHAVIORAL|Diabetic Foot Education|"Patients in the intervention group will be interviewed and their diabetic foot knowledge will be evaluated. During the interview, the individual's knowledge about the definition of diabetic foot, risk factors, symptoms, treatment, complications, care and prevention will be evaluated.~In order to systematically plan, implement and evaluate the training to be used in the intervention, it is aimed to implement androgogical training based on the 'Interpersonal Relations Theory'. In this context, the stages in the theory will be followed as follows."
223764864|NCT04143451|BIOLOGICAL|Vaxigrip tetra|quadrivalent influenza vaccine
223764865|NCT04143451|BIOLOGICAL|Fluzone high-dose|high-dose trivalent influenza vaccine
224225107|NCT02922959|BEHAVIORAL|Peer Intervention|The Peer Intervention is a 20-minute telephone call delivered by a Peer Interventionist, who is trained to answer questions about the content of the personally-tailored information packets. The primary goal of the call is for the participant and the Peer Interventionist to have an open exchange of information about medication-assisted treatment (MAT) for opioid use disorder.
224225108|NCT02922959|DRUG|naloxone nasal spray kit|Naloxone nasal spray (NARCAN) is a potentially life-saving medication that can stop or reverse the effects of an opioid overdose. This nasal spray is approved by the FDA for reversing OODs and has a favorable side-effects profile. A take-home kit will be provided to the patient participants, which may be useful in the event of a future opioid overdose.
224225109|NCT02922959|BEHAVIORAL|Personally-tailored opioid overdose prevention education (information packet)|"Personally-tailored information packet with three participant-specific reports (Personal Overdose Risk Factors Report; Medication Assisted Treatment (MAT) Report; and the Opioid Overdose Information Report), and general written information about opioid overdose and treatment for opioid use disorder."
224318771|NCT01026987|DRUG|G-CSF|Unrelated donors will receive only G-CSF (10 ug/Kg S/C qDay x5-6 days) prior to pheresis (collection of the stem cells). Unrelated donors will only be followed per NMDP guidelines.
224318772|NCT01026987|DRUG|AMD3100|
224318773|NCT01026987|PROCEDURE|Leukapheresis|
224318774|NCT01026987|PROCEDURE|Stem Cell Infusion|
224318775|NCT00392912|DRUG|AndroGel (Solvay Pharmaceuticals)|Testosterone Replacement Therapy: AndroGel 1% 5g packets (Solvay Pharmaceuticals). Initial dosage: 5g daily (1 packet). Patients who do not achieve eugonadal levels of 400-600 mg/dL within 2 weeks will be raised to 10g daily.
224318776|NCT06216678|OTHER|Healthy Dietary Pattern with Cottonseed Oil|Cottonseed Oil
224318777|NCT06216678|OTHER|Healthy Dietary Pattern with Fatty Acid-Matched Plant Oils|Plant oil blend fatty acid matched
224318778|NCT06216678|OTHER|Healthy Dietary Pattern with PUFA:SFA Ratio-Matched Plant Oil|Plant oil with matched PUFA to SFA ratio
224318779|NCT00117832|DRUG|Azelastine nasal spray|
224318780|NCT01130597|DRUG|patiromer|Active investigational drug
224318781|NCT01130597|DRUG|spironolactone|
224318782|NCT05931978|OTHER|CKD dashboard|Online dashboard that visualizes patients' individual PROM- and clinical data related to their kidney disease.
224318783|NCT04529954|DRUG|Valproic Acid delivered to ICV|Valproic Acid delivered to ICV via an implantable pump and catheter system
224318784|NCT05052476|DIETARY_SUPPLEMENT|Bactecal® D Liquid|The patients will be randomized into two arms, A and B, in function of the intervention dose
224318785|NCT03816943|BEHAVIORAL|Whatsapp|a WhatsApp message with encouraging words will be sent after bond up
223636181|NCT00704015|BEHAVIORAL|Smoking cessation|Nurses, specifically trained for smoking cession program, contacted the patients at the orthopedic wards and initiated the intervention (stop smoking) within 1-2 days after acute hospitalization. The intervention included one or two personal meetings and weekly phone contacts during 6 weeks with a trained nurse. A phone number to a non-smoking hotline was provided for all patients. The patients were continuously encouraged not to smoke and free nicotine substitution (Nicorette®) was offered those who needed it. No other drug therapy was used.
223636182|NCT04835311|PROCEDURE|surgical perineal repair|women who have undergone surgical perineal repair (codes CCAM JMMA002 and/or HKCA005)
223636183|NCT01651728|DRUG|Simvastatin|Tablet 20 mg once daily for 30 days
223636184|NCT01651728|DRUG|Placebo|daily for 30 days
223636185|NCT04647370|PROCEDURE|remote ischemic preconditioning|3 cycles of 5-minutes inflation of a blood pressure cuff to 200mmHg (or at least to a pressure 50mm Hg higher than the systolic arterial pressure) to one upper arm, followed by5-minutes reperfusion with the cuff deflated
223636186|NCT04647370|PROCEDURE|Sham remote ischemic preconditioning|3cycles of upper limb pseudo ischemia (low pressure, 5-minutes blood pressure cuff inflation to a pressure of 20 mm Hg and 5-minutes cuff deflation).
223636187|NCT00982293|DEVICE|Resonator device|Low level electromagnetic fields for whole body immersion, 3 times weekly for 13 weeks (39) sessions of approximately 11/2 hours each.
223636188|NCT00982293|DEVICE|Resonator device - sham|"Treatment, 3 times weekly for 13 weeks (39) sessions - device will not be on"
223636189|NCT03183453|BEHAVIORAL|Neuropsychological treatment|Participants had to learn some brief material (words, faces, pictures, news), after which they were asked for an immediate and a delayed recall. After both recalls, participants were confronted with feedback about correct responses, non-responses and errors (i.e., confabulations and errors of attribution). This type of feedback worked on: 1) selective attention during the learning phase, training patients to focus on the relevant details of the stimuli; 2) monitoring processes during the retrieval phase, reinforcing the strategic search and training patients to inhibit traces that were irrelevant; and 3) memory control processes after the retrieval phase. The treatment consisted of 9 sessions and lasted for 3 weeks and the participants performed a baseline before and after treatment.
223636190|NCT01343953|PROCEDURE|Cord Blood Transplantation|One or 2 cord blood units containing alone or both together more than 4x107 frozen nucleated cells/Kg with no more than 2 out of 6 HLA mismatches between them and with the patients for acquired Severe Aplastic Anemia
223636191|NCT04546711|OTHER|Ketogenic Diet|The ketogenic diet (KD) is a high fat, very low carbohydrate diet
223636192|NCT02201953|DRUG|SOF/VEL|400/100 mg FDC tablet administered orally once daily
223636193|NCT02201953|DRUG|SOF|400 mg tablet administered orally once daily
223636194|NCT02201953|DRUG|RBV|Tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
223636195|NCT06589869|DEVICE|EM Chair|Patients who randomised to intervention group (Arm A) will receive HIFEM assisted (BTL EMsella) pelvic floor muscle training for total 6 sessions (2 session per week, 30 minutes per session with modulated intensity) plus standard of care. The intervention will be started within 2 weeks after Foley Catheter removed. Patients will attend follow up for training and at 1, 3 and 6 month post-operatively.
223636196|NCT06589869|OTHER|Standard of care|Standard of care. Perioperative education for information related to prostatectomy and pelvic floor exercise training. Patient were advice to perform pelvic floor exercise at least 30 times per day
223636197|NCT06592196|OTHER|stain|This research was conducted in two phases. Initially, a cross-sectional study was performed to assess the correlation between statin usage prior to hospital admission and the initial state of liver enzymes among patients. Subsequently, a retrospective cohort study was undertaken, wherein patients who had not been on statins prior to admission were categorized into two groups based on their statin usage post-admission.
223636198|NCT06603116|OTHER|treatment of class two cavities|restorations in class 2 cavities
223636199|NCT06398197|BEHAVIORAL|Nourish Intervention then No Intervention|Participants will attend a weekly in-person class with brief instructional video clips, hands-on cooking and tasting experiences. Participants will work individually and as part of small groups during instructional sessions. At the end of each class, participants will receive a grocery bundle and a kitchen gadget that serves both as an incentive and implementation support to promote improved cooking frequency and confidence. Participants will be asked to post photos of what they made with their groceries to an instant messaging software (GroupMe application) and be encouraged to engage with fellow classmates on GroupMe to encourage social support of cooking. After 8 weeks, participants crossover into the No Intervention group.
224318786|NCT03816943|BEHAVIORAL|Call|a telephone call will be made after bond up to provide encoring words
223636200|NCT06398197|BEHAVIORAL|No Intervention then Nourish Intervention|Participants will receive no intervention for 9 weeks. After 9 weeks, they crossover into the Nourish Intervention group where they will attend a weekly in-person class with brief instructional video clips, hands-on cooking and tasting experiences. Participants will work individually and as part of small groups during instructional sessions. At the end of each class, participants will receive a grocery bundle and a kitchen gadget that serves both as an incentive and implementation support to promote improved cooking frequency and confidence. Participants will be asked to post photos of what they made with their groceries to an instant messaging software (GroupMe application) and be encouraged to engage with fellow classmates on GroupMe to encourage social support of cooking.
224225110|NCT01266382|DEVICE|AposTherapy|a biomechanical device including 2 hemispheric biomechanical elements attached to a platform in a form of a shoe. the biomechanical device is calibrated to each patient by a physiotherapist specialized with the treatment methodology. patient are instructed to walk indoor with the device. time of exercise is gradually increase
224225111|NCT05197010|OTHER|Home based exercise program via a smartphone application|Daily home based exercise program (30min/day, 7days/week for 6 weeks).
224225112|NCT01360450|DRUG|Clonidine HCL|At day 5 on opioid and/or benzodiazepine (BZD), the infant will be randomized to receive either placebo (normal saline) or clonidine 1μg/kg/q 4 hrs to a maximum dose of 2μg/kg/q 4. Weaning from the study drug: When the opioid is no longer required, 24 hrs later the study drug (placebo or study drug) will be reduced by 50% and then discontinued 24 hours later provided that the Modified Finnegan scores remain between \< 9.
223636201|NCT06598904|OTHER|Aroma diffuser with single-note lavender essential oil|In a space of 3\*4\*2.6 cubic meters, positioned 10 cm away from the patient, add 4-6 drops (each drop being 0.05 ml) of 100% concentration single-note lavender essential oil into the aroma diffuser reservoir containing 120 ml of water.
223636202|NCT06598904|OTHER|Aroma diffuser with single-note orange essential oil|In a space of 3\*4\*2.6 cubic meters, positioned 10 cm away from the patient, add 4-6 drops (each drop being 0.05 ml) of 100% concentration single-note orange essential oil into the aroma diffuser reservoir containing 120 ml of water.
223636203|NCT06598904|OTHER|Aroma diffuser with deionized water|In a space of 3\*4\*2.6 cubic meters, positioned 10 cm away from the patient, add 4-6 drops (each drop being 0.05 ml) of water into the aroma diffuser reservoir containing 120 ml of deionized water.
223636204|NCT06597136|OTHER|Diaphragmatic kinesiology taping|The taping on the diaphragm from the abdomen was performed when the participant was standing and breathed-out and the body was in extension. The base of the tape was about 1 inch below the xiphoid process area. Then the arms were lifted above the head and, with maximum deep inspiration and after maximum rib cage expansion, the tails were applied with 10% tension on the rib cage. Diaphragmatic kinesiology taping will be applied in addition to conventional treatment for 3 days.
223636205|NCT06597136|OTHER|Accessory respiratory muscle kinesiology taping|Tapings of the accessory inspiratory muscles were applied in a sitting posture. Sternocleidomastoideus taping was applied when the neck of the participant was in lateral flexion to the opposite side to be taped and in rotation to the same side; and anterior and medius scalene tapings were applied when the neck of the participant was in the lateral flexion position to the opposite side to be taped. Tapings were repeated on the opposite side.Taping was applied to accessory expiratory muscles in the supine position. While the participant was supporting one leg in the hip and knee flexion position on the bed, the other leg was extended from the bed and the hip was kept in the extension position. The obliquus externus muscle was taped on the side with hip-knee flexion and the obliquus internus muscle was taped on the side with hip extension.In addition to conventional treatment, kinesiology taping will be applied to the accessory respiratory muscles for 3 days.
223636206|NCT06597136|OTHER|Sham kinesiology taping|Sham kinesiology taping will be applied for 3 days. Sham KT was performed with the same taping material. A 2-blocked I strip was applied vertically to the sternum. The same procedures were followed.
223636207|NCT06594718|PROCEDURE|Endoscopic diverticulotomy with Z-POEM|Endoscopic diverticulotomy with Z-POEM
223636208|NCT06594718|PROCEDURE|Endoscopic diverticulotomy using a non-tunnelization technique|Endoscopic diverticulotomy with diverticuloscope, Knife Septotomy, or Clutch Cutter
223636209|NCT06595641|DEVICE|Transfer Energy Capacitive Resistive Therapy|It's a physical treatment modality commonly used to treat musculoskeletal pain. It normally uses a longwave radiofrequency of \~0.5 MHz. The system consists of a neutral plate and two different electrodes that can transfer energy in two modalities: capacitive and resistive
223636210|NCT06595641|OTHER|strength training program|"Each session includes five exercises, each performed for three sets of 10 repetitions:~Shoulder Retraction - Strengthens muscles between shoulder blades. Shoulder Scaption - Improves stability and range of motion. Shoulder External Rotation from Side Lying - Targets rotator cuff muscles. Shoulder Protraction - Enhances shoulder blade function. Shoulder Extension - Strengthens posterior shoulder muscles"
223636211|NCT06590818|PROCEDURE|High tibial osteotomy (HTO|To investigate the effect of body mass index (BMI) on the early efficacy of high tibial osteotomy (HTO) in the treatment of varus knee osteoarthritis
223636212|NCT06591013|PROCEDURE|Fecal microbiota transplantation|Transplantation of fresh fecal bacterial fluid into the ileocecum of patients with ulcerative colitis via the colonoscopic route
223636213|NCT06602713|OTHER|Questionnaires|Western Ontario Shoulder Instability questionnaire Western Ontario Rotator Cuff questionnaire Shoulder Instability Return to Sport after Injury questionnaire
223636214|NCT06602713|OTHER|Exercices|isokinetic evaluation
223636215|NCT06595979|DRUG|Polymyxin B|Participants in this group will receive polymyxin B administered directly into the brain (intracranial administration) without intravenous (IV) infusion.
224225113|NCT01360450|DRUG|saline|Infants randomized to placebo will be administered IV saline or oral sterile water in the same volume as study drug. The placebo will be give every 4 hrs as outlined in the algorithm for the study.
224225114|NCT00209209|DRUG|Rituximab|antibody
224225115|NCT00209209|DRUG|Cyclophosphamide|chemotherapy
223636216|NCT06595043|DEVICE|the tip opening angle to the left|After fixing the position of the tracheal catheter, the opening of the tip of the blocker will be adjusted to left under the guidance of the fiber bronchoscope.
223636217|NCT06595043|DEVICE|the tip opening angle to the right|After fixing the position of the tracheal catheter, the opening of the tip of the blocker will be adjusted to right under the guidance of the fiber bronchoscope.
223636218|NCT06602843|PROCEDURE|Neoadjuvant chemoimmunotherapy followed by surgery and postoperative radioimmunotherapy|Neoadjuvant chemoimmunotherapy followed by surgery and postoperative radioimmunotherapy
223636219|NCT06596512|DRUG|PARTICS using a single ICS add on|Participants randomized to PARTICS who use a nebulizer less than once a week are instructed to use the study prescribed ICS each time they use their rescue inhaler and take 5 puffs of the newly prescribed ICS after each rescue nebulizer use.
223764866|NCT04143451|DRUG|Aldara 5% Topical Cream|imiquimod cream
223764867|NCT04143451|DRUG|Aqueous cream BP|inactive aqueous cream
224225116|NCT00209209|DRUG|Doxorubicin|chemotherapy
224225117|NCT00209209|DRUG|Vincristine|chemotherapy
224225118|NCT00209209|DRUG|Prednisone|coricosteroide
224225119|NCT00209209|DRUG|Fludarabine|chemotherapy
224225120|NCT00209209|DRUG|Interferon-alpha|cytokine
224225121|NCT00209209|DRUG|pegylated formula Interferon-alpha 2b|cytokine
224225122|NCT00209209|PROCEDURE|chemotherapy: R-CHOP|immuno-chemotherapy
224225123|NCT00209209|PROCEDURE|chemotherapy: R-FC|immuno-chemotherapy
224225124|NCT00209209|PROCEDURE|Interferon maintenance|cytokine
224225125|NCT00209209|PROCEDURE|Rituximab maintenance|antibody
224318787|NCT02693860|DRUG|huJ591|Antibody is derived from a hybridoma originally produced in the Weill Medical College Laboratory of Urological Oncology. Treatment with 100 mg of HuJ591 will be administered as an intravenous infusion at a concentration of 5 mg/mL and rate of \<5 mg/minute.
223764868|NCT03618797|DRUG|HL-PIF cap.160/2mg + Placebo|Fenofibrate pellet (as micronized fenofibrate 160mg) and Pitavastatin Ca 2mg
224225126|NCT03361514|BEHAVIORAL|Supported Protocolized Discontinuation (SPD)|Patients who choose to discontinue their medication will make a personal tapering schedule with their GP based upon a discontinuation protocol with tapering suggestions. The protocol offers suggestions to taper within a maximum of 6 months describing all types of available dosages per antidepressant so individualized schedules can be constructed. In addition, they will be offered supportive meetings with the GP's mental health assistant. The assistant will receive basic information about discontinuation guidance, i.e. the information brochure, decision aid, discontinuation protocol and a short guideline how to organise consultations.
224225127|NCT03361514|BEHAVIORAL|Mindfulness Based Cognitive Therapy (MBCT)|In addition to the SPD patients are offered Mindfulness Based Cognitive Therapy (MBCT) in homogeneous groups of patients willing to withdraw from their medication. MBCT will be offered according to the treatment protocol developed for recurrent depression, adaptated to the specific needs of patients discontinuing their antidepressant medication. The mindfulness courses will be provided by teachers qualifying the advanced criteria of the Association of Mindfulness Based Teachers in the Netherlands and Flanders. All teachers will receive additional training in using the specific study protocol at the start of the project.
224225128|NCT06424847|BEHAVIORAL|Lifestyle intervention (physical activity and diet)|"The physical activity intervention will be based on validated behavior change theories aimed at the initiation and long-term maintenance of physical activity.~Participants will be referred to specialists in Adapted Physical Activity for a 6-month program. Exercise sessions will include aerobic exercise and muscle strengthening exercises. Participants will participate in one supervised sessions per week. They will receive instructions for exercising on their own on the other days in order to reach physical activity guidelines. They will also receive instructions and tips to limit sedentary behavior and increase their physical activity throughout the day.~Participants will benefit from an initial consultation with a dietitian and 4 follow-up visits. The follow-up visits will be either group-based or individual, based on participants choice and availabilities. Dietary recommendations will be based on public health guidelines in France aimed at eating a healthy, balanced diet."
224318788|NCT02693860|DRUG|89Zr-J591|Drug product is manufactured by the radiochemistry staff of Citigroup Biomedical Imaging Center (CBIC) research core facility. Radiolabeling of DFO-huJ591 with 89Zr is achieved by the addition of 89Zr-oxalate to the DFO-huJ591 in ammonium acetate buffer.
223515012|NCT06570330|DIETARY_SUPPLEMENT|Non-GMO corn Maltodextrin, Rapid Absorption|he composition and absorption properties are similar to the investigational product and will be given in the same dosage (2.1g/day for days 1-5 and increasing to 4.2 g/day for days 6-30) and route of administration as the investigational product.
223515013|NCT02688231|OTHER|Task-oriented upper limb training|"Participants in the experimental groups (high-intensity and low-intensity) receive for 8 weeks, 60 min/day, 5 days/week a task-oriented upper limb rehabilitation training at a high or low intensity, respectively, instead of their regular occupational therapy hours provided in the conventional multidisciplinary rehabilitation program.~The task-oriented training involves practicing of functional daily tasks, with the intention to acquire or reacquire a skill. Most functional upper limb tasks require following essential movement components: reaching, moving, positioning, transporting, lifting the upper limb and/or an object and grasping, releasing, stabilizing, manipulating an object.~The Tagtrainer of SymbioTherapy is used to support the independent training of tasks with real objects with different sizes and weights. The Diego of Tyromotion is used in patients who require assistance (gravity support) during the performance of different upper limb tasks."
223515014|NCT02688231|OTHER|Control intervention|"The participants in the control group receive for 8 weeks the conventional multidisciplinary rehabilitation program (physiotherapy, occupational therapy and speech or cognitive therapy if needed).~The training sessions are scheduled for 60 min/day, 5 days/week for the duration of 8 weeks."
223515015|NCT06570837|DIETARY_SUPPLEMENT|Iron|observation effect of iron dificincy
223515016|NCT00283569|OTHER|Mouth Swab, Toe Nail Clippings, Questionnaires|The objective of this study is to establish a clinic based case control study for examination of potential risk factors for primary adult brain tumors.
223515017|NCT06570811|DRUG|Placebo|Placebo tablets is supplied to breast cancer patients who receive 80 mg/ m2 paclitaxel (taxol®) chemotherapy.
223515018|NCT06570811|DRUG|Coenzyme Q10 200mg twice daily|400 mg daily (200mg twice daily) of Coenzyme Q10 (an antioxidant that's in many foods, and it's made naturally in the investigator's bodies) is supplied to breast cancer patients who receive 80 mg/ m2 paclitaxel (taxol®) chemotherapy.
223515019|NCT04093882|DIAGNOSTIC_TEST|Contrast agent enhanced MRI using Gadovist|By using the contrast agent Gadovist we aim to visualize the blood-brain barrier. Furthermore, we aim to measure a newly developed biomarker of the blood-brain barrier in the cerebro-spinal fluid.
223515020|NCT06289582|DRUG|[F-18]DPA714 administration IV|brain PET/MRI imaging after \[F-18\]DPA-714 administration
223515021|NCT03841474|DRUG|Psychiatric treatment with sertraline|Psychiatric treatment with sertraline (range from 50 mg/day to 200mg/day according to clinical appearance) of newly recognized depression in patients after PCI
223515022|NCT03841474|DRUG|Psychiatric treatment with escitalopram|Psychiatric treatment with escitalopram (range from 10 mg/day to 20 mg/day according to clinical appearance) of newly recognized depression in patients after PCI
223515023|NCT03538821|DIETARY_SUPPLEMENT|Intact cod protein from fillet|Intact cod protein from fillet 8 g protein daily for 8 weeks
223515024|NCT03538821|DIETARY_SUPPLEMENT|Intact cod protein from residual material|Intact cod protein from residual material, 8 g protein daily for 8 weeks
223515025|NCT03538821|DIETARY_SUPPLEMENT|Control|Control group receive tablet containing fillers
223515026|NCT01668199|DRUG|TZP-101|
223515027|NCT03113188|DRUG|CBP501|CBP501, CDDP plus Nivolumab
223515028|NCT05075473|OTHER|Segmental stabilization|Physiotherapist will perform activation of multifidus in prone position. It also includes activation of transverse abdominas in crook lying position, in sitting as well as in point kneeling position to re-establish simultaneous contraction of deep muscles synergy.
223515029|NCT05075473|OTHER|Generalized Lumber stabilization exercsies|It can by performed by patient him or her self under physiotherapist's assistance. Lumber neutral position is maintained. Bridging in prone as well as supine position will be maintained.
224225129|NCT06424847|BEHAVIORAL|Lifestyle (physical activity and diet) and Sleep intervention|"Participants will benefit from the physical activity and diet intervention detailed above and the following sleep intervention. Participants will fill out an online sleep diagnostic tool includes validated sleep questionnaires (Pittsburgh Sleep Quality Index, Epworth sleepiness scale, Insomnia Severity Index, Berlin questionnaire, Horne and Ostberg questionnaire).~Participants will also log their sleep habits in a 14-day sleep diary. Based on the sleep specialists' review of the results of the questionnaires, sleep diary and analysis of sleep-wake patterns, participants who require further exploration will be referred to a sleep specialist for a consultation and if necessary the appropriate treatment for their sleep disorder.~All participants in this group will benefit from an individualized sleep hygiene intervention. They will benefit from a baseline interview and 3 follow-up visits."
224225130|NCT06424847|BEHAVIORAL|Health education intervention|Participants randomized to the control group will benefit from a health education intervention in order to limit deception bias.
224225131|NCT03107949|DEVICE|Lungpacer DPTS (Diaphragm Pacing Therapy System)|Lungpacer Diaphragm Pacing therapy (DPTS) will be conducted in daily sessions until the patient has been extubated or day 30 if not extubated.
224225132|NCT05551377|OTHER|Head-up tilt sleeping|Whole-body head-up tilt sleeping (HUTS) will be carried out in three different angles, each for the duration of two weeks. Prior to the first angle the participant will sleep in a horizontal position for 1 week. The different angles will be installed using a wedge between the mattress and bed frame.
223515030|NCT02051387|DRUG|Cannabidiol CR|
223515031|NCT02051387|DRUG|Cannabidiol|
223515032|NCT02051387|DRUG|Amisulpride|
223515033|NCT02051387|DRUG|Olanzapine|
223515034|NCT02051387|DRUG|Quetiapine|
223515035|NCT02051387|DRUG|Risperidone|
223515036|NCT02051387|DRUG|Placebo|
223515037|NCT01832298|DRUG|Simmitecan Hydrochloride for Injection|Either at 12.5 mg, 25 mg、50 mg、80 mg、120 mg、160 mg、200 mg
223515038|NCT00615160|DRUG|PTK787/ZK 222584|PTK-ZK capsules taken orally with a daily flat dose of 1250 mg
223515039|NCT00615160|DRUG|Dacarbazine|Dacarbazine 850 mg/m² on day 1 q4w
223515040|NCT01661595|DRUG|Sildenafil|50 mg/day for 4 weeks
223515041|NCT01661595|DRUG|tadalafil|10 mg/day for 4 weeks.
223515042|NCT01661595|DRUG|Placebo|Placebo 1 capsule per day for four weeks.
223515043|NCT04578041|DEVICE|TRPMS (Transcranial Rotating Permanent Magnet Stimulation)|"TRPMS ( is administered through a head cap worn by the participant and controlled by QHTimeStimulate application via computer tablet.~* Modality: Excitatory stimulation~* Frequency: 5 Hz~* Interval between stimulus: 100 ms~* Duration of each stimulus: 25 ms~* Duration of stimulation: 40 minutes~* Position of microstimulators: over primary motor cortex and supplementary motor area for Arm 1; over left and right dorsolateral prefrontal cortex for Arm 2"
223515044|NCT04578041|OTHER|Aerobic Exercise Program|Aerobic exercise consisting of 40 minutes of cycling training with a seated elliptical machine. The daily physical activity program will consist of three 10-minute bouts of aerobic exercise interspersed with two 5-minute bouts of rest. The participants will exercise maintaining their Heart Rate (HR) at least between 60-80% of the maximum age-related HR.
223515045|NCT04578041|OTHER|Computerized CT (Cognitive Training)|"Computerized cognitive training (CT) consisting of 40 minutes Brain-HQ training.~The adaptive cognitive training games also serve to engage them during the stimulation session, and to keep them seated at the computer for the entire duration of the session."
223515046|NCT02368873|PROCEDURE|Application of IPOM mesh|
223515047|NCT04808011|DEVICE|Intelligent Dialysis Assistant (IDA)|The IDA is intended for home dialysis for subjects who are stage 5 kidney diease patients and who perform Peritoneal Dialysis. The system is used deveral times a day for approximately 20 minutes for each cycle. During the interventional period, subjects will use only the investigational IDA system for their in/out exchanges.
223515048|NCT01327729|DRUG|pegylated interferon alpha 2a YPEG-IFN α-2a 180mcg|YPEG-IFN α-2a 180mcg dose form: subcutaneous dosage : 180 mcg frequency every week or ten days or 2 weeks according to the group
223515049|NCT00364195|DRUG|Tesmilifene (YMB1002)|
223515050|NCT00912509|DRUG|riboflavin|riboflavin 0.1% is applied every 2 minutes for 30 minutes
223515051|NCT00912509|DEVICE|UVX Light|UVX 365 nm wavelength light source is applied with continued application of riboflavin 0.1%
223515052|NCT01218321|BIOLOGICAL|antiepileptic treatment|White blood cells from peripheral blood samples
223515053|NCT02576197|DIETARY_SUPPLEMENT|Probiotic|one capsule per day, containing the probiotic along with the patient's customary psoriasis treatment (excluding systemic treatments)
223515054|NCT02576197|DIETARY_SUPPLEMENT|Placebo|one capsule per day, containing the placebo, along with the patient's customary psoriasis treatment (excluding systemic treatments)
223515055|NCT02715856|OTHER|Monitoring Device|Undergo surgical wound and physical activity monitoring
223515056|NCT02715856|OTHER|Physical Activity Measurement|Undergo physical activity measurement
223515057|NCT02715856|OTHER|Quality-of-Life Assessment|Ancillary studies
223515058|NCT02715856|OTHER|Questionnaire Administration|Ancillary studies
223515059|NCT02715856|PROCEDURE|Standard Follow-Up Care|Undergo standard follow-up care
223515060|NCT02715856|OTHER|Survey Administration|Ancillary studies
223515061|NCT05227365|DEVICE|Lenire|The sound stimulus of PS6 is comprised of sequences of tones and is spectrally modified according to the participant's hearing thresholds so that different components of the sound stimulus can be sufficiently heard by the participant irrespective of their hearing characteristics (audiological profile). The tongue stimulus of PS6 is delivered by an array of electrical signals via 32 transmucosal electrodes contacting the anterodorsal surface of the tongue. The sound and tongue stimulus parameters are presented with certain stimulus rates and timing relationships between modalities.
223515062|NCT04551586|DRUG|ACH-0145228: Immediate Release|ACH-0145228 (240 milligrams) will be administered orally on Day 1.
223515063|NCT04551586|DRUG|ACH-0145228: Powder-in-capsule|ACH-0145228 (240 milligrams) will be administered orally on Day 1.
223636220|NCT06596512|DRUG|MART|Participants are instructed to use prescribed study ICS/LABA for maintenance and as needed for rescue.
223636221|NCT06592729|BEHAVIORAL|education|intervention group was taken to scenario-based simulat
224318789|NCT04646876|DRUG|Magnesium Sulfate|Prospective , comparative , double blind study
224318790|NCT04646876|DRUG|Placebo|Prospective , comparative , double blind study
223636222|NCT06593873|OTHER|Use of typodont head model in addition to theoretical periodontal education|Use of typodont phantom head model in addition to theoretical periodontal education
223636223|NCT06593873|OTHER|Theoretical periodontal education|Theoretical periodontal training only
223636224|NCT06595927|DIAGNOSTIC_TEST|Cervical extensor endurance test|Monitoring the clinical parameters of head and neck immobility during the cervical extensor endurance test to correlate them with muscular activity by MRI and other cervical clinical tests
223636225|NCT06594276|OTHER|Local instillation of antibiotics|Systemic antibiotics are usually used with needle aspiration of breast abscess. However local instillation of antibiotics will be an in intervention in this study.
223636226|NCT06591260|OTHER|support treatment, cardiac medical treatment, aetiology-specific treatment, device implant, arrhythmia ablation|Treatment will be patient-tailored, integrating international guidelines recommendation and the experience of the center where enrollment takes place.
223636227|NCT06592560|DEVICE|ELISA|Specific test: Assay of asprosin marker will be measured by enzyme-linked immunosorbent assay ( ELISA).
223636228|NCT06603974|PROCEDURE|surgery|After receiving the corresponding neoadjuvant treatment for 2 cycles, surgery was performed within 3-6 weeks after drug withdrawal.
223636229|NCT06603974|DRUG|Benmelstobart|1200mg, diluted to 250ml with normal saline, infusion time 60 ± 10mins. The first day of each cycle, 3 weeks (21 days) as a treatment cycle
223636230|NCT06603974|DRUG|tegafur|it needs to be administered according to the patient\&#39;s body surface area\&lt; 40mg / time at 1.25m2; \&gt; 50mg/ time for 1.25m2 and \&lt;1.5m2; \&gt; 60mg/ time at 1.5m2; Oral, twice a day, after morning and evening meals, for 14 consecutive days, rest for 7 days, as a treatment cycle; Repeat every 3 weeks;
223636231|NCT06603974|DRUG|oxaliplatin|130mg/m2, administered on the first day of each cycle, repeated every 3 weeks;
223636232|NCT06603974|DRUG|albumin paclitaxel|260mg/m2, intravenous infusion, 30 minutes per infusion, once every 3 weeks, administered on the first and eighth days of each cycle
223636233|NCT06598566|OTHER|Nottingham Hip Fracture Score (NHFS) score|Nottingham Hip Fracture Score (NHFS) score in patients above 60 years undergoing hip fracture surgery.
223636234|NCT06598566|OTHER|Acute Physiology and Chronic Health Evaluation (APACHE)-II score|Acute Physiology and Chronic Health Evaluation (APACHE)-II score in patients above 60 years undergoing hip fracture surgery
223636235|NCT06594341|PROCEDURE|Visit frequency|"Fortnightly visit frequency for moderate phase~Nutritional supplement: 1 daily sachet of RUTF as soon as a child admitted with MUAC\<115mm or edema reaches a MUAC=\>115mm or absence of edema."
223636236|NCT06594341|DIETARY_SUPPLEMENT|Suppression of the transition period|Transitioning children admitted with MUAC\<115mm or edema to receiving 1 daily sachet of RUTF as soon as they reach a MUAC=\>115mm and absence of edema
223636237|NCT06594341|PROCEDURE|Simplified treatment|Admitting children with MUAC\<125mm or edema to treatment prescribing 2 daily sachets for children with MUAC\<115mm or edema and 1 daily sachet for children with MUAC 115mm to 124mm. Treatment visits are done on a weekly basis and children with MUAC\<115mm are transitioned to receiving 1 daily sachet of RUTF once they reach a MUAC=\>115mm for 2 consecutive measurements. Treatment is continued until recovery defined as a MUAC=\>125mm for 2 consecutive weeks.
223636238|NCT06589427|OTHER|Invasive ventilation.|Patients were subjected to invasive ventilation.
223636239|NCT06443814|BEHAVIORAL|Health Education|This was a didactic classroom-based control which educates the patient on adapting a healthier lifestyle through proper diet, exercise, and moderating substance usage according to current AHA guidelines. This intervention does not include a stress management component.
223636240|NCT06443814|BEHAVIORAL|Transcendental Meditation|TM was taught in a standardized and validated format as a simple, natural mental technique practiced for 20 minutes twice a day (morning and evening) to give rest and relaxation to mind and body. TM was taught by a certified instructor and a 7-step process taking place over 4 consecutive days after which the meditator can practice at home twice a day.
224225133|NCT01398579|PROCEDURE|Gastroscopy|"20 patients will be randomized into two groups. All of them will be examined using four different endoscopy imaging technologies by one trained specialist. 10 patients will be in group A and another 10 patients will be in group B.~Group A: WLE followed by AFI followed by NBI followed by pCLE. Group B: WLE followed by NBI followed by AFI followed by pCLE."
224225134|NCT01789008|OTHER|Determination of Advanced Fibrosis in Alcoholic Liver Disease|
224225135|NCT03867383|DRUG|Calcium Chloride|"All included in intervention description.~1 gram of calcium chloride in total 60 milliliters normal saline"
223636241|NCT00505271|GENETIC|Rexin-G|"Three patients will receive Rexin-G at Dose Level I. If 1 of 3 patients at Dose Level I develops a grade 3 or 4 adverse event (CTCAE Version 3.0) which appears to be related or possibly related to Rexin-G, then 3 additional patients will be enrolled at the same dose level. If at least 2 of the first 3, or 3 of 6 patients at Dose Level I develop a grade 3 to 4 adverse event which appears to be related or possibly related to Rexin-G, accrual into the study will be held.~At any dose level, up to six patients may be enrolled if there is evidence of biological activity in the first three patients. Dose escalation may stop if there is impressive evidence of biological activity. An amendment would be submitted to allow further expansion of dose level based on impressive biological activity."
223636242|NCT06599372|OTHER|The rTMS method|The patient receives treatment under naturalistic conditions in routine practice.
223636243|NCT06599372|OTHER|The cTBS method|The patient receives the treatment under naturalistic conditions in routine practice.
223636244|NCT03493997|COMBINATION_PRODUCT|Radiotherapy+IAluril®+Ialuril Soft Gels®|Radiotherapy+IAluril®+Ialuril Soft Gels®
223636245|NCT03493997|RADIATION|Radiotherapy only|Radiotherapy only
223764869|NCT03618797|DRUG|Livalo tab. 2mg + Placebo|Pitavastatin ca 2mg
224225136|NCT03867383|DRUG|Placebo|60 milliliters normal saline
224225137|NCT03878355|PROCEDURE|radical endoscopic sinus surgery (RESS) plus Draf 3 surgery.|"The procedure of RESS was completed as described in full-house FESS (FHF) approach, involving complete removal of all nasal polyps along with a full maxillary antrostomy, total ethmoidectomy, wide sphenoidotomy, and a Draf 2A frontal sinusotomy. Moreover the bilateral inferior two-thirds of MTs were meanwhile resected. The technique for the Draf 3 frontal drillout procedure was described in detail in previous publications with resection of the superior nasal septum, central frontal sinus floor, and frontal beak region, resulting in a widely patent, oval-shaped, common frontal sinus neo-ostium"
224225138|NCT03878355|PROCEDURE|radical endoscopic sinus surgery (RESS)|"The procedure of RESS was completed as described in full-house FESS (FHF) approach, involving complete removal of all nasal polyps along with a full maxillary antrostomy, total ethmoidectomy, wide sphenoidotomy, and a Draf 2A frontal sinusotomy. Moreover the bilateral inferior two-thirds of MTs were meanwhile resected"
224225139|NCT03878355|PROCEDURE|functional endoscopic sinus surgery (FESS)|FESS was performed by Messerklinger technique with middle turbinate preservation
224225140|NCT01848652|DRUG|infusion of MYOCET|
223515064|NCT06244823|DRUG|Fremanezumab Prefilled Syringe|MRI will be scanned prior to the first administration of Fremanezumab, within 0-14 days, prior to Fremanezumab injection. The second MRI will be acquired at 12 ± 1 weeks after the first Fremanezumab injection.Images will be acquired during interictal periods, defined as at least 24 hours from last migraine attack. All the scans will be acquired during the same session, starting with the T1-weighted scan, followed by the diffusion-weighted scan and ending with the rs-fMRI scan. Total acquisition time for a single subject is approximately 28 minutes, divided in the following periods of time: six minutes for the T1-weighted scan, 12 minutes for the diffusion-weighted scan and 10 minutes for the rs-fMRI scan. If we consider patient preparation, obtainment of documents and informed consent form, the whole process will take about 50-70 minutes.
223515065|NCT02206438|DEVICE|Insertion of C-LMA|After induction of general anesthesia, C-LMA or Air-Q was inserted according to randomly allocated group.
223515066|NCT02206438|DEVICE|Insertion of air-Q according|After induction of general anesthesia, C-LMA or Air-Q was inserted according to randomly allocated group.
223515067|NCT01623427|PROCEDURE|Application of vacuum|The vacuum will be applied to the wound dressing of the umbilical port site using a 22 g needle on a 10 ml syringe passed percutaneously from the outside of the dressing into the gauze and the air around the gauze is evacuated.
223515068|NCT01623427|PROCEDURE|No vacuum|Except for the vacuum, the wound dressing for the umbilical port site will be the same. No vacuum will be applied to the wound dressing of this group
223515069|NCT01242384|DEVICE|Device: Silicon ring (Arabin Pessary)|Placement of a silicon pessary in the vagina, around the cervix.
223515070|NCT03379584|DRUG|SGN-CD48A|Intravenous (IV) infusion on days 1, 8, and 15 of a 28-day cycle
223515071|NCT02944045|DRUG|Methylprednisolone|"Methylprednisolone intra veinous~* Day 1 to 5 : 30mg twice per day~* Day 6 to 10 : 30mg per day~* Day 11 to 21 : 20mg per day"
223515072|NCT02944045|DRUG|Placebo|saline serum
223515073|NCT02462057|OTHER|Email message regarding the HealthyFood benefit|
223515074|NCT01682603|DRUG|Botulinum toxin A|BoNT-A (BOTOX 300U)
223515075|NCT04582487|OTHER|bone marrow and/or peripheral blood samples withdrawal|bone marrow and/or peripheral blood samples evaluation
223515076|NCT03382860|DIAGNOSTIC_TEST|Fundus videos|Recordings of fundus videos
223515077|NCT00078195|BIOLOGICAL|omalizumab|A minimum equivalent dose of 0.016 mg/kg/IgE (IU/mL) every 4 weeks will be administered. Omalizumab is administered in two separate phases. In the pre-treatment period omalizumab will be administered to condition the participants to an immune tolerance state. Omalizumab will be also administered after RIT and during the maintenance immunotherapy phase.
223515078|NCT00078195|BIOLOGICAL|Placebo omalizumab|The placebo for omalizumab will contain the excipients and diluents of the omalizumab.
223515079|NCT00078195|BIOLOGICAL|Ragweed rush immunotherapy (RIT)|RIT will consist of a series of injections containing ragweed extract. The series of injections will have progressively greater amounts of ragweed extract: starting from the 1:1000 dilution of the maintenance vial and progressing to the 0.3 mL of 1:10 dilution of the maintenance vial or the maximally tolerated amount.
223515080|NCT00078195|BIOLOGICAL|Placebo rush immunotherapy (RIT)|The placebo for rush immunotherapy will contain the diluents and histamine.
223515081|NCT00078195|BIOLOGICAL|Ragweed immunotherapy (IT)|Participants will receive weekly maintenance IT dosing for a total of 12 weeks.
223515082|NCT00078195|BIOLOGICAL|Placebo immunotherapy (IT)|The placebo for immunotherapy will contain the diluents and histamine.
223515083|NCT03607669|OTHER|Mangafodipir trisodium|Manganese-based MRI contrast agent
223515084|NCT02336555|DRUG|MK-8291|MK-8291 oral tablets
223515085|NCT02336555|DRUG|Placebo|Placebo oral tablets
223515086|NCT03390400|DEVICE|Femtosecondlaser-assisted|Femtosecondlaser-assisted Cataract Surgery will be performed bilateral on the same day with different laser settings.
223515087|NCT03390400|PROCEDURE|Anterior Capsulotomy|Cataract Surgery
223515088|NCT03390400|PROCEDURE|Lens Fragmentation|Cataract Surgery
223515089|NCT03333889|OTHER|Vita Enamic hybrid crown|hybrid ceramic material in the form of mesoblocks where the ceramic block is attached to a ti base .The whole assembly is screw retained superstructure.
223515090|NCT03333889|OTHER|emax hybrid crown|high srength glass ceramic that can be milled in sections up to 1mm .
223515091|NCT00993473|DRUG|Insulin glargine (HOE901)|"100 U/mL commercial solution for injection available as both disposable pen devices Solostar® each containing 300 U and as 10 mL vials each containing 1000 U~Dose: titrated to achieve the following glycemic targets without hypoglycemia:~* Fasting blood glucose (BG) between 90 and 145 mg/dL (5.0 to 8.0 mmol/L), inclusive,~* Bedtime BG between 120 and 180 mg/dL (6.7 to10.0 mmol/L), inclusive,~* Nocturnal BG between 80 and 162 mg/dL (4.4 to 9.0 mmol/L), inclusive; and~* HbA1c \<7.5%."
223515092|NCT00993473|DRUG|Neutral Protamine Hagedorn (NPH) insulin|"NPH insulin 100 U/mL commercial (Huminsulin Basal) solution for injection available as both disposable pen devices (Huminsulin Basal Pen) each containing 300 U and as 10 mL vials each containing 1000 U~Dose: titrated to achieve glycemic targets as described above for insulin glargine"
223515093|NCT00993473|DRUG|Insulin lispro|Insulin lispro used as the principal bolus insulin; regular human insulin permitted. Administration: multiple injection before meals and/or at bedtime at the discretion of the Investigator.
223515094|NCT02363426|DEVICE|INVOcell Culture Device|INVOcell is a vaginal culture device
223515095|NCT02363426|DEVICE|IVF Incubation|IVF Incubator
223515096|NCT03258229|DIETARY_SUPPLEMENT|Angelica gigas N. extract|capsules(2cap/d, 1,000mg/d) for 8 weeks.
223515097|NCT03258229|DIETARY_SUPPLEMENT|Placebo|Placebo for 8 weeks
223515098|NCT06323083|OTHER|Emotional Freedom Technique|Emotional freedom techniques is a psychophysiological intervention that combines psychological methods from traditional therapies with somatic stimulation. EFT involves tapping acupuncture points to desensitize negative emotions by focusing on the emotion.
223515099|NCT05752838|OTHER|No intervention|This is a survey study, and there were no intervention
223636246|NCT06597552|OTHER|Training Group|"Inspiratory muscle training (IMT) was performed using the Threshold IMT device using the threshold loading method. The IMT was administered to the patients in the training group at 30% of the MIP value, 5 days a week, twice a day, for 15 minutes for 8 weeks. The patients in the training group were called for a check-up once a week and the MIP value was re-evaluated. The training workload for that week was determined by taking 30% of the new measured MIP value.~During the training, the patients were asked to sit with their upper body (shoulders and upper chest) in a relaxed position, and after the nose was closed with the clip, the mouthpiece of the device was tightly closed with the lips. While in this position, the patient was asked to inhale and exhale 5 times into the device, then remove the device from their mouth and listen for 5 breaths, and continue this cycle for 15 minutes."
223636247|NCT06597552|OTHER|Control Group|The training intensity of the control group was given at the lowest load (9 cm H2O) for 8 weeks, five days a week, twice a day for 15 minutes. To eliminate the effect of learning, the MIP measure of the control group was measured once a week, but the intensity of the training was not increased during the 8 weeks.
223636248|NCT06592235|OTHER|No intervention|No intervention
223636249|NCT06590714|DRUG|Experimental(Acelex cap m2mg)|"Experimental Arm (Polmacoxib (Acelex cap 2mg + NSAIDs-excluded non-opioid or opioid analgesics))~Polmacoxib (preventive Acelex cap 2mg) administered, dosage: 1 tablet orally once daily, regardless of meals.~NSAIDs-excluded non-opioid or opioid analgesics, dosage: as needed (PRN)."
223636250|NCT06590714|DRUG|Active Comparator(NSAIDs-excluded non-opioid or opioid analgesics)|NSAIDs-excluded non-opioid or opioid analgesics, dosage: as needed (PRN).
223636251|NCT06991491|COMBINATION_PRODUCT|GnP in combination with Ivonescimab and SBRT|Gemcitabine 1000mg/m2, ivgtt,vdays 1 and 8, nab-Paclitaxel 125mg/m2, ivgtt, days 1 and 8 in combination with Ivonescimab 20mg/kg d1, every 21 days. Cycle 2 will be synchronized with primary or metastatic SBRT.
223636252|NCT06861998|BEHAVIORAL|Message-based bedtime routine|The intervention group implemented sleep hygiene education and the Message-based bedtime routine, including nutritional activities-hygiene-communication-message.
224225141|NCT06246851|BIOLOGICAL|BCG Danish|BCG Danish 1331 is on the WHO list of pre-qualified vaccines and has a well-defined side effect profile. BCG is licensed for delivery via the intradermal route. It is not licensed for delivery via the aerosol route.
224225142|NCT01745328|DRUG|LVX-AMX|Subjects were treated with Levofloxacin, 200mg bid, Amoxicillin, 500mg tid for 1 week, followed by 3 week of placebo.
224225143|NCT01745328|DRUG|TCM|Subject is treated with TCM for 4 weeks.
224225144|NCT01745328|DRUG|LVX-AMX|treatment with placebo from 2 to 4 weeks.
223636253|NCT06861998|BEHAVIORAL|sleep hygiene education|Sleep hygiene education includes sleep environment, sleeping location, regular sleep schedule, bedtime routines, sleeping methods, and sleeping posture.
223636254|NCT06992128|DRUG|Romiplostim N01 combined with dexamethasone|Dexamethasone (HD-DXM) at a dose of 40mg/d for 4 days constitutes one cycle. If there is no response on the 10th day, repeat it once. The administration can be either oral or intravenous. Meanwhile, romiplostim N01 is administered with an initial dose of 3µg/kg by subcutaneous injection within 4 days of dexamethasone treatment once a week for up to 6 months.
223636255|NCT06992128|DRUG|Dexamethasone monotherapy|Dexamethasone (HD-DXM) 40mg/d × 4 days, one cycle. If there is no response on the 10th day, repeat once, administered either orally or intravenously.
223636256|NCT06991439|DEVICE|A self-monitoring mobile application for stress management at work|STAPP@Work is a digital self-monitoring intervention designed for the workplace to manage work-related stress. The app prompts users multiple times per day to self-monitor their stress by answering short questions about their current activity, mood, and stress signals. It provides real-time feedback, visual summaries of stress patterns over time, and practical tips for stress management.
223764870|NCT01424488|DRUG|sugammadex|Anesthetised patients will receive a single intubation dose of succinylcholine (1.0 mg/kg) and maintenance bolus dose of pipecuronium (0.08 mg/kg) to maintain the level of neuromuscular blockade at reappearance of T2 Sugammadex in the dose of 4 mg/kg is to be administered as an intravenous bolus dose at the level of neuromuscular blockade of reappearance of T2 (moderate blockade) by means of TOF-Watch SX after the last dose of pipecuronium according to randomization
224225145|NCT04203706|OTHER|Neurofunctional imaging|Subjects will be submitted to a functional neuroimaging scanning procedure
224225146|NCT03369756|DEVICE|Prontosan Wound Irrigation Solution and Prontosan Wound Gel|Wound cleansing using Prontosan solution and gel
224225147|NCT04262596|OTHER|Interactive Consulting System|Potential participants use the Interactive Consulting System on a mobile application with information about cataract surgery choice, and outcome data will be gathered using standardized questions in a structured interview after 2 weeks.
224225148|NCT04262596|OTHER|A traditional patient decision aid brochure|Potential participants receive a traditional patient decision aid brochure with information about cataract surgery choice, and outcome data will be gathered using standardized questions in a structured interview after 2 weeks.
224225149|NCT02878850|OTHER|Augmented Blood Pressure|Subjects will have their blood pressure kept in a higher range.
224225150|NCT03247296|DRUG|Sofosbuvir 400 mg, Daclatasvir, Ribavirin|No intervention made this is an observational study to monitor the already existing protocols of the facility
224225151|NCT05087394|OTHER|Comorbidities|Risk factors (comorbidities), requirements of respiratory suppot and chest imaging will are considered exposure for primary outcomes
224225152|NCT04524299|RADIATION|chest radiation(IMRT)|Patients will receive intensity modulated radiotherapy (IMRT) once a day, 5 days a week. The first stage: DT 3000 cGy / 6 FX; the second stage, DT 3500 cGy / 7 FX. Or: the first segment: DT 4000 cGy / 10 FX; the second segment DT 2400 cGy / 6 FX. The interval between two stages of radiotherapy was 4 weeks.
224225153|NCT04524299|DRUG|Concurrent chemotherapy twice a week|"During the same period of radiotherapy, 30 mg / m2 albumin bound paclitaxel was intravenously infused twice a week for 0.5 hours, and nedaplatin 10 mg / m2 twice a week for 0.5 hours.~1. When the radiotherapy dose was 3000 cGy / 6 FX + DT 3500 cGy / 7 FX, the infusion time was D1, D4, D8 of the first stage of radiotherapy; D1, D4, D8 of the second stage of radiotherapy.~2. When the radiotherapy dose was 4000 cGy / 10 FX + DT 2400 cGy / 6 FX, the infusion time was D1, D4, D8, D11 of the first stage of radiotherapy; D1, D4, D8 of the second stage of radiotherapy"
224318791|NCT03921593|PROCEDURE|Solid Organ Pancreas Transplantation with or without Kidney Transplantation|Deceased donor pancreas transplantation
223636257|NCT06992830|PROCEDURE|cardioneuroablation|Participants diagnosed with medication-refractory variant angina or those unable or unwilling to take medications regularly will undergo a catheter-based cardioneuroablation (CNA) procedure. CNA targets epicardial cardiac ganglionated plexi (GP), which are clusters of autonomic ganglia involved in parasympathetic modulation of cardiac function. The procedure is designed to reduce parasympathetic overactivity contributing to coronary artery spasms. Ablation will be performed using a radiofrequency catheter to eliminate GP areas identified by anatomical landmarks and electrophysiological mapping. No control or sham procedure is included in this single-arm study.
223636258|NCT06991660|BEHAVIORAL|sleep hygiene education|This study will be conducted to examine the effects of sleep hygiene training, which is given to women in menopause to eliminate sleep problems and menopause symptoms that they often experience, on sleep and menopause symptoms experienced by women.
223636259|NCT06998732|DRUG|remimazolam sedation|remimazolam sedation
223636260|NCT07000071|DEVICE|NCPAP|Apply nasal continuous positive airway pressure in intubated patients with respiratory distress at time of weaning
223636261|NCT07000071|DEVICE|NIPPV|Apply nasal intermittent positive pressure ventilation in intubated patients with respiratory distress at time of weaning
223636262|NCT07000071|DEVICE|NHFOV|Apply nasal high frequency ventilation in intubated patients with respiratory distress at time of weaning
223636263|NCT06601972|PROCEDURE|Beautifil II LS (Low-Shrinkage)|The most remarkable feature of this light-cured universal composite for anterior and posterior restorations is its unique shrinkage of 0.85 percent by volume
223636264|NCT06601972|PROCEDURE|Nanohybrid resin composite|Nanohybrid resin composites are the most popular, because they improve the distribution of fillers in the matrix by combining nanoparticles with submicron particles to achieve better mechanical, chemical, and optical properties
223636265|NCT06998173|DRUG|DAT-1604 tablet|DAT-1604, a potent and selective oral small molecule inhibitor of DNA Polymerase θ (Pol θ).
223636266|NCT06998004|BIOLOGICAL|AVX70120 low dose level|Low dose level of AVX70120, AstriVax' investigational vaccine for the prevention of yellow fever
224225154|NCT04524299|DRUG|Concurrent chemotherapy once a week|During the same period of radiotherapy, albumin bound paclitaxel (50 mg / m2) was intravenously infused once a week for 0.5 hours; nedaplatin (25 mg / m2) was intravenously infused once a week for 0.5 hours. The infusion time was D1, D8 of the first radiotherapy and D1, D8 of the second radiotherapy.
224225155|NCT04014959|DEVICE|Transcranial Magnetic Stimulation|"Transcranial Magnetic Stimulation (TMS) is a non-invasive form of brain stimulation. TMS can influence activity in various brain regions, and it allows researchers to test or modify brain circuit communication. Repetitive TMS (rTMS) is FDA-approved for depression treatment.~TMS is administered over 5 study visits: an initial TMS/fMRI session, a 3-day TMS intervention regimen, and a post-intervention TMS/fMRI session. During TMS/fMRI sessions, participants receive single pulses of TMS pre/post a short round of Intermittent Theta Burst Stimulation (iTBS), a modified rTMS protocol. Throughout the 3-day intervention regimen, participants receive two full rounds of iTBS daily.~All study participants receive active TMS."
224225156|NCT05763433|OTHER|upper extremity bone surgery|any ambulatory upper limb bone surgery carried out under axillary PNB
223636267|NCT06998004|BIOLOGICAL|AVX70120 middle dose level|Middle dose level of AVX70120, AstriVax' investigational vaccine for the prevention of yellow fever
224225157|NCT02026414|DIETARY_SUPPLEMENT|PrimaVie|Subjects will take 250 mg of PrimaVie (herbal supplement manufactured by Natreon, Inc) twice a day for the first 8 weeks they are enrolled in the study. For the last 4 weeks of the study, subjects will take 250 mg of PrimaVie (herbal supplement manufactured by Natreon, Inc) supplement twice a day while also completing supervised exercise on a treadmill (70-75% of maximum Heart Rate for 20 mins, plus 5 minutes of warm up and 5 minutes of cool down exercises for a total of 30 minutes a day 3 days a week). Subjects will participate for a total of 12 weeks and come for three total visits. At each visit, subjects will have muscle biopsies taken from their thigh or calf as well as approximately 2 tablespoons of blood drawn.
223636268|NCT06998004|BIOLOGICAL|AVX70120 high dose level|High dose level of AVX70120, AstriVax' investigational vaccine for the prevention of yellow fever
223636269|NCT06998004|BIOLOGICAL|AVX70481 low dose level|Low dose level of AVX70481, AstriVax' investigational vaccine for the prevention of rabies
223636270|NCT06998004|BIOLOGICAL|AVX70481 middle dose level|Middle dose level of AVX70481, AstriVax' investigational vaccine for the prevention of rabies
223636271|NCT06998004|BIOLOGICAL|AVX70481 high dose level|High dose level of AVX70481, AstriVax' investigational vaccine for the prevention of rabies
223636272|NCT06998004|OTHER|Placebo|Placebo
224225158|NCT02026414|OTHER|Exercise|
224225159|NCT03827213|DRUG|Exparel|A shot of long acting local anesthetic for post operative pain management
224225160|NCT03827213|DEVICE|Indwelling Interscalene Catheter|ropivacaine, given through a catheter inserted between the shoulders
223636273|NCT06999681|OTHER|No Interventions|this is an observational cohort study. There was no intervention.
223636274|NCT06999681|OTHER|No interventions|No interventions in this study. This study is an observational study.
223636275|NCT05491811|DRUG|Ensartinib|Participants will receive Ensartinib 225 mg oral once daily from baseline until disease progression, unacceptable toxicity, withdrawal of consent or death.
223636276|NCT05491811|DRUG|Bevacizumab|Participants will receive 7.5 mg/kg intravenous on Day 1 of 21 day cycles (every 3 weeks) from baseline until disease progression, unacceptable toxicity, withdrawal of consent or death.
223636277|NCT06541574|DRUG|Methotrexate Injection|Methotrexate injection
223636278|NCT06541574|DRUG|Methotrexate Infusion|Methotrexate Infusion
223636279|NCT06541574|DRUG|Sham Injection|Sham Injection
223636280|NCT06867380|DEVICE|Investigational sound coding strategy|SPARC (Stimulation Place and Rate Coding) sound coding strategies
223636281|NCT06867380|DEVICE|Cochlear default sound coding strategy|ACE (Advanced Combination Encoder) sound coding strategy
223636282|NCT06407921|DEVICE|Whole Body Vibration|On vibration plate pate child will do kneeling, and one leg standing, standing horizontally or vertically. Along routine physical therapy such as stretching activities to keep up muscle elasticity particularly Achilles tendon, hamstring muscles, hip flexors and adductors, shoulder internal rotators, elbow and wrist flexors, pronators, and ulnar deviators, each stretch will be given for 30 seconds with 3 repetitions.Strength training to hip flexor, knee extensor, and ankle dorsiflexors for 15 minutes 3 times a week for 8 weeks. Session will be of 30 minutes
224318792|NCT06824259|PROCEDURE|Follow up if MRI is negative|Enter the follow-up cohort without systematic biopsy when prostate cancer is clinically suspected and no PIRADS v2.1 score ≥3 lesions are detected on initial examination. MR plus regional saturation biopsy was performed when MRI progressed.
223515100|NCT05384548|BEHAVIORAL|Problematic smart phone use course|A 6 session, online, group-based, psychological course targetting problematic smart phone use.
223515101|NCT01202357|BEHAVIORAL|Community Case Management|Community case management for psychosis by designated key-worker according to specified protocol
223515102|NCT00900042|GENETIC|DNA ploidy analysis|
223515103|NCT00900042|GENETIC|DNA stability analysis|
223515104|NCT00900042|GENETIC|chromosomal translocation analysis|
223515105|NCT00900042|GENETIC|cytogenetic analysis|
223515106|NCT00900042|OTHER|flow cytometry|
223515107|NCT00900042|OTHER|laboratory biomarker analysis|
223515108|NCT05308459|BEHAVIORAL|Data-driven health promotion at Vocational Education and Training schools (Data Health VET)|"The intervention consists of the following steps:~1. A local health profile is conducted among all students~2. Results are shortly hereafter presented and discussed with all student and staff, and the school decide what health problem they will work with during the next year~3. A participatory group model process based on a dynamic systems approach is conducted to develop sustainable and system changing activities to address the chosen health problem~4. The activities are implemented~5. A new health profile is conducted to a) evaluate the effects of the implemented activities and to b) determine if a new health problem warrant focus and new activities are needed (the process repeats itself)."
223515109|NCT01235637|DRUG|Alfentanil|"dosage form: injectable drug, opioid analgesic morphine, intravenous drug.~Dosage: 10μg/Kg, dilution: 1 ml = volume equivalent to 66μg or 10μg/kg = 1.43μg/kg fentanyl.~Frequency and duration: 2 bolus injection before 2 tracheal suctions at 0 and 4 hours respectively."
223515110|NCT01235637|DRUG|Sufentanil|"dosage form: injectable drug, opioid analgesic morphine, intravenous drug.~Dosage: intravenous drug to 0,15 µg/Kg : Blisters of 10 ml, box of 20. MERCK~Frequency and duration: 2 bolus injection before 2 tracheal suctions at 0 and 4 hours respectively."
223515111|NCT02213991|DEVICE|Intraoperative radiotherapy using Intrabeam®|"Operation day~1. Aftuer tumor lump is removed and negative tumor margins are achieved, applicator of Intrabeam® is located within tumor cavity.~2. Purse string suture pulles up tissues and wraps up the applicator.~3. Intraoperative radiotherapy using Intrabeam® (20Gy) is followed.~4. After IORT, applicator was out of the operative field, and usual wound closure will be done.~   * Postoperative period~     * Chemotherapy WBRT (46 Gy) for 4\~5 weeks~    * Endocrine therapy or target therapy"
223515112|NCT03609944|PROCEDURE|ERCP with miES|Endoscopic retrograde cholangiopancreatography with minor papilla endoscopic sphincterotomy
223515113|NCT03609944|PROCEDURE|EUS|Endoscopic ultrasound
223515114|NCT03863301|RADIATION|MR-guided single dose preoperative PBI|A single dose of 20Gy to the gross tumor volume (GTV) is prescribed, to the clinical target volume (GTV + 20mm margin) 15Gy is prescribed.
223515115|NCT04054180|OTHER|CPAP associated with connected devices: blood pressure monitor , scales and activity monitor|CPAP associated with connected devices: blood pressure monitor , PROMs and activity monitor Patients will use their connected devices for one year. Data from the connected devices will be transmitted to their smartphone application Sefam Access. At the beginning of the study, patients will have a dietary assessment and start a support program for nutrition counselling and physical activity. At each study visit the dietician and physical exercise coach will give the patient advices on diet and for adjusting physical activity.
223515116|NCT01772693|DEVICE|ExAblate Transcranial MRgFUS|ExAblate Transcranial MR Guided Focused Ultrasound
223515117|NCT01772693|DEVICE|Sham ExAblate Transcranial MRgFUS|Sham ExAblate Transcranial MR Guided Focused Ultrasound
223515118|NCT06143423|DRUG|AP026 (TQA2226) for injection|AP026 (TQA2226) for injection is a GLP-1-FGF21-Fc bifunctional fusion protein.
223515119|NCT06143423|DRUG|AP026 (TQA2226) for injection matching placebo|AP026 (TQA2226) for injection matching placebo is a placebo produced according to AP026 (TQA2226) for injection, and has no effect on GLP-1 and FGF21.
223515120|NCT05572632|BEHAVIORAL|COPD Wellness|COPD Wellness consists of 10 weekly sessions led by the COPD Wellness Coach. The intervention was designed to be portable, rely on little equipment, and require limited space (\~300sqft). The curriculum was iteratively developed with patient input and builds behavioral capability and self-efficacy through 30 minutes blocks of disease education and self-management skill building, exercise training, and social support.
223515121|NCT05572632|BEHAVIORAL|COPD Wellness Plus+|Couples COPD Wellness with the ZSFG Health Advocates Program. The HA will help the participant prioritize identified needs and, using an algorithm informed approach to connect the individual to the needed resource, this includes providing referrals to outside social or legal service agencies, help with applications for social benefits, or other services. The HA will use a checklist to track activities including review and prioritization of needs, referrals or resources provided, and contacts/contact attempts.
223515122|NCT05572632|BEHAVIORAL|Usual Care|Includes access to comprehensive primary care services that is standardized across the SFHN. Participants randomized to the usual care arm will be offered referral to the Better Breathing Program that is part of SFHN standard care for COPD. At end of study enrollment, usual care participants will be offered the COPD Wellness intervention.
223515123|NCT04525469|BEHAVIORAL|Narrative Exposure Therapy|"NET involves: 1) diagnostic interview and psychoeducation, 2) laying out the Lifeline, 3) NET therapy sessions (constructing the trauma narrative in context of the life course), 4) final session rituals. Laying out the Lifeline (using rope or string) allows participants to take a bird's eye view of the events of their life using simple items such as flowers to represent positive events and stones to represent traumatic events. The focus of NET sessions is to encourage participants to describe the details of traumas and integrating the cold memories (i.e., facts) with the hot memories (e.g., cognitions, emotions, physiological feelings, and sensory information). The therapist makes notes after each session narrating the details of the traumas (stones) and reads this at the beginning of each subsequent session. Final session rituals involve re-reading the trauma narrative, hopes for the future, and laying out the final Lifeline placing flowers for hopes and wishes for the future."
223636283|NCT06407921|DEVICE|BOSU ball|Exercises such as (1) standing on a BOSU ball while throwing and catching a ball (2) 1-legged standing (affected leg) on the BOSU ball while throwing and catching a ball with therapist support; and (3) small jumps on the BOSU ball. Three sets of 6 repetitions for each exercise will be perform every 2 weeks up to a maximum of 10 repetitions if the participants were still able to perform the training easily. Total dose of balance training in 1 session will be 15 minutes
223515124|NCT01927848|DIETARY_SUPPLEMENT|Rosehip|Rosehip powder made from the fleshy orange walls (hypanthiums) of Rosehips with the achenes (seeds) removed, from the wild growing species Dog Rose (Rosa canina L.), in addition to vitamin C as sodium ascorbate. The active ingredient complex is Rosenoids®, Vitamin C, flavonoids, carotens, triterpene acids, and galactolipids. Rosenoids® is the registered name for the bioactive complex isolated from the rose-hip (Rosa canina) used in RH01. It is being supplied as capsules containing 750 mg of the Rosehip powder and 26.7 mg vitamin C.
223636284|NCT05010629|DRUG|9-ING-41|Intravenous infusion
223636285|NCT05010629|DRUG|Carboplatin|Intravenous infusion
223636286|NCT06596200|DEVICE|Spinal Cord Stimulation Implant|Spinal Cord Stimulation using 10 kHz stimulation to the thoracic spinal cord
223636287|NCT06695130|BIOLOGICAL|RIV (recombinant influenza vaccine)|Influenza, inactivated, split virus or surface antigen
223636288|NCT06695130|BIOLOGICAL|rC19 (dose 1)|Protein subunit
223636289|NCT06695130|BIOLOGICAL|RIV + rC19 (dose 1)|RIV component: Influenza, inactivated, split virus or surface antigen NVXC19 component: Protein subunit
223636290|NCT06695130|BIOLOGICAL|RIV + rC19 (dose 2)|RIV component: Influenza, inactivated, split virus or surface antigen NVXC19 component: Protein subunit
223636291|NCT06695130|BIOLOGICAL|RIV + rC19 (dose 3)|RIV component: Influenza, inactivated, split virus or surface antigen NVXC19 component: Protein subunit
223636292|NCT06695130|BIOLOGICAL|RIV + rC19 (dose 4)|RIV component: Influenza, inactivated, split virus or surface antigen NVXC19 component: Protein subunit
224225161|NCT04043520|DRUG|GnRH antagonist|GnRH antagonist will be given once for premenopausal women (12-week intervention) and twice for postmenopausal women (24-week intervention)
224225162|NCT04043520|DRUG|Estrogen Product|Estrogen patches will be worn by those randomized to the Estradiol arms in both premenopausal and postmenopausal groups. Patches will be applied weekly and will be worn for the for entirety of the intervention (12 or 24 weeks).
224225163|NCT04043520|DRUG|Placebo estradiol|Placebo patches will be worn by those randomized to the placebo arms in both premenopausal and postmenopausal groups. Patches will be applied weekly and will be worn for the for entirety of the intervention (12 or 24 weeks).
223636293|NCT06695130|OTHER|Placebo (0.9% NaCl)|Normal saline
224225164|NCT04043520|DRUG|Placebo GnRH antagonist|Postmenopausal women randomized to the placebo injection arm will receive two placebo drug injections of normal saline (24-week intervention)
224225165|NCT01956279|DRUG|Pregnenolone|Pregnenolone 50mg BID x 14 days, followed by Pregnenolone 150 x 14 days, followed by Pregnenolone 250 mg BID x 28 days
224225166|NCT01956279|DRUG|Placebo|Placebo 50mg BID x 14 days, followed by Placebo 150 x 14 days, followed by Placebo 250 mg BID x 28 days
224225167|NCT03192774|DEVICE|Transcatheter Aortic Valve Implantation|Interventional replacement of the aortic valve
224225168|NCT03083210|DRUG|Lanreotide|Lanreotide, at a dose of 120mg subcutaneous injection every 28 days.
224225169|NCT06527352|DEVICE|glottis mask airway|the glottis mask airway is used for maintaining ventilation during general anesthesia
223515125|NCT01927848|DIETARY_SUPPLEMENT|Placebo|The placebo used in this study will be identical to the Rosehip capsules in both appearance and taste, except that it will not contain the active Rosehip powder ingredient Rosenoids® or vitamin C.
223515126|NCT05513105|DIAGNOSTIC_TEST|Iron study of neonates|Blood sambles
223636294|NCT06448117|BEHAVIORAL|Mind Nutrition|"The 6-month nutrition intervention includes two individual and three group dietary counseling sessions. During the first individual meeting, a research dietitian will assess the participants' diet quality and eating habits, and each participant will set personal goals in cooperation with the research dietitian. At the second individual meeting, the attainment of the goals will be evaluated, and potential challenges and solutions discussed. Each group session has its theme and content in the following chronological order:~1. Introduction to the theme and importance of a regular meal frequency~2. Principals of health-promoting diet, mindful eating~3. Successful eating regulation skills, psychology of the long-term lifestyle changes.~Additionally, participants receive home assignments and a workbook containing informational material and exercises."
223636295|NCT06702072|DEVICE|Endobronchial valve treatment|Endobronchial valve treatment
223636296|NCT06705803|PROCEDURE|Prostate Ablation|Patients with prostate cancer undergoing prostate ablation for the management of prostate cancer.
223764871|NCT01424488|DRUG|placebo|Anesthetised patients will receive a single intubation dose of succinylcholine (1.0 mg/kg) and maintenance bolus dose of pipecuronium (0.08 mg/kg) to maintain the level of neuromuscular blockade at reappearance of T2. 3,0 ml of saline (placebo) is to be administered as an intravenous bolus dose at the level of neuromuscular blockade of reappearance of T2 (moderate blockade) by means of TOF-Watch SX after the last dose of pipecuronium according to randomization
223764872|NCT03704181|DRUG|Colchicine 0.5 MG twice day for one year|placebo twice day for one year
224225170|NCT06527352|OTHER|tulip shaped|the tulip shaped mask airway is with a tulip shaped tip
224225171|NCT06527352|OTHER|classical shaped|the classical shaped mask airway is with a water-drop shaped tip
224225172|NCT05858385|OTHER|Intervention based on key factors identified by the severe RIOM prediction model|Intervention based on key factors identified by the severe RIOM prediction model
224225173|NCT00240006|PROCEDURE|Shared Solutions® plus MS Center v. Shared Solutions®|Copaxone
224225174|NCT02989766|BEHAVIORAL|Education on Breast Feeding|Subjects in the intervention arm will complete 3 activity sheets prenatally-study related.
224225175|NCT00401219|DRUG|conjugated estrogens/progestin (MPA)|
224225176|NCT03961464|DRUG|d-cycloserine|Single dose
224225177|NCT03961464|DRUG|Placebo|Single dose
224318793|NCT06824259|PROCEDURE|Systematic biopsy if MRI is negative|Systematic biopsy was performed if there was clinical suspicion of prostate cancer and no PIRADS v2.1 score ≥3 lesions were detected on initial examination. If the biopsy was negative enter the follow-up cohort.
224318794|NCT01956305|DRUG|DS-7309|DS-7309 powder in bottle
224318795|NCT01956305|DRUG|placebo|placebo to match DS-7309 powder in bottle
223636297|NCT06884592|PROCEDURE|Difficult Intubation|Determination of difficult intubation, according to the Cormack-Lehane scale, intubation will be considered easy for grade I or II and difficult for grade III or IV. If intubation could not be performed with the Macintosh laryngoscope in three attempts, the next step would be to perform intubation with the videolaryngoscope and the third step would be to place the laryngeal mask airway (LMA). The correct position of the tube in the trachea will be confirmed after intubation, preferably by visual confirmation of the tube passing through the glottic opening, auscultation of the chest with a stethoscope and a normal capnograph. If the LMA attempt fails, the patient will be allowed to awaken, with the final step being ventilation using a face mask and consideration of reversing the muscle relaxant effect with sugammadex (4-5 mg/kg). If intubation fails on the first attempt, an intubation stylet will be used if necessary. The intubation method used, total number of attempts for successful i
223636298|NCT06704880|OTHER|rehabilitation|children in the CIMT group will RECIEVE lower limb CIMT for the non-hemiplegic limb using whole leg orthosis. Children in cross-education group will receive strengthening training for the non-hemiplegic lower limb
223636299|NCT06705036|OTHER|surgery|Samples were obtained from patients by surgical excision and matched into groups
223636300|NCT06706648|BEHAVIORAL|Nursing-Led Psychological Capital Interventions|The participating nurses received session about Nursing-Led Psychological Capital Interventions
223636301|NCT06704984|BEHAVIORAL|Intervention Name: WeChat Intervention Based on the IMB Model|A six-week intervention leveraging an online WeChat public account was implemented, integrating the IMB (Information-Motivation-Behavioral Skills) model into its design. Drawing from literature analysis, the intervention plan was structured into three distinct modules: information, motivation, and behavioral skills. The comprehensive intervention encompassed disseminating knowledge on Internet addiction, identifying and avoiding triggers, fostering withdrawal motivation, imparting coping strategies for cravings and challenging situations, enhancing self-efficacy, and facilitating access to personal and social support. Participants who followed the WeChat public account received automated push notifications containing articles or videos every two days. Throughout the intervention period, engagement was monitored by tracking the readership of the sent content through the WeChat public account's backend data.
223636302|NCT06704854|DIAGNOSTIC_TEST|Screening Platform|assessment of low-frequency fatigue using myocene
223636303|NCT06706635|DEVICE|Application of App|Full Access to Mobile App
223636304|NCT06705179|BEHAVIORAL|Behavioral task performance|Measures of performance on behavioral tasks
223636305|NCT06704659|RADIATION|Breast conserving surgey and radiotherapy|The patients will undergo repeat Breast Conserving Surgery and Radiotherapy
223636306|NCT06704659|PROCEDURE|Mastectomy|The patients will undergo mastectomy
223636307|NCT06917742|DRUG|CPTX2309|Single Escalating Dose of CPTX2309. CPTX2309 is a targeted lipid nanoparticle designed to deliver an anti-CD19 CAR mRNA preferentially to CD8+ T cells.
223636308|NCT06917742|DRUG|CPTX2309|Multiple Escalating Dose of CPTX2309.CPTX2309 is a targeted lipid nanoparticle designed to deliver an anti-CD19 CAR mRNA preferentially to CD8+ T cells.
223636309|NCT06656988|DRUG|CO2|CO2 will be used as contrast medium sparing strategy during peripheral angiography
223636310|NCT06656988|DRUG|Iodinated Contrast Media (ICM)|Iodinated contrast medium will be used as in routine care during peripheral angiography
223636311|NCT02077010|DRUG|Inhaled nebulized milrinone|inhaled nebulized milrinone 60mg/4ml
223636312|NCT06736340|DRUG|Rupatadine|10mg tablets
223636313|NCT06604455|OTHER|acupressure/relaxation with acupuncture|The acupressure/acupuncture points will be designated based on evidence-based research. For example, clinical guideline-based integrative oncology protocol for pain relief will include the following analgesia-related acupressure/acupuncture points: Liver-3, Taichong; Large-Intestine 4, Hegu; Stomach-36, Zusanli; Pericard-6, Neiguan; Spleen-6, Sanyinjiao; Yin tang; as well as battlefield ear acupuncture points. In both intervention groups, relaxation techniques will be tailored to the patient's quality of life related concerns, with the option of including breathing and guided imagery modalities as well.
223636314|NCT06604455|OTHER|acupressure/relaxation|The acupressure points will be designated based on evidence-based research. In both intervention groups, relaxation techniques will be tailored to the patient's quality of life related concerns, with the option of including breathing and guided imagery modalities as well.
223636315|NCT06748209|DEVICE|Left prefrontal Transcranial Magnetic Stimulation (TMS)|FDA cleared TMS
223636316|NCT06748209|DEVICE|FDA cleared TMS for treating depression|This is FDA approved TMS
223636317|NCT06754670|DRUG|Sodium Glycerophosphate 216 MG/ML|Low phosphorus patients receive intravenous phosphate supplementation according to the clinical phosphate supplementation protocol at our center: patients with blood phosphorus \< 0.4mmol/L receive 40mmol of glycerol phosphate sodium intravenously via infusion or injection over 4-6 hours; patients with blood phosphorus 0.4-0.8mmol/L receive 30mmol of glycerol phosphate sodium intravenously via infusion or injection; Normal phosphorus patients do not require any special treatment.
223764873|NCT03704181|DRUG|Placebo Oral Tablet|placebo twice day for one year
223764874|NCT05277896|DRUG|Ketamine|Intravenous ketamine as the sedative for induction of anesthesia during emergency tracheal intubation
223764875|NCT05277896|DRUG|Etomidate|Intravenous etomidate as the sedative for induction of anesthesia during emergency tracheal intubation
223764876|NCT04863703|DRUG|Bulevirtide|Patients with liver cirrhosis and HBV/HDV coinfection receive Bulevirtide as an antiviral therapy irrespective of the study, this study is observational.
224225178|NCT01892579|BEHAVIORAL|Tailored Activity Program|TAP is designed to tap into spared or residual abilities and provide an environment supportive of these abilities. Activities are selected that build on preserved capabilities, long-term interests and procedural memory, but which do not tax areas of cognition that are most impaired (e.g., memory, new learning). Activities selected are simplified (1 to 2 vs multiple, complex steps), thereby minimizing errors. The activity environment is set up to provide auditory or tactile cues to facilitate recall and guide initiation and sequencing. By grading activities to match PwD capabilities, the interventionist minimizes demand that may heighten stress (e.g., high functioning individuals are introduced to more goal-directed, multi-step activities, whereas lower functioning individuals are introduced to activities involving repetitive motion (e.g., washing windows, folding towels, placing materials in a bin) and integrate multi-sensory stimulation (e.g., soft music, objects pleasant to touch).
223764877|NCT03988699|DEVICE|Tinnitus Implant System|Device will deliver stimulation below hearing thresholds continuously or intermittently.
224318796|NCT01956305|DRUG|Metformin|Metformin 500mg tablet for Cohort F
223636318|NCT06874478|DIAGNOSTIC_TEST|Ultrasound|The main pulmonary artery will be seen between the pulmonary valve and the bifurcation of the right and left branches. The pulsed Doppler sample gate will be adjusted to 3 mm, and the angle of insonation will be kept at or around 15°. Doppler gain and scale will be tailored for optimizing the velocity waveform display, clearly showing the peak systolic velocity (PSV) and early diastolic notch. The MPA Doppler waveform will show a sharp systolic peak blood flow with a needle-like appearance. After the optimum fetal main pulmonary artery waveform, Doppler velocity will be manually traced three times, and the average will be taken.
223636319|NCT06839105|DRUG|Taxol|135\~175 mg/m2, Q3W
223636320|NCT06839105|DRUG|Cisplatin or Carboplatin|Cisplatin(75 mg/m2, Q3W) or Carboplatin (AUC=5\~6, Q3W)
223636321|NCT06839105|DRUG|Pemetrexed|500 mg/m2, Q3W
223636322|NCT06839105|DRUG|Oxaliplatin|130 mg/m2, Q3W
223636323|NCT06839105|DRUG|Capecitabine|1000 mg/m2, BID, day1-14, oral, q3w
223636324|NCT06839105|DRUG|Bevacizumab|7.5 mg/kg, Q3W
223636325|NCT06839105|DRUG|Renvastinib|8mg or 20mg, QD
223636326|NCT06839105|DRUG|AWT020|q3w or q2w, i.v.
223636327|NCT05844501|DRUG|Ondansetron 8mg|Ondansetron 8 mg orally twice daily for 28 days
223636328|NCT05844501|DRUG|Placebo|Matched placebo orally twice daily for 28 days
223636329|NCT06780891|BEHAVIORAL|Telephysical therapy|The experimental group is undergoing a tele-assisted therapeutic exercise program (T-TPT/T-FIS), which involves physical exercises aimed at improving cardiovascular fitness, muscle strength, and balance, among others. Participants will complete exercises under virtual supervision and submit progress reports.
223636330|NCT06780891|BEHAVIORAL|Educational session|The educational session will focus on raising awareness about stroke risk factors, such as hypertension, diabetes, and smoking, while promoting healthy lifestyle changes. The goal is to empower them with the knowledge to reduce stroke risk and improve overall well-being.
223636331|NCT06772363|DIAGNOSTIC_TEST|Serum Raman spectroscopy intelligent diagnostic system|1\. Screening interested participants should sign the appropriate informed consent (ICF) prior to completion any study procedures. 2. The investigator will review symptoms, risk factors, and other non-invasive inclusion and exclusion criteria. 3. The following is the general sequence of events during the 3 months evaluation period: 4. Completion of baseline procedures Participants were assessed for 3 months and completed all safety monitoring.
223636332|NCT04498598|DEVICE|A/Z Supraglottic airway|Patient receive supraglottic airway for general anesthesia which can be converted to endotracheal ventilation reversibly
223636333|NCT00595088|BIOLOGICAL|BC-819/PEI|Papillary tumors will be resected with the exception of one marker tumor that will remain to examine the effects of the treatment on the remaining tumor. Study treatments will consist of an induction course of six weekly instillations of 20 mg of DTA-H19/PEI into the urinary bladder. Intravesical therapy will be delivered through a Foley catheter. Patients will be instructed to hold the dose in the bladder for two hours after administration. If the patient has a complete response, then she/he will be eligible to receive three additional courses of 3 weekly intravesical administrations of the same dose of investigational product every 12 weeks.
223636334|NCT06831110|PROCEDURE|Aquagenic Wrinkling|Participants will be asked to remove all jewelry from the hand(s) and wrist(s) that will be undergoing the aquagenic wrinkling procedures. Photographs will be taken of the palmar surface of the hand(s). The participant will submerge the hand(s) undergoing testing in a water bath for one minute. After one minute, they will remove their hand(s), dry them gently with a towel, and photographs will be taken of the palmar surface of the hand(s). The participant will re-submerge their hand(s) in the appropriate conditions for another minute and the process will be repeated 20 times for 20 total minutes submerged in the water.
223636335|NCT01615939|DRUG|Bupivacaine|Bupivacaine 0.625% with epinephrine 1:300,000
223636336|NCT01615939|DRUG|Ropivacaine|0.2% ropivacaine 5 ml/hr with a 5 ml bolus/hr.
223636337|NCT04671017|BIOLOGICAL|VLA2001|whole virus inactivated SARS-CoV-2 vaccine adjuvanted with cytosine phospho-guanine (CpG) 1018 in combination with aluminium hydroxide
223636338|NCT02892344|DRUG|QMF149 150/80 μg|QMF149 150/80 μg o.d via Concept1
223636339|NCT02892344|DRUG|MF 200 μg|MF 200 μg o.d. via Twisthaler®
223636340|NCT04062539|DEVICE|Sentinel and Spider|Dual filter and single filter
223636341|NCT02611297|PROCEDURE|Cryoprobe|
223636342|NCT05661617|DIAGNOSTIC_TEST|Nine Hole Peg Test, Purdue Pegboard Test, Box and Block Test|"Research participants were tested in one meeting after giving informed consent, answering a few short questions regarding health status and filling out a short questionnaire using the Czech extended version of the manual for the Nine Hole Peg Test, Purdue Pegboard Test and Box and Block Test, and always according to a predetermined order. Intentionally, all research participants from experimental group with a dominant right upper limb will be tested as if they were left-handed, and vice versa.~All research participants from normative study were tested normally according to the Czech extended manuals for those tests."
223636343|NCT04459884|PROCEDURE|mechanical ventilation|mechanical ventilation \> 48h
223636344|NCT02998463|DEVICE|skin-to-skin facilitating garment|Fabric garment designed to accommodate term neonates having skin-to-skin contact.
223636345|NCT05678881|DRUG|High dose RLS103|8 mg CBD inhaled powder
223636346|NCT05678881|DRUG|placebo inhaled powder|placebo inhaled powder
223636347|NCT05678881|DRUG|Low dose RLS103|4 mg CBD inhaled powder (open label)
223636348|NCT02705742|BIOLOGICAL|Mesenchymal Stem Cells|1.000.000 (one million) cells/kg, IV of dose in the Peripheral vein and 3.000.000 (three million) cells/kg of dose into the right hepatic artery)
223636349|NCT03554525|DIETARY_SUPPLEMENT|Fat-binder damm|3 sticks every day during 12 months
224318797|NCT02376673|OTHER|Children's Book|A specially-designed, illustrated (full color) children's book written at a first-grade level, conveying American Academy of Pediatrics safe sleep guidelines through the story. Expanded guidelines are listed on the back cover, at a 4th grade reading level. This book will be exclusively used for safe sleep education at 3 study home visits: prenatal between 32 weeks and term, 1 week postnatal, and 2 months postnatal. The mother will be encouraged to share the book with her baby.
224318798|NCT02376673|OTHER|Standard Brochures|An assortment of standard safe sleep educational brochures provided by home visitors during prescribed home visits, covering various recommendations for safe sleep.
224318799|NCT04873934|DRUG|Inclisiran|Inclisiran sodium 300 mg / 1.5 ml (equivalent to 284 mg of inclisiran)
223636350|NCT03554525|DIETARY_SUPPLEMENT|Placebo|3 sticks every day during 12 months
223636351|NCT03072407|BIOLOGICAL|PB-119 injection|
223636352|NCT03072407|BIOLOGICAL|PB-119 injection placebo|
223636353|NCT06109896|OTHER|Self Report Questionaires|Collection and analysis of information from patient self-report assessments and integration with clinical information from assessments performed routinely during cancer treatment.
223636354|NCT05379374|COMBINATION_PRODUCT|bupivacaine and morphine|Bupivacaine group will receive 0.25% bupivacaine 20 ml in TAP block. Bupivacaine morphine group will receive 0.25% bupivacaine 20 ma with 3 mg morphine in TAP block.
223636355|NCT03980054|DRUG|Pyrotinib|pyrotinib 400 mg, orally once daily for one year
223636356|NCT03980054|DRUG|Placebo|placebo 400mg, orally once daily for one year
223636357|NCT05233306|DEVICE|MRI scanner (7 Tesla)|MRI and MRS examination at 7 Tesla; protocol duration of approx. 75 min
223636358|NCT04464486|OTHER|SCH Intervention|In addition to receiving usual care from their oncologist and staff, the SCH intervention group will report COVID-19 and cancer-related symptom presence and severity daily into the automated SCH system. Participants in the intervention receive automated self-management support messages for symptoms reported. In addition, COVID-19 symptoms and poorly controlled or worsening cancer symptoms will generate alerts. Based on preset thresholds, alerts automatically generate immediately from the patient's daily call data. The study nurse practitioners (NPs) monitor alerts. The NPs provide follow-up care using the guideline based SCH symptom clinical decision support system. The NPs log into the SCH Alert and Call Data website which displays all of the patients who have called that day and met an alert threshold. The NP calls the patient, delivers symptom management care by phone, and documents care in the patients' electronic health records.
223636359|NCT05019326|DRUG|Andrographis Paniculata|Andrographis extract, equivalent to andrographolide 20 mg per capsule, for a total of 180 mg of andrographolide per day, dosing into 3 capsules taking before meal for 3 times per day, for 5 days.
223636360|NCT05019326|DRUG|Boesenbergia|Boesenbergia extract, equivalent to pinostrobin 30 mg per capsule, for a total of 180 mg of pinostrobin per day, dosing into 2 capsules taking after meal for 3 times per day for 5 days.
223636361|NCT05019326|OTHER|Standard supportive treatment|as recommended by guidelines from the Ministry of Public Health, Thailand. No antivirus was given.
223636362|NCT03638193|BIOLOGICAL|CART-meso cells|CART-meso is a 2nd CAR, with mesothelin as target protein, 4-1BB as co- stimulator. The infusion will be scheduled to occur 3 (±1) days after a single dose of 1.5 grams/m\^2 of cyclophosphamide, which will be administered according to standard procedures, Thereby enhancing the efficacy of anti-tumor, reducing the potential of side effects.
223636363|NCT02456415|DEVICE|K-MET™ Bioresorbable Bone screw|The biodegradable screw inserted into bone with an appropriate driver is slowly degraded and is completely degraded after completion of bone union and absorbed into the body. The screw is indicated for fixing damaged bone.
223636364|NCT06102005|DRUG|Lunsekimig|Pharmaceutical form: solution for injection Route of administration: subcutaneous
223636365|NCT06102005|DRUG|Placebo|Pharmaceutical form: solution for injection Route of administration: subcutaneous
223636366|NCT02767414|DEVICE|Respirio Flu Test|The Respirio Flu Test is a rapid in vitro diagnostic test for the detection of influenza A or influenza B in nasal secretions. The Respirio Flu Test is designed to be simple to use and generates a result within 20 minutes.
223636367|NCT02767414|DEVICE|eLab Flu Test|The eLab Flu Test is an in vitro diagnostic test intended to be used at point-of-care for the detection of influenza A or influenza B in nasopharyngeal swab samples. The eLab Flu Test generates a result within 10 minutes.
223636368|NCT02767414|DEVICE|Reverse Transcriptase Polymerase Chain Reaction (RT-PCR)|Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) is a molecular diagnostic technique for the detection and identification of influenza viruses, both for clinical samples and isolates. The reverse transcriptase polymerase chain reaction (RT-PCR) allows template viral RNA to be reverse transcribed producing complementary DNA (cDNA) which can then be amplified and detected.
223636369|NCT02804113|DEVICE|Supera Peripheral Stent System|
223636370|NCT04179136|DIETARY_SUPPLEMENT|lignan capsules contain 300 mg flaxseed (SDG) extract|lignan capsules contain 300 mg flaxseed (SDG) extract
223636371|NCT04179136|DIETARY_SUPPLEMENT|Placebo treatment matching intervention|Placebo treatment matching intervention
223636372|NCT06016049|OTHER|EMLA® adjuvant|cutaneous forearm deafferentation
224225179|NCT01892579|OTHER|Home Safety and Education Program|The control group intervention is designed to control for the nonspecific elements of TAP such as social engagement with PwD and CG which may affect outcomes. It is a fully-structured, nondirective, supportive education approach that conveys empathy, respect and specific disease education elements of which have been tested in other trials. Unlike TAP, this group contains no active elements beyond its nonspecific components, has no long-lasting treatment effects, and no theoretical basis to support an effect on agitation. It is delivered by a trained research team member who uses active listening, open questioning, reflecting back, and summation with CGs.
224318800|NCT05794503|DRUG|Neostigmine|Maintenance neuromuscular blockade with boluses of rocuronium. For reversal, neostigmine.
224318801|NCT05794503|DRUG|Sugammadex|Maintenance neuromuscular blockade with boluses of rocuronium. For reversal, sugammadex
223636373|NCT06016049|BEHAVIORAL|Sensory training|Sensibility training of the median nerve
223636374|NCT02397161|OTHER|EEG biofeedback mental attention-neuromuscular training|Mental attention training using EEG biofeedback and neuromuscular training using physio-therapeutic exercises
223636375|NCT02397161|OTHER|Neuromuscular training|Neuromuscular training using physio-therapeutic exercises
223636376|NCT02397161|OTHER|EEG biofeedback mental attention training|Mental attention training using EEG biofeedback
223636377|NCT02084992|OTHER|Expanded technology disease management|Tablet computers loaded with a web-based disease management program will be given to patients for the duration of the study.
223636378|NCT02084992|OTHER|Telephonic disease management|
223636379|NCT04255238|DRUG|Gemigliptin 50mg|The subjects should visit a study site 6-7 times during the treatment period for about 24 weeks in total. - Background therapy should be administered keeping the same dosage administered before the study, according to the following criteria: Metformin ≥ 1,000 mg / day
223764878|NCT04592003|PROCEDURE|Endoscopic submucosal dissection|Endoscopic submucosal dissection
223636380|NCT04255238|DRUG|Dapagliflozin 10mg|The subjects should visit a study site 6-7 times during the treatment period for about 24 weeks in total. - Background therapy should be administered keeping the same dosage administered before the study, according to the following criteria: Metformin ≥ 1,000 mg / day
223636381|NCT05910437|OTHER|Hospitalized patient for decompensated heart failure|Describe the evolution of heart failure medications during hospitalization for decompensated heart failure.
223636382|NCT03847597|PROCEDURE|Explantation of the femoro-popliteal arterial segment from the amputed limb|Explantation of the femoro-popliteal arterial segment from the amputed limb
223636383|NCT03045796|DEVICE|Oxygen Saturation measured by WristOx|Patients will be hooked up to finger cuffs as well as ECGs to monitor oxygen saturations in different part of the body.
223636384|NCT00248404|DRUG|NB1011|
223636385|NCT02415322|OTHER|refer to mental health specialists|children who have diagnosed internet and/or smartphone disorder by psychiatrists referred to mental health specialists
223636386|NCT06185816|DEVICE|Active Treatment|The treatment is a non-invasive pulsed radio frequency current that emits a high frequency magnetic field. It has a pulse width of 0.2ms, a pulse rate of 2Hz and an intensity between 0 - 30ma. There is a 'beep' sound as the pulses occur. There are 2 electrodes used - one is the indifferent electrode that is placed on the skin at a suitable distance away from the active electrode and the other, an active electrode - is a probe that is applied to the target nerve to treat the mononeuropathy
223636387|NCT06185816|DEVICE|Non-active Treatment|The placebo device will be inert with nil current emitted however the device will look and be used in exactly the same way. There will also be a 'beep' sound emitted and only the investigator will know the difference. The placebo device will not deliver any electrical stimulation.
223636388|NCT01507259|OTHER|cocoa|70% versus 34%
223636389|NCT00625170|DRUG|olanzapine|olanzapine 10 mg/day for 8 days
223636390|NCT00625170|DRUG|Haloperidol|haloperidol 3 mg/day for 8 days
223636391|NCT03098875|DRUG|Sevoflurane|General anesthesia using sevoflurane as a hypnotic agent
223636392|NCT03098875|DRUG|Propofol|General anesthesia using propofol as a hypnotic agent
223636393|NCT03098875|DRUG|Remifentanil|General anesthesia using remifentanil as an analgesic.
223636394|NCT04937218|BEHAVIORAL|Egg demand creation campaign|Egg demand creation campaign including 14 months of above-the-line and below-the-line messaging.
223636395|NCT05056389|DRUG|Oxaliplatin|Administration of oxaliplatin intraperitoneally
223636396|NCT00239330|DRUG|Rosuvastatin|
223636397|NCT00239330|DRUG|Atorvastatin|
223636398|NCT03841461|OTHER|International Physical Activity Questionnaire-Short Form|IPAQ has been developed to obtain valid and comparable information about the level of physical activity based on individual reports on daily physical activity in the international arena. This form consists of 7 questions; provides information about time spent in walking, moderate and violent activities, and time spent sitting. The calculation of the total score of the short form includes total of duration and frequency whom walking, moderate activity and severe activity. The energy required for the activities is calculated by the MET-minute score.Standard MET values for these activities has been established. These; Walking = 3.3 MET;Moderate Severe Physical Activity = 4.0 MET;Severe Physical Activity = 8.0 MET;Seating = 1.5 MET.Classification is based on the numerical data obtained.Accordingly,there are 3 activity levels: Inactive,minimal active and very active.
223636399|NCT03841461|OTHER|The Pittsburgh Sleep Quality Index|It is a scale that provides information about the sleep quality of the individuals and the type and severity of the sleep disorder in the last month. It consists of 24 questions, 19 of which are evaluated. The PSQI consists of 1 total score and 7 sub-dimensions (subjective sleep quality, sleep latency, sleep duration, usual sleep efficiency, sleep disturbance, sleep medication use, daytime dysfunction). Each item in the scale has a value between 0 (no distress) and 3 (serious distress). The sum of the scores related to the seven sub-dimensions gives the total PSQI score. The score of each sub-dimension ranges from 0 to 3. The total PSQI score ranged from 0 to 21. While the sleep quality of the patients with a total score of 5 and below is considered as 'good'; \>5 refers to poor sleep quality.
223636400|NCT03841461|OTHER|The Fatigue Severity Scale|Each question on this scale, which is composed of Likert type questions: 1.I strongly disagree 2.I do not agree 3.No tend to disagree 4. Indefinitely. The score of the scale, which consists of 9 questions, varies between 9-63. People are asked to mark the appropriate options for each question taking into account their status in the last 1 month period.
223636401|NCT03841461|OTHER|General Information Form|A form, which is prepared by us, including the purpose of the study, demographic information, daily working hours and assignment durations.
223636402|NCT01074814|DRUG|Approved therapy will be assigned based on molecular profile and RPMA results|treatment will be assigned based on IHC\< FISH, DNA microarray and RPMA results
223636403|NCT01114243|DEVICE|Ultrasound imaging|
223636404|NCT00364104|DRUG|Quadruple sequential Helicobacter pylori eradication + iron sulfate|A 10-day course of Hp infection sequential eradication therapy plus 6-weeks of iron supplementation
223636405|NCT00364104|DRUG|Quadruple sequential Helicobacter pylori eradication therapy|A 10-day course of Hp infection sequential eradication therapy only plus 6-weeks of matching placebo of iron supplementation
223636406|NCT00364104|DRUG|Ferrous sulfate|6-weeks of iron supplementation only plus 10-days matching placebo of Hp infection eradication therapy
223636407|NCT00364104|DRUG|Placebo|Placebo only (10-days of matching placebo of Hp eradication therapy and 6-weeks of matching iron supplementation).
223636408|NCT00961077|DRUG|S-1 (TS-1) and Oxaliplatin (Oxalitin)|"S-1(TS-1) 60mg/m2/day (D1-14) Oxaliplatin: 85mg/m2 + 5DW 250mL MIV over 2-hours~every 3 weeks"
224318802|NCT06633523|PROCEDURE|PVI + Posterior Wall Isolation (PWI) + Electrogram Ablation (EGM)|PVI + Posterior Wall Isolation (PWI) + Electrogram Ablation (EGM) After performing PVI, electrogram mapping of the posterior left atrial wall is conducted. Subsequently, PWI and EGM ablation are performed. In this group, multipolar mapping catheters are used for EGM mapping. Target EGMs include spatially discrete potentials (STPs), localized short cycle length potentials (SCLPs), and focal activities.
223636409|NCT01222052|DRUG|5-Fluorouracil, Epirubicin, Cyclophosphamide, Docetaxel|"Arm A 5-FU 500mg/m2, Epirubicin 100mg/m2, Cyclophosphamide 500mg/m2 q3weeks followed by Docetaxel 100 mg/m² q3weeks~Arm B 5-FU 500mg/m2, Epirubicin 100mg/m2, Cyclophosphamide 500mg/m2 q6weeks"
223636410|NCT02865447|DEVICE|total hip arthroplasty implant|PROFEMUR PRESERVE total hip arthroplasty femoral stem
223636411|NCT05727124|DEVICE|Poul Gjessing|maxillary canine retraction
223636412|NCT05727124|DEVICE|T loops|T loops
223636413|NCT04909047|DEVICE|parassacral transcutaneous electrostimulation|Use of parassacral transcutaneous electrostimulation
223636414|NCT05592717|DRUG|Yutiq|YUTIQ® 0.18 mg as an intravitreal injection in the designated study eye.
224225180|NCT04388891|DEVICE|Minimally supervised therapy with the ReHapticKnob|The therapy with the ReHapticKnob is performed in the clinic in addition to the conventional therapy. During the supervised and semi-supervised phases (first 2 weeks), the intervention dose is 5 sessions of approximately 45 minutes per week. During each session, the robot proposes a set of 3 exercises, each lasting between 10 and 15 minutes. During the minimally supervised phase (third and fourth week), the duration of the ReHapticKnob therapy is not specified, since the patient can decide by him/herself when to use the device, e.g. during freetime or during the weekend.
224225181|NCT02506166|DEVICE|Positive Airway Pressure Therapy|Positive Airway Pressure Therapy will be used in Group 3 for treatment of predominant obstructive sleep apnea
223515127|NCT03474601|OTHER|Dynamic hormone study and Magnetic resonance imaging|"1. Medical history~2. Imaging examination including brain magnetic resonance imaging~3. Blood (Basal hormone study and follow-up study) and pituitary tumor tissue"
223515128|NCT02704377|OTHER|Undergo HRV and wear accelerometer to assess therapy complications|Wear accelerometer undergo heart rate variability(HRV) testing over 10-15 minutes while both lying down and standing, complete a walking test, wear an accelerometer for a period of 1 week
223515129|NCT02704377|PROCEDURE|Dual X-ray Absorptiometry|Undergo iDXA
223515130|NCT02704377|OTHER|Laboratory Biomarker Analysis|Correlative studies
223515131|NCT02704377|OTHER|Quality-of-Life Assessment|Ancillary studies
223515132|NCT02704377|OTHER|Questionnaire Administration|Ancillary studies
223515133|NCT02115971|OTHER|Jumping exercise|Total 120min exercise
223515134|NCT02115971|OTHER|Strength exercise|Total 120 min exercise
223515135|NCT01959919|DEVICE|Refacto FusENGO|Dosage will be chosen by PI based on patient condition.
223515136|NCT00383032|DRUG|mifepristone|
223515137|NCT03934619|DEVICE|Dolores One|Dolores One, which is a will be applied personal sounds amplification device, will be used to determine if it improves the ability to communication and improves intelligibility
223515138|NCT01816399|PROCEDURE|Routine coronary angiography|
223515139|NCT05134519|DRUG|Recombinant humanized anti-HER2 monoclonal antibody-MMAE coupling agent (RC48-ADC)|Regimen: RC48-ADC: 2.0 mg/kg, intravenous drip, once every 2 weeks,4-6 cycles
223515140|NCT01697501|OTHER|Interleukin 28B testing|Blood sampling for IL28B genotyping
223515141|NCT02944331|PROCEDURE|Endovenous steam ablation|
223515142|NCT01160718|DRUG|fulvestrant|Arm A: Fulvestrant 500mg i.m. day 1, 15, day 1 of cycle 2, then every 28 +/- 3 days Arm B: Fulvestrant 500mg i.m. day 1, 15, day 1 of cycle 2, then every 28 +/- 3 days
223515143|NCT01160718|DRUG|selumetinib|AZD6244 75 mg p.o. bid
223515144|NCT02525432|BIOLOGICAL|Placebo Infusion|In addition to the standard of care provided to all patients with traumatic brain injury, subjects assigned to the placebo control group will undergo a sham bone marrow harvest and receive a placebo infusion of saline.
223515145|NCT02525432|BIOLOGICAL|Autologous BMMNC Infusion|In addition to the standard of care provided to all patients with traumatic brain injury, subjects assigned to the BMMNC treatment group will undergo a bone marrow harvest and then receive an autologous stem cell infusion.
223515146|NCT05646693|DIETARY_SUPPLEMENT|Drusen Mega®|It consists of a dietary supplement composed of Vitamin C 60.0mg, Vitamin E 30.0mg, Zinc 12.5mg, Copper 1.0mg, Astaxanthin 4.0mg, Zeaxanthin 2.0mg, Lutein 10.0mg and Omega 3 Acids 500.0mg. It is suggested to consume one capsule per day, preferably with food. This supplement is indicated for nutritional deficiencies and in patients with ophthalmological pathologies.
223515147|NCT05646693|DRUG|Sertraline|It consists of a drug capsule composed of Sertraline Hydrochloride 50mg. In adults it is suggested to consume one to four capsule(s) per day, administering (preferably) the highest dose in the evening, before going to bed. This drug is indicated in the treatment of depressive states with anxiety or moderate to severe agitation, which are accompanied by tension, excitement, insomnia, obsessive and hypochondriac traits. It is also indicated in obsessive-compulsive disorder, panic attacks, stress disorder, post-traumatic disorder, social anxiety disorder and used to relieve the symptoms of premenstrual dysphoric disorder.
223515148|NCT05646693|DRUG|Placebo|It consists of a placebo capsule composed of Magnesium Oxide 100mg. This component is inert in the dose at which it will be administered.
223515149|NCT02985944|PROCEDURE|Colonoscopy|Colonoscopy performed in adult consecutive patients for different indications
223515150|NCT03497702|DRUG|Doxorubicin|60mg/m2 IV every 3 weeks for 4 cycles
223515151|NCT03497702|DRUG|Cyclophosphamide|600mg/m2 IV every 3 weeks for 4 cycles
223515152|NCT03497702|DRUG|Docetaxel|75mg/m2 IV every 3 weeks for 4 cycles
223515153|NCT03497702|DRUG|Letrozole|2.5 mg once daily preoperably
223515154|NCT03497702|DRUG|leuprorelin|3.75 mg SC every 4 weeks for premenopausal patients
223515155|NCT00253955|DRUG|Levofloxacin|
223515156|NCT00253955|DRUG|Piperacillin/Tazobactam|
223515157|NCT04867629|DIETARY_SUPPLEMENT|Rapeseed oil|20mL of rapeseed oil to be consumed daily in replacement to habitual oil
223515158|NCT04867629|DIETARY_SUPPLEMENT|Sunflower oil|20mL of sunflower oil to be consumed daily in replacement to habitual oil
223515159|NCT01212692|BEHAVIORAL|mentally stimulating activities|The study will compare the effects of different methods of mental stimulation. The intervention involves 6 classroom-style educational sessions and 10 mental stimulation studies involving computerized memory tasks.
223515160|NCT06222957|OTHER|None (Observational study)|Both groups recieve standard care as decided by the responsible clinicians at the department of Oncology. The course of the treatment is completely independent from the observations in the present study.
223515161|NCT05299320|DIAGNOSTIC_TEST|Neuromuscular fatigue and postural sway evaluation|Neuromuscular fatigue will be established by using the Excalibur Sport Ergometer device and the Wingate Anaerobic Strength Test. Postural sway will be evaluated with Cyst Force Plate Balance device. This device is a precision device that provides objective measurable data.
223636415|NCT03591406|DRUG|Ferric carboxymaltose|Dosage Form: Injection, Sterile FCM solution as a 5% w/v iron solution in water for injection Strength: 10 mL vials containing 500 mg iron per vial Dosage: 500mg/week or 1000mg/week (based on subject BW and Hb value at screening) Route of administration: IV injection (undiluted solution) or drip infusion (500 mg iron diluted in 100 mL 0.9% w/v physiological saline or 1,000 mg iron diluted in 250 mL 0.9% w/v physiological saline) Dosing schedules: baseline (Day 1) and, if required, at Day 8 and Day 15.
223636416|NCT03591406|DRUG|Iron sucrose|Dosage Form: Sterile solution for injection containing 2% w/v iron Strength: 5 mL ampoules containing 100 mg iron per ampoule Dosage: single doses of IS of 200mg iron based on the formula of Ganzoni: Cumulative iron deficit \[mg\] = BW \[kg\] x (target Hb- actual Hb) \[g/dL\] x 2.4 + 500 mg, up to 11 IS injections will be given Route of administration: IV injection or drip infusion Dosing schedules: three times a week, with an initial dose at baseline and will receive iron, as per approved label, until the subject has received the calculated iron dose.
223636417|NCT03599674|BEHAVIORAL|Family Bridge Program|Families receive Family Bridge Program services which include orientation to the hospital, concrete needs assessment, communication preferences assessment, communication coaching, follow-up during the hospital stay, and a follow-up phone call after discharge.
223636418|NCT02644421|DRUG|VVZ-149|
223636419|NCT02644421|DRUG|Lidocaine|
223636420|NCT02644421|DRUG|Placebo|
223636421|NCT01083771|DIETARY_SUPPLEMENT|Olive Oil|Minimum of 3 tablespoon of olive oil per day
223636422|NCT02066181|OTHER|Laboratory Biomarker Analysis|Optional correlative studies
223636423|NCT02066181|OTHER|Placebo Administration|Given PO
224225182|NCT03987438|BEHAVIORAL|Lifestyle intervention with APP|The lifestyle intervention will be launched by an APP installed in participants' private mobile phones, including health knowledge education, mental health counseling, smart diet advice, intelligent exercise guidance, and target weight management. Nutrition recommendation is conducted according to the Chinese Dietary Guide, Chinese and International Guidelines of Gestation Diabetes Management. Exercise guidance is given based on the Guidelines for National Fitness of China, Chinese and International Guidelines of Gestation Diabetes Management. Psychological support is given by sending education articles on mental health. Participants are encouraged to update data about their diet, exercise and body weight through the APP. The face to face education class will be conducted by an obstetrician, an endocrinologist and a nutritionist together to modify the behavioral supports individually based on the feedback of their characteristics and performance recorded in the APP.
224225183|NCT00902135|DRUG|Interferon beta-1b (Betaseron, BAY86-5046)|Interferon beta-1b (Betaferon) and Personal Digital Assistant together with a reminder
223636424|NCT02066181|OTHER|Quality-of-Life Assessment|Optional ancillary studies
223636425|NCT02066181|DRUG|Sorafenib Tosylate|Given PO
223636426|NCT02393378|DRUG|Namilumab|Namilumab injection
223636427|NCT02393378|DRUG|Adalimumab|Adalimumab SC injection
223636428|NCT02393378|DRUG|Methotrexate|Methotrexate tablet
223636429|NCT02393378|DRUG|Folic Acid|Folic Acid Tablet
223636430|NCT00939393|DEVICE|FESS instruments with or without balloon treatment|Intervention with metal instruments with or without balloon treatment
223636431|NCT00939393|DEVICE|Balloon Sinuplasty|Balloon dilatation of sinuses
223636432|NCT02851615|BEHAVIORAL|SCThrive Intervention for Adolescents with SCD|Chronic Disease Self-Management Program
223636433|NCT04871126|OTHER|inflammatory indexes and CHA2DS2-VASc score|inflammatory indexes and CHA2DS2-VASc score
223636434|NCT06299046|PROCEDURE|robot-assisted radical prostatectomy|surgical removal of the entire prostate and the seminal vesicles, followed by the vescico-urethral anastomosis to restore the continuity of the lower urinary tract performed using Da Vinci Si and Xi Surgical System (Intuitive Surgical, Sunnyvale, California, USA)
223636435|NCT00354978|DRUG|5-Fluorouracil|"400 mg/m\^2 injection by vein Day 1 of 14 day cycle immediately after completion of leucovorin infusion.~2.4 g/m\^2 by vein over 46 hours over Days 1-3 of 14 day cycle immediately after completion of 400 mg/m\^2 injection."
223636436|NCT00354978|DRUG|Bevacizumab|"5 mg/kg over 90 minutes on Day 1 of first 14 day cycle as initial dose, administered alone without other drugs.~5 mg/kg by vein on Day 1 of 14 day cycle."
223636437|NCT00354978|DRUG|Leucovorin|400 mg/m\^2 over 2-4 minutes by vein on Day 1 of 14 day cycle.
223636438|NCT00354978|DRUG|Irinotecan|180 mg/m\^2 by vein over 90 minutes on Day 1 of 14 day cycle.
223636439|NCT05764785|BEHAVIORAL|MentorPRO|MentorPRO is a novel application and web platform for mentoring programs that allows students to set goals, track their challenges, and find just-in time resources, while connecting to a mentor for personalized support and progress monitoring.
223636440|NCT01843621|BIOLOGICAL|DEN vaccine F17|The dengue booster vaccine was administered subcutaneously in the non-dominant arm (deltoid). The tetravalent, live attenuated DEN F17 vaccine was administered in this study. This pre-transfection formulation contained dengue virus types 1, 2, 3 and 4 (DEN-1, -2, -3 and -4).
223636441|NCT03937570|DEVICE|echo-optimization|LVAD echo-optimization consists of routine comprehensive transthoracic echocardiography at the baseline speed setting, followed by stepwise incremental adjustments to the LVAD speed (revolutions per minute: rpm), with collection of prespecified echocardiographic parameters at each new speed (eg, left ventricle end-diastolic diameter, interventricular septal position, aortic valve opening frequency/duration, tricuspid and/or mitral regurgitation severity). The optimal velocity is defined as the one that allows an intermittent aortic valve opening and a neutral position of the interventricular septum without increasing aortic or tricuspid regurgitation, associated or not to a dilatation of the right ventricle. The recommended speed range varies according to the indications given in the data sheet for each specific device.
223636442|NCT03606369|DRUG|Palonosetron|Palonosetron 0.25 mg IV + Dexamethasone 12 mg IV + Fosaprepitant 150 mg IV for early emesis and for delayed emesis Dexamethasone 8 mg orally on days 2, 3 and 4.
223636443|NCT03606369|DRUG|Ondansetron|Early emesis: Ondansetron 16 mg IV + Dexamethasone 12 mg IV + Fosaprepitant 150 mg IV. and for delayed emesis: Metoclopramide 10 mg orally every 6 hours + Dexamethasone 8 mg orally every 24 hrs.
223636444|NCT03742323|DRUG|Idelalisib|Idelalisib Dose: 100, 150, 200 or 300 mg (in four cohorts of six patients each).
223636445|NCT01533207|OTHER|Clinical Observation|Patients followed clinically
223636446|NCT01533207|DRUG|Docetaxel|Given IV
223636447|NCT01533207|DRUG|Doxorubicin Hydrochloride|Given IV
223636448|NCT01533207|BIOLOGICAL|Filgrastim|Given subcutaneously (SC)
223636449|NCT01533207|DRUG|Gemcitabine Hydrochloride|Given IV
223636450|NCT01533207|BIOLOGICAL|Pegfilgrastim|Given SC
223636451|NCT04057326|DRUG|Oryz-Aspergillus Enzyme and Pancreatin Tablet|2 tablets/time, 3 times daily,Oral Administration.
223636452|NCT04057326|DRUG|Placebo|2 tablets/time, 3 times daily,Oral Administration.
223636453|NCT04489836|DIETARY_SUPPLEMENT|Glutalytic®|Glutalytic® capsule
223636454|NCT04489836|DIETARY_SUPPLEMENT|DE111®|DE111® capsule
223636455|NCT04489836|OTHER|Meal A|Oatmeal porridge - serving of oat porridge (cooked) containing 50g of carbohydrates (excluding sugars); Wheat cereal - serving of wheat cereal providing 1g of gluten; Water - 125 mL
223636456|NCT01100619|DRUG|rosiglitazone|one 4 mg dose as a tablet followed by a second 4 mg dose 3 weeks later
223636457|NCT01100619|DRUG|XL184|dosed with capsules daily
223636458|NCT05887388|BEHAVIORAL|Connect-Home Plus|Connect-Home Plus will introduce organizational structure to support delivery of transitional care processes. New elements of structure include:electronic health record (EHR) template, Connect-Home Plus Toolkit, and Staff Training. After structural elements are added, SNF staff will use Connect-Home Plus care processes to deliver the 2-step transitional care intervention.In Step 1, SNF nurses,therapists, and social workers will develop a Transition Plan of Care and prepare the patient and caregiver to manage the illness and functional needs. In Step 2, a dementia caregiving specialist will call the patient's home three times within 30 days of discharge. Both intervention steps will focus on key care needs, such as 1) home safety; 2) care of symptoms of ADRD; 3) symptom management; 4) medication reconciliation; 5) function and activity; and 6) coordination of follow-up medical care.
224225184|NCT00902135|DRUG|Interferon beta-1b (Betaseron, BAY86-5046)|Interferon beta-1b (Betaferon) and Personal Digital Assistant without a reminder
224225185|NCT00902135|DRUG|Interferon beta-1b (Betaseron, BAY86-5046)|Interferon beta-1b (Betaferon)
223636459|NCT02451722|DEVICE|Kyboot shoes|The Kyboot shoe - construction is based on a soft, supple air cushioned sole. The honeycomb air structure of the kyBoot sole creates an air cushion between your foot and the ground, with one fifth of the volume of air being pumped into the foot area at every step. This design could offer a better distribution of pressure
223636460|NCT01238926|DIETARY_SUPPLEMENT|PD vitamin supplementation|25 mg/day of Vitamin B6 2,000 mcg/day of Vitamin B12 5 mg/day of Folic Acid
224318803|NCT06633523|PROCEDURE|PVI + Posterior Wall Isolation (PWI)|After performing PVI, the mapping catheter will be placed on the posterior wall to assess electrical activity and guide ablation. A bottom linear ablation (25-40W) will be performed, connecting the lowest points beneath the lower PVs. A top linear ablation (25-40W) will be conducted at the top of the left atrium, connecting the highest points above the upper PVs. If posterior wall isolation is not achieved after completing the bottom and top lines, mapping and localization of the earliest activation point within the box will be performed during pacing from the coronary sinus (CS). Posterior wall isolation will be completed by identifying and ablating local potentials at the entry and exit sites.
223636461|NCT01238926|OTHER|PD exercise intervention|Cardiovascular training (treadmill and StairMaster), 20 min; and strength training (2 sets of 15 repetitions of 60-70% of 1 repetition maximum \[RM\]) using machines that provide the following motions: knee extension, knee flexion, leg press, elbow flexion, elbow extension, seated dip.
223636462|NCT01238926|OTHER|PD vitamin + exercise|25 mg/day of Vitamin B6 2,000 mcg/day of Vitamin B12 5 mg/day of Folic Acid Cardiovascular training (treadmill and StairMaster), 20 min; and strength training (2 sets of 15 repetitions of 60-70% of 1 repetition maximum \[RM\]) using machines that provide the following motions: knee extension, knee flexion, leg press, elbow flexion, elbow extension, seated dip.
223636463|NCT02515370|OTHER|Friends for Life Circles (FLCs).|"The intervention 'Friends for Life Circles (FLCs) will build dynamic peer group support in the community aimed at supporting maternal adherence to appointment keeping and taking lifetime antiretroviral drugs"
223636464|NCT01123798|DEVICE|near-infrared spectroscopy|Non-invasive monitoring device applied on the surface of the skin that emits harmless red light to measure tissue perfusion.
223636465|NCT01038843|DRUG|VA106483|"Drug: VA106483 Once daily oral dose of 1 mg VA106483 or matching placebo for 14 (+3) days. Once daily oral dose of 2 mg VA106483 or matching placebo for 14 (+3) days. Once daily oral dose of 4 mg VA106483 or matching placebo for 28 days.~Placebo: as above"
223636466|NCT01747876|DRUG|LEE011|LEE011 is a small molecule inhibitor of CDK4/6.
223636467|NCT02092610|DEVICE|Novel Implant BI300|The Novel Implant BI300 was the new titanium implant and abutment for the Baha system developed by Cochlear Bone Anchored Solutions AB. The novel implant is 4.5 mm wide and 4.0 mm long.
223636468|NCT02092610|DEVICE|Standard Implant BI300|The Standard Implant BI300 was the standard titanium implant and abutment in the Baha system developed by Cochlear Bone Anchored Solutions AB. The implant is 3.75 mm wide and 4.0 mm long
224318804|NCT06633523|PROCEDURE|Pulmonary Vein Isolation (PVI) alone|The distance between the ablation lines on the posterior wall after circumferential pulmonary vein isolation should be at least 2 centimeters to limit the portion of the posterior wall within the PVI ablation zone. PVI will be confirmed by verifying entrance and exit block at the PV orifices.
224318805|NCT01051947|DRUG|Nebivolol|10 mg by mouth daily for 2 weeks 20 mg by mouth daily for 2 weeks 40 mg by mouth daily for 2 weeks
223636469|NCT02987426|BEHAVIORAL|Mindfulness-oriented intervention|"The 10 minutes daily sessions every weekday, will take place at the inpatient unit in groups of 10 people. The intervention will be alternating between three forms of moving mindfulness-oriented interventions as detailed below:~Seated Tai Chi: patients will slowly move their arms in soft movements coordinated with slow breaths Gentle stretching: patients will slowly stretch their bodies coordinated with the breath and with awareness of physical sensations throughout the body4 Walking meditation: patients will walk slowly in no particular direction, focusing close attention on the act of walking"
223636470|NCT00685191|DRUG|Salvage antiretroviral therapy including raltegravir|Initiation of raltegravir-including salvage antiretroviral therapy
223636471|NCT01790724|BEHAVIORAL|Walking exercise|
223636472|NCT05194644|OTHER|Routine physical therapy+ Sensorimotor stimulation|Gustatory, Tactile, Olfactory, Visual and Auditory Stimulation will be applied in sensory stimulation and in motor stimulation strengthening, Proprioceptive neuromuscular facilitation techniques, Balance exercises will be performed
223764879|NCT06521476|DRUG|Acetazolamide|Oral acetazolamide 250 mg daily for 7 days
224318806|NCT01051947|DRUG|Metoprolol|dosage prescribed prior to starting on study
224318807|NCT05758857|BEHAVIORAL|Experimental: Guidelines-based physical activity|Through a combination of exercise trainer-led in-person and virtual sessions, as well as counselling for independent aerobic exercise, participants will be guided to achieve 150 weekly minutes of moderate-intensity aerobic activity and twice weekly whole-body muscle strengthening.
224318808|NCT05758857|BEHAVIORAL|Experimental: Guidelines-based healthy eating|One-on-one phone/virtual counselling from a registered dietitian to change dietary habits to be in line with Canada's Food Guide.
224318809|NCT05758857|BEHAVIORAL|Stretching exercise|Twice weekly virtual instructor-led whole-body stretching class.
224318810|NCT07133789|OTHER|blood sampling of all patients and their parents|blood sampling of all patients and their parents
224318811|NCT07133529|BEHAVIORAL|Perceived food uncertainty|Participants remain unaware of both the scheduled time and the length of the next meal.
223636473|NCT05194644|OTHER|Routine physical therapy|Active and passive Range of motion exercise of upper and lower limb, Transfer from bed to chair, Sit to stand practice
223636474|NCT02170571|DRUG|Dabigatran etexilate|
223636475|NCT00331097|DRUG|docetaxel|35 mg/m2 intravenously on days 1, 8, and 15 every 28 days
223636476|NCT00331097|DRUG|cyclophosphamide|600 mg/m2 intravenously days 1, 8 every 28 days
223636477|NCT00331097|DRUG|methotrexate|40 mg/m2 intravenously days 1 and 8 every 28 days
223636478|NCT00331097|DRUG|5-fluorouracil|600 mg/m2 intravenously days 1 and 8 every 28 days
223636479|NCT03891407|DIAGNOSTIC_TEST|Self-Testing Education and Promotion|Camp members will receive the Self-Testing Education and Promotion (STEP locally referred to as Mate Yako Afya Yako) intervention and will receive HIV-counseling and oral HIV self-testing kits.
223636480|NCT00740649|DRUG|HSD-016|
223636481|NCT00740649|DRUG|placebo|
223636482|NCT03131219|BIOLOGICAL|Ravulizumab|Participant received weight-based dosages for 26 weeks during the Initial Evaluation Period. Participants received a loading dose on Day 1, followed by maintenance dosing on Day 15 and once every 8 weeks thereafter for participants weighing ≥ 20 kg, or once every 4 weeks for participant weighing \< 20 kg.
223636483|NCT03819530|DIETARY_SUPPLEMENT|Vitamin and Mineral Powder|Vitamin and mineral nutritional supplement. Each packet is 1g of powder, to be taken with food.
223636484|NCT00600080|DEVICE|etafilcon A|contact lens worn daily for one week (first or second week depending on arm)
223636485|NCT00600080|DEVICE|nelfilcon A|Contact lens worn daily for one week (first or second week depending on arm)
223764880|NCT06521476|DRUG|Placebo|Oral placebo daily for 7 days
224225186|NCT04782102|BEHAVIORAL|SOPHIE Intervention|SOPHIE is an online-intervention aiming to reduce social anxiety in adolescents. SOPHIE has 8 modules, one module per week, which lasts about 60 minutes. SOPHIE includes elements of evidence-based psychotherapeutic interventions to reduce social anxiety and of an existing online-intervention for adults with social anxiety adopted to the needs of adolescents. The intervention consists of psychoeducation (how social anxieties arise), application examples (e.g. setting up a personal anxiety cycle or anxiety pyramid, imagination exercise: journey to a safe place), and contains weekly tasks for which regular repetition in everyday life is important (e.g. progressive muscle relaxation, observing anxiety in everyday life, exposures in various situations). At the end of each module, a short quiz allows participants to recall and consolidate what they have learned. The content is presented in video inputs, short explanatory texts, application tasks and quizzes.
224225187|NCT03445975|PROCEDURE|3-in-1 perineal care washcloths|The 3-in-1 washcloth was used for daily routine perineal skin hygiene and after each diaper/underpad change. This procedure was intended for cleansing, moisturizing, and application of a barrier protection (dimeticone 3%). 3-in1 washcloths pH range is 3.5 to 5.0.
224225188|NCT03592875|BEHAVIORAL|Professional nurses|The nurses will be interviewed by a semi-structured guiding with 16 questions addressing aspects related to Nursing Care Systematization knowledge and practices.
224225189|NCT06484036|PROCEDURE|periodontal treatment strategy|Periodontal treatment sessions (Experimental Group only) (1 to 3 months) after randomization
224225190|NCT00387998|OTHER|AHRQ staying healthy booklet|educational booklet about prevention
224225191|NCT00387998|OTHER|Risk primer|Know your chances booklet
224318812|NCT07133529|BEHAVIORAL|Perceived food certainty|Participants are aware of both the scheduled time and the length of the next meal.
224318813|NCT07133438|DRUG|Anti-VEGF drug|conventional anti-VEGF therapy (intravitreal injections of conbercept 0.5 mg initially once a month for 3 months, followed by on-demand therapy which based on recurrence criteria)
224318814|NCT07133438|DRUG|Mecobalamin 5 MG|oral mecobalamin capsules 0.5 mg three times daily for 6 months
224318815|NCT07133438|DRUG|Placebo|placebo capsule with a similar appearance and odor to the mecobalamin capsules three times daily for 6 months
224318816|NCT06866444|DRUG|Observational|In a cohort of patients treated with duloxetine for fibromyalgia, participants vitals signs (blood pressure, heart rate, oxygen saturation level, temperature) will be taken as well as height and weight. Participants will fill out a questionnaire regarding their fibromyalgia diagnosis and symptoms. Lastly, participants will complete two sets of blood samples. One blood sample will evaluate genetic variants for duloxetine metabolizing capacity. The other sample will be used to analyze the level of concentration of duloxetine.
223764881|NCT05297903|DRUG|XmAb20717|10mg/kg IV
223764882|NCT06022939|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Given IV
223764883|NCT06022939|PROCEDURE|Biopsy|Undergo fat pad biopsy
223764884|NCT06022939|PROCEDURE|Biospecimen Collection|Undergo blood and urine specimen collection
224318817|NCT07134764|DEVICE|Virtual reality session|Patients included in the intervention group (VR group) participated in a comprehensive virtual reality program designed to reduce perioperative anxiety and pain. Prior to their surgery, they attended an introductory VR session aimed at familiarizing them with the technology and providing a calming, immersive environment to help alleviate preoperative stress. Throughout their surgical journey, these patients continued to receive the usual standard care, which included thorough preoperative consultations with healthcare providers, detailed information about the planned surgical procedure, and the provision of standard postoperative care to support recovery. Additionally, during the surgery itself, patients underwent a VR session delivered via a headset, offering real-time immersive distraction and relaxation to minimize intraoperative anxiety and pain perception.
224318818|NCT07003529|OTHER|Unenhanced brain MRI|Unenhanced brain MRI in five sequences: 1) T1-weighted anatomical sequences 2) Resting-state functional sequences 3) Task-based functional sequence 4) Structural sequence using Diffusion Tensor Imaging (DTI) 5) Routine magnetic resonance spectroscopy sequence
223636486|NCT05621434|DRUG|Inetetamab, pyrotinib, chemotherapy|"Inetetamab: was administered as an intravenous (IV) loading dose of 8mg/kg q3w on Day 1 of Cycle 1 (1 Cycle length = 21 days), and 6mg/kg q3w on Day 1 of subsequent cycles, until investigator-assessed radiographic or clinical progressive disease, unmanageable toxicity, or study termination.~pyrotinib: 400 mg once daily orally within 30 minutes after a meal at the same time each day.~chemotherapy:Taxanes (paclitaxel, docetaxel, liposomal paclitaxel, nabpaclitaxel), vinorelbine, capecitabine, eribulin, and other chemotherapeutic agents indicated in advanced breast cancer are permitted. Refer to the appropriate package insert for dosage and administration recommendations."
223636487|NCT00991016|DRUG|PF-04805712|ascending single and multiple doses starting at 30 mg
224225192|NCT04586647|BEHAVIORAL|Noom Healthy Weight; mobile behavior change program for weight loss.|"The intervention consists of a curriculum, provided through daily articles that users are encouraged to read; logging features for weight, meals, and physical activity; in-app groups; and a virtual coach, who will communicate with participants via in-app messaging. During the first week of the study, participants will be introduced to the program, the Noom app, and their coach.~Coaches will use a secure dashboard to monitor patient progress, which is used to increase engagement and motivation. Participants are encouraged to log their weight and physical activity on a weekly basis, and meals daily."
224225193|NCT02745002|DEVICE|navigated bronchoscopy|
224225194|NCT02100865|DEVICE|Solar powered oxygen|
223636488|NCT04554680|DRUG|dabrafenib and trametinib|"Participants will receive systemic therapy in the form of oral tablet dabrafenib 150mg twice a day \& oral tablet trametinib 2mg once a day for 1 or 4 weeks.~Pre- \& post-systemic therapy assessment of tumor iodine absorption is done using I-124 PET CT scan. Participants are prepared for this scan with intramuscular injection of thyrogen 0.9mg on 2 consequent days, followed by I-124 PET-CT scan over the next 3 days for tumoral lesional dosimetry.~Participants are then started on systemic therapy for 1 week, followed by I-124 PET-CT scan. If at least one tumor site can attain adequate dosimetry, RAI (I-131) treatment under thyrogen stimulation will be considered. Systemic therapy will be stopped 3 days after I-131.~If after 1 week of systemic therapy, tumors do not reach dosimetry criteria, participants will be continued on systemic therapy for a total of 4 weeks duration, followed by I-124 PET-CT scan. If tumor can attain adequate dosimetry, I-131 treatment will be considered."
223636489|NCT06172062|OTHER|laparoscopic pancreaticoduodenectomy|we recorded the surgical videos of laparoscopic pancreaticoduodenectomy, and labeled the information in the video to build and test the algorithms.
224225195|NCT02100865|DEVICE|Oxygen from cylinders|
224225196|NCT00295126|PROCEDURE|cellular therapy : Autologous platelet concentrate (APC)|
224225197|NCT01604044|DRUG|Meropur 150 a day|one subcutaneous injection a day
224225198|NCT01604044|DRUG|Gonal-f 150 plus Luveris 150|one subcutaneous injection a day
223636490|NCT01497288|DRUG|INFS (Intranasal Fentanyl Spray)|Intranasal Fentanyl Spray
223636491|NCT05313295|OTHER|Home-based physiotherapy|Manual Therapy, passive and active mobilizations, stretching, respiratory techniques
223636492|NCT05313295|OTHER|Usual Physiotherapy|Usual care provided for the management of neurological disorders in children
223636493|NCT04782583|OTHER|Questionnaire|questionnaire for the patients and the volontaire
223636494|NCT01391546|BIOLOGICAL|ZOSTAVAX|1 dose 0.65 mL
223636495|NCT00312156|DRUG|insulin detemir|
223636496|NCT00312156|DRUG|insulin NPH|
223636497|NCT00312156|DRUG|insulin aspart|
224225199|NCT03997448|DRUG|Pembrolizumab|Pembrolizumab 200mg IV
224225200|NCT03997448|DRUG|Abemaciclib|Abemiciclib 150mg PO
224225201|NCT02661126|DRUG|MK-3682B|FDC oral tablet containing 225 mg uprifosbuvir + 50 mg grazoprevir + 30 mg ruzasvir.
224225202|NCT05408286|BEHAVIORAL|administration of questionnaires|administration of questionnaires
224225203|NCT03110666|BIOLOGICAL|Injection of autologous concentrated bone marrow aspirate|Percutaneous injections at the bone-cartilage interface (distal femur and proximal tibia)
224318819|NCT07134075|DRUG|intracochlear triamcinolone acetonide injection|intracochlear triamcinolone acetonide injection of through the round window membrane
224225204|NCT03778866|OTHER|Bicarbonate-buffered handling medium|The investigators will evaluate whether the usual bicarbonate culture medium can replace the HEPES buffered medium effectively.
224225205|NCT01921426|DRUG|GC4419|GC4419 is a novel, highly stable manganese-containing macrocyclic ligand complex with a molecular weight of 483, whose activity mimics that of naturally occurring superoxide dismutase (SOD) enzymes. It is therefore a prototype of a new class of drugs termed selective SOD mimetics. GC4419 selectively removes superoxide anions without reacting with other reactive oxygen species, including nitric oxide, hydrogen peroxide, and peroxynitrite.
224318820|NCT07134075|DRUG|intracochlear injection of dexamethasone through the round window membrane|intracochlear injection of dexamethasone sodium phosphate through the round window membrane
223636498|NCT05581680|OTHER|dental impressions|dental impressions
223636499|NCT05581680|OTHER|Simultaneous MoCap and EMG acquisition|Simultaneous MoCap and EMG acquisition
223636500|NCT05581680|OTHER|Eye-tracking acquisition for pathological subjects|Eye-tracking acquisition for pathological subjects
223636501|NCT05581680|OTHER|Follow-up visit for pathological subjects|Follow-up visit for pathological subjects
224225206|NCT04208139|DIAGNOSTIC_TEST|IVUS|IVUS
224225207|NCT00040872|BIOLOGICAL|filgrastim|
224225208|NCT00040872|BIOLOGICAL|monoclonal antibody 3F8|
224225209|NCT00040872|BIOLOGICAL|sargramostim|
224225210|NCT00040872|DRUG|carboplatin|
224225211|NCT00040872|DRUG|cisplatin|
224225212|NCT00040872|DRUG|cyclophosphamide|
224225213|NCT00040872|DRUG|doxorubicin hydrochloride|
224318821|NCT07134075|DRUG|intracochlear dexamethasone injection and intratympanic dexamethasone injection|intracochlear dexamethasone sodium phosphate injection of through the round window membrane, intratympanic dexamethasone sodium phosphate injection through the tympanic membrane
224318822|NCT07134075|DRUG|intratympanic dexamethasone injection|intratympanic dexamethasone sodium phosphate injection (10mg/ml) through tympanic membrane，once every other day, for a total of 4 injections.
223636502|NCT02156076|DRUG|BMS-919373|
223636503|NCT02156076|DRUG|Placebo (Matching with BMS-919373)|
223636504|NCT04279717|OTHER|Observation|No interventions planned: treatment of patients at the discretion of the treating/responsible physician
223636505|NCT04279717|OTHER|Observation|No interventions planned: treatment of patients at the discretion of the treating/responsible physician
223636506|NCT05917197|OTHER|survey based information|Only survey based information collected
223636507|NCT01100801|DRUG|TS-1 with cisplatin|
223636508|NCT01100801|DRUG|TS-1 with oxaliplatin|
223636509|NCT02986295|DEVICE|BioMimeTM Stent, Ultimaster® Stent|
223636510|NCT06432218|OTHER|video education|A re-watchable video provided before pessary fitting which mainly includes a short introduction of pessary treatment for pelvic organ prolapse, tips and tricks for wearing and self-management of pessary, possible adverse reactions and remedy.
223636511|NCT06432218|OTHER|conventional education|Conventional verbal/paper instruction and counseling from a specialized doctor or nurse before pessary fitting.
224225214|NCT00040872|DRUG|etoposide|
224225215|NCT00040872|DRUG|isotretinoin|
224225216|NCT00040872|DRUG|thiotepa|
224225217|NCT00040872|DRUG|topotecan hydrochloride|
224225218|NCT00040872|DRUG|vincristine sulfate|
224225219|NCT00040872|PROCEDURE|autologous bone marrow transplantation|
224225220|NCT00040872|PROCEDURE|bone marrow ablation with stem cell support|
224225221|NCT00040872|PROCEDURE|conventional surgery|
224225222|NCT00040872|PROCEDURE|drug resistance inhibition treatment|
224318823|NCT05737784|DRUG|PRAX-222 - Initial Dose|PRAX-222
224318824|NCT05737784|DRUG|PRAX-222 - Initial Ascending Doses|Ascending doses of PRAX-222
223636512|NCT06055270|PROCEDURE|Stellate Ganglion Block|All SGBs will be performed by a board-certified anesthesiologist and pain management specialist with extensive experience performing SGBs. The laterality of the SGB will be randomized between the left and right sides of the neck. Participants will be asked to abstain from eating and drinking for 8 hours prior to the SGB. Using ultrasound guidance, the transverse process of the C6 vertebra is identified. Color-doppler is used to identify blood vessels. A 27-gauge needle is used to anesthetize the superficial skin with 1% lidocaine. Then, a 21-gauge ultrasound needle is advanced using an in-plane technique from lateral to medial with careful avoidance of neurovascular structures. After negative aspiration, 8 mL of 1% Lidocaine is deposited beneath the prevertebral fascia and above the Longus coli muscle into the stellate ganglion.
223636513|NCT06055270|OTHER|Placebo|The placebo sham injection will be performed in an identical fashion as the stellate ganglion block, with the exception of using 8 mL of 0.9% saline injection instead of Lidocaine
223636514|NCT04984616|DRUG|40 mg Atorvastatin/day for 120 days P.O.|Oral administration of Atorvastatin 40 mg/daily for 120 days
223636515|NCT04984616|DRUG|Atorvastatin 80|Oral administration of Atorvastatin 80 mg/daily for 120 days
223636516|NCT04984616|DRUG|Placebo|Oral administration of Placebo daily for 120 days
223636517|NCT05513534|OTHER|Yoga|A standard yoga program will be provided using Hatha poses.
224225223|NCT00040872|PROCEDURE|peripheral blood stem cell transplantation|
224225224|NCT00040872|PROCEDURE|syngeneic bone marrow transplantation|
224225225|NCT00040872|RADIATION|radiation therapy|
224225226|NCT03932084|BEHAVIORAL|Control group|"During hospitalization:~1. Monitor subjects' blood glucose;~2. One-on-one education: Education includes skills related to diabetes self-management, basic knowledge of diabetes, diet, exercise, medication, blood glucose monitoring, risks of glucose fluctuations;~3. Teaching patients and their families to use blood glucose meters and correctly record results. The diabetes specialist nurses demonstrate correct methods for self-monitoring blood glucose.~During discharge: Patients were given standard hospital discharge instructions and were asked to monitor their blood glucose 5 times daily after discharge.~Follow-up: If a patient FPG was less than 7 mmol/L, 2hPG was less than 10 mmol/L, or A1c was less than 7%, no intervention would be implemented. If one of these items was above the numbers, a referral would be made to an endocrinologist for medication adjustment. Participants received telephone follow-up one week after discharge, thereafter, follow-up were conducted once a month."
224225227|NCT03932084|BEHAVIORAL|Glucose fluctuation targeted intervention|We set achieving goals for this intervention group (both A1c\<7% and LAGE\<80mg/dl). Participants received the same usual care as the control group; though additional attention was paid to glucose fluctuation on the basis of glucose control. Even the patient's FPG, 2hPG, and A1c were all well controlled, If his or her LAGE≥80mg/dl, we would carefully assess the patient's diet and exercise and daily activities first. If it was caused by lifestyle or events, the researchers worked with patients to find a self-care behavioral solution for the glucose fluctuation, and set behavioral goals, otherwise, the researchers would refer the patient to an endocrinologist for medication adjustment. During next follow-up, we evaluated the glucose fluctuation and target completion.
224318825|NCT05737784|DRUG|PRAX-222 - Optional Ascending Doses|Escalation of PRAX-222 dose(s)
224318826|NCT05737784|DRUG|PRAX-222 - Fixed Doses|Fixed-dose(s) of PRAX-222 not to exceed the maximum tolerated dose of PRAX-222
224318827|NCT05737784|PROCEDURE|Placebo|Placebo procedure
223636518|NCT05513534|OTHER|High-speed Resistance Training|Each session will consist of three sets of 10 repetitions each with 1.5 to 2-minute rest periods between sets. Participants will be instructed to control the concentric and eccentric velocity of each exercise, with each phase lasting approximately two to three seconds
223636519|NCT00209235|BEHAVIORAL|Neurocognitive and psychosocial testing|Neurocognitive and psychosocial testing
223636520|NCT02850653|BIOLOGICAL|PCR : 16S ribosomal DNA and real-time targeted PCR|
223636521|NCT02850653|BIOLOGICAL|Sampling of aqueous humour|
223764885|NCT06022939|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
223764886|NCT06022939|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
223764887|NCT06022939|DRUG|Bortezomib|Given SC
223636522|NCT00003475|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|"Adults with a primary malignant brain tumor that has not responded to standard therapy will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
223636523|NCT00167843|DRUG|sulfadoxine-pyrimethamine|
223636524|NCT03288103|DRUG|Norditropin|Single dose of daily growth hormone regimen. Dose will be 50 micrograms/kg/day.
223636525|NCT01498068|DRUG|Telaprevir|Telaprevir Type = exact number, unit = mg, number = 750, form = tablet, route = oral. Telaprevir 750 mg (2 oral tablets) is taken every 8 hours for 12 weeks
223636526|NCT01498068|DRUG|Pegylated-interferon-alfa-2a|Pegylated-interferon-alfa-2a type = exact number, unit = microgram, number = 180, form = injection, route = subcutaneous. 180 microgram (µg) per week, subcutaneous injection, for 24 or 48 weeks
223636527|NCT01498068|DRUG|Ribavirin|Ribavirin Type = exact, number = 1000 or 1200, unit = mg, form = tablet, route = oral. 1000mg (if participant's weight is \< 75kg) or 1200mg (if participant's weight is \>= 75kg) per day for 24 or 48 weeks.
223636528|NCT06035016|DRUG|pyrotinib combined with Capecitabine|Pyrotinib 400mg, qd, po, day 1-21, q3w, Capecitabine 1000mg/m2, bid po d1-14, q3w
223636529|NCT06035016|DRUG|treatment of physician's choice|Treatment of physician's choice
223636530|NCT00743834|DRUG|Luvox CR|In light of the Luvox-CR dosing procedure of Hollander et al (2003) (50 mg increments weekly) and the available dose capsules of Luvox-CR (100 mg and 150 mg), the Luvox-CR dose will be increased over the first 6 weeks of treatment as tolerated in 50 mg to 100-mg increments every week, as tolerated and clinically indicated, to a bedtime dose between 100 and 300 mg/day. The dose will then be held constant for the duration of the study
224225228|NCT04581538|DEVICE|Intervention of parallel arm 2|"This intervention consists of the e-learning platform and the networking platform from the newly developed client-server software solution 24-h-QuAALity.~The e-learning platform offers concise evidence-based information on common clinical patterns, as well as examples of assistance, physical activity, nutrition and daily routine provided in the caregivers' mother tongues.The caregivers use the e-learning content according to the needs of their clients and their caring skills. After completing the e-learning courses they do a test to prove their knowledge.~The networking platform supports caregivers in communicating with other caregivers and relatives of the care receiver, with special consideration of language barriers. The caregivers use the networking platform primarily to get information or exchange it, if there are uncertainties in the care."
224318828|NCT07021053|BEHAVIORAL|Alcohol Change Course Enhanced|The Alcohol Change Course Enhanced is an adaptation of the Alcohol Change Course, originally developed and evaluated in Switzerland. The Course is a six-lesson ICBT intervention delivered over eight weeks to individuals who self-report alcohol misuse. Due to therapist registration and availability, eligible clients residing in Saskatchewan will be offered the option of receiving therapist assistance (or not) alongside the Course, while clients from other Canadian provinces will not receive therapist support. In addition to the monitoring of weekly measures available to all clients, those receiving therapist support will receive weekly secure messaging from their assigned therapist for eight weeks. Therapists will spend approximately 15 minutes per week/per client receiving therapist support. Phone calls will be used in the event that there is a significant clinical issue requiring therapist attention that cannot be addressed over messaging (e.g., sudden increase in symptoms).
223636531|NCT00743834|BEHAVIORAL|Behavioral Therapy|The web-based CBT (CT STEPS) includes an introductory session explaining the treatment, with videotapes of OCD patients who used an earlier version, along with 9 subsequent treatment modules. The CBT will include weekly email feedback from a psychologist in response to questions asked about the CBT by the subjects assigned to this treatment arm.
223636532|NCT02252666|DEVICE|Neuromodulation Rehabilitation|CN-NINM uses sequenced patterns of electrical stimulation on the tongue. Our hypothesis is that CN-NINM induces neuroplasticity by noninvasive stimulation of two major cranial nerves: trigeminal, CN-V, and facial, CN-VII.
223636533|NCT01499836|OTHER|PVB|paravertebral block
223636534|NCT05324475|DIETARY_SUPPLEMENT|BCAA|daily administration of oral nutritional supplements (ONS) 1) providing whole proteins together with dietary advice according with the ESPEN nutrition guidelines. All the patients will receive the standard commercially available product used at CHUV (Resource protein ®, nestle) and nutritional counselling (SC) and 4 gram per day of BCAAs mixture. Ratio between the BCAAs will be Leucine/Isoleucine/Valine=2:1:1
223636535|NCT05324475|DIETARY_SUPPLEMENT|Micronutriments|daily administration of oral nutritional supplements (ONS) 1) providing whole proteins together with dietary advice according with the ESPEN nutrition guidelines. All the patients will receive the standard commercially available product used at CHUV (Resource protein ®, nestle ) and nutritional counselling (SC) and Vitamin A 1200 mg RE, Vitamin D3 2000 IU, Thiamine B1 100 mg, Cobalamin B12 10 mcg, Ascorbic acid C 200 mg, Iron 30 mg, Selenium 100 mcg, Zinc 20 mg, Omega-3 PUFA 1 g
223636536|NCT05324475|DIETARY_SUPPLEMENT|standard treatment + placebo|daily administration of oral nutritional supplements (ONS) 1) providing whole proteins together with dietary advice according with the ESPEN nutrition guidelines. All the patients will receive the standard commercially available product used at CHUV (Resource protein ®, nestle ) and nutritional counselling (SC) and maltodextrin 4 g as placebo
223636537|NCT00253149|DRUG|risperidone|
223636538|NCT02528994|DIETARY_SUPPLEMENT|L-serine|Participants will take dietary serine supplementation daily
223636539|NCT01353898|DRUG|MK-1972|MK-1972 will be supplied as 25 and 100 mg capsules, and will be given orally, at a dose dependent on the treatment arm; participants will take ten capsules (active drug and/or placebo) once or twice per day for 10 days
223636540|NCT01353898|DRUG|Placebo to MK-1972|Placebo will be supplied as matching 25 and 100 mg capsules, and will be given orally, at a dose dependent on the treatment arm; participants will take ten capsules (active drug and/or placebo) once or twice per day for 10 days
223764888|NCT06022939|PROCEDURE|Computed Tomography|Undergo CT scan
223764889|NCT06022939|DRUG|Cyclophosphamide|Given PO or IV
223764890|NCT06022939|DRUG|Daratumumab and Hyaluronidase-fihj|Given SC
223764891|NCT06022939|DRUG|Dexamethasone|Given PO or IV
223764892|NCT06022939|PROCEDURE|Echocardiography|Undergo echocardiography
223636541|NCT06130761|PROCEDURE|Pericapsular Nerve Group Block Combined With Lateral Femoral Cutaneous Nerve Block|"For PENG block transducer is placed in the transverse plane over the anterior inferior iliac spine (AIIS) and moved inferiorly to visualize the pubic ramus. The femoral artery and iliopubic eminence are visualized, and then, using an in-plane technique, a 22-gauge 50 mm needle is advanced from lateral to medial then 0.5 ml/kg of 0.25% bupivacaine is deposited between the psoas tendon anteriorly and pubic ramus posteriorly lifting it.~For LFCN the transducer is placed immediately inferior to the anterior superior iliac spine (ASIS), parallel to the inguinal ligament. The tensor fasciae lata muscle (TFLM) and sartorius muscle (SaM) are then identified. The nerve appears as a small hypoechoic oval structure with a hyperechoic rim between the TFLM and SaM in a short-axis view or superficial to the SaM. A 22-gauge 50 mm needle is inserted in-plane in a lateral-to-medial orientation through the subcutaneous tissue. A fascial pop may be felt as the needle tip enters the plane."
223636542|NCT06130761|PROCEDURE|trans muscular quadratus lumborum block|With the patient in the lateral position, after standard sterilization of skin and probe identify 3 layers of the abdomen. The transversus abdominis is traced more posteriorly until the transversus aponeurosis. usually we can find the peritoneum curves away from the muscles from anterior to posterior . Tilting the probe slightly caudal into the pelvis thus improves the view of the retroperitoneal fat and the tapered end of transversus aponeurosis. QL is usually identified medial to the aponeurosis of transversus abdominis muscle vertically attached above the iliac crest. A 22-gauge 50 mm needle will be inserted in the plane from the posterior edge of the convex probe through the QL in an anteromedial direction. The needle tip will be placed between the PM muscle and the QL muscle and the local anesthetic will be injected into the fascial plane after aspiration test is negative. A volume 0.5 ml/kg of 0.25% bupivacaine is injected with maximum dose 2.5mg per kg of bupivacaine.
223636543|NCT05370196|DEVICE|Test Product|Synthetic Male Condom
223636544|NCT05370196|DEVICE|Control Product|Latex Male Condom
223636545|NCT03558737|OTHER|Nasal high-frequency jet ventilation (nHFJV)|Non-invasive high-frequency jet ventilation provided via the Bunnell Life Pulse high-frequency JET ventilator through a Rusch latex nasopharyngeal airway
223636546|NCT03558737|OTHER|Nasal intermittent positive pressure ventilation (NIPPV)|Non-invasive positive pressure ventilation delivered via a conventional ventilator through Hudson prongs
223636547|NCT00284947|DRUG|basiliximab|40 mg once every 28 days intravenously for 24 weeks
224225229|NCT04581538|DEVICE|Intervention of parallel arm 3|"Intervention Description: This interventions represents the entire 24-h-QuAALity package consisting of the e-learning platform and networknig platform as specified under intervention 1 and the digital care documentation from the newly developed client-server software solution 24-h-QuAALity.~The digital care documentation aims at supporting caregivers in managing their daily tasks and facilitates exchange with other health professionals and palliative supply. The caregivers use the care documentation every day. They describe the caring and household activities they have done by their clients. The integrated emergency management empowers caregivers with lifesaving first aid skills and knowledge including an integrated voice communication and emergency call system. The emergency management system is used by caregivers when an emergency happens in which life-threatening diseases have to be managed."
224225230|NCT04758650|DRUG|68GaNOTA-Anti-MMR-VHH2|"All subjects will receive at least one single intravenous injection of the IMP followed by a total body PET/CT prior to receiving standard-of-care therapy.~For patients in cohorts 1 and 2 : an optional injection of the IMP during or after therapy can be administered if a patient is treated with non-surgical modalities. Patients in cohorts 6 and 7 who receive standard-of-care treatment can receive an optional injection of the IMP."
224225231|NCT04632823|COMBINATION_PRODUCT|Comprehensive Non-pharmacological Treatment Program|dietary supplement, specific type of exercise, self-management education
224225232|NCT04363983|BIOLOGICAL|Blood sampling|"Blood collection (50 ml) will be performed for all patients at baseline, at 1 month post-operative for resected patients (+ at the end of neoadjuvant treatment / before surgery if patient receives neoadjuvant treatment), and at 2-3 months after the beginning of the treatments in patients with metastases (+ at each progression).~Following analysis should be performed with~* serum for protein assays and characterization analysis of cytokines, new tumor markers and micro-RNA ...;~* plasma for protein assays and characterization analysis of micro-RNA, VEC (the content of proteins, RNA, micro-RNA and DNA) and metabolomics;~* PBMC for flow cytometry analysis, isolation macrophages;~* whole blood for circulating tumor DNA (mutations by NGS, ddPCR,…; methylation) and circulating tumor cells."
224225233|NCT04363983|PROCEDURE|Liver biopsy|"An intraoperative liver biopsy will be performed at free edge of liver with a triangular sample for local resected patients.~This biopsy will be done with scissors, then patients will receive intraoperative hemostasis with mono- or bipolar coagulation. This procedure will be under laparoscopy or laparotomy without extending standard processing time.~This biopsy seeks to allow the evaluate liver modifications testifying the preparing for premetastatic niche, which would allow to identify the patients with risk for hepatic relapsing; the same analysis on the tumors will be performed."
224225234|NCT04363983|BIOLOGICAL|Stool collect|"Stool collection will be performed for all patients at baseline, at 1 month post-operative for resected patients (+ at the end of neoadjuvant treatment / before surgery if patient receives neoadjuvant treatment), and at 2-3 months after the beginning of the treatments in patients with metastases (+ at each progression).~Analysis will be performed for microbiota and metabolism analysis."
223636548|NCT00284947|DRUG|MMF/EC-MPS|1g MMF or 720mg EC-MPS p.o twice daily
224225235|NCT01544790|PROCEDURE|Esophagectomy|In this monocenter prospective randomized controlled trial, we compare robot-assisted minimally invasive esophagectomy with conventional open transthoracic esophagectomy.
224225236|NCT03892759|OTHER|Osteopathic Manipulative Therapy|A set of hands-on techniques used by Osteopathic Physicians for the assessment and treatment of somatic dysfunction.
223636549|NCT00284947|DRUG|Corticosteroids|Oral corticosteroids, equivalent to prednisone p.o, ≥ 5mg daily or ≥ 10mg on alternate days
223764893|NCT06022939|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223764894|NCT06022939|DRUG|Melphalan|Given IV
223764895|NCT06022939|PROCEDURE|Positron Emission Tomography|Undergo PET-CT
223764896|NCT06022939|PROCEDURE|Stem Cell Isolation|Undergo stem cell collection
223764897|NCT06022939|OTHER|Survey Administration|Ancillary study
223636550|NCT05698550|DRUG|Erzhi Tiangui Granule|The Drug Manufacturing Unit of the Affiliated Hospital of Shandong University of Traditional Chinese Medicine produced the EZTG granule.The EZTG was packaged as 3 g/bag, batch number 01-FZ032-03. The daily dose is equivalent to 15g of Ligustrum lucidum (Nv Zhen Zi),15g of Lotus japonicus (Han Lian Cao),15g of the fruit of Chinese wolfberry(Gou Qi Zi),15g of Cuscuta chinensis(Tu Si Zi), 15g of Radix Rehmanniae Preparata(Shu Di Huang),12g of Angelica sinensis(Dang Gui),12g of Paeonia lactiflora(Bai Shao),12g of Ligusticum wallichii(Chuan Xiong),12g of Rhizoma cyperi(Xiang Fu),and 9g of Radix Glycyrrhizae (Zhi Gan Cao).The placebo granule,which was Preparata mainly composed of dextrin, was made in a similar color and shape to EZTG.Placebo granules were packaged as 3g/bag, with the same package of the EZTG, batch number 01-FZ032-03-1. The EZTG or placebo was orally administered after being dissolved in water, 3g each time, 2 times a day.
223636551|NCT05698550|DRUG|Erzhi Tiangui Placebo|The placebo consisted mainly of yellow bean powder, starch, carbogen, molasses and could mimic the appearance, color and smell of Erzhi Tiangui granules, but without any active ingredients. Daily doses of placebo were delivered in the same packaging as Erzhi Tiangui granules.
223636552|NCT01729780|DEVICE|EEG-NF|
223636553|NCT00103584|BIOLOGICAL|LC16m8 Smallpox Vaccine|
223636554|NCT00022191|DRUG|cisplatin|
223636555|NCT00022191|DRUG|gemcitabine hydrochloride|
223636556|NCT00022191|DRUG|paclitaxel|
223636557|NCT01318915|DRUG|ATG|1.5 mg/kg IV infusion on day of transplant, and 3 additional on days 2 through 7 after transplant.
223636558|NCT01318915|DRUG|Rituximab|375 mg/m\^2 IV infusion on day -6 before transplant and on day 1 after transplant.
223636559|NCT01318915|DRUG|Tacrolimus|Taken orally. Tacrolimus dose adjusted to maintain target blood levels of 6-10 ng/mL.
224225237|NCT01182233|RADIATION|Total Skeletal Irradiation|Escalating doses of TSI starting at 200cGy (escalating up to 400cGy unless maximum tolerated dose is determined in lower dose level) in cohort 1 over 5 days followed by high dose melphalan and cytoprotection followed by autologous hematopoietic stem cell transplant
224318829|NCT02988635|OTHER|Early Palliative Care|Subjects who are randomized to the Standard Oncology Care with Early Palliative Care will meet with the palliative care team at their next medical oncology or infusion visit. They will meet with the palliative care clinician at least every three weeks. They will complete questionnaire at 12 weeks after enrollment.
224318830|NCT02266537|DRUG|Tamsulosin|
223636560|NCT01318915|DRUG|Sirolimus|Taken orally. Initial dose, 2 mg daily on day 10 post-transplant, subsequently adjusted to achieve trough levels of 8-12 ng/mL through week 56. Sirolimus withdrawal will be initiated between week 56 and week 88 in eligible participants.
223636561|NCT01318915|DRUG|MMF|1 g twice daily on days 0 through 12
223636562|NCT02183662|DRUG|BI 224436|
223636563|NCT02183662|DRUG|Placebo to BI 224436|
223636564|NCT05954637|DEVICE|Optical coherence tomography|Heidelberg Engineering Spectralis
223636565|NCT00453206|PROCEDURE|allogeneic bone marrow transplantation|
223636566|NCT00453206|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
223636567|NCT00453206|PROCEDURE|nonmyeloablative allogeneic hematopoietic stem cell transplantation|
223636568|NCT00453206|PROCEDURE|peripheral blood stem cell transplantation|
223636569|NCT06184217|OTHER|Experimental group (MSPE programme group).|Experimental group. MSPE Programme. This group will receive a face-to-face mindfulness MSPE programme for 6 weeks, once a week for 1h 50min-2 hours. In addition to doing mindfulness activities at home. Each session contains the following exercises: (1) intention meditation, sultana exercise, diaphragmatic breathing and sitting meditation with a focus on breath, body and sound; (2) diaphragmatic breathing, Body Scan; (3) sitting meditation, dynamics of emotions, Mindful Yoga on the floor; (4) letting go of attachments, mindful Yoga on the floor walking meditation; (5) sports meditation, sitting meditation with a focus on breath, body and sound; (6) intention meditation, body scan analysis and review of sports meditation.
223636570|NCT06184217|OTHER|Control group (relaxation group).|These instructions included a combination of tension-relaxation of specific muscles and simple breathing techniques. They were recommended to do this on a daily basis, with a minimum of 4 sessions per week.
223636571|NCT00133783|BEHAVIORAL|intermedin|
223636572|NCT06072053|PROCEDURE|Burr Hole Craniostomy and Postoperative Exhaustive Drainage Strategy|According to the preoperative CT results, drilling and drainage was performed at the thickest level of the hematoma; during the operation, the hematoma cavity was adequately flushed with saline and a drainage tube was left in the hematoma cavity; after the operation, the hematoma cavity was flushed with urokinase, and the drainage tube was removed after adequate drainage.
223636573|NCT06072053|PROCEDURE|YL-1 puncture needle and Postoperative Exhaustive Drainage Strategy|Based on preoperative CT, the thickest level of the hematoma was selected and localized. During the operation, an electric drilling needle was used to rapidly break through the skull and dura to enter the cavity of the subdural hematoma, and the puncture needle was fixed to the skull to drain the subdural hematoma. After the operation, the hematoma cavity was flushed with urokinase, and the drainage tube was removed after adequate drainage.
223636574|NCT00121498|DRUG|Lidocaine (local anesthetics) 20 ml of 1 % subcutaneously|
223764898|NCT06505590|DEVICE|Educational content|Patients will have access to educational content on the mobile app Resilience © in the format of articles, videos or podcasts on treatment related symptoms and on validated supportive care interventions. This version is currently public available in France and Belgium at www.resilience.care and is considered the control group (education only).
223764899|NCT06505590|DEVICE|Educational material plus self-management program - self-administered version|Patients will have access to the same mobile app (Resilience ©) with its educational content will be powered with a self-guided fatigue self-management program based on a cognitive behavioral therapy approach.
224225238|NCT02912013|DEVICE|Me Mini|Home use hair removal device
224225239|NCT04383002|DRUG|Nitric Oxide|iNO will be given at 160ppm for 6 hours, once a day, for 2 days
224225240|NCT03916653|PROCEDURE|osseous resection using piezoelectric device in surgical crown lengthening|In this group piezoelectric device will be used for osseous resection in crown lengthening procedure with copious irrigation of sterile saline.
224318831|NCT02266537|DRUG|Alfuzosin|
224318832|NCT02266537|DRUG|Doxazosin|
224318833|NCT02266537|DRUG|Placebo|
224318834|NCT01382654|DRUG|epinastine 0.1%|nasal spray 2 sprays to each nostril for a total of 3 doses
223636575|NCT03429699|BEHAVIORAL|Stage-based Lifestyle Modification Intervention for the Management of Childhood Obesity|The participants will receive treatment based on nutrition clinical practice guideline for the management of childhood obesity. Participants in IG will be received a nutrition clinical practice guideline for the management of childhood obesity that comprised several activities, including nutrition counselling, aerobic sessions, a hands-on activity (healthy food preparation) and 'Sharing is Caring'. The Nutrition Practice Guideline for the Management of Childhood Obesity that comprised recommendations for assessment of nutritional status, determination of energy requirement, dietary prescriptions and physical activity modifications will be used. Participants' SOC for dietary and physical activity behaviors will be determined before any information was given to ensure that the selected educational topic will be tailored to the participant's current SOC.
223636576|NCT03429699|BEHAVIORAL|Existing practice for the management of childhood obesity|The participants will receive treatment based on the existing practice for the management of childhood obesity. Only nutritional counseling will be received by CG and standard treatment based on current practices by most dietitians in Malaysia for weight management of obese children will be used.
223636577|NCT01338740|DRUG|Adalimumab and Infliximab|Patients with moderately to severely active Crohn's disease with primary non-response or loss of response to Adalimumab switch to Infliximab.
223636578|NCT01298089|DEVICE|Carriazo Pendular microkeratome|
223636579|NCT00013533|PROCEDURE|Stem cell transplantation|\>3 x 106/kg CD34+ stem cells by IV infusion
223636580|NCT00810563|DRUG|Saline solution (laparoscopic tubal ligation)|5ml of saline solution in each portal of the trocar (2 portals)
223636581|NCT00810563|DRUG|Bupivacaine|5ml of bupivacaine 0.5% in each trocar portal
223636582|NCT03760094|DEVICE|Colour Doppler|evaluation of lymph nodes by Doppler
223636583|NCT04243564|DEVICE|Supraglottic device (SGD)|Positioning of SGD as temporary ventilatory device before tracheal intubation
223636584|NCT01933737|DEVICE|Kinesio Taping|The Kinesio Taping group (KTG) (n = 31 elderly women) were submitted to the protocol of applying Kinesio Taping for gastrocnemius muscle and the muscles of the median foot. The application of the tapes was bilateral limbs. The subjects were evaluated post-application and 48 hours after application of the tape.
223636585|NCT01933737|DEVICE|3M Micropore|The placebo tape group (PTG) (n = 31 elderly women) were submitted to the protocol of applying placebo tape (3M Micropore) for gastrocnemius muscle and the muscles of the median foot in the same way that KTG. The application of the tapes was bilateral limbs. The subjects were evaluated post-application and 48 hours after application of the tape.
223636586|NCT01629264|DEVICE|Ocular Response Analyzer|To measure corneal biomechanics, specifically corneal hysteresis (CH) and the Corneal Resistance Factor (CRF). The devise measures in a non-contact manner, by analyzing the deformation of the cornea upon a defined pulse of air.
223636587|NCT01629264|DEVICE|Scheimpflug measurement|A Scheimpflug camera will be used in a non-contact manner to assess topographical data from the anterior and posterior corneal surface as well as detailed data on corneal thickness.
223636588|NCT01629264|OTHER|Blood sample|A blood sample will be taken at 6 months after surgery to determine the levels of several hormones. The blood needed to détermine hormone levels during pregnancy will be acquired during the routine examinations that are performed during pregnancy. Here, blood is taken routinely and an additional volume is taken for the purpose of this study.
224225241|NCT03916653|PROCEDURE|Osseous resection using conventional rotary instruments in surgical crown lengthening|For osseous resection in crown lengthening procedure, conventional rotary instruments will be used with copious irrigation of sterile saline.
224225242|NCT00423956|PROCEDURE|Repairing Induced tooth root resorption by ultrasound|Repairing Induced tooth root resorption by ultrasound
224318835|NCT01382654|DRUG|epinastine 0.1% with taste masking agent|nasal spray 2 sprays to each nostril for a total for a 3 doses
224318836|NCT01382654|DRUG|epinastine 0.2%|nasal spray 2 sprays to each nostril for a total of 3 doses
223636589|NCT03026595|OTHER|no intervention|no intervention
223636590|NCT05471323|BIOLOGICAL|RC1012 injection (allo-DNT cells)|RC1012 injection (allo-DNT cells) from healthy donors and have been proved to be safe and demonstrated potent cytotoxicity against AML blasts from AML patients in preclinical and preliminary clinical studies. Allo- DNT cells will be collected from healthy donors (NO MHC match needed) and injected into patients. The drug for this study is an off-the-shelf product. Patients DO NOT need to wait for the cell manufacturing.
223636591|NCT00107341|DRUG|bortezomib|
224318837|NCT01382654|DRUG|epinastine 0.2% with taste masking agent|nasal spray 2 sprays to each nostril for a total of 3 doses
224318838|NCT01382654|DRUG|azelastine 0.1%|nasal spray 2 sprays to each nostril for a total of 3 doses
223636592|NCT00107341|DRUG|carboplatin|
223636593|NCT00107341|DRUG|paclitaxel|
223636594|NCT00306501|PROCEDURE|Swallowing Training|Swallowing Training with press of button
224225243|NCT02269215|DRUG|BIII 890 CL|
224225244|NCT02269215|DRUG|Placebo|
224225245|NCT00600197|BEHAVIORAL|back school|A kind of educational program for low back pain
224225246|NCT02482805|BEHAVIORAL|Cognitive Behavioral Therapy|Exposure therapy for social anxiety disorder
224225247|NCT00440154|DRUG|AVE5530|
224225248|NCT00440154|DRUG|placebo|
224225249|NCT00440154|DRUG|ezetimibe|
224225250|NCT02314533|DRUG|fenofibrate|Fenofibrate (Lipanthyl®) 200mg capsule will be administered orally with breakfast once daily
224225251|NCT00879554|BIOLOGICAL|CVX-045|Weekly, intravenous dose
224225252|NCT05163509|COMBINATION_PRODUCT|Unity-based MR-Linac guided Radiotherapy|The radiotherapy was delivered using the Unity-based MR-Linac treatment machine.
224318839|NCT01864395|PROCEDURE|Centrifugation Method|Currently used to separate whole blood into red blood cells (RBCs) and plasma components. The RBCs are washed with normal saline and re-infused into the patient, while the plasma portion is discarded.
224318840|NCT01864395|PROCEDURE|Online MUF|Hemofilter is used online while the heart-lung machine is connected to the patient.
224318841|NCT01864395|PROCEDURE|Offline MUF|Hemofilter is used offline when the heart-lung machine is not connected to the patient.
224318842|NCT01909063|DIETARY_SUPPLEMENT|Vitamin D|Fortification of orange juice with 200 IU vitamin D to be drunk twice per day for 12 weeks
224318843|NCT01909063|DIETARY_SUPPLEMENT|Vitamin D, Vitamin E, and Vitamin A|Fortification of orange juice with Vitamin D, Vitamin E, and Vitamin A to be drunk twice per day for 12 weeks
224225253|NCT02917447|BEHAVIORAL|DESTRESS-WV|This is an online intervention for PTSD tailored for women Veterans. The intervention is based on cognitive behavioral therapy (CBT). The goal of CBT is to help people recognize and address their thoughts and behaviors in positive ways with the aim of improving their ability to function as well as possible in their lives. Participants will be asked to log on to the website twice per week for about 30-60 minutes each time. Homework assignments will include stress management skills that participants will be asked to practice and apply. A study coach will call each participant once a week for 8 weeks for about 15 minutes to review their progress with the program.
224225254|NCT02917447|BEHAVIORAL|Phone Monitoring|A study coach will call participants once a week for 8 weeks for approximately 15 minutes. The coach will assess participants' PTSD symptoms and safety. She will encourage participants to use the time on the call to discuss any current life issues or problems that they would like. Active listening and rephrasing will be used, while teaching cognitive-behavioral strategies will be avoided.
224225255|NCT02934295|BIOLOGICAL|Determination of Anti-Rubella Antibody, E1|
224225256|NCT04590469|OTHER|COVID WHELD|COVID WHELD is a COVID-19 adapted version of an established nursing home training intervention that confers benefits in well-being and neuropsychiatric symptoms for people with dementia. The adaptations include the development of digital resources to support the programme and virtual coaching.
224225257|NCT01144663|BIOLOGICAL|Nimenrix™|4- or 3-dose intramuscular injection
224225258|NCT01144663|BIOLOGICAL|Menjugate®|3-dose intramuscular injection
224225259|NCT01144663|BIOLOGICAL|NeisVac-CTM|3-dose intramuscular injection
224225260|NCT01144663|BIOLOGICAL|Infanrix™ hexa|4-dose intramuscular injection
224225261|NCT01144663|BIOLOGICAL|Synflorix™|4-dose intramuscular injection
224225262|NCT03557138|BEHAVIORAL|alpha-Methyl-4-deoxy-4-[(18)F]fluoro-D-glucopyranoside|positron emission tomography and magnetic resonance imaging (PET/MRI) of kidneys of diabetic patients using alpha-Methyl-4-deoxy-4-\[(18)F\]fluoro-D-glucopyranoside (Me4FDG)
224225263|NCT05389410|DEVICE|PICO 7|Participant will receive 7 days of NPWT following revision hip or revision knee surgery.
224225264|NCT05389410|DEVICE|PICO 14|Participant will receive 14 days of NPWT following revision hip or revision knee surgery.
224225265|NCT06214377|DEVICE|Active Transcranial Direct Current Stimulation|The Starstim tCS® equipment will be used, with 35 cm2 sponge electrodes. The tDCS over M1 will be performed by placing the active anode on the C3 point (10/20 EEG system) and the cathode on the contralateral supraorbital area (Fp2). Regarding the stimulated hemisphere, in cases of asymmetric pain, it will be applied to the contralateral M1, and in cases of bilateral pain, it will be applied to the M1 of the dominant hemisphere. A constant current of 2 mA (subthreshold intensity) will be applied for 20 minutes, with the first 30 seconds used as a ramp-up and the last 30 seconds as a ramp-down. Number of sessions: 1.
224225266|NCT06214377|DEVICE|Sham Transcranial Direct Current Stimulation|The Starstim tCS® equipment (Neuroelectrics Inc, Barcelona, Spain) will be used with 35 cm2 sponge electrodes. The tDCS sham over M1 will be performed by placing the electrodes in the same position as in the active tDCS protocol. However, the stimulator will automatically turn off after 30 seconds of stimulation, making it a reliable sham stimulation method. Therefore, subjects will feel the same tingling sensation but will not receive current for the remainder of the stimulation time.
224225267|NCT06214377|DRUG|Dopaminergic medication|After tDCS, the participant will take their regular dopaminergic medication in order to go from OFF state to ON state.
224225268|NCT03775395|DRUG|Lenvatinib|12 mg (or 8 mg) once daily (QD) oral dosing.
223636595|NCT01236209|OTHER|Webpage|one arm having access to a webpage with information about coping with pain and relaxation exercises
223636596|NCT01236209|OTHER|Webpage and situation feedback|having access to the same web-page with information about coping with pain and relaxation relaxation and completing 3 diaries and receiving situational feedback for 4 weeks at home through a web enabled mobile phone.
223636597|NCT03779009|OTHER|ICG-nanocoll (indocyanine green coupled to the human albumin colloidal particle nanocoll)|Under laparoscopic control, 2.0 ml of ICG-nanocoll will be injected into the subserosa at four quadrants around the tumor. Directly after injection, near infrared (NIR) fluorescence images (Olympus, Tokyo, Japan) will be acquired. SLNs will be identified and marked.
223636598|NCT05386329|BEHAVIORAL|Mindset: Therapist-guided smartphone-delivered CBT|All participants will receive the app-delivered CBT, including modules such as cognitive skills (e.g., cognitive restructuring, core belief work), behavioral skills (e.g., activity scheduling), and mindfulness. Therapists will also conduct brief weekly virtual appointments with participants.
223636599|NCT02008799|PROCEDURE|Bone marrow stem cell injection|Injection should be in testis and testicular artery
223636600|NCT02507232|DEVICE|NovoTTF-200A|12 cycles
223636601|NCT02507232|DRUG|Temozolomide|50 mg/m2/day rounded to the nearest 5 mg. One cycle is 28 days and will be given for 12 cycles
223636602|NCT03094325|DEVICE|Pre Operative On-pump intraoperative echocardiography|Center tendency parameters(mean, standard deviation) will be reported for each outcome.
223636603|NCT03094325|DEVICE|Pre Operative Transesophageal echocardiography (TEE) imaging|Center tendency parameters(mean, standard deviation) will be reported for each outcome.
223636604|NCT03094325|DEVICE|Post Operative On-pump intraoperative echocardiography|Center tendency parameters(mean, standard deviation) will be reported for each outcome.
224225269|NCT03775395|DRUG|Sorafenib|400mg BID daily oral dosing
224225270|NCT03775395|PROCEDURE|Hepatic arterial infusion chemotherapy|administration of Oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries
224225271|NCT03492073|BEHAVIORAL|Emotional Supportive Mindfulness-based Program|Mindfulness training
224225272|NCT03492073|BEHAVIORAL|Emotional Supportive Program|Narrative-orientated therapy.
224225273|NCT00002582|DRUG|CMF regimen|
224225274|NCT00002582|DRUG|cyclophosphamide|
224225275|NCT00002582|DRUG|doxorubicin hydrochloride|
224225276|NCT00002582|DRUG|fluorouracil|
224225277|NCT00002582|DRUG|goserelin acetate|
224225278|NCT00002582|DRUG|leuprolide acetate|
224225279|NCT00002582|DRUG|methotrexate|
224225280|NCT00002582|DRUG|tamoxifen citrate|
224225281|NCT00002582|PROCEDURE|oophorectomy|
224225282|NCT00002582|RADIATION|radiation therapy|
224225283|NCT00708929|PROCEDURE|Squatting|Squatting for 6 minutes
224225284|NCT04376723|OTHER|Mental Health Mobile Application|Mobile phones will not be provided to participants, but app subscriptions will be provided.
223636605|NCT03094325|DEVICE|Post Operative Transesophageal echocardiography (TEE) imaging|Center tendency parameters(mean, standard deviation) will be reported for each outcome.
223636606|NCT05471466|PROCEDURE|Surgical incision|Surgical incisions to the neck as part of the management of the head and neck condition.
223636607|NCT03041181|DRUG|Docetaxel|Docetaxel 75 mg/m2 IV Day 1 of each cycle (21 days = 1 cycle)
223636608|NCT03041181|DRUG|Nivolumab|Nivolumab 360 mg IV Day 1 of each cycle (21 days = 1 cycle)
223636609|NCT03041181|DRUG|Gemcitabine|Gemcitabine 1000 mg/m2 IV Day 1 and Day 8 of each cycle (21 days = 1 cycle)
223636610|NCT03041181|DRUG|Pemetrexed|Pemetrexed 500 mg/m2 IV Day 1 of each cycle (21 days = 1 cycle)
224225285|NCT06544213|BEHAVIORAL|Control Group|60 days of strict head down tilt bed rest at all time. No countermeasure program is performed.
223636611|NCT01850121|DRUG|Infliximab|5 mg/kg every 6 weeks during the first year and 3 mg/kg every 8 weeks during the second year. Concomitant treatment with methotrexate 7.5 mg/week.
223636612|NCT01547611|OTHER|Customary treatment|The staff at the Neurosurgical clinic will give the patient ordinary pre- and postoperative information. The physiotherapist at the Neurosurgical clinic informs the patients what to avoid the first weeks after surgery and the importance of a good posture and ergonomic thinking in daily life. The patient is also instructed how to do exercises for the shoulder range of motion. Patients have ordinary post-surgery visit to the surgeon and to the physiotherapist about 6 weeks after the surgery, where physiotherapist instructs the patient in exercises for active neck range of motion.
223636613|NCT01547611|OTHER|Structured behavioural medicine program|The behavioural medicine program includes functional behavioural analysis of the problem, medical exercise therapy, strategies to increase self-efficacy in activities and problem-solving strategies for coping with disability.
223636614|NCT06173687|DEVICE|The impedance measurement task using the Mobile Research App (MRA)|Characterisation of impedance and real-world monitoring of hearing difficulty in range of listening environments.
223636615|NCT04500366|BEHAVIORAL|Socialization|Social interaction is associated with better mental and physical health, and evidence suggests that group versus individual engagement may offer unique cognitive benefits for older adults as well as peer reinforcement and encouragement.
223636616|NCT04500366|BEHAVIORAL|Virtual Group Exercise|Participants will receive twice-weekly (one hour per class) virtual exercise via small-group physiotherapy sessions for a total of 12 weeks. All exercise sessions will occur virtually via a videoconferencing system. The classes will focus on functional movements specifically designed for seniors with frailty and mobility challenges, and will include modifications for gait aids such as canes or walkers. Class sizes will be small to allow for tailoring of exercises based on challenging, safe, progressive, evidence-based exercises. In accordance with recent guidelines to achieve 3 hours/week for fall prevention practice in older adults, participants will also be provided with tailored supplemental home exercises developed by the study physiotherapist to gain an additional 1 hour of physical activity.
223636617|NCT04500366|COMBINATION_PRODUCT|Nutrition Consult and Protein Supplementation|"Nutrition Consult: Participants will be scheduled for a one-on-one virtual nutrition consult. During the consultation, study staff will assess the nutritional status of the participant and will provide them with counselling and coaching to improve their nutrition.~Protein Supplementation: Oral nutrition supplements commercially available from Nestle will be provided unless contraindicated. The oral nutrition supplement contains 360 calories and 14 grams of protein per serving. Participants are advised to take this with a meal or within 3 hours of exercise on activity days."
223636618|NCT04500366|BEHAVIORAL|Medication Review|A study pharmacist will review the participant's medication list and will utilize Beers and/or START/STOPP criteria to provide recommendations to optimize/update their medications to the participant's healthcare provider. Study geriatricians will be listed as contacts on the primary care provider recommendations and available for consultation.
223636619|NCT00000794|DRUG|Sulfadiazine|
223636620|NCT00000794|DRUG|Clarithromycin|
223636621|NCT00000794|DRUG|Atovaquone|
223636622|NCT00000794|DRUG|Pyrimethamine|
223636623|NCT00000794|DRUG|Leucovorin calcium|
223636624|NCT02712346|DRUG|Ambrisentan|Ambrisentan 5 milligrams a day or a placebo (sugar pill) for twelve weeks
223636625|NCT02712346|DRUG|Placebo|One inactive pill daily for twelve weeks
223636626|NCT03396796|PROCEDURE|Vagus nerve-preserving group|The modified vagus nerve-preserving procedure was performed in the following order: (1) left gastroepiploic vein along greater curvature; (2) the posterior surface of stomach, including the posterior gastric veins; (3) the left lateral surface of the distal esophagus; (4) the left inferior phrenic veins; (5) the posterior surface of the distal esophagus;(6) the anterior surface of the distal esophagus; and (7) the right lateral surface of the distal esophagus. The hepatogastric ligament was conserved. the adherent junction between visceral peritoneum and the right crural diaphragm, and divided it into the lesser omental sac. The left gastric artery and vein and the posterior gastric veins were transected en bloc using a linear laparoscopic vascular stapler.
223636627|NCT02174965|DEVICE|MiniHip (Corin U.K.)|MiniHip (Corin U.K.) femoral component
223636628|NCT02174965|DEVICE|Metafix (Corin, U.K)|Metafix (Corin, U.K) conventional cementless stem
223636629|NCT03104868|BEHAVIORAL|TAKE IT Strategy|"The TAKE IT Strategy includes:~1. Programming the electronic health record (EHR) to organize/simplify daily regimen schedules and generate electronic, tangible, print, low literacy medication education materials at every clinical encounter.~2. SMS text-messaging to remind patients when to take all their medicine.~3. A web-based patient portal that requests patients to periodically report upon their medication use, providing a continuous link between the transplant center and patient beyond routine in-person visits.~4. EHR notifications directed to the transplant center nurse coordinator if an adherence-related problem is identified by the web-based portal assessment, who then can activate appropriate staff to respond."
224225286|NCT06544213|BEHAVIORAL|Countermeasure Supine Bike|"60 days of strict head down tilt bed rest at all time. The exercise starts at 40% of VO2max for 5 minutes, followed by a series of 2-minute high- and low-intensity intervals for 20 minutes. 2-minute high-intensity intervals are at 65% VO2max, 70% VO2max, 80% VO2max, 80% VO2max, 70% VO2max and 65% VO2max. 2-minute low-intensity intervals are at 40% VO2max. 3 minutes at 40% of VO2max will end the exercise.~VO2max is measured for each volunteer in supine position."
224318844|NCT01909063|DIETARY_SUPPLEMENT|Control, 700 mg Calcium|Orange juice with 700 mg calcium to be drunk twice per day for 12 weeks
224225287|NCT06544213|BEHAVIORAL|Countermeasure AG-Bike|"60 days of strict head down tilt bed rest at all time. The exercise starts at 40% of VO2max for 5 minutes, followed by a series of 2-minute high- and low-intensity intervals for 20 minutes. 2-minute high-intensity intervals are at 65% VO2max, 70% VO2max, 80% VO2max, 80% VO2max, 70% VO2max and 65% VO2max. 2-minute low-intensity intervals are at 40% VO2max. 3 minutes at 40% of VO2max will end the exercise.~VO2max is measured for each volunteer in supine position.~The supine bike exercise is performed in a short arm centrifuge in rotation. Volunteers will start pedalling and the centrifuge will start at 0.15 Gz less than individual's threshold.~Every 4 minutes thereafter, the AG will be increased by 0.15 Gz, synchronized with the ramping up of cycle ergometer interval intensity. The AG will increase only up to 70 % of their tolerance level,.~It will then decrease by 0.15 Gz every 4 minutes, and until the 30-minute exercise is completed."
223636630|NCT01359488|DRUG|VRS-317|VRS-317 Single Dose
224225288|NCT05702359|OTHER|Glucose as reference food|Eleven healthy, normal body weight subjects after 10-14hr fast, consumed 50g glucose diluted in 300mL water, tested two times, in different visits, within 5-10 min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90, 120, 150 and 180 min. Salivary insulin samples were taken at baseline, 15, 30, 45, 60, 90, 120, and 180 min.
224225289|NCT05702359|OTHER|Control juice|Eleven healthy, normal body weight subjects after 10-14hr fast, consumed 50g available carbohydrates from control juice (consisted of pomegranate, grape, apple and orange), tested once, within 5-10 min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90, 120, 150 and 180 min. Salivary insulin samples were taken at baseline, 15, 30, 45, 60, 90, 120, and 180 min.
224225290|NCT05702359|OTHER|Juice with vitamin D3|Eleven healthy, normal body weight subjects after 10-14hr fast, consumed 50g available carbohydrates from juice (consisted of pomegranate, grape, apple and orange) containing vitamin D3, tested once, within 5-10 min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90, 120, 150 and 180 min. Salivary insulin samples were taken at baseline, 15, 30, 45, 60, 90, 120, and 180 min.
224225291|NCT05702359|OTHER|Juice with n-3 fatty acids|Eleven healthy, normal body weight subjects after 10-14hr fast, consumed 50g available carbohydrates from juice (consisted of pomegranate, grape, apple and orange) containing n-3 fatty acids, tested once, within 5-10 min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90, 120, 150 and 180 min. Salivary insulin samples were taken at baseline, 15, 30, 45, 60, 90, 120, and 180 min.
224225292|NCT05702359|OTHER|Juice with probiotics|Eleven healthy, normal body weight subjects after 10-14hr fast, consumed 50g available carbohydrates from juice (consisted of pomegranate, grape, apple and orange) containing probiotics, tested once, within 5-10 min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90, 120, 150 and 180 min. Salivary insulin samples were taken at baseline, 15, 30, 45, 60, 90, 120, and 180 min.
224225293|NCT05702359|OTHER|Juice with probiotics, vitamin D3, and n-3 fatty acids|Eleven healthy, normal body weight subjects after 10-14hr fast, consumed 50g available carbohydrates from juice (consisted of pomegranate, grape, apple and orange) containing probiotics, vitamin D3 and n-3 fatty acids, tested once, within 5-10 min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90, 120, 150 and 180 min. Salivary insulin samples were taken at baseline, 15, 30, 45, 60, 90, 120, and 180 min.
224225294|NCT02889328|DRUG|Regorafenib|Regorafenib 100mg continuous dosing arm
224225295|NCT03287050|DRUG|Pembrolizumab|200 mg IV q 21 days
224225296|NCT03287050|RADIATION|SBRT|Stereotactic body radiation therapy (SBRT) that will commence not later than the initiation of the second cycle of pembrolizumab. SBRT dose and fractionation will be at the discretion of the treating radiation oncologist, and will be selected to respect the normal tissue tolerance of adjacent organs at risk.
224225297|NCT00623025|DRUG|Creon 25000|6 to 9 capsules Creon 25000 per day
224225298|NCT00623025|DRUG|Placebo|6 to 9 capsules placebo per day
224225299|NCT02497391|DRUG|Evacetrapib|administered orally
223636631|NCT01359488|DRUG|VRS-317|VRS-317 Single Dose
223636632|NCT01359488|DRUG|VRS-317|VRS-317 Single Dose
223636633|NCT01359488|DRUG|VRS-317|VRS-317 Single dose
223636634|NCT01359488|DRUG|VRS-317|VRS-317 Single dose
223636635|NCT00657319|DRUG|biphasic insulin aspart 30|The observation is performed under normal clinical practice conditions without any additionally required diagnostic/therapeutic features. Physicians are allowed to decide the treatment regimen according to the medical standards.
223636636|NCT01849510|RADIATION|hypofractionated 12x3 Gy + integrated boost 12x4 Gy|hypofractionated, homogeneous radiation (12x3 Gy) with simultaneously administrated, integrated boost (12x4 Gy) mediated by IGRT \& hfSRT
223636637|NCT01849510|RADIATION|hypofractionated 10x3 Gy|hypofractionated, homogeneous radiation (10x3 Gy)
223636638|NCT00548665|DEVICE|Carotid ultrasound for plaque screening|Carotid ultrasound for plaque screening
223636639|NCT00548665|BEHAVIORAL|Brief advice for smoking cessation|We will use the 5A's heuristic (Ask about smoking, Advise on cessation, Assess willingness to change, and for those willing to make quit attempt: Assist with attempt to quit, and Arrange for follow-up) and the gold standard for brief smoking cessation advice. At each visit, smokers will receive smoking cessation counseling and nicotine replacement therapy, similar to the experimental group.
223636640|NCT00003574|PROCEDURE|surgical procedure|
223636641|NCT00003574|RADIATION|brachytherapy|
223636642|NCT00003574|RADIATION|intraoperative radiation therapy|
223636643|NCT00003574|RADIATION|iodine I 125|
223636644|NCT04757506|DRUG|Naltrexone|opioid receptor antagonist
223636645|NCT04757506|DRUG|Placebo|
223636646|NCT02362815|OTHER|Apple juice|Intervention consists in allowing drinks during labour
223636647|NCT04789603|OTHER|6-min-walk surgical mask|To walk as fast as possible without running for 6 minutes with surgical mask
223636648|NCT04789603|OTHER|6-min-walk Fpp2|To walk as fast as possible without running for 6 minutes with Fpp2 mask
223636649|NCT04789603|OTHER|6-min-walk without mask|To walk as fast as possible without running for 6 minutes without mask
223636650|NCT04545749|BIOLOGICAL|UB-612|UB-612 is a proprietary high-precision designer S1-RBD-protein based vaccine incorporating a Th/CTL epitope peptide pool which could bind to human MHC-I and MHC-II to activate T cells.
223636651|NCT05958901|OTHER|pulmonary hypertension|The final outcome observed was a diagnosis of pulmonary hypertension.
223636652|NCT01292135|DRUG|PCI-32765|420 mg daily
223636653|NCT00566436|PROCEDURE|Remote endarterectomy of the superficial femoral artery|Exposure of the common femoral, superficial femoral and profunda femoral artery through a single groin incision. Arteriotomy in the proximal SFA followed by dissection of the intima core beyond the occluded segment using the Vollmar ringstripper. The ringstripper is exchanged for a Mollring cutter all under fluoroscopic guidance. With the Mollring Cutter transection of intima core is carried out, remote from the site of entry. After removal of the intima core the transection zone is secured with an aSpire stent after balloon angioplasty. A completion arteriography will verify a patent artery, and embolectomy can be performed when necessary. As indicated a common femoral artery and profundaplasty can be performed and the arteriotomy may be closed with or without patch.
223636654|NCT00566436|PROCEDURE|Suprageniculate femoropopliteal bypass|Groin and suprageniculate incision, venous (Saphenous vein) or PTFE graft with end to side anastomoses. If the saphenous vein is truly applicable for grafting will ultimately be an intra-operative decision (despite pre-operative venous mapping)
223636655|NCT02769923|DEVICE|Westpharma ID adapter|device used for administering intradermal injection
223636656|NCT02769923|DEVICE|Star ID syringe|device used for administering intradermal injection
223636657|NCT02769923|DEVICE|BCG NS|syringe used for administering intradermal injection
223636658|NCT04696484|BEHAVIORAL|coopeRATE Prompt|The coopeRATE Prompt intervention is a set of two questions delivered to patients before the clinical encounter that elicit their concerns and goals. The intervention is delivered to patients online, outside the clinic setting.
223636659|NCT03050801|DEVICE|rTMS|Altering the connectivity of trans-synaptic pathways
223636660|NCT03817164|DEVICE|Autonomic Nerve Modulation - Active|Thync ANM is a portable, battery-powered, electrical neuromodulation device connected to single-use gel electrode pads that are applied to the base of the neck.
223636661|NCT03817164|DEVICE|Autonomic Nerve Modulation - Control|Thync ANM is a portable, battery-powered, electrical neuromodulation device connected to single-use gel electrode pads that are applied to the base of the neck.
223636662|NCT00005780|DRUG|EPOCH-R|EPOCH-R for 6 cycles
223636663|NCT00005780|BIOLOGICAL|GM-CSF|Granulocyte-macrophage colony-stimulating factor (GM-CSF) monthly with the vaccine for 5 doses
223636664|NCT00005780|BIOLOGICAL|Idiotype vaccine|1 injection of vaccine monthly for 5 doses
223636665|NCT05656417|BEHAVIORAL|Temporary cessation of all oral hygiene|Participants will refrain from all oral hygiene for 3 weeks.
224225300|NCT01470794|BIOLOGICAL|Toca 511 vector|All patients will receive Toca 511, a retroviral replicating vector that expresses the cytosine deaminase (CD) gene. CD converts the antifungal 5-FC to the anti-cancer drug 5-FU in cells that have been infected by the Toca 511 vector. Beginning approximately 6 weeks after administration of Toca 511, patients will begin courses of oral Toca FC at pre-specified intervals, depending on cohort, during the approximately 30 week study.
224225301|NCT01470794|DRUG|Toca FC|
224225302|NCT01555281|DRUG|Nelfinavir|In phase II, the recommended dose of nelfinavir will be administered orally twice daily (in the morning and in the evening) on d1-d21 every 28 days for a maximum of 4 cycles
224225303|NCT01555281|DRUG|Lenalidomide|25 mg of lenalidomide (capsules) will be administered orally daily on d1-d21 every 28 days for a maximum of 4 cycles
224225304|NCT01555281|DRUG|Dexamethasone|40 mg (for patients \<75 years) or 20 mg (for patients ≥75 years) of dexamethasone (tablets) will be administered orally once per day on d1, 8, 15 and 22 every 28 days for a maximum of 4 cycles
223636666|NCT03520881|OTHER|Pediatric ASTHMA-Educator mobile application|This intervention represents a mobile application (accessible by iOS and Android devices) that provides asthma education through games and videos.
223636667|NCT02249364|PROCEDURE|Control|Routine practice
223636668|NCT02249364|PROCEDURE|Hypnosis|Hypnosis session before induction of anesthesia
223636669|NCT02249364|DRUG|propofol|Closed-loop administration of propofol for anesthesia induction
223636670|NCT00822614|DRUG|Fentanyl TAIFUN|Inhalation of Fentanyl via TAIFUN inhaler
223636671|NCT00822614|DRUG|Opioid|Current optimized BTP treatment
224225305|NCT03657199|DIAGNOSTIC_TEST|Cardiac computed tomography|Routine computed tomography of the heart before discharge
224225306|NCT04160078|BEHAVIORAL|Mindfulness-based stress reduction (MBSR) Intervention|"* 1-hour session on sleep hygiene and 7-week follow up using a mindfulness app, an app that features guided meditation and can be used to assess adherence.~* Sleep log diary: self report of sleep records~* Wrist Actigraphy, to monitor sleep patterns. Participants will be instructed on wearing the sleep monitor (Spectrum, Philips Respironics, Murrysville, PA) on their non-dominant wrist for the next 7-weeks"
224225307|NCT03401645|OTHER|Wrist Alarm|Wrist device with alarm timer
224225308|NCT03401645|BEHAVIORAL|Home-based Arm and Hand Exercise|Repeated visuomotor tasks, unilateral arm and hand movements, bilateral arm and hand movements
224318845|NCT03303209|OTHER|Patient-centered opioid tapering protocol|All patients who entered the study agreed to partner with their pain physician on a patient-centered opioid tapering program. The research component of the study was to observe patient response (in terms of change in MEDD and pain intensity) at month 4.
224318846|NCT01589497|DRUG|Rifampicin|Participants with body weight \</= 50kg were administered one 450 mg tablet orally once daily. Participants with body weight \>50kg were administered one 600 mg tablet orally once daily.
223636672|NCT03987360|OTHER|Observational|Participants who attended different educational and cultural activities either in a community centers or public institutions like arts museums or universities.
223636673|NCT02803788|DRUG|ramosetron, ondansetron, dexamethasone|prevention of post-operative nausea vomiting
223636674|NCT01131975|DRUG|Lamotrigine|Lamotrigine Tablets (chewable, dispersible), 25 mg
223636675|NCT03340389|PROCEDURE|a ray-tracing aberrometry|The Dysfunctional Lens Index is obtained by a ray-tracing aberrometry
223636676|NCT03600909|DRUG|Busulfan|"A standard dose of busulfan, associated with excellent outcomes in our previous trial will be used for young patients with marrow aplasia (arm A).~A higher dose of busulfan will be used in younger patients with MDS and AML (arm B) to maximize disease control.~A lower dose of busulfan will be used in older patients (arm C) to minimize toxicity."
224318847|NCT01589497|DRUG|Isoniazid|Participants were administered three 100 mg tablets or one 300 mg tablet once daily.
223636677|NCT03600909|DRUG|Fludarabine|Arms A, B and C - Fludarabine will be given IV over 30 minutes daily for 4 days. The dose will be adjusted according to renal function according to Institutional guidelines.
223636678|NCT03600909|DRUG|Cyclophosphamide|Arms A, B and C - Cytoxan will be given as a 1-2 hour infusion for 4 days. The dose will be adjusted according to patients ideal body weight for obese patients.
223636679|NCT03600909|DRUG|Anti-Thymocyte Globulin (Rabbit)|Arms A, B and C - 4 doses will be given prior to transplant to promote engraftment
223636680|NCT03600909|DEVICE|The CliniMACS device|The source of stem cells for all patients will be peripheral blood stem cells (PBSC) induced and mobilized by treatment of the donor with G-CSF for 4-6 days. T-cell depletion will be uniformly performed by positive CD34 selection with the use of the Miltenyi system (CliniMACS device)
223636681|NCT03600909|DRUG|G-CSF|All patients will also receive G-CSF post-transplant to foster engraftment.
223636682|NCT03667274|PROCEDURE|cardiac valve surgery|cardiac double valve surgery (aortic and mitral valve)
223636683|NCT05763043|DRUG|Ferric derisomaltose|Participants between the gestational ages of 14 to 42 weeks with iron deficiency will receive IV Ferric derisomaltose at a routine prenatal visit.
223636684|NCT03002961|DRUG|RBP-6000|single dose of RBP-6000, preceded by a pharmacokinetic (PK) sample followed by serial PK samples post-dose. Additionally subjects to remain in the clinic through Day 21 for safety assessments
223636685|NCT03002961|DRUG|Suboxone|RBP-6000 injection after 7 days of SL Suboxone administration. Interventions as above with additional daily PK collections during Suboxone treatment prior to RBP-6000 administration
223636686|NCT02651675|GENETIC|AAV directed hLDLR gene therapy|AAV directed hLDLR gene therapy is a novel adeno-associated viral (AAV8) vector with human low-density lipoprotein receptor (hLDLR) gene
223636687|NCT03674411|DRUG|Fludarabine (FLU)|25 mg/m2 IV over 1 hour (\<10 kg: 0.83 mg/kg IV over 1 hour)
224225309|NCT05773079|DRUG|Toripalimab|Within 4 to 12 weeks after the first line of treatment, the maintenance treatment of Toripalimab was started, and 240 mg of Toripalimab was injected intravenously every 3 weeks (the maintenance treatment time was not more than 1 year, until there was an intolerable toxic reaction, or disease progression, or withdrawal of consent, or the investigator judged that it was necessary to withdraw from the treatment, or the subject had received treprizumab treatment for a cumulative period of 1 year or other reasons specified in the protocol). During the treatment period, tumor imaging evaluation shall be conducted every 3 months to see the research process description for details, and the evaluation shall be conducted according to the evaluation criteria of recist. If the evaluation is progress, the treatment shall be stopped.
224225310|NCT03940001|BIOLOGICAL|Sintilimab|Other Name: (IBI308)
224225311|NCT03940001|DRUG|carboplatin/paclitaxel|carboplatin AUC 2/paclitaxel 50 mg/m2 weekly
224225312|NCT03940001|RADIATION|Radiation|IMRT or VMAT
224225313|NCT05852782|OTHER|White Light therapy|Participants will be exposed to broadband light for one hour
224225314|NCT05852782|OTHER|Blue light therapy|Participants will be exposed to blue light for one hour
223636688|NCT03674411|DRUG|Cyclophosphamide (CY)|60 mg/kg IV over 2 hours
223636689|NCT03674411|DRUG|Total Body Irradiation (TBI)|165 cGy twice daily
223636690|NCT03674411|DRUG|Tacrolimus (Tac)|Tacrolimus will start day -3 and will be administered as a continuous IV infusion at a starting dose of 0.03 mg/kg/day. Goal trough levels will be 10-15 ng/mL for the first 14 days post-transplant and then decreased to a goal of 5-10 ng/ml thereafter.
224225315|NCT05852782|OTHER|Red light therapy|Participants will be exposed to re light for one hour
224225316|NCT05852782|OTHER|Darkness|Participants will be in complete darkness for one hour
224225317|NCT00397319|DRUG|Growth Hormone|
224225318|NCT00783679|DEVICE|NICO device|"Measurement of cardiac output and simultaneous blood sampling.~The subjects' cardiac output will be measured by NICO device and also by thermodilution method. Simultaneously blood samples will be drawn from the pulmonary artery catheter and arterial line. The calculated and measured cardiac output values will be compared for accuracy."
224225319|NCT04561310|OTHER|Post facilitation stretch|"Post facilitation stretch with maitland mobilization Grade I \& II Maitland mobilization of shoulder joint in 1st and 2nd week progressing to Grade III oscillatory mobilization of shoulder joint in 3rd week. It will further progress to Grade IV Maitland oscillatory mobilizations in the 4th or 5th week.~Treatment will be provided 3 session/week for 6 weeks with 40 minutes/session"
224225320|NCT04561310|OTHER|Active release technique|"Active release technique with maitland mobilization Grade I \& II Maitland mobilization of shoulder joint in 1st and 2nd week progressing to Grade III oscillatory mobilization of shoulder joint in 3rd week. It will further progress to Grade IV Maitland oscillatory mobilizations in the 4th or 5th week.~Treatment will be provided 3 session/week for 6 weeks with 40 minutes/session"
224225321|NCT03306056|OTHER|Control|Individualized, weight-reducing nutritional therapy and counseling, during a study period of 12 weeks
223636691|NCT03674411|DRUG|Mycophenolate Mofetil (MMF)|MMF 3 gram/day IV/PO for adult patients divided in 2 or 3 doses. Pediatric patients will receive MMF at the dose of 15 mg/kg/dose (max 1 gram per dose) every 8 hours beginning day -3.
223636692|NCT03674411|DRUG|Granulocyte Colony-Stimulating Factor (G-CSF)|5 ug/kg/d until the absolute neutrophil count (ANC) is \>2500/uL for 2 consecutive days
223636693|NCT03674411|DRUG|Busulfan (BU)|BU IV once daily with dose based on Pharmacokinetics (PK) calculator over 3 hours
223636694|NCT03674411|DRUG|Melphalan|50 mg/m2/day (1.7 mg/kg/day if \< 10 kg) IV over 30 min
223636695|NCT03674411|DRUG|MGTA 456 Infusion|The target cell dose is \>10 x 106 CD34/kg with a maximum TNC 2.7 x 108/kg for children (\<18 years) and 8.1 × 108 cells/kg \[expanded product only\] for adults based on the highest cell dose windows evaluated in prior studies.
223636696|NCT01748734|PROCEDURE|quality-of-life assessment|Ancillary studies
223636697|NCT01748734|OTHER|questionnaire administration|Ancillary studies
223636698|NCT01748734|OTHER|counseling intervention|Undergo cognitive behavioral therapy
223636699|NCT01748734|BEHAVIORAL|behavioral intervention|Undergo cognitive behavioral therapy
223636700|NCT04685863|OTHER|Mobilizing the knee with active neurodynamic sliding technique (active Slump slider)|60 physiotherapy students perform measurements during three tutorials. The first involves training in evaluation techniques. The second involves mobilizing the knee, out of the SLUMP position. The third tutorial includes neuronal mobilization in SLUMP.
224225322|NCT03306056|OTHER|Standard Strength Training|"Procedures: Nutritional therapy (individualized, weight-reducing nutritional therapy and counseling) during a study period of 12 weeks combined with a standard strength training program:~* 5 strength training exercises (chest, upper/lower back, abdominals, legs)~* 3 sets per exercise~* time-effort per session: \~90 min~* 2 training sessions per week~* duration of exercise intervention: 12 weeks"
224225323|NCT03306056|OTHER|Low-volume Strength Training|"Procedures: Nutritional therapy (individualized, weight-reducing nutritional therapy and counseling) during a study period of 12 weeks combined a low-volume strength training program:~* 5 strength training exercises (chest, upper/lower back, abdominals, legs)~* 1 set per exercise~* time-effort per session: \~20 min~* 2 training sessions per week~* duration of exercise intervention: 12 weeks"
224225324|NCT03306056|OTHER|Whole-Body Electromyostimulation (WB-EMS)|"Procedures: Nutritional therapy (individualized, weight-reducing nutritional therapy and counseling) during a study period of 12 weeks combined with WB-EMS:~* time-effort per session: \~20 min~* duration of exercise intervention: 12 weeks"
224225325|NCT06243978|BEHAVIORAL|liebria|Participants will receive access to the digital health intervention liebria in addition to TAU
223515162|NCT04007679|OTHER|Pain neuroscience education|Pain neuroscience education (PNE) was conducted in physical conditions similar to the university classrooms where the study was performed. The sessions were conducted as 70-minute didactic group lessons with the same content held in separate sessions for students in each class. PowerPoint (Microsoft Corp., Redmond, WA, USA) presentations prepared by the instructor were used in all sessions. Metaphors, anecdotes, graphics, and pictures were used in an attempt to convey the information and messages about pain physiology and theory more permanently and effectively. In the PNE sessions, it was explained that the nervous system can be overprotective and that in addition to the sensitivity of the central nervous system, nociceptive transmission can be affected by an individual's thoughts, beliefs, and surroundings. At the end of the session, the students were given time to ask questions, but group discussion was limited to 15 minutes due to time restrictions.
223515163|NCT00370084|DRUG|Itopride|oral, three times daily
223515164|NCT00370084|OTHER|Placebo|oral, three times daily
223515165|NCT06438731|OTHER|BREAST MILK|The preterm will be monitored for 5 minutes before birth, during the procedure cycle, and then by camera recording for 5 minutes
223515166|NCT06438731|OTHER|KNITTED OCTOPUS|The preterm will be monitored for 5 minutes before birth, during the procedure cycle, and then by camera recording for 5 minutes
223515167|NCT00003455|DRUG|antineoplaston A10|
223515168|NCT00003455|DRUG|antineoplaston AS2-1|
223515169|NCT00003455|PROCEDURE|alternative product therapy|
223515170|NCT00003455|PROCEDURE|biological therapy|
223515171|NCT00003455|PROCEDURE|biologically based therapies|
223515172|NCT00003455|PROCEDURE|cancer prevention intervention|
223515173|NCT00003455|PROCEDURE|complementary and alternative therapy|
223515174|NCT00003455|PROCEDURE|differentiation therapy|
223515175|NCT05929911|BEHAVIORAL|Trauma-focused psychodynamic psychotherapy|"This psychotherapy addresses disruptions in the ability to reflect and affective regulation by exploring the psychological meanings of symptoms and their relation to traumatic events. The therapist works to identify intrapsychic conflicts, intense negative affects, and defense mechanisms related to the PTSD syndrome using a psychodynamic formulation that provides a framework for intervention. The transference provides a forum for patients to address feelings of mistrust, difficulties with authority, fears of abuse, angry and guilty feelings, and fantasies.~This treatment will be provided in-person or over teletherapy as the public health situation demands."
223515176|NCT06015334|PROCEDURE|cataract surgery with implantation of intraocular lens|Cataract surgery with implantation of bilateral trifocal IOL (TECNIS Synergy) implantation or bilateral monofocal IOL (Tecnis monofocal) with monovision.
223515177|NCT00003151|DIETARY_SUPPLEMENT|bismuth subcitrate|
223515178|NCT00003151|DRUG|amoxicillin|
223515179|NCT00003151|DRUG|clarithromycin|
223515180|NCT00003151|DRUG|metronidazole hydrochloride|
223515181|NCT00003151|DRUG|omeprazole|
223515182|NCT00003151|DRUG|tetracycline hydrochloride|
223515183|NCT00128492|DRUG|AZLI 75 mg two times a day (BID)/ three times a day (TID)|
223515184|NCT00612768|BIOLOGICAL|TRUE Test allergens Fragrance Mix and Thimerosol|"* Thimerosal, 0.008 mg/cm2 in hydroxypropylcellulose~* Thimerosal, 0.008 mg/cm2 in polyvinylpyrrolidone~* Fragrance mix, 0.43 mg/cm2 in hydroxypropylcellulose with β-cyclodextrin~* Fragrance mix, 0.43 mg/cm2 in polyvinylpyrrolidone with β-cyclodextrin~Patches are placed at day one and removed 48 hours. The duration of the study lasts 21 days. However, the subject is only exposed the the study allergen for 48 hours."
223515185|NCT05209737|PROCEDURE|Trendelenburg position|A 10-degree head-down position will be used in this group
223515186|NCT05209737|PROCEDURE|Semirecumbent position|A 30-degree head-up position will be used in this group
223515187|NCT00989443|DRUG|Cidofovir gel|topical gel applied once a week for 3 weeks
223515188|NCT06424535|OTHER|Chinese medicine for internal or external use、Acupuncture or Laser acupuncture pen treatment、Acupoint Tuina massage、Acupoint application of traditional Chinese herbal medicinal cake|"The treatment project a Chinese medicine practitioner based individual needs of the patient, and will be followed by a four-week treatment.~1. Traditional Chinese medicine for internal or external use: prescribe Chinese medicine based on syndrome differentiation and treatment of the patient's condition.~2. Acupuncture or laser acupuncture treatment: Traditional Chinese medicine practitioners select acupuncture points to treat based on the patient's condition, and treat them twice a week for 20 minutes each time.~3. Acupoint massage: Select treatment acupoints and techniques according to the patient's condition, 20 minutes at a time.~4. Traditional Chinese Medicine Cake Acupoint Application: Warm Navel Cream to the CV-4 (Guanyuan) acupoint once a day~5. Nursing and health education and guidance~6. Dietary hygiene education: personalized western nutrition and TCM dietary guidance suggestions based on TCM constitution syndromes."
223515189|NCT06424535|OTHER|Western medicine|Patients will receive routine Western medicine treatments as per individual patient's needs. The medications and bandages can vary due to the depth and size of the burn and scald.
223515190|NCT00460915|DRUG|Lacidipine & Amlodipine|
223515191|NCT01201044|DRUG|Gemcitabine, Nedaplatin, iV|Gemcitabine, Injection, 1000mg/m2, D1 \& D7/ 4weeks/cycle, 2 cycles Nedaplatin, Injection, 75mg/m2, d1/4weeks/cycle, 2 cycles.
223515192|NCT01201044|RADIATION|3DCRT|non-PD Patient will be treated with 3DCRT after 2 cycles of chemo.
224318848|NCT01589497|DRUG|Pyrazinamide|Participants with a body weight of 40-55 kg were administered two 500 mg tablets orally once daily. Participants with a body weight of 56-75 kg were administered three 500 mg tablets orally once daily. Participants with a body weight of 76-90 kg were administered four 500 mg tablets orally once daily.
224318849|NCT01589497|DRUG|Ethambutol|Participants with a body weight of 40-55 kg were administered two 400 mg tablets orally once daily. Participants with a body weight of 56-75 kg were administered three 400 mg tablets orally once daily. Participants with a body weight of 76-90 kg were administered four 400 mg tablets orally once daily.
224225326|NCT06243978|OTHER|information brochure on hypertension|Participants will receive an information brochure on hypertension
224318850|NCT01589497|DRUG|Moxifloxacin|Participants were administered one 400 mg tablet orally once a day.
224318851|NCT06435156|DRUG|Sotagliflozin|Sodium-glucose Co-transporter inhibitor
224318852|NCT06435156|DRUG|Placebo|Matched placebo
224225327|NCT00213954|PROCEDURE|ultrasound-guidance with echography|Locoregional anesthesia with or without ultrasound guidance practice
224225328|NCT00878345|DRUG|dexmedetomidine sedation protocol|Arm 1 will undergo sedation with dexmedetomidine, using 2 mcg/kg load IV over 10 minutes followed by an IV infusion of 1 mcg/kg/hr. May use versed 0.5 mg/kg IV x 1 for incomplete sedation, followed by increase of dexmedetomidine infusion to 1.5 mcg/kg/hr. Infusion will run throughout non-painful procedure (most likely MRI).
224318853|NCT04771975|BEHAVIORAL|Exercise Counselling|Phase 1: See previous description for MatchQEP (Intervention) group. Phase 2: Was not an RCT (i.e., all Phase 1 participants were approached to participate in Phase 2). Phase 2 is a pre-post intervention design, with no control group. Phase 2 participants had the option to extend their time in the study for an additional 8-weeks, which includes an online virtual (zoom) resistance training program with a qualified exercise professional (QEP) with a new study partner. The 8-week program was open to all participants from Phase 1 who choose to continue in the study, regardless of initial randomization status. Behavioural and exercise counselling were offered to phase 2 participants.
224318854|NCT04771975|BEHAVIORAL|Partner Matching|"Phase 1: All participants will be matched with another participant (fellow BCS) and will facilitate / support exercise with their partner for the duration of the study.~Phase 2: Was not an RCT (i.e., all Phase 1 participants were approached to participate in Phase 2). Phase 2 is a pre-post intervention design, with no control group. Phase 2 participants were rematched with different partner for this phase of the trial.~Participants will be matched based on personal and cancer-related characteristics."
224318855|NCT04771975|BEHAVIORAL|Resistance training sessions led by a QEP|Phase 2: participants were offered the option to extend their time in the study for an additional 8-weeks, which includes an online virtual (zoom) resistance training program with a qualified exercise professional (QEP) with a new study partner.
224318856|NCT02648100|OTHER|biomarker study|
224225329|NCT00878345|DRUG|pentobarbital sedation protocol|"Pentobarbital Sedation Protocol IV: 2.5 mg/kg, followed by 1.25 mg/kg as needed x2. Maintenance: May give additional 1.25 mg/kg IV x 2 if needed. Max total dose of 200 mg pentobarbital throughout sedation.~May give midazolam 0.05 mg/kg IV x 1 PRN agitation for rescue sedation."
224225330|NCT05058144|DIETARY_SUPPLEMENT|Drinkable solution|the volunteer will consume the volume 300 ml of water with
224318857|NCT02942641|PROCEDURE|Indwelling urethral catheterization (Foley)|"Hospitalized patients who developed first-time AUR were randomly divided into two groups depending on the type of assigned intervention: CIC and indwelling urethral catheter groups.~Patients in this group received indwelling urethral catheter as the intervention."
224318858|NCT02942641|PROCEDURE|Clean intermittent catheterization (CIC)|"Hospitalized patients who developed first-time AUR were randomly divided into two groups depending on the type of assigned intervention: CIC and indwelling urethral catheter groups.~Patients in this group received CIC as the intervention."
224318859|NCT02942641|DEVICE|Foley|
224318860|NCT02494180|DRUG|fentanyl|arm A receiving iv fentanyl
223515193|NCT01201044|RADIATION|3DCRT|non-PD Patient will be treated with 3DCRT after 2 cycles of chemo.
223515194|NCT01201044|DRUG|Gemcitabine，Nedaplatin, BAI|"Drug: Gemcitabine, Nedaplatin, iV~Gemcitabine, Injection, 1000mg/m2, D1/4weeks/cycle, 2 cycles Nedaplatin, Injection, 75mg/m2, d1/4weeks/cycle, 2 cycles. BAI"
223515195|NCT01258699|DRUG|Thiocacid HR Tab 600mg|600mg for 1 day
224225331|NCT00514293|DRUG|bexarotene|
224225332|NCT00514293|DRUG|capecitabine|
224225333|NCT00514293|DRUG|carboplatin|
224225334|NCT00514293|DRUG|cisplatin|
223515196|NCT01258699|DRUG|BK-C-0701 320mg|320mg for 1 day
223515197|NCT01258699|DRUG|BK-C-0701 480mg|480mg for 1 day
223515198|NCT00636337|BEHAVIORAL|Attention Training|Computer program training for attention difficulties.
223515199|NCT00636337|BEHAVIORAL|Placebo|Comparison computer program
223636701|NCT01066013|OTHER|Antimicrobial de-escalation strategy|The antimicrobial de-escalation team will record recommendations for de-escalation in the patient's progress notes for the attending physicians to review and act upon as appropriate. The attending physician will be responsible for making changes to antimicrobial therapy and following up on patient progress as per the usual practice.
223636702|NCT00619034|DRUG|Latanoprost, diclofenac and dorzolamide (eyedrops)|1 eyedrop twice daily in one week
223636703|NCT00619034|DRUG|Diclofenac|dicolfenac eyedrops twice daily i one eye
223636704|NCT00619034|DRUG|Dorzolamide|dorzolamide eyedrops twice daily, in one eye for one week
223636705|NCT02012140|DRUG|ticagrelor|
223636706|NCT02689635|OTHER|Sodium Restricted Diet|Cardiac Diet, as defined by our Hospital Nutritional Services (containing less than 2000 mg sodium per day)
223636707|NCT02689635|OTHER|Regular Diet|Non-Cardiac Diet, as defined by our Hospital Nutritional Services
223636708|NCT02858622|DRUG|bupivacaine|bupivacaine 0.25% at a dose 2 mg/kg in the transversus abdominis plane
224225335|NCT00514293|DRUG|docetaxel|
224225336|NCT00514293|DRUG|tretinoin|
224225337|NCT05118282|BEHAVIORAL|Combined coping skills + asthma management|This arm includes a curriculum teaching coping skills and culturally relevant asthma management skills.
224225338|NCT05118282|BEHAVIORAL|Standard Asthma Management (AM)|This arm includes a curriculum teaching standard asthma management skills.
224225339|NCT00401882|DRUG|Epinephrine|Epinephrine (1 mg) IV additional doses
224225340|NCT00401882|DRUG|Metoprolol|Metoprolol 5 mg IV (up to two times only) instead of epinephrine additional doses
223636709|NCT02858622|DRUG|Pethidine|pethidine intravenous at a dose 1mg/kg when pain score more than 5 postoperative rescue analgesia
223636710|NCT02858622|DRUG|perfalgan|intravenous paracetamol
223636711|NCT02858622|DRUG|fentanyl|
223636712|NCT05721456|BIOLOGICAL|12-Valent Pneumococcal Conjugate Vaccine|PCV12 group 1: 550 subjects receiving the 12-valent pneumococcal polysaccharide conjugate vaccine (12Pn-PD-DiT-CRM), defined as PCV12 in this protocol
223636713|NCT06513845|BEHAVIORAL|Communal drumming recordings|Segments (\~30 sec duration) of recordings taken from the music made during the previous drum circle. Segments will be categorized as highly synchronized
223636714|NCT06345274|BEHAVIORAL|Measurement Based Care Training and Monthly Consultation|Participating opioid treatment program leaders and treatment providers will receive two measurement-based care implementation strategies: 1) didactic training including a total of four hours of workshop training led by a measurement-based care expert, and 2) monthly consultation calls led by a measurement-based care expert for 6 months.
223636715|NCT06266429|DIAGNOSTIC_TEST|Blood collection|Collecting blood pre-op and post-op for metabolite levels.
223636716|NCT01128933|PROCEDURE|Renal artery stenting|
223636717|NCT00247663|DRUG|Letrozole|
223636718|NCT05795036|DEVICE|mHealth 1|Participants will use Fitbit device to self-monitor their physical activity in 8 weeks.
223636719|NCT05795036|DEVICE|mHealth 2|Participants will use Fitbit device to self-monitor their physical activity in 8 weeks. In addition, they will receive daily motivational text message.
223636720|NCT06190171|BEHAVIORAL|Active respiratory muscle strength training|Devices will be set to 60% of participants' maximum expiratory pressure and maximum inspiratory pressure. Participants will complete training 7 days per week by performing 5 sets of 5 repetitions for both expiratory and inspiratory muscle strength training (a total of 50 repetitions).
223636721|NCT06190171|BEHAVIORAL|Sham respiratory muscle strength training|Springs will be removed from devices to ensure training is done without resistance. Participants will complete training 7 days per week by performing 5 sets of 5 repetitions for both expiratory and inspiratory sham muscle strength training (a total of 50 repetitions).
223636722|NCT06410274|DEVICE|Transcranial Doppler ultrasonography (TCD)|TCD will be used to measure cerebral blood velocity (CBv) in the middle and posterior cerebral arteries (MCA and PCA). Following confirmation of a suitable TCD window, participants will undergo a ten-minute rest period in the supine or semi-supine position. Continuous measurements of CBv, blood pressure (BP), heart rate, and end-tidal carbon dioxide will be recorded. Baseline BP will be measured using an automated BP device prior to each recording to allow calibration of the files offline for analysis. This will occur at the first visit and at follow-up, 4-7 days post-onset of intracerebral haemorrhage.
223636723|NCT05865990|DRUG|Patritumab deruxtecan|HER3 directed antibody drug conjugate (ADC) that is comprised of a fully human anti-HER3 immunoglobulin gamma-1 (IgG1) monoclonal antibody attached to a topoisomerase I inhibitor payload (an exatecan derivative, DXd) via a stable tetrapeptide-based cleavable linker.
223636724|NCT05122975|DRUG|S48168 (ARM210)|Ryanodine Receptor modulator
223636725|NCT05122975|DRUG|Matching Placebo|Placebo of same size and consistency as S48168 (ARM210)
223636726|NCT03632863|BEHAVIORAL|Electronic Patient Decision Aid|"The electronic PDA is an interactive website with 3 main sections:~1. Review of depression treatment options (non-pharmacological and pharmacological) along with their respective risks and benefits.~2. Interactive values clarification exercises to help women determine which risks and benefits are most important to them.~3. Exercises to help women consider how partners, family, providers and the social context impacts decision-making.~A summary of how a woman feels about each option along with risks and benefits is generated which can be provided to treating clinicians for use in follow-up.~A printable pdf with standard published information and resources is also included."
223636727|NCT03632863|BEHAVIORAL|Standard Resource Sheet|A control group aims to isolate the PDA's effects from time and clinical care. Controls login to the study website and receive the same printable pdf as in the PDA so that they can access standard publicly available information/resources, even if they will not receive the PDA.
223636728|NCT06198933|DEVICE|Pulsed-field ablation|Patients will atrial fibrillation will undergo catheter ablation using pulsed-field energy
223636729|NCT05659589|OTHER|blood sample|Blood sample withdrawal will be done and serum creatinine, IS, PCS, FGF-23, Angiopoietin-2, VCAM-1, E-Selectin and Troponin will be measured.
224225341|NCT02802514|DRUG|Albiglutide 50mg|It is provided as a single use fixed dose disposable pen injector (0.5 mL) system for SC delivery. A 50 mg pen contains 67 mg lyophilized albiglutide and 0.65 mL diluents. It will be injected subcutaneously (SC) in the upper arm.
224318861|NCT02494180|DRUG|pethidine|arm B receiving iv pethidine
223636730|NCT04579094|OTHER|Feces sampling at inclusion (J0)|Feces sampling at inclusion (J0)
223636731|NCT04789655|DRUG|CC-96191|CC-96191
223636732|NCT04408989|DRUG|MB02-SP|Solution for intravenous infusion, single dose of 1mg/kg, administered as 90-minute infusion
223636733|NCT04408989|DRUG|MB02-DM|Solution for intravenous infusion, single dose of 1mg/kg, administered as 90-minute infusion
223636734|NCT04408989|DRUG|US licenced Avastin®|Solution for intravenous infusion, single dose of 1mg/kg, administered as 90-minute infusion
223636735|NCT05540132|DIETARY_SUPPLEMENT|maltodextrin|Pre-exercise carbohydrate, fast-acting
223636736|NCT05540132|DIETARY_SUPPLEMENT|super starch|Pre-exercise carbohydrate, slow-acting
223636737|NCT04211753|BEHAVIORAL|Treatment as usual (schema therapy)|weekly group psychotherapy and bimonthly individual psychotherapy
223636738|NCT04211753|DEVICE|Mobile app|Medical device for crisis intervention
223764900|NCT06505590|DEVICE|Educational material plus self-management program - guided version with mental health professional|Patients will have access to the same mobile app (Resilience ©) with its educational content and the self-management program of arm 2 and weekly calls with a certified mental health professional certified in cognitive behavioural therapy for guided coaching across the self-management program.
223764901|NCT05744427|DRUG|JSKN003|JSKN003 should be administered intravenously on the first day of each 3-week cycle.
223764902|NCT04836429|DRUG|Porfimer Sodium|Given IV
223764903|NCT04836429|PROCEDURE|Video-Assisted Thoracic Surgery|Undergo VATS
223764904|NCT04836429|DRUG|Photodynamic Therapy|Undergo photodynamic therapy
223764905|NCT04836429|DEVICE|Intraoperative PDT|Subjects will receive one course of light therapy at the time of surgery
223636739|NCT02694185|OTHER|Caplan IVR|This intervention will consist of: proactive real-time adherence monitoring of patients and targeting of individuals only when they have exhibited non-adherence behavior (i.e., if patients have not refilled their medication more than 4 or 7 days after it was due to be refilled). The intervention will employ a tailored, escalating-intensity approach which begins with some combination of personalized short messaging service (SMS) text messages and interactive voice response (IVR) telephone technology, depending on patient preference. Patients failing SMS and then IVR by not refilling their medication (or declining SMS and failing IVR) escalate to a trained research interventionalist (typically, a clinical pharmacist). The interventionalist will contact the patient and address adherence barriers based on the dimensions outlined by the World Health Organization (WHO) that are specific to each patient.
223636740|NCT05082857|BEHAVIORAL|"traditional Parents as Teachers (PAT)"|A twice-a-month home visits from trained family educators. Home visits will continue for the remainder of the study period as will the other components of the Parents as Teachers model: regular Group Connections for peer interactions and support, age-appropriate health and developmental screenings, and referrals that reflect mother and infant needs to community agencies that include the Child Development Services Agency (which provides screening for Individuals with Disabilities in Education Act (IDEA) Part C services), family services, intensive mental health services, among others.
223636741|NCT05082857|BEHAVIORAL|"hybrid PAT model"|A six-week virtual evidence-based parenting class entitled What You Do Matters, which will be delivered in partnership with the Pediatric Advocacy Program at WFBMC which combines short parent-educator discussions followed by interactive activities and peer to peer networking.
224225342|NCT02802514|DRUG|Albiglutide matching placebo|It is provided as a single use fixed dose disposable pen injector (0.5 mL) system for SC delivery. It will be injected subcutaneously (SC) in the upper arm
223636742|NCT05625061|BEHAVIORAL|Core Behavioral Weight Loss (BWL) Intervention|"All participants receive a mobile behavioral weight loss intervention delivered through a study smartphone app with weekly behavioral lessons, food tracking log, weekly tailored feedback, and daily weight-related behavioral goals; a connected physical activity tracker and wireless scale. As micro-randomized trials are sequential, full factorial experiments, this core intervention component is combined with each of the 7 intervention messages (i.e., Behavior Change Technique (BCT) messages) to be tested repeatedly over time.~Participants will be evaluated at each of 3 decision points (morning, midday, evening) on each day of the study, and if eligible then micro-randomized, to receive or not receive, 1 of 7 types of daily intervention messages promoting achievement of proximal weight-related behavioral goals."
223636743|NCT05625061|BEHAVIORAL|Behavior Change Technique 1 Message (Action Planning)|Core BWL Intervention + Message in smartphone app prompts detailed planning of performance of one of the 3 target behaviors (daily weighing, active minutes, red food intake).
223636744|NCT05625061|BEHAVIORAL|Behavior Change Technique 2 Message (Discrepancy between Current Behavior and Goal)|Core BWL Intervention + Message in smartphone app provides feedback on each of the 3 target behaviors (daily weighing, active minutes, red food intake) in the form of information drawing attention to discrepancies between participants' current behavior and participants' daily goals.
223636745|NCT05625061|BEHAVIORAL|Behavior Change Technique 3 Message (Feedback on Outcome of Behavior)|Core BWL Intervention + Message in smartphone app provides participants with feedback on their weight change, relating it to their performance on one of the 3 target behaviors (daily weighing, active minutes, red food intake).
223636746|NCT05625061|BEHAVIORAL|Behavior Change Technique 4 Message (Social Support)|Core BWL Intervention + Message in smartphone app advises participants on eliciting the provision of social support from their existing network related to one of the 3 target behaviors (daily weighing, active minutes, red food intake).
223636747|NCT05625061|BEHAVIORAL|Behavior Change Technique 5 Message (Social Comparison)|Core BWL Intervention + Message in smartphone app systematically induces comparison of participants' behavioral performance with other participants, including general, upward (i.e., comparison to participants doing better: weighing more, engaging in more activity, staying within red food limits), and downward comparisons (to participants doing worse).
223636748|NCT05625061|BEHAVIORAL|Behavior Change Technique 6 Message (Social Reward)|Core BWL Intervention + Message in smartphone app reinforces participants' effort or progress in performing one of the 3 target behaviors (daily weighing, active minutes, red food intake).
223636749|NCT05625061|BEHAVIORAL|Behavior Change Technique 7 Message (Focus on Past Success)|Core BWL Intervention + Message in smartphone app advises participants to think about or list previous successes related to performing one of the 3 target behaviors (daily weighing, active minutes, red food intake).
224225343|NCT02802514|DRUG|Exenatide 10microgram|It is provided as a sterile solution containing 250 microgram/mL exenatide. One dose of 10 microgram is equivalent to 0.04 ml. It will be injected subcutaneously (SC) in the upper arm
224225344|NCT02802514|DRUG|Exenatide placebo (saline)|It is provided as a sterile saline. It will be injected subcutaneously (SC) in the upper arm
223636750|NCT04363320|BEHAVIORAL|NIATx Coaching|NIATx framework provides each participating site with a NIATx Coach who is an expert in MOUD implementation and organizational change and will help the organization adopt, implement, and increase the use of MOUD. Coaches help the sites think through key issues, offer process improvement training, and suggest changes.
223764906|NCT05994378|DRUG|SHR7280；Ganirelix Acetate Injection simulant|SHR7280 200mg Q12h and Ganirelix Acetate Injection simulant 0.5mL qd;
223764907|NCT05994378|DRUG|SHR7280 simulant； Ganirelix Acetate Injection|SHR7280 simulant 200mg Q12h and Ganirelix Acetate Injection 0.5mL:0.25mg qd;
223764908|NCT02171481|DRUG|Dabigatran etexilate polymorph II|
223764909|NCT02171481|DRUG|Dabigatran etexilate polymorph I|
224225345|NCT01828255|DEVICE|SENSIMED Triggerfish®|
224225346|NCT03729765|DEVICE|hemoperfusion|The patients in the simultaneous hemoperfusion arm will receive hemoperfusion when extracorporeal membrane oxygenation (ECMO) is commenced. veno-arterial extracorporeal membrane oxygenation (VA-ECMO) patients treat with hemoperfusion three times in a row，each time for 6 hours.
224225347|NCT05001490|OTHER|Smartphone application based reminder|Brushing reminders were given to the patients in experimental group through a smartphone application twice daily
224225348|NCT01087879|DRUG|Desogestrel-Ethinyl Estradiol contraceptive pill|150 microg Desogestrel and 20 microg Ethinyl Estradiol combination. One pill once a day for 9 weeks, continual administration.
224318862|NCT02494180|DRUG|Diazepam|arm B receiving iv diazepam
224318863|NCT02494180|DRUG|Midazolam|arm A receiving iv midazolam
223636751|NCT04363320|BEHAVIORAL|ECHO|The ECHO model connects MOUD prescribers and experts with primary care providers and medical teams to promote high-quality MOUD practices. ECHO is provided monthly through videoconferences. Experienced MOUD prescribers address topics such as counseling strategies, urine test interpretation, and transitioning from buprenorphine, naltrexone and methadone.
223636752|NCT06052852|DRUG|BDC-3042|Dectin-2 agonist antibody
223636753|NCT06052852|DRUG|Cemiplimab|Drug which blocks checkpoint proteins from binding with their partner proteins, allowing T cells to kill cancer cells
223636754|NCT05525416|DRUG|Sodium Nitroprusside|A bolus injection of sodium nitroprusside will be given to lower blood pressure and evaluate baroreflex function.
223636755|NCT05525416|DRUG|Phenylephrine Hydrochloride|A bolus injection of phenylephrine will be given to raise blood pressure and evaluate baroreflex function immediately following the sodium nitroprusside infusion.
223636756|NCT05525416|DRUG|Phenylephrine Hydrochloride|Investigators will give three incremental doses via brachial artery catheter to observe α1-adrenoreceptor mediated vasoconstriction. This will occur three times throughout the protocol.
223764910|NCT01946204|DRUG|Apalutamide|240 mg tablets administered by mouth on a continuous once daily dosing regimen
223636757|NCT05525416|DRUG|Norepinephrine|Investigators will give three incremental doses via brachial artery catheter to observe adrenoreceptor activation. This will occur three times throughout the protocol.
223636758|NCT05525416|OTHER|Isometric Handgrip and Post-Exercise Circulatory Occlusion|Participants will perform 2 minutes of isometric handgrip at 30% maximal voluntary contraction followed by 2 minutes of post-exercise circulatory occlusion to assess the reactivity of the blood vessels to exercise and the metaboreflex.
223764911|NCT01946204|DRUG|Placebo|Matched placebo tablets administered by mouth on a continuous once daily dosing regimen
223764912|NCT06423898|DRUG|Ampicillin plus ceftriaxone in continuous infusion|Continuous intravenous antibiotic infusion during 42 days for Infective Endocarditis
223764913|NCT06423898|DRUG|Ampicillin plus ceftriaxone in intermittent infusion of 14 days, after which the treatment may be changed|"Ampicillin plus ceftriaxone as an intermittent infusion for a minimum of 14 days. After, if the patient is discharged from the hospital, the following treatments, until the 42-day treatment period is completed:~1. Intravenous treatment according to the following regimens:~   Ampicillin plus ceftriaxone as an intermittent infusion, teicoplanin, daptomycin, dalbavancin or linezolid.~2. Oral treatment according to the following regimens: amoxicillin plus moxifloxacin, amoxicillin plus linezolid, amoxicillin plus rifampin, linezolid plus moxifloxacin or linezolid plus rifampin."
224225349|NCT01087879|DRUG|Etonogestrel-Ethinyl Estradiol vaginal ring|Etonogestrel-Ethinyl Estradiol vaginal ring, which consists of 11,7 mg etonogestrel and 2,7 mg ethinyl estradiol. It delivers 0,120 mg etonogestrel and 0,015 mg ethinyl estradiol per day. Treatment continues continual for 9 weeks and the vaginal ring is changed every three weeks.
224225350|NCT01087879|DRUG|Norelgestromin-Ethinyl Estradiol contraceptive patch|A combination transdermal contraceptive patch with 6 mg of norelgestromin and 600 microg of ethinyl estradiol. It delivers 203 microg of norelgestromin and 33,9 microg ethinyl estradiol per day. A continual use of patch for 9 weeks and the patch is changed every week.
224225351|NCT00439608|DRUG|Cetuximab,Paclitaxel, Carboplatin|IV treatment for 6 weeks
224225352|NCT00040859|DRUG|capecitabine|
224225353|NCT00040859|DRUG|oxaliplatin|
224225354|NCT02565342|PROCEDURE|Interscalene brachial plexus block|
224225355|NCT00633152|DRUG|ceftaroline|600 mg injected every 12 hours for at least 5 but not more than 14 days
224225356|NCT00633152|DRUG|linezolid|600 mg parenteral infused over 60 minutes for a minimum of 5 days and a maximum of 14 days
224225357|NCT00633152|DRUG|Aztreonam|1000 mg infused over 60 minutes every 24 hours may be started with linezolid or added later (up to 72 hours after the first dose of linezolid) for subjects with a gram-negative infection indicated.
224225358|NCT00279942|DIETARY_SUPPLEMENT|Soy|Drink a shake (vanilla and chocolate taste) once a day for 6 weeks.
224225359|NCT00279942|OTHER|Placebo|Drink a shake (vanilla and chocolate taste) once a day for 6 weeks.
224318864|NCT02312908|DRUG|Clonazepam|For experimental treatment of RBD
224318865|NCT02312908|DRUG|Placebo|Placebo pill manufactured to mask clonazepam 0.5mg tablet
224318866|NCT04815655|PROCEDURE|Cartilage tympanoplasty|is the reconstruction of the tympanic membrane (TM) by using catilage
224318867|NCT02576912|DRUG|Active Delta-9-THC|Active Delta-9-THC (0.036 mg/kg) given intravenously.
224318868|NCT02576912|DRUG|Active Pregnenolone|A dose given sublingually.
224318869|NCT02576912|DRUG|Placebo|A placebo dose given sublingually.
224318870|NCT02576912|DRUG|Placebo|Placebo dose given intravenously.
223636759|NCT05525416|OTHER|Rhythmic Handgrip|Participants will perform 3 minutes of rhythmic handgrip at 25% maximal voluntary contraction to assess the reactivity of blood vessels to dynamic exercise.
223636760|NCT05525416|OTHER|Cold Pressor Test|Standardized sympathetic stressor involving submersion of the hand in ice-cold water for 3-minutes, aiming to elicit endogenous neurotransmitter release and blood pressure increases.
223636761|NCT05525416|DRUG|Propranolol Hydrochloride|Local infusion via brachial artery catheterization will occur continuously for the remainder of the study. Propranolol is a beta-adrenergic antagonist and will allow investigation of the role of beta receptors in responses to various stressors. The above phenylephrine, norepinephrine, isometric handgrip, post-exercise circulatory occlusion, and rhythmic handgrip protocols will be repeated under propranolol infusion.
223636762|NCT05525416|DRUG|Phentolamine Mesylate|Local infusion via brachial artery catheterization will occur continuously for the remainder of the study. Phentolamine is an alpha-adrenergic antagonist and will allow investigation the role of alpha receptors in responses to various stressors. It will be continuously infused with propranolol. The above phenylephrine, norepinephrine, isometric handgrip, post-exercise circulatory occlusion, and rhythmic handgrip protocols will be repeated under propranolol infusion.
223636763|NCT04855916|DEVICE|ABLE Exoskeleton|Participants will use the ABLE Exoskeleton to perform therapy activities (sit-to-stand transfers, walk, turns, balance exercises, normalized tests). Participants will perform a total of 10 training sessions of an approximate duration of 90 minutes.
223636764|NCT04855916|DEVICE|KAFO Orthosis|Participants will use a pair of KAFO-type passive orthosis to perform therapy activities (sit-to-stand transfers, walk, turns, balance exercises, normalized tests). Participants will perform a total of 10 training sessions of an approximate duration of 90 minutes.
223636765|NCT04324827|DEVICE|Graston Technique|FR is a dense foam cylinder that the person rolls before using the body weight to warm up and increase their ROM. There are different types that vary in size, shape and density.
223636766|NCT04324827|OTHER|Dynamic stretch exercise|Dynamic stretch includes controlled movements in the active ROM for a joint. This type of exercise is actually the basis of sports movements used in training or competition.
223636767|NCT05632211|BIOLOGICAL|AVT05|Pre filled syringes filled with AVT05
223636768|NCT05632211|BIOLOGICAL|Simponi|Pre filled syringes filled with Simponi
223636769|NCT03807986|PROCEDURE|Nanofat grafting|Nanofat grafting will be applied once every three months for 2 times.
223636770|NCT03807986|PROCEDURE|Microfat grafting|Microfat grafting will be applied once every three months for 2 times.
223636771|NCT03807986|PROCEDURE|Platelet-rich plasma (PRP) Injection|PRP Injection will be applied once a month for 6 times.
223636772|NCT02202122|OTHER|OSA Scoring|Comparison of the preoperative OSA scoring (STOP-BANG, DES-OSA, P-SAP and OSA50) with the postoperative mortality at one month.
223636773|NCT01943643|PROCEDURE|multislice CT angiography|Study patients will undergo MSCTA on Toshiba Aquilion CXL 128 slice CT scanner using predefined protocol. The procedure will include calcium scoring (Agatston) then CT angiography using Ultravist 370 contrast agent ((iopromide concentration 370 mg/ml, Bayer Health Care, Germany). MSCTA angiograms will be analyzed using dedicated software Vital Vitrea Advanced 6.2, Vital Images, Minnetonka, Minnesota, US. The bifurcation lesion analyses will include: the measurement of the angle between MB and SB, measurement of the lesion length, reference diameter of the vessel, degree of stenosis, atherosclerotic plaque analysis 10 mm proximal and distal in the MB, and 5 mm from the ostium of the SB, and at the level of maximum stenosis (minimal lumen diameter).
223636774|NCT04672239|BEHAVIORAL|"Smartphone app Smiling instead of Smoking (SiS) Version 3"|Participants will be onboarded to the smartphone app SiS and will be asked to use it for 7 weeks to support them in quitting smoking.
223636775|NCT04672239|BEHAVIORAL|"Smartphone app QuitGuide (QG)"|Participants will be onboarded to the NCI smartphone app QG and will be asked to use it for 7 weeks to support them in quitting smoking.
223636776|NCT04672239|BEHAVIORAL|"Brochure Clearing the Air (CTA)"|"Participants will be onboarded to the brochure Clearing the Air and will be asked to use it for 7 weeks to support them in quitting smoking."
223636777|NCT04606134|DEVICE|Hybrid fractional laser|two treatments given one month apart
223636778|NCT04606134|OTHER|Alastin Regenerating Skin Nectar with TriHex Technology|applied twice daily
224225360|NCT05124756|DEVICE|Bioelectric stimulation|The sessions will include 20 minutes for stimulation of the thigh muscles and 45 minutes for stimulation of the kidneys. The electrodes will be placed on the motor point of the quadriceps muscle in both lower limbs. The neuromuscular electric stimulation will be applied by symmetrical biphasic pulsed current, at an 80 Hz frequency, 400 ms pulse width, 10 s contraction time, rest time decreasing as the protocol advanced, at reciprocal mode. The intensity will be individually adjusted to produce visible muscle contraction. Concomitant, two electrodes will be placed in the abdominal corresponding to the kidney anatomical site and two electrodes on the dorsal region at the level of the 10th thoracic vertebra. The stimulation of the kidneys will include in addition to Klotho, precise signals for several pro-regenerative proteins. The intensity of the electric current will be individually adjusted to sensory stimulation.
224225361|NCT05489185|DRUG|Tranexamic acid|Intravenous or topical administration
223636779|NCT04606134|OTHER|Cetaphil face cream|applied twice daily
223636780|NCT00937313|OTHER|Champagne wine intervention|Placebo-controlled randomised cross-over human trial
223636781|NCT04266067|OTHER|PNF exercise|Proprioceptive neuromuscular facilitation (PNF) is a form of neuromuscular retraining type containing the stimulation of sensory receptors to provide information about the body position and movement to facilitate the intended movement
223636782|NCT04266067|OTHER|Frenkel exercise|The Frenkel exercises consist of a series of slow, repetitive movements performed in different positions while lying, sitting and standing.
223636783|NCT00000336|DRUG|Selegiline|
223636784|NCT01752335|OTHER|Braquial ecography|At the moment of the ecography, the clinician evaluates the endothelial responses via applying braquial ischemia and administering sublingual nitroglicerin spray to evaluate vasodilation.
223636785|NCT04543708|PROCEDURE|Incision drainage|"Oropharyngeal pre-anesthesia is performed with 10% xylocaine spray, then submucosal anesthesia of the anterior pillar of the tonsil is performed with 2 ml of Rapidocaine or Rapidocaine 1 or 2% adrenaline. A scalpel incision is made with the search for the abscess pocket with a crile. If pus is present, a NaCl / Betadine rinse is performed. A syringe puncture can help locate the abscess if needed. The duration is approximately 15 minutes.~If no purulent pouch is found, the procedure is completed with tonsillectomy under general anesthesia."
223636786|NCT04543708|PROCEDURE|Tonsillectomy|Under general anesthesia, in dorsal decubitus, an autostatic mouth opener is placed, an incision of the anterior pillar of the tonsil allows the opening of the capsular space, along which the entire tonsil is dissected until complete extraction, hemostasis is performed, then the patient is awakened. The duration is approximately 30 minutes.
224225362|NCT05489185|OTHER|Physiologic saline|Placebo
224225363|NCT02180061|BIOLOGICAL|Pembrolizumab|IV infusion
224225364|NCT04543045|OTHER|not an intervention|not an intervention
224225365|NCT01469364|DRUG|Aztreonam Lysine for Inhalation (AZLI)|The intervention will involve open label treatment with AZLI inhaled 75mg TID self-administered intermittently for 28 days on study drug and 28 days off study drug over a study period of 5 consecutive months (on/off/on/off/on AZLI)
224225366|NCT01469364|PROCEDURE|Status Post Lung Transplant|Bronchoscopy, pulmonary function testing, and laboratory testing will be performed on a regular basis during study enrollment consistent with each center's usual standard clinical care.
224225367|NCT03242122|OTHER|CHO Control 1 and 2 Glucose|mixed in 237 ml/8 fl oz of a flavored non-caloric beverage; 1 time consumption
224225368|NCT03242122|OTHER|CHO Experimental 1 Slowly Digested|mixed in 237 ml/8 fl oz of a flavored non-caloric beverage; 1 time consumption
224225369|NCT03242122|OTHER|CHO Experimental 2 Digestion Resistant|mixed in 237 ml/8 fl oz of a flavored non-caloric beverage; 1 time consumption
223636787|NCT06139510|OTHER|Quantitative sensory testing|Quantitative sensory testing is a standard type of pain testing that measures changes in sensitivity to different type of sensations that include temperature, touch or pressure.
223636788|NCT00006020|DRUG|nelarabine|1.5 gm/m2 IV over 2 hours days 1, 3, 5 q21 days
223636789|NCT06016803|DEVICE|Cicatryl (RL3010A - DP0378)|Tested product is applied twice a day. The maximum duration of application is 7 days.
223636790|NCT02961894|DEVICE|Revolution™ Peripheral Atherectomy System|The Rex Medical Revolution™ Peripheral Atherectomy System is a minimally invasive catheter-based atherectomy system used to treat patients who suffer from PAD. This system is designed to treat a broad range of plaque types both above and below the knee and may address many of the limitations associated with existing treatment options.
223636791|NCT05198869|DEVICE|Spectral scan|Consenting participants will have a SpotLight-19 scan
223636792|NCT02658526|BEHAVIORAL|anesthesia - surgery|
223636793|NCT05522439|DRUG|SHR-1703|SHR-1703 will be administered by SC injection.
223636794|NCT05522439|DRUG|SHR-1703 Placebo|Matching Placebo will be administered by the SC route.
223636795|NCT03373240|BEHAVIORAL|TAU plus Cognitive Remediation Program|Treatment normally received at this clinic that generally includes individual or group sessions and regular urine monitoring PLUS computerized games that focus on cognitive-affective self-regulatory processes.
223636796|NCT03373240|BEHAVIORAL|TAU plus Control Tasks|Treatment normally received at this clinic that generally includes individual or group sessions and regular urine monitoring PLUS a series of computerized word games.
223636797|NCT03633370|OTHER|Multifaceted intervention including 3 components|Multifaceted intervention including Dispatcher training to improve cardiac phone recognition, mobile application to send bystanders on cardiac arrest location before first professionals rescuers and motivational support for volunteer bystanders
223636798|NCT03871777|OTHER|Placebo mouthwash|Participants received placebo mouthwash (ultrapure unflavoured water) with which they rinsed their mouth for one minute, twice a day for 7 days. Resting metabolic rate and blood pressure were measured on day eight. Additionally, blood and saliva samples were taken from all the participants. Dietary records of seven days were also collected in order to confirm the foods and portion sizes consumed, preparation methods, recipes and any brand names.
223636799|NCT03871777|OTHER|Chlorhexidine mouthwash|After using placebo and complete all the physiological measurements, participants were given a further one-week supply of antibacterial mouthwash containing 0.2% chlorhexidine (Corsodyl, GlaxoSmithKline, UK), encouraged to rinse their mouth for one minute, twice a day for 7 more days. They returned to the laboratory in 7 days to repeat all measurements in the same order.
223636800|NCT00370734|DRUG|Botulinum toxin A injection|
224225370|NCT03242122|OTHER|CHO Experimental 3 Low Sugar|mixed in 237 ml/8 fl oz of a flavored non-caloric beverage; 1 time consumption
224225371|NCT03242122|OTHER|CHO Experimental 4 Maltodextrin|mixed in 237 ml/8 fl oz of a flavored non-caloric beverage; 1 time consumption
224225372|NCT06530069|OTHER|exposures|exposures: Ear cleaning, swimming, wearing earphones, diabetes, immunosuppression, antibiotic ear drops, narrowing of the external auditory canal, etc.
223636801|NCT04730102|PROCEDURE|Rectal washout|Rectal washout is performed intraoperatively before transection and means irrigation of the rectum following the closure of the rectal lumen below the tumour with a purse string suture. Rectal washout is performed with a total of 500 ml sterile water. Fluid samples are collected after every 100 ml by instilling 50 ml of saline after each washout. A sixth sample is collected from the presacral cavity.
223636802|NCT05369351|DRUG|Standard treatment+mirabegron|In addition to standard treatment, the first dose of mirabegron 50mg/day will be given within 72 hours of symptom onset and continued until the 7th day after onset.
223636803|NCT05369351|OTHER|Standard treatment|Standard treatment
223636804|NCT02345447|DRUG|Herbal-based medication|Aconitum napellus, Capsicum annuum; Chamomilla recutita; Echinacea purpurea; Hydrargyrum bicyanatum; Hydrastis canadensis; Iodum; Natrium tetraboracicum; Sambucus nigra; Sanguinaria canadensis
223636805|NCT02345447|DRUG|Placebo|Aqueous ethanol solution non-distinguishable from verum
223636806|NCT05428501|OTHER|no treatment given|People / Person Living with Obesity (PLwO) Health Care Professionals (HCPs)
223636807|NCT00417326|DRUG|ONO-5046Na|twenty four hour infusion at 0 mg/kg/hr for 14 days
223636808|NCT00417326|DRUG|ONO-5046Na|twenty four hour intravenous infusion at 0.2 mg/kg/hr for 14 days
223764914|NCT00524446|DIETARY_SUPPLEMENT|Milk-containing fortified spread|Counseling + Vitamin A as for ST-DI + 750 g of fortified spread (FSm) 2-weekly (54 g / day) between 6 and 18 months of age.
223764915|NCT00524446|DIETARY_SUPPLEMENT|Soy-containing fortified spread|Counseling + Vitamin A as for ST-DI + 750 g of modified fortified spread (FSs) 2-weekly (54 g / day) between 6 and 18 months of age.
224225373|NCT04137263|OTHER|DOSE formulation|over-the-counter topical
224225374|NCT02542124|BIOLOGICAL|NM-IL-12 and TSEBT|The LD-TSEBT treatment will start on Day 1 of the study. NM-IL-12 will be administered subcutaneously.
224225375|NCT04556110|DRUG|Perindopril tert-Butylamine tablets （ Produced by Haisco）|The trial was divided into four cycles, between of each cycle with a 14-day wash-out period.In the first cycle，subjects in experimental group took the test preparation Perindopril tert-butylamine after meal, and subjects in control group took the reference preparation ACERTIL® after meal; In the second cycle subjects in experimental group took the reference preparation ACERTIL® after meal , the trial preparation perindopril tert-butylamine was taken orally after meals for the subjects in control group ; the order of taking the medicines for the subjects in the third cycle was the same as that in the first cycle, and the taking order of the subjects in the fourth cycle was the same as that in the second cycle. A single oral administration was used for the four cycles, and the dose was 4 mg.
223764916|NCT00524446|DIETARY_SUPPLEMENT|Maize-soy flour|Counseling + Vitamin A as for ST\_DI + 1 kg fortified maize / soy flour 2-weekly (71 g / day) between 6 and 18 months of age.
224225376|NCT04556110|DRUG|Perindopril tert-Butylamine tablets（ACERTIL®）|The trial was divided into four cycles, between of each cycle with a 14-day wash-out period.In the first cycle，subjects in experimental group took the test preparation Perindopril tert-butylamine after meal, and subjects in control group took the reference preparation ACERTIL® after meal; In the second cycle subjects in experimental group took the reference preparation ACERTIL® after meal , the trial preparation perindopril tert-butylamine was taken orally after meals for the subjects in control group ; the order of taking the medicines for the subjects in the third cycle was the same as that in the first cycle, and the taking order of the subjects in the fourth cycle was the same as that in the second cycle. A single oral administration was used for the four cycles, and the dose was 4 mg.
224225377|NCT03467412|DRUG|FOL-005|intradermal injection
223636809|NCT04634422|PROCEDURE|Plasma exchange and convalescent plasma|In addition to standard care, participants will receive 2 plasma exchange procedures max. 30 hours apart using the membrane or centrifuge method. PLEX will be initiated within 30 hours of randomization. The exchange volume of 60 mg of plasma per kg body weight will be substituted with albumin 5% and Ringer/saline 50% at the beginning followed by 50% FFP towards the end of the procedure. At the end of the 2nd procedure, participants will receive additional 2 units of CCP (equalling 600 ml CCP) with an administration rate of 100 to 250 ml/hr. Anticoagulation may be provided by citrate or by heparin but it is suggested that in patients with active bleeding regional citrate anticoagulation be utilized. PLEX may be performed via a central venous catheter if patient is deemed unsuitable for peripheral venous access, the latter is recommended. Possible SAE related to PLEX+CCP will be recorded as air embolism, anaphylaxis, TRALI and reported as an outcome.
223636810|NCT06326814|DRUG|Humanized anti-Factor Bb monoclonal antibody|Pharmaceutical form:Solution for injection-Route of administration:IV and SC routes of administration
223636811|NCT06326814|DRUG|Placebo|Pharmaceutical form:Solution for injection-Route of administration:IV and SC routes of administration
223636812|NCT06008314|OTHER|ePNa|"Real-time, automated clinical decision support tool for pneumonia (called ePNa)"
223636813|NCT04827069|DRUG|Clifutinib Besylate|receive oral Clifutinib Besylate once daily until disease progression or unacceptable toxicity occurs, each cycle is defined as 28 days
223636814|NCT04599244|OTHER|emergency pulpotomy|removal of coronal pulp
223636815|NCT04551547|BIOLOGICAL|Two doses of low dosage inactivated SARS-CoV-2 vaccine at the schedule of day 0,28|The inactivated SARS-CoV-2 vaccine was manufactured by Sinovac Research \& Development Co., Ltd., with a antigen content of 300SU/0.5ml
223636816|NCT04551547|BIOLOGICAL|Two doses of medium dosage inactivated SARS-CoV-2 vaccine at the schedule of day 0,28|The inactivated SARS-CoV-2 vaccine was manufactured by Sinovac Research \& Development Co., Ltd., with a antigen content of 600SU/0.5ml
223636817|NCT04551547|OTHER|Two doses of placebo at the schedule of day 0,28|The placebo contains no active ingredient and manufactured by Sinovac Research \& Development Co., Ltd.
223764917|NCT01274624|BIOLOGICAL|REOLYSIN®|1 hour intravenous infusion administered on Days 1, 2, 3, 4, and 5 every 4 weeks.
224225378|NCT03467412|DRUG|Placebo|intradermal injection
224225379|NCT00565981|DRUG|Fludarabine phosphate|orally, 40 mg/m2 d1-3 q4w, x4 cycles
224225380|NCT00565981|DRUG|Alemtuzumab|subcutaneous, starting dose 3 mg and escalation to 10 mg, then 30 mg, followed by 30 mg thrice weekly for 16 weeks in escalated dose
224225381|NCT06528041|OTHER|Inulin|12 g/day prebiotic supplement taken daily split into 2 dosages of 6 g dissolved in water
224225382|NCT06528041|OTHER|Maltodextrin|6 g/day maltodextrin taken daily split into 2 dosages of 3 g dissolved in water
224225383|NCT00789802|DRUG|transdermal estradiol|transdermal estradiol 0.1mg patch to be changed weekly for 12 weeks.
224225384|NCT00789802|DRUG|naproxen|naproxen 500mg by mouth twice daily for the first 5 days of every 4 week period for a total of 12 weeks
224225385|NCT00789802|DRUG|oral placebo|oral placebo to be taken by mouth twice daily for the first 5 days of a 4 week block for a total of 5 weeks
224225386|NCT01100684|DRUG|Asimadoline|0.5 mg Asimadoline BID
224225387|NCT01100684|DRUG|Placebo|Placebo
224225388|NCT05765955|DRUG|POLB 001|Investigational Medicinal Product
224225389|NCT05765955|DRUG|Placebo|Matching Placebo
224225390|NCT05628623|DRUG|Cytarabine|Arm A: CBF-Cytarabine 3000 mg/m2 or 1500 mg/m2 IV twice daily (BID), 12 hours apart x 6 doses either on Days 1, 3, and 5 OR Days 1, 2, and 3
224225391|NCT05628623|DRUG|Venetoclax|Venetoclax 100 mg daily Day 1 through Day 8 Venetoclax 400 mg orally once daily on Days 1-14 Venetoclax 400 mg orally once daily on Days 1-28
224225392|NCT05628623|DRUG|CPX-351|Daunorubicin 29 mg/m2/Cytarabine 65 mg/m2 liposome IV on Days 1 and 3
223764918|NCT01274624|DRUG|Irinotecan|90-minute intravenous infusion on Day 1 every 2 weeks. Dose levels of 125 mg/m2, 150 mg/m2, 150 mg/m2, 180 mg/m2.
223764919|NCT01274624|DRUG|Leucovorin|2-hour infusion of 400 mg/m2 on Day 1 every 2 weeks.
224225393|NCT05628623|DRUG|Azacitidine|Azacitidine 75 mg/m2 IV/SC on Days 1-7 OR Days 1-5 and Days 8-9 (per institutional preference)
224225394|NCT04434313|DEVICE|Delivery of iStride™ device gait treatment using telemedicine|The gait device used in this study mimics the actions of the split-belt treadmill but can be used during overground walking and in one's own home, thus enabling long-term training. This device does not require any external power and is completely passive; all necessary forces are redirected from the natural forces present during walking. This research aims to adapt the delivery mechanism of treatment with the iStride™ device to include telemedicine. The telemedicine platform of reference in this study, the Moterum Digital Platform, is an integrated therapeutic platform which offers an activity library, real-time video conferencing, and outcomes tracking. Our primary study objective is to determine if telemedicine is a safe and feasible delivery method for treatment with the iStride ™ gait device.
223764920|NCT01274624|DRUG|Fluorouracil (5-FU)|400 mg/m2 intravenous bolus followed by 2400 mg/m2 as a continuous intravenous infusion over 46 hours administered on Day 1 every 2 weeks.
223764921|NCT01274624|DRUG|Bevacizumab|30, 60 or 90 minute infusion on Day 1 every 2 weeks. Dose level 5 mg/kg.
223764922|NCT06374433|PROCEDURE|Occipital tACS at IAF-2Hz|tACS applied to occipital areas at 2 Hz below the individual alpha frequency (IAF)
223764923|NCT06374433|PROCEDURE|Occipital tACS at IAF+2Hz|tACS applied to occipital areas at 2 Hz above the individual alpha frequency (IAF)
223764924|NCT06374433|PROCEDURE|Frontal tACS at 4-7 Hz|tACS applied to frontal areas at 4-7 Hz
223764925|NCT06374433|PROCEDURE|Occipital tRNS|tRNS applied to occipital brain regions
224225395|NCT01975090|DEVICE|SENTRY IVC Filter|The SENTRY IVC Bioconvertible Filter is designed to provide temporary protection to subjects at transient, high risk of pulmonary embolism. Following conclusion of the protection period The SENTRY filter bioconverts, and filter arms withdraw towards the IVC wall for incorporation; obviating the need for retrieval.
224318871|NCT04966273|DEVICE|Microcatheter|Only to be used if Biosensor Microcatheter does not perform accordingly
224318872|NCT03072979|RADIATION|Stereotactic body radiotherapy|Stereotactic body radiotherapy
224318873|NCT00070200|BIOLOGICAL|filgrastim|
224318874|NCT00070200|DRUG|cisplatin|
224318875|NCT00070200|DRUG|cyclophosphamide|
224318876|NCT00070200|DRUG|doxorubicin hydrochloride|
224318877|NCT00070200|DRUG|etoposide|
223636818|NCT03010215|OTHER|Distal Metatarsal Minimally invasive Osteotomy (DMMO)|"Percutaneous dorsal incision at the level of the the distal part of the metatarsal bone, a Shannon burr is introduced at the level of metatarsal neck, with orientation of at approximately 45°, keeping the articular cartilage surface of the metatarsal head as reference point on the superior cortex.~In this position, under fluoroscopic control, the osteotomy is started following a distal-dorsal and proximal-plantar direction. In this way the metatarsal head moves proximally and dorsally reducing the metatarsal pressure on the plantar ulcer."
223636819|NCT05552287|DRUG|Infliximab|IFX will be given intravenously at 10 mg/kg at week 0, and 5 mg/kg at weeks 2, 4, and 8 to all patients (induction). Maintenance will start at week 12, and then ideally continue every 6 weeks till week 24 (end of study). IFX trough levels will be measured at weeks 4, 12, and 24. During the maintenance, the IFX dose and/or interval adjustments, the IFX discontinuation or the start of a co-medication (i.e., an immunomodulator) will be possible on indication (i.e., primary nonresponse, secondary loss of response, intolerance to study medication) at the physicians' discretion.
223636820|NCT05187689|BEHAVIORAL|VR + MHL intervention|The intervention will include: 1) a Virtual Reality (VR) interactive and immersive 30-minute session viewed using a low cost VR headset; and 2) an 8-week program of weekly WelTel SMS check-ins managed by Peer Navigators (PNs), weekly WelTel SMS blasts informed by Psychological First Aid (PFA) with mental health literacy (MHL) messages developed with PN, and weekly WelTel web-based secure platform social group discussions on MHL, stress coping, and stigma moderated by PN alongside a trained Coordinator. Weekly MHL WelTel platform moderated discussion foci will address MHL, stigma and stress coping strategies, including self-compassion and other strategies that emerge from the urban refugee youth interviews and focus groups, through diverse methods, including: 'scenarios' mimicking real life situations; a 'question box'; sharing photos demonstrating stress coping strategies; memes; songs; and ways participants interrupted stigma in their daily lives.
223636821|NCT05187689|BEHAVIORAL|Group PM+|"Participants will attend small groups (5-6 participants with a PN and a coordinator supporting) outdoors with physically distancing, for Group PM+ sessions following the adapted WHO Group-PM+ manual (adaptations made in Phase 1 explain above) 5 weekly 3-hour sessions delivered by PN who will co-facilitate sessions with the Coordinator. Each session has a mechanism of action:~1. Managing stress: mechanism of action-identify goals, learn deep breathing and techniques for stress management~2. Managing problems: mechanism of action-identify 1 solvable practical problem, brainstorm possible solutions together~3. Get going, keep doing: mechanism of action-learn about depression and inactivity, identify and plan small enjoyable activities~4. Strengthen social support: mechanism of action-discuss a range of social support resources, make plan to increase social support~5. Staying well: mechanism of action- this session reviews all of the mechanisms of action in the prior 4 sessions"
223636822|NCT03043417|BEHAVIORAL|CHC's given the intervention|CHC's NOT given the intervention
223636823|NCT03843814|PROCEDURE|APT MRI|
223636824|NCT05572255|DRUG|Cenobamate|200 mg Cenobamate Tablet
223636825|NCT01551186|DIETARY_SUPPLEMENT|Lactobacillus rhamnosus GG|1 capsule containing 10 billion cells of Lactobacillus rhamnosus GG on a twice-daily basis
223636826|NCT00872820|BEHAVIORAL|Acceptance- and commitment-based behavioral therapy|12 weekly treatment sessions conducted individually with a therapist; strategies for dealing with anxiety will include mindfulness and acceptance of negative feelings
223636827|NCT00872820|BEHAVIORAL|Cognitive behavioral therapy|12 weekly treatment sessions conducted individually with a therapist; methods for dealing with anxiety will include cognitive and breathing strategies
224225396|NCT01063179|DRUG|Bortezomib, Melphalan, Prednisone, Thalidomide|"Induction therapy:~9 courses with weekly VELCADE (4 doses) in combination with oral Melphalan 9 mg/m2,oral Prednisone 60 mg/m2 once daily on Days 1 to 4 of each course and Thalidomide 50 mg/day continuously. The dose of VELCADE is 1.3 mg/m2 administered as a bolus IV injection, on days 1, 8, 15, 22.~Maintenance therapy:~Thalidomide 50 mg/day continuously in combination with VELCADE 1.3 mg or maximum dose tolerated/m2/2 weeks. The maintenance will be initiated at the end of the 9th course and will be stopped after progression. The median expected duration of the maintenance treatment is approximately 2 years."
224225397|NCT01063179|DRUG|Bortezomib, Melphalan, Prednisone|Induction therapy: 9 courses with weekly VELCADE(4 doses) in combination with oral Melphalan 9 mg/m2 and oral Prednisone 60 mg/m2 once daily on Days 1 to 4 of each course. No maintenance therapy is scheduled
224318878|NCT00070200|DRUG|isotretinoin|
224318879|NCT00070200|DRUG|melphalan|
224318880|NCT00070200|DRUG|topotecan hydrochloride|
224318881|NCT00070200|DRUG|vincristine sulfate|
224318882|NCT00070200|PROCEDURE|conventional surgery|
224318883|NCT00070200|PROCEDURE|peripheral blood stem cell transplantation|
224318884|NCT00070200|RADIATION|radiation therapy|
223636828|NCT03391362|RADIATION|Stereotactic Radiation|Stereotactic radiation involves using a high dose of radiation that only targets the specific metastases
224318885|NCT05312320|OTHER|Information film|"* Sexual activity after MI does not increase risk of recurrence or death~* Sexual activity is associated with improved outcome after MI~* Resuming sexual activity as normal is recommended and completely safe"
224318886|NCT03269227|RADIATION|Accelerated hypofractionation with Tomotherapy|"Tomotherapy TPS will be used for treatment plannings. Patient' set-up daily control through Tomo-image (CT megavoltage) immediately before each sitting of all the patients.~Prescription doses:~Prescription dose to the target: 30 Gy in 5 daily fraction (at the reference isodose 60-70%) with an internal increasing inhomogenous dose of up to 37.5 Gy-40 Gy for GTV.~Steroids (methylprednisolone 4 mg daily) should be used from day 1 of radiotherapy to day + 30 after the end of the treatment."
223636829|NCT05897203|DRUG|TAZCOV|Herbal Syrup
223636830|NCT05897203|DRUG|Vidicine|Herbal Syrup
223636831|NCT05579678|BEHAVIORAL|Supportive nursing, nutritional and physical activity with a handheld 'app'|Supportive nursing, nutritional and physical activity with a handheld 'app'
223636832|NCT06064279|DRUG|Poly ICLC|Tol like receptor 3 agonist
223636833|NCT06064279|DRUG|IVIG|pooled IVIG
223636834|NCT05494385|DRUG|Preoperative Gabapentin/Postoperative Placebo|Postoperatively, this group will receive scheduled acetaminophen and ibuprofen every 6 hours, in addition to placebo every 12 hours. The placebo is encapsulated to appear identical to the active drug. This group will have oxycodone 5 mg every 6 hours as needed for pain.
223764926|NCT06374433|PROCEDURE|Frontal tRNS|tRNS applied to frontal brain regions
223636835|NCT05494385|DRUG|Preoperative Gabapentin/Postoperative Gabapentin|Postoperatively, this group will receive scheduled acetaminophen and ibuprofen every 6 hours, in addition to gabapentin every 12 hours. The gabapentin is encapsulated to appear identical to the placebo. This group will have oxycodone 5 mg every 6 hours as needed for pain.
223636836|NCT04137952|BEHAVIORAL|size of error visual feedback|The strategies are expected to enhance opportunities of error experience and motor exploration via modified visual feedback, underlying facilitations of attentional resource and error-related neural networks.
223636837|NCT05372757|PROCEDURE|Partial Heart Transplantation|The donor heart will be recovered and the new heart valve will be removed from this heart by the clinical team. The child will be scheduled for an emergent operation once the donor heart valve is deemed acceptable. The child will have general anesthesia during surgery. This is a state of unconsciousness, which is carefully controlled by the anesthesiologist with a mixture of very potent drugs, to prevent or lessen pain. The child will have a partial heart transplant using the donated heart valve to replace the dysfunctional heart valve. Expected hospital stay will range from weeks to months. The medical care after surgery is performed by the child's clinical team. This type of re-operation could similarly be required after a standard heart valve replacement.
223636838|NCT04139733|PROCEDURE|Prone positon|Prone position within 24 hours after VV-ECMO support. Prone position for at least conservative hours per day for a minimum of 5 days.
223636839|NCT04139733|PROCEDURE|Supine positon|Conventional supine position ventilation, no prone position.
223636840|NCT05542069|DEVICE|Threshold IMT (Inspiratory muscle trainer) by Philips|Apply a resistive load with the IMT device according the maximal inspiratory pressure of each subject.
223636841|NCT05276596|DRUG|Ephedrine|The control group will be taken care of according to the protocols in force. The first anesthetic post-induction hypotension will be managed by intravenous injection of ephedrine (dilution: 3 mg / ml) at a dose of 6 mg (i.e. 2 ml). Any subsequent hypotension will be treated with ephedrine until injection of a total dose of 30 mg. Thereafter, if a new arterial hypotension occurs, we will pass to the administration of noradrenaline in intravenous injection using an electric syringe pump, at the dilution of 0.016 mg / ml, posology adapted to the objectives. blood pressure.
223636842|NCT05276596|DRUG|Norepinephrine|Immediately use of norepinephrine by intravenous injection using an electric syringe pump, at a dilution of 0.016 mg / ml, at the time of anesthetic induction and without waiting the 1st possible arterial hypotension. Noradrenaline will be started at a dose of 0.48 mg / h and then adapted according to the blood pressure objectives.
223636843|NCT06057766|OTHER|Physical activity tele coaching program|"The program includes~1. one-to-one semi-structured interview with the coach discussing the importance of physical activity, motivation, self-efficacy, barriers, favourite activities, and (coping) strategies to become more active resulting in an individual action plan;~2. step counter (Fitbit) providing direct feedback which automatically sends data to the smartphone via blue-tooth. Patients will be asked to wear this step counter every day during the intervention;~3. smartphone coaching application (mPAC), installed on a smartphone and linked to the step counter, will provide automated coaching by displaying an individual activity goal (expressed as daily step count) and daily and weekly feedback on the performance (steps) of the patient.~4. phone calls by the coaches initiated in pre-defined situations (non-compliance with wearing the step counter, failure to transmit the data, failure to progress).~Evidence-based behaviour change techniques will be implemented."
224225398|NCT03005470|DEVICE|TELEM|Participants in the telemonitoring home blood pressure (TELEM) group will receive an oscillometric monitor to measure blood pressure at home for six months. Measurements will be made early in the morning (5:00 to 10:00) and in the evening (18:00 to 21:00) for at least five days a week (including one day during the weekend). Each blood pressure measure will be sent to the center of the study coordination center through software downloaded on the participant's smartphone.
224225399|NCT03005470|DEVICE|TELEMEV|In the lifestyle telemonitoring group (TELEMEV), participants will receive customized standardized text messages to stimulate lifestyle changes and adherence to blood pressure lowering medication. The messages will be focused on the adoption of DASH diet, sodium restriction, increase of physical activity, weight control and adherence to drug treatment. They will be sent out on four of the five days of the week at random times. The messages will be sent to the smarphones through a software developed for this study.
223515200|NCT01313325|OTHER|Hippotherapy|Children will receive treatment by a licensed physical therapist using hippotherapy as the treatment strategy. This includes sitting on a horse who's movement is controlled by a horse leader, with the PT directing the movements required of the horse, as well as supplying supplemental cues to the participant. Alternative positions (such as sitting backward and sideways) may also be used during the treatment session.
223636844|NCT03108131|DRUG|Atezolizumab|Given IV
223636845|NCT03108131|DRUG|Cobimetinib|Given PO
223636846|NCT06458465|DIETARY_SUPPLEMENT|Curcumin|\- Curcumin capsules 500 mg twice daily for 6 months
223636847|NCT06458465|DRUG|Pentoxifylline 400 MG|\- Pentoxifylline 400 mg twice daily for 6 months.
223636848|NCT06498349|PROCEDURE|bilateral high frequency deep brainstimulation of the subthalamic nucleus combined with best medical treatment|according to widely accepted expert consensus paper
223764927|NCT06374433|PROCEDURE|Sham/placebo tACS|tACS is activated only for 30 seconds and then turned off, thus resulting ineffective
224225400|NCT03005470|DEVICE|TELEM-TELEMEV|Participants in the TELEM plus TELEMEV (TELEM-TELEMEV) will receive both interventions as previously described.
223515201|NCT00692237|DRUG|Sildenafil|100 mg daily (3 capsules/day)
223515202|NCT00692237|DRUG|Placebo|Placebo 100 mg (3 capsules/day)
223515203|NCT00359398|PROCEDURE|Platelet rich plasma sequestration|Venesection of blood (14 ml/kg) and separation to red cells and platelet rich plasma.
223515204|NCT03599726|DRUG|Donepezil|Donepezil 5 mg per day for week 1-2 or 5-6
223515205|NCT03599726|DRUG|Placebo|Placebo 5 mg per day for week 1-2 or 5-6
223515206|NCT02475863|DEVICE|Warfarin Dosing Aid|A pharmacokinetic/pharmacodynamic model-based dosing algorithm for warfarin
223515207|NCT02475863|OTHER|Standard Practice|Warfarin dose adjustments according to standard unit protocol
223515208|NCT01601561|DRUG|Regular human insulin injection|"Hyperinsulinemic normoglycemic clamp from beginning of surgery until 8 hours after surgery.~Humulin R 5 mU/kg/min and a variable infusion of glucose."
223636849|NCT06498349|DRUG|best medical treatment (BMT): Adjustment of the dopaminergic medication and non-dopaminergic therapy customized for each patient according to the latest published Consensus Group Recommendations|according to (Debove et al (2024), 'Management of Impulse Control and Related Disorders in Parkinson's Disease: An Expert Consensus, Mov Disord.
223636850|NCT06561919|PROCEDURE|bilateral high frequency deep brain stimulation of the subthalamic neucleus combined with best medical treatment according to widely accepted expert consensus paper|Best medical treatment according to widely accepted expert consensus Paper
223636851|NCT06561919|DRUG|best medical treatment for management of impulse control in Parkinson´s disease according to widely accepted expert consensus paper|Best medical treatment according to widely accepted consensus Paper
223636852|NCT06555406|BEHAVIORAL|Time-restricted eating for 8 weeks|limiting food intake to 10 hours per day
223636853|NCT04727970|DRUG|Tricaprilin|Tricaprilin will be emulsified in infant formula/milk
223636854|NCT01838395|DRUG|Ara-C|IV (intravenous administration)
223636855|NCT01838395|DRUG|BL-8040|SC (subcutaneous injection)
223636856|NCT05146882|DRUG|Belcesiran|Belcesiran will be administered subcutaneously (SC) in the treatment arm.
224225401|NCT03005470|OTHER|UCT|Participants in the control group will receive usual clinical treatment (UCT) on pre-scheduled visits, but will not receive any technological tool to stimulate blood pressure control or lifestyle modification.
224225402|NCT05455242|BEHAVIORAL|Habit formation|Habit formation interventions to promote context-dependent automatic behaviors to support diabetes self-management.
224225403|NCT06437132|OTHER|No intervention|The study is observational and will not include any specific interventions other than the regular care practice that the participants receive from their care providers. The study will use a wrist-mounted smartwatch for monitoring (Garmin VivoActive5). Previous studies show acceptability toward wearable devices among persons with dementia. Moreover, the investigator will use Somnofy, VitalThings, a radar installation mounted behind the patients bed. At the very end of life, the investigator will also apply Shimmer3 Ebio sensor measuring the patients breathing activities. Before starting the data collection, care staff will recognize any discomfort or distress potentially caused by the devices, in which case the relevant device will be immediately removed.
224225404|NCT03408600|OTHER|Management|To evaluate vital signs in a global cohort of patients with acute peritonitis, determining which parameters are statistically significant to predict in-hospital mortality and ICU admission.
224225405|NCT02067793|DRUG|NRX-1074 1 mg|Single intravenous administration of 1 mg into arm on Day 0
224225406|NCT02067793|DRUG|Placebo|Single intravenous injection into the arm on Day 0
223636857|NCT05070923|BEHAVIORAL|HealthyLifetime|HL augments existing case management services by focusing on building the participant's personal capacity for independence in self - care skills, health behavior change, and health decision making. The HL program coordinates and interfaces with the enrollee's primary medical provider, case managers, and caregivers as necessary
223636858|NCT05684419|OTHER|Fate and quality of medical follow-up of children born very premature (≤33SA) to homeless mothers|Evaluation of the fate and quality of medical follow-up of children born very premature (≤33SA) to homeless mothers.
223636859|NCT03866577|BIOLOGICAL|Biological: M254|M254 administered as intravenous infusion
223636860|NCT03866577|DRUG|Placebo|Placebo administered as intravenous infusion
223636861|NCT03866577|BIOLOGICAL|Intravenous immunoglobulin (IVIg)|IVIg administered as intravenous infusion
223764928|NCT06374433|PROCEDURE|Sham/placebo tRNS|tRNS is activated only for 30 seconds and then turned off, thus resulting ineffective
223764929|NCT04564755|DRUG|abrocitinib|Participants will receive abrocitinib 100 mg or 200 mg orally once a day as directed by the investigator's clinical judgement
223636862|NCT03671330|DRUG|Ribociclib Placebo|Film-coated tablets for oral use (200 mg x 3) form Day 1 of 21 of each 28 day cycle.
223636863|NCT03671330|DRUG|Ribociclib|Film-coated tablets for oral use (200 mg x 3) form Day 1 of 21 of each 28 day cycle.
223636864|NCT03671330|DRUG|NSAI: Letrozole or Anastrazole|"Letrozole: Tablets for oral use, 2.5mg daily (all days of every cycle without interruption).~Anastrazole: Tablets for oral use, 1mg daily (all days of every cycle without interruption) For Premenopausal cohort, it is the investigators choice for NSAI based on patients past history.~For postmenopausal and PK cohorts, all patients will be on Letrozole."
223636865|NCT03671330|DRUG|Letrozole|Letrozole: Tablets for oral use, 2.5mg daily (all days of every cycle without interruption).
223764930|NCT05033964|COMBINATION_PRODUCT|Percutaneous Coronary Intervention with drug eluting stents|Coronary drug eluting stent implantation
223764931|NCT03495882|DRUG|AGEN1884 + AGEN2034|AGEN1884 + AGEN2034 according to protocol design
223764932|NCT05520034|BEHAVIORAL|Health Education|The participants received a 45mins, face-to-face group health education after enrollment and during the 6th month by a RA nurse. Participants received the same health education over the phone call if the patient and family caregiver could not come for any reason. They also received a digital BP machine, a salt-measurement spoon, a medication box, and a recording notebook for monitoring. The intervention group receives health education above and reminder telephone calls provided by research assistant nurses every month (1st month to 3rd month: twice a month, and 4th month to 12th month: once a month)
223764933|NCT02151526|DRUG|LentiGlobin BB305 Drug Product|LentiGlobin BB305 Drug Product was administered by intravenous (IV) infusion.
223764934|NCT05929482|BEHAVIORAL|Infección de Amor (Infectious Love)|"Infectious Love is a filmed dramatized story (telenovela/soap opera) culturally tailored for US Latinas and delivered online.~IA is a four-episode HIV prevention telenovela co-created with Latinas and a community-based participatory and interdisciplinary. Participants have one week window to watch the 10-minute episodes from their preferred device and location."
223636866|NCT03671330|DRUG|Goserelin|Subcutaneous implant, 3.6mg on Day 1 of each 28 day cycle
223636867|NCT04825678|DRUG|Erenumab|Administered as a subcutaneous injection via the SureClick® Autoinjector Pen (AI/Pen).
224225407|NCT02067793|DRUG|NRX-1074 5 mg|Single intravenous injection of 5 mg into the arm on Day 0
224225408|NCT02067793|DRUG|NRX-1074 10 mg|Single intravenous injection of 10 mg into the arm on Day 0
224225409|NCT05598437|DEVICE|Dry eye device|Dry eye analysis
224318887|NCT04290273|DIAGNOSTIC_TEST|MED Test|Participant is irradiated with several doses of UV light on small areas of the outer thigh. 24 hours later this area is visually inspected for erythema, and the minimal erythemal dose (MED) is determined.
224225410|NCT04763837|DEVICE|Intraureteral stent|This intervention involves the placement of an intraureteral stent, a tube that drains urine from the kidney to the bladder and has a loop of tube only in the kidney and NOT in the bladder. The distal end of the tube will stay in the ureter just proximal to the opening to the bladder.
223636868|NCT05530252|DRUG|Oral biological antimicrobial gel|The patients were divided into subgingival scaling, and Oral Biological Antimicrobial Gel was used in the periodontal pocket after scaling. The injection probe with gel was inserted into the periodontal pocket, and the injection was slowly pushed, and the injection was gradually withdrawn during the injection, until a little gel was found at the mouth of the bag.
223636869|NCT05530252|DRUG|minocycline hydrochloride ointment|The patients were divided into subgingival scaling, and minocycline hydrochloride ointment was used in the periodontal pocket after scaling. The injection probe with gel was inserted into the periodontal pocket, and the injection was slowly pushed, and the injection was gradually withdrawn during the injection, until a little gel was found at the mouth of the bag.
223636870|NCT05530252|OTHER|SRP|only scaling and root planning was performed on the patient
223636871|NCT02067078|DRUG|Dexamethasone 4 mg + Clonidine 75 microgram + Marcaine 90 mg + Adrenaline 90 microgram|Dexamethasone 4 mg Clonidine 75 microgram Marcaine 90 mg Adrenaline 90 microgram
223636872|NCT02067078|DRUG|Dexamethasone 2 mg + Clonidine 37,5 microgram + Marcaine 45 mg + Adrenaline 45 microgram|Dexamethasone 2 mg Clonidine 37,5 microgram Marcaine 45 mg Adrenaline 45 microgram
223636873|NCT02067078|DRUG|Ropivacaine + Toradol + Adrenaline|Ropivacaine 300 mg + Toradol 45 mg + Adrenaline 0,75 mg
223636874|NCT05949333|DRUG|Eflapegrastim|long-acting granulocyte-colony stimulating factor
223636875|NCT04336553|BEHAVIORAL|Social prescribing in Sweden (SPiS)|Social prescribing in sweden (SPiS)
223636876|NCT03827096|DRUG|Suspension of human autologous MSC 3P in 1.5 ml|During the posterolateral spine fusion operation, 1.5 ml of cell suspension was mixed with 5cc of beta-tricalcium phosphate foam and 3.5 ml of patient's blood, and inserted between the right transverse processes of the lumbar spine.
224225411|NCT04763837|DEVICE|Conventional Double-J stent|This intervention involves the placement of a conventional double-J stent, a tube that drains urine from the kidney to the bladder and has a loop of tube in both the kidney and in the bladder.
223636877|NCT00873483|DRUG|Ethinylestradiol/Gestodene (BAY86-5016)|0.55 mg ethinyl estradiol \& 2.1 mg gestodene, 21 days for 3 cycles
223636878|NCT05494190|DRUG|Docetaxel|60 mg/m2 i.v. day 1
223636879|NCT05494190|DRUG|Cisplatin|60 mg/m2 i.v. day 1-3
223636880|NCT05494190|DRUG|Capecitabine|750 mg/m2 po bid day 1-14
223636881|NCT05494190|RADIATION|Concomitant chemoradiotherapy|"Radiotherapy: using intensity-modulated radiation therapy (IMRT)~Gross tumor volume (GTV) for primary tumor: 66-70 Gy in total, 2.0\~2.2 Gy per day, 5 days per week~Clinical target volume (CTV) for lesions closely related to the primary lesion and metastatic lymph nodes: 65\~70 Gy in total, 1.7\~2.0 Gy per day, 5 days per week~Prophylactic irradiation for sites of suspected subclinical spread: 50\~60 Gy in total, 1.7\~2.0 Gy per day, 5 days per week~Concurrent chemotherapy: cisplatin 80 mg/m2 on days 1-3 every 3 weeks."
223636882|NCT05494190|PROCEDURE|Surgery|Neck dissection and primary tumor resection
223636883|NCT06080334|DEVICE|Dry needling|Dry needling using the Hong technique on the most hyperalgesic trigger point in the gastrocnemius muscle.
223764935|NCT04601688|DRUG|Bevacizumab Ophthalmic and Intravitreal Dexamethasone|Pro re nata patients with BRVO will initially receive Bevacizumab and intravitreal Dexamethasone. And then depending on their clinical status of BRVO, Bevacizumab will be injected.
223764936|NCT04601688|DRUG|Bevacizumab Ophthalmic|Pro re nata patients with BRVO will receive Bevacizumab. And then depending on their clinical status of BRVO, Bevacizumab will be injected.
223764937|NCT03858387|DRUG|Meropenem|"This group is composed of 52 critically ill patients, meropenem dosage is chosen by the intensivist in charge of the case.~Blood sampling: 5 blood samples (3 mL) were obtained from a heparinized intravascular catheter by direct venipuncture at the following time: before (time 0) and during 0-0.5 h, 0.5-2.5 h, 2.5-4 h, 4-8 h or 4-12 after meropenem administration."
224225412|NCT01889511|BEHAVIORAL|Intervention group - texts|"Patients will be instructed to respond to the text message by sending a text stating if the oral agent was taken. If there is no response after 15 minutes, a second text message will be sent out, again requesting a response. Satisfaction surveys will occur in the intervention group at week 5 when the text messages end; and will take five minutes."
224225413|NCT02371083|OTHER|Extended timing of pessary care|
223636884|NCT06080334|DEVICE|Electrolysis|Electrolysis on the Achilles tendon using ultrasound-guided technique.
224225414|NCT00544583|PROCEDURE|Interrupted sutures|Interrupted sutures for abdominal fascia closure with Vicryl equivalent sutures (USP 2, 45 cm)
224225415|NCT00544583|PROCEDURE|Continuous sutures|Continuous sutures for abdominal fascia closure with PDS II equivalent USP 1, 150 cm loops
224225416|NCT05890066|PROCEDURE|single-port laparoscopy|Compare the effectiveness and safety between single-port and multi-port laparoscopic surgery
224225417|NCT00322257|DRUG|inhaled human insulin|Treat-to-target dose titration scheme, inhalation.
223636887|NCT05826314|OTHER|Boxing training|Training protocol will be held for 24 weeks, twice per week/ 45 min per sessions.
223636888|NCT05826314|OTHER|Exercise|Training protocol will be held for 24 weeks, twice per week/ 45 min per sessions.
223636889|NCT04052854|DRUG|Zanubrutinib|Zanubrutinib will be orally administered in participants with treatment naive or R/R WM
223636890|NCT05271240|DRUG|Repeated Superselective Intraarterial Cerebral infusion (SIACI) of Bevacizumab (Avastin) with Temozolomide and Radiation|Subjects who are assigned to the IA BV+TMZ/RT group (Treatment Group), in addition to your standard of care cancer treatment, you will have a dose of bevacizumab delivered directly to your brain through superselective intra-cranial intra-arterial catheterization of the arteries that supply blood to your brain tumor along with the start of the initial 42 day oral temozolomide treatment. IA BV will be repeated every three months for a total of 3 infusions.
223636891|NCT05271240|DRUG|Temozolomide and Radiation Alone|Subjects who are assigned to the TMZ/RT alone group (Control Group) you will receive standard of care cancer treatment that involves a daily oral dose of temozolomide for 42 days with radiation to the tumor followed by 28 days of rest and then repeated maintenance treatment cycles of daily oral temozolomide 5 days on and 23 days off.
224225418|NCT00322257|DRUG|insulin detemir|Injection s.c., 50% of daily dose
224225419|NCT00322257|DRUG|insulin aspart|Treat-to-target dose titration scheme, injection s.c.
224225420|NCT00190853|DRUG|Duloxetine|
223636892|NCT05226442|DRUG|Argatroban|Argatroban is a synthetic, univalent DTI, that directly binds to the catalytic thrombin binding site exerting its effects
224225421|NCT00222677|DRUG|aspirin|100 mg daily
223636893|NCT05226442|DRUG|Unfractionated heparin|Unfractionated heparin produces its major anticoagulant effect by inactivating thrombin and activated factor X (factor Xa) through an antithrombin (AT)-dependent mechanism.
223636894|NCT04895891|DEVICE|EOS hand imaging|For each patient, EOS images are compared with CT images
223636895|NCT06242574|OTHER|Survey|Each group will have to complete a questionnaire online, taking about 30 minutes.
224225422|NCT00000898|DRUG|Ritonavir|
224225423|NCT00000898|DRUG|Nelfinavir mesylate|
224225424|NCT00000898|DRUG|Saquinavir|
224225425|NCT00746668|BEHAVIORAL|Module 1: Visual Awareness and Eccentric Viewing|"In this module, awareness of the PRL location and eccentric viewing were trained. Exercises based on published sources were administered. One example of these exercises is the clock face display adapted from Holcomb and Goodrich and Maplesden.~This module also focused on awareness of the perceptual consequences of using a PRL. The purpose of these training exercises was to allow the subjects to appreciate perceptual alterations that occur when using a PRL and to practice making perceptual discriminations with the peripheral retina. Previously published work has demonstrated that perception in the peripheral retina can be affected by practice."
224225426|NCT00746668|BEHAVIORAL|Module 2: Control of Reading Eye Movements|In this module, control of eye movements was trained. These exercises began with a series of saccade tasks to nonalphabetical stimuli and then progressed to single letter, letter pairs, and word stimuli. Subjects were instructed to make a saccade between the dots. The experimenter provided feedback concerning the appropriateness of the saccades, and the alternation rate of the dots was increased as performance improved.
224225427|NCT00746668|BEHAVIORAL|Module 3: Reading Practice with RSVP|In module 3, we wanted to assess only the higher-level effects of reading practice. Subjects practiced reading using stimuli that did not require reading eye movements. An example is short sentences that were presented one word at a time at a single location on a screen (Rapid Serial Visual Presentation \[RSVP\]). At the end of the sentence, subjects reported whether the sentence made sense or not. We also had our subjects practice reading scrolled text. Although, eye movements and saccades may spontaneously occur under the text presentation conditions of this module, they are not the efficient saccades necessary for reading.
224225428|NCT01806974|OTHER|oral exam and|The study will be conducted with patient presenting a rheumatoid arthritis and for which an anti IL6 biotherapy treatment is planned. Each patient will benefit a record oral exam that will evaluate his periodontal status and on a possible periodontitis associated. Bacterial samples and cytokine will be realized (in defined periodontal pocket or in the most affected periodontal pocket depending of the periodontal status of patients) before the IL6 biotherapy and 6 month after. A periodontal charting will be realized at the same time.
224225429|NCT04910230|DRUG|nicotinamide|In addition to usual care, the treatment group was given 500mg nicotinamide daily, divided into 5 doses
224225430|NCT04721457|DRUG|Distilled Water|Control group
224225431|NCT04721457|DRUG|1% Povidone Iodine (PVP-I)|Over-the-counter antiseptic mouth rinse
224225432|NCT04721457|DRUG|1.5% Hydrogen Peroxide (H2O2)|Over-the-counter antiseptic mouth rinse
224225433|NCT04721457|DRUG|0.075% Cetylpyridinium Chloride (CPC)|Over-the-counter antiseptic mouth rinse
223636896|NCT04377100|BEHAVIORAL|Computer task questionnaires|MH COVID-19 Adult, MASQ-SF, STAI, ACS, Hollingshead, DSM XC, PMHC, AUDIT, debriefing questionnaire, and finger-tapping task
223636897|NCT03353688|DEVICE|Boston Scientific Vercise PC IPG with directional DBS lead|Deep brain stimulation
223636898|NCT05609565|DRUG|spinal anesthesia with hyperbaric prilocaine+adductor canal block (ACB) with bupivacaine|spinal anesthesia with hyperbaric prilocaine+adductor canal block (ACB) with bupivacaine
223636899|NCT05609565|DRUG|spinal anesthesia with bupivacaine|spinal anesthesia with bupivacaine
223636900|NCT04249999|BEHAVIORAL|ActivOnline|Access to online physical activity platform (www.activonline.com.au)
223636901|NCT06305650|DIETARY_SUPPLEMENT|Probiotic|Through oral probiotic intervention for 12 weeks, participants' BMI, body fat percentage, and waist-to-hip ratio will be measured at weeks 0, 6, and 12, and fecal samples will be collected at weeks 0 and 12 for gut microbiota analysis.
223636902|NCT06584903|OTHER|Temperature Ramp Protocol|Following a 45 minute baseline in 37°C seated on a chair, the indoor temperature in the climate-controlled room increased from 37°C to 47°C at \~0.06°C/min (relative humidity \~26%) over 180 minutes.
223636903|NCT04760613|DRUG|Cannabidiol|600 mg oral daily use (each capsule of active drug contains 50 mg of CBD)
223636904|NCT04760613|DRUG|Placebo|identical capsules containing placebo (taken daily by mouth)
223636905|NCT05754645|OTHER|Blood withdrawal|venous punction with blood withdrawal Vaginal and rectal swab, done by patient itself
223636906|NCT06551610|OTHER|Triage Tool|Tool that uses patient characteristics to triage patients for an earlier procedure date vs the standard of care 12 week wait for procedure.
223636907|NCT06465147|BIOLOGICAL|SCRI-CAR19v3|Single infusion of SCRI-CAR19v3
224225434|NCT04721457|DRUG|0.1% Sodium Hypochlorite|Over-the-counter antiseptic mouth rinse
224225435|NCT04721457|OTHER|No rinse group|second control group
224225436|NCT03607630|OTHER|Imagery Rescripting|psychological therapy
224225437|NCT03043274|DRUG|Cangrelor|Cangrelor 30 mcg/kg bolus followed by a 4 mcg/kg/min intravenous infusion prior to PCI will be given. It will be continued for ≥ 2 hours or for the duration of the procedure, whichever is longer.
224225438|NCT03433001|DRUG|Ixazomib|Ixazomib capsules
224225439|NCT03433001|DRUG|Lenalidomide|Lenalidomide capsules
224225440|NCT03433001|DRUG|Dexamethasone|Dexamethasone tablets
224225441|NCT03385096|DRUG|Busulfan (BU)|"Busulfan was administered at 3.2 mg/kg/day on days -8 to -6.~-7 to -4."
224225442|NCT03385096|DRUG|Cyclophosphamide (CY)|Cyclophosphamide was administered at 60 mg/kg/day on days -5 to -4. on days -3 to -2.
224225443|NCT03385096|DRUG|Etoposide (VP-16)|"Etoposide was administered at 10 mg/kg/day on days -3 to -2.~-3 to -2."
224225444|NCT03385096|DRUG|Melphalan|Melphalan was administered at 200mg/m2 on day -2.
224225445|NCT02815904|OTHER|Yakson touch|Yakson is a Korean therapeutic touch given to neonates and infants by caressing their abdomen with one hand while the other hand is placed on the back of the neonate\\infant to relieve their pain or to calm them down.
223636908|NCT06578468|DEVICE|End-tidal oxygen monitor|"The only additional equipment required for this study is the Philips™ IntelliVue G7m Gas Analyser Module 866173. This provides a non-dispersive infrared measurement of respiratory gases and a paramagnetic measurement of oxygen. At Lincoln Medical Center, the gas analyser used will be a Philips G5 gas analyser connected to a Philips Intellivue MP 70. At the University of New Mexico Medical Center, the Masimo root monitor is used.~The gas analysers produce display waves for O2 and CO2, together with numerics for end-tidal values for O2 and CO2 and to our knowledge, there are no differences in values between the various devices used. The gas sampling occurs through a side-stream sampling tube at a rate of 200ml/min ±20 ml/min, which is either obtained from a nasal cannula in the spontaneously breathing patient or a sidestream line if connected to a BVM."
223636909|NCT05739019|OTHER|frozen embryo transfer|transfer one or two embryos in frozen embryo transfer cycles
224225446|NCT02815904|OTHER|Conventional handling|Positioning of preterm infants for optimal physiological development
223636910|NCT05724329|DRUG|Tislelizumab + Dasatinib + Quercetin (neoadjuvant)|Patients receive Tislelizumab (IV) on day 1, dasatinib (PO) on day 1,2,3 and quercetin (PO) on day 1,2,3. Treatment repeats every 21 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.
223636911|NCT05724329|PROCEDURE|surgery|Standard of care
223636912|NCT05724329|DRUG|Tislelizumab + Dasatinib + Quercetin (adjuvant)|Tislelizumab (200 mg, day=1) Cycle=1-15cycle Dasatinib (100mg/day, day= 1,2,3) Cycle=1、2、3、8、9、10 Quercetin (1250mg/day, day= 1,2,3) Cycle=1、2、3、8、9、10
223636913|NCT04844827|GENETIC|Conserving routinely performed pleural biopsies in our biological resources center to realize multiomics and bioinformatics analyzes secondarily|Interventions will consist of a diagnostic and symptomatic videothoracoscopy in patients with pleural metastasis under general anesthesia, as part of a standard of care procedure. Fragments of these pleural biopsies (one for routine diagnosis and two for scientific purposes) will enrich the biocollection. Five blood samples will be taken at the time of surgery (3 to 5 ml / tube). These biological samples will be stored in the HCL CRB tumor bank. At the same time, patient demographic data will be collected and anonymized. In the long term, the biological material will be used by IARC for carrying out multi-omics and bioinformatics analyzes
223636914|NCT04499326|OTHER|Validated quality of life questionnaire (EQ-5D & C-CAP)|Patient quality of life to be assessed at baseline, 1, 2, 3, 4, 6, 9 and 12 months
223636915|NCT05148156|DEVICE|Urolift|Study intervention involves a one-time administration of Urolift in out-patient setting prior to Stereotactic body radiation therapy (SBRT).
223636916|NCT03043794|RADIATION|Stereotactic Body Radiation Therapy SBRT|Stereotactic Body Radiation Therapy to the breast to 21 Gy
223636917|NCT06306599|DIAGNOSTIC_TEST|S-Detect for Thyroid|"Deep learning based program on Samsung ultrasound machines designed to do real-time semi-automated analysis of thyroid nodules. The ultrasound operator freezes a transverse image of the patient's thyroid nodule and activates S-Detect. The operator selects the nodule on the screen, and the program automatically draws a region of interest. Then S-Detect gives a dichotomous diagnosis of either Possibly benign and Possibly malignant. In addition, it measures the nodule and characterises it with a lexicon based on EUTIRADS."
223636918|NCT05819658|DRUG|GV1001 Placebo|0.9% normal saline
223636919|NCT05819658|DRUG|GV1001 0.56mg|Lyophilized peptide from hTERT
223636920|NCT05819658|DRUG|GV1001 1.12mg|Lyophilized peptide from hTERT
223636921|NCT06462794|DRUG|CX-801|Investigational drug
224225447|NCT02815904|OTHER|Kinesthetic stimulation|For kinesthetic stimulation, all the limbs were given six passive flexion and extension movements
224225448|NCT02815904|OTHER|Kangaroo Mother Care|Providing skin to skin human touch
224225449|NCT01423435|DRUG|TRK-100STP|oral
224225450|NCT06153524|BEHAVIORAL|Physical activity|12x weekly advice sessions and autonomous physical activity to gradually build up moderate-vigorous exercise.
223636922|NCT06462794|DRUG|pembrolizumab|Standard of Care Therapy
223636923|NCT03600324|BEHAVIORAL|T-REV|For any intervention that involves physical exercise, four parameters must be specified to complete the prescription; Type (mode), Intensity, Frequency, and Time. o The standard of care vestibular rehabilitation exercise program consists of three types of treatments that target the specific impairments and limitations discovered during the examination. The three types are: 1) gaze stabilization for vestibulo-ocular reflex dysfunction, 2) visual-vestibular habituation exercise for visual motion sensitivity, and 3) balance exercises for standing balance or gat dysfunction.
223636924|NCT05331638|BEHAVIORAL|Prostate Cancer Genius App|Participants assigned to use the Prostate Cancer Genius App will receive a combination of (a) scheduled and (b) on-demand content prostate cancer for one month. Scheduled content will be delivered on specific days each week using app notifications. Participants will also receive tailored navigation for ordering a home-based PSA kit, including receiving follow-up information from trained medical professionals about their test results.
224225451|NCT06153524|BEHAVIORAL|Smartphone time|12x weekly advice sessions and autonomous use of replacement activities and strategies to gradually reduce daily smartphone use.
224225452|NCT00373724|PROCEDURE|radiofrequency denervation|
224225453|NCT01007916|DEVICE|Lotrafilcon B contact lens|Commercially marketed, silicone hydrogel, spherical contact lens having a recommended replacement schedule of monthly.
224225454|NCT01007916|DEVICE|Habitual contact lens|Habitual soft spherical contact lens having a recommended replacement schedule of 2 weeks or monthly.
224225455|NCT05585463|PROCEDURE|acupuncture|Acupuncture with needles and intracutaneous needles in the ear or body. The insertion is done with gloves, a guide to puncture the needle, and exhaustive skin disinfection.
224225456|NCT05333419|DRUG|100ng/day PA5346 Latanoprost FA SR Ocular Implant|PA5346 ocular implant is a small, clear rod-shaped implant that is placed in the anterior (front) chamber of the eye, at a single timepoint, and slowly releases a drug called latanoprost free acid (100ng/day) over a period of approximately 30 weeks
224318888|NCT04290273|DEVICE|Wearing device|Participants wear a portable erythema measurement device for 48 hours. The device shines light on the skin at frequent intervals and measures skin 'redness'. The device is removed by a technician after the 48 hours.
224318889|NCT06427837|OTHER|Same 2nd course|The same snack food will be served in the second course
224318890|NCT06427837|OTHER|Different 2nd course|A different snack food will be served in the second course
224318891|NCT00797537|PROCEDURE|Echography|Echography
223636925|NCT05331638|BEHAVIORAL|US Prevention Taskforce App|Participants assigned to use the US Prevention Task Force app will download the app from Google Play and will be instructed to use the app for one-month to to become more informed about prostate cancer. They will also be instructed to download a companion app from the Google Play store. This companion app will be used to deliver weekly assessments and order a home-based PSA test kit if the participant chooses to so. Participants assigned to the Prevention Taskforce app will receive a brochure providing details about the purpose of the home-based PSA test.
223636926|NCT05897658|DRUG|Levetiracetam|Tablets
223636927|NCT05897658|OTHER|Placebo|Tablets
223636928|NCT05321134|DEVICE|Single port robotic colorectal surgical procedure|"After screening and counseling, study subjects who wish to participate will undergo the colorectal surgical procedure (determined based on routine standard clinical care) using the alternate Intuitive Da Vinci Single Port SP system rather than the currently used multiport system, (Intuitive Da Vinci Multiport Xi System).~Using standardized case report forms, the investigators will track clinical parameters and describe the safety \& quality event rate for SP platform transabdominal and transanal colorectal operations."
223636929|NCT02444338|DEVICE|MitraClip|Implantation of the MitraClip System for patients with chronic heart failure.
223636930|NCT02444338|OTHER|standard of care|
223636931|NCT03008291|PROCEDURE|CRT-D Implantation|Cardiac resynchronization therapy defibrillator
223636932|NCT03008291|PROCEDURE|CRT-P Implantation|Cardiac resynchronization therapy pacemaker
223636933|NCT03008291|PROCEDURE|Dual Chamber Pacemaker Implantation|
223636934|NCT01416220|DRUG|Lithium|"Study drug will be packaged and supplied in an open-label fashion. There will be a washout period of all active psychotropic medication. Psychotropics will be withdrawn over 5 half-lives with the exception of drugs known to cause withdrawal symptoms (primarily antidepressants), which will be tapered over 10 days.~Following the enrollment period, subjects will enter a six-week randomized treatment period with either lithium or paroxetine. Lithium carbonate will be commenced at 600mgs hs, with increase to 900mgs at day 7. Dose will be flexibly titrated to give a serum level between 0.5 and 1.1mmol/l. At visit 4, the dose of lithium may be adjusted (within the range of 0.6 and 1.1 mmol/l."
223636935|NCT01416220|DRUG|Paroxetine|"Study drug will be packaged and supplied in an open-label fashion. There will be a washout period of all active psychotropic medication. Psychotropics will be withdrawn over 5 half-lives with the exception of drugs known to cause withdrawal symptoms (primarily antidepressants), which will be tapered over 10 days.~Following the enrollment period, subjects will enter a six-week randomized treatment period with either lithium or paroxetine. Paroxetine will be commenced at 10mgs and increased to 20mgs on day 7. At visit 4, the dose of paroxetine may be increased to 40mgs, if there is no response (less than 20% reduction in MADRS score) as per current Canadian guidelines."
223636936|NCT05205031|DEVICE|Intraosseous access|Needle placed in the bone marrow.
223636937|NCT05205031|DEVICE|Intravenous|Needle placed in a vein.
223636938|NCT04838171|OTHER|White blood cell and blood collection|Mononucleocytes will be collected via apheresis
223636939|NCT05565742|DRUG|LY3819469|Administered SC
223636940|NCT05565742|DRUG|Placebo|Administered SC
223636941|NCT06500338|PROCEDURE|free-fall|"The aircraft will fly in parabolas that initially produce increased gravity (1.8-G, hypergravity), followed by \~20-50 second periods of partial gravity or weightlessness. Flights which produce partial gravity (0.25-, 0.50-, and 0.75-gravity) generally will consist of 31 parabolas (at least 10 parabolas at each gravity level), and flights that produce weightlessness generally will consist of 16 parabolas."
223636942|NCT06284343|DRUG|Anticoagulant|Prescription of pharmacological thromboprophylaxis according to current clinical practice and international guidelines recommendation
223636943|NCT04163341|BEHAVIORAL|Adapted Common Elements Treatment Approach|The intervention is a transdiagnostic cognitive behavioral therapy approach to treating any combination of depression, anxiety, post-traumatic stress, or substance use disorder that has been adapted the needs of adults with HIV and to additionally address HIV care engagement.
223636944|NCT05773755|DEVICE|Medtronic Percept PC DBS system|Open label active Deep Brain Stimulation (DBS)
223636945|NCT02855125|DRUG|TAS-114|TAS-114 was a modulator of 5-fluorouracil (5-FU).
223636946|NCT02855125|DRUG|S-1|S-1 was designed to provide oral delivery of 5-FU and to reduce the rate of degradation of 5-FU in vivo.
223636947|NCT03161249|BEHAVIORAL|Experimental group|The experimental group receiving mobile treatment: treatment as usual plus a psychotherapy intervention by the telephone app (a total of 5 modules of psychotherapy: psychoeducation plus mindfulness plus alerts plus social wall plus problems solving)
223636948|NCT03161249|OTHER|Control group|Group that does not receive any treatment added to its usual treatment
223636949|NCT06653907|DRUG|Levothyroxine Sodium (LT4) Tablets|"Participants in our study will determine the dosage of L-T4 based on their weight (BW):~1. BW ≥50kg: Starting with a daily dose of 1 tablet;~2. BW \< 50kg: Starting with a daily dose of half a tablet.~At 12 weeks, 18-20 weeks, 24-26 weeks, and 34-36 weeks of gestation, the serum TSH, FT3, and FT4 will be measured, and investigator will adjust dosage according to TSH:~1. When TSH \> ULRR, the participants will receive L-T4 in addition to their original medication, and additional unplanned follow-up;~2. When TSH at 2.5mIU/L-ULRR, add 1/4 tablet of medictaion;~3. When TSH at LLRR -2.5mIU/L, maintain the original dose;~4. When TSH \<LLRR, reduce 1/4 tablets of medictaion.~5. If TSH continues to be lower than LLRR after discontinuation, investigator will measure FT4, TRAb and other indicators to determine if it is clinical hyperthyroidism. If so, antithyroid drugs will administered according to guidelines. Participants will stop all trial medictaion after delivery."
223636950|NCT06653907|DRUG|Placebo|"Participants in our study will determine the dosage of placebo based on their weight (BW):~1. BW ≥50kg: Starting with a daily dose of 1 tablet;~2. BW \< 50kg: Starting with a daily dose of half a tablet.~At 12 weeks, 18-20 weeks, 24-26 weeks, and 34-36 weeks of gestation, the serum TSH, FT3, and FT4 will be measured, and investigator will adjust dosage according to TSH:~1. When TSH \> ULRR, the participants will receive L-T4 in addition to their original medication, and additional unplanned follow-up;~2. When TSH at 2.5mIU/L-ULRR, add 1/4 tablet of medictaion;~3. When TSH at LLRR -2.5mIU/L, maintain the original dose;~4. When TSH \<LLRR, reduce 1/4 tablets of medictaion.~5. If TSH continues to be lower than LLRR after discontinuation, investigator will measure FT4, TRAb and other indicators to determine if it is clinical hyperthyroidism. If so, antithyroid drugs will administered according to guidelines. Participants will stop all trial medictaion after delivery."
223636951|NCT06652893|DRUG|Sinovial|"A single intra-articular injection of hybrid HA complex, Sinovial® HL (IBSA Pharmaceuticals, Italy, patent number WO/2012/032151 ) in the knee was performed from the lateral approach to the suprapatellar recess using ultrasound. For the ultrasound-guided infiltration method, a sterile linear probe with a 20 G guide was used to visualize the joint suprapatellar recess and avoid intrasynovial infiltration. The patient was positioned supine with the knee in full extension. From the lateral approach to the suprapatellar recess, HA was then injected into the knee joint, verifying intra-articular positioning in real-time via ultrasound imaging (direct visualization of viscous fluid or air bubbles).~Patients did not receive anti-inflammatory or pain-relieving drugs in the week before the first injection . Patients were evaluated at four time points: at baseline and after 28, 42, 84, and 168 days after the intervention. At each evaluation, clinical data relating to the status of the disea"
223636952|NCT04467905|DRUG|Etripamil|The formulation of etripamil nasal spray consists of MSP-2017 (etripamil), water, acetic acid, disodium ethylene-diamine-tetra-acetic acid (EDTA), and sulfuric acid. The dose of etripamil to be evaluated in this study is 70 mg.
223636953|NCT04467905|DRUG|Placebo|The formulation of placebo nasal spray consists of water, sodium acetate, disodium, disodium ethylene-diamine-tetra-acetic acid (EDTA), and sulfuric acid to reproduce the same pH as the etripamil formulation.
223636954|NCT06809764|OTHER|No drug|This is an non-interventional, observational study. No drug will be provided or administered as part of this protocol; however, participants on T-DXd will be enrolled in this study.
223636955|NCT06291441|OTHER|No intervention|No intervention (observational study)
223636956|NCT06654817|DRUG|Ofatumumab subcutaneous injection|To compare the efficacy and safety of two treatment strategies: ofatumumab combined with corticosteroids versus corticosteroids along with azathioprine, in pemphigus patients.
223636957|NCT01664975|DRUG|GDPT regimen|GDPT regimen(Gemcitabine,Cisplatin,Prednisone ,Thalidomide) Cisplatin(DDP) 25 mg/m2,ivgtt（intravenously guttae）,d1-3;Prednisone 60mg/m2,p.o,d1-5;Gemcitabine(GEM) 800mg/m2,ivgtt,30min,d1,8;Thalidomide,p.o,200mg/d,Continued use to the end of chemotherapy .Every 21 days for one cycle and three cycles are required. Efficacy was evaluated every two cycles.
223636958|NCT01664975|DRUG|CHOP regimen|CHOP regimen(Cyclophosphamide,Vincristine,Doxorubicin,Prednisone) Cyclophosphamide 750mg/d,ivgtt, d1;Vincristine,1.4g/m2,ivgtt, d1;Doxorubicin,50mg/m2,ivgtt,d1;Prednisone 60mg/m2,p.o, d1-5.
223636959|NCT06590922|DEVICE|Group using new oropharyngeal airway (experimental group)|Before anesthesia induction, study participants in the experimental group received 5-6L/min oxygen for about 1min through an endoscopic bite oxygen supply device, and anesthesia induction was administered with propofol 3mg/kg and sufentanil 7μg.Sufentanil was given at the beginning of pre-oxygen inhalation, and propofol was given 1min later. When participants achieved sufficient sedation (about BIS40), they were placed into the oropharyngeal airway through the endoscopic bite and began gastroscopy.Anesthetic maintenance was administered with a continuous pump of 5mg/kg·h propofol until completion of the examination.
223636960|NCT06590922|DEVICE|The conventional endoscopic biting group (control group)|Prior to induction of anesthesia, control study participants inhaled 5 to 6L/min of oxygen through a nasal catheter for approximately 1 minute.Anesthesia was induced by propofol 3mg/kg and sufentanil 7μg.Sufentanil was given at the beginning of pre-oxygen inhalation, and propofol was given 1min later. The endoscopic procedure began when the study participants reached sufficient sedation (about BIS40) and the ordinary endoscopic bite group reached sufficient sedation.Anesthetic maintenance was administered with a continuous pump of 5mg/kg·h propofol until completion of the examination.
223636961|NCT06593223|DEVICE|Assess Non-invasive filling pressure(NIFP) in heart failure patients|Assess Non-invasive filling pressure(NIFP) in outpatients with stable heart failure and inpatients with acute heart failure in ward
223636962|NCT06597643|OTHER|Eccentric Training|"Exercise 1: Eccentric Wrist Extension with Dumbbell~Position: Seated, elbow extended, wrist maximally extended.~Action:~Lower: Slowly flex the wrist for 30 seconds. Return: Use the opposite hand to bring wrist back to extension. Load: Increase weight based on 10 Repetition Maximum (10RM). Exercise 2: Eccentric Wrist Extension with Twist-Bar~Position: Hold Flex Bar with involved hand in extension.~Action:~Twist: Rotate the bar with the non-involved hand while keeping the involved wrist extended.~Untwist: Allow the wrist to flex slowly. Exercise 3: Eccentric Supination with Elastic Band~Position: Anchor band, elbow flexed to 90°.~Action:~Supinate: Rotate forearm with palm up. Flex: Slowly rotate to palm down, then return"
223636963|NCT06597643|OTHER|Deep Friction Massage|The patient will sit on a chair while holding a pillow. DFM will be performed in perpendicular direction to the Extensor carpi radialis brevis tendon the site of the application will be on the upper attachment of the common extensor origin (palpated one cm distal to the lateral epicondyle of the humerus) for 5 minutes. Using the thumb, Firm pressure will be applied to compress the extensor tendons, their origins, and the musculotendinous junctions between the underlying bone and the fingertips. This pressure will be maintained while the therapist applies DFM in the direction of their fingers,
224225457|NCT05107284|BEHAVIORAL|e-checkup to go|The e-checkup to go alcohol program is designed to motivate individuals to reduce their alcohol consumption using personalized information about their own use and risk factors. The program is a combination of several components including alcohol education, personalized feedback, attitude-focused strategies, and skills training. It is self-guided and requires no face-to-face time with an administrator. It provides tailored feedback regarding quantity and frequency of alcohol use, normative comparisons, physical health information, amount and percent of income spent on alcohol, negative consequences feedback, explanation and advice for how to reach their goals, and resources.
224225458|NCT05107284|BEHAVIORAL|Delayed feedback booster|Booster emails will contain normative feedback indicating average consumption for students at the same institution by sex, their perceptions of student drinkers at the same institution, their own reported consumption, and reminders of strategies they can use to protect themselves from alcohol-related harm.
224225459|NCT00958581|DRUG|Tranexamic Acid|For TXA, the loading dose is 10mg/kg infused over 15 minutes, while the maintenance dose is 1/mg/kg hr.
223636964|NCT06590272|DEVICE|TECNIS PCB00 intraocular lens|In this study, we select TECNIS PCB00 IOL for inserting in the eyes during the cataract surgery
223636965|NCT06590272|DEVICE|HumanOptics Diff-Aay intraocular lens|In this study, we select HumanOptics Diff-Aay IOL for inserting in the eyes during the cataract surgery
223636966|NCT06590272|DEVICE|TECNIS Symfony ZXR00 intraocular len|In this study, we select TECNIS Symfony ZXR00 IOL for inserting in the eyes during the cataract surgery
223636967|NCT06590272|DEVICE|ZEISS AT LISA tri 839MP intraocular len|In this study, we select ZEISS AT LISA tri 839MP IOL for inserting in the eyes during the cataract surgery
223636968|NCT06594029|BEHAVIORAL|Community Navigator Intervention|see previous section
223636969|NCT06594029|OTHER|Control Group|Participants receive information on how to increase their community participation
223636970|NCT06594003|PROCEDURE|Radiofrequency|There has recently been considerable interest in the role of radiofrequency ablation (RFA) of the genicular nerves for KOA. In the majority of previous studies, ablation was done via a radiofrequency technique using either fluoroscopy or ultrasound for only three genicular nerves, whereas the knee joint is also supplied by a few other nerves . Interestingly, neurolytic agents can also be used to ablate the nerves, and are readily available, less costly, and need less logistic support
223636971|NCT06591676|BEHAVIORAL|Dysfunctional Attitude Scale (DAS)|Dysfunctional Attitude Scale (DAS) is a self-report scale designed to measure the presence and intensity of dysfunctional attitudes. It is widely used to assess impaired cognitive patterns associated with depression and other mental health conditions. Initially developed in English, its usefulness can be extended by translating and culturally adapting it into Urdu language.
223636972|NCT06596928|DIETARY_SUPPLEMENT|Essential Elements T-Hero Platinum|Participants will take two capsules daily for 90 days
223636973|NCT06596928|DIETARY_SUPPLEMENT|Placebo|Participants in the placebo group will take two placebo capsules daily for 90 days.
223636974|NCT06588790|OTHER|Home-based rapid testing|Participants will be provided with rapid diagnostic tests for HIV, pregnancy and malaria (in Kenya and Zambia only) for on-demand, at-home self testing if/when indicated.
223636975|NCT06588790|OTHER|Community health worker rapid testing|Participants will have access to rapid testing through a community health worker who will conduct rapid testing in the home or at a community-based location when indicated.
224225460|NCT00958581|DRUG|Normal Saline|Normal saline of same volume as the intervention group will be given as the intervention group as a loading dose and maintenance dose.
224225461|NCT00958581|DRUG|Epsilon aminocaproic acid|For EACA, the loading dose is 100mg/kg infused over 15 minutes, while the maintenance dose is 10mg/kg hr.
224225462|NCT02660190|DRUG|hexaminoavolunate|
223636976|NCT06606600|OTHER|Intensive Kebbi robot interventions|The intensive Kebbi robot interventions will receive 30 minutes, 3 times per week for 12 weeks.
223636977|NCT06594302|OTHER|Functional performance tests and scales measuring biopsychosocial characteristics|Functional performance tests and scales applications
223636978|NCT06600568|OTHER|Translation analysis|Novel strategies to selectively eliminate neoplastic T cells by modulating intracellular ROS levels.
223764938|NCT03858387|DRUG|Imipenem|"This group is composed of 50 critically ill patients, imipenem dosage is chosen by the intensivist in charge of the case.~Blood sampling: 5 blood samples (3 mL) were obtained from a heparinized intravascular catheter by direct venipuncture at the following time: before (time 0) and during 0-0.5 h, 0.5-2 h, 2-4 h, 4-6 h or 4-12 after imipenem administration."
224225463|NCT02660190|PROCEDURE|WL cystoscopy|
224225464|NCT03942510|OTHER|eccentric exercise with blood flow restriction|High/low intensity eccentric training group (80% and 40% of isometric peak torque) with or not blood flow restriction.
223515209|NCT04544605|OTHER|Individualized-Chinese herbal medicine|"I. Lung and spleen qi deficiency syndrome Clinical manifestations: shortness of breath, fatigue, fatigue, anorexia, nausea, fullness, weak stool, and uneasiness. The tongue is pale and greasy. Recommended prescription: French Pinellia 9g, Chenpi 10g, Codonopsis 15g, Sunburn Astragalus 30g, Stir-fried Atractylodes 10g, Poria 15g, Huoxiang 10g, Amomum villosum 6g (later), and Licorice 6g~II. Qi and Yin deficiency syndrome Clinical manifestations: fatigue, shortness of breath, dry mouth, thirst, palpitations, sweating, poor appetite, low or no lever, dry cough and little sputum; dry tongue, fine or weak pulses. Recommended prescription: North and south radix salviae 10g, 15g ophiopogonis, 6g American ginseng, 6g schisandra, 6g gypsum l5g, 10g light bamboo leaves, 10g mulberry leaves, 15g reed root, 15g salviae miltiorrhiza, 6g raw liquorice."
223636979|NCT06598176|DEVICE|Colli-Pee 20mL device with UCM|Women will collect a first-void urine (the initial part of the urine stream) sample at home the day before a hospital appointment using the 20mL Colli-Pee device prefilled with urine conservation medium (UCM, Novosanis, Belgium).
223636980|NCT06598176|DEVICE|Evalyn Brush|Women will collect a vaginal self-sample using the Evalyn Brush (Rovers Medical Devices, The Netherlands) at home the day before a hospital appointment.
223636981|NCT06586866|DRUG|JK-1201I|JK-1201I will be administered as an IV infusion at dose of 125mg/m2 on Day 1 of each 14-day cycle.
223764939|NCT04865432|DEVICE|UVB treatment|5 weeks of UVB titration to determine individual's UVB sensitivity followed by 4 weeks of UVB exposure intervention
223764940|NCT05124873|DEVICE|Moisture Management Liner|A prototype liner designed to reduce heat that builds up on the limb.
223764941|NCT00376168|DRUG|Plant cell expressed recombinant glucocerebrosidase (prGCD)|Intravenous infusion every two weeks for 9 months
224225465|NCT00380003|DRUG|EVT 201|
224225466|NCT02319681|BEHAVIORAL|Simple Reminiscence (SR)|SR is a 30-minute psychoeducational activity administered by a trained RA at 4 home visits (week 2, week 3, week 7, and week 19). SR has a didactic component using the SR manual that the couple retains, viewing one of the brief video-vignettes illustrating the application of reminiscence techniques (a different video-vignette will be viewed at each visit), and facilitation of caregiver practice in applying the techniques, using a recent example of anxiety-linked experience of the person with EAD.
224225467|NCT02319681|BEHAVIORAL|Attention Control (AC)|AC is a 30-minute in which the person with EAD, the caregiver and the RA review and discuss the day's newspaper headlines. The RA will use communication techniques specifically designed to keep the conversation present focused at 4 home visits (week 2, week 3, week 7, and week 19).
224225468|NCT00784212|DRUG|BGG492|
224225469|NCT00784212|DRUG|BGG492|
224225470|NCT00784212|DRUG|Placebo|
224225471|NCT00349895|DEVICE|Coronary stent implantation|Percutaneous Coronary Intervention
224225472|NCT04254523|DEVICE|Programmed intermittent epidural bolus (PIEB) of bupicavaine|Programmed intermittent epidural boluses of bupivacaine 0,1% are administered every hour. Protocolized adjustments of the dose are performed in order to obtain adequate analgesia. Standardized patient-controlled epidural boluses are available as top-ups.
224225473|NCT04254523|DEVICE|Continuous epidural infusion (CEI) of bupivacaine|A continuous epidural infusion of bupivacaine 0,1% is administered at a prescribed rate. Protocolized adjustments of the dose are performed in order to obtain adequate analgesia. Standardized patient-controlled epidural boluses are available as top-ups.
224225474|NCT04254523|DEVICE|Continuous epidural infusion (CEI) of morphine|A morphine infusion (0,1mg/ml) is administered in both groups at a prescribed rate. Protocolized adjustments of the dose are performed in order to obtain adequate analgesia.
224225475|NCT02546713|OTHER|Abutment with concave subcritical contour|Implants will be restored with abutments with concave configuration of the subcritical contour
224225476|NCT02546713|OTHER|Abutment with convex subcritical contour|Implants will be restored with abutments with convex configuration of the subcritical contour
224225477|NCT00551564|DRUG|rosiglitazone maleate|Rosiglitazone tablets 4 mg dose will be administered orally by subjects
224225478|NCT02193984|BEHAVIORAL|Peer support|
224225479|NCT00682721|DRUG|Placebo|Matching placebo two pills once daily
224225480|NCT00682721|DRUG|Valacyclovir|1 gram daily x number of days active in the study
224225481|NCT04576806|OTHER|Body temperature|Warming of administered fluid bolus
224225482|NCT04576806|DRUG|Fluid bolus|Administration of fluid bolus of crystalloid of 500ml over 15 minutes
224225483|NCT04576806|OTHER|Room temperature|Cooling of administered fluid bolus
224225484|NCT00793052|DRUG|Etodalac, Etoricoxib and Dexamethasone|"Dexamethasone sodium phosphate 8 mg 1 hour before the extraction, 4 mg the day after the extraction and another 4 mg at second day to the extraction.~Etoricoxib 120 mg 1 hour before the extraction, 120 mg the day after the extraction and another 120 mg at second day to the extraction.~Etodalac 600 mg 1 hour before the extraction, 600 mg the day after the extraction and another 600 mg at second day to the extraction."
224225485|NCT03971942|BEHAVIORAL|Neutral ABMT|In the neutral attention bias, there are 108 pairs of neutral-negative words, 54 pairs of which are used in the training group and 54 pairs of which are used in the placebo group. The word pairs in each group are repeated 4 times, with a total of 216 trial. Participants received 8 sessions over 2 weeks (1 session every other day).In booster ABMT, participants received 4 sessions over 2 weeks (1 session every three days).90% of the targets in the training group appear in the neutral word position and 10% of the targets appear in the negative word position, while 50% of the targets in the placebo group appear in the neutral word position and 50% of the targets appear in the negative word position.
224225486|NCT03971942|BEHAVIORAL|Positive ABMT|In the positive attention bias, there are 54 pairs of neutral-negative words, 27 pairs of which are used in the training group and 27 pairs of which are used in the placebo group. The word pairs in each group are repeated 8 times, with a total of 216 trial.Participants received 8 sessions over 2 weeks (1 session every other day). In booster ABMT, participants received 4 sessions over 2 weeks (1 session every three days).90% of the targets in the training group appear in the positive word position and 10% of the targets appear in the neutral word position, while 90% of the targets in the placebo group appear in the neutral word position and 10% of the targets appear in the positive word position.
224225487|NCT04658875|DIETARY_SUPPLEMENT|Spirulina maxima supplementation|Supplementation with Spirulina maxima (4.5 g/d) in capsules during 12 weeks.
224225488|NCT04658875|OTHER|Wash-out|2 weeks washout period to each study subject to avoid any possible carryover effect.
224225489|NCT04658875|OTHER|Placebo supplementation|Supplementation with placebo (4.5 g/d) in capsules during 12 weeks.
224225490|NCT04658875|OTHER|Isoenergetic diet|All participants will have a personal isoenergetic diet according to their height, weight, body composition and daily physical activity during 26 weeks
223515210|NCT01347086|DRUG|Matching placebo (low dose)|single dose of matching placebo
223515211|NCT01347086|DRUG|BI 207127 NA (medium dose)|Single does of BI 207127 NA
223515212|NCT01347086|DRUG|BI 207127 NA (low dose)|single dose of BI 207127 NA
223515213|NCT01347086|DRUG|Matching placebo (medium dose)|Single dose of matching placebo
223515214|NCT01347086|DRUG|BI 207127 NA (high dose)|Single dose of BI 207127 NA
223515215|NCT01347086|DRUG|Matching placebo (high dose)|Single dose of matching placebo
223515216|NCT05272605|BIOLOGICAL|Adjuvanted SARS-CoV-2 beta variant RBD recombinant protein vaccine (DoCo-Pro-RBD-1 + MF59)|Single booster dose in healthy adults previously vaccinated with two doses of CominartyTM (BNT162b2 \[mRNA\]) or VaxzevriaTM (ChAdOx1-S) COVID-19 and a third booster dose of either ComirnatyTM or SpikevaxTM vaccines.
223515217|NCT05272605|BIOLOGICAL|SARS-CoV-2 beta variant RBD mRNA vaccine|Single booster dose in healthy adults previously vaccinated with two doses of CominartyTM (BNT162b2 \[mRNA\]) or VaxzevriaTM (ChAdOx1-S) COVID-19 and a third booster dose of either ComirnatyTM or SpikevaxTM vaccines.
223515218|NCT05272605|OTHER|Normal Saline|Placebo comparator
223515219|NCT03161496|GENETIC|detection of genotype|detection of genotype by next generation sequencing
223515220|NCT05293002|DEVICE|Restorer Iliac Stent System|Not applicable (only one intervention)
223515221|NCT03536858|BEHAVIORAL|COACH (Communicating about Choices in Transplantation)|COACH is a behavioral communication intervention designed specifically for ESRD patients pursuing kidney transplantation. The COACH program consists of four modules: 1) Kidney transplant options, 2) Discussing your transplant options, 3) Requesting living donation, and 4) Maintaining positive relationships. The content and teaching strategies were guided by the concepts of social cognitive theory as well as principles of adult learning and communication skill acquisition. We believe that patients will transfer these skills to other patients at the hemodialysis clinic who are on their shift.
223515222|NCT00395447|PROCEDURE|Straight-forward Device Replacement|
223515223|NCT00395447|PROCEDURE|Device Replacement with Upgrade|
223515224|NCT01424137|DEVICE|Easyhaler type A|Easyhaler type A inhaler, 3 consecutive inhalations
223515225|NCT01424137|DEVICE|Easyhaler type B|Easyhaler type B inhaler, 3 consecutive inhalations
223515226|NCT01424137|DEVICE|Diskus inhaler|Diskus inhaler, 3 consecutive inhalations
223515227|NCT00019825|DRUG|decitabine|
223515228|NCT05818930|DIAGNOSTIC_TEST|REMI|Diagnostic monitoring
223636982|NCT06589622|PROCEDURE|Atraumatic Restorative Treatment|Caries excavation with hand instruments only and restoration with Glass ionomer filling
223636983|NCT06589622|PROCEDURE|Hall technique|Crown placement without tooth preparation
224225491|NCT04658875|OTHER|Systematic physical exercise program|Participants in the systematic physical exercise program groups will exercise for five days a week. The physical activity program will consist of Monday to Friday chair exercises performed during 24 weeks. The approximate exercise duration will be 40 to 50 min. Each exercise session has an initial or warm-up phase (\~ 10 min), a main physical conditioning phase (\~ 25 min), and a cool-down or relaxation phase (\~ 10 min). The physical activities to select have a metabolic equivalent tasks (METs) considered as moderate, between 3.0 and 6.0 METs. Trained personnel will assist older adults to perform the activities, including articular flexibility using elastic bands, postural and proprioception exercises with materials such as rubber balls, wood sticks, and small sandbags. These activities will be selected according to the deterioration and joint stiffness that the participants could present.
223515229|NCT03851952|DEVICE|Optilume Drug Coated Balloon|The Optilume Drug Coated Balloon (DCB) is a guidewire compatible catheter with a tapered atraumatic tip. The distal end of the catheter has an inflatable balloon coated with a proprietary coating containing the drug paclitaxel that facilitates the drug's transfer to the urethral wall upon inflation.
223515230|NCT02090894|DEVICE|UV Light (Laser Genesis)|
223515231|NCT03678857|DIETARY_SUPPLEMENT|Creatine|"Participants will resistance train their left arm and left leg one day and their right arm and right leg the next day. Participants will supplement with creatine BEFORE one of the training days (randomized to either left or right side) and on the opposite training day (opposite side of the body to the previous training day) supplement with creatine AFTER training. Having the same person in both conditions will control for genetics, habitual diet, other daily activities, and so on, that may have confounded previous research. Muscle mass and strength changes will be measured in each limb prior to and following 8 weeks of training to determine whether creatine timing influenced muscle growth.~Research Question: To determine whether creatine supplementation timing (i.e., before versus after training) effects 8 weeks of resistance training adaptations (i.e., muscle growth and strength changes)."
223515232|NCT03226665|DIAGNOSTIC_TEST|ultrasound|"definition of prevalence of US detected obstruction in patients referred to an emergency facilities with symptoms potentially suggestive for such diagnosis.~Moreover, which clue, if any, could reinforce the need of US intestinal study, such as anaemia, CRP, NLR, hypotension.~This information is not yet available elsewhere. Moreover, in this context, sensitivity and specificity of ultrasound vs. confirm by CT and other procedures will make more sense and will be consequently assessed."
223515233|NCT05703295|PROCEDURE|Biopsy|Sentinel lymph node biopsy
223515234|NCT04582812|OTHER|Bilateral and simultaneous diaphragm ultrasonography reeducation plus inspiratory training|Bilateral and simultaneous diaphragm biofeedback reeducation plus inspiratory training during 6 weeks
223515235|NCT04582812|OTHER|Isolated inspiratory training|Isolated high-intensity inspiratory muscle training during 8 weeks
223515236|NCT06500585|OTHER|Mill's Manipulation|"Mill's Manipulation: The therapist should apply a high-velocity low-amplitude thrust accompanied by a single application . Patients will be treated 3 times a week for 2 consecutive weeks.~Conventional Therapy:~Ultrasound therapy: Frequency: 1Mhz Pulse ultrasound: 1:4 Intensity: 1.5 W/cm2 Duration: 5 min.~Stretching of Wrist Extensors: 15 sec hold, 10 stretches/session/day. Wrist extensors Isometric: resistance 5 to 10 seconds, 15 contractions/ session/day.~Patients will be treated 3 times a week for 2 consecutive weeks."
223515237|NCT06500585|OTHER|Mill's Manipulation and Muscle Energy Technique|"Mill's Manipulation:The therapist should apply a high-velocity low-amplitude thrust accompanied by a single application . Patients will be treated 3 times a week for 2 consecutive weeks.~Muscle Energy Technique: Extensor carpi radialis stretch for 30 sec repeated 5 times during a single treatment session. Patients will be treated 3 times a week for 2 consecutive weeks.~Conventional Therapy:~Ultrasound therapy: Frequency: 1Mhz Pulse ultrasound: 1:4 Intensity: 1.5 W/cm2 Duration: 5min.~Stretching of Wrist Extensors, 15 sec hold, 10 stretches/session/day. Wrist Extensors Isometric, resistance 5 to 10 seconds, 15 contractions/ session/day.~Patients will be treated 3 times a week for 2 consecutive weeks."
223515238|NCT03975946|PROCEDURE|Rheopheresis procedure|Rheopheresis is performed using an automated monitor in a double-filtration cascade. Plasma purify from of high molecular weight proteins through a secondary filter is then returned to the patient. This technique is performed in tandem with a hemodialysis monitor.
223515239|NCT03975946|BIOLOGICAL|Blood Sample|Biological analysis
223515240|NCT03975946|PROCEDURE|Shamapheresis procedure|Shamapheresis is performed with the same automated monitor (Plasauto, HemaT company). Extracted plasma is not treated through the secondary filter (Rheofilter) and return to the patient. This technique is performed in tandem with a hemodialysis monitor.
223515241|NCT02150863|DEVICE|Ultrapulse Carbon Dioxide Laser|
223515242|NCT02150863|DEVICE|Cellutome epidermal harvesting system|
223515243|NCT01943084|DRUG|Norditropin® FlexPro® pen|Administered as a single subcutaneous (s.c., under the skin) dose (4.0 mg) on 2 separate dosing visits (treatment periods). The 2 treatment periods will be separated by a 7-day washout period.
223515244|NCT01943084|DRUG|Genotropin Pen®|Administered as a single subcutaneous dose (4.0 mg) on 2 separate dosing visits (treatment periods). The 2 treatment periods will be separated by a 7-day washout period.
223515245|NCT01942369|DRUG|Triptorelin Acetate 3.75mg intramuscular injection|"Triptorelin Acetate is a Gonadotrophin Releasing Hormone agonist (GnRHa).~Triptorelin acetate for injection 3.75mg administered as described in the patient information sheet approved in China: one intramuscular injection of the product repeated every 4 weeks."
223515246|NCT00035984|DRUG|AC2993|Placebo Lead In (0.02 mL) for 4 weeks / AC2993 5mcg (0.02 mL) for 4 weeks / AC2993 5mcg (0.02 mL) for 26 weeks - All are subcutaneously injected twice daily
223515247|NCT00035984|DRUG|AC2993|Placebo Lead In (0.02 mL) for 4 weeks / AC2993 5 mcg (0.02 mL) for 4 weeks / AC2993 10 mcg (0.04 mL) for 26 weeks - All are subcutaneously injected twice daily
223515248|NCT00035984|DRUG|Placebo|Placebo Lead In (0.02 mL) for 4 weeks / AC2993 5mcg (0.02 mL) for 4 weeks / AC2993 5mcg (0.02 mL) for 26 weeks - All are subcutaneously injected twice daily
223515249|NCT00035984|DRUG|Placebo|Placebo Lead In (0.02 mL) for 4 weeks / Placebo mcg (0.02 mL) for 4 weeks / Placebo (0.04 mL) for 26 weeks - All are subcutaneously injected twice daily
223764942|NCT00376168|DRUG|Plant cell expressed recombinant glucocerebrosidase (prGCD)|Intravenous infusion every 2 weeks for 9 months
223764943|NCT02946060|OTHER|Audiobooks|iPods with audiobooks
223636984|NCT06603935|OTHER|QHSLab Digital Tools (AME and ARIS)|Participants will use the QHSLab digital platform, which includes two tools: the Allergy Management Evaluation (AME) and the Allergic Rhinitis Intervention Steps (ARIS). The AME provides a comprehensive digital assessment for identifying and monitoring allergic rhinitis symptoms. The ARIS offers personalized feedback based on patient-reported outcomes and continuously adjusts treatment recommendations through an algorithm. These tools support better symptom management, adherence to medication, and overall improvement in quality of life.
223636985|NCT06602622|DRUG|Integrase inhibitor|Second generation integrase inhibitor 1) Bictegravir 50 mg/ alafenamide tenofovir 25 mg/ emtricitabine 200 mg (BIC/TAF/FTC); 2) Dolutegravir 50 mg/ abacavir 600 mg/ lamivudine 300 mg (DTG/ABC/3TC); 3) DTG 50mg+TDF 300mg/FTC 200mg (DTG+TDF/FTC) Each will be prescribed one tablet every day during 48 weeks
223636986|NCT06602622|DRUG|Doravirine + tenofovir DF + lamivudine|Individuals who meet the selection criteria will be randomized to maintain their same regimen with second-generation integrase inhibitors or switch to DOR/TDF/3TC 100/ 300/300 mg It will be prescribed one tablet every day during 48 weeks
223636987|NCT06587126|DEVICE|Curie Artificial Intelligence (AI) cough monitor|All patients are given nighttime cough monitors for home use for 3-4 months
223636988|NCT06596837|DEVICE|virtual reality|"The investigators manipulated the following two variables within the experimental design:~Immersion in the virtual environment. This was a nominal variable with two levels: a low-immersive environment (Other group) and a highly immersive environment (Experimental group) using the Cold River application.~Order of virtual reality (VR) deployment during the first session. This was also a nominal variable with two levels: VR during the first part of the dressing change (removing the dressing) and VR during the second part of the dressing change (cleaning the wound and applying a new dressing). In each subsequent session, the order of VR deployment was swapped for each participant.~The values of both variables were assigned to participants according to their numbers (e.g., 1. highly immersive, VR first; 2. low immersive, VR first; 3. highly immersive, VR last; 4. low immersive, VR last, etc.)."
223636989|NCT06595836|DEVICE|Silicone Lubricated Synthetic polyisoprine condom|Synthetic polyisoprene condom are made from softer materials for a more natural feel and increased sensitivity
224225492|NCT05774106|BEHAVIORAL|Participatory action research|First, a participatory intervention with nurses through the recording of four focus groups with the aim of understand, plan, change and maintain the practices surrounding the relationship therapy with their patients. Second, this intervention will be measured by administering scales to patients linked to the mental health case management program that provides service to different areas of the Barcelona Metropolitan Area. The variables to measure will be the quality of the therapeutic relationship, the recovery of the person and the overall functionality. These variables will be measured before and after finishing the participatory intervention.
224225493|NCT04381585|DEVICE|A MINI DISTRACTOR WITH A SUBMERGED ACTIVATION COMPONENT|Mini distractor is used to regenerate alveolar bone which is resorbed due various reasons. The distractor uses a winch-like submucosal activation component which is buried in the tissue; Flicking the winch turns the screw which moves the segment upwards in the direction of black arrow increasing height.
224225494|NCT05855915|DIAGNOSTIC_TEST|Kinesio taping|Kinesotaping will be applied with routine physical therapy
224225495|NCT05855915|DIAGNOSTIC_TEST|Sham taping|Sham taping will be applied with routine physical therapy
223515250|NCT05880784|OTHER|Reinforcement of Peer coaching and clinical audit|The goal of the proposed research study is to test the effectiveness and feasibility of an intervention to enhance peer coaching and clinic audit activities to facilitate the implementation of the Package of Essential Non- Communicable Diseases (PEN) in Nepal.
223515251|NCT05880784|OTHER|Continuation of usual practice without intervention|No intervention will be carried out, instead usual practice will be evaluated at the start and the end of the study period.
223636990|NCT06595836|DEVICE|Silicone Lubricated Natural Rubber Latex Condom|Natural rubber latex condoms are made from natural rubber
223636991|NCT06604611|DRUG|Colchicine 0.5 MG Oral Tablet Once Daily|The intervention in this study is colchicine, patients randomized to the experimental group will be given oral colchicine 5mg once a day in 12 weeks.
223636992|NCT06592105|PROCEDURE|Endovascular aortic aneurysm repair (EVAR)|Intervention description: - patients who underwent elective EVAR for non-ruptured AAA for the first time, - patients who underwent non-complex EVAR procedure with commercially available endografts with CE mark, - patients with non-syndromic AAA or with non-infective AAA, - patients aged more than 18 years old.
223636993|NCT06590597|BEHAVIORAL|EDUCATIONAL INTERVENTION FOR MALARIA PREVENTION|The intervention consisted of 4 modules administered in the same number of face-to-face sessions in which educational strategies such as classes, guided discussions, workshops and a booklet designed for the study were used.
223636994|NCT06601855|PROCEDURE|Cholecystectomy|Cholecystectomy, whether open or laparoscopic
223636995|NCT06598267|PROCEDURE|SASI|single anastomosis sleeve ileal bypass
223636996|NCT06598267|PROCEDURE|RYGB|Roux-en-Y gastric bypass
223764944|NCT02946060|OTHER|Tempo-pace synchronized playlists|Playlists with or without RAS
223764945|NCT02946060|OTHER|Usual Care|iPods containing either a silent track or white noise
223764946|NCT02957890|BIOLOGICAL|Inactivated influenza vaccine (NH formulation)|Round 1 (November): 0.5mL FluQuadri®, Sanofi Pasteur, containing 60μg antigen - 15μg for each influenza strain included - with strains recommended by the WHO for the northern hemisphere formulation
223764947|NCT02957890|BIOLOGICAL|Inactivated influenza vaccine (SH formulation)|Round 2 (May): 0.5mL Vaxigrip®, Sanofi Pasteur, containing 45μg antigen - 15μg for each influenza strain included - with strains recommended by the WHO for the southern hemisphere formulation
223764948|NCT02957890|BIOLOGICAL|Placebo|Round 2 (May): 0.5mL normal saline
224225496|NCT01663909|BEHAVIORAL|Guided imagery intervention|A 30-min DVD was developed which included general information on pain management as well as a section on guided imagery using sounds and images.
224225497|NCT02509871|OTHER|Body composition measurement|DXA, impedance
224225498|NCT02040428|BIOLOGICAL|EVARREST™ Fibrin Sealant Patch|
224225499|NCT02040428|BIOLOGICAL|Topical hemostat|
224225500|NCT00054483|DRUG|bortezomib|Given IV
224225501|NCT00054483|OTHER|laboratory biomarker analysis|Correlative studies
224225502|NCT00054483|OTHER|pharmacological study|Correlative studies
223636997|NCT06601491|BEHAVIORAL|Lifestyle Intervention|Participants in the intervention group receive structured, pesonalised lifestyle, dietary and physical activity consultations. They undergo various assessments such as aortic stiffness measurement, blood pressure measurement, and complete several questionnaires (e.g., whole exome sequencing, IPAQ, handgrip strength, socio-demographic, clinical history, quality of life, smoking, alcohol consumption, sleep patterns, stress assessment).
224225503|NCT05728177|COMBINATION_PRODUCT|Inhalation Aromatherapy|"Aromatherapy is safe, well prepared mixture used in the study that prepared by professor of pharmacology, faculty of pharmacy by mixing lavender essential oil and lavender hydrolate~Patients' medical charts in the outpatient clinic were reviewed to identify those who meet the inclusion criteria. Patients who meet the predetermined inclusion criteria were recruited in the study using simple randomization technique using computer-generated sequence technique to pick up these patients. After simple sampling and dividing patients into two groups of study and control. Patients from the study and control groups were interviewed individually by the researcher to apply the study tools as a pretest. Aromatherapy intervention was carried out for patients in the study group while those in the control group were left without any intervention to undergo the usual outpatient routine care."
224225504|NCT01409850|DEVICE|Aqualizer|The Aqualizer is a soft splint with water-filled pads.
224225505|NCT01409850|DEVICE|Soft splint|
224225506|NCT03339882|DRUG|Remifemin|Remifemin 0.2g po bid\*12 weeks at the beginning of the LHRH-a treatment
224225507|NCT03765268|PROCEDURE|Neurectomy in inguinal hernia repair|Mesh hernioplasty of inguinal hernia with neurectomy of ilioinguinal and iliohypogastric nerve
224225508|NCT03765268|PROCEDURE|nerve sparing in inguinal hernia repair|Mesh hernioplasty of inguinal hernia with sparing of ilioinguinal and iliohypogastric nerve
224225509|NCT00913965|DRUG|Atenolol Tablets 100 mg (Cord Laboratories)|
224225510|NCT00913965|DRUG|Atenolol Tablets 100 mg (Stuart Pharmaceutical)|
223515252|NCT01651208|BEHAVIORAL|Motivational Interviewing (MINT)|"We will hire a Latino and an AA nurse to deliver the interventions and will match their race/ethnicity with that of the subject. Past experience suggests that at 4-7 calls per subjects each lasting about 30-45 minutes, a nurse can carry a caseload of about 125-150 subject (we propose 125 per nurse) Each telephone encounter will have a patient centered approach having the following basic structure and goals:~a)Establishing a connection and reinforcing autonomy b)Empathizing with ambivalence and rolling with resistance.c)Coach the subject towards expressions of commitment."
223515253|NCT01651208|BEHAVIORAL|Mailed DVD|The DVD will have a documentary format that will engage subjects as the portrayed real patients relate their struggles and successes, that will entertain and ultimately motivate subjects to succeed in a similar way as the role models in the video. That personal connection will activate patients to address their own adherence issues and will show real life ways to deal with the health behaviors recommended post PCIS. Key concepts regarding adherence to medications and other behaviors will be imbedded in the story telling. The DVD will also feature a humanistic perspective of a cardiologist talking about his concerns for his patients that do not adhere to the antiplatelet therapy, the difficulties that his patients face, and the merit of the success stories he witnesses.
223515254|NCT06791538|PROCEDURE|Robotic Gastrectomy|"The intervention measures for robotic gastrectomy include:~Preoperative Preparation: Comprehensive preoperative examinations, including imaging studies, laboratory tests, and tumor marker assessments, to confirm the diagnosis and staging.~Surgical Procedure: Utilizing the da Vinci Surgical System, which provides a high-definition 3D view and flexible robotic arms for enhanced surgical precision.~Lymphadenectomy: Systematic D2 lymph node dissection according to oncological standards to ensure thorough removal of regional lymph nodes.~Gastrectomy and Reconstruction: Performing subtotal or total gastrectomy based on tumor location and extent, with intracorporeal reconstruction assisted by the robotic system.~Postoperative Management: Close monitoring of vital signs, pain management, and early mobilization to facilitate recovery, along with prevention and management of postoperative complications."
223515255|NCT06791538|PROCEDURE|Laparoscopic Gastrectomy|"Preoperative Preparation: Confirm diagnosis and staging through imaging and laboratory tests.~Surgical Procedure: Use standard laparoscopic instruments and 2D HD camera. Lymphadenectomy: Perform systematic D2 lymph node dissection. Gastrectomy and Reconstruction: Conduct subtotal or total gastrectomy and intracorporeal reconstruction.~Postoperative Management: Monitor vital signs, manage pain, and promote early mobilization."
223515256|NCT06036524|DIAGNOSTIC_TEST|Multi-modal, multi-parametric, multiscale imaging of the myofascial unit|Study Participants will undergo four study procedures at one visit, including magnetic resonance imaging (MRI), surface electromyography (sEMG), fiber-optic imaging and sensing, and questionnaires.
223515257|NCT06642038|PROCEDURE|Transbronchial Endoscopic Thermal Vapor Ablation|Transbronchial Endoscopic Thermal Vapor Ablation
223515258|NCT06640803|BEHAVIORAL|Stepped-Care including Cognitive Behavioral Case Management|Step 1:assessment and feedback, general engagement strategies, assessment of needs and social determinants of health, begin case management, goal setting. Step 2: TAU. Initiation of team-based care at community clinics and 'enhanced monitoring'. Step 3: atheoretically-based stress management skills (stress thermometer, coping skills and coping plans), problem solving strategies. Step 4: targeted intervention for CHRp. Initiation of formulation-based CBT modules, therapy consultation groups with the UC Davis team (UCD), regular meetings between clinic leadership and UCD. Participants may switch providers to increase level of early psychosis specialization. Step 5: add prescriber consultation groups with UCD. Step 6: assessment of trauma and family conflict then Family-Focused Therapy, Trauma-Focused Cognitive Behavioral Therapy, or CBT for CHR at UCD. Termination: At 24 months, referral to UCD coordinated specialty care clinic or other appropriate service for those still CHRp+.
224225511|NCT01038557|BIOLOGICAL|RBC units|When a transfusion is ordered, enrolled subjects will receive RBC units 1) up to 14 days old, 2) 14-42 days old, or 3) that are frozen when stored.
224225512|NCT00631865|BIOLOGICAL|Melanocyte transplantation|Injection of melanocytes directly in Epidermis
224225513|NCT01411267|DRUG|AC220|Dose assigned at study entry. AC220 will be given orally once daily on days 7-28.
224225514|NCT01411267|DRUG|Cytarabine|"All patients receive 1000 mg/m2/day IV given every 12 hours on days 1 through 5. Additionally, AML patients and patients with ambiguous leukemia receive cytarabine intrathecally on day 1 of course 1 and 2. Dose defined by age:~* 20 mg for patients age \<1 yr~* 30 mg for patients age 1-1.99 years of age~* 50 mg for patients age 2-2.99 years of age~* 70 mg for patients \>3 years of age"
224225515|NCT01411267|DRUG|Etoposide|150 mg/m2/day IV on days 1 through 5.
223636998|NCT06594874|DRUG|HS-10370|HS-10370 administered orally every day
223636999|NCT06594874|DRUG|Adebrelimab|Administered intravenously every 21 days; dose by label.
223637000|NCT06594874|DRUG|Cisplatin|Administered intravenously every 21 days; dose by label.
223637001|NCT06594874|DRUG|Carboplatin|Administered intravenously every 21 days; dose by label.
223764949|NCT04181827|DRUG|Cilta-cel|Cilta-cel infusion will be administered at a target dose of 0.75 \* 10\^6 CAR-positive viable T cells/kilogram (kg).
223764950|NCT04181827|DRUG|Pomalidomide|Pomalidomide 4 mg will be administered orally.
224225516|NCT01411267|DRUG|Methotrexate|"IT methotrexate given intrathecally to patients with ALL on day 0 of course 1 and 2. Dose defined by age~* 6 mg for patients age \< 1yr~* 8 mg for patients age 1-1.99~* 10 mg for patients age 2-2.99~* 12 mg for patients 3-8.99 years of age~* 15 mg for patients \>9 years of age"
224225517|NCT02342444|DRUG|Enoxaparin Sodium Injection 30 mg BID|
224225518|NCT02342444|DRUG|Enoxaparin Sodium Injection 40 mg QD|
224225519|NCT05581186|OTHER|Pulse electromagnetic field therapy|"It was applied with an electromagnetic field device (ASA Pmt Quatro Pro, ASA Srl Via A.Volta 9-36057 Italia) at 25 Hz frequency, 30 Gauss, %35 intensity and for 25 minutes. The treatment period was 5 days a week for 3 weeks, in total. It was applied as 15 sessions.~Therapeutic Exercise As a therapeutic exercise program (neck stability exercises); active cervical ROM, cervical isometric and progressive (selfexercise with Thera-Band) strengthening muscles; trapezius, scalene, rhomboid, levator scapular, pectoral, suboccipital muscles stretching exercises, scapular stabilization exercises. It was planned to implement a total of 15 sessions 5 days a week for 3 weeks, for approximately 30 minutes. Exercises will be performed by a trained (at least 5 years experienced) physiotherapist, three times a day, in 3 sets, 10 repetitions."
223764951|NCT04181827|DRUG|Bortezomib|Bortezomib 1.3 milligram per meter square (mg/m\^2) will be administered subcutaneously (SC).
223764952|NCT04181827|DRUG|Dexamethasone|Dexamethasone 20 mg/day (10mg/day for participants \>75 years of age) (on bortezomib treatment days and the days following bortezomib treatment) will be administered orally in PVd treatment; and orally or intravenous (IV) at 40 mg weekly (20mg weekly for participants \>75 years of age) in DPd treatment.
223764953|NCT04181827|DRUG|Daratumumab|Daratumumab 1800 mg will be administered SC.
224225520|NCT05581186|OTHER|Sham pulse electromagnetic field therapy|"Sham pulse electromagnetic field therapy was applied five sessions a week for four weeks, for a total of 15 sessions a day, using electromagnetic field device (ASA Pmt Quatro Pro, ASA Srl Via A.Volta 9-36057 Italy) without current flowing through the device.~Therapeutic Exercise As a therapeutic exercise program (neck stability exercises); active cervical ROM, cervical isometric and progressive (selfexercise with Thera-Band) strengthening muscles; trapezius, scalene, rhomboid, levator scapular, pectoral, suboccipital muscles stretching exercises, scapular stabilization exercises. It was planned to implement a total of 15 sessions 5 days a week for 3 weeks, for approximately 30 minutes. Exercises will be performed by a trained (at least 5 years experienced) physiotherapist, three times a day, in 3 sets, 10 repetitions."
224225521|NCT05581186|OTHER|Therapeutic Exercise|Therapeutic Exercise As a therapeutic exercise program (neck stability exercises); active cervical ROM, cervical isometric and progressive (selfexercise with Thera-Band) strengthening muscles; trapezius, scalene, rhomboid, levator scapular, pectoral, suboccipital muscles stretching exercises, scapular stabilization exercises. It was planned to implement a total of 15 sessions 5 days a week for 3 weeks, for approximately 30 minutes. Exercises will be performed by a trained (at least 5 years experienced) physiotherapist, three times a day, in 3 sets, 10 repetitions.
224225522|NCT02001779|DEVICE|Biliary SEMS loaded with 125I seeds|A self-expandable metallic biliary stent loaded with 125 iodine seeds is inserted in patients with inoperable malignant biliary obstruction.
224225523|NCT02001779|DEVICE|Conventional biliary SEMS|A self-expandable metallic stent is inserted in patients with inoperable malignant biliary obstruction.
224225524|NCT01055249|DRUG|Ibuprofen, Hydrocortisone|Ibuprofen 600 mg film coated tablets, b.i.d., Hydrocortisone-21-acetate creme (25%) 15 microl/cm2 b.i.d.
224225525|NCT01055249|DRUG|Hydrocortisone|Hydrocortisone-21-acetate creme (25%) 15 microl/cm2 b.i.d.
224225526|NCT05830006|PROCEDURE|Microfat grafting|Microfat grafting in cleft lip nasal deformities
224225527|NCT01768728|PROCEDURE|Laparoscopic left hemihepatectomy|participants will be performed with laparoscopic left hepatectomy using laparoscopic instruments
224225528|NCT01768728|PROCEDURE|Open left hemihepatectomy|participants will be performed with traditional open left hepatectomy using laparotomic instruments
224225529|NCT01417897|DRUG|Insulin glulisine|Dosage will be pro re nata. Patients should aim an blood glucose level of 2h ppBG ≤ 135 mg/dL.
224225530|NCT01417897|DRUG|Insulin aspart|Dosage will be pro re nata. Patients should aim an blood glucose level of 2h ppBG ≤ 135 mg/dL.
224225531|NCT01417897|DRUG|Regular human insulin|Dosage will be pro re nata. Patients should aim an blood glucose level of 2h ppBG ≤ 135 mg/dL.
224225532|NCT01508273|BEHAVIORAL|Exercise Program|Resistance training bands, guidebook, and pedometer given at baseline visit. Internet-based curriculum access given to teach goal-setting, overcoming barriers to physical activity, self-management strategies, and time-management skills. Access given website that will allow participant to track exercise behavior and help set goals.
224225533|NCT01508273|BEHAVIORAL|Website|Website access given that allows participant to track exercise behavior and help to set goals.
224225534|NCT01508273|BEHAVIORAL|Exercise DVD|Participants receive chair-based exercise DVD. Participants in this chair-based exercise program for a total of 8 weeks.
223637002|NCT06594874|DRUG|Pemetrexed|Administered intravenously every 21 days; dose by label.
223637003|NCT06591689|OTHER|Evaluation of Cases with Quadriparetic Cerebral Palsy|20 quadriparetic cerebral palsy cases were evaluated with the Communication Function Classification System (CFCS), Pediatric Functional Independence Scale (WeeFIM) and Gross Motor Function Measure-88 (GMFM-88).
223637004|NCT06603350|OTHER|No intenvention|No intenvention
223764954|NCT05812053|PROCEDURE|pulpotomy|Teeth will be anesthetized then Rubber dam and high suction will be used in pulpotomy procedure. Cavity outline was performed by sterile #330 high speed bur using water spray. Caries was removed by large spoon excavator. When pulpal exposure occurred, the roof of pulp chamber removed by low speed round bur. Haemostasis was obtained by applying pressure with moist cotton pellet with saline. Then the test materials was applied. after that, pulp stumps of all molars in each group will be dressed using Intermediate restorative material then the tooth will be restored with a preformed stainless steel crown
223637005|NCT06600932|PROCEDURE|TMS|TMS treatment in this study indicates a non-invasive procedure called transcranial magnetic simulation (TMS) on visual cortex. The treatment intensity is set as 80% of the threshold of each participant. The treatment will be conducted every day for consecutive 5 days.
223637006|NCT06600932|PROCEDURE|control group|The control treatment is a sham-controlled procedure, in which participants will be exposed to the recorded sounds of TMS pulses but without real magnetic stimulation.
223637007|NCT06604260|DIAGNOSTIC_TEST|68Ga-FAPi-46|68Ga FAPi PET-CT scan
223637008|NCT04152018|DRUG|PF-06940434|PF-06940434 is given intravenously (IV) every 2 or 4 weeks in a 28 day cycle or every 3 weeks in a 21 day cycle. Multiple dose levels will be evaluated
223637009|NCT04152018|DRUG|PF-06801591|PF-06801591 will be administered subcutaneously on Day 1 of each 28 day cycle or Day 1 of each 21 day cycle.
224225535|NCT01508273|BEHAVIORAL|Survey|"Exercise Intervention Program Group : Survey completion monthly about attitudes and beliefs about physical activity.~Sedentary Behavior and Dietary Intervention Group: Survey completion monthly attitudes and beliefs about sedentary behavior and dietary intake."
223637010|NCT03396809|DEVICE|Punctal plug|Punctal plugs are FDA approved for the treatment of dry eye. They increase lubrication of the eye by blocking the drainage of tears into the lacrimal sac. The nose portion of the plug has a larger diameter which is designed to fit in the canaliculum in order to retain the plug in the punctum. The plugs will be used on-label, as it is FDA approved in the treatment of dry eye. The purpose of punctal plugs are to increase tear volume by preventing drainage of tears into the lacrimal sac. The plugs are removable if necessary. Investigators are not testing this device for effectiveness or safety.
223637011|NCT06597851|DIAGNOSTIC_TEST|Thermodilution based assessment of coronary microcirculation|Coronary microvascular assessment with the derivation of CFR, IMR and MRR will be performed using a standard pressure/thermodilution guidewire.
223637012|NCT06597851|DIAGNOSTIC_TEST|Hyperinsulinemic-euglycemic Clamp test|Infusion of insulin and glucose adjusting rate of glucose infusion to maintaine plasma glucose around 90 mg/dL by monitoring plasma glucose levels every 5-10 minutes
223637013|NCT06825520|BEHAVIORAL|Habit Reversal Training|Participants learn to identify when their tics occur and then learn a competing response to engage in instead of the 3 identified tics and then practice competing responses learned in session during the practice sessions throughout the week.
223637014|NCT05488444|BEHAVIORAL|Navigator Phone Calls|"The patient navigator will call you every week as described above in Study Groups. These phone calls will continue until you begin receiving chemotherapy."
223637015|NCT05488444|BEHAVIORAL|Exit Interview|Participants will be asked to complete an exit interview either in person or by phone
223637016|NCT06982807|PROCEDURE|Group 4.0-VISULYZE|The 4.0-VISULYZE group had their infusion rates precisely calibrated using 4.0-VISULYZE
223764955|NCT05812053|RADIATION|cone beam computed tomography (CBCT) assessment|a post-operative CBCT image will be taken immediately after completing the procedure with fixed exposure parameters (120 Kv, 5mA, and 0.125mm voxel size) using the smallest field of view (8D, 8Hcm) also, after 12 months follow-up periods.
223764956|NCT05091528|DRUG|SBT6050|Dose range of 0.45 to 0.6 mg/kg by subcutaneous (SC) injection in 21-day cycles
223764957|NCT05091528|DRUG|trastuzumab deruxtecan|5.4 mg/kg by intravenous (IV) infusion in 21-day cycles
224225536|NCT01508273|BEHAVIORAL|Self-Report Assessments|Self-report assessments given about quality of life and physical assessments of balance and coordination.
224225537|NCT03602690|DRUG|Dolutegravir + Darunavir/ritonavir + optimized NRTI|Dolutegravir 50mg once daily Darunavir/ritonavir 600/100 twice daily Optimized NRTI recycling with lamivudine and one other NRTI (zidovudine or tenofovir or abacavir)
224225538|NCT01165996|OTHER|flow cytometry|Correlative studies
224225539|NCT01165996|OTHER|DNA methylation analysis|Correlative studies
223637017|NCT06982807|PROCEDURE|traditional group|The traditional group had their infusion rates based on past experience.
223637018|NCT06991309|BEHAVIORAL|MBSR|MBSR will be conducted as group sessions, with each session lasts for 2.5 hours, once a week for 8 weeks with another 45 minutes of home practice on daily basis. The MBSR sessions will be based on therapy format developed by Kabat-Zinn. All the sessions focus on mindfulness practices, sharing of experiences with others, and didactic teaching on stress. Mindfulness practices which will be discussed include body scan exercise, and mindful breathing meditation techniques, three-minute breathing exercises, five-minute seeing or hearing exercises, bodily mindfulness in movement and mindful stretching, yoga and sitting meditation. The therapists will review feedbacks for each session, acknowledge the thoughts, feelings, and senses, examine how participants practice mindfulness, and give assignments to encourage participants to continually practice mindfulness at home. Each participant will receive a CD detailing on meditation practices and a workbook on the mindfulness practices.
223637019|NCT05607446|DRUG|TQC3564 tablets|TQC3564 tablets are CRTH2 antagonists.
223637020|NCT05607446|DRUG|Placebo tablets|The intervention drug is placebo.
223637021|NCT05607446|DRUG|TQC3564 tablets, montelukast sodium tablets|The intervention drugs are TQC3564 tablets combined with montelukast sodium tablets. TQC3564 is a CRTH2 antagonist, montelukast sodium is Leukotriene receptor antagonist.
223764958|NCT05091528|DRUG|tucatinib|300 mg by mouth (PO) twice daily (BID)
223764959|NCT05091528|DRUG|trastuzumab|8 mg/kg loading dose (first dose), then 6 mg/kg maintenance dose (subsequent doses) IV infusion in 21-day cycles
223764960|NCT05091528|DRUG|capecitabine|1000 mg/m2 PO BID for 14 days of each 21-day cycle
223764961|NCT05091528|DRUG|trastuzumab deruxtecan|6.4 mg/kg by IV infusion in 21-day cycles
223764962|NCT06390020|OTHER|MBSR|The MBSR training spans eight weeks and follows a standardized protocol. It consists of eight weekly sessions, each lasting 2.5 hours, a single 6-hour silent day, and daily home exercises. Additionally, the program incorporates personalized psychoeducation on high sensory processing sensitivity, covering its characteristics, scientific foundations, its relation with stress-related symptoms, and why mindfulness might be helpful.
224225540|NCT01165996|OTHER|cytogenetic analysis|Correlative studies
224225541|NCT01165996|DRUG|decitabine|Given subcutaneously
224225542|NCT01165996|GENETIC|microarray analysis|Correlative studies
224225543|NCT01165996|GENETIC|gene expression analysis|Correlative studies
224225544|NCT01165996|OTHER|pharmacological study|Correlative studies
224225545|NCT01165996|GENETIC|polymorphism analysis|Correlative studies
224225546|NCT00679523|DRUG|AN2690 Solution, 5.0%|Once daily application for 180 days
223764963|NCT05550012|OTHER|low-dose CT|those patients undergo low-dose liver CT in portal vein and delayed phase.
223764964|NCT01857063|DRUG|Montelukast|Montelukast 5 mg chewable tablets, taken orally once daily at bedtime for 7 days
223764965|NCT01857063|DRUG|Placebo|Matching placebo chewable tablets, taken orally once daily at bedtime for 7 days
224225547|NCT00679523|DRUG|AN2690 Solution, 7.5%|Once daily application for 180 days
224225548|NCT00992264|BEHAVIORAL|Message Tone|All participants receive an tailored, online smoking cessation program. Participants in this intervention group either receive content written in a prescriptive tone or a motivational tone.
224225549|NCT00992264|BEHAVIORAL|Navigation|Persons in this arm either have their ability to navigate the site dictated for them based on their readiness to quit smoking or they are able to freely navigate through the website.
224225550|NCT00992264|BEHAVIORAL|Proactive Outreach|Persons receive periodic, proactively delivered email reminders to visit the intervention website.
224225551|NCT00992264|BEHAVIORAL|Testimonials|People receive a personally-tailored testimonial as part of their online smoking cessation program.
224225552|NCT01135771|OTHER|glucose and insulin IV to alter blood glucose|
224225553|NCT02046291|DRUG|Romiplostim|Romiplostim at the assigned dose will be administered subcutaneously (SQ) once a week for 6 weeks. The dose will be assigned at the time of subject registration. This is a dose escalation to determine the maximum tolerated dose. The doses include 4 mcg/kg/dose, 6 mcg/kg/dose, 8 mcg/kg/dose, and 10 mcg/kg/dose.
224225554|NCT01927757|BIOLOGICAL|Etanercept|Administered by subcutaneous injection
224225555|NCT01927757|DRUG|Methotrexate|Background methotrexate at least 15 mg weekly
224225556|NCT06398782|DEVICE|body composition assessment|body composition of cancer survivors were assessed by Dual-energy X-ray absorptiometry
224318892|NCT03835676|DRUG|Treprostinil|"After inclusion and baseline measurements, patients will receive treprostinil in addition to background therapy for 24 months. Follow-up assessment will include:~* Clinical, echocardiographic, laboratory assessments will be repeated at 1, 3, 6, 12, 18, and 24 month (or when there is clinical indication)~* CMR will be performed at 6 monthly intervals for 2 years.~* Peak power output at 6,12, 18 and 24 month~* Right-side cardiac catheterization will be performed at 6, 12 , 18 and 24 months (or when there is clinical indication)"
223515259|NCT06638138|DEVICE|Flexband|Artelon FLEXBAND is a commercially available, polycaprolactone polyurethane urea (PCL/PUUR) multipolymer synthetic knitted mesh that is used for soft tissue reinforcement procedures. The device is biocompatible and degradable and has been used as an augmentation device in over 50,000 Orthopedic tendon and ligament reconstructive procedures. The FLEXBAND kits contain the device and all of the instrumentation needed to insert the device.
223515260|NCT06640712|DIAGNOSTIC_TEST|Dental caries was assessed using the DMFT index (Decayed, Missing, and Filled Teeth) according to the World Health Organization's caries diagnostic criteria.|The same psychiatrist administered the Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) to all participants. Oral health examinations were performed by a trained dental student and a specialist dentist using a portable dental chair, artificial light, and a dental mirror. Dental caries was assessed using the DMFT index (Decayed, Missing, and Filled Teeth) according to the World Health Organization's caries diagnostic criteria. This index included the number of decayed, missing (due to caries, excluding 3rd molars), and filled teeth in the permanent dentition. The oral health examiners were blinded to each participant's substance use type and sociodemographic information.
223515261|NCT06640712|DIAGNOSTIC_TEST|Substance Use Disorder Diagnosis|This intervention involves a psychiatric evaluation conducted by a licensed psychiatrist to diagnose Substance Use Disorder according to the criteria outlined in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5). The psychiatrist performs a comprehensive assessment of each participant's substance use history and related behaviors. This diagnosis step is essential for identifying participants with specific substance use disorders, such as Methamphetamine, Cannabis, or Polysubstance Use Disorders, before proceeding with the dental health examination.
223515262|NCT06442228|DIAGNOSTIC_TEST|spermiogram test|"Approximately 7 mL of blood sample will be taken by the health personnel in a vacuum gel tube for hormonal and biochemical analyses. The blood samples will be centrifuged at 1000xg for 20 minutes by the researchers. In the next step, the supernatant portion will be separated and transferred to 3 mL ependorfs. Serum samples will be stored in the -800C deep freezer of our hospital until the time of analysis.~Sperm samples from individuals will be collected in our hospital in accordance with the protocol and the results will be reported."
223515263|NCT04013854|DRUG|nivolumab|All arms will receive a pre-surgery dose of nivolumab (480 mg IV). Post-surgery nivolumab doses will be determined by pathologic response and randomization.
223515264|NCT04013854|DRUG|Ipilimumab|Only subjects who fail to achieve a complete, or near complete, pathological response, and are then randomized to Arm C will receive Ipilimumab (1 mg/kg) )
223515265|NCT03687671|OTHER|Animal-assisted therapy|Animal-assisted occupational therapy, animal-assisted physiotherapy and animal assisted speech therapy with different animals. All animals are trained for the specific service with vulnerable patients. There are guinea pigs, rabbits, miniature pigs, sheeps, goats, chicken, dogs, cats and horses.
223515266|NCT03687671|OTHER|Treatment as usual|Speech therapy, occupational therapy or physiotherapy
223515267|NCT06637735|OTHER|education|pregnant women will be given a 4-week training and the pre-test post-test will be analyzed
223515268|NCT00601731|BIOLOGICAL|MenACWY-CRM197|Blood test, 40-months and 60-months children
223515269|NCT00601731|BIOLOGICAL|Blood test|Blood test, 40-months and 60-months children
223515270|NCT05215561|OTHER|Cosentyx|There was no treatment allocation. Patients administered Cosentyx by prescription that had started before inclusion of the patient into the study were enrolled.
223515271|NCT00104884|DRUG|Depsipeptide|Given IV
223515273|NCT05702489|DRUG|ZX-7101A|a drug to treatment influenza in Chinese adults
223515274|NCT05300607|OTHER|Cross-cultural adaptation, validity, and reliability|evaluation, translation, cultural adaption, validation, and investigation of the reliability of Arabic version of The Western Ontario Rotator Cuff Index (WORC) to be used in Arabic countries.
223515275|NCT05526157|DRUG|Finerenone (Kerendia, BAY 948862)|Retrospective analysis using secondary data collection from various sources
224318893|NCT01609712|PROCEDURE|Radiofrequency Kyphoplasty|"Radiofrequency kyphoplasty is a new form of surgical treatment. It injects an ultrahigh viscosity cement into the fractured vertebral body, using radiofrequency to achieve the proper consistency of the cement. This ultrahigh viscosity cement is designed to first restore proper height and alignment to the fractured vertebra and then to stabilize the fracture, thereby preventing further intravertebral motion and reducing pain.~The RF-Kyphoplasty is standard of care in our hospital. It is FDA and CE approved."
224318894|NCT04104802|DEVICE|MRI|"All patients included will benefit from both methods of assessing anatomical relationships between the facial nerve and the parotid tumor:~1\) New medical imaging technique evaluated: 3 Tesla Parotidic MRI High Resolution with Specific Sequences and Gadolinium Injection 2) Standard Gold: Intraoperative Exam"
224318895|NCT03006302|DRUG|Epacadostat|Patients will receive treatment every 3 weeks for 6 cycles of treatment within a course (total of 18 weeks). Epacadostat (100, 300, or 600 mg) is taken by mouth twice a day, every day.
224318896|NCT03006302|DRUG|Pembrolizumab|Patients will receive treatment every 3 weeks for 6 cycles of treatment within a course (total of 18 weeks). Pembrolizumab (200 mg) will be administered IV on day 1 of Cycles 1-6.
224318897|NCT03006302|BIOLOGICAL|CRS-207|CRS-207: Patients will receive treatment every 3 weeks for 6 cycles of treatment within a course (total of 18 weeks). CRS-207 (1 × 10\^9 CFU) will be administered IV on Day 2 of Cycles 3-6.
223637022|NCT05607446|DRUG|Placebo tablets, montelukast sodium tablets|The intervention drugs are placebo combined with montelukast sodium tablets. Montelukast sodium is Leukotriene receptor antagonist.
223637023|NCT06611501|DRUG|Metformin Hydrochloride|Metformin dosage titrated from 500 mg/daily for 2 weeks, then 1000 mg/daily for 2 weeks, 1500 mg/daily for 2 weeks, and then achieving 2000 mg/daily for a duration of 6 months of treatment.
223637024|NCT06611501|DRUG|Placebo|1 tablet orally with evening meal for 2 weeks, then 1 tablet twice daily for 2 weeks, then 3 tablets split twice daily for 2 weeks, then 4 tablets split twice daily, for a total of 6 months of treatment.
223637025|NCT06586944|BEHAVIORAL|Nursing Practices Based On Roy Adaptation Model Integrated With Virtual Reality|After the research groups were formed, a six-session interview programme was created for the participants included in the experimental group (Table...). In the sessions, nursing and psychiatric nursing interventions (psychoeducation, relaxation, awareness, effective coping, cognitive restructuring) based on the Roy Adaptation Model were carried out for the negative situations caused by anxiety and anxiety experienced by individuals. Subjective goals were determined for adaptive or maladaptive behaviour, attitude and thought patterns caused by anxiety-causing stimulus(s) and appropriate nursing interventions from the Nursing Interventions Classification System (NIC) were applied for these goals.Virtual reality-based intervention was effectively used as an important intervention tool in the implementation of the interventions and in the evaluation of the implemented interventions in four sessions of a total of six sessions.
223637026|NCT06586944|BEHAVIORAL|Roy Adaptation Model|After the research groups were formed, a six-session interview programme was created for the participants included in the experimental group. In the sessions, nursing and psychiatric nursing interventions (psychoeducation, relaxation, awareness, effective coping, cognitive restructuring) based on the Roy Adaptation Model were carried out for the negative situations caused by anxiety and anxiety experienced by individuals. Subjective goals were determined for adaptive or maladaptive behaviour, attitude and thought patterns caused by anxiety-causing stimulus(s) and appropriate nursing interventions from the Nursing Interventions Classification System (NIC) were applied for these goals
223637027|NCT06991920|DRUG|Blinatumomab|CD19-positive, Ph+ patients with favorable financial status may receive VP + TKI + blinatumomab therapy；CD19-positive, Ph- patients with favorable financial status may receive VCP + blinatumomab therapy.
223637028|NCT06991920|DRUG|Venetoclax|CD19-positive, Ph+ patients with poor financial status may receive VP + TKI + VEN therapy；CD19-negative or CD19-positive, Ph- patients ineligible for blinatumomab may receive VPCLP + VEN therapy.
223637029|NCT06992648|DRUG|Trifluridine/Tipiracil + Regorafenib|Trifluridine/tipiracil will be administered orally BID at a starting dose of 30 mg per square meter of body-surface area, on days 1 through 5 every 2 weeks. Regorafenib will be administered orally QD at a dose-escalation strategy (80 mg/day, followed by weekly increase of 40 mg to 120 mg/day), if no significant drug-related adverse events occurred and 120 mg/day for 21 days of a 28-day cycle.
223637030|NCT06992648|DRUG|Trifluridine/tipiracil + bevacizumab|Trifluridine/tipiracil will be administered orally BID at a starting dose of 35 mg per square meter of body-surface area, on days 1 through 5 every 2 weeks. Bevacizumab, at a dose of 5 mg per kilogram of body weight, will be administered IV every 2 weeks (day 1 and day 15).
223764966|NCT00531843|DRUG|fondaparinux sodium|fondaparinux 2.5mg SubQ daily for DVT prophylaxis to be started by treating physicians once deemed safe and to be discontinued once patient in discharged from the hospital or at discretion of treating physicians.
223764967|NCT00531843|DEVICE|sequential compression devices|Sequential compression devices at all times during the patient's hospital admission will be used in patients who have a contraindication to pharmacologic DVT prophylaxis. This is already the current standard of care.
223764968|NCT00375843|DRUG|Escitalopram|Level 1 of the study involves open-label treatment with escitalopram, up to 30 mg/day for up to 12 weeks.
224318898|NCT03006302|DRUG|Cyclophosphamide|Patients will receive treatment every 3 weeks for 6 cycles of treatment within a course (total of 18 weeks). Cyclophosphamide (200 mg/m\^2) will be administered IV on day 1 of Cycles 1 and 2.
224318899|NCT03006302|BIOLOGICAL|GVAX Pancreas Vaccine|Patients will receive treatment every 3 weeks for 6 cycles of treatment within a course (total of 18 weeks). GVAX will be administered on Day 2 of Cycles 1 and 2.
224318900|NCT01581866|DRUG|Ziprasidone Hydrochloride|Ziprasidone HCL Capsules, 20 mg
224318901|NCT03578666|OTHER|Massage|The intervention will be applied to both legs to a constant distal to proximal stroking rhythm. Firstly, participants will be lying in a prone position for 22 min: 1 min on the sole of the foot, 1 min on the Achilles tendon, 1 min on the soleus muscle, 3 min on the triceps muscle, 4 min on the hamstring muscles, 30 s tapotement from the sole of the foot to the hamstrings and 30 s superficial effleurage from the sole of the foot to the hamstrings. Then they will assume a supine position for 18 min: 1 min on the sole of the foot, 3 min on the tibialis anterior and peroneus lateralis muscles and 4 min in the quadriceps, adductors and lata muscles, 30 s tapotement from the sole of the foot to the hamstrings and 30 s superficial effleurage from the sole of the foot to the hamstrings.
223764969|NCT00375843|DRUG|Sertraline|Level 2 of the study involves open-label treatment with sertraline, up to 200 mg/day for up to 12 weeks.
223764970|NCT05221853|DIAGNOSTIC_TEST|cardiovascular magnetic resonance|CMR scan at 3 Tesla
224225557|NCT06465823|DRUG|Bumetanide|"Patients in the Bumetanide group will be treated for 3 months with a dose of 0.02 mg/kg twice a day, oral administration. It will be labeled (pre-printed and indistinguishable) with the randomization number and site number and will be delivered in separate blocks during the first, second and fourth appointment.~The patients will start the treatment with half of the full target dose during the first week:~* If the target dose is 0.5mg BID, only the morning dose will be administrated.~* If the target dose is 1.0 mg BID the dose will be 0.5 mg BID.~* If the target dose is 1.5mg BID, the morning dose will be 1.0 mg, the evening dose will be 0.5 mg.~* If the target dose is 2.0 mg BID the dose will be 1.0 mg BID The patient will continue with the full dose starting from Visit 2 after 1 week of dosing."
224225558|NCT06465823|DRUG|Placebo|Patients in the control (placebo) group will be given placebo for 3 months twice a day, oral administration. The Placebo tablets will be visually indistinguishable from Bumetanide and packaged as Bumetanide. The placebo will be labeled (pre-printed and indistinguishable) with the randomisation number and site number and will be delivered in separate blocks during the first, second and fourth visits.
224225559|NCT01399723|DRUG|Amoxicillin|Oral 45mg/kg 12 hourly
224225560|NCT01399723|DRUG|Benzyl penicillin|Intravenous 50,000IU/kg 6 hourly
224225561|NCT00118300|DRUG|capecitabine|Patients also receive oral capecitabine twice daily 7 days a week in weeks 1-5 and 7-8. Courses repeat every 12 weeks in the absence of disease progression or unacceptable toxicity.
224225562|NCT00118300|RADIATION|brachytherapy|1 or 2 applications of low-dose rate intracavitary brachytherapy in weeks 7-8 OR 5 applications of high-dose rate (HDR)\* intracavitary brachytherapy once weekly in weeks 4-8.
224318902|NCT03578666|OTHER|Cold water immersion|The cold water immersion group immersed their lower limbs (ensuring that the iliac crests were fully immersed) in an ice bath filled with cooled water for 10 min. The water was maintained at a mean temperature of 10 degrees (±0.5°) by the addition of ice.
224318903|NCT04364659|BEHAVIORAL|Food-Specific Inhibitory Control Training (FoodT App)|FoodTrainer (FoodT) is a simple game that aims to train individuals to 'stop' to certain unhealthy foods. Repeatedly playing this game is hypothesised to help build associations between certain foods (such as chocolate) and stopping, putting the brakes on unhelpful eating behaviour.
223515276|NCT05526157|DRUG|Sodium-glucose cotransporter 2 inhibitors (SGLT2i)|Retrospective analysis using secondary data collection from various sources
223515277|NCT05526157|DRUG|Glucagon-like peptide-1 receptor agonists (GLP 1 RA)|Retrospective analysis using secondary data collection from various sources
223515278|NCT05526157|DRUG|Steroidal mineral corticoid receptor antagonists (sMRA)|Retrospective analysis using secondary data collection from various sources
223515279|NCT05526157|DRUG|Non-steroidal mineral corticoid receptor antagonists (nsMRA)|Retrospective analysis using secondary data collection from various sources
223515280|NCT06357377|DRUG|NEO100|"NEO100 is a purified form (\>98.5%) of the naturally occurring monoterpene perillyl alcohol.~NEO100 drug product is a non-sterile solution for intranasal administration. It is compounded as a 10% solution in a 50:50 mixture of ethanol:glycerol."
223515281|NCT02517918|DRUG|Sirolimus combined with CP, MT and ZA|"Cyclophosphamide, Methotrexate and Sirolimus will be administrated orally. Zoledronic Acid will be administrated by infusion (IV).~Trial based on a dose escalating study design assessing two dose levels of sirolimus when prescribed in combination with metronomic cyclophosphamide (CP), methotrexate (MT) and zoledronic acid (ZA) followed by an expansion cohort once the MTD is established."
223515282|NCT05460169|DEVICE|Renal denervation|The Paradise® Renal Denervation System (Paradise System) is CE-marked in countries accepting the CE mark. The system is a catheter-based device designed to use ultrasound energy to thermally ablate the afferent and efferent nerves surrounding the renal artery and serving the kidney.
223515283|NCT05071027|OTHER|Endovascular Neurosurgery|Custom Dual Antiplatelet Therapy reminders for patients receiving endovascular treatment of cerebral unruptured aneurysms. The app utilized to generate reminders is available on the Apple app store.
223515284|NCT05336565|OTHER|Electronic medical record analysis|"Medical information system (MIS) BARS will be used for inclusion and retrieval of relevant data of cardiovascular patients enrolled in the reimbursement programs in the Tomsk Region. Incidence rates and patterns of PIM prescription, polypharmacy, and PDDIs in the time of COVID-19 pandemic will be studied."
223515285|NCT05818943|DRUG|Radiprodil|Radiprodil is an orally active, negative allosteric modulator of the NR2B subunit of the NMDA receptor.
223515286|NCT03287349|OTHER|Blood draw|Two 12.5 mL blood draws
223515287|NCT03287349|OTHER|Photograph|Photograph of severe reaction, will be anonymized
223515288|NCT03287349|DIAGNOSTIC_TEST|Autoimmune testing|Autoimmune testing in patients without prior testing
223515289|NCT06334211|DRUG|FP-020|MMP-12 inhibitor
223515290|NCT06334211|OTHER|placebo|placebo
223515291|NCT05804084|DRUG|Acetazolamide|Acetazolamide tablet (encapsulated)
223515292|NCT05804084|DRUG|Placebo|Sugar capsule manufactured to match encapsulated Acetazolamide
223515293|NCT00771147|DRUG|Sorafenib (Nexavar, BAY43-9006)|Patients with diagnosis of advanced renal cell cancer and decision taken by the investigator to prescribe Nexavar®.
223515294|NCT03136302|PROCEDURE|Deep Brain Stimulation|Deep Brain Stimulation
223515295|NCT06628960|BEHAVIORAL|Su Jok Therapy|Su Jok Therapy
223515296|NCT02522260|OTHER|Resistance and aerobic training|Group 1) includes strength exercise of the large muscle groups (2-3 sets, 8-12 repetitions on an intensity of 80 % of 1-RM) and 3x3 min high intensity aerobic exercise (16-18 on Borg scale) on an exercise bike or treadmill twice a week for 16 weeks
223515297|NCT02522260|OTHER|Aerobic training|Group 2) includes aerobic exercise on an exercise bike or treadmill, 20 min moderate intensity (13-15 on Borg scale), and 3x3 min high intensity (16-18 on Borg scale) twice a week during 16 weeks
223515298|NCT02522260|OTHER|Standard supportive care|Standard supportive care
223637031|NCT06992700|DEVICE|Dynamic perturbation-based intervention|The patient will be asked to perform simple motor tasks while wearing the glove at home under remote supervision of the staff involved in the study. In this way, in order to complete the task, the patient will be forced to overcome the elastic force and perform the movement with greater control. What is innovative compared to the common application of this device is its purpose: specifically, the orthosis will be used by applying resistance to the distal phalanx of the fingers of the hand characterised by a stenic deficit. Contrary to the usual application, which involves the use of this device to facilitate deficient movements, it is hypothesised that the application of resistance will induce the central nervous system (CNS) to create alternative strategies offering them the variety and difficulty necessary to stimulate adaptation without subjecting them to stress resulting from sudden and excessive levels of challenge.
223637032|NCT06992700|OTHER|Exercises without dynamic perturbations|Patients in this group will perform the exercises at home with the paretic upper limb wearing the orthosis (to stabilise the wrist and eliminate this possible confounding variable), but without the springs that determine resistance (i.e., eliminating the elastic resistance that is the subject of this study);
223637033|NCT06992349|DEVICE|bioptron light therapy|"BIOPTRON® Hyperlight is a proprietary, optimized blend of visible and infrared light properties that Bio-stimulate cells and speeding up the healing process of a wide range of medical diseases.~Bioptron© light therapy has been utilized as a non-invasive treatment for wound healing, skin ulcers, and various musculoskeletal conditions(Abd Elhamid et al., 2020)."
223637034|NCT06992011|PROCEDURE|SMILE|Small Incision Lenticule Extraction
223637035|NCT06992011|PROCEDURE|SMILE Xtra|Small Incision Lenticule Extraction combined with Corneal Cross-linking (SMILE Xtra)
223637036|NCT06991361|BIOLOGICAL|EVE-Treg|Ex Vivo-Expanded (EVE) Regulatory T cells.
223637037|NCT06991517|OTHER|The ABC Bicuspid Sizing Algorithm|The ABC Bicuspid Sizing Algorithm is a valve sizing algorithm. It guides operators' evaluations of CT scans, helping inform (1) treatment allocation between TAVR and surgical aortic valve replacement, and (2) valve choice for patients undergoing TAVR. In select cases, the algorithm will suggest gated CT evaluation or artificial intelligence-based simulation models be used to further evaluate the risk of the planned valve size and deployment volume. The operators will consider the findings of the ABC Bicuspid Sizing Algorithm as well as other clinical factors when making their final treatment decisions.
223637038|NCT06993337|DIETARY_SUPPLEMENT|35% Topical Bromelain in Orabase|Bromelain is a natural proteolytic enzyme derived from pineapple, recognized for its broad range of pharmacological properties. It exhibits significant anti-inflammatory effects by reducing edema. In addition to its anti-inflammatory activity, bromelain possesses antioxidant and analgesic properties.
223637039|NCT06993337|DIETARY_SUPPLEMENT|50% Topical Bromelain in Orabase|Bromelain is a natural proteolytic enzyme derived from pineapple, recognized for its broad range of pharmacological properties. It exhibits significant anti-inflammatory effects by reducing edema. In addition to its anti-inflammatory activity, bromelain possesses antioxidant and analgesic properties.
223637040|NCT06993337|DRUG|0.1% Topical Triamcinolone Acetonide in Orabase|Triamcinolone acetonide in orabase, a corticosteroid-based standard treatment for Recurrent Aphthous Stomatitis (RAS), is used for its strong anti-inflammatory and immunosuppressive effects. In this study, it serves as the conventional treatment against the novel therapy
223637041|NCT06992219|OTHER|Non surgical periodontal treatment evaluated through probing pocket depth reduction|Patients were treated with Minimally invasive non surgical treatment (MINST) or quadrant-subgingival instrumentation (Q-SI). The efficacy of treatment in both groups was evaluated through Probin Pocket Depth reduction in millimetres measurement before and after treatment.
224318904|NCT01754337|OTHER|Closed-loop system|Patients will be admitted at the research clinical facility at 7:00. At 8:00, a mixed meal will be served. At 9:00, patients will be asked to perform two 30-min standardized activities. At 12:00, a mixed meal will be served. At 13:00, patients will be asked to perform two 30-min activities. At 17:00, a mixed meal will be served. At 19:30, patients will perform 60 minutes of aerobic treadmill exercise at an intensity of 60% VO2max. A bedtime snack of 20g carbohydrate will be given at 21:00. Patients will be discharged at 8:00 the next morning
224318905|NCT02655783|OTHER|5% dextrose|women with an elective induction of labor receive IV hydratation (250 ml/h) with a normal saline solution + 5% dextrose
224318906|NCT02655783|OTHER|normal saline|women with an elective induction of labor receive IV hydratation (250 ml/h) with a normal saline solution
223637042|NCT06991881|OTHER|Biobank sampling for new biomarkers|Using biopsies as the gold standard, the project aims towards validating non-invasive biomarkers as specified previously against biopsies.
224225563|NCT00118300|RADIATION|radiation therapy|Patients undergo external beam radiotherapy to the whole pelvis once daily 5 days a week in weeks 1-5.
224225564|NCT05134064|DEVICE|total-body PET/CT|PCa patients who underwent PSMA PET/CT in our clinical center received two-time points scans at 1 h p.i. and 3 h p.i. on a total-body PET/CT scanner.
224225565|NCT03051256|DRUG|REL-1017|REL-1017 will be administered as an oral solution. Patients will continue to take the same, stabilized antidepressant medication that they were taking at screening throughout the course of the study.
224225566|NCT03051256|DRUG|Placebo|Placebo will be administered as an oral solution. Patients will continue to take the same, stabilized antidepressant medication that they were taking at screening throughout the course of the study.
224225567|NCT00338247|DRUG|lapatinib + capecitabine|Experimental
224225568|NCT06301555|BEHAVIORAL|Reinforcement learning algorithm powered cognitive and behavioral intervention|Reinforcement learning algorithm powered cognitive and behavioral intervention
224225569|NCT06301555|BEHAVIORAL|cognitive and behavioral intervention|cognitive and behavioral intervention
224225570|NCT02311023|OTHER|Intermittent fasting|
224225571|NCT04395365|DRUG|Co-Trimoxazole 960Mg Dispersible Tablet|Antibiotic prophylaxis of Spontaneous Bacterial Peritonitis
224225572|NCT04395365|DRUG|Placebo oral tablet|Placebo
224225573|NCT04392089|DEVICE|Masimo, LidCO|"* Near-infrared spectroscopy (NIRS), pulse oxymetry (saturation), continous hemoglobine, peripheral perfusion index (PPI) as measured with Massimo~* Systolic arterial pressure (SAP), diastolic arterial pressure (DAP), mean arterial pressure (MAP), stroke volume (SV), heart rate (HR), cardiac output (CO), systemic vascular resistance (SVR) as measured with LiDCO"
224225574|NCT04152629|DRUG|Methylphenidate Hydrochloride|CR Methylphenidate Hydrochloride given once daily (25 mg, 35 mg, 45 mg, 55 mg, 70 mg, 85 mg or 100 mg)
223637043|NCT06992895|DEVICE|The visual presentation utilizes a three-dimensional holographic fan device.|This study is among the first to examine the effect of holographic fan technology on pain, anxiety, and fear in children during burn dressing. In comparison with other distraction methods, holographic fans represent a novel technological intervention designed to mitigate pain and anxiety by engaging children's attention through the use of visual illusions. Furthermore, extant studies on the effectiveness of this technology during prolonged and distressing procedures, such as burn dressing, have been found to lack sufficient data.
223637044|NCT06992050|DEVICE|Submariner suit|Participants wearing full-body Submarine Escape Immersion Equipment (SEIE) suits
223637045|NCT06993493|GENETIC|CD19 CART|"The dose escalation is carried out according to the principle of 3+3 escalation, with a total of 3 dose groups set up.~Expected sample size (± 30%, CAR+T cells/kg)~1. 0.5 × 106 0.4 × 106\~0.6 × 106 3-6 cases~2. 1.0 × 106 0.7 × 106\~1.3 × 106 3-6 cases~3. 2.0 × 106 1.4 × 106\~2.6 × 106 3-6 cases The enrollment starts from dose group 1, and if no DLT occurs in the 3 subjects included, they will be transferred to the next dose group. If one of the three subjects in a certain dose group develops DLT, three additional subjects will be added to the group for cell infusion at the same dose. If there is ≥ 1 case of DLT in the 3 additional cases (i.e. ≥ 2/6 cases in this dose group), it will be reduced to the previous dose group. If there are only 3 subjects in the previous dose group at this time, an additional 3 subjects need to be added for the trial; If there are already 6 subjects in the previous dose group, the trial ends and this dose is MTD."
223637046|NCT06991946|GENETIC|Liquid Biopsy|Patients with metastatic breast cancer in disease progression will undergo a liquid biopsy
223637047|NCT06991946|GENETIC|Archival Tumor DNA|Patients will be prompted to request an archival tumor sample from metastatic origin (preferably) and to send it to the central laboratory for analysis
223637048|NCT06993246|DIAGNOSTIC_TEST|Contrast-Enhanced Mammography (CEM)|The intervention involves the use of contrast-enhanced mammography (CEM) to supplement standard mammography for breast cancer screening. This method utilizes iodinated contrast medium to enhance the visualization of breast lesions by assessing tumor neovascularization. CEM will be offered to women with dense breast tissue who are currently awaiting supplemental ultrasound screening. It is designed to be performed in conjunction with regular mammography, offering a more efficient and cost-effective alternative to MRI, with comparable sensitivity in detecting breast cancer. Participants will undergo the CEM procedure in a single visit, allowing for reduced wait times and improved detection rates compared to traditional methods. The procedure is well-tolerated, with minimal side effects, and provides a quicker and more accessible option for supplemental breast cancer screening.
223764971|NCT05265611|BEHAVIORAL|low intensity psychosocial intervention - Problem Management Plus (PM+)|Syrian refugee young adults will be trained to implement Problem Management Plus (PM+). PM+ is a low-intensity mental health intervention, developed by WHO, and delivered by non-specialized CMHW. It is a transdiagnostic treatment approach that includes four evidence-based problem solving and behavioral treatment techniques: managing stress, managing problems, get going/get doing, and social support. These strategies are implemented over five weekly sessions, of 90 minutes each.
223764972|NCT05265611|BEHAVIORAL|Tutoring|Young adults will be trained to tutor students in elementary school.
223764973|NCT05454501|OTHER|Exercise Training|For eight weeks, they will receive real-time online exercise training for 30 minutes, three days a week, with a peer group of 5-6 people. Before starting the exercise, physical activity will be monitored for seven days.
224225575|NCT04152629|DRUG|Lisdexamfetamine Dimesylate|Lisdexamfetamine Dimesylate given once daily (10 mg, 20 mg, 30 mg, 40 mg, 50 mg or 60 mg)
224225576|NCT03804320|OTHER|Active Surveillance|
224225577|NCT00268346|DRUG|ZD1839|ZD1839 treatment will be taken once a day PO, every day about the same time
224225578|NCT03069079|PROCEDURE|Oral hygiene advice, non surgical periodontal treatment|For children affected by periodontal disease, oral hygiene advice, non surgical periodontal treatment will also be performed according to needs. This can be accompanied, when appropriate, by the use of local anaesthesia and adjunctive antimicrobials (systemic or locally applied subgingivally), according to the clinical presentation and the child's medical conditions. Accurate supra- and sub-gingival removal of calculus and dental plaque will be performed both with ultrasonic and/or manual instruments. The necessary sub-gingival debridement will be performed in 1 to 4 visits (either full mouth treatment, half-mouth treatment or quadrant-wise treatment) depending on patient preference and practical considerations, using manual (Gracey curettes, Hu-Friedy) and ultrasonic devices (EMS). .
224225579|NCT03092908|DIETARY_SUPPLEMENT|mature vinegar|Administer 5 ml mature vinegar (Brand: Ninghuafu) three times a day.
224225580|NCT03092908|DIETARY_SUPPLEMENT|placebo (water)|Administer 5 ml placebo (water) three times a day.
224225581|NCT02776007|DEVICE|Libre Flash CGMS|
224225582|NCT02776007|DEVICE|Self-Measurement Blood Glucose|Patients will use their personal glucose meter to perform Self-Measurement Blood Glucose
224225583|NCT06193278|DEVICE|Neuromodulation|Noninvasive brain stimulation (NIBS) includes a variety of noninvasive neuromodulation techniques such as transcranial magnetic stimulation (TMS), transcranial direct current stimulation (TDCS), and so on. Theta burst stimulation(TBS) is a new form of excitatory or inhibitory rTMS treatment that is less time-consuming and more effective than traditional rTMS in a single treatment session.
224225584|NCT06325878|GENETIC|Genome-wide association study|Alleles/haplotypes evidence through GWAS will be compared between patients with CIDP and control subjects without CIDP
224225585|NCT01554761|PROCEDURE|phacoemulsification|After topical anesthesia with Alcaine, 3.0-mm clear corneal incisions were made. Torsional phacoemulsification was performed using the Infiniti Vision System with the OZil handpiece, a 45-degree Kelman miniflared tip, and DuoVisc viscoelastic (all from Alcon).
224225586|NCT01554761|DEVICE|Pentacam (Oculus,Germany)examination|Total corneal astigmatism is obtained by Pentacam at every visit.
224225587|NCT00294723|DRUG|liraglutide|1.8 mg for s.c. (under the skin) injection
224225588|NCT00294723|DRUG|glimepiride|8 mg capsule
224225589|NCT00294723|DRUG|liraglutide|1.2 mg for s.c. (under the skin) injection
224225590|NCT00294723|DRUG|placebo|Glimepiride placebo, 8mg capsule
224225591|NCT00294723|DRUG|placebo|Liraglutide placebo, 200 mcl
224318907|NCT06633354|BIOLOGICAL|CD5 CAR T-cells|Each subject receive CD5+ T-ALL Targeted CAR T-cells by intravenous infusion
224318908|NCT05238454|BIOLOGICAL|SCTV01C|intramuscular injection
224318909|NCT05238454|BIOLOGICAL|Sinopharm inactivated COVID-19 vaccine|intramuscular injection
223637049|NCT06596343|DRUG|Adjuvant Chemotherapy Combined with Traditional Chinese Medicine (TCM) Supportive Therapy|"1. Chemotherapy Regimen:~   * Postoperative adjuvant chemotherapy: A dual-drug concurrent regimen will be used, with each cycle lasting 21 days. On day 1 of each cycle, oxaliplatin will be administered intravenously at a dose of 130 mg/m². From day 1 to day 14 of each cycle, capecitabine will be taken orally at a dose of 1000 mg/m², twice daily. The treatment duration will follow the CSCO 2023 guidelines for colorectal cancer, with chemotherapy lasting for 6 months.~2. TCM Treatment:~   * TCM treatment will be based on syndrome differentiation (Zheng) and guided by the Guidelines for TCM Diagnosis and Treatment of Malignant Tumors."
223637050|NCT06594380|DEVICE|Group using new oropharyngeal airway (experimental group)|Before anesthesia induction, study participants in the experimental group received 5-6L/min oxygen for about 1min through an endoscopic bite oxygen supply device, and anesthesia induction was administered with propofol 3mg/kg and sufentanil 7μg.Sufentanil was given at the beginning of pre-oxygen inhalation, and propofol was given 1min later. When participants achieved sufficient sedation (about BIS40), they were placed into the oropharyngeal airway through the endoscopic bite and began gastroscopy.Anesthetic maintenance was administered with a continuous pump of 5mg/kg·h propofol until completion of the examination
223637051|NCT06594380|DEVICE|Endoscopic bite group (control group)|Prior to induction of anesthesia, control study participants inhaled 5 to 6L/min of oxygen through a nasal catheter for approximately 1 minute.Anesthesia was induced by propofol 3mg/kg and sufentanil 7μg.Sufentanil was given at the beginning of pre-oxygen inhalation, and propofol was given 1min later. The endoscopic procedure began when the study participants reached sufficient sedation (about BIS40) and the ordinary endoscopic bite group reached sufficient sedation.Anesthetic maintenance was administered with a continuous pump of 5mg/kg·h propofol until completion of the examination.
223637052|NCT06594601|PROCEDURE|lung recruitment potential assessed by 3D EIT|"Patients were ventilated based on the ARDS-Net suggestions. The patients were kept at supine position. The lung recruitment potential assessed by 3D EIT was as follows:~1. All patients were under pressure control mode (driving pressure 12-15 cmH2O with a tidal volume of 6-8 ml/kg predicted body weight, respiration rate12-15 bpm).~2. PEEP was switched to a zero end-expiratory pressure (ZEEP) for 10 min, and FiO2 was titrated to obtain peripheral oxygen saturation (SpO2 ) \&gt; 90%.~3. PEEP was stepwise increase from 0 to 15 cmH2O PEEP in steps of 5cm H2O every 3min.And 3D EIT was used to assess lung recruitment potential."
224225592|NCT00294723|DRUG|placebo|Liraglutide placebo, 300 mcl
224225593|NCT00752791|DRUG|Peginesatide|Peginesatide 0.04 to 0.16 mg/kg, subcutaneous injection, once every 4 weeks for up to 25 weeks. Initial dose based on patient's previous total weekly Epoetin dose, and thereafter could be adjusted to maintain hemoglobin values in the target range of 10 to 12 g/dL and ±1.5 g/dL from Baseline.
224225594|NCT02254148|DRUG|midazolam|single dose of midazolam given as oral solution (day 1 of visits 2 and 3)
223637053|NCT06594601|PROCEDURE|PEEP titration by 3D eit|"Patients were ventilated based on the ARDS-Net suggestions. The patients were kept at supine position. The PEEP titriatino by 3D EIT fwas as follows:~1. All patients were under pressure control mode (driving pressure 12-15 cmH2O with a tidal volume of 6-8 ml/kg predicted body weight, respiration rate12-15 bpm).~2. RM: PEEP was switched to a 21cmH2O for 2min, and FiO2 was titrated to obtain peripheral oxygen saturation (SpO2 ) ≥90%.~3. PEEP was stepwise decrease from 21 to 0 cmH2O PEEP in steps of 3cm H2O every 2min.~4. 3D EIT was used to monitor regional ventilation distribution during PEEP titration."
224225595|NCT02254148|DRUG|caffeine|single dose of caffeine given as tablets (day 1 of visits 2 and 3)
224225596|NCT02254148|DRUG|digoxin|single dose of digoxin given as tablets (day 3 of visits 2 and 3)
224225597|NCT02254148|DRUG|warfarin|single dose of warfarin given as tablets (day 1 of visits 2 and 3)
224225598|NCT02254148|DRUG|omeprazole|single dose of omeprazole given as tablet (day 1 of visits 2 and 3)
224225599|NCT02254148|DRUG|BI 187004|multiple doses of BI 187004 given as tablets (day 7-12 of visit 2 and day 1-6 of visit 3)
224225600|NCT02254148|DRUG|metoprolol|single dose of metoprolol given as tablets (day 1 of visits 2 and 3)
224225601|NCT05730686|PROCEDURE|Registry of Therapy of patient's diagnosed with FibroLamellar|Registry of Therapy of patient's diagnosed with FibroLamellar
224225602|NCT04356521|PROCEDURE|Lateral Sagittal Approach|The US probe will be located medial to the coracoid process in the sagittal plane in the infraclavicular region, and then three cords of the brachial plexus will be viewed. Using the in-plane technique, bupivacaine 0.5% will be administered around the posterior cord (7ml), lateral cord (7ml), and medial cord (6ml).
224225603|NCT04356521|PROCEDURE|Costoclavicular Approach|The US probe will be placed parallel to the clavicle in the midclavicular area and tilted toward the cephalad and the axillary artery, and three cords will be viewed. A needle will be forwarded from lateral to medial with the in-plane technique, and 20 ml of bupivacaine 0.5% will be administered at the center of the three cords.
224225604|NCT05736965|DRUG|Selinexor|Selinexor 60mg, PO d3,10,17
224225605|NCT05736965|DRUG|Azacitidine|Azacitidine 75mg/m2, IV d1-3, 8-9, 15-16
224225606|NCT05736965|DRUG|Venetoclax|Venetoclax 100mg PO on day 1 and 200mg on day 2, 400mg on day 3-14
224225607|NCT00103675|PROCEDURE|Acupuncture|
224225608|NCT06503341|OTHER|Cardiovascular risk assesment|ASCVD Score and WHO Cardiovascular Risk score.
224318910|NCT05238454|BIOLOGICAL|Comirnaty|intramuscular injection
224318911|NCT00788944|PROCEDURE|blood draw|Test Article was not provided to subjects for this study.
224318912|NCT03131544|DEVICE|MRI Guided Transrectal Periuretheral Transitional Zone Ablation|Patients will undergo an MRI guided transrectal ablation of tissue within the periuretheral transitional zone.
224318913|NCT05637164|DRUG|norepinephrine bitartrate|The treatment group will receive a continuous infusion of norepinephrine at the beginning of anesthesia induction until 15 minutes after intubation. The dosage of norepinephrine was decided by the up-and-down sequential allocation method with an initial dose of 0.05 µg/kg/min and a 0.005 µg/kg/min gradient.
224318914|NCT05607979|DRUG|Lavior Diabetic Wound Gel|Daily application of hydrogel treatment for 60 days.
224318915|NCT05607979|DRUG|Smith & Nephew Solosite Gel Hydrogel Wound Dressing|Daily application of hydrogel treatment for 60 days.
224318916|NCT00076076|DRUG|Roflumilast|
224318917|NCT02111928|DEVICE|NovaTears® Eye Drops|Topical eye drops for lubrication of the ocular surface
223637054|NCT06602882|BEHAVIORAL|chatbot-delivered screening and brief intervention|"1. Screening and personalised advice based on AUDIT-C scores, personal reasons for drinking, and specific barriers: For a score of ≥ 3, the participant will be reminded of the level of risks and dangers of alcohol consumption and the benefits of consumption reduction/cessation and will be assessed for the personal reasons for drinking and specific barriers.~2. Warning of alcohol and alcohol-related harms and reminding of benefits of reduced consumption: The Department of Health's health warning booklet, which has been designed by two of our Co-Is, will be used as the educational content.~3. Realistic and personal goals setting: A specific and measurable goal will be set for the upcoming week. For example, I will reduce to 1 bottle of beer in the upcoming week.~4. Motivational enhancement and practical coping strategies: Tangible advice will be given for coping with situational barriers according to their personal reasons for drinking."
223637055|NCT06603038|DIETARY_SUPPLEMENT|Gainful Daily Performance Greens|Daily supplementation for 28 days
223637056|NCT06604390|DIETARY_SUPPLEMENT|catechin extracts (health food)|"Type of intervention:~1. Purified gambir ≥ 90% (+)-Catechin~2. Dosage of 224 mg catechin capsule, once daily~3. Dosage of 224 mg placebo capsule, once daily~4. Cognitive function was assessed using MoCA-Ina and gene markers APP, MAPT, BDNF, IL-10, TGF-Beta and MDA Plasma.\&#34;"
224225609|NCT03813485|OTHER|Dry Needling in upper trapezius|"The following criteria are required for a patient to have latent TrPs: the presence of a palpable taut band in the upper trapezius muscle, the presence of a hypersensitive spot in the taut band, a palpable or visible local twitch on snapping palpation, and a no familiar reproduction of referred pain elicited by palpation of the sensitive spot.~Dry needling is performed with solid filiform needles (0.30x30 mm), these needles are sterile and separately packaged. Needles are not reused and are immediately deposited in a needle container after usage. Patients receive dry needling in latent myofascial trigger point (LTRs) in upper trapezius. The needle is penetrated into the muscle fibers of the taut band and was moved upward and downward (fast in, fast out) in different directions with the aim to elicit LTRs"
224225610|NCT03813485|OTHER|Dry Needling in lower trapezius|"The following criteria are required for a patient to have latent TrPs: the presence of a palpable taut band in the lower trapezius muscle, the presence of a hypersensitive spot in the taut band, a palpable or visible local twitch on snapping palpation, and a no familiar reproduction of referred pain elicited by palpation of the sensitive spot.~Dry needling is performed with solid filiform needles (0.30x 30 mm), these needles are sterile and separately packaged. Needles are not reused and are immediately deposited in a needle container after usage. Patients receive dry needling in latent myofascial trigger point (LTRs) in lower trapezius. The needle is penetrated into the muscle fibers of the taut band and was moved upward and downward (fast in, fast out) in different directions with the aim to elicit LTRs"
223637057|NCT06604390|OTHER|plasebo|Dosage of 224 mg placebo per capsule, once daily. Cognitive function was assessed using the MoCA-Ina and biomarkers including APP, MAPT, BDNF, IL-10, TGF-Beta, and plasma MDA.
223637058|NCT06593821|DEVICE|Occlusal splint|The occlusal splint was fabricated from a 2 mm hard splinting resin material on the plaster model obtained by taking impressions of the patients\&amp;#39; upper jaw.
223637059|NCT06593821|BEHAVIORAL|preventive advice|Control group given protective advice such as supporting the jaw when yawning, not chewing gum, not opening the mouth for too long and not opening it too wide, and chewing on both sides when eating.
223637060|NCT06593821|DRUG|Botulinum toxin|A total of 50 U of botulinum toxin, 25 U in each muscle, was injected
223637061|NCT06603233|DIAGNOSTIC_TEST|The Difference Between The AI Model and Dentists Group|The clinical feasibility of the best performing model, statistical hypothesis tests are performed that compares the predictions of the AI model with the assessments from three dentists.
223637062|NCT06603233|DIAGNOSTIC_TEST|Deep Learning Models|DeepLabV3+, Mask R-CNN (Detectron2), YOLOv8, U-Net, Super Vision U-net and U-Net Transformer were trained on 354 images and tested on 79 images.
223637063|NCT06586684|DRUG|Inclisiran|Patients with carotid plaques undergoing treatment with inclisiran
223637064|NCT06586502|OTHER|Model of Care|The intervention described in the RECOVER study involves developing, implementing, and evaluating a comprehensive Model of Care for childhood cancer survivors. This model, known as the RECOVER Model of Care, integrates digital health solutions and is co-designed with input from childhood cancer survivors, caregivers, and clinical experts. The intervention aims to address the long-term and late effects of cancer treatment by providing continuous, risk-based, interdisciplinary care. It includes steps such as identifying patients nearing the end of treatment, conducting health assessments, creating personalized care plans, and coordinating follow-up care through digital platforms. The study will assess the feasibility, acceptability, and effectiveness of this model in improving the quality of life and care experience for survivors and their families.
223637065|NCT06589544|DEVICE|Virtual Reality-based Cognitive Remediation (VR-COG) + Treatment as Usual (TAU)|"The CEREBRUM-VELA virtual reality software is made up of exercises designed to train different cognitive functions (i.e.: executive functions, motor ability, language). The different degrees of difficulty are designed to adapt to the user's functional diagnosis. Each session, after an initial part of welcome, psychoeducation and orientation to the instrument, involves alternating virtual reality exercises, positive and corrective feedback and suggestions of practical homework that the individual should try to do during his day.~Treatment as usual (TAU) The path, following the guidelines of the Italian Association of Medical Oncology (AIOM-SIPO: https:// www.aiom.it), includes an initial psychiatric visit aimed at assessing the presence of psychopathological conditions that may necessitate pharmacological therapy (antidepressants, hypnotic-sedatives) and subsequent psychiatric follow-up. The treatment also involves psychological counseling (monthly sessions)."
223637066|NCT06589544|DEVICE|Repetitive transcranial magnetic stimulation (rTMS) + Treatment as usual (TAU)|"Active rTMS stimulation will be delivered at 90% of the resting Motor Threshold (rMT), adjusted for the depth of the fcMRI-identified target. Personalized targets created for each individual will be located at various cortical depths. For safety reasons, the stimulation intensity will never exceed 120% of the rTMS.~Treatment as usual (TAU) The path, following the guidelines of the Italian Association of Medical Oncology (AIOM-SIPO: https:// www.aiom.it), includes an initial psychiatric visit aimed at assessing the presence of psychopathological conditions that may necessitate pharmacological therapy (antidepressants, hypnotic-sedatives) and subsequent psychiatric follow-up. The treatment also involves psychological counseling (monthly sessions)."
224225611|NCT00001228|DRUG|Interferon|
224225612|NCT02179684|PROCEDURE|Baby-sitter surgery N. fascialis|
223637067|NCT06589544|OTHER|Treatment as Usual (TAU)|Treatment as usual (TAU) The path, following the guidelines of the Italian Association of Medical Oncology (AIOM-SIPO: https:// www.aiom.it), includes an initial psychiatric visit aimed at assessing the presence of psychopathological conditions that may necessitate pharmacological therapy (antidepressants, hypnotic-sedatives) and subsequent psychiatric follow-up. The treatment also involves psychological counseling (monthly sessions).
223637068|NCT06586554|OTHER|Static stretching|The SS group received static stretching, which was applied with gentle and firm pressure while pulling opposite the hamstring muscle contraction.
223637069|NCT06586554|OTHER|Myofascial release|Myofascial release is applied with cross-handed stretches over hamstring muscle
223637070|NCT06600503|BEHAVIORAL|RehabLung mobile application|Participants in the intervention group will receive in-person pulmonary rehabilitation during their surgical admission and access to a mobile pulmonary rehabilitation application for self-training. This program begins one month before surgery and continues for seven weeks after surgery. The application is designed to encourage participants to engage in pulmonary rehabilitation exercises from preoperative preparation through postoperative care. It offers guided chest breathing exercises, using visual and movement instructions created and remotely prescribed by a physical therapist. Participants will receive daily breathing exercise prescriptions throughout the study period.
223637071|NCT06600503|BEHAVIORAL|Lung cancer postoperative standard care|Participants in the usual care group will receive in-person pulmonary rehabilitation during surgical admission, pre-operative healthcare, and guidance on breathing exercises to practice before surgery. They will also receive post-operative breathing exercise prescriptions to follow at home.
223637072|NCT06600503|OTHER|Healthcare interactive Web Platform|The healthcare interactive Web Platform provides patients with surgical information through animations. This includes an introduction to lung surgery, preparation procedures, answers to common patient questions, post-surgery wound care, and a brief guide to pulmonary rehabilitation.
223637073|NCT06592976|DIETARY_SUPPLEMENT|Multi-strain Oral Probiotic (CDS22-formula)|All patients received the probiotic product CDS22-formula (also known under the tradenames Visbiome, De Simo-ne, Vivomixx) as acid-resistant oral capsules (twice daily for 2 months), containing 1.12 x 10\^11 live bacteria per capsule.
223637074|NCT06587542|OTHER|Injection of protein purified derivative|Injection of purified protein derivative for anogenital warts in HIV and non HIV patient, on the largest lesion
223637075|NCT06590415|PROCEDURE|Subcutaneous adipose tissue biopsy|Under local anesthesia, subcutaneous adipose tissue will be collected from 2 puncture points in the umbilical region for a total volume of 2 mL.
223637076|NCT06590415|OTHER|Blood sampling|One 4 mL tube of blood will be collected
223637077|NCT06596707|PROCEDURE|Zirconomer|zirconia modified glass ionomer
223637078|NCT06596707|PROCEDURE|Nanohybrid composite|conventional composite
223637079|NCT05393791|OTHER|Patient-specific adaptive therapy|Patients will start taking abiraterone or enzalutamide (AA/ENZ) daily. PSA will be measured every month as well as radiological evaluation by CT-scan and bone scan. Treatment will be continued until PSA has dropped \>50%. The treatment will then be paused. Once the PSA has risen again above the pretreatment baseline, treatment will be re-initiated. AA/ENZ will be stopped again after the PSA declines \>50% from the baseline. This will be continued until criteria for treatment failure are met (death by any cause or at least 2 out of 3 of the following events while on treatment: radiographic progression on CT-scan and/or bone scan, PSA progression or clinical progression).
224225613|NCT02179684|OTHER|Conventional treatment and follow-up|Patient´s with Bells´palasy are treated with conventional treatment and follow-up
224225614|NCT00427622|OTHER|physiologic testing|
224225615|NCT01557647|DRUG|Inhaled treprostinil|0.6mg/mL treprostinil for inhalation solution. Titrated up to 12 breaths QID.
223637080|NCT05393791|DRUG|Abiraterone acetate|Use of abiraterone or enzalutamide
223637081|NCT05393791|DRUG|Enzalutamide|Use of abiraterone or enzalutamide
223637082|NCT06672406|DIETARY_SUPPLEMENT|Lactobacillus reuterii|Participants in the intervention group received probiotic Lactobacillus reuterii if they received enteral feeding \> 30 cc/kgBW. 5 drops of probiotics were given for 7 days in the breast milk or formula milk that did not contain probiotics
223637083|NCT06992583|BIOLOGICAL|Targeted CEA CAR-T|Subjects meeting the transfusion criteria will receive pre-treatment, which is as follows: fludarabine 25mg/m2/d×3day and cyclophosphamide 300mg/m2/d×3day, and intravenous CEA CAR-T therapy after 1-2 days of rest
223637084|NCT06992583|BIOLOGICAL|Targeted CEA CAR-T|Subjects meeting the reinfusion criteria will receive pre-treatment with fludarabine 25mg/m2/d×3day and cyclophosphamide 300mg/m2/d×3day, rest for 1-2 days, and intraperitoneal reinfusion targeted CEA CAR-T therapy
223637085|NCT06992414|DIETARY_SUPPLEMENT|Creatine monohydrate|8 g/day creatine monohydrate powder
223637086|NCT06992687|DRUG|HB0052 Injection|An antibody- drug conjugate (ADC) that targets CD73 with SN38 as the payload
223637087|NCT04574284|DRUG|TQB2450|TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.
223764974|NCT05454501|OTHER|Patient Education|After the first face-to-face evaluation session, these patients and their families will receive a 1-hour patient education program specific to the disease and exercise. Information brochures containing physical activity and exercise recommendations will be given. They will be followed up with weekly phone calls throughout the study period. At the end of 8 weeks, the second evaluation interview will be held. Afterward, the patients in the control group will be able to participate in the online exercise training program if they request it.
223764975|NCT06205927|RADIATION|Standard carbon ion beam radiotherapy|The standard treatment arm will receive carbon ion beam radiotherapy of 77Gy (RBE equivalent) per 22 fractions for gross tumor volume.
224225616|NCT01557647|DRUG|Placebo|placebo inhalation solution
224225617|NCT05388682|DEVICE|Percutaneous transluminal pulmonary angioplasty|Percutaneous transluminal pulmonary angioplasty
224225618|NCT05694468|OTHER|Psychomotor Relaxation|Psychomotor relaxation sessions.
224225619|NCT01958281|DRUG|SOF|Tablet(s) administered orally once daily
224225620|NCT01958281|DRUG|RBV|200 mg tablet administered orally once daily
224225621|NCT01958281|DRUG|LDV/SOF|90/400 mg fixed-dose combination (FDC) tablet administered orally once daily
224225622|NCT04356859|DRUG|Albumin Human|Addition of albumin during acute resuscitation following burn injury
223637088|NCT04574284|DRUG|Anlotinib|A multi-target receptor tyrosine kinase inhibitor.
223637089|NCT06999473|DEVICE|Virtual reality training|This training is built for the HMD Pico 4 Enterprise, which has six degrees of freedom, a 4k RGB display, a 101-degree field of view, and built-in eye-tracking hardware and software. The virtual environment is a 3-dimensional immersive environment in which the participant will be placed in three different virtual scenes: a picnic table, a kitchen, and a playground. This allows for the placement of stimuli in three different regions: near peripersonal (reaching) space, far peripersonal space, and extrapersonal (far) space. The goal of the game is to search for items that appear in front of the view, as accurately and quickly as possible.
223637090|NCT06999473|BEHAVIORAL|physiotherapy and occupational therapy|The conventional treatment consists of a problem-solving approach mainly based on the neurodevelopmental treatment approach. For VSN, the conventional treatment mainly consists of a mix of prism adaptation, visual scanning, and compensatory strategies based on the individual needs of the patient.
223637091|NCT06999473|DEVICE|Assessment|During assessments with SpatialSense, participants will sit in a wheelchair or on a straight-back chair. The trunk will be restricted to the chair. Finally, the data will be exported from SpatialSense and analyzed by investigators to define different search strategies while performing scanning tasks.
223637092|NCT06597708|BEHAVIORAL|keto diet|They were advised to eat ad libitum but to limit their carbohydrate intake to a maximum of 20-40 g/day to derive at leasut 75%, 15-20%, and 5-10% of total energy from fats, protein, and carbohydrates, respectively.
223637093|NCT06597708|BEHAVIORAL|intermittent fasting with calorie restriction|The 16/8 TRF group was asked to consume their daily calorie intake during an 8-hour window during the daytime and then fast for the remaining 16 hours each day throughout the intervention period.
223637094|NCT06998862|DRUG|colchicine treatment in chronic kidney disease patients|colchicine treatment 0.5 mg/day
223637095|NCT06998862|DRUG|placebo treatment|placebo treatment 1 pill/day
223637096|NCT06588361|OTHER|Training Based on Kolcoba Comfort Theory|Training Based on Kolcoba Comfort Theory
223637097|NCT06591559|DEVICE|Permobil Explorer Mini|The Explorer Mini (Permobil AB, Sweden) is a commercially available, FDA approved powered mobility device intended for young children between 12-36 months of age with mobility limitations (weight limit: 35 lbs; height limit: 39.4 inches). It is lightweight (52 lbs. including battery) and fits in most automobiles (length: 25 inches; width: 19 inches; adjustable height: 29-37 inches). The Explorer Mini runs on a 12-volt battery with a driving range of 3.5 miles and a maximum speed of 1.5 mph, is controlled via a joystick with a 360-degree turning radius, has proportional speed control with 5 speed options, and can be used in a seated or standing position.
223637098|NCT06591559|DEVICE|Portable Mobility Aid for Children (PUMA)|The Portable Mobility Aid for Children (PUMA; Enliten LLC) is a portable canopy system that utilizes an overhead support rail structure and a counterweight. The rail structure consists of two rigid parallel beams that mount to the canopy structure and one perpendicular mobile beam that allows for freedom of movement in one direction. Freedom of movement in the opposite direction is achieved by a system of pulleys along the movable beam that connects the harness to a counterweight. The counterweight provides a passive vertical force, counteracting gravity. The PUMA provides 2-dimensional mobility support over 81 ft2 (9 ft x 9 ft). The overhead bar is connected at 4 points to a child-worn harness. Children are free to move through many postures including sitting, crawling, standing, and walking.
223637099|NCT06600594|OTHER|Beginners dance training|Trainings will be conducted twice a week for two hours. The training includes a general warm-up, polishing the steps, including regional dances, and then dancing entire dance routines.
223637100|NCT06600594|OTHER|Experience dance training|Trainings will be conducted twice a week for two hours. The training includes a general warm-up, polishing the steps, including regional dances, and then dancing entire dance routines.
223637101|NCT06603129|DIAGNOSTIC_TEST|prognostic nutritional index|Prognostic nutritional index is an inflammation-based scoring that measures the nutritional and immunological status of patients and has been used to determine prognosis and predict postoperative complications.
223637102|NCT06586307|OTHER|quantitative analysis of DNA methylation at single-base resolution (QASM)|qPCR-based quantitative analysis for single-base methylation (QASM) The methylation percentage of each candidate CpG site was determined in multiple cohorts using a MethyLight-based QASM assay that has been developed and validated in our previous work. In short, the bisulfite-converted DNA was amplified, in which we exploited the locus-specific PCR primers flanking a pair of methylated and unmethylated probes labeled with the fluorescent dyes 6-carboxyfluorescein (6-FAM) and 2-chloro-7phenyl-1,4-dichloro-6-carboxyfluorescein (VIC), respectively. The methylation percentage was calculated by methylation/(methylation+unmethylation)×100%. QASM was performed using the Applied Biosystems QuantStudio 7 Flex Real-Time PCR System (Thermo).
224225623|NCT02784106|DRUG|Placebo|Participants received placebo matched to M2951 twice daily up to Day 84 during the double-blind treatment period.
224225624|NCT02784106|DRUG|M2951|Participants received 50 milligrams (mg) M2951 orally twice daily up to Day 84 during the double-blind treatment period.
224225625|NCT02784106|DRUG|M2951|Participants who received placebo matched to M2951 or M2951 in double-blind treatment period, received 50 mg M2951 orally twice daily up to 26-weeks during the open label extension period.
224225626|NCT05677607|DIAGNOSTIC_TEST|Magnetic resonance imaging|Imaging diagnostics mainly based on Magnetic resonance imaging.
224225627|NCT04897828|DEVICE|Covered Stent placement|Covered stent placement for the treatment of dysfunctional vascular access of hemodialysis patients
224225628|NCT05635149|RADIATION|radiotherapy|In radiotherapy group, the modality of radiotherapy was conventional radiotherapy (CRT) or stereotactic body radiotherapy (SBRT) for cancer.
224225629|NCT04117165|DIAGNOSTIC_TEST|Biotherapy Prescription with SinnoTest® software|The rheumatologist will use the SinnoTest® software to give the best biotherapy to the patient according to the results of the software.
224225630|NCT04117165|DRUG|Patient Current Care|The rheumatologist will use the french guidelines of rheumatoid arthritis to choose the more adapted biotherapy treatment to the patient.
224225631|NCT04243174|BEHAVIORAL|SMS Messaging|Patients with type 2 diabetes will be recruited and will start receiving short SMS messages about physical activity, encouraging them to be more active and help them to build a healthy life style routine.
224225632|NCT00850278|OTHER|FLT-PET imaging|Prior to surgical resection, patient will undergo \[11C\]MET PET imaging, \[18F\]FLT PET imaging, MRI, and spectroscopy imaging.
223637103|NCT06998589|OTHER|DPL|The DPL treatment was randomly applied to one side of the face, with an energy density of 6-8 J/cm². Sessions were performed at intervals of 2-3 weeks, for a total of six treatments..The randomly assigned half of the face received large-spot, low-energy 1064 nm laser treatment at an energy density of 0.8-1 J/cm², performed at intervals of 2-3 weeks for a total of six sessions.
223637104|NCT06592170|DRUG|Linperlisib combination with obinutuzumab|"Safe import period: Linperlisib: 80 mg, oral (pre - and post meal), QD; obinutuzumab: 1000 mg, intravenous infusion, administered on the first day (1st cycle on days 1, 8, and 15); Every 28 days, there is one cycle in total.~Extended treatment period: Combination induction: Linperlisib: RP2D, oral (pre - and post meal), QD; obinutuzumab: 1000 mg/time, intravenous infusion, administered on the first day (1st cycle on days 1, 8, and 15); Every 28 days, there are 2 cycles in total. Afterwards, single drug maintenance: Linperlisib: RP2D, oral (before and after meals), QD; every 28 days per cycle."
223637105|NCT06601985|PROCEDURE|J-pouch anastomosis|Patient with ultra-low rectal cancer undergoing Sphincter- preserving surgery with one-stage anastomosis using a colon J-pouch.
223637106|NCT06601985|PROCEDURE|direct anastomosis|Patient with ultra-low rectal cancer undergoing Sphincter- preserving surgery with one-stage direct anastomosis.
223637107|NCT06595537|DEVICE|Hand held ultrasound|Determination of gastric feeding tube position with the use of Lumify handheld ultrasound
223637108|NCT04272086|DRUG|Bupivacaine|0.25%
223637109|NCT04272086|DRUG|Bupivacaine liposome|10mL
223637110|NCT04272086|DRUG|normal saline|10ml
223637111|NCT06617897|BIOLOGICAL|CSL511 Fibrinogen concentrate (human)|CSL511 will be prepared in sterile water for injection and administered as an intravenous (IV) infusion.
223637112|NCT06617897|BIOLOGICAL|Cryoprecipitate|Cryoprecipitate will be administered via IV infusion.
223764976|NCT06205927|RADIATION|Carbon ion beam radiotherapy simultaneously dose boost|The hypoxic lesions dose boost arm will receive 77Gy (RBE equivalent) per 22 fractions for gross tumor volume and a simultaneously dose boost of 83.6Gy (RBE equivalent) per 22 fractions for hypoxic lesions detected by 18F-Misonidazole PET/CT.
223637114|NCT06775587|DIAGNOSTIC_TEST|Serum Raman spectroscopy intelligent diagnostic system|"1. Screening interested participants should sign the appropriate informed consent (ICF) prior to completion any study procedures.~2. The investigator will review symptoms, risk factors, and other non-invasive inclusion and exclusion criteria.~3. The following is the general sequence of events during the 3 months evaluation period:~4. Completion of baseline procedures Participants were assessed for 3 months and completed all safety monitoring."
223637115|NCT00735436|DRUG|Gliadel/Avastin/CPT-11|
223637116|NCT04586205|DEVICE|active TMS|Participants receive active repetitive transcranial magnetic stimulation (rTMS) while performing the International Affective Picture System (IASP). Stimulation is delivered at 120% of resting motor threshold (RMT), in triplet 50 Hz bursts, repeated at 5 Hz (2s on, 8s off), totaling 600 pulses per session.
223637117|NCT04586205|DEVICE|sham TMS|Participants receive sham rTMS while performing the IASP task. Stimulation is mimicked without actual neural activation using the same schedule and coil placement as the active condition.
223637118|NCT04586205|BEHAVIORAL|IASP Task|Participants complete the IASP (emotional image viewing) task during each TMS session (active and sham). The task includes both high- and low-load trials, designed to activate the dorsolateral prefrontal cortex (DLPFC). Task order and load levels are consistent across both stimulation sessions.
223637119|NCT04586205|BEHAVIORAL|SST Task|In a separate MRI session prior to TMS sessions, participants complete the SST which includes both high-load and low-load trials. This cognitive task is used to examine baseline DLPFC activation and to contrast cognitive vs. emotional activation profiles.
223637120|NCT04586205|OTHER|MRI|Participants undergo MRI sessions to measure DLPFC cortical reactivity and connectivity.
223637121|NCT04856358|DRUG|GLPG3121|GLPG3121 modified-release tablet
223637122|NCT04856358|DRUG|Placebo|Matching placebo
223637123|NCT05687851|DRUG|Cadonilimab（AK104）|q3w iv
223637124|NCT05687851|RADIATION|EBRT|45-50.4Gy
224225633|NCT02920164|DEVICE|Auricular acupuncture|Auricular acupuncture with indwelling permanent needles
223637125|NCT05687851|RADIATION|BT|≥80Gy
223637126|NCT02633124|DEVICE|Edelvaiss Multiline NEO|Use of Edelvaiss Multiline NEO to infuse the parenteral nutrition and drugs during the study period
224225634|NCT02920164|DEVICE|Placebo acupuncture|Placebo acupuncture with placebo needles
224225635|NCT03075033|DEVICE|Shikani optical stylet|Tracheal intubation is performed using Shikani optical stylet. The shikani optical stylet was bent to the same bend as a Mackintosh laryngoscope blade, lubricated and the endotracheal tube was mounted on it. The tube was settled to the stylet by the 'adjustable tube stop' so that the tip of the stylet did not project beyond the end of the tube. After intubation the 'tube stop' was released and the tube was unmounted into the trachea; the stylet was removed.
224225636|NCT03075033|DEVICE|Flexible fiberoptic bronchoscope for|AwakeRracheal intubation using flexible fiberoptic bronchoscope in patients with cervical spine instability
224225637|NCT02370706|DRUG|PIM447|pan-pim inhibitor
224225638|NCT02370706|DRUG|Ruxolitinib|JAK1/JAK2 inhibitor
224225639|NCT02370706|DRUG|LEE011|CDK4/6 inhibitor
223637127|NCT02633124|DEVICE|Standard Infusion Set|Use of Standard Infusion Set to infuse the parenteral nutrition and drugs during the study period
223637128|NCT00204178|BEHAVIORAL|Oxidative stress in kidney transplant recipients|
223637129|NCT04103619|DEVICE|AccuTite|Subjects will undergo treatment with AccuTite
223637130|NCT04103619|DEVICE|AccuTite + Morpheus 8|Subjects will undergo treatment with AccuTite and Morpheus 8
223637131|NCT03913507|DEVICE|Macroduct® Advanced Model 3710 SYS, Wescor|for each subject, both methods will be tested in order to compare the efficacy of the new sweat collection method (Macroduct® Advanced Model 3710 SYS, Wescor) to the method currently used in clinical routine.
224225640|NCT01665170|DRUG|Passiflora incarnata|3 x 1 tablet per day for 3 days
224225641|NCT01665170|DRUG|Placebo|3 x 1 ablet per day for 3 days
224225642|NCT03222141|DEVICE|TAVR Implantation of the THV Prosthesis|Patients with TAVR implantation
224225643|NCT03541564|DRUG|BMS-986165|Specified dose on specified days
224225644|NCT03541564|DRUG|Moxifloxacin|Specified dose on specified days
224225645|NCT03541564|OTHER|Placebo|Specified dose on specified days
224225646|NCT04023279|OTHER|TENS|100 Hz and 100 usec for 20 minutes
223637132|NCT04374669|PROCEDURE|Neuroplasty with Racz catheter|The patient is placed in the prone position with a pillow placed under the abdomen to correct the lumbar lordosis. After sterile preparation and draping, the epidural space via the sacral hiatus using a 16 gauge needle is accessed. Then, the Racz catheter is advanced to the site of adhesions under the fluoroscopic guidance. The target site is determined by the location of pathology on lumbar MRI, preprocedural epidurography, and clinical symptoms before the adhesiolysis. Adhesiolysis is performed through the high-volume administration of medications, which consist of a combination of a steroid, local anesthetics, hyaluronidase, and 5% hypertonic saline. As needed, the catheter remains in the epidural space for two days, with the additional injection on each of the days.
223637133|NCT06319690|OTHER|Lion's Breath Technique|"Patients receive training in Lion's Breath Technique, emphasizing deep diaphragmatic breathing and controlled exhalation.~Daily supervised Lion's Breath Technique sessions for 20 minutes for 1 week"
223637134|NCT06319690|OTHER|Chest Percussion Therapy|"Trained physiotherapists administer chest percussion therapy to mobilize secretions and improve lung function.~Daily session for 30 minutes for 1 week."
223637135|NCT00821548|PROCEDURE|electrostimulation|Electrostimulation of shoulder girdle and quadriceps muscles in facioscapulohumeral muscular dystrophy patients
223637136|NCT04041635|PROCEDURE|Stimuli reduction|Phototherapy goggles and earmuffs will be placed 3 minutes before the venipuncture (leaving the patient in resting state after the manipulation) and will be maintained during the procedure. Monitor alarms and devices will be silenced and will remain silenced and noise in the unit will be minimized during the procedure.
223637137|NCT04041635|PROCEDURE|Usual care|Babies in the control group will receive physical contention with administration of sucrose two minutes before carrying out the venipuncture procedure (usual care). Venipuncture will be performed with 22G extraction needles, or peripheric venous catheter. During the puncture the eyes will not be covered, and monitor alarms and devices be not be silenced.
223764977|NCT05539235|DRUG|different degrees of adjustment of the injection interval|"Treatment was an intravitreal injection of 0.5 mg conbercept using modified T\&E treatment plans. After 3 months of monthly intravitreal injections, the patients were randomly divided into two groups, and the degree of adjustment of the injection interval was divided into 2 weeks and 4 weeks."
223764978|NCT05052229|DRUG|Nitric Oxide|Nitric oxide gas for inhalation
224318918|NCT02796794|DIETARY_SUPPLEMENT|Genistein|Total 30 patients will be included into the study They will be divided into two groups each containing 15 patients. Intervention group will receive supplemental genistein (60 mg/day) to enteral nutrition
223637140|NCT00265993|DRUG|enoxaparin|"* All patients will be treated with enoxaparin 1.5 mg/kg, once a day, subcutaneously for up to 10 days.~* Long-term oral anticoagulation will be started in all patients after 24 hours of initiation of enoxaparin treatment and continued at least for 3 months."
224225647|NCT04023279|OTHER|Myofascial therapy|Seven to fifteen transverse sliding repetitions and three repetitions of longitudinal sliding of myofascial release therapy
224225648|NCT04715607|DIAGNOSTIC_TEST|Sequence of testing.|The participants will be tested in the following sequences of sampling technique: (1) nasopharyngeal swab, oropharyngeal swab, and salvia collection OR (2) oropharyngeal swab, salvia collection, and nasopharyngeal swab OR (3) salvia collection, nasopharyngeal swab, and oropharyngeal swab. Only the sequence is different in the different arm, while the sampling technique for each method is the same in all arms.
224225649|NCT03784456|DIETARY_SUPPLEMENT|25% protein|Compared to usual group of 15% protein in meals, intervention group will receive 25% protein contents under same estimated calorie menus. Protein may come from either egg, meat, fish, soy, or milk product.
223637141|NCT03384615|BEHAVIORAL|Compassion-Focused Therapy|CFT for PGD symptoms in the present project is inspired by two well-established CFT treatment manuals. The first is used for treatment of PTSD (Lee \& James, 2011) and the other for treatment of anger (Kolt, 2011). The manual for CFT for PGD adopts both structure and techniques from these into an 8-week, group-based program with weekly 2 1/4-hour sessions. Each session contains elements of psychoeducation on uncomplicated and prolonged grief reactions, identifying unhelpful strategies for self-protection and facilitating use of more helpful strategies, and training an open and compassionate management of grief-related distress through CFT exercises. Between the sessions the participant will train the exercises introduced at the previous session.
223637142|NCT01184092|DRUG|Treatment A|Single oral dose of 10 mg tasocitinib citrate (CP-690,550-10)administered as one 10 mg immediate release tablet (ICH -commercial image tablet).
223637143|NCT01184092|DRUG|Treatment B|Single oral dose of 10 mg CP-690,550 -10 administered as two 5 mg immediate release filmcoated tablets (Phase 3 tablets).
223637144|NCT01184092|DRUG|Treatment C|Single oral dose of 10 mg CP-690,550 -10 administered as two 5 mg tablets (Phase 2B tablets).
223637145|NCT01184092|DRUG|Treatment A|Single oral dose of 10 mg tasocitinib citrate (CP-690,550-10)administered as one 10 mg immediate release tablet (ICH -commercial image tablet).
223637146|NCT01184092|DRUG|Treatment C|Single oral dose of 10 mg CP-690,550 -10 administered as two 5 mg tablets (Phase 2B tablets).
223637147|NCT01184092|DRUG|Treatment B|Single oral dose of 10 mg CP-690,550 -10 administered as two 5 mg immediate release filmcoated tablets (Phase 3 tablets).
223637148|NCT01184092|DRUG|Treatment B|Single oral dose of 10 mg CP-690,550 -10 administered as two 5 mg immediate release filmcoated tablets (Phase 3 tablets).
223637149|NCT01184092|DRUG|Treatment C|Single oral dose of 10 mg CP-690,550 -10 administered as two 5 mg tablets (Phase 2B tablets).
223637150|NCT01184092|DRUG|Treatment A|Single oral dose of 10 mg tasocitinib citrate (CP-690,550-10)administered as one 10 mg immediate release tablet (ICH -commercial image tablet).
223764979|NCT05052229|DRUG|Medical air|Medical grade air for inhalation (placebo)
224225650|NCT03784456|DIETARY_SUPPLEMENT|15% protein|Designed as comparator , compared to empirical arm of 25% protein in meals, intervention group will receive 15% protein contents under same estimated calorie menus. Protein may come from either egg, meat, fish, soy, or milk product.
224318919|NCT02796794|OTHER|enteral nutrition only|These are the patients receiving enteral nutrition
223637151|NCT01184092|DRUG|Treatment B|Single oral dose of 10 mg CP-690,550 -10 administered as two 5 mg immediate release filmcoated tablets (Phase 3 tablets).
223637152|NCT01184092|DRUG|Treatment A|Single oral dose of 10 mg tasocitinib citrate (CP-690,550-10)administered as one 10 mg immediate release tablet (ICH -commercial image tablet).
223637153|NCT01184092|DRUG|Treatment C|Single oral dose of 10 mg CP-690,550 -10 administered as two 5 mg tablets (Phase 2B tablets).
223637154|NCT01184092|DRUG|Treatment C|Single oral dose of 10 mg CP-690,550 -10 administered as two 5 mg tablets (Phase 2B tablets).
223637155|NCT01184092|DRUG|Treatment A|Single oral dose of 10 mg tasocitinib citrate (CP-690,550-10)administered as one 10 mg immediate release tablet (ICH -commercial image tablet).
223637156|NCT01184092|DRUG|Treatment B|Single oral dose of 10 mg CP-690,550 -10 administered as two 5 mg immediate release filmcoated tablets (Phase 3 tablets).
223637157|NCT01184092|DRUG|Treatment C|Single oral dose of 10 mg CP-690,550 -10 administered as two 5 mg tablets (Phase 2B tablets).
223637158|NCT01184092|DRUG|Treatment B|Single oral dose of 10 mg CP-690,550 -10 administered as two 5 mg immediate release filmcoated tablets (Phase 3 tablets).
223637159|NCT01184092|DRUG|Treatment A|Single oral dose of 10 mg tasocitinib citrate (CP-690,550-10)administered as one 10 mg immediate release tablet (ICH -commercial image tablet).
223637160|NCT00320450|DRUG|SB-681323|
223637161|NCT00587522|DEVICE|NDO Full-thickness Plicator|The Plicator and gastroscope assembly were passed into the stomach. The stomach was distended with air. The gastroscope was advanced and retroflexed so that the instrument could be visualized and accurately positioned. The Plicator was retroflexed to within 1cm below the GE junction, and the helical tissue retractor was advanced deeply into the gastric wall. The gastric wall was retracted into the Plicator instrument arms. The arms were then closed, and the suture-implant was deployed to secure the full-thickness plication. The tissue retractor is then disengaged and the suture-implant released from the instrument.
223637162|NCT01586364|DRUG|Ospemifene 60Mg Oral Tablet|
223637163|NCT04475367|OTHER|App hypercross group|hypertensive patients using HyperCrossApp
223637164|NCT04475367|OTHER|without App hypercross group|Interdisciplinary health care
223637165|NCT03630315|DRUG|OTX-TKI|OTX-TKI is a dried polyethylene glycol-based hydrogel fiber containing dispersed microcrystals of a small molecule tyrosine kinase inhibitor (TKI).
223637166|NCT03630315|DRUG|OTX-TKI|OTX-TKI is a dried polyethylene glycol-based hydrogel fiber containing dispersed microcrystals of a small molecule tyrosine kinase inhibitor (TKI).
223637167|NCT03630315|DRUG|OTX-TKI|OTX-TKI is a dried polyethylene glycol-based hydrogel fiber containing dispersed microcrystals of a small molecule tyrosine kinase inhibitor (TKI).
223637168|NCT03630315|DRUG|OTX-TKI|OTX-TKI is a dried polyethylene glycol-based hydrogel fiber containing dispersed microcrystals of a small molecule tyrosine kinase inhibitor (TKI).
223637169|NCT03630315|DRUG|Anti-VEGF|Standard of care therapy used to block vascular endothelial growth factor
223637170|NCT03630315|DRUG|OTX-TKI|OTX-TKI is a dried polyethylene glycol-based hydrogel fiber containing dispersed microcrystals of a small molecule tyrosine kinase inhibitor (TKI).
223637171|NCT03630315|DRUG|Anti-VEGF|Standard of care therapy used to block vascular endothelial growth factor
223637172|NCT02121535|DRUG|T80/A5 mg FDC tablet|
224225651|NCT03379077|BEHAVIORAL|LTP Plus|LTP Plus is comprised of two components; Learning through play (LTP) and Cognitive Behavior Therapy (CBT). The LTP Plus is a low-literacy, sustainable program intended to provide parents with information on the healthy growth and development of their young children. The LTP research-based activities enhance children's development while simultaneously promoting attachment security through building parents' ability to read and be sensitive to their children's cues and through active involvement in their children's development. Plus the Thinking Healthy Program (THP) which adopts 'here and now' problem-solving approach. THP uses cognitive behavior therapy (CBT) techniques of active listening, changing negative thinking, and collaboration with the family.
224225652|NCT06380465|OTHER|"The water extract of Biang variety purple sweet potato"|"Purple sweet potato extract is a mixture of water and Biang variety of purple sweet potato puree, enhanced with a touch of flavoring"
223637173|NCT02121535|DRUG|T80/A5 mg FDC tablet|A Telmisartan 80 mg/ Amlodipine 5 mg FDC tablet
223637174|NCT02121535|DRUG|H12.5 mg tablet|
223637175|NCT02121535|DRUG|T80/A5/H12.5 ng FDC tablet|A Telmisartan 80 mg/Amlodipine 5 mg/HCTZ 12.5 mg FDC tablet
223637176|NCT02121535|DRUG|H12.5 mf tablet|A HCTZ 12.5 mg tablet
223637177|NCT02121535|DRUG|T80/A5/H12.5 mg FDC tablet|
223637178|NCT06440434|BEHAVIORAL|Time of night shift|Early vs. late night split night shift
223637179|NCT01780740|DRUG|Atorvastatin|Atorvastatin (80 mg od) started not earlier than 6 days before surgery and continued until the 5th post-operative day included;
223637180|NCT01780740|DRUG|Placebo|Placebo started not earlier than 6 days before surgery and continued until the 5th post-operative day included;
223637181|NCT05447780|PROCEDURE|regional anesthesia|regional anesthesia in lumbar surgery, TLIP block in spinal surgery, ESP block in spinal surgery
223637182|NCT00091949|DRUG|pioglitazone|a thiazolidinedione drug
223637183|NCT00091949|DRUG|placebo|an inactive substance
223637184|NCT05969158|DRUG|Hetrombopag|"After screening, patients who were treated with XPO-1 inhibitor Selinexor combined with chemotherapy and developed chemotherapy-related thrombocytopenia (CIT) after treatment and met the secondary prevention criteria were eligible for inclusion criteria.~The platelet reduction after the previous chemotherapy was used as the control group:~The patients did not routinely receive prophylactic platelet elevation therapy after the previous Selinexor combined chemotherapy, and when PLT \< 50×109/L.~Platelet reduction after chemotherapy in secondary prevention unit was used as the experimental group:~The subjects will initiate treatment with 5 mg hetrombopag once a day, starting orally 5 days before chemotherapy, take it for 5 days (D-5-D-1), and continue taking it orally for 5 days after chemotherapy (D1-D5)."
223637185|NCT06176079|DRUG|Hyperpolarized (HP) 13C|A dosage of 0.43 mL/kg body weight at the maximum dosage will be injected intravenously at a rate of 5 mL/second.
223637186|NCT06176079|DRUG|Hyperpolarized 13C-Urea|Given intravenously (IV)
223637187|NCT06176079|PROCEDURE|Magnetic Resonance Imaging|Imaging procedure
223637188|NCT06176079|PROCEDURE|Saline Flush|A 20 milliliter (mL) saline flush at 5 mL/second will be given after each dose of HP 13C
223637189|NCT02911168|PROCEDURE|Proximal Intercostal Block|After identifying the correct intercostal space, the ultrasound probe will be moved medially to identify the transverse processes, then again laterally from the transverse processes to rest over the ribs so as to obtain the best view of ribs and pleura. A 10cm, 21G needle will be inserted in-plane at the caudal border of the probe. An attempt will be made to keep the needle tip and the target injection position (just under the internal intercostal membrane (IIM)) in view. Correct needle tip placement will be demonstrated by depression of the pleura/endothoracic fascia upon local anesthetic injection and by lack of retrograde spread of LA over the muscles or the ribs. The LA will be injected in 4 cc aliquots after negative aspiration of air, CSF and blood.
223637190|NCT02911168|PROCEDURE|Paravertebral Block|After identifying the correct intercostal space, the ultrasound probe will be placed between the adjacent transverse processes in a longitudinal/parasagittal plane measuring 2.5cm from the midline. The best possible view of the transverse processes, the superior costotransverse ligament and pleura will be obtained. An attempt will be made to keep the needle tip and the target injection position (immediately beneath the costotransverse ligament) in view. Correct placement of the needle tip will be demonstrated by depression of the pleura upon injection of local anesthetic and by lack of retrograde spread of LA over the muscles or transverse processes. The LA will be injected in 4 cc aliquots after confirming negative aspiration of air, CSF and blood.
223637191|NCT04093102|DIAGNOSTIC_TEST|biomarkers|bio-markers testing will be made to all suspected OSA patients(CRP, Hba1C,uric acid, ESR, plasma fibrinogen, pentraxin3), and to control cases.
223637192|NCT04165577|DEVICE|rTMS|1-Hz rTMS targeting frontal pole
223637193|NCT04165577|DEVICE|sham rTMS|sham rTMS targeting frontal pole
223637194|NCT01954446|DEVICE|3M|Conventional measuring of BP
223637195|NCT01954446|DEVICE|ContiPressTM|"New way of measuring BP - ContiPressTM~Investigational device"
223637196|NCT01954446|DEVICE|Mobil-O-Graph|2 different devices for oscillometric measurement of BP
223637197|NCT04240535|DRUG|OnabotulinumtoxinA 50 UNT [Botox Cosmetic]|Injections to the Depressor Anguli Oris
223637198|NCT03399019|DRUG|Dexmedetomidine|initial loading dose (0.5 \~ 1㎍/kg for 10 minutes) and maintenance infusion (0.2-0.7㎍/kg/hr)
223637199|NCT03399019|DRUG|Propofol|continuous infusion (0.75-3mg/kg/hr)
223637200|NCT03399019|DRUG|Midazolam|0.05mg/kg bolus injection and if not OAA/S ≤ 3 within 5 minutes, add 0.01mg/kg at intervals of 1\~2 minutes
223637201|NCT00890123|DIETARY_SUPPLEMENT|Omegaven-IV FO|Will receive IV Omega 3 fatty acids (Omegaven®) for 3 pre operative days
223637202|NCT04259814|BEHAVIORAL|Speech-language therapy (SLT)|Age-appropriate play activities with speech-language pathologist (SLP) to elicit speech, using stimulation strategies including but not limited to recasts, expansion, parallel talk, interactive modeling, communication temptations, and phrase completions. Activities will include an age-appropriate story, pretend play (i.e., house with people, playing with a baby doll), an assembly task (i.e., building blocks, making pretend pizza), and a highly motivating, clinician-controlled activity (i.e., blowing bubbles, swing, pushing cars down a ramp).
223637203|NCT04259814|BEHAVIORAL|Modified constraint-induced movement therapy (mCIMT)|Participants will wear a removable cast and an occupational therapist will be present during therapy to focus on facilitating play with the affected arm.
223637204|NCT03347721|DRUG|lidocaine gel|2% lidocaine jelly, injected into the urethra
224225653|NCT02002780|BEHAVIORAL|Day Camp|"The intervention will be delivered using a day camp structure, on a weekend or during school break in July 2011. Separate interventions will be offered for boys and girls. Each intervention will include two full days (0900 to 1600) of group activities lead by the researchers. Details of the camp activities will be developed by the researchers, based on the types of psychosocial stress identified during the screening phase of the project."
224225654|NCT02003040|DEVICE|Mespere Venus 1000 CVP System|An adhesive patch (connected to the Mespere Venus 1000 System) is placed on the neck of the subject. A CVP measurement is recorded at time of patient's hospital admission and discharge. CVP readings will remain concealed from the treating team.
223637205|NCT03347721|DRUG|Lubricant Gel|Lubricating gel
223637206|NCT03405194|DRUG|Elvitegravir, Cobicistat, TAF, FTC|Started on day of HIV diagnosis
223637207|NCT03405194|DRUG|Efavirenz, TDF, and 3TC|Started on day of HIV diagnosis
223637208|NCT04289064|DEVICE|Taking a fundus image|The participant only needs to take a fundus image as usual.
223637209|NCT05908825|DRUG|Vitamin C with AHA Exfoliative Serum|Catalyst is a novel skincare product comprised of low concentrations of multiple hydroxy acids and will be randomly assigned as Product A or Product B to be applied to one side of the face.
223637210|NCT05908825|DRUG|Placebo serum|Placebo serum will be randomly assigned as Product A or Product B to be applied to one side of the face.
223637211|NCT02044640|PROCEDURE|Appendectomy|
223637212|NCT02083354|DRUG|Dabrafenib|Dabrafenib will be provided as 50 mg and 75 mg capsules. Each capsule will contain 50 mg or 75 mg of free base (present as the mesylate salt)
223637213|NCT02083354|DRUG|Trametinib|Trametinib study medication will be provided as 0.5 mg and 2.0 mg tablets. Each tablet will contain 0.5 mg or 2.0 mg of trametinib parent (present as the DMSO solvate)
223637214|NCT06339372|DIETARY_SUPPLEMENT|Standard feeding|Patients received only standard feeding with caloric distribution (45%-50% carbohydrates,20\_35% from fats and 10-35% from protein)
223637215|NCT06339372|DIETARY_SUPPLEMENT|Omega 3 and dipeptiven|Patients received perioperative supplementation with omega 3 and dipeptiven (immunonutrition mixture) plus standard feeding.
223637216|NCT02415413|DRUG|carfilzomib|
223637217|NCT02415413|DRUG|Lenalidomide|
224225655|NCT01840956|BIOLOGICAL|HAVG|HAVG is implanted into patients' arm.
223637218|NCT02415413|DRUG|Dexamethasone|
223637219|NCT02415413|DRUG|Melphalan|
223637220|NCT05957835|DIETARY_SUPPLEMENT|BR-HIGH|4 x nitrate-rich beetroot juice shots (26 mmol of nitrate)
223637221|NCT05957835|DIETARY_SUPPLEMENT|BR-MOD|2 x nitrate-rich beetroot juice shots + 2 x nitrate-depleted beetroot juice shot (12 mmol of nitrate)
223637222|NCT05957835|DIETARY_SUPPLEMENT|BR-LOW|1 x nitrate-rich beetroot juice shot + 3 x nitrate-depleted beetroot juice shots (6 mmol of nitrate)
223637223|NCT05957835|DIETARY_SUPPLEMENT|PL|4 x nitrate-depleted beetroot juice shots (0 mmol of nitrate)
223637224|NCT02757235|PROCEDURE|Irrigation fluid of body temperature|Irrigation fluid of body temperature will be used during burr hole evacuation of chronic subdural hematoma
223637225|NCT02757235|PROCEDURE|Irrigation fluid of room temperature|Irrigation fluid of room temperature will be used during burr hole evacuation of chronic subdural hematoma.
223637226|NCT02853617|BIOLOGICAL|AV0328 - Cohort 1|Cohort 1 will receive 15 µg to be given as an IM injection
223637227|NCT02853617|BIOLOGICAL|AV0328 - Cohort 2|Cohort 2 will receive 30 µg to be given as an IM injection
223637228|NCT02853617|BIOLOGICAL|AV0328 - Cohort 3|Cohort 3 will receive 75 µg to be given as an IM injection
223637229|NCT02853617|BIOLOGICAL|AV0328 - Cohort 4|Cohort 4 will receive 150 µg to be given as an IM injection
223637230|NCT04328077|DRUG|TERN-101|Investigational drug
224225656|NCT03933657|DEVICE|SoundBite™ Crossing System - Peripheral|SoundBite™ Crossing System consisting of the SoundBite™ Console and SoundBite™ Active Wire 18. The Investigator may use the SoundBite™ Active Wire during the procedure to cross the proximal aspect and/or to cross multiple lesions.
224225657|NCT02649283|DEVICE|OrbiSymm device|Breast symmetrisation following unilateral mastectomy and referred to contralateral symmetrisation procedure, with the OrbiSymm device, that requires reduction of at least 150grams.
224225658|NCT02649283|PROCEDURE|Breast symmetrisation|Breast symmetrisation following unilateral mastectomy and referred to contralateral symmetrisation procedure, without the OrbiSymm System, that requires reduction of at least 150grams.
224225659|NCT00261157|DEVICE|InTouch Telerounding Robot|
224225660|NCT03891056|PROCEDURE|metabolic surgery|The study will randomize patients into two arms, one where a laparoscopic gastric bypass will be performed and another that will perform slevee gastrectomy.
223637231|NCT04328077|OTHER|Placebo|Matching placebo
223637232|NCT02983201|OTHER|filiform needle|Patients will receive filiform needle treatment only.During the study period, a maximum of two courses of acupuncture therapy, consisting of 7 sessions each, will be administered. Treatment will be given twice per week. After completing the first course of 7 sessions, there will be a break of one week, at the end of which the second course will commence. Treatment will come to a halt as soon as the pain has totally subsided.
223637233|NCT02983201|OTHER|thumbtack needle|Thumbtack intra-dermal needle will be applied to selected acupuncture points after filiform needle treatment. The thumbtack needle will remain embedded in the patient's dermal part for 2-3 days as per instruction.During the study period, a maximum of two courses of acupuncture therapy, consisting of 7 sessions each, will be administered. Treatment will be given twice per week. After completing the first course of 7 sessions, there will be a break of one week, at the end of which the second course will commence. Treatment will come to a halt as soon as the pain has totally subsided.
223637234|NCT02699424|RADIATION|External radiation therapy|
223637235|NCT03366896|DIAGNOSTIC_TEST|Malay 3D-CAM diagnostic tool 1|Assessor 1 uses Malay 3D-CAM to detect Delirium
223637236|NCT03366896|DIAGNOSTIC_TEST|Malay 3D-CAM Diagnostic tool 2|Assessor 2 uses Malay 3D-CAM to detect Delirium
223637237|NCT01615120|DRUG|GTx-758 125 mg|One 125 mg tablet once a day
223637238|NCT01615120|DRUG|GTx-758 250 mg|two 125 mg tablets once daily
223637239|NCT02751723|OTHER|validated questionnaires|
223637240|NCT06274736|DEVICE|Motiva Sizer|No intervention will be made,
224225661|NCT05287880|DIAGNOSTIC_TEST|Dynamic PET/CT|After transmission CT scan for subsequent PET data attenuation correction, continual dynamic clinical PET scans were performed in a single bed position immediately after 18F-FAPI intravenously injection (210 ± 30 MBq) in list mode for 60 minutes in supine position, dynamic 48 time frames PET/CT imaging was obtained. And then underwent whole body static PET scan.
223637241|NCT01744106|DRUG|pseudoephedrine hydrochloride 30 mg tablets|
223637242|NCT01744106|DRUG|Placebo tablets|
223637243|NCT01601236|DRUG|Repository Corticotropin Injection|H.P. Acthar Gel (repository corticotropin injection) is administered via daily SC injection for 36 weeks in the three dose groups \[8 U (0.1 mL), 16 U (0.2 mL), or 32 U (0.4 mL)\].
223637244|NCT01601236|DRUG|Placebo|Placebo contains the same inactive ingredients as H.P. Acthar Gel without the active pharmaceutical ingredient (API). Placebo is administered via daily SC injection for 36 weeks in equal volumes as the Acthar comparator volumes.
223637245|NCT03821727|PROCEDURE|Hematopoietic Stem Cell Transplantation|Hematopoietic Stem Cell Transplantation in Acute Leukemia Ph positive
223637246|NCT00218868|PROCEDURE|Skin scrape|scrape cytology using two different cytological staining techniques, and additional touch imprint cytology compared with histopathology of superficial basal cell carcinoma and actinic keratosis
224225662|NCT05287880|DIAGNOSTIC_TEST|Dynamic PET/CT|After transmission CT scan for subsequent PET data attenuation correction, continual dynamic clinical PET scans were performed in a single bed position immediately after 18F-FAPI intravenously injection (210 ± 30 MBq) in list mode for 60 minutes in supine position, dynamic 48 time frames PET/CT imaging was obtained. And then underwent whole body static PET scan.
223637247|NCT04371159|DEVICE|Velieve U.S.|The Velieve U.S. is a home use, in-vitro diagnostic (IVD) device. The device is used for the semi-quantitative detection of blood and leukocytes, and the qualitative detection of nitrites in urine.
223637248|NCT01340846|DRUG|Warfarin|Warfarin dosed at 15mg on Day 1 and Day 22
223637249|NCT01340846|DRUG|Ketoconazole|Ketoconazole dosed at 400mg daily on Days 19 through 22
223637250|NCT01340846|DRUG|Gemfibrozil|Gemfibrozil dosed at 600mg twice daily on Days 19 through 22
223637251|NCT01340846|DRUG|GSK2118436 150mg|GSK2118436 dosed at 150mg twice daily
223637252|NCT01340846|DRUG|GSK2118436 75mg|GSK2118436 dosed at 75mg twice daily
223637253|NCT04968002|DRUG|pablizumab combined with apatinib and neoadjuvant chemotherapy|The patients with stage IIa-IIIa non-small cell lung cancer are treated with pablizumab combined with apatinib and neoadjuvant chemotherapy
223637254|NCT01524055|DEVICE|Single-Balloon-Enteroscopy with Air as insufflation gas.|Single-Balloon-Enteroscopy will be performed using Air as insufflation gas to inflate the intestine for complete examination.
223637255|NCT01524055|DEVICE|Single-Balloon-Enteroscopy with CO2 as insufflation gas.|Single-Balloon-Enteroscopy will be performed using CO2 as insufflation gas to inflate the intestine for complete examination.
223637256|NCT05682716|COMBINATION_PRODUCT|Controlled low central venous pressure (CLCVP) technology|Controlled low central venous pressure (CLCVP) technology: after cardiopulmonary bypass, pumping nitroglycerin (0.2-1 ug/kg \* min) and other methods until the end of surgery to maintain the central venous pressure below 10 mmHg.
223637257|NCT05682716|DRUG|Nitroglycerin|nitroglycerin (0.2-1 ug/kg \* min)
223637258|NCT01777386|PROCEDURE|preexpanded perforator flap surgery|
223637259|NCT06398756|OTHER|conventional rehabilitation|17 patients with cerebral palsy meeting the criteria will undergo conventional rehabilitation
223637260|NCT06398756|OTHER|aquatic therapy|17 patients with cerebral palsy meeting the criteria will undergo convertional rehabilitation and aquatic therapy
223637261|NCT02189317|DRUG|Exparel|For the treatment group a total of 40 cc consisting of 20 cc of 1.3% Exparel® and 20 cc of 0.5 % marcaine will be administered to the ACL harvest site, into the periosteum surrounding the distal tibial tunnel site, and in the proximity of the skin incisions. No infiltration of Exparel will be provided intra-articularly.
224225663|NCT01224210|DRUG|Ambrisentan|Ambrisentan once-daily in the morning with or without food. The adult dose selected for this study will be 5 mg for the first 4 weeks. After the initial 4 weeks the dose will be increased to 10mg (available doses are 5, and 10 mg) based on tolerance safety. Subjects will remain on 10mg until they complete the study. Dose adjustments may be made based on side effects.
224225664|NCT00604110|OTHER|Biventricular pacing post cardiac surgery|Determine which biventricular pacing after cardiac surgery, in patients with reduced left ventricular function (EF\<45%), is hemodynamically favourable.
224225665|NCT03457025|DRUG|Oral Corticosteroids|Prednisone 10 day taper: 60mg for 5 days, then taper for five days to 0mg
224225666|NCT03457025|DRUG|Oral antivirals|acyclovir 400mg: one pill 4 times daily for 7 days
224225667|NCT03457025|DEVICE|Hyperbaric Oxygen Therapy|2.4atm administered for twice daily dives for 5 days, 10 dives total. To be begun in the first 1 week after onset of paralysis.
223637262|NCT00680108|DRUG|diquafosol tetrasodium (INS365) ophthalmic solution|
223637263|NCT05514977|PROCEDURE|Erector spine plane block|Thoracic ESPB
223637264|NCT04195763|DRUG|asfotase alfa|This is an observational study and no intervention will be administered. All participants will be treated by their physician in accordance with standard of care. All medications are commercially available and will be used as directed by the treating physician.
223637265|NCT02419001|DRUG|Period 1 - Treatment Sequence AB|Period 1: Ceftriaxone 1 g infused IV over 30 minutes only, no SYN-004
223637266|NCT02419001|DRUG|Period 1 - Treatment Sequence AC|Period 1: Ceftriaxone 1 g infused IV over 30 minutes only, no SYN-004
223637267|NCT02419001|DRUG|Period 2 - Treatment Sequence AB|Period 2: Ceftriaxone 1 g infused IV over 30 minutes and SYN-004 75 mg
224225668|NCT02229266|BIOLOGICAL|NK cells|
224225669|NCT02229266|DRUG|Cytarabine|1 cycle of consolidation chemotherapy with high-dose cytarabine
224225670|NCT03801096|BEHAVIORAL|Narrative Based Therapuetic Assessment (NbTa)|The NbTa interventiom will guide participants through an exploration of their human experience through stories and narratives. The interventionist will facilitate a collaborative process by which participants will explore the unique themes and meanings of their personal narrative (Parry \& Doan, 1994) with respect to alcohol and drug use. In addition, participants will also be guided towards considering the re-authorship of personal narratives. The techniques utilized in NbTa aim to dislodge problem saturated narratives and derive more complete personal narratives and meanings (White \& Epston, 1990).
224225671|NCT03801096|BEHAVIORAL|Health Education Control Condition (HE)|The Health Education session is a didactic 45-minute session that focusses on three health-related topics: 1) Sleep, 2) Physical Activity, and 3) Nutrition. The goal of the session is to present health-related information to participants through videos and dydadic presentation.
224225672|NCT00451932|DRUG|FK778|
224225673|NCT02673671|DEVICE|G-Tech Myoelectric recording device|A minimum of three patches are placed on the abdomen of the patient to record myoelectric activity.
224225674|NCT02125578|DRUG|BIIB017 (PEGylated Interferon Beta-1a)|Each participant will receive BIIB017 every other week or every 4 weeks.
223637268|NCT02419001|DRUG|Period 2 - Treatment Sequence AC|Period 2: Ceftriaxone 1 g infused IV over 30 minutes and SYN-004 150 mg
223637269|NCT00313014|DRUG|Buprenorphine|Buprenorphine transdermal patch 5 mcg/h applied for 7-day wear.
223637270|NCT00313014|DRUG|Buprenorphine|Buprenorphine transdermal patch 20 mcg/h applied for 7-day wear
223637271|NCT00313014|DRUG|Oxycodone Immediate-Release|Oxycodone HCl immediate-release 40 mg (two 5-mg capsules every 6 hours).
223637272|NCT04089995|OTHER|data collection|No intervention
223637273|NCT02922322|OTHER|Pilates Group|The Pilates group program (PG) was composed of 16 sessions, 2x per week, 60 minute session each for 8 weeks. The intervention was based on 20 out of the 34 original mat exercises proposed by the Pilates method, classified into basic, intermediate or advanced levels divided into 4 cycles of 5 exercises each. The exercises were performed during two series of 10 repetitions respecting the patients skills.
223637274|NCT00393731|DRUG|Misoprostol|
223637275|NCT00393731|DRUG|oxytocin|
223637276|NCT04402034|BEHAVIORAL|Application of tele-rehabilitation|Individuals that will perform the virtual reality intervention.
223764981|NCT04973605|DRUG|Sonrotoclax|Administered orally daily
223764982|NCT04973605|DRUG|Dexamethasone|Once weekly either orally or intravenously
223764983|NCT04973605|DRUG|Carfilzomib|Administered intravenously weekly
224225675|NCT02125578|DRUG|Placebo|Each participant will receive placebo every other week or every 4 weeks.
224225676|NCT00857025|BIOLOGICAL|beta-glucan MM-10-001|Dose escalation with six patients treated at each of the following oral dosages: 2.5, 5.0, 7.5, 10, 15, 20, 30, 40, 50, and 80 mg/day
224225677|NCT00857025|OTHER|flow cytometry|Performed on blood samples collected within 14 days prior to study treatment and at week 1, week 5, week 9, week 13 and every 4 weeks until the end of study treatment.
224225678|NCT00857025|OTHER|laboratory biomarker analysis|Performed on blood samples collected within 14 days prior to study treatment and at week 1, week 5, week 9, week 13 and at the end of study treatment.
223637277|NCT00188344|PROCEDURE|pneumatic dilatation|"The patient is on a liquid diet for 2 days prior to procedure. A sedative and pain killer by IV are given and the throat will be sprayed with local anesthetic.~The gastroenterologist may perform an endoscopy prior to the dilatation to safely guide the dilator into position. A special dilator with a small balloon will be passed down the esophagus until it meets the stomach then the balloon will be inflated with air until the narrow part of the esophagus is opened. The patient will then be assessed for any perforation of the esophagus and monitored in the post-procedure unit for a few hours."
223637278|NCT00188344|PROCEDURE|laparoscopic myotomy with partial fundoplication|The abdomen is inflated with gas and cameras and instruments are inserted. The junction between the esophagus and stomach is identified. The muscle of the lower esophageal sphincter is divided. A portion of the stomach wall is secured to the lower esophagus. After surgery the patient is taken to the recovery room and when well enough moved to a ward. The patient may be discharged the following day.
223637279|NCT03515668|DRUG|Ritalin 20 mg Tablet|Single dose for all participants
223637280|NCT03515668|DRUG|Placebo Oral Tablet|Placebo with same appearance/taste
223637281|NCT00644800|DRUG|Ziprasidone|Intramuscular ziprasidone 10 or 20 mg at the investigator's discretion for 1 to 3 days followed by oral ziprasidone capsules 40 to 80 mg twice daily at the investigator's discretion to complete 7 days of treatment
223637282|NCT05497999|OTHER|Proactive Outreach|"The treatment is proactive outreach that sought to enroll individuals in a VBID program available to all enrollees that provided: 1) large reductions in cost-sharing for maintenance inhalers, and 2) telephone-based COPD medication management services.~Proactive outreach for those randomized to the treatment arm included, at a minimum, a phone call and letter in the mail from Humana. Proactive outreach could also have included an email, text message, and/or provider referral."
223637283|NCT05497999|OTHER|No Proactive Outreach|Control group participants received no proactive outreach but could call to enroll themselves in the VBID program if they learned about it through traditional means, such as the benefits description manual.
224225679|NCT00857025|OTHER|questionnaire administration|Assessment pre-study and week 5, week 9, week 13 and at off study.
224225680|NCT00737230|OTHER|educational intervention|
224225681|NCT00737230|OTHER|questionnaire administration|
224225682|NCT00737230|PROCEDURE|assessment of therapy complications|
224225683|NCT00737230|PROCEDURE|gastrointestinal complications management/prevention|
224225684|NCT00737230|PROCEDURE|management of therapy complications|
224225685|NCT00737230|PROCEDURE|quality-of-life assessment|
224225686|NCT00296114|PROCEDURE|Serum and DNA Samples|To collect serum and DNA samples from subjects
224225687|NCT00818714|RADIATION|SBRT|"SBRT x 3 (start 6-9 weeks following standard ChemoRT; Time between SBRT Boost treatments: 40 hours to 8 days)~Dose Escalation Schema:~Cohort -3: 4 Gy x3 Cohort -2: 5 Gy x3 Cohort -1: 6 Gy x3 If de-escalation is required after initial cohort~Cohort 1: 7 Gy x 3 INITIAL COHORT Cohort 2: 8 Gy x 3 Cohort 3: 9 Gy x 3~Continue +1 Gy x 3 until reach MTD"
223637284|NCT00663182|DRUG|Entecavir|Entecavir 0.5 mg/d
223637285|NCT04350762|DIETARY_SUPPLEMENT|Protein shake + Fish Oil|2 shakes of protein as well as 1 fish oil daily.
224225688|NCT04571242|DEVICE|DTM Programming|DTM-SCS programming
224318920|NCT05992766|OTHER|Reformer Pilates|Reformer Pilates exercises activates the lumbopelvic muscles and supports functional movement. Activated muscles support the spine and reduce the load on the spine by correcting the posture, helping the core muscles such as the abdomen and spine stay healthier by attaching them to a neutral pelvis Pilates consists of a sliding platform working with the help of a pulley system specific to the use, allowing the individual to apply certain resistances, and providing the opportunity to exercise sitting, standing, or lying down.
223637286|NCT02268357|DRUG|Propranolol|Oral propranolol capsules
223637287|NCT00999778|BEHAVIORAL|Caregiver-Mediated Intervention|1 (two- 1/2 jour sessions weekly) hour of intervention per week for 10 weeks in which parents and their child meet with the interventionist together using the caregiver as a means to facilitate change in their child's development
223637288|NCT00999778|BEHAVIORAL|Caregiver-Education Intervention|The caregiver meets 1 time (1 hour each session) a week for 10 weeks with an interventionist - caregiver will receive information on child development and have the opportunity to ask questions and discuss the information vis-a-vis their own child
223764984|NCT04973605|DRUG|Daratumumab|Administered subcutaneously weekly
223764985|NCT04973605|DRUG|Pomalidomide|Administered orally daily
224225689|NCT04571242|DEVICE|Conventional SCS programming|Conventional SCS programming
224225690|NCT00977964|OTHER|Experimental milk protein infant formula Process A|ad lib for 1-8 days of age until 28 days of age
224225691|NCT00977964|OTHER|Experimental milk protein infant formula Process B|ad lib from 1-8 days of age until 28 days of age
224225692|NCT00977964|OTHER|Experimental milk protein infant formula Process C|ad lib from 1-8 days of age to 28 days of age
224318921|NCT05992766|OTHER|Hammock Yoga|Hammock Yoga is performed with a silk hammock, which is an auxiliary equipment. The most distinctive characteristic that makes Hammock Yoga different from other exercises is the spine traction provided by the upside-down posture, and the smooth and shiny silk hammock allows strengthening exercises. The Hammock Yoga aims to reduce the load on the spine by upside-down postures that defy the laws of physics.
224225693|NCT00977964|OTHER|Experimental milk protein infant formula Process D|ad lib from 1-8 days of age until 28 days of age
224225694|NCT00977964|OTHER|Experimental milk protein infant formula Process E|ad lib from 1-8 days of age until 28 days of age
224225695|NCT00977964|OTHER|Experimental milk protein infant formula Process F|ad lib from 1-8 days of age until 28 days of age
224225696|NCT03998085|DRUG|Anlotinib Hydrochloride|Anlotinib hydrochloride capsule 12 mg, orally, once a day, oral before breakfast, according to the research program for 2 weeks, discontinued for 1 week. Patients with complete remission (CR), partial remission (PR) and stable disease (SD) continued to administer drugs until the disease progressed, intolerable toxicity or withdrawal was required. Patients with progression of illness (PD) discontinued their medication.
224225697|NCT01999790|PROCEDURE|blepharotomy|upper eyelid surgery by blepharotomy
224225698|NCT01999790|PROCEDURE|posterior approach|upper eyelid surgery by posterior approach
223637289|NCT04743778|BEHAVIORAL|Virtual Diabetes Self-Management Education and Support|Diabetes self-management education and support delivered through Zoom for health.
223637290|NCT04841083|DEVICE|Allay Lamp|The Allay Lamp is a consumer product currently available and widely used in the US. It emits low intensity (1-10 lux) narrow band (20 nm) green light (peak wavelength 520 nm) that is marketed as non-irritating to users. In that context, it is not a medical device and does not require a 510(k).
223637291|NCT04988581|OTHER|Intensively integrated care of microvascular risk factors in the intervention group|The intensively integrated care, which will provide a standardized, combined, multi-component intervention according to clinical guideline treatment for diabetes and comorbidities in a primary care setting, will be delivered by trained primary care physicians, health managers and diabetes specialists. Diabetic microvascular risk factors (glycated hemoglobin \[HbA1C\], urinary albumin-to-creatinine ratio \[ACR\], blood pressure \[BP\], estimated glomerular filtration rate \[eGFR\], uric acid \[UA\] and low-density lipoprotein cholesterol \[LDL\]) will be tested every 3 month for the intervention group and clinical treatment decisions based on the test results will be implemented accordingly when necessary. The intensively integrated care intervention will last for 36 months. HbA1C, ACR, BP, eGFR, UA, LDL, other variables and co-morbidities will be measured at baseline and follow-up visits every 3 month.
223637292|NCT00588497|PROCEDURE|Micro-insert hysteroscopic sterilization|Placement of micro-inserts transcervically with the aid of a hysteroscope
223637293|NCT00588497|RADIATION|Plain abdominal Xray|Performed immediately after micro-inserts placement and at 3 months
223637294|NCT00588497|PROCEDURE|Pelvic Ultrasound|Performed immediately after micro-inserts placement and at 3 months.
223637295|NCT00588497|RADIATION|Hysterosalpingogram|Performed 3 months after micro-inserts placement
223637296|NCT04875143|DIETARY_SUPPLEMENT|Citrus aurantium L.|In the first intervention, the volunteers allocated to group I will take a capsule containing 500mg of starch, at the end of this, another capsule containing 500mg of Citrus aurantium L. will be provided for the second intervention.
223637297|NCT00231738|DRUG|Eicosapentaenoic acid ethyl ester(EPADEL Capsule 300 TM)|
223637298|NCT01181349|OTHER|Neuromuscular Blocking Agent (NMBA)|While neuromuscular blockade drug(s) are involved in this study prior to actual study initiation (this is an observational study), it should be noted that the identity, combination(s), and dosages of these drugs (also referred to as general anesthesia drug\[s\]) are not specified in the protocol.
223637299|NCT01181349|OTHER|Neuromuscular Blocking Agent (NMBA)|While neuromuscular blockade drug(s) are involved in this study prior to actual study initiation (this is an observational study), it should be noted that the identity, combination(s), and dosages of these drugs (also referred to as general anesthesia drug\[s\]) are not specified in the protocol.
223637300|NCT06079814|OTHER|virtual reality intervention|Patients will be shown content through the patient's virtual reality glasses throughout the cystoscopy procedure.
223637301|NCT03162263|DEVICE|EKso training|Patients affected by chronic stroke underwent gait training by using the Ekso device; they performed a total of 20 sessions (5 day/week for 4 weeks) of at leat 40min duration.
223637302|NCT05205122|PROCEDURE|Combined trabeculotomy-trabeculectomy with mitomycin C|Combined trabeculotomy-trabeculectomy with mitomycin C Will be done in all cases
223637303|NCT05743491|OTHER|Standard Care|Cancer survivors assigned to this condition continue with the standard follow-up care provided by their treating oncologists as appropriate for individual diagnoses. Participants in the control condition were offered the 4-week YOCAS©® program gratis after completing all study requirements.
223637304|NCT05743491|BEHAVIORAL|YOCAS©®|YOCAS©® is a standardized yoga program designed specifically for use by cancer patients and survivors. The YOCAS©® program is a low to moderate intensity mode of exercise that draws from two basic types of yoga: gentle Hatha and Restorative yoga. The program includes 18 specific physical postures (asanas) and mindfulness exercises focused on breathing (pranayama) and meditation (dhyana). The program is designed to be delivered by certified yoga instructors in community settings, two times a week for 75 minutes over four weeks.
223637305|NCT01926457|OTHER|Treatment of Prediabetes|"Standardized treatment of prediabetes per California Diabetes and Pregnancy Program Sweet Success~* diabetes education~* blood glucose monitoring~* medications as needed per California Diabetes and Pregnancy established protocol~* growth ultrasounds~* antenatal testing"
223637306|NCT03980080|DRUG|OSE-127|"mAb antagonist to CD127 receptor (or IL-7Rα)~Group 1-7~6 escalating dose level groups IV~SC"
223637307|NCT03980080|DRUG|Placebo|Vehicle study drug
223637308|NCT03980080|DRUG|OSE-127|"mAb antagonist to CD127 receptor (or IL-7Rα)~Group 8-9~2 escalating dose level groups IV"
223637309|NCT01515553|DRUG|liraglutide|Two single doses of 0.72 mg liraglutide administered subcutaneously on two different dosing occasions separated by a wash-out period
223637310|NCT01597804|PROCEDURE|Infection Prophylaxis and Management|"Undergo preoperative preparation with the Bathing Bundle"
223637311|NCT01820338|BEHAVIORAL|Behavioral Child Tx Contacts|Each parent and child dyad will participate in group meetings. Children and parents will meet in simultaneous, but separate, groups at each meeting. The intervention will include 12 sessions over 16 weeks. Families will also participate in a maintenance intervention for the next eight months. The primary treatment objectives will be to decrease caloric intake in a nutritionally sound manner and to increase moderate intensity exercise. Changes in dietary habits will be addressed via a modified version of the Stoplight System. Children and adults will be encouraged to eat a well-balanced diet based on the food guide pyramid. Parents and children will also be given pedometers and they will be asked to keep track of the number of steps they take each day. Each week parents and children will set goals to gradually increase physical activity. Parent and their children will be asked to record what they eat and drink, as well as their physical activity on daily food logs.
223764986|NCT03623958|DEVICE|Image guided Video-Assisted Thoracic Surgery (VATS) resection|Image guided placement of a fiducial consisting of a needle directed placement of a T-Bar next to the target lesion in order to lead the surgeon to the lung region to be removed
223764987|NCT03623958|PROCEDURE|Video-Assisted Thoracic Surgery|Standard of Care Video-Assisted Thoracic Surgery (VATS) resection
223764988|NCT01350427|DIETARY_SUPPLEMENT|Leucine supplementation|1 bout of resistance exercise and supplementation of 4.0 g of leucine + 5.6 g of alanine
223764989|NCT01350427|DIETARY_SUPPLEMENT|BCAA supplementation|1 bout of resistance exercise and supplementation of 4.0 g of leucine + 2.8 g of isoleucine + 2.8 g of valine
223637312|NCT01820338|BEHAVIORAL|Behavioral Parent-Tx Contacts|Only the participating parent(s) will attend group meetings. The intervention will include weekly sessions for the first 8 weeks and biweekly sessions for the next 8 weeks. They will also participate in a maintenance intervention for eight months. Each session will last 90 minutes. The sessions for parents in the parent-only program will be structured the same as the parents sessions for the family-based intervention and will also cover the same topics. As with the family-based intervention, the parent and their children assigned to the parent-only intervention will be asked to record what they eat and drink, as well as their physical activity, on a daily basis. Each week group interventionists will model the goal setting process with parents and suggest a general range of age-appropriate dietary and physical activity targets that might be appropriate for each child and parent.
223637313|NCT01820338|OTHER|Dietary and Physical Activity Information|Both the child and parent will attend the treatment sessions in this program. The condition will include a series of meetings addressing key aspects of nutrition, physical activity, and health promotion such as national guidelines regarding proper nutrition, guidelines for physical activity, strategies to cope with stress, healthy sources and guidelines for intake of fiber, calcium, protein, grains \& carbohydrates. Topics will also include use of vitamin \& mineral supplements, dental and sleep hygiene, self-esteem, family communication, and assertiveness training in dealing with peer victimization. The families in the Health Education group will not receive training in behavioral self-regulation strategies, such as goal setting and self-monitoring. Children will participate in a group physical activity during each session such as frisbee, jump rope, stoplight tag. They will also sample healthy snacks such as pretzels or fruits and vegetables.
224225699|NCT01847196|DEVICE|Angel® Catheter|The Angel® Catheter combines the functions of an inferior vena cava (IVC) filter and a multi-lumen central venous catheter (CVC). The device is designed to be placed in the inferior vena cava, via the femoral vein, for the prevention of Pulmonary Embolism (PE), and for access to the central venous system. The device is intended for short-term use (less than 30 days) and must be removed before hospital discharge.
223637314|NCT02928965|DRUG|Minocycline|Capsules containing 100mg minocycline (modified release), administered orally by the patient, two per day for the first two weeks and then three per day for the reminder of the 12 month treatment period in addition to standard therapy.
224225700|NCT03208959|DRUG|HTI-1090|IDO/TDO inhibitor
223637315|NCT02928965|DRUG|Placebo|Matching placebo with appearance of over - encapsulated minocycline
223637316|NCT04818788|DRUG|Biological Drug|we will give biological drugs to indicated ulcerative colitis patients and we will investigate the predictive ability of fecal calprotectin and hematological indices to histological remission
223637317|NCT06139120|DIAGNOSTIC_TEST|Assessment of hypersensitivity|Assessment of pain hypersensitivity in body segments was performed using pressure pain measurement
223637318|NCT01198795|DRUG|Escitalopram|Patients who meet eligibility criteria will receive open-label escitalopram. 10-20mg oral administration (10mg tablets) once daily for 24-weeks with a 2-week downtaper period.
223637319|NCT00744497|DRUG|Placebo|
223637320|NCT00744497|DRUG|Dasatinib|
223637321|NCT00744497|DRUG|Docetaxel|
224318922|NCT05992766|OTHER|Traditional mat exercises|The mat exercises help build core strength, stamina, and motor control of the abdominal and lumbar trunk musculature. The exercises focus on the re-education of a precise co-contraction pattern of local muscles of the spine. Also mat exercise increases the level of endorphins and the stimulation of mechanoreceptors, causing biomechanical stress to support healing in tissues.
224318923|NCT04940559|DRUG|Danicopan - Tablet|Oral tablet.
223637322|NCT00744497|DRUG|Prednisone|
223637323|NCT03925012|BEHAVIORAL|Intervention|
223637324|NCT03928184|DRUG|Lorecivivint|Healthcare professional-administered intra-articular injection; performed on Day 1
223637325|NCT03928184|DRUG|Placebo|Healthcare professional-administered intra-articular injection; performed on Day 1
223637326|NCT06284889|BEHAVIORAL|Behavioural activation|"Session 1: Face-to-face; Psychoeducation about depression; treatment rationale for Behavioral Activation (BA); rationale and instructions for activity log;~Session 2: Via telephone; Discussion of life goals and values; planning of activities aligned with life goals and values for coming week~Session 3: Via telephone; Troubleshooting any problems carrying out activities; planning activities aligned with life goals and values for coming week.~Session 4: Via telephone; Troubleshooting any problems carrying out activities; planning activities aligned with life goals and values for the coming week; instructing the participant to independently continue to plan activities for the coming month.~Session 5: Via telephone; Troubleshooting any problems carrying out activities; reviewing treatment; stressing the importance of continuing to engage in activities aligned with life goals and values; creating a maintenance plan."
223637327|NCT06284889|OTHER|Treatment as usual (TAU)|Treatment as usual regarding depression received at their primary care centre.
223637328|NCT05784038|DIAGNOSTIC_TEST|Viral genomic|Evaluation of mpox viral genomic
223637329|NCT05784038|DIAGNOSTIC_TEST|Untargeted Metabolomics|Evaluation of metabolomics of the total plasma, oropharynx, and skin samples.
224225701|NCT04370145|DRUG|Sulperazon|moderate cholangitis patients were treated with these drugs for 7days,unless the patients were cured or must be changed the therapeutic.
224225702|NCT04370145|DRUG|Teicoplanin|severe cholangitis patients were treated with these drugs for 7days,unless the patients were cured or must be changed the therapeutic.
224225703|NCT04370145|DRUG|Meropenem Injection|cholangitis in control group were treated with these drugs for 7days,unless the patients were cured or must be changed the therapeutic.
224225704|NCT04256993|DRUG|Radium-223 dichloride (Xofigo, BAY88-8223)|Follow the physician's prescription in routine clinical practice. This study does not involve prescription of the drugs.
224225705|NCT04256993|DRUG|Other standard care|Docetaxel, cabazitaxel, enzalutamide, abiraterone and others standard of care following the physician's prescription in routine clinical practice.
224225706|NCT01210183|DRUG|Dextrose intraarticularly administered|9 ml of 12.5% dextrose
224225707|NCT03801837|DIETARY_SUPPLEMENT|Macadamia Nut|Participants will be provided with the appropriate portion of macadamia nuts \[15% of daily calories or 30-45 grams based on kcal requirement of the individual\]
224318924|NCT04940559|DRUG|Danicopan - Softgel|Oral softgel capsule.
224318925|NCT04940559|DRUG|Danicopan - LFC|Oral LFC.
224318926|NCT01559883|OTHER|no intervention is being made|This is a Non-Interventional Study (NIS)
223637330|NCT04830332|DIAGNOSTIC_TEST|abdominal fluid CA-125 levels test|One hundred milliliters of normal saline was used as the abdominal washing liquid to obtain the sample for CA-125 measurement. Serum and abdominal washing fluid CA-125 levels were measured with a double antibody sandwich immunoenzymatic method, using Beckman Coulter DXI (Ireland) analyzer. I
223637331|NCT01197118|RADIATION|sequence chemoradiotherapy|"Postoperative radiotherapy regimen: Therapy plan system was formulated by Computed tomographic (CT) simulation. Radiation was delivered with 15MV photons. Radiotherapy consisted of 4500 cGy of radiation at 180 cGy per day, five days per week for five weeks, to the tumor bed, to the margins of resection or the stoma, to the regional nodes. Protection of spinal cord, heart, liver and kidney should be considered.~Postoperative chemotherapy regimen: see arm 2"
223637332|NCT01197118|DRUG|chemotherapy alone following radical resection|Postoperative chemotherapy regimen: The OLF regimen was administrated: Oxaliplatin, 130 mg/m2/day on day1, i.v. 2 h; fluorouracil, 425 mg/m2/day on day1\~5, i.v.; leucovorin, 200 mg/m2/day on day 1\~5, i.v.; every 21 days repeated, for 6 cycles.
224225708|NCT03801837|DIETARY_SUPPLEMENT|Control Diet|Participants will continue with their Habitual Diet during this part of the intervention
224225709|NCT01766011|OTHER|study pre-term formula|24 kcal/fl oz pre-term formula for in-hospital use
224225710|NCT02818283|DIETARY_SUPPLEMENT|Soy Pretzel|Each packet (5oz.) of soy pretzel contains high gluten wheat flour, soy flour, soymilk, vegetable shortening, sugar, yeast, salt, and ascorbic acid. Each packet provides \~280 calories (16% fat, 54% total carbohydrates, and 30% protein).
224225711|NCT02818283|OTHER|Wheat Pretzel|Each packet (5oz.) of wheat pretzel contains high gluten wheat flour, vital wheat gluten, shortening, sugar, yeast, salt, and ascorbic acid. Each packet provides \~290 calories (16% fat, 54% total carbohydrates, and 30% protein).
223637333|NCT03298035|DEVICE|NCPAP as mode for apnea prevention|With recurrence of apneic events, infants on NCPAP will have changes made in NCPAP settings per the clinical team's discretion in attempt to prevent future apneic events. If apneic events persist despite NCPAP adjustments, clinicians may intubate based on clinical judgment.
223637334|NCT03298035|DEVICE|NIPPV as rescue mode for apnea prevention|With recurrence of apneic events, infants will be placed on NIPPV with settings and adjustments per the clinical team's discretion. If apneic events persist despite NIPPV placement and setting adjustments, clinicians may intubate based on clinical judgment.
223637335|NCT01116986|BEHAVIORAL|Counseling before quit attempt|Participants randomized to this condition will have 20-minute in-person counseling sessions 1 and 3 weeks before their target quit day and a 20-minute phone counseling session 2 weeks before their target quit day. In the in-person counseling session, the case manager will address issues such as smoking reduction, withdrawal coping, environmental restrictions on smoking, intra-treatment social support, autonomous motivation, and practice quit attempts. Participants will be asked to engage in two practice quit attempts. These attempts will each last 8 hours and will be assigned (in collaboration with the smoker) to occur on one weekend day and one weekday the second and third weeks after the quit day.
223637336|NCT01116986|BEHAVIORAL|Minimal In-person counseling during quit attempt|Participants randomized to minimal in-person counseling will receive one 3-minute in-person session occurring one week before their target quit day. The clinician will also inform the participant of the sort of phone counseling follow-up that s/he will receive in 1 and 2 weeks after their quit date. (This resembles the real-world situation in which the clinician discusses the sort of follow-up intervention a patient will receive.)
223637337|NCT01116986|BEHAVIORAL|Intensive in-person counseling during the quit attempt|Participants randomized to intensive in-person counseling will receive three 20-minute face-to-face counseling sessions: one during the week before the target quit day, one on the target quit day and one during the week after the target quite day. The counseling will include intra-treatment social support and skill-based competence intervention components.
223637338|NCT01116986|BEHAVIORAL|Minimal phone counseling during the quit attempt|Participants randomized to this condition will receive minimal phone counseling consisting of one 10-minute phone counseling session on the morning of the target quit day. This session will address motivation to quit, strategies for coping with urges to smoke and use of the medication, and will provide support. Thus, all participants will get some counseling support on the quit day, which reflects the fact that initial lapses often occur on the target quit day, and quit day smoking is an important determinant of ultimate outcome.
223764990|NCT01350427|DIETARY_SUPPLEMENT|Alanine supplementation|1 bout of resistance exercise and supplementation of 9.6 g of alanine
224225712|NCT02804828|DIETARY_SUPPLEMENT|Individualized mitochondrial cocktail|Nutrient cocktail comprising: thiamine, nicotinamide, pantothenic acid, riboflavin, L-carnitine, alpha lipoic acid, CoQ10, vitamin C, vitamin E, and omega 3 fatty acids (Cod Liver Oil).
224225713|NCT02804828|DIETARY_SUPPLEMENT|Placebo|6 months for the double-blind phase
224225714|NCT04443283|OTHER|No intervention|This is a observation study, with no intervention
224225715|NCT00189397|DRUG|azathioprine and corticosteroids for Parthenium dermatitis|
224225716|NCT03668028|BIOLOGICAL|TPX-114|Subjects will be treated with autologous fibroblasts (TPX-114) during arthroscopic surgery.
224225717|NCT03668028|PROCEDURE|Arthroscopic surgery|Subjects undergo conventional arthroscopic surgery for rotator cuff repair.
224225718|NCT01944228|DEVICE|Vagal Nerve Stimulation|30 minutes of vagal nerve stimulation using a catheter in the IJV
224225719|NCT01944228|DEVICE|Sham Stimulation|Catheter placed in the IJV without stimulation
224225720|NCT02544061|BIOLOGICAL|NM-IL-12|single 12 µg unit subcutaneous (SC) dose of NM-IL-12
224225721|NCT02544061|DRUG|Placebo|single subcutaneous dose
224225722|NCT06206733|DRUG|ASKB589|ASKB589 will be administered as a minimum 3-hour IV infusion
224225723|NCT06206733|DRUG|Oxaliplatin|Oxaliplatin will be administered as a minimum 2-hour IV infusion
224225724|NCT06206733|DRUG|Capecitabine|Capecitabine will be administered orally twice daily (bid).
224225725|NCT06206733|DRUG|Tislelizumab|Tislelizumab will be administered every 3 weeks Intravenous infusion on day 1 of each cycle.
224225726|NCT06206733|DRUG|Placebo|Placebo will be administered as a minimum 3-hour IV infusion
224318927|NCT00143247|DRUG|Exubera® (inhaled insulin)|Treatment of type 1 and type 2 diabetes with short-acting insulin
224318928|NCT06548945|DRUG|GZR18|5 mg-maximum tolerated dose (MTD), single dose
224318929|NCT06548945|OTHER|Placebo|administered the same volume as GZR18
223637339|NCT01116986|BEHAVIORAL|Intensive phone counseling during the quit attempt|Participants randomized to this condition will receive intensive phone counseling consisting of three 15-minute phone sessions (on the morning of the target quit day and on days 2 and 10 after the quit day). The content of the target quit day phone call will emphasize intra-treatment social support, skill execution and avoidance of danger situations. The quit day phone call is intended to augment any other clinician counseling received either on the phone or in person; such interventions tend to have additive effects and produce strong dose-response effects as a function of the duration of the counseling intervention.
223637340|NCT01116986|DRUG|Long Term Nicotine Patch+ Nicotine Gum During Quit Attempt|"If randomized to this condition:~After the target quit day:~Patch:~IF \> 10 cigs/day: one 21 mg nicotine patch per day for 12 weeks, THEN one 14 mg nicotine patch per day for 2 weeks, THEN one 7 mg nicotine patch per day for 2 weeks.~IF \< or = 10 cigs/day: one 14 mg nicotine patch per day for 12 weeks, then one 7 mg for 4 weeks.~Gum:~IF \> 24 cigs/day: ten 4 mg nicotine gum per day for 16 weeks. IF \< or = 24 cigs/day: ten 2 mg nicotine patch per day for 16 weeks."
223637341|NCT01116986|DRUG|Short Term Nicotine Patch + Nicotine Gum during the quit attempt|"If randomized to this condition:~After the target quit day:~Patch:~IF \> 10 cigs/day: one 21 mg nicotine patch per day for 4 weeks, THEN one 14 mg nicotine patch per day for 2 weeks, THEN one 7 mg nicotine patch per day for 2 weeks.~IF \< or = 10 cigs/day: one 14 mg nicotine patch per day for 4 weeks, then one 7 mg for 4 weeks.~Gum:~IF \> 24 cigs/day: ten 4 mg nicotine gum per day for 8 weeks. IF \< or = 24 cigs/day: ten 2 mg nicotine gum per day for 8 weeks."
223637342|NCT01116986|DRUG|Pre-Quit Nicotine Gum|"If randomized to only the Pre-Quit Nicotine Gum condition (and not the Pre-Quit Nicotine Patch):~Before quitting: Everyone will have ten 2 mg nicotine gum per day for 2 weeks before the target quit day."
223637343|NCT01116986|DRUG|Pre-Quit Nicotine Patch|"If randomized to only the Pre-Quit Nicotine Patch condition (and not the Pre-Quit Nicotine Gum):~Before quitting: Everyone will have one 14 mg nicotine patch per day for 2 weeks before the target quit day."
223637344|NCT01116986|DRUG|Pre-Quit Nicotine Patch + Pre-Quit Nicotine Gum|"If randomized to both the Prequit Patch and Prequit Gum Conditions:~Before quitting: Everyone will have ten 2 mg nicotine gum per day for 2 weeks and one 14 mg nicotine patch per day for 2 weeks before the target quit day."
223637345|NCT04154904|OTHER|Exercise|Subjects will be randomized to complete either aerobic, high intensity interval training, or resistance exercise videos twice weekly at home.
223637346|NCT03469414|OTHER|Life Space Assessment Scale|This nine question survey asks participants where they have gone in the last week, frequency of those visits, and how independently they went there.
223637347|NCT03469414|OTHER|6-Minute Push Test|The 6 Minute Push Test is a measure of endurance, and requires that the participant wheel themselves around two pylons that are located 15 meters apart for 6 minutes.
223637348|NCT03469414|OTHER|Forward Push Test|This measure of wheelchair propulsion speed asks patients to propel themselves as fast as they can over 20 meters. This task is performed twice, and the average time is used for the score.
223637349|NCT03469414|OTHER|Wheelchair Slalom Test|In this measure, participants propel themselves through an 18 meter slalom course at their maximum self-selected speed, wheeling around seven cones, separated by three, two, or one meter.
224225727|NCT05425966|BEHAVIORAL|CLS-R-FUERTE|The CLS-R-FUERTE program is a remote school clinician training and comprehensive psychosocial intervention designed to improve attention and behavior in Mexican school-aged youth (grades 1-5). It contains the same evidence-based service components to improve youth attention/behavior as the in-person CLS-FUERTE program; specifically, it features school clinician training by a clinical research team to lead parent skill groups, child skill groups, and teacher consultation in a behavioral classroom management system.
223637350|NCT03469414|OTHER|Craig Handicap Assessment and Reporting Technique|A measure of social participation in individuals with SCI.
223637351|NCT03469414|OTHER|PART-O|The PART-O is a community participation measure.
223637352|NCT03469414|OTHER|GPS Tracking|A GPS tracker will be attached to the wheelchairs of a subset of participants for one week. The GPS location is collected every minute, and mapped to Google Maps, which would allow calculation of speed of movement.
223637353|NCT00936715|DRUG|FTC/TDF|200/300 mg tablet administered orally once daily
223637354|NCT05048277|BEHAVIORAL|Single Session Consultation|"Single-Session Consultation (SSC) is a low-intensity, goal-directed, solution-focused counseling service used for treatment of mental health problems. The intervention consists of a 60-minute session conducted through NYU ZOOM, a HIPAA compliant teleconferencing platform. Sessions will be conducted between a parent and a study consultant. The consultant will 1) identify the participant's specific modifiable goal (and associated hope); 2) the smallest-possible step taken to overcome their problem; and 3) work collaboratively in creating an Action Plan, drawing on their inner abilities and external resources. This intervention does not act as therapy but instead, to potentially jumpstart progress and facilitate hope and agency. Following completion, participants will receive their Action Plan. Additional personalized resources will be provided following completion of the follow-up assessment, which includes referrals for further services and online resources."
223637355|NCT05247671|GENETIC|ERCC1|ERCC1 is a rate-limiting enzyme in the nucleotide excision repair pathway that is known to repair cisplatin-induced DNA damage. Polymorphisms in ERCC1 are known to affect response to cisplatin treatment. A mechanism explaining the effect of the ERCC1 polymorphism on the kidney may be that the homozygous carriers of this rs3212986 allele might have a greater capacity to repair cisplatin-induced DNA damage in their kidney epithelia, and thus would be more resistant to cisplatin-induced nephrotoxicity
223637356|NCT05247671|GENETIC|OCT2|OCT2 is expressed on the basolateral membrane of Proximal Tubular Epithelial Cell (PTEC) and plays a central role in cisplatin uptake into tubular cells. Genetic variants in the cisplatin uptake transporter OCT2 showed association with the preservation of kidney function. Patients with the CT genotype in OCT2 polymorphism rs596881 exhibited positive changes in eGFR compared to individuals with the wild type CC genotype
223637357|NCT03819114|DRUG|Levonorgestrel (LNG)|LNG tablet(s) were administered by mouth in a directly observed manner.
224225728|NCT02804269|OTHER|Cardiovascular Magnetic Resonance|For the evaluation of heart function and structure of the cardiovascular system.
224225729|NCT02804269|OTHER|Fatmass measurement|It utilizes a scale machine to measure the body fat and skeletal muscle percentage
223637358|NCT01840241|DRUG|sodium bicarbonate|BIVON group were received 0.5 mmol/kg of sodium bicarbonate for 1hours after induction of anesthesia and following 0.15 mmol/kg of sodium bicarbonate during the operation.
224225730|NCT03459326|OTHER|IIEF (International Index of Erectile Function questionnaire )|"The questionnaire is presented and answered without help. Answers to the IIEF Questionnaire will be collected in order to obtain the following scores (the total score is of no interest):~* Erectile function (score 1 to 30)~* Orgasmic function (score 0 to 10)~* Desire (score 2 to 10)~* Sexual satisfaction (score 0 to 15)~* Overall satisfaction (score 2 to 10)"
224318930|NCT05812443|OTHER|Shabad Kriya Meditation|The Shabad Krya meditation technique, used in Kundalini Yoga, will be performed by the participants of this intervention group for 8 consecutive weeks, for 30 minutes, before going to sleep. This group will be trained by a Kundalini Yoga teacher with extensive experience in Shabad Krya meditation. The evaluation of Sleep Quality, Mental Health and Spirituality parameters will be measured through specific questionnaires, shortly after the end of the eighth week of intervention, and also one month and three months after the end of the intervention.
224318931|NCT05812443|OTHER|Relaxing reading|Relaxing reading will be performed by the participants of this control group for 8 consecutive weeks, for 30 minutes, before going to sleep. The evaluation of Sleep Quality, Mental Health and Spirituality parameters will be measured through specific questionnaires, shortly after the end of the eighth week of intervention, and also one month and three months after the end of the intervention.
223637359|NCT01840241|DRUG|normal saline|
223637360|NCT03247946|BEHAVIORAL|upright head position|Bottle feeding of infants with their head in upward and not supine head position
223637361|NCT04286945|PROCEDURE|LATERAL RECTUS MUSCLE AUGMENTED RECESSION BY ELONGATION OF THE TENDON WITH AUTOGRAFT FROM RESECTED MEDIAL RECTUS MUSCLE|After resection of the medial rectus muscle, the resected segment is sutured to the lateral rectus muscle after dissection and marking to elongate and slaken the muscle then the elongated muscle is sutured to the sclera at the desired amount of conventional recession.
223637362|NCT05027555|OTHER|Multisensory training|Multisensory training included marching on the foam with visual deprivation and treadmill training with visual deprivation
223637363|NCT05027555|OTHER|Conventional training|Conventional training included strengthening, balance training and gait training
223637364|NCT03868657|DRUG|Moxifloxacin|Moxifloxacin is solely used to cause a known and for the drug well documented effect, namely blockade of the Kv11.1 channel.
223637365|NCT03868657|DRUG|Placebo|Placebo
223637366|NCT03813927|DIETARY_SUPPLEMENT|Vitamin D|Supplementation with tablet 170 μg Vitamin each day.
223637367|NCT03813927|DIETARY_SUPPLEMENT|Placebo|Placebo with tablet 20 μg Vitamin each day.
223637368|NCT03532867|OTHER|Examination of pressures before stopping the exercise|"In healthy volunteers performing aerobic physical exercise in the Department of Sports Medicine, the investigators will perform different examinations :~* Macular and peri-papillary OCT in EDI mode (bilateral examination),~* Intraocular pressure (bilateral examination)~* Measurement of systolic and diastolic blood pressure~* Heart rate measurement Exercise testing will be performed on bicycle measuring session with 10 minutes at moderate intensity ( 30% OF MPA), 10 minutes at sustained intensity ( 50% of MPA) and 3 minutes at maximum (70% of MPA).~The theoretical maximal aerobic power was calculated by a mathematical formula."
223637369|NCT03532867|OTHER|Examination of pressure during the exercise|"In healthy volunteers performing aerobic physical exercise in the Department of Sports Medicine, the investigators will perform different examinations :~* Macular and peri-papillary OCT in EDI mode (bilateral examination),~* Intraocular pressure (bilateral examination)~* Measurement of systolic and diastolic blood pressure~* Heart rate measurement Exercise testing will be performed on bicycle measuring session with 10 minutes at moderate intensity ( 30% OF MPA), 10 minutes at sustained intensity ( 50% of MPA) and 3 minutes at maximum (70% of MPA).~The theoretical maximal aerobic power was calculated by a mathematical formula."
223637370|NCT03532867|OTHER|Examination of pressures after stopping the exercise|"In healthy patients performing aerobic physical exercise in the Department of Sports Medicine, the investigators will perform different examinations :~* Macular and peri-papillary OCT in EDI mode (bilateral examination),~* Intraocular pressure (bilateral examination)~* Measurement of systolic and diastolic blood pressure~* Heart rate measurement Exercise testing will be performed on bicycle measuring session with 10 minutes at moderate intensity ( 30% OF MPA), 10 minutes at sustained intensity ( 50% of MPA) and 3 minutes at maximum (70% of MPA).~The theoretical maximal aerobic power was calculated by a mathematical formula."
223637371|NCT00563056|DRUG|Flutiform|
223637372|NCT00563056|DRUG|Flixotide plus Foradil|
223637373|NCT01744977|BEHAVIORAL|packaging|Intervention provides usual statin medication dispensed in pre-prepared adherence packaging (blister packaging) rather than the previously received prescription bottles
223637374|NCT00821795|DRUG|NPH/Regular 70/30 mix|injectable solution, subcutaneous,0.3-0.5 units/kg/day divided into twice per day dosage, 16 weeks duration
223637375|NCT00821795|DRUG|insulin aspart protamine/insulin aspart 70/30 mix|injectable solution, subcutaneous, 0.3-0.5 units/kg/day divided into twice per day dosage, for 16 weeks
223637376|NCT02327832|PROCEDURE|Autologous BMSCs|Cultured autologous bone marrow-derived mesenchymal stem cells
223637377|NCT02327832|DRUG|bone marrow-derived mesenchymal stem cells|
223637378|NCT06483295|OTHER|Using mobile internet platforms for follow-up management of postoperative symptoms in lung cancer patients.|Using mobile internet platforms for follow-up management of postoperative symptoms in lung cancer patients.
224318932|NCT01952314|DRUG|Naftopidil 75mg|naftopidil 75mg 1T qd hs
224318933|NCT01952314|DRUG|Placebo for Naftopidil|Placebo 1T qd hs
224318934|NCT01952314|DRUG|Standard treatment|Aceclofenac 100mg or tramadol37.5mg/acetaminophen 325mg on demand
223637379|NCT04052880|DRUG|Daratumumab|Daratumumab 1800 mg will be delivered by subcutaneous injection given through a syringe and needle by a manual push over approximately 3 to 5 minutes. Doses will be administered at alternating locations on the abdomen. Daratumumab will be administered weekly during treatment in Cycles 1 to 2, every 2 weeks during cycles 3-6, and every 4 weeks thereafter.
223637380|NCT04052880|DRUG|Bortezomib|Subjects will receive 1.3 mg/m2 bortezomib as a subcutaneous infusion on Days 1, 8, and 15 during the 28-day cycles.
223764991|NCT03640676|DEVICE|FlowOx|FlowOx is a CE marked device developed to increase blood flow to the lower extremities. A pressure chamber is sealed around the leg below the knee and is connected to a control unit which induces pulses of 10 sec negative pressure, and 7 sec of atmospheric pressure.
224225731|NCT05941091|BEHAVIORAL|HafifMod Programme|"MODULAR EDUCATION PROGRAMME: A training program consisting of five modules, shaped by the main headings of fluid and salt control in hemodialysis patients, was created. It is aimed that the patients receive training on a topic each week in a gradual manner. It will be ensured that HD patients can watch the modular training videos prepared in the computer environment on a tablet or computer.~MOBİLE APPLICATION: Through the mobile application to be developed, the maximum amount of fluid that HD patients should consume per day will be calculated automatically based on their dry weight. In addition, a system will be created where the user can manually enter the amount of fluid consumed daily and add it to the total amount of fluid consumed. In this way, people will be able to learn the amount of fluid they consume daily. In addition, the content of the application will include informative messages in the form of educational short tips and modular training videos."
223637381|NCT04052880|DRUG|Lenalidomide|"In Cycles 1 through 12, lenalidomide will be self-administered at a dose of 15 mg orally each day on Days 1 through 21 of each 28-day cycle.~For subjects with CrCl 30-60mL/min, lenalidomide will be reduced to 10mg daily, and for subjects with CrCl 15-30 mL/min, lenalidomide will be reduced to 5mg daily.~In maintenance phase: lenalidomide will be administered at one dose level below Cycles 1-12 dosing ie 10 mg orally daily.~In maintenance, for subjects with CrCl 30-60 mL/min, lenalidomide will be reduced to 5 mg daily during maintenance treatment, and for subjects with CrCl 15-30 mL/min, lenalidomide will be reduced to 5 mg every other day during maintenance treatment."
223637382|NCT04052880|DRUG|Dexamethasone|"Dexamethasone will be self-administered orally at a total dose of 20 mg weekly during cycles.~However, the dexamethasone 20 mg oral or IV (only if oral is not available) dose administered as a preinfusion medication on daratumumab infusion days replaces the oral dexamethasone dose for that day. Dexamethasone will be administered until the subject experiences disease progression or unacceptable toxicity.~In the maintenance phase, dexamethasone/steroid premedications may be tapered or discontinued in the absence of daratumumab related infusion reactions/based on patient tolerance. In the event of persistent daratumumab related infusion reactions, the least amount of steroid premedications needed to prevent the same may be used."
223637383|NCT04052880|DRUG|Ixazomib|During maintenance treatment, if choice of maintenance therapy includes ixazomib, ixazomib will be administered at 3 mg orally daily on Days 1,8, and 15 of each cycle. For subjects with CrCl 15-30 mL/min, ixazomib will be reduced to 2.3 mg once per week during maintenance treatment.
223637384|NCT00420446|BEHAVIORAL|Adjusted diet|
223637385|NCT02620748|DRUG|Tranexamic Acid|
223637386|NCT02620748|OTHER|Saline Solution|
223637387|NCT03687060|BEHAVIORAL|Knowledge assessment|Investigators will conduct semi-structured interviews with medical directors, clinical leadership and all participating physicians to gain insight on knowledge about and barriers to prescribing statins for people living with HIV. People living with HIV will participate in focus groups.
223637388|NCT03687060|BEHAVIORAL|Education Intervention|"Education intervention will be adapted from the the findings of these interviews and focus groups.~Clinics will be randomized to receive the education intervention and feedback implementation strategies at different times.~Medical directors and providers will receive a brief educational intervention about cardiovascular disease risk in people living with HIV. Providers will additionally receive a web-based survey before and after the education intervention.~Patients will receive pamphlets tailored to the effects of cardiovascular disease treatment for people living with HIV."
223637389|NCT03687060|BEHAVIORAL|Provider Feedback|Six months after the education intervention, providers will receive monthly emails with feedback regarding their rates of prescribing statins, with language targeted at increasing motivation to prescribe by leveraging social norms and self-image.
223637390|NCT03770988|DRUG|Treatment with Poziotinib|Treatment with Poziotinib
223637391|NCT04737616|DEVICE|CO2 laser|Fractional CO2 vaginal laser for genitourinary syndrome of menopause
223637392|NCT04737616|DEVICE|OCT|Optical coherence tomography endoscope
223637393|NCT06119282|OTHER|inhaler|Experimental: After the cesarean section, at the 8th hour postpartum, the VAS/GCA is evaluated, 4 drops of carrier oil are dropped on the upper and lower parts of the wick of the aroma stick, and then 15-20 drops of the prepared essential mixture are dropped and the woman is explained about its use. By the 8th hour of the postop, 4\*1 women are allowed to sniff. Before the application, the 30th and 60th minutes VAS/GOC, vital parameters are evaluated.
223637394|NCT06119282|OTHER|Control Group|Control Group Pregnant women included in the control group will be left to clinical care, and pain and vital parameters will be monitored starting from the 8th postoperative hour. The scales applied to the experimental groups will be applied on the 2nd postoperative day. Women in the control group who completed the study will be informed about the postpartum use of aromatherapy. Women who want aromatherapy application will be directed to GETAT center.
223637395|NCT06119282|OTHER|massage|Experimental: Test Massage When the studies conducted with the massage method are examined, back massage is applied for 10-30 minutes. Considering the working conditions of the institution, it is thought that a 10-minute massage may be sufficient for the application. The massage application is started at the postpartum 8th hour and applied for 10 minutes on the postoperative 0th day 1\*1, 2 times on the postoperative 1st and 2nd days when the woman feels ready. 30 and 60 minutes before application. then VAS/GCS, vital parameters are monitored.
223637396|NCT02878343|BEHAVIORAL|Incentives|Daily lottery type incentives tied to achievement of weight loss goals
223637397|NCT02878343|BEHAVIORAL|Environmental strategies|Individually tailored environmental strategies around food intake and physical activity; automated text/emails sent from study website platform
223637398|NCT04980404|DRUG|Inqovi|Tablet combination of drugs decitabine and cedazuridine, given orally.
223637399|NCT00611104|DIETARY_SUPPLEMENT|standardized freeze-dried table grape powder|
223637400|NCT00611104|OTHER|laboratory biomarker analysis|
223637401|NCT00611104|OTHER|pharmacological study|
223637402|NCT05481463|DRUG|Surufatinib|surufatinib,250mg, qd, po, 28 days for a cycle
223637403|NCT05481463|DRUG|TAS-102|TAS-102,35mg/m2, po, d1-5, d8-12, bid, 28 days for a cycle
223637404|NCT02647996|PROCEDURE|MRI: functional (resting state) and structural (DTI)|One hour brain MRI recording without active task for the patient, no sedation
223764992|NCT04352140|DEVICE|Tetragraph|FDA approved neuromuscular transmission monitor capable of measuring the depth of neuromuscular block in anesthetized patients who received neuromuscular blocking agents. TetraGraph uses EMG to measure the muscle action potentials that are generated in response to electrical neurostimulation via skin electrodes.
223637405|NCT04090203|DRUG|Boiled Peanut Powder|Oral Immunotherapy will be administered utilizing a powder derived from boiled peanuts. Treatment will begin with an initial escalation day in which dosing is begun at 0.1 mg peanut protein and escalated to a final dose of 6 mg peanut protein. Doses are ingested orally. The subjects will continue daily oral ingestion of doses at home and return for updosing every 2 weeks to a final maintenance dose of 300 mg peanut protein. The subjects will continue daily oral ingestion of the peanut product for a minimum duration of 28 days before undergoing exit DBPCFC. At the conclusion of the study, patients will be offered continued maintenance therapy off study in line with current specialty standards.
223637406|NCT06488820|DEVICE|Catheter ablation using pulsed-field ablation (PFA) system|PFA will be used to isolate the pulmonary veins and additional left atrial structure as needed
223637407|NCT04225897|DRUG|RV521|RV521 is an RSV F protein inhibitor administered orally
223637408|NCT04225897|DRUG|Placebo|vehicle administered orally
223637409|NCT06024824|RADIATION|Dose-Painted Intensity Modulated Radiotherapy|"Fifteen fractions of external beam radiation therapy (EBRT) delivered via IMRT/ VMAT.~Cohort 1 (n = 3-6) Single PTV 40.05 Gy/15#, homogenous dose. Cohort 2 (n = 3-6) High Risk PTV 45 Gy/15# SIB to PTV tumour, Elective PTV 40.05 Gy/15# to nodal regions.~Cohort 3 (n = 3-6) High risk PTV 48 Gy/15# SIB to PTV tumour, Elective PTV 40.05 Gy/15# to nodal regions."
223637410|NCT05705934|OTHER|Exercise|Each session of the exercise program will last 50 minutes and will consist of 4 stages. At these stages, it is aimed to work the social, physical, spiritual and mental parameters of the holistic approach.
223637411|NCT02995746|DRUG|Dexamethasone|"* On study visit #1 all patients will have a SD-OCT scan and measurement of baseline visual acuity. All patients will receive the 0.7mg dexamethasone intravitreal implant~* Subsequent follow-up visits will be at 1 month, 2 months, 3 months, 4 months, 5 months, and 6 months after intravitreal injection of dexamethasone implant~* Each visit will consist of measurement of visual acuity, intraocular pressure, dilated fundoscopic examination, and SD-OCT scan~* Anticipated duration of the study: 6 months"
223637412|NCT06184022|COMBINATION_PRODUCT|Augmented reality serious game design for promoting children's science education cognition:|"The experimental group utilized the three game lesson modules of the AR science education app designed for this study, including Animals vision,  Light transmission, and Color-Light mixing.~The experimental group's total learning time was limited to 20 minutes, the testing process was completed under the supervision of the instructor and the experimenter, and the children's behavioral characteristics were recorded. During the experiment, the participants were not disturbed in any way; researchers only intervened when they faced difficulties or requested assistance. The participants were given a 15-minute respite at the conclusion of the trial to take another POE test. Before and after the intervention, each participant's performance on the game was recorded."
223637413|NCT05493917|BIOLOGICAL|an inactivated SARS-CoV-2 vaccine named BBIBP-CorV|Completed 2 doses of an inactivated SARS-CoV-2 vaccine more than 6 months ago and received a third dose of the vaccine
223637414|NCT02703597|BEHAVIORAL|Surveys|Surveys include questions related to tobacco use behavior and attitude toward tobacco, as well as demographic and personality questions. Psychosocial surveys and social network surveys are also completed to capture adolescents' network of friends and opinion leaders.
223637415|NCT02703597|BEHAVIORAL|ASPIRE|Participants engage in four to five 70-minute sessions of ASPIRE spread over a period of 4 weeks. During ASPIRE use, participants face a screen and individually watch videos and engage in computer-based activities related to the negative effects of tobacco.
223637416|NCT02703597|BEHAVIORAL|GSA-ASPIRE-Network|In groups, participants engage in four to five 70-minute sessions of ASPIRE conducted over a period of 4 weeks. However, during each session, ASPIRE use is coupled with game-based social activities (GSAs). During ASPIRE use, participants watch videos and engage in computer-based activities on the same computer screen. Also, in groups, participants engage in the paper-based GSAs as a team and collaborate as they complete the activities. The GSAs contain games about the effects of tobacco. Groups are allocated based on adolescents' network of friendships.
223637417|NCT04970485|BEHAVIORAL|Talking Matters|Group-level, facilitator-led behavioral intervention for 14-19 year old Black and African American adolescents with an intergenerational component to reduce teen pregnancy, strengthen protective factors to improve optimal health, and increase access to trusted adults.
223637418|NCT01539421|BEHAVIORAL|Use of Home exercise computer program|After a 30-minute rest period the study patient performed a series of 4 representative exercises from the Wii under direct supervision by an investigator. Five minutes' rest was allotted between each exercise. The patient was instructed to exercise at his/her own pace, with a maximal duration of 5 minutes per exercise. The Oxycon Mobile was worn throughout this exercise, and the metabolic measurements listed above were recorded over the last 30 seconds of each exercise. The exercises included running in place, upper arm movements, stepping in place, and obstacle course.
223637419|NCT01351181|BEHAVIORAL|Leaflet|Advice Leaflet
223637420|NCT01351181|BEHAVIORAL|Exercise Advice|Leaflet
223637421|NCT01351181|BEHAVIORAL|Normal Care|Normal Care
223637422|NCT05329441|BEHAVIORAL|Trier Social Stress Test (TSST)|In this mechanistic study, all participants will undergo a modified version of the Trier Social Stress Test (TSST), which is a well-validated psychosocial stress paradigm, adapted for adolescents that involves no deception and is considered a very mild stressor. The TSST comprises of two stress tests: a 5-minute arithmetic task and a 5-minute speech task. Due to repeated testing of the TSST, participants will be randomized to one task at T1 and complete the second task at T2 (counterbalanced design). Every 5 minutes, participants will provide ratings of their mood using a visual analogue scale (1-10) of eight mood states (Afraid, Confused, Sad, Angry, Energetic, Tired, Happy, and Tense) that will be used as potential behavioral responses to social stress. Glutamate and inflammation outcomes will be examined acutely and from T1 and T2.
224225732|NCT05941091|BEHAVIORAL|Distribution of printed material|In the study, a general dietary guideline including fluid and salt restriction, which is a printed educational material for the control group, will be used. Thus, it is planned that the participants in the control group will have a guide resource that will enable them to be informed about nutrition. In this way, an educational practice based on the distribution of printed material will be carried out for the control group. Except for the material distribution practice, the routine care procedures the unit will be maintained in the same way, and no different a practice will be made.
224225733|NCT04813822|DRUG|Miconazole Nitrate 2% + Domiphen Bromide Low Dose|Dosage 1
224225734|NCT04813822|DRUG|Miconazole Nitrate 2% + Domiphen Bromide High Dose|Dosage 2
223637423|NCT02131259|DRUG|Afatinib dimaleate|20mg - 50mg
223637424|NCT05955716|DEVICE|Virtual reality glasses|Virtual reality glasses are a device suitable for every mobile phone. It is used to watch the 360 degree video selected from the Youtube program.
223637425|NCT02796170|DRUG|Dapagliflozin|5mg pill taken once daily
223637426|NCT02796170|DRUG|Placebo|5mg pill taken once daily- placebo of Dapagliflozin
223637427|NCT03823521|DRUG|Cardioplegia Solution|Cardioplexol™ will be adminstered in cardiac surgery as cardioplegic solution
223637428|NCT02029716|DRUG|RTA 408 Lotion 0.5%, 1%, 3%|
223637429|NCT02029716|DRUG|Lotion vehicle/placebo|
223637430|NCT01753232|DEVICE|DALI-adsorber|Recording of treatment data. No extra interventional treatment
223637431|NCT01753232|DEVICE|MONET-Lipoprotein filter|Only treatment data recording. No extra interventional treatment
223637432|NCT04240496|OTHER|Determination of plasma concentration of clozapine/ Genotyping|Determination of trough plasma concentration of clozapine (C0) Genotyping of CYP1A2 \& CYP2C19
223637433|NCT00089752|DEVICE|Continuous Positive Airway Pressure (CPAP) Treatment|CPAP device used at night
223637434|NCT00089752|DEVICE|Sham CPAP device - CPAP device with pressure delivered <1 cm H20|Sham CPAP device used at night
223637435|NCT06003972|DRUG|Copaxone|Paptients allocated to this arm receive 20 mg GA given s.c daily for a total of 14 days
223637436|NCT06003972|DRUG|guideline directed medical therapy (GDMT)|GDMT for heart failure according to the AHA guidelines.
223637437|NCT02933749|DEVICE|SctO2|The non invasive cerebral oxymetry (INVOS-Covidien) has been used to measure cerebral oxygen saturation.
224225735|NCT04813822|DRUG|Miconazole Nitrate 2%|Active Comparator
224225736|NCT04451265|OTHER|MRI|Diffusion sequence (8 minutes long) added to the initial MRI
223637438|NCT02933749|DEVICE|BIS|Bispectral index
223637439|NCT00424710|DRUG|ranibizumab intravitreal injection|liquid, 0.5 mg ranibizumab intravitreally, once a month for 1 year
223637440|NCT05266989|OTHER|Transcranial Direct Current Stimulation|Non-invasive technique that modulates the excitability of the cortex by applying low-intensity current
223637441|NCT02992795|DEVICE|BrainPulse|JanMedical's BrainPulse measures the brain motion caused by pulsatile blood flow from the cardiac cycle referred to as the BrainPulse signal. The BrainPulse measures skull acceleration in response to tge brain motion using an array of sensors placed on the head.
223637442|NCT02972437|OTHER|sample taking|throat culture and oral cavity sample
223637443|NCT01403532|DRUG|Traditional intervention for HH using HCG and FSH|Human chorionic gonadotropin(HCG),2000U,im,2 times/week, one year and a half; Follicle stimulating hormone(FSH),75U, im, 3 times/week, one year;
223637444|NCT01403532|DRUG|Sequential intervention for HH using HCG and FSH|Human chorionic gonadotropin,2000U,im, 2 times/week, one and half a year Follicle stimulating hormone,75U,im,3 times/week, every other three months
223637445|NCT01403532|DRUG|Sequential intervention for HH using HCG and FSH plus zinc|Human chorionic gonadotropin,2000U,im,2 times/week, one year and a half Follicle stimulating hormone,75U, im, 3 times/week, every other three months Zinc gluconate 20mg,P.O, twice daily
223637446|NCT03818321|DRUG|Methenamine Hippurate 1 g tablet|Methenamine Hippurate (study drug) is an FDA approved medication in the prevention of UTI. Methenamine Hippurate 1g contains Hippuric acid salt of Methenamine (hexamethylene tetramine), Magnesium Stearate, Povidone, Saccharin Sodium, FD\&C Yellow No. 5 (tartrazine) (www.iodine.com/drug/hiprex/fda-package-insert).
223637447|NCT03818321|DRUG|Placebo tablet|Placebo is a tablet that will be provided to you that looks like the study drug but does not contain any medication. These pills are comprised of gelatin and minimal amounts of lactose powder. The pills are designed to have no effect on the patient.
223637448|NCT01961037|OTHER|Tai Chi: Moving for Better Balance|Participants will attend one-hour Tai Chi classes twice weekly for 16 weeks.
223637449|NCT01525069|DRUG|Floxuridine|
223637450|NCT01525069|DRUG|Dexamethasone|
223637451|NCT01525069|DRUG|Gemcitabine|
223637452|NCT01525069|DRUG|Oxaliplatin|
224225737|NCT04177810|DRUG|Cemiplimab|Cemiplimab (350 mg) will be administered IV on day 1 of each cycle (21 day cycle) for up to 2 years.
224225738|NCT04177810|DRUG|Plerixafor|Plerixafor (80mcg/kg/hr) will be administered as a continuous IV infusion of the first 7 days of each cycle (21 day cycle) for up to 2 years.
224225739|NCT04756141|DEVICE|Continuous Glucose Monitor (CGM)|A CGM will be placed on patients with diabetes mellitus and COVID-19 infection and interstitial glucose will be monitored continuously while the patients are in the hospital.
223637453|NCT06403969|BEHAVIORAL|Applied Behavior Analysis|Applied Behavior Analysis focusing on nocturnal awakenings. It starts with identification of target behaviors and goals. A functional analysis is conducted to analyze the underlying function of a behavior in connection to the problem. A treatment plan is formulated, including strategies to achieve the goals, and methods to evaluate. Families receive education sleep hygiene. Adaptations focus on antecedents and consequences, with an emphasis on positive reinforcement of favorable behaviors. Various components of Cognitive Behavioral Therapy may be applicable. These include changes in sleep environment, stimulus control, bedtime routines with visual support and prompting. Sleep restriction and bedtime fading are included. Modified extinction techniques with parental presence can be applied, gradually phasing out parental immediate presence. The intervention continues until goals are achieved or for a maximum of 8 sessions (each lasting up to 60 minutes) spread over 8 weeks.
223637454|NCT01867671|BIOLOGICAL|Peanut Oral Immunotherapy - Liquid Extract|Used during initial dose escalation for doses 0.1 to 0.8 mg.
223637455|NCT01867671|BIOLOGICAL|Placebo for Peanut Oral Immunotherapy - Liquid Extract form|Similar in appearance, texture, and taste to peanut liquid extract.
223637456|NCT01867671|BIOLOGICAL|Peanut Oral Immunotherapy - Peanut Flour|This will be used for the remainder of dose escalation, build-up, and maintenance.
223637457|NCT01867671|BIOLOGICAL|Placebo for Peanut Oral Immunotherapy - Peanut Flour|Similar in appearance, texture, and taste to peanut flour.
223637458|NCT01523366|DRUG|Ticagrelor|Min - 90mg/Max - 180mg tablets (loading dose)
223637459|NCT01523366|DRUG|Clopidogrel|75mg (once daily)/Max - 600mg tablets (loading dose)
223637460|NCT03488017|DEVICE|Ocular Coil|Non-invasive ocular device
224225740|NCT04166981|PROCEDURE|Instrumented posterolateral spine fusion.|Posterolateral fusion with autologous and allogenic bone graft with supplementary pedicle screw fixation.
223637461|NCT01885130|OTHER|Cetaphil Daily Advance Ultra Hydrating Lotion|0.2ml or 0.2g of Cetaphil on occlusive, hypoallergenic patch applied to skin for 24 hrs 9 times on Monday, Wednesday, and Friday for 3 weeks
223637462|NCT02945488|OTHER|Exercise|Exercise intervention will entail 30 minutes of moderate intensity cardiovascular training 3 days/week and full body resistance training 2 days/week (supervised). Cardiovascular training will entail any weight-bearing activity that would achieve target heart rate, such as walking, jogging, stair climbing, dancing, etc. Resistance training will entail 2-3 sets of 8-12 repetitions of exercises targeting all major muscle groups with an external load applied, such as a dumbbell, barbell, medicine ball, etc.
224225741|NCT04166981|PROCEDURE|Non-instrumented posterolateral spine fusion.|Posterolateral fusion with autologous and allogenic bone graft.
224225742|NCT04221581|DEVICE|Knee prosthesis - FHK ASYMETRIQUE total knee prosthesis|FHK ASYMETRIQUE prosthesis are intended to be implanted in the tibial and femoral regions during total knee arthroplasty in order to restore joint function.
224225743|NCT03267030|DRUG|GRASPA|Administration of 1-7 doses of 150 IU/kg IV infusion. (every 2 weeks for a maximum of 4 doses and every 6 weeks for maximum 3 doses).
224225744|NCT01851590|DEVICE|Resin Lacquer|30% Resin Lacquer is applied once daily for 9 months (Abicin®) in toenail onychomycosis.
224225745|NCT01851590|DRUG|Amorolfine|5% Amorolfine Lacquer is applied once weekly for 9 months (Loceryl®) in toenail onychomycosis.
224225746|NCT01851590|DRUG|Terbinafine|250 mg of Terbinafine is taken orally once daily for 3 months (Generics) in toenail onychomycosis.
224225747|NCT00417313|DEVICE|periosteal electro-acupuncture (osteopuncture).|
224225748|NCT05571761|BEHAVIORAL|Cognitive stimulation program|"The cognitive stimulation program consists of 12 sessions of approximately 45 minutes, distributed in a first stage of training and psychoeducation (1 session), a second stage to address emotional aspects of anxiety and depression (2 sessions), and neuropsychological training (8 sessions) and a final closing stage with one session. There will be two sessions per week for 6 weeks.~The neuropsychological training includes 20 activities whose level of difficulty will vary according to the number of stimuli and the time of stimuli presentation. It includes 5 attentional activities, 3 memory activities, 5 executive functioning activities, one visuospatial skills activity and 6 ecological activities. These activities will be developed on a digital computer platform where patients will be assigned an identification and password to ensure confidentiality."
224225749|NCT00394745|DRUG|Valsartan|
224225750|NCT01714505|DEVICE|Diabetes Assistant (DiAs)|A medical platform that uses a smart-phone to connect to a continuous glucose sensor to insulin pump and run closed-loop control. The cell phone runs the Control to Range and is connected to work with the insulin pump and continuous glucose monitor to help keep the blood sugar in a desired range (80-180 mg/dL during the day) and help avoid hypoglycemia during the night.
224225751|NCT01513057|DRUG|Mycophenolate Mofetil|Mycophenolate Mofetil 250 mg capsules of Dr. Reddy's Laboratories Limited
224225752|NCT01513057|DRUG|Mycophenolate Mofetil|250 mg capsules of Roche Laboratories Inc.
224225753|NCT00359437|DRUG|Satavaptan|oral administration once daily
224225754|NCT00359437|DRUG|placebo|oral administration once daily
224225755|NCT03103009|DRUG|Pasireotide|Somatostatin analogues are a last resort for medical intervention in hyperinsulinemic hypoglycemia (HH). The hypoglycemia is very debilitating and can be even life threatening. There is limited experience with pasireotide in hyperinsulinemic hypoglycemia (only one publication); there is more experience with octreotide, both in adults and children and successful interventions with octreotide in hyperinsulinemic hypoglycemia have been published. Pasireotide via its different somatostatin receptor binding profile has clear effects on insulin, glucagon and incretin secretion and can ultimately lead to hyperglycemia. This mode of action (especially the effects on insulin and incretin secretion) could be very useful in the setting of hyperinsulinemic hypoglycemia.
224225756|NCT03128593|DRUG|JR-141|IV infusion (lyophilized powder), 0.01-2.0 mg/kg/week
224225757|NCT03229993|DIAGNOSTIC_TEST|OCT|OCT is used to assess whether PCI will be of benefit to the treatment of the borderline coronary artery lesions
224225758|NCT05618483|DEVICE|Nasal Spray|The nasal spray is made of xylitol and grapefruit seed extract. The spray is antiviral, but there is no data of its clinical efficacy against Covid-19.
224318935|NCT00627510|OTHER|Routine psychiatric inpatient treatment|Routine psychiatric inpatient treatment. This is not an interventional study.
224318936|NCT00444379|DRUG|Lopinavir/ritonavir plus Emtricitabine/Tenofovir versus Efavirenz plus Emtricitabine/Tenofovir|Lopinavir/ritonavir 200/50mg plus Emtricitabine/Tenofovir 200/300mg versus Efavirenz 600mg plus Emtricitabine/Tenofovir 200/300mg
223637463|NCT02945488|OTHER|Dietary plan|Mediterranean dietary plan, which contains foods, such as fish, vegetables, nuts, and oils, which are anti-inflammatory in nature.
223637464|NCT02945488|OTHER|Stretching|Stretching intervention will entail 30 minutes of flexibility training 3 days/week of stretches targeting all major muscle groups held for 20-30 seconds.
223637465|NCT05324852|DRUG|Intranasal midazolam|Midazolam, 5 mg, injectable solution in 5mg/ml, intranasal administration, atomize into nose with Mucosal Atomizer Device (MAD) 5mg(1ml) up each nostril , one time
223637466|NCT05324852|DRUG|Intramuscular loxapine|Loxapine, 100mg, injectable solution in 50mg/2ml intramuscular, intra muscular administration, one time
223637467|NCT03941288|DRUG|Cannabidiol|"Cannabidiol and the matching placebo solution (excipients alone) will be provided in identical 100ml amber glass bottles. At the end of the treatment period, the treatment solutions will be tapered (10% volume each day) over 10 days.~In accordance with Food and Drug Administration guidance, prior to starting treatment and at end of 1 month treatment, we shall obtain serum transaminases (alanine and aspartate) and total bilirubin levels. These tests will also be performed if patient develops clinical signs or symptoms suggestive of hepatic dysfunction (e.g., unexplained nausea, vomiting, right upper quadrant abdominal pain, fatigue, anorexia, or jaundice and/or dark urine); if such features develop the treatment will be interrupted or discontinued."
223764993|NCT04352140|DEVICE|ToFscan|ToFscan is a nerve stimulator module used for the measurement of neuromuscular transmission via accelerometry. ToFscan was developed by Drager Technologies, Canada, and it uses a three-dimensional piezoelectric sensor that attaches to the thumb via a hand adapter to measure acceleration in multiple planes (Murphy et al, 2018). Following simultaneous ulnar nerve stimulation on each arm, the response of the adductor pollicis will be measured
223764994|NCT02121340|BEHAVIORAL|Behavioral Activation|
224318937|NCT02766283|DRUG|iodinated contrast agents|Intravascular application
223637468|NCT03941288|OTHER|placebo|"Cannabidiol and the matching placebo solution (excipients alone) will be provided in identical 100ml amber glass bottles. At the end of the treatment period, the treatment solutions will be tapered (10% volume each day) over 10 days.~In accordance with Food and Drug Administration guidance, prior to starting treatment and at end of 1 month treatment, we shall obtain serum transaminases (alanine and aspartate) and total bilirubin levels. These tests will also be performed if patient develops clinical signs or symptoms suggestive of hepatic dysfunction (e.g., unexplained nausea, vomiting, right upper quadrant abdominal pain, fatigue, anorexia, or jaundice and/or dark urine); if such features develop the treatment will be interrupted or discontinued."
223637469|NCT00399906|DRUG|BMS-582949|Tablets, Oral, Once daily, 12 weeks
223637470|NCT00399906|DRUG|Placebo|Tablets, Oral, Once daily, 12 weeks
223637471|NCT06295484|OTHER|Alternating traditional CPAP, NIPPV, and high CPAP|The investigators will continue to record the Edi signals during the 3 methods (traditional CPAP, NIPPV, and high CPAP)
223637472|NCT06521307|DIETARY_SUPPLEMENT|Nicotinamide riboside|"We will recruit the participant 24 hrs prior intervention, once the participant decides to enroll, we will administer by oral intake the supplement or placebo due to the result at randomizer.org.~The first NAD Riboside arm will be administered by oral intake with 2000 mg at enrollment, then we will administer 3000mg prior undergoing surgery with NG tube, 3000mg 12 hrs post-surgery with NG tube and 2000mg by oral intake 24 hrs after intervention. All the administrations with NG tube will be flushed with 0.9% saline solution."
223637473|NCT06521307|OTHER|Placebo|"We will recruit the participant 24 hrs prior intervention, once the participant decides to enroll, we will administer by oral intake the supplement or placebo due to the result at randomizer.org.~The first dose of placebo arm will be administered by oral intake with 2000 mg at enrollment, then we will administer 3000mg prior undergoing surgery with NG tube, 3000mg 12 hrs post-surgery with NG tube and 2000mg by oral intake 24 hrs after intervention. All the administrations with NG tube will be flushed with 0.9% saline solution."
223637474|NCT04298242|DEVICE|ExAblate 2100|A non-invasive thermal ablation device fully integrated with an MR imaging system
223637475|NCT04543279|DRUG|Fostamatinib|Fostamatinib will be supplied by Rigel Pharmaceuticals.
223637476|NCT04543279|DRUG|Ruxolitinib|Ruxolitinib is commercially available.
223637477|NCT01067053|DRUG|bevacizumab, capecitabine, oxaliplatin|"6 cycles (3 weeks each one) of:~* bevacizumab: 7,5 mg/kg (iv), 1st day of each cycle.~* capecitabine: 1000 mg/m2 bid, oral. Days: 1-14 every three weeks.~* oxaliplatin: 130/mg/m2(iv),1st day of each cycle.~After the first 6 cycles of treatment, continuing only with bevacizumab and capecitabine"
223637478|NCT06243536|DRUG|Semaglutide|Semaglutide will be administered through 12 weeks.
223637479|NCT06243536|DRUG|standard of care|Patients not assigned to receive semaglutide will receive standard of care.
223637480|NCT00393159|DEVICE|Ear Popper|
223637481|NCT01850667|RADIATION|Stereotactic body radiotherapy|"Total stereotactic Body radiotherapy (SBRT) doses will be 60 Gy in 3 fractionations. Patients receive 3 fractionations separated by \>48 hours.~At least 700 ml of normal liver (entire liver minus cumulative GTV) should not receive a total dose of \> 17 Gy in three fractions. If volume of normal liver does not exceed 700 ml, at least 70% of normal liver should not receive a total dose of \> 17 Gy. In patients without gastroduodenal ulcer on Esophagogastroduodenoscopy (EGD) before SBRT, D2ml of gastrointestinal tract should not exceed 35 Gy. In patients with gastroduodenal ulcer on EGD before SBRT, D2ml of gastrointestinal tract should exceed 28 Gy. (D2ml: minimum dose to 2 ml of gastrointestinal tract)"
223637482|NCT03184688|PROCEDURE|platelet rich plasma|Ultrasound-guided PRP injection between proximal carpal tunnel and median nerve.
223637483|NCT03184688|DRUG|Normal saline|Ultrasound-guided normal saline injection between proximal carpal tunnel and median nerve.
223637484|NCT04570007|PROCEDURE|Pars Plana Vitrectomy|removal of vitreous with vitreous cutter
223637485|NCT03354195|PROCEDURE|Unicompartmental knee arthroplasty with the Mako Robotic Arm-assisted system.|All patients will receive the RESTORIS MCK (Multicompartmental Knee) Implant System, which is approved for use in unicompartmental knee arthroplasty with the Mako Robotic Arm-assisted system. The femoral component is constructed from cobalt chrome (CoCr) and the tibial component is constructed from an ultra-high molecular weight polyethylene (UHMWPE) insert and titanium (Ti) baseplate. UKA will be facilitated with MAKO Robotic-Arm Assisted Surgery, which has been shown in prior studies to lower pain and result in more accurate implant placement than manual UKA in a randomized controlled trial.(15)
223637486|NCT06324162|DEVICE|bracket removal pliers, LODI|Brackets on the right side of both dental arches were debonded using the lift-off debonding instrument (LODI), while on the left side, the bracket removal pliers (BRP). The residual adhesive was removed through two methods (manual in the upper arch and rotary in the lower). The same scale was employed to assess pain levels during brackets and adhesive removal.
223637487|NCT05119881|BEHAVIORAL|mirror therapy|a mirror box will be placed in front of the participants with the mirror reflection side toward the non-paretic limb. The paretic arm will be placed behind the mirror, and the mirror box will block the vision of the paretic limb. Through this method, the patients can only view the movement of the non-paretic limb and its mirror reflection from the mirror. The participants will be instructed to move or perform functional tasks with their non-paretic limb and look at the mirror reflection of the non-paretic limb and mentally imagine that it is the paretic arm moving. At the same time, the participants will be encouraged to move the paretic arm along with the mirror reflection of the non-paretic arm. Activities practice during MT will include gross motor movements, fine motor movements, and functional tasks.
223637488|NCT05119881|DEVICE|tDCS|The tDCS will be delivered by a DC-stimulator (Soterix Medical Inc, New York, USA) through 2 saline-soaked surface sponge electrodes (anodal electrode size: 25 cm2; cathode electrode size: 25 cm2). The anodal electrode will be placed over the ipsilesional M1 while the cathodal electrode will be placed over the contralesional M1. The stimulation intensity will be ramped up to 2mA in 15 seconds, and maintained at 2mA throughout the 20-minute stimulation for the MT+tDCS group.
223637489|NCT05119881|BEHAVIORAL|sham mirror therapy|For the sham MT (s-MT) condition, the same mirror box will be used except that the mirror side will be made blurred to view; thus, the participants will not be able to view the mirror reflection of the paretic limb. The participants will perform the same activities as the real MT condition.
223637490|NCT05119881|DEVICE|sham tDCS|For the sham tDCS group, the electrodes will be placed on the brain regions as the real tDCS group. The intensity will first be ramped up to 2mA within 15 seconds and then the stimulator will be turned off gradually within the next 30 seconds.
223637491|NCT00425802|BIOLOGICAL|anti-thymocyte globulin|
223637492|NCT00425802|BIOLOGICAL|filgrastim|
223637493|NCT00425802|BIOLOGICAL|graft-versus-tumor induction therapy|
223637494|NCT00425802|BIOLOGICAL|rituximab|
223637495|NCT00425802|DRUG|cyclophosphamide|
223637496|NCT00425802|DRUG|cyclosporine|
223637497|NCT00425802|DRUG|fludarabine phosphate|
223637498|NCT00425802|DRUG|mycophenolate mofetil|
223637499|NCT00425802|PROCEDURE|nonmyeloablative allogeneic hematopoietic stem cell transplantation|
223637500|NCT00425802|RADIATION|total-body irradiation|
223637501|NCT03430284|BEHAVIORAL|Lifestyle therapy|The key components of lifestyle therapy include medical nutrition therapy, regular physical activity, sufficient amounts of sleep, behavioral support, and smoking cessation and avoidance of all tobacco products.
223637502|NCT03430284|DRUG|Pharmacotherapy|"Pharmacological therapy is individualized. 1.Glucose-lowering agents:~1. Oral antihyperglycemic agents:Biguanides;Sulfonylureas;Thiazolidinediones;Glinides;a-Glucosidase inhibitors;DPP-4 inhibitors;Sodium-glucose cotransporter 2 inhibitors~2. GLP-1 receptor agonist~3. Insulin:Rapid-acting analogs;Short-acting analogs;Intermediate-acting analogs;Basal insulin analogs;Premixed insulin products~2.Blood pressure-lowering agents~(1)ACE inhibitor;(2)Angiotensin receptor blockers (ARBs);(3)Calcium channel blockers (CCB);(4)Diuretics;(5)β-blockers;(6)α1-blockers~3.Lipid-modifying agents~(1)Statins;(2)Fibrates;(3)Others: Nicotinic Acid, Ezetimibe,Probucol,Bile Acid Sequestrants,Policosanol,etc.~4.Medications for weight management~(1)Glucose-lowering agents associated with weight loss;(2)Orlistat;(3)Metabolic Surgery~The above medications are individualized to maintain the risk factors (blood glucose, serum lipid profiles, blood pressure and weight) at appropriate levels."
223637503|NCT03430284|OTHER|Monitoring and management|Before follow-up, patients are divided into low, moderate or high risk for diabetic vascular complications. During follow-up, frequencies of interview and risk factor monitoring are formulated based on the risk stratification.
223637504|NCT03430284|OTHER|General treatment|General treatment is carried out based on the device from the general practitioners at present.
224225759|NCT02047942|BEHAVIORAL|Center-based cardiac rehabilitation|
223637505|NCT01526863|DIETARY_SUPPLEMENT|HA egg|Daily dose of HA egg or placebo for 6 months
223637506|NCT00002337|DRUG|Vesnarinone|
223637507|NCT05393440|BIOLOGICAL|BS-006|BS-006 is an engineered recombinant type II herpes simplex virus (HSV2) designed and produced by Wuhan Binhui Biopharmaceutical Co., Ltd. It was derived from HSV2 strain HG52. ICP34.5 and ICP47 genes were deleted to ensure abortive infection and immune destruction in normal cells. Bispecific T cell engager of anti-CD3 antibody and anti-PD-L1 antibody were constructed and inserted into HG52 strain genome.
224225760|NCT02047942|BEHAVIORAL|Home-based training with telemonitoring guidance|
224225761|NCT01735045|DEVICE|Lagado LSH (mangofilcon A) Soft (hydrophilic) Contact Lens|Daily Wear
224225762|NCT01735045|DEVICE|Benz 3GX (hioxifilcon B) Soft (hydrophilic) Contact Lens|
224318938|NCT03917927|DEVICE|Eztetic dental implant|narrow diameter dental implant
223637508|NCT01615484|PROCEDURE|Transplantation of lungs obtained from Non-Heart-Beating Donors (NHBDs) after ex-vivo perfusion w/ STEEN Solution™|After EVLP, lungs will be cooled in the circuit to room temperature, then flushed with cold Perfadex™, and taken to UNCH where they will have an ex-vivo CT scan. Lungs determined suitable will be offered to consented patients at UNC Hospitals and Duke University Medical Center based on Lung Allocation Score. Lungs not considered for transplantation may be subjected to different experiments but are not to be a part of this research study. In summary, lungs with good and stable function during EVLP will be transplanted into recipients as per current clinical practice.
223637509|NCT01615484|DEVICE|STEEN Solution™|This solution is a buffered dextran and albumin-containing extracellular perfusate with an optimal colloid osmotic pressure developed specifically for extra-corporeal perfusion of lungs.
223637510|NCT05722392|PROCEDURE|Two-step Radical Prostatectomy|The first step is enucleation of the hyperplastic adenoma, and the second step is anterograde RP to residual gland
223637511|NCT04356898|OTHER|No intervention|No intervention
223637512|NCT04565132|DEVICE|High Definition transcranial Direct Current Stimulation|1x1 tDCS low-intensity stimulator and 4x1 multichannel stimulation adaptor (Soterix Medical Inc, New York, NY)
223637513|NCT02886455|OTHER|Standard adhesive strip|This is a standard adhesive strip (hydrocolloid)
223637514|NCT02886455|OTHER|New adhesive strip|This a newly developed adhesive strip.
223637515|NCT03131323|PROCEDURE|• Flexible fiberopticnasopharyngoscope|".~II- Equipments:~* Flexible fiberopticnasopharyngoscope, 2.7 mm in diameter and fiberoptic light cable.~* The camera: fitted with Three-CCD (Charged Couple Device) sensors.~* A high resolution monitor.~* A recording unit. III- Positioning:Infants and small children have to be held by a parent or an adult. Older children and adolescents usually tolerate office flexible nasopharyngoscopy once the procedure is explained. If office flexible nasopharyngoscopy failed because the child is not cooperative or if there is excessive secretions, general anesthesia may be required \[8\].~IV- Technique: Lubricant gel will be applied to the tip of the endoscope which will be now will be passed along the floor of the nose, between the inferior turbinate and the nasal septum, till it reaches the nasopharynx. Now the entire nose and the nasopharynx could be thoroughly examined and any abnormal findings could be detected and documented."
223637516|NCT01671696|OTHER|Cardiac MRI|Cardiac MRI
223637517|NCT02386397|DRUG|Regorafenib|Regorafenib: X mg/d, PO, from day 1 to day 14; day 15 to day 20: off-treatment
223637518|NCT02386397|DRUG|GEMOX|mGEMOX: infusion on days 1 and 8: Gemcitabine 900 mg/m² IV in 30 minutes Oxaliplatin 80 mg/m² IV in 120 minutes immediately after Gemcitabine
224225763|NCT02611752|DRUG|CAM2038|CAM2038 subcutaneous injection
224225764|NCT04300777|DEVICE|SeaSpine Non-Cervical Pedicle Screw Systems|Any patient treated with a SeaSpine Non-Cervical Pedicle Screw System
224225765|NCT00310856|BIOLOGICAL|MenACWY-CRM|Subjects received the full dose (0.5 mL) of MenACWY-CRM, obtained by extemporaneous mixing of lyophilized MenA powder component and the MenCWY suspension, administered by IM injection into the anterolateral area of the right thigh.
224225766|NCT00310856|BIOLOGICAL|MenC-CRM|One dose (0.5 mL) of MenC-CRM was obtained by extemporaneous mixing just before injection of the lyophilized MenC component and a saline solvent, administered by IM injection into the arm region.
224225767|NCT00310856|BIOLOGICAL|DTaP-Hib-IPV|
223637519|NCT06522620|PROCEDURE|Posterior Femoral Cutaneous Nerve Combined With Proximal Sciatic and Saphenous Nerve Block|All nerve blocks were performed under ultrasound guidance，single supragluteal approach sciatic nerve block using a nerve stimulator, 20 ml of drug was injected around the sciatic nerve, the extent of drug diffusion was observed, the needle tip was turned into the deep surface of the gluteus maximus muscle below the deep gluteal artery and 5 ml of drug was injected, followed by a retractile canal saphenous nerve block injected with 15 ml of drug, and the difference in sensation of the posterior thighs of the bilateral thighs was measured after 15 min to ensure posterior femoral cutaneous nerve were blocked
223637520|NCT06522620|PROCEDURE|Simple Sciatic and Saphenous Nerve Blocks|All nerve blocks were performed under ultrasound guidance，single subgluteal approach sciatic nerve block using a nerve stimulator, with 25 ml of drug injected around the sciatic nerve, followed by a retractile canal saphenous nerve block with 15 ml of drug injection
223637521|NCT04909450|BIOLOGICAL|CSB-001 Ophthalmic Solution 0.1%|CSB-001: human recombinant dHGF (5-amino acid deleted hepatocyte growth factor)
223637522|NCT04909450|BIOLOGICAL|Vehicle Control|Matching vehicle control without the drug substance
223637523|NCT05249582|OTHER|Virtual Reality|Virtual reality wireless headset
223637524|NCT05249582|OTHER|Television Condition|Individuals will mimic hand movements of a pre-recorded video of an individual playing the virtual reality climbing game
223637525|NCT03675126|DRUG|SRP-5051|SRP-5051 administered as an IV infusion.
223637526|NCT03772249|DRUG|DCR-HBVS|DCR-HBVS is a synthetic ribonucleic acid interference (RNAi) drug that consists of a double-stranded oligonucleotide conjugated to N-acetyl-D-galactosamine (GalNAc) ligands. DCR-HBVS is a sterile solution of the siRNA (DCR-S219) at a concentration of 195 mg/mL in water for injection (WFI).
223637527|NCT03772249|DRUG|Placebo for DCR-HBVS|Sterile 9% saline for injection.
223637528|NCT05609591|DIETARY_SUPPLEMENT|Liquid diet group|Fluid diet including juice, rice soup, filtered vegetable juice/broth, lotus root powder and milk and egg soup were given to children for bowel preparation.
223637529|NCT05609591|DIETARY_SUPPLEMENT|Enteral nutrition group|100% short peptide enteral nutrition are given to children for bowel preparation
223637530|NCT05609591|DIETARY_SUPPLEMENT|Low residual diet group|Low residua diet included gruel with grain only, peeled carrot, white gourd, powdered skin, tofu, vegetable, mud and fruit. were given to children for bowel preparation
223637531|NCT06511258|BEHAVIORAL|Prehabilitation|The intervention includes 3 aspects (exercise, nutrition and breathing). Our intervention is a home-based multimodal prehabilitation program supported through an online platform.
223637532|NCT00001959|DRUG|Pirfenidone|During the study drug period of 12 months, patients will receive oral pirfenidone daily. For patients whose initial renal function is 50-80 ml/min as assessed by the MDRD equation, the initial pirfenidone dosage will be calculated at 40 mg/kg/d, with a maximum dose of 800 mg TID. For patients whose initial renal function is 30-50 ml/min, the initial dose will be 30 mg/kg/d. For patients whose initial renal function is between 15 and 30 ml/min, the initial dose will be 20 mg/kg/d.
223637533|NCT06153589|OTHER|Musicotherapy|"Musicotherapy will be offered to patients who meet the eligibility criteria, and have been randomized to the experimental arm.~Patients will only be seen once during the study. Patients are placed in individual rooms. Hifi audio headphones (equipped with hygienic earcups) and a tablet equipped with the Music Care application will be offered to patients in the experimental group and the investigators will help them choose the style of music, which respects the U-shaped sequence.~The Music Care application has proven that the use of headphones allows the patient to be isolated and therefore to obtain less parasitic care. He will be told at the start of the session that he can ask to interrupt it if he wishes to communicate with the team, particularly regarding possible pain.~The musicotherapy session begins before the act of debridement (10 minutes before), lasts during the act (40 minutes maximum), and continues for 10 minutes after the end of the debridement."
224225768|NCT00310856|BIOLOGICAL|PC7|One dose (0.5 mL) of PC7, supplied in pre-filled syringe, administered by IM injection into the anterolateral area of the left thigh.
224225769|NCT00310856|BIOLOGICAL|MMR|
224318939|NCT04670276|PROCEDURE|injection of emulsified adipose tissue stromal vascular fraction|Endoscopic injection of 10 cc of autologous microfat into the fistula (through a 6-French catheter), until it was completely filled, and a total of 1-2 cc of tSVFem (through a 22G endoscopic needle) into the submucosa of the 4 quadrants of the fistula borders, to obliterate it completely.
224318940|NCT01531543|DEVICE|V.A.C.- Vacuum assisted closure laparostomy (KCI)|Primary Vacuum Assisted Closure (V.A.C.)laparostomy was indicated after surgery in patients with severe peritonitis. VAC laparostomy was performed using sandwich technique (semi-permeable foil - intraabdominal foam - dynamic sutura of the fascia - foam inserted subcutaneously - non-permeable foil) and connected to the active suction of 125mmHg.
224318941|NCT00886405|DRUG|Transdermal nitroglycerin|Transdermal nitroglycerin (25mg/day) during 5 days (2 days before and 3 days after chemotherapy) at the beginning of each chemotherapy cycle for a total of 4 cycles
224318942|NCT01666392|DIETARY_SUPPLEMENT|Omega-3 fatty acid|Omega-3 fatty acid, Eicosapentaenoic acid+docosahexaenoic acid in capsule form
223637534|NCT04757766|DRUG|in daily everyday routine practice|The treatment of patients with chronic venous disease of CEAP classes C6 will be consistent with routine clinical practice, local label for the medical use of drugs and the specific clinical situation.
223637535|NCT05176899|DEVICE|Use of Eko CORE electronic stethoscope|Recording of heart sounds using electronic stethoscope
223637536|NCT04651192|OTHER|Combat Exposure|Soldiers will be exposed to combat as part of their routine military service. The ROTC students will not be exposed to combat.
223637537|NCT06016504|BEHAVIORAL|Health Education|Participate in an adaptive virtual consultation
223637538|NCT06016504|BEHAVIORAL|Health Education|Participate in a non-adaptive virtual consultation
224225770|NCT00310856|BIOLOGICAL|Varicella|
224318943|NCT01666392|DIETARY_SUPPLEMENT|Placebo|Placebo
224318944|NCT05780476|BEHAVIORAL|Psychoeducation|6 sessions of 2 hours over 6 weeks
224225771|NCT02984839|DEVICE|Stimpod NMS450® Nerve Stimulator, by Xavant™ Technology|Quantitative train-of-four (TOF) ratio will be recorded in the post anesthesia care unit (PACU) via Stimpod NMS450
224225772|NCT00443352|DRUG|duloxetine|Duloxetine: 120 mg. daily or maximum tolerated dose (minimum: 60 mg per day)
223637539|NCT06016504|OTHER|Informational Intervention|Given information-only
223637540|NCT06016504|OTHER|Survey Administration|Ancillary studies
223637541|NCT03286036|OTHER|biomarkers|This is an observational study, there is no intervention
223637542|NCT03450161|DRUG|Fentanyl dosing schemes|We routinely use fentanyl as the opioid of choice in CABG surgery. However, how much and whether or not to apply it in boli or continuously remain uncertain. We will apply 3 routinely used fentanyl dosing schemes in our hospital. To blind care-givers and patients, in each of the arms a bolus and a continous injection will occur, as delineated in the treatment arms.
223637549|NCT03366610|OTHER|Non-interventional|Non-interventional
223637550|NCT05455021|COMBINATION_PRODUCT|Vessel Restoration System (VRS)|"The VRS includes the following components:~* VRS 10-8-10 Dimer Coated Balloon Catheter~* VRS Light Fiber~* VRS Light Source The VRS will collectively refer to all the components used to perform the procedure. Their specific product name will identify individual elements."
223637551|NCT04189952|DRUG|Acalabrutinib|Acalabrutinib 100 mg capsules taken by mouth every 12 hours (PO BID), for a total of 2 daily doses on Days 1 to 21 of each cycle.
224225773|NCT02657993|BEHAVIORAL|Hypnosis|"The hypnosis intervention involves three parts. First, participants will receive three, face-to-face hypnosis sessions delivered by doctoral-level psychology professionals. The sessions are based on materials developed by experienced psychologists in the Integrative Behavioral Medicine Program at the Icahn School of Medicine at Mount Sinai. Second, participants will be taught how to use hypnosis themselves (self-hypnosis) to help manage their pain. Third, participants will receive a hypnosis recording to listen to in-between sessions and throughout the course of the study. At home hypnosis practice will be recommended.~Participants will be asked to complete questionnaires over a period of 12 months."
223637552|NCT04189952|DRUG|Rituximab|Rituximab 375 mg/m2 administered intravenously (IV) on Day 1 of each cycle.
223637553|NCT04189952|DRUG|Ifosfamide|Ifosfamide 5g/m2 administered intravenously (IV) over 24 hours on Day 2 of each cycle.
223637554|NCT04189952|DRUG|Carboplatin|Carboplatin Area Under the Concentration time Curve (AUC) 5 IV administered intravenously (IV) on Day 2 of each cycle.
223637555|NCT04189952|DRUG|Etoposide|Etoposide 100 mg/m2 administered intravenously (IV) on Days 1, 2 and 3 of each cycle.
223637556|NCT06537700|DRUG|OnabotulinumtoxinA OBT-A|Patients will be re-evaluated every 3 months, at each OBT-A cycle, during the whole year of treatment. Every evaluation patients will show their diary of headaches with monthly migraine and headache days and acute medications taken.
223637557|NCT04762095|OTHER|mindfulness stress reduction program|mindfulness stress reduction program
223637558|NCT02884869|DEVICE|Intubating Laryngeal Mask|Direct laryngoscopy
223637559|NCT06666413|DRUG|Avalglucosidase alfa|Pharmaceutical form: Sterile lyophilized powder Route of administration: IV infusion
223637560|NCT03737929|PROCEDURE|Hybrid ablation|In the hybrid ablation arm, the epicardial surgical ablation procedure will be combined with percutaneous endocardial catheter ablation procedure in a single step procedure (same operative time). During the endocardial approach, the isolation of the pulmonary veins and the posterior box will be checked and completed if necessary. Then additional ablation will be performed for atrial tachycardia or ongoing persisting atrial fibrillation (AF) according the same lesions setup or stepwise protocol than the conventional arm
223637561|NCT03737929|PROCEDURE|Percutaneous catheter ablation|In the percutaneous catheter ablation arm, the procedure will be performed according to the current guidelines (pulmonary vein isolation, linear ablation and fragmented potentials ablation if needed, with the achievement of sinus rhythm during the procedure being the optimal endpoint. Any atrial tachycardia will be mapped and ablated as well (DC shock performed otherwise).
223637562|NCT04091555|DIETARY_SUPPLEMENT|HLNatural Tension|Understand the impact of the supplement on Tension Headaches
223637563|NCT01052493|DRUG|PP 1420|Single dose of PP 1420, administered subcutaneously at either 2mg, 4mg or 8mg.
223637564|NCT01052493|DRUG|Placebo|0.9% saline
224318945|NCT05780476|BEHAVIORAL|Psychoeducation + virtual reality|6 sessions of 2 hours over 6 weeks. Virtual reality experience will be carry out in the last 30 minutes of each meeting. Virtual reality consists of 360-degree videos depicting everyday situations and allowing the caregivers to feel the specific symptoms of dementia (e.g., disorientation, agnosia, apraxia and memory loss).
223637565|NCT02524925|PROCEDURE|fast track protocol|Evaluation of postoperative stress
223637566|NCT03931941|DRUG|RBX2660|RBX2660 is a microbiota suspension administered as an enema
223637567|NCT00915746|DRUG|JNJ-31001074; ketoconazole|
223637568|NCT02894346|OTHER|Teachers|Teachers are exposed to the WTMST survey that based on the theory of Self-Determination (SDT) will categorize them according to the elements of the SDT: Intrinsic, identified, introjected, external and a motivation.
223637569|NCT00802308|DRUG|Morphine sulphate|Extended release tablet combined with alcohol or water
223637570|NCT05516446|DEVICE|DEB for de Novo Lesions|The surface of the SeQuent® Please NEO balloon is coated with Paclitaxel at a concentration of 3 μg Paclitaxel per mm² of balloon surface. The matrix composed of Paclitaxel and Iopromide (Paccocath technology) allows homogeneous release of the active ingredient through the vessel surface.
223637571|NCT05516446|DEVICE|DES for de Novo Lesions|The latest generation DES : everolimus-eluting platinum-chromium alloy coronary stent system (Promus Premier, Promus Elite)
223637572|NCT00125255|DRUG|S-Caine™ Peel (lidocaine and tetracaine cream 7%/7%)|S-Caine Peel comprising of a 1:1 eutectic mixture of 7% lidocaine and 7% tetracaine was applied topically. The study drug was applied at approximately 1 mm in thickness and remained on the treatment area for 30 minutes
223637573|NCT00125255|DRUG|Placebo Peel|Placebo Peel applied topically at approximately 1 mm in thickness and remained on the treatment area for 30 minutes
223637574|NCT02811068|OTHER|venepuncture|single venepuncture
223637575|NCT06474338|DIAGNOSTIC_TEST|detection by artificial intelligence|The bladder lesion(s) are detected by artificial intelligence algorithm.
223637576|NCT06474338|DIAGNOSTIC_TEST|detection by urologists|The bladder lesion(s) are detected by urologists.
223637577|NCT00283296|DEVICE|Endeavor|Collapsible, forward folding manual wheelchair
223637578|NCT03278275|DRUG|One injection of 68Ga-NOTA-AE105|One injection of 68Ga-NORA-AE105
223637579|NCT03278275|DEVICE|PET/CT|Following injection of 68Ga-NOTA-AE105 the participants will be subjected to whole body PET/CT
223637580|NCT02512705|DEVICE|Pinel Restraints|
224225774|NCT02657993|BEHAVIORAL|Attention Control|"The attention control intervention involves three face-to-face meetings with a doctoral-level psychology professional. During these sessions, participants will be asked to discuss with the interventionist their experience of taking aromatase inhibitors and associated musculoskeletal pain. The interventionist will not lead the patient in imagery, relaxation, evaluation of thought processes, or even simple discussion. Rather interventionists will allow the patient to direct the flow of the conversation and will provide support and empathy. Interventionist contact time in AC sessions will be identical to that in the hypnosis group. Overall, the attention control intervention will control for professional attention.~Participants will be asked to complete questionnaires over a period of 12 months."
224318946|NCT01270191|DRUG|Exenatide|They will be treated with 5 mcg bid for 4 weeks and then 10 mcg bid for 12 weeks. They also visit every 2 weeks in the first 2 visits and then every month until 4 months.
223637581|NCT02512705|BEHAVIORAL|Seclusion Room|
223637582|NCT04084236|DEVICE|electrical stimulation|electrical stimulation
223637583|NCT04084236|DEVICE|Sham|no stimulation
223637584|NCT06515197|OTHER|Motivational Music|Participants in this group will listen to pre-selected motivational music tracks for 30 minutes before each basketball training and performance test. This intervention will be conducted three times a week for 12 weeks. The aim is to assess the impact of motivational music on mental energy, mental toughness, psychological skills, mindfulness, athletic identity, and sports performance.
223637585|NCT06515197|OTHER|Self-Selected Music|Participants in this group will choose their own music to listen to for 30 minutes before each basketball training and performance test. This intervention will be conducted three times a week for 12 weeks. The goal is to determine the effect of self-selected music on mental energy, mental toughness, psychological skills, mindfulness, athletic identity, and sports performance.
223637586|NCT02167698|DEVICE|Airway Pressure Release Ventilation (APRV)|This is a newer mode of ventilation that has been hypothesized to be equivalent or even superior to the conventional low-tidal volume mode of ventilation
224225775|NCT02861352|OTHER|Diet zinc|4 mg zinc, as zinc sulfate, was added to a controlled diet; 25 mg supplemental zinc was given during the final recovery period when an ad lib diet was consumed
224225776|NCT00036413|DRUG|TCH346|
224225777|NCT03291977|DRUG|Fluorescéine Sodique Faure|Fluorescéine Sodique Faure given intravenously during the induction of the anesthesia, at the dose of 3mg/kg, diluted in 50mL of physiological serum, in 10 minutes.
224225778|NCT03291977|PROCEDURE|White-light surgery|The surgery will be performed under classical conditions
223637587|NCT02167698|OTHER|Low-tidal volume ventilation|This mode of ventilation is the standard of care worldwide for ventilating children with ARDS.
223637588|NCT02167698|DRUG|Methylprednisolone|Children with primary ARDS presenting within the first 14 days would receive IV low dose Methylprednisolone infusion.
223637589|NCT02167698|OTHER|Restrictive fluid therapy|Fluid \& hemodynamics would be titrated as per pre-designed decision-making protocols
223637590|NCT02167698|DRUG|sedo-analgesia titration|
223637591|NCT02167698|OTHER|Protocolized early enteral nutrition|Early enteral nutrition and attempt to meet calorie-protein goals
224318947|NCT01270191|DRUG|Humulin-N|The insulin dose will be initiated with 0.25 unit/Kg per day, and the two thirds of daily dose will be administrated before breakfast and the other will be administrated at bedtime. Insulin doses will be titrated every 3 days to achieve target fasting blood glucose values between 70 and 130 mg/dl.
224318948|NCT01017627|OTHER|Early anemia diagnosis and treatment|Patients returning to the unit are immediately assessed and treated for anemia
224318949|NCT01017627|OTHER|No change from normal routine|Normal unit policy for labs and anemia treatment
224318950|NCT01249573|OTHER|fascia therapy or transcutaneous fibrolysis|fascia therapy or transcutaneous fibrolysis as treatment for an acute ankle distortion
223637592|NCT02167698|OTHER|Protocolized supportive care|Eye care, chlorhexidine mouth wash Q6 hourly, Strict aseptic precautions prior to any procedures, Skin care \& bed sore prevention, Adequate pulmonary toileting and chest physiotherapy, frequent position changes, limb physiotherapy, family-centered care
223637593|NCT02167698|OTHER|Biomarker Assay|Biomarker Assay for patients in both arms
223637594|NCT03942796|DRUG|lyrica, vronogabic (pregabalin)|Patients would receive oral pregabalin is initiated at a dose of 75 mg twice daily and titrated up to 600 mg as tolerated by the patient at 1,2,3 weeks
223637595|NCT03942796|PROCEDURE|pulsed radiofrequency ablation of the dorsal root ganglion under fluroscopic guidance/ radiofrequency neurolysis/ radiofrequency denervation device name: Neuro Therm TM 1100|Patients would receive pulsed radiofrequency ablation of dorsal root ganglion using the following settings: 2-Hz frequency, 20-ms pulses in a 1 second cycle, 120 second duration and 42°C temperature. Impedance ranges between 150 and 400 Ohms at all levels under fluroscopic guidance. For each pulsed RF application, the procedure will be repeated 4 times, for a total duration of 8 minutes
223637596|NCT05618977|BEHAVIORAL|Dramatization simulation|Ethical attitudes of nursing students will be evaluated with dramatization simulation application.
223637597|NCT05618977|BEHAVIORAL|In-class case studies|In-class case studies will be conducted with the control group students.
223637598|NCT05153616|DIAGNOSTIC_TEST|Polysomnography|Full night attended polysomnography to diagnose periodic limb movements
223637599|NCT05655741|OTHER|Questionnaire|"Participants will be asked to complete a series of 3 questionnaires that will be used to gain insight into the current expert consensus for Genomic Bereavement care for Pregnancy Loss.~The 2nd and 3rd Questionnaire will be modified from the first to try to generate consensus, depending on the answers from the previous round."
223637600|NCT04137640|DRUG|palbociclib combined with letrozole|Endocrine group will receive palbociclib combined with letrozole: palbociclib (Pfizer Manufacturing Deutschland GmbH, Freiburg, Germany; license number: H20180040) 125 mg/d, every 28 days as a cycle (medication for 3 consecutive weeks and withdrawal for 1 week); letrozole (Novartis Pharma Schweiz AG, Stein, Switzerland; license number: H20140149) 2.5 mg/d, for 6 consecutive months.
223637601|NCT04137640|DRUG|epirubicin combined with cyclophosphamide and sequential docetaxel|Chemotherapy group will receive epirubicin combined with cyclophosphamide and sequential docetaxel: epirubicin (Pfizer Wuxi Pharmaceutical Plant, Wuxi, China; license number: GYZZ H20000496), 90 mg/m2, intravenously, for 120 minutes, once every four weeks, totally four times; cyclophosphamide (Baxter Oncology GmbH, Halle, Germany; license number: H20160468), 600 mg/m2, once every four weeks, totally four times; sequential docetaxel (Sanofi-aventis Deutschland GmbH, Frankfurt am Main, Germany; license number: GYZZ J20150083) 75 mg/m2, intravenously, for 120 minutes, once every four weeks, totally four times.
223637602|NCT00979940|DRUG|Atorvastatin|Atorvastatin 80mg po given one time before PCI in cath lab.
223637603|NCT00974792|BIOLOGICAL|pegfilgrastim|
223637604|NCT00974792|BIOLOGICAL|rituximab|
223637605|NCT00974792|DRUG|cyclophosphamide|
223637606|NCT00974792|DRUG|cytarabine|
223637607|NCT00974792|DRUG|doxorubicin hydrochloride|
223637608|NCT00974792|DRUG|etoposide phosphate|
223637609|NCT00974792|DRUG|ifosfamide|
223637610|NCT00974792|DRUG|leucovorin calcium|
223637611|NCT00974792|DRUG|methotrexate|
223637612|NCT00974792|DRUG|vincristine sulfate|
223637613|NCT04780646|BEHAVIORAL|Nature therapy in urban nature|Nature therapy means visits in nature, actively perceiving the flora and fauna
223637614|NCT04780646|BEHAVIORAL|City Walk|City Walk means walking through urban surroundings (houses, streets, concrete..) with as little as possible contact to nature
223637615|NCT04893369|OTHER|The Low Back Pain and Disability Drivers Management model|"PTs assigned to the intervention arm will undergo a one-day training specific to the PDDM model. The objectives of the workshop are 1) to acquire knowledge on the functioning of the PDDM model by identifying the different domains of the model, and the specific elements that are deemed problematic for a given patient to appropriately establish the clinical profile and 2) to adopt a structured approach to manage and select appropriate interventions to address problematic areas. The model is composed of five domains upon which the clinician can base his assessment and orientate treatment allocation and includes: 1) nociceptive pain drivers, 2) nervous system dysfunction (NSD) drivers, 3) comorbidity drivers, 4) cognitive-emotional drivers and 5) contextual drivers. This profiling will inform and lead the clinician's treatment approach based on the combined contribution of each domain driving the experience of pain and disability."
223637616|NCT04893369|OTHER|Low back pain clinical practice guidelines|For the PTs allocated to the control arm, they will participate in a three-hour training on the most recent CPGs on the management of LBP. The content of the training is based on the results of a thorough review of the literature summarizing the different recommendations from CPGs with a focus on the rehabilitation management of LBP. The objectives of the workshop are 1) to acquire knowledge about the recommendations from the most recent and high-quality CPGs for the management of LBP and 2) to foster their integration into clinical practice. An interactive workshop will be conducted to present the results of the review of the literature with the help of case-studies to facilitate implementation and promote active participation.
223637617|NCT03193255|DEVICE|OPHTECS cleadew GP|Povidone-iodine based disinfecting solutions for rigid contact lenses
223637618|NCT00195364|DRUG|Etanercept|
223637619|NCT02158442|PROCEDURE|Percutaneous Isolated Limb Perfusion (PILP) delivery|The Percutaneous Isolated Limb Perfusion (PILP) delivery intervention procedure enables the use of existing antibiotic therapies in a more targeted and aggressive fashion; it addresses limitations associated with the use of conventional antibiotic drug delivery. As part of the procedure, the circulation of the limb is isolated separately from the general circulatory system enabling the delivery of antibiotic at high therapeutic doses that are not achievable when standard doses are administered intravenously.
223637620|NCT02158442|DRUG|Timentin|The Control Group will receive standard dosings of intravenous Timentin plus other standard care.
224225779|NCT04185558|DEVICE|ActiGraft|Whole Blood Clot (WBC) gel
224225780|NCT04185558|DEVICE|Standard of Care|Alginate dressing, a non-adherent foam dressing, and an outer gauze wrap
224225781|NCT05388188|DRUG|sublingual sufentanil|Dsuvia in patients with SCD VOC as a bridging medication.
224225782|NCT04083014|DRUG|combination of a single dose anti-CD20 antibody and bortezomib|Relapsed and refractory warm AIHA patients receive treatment of combination of a single dose anti-CD20 antibody and bortezomib twice during three months interval.
224225783|NCT04881890|BEHAVIORAL|Low-Carbohydrate Diabetes Prevention Program|LC-DPP participants will be instructed to follow ad-libitum very low-carbohydrate, ketogenic diet, which restricts carbohydrate intake (not including fiber) to 20-35 grams per day with the goal of achieving nutritional ketosis. Participants will be encouraged to eat a normal amount of protein (roughly 80-120 grams per day) and to derive the remaining calories from fat. Allowable foods include: meats, fish, poultry, eggs, cheese, seeds, nuts, leafy greens, non-starchy vegetables, and some fruits
224225784|NCT04502875|DRUG|PRP|Platelet Rich Plasma (PRP) is an autologous blood component derivate from the own patient blood, with a high concentration in platelets. The liquid fraction obtained after the soft centrifugation of Whole Blood (WB) collected with anticoagulant, in a way that most of the red cells and leukocytes are sedimented and removed, but most of the platelets are kept in the supernatant plasma. The platelet concentration in PRP is not well defined.
224225785|NCT04502875|DRUG|PPP|PPP is the liquid fraction obtained after the hard centrifugation of WB collected with any anticoagulant. PPP does not contain cells. (Hematocrit lower than 1% and leukocytes below 1 x 109/L) x but contains WB proteins (including clotting factors), ions, microelements and water. PPP can be also being collected using an apheresis technique.
223637621|NCT01751698|BEHAVIORAL|JASP-EMT|JASP-EMT is a developmentally anchored behavioral intervention that assumes that communication develops from social interactions in which specific social engagement strategies, symbolic representations, and early communication forms are modeled and naturally reinforced by adult partner responses to the child. The goal of JASP-EMT is to increase (a) joint engagement, (b) initiating joint attention gestures, (c) social play involving objects and persons, and (d) verbal and nonverbal communication by facilitating meaningful social interactions. The social interaction foundation of JASP-EMT is critical. Modeling and expansions of communicative behaviors and play are used strategically within meaningful social interactions with therapists and caregivers.
223764995|NCT06267612|DEVICE|Corheart 6 Left Ventricular Assist System|Implantation of left ventricular assist device for hemodynamic support
224318951|NCT00754546|DRUG|Arformoterol tartrate|15 mcg in two ml solution administered via nebulizer
223637622|NCT01751698|BEHAVIORAL|DTT|CORE-DTT is based on behavioral learning theory in which communication and related skills are taught through systematic direct instruction. The goal of CORE-DTT is to help children be successful in learning communication skills by breaking these skills down into small steps, providing systematic direct instruction on each step, and reinforcing children (e.g., with praise or access to preferred items) for demonstrating skills. Imitation and attention skills are a main focus early in intervention. DTT is the most common evidence-based approach for teaching children with ASD, and is often considered the closest to a 'standard of practice' for the field.
223637623|NCT01957995|DRUG|nanosomal docetaxel lipid suspension|Given IV
223637624|NCT01957995|OTHER|pharmacological study|Correlative studies
223637625|NCT00634777|OTHER|pet scan|pet scan
223637626|NCT06338098|BEHAVIORAL|8-week wellness and relaxation meditation program|Heartfulness Meditation program will be provided with guided meditation and relaxation audio clips to spend approximately 20 minutes per day on the meditation and relaxation activities and participate each week in a 20-30 minutes online meditation webinar with a certified meditation trainer. All meditation and relaxation exercises can be performed in the comfort of your own home or other place of your choosing. The intervention will be entirely online.
223637627|NCT05894109|DIETARY_SUPPLEMENT|zinc citrate 50 mg|will take zinc citrate 4 days before and 1 week after botulinum toxin injection
223637628|NCT05894109|OTHER|Placebo Microcrystalline Cellulose|will take placebo 4 days before and 1 week after botulinum toxin injection
223637629|NCT02123901|OTHER|Walking Meditation|"Walking Meditation training program will be based on aerobic walking exercise combined with Buddhist meditation. The subjects will perform walking on the treadmill while concentrated on foot stepping by voiced Budd and Dha with each foot step that contacted the floor to practice mindfulness while walking. Walking Meditation will be conducted at mild to moderate intensity (50-60% maximum heart rate) and in phase 2 (week 7-12), the training intensity will be increased to moderate intensity (60-70% maximum heart rate). In both phases the training will be performed for 30 minutes, 3 times per week."
223637630|NCT02123901|OTHER|Walking|Walking training program will be based on aerobic walking exercise. The subjects will perform walking on the treadmill and conducted at mild to moderate intensity (50-60% maximum heart rate) and in phase 2 (week 7-12), the training intensity will be increased to moderate intensity (60-70% maximum heart rate). In both phases the training will be performed for 30 minutes, 3 times per week.
223637631|NCT02123901|OTHER|No exercise|Sedentary life style.
223637632|NCT02552043|OTHER|Nintendo Wii exercise program|The aerobic training protocol was designed to improve muscular strength, body endurance and flexibility (involved activities as: running, up the knees, butt kickers, etc.). The game used has a strap pouch to hold the Nunchuk© controller placed on the thigh that detects the lower body movements, and also features a number of exercise options supervised by a virtual personal trainer
223637633|NCT06103435|PROCEDURE|Extent od surgical resection|
223637634|NCT01099176|DRUG|To compare monotherapies and combined therapy with each other|"Each patient received two tablets per day. Time interval between pills - 12 hours.~In monotherapies patients received one active tablet and one placebo, in combined treatment both pills were active and in placebo group patients taken two placebo tablets"
223637635|NCT06464601|COMBINATION_PRODUCT|fruquintinib combined with immune checkpoint inhibitors and chemotherapy|"Chemotherapy Drugs: Selection based on clinical guidelines/indications and patient condition.For example, recommended chemotherapy regimens: XELOX or SOX.~Immune Checkpoint Inhibitors:~Selection based on clinical guidelines/indications and patient condition, including but not limited to PD-1 inhibitors, PD-L1 inhibitors.~Fruquintinib: 3mg (starting dose), PO (once daily). Dosing schedule and dosage can be adjusted based on concurrent chemotherapy and immune checkpoint inhibitors. Have received fruquintinib treatment for at least 2 cycles."
223637636|NCT06464601|COMBINATION_PRODUCT|fruquintinib combined with immune checkpoint inhibitors and chemotherapy|"Chemotherapy Drugs: Selection based on clinical guidelines/indications and patient condition.For example, recommended chemotherapy regimens: XELOX or SOX.~Immune Checkpoint Inhibitors:~Selection based on clinical guidelines/indications and patient condition, including but not limited to PD-1 inhibitors, PD-L1 inhibitors.~Fruquintinib: 3mg (starting dose), PO (once daily). Dosing schedule and dosage can be adjusted based on concurrent chemotherapy and immune checkpoint inhibitors. Have received fruquintinib treatment for at least 2 cycles."
223637637|NCT04744246|OTHER|load carriage|35 pound load carried on the back
223637638|NCT02659254|DEVICE|Sirolimus Target Eluting Bioresorbable Vascular Scaffold|Implantation of the Sirolimus Target Eluting Bioresorbable Vascular Scaffold
223637639|NCT05804591|DRUG|Pregabalin 150mg|Single dose of pregabalin 150mg in a capsule per os 1 hour before start of the operation.
223637640|NCT05804591|DRUG|Placebo|1 capsule containing placebo per os 1 hour before start of the operation.
223637641|NCT04885907|BIOLOGICAL|mRNA-1273 vaccine|COVID vaccine 3rd dose
223637642|NCT04885907|OTHER|Normal Saline Placebo|Normal Saline Placebo
223637643|NCT04365725|DRUG|Remdesivir|Compassionate provision
223637644|NCT00622050|BEHAVIORAL|No TV viewing reduction|In the control group, no intervention will be acted upon. This group will receive the exact same protocol as the intervention group, but with observation only.
223637645|NCT00622050|BEHAVIORAL|TV viewing reduction|In the experimental arm, TV viewing time will be reduced for half of the study protocol time (3-4 weeks of a 6-8 week protocol).
223637646|NCT01475760|OTHER|K2CG chewing gum (20mg chitosan)|All participating subjects will chew gum TID for 14 days beginning on Day 1 through Day 14
224225786|NCT05133895|DRUG|Tocilizumab monotherapy|intravenous infusions of TCZ (8 mg/kg) at inclusion and then every 4 weeks for at least 3 months
224225787|NCT01505465|DRUG|Melatonin|5mg of melatonin will be taken by the subject for 3 nights prior and continuing 3 nights after surgery as tolerated.
224225788|NCT01505465|DRUG|Placebo|5mg of placebo will be taken by the subject 3 nights prior to surgery and continuing 3 nights after surgery
224225789|NCT05235308|PROCEDURE|Percutaneous adhesiolysis|Percutaneous adhesiolysis is a minimally invasive technique which involves the use of a spring-wound catheter, ideally placed in the ventrolateral aspect of the epidural space for the lysis of adhesions.
224225790|NCT02742779|DRUG|GDC-0310|Participants will receive single or multiple ascending doses of GDC-0310 orally in fasted or fed state.
224318952|NCT00754546|DRUG|Placebo: Normal Saline|Normal saline was nebulized.
224318953|NCT00754546|OTHER|Treadmill Exercise|
224318954|NCT00754546|OTHER|Cycle Exercise|
223637647|NCT01475760|OTHER|K2CG chewing gum (60mg chitosan)|"Subjects will be randomized in a 1:1 fashion to either chew gum or continue with Standard of Care (no intervention)if they have a change in serum phosphorus of greater than or equal to -0.2 mg/dL from:~Baseline (defined as the mean of values from Visit 2, 3, and 4) to the end of active treatment (defined as the mean of Visit 6 and 7) AND/OR Baseline (defined as the mean of values from Visit 2, 3, and 4) and end of wash out (defined as Visit 7 (Day 22).~If randomized: Chew gum TID for 14 days beginning on Day 29 through Day 42"
224225791|NCT02742779|DRUG|Placebo|Participants will receive placebo matched to GDC-0310 as single or multiple oral dose in fasted or fed state.
224225792|NCT03013166|OTHER|Corticosteroid medication|Patients will be grouped into Cohort 1 (IR hydrocortisone), cohort 2 (IR prednisolone), cohort 3 (MR hydrocortisone), or cohort 4 (IR to MR hydrocortisone) depending on which oral corticosteroid medications were received during the observation period.
224225793|NCT01179282|BIOLOGICAL|dust mite extract or placebo|intervention will be to stop study drug or placebo
224225794|NCT03120156|DEVICE|sensomotoric insoles|sensomotoric insoles were published by Jahrling (2007) and have a certain shape that could improve balance abilities. The toes 2-4 are higher that toe 1, so that the tendons of the toe-flectors are pre-stressed.
224225795|NCT03120156|DEVICE|normal standard insoles|Normal standard insole like you will get them by receipe from an orthotic shop
224225796|NCT03120156|OTHER|No insoles|control group with no insoles in the shoes
224225797|NCT04058483|OTHER|Hypnotizability testing|Hypnotizability testing in-person vs. by phone. All participants will complete both conditions.
224225798|NCT04140006|DRUG|ALN Gel|Flapped surgery for insertion of dental implant with topical application of ALN gel
224225799|NCT04140006|DRUG|BMP Gel|Flapped surgery for insertion of dental implant with topical application of BMP gel
224225800|NCT04140006|DRUG|Mixed Gel|Flapped surgery for insertion of dental implant with topical application of mixed gel of ALN and BMP
224225801|NCT04140006|DRUG|Control|Flapped surgery for insertion of dental implant without topical application of any gel
224225802|NCT03830528|DRUG|KW-6356 Low Dose|KW-6356 will be administered as single doses.
224225803|NCT03830528|DRUG|KW-6356 Middle Dose|KW-6356 will be administered as single doses.
224225804|NCT03830528|DRUG|KW-6356 High Dose|KW-6356 will be administered as single doses.
224225805|NCT03830528|DRUG|KW-6356 X Dose|KW-6356 will be administered as multiple doses.
224225806|NCT03830528|DRUG|KW-6356 Y Dose|KW-6356 will be administered for Japanese healthy men as multiple doses.
224225807|NCT03830528|DRUG|Placebo|All study cohorts (except Part C) are placebo controlled.
224225808|NCT02393196|DRUG|hydroxyethyl starch (% 6 HES 130/0.4) (Voluven®)|Before spinal anesthesia
224225809|NCT02393196|DRUG|hydroxyethyl starch (%6 HES 130/0.4) (Voluven®)|Just after spinal anesthesia
223637648|NCT06189521|OTHER|Extracorporeal shock wave group|In addition to the ten-day of physiotherapy program, in the first group one day for a week a total of 3 sessions of ESWT was applied at 1.8 bar, 10.0 Hz, 2000 beats (Elmed Vibrolith Ortho).
223637649|NCT06189521|OTHER|ultrasound group|In addition to the ten-day of physiotherapy program,In the second group, ten days of ultrasound applied at 1.5 watt/cm2 continuous mode to the painful area for 5 minutes, 5 days a week for two weeks (Chattanooga Intelect Advanced).
223637650|NCT06189521|OTHER|dexamethasone iontophoresis group|In addition to the ten-day of physiotherapy program, In the third group ten days of dexamethasone iontophoresis therapy was applied. 10 days for 10 minutes. 0,1% dexamethasone ophthalmic pomade was applied to the anodal electrode and placed on the lateral epicondyle and 0.1-0.2 milliampere/cm2 galvanic current was applied in each session (ES-522; ITO Physiotherapy and Rehabilitation).
224225810|NCT03495193|OTHER|Exercise training|Exercise training will be performed 3x/week. After 2 sessions, training volume and intensity will progress over the first 4 sessions ramping up the number of sets to increase the volume. The full volume prescription will consist of: 1) 5 movements to improve strength and muscle mass (leg press, knee extension, chest press, overhead press, pull down), 3 sets each of 8-12 repetitions (\~30 total repetitions); 2) trunk exercises to improve postural stability (trunk extension and flexion); 3) 3-4 bodyweight exercises (selected from a menu) to improve power and balance (e.g. step up, squat, jump squat, lunge, side lunge, push-up, assisted pull-up, assisted dip). Bodyweight movements will be modified as necessary to match abilities.
224225811|NCT03495193|BEHAVIORAL|Sleep hygiene|Subjects randomized to the no-exercise group will receive a handout with tips for improving sleep. Additionally, study staff will provide the title page for a book on sleep relaxation techniques that is recommended for persons with sleeping difficulty. Dr. Amara will review the sleep tips with the subjects and make recommendations for improving current sleep habits. Subjects will be contacted by telephone every 4 weeks during the 16-week intervention period.
224225812|NCT00788619|PROCEDURE|Transfer of embryos on day 3 or day 5 after fertilization.|Subjects will be allocated at random to the two arms. Group 1 will have two embryos transferred on day 3 based on nitric oxide concentration. Group 2 will have two embryos transferred on day 5 based on morphologic criteria.
224225813|NCT00788619|PROCEDURE|Day 5 transfer|Subjects will have embryo transfer on day 5 after fertilization. Selection of embryos to transfer will be based on morphologic criteria.
224225814|NCT01855126|OTHER|Blue light|After a two week baseline collection period, half of the subjects will initially be given light masks that deliver blue light through the closed eyelids, while subjects are sleeping. The light mask will always be turned on 120 min before estimated core body temperature minimum (CBTmin); it is expected that blue light exposure will delay the timing of the CBTmin.
224225815|NCT01855126|OTHER|Red light|After a two week baseline collection period, half of the subjects will initially be given light masks that deliver red light through the closed eyelids, while subjects are sleeping. The light mask will always be turned on 120 min before estimated core body temperature minimum (CBTmin); it is expected that red light exposure will have no effect on the timing of the CBTmin.
224225816|NCT06496087|DIETARY_SUPPLEMENT|DEPREXIL|The trial group will be administered 1 capsule of DEPREXIL orally every 8 hours for 6 months of treatment.
224225817|NCT02387814|DRUG|Abemaciclib|Administered Orally
224225818|NCT02086656|DRUG|capecitabine, oxaliplatin, irinotecan and bevacizumab|perioperative COI-B
224225819|NCT00708630|BEHAVIORAL|Extended information on side effects|More detailed information on possible side effects of vaccine
223637651|NCT00648440|DRUG|Midodrine HCl Tablets 5 mg|5mg, single dose fed
223637652|NCT00648440|DRUG|ProAmatine® Tablets 5 mg|5mg, single dose fed
224225820|NCT04078230|PROCEDURE|Extend LymphAdenectomy|Expanded lymph node dissection for right liver tumors included stations 12, 8, and 13, and stations 12, 1, 3, 7, and 8 for left liver tumors
224225821|NCT01657487|DRUG|Fluticasone/Salmeterol high dose|
224225822|NCT00146289|DRUG|MICARDIS® (telmisartan)|
224225823|NCT05547893|OTHER|simulation|participating a simulated clinical ethical situation with simulation patients
224225824|NCT00050895|DRUG|Lopinavir/ritonavir|
224225825|NCT00050895|DRUG|Efavirenz|
224225826|NCT00050895|DRUG|Stavudine|
224225827|NCT00050895|DRUG|Zidovudine|
224225828|NCT00050895|DRUG|Lamivudine|
224225829|NCT00050895|DRUG|Tenofovir disoproxil fumarate|
224225830|NCT05529719|OTHER|Clinical Pilates Exercises|Participants in the experimental group were included in the clinical Pilates intervention, which consisted of three weekly sessions for 50 minutes for 12 weeks. Clinical pilates sessions were performed by a clinically Pilates-certified instructor and a physiotherapist. The intervention was divided into three sections. Each session started with the warm-up section. The warm-up part started with breathing exercises, pelvic tilt centering, activation of deep trunk and pelvic floor muscles, and joint mobility. The Clinical Pilates exercises section consisted of matte level strength and flexibility exercises involving the trunk, upper and lower extremities. Finally, a cooling part was done that included some flexibility exercises.
224225831|NCT00961051|DEVICE|Investigational MPS|Multi-purpose solution
224225832|NCT00961051|DEVICE|Opti-Free|Multi-purpose solution
224225833|NCT01357356|DRUG|SER120 (750 ng/day)|
224225834|NCT01357356|DRUG|SER120 (1000 ng/day)|SER120 (1000 ng/day)
224225835|NCT01357356|DRUG|SER120 (1500 ng/day)|
224225836|NCT01357356|DRUG|Placebo|
223515299|NCT06344923|PROCEDURE|Ileostomy with a support rod instead of the layer of peritoneum and anterior rectus sheath suturing|The terminal ileum about 30cm proximal to the cecum was recognized and was lifted out of the body through the auxiliary incision at the right lower abdomen and made sure that the ileum was not twisted. Appropriate sutures can be used to narrow the peritoneal incision, preferably by inserting one finger. A support rod, made of a 24# silicone drainage tube with a 1ml syringe was passed through the mesentery of the small intestine. The support rod was removed two weeks after surgery. It is appropriate that the ileum wall protruded from the epidermis by about 3cm. After suturing trocar sites, the loop ileostomy was opened along the longitudinal axis of the intestinal wall, and 4-0 absorbable suture was used to fix the stoma and subcutaneous tissue circumferentially with 16-20 stitches.
223515300|NCT06344923|PROCEDURE|Ileostomy with the layer of the peritoneum and anterior rectus sheath suturing|The terminal ileum about 30cm proximal to the cecum was recognized and was lifted out of the body through the auxiliary incision at the right lower abdomen and made sure that the ileum was not twisted. Appropriate sutures can be used to narrow the peritoneal incision, preferably by inserting one finger. The seromuscular layer of the ileum or the mesentery was intermittently sutured with peritoneum and the anterior sheath of the rectus abdominis circumferentially with 8-10 stitches (3-0 silk thread). It is appropriate that the ileum wall protruded from the epidermis by about 3cm. After suturing trocar sites, the loop ileostomy was opened along the longitudinal axis of the intestinal wall, and 4-0 absorbable suture was used to fix the stoma and subcutaneous tissue circumferentially with 16-20 stitches
223515301|NCT06576570|BEHAVIORAL|Education presentation of surgical ergonomics|During an individual meeting with participant, a brief presentation will be supplied for review.
223515302|NCT06576570|BEHAVIORAL|Summary of Ergonomic Measurement System|Participant will view a video of their movements with a visual guideline highlighting high-risk angles and movements.
223515303|NCT02732145|DIAGNOSTIC_TEST|"Three Rings Vulvoscopy (TRIV)"|"Mapping of the vulvar lesions according to the three vulvar rings and specificity of the lesions during Three Rings Vulvoscopy technique (TRIV Form Data). Assessing of the data by the Vulvoscopy Index and the N-S-P Scheme."
223515304|NCT02732145|PROCEDURE|Histopathology|Biopsy of the vulva in symptomatic patients, vulvar samples after labiaplasty in asymptomatic patients.
223515305|NCT04656548|DEVICE|HydroPICC|PICC lines
224225837|NCT01748890|DEVICE|Sonoelastography|Sonoelastography is an imaging technology predicated on reproducible differences in the backscattered ultrasound signal produced by compression of tissues of varying stiffness.
224225838|NCT02410148|DEVICE|Non-invasive ICP measurement (Vittamed 305)|The non-invasive method is based on two-depth TCD technique for simultaneously measuring flow velocities in the intracranial and extracranial segments of the ophthalmic artery (OA).
224318955|NCT05886868|DRUG|BL0020|"Dose Escalation Stage: BL0020 will be administered via intravenous infusion on days 1 of a 21-days treatment cycle.~Dose Expansion Stage: Maximum tolerated dose or the recommended Phase 2 dose (RP2D) from dose escalation Stage."
223515306|NCT00005021|BIOLOGICAL|filgrastim|
223515307|NCT00005021|DRUG|carboplatin|
223515308|NCT00005021|DRUG|paclitaxel|
223515309|NCT00005021|DRUG|topotecan hydrochloride|
223515310|NCT03081923|DRUG|Durvalumab|anti-PD-L1 mono therapy
223515311|NCT03081923|DRUG|Tremelimumab|anti-CTLA4 drug Tremelimumab mono therapy
223637653|NCT06474247|DEVICE|Postbiotic|Postbiotic at 1g/day as an adjunct treatment against vaginal candidiasis in women for 4-weeks
223637654|NCT06474247|DEVICE|Placebo|Placebo at 1g/day as an adjunct treatment against vaginal candidiasis in women for 4-weeks
224225839|NCT03967236|OTHER|Collection of stool and blood samples|"For each visit, stool and blood samples will be collected during a pediatric gastroenterology day hospital stay.~This collection of stool and blood specific IVOIRE study is carried out in the context of examination already planned for the usual care of the patient."
224225840|NCT04984109|PROCEDURE|Sham PENG block|The regional block will be performed with the patient in the supine position in operative area with adequate groin exposure. The probe will first be placed at the anterior superior iliac spine in transverse plane, and then will be moved caudally to identify anterior inferior iliac spine (AIIS). The probe will be then rotated to align the AIIS and iliopubic eminence (IPE). This will reveal the iliopsoas tendon and muscle together with femoral vessels superficially. A 22-G 100-mm echogenic needle will be inserted in-plane from lateral to medial, and the tip will be kept at the midpoint of AIIS and IPE deep to psoas tendon. After lifting of psoas tendon by hydrolocation, the patients in PENG group will receive 1 mL of normal saline.
223637655|NCT05799820|DRUG|QL1706|5 mg/kg administered as IV infusion on Day 1 of each 21-day cycle
223637656|NCT05799820|DRUG|Bevacizumab|7.5 mg/kg administered as IV infusion on Day 1 of each 21-day cycle
223637657|NCT05799820|DRUG|Oxaliplatin injection|130mg/m2 administered as IV infusion on Day 1 of each 21-day cycle
223637658|NCT05799820|DRUG|Capecitabine|1000 mg/m2 orally twice daily for 14 days continuous dosing followed by a 7-day break of each 21-day cycle
223637659|NCT01646580|DRUG|ciclopirox|Doses of 1.0% cream. Topical cream application. Twice daily for 28 days. Duration of treatment: 28 days with four weeks follow-up.
223637660|NCT00742612|DRUG|ARC1779 Injection|Study drug treatment will be initiated 1 hour prior to the induction of anesthesia with a loading dose given over 1 hour in 3 successively increasing, 20-minute step infusions. The ARC1779 treatment group will be dosed to achieve a target ARC1779 steady-state plasma concentration of 3 Ug/mL, using a loading dose infusion sequence of 0.0015 mg/kg/min for 20 minutes, 0.003 mg/kg/min for the next 20 minutes, and then 0.006 mg/kg/min for the final 20 minutes; thereafter, their maintenance infusion rate is to be 0.0006 mg/kg/min.
223637661|NCT00742612|DRUG|Placebo (normal saline)|Study drug treatment will be initiated 1 hour prior to the induction of anesthesia with a loading dose given over 1 hour in 3 successively increasing, 20-minute step infusions. The placebo group will be dosed to a steady-state plasma concentration using a loading dose infusion sequence of 0.0015 mg/kg/min for 20 minutes, 0.003 mg/kg/min for the next 20 minutes, and then 0.006 mg/kg/min for the final 20 minutes; thereafter, their maintenance infusion rate is to be 0.0006 mg/kg/min.
223637662|NCT02277938|DRUG|Amantadine|Amantadine is a drug that has been on the market for several years and is currently approved for the treatment of Parkinson's disease and for prevention against influenza A infection. Amantadine may be of value in detecting the presence of cancer.
223637663|NCT01151189|BIOLOGICAL|MVA85A/AERAS-485|Subjects received intradermal injection of MVA85A/AERAS-485 on Study Day 0, followed 6-9 months later by a booster injection of MVA85A/AERAS-485.
224225841|NCT04984109|PROCEDURE|Real PENG block|The regional block will be performed with the patient in the supine position in operative area with adequate groin exposure. The probe will first be placed at the anterior superior iliac spine in transverse plane, and then will be moved caudally to identify anterior inferior iliac spine (AIIS). The probe will be then rotated to align the AIIS and iliopubic eminence (IPE). This will reveal the iliopsoas tendon and muscle together with femoral vessels superficially. A 22-G 100-mm echogenic needle will be inserted in-plane from lateral to medial, and the tip will be kept at the midpoint of AIIS and IPE deep to psoas tendon. After lifting of psoas tendon by hydrolocation, the patients in PENG group will receive 20 ml of (0.25%) bupivacaine with 0.2 mg/mL dexamethasone that will be injected in 5 ml aliquots after negative aspiration.
224225842|NCT05186350|PROCEDURE|ERCP+ SpyGlass|SpyGlass direct Vision guided laser lithotripsy
224225843|NCT05186350|PROCEDURE|ESWL+ ERCP|ESWL + Stone removal through ERCP
224318956|NCT00000812|DRUG|Thalidomide|
224318957|NCT00355953|DRUG|Genistein|
224318958|NCT06076460|OTHER|Early Total Enteral Feeding|This group will receive enteral feeding volumes at a rate of 80 ml/kg/day starting within the first two hours after birth. Volumes will increased by 20 ml/kg/day till day 4 (total 140 ml/kg/d) and then 150ml/kg/day on day 5.
223637664|NCT01151189|BIOLOGICAL|Placebo|Subjects received an intradermal injection placebo on Study Day 0, followed 6-9 months later by a booster injection of placebo.
223637665|NCT03771924|DIETARY_SUPPLEMENT|inorganic phosphate|Sodium phosphate
223637666|NCT03771924|DIETARY_SUPPLEMENT|placebo|Sodium chlorid
223637667|NCT03558711|DIAGNOSTIC_TEST|18F-PSMA|18F-PET imaging
223637668|NCT03108807|DIAGNOSTIC_TEST|D-dimer test|D-dimer test
223637669|NCT02054689|RADIATION|Fractionated Stereotactic Radiosurgery|SRS SBRT CyberKnife Trilogy True Beam Radiosurgery
223637670|NCT00632229|DRUG|Paliperidone|Paliperidone medication taken daily ranging from 3-9mg/day depending on tolerability and efficacy.
223637671|NCT00632229|DRUG|Placebo|Pill placebo taken daily ranging from 3-9mg/day depending on tolerability and efficacy.
223637672|NCT00026260|DRUG|semaxanib|
223637673|NCT06288997|DEVICE|Active transcranial alternating current stimulation|Hi-tACS with a current level of 15mA with a patented frequency of 77.5Hz.
223637674|NCT06288997|DEVICE|Sham transcranial alternating current stimulation|The device for the sham group has the same appearance and technical settings as the one used in the active group, designed to produce similar sensations on the scalp, but without effective penetration of the electric field into the brain.
224318959|NCT06076460|OTHER|Conventional Enteral Feeding|This group will receive enteral feeding volumes at a rate of 20 ml/kg/day starting within the first two hours after birth and rest of the daily requirement as Total parenteral nutrition. Volumes will be increased by 20 ml/kg/day till day 3 and thereafter by 30 ml/kg/d till 150ml/kg/day on day 6.
223637675|NCT02323217|RADIATION|[11C]BU99008|Baseline Scan, Test-ReTest or Dosimetry
223637676|NCT02323217|DRUG|Idazoxan|Idazoxan block of \[11C\]BU99008
223637677|NCT02323217|DRUG|Isocarboxazid|Isocarboxazid block of \[11C\]BU99008
223637678|NCT03146585|DEVICE|PBR assessment|Sublingual microcirculation will be investigated by specialized handheld videomicroscopy device for PBR index.
223637679|NCT06146920|OTHER|Evaluation of ctDNA using the F1T after 1 year of immunotherapy|"Patients with evidence of disease control after at least 10months of an ICI-based therapy will initially undergo a pre-screen. In patients with successful F1CDx baseline tissue testing whole blood will be collected and evaluated for plasma ctDNA measurement. If there is detectable ctDNA during the pre-screening period, patients will be excluded from enrollment. If there is no detectable ctDNA, patients will be eligible to screen and enroll in the main study.~If enrolled, patients will stop ICI- based treatment and continue with serial ctDNA at pre-specified timepoints. The treating physician will not be blinded to the serial ctDNA results There will be no proscriptive therapeutic measures outlined if ctDNA becomes detectable while on study."
223637680|NCT05654974|OTHER|measurements and questionnaire|paper-based survey administration; erect penis length and girth measurements
223637681|NCT00110448|DRUG|Aspirin|Aspirin 81 mg or 100 mg per day
223637682|NCT00110448|DRUG|No aspirin|No aspirin use
223637683|NCT04864093|DIAGNOSTIC_TEST|muscular ultrasound|respiratroy and muscular ultrasound
223637684|NCT05676619|DEVICE|3D foot scanner|Reliability of 3D foot scanner during repeated scans
223637685|NCT05835817|OTHER|Magnetoencephalography|40 minutes of Magnetoencephalography with Optical Pump Magnetometer
223637686|NCT05345600|OTHER|MILTA probe|"Each woman will be included within the 6h after delivery (to ensure at least 2 days with the treatment / placebo). Once the written informed consent is obtained, the patient will be randomized in one of the 2 groups (MILTA or Placebo): 2 sessions are planned (the first one between 6h and 24h after delivery and the second one day after the first session). The woman will be lying on an exam bed. After a skin cleansing, the MILTA probe covered with a specific single use protection will be placed facing the scar. A 10-min session will include 5 min with the analgesia mode on followed with 5 min with the healing mode on in the MILTA group. For the placebo group, the procedure will be identical, with the probe switched OFF. To ensure that the red light is observable in the bedroom in both groups, a second probe will be used, facing the ceiling of the exam bedroom (and not the woman) for the 10 minutes of the procedure."
224225844|NCT00642031|DRUG|Triciribine|15 mg/m\^2 IV Weekly Over 1 Hour On Days 1, 8, and 15.
224225845|NCT03740100|DRUG|Bimiralisib|Bimiralisib capsules
224225846|NCT03368495|BIOLOGICAL|Co-administration of MMR/YF|Both MMR \& yellow fever vaccines administered on Day 0.
224225847|NCT03368495|BIOLOGICAL|MMR followed by YF|MMR vaccine administered on Day 0 and yellow fever vaccine administered on Day 28.
224225848|NCT03368495|BIOLOGICAL|YF followed by MMR|Yellow fever vaccine administered on Day 0 and MMR vaccine administered on Day 28.
224225849|NCT01472588|BEHAVIORAL|DPP lifestyle intervention-Community Health Coach (CHWs)|Lifestyle counseling. During a 16 month period, the behavioral weight loss program (n=24 sessions of the DPP lifestyle intervention) is delivered by CHWs in group format in community settings.
224225850|NCT01472588|BEHAVIORAL|DPP Lifestyle intervention--health professionals/(PHCs)|Lifestyle counseling. During a 16 month period, the behavioral weight loss program (n=24 sessions of the DPP lifestyle intervention) is delivered by PHCs in group format in community settings.
224225851|NCT01472588|OTHER|Self Help|Public education/information booklet on weight management.
224225852|NCT05544851|OTHER|Education|"Participants who meet the sample selection criteria will be informed about the scope of the study and their verbal and written consent will be obtained. Women who met the sample selection criteria and were accepted into the study group will be randomly assigned to the intervention and control groups. Personal Information Form, Behaviors for Protection from Sexually Transmitted Diseases Scale will be applied to the participants in the intervention and control groups."
224225853|NCT06186167|PROCEDURE|Chest Wall Fat Tissue Collection|As part of routine cardiac device implantation, chest wall fat tissue is collected for histopathological analysis. This tissue, which is typically discarded, will be used to identify amyloid deposits in high-risk cardiac patients. No additional surgical intervention is performed beyond the standard procedure for device implantation.
224225854|NCT06527001|OTHER|No intervention|This is an observational study and did not involve interventions.
224225855|NCT02457728|DEVICE|LiquiBandFix8|Using LiquiBandFix8 for mesh fixation and peritoneal closure following TAPP repair.
224225856|NCT01984281|BEHAVIORAL|Pedometer-based physical activity prescription|After baseline assessments, both groups will receive a educational session, regarding important aspects of asthma plus a unsupervised exercise prescription (walking, 5 times per week, for at least 30 minutes). Only the experimental group will receive a pedometer-based physical activity prescription, consisting of targets (steps per day) to be achieved. The initial target will be determined based on the average of steps per day assessed during the baseline assessments plus 1000 steps. The targets will be biweekly. Both groups will be contact once a week (by phone) and will be asked to return for asthma control assessments once a month.
224225857|NCT02678897|DRUG|Oxynorm on-demand|"We compare different routes of administration (PCA an oral/intramuscular use of oxynorm) in patients undergoing medical termination of pregnancy. Patients are randomized in two groups (for extra pain medication)~1. If analgesia is inadequate oxycodon (OxyNorm®) (10 mg (less than 80 kg) - 15 mg (over 80 kg) po. In an hour oxycodon 5-10 mg more po if needed. Intramuscular or intravenous administration if needed.~2. Patient controlled analgesia (PCA pain pump): Oxycodon dose is 3.0 mg (3 ml) and lock-out time 8 min. Maximum four doses in hour. Dose can be lowered or augmented 0,5 mg at time between 2.0-4.0 mg and maximal number of doses can be up to 5."
224225858|NCT02678897|DRUG|Oxynorm via PCA|"We compare different routes of administration (PCA an oral/intramuscular use of oxynorm) in patients undergoing medical termination of pregnancy. Patients are randomized in two groups (for extra pain medication)~1. If analgesia is inadequate oxycodon (OxyNorm®) (10 mg (less than 80 kg) - 15 mg (over 80 kg) po. In an hour oxycodon 5-10 mg more po if needed. Intramuscular or intravenous administration if needed.~2. Patient controlled analgesia (PCA pain pump): Oxycodon dose is 3.0 mg (3 ml) and lock-out time 8 min. Maximum four doses in hour. Dose can be lowered or augmented 0,5 mg at time between 2.0-4.0 mg and maximal number of doses can be up to 5."
224225859|NCT03089528|DEVICE|Videolaryngoscopy|the trachea will be intubated with a videolaryngoscope
224225860|NCT03089528|DEVICE|laringoscope|the trachea will be intubated with a laringoscope
224225861|NCT03518697|BEHAVIORAL|exercise program|"The exercise program is planned as a low-threshold exercise program with low barriers to participate. Patients will be asked about their interests and preferences of sports activities to conceive the exercise program together with the patients."
224225862|NCT02836340|DRUG|2-Iminobiotin|The Investigational Medicinal Product (IMP) under study is 2-IB, which is a biotin (Vitamin H or B7) analogue and a selective inhibitor of neuronal and inducible nitric oxide synthase (NOS).
224225863|NCT01337154|DRUG|Tamibarotene|Tablet, 6 mg/m2, oral, divided into twice a day dosing.
224225864|NCT01337154|DRUG|Placebo|Tablets, orally, daily
224225865|NCT03387059|DEVICE|Forielle|Participants randomized to receive Forielle endometrial washing (an intrauterine solution) following oocyte retrieval on Study Day 0 (Randomisation).
224318960|NCT01827865|DRUG|Etodolac Extended Release Tablets USP 600mg|Etodolac Extended Release Tablets USP 600mg once a day
224225866|NCT00141596|DRUG|Cardura XL 4 mg bd|
224318961|NCT01827865|DRUG|Etodolac Extended Release Tablets 600mg|Etodolac Extended Release Tablets 600mg once a day
224318962|NCT03857282|OTHER|Aerobic Exercises|5 to 10 min warm up exercises than 30min bicycle exercise and 5 to 10 min cool down exercises
224318963|NCT03857282|OTHER|Tai Chi Exercises|5 to 10 min warm up exercises and 30 min Tai Chi exercises and than than 5 to 10 min cool down exercises.
223637687|NCT05345600|OTHER|placebo probe|"Each woman will be included within the 6h after delivery (to ensure at least 2 days with the treatment / placebo). Once the written informed consent is obtained, the patient will be randomized in one of the 2 groups (MILTA or Placebo): 2 sessions are planned (the first one between 6h and 24h after delivery and the second one day after the first session). The woman will be lying on an exam bed. After a skin cleansing, the MILTA probe covered with a specific single use protection will be placed facing the scar. A 10-min session will include 5 min with the analgesia mode on followed with 5 min with the healing mode on in the MILTA group. For the placebo group, the procedure will be identical, with the probe switched OFF. To ensure that the red light is observable in the bedroom in both groups, a second probe will be used, facing the ceiling of the exam bedroom (and not the woman) for the 10 minutes of the procedure."
223637688|NCT04011176|PROCEDURE|Standard treatment + placebo|Placebo microcurrent
224225867|NCT00141596|DRUG|Amiloride 5 mg bd|
224225868|NCT00141596|DRUG|Furosemide 40 mg bd|
224225869|NCT04877184|DEVICE|Transcranial ultrasound stimulation and rehabilitation|"The participants in experimental group would received transcranial ultrasound stimulation and rehabilitation therapy.~* transcranial ultrasound stimulation: during 4 weeks~* rehabilitation: physiotherapy and occupational therapy (may combine with speech therapy and psychological therapy if needed)"
224225870|NCT04877184|DEVICE|Rehabilitation|"The participants in control group would received rehabilitation therapy.~\- rehabilitation: physiotherapy and occupational therapy (may combine with speech therapy and psychological therapy if needed)"
223637689|NCT04011176|PROCEDURE|Standard treatment + Microcurrent Therapy|Actual microcurrent
223637690|NCT04426734|DEVICE|Dextenza Dexamethasone Implant|The area of the punctum is first anesthetized with eye drops. A localized injection of lidocaine in perform once the surface of the punctum is numbed with the eyedrop. After 5-10 minutes, the corner of the eyelid and the region of the punctum will be fully anesthetic. The upper and lower punctum are then dilated with a punctum dilator to facilitate the insertion of the DEXTENZA medication. The DEXTENZA medication is then inserted using smooth forceps into the dilated opening of the upper and lower punctum. Once the DEXTENZA is inserted into the both the upper and lower punctum, the procedure is down. No repeated insertion of the DEXTENZA is required for the study.
223637691|NCT04426734|DRUG|Topical Prednisolone Acetate 1%|"Topical corticosteroid (Pred Forte, prednisolone acetate 1%) standard of care tapered treatment regimen of~8x/day week 1 4x/day week 2 2x/day week 3~1x/day week 4~Visit schedule: Baseline, Day 3, Day 7, Day 14, and Day 30"
223637692|NCT00534612|PROCEDURE|aspiration biopsy|fine needle aspiration biopsy of the parotid gland masses
223637693|NCT06237725|OTHER|Nutrition of Continuous|The researcher will perform gastric residual volume (GRV) measurements with a syringe, abdominal circumference measurements, and distension assessments daily before starting enteral nutrition from the first day of initiation. They will also record vomiting/defecation frequency. Massage will be applied for 15 minutes. The same criteria will be measured and recorded. The application and measurements will be conducted twice a day for 10 consecutive days.
223637694|NCT06237725|OTHER|Nutrition of Bolus|The researcher will perform gastric residual volume (GRV) measurements with a syringe, abdominal circumference measurements, and distension assessments daily before starting enteral nutrition from the first day of initiation. They will also record vomiting/defecation frequency. Massage will be applied for 15 minutes. The same criteria will be measured and recorded. The application and measurements will be conducted twice a day for 10 consecutive days.
223637695|NCT05035537|PROCEDURE|PGDT|The minimally invasive continuous CI monitor (Edwards ClearSight) was used to guide an optimization of preload with the use of algorithms based on fluids, inotropes and/or vasopressors to achieve a certain goal in medium arterial pressure (MAP), cardiac index (CI) and stroke volume variation (SVV)
223637696|NCT01404819|DRUG|Anesthesia with Xenon|Patients undergo anesthesia with xenon (remifentanil with xenon).
223637697|NCT01404819|DRUG|Standard anesthesia|Patients undergo standard anesthesia (remifentanil with propofol)
223637698|NCT00054886|DRUG|SU-011,248|
223764996|NCT05819034|OTHER|Scoliosis-Specific Exercise Program|"Adolescents in the control group will receive a scoliosis-specific exercise program which will be prescribed to control the progression of the scoliotic curve. This exercise program will include frontal plane active or passive correction exercises for scoliotic posture. The exercise program for every participant will be three sessions per week for 12 successive weeks. Every treatment session was applied for one hour.The exercise program for every participant will be three sessions per week for 12 successive weeks. Every treatment session was applied for one hour.~The exercise program for every participant will be three sessions per week for 12 successive weeks. Every treatment session was applied for one hour."
224225871|NCT01263899|DRUG|SB1518|SB1518 taken orally daily for 28 consecutive days in a 28 day cycle.
224225872|NCT06064253|BEHAVIORAL|health education|adherence to treatment
224225873|NCT04823871|PROCEDURE|Speiser-catheter for uterine and tubal lavage|Procedure/Surgery: Lavage of the Cavum uteri and proximal Fallopian tubes, performed in the luteal phase of the female cycle
224318964|NCT00721227|PROCEDURE|Reduction Gastroplasty|"* Subjects will undergo reduction gastroplasty by gastric plication~* Subjects are followed for 12 months to evaluate outcomes and potential complications."
224225874|NCT05482984|OTHER|video-recorded role-play and guided reflection|The experimental group was divided into 6 teams. Before the course, the teacher in charge and each group developed six scenarios: restraint, suicidal intent, respiratory distress, chronic heart failure, medication refusal, and accidental amputation. The researcher guided each group to write scripts about the clinical situations (30 minutes), create role-play videos (50 minutes), and share literature that was helpful in understanding this context (30 minutes). Each student played a role in the filming process. The final film was viewed by all the students during class. Each live class session was 50 minutes in length, with one session per week for 6 weeks. All students were asked to attend six video-viewing sessions and participate in a reflective discussion.
224225875|NCT03287596|DEVICE|MRI ZTE2 sequence|feasibility of ZTE 2 sequence to quantitatively assess normal and pathological spondyloarthropathy
224225876|NCT01873079|DRUG|Esomeprazole|
224225877|NCT01873079|OTHER|Standard care|No PPI or other study medication given
224225878|NCT01653574|DRUG|Famitinib Malate|The starting dose of Famitinib Malate will be 25 mg/d. Two dose reductions will be allowed to 20 and then 15 mg/d.
224318965|NCT05528601|BEHAVIORAL|use of Endo App®|use of Endo App® smartphone application containing endometriosis relevant exercises and educational material
224225879|NCT06189261|OTHER|Holistic needs assessment based on the use of patient-reported outcome measures|During the study, two intervention consultations will take place 1 and 3 months after the initial clinical team meeting, where each participant's case will be discussed. At the start of each intervention consultation, participants will be asked to complete the intervention patient-reported outcome measure (i.e. Distress Thermometer and Problem Checklist, and Supportive Care Needs Survey-Melanoma Module). The recorded information will be passed to their nurse specialist, who will identify the participant's needs and offer tailored advice and support to meet these needs.
224225880|NCT06306495|OTHER|International Physical Activity Survey|Study data will be collected with the International Physical Activity Survey, Demographic Data Form, Sleep Hygiene Index, Distress Tolerance Scale and Pittsburgh Sleep Quality Index administered to all participants.
224225881|NCT06073795|PROCEDURE|sympathetic block|LSGBs will be performed at the lower third of the L2 or the upper third of the L3 vertebra without any premedication. The targeted lumbar vertebra will be identified with an anteroposterior (AP) fluoroscopic imaging in the FL group or with an US longitudinal tracing approach from the caudad to cephalad direction in the US group. The skin entry point will be infiltrated with 1% lidocaine. Then, a curved 21 G, 15-cm Chiba needle will be advanced toward the target using the posterolateral approach in both groups. Each patient will undergo LSGBs according to the allocated group.
224225882|NCT01531348|OTHER|BM-MSC|Bone marrow-derived mesenchymal stem cells 1 million cells in balanced salt solution 100 microlitres will be injected into the vitreous cavity.
224225883|NCT01453920|DRUG|Ranibizumab|Intravitreal Ranibizumab 0.05cc (10mg/ml)
224225884|NCT01453920|DRUG|Ranibizumab|Intravitreal Ranibizumab 0.05cc (10mg/ml)
224225885|NCT02856815|BIOLOGICAL|Immuncell-LC|Activated T lymphocyte : intravenous dripping of 200ml (1 x 10\^9 \~ 2 x 10\^10 lymphocytes / 60kg adult) for 1 hour
224225886|NCT06140511|DIAGNOSTIC_TEST|Polysomnography|Polysomnography for the assessment of the presence of REM sleep without atonia (RSWA). All Units will recruit subjects to be included in the cohort and this will ensure the inclusion of a sufficiently large sample of subjects without and, especially, with RSWA. From a previous study \[Ferri et al. Sleep 2018:zsy187\] that we carried out on a similar group of subjects, we know that we can expect to find RSWA in approximately 14% of individuals.
224225887|NCT03654261|BEHAVIORAL|Cognitive Behavioural Therapy|The intervention is a 1-day Cognitive Behavioural Therapy based workshop.
224225888|NCT02139683|DEVICE|HIFU treatment|HIFU treatment in patients with fibroadenoma
224225889|NCT02272348|OTHER|Training course to functional insulin therapy|Carbohydrate counting, carbohydrate/insulin ratio, sensitivity to insulin factor
224225890|NCT02272348|OTHER|Usual diabetes management.|
224225891|NCT02896660|DEVICE|ActiGraph Link|Subjects will be asked to wear the actigraph continuously for a 90-day period, and visit a clinician on day 30, 60, and 90 of the study for data collection.
224225892|NCT05700357|PROCEDURE|TPVB with 20 ml|The thoracic paravertebral block will be applied to the patients with 20 ml of 0.25% bupivacaine under real-time ultrasound guidance.
224225893|NCT05700357|PROCEDURE|TPVB with 25 ml|The thoracic paravertebral block will be applied to the patients with 25 ml of 0.25% bupivacaine under real-time ultrasound guidance.
224225894|NCT05700357|PROCEDURE|TPVB with 30 ml|The thoracic paravertebral block will be applied to the patients with 30 ml of 0.25% bupivacaine under real-time ultrasound guidance.
224225895|NCT03208257|DRUG|Esmolol|Esmolol hydrochloride infusion
224225896|NCT02360657|DRUG|JNJ-54861911, 10 mg|JNJ-54861911, 10 mg (2\*5 mg tablet) orally once daily for 4 weeks.
224225897|NCT02360657|DRUG|JNJ-54861911, 50 mg|JNJ-54861911, 50 mg (2\*25 mg tablet) orally once daily for 4 weeks.
224225898|NCT02360657|DRUG|Placebo|Placebo matching to JNJ-54861911 tablet orally once daily for 4 weeks.
224225899|NCT01211847|DRUG|Diazoxide Choline Controlled-Release Tablet|DCCR 290 mg once a day for 126 days
224225900|NCT01211847|DRUG|Placebo|Placebo matching DCCR
224225901|NCT03787108|OTHER|Magnetic resonance spectroscopy measurement|Magnetic resonance spectroscopy measurement will be performed to measure liver fat content.
224225902|NCT04969952|OTHER|For interventional module|Using vedio to assist physicians introducing advance care planning to cancer patients
224225903|NCT01402583|DRUG|PEG IFN/Ribavirin|PEG IFN/Ribavirin
224318966|NCT06632548|DEVICE|telescopic overdenture|two implant retained mandibular overdenture with telescopic attachment
224318967|NCT01159080|DRUG|routine dose tacrolimus and less myfortic|oral regular dose of tacrolimus + less dose of myfortic trough level of tacrolimus will be 5-10 ng/mL and oral myfortic dose will be 180-360 mg twice a day
223515312|NCT03979794|BEHAVIORAL|Behavioral Intervention for Wellness and Engaged Living (Be-WEL)|Behavioral Intervention for Wellness and Engaged Living (Be-WEL) is a 4-session (2 preoperative, 2 postoperative) telephone intervention focused on improving emotional and physical health through relaxation, behavioral activation, increased physical activity, and adherence to medication and wound care.
223515313|NCT02314247|DRUG|Selinexor|"20 mg oral tablets: 60 mg dose on Days 1 and 3 of Weeks 1-4 of each 4-week cycle (Protocol V.3.0).~20 mg oral tablets: 60 mg dose on Days 1 and 3 of Weeks 1-3 of each 4-week cycle (Protocol V.\<3.0).~Number of Cycles: up to 12 but there is no maximal duration for treatment."
223515314|NCT03983070|OTHER|Seated Rowing Ergometer|Seated rowing exercise performed at a specific percentage of maximal Watts according to pre-intervention measures
223515315|NCT03983070|OTHER|Deadlift|Deadlift exercise performed with a set of dumbbell weights at a sepcific percentage of pre-intervention one-repetition maximum.
223515316|NCT03983070|OTHER|Blood flow restriction|An occlusive cuff will be placed around each proximal thigh and inflated to 80% arterial occlusion during exercise sessions.
223515317|NCT06082544|OTHER|mini-screw implant|JEIL SCREW 1.6\* 8 MM 16-G2-008 or JEIL SCREW 1.6\*10 MM 14-G2-010
223515318|NCT06082544|DEVICE|removable partial denture|Acrylic removable partial denture
223515319|NCT02167685|DRUG|CMX001|
223515320|NCT03594656|DRUG|Ganoderma|0.8g twice daily
223515321|NCT03594656|DRUG|Placebos|0.8g twice daily
223515322|NCT03263390|PROCEDURE|Bariatric Surgery|Sleeve gastrectomy or Roux-en-Y Gastric Bypass
223515323|NCT03263390|DRUG|Anti Obesity Drugs|Response to FDA approved anti obesity medications
223637699|NCT05992883|DRUG|Ketorolac|Intervention will be an injection containing 1.0 mL of ketorolac 15 mg/mL (15 mg total of ketorolac).
223637700|NCT05992883|DRUG|Triamcinolone|Intervention will be an injection containing 0.5 mL of triamcinolone 40 mg/mL (20 mg total of triamcinolone).
223637701|NCT04865159|DRUG|Tipifarnib|Cardiac Safety of Tipifarnib
223637702|NCT02338674|DRUG|Tenofovir and telbivudine|tenofovir and telbivudine administered at least 48 weeks
223637703|NCT02338674|DRUG|Tenofovir|tenofovir administered at least 48 weeks
223637704|NCT05083234|OTHER|Moisturizing with SSO|Vital signs of newborns in the sunflower seed oil group were measured. The skin of newborns in the sunflower seed oil group was wiped without rubbing. The skin of newborns in the sunflower seed oil group was evaluated with the NSCS scale.
223637705|NCT05083234|OTHER|Moisturizing with LV|Vital signs of newborns in the liquid vaseline group were measured. The skin of newborns in the liquid vaseline group was wiped without rubbing. The skin of newborns in the liquid vaseline group was evaluated with the NSCS scale.
223637706|NCT05083234|OTHER|The control group was not moisturized.|Vital signs of newborns in the control group were measured. The skin of newborns in the control group was wiped without rubbing. The skin of newborns in the control group was evaluated with the NSCS scale.
223637707|NCT00594412|PROCEDURE|Diagnostic Radiology: 1H-MRS of the liver|
223637708|NCT01511406|BEHAVIORAL|cognitive behavioral therapy|Patients allocated to the treatment arm will receive up to 26 sessions of cognitive behavioral therapy
223637709|NCT02620774|DRUG|Ceftolozane/tazobactam|3 or more doses of ceftolozane/tazobactam intravenously administered over 60 minutes every 8 hours
223637710|NCT02620774|PROCEDURE|Microdialysis Catheter Insertion|A 20 kila-Dalton microdialysis probe (63 MD catheter; MDialysis Inc., N. Chelmsford, MA) will be inserted into the subcutaneous tissue at the margin of the wound (patient group) or in the thigh tissue (healthy volunteers). The probe will be left in place for the final dose and all tissue sampling procedures thereafter. This probe is perfused with a physiologic solution to collect interstitial fluid samples. The probe will then be removed after completion of sample collection.
223637711|NCT00474812|DRUG|dasatinib|
223637712|NCT00474812|PROCEDURE|laboratory biomarker analysis|Correlative study
223637713|NCT00474812|PROCEDURE|physiologic testing|Correlative study
223637714|NCT04426422|DRUG|Metformin Hydrochloride|treated with metformin 1500-2000mg daily
223637715|NCT03096808|RADIATION|Adaptive Radiotherapy|ART involved modification of the radiation treatment plan during treatment course to account for temporal variations in anatomy due to changes in tumor volume and/or patients' weight loss.
223637716|NCT03911167|PROCEDURE|open, laparoscopic, and robotic|Radical resection of rectal cancer in robotic, laparoscopic, and open approach
223637717|NCT03200249|RADIATION|Preoperative chemo-radiation with IG-IMRT dose escalation|
223637718|NCT03542487|BEHAVIORAL|Practice Orientation|Practices will be encouraged to batch order blood glucose flowsheets for all patients with diabetes with active MyChart accounts. This will allow diabetic patients at these practices to enter any self-monitored glucose measurements. The research team will contact physicians and practice managers with an explanation of the initiative and instructions for completing batch orders and viewing entries through the system. Additionally, providers will be given a template for a secure smart-text message to send to all patients receiving the flowsheets, instructing them to enter data for the study period. The secure message will also provide them with information on how to enter data, and on the benefits of tracking blood glucose.
223637719|NCT03542487|BEHAVIORAL|Standard Reminder|Patients receive generic biweekly reminders, addressed from Inova Medical Group, to enter glucose measurements in the electronic flowsheets
224318968|NCT01159080|DRUG|reduced dose tacrolimus and conventional myfortic|low dose of tacrolimus + maximum dose of myfortic target trough level of tacrolimus should be reduced to 2-5 ng/mL for 3 months after randomization and oral MPS dose increased to 540-720mg twice a day
223637720|NCT03542487|BEHAVIORAL|Gift Card Reminder|Patients receive generic biweekly reminders, addressed from Inova Medical Group, to enter glucose measurements in the electronic flowsheets. In these reminders, they will also be notified that that they will be entered to win a $50 gift card for each day entering data.
223637721|NCT03542487|BEHAVIORAL|Physician Reminders|Patients receive biweekly reminders, addressed from their physician, encouraging them to enter glucose measurements in the electronic flowsheets (Note that though messages will be addressed from physician, they will be sent by Inova IT)
223637722|NCT00737672|DEVICE|GORE VIABAHN Endoprosthesis with PROPATEN Bioactive Surface|Deployment of investigational stent graft at the venous anastomosis
223637723|NCT00737672|PROCEDURE|Percutaneous Transluminal Angioplasty|Percutaneous Transluminal Angioplasty at the venous anastomosis
223637724|NCT03529669|DEVICE|Cytosponge™|Cytosponge™ is a capsule-sized device which contains an expandable, spherical mesh which is attached to a string. The capsule dissolves in the stomach after swallowing, releasing the sponge which is then retrieved by gently pulling the string after five minutes. As the sponge is pulled out it collects the cells from the lining of the gullet.
223637725|NCT00296621|DRUG|L-Glutamine|L-Glutamine
223637726|NCT00296621|DRUG|placebo|placebo
223637727|NCT04165460|OTHER|Psychoeducation|Delivering systematic information about cancer, oncological treatment and efficient coping strategies.
223637728|NCT04165460|OTHER|Relaxation|Teaching the patient in diaphragmatic breathing retraining and passive relaxation with guided imagination.
223637729|NCT04165460|OTHER|Cognitive Restructuring|Teaching the patient to identify dysfunctional cognitions about cancer and oncological treatment that trigger maladaptive emotions and behavior. Then, focus in generating alternative thoughts through contrast with empirical reality based on the Beck Model.
223637730|NCT04165460|OTHER|Solving Problems|To generate alternative solutions to practical problems based on the model described by Nezu.
223637731|NCT05459181|DIAGNOSTIC_TEST|HeartCare|Using HeartCare platform as a tool to successfully augment immunosuppressant agents through regular surveillance allowing minimization of doses and number of agents.
223637732|NCT06338787|OTHER|FeSC|Iron/yeast complex
224318969|NCT02944773|PROCEDURE|Facilitated tucking device|20 newborns are using a facilitated tucking device weight during the procedure to assess the level of stress
224318970|NCT03245827|DRUG|Clomiphene|clomiphene capsule 25mg twice a week
224318971|NCT03245827|DRUG|Placebo|placebo capsule 25mg twice a week
224318972|NCT05865548|DRUG|Aspirin 150 mg|Aspirin 150 mg PO daily
223637733|NCT06685302|OTHER|US-guided PNM|The patient will be positioned in supine with approximately 20 degrees of knee flexion, supported by a cushion. The treatment area is sterilized in advance with 2% chlorhexidine, and new needles and ultrasound probe covers are used for each intervention. The femoral nerve is targeted under ultrasound guidance, just distal to the inguinal ligament, with an electrode patch placed on the patellar tendon to complete the circuit. A current of 2 Hz, 250 μs pulse width, and variable intensity is applied to reach the patient's comfortable contraction threshold without inducing pain, for a duration of 25 minutes, following the protocol established by MVClinic Institute. This intervention will be performed on the first day, at 7 days, and at 14 days, following the previously mentioned protocol.
224225904|NCT04822662|BEHAVIORAL|Epilepsy Education Programme|Firstly the Child Introduction Form and Parent Information Form were applied. Then the Child's Attitude Towards Self-Disease Scale, Seizure Self-Efficacy Scale for Children, Quality of Life Scale for Children were filled to children. Nurse-Parent Support Scale were applied to the parents in the Pretest and Post Test data.
224225905|NCT06066385|PROCEDURE|Small bites technique|Closure of the fascia after midline laparotomy using a slowly resorbalbe 2.0 suture, with 0.5 cm bites, and 0.5 cm between the stitches, at least resulting in a 1:4 wound length:suture length ratio.
223637734|NCT06685302|OTHER|US-guided PE|The patient will be positioned in supine with approximately 20º of knee flexion, supported by a cushion. Prior to the EP procedure, the treatment area will be sterilized with 2% chlorhexidine, and new needles and ultrasound probe covers will be used for each session. Three EP interventions will be performed under ultrasound guidance following the protocol developed by MVClinic Institute (2) for treating tendinopathies, using a longitudinal, long-axis view of the patellar tendon. A galvanic current of 3 mA will be applied for 3 seconds, with slight three-dimensional adjustments in needle placement after each impact to administer a total of 3 impacts on the target tissue. This intervention will be performed on the first day, at 7 days, and at 14 days, following the previously mentioned protocol.
223637735|NCT06685302|OTHER|EE|Three sets of 15 repetitions of single-leg squats on a 25º inclined plane, performed twice daily, following Young's protocol for patellar tendinopathies. The speed of execution may be increased as long as, if there is pain during the exercise, it does not exceed a 2-3 on the VAS scale.
223637736|NCT05614817|DRUG|CBP-201|CBP-201 subcutaneous(SC) injection
223637737|NCT05614817|DRUG|Placebo|subcutaneous(SC) injection
223637738|NCT00495196|PROCEDURE|Experimental lung function test|Administration of several CO2 gas mixtures
223637739|NCT03564808|DRUG|MSC|Adipose tissue enriched with mesenchymal stem cells
223637740|NCT03628768|OTHER|Data collection|telephone interview questionnaire, in-home face-to-face interview, and data from the Collection Site
223637741|NCT02250222|DRUG|LGD-6972|LGD-6972 sodium salt powder in Captisol ® (betadex \[β-cyclodextrin\] sulfobutylether sodium, NF)
224225906|NCT06066385|PROCEDURE|Conventional large bites closure|Closure of a midline laparotomy using a slowy resorbable thick suture (e.g. PDS loop) with large bites and large steps (\>= 1 cm).
224225907|NCT00470444|PROCEDURE|Transfusion with Red Blood Cells|Units of donated Red blood cells
224318973|NCT05865548|PROCEDURE|Standard of care|Surgery with or without radiation, palliative chemo as per investigators choice
224318974|NCT05615831|BEHAVIORAL|Resistance Training with Blood flow restriction|Participants will perform six weeks of blood flow restriction (60% occlusion) combined with resistance training at 30% of 1RM. The intervention comprises five exercises: incline chest press, seated row, leg press, knee extension, and knee flexion. The protocol is as follows: 30 repetitions followed by three sets of 15 repetitions for a total of four sets and 75 repetitions per exercise. There will be a one-minute recovery between sets where the cuffs remain inflated and a four-minute recovery between exercises where the cuffs will be deflated.
224318975|NCT05650840|PROCEDURE|Charcoal based whitening toothpaste (signal charcoal white& Detox toothpaste Unilever Mashreq - Egypt|"The labial surface of anterior teeth will be brushed by the circular brushing technique twice daily (morning and after 6 hours) for at least 1 minute using charcoal containing toothpaste. Soft bristles toothbrushes will provided to all patients (Oral-B). After 1 month, re-evaluation of the stains will be performed and the data will be recorded.~Intervention drug : whitening toothpaste charcoal based whitening toothpaste compared to calcium carbonate and perlite whitening toothpaste~FOR IN VITRO:~Human premolars will be obtained from volunteers due to orthodontic reasons. Teeth will be divided into two equal groups (n:18) according to the toothpaste used. Teeth will be brushed with an electric tooth brush (Oral-B PRO 500) that will be held in a holder to standardize the position to the tooth surface for 3 minutes equivalent to 2 times a day for one month. Teeth will be prepared for AFM examination"
223637742|NCT02250222|DRUG|Placebo (Captisol ®)|betadex \[β-cyclodextrin\] sulfobutylether sodium, NF
223637743|NCT00614302|DRUG|TPV|
223637744|NCT02570607|BIOLOGICAL|BNP dosage|
223637745|NCT04612504|BIOLOGICAL|SynOV1.1|SynOV1.1 will be administered intratumorally.
223637746|NCT01625299|DIETARY_SUPPLEMENT|Gluten and dry milk|0.5 g/kg/day of gluten 0.5 g/kg/day of dry milk
223637747|NCT01625299|DIETARY_SUPPLEMENT|Placebo|Rice flour 1.0 g/kg/day
223637748|NCT04123470|GENETIC|delolimogene mupadenorepvec|LOAd703 is an oncolytic adenovirus encoding TMZ-CD40L and 4-1BBL
223637749|NCT04123470|BIOLOGICAL|atezolizumab|Atezolizumab is an anti-PD-L1 antibody
224225908|NCT00470444|BIOLOGICAL|1 unit of donated red blood cells|Units of red blood cells
224225909|NCT00470444|BIOLOGICAL|1 unit of donated red blood cells|Units of donated red blood cells
223637750|NCT04029883|BEHAVIORAL|Text Message|A key insight from BE is that people typically are initially highly motivated to change their behavior, but their enthusiasm declines over time.103 To keep the importance of routinizing pill-taking salient (i.e. high on a person's mental priority list), we will send daily text messages using a freely available web platform.
223637751|NCT04029883|BEHAVIORAL|Behavior Economic Incentive|In this group, participants will be eligible for a prize drawing if they take their medication within +/- 1 hour of the time they carry out their existing routine behavior on at least 80% of days between clinic visits.
223637752|NCT04029883|BEHAVIORAL|Text Message|A key insight from BE is that people typically are initially highly motivated to change their behavior, but their enthusiasm declines over time.103 To keep the importance of routinizing pill-taking salient (i.e. high on a person's mental priority list), we will send daily text messages using a freely available web platform.
223637753|NCT06964217|DRUG|Monotherapy|"Antihypertensive medications, regardless of dose or formulation, will be classified by their pharmacologic class. A total of eight drug classes will be considered: angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), beta-blockers, dihydropyridine calcium channel blockers (DHP-CCBs), non-dihydropyridine calcium channel blockers (non-DHP-CCBs), loop diuretics, thiazide and thiazide-like diuretics, and potassium-sparing diuretics.~Exposure groups will be defined as follows:~* Monotherapy: prescription of a single antihypertensive drug class on the index date.~* Dual therapy: prescription of two ore more antihypertensive drug classes on the same index date.~To qualify for group assignment, all drugs must be initiated on the same day, and the drug of interest is limited to the class described in group/cohort.~Out of the two, this intervention will be monotherapy."
223637754|NCT06964217|DRUG|Combination therapy|"Antihypertensive medications, regardless of dose or formulation, will be classified by their pharmacologic class. A total of eight drug classes will be considered: angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), beta-blockers, dihydropyridine calcium channel blockers (DHP-CCBs), non-dihydropyridine calcium channel blockers (non-DHP-CCBs), loop diuretics, thiazide and thiazide-like diuretics, and potassium-sparing diuretics.~Exposure groups will be defined as follows:~* Monotherapy: prescription of a single antihypertensive drug class on the index date.~* Dual therapy: prescription of two or more antihypertensive drug classes on the same index date.~To qualify for group assignment, all drugs must be initiated on the same day, and the drug of interest is limited to the class described in group/cohort.~Out of the two, this intervention will be combination therapy."
223637755|NCT06419920|OTHER|Flat terrain locomotor training|The training will be comprised of up to 12 sets of 2-min continuous walking on a level treadmill or mat, interspersed with rest breaks of at least one minute. Training will be completed three times per week for four weeks.
223637756|NCT06419920|OTHER|Uneven terrain locomotor training|The training will be comprised of up to 12 sets of 2-min continuous walking on an uneven terrain treadmill or mat, interspersed with rest breaks of at least one minute. Training will be completed three times per week for four weeks.
223637757|NCT05818085|DRUG|ABP-671|Low, medium or high dose (Part 1); Selected dose(s) (Part 2)
223637758|NCT05818085|DRUG|Allopurinol|Standard of care according to American College of Rheumatology (ACR) guideline for the management of gout
223637759|NCT05818085|OTHER|Placebo|ABP-671 matching placebo
223637760|NCT04080505|DRUG|SSKI- Potassium Iodide|1g/mL, 2 drops orally 3 times a day for 7 days before surgery
223637761|NCT03175679|BIOLOGICAL|iNKT cells|The patients received different doses of in vitro-expanded autologous iNKT cells through intravenous infusion. The dosage was escalated from 3x10\^7 cells/m2 to 6x10\^7 cells/m2 to 9x10\^7 cells/m2. The maximum tolerated dose (MTD) was defined as the last dose level, and the dosage would be up to 1x10\^10 cells/m2 if no MTD was observed after a 3+3 design.
223637762|NCT03175679|DRUG|IL-2|IL-2 will be given at a dose of 25,000 IU/kg/day for 5-14 days.
223637763|NCT03175679|DRUG|Tegafur|Tegafur will be given at a dose of 40\~60 mg bis in die (BID) 2 weeks.
223637764|NCT04876521|DRUG|Amisulpride|low dose of Amisulpride at 100-300 mg/day
224225910|NCT04078139|DRUG|The MP/RP group|Miscible liquid of methylprednisolone and ropivacaine in this study will be peri-incisional scalp infiltration with 40mg methylprednisolone, 10 ml 1% ropivacaine and 10 ml normal saline miscible liquids for participants who will undergo elective craniotomy. The local infiltration solution containing will be infiltrated along the incision and throughout the entire thickness of the scalp before skin incision. The volume of local infiltration solution will be decided by surgeons according to the cut length, and the capacity of the solution will be recorded by investigator.
223637765|NCT04876521|DRUG|Olanzapine-Fluoxetine Combination|Olanzapine (5-10 mg/day) and Fluoxetine (20 mg/day)
223637766|NCT05408429|BIOLOGICAL|20-valent pneumococcal conjugate vaccine|20-valent pneumococcal conjugate vaccine
223637767|NCT05408429|BIOLOGICAL|13-valent pneumococcal conjugate vaccine|13-valent pneumococcal conjugate vaccine
223637768|NCT03327948|DEVICE|Axonics Sacral Neuromodulation System (SNM) System|Axonics Sacral Neuromodulation System (SNM) System
223637769|NCT04020809|DRUG|Atezolizumab|Anti-PD-L1 monoclonal antibody
223637770|NCT05569408|DRUG|EVUSHELD|Tixagevimab (AZD8895) and cilgavimab (AZD1061)
223637771|NCT05820581|BEHAVIORAL|Mentalisation|Hypomentalisation, hypermentalisation, correct mentalisation, lack of mentalisation
223637772|NCT06117618|OTHER|Nurse SIRS alert|An electronic alert will display when a nurse opens the patient chart of a patient who meets SIRS criteria.
223637773|NCT06117618|OTHER|Prescribing clinician SIRS alert|An electronic alert will display when a prescribing clinician opens the patient chart of a patient who meets SIRS criteria.
223637774|NCT06116045|DRUG|BZ371A 7.5 mg (1.5 ml)|7.5 mg gel
223637775|NCT06116045|DRUG|BZ371A 5.0 mg (1.0 ml)|5.0 mg gel
223637776|NCT06116045|DRUG|BZ371A 2.5 mg (0.5 ml)|2.5 mg gel
223637777|NCT06116045|DRUG|Placebo (1.5 ml)|BZ371A-matched placebo
223637778|NCT06116045|DRUG|Placebo (1.0 ml)|BZ371A-matched placebo
223637779|NCT06116045|DRUG|Placebo (0.5 ml)|BZ371A-matched placebo
223637780|NCT05972993|BIOLOGICAL|mRNA-CR-04 vaccine 10μg|mRNA CR-04 vaccine, 10 µg, is administered intramuscularly into the deltoid muscle of the non-dominant arm on day 1.
223637781|NCT05972993|BIOLOGICAL|mRNA-CR-04 vaccine 30μg|mRNA CR-04 vaccine, 30 µg, is administered intramuscularly into the deltoid muscle of the non-dominant arm on day 1.
223637782|NCT05972993|BIOLOGICAL|mRNA-CR-04 vaccine 100μg|mRNA CR-04 vaccine, 100 µg, is administered intramuscularly into the deltoid muscle of the non-dominant arm on day 1.
223637783|NCT05972993|DRUG|Placebo|Placebo is administered intramuscularly into the deltoid muscle of the non-dominant arm on day 1.
223637784|NCT05972993|BIOLOGICAL|mRNA-CR-04 vaccine 3μg|mRNA CR-04 vaccine, 3 µg, is administered intramuscularly into the deltoid muscle of the non-dominant arm on day 1.
223637785|NCT03459755|BEHAVIORAL|Physical Activity|"Patients will have a baseline assessment by undergoing a maximal exercise testing protocol.~For 12 weeks, patients will participate in an exercise session 3 days per week~The patient will then enter a 12 week Step Down program in which the number of sessions is decreased to every week, then every 3 weeks.~After the second 12-week period, the patient will enter a 28-week follow up period of unsupervised exercise."
223637786|NCT04792645|DRUG|Placebo|Pill that contains no medicine
223637787|NCT04792645|DRUG|Memantine|Cognition-enhancing medication
223637788|NCT05308537|BEHAVIORAL|Mindful Compassion Care Program|The intervention is a proven effective mindfulness programme based on well-known scientific programmes such as mindfulness-based stress reduction mindfulness-based cognitive therapy and compassion focused therapy.
223637789|NCT03380312|PROCEDURE|rTARUP technique|robot-assisted rTARUP technique
223637790|NCT06704321|DIETARY_SUPPLEMENT|TOTUM-448|16 weeks of TOTUM-448 supplementation (4.284g/day corresponding to 8 capsules per day)
223637791|NCT06704321|DIETARY_SUPPLEMENT|Placebo|16 weeks of placebo supplementation (8 capsules per day)
223637792|NCT00133484|BIOLOGICAL|Anthrax vaccine absorbed made from Bacillus anthracis (AVA)|
223637793|NCT00133484|BIOLOGICAL|Recombinant protein antigen (rPA) made from Bacillus anthrax|
223637794|NCT00133484|BIOLOGICAL|Recombinant protein antigen (rPA) made from Escherichia coli|
224225911|NCT04078139|DRUG|The RP group|Miscible liquid of ropivacaine in this study will be peri-incisional scalp infiltration with 10 ml 1% ropivacaine and 10 ml normal saline miscible liquids for participants who will undergo elective craniotomy. The local infiltration solution containing will be infiltrated along the incision and throughout the entire thickness of the scalp before skin incision. The volume of local infiltration solution will be decided by surgeons according to the cut length, and the capacity of the solution will be recorded by investigator.
224225912|NCT00634283|DRUG|venlafaxine|venlafaxine IR 150mg
224225913|NCT06541535|DRUG|Fluid resuscitation with isotonic saline only|"Isotonic saline only will be used for fluid resuscitation in the first 48 hours of treatment, according to the protocol of English guidelines:~* During the first hour of treatment:~  * In the event of systolic arterial hypotension (SAP\<90mmHg): administration of 500 mL over 15 minutes, renewable once, then administration of 1L over 1 hour.~ * In the absence of systolic arterial hypotension (SAP\>90mmHg): administration of 1L over 1 hour.~* Between 60 minutes and 8 hours of treatment :~  * 1L over 2 hours, repeated once, then 1L over 4 hours~ * Adjust fluid resuscitation according to clinical tolerance~* After the first 8 hours:~  * 1L over 4h then 1L over 6h~ * Clinical re-evaluation according to standard of care in participating centers"
223637795|NCT02512822|PROCEDURE|Noninvasive Radiofrequency TruSculpt|Heating subcutaneous fat up to 45℃ continuously at least 3 minutes without surface damage and induces adipocytes apoptosis.
223637796|NCT03818256|DRUG|Miricorilant|Miricorilant 600 mg (6 X 100 mg tablets) for once-daily oral dosing
223637797|NCT03818256|DRUG|Placebo|Placebo tablets for once-daily oral dosing
223637798|NCT00305513|PROCEDURE|The phasic alerting treatment|
223637799|NCT06655311|BIOLOGICAL|Enlicitide Chloride|Oral administration
223637800|NCT06655311|OTHER|Placebo|Oral administration
223637801|NCT06654583|BEHAVIORAL|Interactive Play Mat|Use of developed interactive play mat that utilizes haptic feedback vibrations to assist children with delayed milestones in achieving Gross Motor Skills. The play mat aims to provide a therapeutic and engaging experience by incorporating visuals, sounds, and lights to encourage movement that might otherwise be challenging for these children.
223637802|NCT06654583|BEHAVIORAL|Conventional Physical Therapy|Stretching and Strengthening exercises
223637803|NCT02873871|DEVICE|Standardized compressive dressing|Standardized compressive dressing
223637804|NCT02873871|DEVICE|Hemostasis with TerumoBand®|Hemostasis with TerumoBand®
223637805|NCT00020488|DRUG|FOLFIRI regimen|
223637806|NCT00020488|DRUG|fluorouracil|
223637807|NCT00020488|DRUG|irinotecan hydrochloride|
223637808|NCT00020488|DRUG|leucovorin calcium|
223637809|NCT06598046|DRUG|Utidelone and capecitabine|Utidelone: intravenous capecitabine: oral
223637810|NCT06603168|OTHER|Autonomic Recalibration Treatment|An initial history to r/o pathology and document a chief complaint relevant to pain is conducted. An initial head to toe assessment of withdrawal or startle reflex behavior in response to palpation is performed to identify trigger points and establish patterns of sympathetic dominance throughout the myofascial system. The pattern of sympathetic dominance (pattern of trigger point) is addressed during treatment by Primal Reflex Release Technique Protocol to inhibit somatic afferent feedback loops and rebalance the autonomic nervous system towards a state of parasympathetic dominance. The absence of a trigger point indicates that the treatment is complete.
223637811|NCT06601413|OTHER|M-TAPA Block|M-TAPA block will administer ultrasound guided (Sonosite, Inc., Bothell, WA, USA) bilaterally by same anesthesiologist (E.E.) who had more than 10 years experience of regional anesthesia, before weaking from general anesthesia after the surgical procedure. A high-frequency (6-13 MHz) linear probe (HFL38) will be used to identify the transversus abdominis, internal oblique, and external oblique muscles on the costochondral angle in the sagittal plane at the 10th costal margin. In the midclavicular line, between the upper fascia of the transversus abdominis muscle and the lower fascia of the costochondral tissue, at the level of the 10th rib, 20 mL of 0.25 percent bupivacaine will be injected (arcus costarum). The same procedure will be followed on the other side.
224225914|NCT06541535|DRUG|Fluid resuscitation with Ringer Lactate|"Ringer Lactate only will be used for fluid resuscitation in the first 48 hours of treatment, according to the protocol of English guidelines:~* During the first hour of treatment:~  * In the event of systolic arterial hypotension (SAP\<90mmHg): administration of 500 mL over 15 minutes, renewable once, then administration of 1L over 1 hour.~ * In the absence of systolic arterial hypotension (SAP\>90mmHg): administration of 1L over 1 hour.~* Between 60 minutes and 8 hours of treatment :~  * 1L over 2 hours, repeated once, then 1L over 4 hours~ * Adjust fluid resuscitation according to clinical tolerance~* After the first 8 hours:~  * 1L over 4h then 1L over 6h~ * Clinical re-evaluation according to standard of care in participating centers"
223637812|NCT06601413|OTHER|Trocar site local anesthetic infiltration|At the end of surgery, infiltration analgesia will be applied to all trocar entry sites (4 port entries) by the surgeon with 10 ml of 0.25% bupivacaine (40 mL in total) without waking the patient.
223637813|NCT06596850|BEHAVIORAL|Wheelchair Skills Training Program|Participants will receive 5, 45-minute weekly WC skills training sessions that will take place in the community, in and around the participants home. Each session will be customized to the participant's' goals and based on the learner's impairments (i.e., weakness, spasticity, movement disorders \[e.g. ataxia, tremor\], contractures, cognition). The WSTP sessions will begin with a 5-minute review of goals/progress, followed by a 10-minute warm-up (wheeling activities, random practice of previously leaned skills); 20 minutes of attempting new skills (training on each skill will be carried to next session until the skills are learned or until the trainer and participant mutually agree that training should be abandoned; the trainer will periodically ask the participant to practice newly learned skills to incorporate variability of practice); 10 minute cool-down, during which the participant will practice skills in a self-controlled environment.
223637814|NCT06603272|DEVICE|The da Vinci robotic system (Intuitive Surgical, Inc., Sunnyvale, CA, USA) was used for all robotic gastrectomy|"Surgical intervention was initiated after obtaining informed consent from all patients, which included the additional costs of robotic surgery, a comprehensive explanation of surgical risks, and potential alternative treatments, thus facilitating informed surgical approach choices (i.e., LG or RG) within the participating institutions. Adherence to the Japanese Gastric Cancer Treatment Guidelines was maintained for determining the extent of gastrectomy and lymphadenectomy."
223637815|NCT06591442|DIAGNOSTIC_TEST|This is an observational study|This study divides the elderly population into two groups: the Elderly group and the Advanced age group. By observing the enhanced recovery after spinal fusion surgery in these two distinct age groups of elderly patients, risk factors affecting postoperative enhanced recovery will be identified. Detection index: Blood routine examination, blood biochemistry, coagulation function, imaging examination (X-ray, CT 3D reconstruction), Japanese Orthopaedic Association (JOA) score, visual analogue scale (VAS) pain score. The number of participants for all adverse events, serious adverse events, implant-related adverse events and drug-related serious adverse events, and the adverse events were summarized accordingly. The severity of adverse events will be rated according to NCI-CTCAE version 4.0.
223637816|NCT06600451|OTHER|observational study, no intervention is required|"Retrospective chart review, investigators provides data after reviewing patient\&#39;s existing medical record; no interaction with patients is required.~Patients were treated as per standard of care"
223637817|NCT06586424|DIAGNOSTIC_TEST|Anion gap|Patient was taken blood examination before PPCI
223637818|NCT06603142|DRUG|Febuxostat 20MG Tablets|Febuxostat 20MG Tablets
223637819|NCT06603142|DRUG|Febuxostat 20MG Placebo|Febuxostat 20MG Placebo
223637820|NCT06603142|DRUG|AR882 25MG|AR882 25 MG Capsules
223637821|NCT06603142|DRUG|AR882 12.5MG|AR882 12.5 MG Capsules
223637822|NCT06603142|DRUG|AR882 25MG Placebo|AR882 25MG Placebo
223637823|NCT06603142|DRUG|AR882 12.5MG Placebo|AR882 12.5MG Placebo
223637824|NCT06603142|DRUG|Febuxostat 40MG Tablets|Febuxostat 40MG Tablets
223637825|NCT06603142|DRUG|Febuxostat 40MG Placebo|Febuxostat 40MG Placebo
223637826|NCT06586099|DRUG|Aza, tislelizumab|combination chemotherapy for the refractory/relapsed AML
223637827|NCT05902260|DIETARY_SUPPLEMENT|Nutritional intervention|Subjects should consume two 200 mL bottles of study product per day next to their cancer treatment (immunotherapy)
223637828|NCT05902260|DRUG|Immunotherapy|Pembrolizumab monotherapy with or without combination chemotherapy according to standard of care
223637829|NCT06591390|DRUG|Ticagrelor 90 MG|The ticagrelor arm will receive (a 180mg loading dose of cilostazol during the first 24 hours of stroke onset, followed by 90mg once daily from the 2nd day to the 90th day) and an open-label loading 300 mg aspirin, followed by a maintenance dose of 75 mg aspirin
223637830|NCT06591390|DRUG|Cilostazol 100 MG|The cilostazol arm will receive (a 200 mg loading dose of clopidogrel during the first 24 hours of stroke onset, followed by 100 mg twice daily from the 2nd day to the 90th day) and open-label loading 300 mg aspirin, followed by a maintenance dose of 75 mg aspirin.
223637831|NCT06586294|DRUG|Drug: AK129 Drug：oxaliplatin Drug：capecitabine|AK129 is administered intravenously according to the frequency every three weeks(Q3W) and different dosage of administration at different stages.Oxaliplatin is administered intravenously according to the frequency and dosage 130 mg/m2 on day 1 Q3W.Capecitabine is administered intravenously according to the frequency and dosage 1000 mg/m2 oral twice daily on day 1 to 14 Q3W.
223637832|NCT06586294|DRUG|Drug: AK129 Drug：cadonilimab Drug：oxaliplatin Drug：capecitabine|AK129 is administered intravenously according to the frequency Q3W and different dosage of administration at different stages. Cadonilimab is administered intravenously according to the frequency and dosage 10mg/kg Q3W.Oxaliplatin is administered intravenously according to the frequency and dosage 130 mg/m2 on day 1 Q3W.Capecitabine is administered intravenously according to the frequency and dosage 1000 mg/m2 oral twice daily on day 1 to 14 Q3W.
223637833|NCT06595394|OTHER|Exercise|Participants in the experimental group will receive treatment for 8 weeks, 3 sessions per week. Each treatment session will be planned to last 60 minutes. People in the experimental group will receive a combined exercise training consisting of aerobic exercise, balance exercise and strengthening exercises for 8 weeks.
224225915|NCT02995837|OTHER|Sleep Study|Overnight, video-recorded sleep study will be performed in a dedicated pediatric sleep lab. Sleep architecture, apneas and hypopneas, arterial oxygen saturation and end-tidal carbon dioxide tension will be evaluated during the sleep study. Safety measures including arterial oxygen saturation using pulse oximetry, EEG and EKG will be continuously monitored during the study.
223637834|NCT06595394|OTHER|Home program|The control group will be followed with a home program for 8 weeks. Patients will be asked to apply the home program, which includes traditional physiotherapy practices, 3 days a week and this will be followed by physiotherapists.
223637835|NCT06593002|BEHAVIORAL|Therapeutic play|The children in the experimental group were given a therapeutic toy designed for them by the student nurse half an hour before the treatment, the toy and game were introduced, and they were allowed to play with this toy for half an hour, accompanied by the student nurse.
223637836|NCT06592339|DRUG|MK-0616|oral administration
224225916|NCT02995837|OTHER|Neurocognitive Testing|Cognitive and behavioral measures including intelligence, attention, working memory, and processing speed will be assessed by a trained psychologist.
223637837|NCT06587152|PROCEDURE|Robot-assisted surgery|Surgery with the Cornerstone Surgical Robot.
223637838|NCT06593899|RADIATION|Hypofractionated Radiotherapy|Hypofractionated radiotherapy Preoperative hypofractionated 5x5 Gy radiotherapy (5 consecutive days) prescribed on planned target volume
223637839|NCT06593899|DRUG|3 cycles of AI|Three courses of doxorubicin and ifosfamide (AI, doxorubicin 75 mg/sqm and ifosfamide 10 g/sqm with prophylactic mesna)
223637840|NCT06655584|DEVICE|Virtual reality headset Bliss DTX|The patient will be installed in a reception room and will benefit from Bliss DTx digital therapy via a video headset and an audio headset for a duration of 13 minutes
223637841|NCT00911170|DRUG|Pegfilgrastim|Administered as a single 6 mg subcutaneous injection using a pre-filled syringe. There will be no dosage adjustments for investigational product.
223637842|NCT00911170|DRUG|Placebo|Administered as a single subcutaneous injection using a pre-filled syringe.
223637843|NCT00911170|BIOLOGICAL|Bevacizumab|5 mg/kg by intravenous (IV) infusion on day 1 of each 14-day cycle.
223637844|NCT00911170|DRUG|Standard Chemotherapy|"Each participant received one of the following chemotherapy regimens at the discretion of treating physician:~FOLFOX: Oxaliplatin, leucovorin, and 5-fluorouracil; FOLFIRI: Irinotecan, leucovorin and 5-flurouracil."
223637845|NCT06986811|PROCEDURE|Standard surgery|The location and size of the tumor determine the type of surgery.
223637846|NCT06986811|DRUG|CEB-01|It is novel formulation for local release of chemotherapy. It consists of a biocompatible and biodegradable nanofiber membrane made of poly(lactic-co-glycolic acid) (PLGA), which is loaded with the anti-tumor drug SN-38 and implanted in the surgical bed after tumor removal.
223637847|NCT06857695|DRUG|AZD5004 film-coated tablet|oral, fasted
223637848|NCT06857695|DRUG|[14C]AZD5004 Solution for Infusion|intravenous, fasted
223637849|NCT06857695|DRUG|[14C]AZD5004 Oral Solution|oral, fasted
223637850|NCT06665789|BEHAVIORAL|Mindfulness-based Stress Reduction|An 8-week Mindfulness-based stress reduction training programme
223637851|NCT04662255|DRUG|Pirtobrutinib|Oral
223637852|NCT04662255|DRUG|Ibrutinib|Oral
223637853|NCT04662255|DRUG|Acalabrutinib|Oral
223764997|NCT05819034|OTHER|Soft orthoses with external strapping.|Adolescents in the experimental group will receive a scoliosis-specific exercises program which will be prescribed to control the progression of the scoliotic curve in addition to wearing the soft orthoses with external strapping. The wearing schedule of the soft orthosis with the external strapping for every participant in this group will be 12 hours daily for 12 successive weeks.
224323240|NCT03099850|OTHER|Data Management and Monitoring|"The Coordinating and Data Management Center (CDMC) at MD Anderson Cancer Center responsible for monitoring protocol and regulatory compliance for consortium. CDMC responsible for maintaining and tracking IRB approval and regulatory documents from each site throughout the life of the study.~* Study participants will complete questionnaires at baseline and during yearly follow-up. In the event a participant does not complete all or part of the patient or coordinator questionnaire, the study coordinator will complete questions via medical record review (e.g., demographics and family history) or via a telephone interview.~* Biospecimen collection: blood, urine, saliva, stool. Biospecimens will be collected and processed in accordance with the CPDPC specimen collection procedures.~* EUS or EGD with pancreatic fluid collection~* imaging studies performed at baseline and at follow-up.~  * IV contrast-enhanced MRI and MRCP with secretin~ * IV contrast-enhanced CT Scan abdomen"
223637854|NCT04662255|DRUG|Zanubrutinib|Oral
223637855|NCT06587594|BEHAVIORAL|Solution Focused Brief Therapy|A behavioral health intervention designed to help autistic adults to make a positive change in their life using strength-based approach.
223637856|NCT06591520|DRUG|AK112, Gemcitabine, Cisplatin|AK112 will be administered at a selected dose intravenously (IV) every three weeks (Q3W). Gemcitabine will be administered at 1000 mg/m2, D1, D8, Q3W, intravenously (IV) for 8 cycles. Cisplatin will be administered at 25 mg/m2, D1, D8, Q3W, intravenously (IV) for 8 cycles.
223637857|NCT06591520|DRUG|Durvalumab, Gemcitabine, Cisplatin|Durvalumab will be administered at 1500mg intravenously (IV) every three weeks (Q3W) for 8 cycles and followed by monotherapy every 4 weeks. Gemcitabine will be administered at 1000 mg/m2, D1, D8, Q3W, intravenously (IV) for 8 cycles. Cisplatin will be administered at 25 mg/m2, D1, D8, Q3W, intravenously (IV) for 8 cycles.
223637858|NCT06591962|OTHER|Questionnaire application for diabetes mellitus|Scales will be applied to individuals diagnosed with diabetes mellitus
223637859|NCT06591962|OTHER|Questionnaire application for without diabetes mellitus|Scales will be applied to individuals diagnosed without diabetes mellitus
223637860|NCT06602531|BIOLOGICAL|ARCT-2304|Each participant will receive 2-dose regimen intramuscular (IM) dose into the deltoid muscle.
223637861|NCT06602531|BIOLOGICAL|Control vaccine younger adults|Each participant will receive one intramuscular (IM) dose into the deltoid muscle.
223637862|NCT06602531|BIOLOGICAL|Control vaccine older adults|Each participant will receive one intramuscular (IM) dose into the deltoid muscle.
223637863|NCT06602531|OTHER|Placebo Vaccine|Each participant will receive one intramuscular (IM) dose into the deltoid muscle.
223637864|NCT06592365|DIETARY_SUPPLEMENT|GTE|oral administration of GTE tablets once daily for 12 weeks
223637865|NCT06592365|DIETARY_SUPPLEMENT|Placebo|oral administration of placebo tablets once daily for 12 weeks
223637866|NCT06596863|DIAGNOSTIC_TEST|The association of serum uromodulin with DN|Meta analysis of association of serum uromodulin with DKD
223764998|NCT02448875|DEVICE|CyPass Micro-Stent|Small tube with a through-lumen designed to redirect aqueous fluid from the front to the back of the eye in order to reduce intraocular pressure. Designed to be permanently implanted in the eye.
223637867|NCT06596863|DIAGNOSTIC_TEST|The DN patients were divided according to the level of albumin to creatinine ratio (ACR), glomerular filtration rate (GFR), or albumin excretion rate (AER) in patients with DN|DN patients were divided according to the level of albumin to creatinine ratio (ACR), glomerular filtration rate (GFR), or albumin excretion rate (AER) in patients with DN
223764999|NCT02448875|DEVICE|Viscoelastic|Healon 5 ophthalmic viscoelastic used to increase the size of the aqueous drainage area created by the CyPass Micro-Stent
223765000|NCT05037565|DIETARY_SUPPLEMENT|Partially hydrolyzed guar gum|Partially hydrolyzed guar gum (PHGG) is a vegetal, water soluble, non-viscous, non-gelling dietary fiber that is derived from guar gum, a water-soluble, viscous, gelling polysaccharide found in the seeds of Cyamopsis tetragonolobus. PHGG is available over the counter as a dietary supplement as fiber.
224225917|NCT02995837|OTHER|CBF During Wakefulness|Cerebral blood flow (CBF) will be measure using Diffuse optical and correlation spectroscopy (DOS/DCS), a non-significant risk device used to collect data for this study but not being tested as part of the protocol. Light sources and detectors which are embedded in a rubber pad will be attached to the subject's head in order to record right and left hemispheric cerebral blood flow, total hemoglobin concentration and tissue oxygen saturation. Measurements will be continuously recorded during the study and averaged for purposes of statistical analysis. With DOS/DCS in place, ventilatory response to hypercapnia will be determined using the rebreathing technique, a standard clinical test. While CBF is being measured, subjects will wear nose clips and sit comfortably breathing through a mouthpiece while the level of carbon dioxide is adjusted over a 3-4 minute period. Oxygen and carbon dioxide levels will be carefully monitored throughout the testing.
224225918|NCT02995837|OTHER|CBF During Sleep|This is the same as the CBF testing during wakefulness/daytime except that it will be done during a sleep study performed with a continuous positive airway pressure (CPAP) mask not nose clips and a mouthpiece. With DOS/DCS in place, ventilatory response to hypercapnia will be determined using the rebreathing technique. While CBF is being measured, OSAS subjects will receive an individualized positive pressure aimed at treating obstructive sleep apnea and controls will receive a standard pressure. End-tidal carbon dioxide will be measured via a port in the mask. A constant flow of carbon dioxide will be introduced to the circuit, a slowly adjusted until the patient arouses or for a maximum of 3 minutes, whichever occurs first. One trial will be attempted in each sleep stage (slow-wave sleep and rapid-eye-movement) with a minimum of 15 minute of breathing room air between challenges. Oxygen and carbon dioxide levels will be carefully monitored throughout the testing.
224225919|NCT02002247|DRUG|sodium selenite|All subjects will receive an IV bolus of 2000µg selenium within 30min after induction of anesthesia via the central venous catheter. After termination of surgery, immediately after admission to the ICU, all patients will receive a second bolus of 2000µg selenium. Then on every further morning during ICU-stay, patients will receive an IV bolus of 1000µg selenium via central or peripheral venous access until death, discharge from ICU to the ward, or for a maximum of 10 days.
223515324|NCT04695626|PROCEDURE|The combination of bone marrow stimulation and modified suture bridge(Greenhouse tec)|According to the anteroposterior diameter of the injury, single or double high braided thread were used to suture the tendon in a modified Mason Allen way without knotting. Bone marrow stimulation was carried out in the footprint area of rotator cuff. A 2.0 mm diameter cone was created with a depth of 1 cm and a spacing of 5 mm. Six to eight holes were made due to the diameter of the tear of rotator cuff until blood and fat droplets exudate. Then the threads were passed through the locking eyelet of the lateral row anchor. After tightening the threads, the anchor was screwed in at the distal part of the gteater tuberosity. With this new technique, the rotator cuff was repaired by one lateral row anchor without medial row knotting.
223515325|NCT02615496|BEHAVIORAL|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|Survey to measure physician awareness and understanding of the key messages in the educational materials: the prescriber guide and video.
223515326|NCT02615496|BEHAVIORAL|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|"Survey to measure patient awareness and understanding of the key messages in the educational materials: the patient booklet Your guide to EYLEA, patient information leaflet, and audio CD."
223515327|NCT03156452|DRUG|Mycophenolate Mofetil|500 mg and 250mg tablets for oral administration
223515328|NCT03156452|DRUG|Prednisolone|5mg tablets for oral administration
223515329|NCT02965976|BIOLOGICAL|Botulinum Toxin Type A|Given IM
223515330|NCT02965976|PROCEDURE|Esophagectomy|Undergo esophagectomy
223515331|NCT02965976|OTHER|Quality-of-Life Assessment|Ancillary studies
223515332|NCT02917538|PROCEDURE|RFA|Both groups will receive radiofrequency ablation treatment
223515333|NCT04420182|OTHER|Virtual Care at Home|Participants will have access to the VIRTUES platform for COVID-19 Virtual Care at Home
223515334|NCT02452593|OTHER|"Tibial stimulation and pelvic floor exercises"|A group will make tibial nerve stimulation and the other will make pelvic floor training. After 8 weeks the patients exchanges their therapeutic approaches for over 8 weeks
223515335|NCT01687595|DRUG|HerpV and QS-21|HerpV (recombinant human heat shock protein 70 \[rh-Hsc70\] polyvalent peptide complex) in combination with adjuvant QS-21
223515336|NCT01687595|DRUG|Placebo|phosphate buffered saline
223515337|NCT00653705|OTHER|Yogurt drink with probiotic bacteria BB12|Probiotic yogurt dairy drink with Bifidobacterium Lactis and prebiotics. One bottle a day for 16 weeks.
223515338|NCT00653705|OTHER|Placebo|Vanilla flavored dairy drink. One bottle a day for 16 weeks.
223515339|NCT01899378|DIETARY_SUPPLEMENT|Lactobacillus reuteri DSM 17938|10\^8 CFU
223515340|NCT01899378|DIETARY_SUPPLEMENT|Bifidobacterium longum infantis|10\^9 CFU
223515341|NCT03374332|DRUG|Gemtuzumab Ozogamicin (GO)|Patients will be given gemtuzumab ozogamicin on days 1,4, and 7. Capped at 4.5mg individual doses. Total doses capped at 13.5mg.
223515342|NCT03374332|OTHER|Donor Leukocytes|The product will be administered unprocessed on day 8/24 hours post GO (same day as leukapheresis) with a minimum of CD3+ cells and maximum of CD3+ cells/kg irrespective of the number of CD34+ cells.
223515343|NCT01307618|BIOLOGICAL|NA17.A2 Peptide Vaccine|Given SC or ID
223515344|NCT01307618|BIOLOGICAL|Recombinant MAGE-3.1 Antigen|Given SC or ID
223515345|NCT01307618|BIOLOGICAL|Recombinant Interleukin-12|Given SC or ID
223515346|NCT01307618|BIOLOGICAL|MART-1 Antigen|Given SC or ID
223515347|NCT01307618|OTHER|Laboratory Biomarker Analysis|Correlative studies
223515348|NCT06300905|DRUG|test product|toothpaste containing 0.45% stannous fluoride
223637868|NCT06591663|BEHAVIORAL|Cognitive Therapy Rating Scale (CTRS)|"CBT is the Cognitive Therapy Rating Scale (CTRS), an important assessment tool designed to assess the quality and effectiveness of cognitive therapy sessions.~Mental health professionals, such as therapists and psychologists, commonly use the CTRS to evaluate various aspects of a therapy session. This includes the extent to which the therapist adheres to CBT principles, their skill in applying cognitive and behavioral techniques, their ability to develop a therapeutic relationship with the client, and the overall quality of the session. The scale may also include specific criteria or items that another trained therapist or researcher observes based on their observations during the therapy session (Pingol, 2023)."
223637869|NCT06590948|DIAGNOSTIC_TEST|contrast-enhanced ultrasound|contrast-enhanced ultrasound with SonoVue and quantitative analysis of liver imaging reporting and data system
223637870|NCT06601725|DIAGNOSTIC_TEST|Clusterin level|Clusterin plays a role in inflammation and oxidative stress processes such as metabolic syndrome, insulin resistance, and atherosclerosis
223637871|NCT06587022|RADIATION|Target volume delineation|Group 1(small target delineation)：The target bolume only includes local tumor. Group 2(small target delineation)：The target bolume includes local tumor and adjacent vertebral area.
223637872|NCT06599307|DRUG|Rituximab|Rituximab 1gm vial diluted on 500 ml normal saline 0.9%
223637873|NCT06599307|OTHER|Saline (NaCl 0,9 %) (placebo)|500 ml of normal saline 0.9%
223637874|NCT06600113|OTHER|Education and teaching of coping strategies|the intervention consists of patient education for children, the same content delivered through either an educational game and storytelling
223637875|NCT06587178|DIETARY_SUPPLEMENT|peptison liquid|CD patients requiring bowel resection and preoperative EEN were randomized to receive peptison liquid for 6 weeks.
223637876|NCT06587178|DIETARY_SUPPLEMENT|Enteral nutritional suspension|CD patients requiring bowel resection and preoperative EEN were randomized to receive enteral nutritional suspension for 6 weeks.
223637877|NCT06601205|DRUG|Flutamide|1 tablet daily until the day before surgery
223637878|NCT06601205|DRUG|Finasteride|1 tablet daily until the day before surgery
223637879|NCT06601205|OTHER|Placebo|1 tablet daily until the day before surgery
223637880|NCT06588998|DEVICE|Xengenic Cortical membranes|soft tissue surgery around dental implant dehiscence
223637881|NCT06588998|PROCEDURE|connective tissue graft|soft tissue surgery around dental implant dehiscence
223637882|NCT06596746|OTHER|Observation|In MARKERS-NDD up to 600 participants will be enrolled and followed longitudinally once identified, over the course of 1-10 years
223637883|NCT06588062|OTHER|Picture Exchange Communication System (PECS)|Picture exchange communication System (PECS) is a widely useful tool for developing skills in ASD children. Visual supports rather work better for their intellectual level as these children usually respond less to verbal and written instructions. PECS is considered as an augmentative communication system commonly used with non-verbal ASD children. It is helpful for an individual with ASD to quickly acquire a functional means of communication. This is highly beneficial for the child to communicate with his parents and caregivers, as well as with their peers. Moreover, the pictorial approach of PECS is a source of facilitating element in attaining student's concentration. The reason for wide acceptance of this tool in clinical and social settings for children with ASD is its' ease of use, ability to teach two-way communication and inexpensiveness. PECS has demonstrated successful use in teaching various skills in ASD affected children lacking speech.
223637884|NCT06599346|OTHER|Standard Care|Participants in this arm will receive standard care for mucosal injuries, which may include oral rinses, topical treatments, and supportive care based on the type of injury.
223637885|NCT06599346|BIOLOGICAL|MSC Supernatant + Standard Care|"Participants in this arm will receive MSC supernatant in addition to standard care. MSC supernatant will be administered as follows:~15 mL for oral mucosal injuries (mouthwash) Topical application for skin mucosal injuries (based on body surface area) 50 mL for bladder injuries (bladder irrigation)"
223637886|NCT06601244|OTHER|Pharmacokinetic|Biliary and blood concentration of the DALBAVANCINE
223637887|NCT06586476|BEHAVIORAL|Nightly Timed Awakening|Patients in this arm will be awakened 1-hr after going to bed by their caregiver(s) to use the restroom and then returned to sleep. This awakening will occur every night.
223637888|NCT06601920|BEHAVIORAL|Forest healing activities|The two-hour forest healing activity, led by horticultural therapists from the Taiwan Horticultural Therapy Association, includes activities such as leaf stacking on stones, listening to sounds with closed eyes, body stretching, blindfolded tree identification, \&#34;my tree friend,\&#34; earth mandala creation, tea tasting, and sharing of reflections.
223637889|NCT06593925|DEVICE|Production of polyoxymethylene telescopic denture|Remaining teeth will be prepared by conventional grinding technique, followed by impression, casting and scanning with extra oral scanner. Inner telescopic crowns will be made of cobalt-chromium alloy by milling technique and outer crowns together with denture framework will be made of polyoxymethylene by the method of single phase injection moulding. Denture delivery is done by inserting both inner and outer crown at the same time, during which the inner crown is cemented to the abutment tooth and the contact surfaces of the outer and inner crown are isolated so that the outer crown and denture framework can be removed.
223637890|NCT06593925|DEVICE|Production of conventional complex partial denture with clasps|A conventional complex partial denture is a removable partial denture with clasps combined with metal-ceramic surveyed crowns with milled surfaces for removable dentures. The metal-ceramic surveyed crowns are shaped in such a way that they build a morphological and functional whole with complementary elements of the removable partial denture's framework. In the control group, as well as in the experimental group, the remaining teeth are prepared using a conventional grinding technique, then an impression is taken for dedicated metal-ceramic crowns, casting, and milling of crowns, ceramic sintering, impression through the metal-ceramic surveyed crowns and fabrication of a removable partial denture's framework with clasps using the casting method. Dedicated fixed restorations will be made of Co-Cr alloy inside the crown and ceramic layer on the surface, and the framework and clasps of the removable partial denture will be made of Co-Cr-Mo alloy.
223765001|NCT04989946|DRUG|Degarelix|standard Gonadotropin-releasing hormone (GnRH) antagonist
223765002|NCT04989946|BIOLOGICAL|pTVG-AR|DNA vaccine encoding androgen receptor ligand-binding domain
223765003|NCT04989946|DRUG|Nivolumab|Nivolumab is a human programmed death receptor-1 (PD-1)-blocking antibody indicated for the treatment of patients with multiple different types of cancer.
223765004|NCT04989946|DRUG|Cemiplimab|Cemiplimab is a human PD-1 blocking antibody approved for the treatment of patients with non-small cell lung cancer, cutaneous squamous cell carcinoma, and locally advanced basal cell carcinoma.
223765005|NCT04989946|DRUG|Fianlimab|Lymphocyte activation gene-3 (LAG-3) is a protein that is upregulated on activated CD4+ and CD8+ T cells following T-cell receptor engagement. Binding of LAG-3 to MHC II on professional antigen-presenting cells suppresses the proliferation, activation, and cytokine secretion of T cells. Fianlimab is a human IgG4 antibody to lymphocyte activation gene-3 (LAG-3) that blocks LAG-3/MHC II-mediated T-cell inhibition.
224225920|NCT02002247|DRUG|Placebo|All patients will receive an IV bolus of normal saline (equals to 40ml prepared solution) within 30min after induction of anesthesia via the central venous catheter. After termination of surgery, immediately after admission to the ICU, all patients will receive a second bolus of normal saline accordingly. Then on every further morning during ICU-stay, patients will receive an IV bolus of normal saline via central or peripheral venous access until death, discharge from ICU to the ward (treatment may continue in a step down or intermediate care unit), or for a maximum of 10 days.
224318976|NCT05650840|PROCEDURE|Calcium carbonate /perlite containing whitening toothpaste (signal whitening moonlight toothpaste Unilever Mashreq - Egypt).|"The labial surface of anterior teeth will be brushed by the circular brushing technique twice daily (morning and after 6hours) for at least 1 minute using calcium carbonate /perlite containing toothpaste. Soft bristles toothbrushes will provided to all patients (Oral-B). After 1 month, re-evaluation of the stains will be performed and the data will be recorded. The main operator will perform the tooth brushing procedures for all the patients himself twice daily.~FOR IN VITRO:~Human premolars will be obtained from volunteers due to orthodontic reasons. Teeth will be divided into two equal groups (n:18) according to the toothpaste used. Teeth will be brushed with an electric tooth brush(Oral-B PRO 500) that will be held in a holder to standardize the position to the tooth surface for 3 minutes equivalent to 2 times a day for one month. Teeth will be prepared for AFM examination Device used is atomic force microscopy to determine enamel abrasion after brushing"
224318977|NCT03928067|BEHAVIORAL|PNF + SAF|Personalized normative feedback (PNF) to correct misperceived peer drinking norms abroad + sojourner adjustment feedback (SAF) to promote cultural engagement abroad.
223515349|NCT06300905|DRUG|Control product|toothpaste containing 0.76% sodium monofluorophosphate
223515350|NCT02858661|OTHER|Nasopharyngeal swab|
224225921|NCT02657720|DEVICE|Radical 7|Comparison between 3 different monitors that measure respiratory rate. The participant is connected to 3 monitors at the same time. Radical 7 measures respiratory rate according to acoustic respiratory rate (RRa).
223515351|NCT05919212|DIAGNOSTIC_TEST|HER2-D is the use of a non-invasive liquid biopsy method to non-invasively and objectively assess HER2 status at recruitment|We study the circulating changes associated with resistance to T-DXd, including changes in HER2 status,studied through a new approach called HER2-2D that simultaneously assesses HER2 amplification and overexpression in blood
223515352|NCT00489359|DRUG|Pemetrexed - Phase 1|500, 600, 700, 800, or 900 milligrams per square meter (mg/m\^2), administered intravenously (IV), every 21 days x 6 cycles, dose escalate to Maximum Tolerated Dose (MTD)
223515353|NCT00489359|DRUG|Carboplatin - Phase 1|area under the concentration time curve (AUC) 5 or 6 mg/mL\*min, administered intravenously (IV), every 21 days x 6 cycles, dose escalation to Maximum Tolerated Dose (MTD)
223637891|NCT06586463|OTHER|kinitic control training|"kinetic control training, Correction of Low cervical flexion UCM Initially, position the lower and upper cervical spine in neutral with the head supported. the person is trained to perform independent upper cervical flexion (nodding). The upper cervical spine can flex only so far as there is no low cervical flexion. As the ability to control upper cervical extension gets easier and the pattern of dissociation feels less unnatural the exercise can be progressed.~Correction of scapula and glenohumeral ( UCM) the arm flexion is performed unsupported through the partial range that can be controlled well. This is eventually progressed throughout the full benchmark range with the elbow straight. With visual, auditory and kinaesthetic cues the person becomes familiar with the task of flexing the glenohumeral joint to 90° without scapula movement or glenohumeral translation."
223637892|NCT06596564|BEHAVIORAL|choice architecture|Display the sugar content of the drink on the platform.
223637893|NCT06596564|BEHAVIORAL|choice architecture|Showing the various harms that can come from long-term excessive consumption of sugary beverages on the platform.
223637894|NCT06596564|BEHAVIORAL|choice architecture|The platform shows the information that the majority of their peers have chosen mineral water.
223637895|NCT06594952|OTHER|Questionnaire and Physical Exam|"Diagnosis of Anxiety using the state-trait anxiety inventory scale (STAI). Depression using Edinburgh Postnatal Depression Scale (EPDS)~* Coping using the Brief Coping Scale~* Socioeconomic using the Socioeconomic Scale of Egypt~* Personality using the short-form Eysenck Personality Questionnaire-Revised (EPQ-R)~* Behaviour using Impact of Erect Scale (IES-22)"
223637896|NCT06593015|DIAGNOSTIC_TEST|Radiological tool for the diagnosis of myosteatosis|Calculation of muscle attenuation at L3 CT scan for each patients and evaluation of the relationship between muscle attenuation values and survival
223637897|NCT06593015|DIAGNOSTIC_TEST|Radiological tool for the diagnosis of myosteatosis|Calculation of muscle attenuation at L3/L4 CT scan for each patients and evaluation of the relationship between muscle attenuation values and survival
223637898|NCT06590753|DEVICE|osseodensification bur|osseodensification bur
223765006|NCT04989946|DRUG|FLT PET/CT|Arms 1-3 only, FLT PET/CT scan at baseline (within 1-6 days of Day 1) and Day 43
224225922|NCT02657720|DEVICE|Capnostream20p|Comparison between 3 different monitors that measure respiratory rate. The participant is connected to 3 monitors at the same time. Capnostream20p measures respiratory rate using capnography (RRetCO2).
223515354|NCT00489359|DRUG|Pemetrexed - Phase 2|Dose determined from Phase 1: 500 mg/m\^2, administered IV, every 21 days x 6 cycles
223515355|NCT00489359|DRUG|Carboplatin - Phase 2|Dose determined from Phase 1: AUC 6 mg/mL\*min, administered IV, every 21 days x 6 cycles
223637899|NCT06592651|BEHAVIORAL|Play Therapy Workshop|"4 session group intervention foucused on psycho-educational knowledge regarding tools for effective emotional coping with stressful events in the context of the Iron Swords war, focusing on building mental resilience in the parent-child dyad through play therapy. Each group consists of 5 parent-child dyads with children aged 3-6 years, who have been evacuated from war zones in the northern and southern regions of the country."
223515356|NCT04476485|OTHER|endocrine therapy|If the expression of sj-subway in the surgical wax block is eligible, it is recommended but not mandatory that patients follow the guidelines to choose the appropriate extended endocrine therapy. 1. For postmenopausal patients: Extend treatment with aromatase inhibitors 10 years: letrozole or anastrozole or exemestane. 2. For premenopausal patients: An initial 5 years tamoxifen treatment followed by additional 5 years extended tamoxifen treatment. Postmenopausals are treated with aromatase inhibitors 5 years. 3. For patients have completed ovarian function suppression plus initial 5-year aromatase inhibitor treatment: Menopausals: Aromatase inhibitors; Non-menopausals: 5 years of tamoxifen treatment or ovarian function suppression plus 5 years of aromatase inhibitor treatment. 4. For patients have completed ovarian function suppression plus initial 5-year tamoxifen treatment: Menopausals: Aromatase inhibitors for additional 5 years; Non-menopausals: Tamoxifen for additional 5 years.
223765007|NCT05459870|BIOLOGICAL|4SCAR T cells|Infusion of 4SCAR T cells at 10\^6 cells/kg body weight via IV
223765008|NCT00689481|DRUG|U0267 Foam|All treatments will be administered topically twice daily (morning and evening) for 8 weeks to areas affected with psoriasis (excluding face and scalp).
223765009|NCT00689481|DRUG|Vehicle foam|All treatments will be administered topically twice daily (morning and evening) for 8 weeks to areas affected with psoriasis (excluding face and scalp).
224318978|NCT00553735|DRUG|Cyclosporine A 0.05%|Topical cyclosporine A 0.05% (Restasis) three times a day for 18 months.
224318979|NCT00553735|DRUG|Arificial Tear|Artificial Tear - three times a day for 18 months.
223515357|NCT03115515|DRUG|levothyroxine|To compare two different methods of adjusting thyroid hormone replacement during pregnancy to maintain TSH within the normal reference range for pregnancy.
223515358|NCT04967001|DIAGNOSTIC_TEST|PSMA PET|68Ga-PSMA PET
223515359|NCT01872754|DRUG|1: Remifentanil|1: Remifentanil group The infusion of Remifentanil by TCI begins at distance from the introduction of fiberoptic. The effect site target is 4 ng / ml.- A titration in increments or decrements (respectively increase or decrease of 1 ng / ml effect site concentration) separated by 1 minute intervals until an OAAS score of 4 and respiratory frequency range between 10 and 20 cycles per minute.
223515360|NCT01872754|DRUG|2: Propofol|2: Propofol group- The infusion of Propofol by TCI begins at distance from the introduction of fiberoptic. The effect site target is 2,5 ng / ml.- A titration in increments or decrements (respectively increase or decrease of 0.5 mg / ml concentration effect site) separated by 1 minute intervals until an OAAS score of 4 and included respiratory rate between 10 and 20 cycles per minute.
223515361|NCT03905174|DEVICE|custom made device|surgical intervention to place custom made orthopaedic device
223515362|NCT01026428|DRUG|Safinamide + Levodopa|Treatment A: 100mg safinamide once daily administration for 6 days + immediate release levodopa formulation (100 mg levodopa + 25 mg carbidopa = Nacom®).
223515363|NCT01026428|OTHER|Placebo + Levodopa|Treatment B: Placebo matching 100mg safinamide once daily administration for 6 days + immediate release levodopa formulation (100 mg levodopa + 25 mg carbidopa = Nacom®).
223515364|NCT03719300|DRUG|inodiftagene vixteplasmid|"BC-819 at 20 mg/50 mL, instilled intravesically into the bladder, with a retention time of at least 30 minutes (up to 2 hours).~Induction Phase (weekly treatments): 10 weekly treatments; Maintenance Phase: treatment every 3 weeks for up to 84 additional weeks"
223515365|NCT02442531|DRUG|CriPec® docetaxel|-3 weekly IV dose. Dose escalation; start dose 15 mg/m2. Number of cycles: 6 or until progression or unacceptable toxicity develops
223515366|NCT03497117|DEVICE|Lung Clearance Index|To assess the efficiency of ventilation distribution and gas mixing by measuring the rate of clearance of an inert gas (nitrogen) from the lungs.
223515367|NCT03497117|DRUG|MRI with PFP|"* Description: inhaled PFP, a gaseous contrast agent (79% PFP, 21% O2, pre-mixed, medical grade gas)~* Administration: Full-face disposable ventilation mask and a standard Douglas Bag system.~* Dosage: Two controlled breaths of contrast gas followed by a full breath and a 12-second breath-hold and scan for image acquisition.~* Frequency: Repeated 5 times followed by an identical five cycles with room air to ensure PFP gas wash-out has occurred."
223515368|NCT04213274|BIOLOGICAL|80 mg RPH-104|solution for subcutaneous administration 40 mg/mL, 2 mL in the 4-mL glass vial
223515369|NCT04213274|DRUG|Placebo|Normal Saline (0.9% Sodium Chloride solution for Injection), 2 mL in the 4 mL-glass vial
223515370|NCT05810116|DRUG|Levagen+|Daily dose of 1-2 capsules (1 capsule containing 350mg Levagen+ equivalent to 300mg PEA)
223515371|NCT05810116|DRUG|Microcrystalline cellulose|Daily dose of 1-2 capsules (1 capsule containing 350mg)
223515372|NCT05587543|BEHAVIORAL|PK Blood Collection|All subjects were subjected to PK blood sampling as prescribed by the protocol.
223515373|NCT05587543|DRUG|CAR|Target A positive subjects will receive CAR-T cell therapy.
223515374|NCT05587543|DRUG|TCR|Target A negative, Target B positive and Target C positive subjects will receive TCR-T cell therapy.
223515375|NCT05596240|OTHER|Dry Needling|A sterile, disposable, solid filament needle (Seirin Corp., Shizuoka, Japan) will be inserted manually into the MTrP of the infraspinatus muscles. Once the needle has been inserted, the technique described by Hong (1994) will be used. The needle will be pistoned in an up and down motion within the infraspinatus muscle at approximately 1Hz for 10 seconds with the aim of eliciting local twitch responses.
223515376|NCT05596240|OTHER|Sham Dry Needling|Streitberger Placebo-needles (Asia-med, Las Vegas, NV) will be used to perform the intervention for participants in the sham DN group. These needles have been reported to be indistinguishable from real needles. The device consists of a plastic tube with a blunted tip needle that allows for the sensation of a prick without penetrating the skin. The sham needle produces a sensation, which causes the participant to feel as if the needle enters the skin, while maintaining similar patient-therapist contact time and total intervention time.
223515377|NCT04191733|DEVICE|KINCISE(TM) Surgical Automated System|Uncemented Total Hip Arthroplasty via Anterior Approach with and without the KINCISE(TM) Surgical Automated System
223515378|NCT00288561|DRUG|ranibizumab|
223515379|NCT03308331|OTHER|Tobacco smoking and nicotine patch|Tobacco smoking at each participant's regular cigarette. Over-the-counter nicotine patch use
223515380|NCT05579288|DRUG|Nitrous oxide (N2O/O2)|Nitrous oxide (N2O/O2) for pain alleviation
224318980|NCT05168943|DEVICE|Nylon (Polyamide) Epidural Catheter|Nylon (Polyamide) Epidural Catheter
224318981|NCT05168943|DEVICE|Polyurethane Epidural Catheter|Polyurethane Epidural Catheter
224318982|NCT00050245|DRUG|Rituximab|
224323241|NCT06495424|DRUG|Capsaicin 8%|Repeat applications every 12 weeks in patients with PDPN of the feet.
223637900|NCT06612060|PROCEDURE|Cardiac surgery with the use of extracorporeal circulation|All randomized patients will undergo open heart surgery with the use of extracorporeal circulation. Criteria for randomization: i) age between 18 and 80 years and ii) elective procedure.
223637901|NCT06992765|DIETARY_SUPPLEMENT|Intervention|2 bottles of light green tea daily containing totally 684 mg of catechin
223637902|NCT06992765|DIETARY_SUPPLEMENT|Placebo|2 bottles of light green tea daily containing totally 108 mg of catechin
224225923|NCT02657720|DEVICE|PTAF2|Comparison between 3 different monitors that measure respiratory rate. The participant is connected to 3 monitors at the same time. PTAF2 measures respiratory rate using flow pressure (RRflow).
224225924|NCT03687021|DRUG|Progesterone|Different routes of administration of progesterone; Whether there is endometriosis
223637903|NCT06992661|DRUG|ICF004 inhaled powder|"ICF004 is an investigational inhaled powder formulation containing epigallocatechin gallate (EGCG), the most biologically active polyphenol component derived from green tea extract. Developed for targeted pulmonary delivery, ICF004 utilizes a proprietary RS01 dry powder inhaler device to achieve localized therapeutic effects in lung tissue while minimizing systemic exposure.~The formulation consists of micronized EGCG (≥90% purity) in precisely dosed capsules (1mg or 4mg per unit). Preclinical studies demonstrate that inhaled administration achieves 10-20× higher lung concentrations compared to oral dosing, with correspondingly lower plasma levels - potentially reducing the hepatotoxicity risk associated with high oral EGCG doses (European Food Safety Authority recommends \<800mg/day orally)."
223637904|NCT06992661|DRUG|Oral Teavigo® capsules|Teavigo® is a standardized, high-purity epigallocatechin gallate (EGCG) supplement developed by DSM Nutritional Products. The oral capsules contain ≥94% pure EGCG extracted from green tea (Camellia sinensis), making them one of the most concentrated commercially available EGCG formulations.
224225925|NCT04801602|DIAGNOSTIC_TEST|Rapid diagnostic tests|To evaluate different RDTs that are commercially available internationally for detecting antigens or antibodies to Salmonella Typhi and use blood culture as standard for comparison.
224225926|NCT01859702|DRUG|Moxifloxacin 0.5%/Dexamethasone 0.1% ophthalmic solution|
224225927|NCT01573247|DRUG|AKN-028|"Part 1 of the study is a sequential dose-escalation evaluation of AKN-028. Part 1 started as an accelerated intra-patient dose escalation design in one patient at a time (the N=1 portion), and has switched to standard 3 + 3 design with inter-cohort dose escalation when AUC of 12 μM\*hrs has been reached. Starting dose of AKN-028 was 60 mg twice a day.~During Part 2 of the study AKN-028 will be administered at the dose level selected in Part 1. Patients will be treated for a maximum of 3 cycles (first cycle of 14 days followed by 2 cycles of 21 days), with at least a 7-day treatment-free period between cycles. Patients with significant benefit after 3rd cycle may continue treatment at discretion of the investigator for as long as the patient continues to show significant benefit."
224225928|NCT02975271|DRUG|Serlopitant|
224225929|NCT02975271|DRUG|Placebo|Matching placebo
223637905|NCT06992973|RADIATION|Treatment based on stereotactic radiosurgery|"Treatment based on stereotactic radiosurgery fractionated within 48-72, followed by surgery for symptomatic brain lesions, amenable to surgical treatment, associated or not with a maximum of 3 additional smaller metastatic brain lesions. The dose will be 27 Gy in three fractions (9 Gy per fraction) on alternate days.~If other lesions are present, up to a maximum of 3 lesions and a total volume of 35 cc, these will be treated with radical stereotactic radiosurgery according to guidelines."
223637906|NCT06587867|BIOLOGICAL|efgartigimod|active drug efgartigimod to be administer
223637907|NCT06587087|DEVICE|Smartest-AE: The lancet that will be used will be the Vitrex Soft Lite lll 28G.|The lancet that will be used for all subjects will be the Vitrex Soft Lite lll 28G.
223637908|NCT06590142|PROCEDURE|Observational study of tissue specimens|No intervention will be made
223637909|NCT06600841|DRUG|Immunotherapy（Adebrelimab）|Adebrelimab plus non-platinum chemotherapy（Liposomal doxorubicin/Gemcitabine/ or nab-paclitaxel）and fluzoparib induction therapy followed by maintenance therapy with adebrelimab plus fluzoparib.
224225930|NCT05840497|OTHER|Resistance exercise|"The intervention group will train 3 times per week (30 minutes with 15 min warm-up). The resistance exercise is described as the voluntary contraction of the skeletal muscle of a particular muscle group against some type of resistance, using light weights, elastic bands or the weight of the body itself.~Patients will be offered online sessions, they will receive a document with recommendations and a link to the videos with instructions.~."
224225931|NCT00609778|DEVICE|LUCAS|Mechanical chest compression
224225932|NCT00609778|OTHER|Conventional manual resuscitation method|Manual compression
224225933|NCT00005960|BIOLOGICAL|filgrastim|
224225934|NCT00005960|DRUG|cyclophosphamide|
224225935|NCT00005960|DRUG|docetaxel|
224225936|NCT00005960|DRUG|doxorubicin hydrochloride|
223637910|NCT06600841|DRUG|immunotherapy（Adebrelimab）|anti-PD-L1
223637911|NCT06600061|OTHER|Erector Spinae Plane Block|Patients will receive erector spinae plane block after induction of anesthesia.
223637912|NCT06999603|DRUG|SNG001|SNG001 nebuliser solution is presented as a ready-to-use aqueous solution (neutral pH) in glass syringes containing 0.65 mL of drug product solution containing 12 MIU/mL of IFNβ 1a.
223637913|NCT06999603|DRUG|Placebo|The placebo nebuliser solution is presented in glass syringes containing 0.65 mL of solution containing the same formulation as the study medication but without IFNβ 1a (i.e., only the excipients of the SNG001 solution).
223637914|NCT06999499|OTHER|Scanner of the whole body using the VECTRA 3D|Whole body image acquisition using the VECTRA 3D Whole Body 360 Imaging System to detect potential melanoma
224225937|NCT00005960|PROCEDURE|pain therapy|
224225938|NCT02267733|DRUG|Fluzone|Fluzone High-Dose will be administered with a planned booster at 30 days post initial administration
224225939|NCT03995303|OTHER|NCP and home-delivered meals|The dietitian (Ph.D. student) will perform an individual nutritional assessment focusing on dietary intake, activity level and weight of each participant, as a basis for developing an individualized nutrition care plan consistent with estimated nutritional requirements and nutritional rehabilitation goals. Total fluid, energy- and protein requirements will be estimated for each patient. Giving the group free food to fulfill protein-and energy needs.
224225940|NCT05723497|OTHER|Elderberry juice|Participants will consume elderberry juice 1-week.
224225941|NCT05723497|OTHER|Placebo beverage|Participants will consume placebo for 1-week.
224225942|NCT01439100|DRUG|Oxycodone/Naloxone Prolonged Release tablets|
223637915|NCT06998706|BIOLOGICAL|REGEND001 Autologous Basal Layer Stem Cell Suspension|REGEND001 Autologous Basal Layer Stem Cell Suspension is an innovative cell therapy product designed for chronic structural lung diseases, such as bronchiectasis. This treatment involves harvesting regenerative stem cells (expressing KRT5/P63 markers) from the patient's own bronchial basal layer via fiberoptic bronchoscopy. After isolation, purification, and ex vivo expansion, the cells are administered as a suspension through bronchoscopic infusion into damaged lung segments.
224225943|NCT01439100|DRUG|Placebo|Dummy tablet
223637916|NCT02514083|DRUG|Ibrutinib|Ibrutinib 420mg PO daily for the duration of the study.
223637917|NCT02514083|DRUG|Fludarabine|Fludarabine 25 mg/m2/day IV on days 1-5 of cycles 3 and 4
223637918|NCT06156514|DRUG|Gemcitabine|Weekly application of gemcitanibe at 300 mg/m2 intravenously in a 30-minute infusion, concomitantly with radiotherapy for a total of 5-6 weeks followed by bachytherapy, in patients diagnosed with locally advanced cervical cancer
223637919|NCT06156514|DRUG|Cisplatin|Weekly application of Cisplatin at 40 mg/m2 intravenously in a 60-minute infusion, concomitantly with radiotherapy for a total of 5-6 weeks followed by bachytherapy, in patients diagnosed with locally advanced cervical cancer
223637920|NCT06591494|DRUG|Classic quadruple therapy|Esomeprazole 20 mg BID Bismuth pectin 200 mg BID Amoxicillin 1 g BID Clarithromycin 500 mg BID
223637921|NCT06591494|DRUG|Quadruple therapy with sodium bicarbonate instead of bismuth|Esomeprazole 20 mg BID Sodium bicarbonate 500 mg TID Amoxicillin 1 g BID Clarithromycin 500 mg BID
223637922|NCT06591494|DRUG|Quadruple therapy with sodium bicarbonate instead of clarithromycin|Esomeprazole 20 mg BID Bismuth pectin 200 mg BID Amoxicillin 1 g BID Sodium bicarbonate 500 mg TID
223637923|NCT06601426|PROCEDURE|CSP|cold snare polypectomy
223637924|NCT06585956|BEHAVIORAL|Comminication via Telemedicine|Comminication via Telemedicine With Patients
223637925|NCT06585956|BEHAVIORAL|Information|Informing the patient and their relatives
223637926|NCT06705569|DRUG|Tafamidis 61 mg free acid tablet (Test)|Tafamidis 61 mg free acid tablet (Test)
223637927|NCT06705569|DRUG|Tafamidis 61 mg free acid capsule (Reference)|Tafamidis 61 mg free acid capsule (Reference)
223637928|NCT06706115|OTHER|Intranasal human breast milk|"The information in the Physiologic Parameter Follow-up Form will be recorded by the investigator just 5 minutes before the intervention. The researcher will drip 0.2 ml of breast milk at room temperature (approximately 22 °C) into the nose of the infant lying in the supine position, 0.1 ml in the right nose-0.1 ml in the left nose. 5 minutes after the intervention (T1), 15 minutes after the intervention (T2) and 30 minutes after the intervention (T3), the data in the Physiologic Parameter Follow-up Form will be recorded by the researcher. After intranasal breast milk administration, the baby will be fed by the neonatal nurse as in routine practice. The implementation of the intervention in the study will last for three days and this process will be repeated three times every day (09.00, 12.00 and 15.00)."
224225944|NCT04968743|DEVICE|Transcranial magnetic stimulation (TMS)|TMS will be administrated with a Magstim 70mm figure-8 coil allowing for focal stimulation. Single-pulse TMS will be applied at different phases, (0, 90, 180, 270 degrees - 4 stimulation conditions), of the ongoing mu-rhythm. Positioning of the TMS coil will be neuronavigated based on individual MRI scans. Stimulation will be applied in a closed-loop fashion while the participant is at rest and their EEG activity is recorded.
224225945|NCT06110585|PROCEDURE|Transcranial Magnetic Stimulation (TMS)|The Intermittent Theta Burst Stimulation (iTBS) protocol will be used. This protocol involves bursts of stimulation at the theta frequency range, approximately 5 to 8 Hz. The specific combination utilized combines bursts of pulses at a frequency of 50 Hz, triggered at a rate of 5 Hz. Thus, a burst of 3 pulses is delivered with intervals of 20 ms between them, and this burst is repeated at intervals of 200 ms (i.e., 5 bursts per second). Every second, 15 pulses are delivered.
224318983|NCT02414776|DRUG|hydroxychloroquine|administration of hydroxychloroquine in combination with the current hormonal therapy
224318984|NCT06764225|OTHER|low-sodium substitute salt|This study specifically customized sodium reducing substitute salts with a sodium chloride content not exceeding 62% and without the addition of potassium chloride.
224318985|NCT03654599|BEHAVIORAL|Baseline Surveys|Baseline surveys contained a series of scaled questions, including sociodemographic variables (age, sex, cancer type, and etc), profile of mood states, social well-being, emotional processing and acceptance.
224323242|NCT04043403|DEVICE|Open Loop DBS|Standard DBS therapy at a constant frequency and voltage
223637929|NCT06704750|BEHAVIORAL|6-minute walk test|patients were instructed to walk back and forth in a marked 30-meter-long straight corridor as fast as they could tolerate
223637930|NCT06771076|OTHER|Cream with CBD and natural ingredients|Topical application of the cream with CBD and natural ingredients on the injured areas, twice per day (after waking up, and before going to bed). A crossover with the other intervention will be done in the next/previous month (depending on the arm).
223637931|NCT06771076|OTHER|Cream without CBD and natural ingredients|Topical application of the cream without CBD and natural ingredients on the injured areas, twice per day (after waking up and before going to bed). A crossover with the other intervention will be done in the next/previous month (depending on the arm).
223637932|NCT05958251|OTHER|Cicaben|Cicaben® powder is an association of special active ingredients for topical dermatological use with a healing, soothing and protective action (zinc oxide, magnesium oxide, corn starch, arnica montana extract, allantoin and undecylenic acid, arginine, glycine and proline, niacinamide).
223637933|NCT05958251|OTHER|Standard Care (in control arm)|Standard care
223637934|NCT06497270|PROCEDURE|Theca and Granulosa Cell Isolation|These patients will receive standard procedure during the risk reducing surgery but their ovaries will be used to extract theca and granulosa cells which will be used for the 3D bioprinted device's realisation.
223637935|NCT06056596|DRUG|Lamivudine 300 MG|Drug to be taken once daily for three days (two days prior to surgery and on the morning of surgery)
223637936|NCT06056596|DRUG|Placebo|Dose to be taken once daily for three days (two days prior to surgery and on the morning of surgery)
223637937|NCT06939166|DRUG|UCAR T-cell|Universal allogeneic anti-CD19/BCMA CAR T-cells
223637938|NCT06940869|OTHER|NURTURE Registry|To improve pregnancy and birth outcomes for women with rheumatic diseases and to understand risk factors associated with poor pregnancy outcomes.
223637939|NCT06939855|DRUG|QL1706 (bispecific antibody targeting PD-1 and CLTA-4)|5mg/kg iv q3w
224225946|NCT06110585|PROCEDURE|Sham|A stimulator with an arm containing a non-functional replica of the stimulation coil will be utilized. The application procedures will be identical to those of the active group, except that the device simulating the stimulation coil will not generate a magnetic field, only producing sound cues mimicking a stimulus.
224225947|NCT04192799|BEHAVIORAL|Direct admission|Process of pediatric admission is through admission directly into the pediatric hospital medicine unit
223515381|NCT05579288|DRUG|Oxygen (O2)|Oxygen (O2) as placebo for control group
223515382|NCT06542380|DEVICE|TAVI, pacemaker|Retrospective analysis of need for pacemaker implantation after TAVI
223515383|NCT02349477|DRUG|Gabapentin|gaba potentiating medication
223515384|NCT02349477|DRUG|Placebo|a pill that looks exactly like the active medication but does not contain medication
223515385|NCT04194619|OTHER|Questionnaire|Interview of women with a rare vascular disease through a phone questionnaire about severe and specific obstetrical complications during and after pregnancy.
223515386|NCT05007860|BIOLOGICAL|PCV13 vaccine and any of the FDA-approved COVID-19 vaccine products (BNT162b2, mRNA-1273, or Ad26.COV2.S) based on local availability.|Vaccines administered per standard of care
223515387|NCT01903733|DRUG|bosutinib|The starting bosutinib dose is 500 mg once daily, however the dose can vary from 300 mg to 600 mg.
223515388|NCT00909688|DRUG|BLI-489|
223515389|NCT00909688|DRUG|placebo|
223515390|NCT00192478|BIOLOGICAL|Medi-524|IM doses of MEDI-524 administered at 3 mg/kg or 15 mg/kg at 30 day intervals
223515391|NCT04938843|DIETARY_SUPPLEMENT|F. prausnitzii and D. piger|Dietary supplementation with capsules containing F. prausnitzii and D. piger once daily for 12 consecutive weeks
223515392|NCT04938843|DIETARY_SUPPLEMENT|Placebo|Dietary supplementation with placebo capsules identical to those containing F. prausnitzii and D. piger once daily for 12 consecutive weeks
223515393|NCT02176759|OTHER|Administration of rice fortified with regular FePP|
223515394|NCT02176759|OTHER|Administration of rice fortified with regular FePP with citrate added during extrusion|
223515395|NCT02176759|OTHER|Administration of rice fortified with regular FePP and citrate added at consumption|
223515396|NCT02176759|OTHER|Administration of rice fortified with ferrous sulphate|
223515397|NCT03150641|PROCEDURE|Umbilical cord clamping|The umbilical cord will be clamped and cut after delivery, with timing as specified in each arm
223515398|NCT06499181|DRUG|Liposomal bupivacaine|The primary objective is to examine differences in post-operative opioid consumption between the two groups.
223515399|NCT06499181|DRUG|Bupivacain|Control group to receive 10cc of 0.5% bupivacaine with 1:50,000 epinephrine at the completion of the procedure per typical standard of care.
223515400|NCT06499181|DRUG|Epinephrin|Control group to receive 10cc of 0.5% bupivacaine with 1:50,000 epinephrine at the completion of the procedure per typical standard of care.
223515401|NCT01340534|DEVICE|Supplemental oxygen 80% FIO2|Use of oxygen 80% FIO2 during surgery and 2 hours after the procedure. For this purpose an oxygen mask with reservoir will be used (to guarantee the supply of 80% oxygen during and after surgery)
223515402|NCT01340534|PROCEDURE|Use of air (no oxygen during surgery)|No use of oxygen during surgery or in the 2 hours after the procedure.
223515403|NCT01714063|DEVICE|Pressurized Metered-Dose Inhaler|Pressurized Metered-Dose Inhaler
223515404|NCT02645370|DRUG|Danzhen|
223515405|NCT02645370|DRUG|Topiramate|
223515406|NCT04147169|BEHAVIORAL|Focused end-of-life conversations to promote connections among patients, family members and clinicians.|All eligible patients and families who were invited to participate in wish elicitation and implementation. For family interviews, criterion sampling was used. For the clinician focus groups, criterion sampling was used, based on involvement in the care of a 3WP patient. For the manager/hospital administrator interviews, purposive sampling was used, based on relevant leadership positions. Investigators employed qualitative and quantitative methods to collect and analyze data. Quantitative data include characteristics of patients, families and clinicians, questionnaire responses from families who agree to interviews, and clinicians who agree to focus groups, respectively, types of wishes elicited and implemented, and their cost. Qualitative data was obtained through individual family interviews, inter-professional clinician focus groups, project team field notes, additional ideas about the costs and benefits of the project from manager interviews, and analysis of project documents.
223515407|NCT02688166|OTHER|Complete Cardiac Magnetic Resonance Imaging (MRI)|Complete Cardiac Magnetic Resonance Imaging (MRI) prior to treatment and then at approximately 1 year after completion of radiation therapy
223515408|NCT00043784|DRUG|enoxaparin|
223515409|NCT04878185|OTHER|Exercise|Preoperative exercise
223515410|NCT02281864|BEHAVIORAL|Smoking Cessation Intervention Bundle|Receipt of the smoke cessation/reduction intervention bundle followed by referral to the Quitline.
223515411|NCT02281864|OTHER|Control Group: Quitline|Referral to the Quitline
223515412|NCT02636335|DEVICE|Phillips Energy Light HF3319|Exposure to Light administered with Phillips Energy Light HF3319.
223515413|NCT00551993|PROCEDURE|robotic laparoscopic sacrocolpopexy|Da Vinci Robot
223515414|NCT00551993|PROCEDURE|Laparoscopic Sacral Colpopexy|Standard laparoscopy
223515415|NCT04928131|OTHER|No intervention - retrospective observational cohort study|
223515416|NCT02487329|OTHER|Calcium Hydroxide|Exposed area was sealed with a self-hardening calcium hydroxide paste then final restoration was completed using a resin-modified glass ionomer and a nanohybrid composite resin
223515417|NCT02487329|OTHER|Er,Cr:YSGG laser + calcium hydroxide|After the exposed area was irradiated with Er,Cr:YSGG laser at an energy level of 0,5 W, a repetition rate of 20 Hz, 140 µs pulse duration with 0% water and 45% air for 10 s, it was sealed with a self-hardening calcium hydroxide paste.Then final restoration was completed using a resin-modified glass ionomer and a nanohybrid composite resin
224225948|NCT04192799|BEHAVIORAL|ED admission|Process of pediatric admission is through the emergency department
224225949|NCT01077713|DRUG|bevacizumab [Avastin]|7.5mg/kg iv on day 1 of each 3 week cycle
224225950|NCT01077713|DRUG|cisplatin|60mg/m2 on day 1 of each 3 week cycle
224225951|NCT01077713|DRUG|gemcitabine|1200mg/m2 on days 1-8 of each 3 week cycle
224225952|NCT01077713|DRUG|gemcitabine|1000mg/m2 on days 1-8 of each 3 week cycle
224225953|NCT01551329|DRUG|Ketalar (ketamine)|Intravenous Ketamine 0.5mg/kg
223637940|NCT04684836|OTHER|Exposure to telemedicine, after the onset of the pandemic|The exposure of interest was the switch to primary care telemedicine prompted by the COVID-19 epidemic
223637941|NCT06943534|DRUG|5mg/kg omalizumab injection|5mg/kg of omalizumab
223637942|NCT06943534|DRUG|15mg/kg omalizumab injection|15mg/kg of omalizumab
223637943|NCT03039218|DEVICE|Dornier Aries 2|Extracorporeal Shock Wave Device for treatment of mild erectile dysfunction
223637944|NCT03039218|DEVICE|Placebo / Sham|Inactive (placebo/sham) Extracorporeal Shock Wave Device for treatment of mild erectile dysfunction
223637945|NCT02183649|DRUG|pentoxyverine citrate|
223637946|NCT02183649|DRUG|Placebo|
223765010|NCT05074290|DRUG|Epidiferphane|"During the phase I portion of the study, subjects will be assigned to take either two (half target dose) or four (full target dose) Epidiferphane tablets orally three times daily following a 3 + 3 design. Three subjects will be sequentially enrolled at each of the 2 dose levels (beginning with the half target dose) until at least one dose-limiting toxicity (DLT) occurs. Dosing escalation will be stopped if two or more DLTs occur at either dose level. The maximum tolerated dose will be one dose level lower than the dose level at which 2 or more DLTs occur. Dose escalation will occur separately for each taxane regimen (docetaxel or paclitaxel).~All subjects in the phase II portion of the study will receive the maximum tolerated dose determined in the phase I portion of the study for their taxane regimen.~Subjects in both portions of the study will receive treatment with Epidiferphane for a maximum of three months."
223765011|NCT05074290|DRUG|Taxane Chemotherapy|All subjects on both phases of the study will be concurrently treated with a taxane regimen containing either paclitaxel given weekly, nab-paclitaxel given weekly or every 3 weeks or docetaxel given every 3 weeks. The choice of taxane regimen will be determined by the treating physician prior to consenting to participate in this trial.
224225954|NCT06224582|DRUG|Yinxingmihuan oral solution|Yinxingmihuan oral solution is made of Ginkgo leaf extract and armillariella mellea powders.
224225955|NCT06224582|DRUG|Placebo|The placebo oral solution is in the same appearance, color, smell and taste as the experimental Yinxingmihuan oral solution.
224225956|NCT00289458|BEHAVIORAL|exercise|A community aquatic exercise program designed for older adults to improve balance, strength and mobility to decrease the risk of falls.
224225957|NCT00289458|BEHAVIORAL|2|Same as 1 with the addition of a 1/week educational group program to improve confidence in movement, learn about fall risk and fall prevention and the rationale for the exercises to decrease fall risk.
224225958|NCT00289458|BEHAVIORAL|Control|no exercise
223515418|NCT02487329|OTHER|TheraCal LC|TheraCal LC was applied directly to the exposed pulp with a needle tip syringe in incremental layers that was not to exceed 1 mm in depth. Then final restoration was completed using a resin-modified glass ionomer and a nanohybrid composite resin
223515419|NCT02487329|OTHER|Er,Cr:YSGG laser + TheraCal LC|After the exposed area was irradiated with Er,Cr:YSGG laser at an energy level of 0,5 W, a repetition rate of 20 Hz, 140 µs pulse duration with 0% water and 45% air for 10 s, TheraCal LC was used to seal the treated area. Then final restoration was completed using a resin-modified glass ionomer and a nanohybrid composite resin
223515420|NCT00318136|DRUG|Bevacizumab|15 mg/kg administered intravenously on Day 1 of each 21- to 28-day cycle, beginning on Cycle 3
223515421|NCT00318136|DRUG|Carboplatin|Dose based on Calvert formula, on Day 1 of each 21- to 28-day cycle for a total of 6 cycles
223515422|NCT00318136|DRUG|Paclitaxel|Dose based on patient's body surface area, on Day 1 of each 21- to 28-day cycle for a total of 6 cycles
223515423|NCT01414790|PROCEDURE|ADM|29 patients (ADM group) had a total parotidectomy with a simultaneous ADM implantation
223515424|NCT05200338|DRUG|Engerix-B|Subjects are vaccinated with an accelerated scheme at 0, +1, +2 months with a booster at +12 months.
223515425|NCT03948620|DRUG|Macrolides|Macrolide antibiotics, including erythromycin, clarithromycin and azithromycin. Prescriptions of macrolides will be identified using a drug code list based on the British National Formulary (chapter 5.1.5) and the date of the first prescription was used as the index date of exposure.
223637947|NCT05979246|DEVICE|Lance CLEAR dental implant|The surgical procedure will be performed by experienced periodontists, all implants will be at least Ø 3.75 mm and 8-11.5 mm long. After reflecting the flaps, a bone biopsy will be harvested as part of the drilling procedure using a Ø 2.4 mm trephine drill and the implants will be seated into a crestal position
223637948|NCT04611646|BEHAVIORAL|Heat-suit endurance training|Participants (elite cyclists) will conduct five 50-minute low-intensity cycling sessions with heat suit per week for five weeks. These sessions will complement their habitual training routines, which will consist of endurance training with intensities at or below lactate threshold. Participants will ingest 100 mg Fe2+ on a daily basis to support de novo synthesis of hemoglobin
223637949|NCT04611646|BEHAVIORAL|Non-heat-suit endurance training|Participants (elite cyclists) will conduct low-intensity cycling without heat suit for five weeks (volume- and intensity-matched to the heat-suit arm). Participants will ingest 100 mg Fe2+ on a daily basis to support de novo synthesis of hemoglobin
223637950|NCT05930223|DRUG|VAL-1221|VAL-1221 20mg/kg intravenous (IV) infusion every other week
223637951|NCT04983446|DRUG|Foralumab|Foralumab is a second generation fully human anti-CD3 antibody
223765012|NCT06600620|DEVICE|Monitoring patients heart rythms with a wireless patch device|The investigators will collect data in patients at high risk of atrial fibrillation (AF) without a known history of AF to determine clinical predicators of AF. This data will be used to generate virtual digital twins to to predict clinical and subclinical episodes of AF
223765013|NCT02801318|PROCEDURE|Polysomnography|
223765014|NCT00316199|DRUG|gemcitabine|1250 mg/m2, intravenous (IV), day 1 and day 8 every 21 days until disease progression
224225959|NCT05385744|BIOLOGICAL|BCD-132|anti-CD20 monoclonal antibody
224225960|NCT05385744|DRUG|Teriflunomide|Teriflunomide 14 mg
224225961|NCT00874757|DRUG|Rosuvastatin|Healthy subjects received rosuvastatin 20 mg orally for 3 weeks. Inflammatory markers measured pre- and post- rosuvastatin treatment.
224225962|NCT04733131|DRUG|Conversion to a belatacept regimen|belatacept intravenous on Days 1, 15, 29, 43, 57 then every 28 days.
224225963|NCT06316960|DRUG|Avapritinib|50mg/m2/day for weighing bodyweight \>10kg, 1.65mg/kg/day for weighing ≤ 10kg, po, qd, d1-28.
224225964|NCT06316960|DRUG|Azacitidine Injection|75mg/m2/d for weighing \>10kg, 2.5mg/kg/d for weighing ≤ 10kg, d1-7, ivgtt, qd, more than 3 hours. Azacitidine and decitabine cannot be used simultaneously.
223637952|NCT04983446|OTHER|Placebo|Placebo will be the vehicle for the foralumab nasal solution without active drug (25 mM sodium acetate/125 mM sodium chloride/0.02% polysorbate 80, pH 5.5 buffer).
223637953|NCT04226742|BEHAVIORAL|ADAPT Platform (Treatment)|The ADAPT platform consists of 2 modules based on evidence-based strategies from cognitive-behavioral therapy including cognitive restructuring and behavioral experiments. The platform includes didactic material, interactive tools, and crowd-features. Crowd-features are present to increase personal relevance of content and to promote engagement with the ADAPT platform through accountability. Crowd-features include requesting, responding, and exemplars.
223637954|NCT04226742|BEHAVIORAL|ADAPT Comparison (Control)|The control platform is a self-guided version of the ADAPT platform that includes no crowd-features. As such it will include only didactic material on cognitive restructuring and behavioral experiments and interactive tools.
223637955|NCT01216553|OTHER|Oxygen Therapy|1 lt/min oxygen via nasal cannulae intermittently for 30 minuets 4 times daily for 7 days
223637956|NCT05341141|DEVICE|Frozen glove and sock|Preparation of frozen glove and sock: 4℃ for 3 hours.
223637957|NCT05341141|DRUG|ddEC-ddT|Epirubicin (E) 90\~100mg/m\^2, i.v., d1 + cyclophosphamide (C) 600 mg/m\^2, i.v., d1, q2w, for 4 cycles followed by albumin-paclitaxel (T) 260 mg/m\^2, i.v., d1, q2w, for 4 cycles.
223637958|NCT02492763|DRUG|MK-8521|Dose strengths: 180 μg QD administered subcutaneously. A 2-step dose escalation regimen \[60 μg, 120 μg\] over the first 2 weeks is used to achieve the final dose up to 180 μg.); 300 μg QD administered subcutaneously (A 3-step dose escalation regimen \[60 μg, 120 μg, 180 μg\] over the first 3 weeks is used to achieve the final dose up to 300 μg.
224225965|NCT06316960|DRUG|Decitabine Injection|20mg/m2/d for weighing \>10kg, 0.67mg/kg/d for weighing ≤ 10kg, d1-5, ivgtt, qd, more than 3 hours. Azacitidine and decitabine cannot be used simultaneously.
224225966|NCT06316960|DRUG|Idarubicin Hydrochloride|5mg/m2/day for weighing \>10kg, 0.17mg/kg/day for weighing ≤ 10kg, d 6, 8, 10 (d 8, 10, 12 for azacitidine) ivgtt, qod, more than 1 hour at 10 am.
224225967|NCT06316960|DRUG|Cytarabine|10mg/m2/day for weighing \>10kg, 0.33mg/kg/day for weighing ≤ 10kg, d6-15 （d8-17 for azacitidine ）, s.c., q12h.
223515426|NCT03948620|DRUG|Penicillins|The comparison group consists of children whose mother were prescribed penicillins during pregnancy. Prescriptions of penicillins will be identified using a drug code list based on the British National Formulary (chapter 5.1.1) and the date of the first prescription will be used as the index date of exposure.
223515427|NCT06569511|DIAGNOSTIC_TEST|N-terminal pro-B-type natriuretic peptide (NT-proBNP)|In patients diagnosed with Acute coronary syndrome, blood samples for serum NT-proBNP value were taken during transfer to the coronary intensive care unit
223515428|NCT06569511|DIAGNOSTIC_TEST|high sensitive cardiac troponin T (hs-cTnT)|In patients diagnosed with Acute coronary syndrome, serum high-sensitive cardiac troponin T (hs-cTnT) levels were measured on admission to the Emergency Department.
223515429|NCT06569849|OTHER|De-Stress and Focus capsule- U001|Two capsules in sequence daily after meal for 60 days.
223515430|NCT06569849|OTHER|De-Stress and Focus capsule - I001|Two capsules in sequence daily after meal for 60 days.
223515431|NCT06569849|OTHER|Placebo capsules 001|Two capsules in sequence daily after meal for 60 days.
223515432|NCT06401733|OTHER|Intensive Aerobic and Resistance Exercise Program (IAREP)|"IAREP is a combined aerobic exercise and resistance training program that developed by qualified exercise professionals. It encompasses a 12-week exercise intervention, conducted in a blended mode which consists of face-to-face exercise, Zoom exercise, and pre-recorded video exercise.~Frequency: 3 times exercise per week. Intensity: moderate to vigorous exercise. Time of the exercise: 45-60 mins. Type of exercise: combined aerobic and resistance training.~Warm-up: aerobic workout with dynamic stretch (for targeted muscles). Aerobic exercise: each session encompasses 5 exercise. Resistance training: each session encompasses 4 exercise, 2 upper body exercise and 2 lower body exercise.~Cool-down: relax targeted muscles."
223515433|NCT02449928|DRUG|sodium lactate Ringer's injection(Baxter, ShangHai, China)|use sodium lactate Ringer's injection to resuscitate the septic shock patients(lactate group)
223515434|NCT02449928|DRUG|Compound Sodium Chloride Injection (CR Double-Crane, Beijing, China)|use Compound Sodium Chloride injection to resuscitate the septic shock patients(control group)
223515435|NCT02631694|DRUG|Propranolol|Intake of propranolol pill (40 milligram)
223515436|NCT02631694|DRUG|Placebo|Intake of placebo pill (40 milligram)
223515437|NCT02631694|OTHER|Carbon dioxide|Inhalation of 35% carbon dioxide
223515438|NCT02631694|OTHER|Compressed air|Inhalation of air
223515439|NCT04151641|DIETARY_SUPPLEMENT|MNGDPF|Standardized mangosteen extract in dry powder form
223515440|NCT04151641|DIETARY_SUPPLEMENT|MNGEF|Standardized mangosteen extract in encapsulated form
223515441|NCT06455254|DRUG|Candonilimab (AK104)|Cadonilimab (AK104): 6mg/kg, i.v. q2w.
223515442|NCT06455254|DRUG|Regorafenib|Regorafenib: 80 mg p.o. qd for 3 weeks of every 4 week cycle (i.e. 3 weeks on, 1 week off).
223515443|NCT01391494|BIOLOGICAL|160Eu/0.5ml in adults|inactivated EV71 vaccine (KMB-17) of 160Eu/0.5ml in 12 adults aged 18-49 years old on day 0, 14.
223515444|NCT01391494|BIOLOGICAL|320Eu/0.5ml in adults|inactivated EV71 vaccine (KMB-17) of 320Eu/0.5ml in 12 adults aged 18-49 years old on day 0, 14.
223515445|NCT01391494|BIOLOGICAL|640Eu/0.5ml in adults|inactivated EV71 vaccine (KMB-17) of 640Eu/0.5ml in 12 adults aged 18-49 years old on day 0, 14.
223515446|NCT01391494|BIOLOGICAL|1280Eu/0.5ml (without adjuvant) in 12 adults|inactivated EV71 vaccine (KMB-17) of 1280Eu/0.5ml (without adjuvant) in 12 adults aged 18-49 years old on day 0, 14.
223515447|NCT01391494|BIOLOGICAL|0Eu/0.5ml in adults|0Eu/0.5ml placebo in 24 adults aged 18-49 years old on day 0, 14.
223515448|NCT01391494|BIOLOGICAL|160Eu/0.5ml in children|inactivated EV71 vaccine (KMB-17) of 160Eu/0.5ml in 12 children aged 3-11 years old on day 0, 14.
223515449|NCT01391494|BIOLOGICAL|320Eu/0.5ml in children|inactivated EV71 vaccine (KMB-17) of 320Eu/0.5ml in 12 children aged 3-11 years old on day 0, 14.
223515450|NCT01391494|BIOLOGICAL|640Eu/0.5ml in children|inactivated EV71 vaccine (KMB-17) of 640Eu/0.5ml in 12 children aged 3-11 years old on day 0, 14.
223637959|NCT02492763|DRUG|Placebo|Double dummy matching placebo for the MK-8521 and placebo arms: matching placebo for MK-8521 300 μg QD administered subcutaneously; matching placebo for MK-8521 180 μg QD administered subcutaneously. A dose escalation regimen consistent with that of the MK-8521 300 μg and 180 μg arms of the study; mock escalation will be performed over the first 2 to 3 weeks.
223637960|NCT02492763|DRUG|Liraglutide|Dose strength: 1.8 mg QD administered subcutaneously. A 2-step dose escalation regimen (0.6 mg, 1.2 mg) over the first 2 weeks is used to achieve the final dose up to 1.8 mg.
223637961|NCT02492763|DRUG|Metformin|Metformin immediate release (IR) or metformin extended release (XR) administered ≥1000 mg QD as background therapy
223637962|NCT05747235|RADIATION|CT chest|All patients will undergo MSCT chest at both inspiratory and expiratory phases in supine position without any contrast media.
223637963|NCT00003553|OTHER|HLA Matched Peripheral BLood Stem Cells|Cell Product
223637964|NCT06271746|DEVICE|FibroNova (Active mode)|FibroNova neurostimulator of conditional pain modulation (CPM)
223637965|NCT06271746|DEVICE|FibroNova (Sham mode)|FibroNova neurostimulator with an electrical output not intended for neurostimulation
223637966|NCT03193502|DRUG|rivaroxaban|rivaroxaban
223637967|NCT00053651|BEHAVIORAL|Survival Skills for Moms with New Babies|
223637968|NCT05969834|DRUG|uHCG|Final oocyte maturation will be triggered by IM administration of 10000 IU of uHCG (Choriomon)
224225968|NCT06316960|DRUG|Granulocyte Colony-Stimulating Factor|300ug/day for weighing \>10kg, 10ug/kg/day for weighing ≤10kg, d0-5, s.c., qd.
224225969|NCT06210269|DRUG|Moxifloxacin 400mg|Oral antibiotic
224225970|NCT06210269|OTHER|Placebo|Oral placebo
224225971|NCT04965649|GENETIC|Phenotyping of total and innate CD8+T cells by flow cytometry|"Blood samples from patients in the active file of the Clinical Cytology and Cytogenetics Laboratory at Nîmes University Hospital will be analyzed (diagnosis already known). Samples will be representative of the different stages of the pathology.~For patients with a confirmed diagnosis of Chronic Myeloid Leukemia and Philadelphia+ Acute Lymphoblastic Leukemia), the remaining whole blood sample taken as part of the usual management will be sent for phenotyping of CD8+ TL (total and innate) by flow cytometry. Phenotyping will be performed on samples pooled at the end of the recruitment period."
224318986|NCT03654599|BEHAVIORAL|Digital Stories Intervention|Digital Stories Intervention Videos contain the following content: caregiver burden, positive and cognitive coping, support from other family and friends, fear of losing the patient, spirituality, guilt of being sick, and expressing emotions/feelings
223637969|NCT05969834|DRUG|rHCG|Final oocyte maturation will be triggered by SC administration of 6500 IU of rHCG (Ovitrelle)
223637970|NCT05969834|DRUG|uHCG and GnRHa|Final oocyte maturation will be triggered by combined SC administration of 0.1 mg of GnRHa (Decapeptyl, Triptorelin) and IM administration of 2500 IU of uHCG (Choriomon)
223637971|NCT04962308|BIOLOGICAL|SARS-CoV-2 Inactivated Vaccine|600SU inactivated virus in 0·5 mL of aluminiumhydroxide solution per injection
223637972|NCT04962308|BIOLOGICAL|The SARS-CoV-2 Inactivated Vaccine|600SU inactivated virus in 0·5 mL of aluminiumhydroxide solution per injection
223637973|NCT05972980|OTHER|COVID-19|The investigators stratified our population based on COVID-19 virus positivity to identify any risk factors in this population compared to the NON-COVID-19 population.
223637974|NCT01337960|BEHAVIORAL|Seated Robot Training (SRT)|Participants at least 6 mos. post-stroke will use the ankle robot in a seated visuo-motor training paradigm. They will train on the robot 3x weekly for 6-weeks (18 sessions) by playing videogames with the paretic ankle. They will be evaluated on outcomes at baseline, post-6 weeks training, and again after a 6-week retention period with no training.
223637975|NCT01337960|BEHAVIORAL|Treadmill Locomotor-based Training (TMR)|Treadmill training with ankle robot group. Participants at least 6 mos. post-stroke will wear the ankle robot during treadmill locomotor training. They will walk on a treadmill with the ankle robot adjusted to promote paretic ankle engagement during 3 x weekly training sessions over 6 weeks (18 sessions). They will be evaluated on outcomes at baseline, post-6 weeks training, and again after a 6-week retention period with no training.
223637976|NCT01337960|BEHAVIORAL|Treadmill Only (TMO)|Treadmill only group. This group will consist of participants at least 6 mos. post-stroke who engage in treadmill training 3x weekly for 6 weeks without robotic support. They will be volunteers from another treadmill training study and evaluated on outcomes at baseline and post-6 weeks training. They will not receive retention testing at 12 weeks because they will be continuing with regular treadmill training beyond the 6-week period.
223637977|NCT00489593|DRUG|Olanzapine|2.5 mg by mouth (PO) Daily x 28 days, increasing about every 3-14 days in increments of 2.5-5 mg until the designated dose for that cohort is reached.
223637978|NCT01772316|DRUG|tocilizumab|162 mg subcutaneously weekly or every two weeks, 96 weeks
223637979|NCT01418625|DRUG|Venlafaxine Hydrochloride Extended-Release Capsules 150mg (Test formulation, Torrent Pharmaceutical Limited., India)|
223637980|NCT01376934|PROCEDURE|procedure hysteroscopy|office hysteroscopy with gas or saline solution
223765015|NCT00316199|DRUG|paclitaxel|175 mg/m2, intravenous (IV), every 21 days until disease progression
224323243|NCT04043403|DEVICE|Adaptive (Closed Loop) DBS|DBS that responds to neural (Percept PC and Summit RC+S) or kinematic (Summit RC+S) features of patient's current state
224323244|NCT04043403|DEVICE|Intermittent Open Loop DBS|Control for aDBS - DBS intensity or frequency changes in a manner that mimics aDBS but is pre-determined and open loop rather than being responsive to neural or kinematic signals.
223637981|NCT01213316|DRUG|Raltegravir|Raltegravir, 400 mg, per oral (p.o.) twice daily (b.i.d.) for 48 or 144 weeks
223637982|NCT01213316|DRUG|Raltegravir|Raltegravir, 400 mg, per oral (p.o.) twice daily (b.i.d.) for 96, 144, or 48 weeks
223637983|NCT06083740|DEVICE|Granudacyn/Veriforte|Wound irrigation solution for all kinds of wounds (Acute, chronic or contaminated wounds).
223637984|NCT02919839|OTHER|non-Interventional|
223765016|NCT00333684|DEVICE|BIO-ALCAMID SOFT TISSUE ENDOPROSTHESIS|prosthetic bioalcamid was injected- amounts determined by the plastic surgeon and depended individual needs
224225972|NCT04058678|DRUG|Danazol/Placebo|This group will be randomized 1:1 for either inactive substance or Danazol, according to a computer-generated randomization list prepared. Women will be treated with Danazol/Placebo oral way for 3 months.
224225973|NCT04058678|OTHER|Without intervention|Women with normal ovarian reserve will not be treated in anyway, thus, randomization will not be necessary.
224225974|NCT06526871|PROCEDURE|Low-Level Laser acceleration|This intervention involves the application of Low-Level Laser Therapy (LLLT) using the Epic X device for patients undergoing orthodontic treatment. The protocol is designed to assess the effects of LLLT on pain reduction and treatment efficacy during the initial leveling and alignment phase of orthodontic therapy using clear aligners .
224225975|NCT06526871|PROCEDURE|clear aligner therapy|Clear aligner therapy involves using a series of custom-made, clear plastic aligners to gradually move teeth into their desired positions. These aligners are worn over the teeth and are typically changed every week as the teeth gradually shift. The treatment process starts with a digital scan or impression of the teeth, which is used to create a 3D model. This model helps in planning the precise movements needed to achieve proper alignment. Throughout the treatment, patients visit their orthodontist periodically to monitor progress and receive new sets of aligners. Clear aligners are popular for their aesthetic appeal and the convenience they offer compared to traditional braces.
224225976|NCT05286528|DRUG|Bosutinib|Bosutinib as prescribed in real world
224225977|NCT05286528|DRUG|Imatinib|Imatinib as prescribed in real world
223515451|NCT01391494|BIOLOGICAL|1280Eu/0.5ml (without adjuvant) in children|inactivated EV71 vaccine (KMB-17) of 1280Eu/0.5ml (without adjuvant) in 12 children aged 3-11 years old on day 0, 14.
223515452|NCT01391494|BIOLOGICAL|0Eu/0.5ml in children|0Eu/0.5ml placebo in 24 children aged 3-11 years old on day 0, 14.
223515453|NCT01391494|BIOLOGICAL|160Eu/0.5ml in infants|inactivated EV71 vaccine (KMB-17) of 160Eu/0.5ml in 24 infants aged 6-35 months old on day 0, 28.
223515454|NCT01391494|BIOLOGICAL|320Eu/0.5ml in infants|inactivated EV71 vaccine (KMB-17) of 320Eu/0.5ml in 24 infants aged 6-35 months old on day 0, 28.
223515455|NCT01391494|BIOLOGICAL|640Eu/0.5ml in infants|inactivated EV71 vaccine (KMB-17) of 640Eu/0.5ml in 24 infants aged 6-35 months old on day 0, 28.
223515456|NCT01391494|BIOLOGICAL|1280Eu/0.5ml (without adjuvant) in infants|inactivated EV71 vaccine (KMB-17) of 1280Eu/0.5ml (without adjuvant) in 24 infants aged 6-35 months old on day 0, 28.
223515457|NCT01391494|BIOLOGICAL|0Eu/0.5ml in infants|0Eu/0.5ml placebo in 48 infants aged 6-35 months old on day 0, 28.
223515458|NCT03368521|OTHER|Back pain screening test|The care giver use the screening tool in order to score the back patient to three levels of risk. For each level of risk, one suggested type of care is provided; 1) simple advise; 2) physiotherapy; 3) multimodal rehabilitation. highest risk level includes multimodal intervention.
223515459|NCT03491085|DRUG|Amoxicillin/clavulanate|after tonsillectomy half of our patients will receive Amoxicillin /clavulanate for one week and the other half will not receive it.
223515460|NCT02294019|DRUG|Ibuprofen 400 mg caplet|400 milligram (mg) caplet according to Drug Facts label
223515461|NCT02369159|DRUG|Peramivir|
223515462|NCT02369159|DRUG|Oseltamivir|
223515463|NCT05214027|OTHER|Treadmill-Based Exercise (60% VO2 Max for 60 minutes)|"Each participant will undergo a single 60-minute treadmill-based exercise intervention in a randomised order.~Treadmill settings are generated based on settings which correspond to participants exercising at 60% VO2 max from their maximal exercise test on visit 2. To confirm that participants are exercising at 60% during the hour session, 1 minute samples of expired air are taken at 15 minute intervals and immediately analysed to check % VO2 max. Participants heart rate and RPE measures are also taken at 15 minute intervals throughout the exercise session and cross-checked against predicted values at 60% VO2 Max."
223515464|NCT05214027|OTHER|Rest (60 minutes)|Each participant will undergo a 60-minute rest period in a randomised order.
223515465|NCT02975115|OTHER|RQ-PCR RNA Analysis|Conventional Q-RT-PCR every 3 months
223515466|NCT00049946|DRUG|talnetant|
223515467|NCT00049946|DRUG|risperidone|
223637985|NCT06324513|DIETARY_SUPPLEMENT|Mediterranean Crohn's Disease Exclusion Diet (Med-CDED)|The Mediterranean Crohn's Disease Exclusion Diet (Med-CDED) is the exclusion diet (CDED) adapted to the Mediterranean diet pattern. The Med-CDED consists of 2 phases in dietary therapy and a maintenance phase: the first phase lasting 8 weeks, the second phase lasting 16 weeks, and the maintenance phase, which for the purposes of the study will last 28 weeks.
223637986|NCT06324513|DIETARY_SUPPLEMENT|Crohn's disease exclusion diet (CDED)|The original Crohn's disease exclusion diet, used as a comparator, is widely employed among first-line treatments in clinical practice for inducing remission in pediatric patients with Crohn's disease.
223765017|NCT00590954|DRUG|Perifosine|"Dosing will be continuous, and for the purpose of this trial a cycle will be defined as 28 days. Perifosine will be given as a 600 mg loading dose on day 1. The loading dose will be divided into 4 equal doses of 150 mg each. The first 3 doses should be given with food in the adult day hospital to allow intravenous antiemetic prophylaxis, and 4th dose at bedtime at home. The interval between doses of perifosine should be no less than 4 hours. On day 2, patients will start the maintenance dose of 100 mg daily at bedtime at home.~In addition to baseline serum, all patients will have weekly serum drawn during weeks 2-4."
223765018|NCT06325540|PROCEDURE|indirect pulp capping with theracal pt|indirect pulp capping using the theracal pt material
224225978|NCT05286528|DRUG|Nilotinib|Nilotinib as prescribed in real world
224225979|NCT05286528|DRUG|Dasatinib|Dasatinib as prescribed in real world
224225980|NCT05286528|DRUG|Ponatinib|Ponatinib as prescribed in real world
224225981|NCT03781856|BEHAVIORAL|La Vida Buena Program|The intervention is series of interactive one hour weekly classes over the course of 8 weeks related to child healthy weight, exercise and nutrition. Facilitated by community health workers, the classes are interactive and play-based and designed to engage both the child and accompanying parent or guardian in activities.
224225982|NCT03781856|BEHAVIORAL|Brief Educational Session|A one hour session about nutrition and physical activity to address obesity facilitated by a community health worker
224225983|NCT03908021|DIAGNOSTIC_TEST|Microbiome analysis and 16S rRNA gene-based analysis|microbial DNA is extracted from the saliva and 16s library is prepared for sequencing.
224225984|NCT01557595|DEVICE|Polarized glasses designed to filter out blue light|"Participants will be given polarized glasses (yellow sun- glasses) which filter out blue light to wear only from sundown until bedtime for two weeks. They will be instructed to turn off fluorescent lights and only use household lamps for evening activities. They will be instructed not to drive while wearing the glasses. In addition to the oral instructions, they will also be given a written Instruction Sheet. Any oral insomnia agent will be held throughout the study, otherwise they are to follow their usual evening routines. This is an alternative treatment already in use in Dr. Fargason's practice for those patients who don't want to take sleep medications. This research focuses on the effectiveness of this treatment and involves questionnaires to do so."
223637987|NCT03002337|BEHAVIORAL|Aromatherapy massage|All of the participants in the aromatherapy group underwent aromatherapy massage for 70 minutes every two weeks between 16 to 36 weeks GA (ten sessions total). The aromatic massage oils were composed of 2 c.c. lavender (Lavandula angustifolia) blended with 98 c.c. almond oil. This concentration of the mixed essential oil was kept at room temperature for massage use.
223637988|NCT03002337|BEHAVIORAL|Yoga exercise|Prenatal yoga was offered in six 70-minute yoga sessions per week for 20 weeks, with 10-12 women in each session. Each participant should attend two sessions of yoga every two days, held in a quiet room near the prenatal clinic. Yoga specifically designed for women during the second and third trimesters, was guided by a midwife who was certified as a yoga instructor. Yoga included physical postures/ stretch, deep breathing, guided imagery, and deep relaxation. Before each posture/stretch, the instructor guided participants to relax each body part and calm their mind.
223637989|NCT01341353|PROCEDURE|catheter ablation|circumferential pulmonary vein isolation complex fractionated atrial electrograms ablation circumferential pulmonary vein isolation combined left atrial roof ablation circumferential pulmonary vein isolation combined left atrial isthmus ablation circumferential pulmonary vein isolation combined left atrial roof and isthmus ablation circumferential pulmonary vein isolation combined complex fractionated atrial electrograms ablation
223637990|NCT01341353|DRUG|Digaoxin,amiodarone,β receptor antagonist, Calcium Antagonists|
223637991|NCT06428292|DEVICE|Virtual reality device branded ''Meta Quest 2''|Combining different exercise equipment with a virtual reality device and using them in a virtual environment can be used to decide which one is more effective.
224225985|NCT02404597|DEVICE|NICOM (non-invasive cardiac output monitor)|"The non-invasive cardiac output monitor (NICOM) will be used to tailor fluid management to optimize resuscitation if the patient has an episode of hypotension (defined as systolic blood pressure \<100 or mean arterial pressure \<65). NICOM consists of two electrodes placed on the patient's chest and back and uses bioreactance technology to transduce signals to compute hemodynamic parameters on an associated monitor.~The electrodes will remain on the patient for twenty minutes. Once the electrodes are in place the patient's leg will be raised to 45 degrees and the monitor to which the electrodes are attached will generate a number that reflects stroke volume of the heart. The electrodes will be removed once this number is determined."
224225986|NCT01479452|PROCEDURE|Bariatric surgery|Gastric banding, vertical banded gastroplasty, gastric bypass
224225987|NCT01479452|OTHER|Usual care|Non-surgical obesity treatment
223637992|NCT04856800|DIETARY_SUPPLEMENT|Whey|20 g protein of whey protein isolate WPI (Lacprodan® ISO.Water. from Arla Foods Ingredients)
223637993|NCT04856800|DIETARY_SUPPLEMENT|Placebo|The placebo contains \<1 kcal and 0 g protein
223637994|NCT01523093|DRUG|Ondansetron|Orally Disintegrating Tablets 8mg
224225988|NCT05168956|OTHER|Collect data of medical record|"Collect data of medical record:~* Genealogy characteristics~* Family characteristics: Number of members in the sibling, rank in the sibling / incestuous relationships or not~* Graphic representation: age / gender / age at time of sexual assault / whether or not a victim of sexual violence / education / family dynamics / living environment during childhood / Criminal category"
223637995|NCT03742557|DRUG|Ketamine 50 MG/ML Injectable Solution, 0.5 mg/kg IV|Ketamine 0.5 mg/kg IV
223637996|NCT03631992|BEHAVIORAL|Low Sweet|Children in the experimental group get repeated exposure to lower sweet snacks and mothers get education lessons on dental care, reading food labels, portion size, and nutrition.
223637997|NCT03631992|BEHAVIORAL|Regular Sweet|Children in sham comparator get typical snacks and mothers get education lessons on portion size, physical activity, sleep, and screen time.
224225989|NCT04296357|DIAGNOSTIC_TEST|Developmental score according to The Ages & Stages Questionnaires®, Third Edition - ASQ®-3|Ages \& Stages Questionnaires®, Third Edition (ASQ®-3) is a developmental screening tool designed for use by early educators and health care professionals. It relies on parents as experts, is easy-to-use, family-friendly and creates the snapshot needed to catch delays and celebrate milestones.
223515468|NCT03969030|OTHER|PEBRA model|"The participants in the intervention clusters are offered the PEBRA model. In the PEBRA model the ART visit/refill is coordinated by the PE, as much as feasible according to the participants' preferences. Thus, the preferences of each participant are captured at enrolment and after a strict schedule thereafter. The PE conducts the preference assessment using a tablet-based application, called PEBRApp, accoring to a specific schedule. First, the participant will be asked his/her preference regarding different domains of DSD (see below) and this will be entered into the PEBRApp. Secondly, the chosen preferences are assessed regarding feasibility with specific questions, as not all preference options are available to everyone all the time. The preference assessment entails the following three domains of DSD:~1. ART Refill~2. SMS notifications~3. Support"
223515469|NCT03038919|DRUG|Testosterone cypionate|Bi-weekly intramuscular injection of testosterone cypionate 200mg.
223515470|NCT03038919|OTHER|Standard nutrition and physical therapy at ICU|follow-up of the patient without use of testosterone cypionate
223515471|NCT04802005|OTHER|Aerobic Interval Training|The aerobic interval training group
223515472|NCT04292496|PROCEDURE|Introperative leak testing|After anastomosis was completed. We test the integrity of anastomosis intraoperatively.
223515473|NCT02635672|DRUG|VIP152 (BAY 1251152)|The starting dose of Cohort 1 will be 5 mg IV (30 minute infusion) fixed dose once weekly (5 mg/week) for 21 day cycles.
223515474|NCT02635672|DRUG|VIP152 (BAY 1251152) 30 mg|30 mg IV (30 minute infusion) fixed dose once weekly of a 21 day cycle.
223515475|NCT02635672|DRUG|Keytruda|200 mg IV fixed dose once every 3 weeks of a 21 day cycle
223637998|NCT03488953|PROCEDURE|Living donor liver transplantation with two-staged hepatectomy.|Two-stage hepatectomy combined with transplantation of left-lateral lobe from a living donor.
223765019|NCT06325540|PROCEDURE|indirect pulp capping with therabase|indirect pulp capping using the therabase material
223765020|NCT06325540|PROCEDURE|indirect pulp capping with biodentine|indirect pulp capping using the biodentine material
223765021|NCT05733351|DRUG|Abiraterone|Given PO
223765022|NCT05733351|PROCEDURE|Biospecimen Collection|Undergo blood and stool sample collection
223765023|NCT05733351|PROCEDURE|Bone Scan|Undergo bone scan
223765024|NCT05733351|PROCEDURE|Computed Tomography|Undergo CT
223637999|NCT03979287|OTHER|Interferential Current and Therapeutic Exercise Program|"The Interferential Current Program will be based on a bipolar application using the Sonopuls 692 device (Enraf Nonius, Rotterdam, The Netherlands). The current parameters will be: a) 4000Hz carrier frequency; and b) 60 Hz AMF with a modulation frequency of 90 Hz. The intensity of the current will be adapted to the sensitivity of each patient.~The Therapeutic Exercise Program will be applied by a physiotherapist and will consist of:~1. Ergonomic advices on reducing repetitive movements and/or maintained positions~2. A protocol of active physiotherapy for neck and shoulder muscles. This protocol will include: active stretching exercises; isometric muscle strengthening exercises; reeducation of the ocular and neck muscles with control retraining exercises"
223638000|NCT03979287|OTHER|Therapeutic Exercise Program|"The Therapeutic Exercise Program will be applied by a physiotherapist and will consist of:~1. Ergonomic advices on reducing repetitive movements and/or maintained positions~2. A protocol of active physiotherapy for neck and shoulder muscles. This protocol will include: active stretching exercises; isometric muscle strengthening exercises; reeducation of the ocular and neck muscles with control retraining exercises"
224225990|NCT04296357|OTHER|Physical development and General Health|Physical development and General health examination
223638001|NCT02135432|DRUG|Ivacaftor|
223638002|NCT02135432|DRUG|Placebo|
223765025|NCT05733351|DRUG|Docetaxel|Given IV
224225991|NCT04296357|DIAGNOSTIC_TEST|Developmental Red flags|Developmental Red flags Questionnaires
224225992|NCT02806232|DRUG|Biltricide (racemate praziquantel) oral tablets|Biltricide (600 mg tablet) was administered to participants at a dose of 20 mg/kg in Part 1, Cohort 1 and at a dose of 40mg/kg in Part 1, Cohort 2.
224225993|NCT02806232|DRUG|Racemate Praziquantel ODT|Racemate Praziquantel (PZQ) (150) mg was administered at a dose of 40 mg/kg in Part 1, Cohort 3 and at a dose of 60 mg/kg in Part 1, Cohort 4.
224318987|NCT03654599|BEHAVIORAL|Information Control Intervention|Information Control Intervention Videos include Information about post-HCT. The topics in the IC include specific guidelines to return to wellness post HCT through (1) an exercise plan, (2) a nutrition (dietary) plan, (3) pain management, (4) information about the complications, (5) caregiver responsibilities, (6) social support, (7) preventing from infections, and (8) symptom management. Participants randomized to the IC will receive the full set of DS modules only after the final 3-month post-intervention data collection point has passed and they can view them as desired.
223765026|NCT05733351|DRUG|Enzalutamide|Given PO
224318988|NCT06828198|DEVICE|KOS® XL|Delivery of medical device as injection
224318989|NCT07133932|DEVICE|Transcutaneous electrical phrenic nerve stimulation|Non-invasive transcutaneous electrical phrenic nerve stimulation which can cause explicit contraction of the diaphragm, and the stimulation current may be set to 5-30mA depending on the participant's condition.
224318990|NCT07133932|DEVICE|Sham (No Treatment)|The stimulation current is set to 0.
224318991|NCT07133984|DIAGNOSTIC_TEST|Cardiac Magnetic Resonance Imaging|Cardiac MRI, also known as cardiac magnetic resonance imaging, is a non-invasive imaging technique that uses strong magnetic fields and radio waves to produce detailed pictures of the heart and its surrounding structures
224318992|NCT07133594|OTHER|RTEQ (RadioTherapy Experience Questionnaire) in French|Complete the RTEQ questionnaire translated and adapted to the French language in patients receiving external radiotherapy. Depending on the number of radiotherapy sessions received, the questionnaire will be completed 1 or 2 times during the study.
224318993|NCT07133594|OTHER|EORTC PATSAT-C33 questionnaire|Complete the EORTC-PATSAT-C33 questionnaire after completing the RTEQ questionnaire. Depending on the number of radiotherapy sessions received, the questionnaire will be completed 1 or 2 times during the study.
223515476|NCT02635672|DRUG|VIP152 (BAY 1251152) 15 mg|The starting dose of Cohort 3 will be 15 mg IV (30 minute infusion) fixed dose once weekly (15 mg/week) for 21 day cycles.
223515477|NCT05933876|DIAGNOSTIC_TEST|To propose a diagnostic test to determine the viability of Stereotactic ABlative Radiotherapy (SABR).|Analyze clinical data, medical images and molecular circulating features to propose which variables serve to select the patients that will achieve complete response after SABR.
223765027|NCT05733351|PROCEDURE|FDG-Positron Emission Tomography|Undergo FDG PET
223765028|NCT05733351|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223765029|NCT05733351|PROCEDURE|PSMA PET Scan|Undergo PSMA PET
223515478|NCT05933876|DIAGNOSTIC_TEST|To propose a diagnostic test to determine the effectiveness of SABR.|Collect blood samples at five different time points before and after treatment and analyze circulating tumoral DNA, medical images, and metabolites to monitor the effect of SABR and its effectiveness.
223515479|NCT05933876|DIAGNOSTIC_TEST|To propose a diagnostic test for Oligometastatic Cancer (OC).|Analyze circulating tumoral DNA and metabolites from blood samples in search of the profile of OC.
223765030|NCT05733351|DRUG|Vudalimab|Given IV
224225994|NCT02806232|DRUG|Levo Praziquantel ODT|Levo PZQ (150 mg) was administered at a dose of 30 mg/kg in Part 1 Cohort 5, 45 mg/kg Part 1 Cohort 6, 60 mg/kg Part 1 Cohort 7, 50 mg/kg Part 2 Cohort 8, and 50 mg/kg Part 2 Cohort 9.
224225995|NCT05583383|DRUG|camrelizumab|camrelizumab was administered intravenously at a fixed dose of 200 mg, on the first day, once every 3 weeks, with a cycle of 3 weeks. Infusion for 30 min each time (no less than 20 min and no more than 60min); SOX: Oxaliplatin: 130 mg/m2, administered intravenously, on the first day, once every three weeks, and every three weeks is a cycle; S-1: according to BSA (\< \<1.25 40 mg；; 1.25-1.5 50 mg； \> \>1.5 60 mg), oral administration, d1-d14 twice a day, 3 weeks as a cycle; Trastuzumab was administered intravenously, with an initial loading dose of 8 mg/kg and a subsequent dose of 6 mg/kg, with a cycle of 3 weeks.
224225996|NCT00406978|DRUG|Prednisone|Prednisone will be given orally at the dose of 1.5 mg/Kg for 4 days followed by a 31-day rest period (days 5 through 35)
224225997|NCT00406978|DRUG|Melphalan|Melphalan will be given orally at the dose of 0.25 mg/Kg for 4 days,
224225998|NCT00406978|DRUG|Thalidomide|Thalidomide will be administered orally at the initial dose of 50 mg/day p.o. once daily, with increment of 50 mg after a month to acceptable tolerance (maximum 100 mg), continuously for the entire 6 courses.
224318994|NCT07081022|DRUG|JS203 in combination with gemcitabine and oxaliplatin|Gemcitabine and oxaliplatin 8 cycles (Q3W) and JS203 (21 days/cycle) Cycle 1 QW,Cycle 2 and therafter Q3W until progression or unacceptable toxicity.
223638003|NCT04761224|DEVICE|Fluido® Irrigation Fluid Heater System|"Patients in the Heated group will benefit from intraoperative warming by means of NaCl bags instilled using the Fluido® Irrigation warming cassette and with the use of specific instillation tubing (SEBAC laboratory, Set URO Fluido® Irrigation): this device allows continuous and precise heating of the solution with an instillation temperature of 38-39°C."
223638004|NCT00997776|OTHER|progressive resistance exercise|lower extremity strengthening: 3 sets of 8 repetitions at the 8 repetition maximum (8RM)for the hip and knee extensors, hip abductors, plantarflexors twice weekly for 10 weeks.
223638005|NCT00997776|OTHER|TENS|Transcutaneous electrical nerve stimulation (TENS) to elicit sensory information (comfortable tingling) for 7 minutes to bilateral muscle groups including the gluteal muscles, quadriceps, and gastroc-soleus muscles. TENS administered twice weekly for 10 weeks.
223638006|NCT02556840|OTHER|insulin therapy|
223638007|NCT00914316|DRUG|Ranolazine|Ranolazine, 1000 mg, capsule, twice daily, by mouth.
223638008|NCT00914316|DRUG|Placebo|twice daily
223638009|NCT00242502|DRUG|Bevacizumab (Avastin)|10 mg/kg IV every 14 days, repeat cycle every 28 days
223638010|NCT00242502|DRUG|Erlotinib|150 mg orally every day continuous dosing, repeat cycle every 28 days
223638011|NCT00122083|DEVICE|Health education information|
223638012|NCT02979496|DIETARY_SUPPLEMENT|0 g pomace (control)|16 oz of juice containing 0 g of citrus pomace will be consumed each day for 3 weeks by participants in the group receiving this assignment (group is unknown, double-blinded)
223638013|NCT02979496|DIETARY_SUPPLEMENT|90 g pomace|16 oz of juice containing 90 g of citrus pomace will be consumed each day for 3 weeks by participants in the group receiving this assignment (group is unknown, double-blinded).
223638014|NCT02979496|DIETARY_SUPPLEMENT|180 g pomace|16 oz of juice containing 180 g of citrus pomace will be consumed each day for 3 weeks by participants in the group receiving this assignment (group is unknown, double-blinded).
223638015|NCT02979496|DIETARY_SUPPLEMENT|Flavored water (control)|16 oz of a flavored, calorie-matched water beverage will be consumed each day for 3 weeks by participants in the group receiving this assignment (group is unknown, double-blinded).
223638016|NCT00355966|DRUG|Misoprostol|In one group of women immediate induction of labour will be done by intravaginal misoprostol 25 microgram 4 hourly , a maximum of 5 doses .
223638017|NCT00355966|DRUG|PGE2 gel|In other group immediate induction of labour will be done by intravaginal application of PGE2 gel 0.5 mg at an interval of 6 hours , a maximum of 2 doses.
223638018|NCT02802540|DRUG|Nabilone|Patients going to take 0.5 mg capsules of nabilone (CESAMET) the first 2 weeks and then increased to 1 mg to complete 8 weeks.
223638019|NCT02802540|DRUG|Placebo|Patients going to take capsules of placebo until complete 8 weeks.
224225999|NCT00406978|DRUG|Defibrotide|Lev - 1 Def = 10 mg/Kg (max 0.6 g) on days 1-4, followed by 1.2 g (400 mg every 8 hours) p.o. through day 35 Lev - 1 Def = 1.2 g p.o (400 mg every 8 hours) on days 1-4, followed by 1.2 g (400 mg every 8 hours) p.o. through day 35 Level + 1 Def = 17 mg/Kg (max 1.2 g) on days 1-4, followed by 1.6 g p.o. (400 mg every 6 hours) through day 35 Lev + 1 Def = 2.4 g p.o. (400 mg every 4 hours) on days 1-4, followed by 1.6 g p.o. (400 mg every 6 hours) through day 35 Lev + 2 Def = 34 mg/Kg (max 2.4 g) as a i.v. injection on days 1-4, followed by 3.2 g p.o. (800 mg every 6 hours) through day 35 Lev + 2 Def = 4.8 g p.o. (800 mg every 4 hours) on days 1-4, followed by 3.2 g p.o. (800 mg every 6 hours) through day 35 Lev + 3 Def = 51mg/Kg (max 3.6 g) as a i.v. injection on days 1-4, followed by 4.8 g p.o. (1200 mg every 6 hours) through day 35 Lev + 3 Def = 7.2 g p.o.(1200 mg every 4 hours ) on days 1-4, followed by 4.8 g p.o. (1200 mg every 6 hours) given p.o. through day 35
224318995|NCT07081022|DRUG|JS203 in combination with ifosfamide, carboplatin and etoposide|Ifosfamide, carboplatin and etoposide, 3 cycles (Q3W) and JS203, Cycle 1 QW, Cycle 2 and therafter Q3W until trasnplant, progression or unacceptable toxicity.
224318996|NCT07081022|DRUG|JS203 in combination with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone|Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone 6 cycles (Q3W) and JS203, 8 cycles (21 days/cycle), Cycle 1 QW, Cycle 2 to Cycle 8 Q3W.
224318997|NCT07081022|DRUG|JS203 combined with lenalidomide|lenalidomide,12 cycles, Cycle 1(Q3W), Cycle 2 to Cycle 12 (Q4W) and JS203, 12 cycles, Cycle 1 (21 days/cycle) QW, Cycle 2 to Cycle 12 (28 days/cycle) Q4W.
224318998|NCT07081152|OTHER|Ferrous sulfate|All participants will receive a single dose of 15 mg of iron as isotopically prepared ferrous sulfate labelled with 57Fe. The iron dose will be given with ascorbic acid to attain a molar ratio of ascorbic acid:iron of 2:1
223638020|NCT01759446|DRUG|Placebo taken first|Snorted in both nostrils within 5 minutes; 48 hours washout between doses
223638021|NCT01759446|DRUG|Generic H/A taken first|Snorted in both nostrils within 5 minutes; 48 hours washout between doses
223638022|NCT01759446|DRUG|Vycavert taken first|Snorted in both nostrils within 5 minutes; 48 hours washout between doses
223638023|NCT01759446|DRUG|Generic H/A plus i taken first|Snorted in both nostrils within 5 minutes; 48 hours washout between doses
223638024|NCT01759446|DRUG|Generic H/A plus p taken first|Snorted in both nostrils within 5 minutes; 48 hours washout between doses
223638025|NCT03843840|DEVICE|Combined Coaxial Optical Coherence Tomography|Taking images of the retina with two wavelengths
223638026|NCT04530084|DEVICE|OMNI Surgical System|Scheduled for canaloplasty and trabeculotomy with or without cataract extraction
223638027|NCT03710499|PROCEDURE|Physical activity|Activities included overall stretching and strengthening (flexion, extension, adduction and abduction movements) and muscular endurance exercises (exercises involving open and closed kinetic chains), along with aerobic conditioning using a functional circuit.
223638028|NCT00195104|DRUG|Arsenic Trioxide (Tricenox)|
223638029|NCT00195104|DRUG|Cytarabine|
223638030|NCT04112719|OTHER|supine position|The patient will be placed in a supine position. Changes in cardiac output will be measured.
223638031|NCT04112719|OTHER|15 degrees lateral tilt|The patient will be placed in 15 degrees lateral tilt position. Changes in cardiac output will be measured.
223638032|NCT04112719|OTHER|30 degrees lateral tilt|The patient will be placed in 30 degrees lateral tilt position. Changes in cardiac output will be measured.
223765031|NCT06858111|BIOLOGICAL|Fertilo|Fertilo is an engineered line of ovarian support cells that aid egg maturation.
224318999|NCT06901115|PROCEDURE|Nesbit technique|it is composed of development of trough at the right prostatic lobe (at 10 o'clock) from the bladder neck proximally down to a level just above the external urethral sphincter distally, then deepening the trough until the prostatic capsule, performing haemostasias then resection of lateral lobes in halves, upper right, lower right, upper left and at last lower left respectively with haemostasias in-between. Then resection of the median lobe if present. Final haemostasias then ensues before insertion of the triple way catheter with normal saline irrigation.
223638033|NCT02338596|PROCEDURE|Total hip replacement|"1. Simultaneous bilateral sequential total hip arthroplasties under the same anesthetic.~2. Randomization to treatment with an ultra-short or a convnetional cementless stem was accomplished with use of study numbers in sealed envelope, which were opened in the operating room before the skin incision was made.~3. The pore size was 250㎛. A 28-mm-diameter Biolox forte ceramic femoral head (CeramTec AG, Polchingen, Germany) ) was used in all hips. A cementless cup and a 28mm internal-diameter Biolox forte ceramic liner was used in all hips in both groups."
223638034|NCT00400166|BEHAVIORAL|Recovery Mentor|Provided Recovery Mentor services
223638035|NCT01751620|BEHAVIORAL|Project ACCEPT|The intervention, Project ACCEPT, combines weekly individual and group sessions that address a range of issues that impact engagement in care for youth living with HIV, including stigma, disclosure, health relationships, substance use, and future life plans.
223638036|NCT01751620|BEHAVIORAL|HEALTH|The comparison condition, HEALTH, matches Project ACCEPT in number of sessions and duration. The weekly sessions will cover information on alcohol, drugs, HIV and other sexually transmitted diseases (STDs) to meet the ethical responsibility to provide risk reduction information to youth assigned.
223638037|NCT02755246|DIETARY_SUPPLEMENT|Polyamine supplementation|3 months of polyamine supplementation (3 capsules/day)
223638038|NCT02755246|DIETARY_SUPPLEMENT|Placebo supplementation|3 months of placebo intake (3 capsules/day)
223638039|NCT04204525|DIAGNOSTIC_TEST|Quantitative sensory testing|"Electrical detection and pain thresholds will be determined (at the sural nerve of the dominant leg and at the median nerve of both arms) with a constant current electrical stimulator.~Endogenous pain facilitation will be assessed by a temporal summation paradigm by delivering 20 electrical stimuli at the intensity of the electrical pain threshold.~Endogenous pain inhibition will be assessed by a conditioned pain modulation paradigm with electrical stimulation as test stimulus and the cold pressor test as conditioning stimulus.~EEG measurements with be performed with scalp EEG with 32 surface Sn electrodes in a headcap in referential montage following the standard 10-20 recording system.~A 5 minute resting state measurement will be performed with eyes closed, followed by EEG measurements during the condition pain modulation paradigm to assess the evoked-related potentials."
223638040|NCT05825352|DEVICE|Carmellose eye drops|Ocular drops based upon carmellose
223638041|NCT02991872|PROCEDURE|Blood draw|Subjects aged from ≥6 to ≤17 years at the time of enrolment in the parent clinical trial (following the CFDA post-marketing commitment requirement) and who received the full PEP rabies regimen as an intramuscular injection according to the vaccine group to which they were assigned in the V49\_24 (NCT01680016) study will be invited to take part in this study. Single blood draw from subjects at Day-1/Visit-1. Subjects will be observed for 15 minutes after the blood draw.
223638042|NCT04513223|DRUG|SHR-A1811|There are six pre-defined dose regimens . Subjects will be enrolled with an initial dose
223638043|NCT01528332|DEVICE|Pain Relief Patch|The Pain Relief Patch is a non CE-marked device that is worn on the painful area of the back, where it shines light (453 ± 7 nm, maximum 42 ± 6 mW/cm2 and average 20 ± 1 mW/cm²). It will be used 5 times over 14 days for 30 minutes each time.
224226000|NCT06114433|OTHER|3D printed educational model|Slide-based presention plus 3D printed educational model
224226001|NCT06114433|OTHER|Traditional model education|Slide-based presention plus traditional model
224226002|NCT01717898|DRUG|BEZ235|BEZ235 - 200 mg, 300 mg, or 400 mg; po, BID. BEZ235 will be supplied in 200 mg, 300 mg, and 400 mg sachets packaged in boxes.
224226003|NCT01717898|DRUG|Prednisone|10/mg po daily. Prednisone can be modified at the investigator's discretion, but should not be discontinued.
224226004|NCT01717898|DRUG|Abiraterone acetate|1000 mg, po. Abiraterone Acetate is supplied in 250 mg white tablets, four tablets are to be taken with a full glass of water on an empty stomach once daily.
224226005|NCT03632174|OTHER|Topical Ointment with L. reuteri|Topical Ointment containing live Lactobacillus reuteri DSM17938 applied twice daily in dry areas of the entire body
223638044|NCT01528332|DEVICE|Control PRP device|The Control PRP device is also a non CE-marked device. It is similar in appearance to the active Pain Relief Patch, except that it shines light of a different wavelength(531 ± 7 nm, maximum 0.4 ± 0.1 mW/cm² and average 0.2 ± 0.05 mW/cm²) for just 5 seconds before it turns off. Participants in the control arm will be treated with the control PRP device 5 times over 14 days for 30 minutes each time.
223638045|NCT03108326|BIOLOGICAL|Stelara, Remicade, Entyvio, Humira, Remsima, Flixabi, Inflectra|The data of Crohn´s Disease (CD)-patients on Ustekinumab will be compared in an explorative analysis with CD-patients on other Biologics.
223638046|NCT03163303|BEHAVIORAL|Tobacco Status Project Intervention|90 days of Facebook messaging, weekly live sessions targeting tobacco use
223638047|NCT03163303|BEHAVIORAL|Tobacco Status Project + Alcohol Intervention|90 days of Facebook messaging, weekly live sessions targeting tobacco use and alcohol use
223638048|NCT03163303|DRUG|nicotine patch|14-day supply of nicotine patch
224226006|NCT03632174|OTHER|Topical Ointment without L. reuteri|Topical Ointment that does not contain Lactobacillus reuteri DSM17938 applied twice daily in dry areas of the entire body
224226007|NCT03265470|DRUG|Dexmedetomidine|Patients will receive Loading dose of dexmedetomidine (0.8μg/kg) over 20 minutes, followed by intravenous infusion (0.4μg/kg/h) during intra-operative period till end of procedure.
224226008|NCT03265470|DRUG|Fentanyl|Patients will receive Loading dose of fentanyl (1μg/kg), followed by intravenous infusion (1μg/kg/h) during intra-operative period till end of procedure.
224226009|NCT01607775|DEVICE|Implantation of a PEEK-cage|A commercially avaliable cuboid cervical cage will be implantet
224226010|NCT01607775|DEVICE|PMMA-cage|The in-house produced cervical cage will be implanted
223638049|NCT04375280|OTHER|"Development of a screening algorithm designed to determine a dysmobility profile in patients with chronic illness."|"Firstly, volunteers will be invited to complete online questionnaires on a secure platform. The mobility assessment will be carried out initially (t1) and up to a maximum of 4 times (t1 to t4) as part of a day hospitalization. Questionnaires will be diverse (SF36, KOOS, HOOS, BROCKER, MNA, TAMPA, etc.) in order to assess several aspects that compose mobility.~Physical evaluations will include various validated tests (isokinetic strength measure, TUG, 6MWT, Berg Balance Scale, etc.)"
223638050|NCT05570825|PROCEDURE|Biopsy|Undergo biopsy
223638051|NCT05570825|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
223638052|NCT05570825|PROCEDURE|Computed Tomography|Undergo PET/CT or CT
223638053|NCT05570825|DRUG|CXCR1/2 Inhibitor SX-682|Given PO
223638054|NCT05570825|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223638055|NCT05570825|BIOLOGICAL|Pembrolizumab|Given IV
223638056|NCT05570825|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
223638057|NCT01157403|BIOLOGICAL|Autologous transplantation|Autologous transplantation of bone marrow mesenchymal stem cells (approximately 2.5 x 106 cells/kg body weight) intravenously
223638058|NCT00705952|OTHER|Lifestyle intervention|Diet, exercise and behavioural change intervention.
223638059|NCT00960882|DRUG|DMMET-01|1050.6 mg daily for 30 days
223638060|NCT05836506|DRUG|ABBV-903 Tablet Form 1|Oral Tablets
223638061|NCT05836506|DRUG|ABBV-903 Tablet Form 2|Oral Tablets
223638062|NCT06192654|PROCEDURE|Small intestinal submucosa (SIS) graft urethroplasty|Standard technique of doing a substitution urethroplasty with no modification to the surgical steps. Instead of an autologous oral bucal mucosa graft, the small intestinal submucosa graft is sutured to the healty urethral area after incision of the urethra at the stricture location.
223638063|NCT06192654|PROCEDURE|Autologous oral bucal mucosa graft urethroplasty|Standard technique of doing a substitution urethroplasty with no modification to the surgical steps. The autologous oral bucal mucosa graft is sutured to the healty urethral area after incision of the urethra at the stricture location.
223638064|NCT05370937|PROCEDURE|ARTROSCOPİC SURGERY WITH ELEVATOR SYSTEM|TRANSTİBİAL PULL OUT REPAİR FOR MEDİAL MENİSCUS POSTERİOR ROOT TEARS
223638065|NCT05370937|PROCEDURE|ARTROSCOPİC SURGERY WITHOUT ELEVATOR SYSTEM|TRANSTİBİAL PULL OUT REPAİR FOR MEDİAL MENİSCUS POSTERİOR ROOT TEARS WITH ELEVATOR SYSTEM
223638066|NCT00897832|OTHER|laboratory biomarker analysis|Using material that is already being acquired as a component of clinical care (only that which is excess after routine clinical care), it will be determined if pre-treatment markers can be used to correlate with clinical outcomes of survival and recurrence. Examples of such markers include studying if the integrity of DNA repair pathway in pancreatic cancers, analyzed by Rad51 and phosphorylated DNA-PK foci formation, correlates with tumor response to radiotherapy, chemotherapy, and overall survival.
223638067|NCT04981483|PROCEDURE|conservative surgery for uterus in placenta accreta|After removal of the placenta, grasping the cervix from the both lips and one from each side of the cervical canal at the level of the internal os, each uterine angle and grasped the remaining lower uterine segment and Nelaton catheter was inserted inside the cervical canal to avoid closing the cervix with sutures of the uterine incision.Closing the uterine incision;taking suture at the lateral angle of the cervix and suturing it to the lower edge of the uterine angle, then another continuous suture was attached to the upper edge of the uterine incision angle\[outside in-in out then out in-in out\] and the same technique was repeated on the other side (cervico-isthmic sutures). controlling bleeding from the inner surface of the remaining lower uterine segment was done by 2-3 interrupted sutures between the lower uterine segment and the anterior cervical lip. closing of the uterine incision in continuous non-locking manner
223638068|NCT02261701|OTHER|Early mobilization|Early mobilization, collar´n cuff 4 weeks post surgery and after this light exercises start and no further bandage.
224226011|NCT04219202|RADIATION|Proton radiation|Therapeutic radiation Treatment with Protons
223638069|NCT02261701|OTHER|Post surgery shoulder lock|Post surgery: Shoulder lock with abduction cushion, additionally 3 weeks with collar´n cuff, and after this period light exercises are allowed and nu further bandage.
223638070|NCT00225485|DRUG|Effexor XR|
223638071|NCT05097079|DRUG|MYOBLOC Low Dose|Subjects assigned to the MYOBLOC Low Dose treatment group will be administered MYOBLOC (60 units/kg; maximum 1800 units) as a single treatment via intraglandular injection (5.0 units/kit per submandibular gland \[maximum 150 units\] and 25.0 units/kg per parotid gland \[maximum 750 units\])
223638072|NCT05097079|DRUG|MYOBLOC High Dose|Subjects assigned to the MYOBLOC High Dose treatment group will be administered MYOBLOC (100 units/kg; maximum 3000 units) as a single treatment via intraglandular injection (25.0 units/kit per submandibular gland \[maximum 300 units\] and 40.0 units/kg per parotid gland \[maximum 1200 units\])
223638073|NCT05097079|DRUG|Placebo|Subjects assigned to the Placebo treatment group will be administered volume-matched placebo (1:1)
223765032|NCT06858111|DEVICE|Medicult IVM|MediCult IVM is a system of culture media designed for the in vitro maturation of immature oocytes.
223765033|NCT06663761|BEHAVIORAL|Stimuli|"Stimuli (the order of stimuli 1-4 will be electronically randomized), with a break time between stimuli of 5-10 minutes:~1. Non-invasive blood pressure measurement~2. Heat~3. Mechanical stimulation~4. Visual stimulation~5. Cold pressor test~6. Spicy taste"
224226012|NCT04219202|RADIATION|Carbon Ion radiation|Therapeutic radiation Treatment with Carbon Ions
224226013|NCT03673826|DRUG|Carfilzomib|9 cycles 20/36mg/m2 days 1,2,8,9,15,16
224226014|NCT03673826|DRUG|Dexamethasone|4 cycles 20 mg days 1,2,8,9,15,16,22,23 followed by 5 cycles 10mg days 1,2,8,9,15,16,22,23
224226015|NCT03673826|DRUG|Lenalidomide|9 cycles 25mg days 1-21 followed by 24 extended dosing cycles 10mg days 1-21
224226016|NCT01883089|BEHAVIORAL|Motivational Enhancement Therapy|
224226017|NCT04606563|DRUG|Losartan|Oral losartan 25 mg, stepped up to 50 mg and then up to 100 mg peak dose, as tolerated.
224226018|NCT04606563|DRUG|Valsartan|Oral Valsartan 40 mg, stepped up to 80 mg and then up to 160 mg peak dose, as tolerated.
224226019|NCT04606563|DRUG|Azilsartan|Oral Azilsartan 40 mg, and stepped up to 80 mg.
224226020|NCT04606563|DRUG|Candesartan|Oral Candesartan 8 mg, stepped up to 16 mg and then up to 32 mg peak dose, as tolerated.
224226021|NCT04606563|DRUG|Eprosartan|Oral Eprosartan 400 mg, stepped up to 600 mg and then up to 800 mg peak dose, as tolerated.
223638074|NCT04266704|BEHAVIORAL|Sharing Intervention|intervention includes both analytic and socioemotional components related to self-management of hypertension and is specifically targeted to African American women. Along with providing education on lifestyle changes to lower blood pressure, DASH diet, exercise, and medication adherence (analytic components), the intervention is designed to promote social activities around blood pressure self-management, in particular, sharing blood pressure management information with peers (socioemotional components).
223638075|NCT06212362|BEHAVIORAL|Step-by-step|"The Step-by-Step follows a stepped care approach, were all children (and caregivers) complete the first step (a brief group intervention followed by an individual session). Those with more needs are offered to continue to step 2 where individual CBT is given.~Step 1 Session 1-4: Group sessions including psychoeducation, parenting skills and mapping stress and vulnerability factors, exposure and coping skills (90 minutes) Session 5: Individual session - If ending after step 1 a maintenance plan is completed. If continuing to step 2 continued exposure and selection of optional focus areas such as emotion regulation, social skills, stress- and vulnerability factors, child worry or parental worry. (45 minutes)~Step 2 Session 6-8: Individual sessions - Exposure and selected focus areas. (45 minutes)"
223638076|NCT06212362|BEHAVIORAL|Cool Kids|"The Cool Kids Program is an Australian manualized group CBT treatment of child anxiety, which has been broadly implemented in Sweden. Several studies have found evidence of its efficacy.~Session 1-10: Group sessions including psychoeducation, cognitive restructuring (gather evidence to reevaluate anxiety related thoughts), parent skills, exposure, social skills, coping skills (cognitive and behavioral strategies to handle anxiety reactions, learning problem-solving skills). (90-120 minutes)"
223638077|NCT05369845|OTHER|questionary|the patient will complete validated questionnaires, at three periods (at the time of the initiation of the CPAP, and during the 2 planned follow-up consultations: four months and at 1 year) The validated questionnaires are as follows: Illness Perception Questionnaire (IPQ-R), Beliefs about Medicines Questionnaire (BMQ), Morisky Medication Adherence Scale (MMAS), Hospital Anxiety and Depression Scale (HADS), Rollnick Scale.
223638078|NCT03499483|DRUG|bictegravir|Single One Pill Formulation of bictegravir, emtricitabine/tenofovir alafenamide (Bictarvy) to be taken once daily orally for a period of 28 days.
223638079|NCT05189808|PROCEDURE|Radiofrequency Ablation|Ultrasound guided radiofrequency ablation (non-experimental)
223638080|NCT06802003|DEVICE|Biometric wearable and handheld devices|In this study, participants will be equipped with biometric wearable devices, i.e. ring and wristband, as well as with a handheld oscillometer, to measure their physiological parameters and lung mechanical changes (lung function).
223638081|NCT06523959|DRUG|Apixaban 2.5 MG|To evaluate the benefits and risks of thromboprophylaxis with oral factor Xa inhibitor Apixaban compared to No anticoagulation
223638082|NCT04941716|DRUG|Acalabrutinib|Given PO
224226022|NCT04606563|DRUG|Irbesartan|Oral Irbesartan 75 mg, stepped up to 150 mg and then up to 300 mg peak dose, as tolerated.
224226023|NCT04606563|DRUG|Olmesartan|Oral Olmesartan 10 mg, stepped up to 20 mg and then up to 40 mg peak dose, as tolerated.
224226024|NCT04606563|DRUG|Telmisartan|Oral Azilsartan 40 mg, and stepped up to 80 mg.
224226025|NCT04230226|DIETARY_SUPPLEMENT|Pre-workout plus and protein recovery plus|Study products consumed prior and after exercise
223638083|NCT04941716|DRUG|Venetoclax|Given PO
223638084|NCT04941716|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223638085|NCT04941716|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration and biopsy
223638086|NCT04941716|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow aspiration and biopsy
223638087|NCT04941716|PROCEDURE|Computed Tomography|Undergo CT
223638088|NCT04941716|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223638089|NCT03961672|DRUG|Duvelisib|Given PO
223638090|NCT01099605|DEVICE|placement of a continuous infusion pump|Each infusion pump is placed below the mucosa of the rectum. Infusion of either the drug or saline will continue for approximately 3-4 days.
223638091|NCT01099605|DEVICE|continuous infusion pump of bupivacaine|bupivacaine 0.25% at 4ml/hr for 3 to 4 days
223638092|NCT04587518|BEHAVIORAL|Personality-Based Cognitive Behavioral Therapy|The study treatment will take place across 18-sessions. The first session will involve psychoeducation regarding BPD.The next two sessions with include exercises drawn from Behavioral Activation (i.e., identification of value-based goals) and Motivational Interviewing (i.e., pros and cons \[long and short-term consequences\] of tolerating emotions, engaging in prosocial behavior, and delaying gratification). Next, patients will receive 5 sessions of cognitive interventions (i.e., cognitive reappraisal related to situations/emotions, schema related to relationships, 5 sessions of behavior change skills (i.e., acting opposite to emotion-driven urges, exposure, assertiveness training), and 5 sessions of mindfulness skills (i.e., nonjudgmental emotion awareness, compassion training, urge surfing). Finally, treatment will conclude with 2 sessions of Relapse Prevention strategies. All sessions will last for 60 minutes in duration.
223638093|NCT05924633|DIETARY_SUPPLEMENT|Supplement containing a protein hydrolysate + beta glucan (Wellmune®)|Supplement taken daily for 4 weeks.
223638094|NCT05924633|DIETARY_SUPPLEMENT|Placebo supplement containing maltodextron|Placebo supplement taken daily for 4 weeks.
223638095|NCT06793917|DRUG|Tislelizumab|Tislelizumab will be administered on day 1 of each cycle at 200mg once every 14 days.
224226026|NCT04230226|OTHER|Placebo|Placebo product consumed prior and after exercise
223638096|NCT06793917|DRUG|Oxaliplatin injection|Oxaliplatin will be administered on day 1 of each cycle at 85mg/m2 once every 14 days.
223638097|NCT06793917|DRUG|Levo-Leucovorin|Levo-Leucovorin will be administered on day 1 of each cycle at 200 mg/m2 once every 14 days.
224226027|NCT02986763|BIOLOGICAL|Questionnaire, blood, urine, hair and dust samplings|
224226028|NCT05659550|DEVICE|Honeywell HT-900 Turbo Force Air Circulator|This is a basic, portable, household fan with a single cost of CDN$21.99.
224226029|NCT00258622|DRUG|NS1209|
224226030|NCT00258622|DRUG|Lidocaine|
224226031|NCT02770950|DRUG|Zushima plaster with high dose|Patients in high dose Zushima plaster group will use Zushima plaster topically on knee(s) for 24h per day.
224226032|NCT02770950|DRUG|Zushima plaster with low dose|Patients in low dose Zushima plaster group will use Zushima plaster topically on knee(s) for 12h per day.
224226033|NCT02770950|DRUG|Indometacin Cataplasms|Patients in Indometacin Cataplasms group will use Indometacin Cataplasms on knee(s)for 24h per day.
224226034|NCT06104696|PROCEDURE|Functional geriatric assessment|Examination of physical and mental status using standardized tests.
223638098|NCT06793917|DRUG|5-fluorouracil|5-fluorouracil will be administered at 2400 mg/m2 over 46-hour every 14 days.
223638099|NCT06793917|DRUG|Paclitaxel|Paclitaxel will be administered on day 1 of each cycle at 135mg/m2
223638100|NCT05856734|DEVICE|Weight and body composition change|1- Anthropometric Measurements: Body Weight (BW), Body Mass Index (BMI), Sitting Height Ratio (SHR), Waist to Hip Ratio (WHR), Finger Ratio (FR), Body Fat (BF%), and Weight-for-age growth charts. (Single measure)
223765034|NCT06670443|DEVICE|experimental group|Electrical neuromuscular stimulation electrode patches will be applied over the intercostal respiratory muscles and leg muscles (placed superficially just below each knee, over the head of the fibula, in close proximity to the common peroneal nerve).
223765035|NCT06670443|DEVICE|control group|Placebo electrical neuromuscular stimulation electrode patches will be applied over the intercostal respiratory muscles and leg muscles (placed superficially just below each knee, over the head of the fibula, in close proximity to the common peroneal nerve).
224226035|NCT04027764|DRUG|Toripalimab Combined With S1 and Albumin Paclitaxel|Toripalimab 240 mg ，every 2-3 weeks S1：80-120mg，bid；oral，d1-14； Albumin Paclitaxel：120mg/m2，D 1 \\8
224226036|NCT01621490|BIOLOGICAL|Nivolumab|
224226037|NCT01621490|DRUG|Ipilimumab|
224226038|NCT02253277|DRUG|Nilotinib|Nilotinib was supplied by Novartis as 150 mg and 200 mg hard gelatin capsules. Nilotinib was not dosed by weight or body surface area. Medication labels were in German and complied with the legal requirements of Germany. They included storage conditions for the drug but no information about the patient. The investigator emphasized compliance and instructed the patient to take nilotinib exactly as prescribed.
224226039|NCT02253277|DRUG|Ruxolitinib|Ruxolitinib was supplied by Novartis as 5 mg, 15 mg, and 20 mg tablets. Medication labels were in German and complied with the legal requirements of Germany. They included storage conditions for the drug but no information about the patient. The investigator emphasized compliance and instructed the patient to take ruxolitinib exactly as prescribed.
224226040|NCT00506753|BEHAVIORAL|MI/CBT|Motivational Interviewing followed by Cognitive Behavior Therapy
224226041|NCT00506753|BEHAVIORAL|RT/SU|Relaxation Training followed by Treatment as Usual
224226042|NCT05870553|DRUG|CTP0301-A|Bowel Preparation
224319000|NCT06901115|PROCEDURE|Corkscrew technique|the Corkscrew technique was performed by resection starting at 3 o'clock and carried on in a clockwise manner till 3 o'clock again. Prostate was resected from bladder neck downwards to the verumontanum after dividing the gland, imaginary, into 3 zones or thirds, proximal, middle and distal zone. The gland was resected zone by zone in this corkscrew manner. Once the proximal third is resected and hemostasis done, the middle third resection is done in the same manner, The process is repeated for the distal third. Hemostasis was performed instantly.
224319001|NCT05052047|OTHER|Brisk Walking Group|Brisk Walk: 20 min/day (The researchers found, for most people, brisk walking could be defined as moving at a pace of 2.7 miles per hour or 100 steps per minute for adults under about age 60 or guidelines define brisk walking as occurring when individuals move at a pace that increases their heart rate to about 70% of their heart rate maximum) Patient will also perform breathing exercises as given to Control group, Positioning (lean forward when needed) Percussion coughing when needed
224226043|NCT05870553|DRUG|CTP0301-B|Bowel Preparation
224226044|NCT05870553|DRUG|Cool prep|Bowel Preparation
224226045|NCT04725149|OTHER|500 ml base solution|Color, taste, aroma, and calorie matched water base
224226046|NCT04725149|OTHER|500 ml containing 30 ml tart cherry concentrate diluted with water and base solution|Montmorency cherry concentrate
224226047|NCT04725149|OTHER|500 ml containing 60 ml tart cherry concentrate diluted with water only|Montmorency cherry concentrate
224226048|NCT00125359|DRUG|erlotinib and bexarotene|Daily Erlotinib 150mg and daily bexarotene oral capsules 400mg.
224226049|NCT03698526|DEVICE|Samsung Gear VR, Galaxy S8, Applied VR App|Virtual Reality Experience
224226050|NCT01150448|DRUG|Paliperidone palmitate Treatment A|All patients will receive a single IM injection of 150mg eq of study drug on Day 1. Patients who tolerate 150mg eq will receive a 2nd IM injection of 150mg eq on Day 8 followed by 12 IM injections (1 every 4 weeks) of 150mg eq. All other patients will be assigned to Treatment B.
224226051|NCT01150448|DRUG|Paliperidone palmitate Treatment B|Patients not tolerating Treatment A will receive a single IM injection of study drug 100mg eq at their next scheduled visit followed by injections (1 every 4 weeks) ranging from 50 to 150mg eq
224226052|NCT04914715|DEVICE|Non-invasive High Frequency Oscillatory Ventilation|We are planning to use (Medin-CNO) for non-invasive ventilation. This machine has option to deliver NHFOV with frequency of 5-20 (300-1200 breathe/min), Amplitude of 1-10, flow1-17.5 liter/min, fiO2 21-100% and integrated pressure triggered sensitivity option.
224226053|NCT04914715|DEVICE|Conventional Invasive Ventilation|Invasive ventilation will be started following endotracheal intubation, mode will be selected as Synchronized Intermittent Mandatory ventilation (SIMV) with rate of 25-60 breath/min, flow of 8 liter, positive inspiratory pressure (PIP) of 14-25, Positive end expiratory pressure (PEEP) 4-5, fio2 of 21-40.
224226054|NCT02361190|DRUG|Testosterone|Administration of 1ml aqueous nasal spray containing 7mg testosterone propionate
224226055|NCT02361190|DRUG|Placebo|Administration of 1ml aqueous saline spray
224226056|NCT03182257|DRUG|ONO-7579|ONO-7579 Tablets
223638101|NCT05856734|BEHAVIORAL|Change in dietary intake|"1. 24-hour recalls using Intake24 (online survey) over 3-day.~2. Self reported questionnaire. (Single measure)"
223638102|NCT05856734|DEVICE|Change in physical activity|"1. ActiGraph GT9X Link accelerometer over 7-day.~2. Self reported questionnaire. (Single measure)"
223638103|NCT05856734|BEHAVIORAL|Change in stress|1- Self reported questionnaire. (Single measure)
223765036|NCT06683729|DEVICE|Trans-septal (TS) Mitral Valve Replacement (TSMVR) Valve system|Trans-catheter, trans-septal mitral valve replacement.
223765037|NCT02313025|OTHER|speech sound intervention|"An intervention that stimulates speech sound perception and production in four-year-olds.~Each day at preschool the children receive a 15 to 20 minutes intervention, for 12 weeks"
223765038|NCT02313025|OTHER|World-project|An intervention that stimulates vocabulary development in four-year-olds. Each day at preschool the children receive a 120 minutes intervention, for 10 weeks
224226057|NCT02451670|BEHAVIORAL|Prioritized Clinical Decision Support|After entry of blood pressure data at all primary care visits, relevant electronic health record data were automatically extracted, encrypted and processed through Web-based clinical algorithms that determined if the patient met intervention eligibility criteria. In intervention clinics, the rooming staff received a best practice alert and printed patient and primary care provider versions of the clinical decision support that identified evidence-based treatment options for any uncontrolled cardiovascular risk factors and prioritized treatment recommendations based on potential cardiovascular risk reduction. Cardiovascular risk factors addressed in study participants were control of lipids, blood pressure, weight, tobacco, glucose and appropriate aspirin use. In control clinics, rooming staff did not receive a best practice alert and patients and primary care providers did not receive and were not able to access the clinical decision support.
224226058|NCT00461500|DRUG|Salmeterol xinafoate/fluticasone propionate combination|SFC 100
224226059|NCT00461500|DRUG|Fluticasone propionate|FP 100
224226060|NCT01151813|DRUG|Varenicline|Varenicline, oral target dose of 1.0 mg BID, one week titration.
224226061|NCT01151813|DRUG|Placebo|Placebo
224226062|NCT02194309|DRUG|Telmisartan low|
224226063|NCT02194309|DRUG|Telmisartan high|
224226064|NCT02194309|DRUG|amlodipine|
224226065|NCT00521456|DRUG|ketorolac eye drops|"1 drop twice daily day preop and Days 1-14, and 6 doses on surgery day~Placebo"
224226066|NCT01361399|DRUG|Acetylsalicylic acid (Aspirin, BAYE4465) & Lidocain|Single oral application of a fixed combination of Aspirin and Lidocain (as one lozenge)
224319002|NCT05052047|OTHER|Conventional Breathing Exercise Group|"Breathing exercises: 20 min/day~Breathing Ex includes:~• Pursed lip breathing: Sit with your back straight, inhale through your nose for 2 seconds. Purse your lips like you rae blowing on hot food and then breath out slowly, take twice as long to exhale as you took to breath in 4-5 times a day~• Diaphragmatic breathing: Lie on your back on a flat surface, knees bent and head supported. Use pillow under knees to support your legs . breathe in slowly through your nose tighten your stomach, letting them fall inward as you exhale through your pursed lips. Practice these exercises 5-10 minutes about 3-4 times a day.~Positioning (lean forward when needed) Percussion coughing when needed"
224319003|NCT05002998|DRUG|Teprotumumab|"Teprotumumab is a fully human anti-IGF-1R mAb. Teprotumumab will be provided in single-dose 20-mL glass vials as a freeze-dried powder containing, in addition to the drug substance, 20 mmol/L histidine-histidine chloride, 250 mmol/L trehalose and 0.01% polysorbate 20 (w/w).~Prior to administration, each vial containing 500 mg teprotumumab freeze-dried powder will be reconstituted with 10 mL of sterile water for injection. The resulting solution will have a concentration of 47.6 mg/mL teprotumumab-trbw antibody. The reconstituted teprotumumab solution must be further diluted in 0.9% (w/v) sodium chloride (NaCl) solution prior to administration"
224319004|NCT05002998|DRUG|Placebo|Placebo will consist of a normal saline (0.9% NaCl) solution and will be administered in 100 mL or 250 mL infusion bags, as appropriate, per weight-based dosing volumes.
224319005|NCT06071169|OTHER|progressive relaxation exercise|Nurses will be asked to perform relaxation exercises 3 days a week for 5 weeks, 20 minutes in each practice.
224319006|NCT04084548|DRUG|Lidocaine and ketamine|Perioperative lidocaine and ketamine infusion (see below for dosages and timings)
224319007|NCT04084548|DRUG|Lidocaine|Perioperative lidocaine infusion (1.5 mg/kg bolus followed by an infusion of 2 mg/kg/hour based on actual body weight; the bolus and infusion will be started after anesthesia induction and before surgical incision, and continued until 1 hour after transfer from the operating room to the PACU)
224319008|NCT04084548|DRUG|Ketamine|Perioperative ketamine infusion (0.5 mg/kg bolus followed by an infusion of 0.3 mg/kg/hour based on actual body weight; the bolus and infusion will be started after anesthesia induction and before surgical incision, and continued until 1 hour after transfer from the operating room to the PACU)
224319009|NCT04084548|DRUG|Placebo|Perioperative placebo infusion (normal saline)
223515480|NCT02467881|BEHAVIORAL|Physical Activity Increase (GLB-MOD)|"The Group Lifestyle Balance (GLB) program was adapted from the original DPP lifestyle intervention. As in the original DPP lifestyle program, the GLB goals are to achieve and maintain a 7% weight loss, and to safely and progressively increase physical activity to 150 minutes/week of moderately intense physical activity similar to a brisk walk.~The curriculum will be administered in intervention groups with an average of 10-15 individuals per group; sessions will be conducted by trained coaches, with participants attending 22 sessions over one year.~The two intervention arms will only differ in the aerobic activity portion of the intervention, which is covered in sessions #4, #10 and 19 as well as participant record keeping and goal setting in regards to activity/inactivity progression."
223638104|NCT05856734|BEHAVIORAL|Change in socio-demographic characteristics|1- Self reported questionnaire. (Single measure)
223638105|NCT05856734|DEVICE|Change in sleep|ActiGraph GT9X Link accelerometer over 7-day. (Single measure)
224319010|NCT07134569|BEHAVIORAL|VR-based motor training|Six weeks, twice per week.
223638106|NCT04560400|DIAGNOSTIC_TEST|Conventional King-Devick test|Conventional King-Devick test involves a series of number reading task from left to right and top to bottom, intending to test subjects' neuro-ophthalmologic function
224319011|NCT02072304|BEHAVIORAL|web-based CBT|A cognitive behavioral program in 8 weeks that will provide participants with the following: online interactive tools to do their homeworks and guidance on using cognitive and behavioral strategies to help reduce depressive symptoms, information about the depressive symptoms and cognitive behavioral therapy
224319012|NCT02072304|BEHAVIORAL|supportive care|supportive care group will receive supportive care for treating depression by e-mail per a week for 8 weeks with the following: psychoeducation about depression, stigma of mental illness, distraction technique, emotional regulation, active scheduling.
223638107|NCT04560400|DIAGNOSTIC_TEST|Reverse King-Devick test|Reverse King-Devick test involves a series of number reading task from right to left and bottom to top, intending to test subjects' neuro-ophthalmologic function
223638108|NCT03343912|DRUG|Estriol 0.400 mg/day and Trimegestone 0.06 mg/day|Vaginal ring with a nominal delivery rate of 0.400 mg/d estriol (E3) and 0.06 mg/d trimegestone (TMG), vaginal application
224226067|NCT01361399|DRUG|Acetylsalicylic Acid (Aspirin, BAYE4465)|Single oral application of Aspirin (as lozenge)
224226068|NCT01361399|DRUG|Lidocain|Single oral application of Lidocain (as lozenge)
223638109|NCT03343912|DRUG|Estriol 0.300 mg/day and Trimegestone 0.12 mg/day|Vaginal ring with a nominal delivery rate of 0.300 mg/d estriol (E3) and 0.12 mg/d trimegestone (TMG), vaginal application
224226069|NCT01361399|DRUG|Placebo|Single oral application of Placebo (as lozenge)
224226070|NCT02620345|DRUG|Dydrogesterone M ( case 1 )|"Dydrogesterone Multivitamin nature~* Fibroids / Women Pregnancy ( discovered fibroids during pregnancy ) Dydrogesterone Multivitamin nature.~* 1tablet/24 hours/day (to 4 weeks after postpartum)"
224319013|NCT07104461|OTHER|Oat porridge|"Oat flakes, 81g (equivalent to 9 g of protein), were presented to participants in the form of porridge, prepared with 500 mL coconut milk (equivalent to 0.5 g of protein) and 10 g of zero calorie sugar free syrup.~The total energy content was equivalent to 400 Kcal.~Participants were instructed to consume the entire meal presented to them in 15 minutes on an empty stomach when attending the study."
223515481|NCT02467881|BEHAVIORAL|Sedentary Time Decrease (GLB-SED)|"As in the original DPP, the GLB goal for weight is to achieve and maintain a 7% weight loss. For this intervention arm, instead of focusing on increasing moderate physical activity, the GLB curriculum will be adapted to address decreasing sitting time. Participants will have a goal of decreasing sitting time by 45 minutes/day. The curriculum will be administered in intervention groups with an average of 10-15 individuals per group; sessions will be conducted by trained coaches, with participants attending 22 sessions over one year.~The two intervention arms will only differ in the aerobic activity portion of the intervention, which is covered in sessions #4, #10 and 19 as well as participant record keeping and goal setting in regards to activity/inactivity progression."
223515482|NCT02467881|OTHER|6-month delayed (DELAYED)|Individuals assigned to 6 month delay will wait for 6 months from baseline to be randomly assigned to one of the two interventions and will begin intervention at that time. During the waiting period they will receive health information newsletters.
223515483|NCT01173926|DRUG|insulin degludec|Each trial participant will receive one single dose of each trial product in varying order (NN5401, NN1250 and insulin aspart) on 3 separate dosing visits. The trial products will be administered subcutaneously (under the skin).
223515484|NCT01173926|DRUG|insulin degludec/insulin aspart|Each trial participant will receive one single dose of each trial product in varying order (NN5401, NN1250 and insulin aspart) on 3 separate dosing visits. The trial products will be administered subcutaneously (under the skin).
223515485|NCT01173926|DRUG|insulin aspart|Each trial participant will receive one single dose of each trial product in varying order (NN5401, NN1250 and insulin aspart) on 3 separate dosing visits. The trial products will be administered subcutaneously (under the skin).
223515486|NCT00932503|DEVICE|Vicryl plus|triclosan-coated polyglactin 910 suture materials with antiseptic activity (Vicryl plus®, Ethicon GmbH, Norderstedt, Germany)
223515487|NCT03769116|GENETIC|delandistrogene moxeparvovec|Single IV infusion of delandistrogene moxeparvovec
223515488|NCT03769116|GENETIC|placebo|Single IV infusion of matching placebo
223515489|NCT06500871|DRUG|Diclofenac Potassium|NSAID
223515490|NCT04743206|DEVICE|Standard Airway Clearance device|Subjects will be using their home standard airway clearance device, VEST (High Frequency Chest Wall Oscillation VEST) for 2 weeks followed by PIAPD.
223515491|NCT04743206|DEVICE|Portable Internal Airway Percussion device|Subjects will be using the investigational device, PIAPD (Portable Internal Airway Percussion Device) for 2 weeks.
223515492|NCT04094090|COMBINATION_PRODUCT|PXL-330 Platinum device for crosslinking with Peschke riboflavin solution|Riboflavin will be used to load the cornea, followed by UV-A crosslinking of the cornea
223515493|NCT01821872|DRUG|Administration of paracetamol|Administration of 1g intravenous paracetamol
223515494|NCT06265610|PROCEDURE|TIVA/TCI|: The aim of this study was to evaluate the effects of total intravenous anesthesia with target-controlled infusion (TCI/TIVA) on intraoperative hemodynamic parameters and postoperative awakening criteria in pediatric endovascular intervention patients
223515495|NCT04530695|OTHER|Scaling and Root Planing|Periodontal treatment by scaling and root planing (SRP), deep cleaning
223515496|NCT00003008|DRUG|indinavir sulfate|
223515497|NCT00003008|DRUG|nelfinavir mesylate|
223515498|NCT00003008|DRUG|paclitaxel|
223515499|NCT00003008|DRUG|ritonavir|
223515500|NCT00003008|DRUG|saquinavir mesylate|
223515501|NCT06125327|DRUG|SC1011|Patients receive the dose of SC1011 tablets orally twice daily (b.i.d) for 52 weeks.
223515502|NCT06125327|DRUG|Placebo comparator|Patients receive the dose of placebo orally twice daily (b.i.d) for 52 weeks.
223515503|NCT03540485|DRUG|Melatonin|Daily administration of 100 mg of melatonin orally, for 24 months, single dose of melatonin between 10pm to 11pm
223515504|NCT03540485|OTHER|Placebo|Daily administration of placebo orally, for 24 months between 10pm to 11pm
223515505|NCT06461273|BEHAVIORAL|Lifestyle Medicine Program|"Participants will engage in culinary and nutrition education for 6 weeks curated by a professional chef working in conjunction with the project team from community partner Ethos Farm to Health. Lessons will be adapted from the American College of Lifestyle Medicine (ACLM) Culinary Medicine Curriculum~Participants will engage in exercise sessions on weeks without culinary and nutrition instruction for a total of 6 weeks. Exercise sessions will include a variety of activities to include calisthenics, weight training, walking, running, dance, and games delivered by the Rutgers physical therapy team.~Urban Agriculture lessons will occur longitudinally throughout the 12-week course. Participants will learn to cultivate a variety of crops in limited spaces, emphasizing sustainable practices and the importance of local food systems in urban communities.~Additionally, this arm will receive a supplemental food box weekly consistent with the dietary pattern set forth by ACLM."
223638110|NCT03343912|DRUG|Estriol 0.200 mg/day and Trimegestone 0.18 mg/day|Vaginal ring with a nominal delivery rate of 0.200 mg/d estriol (E3) and 0.18 mg/d trimegestone (TMG), vaginal application
223638111|NCT05577507|DRUG|Cholestyramine Resin 4000 MG [Questran]|cholestyramine 4 gram sachets (questran) will be administered orally three times daily for 8 weeks period trial
223638112|NCT05577507|DRUG|Calcium Carbonate 500 MG Oral Tablet|control group will administer standard therapy calcimate 500 mg three times daily within meals
223638113|NCT01253278|DRUG|LY2393910|as capsules, administered orally once daily for two weeks
224226071|NCT02620345|DRUG|Dydrogesterone M ( case 2 )|"Dydrogesterone Multivitamin nature~* Fibroids/ Women of Reproductive age ( discovered fibroids )~* 1tablet/24 hours/day ( from discovered fibroids through 6 months)"
223638114|NCT01253278|DRUG|Placebo|as capsules, administered orally once daily for two weeks
223638115|NCT03713736|DIAGNOSTIC_TEST|Cervical smear|Cervical smear will be obtained using an Ayre spatula and a cervical brush (Cervex-Brush®). HPV test will be performed using the CLART® HPV2 kit (Genomica).This kit enables the detection of 35 genotypes: HPV6, 11, 16, 18, 26, 31, 33, 35, 39, 40, 42, 43,44, 45, 51, 52, 53, 54, 56, 58, 59, 61, 62, 66, 68, 70, 71, 72, 73, 81, 82, 83, 84, 85 et 89.
223638116|NCT03713736|DIAGNOSTIC_TEST|Pregnancy test|Urinary pregnancy test
223638117|NCT03713736|BEHAVIORAL|Sexual activity questionnary|Sexual activity questionnary
223638118|NCT01101867|DRUG|Aspart fixed dose|fixed dose
223638119|NCT01101867|DRUG|Aspart flexible dose|dose based upon carbohydrate intake and total daily requirements
224226072|NCT01513551|BIOLOGICAL|Pneumococcal Conjugate Vaccine (V114)|15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, 33F (2 mcg each), serotype 6B (4 mcg) and aluminum phosphate adjuvant (125 mcg) in each 0.5 mL dose.
224226073|NCT01513551|BIOLOGICAL|PNEUMOVAX® 23|23-valent pneumococcal polysaccharide vaccine with serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, 33F (25 mcg each) in each 0.5 mL dose.
224226074|NCT01513551|BIOLOGICAL|PREVNAR 13®|13-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F, serotype 6B (4.4 mcg each) and aluminum phosphate adjuvant (125 mcg) in each 0.5. mL dose.
224226075|NCT03150251|OTHER|Cereal - oats|Consumption of one cereal in the beginning of each visit
224226076|NCT03150251|OTHER|Cereal - cream of rice|Consumption of one cereal in the beginning of each visit
224226077|NCT00395798|DEVICE|Soft or stiff cervical collar(device), neck school(behavior)|
224226078|NCT01240005|BIOLOGICAL|DCIK|Renal cell carcinoma patients were treated with three intravenous infusions of DC activated CIK cells at 1-day intervals. Clinical examinations of these patients were performed.
224226079|NCT06044181|PROCEDURE|Diode laser photocoagulation.|If there is evidence of active leakage by FFA The confluent laser burns will be applied to the entire avascular retina from the ridge to the ora serrata for 360 through the transpupillary route. The laser settings used are: power 250-400 mW and duration of 200-400 ms for 810 nm DLPC.
224226080|NCT00617110|OTHER|live attenuated influenza virus (LAIV) with clean air|Allergic subjects will be exposed to air followed by administration of live attenuated influenza virus
224226081|NCT00617110|OTHER|LAIV and diesel exhaust particles|subjects with allergic rhinitis will be exposed to diesel exhaust particles followed by LAIV
224226082|NCT01519583|BEHAVIORAL|Basic Intervention|Participants will have the goal of obtaining 10,000 steps/day. In addition, participants will attend a meeting once a week with study staff, during which pedometers will be checked, and staff will provide a behavioral intervention to improve physical activity levels
224226083|NCT01519583|BEHAVIORAL|Enhanced Pedometry|Intensity Enhanced Pedometry: Participants will have the goal of obtaining 10,000 steps/day at least 30 minutes in moderate intensity (i.e., at a cadence of at least 100 steps/min). In addition, participants will attend a meeting once a week with study staff, during which pedometers will be checked, and the staff will provide a behavioral intervention to improve physical activity levels.
224319014|NCT07104461|DIETARY_SUPPLEMENT|Whey protein isolate|"Whey protein isolate, 38g (equivalent to 34.2 g of protein), was presented to participants in the form of a porridge.~Other ingredients in the whey protein enriched porridge:~* Oat flakes 54 g (equivalent to 6 g of protein)~* Coconut milk 300 mL (equivalent to 0.3 g of protein)~* Water 150 mL~* Zero calorie sugar free syrup 10 g~The total energy content was equivalent to 401.74 Kcal.~Participants were instructed to consume the entire meal presented to them in 15 minutes on an empty stomach when attending the study"
223638120|NCT01213472|BIOLOGICAL|GSK Biologicals' 2241658A Antigen-Specific Cancer Immunotherapeutic (ASCI)|Up to 24 intramuscular administrations
223638121|NCT00738933|DIETARY_SUPPLEMENT|Dietary plant stanols|Daily 2 grams of plant stanols in a margarine preparation for 4-8 weeks before the operation
223638122|NCT00738933|DIETARY_SUPPLEMENT|Dietary plant sterols|Daily 2 grams of plant sterols in a margarine preparation for 4-8 weeks before the operation
223638123|NCT00738933|DIETARY_SUPPLEMENT|placebo|Margarine product without plant stanol or sterol esters
223638124|NCT03421483|DIETARY_SUPPLEMENT|Folic Acid supplementation|Participants receive a 400 microgram Folic Acid supplement
223638125|NCT03421483|DIETARY_SUPPLEMENT|Adult Multivitamin|Participants will receive an adult multivitamin supplement
223638126|NCT04734691|PROCEDURE|PIPAC|PIPAC is a laparoscopic procedure for intraperitoneal administration of chemotherapy
223638127|NCT02600234|DEVICE|Inter-Atrial Shunt Device|An implantable device placed in the interatrial septum
223638128|NCT02600234|OTHER|Intracardiac Echo|Patients randomized to the control arm will undergo intra cardiac echocardiography, with examination of the atrial septum and left atrial appendage.
223638129|NCT02910882|DRUG|PEGylated Recombinant Human Hyaluronidase (PEGPH20)|"PEGPH20 Dosing (Cohort I, Dose Escalation, First 3 patients): Administered as an IV infusion over 10 minutes (+/- 2 Minutes), approximately 1mL/minute:~Dose level 1 - 1 mcg/kg; Dose level 2 - 1.6 mcg/kg; Dose level 3 - 3 mcg/kg.~PEGPH20 Dosing (Cohort II, Patients 4-10): Administered at a dose of 3 mcg/kg as an IV infusion over 10 minutes (+/- 2 Minutes), approximately 1mL/minute.~Dosing Schedule: Twice per week beginning Day #1 for 8 doses, then weekly until end of radiotherapy."
224226084|NCT01519583|BEHAVIORAL|Control Group|Maintain usual physical activity, and return for follow-up measures.
224226085|NCT00002252|DRUG|Octreotide|
224226086|NCT02772536|OTHER|Visual Stimulus Condition Set|"In this single arm study, all participants are subject to a set of three visual stimulus conditions.~Low ambient light for 10 mins: Self selected tinted light (20 Mins); White light (20 mins).~VAS/CGI scores for each stimulus condition in the above set are reported at five minute intervals."
224226087|NCT05215899|OTHER|MINDFULNESS-BASED YOGA AND MEDITATION|The application was carried out by the researcher who had completed mindfulness-based yoga and meditation training.
224226088|NCT01428505|RADIATION|[18F]PBR111|radioligand to assess binding to TSPO
223638130|NCT02910882|DRUG|Gemcitabine|"Gemcitabine Dosing: Administered at a dose of 600 mg/m2 as an IV infusion over 30 - 60 minutes with standard antiemetic pre-medication. If administered on PEGPH20 day, Gemcitabine will be infused 2-4 Hours after PEGPH20 infusion is completed.~Dosing Schedule: Weekly, beginning Day #2, per standard regimen."
223638131|NCT02910882|RADIATION|Radiation|Radiotherapy, beginning Day #2, delivered at 1.8 Gy per fraction, 5 fractions per week (Monday - Friday), until a total dose of 50.4 to 54 Gy for up to 6 Weeks.
223638132|NCT00004169|DRUG|carboplatin|
223638133|NCT00004169|DRUG|cyclophosphamide|
223638134|NCT00004169|DRUG|etoposide|
223638135|NCT00004169|PROCEDURE|peripheral blood stem cell transplantation|
223638136|NCT00004169|RADIATION|radiation therapy|
223638137|NCT01046708|DRUG|micronized progesterone|600mg in 3 separate doses per day
223638138|NCT02790892|BEHAVIORAL|Art therapy - pre and post test measures|12 weeks of 90 minutes of art therapy with pre and post test measures to determine changes in social support and levels of diabetes distress
223638139|NCT02299843|PROCEDURE|RALPPS|Using radiofrequency ablation assisted ALPPS（RALPPS）instead of in-situ split of liver to form a coagulation band in stage I.Habib 4X was used in RFA.
223638140|NCT02299843|PROCEDURE|ALPPS|Treat the hepatocellular carcinoma with ALPPS.
223638141|NCT03678519|DIAGNOSTIC_TEST|Pulmonary function test|Pulmonary Function tests using Spirometry. It will show following indices of ventilatory functions: Forced vital capacity (FVC), Forced expiratory volume in the 1st second (FEV1) and Forced expiratory volume in the 1st second as a percentage of the Forced vital capacity (FEV1/FVC %).
223638142|NCT02342236|DEVICE|cemented or cementless type of hip prothesis|
223638143|NCT04909281|DIAGNOSTIC_TEST|Self-sampling HPV|In this cohort study nested in the organized cervical screening program, all women who had not participated in the organized screening program for at least 10 years in one Swedish county were eligible.
224226089|NCT06338397|OTHER|SCANN|Administering 11 tests of social \& affective cognition to each participant as well as 6 scales to their study-partner, in order to have a detailed profile of social \& affective cognitive abilities that we can correlate to an 3DMRI with resting state procedure.
224226090|NCT04360811|DIAGNOSTIC_TEST|COVID 19 diagnostic test by PCR|"1. Inclusion of patients with clinical data (in a eCRF) and various samples collection according to the outcome of pregnancy~2. Storage and freezing samples for subsequent analysis by RT-PCR COVID-19 (maternal saliva, cord blood, fetal stools, placenta, fetal tissue, amniotic fluid according to pregnancy outcomes) and by maternal and newborn and / or fetal serologies testing~3. Pathological study of placentas and fetal autopsies~   * Histology of positive COVID-19 placentas~  * Brain and visceral histology of positive COVID-19 fetuses autopsied~4. Analysis of patient comorbidities and comparison in the different groups~5. Final statistical analysis"
224226091|NCT05031728|BEHAVIORAL|Cognitive Processing Therapy (CPT)|Cognitive processing therapy (CPT) (Resick et al., 2016) which is a specific type of cognitive behavioral therapy that has been effective in reducing symptoms of Post-Traumatic Stress Disorder (PTSD) that may have developed after experiencing a variety of traumatic events including child abuse, emotional abuse, combat, rape war, and natural disasters. CPT helps patients learn how to challenge and modify unhelpful beliefs related to the trauma and emotional pain. In so doing, the client creates a new understanding and conceptualization of the traumatic event so that it reduces its ongoing negative effects on current life.
224319015|NCT07104461|DIETARY_SUPPLEMENT|Potato protein isolate|"Potato protein isolate, 38g (equivalent to 34.39 g of protein), was presented to participants in the form of a porridge.~Other ingredients in the potato protein enriched porridge:~* Oat flakes 54 g (equivalent to 6 g of protein)~* Coconut milk 300 mL (equivalent to 0.3 g of protein)~* Water 150 mL~* Zero calorie sugar free syrup 10 g~The total energy content equiv. 401.36 Kcal.~Participants were instructed to consume the entire meal presented to them in 15 minutes on an empty stomach when attending the study."
223638144|NCT05408741|OTHER|The Intervention Group|Participants will complete a 20-minute guided imagery exercise (which includes deep breathing exercises) every day at home using the selected app and/or resource you downloaded at the beginning of this study.
223638145|NCT05408741|OTHER|The Control Group|Participants will continue to receive your current care, but will not receive guided imagery or deep breathing exercises from a social worker.
223638146|NCT05955482|OTHER|NuvoAir Clinical Service|The NuvoAir clinical service offers comprehensive monitoring of health parameters and patient-reported outcomes as well as personalized clinical and behavioral interventions tailored to the patients' unique needs and their clinical risk. Furthermore, it involves virtual interaction with a NuvoAir Coach who provides guidance and assistance in navigating and utilizing the service. A dedicated NuvoAir care coordinator is available to offer self-management support and educational resources, aiming to enhance the management of COPD and other comorbidities. In situations where patients encounter new or worsening symptoms, the NuvoAir clinical team is accessible to provide medical intervention, advice and triage as required.
223638147|NCT04361396|OTHER|Collection of samples|Only in enrolled patient : different samples will be taken at different times of the surgery (3 samples of pneumoperitoneum, 1 sample of peritoneal effusion or peritoneal lavage fluid and 1 sample of bile, in case of cholecystectomy.
223638148|NCT01843413|RADIATION|stereotactic radiosurgery|Undergo SRS
223638149|NCT01843413|PROCEDURE|quality-of-life assessment|Ancillary studies
223638150|NCT01843413|PROCEDURE|cognitive assessment|Ancillary studies
223638151|NCT01510483|BEHAVIORAL|Obesity Prevention|Those in the experimental, obesity prevention, condition will be exposed to the office-wide intervention for diet and activity. The intervention will consist of training of orthodontists and office staff to provide appropriate social prompts, reinforcement and counseling, and modification of the offices to provide supportive physical and social resources for their patients and parents.
223765039|NCT04222179|DEVICE|ultrathın esophagogastroduodenoscope|Place the naso-enteric tube together with the ultrathin esophagogastroduodenoscope from the same nasal cavity
224226092|NCT06267261|DEVICE|KOLMI® surgical face mask (OP-Air)|12 subjects are exposed to birch pollen allergen in ALYATEC EEC while wearing a KOLMI® surgical face mask (OP-Air)
224226093|NCT00087061|DRUG|gimatecan|
224226094|NCT06442683|DIAGNOSTIC_TEST|TTE simulation-based medical training|half-day simulation-based neonatal echocardiography training.
224226095|NCT05925153|OTHER|No intervention|No intervention
224226096|NCT01806597|BIOLOGICAL|secukinumab 150 mg|Study treatment were provided in pre-filled syringes of secukinumab 150 mg in 1 mL. Each dosing consiseds of one secukinumab 150 mg s.c. injection plus one placebo secukinumab s.c. injection and took place once weekly during five weeks (at Baseline, Weeks 1, 2, 3 and 4), then once every four weeks starting at Week 8 until Week 128 inclusive. In order to maintain the blinding, patients also received two placebo injections at Weeks 17, 18 and 19. Patients self-administered study treatment under the supervision of site personnel when injections occur during study visits, or at home otherwise.
224226097|NCT01806597|BIOLOGICAL|secukinumab 300 mg|Study treatment were provided in pre-filled syringes of secukinumab 150 mg in 1 mL. Each dosing consisted of two secukinumab 150 mg s.c. injections and took ke place once weekly during five weeks (at Baseline, Weeks 1, 2, 3 and 4), then once every four weeks starting at Week 8 until Week 128 inclusive. In order to maintain the blinding, patients also receives two placebo injections at Weeks 17, 18 and 19. Patients self-administered study treatment under the supervision of site personnel when injections occur during study visits, or at home otherwise.
224226098|NCT01806597|BIOLOGICAL|Placebo|Placebo were provided in 1 mL pre-filled syringes. Each dosing consisted of two s.c. injections and took place once weekly during five weeks (at Baseline, Weeks 1, 2, 3 and 4), then at Week 8 and at Week 12. At Week 16, ppIGA responders continued on placebo with dosing at Weeks 16, 17, 18, 19 and 20, then once every four weeks from Week 24 until Week 76 inclusive. At Week 80, ppIGA responders ended their participation in the study while ppIGA non-responders were re-randomized, to receive 150 mg or 300 mg secukinumab once every four weeks starting at Week 80 until Week 128 inclusive. Patients self-administered study treatment under the supervision of site personnel when injections occur during study visits, or at home otherwise.
224226099|NCT04154709|BIOLOGICAL|CTA101|Universal CD19-directed CAR-T cells by a single infusion intravenously will be given in escalating doses.
224226100|NCT05938153|OTHER|observational physical tests|"Geriatric Locomotive Function Scale:~This scale consists of a questionnaire of 25 items that can be easily understood by the elderly and each item is graded between 0 and 4 points. The total score is the result of the sum of all items ranging from 0 to 100; the higher the score, the higher the physical impairment of the elderly, with a score of 16 being the cut-off point for locomotive syndrome. The GLFS-25 includes 4 questions about pain, 16 questions about activities of daily living, 3 questions about social performance and 2 questions about mental health status to assess geriatric individuals. Turkish validity and reliability of the questionnaire was conducted by Sadikoglu."
224226101|NCT02347670|BEHAVIORAL|Efficacy-patient navigator to improve follow-up adherence|Over the course of 1 year, a 6-person team comprised of one attending physician ; ophthalmic technicians, project managers/community health educators , and patient navigators will complete a baseline eye examination visit, baseline assessment, and 2-3 follow-up visits. The equipment will occupy a designated location at each site for 1 to 2 days, from 9 a.m. to 3 p.m., with at least 15 eye examinations performed each day. With assistance from the patient navigator, participants will receive assistance with scheduling appointments, arranging transportation, reminder letters, and referral s for ocular care.
224226102|NCT02347670|BEHAVIORAL|Office-Based Usual Care|"Over the course of 1 year, a 6-person team comprised of one attending physician ; ophthalmic technicians, project managers/community health educators , and patient navigators will complete a baseline eye examination visit, baseline assessment, and 2-3 follow-up visits. The equipment will occupy a designated location at each site for 1 to 2 days, from 9 a.m. to 3 p.m., with at least 15 eye examinations performed each day.~This intervention group will receive a phone number to schedule an appointment. Participants in the usual-care group who have scheduled an appointment will receive an automated phone call similar to the standard appointment-reminding procedure used at the Wills Eye Hospital."
224226103|NCT04331756|PROCEDURE|Guiding Emergence From Anaesthesia With Tragus Pressure|Use of tragus pressure in guiding patients from emergence from anaesthesia post-surgery
224226104|NCT04331756|PROCEDURE|Guiding Emergence From Anaesthesia Without Tragus Pressure|Usual clinical routine practice in guiding patients from emergence from anaesthesia post-surgery
224226105|NCT03890185|COMBINATION_PRODUCT|Chemo + Low dose RT|Intervention will include chemotherapy using Docetaxel 75mg/m2 IV D1, Cisplatin 75mg/m2 IV D1.Radiathion therapy (LDFRT) using 50 cGy of radiation per fraction BID on the day of chemotherapy and the day after during induction i.e. 50 cGy x 4 times per cycle given for total of 2 cycles every 21 days.
224226106|NCT03890185|DRUG|Chemo alone|Chemo alone: Intervention will include chemotherapy using Docetaxel 75mg/m2 IV D1 and Cisplatin (CDDP) 75mg/m2 IV D1 given for 2 cycles every 21 days.
224226107|NCT04393506|DRUG|Camrelizumab|Inductive therapy with Camrelizumab of 200mg, iv, qd, on day 1, 15, 29.
224226108|NCT04393506|DRUG|Apatinib|Inductive therapy with Apatinib of 250mg, po, qd, initiating on day 1, ending on the fifth day before surgery.
224226109|NCT04393506|PROCEDURE|Radical surgery|Radical surgery will be performed on the 42th-45th after initiation of inductive therapy
224226110|NCT04393506|RADIATION|Post-operative radiotherapy/chemoradiotherapy|Post-operative radiotherapy/chemoradiotherapy will be performed within 1.5 months after radical surgery, depending on the post-operative pathologic diagnosis.
224226111|NCT05627609|DEVICE|311 nm narrowband UVB irradiation|Participants will be irradiated with 311nm UVB for 5 days per week and 4 weeks in total.
224226112|NCT01972022|DEVICE|EES SYNERGY™|percutaneous coronary intervention with implantation of Bioabsorbable Polymer EES
224226113|NCT01972022|DEVICE|ZES, RESOLUTE Integrity™|percutaneous coronary intervention using ZES, RESOLUTE Integrity™ coronary stent
224226114|NCT01909622|DIETARY_SUPPLEMENT|Vitamin D|
224226115|NCT01909622|DIETARY_SUPPLEMENT|No vitamin D|
224226116|NCT03873480|PROCEDURE|Administration of Marcaine without Epinephrine prior to the start of surgery|The intervention is the timing of administration of marcaine without epinephrine during a trigger thumb surgery.
224319016|NCT07104461|DIETARY_SUPPLEMENT|Meal replacement shake|"A meal replacement, 90 g (equivalent to 40 g of total protein), was presented to participants in the form of a shake.~Other ingredients in the meal replacement shake:~\- Water 500 mL~The total energy was equivalent to 400 Kcal~Participants were instructed to consume the entire meal replacement shake presented to them in 15 minutes on an empty stomach when attending the study."
224319017|NCT03554434|BIOLOGICAL|AM0010|AM0010
223638152|NCT01510483|BEHAVIORAL|Tobacco Prevention|Those in the control, tobacco prevention, condition will be exposed to the office-wide intervention for avoidance of tobacco and second hand smoke. The intervention will consist of training of orthodontists and office staff to provide appropriate social prompts, reinforcement and counseling, and modification of the offices to provide supportive physical and social resources for their patients and parents.
223638153|NCT03244332|OTHER|Collecting Clinical Data|Clinical data as height, weight, mid upper arm circumference, jaundice, portal hypertension signs (ascites, splenomegaly, umbilical veinous circulation)
223638154|NCT03244332|OTHER|Collecting laboratory data|Laboratory data as CRP, hemogram, albumin, total and conjugated bilirubin, creatinin, urea, liver enzymes, tests of hemostasis.
224226117|NCT06094868|DRUG|Fruquintinib|"Fruquintinib: 4mg, QD, PO, D1-D14, Q3W; Sintilimab: weight \< 60kg, 3mg/kg; weight≥60kg, 200 mg; I.V.， D1，Q3W；. XELOX regimen: Oxaliplatin: 130 mg/m2, ivgtt, D1, Q3W; Capecitabine: 1000 mg/m2, bid, D1-D14, Q3W; After 6 cycles of treatment, chemotherapy was given and maintenance treatment was given with Fruquintinib combined with Sintilimab. The above medication regimen can be adjusted according to the adverse reaction tolerance of the subjects.~\* Maintenance of treatment until disease progression, or intolerable toxic reactions, or other conditions determined by the investigator"
224226118|NCT05518435|OTHER|None, observational study|The MAP study involves mapping current practice (WP1), exploring current experiences (WP2), and co-creating guidance based on existing evidence (WP3).
224226119|NCT05905848|DRUG|administering RASI (the trade name or universal name will not be stipulated) before stenting|"Pre-operative antihypertensive drugs before stenting will be random assigned (RASI or CCB) at least 5 days before stenting. Patients in RASI group will receive RASI (all kinds of RASI will be permited and the trade name or universal name of drugs will not be limited), with or without other antihypertensives except for CCB (any kind of CCB).~Blood pressure of patients should be controlled within the target range (140/90 mmHg); and usage and dosage of antihypertensive drugs will not be stipulated. Grapefruit intaking should be avoid."
224226120|NCT05905848|DRUG|administering CCB (the trade name or universal name will not be stipulated) before stenting|"Pre-operative antihypertensive drugs before stenting will be random assigned (RASI or CCB) at least 5 days before stenting. Patients in CCB group will receive CCB (all kinds of CCB will be permited and the trade name or universal name of drugs will not be limited), with or without other antihypertensives except for RASI (any kind of RASI).~Blood pressure of patients should be controlled within the target range (140/90 mmHg); and usage and dosage of antihypertensive drugs will not be stipulated. Grapefruit intaking should be avoid."
224226121|NCT04437342|OTHER|PHQ-9 (Patient Health Questionnaire) Depression Scale|9 question questionnaire for assessment of depression
224226122|NCT04437342|OTHER|GAD-7 (General Anxiety Disorder) scale|7 question questionnaire for assessment of General Anxiety Disorder
224226123|NCT04437342|OTHER|38 questions questionnaire|38 questions questionnaire
224226124|NCT04437342|OTHER|EPDS (Edinburgh Postnatal Depression Scale)|10 questions scale for detection of postpartum depression
224226125|NCT05569148|COMBINATION_PRODUCT|Faricimab PFS Configuration|Participants will receive a single intravitreal (IVT) injection of the 6-milligram (mg) faricimab dose formulation delivered via prefilled syringe (PFS) with a co-packaged injection filter needle.
224226126|NCT03081767|DIAGNOSTIC_TEST|Digital PET/CT scan|The Division of Nuclear Medicine and Molecular Imaging at Stanford has installed the first ever GE-made digital PET/CT scanner worldwide. The investigators wish to determine if the digital PET/CT scanner offers equivalent image quality as the standard PET/CT scanner.
224226127|NCT04276038|DEVICE|B-Cure laser pro|The B-Cure laser pro is a portal, non-invasive, low level laser therapy device, that emits light in the near infrared (808nm) over an area of 1X4.5 cm2 with power output of 250mW, and energy dose of 1J/cm2. The device is used at home and is self-applied by the patient. The device is AMAR approved (approval # 14810408) for pain reduction and for ulcer treatment. The device is also approved for marketing in Canada and as a medical device in Europe (CE medical mark).
224226128|NCT04826796|BEHAVIORAL|WhatsApp peer support|Trained peer supporters will provide breastfeeding and emotional support for participants in the WhatsApp group.
224226129|NCT05116995|DRUG|Rivaroxaban|rivaroxaban 2.5 mg twice a day for 7 days
224226130|NCT05116995|DRUG|Ticagrelor|Ticagrelor 60 mg twice a day for 7 days
224226131|NCT04000503|BEHAVIORAL|Self-collected HPV testing for cervical cancer screening|Self-collection cervical cancer screening, STI screening, and education on HIV by a community health worker. Women who test positive for high-risk HPV types will be referred to a designated health centre for VIA follow-up and treatment if indicated.
223638155|NCT05773664|DRUG|Azeliragon|Given PO
223638156|NCT05773664|PROCEDURE|Biospecimen Collection|Undergo collection of cavity fluid and blood samples
223638157|NCT05773664|PROCEDURE|Computed Tomography|Undergo CT scan
224226132|NCT02149303|DRUG|Dabigatran 75 mg|PO BID
224226133|NCT02149303|DRUG|Dabigatran 150 mg|PO BID
224226134|NCT04491149|DEVICE|virtual reality glasses|In the intervention arm, women undergoing amniocentesis/foeticide will use virtual reality glasses during the procedure.
224226135|NCT02247479|DRUG|Lampalizumab|Participants will receive 10 mg dose of lampalizumab administered intravitreally.
224226136|NCT02247479|OTHER|Sham|A sham injection is a procedure that mimics an intravitreal injection of lampalizumab.
223638158|NCT05773664|DRUG|Dexamethasone|Given PO or IV
223638159|NCT05773664|PROCEDURE|Magnetic Resonance Imaging of the Brain with and without Contrast|Undergo MRI with or without contrast
223638160|NCT02085460|DRUG|Placebo|
223638161|NCT02085460|DRUG|2% Rebamipide liquid|
223638162|NCT02085460|DRUG|4% Rebamipide liquid|
223638163|NCT02212639|DRUG|digoxin|All patients will receive Digoxin without interruption. Doses can be modified individually to reach a serum drug concentration of 0.6 to 1.2 ng/ml for patients \<75 years and between 0.5-0.8 ng/ml in patients older than 75 years
223638164|NCT01285323|DRUG|Reslizumab|Patients were administered intravenously over 15 to 30 minutes reslizumab at a dosage of 3.0 mg/kg at baseline and once every 4 weeks relative to baseline over 48 weeks for a total of 13 doses.
223638165|NCT01285323|DRUG|Placebo|Matching placebo (acetate sucrose buffer), administered intravenously (iv) once every 4 weeks for a total of 13 doses.
223638166|NCT02476253|DRUG|Sodium Bicarbonate|Intravenous 4.2% Sodium Bicarbonate 125ml to 250ml / 30min up to 1000ml/24h to maintain plasma pH equal or greater than 7.30
223638167|NCT02234167|BEHAVIORAL|Risk behaviour and infectious diseases|through counselling, testing vaccination
224226137|NCT03849313|DRUG|Adalimumab|"AVT02, a proposed similar biological product (biosimilar) of Humira which contains adalimumab . Adalimumab is a recombinant, fully human monoclonal immunoglobulin G1 (IgG1) antibody that binds specifically and with high affinity to the soluble and transmembrane forms of tumor necrosis factor (TNF)-α thereby inhibiting the binding of TNF-α with its receptor, and inhibiting TNF -α's biological function.~Tumor necrosis factor-α is a naturally occurring cytokine that is key to normal inflammatory and immune responses. Elevated levels of TNF-α are found in the synovial fluid of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis patients and psoriasis plaques and play an important role in both the pathologic inflammation and joint destruction that are hallmarks of these inflammatory diseases"
224226138|NCT00226720|PROCEDURE|Outpatient detoxification program|Outpatient detoxification program
224226139|NCT04552574|DIETARY_SUPPLEMENT|HMR(Home meal replacement)-type omega-3-balanced diet|A diet of which omega-3 to omega-6 ratio is below 1:4 was developed by Agricultural entity Green Grass Co., Ltd.. A committee of experts that is composed of several university professors in authorities of IPET(Institute of Planning and Evaluation for Technology in food, agriculture and forestry) also participated in the development of this diet.
224226140|NCT03202836|DRUG|progesterone|vaginal utrogestan
224226141|NCT03202836|DRUG|Tocolytics|tocolysis for 48 hours
224226142|NCT03202836|DRUG|Steroids|antenatal corticosteroids for 48 hours
224226143|NCT03699267|OTHER|US-guided Bilateral TAP block|
224226144|NCT01572649|DRUG|Lixisenatide (AVE0010)|"Pharmaceutical form:Solution for injection~Route of administration: subcutaneous"
224226145|NCT01572649|DRUG|Placebo|"Pharmaceutical form:Solution for injection~Route of administration: subcutaneous"
224226146|NCT04112251|DIETARY_SUPPLEMENT|Cocoa Flavonols Supplement|Whose total capsule content of 500 mg of cocoa flavonoids, 50 mg correspond to (-) - epicatechin per capsule, with a total dose of this compound being 100 mg/day.
224226147|NCT04611256|BIOLOGICAL|MSC|Two intravenous infusion of 1\*10E6 adipose tissue derived-MSCs /kg body weight reach
224226148|NCT04611256|DRUG|Control|Conventional treatment that may include analgesic, anti-inflammatory, antibiotic, steroid, antiplatelet, and anticoagulant.
224226149|NCT02705053|DEVICE|CGM and Insulin Pump|Dexcom G4 Platinum CGM with Share AP Receiver Roche Accu-Chek insulin pump.
224226150|NCT02705053|DEVICE|Closed-Loop Control System|"The devices that will be used in the Closed-Loop Control System include the following components:~DiAs - a smart-phone medical platform; Dexcom G4 Platinum connected to DiAs via Bluetooth CGM receiver; Roche Accu-Chek insulin pump connected to DiAs via wireless Bluetooth; Remote Monitoring Server connected to DiAs via 3G or local Wi-Fi network, and Zone-MPC and HMS algorithms running on DiAs (MPC and HMS)"
223638168|NCT00237406|PROCEDURE|interactive voice response|
223638169|NCT01293734|OTHER|warming lung and relieving asthmatic granule and Securing origin and warming lung emplastrum|warming lung and relieving asthmatic granule:once 1 bag, 3 times a day. Securing origin and warming lung emplastrum: paste on acupuncture point and take the emplastrum down after 3 hours, once a day
224226151|NCT01840189|OTHER|Cortef|Treatment A is oral hydrocortisone replacement ( Cortef 5 mg) administered according to weight-adjusted doses for 2 months
224226152|NCT01840189|OTHER|Solu-cortef|"Treatment B is continuous subcutaneous hydrocortisone infusion with the initial standard dose of 10mg/m2/24hrs. Body surface area will be calculated according to the nomogram from the formula of Du Bois and Du Bois.~This part of the study will take 2 months."
224319018|NCT06085573|DRUG|Dexmedetomidine Hydrochloride|"\<Sedation of non-invasive procedures and tests without intubation in pediatrics\> For children aged 2 years or older, the usual dosage of dexmedetomidine is 12 μg/kg/hr given as a continuous intravenous infusion over 10 minutes (initial loading dose) followed by a maintenance dose of 1.5 μg/kg/hr (maintenance dose).~For children aged 1 month to \< 2 years old, the usual dosage of dexmedetomidine is 9 μg/kg/hr given as a continuous intravenous infusion over 10 minutes (initial loading dose) followed by a maintenance dose of 1.5 μg/kg/hr (maintenance dose).~The infusion rate should be reduced according to patient's condition."
223515506|NCT06461273|BEHAVIORAL|Medically Tailored Groceries|"Participants in the Food is Medicine arm will receive a supplemental food box weekly curated by a registered dietician and dietetics students. Each food box will contain seasonally available fruit and vegetables and other items including protein, dairy/cheese, and legumes that may be available at the time of the food box delivery. Each box will contain approximately 8 pounds of food and all participants in this group will receive the same food items. Classes and educational materials provided will be tailored to the specific foods contained in the weekly food box and will include simple preparation methods, recipes, nutrition information and grocery shopping tips."
223515507|NCT06006468|GENETIC|High genetic risk for type 1 diabetes|in individuals without diabetes comparison of prevalence of islet auto antibodies between individuals at high genetic risk of type 1 diabetes versus controls
223515508|NCT06006468|GENETIC|High gentic risk for Coeliac disease|in individuals without Coeliac disease comparison of prevalence of anti tissue transglutaminase antibodies between individuals at high genetic risk of coeliac disease versus controls
223515509|NCT01346917|DRUG|Lidocaine|Lidocaine 1mg/kg(loading dose, just before skin incision) and lidocaine(in normal saline, total 240cc) 1mg/kg/hr with ketorolac 90mg for 24hrs.
223515510|NCT01346917|DRUG|Normal saline|Normal saline 5cc(loading dose, just before skin incision) and normal saline 240cc with ketorolac 90mg for 24hrs.
223515511|NCT01166698|DRUG|AZD9819|Inhaled single doses of suspension via SPIRA nebuliser
224226153|NCT00116922|DRUG|Avandamet [Rosiglitazone 2mg/Metformin 500mg] BID|\[Rosiglitazone 2mg/ Metformin 500mg\] twice daily
224226154|NCT04807127|DRUG|Immune checkpoint blockade|ICI, administered as standard-of-care treatment
224226155|NCT04807127|DRUG|Targeted therapy|TKI, administered as standard-of-care treatment
224226156|NCT04807127|RADIATION|Radiotherapy|RT, administered as standard-of-care treatment
224226157|NCT01073020|DEVICE|Allergan Adjustable Gastric Band Surgery|
224226158|NCT01073020|OTHER|Intensive Medical Diabetes & Weight Management (Why WAIT) - Band Group|Intensive Medical Diabetes \& Weight Management (Why WAIT) - Band Group
224226159|NCT01073020|PROCEDURE|Roux-en-Y Gastric Bypass (RYGB) Surgery|
224226160|NCT01073020|OTHER|Intensive Medical Diabetes & Weight Management (Why WAIT) - Bypass Group|Intensive Medical Diabetes \& Weight Management (Why WAIT) - Bypass Group
223765040|NCT03869138|BEHAVIORAL|Virtual-reality based dance training|"Participants will receive therapy using the Just Dance using the commercially available Kinect gaming system (Microsoft Inc, Redmond, WA, USA. Each song involves repetitive action for each dance step (at least 20 repetitions over the entire song) and visual cues on the screen (a stick figure at the bottom right) indicating the upcoming dance step. Participant's playing the game to reduce risk of exercise related adverse effects. Participants will dance on 10 songs starting from a slow-pace progressing to a medium pace (each max 5 minutes long). Participants will receive 5 minutes rest after playing on each song. This will be conducted by two physical therapists."
223765041|NCT06669403|DRUG|OPT101|OPT101, is a 15-mer peptide derived from the sequence of mouse CD40L and was designed to target CD40-mediated inflammation. On the day of administration, the product will be diluted in saline to result in 50 mL for intravenous (IV) infusion over 120 minutes.
224226161|NCT03961776|DEVICE|MRI-guided radiotherapy by on-board DWI sequences|The radiotherapy treatment will be delivered on the MRI-guided radiotherapy platform. The on-board DWI sequences will be performed every three fractions in addition to the treatment session and will last approximately 3-4 minutes.
224226162|NCT00135213|BEHAVIORAL|training in smoking cessation|
224226163|NCT00003908|DRUG|carboplatin|
224226164|NCT00003908|DRUG|docetaxel|
224226165|NCT00889590|DRUG|Zoledronic acid|4 mg, monthly for 3 months followed by a 3-monthly schedule for up to one year after surgery
224226166|NCT01218620|DRUG|Gamma-Secretase Inhibitor RO4929097|Given PO
224226167|NCT01218620|DRUG|Ketoconazole|Given PO
224226168|NCT01218620|DRUG|Rifampin|Given PO
224226169|NCT01218620|DRUG|Midazolam Hydrochloride|Given IV
224226170|NCT01218620|DRUG|Omeprazole|Given PO
224226171|NCT01218620|DRUG|Tolbutamide|Given PO
224226172|NCT01218620|DRUG|Dextromethorphan Hydrobromide|Given PO
224226173|NCT01218620|OTHER|Pharmacological Study|Correlative studies
224226174|NCT01218620|OTHER|Laboratory Biomarker Analysis|Correlative studies
224226175|NCT02881476|OTHER|Biological: Cell-based therapy|Human allogeneic Wharton's jelly-derived mesenchymal stem cell transplantation in ALS patients.
224226176|NCT01335477|DRUG|placebo|placebo matching BIBF 1120 BID
224226177|NCT01335477|DRUG|BIBF 1120|BIBF 1120 BID (twice daily)
224226178|NCT03780894|DRUG|Fibrinogen Concentrate (Human) 1 MG [RiaSTAP]|Administration of 2 mg of FC together with RBC and TXA
224226179|NCT03780894|BIOLOGICAL|Red blood cells concentrate|Administration of 2 red blood cells concentrates together with FC and TXA
224226180|NCT03780894|DRUG|Tranexamic Acid|Administration of 1g of TXA together with FC and RBC
224226181|NCT05989360|DIAGNOSTIC_TEST|Lung Clearance Index|Normative values in healthy children from ethnic backgrounds
224226182|NCT00276874|DRUG|Aripiprazole|Aripiprazole; 0-30 mg; oral; daily
224226183|NCT00276874|DRUG|Placebos|Placebo; 0 mg; oral; daily
224226184|NCT03807882|OTHER|Bilateral M-ECT|Following acute treatment with bilateral ECT of 6 sessions over a period of two weeks, Bilateral M-ECT will be administered at a frequency of 1 session/week for one month, then 1 session / 2 weeks for 2 months and then 1 session/month for next 3 months.
224226185|NCT03807882|DRUG|Clozapine|Clozapine will be given in accordance with Maudsley guideline: 12.5 mg on the first day, followed by 12.5mg twice daily on the second day, followed by 25mg twice daily for next two days and then increment of 25mg every two days till the target dose of 250-400 mg per day in two divided doses as per tolerability of the patients
224226186|NCT04505514|DRUG|Iron Isomaltoside 1000|"single dose of 1000 mg iron isomaltoside diluted in 100 ml of 0.9% sodium chloride, infused intravenously over ≥ 20 minutes.~\- infusion set will be covered for blinding"
224226187|NCT04505514|DRUG|Placebo|"100 ml of 0.9% sodium chloride, infused intravenously over ≥ 20 minutes.~\- infusion set will be covered for blinding"
224226188|NCT04505514|DRUG|Iberet-Folic-500|once a day dose, to start 5 days after the intervention
224226189|NCT02607761|OTHER|Video|Video-Audio Media
224226190|NCT03577626|DRUG|Hemay005|Hemay005 tablets will be taken orally in dose of 52.5mg at fasted dosing on period one followed by fed dosing on period two.
224226191|NCT03577626|DRUG|Hemay005|Hemay005 tablets will be taken orally in dose of 52.5mg at fed dosing on period one followed by fasted dosing on period two
224319019|NCT00274118|DRUG|telmisartan|
224319020|NCT00274118|DRUG|enalapril|
224319021|NCT07134868|DIAGNOSTIC_TEST|Thiol- Disulfide Blood Sample Measurement|Measurement of thiol-disulfide homeostasis parameters and inflammatory markers from serum samples.
223515512|NCT01166698|DRUG|AZD9819|Inhaled multiple doses of suspension via SPIRA nebuliser, once daily for 10 (maximum 14) days
223515513|NCT01166698|DRUG|Placebo|Inhaled doses of suspension via SPIRA nebuliser given either as single (Part A) or multiple doses (Part B)
223515514|NCT06275958|DRUG|Doublet Chemotherapy, Standard Dose (100%)|Capecitabine 1000mg / m2 oral at day 1-14 (every 3 weeks) Oxaliplatin 130mg/m2 at day 1 (every 3 weeks) OR 5-FU 400mg/m2 IV bolus at day 1 followed by 2400mg/m2 in 46 hours (every 2 weeks) Leucovorin 400mg/m2 day 1 (every 2 weeks) Oxaliplatin 85mg/m2 day 1 (every 2 weeks)
223515515|NCT06275958|DRUG|Doublet Chemotherapy, Dose-reduced (75%)|75% of: Capecitabine 1000mg / m2 oral at day 1-14 (every 3 weeks) Oxaliplatin 130mg/m2 at day 1 (every 3 weeks) OR 5-FU 400mg/m2 IV bolus at day 1 followed by 2400mg/m2 in 46 hours (every 2 weeks) Leucovorin 400mg/m2 day 1 (every 2 weeks) Oxaliplatin 85mg/m2 day 1 (every 2 weeks)
223515516|NCT06275958|DRUG|Monotherapy, Standard Dose (100%)|\- Capecitabine 1000mg/m2 oral at day 1-14 (every 3 weeks)
223515517|NCT06275958|DRUG|Monotherapy, Dose-reduced (75%)|"75% of:~\- Capecitabine 1000mg/m2 oral at day 1-14 (every 3 weeks)"
223515518|NCT02344498|DRUG|Tenofovir disoproxil|
223515519|NCT01887600|DRUG|Roxadustat|Roxadustat was administered initially according to the tiered weight-based dosing, where participants with weight from ≥ 45 to ≤ 70 kg received 70 mg and participants with \> 70 to ≤ 160 kg received 100 mg of roxadustat. Dose-titration based upon regular measurement of Hb levels was performed until participants achieved central Hb value of ≥ 11.0 g/dL and Hb increase from baseline (BL) of ≥ 1.0 g/dL at two consecutive study visits, separated by at least 5 days. Once target Hb level was reached participants entered maintenance period during which roxadustat dosage was adjusted every 4 weeks to maintain participants Hb level within the target range of 10.0 g/dL and 12.0 g/dL.
223638170|NCT01293734|OTHER|clearing lung and relieving asthmatic granule and securing origin and clearing lung emplastrum|clearing lung and relieving asthmatic granule: once 1 bag, 3 times a day. securing origin and clearing lung emplastrum: paste on acupuncture point and take the emplastrum down after 3 hours, once a day
223638171|NCT01293734|OTHER|securing origin and relieving asthmatic granule and securing origin and nourishing lung emplastrum|securing origin and relieving asthmatic granule: once 1 bag, 3 times a day. securing origin and nourishing lung emplastrum: paste on acupuncture point and take the emplastrum down after 3 hours, once a day
223638172|NCT01293734|DRUG|Theophylline Sustained-release Tablets and budesonide suspension|Theophylline Sustained-release Tablets 0.2g a time, twice a day. budesonide suspension for inhalation 100ug, twice a day
223638173|NCT00213044|DRUG|Carraguard (PC-515)|
223638174|NCT00763035|DRUG|Regadenoson|Each participant will receive regadenoson 0.4mg (5ml) one time bolus dose at one visit.
224226192|NCT05434481|OTHER|Mitochondrial dynamic analysis in the aorta samples and metabolomic profiling in the aortic diseases|"* For each patient: a segment of aorta will be sampled and cutted into 4 parts~  * 1 fragment placed in a Falcon tube containing DMEM (Dulbecco's Modified Eagle Medium, Thermo Fisher®), temporarily stored at + 4°C, for primary culture of smooth muscle cells will allow analysis of the mitochondrial network.~ * 1 fragment placed in a Falcon tube containing Allprotect Tissue Reagent (QIAGEN®), stored at -80°C for gene (RT-PCR) and protein (Western Blot) analysis.~ * 2 fragments each placed in dry cryotube stored at - 80°C will be used for metabolomic analysis.~* For each patient, 2 arterial blood samples will be collected before general anaesthesia~  * One tube of whole blood stored at -80°C for metabolomic analysis.~ * One tube of blood stored at -80°C for plasma cytokines"
224226193|NCT05680350|PROCEDURE|Laparoscopic Exploration|Laparoscopic Exploration to diagnose \& grade endometriosis
223638175|NCT00763035|DRUG|Dobutamine|Each participant will receive dobutamine infusion (as per protocol to achieve a target heart rate of 85% of predicted for age) at another visit.
223638176|NCT03548948|OTHER|High heme iron diet|"A Typical American diet with high heme/non-heme iron (18 mg total). Diet is isocaloric and has a macronutrient composition of total fat 35%, carbohydrates 50%, protein 15% of calories and fiber 9g/1000 calories. Subjects consumes the diet for 3 weeks with a minimum 3 week washout before the next diet."
223638177|NCT03548948|OTHER|Low iron diet|"A Typical American diet with low heme/non-heme iron (8 mg total). Diet is isocaloric and has a macronutrient composition of total fat 35%, carbohydrates 50%, protein 15% of calories and fiber 9g/1000 calories. Subjects consumes the diet for 3 weeks with a minimum 3 week washout before the next diet."
224226194|NCT05680350|DIAGNOSTIC_TEST|Estimation of Plasma Expression level of MICRO RNA 203 & 210|"estimation of Plasma Expression level for GeneMicro RNA 203 \& 210 by qRT-PCR"
224226195|NCT00003533|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Metastatic Pancreatic Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
223638178|NCT03548948|OTHER|Plant-based high non-heme iron diet|"A plant-based diet with high non-heme iron (18 mg total). Diet is isocaloric and has a macronutrient composition of total fat 35%, carbohydrates 50%, protein 15% of calories and fiber 9g/1000 calories. Subjects consumes the diet for 3 weeks with a minimum 3 week washout before the next diet."
223638179|NCT01716377|DRUG|Venlafaxine|Sixty patients who present following a minor motor vehicle collision will be randomized to venlafaxine vs. placebo, and the ability of venlafaxine to decrease acute and persistent musculoskeletal neck pain will be assessed.
223638180|NCT01371396|OTHER|Low-fat diet|The subject will consume a diet that is calorically restricted to cause at least a 6% body weight loss over 4 months. Fat will make up less than 30% of dietary energy.
223638181|NCT01371396|OTHER|Low-carbohydrate diet|The diet will be restricted in energy to cause at least a 6% loss of body weight over a 4 month period. Carbohydrate will provide less than 40% of total dietary energy.
223638182|NCT02606643|PROCEDURE|Slight traction|Slight traction will be applied to the balloon catheter
223638183|NCT02606643|PROCEDURE|Foley Catheter to no traction|Foley Catheter to no traction
223638184|NCT03989258|DIAGNOSTIC_TEST|Mammography outside official screening|Radiologic study
223638185|NCT04663282|DRUG|INS068 injection|INS068 injected subcutaneously once daily. Treat-to-target dose titration during the trial
223638186|NCT04663282|DRUG|Insulin Degludec|Insulin Degludec injected subcutaneously once daily. Treat-to-target dose titration during the trial
223638187|NCT05386420|DRUG|Hymecromone tablets|Conventional treatment combined with Hymecromone tablets, 0.4g , tid ac, 7 days.
223638188|NCT05386420|OTHER|Placebo|Conventional treatment combined with Placebo.
223638189|NCT01068847|DRUG|2-4 of the drugs listed below|Cycloserine: 500, 675, 750 mg oral capsules may possibly given. Naloxone: 0.15mg/70Kg or 0.2mg/70kg I.M. injection may possibly be given. Nifedipine: 10, 20 mg oral capsules may possibly be given. Placebo (sugar pill or microcrystalline cellulose): oral capsules may be given. Saline: I.M. injection may possibly be given. Tizanidine: 4, 8, 12 mg oral capsules may possibly be given. Verapamil: 30, 60, 120 mg oral capsules may possibly be given.
223765042|NCT06669403|OTHER|Placebo|0.9% Sodium Chloride Injection USP, Placebo. On the day of administration, a 50mL IV bag containing saline (0.9% Sodium Chloride Injection USP) which will serve as the placebo will be administered via intravenous (IV) infusion over 120 minutes.
223765043|NCT06669897|OTHER|Questionnaire|Chronic cough questionnaire
223765044|NCT06994897|DRUG|PF-07985631|Experimental Pfizer compound which will be SC or IV
223765045|NCT06994897|DRUG|Placebo|Placebo which will be SC or IV
223765046|NCT04853667|OTHER|Interview|Semi-structured interview, lasting a maximum of one hour
224226196|NCT01724398|OTHER|Conventional plus UC-MSC treatment|Received conventional treatment and umbilical cord mesenchymal stem cells transplantation by peripheral vein slowly for 30minutes. (1×105/Kg, once a week, 4 times).
224226197|NCT01724398|OTHER|Conventional plus PE treatment|Received conventional treatment plus 2000 milliliter plasma exchange (every 3 days, 3 times).
224226198|NCT01724398|OTHER|Conventional plus UC-MSC and PE therapy|Received conventional treatment plus 2000 milliliter plasma exchange (every 3 days, 3 times). Meantime taken i.v umbilical cord mesenchymal stem cells transplantation slowly for 30minutes (1×105/Kg, once a week, 4 times), the first two times is taken after plasma exchange.
223638190|NCT02376998|DEVICE|Valiant™ endoluminal procedure|"Thoracic endovascular aortic repair with Endoluminal stent-graft placement (Valiant™ endoluminal stent-graft systems (Medtronic Inc., Santa Rosa, CA, USA) will be performed as follows:~The diameter of the stent graft will be calculated from the largest diameter of the proximal/distal neck with an oversizing factor of 10-20%. The procedures will be done with local or general anaesthesia in case of unstable pre-operative hemodynamic conditions.~After the procedure will be completed, a digital subtraction angiography and echocardiography with color-flow mapping were performed to verify the correct positioning of the stent and to detect any primary endoleak."
223638191|NCT05394155|DIETARY_SUPPLEMENT|Leucine|7 intake levels of leucine, ranging from 10 to 75 mg/kg/d.
223638192|NCT00523510|PROCEDURE|Infant feeding counseling that includes Flash-heat|Intensive infant feeding counseling which includes description and demonstration of the WHO recommended option for HIV-infected mothers to pasteurize their breastmilk. Flash-heat pasteurization will be described and demonstrated to interested mothers. More intensive counseling and support will be provided home visits.
223638193|NCT05410184|DEVICE|Virtual Reality Glasses group|Except for the preparation of the patient for the procedure, since the colonoscopy procedure takes approximately 30 minutes, 30-minute 360-degree VR video scenes will be watched using the phone and VR head device
223638194|NCT05410184|OTHER|mural curtain group|the mural curtain group; they will be asked to focusing the mural curtain with a nature view during the colonoscopy procedure.
223638195|NCT04467203|DRUG|Fadanafil|"Seven subjects in group A will receive treatment in the following order:~At Day 1, a single dose of Fadanafil 100mg will be administered orally after overnight fasting-\>~At Day 8, a single dose of Fadanafil 100mg will be administered orally with high fat meal;Seven subjects in group B will receive treatment in the following order:~At Day1, a single dose of Fadanafil 100mg will be administered orally with high fat meal-\> At Day 8, a single dose of Fadanafil 100mg will be administered orally after overnight fasting"
224226199|NCT01724398|OTHER|Conventional treatment|Received conventional treatment including antiviral drugs, lowering aminotransferase and jaundice medicine.
224226200|NCT04642950|DRUG|Sargramostim|250 μg/vial of sargramostim will be dissolved in 4 mL of physiological saline and 125 μg of which will be administered using inhaler twice daily in approximately 10-15 minutes.
224226201|NCT04642950|DRUG|Placebo|2 mL of physiological saline will be administered using inhaler twice daily in approximately 10-15 minutes.
224226202|NCT02275923|DEVICE|Reveal LINQ™ Insertable Cardiac Monitor|Insertable cardiac monitor
224226203|NCT03914313|DEVICE|Robotic Treatment plus VR|The patients included will be divided into three groups of 30 patients each. In this group patients will undergo a rehabilitation training with the Lokomat-Pro, in which the exoskeleton device is equipped with a screen with virtual reality. The rehabilitation protocol consists of 24 training sessions (3 sessions per week, for 8 weeks, each session lasting about 45 minutes). The Lokomat-Pro will be used to improve gait, whereas motor and cognitive function will be normally trained by using conventional neurorehabilitation. Patients will be evaluated at baseline (T0), immediately (T1) and after 3.month (T2) of treatment.
224226204|NCT04585321|DRUG|Diclofenac Sodium 140mg Medicated Plaster|"Part 1: two seven-day study periods, separated by at least 7 days of wash-out. In the first period, a single plaster of Test Drug or Reference Drug will be applied on the back (lumbar region) for seven consecutive days. In the second period, a single plaster of the Reference Drug or Test Drug will be applied on the back (lumbar region) daily for seven consecutive days.~Part 2: two seven-day study periods separated by at least 7 days of wash-out. In the first period, the Test Drug or Reference Drug plaster will be applied on the back (lumbar region) twice a day. In the second period, the Reference Drug or Test Drug plaster will be applied on the back (lumbar region) twice a day."
224319022|NCT07133776|DRUG|PD-1 Inhibitor Combined with Tenofovir, Chidamide, and Lenalidomide for the Treatment of EBV Infectious Diseases.|This study involves a four-drug combination regimen consisting of a PD-1 inhibitor, tenofovir, chidamide, and lenalidomide for the treatment of EBV Infectious diseases, aiming to inhibit viral replication and restore immune function through multiple mechanisms. The intervention includes not only pharmacological treatment but also pre-treatment assessments (such as EBV-DNA load, immune status, cardiac and renal function), efficacy monitoring during treatment (e.g., ORR, changes in EBV-DNA), and post-treatment follow-up for safety and survival outcomes (including OS, PFS, and adverse events), in order to comprehensively evaluate the clinical value and feasibility of this combination therapy.
224319023|NCT07134491|BIOLOGICAL|Piece of kidney removal|removal for a piece of kidney for research purposes during biopsy or graft removal performed as part of routine care
223638196|NCT00180336|DEVICE|CRT-D|
224319024|NCT07134491|BIOLOGICAL|Stool collection|Stool collection for research purposes
224319025|NCT07134491|BIOLOGICAL|Blood collection|Additional blood volume for research purposes during a routine blood collection
223638197|NCT03216512|OTHER|Use of Noise Cancelling Headphones|During the 2 experimental sessions, participants will complete study assessments using either a noise cancelling headphone first (session 1) and then sham control second ( session 2), or vice versa, in the presence of noise distractions.
223638198|NCT06486194|DEVICE|Targeted breast milk fortification using preemie device|Mother's breast milk will have additional macronutrient added to it based on analysis with the Preemie device, to ensure it meets current European recommendations for nutrient intakes for preterm infants
223638199|NCT06486194|DIETARY_SUPPLEMENT|Standard Breast milk fortification|Standard multicomponent breast milk fortifier will be added to mother milk as per usual practice for preterm infants
223765047|NCT05972044|DRUG|Solriamfetol 150 mg|Solriamfetol tablets, taken once daily
224323245|NCT06018311|BEHAVIORAL|Exercising together|The Exercising Together program is a partnered functional strength training program that encourages participating dyads to interact with one another, verbally and physically, during exercise sessions. In Exercising Together, the survivor and their caregiver will build skills to work as a team. We will incorporate skills that promote and reinforce communication, motivation, and support and use this to guide training of survivor-caregiver dyads to maximize their teamwork during each exercise session. Group sessions are delivered remotely through videoconferencing software and are supervised by two trained exercise instructors. Intervention and assessment is available in English or Spanish.
223765048|NCT05972044|DRUG|Solriamfetol 300 mg|Solriamfetol tablets, taken once daily
223765049|NCT05972044|DRUG|Placebo|Placebo tablets, taken once daily
224226205|NCT04585321|DRUG|Flector® topical plaster containing 180 mg of diclofenac hydroxyethylpyrrolidine equivalent to 140 mg of sodium diclofenac|"Part 1: two seven-day study periods, separated by at least 7 days of wash-out. In the first period, a single plaster of Test Drug or Reference Drug will be applied on the back (lumbar region) for seven consecutive days. In the second period, a single plaster of the Reference Drug or Test Drug will be applied on the back (lumbar region) daily for seven consecutive days.~Part 2: two seven-day study periods separated by at least 7 days of wash-out. In the first period, the Test Drug or Reference Drug plaster will be applied on the back (lumbar region) twice a day. In the second period, the Reference Drug or Test Drug plaster will be applied on the back (lumbar region) twice a day."
224226206|NCT05909475|DIETARY_SUPPLEMENT|GKEX|GKEX group. Probiotic capsules contain 10 billion CFU (colony forming units) of GKEX, , 2 caps daily use.
224226207|NCT05909475|OTHER|Placebo|The placebo capsule contains microcrystalline cellulose, 2 caps daily use.
224226208|NCT04822870|PROCEDURE|quadratus lumborum block|Quadratus lumborum block is an effective nerve block method in post-cesarean section analgesia. It is a relatively new technique that may provide analgesic effect in somatic pain and visceral pain, but has not been verified yet.
224226209|NCT04822870|PROCEDURE|iliohypogastric/ilioinguinal nerve block|Iliohypogastric/ilioinguinal nerve block is a widely used nerve block technique. It can provide somatic analgesia effect in post-cesarean section.
224226210|NCT04822870|PROCEDURE|epidural analgesia|Epidural analgesia is a traditional analgesia method. Epidural morphine can provide effective analgesia but may cause plenty adverse effect.
224226211|NCT00099736|DRUG|FTY720 5 mg + reduced-dose Neoral (RDN) + corticosteroids|FTY720 5 mg + reduced-dose Neoral (RDN) + corticosteroids
224226212|NCT00099736|DRUG|FTY720 2.5 mg + full dose Neoral (FDN) + corticosteroids|FTY720 2.5 mg + full dose Neoral (FDN) + corticosteroids
224226213|NCT00099736|DRUG|MMF 2 g + full-dose Neoral (FDN) + corticosteroids|mycophenolate mofetil (MMF) + full-dose Neoral (FDN) + corticosteroids
224226214|NCT04053790|DRUG|lactobacillus LB|administration of different doses of Lactobacillus LB according to the treatment groups described previously
224226215|NCT04053790|OTHER|placebo|a tablet of placebo every 12 hours given by mouth
223515520|NCT01887600|DRUG|Placebo|Placebo was administered initially according to the tiered weight-based dosing, where participants with weight from ≥ 45 to ≤ 70 kg received 70 mg and participants with \> 70 to ≤ 160 kg received 100 mg of roxadustat. Dose-titration based upon regular measurement of Hb levels was performed until participants achieved central Hb value of ≥ 11.0 g/dL and Hb increase from baseline (BL) of ≥ 1.0 g/dL at two consecutive study visits, separated by at least 5 days. Once target Hb level was reached participants entered maintenance period during which roxadustat dosage was adjusted every 4 weeks to maintain participants Hb level within the target range of 10.0 g/dL and 12.0 g/dL.
223515521|NCT03688139|BEHAVIORAL|Engage Therapy|"Engage therapy is designed to help individuals with depression become involved in activities they previously enjoyed but have not been participating in since developing depression. In Engage therapy, individuals with depression work with a therapist to develop action plans to pursue rewarding activities of their choice."
224323246|NCT06581406|BIOLOGICAL|RP2|Genetically modified herpes simplex type 1 virus for tumor lysis and immune stimulation.
224323247|NCT06581406|BIOLOGICAL|Ipilimumab|Ipilimumab: human cytotoxic T-lymphocyte antigen 4 (CTLA-4)-blocking antibody
223515522|NCT03688139|BEHAVIORAL|Supportive Therapy|Supportive therapy is designed to provide a warm and supportive environment in which individuals with depression can feel comfortable expressing their thoughts and feelings. In supportive therapy, therapists help patients identify themes in their thinking, provide reassurance, emphasize coping skills, and provide guidance as needed.
223515523|NCT00420056|DRUG|PD-0332991|125 mg, oral, Days 1-21 of a 28-day cycle
223515524|NCT02380235|BIOLOGICAL|PEG-somatropin|0.20mg/kg/w
223515525|NCT02380235|BIOLOGICAL|PEG-somatropin|0.12mg/kg/w
223515526|NCT03274661|DRUG|Pembrolizumab 200 mg Q3W|Pembrolizumab 200 mg Intravenous Infusion every 3 weeks administered on Day 1 of each 3 week cycle
223515527|NCT02783859|DRUG|Amoxicillin-clavulanic Acid|
223515528|NCT02783859|DRUG|Placebo (for Amoxicillin-clavulanic Acid)|
223515529|NCT01083472|DEVICE|Strattice(TM) Reconstructive Tissue Matrix|Strattice(TM) TM will be used to support the repair of abdominal wall defect
223515530|NCT01083472|PROCEDURE|Suture/suture with absorbable mesh|Abdominal wall defect will be repaired with suture alone or absorbable mesh with suture
223638200|NCT02614001|DEVICE|Threshold® IMT HS730, RESPIRONICS Inc, Cedar Grove, NJ, USA|Patient will be trained daily, total 30 minutes or 15 minutes twice per day, at least 5 times a week, for 10 weeks
223765050|NCT01811121|DRUG|5-aminolévulinique acid (5-ALA)|oral administration of 20mg/kg of 5-ALA 3-5 hours before the surgical incision
224226216|NCT00649870|DRUG|Valacyclovir Hydrochloride Tablets 1000 mg|1000mg, single dose fed
223515531|NCT02451475|DRUG|Amitriptyline|Amitriptyline 25 mg/day
223515532|NCT02451475|DRUG|Venlafaxine|Venlafaxine 75 mg/day
223515533|NCT02451475|DRUG|Paroxetine|Paroxetine 25 mg/day
223515534|NCT03093168|BIOLOGICAL|Anti-BCMA CAR-T cells|Retroviral vector-transduced autologous T cells to express anti-BCMA CAR
223515535|NCT03093168|DRUG|Fludarabine|dose: 25mg/m2/d
223515536|NCT03093168|DRUG|Cyclophosphamide|Dose: 40mg/kg
223515537|NCT05802849|DRUG|Acetazolamide|Acetazolamide is a diuretic with a mild diuretic effect. Inhibits the enzyme carbonic anhydrase in the proximal convoluted tubule of the nephron. Increases urinary excretion of sodium, potassium, bicarbonate ions, does not affect the excretion of chlorine ions; causes an increase in urine pH.
223638201|NCT02614001|OTHER|post-stroke rehabilitation program|
223638202|NCT04805034|OTHER|Age, BMI,Baseline HBV DNA, Baseline HBeAg level, Baseline HBsAg level, Antiviral treatment, Serum ALT level|Exposure factors: Age, BMI, Family history, Baseline HBV DNA, Baseline HBeAg level, Baseline HBsAg level, Antiviral treatment, Serum ALT level
224226217|NCT00649870|DRUG|Valtrex® Tablets 1000 mg|1000mg, single dose fed
224226218|NCT05584475|BEHAVIORAL|Mindful Awareness Practices (MAPs)|MAPs is an 8-session, group-based approach for individuals with ADHD to improve attentional difficulties and related impairments by enhancing attending to and accepting experiences in the present moment. Sessions typically last between 60 and 90 minutes, though may last up to 120 minutes.
224323248|NCT06581406|BIOLOGICAL|Nivolumab|Nivolumab: Anti-PD-1 Monoclonal antibody
224323249|NCT06637631|DRUG|SAR441566|Pharmaceutical form: Tablet Route of administration: Oral
223638203|NCT01011894|DRUG|lenalidomide|Lenalidomide will be administered orally at a starting dose of 2.5mg once daily, days 1-28. Patients will be evaluated prior to treatment and at 4 weeks, 8 weeks, 12 weeks, 16 weeks and at a minimum of 4 weeks thereafter until removal from study. Patients with stable disease or better will continue at their current dose unless they experience toxicity requiring dose reduction. For those patients who have progressive disease on their current dose and have no dose-limiting toxicity, their dose will be increased from 2.5mg, to 5mg, to 10mg, to 15mg, to 20mg one dose level at a time not more frequently than once every 4 weeks. The maximum dose will be 20mg.
223638204|NCT03418714|DRUG|Salvinorin A|Salvinorin A, blinded doses
223638205|NCT05468996|DRUG|Remimazolam|A loading dose of remimazolam is 1mg/kg/hr. When sedation is achieved, the dose of remimazolam is adjusted to the assigned dose. The maintenance dose of remimazolam begins at 1.0mg/kg/hr. When the maintenance is not successful during the surgery, the maintenance dose will be increased by 0.1-0.2mg/kg/hr in the next patient. When the maintenance is successful, the dose will be decreased by 0.1-0.2mg/kg/hr. (maximal dose: 2mg/kg/hr)
223638206|NCT04782869|DEVICE|transcranial direct current stimulation|Patients will be treated using Starstim 8 device, a device allowing to perform transcranial direct current stimulation. The position of electrodes will be personalized based on the localization of the epileptogenic zone.
223638207|NCT03711968|OTHER|Rehabilitative treatment protocol|A combination of: postural exercise with visual spatial tasks, relaxation, balance exercise, motricity improvement and cognitive rehabilitation.
223638208|NCT05586438|DRUG|Colistin Sulfomethate|The patients receive colistin 150 mg intravenous once daily on non-dialysis day and receive colistin 150 mg intravenous every 12 hours on dialysis day
223638209|NCT03690687|PROCEDURE|Primary anastomosis|
223638210|NCT03690687|PROCEDURE|Delayed anastomosis|
223638211|NCT03690687|PROCEDURE|Enterostomy|
224226219|NCT01768806|BEHAVIORAL|PLAY Project Intervention for Autism|Children diagnosed with autism were recruited to the PLAY Project Intervention grant and assigned to a community standard arm (CS) or a CS plus PLAY Project arm of the study. Those in the PLAY Project arm of the study received a one time per month home visit to train caregivers in the PLAY Project methods including video feedback and caregivers also receive mid month feedback based on the video review of interaction.
223638212|NCT04313244|BIOLOGICAL|9vHPV Vaccine|9vHPV intramuscular injection
223638213|NCT04313244|BIOLOGICAL|Dengue Tetravalent Vaccine (TDV)|TDV subcutaneous injection
223638214|NCT05106400|DRUG|ZTlido (Lidocaine Topical System) 1.8%|1 ZTlido (Lidocaine Topical System) 1.8% is applied predetermined area on the right or left side of the mid to upper back and worn for 12 hours
223638215|NCT05106400|DRUG|Salonpas (Lidocaine Patch 4%)|1 Salonpas (Lidocaine Patch 4%) is applied predetermined area on the right or left side of the mid to upper back and worn for 12 hours
223765051|NCT01811121|DRUG|Placebo|Oral administration of 1g of ascorbic acid LAROSCORBINE in 50ml of water 3 hours before surgery
223765052|NCT05433389|BEHAVIORAL|Breath Counting|Patients will listen to a 5-minute, audio-recorded breath counting practice.
223765053|NCT05433389|BEHAVIORAL|Body Scan|Patients will listen to a 5-minute, audio-recorded body scan practice.
223765054|NCT05433389|BEHAVIORAL|Mindful Breathing|Patients will listen to a 5-minute, audio-recorded mindful breathing practice.
223765055|NCT05433389|BEHAVIORAL|Mindfulness of Pain|Patients will listen to a 5-minute, audio-recorded mindfulness of pain practice.
223765056|NCT05433389|BEHAVIORAL|Mindful Savoring|Patients will listen to a 5-minute, audio-recorded mindful savoring practice.
224226220|NCT01768806|BEHAVIORAL|Special education pre-school|Special education preschool services included 10-12 hours per week of educational services including speech and language and occupational therapy
224226221|NCT01400269|BEHAVIORAL|Pacific Autism Center for Education (PACE ) developmentally based parent delivered intervention|Pacific Autism Center for Education (PACE ) developmentally based parent delivered intervention
224226222|NCT00583869|DRUG|Placebo|"Two hours before surgery, patients will receive 75mg of pregabalin. Patients will be placed on a patient-controlled anesthesia pump (PCA) for 24 hours. On post-operative day one, the patients will be switched to oral oxycodone as needed with supplementation with IV Demerol for breakthrough pain. In addition, patients will receive a placebo PO BID beginning on the day of surgery until discharge.~Upon discharge, the patient will be given study medication (placebo PO BID). Rescue medications will be allowed during the study (including post-operative and outpatient periods). Outpatient rescue medications will consist of hydrocodone/APAP 7.5mg PO Q6H PRN. Patients will be followed for three months as an outpatient."
224226223|NCT00583869|DRUG|Pregabalin|"Two hours before surgery, patients will receive 75mg of pregabalin. Patients will be placed on a patient-controlled anesthesia pump (PCA) for 24 hours. On post-operative day one, the patients will be switched to oral oxycodone as needed with supplementation with IV Demerol for breakthrough pain. In addition, patients will receive 75mg PO BID beginning on the day of surgery until discharge.~Upon discharge, the patient will be given study medication (pregabalin 75mg PO BID). Rescue medications will be allowed during the study (including post-operative and outpatient periods). Outpatient rescue medications will consist of hydrocodone/APAP 7.5mg PO Q6H PRN. Patients will be followed for three months as an outpatient."
224226224|NCT00583869|DRUG|Pregabalin|"Two hours before surgery, patients will receive 75mg of pregabalin. Patients will be placed on a patient-controlled anesthesia pump (PCA) for 24 hours. On post-operative day one, the patients will be switched to oral oxycodone as needed with supplementation with IV Demerol for breakthrough pain. In addition, patients will receive 150mg PO BID beginning on the day of surgery until discharge.~Upon discharge, the patient will be given study medication (pregabalin 150mg PO BID). Rescue medications will be allowed during the study (including post-operative and outpatient periods). Outpatient rescue medications will consist of hydrocodone/APAP 7.5mg PO Q6H PRN. Patients will be followed for three months as an outpatient."
224226225|NCT02452060|DRUG|Ketamine|0.4mg/kg infusion
224226226|NCT02452060|OTHER|Placebo Comparator|0.4mg/kg infusion
224226227|NCT00004576|DRUG|LY300164|
224323250|NCT06637631|DRUG|SAR441566 matching Placebo|Pharmaceutical form: Tablet Route of administration: Oral
224323251|NCT02710123|OTHER|Sub-Threshold exercise prescription|Participants will be given a prescription to exercise at 80% of their threshold HR for symptom exacerbation. HR Threshold will be monitored weekly and exercise level increased accordingly.
223638216|NCT05106400|DRUG|Aspercreme (Lidocaine Patch 4%)|1 Aspercreme (Lidocaine Patch 4%) is applied predetermined area on the right or left side of the mid to upper back and worn for 12 hours
223638217|NCT05106400|DRUG|IcyHot (Lidocaine 4% + Menthol 1% Patch)|1 IcyHot (Lidocaine 4% + Menthol 1% Patch) is applied predetermined area on the right or left side of the mid to upper back and worn for 12 hours
223638218|NCT05751187|BIOLOGICAL|Pembrolizumab|Pembrolizumab was given as 200 milligrams (mg) via intravenous (IV) infusion over 30 minutes on Day 1 of each 21-day cycle.
223638219|NCT05751187|BIOLOGICAL|Bevacizumab|Bevacizumab was given as 15 mg/kg via intravenous (IV) infusion on Day 1 of each 21-day cycle.
223638220|NCT05751187|DRUG|Pemetrexed|Pemetrexed was given as 500 mg/m\^2 via intravenous (IV) infusion (with vitamin supplementation) on Day 1 of each 21-day cycle for 4-6 cycles.
223638221|NCT05751187|DRUG|Cisplatin|Cisplatin was given as 75 mg/m\^2 via intravenous (IV) infusion (administered approximately 30 minutes after pemetrexed infusion) on Day 1 of each 21-day cycle for 4-6 cycles.
223638222|NCT05751187|DRUG|Carboplatin|Carboplatin was given as Aare Under the Curve (AUC) 5 (5 mg/mL/min; over 15-60 min) via intravenous (IV) infusion (administered immediately after pemetrexed infusion) on Day 1 of each 21-day cycle for 4-6 cycles.
223638223|NCT05751187|DIETARY_SUPPLEMENT|Folic acid 350-1000 μg|Orally; at least 5 doses of folic acid must be taken during the 7 days preceding the first dose of pemetrexed, and folic acid dosing must continue during the full course of therapy and for 21 days after the last dose of pemetrexed.
223638224|NCT05751187|DIETARY_SUPPLEMENT|Vitamin B12 1000 μg|Intramuscular injection in the week preceding the first dose of pemetrexed and once every 3 cycles thereafter. Subsequent vitamin B12 injections may be given on the same day as pemetrexed administration.
223638225|NCT05751187|DRUG|Dexamethasone 4 mg|For prophylaxis; orally twice per day (or equivalent). Taken the day before, the day of, and the day after pemetrexed administration.
223638226|NCT03513159|BEHAVIORAL|Pathfinder support|A pathfinder will support the patient with structured activities.
223638227|NCT03946475|OTHER|Intervention group|"Training of Trainers (ToT) was conducted among teacher who would deliver the messages. Remaja ASIK is Indonesian tagline meant girls who are active, healthy, smart, and creative. Nutrition education was performed in every Friday, at least 30 minutes during 20 weeks. In brief, this is the key messages of optimized food based recommendations: 1) 3 meals and 2 snack every day, 2) At least 2 portions of vegetables/day including at least 5 portions/week of green leafy vegetables, 3) At least 2 portions/day of animal protein including at least 2 portions/week of liver, 4) At least 1 portion/day of tempe or tofu, 5) At least 1 portion/day of fruit, 6) At least 3 portions/week of milk.Trained teachers delivered the messages accompanied by supervisor. The delivered topics were key messages, balance nutrition, anemia, menstruation, BMI, healthy and smart, strong bone, lunch box, safe snack, and food label."
223638228|NCT01686919|DIETARY_SUPPLEMENT|milk-free|milk-free diet during 8 preoperative weeks
223638229|NCT01271946|DEVICE|Diagnostic catheterization procedure|Intervention includes diagnostic catheterization procedure involving access through a 5F or 6F introducer in the femoral artery.
223638230|NCT03149562|DRUG|plasma transfusions|These critical ill neonates with plasma transfusions
224226228|NCT03091530|OTHER|Sleeper Stretch|The sleeper stretch protocol will follow the process described by Wilk with the subject lying on his throwing shoulder side, with the lateral border of the scapula on the table, and the glenohumeral and elbow joints both at 90 degrees of flexion. Participants will be instructed to passively internally rotate the shoulder with gentle overpressure applied on the dorsum of the dominant arm wrist by the nondominant hand to the point of stretch on the posterior aspect of the shoulder. Stretches will be held for 20 seconds each and repeated 4 times for optimal sustained collagen elongation. This protocol will be performed on days 0-4 after the throwing session.
224226229|NCT03091530|OTHER|90/90 Hip Lift with Balloon Blow Exercise|The 90/90 Hip Lift with Balloon Blow Exercise (BBE) will follow the guidelines described by the Postural Restoration Institute. The subjects will lie supine with hips and knees flexed to 90 degrees, the right arm flexed to end range and resting on the floor. Using the left arm to hold the balloon, subjects will inhale fully and exhale into a balloon while holding a posterior pelvic tilt. The subjects inhale and then exhale into the balloon fully, then hold their breath for 5 seconds while putting their tongue on the roof of their mouth.
224226230|NCT02951663|DIETARY_SUPPLEMENT|Protein|
224226231|NCT03031899|PROCEDURE|Biopsy|rose bengal stain and toluidine is applied over a premalignant lesion and positively stained lesions are subjected to biopsy.
224226232|NCT03031899|DIAGNOSTIC_TEST|Rose Bengal|the lesions stained positive were subjected to biopsy
224226233|NCT03031899|DIAGNOSTIC_TEST|toluidine blue|the lesions stained positive were subjected to biopsy
224323252|NCT02710123|OTHER|Structured stretching prescription|Participants will be given a prescription for daily stretching lasting approximately 20 minutes.
224323253|NCT06462469|DRUG|Ruxolitinib|Ruxolitinib is taken orally daily at 10 mg BID, given as two 5-mg tablets.
223638231|NCT03149562|DRUG|non-plasma transfusions|These critical ill neonates without plasma transfusions
223638232|NCT01472289|OTHER|Autologous Bone Marrow Mononuclear cells (BMMNCs)|Multiple intramuscular injections of concentrated bone marrow derived mononuclear cells (0.5 cc/injection) into the ischemic muscle of the affected limb.
223638233|NCT06169969|DEVICE|magnetic therapy|Kegel exercises
224323254|NCT05381948|DRUG|EYP-1901|Intravitreal Injection
223638234|NCT04725578|BEHAVIORAL|Telehealth Single Session Consultation|A remotely delivered, single, goal-directed consultation session based on Solution-Focused Brief Therapy (SFBT). SFBT is an evidence-based therapy approach that is primarily focused on the client's present problems and their immediate future. When using SFBT in a single-session the aim of the intervention becomes empowering the client to take the smallest possible steps towards their desired future.
223638235|NCT00907335|DRUG|Retin-A Micro 0.04% facial acne treatment|Retin-A Micro 0.04% facial acne treatment used once daily
223638236|NCT00907335|DRUG|Vehicle control|Color-matched facial gel vehicle control used once daily
223638237|NCT03052270|DRUG|Arabin Pessary|Insertion of Arabin pessary for the prevention of preterm delivery
223638238|NCT02631239|DRUG|Methotrexate|1g/m2/d IV \*1d
223638239|NCT02631239|DRUG|Etoposide|200mg/d PO \*3d
224323255|NCT05381948|DRUG|Aflibercept 2mg/0.05mL Inj,Oph|Intravitreal Injection
224323256|NCT05335811|DRUG|4-[18F]Fluoro-1-Naphthol|By vein (IV)
224226234|NCT05772299|RADIATION|Er:Yag laser|Submucosal debridement is performed with Er:Yag laser using a P-400 tip under rinsing water.
223638240|NCT02631239|DRUG|Dexamethasone|40mg/d PO \*3d
223638241|NCT02631239|DRUG|Pegaspargase|2500IU/m2/d IM \*1d
223638242|NCT02631239|RADIATION|Radiotherapy|50-56Gy
223638243|NCT04475796|PROCEDURE|Laparoscopic cholecystectomy|Laparoscopic cholecystectomy performed after ERCP
223638244|NCT00005966|BIOLOGICAL|recombinant interferon alfa|
223765057|NCT06856590|DIETARY_SUPPLEMENT|Zinc Supplementation|Participants assigned to zinc-containing arms will receive oral zinc gluconate supplementation (78 mg twice daily) for 8 weeks. This intervention aims to evaluate the effect of zinc in preventing and reducing the severity of regorafenib-induced hand-foot skin reaction (HFSR).
223765058|NCT06856590|DRUG|Clobetasol Propionate 0.05% Cream|Participants assigned to clobetasol-containing arms will receive topical clobetasol propionate 0.05% cream, applied twice daily to the palms and soles for 8 weeks. This intervention aims to assess the efficacy of clobetasol in preventing regorafenib-induced HFSR.
224226235|NCT05772299|DEVICE|EMS ultrasound|Submucosal debridement is performed with piezoelectric ultrasound (EMS) with a PEEK (plastic coated) tip under rinsing water.
224226236|NCT04782115|BIOLOGICAL|intravitreal injection of RC28-E|a chimric decoy receptor trap fusion protein by dual blockage of VEGF and FGF
224226237|NCT04782115|BIOLOGICAL|Conbercept|KH902(Conbercept）
224226238|NCT03740698|DEVICE|BiAP|The bio-inspired artificial pancreas (BiAP) system uses a control algorithm based on a mathematical model of beta-cell behaviour derived from physiological experiments, carried out by other groups, which have demonstrated how the beta cells in the pancreas produce insulin in people without diabetes. Utilising the data from these experiments it has been possible to implement the behaviour of the beta cell in software and we have used a simulator with 200 virtual patients to demonstrate the safety and efficacy of the algorithm. The data from the simulator have previously been published. The BiAP algorithm is implemented on a miniature silicon microchip within a portable handheld device, which interfaces the components of the artificial pancreas.
224226239|NCT03740698|DEVICE|ABC4D|The Advanced Bolus Calculator for Diabetes (ABC4D) is a novel, adaptive decision support algorithm based on case-based reasoning (CBR) providing real-time insulin advice through a smartphone application.
224226240|NCT03120585|OTHER|Fluid Management Intervention|Fluid management intervention is fluid restriction to 60 mL/kg/day on Day of Life (DOL) 1 for preterm and 40 mL/kg/day on DOL 1 for term neonates, calculated as total of IV and enteral fluid intake. Infants randomized to low infusion with be placed on 10% dextrose and the Infant will be monitored by obtaining serum glucose levels by point of care testing. Glucose infusion rates (GIR) would be calculated to the corresponding serum glucose and recorded. After 24 hours, infusion rate will be increased to 60ml/kg/d providing minimum GIR \>4mg/kg/d. . Total fluid intake will be increased by 20 mL/kg/day until 150 mL/kg/day .
224226241|NCT03732105|RADIATION|Surgery-radiotherapy|Patients in the surgery-radiotherapy group will receive Intensity Modulated Radiation Therapy (IMRT) at a dose of 50Gy/25fraction after randomization.
224226242|NCT02179983|PROCEDURE|Pulmonary rehabilitation|6 weeks of supervised exercise and education (pulmonary rehabilitation)
224226243|NCT02179983|PROCEDURE|Pulmonary rehabilitation|6 weeks of exercise and patient education following exacerbation (pulmonary rehabilitation)
224226244|NCT05587088|DRUG|Petiveria Alliacea Preparation|Petiveria Alliacea Preparation in pill
224226245|NCT05587088|DRUG|Placebo|Placebo in pill
224226246|NCT01298388|OTHER|medical chart review|
224226247|NCT01298388|OTHER|questionnaire administration|
224226248|NCT01298388|OTHER|study of socioeconomic and demographic variables|
224226249|NCT00489203|DRUG|beclomethasone dipropionate|Given orally
224226250|NCT00489203|DRUG|placebo|Given orally
224226251|NCT00489203|DRUG|tacrolimus|Given after transplant
223638245|NCT00005966|DRUG|thalidomide|
223638246|NCT00784914|DRUG|temsirolimus|Receive temsirolimus IV
223638247|NCT00784914|OTHER|pharmacological study|Plasma levels of temsirolimus and sirolimus will be evaluated in serial blood samples.
223638248|NCT00784914|OTHER|cytokine levels|Dialysate samples are collected at regular intervals during the 96 hours following placement of the catheter to measure changes in levels of cytokines, chemokines and growth factors
223638249|NCT01387477|DRUG|Lactate|Infusion of 66 mmol of lactate
223638250|NCT01387477|DRUG|Glucose|Infusion of 33 mmol of glucose
223638251|NCT04444726|DEVICE|Ultra Violet A Device.+ Topical medical treatment|"Hands of the patient are irradiated in the UVA device after soaking for 20 minutes into 10 litres of water containing psoralen meladenine capsule."
223638252|NCT04444726|DEVICE|Iontophoresis device + Topical medical treatment|Tap-water iontophoresis was given 3 times weekly for 10 min. The direct current level was slowly increased, guided by the occurrence of tingling sensations. The maximum level was 30 mA.
223638253|NCT04444726|DRUG|"Topical medical treatment (Betamethasone dipropionate 0.05%  diprolene  )"|thin film of the cream is being applied to the affected areas for 2 times per day.
223638254|NCT03483402|PROCEDURE|Micropulse laser trabeculoplasty|Micropulse laser trabeculoplasty is performed using the Iridex IQ 532 laser system (Iridex Corporation, 1212 Terra Bella Avenue, Mountain View, CA, USA) and 532 nm (green) wavelength MLT is applied with confluent applications to pigmented trabecular meshwork over 360 degrees using a 300 µm spot size, 300 ms duration, 1000 mW power and 15% duty cycle.
223638255|NCT03879772|DRUG|Mometasone furoate nasal spray|intranasal administration
223638256|NCT03879772|DRUG|Beclomethasone dipropionate nasal spray|intranasal administration
224226252|NCT00489203|DRUG|methotrexate|Given after transplant
224226253|NCT00489203|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Undergo stem cell transplant
224226254|NCT04852003|DRUG|SHR0410 Injection|SHR0410 Injection
224226255|NCT04852003|DRUG|Placebo|Placebo for SHR0410 Injection
224226256|NCT04852003|DRUG|Morphine|Morphine
224226257|NCT00094302|DRUG|Spironolactone|Spironolactone (an aldosterone antagonist) is supplied as 15 mg tablets. Drug is taken orally by subjects. The initial study drug dose is 15 mg/day (one tablet) and may be titrated up to 30 mg/day (two tablets) or 45 mg/day (three tablets). Subjects are on study drug for the duration of the trial.
224226258|NCT00094302|DRUG|Placebo|Placebo of spironolactone
224323257|NCT06380751|DRUG|Saruparib (AZD5305)|Saruparib (AZD5305) is a potent and selective inhibitor of PARP1, with minimal effect on PARP2.
224323258|NCT06380751|DRUG|Camizestrant|Camizestrant (AZD9833) is an orally bioavailable, next generation SERD with non-clinical and clinical activity in both ESR1 mutant and wild type settings .
224323259|NCT06380751|DRUG|Abemaciclib|CDK4/6 Inhibitor
224323260|NCT06380751|DRUG|Ribociclib|CDK4/6 Inhibitor
224323261|NCT06380751|DRUG|Palbociclib|CDK 4/6 Inhibitor
223638257|NCT03879772|DRUG|Placebo nasal spray|intranasal administration
223638258|NCT03879772|DRUG|Chlorpheniramine maleate syrup|oral administration
223638259|NCT06066320|BEHAVIORAL|MMST|Participants randomised to the MMST group will complete the computer based paced auditory serial addition task (PASAT-C) in the presence of one observer and is informed that incorrect answers result in reduced monetary compensation. Simultaneously, the participant is exposed to emotionally evocative images and white noise via headphones
223638260|NCT06066320|BEHAVIORAL|TSST|Participants randomly assigned to the TSST condition will be exposed to a traditional TSST protocol. The TSST consists of a preparation phase (5 min), followed by a mock job interview and a mental arithmetic task (5 min each) in front of a panel consisting of two observers and a video recording device.
223638261|NCT06236269|DRUG|Sacituzumab Govitecan|Sacituzumab Govitecan 10 mg/kg will be administrad intravenously (IV) on Days 1, 8 of a 21-day cycle
223638262|NCT01670084|DRUG|nilotinib|Given PO
223638263|NCT01670084|BIOLOGICAL|rituximab|Given IV
223638264|NCT01670084|DRUG|cyclophosphamide|Given IV
223638265|NCT01670084|DRUG|doxorubicin hydrochloride|Given IV
223765059|NCT06864013|DRUG|Experimental|The experimental group will receive neoadjuvant short-course radiotherapy (dose 25Gy/5f), followed by CAPEOX+Iparomlimab and Tuvonralimab (capecitabine 1000mg/m2 bid po d1-d14, q3w; oxaliplatin 130mg/m2 iv d1, q3w; Iparomlimab and Tuvonralimab 5mg/kg iv d1, q3w) for 4 cycles. Patients who undergo surgery will receive CAPEOX combined with Iparomlimab and Tuvonralimab for 4 cycles, followed by sequential treatment with Iparomlimab and Tuvonralimab for up to 1 year.
224323262|NCT06380751|DRUG|Fulvestrant|Endocrine Therapy
223638266|NCT01670084|DRUG|vincristine sulfate|Given IV
223638267|NCT01670084|DRUG|methotrexate|Given IV or IT
223638268|NCT01670084|DRUG|cytarabine|Given IV or IT
224226259|NCT02457013|DEVICE|HFNC|Hygh flow nasal canula HFNC
224226260|NCT02457013|DEVICE|nCPAP|nasal nCPAP
223638269|NCT01670084|DRUG|prednisone|Given PO
223638270|NCT01670084|DRUG|mesna|Given IV
223638271|NCT01670084|DRUG|dexamethasone|Given IV or PO
223638272|NCT01670084|DRUG|leucovorin calcium|Given IV
223638273|NCT05536401|DEVICE|P200TE|The P200TE Ophthalmoscope provides widefield Scanning Laser Ophthalmoscope (SLO) fundus imaging and Optical Coherence Tomography (OCT) imaging in one device.
223638274|NCT05536401|DEVICE|Predicate Device|The predicate device is an optical coherence tomography system intended for in vivo imaging, axial cross-sectional, three-dimensional imaging and measurement of anterior and posterior ocular structures.
223638275|NCT05367596|BEHAVIORAL|Continuous Energy Restriction (CER)|Energy intake will be prescribed at approximately 1,200-1,500 kcal/day with high protein. The diet will consist of low-calorie shakes provided by the study, as well as commercially available portion-controlled entrées, fruits/vegetables, and low energy-density foods available in grocery stores.
223638276|NCT05367596|BEHAVIORAL|Alternate Day Modified Fasting (ADMF)|Enhanced Care participants will have an alternate between three days of very-low energy intake (VLED; approximately 600-800 kcal/d) and four days of healthy eating (HE) each week. On HE days, participants will consume foods ad libitum for satiety.
223638277|NCT05367596|BEHAVIORAL|Group Health Education Sessions|Using video conferencing, all participants will attend weekly approximately 45-60 minutes group health education sessions led by a registered dietitian. The session will deliver a comprehensive nutritional and lifestyle change program to promote lifestyle changes and improve compliance.
223638278|NCT05367596|BEHAVIORAL|Late Evening Snack|The participants will have a late evening snack with a protein supplement.
223638279|NCT05367596|BEHAVIORAL|Physical activity|All participants will be prescribed moderate-intensity aerobic activities that do not require access to specialized exercise facilities.
223638280|NCT05367596|BEHAVIORAL|Self-monitoring|Weekly data related to adherence, food intake, physical activity, weight measurement, and nonserious adverse events will be self-reported via a REDCap survey. Participants will also be provided with a wireless activity tracker to measure total physical activity and intensity of activity objectively. These data will be used to counsel participants in addition to providing valuable feasibility data.
224226261|NCT06354803|OTHER|proprioceptive training|Proprioceptive training using swiss ball for 12 sessions
224226262|NCT03881826|OTHER|collection of clinical data and biological samples|"* nutritional assessement~* cachexia symptoms~* urine, feces and blood samples"
224226263|NCT00005520|DRUG|Hydrochlorothiazide|
224226264|NCT00005520|DRUG|Candesartan|
224226265|NCT03238027|DRUG|Axatilimab|Humanized IgG4 mAb that blocks colony stimulating factor 1 receptor (CSF-1R)
224226266|NCT03238027|DRUG|Durvalumab|Durvalumab (MEDI4736) is a humanized IgG1 kappa mAb that blocks the interaction of PD-L1 with PD-1 CD80 (B7.1) molecules
224226267|NCT06218420|RADIATION|Stereotactic Body Radiotherapy (SBRT)|Stereotactic Body Radiotherapy (SBRT) is a non-invasive alternative and potentially efficient treatment of single or bilocular HCC. However, SBRT has not been validated as bridging therapy before LT in a prospective study yet.
224226268|NCT01039220|BIOLOGICAL|naso-pharyngeal swab|Selected patients will be asked to contact the clinical staff on site as soon as any influenza like symptoms appear. In the case of influenza like illness patients are requested to attend to the clinic within 24 hours for physical examination and naso-pharyngeal swab for diagnosis of A(H1N1)v infection.
224226269|NCT02779582|DRUG|Oral Micronized Progesterone|The dose of 300 mg of Progesterone is a physiological one that maintains the serum progesterone at or above the luteal (normal post-ovulatory) threshold for 24 hours. This duration of action is important because Progesterone is not safely taken during waking hours because of its soporific effects.
224226270|NCT02779582|DRUG|Placebo|pill with no effect
224226271|NCT00469820|BIOLOGICAL|autologous tumor cell vaccine|
224226272|NCT00469820|BIOLOGICAL|peripheral blood lymphocyte therapy|
224226273|NCT03788525|BEHAVIORAL|Reduced recreational screen time|Participants must remove all recreational screen-based media use beyond 3 hours/week. This includes all recreational screen-based media use inside and outside the household. As a tool to comply with the intervention the families will hand-over all portable screen-based media devices. In return, each participant who own a smartphone will receive a regular cell-phone which can only make phone calls and send text messages. For a maximum of ½ an hour a day, adult participants may use this device for necessary contact. The families are allowed a maximum of 3 hours/week of recreational screen time. If participants can not hand over their smartphones due to daily use for work purposes we will install an app tracking screen use on these devices.
224319026|NCT07133269|OTHER|Care Coach-led Palliative Surgical Oncology (PSO)|"* Patients will receive the current standard of care based on their surgeon's usual clinical practice.~* Additionally, patients will receive the Care Coach-led Palliative Surgical Oncology (PSO) intervention. The PSO intervention will be delivered during all phases of an advanced cancer patient's surgical journey.~  * Pre-surgery: After pre-surgery consultations, care coaches will conduct Serious Illness Conversations (SIC) and focus on exploration of patients' hopes and worries, critical functions, social setup, and identification of a healthcare proxy.~ * The Care coach will also screen for psychological and emotional needs using the Distress Thermometer pre-surgery upon recruitment, and at 1, 3, 6, 9 \&12 months post-surgery. This will help to identify areas requiring palliative interventions such as symptom management or psychosocial support and for follow-up actions to be taken."
224319027|NCT07133269|OTHER|Rehabilitation|"• Patients will receive services from a dedicated rehabilitation service comprising of a Rehabilitation Physician, Physiotherapist, and Dietician.~* Pre-surgery: Patients will be triaged based on their frailty \[Clinical Frailty Scale (CFS)\], malnutrition risk \[Malnutrition Universal Screening Tool (MUST)\], and physical function \[5-sit-to-stand (5-STS)\] and will receive preventive rehabilitation interventions tailored to their functional needs.~* During surgical admission: The rehabilitation physician will review the progress of patients and refer them to a dietitian if needed. Patients may be followed-up by a rehabilitation physician one-month post-discharge and referred to a physiotherapist if required.~* Post-surgery: Patients will be screened by care coaches for functional needs using the CFS and 5-STS at months 3, 6, 9 \& 12 post-surgery who will make referrals to rehabilitation professionals as needed."
224319028|NCT07133412|DEVICE|TetraGraph|TetraGraph is a unique, EMG-based portable device for quantitative (objective) monitoring of neuromuscular function. It is a precise and easy to use tool for monitoring depth of block, ensuring adequate recovery of muscle function, and aiding the clinician to reduce the incidence of residual block.
224319029|NCT07134023|OTHER|Supportive Care|"Initial Educational Assessment In addition to standard care, patients will meet the coordinating nurse for an initial educational assessment to evaluate their needs and present the multidisciplinary workshop program and individual support options. The nurse will register the patient for the first session, provide program materials, schedule the first follow-up call (1 month post-inclusion), and collect study questionnaires and demographics. If needed, the assessment may be scheduled within 15 days of inclusion.~Educational Workshops Patients may attend workshops on topics like endometriosis, diet, sexuality, pain, fatigue, emotions, Pilates, non-drug symptom management, hypnoanalgesia, and fertility. At least three workshops are required, offered over two days.~Telephone Follow-up Monthly calls for 6 months, then at 9 and 12 months, will monitor symptoms and refer patients to support services as needed."
224319030|NCT07134907|DRUG|Silodosin|Silodosin is an α1A-adrenergic receptor antagonist which can relax the smooth muscle of bladder and prostate, relieve the dynamic obstruction of bladder outlet, and improve the lower urinary tract symptoms caused by BPH. The instruction of Silodosin Capsule (Qianweitai®) is 4mg/capsule，1 capsule/time, bid, after breakfast and dinner.
224319031|NCT07134907|DRUG|Tamsolusin|Tamsulosin is an α1A-adrenergic receptor blocker which has used in treatment of BPH for few years. The instruction of Tamsulosin Capsule is 1 tablet at a time, 1 time a day.
224323263|NCT06380751|DRUG|Letrozole|Endorcine Therapy
223638281|NCT05367596|BEHAVIORAL|Remotely Supervised Exercise Sessions|Sessions of 45 minutes duration will be delivered via video conferencing 2-3 times per week.
224226274|NCT03788525|BEHAVIORAL|Timed recreational screen time|Participants must remove all recreational screen-based media use after 6 PM. There are no restrictions on the amount of screen-based media use before 6 PM. Thus, before 6 PM, the participants must continue their habitual screen-based media use completely. However, after 6 PM, both work-related and recreational screen-based media use must be removed completely.
224226275|NCT03056326|DRUG|CHF6333 (Part 1 - SAD)|Single doses of CHF6333 at each period
223638282|NCT00930046|DEVICE|Ropivacaine wound catheter|19 gauge fenestrated wound catheter inserted into the fascial planes of the surgical site prior to skin closure with a separate exit site.
224226276|NCT03056326|DRUG|Placebo (Part 1 - SAD)|Single doses of placebo matching CHF6333 at each period
224323264|NCT06380751|DRUG|Anastrozole|Endocrine Therapy
224323265|NCT06380751|DRUG|Exemestane|Endocrine Therapy
224323266|NCT06246643|DRUG|Regorafenib (Stivarga, BAY73-4506)|Participants will be treated with the regorafenib dose taken during the last cycle of the feeder study. Adult participants will receive either 60, 80, 90, 120, or 160 mg orally (p.o.) once daily (qd) for 3 weeks of every 4-week cycle (i.e. 3 weeks on, 1 week off). Pediatric participants will receive 82 mg/m\^2 p.o. qd for 14 days, in a 14 days on/7 days off schedule (21-day cycle).
223638283|NCT00930046|DEVICE|Saline wound catheter|19 gauge fenestrated wound catheter will be inserted into the fascial planes of the surgical site prior to wound closure
223638284|NCT01109472|OTHER|patient magazine|patient magazine individually tailored to patient's prior feedback
223638285|NCT00183040|DRUG|Topical testosterone|
223638286|NCT00183040|DRUG|Recombinant human growth hormone|
224226277|NCT03056326|DRUG|CHF6333 (Part 2 - MAD)|once daily multiple doses of CHF6333 for 14 days
224226278|NCT03056326|DRUG|Placebo (Part 2 - MAD)|once daily multiple doses of placebo matching CHF6333 for 14 days
223638287|NCT02161016|DEVICE|map3|Patients will receive map3® Cellular Allogeneic Bone Graft containing donor matched stem cells.
223638288|NCT00646880|DRUG|propiverine|Two week washout period followed by propiverine 20 mg capsule daily for 1 week, followed by a second 2-week washout; patients were then crossed over to tolterodine PR 4 mg capsule daily for 1 week.
224226279|NCT04942041|OTHER|Simulation based quality program|Stroke team simulation. Virtual reality task training simulation.
224226280|NCT01928914|DRUG|Tafenoquine 300mg|Single dose of Tafenoquine give on Day 3 only
224226281|NCT01928914|DRUG|Tafenoquine 600mg|Single dose of Tafenoquine given on Day 3 only
224226282|NCT01928914|DRUG|Tafenoquine 1200mg|400mg Dose of Tafenoquine given on each of the three consecutive dosing days
224226283|NCT01928914|DRUG|moxifloxacin|moxifloxacine given on Day 3 only
224226284|NCT01928914|DRUG|Placebo for Tafenoquine|Placebo given on all three days to all groups except for group 5 on Day 3
224226285|NCT01928914|DRUG|Placebo for moxifloxaxin|Placebo for moxifloxacin, given to all groups on all days except for Group 3 on Day 3
224226286|NCT06201481|PROCEDURE|anterior and posterior full coverage crowns|Teeth preparation,crown fitting and cementation
224226287|NCT06302855|DIAGNOSTIC_TEST|dental expertise|dental visit based on dental expertise
224226288|NCT02902731|DRUG|PLACEBO|subcutaneous injection of placebo every day during 16 weeks
224226289|NCT02902731|DRUG|ANAKINRA|subcutaneous injection of anakinra every day during 16 weeks
224226290|NCT04289636|BEHAVIORAL|Behavioral weight loss program|Using a combination of individual (\~1x/month) and group-based (\~3x/month) meetings, participants will be taught behavioral approaches for changing diet and exercise behaviors. This intervention will be 15 weeks in duration and will be delivered remotely using a video-conferencing platform.
224226291|NCT04289636|BEHAVIORAL|Self-compassion|This 8-week, group-based program will help train individuals on how to handle difficult emotions with greater ease, how to transform difficult relationships, and how to motivate and encourage oneself, rather than being self-critical.
224226292|NCT04289636|BEHAVIORAL|Nutrition and cooking education|This 8-week, group-based program will help individuals to improve the quality of their diet through nutrition education and basic cooking skills for preparing healthy meals.
224319032|NCT07133763|DRUG|PD-1 Inhibitor Combined with Tenofovir, Chidamide, and Lenalidomide for the Treatment of EBV-Associated Lymphoproliferative Disorders.|This study investigates a novel multi-targeted regimen combining a PD-1 inhibitor, tenofovir, chidamide, and lenalidomide for relapsed/refractory EBV-associated lymphoproliferative disorders (LPDs). Unlike conventional therapies focused on antivirals or chemotherapy alone, this approach integrates antiviral suppression, epigenetic reactivation, immune modulation, and checkpoint blockade to achieve synergistic antitumor and antiviral effects. Preliminary data show effective EBV inhibition and tumor regression. This strategy offers a promising and distinct therapeutic option for EBV-driven lymphoid malignancies resistant to standard treatment.
224319033|NCT07134322|BEHAVIORAL|The aim of this research is to record how many families go to court for the breakdown of parent-child relationships and to understand how many of these families, one year after the judge's ruling, hav|"This is the first qualitative and quantitative study on conflict-ridden families who go to court and involve social and psychological support services.~Furthermore, the survey will provide precise data on the extent of the phenomenon being investigated."
224319034|NCT07135011|DEVICE|Primary gluteal enhancement|120 participants will undergo primary buttock enhancement procedures utilizing the Ergonomix2® Diamond®, Motiva Injector®, Motiva® Inflatable Balloon, Motiva® Reusable Channel Dissector, and Motiva® GEM Channel Separator devices.
224323267|NCT06136559|DRUG|Nemtabrutinib|Administered orally
223515538|NCT00996177|DRUG|IONSYS (fentanyl HCl) Iontophoretic TransdermalSystem|40 µg fentanyl on-demand (240µg/hr) or a maximum of 80 doses (3.2 mg) per day
223515539|NCT00996177|DRUG|IV Morphine Patient-Controlled Analgesia (IV PCA)|20mg/2hr (240 mg during 24 hours)
223515540|NCT01946100|GENETIC|Multifocal Lung Adenocarcinoma|Tissue collection at the time of surgery for genetic testing and blood sample for germ line DNA.
223515541|NCT01522027|PROCEDURE|Percutaneous tracheostomy|Twenty ICU patients will receive percutaneous tracheostomy via insertion of a needle/catheter connected to a nerve stimulator.
223515542|NCT06305546|DRUG|Chlorhexidine Gluconate|For two weeks, all individuals were instructed to use pea-sized gel on their gingiva two times a day. To ensure patient compliance, we assigned patients with log sheets to fill daily on whether they used the gel consistently every day twice a day for 2 weeks. Patients were also instructed to return the container of gel on the day of follow-up.
223515543|NCT06305546|DRUG|Metronidazole|For two weeks, all individuals were instructed to use pea-sized gel on their gingiva two times a day. To ensure patient compliance, we assigned patients with log sheets to fill daily on whether they used the gel consistently every day twice a day for 2 weeks. Patients were also instructed to return the container of gel on the day of follow-up.
223515544|NCT06305546|DRUG|combination gel (chlorhexidine and metronidazole)|For two weeks, all individuals were instructed to use pea-sized gel on their gingiva two times a day. To ensure patient compliance, we assigned patients with log sheets to fill daily on whether they used the gel consistently every day twice a day for 2 weeks. Patients were also instructed to return the container of gel on the day of follow-up.
223515545|NCT06305546|DRUG|Placebo|For two weeks, all individuals were instructed to use pea-sized gel on their gingiva two times a day. To ensure patient compliance, we assigned patients with log sheets to fill daily on whether they used the gel consistently every day twice a day for 2 weeks. Patients were also instructed to return the container of gel on the day of follow-up.
224226293|NCT00289627|DRUG|ipilimumab (MDX-010, BMS-734016)|IV solution, IV, 10 mg/kg, Q 3 wks for 12 wks then Q 12 wks, 48+ weeks depending on response.
224226294|NCT04385810|PROCEDURE|Ophthalmologic exam|Direct exam and Slit lamp exam Shirmer test Retinophotography At inclusion, day 7, day 14 and discharge from hospital
224226295|NCT01045499|DEVICE|Laparoscopic adjustable gastric banding (Allergan Lap Band)|Pre-op evaluation, surgical placement of a gastric band, and follow-up for a minimum of 5 years after surgery. Surgery is laparoscopic adjustable gastric band placement using a single brand of gastric band. Evaluations before and after surgery include but are not limited to history and physical examination, serum chemistry studies, imaging, sleep studies, and pulmonary function testing.
224226296|NCT01573520|OTHER|Monitoring of drug adherence|In the IC group, biological and drug adherence results are shown and discussed through a nephrologists leaded semi-structured motivation interviews at interval of 2 months.
224226297|NCT05266781|PROCEDURE|Surgical repair|Patients affected by a thoracoabdominal aortic aneurysm who received an open surgical repair (aneurysmectomy and aortic reconstruction with a surgical graft
224226298|NCT05266781|PROCEDURE|Endovascular repair|Patients affected by a thoracoabdominal aortic aneurysm who received endovascular repair (with off-the-shelf or custom-made Fenestrated/Branched-Endovascular Aortic Repair - F/BEVAR)
223638289|NCT00646880|DRUG|tolterodine PR|Two week washout period followed by tolterodine PR 4 mg capsule daily for 1 week, followed by a second 2-week washout; patients were then crossed over to propiverine 20 mg capsule daily for 1 week.
223638290|NCT05955248|DIETARY_SUPPLEMENT|Mixed-nutriend supplement (NUT)|Participants will follow ERAS protocol and will receive dietary counselling and anxiety management counselling as needed. They will receive the active multi-nutrient supplement made of whey protein + leucine + vitamin D doses pre-mixed in unlabeled packets prepared by Gruppo Nutrition to dilute in a cup (250 mL) of water. In addition, participants will ingest 15 mL of fruit-flavored fish oil, provided as a liquid oil. They will receive a dosing cup, pre-marked to 15 mL, for a total dose providing 2120 mg eicosapentaenoic acid (EPA) and 1320 mg docosahexaenoic acid (DHA).
223765060|NCT06864013|DRUG|Control|The control group will receive neoadjuvant short-course radiotherapy,followed by CAPEOX (capecitabine 1000mg/m2 bid po d1-d14, q3w; oxaliplatin 130mg/m2 iv d1, q3w) for 4 cycles. Patients who undergo sugery will receive CAPEOX for 4 cycles.
223765061|NCT01686412|DEVICE|Electromagnetic Fields of Low Energy (EEFLE)|Are employed three sets of programs of different frequencies are modulated specifically for each group of patients in accordance with diagnostic (hepatocellular carcinoma, breast carcinoma and healthy subjects). These frequencies ranging between 0.1 and 114.000Hz.
223765062|NCT02863835|OTHER|EIT|All participants will have continuous monitoring of EIT whilst self venting
224226299|NCT00796237|DEVICE|Whole body vibration therapy|In their regular physiotherapy sessions, the subjects in the experimental group will receive WBV (20-240Hz, 10-minute sessions, 1 session per day, 5 sessions per week). The vibration loading will be carried out using the Fit-Vibe System (Germany), which is a vibration platform that is capable of generating vertical vibration.
224226300|NCT00796237|OTHER|standing on the vibration platform but no vibration will be applied|The subjects in this group will perform the same exercises on the vibration platform as in the experimental group for the same duration, but no vibration will be given.
224226301|NCT01206361|DRUG|XALACOM|Xalacom eye drops
224226302|NCT01206361|DRUG|Duotrav|Duotrav eye drops
224226303|NCT01206361|DRUG|Ganfort|Ganfort eye drops
224226304|NCT00337805|OTHER|Pentaspan|When fluids are indicated either pentaspan or saline are given in a double blind randomized assignment
224226305|NCT04380220|DIAGNOSTIC_TEST|Blood samples and processing|DSC perfusion technique at 3.0-T MRI only in MS patients
224226306|NCT04522414|OTHER|cries longitudinally registered|Their cries will be longitudinally registered from the age of birth to the return home using an automatic record device: Song Meter SM4.
224226307|NCT03191721|PROCEDURE|Surgical anti-infective therapy|Two months before randomization, implants with peri-implantitis received surgical anti-infective therapy. After local anesthesia (2% lidocaine with 1:100,000 epinephrine), intrasulcular incisions were done and buccal and lingual full-thickness flaps were dissected. Granulation tissue was removed to expose the implant threads and bone defect. To remove biofilm and calculus, the implant surface was scaled with teflon curettes and decontaminated with bicarbonate jet (Jet Sonic System). The flap was repositioned in the original position and stabilized with interrupted sutures, which were removed after 10 days
224319035|NCT07134556|DRUG|Zimberelimab (AB122)|Patients will receive zimberelimab as an IV at a dose of 360 mg on D1 of each 21-day cycle until unacceptable toxicity, disease progression, death, discontinuation from the Study treatment for any other reason or End of Study (EoS), whichever occurs first.
224319036|NCT07134556|DRUG|Domvanalimab (DOM)|Patients will receive domvanalimab as an IV at a dose of 1200 mg on D1 of each 21-day cycle until unacceptable toxicity, disease progression, death, discontinuation from the Study treatment for any other reason or End of Study (EoS), whichever occurs first.
224319037|NCT07134556|DRUG|Sacituzumab Govitecan (SG)|Patients will receive sacituzumab govitecan as an IV at a dose of 10 mg/kg on D1 and D8 of each 21-day cycle until unacceptable toxicity, disease progression, death, discontinuation from the Study treatment for any other reason or End of Study (EoS), whichever occurs first.
224323268|NCT06136559|DRUG|Ibrutinib|Administered orally
224323269|NCT06136559|DRUG|Acalabrutinib|Administered orally
224323270|NCT06131398|DRUG|AMG 355|Short-term intravenous (IV) infusion
224323271|NCT06131398|DRUG|Pembrolizumab|Short-term IV infusion
224323272|NCT04518228|DRUG|Bictegravir (BIC)|Administered consistent with the package inserts and/or instructions provided by the non-study sources who prescribe or supply the drugs to participants
223515546|NCT00025233|BIOLOGICAL|bevacizumab|Given IV
223515547|NCT00025233|OTHER|laboratory biomarker analysis|Correlative studies
223515548|NCT02382900|BIOLOGICAL|quadrivalent human papillomavirus (types 6, 11, 16,18) recombinant vaccine|dose scheme (0 and 6 month)
223515549|NCT02882984|DRUG|Gefitinib 250mg po qd or Tarceva 150mg po qd or Icotinib 125mg po tid Other Name: Gefitinib/Tarceva/Icotinib|radiation given along with one of kind TKI
223515550|NCT02882984|RADIATION|WBRT|3750 cGy in 15 fractions given within 3 weeks time.
223515551|NCT02882984|RADIATION|HFSRS|All HFSRS given in 5 fractions. dose per fraction ranges from 5 to 8 Gy depending on the target volume and organs at risk tolerance.
223515552|NCT02580006|DRUG|EPORON|single dose administration subcutaneously
223515553|NCT02580006|DRUG|EPREX|single dose administration subcutaneously
223515554|NCT05013086|DRUG|1.48 GBq of 177Lu-AB-3PRGD2|accepted intravenous injection of 177Lu-AB-3PRGD2
223515555|NCT02609451|PROCEDURE|Ileostomy closure|Ileostomy closure at a different time point
223515556|NCT01105832|DRUG|Teriparatide|Teriparatide (Forsteo) 20 micrograms daily during four weeks
223515557|NCT03517293|BEHAVIORAL|Aerobic Exercise training|
223515558|NCT05383950|DEVICE|smartphone application|In this study, the investigators will provide smartphone application based 12-week pulmonary or cardiac rehabilitation program to patients with chronic respiratory, cardiac, or geriatric diseases.
223515559|NCT01746069|BEHAVIORAL|Quit smoking combined cessation programme|Support sms messages to patient's mobile phone and health advice
223515560|NCT01746069|BEHAVIORAL|health advice|routine clinical practice
223515561|NCT00493558|DEVICE|Trabecular Metal Intervertebral Cage with RSA beads|Roentgen Stereophotogrammetric Analysis beads will be inserted at time of implant of the Trabecular Metal Intervertebral Cage.
223515562|NCT01232582|DEVICE|Exablate treatment|MR guided Focused Ultrasound treatment
223515563|NCT02080000|OTHER|Optimisation of V-V timing using R wave on surface ECG|
223515564|NCT02080000|OTHER|Standard V-V timing settings|
223638291|NCT05955248|OTHER|Multimodal Prehabilitation (MM)|Participants will follow ERAS protocol and will receive dietary counselling and anxiety management counselling as needed. They will receive the NUT intervention + structured exercise training prescribed by a kinesiologist (1. 30 min of aerobic exercise per day of their preferred type (ex. walking) and 2. 30 min of resistance exercise targeting major muscle groups, every second day for 2 sets of 8-12 reps). Training will be performed for 4 weeks prior to surgery (1x/week supervised by kinesiologist at hospital, 2x/week at alone at home)
224226308|NCT03191721|PROCEDURE|Periodontal treatment|Two months before randomization, all subjects received full-mouth supragingival plaque removal and scaling and root planing (SRP), as needed. The SRP was performed in four to six appointments lasting approximately 1 h each, using manual curettes (Hu-Friedy, Chicago, IL, USA) and ultrasonic device (Cavitron Select SPC, Dentsply professional, York, PA, USA) under local anesthesia. The deep sites were scaled throughout the first week and treatment of the entire oral cavity was completed in 14 days.
224226309|NCT03191721|PROCEDURE|Oral Hygiene Instruction|Delivery of a soft bristle adult toothbrush (Colgate Palmolive, Brazil), dental floss (Colgate Palmolive, Brazil), and interdental toothbrushes (Colgate Palmolive, Brazil) , according to their individual needs at pre-baseline, baseline, 3, 6, 12, 18 and 24 months. Information was given about the importance of keeping an excellent oral hygiene over the course of the study. The subjects were instructed to brush their teeth for one minute twice a day (morning and evening) using only the toothbrush and toothpaste provided.
224226310|NCT03191721|DRUG|Triclosan toothpaste|Dental brushing with a toothpaste containing 0.3% triclosan and 1450 ppm sodium fluoride in a regular maintenance program for 24 months.
224226311|NCT03191721|DRUG|Fluoride toothpaste|Dental brushing with a toothpaste containing 1450 ppm sodium monofluorphosphate in a regular maintenance program for 24 months.
224226312|NCT03191721|PROCEDURE|Regular maintenance program|OHI, supragingival and subgingival biofilm removal from teeth and implants, and oral prophylaxis. If the examiner suspected of peri-implant disease progression, periapical radiographs were taken. If the implant showed ≥ 2 mm of bone loss, it was withdrawn from the study to receive additional treatment (e.g. another surgery procedure). Implants showing severe disease progression associated with mobility were removed. Maintenance visits were performed every 3 months.
223638292|NCT05955248|DIETARY_SUPPLEMENT|Placebo Control (CTRL)|Participants will follow ERAS protocol and will receive dietary counselling and anxiety management counselling as needed. They will receive a placebo dietary supplement made of maltodextrin and sunflower oil.
223515565|NCT00655356|BIOLOGICAL|Autologous Human Fibroblasts (azficel-T)|"1. Collection of 3 mm post auricular skin punch biopsies.~2. Three treatment visits with injections administered 5 ± 1 weeks apart on each side of the face."
224226313|NCT00495118|DRUG|risperidone|
224226314|NCT03395444|DEVICE|pulsed shortwave therapy|Pulsed shortwave therapy us the RecoveryRx device. Emits a pulsed signal a the 27.12Mhz wavelength
224226315|NCT03085082|DIAGNOSTIC_TEST|blood type test|a blood sample will be withdrawn from the subjects tested by anti A anti B and anti D antigens to detect the individuals blood group and RH. then statistical analysis to detect presence of a relationship between skeletal types of malocclusion and ABO blood groups
224226316|NCT01506089|OTHER|36 degrees Celsius|Embryos in this group will be cultured in incubators set to 36 degrees Celsius.
223515566|NCT00655356|BIOLOGICAL|Placebo|"1. Collection of 3 mm post auricular skin punch biopsies.~2. Three treatment visits with injections administered 5 ± 1 weeks apart on each side of the face."
223515567|NCT04129333|OTHER|Hypnosis|"The hypnosis session :~* Creation of the therapist-patient link~* Choice of a theme and the preferred sensory channel by the patient~* Collection of the theme chosen by the patient~* Orientation in the here and now.~* Induction~* Realization of the gesture and hypnosis~* At the end of the procedure, reassociation of the patient in the here and now"
223515568|NCT04129333|OTHER|No hypnosis|No hypnosis
223638293|NCT00157131|BIOLOGICAL|Fibrin Sealant, ARTISS 4IU/ml VH SD|FS 4IU VH S/D, a two-component fibrin sealant with 4 IU/mL human thrombin, vapor heated, solvent detergent treated, provided in a frozen, ready-to-use formulation. Administration by a topical spray application using the TISSOMAT device and Spray Set.
223765063|NCT02863835|OTHER|Salbutamol nebulisation and with CPAP|All participants will have continuous monitoring - salbutamol nebulisation will be given during 15 minutes using 5mg of salbutamol. Assessments on CPAP will be performed at 3 different level of pressure during this time.
223765064|NCT05124782|OTHER|Rheumatoid Arthritis Impact of Disease questionnaire|Rheumatoid Arthritis Impact of Disease questionnaire
223765065|NCT02626065|BIOLOGICAL|blood sampling|Blood samples (44mL) will be taken before starting treatment with Nivolumab and at week 2, week 12, week 54 or at relapse (before week 54)
223765066|NCT02626065|DRUG|Nivolumab|injection of Nivolumab every two weeks from day 0 and until relapse, toxicity motivating withdrawal or temporary suspension of treatment or up to 54 weeks.
224226317|NCT01977430|DRUG|Hydrochlorothiazide and furosemide|This clinical trial is cross-over study. The diuretic arm's patients will receive combined diuretic treatment for 1 month: 20 mg of furosemide three times daily and 50 mg of hydrochlorothiazide twice daily
224226318|NCT05692674|RADIATION|adjuvant hypofractionated intensity-modulated proton radiotherapy|CTV1: chest wall ± regional lymph drainage area, 40.05Gy (RBE) in 15 fractions with proton radiotherapy;
224226319|NCT06379074|BEHAVIORAL|Improving sleep health and resilience during pregnancy|"Weekly sessions include: a video clip (ca. 20 min) and a pdf; short questions on participants' experience related to the session's content; brief feedback questions on session's contents. Participants will have weekly opportunity for private online chats with a clinician.~Sessions' contents:~1. Aims of the intervention; introducing the physiological regulation of sleep, sleep health and how sleep changes during pregnancy;~2. Psychological regulation of sleep and the impact of behaviors on sleep regulation; introducing the basics of CBT-I behavioral techniques;~3. Cognitive factors maintaining sleep difficulties; introducing cognitive techniques;~4. Emotional factors maintaining sleep difficulties and on the bidirectional association between sleep and emotions; introducing emotion regulation techniques;~5. Sleep in the postpartum and the development of sleep regulation in children;~6. Relapse prevention and focus on acquired skills and how to prioritize sleep."
223638294|NCT00157131|OTHER|Staples|Administration by mechanical/multiple point fixation.
223638295|NCT00813202|DRUG|Nesiritide|Nesiritide 0.01 mcg/kg/min intravenous (IV) infusion (with or without 2 mcg/kg bolus) for 24 to 168 hours (hrs)
223638296|NCT05338619|DRUG|Lazertinib|Lazertinib 240mg (3 Tabs as Laclaza Tab 80mg) once daily in oral can continue until disease progression, unacceptable toxicity or other discontinuation criteria are met.
223638297|NCT01230983|DRUG|asparaginase|Given IV
223638298|NCT01230983|DRUG|cytarabine|Given IV
223638299|NCT01230983|DRUG|dexrazoxane hydrochloride|Given IV
223638300|NCT01230983|DRUG|doxorubicin hydrochloride|Given IV
223638301|NCT01230983|DRUG|leucovorin calcium|Given IV
223638302|NCT01230983|DRUG|mercaptopurine|Given orally
223638303|NCT01230983|DRUG|methotrexate|Given IV
223638304|NCT01230983|DRUG|prednisone|Given orally
224226320|NCT06379074|BEHAVIORAL|Information on pregnancy-related issues|"Each session will include: video clip (ca. 20 minutes) on aspects related to pregnancy and sleep; brief feedback questions. Participants in the placebo intervention will not be given specific indications on skills or techniques for sleep difficulties and will not have access to the weekly chat with the clinician.~Sessions will cover the following contents:~Session 1: phases of pregnancy; Session 2: sleep disorders; Session 3: nutrition and physical activity during pregnancy; Session 4: childbirth; Session 5: psychophysical development of the child in the first three years of life; Session 6: synthesis of previous sessions."
224226321|NCT00551122|BIOLOGICAL|filgrastim|
224226322|NCT00551122|BIOLOGICAL|lenograstim|
224226323|NCT00551122|BIOLOGICAL|pegfilgrastim|
224226324|NCT00551122|DRUG|cisplatin|
224226325|NCT00551122|DRUG|gemcitabine hydrochloride|
223515569|NCT05324787|DEVICE|Grency venous stent system|Venous stent implantation during the index procedure
224226326|NCT00551122|DRUG|ifosfamide|
224226327|NCT00551122|DRUG|paclitaxel|
223515570|NCT05995418|OTHER|There was no intervention as this was an observational study.|There was no intervention as this was an observational study.
223515571|NCT03996421|DIETARY_SUPPLEMENT|nutritional iron (14 mg) supplement in form of ferrous fumarate|nutritional iron (14 mg) supplement in form of ferrous fumarate
223515572|NCT03996421|DIETARY_SUPPLEMENT|ferrous fumarate + 15 g GOS|nutritional iron (14 mg) supplement in form of ferrous fumarate with addition of prebiotics (15 g GOS)
223515573|NCT01290354|DRUG|Lapatinib|Unlabelled, administered orally
223515574|NCT01290354|DRUG|[11C] lapatinib|Radiolabelled, administered intravenously
223515575|NCT05143515|BEHAVIORAL|PACE label|There were 34 food and drinks choices available for consumption in the pop up café. The labels were displayed next to the food/drink item in the pop up café. The food items were kept in the same position for each participant kitchen to simulate the café environment. Then researchers changed the labels on the display according to the randomisation allocation of each participant. After randomsation participants were informed that they have £10 to spend in the pop-up café and that they could eat the food they selected in a private social eating room.
223515576|NCT01179620|DRUG|Certoparin|Certoparin
223515577|NCT06497686|DIAGNOSTIC_TEST|mesoscale nonlinear optical gigascope|An nonlinear optical microscope with ultra-large field of view and ultra-high resolution.
223515578|NCT06497686|DIAGNOSTIC_TEST|Fluorescence microscope|An optical microscope used to examine the fluorescence signal from stained tissues.
223515579|NCT06190379|OTHER|Essential oil blend|an aroma stick containing a blend of essential oils
223515580|NCT06190379|OTHER|Placebo|an aroma stick containing an inert blend of oils
223515581|NCT04918797|BIOLOGICAL|COVAXIN|Whole-Virion Inactivated SARS-CoV-2 Vaccine (COVAXIN®)
223515582|NCT03256656|OTHER|electrical stimulation (non painful) of the lower urinary tract to determine the current perception threshold and record sensory evoked potentials|
223515583|NCT01412983|DEVICE|Bausch & Lomb Test lens|Lens to be worn on a daily wear basis for one week. Participants will be provided with Bausch + Lomb renu® fresh™ multi-purpose solution for daily rinsing, cleaning, and disinfecting of their lenses.
223515584|NCT01412983|DEVICE|Ciba Vision soft contact lens|Lens to be worn on a daily wear basis for one week. Participants will be provided with Bausch + Lomb renu® fresh™ multi-purpose solution for daily rinsing, cleaning, and disinfecting of their lenses.
223515585|NCT01694771|DRUG|Tiotropium|Marketed dose
223515586|NCT01694771|DRUG|Placebo matching Olodaterol|One dose
223515587|NCT01694771|DRUG|Olodaterol|One dose
223515588|NCT01694771|DRUG|Tiotropium|Marketed dose
223515589|NCT05672537|DRUG|Durvalumab|1500mg intravenous injection for 21d cycle
223638305|NCT01230983|DRUG|therapeutic hydrocortisone|Given IT
224226328|NCT04144296|DIAGNOSTIC_TEST|Study procedure|"* Measurement of the flow rate of supplemental oxygen~* Measurement of the peripheral arterial saturation (SpO2) by pulse oximetry~* Taking of an ABG sample (ABG1) from the arterial line~* Taking of capillary blood gas analysis from the earlobe and from the finger tip~* Taking of an a second ABG (ABG2) from the arterial line"
223515590|NCT05672537|PROCEDURE|Surgery|Surgery
223515591|NCT05672537|DRUG|Gemcitabine|gemcitabine 1000mg/m2, D1\&D8, 21d cycle.
223515592|NCT05672537|DRUG|Cisplatin|cisplatin 25mg/m2, D1\&D8, 21d cycle.
223638306|NCT01230983|DRUG|vincristine sulfate|Given IV
223638307|NCT01230983|RADIATION|radiation therapy|Radiation to cranium
223638308|NCT02531802|BIOLOGICAL|ETVAX|"Varying dosages of liquid ETVAX vaccine (Batch BX1003574). A full dose consisted of:~* Hybrid protein between the B-subunit of the E. coli heat-labile enterotoxin and the B-subunit of the cholera toxin (LCTBA): 1 mg~* E. coli ETEX 21 formalin inactivated: 1.3 mg colonization factor 1 (CFA/I)~* E. coli ETEX 22 formalin inactivated: 6.4 mg coli surface antigen 3 (CS3)~* E. coli ETEX 23 formalin inactivated: 1.1 mg coli surface antigen 5 (CS5)~* E. coli ETEX 24 phenol inactivated: 0.5 mg coli surface antigen 6 (CS6)~The vaccine was given together with sodium bicarbonate effervescent granules (Recip), which was dissolved in water and mixed with the vaccine suspension prior to oral administration. The buffer was used to prevent degradation of LCTBA hybrid protein by the gastric acid."
224226329|NCT00228904|PROCEDURE|Placebo|Control patients diagnosed with diabetic neuropathy are tested at baseline and every six months thereafter to compare to patients treated with pulsatile intravenous insulin therapy
224226330|NCT00228904|PROCEDURE|Pulsatile IV insulin delivery (humalog, humulin, novolog)|Patients with diagnosed diabetic neuropathy have objective testing and questionnaires performed at baseline and every six months thereafter to evaluate and analyze progress of diabetic neuropathy after start of treatment of pulsatile intravenous insulin therapy
224226331|NCT02386592|DRUG|Chlorhexidine gluconate (CHG)|All enrolled neonates admitted to the NICU during the implementation and intervention periods will undergo CHG bathing (sparing head and face) at the time of admission at and thereafter once weekly.
224226332|NCT02386592|BEHAVIORAL|Hand hygiene (HH)|Alcohol hand rub will be produced in the hospital pharmacy and will be readily available in the NICU (via wall-mounted dispensers) throughout the intervention period. Hand hygiene among NICU physicians and nurses will actively be promoted through the intervention period.
224226333|NCT02386592|BEHAVIORAL|Infection control training|All NICU healthcare workers will receive infection prevention training which will involve structure training on HH, universal precautions, neonatal skin antisepsis and peripheral IV placement and line care.
224226334|NCT02386592|OTHER|Infection control reminders via SMS text|Infection control practice reminders will be sent to NICU healthcare workers on a daily basis via SMS messages.
224226335|NCT01127490|DRUG|Duloxetine|Subjects will be titrated onto Duloxetine over one week by taking 30 mg every day for seven days. Week 2 the subject will begin to take 60 mg per day until the end of the study. If the subject wishes to stop taking Duloxetine, she will be given 30 mg per day for one week for down titration.
224226336|NCT01127490|PROCEDURE|Skin biopsy|3 mm skin biopsies will be obtained from the dominant trapezius and the glabrous hypothenar area of the hand
224226337|NCT03548714|DRUG|PT150|Intervention 1 includes PT150 with alcohol consumption
224226338|NCT03548714|OTHER|Beverage|Alcohol beverage will be prepared by an in-house pharmacist at the MEDVAMC in a volume of 450 ml for a 70 kg individual and adjusted for body weight by varying the volume. Alcohol will be administered in a concentration of 16% alcohol (Everclear, St. Louis, MO) by volume in grape Kool-Aid (Kraft Foods, Northfield, IL). Placebo will be prepared in the same manner but contain 1% alcohol to mask taste.
224226339|NCT03717766|DEVICE|intraoperative neuronavigation ultrasound, intraoperative tractography, intraoperative fluorescence, advanced neuronavigation and intraoperative neurophysiology|"5-aminolevulinic acid (5-ALA) is a pro-drug that causes fluorescent protoporphyrins that accumulate in malignant gliomas. Fluorescence can be visualized during surgery by the use of a modified microscope, which helps the surgeon define the margins of the tumor.~Neuro-navigated intraoperative ultrasound is an imaging technique that allows us to visualize intracranial lesions during surgery and correlate them with the image provided by the neuronavigator, obtaining a real-time view of the lesion and possible tumor remains.~To achieve greater tumor resections without increasing the incidence of neurological deficits, the use of intraoperative neuromonitoring has been progressively implemented. This technology and specifically the brain mapping allows us to locate the functional areas of the brain and perform more aggressive resections with lower morbidity"
224226340|NCT02203136|PROCEDURE|Tissue Biopsy|During bladder cancer surgery, tissue specimen taken for molecular profiling.
224226341|NCT02203136|PROCEDURE|Magnetic Resonance Imaging (MRI)|3 Tesla pelvic magnetic resonance imaging (MRI) performed four weeks after bladder cancer surgery.
223515593|NCT01950598|PROCEDURE|Boston KPro type I - fresh graft|Boston KPro mounted on fresh corneal carrier graft for implantation
223515594|NCT01950598|PROCEDURE|Boston KPro type I surgery - frozen graft|Boston KPro mounted on frozen corneal carrier graft for implantation
223515595|NCT03907956|OTHER|Dry Needling with Fascial Winding Technique|"For placement of Dry Needling (DN) needles with Fascial Winding Technique (FWT) according to the Four-pole Carpal Dry Needling (FCDN) approach model, only anatomical references are used, in all cases from a carpal ventral approach. The needles used are the Chinese type with silver handle and guide tube, measuring 25x0.30 mm., Agupunt® brand. Four needles are placed, at the level of the bones: scaphoid, pisiform, trapezius and hamate. The four needles follow an oblique direction, always on the back and looking for the midline of the center of the carpal tunnel, with an inclination of approximately 45º, both in the cranio-caudal and medial-lateral directions. In each of the needles, it deepens until it reaches a firm elastic stop, attributable to the Transverse Carpal Ligament. Next, the FWT is applied to each of the needles, consisting of rotating them in the same direction until you feel the final stop of the needle grasp."
223515596|NCT04249193|OTHER|Transfusion|pRBC and non-pRBC transfusions
223515597|NCT03059342|PROCEDURE|single event multilevel surgery|
223515598|NCT00392509|PROCEDURE|ALDH-br bone marrow cells vs. mononuclear bone marrow cells|Surgery
223515599|NCT00705276|DRUG|Lactic acid (Dermacyd Femina Delicata)|
223515600|NCT01391871|DEVICE|OCT|Optical coherence tomography
223515601|NCT01391871|DEVICE|Transthoracic echocardiography CFR measurement|CFR will be assessed using transthoracic echocardiography with adenosine infusion.
223515602|NCT03870971|OTHER|blood glucose measurement|After the patient has performed the manual reading, the investigator or staff member will obtain another capillary blood sample and a reference reading by means of the YSI 2300 Stat plus analyzer will be performed and recorded. If patients need more than one attempt to get a successful blood glucose reading, the number of attempts will be documented. A questionnaire needs to filled by the participant
223515603|NCT05777278|DRUG|Savolitinib|Savolitinib (300mg or 200mg according to safety run-in recommendation, p.o., BID)
223515604|NCT05777278|DRUG|Docetaxel|Docetaxel (60 mg/m2, ivgtt, q3w)
223515605|NCT05515263|DIETARY_SUPPLEMENT|Intervention snack|To be eaten in replacement of usual snacks twice a day for 8 weeks.
223515606|NCT05515263|DIETARY_SUPPLEMENT|Control snack|To be eaten in replacement of usual snacks twice a day for 8 weeks.
223515607|NCT00289900|DRUG|MK-0524A|
223515608|NCT00289900|DRUG|Atorvastatin|
223515609|NCT00289900|DRUG|Simvastatin|
223515610|NCT06209125|DEVICE|hybrid aesthetic functional appliance|treatment of class II division one malocclusion
223515611|NCT01152385|DRUG|AZD1656|Oral tablet administered twice daily during 4 months
223515612|NCT01152385|DRUG|Placebo|administered twice daily during 4 months
223515613|NCT04029051|OTHER|Focus thoracic ultrasound for dyspnea diagnosis|Focus thoracic ultrasound is composed by an advanced cardiac ultrasound with Doppler measures and a lung ultrasound.
224323273|NCT04518228|DRUG|Tenofovir alafenamide (TAF)|Administered consistent with the package inserts and/or instructions provided by the non-study sources who prescribe or supply the drugs to participants
224323274|NCT04518228|DRUG|Cabotegravir (CAB)|Administered consistent with the package inserts and/or instructions provided by the non-study sources who prescribe or supply the drugs to participants
223638309|NCT02531802|BIOLOGICAL|dmLT|Varying dosages of dmLT, a derivative of wild-type enterotoxigenic Escherichia coli LT that has been genetically modified by replacing the arginine at amino acid position 192 with glycine and the leucine at amino acid position 211 with alanine. These two amino acid substitutions take place in proteolytic cleavage sites which are critical for activation of the secreted toxin molecules.
223638310|NCT02531802|OTHER|Bicarbonate Buffer|Sodium bicarbonate buffer dissolved in 150 ml of potable water
224226342|NCT02611284|PROCEDURE|LISA|All infants were supported with nCPAP while breathing spontaneously during instillation. A 5Frenchgamma sterilized multi-access catheter specifically designed to deliver surfactants for Neonates was placed 1-2 cm below the vocal cords by direct laryngoscopy without the use of a Magill forceps. Beractant was used as exogenous natural surfactant, (100mg/kg; 4ml/kg) and administered in two aliquots during 1-3 minutes. Positive pressure inflations were given by a mask and bag only if the infant was apneic or bradycardia develops despite the interruption of the procedure. The surfactant administration catheter was removed after surfactant instillation and nCPAP support was maintained. A second dose of surfactant was administered during the first 3 days of life if more than 40% of FiO2 was needed while on nCPAP with at least 6 cm H2O pressure.
224226343|NCT02611284|PROCEDURE|INSURE|"The INSURE technique was performed using Beractant (4ml/kg) after endotracheal intubation. A multi-access catheter for Neonates/Pediatrics designed to deliver surfactants (KimVentTrach Care Technology ®, United Kingdom) was pre-connected to the endotracheal tube and used for surfactant administration without having to disconnect the ventilator. While surfactant was administered all infants were connected to pressure support ventilation modality (PSV) combined with volume guarantee (VG), Dräger ventilator). A tidal volume of 4ml/kg was initially adjusted.~After surfactant administration, all infants were to be extubated, in accordance with our institutional extubation guidelines, if FiO2\< 0.35; for a target Oxygen Saturation (SpO2) of \>90%, and if a consistent respiratory effort was present. Extubation was supported with nCPAP in all patients."
224226344|NCT03657979|DRUG|Ropivacaine|TAP-block Ropivacaine 0.2% during 48 hours
224226345|NCT03657979|DRUG|Placebo|TAP-block with placebo
224226346|NCT04669821|DRUG|HSK3486|Loading Dose：0.1 mg/kg，Maintenance Dose：Maintenance is started at 0.3 mg/kg/h, and the dose can be adjusted up and down by 0.05-0.1 mg/kg/h.
224226347|NCT04669821|DRUG|Propofol|Loading Dose：0.5 mg/kg，Maintenance Dose：Maintenance is started at1.5 mg/kg/h, and the dose can be adjusted up and down by 0.25-0.5mg/kg/h.
224226348|NCT02089542|OTHER|MB and fluorescent imaging|Single arm study for the development of a protocol stipulating the optimum dose and time to peak near infra-red fluorescence from intraoperative injection of low dose Methylthioninium chloride
224226349|NCT05126875|RADIATION|Repeated stereotactic radiosurgery|Repeated stereotactic radiosurgery to recurring brain metastases
224226350|NCT00006170|DRUG|Bupropion|smoking cessation medication aid
224226351|NCT00006170|DRUG|Placebo|A matched placebo pill
224226352|NCT00006170|BEHAVIORAL|weight concerns intervention|cognitive behavioral treatment to address weight concners
224226353|NCT00006170|BEHAVIORAL|smoking cessation intervention|Cognitive behavioral intervention for smoking cessation
224226354|NCT00312000|DRUG|capecitabine-irinotecan|"1. st line capecitabine 1250 mg/m2 orally b.i.d. on day 1-14~2. nd line q 3 w irinotecan 350 mg/m2 IV infusion on day 1"
224226355|NCT00312000|DRUG|capecitabine+irinotecan (1st line)|q 3 w irinotecan 250 mg/m2 IV infusion in 30 minutes on day 1 2 hours after discontinuation of the infusion followed by capecitabine 1000 mg/m2 orally b.i.d. on day 1-14
224226356|NCT04449042|PROCEDURE|airway management during sedation or general anesthesia|airway management in children receiving sedation or general anesthesia for an elective, emergency, or urgent diagnostic or surgical procedure
223515614|NCT03813251|DEVICE|ForConti Contix Fecal Incontinence Management System (FIMS)|Use the device for up to 12 hours per use for 4 weeks
223515615|NCT05751811|DEVICE|Virtual reality|"The immersive video simulated a magical journey through a calming starry sky on a flying carpet. The headset will play the immersive video content throughout the hysteroscopic procedure; and will stop playing the content as the procedure comes to an end. Participant can adjust the volume of the sound according to her comfort.~The duration of hysteroscopic operation will be 5 to 20 minutes."
223515616|NCT05751811|PROCEDURE|Music therapy|"Relaxing and light music will play throughout the hysteroscopic procedure; and will stop playing as the procedure comes to an end. Participant can adjust the volume of the sound according to her comfort.~The duration of hysteroscopic operation will be 5 to 20 minutes."
223515617|NCT05486065|DRUG|Semaglutide|Semaglutide s.c. injection once-weekly for 40 weeks. Dose gradually increased over 24 weeks, followed by a 16 week maintenance period.
223515618|NCT05486065|DRUG|Placebo|Semaglutide placebo s.c. injection once-weekly for 40 weeks. Dose gradually increased over 24 weeks, followed by a 16 week maintenance period.
223515619|NCT06663293|OTHER|Conventional Nasal Cannula|The initial flow rate for nasal cannula oxygen was set at 3 L/min. In cases of hypoxia, the oxygen concentration was adjusted by increasing the flow rate by 1 to 2 L/min.
223638311|NCT01745939|OTHER|Lumbar Manipulation|Manual therapy intervention
223638312|NCT01745939|OTHER|Sham manipulation|Manual therapy intervention
224226357|NCT03000400|BEHAVIORAL|The Traumatic Brain Injury Family System Intervention.|Theoretically based intervention consisting of 8 weekly 90 minutes sessions addressing specific topics according to a manual.
224226358|NCT03000400|BEHAVIORAL|Psycho-educational session at OUH|2.5 hour psycho-educational session for the patient's family members.
224226359|NCT01162499|DRUG|Exendin-(9-39)|IV infusion of exendin-(9-39) for 5 hours
224226360|NCT01162499|OTHER|Vehicle|Normal saline (vehicle) infusion for 5 hours at 0.06 mL/kg/hr
224226361|NCT01590433|DRUG|Exenatide|Subjects will inject 5mcg of exenatide subcutaneously 15 minutes before the morning and evening meal for the first 2 weeks of the study. At study week 2, subjects will increase to 10mcg twice daily for the remainder of the study.
224226362|NCT01590433|DRUG|Placebo|Subjects will inject 5mcg of identically dispensed placebo subcutaneously 15 minutes before the morning and evening meal for the first 2 weeks of the study. At study week 2, subjects will increase to 10mcg twice daily for the remainder of the study.
224226363|NCT01590433|BEHAVIORAL|Dietary counseling|All subjects will also receive individualized dietary counseling. Subjects in the placebo group will be counseled to follow a hypocaloric diet.
224226364|NCT03309800|DRUG|HL301|HL301: 2Tab/day: 1 Tablet at once, 2 times a day, 7 days of treatment
223638313|NCT03856788|DRUG|Saline|40 mL sterile normal saline
224226365|NCT03309800|DRUG|HL301(Placebo)|HL301(Placebo): 2Tab/day: 1 Tablet at once, 2 times a day, 7 days of treatment
223638314|NCT03856788|DRUG|Bupivacaine|40 mL 0.25% bupivacaine
223638315|NCT01642576|BEHAVIORAL|weight loss counselling|Diet counselling with or without sports trainers, over 8 months
223638316|NCT05973032|OTHER|MRD|Calculate the 3-year EFS based on the MRD status (MRD positive and negative groups)
223638317|NCT03345784|DRUG|Adavosertib|Given PO
223638318|NCT03345784|DRUG|Cisplatin|Given IV
224226366|NCT03926078|OTHER|3D optical surface image|3D optical surface images will be acquired and used to calculate the EHI
223638319|NCT03345784|RADIATION|External Beam Radiation Therapy|Undergo external beam radiation therapy
223638320|NCT01655732|PROCEDURE|Atraumatic Restorative Treatment|ART is simple uninvasive technique involving removal of soft carious enamel and dentine by hand instrument only and then restore the cavity with adhesive restorative material.
223638321|NCT06048120|DRUG|BAY2701250 IV|Single does, intravenous infusion
224226367|NCT03926078|RADIATION|Chest radiography|Chest radiographies will be acquired and used to calculated the HI and EHI
224226368|NCT03926078|RADIATION|CT scan|CT scans will be acquired and used to calculate the HI and EHI
224226369|NCT04468971|BIOLOGICAL|CK0802|Cryopreserved, off the shelf, cord blood derived T regulatory cells
224226370|NCT04468971|DRUG|Placebo|Expicient
224226371|NCT00367315|DRUG|Lumiracoxib|
224226372|NCT05079737|OTHER|Mutation Burden|Subjects will have their facial samples analyzed for DNA mutation burden.
224226373|NCT05480878|DRUG|Placebo|Placebo will be administered to the control group for 12 weeks as an add-on treatment to the current DMARDs treatments for rheumatoid arthritis.
224226374|NCT05480878|DRUG|Nitazoxanide 500Mg Oral Tablet|All subjects will receive Nitazoxanide 500gm twice daily for 12 weeks as an add-on treatment to the current DMARDs treatments for rheumatoid arthritis.
223638322|NCT06048120|DRUG|Placebo IV|Matching placebo for BAY2701250 IV
223638323|NCT06048120|DRUG|BAY2701250 SC|Single dose, subcutaneous injection will be administered into abdominal subcutaneous fat tissue
223638324|NCT06048120|DRUG|Placebo SC|Matching placebo for BAY2701250 SC
223638325|NCT04560699|OTHER|Physiotherapeutic treatment and medical care|Physiotherapeutic treatment twice a week for twelve weeks and medical care three times at baseline, week 13 and week 26
223638326|NCT04560699|OTHER|medical care|medical care three times during the study period; baseline, week 13 and week 26
223638327|NCT06515600|DEVICE|Practice flow trigger sensitivity adjustment on mechanical ventilation for 1 week twice daily in addition to their plan of treatment.|"All patients were investigated by routine investigation (vital signs, arterial blood gas, ventilator mode, and the parameters).~Two sessions were implemented per day for the study group for one week. The Trigger sensitivity adjustment trial begins with applying a load of 30% of the first recorded Negative Inspiratory Force (NIF).~1. st Day 1st session, 30% 5 min.~2. nd session, 30% 10 min.~2nd Day 1st session, 30% 15 min 2nd session, 30% 20 min.~3rd Day 1st session, 30% 25 min. 2nd session, 30% 30 min.~4th Day 1st session, 40% 5 min. 2nd session, 40% 10 min.~5th Day 1st session 40% 15 min 2nd session 40% 20 min.~6th Day 1st session 40% 25 min. 2nd session 40% 30 min.~7th Day 1st session 50% 5 min. 2nd session 50% 10 min."
224226375|NCT05480878|DRUG|Escitalopram 10mg|All subjects will receive Escitalopram 10 mg/day for 12 weeks as an add-on treatment to the current DMARDs treatments for rheumatoid arthritis.
224226376|NCT05965193|DEVICE|Normobaric Hyperoxia|Within 4.5 hours after stroke onset, patients were randomized into the NBO group and immediately given 100% oxygen inhalation (no more than 30 minutes after randomization) at a ventilation rate of 10L/ min using a sealed non-ventilating oxygen storage mask and keep giving oxygen for 4 hours. If the patient needs to be intubated with a ventilator to maintain ventilation, the FiO2 should be set to 1.0.
223638328|NCT05827172|PROCEDURE|AF ablation|The aim of the ablation procedure was to achieve isolation of all pulmonary veins and to restore sinus rhythm.Additional ablation strategies were made at the discretion of the operators.
223638329|NCT05827172|OTHER|medical therapy|The medical therapy for atrial fibrillation was administered in accordance with the guidelines that were available at the time of the trial.Efforts to maintain sinus rhythm were recommended. The aim of the treatment was a ventricular rate of 60 to 80 beats per minute at rest.
223638330|NCT03013270|OTHER|Aerobic-Resistance-Inspiratory|Patients will be submitted to a 12 week, 3 times/week, continuous aerobic (e.g. bike) training programme at an intensity of 60-80% max HR (or peakVO2) for 30 min combined with resistance training at an intensity of 50% of 1 Repetition Maximum (1RM) for quads training and upper limb exercises (elbow flex/shoulder flex/abd) using dumbbells (1-2 kg) (12-15 reps/3sets) for 10 min, combined also with inspiratory muscle training with a flow-resistive loading system at an intensity of 60% of maximal inspiratory pressure/sustained maximal inspiratory pressure (PImax/SPImax) for 20 min (Aerobic (30min) + Resistance (10min) + Inspiratory (20min) = 60 min)
223638331|NCT03013270|OTHER|Aerobic-Resistance|"Patients will be submitted to a 12 week, 3 times/week, continuous aerobic (e.g. bike) training programme at an intensity of 60-80% max HR (or peakVO2) for 30 min combined with resistance training at an intensity of 50% of 1RM for quads training, pectoralis m, serratus anterior m, and latissimus dorsi m and upper limb exercises (elbow flex/shoulder flex/abd) using dumbbells (1-2 kg) (12-15 reps/3sets).~(Aerobic (30min) + Resistance (30min) = 60 min)"
224226377|NCT05965193|DEVICE|Nasal oxygen|For nasal oxygen group, Patients were immediately given oxygen inhalation (no more than 30 minutes after randomization) at a ventilation rate of 1L/min using nasal cannula and keep giving oxygen for 4 hours. If the patient needs to be intubated with a ventilator to maintain, the FiO2 should be set to 0.3 and gradualy incerased if spO2≤94%.
224226378|NCT05965193|DRUG|Intravenous thrombolysis(rt-PA)|10% dose of rt-PA (0.9 mg/kg) is given as bolus and the rest given as an infusion over the remaining 1 hour. Maximum dose 90mg.
224226379|NCT00555009|DRUG|Genotropin|Subcutaneous injection, starting dose 0.2mg/day for males and 0.3mg/day for female with dose titration at 0.1mg to 0.2 mg increments in accordance to IGF-1 results for a total duration of 36 weeks.
224226380|NCT00555009|DRUG|Placebo|Subcutaneous injection, with dummy dose titration for a total duration of 36 weeks.
224226381|NCT01205698|OTHER|Nutritional drink|
224323275|NCT04518228|DRUG|Dolutegravir (DTG)|Administered consistent with the package inserts and/or instructions provided by the non-study sources who prescribe or supply the drugs to participants
223515620|NCT06663293|OTHER|High-flow nasal cannula|The high-flow nasal oxygenation device was set to a temperature of 36°C and an FiO2 of 0.4. The initial oxygen flow rate for the high flow group was determined according to the age and weight of the patients, based on our pediatric intensive care team's guidelines and the reference from the Slain study. When SpO2 fell below 94%, it was considered hypoxia, and the flow rate was increased by 2 to 4 L/min.
223515621|NCT06663293|DRUG|midazolam, ketamine, propofol|Sedation was done with IV midazolam 0.025 to 0.1 mg/kg, IV ketamine 0.25 to 0.5 mg/kg, and IV propofol (1%) 0.25 to 0.5 mg/kg
223515622|NCT06663293|DRUG|Propofol|Sedation maintenance was done by propofol 0.5 to 1 mg/kg/h
224226382|NCT01786811|BEHAVIORAL|Training|"1. Initial Training: The training program for clinicians randomized into the intervention arm will be 2.5 hours. The project will be introduced and the Serious Illness Conversation Guide shared. The training session will include a brief didactic session on Challenges in discussing advance care planning/values and goals followed by practice using the SICG.~2. Coaching and Feedback: We will also provide individual coaching for clinicians. Clinicians will be able to contact the study doctor to request coaching/debriefing on a challenging case; one of the investigators will respond within 24-48 hours for urgent or distressing cases (up to 72 hours on weekends). In-the-moment coaching will be by telephone or in person."
224226383|NCT04568928|DEVICE|OLTP/PE + FES|12 sessions OLTP/PE + FES
224226384|NCT05944705|DIETARY_SUPPLEMENT|Immune Support Supplement|Cannabinoid and co-active emulsion
224226385|NCT00793728|PROCEDURE|Sleeve gastrectomy|Perform a gastrectomy guided by a 38F catheter and parallel to the small curvature of the stomach
224226386|NCT02545153|DRUG|Tisseel, Baxter (Aprotinin and Fibrinogen)|After introducton of t tube and closure of the incision with running sutures, fibrin sealant is applied on the incision.
224226387|NCT02545153|DRUG|Control|No fibrin sealant applied
224226388|NCT05198128|DRUG|Calcium intravenous infsuion|"intravenous infusion of 10 % calcium gluconate 10 mL in 200 mL of physiologic saline on the day of ovum pickup, day 1,day 2, and day 3 after ovum pickup were administered in study group.~Intravenous infusion was performed within 30 minutes"
223515623|NCT04132427|COMBINATION_PRODUCT|vancomycin, magnesium citrate, microbiota|10 days of oral vancomycin, then 1 day of oral magnesium citrate, , then 4 days of high-dose oral microbiota, followed by 12 weeks of low-dose oral microbiota
224226389|NCT05198128|DRUG|0.9 % saline|0.9 % saline
223515624|NCT04132427|COMBINATION_PRODUCT|placebo vancomycin, real magnesium citrate, placebo microbiota|10 days of oral placebo vancomycin, then 1 day of oral real magnesium citrate, , then 4 days of high-dose oral placebo microbiota, followed by 12 weeks of low-dose oral placebo microbiota
224226390|NCT00543361|DRUG|MK0767|Duration of Treatment: 52 Weeks
224226391|NCT00543361|DRUG|Comparator: placebo (unspecified)|Duration of Treatment: 52 Weeks
223515625|NCT01426555|OTHER|FES-Rowing|FES- Rowing Exercise
223515626|NCT01426555|DRUG|Zoledronic acid|5 mg IV single dose
223515627|NCT03685435|OTHER|Bedside ultrasound|Checking for gastric content using bedside ultrasound
223515628|NCT05530707|OTHER|Moisturizer containing saccharide isomerate and niacinamide|Moisturizer containing saccharide isomerate and niacinamide
223515629|NCT03103308|OTHER|Walk Training and Transplant|Subjects will receive free activity monitors and have three training sessions per week for the duration of their bone marrow transplant treatment
223515630|NCT03103308|OTHER|Activity Monitoring and Transplant|Subjects will receive free activity monitors for the duration of their bone marrow transplant treatment
223638332|NCT03013270|OTHER|Aerobic-Inspiratory|Patients will be submitted to a 12 week, 3 times/week, continuous aerobic (e.g. bike) training programme at an intensity of 60-80% max HR (or peakVO2) for 30 min combined with inspiratory muscle training with a flow-resistive loading system at an intensity of 60% of maximal inspiratory pressure/sustained maximal inspiratory pressure (PImax/SPImax) for 30min (Aerobic (30min) + Inspiratory (30min) = 60 min)
223638333|NCT03013270|OTHER|Aerobic Training|Patients will be submitted to a 12 week, 3 times/week continuous aerobic (e.g. bike) training programme at an intensity of 60-80% max HR (or peakVO2) for 30 min combined with callisthenics progressing to treadmill or bike (at the same intensity) for 30 min (Aerobic training = 60 min)
224226392|NCT00543361|DRUG|Comparator: metformin|Duration of Treatment: 52 Weeks
224226393|NCT01225328|BEHAVIORAL|Behavioral activation/problem-solving (BA/PS)|Six weekly telephone sessions to train participant in BA/PS procedures
224226394|NCT02058628|DRUG|Clindamycin + BPO|Gel containing 1.2% clindamycin and 3% BPO for once daily application
224226395|NCT02058628|DRUG|Azelaic acid|Cream containing 20% azelaic acid for twice daily application
224226396|NCT04727697|OTHER|Augmented Reality|Patients will receive the preoperative AR experience during their immediately preoperative office visit. The duration of the exposure is approximately 15 minutes.
224226397|NCT04727697|OTHER|Standard of Care preoperative teaching and handouts|At preoperative appointments, patients receive verbal teaching and written handouts about day of surgery instructions and expectations.
224226398|NCT03355742|DEVICE|XIENCE|Subjects who received XIENCE family stent systems will be included.
224226399|NCT03355742|DRUG|DAPT|1-month clear subjects will receive 1 month of P2Y12 inhibitor and 12 months of aspirin after index procedure.
224226400|NCT01006668|DRUG|Administration of sevoflurane|Administration of sevoflurane (SEVORANE) by inhalation until a maximal concentration of 4% of inspired gas.
224226401|NCT01006668|DRUG|Administration of propofol|Administration of propofol (DIPRIVAN) by intravenous injection (1 mg/kg to turn over twice if necessary.
224226402|NCT04661462|OTHER|online survey|We invite volunteers after COVID-19 to participate in an online survey.
224226403|NCT04530786|DRUG|Influenza vaccine|"influenza vaccine 0.5 ml intramuscularly each season, antigens measured for 3 years following vaccination in:~* 2004-2005: A/Wyoming H3N2; B/Shanghai~* 2006-2007: A/New Caledonia H1N1~* 2007-2008: A/Solomon Islands; A/Wisconsin H3N2; B/Malaysia"
224226404|NCT04141410|DRUG|Levosimendan|Use of Levosimendan in cardiogenic shock during sepsis
224226405|NCT04141410|DEVICE|Echocardiography|Use of global longitudinal strain in cardiogenic shock during sepsis
224226406|NCT04373109|BEHAVIORAL|Observation|Observation of intensity of rehabilitation therapy, daily life upper limb use, physical activi-ty engagement, patient-reported quality of life, and motor outcome after stroke
224226407|NCT03471962|OTHER|surgery|Indirect measurement of RQ was performed by anesthesia ventilator and compared to marker of anaerobic metabolism (arterial lactate, venoarterial PCO2 gradient, venoarterial PCO2 gradient/ arteriovenous O2 content difference, ScVO2) at different time of the srugery (every hours). In post-operative time, complications and hospital's length of stay were recorded.
224226408|NCT02110420|DRUG|CC-90001|CC-90001 10mg will be administered as a single dose
224226409|NCT02110420|DRUG|CC-90001|CC-90001 30mg will be administered as a single dose
224226410|NCT02110420|DRUG|CC-90001|CC-90001 60mg will be administered as a single dose
224226411|NCT02110420|DRUG|CC-90001|CC-90001 120mg will be administered as a single dose
224226412|NCT02110420|DRUG|CC-90001|CC-90001 240mg will be administered as a single dose
224226413|NCT02110420|DRUG|CC-90001|CC-90001 10mg will be administered daily for 14 days
224226414|NCT02110420|DRUG|CC-90001|CC-90001 30mg will be administered daily for 14 days
224226415|NCT02110420|DRUG|CC-90001|CC-90001 60mg will be administered daily for 14 days
224226416|NCT02110420|DRUG|CC-90001|CC-90001 120mg will be administered daily for 14 days
223638334|NCT04798196|BEHAVIORAL|ElderTree on laptop (ET- LT)|"ElderTree (ET) is an existing intervention providing tools, motivation, and support on a computer platform to help older adults manage their health.~ET is based on the extensively tested Comprehensive Health Enhancement Support System (CHESS). ET is a walled garden free of ads, with design features based on older users' feedback as well as best-practice principles such as uncluttered screens and large type. ET uses computers to deliver key elements of successful interventions: long duration, ongoing outreach, prompts, monitoring, cognitive reframing, action planning, problem solving, self-tailoring, and peer support. ET-LT arm will access ET on Laptop (ET- LT)"
223638335|NCT04798196|BEHAVIORAL|ElderTree on smart system (ET- SS)|"ElderTree (ET) is an existing intervention providing tools, motivation, and support on a computer platform to help older adults manage their health.~ET is based on the extensively tested Comprehensive Health Enhancement Support System (CHESS). ET is a walled garden free of ads, with design features based on older users' feedback as well as best-practice principles such as uncluttered screens and large type. ET uses computers to deliver key elements of successful interventions: long duration, ongoing outreach, prompts, monitoring, cognitive reframing, action planning, problem solving, self-tailoring, and peer support.~ElderTree on smart system (ET- SS) will use voice-activated smart speakers connected to the Internet. Because they are used by talking and listening rather than typing and reading, many barriers associated with laptop use can be avoided."
223638336|NCT04798196|BEHAVIORAL|Treatment as usual (TAU)|Treatment as usual (TAU)
223638337|NCT03415685|DEVICE|PicoPlus laser system|Laser treatment using specific pulse durations and wavelengths for selective pigment photothermolysis.
223638338|NCT00911456|PROCEDURE|Image-Guided Radiation Therapy using 3D Ultrasound Guided-Therapy|Subjects will have 3 x 3DUS during radiation therapy
223638339|NCT00911456|PROCEDURE|Ultrasound Guided Imaging|"Subjects will undergo a CT scan and an US of your breast for the planning of radiation therapy after a breast conserving operation.~About 1 week after the start of radiation treatment subjects will have a second CT and US. During this visit subjects will have one CT and three US's. These US's will be performed by 3 different radiation therapists. Part of the current study is to compare the similarity of the 3 US pictures taken by different individuals."
223638340|NCT00911456|PROCEDURE|3 DUS|3 DUS
223638341|NCT03836313|DEVICE|iovera°|"Cryoneurolysis treatment using the iovera° device targeting the anterior femoral cutaneous nerve (AFCN) and the infrapatellar branch of the saphenous nerve (ISN) will occur approximately 4 weeks before surgery by a trained member of the study staff. Treatment will occur in clinic using suggested anatomical markings to target appropriate the AFCN and infrapatellar branch of the saphenous nerve (ISN) of the operative knee.~The iovera° device contains three 27- gauge needles, all 6.9mm in length which will indent the subjects' skin and be inserted under the subcutaneous fat about 7 mm. Lidocaine will be used for superficial anesthetic at the treatment site before the needles puncture the patient's skin.There are a total of 9 iovera° cooling cycles. Treatment will be performed unilaterally and will be guided by visualization and palpation of anatomical landmarks."
223638342|NCT04252534|COMBINATION_PRODUCT|PRP combined Magnovision|The rEMS helmet is used to stimulate the retina and visual pathways. (MagnovisionTM) combined with subtenon platelet rich plasma injection
223638343|NCT04252534|BIOLOGICAL|PRP|Fresh autologous platelet rich plasma, injected subtenon space.
223638344|NCT01034332|PROCEDURE|TP-HDFL,TP-CCRT, Esophagectomy|To determine whether clinical response to one cycle of induction chemotherapy (TP-HDFL) could predict the pathologic complete response to preoperative chemoradiotherapy (TP-CCRT) in patients with locally advanced esophageal cancer.
223638345|NCT00637975|DRUG|oxycodone|"Arm A - 20 mg/day~Arm B - increasing dose startnig at 20 mg/day~For 15 days or until unacceptable toxicity develops."
223638346|NCT00637975|DRUG|pregabalin|"Arm A - pregabalin at increasing dose starting from 50 mg/day~Arm B - pregabalin 50 mg/day~For 15 days or until unacceptable toxicity develops."
223638347|NCT03704896|OTHER|Lung function measurement|Spirometry-derived lung function measurements
223638348|NCT04496713|OTHER|Internet-connected computer tablet|An internet-connected tablet provided to patient for upcoming visit with physician by audio/video which can also be used to complete a survey.
223638349|NCT00000715|DRUG|Pentamidine isethionate|
223638350|NCT00000715|DRUG|Sulfamethoxazole-Trimethoprim|
223638351|NCT01096875|DRUG|Atorvastatin|40mg/day once daily for two weeks prior to surgery
224226417|NCT02110420|DRUG|CC-90001|CC-90001 240mg will be administered daily for 14 days
224226418|NCT02110420|DRUG|Placebo|Placebo will be administered once daily for up to 14 days depending on the Part of the study
224226419|NCT02110420|DRUG|CC-90001|CC-90001 480mg will be administered as a single oral dose
224226420|NCT02110420|DRUG|CC-90001|CC-90001 720mg will be administered as a single oral dose
224226421|NCT02110420|DRUG|CC-90001|CC-90001 480mg will be administered daily for 14 days
224226422|NCT02585674|DRUG|Insulin glargine (U300)|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
224226423|NCT02585674|DEVICE|MyStar DoseCoach|Glucose meter
224226424|NCT04990622|DIETARY_SUPPLEMENT|Flavonoid-rich diet|Inclusion of foods rich in flavonoids.
224226425|NCT02935075|DRUG|Tenofovir disoproxil fumarate|Oral daily
224226426|NCT02935075|DRUG|Lamivudine|Oral daily
224226427|NCT02935075|DRUG|Efavirenz|Oral daily
224319038|NCT07133919|BEHAVIORAL|AI-Assisted Child-Friendly Communication|"AI-assisted communication tailored to the developmental stage, age, and gender of children aged 7-12 will be used. Using ChatGPT, voice recordings explaining the local anesthesia process in a child-friendly and reassuring way-avoiding anxiety-provoking terms such as pain and needle-will be prepared. Additionally, a one-minute calming and distracting story will be generated to be played during anesthesia to reduce anxiety and improve cooperation. Children will listen to the AI-generated explanation before the procedure and the story during anesthesia."
224226428|NCT02386059|DRUG|PLACEBO|received normal saline, intravenously
224226429|NCT02386059|DRUG|Dexamethasone|4 mg, intravenously, at the start of surgery
224226430|NCT02386059|DRUG|Ondansetron|4 mg, intravenously, 15 minutes before the end of surgery.
224226431|NCT02386059|DRUG|Dexamethasone + Ondansetron|4 mg dexamethasone, intravenously at the start of surgery and 4 mg ondansetron intravenously 15 minutes before the end of surgery.
224226432|NCT01216111|DRUG|Paclitaxel Cisplatin|"Paclitaxel 80 mg/m2 D1，8，15 Cisplatin AUC=2 D1，8，15~1 cycle = 28days~PC\*6"
224226433|NCT01216111|DRUG|fluorouracil epirubicin cyclophosphamide and docetaxel (FEC-T)|fluorouracil 500 mg/m2, epirubicin 100 mg/m2, and cyclophosphamide 500 mg/m2 intravenously on day 1 every 21 days for three cycles followed by docetaxel 100 mg/m2 intravenously
224226434|NCT01727245|OTHER|Obese|gastric bypass
224226435|NCT01727245|OTHER|Control group|Cholecystectomy and anti-reflux surgery
224226436|NCT05074082|PROCEDURE|Flap reconstruction|Formation of a (myo-/fascio-)cutaneous flap for repair of a skin and soft tissue defect
224226437|NCT04259606|DIETARY_SUPPLEMENT|Cassia Cinnamon|Reddish - brown to light brown, typical sweet and aromatic free flowing powder.
224226438|NCT04259606|OTHER|Calcined magnesia|White, odor, color and flavorless thin powder.
224226439|NCT02457858|DRUG|Islet isolation using BMX-010|BMX-010 will be used as a supplement in islet isolation process.
224226440|NCT00604409|RADIATION|SIRT|Undergo SIRT
224226441|NCT00604409|DRUG|capecitabine|Given PO
224226442|NCT05226520|DIETARY_SUPPLEMENT|Experimental probiotic product|Probiotic supplementation
224226443|NCT05226520|OTHER|Placebo comparator|Placebo
224226444|NCT00062140|DRUG|cyclophosphamide|
224319039|NCT07133919|BEHAVIORAL|Traditional Behavior Management Techniques|"Before local anesthesia, traditional behavior management techniques will be applied by the pediatric dentist based on clinical experience. These include a modified Tell-Show-Do approach (avoiding direct exposure to anxiety-provoking items like dental syringes), voice control, and positive reinforcement. The anesthesia procedure will be explained verbally in an age-appropriate and reassuring manner, for example by describing the use of a magic sleepy spray to numb the tooth. Following this, topical anesthesia and then local anesthesia will be administered. The total procedure will not exceed 5 minutes."
223638352|NCT01096875|DRUG|Placebo|1tb/day once daily for two weeks prior to surgery
223638353|NCT02512783|DRUG|Lidocaine|Administration of 1ml of pre-treatment 1% lidocaine 1-minute prior to sedation
223638354|NCT02512783|DRUG|Normal Saline|Administration of 1ml of pre-treatment normal saline 1-minute prior to sedation
223638355|NCT02512783|DRUG|Propofol|Intravenous administration of propofol according to standard care to sedate patient.
224226445|NCT00062140|PROCEDURE|allogeneic bone marrow transplantation|
224226446|NCT00062140|PROCEDURE|peripheral blood stem cell transplantation|
224226447|NCT00062140|RADIATION|radiation therapy|
224226448|NCT03295643|DEVICE|Mobile smoking cessation program and CO breath sensor device|Mobile smoking cessation program delivered through an app with access to a breath sensor device and coaching support.
224226449|NCT06314321|OTHER|Baduanjin exercise|Baduanjin has 8 movement forms, which are relatively less demanding. Assistive equipment is also not necessary during Baduanjin. These advantages make Baduanjin a suitable form of exercise training for dialysis patients.The movements involved in Baduanjin require the individual to reach beyond the base of support, change the base of support between bilateral and unilateral stance, and perform movements in a sustained squatting posture. These maneuvers challenge balance and require muscle strength to be executed successfully. In 8 movement forms of Baduanjin all include shoulder joint function exercises, thus making Baduanjin a potentially useful method for improving activity level and arm strength.
224226450|NCT00676000|PROCEDURE|Interrupted vaginal closure|Horizontal mattress closure of vaginal mucosa over mesh
224226451|NCT00676000|PROCEDURE|Continuous vaginal closure|Running closure of vaginal mucosa over mesh
224226452|NCT01297647|PROCEDURE|urodynamic examination|"Standard urodynamic investigation according to the ICS standard, Good urodynamic practice.Following insertion of 8 F transurethral catheter, retrograde filling of the bladder (20 mL/min) with body warm saline.~Current recording of pabd. , pves and pdet., subsequently pressure flow study. Additionally imaging with fluoroscopy to detect possible vesico ureteral renal reflux."
224226453|NCT03717285|PROCEDURE|Insert the UAS under direct vision|Patients in this group，we use rigid ureteroscopy to insert the UAS under direct vision.
224226454|NCT03717285|PROCEDURE|Insert the UAS under non direct vision|Patients in this group，we insert the UAS by the experience of the surgeon and under non direct vision .
224226455|NCT04676932|OTHER|Nursing Care Based on Kolcaba's Comfort Theory|In this study, Nursing care based on Kolcaba's Comfort Theory will be applied for women undergoing HSG.
224226456|NCT00041574|DRUG|Inhaled Nitric Oxide|Inhaled Nitric Oxide will be delivered through the INOpulse® at a Low Dose Range (3mL to 10mL; in 1mL increments) and Ultra Low Dose Ranges (0.5mL to 4mL; 0.5mL, then 1 to 4mL in 1mL increments).
224226457|NCT02142764|BIOLOGICAL|Blood samples|The blood will be sampled in order to be tested in Immunology, twice, the day they sign their agreement and six months after in case of positive myelin pentamer test (at inclusion and 6 months after the inclusion).
224226458|NCT02142764|BIOLOGICAL|Blood samples|The blood will be sampled in order to be tested in Immunology, once, the day they sign their agreement (at the inclusion)
224226459|NCT00153088|DRUG|Telmisartan capsule 40 mg|
224226460|NCT00153088|DRUG|Placebo|
224226461|NCT00153088|DRUG|Telmisartan capsule 80 mg|
224323276|NCT04518228|DRUG|Atazanavir/ritonavir (ATV/r)|Administered consistent with the package inserts and/or instructions provided by the non-study sources who prescribe or supply the drugs to participants
223638356|NCT04337918|DRUG|NORS (Nitric Oxide Releasing Solution)|NORS treatment will consist of daily self-administration of three routes; Nitric Oxide Gargle (NOG) every morning, Nitric Oxide Nasophyaryngeal Irrigation (NONI) every evening, and Nitric Oxide Nasal Spray (NONS) up to 5 times per day.
223638357|NCT04337918|DRUG|NORS (Nitric Oxide Releasing Solution)|"Up to ten volunteers who are found to be COVID-19 positive during screening will be eligible to enroll in the 21-day Treatment sub-study and receive daily NORS treatment for 14 days. NORS treatment will consist of daily self-administration of three routes; Nitric Oxide Gargle (NOG) every morning, Nitric Oxide Nasophyaryngeal Irrigation (NONI) every evening, and Nitric Oxide Nasal Spray (NONS) up to 5 times per day.~Any participants enrolled in the Prevention study who meet the criteria for the sub study will roll over into the Treatment Sub-Study but must remain in their randomly assigned group."
223638358|NCT03591211|BEHAVIORAL|Qigong Training|Eight-Section Brocades; participants were trained individually.
223638359|NCT03591211|BEHAVIORAL|Cognitive Training|Cognitive Training of Memory and Executive Function with Activities requiring Mobilization
223638360|NCT03543644|OTHER|Sugar-sweetened beverage (SSB)|SSBs will be provided to each participant. Participants will be able to choose their SSB of choice from the list in the protocol. They will be instructed to drink their usual SSB intake, study drinks provided, while freely consume their usual background diets. They will revert to their usual SSB intake during wash-out phase during which they will not receive any beverage drinks from the study.
223638361|NCT03543644|OTHER|Non-nutritive sweetened beverages (NSB)|NSBs will be provided to each participant. Participants will be be given the NSB equivalent to the usual SSB chosen from the list in the protocol. They will be instructed to replace their usual SSBs with the NSBs while freely consume their usual background diets. They will revert to their usual SSB intake during wash-out phase during which they will not receive any beverage drinks from the study.
223638362|NCT03543644|OTHER|Water|Water will be provided to each participant. They will be instructed to replace their usual SSBs with the water while freely consume their usual background diets. They will revert to their usual SSB intake during wash-out phase during which they will not receive any beverage drinks from the study.
223638363|NCT02282618|DEVICE|Cardiac Sympathetic Blockade|
223638364|NCT02955667|PROCEDURE|invivo microscopy group|patients receive invivo micro-colposcopy examination
223638365|NCT02955667|PROCEDURE|normal group|patients receive normal colposcopy examination and the biopsy specimens are sent for pathological HE staining and analysis
223638366|NCT03031015|DEVICE|Cemented K-wire Fixation|Fractures were reduced and then fixed with cemented K-wires.
223638367|NCT03031015|DEVICE|Plating|Fractures were reduced and then fixed with Plate.
223638368|NCT01874899|DEVICE|RestoreSensor Neurostimulation|
223638369|NCT03189004|BEHAVIORAL|Impact of Mobile Phone Technology to Improve Health Nutrition and Population (HNP) Service Utilization in Rural Bangladesh|"1. Identification and registration of pregnant women and services for them~2. Birth notification~3. Childhood vaccination services under EPI~4. Newly married couple identification~5. e-Referral.~6. e-monitoring"
223638370|NCT04778137|DRUG|Omalizumab|Biological: CMAB007 Biological: Xolair
223638371|NCT02729532|DEVICE|Xpert|The Xpert MTB/RIF assay is a nucleic acid amplification (NAA) test that uses a disposable cartridge with the GeneXpert Instrument System
223638372|NCT04129996|DRUG|camrelizumab in combination with nab-paclitaxel and famitinib|camrelizumab in combination with nab-paclitaxel and famitinib for triple negative breast cancer
223638373|NCT06369727|DRUG|MOB015B|Topcal formulation
223638374|NCT06369727|DRUG|MOB015B vehicle|Topcal formulation
223638375|NCT06369727|DRUG|Negative irritant solution of 0.9% saline|Negative control
224226462|NCT01829009|OTHER|Resistance Exercise Group|"An individualized resistance exercise program wil be applied twice a week by an expert physiotherapist. Every 2 weeks, intensity will be reassessed by the same physiotherapist. Weekly, participants will be asked about incidents such as the occurrence of falls or hospitalizations during this study period.~Physical performance and functional status will be assessed by the blind investigator at weeks 6,12 and 24"
223638376|NCT01153932|DRUG|GSK2402968|Subcutaneous injection
223638377|NCT01153932|DRUG|matched placebo|Subcutaneous injection
223638378|NCT03611829|BEHAVIORAL|ACT Intervention|
223638379|NCT03611829|BEHAVIORAL|Standard Care|
223638380|NCT01387997|DEVICE|Electrosensing antibody probing system (e- Ab sensor)|Electrosensing antibody probing system (e- Ab sensor), which was developed for the rapid and sensitive detection of hapten, proteins, or viral antigen in medical samples, will be used for analyzing the interaction kinetics between anti-high risk HPV and its antigen (high-risk HPV) present in patients. The system incorporates the use of engineered semiconducive antibodies or virus in vertical and lateral chip (eAbchip) or lateral flow through (eAbsignal) formats. In electrosensing antibody probing, semiconductive antibodies are bound as a suitable electrosensing probe, which specifically and selectively binds targeted molecules (high-risk HPV) in the test specimens. From assessment of the electric signature of semiconductive anti- high-risk HPV antibodies, the eABprobe could offer sensitive detection and precise quantification of high-risk HPV.
223638381|NCT04404413|BEHAVIORAL|Intensity interval training (HIIT)|2x8 weeks of high-intensity interval training (HIIT)
223638382|NCT04404413|BEHAVIORAL|Intensity interval training (HIIT) + intermittent fasting|2x8 high-intensity interval training with (HIIT+IF) intermittent fasting caloric restriction (20% reduction in weekly energy intake).
223638383|NCT05708053|DRUG|Metformin|Metformin 500 mg twice
224226463|NCT04299854|DRUG|Dinoprostone 10mg|Vaginal delivery system containing 10mg of dinoprostone placed at the bottom of the vagina
224226464|NCT04299854|DEVICE|single balloon Foley catheter|A single balloon Foley catheter is being inserted on transcervical and inflated above the internal cervical os
224226465|NCT04906577|OTHER|photography+odour|Daily from D0 to D5: a square of cotton cloth will be placed against the child's scalp by the childcare worker in charge of the child, then removed and placed in a sealed box containing a photograph of the child, which will then be given to the mother.
224226466|NCT04906577|OTHER|photography|A neutral smelling cloth will be placed with the child's photograph which will then be given to the mother.
224323277|NCT04518228|DRUG|Darunavir/ritonavir (DRV/r)|Administered consistent with the package inserts and/or instructions provided by the non-study sources who prescribe or supply the drugs to participants
223638384|NCT06141525|DEVICE|Remote ischemic conditioning|An automatic programmed blood pressure cuffs will be placed on two upper limbs of the patient and pressurized to 200 mmHg (or at least 20 mmHg higher than the systolic blood pressure if the systolic blood pressure of the patient is above 180 mmHg) with 5 minutes of pressurization and 5 minutes of rest. One pressurization with rest is deemed as one cycle (10 minutes), and 4 cycles will be performed each time (for a total of 40 minutes).
223638385|NCT01190462|BIOLOGICAL|cetuximab|
223638386|NCT01190462|DRUG|simvastatin|
223638387|NCT01190462|OTHER|laboratory biomarker analysis|
223638388|NCT00728689|DRUG|ST-246 Days 1 - 3|First Intervention is on Days 1 - 3, and includes 6 patients dosed once orally with ST-246 Form I (Arm 1), and 6 patients dosed once orally with ST-246 Form V (Arm 2).
223638389|NCT00728689|DRUG|ST-246 Days 11 - 13|Second Intervention is on Days 11 - 13 (after a 3 day post-treatment monitoring and 7 day wash-out period) where the 6 patients previously given ST-246 Form I (Arm 1) are now dosed once orally with ST-246 Form V, and the 6 patients previously given ST-246 Form V (Arm 2) are now dosed once orally with ST-246 Form I.
223638390|NCT04210531|DIETARY_SUPPLEMENT|Beetroot juice (BJ) acute supplementation|One serving 140 mL of BJ (12.8 mmol of NO3-; Beet-It-Pro Elite Shot, James White Drinks Ltd., Ipswich, UK) after an overnight fast and 3 h before initiating the testing session.
223638391|NCT04210531|DIETARY_SUPPLEMENT|Placebo acute supplementation|One serving placebo drink (0.08 mmol of NO3-; Salud Viva, Nano Salud 32 S.L) after an overnight fast and 3 h before initiating the testing session.
223638392|NCT05248152|COMBINATION_PRODUCT|Paracetamol and Ibuprofen|Patients will receive paracetamol 1g and ibuprofen 400 mg before surgical incision.
224226467|NCT01024933|BEHAVIORAL|Positive Affect/Self-Affirmation/Motivational Interviewing|The PASA group-intervention will receive small gifts one week prior to their scheduled follow up. The PASA intervention involves reminding participants to think about their proud and positive moments. The motivational interviewing intervention includes assessing the patient's motivation and confidence; elicit barriers and concerns; summarize in a non-threatening manner the 'pros' and 'cons' of patient's concerns, thereby eliciting positive self-motivational statements about the behavior. Follow up will be every two months.
224319040|NCT07135141|DRUG|Sleeve gastrectomy plus early mazdutide initiation|After sleeve gastrectomy is preformed, mazdutide injection (pre-filled auto-injector pen) is administered subcutaneously at the same time each week at 5th month post procedure. The treatment begins with a starting dose of 2.0 mg, followed by a titration schedule increasing by 2.0 mg every 4 weeks (2.0 mg → 4.0 mg). If well-tolerated, participants reached the target maintenance dose of 6.0 mg (4.0 mg → 6.0 mg)weekly for maintenance. The protocol permits adaptive dose downgrade to 4.0 mg weekly when clinically indicated, such as intolerance. The total intervention is maintained until 48 weeks post procedure.
224319041|NCT07135141|DRUG|Sleeve gastrectomy followed with early mazdutide placebo initation|After sleeve gastrectomy is preformed, mazdutide placebo injection (pre-filled auto-injector pen) is administered subcutaneously at the same time each week at 5th month post procedure. The treatment begins with a starting dose of 2.0 mg placebo, followed by a titration schedule increasing by 2.0 mg every 4 weeks (2.0 mg → 4.0 mg). If well-tolerated, participants reached the target maintenance dose of 6.0 mg placebo(4.0 mg → 6.0 mg) weekly for maintenance. The protocol permits adaptive dose downgrade to 4.0 mg weekly when clinically indicated, such as intolerance. The total intervention is maintained until 48 weeks post procedure.
224319042|NCT04159103|BIOLOGICAL|mRNA-3927|mRNA-3927 dispersion for IV infusion
224319043|NCT06934564|BEHAVIORAL|Active de-Implementation|During active de-implementation (3 months), the local team will distribute the strategy components (i.e., clinician education, decision support, evaluation, consensus building around perioperative testing pathways, facility-specific feedback, and a pay-for-performance incentive) at the local site.
224319044|NCT02834676|DRUG|Gelified Ethanol|Pain relief with chemonucleolysis by using gelified ethanol regard to age, sex, ASA score, and complications.
224319045|NCT05788783|BEHAVIORAL|Recovery & Care Canine-Assisted Therapy|Active intervention. An 6-week session of structured, goal-oriented activities where youth focus on mastering dog obedience and dog training skills. Each session is 1 hour and 15 minutes in length and includes education, review of prior sessions, and specific skill-building activities. Skill-building activities progress in complexity during the course of the 6-week curriculum.
224226468|NCT01024933|BEHAVIORAL|Educational and Behavioral|The Education and Behavioral Contract (Control group)will receive an educational workbook and behavioral contract. In addition, each patient will receive a home blood pressure device for self-monitoring, and will be called every two months.
224319046|NCT05788783|OTHER|Canine Education & Bonding|Active control intervention. An 6-week session of semi-structured activities. Sessions are 45 minutes in length. Youth in this condition engage in an educational component, passive observation of dog-training skills, and an active free-play session with the dog-handler teams.
223638393|NCT05248152|DRUG|Pregabalin 150mg|Patients will receive pregabalin 150 mg in the hour before surgery
223765067|NCT06339736|OTHER|Questionnaires administered to all study participants|Ten treatment sessions were performed, which initially involved muscular stretching and relaxation exercises and then strengthening and endurance exercises to achieve stabilization. An oral splint was applied to he upper dental arch.
224226469|NCT00303745|DRUG|capecitabine|
224226470|NCT00303745|DRUG|irinotecan hydrochloride|
224226471|NCT01787825|DEVICE|PillCam SB2 capsule|Capsule Endoscopy system
224226472|NCT01787825|DEVICE|CapsoCam SV-1|Capsule endoscopy
223638394|NCT05248152|DRUG|Placebo|Patients will receive a placebo capsule in the hour before surgery and two intravenous doses of saline before surgical incision.
223638395|NCT04442828|DIAGNOSTIC_TEST|Use of 3D echocardiography in patient follow-up|Patients will undergo clinical and echocardiographic examination including detailed 3D echocardiography at study inclusion and at least one follow-up visit.
224226473|NCT00805909|DRUG|NI-0401|5 daily infusions with escalating doses of NI-0401
224226474|NCT05731427|DIAGNOSTIC_TEST|Pseudomonas aeruginosa colonization infection|With or without airway Pseudomonas aeruginosa colonization infection
224226475|NCT05731427|DRUG|Macrolides|Before or after 6 months of treatment with macrolides for patients with bronchiectasis
224226476|NCT06396468|DRUG|sevoflurane|sevoflurane (1-1.2 MAC)
224226477|NCT06396468|DRUG|propofol|100-400 mcg/kg /min of propofol
224319047|NCT01288144|OTHER|Quality improvement initiative|In intervention clinics, the LMR will use the existing reminder function to alert providers that a patient has a probable history of gestational diabetes. The provider will then have the opportunity to clarify the subject's history and order appropriate screening testing. Providers will also have access to online reference material regarding GDM follow-up screening and lifestyle interventions.
223638396|NCT06209307|BEHAVIORAL|Pelvic floor physical therapy|"Pelvic floor physical therapy (i.e., Kegel exercises):~* Finding the right muscles: To identify pelvic floor muscles, the patient should stop urination in midstream or tighten the muscles that keep from passing gas. These maneuvers use pelvic floor muscles. Once the pelvic floor muscles are identified, the patient can do the exercises in any position, although doing them lying down at first might be the easiest approach.~* Perfecting the technique: Tighten pelvic floor muscles, hold the contraction for three seconds, and then relax for three seconds. Try it a few times in a row. When muscles get stronger, try doing Kegel exercises while sitting, standing, or walking.~* Maintaining focus: For best results, focus on tightening only pelvic floor muscles. Be careful not to flex the muscles in the abdomen, thighs, or buttocks. Avoid breath-holding. Instead, breathe freely during the exercises.~* Repeat 3 times a day. Aim for three sets of 10 repetitions a day."
223638397|NCT03449290|OTHER|Kinesio taping|Kinesio taping was applied on both sides of rectus abdominus, obliquus internus, obliquus externus and sacrospinalis muscles with muscle technique
223638398|NCT03449290|OTHER|Sham Kinesio taping|Kinesio taping was applied on both sides of rectus abdominus, obliquus internus, obliquus externus and sacrospinalis muscles without any technique
224226478|NCT04281680|DRUG|Pasireotide 0.9 MG/ML|900-ug pasireotide administered subcutaneously twice daily for a week or until discharged from the hospital
224226479|NCT00032162|DRUG|carboplatin|AUC 6 q4w
224226480|NCT00032162|DRUG|pegylated liposomal doxorubicin hydrochloride|20/30/40 mg/qm q4w Dose finding study
224226481|NCT02323490|PROCEDURE|with microfractures|following meniscal repair, microfractures will be created on the intercondylar and outer part of femoral condyle (outside of joint surface), lateral or medial, respectively
224226482|NCT02323490|PROCEDURE|without microfractures|standard procedure meniscal repair without augmentation.
224226483|NCT06340464|OTHER|GNRI, PNI, MNA|Nutrition scoring systems
224226484|NCT03493737|BEHAVIORAL|Quality of life surveys|Quality of life surveys by EQ-5D and QLQ-C30
224226485|NCT04394754|DEVICE|BodyPort|Patients will receive BodyPort, a smart scale that provides advanced cardiac monitoring.
224319048|NCT04399044|PROCEDURE|Prophylactic muscle flap|"A muscle flap refers to taking an expendable muscle with its vascular supply and moving it to a new area. In this case, the investigators will take a muscle from the leg or abdomen that is redundant (other muscles perform the same function) and moving it to cover vascular grafts to provide healthy tissue to prevent infection."
224319049|NCT06935760|OTHER|Fire and forget|Evidence informed prescription of BP lowering drugs based on the average observed blood pressure (BP) reduction and risk of treatment discontinuation due to adverse effects in double-blind placebo-controlled randomised clinical trials. Clinicians will prescribe BP treatment regimen using generic, established BP lowering medications that will be expected to achieve at least 80% of future systolic BP values under 130 mmHg. Treatment will be delivered remotely through telehealth consultation. Participants will be asked to avoid routine BP measurements after treatment is commenced to avoid misleading chance fluctuations in BP before 12 weeks. Adverse events will be monitored remotely, and treatments can be adjusted according to adverse events but not according to BP measurements
224319050|NCT06935760|OTHER|Usual care with more intensive BP monitoring|"Participants will follow-up with their usual general practitioner, who will treat participants BP according to local practice guidelines. General practitioners will have access to the same BP lowering medications as the fire and forget treatment group. Participants will continue to monitor their BP throughout the 12 week period through home BP monitoring with optional 24 hour ambulatory BP monitoring. Participants will maintain a BP diary and present their BP results to their treating physician."
224323278|NCT04518228|DRUG|Lopinavir/ritonavir (LPV/r)|Administered consistent with the package inserts and/or instructions provided by the non-study sources who prescribe or supply the drugs to participants
223515631|NCT06057337|BEHAVIORAL|"Families with Pride (Familias con Orgullo)"|Families with Pride (Familias con Orgullo) aims to prevent the co-occurring epidemics of drug use and depression in Hispanic sexual minority youth. It focuses on improving parent support for the adolescent, parent acceptance of the adolescent, family functioning (e.g., communication), and decreasing stress and sexual minority stress. The program consists of 11 weekly, in-person sessions: 7 parent group sessions, 3 concurrent adolescent group sessions, both lasting two hours, 4 family sessions lasting 1 hour in either Spanish or English, depending on participant language preference. In the parent group sessions, parents come together to foster social support, family functioning, and increase parental support and acceptance for the adolescent. In the adolescent sessions, adolescents build skills in confronting and managing stressors related to being a sexual minority.
223515632|NCT06600802|BIOLOGICAL|Blood samples|A total of 3 blood samples (2 tubes of 9mL each) are added. The first sample will be taken at the inclusion visit, the 2nd at the end of the 2nd treatment cycle and the last at the end of Lu-PSMA treatment.
223638399|NCT02661334|DIETARY_SUPPLEMENT|Creatine Monohydrate|Creatine monohydrate is a very common supplement used by enthusiasts, athletes, and the general populace
223638400|NCT02661334|DIETARY_SUPPLEMENT|Rice Flour|rice flour powder matched for color, appearance, taste, and solubility
224226486|NCT04394754|OTHER|Noom|Patients will receive a subscription to use Noom, a personalized diet and weight management application.
224226487|NCT04394754|OTHER|Conversa|patients will receive a subscription to use Conversa, a personalized automated coaching and motivational application.
224226488|NCT00989261|DRUG|Compound AC220|Precomplexed powder in bottle formulation supplied as 200 mg in a 60 cc polyethylene terephthalate (PET) plastic bottle. Requires reconstitution by a pharmacist, must be stored securely, and protected from light.
224226489|NCT04943809|DEVICE|POD 26P AY FT|Routine cataract surgery
224226490|NCT04943809|DEVICE|POD 26P AY F|Routine cataract surgery
224226491|NCT03535909|DIAGNOSTIC_TEST|Noninvasive Hemodynamic Measurement System|Ability of the noninvasive hemodynamic measurement system to determine changes in the hemodynamic status of heart failure patients admitted to the hospital with a primary diagnosis of acute decompensated heart failure.
224226492|NCT00004193|DRUG|ISIS 2503|
223638401|NCT05556044|DRUG|Empagliflozin 10 MG|This is an investigator-initiated, prospective, single-centre, non-randomized open label study that evaluates the efficacy and safety of initiating empagliflozin during index hospitalization for acute heart failure regardless of LVEF.
223638402|NCT00624182|BIOLOGICAL|Peptide vaccine for URLC10|Increasing the doses of URLC10 peptides will be administered by subcutaneous injection on day 1, 8, 15, and 22 of each 28-day treatment cycles. Doses of 0.5, 1.0, 2.0mg/body are planned. Repeated cycles of this therapy will be continued until patients develop progressive disease or unacceptable toxicity, or maximum 2 cycles, whichever occurs first.
224226493|NCT05353556|DEVICE|Inspiratory Muscle Training (IMT)|The IMT protocol will consist of home-based high-intensity daily training - two cycles of 30 breaths with a 1-min rest between sets, twice a day for 8 weeks using an IMT Threshold device (Threshold IMT Philips® Respironics, Inc). The intensity of the training will be set to 50% of each patient's maximal inspiratory pressure measured every week and was adjusted weekly based on the modified Borg scale from 4 to 6 regarding respiratory effort performed during the session.
224226494|NCT05353556|DEVICE|Sham IMT|The IMT protocol will consist of home-based daily training - two cycles of 30 breaths with a 1-min rest between sets, twice a day for 8 weeks using an IMT Threshold device (Threshold IMT Philips® Respironics, Inc). The intensity of the training will be set to the lowest intensity of the IMT Threshold device.
224226495|NCT01694511|PROCEDURE|HRME+CVC|High resolution magnification endoscopy with computed virtual chromoendoscopy and directed biopsy
224226496|NCT01694511|PROCEDURE|conventional endoscopy|Conventional white light endoscopy with four-quadrant biopsy
224226497|NCT00164320|BEHAVIORAL|TEAM|
224226498|NCT01806233|PROCEDURE|Acupuncture|The treatment group：60 patients receive Acupuncture ，selecting acupoint on:Shenting（DU24), Baihui（DU20）, Fengchi（GB20), Hanyan（GB4）, Jianyu（LI15）, Quchi（LI11）,Waiguan（SJ5）, Zusanli（ST36）, Fenglong（ST40）, Xingjian(LV2), Yongquan（KI1）, 20minutes each time，ten times / treatment course，two treatment courses in total.
224226499|NCT01806233|PROCEDURE|Rehabilitation|The matched group：60 patients receive rehabilitation treatment，45 minutes each once，ten time as a period of treatment，two periods of treatment in all.
224226500|NCT00101608|DRUG|vinflunine|solution for injection, IV, 280/320 mg/m2, every 3 wks, variable duration
224226501|NCT00597233|DRUG|insulin aspart|
224226502|NCT00597233|DRUG|soluble human insulin|
224226503|NCT00597233|DRUG|insulin NPH|
224226504|NCT03199248|PROCEDURE|Aspiration with percutaneous capsulotomy For digital mucous cysts|The surgical procedure for DMCs was using a 18G needle performing aspiration first and then cutting the stalk tract by the needle tip for capsulotomy. All procedure were done with anesthesia. After operation, we asking patient using dressing to pressure the wound about 10 mins to stop bleeding. Later on, the wound was covering with antimicrobial oint(Neomycin) and simple dressing. Educating patient from water for 24 hr.
224226505|NCT06054932|DRUG|LK101 injection|LK101 administrated Q2W as the prime dose, and Q3W in the boost phase
224226506|NCT06054932|DRUG|LK101 injection|LK101 administrated QW as the prime dose, and Q3W in the boost phase
224226507|NCT05178407|DIETARY_SUPPLEMENT|Multiple micronutrient-fortified bouillon cube|Bouillon cube fortified with 80 µg/g folic acid, 1.2 µg/g Vitamin B12, 3 mg/g Zinc (ZnO), 4 mg/g Iron (FePP/citric acid/trisodium citrate), 200 µg/g Vitamin A (retinyl palmitate), 30 µg/g Iodine (KIO3)
224226508|NCT05178407|DIETARY_SUPPLEMENT|Control bouillon cube (iodine-only)|Bouillon cube fortified with 30 µg/g Iodine (KIO3)
224226509|NCT00684333|DEVICE|painless subcutaneous injection by EZ-Ject Injector|EZ-Ject Injector device employee cutaneous local anesthesia on the injection site by an electronic anesthetic system
223515633|NCT05706376|BEHAVIORAL|Promoting Positive Family Futures|Promoting Positive Family Futures is a group-based program that aims to help parents and their adolescent children (13-16 yrs) cope with chronic violence by developing emotional and cognitive awareness, learning constructive conflict resolution strategies, and developing family-wide emotional security and positive family relationships. Emotional Security Theory is the foundational conceptual model for the program, and as such, the PPFF focuses on promoting family-wide communication and establishing emotional security in both the family and community across multiple sessions.Firmly grounded the cultural context of Palestine, the intervention also incorporates intervention elements derived from social ecological theories of resilience, and cognitive behavioral approaches to coping. In total, the program includes 8 sessions lasting approximately 1.5 hours each.
223515634|NCT05706376|BEHAVIORAL|Treatment as Usual|Families assigned to the TAU condition will participate in a common service offered by both PCC and CRS - a weekly adolescent-only support group. Both CRS and PCC conduct extended group programs for children and adolescents (24 sessions at PCC; 25 sessions at CRS).
223515635|NCT06671899|OTHER|Constraint-induced movement therapy (CIMT)|Clinically implemented modified CIMT. Including the three main components; intensive and repetitive task-oriented training of the affected limb, constraint of the non-affected limb and behavioural strategies known as the Transfer Package. In this model the training is supervised by therapist from several professions and some training sessions is performed in group settings with other inpatients and outpatients undergoing primary rehabilitation at the clinic.
224319051|NCT03623347|OTHER|TMZ and BEV induction before chemoradiotherapy|New approaches are needed for patients newly diagnosed with bulky glioblastoma (GB) and/or with severe neurological impairment that cannot benefit from first line temozolomide (TMZ)-based chemoradiotherapy.
223515636|NCT06521853|OTHER|PEEK With Autogenous Bone Graft|placement of PEEK With Autogenous Bone Graft
223515637|NCT06521853|OTHER|PEEK With Xenograft|placement of PEEK With xenograft
223515638|NCT04822558|OTHER|Plantar pressure measurement|Biomechanical and clinical evaluation of the reconstructive procedures of ankle and hindfoot using a 3D multisegment foot model
223515639|NCT04822558|OTHER|Gait analysis|Biomechanical and clinical evaluation of the reconstructive procedures of ankle and hindfoot using a 3D multisegment foot model
223515640|NCT04822558|PROCEDURE|Ankle and hindfoot reconstruction surgery|Ankle and hindfoot reconstruction surgery
223515641|NCT04774146|PROCEDURE|pars plana vitrectomy|silicone oil active aspiration and isovolumetric BSS replacement followed by irrigation and /o gas fluid exchange
223515642|NCT04167436|OTHER|Prehabilitation|A minimum of four weeks of prehabilitation with exercise three times a week, protein and vitamin supplements, dietitian consultation and medical optimization prior to surgery.
223638403|NCT00624182|DRUG|Gemcitabine|Gemcitabine will be administered intravenously at a fixed dose of 1000mg/m2 on day 1, 8, and 15. Repeated cycles of this therapy will be continued until patients develop progressive disease or unacceptable toxicity, or maximum 2 cycles, whichever occurs first.
223638404|NCT00589394|BIOLOGICAL|pneumococcal vaccination (Pneumovax)|pneumovax was given
223638405|NCT05166200|OTHER|Experimental Formula|Diabetes-specific study formula
223638406|NCT05166200|OTHER|Test Meal|Instant oatmeal
223638407|NCT02910531|DIETARY_SUPPLEMENT|Alpha lipoic acid|Already mentioned in arm/group descriptions.
223638408|NCT02910531|DRUG|Placebo|Already mentioned in arm/group descriptions.
223638409|NCT05185869|DRUG|SHR6390|SHR6390, Oral Administration
223638410|NCT05185869|DRUG|Nab-paclitaxel|Paclitaxel-albumin, Intravenous Injection
223638411|NCT05185869|DRUG|Gemcitabine|Gemcitabine, Intravenous Injection
224226510|NCT03678636|DEVICE|Silver antimicrobial dressing|Silver dressing suitable for exudate level
224226511|NCT03678636|DEVICE|Standard care|Usual care for wound type and condition
224226512|NCT03463525|DRUG|Osimertinib|Osimertinib 80 mg once daily p.o. will be taken continuously by the patient from the day of the second PET exam.
224226513|NCT03463525|DRUG|[11C]osimertinib|Patients will receive 3 single IV microdose administrations of \[11C\]osimertinib and PET exams on: Day 1, Day 2 (or up to Day 8) and Day 29.
223638412|NCT00254696|DRUG|Extended-Spectrum-Lactamases (ESBLs)|
223638413|NCT04367818|PROCEDURE|Peri-anal local anaesthetic infiltration|postoperative pain relieve, among pediatrics patient
223638414|NCT04367818|PROCEDURE|Caudal anaesthesia|Regional anaesthesia for postoperative pain relieve, among pediatrics patient
223638415|NCT04055077|DEVICE|Low-flow nasal oxygenation (LFNO) ASA I|Active comparator LFNO: O2 flow 5 L/min, FiO2 40%
223638416|NCT04055077|DEVICE|Low-flow nasal oxygenation (LFNO) ASA II|Active comparator LFNO: O2 flow 5 L/min, FiO2 40%
223638417|NCT04055077|DEVICE|Low-flow nasal oxygenation (LFNO) ASA III|Active comparator LFNO: O2 flow 5 L/min, FiO2 40%
223638418|NCT04055077|DEVICE|High-flow nasal oxygenation (HFNO) ASA I|Experimental HFNO: O2 flow 40 L/min, FiO2 40%
223638419|NCT04055077|DEVICE|High-flow nasal oxygenation (HFNO) ASAII|Experimental HFNO: O2 flow 40 L/min, FiO2 40%
223638420|NCT04055077|DEVICE|High-flow nasal oxygenation (HFNO) ASA III|Experimental HFNO: O2 flow 40 L/min, FiO2 40%
223638421|NCT00023660|DRUG|celecoxib|
223638422|NCT00023660|DRUG|cisplatin|
223638423|NCT00023660|DRUG|fluorouracil|
223638424|NCT00023660|RADIATION|brachytherapy|
223638425|NCT00023660|RADIATION|radiation therapy|
223638426|NCT00782990|PROCEDURE|Surgical treatment: TVT|
223638427|NCT00782990|PROCEDURE|Surgical treatment: colposuspension|
223638428|NCT00272584|DRUG|Risperidone|
223638429|NCT04712682|OTHER|Assessment of neck posture.|pain, pain threshold, CVA angle, muscle strenght test, joint position sense test
223638430|NCT05447052|DEVICE|Bio-MIMICS 3D Stent|Bio-MIMICS Stent implantation
223638431|NCT05447052|DEVICE|Innova Stent|Innova Stent implantation
223638432|NCT00456222|BEHAVIORAL|Disrupting or changing the timing or the duration of sleep|Disrupting or changing the timing or the duration of sleep
223638433|NCT00929695|DRUG|prednisone|immunosuppressive drug
223638434|NCT00929695|DRUG|methylprednisolone|immunosuppressive drug
223638435|NCT00929695|OTHER|questionnaire administration|Ancillary studies
223638436|NCT03216226|DRUG|dasiglucagon|Glucagon Analog
223638437|NCT03216226|DRUG|GlucaGen|Native Glucagon
223638438|NCT05669274|OTHER|Milk containing A1 and A2 beta-casein|Milk dose for 2 weeks
223638439|NCT05669274|OTHER|Milk containing only A2 beta-casein|Milk dose for 2 weeks
223638440|NCT00002485|PROCEDURE|psychosocial assessment and care|
223638441|NCT01213628|DEVICE|humidified warmed CO2|Additional insufflation of humidified carbon dioxide (approx. 30ºC, approx. 80-100% relative humidity) via a simple humidifier (sterile water in plastic bottle) connected to a gas diffuser (Cardia Innovation AB) that is able to create a local atmosphere of 100% carbon dioxide (humidified) in the wound cavity.
223765068|NCT07003997|DRUG|Baricitinib|This small molecule, orally bioavailable agent is an immunosuppressant (a medicine that reduces the activity of the immune system). It works by blocking the action of enzymes known as Janus kinases (JAK). These enzymes play an important role in the processes of inflammation. Patients will receive a dose of 2 mg oral daily.
223765069|NCT07003997|DRUG|Placebo|A placebo is a sugar pill that has no therapeutic effect and will be administered orally. Participants will receive 1 placebo tablet matching the baricitinib tablet.
224226514|NCT00872560|DEVICE|NovoFine® needle 6 mm|
224226515|NCT00872560|DEVICE|NovoFine® needle 8 mm|
224226516|NCT04849026|DRUG|Clozaril 100 mg (Clozapine)|2 Doses/Day for 10 days
224226517|NCT04849026|DRUG|WID-CLZ18|2 Doses/Day for 10 days
224226518|NCT06543225|OTHER|No intervention|No intervention
224226519|NCT01439503|BEHAVIORAL|Intervention|"The intervention will consist of an education program. The education program includes providing the ability to enjoy condom use through improved skills related to finding the right fit and feel of condoms, using lubricants that are compatible with latex, negotiating condom use, negotiating sex, and talking with new and existing sex partners about ways to sexualize condoms."
224226520|NCT00740064|DRUG|Raltegravir and Abacavir/Lamivudine|Raltegravir 400mg BID Abacavir/Lamivudine 1 tablet QD
224226521|NCT06542926|PROCEDURE|liver resection|Resection of non-colorectal liver metastases
224226522|NCT06103526|DIETARY_SUPPLEMENT|Immunonutrition|enteral supplementation with high amount of proteins, arginine, glutamine, nonessential fatty acids, branched chain fatty acids, nucleotides, or RNA
224226523|NCT05588206|RADIATION|Hypofractionated Stereotactic Radiotherap|A standard 3+3 statistical design was employed. Three patients will initially be treated at dose level 1, 6 Gy in 5 fractions, 3 fractions a week. Dose limiting toxicities (DLT) were defined as any grade 3-5 radiation injury or any non-hematologic toxicity felt to be possibly, probably, or definitely related to radiation, identified within the evaluation period of 3 months following the completion of radiotherapy.
224226524|NCT02945462|BIOLOGICAL|autologous mesenchymal stem cells|Patients will be injected with autologous mesenchymal stem cells, intracavernously
224319052|NCT06937593|DRUG|VIS954|A humanized immunoglobulin G4 (IgG4) monoclonal antibody (mAb)
224319053|NCT06937593|DRUG|Placebo|VIS954 Placebo
224319054|NCT01243775|DRUG|Belotaxel|60 mg/m2 3 weekly (day 1)
224319055|NCT01243775|DRUG|Belloxa|70 mg/m2 3 weekly (day 2)
224319056|NCT05529667|DRUG|INCB054828, Paclitaxel|"phase 1\>~\- Approximately 3-12 patients will be enrolled. The dose escalation will be three patients registered for each cohort until the first dose-limiting toxicity appears during the four weeks of treatment and observation.~phase 2\> Phase 2 studies will be extended to a total of 30 patients with a two-phase recommended dose. Patients will be treated until the time of disease progression, intolerable toxicity, rejection of the patient, or withdrawal of consent."
224319057|NCT06953154|DIAGNOSTIC_TEST|monocyte distribution width|We compare the measured value with the MDW threshold value already established in the literature and its correlation with the SOFA score, qSOFA, lactate, and PVI in terms of sensitivity, specificity, negative predictive value (NPV), and positive predictive value (PPV).
223765070|NCT07003620|DRUG|Neoadjuvant immunochemotherapy|All patients will receive three cycles of paclitaxel and carboplatin chemotherapy combined with PD-1/PD-L1 inhibitor therapy, followed by open radical hysterectomy and pelvic lymphadenectomy. Postoperative adjuvant therapy (chemotherapy, chemoradiation, or maintenance immunotherapy) will be determined based on pathological assessment. Tumor tissue samples will be collected during treatment for single-cell sequencing analysis.
224226525|NCT01544166|DRUG|Gadobutrol (Gadavist, BAY86-4875)|Single intravenous bolus injection of gadobutrol 0.1 mmol/kg BW in term newborns to infants \<2 years of age.
224319058|NCT06514742|DRUG|Aticaprant|Aticaprant tablet will be administered orally.
224226526|NCT04931628|DRUG|Salvianolic Acid|salvianolic acid, injection, 100mg+0.9%NaCl 250ml, qd, 14 days
224226527|NCT04931628|DRUG|0.9% NaCl|0.9% NaCl
224226528|NCT00244920|DRUG|bicalutamide|
224226529|NCT00244920|DRUG|leuprolide acetate|
224226530|NCT00244920|DRUG|squalamine lactate|
224226531|NCT00244920|PROCEDURE|adjuvant therapy|
224226532|NCT00244920|PROCEDURE|antiandrogen therapy|
224226533|NCT00244920|PROCEDURE|antiangiogenesis therapy|
224319059|NCT06514742|OTHER|Placebo|Placebo tablet will be administered orally.
224319060|NCT03424122|DRUG|Parsaclisib|Parsaclisib administered orally once daily for 8 weeks followed by once weekly.
224319061|NCT03424122|DRUG|Rituximab|Rituximab administered intravenously at the protocol-defined dose regimen according to treatment group.
224319062|NCT03424122|DRUG|Bendamustine|Bendamustine administered intravenously on Days 1 and 2 of each cycle for up to 6 cycles.
224319063|NCT03424122|DRUG|Ibrutinib|Ibrutinib administered orally once daily.
224226534|NCT00244920|PROCEDURE|conventional surgery|
224226535|NCT00244920|PROCEDURE|neoadjuvant therapy|
224226536|NCT00244920|PROCEDURE|releasing hormone agonist therapy|
224226537|NCT01507896|BIOLOGICAL|Recombinant factor IX|Following a loading dose with BAX326, participants will receive BAX326 as a bolus infusion. The treatment regimen will be determined by the intensity and duration of the hemostatic challenge and the institution´s standard of care. The dose will be tailored to raise FIX concentration to at least 80%-100% of normal for major surgeries and to at least 30%-60% of normal for minor surgeries.
224226538|NCT03820193|DRUG|Celecoxib|Post-Operative Non Opioid Pain Protocol
224319064|NCT04951700|OTHER|Other|This is not an intervention study
224319065|NCT06390826|PROCEDURE|Biopsy Procedure|Undergo biopsy
224319066|NCT06390826|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
224319067|NCT06390826|PROCEDURE|Computed Tomography|Undergo CT scan
224319068|NCT06390826|PROCEDURE|Echocardiography Test|Undergo ECHO
224319069|NCT06390826|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223515643|NCT06212739|PROCEDURE|Laser|Diode laser used to effect closure of the anal fistula tract
223515644|NCT06212739|PROCEDURE|LIFT|The intersphincteric portion of the fistula is excised and ligated.
224226539|NCT03820193|DRUG|Hydrocodon/Acetaminophen|Traditionally used narcotic pain control
224226540|NCT03820193|DRUG|Ketorolac|Post-Operative Non Opioid Pain Protocol
223515645|NCT06674759|DRUG|Tongren-Dahuoluo Bolus|0.72g,2 times a day, oral, for 24 weeks.
223515646|NCT06674759|DRUG|Tongren-Dahuoluo Bolus Placebo|0.72g,2 times a day, oral, for 12 weeks.
223515647|NCT06673537|OTHER|Connective Tissue Massage (CTM)|"Connective Tissue Massage (CTM) was administered to the lumbar and abdominal regions by an experienced physiotherapist three times a week for 15 minutes over six weeks. The treatment started from the predicted day of ovulation (cycle length minus 14 days) until the onset of the next menstrual period. Both short and long strokes were utilized during CTM. Each stroke was repeated three times, first on the right side and then on the left side, across all manipulated areas. During the manipulation, the tip of the middle finger remained in contact with the patient's skin. The finger was positioned at a 45° angle, with the distal interphalangeal joint in flexion, and was moved to create traction.~During the lumbar region treatment, participants were instructed to sit upright with their hips, knees, and ankles flexed at 90°, ensuring that their thighs and feet were fully supported. For the abdominal region treatment, participants lay supine with pillows placed under their head and knees."
224226541|NCT03820193|DRUG|Gabapentin|Post-Operative Non Opioid Pain Protocol
224226542|NCT03820193|DRUG|Acetaminophen|Post-Operative Non Opioid Pain Protocol
224226543|NCT03820193|DRUG|Diazepam|Post-Operative Non Opioid Pain Protocol
224226544|NCT05505123|DRUG|Sevoflurane|induction and maintenance with sevoflurane for deep sedation
224319070|NCT06390826|PROCEDURE|Radionuclide Imaging|Undergo nuclear study
224319071|NCT06390826|DRUG|Sunitinib|Given PO
224319072|NCT04657224|DRUG|JNJ-64264681|JNJ-64264681 capsules will be administered orally.
224319073|NCT04657224|DRUG|JNJ-67856633|JNJ-67856633 capsules or tablets will be administered orally.
224319074|NCT06772623|DRUG|Telisotuzumab Adizutecan|Intravenous (IV) Infusion
224319075|NCT06772623|DRUG|Budigalimab|IV Infusion
224319076|NCT06772623|DRUG|Pembrolizumab|IV Injection
224319077|NCT06772623|DRUG|Pembrolizumab|IV Infusion
224319078|NCT06772623|DRUG|Carboplatin|IV Infusion
224319079|NCT06772623|DRUG|Pemetrexed|IV Infusion
224319080|NCT06772623|DRUG|Cisplatin|IV Infusion
224323279|NCT04518228|DRUG|Cobicistat|Administered consistent with the package inserts and/or instructions provided by the non-study sources who prescribe or supply the drugs to participants
223638442|NCT02870595|DEVICE|Microvibratory Stimulator|Informed consent will be obtained from patients undergoing finger local anesthesia digit blocks. Subjects will be randomly assigned (using GraphPAD Randomization Software Tool) to receive the first of their two digit block injections with either the traditional technique (control) or while using the DVICS/ Microvibratory Stimulator. All injections will utilize a 27-gauge needle. The subjects will be given a standard dose of 2mls of 1% lidocaine without epinephrine delivered over 30 seconds. Injections will be timed and performed by a single clinician to avoid large variations in technique and expertise.
223638443|NCT02870595|DEVICE|Microvibratory Stimulator'|As above, Microvibratory Stimulator will be used as a sham device in parallel group.
223638444|NCT03788512|OTHER|observational only- no intervention|observational only- no intervention
223638445|NCT01592357|BEHAVIORAL|Tai Chi exercise|A short and simple 8-forms Tai Chi routine will be used in this study. This routine has been previously standardized and field tested. Participants will be coached, by a certified Tai Chi instructor, in practicing the proper mechanics of executing each of the eight physical movements comprising the 8-forms of Tai Chi. A brief 5 minute period of walking calisthenics pertinent to Tai Chi movements, postures and diaphragmatic breathing will take place before training to warm up and after training to cool down. The Tai Chi training will be 2 times a week and the total exercise time, including warm-up and cool down, will be 50 minutes for each session. Over a period of 12 weeks, the participants will learn all 8-forms and continue practicing them for the final 12 weeks of the training period.
223638446|NCT01592357|BEHAVIORAL|Sham Exercise|"The sham exercise (control) group will be involved in low-intensity stretching exercises two times per week. These exercises will be designed as a sham exercise condition. A brief 5 minute period of walking will take place before the sham exercise to warm up and after the sham exercise to cool down. Sham exercise sessions will include stretching exercises of the neck, trunk and extremities. The total exercise time for the sham exercise group will be 50 minutes and participants will meet 2 times per week for a period of 24 weeks."
224226545|NCT05505123|DRUG|Propofol|induction and maintenance with propofol for deep sedation
224226546|NCT01189864|DRUG|Ciprofloxicin or Vigamox or other.|Ciprofloxicin or Vigamox or other to be used qid till epithelialized.
224226547|NCT01189864|DRUG|Nonsteroidal (Acular, Acuvail, Voltaren Xibrom, etc)|Nonsteroidal (Acular, Voltaren Xibrom, etc) qid up to 5-10 days post-op
224226548|NCT01189864|DRUG|Steroid (FML, Pred Forte, Flarex, etc.)|Steroid (FML, Pred Forte, Flarex, etc.) to be used qid to qd for 1-8 weeks.
224226549|NCT00953979|DRUG|kunxian capsule|The main element of kunxian capsule is Tripterygium. Patients should take 2 tablets per time and 3 times per day for 12 weeks.
224226550|NCT02422290|DRUG|Ketamine|Single infusion of IV Ketamine, 0.5mg/kg
224226551|NCT00362700|DRUG|Clevudine|
224226552|NCT00585351|DRUG|Ranitidine|50 mg single dose injection of Ranitidine
224226553|NCT00585351|DRUG|Placebo|50 mg single dose injection of normal saline (placebo)
224226554|NCT00585351|OTHER|Advanced notification|Advanced notification of study via faxed consent to local Emergency Room (ER)
224226555|NCT00585351|OTHER|No advanced notification|No advanced notification of study via faxed consent to local Emergency Room (ER)
224226556|NCT02659202|DEVICE|Precision Spinal Cord Stimulator System|The precision system will consist of a pulse generator that will not be implanted, temporary percutaneous leads, surgical paddle leads and lead extensions, each packaged as a separate kit.
224226557|NCT05647421|DEVICE|IOL implantation|after phacoemulsification of the cataract , implantation of Acrysof IQVIVITY IOL .
224226558|NCT05647421|DEVICE|IOL implantation|after phacoemulsification of the cataract , implantation of TECNIS Synergy™ Intraocular Lens (Model ZFR00V )
224226559|NCT03662919|DRUG|Infliximab|Administered as specified in the treatment arm.
224226560|NCT03662919|DRUG|Adalimumab|Administered as specified in the treatment arm.
224226561|NCT03510299|DEVICE|Mcgrath|McGrath assisted insertion of LMA flexible
224226562|NCT03510299|DEVICE|Control|Digital manipulation technique of LMA flexible insertion
224226563|NCT02741492|PROCEDURE|Transversus Abdominis Plane Block|Continuous Nerve Block
224226564|NCT02741492|PROCEDURE|Sham Block|Continuous Sham Catheter
224226565|NCT00882622|PROCEDURE|Remote Ischemic Preconditioning|RIPC will be induced during anesthesia by four 5-min cycles of upper limb ischemia and 5-min reperfusion using a blood-pressure cuff inflated to a pressure 15 mm Hg greater than the systolic arterial pressure measured via the arterial line.
224319081|NCT05235126|DEVICE|Decoria intense|All subjects will receive treatment at Visit 1 with the option to receive a touch-up treatment at Visit 2. Evaluation of the nasolabial folds will be performed by PI using the Wrinkle Severity Rating Scale (WSRS).
223638447|NCT04902976|OTHER|CPC+ZN|In patients hospitalized in common beds, and without mechanical ventilation, the it will be asked to perform the following procedures: mouth rinse with 20 mL of the solution for 30 s
223638448|NCT04902976|OTHER|CPC|In patients hospitalized in common beds, and without mechanical ventilation, the it will be asked to perform the following procedures: mouth rinse with 20 mL of the proposed solution for 30 s;
224226566|NCT00882622|PROCEDURE|Control/sham procedure|Sham placement of the blood pressure cuff around the upper limb without inflation.
224226567|NCT01842958|DEVICE|Straumann Bone Level Implants, 4.1 mm implant diameter|Straumann Bone Level Implants, 4.1 mm implant diameter
224226568|NCT01842958|DEVICE|Straumann Bone Level Implants, 3.3 mm implant diameter|Straumann Bone Level Implants, 3.3 mm implant diameter
224226569|NCT01482624|DEVICE|Hyaluronan (0.5%, 5 mg/10 ml)|Standard arthroscopic meniscal surgery and add-on treatment with VISCOSEAL® SYRINGE. Single injection of Hyaluronan directly after arthroscopic procedure.
224226570|NCT01482624|PROCEDURE|Standard arthroscopic meniscal surgery|Standard arthroscopic meniscal surgery without add-on treatment.
224226571|NCT01332409|DRUG|Salmeterol and Fluticasone|Administered according to the prescribing information in the locally approved label by the authorities.
224319082|NCT01503632|BEHAVIORAL|Behavioral Intervention|Receive intervention program
224319083|NCT01503632|BEHAVIORAL|Compliance Monitoring|Correlative studies
224319084|NCT01503632|OTHER|Laboratory Biomarker Analysis|Correlative studies
224319085|NCT01503632|DRUG|Mercaptopurine|Given orally
224319086|NCT01503632|OTHER|Questionnaire Administration|Ancillary studies
224319087|NCT01503632|PROCEDURE|Standard Follow-Up Care|Receive usual standard of care
223638449|NCT04902976|OTHER|Negative Control|In patients hospitalized in common beds, and without mechanical ventilation, the it will be asked to perform the following procedures: mouth rinse with 20 mL of distilled water for 30 s.
223638450|NCT00887809|DRUG|gemcitabine|
223638451|NCT00887809|DRUG|docetaxel|
223638452|NCT00887809|DRUG|bevacizumab|
223638453|NCT05627830|PROCEDURE|Prolotherapy|Prolotherapy is an injection treatment used to relieve pain. And for Cellular Regeneration
224226572|NCT01016509|DRUG|Insulin|Insulin infusion will be started when blood glucose levels exceeded 140 mg/dl and adjusted to maintain glycemia at 80-140 mg/dl. During insulin infusion, oral feeding will be stopped and parenteral nutrition (13±5 Kcal/kg-1/day-1) will be started. After the start of insulin infusion protocol a glycemic control will be provided every hour in order to obtain three consecutive values that were within the goal range. The infusion will be lasted until stable glycemic goal (80-140 mg/dl) at least for 24 h. After glycemic goal will be maintained for 24 h, a parenteral nutrition was stopped and feeding will be started according to European guidelines. Subcutaneous insulin will be initiated at the cessation of the infusion. After discharge from the hospital, insulin will be given as short-acting insulin before meals and long-acting insulin in the evening for 30 days from PCI. The treatment goal will be a fasting blood glucose level of 90-140 mg/dl and a non-fasting level of \<180 mg/dl.
224226573|NCT01016509|DRUG|Insulin|Continuous insulin infusion of 50 IU Actrapid HM (Novo Nordisk) in 50 ml NaCl (0.9% using a Perfusor-FM pump) will be started only when blood glucose levels exceeded 200 mg/dl and adjusted to keep blood glucose between 180 and 200 mg/dl. When blood glucose fell \<180 mg/dl, insulin infusion will be tapered and eventually stopped.The infusion will be lasted until stable glycemic goal (180-200 mg/dl) at least for 24 h. After glycemic goal will be maintained for 24 h, a parenteral nutrition was stopped and feeding will be started according to European guidelines. Subcutaneous insulin will be initiated at the cessation of the infusion. After discharge from the hospital, insulin will be given as short-acting insulin before meals and long-acting insulin in the evening for 30 days from PCI in both group. The treatment goal will be fasting blood glucose and postprandial levels of \<200 mg/dl.
224226574|NCT01829477|DRUG|TAK-875|TAK-875 50 mg tablets
224226575|NCT01829477|DRUG|TAK-875 Placebo|TAK-875 placebo-matching tablets
224226576|NCT01829477|DRUG|Glimepiride|Glimepiride tablet.
224226577|NCT05433428|DRUG|Lubricant Eye Drops|Prolonged use of lubricant eye drops pre and post-op.
224226578|NCT05433428|DRUG|Preservative Free|Preservative free eye drops
224226579|NCT05433428|DRUG|Preservative|Eyedrops with preservatives
224226580|NCT06264947|DEVICE|laser acupuncture|wavelength: 808nm energy: 18j power: 100mw
224226581|NCT06264947|DEVICE|sham laser acupuncture|wavelength: 0nm energy: 0j power: 0mw
224226582|NCT01919268|DEVICE|Electrotherapy|Combination of active interferential current with exercises of the Pilates method. Patients will receive 18 sessions of treatment over a period of 6 weeks (3 sessions/week). The exercises of Pilates method will be individualized to each patient's needs (pragmatic treatment).
224226583|NCT01919268|DEVICE|Pilates|Combination of placebo interferential current with exercises of the Pilates method. Patients will receive 18 sessions of treatment over a period of 6 weeks (3 sessions/week). The exercises of the Pilates method will be individualized to each patient's needs (pragmatic treatment).
224226584|NCT00002175|DRUG|Dinitrochlorobenzene|
224226585|NCT02511236|BEHAVIORAL|Group Cognitive Behavioral Therapy|The four-week CBT protocol includes 4 sessions during week 1, 2 sessions during week 2, 1 session during week 3, and 1 session during week 4. Sessions may include a functional analysis of smoking patterns, environmental cues, and motivation for change, and cover nicotine addiction and withdrawal, health consequences, benefits of cessation, stress management, negative affect, alcohol use, triggers, coping responses, cognitive restructuring, social support, decision making, weight control, and physical activity.
224226586|NCT02511236|BEHAVIORAL|General Health Education|The four-week CBT protocol includes 4 sessions during week 1, 2 sessions during week 2, 1 session during week 3, and 1 session during week 4. Sessions may include didactic information on tobacco-associated morbidities, such as heart disease, diabetes, and hypertension. Content may include Power Point-delivered lectures on the prevalence, etiology, basic pathology, symptom patterns, and treatment of the conditions, and discussion questions designed to facilitate learning and interest. Smoking cessation specific topics will not be addressed, and coping skills will not be provided. Participants will be allowed to share feelings regarding smoking (if they mention them) and general questions will be answered, although no specific behavioral quitting advice will be provided (i.e., they will be encouraged to adhere to the TNP protocol).
224226587|NCT02511236|DRUG|Transdermal Nicotine Patch|Participants will be prescribed up to 8 weeks of transdermal nicotine patch therapy, including 21 mg for 4 weeks, 14 mg for 2 weeks, and 7 mg for 2 weeks. Dosages will be adjusted per manufacturer recommendations.
224226588|NCT00003942|BIOLOGICAL|RevM10 gene|
224226589|NCT00003942|BIOLOGICAL|RevM10/polAS gene|
224226590|NCT00003942|PROCEDURE|in vitro-treated peripheral blood stem cell transplantation|
224226591|NCT00003942|PROCEDURE|peripheral blood stem cell transplantation|
224226592|NCT02210351|DEVICE|MRI test|
224226593|NCT00380471|DEVICE|Bath PUVA|
223638454|NCT06161246|DEVICE|Vibrating Beauty Bar|A vibrating beauty bar will be used at the injection site for patient comfort.
223638455|NCT00497081|DRUG|mirtazapine|mirtazapine 30 mg daily for 3 months
223638456|NCT00497081|DRUG|placebo|placebo 30 mg daily for 3 months
223638457|NCT06222892|DRUG|Camlipixant|Camlipixant will be administered.
223638458|NCT03631251|DRUG|Open Placebo|Open placebo in addition to the standard course of opioids. Opioids are given consistent with standard care.
223638459|NCT01352715|DRUG|Lopinavir/ritonavir|Lopinavir 400mg/ritonavir 100mg (given as two LPV 200mg/RTV 50mg fixed-dose combination tablets) orally twice daily, with or without food, throughout follow-up.
223638460|NCT01352715|DRUG|Lopinavir/ritonavir|Lopinavir 400mg/ritonavir 100mg (given as three LPV 133.3 mg/RTV 33.3 mg fixed-dose combination soft gelatin capsules) orally twice daily, with food, throughout follow-up.
223638461|NCT01352715|DRUG|Raltegravir|Raltegravir 400 mg tablet orally twice daily, with or without food, throughout follow-up.
223638462|NCT01352715|DRUG|Emtricitabine/tenofovir disoproxil fumarate|Emtricitabine 200 mg/tenofovir disoproxil fumarate 300mg fixed-dose combination tablet orally once daily, with or without food, throughout follow-up.
223638463|NCT01352715|DRUG|Abacavir/lamivudine/zidovudine|Abacavir 300 mg/lamivudine 150 mg/zidovudine 300 mg fixed-dose combination tablet orally twice daily, with or without food, throughout follow-up.
223638464|NCT01352715|DRUG|Abacavir/lamivudine|Abacavir 600 mg/lamivudine 300 mg fixed-dose combination tablet orally once daily, with or without food, throughout follow-up.
223638465|NCT01352715|DRUG|Lamivudine/zidovudine|Lamivudine 150 mg/zidovudine 300 mg fixed-dose combination tablet orally twice daily, with or without food, throughout follow-up.
223638466|NCT01352715|DRUG|Abacavir|Abacavir 300 mg tablet orally twice daily or 600 mg (given as two 300 mg tablets) once daily, with or without food, throughout follow-up.
223638467|NCT01352715|DRUG|Zidovudine|Zidovudine 300 mg tablet orally twice daily, with or without food, throughout follow-up.
223638468|NCT01352715|DRUG|Lamivudine|Lamivudine 150 mg tablet orally twice daily, with or without food, throughout follow-up.
223638469|NCT03500718|DEVICE|Cochlear implant|After cochlear implantation, cochlear nerve is stimulated by giving a current over the electrodes placed in the cochlea and the current is measured by electrically evoked Compound Action Potential (ECAP).
223638470|NCT06019702|BIOLOGICAL|iNeo-Vac-R01|Personalized mRNA vaccine encoding neoantigen, IH injection
223638471|NCT03990961|DRUG|Pembrolizumab|Subjects will receive pembrolizumab treatment at a dose of 200mg IV every 3 weeks for a duration of 2 years (35 cycles).
223638472|NCT04596267|DRUG|Pitolisant|8.9mg Pitolisant for 5 days
223638473|NCT04596267|DRUG|Placebo|Inert ingredients
224226594|NCT04459481|DEVICE|bending angle|patients in 70-degree bending angle group are intubated with video stylet at 70-degree bending angle patients in 90-degree bending angle group are intubated with video stylet at 90-degree bending angle
224226595|NCT06103409|BIOLOGICAL|Implantation of allogeneic MSCs on burn wounds|Transplantation of allogeneic MSCs in patients with deep- or full-thickness burns. Allogeneic MSCs embedded in autologous platelet rich plasma clot (PRP) are implanted onto the burned areas. The treated areas will be covered with conventional dressings and burned roll. Dressings will be changed after 5 days and then weekly. The total number of MSCs used in each patient varied according to the burn injury. In patients with larger burned areas, its necessary to apply new treatments with MSCs in affected areas, at intervals of at least 1 month. Implantation will be performed in the operating room. Patients will receive first line treatments.
224226596|NCT01338844|DIETARY_SUPPLEMENT|Myo-inositol|
224226597|NCT01338844|DIETARY_SUPPLEMENT|D-chito-Inositol|
224226598|NCT01073436|OTHER|Discontinuation of therapy|Patients with chronic-phase chronic myeloid leukemia (CP-CML) previously treated with interferon-alpha (IFN) and presently on a tyrosine kinase inhibitor (TKI) (imatinib mesylate, dasatinib, or nilotinib) with achievement of a complete cytogenetic and at least a major molecular remission.
223638474|NCT02511548|OTHER|Financial incentive|Financial incentive will be proposed to participant of the intervention arm
223638475|NCT01310452|DRUG|insulin detemir|insulin detemir once daily with metformin
224319088|NCT00391560|DRUG|perifosine|Identical intervention in both arms.
223638476|NCT01310452|DRUG|neutral protamine insulin|neutral protamine insulin once daily with metformin
223638477|NCT00071058|DRUG|XR9576 (Tariquidar)|
224226599|NCT01664689|PROCEDURE|Microcoaxial Phacoemulsification|
223638478|NCT02096302|DIETARY_SUPPLEMENT|Infant Formula with a novel probiotic CECT7210|Bottle-feeding with a new infant formula enriched with probiotic CECT7210 during the first 3 months of life.
223638479|NCT02096302|DIETARY_SUPPLEMENT|Standard formula|Standard formula without probiotics
224226600|NCT05026515|BEHAVIORAL|Parents|To observe the influence of the parents/caregivers behavior on their child during dental treatment
224226601|NCT01649141|BEHAVIORAL|Trauma-Focused Cognitive Behavioral Therapy|Trauma-Focused Cognitive Behavioral Therapy (TF-CBT) is a structured, 12-16 session outpatient intervention originally developed to treat Posttraumatic Stress Disorder (PTSD) and related emotional and behavioral difficulties in youth with a history of child sexual abuse. TF-CBT's eight components are delivered in 90-minute weekly sessions split evenly between children and their parents. These components are summarized by the acronym PRACTICE including: psychoeducation and parenting skills (P), relaxation (R), affective expression and regulation (A), cognitive coping (C), trauma narrative development and processing (T), in vivo gradual exposure (I), conjoint parent/child sessions (C) and enhancing safety and future development (E).
224319089|NCT01876225|BEHAVIORAL|Forced coughing during cervical punch biopsy|
224319090|NCT00347386|DRUG|Drug: Zinc (zinc sulphate)|Dissolvable tablet 10 mg. Once daily during the illness
224319091|NCT00347386|DRUG|Placebo|Placebo tablet, once daily
223638480|NCT05781906|DRUG|HMPL-523|D1-D7: HMPL-523 Tablet 300 mg QD
223638481|NCT05781906|DRUG|150 µCi [14C]HMPL-523|D8: \[14C\] HMPL-523 Suspension 300 mg/150 μCi Single dose
223638482|NCT01523106|DRUG|L-carnitine|dietary supplement
223638483|NCT01523106|OTHER|Placebo|Patients will receive placebo, which will be manufactured by the same supplier as L-carnitine and appears identical. Patients will take an equal number of pills (8 pills/day).
223638484|NCT06458881|COMBINATION_PRODUCT|Mixture of Simethicone and Tyndallized Bacillus Coagulans|. Enrolled infants were treated for 28 days with a mixture of Tyndallized B. Coagulans and Simethicone: 20 drops, four times a day. At enrolment, clinical and dietary history, obstetrical data and anthropometry were recorded. The subjects were classified as having IC based on their parents' responses to the validated questionnaires regarding IC according to Rome IV criteria.
223638485|NCT00981448|DIETARY_SUPPLEMENT|Zinc acetate|50mg of elemental zinc to be administered 2 times daily orally for 14 days.
223638486|NCT03297450|DEVICE|tDCS|C-tDCS during the first 20 minutes of aphasia therapy, at an intensity of 1mA
223638487|NCT03297450|BEHAVIORAL|Aphasia therapy|Based on linguistic tests, individualized aphasia therapy will be provided
223638488|NCT03297450|DEVICE|Sham-tDCS|tDCS during the first 20 minutes of aphasia therapy at an intensity of 0mA (Sham)
223638489|NCT01649778|DRUG|Pazopanib|Prospective Observational study collecting real world data on Pazopanib in patients with advanced or metastatic Renal Cell Carcinoma. Study is considered non-interventional, no drug will be provided. No study visits or procedures are mandated per protocol.
223638490|NCT01134185|DRUG|prucalopride|single oral dose of 2 mg prucalopride
223638491|NCT01134185|DRUG|prucalopride|single oral dose of 2 mg prucalopride
223638492|NCT01134185|DRUG|prucalopride|single dose of 2 mg prucalopride
223638493|NCT04109547|DRUG|Oral semaglutide|Tablets to be taken once-daily for 26 weeks
223638494|NCT04109547|DRUG|Placebo|Tablets to be taken once-daily for 26 weeks
223638495|NCT01550003|DRUG|Certolizumab Pegol (CZP)|"CZP will be administered subcutaneously as a fixed dose based on weight every 2 weeks (Q2W) or every 4 weeks (Q4W) throughout the study.~CZP will be provided by UCB as a CZP 200 mg/ml solution for single subcutaneous (sc) injection, in a single use prefilled syringe (PFS). Each PFS contains an extractable volume of 0.25 mL, 0.5 mL or 1 mL of CZP solution.~Eligible subjects will begin with 3 loading doses of CZP followed by a treatment dose for the duration of the study based on the weight range.~Reduced CZP regimen (after implementation of protocol amendments 4 and 5):~* 10 to \< 20 kg: Loading dose = 50 mg Q2W (1 x 0.25 mL sc); treatment dose = 50 mg Q4W (1 x 0.25 mL sc);~* 20 to \< 40 kg: Loading dose = 100 mg Q2W (1 x 0.5 mL sc,); treatment dose = 50 mg Q2W (1 x 0.25 mL sc);~* ≥ 40 kg: Loading dose = 200 mg Q2W (1 x 1.0 mL sc); treatment dose = 100 mg Q2W (1 x 0.5 mL sc);"
223638496|NCT01550003|DRUG|Certolizumab Pegol (CZP)|"CZP will be administered subcutaneously as a fixed dose based on weight every 2 weeks (Q2W) or every 4 weeks (Q4W) throughout the study.~CZP will be provided by UCB as a CZP 200 mg/ml solution for single subcutaneous (sc) injection, in a single use prefilled syringe (PFS). Each PFS contains an extractable volume of 0.25 mL, 0.5 mL or 1 mL of CZP solution.~Eligible subjects will begin with 3 loading doses of CZP followed by a treatment dose for the duration of the study based on the weight range.~Original CZP regimen (prior to implementation of protocol amendments 4 and 5 and after implementation of protocol amendment 9):~* 10 to \< 20 kg: Loading dose = 100 mg Q2W (1 x 0.5 mL sc); treatment dose = 50 mg Q2W (1 x 0.25 mL sc);~* 20 to \< 40 kg: Loading dose = 200 mg Q2W (1 x 1.0 mL sc,); treatment dose = 100 mg Q2W (1 x 0.5 mL sc);~* ≥ 40 kg: Loading dose = 400 mg Q2W (2 x 1.0 mL sc); treatment dose = 200 mg Q2W (1 x 1.0 mL sc);"
223638497|NCT06318741|OTHER|aerobic exercise on the treadmill+For both groups, patients will be recommended joint range of motion (ROM), stretching, strengthening, posture and balance and flexibility exercises for all joints.|aerobic exercise on the treadmill
223638498|NCT06318741|OTHER|Walking at an intensity of 12-13 RPE+For both groups, patients will be recommended ROM, stretching, strengthening, posture and balance and flexibility exercises for all joints.|Walking at an intensity of 12-13 RPE
223638499|NCT01656408|DRUG|MK-8150|
224226602|NCT05670652|OTHER|clinical examination|Clinical examination with optimal (Lighting, using a disposable mouth mirror and a millimeter-ruler) will be performed, in addition to an upper and lower arch impression will be made and a study cast will be prepared.
223638500|NCT01656408|DRUG|Placebo for MK-8150|
224226603|NCT02746263|DRUG|IV acetaminophen|
224226604|NCT02746263|DRUG|Oral acetaminophen|
224226605|NCT02746263|DRUG|Morphine|Patient controlled analgesia
224226606|NCT00818623|DRUG|Degarelix|Degarelix (120 mg (20 mg/mL)) was given as a subcutaneous injection
224226607|NCT00818623|DRUG|Degarelix|Degarelix (120 mg (40 mg/mL)) was given as a subcutaneous injection
224226608|NCT00818623|DRUG|Degarelix|Degarelix (160 mg (40 mg/mL)) was given as a subcutaneous injection
224226609|NCT00818623|DRUG|Degarelix|Degarelix (200 mg (40 mg/mL)) was given as a subcutaneous injection
224226610|NCT00818623|DRUG|Degarelix|Degarelix (200 mg (60 mg/mL)) was given as a subcutaneous injection
224226611|NCT00818623|DRUG|Degarelix|Degarelix (240 mg (40 mg/mL)) was given as a subcutaneous injection
224226612|NCT00818623|DRUG|Degarelix|Degarelix (240 mg (60 mg/mL)) was given as a subcutaneous injection
224226613|NCT00818623|DRUG|Degarelix|Degarelix (320 mg (60 mg/mL)) was given as a subcutaneous injection
224226614|NCT00602030|DRUG|Entinostat|Entinostat tablets on Days 1 and 15 of a 28-day cycle.
224226615|NCT00602030|DRUG|Placebo|Placebo-matching entinostat tablets on Days 1 and 15 of a 28-day cycle.
223515648|NCT06673537|OTHER|Spinal Manipulation|Spinal manipulation was performed by an experienced physiotherapist on the intervention group three times a week following Connective Tissue Massage (CTM). Participants in this group were positioned laterally, ensuring their lower leg remained straight and in contact with the treatment table. The contralateral or upper hip and knee were flexed and positioned so that they did not touch the table, allowing an unopposed force to be applied at the selected joint. Following CTM, manipulation was carried out with high-velocity, low-amplitude (HVLA) force applied bilaterally to all clinically relevant vertebral levels from T10 to L5 and the sacroiliac joints, accompanied by an audible sound from one or more joints.
224226616|NCT00602030|DRUG|Erlotinib|Erlotinib 150 mg tablets once daily.
224226617|NCT03263299|DRUG|cabergoline|Cabergoline was administered in a dose of 1 mg/week in two divided doses which was terminated after embryo transfer
224226618|NCT03263299|DRUG|Aspirin|Aspirin was administered in daily dose of 80 mg initiated at the start of down-regulation with luteal leuprolide
224226619|NCT03263299|DRUG|GnRH agonist|Microdose flare-up regimen. The patient received diluted doses of the GnRH agonist leuprolide acetate 40 µg, given subcutaneously twice daily. Two days later, stimulation is initiated by intramuscular (IM) injections of HMG (Merional, IBSA, Germany) in a dose of 300 IU/day.
224226620|NCT00371800|DRUG|cinnamon|
224226621|NCT00650299|DRUG|Alprazolam Extended-release Tablets 3 mg|3mg, single dose fed
224319092|NCT01080560|DRUG|Cyclosporine Capsules USP (Modified) 100 mg|Subjects will be administered either Test Product or Reference Product with 240ml of water according to randomization schedule
224323280|NCT04518228|DRUG|Ritonavir|Administered consistent with the package inserts and/or instructions provided by the non-study sources who prescribe or supply the drugs to participants
224226622|NCT00650299|DRUG|Xanax XR® Tablets 3 mg|3mg, single dose fed
224226623|NCT05747638|BEHAVIORAL|Revised Children's Manifest Anxiety Scale (RCMAS)|All participants will be invited to complete a paper questionnaire.
224226624|NCT00910182|PROCEDURE|splenorrhaphy|surgical treatment of splenic injuries after blunt abdominal trauma.
224226625|NCT01684410|BIOLOGICAL|Alpha-1 HC 100 mg|Alpha-1 HC is a sterile, liquid preparation of purified alpha1-proteinase inhibitor prepared from pooled human plasma. Alpha-1 HC 100 mg inhaled once daily for 21 days for a total of 21 inhaled treatments.
224226626|NCT01684410|BIOLOGICAL|Placebo|Phosphate Buffer Saline with Polysorbate (placebo) composed of the same elements listed for Alpha-1 HC, minus the 50 mg/mL of Alpha-1 HC. Placebo inhaled once daily for 21 days for a total of 21 inhaled treatments.
223638501|NCT06246773|BEHAVIORAL|Positive Parenting Program|During the first week, women will receive one session of Recovering from Intimate partner violence through Strengths and Empowerment (RISE) and from week 2 they will receive RISE and PALS simultaneously. Participants will receive four to six components of RISE - education on health effects of violence, improving coping and self-care, enhancing social support, and addressing sexual violence, increase safety planning, and assist in making difficult decisions. During each of the PALS sessions, parents will receive instruction on four responsive parenting constructs: contingent responsiveness, warm sensitivity (responses include high levels of affection and understanding of child states), maintaining vs. redirecting attention to objects and topics of conversation, and verbal scaffolding .In addition to direct instruction, parents will video-record themselves interacting with their child and engage in self-reflection of their own parenting behavior.
223638502|NCT06246773|BEHAVIORAL|Usual Care|Participants will receive services available to them at the shelter or housing facility
223638503|NCT00871975|DEVICE|Urodynamics + TETRA - NIRS|Urodynamics will be performed as per standard of care for patients enrolled, whereby one catheter is inserted into the bladder and one in the rectum to analyze bladder filling, storage and voiding conditions via pressures measured and urine flow rates detected by a uroflowmeter. Tetra-NIRS will be concurrently performed where Tetra-NIRS unit uses near infrared light at 3 different wavelengths to measure changes in haemoglobin and cytochrome. A patch is applied externally to measure these changes in the detrusor muscle of the human bladder wall. This process is similar to what is used for cerebral and muscle oxygenation monitoring (e.g., pulse oximetry). Previous clinical feasibility studies have identified a correlation between the changes in haemoglobin and cytochrome and the pressure values obtained during urodynamics procedures.
223638504|NCT05515809|DRUG|parasternal block|"Echo-guided loco-regional anesthesia by bilateral parasternal block in immediate preoperative.~The drug used is Ropivacaine 2mg/ml, 0.2%. Injection of 20ml per side, under ultrasound control, after general anaesthesia and before skin incision, and therefore before surgery"
223638505|NCT05515809|DRUG|Standard pain management|Standard pain management care involves a multimodal strategy that includes the use of intravenous analgesics. Morphine medications are the mainstay of pain management
223638506|NCT03469557|DRUG|Tislelizumab|Subjects will be treated with BGB A317 200 mg IV on Day 1 during each 21-day cycle. BGB A317 will be administered until disease progression, intolerable toxicity, or treatment discontinuation for any other reason.
223638507|NCT03469557|DRUG|Cisplatin|Subjects will be treated with cisplatin 80 mg/m² IV on Day 1 during each 21-day cycle. Cisplatinwill be given for up to 6 cycles.
223638508|NCT03469557|DRUG|5-FU|Subjects will be treated with 5-FU 800 mg/m²/day IV using continuous pumping system on Days 1 through 5 during each 21-day cycle. 5-FU will be given for up to 6 cycles.
223638509|NCT03469557|DRUG|Oxaliplatin|Subjects will be treated with oxaliplatin 130 mg/m² IV on Day 1 during each 21-day cycle. Oxaliplatin will be administered for up to 6 cycles.
223638510|NCT03469557|DRUG|Capecitabine|Subjects will be treated with capecitabine 1000 mg/m² orally twice daily (bid) Days 1 through 14 (14 days total) during each 21-day cycle. Capecitabine will be administered until disease progression, intolerable toxicity, or treatment discontinuation for any other reason.
224226627|NCT01684410|BIOLOGICAL|Alpha-1 HC 200 mg|Alpha-1 HC is a sterile, liquid preparation of purified alpha1-proteinase inhibitor prepared from pooled human plasma. Alpha-1 HC 200 mg inhaled once daily for 21 days for a total of 21 inhaled treatments.
224226628|NCT05305209|OTHER|Intervention group|The patients will receive 12 minutes of intravaginal application with an average power of 1 watios and total applied energy of 720J and an extracavitary application for 4 minutes with an average power of 3 watios and a total dose of 720J with all effects at 200%, twice a week for 6 weeks.
223638511|NCT03115866|BEHAVIORAL|FRUVEDomics|FRUVEDomics is a behavioral nutrition intervention in young adults 'at risk for metS' and young adults 'with metS' to identify modifiable metabolomics and microbiome risk. Group nutrition education including basic nutrition for the prescribed intervention, culinary tool kit distribution, sample budget and grocery shopping tips were delivered to each participant group prior to the start of the intervention. Participants underwent individual weekly consultations with a Registered Dietitian Nutritionist using food logs, food pictures and receipt management, to assess adherence and cost of the intervention.
223638512|NCT05100121|DEVICE|Interactive app|In the app, the patients will report frequency and distress on commons concerns regarding urine dysfunction, bowel dysfunction, emotional distress, sleep, pain, loss of appetite, hot flashes/sweating, edema, and sexual dysfunction. Free text comments will also be possible to make to cover the patients' other potential needs. Questions regarding symptoms of acute character that might need to be treated quickly like severe pain, blood in stool and urine, and involuntary weight loss will also be asked for to timely detect and treat signs of for example cancer relapse. Information about the concerns will be included in the app containing; a) general information of why they have the side effect and what it means b) evidence-based advice about self-management; c) when they should contact health care providers, and d) further information linked to reliable documents and web pages.
224226629|NCT05305209|OTHER|Control Group|The patients will receive 12 minutes of intravaginal application and 4 minutes of extracavitary application, twice a week for 6 weeks. The difference compared to the intervention of group 1 is that the device will be off and therefore will not emit energy.
224226630|NCT01669395|OTHER|Early homebased rehabilitation after hospital admission|Training begins 3-5 days after discharge from hospital, performed by an occupational therapist and a physiotherapist from Gentofte Hospital in the first two weeks. From week three to six the training will be carried out by an occupational therapist and a physiotherapist from the local municipality (Gentofte municipality and Lyngby Taarbæk municipality). Training will take place at home twice a week for 6 weeks, each session lasting 45 minutes. The intervention is individualized and focuses on functional physical and compensatory training to help the patient to manage everyday life at home. A training program will be provided and the patient will be instructed to do the exercises every day
224319093|NCT01659125|BEHAVIORAL|"OCFighter"|OCFighter™ s an interactive, internet guided self-help (GSH) treatment program for obsessive-compulsive disorder (OCD). It uses the evidence based approach known as Cognitive Behavioral Therapy (CBT) and was adapted from the previously validated BT STEPS program for OCD. The program teaches the best practice CBT technique to help with OCD called exposure with ritual prevention (ERP).
224319094|NCT01913886|PROCEDURE|MSCs injection|MSCs cells will be injected in two aliquots of 10 ml by catheterism
223638513|NCT05100121|OTHER|Supportive Care|During the health dialogues with the nurse, the patient reported assessments will be used to discuss the individual's current situation and to plan eventual additional actions needed such as support from a physiotherapist, social worker, dietitian or if a visit to the physician if needed. This is documented in the patients health record.
223638514|NCT03302325|PROCEDURE|research blood draws|Twenty-five mL of peripheral blood (PB) will be collected for research. Blood will be collected in EDTA tubes and used to isolate ctDNA. For each subject we will request that he/she contribute 25 mL of plasma no more frequently than every 6 weeks, and at same time of standard of care blood draws and routine clinic visit, and for no more than 3 times (including baseline and end of study).
223638515|NCT04245150|OTHER|Stool sample|Stool sample
223638516|NCT04245150|OTHER|Skin Swab Sample|Skin Swab Sample
223638517|NCT00648102|BIOLOGICAL|CDX-1307|
224226631|NCT01669395|OTHER|Usual care|After discharge from the hospital the patients are offered the usual symptom-oriented and preventive medical care and psychosocial support
224226632|NCT01695070|DRUG|Melatonin|4mg prolonged release melatonin oral tablets twice daily
224226633|NCT06135532|PROCEDURE|Non-Surgical Periodontal Treatment|Nonsurgical periodontal therapy primarily aims to control microbial periodontal infection by removing bacterial biofilm, calculus, and toxins from periodontally involved root surfaces. Performing a thorough periodontal debridement under local anesthesia will stop disease progression and improve active disease's clinical signs and symptoms.
224226634|NCT00338494|DRUG|Clofarabine|The starting dose of clofarabine will be 10 mg/m2 once a week for 3 weeks repeated every 4 weeks with dose escalations to 15, 20 , 30 and 40 mg/m2/week.
224226635|NCT04881422|BEHAVIORAL|B-HIPE (Brief High Impact Preparatory Experience)|The intervention consists in a one-week intensive rehabilitation in which participants underwent to a multidimensional rehabilitation composed by physical rehabilitation, mental wellbeing, a proper diet and engaging physical activity (a sail course). Digital motivating reinforcements are proposed to the participants with the aim to maintain the correct lifestyle learned in the B-HIPE program.
224226636|NCT06056700|BEHAVIORAL|Education|All study follow-up information was collected through this app. The information offered to all the mothers through the mobile application contained a welcome message, contact data, sociodemographic and clinical variables, and access to the TMM-24 questionnaire. However, the GI through the app had access to complementary information content regarding the CG. The mothers of the IG had additional training material related to the first two prenatal face-to-face training sessions and new information during the postnatal period throughout consecutive weeks 1 to 8.
224226637|NCT03075657|DRUG|Risperidone|Risperidone will be prescribed at dose of 2 mg per day
224226638|NCT03075657|DRUG|Risperidone and Ramelteon|Ramelteon will be prescribed 8mg/day as an add-on therapy to Risperidone 2 mg per day
224226639|NCT03075657|DRUG|Haloperidol|Haloperidol will be prescribed at a dose of 4 mg per day
223638518|NCT05589662|OTHER|Clinical and functional assessment|The dependent variables (muscle strength, muscle activation, pressure pain threshold and joint status) and the outcome measures used to measure these variables will be: pressure dynamometer, surface electromyography, pressure algometer and Hemophilia Joint Health Score
223638519|NCT00870740|BIOLOGICAL|BIIB019 (Daclizumab High Yield Process)|SC injection
223638520|NCT00870740|DRUG|Placebo|Placebo SC injection
224226640|NCT03075657|DRUG|Haloperidol and Ramelteon|Ramelteon will be prescribed 8mg/day as an add-on therapy to Haloperidol 4 mg per day
224226641|NCT00212771|DRUG|asenapine|Flexible dose, 1-2 tablets sublingual two times per day (1 or 2 tablets in the morning and 1 or 2 tablets in the evening). Each tablet contains either 5 mg asenapine or matching placebo.
224226642|NCT00212771|DRUG|olanzapine|Flexible dose, 1-2 capsules oral once per day (in the morning). Each capsule contains 10 mg olanzapine or matching placebo.
224226643|NCT02462070|DRUG|IDP-118 Lotion|Lotion
224226644|NCT02462070|DRUG|IDP-118 Vehicle Lotion|Lotion
224226645|NCT01643083|DRUG|Rifaximin|Rifaximin 400mg tid for 2 wk
224226646|NCT01643083|DRUG|Placebo|Placebo for 2 week
224226647|NCT05544383|BEHAVIORAL|Interdisciplinary Pain Education Program|It is an operative group model, with the objective of promoting education in pain, where the patient occupies an active and central space in the learning process, with work focused on the dysfunctional beliefs of chronic pain, performing programmed tasks to promote autonomy in activities daily life and behavior change. The group works with one meeting per week, during the routine opening hours of the clinic, with each day a theme of a professional area being addressed, totaling 5 meetings, lasting approximately two hours.
223638521|NCT00148395|DRUG|Gemcitabine|
223638522|NCT00148395|DRUG|Navelbine|
223638523|NCT00148395|DRUG|Carboplatin|
223638524|NCT00148395|DRUG|Cisplatin|
223638525|NCT00148395|DRUG|Mitomycin|
223638526|NCT00148395|DRUG|Ifosfamide|
223638527|NCT05005234|DRUG|GFH925|Administered as an oral tablet formulation
223638528|NCT03592186|BEHAVIORAL|Parenting Wisely+|Parenting Wisely+ experimental intervention
223638529|NCT03592186|BEHAVIORAL|Treatment as Usual|Treatment as Usual
223638530|NCT06180343|OTHER|Mandala|"Participants will be asked to choose the pages they want from the 12 colored felt-tip pen paint sets and mandala coloring book given to each participant by the researcher, and color them in the colors they want, for 6 weeks, once a week, at any time of the day and for an average of 20-30 minutes each time.~Participants will be asked to send a message before they start painting the mandala, and after the process, they will be asked to take a picture of the mandala they have painted and send it to the researcher. If the participants forget to color the mandala, a reminder message will be sent by the researcher twice a week."
223638531|NCT00817843|DRUG|Simvastatin|6 weeks of treatment with simvastatin 80 mg
223638532|NCT00817843|DRUG|Simvastatin/Ezetimibe|6 weeks of treatment with simvastatin 10 mg / ezetimibe 10 mg combination
223638533|NCT03557749|DIAGNOSTIC_TEST|Blood Sample|60 ml heparinized blood 10 ml serum
223638534|NCT03557749|DIAGNOSTIC_TEST|Stool Sample|pea-sized amount
223638535|NCT03557749|DIAGNOSTIC_TEST|Urine Sample|10 ml
223638536|NCT03557749|DIAGNOSTIC_TEST|Bronchoalveolar Lavage (BAL) fluid|10 ml
223638537|NCT03557749|DIAGNOSTIC_TEST|Gastrointestinal biopsy x 2-4|rectosigmoid site preferred
223638538|NCT03557749|DIAGNOSTIC_TEST|Skin biopsy|2-4 mm punch
223638539|NCT03557749|DIAGNOSTIC_TEST|Skin, mouth, and/or ocular swab|Involved skin, mouth, and/or ocular swab for microbiota studies
223638540|NCT03557749|DIAGNOSTIC_TEST|Apheresis Product|Up to 10 ml of apheresis product
223638541|NCT03557749|DIAGNOSTIC_TEST|Final cellular product|A second washing from the infusion bag after product and initial bag wash has infused, or up to 10 ml of final cellular product
223638542|NCT02079896|DRUG|Lexaptepid pegol (NOX-H94)|anti-hepcidin L-RNA-aptamer (Spiegelmer)
223638543|NCT02079896|DRUG|Placebo|
223638544|NCT00307801|DRUG|Estradiol valerate/Dienogest (Natazia, Qlaira, BAY86-5027)|1 pill per day taken orally over 7 cycles of 28 pills per cycle
223638545|NCT00307801|DRUG|Placebo|1 pill per day taken orally over 7 cycles of 28 pills per cycle
223638546|NCT03431259|OTHER|Patient Gateway|Patients will be enrolled in the Patient Gateway app.
223638547|NCT03476486|PROCEDURE|Thread carpal tunnel release|Ultrasound-guided percutaneous minimally invasive thread carpal tunnel release using a looped thread technique
223638548|NCT00551642|DRUG|Nitric oxide|Nitric Oxide vapour (gas) for inhalation (400 ppm)
223638549|NCT00551642|DRUG|Placebo|Placebo gas for inhalation
223638550|NCT06059482|OTHER|Assessment|Evaluations will be made once.
223638551|NCT02596867|DRUG|propanolol|Participants will take 1.5 mg/kg/day propranolol, twice daily for 3 weeks until surgical resection of the breast tumor is performed
223638552|NCT04822116|OTHER|goal directed intraoperative haemodynamic optimization|all interventions that were pre-specified to be administered as part of the protocol
223638553|NCT01808586|PROCEDURE|Betamethasone|6 mg/mL injected into the facet joint as dictated by modified dual-comparative medial branch block diagnostic protocol
223638554|NCT01808586|PROCEDURE|Dexamethasone|4mg/mL
223638555|NCT01808586|PROCEDURE|Intramuscular Lidocaine|2%
223638556|NCT01808586|BEHAVIORAL|Home Exercise|Standardized home exercise program
223638557|NCT03521128|PROCEDURE|radiological tubal blockage|In radiological tubal blockage group, under the fluoroscopy of X-ray, after confirming HX by HSG, selective catheterization will be done for the affected tube and micro spring coils will be put in to the interstitial tube and isthmus through micro catheter. The micro spring coil will be placed into the proximal end of the Fallopian tube (unilateral or bilateral depending on whether one or two HX were present) through micro catheter under the fluoroscopy of X-ray. Then HSG will be carried out to check the position of the micro spring coil and confirm complete blockage. Four weeks after the radiological procedure, a HSG will be performed to recheck the position of the micro spring coil and complete blockage of the tubes. FET is proceeded in the next menstrual cycle after HSG examination.
223638558|NCT03521128|PROCEDURE|laparoscopic salpingectomy|In the laparoscopic salpingectomy group, after confirming HX, a unilateral or bilateral salpingectomy will be performed in a standard manner, depending on whether unilateral or bilateral HX are present. In women with extensive pelvic adhesions during laparoscopy, proximal tubal ligation will be performed as an alternative procedure to salpingectomy. FET is proceeded in the next menstrual cycle after the laparoscopic operation.
223638559|NCT02032732|OTHER|leukocyte esterase test|leukocyte esterase test on fluid removed by intra-articular aspiration
223638560|NCT02968758|DEVICE|Comparison between GenePOC PCR and Reference Method|Stool specimen will be tested with the GenePOC CDiff test on the GenePOC Instrument. The results will be compared to Reference Method defined as direct and enriched culture method for observation of a toxigenic Clostridium difficile strain.
223638561|NCT03011099|DEVICE|Robotic exoskeleton training|During the training, subjects will wear a lower extremity exoskeleton robotic walking device. Subjects will participate in individualized treatment sessions which may include: sit to stand, static and dynamic standing balance, weight shifting, walking, turning, and stand to sit. Each training session will last up to 90 minutes (60 minutes of training with 30 minutes for setup, don/doff of device) and training will be held 5 days per week for 3 weeks with a total of 15 sessions. During the training period, subjects will be required to maintain the same amount and level of regular daily physical activity and exercise.
223638562|NCT03011099|OTHER|Conventional physical therapy|During the training, subjects will receive conventional physical therapy that is designed to facilitate/promote gait. This will include individualized treatment sessions for each subject and may involve stretching, strengthening, balance training, standing, and gait training. Subjects will not be able to participate in any form of robotic assisted or body weight supported treadmill training. Each training session will last up to 60 minutes and training will be held 5 days per week for 3 weeks with a total of 15 sessions. Consistent with the RET group, subjects will be required to maintain the same amount and level of regular daily physical activity and exercise during study period.
223638563|NCT06000228|PROCEDURE|Recession coverage with CTG using minimally invasive access technique in shallow vestibule|After enrolment, participants will be instructed about oral hygiene and undergo nonsurgical periodontal treatment in the form of scaling and root planing using ultrasonic and hand instruments as needed. After resolution of inflammation, a full thickness tunnel will be preapred using minimally invasive access technique under local anesthesia with the aid of specific tunnelling instruments and connective tissue graft will be procured from the palate or tuberosity area for root coverage procedure by single incision technique.
223638564|NCT06000228|PROCEDURE|Recession coverage with CTG using minimally invasive access technique in deep vestibule|After enrolment, participants will be instructed about oral hygiene and undergo nonsurgical periodontal treatment in the form of scaling and root planing using ultrasonic and hand instruments as needed. After resolution of inflammation, a full thickness tunnel will be preapred using minimally invasive access technique under local anesthesia with the aid of specific tunnelling instruments and connective tissue graft will be procured from the palate or tuberosity area for root coverage procedure by single incision technique.
224319095|NCT04392895|PROCEDURE|Para Aortic Lymphadenectomy (PAL) by laparoscopy|Para Aortic Lymphadenectomy (PAL) by laparoscopy
223638565|NCT02575963|DRUG|Cytarabine (Phase 1 only)|Low dose cytarabine administered at 20 mg subcutaneously every 12 hours for the first 10 days (Days 1 to 10) of every cycle. Cycle 1 can last up to 52 days (depending on the schedule of study drug dosing) in order to allow for recovery from Lintuzumab-Ac225. Cycles 2-12 will last 28 days each.
224319096|NCT03251170|DRUG|Ketamine|Patients will receive :1 mg/Kg ketamine for induction of anesthesia
224319097|NCT03251170|DRUG|Fentanyl|Patients will receive :2.5 mcg/Kg fentanyl for induction of anesthesia
224319098|NCT03251170|DRUG|Midazolam|Patients will receive 0.05 mg/Kg midazolam
223638566|NCT02575963|BIOLOGICAL|Lintuzumab-Ac225|In Phase 1 the starting dose level was 1.0 μCi/Kg of Lintuzumab-Ac225 and 15 μg/Kg unlabeled HuM195 divided into 2 equal fractionated doses (0.5 μCi/Kg and 7.5 μg /Kg + 0.5 μCi/Kg and 7.5 μg /Kg) with the first fraction administered approximately 4-7 days after 1 cycle of low dose cytarabine and the second fraction administered 4-7 days after the first fraction, followed by up to 11 more cycles. In Phase 2 the dose will be 4.0 μCi/Kg Lintuzumab-Ac225 and 25 μg/Kg unlabeled HuM195 divided into 2 equal fractions with the first fraction given on Day 1 and the second fraction given on Day 5-8.
223638567|NCT02575963|DRUG|Furosemide (Phase 1 only)|40 mg by mouth daily one day prior to treatment with Lintuzumab-Ac225 and continuing for 10 days following administration of the 2nd divided dose.
223638568|NCT02575963|DRUG|Spironolactone|25 mg by mouth daily, administered 10 days after second dose of 225Ac-HuM195 and continued for 12 months.
223638569|NCT05773729|GENETIC|BD211|Genetically modified CD34+ autologous stem cells were transfused intravenously with single dosing.
223638570|NCT00129246|DRUG|Naltrexone|Participants received naltrexone hydrochloride on the sixth day of bupropion treatment, and the initial dose was 12.5 mg, followed by 25 mg daily for the duration of the 7-week treatment.
223638571|NCT00129246|DRUG|Bupropion|Starting with the baseline visit, all participants received 150 mg of bupropion SR once per day for 3 days, then twice per day for the duration of the 7-week treatment period.
223638572|NCT04181658|OTHER|Real tDCS and Physical Therapy|The participant will receive 20-minute sessions of real tDCS before each physical therapy visit for up to 10 combined sessions, over approximately 6 weeks.
223638573|NCT04181658|OTHER|Sham stimulation and Physical Therapy|The participant will receive 20-minute sessions of sham stimulation before each physical therapy visit for up to 10 combined sessions, over approximately 6 weeks.
223638574|NCT06183762|OTHER|No treatment is included in this protocol.|No drug intervention or tissue sampling will be included in this study.
224226648|NCT05544383|OTHER|Conventional Physiotherapy treatment|The therapeutic approach consists of rehabilitation methods and techniques, with the aim of restoring, developing and conserving the patient's physical capacity and functionality, including manual therapy and kinesiotherapy, in addition to the use of resources such as electrotherapy, thermotherapy and auriculotherapy. The treatment is performed at the Physiotherapy outpatient clinic, twice a week, with an average duration of 45 minutes, for a period that lasts an average of 10 sessions in clinical cases of chronic musculoskeletal pain.
224226649|NCT00508378|BEHAVIORAL|Interview|Interview regarding side-effects of chemotherapy, 30-45 minutes.
224226650|NCT00508378|BEHAVIORAL|Questionnaire|Quality of life survey and symptom assessment questionnaire, 15 minutes.
224226651|NCT03954028|PROCEDURE|Gingival Punch Biopsy after healing of Gingival Soft Tissue Augmentation|Patients needing gingival soft tissue augmentation will receive two kinds of gingival tissue graft material in a split-mouth design. The autogenous connective tissue (CTG) graft material will be randomized to apply to one half, and commercial acellular dermal matrix (ADM) materials will be used in the opposite half. After 3 months of healing, a gingival punch biopsy will be performed in both sides to collect the tissues for analysis.
224226652|NCT03449628|DIETARY_SUPPLEMENT|L.casei DG|"(At least 24 billion live cells per capsule)~1 capsule, b.i.d. for 12 weeks"
224226653|NCT03449628|DIETARY_SUPPLEMENT|PLACEBO|1 capsule, b.i.d. for 12 weeks
224226654|NCT00059995|BIOLOGICAL|iratumumab|
224226655|NCT01832090|DEVICE|Radiesse® Injectable Dermal Filler|Calcium hydroxylapatite particles suspended in an aqueous based gel carrier.
224226656|NCT05049889|OTHER|Terrestrial exercise|"At visit 1 (Day 0), an exercise test will be performed (maximal incremental test), followed by a 30-minute submaximal exercise at constant load.~During this exercise, continuous data collection will be performed:~* Continuous 12-lead electrocardiogram~* Continuous monitoring of blood pressure and ventilation."
223638575|NCT02192580|DRUG|Omega-3|Children less than 18 kg:26 mg/kg EPA and 11 mg/kg DHA Children 18-24 kg:504 mg EPA and 216 mg DHA Children 25-32 kg:672 mg EPA and 288 mg DHA Children 33-41 kg:840 mg EPA and 360 mg DHA Children 5-15 years:1000 mg EPA and 878 mg DHA omega-3 in divided 3 times/day in addition to standard regimens
223638576|NCT03675347|OTHER|angioplasty|angioplasty
223638577|NCT01651156|DRUG|Tolvaptan|oral taken
224226657|NCT05049889|OTHER|Swimming exercise|"At visit 2 (Day 7), the subjects will perform a swimming exercise in the experimental pool equipped with a turbine to create a counter-current. The water speed will be constant (4 min per 100 m, i.e. 1.5 km/h). The duration of the exercise will be 30 minutes. Each diver will breathe with the help of a snorkel.~During this exercise, continuous data collection will be performed:~* Continuous 12-lead electrocardiogram~* Continuous monitoring of blood pressure and ventilation."
224226658|NCT05049889|DEVICE|Transthoracic cardiac ultrasound|The participants will have a transthoracic cardiac ultrasound to measure the dilatations of the cardiac cavities at visit 1 and 2.
224226659|NCT05049889|DEVICE|Transthoracic pulmonary ultrasound|The participants will have a transthoracic pulmonary ultrasound to quantify the presence of signs of pulmonary vascular overload (comet tails) at visit 1 and 2.
224226660|NCT05049889|BIOLOGICAL|Blood collection|Several blood samples will be collected at visit 1 and 2.
224226661|NCT06527092|DEVICE|Virtual Reality|VR is an interactive, multidimensional, computer-simulated environment accessed through a head-mounted device that blocks the view of the real world. This environment is projected in front of the user's eyes through sophisticated head-mounted displays, including a wide field of view and motion tracking systems
223638578|NCT01651156|DRUG|Placebo|
224226662|NCT06527092|DEVICE|Bubbles|A colorful light bubble gun was used for bubble therapy, which is one of the distraction methods.
223638579|NCT04692259|DIAGNOSTIC_TEST|MRI|Liver MRI before liver resection
223765071|NCT06541795|DEVICE|AcrySof IQ Vivity Extended Vision IOL|UV-absorbing, with or without blue light filtering, foldable IOL implanted in the capsular bag of the eye for the visual correction of aphakia in adult patients from whom a cataractous lens has been removed. The IOL mitigates the effects of presbyopia by providing an extended depth of focus. The toric models in addition reduce residual refractive astigmatism in patients with pre-existing corneal astigmatism.
224319099|NCT02126826|DRUG|BI 1026706|Multiple Rising Doses (oral solution, tablet)
224319100|NCT02126826|DRUG|Placebo to BI 1026706|Multiple Rising Doses (oral solution / tablet, identical to active treatment)
224319101|NCT03381170|BIOLOGICAL|Ublituximab|Enrolled Subjects will be infused with ublituximab on Weeks 1E, 24E, 48E, 72E and 96E
223638580|NCT03902353|OTHER|Screening of adult without diagnosis of PH carrying an heterozygous EIF2AK4 mutation.|will be performed : a clinical evaluation (dyspnea assessed by New York Heart Association functional class (I-IV), signs of right heart failure), a 6min walk test, a Computerized Tomography scan of the chest, an electrocardiogram, an echocardiography (measurement of the velocity of tricuspid regurgitation, measurement of Tricuspid Annular Plane Systolic Excursion (TAPSE) and Tei index, pericardial effusion, dilatation and hypertrophy of the right ventricle), an abdomina ulstrasound, a stress Test (ventilation oxygen peak and ventilation oxygen specific, minute ventilation, dead-space ventilation / dead space, ventilatory reserve, alveolar-arterial gradient, pulse oxygen, PaO2), a lung function tests and measurement of Diffusing capacity or transfer factor of the Lung for Carbon mOnoxide (DLCO) and Nitric Oxide (DLNO), and a blood sample.
224319102|NCT02972190|PROCEDURE|Bilateral decompression with TLIF|Bilateral decompression of neural elements combined with TLIF
224319103|NCT02972190|PROCEDURE|laminectomy with PLIF|Decompression of neural elements using laminectomy combined with PLIF
223638581|NCT04409925|DRUG|rhDNase I|Inhaled nebulisations
224226663|NCT01801696|OTHER|Parent massage tx group|The parent-delivered massage is based on Chinese medicine. There are specific techniques for each area of difficulty, e.g. the head, fingers, and toes. After a few months, massage becomes relaxing and enjoyable, and parent touch comes back into use to effectively help the child self-regulate.
224226664|NCT01801696|OTHER|Parent massage wait-list control group|The parent-delivered massage is based on Chinese medicine. There are specific techniques for each area of difficulty, e.g. the head, fingers, and toes. After a few months, massage becomes relaxing and enjoyable, and parent touch comes back into use to effectively help the child self-regulate.
224226665|NCT02343887|OTHER|neuropsychological tests|
224226666|NCT02343887|OTHER|STAI-Y scale for anxiety|
224226667|NCT02343887|OTHER|Beck scale for depression|
224226668|NCT02343887|OTHER|without intervention|
224226669|NCT03393442|DIAGNOSTIC_TEST|Brain MRI scan|Diagnostic brain MRI scan with the purpose to detect signal changes due to brain deposits of Gd.
224226670|NCT00939133|DRUG|tretinoin microsphere 0.04% gel|Applied daily to entire face for six months
224226671|NCT00939133|DRUG|vehicle gel|Placebo
224226672|NCT00947856|DRUG|brentuximab vedotin|Every 3 weeks by IV infusion (1.2 or 1.8 mg/kg) until disease progression, unacceptable toxicity, or study closure
224226673|NCT01536756|OTHER|Exercise Intervention -- Physical Rehabilitation Program|"The intervention group will participate in a Physical Rehabilitation Program which includes a 60-minute training session at a frequency of 3 times a week over a total of 12-week duration. The training session consists of 45 minutes of warm-up stretching and circuit training. This includes 3 stations of aerobic exercises for physical work up of different body parts, and 3 stations of strengthening exercises of major muscles groups at 3 sets of 10 repetitions. The final 15-minute training session will be the cooling down exercise with emphasis on stress management incorporating mindful breathing, stretching and body awareness exercise."
224226674|NCT01536756|OTHER|Wait List Control Group|The subjects of the control group will be asked to maintain their usual activities while awaiting for the physical rehabilitation program at the 12-week waiting time. They will be allowed to receive any other usual medical services including social services and psychotherapy but not physiotherapy services. At the end of the 3rd month, the control group will be recruited into the Physical Rehabilitation Program. Patients in the control group will then join in as the intervention group and follow the intervention and assessment protocol.
224226675|NCT05332210|DRUG|HBM9161 Injection (680mg)|HBM9161 Injection
224226676|NCT04202900|OTHER|phototherapy protocol|"Pretest：Common symptoms in the elderly include insomnia, depression, pressure sore wounds, blood sugar, blood pressure, body temperature,fatigue,cold limbs.~Intervention：LED light therapy for 6 weeks, 2-3 times a week, every 30 minutes. Post test：Common symptoms in the elderly include insomnia, depression, pressure sore wounds, blood sugar, blood pressure, body temperature,fatigue,cold limbs."
224226677|NCT01075620|DEVICE|PFC-Sigma RP|Posterior stabilizing rotating platform total knee components
224226678|NCT01075620|DEVICE|LPS RP|non-posterior stabilized rotating platform design
224319104|NCT02972190|DEVICE|Pedicle screw and interbody cage|Pedicle screw and interbody cage
224319105|NCT04211116|DEVICE|Central venous line insertion|Pediatric patients indicated to central venous line insertion
224319106|NCT04622241|OTHER|Eave Tubes|The eave tubes are PVC tubes with a diameter of 15 cm installed in the outer wall of occupied rooms (e.g. bedrooms and living rooms but not storage rooms) at 1.5-2 m intervals, fitted with electrostatic mesh inserts coated with insecticides. No additional screening will be done. All households will be provided with piperonyl butoxide (PBO) long-lasting insecticidal nets (LLINs) - one for every two residents.
224319107|NCT04622241|OTHER|Eave Ribbons|"Eave ribbons are 15 cm-wide triple-layered hessian fabrics (burlap-line fabric woven from sisal fibres, procured locally), in lengths starting 1 m that can be attached to houses using nails, adhesives or Velcro, without completely closing eave-spaces. The eave ribbons will be treated by study staff with a commonly used spatial repellent, transfluthrin. Eave ribbons will be retreated by study staff after 6 months (only in Phase II, if selected for inclusion in the cluster-randomised trial).~All households will be provided with piperonyl butoxide (PBO) long-lasting insecticidal nets (LLINs) - one for every two residents."
223638582|NCT03238378|RADIATION|Brachytherapy|Brachytherapy d 1-5(6)
223638583|NCT03238378|OTHER|Hyperthermia|Hyperthermia d 2 + 5
224226679|NCT03158259|OTHER|Prehospital diagnosis and treatment|The patient will be diagnosed and treated by anesthesiologist in the mobile stroke unit (MSU). The diagnosis will be NIHSS, CT scans by a CT-scanner fitted in the MSU, and blood-analysis in a mobile lab inside the MSU. All performed by a three-person crew consisting of an anesthesiologist, paramedic and nurse-paramedic. The CT images will be sent to the lokal hospital and contact with neurologist in ward established. A decision to treat will be given in collaboration between the neurologist and anesthesiologist.
224226680|NCT00543439|BIOLOGICAL|Moroctocog alfa (AF-CC)|On-demand therapy for 6 months, followed by routine prophylaxis 25 IU/kg, administered every other day for 1 year.
223638584|NCT06473740|DRUG|Deoxyribonucleic acid supercoiled plasmid pCMV-VEGF165 (Neovasculgen)|"The drug Neovasculgen is a highly purified supercoiled form of the pCMV-VEGF165 plasmid, encoding the Vascular endothelial growth factor (VEGF) under the control of a promoter (DNA control region). Recombinant plasmid DNA consists of the following components: a fragment of the regulatory region (22 nucleotide pairs), which determines the transcription of the gene, the VEGF minigene, upon expression of which the VEGF isoform is synthesized, consisting of 165 amino acids, a splicing signal, a polyadenylation signal and the SV40 transcription terminator, ensuring the synthesis of the mature RNA gene and auxiliary regions required for efficient biosynthesis of plasmid DNA in the cells of the producer strain of Escherichia coli. When molecules of this plasmid penetrate into mammalian cells, VEGF is produced, which stimulates endothelial cells, which leads to the growth of blood vessels (vascularization) in the area of injection."
223638585|NCT04885452|OTHER|biobank|"* Blood samples (biobank) at Day 0, Day 7, Month 1 and possibly Month 3 (only for the first 100 participants) (serum, plasma and whole blood)~* For participants in the immunological ancillary study: additional blood sampling at Day 0, Day 7 and Month 1 (PBMC)~* Nasopharyngeal swabs: Day 0, Day 7 (Day 14 and Day 21 if RT-PCR positive respectively at Day 7 and Day 14)~* Specific nasopharyngeal swabs in hospitalized patients: Day 3, Day 5"
223638586|NCT05318586|PROCEDURE|individual rTMS based on fNIRS|The rTMS parameters will be set according to fNIRS results.
223638587|NCT05318586|PROCEDURE|Traditional rTMS strategy|The low-frequency rTMS to contralesional M1 will always be used.
223638588|NCT02668653|DRUG|Chemotherapy|
223638589|NCT02668653|DRUG|Quizartinib|
223638590|NCT02668653|DRUG|Placebo|
223638591|NCT02294708|BEHAVIORAL|postoperative postures|two postoperative postures: supine and temporal-lateral
223638592|NCT06199843|DRUG|Rifaximin|Rifaximin 550 mg BD
223638593|NCT06199843|DRUG|Norfloxacin|Norfloxacin 400 mg OD
224226681|NCT00543439|BIOLOGICAL|Moroctocog alfa (AF-CC)|"Routine prophylaxis crossover:~45 IU/kg, administered 2 times a week for 1 year followed by 25 IU/kg administered every other day for 1 year, or, 25 IU/kg, administered every other day for 1 year, followed by 45 IU/kg, administered 2 times a week for 1 year."
224226682|NCT04905979|DRUG|AD113|Two oral capsules administered before bed
223638594|NCT05698485|OTHER|Cleansing Balm|DermResults Cleansing Balm w/ Avocado Oil twice daily
224226683|NCT04905979|DRUG|Atomoxetine|Two oral capsules administered before bed
224226684|NCT01211769|DRUG|Naltrexone|A pill of naltrexone chlorhydrate 50mg, associated to yellow liquid paraffin pills simulating borage seed and fish oil.
224226685|NCT01211769|DRUG|PUFAs|Borage Oil (Borago officinalis L. Boraginaceae) - rich in omega 6 PUFA, dosage of 1 gram and Fish oil 1 gram - rich in omega 3 PUFAs; associated to a pill with 50mg of talcum powder, identical to the pill of naltrexone.
224319108|NCT04622241|OTHER|Full House Screening|"Full house screening includes screening eaves/ceilings, ventilation openings, and windows. Eaves/ceiling, air vents, and windows of eligible houses will be screened with wire mesh or other locally available screening materials. or ceilings, if eaves are closed and ventilation openings. We are also filling in any gaps in the walls. All households will be provided with piperonyl butoxide (PBO) long-lasting insecticidal nets (LLINs) - one for every two residents."
224319109|NCT04622241|OTHER|Partial House Screening|Partial screening will include either screening of the eaves or installing a screened ceiling, where no ceiling is present. In traditional houses, a netting (either insecticide-impregnated or untreated) may be either fixed in multiple places in the rafters or by hanging from a single central point and attached to the walls. No other screening or filling of the gaps will be done in partially screened houses.All households will be provided with piperonyl butoxide (PBO) long-lasting insecticidal nets (LLINs) - one for every two residents.
223638595|NCT05698485|OTHER|Facial Serum|DermResults Advanced Serum w/ Hyaluronic Acid twice daily
223638596|NCT05698485|OTHER|Moisturizer|DermResults Advanced Moisturizer w/ Hyaluronic Acid twice daily
223638597|NCT02574117|PROCEDURE|flap with corticotomy and bone allograft|A maxillary expansion with quad helix appliance was placed on the posterior teeth with cross bite. A Luebke buccal flap was opened in the area of maxillary 1st premolar, 2nd premolar and first molar with a no. 15 scalpel. Corticotomy procedure was performed using low speed round bur size 3, holes to create a 0.5 mm deep hole penetrating the cortical bone. Multiple holes were performed leaving 1.5 mm distance in between. The defects were covered with demineralized freeze-dried bone allograft and the flap was sutured in its original position with 3-0 black silk suture.
223638598|NCT05362656|DEVICE|VX1+ dispersion mapping|Careful biatrial high density dispersion mapping is performed as the first step of the procedure. Operators map each region of both atria carefully by moving the mapping catheter slowly. If VX1+ application detects dispersion regions, the corresponding dipoles location will be automatically tagged on the 3D-map. Accuracy and relevance of dispersion regions should be confirmed by the operator by checking EGMs visually.
223638599|NCT02786017|BIOLOGICAL|Conventional therapy|Patients will receive the conventional therapy.
223638600|NCT02786017|BIOLOGICAL|Injectable Collagen Scaffold + HUC-MSCs|Injectable collagen scaffold combined with HUC-MSCs was injected into left lateral segment, left medial segment, right anterior segment, right posterior segment and caudate lobe under B-mode ultrasound supervision, respectively. The total amount of HUC-MSCs was 5\*10\^8.
223638601|NCT02046967|PROCEDURE|Endovenous laser ablation with 940 nm bare fiber|Endovenous laser ablation with 940 nm Diode laser using a bare fiber for treating the Great Saphenous Vein.
223638602|NCT02046967|PROCEDURE|Endovenous steam ablation with steam vein sclerosis system.|Endovenous steam ablation with steam vein sclerosis.
223638603|NCT00732056|DRUG|GRN163L|25% dose escalation infused over 2 hours weekly
223638604|NCT01088867|OTHER|Acupuncture|Electroacupuncture
223638605|NCT02405741|DEVICE|Hyperbaric chamber treatment|
223638606|NCT03377608|DRUG|Tenofovir Disoproxil Fumarate|Two cervical biopsies, blood plasma, PBMC, urine, and two cervicovaginal swabs will be collected at a single study visit
223638607|NCT03377608|DRUG|Depo-Provera|Two cervical biopsies, blood plasma, PBMC, urine, and two cervicovaginal swabs will be collected at a single study visit
224226686|NCT01211769|DRUG|Placebo|A pill with 50mg of talcum powder, identical to the pill of naltrexone; associated to PUFAs Placebo pills (yellow liquid paraffin identical to the pills of borage seed and fish oil).
223638608|NCT04907058|DEVICE|novel device with a comfortable mask|Using a device with a comfortable mask to supply constant low dose CO2 to treat patients.
223638609|NCT06286345|BEHAVIORAL|GLI-LEEF|"GLI-LEEF is an 18-week program, during which various lifestyle topics are discussed, such as nutrition, exercise, sleep, relationships and intimacy, and specific education about depression and its influence on lifestyle. GLI-LEEF is aimed at improving the activity level, quality of life and (cardiovascular) health of patients and thus increasing the general functioning and well-being of patients and at the same time reducing psychological complaints.~GLI-LEEF consists of 14 group meetings and 4 individual meetings, the group meetings last 90 minutes, the individual meetings 30 minutes. Patients are asked to wear a FitBit and to complete short homework assignments. Each group contains 8-10 patients. Patients are asked to find a buddy who can support them during the program."
223765072|NCT06924034|OTHER|Phase I and Phase II Cardiac Rehabilitation Program|The program consisted of two stages: an inpatient phase lasting until discharge, followed by an outpatient-supervised Phase II lasting eight weeks. In the intervention group, the participants in the inpatient phase received active-participatory lower extremity movements and progressive walking training (i.e., progressive walking in the room-corridor-hospital) to prepare them for discharge. The inpatient phase I was conducted with supervision following the American Heart Association recommendations. Participants in the intervention group were then administered phase II of the supervised CR program. Phase II CR was performed 3 non-consecutive days a week for 8 weeks as an aerobic exercise program.
224319110|NCT03888066|DRUG|Patiromer|The starting dose of patiromer will be 1 packet/day and may be taken either with food or without food. Based upon the patiromer treatment algorithm patiromer may be increased by 1 packet per day in intervals of at least 1 week (± 3 days). For subjects who become hypokalemic, patiromer may be decreased to a minimum of 0 packets/day. Doses of patiromer will be 0 packets/day, 1 packet/day, 2 packets/day, and 3 packets/day (maximum dose).
223765073|NCT06592820|DEVICE|Endoscopic Ultrasound Shear Wave Elastography (EUS) and Attenuation Imaging|EUS combines ultrasound technology with endoscopy to gain an internal vantage point to obtain higher resolution ultrasound images. Shear Wave is a software option on the ultrasound system EUS that provides an advanced measure and dynamic display of tissue stiffness which is being evaluated for use in assessing liver fibrosis. Attenuation Imaging (ATI) is a novel application that provides the capability to quantify and color-code the changes in attenuation coefficient of the liver that may arise with changes in liver composition (e.g., increased fat levels).
223765074|NCT06592820|DEVICE|FibroScan|A small ultrasound probe to measure the velocity of a sound wave passing through the liver. This is converted into kilopascals (kPa), which is used to assess liver fibrosis.
224226687|NCT01211769|DRUG|Naltrexone + Placebo|A pill of naltrexone chlorhydrate 50mg, associated to Borage Oil (Borago officinalis L. Boraginaceae) - rich in omega 6 PUFA, dosage of 1 gram and Fish oil 1 gram - rich in omega 3 PUFAs.
224226688|NCT01214330|DEVICE|Patient-Collected Cervical Pap Smear|Patient-Collected Cervical Papanicolaou Smear
224226689|NCT02689895|OTHER|modified directly administered anti-retroviral therapy (mDAART)|As described before
224226690|NCT02140489|DRUG|amosartan|
224226691|NCT02140489|DRUG|rosuvastatin|
224226692|NCT02140489|DRUG|amosartan and rosuvastatin|
224226693|NCT02419482|BEHAVIORAL|4x4 minutes high intensity interval training|Treadmill running/walking with 10 minutes varm-up at 60-70% of maximum heart rate, 4x4 minute intervals at 90-95% of maximum heart rate separated by 3-minutes active pauses at 60-70% of maximum heart rate, and 3 minutes cool-down.
224226694|NCT02419482|BEHAVIORAL|10x1 minute high intensity interval training|Treadmill running/walking with 10 minutes varm-up at 60-70% of maximum heart rate, ten 1-minute intervals at maximal intensity (that can be performed for one minute), separated by 1-minutes active pauses at 60-70% of maximum heart rate, and 3 minutes cool-down.
224226695|NCT04122222|BIOLOGICAL|Influenza vaccine|A single standard dose of inactivated trivalent influenza vaccine: Influvac® vaccines (Abbott, the Netherlands), intramuscularly.
224319111|NCT03888066|DRUG|Placebos|The starting dose of placebo will be 1 packet/day and may be taken either with food or without food. Based upon the placebo treatment algorithm placebo may be increased by 1 packet per day in intervals of at least 1 week (± 3 days). For subjects who become hypokalemic, placebo may be decreased to a minimum of 0 packets/day. Doses of placebo will be 0 packets/day, 1 packet/day, 2 packets/day, and 3 packets/day (maximum dose).
224319112|NCT06115525|OTHER|mNUTRIC score|The mNUTRIC score is a useful means of gauging the nutritional risk of patients in intensive care. Originally designed for IC unit patients, the score is calculated even when patient cooperation is unfeasible, making it applicable for intubated patients. Information necessary for calculation can be obtained from the patient's kin. The mNUTRIC score (without IL-6) classifies patients according to predefined metrics. The following information is necessary: (1) the patient's age, (2) their APACHE II score, (3) their SOFA score, (4) their comorbidities, and (5) the number of days they were hospitalized before being admitted to ICU.
224319113|NCT06115525|OTHER|NRS-2002|The NRS-2002 score is a tool utilised to measure the nutritional risk of patients in intensive care units. This tool was specifically developed for the purpose of evaluating intensive care unit patients and can be calculated without requiring the patient's active involvement. Additionally, it can be applied to patients who have been intubated and the required information can be sourced from their family members or relatives. The Nutritional Risk Screening (NRS)-2002 assesses a patient's nutritional risk based on five variables: (1) recent unexplained weight loss, (2) appetite, (3) BMI, (4) disease-related stress factors (comorbidities), and (5) age over 70 years which is an additional risk factor.
224226696|NCT00349063|DEVICE|soft contact lens|
224226697|NCT00349063|DRUG|Soft contact lens multipurpose disinfection regimen|
224226698|NCT06383559|DRUG|Lenvatinib and Sintilimab|XELOX regimen combined with Sintilimab and Lenvatinib
224226699|NCT05053893|DRUG|Roxadustat;Sacubitril Valsartan Sodium Tablets;|Select the appropriate dose according to the patient's situation
224226700|NCT05053893|DRUG|EPO; ACEI / ARB|Select the appropriate ACEI /ARB according to the subject's situation or follow its previous medication
224226701|NCT00841256|BIOLOGICAL|Grass pollen allergens in a water/glycerol solution|In total up to 4 drops (dose for maintenance therapy) are administered under the tongue.
224226702|NCT00841256|DRUG|Placebo|Placebo was given in the same way as the sublingual active treatment. Symptomatic standard treatment, i.e. antihistamines and glucocorticoids as well as alphamimetics is allowed during grass pollen season.
223638610|NCT01796808|PROCEDURE|Pedal Fat Grafting|"Fat grafting is a minimally invasive clinical procedure that has been widely used by plastic surgeons within reconstructive surgery for many years and is considered a standard of care procedure in plastic surgery. Fat tissue to be used for grafting is harvested (usually from abdomen or thighs) with a small liposuction cannula. The fat tissue is then sterilely centrifuged and allowed to decant before separating the fluid and oil layers from the fat tissue fraction. The aspirated fat is then loaded into 1cc syringes and injected into the plantar fat pad using specialized injection cannulas.~Postoperatively, the foot will be bandaged for twenty-four hours and the subject will be advised to limit ambulation. Over the next three weeks, the patient will be instructed to wear a cushioned, supportive sneaker and participate in only activities of normal daily living, with no excessive aerobic activity."
223765075|NCT06592820|DEVICE|Liver biopsy|"A biopsy of liver tissue could be obtained under endoscopic ultrasound guidance, interventional radiology (percutaneously), or surgically.~Endoscopic Ultrasound-guided liver biopsy provides high resolution images of left lobe of the liver and a good portion of the right lobe of the liver. This, coupled with Doppler capability, allows the physician to direct the biopsy needle safely into the liver for sampling under real time image guidance."
224226703|NCT05105711|BEHAVIORAL|QI coaching intervention|The intervention consists of two main components: a webinar communication workshop and use of the Checkup Coach mobile app. The Checkup Coach intervention begins with a brief (\<1 hour), communication training workshop that reviews evidence on HPV vaccination, models guideline-consistent recommendations, trains providers to address parent concerns, and facilitates discussion of shared goals for improving. Next, providers are invited to download and use the Checkup coach mobile app at their discretion for the 12-week study period. Providers complete in-app self-assessments and receive tailored feedback about their HPV vaccine recommendation quality, progress toward improving recommendation practices, a dashboard of aggregate HPV vaccination coverage for patients in their clinic, and tips for addressing parents' concerns about HPV vaccination every time they use the app.
224226704|NCT05350098|OTHER|Plant-protein Diets|Participants will consume meals with 70% plant-based protein three times a day. Participants will be prohibited to have meals other than experimental diets and to drink milk and soy milk.
224226705|NCT05350098|OTHER|Control Diets|Participants will consume meals with 50% plant-based protein three times a day. Participants will be prohibited to have meals other than experimental diets and to drink milk and soy milk.
224226706|NCT00496106|BEHAVIORAL|Telephone counseling|6 telephone counseling sessions
224226707|NCT00496106|BEHAVIORAL|Telephone interview|telephone interview
224226708|NCT01504828|DRUG|Ramipril|Ramipril in one dose to reduce vascular stiffness to determine effects of this on left ventricular function and energetics
224226709|NCT05664750|DRUG|TNM002|"Dosage Form: Injection, solution~Route of administration: IM gluteal injection"
224226710|NCT05664750|DRUG|Human tetanus immunoglobulin (HTIG)|"Dosage Form: Injection, solution~Route of administration: IM gluteal injection"
224226711|NCT01996176|BEHAVIORAL|Intervention group|"The intervention consists of four components, which as described below:~1. Information about sedentary behaviour and health: Delivered at the kick-off workshop, in a leaflet and the project website.~2. Local adaptation: Participants adapt the intervention to their personal and local environment setting individual and common goals. Local ambassadors are chosen and support from the management is emphasised.~3. Structural changes: Facilities for standing meetings, both formal and informal. Routes for walking meetings should be defined.~4. Individual support: At the kick-off workshop participants set individual goals. The individual can choose to receive e-mails and text messages (SMS)from the project. The individual receives a post-it block and a postcard to remind them of the project."
224226712|NCT01996176|BEHAVIORAL|Control group|The control group receives the intervention after the last follow-up, the exact time will be settled together with each workplace in the control group.
224226713|NCT04978285|OTHER|Anemia|Depends on Day 3 Hb result
224226714|NCT02659878|PROCEDURE|bleeding, intraventricular and/ or intracerebral hemorrhage.|Patient's age, sex, comorbidities, medications, the exact time point of bleeding, the circumstances of bleeding neurological and cardiological status are recorded, laboratory tests, Transcranial Color Doppler (TCCD), echocardiography and chest X-ray examinations are carried out within 24 hours after the patient is being admitted to the ICU.
224226715|NCT05727293|OTHER|noting|Non intervention
224226716|NCT04222322|DEVICE|Epitomee Capsule|Arm treatment: Epitomee Capsule combined with moderate intensity lifestyle counseling.
224226717|NCT04222322|OTHER|Control-Placebo|Arm treatment: Visually matching placebo capsule combined with moderate intensity lifestyle counseling.
224226718|NCT04639687|BEHAVIORAL|Food as Medicine Delivery|12 consecutive weeks of home-delivered vegetables plus whole grain foods along with weekly text containing educational video
224319114|NCT03278626|DRUG|Nivolimumab+Carboplatin/paclitaxel+Radiation|In the phase I portion of the study, up to six patients will be treated (radiation will be 50.4 Gy (1.8 Gy/fraction × 28 fractions)) and then observed for 28 days (following last day of treatment (Day 64)).
224319115|NCT02428439|DRUG|bupropion or lamotrigine|Participants who take the standardized pharmacotherapy (bupropion or lamotrigine) for depression will be observed for 8 weeks. Drugs using in this study are the standard treatment for depression, and are NOT administered as part of this study.
224319116|NCT01613768|DRUG|eribulin mesylate|Given IV
224226719|NCT00270699|BIOLOGICAL|rDEN4delta30-200,201|Live attenuated dengue 4 vaccine (one of three doses)
224226720|NCT00270699|BIOLOGICAL|Placebo|Placebo for rDEN4delta30-200,201
224226721|NCT01730859|OTHER|Balance exercise and ankle taping|"Balance Exercises: The first group performed balance exercise which last for six weeks, 3 times a week, and 40 minutes each session. Each session started by several minutes of slow walking and progressive stretching of ankle, knee and hip muscles which was gradually increased in time and repetition. After that, balance exercises were performed.~Ankle taping: In second group Ankle joint taping continued for 6 weeks and was renewed three times a week."
224226722|NCT01055444|DRUG|Heated lidocaine and tetracaine topical patch|Patients will be instructed to apply one heated lidocaine 70 mg and tetracaine 70 mg topical patch to the affected shoulder every 12 hours starting on the evening of Day 1 through the morning of Day 14 (morning and evening applications) and to remove the patch after 2-4 hours.
224226723|NCT01348542|DRUG|Trazodone|50 mg once a day, for 3 months
224319117|NCT00168935|DRUG|Fresubin protein energy Drink (CAVE! nutritional intervention)|
223638611|NCT01796808|OTHER|Local anesthetic|"To numb the foot for the fat grafting procedure, lidocaine with epinephrine will be used. This will be injected near the posterior tibial nerve to numb the bottom of the foot.~Local anesthetic of lidocaine with epinephrine will also be used to numb the fat graft harvest site (i.e. abdomen or thigh). This will allow a small incision to make so that tumescent solution can be injected into the area of fat graft harvest. Tumescent solution is a combination of injectible saline, epinephrine and lidocaine that causes numbness and vasoconstriction in the area where the fat will be harvested. This limits pain and bruising during the procedures. Only a very small amount of tumescent should be needed (i.e. \<200ml). Only a few cc's of fat are needed for injection into the foot."
223638612|NCT05893784|OTHER|Use of progressive relaxation exercises education|Progressive relaxation exercises education It starts with deep breathing exercises along with music. Then stretching and relaxation exercises are performed. After the education, an 8-minute video in which the progressive relaxation exercises was explained practically to the individuals was sent to their mobile phones. The participants were asked to perform these exercises regularly for 4 weeks, each day one hour before going to bed, simultaneously with the video.
223638613|NCT05686603|DEVICE|a fractional 1064-nm neodymium-doped yttrium aluminum garnet (Nd:YAG) picosecond laser with MLA handpiece|Picosecond laser is a novel technology characterized by ultra-short, picosecond pulse duration which can be effective for many skin conditions, such as pigmentation, photoaging and wrinkles reduction. When combined with micro-lens array (MLA) optics, high-intensity, micro-injury zones can be generated in the epidermis and dermis, causing optical breakdown of surrounding tissue and stimulating of dermal remodeling with mild side-effects. Previous studies had showed the picosecond lasers with MLA afforded better or similar clinical outcomes as well as fewer side-effects in treating acne scar than non-ablative lasers.
223638614|NCT05686603|DEVICE|a ablative fractional 2940-nm Er:YAG laser|2940-nm erbium yttrium aluminum garnet (Er:YAG) laser is one of the most commonly used treatments for atrophic acne scars, which can remove the damage tissue of the scars and allow collagen remodeling and re-epithelialization.
223638615|NCT03264326|OTHER|Blood Flow Restriction Training|Delfi Personalized Tourniquet System occludes 80% venous pressure during lower extremity exercise.
223638616|NCT03264326|OTHER|Sham Blood Flow Restriction Training|Delfi Personalized Tourniquet System occlude 20 mmHG venous pressure during lower extremity exercise as a sham treatment.
223638617|NCT03264326|OTHER|Eccentric Exercise|Subjects perform eccentric calf lowering off a step for 90 repetitions twice daily.
223638618|NCT02514135|OTHER|No intervention|
224226724|NCT01348542|BEHAVIORAL|Cognitive Behavioral Therapy|The CBT Protocol is implemented over a period of 12 weeks, with 4 consultations held on a weekly basis and 4 held on a biweekly basis.
224226725|NCT00038519|DRUG|Amprenavir/ritonavir|
224226726|NCT00038519|DRUG|Saquinavir/ritonavir|
224226727|NCT04164485|BIOLOGICAL|Functional collagen scaffold transplantation|Injectable collagen scaffold combined with autologous adipose-derived cells will be injected into submucosa of vocal cord and paraglottic space under the surgical microscope
224226728|NCT04164485|BIOLOGICAL|Autologous adipose cell transplantation|Autologous adipose-derived cells will be injected into the submucosa of vocal cord and paraglottic space under the surgical microscope
224226729|NCT03409679|DRUG|Murepavadin|Murepavadin IV every 8 hours + 1 anti-pseudomonal antibiotic (Piperacillin-tazobactam, ceftazidine, cefepime, meropenem, amikacin, ciprofoxacin, levofloxacin, colistin)
223638619|NCT00628420|DRUG|ACP-104|25mg, 75mg, 125mg, 175mg, 225mg, or 275mg once a day for 2 weeks
223638620|NCT00628420|DRUG|ACP-104|Patient will be given either 50mg, 100mg, 150mg, 200mg, 250mg, or 300mg daily for 2 weeks
223638621|NCT00628420|DRUG|Placebo|patients will be given a placebo: 25mg, 50mg, 75mg, 100mg, 125mg, 150mg, 175mg, 200mg, 225mg, 250mg, 275mg, or 300mg (to match the doses given) daily for 2 weeks.
223638622|NCT01294553|DRUG|Administration of rosiglitazone/metformin|Subjects who are administered rosiglitazone/metformin at least once
224226730|NCT03409679|DRUG|Two anti-pseudomonal antibiotics|Piperacillin-tazobactam, ceftazidine, cefepime, meropenem, amikacin, ciprofoxacin, levofloxacin, colistin
224226731|NCT04996810|BIOLOGICAL|PROTOXIN|Botulinum toxin Type A
224226732|NCT04996810|BIOLOGICAL|Botox®|Botulinum toxin Type A
224319118|NCT01860235|DRUG|EMLA|% eutectic mixture of 25mg/g lidocaine and 25 mg/g of prilocaine
224319119|NCT01860235|DRUG|Injectable anesthesia|Injectable anesthesia 2% lidocaine with epinephrine 1:100.000
224319120|NCT01860235|DRUG|2% Benzocaine|Topical anesthetic - 200mg/g of 2% benzocaine
223638623|NCT01217229|DRUG|PLX3397|Capsules administered once or twice daily, continuous dosing. Subjects will begin with 900 mg/day, but should safety data allow in our PLX108-01 study, subject may dose at 1200 mg/day.
223638624|NCT03800381|OTHER|Observational PK study|The study team will examine the PK and tolerability of the new HRZ 50/75/150 mg dispersible tablet in children with TB with and without HIV coinfection. Intensive PK testing will be performed after at least 4 weeks of treatment in children on first-line anti-TB therapy using the new pediatric HRZ FDC tablet.
223638625|NCT04142931|COMBINATION_PRODUCT|ImmunicomAIAC|filtration through the ImmunicomAIAC followed by Nivolumab Administrated IV starting C2.
223638626|NCT06038604|BEHAVIORAL|Psychosocial Support Intervention|Participants will receive six weekly 60-minute sessions conducted by videoconference.
224226733|NCT04866485|DRUG|HBM4003 and pembrolizumab|Subjects will be treated with HBM4003 and pembrolizumab on Day 1 during each 21-day cycles.
224226734|NCT00884130|PROCEDURE|laparoscopic colorectal resection|
224226735|NCT00884130|PROCEDURE|open colorectal resection|
224226736|NCT03402893|DRUG|ONEXTON Topical Gel|Onexton gel applied once daily to face
224226737|NCT03842371|OTHER|Metabolic level of BCAAs in monocytes and macrophages|Metabolic level of BCAAs in monocytes and macrophages
224226738|NCT00852085|BEHAVIORAL|Enhanced community service|Two educational sessions and volunteering at a local community service site
224226739|NCT00852085|BEHAVIORAL|Group MI|Four group counseling sessions and two directed observational visits to an emergency department
224226740|NCT00016055|BIOLOGICAL|lymphokine-activated killer cells|
224226741|NCT00016055|DRUG|temozolomide|
224226742|NCT00686036|DRUG|vandetanib|300 mg orally, once daily for up to 18 months
224226743|NCT00686036|DRUG|Placebo|
224319121|NCT01860235|DRUG|Placebo|Manipulated with the same appearance and viscosity of topical anesthetics mentioned above
223638627|NCT01437657|DRUG|Placebo|Matching RO4917523 placebo orally daily, 6 weeks
224226744|NCT00674180|BEHAVIORAL|Workbook|The workbook developed as a do-it-yourself program in which participants completed self-help sheets that guided them to sections of the workbook most salient to their needs.
224226745|NCT00674180|BEHAVIORAL|Computer Intervention|The computer intervention was provided using a network system that included a file server plus 5 multimedia computers with touch screens. The expert software program was written to guide participants in using the workbook and tail behavioral goals based on their prior computer use and the answers they provided on baseline questionnaires. The three primary paths in the computer addressed nutrition, fitness, and psychobehavioral content.
224226746|NCT00674180|BEHAVIORAL|Staff Consultation|The staff consultation component included 6 closed-group workshop sessions and up to 18 telephone or face-to-face consultations with a registered dietician and/or a cognitive behavioral therapist. The workshop curriculum focused on specific activities and assignments in the workbook, and it encouraged use of the computer to identify problems and issues.
224226747|NCT00294424|PROCEDURE|Short waiting time|
224226748|NCT00294424|PROCEDURE|Non-fixed waiting time|
224226749|NCT02972411|BEHAVIORAL|Voluntary ventilatory response|Training of the subjects for voluntary increase in the respiratory minute ventilation
224226750|NCT02972411|DRUG|Acetazolamide|Acetazolamide 125mg. PO every 12 hours since 24 hours before ascent, until 48 hours at high altitude
224226751|NCT04359992|OTHER|Extra blood sample|3 extra blood samples at day 0, 2 and 7
224226752|NCT00926289|DRUG|Telmisartan|Telmisartan 80mg
224226753|NCT00926289|DRUG|Telmisartan|Telmisartan 80mg
224226754|NCT00926289|DRUG|Hydrochlorothiazide|Hydrochlorothiazide25mg
224226755|NCT00981604|PROCEDURE|SILS|Single Incision Laparoscopic Cholecystectomy
224226756|NCT00981604|PROCEDURE|Standard Laparoscopic Cholecystectomy|4 port technique
224226757|NCT01555606|OTHER|No intervention|Patients will not be administered any treatment as part of the study and will receive usual care. Patients will be evaluated for PROs by obtaining narratives and photographs.
224226758|NCT01000857|DRUG|Paroxetine CR and Paroxetine IR|Randomized, 2-period crossover repeat dosing of Paroxetine CR at 25 mg/day for 14 days and Paroxetine IR at 20 mg/day for 14 days in Japanese healthy male volunteers
224226759|NCT02273674|DEVICE|Left rTMS 5 Hz|The subjects will receive transcranial magnetic stimulation (5 Hz of frequency over left dorsolateral prefrontal cortex . Once a day on monday to friday. Until receive 15 sessions. After this the subjects, will be received 8 more sessions of TMS, one session at week for next eight weeks
224226760|NCT02273674|DEVICE|Right r TMS 1 Hz|The subjects will receive transcranial magnetic stimulation (1 Hz of frequency over right dorsolateral prefrontal cortex . Once a day on monday to friday. Until receive 15 sessions. After this the subjects, will be received 8 more sessions of TMS, one session at week for next eight weeks
224226761|NCT00146770|BIOLOGICAL|Aldurazyme|Placebo for 26 weeks then 0.58 mg/kg Aldurazyme every week for 182 weeks
224226762|NCT00146770|BIOLOGICAL|Aldurazyme|0.58 mg/kg Aldurazyme every week for 208 weeks
224226763|NCT00146770|BIOLOGICAL|placebo|Placebo for 26 weeks
224226764|NCT01297257|DEVICE|Stent implantation|Single arm, open label stent implantation
224226765|NCT02478060|BIOLOGICAL|Birch-SPIRE|
224226766|NCT02478060|BIOLOGICAL|Placebo|
224226767|NCT04984850|OTHER|Oral chemotherapy information and support|Multimodal intervention : (1) handouts and videos presenting information and supportive resources for common oral chemotherapy related issues, (2) phone call(s) from a nurse in oncology, and (3) e-reminders to take medication. The intervention will be available to experimental group participants on mobile platform.
224319122|NCT03196063|OTHER|Eccentric|Exercises based on eccentric contractions of the quadriceps femoris muscle, using a 15º inclined plane. A serie of 15 repetitions of the squat will be performed, with the frequency of three times a week for eight weeks. The load of the exercises will be increased weekly.
224319123|NCT03196063|OTHER|Modified Protocol|Protocol based on the Heavy Slow resistance program, with the addition of an isometric phase at the beginning of the protocol, and with exercises using body weight without the use of mechanotherapy.
224319124|NCT01824381|PROCEDURE|Place amniotic membrane in large wounds|"After the process of obtaining the amniotic membrane, it must be processed, frozen and thawed.~The wound is washed with saline and, if necessary it will be debrided. We will take microbiological control cultures. Then apply the amniotic membrane fragments sufficient to cover the wound by contacting the basal membrane of the amniotic membrane with granulation tissue.~We will place a new membrane weekly to a maximum of 6 times."
224319125|NCT01824381|PROCEDURE|Obtaining and Cryopreservation of amniotic membrane|
223638628|NCT01437657|DRUG|RO4917523 0.5 mg|0.5 mg orally daily, 6 weeks
223638629|NCT01437657|DRUG|RO4917523 1.5 mg|1.5 mg orally daily, 6 weeks
223638630|NCT05716802|BEHAVIORAL|dance/movement therapy|dance/movement therapy plus treat as usual
223638631|NCT05716802|BEHAVIORAL|treatment as usual|The patients received regular daily antipsychotic medication and supportive psychotherapy once a week. They also participated in daily activities from Monday to Friday for at least two hours each day, including indoor activities (watching TV, playing games, playing poker) and outside activities (walking and doing radio gymnastics).
223638632|NCT03729739|DIAGNOSTIC_TEST|QFR-based diagnostic strategy|Novel computer based calculation of lesion severity. Pressure wire-free and adenosine-free
223638633|NCT03729739|DIAGNOSTIC_TEST|FFR-based diagnostic strategy|Standard FFR based diagnostic method. Pressure drop across the stenosis is measured with a pressure wire during medical induced hyperaemic conditions
224226768|NCT04319666|DEVICE|Left main stenting with intravascular lithotripsy|Intravascular lithotripsy (IVL) will be used to modify coronary artery calcification prior to stent implantation in left main coronary disease. Intravascular ultrasound (IVUS) will be used pre and post IVL and post stenting.
224226769|NCT01213719|DIETARY_SUPPLEMENT|creatine|20g/d throughout 10 days
224319126|NCT01824381|DRUG|amniotic membrane|
224226770|NCT01213719|DIETARY_SUPPLEMENT|betaine|2g/d throughout 10 days
224226771|NCT01213719|DIETARY_SUPPLEMENT|dextrose|dextrose (placebo), 20 g/d throughout 10 days
224226772|NCT01213719|DIETARY_SUPPLEMENT|creatine plus betaine|creatine (20g/d) plus betaine (2g/d) throughout 10 days
224226773|NCT02429700|DRUG|Paclitaxel|Patients receive paclitaxel 175mg/㎡ IV over 3 hours on day 1. Treatment repeats every 21 days for 4-6 courses in the absence of disease progression or unacceptable toxicity.
223638634|NCT05713656|OTHER|Physiotherapy care|Physiotherapy care including a bike fit, education and exercises provided by a physiotherapist with a BikePT bronze to gold certification.
223638635|NCT05542420|OTHER|No treatment given|The study will be based on data already recorded in the medical record
223638636|NCT00926237|DEVICE|Sham rTMS - Sham repetitive transcranial magnetic stimulation|Sham rTMS will be delivered using a commercially available sham coil and targeted to the same brain site in the temporal lobe and in a manner identical to that for active rTMS except that scalp electrodes are used to stimulate the temporalis muscle electrically during sham stimulation to replicate the feel of active TMS.
223638637|NCT00926237|DEVICE|Active 1 Hz rTMS - Active repetitive transcranial magnetic stimulation delivered at 1 Hz frequency|Active rTMS will be targeted either to the mid-superior temporal gyrus opposite the ear with loudest tinnitus or to the same region in the left hemisphere if no asymmetry in tinnitus is present. 1 Hz active rTMS will be delivered at 110% of motor threshold (MT) for a total of 1800 magnetic pulses per session, 4 sessions per week.
223638638|NCT00926237|DEVICE|Active 10 Hz rTMS - active repetitive transcranial magnetic stimulation delivered at 10 Hz frequency|Active rTMS will be targeted either to the mid-superior temporal gyrus opposite the ear with loudest tinnitus or to the same region in the left hemisphere if no asymmetry in tinnitus is present. 10 Hz active rTMS will be delivered at 110% of motor threshold (MT) for a total of 1800 magnetic pulses per session, 4 sessions per week.
223638639|NCT05220072|DRUG|Carbon-14 BIA 28-6156|Carbon-14 BIA 28-6156 60 mg, containing NMT 3.7 MBq Carbon-14
223638640|NCT00153244|DRUG|Lamotrigine|
224226774|NCT02429700|DRUG|Carboplatin|and carboplatin AUC 5-6 IV over 1 hour on day 1. Treatment repeats every 21 days for 4-6 courses in the absence of disease progression or unacceptable toxicity.
224226775|NCT02429700|DRUG|Bleomycin|Bleomycin 30000IU IM per day for 3 days every 3 weeks for 3-4 cycles.
224226776|NCT02429700|DRUG|Etoposide|Etoposide 100mg/㎡ IV per day for 5 days every 3 weeks for 3-4 cycles.
224226777|NCT02429700|DRUG|Cisplatin|Cisplatin 20mg/㎡ IV per day for 5 days every 3 weeks for 3-4 cycles in the absence of disease progression or unacceptable toxicity.
224226778|NCT01343628|DRUG|Placebo Comparator|16 NET SNP rs 11648486 CC and CT individuals will receive placebo and then after one week washout period, receive atomoxetine. Medications will be given as 2 capsules 1x day for 5 days; active atomoxetine groups will receive 40 mg for 3 days, followed by 80 or 120mg (.91-1.4 mg/kg) on days 4 and 5
224226779|NCT01343628|DRUG|Active Comparator: Atomoxetine, Placebo|16 NET SNP rs 11648486 CC and CT individuals will receive atomoxetine and then after one week washout period, receive placebo.Medications will be given as 2 capsules 1x day for 5 days; active atomoxetine groups will receive 40 mg for 3 days, followed by 80 or 120mg (.91-1.4 mg/kg) on days 4 and 5.
224226780|NCT00864942|DRUG|bendamustine and lenalidomide|Lenalidomide is given daily orally for one week followed by bendamustine HCL 90 mg/m2 IV over 30 to 60 minutes on days 1 and 2 in combination with lenalidomide, given orally, in dose-escalating cohorts. After a maximum of 6 cycles of combination therapy with bendamustine and lenalidomide, lenalidomide monotherapy is continued for an additional 6 cycles as tolerated or until disease progression.
223638641|NCT03800992|OTHER|assessment of perception and evaluation of physicians advisory skills per questionnaire|questionnaire according to SPIKES - a Six-Step Protocol for Delivering Bad News to be completed by parents and children (older than eleven)
223638642|NCT05525325|PROCEDURE|General Anesthesia|Patients randomized to the GA arm are intubated after anesthetic induction. For this purpose, they are pre-oxygenated with an oxygen mask and non-invasive monitoring is established. After sufficient pre-oxygenation has been applied, analgesic and sedative medication are administered. If the patient is sufficiently long nil by mouth they are manually ventilated before a muscle relaxant is administered. A rapid-sequence induction is performed with administration of an opioid, sedative and muscle relaxant in rapid succession and without intermediate manual ventilation in non-nil by mouth patients. To secure the airway, an endotracheal tube is inserted into the trachea with the aid of a laryngoscope. After insertion of the endotracheal tube, its endotracheal position is confirmed with auscultation and capnography. GA maintenance therapy with opioids, sedatives and catecholamines, if needed, will then be started.
223638643|NCT04796155|DIAGNOSTIC_TEST|Intrapartum ultrasound|Intrapartum ultrasound will be performed by suprapubic and transperineal approach for 30 seconds.
224226781|NCT00864942|DRUG|BL-NHL|Bendamustine HCL 90 mg/m2 given intravenously over 30 to 60 minutes on days 1 and 2 in combination with lenalidomide, given orally, in dose-escalating cohorts. After a maximum of 6 cycles of combination therapy with bendamustine and lenalidomide, lenalidomide monotherapy is continued for an additional 6 cycles as tolerated or until disease progression.
224226782|NCT00864942|DRUG|BLR-CLL|Lenalidomide is given orally for 7 days followed by rituximab 375 mg/m2 on day 1 in addition to bendamustine 90 mg/m2 intravenously over 30-60 minutes on days 1 and 2 and lenalidomide orally daily every 28 days for a total of 6 cycles. After 6 cycles of bendamustine, lenalidomide and rituximab, lenalidomide monotherapy is administered as continued therapy for an additional 6 cycles as tolerated or until disease progression.
223638644|NCT06333912|PROCEDURE|dental implant placement with ridge splitting.|ridge splitting to increase bone width in atrophic maxilla with simultaneous implant placement
223638645|NCT03239392|DRUG|BNZ132-1-40|Injectable PEGylated peptide antagonist that binds to the common gamma chain (γc) signaling receptor for the cytokines interleukin (IL)-2, IL-9, and IL-15
223638646|NCT01617824|DRUG|Linagliptin|Linagliptin 5 mg tablets for 4 days
223638647|NCT01617824|DRUG|Placebo|Placebo tablets for 4 days
223638648|NCT04278599|DRUG|Oral Zinc supplementation|In the test group, the patients will be administered Zinc Acetate tablets (equivalent to 30 mg of elemental zinc/day) for 6 weeks from the baseline. They will also be will be administered, topical corticosteroid paste- Triamcinolone acetonide- 0.1%, to be applied thrice a day till the lesions disappeared and the dosage will be tapered accordingly.The patients will be instructed to take the tablets and apply the paste after meals.The patients will be kept on a monthly follow-up for 3 months.
223765076|NCT06920147|DRUG|Ertapenem|Participants will receive a single dose of IV ertapenem (1g) in the operating room prior to incision or as soon as possible given the patient's hemodynamic status
223638649|NCT04278599|DRUG|Oral placebo supplementation|In the control group, the patients will be administered Placebo tablets for 6 weeks from the baseline. They will also be administered, topical corticosteroid paste- Triamcinolone acetonide- 0.1%, to be applied thrice a day till the lesions disappeared and the dosage will be tapered accordingly.The patients will be instructed to take the tablets and apply the paste after meals.The patients will be kept on a monthly follow-up for 3 months.
223638650|NCT05373459|BIOLOGICAL|Third COVID-19 booster|Third COVID-19 booster
223638651|NCT03658681|OTHER|Saturated fat 14.9 E%|Dietary cross-over study with saturated fat
223638652|NCT03658681|OTHER|Polyunsaturated fat 13.6 E%|Dietary cross-over study with polyunsaturated fat
223638653|NCT00577889|DRUG|gemcitabine hydrochloride|750 mg/m2 Given IV
223638654|NCT00577889|DRUG|tanespimycin|154 mg/m2 Given IV
224226783|NCT00864942|DRUG|BLR-NHL|Rituximab 375 mg/m2 is given on day 1 on day 1 in addition to bendamustine 90 mg/m2 intravenously over 30-60 minutes on days 1 and 2 and lenalidomide orally daily every 28 days for a total of 6 cycles. After 6 cycles of bendamustine, lenalidomide and rituximab, lenalidomide monotherapy is administered as continued therapy for an additional 6 cycles as tolerated or until disease progression.
224226784|NCT01070394|DRUG|LDX Treatment|30 mg, 50mg, or 70 mg. Oral capsule, once a day, for 12 weeks.
224226785|NCT01098240|DRUG|CP-601,927|CP-601,927 1-2 mg twice per day, oral 1 mg tablets, for 6 weeks.
224226786|NCT01098240|OTHER|Placebo|Matching placebo tablets, taken orally, twice per day, for 6 weeks.
224226787|NCT01623232|BIOLOGICAL|MAS-1 adjuvant and influenza HA antigen|"Vaccines will be administered IM in the deltoid muscle. HA antigen of each of three viral strains at doses of 1 micrograms, 3 micrograms, or 5 micrograms per viral strain adjuvanted with MAS-1 adjuvant and as nonadjuvanted standard dose TIV will be tested.~1. Treatment Group 1:each 0.3 mL dose will be administered as an emulsion containing 0.186 grams of MAS-1 oil vehicle and 1 micrograms HA of each of three viral strains in 0.08 mL sterile phosphate buffered saline (PBS).~2. Treatment Group 2:each 0.3 mL dose will be administered as an emulsion containing 0.186 grams of MAS-1 oil vehicle and 3 micrograms HA of each of three viral strains in 0.08 mL sterile PBS.~3. Treatment Group 3:each 0.3 mL dose will be administered as an emulsion containing 0.186 grams of MAS-1 oil vehicle and 5 micrograms HA of each of three viral strains in 0.08 mL sterile PBS."
224226788|NCT01623232|BIOLOGICAL|standard dose, inactivated trivalent influenza vaccine (TIV)|"Vaccine will be administered IM in the deltoid muscle. HA antigen of each of three viral strains as nonadjuvanted standard dose TIV will be tested.~4\. Treatment Group 4:0.5 mL dose of licensed, unadjuvanted, standard dose influenza virus vaccine with 15 micrograms HA of each of 3 viral strains."
224226789|NCT03280537|DRUG|Omalizumab|Participants received omalizumab as a subcutaneous injection once every 2 weeks (q2w) or once every 4 weeks (q4w). The dose (from 75 mg up to 600 mg) and dosing frequency (q2w or q4w) was determined by serum total IgE level and body weight using the study-drug dosing table.
224226790|NCT03280537|DRUG|Placebo|Participants received matching placebo as a subcutaneous injection once every 2 weeks or once every 4 weeks. The dose and dosing frequency was determined by serum total IgE level and body weight using the study-drug dosing table.
223638655|NCT03937934|BEHAVIORAL|Nutrition Education|Weekly box of healthy groceries and nutrition education including a recipe, food to make the recipe, extra fruit and vegetables.
223638656|NCT05607758|BEHAVIORAL|StressProffen©™|An app-based program for stress management consisting of 10 modules that teaches stress management, cognitive behavioral coping skills and relaxation training.
224226791|NCT04989062|DIAGNOSTIC_TEST|Fibroscan|Controlled attenuation parameter and liver stiffness measurement are measured.
223638657|NCT02261935|OTHER|Existing home care nursing practice|"Home care nurses in this comparator group will provide care as per usual to their patients and family caregivers. The family is seen as the unit of care but no formal assessment of the caregiver will be done."
223638658|NCT02261935|OTHER|Practice support tool intervention|"The intervention will be the routine use of the Carer Support Needs Assessment Tool (CSNAT) in the practice of home care nurses (once every 4 weeks with each family caregiver) to document, monitor and address family caregiver support needs.~The completed CSNAT tool will be kept in the patient chart and will be integrated into the care provided by the nurse.~Update - December 22, 2016 - In some offices only, the CSNAT will be administered by a separate study nurse. Findings will be communicated to the home care nurse to inform the documenting, monitoring and addressing of family caregiver support needs."
223638659|NCT05063799|OTHER|pulmonary rehabilitation|pulmonary rehabilitation programs
223638660|NCT06436131|BEHAVIORAL|In-phase Bilateral Exercise|"The exercise program of the experimental group consisted of exercises based on in-phase bilateral movements of the upper and lower limbs, which were adapted to different sport activities and to fitness functional exercises.~The participants of experimental group performed the specific type exercises three times per week, for 12 consecutive weeks."
223638661|NCT06436131|BEHAVIORAL|Conservative exercises|The participants of the active control group, underwent an exercise program based on conventional exercises, such as strengthening of the major muscle groups of the trunk, resistance exercises for the upper and lower limbs and body weight support treadmill exercise.
223638662|NCT03745534|OTHER|eABR|eABR
223638663|NCT02667119|BEHAVIORAL|Prolonged Exposure with Contingency Management|"Prolonged Exposure therapy for posttraumatic stress disorder includes psychoeducation, breathing retraining, in vivo exposure, and imaginal exposure.~Contingency Management for substance abuse disorders: participants will have the chance to win prizes for each negative urine drug screen/breathalyzer provided."
223638664|NCT02667119|BEHAVIORAL|Standard Care|Standard care will consist of treatment as usual in a community-based substance use treatment center.
224226792|NCT04989062|DIAGNOSTIC_TEST|Bioelectrical impedance analysis|Body composition measures including fat mass, fat-free mass, percentage body fat in total body and body segments are obtained.
224226793|NCT04989062|DIAGNOSTIC_TEST|Urine unclear magnetic resonance metabolomics|Metabolites in the urine are estimated by 600 MHz nuclear magnetic resonance.
224226794|NCT04989062|DIAGNOSTIC_TEST|Hand grip strength|Hand grip strength in both hands is measured by hand-held dynamometer.
224226795|NCT05181137|DRUG|SHR0302|Oral tablets taken once daily (QD)
224226796|NCT05181137|DRUG|Placebo|Oral tablets taken once daily (QD)
224226797|NCT06360731|OTHER|4-7-8 breathing exercise technique and informative session on tinnitus|Participants in experimental group will be individually provided with informative session on tinnitus for one hour by researchers. During the informative session, the participants will be given general information about tinnitus and will be informed about the possible causes, symptoms, diagnosis, therapy, or treatment processes, and coping methods. The participants will be also given a printed informative brochure on tinnitus. In the same session, after one hour of informative session, the 4-7-8 breathing exercise method will be demonstrated by the same researchers. In addition, a video showing how to perform the 4-7-8 breathing exercise technique will be sent as a text message to their cell phones.
224226798|NCT06360731|OTHER|Informative session on tinnitus|Participants in control group will be individually provided with informative session on tinnitus only for one hour by researchers G.K. and G.S.U. from both clinics. During the informative session, the participants will be given general information about tinnitus and inform about the possible causes, symptoms, diagnosis, therapy, or treatment processes, and coping methods. The participants will be also given a printed informative brochure on tinnitus.
224226799|NCT02281630|DRUG|KWA-0711|
224226800|NCT02281630|DRUG|Placebo|
224226801|NCT01860391|DEVICE|Diammine Silver Fluoride|Diammine SIlver Fluoride will be applied to teeth. The levels of silver and fluoride in saliva will be measure up to 7 days
224226802|NCT01880645|PROCEDURE|Fine Needle Aspiration (FNA)|If patient received chemotherapy before surgery, fine needle aspiration (FNA) performed of any abnormal lymph nodes either right before or during standard breast and underarm surgery. To perform FNA, area is numbed with anesthetic and a needle is inserted into the affected area so that cells can be collected.
224226803|NCT01880645|PROCEDURE|Ultrasound|Patient receives an ultrasound of lymph nodes at diagnosis and on the day of surgery. Marker clip(s) placed using a needle in the abnormal lymph node(s).
224226804|NCT01880645|PROCEDURE|Breast Surgery + Lymph Node Removal|Patient receives standard breast and underarm surgery (underarm lymph node removal and either a partial mastectomy or total mastectomy with or without reconstruction).
224226805|NCT02309632|OTHER|Pancreatic Cancer Screening Pathway 1|Screening with imaging and biomarker testing
224226806|NCT02309632|OTHER|Pancreatic Cancer Screening Pathway 2|Screening with biomarker testing only
224226807|NCT05765045|DIAGNOSTIC_TEST|Nursing triage protocol|Medically approved and supervised standing order that allows trained ER nurses to start medical imaging (RX) for adult patients with minor traumata to the limbs.
224226808|NCT03908112|BEHAVIORAL|Standard Community Concussion Care (SC)|temporary rest, gradual increase in activity, and return to school and sports. In some cases vestibular an balance therapy are necessary, aerobic exercises, medication, counseling.
224226809|NCT03908112|BEHAVIORAL|SC plus Simple Convergence Exercises (SC+)|In addition to standard community care in this intervention the participants must perform convergence therapy every day at home
224226810|NCT03908112|BEHAVIORAL|SC plus Office-based Vergence/Accommodative Therapy (SC+OBVAT)|In addition to standard community care in this intervention the participants must come to the office once a week for a 1-hour therapy session with a therapist. Office-based vergence/accommodative therapy is performed for 12 weeks with home reinforcement.
224226811|NCT04365283|PROCEDURE|New Bioactive Restorative Material (ACTIVA Presto)|New Bioactive Restorative Material
224226812|NCT04365283|OTHER|High Viscosity Glass Hybrid Reinforced Glass Ionomer (EQUIA Forte)|High Viscosity Glass Hybrid Reinforced Glass Ionomer
223638665|NCT01925456|DRUG|Toviaz|Means of effectiveness, adherence, and utility instruments over time will be examined to evaluate whether changes are linear from baseline to 8 weeks and 3 months. We will demonstrate the validity and responsiveness of pragmatic instruments against existing established measures (Table 3).
224226813|NCT01526915|PROCEDURE|Bone curettage + PRF|Bone curettage and PRF insertion
224226814|NCT01526915|PROCEDURE|Bone curettage alone|Bone curettage without PRF insertion
224226815|NCT03083132|DRUG|modafinil 50mg|1 capsule oral daily
224226816|NCT03083132|DRUG|Placebo oral capsule|1 capsule oral daily
224226817|NCT06541275|DIAGNOSTIC_TEST|brain MRI and CT|The diagnostic tests will be conducted at 6, 12, and 24 months of follow-up.
224226818|NCT00206206|PROCEDURE|Hyperglycemia Protocol Procedure|
224226819|NCT03118739|DRUG|Verinurad 9 mg+Febuxostat 80 mg|Capsule administered orally, once daily for 24 weeks
224226820|NCT03118739|DRUG|Placebo|Capsule administered orally, once daily for 24 weeks
224226821|NCT02938806|OTHER|No intervention|No intervention
224226822|NCT06338020|OTHER|Adaptive variable-resistance training|"The training was conducted thrice weekly for eight successive weeks under the close supervision of a licensed pediatric physical therapist in accordance with the safety performance guidelines defined by the American Academy of Pediatrics and the US National Strength and Conditioning Association.~The training protocol included maximum voluntary concentric knee flexor/extensor actions. Three sets of five to 10 repetitions of maximum-effort concentric action at angular speeds of 240, 180, and 120 degrees/second.~The training started with a 10-minute warm-up exercise and ended up with a 5-minute cool-down exercise."
224226823|NCT06338020|OTHER|Standard physical therapy|The program encompassed the standard exercises for survivors of ALL (flexibility, graduated active strengthening, and conditioning exercises). The training was conducted for 45 minutes, two times a week for six successive weeks.
224226824|NCT00893542|DRUG|Mycophenolate Mofetil|mycophenolate mofetil 250 mg capsule
224226825|NCT03764410|PROCEDURE|Non-surgical periodontal treatment|all the individuals included in the study received periodontal treatment with scaling and root planing with the use of local anesthesia and removal of factors that could cause biofilm retention such as fixed prosthesis, restorations, cervical abrasions. Four weekly sessions lasting 30 minutes each.
224226826|NCT04066179|DRUG|Gcsf|Granulocytes-Colony Stimulating Factor 300 mcg for 7 days followed by 300 mcg every 3 days
224226827|NCT04066179|DRUG|Prednisolone|Prednisolone 40 mg for initial 7 days
224226828|NCT03311009|DRUG|GLPG1972 cohort 1|GLPG1972 dose 1 provided as oral tablets q.d.
224226829|NCT03311009|DRUG|GLPG1972 cohort 2|GLPG1972 dose 2 provided as oral tablets q.d.
224226830|NCT03311009|DRUG|GLPG1972 cohort 3|GLPG1972 dose 3 provided as oral tablets q.d.
224226831|NCT03311009|DRUG|Placebo|Matching placebo provided as oral tablets q.d.
224226832|NCT00669955|DRUG|Omeprazole, amoxicillin, clarithromycin|Triple therapy given for 7 days at a dose of omeprazole 20 mg BID, amoxicillin 500 mg 2 capsules BID, and clarithromycin 500 mg 1 tablet BID
223638666|NCT04816110|BIOLOGICAL|mineralized plasmatic matrix with collagen membrane|"Two tubes of 9 ml of patient's venous blood were collected, the tubes were placed in the centrifuge machine at 2500 rpm for 12 minutes. The resultant product consists of the following two layers:~* A yellow plasma liquid on the top of the tube.~* Red blood cells at the bottom. - The yellow part was collected using a syringe and added to a cup that contains the bone grafting material (hydroxyapatite 20% + β-TCP 80%). The whole preparation was mixed for few seconds to obtain MPM.~After implant placement, the buccal bone defect was grafted with MPM and covered by collagen membrane"
223638667|NCT04816110|BIOLOGICAL|mineralized plasmatic matrix (MPM) without collagen membrane|"Two tubes of 9 ml of patient's venous blood were collected, the tubes were placed in the centrifuge machine at 2500 rpm for 12 minutes. The resultant product consists of the following two layers:~* A yellow plasma liquid on the top of the tube.~* Red blood cells at the bottom. - The yellow part was collected using a syringe and added to a cup that contains the bone grafting material (hydroxyapatite 20% + β-TCP 80%). The whole preparation was mixed for few seconds to obtain MPM.~After implant placement, the buccal bone defect was grafted with MPM."
223638668|NCT03994081|DEVICE|tACS|XCSITE100
223638669|NCT03994081|DEVICE|Sham tACS|XCSITE100
223638670|NCT06521749|DEVICE|USB as a stylet|USB used as a bougie
223638671|NCT06521749|DEVICE|USB as a bougie|USB used as a bougie
224226833|NCT00669955|DRUG|Pylera (Bismuth subcitrate potassium, metronidazole, tetracycline) given in combination with omeprazole|Pylera is a three in one capsule containing bismuth subcitrate potassium 120 mg, metronidazole 125 mg and tetracycline 125 mg given as 3 capsules QID, with omeprazole 20 mg BID.
224226834|NCT00367406|DEVICE|Gamma 3 nail versus ACE trochanteric nail|Comparing Gamma 3 nail versus ACE trochanteric nail
224226835|NCT01066481|DRUG|PF-01913539 5 mg|PF-01913539 5 mg three times daily for 6 months
223638672|NCT03783078|DRUG|Pembrolizumab (MK-3475)|200 mg (adult participants) or 2 mg/kg (up to 200 mg; pediatric participants) on Day 1 of each 3-week cycle (Q3W) IV up to 35 administrations (approximately 2 years).
223638673|NCT06122831|DRUG|TQ05105 Tablets|TQ05105 Tablets is a Janus kinase 1 (JAK1) and Janus kinase 2 (JAK2) Inhibitor.
223638674|NCT06122831|DRUG|TQB3617 Capsules|TQB3617 Capsules is a Bromodomain and Extra-Terminal (BET) Inhibitor
223638675|NCT04544813|DRUG|JNJ-77474462|Participants will receive JNJ-77474462 as a liquid formulation in Cohort A, B, C, D, F and G (SC injection) and in Cohort E, H and I (IV infusion).
223638676|NCT04544813|DRUG|Anakinra|Participants will receive a SC injection of anakinra 100 mg once daily for 3 days.
223638677|NCT02758210|DEVICE|Use of a Tablet|Testing of the electromagnetic field exposure and it's affect on the participant's previously implanted MICRA device is assessed by interrogation of the device before using Tablet and while using the Tablet. The measured position of the Tablets tested will be normal routine position (noting at least 6 inches/15 centimeters from their pacemaker).
223638678|NCT02758210|DEVICE|Use of a Smart Phone|Testing of the electromagnetic field exposure and it's affect on the participant's previously implanted MICRA device is assessed by interrogation of the device before using a Smart phone and while using the Smart phone. The position of the Smart phone tested will be normal position at the ear and while texting (noting at least 6 inches/15 centimeters from their pacemaker).
223638679|NCT04500912|DEVICE|Supraflex Cruz 60 Micron|percutaneous coronary intervention
223765077|NCT06920147|DRUG|Cefazolin and Metronidazole.|Participants will receive a single dose of a combination of IV cefazolin (re-dosed during the case every 4 hours and/or after every 1,500 mL of blood loss) and IV metronidazole (single dose 500 mg) in the operating room prior to incision or as soon as possible given the patient's hemodynamic status
224226836|NCT01066481|DRUG|PF-01913539 5 mg|PF-01913539 5 mg three times daily for 6 months
224226837|NCT01066481|DRUG|Placebo|Placebo three times daily for 6 months
224226838|NCT05480917|OTHER|Patients receiving PsoPlus care|As stated before, both outcomes (via VOS) and costs will be collected. Data on clinical outcomes, such as skin clearance, in the VOS will be collected during follow-up visits at our clinic. Outcomes which are assessed via a questionnaire will be collected using a specialized patient platform (PsoQuest). In addition, for this study the EuroQol 5 Dimensions 5 Level (EQ-5D-5L) questionnaire will need to be filled in. When consultations do not coincide with the time points, data will be collected by a study nurse on a study visit (at our department or the patient's home) and via PsoQuest. A 1 month period will be in place around the time point, meaning that the data can be collected 2 weeks beforehand or afterwards. Cost data will be collected using the TD-ABC approach over the full cycle of care.
224226839|NCT02022501|DRUG|DE-120|
224226840|NCT00003938|DRUG|liposomal amphotericin B|
224226841|NCT03591549|DRUG|Faslodex|intramuscular injection monthly
224226842|NCT03591549|DRUG|Zoladex|intramuscular injection monthly
224226843|NCT03061760|PROCEDURE|Radical prostatectomy|Radical prostatectomy due to prostate cancer.
224226844|NCT03061760|DIAGNOSTIC_TEST|Initial evaluation|Questioners, Ultrasound, Uroflowmetry
224319127|NCT05013008|DRUG|Finerenone (Kerendia, BAY94-8862)|Oral tablet; starting at 10 mg or 20 mg; once daily; received in previous interventional Phase 3 trial FIGARO-DKD; no new intervention was administered in this biomarker study.
223638680|NCT04500912|DEVICE|Ultimaster Tansei 80 Micron|percutaneous coronary intervention
223638681|NCT03571438|COMBINATION_PRODUCT|CK2 and ATM inhibitors serine/ threonin Kinase combination|Treatment of cell culture with CK2 and ATM inhibitors serine/ threonin Kinase combination
223638682|NCT03571438|DRUG|Sunitinib|Treatment of cell culture with Sunitinib
223638683|NCT03571438|DRUG|Pazopanib|Treatment of cell culture with Pazopanib
223638684|NCT03571438|DRUG|Temsirolimus|Treatment of cell culture with Temsirolimus
223638685|NCT05194254|OTHER|MRI-ET|coupled fMRI and Eye Tracking tools
223638686|NCT06226129|DRUG|Gadopiclenol|Gadopiclenol for contrast enhanced MRI
223638687|NCT02346123|GENETIC|Gathering of samples of genetic material|The samples will be obtained from peripheral blood mononuclear cells and the genotyping of the polymorphisms will be done by real time PCR.
223638688|NCT00685230|BIOLOGICAL|Antivenin Centruroides (scorpion) equine immune F(ab)2|3 vials of Alacramyn reconstitued in 50 ml of normal saline as a IV infusion over 10 minutes.
224226845|NCT03061760|DIAGNOSTIC_TEST|Evaluation after 1,3,6,9,12 months|Questioners, Ultrasound, Uroflowmetry
223638689|NCT00685230|OTHER|Placebo|Placebo reconstituted in 50 ml of normal saline administered over 10 min
223638690|NCT00700479|DRUG|aldosterone|4 hour infusion
223638691|NCT00700479|DIETARY_SUPPLEMENT|low or high sodium diet|
223638692|NCT00700479|DRUG|placebo|placebo
223638693|NCT02997215|DRUG|Lidocaine|lidocaine infusion during surgery
223638694|NCT02997215|DRUG|Saline Placebo|saline infusion at same rate as intervention group during surgery
223638695|NCT03785015|OTHER|Resume Aspirin within 12 hours|Resume the standard treatment within 12 hours after endoscopic haemostasis
223638696|NCT03785015|OTHER|Resume Aspirin 72 - 84 hours|Resume the standard treatment between 72 and 84 hours after endoscopic haemostasis
223638697|NCT02059278|DRUG|T-2345|T-2345 Ophthalmic Solution
223638698|NCT02059278|DRUG|Xalatan|Xalatan (latanoprost 0.005% ophthalmic solution)
223638699|NCT00061438|DRUG|meropenem|
223638700|NCT01723982|DRUG|Barusiban (FE 200440)|
223638701|NCT01723982|DRUG|Placebo Comparator|
224226846|NCT03323632|DEVICE|MyndMove|During a MyndMove therapy session, the patient is instructed to attempt to execute a task voluntarily. As the patient is attempting to perform the designated task, specific muscles in the arm are stimulated to generate contractions that produce the desired movement. After a brief interval of the patient attempting to initiate a movement the therapist activates the MyndMove stimulation protocol, which generates bursts of short electrical pulses, using surface electrodes, to produce muscle contractions enabling the patient to complete the desired/instructed task. Proper sequencing of the muscle contractions as per the MyndMove protocols are tailored to achieve a wide range of reaching and grasping functions. The technique stimulates non-damaged pathways of the central nervous system.
224226847|NCT04261296|OTHER|dry needling|In this treatment, depending on the thickness of the adipose tissue under the skin, 13 mm, 25 mm or 30 mm long; 0.20 mm thick acupuncture needle is used
223638702|NCT04834661|OTHER|surgery inside the primary institution|to perform laparoscopic surgery for colorectal and gastric cancer inside the primary registered medical institution
223638703|NCT04834661|OTHER|surgery outside the primary institution|to perform laparoscopic surgery for colorectal and gastric cancer outside the primary registered medical institution
223638704|NCT00446004|DRUG|Imatinib Mesylate|Dosage form: tablets Dosage: 400 mg Frequency \& duration: On an 18-day schedule, one dose administered once on day 1 and once on day 15 (2 doses total)
223638705|NCT00446004|DRUG|Omeprazole|Dosage form: capsules Dosage: 40 mg Frequency: On an 18-day schedule, once daily day 10 through day 16 (for Arm A); or once daily day -4 through day 1 (for Arm B)
223638706|NCT00541658|DRUG|risedronate|5 mg Immediate-release Risedronate Administered At Least 30 Minutes Before Breakfast Daily
223638707|NCT00541658|DRUG|risedronate|35 mg Delayed-release Risedronate Administered Immediately Following Breakfast Weekly
224226848|NCT04261296|OTHER|balneotherapy|"This treatment method; An alert-fit performed in a certain time interval and in a cure style by using the methods and doses of hot mineral waters, gases and peloids (sludge) from natural underground, determined in detail, repeatedly in series as bath, drinking and inhalation treatments. treatment can be defined as. There are studies showing that the effect of balneotherapy is mechanical, thermal, chemical, anti-inflammatory and immunological."
224226849|NCT04261296|OTHER|dry needling +balneotherapy|Both of these methods will be applied to patients in the third group.
224226850|NCT01170260|BEHAVIORAL|INFORMATION-ONLY SEXUAL RISK REDUCTION (INFO-ONLY)|Intervention includes presentation of STD facts, safe sex activities, condom demonstration, video about sexual decision making, group discussion
223638708|NCT00541658|DRUG|risedronate|35 mg Delayed-release Risedronate Administered At Least 30 Minutes Before Breakfast Weekly
223638709|NCT06274645|DEVICE|The OptiCross High Definition (60 MHz) and OptiCross (40MHz) Intravascular Ultrasound (IVUS) catheter from Boston Scientific|The IVUS-guided PCI procedure includes the use of IVUS before PCI (highly recommended) and after PCI (mandatory)
223638710|NCT04440033|OTHER|Baseline assessment of demographic, anthropometric and clinical characteristics|"* Age~* Sex~* Height~* Body weight~* Handedness~* Medication use~* Blood pressure~* Global cognition (Montreal Cognitive Assessment)~* Fear of falling (Shortened Iconographical Falls Efficacy Scale)~* History of falls (number of falls in the past month)~* Time since diagnosis and symptom onset~* Disease severity (UPDRS part III, Hoehn and Yahr)~* Non-motor symptoms (UPDRS part I)~* Motor symptoms (UPDRS part III)~* Motor complications (UPDRS part IV)~* Disease-dominant side (UPDRS part III)~* Freezing of gait (New Freezing of Gait Questionnaire)"
223638711|NCT04440033|OTHER|Baseline assessment of demographic, anthropometric and clinical characteristics|"* Age~* Sex~* Height~* Body weight~* Handedness~* Medication use~* Blood pressure~* Global cognition (Montreal Cognitive Assessment)~* Fear of falling (Shortened Iconographical Falls Efficacy Scale)~* History of falls (number of falls in the past month)"
223638712|NCT04440033|OTHER|Locomotor assessments|"First, 9 anthropometric measurements will be taken, 39 reflective markers will be placed, and a 6-min practice walking session will be conducted to familiarize participants with self-paced treadmill walking (SPTW). Thereafter, participants will partake in 7 experimental conditions in a (semi-)randomized order:~* 3 min standing~* 3 min standing while answering semi-standardized questions~* 3 min SPTW~* 3 min SPTW while answering semi-standardized questions (SPTW-Q)~* 3 min SPTW while verbally describing a VR environment (SPTW-VR1)~* 6 min SPTW in a VR environment containing freezing of gait provoking elements (SPTW-VR2)"
223638713|NCT04440033|OTHER|Speech assessments|"* Acoustic analysis (including voice reports and formant analysis), video recording and motor speech profile (including analysis of diadochokinesis, voice, standard syllabic rate, intonation and second formant (F2)).~* Spontaneous speech production will be assessed by answering semi-standardized questions based on the Aachen Aphasia Test and by describing a VR environment projected on a 180-degree cylindrical screen~* The Speech Handicap Index (a 15-item self-reported questionnaire)"
223638714|NCT04440033|OTHER|Audiology assessments|"* Otoscopy~* Tympanometry~* Pure tone audiometry~* Otoacoustic emissions~* Video Head Impuls Test~* Cervical Vestibular Evoked Myogenic Potentials~* Ocular Vestibular Evoked Myogenic Potentials~* Oculomotor function testing~* Positional testing~* Static visual acuity test~* Dynamic visual acuity test~* Dizziness Handicap Inventory (a 25-item self-assessment inventory)"
223638715|NCT05196152|BEHAVIORAL|MomMoodBooster|MomMoodBooster is an empirically validated online intervention for perinatal women.
223638716|NCT05196152|BEHAVIORAL|Phone Coaching|Phone coaching calls occur weekly in conjunction with MomMoodBooster online modules.
224226851|NCT01170260|BEHAVIORAL|SEXUAL PLUS ALCOHOL RISK REDUCTION (SRRI+ETOH)|Intervention includes presentation of STD/alcohol facts, safe sex activities, condom demonstration, video about alcohol/sexual decision making, group discussion
223765078|NCT07005141|DEVICE|Endovascular Iliac Branch Stent-Graft Implantation|Implantation of a self-expanding dual-lumen iliac branch stent-graft designed to treat iliac artery aneurysms while preserving perfusion to the internal iliac artery. The device enables connection to bridging stent-grafts directed to both the internal and external iliac arteries. It is compatible with previously implanted or concurrently implanted bifurcated aortic stent-grafts with branch diameters between 14 and 16 mm. The stent-graft is delivered endovascularly using a low-profile catheter-based system under fluoroscopic guidance. Once in position, the device is deployed via a controlled pull-back release mechanism. Radiopaque markers assist in precise alignment and facilitate the placement of bridging components.
224226852|NCT01170260|BEHAVIORAL|SEXUAL + ALCOHOL + MARIJUANA RISK REDUCTION|Intervention includes presentation of STD/alcohol/marijuana facts, safe sex activities, condom demonstration, video about alcohol/marijuana/sexual decision making, group discussion
224226853|NCT05919459|BEHAVIORAL|5-week online synchronous ACT intervention|Parents will meet a trained ACT counsellor to undergo five weekly sessions of ACT group training via Zoom. Specifically, each 120-minute synchronous videoconferencing session will involve the ACT counsellor and 6-8 parents.
224226854|NCT05919459|BEHAVIORAL|asynchronous online AIS education|A healthcare educator with a background in nursing, physiotherapy, or occupational therapy will meet with parents in five weekly 120-minute interactive AIS-related education videoconferencing via Zoom. Specifically, each 120-minute synchronous videoconferencing session will involve the ACT counsellor and 6-8 parents.
224226855|NCT03507439|DEVICE|AVIVO Mobile Patient Management (MPM) System|Wearable, wireless physiological monitoring and arrhythmia detection system, used by participants for 5 monitoring periods of 5 days each in the study
224226856|NCT03507439|DEVICE|VitalPatch biosensor|Wearable, wireless physiological monitoring and arrhythmia detection system, used by participants for 5 monitoring periods of 5 days each in the study
224226857|NCT03507439|DEVICE|DynaPort Move Monitor|Wearable device for ambulatory monitoring of physical activity, used by participants for 2 monitoring periods of 7 days each in the study
224226858|NCT04274192|OTHER|Synchronized HFNC at 6 liters per minute (LPM)|HFNC given in synchrony with the subject's own respiratory effort using NAVA at 6 LPM
224226859|NCT04274192|OTHER|Continuous HFNC at 6 liters per minute (LPM)|Standard HFNC therapy at 6 LPM
224226860|NCT04274192|OTHER|Synchronized HFNC at 8 liters per minute (LPM)|HFNC given in synchrony with the subject's own respiratory effort using NAVA at 8 LPM
224226861|NCT04274192|OTHER|Continuous HFNC at 8 liters per minute (LPM)|Standard HFNC therapy at 8 LPM
224226862|NCT05216614|DRUG|Fluvoxamine|Fluvoxamine is an SSRI used for depression and anxiety disorders. This study will investigate the efficacy of fluvoxamine for improvement of olfactory dysfunction in subjects with post-Covid-19 parosmia.
224226863|NCT05216614|DRUG|Placebo|lactose placebo capsules identical to fluvoxamine capsules in order to preserve blind
224226864|NCT06320379|DIETARY_SUPPLEMENT|Zypan|The study product is a dietary supplement manufactured by Standard Process Inc (i.e., Zypan®). One serving (i.e., two tablets) contains a proprietary blend (595 mg) of the following: Betaine hydrochloride, bovine pancreas Cytosol™ extract, pepsin (1:10,000), pancreatin (3x), stearic acid (vegetable source), ammonium chloride, bovine spleen, and ovine spleen. Non active ingredients will include cellulose and calcium stearate. Participants will be instructed to take two tablets three times daily with meals
224226865|NCT06320379|DIETARY_SUPPLEMENT|Placebo Comparator|The control supplement will not contain any of the active ingredients in Zypan® and will also be manufactured by Standard Process Inc. Two tablets will contain 435 mg of cellulose (42%), 288 mg rice bran powder (28%), 201 mg of calcium lactate powder (19.5%\*), 103 mg citric acid (10%), and 2.6 mg calcium stearate (0.25%)
224226866|NCT00855452|PROCEDURE|one - three cycles of cell therapy during 4-6 weeks (3-5x10^7 cells/kg will be given through IV systemically|Patients will be eligible to participate in a treatment program based on systemic administration of mismatched lymphocytes activated in vitro with rIL-2(LAK) followed by rIL-2 inoculation in vivo
224226867|NCT03957733|DRUG|Chemotherapy|Long course CRT is followed by 4 cycles of combination chemotherapy of modified FOLFOX6 or 3 cycles of XELOX (capecitabine and oxaliplatin) and then surgery
224226868|NCT04336956|OTHER|hospitalized children with Covid19|All patients under 18 years hospitalized with a covid19 diagnosis
224226869|NCT03588156|DRUG|Benapenem|Dose-escalation For 11 level dose groups A1 \~ A11(each 62.5mg/kg, 125mg/kg, 250mg/kg, 500mg/kg, 1000mg/kg 60min infusion, 1000mg/kg 30min infusion, 2000mg/kg 60 min infusion, 2000mg/kg 30min infusion, 3000mg/kg, 4000mg/kg), 10 subjects (8 for the study drug and 2 for placebo) are randomized to each dose group
224226870|NCT03588156|DRUG|Placebo|Placebo
224226871|NCT00955032|DEVICE|High-Frequency Repetitive Transcranial Magnetic Stimulation|In patients randomized to receive left prefrontal rTMS, each treatment will consist of 2000 stimuli (50 - 8-second trains of 40 stimuli at 5 Hz). We will administer rTMS trains every 30 seconds for 25 minutes. Stimulus intensity for the first and second trains will be 80 and 90% of MEP threshold, respectively.
223515649|NCT06673537|OTHER|Sham Spinal Manipulation|Sham spinal manipulation was administered by an experienced physiotherapist to the Sham Manipulation group three times a week following Connective Tissue Massage (CTM). In this group, participants were positioned laterally with their lower legs straight and in contact with the treatment table. The contralateral or upper hip and knee were flexed and positioned so that they did not touch the table, thereby allowing an unopposed force to be applied at the selected joint. Following CTM, low-amplitude force was applied bilaterally to all clinically relevant vertebral levels from T10 to L5 and the sacroiliac joints, without creating an audible sound.
224319128|NCT05013008|DRUG|Placebo|Oral tablet; starting at 10 mg or 20 mg; once daily; received in previous interventional Phase 3 trial FIGARO-DKD; no new intervention was administered in this biomarker study.
223515650|NCT05787119|OTHER|Conventional therapy|The CT consists of 1 session of 30 minutes of physical therapy (type of re-education established according to the pain at rest and during movement assessed every day) and 1 session of 30 minutes of occupational therapy (type of re-education established according to the pain at rest and during movement assessed every day). CT is performed 5 days a week.
223765079|NCT07007234|BEHAVIORAL|Physical activity intervention|The INTERVENTION group will participate in a 4-month goal-setting intervention aimed to replace mentally passive sedentary behaviors with mentally active sedentary behaviors, light physical activity, or moderate-to-vigorous activity.
224226872|NCT00955032|DEVICE|Sham Repetitive Transcranial Magnetic Stimulation|Patients randomized to receive sham rTMS will undergo the same procedure for identifying stimulus location used in patients receiving real rTMS. Simulated rTMS will be administered using Magstim Placebo 70 mm figure-of-8 shaped coils which produce discharge noise and vibration similar to a real 70 mm coil without stimulating the cerebral cortex. However, in addition to obvious coil discharge noise, rTMS also causes electrical stimulation of the scalp. We will simulate this experience by attaching surface electrodes underneath the sham coil and in contact with the scalp.
224226873|NCT04527471|DRUG|Ensifentrine Dose 1|Study drug delivered twice daily via pMDI
224226874|NCT04527471|DRUG|Placebo pMDI|Placebo delivered twice daily via pMDI
224226875|NCT05875415|OTHER|Bilateral dry needling in latent trigger points of the Flexor digitorum Brevis Muscle|Bilateral dry needling in latent trigger points of the Flexor digitorum Brevis Muscle in flatfoot
224226876|NCT05875415|OTHER|Bilateral non emission Laser in latent trigger points of the Flexor digitorum Brevis Muscle|Bilateral non emission Laser in latent trigger points of the Flexor digitorum Brevis Muscle in flatfoot
224226877|NCT03244956|DRUG|Trametinib|2mg daily for a maximum of 6 weeks of treatment
224226878|NCT03244956|DRUG|Dabrafenib|150mg twice daily
224226879|NCT03244956|RADIATION|131I|5.5 GBq
224226880|NCT03244956|DRUG|rhTSH|0.9mg on two consecutive days after 35 days of treatment
224226881|NCT05432271|BEHAVIORAL|Exposure to calorie information|Calories for all beverages and foods
224226882|NCT05432271|BEHAVIORAL|Exposure to healthy labels only|Green labels only for beverages and foods scored as healthy
224226883|NCT05432271|BEHAVIORAL|Exposure to healthiness information|All beverages and foods labeled as either healthy (green), moderately healthy (yellow), or less healthy (red)
224226884|NCT05432271|BEHAVIORAL|Exposure to physical activity equivalents|All beverages and foods labeled with physical activity required to burn their calories
223515651|NCT05787119|OTHER|ARMT|The ARMT consists of 1 session of 30 minutes (type of rehabilitation established according to the pain at rest and during movement evaluated daily). ARMT is performed 5 days a week for 1 month.
223515652|NCT05787119|OTHER|cortical reactivity|An electroencephalogram was taken at the start and end of the study to study cortical reactivity during the performance of 3 different tasks repeated 30 times: a resting task (consisting of looking at a cross on a screen), a motor imagery task (consisting of imagining performing wrist flexions/extensions) and a motor execution task (consisting of performing wrist flexions/extensions).
223515653|NCT05787119|OTHER|Fluidity of movement|Motion capture at the start and end of the study to study the fluidity of movement during 3 different tasks repeated 30 times: a resting task (looking at a cross on a screen), a motor imagery task (imagining wrist flexions/extensions) and a motor execution task (performing wrist flexions/extensions).
223515654|NCT06689579|DEVICE|Unipolar hemiarthroplasty|
223515655|NCT06689579|DEVICE|Bipolar hemiarthroplasty|
223515656|NCT06688552|OTHER|Proprioception Measurements|Laser cursor-assisted angle repetition test was used for proprioception assessment. A coordinate plane with different movement angles was fixed on a wall and the person was positioned 1 meter from this wall. The laser pointer was fixed on the person's arm for shoulder proprioception measurement, 5 cm above the elbow to avoid being affected by other joints, 5 cm above the person's wrist for elbow joint proprioception and fixed on the person's second metatarsal bone for wrist proprioception.
223515657|NCT06688552|OTHER|Fatigue Measurement|Myoton PRO® (Myoton AS, Tallinn, Estonia) muscle palpation device was used to assess fatigue, and the dynamic stiffness parameter was taken as the basis. The stiffness value is calculated as the maximum acceleration (N/m) of oscillation and deformation in the tissue sensed by the transducer (Chen et al., 2017). The increase in muscle dynamic stiffness has been associated with fatigue level (Klich et al., 2019; Shitova et al., 2020; Wang, 2017). Before the measurement, the athletes' pectoralis major, deltoideus and triceps brachii muscle reference points were determined and marked, and measurements were taken over these points. The athletes were asked to keep their muscles relaxed throughout the measurement in order not to affect the tissue stiffness and the application was performed at room temperature.
223515658|NCT05414747|DEVICE|ABV-1701|ABV-1701 is an injectable, in-situ-forming hydrogel, composed of oxidized hyaluronic acid (oxi-HA) and adipic acid dihydrazide (ADH)
223515659|NCT05414747|DEVICE|SF6 Gas|SF6 is a commercial gas tamponade as a vitreous substitute in pars-plana vitrectomy surgery (PPV)
223515660|NCT02516111|PROCEDURE|Open flap debridement (OFD)|Oral prophylaxis followed by Open flap debridement (OFD)
223515661|NCT02516111|BIOLOGICAL|OFD with PRF|Oral prophylaxis followed by Open flap debridement (OFD) with Platelet rich fibrin (PRF) placement into the bone defect
223515662|NCT02516111|DRUG|OFD with ALN|Oral prophylaxis followed by Open flap debridement (OFD) with 1% ALN gel placement into the bone defect
223515663|NCT02516111|DRUG|OFD with ATV|Oral prophylaxis followed by Open flap debridement (OFD) with 1.2% ATV gel placement into the bone defect
223515664|NCT02499536|DEVICE|ultrasound|Juxtapleural consolidation, loss of A lines, presence of B lines, air bronchogram, loss of sliding sign and presence of pulse sign on lung ultrasound finding will be investigated and recorded.
223515665|NCT06679504|PROCEDURE|Fibrin glue fixation|Laparoscopic Totally Extraperitoneal Inguinal Hernia Repair With Fibrin Glue fixation
223515666|NCT06679504|PROCEDURE|Tack fixation|Laparoscopic Totally Extraperitoneal Inguinal Hernia Repair With Tack Mesh Fixation
224226885|NCT05432271|BEHAVIORAL|"Exposure to high in nutrient warning labels"|Warning labels only for beverages and foods that exceed the thresholds for sugar, sodium, saturated fat, or calorie content
224226886|NCT05313828|DRUG|Acyclovir|acyclovir 4 times /day
224226887|NCT05313828|DRUG|Tobramycin|tobramycin 4 times /day
224226888|NCT05313828|DRUG|Fluorometholone|Fluorometholone 4 times/ day
224226889|NCT05313828|DRUG|Sodium Hyaluronate|Sodium Hyaluronate 4 times/day
224226890|NCT05147454|OTHER|Quantitative Sensory Testing|Non-invasive assessment of Sensory Profile
224226891|NCT02721797|PROCEDURE|Orthopaedic & Gynaecology surgery|Patients will have the surgery they require for their treatment. During surgery, debrided tissues will be retained for research. No treatment plans will be altered for this research.
224226892|NCT03158298|OTHER|Specimen collection|Maternal blood sample of 10 ml collected by venepuncture upon delivery
224226893|NCT05720871|DEVICE|rTMS + capsaicin 150μM (natural TRPV1 agonist)|"Repetitive transcranial magnetic stimulation (non-invasive brain stimulation) + Capsaicin.~5 consecutive days of active treatment consists of swallowing 10mL capsaicin (150μM) and, just after, of applying focal (alpha D70 coil) rTMS (Magstim Rapid2, UK) over the pharyngeal M1 hotspot of the unaffected hemisphere. A total of 500 pulses/session are delivered consisting of 10 5Hz-trains of 10s of 50 pulses each (total 2500 pulses), with a 1min interval between trains at an intensity of 90% of the resting motor threshold (RMT).~The intervention has its respective sham rTMS+placebo group that is also applied over 5 consecutive days."
224226894|NCT05720871|DEVICE|tDCS + capsaicin 150μM (natural TRPV1 agonist)|"Transcranial direct current stimulation (non-invasive brain stimulation) + Capsaicin.~Treatment consists of swallowing 10mL capsaicin (150μM) and, just after, of applying 30min of 2.0mA tDCS (DC-Stimulator Plus, NeuroConn, Germany) with the anode placed over the pharyngeal primary motor cortex (M1) of the unaffected hemisphere (3.5cm lateral / 1cm anterior to the vertex) and the cathode over the opposite supraorbital region.~The intervention has its respective sham tDCS+placebo group that is also applied over 5 consecutive days."
224226895|NCT01753037|DIETARY_SUPPLEMENT|Dehydroepiandrosterone (DHEA)|DHEA 130 mg administered orally for 5 days.
224226896|NCT01753037|OTHER|Placebo|Placebo contained in a capsule that is identical in appearance to the one used to package DHEA for 5 days.
224226897|NCT06135285|DEVICE|Control subjects|The subject will be repositioned from the prone to recovery position
224226898|NCT03215173|BEHAVIORAL|Fit After Baby|Mobile application
224226899|NCT03215173|BEHAVIORAL|Text4Baby Control Group|Receive free text messages
224226900|NCT04251182|DRUG|15mg T3D-959|Oral administration once daily in the morning
224226901|NCT04251182|DRUG|30 mg T3D-959|Oral administration once daily in the morning
224226902|NCT04251182|DRUG|45 mg T3D-959|Oral administration once daily in the morning
224226903|NCT04251182|DRUG|Placebos|Oral administration once daily in the morning
224226904|NCT01466803|DRUG|Placebo|The subjects will be given placebo twice a day for 5 days prior to the study
224226905|NCT01466803|DRUG|Vorikonazole|The subject will be given vorikonazole twice a day for 5 days prior to the study. The dose will be 400 mg twice a day on day one ans 200 mg twice a day on days 2-5.
224226906|NCT02450565|OTHER|Questionnaire|
224226907|NCT00624767|DRUG|Insulin (recombinant human insulin)|Insulin Nasal Spray at doses up to 200 IU.
224226908|NCT00624767|DRUG|NovoLog|NovoLog at doses up to 30 IU
224226909|NCT03020472|BIOLOGICAL|2008-2009 FluMist LAIV (Intranasal)|2008-2009 FluMist vaccine delivered intranasally
224319129|NCT01094015|DRUG|lidocaine-prilocaine cream|Implementation of 3 cm of lidocaine-prilocaine in the endocervical canal, 10 minutes before the intervention with a syringe without needle 5ml. Application, with a swab of the anesthetic cream ectocervix level.
223515667|NCT06543758|DEVICE|Wearable exoskeletal robot|Participants will wear a wearable exoskeletal robot for gait training and undergo 10 sessions of 30-minute gait training over 4 weeks at home or in nearby indoor spaces. Participants will participate in physical function assessments, including the 10-meter walk test, Timed Up and Go (TUG) test, and Berg Balance Scale, both before and after the intervention. Additionally, participants will complete quality of life and depression inventories before and after the intervention.
223515668|NCT06675006|COMBINATION_PRODUCT|Medical Massage|This intervention refers to the application of therapeutic massage techniques aimed at alleviating pain and enhancing muscle relaxation in patients with nonspecific low back pain. The treatment focuses on manipulating soft tissues, including muscles, tendons, and fascia, to improve circulation, reduce muscle tension, and promote overall wellness. Medical massage is tailored to each patient's specific needs and can incorporate various techniques, including Swedish massage, Bowen Therapy, a gentle and non-invasive manual therapy, utilizes precise movements on specific points of the body to promote healing and restore balance. The therapist applies light pressure with the fingers, allowing the body to respond and relax. This technique aims to stimulate the body's innate healing mechanisms, encouraging improvements in pain levels and functional capacity. Sessions are typically structured to allow for periods of rest, giving the body time to process the treatment and enhancing its effects.
223515669|NCT03810495|DRUG|naltrexone implant|1.8 g implant containing 60% naltrexone
223515670|NCT03289741|DRUG|Octreotide|Patients will receive three monthly injections every 28 (+/- 3) days. Octreotide LAR for 3 injections followed by lanreotide for 3 injections
223515671|NCT03289741|DRUG|LAR Lanreotide|Patients will receive three monthly injections every 28 (+/- 3) days. Lanreotide for 3 injections followed by octreotide LAR for 3 injections
223515672|NCT03289741|BEHAVIORAL|Questionnaires|Baseline questionnaire, Post-treatment questionnaire (after the first 3 injections), Preference questionnaire and Pain Score Diary.
223515673|NCT06674369|DEVICE|Peli prism for hemianopia|Peli prism uses high-powered prisms (40 Dioptre) that expand a hemianopic patient's awareness of their blind side. This awareness enables patients to better detect obstacles and navigate around them. Effect of the prism considered as temporary We investigated whether the effect persists after the prism is removed.To understand the persistence of the effect, we examined the changes in the visual field with CVF (Computerized visual field examination)before the prism was applied, with the prism and 1 week after the prism was removed.
223515674|NCT06675305|DIETARY_SUPPLEMENT|Beetroot juice (James White, UK)|One serving 140 mL of BJ (12.8 mmol of NO3-; Beet-It-Pro Elite Shot, James White Drinks Ltd., Ipswich, UK) after an overnight fast and 2.5 h before initiating the testing session.
223515675|NCT06675305|DIETARY_SUPPLEMENT|Placebo acute supplementation (James White, UK)|One serving 140 mL of BJ (0.04 mmol of NO3-; Beet-It-Pro Elite Shot, James White Drinks Ltd., Ipswich, UK) after an overnight fast and 2.5 h before initiating the testing session.
223515676|NCT06683924|PROCEDURE|Pulsed Radiofrequency Ablation|The area where the lateral femoral cutaneous nerve is seen with US will be anesthetized with 1 ml of 1% lidocaine and a 22 Gauge, 10 cm-5 mm RF cannula will be inserted. Sensory fibers will be stimulated with 0.3-0.5 V. Then, motor fibers will be stimulated up to 1.5 V. If no motor contraction is seen, LFCN will be ablated at 42 degrees Celsius for 240 seconds. The procedure will be completed with the injection of 2 ml of 2% lidocaine and 2 ml (8 mg) dexamethasone through the RF cannula.
223515677|NCT06683924|DRUG|Steroid (dexamethasone) Injection|Where the lateral femoral cutaneous nerve is visible with US, 2 ml of 2% lidocaine and 2 ml (8 mg) dexamethasone will be injected.
223638717|NCT04370873|DRUG|Frespaciguat|Frespaciguat 32 µg, 100 µg, 195 µg, 360 µg or 380 µg administered as dry powder inhalation according to randomization. Following review of pharmacokinetic (PK) and safety data, a second 7 days of dosing may be initiated. A dose of up to 360 μg up to twice a day may be administered based on PK data. Dosage may be adjusted downwards in Part 2, if indicated by PK results in Part 1.
223638718|NCT04370873|DRUG|Placebo|Placebo administered as dry powder inhalation according to randomization
223638719|NCT06133179|PROCEDURE|Transtemporal ultrasound with contrast product (Sonovue)|"During their hospitalization and in the 7 days following their stroke, all patients will perform a transtemporal ultrasound including the use of Sonovue contrast product.~The examination will last 1 hour and will be carried out on the opposite side of the stroke then on the side of the stroke"
223638720|NCT02344108|DEVICE|Inspire® Upper Airway Simulation System (Model 3028 IPG )|Subjects will be implanted with a hypoglossal nerve stimulator. Safety and efficacy of implantation will be evaluated.
223638721|NCT04482647|OTHER|Media Intervention|View instructional video
223638722|NCT04482647|PROCEDURE|Meditation Therapy|Perform meditation
223638723|NCT04482647|OTHER|Quality-of-Life Assessment|Ancillary studies
223638724|NCT04482647|OTHER|Questionnaire Administration|Ancillary studies
223638725|NCT04482647|PROCEDURE|Yoga|Perform breathing techniques
223638726|NCT03670966|BIOLOGICAL|Astatine At 211 Anti-CD45 Monoclonal Antibody BC8-B10|Given via infusion
223638727|NCT03670966|DRUG|Cyclophosphamide|Given IV
223638728|NCT03670966|RADIATION|Total-Body Irradiation|Undergo TBI
223638729|NCT03670966|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo PBSC transplantation
223765080|NCT07007234|BEHAVIORAL|Standard of care|The CONTROL group also will participate of 4 face-to-face individual sessions during the experimental period, lasting \~15-30 minutes, however they will receive general instructions related to WHO guidelines for physical activity
223765081|NCT06864403|DRUG|Mirikizumab - Intravenous (IV)|300 mg mirikizumab at Weeks 0, 4, and 8
224226910|NCT04280172|OTHER|Cultural Competence Education|Cultural competence education for participants in the intervention group comprises of completion of an online learning module and participation in an eight-hour training day. The educational content includes various topics related to cultural and linguistic diversity and cultural competence in mentoring.
224319130|NCT01094015|OTHER|gel application for the transmission of ultrasound|3 cm of gel application for the transmission of ultrasound into the endocervical canal 10 minutes before surgery, with a 5ml syringe without needle. Application, with a swab in gel ectocervix
223515678|NCT06686004|DIETARY_SUPPLEMENT|Carrots|Detection of polyacetylene and carotenoids in human biofluids
223515679|NCT06685978|DRUG|Xiang Ju Ru Pi Ning capsule Placebo|Xiang Ju Ru Pi Ning capsule Placebo(0.45g per capsule ) 4 capsules each time,p.o.,tid,for 3menstrual cycle.
223515680|NCT06685978|DRUG|Xiang Ju Ru Pi Ning capsule|Xiang Ju Ru Pi Ning capsule (0.45g per capsule ) 4 capsules each time,p.o.,tid,for 3menstrual cycle.
223515681|NCT00879619|DRUG|sunitinib malate|Given PO
223515682|NCT00879619|DRUG|docetaxel|Given IV
223638730|NCT03670966|PROCEDURE|Bone Marrow Transplantation|Undergo bone marrow transplant
223515683|NCT00879619|DRUG|prednisone|Given PO
224226911|NCT04280172|OTHER|Standard Mentoring Education|Participants in the control group will not receive the educational intervention but will participate in standard mentoring education. This education is offered in an online learning environment and participants can complete the education at their own pace. The educational content focuses on general issues related to mentoring and does not contain topics specific to cultural competence in mentoring.
223638731|NCT03670966|DRUG|Mycophenolate Mofetil|Given IV or PO
223638732|NCT03670966|BIOLOGICAL|Recombinant Granulocyte Colony-Stimulating Factor|Given IV or SC
223638733|NCT03670966|DRUG|Fludarabine Phosphate|Given IV
223638734|NCT03670966|DRUG|Tacrolimus|Given IV or PO
223638735|NCT03670966|PROCEDURE|Bone Marrow Aspiration and Biopsy|Undergo bone marrow biopsy and aspiration
223515684|NCT02536339|DRUG|Pertuzumab|Participants will receive 840 milligrams (mg) loading dose of pertuzumab, followed every 3 weeks thereafter by a dose of 420 mg via intravenous (IV) infusion until disease progression, unacceptable toxicity, withdrawal of consent, or study termination.
223515685|NCT02536339|DRUG|Trastuzumab|Participants will receive trastuzumab at a dose of 6 milligrams per kilogram (mg/kg) of body weight once weekly via IV infusion until disease progression, unacceptable toxicity, withdrawal of consent, or study termination.
223515686|NCT06695520|PROCEDURE|Caudal epidural block|Ultrasound Guidance: Using ultrasound improves the accuracy of the block by allowing real-time visualization of the anatomy and needle placement . injection: .5-1mg/kg of 25% bupivacaine according to the needed block level.
223515687|NCT02037984|BIOLOGICAL|Prevnar 13®|Pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F (2.2 µg each), and 6B (4.4 µg) in each 0.5 mL dose.
223638736|NCT03670966|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223638737|NCT05271643|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|CF-CBT-A is an 10-session program for adolescents with cystic fibrosis introducing cognitive-behavioral coping skills for managing stress, and for prevention and treatment of anxiety and depression. The content of the program was developed to address stressors related to coping with cystic fibrosis. Participants will receive a patient workbook, and meet with a trained mental health clinician on their CF team who will guide them through learning and practicing coping skills. Parents/guardians involvement will be encouraged. A parent/guardian will attend the baseline and final session, have the opportunity for a mid-program check-in, and receive a workbook of psychoeducational material that parallels the adolescent workbook, featuring tips for supporting their teens, and weekly e-mail communication.
223638738|NCT03751241|DEVICE|EyeTracker|The EyeTracker is used to determine reading quality of patients with different intraocular lens types (EROV, monofocal, minimonovision)
223638739|NCT06655129|DEVICE|intense pulsed light|intense pulsed light (IPL) using the Medical Device Anthelia
223765082|NCT06864403|DRUG|Mirikizumab - Subcutaneous (SC)|Pre-filled syringes administered at Weeks 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52.
223765083|NCT07010432|DRUG|Cagrilintide|Participants will receive once-weekly cagrilintide subcutaneously.
223765084|NCT07010432|DRUG|Semaglutide|Participants will receive once-weekly semaglutide subcutaneously.
224226912|NCT03799601|DRUG|Anlotinib|Anlotinib which has shown an affirmatory efficacy in ALTER0303 controlled trial as a 3rd-line treatment on advanced NSCLC is a tyrosine kinase inhibitor with a favorable safety profile in phase I trial which mainly targets VEGFR1/2/3, FGFR, PDGFR and c-kit.
224226913|NCT03799601|DRUG|Docetaxel|a chemotherapy medication used to treat a number of types of cancer.This includes breast cancer, head and neck cancer, stomach cancer, prostate cancer and non-small-cell lung cancer.It may be used by itself or along with other chemotherapy medication.It is given by slow injection into a vein.
224226914|NCT03799601|DRUG|Carboplatin|Carboplatin is used to treat a number of forms of cancer. This includes ovarian cancer, lung cancer, head and neck cancer, brain cancer, and neuroblastoma. It may be used for some types of testicular cancer but cisplatin is generally more effective.
223638740|NCT06595017|DRUG|Magnesium sulphate|After localization of the trigger points, the skin was disinfected with alcohol, the tight muscle band was grabbed between two fingers, and a 30-gage 3/4-inch needle was introduced 1-2 cm away from the trigger points at a 30º angle to the skin. Negative aspiration was performed and each trigger point was injected with 2 ml of magnesium sulphate
223638741|NCT06595017|DRUG|Lidocaine (drug)|After localization of the trigger points, the skin was disinfected with alcohol, the tight muscle band was grabbed between two fingers, and a 30-gage 3/4-inch needle was introduced 1-2 cm away from the trigger point at a 30º angle to the skin. Negative aspiration was performed and each trigger point was injected with 2 ml of Lidocaine
223638742|NCT06595017|DRUG|Saline|After localization of the trigger points, the skin was disinfected with alcohol, the tight muscle band was grabbed between two fingers, and a 30-gage 3/4-inch needle was introduced 1-2 cm away from the trigger point at a 30º angle to the skin. Negative aspiration was performed and each trigger point was injected with 2 ml of Saline
223638743|NCT06594081|BEHAVIORAL|Intervention podcasts|Students in the experimental group will listen to podcasts.
223638744|NCT06595316|OTHER|Exercise intervention group|"Exercise will consist of two supervised sessions per week. Starting with vital signs monitoring (blood pressure, temperature, blood oxygen levels, heart rate).~The aerobic component consists of a 5-minute warm-up, followed by 3 bouts of 4-minute cycling at an intensity of 60-65% HRR, with 2-minute active recovery periods in between and a 5-minute cool down. The goal is to increase up to an intensity of around 80%-85% HRR by weeks 16 to 18. Intensity will be monitored with The Borg Rating Scale of Perceived Exertion (RPE). The resistance component will consist of upper body and lower body exercises (door frame rows, wall push-ups, glute bridges, triceps lifts and squat to calf rise) starting on week one with a set of 12 repetitions of each exercise, with 2-minute recovery in between exercises aiming to increase the number of sets and reducing the number of repetitions."
223638745|NCT06599151|DRUG|[18F]FTC-146|Adult participants will be injected with 5-10 mCi of \[18F\]FTC-146 and undergo a PET/MRI scan.
223638746|NCT02484391|DRUG|6,8-Bis(benzylthio)octanoic Acid|Given IV
223638747|NCT02484391|DRUG|Cytarabine|Given IV
223638748|NCT02484391|PROCEDURE|Hematopoietic Cell Transplantation|Undergo stem cell transplant
223638749|NCT02484391|DRUG|Mitoxantrone Hydrochloride|Given IV
223638750|NCT06587503|BIOLOGICAL|BioNTech - Pfizer COVID-19 vaccine|Vaccine for protection from COVID-19
223638751|NCT06587503|BIOLOGICAL|1mL saline solution|Placebo
223638752|NCT06587503|BIOLOGICAL|rVSV∆G-ZEBOV-GP|Vaccine for protection from Zaire Ebola virus
223638753|NCT06599450|DEVICE|Root form dental implant|Placement of titanium endosteal root form threaded tapered two-piece dental implant to assist mandibular complete overdenture
223638754|NCT06591117|DEVICE|Vizio Aqueous Microshunt|Ocular microshunt placement for the treatment of Glaucoma
223638755|NCT06598748|OTHER|Mechanical Interface Mobilisation Technique|In the mechanical interface group, five techniques, including; wrist distraction (3 sets for 3 minutes), rhythmic and gentle stretching of the transverse carpal ligaments, release of palmar hand fascia, gliding of the finger flexor tendons (using oscillatory flexion-extension movement of metacarpophalangeal joint), and release of the upper forearm muscle and fascia will be applied. To release the upper forearm muscle as demonstrated for pronator teres muscle in, the therapist applied a firm pressure on the origin of the muscle by one thumb and concurrently moved the forearm into extension and supination (17).
224226915|NCT03636321|PROCEDURE|living donor liver transplantation with internal biliary stent|living donor liver transplantation without internal biliary stent
224226916|NCT01021995|DRUG|echinacea|drops, 0.9 ml, tid for 4 months
224226917|NCT01021995|DRUG|placebo|drops, 0.9 ml tid for 4 months
224226918|NCT00096265|RADIATION|3-Dimensional Conformal Radiation Therapy|Patients undergo radiation therapy once daily for approximately 3 weeks
223515688|NCT02037984|BIOLOGICAL|V114 1x:1x:1x|V114 1x:1x:1x contains 2.0 μg of polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F; 4.0 μg of polysaccharide serotype 6B; and 125 µg of Aluminum Phosphate Adjuvant (APA).
224226919|NCT00096265|DRUG|Erlotinib Hydrochloride|Given orally
224226920|NCT00096265|RADIATION|Stereotactic Radiosurgery|Patients undergo surgery after radiation therapy
223515689|NCT02037984|BIOLOGICAL|V114 2x:2x:2x|V114 2x:2x:2x contains 4.0 μg of polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F; 8.0 μg of polysaccharide serotype 6B; and 250 µg of APA.
223515690|NCT02037984|BIOLOGICAL|V114 2x:1x:2x|V114 2x:1x:2x contains 4.0 μg of polysaccharide serotypes 6A, 18C, 19A, 19F, and 23F; 2.0 μg of polysaccharide serotypes 1, 3, 4, 5, 7F, 9V, 14, 22F, and 33F; 8.0 μg of polysaccharide serotype 6B; and 250 µg of APA.
223515691|NCT02037984|BIOLOGICAL|V114 1x:1x:2x|V114 1x:1x:2x contains 2.0 μg of polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F; 4.0 μg of polysaccharide serotype 6B; and 250 µg of APA.
223515692|NCT02037984|BIOLOGICAL|V114 0.5x:0.5x:2x|V114 0.5x:0.5x:2x contains 1.0 μg of polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F; 2.0 μg of polysaccharide serotype 6B; and 250 µg of APA.
223765085|NCT07010432|DRUG|Placebo cagrilintide|Participants will receive once-weekly placebo matched to cagrilintide subcutaneously.
224226921|NCT00096265|DRUG|Temozolomide|Given orally
224319131|NCT04109092|DRUG|E7766|E7766, solution, intravesically.
224319132|NCT02351661|OTHER|There was no intervention|observational study, no intervention
224226922|NCT01506323|BEHAVIORAL|Mantram Repetition Program (MRP)|The MRP teaches three portable, mindfulness strategies to train attention and manage symptoms: 1) Mantram (sacred word) Repetition, 2) Slowing Down, and 3) One-Pointed Attention. These tools are presented as working together synergistically and cumulatively, over time, to interrupt negative thoughts, behaviors, and emotional states such as anger, rage, irritability and impatience. Participants choose their own words or phrases and are encouraged to practice repeating a mantram at any time or place. In this study, MRP is delivered individually in eight weekly, 1-hour sessions, using a standardized manual, instructor guide, and homework assignments for experiential learning.
224323281|NCT04518228|DRUG|First-Line TB Treatment|"Participants will be receiving first-line TB treatment with at least two of the following TB treatment drugs: isoniazid (INH), rifampin (RIF), rifabutin (RFB), ethambutol (EMB), pyrazinamide (PZA), or moxifloxacin (MFX).~Drugs will be administered consistent with the package inserts and/or instructions provided by the non-study sources who prescribe or supply the drugs to participants."
223515693|NCT03529149|COMBINATION_PRODUCT|Urapidil Hydrochloride Injection|"Accurate monitoring of blood pressure is carried out under TCD monitoring, that is to maintain （mean flow velocity）MFV or （pulse index）PI target blood pressure. The target values of MFV and PI are MFV\>37cm/s of （middle cerebral artery)MCA, PI \< 1.34cm/s, aMFV\>40cm/s of (basilar artery)BA, PI \< 0.8cm/s.~TCD shows that when the MFV of MCA or BA is lower than the target value, the blood pressure is reduced or discontinued according to the insufficiency of blood flow. and the current blood pressure is maintained once MFV is met. TCD showed that the PI index of MCA or BA was higher than the target value . The blood pressure reduction was treated by excessive perfusion: intravenous infusion of blood pressure drugs , once PI index is up to the standard, maintaining the current blood pressure."
223515694|NCT06891222|DIAGNOSTIC_TEST|AI-ECG (artificial intelligence-enabled electrocardiogram)|Participants will undergo electrocardiogram analysis using AI-ECG during the baseline visit
223515695|NCT06891222|DIAGNOSTIC_TEST|Focus Screening (focused cardiac ultrasonography)|Participants will undergo a focused cardiac ultrasound if the AI-ECG reflects a positive value
223515696|NCT01529151|OTHER|Osteopathic Manipulative Treatment (OMT)|Direct action OMT procedures, including HVLA, involve the application of a force in the direction of restricted joint motion in order to resolve somatic dysfunction. Indirect techniques, including counterstrain, balanced ligamentous tension and myofascial release, entail applying a force away from the restrictive barrier of a joint or soft tissue structure.
223515697|NCT01529151|OTHER|Vestibular Rehabilitation Therapy (VRT)|Participants categorized as having a peripheral motion hypersensitivity will receive habituation exercises that reproduce the provocative motion, seated and standing balance exercises with gaze stabilization, kinesthetic and proprioceptive retraining. Participants will be given a monthly exercise log at onset and will be asked to report exercise levels at subsequent follow up periods.
223515698|NCT00851136|DRUG|bevacizumab|Intravenous repeating dose
223515699|NCT00851136|DRUG|FOLFOX|Intravenous repeating dose
223515700|NCT00851136|DRUG|PRO95780|Intravenous repeating dose
223515701|NCT05626608|DEVICE|Classical ring stimulation|Unilateral or bilateral subthalamic nucleus stimulation in the treatment of Parkinson's disease using Boston Cartesia(TM) electrodes
223515702|NCT05626608|DEVICE|Stimulation in directional mode|Directional stimulation of the subthalamic nucleus in the treatment of Parkinson's disease using Boston Cartesia(TM) electrodes
223515703|NCT06942780|BEHAVIORAL|Exercise intervention|"The multi-component exercise mode is adopted, and the three-stage structured design of warm-up preparation - main training - finishing and relaxation is adopted, and the participants' heart rate is monitored in real time with the exercise bracelet throughout the whole process to ensure that the training intensity is reached. The movement process is guided synchronously by the video music teaching system, and the specific process is as follows:~1. Warm-up preparation (3 minutes) : Warm up the head and neck, shoulder joints, arms and wrists, waist and abdomen, thighs and ankles in turn, and perform 30 seconds for each movement.~2. Main training stage (60min) : aerobic exercise adopts basic steps of square dance or advanced step training; The resistance training module carries out compound resistance exercises of sitting posture, leg lift and arms forward lift.~3. Finishing and relaxing stage (12min) : select the traditional health exercise eight Duan Jin."
223515704|NCT06942780|BEHAVIORAL|Social intervention|"The duration of each intervention was 40min, mainly group social interaction, guided by professionals (medical social workers). Divided into three stages:~The first stage (3min) : The facilitator will go through small jokes, soothing music, etc.Create a relaxed atmosphere and briefly introduce the theme of the week.~The second stage (35min) : During the activity, participants began to chat around the theme, and the host guided them timely.~The third stage (2min) : Summarize the intervention and praise the participants."
223515705|NCT06942780|BEHAVIORAL|Dietary intervention|The researcher distributed the health education manual of the cognitive disorder diagnosis and treatment center, and conducted a 5-minute MIND diet health education, explaining relevant dietary requirements and focusing on the collocation of one type of food every week. The participants were then given homework that asked them to strictly follow the MIND diet in their daily diet. At the same time, the participants' caregivers are required to upload photos of their daily meals to the wechat group for supervision and feedback.
223515706|NCT06942780|BEHAVIORAL|Cognitive intervention|Cognitive digital therapy was adopted, and participants were supervised by their caregivers for 5 days a week and 30min each time for cloud-based home training (avoiding 2 hospital intervention days) for 8 weeks. The training covers core cognitive functions such as attention, memory and logical reasoning.
223515707|NCT06942780|BEHAVIORAL|Health Education Manual|Distribute health education handbooks to guide patients to establish a good awareness of a healthy lifestyle. The manual can popularize health knowledge, covering various aspects such as diet, exercise, and rest, enabling patients to understand the importance of a healthy lifestyle, encouraging them to actively improve their living habits, slow down the progression of the disease, and enhance their quality of life.
223638756|NCT06598748|OTHER|Exercise Therapy|"Participants in this group will perform myofascial stretching of the carpal ligament, 3 days per week for four weeks along with isometric exercises at wrist joint as demonstrated by the physiotherapist.~The participants will be instructed to perform gentle, pain-free isometrics of the wrist and hand musculature (25). Exercise would be performed with 5-10-second hold, with 10 repetitions (26)."
223765086|NCT07010432|DRUG|Placebo semaglutide|Participants will receive once-weekly placebo matched to semaglutide subcutaneously.
223638757|NCT06604312|OTHER|Sacroiliac Joint Manipulation|Sacroiliac manipulation was performed using manual treatment method by lying patients on their sides. First, the patient was positioned firmly on the edge of the examination table, while the restricted sacroiliac joint remains on the upper side. Then, the physician's hand was positioned on the patient's hip, and the flexion was made on the lumbar spine with the movement from the hip to the upper thigh, and the impulse given by the HVLA technique was applied in the anteroinferior direction to the iliac crest and trochanter major.
224226923|NCT01506323|BEHAVIORAL|Present Centered Therapy (PCT)|The PCT is a form of individual therapy that is problem-oriented to improve current coping. It avoids details of traumatic experiences. In this study, it is delivered individually in 8 weekly, 1 hour sessions to serve as an active, attention control arm. Sessions are unstructured and managed so that there is some engagement of the participant's emotional concerns with an emphasis on strengths and process encouragement rather than skills training. Three components of PCT include 1) developing a therapeutic relationship for social support, 2) focusing on current problems and problem solving, 3) and setting goals.
224226924|NCT00424814|DRUG|Kaletra (lopinavir/ritonavir)|(200/50 mg x2)x 2/d= 2 pills twice daily
224226925|NCT00424814|DRUG|Kaletra (lopinavir/ritonavir) + Combivir (zidovudine/lamivudine)|Kaletra (lopinavir/ritonavir): (200/50 mg x2)x 2/d= 2 pills twice daily Combivir (zidovudine/lamivudine): (300/150mg) x 2/d=1 pill twice daily
224226926|NCT05385679|PROCEDURE|Surgical Extraction of lower third molar|The surgical removal of mandibular third molar is one of the most common procedures done in oral and maxillofacial surgery. Patients often experience pain, swelling, trismus, dehiscence, alveolar osteitis, infection, nerve injury and periodontal tissue damage after third molar surgery. Flap design is an important step in third molar surgery. Envelope flap and modifications of triangular flap are the two most commonly used flaps in surgical removal of lower third molar.
223515708|NCT06955962|OTHER|Mandala Art Therapy|Arm Description: The mandala art therapy for individuals in the intervention group is planned to be conducted in their home environments under suitable conditions. The therapy sessions will be accompanied by music of the participants' choosing and are scheduled to take place over a six-week period, at least three to four times per week, for a minimum of 30 minutes per session. Before the first mandala art therapy session, participants in the intervention group will receive a brief orientation by the researcher on the appropriate environment for the practice and an introduction to mandala art therapy. This orientation will include information on the definition and characteristics of mandala art therapy, the application setting and duration, and general guidelines to be followed during the sessions. At the end of the six-week mandala art therapy program, Post-tests ill be administered face-to-face, and the archived mandala folders will be collected
223515709|NCT05812495|PROCEDURE|Esophagogastric Side to Side Anastomosis|Esophagogastric Side to Side Anastomosis
223515710|NCT05812495|PROCEDURE|Esophagogastric End to Side Anastomosis|Esophagogastric End to Side Anastomosis
223515711|NCT03756935|PROCEDURE|All monitoring|Dicpleth and PI are obtained a posteriori from the PPG waveform reconstruction and blindly from ABP values. Dicpleth is defined as the ratio of the height of the dicrotic notch (from nadir point of the complex to the notch) to the height of the systolic peak (from nadir point of the complex to the pic), measured at end-expiratory time (average of 3 consecutive complex). PI is calculated as the ratio of the pulsatile component of the PPG signal and the continuous component.
223515712|NCT03971045|DRUG|Pembrolizumab|Patients will be treated with pembrolizumab administered as an intravenous infusion at 200 mg in 21-day treatment cycles and oral cyclophosphamide (CTX) 50 mg per day in metronomic administration as a 21 days cycle
223638758|NCT06593444|PROCEDURE|Thalamic Ventral Intermediate-DBS|Participants will undergo Thalamic Ventral Intermediate-DBS ON with the individual stimulation parameters determined in the parameter determination period, then continue to receive stimulation for the remainder of the study.
223638759|NCT06987110|OTHER|Transverse thoracic plane block|Patients will receive a transverse thoracic plane block.
223638760|NCT06987110|OTHER|Midpoint transverse process plane to pleura block|Patients will receive a midpoint transverse process plane to pleura block.
223638761|NCT06987110|OTHER|Erector spinae plane block|Patients will receive an erector spinae plane block.
223638762|NCT05189314|PROCEDURE|Thyroidectomy|Surgical Resection of thyroid nodules
223638763|NCT05189314|DEVICE|Radiofrequency Ablation|Radiofrequency Ablation of thyroid nodules
223638764|NCT02594124|DRUG|nusinersen|Administered by intrathecal (IT) injection
223638765|NCT06992180|BEHAVIORAL|Generative Artificial Intelligence Intervention|The intervention is delivered via a generative artificial intelligence platform called Emohaa. Participants will register and gain access to the platform prior to the start of the trial. Emohaa's responses are based on Hill's helping skills theory in psychology and are designed to simulate the basic communication strategies of a human counselor. The system demonstrates strong capabilities in active listening, emotional mirroring, and empathy, supporting users in understanding their own thoughts and feelings, learning to cope with emotional challenges, and achieving a more optimistic and positive mental and emotional state.
223638766|NCT06992180|BEHAVIORAL|Individual Psychological Counseling|Participants in the traditional counseling group will receive individual psychological counseling sessions conducted by certified psychotherapists.
223638767|NCT06993428|DRUG|EMP16-02 120 mg orlistat/40 mg acarbose|Days 1 to 14: 1 capsule/day, Day 15 to 28, 1 capsule TID and Days 29 to 39: 2 capsules TID).Target dose EMP16: 120 mg orlistat/40 mg acarbose.
223638768|NCT06993428|DRUG|Alli® 60 mg|Days 1 to 14: 1 capsule/day, Day 15 to 28, 1 capsule TID and Days 29 to 39: 2 capsules TID).Target dose EMP16: 120 mg orlistat/40 mg acarbose.
223638769|NCT06993428|DIETARY_SUPPLEMENT|Vi-Siblin® S|Vi-Siblin® S will be taken according to a dose-escalation schedule, with 20 ml (corresponding to approximately 8 g) in the morning during Days 1 to 14; then 20 ml in the morning and evening the rest of the trial (total daily dose 16 g).
223638770|NCT06993428|DIETARY_SUPPLEMENT|Maltodextrin|Maltodextrin will be taken according to a dose-escalation schedule, with 20 ml (corresponding to approximately 8 g) in the morning during Days 1 to 14; then 20 ml in the morning and evening the rest of the trial (total daily dose 16 g).
224226927|NCT05646121|DEVICE|Suprasorb® A + Ag wound dressing and rope|Suprasorb® A + Ag Antimicrobial Calcium Alginate Wound Dressings / Packing Rope are soft, conformable wound coverings with a high mannuronic acid content (mass per unit area ≥100 g/m2). The silver impregnated calcium alginate fibres react with wound exudate or blood to form a gel which creates a moist wound environment. The silver contained in the wound dressing has broad antimicrobial activity, including against MRSA and VRE. Antimicrobial action (\>3 log steps) associated with the ionic silver from the silver alginate fibres (1.5%) is observed in vitro after just 24 h and this remains stable for up to seven days
224226928|NCT04381884|DRUG|IVERMECTIN (IVER P®) arm will receive IVM 600 µg / kg once daily plus standard care. CONTROL arm will receive standard care.|IVERMECTIN (IVER P®) arm will receive IVM 600 µg / kg once daily plus standard care. CONTROL arm will receive standard care.
224226929|NCT02891200|OTHER|Peer support program|The Peer Support Program offers education and support to participants by especially trained 'peer mentors' with oversight from a social worker.
224226930|NCT02891200|OTHER|HCP support|Healthcare professional (HCP) support will be provided by a trained respiratory therapist who will provide COPD self-management education and support via an in-person session and written materials .
224226931|NCT03465371|OTHER|CSC OnDemand Training Intervention|"Level 1: Readiness~Online readiness tool~Level 2: Core Knowledge~Week 1-self-paced core curriculum, totaling 8 hours of instruction~Level 3: Going Deeper~Week 2-instructor-led, role-specific, and advanced topics, totaling 12 hours of instruction~Level 4: Sustainability~9 months of online community of practice support; a discussion forum; open office hours with experts; multisite case conferencing; access to online materials"
224226932|NCT03465371|OTHER|InPerson Intervention|"Level 1: Readiness~Telephone conversations with program leaders to determine structures, roles, staffing, recruitment~Level 2: Core Knowledge~1 day of in-person training on FEP basics and CSC components~Level 3: Going Deeper~1.5 days of in-person training on how the team works, followed by breakout sessions by role~Level 4: Sustainability~9 months of monthly implementation coaching calls with team leads; monthly telephone case conferences; monthly care coordination calls split out by role"
224226933|NCT03465371|OTHER|Virtual InPerson Intervention|"Level 1: Readiness~Telephone conversations with program leaders to determine structures, roles, staffing, recruitment~Level 2: Core Knowledge~1 day of virtual (via Zoom) in-person training on FEP basics and CSC components~Level 3: Going Deeper~1.5 days of virtual (via Zoom) in-person training on how the team works, followed by breakout sessions by role~Level 4: Sustainability~9 months of monthly implementation coaching calls with team leads; monthly telephone case conferences; monthly care coordination calls split out by role"
224226934|NCT04499183|DIETARY_SUPPLEMENT|fructo- and galacto-oligosaccharides|15 gram/day fructo- and galacto-oligosaccharides
224226935|NCT02318927|DEVICE|Deep Brain Stimulation|Deep Brain Stimulation (DBS) of Globus Pallidum plus Pedunculopontine Nucleus, including lead implant and battery placement. Magnetic Resonance Imaging and Computed Tomography (CT) scan will be obtained prior to implant. Measurement of number of Freezing of Gait (FoG) episodes during a FoG test at a lab. Other measures include freezing of gait questionnaire, gait and falls questionnaire, activities/balance confidence scale, Parkinson's disease quality of life questionnaire, Unified Parkinson's Disease Rating Scale physiology collection and sensor testing, adverse event recording, falls diaries, tracking use of assistive devices, gait and balance testing, and neuropsychological, neurosurgical, neurological, and physical exams.
224226936|NCT00246974|DRUG|Gemcitabine|intravenous
224226937|NCT00246974|DRUG|Cisplatin|intravenous
224226938|NCT00246974|DRUG|Gefitinib|oral
224226939|NCT04921280|BEHAVIORAL|Internet based Cognitive Behavioural Therapy|"The treatment program consists of 12 chapters or modules spread over 12 weeks and contains written information, different exercises and weekly homework assignment. Patients get access to the CBT program via an internet portal and they have weekly contact with a licenced psychologist via encrypted email. Focus of the therapist support is to review the content of the weekly module, reinforce progress and engagement in therapy and assist with treatment difficulties. If needed, therapist can contact patients via telephone. Patients receive weekly reminders via SMS to login to the portal and fill out self-report measures."
224226940|NCT05966857|DEVICE|Wearable: Smartwatch|The SAMSUNGTM Galaxy Watch5 Smartwatch, is a new generation of smartwatches, features an innovative 3-in-1 BioActive sensor, which uses a chip to capture optical and read cardiac electrical current, allowing to carry out high-quality real-time single-lead electrocardiogram. Despite the more compact design, there is no decrease in accuracy. These signals are then processed by the device's algorithms and can be sent to a trained professional for evaluation immediately after the measurement, facilitating the monitoring and diagnosis of arrhythmias.
223638773|NCT06991582|BIOLOGICAL|Injectable composite resin restoration|Injectable composite Beautifil flow Plus X (Shofu INC., Koyoto, Japan)
223638774|NCT06991582|BIOLOGICAL|packable composite|Packable Composite Beautifil II (Shofu INC., Koyoto, Japan)
223638775|NCT06992206|OTHER|Metabolik taş analizi ile retrospektif gözlem|This study did not involve an active intervention. It retrospectively analyzed medical records of 506 patients who underwent compositional analysis of kidney stones to identify metabolic abnormalities. The aim was to evaluate stone composition in relation to metabolic parameters such as serum and 24-hour urine values, without modifying patient treatment.
223638776|NCT06992336|DRUG|Anlotinib ,|Anlotinib 8mg qd PO，357days
223638777|NCT06992336|DRUG|Benmelstobart|Benmelstobart 200mg i.v. Q3W
223638778|NCT06992336|DRUG|Capecitabine|Capecitabine 1000 or 1250 mg/m2 BID day1-14
223638779|NCT06992453|OTHER|Fecal microbiota transplantation (FMT)|Patients will receive a first donor FMT by colonoscopy, after a pre-conditioning with vancomycin and neomycin + bacitracin for 3 days, because data from our group show that pre-FMT antibiotics are associated with higher rates of microbial engraftment. Then they will receive two cycles, respectively after 3 and 7 days after colonoscopy - FMT, of frozen donor FMT capsules (15 capsules b.i.d. per 3 days). Patients will always receive feces from the same donor.
223638780|NCT06992388|OTHER|Manual Therapy|This technique involves a low-amplitude, high-velocity push on the shoulder joints with an additional two-second tension
223638781|NCT06992388|OTHER|Placebo|This technique involves a low-amplitude, high-velocity push on the shoulder joints with an additional two-second tension
223638782|NCT06992388|OTHER|Tape elastic|The following intervention will be performed: application with an elastic band
223638783|NCT06991933|BEHAVIORAL|Plastination Model Group|"Model Specifications:~S10 silicone plastination models of brainstem structures (1:1 scale) with:~• Sectioned at 2mm intervals to reveal internal architecture"
223638784|NCT06991933|BEHAVIORAL|Traditional Methods Group|"1. Netter's Atlas of Human Anatomy (9th ed.)~2. Standardized PowerPoint lectures"
223638785|NCT06587581|OTHER|Control Group|Participants from the intervention group will receive the usual care over the 6-month intervention period
223638786|NCT06587581|OTHER|Intervention Group|Participants from the intervention group will receive the usual care and an additional three text messages per week via WhatsApp over the 6-month intervention period
223638787|NCT06593509|DEVICE|Maquet,Servo I.|Model number: 06487800, Serial Number: 19761, SKU#: Inv-00344191, Made in Sweden
223638788|NCT06593509|DEVICE|Vapotherm|INC ,100 domain drive Exeter, NH 03833, Made in U.S.A
223638789|NCT06593509|DEVICE|venturi mask|Intersurgical Ltd, Crane House, Molly Millars Lane, Wokingham, Berkshire, RG41 2RZ, UK.,REF. 1107085, LOT,31757961
223638790|NCT06999148|PROCEDURE|Sonodynamictherapy|SDT: Hematoporphyrin 5 mg/kg.Sonodynamic therapy is administered 40 hours later, twice a day with an interval of 10-12 hours, for 5 consecutive days. One cycle lasts 28 days, and a total of 4-6 cycles are conducted Radiotherapy: The dose is 50-54 Gy, 1.8-2 Gy per day, 5 times a week, for a total of 25 sessions Chemotherapy: When temozolomide is administered concurrently with radiotherapy, the dose is 75 mg/m² per day, taken daily until the end of radiotherapy. For adjuvant chemotherapy with temozolomide, the dose is 150 mg/m² per day from day1to day 5, followed by a 23-day rest period. Each cycle lasts 28 days. If well-tolerated, the dose should be adjusted to 200 mg/m² per day for the 2nd - 6th cycles Targeted Therapy: Bevacizumab 7.5-10 mg/kg, once every 3 weeks, for a total of 4-6 courses
223638791|NCT06999148|DRUG|Radiotherapy plus temozolomide|Radiotherapy: The dose is 50-54 Gy, 1.8-2 Gy per day, 5 times a week, for a total of 25 sessions Chemotherapy: When temozolomide is administered concurrently with radiotherapy, the dose is 75 mg/m² per day, taken daily until the end of radiotherapy. For adjuvant chemotherapy with temozolomide, the dose is 150 mg/m² per day from day 1 to day 5, followed by a 23 - day rest period. Each cycle lasts 28 days. If well - tolerated, the dose should be adjusted to 200 mg/m² per day for the 2nd - 6th cycles Targeted Therapy: Bevacizumab 7.5-10 mg/kg, once every 3 weeks, for a total of 4-6 courses
223638792|NCT06999291|BEHAVIORAL|Glaskow coma scala, The Acute Physiology and Chronic Health Evaluation System- APACHE, Injury Severity Score- ISS)|The uterus, endometrium and ovarian characteristics, endometrial thickness, ovarian follicle number and ovarian volume parameters, hormone panel (FSH, LH, E2, AMH), cortisol, prolactin and thyroid function tests routinely examined for ovarian reserve will be evaluated in the study.
223638793|NCT06997913|COMBINATION_PRODUCT|Adjuvant Immunotherapy Combined With ChemoRadiation for Patients With High-risk resectable Extrahepatic Cholangiocarcinoma（AICRC）|The purpose of this prospective, observational study is to investigate whether adjuvant chemoradiotherapy combined with immunotherapy for high-risk recurrence populations after extrahepatic cholangiocarcinoma resection can improve patients' recurrence-free survival. The primary study endpoint of this prospective study is the 2-year recurrence-free survival.
223638794|NCT06999915|PROCEDURE|Group 1 (Test Group): IP and GBR as an over-contour augmentation beyond IPD|In this group, a bone level implant (Straumann BLC, SLActive®, Roxolid, Straumann AG, Switzerland) will be placed in an ideal 3D prosthetically guided position to allow for a screw-retained restoration, following the manufacturer's protocol. Guided bone regeneration (GBR) will be performed simultaneously with the implant placement with the aim to re-establish the original bone contour as defined by IPD. A bovine bone mineral graft (Bio-Oss collagen®, Geistlich, Wolhusen, Switzerland) will be placed on the buccal aspect of the implant and covered with a collagen membrane (Bio-Gide®, Geistlich, Wolhusen). In the test group, bone augmentation will be performed by adding biomaterial 3 mm beyond the Individual Phenotypical Dimension (IPD) to achieve over-contour augmentation. IPD will be clinically defined during surgery by connecting the most labially prominent points of adjacent ridges at the level of the bone zenith of neighboring teeth.
223638795|NCT06999915|PROCEDURE|Group 2 (Control Group): IP and GBR as a contour augmentation up to IPD|In this group, a bone level implant (Straumann BLC, SLActive®, Roxolid, Straumann AG, Switzerland) will be placed in an ideal 3D prosthetically guided position to allow for a screw-retained restoration, following the manufacturer's protocol. Guided bone regeneration (GBR) will be performed simultaneously with the implant placement with the aim to re-establish the original bone contour as defined by IPD. A bovine bone mineral graft (Bio-Oss collagen®, Geistlich, Wolhusen, Switzerland) will be placed on the buccal aspect of the implant and covered with a collagen membrane (Bio-Gide®, Geistlich, Wolhusen). In the control group, bone augmentation will be performed by adding biomaterial up to the IPD line in order to achieve a contour augmentation with bone grafting remaining within the boundaries defined by the IPD. IPD will be clinically defined during surgery by connecting the most labially prominent points of adjacent ridges at the level of the bone zenith of neighboring teeth
224226941|NCT01811446|DEVICE|Muscle Activation with Niveus and Intelect Devices|Subjects will receive muscle activation technology from the Niveus device on one leg and from the Intelect (commercially-available third-party) device on the other. The order of use and the leg applied to will be randomized.
224226942|NCT00268320|DEVICE|Cardiac Resynchronization Therapy+Implantable Cardioverter Defibrillator|
224226943|NCT05779150|OTHER|CeraVe® Moisturising Cream|CeraVe® Moisturising Cream contains 3 kinds of skin-native ceramides, which can protect the skin against external stimuli, strengthen the damaged skin barrier, fill the intercellular lipids to deeply trap water, relieve dry skin, and increase skin hydration.
224226944|NCT05779150|OTHER|Standard Cream|placebo cream
224226945|NCT05729750|DIAGNOSTIC_TEST|Trans abdominal ultrasound for assess biophysical profile|The biophysical profile (BPP) was developed as a method of integrating real-time observation of the fetus in an intrauterine environment. Manning et al introduced the BPP test in 1980, and since then it has been widely used as a comprehensive assessment tool for both acute and chronic fetal health and fetal congenital malformations in the antepartum period which is a method that uses an overview of 5 key indicators, namely fetal tone, fetal breathing, fetal movement, deep ventricular pocket and NST, thus making it more accurate than either viewing.
224226946|NCT02240758|PROCEDURE|confocal endomicroscopy with the CELLVIZIO® system (Mauna Kea technology)|The CELLVIZIO® system (Mauna Kea technology) will be used for confocal endomicroscopy during a surgical procedure (either open surgical approach or stereotaxic biopsy). The probe dedicated to the CELLVIZIO® system will be positioned against the surface of the brain, sequences will be acquired, and finally compared with anatomapathology exams. Two specific medications will be used as contrast agent in the study: Fluorescein FAURE 500mg/5mL IV with a maximum of two doses per patient OR 5 amino-levulinic hydrochloride (GLIOLAN, MEDAC) orally at the dose of 20mg/kg of body weight.
224226947|NCT00017563|DRUG|docetaxel|35 mg/m2 i.v. over 15 - 30 minutes will be administered immediately after the mitoxantrone on the same schedule.
224226948|NCT00017563|DRUG|mitoxantrone hydrochloride|Initial dose will be 2 mg/m2 weekly for 3 of every 4 weeks. The dose will then be escalated as described in the dose escalation section up to a maximum dose of 6 mg/m2 weekly for 3 of every 4 weeks.
224226949|NCT00017563|PROCEDURE|conventional surgery|Prostatectomy will be scheduled 2 - 4 weeks after the last dose of chemotherapy.
224226950|NCT00511563|DRUG|GW876008 and GSK561679|GW876008 and GSK561679
224226951|NCT01908114|BEHAVIORAL|Enhanced Community mobilization|
224226952|NCT01908114|BIOLOGICAL|Combined Oral Polio Vaccine and Inject able Polio Vaccine during SIA|
224226953|NCT00444795|DRUG|Sunitinib malate|Sunitinib : dosing not pre-determined
224226954|NCT00444795|DRUG|Sunitinib malate|Sunitinib : dosing not pre-determined
224226955|NCT00444795|DRUG|sunitinib malate|Sunitinib : dosing not pre-determined
224226956|NCT03788681|DRUG|Estradiol Valerate|"oral estradiol  estradiol valerate  (Cyclo-Progynova)"
224226957|NCT03788681|DRUG|Placebo Oral Tablet|placebo
224226958|NCT00545012|DRUG|Levetiracetam|
224226959|NCT00988169|DRUG|oral erlotinib and pulsed doses of oral AT-101|Patients will receive oral erlotinib 100 mg daily and pulsed doses of oral AT-101 given 40 mg twice daily on days 1-3 of a 21-day cycle. If the initial combination of erlotinib and AT-101 is tolerated, dose escalation of erlotinib to 150 mg daily will be allowed at the discretion of the treating investigator at the start of cycle 2. Patients will continue receiving treatment on study until they refuse further therapy, develop evidence of progressive disease, or develop unacceptable toxicity or a medical condition that would, in the judgment of the investigator,
224226960|NCT03454971|OTHER|MinOS protocol|"At Day 1, Cycle 1 and 2 of the patient's oral therapy :~* Consultation with a hospital pharmacist~* Consultation with a nurse care coordinator~* Consultation with the patient's oncologist/hematologist~During this multidisciplinary consultation, will be reviewed :~* potential medical interactions,~* possible adverse effects of therapy,~* information on the prescribed drug,~* informations on the patient's lifestyle, ...~At day 8 and 15, cycle 1 and 2 :~Phone call from the nurse care coordinator during which will be reported the adverse effects and adherence issues. If needed, the nurse care coordinator can provide complementary information about the treatment.~The MINOS protocol follow up will end with a consultation with the patient's oncologist/hematologist, at day 1 cycle 3."
224226961|NCT00003361|DRUG|decitabine|
224226962|NCT04674098|DEVICE|The Beat Analytics System (BAS)|There are three subsystems to the BAS; data aggregation, data analysis and data presentation.
224226963|NCT03265496|PROCEDURE|Clinical exam|Clinical exam is performed before treatment start
223638796|NCT06591169|BEHAVIORAL|diet restriction and exercise|this group will contain twenty obese females with a complaint of NAFLD, PCOS and OSA. for eight weeks, these obese females will receive metformin tablet (thrice daily), program of low diet intake, and daily walking for 30 minutes
223638797|NCT06591169|BEHAVIORAL|diet restriction|this group will contain twenty obese females with a complaint of NAFLD, PCOS and OSA. for eight weeks, these obese females will receive metformin tablet (thrice daily) and program of low diet intake
223638798|NCT06587048|PROCEDURE|periapical surgery|In piezo group, the periapical surgery will be performed using piezoelectric device.
223638799|NCT06587048|PROCEDURE|periapical surgery|In conventional bur group, the periapical surgery will be performed using rotary burs.
223638800|NCT05370495|DRUG|SY-201 Ophthalmic Solution 2.0%|SY-201 Ophthalmic Solution 2.0%
223638801|NCT05370495|DRUG|SY-201 Ophthalmic Solution 1.0%|SY-201 Ophthalmic Solution 1.0%
223638802|NCT05370495|DRUG|SY-201 Ophthalmic Solution 0.5%|SY-201 Ophthalmic Solution 0.5%
223638803|NCT05370495|DRUG|SY-201 Ophthalmic Solution Vehicle|SY-201 Ophthalmic Solution Vehicle
223638804|NCT01899040|DEVICE|neuromodulation for episodic migraine headache|
223638805|NCT03712358|BIOLOGICAL|PVSRIPO|Intralesional injection of PVSRIPO.
223638806|NCT06778109|OTHER|hypnosis|T0) basal evaluation of physiological data T1) evaluation of physiological data after recollecting a negative memory for 3 minutes T2) evaluation of physiological data after that a brief session of hypnosis (performed with positive memories) T3) evaluation of physiological data recolling, for the second time, the negative memory.
224226964|NCT03265496|PROCEDURE|Liquid biopsy|Liquid biopsy will be performed at baseline and every 3 cycles of chemotherapy until progression disease
224226965|NCT03265496|PROCEDURE|Diagnostic exam|Diagnostic exam (biopsy and imagery exam) will be performed at baseline if not previously done or incompletely done.
224226966|NCT03265496|DRUG|1st line treatment|1st line chemotherapy (chemotherapy or EGFR targeted therapy) will be performed until progression disease.
224226967|NCT03265496|PROCEDURE|tumor evaluation|Tumor evaluation will be performed every 3 cycles of chemotherapy
224226968|NCT03265496|BIOLOGICAL|Biopsy|Biopsy will be performed at the end of study, after progression disease, if a mutation of EGFR is detected in tumor DNA.
224226969|NCT02923466|BIOLOGICAL|VSV-IFNβ-NIS|Intratumoral injection of a single dose of VSV-IFNβ-NIS
224226970|NCT02923466|BIOLOGICAL|VSV-IFNβ-NIS and avelumab|Intratumoral injection of a single dose of VSV-IFNβ-NIS and intravenous infusion of avelumab
224226971|NCT04050397|OTHER|Progressive supervised weight training|12 weeks of progressive weight training twice a week supervised by a qualified physiotherapist.
223638807|NCT06772740|PROCEDURE|Middle meningeal artery embolization|Middle meningeal artery embolization within 7 days after randomization
223638808|NCT06896708|DRUG|Intensive lipid-lowering strategy|The initial recommended therapy is 20mg atorvastatin/10mg rosuvastatin plus Ezetimibe or PCSK9i, and the type and dosage of drugs can be adjusted according to the situation. If the target LDL-C level is not achieved during the Follow-up periods, adjustment of drug type and dosage will be carried out according to procedures defined in the protocol.
223638809|NCT06896708|DRUG|Standard lipid-lowering strategy|The initial recommended therapy is 20mg atorvastatin/10mg rosuvastatin, and the type and dosage of drugs can be adjusted according to the situation. If the target L-DLC level is not achieved during the Follow-up periods, adjustment of drug type and dosage will be carried out according to procedures defined in the protocol.
223638810|NCT06906770|OTHER|Eye movement desensitization and reprocessing phobia treatment in virtual reality|Short form and frequent eye movement desensitization and reprocessing (EMDR) in virtual reality for specific phobia treatment.
223638811|NCT00905164|DRUG|Topiramate Capsules, 25 mg|Topiramate Capsules, 2 x 25 mg
223638812|NCT00905164|DRUG|Topamax® Capsules, 25 mg|Topamax® Capsules, 2 x 25 mg
223638813|NCT06134518|OTHER|The education program|The intervention group will receive the competency-based education program for 1 month at each PHC, after baseline data collection. The education program will be conducted weekly. This education session will be conducted for 4 hours per session, with 20 health cadres in a group per PHC. The competency level is measured by the researcher developing a competency questionnaire which consists of a knowledge test, skill, and attitude checklist score at the 2nd post-assessment (2 months after being given the education program).
224226972|NCT04050397|OTHER|Lecture|Urologist informs participants on adverse effects of castration treatments and benefits of regular exercise. Physiotherapist gives an exercise program to follow at home, and nutritionist informs patients on correct nutrition to assist physical exercise.
224226973|NCT04170179|PROCEDURE|Systemic chemotherapy|administration of oxaliplatin , fluorouracil, and leucovorin via the peripherally inserted central catheter every 3 weeks
224226974|NCT04170179|DRUG|Lenvatinib|12 mg (or 8 mg) once daily (QD) oral dosing.
224226975|NCT04170179|DRUG|Toripalimab|240mg intravenously every 3 weeks
224226976|NCT02346968|OTHER|Blood and urine sampling|Blood and urine sampling (in the context of routine sampling)
224226977|NCT02497833|DIETARY_SUPPLEMENT|retinoic acid|During the trial period, the participants are instructed to consume retinoic acid capsules twice daily (30 min after breakfast and supper).The retinoic acid capsules provided a total daily intake of 10 mg of retinoic acid.
224226978|NCT02497833|OTHER|placebo|During the trial period, the participants are instructed to consume placebo capsules twice daily (30 min after breakfast and supper).The placebo capsules are composed of starch and pigment.
224226979|NCT01400282|DEVICE|High frequency spinal cord stimulation|
224226980|NCT02642627|DEVICE|Bellafill|
224226981|NCT02067780|DRUG|Levofloxacin 500mg|One tablet per day for 7days.
224226982|NCT02414880|DRUG|Sugammadex|Rocuronium-induced neuromuscular blockade will be reversed at the end of the operation when two responses to train-of-four ulnar nerve stimulation are detected (T2) by injection of sugammadex 2mg/kg.
224226983|NCT02414880|DRUG|Neostigmine|Rocuronium-induced neuromuscular blockade will be reversed at the end of the operation when two responses to train-of-four ulnar nerve stimulation are detected (T2) by injection of neostigmine 50 micro-gram/kg combined with atropine 20 micro-gram/kg.
224226984|NCT02414880|DRUG|Rocuronium|An intubating dose of Rocuronium (0.6 mg/kg) will be given with induction of anesthesia and the degree of muscle relaxation will be evaluated through out the operation by recording the response of the hand muscles to train-of-four ulnar nerve stimulator (Mechanosensor Neuromuscular Transmission Module of General Electric AISYS Anaesthesia machine USA) according to the Good Clinical Research Practice (GCRP) guidelines for pharmacodynamic neuromuscular studies. Muscle relaxation will be maintained by additional top-up doses of Rocuronium (0.15mg/kg) which will be administered after detection of the first response to TOF stimulation (T1).
224226985|NCT05400265|DRUG|HLX26|Humanized Anti-Lymphocyte Activation Gene-3 Monoclonal Antibody
224226986|NCT05400265|DRUG|HLX10|Humanized Anti-Programmed Death-1 Monoclonal Antibody
224226987|NCT01383525|DEVICE|Direct Selective Trabeculoplasty device|Patients will be treated with a Direct Selective Trabeculoplasty (DLTP) laser. Placement of the spots is on the sclera around the limbus.
224226988|NCT05371522|RADIATION|[18F]DPA-714 positron emission tomography (PET) scan|60 minute dynamic brain \[18F\]DPA-714 positron emission tomography (PET) scan followed by a 30 minute static whole body positron emission tomography (PET) scan
224226989|NCT00544765|DRUG|TAC|Docetaxel 75 mg/m² as a 1 hour i.v. infusion on day 1 every 3 weeks in combination with Doxorubicin 50 mg/m² as an i.v. bolus and Cyclophosphamide 500 mg/m2 as an i.v. bolus on day 1 every 3 weeks
224226990|NCT00544765|DRUG|NX|Vinorelbine 25 mg/m² as a \< 10 min i.v. infusion on days 1 and 8 repeated every 3 weeks and Capecitabine 2000 mg/m² orally in 2 daily doses on days 1-14 repeated every 3 weeks
224226991|NCT01989065|BEHAVIORAL|Lifestyle counseling|see arm description
224226992|NCT01989065|BEHAVIORAL|Text Messaging|See Arm Description
224226993|NCT03522922|DEVICE|Dermaroller|The derma roller used (dermaroller MF8, MT dermaroller Beverly Hills, California USA) is a plastic device with a 12-cm handle that holds a drum-shaped cylinder at the end, similar to a small paint roller, 2 cm in diameter and 2 cm in width. The surface of the cylinder holds 192 titanium needles in eight rows. Each 0.25 mm in diameter and 1.5 mm length sterilized by UV/ Gamma rays.
223638814|NCT06134518|OTHER|the initial orientation from the PHCs|the initial orientation from the PHCs
223638815|NCT05452863|DEVICE|O2matic administered oxygen|Oxygen supply is adjusted from an almost continuous measurement of the oxygen saturation with an appropriate an previously tested algorithm.
223638816|NCT05452863|DEVICE|Manual oxygen supply and adjustments|Oxygen supply is adjusted from manual measurements of the oxygen saturation
223638817|NCT03401801|PROCEDURE|Stellate ganglion block|Well trained pain physician performs all the ultrasound(US)-guided stellate ganglion block(SGB)s, who is not involved in evaluating study variables. Electrocardiography, noninvasive blood pressure, heart rate, and peripheral oxygen saturation were monitored for all patients before, while, and after conducting procedure. For US-guided SGB, patients are supine positioned, and skin preparation on injection site is done with chlorohexidine. Procedure is conducted under ultrasound guidance at C6 level. 4 ml, 6 ml, and 8 ml of 1% lidocaine is injected for the each group, respectively.
223638818|NCT06215170|DEVICE|SafeMedWaste|SafeMedWaste opioid disposal kit
223638819|NCT03745612|BEHAVIORAL|Time restricted feeding|Participants will receive a diet of 1500-1800kcal/d for men and 1200-1500kcal/d for women during a window of 8 h/d (8 am to 4 pm).
223638820|NCT03745612|BEHAVIORAL|Continuous Energy Restriction|Participants will follow receive a diet of 1500-1800kcal/d for men and 1200-1500kcal/d for women, without a restriction of feeding time.
223638821|NCT01968200|DRUG|Enalapril|Naprilene 5 mg tablets; Dosage: 2.5 to 10 mg/12h Duration of treatment: up to end of follow up
223638822|NCT03266510|OTHER|Inspiratory muscle strength training|Subjects will perform inspiratory muscle strength training for 6 weeks.
223638823|NCT03266510|OTHER|Sham training|Subjects will perform sham training for 6 weeks.
224226994|NCT03522922|DRUG|Topical Vitamin C|The used vitamin C product was in the form of 17% concentration of L- Ascorbic Acid serum that was encapsulated in gelatinous capsules each contain 1 mg of the serum. The patient instructed to open one capsule and apply its serum content on the treatment area daily at night. This capsule form for topical application help to insure stability of the product and also insure use of equal dose in each application
224226995|NCT02943525|PROCEDURE|vaginal packing|Packing vagina with a Boric acid soaked gauze at the end of surgery
224226996|NCT05764122|DRUG|BIIB131|Administered as specified in the treatment arm.
224226997|NCT05764122|DRUG|Placebo|Administered as specified in the treatment arm.
224226998|NCT05159310|PROCEDURE|Cast vs Splint|Patients presenting with DRF will be screened by the attending consultant. The temporary backslab will be removed, X-rays will be obtained, and the attending consultant will discuss the treatment options. Patients who are planned for non-operative treatment and meet the inclusion criteria will be eligible for the study. The purpose and details of the study will be explained and informed consent will then be taken by the research coordinator (RC). The participants will then be randomized (using a block-randomization method) to either treatment by splint or cast.
223638824|NCT02769117|PROCEDURE|Ultrasound on fractured bone|A new ultrasound technique for children and adults who have sustained forearm or clavicle fractures
223638825|NCT02769117|PROCEDURE|Ultrasound on contralateral intact bone|A new ultrasound technique for the intact bone as the control for children and adults who have sustained forearm or clavicle fractures
223638826|NCT04427813|BEHAVIORAL|questionaire to husband and wife|a form of questions will be asked to every partner
223638827|NCT01669837|DEVICE|Mesh fixation with surgical tissue glue|Laparoscopic inguinal hernia repair using surgical tissue glue for mesh fixation
223638828|NCT03390946|DRUG|Poor responder group adjuvant chemotherapy|"Poor responder group (necrosis ≤ 90%)~: week 0, 7 and 14, doxorubicin; week 2, 9 and 16, ifosfamde, week 4, 11, 18 and 19, methotrexate; wk 5, 12 and 20~B. Resection of tumor~C. Adjuvant chemotherapy~1. Poor responder group (necrosis ≤ 90%)~   * week 0, 7 and 14, doxorubicin; week 2, 9 and 16, ifosfamde, week 4, 11, 18 and 19, methotrexate; wk 5, 12 and 20~2. Good responder group (necrosis \> 90%)~   * week 0 and 8, doxorubicin; week 2 and 10, ifosfamide; week 4, 5, 12 and 13, methotrexate; week 6 and 14, cisplatin"
223638829|NCT03390946|DRUG|Good responder group adjuvant chemotherapy|"Good responder group (necrosis \> 90%)~: week 0 and 8, doxorubicin; week 2 and 10, ifosfamide; week 4, 5, 12 and 13, methotrexate; week 6 and 14, cisplatin"
223638830|NCT01256788|DEVICE|Euflexxa|4 injections of 2ml of Euflexxa
223638831|NCT01256788|OTHER|Saline|4 injections of 3 ml of sterile saline
223638832|NCT04911140|RADIATION|Photobiomodulation twice a week|The photobiomodulation will be applied with a LED facial mask, Cosmedical brand (São Paulo, Brazil), containing 92 red LEDs, 660 nm of wavelength, in continuous mode for 21 minutes, twice a week, for 4 weeks.
223638833|NCT04911140|RADIATION|Photobiomodulation three times a week|The photobiomodulation will be applied with a LED facial mask, Cosmedical brand (São Paulo, Brazil), containing 92 red LEDs, 660 nm of wavelength, in continuous mode for 21 minutes, three times a week, for 4 weeks.
223638834|NCT04911140|OTHER|Simulated Photobiomodulation|Photobiomodulation will be simulated, with the device turned off, twice a week, for 4 weeks. The characteristic sound of the device will be triggered by recording.
223638835|NCT03469453|BEHAVIORAL|Internet-Delivered Cognitive Behavioral Therapy|Therapist-supported CBT delivered online.
223638836|NCT02750917|DRUG|Lornoxicam|At the end of surgery patients in group LORNOXICAM received one pill of 8 mg lornoxicam every 12 hours in the surgery day and first postoperative day.
223638837|NCT02750917|DRUG|Etoricoxib|At the end of surgery patients in the ETORICOXIB group received one pill of 120 mg etoricoxib at the end of surgery and a second one after 24 hours. This group also received placebo pills at 12 h, between the active pills.
223638838|NCT01955421|DRUG|Erlotinib 100mg qd|
223638839|NCT01955421|DRUG|Gefitinib 250mg qd|
223638840|NCT00844961|BEHAVIORAL|Internet delivered cognitive behavior therapy|10 weeks of internet delivered cognitive behavior therapy targeted at reducing experience of IBS symptoms and improving quality of life. Patients are offered guidance via email by a therapist.
223638841|NCT04942821|PROCEDURE|Platelet rich fibrin and coronally advanced flap|CAF were used in treatment arms. Root planning was performed on the exposed part of roots to provide more biocompatible surface for re-attachment. Two 10 cc tubes with clot activator were used to collect blood from the patient; blood was centrifuged at 2700 rpm for 12 min. PRF box was used to form fibrin clots into membranes. PRF was positioned at the level of the cemento-enamel junction (CEJ), and sutured on the periosteum bed with 6/0 absorbable sutures. Gingival margins on the flap were placed at least 1 mm coronally of the CEJ and sutured with 5/0 absorbable sutures. Sutures were removed at 2nd week.
223638842|NCT04942821|PROCEDURE|Connective tissue graft and coronally advanced flap|Control sites were treated by coronally advanced flap (CAF) combined with connective tissue graft (CTG). CAF were used in both treatment arms. Root planning was performed on the exposed part of roots to provide more biocompatible surface for re-attachment. CTG was obtained with single incision method. CTG was positioned at the level of the cemento-enamel junction (CEJ), and sutured on the periosteum bed with 6/0 absorbable sutures. Gingival margins on the flap were placed at least 1 mm coronally of the CEJ and sutured with 5/0 absorbable sutures. Sutures were removed at 2nd week.
223638843|NCT03475836|DIETARY_SUPPLEMENT|Mentha piperita|Commercially available essential oil suspended in an off-the-shelf vegetable oil.
223638844|NCT03475836|DIETARY_SUPPLEMENT|Placebo|Inert placebo control in the form of vegetable oil. This matches the vegetable oil in the active intervention condition.
224226999|NCT04709159|OTHER|Call for Life Uganda|"Call for Life™ Uganda (C4LU) is a web-based mHealth tool that provides treatment support to patients in the form of daily or weekly pill adherence reminders, health messages, clinic appointment reminders and a remote symptom reporting service. The tool interacts with patients by text message (SMS) or using voice and tone input via keypad (Interactive Voice Response - IVR) on both analogue and smart phones.~The tool uses CONNECT FOR LIFE technology, which is on an open source platform developed by Grameen Foundation and the University of Southern Maine with financial support from the Bill and Melinda Gates Foundation. It was supported by Janssen, the Pharmaceutical Companies of Johnson and Johnson and was released under the terms of the MOTECH open source license agreement."
224227000|NCT00810732|DRUG|Open|Sitaxsentan sodium 100 mg orally administered once daily (double blind arm)
224227001|NCT00810732|DRUG|Nifedipine|Nifedipine = 30 mg extended release tablets, orally administered once daily (open label arm)
224227002|NCT00810732|DRUG|Placebo|Placebo for sitaxsentan, orally administered once daily (double blind arm)
224227003|NCT01241409|DRUG|Rabeprazole sodium: Treatment A|One single oral dose of 10 mg (1 x 10-mg capsule) rabeprazole to be-marketed sprinkle capsule granule formulation administered in fasted state. After the capsules are opened, the granules will be sprinkled on applesauce (1 tablespoon).
224227004|NCT01241409|DRUG|Rabeprazole sodium: Treatment B|One single oral dose of 10 mg (2 x 5-mg capsules) rabeprazole Phase 3 sprinkle capsule granule formulation administered in fasted state. After the capsules are opened, the granules will be sprinkled on applesauce (1 tablespoon).
224227005|NCT01241409|DRUG|Rabeprazole sodium: Treatment C|One single oral dose of 10 mg (1 x 10-mg capsule) rabeprazole to be-marketed sprinkle capsule granule formulation administered after consumption of a standardized high-fat high-caloric breakfast. After the capsules are opened, the granules will be sprinkled on applesauce (1 tablespoon).
224227006|NCT00957983|DRUG|BGC20-1531|oral administration followed by Prostaglandin E2 infusion
224227007|NCT06291883|COMBINATION_PRODUCT|Kang Guan Recipe (Treat)|Accurately weigh the Chinese medicinal herbs in the formula by weight, conduct the origin identification of the medicinal materials, and follow the scientific traditional Chinese medicine preparation process. After extraction, concentration, and granulation, package them in aluminum foil, with each package containing 6 grams of concentrated powder.
224227008|NCT06291883|COMBINATION_PRODUCT|Kang Guan Recipe (Placebo)|Use 3% Kang Guan Recipe concentrated powder, mix evenly with starch, and package in aluminum foil, with each package containing 6 grams of concentrated powder.
224227009|NCT00580853|DRUG|varenicline|2mg/day, with 1-week lead-in medication period The starting dose is 0.5 mg/day for days 1-2, followed by 0.5mg twice daily for days 3-5 and then 1mg twice daily for days 4-7. 1mg administered during laboratory session (day 8).
224227010|NCT00580853|DRUG|bupropion|300mg/day, with 1-week lead-in medication period The starting dose is 150mg/day for days 1-3, 300mg/day for days 4-7. 300mg administered during laboratory session (day 8).
224227011|NCT00580853|DRUG|Placebo|Placebo
224227012|NCT03083483|DEVICE|transcranial direct current stimulation (tDCS)|tDCS will apply a low, direct current for the duration of the study session while the subject is training the specific laparoscopic tasks.
224227013|NCT02710071|DRUG|Nebivolol|Nebivolol 5mg then nebivolol 10 mg
224227014|NCT02710071|DRUG|Hydrochlorothiazide|Hydrochlorothiazide 12.5 mg then hydrochlorothiazide 25 mg
223638845|NCT04581213|PROCEDURE|General anesthesia|Children under general anesthesia for an elective surgery, aged between 6 months and 5 years old, ASA 1-2.
223638846|NCT01963416|DIETARY_SUPPLEMENT|macro- and micro-nutrient matched control (240 ml)|
223638847|NCT01963416|DIETARY_SUPPLEMENT|Orange juice|
223638848|NCT01963416|DIETARY_SUPPLEMENT|whole orange fruit|
223638849|NCT01963416|DIETARY_SUPPLEMENT|Processed whole orange|
223638850|NCT04687982|BIOLOGICAL|modified donor lymphocytes infusion (mDLI)|"The planned number of mDLI is 3.~1. Day +50 (+/- 7 days) from allogenic transplant, 1st mDLI 5x105CD3+/kg of recipient.~2. 4-6 weeks after 1st DLI, 2nd mDLI 1x106CD3+/kg of recipient.~3. 4-6 weeks after 2nd DLI, 3rd mDLI 5x106CD3+/kg of recipient."
223638851|NCT03312634|DRUG|Palovarotene|Palovarotene was taken orally once daily at approximately the same time each day following a meal.
223638852|NCT05366738|DRUG|Vonoprazan|Orally via tablet
223638853|NCT05366738|DRUG|Vonoprazan|Orally via sprinkle pellets
223638854|NCT06465628|BEHAVIORAL|Self-administered acupressure|The participants should perform self-administered acupressure 12 weeks after training
223638855|NCT06465628|OTHER|Oral health education|The participants should perform general oral care by themselves after the oral health education relating to xerostomia
223638856|NCT05668052|OTHER|questionnaire|This survey was conducted in Zhejiang Provincial Hospital of Traditional Chinese Medicine from December 2022 to December 2023. The research objects were patients with COVID-19.
223638857|NCT00000285|DRUG|Phenytoin|
223638858|NCT01931293|DIETARY_SUPPLEMENT|Supplementation of vitamin B complex, C, B12, folic acid, Iron and Zinic|Vitamin Supplement therapy
223638859|NCT01660724|PROCEDURE|Ultrasound guided arterial puncture|Arterial puncture is performed using simultaneously ultrasound in order to guide the passage of the syringe from the patient's skin to the artery
223638860|NCT01660724|PROCEDURE|Conventional arterial puncture technique|Arterial puncture is performed using the conventional technique
223638861|NCT02230995|DRUG|metformin|single dose of metformin given as tablets
223638862|NCT02230995|DRUG|empagliflozin/metformin|Single dose empagliflozin/metformin given as fixed-dose combination tablet
223638863|NCT02230995|DRUG|empagliflozin|single dose of empagliflozin given as tablet
224227015|NCT03306576|DEVICE|ELS Extra composite|One of the teeth will be restored using ELS composite. Procedures will be done under local anesthesia if necessary. The preparation and restoration of the tooth will be done according to to the guidelines for ordinary restorative techniques.
224227016|NCT03306576|DEVICE|ELS composite|the other teeth will be restored with a ELS resin composite with ordinary restorative techniques.
224227017|NCT03270176|DRUG|Debio 1143|Debio 1143 100 to 250 mg, capsule orally for 10 days every 2 weeks.
224227018|NCT03270176|DRUG|Avelumab|Avelumab 10 mg/kg intravenous infusion every 2 weeks.
224227019|NCT01633827|DRUG|Placebo pill|Subjects will receive a sugar pill (in combination with room air) during their placebo arm studies
224227020|NCT01633827|DRUG|Sedative|Subjects will receive eszopiclone (in combination with medical oxygen) during their treatment arm studies
224227021|NCT01633827|OTHER|Room air|Subjects will receive room air (in combination with a sugar pill) during their placebo arm studies
224227022|NCT01633827|OTHER|Oxygen|Subjects will receive medical grade oxygen (in combination with eszopiclone) during their treatment arm studies
224227023|NCT05713474|DIAGNOSTIC_TEST|Diagnostic EMG exam with microEMG|Diagnostic EMG exam with microEMG
224227024|NCT05713474|DIAGNOSTIC_TEST|Conventional EMG|Diagnostic EMG exam with conventional EMG
224227025|NCT03581474|DEVICE|Bronchoscopic procedure|Single-use flexible bronchoscope aScope 3 Large
224227026|NCT01626820|BIOLOGICAL|Fluviral®|1 dose administered intramuscularly in deltoid region of non-dominant arm at Day 0
224227027|NCT04266691|OTHER|nonIntervention|nonIntervention
224227028|NCT02470195|BEHAVIORAL|workshop|workshop for procedural simulation for education in difficult airway situation
224227029|NCT04579926|OTHER|Pinpoint app|Tablet and smartphone app with pain assessment and communication education, and pain assessment tool.
224227030|NCT03709082|DRUG|Palbociclib 75mg|Oral Administration
224227031|NCT03709082|DRUG|Letrozole 2.5mg|Oral Adminstration
224227032|NCT03709082|DRUG|T-DM1|Intravenous Administration
224227033|NCT03709082|DRUG|Palbociclib 100mg|Oral Administration
224227034|NCT03709082|DRUG|Palbociclib 125mg|Oral Administration
224227035|NCT03709082|DRUG|Palbociclib|Oral Administration
224227036|NCT04032873|OTHER|Monetary Cost of Immobilization Treatments|Information regarding the monetary cost of casting and splinting patient's buckle fracture to be presented to adult subject/payer.
224227037|NCT04032873|OTHER|Physician|The monetary cost information is relayed by the patient's physician
224227038|NCT04032873|OTHER|Study Team|The monetary cost information is relayed by a member of the study team
224227039|NCT04032873|OTHER|Before Initial Treatment Decision|Monetary cost information is relayed during the initial consult, before the treatment decision is made.
224227040|NCT04032873|OTHER|After Initial Treatment Decision|Monetary cost information is relayed after the initial consult with the treating physician, after the treatment decision is made.
223638864|NCT00309491|DRUG|Tamoxifen alone|2 x 20 mg tamoxifen daily, start of therapy within 4 weeks after surgery; therapy duration 5 years
223638865|NCT00309491|DRUG|Tamoxifen + Aminoglutethimide|"2 x 20 mg tamoxifen daily (5 years) plus Aminoglutethimide daily (first 2 years)~* 1st therapy week:125mg/-/125mg Aminoglutethimide daily~* 2nd therapy week: 125mg/-/250mg Aminoglutethimid daily~* as of 3rd therapy week: 250mg/-/250mg Aminoglutethimid daily"
223638866|NCT00139152|DRUG|Placebo|Saline, Sub-Cuteanous (SQ)
223638867|NCT00139152|DRUG|Xolair|Xolair, 0.016 mg/kg Immunoglobulions E (IgE) , SQ
223638868|NCT00671294|DRUG|Ramelteon and Placebo (9 possible combinations total)|"Randomized sequence over two consecutive nights for a total of three treatment periods to include the following:~Ramelteon 4 mg, tablets, orally over two nights~Ramelteon 8 mg, tablets, orally over two nights~Ramelteon placebo-matching tablets, orally over two nights"
223638869|NCT00906204|BIOLOGICAL|Single-dose rabbit Anti-thymocyte Globulin induction|6 mg of rATG administered in a single dose on the day of kidney transplantation
223638870|NCT00906204|BIOLOGICAL|Divided-dose rabbit Anti-thymocyte Globulin induction|6 mg/kg total rabbit Anti-thymocyte Globulin dose administered as 1.5 mg/kg doses on 4 sequential days, beginning on the day of kidney transplantation.
223638871|NCT01680042|DRUG|Phenytoin paste|
223638872|NCT01680042|DRUG|Placebo|
223638873|NCT06769334|OTHER|PLAY Program|The PLAY Program is a web-based program created for caregivers of childhood cancer survivors. The program consists of seven modules with the following topics: 1) Introduction to the program 2) Self-Care 3) Relationships 4) Getting Ready for School 5) Talking, Reading, and Counting together 6) Social and Emotional Development 7) Review Module. The program is meant to be completed over approximately three months, and caregivers in the program will meet with a coach on a weekly or bi-weekly basis to discuss what they learned in the modules and how to practice it in their daily lives.
224227041|NCT02637557|DRUG|IW-3718|
224227042|NCT02637557|DRUG|Matching Placebo|
224227043|NCT02637557|DRUG|PPI|All participants were taking a standard dose QD PPI (dexlansoprazole, esomeprazole, esomeprazole magnesium, lansoprazole, omeprazole, pantoprazole, pantoprazole sodium sesquihydrate, rabeprazole or rabeprazole sodium) during the study.
224227044|NCT01773148|DEVICE|Arstasis Access System (AXERA)|Placement of the AXERA device in the Femoral Artery.
224227045|NCT03940430|DRUG|Lactoferrin|This study aims to compare the efficacy of lactoferrin versus iron supplementation versus two combined supplementation on iron deficiency anemia in female medical Ain Shams students by using iron profile.
224227046|NCT03940430|DRUG|Ferrous sulfate|This study aims to compare the efficacy of lactoferrin versus iron supplementation versus two combined supplementation on iron deficiency anemia in female medical Ain Shams students by using iron profile.
224227047|NCT02267057|DRUG|Paracetamol|Paracetamol granulate supplied by Weifa (Paracet) and 1 g paracetamol tablets produced by Kragerø tablettproduksjon for blinding purposes.
224227048|NCT02267057|DRUG|Buprenorphine|Buprenorphine 5 micrograms/hour and 10 micrograms/hour transdermal system produced by Mundipharma, identical to placebo transdermal system.
224227049|NCT02267057|DRUG|Paracetamol placebo|Paracetamol placebo tablets produced by Kragerø tablettproduksjon.
224227050|NCT02267057|DRUG|Buprenorphine placebo|Buprenorphine transdermal system placebo produced by Mundipharma.
224227051|NCT00613574|DRUG|tiotropium-bromide|Spiriva® inhaled capsule 18 mcg once daily administered via HandiHaler® on the top of usual care
224227052|NCT01800565|OTHER|Measurement of LH in first-voided urine|participants in this study will be studied by the standard GnRH stimulation test. In addition, they will provide first voided urine sample (the experimental part)for the measurement of LH.
224227053|NCT01800565|OTHER|collection of first-voided urine sample for LH level|participants in this study will be studied by the standard GnRH stimulation test. In addition, they will provide first voided urine sample (the experimental part)for the measurement of LH.
224227054|NCT03534986|DEVICE|International Biophysics AffloVest|High-frequency chest wall oscillation vest
224227055|NCT03534986|DEVICE|Hill-Rom The Vest|High-frequency chest wall oscillation vest
224227056|NCT03534986|DEVICE|Respirtech inCourage|High-frequency chest wall oscillation vest
224227057|NCT03534986|DEVICE|Electromed SmartVest|High-frequency chest wall oscillation vest
223638874|NCT05764447|BEHAVIORAL|Combined qigong Baduanjin and self-administered acupressure|The intervention will combine Baduanjin (BQ) and acupressure. The general design of the combination intervention is for BQ to be performed first (20 min), followed by self-administered acupressure (10 min). BQ comprises eight simple standardized movements. The combination of these simple body movements, breath control, and mindful meditation is designed to improve qi function.The acupressure protocol comprises six acupoints, i.e., Hegu, Quchi, Zusanli, Sanyinjiao, Qihai, and Taichong, which are the most commonly used acupoints in acupuncture trials for relieving CIPN according to previous reviews. These acupoints, based on TCM theory, are beneficial for strengthening the origin of qi and directing its flow to the upper and lower extremities. A massage pen will be used to stimulate the acupoints because participants with CIPN may have difficulty applying pressure with their hands/fingers.
224227058|NCT02588573|DEVICE|etafilcon A (control)|contact lens
224227059|NCT02588573|DEVICE|somofilcon A (test)|contact lens
224227060|NCT00176904|PROCEDURE|Stem Cell Transplant|The purpose of hematopoietic cell transplantation is to introduce hematopoietic cells from a normal donor that contains an enzyme able to get rid of the substances that have accumulated in the body of patients with storage diseases. Hematopoietic cells can come from bone marrow, peripheral blood (i.e., the blood circulating in our body's blood vessels) or umbilical cord blood (i.e., blood taken from the umbilical cord after a baby is born and umbilical cord is cut).
224227061|NCT00176904|DRUG|Busulfan, Cyclophosphamide, Antithymocyte Globulin|"Subjects will receive BUSULFAN intravenously (IV)- patients \< or= 12 kg 1.1 mg/kd/dose IV every 6 hours for 16 doses; patients \> 12kg 0.8 mg/kg/dose IV every 6 hours for 16 doses - via the Hickman line four times daily for 4 days, CYCLOPHOSPHAMIDE intravenously (50 mg/kg/day IV over 2 hours) via the Hickman line once a day for 4 days, and ANTI-THYMOCYTE GLOBULIN IV (15 mg/kg/day over 2 hours) via the Hickman line twice daily for three days before the transplant. These three drugs are being given to help the new marrow take and grow. METHYLPREDNISOLONE will be given as a pre-medication for the ATG."
224227062|NCT05474625|DEVICE|High Intensity Laser Therapy|For each 25 cm² of painful area, 1.02 minutes of treatment will give in the analgesic phase, with an energy of 8.0 watt, a dose of 5 Joules/ cm², a frequency of 25 Hertz(Hz) and a total energy of 125 joules. The application time for one session was approximately 15 minutes. Total 15 sessions will be applied to the neck area for a period of 3 weeks, 5 days a week.
224227063|NCT05474625|DEVICE|Ultrasound|This treatment was applied to the cervical paravertebral region with a direct contact with the skin with the aid of an ultrasonic gel, at a dose of 1 megahertz(MHz) and 1.5 Watt/cm² for 4 minutes
224227064|NCT05474625|DEVICE|Transcutaneous nerve stimulation (TENS)|TENS was performed using 4 adhesive electrodes 5 × 5 cm size in the cervical paravertebral region, 80 Hertz (Hz) frequency and 180 miliseconds current for 20 minutes.
224227065|NCT05474625|OTHER|Exercise|A specific program consisted of 15 minutes exercise sessions was provided under the supervision of a physiotherapist . All patients will perform isometric strengthening exercises, active range of motion exercises, and cervical region stretching exercises for 15 sessions (during 3 weeks, on weekdays).
224227066|NCT06546644|BEHAVIORAL|Structured school-based intervention|A pre-tested validated structured school-based intervention is developed for children in the intervention group. The intervention included behavior change regarding dietary patterns and physical activity. Education will be provided to children in lectures, PowerPoint, smart handouts, and videos. The parents will also be involved in this educational stream through seminars and parent schools specially organized events.
224227067|NCT06543641|DIAGNOSTIC_TEST|Coronary computed tomography angiography|All patients received coronary computed tomography angiography.
224227068|NCT06543641|DIAGNOSTIC_TEST|Invasive coronary angiography|According to the study criteria some of the patients received confirmation imaging with invasive coronary angiography.
224227069|NCT04604184|DRUG|BI 764198|BI 764198
224227070|NCT04604184|DRUG|Placebo|Placebo
224227071|NCT01751412|RADIATION|Proton Radiation|
224227072|NCT02051803|BEHAVIORAL|Distress Tolerance Treatment for Weight Concern (DT-W)|
224227073|NCT02051803|BEHAVIORAL|Health Education (HE)|
224227074|NCT05382923|BEHAVIORAL|Bright Light|3 consecutive days of 1 hour bright light
224227075|NCT05382923|BEHAVIORAL|Bright Light + Exercise + Melatonin|3 consecutive days of bright light, exercise, and melatonin
224227076|NCT05382923|BEHAVIORAL|Control|3 consecutive days of dim red light + light stretching + placbo
224227077|NCT01838902|DRUG|DHA-PPQ|Participants will receive a 3 day course of DHA-PPQ
224227078|NCT01838902|DRUG|PQ (0.75)|Participants will receive a single dose of PQ at 0.75mg base/kg body weight
223638875|NCT05764447|BEHAVIORAL|Wait-list Control|The participants will receive usual care alone during the study period and will be offered the training after the last follow-up.
223638876|NCT05291520|BIOLOGICAL|VH3810109|VH3810109 was administered.
223638877|NCT05291520|BIOLOGICAL|rHuPH20|rHuPH20 was administered.
223638878|NCT01347112|DRUG|Varenicline|varenicline 1.0 mg dose, twice daily for 12 weeks
223638879|NCT01347112|DRUG|placebo|sugar pill twice daily for 12 weeks
223638880|NCT04190641|DEVICE|Ambu aScope 4 Cysto and aView Urologia|Visualization of the urethra and the bladder
223638881|NCT05202886|DIAGNOSTIC_TEST|Liver from deceased donors|Liver donors photographed
223638882|NCT01679314|DEVICE|AlphaCore device|Each study group will go under the same treatment regimen and assessments.
223638883|NCT02342808|BEHAVIORAL|Structured center-based lifestyle intervention|Participants will meet with interventionists weekly for 16 weeks and receive instruction on the DASH diet with caloric and sodium restriction and will exercise three times per week at one of the designated CR facilities, under the supervision of medically trained staff, 3 times per week for 16 weeks.
223638884|NCT02342808|BEHAVIORAL|Standard education and physician advice|Participants will receive routine medical care provided by the participants' primary care physician(s) supplemented by an educational session on hypertension management. Participants will receive a dietary consultation from the study nutritionist and an individualized exercise prescription from an exercise physiologist, but not participate in a structured program. Participants will be free to engage in diet and exercise for the 16-week intervention.
224227079|NCT01838902|DRUG|PQ (0.4)|Participants will receive a single dose of PQ at 0.4mg base/kg body weight
224227080|NCT01838902|DRUG|PQ (0.2)|Participants will receive a single dose of PQ at 0.2mg base/kg body weight
224227081|NCT02018146|OTHER|Mask then nasopharyngeal|Patients will be randomly assigned to Mask ventilation followed by naso-pharyngeal ventilation
224227082|NCT02018146|OTHER|Nasopharyngeal then mask|Patients will be randomly assigned to naso-pharyngeal ventilation followed by mask ventilation.
224227083|NCT01711021|DRUG|d-Amphetamine Transdermal Patch|"The study was conducted in 2 parts: a 5 week, open-label, step-wise Dose Optimization Period and a 2-week, randomized, cross-over Double-Blind Treatment Period.~Patches will be worn for 9 hours every day. After 9 hours the patch will be removed. Every day a new patch will be applied."
224227084|NCT01711021|DRUG|Placebo patch|"The study was conducted in 2 parts: a 5 week, open-label, step-wise Dose Optimization Period and a 2-week, randomized, cross-over Double-Blind Treatment Period.~Patches will be worn for 9 hours every day. After 9 hours the patch will be removed. Every day a new patch will be applied."
224227085|NCT04200508|OTHER|Targeted gown and gloves use|Gown and glove use for high risk care activities in high risk residents
224227086|NCT00163384|DRUG|Ciclesonide|
224227087|NCT03430375|DEVICE|Alternating air wheelchair cushion|The Ease alternating air cushion has longitudinal air bladders which alternately inflate and deflate at 3 minutes intervals in order to change the areas of pressure to the skin for areas in contact with the wheelchair cushion/seat (buttock and posterior thighs). The Ease Alternating Pressure wheelchair cushion is 510(k) exempt.
224227088|NCT03430375|DEVICE|Static air cushion|The Roho static air cushion is composed of multiple air bladders that are inflated to proper levels according to the individual's weight. This cushion is commonly used for individuals post spinal cord injury and sometime for individuals post stroke. The Roho wheelchair cushion is 510(k) exempt.
224227089|NCT01499875|DRUG|Phenoxymethylpenicillin|mixture, 25 or 50 mg/kg taken once.
224227090|NCT05411042|DEVICE|Dance somatosensory game|dance somatosensory game (DSG), DANZ BASE developed by International Games System Company
224227091|NCT03265899|DRUG|Oxytocin|40 IU; 5 puffs balanced across nostrils, at an inter-puff interval of 30 seconds
224227092|NCT03265899|DRUG|Placebo|Placebo nasal spray, 5 puffs balanced across nostrils, at an inter-puff interval of 30 seconds
224227093|NCT03734237|BIOLOGICAL|Egg based influenza vaccines|Participants will be randomly allocated to one of three vaccine types in accordance with standard clinical practices for those in the US military. All vaccines are FDA licensed for use in the United States.
223638885|NCT03208010|BEHAVIORAL|Diabetes Prevention Intervention|"* Educational sessions with emphasis on physical activity, healthy cultural diets, and strategies to promote positive behavioral changes.~* Specific goals set for weight loss and physical activities~* Fitbits provided for monitoring physical activity goals~* Weekly review of and feedback on effects of physical activity (Fitbits) and dietary changes (checklists)~* 15 biweekly support group sessions plus 3 booster sessions every 6 months thereafter~Note: In response to the COVID-19 pandemic, a remote version of the intervention was designed to provide the program remotely instead of via the usual in-person group format. This alternative strategy is designed to replace the biweekly support groups, which in the past focused on similar content, i.e., reviewing key educational content, demonstrations of healthy Mexican American recipes."
223638886|NCT03208010|OTHER|Enhanced Usual Care|"* Monitoring by existing personal physicians~* Feedback on lab results~* Referrals to physicians or clinics, if needed~* Diabetes prevention educational materials"
223638887|NCT00696072|DRUG|Dasatinib|Tablets, Oral, 100 mg once daily, up to 2 years
223638888|NCT00696072|DRUG|Letrozole|Tablets, Oral, 2.5 mg, once daily, up to 2 years
223638889|NCT01597596|BIOLOGICAL|alglucosidase alfa|Intravenous (IV) infusion of alglucosidase alfa (4000 L material) 20 mg/kg every other week (QOW)
223638890|NCT01597596|BIOLOGICAL|alglucosidase alfa|IV infusion of alglucosidase alfa (160 L material) 20 mg/kg QOW.
223638891|NCT05990010|DIAGNOSTIC_TEST|Berlin Questionnaire|The Berlin Questionnaire is a simple survey that helps doctors identify OSA risk. It looks at snoring, daytime sleepiness, obesity, and hypertension. A positive score in two or more areas indicates high risk, while one or none suggests low risk. It is an easy and effective tool to assess OSA risk, with proven validity.
223638892|NCT06517420|OTHER|kefir consumption|Support and information was received from the Food Technology Department of a university's Experimental Medicine Application and Research Center. It was decided to choose the kefir to be used, which is produced from pasteurized cow's milk, lactase enzyme, probiotic culture (B. Lactis) and kefir culture, will meet the B12 need, contribute to increasing vitality and energy, and has the most suitable content in the market. Kefir, supplied by the researcher, was given to the patients at the end of each session in the amount that the patients should consume for a week, following the cold chain rule. While consuming kefir, it was recommended to gargle it in the mouth, hold it for a while, and then swallow. Patients were contacted for a week after the session to ensure that they applied kefir correctly.
223638893|NCT02124369|DRUG|Abraxane|125mg/m2, IV, on days 1,8 \& 15 of each 28 day cycle, up to 6 cycles.
223638894|NCT02124369|DRUG|Gemcitabine|1000mg/m2, IV, on days 1,8 \& 15 of a 28 day cycle, up to 6 cycles.
223638895|NCT00915382|DRUG|S-1 and cisplatin|"S-1: 80 mg/m2/day po on Days 1-14~cisplatin: 60 mg/m2 iv on Day 1"
223638896|NCT00915382|DRUG|S-1 and cisplatin|"S-1: 80 mg/day with BSA less than 1.25 m2, 100 mg/day with BSA more than 1.25 m2 and less than 1.5 m2, 120 mg/day with BSA more than 1.5 m2 on Days 1-21 and~cisplatin: 60 mg/m2 iv on Day 1 or 8"
224227094|NCT03734237|BIOLOGICAL|Recombinant influenza vaccines|Participants will be randomly allocated to one of three vaccine types in accordance with standard clinical practices for those in the US military. All vaccines are FDA licensed for use in the United States.
224227095|NCT03734237|BIOLOGICAL|Cell-culture based influenza vaccines|Participants will be randomly allocated to one of three vaccine types in accordance with standard clinical practices for those in the US military. All vaccines are FDA licensed for use in the United States.
224227096|NCT02711956|DRUG|ZEN003694|
224227097|NCT02711956|DRUG|Enzalutamide|
224227098|NCT00555256|DRUG|sunitinib and rapamycin (Drug will be held)|Any toxicity causing a total of 14 days delay of therapy will be considered dose limiting.
224227099|NCT05059756|DEVICE|PTNS|PTNS and PFR
224227100|NCT05059756|DEVICE|Sham PTNS|Sham PTNS and PFR
224227101|NCT00035009|DRUG|MK0869, aprepitant|
224227102|NCT00035009|DRUG|Comparator: paroxetine HCL|
224227103|NCT01784133|DRUG|omiganan|
224227104|NCT01784133|DRUG|placebo|
224227105|NCT02137083|DRUG|Docetaxel|75mg/m2 D2 every 21 days
223638897|NCT04950647|DRUG|Nitrofurazone Group 1|Test group 1: Nitroketazine tablet 600 mg group (Nitroketazine 300 mg tablet X2 + placebo 300 mg tablet ×2 tablets each time; If the subject progresses and cannot take 300mg tablets, Nitroketazine 100mg tablets x6 + placebo 100mg tablets x6) can be replaced.
223638898|NCT04950647|DRUG|Nitroketazine Group 2|Test group 2: Nitroketazine tablets 1200 mg group (each oral Nitroketazine 300 mg tablets x4 tablets; If the subject progresses and cannot take 300 mg tablets, Nitroketazine 100mg tablets x12 tablets can be taken instead).
224227106|NCT02137083|DRUG|Fulvestrant|500mg D1, D15, D29, D57, every 28 days later
223638899|NCT04950647|DRUG|placebo group|Control group: placebo group (placebo 300mg tablets x4 tablets each orally; If subjects progress and cannot take 300mg tablets, they may take placebo 100 mg tablets x 12 tablets instead).
223638900|NCT06137417|DEVICE|PET/CT|• Suspected patients known to have a primary malignant tumour, patients with metastasis of unknown primary and had incidental peritoneal lesions.
223638901|NCT03714958|DRUG|HDM201|Treatment will be administered as long as patient experience clinical benefit in the opinion of the investigator or until unacceptable toxicity or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status or withdrawal of consent.
223638902|NCT03714958|DRUG|Trametinib|Treatment will be administered as long as patient experience clinical benefit in the opinion of the investigator or until unacceptable toxicity or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status or withdrawal of consent.
223638903|NCT02937116|DRUG|IBI308|
223638904|NCT02937116|DRUG|IBI308\Cisplatinum\Pemetrexed|
223638905|NCT02937116|DRUG|IBI308\cisplatin\gemcitabine|
223638906|NCT02937116|DRUG|IBI308\oxaliplatin\capecitabine|
223638907|NCT02937116|DRUG|IBI308\etoposide\cisplatin|
223638908|NCT02937116|DRUG|IBI308\irinotecan\5-FU|
223638909|NCT05403346|DEVICE|CoviDx™ Covid-19 Antigen Self-Test|All patients will self-collect a mid-turbinate nasal swab for CoviDx™ Covid-19 Antigen self-testing
223638910|NCT06523361|DEVICE|H'ability|H'ability is introduced depending the randomization result, during the baseline (before session 4, 5, 6 or 7 with occupational therapist
224227107|NCT01844583|DRUG|Alisertib|Alisertib tablets
224227108|NCT01844583|DRUG|Esomeprazole|Esomeprazole capsules
224227109|NCT01844583|DRUG|Rifampin|Rifampin capsules
224227110|NCT02840383|OTHER|Delayed Intervention|Schools not receiving intervention until two years after implementation.
224227111|NCT02840383|OTHER|Intervention|intervention at the beginning of study.
224227112|NCT00306345|BEHAVIORAL|Outreach|
224227113|NCT03231254|DEVICE|Remotely Controlled Mandibular Positioner (RCMP)|RCMP device can accurately identify patients who are likely to be successful OA candidates. With a temporary dental appliance connected to a RCMP, the mandible could be progressively, mildly and precisely protruded in only anterior-posterior dimension, under the monitor of PSG, without disturbing sleep, until obstructive apneas and hypopneas were eliminated, particularly in REM sleep while supine. Besides, RCMP device can also determine the optimal therapeutic level of mandibular protrusion during sleep.
224227114|NCT01625377|DRUG|tacrolimus|Arm 1 : tacrolimus (C0 6-10 ng/ml) from D3-D5 post-transplantation to month 6 post-transplantation. Arm 2 : tacolimus (C0 6-10 ng/ml) from D3-D5 post-transplantation to 16 weeks post-transplantation at the latest.
224227115|NCT01625377|DRUG|everolimus|Arm 1: no everolimus Arm 2: everolimus (C0 6-10 ng/ml) from randomization to month 6 post-transplantation
223638911|NCT04122716|DRUG|Liraglutide|"Daily injections (3mg) with weight consultations starting at dose of 0.6 mg injections with 0.6 mg increments weekly until 3.0 mg is achieved. For subjects who do not tolerate the fast weekly up-titration of 0.6 mg study drug until the 3mg, the titration procedure can be prolonged with up to three weeks for each up-titration.~Subjects who do not tolerate the 3mg dose may in special circumstances stay at 2.4 mg, however the overall aim is to reach 3 mg for all study subjects.~The dosage and up-titration follow the recommendations from the summary of product characteristics."
223638912|NCT04122716|BEHAVIORAL|Exercise|"150 min of moderate intensity, 75 min of vigorous intensity, or an equivalent combination of moderate and vigorous intensity exercise per week in accordance with WHO recommendations.~Exercise prescription will be performed under strict control of the scientific personnel.~There will be aerobic exercise and will include 4 sessions per week after the ramp-in period.~2 sessions per week will be performed under supervision of the staff and 2 sessions will be performed individually but monitored by the staff.~Supervised sessions include structured exercise with a duration of 45 min. Of this 30 min will comprise of interval-based spinning session and 15 min circuit training program focusing on large muscle groups.~Individual exercise includes aerobic exercise and general physical activity (e.g brisk walking and cycling to work).~Participants will use heart rate monitors during sessions."
223638913|NCT05663606|COMBINATION_PRODUCT|Happy Bob|Application, which gives stars when subject reachs Time In Range
223638914|NCT05663606|DEVICE|CGM|Dexcom CGM
223638915|NCT02398435|BIOLOGICAL|Tadekinig alfa (recombinant human IL-18 binding protein)|Patients received the study treatment three times a week subcutaneously.
223638916|NCT01684761|BIOLOGICAL|Tcelna|Autologous pool of myelin reactive T-cells (MRTC) expanded ex vivo with immunodominant epitopes selected from the three myelin antigens, MBP, PLP and MOG on a per subject basis. Attenuated by irradiation to prevent further proliferation before releasing product for administration.
224227116|NCT01625377|DRUG|Basiliximab|Basiliximab was supplied to the participating centers as marketed, i.e. in packs containing one vial of 20-mg powder, and water for injection (WFI). 20 mg at D0 and D4
223638917|NCT01684761|BIOLOGICAL|Placebo|2 ml of Tcelna excipients, prepared daily as individual doses and irradiated before releasing product for administration.
223638918|NCT02876549|DRUG|Chloroquine|10 mg/kg on day 0 \& 1 and 5mg/kg on day 2, (Afghanistan NMLCP guidelines)
223638919|NCT02876549|DRUG|Primaquine 0.25 mg/kg/day|0.25 mg/kg/day for 14 days
223638920|NCT02876549|DRUG|Primaquine 0.75 mg/kg weekly|0.75 mg/kg weekly for eight weeks
223638921|NCT00966134|OTHER|exposure to high altitude|
223638922|NCT00740311|DEVICE|MBCP gel TM|alveoli filling with an injectable calcium phosphate after extraction of mandibular molar or pre molar
224227117|NCT01625377|DRUG|Mycophenolic Acid|Dose of 1440 mg/day from transplantation to month 6 post- transplantation
223638923|NCT01610934|DRUG|liraglutide|The initial daily dose will be 0.6 mg for one week, 1.2 mg the following week and then 1.8 mg for the remaining treatment period. Patients who, due to adverse events, do not tolerate up-titration to 1.8 mg liraglutide will remain on 1.2 mg of liraglutide. The injection is administered once daily in the morning.
223638924|NCT01610934|DRUG|Glimepiride|At randomisation patients will be initiated on their pre-study daily dose of glimepiride minus 0.5 mg. After one week the dose will be titrated (see below). Drug naïve patients will be initiated on an initial dosage of glimepiride of 0.5 mg for one week. Thereafter, glimepiride is increased to 1.0 mg and after another one week to 1.5 mg, and there after further up to 3 mg (if the average FPG during one week is above 6 mM). The dose of glimepiride can be increased up to 4 mg if average FPG is above 6 mM and no symptoms of hypoglycaemia are observed.
223638925|NCT06514560|DRUG|Miltefosine|Miltefosine will be prescribed by the treating physician for a minimum of 4 weeks. If treatment response is not sufficient, treatment extension could be decided by the treating physician up to 8 weeks
223638926|NCT06472843|BEHAVIORAL|Exercise Intervention|The exercise session is a fitness test using a hand bike, and you will be randomly assigned to one of two exercise sessions. The fitness test and exercise sessions are short (less than 10 minutes).
223638927|NCT04056390|PROCEDURE|Catheter ablation using irrigated radiofrequency current ablation or cryothermal energy|Substrate ablation in terms of voltage abatement versus electrical left atrial appendage isolation.
223638928|NCT05128916|BIOLOGICAL|intralesional platelet rich plasma|Three to fifteen milliliters of blood will be drawn from each patient then evacuated after detachment of syringe needle into 15 ml conical tube containing 3.8% sodium citrate solution. Blood will be centrifuged at 300 G-force (\~ 1500 RPM) for 10 minutes. This will allow the blood to separate into 3 layers: Upper platelet-poor plasma, middle platelet-rich plasma, and lower RBCs layers. The supernatant (upper third) will be removed and the middle third (PRP) will be aspirated and used for intralesional injection of affected nails.
223638929|NCT05128916|DRUG|Oral terbinafine|Patients in (PRP + terbinafine) and (terbinafine) groups will receive oral 250 mg terbinafine tablets taken immediately after a fatty meal, daily for a total of 3 months
223638930|NCT03517878|BEHAVIORAL|Comprehensive CHW Program|"The comprehensive CHW Cohort will receive home visits from CHWs recruited, trained, and supervised by the Philani organization. Philani has a 30-year history of non-stigmatizing home-based support for women and children in Cape Town. The organization has been operating their comprehensive CHW program in the rural Eastern Cape since 2010; however, in the research areas, CHWs have only been active for one year prior to initiation of the study. Philani recruits CHWs that are positive peer deviants to serve as role models in the community. The CHWs then receive training, materials, and skills to address major community health challenges of HIV, TB, malnutrition, alcohol use, and depression. The CHWs also receive ongoing monitoring and supervision as well as support for difficult cases."
223638931|NCT01895413|PROCEDURE|Bone marrow aspiration|Single intra-articular injection of autologous bone marrow-derived mesenchymal stem cells by arthroscopy
223638932|NCT03008434|OTHER|Assigned Interventions|Yoga Group: designed for chronic TBI was provided two times a week for 8 weeks.
223638933|NCT05650385|DRUG|B1962|B1962 is a PD-L1/VEGF bispecific antibody fusion protein.
223638934|NCT00104286|DRUG|Troxatyl™ (Cytotoxic Chemotherapeutic)|
224227118|NCT01625377|DRUG|Corticosteroids|Administration of oral corticosteroid therapy was at the discretion of the centers according to their usual practice
224227119|NCT01000753|OTHER|Cytology Specimen Collection Procedure|Correlative studies
224227120|NCT03513497|OTHER|Customized acrylic mouthguard|Customized acrylic mouthguards extended to cover approximately 2 mm over gingival margins will be fabricated for each subject. Stents will form a seal and rest on the gingiva, but will be relieved on the tooth and tissue side except for the occlusal surfaces to avoid disturbing plaque or gingival tissues. Acrylic stents will cover the area in one sextant where no brushing and flossing teeth is to occur for 21 days.
224227121|NCT01997554|OTHER|Blood sample|An extra blood sample of 10 ml is collected
224227122|NCT03028662|BEHAVIORAL|Retrieval-Extinction Learning|The intervention consists of the accomplishment of the task of approach-avoidance of alcohol during 4 days of training. Subjects are instructed to respond with an approach movement (pulling a lever) to neutral images and to respond with avoidance movement (pushing the lever) to images of alcohol.
224227123|NCT03368989|DRUG|Radium-223 dichloride|Previously known as Alpharadin, Radium-223 dichloride is a calcium-mimetic, alpha emitting radiopharmaceutical, which introduces double-stranded DNA breaks in metastatic cancer cells.
224227124|NCT00445289|DEVICE|SmartCare/PS|
224227125|NCT06202157|OTHER|LMB|A baseline blood sample (t=0) is collected from each participant prior to the intervention (LMB), and subsequent blood samples are collected at 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24 hours post-intervention.
224227126|NCT06202157|OTHER|DHB|A baseline blood sample (t=0) is collected from each participant prior to the intervention (DHB), and subsequent blood samples are collected at 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24 hours post-intervention.
224227127|NCT04509973|DRUG|Dexamethasone|ATC code: H02AB02
224227128|NCT00020891|PROCEDURE|computed tomography|
224227129|NCT00020891|RADIATION|radiation therapy|
224319133|NCT05327153|BEHAVIORAL|Acceptance and Commitment Therapy|The theoretical foundation of ACT is Relational Frame Theory (RFT) based on the functional contextualism philosophy, which suggests that the main psychological problem derived verbal and cognitive interaction with environment, leading to behaviors contrary to long-term values and psychological inflexibility. The psychopathological model of ACT includes six core parts: experiential avoidance, cognitive fusion, attachment to the conceptualized self, conceptualized past and feared future, lack of value clarity, inaction.
223638935|NCT01699438|DRUG|Mesalazine|2400 mg q.d. for 8 weeks
223638936|NCT01699438|DRUG|Placebo|3 tablets q.d. for 8 weeks
224227130|NCT04990830|DRUG|Inhaled Low molecular weight heparin|Application with Soft Mist Inhaler
224227131|NCT04990830|DRUG|Standard Treatment|Control Group
224227132|NCT00279448|DRUG|exemestane|On tablet of 25 mg per day during 5 years
224227133|NCT00279448|DRUG|tamoxifen|Two tablets of tamoxifen 10 mg per day during 2.5 to 3 years followed by one tablet of exemestane 25 mg per day during 2 to 2.5 years for a total duration of 5 years of treatment
223638937|NCT04349332|DEVICE|Helmet non-invasive ventilation (NIV)|After application of the helmet, arterial blood gas sampling will be utilized to follow gas-exchange; Noninvasive support will be reduced progressively in accordance to clinical improvement and will be discontinued if patient maintains respiratory rate \<30breaths/min and PaO2 \>75mm Hg with FiO2 0.5 without ventilatory support. If endotracheal intubation is required, the helmet will be removed and the patient will be intubated without delay.
223638938|NCT04053660|PROCEDURE|Non-surgical periodontal treatment|Mechanical non-surgical treatment were performed
223638939|NCT02351622|DRUG|Caffeic acid|Oral administration of caffeic acid tablet 0.3g three times per day for 1 year
223638940|NCT02351622|DRUG|Dexamethasone|Oral administration of dexamethasone 40 mg for four consecutive days then proceed another cycle 10 days later, 3 cycles in total.
223638941|NCT02351622|DRUG|Placebo|Sugar pills manufactured to mimic caffeic acid tablet. Oral administration of placebo tablet 0.3g three times per day for 1 year.
223638942|NCT03217604|DRUG|Placebo|Treatment with placebo
223638943|NCT03217604|DRUG|PF-06852231|Treatment with PF-06852231
223638944|NCT04643210|BEHAVIORAL|F2F MoB EI|"The MoB F2F EI will comprise a total of 12 educational F2F sessions. Each session will have a duration of 1.5 hours and the maximum number of participants in the groups will be 12 patients.~The intervention group will receive the MoB F2F EI on group or personal form according to the participant's choice. The implementation methodology of the MoB F2F EI will include videos and power point presentations, as well as interactive learning methods such as role-playing, empowerment exercises, live discussions."
223638945|NCT04643210|OTHER|MoB DP|This is a technology-based intervention, which regards access to a dfigital platform, the MoB DP. The structure of the Digital platform has been partially based on the preferences and needs of the participants (as described in the qualitative part of the study) and its goal is to create an ecosystem where users will be educated and empowered making use of the internet of things (IOT) via a computer, tablet or mobile. The Digital platform will be in the form of a dynamic website with user generated content as well as static information.
223638946|NCT02856672|DEVICE|Supreme Laryngeal Mask Airway|Supreme Laryngeal Mask Airway
223638947|NCT02856672|DEVICE|Laryngeal Tube Suction Disposable|Laryngeal Tube Suction Disposable
223638948|NCT04626908|DRUG|GC022F CAR-T cells|Each subject receive GC022F CAR-T cells by intravenous infusion
223638949|NCT05777499|BEHAVIORAL|Music Therapy|Music Therapy will comprise individual and group sessions 20-45 minutes. Participants usually have 1-2 individual sessions, and 1 group session/week. Group sessions include 2-6 participants. On average, participants receive an average 1 hour 30 minutes Music Therapy/week, timetabled when they would not otherwise be undergoing any therapy sessions. The Music Therapist will use the Nordoff Robbins approach and work flexibly as a musician. Techniques include (but are not limited to) empathic listening, musically matching, turn taking and sequencing, call and response. Sessions may also involve songwriting, singing familiar songs, listening to, sharing and discussing music, developing specific musical skills of interest to the participant, structured musical games and activities, joint working with other members of the therapy team in sessions focused on functional development and communication skills.
223638950|NCT05777499|BEHAVIORAL|Control Therapy|Control Therapy sessions will be carried out by a member of the clinical team, matched in duration and number to Music Therapy sessions as closely as possible. Participants will usually have 1-2 individual sessions and 1 group session/week. Group sessions include 2-6 participants. The Control Therapy intervention will continue throughout participant's rehabilitation program until participants have completed a total of 15 hours intervention, which will usually take 10 weeks to complete. The content of sessions is designed to reflect 'usual care' however control therapy sessions will not include access to specific specialist equipment such as MOTOmed, therabike or neuro-muscular electrical stimulation, to ensure the control group does not get additional specialist intervention beyond usual care. Content of control therapy sessions will therefore be restricted to the following five domains: gaming, education, mindfulness, current affairs discussions, and passive and dynamic stretching.
223638951|NCT02208310|DRUG|Cholecalciferol 10,000 IU|Cholecalciferol 10,000 IU po daily
223638952|NCT02208310|DRUG|Cholecalciferol 400 IU|Cholecalciferol 400 IU po daily
223638953|NCT05483777|PROCEDURE|PRF|Platelet-rich fibrin preparation and application technique will applied to the experimental group.
223638954|NCT05809375|OTHER|Coping Skills Training|In the intervention, it was acted in a way to include the educational content determined by the International Headache Association and with a problem-solving perspective. The coping skills training contents in the literature were combined, and the CST prepared by including the most used and related contents will be given. CST includes a targeted therapy specifically developed for this study to address the needs and expectations of individuals with migraine. The targeted CST was designed by the authors, consisting of an occupational therapist, and two physiotherapists with clinical, and academic experience. It is planned as a total of eight sessions, and two sessions per week. CST includes giving information about migraine, activity tempo, progressive muscle relaxation exercise, stress management, social participation, leisure time management, general evaluation of the program, and home program.
223638955|NCT06165289|OTHER|PRP Injection|Endoscopic balloon dilatation combined with autologous platelet-rich plasma (PRP) injection with different concerntrations
223638956|NCT05322681|DRUG|Pregabalin 150mg|Case management consists confirmation of hospital visit date, checking the adverse effect and treatment compliance.
223638957|NCT01323101|DRUG|Doxycycline|Doxycycline 40mg, 100mg, 200mg tablet once daily, or no drug for 28 days.
223638958|NCT01323101|OTHER|No doxycycline|
224227134|NCT03246230|BIOLOGICAL|Hepatitis B vaccine (HBV)|Licensed pediatric HBV vaccine will be administered at birth (Day of Life 0) or delayed to Day of Life 7.
223638959|NCT03510546|DRUG|Pyridostigmine|Study dose as per protocol.
223638960|NCT03510546|DRUG|Placebo oral capsule|Study dose as per protocol.
223638961|NCT02141295|DRUG|5-FU|5-FU will be administered according to dose and schedule described in respective arm.
223638962|NCT02141295|DRUG|Bevacizumab|Bevacizumab will be administered according to dose and schedule described in respective arm.
224227135|NCT03246230|BIOLOGICAL|Bacillus Calmette-Guérin (BCG)|Licensed BCG vaccine will be administered at birth (Day of Life 0) or delayed to Day of Life 7.
223638963|NCT02141295|DRUG|Folinic acid|Folinic acid will be administered according to dose and schedule described in respective arm.
223638964|NCT02141295|DRUG|Oxaliplatin|Oxaliplatin will be administered according to dose and schedule described in respective arm.
224227136|NCT05096325|DEVICE|YpsoPump® insulin pump system|The subjects will receive a CE-certified mylife™ YpsoPump® insulin pump system that allows detailed logging of pressure data. Data will then be analysed in silico comparing the new occlusion detection algorithm with the common occlusion detection algorithm.
224227137|NCT02470039|DRUG|insulin 338 (GIPET I)|Oral administered once daily in combination with metformin with or without DPP-4 inhibitor
224227138|NCT02470039|DRUG|insulin glargine|Injected s.c./subcutaneously (under the skin) once daily in combination with metformin with or without DPP-4 inhibitor
224227139|NCT02470039|DRUG|placebo|Administered once daily
224227140|NCT01448135|OTHER|VITAL AF|Semi-elemental, high protein, and high omega-3 fish oil enteral formula
224227141|NCT01448135|OTHER|Osmolite 1.2|High protein enteral formula
224319134|NCT00956423|BEHAVIORAL|moderate-intensity aerobic and resistance training|Individuals will complete four days of aerobic exercise of moderate intensity (60% of maximal VO2, approximated from heart rate). Duration of aerobic activity will gradually increase from weeks 1 through 4 until 180 min of aerobic exercise at the prescribed intensity is performed each week. Following aerobic exercise on two days per week, moderate-intensity resistance training will be performed using eight different resistance machines. One set of 8-12 repetitions will be performed during weeks 1-4; from week 5-on, 2 sets of 8-12 repetitions will be performed.
223638965|NCT02141295|DRUG|Vanucizumab|Vanucizumab will be administered according to dose and schedule described in respective arm.
223638966|NCT01466712|DRUG|Tiotropium + formoterol/beclometasone|Tiotropium 18 µg/dose once daily (handihaler device) + formoterol, fumarate 6µg + beclometasone, dipropionate 100µg / dose (Pressurised inhaler): 2 puffs bid, for one month.
223638967|NCT01466712|DRUG|tiotropium + placebo|Tiotropium 18 µg/dose once daily (handihaler device) + placebo (Pressurised inhaler): 2 puffs bid, for one month.
223638968|NCT00551811|DRUG|SB-656933-AAA|SB-656933-AAA tablets will be available with a dose strength of 50 milligrams, administered orally.
223638969|NCT00551811|DRUG|Placebo|Placebo tablets will be intended to be administered orally.
223638970|NCT03902977|PROCEDURE|quilting|After mastectomies or ALND dissections using standard technique for wound closure multiple sutures (monocryl 3.0) every 3 to 4 cm in the site of the mastectomy (1 or 2 rows) or in the dissected axilla.Placement of one drain into the breast and axilla or in the axillary cavity by a separate stab incision
223638971|NCT03902977|PROCEDURE|conventional suture|After mastectomies or ALND dissections standard technique for wound closure. Placement of one drain into the breast and axilla or in the axillary cavity by a separate stab incision
223638972|NCT01710501|DRUG|Grazoprevir|Grazoprevir tablet, orally, once per day at assigned dose
223638973|NCT01710501|BIOLOGICAL|pegylated interferon alfa-2b|1.5 mcg/kg/week, administered as a weekly subcutaneous (SC) injection
223638974|NCT01710501|DRUG|Ribavirin|Ribavirin capsule, orally, twice daily, at a dose of 800 to 1400 mg based on participant weight
223638975|NCT01710501|DRUG|Placebo|Placebo to match grazoprevir tablets to maintain dose blinding
223638976|NCT06185543|DRUG|PrimeC|Ciprofloxacin and celecoxib combination extended release formulation
223638977|NCT06185543|DRUG|Placebo|Placebo matches active drug in size, color and taste
223638978|NCT02536976|DRUG|mirabegron|
223638979|NCT02536976|DRUG|Placebo|
223638980|NCT03986086|DRUG|MPH966|RP2D tablet
223638981|NCT03986086|DRUG|Placebo|MPH966 placebo table
223638982|NCT03053817|OTHER|Exercise group|Interval training will be performed for 21 minutes including a 3 minute warm-up and cool-down period. The interval program will be 15 minutes at 65-75% of maximal heart rate with 30 sec. bursts of exercise to 80-85%; intervals. Resistance training will be done as a circuit and will make use of weight machines and functional exercises. Resistance will be done in 2 sets of 15 repetitions and will last 24 minutes. The work load of the program is calibrated and is conducted at a specified rhythm. All exercise sessions will be supervised.
223638983|NCT00553878|DRUG|Dutasteride|dutasteride 0.5mg capsule daily until serum PSA rises to 5ng/ml in the off treatment interval
223638984|NCT04216056|BEHAVIORAL|Frailty intervention program|There will be 2 sessions per week for 12 weeks. Each session includes 1 hour exercise (including 5-10 minute warm-up and cool-down routine, 20-30 minute chair-based resistance exercises using Thera-Bands for muscle groups in both the upper and lower body, and 20-30 minutes aerobic exercises); and 1 hour game training using computer video games, board games and card games. Nutrition education will be given to the subjects based on their weight status. The 1st level of nutrition information (healthy eating tips for frailty prevention and management) will be given to all subjects on regular basis during the 12-week study period via short videos, text messages or Whatsapp reminders. On top of the 1st level nutrition information, 3 nutrition heath talks (1-1.5 hours per talk) about weight management will be given to those with BMI \>=25 kg/m2, and/or waist circumference \>=90 cm (male) or \>=80 cm (female) during the 12-week study period.
223638985|NCT00071890|DRUG|Interleukin 2|Three cycles of IL-2 (6 MUI bid during 5 days = one cycle)
223638986|NCT00071890|DRUG|HAART|HAART from week 0 to week 24
223638987|NCT00071890|DRUG|Treatment interruption|HAART is interrupted from week 24 in both arms
223638988|NCT00301314|PROCEDURE|Autologous stem cell transplant|
223638989|NCT01671319|DRUG|docetaxel + cyclophosphamide + pegfilgrastim|docetaxel 75 mg/m2 + cyclophosphamide 600 mg/m2 IV every 2 weeks x 4 cycles plus pegfilgrastim 6mg sq 24-48 hours post day 1 of each cycle
224227142|NCT03340168|OTHER|Bisphenol-S|Oral and dermal exposure in volunteers
224227143|NCT02025114|DRUG|selumetinib|The starting dose of selumetinib in combination with the standard dose of gefitinib (250mg QD) on a continuous dosing schedule will be 50mg QD. Total 3 doses of selumetinib will be tested (50mg QD, 50mg BID and 75mg BID).
224227144|NCT03422146|OTHER|Tea Tree Oil (TTO)|Participants will use the Cliradex® eyelid hygiene lid wipe / towelette for BID for 2 weeks
224227145|NCT03422146|OTHER|I-Lid'n Lash® Hygiene|Patients will use the I-Lid'n Lash® Hygiene lid wipe / towelette for BID for 2 weeks
224227146|NCT02271555|DRUG|Sevoflurane|Anesthetic induction will be achieved via 8% sevoflurane
224227147|NCT02271555|DRUG|Remifentanil|After the loss of consciousness remifentanil will be administered to Group sevoflurane-remifentanil in the form of a 1 µg/kg intravenous bolus.
224227148|NCT02271555|DRUG|Saline|After the loss of consciousness saline will be administered to Group sevoflurane-saline intravenous bolus.
224319135|NCT00956423|BEHAVIORAL|low-intensity stretching|Individuals will perform supervised whole-body flexibility exercises on two days per week. Two sets of each exercise will be performed, with the duration of each stretch gradually increasing from 15 sec to 30 sec. A total of 15-20 stretches, focusing on whole-body flexibility, will be performed.
224319136|NCT06582797|OTHER|discontinuation of ART|patient will discontinue their standard of care HIV treatment with ART while being closely monitored
223638990|NCT01389596|DRUG|Pregabalin add-on therapy|Subjects will be randomized to receive a fixed dose of either placebo, pregabalin Level 1 (maximum 150 mg/day) or pregabalin Level 2 (maximum 600 mg/day) in a 1:1:1 ratio, in addition to the subjects current AED medication regimen. Either capsules or oral liquid form will be administered, depending on subjects preference and ability to swallow capsules, in two equally divided daily doses. The study will have an 8 week baseline period; a 2 week dose escalation period; a 9 week dose maintenance period; and a 1 week dose taper period.
223638991|NCT01389596|DRUG|Pregabalin add-on therapy|Subjects will be randomized to receive a fixed dose of either placebo, pregabalin Level 1 (maximum 150 mg/day) or pregabalin Level 2 (maximum 600 mg/day) in a 1:1:1 ratio, in addition to the subjects current AED medication regimen. Either capsules or oral liquid form will be administered, depending on subjects preference and ability to swallow capsules, in two equally divided daily doses. The study will have an 8 week baseline period; a 2 week dose escalation period; a 9 week dose maintenance period; and a 1 week dose taper period.
223638992|NCT01389596|DRUG|Pregabalin add-on therapy|Subjects will be randomized to receive a fixed dose of either placebo, pregabalin Level 1 (maximum 150 mg/day) or pregabalin Level 2 (maximum 600 mg/day) in a 1:1:1 ratio, in addition to the subjects current AED medication regimen. Either capsules or oral liquid form will be administered, depending on subjects preference and ability to swallow capsules, in two equally divided daily doses. The study will have an 8 week baseline period; a 2 week dose escalation period; a 9 week dose maintenance period; and a 1 week dose taper period.
223638993|NCT04164875|DIAGNOSTIC_TEST|Temperature measurement|The 'intervention' is repeated rectal temperature measurements
223638994|NCT01709084|DRUG|Rilpivirine|Type=exact number, unit=mg, number=25, form=tablet, route=oral. Rilpivirine will be administered in a fixed dose combination along with tenofovir disoproxil fumarate and emtricitabine, as a single dose tablet.
223638995|NCT01709084|DRUG|Efavirenz|Type=exact number, unit=mg, number=600, form=tablet, route=oral. Efavirenz will be administered in a fixed dose combination along with tenofovir disoproxil fumarate and emtricitabine, as a single dose tablet.
223638996|NCT01709084|DRUG|Tenofovir disoproxil fumarate|Type=exact number, unit=mg, number=300, form=tablet, route=oral. Tenofovir disoproxil fumarate will be administered in a fixed dose combination along with rilpivirine and emtricitabine in Group 1, and along with efavirenz and emtricitabine in Group 2.
223638997|NCT01709084|DRUG|Emtricitabine|Type=exact number, unit=mg, number=200, form=tablet, route=oral. Emtricitabine will be administered in a fixed dose combination along with rilpivirine and tenofovir disoproxil fumarate in Group 1, and along with efavirenz and tenofovir disoproxil fumarate in Group 2.
223638998|NCT01955252|DRUG|Azithromycin|"Investigators will do a baseline survey of every children from 5 to 15 years in the village. To detect yaws infection, investigators will collect a blood specimen for serology (qualitative and quantitative RPR testing and TPHA assay).~Investigators will identify yaws-like ulcers by means of dermatological examination. Investigators will swab papilloma and ulcers and specimens will be flown to University of Washington (Seattle). PCR methods will consist of primary screening for the presence or absence of T. p. pertenue DNA, Haemophilus ducreyi DNA and detection of the A2058G and A2059G mutations associated with azithromycin resistance.~Investigators will begin treatment with antibiotics immediately after completion of the baseline survey. Everyone in the villages will be offered azithromycin, subsequently a field team will treat all active clinical cases and their contacts 6 monthly.~For all subjects, follow-up examination will be performed at 6,12,18,24,30,36,40,and 42 months"
223638999|NCT00941096|DRUG|Bimatoprost and Bimatoprost/Timolol fixed combination.|Following an appropriate wash-out period, participants were given a 5-week long treatment with Bimatoprost 0.03% once daily in the evening followed by a further 5-week long treatment with the Bimatoprost 0.03%/Timolol 0.5% fixed combination administered in the evening.
223639000|NCT02144610|BIOLOGICAL|HGF Plasmid (AMG0001)|IM
223639001|NCT02144610|BIOLOGICAL|Matching Placebo|IM
223639002|NCT02644499|DRUG|Methotrexate|Methotrexate, a structural analogue of folic acid, can be administered orally or parenterally to treat a variety of rheumatic dise
223639003|NCT02644499|DRUG|Leflunomide|Leflunomide inhibits pyrimidine synthesis, resulting in blockade of T-cell proliferation. Leflunomide is used in patients with moderate to severe active rheumatoid arthritis with early or late disease
223639004|NCT02644499|DRUG|Hydroxychloroquine|Hydroxychloroquine (HCQ) is a well-tolerated DMARD that is commonly used in combination therapy regimens for RA. HCQ is more commonly used than chloroquine.
224227149|NCT00821210|DEVICE|Sham CPAP|CPAP with pressure of 3cm H2O
224227150|NCT00821210|DEVICE|CPAP of optimal pressure|CPAP of optimal pressure
224227151|NCT01412541|PROCEDURE|Standard Uncoated Angioplasty Balloon|Subjects will be randomized 2:1 to the Moxy Drug Coated Balloon or Standard Angioplasty Balloon
224227152|NCT01412541|DEVICE|Moxy Drug Coated Balloon|Subjects will be randomized 2:1 to the drug coated or standard angioplasty balloon
224227153|NCT05876702|DEVICE|endoscopy|use of upper endoscopy with i-scan specially , in diagnosis of esophageal lesions and comparison of results with histopathology.
224319137|NCT01194167|DRUG|Eltrombopag|75 mg per day with possible dose escalation to 150 mg per day and 300 mg per day
224319138|NCT02077140|DRUG|MDT-10013|
224319139|NCT02077140|DRUG|Standard of care for pain|
224227154|NCT03294538|DRUG|Generic Estradiol Vaginal Cream USP, 0.01%|Vaginal cream, generic formulation of the brand product.
224227155|NCT03294538|DRUG|Estrace® Vaginal Cream USP, 0.01%|Vaginal cream, brand product.
224227156|NCT03294538|DRUG|Vehicle Vaginal Cream|Vaginal cream, placebo. Has no active ingredient
223639005|NCT02644499|DRUG|Prednisolone|Low dose prednisolone (weeks 1-2: 15 mg/day, weeks 2-4: 10 mg/day, weeks 4-6: 5 mg/day and weeks 6-8: 2.5 mg/day then stop)
223639006|NCT02644499|DRUG|Folic Acid|Folic acid is to be given to all patients receiving methotrexate at a dose of 5 mg twice a week.
223639007|NCT03290885|COMBINATION_PRODUCT|Combined contact aspiration/Stent Retriever Technique|Combined contact aspiration/SR is performed using a balloon-guide catheter (BGC). A 0.021 to 0.027 inch inner lumen microcatheter with a 0.014 to 0.016 inch micro-wire inside is introduced into a large-bore aspiration catheter and this construct is introduced into BGC. The BGC is placed into the origin of the cervical internal carotid artery (ICA). The catheter is advanced past the thrombus over the micro-wire to allow the SR deployment. The SR is deployed across the occlusion. Then the large bore distal access catheter is advanced to contact the proximal edge of the SR. The aspiration pump is connected to the large bore distal access catheter. After at least 90 sec, the SR and the large bore distal access catheter are pulled out as an unit from the BGC and the patient. Manual aspiration is also be applied to the BGC during the pull-out manoeuver which is performed after the temporary inflation of the balloon at the tip of the BGC to ensure flow arrest into the carotid
223639008|NCT03290885|DEVICE|Stent retriever technique|"The technique used should be in accordance with the device instruction for use. A large bore balloon guide catheter has to be placed into the cervical ICA.~A suitable delivery microcatheter is navigated over a micro-wire into the occluded major coronary artery MCA and across the occlusion. A control superselective angiogram may be used to document the extent of occlusion and thrombus. The stent retriever device is then deployed across the occlusion.~After at least 90 seconds, removal should occur with proximal occlusion by inflation of the balloon guide catheter."
223639009|NCT04280250|OTHER|Volitional Help-Sheet|Self-help sheet in order to form implementation intentions
223639010|NCT04280250|OTHER|Control condition|Psychoeducational self-help sheet
224227157|NCT03616613|DIAGNOSTIC_TEST|ABDOMINAL DUPLEX ULTRASONOGRAPHY|Abdominal ultrasonography performed by both primary care doctors or vascular surgeons in Hospital de la Santa Creu i Sant Pau area
223639011|NCT01288885|DRUG|ASP1941|Oral
223639012|NCT01288885|DRUG|Placebo|Oral
223639013|NCT01054885|DRUG|FF Inhalation Powder|Inhaled Corticosteroid (ICS)
223639014|NCT01054885|DRUG|FF/GW642444 Inhalation Powder|Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA) for COPD
223639015|NCT01054885|DRUG|GW642444 Inhalation Powder|Long Acting Beta Agonist(LABA)
224227158|NCT03329118|DRUG|SHR3824, Simvastatin|two 20mg tablets of simvastatin once daily on Day 1 followed by one 10mg tablet of SHR3824 once daily on Day 4,5,6,7,followed by two 20mg tablets of simvastatin and one 10mg tablet of SHR3824 on Day 8.
224227159|NCT04247490|DIAGNOSTIC_TEST|pediatric AIH|pediatric patients with clinical, laboratory (transaminase and IgG increase), instrumental (ultrasound, liver biopsy) characteristics
223639016|NCT01054885|DRUG|Placebo|Placebo
223639017|NCT00545454|DRUG|SSR150106|
223639018|NCT00545454|DRUG|Placebos|
223639019|NCT04669626|OTHER|Use of Ocetnilin|"Visits to the outpatient wound-care centre as directed by a physician. Wound care performed by the respective study nurse according to the study-protocol. Each dressing change will be the same and will be as follows:~* Removal of old dressing~* Applying a soaked gaze with Octenilin® on the wound (5 minutes)~* Mechanical debridement if necessary~* Wound cleansing with Octenilin®~* Application of new dressing (according to the wound healing phases, medical prescription)"
223639020|NCT04669626|OTHER|Use of NaCl 0.9%|"Visits to the outpatient wound-care centre as directed by a physician. Wound care performed by the respective study nurse according to the study-protocol. Each dressing change will be the same and will be as follows:~* Removal of old dressing~* Applying a soaked gaze with NaCl 0.9% solution on the wound (5 minutes)~* Mechanical debridement if necessary~* Wound cleansing with NaCl 0.9% solution~* Application of new dressing (according to the wound healing phases, medical prescription)"
223639021|NCT00330434|OTHER|Trial Withdrawn 1|Trial Withdrawn 1
223639022|NCT00330434|OTHER|Trial Withdrawn 2|Trial Withdrawn 2
223639023|NCT04248426|DRUG|ATI-2173|ATI-2173 is a liver-targeted phosphoramidate prodrug of clevudine designed to enhance anti-HBV activity while decreasing systemic exposure to clevudine. It will be dosed as a capsule by mouth.
223639024|NCT04248426|DRUG|ATI-2173 Placebo|ATI-2173 Placebo is used as an inactive comparator to ATI-2173. It will be dosed as a capsule by mouth.
223639025|NCT00848601|DRUG|SGI-1776|Starting dose 100 mg (total daily dose) administer as 50 mg every 12 hours for 14 days of a 21-day cycle, dose escalation in successive cohorts until progression or toxicity develops
223639026|NCT01453218|DRUG|ATeGe-Fresenius|Administered at 1 , 3, 5 and 7 day post-transplant at 2-3mg/kg with dose adjustment according to CD2/CD3 levels
223639027|NCT05558202|OTHER|Turkish validity and reliability|"1. Explanation of the Turkish version of the scale.~2. Translating the Turkish version of the scale into English to ensure consistency with the original scale.~3. First application of scales to participants by two examiners separately.~4. Second application of the scales to the participants by one examiner.~5. Statistical analysis and scaling"
223639028|NCT03056508|BEHAVIORAL|Exercise plus nutrition|On the same day as the exercise class, participants will also receive nutrition support. Participants will alter their overall diet to be consistent with recommendations outlined in our brain health food guide (BHFG) and receive diet counseling and strategy training to promote retention and enable this dietary change. For the first two months, diet group sessions will be held on a weekly basis. For the remaining four months, sessions will be divided between group sessions and individual meetings with study dietitians, on a predefined schedule. Participants will submit weekly logs outlining diet goals, plans, successes and obstacles to help direct identification of sequential goals.
223639029|NCT03056508|BEHAVIORAL|Exercise|Supervised group exercise will be performed once per week (60 minutes) and self-directed exercise (4 additional aerobic and 2-3 resistance training sessions per week) will be monitored by an exercise diary. The initial walking prescription will be set at \~1.6 km and an intensity equivalent to the anaerobic threshold and/or 60% VO2-peak. Progressions will be made every 2 weeks, increasing distance to a maximum of 6.4 km and then increasing to a max intensity of 80% of VO2-peak and/or max duration of 60 minutes. Heart rate and perceived exertion will be monitored. The program will last 6 months.
223639030|NCT01639378|PROCEDURE|Renal Denervation|Symplicity Catheter System
224227160|NCT03881813|DEVICE|Orthodontic retainers|Orthodontic retainers were bonded on the lower teeth of the subjects after fixed orthodontic treatment and were evaluated for their effectiveness for the followup of one year.
224227161|NCT02366221|OTHER|60-minute visit to the outpatient clinic|An interview, an injury-specific physical exam and/or a set of xrays.
224227162|NCT02366221|OTHER|Phone Interview|If subject cannot return to office in Boston, researcher may conduct interview over the phone.
224227163|NCT00899288|PROCEDURE|spectroscopy|Nails will be chemically characterized using Raman spectroscopy.
224227164|NCT04774575|BIOLOGICAL|biomarker-guided strategy|Patients will follow a biomarker-guided strategy based on specific non-invasive biomarkers as defined in EUTRAIN-1 study on the basis of its detection and prediction capacities for rejection at M3 to decide whether a biopsy is performed. At M12 a routine biopsy is performed
224227165|NCT04964999|OTHER|Exercise|Participants will undergo an exercise program during the 2-week bed rest period.
224227166|NCT00959959|DRUG|TOK-001|2 capsules (325 mg each), once per day
224227167|NCT00959959|DRUG|TOK-001|4 capsules (325 mg each), once per day
224227168|NCT00959959|DRUG|TOK-001|6 capsules (325 mg each), once per day
224227169|NCT00959959|DRUG|TOK-001|3 capsules (325 mg each), once per day
224227170|NCT00959959|DRUG|TOK-001|3 capsules (325 mg each), once per day with supplement
224227171|NCT00959959|DRUG|TOK-001|6 capsules (325 mg each), split dose (3 capsules with breakfast, 3 capsules with dinner)
224227172|NCT00959959|DRUG|TOK-001|8 capsules (325 mg each), once per day
224227173|NCT00959959|DRUG|TOK-001|8 capsules (325 mg each), split dose (4 capsules with breakfast, 4 capsules with dinner)
224227174|NCT02760550|OTHER|No intervention|Participants of all three groups completed a questionnaire.
224227175|NCT04189094|DRUG|Sintilimab|Etoposide and cisplatin (carboplatin) plus Sintilimab induction therapy will be administered for 2 cycles and then thoracic radiotherapy (45 Gy/30 fractions) be administered with concurrent EP/EC chemotherapy for 2cycles. Patients who achieve CR or PR then receive prophylactic cranial irradiation (PCI, 25 Gy/10 fractions).Sintilimab maintenance therapy will be administered once every 3 week for 13 cycles.
224227176|NCT04189094|DRUG|Etoposide|Etoposide will be administered IV 100mg/m2 on days 1-3, 22-24, 43-45 and 64-66.
224227177|NCT04189094|DRUG|Cisplatin|cisplatin will be administered IV 80mg/m2 on days 1, 22, 43 and 64.
224227178|NCT04189094|RADIATION|radiotherapy|Thoracic radiotherapy (45 Gy/30 fractions) and prophylactic cranial irradiation (25 Gy/10 fractions).
224227179|NCT00979160|DRUG|Dasatinib|Starting dosage 20mg once daily, that can be escalated up to 100mg once daily. Patient will remain on treatment for 12 months.
224227180|NCT04472975|DRUG|Exposure to one or more disease-modifying drug(s)(DMDs) used to treat MS|Individuals with MS exposed to one or more DMDs (beta-interferon, glatiramer acetate, natalizumab, fingolimod, dimethyl fumarate, teriflunomide, alemtuzumab, daclizumab or ocrelizumab; regardless of dose, frequency or duration of treatment) between 1st January 1996 and 31st March 2018 in five Canadian provinces.
224227181|NCT05267756|DEVICE|(kurki-application),VR glasses|it is virtual reality immersive based-exercise game
224227182|NCT02517190|OTHER|Parabolic flight|
224227183|NCT02517190|OTHER|neuro-endocrine measurements|psychic stress tests, stress hormones: prolactin, cortisol, endo-cannabinoids
224227184|NCT02517190|OTHER|immunological measurements|blood cell counts, B2 integrins, cytokines, C-reactive protein
224227185|NCT02517190|OTHER|cellular energy metabolism measurements|purines, lactate
223639031|NCT03714152|DRUG|ABI-H2158|5 mg or 25 mg tablets
223639032|NCT03714152|DRUG|Placebo for ABI-H2158|Sugar pill manufactured to mimic the ABI-H2158 5 mg or 25 mg tablets
223639033|NCT02169427|DRUG|OPC|The drug substance of 100 mg OPC was administered as 1 capsule.
224227186|NCT02984306|DIETARY_SUPPLEMENT|Cherry powder|
224227187|NCT02984306|DIETARY_SUPPLEMENT|Placebo|
224227188|NCT05008289|DEVICE|Magnetic transcutaneous spinal cord stimulation|In the active group, non-invasive spinal cord stimulation will be applied by placing a circular magnetic coil (Magventure®️ MagPro®️ R20) on the skin, in the upper thoracic region (thoracic level T2-T3). The intensity of stimulation will represent 100% of the motor threshold, which is determined by abdominal muscle contractions, found from single pulses, gradually applied every 10 seconds until the onset of contractions. The intermittent theta burst stimulation protocol will consist of 20 stimulation trains, with an interval of 8 seconds between trains, each train will have 20 bursts, and each burst will have 3 pulses at 50 Hertz repeated at 5 Hertz. In total 1200 pulses will be applied for 3 minutes and 58 seconds.
224227189|NCT05008289|DEVICE|Transcutaneous electrical nerve stimulation|"To create a sensation of muscle contraction and impression of active stimulation, both the placebo and active groups will be subjected to the sensory effect of transcutaneous electrical neurostimulation (TENS). The surface electrodes of TENS (model Neurodyn®️, Ibramed®️) will be placed in parallel at the height of the thoracic level T2-T3, with the following parameters: 80Hertz, 150ms, approximately at 60 miliampère.~In the placebo group, a coil will be allocated in the thoracic region T2-T3, however this coil will not be connected to the stimulation device, and another active coil will be positioned about 15cm behind, away from its field of view, to provide the idea from the sound stimulus that it is being stimulated."
224227190|NCT02827903|DRUG|Metformin + Rosuvastatin|Group I: Metformin + Rosuvastatin,
224227191|NCT02827903|DRUG|Metformin + placebo|Group II: Metformin + placebo,
223639034|NCT05360121|OTHER|Muscle energy technique of erector spinae muscle|"Therapist will develop cross hand position left hand on lower thoracic and right hand on sacrum. Patient will asked to lift shoulder out of couch to contract the lumber erector spinae and apply force twenty percent against therapist force and keep this position of muscle contraction 7 to 10 seconds then 5 second relax .~Then therapist will take new position of muscle restriction by slacking and will hold 30 second that position at the end of restriction then will finally end stretch with three repetition. Muscle energy technique of erector spinae muscle."
224227192|NCT02827903|DRUG|placebo + Rosuvastatin|Group III: placebo + Rosuvastatin
224227193|NCT03686709|DIAGNOSTIC_TEST|Post therapy PET/CT Imaging|whole-body PET/CT following Y90 radioembolization
224227194|NCT00422656|DRUG|Perifosine|
224227195|NCT05737056|OTHER|Management of rheumatoid purpura|Collection of data on the management in pediatric emergency departments (method of diagnosis, complementary examinations, proposed treatment, number of hospitalizations, follow-up after hospital discharge).
224319140|NCT03808480|DRUG|CA and Nivolumab|Cyclophosphamide 500mg/m2 IV on D1 (C1-4), 1cycle=21days) Doxorubicin 50mg/m2 IV on D1 (C1\~4, 1cycle=21days) Nivolumab 360 mg/IV C2\~4 D1 (1cycle=21days) Nivolumab 400mg/IV on D1 from Cycle 5 every 4 weeks.
224319141|NCT04929327|PROCEDURE|Self etch Pit and fissure sealant application (prevent seal)|Sealing deep pits and fissures
224319142|NCT04929327|PROCEDURE|Self etch Pit and fissure sealant application (prevent seal) with prior sandblasting|Sandblasting before Sealing deep pits and fissures
224319143|NCT04929327|PROCEDURE|Total etch resin based sealant ultraseal xt|Sealing deep pits and fissures
223639035|NCT05360121|OTHER|Muscle energy technique of quadratus lumborum muscle|Therapist will take step over the patient off leg and squeezes gently with their thigh. Patient will abduct leg with 20 percent force against the resistance of therapists thigh for 7 to 10 second. the therapist gently and passively will move patient leg towards adduction by squatting down slowly. Therapist at same time with both hands cradling the iliac crest of pelvic for 30 second stretch and 3 repetition.
223639036|NCT05360121|OTHER|Stretching of erector spinae muscle|The therapist standing on the side in a way to place his elbow placed on erector spine and apply stretching on the muscle belly in the direction of longitudinal or transverse plane( figure 1).Duration of stretch will be 15 seconds and four repetition.
223639037|NCT05360121|OTHER|Stretching of quadratus lumborum muscle|Placing patient's legs to one side of the table and upper body also move to the same side in lateral flexion. This position generate a basic gentle stretch of the muscle. The therapist use elbow on tight/ flat part of muscle belly to stretch out the muscle(figure 2). Duration of stretch will be 15 seconds and four repetition
223639038|NCT05360121|OTHER|Back strengthening exercises|"1. Supine Abdominal Draw In~2. Supine Butt Lift with Arms at Side~3. Abdominal Draw In with Heel Slide~4. Abdominal Draw In with Knee to Chest~5. Abdominal Draw In with feet on the ball~6. Abdominal Draw In with feet on the ball- add movement"
224227196|NCT02833415|DRUG|[U-13C3] glycerol|Ingestion of \[U-13C3\] glycerol based on human's body weight such as (50 mg/kg body weight).
224227197|NCT02833415|DRUG|Empagliflozin|Active drug
224227198|NCT02833415|DRUG|Placebo (for Empagliflozin)|Placebo tablet manufactured to mimic EMPA 10 mg tablet.
224227199|NCT04383756|BIOLOGICAL|Donor Blood|Up to 4 units (each unit contains 350mL) of leukoreduced donor whole blood
224227200|NCT04383756|BIOLOGICAL|Banked Blood|Up to 350mL of Allogenic banked component blood transfusion in a 1:1:1 manner (packed red blood cells : plasma : platelets)
224319144|NCT02478229|DRUG|Sofosbuvir (SOF) and Ledipasvir (LDV)|
223639039|NCT05360121|OTHER|Thermotherapy|Ten minute duration of hot pack given on low back for local superficial heat.
223639040|NCT01935778|DRUG|Docetaxel and capecitabine and oxaliplatin|Docetaxel 60 mg/m² IV Day 1 Capecitabine 800 mg/m² bid (Day 1-Day 14) Oxaliplatin 100 mg/m² IV Day 1
223639041|NCT01935778|DRUG|capecitabine and oxaliplatin|Capecitabine 1,000 mg/m² bid(D1-14) Oxaliplatin 130 mg/m² IV Day 1
224227201|NCT01363037|DRUG|Dapivirine Vaginal Ring|dosage form: dapivirine vaginal ring dosage:25 mg frequency:continuous use duration:28 days
224227202|NCT01363037|DRUG|Maraviroc Vaginal Ring|dosage form: maraviroc vaginal ring dosage:100 mg frequency:continuous use duration:28 days
224227203|NCT01363037|OTHER|Placebo Vaginal Ring|dosage form: placebo vaginal ring dosage:N/A frequency:continuous use duration:28 days
223639042|NCT06342505|PROCEDURE|Venipunctures|Extra venipunctures
224227204|NCT01363037|DRUG|Dapivirine-Maraviroc Vaginal Ring|dosage form: combination vaginal ring dosage:25 mg dapivirine + 100 mg maraviroc frequency:continuous use duration:28 days
224227205|NCT00141752|DEVICE|Toronto Bedside Swallowing Screening Test (TOR-BSST)|Toronto Bedside Swallowing Screening Test
224227206|NCT01173809|DRUG|Amiodarone|Patient will continue taking Amiodarone before, during and after ablation (8 weeks post-ablation).
224227207|NCT01173809|DRUG|Amiodarone|Amiodarone therapy will be stopped at least 5-months before ablation procedure and ablation will be performed off Amiodarone. Patients will not take Amiodarone during the blanking period (8 weeks post-ablation).
224227208|NCT01530815|DRUG|Bupivicaine Infusion|Investigators and Caregivers will be blinded to either 0.9% Normal Saline or 0.5% Bupivicaine infusion between the mesh and abdominal wall
224227209|NCT04535609|DRUG|Mavodelpar|Once daily
224227210|NCT04535609|DRUG|Placebo|Once daily
224227211|NCT01977261|PROCEDURE|Opening-wedge HTO|Opening-wedge high tibial osteotomy fixated with a Puddu plate
224227212|NCT01977261|PROCEDURE|Closing-wedge HTO|Closing-wedge high tibial osteotomy fixated with two staples
224227213|NCT00963183|DRUG|AZD5423|Solution for nebulisation, inhaled. Each subject will receive a single-dose of AZD5423 or placebo. Starting dose 8.4µg (lung deposited dose) with up to 8 dose escalations not exceeding AstraZeneca pre-defined exposure limits.
224227214|NCT00963183|DRUG|Placebo|Solution for nebulisation, inhaled. Each subject will receive a single-dose.
224227215|NCT06358183|OTHER|No intervention|no intervention used
224227216|NCT00449072|OTHER|Placebo|Placebo to TAA-AQ was administered once at the study site in each nostril during the baseline/screening period to demonstrate intranasal IP administration
224319145|NCT05473494|OTHER|training group|Trainings on diabetic foot care consisting of min 20 max 40 minutes will be given in 5 sessions for nine weeks. Training will be given face to face online.
224319146|NCT05473494|OTHER|control group|Group not to be trained.
224319147|NCT06230445|OTHER|UHealth digital therapeutic|UHealth digital therapeutic is an application that patients can report their symptoms. If the contents that patients fill in reach the threshold, UHealth application will automatic report to doctor and the doctor will give medical advisement through UHealth digital therapeutic application.
224319148|NCT04965805|DEVICE|cold plasmaJet kINPen Med|experimental, non-inferiority
224319149|NCT04965805|DEVICE|Best practice wound dressings|comparative,
224319150|NCT06531278|DRUG|Irinotecan liposome|"* Patients are planned to receive irinotecan liposomal (60 mg/m2; d1) of every cycle.~* 27 days a cycle"
224319151|NCT06531278|DRUG|Adebrelimab|"* Patients are planned to receive Adebrelimab (20 mg/kg; d1) of every cycle.~* 27 days a cycle"
224319152|NCT06531278|DRUG|Oxaliplatin|"* Patients are planned to receive Oxaliplatin (85 mg/m2; d1) of every cycle.~* 27 days a cycle"
224319153|NCT06531278|DRUG|Fluorouracil|"* Patients are planned to receive fluorouracil (2400mg/m2; d1) of every cycle.~* 27 days a cycle"
224227217|NCT00449072|OTHER|Placebo|Placebo to TAA-AQ was administered intranasally once daily in each nostril during the double-blind period
224227218|NCT00449072|DRUG|TAA-AQ, Nasacort® AQ|110 μg TAA-AQ was administered once daily intranasally (1 spray delivering 55 μg of TAA-AQ in each nostril) during the double-blind treatment period
224227219|NCT00449072|DRUG|Claritin®|Participants were provided Children's Claritin® Syrup (5 mg of loratadine per 5 mL), as rescue medication for the relief of allergic rhinitis (AR) symptoms, and could be used throughout the study on an as needed basis according to the Food and Drug Administration-approved manufacturer's label
224227220|NCT05822596|DEVICE|Tablet-based interactive games experimental group intervention|"The program consists of 24 facilitated sessions and, depending on the capability of the participants, the availability of mobile devices and the service setting, 0 - 84 non-facilitated sessions.~In 30-minute facilitated session, a program facilitator will lead 1-8 participants in playing the tablet-based interactive games and helpers (e.g., health workers, program workers, and volunteers) will assist the program facilitator in running the sessions. The games may be played individually or together with other participants. In non-facilitated sessions, the participants can play cognitive games depending on the capability of themselves and at their own pace for 10 - 30 minutes"
224227221|NCT02302573|DRUG|contast-enhanced ultrasound with sonovue|contast-enhanced ultrasound with sonovue
224227222|NCT02410525|DRUG|[11C]PF-06427878|Single administration via intravenous infusion of 20 ug \[11C\]PF-06427878 on Day 1 of all 3 Periods
224227223|NCT02410525|DRUG|PF-06427878 10 mg|Single oral administration of 10 mg PF-06427878 on Day 1 of Period 2 or 3, at approximately 2.5 hours prior to \[11C\]PF-06427878 administration
224227224|NCT02410525|DRUG|PF-06427878 600 mg|Single oral administration of 600 mg PF-06427878 on Day 1 of Period 2 or 3, at approximately 2.5 hours prior to \[11C\]PF-06427878 administration
223639043|NCT01112839|BEHAVIORAL|Less Intensive|Participants in this group would receive print materials on diet and exercise and two individual counseling sessions; one at the beginning of the study and another 6 months later.
224227225|NCT04431986|OTHER|No intervention: secondary use of a database|Statistical analyses
224227226|NCT04319484|DRUG|lenvatinib|1-2 months after liver transplantation, participants are given lenvatinib with an initial dose of 8 mg (body weight \< 60 kg) or 12 mg orally once a day. The initial dose was 8 mg (body weight \< 60 kg) or 12 mg orally once a day.
224227227|NCT04319484|DRUG|Placebo|1-2 months after liver transplantation, participants are given Placebo with an initial dose of 8 mg (body weight \< 60 kg) or 12 mg orally once a day. The initial dose was 8 mg (body weight \< 60 kg) or 12 mg orally once a day.
224227228|NCT06543147|OTHER|breast cancer and breast self- examination education|The experimental group were given education about breast cancer and BSE. Slide presentations used during training provided information about breast anatomy and physiology, breast cancer symptoms and risk factors, early diagnosis methods for breast cancer and breast cancer screening programs, and barriers to breast cancer screening programs were discussed. In addition to slide presentations about breast cancer and BSE, women were also given BSE training on a breast examination mannequin and given brochures after training. The training lasted 40-50 minutes. After women in the experimental group were given training, they were called by telephone once per month until 6 months and reminded about doing BSE.
224227229|NCT06169098|PROCEDURE|Auricular acupressure on the left ear|Auricular acupressure is applied at the Kidney point on the left ear using a tape with a Vaccaria seed (2mm in diameter). After placement on this acupoint, apply consistent moderate pressure for 5 minutes.
224227230|NCT06169098|PROCEDURE|Auricular acupressure on the right ear|Auricular acupressure is applied at the Kidney point on the right ear using a tape with a Vaccaria seed (2mm in diameter). After placement on this acupoint, apply consistent moderate pressure for 5 minutes.
224227231|NCT06169098|PROCEDURE|Sham auricular acupressure|Sham auricular acupressure is applied at Kidney point on the left ear using a tape without any seed. After placement on this acupoint, apply consistent moderate pressure for 5 minutes.
224227232|NCT06117488|DEVICE|endoscopy|gastro duodenal endoscoe
224227233|NCT05053698|OTHER|Aqueous flare measurement|Aqueous flare was measured preoperatively and postoperatively with a laser flare-cell meter (LFCM ; Kowa FM-500, Kowa Company Ltd, Tokyo, Japan).
224227234|NCT02326077|OTHER|Ultrasound|Monitoring of the mechanism of labor
224227235|NCT02326077|OTHER|Acceptability of ultrasound monitoring of labor|Evaluation of the acceptability of intrapartum ultrasound monitoring - the rate of uptake ultrasound protocol during labor
224227236|NCT02326077|OTHER|Patients' experience regarding intrapartum ultrasound|The day after birth, consenting women are invited to take part in a questionnaire survey. Questionnaires contained no identifying information other than a code number and contains features regarding the patient's impression about the ultrasound monitoring scans during labor. The final questions concerned the willingness of having again another such protocol for labor monitoring in the future.
224227237|NCT03788577|DIETARY_SUPPLEMENT|Oligonol intake|Major intervention of Oligonol component , as suggested Oligonol safe dose for adults is 200mg per day.
224227238|NCT03788577|DIETARY_SUPPLEMENT|Placebo|Placebo
224227239|NCT03395821|BEHAVIORAL|Conventional training|traditional training according to residency program
224227240|NCT03395821|BEHAVIORAL|Virtual Reality+conventional training|virtual reality training+traditional training using virtual reality
223639044|NCT01112839|BEHAVIORAL|Intensive Group|Participants in this group would receive print materials on diet and exercise and attend group sessions that would meet weekly for the first 4 months, then every two weeks for the next 2 months, and then monthly for the next 6 months over the course of one year.
223639045|NCT06248749|DRUG|IV iron|Intravenous Iron supplement
223639046|NCT00214201|DRUG|Calcineurin inhibitor withdrawal|stopping tacrolimus or cyclosporine in subjects who received Campath-1H induction therapy
223639047|NCT00274729|BEHAVIORAL|Mono Unsaturated Fatty Acids in Obesity|
223639048|NCT05959148|OTHER|Monochromatic infrared energy|The monochromatic infrared energy was delivered through an Anodyne Therapy Professional Infrared Therapy System. Light energy (parameter: a wavelength of 890 nm and radiant power at a rate of 6.24 W) was produced through 8 array diode therapy pads applied on both knees (on the medial, lateral, anterior, and posterior aspects of each knee), each including 60 super-luminescent gallium-aluminum arsenide diodes. The MIRE was applied for 40 minutes/session, three times a week, for three successive months.
223639049|NCT05959148|OTHER|Traditional physical therapy|The traditional physical therapy program consisted of stretching and strengthening exercises for the muscles surrounding the hip and knee, balance exercises, as well as other electrotherapeutic modalities (ultrasound and hot application).
223639050|NCT04433676|OTHER|no intervention|
223639051|NCT05022732|DIETARY_SUPPLEMENT|Polyglucosamine L112|750 mg of chitosan for tablet formulated with ascorbic acid and tartaric acids in the relative proportions of 91-6-3% with the addition of formulating excipients
223639052|NCT05022732|COMBINATION_PRODUCT|Placebo|excipients and gum arabic
224227241|NCT03739190|DEVICE|NRL Condom|A minimum of 5 condoms (maximum 7 condoms) of each condom type will be provided to Subjects to be used during vaginal intercourse over a 4 week period, the assessment period. Couples will repeat the assessment period each of the 3 condom types.
224227242|NCT01712880|PROCEDURE|open debridement with modular exchange|
224227243|NCT01712880|PROCEDURE|one stage exchange|
224227244|NCT01627873|DRUG|Remifentanil|In group A induction of anesthesia will be performed with Propofol (2mg/kg), Cisatracurium (0.15mg/kg)and continous infusion of Remifentanil (0.15mcg/kg/min).Anesthesia will be maintained by Sevoflurane with oxygen (Fi=40%)and air, with a MAC value to maintain BIS between 40 and 60. Intraoperative analgesia will be obtained with Remifentanil 0.15-0.25mcg/kg/min. Additional boluses of Cisatracurium (0.02mcg/kg)will be administered as needed during surgery. At the beginning of closure of the peritoneum bolus of morphine (0.1mg/kg)and acetaminophen 1g will be administered. Propofol and remifentanil infusions will be interrupted at the end of wound closure.
224227245|NCT01627873|DRUG|Fentanyl|In group B anesthesia will be induced by Propofol (2mg/kg), Fentanyl (2mcg/kg)and Cisatracurium (0.15mg/kg). Anesthesia will be maintained by Sevoflurane, oxygen (Fi=40%) and air and boluses of Fentanyl (50mcg). additional boluses of Cisatracurium (0.02mg/kg)will be administered as needed during surgery. At the beginning of closure of the peritoneum acetaminophen 1g will be administered.
224227246|NCT02123992|DEVICE|Elevate Apical and Posterior|
224227247|NCT02123992|PROCEDURE|Native Tissue Repair for pelvic organ prolapse|
224227248|NCT01323348|BEHAVIORAL|Diabetes Education|"The intervention will consist of the following at enrollment and at each follow-up visit (but no more frequently than once every 12 weeks):~* Measurement of HbA1c in office with immediate feedback~* Measurement of blood pressure with immediate feedback~* Assessment of retinopathy risk with immediate feedback~* Personalized risk assessment reports based on current HbA1c~* Brief assessment of patient understanding of key issues with immediate feedback~* Supplemental diabetes management educational materials (provided at baseline only)~* Feedback to primary care provider~* Email reminder to study participants with email access of individualized risk assessment findings"
224227249|NCT03955679|GENETIC|AVXS-101|AVXS-101 is a non-replicating recombinant adeno-associated virus serotype 9 (AAV9) containing the human survival motor neuron (SMN) gene under the control of the cytomegalovirus (CMV) enhancer/chicken β-actin-hybrid promoter (CB). AVXS-101 will be administered as a one-time intravenous infusion over approximately 60 minutes. Dosage will be determined by the participants weight.
224319154|NCT06531278|DRUG|Calcium folinate|"* Patients are planned to receive Calcium folinate (400mg/m2; d1) of every cycle.~* 27 days a cycle"
224319155|NCT05629715|DEVICE|ROSA Knee System|The Zimmer Biomet ROSA Knee System is a commercially available, FDA approved robotic assistant for performing TKA. It uses preoperative x-rays to create a three-dimensional image of the patient's knee anatomy which is used to create a preoperative template of the implants to be used and provides intraoperative guidance for bone cuts during the TKA. The robotic system also assesses the soft tissue envelope around the knee and can assist with the soft tissue balancing of the knee arthroplasty. Alternatively, it can also be used in an imageless mode where bone cuts are performed based on intra-operative mapping using anatomic landmarks.
224319156|NCT05629715|DEVICE|KneeAlign Computer Assisted Navigation System|The OrthAlign KneeAlign computer assisted navigation system is a commercially available device that uses gyroscopic limb position sensing technology mounted to intramedullary and extramedullary jigs to measure bone resection cuts in TKA that ultimately dictate implant position.
223639053|NCT00006206|DRUG|naltrexone (Revia)|
223639054|NCT00006206|DRUG|acamprosate (Campral)|
223639055|NCT04667130|BEHAVIORAL|Preventive Complex Program for Newly Diagnosed People With Multiple Sclerosis|Preventive program included informations of the possibilities of physiotherapy in the treatment of multiple sclerosis focused on fatigue management - recommending lifestyle changes. Program included a the treatment of psychosomatic, viscerosomatic functional disorders by reflexively poor connection through the locomotor system using computer kinesiology, psychotherapy, manual therapy - where patients are corrected into a postural position and the joints are functionally centred, and aerobic exercise to influence fatigue and improve the performance of the cardiovascular system.
224227250|NCT02391428|PROCEDURE|blood test|Blood test: Small volume (3 ml) of blood will be taken by venipuncture into ethylenediaminetetraacetic acid (EDTA) tube.
223639056|NCT03944317|DRUG|Sulfadoxine pyrimethamine|SP 1500/75mg tablet orally once starting from 16 weeks, at least at four weekly interval until delivery.
223639057|NCT03944317|DRUG|Azithromycin|A total of 1500mg Azithromycin tablets taken orally as 500mg daily for three consecutive days starting starting from 16weeks of pregnancy and to be repeated once at least after 4 weeks
223639058|NCT03038828|BIOLOGICAL|Leukocyte Interleukin, Injection|Immunotherapy
223639059|NCT03024099|OTHER|Hippotherapy once a week|Hippotherapy once a week
223639060|NCT03024099|OTHER|Hippotherapy twice a week|Hippotherapy twice a week
224227251|NCT02391428|DIETARY_SUPPLEMENT|omega3 capsules|Only ADHD children will be given a supply of omega3 capsules (containing 400 mg EPA and 200 mg DHA)
224227252|NCT01773564|DEVICE|Current hospital dressing|Patients were assigned to either arm following a randomization scheme 1:1.
224227253|NCT01773564|DEVICE|3M™ IV Advanced Securement dressing|Patients were assigned to either arm following a randomization scheme 1:1.
224227254|NCT01769378|DRUG|Placebo|Administered SQ
224227255|NCT01769378|DRUG|Dulaglutide|Administered SQ
224227256|NCT01769378|DRUG|Glimepiride|Administered PO
224227257|NCT00000882|DRUG|Indinavir sulfate|
224227258|NCT00000882|DRUG|Delavirdine mesylate|
224227259|NCT00000882|DRUG|Lamivudine|
224227260|NCT00000882|DRUG|Stavudine|
223639061|NCT02694692|PROCEDURE|Vaccinations at 2, 6, 12 and 18 month|Participants will be invited back to IWK Health Centre at time points that correspond to their 2, 6, 12 and 18 month vaccinations and will receive their vaccinations according to Nova Scotia schedule.
223639062|NCT02694692|BEHAVIORAL|Neurodevelopment assessment at 18 corrected age|During the 18 month follow-up visit, the infants will also undergo neurodevelopmental assessment. Trained medical assessors also blind to original study group assignment will examine the child using the BSID-III Cognitive and Motor Sections. Participants will also be contacted at the infants 18 month corrected postnatal age for the BSIDIII. Parents will be asked to complete the Early Childhood Behaviour Questionnaire and the Brief Infant Toddler Social Emotional Assessment.
223639063|NCT00660634|PROCEDURE|Endovascular Revascularization|Angioplasty/Stenting of femoro-popliteal lesions
223639064|NCT00161772|BIOLOGICAL|Tick-borne Encephalitis Vaccine|
223639065|NCT02442388|PROCEDURE|Instrumentation technique with hand file|type of instrumentation technique for root canal treatment
223639066|NCT02442388|PROCEDURE|Instrumentation technique with ProTaper|type of instrumentation technique for root canal treatment
223639067|NCT02442388|PROCEDURE|Instrumentation technique with WaveOne|type of instrumentation technique for root canal treatment
223639068|NCT05145101|BIOLOGICAL|Prevnar13|Patients receive one dose of Prevenar13 followed by one dose of Pneumovax23 2 months later
223639069|NCT04220541|BEHAVIORAL|Motor learning based exercise|Symptomatic exercise
223639070|NCT02256280|DRUG|Sugammadex|"Sugammadex will be diluted in a saline water solution in a 10 mL syringe.~Administration will be according to the neuromuscular blockade:~* If Post tetanic count = 1-15: 4 mg/kg~* If at least 1 twitch at the Train-of-four stimulation: 2 mg/kg"
223639071|NCT02256280|DRUG|Neostigmine|"Neostigmine will be diluted with atropine in a saline water solution in a 10 mL syringe.~Administration will be according to the neuromuscular blockade:~* If Post tetanic count = 1-15: 0.07 mg/kg~* If at least 1 twitch at the Train-of-four stimulation: 0.05 mg/kg Atropine will be administered at a 0.02 mg/kg dosage."
224227261|NCT00000882|DRUG|Zidovudine|
224319157|NCT03884361|DIAGNOSTIC_TEST|Vaginal Microbiome as result of aminocentesis|we will take a blood samples and a vaginale samples after and before the aminicentesis and check if the sample that we took after is different and contain microrganisms , if we find a different o we can say that as result of the Elective Amniocentesis
223639072|NCT03674905|PROCEDURE|Intra-articular injection|Intra-articular injection at the completion of TAA procedure.
223639073|NCT03674905|PROCEDURE|Peripheral nerve block|Pre-operative peripheral nerve block.
223639074|NCT01764880|DRUG|SST0001 (Roneparstat)|SST0001 once daily for 5 or 10 days in a cycle of 28 days.
223639075|NCT05252780|BEHAVIORAL|My Body, My Rhythm, My Voice|My Body was a behavioral intervention informed by the social cognitive and self-determination theories. Based on the discussions and a systematic review of the literature, we designed the 8-week, 3 times/week rumba physical activity intervention. The goal of the intervention was to gradually increase all participants' physical activity levels to achieve significant health benefits. As part of the physical activity intervention, participants were also taught by their instructor during each class how to utilize behavioral and cognitive self-regulatory skills to increase and maintain their physical activity participation. Examples of such skills were action planning, coping planning, counter conditioning, self-evaluation, among others.
223639076|NCT05659186|DRUG|Tislelizumab|200mg IV Q3W
223639077|NCT05659186|DRUG|Anlotinib|12mg PO QD
223639078|NCT05659186|RADIATION|Radiotherapy|Multimodal Radiotherapy
223639079|NCT04585126|DRUG|Intermediate cervical block|Local anesthesia performed in addition to the general anesthesia
223639080|NCT01150188|DIETARY_SUPPLEMENT|Amino acids|11 g amino acids two times per day for eight weeks
223639081|NCT01150188|DIETARY_SUPPLEMENT|Placebo|Placebo of inert compounds, 11 g two times per day for eight weeks
223639082|NCT04082819|DEVICE|Contec CMS50EW|Participants' blood pressure will be measured 3 times with the wearable finger pulse oximeter at their study visit.
223639083|NCT04082819|DEVICE|Sphygmomanometer|Participants' blood pressure will be measured 4 times manually with a blood pressure cuff at their study visit.
223639084|NCT00169897|BEHAVIORAL|Pulmonary rehabilitation (teaching and exercise)|After a 4-week education program, patients took part to home-based rehabilitation or outpatient hospital-based rehabilitation for 8 weeks. Patients were subsequently followed for 40 weeks to complete the one-year study.
223639085|NCT02805829|DRUG|Trastuzumab + NK cells|NK cellular therapy conduct 2 cycles per year. Herceptin initial dose of 8 mg/kg over 90 minutes IV infusion, followed by 6 mg/kg over 30 to 90 minutes IV infusion every 3 weeks till to disease progress.
223639086|NCT03599739|BIOLOGICAL|Influenza|Facilities will be asked to complete a survey to evaluate the impact of the influenza vaccine choice on hospitalization risk for the 2017-2018 influenza season.
223639087|NCT00897299|GENETIC|microarray analysis|
223639088|NCT00897299|GENETIC|protein expression analysis|
223639089|NCT00897299|OTHER|immunohistochemistry staining method|
223639090|NCT00897299|OTHER|laboratory biomarker analysis|
224227262|NCT00885690|DRUG|Sertindole|Sertindole 16-24 mg once daily
224227263|NCT00885690|DRUG|Olanzapine|Olanzapine 10-20 mg
224227264|NCT03558100|BEHAVIORAL|Obstacle crossing intervention for adults with obesity|The obstacle crossing intervention will be done for reducing falls risks in obesity. The intervention will provide gait practice to individuals with obesity who are eligible for and prior to weight loss surgery.
224227265|NCT05056142|PROCEDURE|Epidural Anesthesia|Patients will receive epidural analgesia with 15 ml isobaric bupivacaine 0.125% plus fentanyl 2 μg/mL.
224227266|NCT05056142|PROCEDURE|Spinal Analgesia|Patients will receive Spinal analgesia with 5 mg bupivacaine and 25 μg of fentanyl in a 2 ml volume.
224227267|NCT04318470|DIAGNOSTIC_TEST|mNGS|Metagenomic next generation sequencing for microbial DNA
224227268|NCT01386346|DRUG|Azacitidine|Dose level -1: 50 mg/m2 subcutaneous injection on Day 1-3 of a 21 day cycle. Repeat for a total of 3 cycles. Dose level 1: 75 mg/m2 subcutaneous injection on Day 1-3 of a 21 day cycle. Repeat for a total of 3 cycles. Dose level 2: 75 mg/m2 subcutaneous injection on Day 1-5 of a 21 day cycle. Repeat for a total of 3 cycles.
224227269|NCT01386346|DRUG|Oxaliplatin|130 mg/m2 IV on Day 3 or 5 of each 21 day cycle. Repeat for a total of 3 cycles.
223639091|NCT04065672|DRUG|Low-dose IL-2|After a 4-week screening period, patients received IL-2 at a dose of 1 million IU subcutaneously every other day. After the initiation of the therapy, patients could continue with concurrent medication but were prohibited from changing or adding immunosuppression therapy during the course of the study with a 12-week observational followed up.
223639092|NCT04065672|DRUG|Placebo|After a 4-week screening period, patients received placebo subcutaneously every other day. After the initiation of the therapy, patients could continue with concurrent medication but were prohibited from changing or adding immunosuppression therapy during the course of the study with a 12-week observational followed up.
223639093|NCT01399372|BIOLOGICAL|Rituximab|One 28-day cycle = 500 mg/m\^2 intravenously on day 1 and day 5.
223639094|NCT01399372|DRUG|Cytarabine|One 28-day cycle = 3 g/m\^2 intravenously on day 1 and day 2.
223639095|NCT01399372|DRUG|Methotrexate|One 28-day cycle = 3.5 g/m\^2 intravenously (standard hydration/leucovorin support) on day 2.
223639096|NCT01399372|DRUG|Procarbazine|One 28-day cycle = 100 mg/m\^2 orally on days 2-8.
224227270|NCT01386346|DRUG|Epirubicin|50 mg/m2 IV on Day 3 or 5 of each 21 day cycle. Repeat for a total of 3 cycles.
224227271|NCT01386346|DRUG|Capecitabine|625 mg/m2 orally twice daily beginning on Day 3 or 5 and will be taken without interruption for each 21-day cycle.
224227272|NCT03475797|DEVICE|Occipital nerve stimulation|Occipital nerve stimulation with percutaneous or surgical lead
224319158|NCT03080025|BEHAVIORAL|CBCT® (Cognitively Based Compassion-Training)|"The CBCT® (Cognitively Based Compassion-Training) as a secular approach was established as a structured protocol.~The therapeutic tools are based on systemic approaches \& techniques, which contains a resource- \& solution orientation and the approach of Gottman's model of healthy relationships (e.g. trust and commitment - based on that - elements like the positive perspective).~Four dyadic exercises are introduced to enhance positive reciprocity between the romantic partners (based on concepts of couple communication training):~a) Building mindful ability to talk, b) building mindful ability to listen (without reacting initially), c) appreciation in action - indulging the partner, d) noticing, how the partner is doing something good for me - gratefulness in action verbally/non-verbally. Finally, the empathy exercise has been added inspired by CBASP therapy for chronic major depression."
224319159|NCT06109155|DRUG|Tranexamic acid|tranexamic acid will be used in two different doses (50mg/kg vs 20mg/kg). the tranexamic acid pump will start from the begin of anesthesia until all dose is administrated.
224319160|NCT00550511|RADIATION|Surgeon-performed ultrasound|After clinical investigation including standardized laboratory tests the patient in the intervention arm is examined with abdominal ultrasound performed by the study surgeon.
224319161|NCT03134248|DEVICE|Dailies Aquacomfort Plus Toric|daily disposable contact lens
224319162|NCT03134248|DEVICE|1-Day Acuvue Moist for Astigmatism|daily disposable contact lens
224319163|NCT03134248|DEVICE|MyDay Toric|daily disposable contact lens
224319164|NCT02836522|BEHAVIORAL|Assessment of Health-Related Quality|Demographic Questionnaire, ANCHOR HRSI, FACT-G, MDASI, Patient ECOG PS, PGIC
224227273|NCT03475797|OTHER|Optimal Medical Management|Optimal Medical Management according to what is done in routine clinical practice : drug, psychobehavioral approach, acupuncture, sophrology, etc.
224227274|NCT05260645|BEHAVIORAL|Back School|Intervention was carried out for 8 weeks with a frequency of two sessions per week, with a total of 16 sessions lasting 45 min. Of all the sessions, 14 had a practical focus and the other two had a theoretical focus. In the practical part, strengthening and stretching exercises were performed. In the theoretical part, self-management and pain neuroscience education were performed.
224227275|NCT04305964|DEVICE|Nastent® (a distally perforated soft silicon nasal tube)|Insertion of the Nastent® to nostril during sleep hours
224227276|NCT04305964|DIAGNOSTIC_TEST|Polygraphy with WatchPAT™ 300|WatchPAT™ 300 is an innovative diagnostic Home Sleep Apnea Test (HSAT) that utilizes the proprietary Peripheral Arterial Tone signal (PAT™) to enable simple, accurate and reliable sleep apnea testing.
224227277|NCT00503620|DRUG|Botulinum Toxin A|Injection into the gastrocnemius/soleus muscles for spasticity
224227278|NCT00647582|PROCEDURE|adjuvant therapy|
224227279|NCT00647582|PROCEDURE|therapeutic conventional surgery|
224227280|NCT00647582|RADIATION|intraoperative radiation therapy|
224227281|NCT00647582|RADIATION|radiation therapy|
224319165|NCT02735759|DEVICE|Photoacoustic flow cytometry device|The device for subjects enrolled on cohort 2 will be completed on day 0 (immediately after venous thromboembolism diagnosis and prior to anticoagulation therapy), day 7 ± 3 days after initiation of anticoagulation therapy, one week ± 3 days after completion of planned anticoagulation therapy and one month ± 3 days after completion of planned anticoagulation therapy. Anticoagulation therapy is part of the patient's normal standard of care and is not part of this study however data from what therapy was received may be captured. Patients will then be followed in hematology clinic to monitor the venous thromboembolism recurrence every 3 months for one year.
224319166|NCT01762800|DRUG|fluticasone propionate/salmeterol 50/250mcg|Active, 50/250mcg, Twice daily (morning and evening)
224319167|NCT01762800|DRUG|fluticasone propionate/salmeterol placebo|Placebo, Twice daily (morning and evening)
224319168|NCT01762800|DRUG|tiotropium bromide 18mcg|Active, 18mcg, Once daily(morning)
223639097|NCT01399372|DRUG|Vincristine|One 28-day cycle = 1.4 mg/m\^2 intravenously, dose capped at 2.4mg, on day 2 and day 16.
223639098|NCT01399372|RADIATION|low-dose whole-brain radiation therapy|Total dose of 2340 cGy administered as 13 daily fractions of 180 cGy over 3 weeks. Participants with progressive disease on magnetic resonance imaging (MRI) do not receive WBRT.
224227282|NCT05305274|OTHER|screening|This study included 34,400 students, as part of the Tianjin Eye Study who performed a 3-year follow-up from 2019 to 2021. All participants underwent yearly noncycloplegic refraction and ocular examinations. Time-related changes in sphere, cylinder, and spherical equivalent (SE) measurements in both sexes were analyzed.
224319169|NCT01762800|DRUG|tiotropium bromide placebo|Placebo, Once daily(morning)
223639099|NCT06355700|PROCEDURE|Liver biopsy|The liver biopsy is ultrasound-guided and target the hepatic lesions. It is performed with 18G or 19G Menghini needle. A part of bioptic sample will be used for genomic analysis. An other part of sample will be cultured to create the organoid. The organoid's cultures will be integrated with the host gut microbiota (collected by a fecal sample) and peripheral blood mononuclear cells (from venous blood sample) and they will be used for research such as molecular analysis and pharmacological tests.
223639100|NCT04989335|DRUG|Bisantrene|Combined escalated dose chemotherapy
223639101|NCT04989335|DRUG|Fludarabine|Combined escalated dose chemotherapy
223639102|NCT04989335|DRUG|Clofarabine|Combined escalated dose chemotherapy
223639103|NCT05641480|DEVICE|Transcutaneous electrical acupoint stimulation&Music therapy|"Procedure: electro-acupuncture;Points: Shenting（DU24）, Benshen（BG13）, Tou Wei （ST8）.The specially-made pad is stick on pierced acupoints, until local sour and heavy feeling coming. The electric stimulator is applied to bilateral BG13 and ST8, with dilatational wave,10/50 Hz and electric current 1-5mA(milliampere).Every session lasts for 30 min per day. The participants are treated continuously for 8 weeks for 3 sessions a week, 24 sessions for each participants in all.~Selecting the participants' music of memory and music of favourite(Music is purchased and downloaded from music stores), forming a personalized music playlist, and the decibel level is suitable for participants.~The treatment is designed based on recent literature research in 10 years, former result and expert consensus.~Other Names:~* JS-502-A Intelligent and portable electroacupuncture~* apparatus(Han's low frequency neuromodulator, made in China)"
223639104|NCT05641480|DRUG|Donepezil hydrochloride tablets or carpalatine bitartrate tablets|"① Donepezil hydrochloride tablets 5 mg, once a day, one tablet each time, before going to bed. The treatment period is 6 months.~② Carpalatine heavy tartrate tablets 1.5mg, 1 tablet/time 2 weeks before treatment, twice a day, breakfast and dinner with food, swallow. If there is no obvious adverse reaction after 2 weeks, the dosage can be increased to 2 tablets/time, twice a day. The treatment period is 6 months."
223639105|NCT00781703|OTHER|DIAMOND depression care model|Patients in activated clinic sites will receive the DIAMOND depression care model, including a care manager, frequent use of the PHQ9, treatment adjustment as indicated, psychiatric consultation, relapse prevention.
223639106|NCT04669444|DEVICE|Ventilator|The patient starts at a ventilator driving pressure of 10-15 cm of H2O as per guidelines for patients on ECMO with ARDS. The driving pressure is then decreased as tolerated for two hours to evaluate the effects on pulmonary, cardiac, and inflammatory biomarkers.
223639107|NCT02027441|OTHER|Standard Counseling and Testing|"Individuals who opt for standard counseling and testing will complete the following procedures:~• Standardized pre- and post-test counseling and HIV testing using HIV rapid test per approved national guidelines"
223639108|NCT05098431|OTHER|Quadriceps and Rectus Femoris MEP Recording|Participants will receive additional electrodes placed intramuscularly to facilitate three separate approaches of quadriceps MEP recording
223765087|NCT06691269|DEVICE|Photobiomodulation|Photomodulation (PBM) is a promising non-tissue penetrating (i.e. minimally invasive) approach for achieving tooth and soft tissue anesthesia/analgesia in dental patients. A patent pending near-infrared laser technology that aims to provide dental analgesia will be used for PBM. This intra-oral PBM device comes with a tip comprising of a series of photonic emitters with specific wavelengths that can go through the tooth structure and bone, blocking the nerve conduction like local anesthetics. Research has shown that one burst of light application (for about 20 second) can provide up to 15-20 minutes of pain relief. Based on existing research PBM does not present a serious risk to health, safety, or welfare of a subject.
224227283|NCT06412562|DIAGNOSTIC_TEST|The Maudsley 3-item Visual Analogue Scale (M3VAS)|Patients will be asked to complete The Maudsley 3-item Visual Analogue Scale (M3VAS) and 16-item Quick Inventory of Depressive Symptomatology (QIDS-SR-16).
224227284|NCT05089123|BIOLOGICAL|Flu-M [Inactivated split influenza vaccine]|solution for intramuscular injection, 0.5 ml
224227285|NCT05089123|BIOLOGICAL|Inactivated Split Influenza Vaccine|solution for intramuscular injection, 0.5 ml
224227286|NCT05091788|DEVICE|Venus Aime|Venus Aime is a micro-coring device of the skin that can potentially help reduce moderate to severe facial wrinkles.
224227287|NCT01943071|BEHAVIORAL|Day care for patients with dementia|Day care centres designed by the local authorities for patients with dementia
224227288|NCT01555320|DRUG|Qishen Yiqi Dripping Pills|One packet of Qishen Yiqi Dripping Pills (0.52g) will be given three times a day in addition to regular western medications for the first 6 months, and regular western medications only for the subsequent 6 months.
224227289|NCT01555320|DRUG|Qishen Yiqi dripping pills dummy|One packet of Qishen Yiqi Dripping Pills dummy (0.52g) will be given three times a day in addition to regular western medications for the first 6 months, and regular western medications only for the subsequent 6 months.
224227290|NCT02547857|OTHER|Pelvic US|To be eligible for inclusion, a woman will have pelvic US completed as part of her ED stay. This is a non-interventional study.
224227291|NCT06401083|DRUG|Caffeine citrate|20 mg/kg caffeine-citrate before the planned extubation.
224227292|NCT02459054|DEVICE|SynCardia 50cc temporary Total Artificial Heart (TAH-t)|Replacement of both ventricles and all four valves with the investigational device as a bridge to transplantation.
224227293|NCT05289765|OTHER|A natural neutral Ecological Extra Virgin Olive Oil based gel|A natural neutral Ecological Extra Virgin Olive Oil based gel will be applied to the peristomal skin area at the time of peristomal skin care. Hygiene shall be performed by patients themselves following a standardised procedure recommended by Clinical Guideline.
224227294|NCT05289765|OTHER|A conventional neutral gel, without Ecological Extra Virgin Olive Oil or any other olive oil-derived products|A conventional neutral gel, without Ecological Extra Virgin Olive Oil or any other olive oil-derived products will be applied to the peristomal skin area at the time of peristomal skin care. Hygiene shall be performed by patients themselves following a standardised procedure recommended by Clinical Guideline
224227295|NCT04807114|DRUG|Immune checkpoint inhibitor|Standard-of-care treatment for st.IV NSCLC (no driver mutation, PD-L1 \> 50%)
224227296|NCT04807114|DRUG|Chemotherapy + Immune checkpoint inhibitor|Standard-of-care treatment for st.IV NSCLC (no driver mutation, PD-L1 \< 50%)
224227297|NCT00718159|DRUG|LY573636-sodium|Individualized dose is dependent on participant's height, weight, gender and is adjusted to target a specific exposure range corrected for a participant's laboratory parameters. Dosing will be done on Day 1 of a 35-day cycle for acute myeloid leukemia (AML) and Day 1 of a 28-day cycle for essential thrombocythemia (ET) for at least one cycle. A participant may have additional cycles of LY573636 if he or she is receiving benefit from the study drug and does not fulfill any of the criteria for study discontinuation.
224227298|NCT04024956|DEVICE|Sealing Device|The Sealing Device is indicated for use in hepato-pancreato-biliary (HPB) surgery to reduce leakage of fluids from the site of surgery into the abdominal cavity and as an adjunctive hemostatic device to control minimal to moderate bleeding at the surgical site.
223639109|NCT00938067|BEHAVIORAL|Staying Connected|The overarching goal of the Staying Connected intervention is to establish a compassionate and culturally sensitive treatment trajectory that diminishes posttraumatic suffering by reducing symptomatic distress, improving functional recovery, and reducing the risk of injury recurrence. This trajectory begins with surgical treatment and extends through outpatient care and community rehabilitation. The collaborative care intervention fundamentally restructures the delivery of mental health care within trauma care systems by bringing together providers currently working independently to form an interdisciplinary mental health team. Team members work together and in a liaison capacity with other trauma center providers and community practitioners in order to bridge care across service delivery sectors.
223639110|NCT05243511|DEVICE|Digital ACT|Participants in this arm receive Digital ACT as well as standard of care.
223639111|NCT05243511|OTHER|Digital Symptom Tracker|Participants in this arm complete a digital symptom and function tracker and monitor, are provided access to digital fibromyalgia and health education, and receive standard of care.
223639112|NCT04976101|DEVICE|Sinosuidal Galvanic Vestibular Stimulation|stimulus will be given by applying paste electrodes over the mastoid processes and plugging the leads into a battery driven-stimulus box, which when activated by a switch, will provide a very low frequency (VLF) bipolar, ± 2 mA, 0.025 Hz oscillating current sGVS between the mastoids
223639113|NCT04976101|DEVICE|Placebo|When assigned to placebo arm of the study, the patients will undergo same procedure as the treatment, only current will not be passed. (the device will still be placed on the mastoid process)
223639114|NCT01432730|DRUG|Gefapixant|Oral tablets, BID
223639115|NCT01432730|DRUG|Placebo|Oral tablets, BID
223639116|NCT05461534|BEHAVIORAL|mindfulness yoga|Each mindfulness yoga session will last for 90 minutes and will be conducted in a group format once a week. Each session includes breathing exercise (10 min), mindfulness meditation and body scan (20 min) and yoga practice (60 min).
223639117|NCT05402488|BEHAVIORAL|Auditory stimulation|Auditory stimulation during sleep
223639118|NCT02505919|DEVICE|AQUABEAM System|The AQUABEAM system, a personalized image-guided tissue removal system, utilizes proprietary heat-free high-velocity waterjet technology to resect and remove prostate tissue.
223639119|NCT02505919|PROCEDURE|Transurethral Resection of the Prostate (TURP)|Transurethral resection of the prostate (TURP) is a type of prostate surgery done to relieve moderate to severe urinary symptoms caused by an enlarged prostate, a condition known as benign prostatic hyperplasia (BPH)
223639120|NCT03881852|DRUG|AXS-12 (Reboxetine)|Dosed orally, twice daily for up to 3 weeks
223639121|NCT03881852|DRUG|Placebo|Dosed orally, twice daily for up to 3 weeks
223639122|NCT01955330|PROCEDURE|Robotic Hybrid coronary artery revascularization|Lita to LAD performed by robot, Hybrid stent to other diseased coronary artery
223639123|NCT02297594|DRUG|AK0529|AK0529 capsule for oral administration
223639124|NCT02297594|DRUG|Placebo|Sugar placebo capsule for oral administration
223639125|NCT05777356|DIAGNOSTIC_TEST|Urine collection and assessment of dietary intake by food frequency questionaire|urinary iodine, creatinine and methylmalonic acid, iodine and vitamin B12 dietary intake from foods and supplements
224227299|NCT00929409|DRUG|Ferric carboxymaltose|Intravenous infusion of Ferric carboxymaltose in a dose calculated to meet the individual patient's requirements following the Ganzoni formula
224227300|NCT00929409|DRUG|Ferrous sulfate tablets|Standard tablets containing 100 mg ferrous sulfate, 1 tablet two times daily
224227301|NCT03912207|BIOLOGICAL|BCG Danish|BCG Danish 1331 is on the WHO list of pre-qualified vaccines and has a well-defined side effect profile. BCG is licensed for delivery via the intradermal route. It is not licensed for delivery via the aerosol route.
224227302|NCT03912207|OTHER|Saline placebo|Saline is a routinely used placebo.
224227303|NCT03125083|BIOLOGICAL|Biological dosage from plasma|The purpose of this study is to determine the role of inflammation in the high prevalence of psychiatric disorders in skin-restricted lupus (SRL) patients. SRL is an inflammatory disease. Inflammation can lead to a decrease in the synthesis of neurotransmitters via the activation of the IDO enzyme and to induce the synthesis of neurotoxic molecules (kynurenin pathway). This leads to the development of psychiatric disorders.
224227304|NCT05162404|BEHAVIORAL|Video Education Program|"The following topics are addressed in each module of the videos:~1. Understanding cancer and cancer treatment - including an understanding of stage, site of origin, metastases, treatment options, toxicities and anticipated outcomes.~2. Care coordination basics (CC: Communication) - including navigating care related to appointments, how to handle issues after-hours, and the expected roles of other healthcare providers (e.g., PCPs).~3. How to be a self-advocate (CC: Navigation and Operational) - including how to ask questions, being empowered to talk to your doctor, when a second opinion is needed, when to explore clinical trials, and how to best incorporate a caregiver into your treatment."
223639126|NCT01421719|DRUG|Cystoscopic injection of Botox into the urinary bladder|100 U of Botox A injected transurethrally into the urinary bladder muscle and submucosa.
223639127|NCT05674305|DRUG|Radiotherapy|IMRT for primary and regional field
223639128|NCT05674305|DRUG|Cisplatin|Cisplatin 80mg/m2, 21days/cycle, 2 cycles
223639129|NCT03924167|BEHAVIORAL|Weaving Healthy Families Program|The Weaving Healthy Families program is created from integrating the widely disseminated, ecological, innovative, and culturally grounded Framework of Historical Oppression, Resilience, and Transcendence (FHORT) with the the Celebrating Families! evidenced-based program (EBP). The goal of this program is to reduce and postpone Alcohol and other Drug (AOD) use, decrease and prevent violence in families, and promote resilience and wellness (including mental health) among NA adults and youth. This intervention seeks to promote wellness by targeting key behavioral (AOD), mental/emotional (emotional regulation/anger management, cognitions, resilience), social and familial (healthy and safe relationships, the family environment, and parenting), cultural (values, traditions), and physical (nutrition) factors.
223765088|NCT06691269|DRUG|Topical Benzocaine|Topical Benzocaine at injection site to reduce discomfort of local infiltration
223765089|NCT06691269|DRUG|Local Anesthesia|Local infiltration using local anesthetics with epinephrine
223765090|NCT07019766|OTHER|A combined retrospective and prospective observational follow-up|The NICHE-LGLL will collect basic information, diagnostic and treatment information, as well as health costs information of patients from medical records. The study will use questionnaire to measure the exposure of patients, and prospectively follow-up to collect the prognosis information.
223639130|NCT03877328|OTHER|BiotechCoachForAll|A group of thirty subjects diagnosed with heart failure (HF) of any etiology undergo an experimental procedure in the following order: resting-state (eyes-closed), passively viewing thirty two agents which are grouped with respect to different appearance characteristics and passively viewing combinations of virtual agents. During the experiment, brain activity, heart rate, skin conductance, temperature and eye-gaze biosignals are collected by means of electroencephalography, Empatica E4 and Gazepoint. Subsequently, a prospective cohort study is performed in a subgroup of ten participants which undergo a three additive stage procedure. Stage 1, a wearable monitoring device (Wavelet Health) is given in order to provide objective information on the patient's activity. Stage 2, the FitForAll physical exercise program is introduced. Stage 3, introduces the coaching aspects, where personalized recommendations and suggestions are delivered through home surfaces' projection.
223639131|NCT01124006|DRUG|Intradiscal rhGDF-5|The API is recombinant human growth and differentiation factor-5 (rhGDF-5), a recombinant version of human GDF-5. GDF-5 is a member of the transforming growth factor-b (TGF-b) superfamily and the bone morphogenetic protein (BMP) subfamily, and is known to influence the growth and differentiation of various tissues, including the intervertebral disc. In vitro experiments have shown that rhGDF-5 can stimulate gene expression and synthesis of the extracellular matrix proteins type II collagen and aggrecan. In vivo experiments in rabbit models of disc degeneration have shown that intradiscal injections of rhGDF-5 can stimulate an increase in disc height and hydration.
223639132|NCT01124006|OTHER|Water for injection|Sterile water for injection
223639133|NCT00684008|DRUG|CYT107 - Recombinant glycosylated human interleukin 7.|Patients will be treated with CYT107 60 to 210 days post transplantation, in 3 successive cohorts of 3 patients. Escalating doses of CYT107 will be given to successive cohorts. Patients will receive 1 dose of CYT107 by the subcutaneous route, once a week for 3 weeks. Dose level 1: 10 mcg/kg/dose for 3 doses; Dose level II: 20 mcg/kg/dose for 3 doses; Dose level III: 30 mcg/kg/dose for 3 doses. Only 1 treatment course for this initial study.
223639134|NCT00684008|DRUG|rhIL-7 (CYT107)|10, 20, or 30 mcg/kg once a week for 3 consecutive weeks via the subcutaneous route.
223639135|NCT02433808|DRUG|Neostigmine Group|Neostigmine will be used to reverse neuromuscular block at the conclusion of the surgical procedure. The effect on muscle strength will be determined using the TOF-Watch-SX and clinical examination
223639136|NCT02433808|OTHER|No Neostigmine group|Saline will be administered to patients at the end of the surgical procedure when neuromuscular function has recovered
223639137|NCT01896219|DEVICE|Navigation station (IMACTIS-CT®)|
223639138|NCT01896219|DEVICE|CT|Reference method for gestures (carried out under CT) guidance
223639139|NCT04405453|PROCEDURE|trapezius muscle injection|TMI group will receive ultrasound guided trapezius muscle injection two times with one week interval.
223639140|NCT04405453|PROCEDURE|erector spina plane block|1th week will receive ultrasound guided trapezius muscle injection and in the 2nd week ultrasound guided erector spina plane block will receive
223639141|NCT00565084|DRUG|ibuprofen|Patients will receive 800 mg ibuprofen in one of the three treatment periods.
223639142|NCT00565084|DRUG|Placebo|Patients will receive placebo to ibuprofen in two of the three treatment periods.
224227305|NCT02210767|OTHER|Walnut Diet|2 oz. walnuts/day (2-3% of total calories from ALA)
224227306|NCT02210767|OTHER|Walnut Control Diet|2-3% ALA but no walnuts provided
224227307|NCT02210767|OTHER|Low ALA Diet|ALA replaced by oleic acid
224227308|NCT00417274|DRUG|Quinacrine|100 mg daily
224227309|NCT06076681|DRUG|TNP-2198|On Days 1 to 14, all subjects in each group received TNP-2198 capsule within 30 minutes after breakfast and dinner (BID) for 14 consecutive days. On Day 15, the subjects were only administered once within 30 minutes after breakfast.
224227310|NCT06076681|DRUG|Rabeprazole Sodium|On Days 1 to 14, all subjects in each group received rabeprazole within 30 minutes before breakfast and dinner (BID) for 14 consecutive days. On Day 15, the subjects were only administered once within 30 minutes before breakfast.
224227311|NCT06076681|DRUG|Amoxicillin|On Days 1 to 14, all subjects in each group received Amoxicillin capsule within 30 minutes after breakfast and dinner (BID) for 14 consecutive days. On Day 15, the subjects were only administered once within 30 minutes after breakfast.
224227312|NCT01038570|DRUG|Syntocinon®/- Spray|3 sprays corresponding to 24 IU in each nostril
224227313|NCT01038570|DRUG|Physiological serum (Sodium chloride)|Sodium chloride 0.9 % (0.3 ml) in each nostril
224227314|NCT05893056|PROCEDURE|Cryoablation|Cryoablation is performed under US or CT guidance per Investigator decision.
224227315|NCT05893056|DRUG|Tislelizumab|a PD-1 immune check inhibitor
224227316|NCT05893056|DRUG|Lenvatinib|Lenvatinib capsules
224227317|NCT03659409|BEHAVIORAL|Mindfulness-Based Intervention|4 weekly 2-hour sessions. Participants will be introduced, taught and guided in practice of mindfulness-based interventions that are focused on their (1) breath, (2) senses, (3) body and bodily movements, (4) feelings of empathy and compassion.
224227318|NCT03659409|BEHAVIORAL|Waitlist - Mindfulness-Based Intervention|Participants in this group will only receive the Mindfulness-Based Intervention 3-months after they have started the study and baseline measurements. While participants in the Intervention Arm are receiving the treatment, this group will receive No intervention for the first four weeks and will continue as treatment as usual until it is their turn to receive the Intervention.
224227319|NCT01258491|DRUG|Nicotinic Acids|
224319170|NCT01762800|DRUG|fluticasone propionate/salmeterol 50/250mcg and tiotropium 18mcg|Active. The randomized treatment may be switched to TRIPLE therapy when COPD symptoms are uncontrolled or the subject is not satisfied with the randomized treatment at each scheduled or unscheduled visit.
224319171|NCT00478062|BIOLOGICAL|Hodgkin's antigens-GM-CSF-expressing cell vaccine|
224227320|NCT00192127|BIOLOGICAL|FluMist|A single dose of either bivalent vaccine or placebo mist by intranasal spray on Study Day 0.
224227321|NCT00192127|OTHER|Placebo|A single dose of either bivalent vaccine or placebo mist by intranasal spray on Study Day 0
224227322|NCT01880710|PROCEDURE|Subtotal hysterectomy|Subtotal abdominal hysterectomy where the body of the uterus is removed but the cervix is spared.
224227323|NCT01880710|PROCEDURE|Total Hysterectomy|total abdominal hysterectomy where the body as well as the cervix of the uterus are removed.
224227324|NCT01268176|DIETARY_SUPPLEMENT|cholecalciferol|50,000 IU once per month for 3 months
224319172|NCT00478062|PROCEDURE|adjuvant therapy|
223639143|NCT00500435|PROCEDURE|Extraperitoneal Laparoscopic Lymphadenectomy|Laparoscope used to find and remove para aortic lymph nodes in abdomen.
223639144|NCT04812717|DEVICE|CytoSorb device|The CytoSorb device will be placed in the CPB circuit in half of the study population during their cardiac operation.
223639145|NCT05360797|OTHER|Outpatient|After a 24-hour stay in the emergency department, the predictive factors of severity evaluation and the diagnosis of mild acute pancreatitis is confirmed, the patient is discharged and contacted daily for 4 consecutive days by the study investigators in each center.
223639146|NCT05360797|OTHER|Medical home care|After a 24-hour stay in the emergency department, the predictive factors of severity evaluation and the diagnosis of mild acute pancreatitis is confirmed, the patient is discharged and contacted daily for 4 consecutive days by the medical home care department in each center.
223639147|NCT05360797|OTHER|Hospitalization|After a 24-hour stay in the emergency department, the predictive factors of severity evaluation and the diagnosis of mild acute pancreatitis is confirmed, the patient is hospitalized with usual treatment (PADI\_1) in each center.
223639148|NCT03782506|BEHAVIORAL|Interactive Music Therapy|Ten 45-minutes individual interactive music therapy (IMT) sessions delivered by a board-certified music therapist. Sessions start with music-guided breathing or humming. The music therapist then engages the participant in singing of familiar songs and co-created vocal or instrumental music improvisations. Discussion about the meaning assigned to songs and emotions expressed through the improvisations follow. Each session involves learning and practicing music-based techniques for the self-management of pain, anxiety, stress, mood, fatigue, and sleep disturbance as these are common opioid withdrawal symptoms. Psychoeducation about opioid tapering is provided and tapering challenges experienced by the patient will be actively addressed through music-based interventions.
223639149|NCT03782506|BEHAVIORAL|Verbal-based support|Ten 45-minute individual sessions delivered by a master's level clinician with training in counseling. The sessions are focused on patient-initiated conversations about their pain, life stressors and the impact on their daily life. The intervener provides nondirective, supportive care by offering supportive, validating statements and reflective listening. The intervener refrains from employing active suggestion, problem-solving or behavioral or cognitive therapy techniques. The verbal support sessions are aimed at providing an empathic, therapeutic environment to facilitate emotional expression and sharing of worries and fears. As in the IMT protocol, psychoeducation about opioid tapering will be included and will be considered the only active treatment factor for this intervention.
223639150|NCT05467969|BEHAVIORAL|Teleteaching of procedural skills through the online multiscreen display teleconference platform|Teleteaching of procedural skills include three different techniques through three different workshops. Each of the workshops was delivered by a respected expert faculty and then accompanied by skills assessment subsequently. Three different group of learners joined the workshops on knotting skills, suturing skills and laparoscopic hand-eye coordination skills respectively.
223639151|NCT01875406|OTHER|diagnostic exercises|
223639152|NCT04228380|OTHER|No intervention|No intervention
224227325|NCT01252433|OTHER|Energy density feeding study|In a crossover study, children are served all foods 1 day a week for 3 weeks. Meal entrees will vary in energy density (100%, 85%, 75%).
224227326|NCT03905291|DRUG|MT921|Formulated as an injectable solution
224227327|NCT03905291|DRUG|Placebo|normal saline
224227328|NCT02278679|PROCEDURE|Digital Rectal Exam|The DRE digital rectal exam is an essential component of physical examination, but physicians enter their residency having neither been appropriately exposed nor trained in performing DREs. , the attending physician, resident physician(s), and medical student(s) will each perform a digital rectal exam on the subject, and independently document their examination on the DiRECT instrument.
224227329|NCT02971956|DRUG|Pembrolizumab|Immune checkpoint inhibitor
224227330|NCT05289622|DEVICE|Polyurethane expandable valve stent implant|The baseline assessment of patients will include the admission of patients and the performance of preoperative exams (cardiological imaging for the correct selection). An estimated surgery time of 5 hours. During the entire procedure, patients will be under general anesthesia and controlled mechanical ventilation. The material collected in the laboratory will be processed, the result released and discarded. After the patient enters the operating room, hemodynamic monitoring, ECG, arterial saturation, with peripheral sensor, central venous access with double lumen catheter will be carried out; blood pressure monitoring by radial artery puncture, bladder catheter and thermometer in the nasopharynx and rectum. After preoperative preparation, patients will undergo a surgical approach by median thoracotomy and installation of the Cardiopulmonary bypass (ECC) circuit, by placing a cannula in the ascending aorta, Superior Vena Cava (SVC) and Inferior Vena Cava (IVC).
224227331|NCT00427492|DRUG|Magnesia|Tablet magnesia 500mg. 2 tablet 2 times a day for a week
224227332|NCT00427492|DRUG|Placebo|
224227333|NCT01761357|OTHER|answering to questionnaires of quality of live|
224227334|NCT01608009|DRUG|Pazopanib and paclitaxel|Pazopanib 800mg od for 7 days, followed by 18 weeks of combination therapy (paclitaxel 80mg/m2 weekly and pazopanib 800mg od). Following the completion of combination therapy, patients will continue on maintenance pazopanib 800mg od until disease progression.
224227335|NCT03718338|PROCEDURE|Evaluation|Undergo clinical evaluations
224227336|NCT03718338|OTHER|Quality-of-Life Assessment|Ancillary studies
224227337|NCT03181438|PROCEDURE|TAP Block|It will be performed a ultrasound-guided transverse abdominal plane block with 20 ml of 0.375% of ropivacaine for patients submitted to renal transplantation
224227338|NCT03181438|PROCEDURE|Saline Group|t will be performed a ultrasound-guided transverse abdominal plane block with 2o mL of saline for patients submitted to renal transplantation
224227339|NCT00612326|PROCEDURE|MRI and PET scanning procedures|a CT scan, MRI, and C-11 Acetate PET scan. All these scans will be done as an outpatient. After you finish these scans, your doctor will schedule you for surgery to remove your bladder and lymph nodes.
224227340|NCT02619604|OTHER|Education Intervention|Education interventions will be delivered sporadically within the 6-month window between the time the clinician completes the pre-survey and when he/she completes the post-survey. Interventions consist of e-brief publications, teleconferences with project faculty, and evidence based resources.
224227341|NCT00289601|DRUG|eptifibatide|
224227342|NCT02498522|DRUG|Metformin|83 patients will continue metformin until end of 1st trimester
224227343|NCT03330756|PROCEDURE|laparoscopic Roux-en-Y gastric bypass|laparoscopic Roux-en-Y gastric bypass with a 50 cm biliary limb and a 150 cm alimentary limb
223639153|NCT03124342|OTHER|VANDERBILT ICU RECOVERY PROGRAM|"10-component ICU Recovery Program intervention, including:~1. Nurse Practitioner In-Person Visit at the time of transfer from the ICU~2. Provision of an ICU Recovery Program Pamphlet describing post-intensive care syndrome and providing online resources~3. Performance of formal medication reconciliation at the time of transfer from the ICU~4. Access to a dedicated 24-hour a day, 7-day a week contact line~5. ICU Recovery Clinic Visit Medical Examination.~6. ICU Recovery Clinic Medication Reconciliation and Counseling~7. ICU Recovery Clinic Cognitive/Mental Health Assessment and Psychoeducation. A brief session of psychotherapy conducted by a clinical psychologist~8. ICU Recovery Clinic Case Management. A brief case management consultation~9. ICU Recovery Clinic Patient Centered Consultation. A final consultation with patients and families by a PCCM physician~10. Directed Subspecialty Referrals"
224227344|NCT03330756|PROCEDURE|laparoscopic Mini gastric bypass|laparoscopic Mini gastric bypass with a gastrojejunostomy at 200 centimeters measured from the ligament of Treitz
224227345|NCT04573842|OTHER|Ultrasound assessment of SCV|An ultrasound examination of the SCV will be performed before anesthesia induction. Apart from this, the protocol does not differ at all from the ordinary fashion
224227346|NCT02756312|OTHER|IV Anesthesia|The patients will receive intravenous anesthesia
224319173|NCT02640482|DRUG|ABT-493/ABT-530|Tablet; ABT-493 coformulated with ABT-530
224319174|NCT02640482|DRUG|Placebo for ABT-493/ABT-530|tablet
224319175|NCT00517881|DRUG|Methoxy polyethylene glycol-epoetin beta (C.E.R.A.)|Subcutaneous methoxy polyethylene glycol-epoetin beta (C.E.R.A.) at starting dose of 120, 200, or 360 mcg every 4 weeks for 20 weeks. Further dose adjustments will be performed during the study depending on the participant's blood hemoglobin levels.
223639154|NCT01712399|BIOLOGICAL|Mavrilimumab 100 mg|Participants will receive 100 mg mavrilimumab once in every 2 weeks (Q2W) subcutaneously for up to 3 years
223639155|NCT05650359|DEVICE|OrthoPulse|"The OrthoPulse device is intended to accelerate orthodontic movement of teeth and reduce the overall treatment time for the patient. The device is intended to be used in conjunction with traditional orthodontic treatment with brackets and wires or aligners.~OrthoPulse is an intra-oral (iO), Light Emitting Diode (LED) based, phototherapy device for the stimulation of metabolic activity of the alveolar bone, and the acceleration of orthodontic tooth movement during orthodontic treatment. The device uses safe, high-power LED arrays to produce photons at therapeutic wavelengths in the near infrared (nIR) portion of the light spectrum.~OrthoPulse is an established device that uses low levels of light energy to stimulate the bone surrounding the roots of teeth and facilitate tooth movement which may reduce treatment time for braces or clear aligners."
223639156|NCT05650359|OTHER|No intervention|No intervention
223639157|NCT06598085|DEVICE|Robot-assisted surgery|Surgery with the Cornerstone Surgical Robot.
223639158|NCT03692299|DRUG|Saccharomyces Boulardii Oral Tablet|Saccharomyces boulardii 200 mg b.i.d. during 2 weeks, followed by a 2-week rest period and then again 200 mg b.i.d. during 2 consecutive months.
223639159|NCT03692299|DRUG|Metronidazole|Metronidazole 500 mg b.i.d during 1 week, followed by a 3-week rest period and then again 500 mg b.i.d during 2 consecutive months
223639160|NCT05913765|DEVICE|Air cleaner|Austin Air Healthmate air cleaner with or without standard filter
223639161|NCT02896803|DRUG|mFLOX|5-fluorouracil 500 mg/m2 and folinic acid 20 mg/m2 infused both bolus weekly for 6 weeks (d1, 8,15, 22, 29 and 36) and oxaliplatin 85 mg / m2 infused over 2 hours at weeks 1,3 and 5 (d1,15 and 29). The scheme will be repeated every 8 weeks.
223639162|NCT01696110|DRUG|Bivalirudin|Patients would be given anticoagulant therapy with bivalirudin in acute myocardial infarction during emergency PCI operation.
223639163|NCT01696110|DRUG|heparin|heparin monotherapy
223639164|NCT01696110|DRUG|heparin plus tirofiban|combined use of heparin and tirofiban during PCI
223639165|NCT03056092|DRUG|Intravitreal ranibizumab|Patients will be treated with intravitreal ranibizumab and have their aqueous humor obtained for cytokine analysis at every visit that an intravitreal injection is done
223639166|NCT01942837|DRUG|Enzalutamide|Enzalutamide, formerly known as MDV3100, is a rationally-designed second generation AR inhibitor which functions by blocking several steps in the AR signaling cascade. Enzalutamide competitively binds the AR with great potency. Additionally, enzalutamide inhibits nuclear translocation of activated AR and inhibits the association of activated AR with DNA.
223639167|NCT02484118|PROCEDURE|Hemodialysis blood flow|The impact of blood flow rates of 320 ml/m and 380 ml/m will be compared to determine any impact on hemodialysis urea clearance
223639168|NCT05511584|PROCEDURE|VO2 estimation|"1. st) VO2 (ml/min) will be estimated based on the formula: Inspired fraction of O2 (FiO2) - Expired fraction of O2 (FeO2) \* minute volume (Volmin)~2. nd) Assuming the estimation of VDphys obtained with Fluxmed®, the investigators will calculate the VO2 corresponding to effective alveolar ventilation (VO2.alv), which will be the result of subtracting VDphys from Volmin.~3. rd) The investigators will calculate the O2 delivered fraction (DO2) (ml/min) corresponding to the estimated VO2.alv, and will supply it to the system while working in a closed-circuit mode."
223639169|NCT05511584|PROCEDURE|SEVOup estimation|"1. st) SEVOup (ml/min) will be estimated based on the formula: Inspired fraction of sevoflurane (Fi.sevo) - Expired fraction of sevoflurane (Fe.sevo) \* Volmin~2. nd) Assuming the estimation of VDphys obtained with Fluxmed®, the investigators will calculate the SEVOup corresponding to effective alveolar ventilation (SEVOup.alv), which will be the result of subtracting VDphys from Volmin.~3. rd) The investigators will calculate the sevoflurane delivered fraction (SEVOsuppl) (ml/min) corresponding to the estimated SEVOup.alv, and will supply it to the system while working in a closed-circuit mode."
223639170|NCT03404700|BEHAVIORAL|Egg breakfast|"Containing:2 Scrambled Eggs, 120 mL Skim Milk, 2 Slices Nature's Own Double Fiber Wheat Bread, 30g Margarine, 18g Smuckers Strawberry Jam~10 g of Margarine, 18 g of Smuckers® Strawberry Jam"
224227347|NCT02756312|OTHER|IH anesthesia|The patients will receive inhalation anesthesia
224227348|NCT00624156|BEHAVIORAL|Writing Intervention|Participants in the emotional disclosure condition will be instructed to write continuously for 20 minutes about their deepest thoughts and feelings regarding their cancer experience.
224319176|NCT04933383|DRUG|AQ001S 0.125 mg/ml|administered by nebulization once daily
224319177|NCT04933383|DRUG|Budesonide 0.125 mg/ml inhalation suspension|administered by nebulization once daily
224319178|NCT02743624|PROCEDURE|Variation of the level of pressure support during the mechanical ventilation|The pressure support of the patient was changed form the baseline to 20 cmH20 and then stepwise decreased to 2 cmH20,
224227349|NCT00624156|BEHAVIORAL|Writing Intervention|Participants assigned to the control condition will be instructed to describe in a detailed, nonemotional manner their daily activities. The 20-minute writing task will be introduced as a time management intervention
224227350|NCT02553369|OTHER|Biological sample collection|A blood sample is collected during a follow up visit for HIV infection.
224227351|NCT04061889|OTHER|intervention name is not applicable|Another intervention is not applicable either, due to the observational study design
224227352|NCT00354510|DRUG|GW842470X cream|
224227353|NCT04861896|BEHAVIORAL|"My Guide (psychoeducation & self-management program)"|12-week long health promotion Smartphone application to support patient's side effects self-management and adherence to endocrine therapy.
224227354|NCT03803722|DEVICE|Eyestil Protection® unidose|to demonstrate the non-inferiority of Eyestil Protection® in terms of performance and safety, when compared to Vismed® in treatment of dry eye disease.
224227355|NCT01798485|DRUG|Docetaxel|Docetaxel, 75 mg/m\^2, was administered according to prevailing practice and Investigator decision, generally until disease progression, intolerability, or patient's withdrawal of consent.
224227356|NCT01798485|DRUG|Ganetespib|Ganetespib, 150 mg/m\^2, was administered with docetaxel. After docetaxel treatment ceased, participants whose disease has not progressed continued to receive ganetespib alone until disease progression, unacceptable toxicity, or patient's withdrawal of consent.
224227357|NCT01916785|DRUG|Dasatinib|Dasatinib is a multitargeted tyrosine kinase inhibitor with a 300-fold more potent activity on the BCR-ABL tyrosine kinase in vitro compared to imatinib mesylate
224227358|NCT03582371|PROCEDURE|Stand-Up Paddle Rehabilitation|Patients in the Aqua SUP group will benefit from a 1 hour Aqua SUP session, twice a week, for 8 weeks in a therapeutic pool.
224227359|NCT03582371|PROCEDURE|Physiotherapy Rehabilitation|Patients in the control group will receive a conventional physiotherapy session of 1 hour, twice a week, for 8 weeks.
224227360|NCT01732965|OTHER|Phototherapy|
224227361|NCT01732965|OTHER|Phototherapy and Photochemotherapy|
224227362|NCT00681863|DRUG|pramipexole 0.125 mg BID|titrated dose for those patients whose symptoms were not controlled on the 0.0625 mg BID dose
224227363|NCT00681863|DRUG|pramipexole 0.0625 mg QD|dose down titrated for those patients unable to tolerate the 0.0625 mg BID dosing
224227364|NCT00681863|DRUG|pramipexole 0.125 mg TID|titrated up for those patients whose symptoms were not adequately controlled on 0.125 mg BID dose
224227365|NCT00681863|DRUG|pramipexole 0.25 mg BID|titrated for those patients whose symptoms were not adequately controlled on 0.125 mg TID dose
224227366|NCT00681863|DRUG|pramipexole 0.0625 mg BID|0.0625 mg BID given for first 4 wks of treatment
224227367|NCT01677455|DRUG|ganetespib|Ganetespib 150 mg/m2 will be administered intravenously, twice weekly, for three consecutive weeks of each 4 week cycle.
224227368|NCT01249339|PROCEDURE|Buccal Administration of nicotine|Oral pouch 1g, single dose. One pouch administered over 30 minutes.
224227369|NCT01249339|PROCEDURE|Buccal Administration of nicotine|Oral pouch 1g, single dose. One pouch administered over 30 minutes.
223639171|NCT03404700|BEHAVIORAL|Egg breakfast with high saturated fat|Containing:2 Scrambled Eggs, 120 mL 2% milk, 2 Slices Nature's Own Double Fiber Wheat Bread, 15 g Butter, 15g Smuckers Strawberry Jam
223639172|NCT03404700|BEHAVIORAL|Cereal breakfast|Containing: 1c Special K ready-to-eat (RTE) High Protein Cereal, 200 mL Silk Original Soy milk, 1 Slice Mrs. Bairds Extra Thin Bread, 35g Margarine, 10 g Smuckers Sugar Free Strawberry Jam
223639173|NCT03404700|BEHAVIORAL|Cereal breakfast with high saturated fat|Containing: 1c Special K ready-to-eat (RTE) High Protein Cereal, 200 mL Silk Original Soy milk, 1/2 Slice Arnold Double Protein Whole Grain Bread, 15 g Butter
223639174|NCT02267551|OTHER|Mimic dv-Trainer|
223639175|NCT02267551|OTHER|daVinci Skills Simulator|
223639176|NCT04411498|DIAGNOSTIC_TEST|Fibromyalgia diagnosis in patients with SSc|American College of Rheumatology (ACR) FMS diagnostic criteria set:It is evaluated by the common pain index \[WPI\] and symptom severity (SS) scale \[19\]. Diffuse pain index \[WPI\]; It is a scale that can be scored between 0-19 and obtained by indicating the aching regions of the patient during the last 1 week. Right shoulder, left shoulder, right hip \[gluteal region\], left hip \[gluteal region\], left chin, right chin, left upper arm, left lower arm, right upper arm, right lower arm, left upper leg, left lower leg, includes right upper leg, right lower leg, chest, neck, abdomen, upper back, lower back. Symptom Severity Scale \[SSS\]; evaluates weakness, tired awakening and cognitive functions. In addition, muscle pain, weakness, irritable bowel syndrome, memory problems, headache, abdominal pain, numbness, dizziness, insomnia, depression, constipation, irritability, dry mouth etc. It also evaluates somatic symptoms.
223639177|NCT06172309|DRUG|NTQ1062|tablet(s) PO
223639178|NCT01060332|OTHER|Body Constitution Questionnaire|Body Constitution Questionnaire was a tool for the study of objective evaluation of diagnostics of Traditional Chinese Medicine. It has been well developed with good validation and consistency.
223639179|NCT02201394|DRUG|Ticagrelor loading dose|Single loading dose of Ticagrelor 180 mg
223639180|NCT02201394|DRUG|Aspirin loading dose|Single loading dose of Aspirin 325 mg
223639181|NCT02201394|DRUG|Ticagrelor maintenance dose|Ticagrelor 90 mg twice daily x 7 days
223639182|NCT02201394|DRUG|Aspirin maintenance dose|Aspirin 81 mg once daily x 7 days
223639183|NCT02628912|OTHER|blood draw|
223639184|NCT02628912|BEHAVIORAL|study questionnaire|
223639185|NCT02628912|OTHER|cardiopulmonary exercise testing (CPET)|
224227370|NCT01249339|PROCEDURE|Buccal Administration of nicotine|Oral pouch 0.5 g, single dose. One pouch administered over 30 minutes.
224227371|NCT01249339|PROCEDURE|Buccal Administration of nicotine|Oral pouch 0.3 g, single dose. One pouch administered over 30 minutes.
224227372|NCT03741218|OTHER|Freeze-dried grape (GRAP)/Placebo (PLA)|The subjects will receive, after overnight fasting, either a monodose of freeze-dried grapes (equivalent to 300 g of fresh grapes) or isocaloric placebo solved in water, together with a high-fat breakfast. Blood samples will be collected before the intake, up to 5 h after breakfast, then a medium-fat lunch will be provided and blood samples will be collected for three additional hours. A total of 10 samples will be collected: 0-30-60-120-180-240-300-330-360-420 min. Both interventions will be separated by two weeks. Subjects will be instructed not to modify their dietary habits during the development of the study, but during the 72 h before each visit they will have to restrict the intake of polyphenol-rich foods (a detailed list will be provided).
223639186|NCT02628912|OTHER|DXA (dual-energy x-ray absorptiometry) scan|
223639187|NCT02648919|DRUG|Noni extract|Intervention will be administered on an outpatient basis.Six bottles containing 60 capsules will be dispensed to all participants upon enrollment. Then 12 bottles (at 30-day visit) and 18 bottles (at 3, 6 and 9 month visits) will be dispensed to all participants.
223639188|NCT01660048|PROCEDURE|SILS TEP repair|perform the laparoscopic total extraperitoneal inguinal hernia repair using a single port
223639189|NCT01660048|PROCEDURE|Total extraperitoneal inguinal hernia repair|Conventional multiport laparoscopic total extraperitoneal inguinal hernia repair
224227373|NCT04810195|DEVICE|Boston Scientific Acurate neo2 TAVR device|The newest generation of the Acurate neo2 TAVR device, launched in Europe in 2020.
224227374|NCT03035279|DRUG|SC-006|Intravenous
224227375|NCT03035279|DRUG|ABBV-181|Intravenous
224227376|NCT04793503|OTHER|conventional complete denture|the complete denture constructed by packing technique
224227377|NCT04793503|OTHER|CADCAM 3D printed denture|The files from the laser-scan will be translated into stereolithography (STL) files and the CDs are virtually designed in ExoCad software
224227378|NCT04793503|OTHER|CAD/CAM milled denture|Once the complete denture has been virtually designed in CAD software (ExoCad software) a preview will be sent for evaluation using 3D viewing software
224227379|NCT06112457|OTHER|Survey|Anonymous self-administered questionnaire
224227380|NCT00720850|DRUG|lenalidomide|p.o. 10 mg/d for 21 days every 4 weeks for 1 year (12 cycles) after HSCT
224227381|NCT01403350|DEVICE|Malaria Rapid Diagnostic test|Study Phase I: RDT used under the standard programme of training and support; Study Phase II: RDTs deployed with additional programme components including improved training and supportive interventions
224227382|NCT00000616|BEHAVIORAL|diet, sodium-restricted|
224319179|NCT05032781|DRUG|Intra-arterial cold saline, minocycline, and magnesium|See study design
224319180|NCT05690932|DRUG|PBI-200 Tablet|Single dose of PBI-200 tablet
223639190|NCT02575638|DRUG|CZ48|CZ48 is an analog of the topoisomerase I inhibitor Camptothecin (CPT). CPT is a natural extract from the tree Camptotheca acuminata
223639191|NCT01635166|DEVICE|Delta Motion|A cementless acetabular cup with a pre-assembled ceramic liner for use in total hip replacement.
223639192|NCT03252431|DRUG|F-627|single dose pre-filled syringe
223639193|NCT03252431|DRUG|Neulasta|single dose pre-filled syringe
223639194|NCT02242526|DEVICE|Parietex™ Composite Hiatal Mesh, North Haven, CT|Parietex™ Composite Hiatal Mesh (North Haven, CT) designed for hiatal hernia repair.
223639195|NCT02242526|DEVICE|Biodesign™ Surgisis® Graft, Cook Medical, Bloomington|Biodesign™ Surgisis® Graft (Cook Medical, Bloomington) designed for hiatal hernia repair.
223639196|NCT05692375|OTHER|"Invitation to play the game Save the shame!"|The experimental group was asked to use the game. Two weeks were defined as the time to use the game. The use of the game can be seen by the coded digital record on its digital platform . The control group neither used nor had access to the game. Afterwards both groups performed the ALS knowledge assessment test. It is a test with 20 multiple choice questions each scored as right (0.5 points) or wrong (0 points).
223639197|NCT01803607|DRUG|odanacatib|odanacatib 50 mg oral tablet
223639198|NCT01803607|OTHER|placebo to odanacatib|dose-matched placebo to odanacatib, oral tablet
223639199|NCT04289974|DRUG|Palbociclib|Palbociclib (125 mg PO qDay for Days 1-21 of each 28-day cycle) combined with Fulvestrant (500 mg IM on Days 1, 15, and 29, and then once monthly thereafter)
223639200|NCT04299607|DIAGNOSTIC_TEST|DPP Fever Panel II assay and DPP Micro Readers|Detection of common causes of acute febrile illnesses in Asia
223639201|NCT00055757|DRUG|tipifarnib|Given orally
223639202|NCT00055757|DRUG|cisplatin|Given IV
224227383|NCT00000616|BEHAVIORAL|diet, fat-restricted|
224227384|NCT00000616|BEHAVIORAL|exercise|
224227385|NCT00000616|BEHAVIORAL|diet, reducing|
224227386|NCT00000616|BEHAVIORAL|alcohol drinking|
224319181|NCT05690932|DRUG|PBI-200 Capsule|Single dose of PBI-200 capsule
224319182|NCT05690932|DRUG|PBI-200 Suspension|Single dose of PBI-200 suspension
224319183|NCT03194828|BEHAVIORAL|Medication reminder|Using the real-time data capture of the electronic device, an automated voice call or text message will be sent to active arm participants only when a missed dose is determined
224319184|NCT03194828|BEHAVIORAL|Medication monitoring only|Patients will use an electronic medication monitoring device to record their actual medication use
224319185|NCT05794893|BEHAVIORAL|Good Behavior Game|Universal school-based intervention reinforcing prosocial behaviors and discouraging disruptive behaviors in young students.
224319186|NCT05677919|PROCEDURE|Biospecimen Collection|Undergo collection of blood, tissue, stool, and saliva samples
224319187|NCT05677919|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
224319188|NCT05677919|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
224319189|NCT05677919|PROCEDURE|Computed Tomography|Undergo CT scan
223639203|NCT00055757|DRUG|gemcitabine hydrochloride|Given IV
223639204|NCT00055757|OTHER|laboratory biomarker analysis|Correlative studies
223639205|NCT04469907|DRUG|AZD9977|Participants will receive a single oral dose of AZD9977 under fasted conditions.
223639206|NCT02650076|DRUG|SK-1405|
223639207|NCT03586492|DIAGNOSTIC_TEST|CZT SPECT acquisition|CZT SPECT acquisition, with dynamic stress and rest acquisitions to calculate CFR If pathological, coronarography with FFR measurement if necessary In case of intermediate coronary stenosis with medical treatment, SPECT CFR evaluation after one year of treatment
223639208|NCT03478098|OTHER|Low GI mealtest|Meal with low glycaemic index (GI) is consumed over 20 min
223639209|NCT03478098|OTHER|Low GI mealtest and subsequent exercise|Meal with low glycaemic index (GI) is consumed over 20 min and the subject postprandially exercises for 30 min
224227387|NCT01919294|DRUG|testosterone undecanoate|Preparation: 1 gram in 4 ml of oily base. Requires no special storage conditions. Proposed regime: 1 mg as a single intramuscular injection at 0, 6, 18, 30 and 42 weeks
224227388|NCT01164033|DRUG|RO5045337|single oral dose
224227389|NCT05074589|DRUG|Irinotecan liposome、5-Fluorouracil、Leucovorin|Irinotecan liposome、5-Fluorouracil、Leucovorin
224227390|NCT05074589|DRUG|Placebo、5-Fluorouracil、Leucovorin|Placebo、5-Fluorouracil、Leucovorin
224227391|NCT03316937|PROCEDURE|Types of scalers|Scaling
223639210|NCT03478098|OTHER|High GI mealtest|Meal with high glycaemic index (GI) is consumed over 20 min
223639211|NCT03478098|OTHER|High GI mealtest and subsequent exercise|Meal with high glycaemic index (GI) is consumed over 20 min and the subject postprandially exercises for 30 min
223639212|NCT05956015|OTHER|stable isotopes|The tracer 2H5-phenylalanine is an essential amino acid labeled with deuterium that is a stable isotope, i.e. no radiation is emitted, but the tracer can still be assessed by a combination of gas chromatography and mass spectrometry. The tracer has no measurable effects, but are used for assessment of human physiology.
223639213|NCT00632814|DRUG|rFVIII-FS (Kogenate FS, BAY14-2222) 70 IU/kg, dosing once per week|rFVIII-FS (Octocog-alfa, antihemophilic factor \[recombinant\]) 70 IU/kg, dosing by injection once per week (weekly on Day 7 + 1 after previous injection) for 9 months. Dose escalation was permitted due to joint bleeding (escalation to 35 IU/kg twice a week or further escalation to 25 IU/kg three times a week)
224227392|NCT01811277|DRUG|SOX sequential S-1|"4-6 cycles SOX followed by S-1 monotherapy until disease progression~S-1: 40\~60mg bid，po, d1\~14 （S-1：BSA \<1.25m2, 40mg bid, 1.25m2≤BSA≤1.5m2,50mg bid, BSA\>1.5m2, 60mg bid） oxaliplatin：130mg/m2，iv drip for 2h，d1"
224227393|NCT03757455|PROCEDURE|ERAS protocol preoperative actions|"First appointment:~\- Enlightenment on the benefits and objectives of the ERAS protocol~Call to the patient day before the surgery:~Discussing the course, benefits and goals of care in ERAS 4 dl PreOp drink before bedtime~Operation day:~Fluid intake allowed 2 hours before surgery 2 dl PreOP drink 2 h before cutting"
224227394|NCT03757455|PROCEDURE|ERAS protocol intraoperative actions|"Intraoperative:~Drains in the peripancreatic or perihepatic regions are not set unless the surgeon sees this particular reason The nasogastric tube is removed at the end of the surgery"
224227395|NCT03757455|PROCEDURE|ERAS protocol postoperative actions|"Postoperatively:~Mobilization with nurses assisted Drinks allowed after 4h surgery~POP 1:~Drinking and normal food Removal of urinary catheter Intravenous liquids only if needed Mobilization Pain management by epidural cannula Discussion of the ERAS protocol Pancreatin capsules per os before eating~Postoperative day 2:~\- Mobilization: As much as possible, autonomous movement~Postoperative day 3:~Ending epidural infusion cannula removal Mobilization as independently as possible~Pain relief: oxycodone/naloxone p.o. to keep mobilization possible:~Postoperative day 4:~Support and encouragement continues Pain management at a level that allows mobility"
224227396|NCT03378622|OTHER|Anchor|Anchor technique for mesh attachment
224227397|NCT03378622|OTHER|Suture|Suture technique for mesh attachment
224227398|NCT03401905|PROCEDURE|Low frequency|A dry needling on trapezius muscle is performed, until two local twitch responses are obtained. The needle is kept inside the trigger point, as it will be the negative electrode, and an adhesive electrode will be added as the positive one. After that, a low frequency TENS is applied, at 2 Hz frequency and 120 microseconds of pulse width.
224227399|NCT03401905|PROCEDURE|High frequency|A dry needling on trapezius muscle is performed, until two local twitch responses are obtained. The needle is kept inside the trigger point, as it will be the negative electrode, and an adhesive electrode will be added as the positive one. After that, a high frequency TENS is applied, at 12o Hz frequency and 200 microseconds of pulse width.
224319190|NCT05677919|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI scan
223639214|NCT00632814|DRUG|rFVIII-FS (Kogenate FS, BAY14-2222), 70 IU/kg twice per week (30 IU/kg + 40 IU/kg)|rFVIII-FS (Octocog-alfa, antihemophilic factor \[recombinant\]) 70 IU/kg, dosing by injection twice per week (30 IU/kg \[day 1\] + 40 IU/kg \[day 4\]) for 9 months. Dose escalation was permitted due to joint bleeding (escalation to 25 IU/kg three times a week)
223639215|NCT00632814|DRUG|rFVIII-FS (Kogenate FS, BAY14-2222) 75 IU/kg, dosing three times per week (3 x 25 IU/kg)|rFVIII-FS (Octocog-alfa, antihemophilic factor \[recombinant\]) 75 IU/kg, dosing by injection three times per week (3 x 25 IU/kg \[day 1, 3, 5\]) for 9 months. No escalation opportunity for patients in this group
224319191|NCT05677919|DRUG|Pirtobrutinib|Given PO
223639216|NCT02501291|DRUG|Thalidomide|
223639217|NCT01831388|OTHER|breathing techniques|"During all practice sessions, patients are seated in a chair, where they are guided through a set routine of various breathing techniques (detailed in Appendix A). No yoga poses are involved. There is no demand on the patient's physical condition and no risk of injury. The breath training program, with patients seated throughout, includes:~\- an initial teaching session (approximately 30-minute) at main campus by an MSKCC Integrative Medicine Service yoga-breathing instructor; - twice daily,breathing exercises (each approximately 15-minute) for 6 weeks practiced by patients at home with supplied recorded audio instructions; - and weekly follow-up phone calls by research staff (+/- 3 days from day 7 of each week) to identify and manage problems and to determine compliance."
223639218|NCT01831388|BEHAVIORAL|Self-Administered Baseline and Transition Dyspnea Indexes|Patients are asked to complete baseline SAC-BDI/TDI questionnaires at the pulmonary clinic. Patients will return to the pulmonary clinic at about week 6 for SAC-BDI/TDI and tests, and to return the diary recording their home exercises. Resting and post-6MWT pulse oximetry, and Hospital Anxiety and Depression Scale (HADS) will be evaluated as well.
223639219|NCT00912535|DRUG|Quetiapine extended release tablet|Quetiapine extended release tablet of 50-300mg/day
223639220|NCT00912535|DRUG|Placebo|Placebo orally, as adjunct to the same antidepressant at the same dose.
223765091|NCT07021144|BEHAVIORAL|"VA|PREVENTION web application (digital intervention)"|"VA\|PREVENTION web app, a digital intervention incorporating behaviour change techniques delivered by a Virtual Human Coach (VHC), educational content and progress tracking via a dashboard."
224227400|NCT01836835|OTHER|Pregnancy Unique Questionnaire of Emesis (PUQE)|For hyperemesis gravidarum patients the Pregnancy Unique Questionnaire of Emesis (PUQE) (3 questions regarding the amount of nausea and vomiting during 24 hours) will be answered both at hospital admittance and discharge. For control patients the questionnaire will be answered at inclusion.
224227401|NCT01836835|OTHER|24 hours self-reported nutritional intake form|A nutritional intake form where relevant food and liquid items can be checked prospectively after consummation during 24 hours. This form will be filled in starting the morning following inclusion.
224227402|NCT02408666|OTHER|Interview|
224319192|NCT05677919|PROCEDURE|Positron Emission Tomography|Undergo PET scan
224319193|NCT05677919|DRUG|Venetoclax|Given PO
224319194|NCT05677919|PROCEDURE|Echocardiography|Undergo ECHO
224319195|NCT05677919|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
224319196|NCT05677919|PROCEDURE|Biopsy|Undergo tissue biopsy
223639221|NCT01152957|BEHAVIORAL|CARIÑO Project|Care Attention Resources Information Nutrition \& Optimism Project (CARIÑO) is a CHW intervention that will involve 4 or more (as required) home visits, 10 group sessions, and 10 follow-up phone calls per subject over a 12-month period. The primary outcome is lower HgA1C levels. The secondary outcomes are to lower LDL levels, and systolic and diastolic blood pressure, medication adherence and improved diet and exercise. CARIÑO Project will provide outreach support services to patients with poorly controlled diabetes, such as health education, lifestyle changes, home visits, follow-up phone calls, support groups, one on one counseling and coaching, and assistance with resource referrals.
223639222|NCT01152957|BEHAVIORAL|Enhanced Usual Care|Usual care plus 4 health education brochures
223639223|NCT01725516|PROCEDURE|Myofascial release technique|
223639224|NCT01424215|DRUG|Indocyanine Green (ICG)|Injection of ICG intravenously then intraoperative imaging of the biliary anatomy during laparoscopic cholecystectomy using a near infrared (NIRF) imaging camera(Spy scope, Novadaq Canada)
223639225|NCT04125589|BEHAVIORAL|Speaking Activity|Participants will engage in a speaking activity where they are given a topic to speak about.
223639226|NCT04125589|BEHAVIORAL|Talking Activity|Participants will engage in a talking activity where they may talk about a topic of their choice.
223639227|NCT02781714|BEHAVIORAL|Two-way SMS|"SMS messages will provide tailored and actionable education, counseling, and reminders specific to antenatal/postpartum timing and partner track. Messages will include questions and prompts; women and their male partners have the option of writing back to a nurse with questions or concerns, who will provide real-time responses via text and/or make referrals to a clinic. Message content will be tailored to women and couples, and will range from health benefits of child spacing and an emphasis on contraceptive options, to the hierarchy of effectiveness and information on specific methods, to simple reminders about postpartum visits.~Prior to randomization, each enrolled woman will be asked if she has a male partner, and whether she would like to refer her male partner for recruitment and enrollment into the study. The partner tracks are as follows:~1. Male partner invited to enroll/enrolled~2. Male partner not invited to enroll~3. Unpartnered"
223639228|NCT03642587|OTHER|There is no intervention in this study.|There is no intervention in this study.
223639229|NCT02396121|DIETARY_SUPPLEMENT|Oral nutritional supplement : Renutryl® Booster|
223639230|NCT02993107|BIOLOGICAL|AR101|AR101 powder provided in capsules \& sachets
223639231|NCT02817646|OTHER|Computed tomography scan made for clinical reasons|Patients were included if a computed tomography scan of the abdomen or thorax was made early during intensive care admission (1 day before up to 4 days after admission)
223639232|NCT02817646|DIETARY_SUPPLEMENT|Nutrition as per hospital protocol|Patients received enteral and/or parenteral nutrition as per usual hospital protocol
223639233|NCT03549767|DEVICE|Springfusor|Springfusor for administration of magnesium sulphate
223639234|NCT03549767|PROCEDURE|Standard of care|Pritchard regimen. Magnesium sulphate is administered using hospital practice
223639235|NCT01308177|DRUG|Ecabet|comparison between PPI+ ES (lanston 30mg bid+ ES 1g/1.5g/pkg bid) and PPI+placebo (lanston 30mg bid)for 28 days
224227403|NCT05585658|BIOLOGICAL|Erythropoietin alpha|To analyze bio-similarity of GBPD002 with Eprex®, the Globe Biotech Ltd performed quite a few experiments to determine total analytical study of GBPD002. They performed peptide mapping to determine amino acid composition of GBPD002 and found similar result with erythropoietin alpha. The molecular weight was determined through SDS-PAGE analysis of GBPD002 and was compared with Eprex. The western blot analysis was performed to determine immune chemical characterization. Characterization of different isoforms was conducted through 2D gel electrophoresis.
224227404|NCT00323947|DRUG|Extended Release Methylphenidate (OROS-Methylphenidate)|"Participants will first take either immediate release MPH or placebo A for 1 day. On Day 2 of treatment, participants assigned to receive XR-MPH will begin taking it, and participants assigned to receive placebo will switch to placebo B. This treatment phase will continue for 6 days to 4 weeks, depending on weight, and will then be followed by a 1-week medication washout period. Target dose depends on the weight of the participant. Possible dose forms include 18, 36, 54 mg OROS-MPH."
224227405|NCT04044430|DRUG|Binimetinib|Given PO
224227406|NCT04044430|DRUG|Encorafenib|Given PO
224227407|NCT04044430|BIOLOGICAL|Nivolumab|Given IV
223639236|NCT05002712|OTHER|Heavy resistance training|Their training program included 4 resistance exercises with heavy weight lifting of the leg muscles. 3 sets of 6-8 repetitions of 80-90 % of maximal load were performed with a barbell squat (range of 0 to 90º knee flexion), lying leg curl, seated calf raises, and leg extension. The rests between the sets and the exercises lasted 5 minutes.
223765092|NCT07021144|BEHAVIORAL|Type 2 Diabetes Guidebook|T2D prevention guidebook, an educational material that include standard guidelines on healthy eating and the importance of regular physical activity and reduction of sedentary behaviour.
224227408|NCT04044430|OTHER|Questionnaire Administration|Ancillary studies
224227409|NCT05743283|DEVICE|SynEx Wound Cleanser|SynEx is a concentrated form of SynePure®, an FDA 510(k) cleared aqueous, osmotically balanced wound cleanser containing patented chitosan derivatives. The ingredients are USP purified water, chitosan arginine (a patented chitosan derivative), sorbitol powder, and betaine. SynEx cleanser is packaged in a collapsible plastic pouch for reconstitution in water before debriding and cleansing a wound.
224227410|NCT05743283|OTHER|Saline|The saline solution is composed of water and salt. It is packaged in a collapsible plastic pouch.
224227411|NCT03327896|OTHER|Charlson score and Community Social Deprivation|This is an observational study of the association of clinical comorbidity and neighborhood social deprivation characteristics with healthcare performance assessment.
224227412|NCT01076166|DRUG|clarithromycin (Klacid) granules for oral suspension|clarithromycin (Klacid) Granules for Oral Suspension
224227413|NCT06039787|BEHAVIORAL|single bout of moderate intensity continuous training (MICT)|the MICT consists of 60 min continuous cycling
224227414|NCT06039787|BEHAVIORAL|single bout of High Intensity Interval Training (HIIT)|HIIT consists of 10-min warm-up at the power output corresponding to 50% peak power output (PPO), 4 x 4-min intervals at a power output corresponding to 75% PPO with a 4-min active resting period at 30% PPO to recover
224227415|NCT06039787|BEHAVIORAL|waiting control|sitting in a waiting room for 60 min
224227416|NCT02235428|DRUG|Ipratropium bromide|
224227417|NCT02235428|DRUG|Placebo|
224227418|NCT02235428|DRUG|Salbutamol|
223639237|NCT05002712|OTHER|Contrast strength training|Their resistance training program contained the same exercises as the high resistance training group, but with different intensity. Athlete performed each exercise for the first time with 5-7 reps with 80 % of the 1RM load followed by 15-20 reps with 40 % of the maximal load to complete the 3 sets for each exercise. The rest period between series was 60 seconds and the rest period between exercises was 5 minutes. For example, 5 heavy barbell squats followed immediately by 20 squat with lighter weight to complete 3 sets.
223639238|NCT05002712|OTHER|Elastic resistance training|During the intervention, the group conducted a 'elastic resistance training' with the same muscle groups. External resistance was provided by blue thera-band latex-free exercise bands in this training. Each exercise was performed three times for a total of 15-25 repetitions. In between sets, a 5-minute rest period was given and there was a 25-second rest period in between exercise performance. The intensity of each exercise was increased with the black thera band at the midpoint (start of week 7) of the training. The following figure shows the resistance of the blue and black bands to 100 percent elongation. Following figure shows the resistance offered by blue and black band at 100% elongation.
223639239|NCT00972062|OTHER|Bach's Rescue Remedy Cream|0.5 ml of cream applied to skin site reactions as needed
223639240|NCT00972062|OTHER|Placebo Cream|Placebo cream 0.5 ml two times a day as needed
223639245|NCT03303963|DIAGNOSTIC_TEST|Deeplex test, MolBio TrueNat for 2nd line, GeneXpert 2nd line|"Improvement of the diagnosis of Multi Drug Resistant-Tuberculosis patients with culture-free approaches. We have planned to diagnose Tuberculosis resistance to 1st and 2nd line drugs through novel molecular multiplex assays (Study 1) by:~* Validating the Deeplex test and establish a network for shipment of sputum samples in ethanol to regional reference laboratories (Study 1 - phase 1)~* Validating the Molbio Truenat test as a point of care test (Study 1 - phase 2)~* Validating the Cepheid GeneXpert 2nd line cartridge at the district level (Study 1 -phase2)"
223639246|NCT03303963|DIAGNOSTIC_TEST|Fluorescein DiAcetate (FDA) Microscopy,GeneXpert Ct value, pre-rRNA synthesis|"Improvement of the management of Multi Drug Resistant-Tuberculosis patients with culture-free approaches. We have planned to set up alternative culture-free approaches for the monitoring of patients' response to Multi Drug Resistant-Tuberculosis treatment (Study 2), with:~* FDA microscopy~* Measurement of bacterial load by following Cycle threshold (Ct) values in GeneXpert Mycobacterium tuberculosis/Rifampicin~* Measurement of pre-rRNA synthesis"
223639247|NCT06025214|DRUG|Fluticasone propionate 500 mcg and salmeterol xinafoate 50 mcg/Respirent Pharmaceuticals|2 inhalations in one study period
223639248|NCT06025214|DRUG|ADVAIR DISKUS® 500/50|2 inhalations in one study period
224227419|NCT04371419|BEHAVIORAL|Messaging|"o The video messages each participant in one of the treatment groups sees will be randomized on the following dimensions. The different versions are clearly demarcated in the US Doctors Scripts document.~* Racial or ethnic identity of the doctor delivering the messages: concordant vs. discordant identity to the subject.~* Whether the message includes an acknowledgment of elephant in the room issues for each target group: trust in the medical system or fear of deportation.~* Whether the social distancing component of the message is delivered by Dr. Birx of the CDC or recorded by the MGH physicians.~* Whether individuals are given information about how representative individuals perceive mask wearers of color. This information comes from results of our nationally representative pilot survey.~* Some individuals in a control group will see messages later."
223639249|NCT04146948|OTHER|no intervention|no intervention in this study
224227420|NCT02987595|OTHER|Whole-grain rye, high lignan|Intervention week 1-8: 50 g rolled rye + 50 g puffs + 4 pieces of crisp bread + 70 g pasta. Additionally for intervention week 4-8: 4 lignan capsules per day
223639250|NCT03729700|OTHER|Almond|The almond dose will be provided as 20% of total energy (20% E) in the diet.
223639251|NCT02038933|DRUG|Nivolumab|
223639252|NCT02170623|DRUG|BIBR 1048 MS Capsule I|25 mg BIBR 1048 MS
223639253|NCT02170623|DRUG|BIBR 1048 MS Capsule K|50 mg BIBR 1048 MS
223639254|NCT02170623|DRUG|Pantoprazole|40 mg pantoprazole
223639255|NCT02170623|DRUG|BIBR 1048 MS drinking solution|50 mg BIBR 1048 MS powder plus solution
224227421|NCT02987595|OTHER|Whole-grain wheat, low lignan|Intervention week 1-8: 100 g puffs + 4 pieces of crisp bread + 70 g pasta.
224227422|NCT02931565|DRUG|Olinciguat|oral tablet
224227423|NCT02931565|DRUG|Matching Placebo|oral tablet
224319197|NCT02013817|DRUG|rituximab [MabThera/Rituxan]|Every 4 weeks for 6 cycles of induction, followed by maintenance therapy every 3 months x 8
223639256|NCT03250273|DRUG|Entinostat|Entinostat (5mg) will be administered starting with 2 lead-in doses at 14 and 7 days before the first dose of nivolumab in combination with entinostat. After the lead-in dose, entinostat will be administered once a week (days 1, 8, 15, and 21 of each treatment cycle).
223639257|NCT03250273|DRUG|Nivolumab|After both lead-in doses of entinostat, nivolumab (240 mg) will be administered every 2 weeks (day 1 and day 15 of a cycle).
223639258|NCT03250273|DRUG|Entinostat|Entinostat (5mg) will be administered starting with 2 lead-in doses at 14 and 7 days before the first dose of nivolumab in combination with entinostat. After the lead-in dose, entinostat will be administered once a week (days 1, 8, 15, and 21 of each treatment cycle).
223639259|NCT03250273|DRUG|Nivolumab|After both lead-in doses of entinostat, nivolumab (240 mg) will be administered every 2 weeks (day 1 and day 15 of a cycle).
223765093|NCT07019038|OTHER|A combined retrospective and prospective observational follow-up|The NICHE-AIHA will collect basic information, diagnostic and treatment information, as well as health costs information of patients from medical records. The study will use questionnaire to measure the exposure of patients, and prospectively follow-up to collect the prognosis information.
224319198|NCT02013817|DRUG|fludarabine|Every 4 weeks, 6 cycles
224227424|NCT03759769|OTHER|Wheelchair simulator|Computer application providing 3D first person view of a wheelchair, with six different activities: street crossing, entering an elevator, entering an adapted van, bathroom, shopping mall and supermarket
224227425|NCT03759769|OTHER|Video game|'Kart' driving video game
224227426|NCT03016182|PROCEDURE|Remote Ischemic Preconditioning|RIPC will be induced during anesthesia by 3 cycles of 5-min upper limb ischemia and 5-min reperfusion using a blood-pressure cuff inflated to a pressure 200mmHg
224227427|NCT03016182|PROCEDURE|Control|Control group witnout remote ischemic preconditioning
224227428|NCT00638157|DRUG|daptomycin|Intravenous (i.v.) 6 mg/kg q24h
224227429|NCT00638157|DRUG|daptomycin and gentamicin|i.v. daptomycin 6 mg/kg q24h plus initial i.v. gentamicin
223639260|NCT04862546|DEVICE|Laser Acupoint|Step 1: The subject was in sitting position and exposure area for applying laser then therapist use tap measurement to find the point. Parameters was used in this study : PROBE :ML A1\\25 TIME:01:00 FREQUENCY: 10000Hz (25mw), DUTY-CYCLE:100% DENESITY: 1J\\CM2 AREA :1CM2 Step 2: Apply laser on acupuncture points by using 10000HZ for 1 minute for every point. Totally cession: 10 minutes Step 3: ensure that all point done Repeat all steps for every subject
223639261|NCT04862546|DEVICE|Tap water iontophoresis|"Enough tap water is placed in the pans, then the generator is plugged in and switched on. After that, the patient's hands are placed in the pans.~The treatment is administrated by slowly increased intensity to tell the patient to feel a tingling sensation or up to 20 milliamperes and continue with this polarity for 10 minutes. After that, the polarity reversed and intensity increased again to the desired level for another 10 minutes."
223639262|NCT00528034|PROCEDURE|Lymphoscintigraphy|Procedure where a very small amount (less than one tenth of a teaspoon) of a radioactive material is injected around the edge of the tumor in the vagina, followed immediately by the scan. The scan is done before the patient has surgery or begins radiation therapy.
223639263|NCT02960581|BIOLOGICAL|PGT121 3mg/kg IV|3mg/kg administered by IV Infusion
223639264|NCT02960581|BIOLOGICAL|PGT121 10mg/kg IV|10mg/kg administered by IV infusion
223639265|NCT02960581|BIOLOGICAL|PGT121 30mg/kg IV|30mg/kg administered by IV infusion
223639266|NCT02960581|BIOLOGICAL|PGT121 3mg/kg SC|"3mg/kg administered by SC injection~Placebo: None"
223639267|NCT02960581|BIOLOGICAL|Placebo (0.9% Sodium Chloride Injection USP (Saline))|
223639268|NCT02190695|DRUG|Decitabine|20 mg/m2 by vein daily over 1 hour on Days 1-5 of each 28 day cycle.
223639269|NCT02190695|DRUG|Carboplatin|AUC 5 by vein over 1 hour on Day 8 of each 28 day cycle.
223639270|NCT02190695|DRUG|Arsenic trioxide|0.15 mg/kg by vein over 1 hour on Days 1-5 of each 28 day cycle.
223639271|NCT01647217|DRUG|Terpinen-4-ol|Lid scrub once or twice per day for one month.
223639272|NCT01647217|OTHER|Placebo|Lid scrub once or twice per day for one month
223639273|NCT04282603|COMBINATION_PRODUCT|Weight Loss and Weight Maintenance|Participants will consume a 1,200 kcal/day diet for twelve weeks. This is the amount of calories most commonly provided in medical weight loss programs, and considered the maximum allowable caloric intake to induce a physiologically significant weight loss. Following the weight loss portion of the trial, participants will enter the twelve week maintenance period, during which time they will consume one serving per day in place of lunch of the same meal replacement beverage used during medical weight loss.
223639274|NCT01774721|DRUG|Dacomitinib (PF-00299804)|Dacomitinib (PF-00299804) 45 mg tablets, continuous oral daily dosing.
223639275|NCT01774721|DRUG|Gefitinib|Gefitinib 250 mg tablets, continuous oral daily dosing.
223639276|NCT00228267|DRUG|Propofol|
223639277|NCT01047358|DRUG|Aromasin|25 mg table QD
223639278|NCT01047358|DRUG|Aromasin|25 mg table QD
223639279|NCT00648063|DRUG|Letrozole Tablets 2.5 mg|2.5mg, single dose fasting
223639280|NCT00648063|DRUG|Femara® Tablets 2.5 mg|2.5mg, single dose fasting
223639281|NCT00988806|DRUG|Levosimendan|"Patients included in the intervention group receive optimal drug therapy for heart failure symptoms and also infusion of levosimendan at doses of 0.1 mcg / kg / min for 24 hours every 30 days.~Failure to reach an appropriate level of heart failure compensation before the deadline of 30 days for the next study drug administration or placebo, the administration of them will be every 15 days. Thereafter, failure to reach an appropriate level of heart failure compensation for patients or worsen after two consecutive infusions of study drug or placebo every 15 days, proceed to open the code patient randomization and and apply the most appropriate treatment."
223639282|NCT00988806|DRUG|Placebo|"Patients included in the placebo group receive optimal drug therapy for heart failure and also infusion of placebo at the same infusion rate as levosimendan doses of 0.1 mcg / kg / min for 24 hours every 30 days.~Failure to reach an appropriate level of heart failure compensation before the deadline of 30 days for the next study drug administration or placebo, the administration of them will be every 15 days. Thereafter, failure to reach an appropriate level of heart failure compensation for patients or worsen after two consecutive infusions of study drug or placebo every 15 days, proceed to open the code patient randomization and and apply the most appropriate treatment."
223639283|NCT04683614|DRUG|Norepinephrine|5 mic/kg/hr norepinephrine
223639284|NCT04683614|BIOLOGICAL|Fresh frozen plasma|early administration of fresh frozen plasma
223639285|NCT00543413|DRUG|MK8141|MK8141 250 mg tablet once daily; 500 mg tablet once daily 4 week treatment period
223639286|NCT00543413|DRUG|Comparator: placebo (unspecified)|MK8141 Pbo tablet once daily. 4 week treatment period.
223639287|NCT00543413|DRUG|Enalapril|Enalapril 20 mg tablet once daily. 4 week treatment period.
223639288|NCT05790369|BEHAVIORAL|Resistance training (New ankle machine training)|A six week workout plan, the subjects receive on site or online guidance from professional coaches every two weeks.
223639289|NCT05790369|BEHAVIORAL|Resistance training (Elastic band training )|A six week workout plan, the subjects receive on site or online guidance from professional coaches every two weeks.
223639290|NCT05757544|DRUG|IV Ganaxolone|IV Ganaxolone will be administered.
223639291|NCT05757544|DRUG|IV Placebo|IV Placebo will be administered
224227430|NCT02532777|DRUG|Prednisone|
224227431|NCT02532777|DRUG|Cyclophosphamide(CTX)|
224227432|NCT02532777|DRUG|Mycophenolate mofetil(MMF)|
224227433|NCT02532777|DRUG|Leflunomide(LEF)|
224227434|NCT02532777|DRUG|Angiotensin-converting enzyme inhibitor(ACEI)|
224227435|NCT02532777|DRUG|Methylprednisolone|
224319199|NCT02013817|DRUG|cyclophosphamide|Every 4 weeks, 3 cycles
223639292|NCT06519474|DEVICE|Theraband chest compression|Chest compression applicated via a Red Theraband over the upper or lower chest region
223639293|NCT02198404|DRUG|sedation with propofol|induction with propofol at 20mg/kg/h. Then, when the patient is sleeping, dosage is decreased to 6 mg/kg/h
223639294|NCT03308071|BEHAVIORAL|Hypnosis|Hypnotic induction, relaxation, and guided imagery specific to perioperative symptoms will be administered.
223639295|NCT04539132|BEHAVIORAL|ABI Wellness Program|The ABI Wellness program includes a computerized task which will be completed by all participants remotely. The exercise is a sustained visual-spatial processing task of progressively increasing difficulty. Subjects are presented with an analog clock face, initially showing only one hand. The subject uses a keyboard to enter a value for the hour shown. Feedback on the computer screen indicates whether the response is correct or incorrect. If the response was incorrect, the subject continues to respond until the correct response is entered. After this, a new clock face is shown. Once subjects reach a criterion of 90% accuracy over a series of consecutive responses, an additional hand is added to the clock face. Participants will complete the program at home, online, and will be required to be present on a video call during the exercise with the other participants and research assistants. The program is 150 hours over 6 months, through twice weekly 3-hour sessions.
223639296|NCT01377103|DRUG|testerone gel|5g daily for 4 weeks then 7.5 or 10g daily for 8 weeks; transdermal testosterone gel
223639297|NCT01377103|DRUG|Placebo|
223639298|NCT03400839|DIAGNOSTIC_TEST|Daily physical activity levels|Objectively measured physical activity using activity monitors.
223639299|NCT03400839|DIAGNOSTIC_TEST|6-minute walk test|Assessment of functional exercise capacity.
223639300|NCT03400839|DIAGNOSTIC_TEST|Cardiopulmonary exercise testing|Assessment of maximal exercise capacity.
224227436|NCT04992052|DEVICE|Bone wax|The surgeons will apply the bone wax to the exposed cancellous bone after the implant has been cemented in place in patients randomized to the treatment arm.
224227437|NCT05717829|PROCEDURE|Modified hip capsular incision|modified incision to make re -suturing of the capsule easier with multiple stitches.
224227438|NCT02531022|BEHAVIORAL|Financial incentive|A daily financial incentive framed as a loss of $2 each day goal is not acheived
223639301|NCT03400839|DIAGNOSTIC_TEST|Muscle Function|Assessment of muscle force, muscle endurance and muscle fatigability
223639302|NCT03400839|DIAGNOSTIC_TEST|Lung Function|Assessment of whole-body plethysmography and spirometry.
223639303|NCT03400839|DIAGNOSTIC_TEST|Body composition|Assessment of bioelectrical impedance.
223639304|NCT03400839|DIAGNOSTIC_TEST|HRQoL - SGRQ-I|"Assessment of Health-related quality of life by the Saint-George Respiratory questionnaire (SGRQ-I)"
223639305|NCT03400839|DIAGNOSTIC_TEST|Symptoms - UCSD/SOBQ|"Assessment of symptoms by the UCSD Short of breath questionnaire"
223639306|NCT03400839|DIAGNOSTIC_TEST|HRQoL - SF36|"Assessment of Health-related quality of life by the SF-36 questionnaire"
223639307|NCT03400839|DIAGNOSTIC_TEST|Anxiety and depression|"Assessment of anxiety and depression by the Hospital Anxiety And Depression (HADS) Scale"
223639308|NCT03400839|DIAGNOSTIC_TEST|Symptoms - mMRC|"Assessment of symptoms by the modified Medical Research Council (mMRC) scale"
223639309|NCT03400839|DIAGNOSTIC_TEST|Sleep quality|"Assessment of sleep by the Pitsburg Sleep Quality Index (PSQI)"
223639310|NCT03400839|DIAGNOSTIC_TEST|Sleepiness|"Assessment of sleepiness by the Epworth Sleepiness Scale"
223639311|NCT03400839|DIAGNOSTIC_TEST|Inflammatory markers and oxidative stress|"blood assessment of inflammatory markers: IL-2, IL-10, IL-6, IL-4 e IL-17A, TNF, Interferon-γ, CK and CRP.~Blood assessment of oxidative stress: TRAP, SH, SOD, CAT, PON 1, Gpx, MDA, NOx, FOX and AOPP."
223639312|NCT03400839|DIAGNOSTIC_TEST|Functional performance tests|Timed-up-and-go at usual pace (TUGu) and at a fast pace (TUGf), four-metre gait speed test (4MGS), sit-to-stand test using three protocols: 30 seconds (30sec-STS), one minute (1min-STS) and five-repetition (5rep-STS) and Short Physical Performance Balance (SPPB).
223639313|NCT03106311|DIAGNOSTIC_TEST|assessment of beta subunit of human chorionic gonadotropin|Vaginal washing fluid will be collected and sent for measurement of beta subunit of human chorionic gonadotropin
223639314|NCT06282978|DRUG|Elranatamab (PF-06863135)|The scheme of administration includes weekly administrations for at least six 4-weeks cycles and, if patients have achieved at least PR (or better) persisting for at least 2 months, the dose interval should be changed from weekly to every other week. Treatment will be scheduled with a response-adapted duration and patients achieving undetectable measurable residual disease (MRD) and maintained for 12 months will stop therapy. After stopping therapy, and if the patient is in sustained undetectable MRD for at least 12 months, it would be possible to re-start treatment with elranatamab in case the MRD will be detectable or relapse from CR will occur. Patients who will not achieve undetectable MRD sustained for 12 months will receive continuous treatment until progressive disease.
224227439|NCT02531022|BEHAVIORAL|Daily feedback|Daily feedback from an activity tracking device worn on the wrist to track step counts and sleep patterns
223639315|NCT02192411|DRUG|Lidocaine|1/4 dose lidocaine
223639316|NCT06519708|DRUG|Erector Spinae Plane Block|Patients will receive an ultrasound-guided erector spinae plane block with the injection of 30 ml bupivacaine 0.25% after induction of general anesthesia.
223639317|NCT06519708|DRUG|External Oblique Intercostal Plane Block|Patients will receive an ultrasound-guided external oblique intercostal plan block Intraoperative with the injection of 30 ml bupivacaine 0.25% after induction of general anesthesia.
223639318|NCT02399163|DRUG|Fluoride free toothpaste|Brushing with fluoride free toothpaste
223639319|NCT02399163|DRUG|Fluoride toothpaste|Brushing with fluoride containing toothpaste
223639320|NCT02399163|DRUG|Fluoride mouthwash|"Fluoride mouth wash to be followed after brushing with fluoride free toothpaste in Placebo dentifrice/Fluoride rinse arm and in Fluoride dentifrice/Fluoride rinse arm"
223639321|NCT01357525|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|"An SBRT plan will be created by a medical physicist based on the PTV contoured on the CT scan. The plan will be to deliver fractionated SBRT to the isodose line best encompassing the PTV:~12 Gy x 3 fractions (36 Gy total)"
223639322|NCT03766737|DEVICE|An intelligent visual acuity diagnostic system for children|An artificial intelligence to make evaluation and of children's vision.
223639323|NCT04646044|DRUG|Bempegaldesleukin|Administered as an intravenous infusion
223639324|NCT04646044|DRUG|Standard of Care|Standard of Care Treatment for COVID-19 Infection
223639325|NCT04646044|OTHER|Placebo|Administered as an intravenous infusion
224227440|NCT00162435|DRUG|Warfarin|
224227441|NCT03082456|DIAGNOSTIC_TEST|Molecular breast imaging|Molecular breast imaging will be performed at 5-10 minutes after intravenous injection of 15-20 millicurie (mCi) Tc-99m sestamibi. Both craniocaudal (CC) view and mediolateral oblique (MLO) images of the breast are taken.
224227442|NCT03082456|DIAGNOSTIC_TEST|Mammography|During the procedure, the breast is compressed using a dedicated mammography unit. Parallel-plate compression evens out the thickness of breast tissue to increase image quality by reducing the thickness of tissue that x-rays must penetrate, decreasing the amount of scattered radiation, reducing the required radiation dose, and holding the breast still (preventing motion blur). Both craniocaudal (CC) view and mediolateral oblique (MLO) images of the breast are taken.
224227443|NCT03082456|DIAGNOSTIC_TEST|Breast ultrasound|Ultrasound investigation of breast is performed by members of breast cancer team. If abnormality is found by the procedure, biopsy will not be performed directly.
224227444|NCT01438554|DRUG|Pazopanib|
224227445|NCT01438554|DRUG|GSK1120212|
224227446|NCT03843177|OTHER|No intervention|No intervention will be performed. Only assessment will be done.
224227447|NCT05583175|DRUG|Venetoclax plus RIC|Eligible patients will receive Venetoclax plus RIC regimen allogeneic transplantation. The treatment regimen is: Venetoclax 100mg/d - 10d, 200mg/d - 9d (first use and NR or untreated MDS), 400mg/d, - 8d\~ - 2d (7d); Fludarabine: 30mg/m2/d, - 6d\~-2d (5d), Cytarabine: 1g/m2/d, - 6d\~-2d (5d) Busulfan: 3.2mg/m2/d, - 6d\~-5d (2d), TBI: 3 Gray, - 1d.
224227448|NCT02843074|DRUG|elotuzumab|Given intravenously (IV)
224227449|NCT02843074|DRUG|Lenalidomide|Given by IV
224227450|NCT02843074|DRUG|Dexamethasone|Given orally (PO) or by IV
224227451|NCT02843074|PROCEDURE|autologous stem cell transplantation|
224227452|NCT00956228|RADIATION|radioimmuniguided intenstiy modulated radiotherapy|All patients recieved 75.6 Gy in 42 fractions to the prostate and the region of the prostate which enhanced on prostascint scan was simaltaneously boosted to a total dose of 82 Gy
224227453|NCT04447274|DRUG|Camrelizumab and Apatinib|Subject will receive SHR-1210 200mg every 2 weeks, with intravenous drip Apatinib 425 mg, oral, 5 consecutive days, 2 days off,each 14 day of a cycles
224319200|NCT05211518|OTHER|Tasty&Healthy|exclude pro-inflammatory dietary components
224227454|NCT01077206|DRUG|Simvastatin|80mg daily versus 40mg daily, for 21 days.
224227455|NCT01982487|BIOLOGICAL|ALVAC(2)-NY-ESO-1 (M)/TRICOM vaccine|Given SC
224227456|NCT01982487|DRUG|IDO1 inhibitor INCB024360|Given PO
224227457|NCT01982487|OTHER|laboratory biomarker analysis|Correlative studies
224319201|NCT05211518|OTHER|Habitual diet|subjects will continue their habitual diet.
224319202|NCT05869903|DRUG|Orforglipron|Administered orally.
224319203|NCT05869903|DRUG|Placebo|Administered orally.
223639326|NCT02939443|RADIATION|supine- and prone-position Computed Tomography|
223639327|NCT03329638|DRUG|DE-127 Ophthalmic Solution low dose|Low dose of DE-127 Ophthalmic Solution dosed once daily for 12 months
223639328|NCT03329638|DRUG|DE-127 Ophthalmic Solution medium dose|Medium dose of DE-127 Ophthalmic Solution dosed once daily for 12 months
223639329|NCT03329638|DRUG|DE-127 Ophthalmic Solution high dose|High dose of DE-127 Ophthalmic Solution dosed once daily for 12 months
223639330|NCT03329638|DRUG|Placebo Ophthalmic Solution|Placebo Ophthalmic Solution dosed once daily for 12 months
223639331|NCT05530564|PROCEDURE|low-pressure pneumoperitoneum|insufflation of the abdomen for creation of pneumoperitoneum, pressure set points between 8 to 10 mm Hg
223639332|NCT05530564|PROCEDURE|standard-pressure pneumoperitoneum|insufflation of the abdomen for creation of pneumoperitoneum, pressure set points between 12 to 14 mm Hg
223639333|NCT00467116|BIOLOGICAL|cetuximab|400mg/m2 initial dose week 1; followed by 250mg/m2/weekly starting week 2 with gemcitabine at fixed dose rate (10 mg/m2/min) + XRT. Cetuximab will start 1 week prior to all other treatment.
223639334|NCT00467116|DRUG|gemcitabine hydrochloride|"Dose Level Gemcitabine dose Gemcitabine infusion~-1 150mg/m2 15 Minutes 0 200mg/m2 20 minutes~1. 300mg/m2 30 minutes~2. 400mg/m2 40 minutes"
223639335|NCT00467116|RADIATION|radiation therapy|"50.4 Gy, 28 fractions, 5.5 weeks (1.8 Gy/day). A cone down after 45 Gy will be performed to encompass gross disease with a margin of 1-1.5 cm.~The prescription point will be designated at the intersection of the multiple beams.~There are no planned interruptions \> 3 days."
223639336|NCT04075032|DIETARY_SUPPLEMENT|Pomegranate extract|Pomegranate extract consumption (900 mg/day) for 4 weeks
223639337|NCT04075032|OTHER|Placebo|Placebo (microcrystalline cellulose) consumption (900 mg/day) for 4 weeks
224227458|NCT01982487|OTHER|pharmacological study|Correlative studies
224227459|NCT01387100|BEHAVIORAL|Vocational Rehabilitation Intervention|Physical or occupational therapist will deliver a vocational rehabilitation intervention using the Work Experience Survey for Persons with Rheumatic Conditions (WES-RC) assessment tool to assess subject's health and vocational background as well as work barriers.
224227460|NCT05303142|OTHER|Heat Tolerance Assessment|60-90 minutes exercise in hot (34 °C; 45% R.H.) conditions at 60%VO2max
224227461|NCT04025385|OTHER|High Intensity Interval Training|Training for 25 min with four 1 minute intervals when participants exercise up to 80% of their individual limits.
224227462|NCT04179071|DRUG|Savolitinib|Subject will receive savolitinib tablet 600mg orally after a high-fat, high-calorie meal.
224227463|NCT04179071|DRUG|Famotidine|Subjects will receive famotidine tablet 40mg orally after an overnight (minimum 8hours) of fasting.
224227464|NCT03237585|BEHAVIORAL|Rural response system (RRS) intervention to reduce violence against women|The Rural Response System which uses the strategy of trained community members known as Community-based action team, COMBAT to undertake awareness-raising on gender-based violence as well as providing support to victims of violence to access justice and other relevant services.
224227465|NCT00219856|DRUG|Propofol|"* Induction : intravenous propofol aiming a concentration of 4 to 8 µg/ml~* Maintenance : intravenous propofol aiming a concentration of 3 to 6 µg/ml"
224227466|NCT00219856|DRUG|Penthotal|Intravenous penthotal at the dose of 3 to 5 mg/kg
224227467|NCT00219856|DRUG|Desflurane|Inhaled desflurane aiming an alveolar concentration of 4 to 6 per cent.
224227468|NCT02600169|DRUG|Pemprolizumab|All patients in this study have received treatment with pembrolizumab for the indication of an advanced melanoma.
224319204|NCT03263650|DRUG|Cabazitaxel|25mg/m2 administered intravenously over 60 minutes on day 1 of cycles 1-6; given before carboplatin.
224319205|NCT03263650|DRUG|Carboplatin|AUC 4 administered intravenously over 60 minutes on day 1 of cycles 1-6
224227469|NCT05358210|BEHAVIORAL|Blueberry Consumption|Participants will consume 1 cup of frozen blueberries daily for the 12 weeks of the intervention. The study dietitian will provide educational materials and monitor compliance through weekly check-ins. Participants will be instructed to avoid all other high-anthocyanin foods including other berries, cherries, currants, cabbage, red wine, and eggplant.
224227470|NCT05358210|BEHAVIORAL|Dried Date Consumption|Participants will consume 2-3 dried dates daily for the 12 weeks of the intervention, an isocaloric portion of fruit compared to the blueberry group. The study dietitian will provide educational materials and monitor compliance through weekly check-ins. Participants will be instructed to avoid all other high-anthocyanin foods including blueberries, other berries, cherries, currants, cabbage, red wine, and eggplant.
224227471|NCT01799733|OTHER|LWT+AM BWL|One night of late wake therapy (LWT)(sleep 21:00-01:00 h, followed by wakefulness) plus 7 days of morning bright white light (AM BWL)(light-emitting diode-LED administered for 60 minutes, starting within 30 minutes of habitual wake time)
224227472|NCT01799733|OTHER|EWT+PM BWL|One night of early wake therapy (EWT) (wakefulness until 03:00 h, then sleep 03:00-07:00 h) plus 7 nights of evening bright white light (PM BWL)(light-emitting diode-LED administered 90 minutes before habitual sleep onset, for 60 minutes)
224227473|NCT00875368|DRUG|maraviroc|maraviroc dose dependent on co-medication
224227474|NCT00875368|DRUG|Placebo|Placebo drug
224227475|NCT05476679|DRUG|RZL-012|50mg/ml drug formulation
224227476|NCT05476679|DRUG|RZL-012+Lidacaine injection prior treatment|5ml lidocaine will be injected 10 minutes before RZL-012 treatment
224227477|NCT05476679|DRUG|RZL-012+Medrol|oral Medrol dose pack (8 mg (2 tablets) on Day 1 before treatment followed by 16 mg after treatment (as per Instructions for Use)). From Day 2, a daily tapering off by 4 mg until Day 6 will be administered per Rx Instructions for use
224227478|NCT05476679|DRUG|RZL-012+Celecoxib+Zyrtec|200 mg Celecoxib BID and 10 mg Zyrtec BID on Days 1, 2, 3, 4, 5 and 6
224227479|NCT05476679|DRUG|RZL-012+facial and neck wrap|Universal Facial Band
224319206|NCT03263650|DRUG|Prednisone 5Mg|5 mg administered by mouth twice daily on days 1-21 of cycles 1-6.
224319207|NCT03263650|DRUG|Olaparib|Administered by mouth twice daily at a dose of 300 mg by mouth twice daily, dispensed on Day 1 of cycle 7 to participants randomized to receive olaparib maintenance and every 21 days thereafter until the participant completes the study, withdraws from the study or the closure of the study.
224319208|NCT05854381|BIOLOGICAL|VIR-1388|VIR-1388 is given by subcutaneous injection
224319209|NCT05854381|BIOLOGICAL|Placebo|The HT Diluent Placebo is HT buffer (20 mM histidine, 10% trehalose-dihydrate, pH 7.2) and contains no active ingredient and will be administered by subcutaneous injection
224319210|NCT06101342|DRUG|Lenacapavir Injection|Administered subcutaneously
224319211|NCT06101342|DRUG|Lenacapavir Tablet|Administered orally
223639338|NCT01326949|PROCEDURE|Transjugular intrahepatic portosystemic shunt (TIPS)|Transjugular intrahepatic portosystemic shunt(TIPS)- TIPS was performed in a conventional fashion or in combination of percutaneous transhepatic or transsplenic approach. Postoperatively, intravenous heparin (8,000-12,000 u/d) for five days, warfarin for six months were given.
223639339|NCT01326949|PROCEDURE|ET+NSBB|"ET-Esophageal varices was treated by endoscopic variceal ligation (EVL). EVL was repeated at intervals of 1-2 weeks until the varices were obliterated or reduced to grade-I size.~NSBB-Propranolol started at a dose of 20mg twice a day. The dose is adjusted to the maximal tolerated doses to heart rate (HR) of 55 bpm or to decrease the HR 25% from baseline.~AT-A continuously intravenous infusion of unfractionated heparin followed by oral warfarin is employed. Initially, heparin is administered intravenously for 5 days. Subsequently, oral warfarin is prescribed at the dosage of 2.5 mg/d for 6 months or until complete portal vein recanalization and adjusted to maintain the INR at a target of 2.5 (range 2.0-3.0)."
223639340|NCT02891577|PROCEDURE|Ultrasonography|At the time of ICU admission, among critically ill patients with shock, the investigators will measure the diameter of the common femoral vein and that of the inferior vena cava by ultrasonography.
223639341|NCT01452698|DRUG|TAK-438|TAK-438 20 mg, tablets, orally, once daily for up to 8 weeks.
223639342|NCT01452698|DRUG|Placebo|"Lansoprazole placebo-matching capsules, orally, once daily for up to 8 weeks.~For participants whose EE is not endoscopically healed at Week 8, the participants will receive additional treatment of TAK-438 40 mg, tablets, orally, once daily for up to an additional 8 weeks."
223639343|NCT01452698|DRUG|Lansoprazole|"Lansoprazole 30 mg, capsules, orally, once daily for up to 8 weeks.~For participants whose EE is not endoscopically healed at Week 8, the participants will receive additional treatment of TAK-438 40 mg, tablets, orally, once daily for up to an additional 8 weeks."
223639344|NCT01452698|DRUG|Placebo|TAK-438 placebo-matching tablets, orally, once daily for up to 8 weeks.
224227480|NCT02768623|OTHER|Pharmacist led Asthma Management|
224227481|NCT02768623|OTHER|Pharmacist Intervention (when requested by patient)|
224227482|NCT04965610|OTHER|Preoxygenation with High Flow Nasal Cannula|Preoxygenation for 5 minutes via High Flow Nasal Cannula. After induction of anaesthesia apnoeic oxygenation with HFNC
224227483|NCT04965610|OTHER|Preoxygenation via face mask|Preoxygenation for 5 minutes via face mask. After induction of anaesthesia apnoeic oxygenation with tight fitting face mask
224227484|NCT03991832|DRUG|Olaparib|Olaparib is a drug that blocks a protein called poly (ADP-ribose) polymerase (PARP). PARP is important in the growth and spread of cancer cells. Because of this, blocking PARP from working is expected to stop the growth of or shrink cancer cells.
224319212|NCT06101342|DRUG|Emtricitabine/tenofovir disoproxil fumarate (F/TDF)|Administered orally
224319213|NCT04158388|OTHER|Mediterranean-diet enriched with a higher dose of tryptophan and magnesium|That gruop eaten at both breakfast and dinner from walnuts (3-5 units), as food with high values of tryptophan and magnesium
224319214|NCT04158388|OTHER|Isocaloric diet|That group eaten isocaloric diet plan based on Mediterranean diet.
224319215|NCT04158388|OTHER|Manual therapy|That group received moderate pressure digital manual therapy.
224319216|NCT04158388|OTHER|Placebo therapy|That group was treated with a US (in off mode) without conductive gel.
224319217|NCT00641628|PROCEDURE|mastectomy|
224319218|NCT02352467|DEVICE|Aurix|Aurix is a platelet-rich plasma gel used in the treatment of non-healing wounds. It will be administered twice weekly for 2 weeks then weekly.
224227485|NCT03991832|DRUG|Durvalumab|Durvalumab is a drug that works by stopping a protein called Programmed Cell Death Ligand 1 (PD-L1) from working. PD-L1 is a protein that is thought to prevent the immune system (the body's defense against diseases) from killing cancer cells. Stopping PD-L1 from working is expected to allow the immune system to once again prevent or slow down cancer growth.
224227486|NCT06095258|DRUG|Traditional Chinese medicine treatment|About four to six Chinese medicine practitioners with five to twenty years of clinical work experience will be responsible for patient diagnosis and prescription treatment, and use a uniformly designed data collection form to record the patient's medical history, clinical symptoms and signs, tongue and pulse conditions, and other information. Patients in the treatment group will receive individualized Chinese medicine treatment prescriptions. Patients in the control group received conventional Western medicine treatment, and about 3 to four Western medicine practitioners with five to twenty years of work experience will be responsible for the conventional medicine prescription. The treatment of the two groups will last for four weeks, and the patients will be followed up for four weeks after the treatment. A patient diary will be provided to all participants for recording the drug compliance and any adverse event during the treatment period.
224227487|NCT06095258|DRUG|Western medicine treatment|Western medicine doctors will mainly use symptomatic drugs to treat long COVID. For example, cough medicine (such as codeine), bronchodilators (such as ventolin), expectorants (such as fluimucil) and so on are used to treat cough, shortness of breath, or other respiratory symptoms. Non-steroidal anti-inflammatory painkillers (such as panadol) are often used for treating headaches, and sedative-hypnotic drugs (such as stilnox) are often used to treat insomnia.
224227488|NCT02390622|OTHER|Fecal microbiota transplantation|bacteria liquid from 60g fecal was infusion via nasointestinal tube for three days
224227489|NCT06485037|BEHAVIORAL|Time-restricted eating|Self-selected 10-hour eating window for 2 months
224227490|NCT02184949|PROCEDURE|Percutaneous Coronary Intervention|
224227491|NCT02184949|PROCEDURE|Primary Percutaneous Coronary Intervention|
224227492|NCT00001128|DRUG|Interleukin-12|
224227493|NCT00001128|DRUG|Paromomycin sulfate|
224227494|NCT00001128|DRUG|Azithromycin|
224227495|NCT00788528|DRUG|S-2367 (velneperit)|Tablet, 4 x 400 mg, taken once daily with morning meal, 54-weeks
224227496|NCT00125996|DRUG|Venofer (intravenous iron sucrose)|
224227497|NCT01569828|DRUG|LCZ696A|
224227498|NCT01569828|DRUG|LCZ696A|once daily administration of 400 mg LCZ696 for 5 days
224227499|NCT00523393|DRUG|Insulin Glargin|Titration of bedtime insulin glargin aiming at normal morning fasting glucose
224227500|NCT00523393|DRUG|Human Insulin|Titration of bedtime human insulin aiming at normal morning fasting glucose
224227501|NCT01973114|DRUG|Latanoprost|
224227502|NCT01973114|OTHER|Placebo|
224227503|NCT03579147|DEVICE|Treatment with BTL EMSCULPT device|The treatment administration phase will consist of four (4) treatments, delivered twice a week. The applicator will be applied over the buttock area. Visible contractions will be induced by the device.
224227504|NCT03717610|PROCEDURE|radical surgery with HIPEC|Straight after macroscopic radical cytoreductive surgery, an intraperitoneal hyperthermic perfusion using the open-abdomen technique will be performed with a single dose of cisplatin 100 mg/m2 administered for 90 minutes in the hyperthermic phase (41°C-43°C).
224227505|NCT02413697|DEVICE|Two-dimensional ultrasound|Two-dimensional ultrasound guided embryo transfer
224227506|NCT02413697|DEVICE|Three-dimensional ultrasound|Three-dimensional ultrasound guided embryo transfer
224227507|NCT00236782|DRUG|norelgestromin + ethinyl estradiol; mercilon|
224319219|NCT05435261|PROCEDURE|BKA|"Below Knee Amputation:~* Under spinal anesthesia~* BKA~* closure in layers (terminal closure) with suction drain."
223639345|NCT01907854|DRUG|liraglutide|Starting dose of 0.6 mg/day, with weekly dose escalations of 0.6 mg/day until the maintenance dose of 1.8 mg/day is reached. Administered subcutaneously (s.c., under the skin) once daily + metformin tablets (at least 1000 mg/day)
223639346|NCT01907854|DRUG|sitagliptin|100 mg/day sitagliptin tablets once-daily + metformin (at least 1000 mg/day)
224227508|NCT03676374|DRUG|Prucalopride|Prucalopride 2mg taken once a day as add-on to PPI (2x/d)
224227509|NCT03676374|DRUG|Placebo Oral Tablet|Placebo tablet taken once a day as add-on to PPI (2x/d)
224227510|NCT02261571|OTHER|Moxibustion|"In the moxibustion treatment group, 3 moxibustion, 3 acupoints(CV12, CV8, CV54) will be heated with indirected moxibustion.~The moxibustion will be removed when the patient feel hotness and require remove them"
224227511|NCT01927081|BEHAVIORAL|discussion group|Participants engage in discussions regarding issues related to coping with advanced cancer and pain
224227512|NCT01927081|BEHAVIORAL|gentle exercise|Patients learn gentle exercise and breathing techniques
224227513|NCT02077959|DRUG|lenalidomide|Given PO
224227514|NCT02077959|BIOLOGICAL|pidilizumab|Given IV
224227515|NCT02077959|OTHER|pharmacological study|Correlative studies
224227516|NCT02077959|OTHER|laboratory biomarker analysis|Correlative studies
224227517|NCT00891878|DRUG|capecitabine|Given orally
224227518|NCT00891878|DRUG|sunitinib malate|Given orally
224227519|NCT04899856|DEVICE|TransAeris|TransAeris is used to provide neuromuscular electrical stimulation to the diaphragm while the patient is on mechanical ventilation to prevent, slow, or reverse diaphragm disuse atrophy and, more generally, to prevent and treat VIDD.
224227520|NCT03792971|DRUG|Dextromethorphan HBr|A single 60 mg dose of DM capsules liquid-filled on Day 1 and Day 3
224227521|NCT03792971|DRUG|GC4419|Daily 90 mg IV infusions over 60 minutes on Day 3 and Day 4
224227522|NCT01478633|DRUG|Galantamine|8 mg/day (4 mg twice daily) for 4 weeks, followed by 16 mg/day (8 mg twice daily) for an additional 4 weeks, followed by dose at 16 mg or increased to 24 mg (with the option of decreasing back to 16 mg) for the remainder of the study (to week 24)
224319220|NCT05435261|PROCEDURE|Debridement with Ex_Fix (salvage)|"Debridement and External Fixation (salvage):~* Under spinal anesthesia~* wound debridement and wash.~* external fixation."
224319221|NCT02654028|PROCEDURE|Autotransfusion|These group of patients will receive autotransfusion before liver resection.
224319222|NCT02654028|OTHER|Control group|These group of patients will not receive autotransfusion before liver resection.
223639347|NCT01907854|DRUG|placebo|Sitagliptin placebo tablets once-daily
223639348|NCT01907854|DRUG|placebo|Sitagliptin placebo tablets once-daily
223639349|NCT04012957|DRUG|Desidustat Oral Tablet|Desidustat tablet
223639350|NCT04012957|DRUG|Darbepoetin Alfa|Darbepoetin injection
223639351|NCT02215252|DRUG|PF-05089771 150 mg|PF-05089771 150 mg twice daily oral dosing with capsules. Treatment period = 4 weeks.
223639352|NCT02215252|DRUG|Matched placebo for PF-05089771 150 mg and pregabalin 300 mg|Matched placebo for PF-05089771 150 mg twice daily and pregabalin 150 mg twice daily oral dosing with capsules. Treatment period = 4 weeks.
223639353|NCT02215252|DRUG|Pregabalin 300 mg|Pregabalin 150 mg twice daily oral dosing with capsules. Treatment period = 4 weeks.
223639354|NCT02215252|DRUG|PF-05089771 150 mg + Pregabalin 300 mg|PF-05089771 150 mg twice daily oral capsules with pregabalin 150 mg twice daily oral capsules. Treatment period = 4 weeks.
223639355|NCT03035357|DRUG|Daratumumab|16 mg/kg by vein once weekly for a total of 4 doses.
223639356|NCT02633306|DEVICE|transcranial magnetic stimulation|Treatment will consist of five daily sessions of transcranial magnetic stimulation of the motor cortex contralateral to the pain.
223639357|NCT04369573|COMBINATION_PRODUCT|Early intra-aortic balloon pump (IABP) implantation|IABP implantation within 6 hours since cardiogenic shock symptoms onset
224227523|NCT04919083|OTHER|Program of Therapeutic Exercise and Functional Recovery|"Specific hip fracture recovery programme,restoring the mobility, strength and balance of the operated patient, in order to facilitate the return to a functional state as close as possible to the state prior to surgery and in the shortest possible time, as detailed in Annex VIII. This programme is part of the standard treatment protocol implemented since January 2021 by the Orthogeriatrics Unit of the San Juan de Dios Hospital.~This programme is divided into 5 phases, each of these phases coincides with a level of the gait assessment scale. Each individual will start at the level assigned by the doctor and will only have access to the videos of the indicated level and the levels below it. As the patient meets the recovery goals, the physician will provide access to the higher level videos.The functional recovery plan begins the day after the hip fracture and continues after the patient has been discharged for a total of 16 weeks."
224227524|NCT04919083|OTHER|Standardised nursing care plan|Consisting of postural changes described in the standardised nursing care plan. Within this plan, the patient was moved to a sitting position prematurely (within the first 24 hours) and started to ambulate within the following 48 hours, provided that the patient's general condition allowed it. This group did not receive any specific functional recovery plan.
224227525|NCT02251587|OTHER|Standard Weight Management Program|Standard Diet program based on diet and exercise.
224227526|NCT02251587|OTHER|Sensible Weigh Program|Weight loss program designed for low income women.
224227527|NCT01928784|DEVICE|Radial Extracorporeal Shock Wave Therapy 2000 impulses|Radial Extracorporeal Shock Wave Therapy, 13 Hz, 2.5 Bar, 2000 impulses
224227528|NCT01928784|DEVICE|Radial Extracorporeal Shock Wave Therapy 4000 impulses|Radial Extracorporeal Shock Wave Therapy, 13 Hz, 2.5 Bar, 4000 impulses
224227529|NCT05178589|DEVICE|One Unit TENS|TENS was administered by the participant at home. Application was limited to the abdominal area and instructed to be placed at the location of pain. Single unit TENS was administered via 2 channels. Participants chose an intensity of comfort and continued the treatment for 30-90 minutes per session with unlimited sessions allowed per day.
224319223|NCT03327259|BEHAVIORAL|Activity Planning|The therapist will work with the participant to select a challenging, yet rewarding or value-driven activity that he/she can engage in 5x and monitor daily over the upcoming week.
224319224|NCT03327259|BEHAVIORAL|Therapist Guided Activity Practice|The therapist will work with the participant to plan and carry out a brief in-vivo version of their goal/target activity. The therapist will guide the participant through the activity for approximately 15 minutes.
224319225|NCT02075307|DIETARY_SUPPLEMENT|Blueberry Powder|
223639358|NCT04369573|OTHER|Standard of care as vasoactive agent|Any agent (inotropes and vasopressors) will be allowed. However, the following guide is provided to increase uniformity: 1) vasopressors allowed will be either epinephrine or norepinephrine; 2) as inotropic agent milrinone or dobutamine or levosimendan could be used; 3) dopamine will be allowed in association with milrinone or dobutamine or levosimendan; 4) the maximum inotropic score allowed will be 20.
223639359|NCT03199586|DRUG|NP-G2-044|capsule
223639360|NCT03910244|DRUG|Pomalidomide Oral Product|Pomalidomide, a third generation derivative of thalidomide, given orally at a starting dose of 4 mg/day for days 1-28 of six 28-day cycles. The dose may be reduced to 3 or 2 mg/day based on specific adverse event (AE) criteria.
223639361|NCT03910244|DRUG|Placebo oral capsule|Matching placebo will be given.
223639362|NCT00492492|PROCEDURE|trans-styloid and intrafocal pinning on the one side|
223639363|NCT00492492|PROCEDURE|volar fixed-angle plating on the other side|
224319226|NCT02075307|DIETARY_SUPPLEMENT|Placebo|
223639364|NCT02906748|PROCEDURE|injection with a syringe in new-site for parathyroid autografting|new-site for parathyroid autografting, close to the antecubital vein
223639365|NCT02906748|PROCEDURE|injection with a syringe in traditional site for parathyroid autografting|traditional-site for parathyroid autografting,not intensively close to the antecubital vein
223639366|NCT03734692|DRUG|Rintatolimod|200 mg by IP administration over 1-2 hours
223639367|NCT03734692|DRUG|Pembrolizumab|200 mg will be administered as a 30 minute IV infusion
223639368|NCT03734692|DRUG|Cisplatin|50mg/m\^2 solution
223639369|NCT03851991|DRUG|Arbidol|oral
223639370|NCT03851991|DRUG|Placebos|controle
223639371|NCT01522222|PROCEDURE|continuous, mechanical ventilatory support|Those in the treatment group will receive ventilation, intermittent positive pressure ventilation, while their heart is arrested. The subjects will have their lungs ventilated six times per minute with a tidal volume equal to 7-10 milliliters per kilogram. This range, when combined with a consistent PEEP of 5cm of water pressure, will allow for the peak inspiratory pressure to be maintained at or below 40cm of water pressure. In addition, the FIO2 will remain consistent at the same level that was needed to maintain the pulse oximetry at 94% as well as the end-tidal CO2 at 35mmHg.
223639372|NCT03371069|OTHER|users of methylphenidate|Children and adolescents who are users of methylphenidate, 2010 to 2015
223639373|NCT00803569|BIOLOGICAL|ALVAC(2)-NY-ESO-1(M)/TRICOM vaccine|The vaccine comprises the modified canary pox vector, ALVAC(2), inserted with the following genes: NYESO-1(M), TRICOM (LFA-3, ICAM-1, B7.1), vvE3L, vvK3L. The vaccine is administered at a dose of 0.5 mL SC.
223639374|NCT00803569|BIOLOGICAL|Sargramostim|The GM-CSF sargramostim is administered at a dose of 100 μg SC.
223639375|NCT05856617|DRUG|Remimazolam besylate|Remimazolam besylate anesthesia induction
223639376|NCT03779295|DEVICE|Pulse laser dye therapy (Device name: Candela Family of Pulsed Dye Laser Systems. 501k Number: K050673.)|The face will be split and randomized, one half will receive pulsed laser dye therapy.
223639377|NCT03779295|DRUG|Clindamycin|The entire face (both halves) will receive clindamycin.
223639378|NCT06041607|BEHAVIORAL|Shared meditation|"Meditation sessions between patients, carers and third parties~* 12 weekly 2-hour sessions,~* 2 half-day 3-hour retreats after the 9th session and at the end of the programme~* 3 monthly follow-up sessions (2h) in remote format (videoconference)"
223639379|NCT06041607|BEHAVIORAL|Meditation with patients oly|"Meditation sessions between patients only~* 12 weekly 2-hour sessions,~* 2 half-day 3-hour retreats after the 9th session and at the end of the programme~* 3 monthly follow-up sessions (2h) in remote format (videoconference)"
223639380|NCT03583892|DRUG|Gabapentin|One of the groups of patients was exposed to preoperative gabapentin. As the pain has a complex involvement of multiple mechanisms, multimodal analgesic techniques utilizing a number of drugs acting on different analgesic mechanisms are being used. In this case, some patients received gabapentin as a part of a multimodal analgesic technique.
223639381|NCT01075529|DRUG|fluoxetine|fluoxetine 20 mg/d
223639382|NCT00000393|DRUG|Peptide T|
224227530|NCT05178589|DEVICE|Two Unit TENS|TENS was administered by the participant at home. Application was limited to the abdominal area and instructed to be placed at the location of pain. Double unit TENS was administered via 4 channels. Participants chose an intensity of comfort and continued the treatment for 30-90 minutes per session with unlimited sessions allowed per day.
223639383|NCT00004854|DRUG|Carvedilol|
223639384|NCT01839955|DRUG|erlotinib hydrochloride|"Dose Escalation Group:~Begins day 1: given 150mg daily, orally~Extension Group:~Begins Day 1: 150mg daily, orally"
223639385|NCT01839955|DRUG|quinacrine dihydrochloride - Escalation dose|Begins Day 8: Loading dose (first cycle only) 50mg three times daily for 7 days followed by 21 days of 50mg maintenance dose. Level -1: Loading dose (50mg three times daily for 7 days), maintenance dose (50mg every other day for three weeks). Level 1 \[starting dose\]: Loading dose (50mg three times daily for 7 days), maintenance dose (50mg daily for three weeks). Level 2: Loading dose (100mg three times daily for 7 days), maintenance dose (100mg every other day for three weeks). Level 3: Loading dose (150mg three times daily for 7 days), maintenance dose (200mg every other day for three weeks). Level 4: Loading dose (200mg three times daily for 7 days), maintenance dose (400mg every other day for three weeks). Subsequent patient cohort(s) will be enrolled depending on the safety and tolerability of subjects
223639386|NCT01839955|OTHER|laboratory biomarker analysis|Correlative studies
223639387|NCT01839955|OTHER|pharmacological study|Correlative studies
223765094|NCT07019116|OTHER|Standard gatekeeping|Human evaluators (mostly physicians) review referrals and determine, based on established protocols, whether they should be authorized.
223765095|NCT07019116|OTHER|AI algorithm|An AI algorithm was developed to perform the first evaluation (triaging) of the referrals inserted in the electronic referral system from the Rio Grande do Sul Health Department.
223765096|NCT07019116|OTHER|Subsequent interactions between primary care and regulation system|After the first evaluation of a referral, several subsequent rounds of interaction between gatekeepers and primary care physicians can be conducted to further detail patient needs and urgency.
223765097|NCT07020117|DRUG|[225Ac]Ac-AKY-1189 (therapeutic)|\[225Ac\]Ac-AKY-1189 Injection
223765098|NCT07020117|DRUG|[64Cu]Cu-AKY-1189 (imaging)|\[64Cu\]Cu-AKY-1189 Injection
224227531|NCT00258973|PROCEDURE|Carotid Ultrasound performed in office practice|
224227532|NCT05928000|DRUG|Bulevirtide|BulevIrtide treatment in patients with chronic hepatitis D
224227533|NCT00492206|DRUG|Cetuximab|The initial dose of cetuximab is 400 mg/m2 intravenously administered over 120 minutes, followed by weekly infusions at 250 mg/m2 IV over 60 minutes. Subjects will receive cetuximab from week 0 through week 26.
224227534|NCT01199601|BEHAVIORAL|Concentrated postpartum counseling|Intrapartum testing and concentrated postpartum counseling for the female patient from a retrained provider focusing on correct breastfeeding practices, postpartum contraception, and infant vaccination.
224227535|NCT01842048|OTHER|Hyperthermia|
224227536|NCT01842048|RADIATION|External-beam radiotherapy|
224227537|NCT00314379|DRUG|Vitamin E 400IU/day|
224227538|NCT01960933|PROCEDURE|Percutaneous coronary intervention|
224227539|NCT01960933|PROCEDURE|FFR|
224227540|NCT02669264|DRUG|ADCT-402|Intravenous infusion
224227541|NCT02521675|BEHAVIORAL|Usual algorithm|"The patient will be fitted with a CGMS (continuous glucose monitoring system) (data not shown) and it will be given the booklet to collect events + food survey~The patient goes home and he must perform 3 physical activities during the week (30-60 minutes) using its usual algorithms (glucose administration or adaptation of the BR), in the afternoon, and spacing them at least 24 hours :~* Moderate activity 3 hours after lunch~* Intense activity 3 hours after lunch~* Moderate activity 90 min after lunch These activities should not exceed 1 hour in wherever possible"
224227542|NCT02521675|BEHAVIORAL|Diabrasport algorithm|"The patient will be fitted with a CGMS (data not shown) and it will be given the booklet to collect events + food survey~The patient goes home and he must perform 3 physical activities during the week (identical to those carried out during the week test algorithms usual and during comparable periods) using DIABRASPORT algorithms, the afternoon and in the spacing at least 24 hours:~* Moderate activity 3 hours after lunch~* Intense activity 3 hours after lunch~* Moderate activity 90min after lunch These activities shall not exceed one hour"
224227543|NCT02521675|BEHAVIORAL|Rest|"The patient will be fitted with a CGMS (data not shown) and it will be given the booklet to collect events + food survey.~The patient goes home and he will not perform any physical activity during the week"
223765099|NCT07018895|DRUG|Sham treatment|ambient air (FiO2 = 21%) will be delivered for 3 days 1 time a day for 45 minutes
223765100|NCT07018895|DRUG|FiO2 reduced by 20% alternating with 34% FiO2|FiO2 reduced by 20% alternating with 34% FiO2
224227544|NCT02521675|DEVICE|Holter Glycemic Ipro2, Medtronic|
224227545|NCT03577184|DRUG|Metformin/Vildagliptin|Vildagliptin belongs to dipeptidyl peptidase-4 (DPP-4) inhibitor. Inhibition of dipeptidyl peptidase-4 (DPP-4) and metformin is a Biguanides.
224227546|NCT00002407|DRUG|Indinavir sulfate|
223639388|NCT01839955|DRUG|quinacrine dihydrochloride - Extension dose|Participants will be treated at recommended dose from expansion group to confirm tolerability and evaluate early response
223639389|NCT01537705|DRUG|Neuron012703 (Medical Food)|2 capsules twice daily for sixty days.
223765101|NCT07021209|BIOLOGICAL|GT719 Injection|GT719 Injection
224227547|NCT00002407|DRUG|Nevirapine|
223639390|NCT01694914|PROCEDURE|corneal graft|
223639391|NCT04004988|DRUG|Tirzepatide|Administered SC
223639392|NCT04004988|DEVICE|Prefilled syringe (PFS)|PFS used to administer tirzepatide
223639393|NCT04004988|DEVICE|Auto-injector (AI)|AI used to administer tirzepatide
223639394|NCT04346381|DRUG|Camrelizumab|Intravenous (IV) camrelizumab on Day 1 of each cycle
223639395|NCT04346381|DRUG|Famitinib|famitinib po qd
223639396|NCT01598532|DEVICE|MedX Health Phototherapy (light therapy)|The treatment period is 6 weeks (3x per week) for a total of 18 Transcranial LED treatments. Each treatment session is 30 minutes each.
223639397|NCT02982746|OTHER|gPCC (Gothenburg Person Centred Care)|
223639398|NCT03144154|BEHAVIORAL|Self-hypnosis + Self-care|Our groupal intervention is divided into 8 weekly 2-hour sessions in which one self-hypnosis exercise is proposed to participants. Self-care techniques are also discussed (knowing our own needs, self-respect, assertiveness, coping with ruminations...) and homework assignments are proposed to participants, in order to foster positive change.
223639399|NCT00912808|DRUG|Donepezil|donepezil, 5 mg, capsule, once a day, 3 weeks
223639400|NCT00912808|DRUG|Sugar Pill (placebo)|sugar pill, one capsule, once a day, 3 weeks
223639401|NCT03873116|DRUG|BCX7353 capsules|BCX7353 capsules administered orally once daily
223639402|NCT03873116|DRUG|BCX7353 capsules|BCX7353 capsules administered orally once daily
223639403|NCT03873116|DRUG|Placebo oral capsule|Matching placebo capsules administered orally once daily
223639404|NCT04682366|DRUG|Tamsulosin|Oral drug: 10 days of 0.4 mg of oral Tamsulosin
223639405|NCT04682366|DRUG|Placebo|Oral drug: 10 days of identical-appearing placebo
223639406|NCT04600596|BEHAVIORAL|Recording of food intake.|The food intake is recorded with a photographic food recognition mobile application. The total energy expenditure is recorded with the DLW method.
223639407|NCT02130843|DEVICE|INSERTION OF URETEHRL CATHETER|USE OF A TIEMANN CATHETER TO INSERT THE URODYNAMIC STUDY CATHETER INTO THE BLADDER
223639408|NCT04051424|DEVICE|ConMed bite block|Investigator will fit ConMed bite block in patient's mouth and bronchoscopist will try to visualize the vocal cords.
223639409|NCT04051424|DEVICE|McKay airway|Investigator will fit McKay airway in patient's mouth and bronchoscopist will try to visualize the vocal cords.
223639410|NCT04051424|DEVICE|Williams Airway|Investigator will fit Williams Airway in patient's mouth and bronchoscopist will try to visualize the vocal cords.
223639411|NCT00702221|BIOLOGICAL|Angiotensin Therapeutic Vaccine plus CoVaccine HT™ adjuvant|Angiotensin Therapeutic Vaccine plus CoVaccine HT™ adjuvant given as 3 separate intramuscular injections into the arm, 21 days apart
224227548|NCT00002407|DRUG|Lamivudine|
224227549|NCT00002407|DRUG|Stavudine|
224227550|NCT00002407|DRUG|Didanosine|
223639412|NCT00702221|BIOLOGICAL|CoVaccine HT™ adjuvant|Given as three separate intramuscular injections into the arm, 21 days apart
223639413|NCT03891108|DRUG|BMS-986231 Formulation A|Participants will be administered BMS-986231 Formulation A as IV infusion for 48 hours.
223639414|NCT03891108|DRUG|BMS-986231 Formulation B|Participants will be administered BMS-986231 Formulation B as IV infusion for 48 hours.
223639415|NCT03891108|DRUG|BMS-986231 Formulation C|Participants will be administered BMS-986231 Formulation C as IV infusion for 48 hours.
223639416|NCT03891108|DRUG|BMS-986231 Formulation D|Participants will be administered BMS-986231 Formulation D as IV infusion for 48 hours.
223639417|NCT02986360|BEHAVIORAL|Vidscrip educational video|Vidscrip educational video provide to women
223639418|NCT03497624|OTHER|Biospecimens collection|Collection of tumor tissue when a participant is having a clinically-indicated biopsy or surgery for their ROS1-fusion cancer.
223639419|NCT02989597|DRUG|Methadone Hydrochloride|IV administration of methadone intra-operatively for a single dose
223639420|NCT02989597|OTHER|Standard pain regimen|Standard medications for pain control administered after spinal surgery to be either fentanyl or morphine
223639421|NCT02989597|PROCEDURE|Spinal Fusion Surgery|Clinically-indicated spinal fusion surgery
224227551|NCT03731351|PROCEDURE|Mechanical Thrombectomy|Acute Ischemic Stroke patient with Large Vessel Occlusion and NIHSS less than or equal to 5 will have a standard of care mechanical thrombectomy. Mechanical thrombectomy is a treatment for stroke that removes clots that block large blood vessels. Some patients may be candidates for this procedure using an angiogram or a catheterization and a device that grabs clots and removes them, to reestablish blood flow to the brain.
223639422|NCT02989597|DRUG|Dexamethasone|Post operative swelling and pain control
223639423|NCT02989597|DRUG|Ketamine|Perioperative anesthesia medication
223639424|NCT02989597|DRUG|Remifentanil|Perioperative pain medication
223639425|NCT02989597|DRUG|Sufentanil|Perioperative pain medication
223639426|NCT00025181|BIOLOGICAL|MART-1 antigen|
223639427|NCT00025181|BIOLOGICAL|gp100 antigen|
223639428|NCT00025181|BIOLOGICAL|incomplete Freund's adjuvant|
223639429|NCT00025181|BIOLOGICAL|ipilimumab|
223639430|NCT00025181|BIOLOGICAL|tyrosinase peptide|
223639431|NCT00025181|PROCEDURE|adjuvant therapy|
223639432|NCT02406508|DEVICE|Melphalan/HDS|
223639433|NCT02406508|DRUG|Sorafenib|
223639434|NCT00419406|PROCEDURE|UVA1 phototherapy|
223639435|NCT00419406|PROCEDURE|NB-UVB phototherapy|
223765102|NCT07019818|DRUG|Esmolol Hcl 10Mg/Ml Inj|Esmolol is an injectable cardioselective beta-blocker, preferentially inhibiting beta-1 adrenergic receptors, while avoiding an increase in peripheral vascular resistance.
223765103|NCT07019818|DRUG|Sufentanil 5 mcg|Sufentanil is a synthetic opioid with the pharmacological properties of a µ-receptor agonist.
223765104|NCT07018323|DRUG|IMVT-1402|Dose 1 for 26 weeks
223639436|NCT04029285|OTHER|Exergaming|The exergaming group played six IREX® exergames. Those in the TGB group performed exercises that were matched to the IREX® exergames for: movement patterns required, physiological demands, sequence, duration and mode of exercise by adopting open and closed kinetic chain movements, in the same range and loading, across both groups. Each IREX® exergame was played for two minutes and was repeated three times within a session. TGB exercise was conducted in sets of two minutes duration, repeated three times within a session. In both groups participants were given rest periods of 10 to 30 seconds, or longer, if required, between exergames or TGB exercise sets.
223639437|NCT04111991|BEHAVIORAL|Usual Care|Usual care in the NCH in the Complex Concussion Clinic involves assessment and treatment with a neurologist for medical management of concussion, weekly sessions with an athletic trainer for exercise therapy, and physical therapy sessions depending on need
223639438|NCT04111991|BEHAVIORAL|C-STEP (Cognitive Behavioral Therapy)|The C-STEP intervention involves 4 primary components: psychoeducation, activity management, sleep hygiene, and relaxation training
223639439|NCT04686669|DRUG|FOR-6219 capsule formulation|FOR-6219 capsule formulation will be available as a soft gelatine capsule with a single dose of 50 milligrams, administered orally.
224227552|NCT04978025|DRUG|Colloidal Silver|"Orally: colloidal silver 1 dose of 30ml, 3 times a day for 5 days (use a plastic measuring cup and not a measuring cup or a metal spoon)~and By inhalation: nebulization of 5ml of colloidal silver solution once, 3 times a day for 5 days."
224227553|NCT04978025|DRUG|Placebo|Orally: EPPI 1 dose of 30 ml, 3 times a day for 5 days By inhalation: nebulization of 5ml of EPPI solution once a day, 3 times a day for 5 days.
224227554|NCT04501471|BEHAVIORAL|SAAF-T|Parents and youth meet separately during first hour to engage in activities then meet in family groups during the second hours of each session.
224227555|NCT04501471|BEHAVIORAL|Fuel for Families|Parents and youth meet separately during first hour to engage in activities then meet in family groups during the second hours of each session.
223639440|NCT04686669|DRUG|FOR-6219 tablet formulation|FOR-6219 tablet formulation will be available as a tablet with a single dose of 50 milligrams, administered orally.
223639441|NCT00257985|DRUG|GTN|
223639442|NCT04318353|OTHER|early enteral feeding within 2 days postoperative|Enteral feeding within 2 days postoperative
223639443|NCT00823017|OTHER|Patient-preferred music|Music of patients' preference
223639444|NCT00823017|OTHER|Relaxation Music|Relaxation music compiled from results of first three stages of study
223639445|NCT00823017|OTHER|Standard Care Environment|Control, no interventions
223639446|NCT03160443|BEHAVIORAL|Ambulatory cares in a day-hospital (University Hospital of Montpellier) specialized in the evaluation of eating disorders|"All patients assessed in the day-hospital will performed the same evaluation :~* Blood sampling~* Calorimetry~* Osteodensitometry~* Psychiatric assessment~* Endocrinologic assessment~* Dietetic assessment~* Neuropsychological assessment~* Self-questionnaires~With the patient agreement, a biological collection will be constituted. The objective is the subsequent study of biological factors involved in eating disorders (in particular genetic factors)"
223639447|NCT04109261|DRUG|Palbociclib|Palbociclib administration in breast cancer patients included in a compassionate use programme. Patients were treated according to the standard of care
223639448|NCT02399176|BEHAVIORAL|Yoga|Subjects assume 10 physical postures for 30 seconds each
223639449|NCT01743222|GENETIC|eASC|"* First cohort: Intra lymph node injection of 2.5 millions of eASCs suspended in 0.5 ml of HypoThermosol per lymph node, total dose 5 millions of cells.~* Second cohort: Intra lymph node injection of 5 millions of eASCs suspended in 0.25 ml of HypoThermosol per lymph node, total dose 10 millions of cells."
223639450|NCT01743222|DRUG|Placebo|"* First cohort (2 volunteers): injection of 0.25 ml of HypoThermosol (HTS) per lymph node~* Second cohort (2 volunteers): injection of 0.5 ml of HypoThermosol (HTS) per lymph node"
223639451|NCT00288132|BEHAVIORAL|Intervention|A 12-month diabetes self-management intervention delivered via telemedicine, with opportunity to receive telemedicine-based screening eye exam, was conducted.
223639452|NCT00288132|BEHAVIORAL|Usual Care|Upon randomization, received one 15-minute diabetes self-management individual session, using American Diabetes Association materials. Continued care, as usual, from their primary care provider throughout duration of active 12 month intervention period.
223639453|NCT01834911|DRUG|Tetrabenazine withdrawal|Tetrabenazine will be withdrawn for at least 3 days in Huntington disease patients currently on the drug. Patients will be examined via Stroop test in the OFF state. Two doses of 12.5 mg tetrabenazine will be introduced, spaced 3 hours apart. Stroop test will be performed 6 hours after initial OFF Stroop test.
223765105|NCT07018323|DRUG|IMVT-1402|Dose 2 for 26 weeks
223765106|NCT07018323|DRUG|Placebo|For 26 weeks
223765107|NCT07019792|OTHER|Protaper ultimate|Using Protaper Ultimate file system for canal preperation
223765108|NCT07019792|OTHER|Truanatomy file system|Using Truanatomy file system for canal preperation
223765109|NCT07019792|OTHER|Hyflex EDM|Using Hyflex file system for canal preperation
223765110|NCT07019792|OTHER|Xp shaper rise|Using XPshaper rise system for canal preperation
224227556|NCT02100852|DRUG|TGR-1202 + Obinutuzumab + Chlorambucil|TGR-1202: Oral dose Obinutuzumab: IV infusion Chlorambucil: Oral dose
224227557|NCT04275947|OTHER|nCapp, a cell phone-based auto-diagnosis system|Combined with 15 questions online, and a predicated formula to auto-diagnosis of the risk of COVID-19
224227558|NCT05718388|OTHER|Physical therapy exercises|For two consecutive months, the children in control group underwent a physiotherapy program for 60min/ three sessions each week: it was based mainly on the neurodevelopment technique, directed toward inhibiting abnormal muscle tone facilitating normal patterns of postural control and hand functions training program
224227559|NCT05718388|OTHER|Isokinetic training|Children in study group received the same program given to control group (A) in addition to isokinetic resistance training of the less affected upper limb for shoulder abductors in concentric mode at the angular velocity of 180 degree/ second under full supervision on the Biodex isokinetic dynamometer three times per week for 8 weeks, making a total of 24 training sessions. Each child was trained in the seated position with the similar precaution of the testing protocol.
224227560|NCT03716505|DEVICE|gammaCore Sapphire active|GammaCore Sapphire™ is a handheld, non-invasive, low voltage electrical device which stimulates the vagus nerve by producing weak 120 second electrical stimulation cycles that may help reduce, ease, lessen or stop your migraine symptoms. GammaCore Sapphire™ has been approved for the treatment of headache, including migraine by the United States Food and Drug Administration (FDA).
224227561|NCT03716505|DEVICE|gammaCore Sapphire Sham|The sham device is a hand-held portable device that appears identical to gammaCore Sapphire, in look, weight, visual and audible feedback, user application, and control. Like gammaCore Sapphire, the sham device is a multi-use device.
224227562|NCT06226454|DRUG|VX-993|Suspension for oral administration.
224227563|NCT06226454|DRUG|Placebo|Suspension for oral administration.
224227564|NCT01688037|DRUG|NBI-98854|25 mg capsule
224227565|NCT01688037|DRUG|NBI-98854|50 mg capsule
224227566|NCT01688037|DRUG|Placebo|
224227567|NCT04646122|DEVICE|Optical Coherence Tomography|Optical Coherence Tomography parameters
223639454|NCT06226493|DEVICE|Transcutaneous vagus nerve stimulation|The Parasym Plus device (https://parasym.io) is a transcutaneous auricular vagus nerve stimulator that has been deemed non-significant risk (NSR) by the FDA. Transcutaneous auricular vagus nerve stimulator is a non-significant risk device, as it involves electrical stimulation of the external ear using an ear clip, with no invasive components. The stimulation parameters will be limited to the confines of existing published data. tVNS is safe and well tolerated at doses tested in research studies. The Parasym device is considered low risk when used in accordance with the instructions for use. Participants will be properly trained to use the device, and those with contraindications will be excluded for extra precaution. A low incidence of skin irritation has been reported. No serious adverse events have been reported.
223639455|NCT02559141|DRUG|Dobutamine|If PPV ≤10%, volume substitution of 500 ml of crystalloids and/or colloids as long as CI was ≥2.5 l/min/m². Maintenance of CI ≥2.5 l/min/m² and MAP ≥65 mmHg was achieved by using dobutamine (10 µg/kg/min) and norepinephrine (0.03 µg/kg/min).
223639456|NCT01028820|DRUG|Aripiprazole|8 weeks, starting dosage 5mg titrating up 5mg every week as needed to maximum dosage of 25mg daily
223639457|NCT02000440|DRUG|Losmapimod|Losmapimod (micronized GW856553X) will be supplied as a film coated white, 7 mm round, biconvex, plain faced, tablet. Oral doses of losmapimod, 7.5 mg (1 tablet) or 15 mg (2 tablets), will be taken twice daily (BID) with food and swallowed whole (not chewed or crushed)
223639458|NCT06442943|BEHAVIORAL|Multi-domain Cognitive Intervention|"* Cognitive rehabilitation includes home-based exercise, three times per week, for 30 minutes each session.~  * Cognitive stimulation involves art therapy, once a week, for 90 minutes per session.~    * Cognitive training encompasses memory, attention, executive function, and visuospatial training, conducted three times per week, with each session lasting 30 minutes.~      * Health education, once a week, covering the prevention and treatment of chronic diseases in the elderly, as well as healthy lifestyles for the elderly."
223639459|NCT06555107|OTHER|questionnaire|Patients included in the study will be asked to complete a questionnaire 48 to 72 hours after surgery to assess their perception of pain and preoperative anxiety
223639460|NCT06555107|OTHER|phone call|Patients will then be interviewed by phone 3 months after their emergency surgery. During the interview, they will be questioned via a standardised questionnaire on the existence of CPSP
223639461|NCT04438265|DRUG|levobupivacaine|local anesthetic
223639462|NCT04438265|DEVICE|ultrasound device|scream
223639463|NCT04349267|BIOLOGICAL|BMS-986315|Specified dose on specified days
223639464|NCT04349267|BIOLOGICAL|nivolumab|Specified dose on specified days
223639465|NCT04349267|BIOLOGICAL|cetuximab|Specified dose on specified days
223639466|NCT03995368|OTHER|Electroencephalography|The investigators will use EEG combined with measures of cognition and clinical interviews to explore connections between these measures and electrical activity in the brain in Veterans with a diagnosis of schizophrenia or TBI, and healthy controls.
223639467|NCT05919186|DRUG|EmbryORP®|EmbryORP® is a novel antioxidant (Cystein 32.9 mM, Glutation 32.6 mM, Ascorbic Acid 22.7 mM)
223639468|NCT05919186|DEVICE|O2 tension 20%|After fertilization check, zygotes were placed in the incubator at 37°C, 8% CO2, and 95%
223639469|NCT05919186|DEVICE|O2 tension 5%|After fertilization check, zygotes were placed in the incubator at 37°C, 8% CO2 and 95%
223639470|NCT04392622|DRUG|D-Limonene Gelcaps|Administered orally at 2 to 8 grams daily
223639471|NCT04392622|RADIATION|Intensity modulated radiotherapy (IMRT)|Standard of Care -All patients will receive standard radiation treatment of 66 to 70 Gy given in 33 to 35 fractions (2 to 2.12 Gy/fractions) over 6.5 to 7 weeks.
223639472|NCT04392622|DRUG|Cisplatin|Standard of Care -Cisplatin as 100 mg/m2 IV
223639473|NCT04392622|OTHER|Xerostomia questionnaire|Xerostomia questionnaire consists of 4 items on dryness while eating/speaking and 4 on dryness at rest. Patients rate each symptom on an 11 point ordinal Likert scale from 0 to 10, with higher scores indicating greater xerostomia
223639474|NCT03755934|DRUG|MEDI7352|Participants will receive IV infusion of MEDI7352 as stated in arm description.
223639475|NCT03755934|OTHER|Placebo|Participants will receive IV infusion of placebo as stated in arm description.
223639476|NCT02628990|OTHER|1.6 g plant stanols|Lipid-lowering effect of Yoghurt Drink with 1.6 g plant stanols
223639477|NCT02628990|OTHER|2 g plant stanols|Lipid-lowering effect of Yoghurt Drink with 2 g plant stanols
223639478|NCT02628990|OTHER|1.6 g plant stanols and camelina oil|Lipid-lowering effect of Yoghurt Drink with 1.6 g plant stanols and camelina oil
223639479|NCT02628990|OTHER|2 g plant stanols and camelina oil|Lipid-lowering effect of Yoghurt Drink with 2 g plant stanols and camelina oil
223639480|NCT02628990|OTHER|Placebo|Lipid-lowering effect of Placebo Yoghurt Drink
224227568|NCT01577095|OTHER|EA + Rosiglitazone|electroacupuncture and Rosiglitazone combined therapy on patient of type II DM
224227569|NCT01577095|DRUG|TZD|Rosiglitazone 8 mg single dose
224227570|NCT02100956|DRUG|oxytocin 100 micrograms|oxytocin 100 micrograms administered intrathecally (IT)
224227571|NCT02100956|DRUG|Normal Saline (preservative free)|Normal Saline (preservative free) administered intrathecally (IT)
224227572|NCT04179591|OTHER|Exercise|Intrinsic foot muscles and tibialis posterior strengthening exercises
224227573|NCT04179591|OTHER|Orthesis|Customized arch support insoles
224227574|NCT00457379|BEHAVIORAL|physical exercise|
223639481|NCT04487366|OTHER|reaching targeted area on the phantom model|resident reach the targeted area on the phantom model using ultrasoun guidance and independently or with asistance inject the solution
223639482|NCT02681029|PROCEDURE|Blastocyte Transferring|Intra-uterine transferring of blastocyst from thawed cleavage embryo in infertile women.
223639483|NCT02681029|PROCEDURE|Embryo Transferring|Inta-uterine transferring of thawed cleavage embryo transfer in infertile women.
223639484|NCT03160261|DRUG|Exenatide Injection|Single injection of Exenatide 10μg subcutaneously
223639485|NCT01720108|DRUG|rivaroxaban and ASA|
223639486|NCT01069003|DRUG|Placebo Arm|Placebo and ASA (75 mg - 325 mg)
223639487|NCT01069003|DRUG|Thienopyridine Therapy|Prasugrel 5 or 10 mg or Clopidogrel 75 mg plus ASA (75 mg - 325 mg)
223639488|NCT01069003|DEVICE|Surveillance Arm|Non randomized arm to understand clinical outcomes in a commercial setting
223639489|NCT00785759|DRUG|AH110690 (18F) Injection|All subjects will receive an I.V. dose of \[18F\]AH110690 (less than 10 mg of total AH110690). The target activity of a single administration of \[18F\]AH110690 will be 185 MBq (equivalent to a dose of approximately 6 mSv).
223639490|NCT02222623|DRUG|Glargine|Glargine given as 100% total daily dose with breakfast. The initial dose will be calculated using the patient's weight or using their basal insulin doses prior to hospitalization.
223639491|NCT02222623|DRUG|NPH|NPH 2/3 of the total daily dose given with breakfast, 1/3 of the total daily dose given at bedtime. The initial dose is calculated using the patient's weight or using the basal insulin dose prior to hospitalization.
223639492|NCT05058339|OTHER|Survey Administration|Complete survey
223639493|NCT03631602|DRUG|antifungal prophylaxis|posaconazole oral suspension vs itraconazole oral solution
223639494|NCT00361296|BIOLOGICAL|K562/GM-CSF cell vaccine|
223765111|NCT07024329|OTHER|Remote Symptom Monitoring and Management|A study nurse will digitally monitor symptom complexity and provide symptom management between clinic visits. This will increase the frequency of collection and use of electronic PROs to provide responsive symptom management. Electronic PROs are collected digitally, and a complexity algorithm is used to flag patients with high symptom complexity. This will allow the study nurse to proactively manage symptoms in a timelier way.
224227575|NCT03035227|PROCEDURE|Catheter Ablation|Catheter ablation of atrial or ventricular arrhythmia. The technique and type of ablation will be at the discretion of the treating electrophysiologists.
224227576|NCT03035227|DRUG|Anti-Arrhythmics|Anti-Arrhythmic drugs that are deemed to be appropriate for the given participants's arrhythmia by the treating physician.
224227577|NCT03458507|DEVICE|Switch of nocturnal NIV interface|"1. test the alternative interfaces (either a nasal mask for the patient used to oronasal mask or inversely an oronasal mask if the usual mask is nasal) during a one-hour diurnal NIV session. SpO2 (polygraphy), PtcCO2 will be monitored continuously during this diurnal session. Patients will use their usual NIV device prescribed at home. NIV settings will be adapted if needed.~2. Interface switch~3. unattended nocturnal polygraphy under NIV (cf details below) will be performed at home with SomnoHolter® (Nomics, Liege, Belgium), synchronized with transcutaneous partial pressure in CO2 (PtcCO2) monitoring by SenTec V-Sign™ System.~The PtcCO2 device will be calibrated before and at the end of each night to allow drift correction."
224227578|NCT03776851|DRUG|erythropoietin|erythropoietin 50 International Units (IU) per kilogram three times weekly by subcutaneous route
224227579|NCT02502409|OTHER|Standard care with blood and urine sample collection|
224227580|NCT02473991|RADIATION|ultrasound|The placental thickness was measured by placing the ultrasound transducer perpendicularly to the plane of the placenta, in the area of the cord insertion, near the mid-placental portion
224227581|NCT00859469|DRUG|Oxaliplatin|Oxaliplatin 100 mg/m2 IV infusion for 2 hours
224227582|NCT00859469|DRUG|Gemcitabine|Gemcitabine 1000mg/m2 IV infusion for 90 minutes
223639495|NCT05516381|DEVICE|Optetrak Logic CR Knee System|The OPTETRAK® Comprehensive Knee System consists of the OPTETRAK® Total Knee System and the OPTETRAK Logic® Total Knee System. The OPTETRAK Comprehensive Knee System comprises both non-porous and porous knee prostheses for use in total-knee joint replacement procedures. (In the USA, the OPTETRAK Comprehensive Knee System is indicated for cemented use only, except for the OPTETRAK Logic PS and CR Porous Femoral Components, which are indicated for cemented or cementless use.) The system includes various sizes and types of modular femoral components, tibial components, patellar components, and accessories for use in primary and revision applications.
223639496|NCT01481753|PROCEDURE|pancreaticoduodenectomy without Braun enteroenterostomy|no Braun enteroenterostomy has been added to standard pancreaticoduodenectomy; pancreaticoduodenectomy without Braun enteroenterostomy
223639497|NCT01481753|PROCEDURE|Braun enteroenterostomy|addition of Braun enteroenterostomy (side-to-side anastomosis between the afferent and efferent loops of the gastrojejunostomy) to standard PD reconstruction can decrease the rates of POPF and/or DGE, improving the perioperative outcome of patients undergoing PD.
223639498|NCT00198822|DIETARY_SUPPLEMENT|Vitamin A or Beta-Carotene Supplements|weekly dosage of either 7000 µg retinol equivalents as preformed vitamin A or 42 mg of beta-carotene from 1st trimester of pregnancy through 12 weeks after termination of pregnancy
223639499|NCT00131079|BEHAVIORAL|Experimental Programme for Physical Activity Promotion|"General practitioner's (GP) physical activity (PA) assessment and advise using a web-based software that prompted open questions to elicit believes about benefits of PA, graphical information about risks of inactivity and examples of type sentences to provide medical advise.~Educational materials summarizing benefits, risks and motivation.~Prescription: 15 minutes educational session in which GP negotiated a goal, addressed possible barriers and anticipated solutions using web-based tools for lack of time, community resources, and health problems. Finally, they designed a 3-month PA activity plan that derived in a standardized printed prescription of frequency, duration, intensity and progression of a selected PA or exercise that included a self-monitoring log."
223639500|NCT00131079|BEHAVIORAL|Control|Control general practitioners assessed physical activity and performed recruitment in a similar way but offered usual care
223639501|NCT01186289|DRUG|atorvastatin|high dose atorvastatin therapy (80 mg/day) beginning 48 to 72-hours preoperatively and continuing until 6-weeks postoperatively
223639502|NCT05007769|DRUG|Ramucirumab|Will be supplied by Lilly Oncology, free of charge to the participant
223639503|NCT05007769|DRUG|Atezolizumab|Atezolizumab will be commercially available.
223639504|NCT05007769|DRUG|N-803|Will be supplied free of charge to the participants by ImmunityBio
223639505|NCT00963859|PROCEDURE|Robotic-assisted laparoscopic surgery|During radical cystectomy, robotic-assisted technique used to perform cystectomy and pelvic lymph node dissections. Each patient will undergo a second-look open lymph node dissection once the incision is made at the end for the urinary diversion.
223639506|NCT06473181|OTHER|Core stability exercises|Exercises applied to trunk , pelvis and abdomen to improve ability to stand , walk and balance.
223639507|NCT04934540|PROCEDURE|En bloc resection of bladder tumour|En bloc resection of bladder tumour (ERBT) is a novel surgical technique in which the bladder tumour is resected in one piece
223639508|NCT01798771|PROCEDURE|Interventional arm|5-ALA fluorescence guided surgery with the additional use of an intraoperative MRI for resection control in patients with contrast enhancing tumors.
223639509|NCT01798771|PROCEDURE|Control arm|5-ALA fluorescence guided surgery in patients with contrast enhancing tumors.
223639510|NCT02420821|DRUG|Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody|Atezolizumab will be administered at a fixed dose of 1200 milligrams (mg) via intravenous (IV) infusion on Days 1 and 22 of each 42-day cycle.
223639511|NCT02420821|DRUG|Bevacizumab|Bevacizumab will be administered at a dose of 15 milligrams per kilogram (mg/kg) via IV infusion on Days 1 and 22 of each 42-day cycle.
223639512|NCT02420821|DRUG|Sunitinib|Sunitinib will be administered at a dose of 50 mg once daily, orally via capsule, on Day 1 through Day 28 of each 42-day cycle.
223639513|NCT03077334|DEVICE|PET-CT|PET-CT will be done before operation and that is routine treatment procedure for pancreatic cancer.
223639514|NCT04291469|DRUG|Probiotics（Live combined bifidobacteria, lactobacillus and maltodextrin tables)|The probiotic compound will consist of tables containing approximately 10\^9 colony forming units of the probiotic organisms, Lactobacillus and Bifidobacteria lactis strain，mixed maltodextrin(oral, daily for 14 weeks).
224227583|NCT03091166|DRUG|Dexmedetomidine|
224227584|NCT02405910|DRUG|Nab-paclitaxel|
224227585|NCT02405910|DRUG|Gemcitabine|
224227586|NCT04914793|DEVICE|Antimicrobial prescribing guideline mobile phone application (MicroGuide)|This session is given to all hospital doctors in all study hospitals at the start of the intervention period of each paired hospital. All participating hospitals will join AMS knowledge survey three times during the study period (1st time= at the start of the project, 2nd time= before entering to the intervention period and 3rd time= at the end of the project).
224227587|NCT03890250|OTHER|Aerobic exercise|A 20-30 minutes low-medium intensity aerobic exercise training with cycling ergometer.
223639515|NCT04291469|DIETARY_SUPPLEMENT|Prebiotics (Combined inulin and maltodextrin tables)|The prebiotic compound will consist of tables containing inulin and maltodextrin (oral,daily for 14 weeks)
223639516|NCT04291469|DIETARY_SUPPLEMENT|maltodextrin|Maltodextrin tables (oral,daily for 14 weeks)
223639517|NCT06530147|OTHER|Transversalis Fascia Plane Block|One-side ultrasound (US)-guided Transversalis fascia plane (TFP) block with 0.25% bupivacaine will performe after placement laryngeal mask airway before surgery.
223639518|NCT06530147|OTHER|Transversus Abdominis Plane Block|One-side ultrasound (US)-guided Transversus abdominis plane (TAP) block with 0.25% bupivacaine will performe after placement laryngeal mask airway before surgery.
223639519|NCT02784548|OTHER|Virtual Reality|Using a VR headset, motion sensors, and VR software, the investigators will create a customized VR treatment for each participant that engages them in movements and exercises involving their missing limb in a game-like environment. For example, participants may use the headset to engage in activities such as driving a race car around a course requiring both arms, ski down simulated slopes, or manipulate objects.
223639520|NCT00602602|BIOLOGICAL|bevacizumab|
223639521|NCT00602602|DRUG|fluorouracil|
223639522|NCT00602602|DRUG|gemcitabine hydrochloride|
223639523|NCT00602602|DRUG|oxaliplatin|
223639524|NCT00602602|OTHER|immunohistochemistry staining method|
223639525|NCT00602602|OTHER|laboratory biomarker analysis|
223639526|NCT00602602|PROCEDURE|conventional surgery|
223639527|NCT00602602|PROCEDURE|endoscopic biopsy|
223639528|NCT00602602|PROCEDURE|laparoscopy|
223639529|NCT00602602|RADIATION|radiation therapy|
223639530|NCT05269459|DRUG|Cannabidiol Administered as Nantheia ATL5|Participants will take 4 gel capsules twice daily containing 100mg of Nantheia ATL5.
223639531|NCT05269459|DRUG|Placebo|Participants will take 4 matching gel capsules twice daily containing no active drug.
223639532|NCT04322526|DRUG|Naltrexone 50 Mg Oral Tablet|Naltrexone hydrochloride (ReVia®. Toronto, ON: Teva Canada Limited; 2015) (onset of action: ≥15 minutes; peak effect: \~1 hour; duration: \~24 hours).
223639533|NCT04322526|DRUG|Placebo oral tablet|Placebo tablet that has no inherent power to produce an effect. In the inert pill condition, participants will receive an oral placebo tablet.
223639534|NCT04575389|DIAGNOSTIC_TEST|Serum uric acid levels ,HBA1C , fasting plasma glucose ,lipid profile , creatinine level|diagnostic tests
223639535|NCT06166615|DRUG|Ramosetron|Ramosetron (a 5-HT3 receptor antagonist) has been developed as an effective treatment for irritable bowel syndrome-diarrhea (IBD-D) and is used to decrease intestinal motility, stiffen stool consistency, and reduce the number of urgency bowel movements. Since one of the goals of treatment for fecal incontinence is the maintenance of stool consistency, this agent is expected to be effective in treating fecal incontinence.
223639536|NCT06166615|DRUG|Psyllium|Psyllium was found to be the most effective at improving symptoms of fecal incontinence among several dietary fibers in a randomized, controlled, single-blind study and is currently used as a first-line treatment for fecal incontinence.
223639537|NCT00993967|DRUG|idebenone|Idebenone 1350 mg/d, patients \< or equal 45 kg Idebenone 2250 mg/d, patients \> 45 kg
223639538|NCT00533455|DRUG|Gabapentin|
223639539|NCT06584006|DRUG|Thymalfasin for injection in combination with Recombinant Human Interleukin-2 Injections|Thymalfasin for injection 1.6mg subcutaneous injection once daily (qd) for 7 days, and Recombinant Human Interleukin-2 Injections 1 million units subcutaneous injection qd for 7 days.
223639540|NCT06584006|DRUG|Recombinant Human Interleukin-2 Injections|Recombinant Human Interleukin-2 Injections 1 million units subcutaneous injection qd for 7 days.
224227588|NCT03890250|OTHER|Neuromuscular electrical stimulation|Bilateral NMES application on Quadriceps femoris muscle will be applied as symmetrical biphasic square wave current with a wave frequency of 35-60 Hz, phase transition time of 8 seconds and active resting time of 15 seconds
224227589|NCT04373759|OTHER|Cardiopulmonary resuscitation|Cardiopulmonary resuscitation
223639541|NCT03131024|DIETARY_SUPPLEMENT|50% caloric restriction|Meals mimicking participant dietary preferences and matching North American macronutrient guidelines will be provided consisting of 50% of total caloric intake for 48 hours
224227590|NCT04373759|OTHER|Modified Rankin score|"0 - no symptoms at all~1. \- no significant disability despite symptoms; able to carry out all usual duties and activities~2. \- Slight disability; unable to carry out all previous activities, but able to look after own affairs without assistance~3. \- Moderate disability; requiring some help, but able to walk without assistance~4. \- Moderately severe disability; unable to walk and attend to bodily needs without assistance~5. \- Severe disability; bedridden, incontinent and requiring constant nursing care and attention~6. \- Dead"
223639542|NCT03131024|OTHER|Aerobic exercise|The supervised exercise session will consist of a 10-minute warm-up, 30 minutes performed at 70-75% of heart rate reserve, which corresponds to a vigorous intensity, followed by a 5-minute cool-down
223639543|NCT02760498|DRUG|cemiplimab|
223639544|NCT03469947|DRUG|Tranexamic Acid|1 gram of prehospital Tranexamic Acid
223639545|NCT00891943|OTHER|Structured lifestyle support|The intervention group will meet with a research nurse on 14 occasions over the 1 year research study, for structured lifestyle support, including dietary, physical activity and behavioral advice. They will also receive a pedometer.
223639546|NCT00317980|DRUG|Meglumine antimoniate|Meglumine antimoniate 5mg/kg/d for 20 days
223639547|NCT00317980|DRUG|Meglumine antimoniate|Meglumine antimoniate 15 mg/kg/d for 20 days
223639548|NCT05035238|BIOLOGICAL|Triple dose vaccination by inactivated Covid19 vaccine|triple dose intramuscular vaccine on Day 0, Day 28, and Day 120.
223639549|NCT00896402|DRUG|Skin antisepsis with chlorhexidine|Chlorhexidine swabs will be used to antiseptically clean the skin, then cultures of the skin and femoral nerve block catheters will be analyzed via standard microbiological techniques
223639550|NCT00896402|DRUG|povidone-iodine|Povidone-iodine swabs will be used to antiseptically clean the skin; then cultures of the skin and femoral nerve catheters will be performed by standard microbiologic techniques
223639551|NCT06411262|OTHER|Parkiboks|A non-contact boxing sessions for individuals with Parkinson disease, made-up of 3 sections: a warm-up, a boxing section, a cool-down. Each section is split into a range of exercises. The session is led by a boxing coach with training and expertise in Parkinson disease.
223639552|NCT02410226|PROCEDURE|Double-space combined spinal-epidural anesthesia|Epidural space identification in Lumbar 2-3 or 3-4 space using loss of resistance to air technique with 18-gauge Tuohy needle, then threading a 20-gauge multi-orifice epidural catheter 4-5 cm into the epidural space. Spinal anesthesia administration in an appropriate lower intervertebral space with intrathecal bupivacaine 12.5 mg and fentanyl 10 mcg through a 27-gauge spinal needle.
223639553|NCT02410226|RADIATION|Preprocedure spinal ultrasound|Lumbar spinal ultrasound using the 2-5 MHz curved probe, performed in both the longitudinal and transverse planes for identification of the appropriate intervertebral spce, estimation of the depth to the epidural space, and noting the proper angle for subsequent needle insertion. Then skin markings relying on the ultrasound procedure are made identifying 2 intervertebral spaces.
223639554|NCT02410226|RADIATION|Sham ultrasound procedure|Applying the ultrasound probe on the patient's back while the ultrasound machine is on the freeze position.Then skin markings relying on landmark palpation are made identifying 2 intervertebral spaces.
223639555|NCT05007054|PROCEDURE|PCI or CABG|The PCI performed following current standard guidelines. All patients were pre-treated with aspirin and clopidogrel before catheterization. Thereafter, heparin (70-100 IU/kg) was administered before PCI, however, the use of glycoprotein IIb/IIIa inhibitors was at the physician's discretion. Dual-antiplatelet medication was administered to the patients after PCI for at least 12 months. For CABG, the left internal mammary artery was routinely used to graft to the left anterior descending artery and completed by venous grafts to other coronary branches with standard bypass techniques. The procedure was performed by surgeons experienced in on-pump or of-pump surgery at the operator's discretion.
223639556|NCT06452563|DIETARY_SUPPLEMENT|ketoanalogue supplementation|This drug contains 5 essential amino acids (L-lysine monoacetate 75mg, L-threonine 53mg, L-tryptophan 23mg, L-histidine 38mg and L-tyrosine 30mg) and 5 essential amino acid substitutes in the form of calcium salts, including 4 keto-analogues (keto-isoleucine, keto-leucine, keto-valine, and keto-phenylalanine) and a hydroxy-analogue (hydro methionine) as calcium salt . The drug is approved by the Egyptian Drug Authority (EDA) with registration number 34677/2021
223639557|NCT06452563|OTHER|intradialytic exercise|low-intensity exercise training composed of knee extension and hip abduction and flexion from a three-repetition maximum (3RM) using ankle weights
223639558|NCT01623570|DRUG|Pergoveris: 150IU r-hFSH + 75IU r-hLH|Fixed formulation of two recombinant gonadotropins
224227591|NCT03376958|DRUG|Apatinib|Apatinib, a novel small molecule vascular endothelial growth factor receptor-2 (VEGFR-2) tyrosine kinase inhibitor, have shown remarkable efficacy in many solid cancers. The result of our study presented that apatinib might have a rapid, safe and high efficacy on lymphoma patients.
224227592|NCT02220907|DRUG|Teneligliptin/Canagliflozin|Co-administration of Teneligliptin and Canagliflozin orally once daily for 52 weeks.
224227593|NCT00468741|BEHAVIORAL|CHESS (Comprehensive Health Enhancement Support System)|Full CHESS for subject use
224227594|NCT00468741|BEHAVIORAL|CHESS|informational services of CHESS available to subject
224227595|NCT00468741|BEHAVIORAL|CHESS|CHESS informational services and social support available to subject
224227596|NCT03982849|DRUG|Hydroquinone 4% Cream|Hydroquinone is tyrosinase inhibitor and thus inhibits melanogenesis.
224227597|NCT03982849|DRUG|silymarin 0.7% cream|Silymarin is a plant derived flavonoid, extracted from fruits and seeds of milk thistle.
224227598|NCT00366379|DRUG|GK Activator (2)|25-200mg po bid for 20 weeks
224227599|NCT01701778|DRUG|Caudal Dexmedetomidine|"Caudal: Levobupivacaine 0.25% 1ml/kg and dexmedetomidine 1µg/kg~Intravenous: 10 ml normal saline"
224227600|NCT01701778|DRUG|Intravenous Dexmedetomidine|"Caudal: Levobupivacaine 0.25% 1ml/kg~Intravenous: dexmedetomidine 1µg/kg"
224227601|NCT01701778|DRUG|Placebo|"Caudal: Levobupivacaine 0.25% 1ml/kg~Intravenous: 10 ml normal saline"
224227602|NCT01701778|DRUG|sevoflurane|Induction and maintain anaesthesia
224227603|NCT03111147|DEVICE|0 degrees humeral component version|RTSA with humeral component positioned in 0 degrees of version
223639559|NCT01623570|DRUG|Menopur: HMG-HP (150 IU)|Human Menopausal Gonadotropin is an urinary estract from menopausal women containing 150IU of FSH and 150 IU of LH-like activity (HCG)
224227604|NCT03111147|DEVICE|30 degrees humeral component retroversion|RTSA with humeral component positioned in 30 degrees of retroversion
224227605|NCT04266678|BEHAVIORAL|Resistance exercise program|Exercise sessions with exercise science professional. Target hypertrophy repetition range and progressive resistance exercise.
224227606|NCT00902824|BIOLOGICAL|ADVAX|Receive 4mg ADVAX at Months 0, 1, and 2 (Biojector), and receive boost of 5x10\^7 pfu TBC-M4 (IM)
224227607|NCT00902824|BIOLOGICAL|TBC-M4|Receive 5x10\^7 pfu TBC-M4 (IM) at Months 0, 1, and 6.
224227608|NCT00902824|OTHER|Placebo|"Group A (n=4) will receive the ADVAX placebo (formulation buffer) via Biojector.~Group B (n=4) will receive the TBC-M4 placebo (formulation buffer) via IM."
224227609|NCT05921084|BEHAVIORAL|MIND diet intervention|The MIND diet intervention, composed of the consumption of whole grains, dark green leafy vegetables, dark red/yellow vegetables, other vegetables, berries and citrus, poultry, fish and seafoods, beans and legume, nuts, olive and seed oils, and green tea, and restricting red and processed meats, animal fat, fried foods, and sweets and pastries.
224227610|NCT05921084|BEHAVIORAL|General dietary advice|General dietary advice
224227611|NCT06008405|DRUG|TQB2928 Injection + Azacitidine for injection|"TQB2928 injection is a fully humanized Immunoglobulin G 4 (IgG4) subtype monoclonal antibody targeting CD47.~Azacitidine for injection is a nucleoside metabolism inhibitor that inhibits DeoxyriboNucleic Acid (DNA) methyltransferase, reduces DNA methylation and alters gene expression."
224319227|NCT03336528|DRUG|Degludec|Degludec is a long-acting human insulin analog indicated to improve glycemic control in adults with diabetes mellitus. Patients will be treated with bolus regimen given half of total daily dose (TDD) as basal once daily and half as aspart divided in three equal doses before meals. Patients with poor oral intake or with medical instruction to withhold oral intake (NPO) will receive the basal dose, but prandial dose will be held. Insulin dose will be adjusted daily to maintain a fasting and pre-dinner blood glucose (BG) between 100 mg/dL and 180 mg/dL.
224319228|NCT03336528|DRUG|Glargine|Glargine is a long-acting human insulin analog indicated to improve glycemic control in adults with diabetes mellitus. Patients will be treated with bolus regimen given half of total daily dose (TDD) as basal once daily and half as aspart divided in three equal doses before meals. Patients with poor oral intake or with medical instruction to withhold oral intake (NPO) will receive the basal dose, but prandial dose will be held. Insulin dose will be adjusted daily to maintain a fasting and pre-dinner BG between 100 mg/dL and 180 mg/dL.
224319229|NCT03336528|DRUG|Aspart|Aspart insulin will be given in three equally divided doses before each meal. To prevent hypoglycemia, if a subject is not able to eat, aspart insulin dose will be held.
223639560|NCT02953002|DEVICE|Calibrated Automated Thrombogram (CAT)|The Calibrated Automated Thrombogram (CAT). Thrombogram describes the concentration of thrombin in clotting plasma and is therefore a general physiologic function test of the thrombotic hemostatic system. The CAT measures thrombotic as well as bleeding tendency.
223639561|NCT02180100|DRUG|Terconazole Vaginal Suppository|Terconazole Vaginal Suppository inserted intravaginally once daily before bedtime for 6 consecutive days
223639562|NCT02180100|DRUG|Fluconazole|orally Fluconazole 150 mg (Pfizer Pharmaceuticals) at day 1 and day 4.
223639563|NCT06318468|OTHER|Nursing health assessment teaching and discussion using humanoid diagrams|The experimental group will receive the nursing health assessment teaching for 50 minutes and discussion using humanoid diagrams for 40 minutes to learn comprehensive nursing assessment.
223639564|NCT06318468|OTHER|Nursing health assessment teaching and discussion using case study|The comparison group will receive the nursing health assessment teaching for 50 minutes and discussion using case study for 40 minutes to learn comprehensive nursing assessment.
223639565|NCT03955146|DRUG|Pamrevlumab|Pamrevlumab will be administered per dose and schedule specified in the arm description.
223639566|NCT03955146|DRUG|Placebo|Placebo matching to pamrevlumab will be administered per schedule specified in the arm description.
223639567|NCT04798183|DIAGNOSTIC_TEST|3-dimensional scan|Facial 3-dimensional scan according to posture
224227612|NCT05004857|BEHAVIORAL|Book reading|Prior to the first session, a research assistant will place electrodes on the infant and mother so that they study team can gather autonomic nervous system (ANS) response (sympathetic and parasympathetic) non-invasively using MindWare Portable Lab System (MindWare Technologies, Gahanna, Ohio). These electrodes will remain on the infant and mother throughout each session and be removed via adhesive removing pads following each session's data collection. This will minimize discomfort to both parties secondary to electrode removal and minimize risk of skin irritation by leaving electrodes in place for a prolonged period of time. Additional observational data before and after the reading sessions will be collected by the research assistant, including but not limited to: where the session is conducted (mother's arms, bassinet), activity level, vital signs, and any other observed behaviors throughout the session.
223639568|NCT06250205|DRUG|Obicetrapib|oral administration
224227613|NCT02140073|DRUG|omeprazole+domperidone SR|omeprazole 20mg+domperidone SR 30mg, 2 capsules in the morning
224227614|NCT02140073|DRUG|omeprazole|40mg in the morning
224227615|NCT06049667|DRUG|NTQ2494 tablet|"Drug: NTQ2494 tablet Part 1: Dose escalation, single and multiple doses of NTQ2494 with dose modifications based on tolerability criteria.~For each dose level, a single dose of NTQ2494 tablets will be first administered orally, then continuous 28-day treatment will start (per cycle).~Part 2: Dose expansion, recommended doses from Part 1. For each dose level, multiple doses of NTQ2494 tablets will be administered as 28-day treatment (per cycle)."
223639569|NCT06250205|DRUG|Obicetrapib + Drospirenone / Ethinyl Estradiol (COC)|oral administration
223639570|NCT06250205|DRUG|Drospirenone / Ethinyl Estradiol (COC)|oral administration
223639571|NCT03783572|OTHER|Clinical evaluation|For the control group : only one clinical evaluation : search for non-inclusion criteria and manual laterality score
223639572|NCT03783572|OTHER|Clinical evaluation and Instrumental evaluation|For the patient : The standard clinical examination to evaluate movement : pain, motive power, spasticity plus Edinburgh's laterality score and Sensitivity deficiency by the Erasmus Nottingham Sensory Assessment (EmNSA) score and the evaluation of the cognitive function An encephalic MRI An instrumental evaluation : with concomitant recording of 3D kinematic data, surface and intramuscular EMG of the flexor and elbow extensor muscles, and EEG during active elbow extension, paretic and non-paretic movements.
223639573|NCT06277687|DIAGNOSTIC_TEST|Virtual Augmented Reality Combined With Finder|After CT examination, the computer carried out three-dimensional reconstruction of blood vessels, and input the CTA data into Cinematic Anatomy reconstruction software to analyze blood vessels, Muscles and other tissues are reconstructed in three dimensions. Before the operation, the Finder is used to restore the position of the thigh during CTA examination. The Hololens is used to match the reconstructed three-dimensional image with the perforator locator and the thigh. Before the operation, the pedicles of the descending branches of the lateral arteries and the perforating vessels are marked on the skin of the thigh to achieve the positioning and marking of the perforating branches.
223639574|NCT02002598|DRUG|Bendamustine|"Bendamustine will be administered IV on days 1 and 2 with dose escalation up to 90 mg/m2 of each 28-day cycle.~Dose escalation is as follows:~-1 \| 60 mg/m2~1. \| 70 mg/m2~2. \| 70 mg/m2~3. \| 90 mg/m2~4. \| 90mg/m2~5. \| 90 mg/m2"
223639575|NCT02002598|DRUG|Carfilzomib|"Carfilzomib will be administered IV on Days 1, 2, 8, 9, 15, and 16 every 28 days.~Dose Escalation is as follows:~-1 \| 27 mg/m2~1. \| 27 mg/m2~2. \| 36 mg/m2~3. \| 36 mg/m2~4. \| 45 mg/m2~5. \| 56 mg/m2"
223639576|NCT02002598|DRUG|Dexamethasone|Dexamethasone will be administered PO or IV, 20 mg, on 1, 2, 8, 9, 15, 16 and 22, 23 of each 28-day cycle.
223639577|NCT02628873|DEVICE|HyCoSy|Saline infused sonogram in which air bubbles are delivered via the FemVue saline air device in order to evaluate the patency (openness) of the fallopian tubes
223639578|NCT04860323|OTHER|Analytical Treatment Interruption|"Participants will stop taking their HIV medication and will stay off HIV medication unless and until the HIV levels in their blood show that their immune system is not controlling their HIV or they meet other ART re-start criteria as noted in section Detailed Description."
224227616|NCT05379569|DRUG|Fludarabine|The combination of fludarabine and cyclophosphamide has synergistic effect, which can better kill B lymphocyte, and can enhance the killing effect of pretreatment regimen on B lymphocyte tumor.
224227617|NCT03780569|DEVICE|NovoTTF-200A|Patients receive continuous TTFields treatment using the NovoTTF-200A device. TTFields treatment will consist of wearing four electrically insulated electrode arrays on the scalp. The treatment enables the patient to maintain regular daily routine.
224227618|NCT03780569|RADIATION|Radiotherapy|60Gy given in 30 2Gy fractions concomitant to temozolomide
224227619|NCT03780569|DRUG|Temozolomide|"Temozolomide(TMZ) will be administered at 75 mg/m\^2 concomitant to radiotherapy(RT) and NovoTTF-200A.~Maintenance treatment is to begin about 4 weeks after the end of TMZ/RT/NovoTTF-200A. TMZ is administered at the conventional dosing regimen for 5 days, every 28 days (i.e. 5 days of therapy, 23 days of rest). Cycle 1 is to be given at a dose of 150 mg/m\^2 p.o. daily x 5 days, dose to be escalated to 200 mg/m\^2 in the absence of toxicity."
224227620|NCT01420835|OTHER|Auriculotherapy (protocol group)|The auriculotherapy points of the protocol group will be 5 points (Liver yang1, Liver yang2, Shenmen, Kidney, Brainstem), during 45 days, twice per week, 12 sessions and assessment of the follow-up (30 days) after finishing the treatment.
223639579|NCT05338294|PROCEDURE|Laparoscopic splenectomy and azygoportal disconnection|Laparoscopic splenectomy and azygoportal disconnection is performed by the same surgical team.
223639580|NCT05076006|DRUG|PF-06700841|Active study drug
223639581|NCT05076006|DRUG|Placebo|placebo comparator
223639582|NCT04501042|PROCEDURE|Bariatric surgery|Bariatric surgery
223639583|NCT03772392|PROCEDURE|HPB resection|:Liver and Pancreas surgery - Compliance with ERAS protocol
223639584|NCT06253351|DEVICE|Hybrid closed loop (HCL)|"* Control IQ : T-Slim pump with Dexcom G6~* Smartguard : Medtronic 780G pump with Guardian G4S~* Diabeloop : Kaliedo pump with Dexcom G6"
223765112|NCT07024329|OTHER|Clinic Team Huddle|Support will be provided to clinic teams to implement a team huddle (team planning session) one week prior to clinics, to assess how additional electronic PROs data for patients participating in RESPONd impacts their ability to identify stable patients with low symptom complexity who could receive virtual care or Registered Nurse (RN) led clinic care.
223765113|NCT07024225|PROCEDURE|Endoscope|Lower endoscopy
224227621|NCT01420835|OTHER|without protocol group|The chinese auriculotherapy is a intervention used by Chinese Traditional Medicine in order to balance the body energy and to treat several kind of diseases using semi-permanent needles in specific points of the auricular pavilion. Five points will be chosen to treat stress according to the symptoms and the Chinese diagnosis.
224323282|NCT04518228|DRUG|Second-Line TB Treatment|"Participants will be receiving second-line TB treatment with at least one of the following second-line TB treatment drugs:~* Levofloxacin (LFX) 750mg - 1000mg q.d.~* Clofazimine (CFZ) 100mg q.d.~* Linezolid (LZD) 300mg - 600mg q.d.~* Bedaquiline (BDQ) 200mg three times per week (t.i.w.)~* Delamanid (DLM) 100mg b.i.d.~* Moxifloxacin (MFX) 400mg or 800mg q.d., and at least one other second-line TB treatment drug under study~Drugs will be administered consistent with the package inserts and/or instructions provided by the non-study sources who prescribe or supply the drugs to participants."
224227622|NCT00618397|DRUG|Ketamine|Ketamine administered in doses of 0.01mg/kg/hr, 0.1mg/kg/hr and 0.5mg/kg/hr to PICU patients.
224227623|NCT03065283|PROCEDURE|Diaphragm lift|The purpose is to generate the stretch of the peripheral fibers of the diaphragm, being performed with the patient in the supine position and the physiotherapist standing on the patient's head and Pulling the Your costal arch In the cephalic direction, for one minute, twice
224227624|NCT03065283|PROCEDURE|Relaxation of the diaphragm pillars|Second technique aims to promote the rhythmic stretching of the double psoas diaphragm pillars, being performed with The patient in the ventral position and the therapist standing at his side placing the ulnar border of his cephalic hand on the last ribs and his caudal hand flattened in front of the popliteal fossa of the popliteal fossa, stretching was done for one minute
224227625|NCT02886975|BEHAVIORAL|low protein diet plus α-keto acid|0.4-0.6g of proteins per kilo of body weight per day, supplemented with α-keto acid tablets
224227626|NCT04650607|OTHER|Adverse event after injection of phages|rate and description of adverse event after injection of phages
224227627|NCT00095199|DRUG|Pemetrexed|Pemetrexed 500 mg/m\^2 administered intravenously on Day 1 of 3 weeks cycle until disease progression or unacceptable toxicity for up to six (3-week) cycles.
224227628|NCT00095199|BIOLOGICAL|Cetuximab|Cetuximab 400/250 mg/m\^2 (initial/weekly) administered intravenously on Days 1, 8, and 15 (3-week) cycles until disease progression or unacceptable toxicity.
224227629|NCT00095199|DRUG|Docetaxel|Docetaxel 75 mg/m\^2 administered intravenously on Day 1 of 3 weeks cycle until disease progression or unacceptable toxicity for up to six (3-week) cycles.
224227630|NCT04036383|OTHER|vestibular exercise training|The home exercise program consists of vestibulookular reflex stimulating exercises, lower extremity somatosensory system training, static and dynamic balance exercises
224227631|NCT04036383|OTHER|Balance training with computerized balance system|Thanks to the receivers under the Neurocom balance master platform, the data of the center of gravity is transferred to the system and visual feedback is provided. Qualitative information reflects progression during static and dynamic postural exercises of the patient. To correct the load distribution, it is necessary to move the cursor to the specified targets in the exercises. The degree of difficulty of training can be increased by increasing the distance between the targets, reducing the time required to reach the targets, changing foot positions or adding upper extremity activity.
223639585|NCT04353141|DIAGNOSTIC_TEST|standardized Lung Ultrasound (LUS) examination|14 areas (three posterior, two lateral and two anterior) will be assigned a COVID-LUS score: Score 0 (Normal pattern), Score 1 (Pattern of mild disease), Score 2 (Pattern of moderate disease), Score 3 (Pattern of severe disease). Classification of LUS result: LUS NEGATIVE: Group A = Score 0 in all 14 areas OR score =1 in areas of one site (right or left). It means that score 1 is pathological only when present bilaterally; LUS POSITIVE: both group B and C have to be considered positive: Group B (MILD DISEASE) = Score 1 in at least two areas localized bilaterally and no areas with score \>1; Group C (MODERATE/SEVERE DISEASE)= Score \>2 in at least two areas localized bilaterally
223639586|NCT03865979|DEVICE|Viz RECRUIT|Viz RECRUIT includes the following modules: Viz ICH, Viz VOLUME, Viz VIEW and Viz HUB
223639587|NCT02195518|DRUG|Tenofovir disoproxil fumarate|Tenofovir disoproxil fumarate tablets supplied will be white, almond-shaped, film-coated tablets containing 300 mg of TDF. Each tablet contains the following inactive ingredients: microcrystalline cellulose, lactose monohydrate, pregelatinised starch, croscarmellose sodium, and magnesium stearate.
223639588|NCT06588881|DEVICE|nebulized application of the haemostatic surgical sealant after gastrointestinal endoscopic resection|ENDONEB, a nebulizing catheter containing the synthetic haemostatic-sealant Glubran®, is inserted in the operative channel of the endoscope until it is pushed out of the endoscope tip approximately 2 cm. The haemostatic-sealant is nebulized over the surface of the post resection mucosal defect by activating the propellant (medical-inert-gas) container. An amount of about 0.3 mL of Glubran® 2 (or more - depending on dimension of the lesion) is applied on mucosal or sub-mucosal defect in order to create a proper haemostaticsealant film.
223639589|NCT06596967|DEVICE|Heat therapy|Participants will be provided with a heat therapy system comprising a controller unit with a water pump and air pump, a portable heater, and leg sleeves featuring inner-layer water-circulating pads and an outer layer of inflatable bladders. The system is engineered to facilitate effective heat transfer through gentle pneumatic inflation, accommodating various limb dimensions. The heater will be set to warm the water to 42°C. Participants will be instructed to administer the therapy for 90 minutes daily in a seated or supine position.
223639590|NCT06596967|DEVICE|Sham|Participants will be provided with a heat therapy system comprising a controller unit with a water pump and air pump, a portable heater, and leg sleeves featuring inner-layer water-circulating pads and an outer layer of inflatable bladders. The system is engineered to facilitate effective heat transfer through gentle pneumatic inflation, accommodating various limb dimensions. The heater will warm the water to 33°C. Participants will be instructed to administer the therapy for 90 minutes daily in a seated or supine position.
223639591|NCT06586567|OTHER|Full history , clinical examination, assesment of disease activity ,Laboratory investigations ( CBC , ESR, CRP Serum creatinine and blood urea, Random plas|"2\. Complete clinical examination 3. Assessment of disease activity~The following disease activity parameters were used to assess the current activity of each disease:~* Disease activity score (DAS-28) for patients with RA.~* SLE disease activity scale (SLEDAI) for patients with SLE. 4. Laboratory investigations: Complete blood count (CBC) Erythrocyte sedimentation rate (ESR). C-reactive protein (CRP) Serum creatinine and blood urea Random plasma glucose level Liver function tests Complete urine analysis. 24 hours urinary protein (g/day) 24 hours creatinine clearance Uric acid Complement 3\& 4. Antinuclear antibody (ANA) Anti-dsDNA antibody Estimation of H.Pylori"
224227632|NCT04036383|OTHER|square step exercises|Elderly individuals in the square step exercise group will perform step exercises on 2.5x1.0 m thin cushions divided into 40 equal parts. Square step exercises include exercises that include anterior, posterior, lateral and diagonal directions of increasing difficulty. The order of the training program is at four different levels and is organized according to small, basic, regular and advanced levels.
224227633|NCT02659267|BEHAVIORAL|Interventions Group|VAMOS is a lifestyle promotion strategy, designed to promote physical activity and healthy eating habits. The intervention is composed by a weekly meeting, 12-week, in group, lasting about 60 min. In each weekly meeting, were discussed guidelines and strategies for physical activities practices in different domains and for adoption of a healthy diet. All aspects and strategies included in the VAMOS strategy are based in behavior changes theories. The participants of this group received educational material and, in the middle of the program, they received a pedometer to aid in motivation and in the self-monitoring physical activity.
224227634|NCT00217828|DRUG|citalopram|
224227635|NCT03754491|BEHAVIORAL|One stage treatment for mild and moderate cholangitis with choledocholithiasis|one stage of stone removal in mild or moderate cholangitis.
224227636|NCT06385977|BEHAVIORAL|lifestyle|Life habits and personal preferences
224227637|NCT06385977|BEHAVIORAL|sexual habits|Sexual experience and activities
224227638|NCT06385977|DRUG|medication|use of medication
224227639|NCT02032290|PROCEDURE|Assessment of Coronary Flow Reserve|
224227640|NCT02032290|PROCEDURE|Percutaneous coronary intervention|
224227641|NCT02032290|DRUG|ticagrelor loading|
224227642|NCT02032290|DRUG|Clopidogrel loading|
224227643|NCT03646253|OTHER|Analysis of radiology (standard radiographies, 2D scan sections and 3D reconstructions)|
224227644|NCT01879800|BEHAVIORAL|Acceptance and Commitment Therapy plus Illness Management|
224227645|NCT01493297|OTHER|Labeled iron solutions|Labeled iron as FeSO4 (4 mg/test meal)
224227646|NCT05684926|OTHER|Telerehabilitation yoga|Yoga consists of bodily postures or poses called asanas, breathing practices called pranayama, and meditation sections that provide focus. Children's yoga aims to teach pre-school (3-6 years) and school (7-12 years) children to breathe correctly, to practice yoga postures using their imaginations, to preserve their existing body flexibility and to teach correct posture. It consists of compositions such as postures, breathing exercises, imitations of living things in nature, memory games. They also relax with the pranayama breathing exercises done during the session. It aims to develop children's creativity through relaxation exercises, moving poses and stories told. Children's yoga also serves an artistic aspect with activities such as listening to music, singing, rhythm games, and drawing.
224227647|NCT01896297|DRUG|Pradaxa, dabigatran etexilate|75mg BID by oral
224227648|NCT02514590|DEVICE|Freedom SCS System|This Freedom SCS System is based on wireless neuromodulation technology. This technology includes octapolar stimulators with embedded receivers. The energy source is a small, external, rechargeable transmitter, which is worn by the subject. The device is programmed to have a 5-1500 Hz therapy.
224227649|NCT00846196|DRUG|risedronate DR (Phase III clinical supply)|Reference - (Phase III clinical supply) one 35 mg DR tablet administered as a single oral dose after an overnight (10-hour) fast, followed by a 4-hour fast
224227650|NCT00846196|DRUG|risedronate 35 mg DR (Commercial Tablet)|Test - (Commercial tablets) one 35 mg DR tablet administered as a single oral dose after an overnight (10-hour) fast, followed by a 4-hour fast
224227651|NCT02401893|BIOLOGICAL|Influenza Vaccine|Everyone immunized as recommended by current guidelines
224227652|NCT03429296|OTHER|Autohypnosis learning|Patients are taught how to do auto-hypnosis by an hypnotherapist before all along their chemotherapy.
224227653|NCT04277195|DIAGNOSTIC_TEST|SPAG5 Assay|Testing for SPAG5 expression in the tumour.
224227654|NCT03473470|DEVICE|forced air warming and warmed intravenous fluids|Use of warming system (forced air)
224227655|NCT03473470|DEVICE|warmed intravenous fluids|Use of warming system to have warmed intravenous fluids
224227656|NCT04062461|OTHER|Multifaceted strategy based on sending text messages(SMS)|"multifaceted strategy based on sending text messages(SMS) to patients with heart failure.~Press educational content on heart failure for the patient (symptoms of the disease, healthy habits for HF, warning signs for severity).~The text messages are about how the patient should take your drugs (evem diuretics), measure blood pressure and weight in Kg, and about signals and symptoms (shorthbreathness during the night), and about how important is practice physical exercises and don't drink alcohol."
224227657|NCT04062461|OTHER|Usual outpatient care|Educational content on heart failure for the patient (symptoms of the disease, healthy habits for HF, warning signs for severity)
224227658|NCT00388882|DRUG|tiotropium|
224227659|NCT00388882|DRUG|ipratropium bromide / albuterol|
224227660|NCT03719183|DIAGNOSTIC_TEST|Conventional Cytogenetics Studies|Metaphase cytogenetic studies will be performed in all cases according to standard methods. Chromosome preparations will be G-banded using trypsin and Giemsa, and karyotypes will be described according to the International System for Human Cytogenetic Nomenclature (ISCN) 2016.
224227661|NCT03719183|DIAGNOSTIC_TEST|Fluorescent in Situ Hybridization (FISH) Panels|"AML Panel includes:~* t(8;21) (RUNX1-RUNX1T1).~* inv(16), t(16;16) (CBFB-MYH11).~* t(9;22) (BCR-ABL).~* 11q23 KMT2A rearrangements.~* inv(3) MECOM rearrangements.~* DEK-NUP214 rearrangements.~* Del(5q) Deletion~* Del(7q) Deletion~Acute Promyelocytic Leukemia panel includes:~* t(15;17) (PML-RARA).~* 17q RARA rearrangements"
224227662|NCT03719183|DIAGNOSTIC_TEST|Multiplex FISH (M-FISH)|24-color karyotyping
224227663|NCT02496871|BEHAVIORAL|Group Phone Calls|University of Kansas Weight Management Program - Group Phone calls
223639592|NCT06585813|PROCEDURE|dental implant|we placed our implants and simultaneously grafted either fibroguide or CTG and after 3 months we did the second stage surgery
223639593|NCT06585813|PROCEDURE|Fibrogide membrane|we were comparing the efficacy of Fibrogide with the Connective tissue graft
223639594|NCT06585813|PROCEDURE|connective tissue graft|the control group was the connective tissue graft group and the test group was the Fibrogide group
223639595|NCT06585813|PROCEDURE|second stage|second stage to determine the thickness gained after the graft and to place a healing abutment
224227664|NCT02496871|BEHAVIORAL|Social Media|University of Kansas Weight Management Program - Social Media (Facebook)
224227665|NCT04896359|DIETARY_SUPPLEMENT|Vitamin C|12.5 grams of ascorbic acid
223639596|NCT06589609|BIOLOGICAL|FluBHPVE6E7|Intratumoral administration for first dose followed by intramuscular administration for subsequent doses at recommended dose level and determined schedule.
223639597|NCT06595511|DEVICE|Sensory Entrainment-Integrated Cognitive Game Kit|Active comparator group will engage with the 40 Hz sensory entrainment-integrated cognitive game kit for one hour a day, at least five days a week, for three months.
223639598|NCT06592885|PROCEDURE|Atraumatic Restorative Treatment in treatment of carious primary molars|ART, which took place in Tanzania during the mid-1980s, is a conservative approach involving the removal of carious lesions using hand instruments, followed by the application of a glass ionomer restoration. This technique aims to be minimally invasive, promoting the preservation of tooth structure. The ART technique, employed in situations where ideal clinical conditions are challenging to achieve, has demonstrated effectiveness as a reliable method for managing cases where conventional treatment methods face resistance from children . However, concerns exist regarding the longevity of ART restorations and the impact of operator skill on outcomes.
224227666|NCT04896359|OTHER|Placebo|vehicle
224227667|NCT04783363|OTHER|Snoezelen session|before one of two repeated invasive care
224227668|NCT05786807|DRUG|K-CAB|Tegoprazan 50 mg 1 tab twice daily Amoxicillin 500mg 2 cap twice daily Clarithromycin 500mg 1tab twice daily
224227669|NCT03591978|DIAGNOSTIC_TEST|Isolation of Circulating Pulmonary Cells in peripheral blood|Blood samples from healthy volunteers will be collected in EDTA tubes (Vacutainer, BD Bioscience). CPC will be isolated according to previous patented method (P201730724)
224227670|NCT05151978|DIAGNOSTIC_TEST|Transcranial Doppler|Transcranial Doppler on middle cerebral arteries
224227671|NCT05127083|RADIATION|Patients will be treated with localized PBM with a diode laser|Toluidine blue was applied on the lesions.The tissue were irradiated with a 660-nm diode laser InGaAlP
223639599|NCT06592885|PROCEDURE|Hall Technique in treatment of carious primary molars|"The Hall technique, proposed by Norna Hall in the 1980s, involves the placement of preformed metal crowns on primary molars without any tooth preparation or local anesthesia.~Advocates of the Hall technique emphasize its simplicity, reduced need for traditional drilling, and high reported success rates in clinical studies.~However, concerns have been raised regarding long-term aesthetics and potential psychological impacts due to the visibility of metal crowns."
223639600|NCT06589011|OTHER|Pressure Support Ventilation|The initial pressure support ventilation setting was a driving pressure of 7 cm H2O, PEEP of 5 cm H2O, and safety backup ventilation of 12 breaths/min
223639601|NCT06589011|OTHER|spontaneously assisted breathing|The basic strategy was to allow the patient to breathe spontaneously and only help respiration if necessary, with intermittent manual assistance.
223639602|NCT06602284|COMBINATION_PRODUCT|Dermapen 4™|Dermapen 4™ conjunction with MG-CLR
223639603|NCT06600724|OTHER|Standard of Care|Beginning at the screening visit, participants will receive weekly treatment with standard of care (cleaning, debridement, ulcer moisture balance, and offloading) until ulcer closure, or a maximum of 12 weeks, whichever occurs first.
223639604|NCT06600724|OTHER|EPIEFFECT|Participants will receive weekly applications of EPIEFFECT and Standard of Care until ulcer closure, or a maximum of 12 weeks, whichever occurs first
223639605|NCT06600724|OTHER|EPIXPRESS|Participants will receive weekly applications of EPIXPRESS and Standard of Care until ulcer closure, or a maximum of 12 weeks, whichever occurs first
223639606|NCT06588517|DRUG|Pirfenidone Modified-Release Tablets|take the tablet under fed condition, 1 tablet at a time, once a day.
223639607|NCT06588517|DRUG|Pirfenidone Tablets|ake the tablet under fed condition, 1 tablet at a time, three times a day.
223639608|NCT06599970|OTHER|No intervention|This is an observational study. No experimental interventions included. The mobility of people will be studied.
223639609|NCT06601829|OTHER|abdominal ultrasound|abdominal ulterasound showing multiple cysts in the kidnets and hepatic fibrosis
223639610|NCT06601283|DRUG|Vitmain C plus herbal medicine|nab-paclitaxel (120 mg per square meter of body-surface area) followed by gemcitabine (1000 mg per square meter) on days 1, 8, and 15 every 4 weeks. Vitamin C 300 mg/day, TID, PO. Reishi, 2 g/day, BID, PO. Cordyceps, 2 g/day, BID, PO.
223639611|NCT06595745|GENETIC|Wolbachia induced incompatible mating|The intervention will be performed by weekly release of male Aedes aegypti carrying Wolbachia (wAlbB strain) to mate with wild females, resulting in the death of their eggs for birth control. Before release, these males will be irradiated with X-rays to minimize the chance of any residual fertile female releases. The intervention will lead to Ae. aegypti population suppression or even elimination and preventing dengue transmission in release sites.
223639612|NCT06595745|COMBINATION_PRODUCT|Standard traditional chemical mosquito control|Traditional and commonly used chemical insecticide will be applied to reduce the mosquito population
223639613|NCT04071990|BEHAVIORAL|FB-CBGT|CBGT for OCD patients, with Involvement of family members (partner, parent, sibling, ...)
223639614|NCT04071990|BEHAVIORAL|CBGT|CBGT for OCD patients, without involvement of family members
224227672|NCT00832078|DEVICE|SpeediCath Compact Male|CH 12 hydrophilic coated intermitten compact catheter
224227673|NCT00832078|DEVICE|Speedicath|CH 12 hydrophilic coated intermittent coated catheter
223639615|NCT06402773|DEVICE|The Signati Separo™ Vessel Sealing System|Vessel Sealing System
223639616|NCT06992570|DIAGNOSTIC_TEST|Quantification of mild trauma brain injury risk|Measure the incidence and severity of mTBI among soldiers engaged in high-risk training activities. (e.g. parachute jumps, high-caliber firearms shooting, artillery fire, explosions). Concentration of brain injury biomarkers (GFAP, UCH-L1) in blood samples collected within 24 hours post-exposure
223639617|NCT06992570|OTHER|Biomechanical Analysis of Head Impact Forces|Evaluate the mechanical forces experienced by soldiers during high-risk activities using wearable accelerometers and high-speed video analysis. Peak head acceleration (g-force) and pressure wave analysis during training activities.
223639618|NCT00526812|DRUG|RTA 744|Aqueous solution added to 10%D/W and infused over 2 hours on three consecutive days. 5 mg vials contain 1 mg/ml.
223765114|NCT07018986|OTHER|MIND Diet|a combination of the Mediterranean and DASH diets emphasizing consumption of high-nutrient, plant-based foods such as green leafy vegetables, nuts, berries, fish, and olive oil while limiting intake of foods high in saturated fat, pre-processed snacks, sugar, red and processed meat.
223765115|NCT07018986|OTHER|Usual Diet|Check-in sessions for the usual diet arm will focus on general health (e.g., healthy hair, skin, eyesight). None of the topics will include dietary information for the usual diet arm.
224227674|NCT01226277|DRUG|GDC-0917|Oral repeating dose
224227675|NCT03386097|OTHER|Collection of interstitial fluid, skin biopsies and blood|Collection of interstitial fluid, skin biopsies and blood
224227676|NCT01767597|OTHER|ELISA testing|Enzyme-linked immuno-assay (ELISA) will be used to determine hepatitis B surface antigen (HBsAg) and anti-HBsAg antibody (anti-HBs Ab) status. Results will be given after test results are available (8-10 days).
224227677|NCT01767597|OTHER|Rapid testing|A rapid test will be performed to determine the subjects' hepatitis B surface antigen (HBsAg, using VIKIA®) and anti-HBs antibody status (anti-HBs Ab, using Quick ProfileTM). Results will be given the same day.
224323283|NCT04518228|DRUG|Doravirine (DOR)|Administered consistent with the package inserts and/or instructions provided by the non-study sources who prescribe or supply the drugs to participants
224227678|NCT05566665|DIAGNOSTIC_TEST|Collection of blood and bronchoalveolar samples to study Pharmacokinetics of ceftazidime/avibactam, meropenem/varbobactam, ceftolozane/tazobactam, or cefiderocol|"The antibiotic treatment with ceftazidime/avibactam, meropenem/vaborbactam, ceftolozane/tazobactam, or cefiderocol will follow the standard clinical practice.~The concentration of ceftazidime/avibactam, meropenem/vaborbactam, ceftolozane/tazobactam, or cefiderocol will be measured at specific timepoints in plasma samples and bronchoalveolar lavage samples, and a PK analysis and modeling will be carried out ."
224227679|NCT02961920|DEVICE|IE ratio 1:1|Set an I:E ratio1:1 in the mechanical ventilator during spine surgery in the prone position in obese patients.
224227680|NCT02961920|DEVICE|IE ratio 1:2|Set an I:E ratio1:2 in the mechanical ventilator during spine surgery in the prone position in obese patients.
224227681|NCT00050921|DRUG|somatropin|
224227682|NCT00050921|BIOLOGICAL|Hepatitis A virus, inactivated|
224227683|NCT00050921|DRUG|Keyhole-Limpet Hemocyanin|
223765116|NCT07023601|OTHER|Sentinel Lymph Node Biopsy in first local recurrent vulvar carcinoma|All patients will undergo a local tumor radical excision and unilateral (if medial border \> 1 cm from midline) or bilateral (medial border \< or equal to 1 cm from midline) Sentinel Lymph Node procedure, followed by bilateral Inguinophemoral lymphadenectomy. .
223765117|NCT07023744|DRUG|Placebo|Placebo arm: participants will receive Placebo MPL-012 oil only through the trial participation. MPL-012 is produced by MediPharm Labs, each mL contains 0mg CBD and 0mg THC.
224227684|NCT05379543|OTHER|Echocardiography|Echocardiography is performed using a GE Vingmed Ultrasound System (GE Healthcare, Horten, Norway), by an experienced expert. Morphological and functional parameters of the heart are measured in a consistent manner.
224227685|NCT04653870|OTHER|cyriax manipulation lumber|"In group A patients were treated with conservative therapy (hot pack, Kaltenborn soft tissue techniques and home plan) and Cyriax manipulation.~Exercises (Guided low back exercises, 3-5times/day). Ankle pumping (5-10 repetition with 15-20 second hold), Quads Isometric (5-10 repetition with 15-20 second hold), Hams \& Calf stretching (5-10 repetition with 15-20 second hold), Bridging (5-10 repetition with 15-20 second hold), Prone Back extension (10 repetition) Precaution Prevent yourself from sitting low on ground, Sitting with support will be directed and be careful during driving and ascending stairs.~Cyriax Manipulation: 2-3 repetitions/session, 2 session/week Lumbar spinal manipulation Rotation Techniques Lumbar spinal manipulation Extension Techniques Lumbar spinal manipulation Antideviation Techniques total of 4 session were given. 2 session/week."
224227686|NCT04653870|OTHER|lumber decompression|"Group B: In group B patients were treated with conservative therapy (hot pack, Kaltenborn soft tissue techniques and home plan) and Decompression Session.~Conservative therapy: Same as Group A~Lumbar spine decompression:~30 Minutes Session (generalized time for every one) . On the account of MRI description level is recommended and acknowledged by MRI the level of disc protrusion, decompression is operated. Patient is lying on table facing upward. For locking of the patient's body it was secured by pelvis and thoracic straps. One part of the decompression table is immobile other is movable. Bottom extreme part of the table is mobile.~Estimation of weight of patient is first thing to do. We calculated it by division of whole weight by 5 and that 5th segment of weight was utilized as an interventional pound for decompression. ."
224227687|NCT02990832|DEVICE|Exciton|"Exsalt® Wound Dressings will be applied by the physician/nursing staff.~The test product, exsalt® Wound Dressings (0.4 mg Ag/cm2) will be applied after wound cleansing or debridement if required.~Dressings will be changed weekly, either at the out-patient facility or at home with provided dressings. At regular intervals throughout the study, as per the existing Diabetes Foot Care Clinical Care Pathway, wound assessment including size determination, Exsalt Wound Assessment Form, any adverse events will be reported, with tracing and/or photography included where available.~Maximum treatment course will be 28 days (end of study) or until wound closure."
224227688|NCT00208156|DRUG|Mifepristone|
224227689|NCT02006485|DRUG|Ublituximab + TGR-1202|Ublituximab IV infusion TGR-1202 oral daily dose
224227690|NCT02006485|DRUG|Ublituximab + TGR-1202 + ibrutinib|Ublituximab IV infusion TGR-1202 oral daily dose Ibrutinib oral daily dose
224227691|NCT02006485|DRUG|Ublituximab + TGR-1202 + bendamustine|Ublituximab IV infusion TGR-1202 oral daily dose Bendamustine IV infusion
224319230|NCT04366687|BEHAVIORAL|Smart Parents - Safe and Healthy Kids|Smart Parents - Safe and Healthy Kids (SPHSK) is a module designed to be added to existing evidence-based parent education programs. Because the module builds off of the core parenting skills developed in existing parent education programs, the module can be delivered in one session. SPSHK is comprised of three key CSA-prevention components: healthy child sexual development, parent-child communication about sex and sexual behaviors, and CSA-specific safety strategies such as vetting a babysitter and monitoring one-on-one time with adults. Behaviorally based, the module presents developmentally comprehensive information to parents of children 0-13 and utilizes role-playing scenarios and activities to maximize parents' use of learned skills.
224323284|NCT06132919|DRUG|MC2-25 cream|Topical application
224323285|NCT06132919|DRUG|MC2-25 vehicle|Topical application
223639619|NCT00526812|DRUG|RTA 744 injection|Aqueous solution in 1mg/ml. Doses are escalated. Drug is infused intravenously over 2 hours one day a week for four consecutive weeks.
223639620|NCT06992193|DEVICE|Digital Anesthesia|Computer-controlled intraosseous anesthesia system (Dental Hi Tec, France) used to deliver 1.3 mL of 4% articaine with 1:200,000 epinephrine in two stages: gingival and intraosseous injection. The system provides consistent flow and reduced pain perception in children.
223639621|NCT06992193|DRUG|Infiltration Anesthesia|1 mL of 2% lidocaine with epinephrine was delivered via buccal infiltration using a conventional aspirating syringe and 27-gauge short needle. Topical benzocaine gel was applied for 30 seconds prior to injection.
223639622|NCT06992193|DRUG|Mandibular Block|1 mL of lidocaine was administered using the inferior alveolar nerve block technique via a conventional dental syringe and 27-gauge long needle. Negative aspiration was confirmed prior to slow deposition.
223639623|NCT06599164|OTHER|Anthrogenic Muscle Inhibition (AMI) Assessment Protocol|This study involves evaluating Anthrogenic Muscle Inhibition (AMI) of the vastus medialis muscle in futsal players. The intervention includes assessments of muscle strength, AMI using electromyography, ultrasound evaluation, and single-leg vertical jump tests. These evaluations are conducted at different stages throughout the season: pre-season, 4 months in, and at the end of the season. The goal is to compare AMI levels and muscle function between players with ACL injuries and those without.
223765118|NCT07023744|DRUG|CBD Isolate|CBD Isolate: MPL-015 is a CBD isolate, produced by MediPharm Labs, each mL contains 100mg CBD and 0mg THC.
223765119|NCT07023744|DRUG|CBD CHE|CBD-CHE arm: MPL -016 is a CBD-enriched cannabis herbal extract, produced by MediPharm Labs, each mL contains 100mg of CBD and 3mg of THC.
223765120|NCT07024992|BEHAVIORAL|ESCAPE app + NRT|ESCAPE is a mobile intervention that targets anxiety sensitivity among Black adults who smoke cigarettes and have HIV. This intervention is framed within the cultural context of interoceptive stress among Black adults who smoke, which is supported by theory, empirical evidence, and characteristics of this group. The intervention employs a variety of features to educate users on how to deal with stress, anxiety, and nicotine withdrawal symptoms. The app contains a series of on-demand features, including a coping toolkit, stress management trainings, and a series of educational videos. ESCAPE also utilizes Ecological Momentary Assessments (EMAs) to gather information and provide personalized messages to users in real time. All participants will receive free nicotine replacement therapy (NRT).
224227692|NCT03760393|BEHAVIORAL|(SB-related planning + daily text messages)|"Participants will receive a one-on-one behavioral counseling session, and planning sheet as reference for developing strategies as part of their Action/Coping Plan. Participants will be asked to form 3-4 actions plans specifying when, where, how, and for how long they would reduce occupational (student) sitting time; and anticipate potential barriers and identify ways they could be overcome. Strategies will explicitly focus on the ultimate objective of increasing break frequency to every 30-45 minutes, achieving a break duration of 2-3 minutes, and increasing time spent standing and engaged in light-intensity PA, in the occupational domain (i.e. as a student; during school-related activities).~Participants will also receive sedentary behaviour-related text messages twice daily, depending on their preferences and schedule, which will act as mini-booster interventions."
224227693|NCT03639428|DRUG|Midazolam|All subjects received a sigle 0.3mg/kg midazolam dose os ADV6209
224227694|NCT04118231|OTHER|Dry needling|Group 1: Dry needling Group 2: static stretching Group 3: IASTM
224227695|NCT04741035|OTHER|Modified sternal precautions|"Use pain and discomfort to guide the safe use of the arms Avoid pushing or pulling with one arm Use both arms close to the body during lifting Use of arms is possible, but keep them close to the body Avoid stretching one or both arms backwards at the same time Use a cushion or perform sternal preservation technique (crossing the arms in a 'self-hugging 'posture) when coughing.~When transferring, roll onto the side, ease the legs over the edge of the bed and carefully use the arms to sit up from a lying position"
224227696|NCT04741035|OTHER|Conventional sternal precautions|Avoid pushing or pulling through the arms Avoid one-arm (unilateral) activity Limit the elevation of the arms to 90 degrees Avoid lifting objects heavier than 2 kg Use a cushion or perform sternal preservation technique (crossing the arms in a 'self-hugging' posture) when coughing Limit the use of the arms when transferring from sitting to standing and getting out of bed Avoid placing the arms behind the back
224227697|NCT02890823|DRUG|Cholecalciferol|
224227698|NCT00202137|BEHAVIORAL|Home blood pressure monitoring|Monitor blood pressure using home blood pressure monitor
224227699|NCT00202137|BEHAVIORAL|Physician monitoring of blood pressure|Blood pressure measured as standard care from physician (no home monitor given for blood pressure monitoring)
224227700|NCT02729155|PROCEDURE|RIPre|Preconditioning 200 mmHg x 5 minutes before procedure
224227701|NCT02729155|PROCEDURE|RIPost|Postconditioning 200 mmHg x 5 minutes after procedure
223639624|NCT06866431|PROCEDURE|Piezoclean|"Following local anesthesia and periotomy, flapless extraction will be performed using forceps and elevators. After socket debridement with Lucas surgical curette, the extraction sockets will be randomly divided into test and control group.Test group sites will receive 90 seconds of ultrasonic cavitation treatment with 0.9% sodium chloride via a specific insert (Piezoclean, Esacrom, Imola, Italy) driven by a piezoelectric device with the following modalities: i) piezo settings: SURGERY 1 U 040 V 080 P 100; ii) no pressure should be applied to prevent the steel insert from coming into contact with the bone; iii) do not create a complete seal to avoid heating the liquid, which could cause potential discomfort or harm to the patient.~An X suture will be then applied using non-resorbable synthetic monofilament."
223639625|NCT06866431|PROCEDURE|Control|"Following local anesthesia and periotomy, flapless extraction will be performed using forceps and elevators. After socket debridement with Lucas surgical curette, the extraction sockets will be randomly divided into test and control group. In control group, a simple 0.9% sodium chloride irrigation (control group) will be performed.~An X suture will be then applied using non-resorbable synthetic monofilament."
223639626|NCT04289935|PROCEDURE|Vacuum assisted biopsy (VAB)|The trial intervention consists of a diagnostic interventional procedure, US-guided or mammographically guided VAB post-NAC, prior to the standard breast surgery.
224227702|NCT02729155|PROCEDURE|Sham-Pre|Sham 10 mmHg x 5 minutes before procedure
224227703|NCT02729155|PROCEDURE|Sham-Post|Sham 10 mmHg x 5 minutes after procedure
224227704|NCT02070848|OTHER|Session 1-4|Familiarization sessions to knee-extensor exercise separated by 72h recovery
224227705|NCT02070848|OTHER|Session 4|After the last familiarization session, 1 maximal incremental test on a bicycle, followed by 72h rest
224227706|NCT02070848|OTHER|Session 5|2 maximal incremental tests of knee-extension exercise (concentric vs eccentric), separated by 3h rest.
224227707|NCT04352374|OTHER|Aerobic exercise|a Low-Intensity Aerobic Exercise with Borg scale RPE at 11.
224227708|NCT04352374|DEVICE|Device guided breathing|The device consists of a control box, headphones and a respiratory rate monitor attached as a sensor belt around the user's chest.
224227709|NCT00736320|DRUG|ABVD (Adriamycin, Bleomycin, Vincristine, Dacarbazine)|chemotherapy with 2 cycles of ABVD (day 1 + 15)
223639627|NCT00029484|BEHAVIORAL|Tai chi chih|
223639628|NCT03824769|BEHAVIORAL|Weight Loss Maintenance + Healthy Thinking|Contingent upon participants losing 5% of body weight or more in Phase I (weight loss) of this trial, participants will receive a 4-month behavioral weight maintenance intervention consisting of 7 sessions that focus on evidence-based weight management strategies focused on diet, exercise, and behavioral skills. In this treatment, participants will be asked to read short passages related to nutrition and a healthy lifestyle through our study website twice a day for the duration of treatment.
223639629|NCT03824769|BEHAVIORAL|Weight Loss Maintenance Treatment + Future Thinking|Contingent upon participants losing 5% of body weight or more in Phase I (weight loss) of this trial, participants will receive a 4-month behavioral weight maintenance intervention consisting of 7 sessions that focus on evidence-based weight management strategies focused on diet, exercise, and behavioral skills. In this treatment, participants will create descriptions of upcoming positive events and will be asked to read short passages through our study website at least twice a day for the duration of treatment.
223639630|NCT01815346|PROCEDURE|Acupuncture|"One group receives acupuncture 2 times a week for 6 weeks.~One group receives acupuncture 3 times a week for 4 weeks.~Participants receive acupuncture to the arms, legs, and abdomen. The acupuncture needles will be left in place for about 20 minutes."
223639631|NCT01815346|BEHAVIORAL|Questionnaires|Three questionnaires completed at baseline, midpoint, and four weeks after completion of acupuncture treatment.
223639632|NCT01815346|OTHER|Hand Function and Balance Tests|Tests completed at baseline, midpoint, and four weeks after completion of acupuncture treatment. These tests should take about 20 minutes to complete.
223639633|NCT04266145|DRUG|intravenous dexmedetomidine|adductor-canal-blockade with 20 mL 0.25% levobupivacaine plus 1 mL normal saline while, the intravenous solution; consists of 0.5µg.kg-1 dexmedetomidine diluted in 20 mL normal saline
224319231|NCT04366687|BEHAVIORAL|Parents as Teachers|Parents as Teachers (PAT) is a parent-support program delivered to parents of children under five and focuses on improving parenting skills through parent-child interactions, development centered parenting, and general well-being. PAT has demonstrated positive effects on child and parent outcomes related to school readiness.
224227710|NCT00736320|RADIATION|20 Gy IFRT (Involved Field Radiotherapy)|20 Gy Involved Field Radiotherapy
224227711|NCT02232074|OTHER|Patient navigation enhanced with legal support|
223639634|NCT04266145|DRUG|adductor canal block dexmedetomidine|adductor-canal-blockade with 20 mL 0.25% levobupivacaine plus 1 mL of 0.5µg.kg-1 dexmedetomidineline while, the intravenous solution;consists of 20 mL normal saline
223639635|NCT05410210|OTHER|Pharmaceutical care|The clinical pharmacists will conduct medication reviews, patient education, and counseling. Moreover, the clinical pharmacists will identify drug-related problems (DRPs) and provide the information through written pharmacist notes to physicians at the clinic.
223765121|NCT07024992|BEHAVIORAL|quiSTART app + NRT|quitSTART is a smartphone-based National Cancer Institute (NCI) intervention for standard mobile smoking cessation treatment. The intervention contains features that allow its' users to better understand their smoking patterns, and build skills needed to become and stay smoke free. The app allows users to track cravings and delivers motivational messages to users for each craving they track. All participants will receive free nicotine replacement therapy (NRT).
224227712|NCT03843957|OTHER|mPATH-CRC|mPATH-CRC is a self-administered iPad program that patients eligible for CRC screening use in primary care clinics to help them receive CRC screening.
224227713|NCT03843957|OTHER|mPATH-Checkin|The mPATH-CheckIn program includes health questions to assist clinics with patient check-in, thereby incentivizing its use for all patients.
224319232|NCT03886883|OTHER|Exercise induced hypoalgesia (EIH)|An EIH response was induced by a 3-minute isometric contraction of the hand flexor muscles at 25% of maximal voluntary contraction (MVC).
224319233|NCT03886883|OTHER|Static stretch (SS)|Two bouts of 30 seconds of static stretching (SS) of the knee flexors.
224319234|NCT03886883|OTHER|Rest|The participants rested in a seated position for 10 minutes
224319235|NCT03886883|OTHER|Conditioned pain modulation (CPM)|A CPM response was induced by way of the cold pressor test.
224319236|NCT00482781|BIOLOGICAL|Infanrix|
223639636|NCT01550224|DRUG|Temozolomide|An alkylating agent administered for induction per standard of care at 200 mg/m²/day for 7days.
223639637|NCT01550224|DRUG|Vorinostat|A synthetic hydroxamic acid derivative with antineoplastic activity administered for both groups at 500 mg orally 3 times daily for 3 days prior to Temozolomide 200 mg/m²/day.
223639638|NCT04512157|BEHAVIORAL|Promoting Alternative Thinking Strategies (PATHS), Preschool Edition|PATHS® is a universal teacher implemented, and school-based intervention that aims to give preschool children a strategically timed boost in social emotional competence. Specifically, PATHS® encourages the use of interactive techniques to bolster children's ability to self-regulate, increase their adeptness at social cognitive problem solving, as well as to gain insight into their emotions and emotions of others.
223639639|NCT04269668|DEVICE|Medtronic Minimed 670G 3.0 HCL|Hybrid closed loop system
223639640|NCT04269668|DEVICE|Medtronic Minimed 670G 4.0 AHCL|Advanced hybrid closed loop system
223639641|NCT04664452|OTHER|Questionnaire|Participants will be asked to fill the questionnaire
223639642|NCT01281124|DRUG|Azacitidine|Given subcutaneously
223639643|NCT01281124|OTHER|Diagnostic Laboratory Biomarker Analysis|Correlative studies
223639644|NCT01281124|OTHER|Pharmacological Study|Correlative studies
223639645|NCT03038100|DRUG|Paclitaxel|Paclitaxel 175 milligrams per square meter (mg/m\^2) IV infusion on Day 1 of each 21-day cycle
223639646|NCT03038100|DRUG|Carboplatin|Carboplatin at a dose to achieve a target area under the curve (AUC) of 6 milligrams per milliliter\*minute (mg/mL\*min) on Day 1 of each 21-day cycle for a total of 6 cycles
223639647|NCT03038100|DRUG|Atezolizumab|Atezolizumab 1200 mg IV infusion on Day 1 of each 21-day cycle
223639648|NCT03038100|DRUG|Bevacizumab|Bevacizumab 15 milligrams per kilogram (mg/kg) IV infusion as per the schedule specified in respective arms
223639649|NCT03038100|DRUG|Atezolizumab Placebo|Placebo matching to atezolizumab on Day 1 of each 21-day cycle
223639650|NCT01697670|DRUG|Photodynamic therapy with Gliolan|Laser light illumination with red light at 635 nm using a cylindrical light diffuser (Model RD, Medlight SA) in a white diffusing inflatable balloon catheter (model CDB OEB, Medlight SA) at a fluence rate of 65.5 mW/cm2 over 153 s resulting in a total light dose of 10 J/cm2 is performed 3 hours after administration of 15mg/kg bodyweight Gliolan
223639651|NCT00013221|BEHAVIORAL|Exercise|
223639652|NCT03484208|OTHER|osteoporotic fracture liaison service|a specific nurse calls patient and propose them to follow the osteoporotic fracture liaison service
223639653|NCT00404144|DEVICE|Drug Eluting Balloon|PCI of small vessels single arm study
223639654|NCT05760040|OTHER|vırtual reality|During the intrauterine device application, 40 women who were included in the virtual reality group will be put on virtual reality glasses and watched the video.
223639655|NCT05760040|OTHER|Control Group|Routine hospital protocol will be applied to 40 women included in the control group while intrauterine device application is being made.
223639656|NCT02651207|OTHER|Questionnaire based study looking at pain scores felt by patients either having a lidocaine injection or ethyl chloride spray prior to insertion of a contraceptive implant|
223765122|NCT07024992|BEHAVIORAL|Control (CTRL)|The CTRL group will complete the same baseline survey, follow-up surveys, and ecological momentary assessments as the ESCAPE app + NRT and the quitSTART app + NRT group. All participants will receive free nicotine replacement therapy (NRT). They will not receive additional intervention content.
223765123|NCT07025356|DRUG|Implantation of a trigeminal Vagus cervical nerve stimulator system|The NS 100 is a medical device used for the treatment of diabetic neuropathy pain. Routine observational monitoring will be performed
224319237|NCT00482781|BIOLOGICAL|Pediatrix|
224319238|NCT04063150|BIOLOGICAL|fIPV (0.1 mL) ID|Fractional dose of inactivated poliovirus vaccine that protects against types 1, 2, and 3 (all polio serotypes). Given as a 0.1 milliliter (mL) dose (fractional) by intradermal (ID) injection in lieu of the full 0.5 mL dose.
224227714|NCT03843957|OTHER|"high touch Implementation strategy"|"The high touch strategy consists of pre-implementation activities, training, and ongoing support.~Pre-Implementation Activities~* Clinic champion identified.~* Study team meeting with clinic champion~* Implementation adaptations as needed for clinic flow~Implementation Kick-Off (Day 1)~• On-site training with key clinic personnel~Months 1 - 6~* Phone/email technical support, as needed.~* Access to web-based QA dashboard~* Monthly program usage report sent to clinic champions~* Scheduled phone-calls with clinic champion to review QA data and explore potential barriers.~* Implementation adaptations as needed for clinic flow~* Goal-triggered follow-up on-site trainings~* Additional on-site trainings as requested.~Months 7 - 12~* Phone/email technical support, as needed~* Access to web-based QA dashboard"
224227715|NCT03843957|OTHER|"low touch Implementation Strategy"|"Clinics randomized to receive the low touch implementation strategy will receive:~Pre-Implementation Activities~• N/A~Implementation Kick-Off (Day 1)~• On-site training with key clinic personnel~Months 1 - 6~* Phone/email technical support, as needed.~* Access to web-based QA dashboard~Months 7 - 12~* Phone/email technical support, as needed~* Access to web-based QA dashboard"
224319239|NCT04063150|BIOLOGICAL|fIPV (0.1mL) IM|Fractional dose of inactivated poliovirus vaccine that protects against types 1, 2, and 3 (all polio serotypes). Given as a 0.1 milliliter (mL) dose (fractional) by intramuscular (IM) injection in lieu of the full 0.5 mL dose.
223639657|NCT06331936|BEHAVIORAL|Emotion regulation|Each participant will attend four intervention sessions. They will also be invited to a booster Session, where they will be invited for interviews to share what they have gained from the sessions. The contents of the intervention and the booster session are as follows: (1) understand emotions, (2) attention and positivity, (3) emotional regulation, (4) connectedness and intimacy, and (5) review and sharing.
223639658|NCT01744262|DRUG|Total intravenous anesthesia|Anesthesia induction with intravenous propofol (effect site concentration 2.5 µg/mL) and remifentanil (effect site concentration 3 ng/mL) using target controlled infusion (TCI). Anesthesia maintenance with propofol effect site concentration 1.5\~4 µg/mL and remifentanil effect site concentration 2\~5 ng/mL.
223639659|NCT01744262|DRUG|Inhalation Anesthesia|Anesthesia induction with intravenous propofol bolus of 1.5\~2.5 mg/kg and remifentanil (effect site concentration 3 ng/mL)using target controlled infusion (TCI). Anesthesia maintenance with sevoflurane 1.5\~2.0 % and remifentanil effect site concentration 2\~5 ng/mL.
223639660|NCT03109964|DEVICE|Bipolar coagulation forceps (ETHICON inc.)|Hemostasis of the base of the ovarian cyst by utilization of a bipolar coagulation device.
223639661|NCT03109964|DEVICE|SURGIFLO hemostatic matrix (ETHICON inc.)|Hemostasis of the base of the ovarian cyst by utilization of a an absorbable gelatin based matrix known as SURGIFLO.
223639662|NCT04899596|OTHER|No intervention|No intervention
223639663|NCT02739906|DRUG|BioChaperone Human Insulin (HinsBet®)|BioChaperone Human Insulin (HinsBet®) individualised single subcutaneous injection followed by test meal intake
223639664|NCT02739906|DRUG|Insulin Lispro (Humalog®)|Insulin Lispro (Humalog®) individualised single subcutaneous injection followed by test meal intake
223639665|NCT02739906|DRUG|Regular human insulin (Huminsulin® Normal)|Regular human insulin (Huminsulin® Normal) individualised single subcutaneous injection followed by test meal intake
223639666|NCT06249802|DRUG|Nebivolol|12-month intake of medication
223765124|NCT07025356|DEVICE|Implantation of a neurostimulator system for trigeminal vagal cervical nerve stimulation|The medium term outcomes of neurostimulation will be assessed on diabetic neuropathy pain, glucose and drug usage
224227716|NCT00536926|DEVICE|Home spirometry with data transfer via cell phone|home spirometry recording
224227717|NCT00536926|DEVICE|Home spirometer with BT-cellphone|Data transfer of home spirometry recordings via bluetooth to clinical database.
224227718|NCT00536926|DEVICE|Home spirometer w/o BT|Standard home spirometry
224227719|NCT01871467|DRUG|Sargramostim|
223639667|NCT06249802|DRUG|Placebo|12-month intake of matching placebo
223639668|NCT01113086|DEVICE|Transcranial direct current stimulation|Subjects will receive a total of 10 stimulation sessions on consecutive days, Monday- Friday for a total of two weeks. During each session, 2 mA of tDCS will be applied for 20 minutes over the left or right DLPFC (active or sham).
223639669|NCT04381754|DEVICE|Passeo-18 Lux|Patients with significant inflow or outflow stenosis between the anastomosis to the axillary-subclavian vein junction, as defined by the insertion of the cephalic vein, who had undergone fistuloplasty with Passeo-18 Lux
223639670|NCT00478543|DRUG|Furosemide|
223765125|NCT07025603|BEHAVIORAL|The social ABCs|"The Social ABCs, a parent-mediated intervention for toddlers with suspected or confirmed Autism Spectrum Disorder (ASD), originally developed in Canada (Brian et al., 2016). It is based on principles of Pivotal Response Treatment (PRT, grounded in Applied Behavioural Analysis). The two main goals of the intervention: early functional verbal communication and positive affect sharing in the context of play and caregiving activities.~The current study follows the Group Social ABCs protocol, a 6-week parent-mediated intervention designed to support early social communication in young children with autism. The program is delivered at two research sites: Soroka and Hebrew University of Jerusalem. Each week, parents participate in: One group session via Zoom, led by a trained Social ABCs coach, with 3-5 parents per group. These sessions introduce strategies and provide peer support, and one to two individual face-to-face coach (See #17-745 for more information)."
224227720|NCT04480463|DRUG|SCD411|IVT (intravitreal) injection
224227721|NCT04480463|DRUG|Aflibercept|IVT injection
224227722|NCT02857881|PROCEDURE|De-epithelization and therapeutic photokeratectomy|
224227723|NCT00290121|DRUG|Olanzapine|
224227724|NCT05170555|DRUG|68Ga-PSMA|Intravenous injection of one dosage of 74-148 MBq (2-4 mCi) 68Ga-PSMA. Tracer doses of 68Ga- PSMA will be used to image lesions of Renal Cell Carcinoma by PET/CT.
224227725|NCT05170555|DRUG|1.85GBq (50 mCi) of 177Lu-EB-PSMA-617|Patients were intravenous injected with the dose about 1.85GBq (50 mCi) of 177Lu-EB-PSMA-617 every 8 weeks (±1 week) for a maximum of 3 cycles.
224227726|NCT04690413|DEVICE|NOWDx COVID-19 Test|The investigational device is the NOWDx COVID-19 Test.
224319240|NCT04063150|BIOLOGICAL|fIPV (0.2mL) IM|Fractional dose of inactivated poliovirus vaccine that protects against types 1, 2, and 3 (all polio serotypes). Given as a 0.2 milliliter (mL) dose (fractional) by intramuscular (IM) injection in lieu of the full 0.5 mL dose.
224319241|NCT04063150|BIOLOGICAL|IPV|Full dose of inactivated poliovirus vaccine that protects against types 1, 2, and 3 (all polio serotypes). Given as a 0.5 milliliter (mL) dose by intramuscular (IM) injection.
223639671|NCT01683357|PROCEDURE|Hepatectomy|"Intraoperative ultrasound (IOUS) criteria for tumor-vessel relations let maximizing the preservation of the hepatic vascular skeleton. Contact between colorectal liver metastases and a major intrahepatic vessel is not by itself a criteria for vessel resection: tumor exposure is not contraindicated.~If resection of a hepatic vein (HV), resection of the liver parenchyma drained by that vein is considered or not based on color-flow IOUS findings (hepatofugal blood flow in the feeding portal branch, evidence or not of communicating veins between adjacent HVs, evidence or not of accessory HVs).~Parenchymal transection is performed under intermittent clamping by the Pringle maneuver. Drains are always inserted and a chest tube is inserted in patients undergoing thoracophrenolaparotomy."
224319242|NCT01960023|DRUG|Cetuximab|400 mg/m2 IV loading dose followed by weekly cetuximab 250 mg/m2 IV until disease progression
224227727|NCT02962011|DEVICE|Knotless barbed suture|uterine incision closure
224227728|NCT02962011|DEVICE|polyglactin 910|uterine incision closure
224227729|NCT01541956|DRUG|Metformin|500 mg twice daily
224319243|NCT01960023|DRUG|Neratinib|"Phase I portion of the study:~Dose level 1: 120 mg/day; Dose level 2: 160 mg/day; Dose level 3: 200 mg/day; Dose level 4: 240 mg/day~Phase II portion of the study: The recommended dose determined in the Phase I portion of the study."
224319244|NCT05597150|DIETARY_SUPPLEMENT|Magnesium Citrate|Each participant should receive a high-magnesium diet for 1-3 weeks and take magnesium supplements for 4-6 weeks.
224319245|NCT02735538|PROCEDURE|osteonecrosis of femoral head group|The patients with osteonecrosis of femoral head will undergo total hip replacement.
224319246|NCT02735538|PROCEDURE|osteoarthritis group|The patients with osteoarthritis will undergo total hip replacement.
224319247|NCT00039338|PROCEDURE|conventional surgery|Radial hysterectomy
224319248|NCT00039338|PROCEDURE|neoadjuvant chemotherapy|Experimental arm: minimal cumulative cisplatin dose of 225 mg/m2. Comparator arm: cumulative cisplatin dose of 200-240 mg/m2.
224319249|NCT00039338|RADIATION|brachytherapy|Brachytherapy at the end of external radiation. Minimal total dose (external with or without external boost + brachytherapy) of 75 Gy EQD2 to point A. Overall treatment less than 50 days.
223639672|NCT02392624|DRUG|Omalizumab|Omalizumab 300 mg administered SC Q4W.
223639673|NCT02392624|DRUG|Placebo|Placebo matched to omalizumab administered SC Q4W.
223639674|NCT04199806|OTHER|Questionnaire review|Review data from questionnaires received about MMS experience.
223639675|NCT05995106|OTHER|Heart4U|Mobile app.
224227730|NCT01541956|DRUG|vildagliptin|Vildagliptin 50 mg twice daily
224319250|NCT00039338|RADIATION|radiation therapy|Between 45-50 Gy, in fractions of 1.8 to 2 Gy.
223639676|NCT04557891|DEVICE|Active LIFUP Treatment|8 LIFUP Treatments
223639677|NCT04557891|DEVICE|Sham LIFUP Treatment|8 sham LIFUP treatments
223639678|NCT00706238|BIOLOGICAL|GSK Biologicals' Recombinant MAGE-A3 Antigen-Specific Cancer Immunotherapeutic (ASCI) GSK1203486A|IM administration in the deltoid or lateral regions of the thighs, alternately on the right and left sides.
223639679|NCT02518438|DRUG|Tramadol|A preprepared 20 ml solution was subcutaneously infiltrated after closure of the uterine incision and the rectus fascia.
223639680|NCT03898739|OTHER|Cervical Traction from different angles|Intermittent traction will be applied, maximum force will be 16 kg, minimum force will be 12 kg, traction cycle of each minute consists of 20 seconds static traction at the maximum force then released down to the minimum force for 20 seconds then repeated for 20 seconds static traction. Traction session time will be 15 minutes, and the traction force will be increased progressively with speed (50%) of increment of force
223639681|NCT03833505|OTHER|Bitestrip|The parents of the patients were asked to complete a survey that included questions about the demographic data, medical history of the patient, clinical findings of E. For diagnosis of sleep bruxism, a single-use BiteStrip® device (Up2dent, Inc.), including an electromyographic electrode, small display screen and lithium cell, was used to record the increased electromyographic activity of the masticatory muscles during sleep and bruxism, other harmful oral habits, family life and habits.
223639682|NCT04836650|DIAGNOSTIC_TEST|Postural stability assessment with a force platform.|The postural stability will be assessed in static by means of the antero-posterior and medio-lateral displacements of the center of pressure in Romberg open and closed eyes test measured with a force platform (NED/SVE-IBV-Spain). Three 30-second measurements will be made in each condition.
224227731|NCT01957683|DEVICE|eCLIPs™ Family of Products|Safety and feasibility of the eCLIPs™ Family of Products for the treatment of unruptured bifurcation intracranial aneurysms
224227732|NCT01579474|DRUG|BI 201335 high dose|BI 201335 high dose with PegIFN/RBV
224227733|NCT01579474|DRUG|BI 201335 low dose|BI 201335 low dose with PegIFN/RBV
224227734|NCT01579474|DRUG|BI 201335 high dose|BI 201335 high dose with PegIFN/RBV
224227735|NCT01579474|DRUG|BI 201335 high dose|BI 201335 high dose with PegIFN/RBV
224227736|NCT02637076|DRUG|Xyrem|single 3.0 gram dose
224227737|NCT01066494|DRUG|Amonafide + cytarabine|Amonafide 600 mg/m2 IV over 4 hours daily on days 1-5 in combination with cytarabine 200 mg/m2 IV continuous infusion (CI) daily on days 1-7
224227738|NCT00130520|DRUG|bevacizumab|10mg/kg every two weeks IV-bevacizumab
224227739|NCT00130520|DRUG|erlotinib|150mg daily by mouth-erlotinib
224319251|NCT00039338|DRUG|cisplatin|Minimal cumulative 225 mg/m2 (experimental arm). Cumulative 200-240 mg/m2 (comparator arm).
224319252|NCT00002638|BIOLOGICAL|filgrastim|
224319253|NCT00002638|BIOLOGICAL|sargramostim|
224319254|NCT00002638|DRUG|carmustine|
224319255|NCT00002638|DRUG|cyclophosphamide|
224319256|NCT00002638|DRUG|cytarabine|
224319257|NCT00002638|DRUG|etoposide|
224319258|NCT00002638|PROCEDURE|peripheral blood stem cell transplantation|
224319259|NCT00002638|RADIATION|radiation therapy|
224319260|NCT00529139|DEVICE|Standard extended dialysis|Standard extended dialysis dosed to maintain plasma urea levels between 120-150 mg/dL (20 -25 mmol/L)
224319261|NCT00529139|DEVICE|Intensified extended dialysis|Intensified extended dialysis dosed to maintain near-normal plasma urea levels, i.e. \<90 mg/dL (\<15 mmol/L)
224319262|NCT02295917|DEVICE|Transvaginal sonography|Transvaginal sonography
224319263|NCT00946517|OTHER|Questionnaires|Parenting and behavioral questionnaires
224319264|NCT06172634|DRUG|dentritic cell infusion and immunecheckpoint inhibitor|dentritic cell infusion and immunecheckpoint inhibitor
223639683|NCT04836650|DIAGNOSTIC_TEST|Muscular assessment with a electromyograph|The activity of the medial and lateral gastrocnemius, soleus and anterior tibial muscles of the dominant leg will be assessed with the mDurance surface electromiograph at the same time as postural stability analysis is performed.Three 30-second measurements will be made in each condition.
223639684|NCT04969302|DIAGNOSTIC_TEST|Follow-up|"The primary outcome of this study was SSI within 30 days of surgery, as defined by the Centers for Disease Control and Prevention. Secondary outcomes were identification of the causative organism, and investigation of clinical factors such as body mass index (BMI), operation time, days of hospitalization, etc. that may be associated with SSI.~All patients were followed up for SSI until discharge from hospital and at the outpatient visits. SSI surveillance data forms were used for the collection of primary and secondary outcome data.~SSI rates and distribution of identified micro-organisms for each group will measured"
223639685|NCT05976412|RADIATION|Regional lymph node radiotherapy|Regional lymph node radiotherapy
223639686|NCT05976412|RADIATION|chest/whole breast irradiation|chest/whole breast irradiation
223639687|NCT05072600|DRUG|Pembrolizumab|pembrolizumab 200 mg Q3W
223639688|NCT04291898|DEVICE|AMPLATZER™ Septal Occluder.|Implantation of the AMPLATZER™ Septal Occluder in the ASD.
223639689|NCT04291898|DEVICE|Occlutech Figulla Flex II®|Implantation of the Occlutech Figulla Flex II® in the ASD.
223639690|NCT04291898|DEVICE|GORE® CARDIOFORM ASD Occluder|Implantation of the GORE® CARDIOFORM ASD Occluder or GORE® CARDIOFORM Septal Occluder in the ASD.
223639691|NCT00309374|DRUG|LPS 2ng/kg intravenous bolus|
223639692|NCT00309374|DRUG|Simvastatin 80mg; administered daily p.o. over 5 days|
223639693|NCT00309374|DRUG|Rosuvastatin 40mg; administered daily p.o. over 5 days|
223639694|NCT00874094|BIOLOGICAL|Platelet rich fibrin matrix|0-2 cc of autologous platelet rich fibrin matrix injected intra and subdermally to effect nasolabial fold.
224227740|NCT05730140|OTHER|this study did not involve interventions; it only observational study|this study did not involve interventions. This study is an observational study for elucidating the intraoperative blood pressure changes, artierial stiffness, and whole exome genome
224227741|NCT02112240|OTHER|Intraoperative Mobile Gamma Camera imaging|Intraoperative images will be taken with a unique mobile gamma camera to identify sentinel lymph nodes in the rectum.
224319265|NCT04271917|DRUG|cannabidiol|Use of cannabidiol as an alternative to standard of care treatment of acute pain.
223639695|NCT01698333|DRUG|122-0551|Applied twice daily for 2 weeks
223639696|NCT04441892|DEVICE|QTc Meter|Development and evaluation of an inexpensive diagnostic device (the QTc Meter) to support simplified widespread screening in the primary care environment for both congenital long QT syndrome (LQTS) and acquired/drug induced-LQTS.
223639697|NCT01392339|PROCEDURE|Continuous Positive Airway Pressure (CPAP)|Continuous Positive Airway Pressure (CPAP) is a method of respiratory ventilation used primarily in the treatment of obstructive sleep apnea
223639698|NCT03841604|DRUG|Safinamide Methanesulfonate|50 mg, 100 mg
223639699|NCT03841604|OTHER|Safinamide methanesulfonate matching placebo|50 mg, 100 mg
223639700|NCT05779540|DEVICE|Safeback SBX|The intervention consists in the test of the active device.
224319266|NCT04271917|DRUG|placebo|Inactive placebo oil to imitate CBD oil
224227742|NCT02112240|DRUG|Endoscopic injection of 99mTc-sulfur colloid|Radiotracer injection around the rectal tumor for pre- and intra-operative imaging.
224319267|NCT04271917|DRUG|acetaminophen 500mg and ibuprofen 200mg combo|standard of care
224319268|NCT03834142|DEVICE|NSS-2 Bridge|The NSS-2 BRIDGE is a battery operated and disposable percutaneous auricular nerve field stimulator (Innovative Health Solutions, Versailles, IN, USA), that was recently cleared by the FDA and assigned a Class II Risk Designation; a class which includes surgical drapes, pumps and power wheelchairs. The indication for the NSS-2 BRIDGE is for the treatment of clinical symptoms related to opioid consumption and opioid withdrawal.
224319269|NCT06349941|DEVICE|Movn app|Participants will have 12-week home-based exercise program delivered via a commercially available home-based cardiac rehabilitation platform called Movn. The plan includes an accelerometer, blood pressure scale, and mobile application.
224319270|NCT06349941|DEVICE|Accelerometer|Participants will receive a FitBit for monitoring of physical function.
224227743|NCT02112240|OTHER|Endoscopic injections of Spot|Dye injection for tattooing rectal tumor prior to surgical resection.
224227744|NCT02112240|PROCEDURE|Preoperative flexible sigmoidoscopy|Flexible sigmoidoscopy prior to surgery to facilitate endoscopic injections of radiotracer and dye.
224227745|NCT02112240|RADIATION|SPECT/CT|Preoperative imaging to identify lymph nodes in rectum.
224227746|NCT01501695|DRUG|5LGr|Dosage form:Granule Strength:5 gram/sack Dosage:1 sack for patients less than 12 yrs 1.5 sacks for patients 13-18 yrs. Frequency: three times per day. Duration: 8 weeks.
224227747|NCT01501695|DRUG|tiapride|"dosage form: tablet Strength:100 mg Dosage: For patients 5-12 yrs: 50mg bid for first 2 weeks, then 100 mg, bid for next 6 weeks; for patients 13-18 yrs:100mg bid for first 2 weeks, then 200 mg bid for next 6 weeks.~Total duration:8 weeks."
224227748|NCT01501695|DRUG|placebo|mimetic granule: same with 5LGr mimetic tablet: same with tiapride
224319271|NCT02202707|DRUG|Gabapentin|Study medication, gabapentin, will be distributed to all study participants and participants will be instructed as to how to take and titrate the medication dose. Participants will take gabapentin daily for up to six weeks.
224319272|NCT05526755|DRUG|Osimertinib 80 mg/40 mg|Participants will receive osimertinib (80 mg or 40 mg orally, once daily).
224319273|NCT00230178|DRUG|Rasburicase (SR29142)|30-min IV infusion
224319274|NCT00230178|DRUG|Allopurinol|Oral administration
223639701|NCT05779540|DEVICE|Sham device|The intervention consists in a similar device to that emits same noise but does not deliver airflow.
223639702|NCT01635439|DRUG|Propess|The vaginal insert is removed 24 h after the application. It is only to be removed earlier in case of the onset of active labour, the rupture of the membranes, or at the occurrence of hyperstimulation.
224227749|NCT03107013|DRUG|[14C]-BTD-001|Carbon-14 labeled BTD-001
224227750|NCT00407849|DRUG|triamcinolone acetonide|Intravitreal injection
224227751|NCT02219191|DRUG|puerarin tablet 50 mg|
224227752|NCT02219191|DRUG|Atorvastatin tablet 20 mg|Approval No.: H19990258
224227753|NCT03811041|OTHER|MDA|Depressed adolescents of depressed parents will be oriented to the MDA of Brest for depression cares.
224227754|NCT03811041|OTHER|Routine Cares|Depressed adolescents of depressed parents will be oriented to routine cares for depression cares.
224227755|NCT03811041|OTHER|Parental depression|Parents of depressed adolescents will be met for a screening test of depression.
224227756|NCT02638831|DRUG|Ketorolac Tromethamine|Ketorolac tromethamine gel 2% for external application. Column of gel about 3-5 cm is applied on the area of maximum pain three times a day for 10 days
224227757|NCT02638831|DRUG|Ketoprofen|Ketoprofen gel 2.5% for external application Column of gel (3-5 cm) is applied with a thin layer on the skin in the area of maximum pain 3 times a day for 10 days
224227758|NCT04145908|PROCEDURE|midline mesh reinforcement|augmentation of midline closure by nonabsorbsble mesh
224319275|NCT01753297|DRUG|Triptorelin 11.25 mg|Triptorelin, one injection every 3 months. A total of 3 injections (at baseline, 3 and 6 months)
223639703|NCT01635439|DRUG|Prostin E2|3 mg tab is placed in the posterior vaginal fornix. dose can be repeated every 6 hours till onset of active labour, the rupture of the membranes, or the occurrence of hyper-stimulation.
223639704|NCT04168918|BEHAVIORAL|Group psychological Intervention|There will be 6 sessions covering 6 topics (Understanding mental disorders, Self-stigma, Social support, Substance use and mental illness, Self-help strategies, Available mental health services). Each session will begin with welcoming, reviewing what was done in the last session and home assignments (where applicable), question-guided discussion, lecture, group sharing and home assignment
223639705|NCT04723277|BEHAVIORAL|Tealeaf-Mansik Swasta (Tealeaf)|Tealeaf is a task-shifting intervention in which teachers deliver transdiagnostic mental health care. Mental health challenges are understood through basic functional behavior assessments, providing a framework for the analysis of observable behaviors. Teachers deliver care primarily through the incorporation of basic therapeutic interactions into classroom instruction time, supplemented by one-on-one interactions with the child and family. Teachers receive ongoing supervision and support from the intervention team including monthly site visits supplemented by monthly and as-needed telephone discussions.
223639706|NCT04723277|BEHAVIORAL|Enhanced Usual Care (EUC)|Enhanced Usual Care (EUC) is a less intensive version of the Tealeaf intervention. The EUC service package has been designed to be the most intensive form of care that could be envisioned as viable in the study setting in the foreseeable future without a significant increase in resource investment.
223639707|NCT00370968|DRUG|Zinc sulphate|
223639708|NCT00984217|RADIATION|Radiation|Radiation 64-70Gy (2.0 Gy/day, 5 days/week)
223639709|NCT00984217|DRUG|Panitumumab|2.5 mg/Kg IV, weekly during RT. 6-7 weeks
223639710|NCT01238068|DEVICE|gamma nail stryker|for acute unstable pertrochantric fractures the subjects will be treated randomaly with either Gamma nail device Vs Dynamic hip screw
223639711|NCT04670302|PROCEDURE|Tendon repair procedure|"Tendon repair procedure:~1. Single senior surgeon (HS) will perform mini-open surgery to decompress the acromioplasty and repair the supraspinatus tendon.~2. Splicing is achieved by installing screw-type anchors on the insertional footprint of the humeral head greater tuberosity.~3. Then, double suturing of the supraspinatus tendon is performed."
223639712|NCT04670302|PROCEDURE|Tendon repair augmented with AAdMSC-HAM composite|After double suturing of the supraspinatus tendon, the composite comprising freeze-dried HAM (2 cm x 2 cm x 0.002 cm) and AAdMSC (20 million cells) is placed on the upper surface of the splice and fixed with stitches at all four corners.
223639713|NCT02642185|PROCEDURE|Microwave ablation|CT-guided percutaneous ablation of 1-5, \<31mm in diameter, colorectal liver metastases, performed with any generic microwave ablation system cleared for clinical use
223639714|NCT02642185|PROCEDURE|Resection|Open or laparoscopic resection of liver metastases using standard of care surgical procedures
224227759|NCT00006291|BIOLOGICAL|ALVAC(2)120(B,MN)GNP (vCP1452)|
224227760|NCT00006291|DRUG|Aldesleukin|
224227761|NCT02494128|OTHER|Education|Education in group leadership
224227762|NCT01148290|PROCEDURE|Tension free vaginal tape|Small incision sites in the vagina and suprapubically. Bilateral retropubic insertion of the sling by means of needles
223639715|NCT02317900|BIOLOGICAL|TV005|TV005 is a live attenuated recombinant tetravalent dengue virus vaccine. It will be administered as a 0.5 mL dose containing 10\^3 plaque forming units (PFUs) of each component (10\^3.3 PFUs/mL of rDEN1∆30, 10\^4.3 PFU/mL of rDEN2/4∆30(ME), 10\^3.3 PFU/mL of rDEN3∆30/31-7164 and 10\^3.3 PFU/mL of rDEN4∆30). It will be delivered by subcutaneous injection in the deltoid region of the upper arm.
223639716|NCT02317900|BIOLOGICAL|Placebo|The placebo vaccine will be administered as a 0.5 mL dose delivered by subcutaneous injection in the deltoid region of the upper arm.
223639717|NCT02317900|BIOLOGICAL|rDEN2∆30-7169|rDEN2∆30-7169 is a live recombinant attenuated DENV-2 candidate vaccine virus. It will be administered as a 0.5 mL dose containing 10\^3 PFUs of rDEN2∆30-7169. It will be delivered by subcutaneous injection in the deltoid region of the upper arm.
223639718|NCT04824924|DRUG|The combination of HHT, venetoclax, AZA, G-CSF|HVAG regimen in a 28-day cycle HHT: d1-d7 1mg/m2; VEN: d1 100mg, d2 200mg, d3-d28 400mg; AZA: d1-d7 75mg/m2; G-CSF: d1-d7 300mg
223639719|NCT03877510|DRUG|IPX203|IPX203 extended release capsules
223639720|NCT01417377|DRUG|Mircera|Participants with chronic kidney disease receiving methoxy polyethylene glycol-epoetin beta (Mircera) and previously on treatment with short-acting epoetin alpha will be observed for a period of 6 months.
223639721|NCT02113982|DRUG|Tagraxofusp|
224227763|NCT01148290|PROCEDURE|Bulking agent injection|Three Periurethral injections of Bulkamid ® (Ethicon,Somerville, NJ, USA)
224227764|NCT03064412|BIOLOGICAL|Urine sample collection|A urine sample will be collected in each of the 3 trimesters of pregnancy, and also at 6 weeks post partum.
224227765|NCT03064412|BIOLOGICAL|Saliva collection|A saliva sample will be collected at one time point during the study - likely at the initial baseline visit.
224227766|NCT00291395|DRUG|PGI2|
224227767|NCT02636127|OTHER|blood samples|"one blood sample will be done for dosage and role of Fractalkine in the serum.~\- Functional study of the interactions between T cells and NK cells and / endothelial cells (HMVEC): immuno mediated endothelial cytotoxicity, endothelial activation and microparticles release by the HMVEC, endothelial progenitor cells analysis and evaluation of the endothelial lysis by fluorescence release."
223639722|NCT05333198|OTHER|Traditional physical therapy using Epley's maneuver|Epley's maneuver was performed once a week for three weeks. The maneuver was performed by patient in sitting position, head was rotated towards involved side and then extended to 30 degrees, it was then rotated to 180 degrees followed by patient rolling onto opposite side. Each position was maintained for 1-2 minutes.
223639723|NCT05333198|OTHER|Oculomotor and Vestibular Ocular Reflex (VOR) exercises|oculomotor and VOR exercises after Epley's maneuver. The exercises were performed for approximately 5 minutes daily or 1 to 2 minutes, 3 to 4 times a day, in sitting position. The exercises were continued for three weeks. The maneuver was performed by patient in sitting position, head was rotated towards involved side and then extended to 30 degrees, it was then rotated to 180 degrees followed by patient rolling onto opposite side. Each position was maintained for 1-2 minutes. Saccadic exercises were performed by moving eyes between two stationary targets. Smooth pursuit exercises were performed by tracking a moving target while keeping head still and VOR exercises were performed by moving head left to right while maintaining eyes on stationary target
223765126|NCT07024628|OTHER|Heat adaptation digital messaging|Digital messages to equip and prepare patients for extreme heat events. The first message will to encourage patients to prepare by creating a heat safety plan, and to form Check-in Companion groups among friends, neighbours, and relatives as well as to connect patients with existing key infrastructure that can be vital during heat events (ex: cooling stations and public facilities with air conditioning). When a heat-advisory is announced, additional messages will be sent to alert patients in the Treated group to activate their heat safety plans.
223765127|NCT07024628|OTHER|Non-heat-related digital messaging|Digital health promotion messages not related to heatwaves
224227768|NCT04459546|BEHAVIORAL|patient education, training booklet, 3 months tele health|Patient education includes general disease information, COPD self-management and symptom control. The education face-to-face and practical training was provided by the researcher. The training booklet was prepared by the researcher. The readability of the booklet was very easy and its comprehensibility was tested by pre-application. Tele monitoring was done by the researcher for support and motivation. The participants were called 4 times by phone.
224227769|NCT02771665|OTHER|Mammographic breast density at diagnosis|Mammographic breast density at diagnosis
224227770|NCT01953666|OTHER|Rehabilitation program|"Rehabilitation program with an occupational therpasit~3 training sessions (one hour) per week for a month (12 sessions)"
224227771|NCT01953666|OTHER|Self - Training at home|Only instructions for a self - training at home
224227772|NCT02020603|DEVICE|epinephrine injection plus soft coagulation using hemostatic forceps|
224227773|NCT02020603|DEVICE|epinephrine injection plus argon plasma coagulation|
224227774|NCT01760603|PROCEDURE|ISFF|Ischia spinous fascia fixation surgery was performed on patient with pelvic organ prolapse.
224227775|NCT04106375|BEHAVIORAL|Online mindfulness based cognitive therapy intervention|MBCT is based on Mindfulness-Based Stress Reduction (MBSR), combining principles of cognitive therapy (CT) with those of mindfulness meditation to prevent depression relapse. Both MBSR and MBCT use contemplative practices, including sitting meditation, body scan and walking meditation, as core methods to teach awareness of negative thoughts and emotions with the aim of disengaging from pervasive patterns of ruminative self-centered mentation. Participants will be given an initial orientation session and then complete an online 8-week MBCT program. Each week participants will take part in one 2-hour online group session and will complete homework assignments anticipated to take 15-30 minutes per day to complete. Additionally, weekly phone coaching will be offered based on the modified tele-coach manual developed by Mohr and colleagues (Duffecy et al. 2010).
224227776|NCT01373775|OTHER|Patient charts reviewing|Reviewing chart and identifying risk factors
224227777|NCT04771000|DRUG|Ambrisentan|Endothelin receptor antagonist
224227778|NCT04771000|DRUG|Placebo|Placebo
224227779|NCT01803152|BIOLOGICAL|Dendritic Cells Vaccine|Subjects will receive DC Vaccine administered once weekly, via intradermal injection, for 4 weeks for a total of four vaccinations, per study protocol.
224227780|NCT01803152|BIOLOGICAL|Lysate of Tumor|Post-DC Vaccine therapy. Up to 1.5 mg of Lysate of tumor per dose administered via intradermal injection at intervals defined by study protocol.
224227781|NCT01803152|DRUG|Gemcitabine|Post-surgery, Leukapheresis and clearance of subject. Gemcitabine 1000 mg/m2 IV will be administered once weekly for 3 weeks per study protocol.
224227782|NCT01803152|DRUG|Imiquimod|Subjects will self-apply Imiquimod topically to each designated vaccine site before and after scheduled administrations of DC Vaccine or Lysate, per study protocol.
224227783|NCT01803152|PROCEDURE|Leukapheresis|Baseline, post-surgery blood draw via catheter to obtain peripheral blood mononuclear cells (PBMCs) from which Dendritic cells will be obtained.
224227784|NCT02942251|OTHER|Clinical features and medication|This group will be suggested to take optimize treatment according to Chinese treatment guidelines.
224227785|NCT02942251|OTHER|Psycho-social|This group will be suggested to add on psychotherapy on medical treatment.
224227786|NCT02942251|OTHER|immunology|This group will be suggested to add on Omega-3 polyunsaturated fatty acid(PUFAs) on medical treatment.
224227787|NCT02942251|OTHER|Laboratory abnormality|This group will be suggested to more safety antidepressants.
224227788|NCT02942251|OTHER|Comorbidity|This group will be suggested to treat their comorbidities as well as treat MDD.
224227789|NCT02942251|OTHER|Treatment as usual|Patients will accept routine treatments based on psychiatrist experience, not based on the relapse predict model.
224227790|NCT01477437|OTHER|Teens Taking Charge: Managing Hemophilia Online- Online self-management intervention|"The content will be delivered on a password-protected website, as part of the About Kids Health interface developed and maintained at the Hospital for Sick Children, Toronto, Canada. The website has been developed as eight discrete educational modules for adolescents. Each module takes approximately 30 to 45 minutes to complete. Content has been written and reviewed by experts from comprehensive hemophilia care clinics across Canada (physicians, nurses, physiotherapists and social workers) and edited by a medical writer to ensure that it is written at the suggested grade 6 reading level for patient education materials. Content has been written in English and will be translated into French prior to program launch. The format is geared towards adolescents and includes narratives with video components and interactive illustrations. In addition, each module will have quiz questions with real-time feedback to promote interactivity and knowledge retention."
224227791|NCT05367856|DRUG|Chidamide combined with BEAM|Chidamide: 30mg po D-7,D-4,D-1 and D+3 Carmustine: 300mg/m2 ivgtt D-7 Etoposide: 100mg/m2/d ivgtt q12h D-6-D-3 Cytarabine: 200mg/m2/d ivgtt q12h D-6-D-3 Melphalan: 140mg/m2 ivgtt D-2
224227792|NCT04000321|OTHER|Windmill at 30 Minutes|The so-called windmill technique of placenta development for the management of the retained placenta involves the application of a continuous 360-degree umbilical traction force with centripetal rotation in such a way that it runs at the level of the introitus perpendicular to the direction of the birth canal. This rotation around a 360-degree traction plane is repeated slowly and continuously with a motion that resembles the motion of the wings of a windmill until the placenta can be safely delivered.
224227793|NCT04000321|OTHER|Windmill at 45 Minutes|The so-called windmill technique of placenta development for the management of the retained placenta involves the application of a continuous 360-degree umbilical traction force with centripetal rotation in such a way that it runs at the level of the introitus perpendicular to the direction of the birth canal. This rotation around a 360-degree traction plane is repeated slowly and continuously with a motion that resembles the motion of the wings of a windmill until the placenta can be safely delivered.
224227794|NCT01621425|OTHER|Lean body mass|Lean Body mass (DEXA scan and Bioelectrical Impedance Assessments) within one week prior to the first docetaxel dose
224227795|NCT01621425|OTHER|Total body weight|Total Body weight (TBW) (scale) within one week prior to the first docetaxel dose
224227796|NCT01621425|OTHER|bloodsampling|Blood samples will be taken during the first docetaxel administration of the first cycle, just before docetaxel infusion (t=0 min.), 30 min after start of infusion (t=30 min.), just prior to end of infusion (t=55 min.) and between 3 to 6 hours post start infusion following a limited sampling model
224227797|NCT04259840|OTHER|Observation|Soft tissue implant measurements
224227798|NCT00719784|DEVICE|Vibration Response Imaging|Recordings will be then performed using the VRI device (Deep Breeze™, Or Akiva, Israel). Forty-two sensors that are assembled on 2 planar arrays will be placed on subject's back. Each row of 3 sensors is held in place by silicone cups that are coupled to the patient's back by a computer-controlled low vacuum seal.
224227799|NCT00006443|DRUG|Indinavir sulfate|
224227800|NCT00006443|DRUG|Nelfinavir mesylate|
224227801|NCT00006443|DRUG|Lamivudine|
224227802|NCT00006443|DRUG|Stavudine|
224227803|NCT01191021|DRUG|Propofol Anesthesia|Volunteers will undergo propofol anesthesia for 90 min.
224227804|NCT00203879|DRUG|MAGE-3/Melan-A/gp100/NA PBMC, rhIL-12 (drug)|draft
224227805|NCT00203879|DRUG|MAGE-3/Melan-A/gp100/NA17 Peptide-pulsed autologous PBMC, rhIL-12 with IL-2|MAGE-3/Melan-A/gp100/NA17 Peptide-pulsed autologous PBMC, rhIL-12 with IL-2
224227806|NCT00656500|BEHAVIORAL|Standard brief advice|Brief general assistance with smoking cessation
224227807|NCT00656500|BEHAVIORAL|Quitline intervention|Brief intervention designed specifically to encourage quitline utilization
224227808|NCT00719342|DRUG|Oxygen + Carbondioxide|Mixture of 92 % oxygen and 8 % carbon dioxide for inhalation
223639724|NCT04281862|DRUG|Dextenza 0.4Mg Ophthalmic Insert|The insert, containing 0.4 mg of active pharmaceutical product, is placed within the canaliculus to provide a sustained and tapered delivery of drug to the ocular surface over 30 days after a one-time insertion. The attributes of the insert reduce the risks for improper corticosteroid tapering and unwanted peaks and troughs in drug concentration.
223639725|NCT04281862|DRUG|Topical Prednisolone|Standard of care topical drop treatment
223639726|NCT00267059|DRUG|Lenalidomide|10 mg/day, orally once a day for 28 days
223639727|NCT02085161|DRUG|placebo to tiotropium + olodaterol|comparator
223639728|NCT02085161|DRUG|tiotropium+olodaterol|tiotropium 5 mcg once daily
223639729|NCT02085161|DRUG|tiotropium +olodaterol|olodaterol 5 mcg once daily fixed dose combination
223639730|NCT02085161|DRUG|tiotropium|tiotropium 5 mcg once daily fixed dose combination
223639731|NCT00549835|PROCEDURE|Real Acupuncture|
223639732|NCT00549835|PROCEDURE|Sham Acupuncture|"Sham needles are developed to exclude sham effect and to prove real acupuncture efficacy. We will use specifically retractable Park Sham Device (AcuPrime, Exeter, UK) for control group. Because this sham device gives the impression of insertion with telescopic needle body and some pricking sensation with a bunt needle tip. It is a valid control for many acupuncture trials as it doesn't penetrate skin and doesn't create active stimulation as much as real needles or acupressure. To avoid unnecessary stimulation of penetrating skin in this population, we plan to use non-penetrating sham device rather than penetrating non-acupuncture point with real needles as control intervention.~All other procedures will be same as Real Acupuncture group except using non-penetrating sham needles on non-acupuncture points. After final session, we will ask all subjects in both groups which form of treatment each subject believe to have during study and will analyze blinding credibility."
223639733|NCT04515316|DEVICE|OPM sensors|Optically-pumped magnetometers (OPM) sensors, which are based on optical probing of alkali atoms in the vapor phase at (or slightly above) room temperature, have recently demonstrated sensitivity levels comparable with SQUID magnetometers in the laboratory. These sensors require no cooling and can potentially be fabricated at much lower cost than SQUIDs. Beginning in the late 1990s, optically-pumped magnetometers began to be used for biomagnetic applications, first for measurement of heart magnetic fields and more recently for measurement of brain fields by several groups around the world.
224227809|NCT00719342|OTHER|full field flickering light at 12.5 Hz|1 minute stimulation with full field flickering light at 12.5 Hz during measurement of vessel diameters and measurement of blood flow.
224227810|NCT06053099|OTHER|Plasma ctDNA|"* Plasma ctDNA before surgery (optional)~* Plasma ctDNA post-surgery : 4 to 8 weeks post-surgery, before starting adjuvant chemotherapy (if given) and before starting adjuvant osimertinib (if given)~* Plasma ctDNA every 6 months~* Plasma ctDNA at relapse"
224227811|NCT06053099|OTHER|FFPE blocks|"* Surgery FFPE blocks~* FFPE blocks at relapse (optional)"
224227812|NCT01161654|DRUG|naratriptan hydrochoride|2.5 mg tablet
224227813|NCT00765700|DRUG|Topical Ketoprofen 10% Cream|Topical Administration
224227814|NCT00765700|DRUG|Topical Placebo Cream|Topical Administration
224227815|NCT04165681|OTHER|Limbix Spark|5-week, self-guided mobile + VR CBT-based program for adolescent depression
224227816|NCT02285127|PROCEDURE|Short versus long cephalomedullary Intramedullary nail|Biomet Affixus Short and Long hip fracture nail. Stryker Gamma Short and Long hip fracture nail.
224227817|NCT03352427|DRUG|Dasatinib|60 mg/m2 orally twice daily
223639734|NCT04515316|DEVICE|SQUID sensors|Magnetic sensors based on superconducting quantum interference devices (SQUIDs) have been the dominant sensor in the field of magnetoencephalography since its birth in the early 1970s. SQUIDs have exceptional sensitivity to enable the detection of these very weak signals. Current FDA-approved MEG devices contain liquid helium gas in a big container that is mounted over the head of the subject
223639735|NCT05411315|OTHER|Restricted-use of arterial catheter|The investigator will restrict the use of arterial catheters unless exclusion criteria is met.
224227818|NCT03352427|DRUG|Everolimus|3.0 mg/m2, with titration of dosing after first cycle to keep trough level of 5-15 ug/ml
224227819|NCT05285280|DIAGNOSTIC_TEST|Echocardiography|The echocardiography will be performed with a GE Vingmed Ultrasoundís Vivid9 (Horten, Norway). All subjects are examined with color TDI, 2-dimensional and M-mode echocardiography, conventional spectral Doppler, 2DSTE, and where possible 4D Echocardiography in the left lateral decubitus position.
224227820|NCT04646174|BEHAVIORAL|Unified Protocol adapted for smoking cessation|Treatment components are cognitive-behavioral strategies adapted from the Unified Protocol (UP) for the Transdiagnostic Treatment of Emotional Disorders. Behavioral counseling strategies for smoking cessation, drawn from current US Public Health Service guidelines, are incorporated in each treatment module.
224227821|NCT04646174|BEHAVIORAL|American Lung Association self-management strategies for smoking cessation|Treatment components are self-management strategies provided through printed self-help materials from the American Lung Association. The materials consist of the Freedom from Smoking guide, Relaxation Exercises for Better Breathing, and COPD; Exercise and Daily Activity guide that address evidence-based smoking cessation and self-management strategies to aid in a quit attempt.
224227822|NCT05339009|BIOLOGICAL|BioADM determination in plasma|BioADM determination in plasma
224227823|NCT03478059|BEHAVIORAL|Cognitive and Motor Dual-task Intervention|The intervention will take place 3 times per week for 6 weeks (60 minutes/session) and employs motor and cognitive challenges. It is based on known motor and cognitive deficits after mTBI and is structured using a theoretical framework published in another domain of neurologic disease. The intervention will consist of 6 stations that target known motor and cognitive impairments after mTBI. Each station will have 3 levels of difficulty with optional cognitive progressions. Subjects will spend 8 minutes at each station with a 2 minute transition/rest period between stations and will be progressed in motor and cognitive difficulty as able.
224227824|NCT02737215|DEVICE|CPAP|patients will receive CPAP therapy with Auto-CPAP
224227825|NCT05361278|OTHER|Chlorhexidine solution|"* Irrigate the root canal with 1 ml of 2% CHx solution between each file 1 mm from the apical foramen by using a 27-gauge irrigation needle.~* Irrigate the root canal with 3 ml of the solution after using the last file.~* Irrigation with 3 ml of 0.5% Tween 80 and 0.07 % lecithin to remove residual chlorhexidine solution.~* Drying the canal with paper points (placing a 20 size paper point for 60 seconds in each canal) to take the bacterial smear.~* Follow-up of endodontic treatment procedures for the treated tooth."
224227826|NCT05361278|OTHER|Activated chlorhexidine solution|"* Irrigate the root canal with 1 ml of 2% CHx solution between each file 1 mm from the apical foramen by using a 27-gauge irrigation needle with activation using an ultrasonic irrigation head.~* Irrigate the root canal with 3 ml of the solution after using the last file with activation using an ultrasonic irrigation head.~* Irrigation with 3 ml of 0.5% Tween 80 and 0.07 % lecithin to remove residual chlorhexidine solution.~* Drying the canal with paper points (placing a 20 size paper point for 60 seconds in each canal) to take the bacterial smear.~* Follow-up of endodontic treatment procedures for the treated tooth."
224227827|NCT05361278|OTHER|Chlorhexidine gel|"* Irrigate the root canal with 1 ml of 2% CHx gel between each file 1 mm from the apical foramen by using a 27-gauge irrigation needle.~* Irrigate the root canal with 3 ml of the gel after using the last file.~* Irrigation with 3 ml of 0.5% Tween 80 and 0.07 % lecithin to remove residual chlorhexidine gel.~* Drying the canal with paper points (placing a 20 size paper point for 60 seconds in each canal) to take the bacterial smear.~* Follow-up of endodontic treatment procedures for the treated tooth."
224323286|NCT06182163|BEHAVIORAL|Sedentary time intervention|Tests the effect of a multi-component mobile health (mHealth) intervention on reducing sedentary behavior among adolescents and young adults (AYAs) with ALL during maintenance therapy. The intervention includes an app-based peer support group for study participants via WhatsApp, individualized coaching sessions with study staff, and prompts to move delivered via a Fitbit wearable fitness tracker.
223639736|NCT05411315|OTHER|Standard-use of arterial catheter|The investigator will allow standard-use of arterial catheters
223639737|NCT04591353|DRUG|PENG Block|The pericapsular nerve group (PENG) block is a novel regional anesthesia technique for providing analgesia after hip fractures and hip arthroplasties.
223639738|NCT04591353|DRUG|Lidocaine|2-3 cc of 2% lidocaine and NO bolus of bupivacaine will be injected.
223639739|NCT00218777|BEHAVIORAL|Comprehensive Behavioral Intervention for Tics|
223639740|NCT06223984|DRUG|pulse steroid and nanogam|patients received pulse steroid and ivig treatments in addition to standard treatment.
223639741|NCT04363970|OTHER|removal of the urinary catheter|in group A, we will remove the catheter after 24 h. In group B, we will remove the catheter after 48 h.
223639742|NCT01936870|DRUG|Fesoterodine (Toviaz)|Fesoterodine 4 mg or 8 mg orally. Toviaz will be dosed according to labeling. The administration and duration of therapy will be determined by the treating physician to meet the patient's needs for treatment.
223639743|NCT03651479|OTHER|real boxing training|In the real boxing (RB) group in addition to the NDT program, real boxing training will be given. Accordingly, the physiotherapist and the patient will wear boxing gloves and the patients will punch the physiotherapist's glove with a pre-specified treatment protocol. Resistance and frequencies between levels will be increased by the physiotherapist as the sessions progress. The RB group will have 30 minutes of real boxing training for 3 sessions per week for 8 weeks.
223639744|NCT03651479|OTHER|virtual boxing training|In the virtual boxing (VB) group, in addition to the NDT program, virtual boxing training will be given by using Kinect Xbox Boxing. For the VB group, virtual boxing training will be held for 3 weeks 30 minutes a week for 8 weeks.
223765128|NCT06097845|DIAGNOSTIC_TEST|Transcranial Ultrasound|Patients who underwent reconstructive sonolucent cranioplasty will receive standard of care postoperative imaging (i.e. CT, MRI) in addition to ultrasound imaging. Ultrasound imaging will be performed by clinicians using FDA-approved ultrasound devices (GE Venue Go, Fujifilm Sonosite X-Porte, GE Volusion E10 and Clarius HD3 etc.) currently used in routine clinical practice.
223639745|NCT04590521|BIOLOGICAL|Gardasil®, Merck|Gardasil® (4vHPV) is a recombinant protein particulate (VLP) vaccine. Each 0.5 mL monodose pre-filled syringe or vial contains approximately 20 μg of HPV 6 L1 protein, 40 μg of HPV 11 L1 protein, 40 μg of HPV 16 L1 protein, and 20 μg of HPV 18 L1 protein as well as approximately 225 mcg of aluminum (as Amorphous Aluminum Hydroxyphosphate Sulfate adjuvant). It has completed phase III trials and is licensed for use in over 100 countries around the world including the United States, Australia and countries in the European Union (EU) for girls aged 9-26 years. Vietnam currently offer this vaccine in private health clinics, as a 3-dose schedule (0, 2 and 6 months).
223639746|NCT03054246|OTHER|Evaluation of chewing side preference|"The visual analog scale (VAS) is used. The individual will be asked to make 1 mark on a 10-cm line with  always left and always right at either end and with  no preference in the middle."
223639747|NCT05345899|DIAGNOSTIC_TEST|Evaluation of vitamin C level in plasma|A protocol-specific blood test wil assess the vitamin C level in plasma
223639748|NCT05345899|OTHER|Evaluation of quality of life|Several questionnaire will be completed by patients to evaluate quality of life: Analog and visual scale (EVA) pain, Neuropathic pain (DN) 4 questionnaire, EVA fatigue, Short Form (SF) 12 questionnaire and Hospital Anxiety and Depression scale (HAD questionnaire)
223639749|NCT00842335|DRUG|JI-101|JI-101, 50 mg capsules, will be administered daily for up to 112 days (four 28-day cycles); treatment may be extended if, in the opinion of the investigator, a patient has tolerated the treatment and appears to be benefitting from receiving study medication
223639750|NCT00541541|PROCEDURE|Phrenic nerve stimulation|Patients receive a phrenic nerve stimulation
223639751|NCT02524782|BIOLOGICAL|MEDI-4166|MEDI-4166 administered subcutaneously
223639752|NCT02524782|BIOLOGICAL|Placebo|Placebo administered subcutaneously
223639753|NCT02532803|OTHER|Novel Pelvic MRI scan assessment|A novel MRI assessment of early rectal cancers will be provided for all patients in MINSTREL
223639754|NCT02658396|DRUG|GO-203-2C|
223639755|NCT02658396|DRUG|Bortezomib|
223639756|NCT02153320|PROCEDURE|Blood Sampling|Single blood sample taken from subjects who had participated in the study 287615 (NCT00508833).
223639757|NCT00220896|DRUG|Donepezil|
224227828|NCT05361278|OTHER|Activated chlorhexidine gel|"* Irrigate the root canal with 1 ml of 2% CHx gel between each file 1 mm from the apical foramen by using a 27-gauge irrigation needle with activation using an ultrasonic irrigation head.~* Irrigate the root canal with 3 ml of the gel after using the last file with activation using an ultrasonic irrigation head.~* Irrigation with 3 ml of 0.5% Tween 80 and 0.07 % lecithin to remove residual chlorhexidine gel.~* Drying the canal with paper points (placing a 20 size paper point for 60 seconds in each canal) to take the bacterial smear.~* Follow-up of endodontic treatment procedures for the treated tooth."
223639758|NCT02944149|PROCEDURE|tubal ligation by minilaparotomy|Tubal ligation will be performed by minilaparotomy as per the Tanzanian government standards, with the standard family planning counseling and minilaparotomy surgical protocols used by the government being followed during the study.
223639759|NCT03762057|DIAGNOSTIC_TEST|Intraabdominal pressure monitoring|Classic manometry technique measurement once daily
223639760|NCT00832299|DRUG|FOLFOX|6 cycles of neo-adjuvant mFOLFOX6
223639761|NCT00832299|PROCEDURE|total mesorectal excision (TME)|TME will be done 4-6 weeks after 6 cycles of neo-adjuvant FOLFOX.
223639762|NCT02732574|DEVICE|Oscilatory Positive Expiratory Pressure (OPEP) device|OPEP devices will be set to the highest pressure setting tolerated on POD #1. If the highest pressure setting is not achieved on POD#1, the PT will increase the pressure daily with the aim to achieve the highest pressure setting as soon as tolerated by the patient or POD#3, whichever comes first. Patients will be instructed to complete 15 breaths in a seated position with the OPEP device twice per waking hour. This will occur in addition to usual care.
223639763|NCT02732574|DEVICE|SHAM Device Group|SHAM devices will be provided to patients on POD #1 and set to the highest pressure setting externally, however no positive expiratory pressure will be provided as the internal pressure regulating mechanism has been removed. Patients will be instructed to complete 15 breaths in a seated position with the sham device twice per waking hour. This will occur in addition to usual care.
223639764|NCT00149266|PROCEDURE|Surgery: abdominal and transhiatal approach|
223639765|NCT00149266|PROCEDURE|Surgery: left thoraco-abdominal approach|
224227829|NCT05361278|OTHER|Sodium hypochlorite solution|"* Irrigate the root canal with 1 ml of 5.25% sodium hypochlorite solution between each file 1 mm from the apical foramen by using a 27-gauge irrigation needle.~* Irrigate the root canal with 3 ml of the solution after using the last file.~* Irrigating the canal with 3 ml of 5% sodium thiosulfate solution to remove residual of sodium hypochlorite.~* Drying the canal with paper points (placing a 20 size paper point for 60 seconds in each canal) to take the bacterial smear.~* Follow-up of endodontic treatment procedures for the treated tooth."
223639766|NCT03758053|OTHER|No intervention|No intervention
223639767|NCT03256461|BEHAVIORAL|Lactate clearance 10% target group|Participants receive the protocolized resuscitation to achieve the goal of 10-percent lactate clearance every two hours within the initial six hours of treatment.
223639768|NCT03256461|BEHAVIORAL|Lactate clearance 20% target group|Participants receive the protocolized resuscitation to achieve the goal of 20-percent lactate clearance every two hours within the initial six hours of treatment.
223639769|NCT03256461|BEHAVIORAL|Standard EGDT group|Participants receive the strategy of early goal-directed treatment of sepsis fluid resuscitation.
223639770|NCT00165477|DRUG|lenalidomide|Given orally once a day for 21 days followed by a 1 week rest period. Subject may continue to receive study drug as long as the disease does not worsen and they experience serious side effects
223639771|NCT00165477|RADIATION|Radiation|Starting 4-7 days after the start of lenalidomide and given once a day, 5 days a week for 6-7 weeks
223639772|NCT02930824|GENETIC|CYP2C19 genotyping|All proton pump inhibitors are metabolized in part by the CYP2C19 enzyme, which is encoded by the highly polymorphic CYP2C19 gene. Based on variations within this gene the effectiveness of the drug may be reduced.
223765129|NCT05277194|BEHAVIORAL|KeepCalm app|The KeepCalm app is designed to help manage stress and prevent challenging behaviors in children with autism.
223765130|NCT07025200|DRUG|Dupilumab|Clinical assessment, lung function, CT-scans and Bronchoscopy prior to and 22 weeks after initiation of Dupilumab.
223765131|NCT03738410|BEHAVIORAL|Mobile Health Messaging application|Mobile messaging sent to participants over a 12-month period.
223639773|NCT01534702|DRUG|clofarabine, cytarabine, idarubicin|"Treatment is stratified according to patients age (\< 60 years vs. ≥ 60 years).~Medication:~Patients \< 60 years:~* idarubicin 7.5 mg/m2 iv, days 1 + 3~* cytarabine 750 mg/m2 iv, days 1 to 5~Patients ≥ 60 years:~* idarubicine 6 mg/m2 iv, days 1 + 3~* cytarabine 750 mg/m2 iv, days 1 to 5~Clofarabine will be given in escalating doses to cohorts of at least three patients:~Clofarabine:~* level -1: 15 mg/m2 iv, days 1 to 5~* level 1: 20 mg/m2 iv, days 1 to 5~* level 2: 25 mg/m2 iv, days 1 to 5~* level 3: 30 mg/m2 iv, days 1 to 5~* level 4: 35 mg/m2 iv, days 1 to 5~Patients will be recruited according to a 3+3 design. New cohorts will be initiated depending on toxicity of the previous cohort during the first induction cycle. Enrollment will begin with dose level 1."
223639774|NCT00112619|DRUG|topotecan hydrochloride|Participants receive intraventricular topotecan, .2 mg, administered via an indwelling ventricular reservoir daily for 5 consecutive days during weeks 1 and 3 of the first four weeks of therapy (induction), during weeks 5 and 8 of the next 6 weeks of therapy (consolidation), and during weeks 11, 15, 19, 23, 27, 31, 35, 39, 43, 47, and 51 (maintenance therapy).
223639775|NCT03586154|COMBINATION_PRODUCT|Platelet rich plasma|combined platelet rich plasma and 1 ml ketamine in a dose of o.5 ml/kg plus 5ml bupivacaine 0.5% in a total volume 10 ml
223639776|NCT03586154|DRUG|ketamine and bupivacaine injection|1 ml ketamine in a dose of o.5 ml/kg plus 5ml bupivacaine 0.5% in a total volume 10 ml
223639777|NCT02324192|OTHER|Ultrasonography|imaging findings
223639778|NCT06384014|DEVICE|retrograde and orthograde root canal filling|Apical resection application after root canal filling
223639779|NCT05136924|DRUG|OC-01 (varenicline 1.2mg/ml) nasal spray vs Placebo|OC-01 nasal spray containing varenicline for treatment of signs and symptoms of DED. OC-01 (varenicline) nasal spray activates the trigeminal parasympathetic pathway and stimulates natural tear production to bathe the corneal nerve endings in a protective layer of tear film. In addition, OC-01 (varenicline) acts as a cholinergic agonist and may provide analgesia by activating the trigeminal parasympathetic pathway VS Placebo
223639780|NCT05136924|OTHER|Placebo (vehicle) nasal spray|Placebo (vehicle) nasal spray
224227830|NCT05415566|COMBINATION_PRODUCT|toy nebulizer and toy mask|The treatment was administered using therapeutic play.
224227831|NCT03148574|DRUG|Misoprostol|intrauterine tablets
224227832|NCT03148574|DRUG|Oxytocin|intravenous
224227833|NCT05272358|OTHER|NETSARC network|MDTB and/or surgery in NETSARC network
224227834|NCT03799263|PROCEDURE|evaluation group|Recordings Pneumologic assessment Severity grades (I-IV: old GOLD and A-D: new GOLD) Smoke History Drug therapy Comorbidities 6MWT performed within previous 10-14 months, if available. Measurements Standard exams usually performed at Rehab Center Lung Function tests and diffusing capacity of the lung for carbon monoxide Arterial Blood Gases Dyspnoea Health Status and Health Related Quality of Life Daily activity Lower limb muscle strength Exercise capacity
224227835|NCT06404411|OTHER|Assigned interventions|Combined aerobic endurance exercise in the control group: individualized exercise prescription, including 5-10 minutes of pre-exercise dynamic stretching and warm-up, 10-30 minutes of formal aerobic exercise, and 5-10 minutes of post-exercise stretching, formal aerobic exercise using a power bike starting from low-intensity and gradually increasing to medium-high-intensity, with a frequency of five times per week.
224227836|NCT06404411|OTHER|conventional rehabilitation|Adoption of conventional rehabilitation, drug therapy, enhanced nutritional support and other conventional treatment
224227837|NCT03166982|PROCEDURE|transvaginal approach|
224227838|NCT03166982|PROCEDURE|laparoscopic approach|
224227839|NCT01238848|DRUG|Hypertonic saline|3 cc nebulized hypertonic saline + albuterol 0.25 mg/kg/day, four times a day (QID), 5 days
224227840|NCT01238848|DRUG|Normal saline|3 cc nebulized normal saline + albuterol 0.25 mg/kg/day, four times a day (QID), 5 days
224227841|NCT02899130|DRUG|Polyherbal|Each capsule contains 3 herbs. Phyllanthus niruri, Boerhaavia diffusa, picrorhiza kurroa
224227842|NCT02899130|DRUG|Placebo|Inactive compound that is similar looking as the intervention
224227843|NCT01462565|DRUG|current marketed FLOLAN (epoprostenol sodium)|continuous intravenous infusion
224323287|NCT05703672|DRUG|Varenicline Tartrate|0.5 mg once daily for days 1-3, 0.5mg twice daily for days 4-7 and 1.0 mg twice daily from day 8 through week 12.
223639781|NCT02431962|PROCEDURE|Computed Tomography|Low dose chest CT screening annually x 3
223639782|NCT02431962|BEHAVIORAL|Active smokers - Smoking cessation arm|Phone based smoking cessation counseling
223639783|NCT02431962|BEHAVIORAL|Active smokers - Control arm|Subjects will be provided with general information on available smoking cessation resources
223639784|NCT02459483|BEHAVIORAL|Nurse phone call|
223639785|NCT03834181|DEVICE|"Monitoring evaluation by connected devices: Wristband activity tracker Garmin Vivosmart® 3, Fora® Scale 550, Terraillon® Tensioscreen, Pulse oximeter Nonin® 3230, thermometer Fora® IR20b"|"All patients will be monitored before and after the bariatric surgery:~* During the preoperative preparation phase: weight, exercise, blood pressure and heart rate~* In the immediate post operative period: continuous monitoring of the heart rate with a telemetry system~* Prolonged follow-up: weight, exercise, blood pressure and heart rate"
223639786|NCT00183482|BEHAVIORAL|Family Group Cognitive Behavioral|Groups of families receive training in parenting and children learn about coping in ten weekly sessions and then three monthly sessions
224227844|NCT01462565|DRUG|new thermo stable formulation of epoprostenol sodium|continuous intravenous infusion
224227845|NCT00576901|DRUG|bevacizumab [Avastin]|15mg/kg iv on day 1 of each 3 week cycle
224227846|NCT00576901|DRUG|Docetaxel|75mg/m2 iv on day 1 of each 3 week cycle
224227847|NCT00576901|DRUG|Xeloda|2000mg/m2 po on days 1-15 of each 3 week cycle
224227848|NCT02004704|DRUG|GZ402665|"Pharmaceutical form: Powder for concentrate for solution for infusion~Route of administration: intravenous infusion"
224227849|NCT01755858|DRUG|Bendavia|
224227850|NCT01755858|DRUG|Placebo|
224227851|NCT03466190|PROCEDURE|Titanium plate fixation|Under General Anesthesia, exposure of the fractured mandibular body segments will be done using a standardized surgical approach. Open Reduction Internal Fixation using conventional titanium plates will be performed.
224323288|NCT05703672|DRUG|Placebo|One pill (white) once daily for days 1-3, one pill (white) twice daily for days 4-7 and one pill (blue) twice daily from day 8 through week 12.
224323289|NCT05703672|OTHER|Electronic cigarette|Nicotine salt pod based e-cigarette in 5% nicotine
223639787|NCT00183482|BEHAVIORAL|Written Information|Families are mailed written materials that describe depression and stress in families with a depressed parent.
223639788|NCT04900116|DRUG|Bupivacaine HCl 0.5 % in 20 ML Injection|In this group, US guided PENG block will be performed with 20 ml 0.5% bupivacaine using a 22 gauge 10 mm block needle.
223639789|NCT04900116|DRUG|Bupivacaine HCl 0.25 % in 20 ML Injection|In this group, US guided PENG block will be performed with 20 ml 0.25% bupivacaine using a 22 gauge 10 mm block needle.
223639790|NCT04900116|DRUG|Bupivacaine HCl 0.125 % in 20 ML Injection|In this group, US guided PENG block will be performed with 20 ml 0.125% bupivacaine using a 22 gauge 10 mm block needle.
223639791|NCT04900116|DRUG|NaCl 0.9%|In this group, US guided PENG block will be performed with 20 ml %0.9 NaCl solution using a 22 gauge 10 mm block needle (Control Group).
223639792|NCT04986267|OTHER|ACL Rupture|Female, aged 18-40 years of age with an acute ACL rupture of the knee that occurred within the last 3 months, who presented to a sports or orthopaedic clinic
223639793|NCT03283501|PROCEDURE|PCI after TAVI|Any patient undergoing PCI after TAVI, irrespective of clinical indications and irrespective of whether planned or not at the time of TAVI
223639794|NCT06374628|PROCEDURE|breast reconstruction|breast reconstruction in two-stages using tissue expander entirely wrapped by acellular dermal matrix
223639795|NCT02540629|PROCEDURE|Bundled EMS CPR approach including dispatcher-assisted CPR, 3-person team CPR, and feedback CPR monitoring device|Gold standard EMS CPR refers to our bundled approach to providing high quality EMS CPR through one or more intervention(s) as applicable including 1) dispatcher-assisted CPR, 2) multi-tiered team CPR, and 3) feedback CPR.
223639796|NCT00628108|DRUG|Levocetirizine 1.25 mg|Levocetirizine dihydrochloride 1.25 mg (5 drops containing 5 mg/mL) dosed once a day for 2 weeks
224227852|NCT03466190|PROCEDURE|Custom made PEEK plate fixation|Under General Anesthesia, exposure of the fractured mandibular body segments will be done using a standardized surgical approach. Open Reduction Internal Fixation using custom made PEEK plates will be performed.
224227853|NCT00241917|BEHAVIORAL|Hepatitis C educational video|
224227854|NCT00241917|OTHER|Video|Prevention education video about hepatitis C
224227855|NCT04714619|DRUG|CB-103|"Patients will receive CB-103 capsules orally (QD) in combination with NSAI therapy (letrozole or anastrozole, continuing prior therapy) also orally once daily, and based on a 28-day treatment cycle.~A run-in phase for safety and tolerability of CB-103 in combination with anastrozole or letrozole will be conducted as an initial step of the phase II trial to confirm the safe dose of CB-103 in combination with NSAI given at standard dose.~Patients will receive treatment until disease progression (as defined by RECIST v.1.1), symptomatic deterioration, unacceptable toxicity, death, consent withdrawal or study termination, whichever occurs first."
224227856|NCT05247710|PROCEDURE|Punch biopsy|Punch biopsy of basal cell carcinoma tumor and a control biopsy of healthy skin are collected during primary tumor excision surgery from each recruited patient.
223639797|NCT00628108|OTHER|Placebo|Placebo oral liquid once a day for two weeks
223639798|NCT05756959|DEVICE|PBM|PBM, is a low intensity red light at wavelength of 650nm; Peripheral defocus spectacels is a peripheral design glasseses for correct myopia and control myopia
224227857|NCT02613923|BEHAVIORAL|GO! To Sleep|Controlled sleep intervention. Provide online education and reminder emails on improving sleep behavior
224227858|NCT02613923|BEHAVIORAL|Sleep information|Participants will receive weekly emails on the health benefits of sleep for 6 weeks
224227859|NCT02613923|PROCEDURE|Blood Draw|blood sample measured for stress and sleep markers
224227860|NCT02613923|OTHER|Pittsburgh Sleep Quality Index (PSQI)|Assessment of sleep quality. This is a continuous measure from 0 (best) to 21 (worst). Sleep duration will be obtained directly from responses.
224227861|NCT02613923|OTHER|Insomnia Severity Index (ISI)|
224227862|NCT02613923|OTHER|SF-12 quality of life survey|
224227863|NCT01408966|DIETARY_SUPPLEMENT|DarkChocolate|Dark chocolatee 0.55 g/kg of body weight was given together with the test meal in sitting position after the baseline measurement of HVPG. The meal + chocolate was ingested in 8 minutes.
224227864|NCT01408966|DIETARY_SUPPLEMENT|WhiteChocolate|White chocolate 0.63 g/kg white chocolate (Lindt Excellence Natural Vanilla, Lindt \& Sprüngli España) in an iso-caloric and iso-volumetric proportion adjusted to body weight was used as a control
223639799|NCT05756959|DEVICE|Peripheral defocus spectacles|plus power design of many peripheral small lenses to achieve myopic defocus of the retina in the peripheral retina
223639800|NCT05756959|DEVICE|Single vision spectacles|Distance vision correction with the single vision spectacles for the myopia correction methods (glasseses for myopia correction)
223639801|NCT02298582|DRUG|intranasal fentanyl|During the two first sessions of care or rehabilitation, patients do not receive Pecfent® in order to assess their basal pain. During the following four sessions, patients will receive transmucosal fentanyl, 10 minutes before care. A titration of PecFent will be done at each session
224227865|NCT02398188|DRUG|LIPO-202|
224227866|NCT02398188|DRUG|Placebo|
224227867|NCT00782509|DRUG|Olodaterol (BI 1744)|Comparison of low and high doses on efficacy and safety in COPD patients
224227868|NCT00782509|DRUG|Olodaterol (BI 1744)|Comparison of low and high doses on efficacy and safety in COPD patients
224227869|NCT00782509|DRUG|Placebo|Olodaterol (BI 1744) placebo inhaled orally once daily from the Respimat inhaler
224227870|NCT04278469|DRUG|Chemotherapy Drugs, Cancer|Clinical high and genomic low Hormone Receptor-positive early breast cancer patients with or without adjuvant chemotherapy
224227871|NCT05166265|DEVICE|Active transcutaneous bone conduction hearing system|The Sentio system consists of the Sentio 1 sound processor (SP) and Sentio Ti implant with fixation band and screws.
224227872|NCT01653665|DRUG|Leukine|Daily subcutaneous injection of either 3 or 6 micrograms per kilo per day, for either 4 or 7 days.
224227873|NCT01653665|DRUG|Normal Saline|Patients in the randomised controlled trial may receive this placebo as a single daily subcutaneous injection. The volume will match that of the active drug.
224227874|NCT01443065|DRUG|Oxaliplatin|85mg/m² over 120 mn every 2 weeks up to progression or toxicity
224227875|NCT01443065|DRUG|Folinic Acid|400mg/m² over 120 mn every 2 weeks up to progression or toxicity
224227876|NCT01443065|DRUG|5-fluoro-uracil|400mg/m² in bolus, then 2400mg/m² over 46 h every 2 weeks up to progression or toxicity
224227877|NCT01443065|DRUG|panitumumab|6mg/kg over 60-90 mn every 2 weeks up to progression or toxicity
224227878|NCT01443065|DRUG|AMG102|10mg/kg over 60 mn every 2 weeks up to progression or toxicity
224227879|NCT01259869|DRUG|PX-866|1 cycle = 8 weeks on study PX-866 - 8mg PO Daily
224227880|NCT00175019|DRUG|Febuxostat|Febuxostat 80 mg, tablets, orally, once daily.
224227881|NCT00175019|DRUG|Febuxostat|Febuxostat 120 mg, tablets, orally, once daily.
224227882|NCT00175019|DRUG|Allopurinol|Allopurinol 100 mg or 300 mg, tablets, orally, once daily.
224227883|NCT01808664|BEHAVIORAL|Standardized Patient Instructor Intervention|"In each case, patients will harbor underlying concerns about a serious underlying condition (e.g., either disc herniation or osteoporosis) and will request inappropriate tests. Standardized patient instructors (SPIs) will portray new patients visiting the clinic for the first time, and electronic medical records will be identical to that of actual new patients.~During the initial part of intervention visits, SPIs will assess the extent to which PCPs engage in patient-centered techniques specified in the final intervention model. SPIs will then break of their role and either teach or reinforce PCP use of the techniques, presenting techniques in a logical sequence while emphasizing flexibility in their use. SPIs will use scripts to deliver the interventions, providing opportunities for PCPs to ask questions, discuss concepts, and practice (by role playing) patient-centered techniques."
224227884|NCT01808664|BEHAVIORAL|Control|"In the latter half of visits with control PCPs, standardized patient instructors will share information with physicians regarding the acute low back pain self-care and bone health, but will not discuss patient-centered techniques or conduct training. The total duration of the control information sharing will be about one-third the SPI intervention to enhance patient-centeredness."
224227885|NCT03209570|OTHER|Care planning using TENA Identifi sensor wear data|All individuals in this arm will receive TENA Identifi sensor wear and will have data available for care planning.
224227886|NCT03209570|OTHER|Care planning without using TENA Identifi sensor wear data|All individuals in this arm will receive TENA Identifi sensor wear but the sensor wear data will not be used for care planning.
224227887|NCT06211985|DIAGNOSTIC_TEST|Copeptin level measurement|Throughout the study period, a total of 202 eligible patients were admitted to the hospital. Twenty-four patients were excluded due to lack of consent from their families, and an additional 103 patients were excluded based on the predefined exclusion criteria. In the control group, 72 individuals without chronic or acute diseases were initially eligible, but 46 of them were excluded due to lack of consent from their families. The study included patients who met the inclusion criteria and whose families provided consent, and it concluded upon reaching a total of 25 patients for each group. Additional blood samples were collected from each child within every group to assess copeptin levels, in conjunction with routine tests
223639802|NCT01886066|BIOLOGICAL|Indocyanine Green (ICG)|ICG (Indocyanine Green) will be used as a fluorescent agent to identify sentinel lymph nodes intraoperatively. One 25 mg vial of ICG will be reconstituted in 10 mL of aqueous solvent (2.5 mg/mL). The solution will be injected at the 3 and 9 o'clock positions of the cervical stroma. 0.5 mL is injected superficially (submucosa) and 0.5 mL is injected deep (\~8mm) in the cervical stroma for a total injection volume of 2 mL.
223639803|NCT02292589|DEVICE|Frontal Stimulation|The patient will receive anodal tDCS on left dorsolateral prefrontal cortex with an intensity of 1.5 mA for 20 minutes.
223639804|NCT02292589|DEVICE|Temporal Stimulation|The patient will receive anodal tDCS on left temporal cortex with an intensity of 1.5 mA for 20 minutes.
223639805|NCT02292589|DEVICE|Sham Stimulation|The patient will receive anodal tDCS over the occipital area for 30 seconds only and then it will be turned off without the patient's knowledge.
223639806|NCT00668278|DEVICE|Insertion of laryngeal mask airway (AuraOnce mask)|Insertion of laryngeal mask airway under anaesthesia: Fentanyl 1-2mcg/kg; Propofol 1-3mg/kg; Atracurium 0.5mg/kg; AuraOnce disposable laryngeal mask
223639807|NCT00668278|DEVICE|Insertion of I-gel airway|Insertion of I-gel airway under anaesthesia; Fentanyl 1-2mcg/kg; Propofol 1-3mg/kg; Atracurium 0.5mg/kg
223639808|NCT00668278|OTHER|Measurement of airway pressures|Measurement of peak airway pressure under steady state; measurement of device seal pressure
223639809|NCT04617626|DRUG|Azithromycin|Single dose of azithromycin suspension
223639810|NCT04840823|DRUG|Enoxacin|Oral 200mg tablet
223639811|NCT04840823|DRUG|Placebo|Oral tablet
223639812|NCT03848832|DRUG|GWP42003-P|GWP42003-P presented as an oral solution containing cannabidiol
223639813|NCT03848832|DRUG|Placebo|Matching placebo oral solution
223639814|NCT00232427|PROCEDURE|Hemodynamic monitoring system PiCCO|
223639815|NCT03074838|PROCEDURE|Transarterial aortic valve implantation - TAVI|After insertion of a guidewire, either through the femoral artery or through the ascending aorta, the aortic ostium is dilated by a balloon and the valve is introduced through a catheter and expanded in the ostium.
223639816|NCT03074838|PROCEDURE|Surgical aortic valve replacement - SAVR|The patient is operated through a sternotomy and coupled to a heart lung machine. The aorta is opened and the native valve excised. Then a biological artificial heart valve is sutured in place.
223639817|NCT04202107|OTHER|Food Frequency Questionnaire|Food frequency questionnaires (FFQs) are a common method for measuring dietary intake in large epidemiological studies, in particular in low literacy settings were diaries and food history would not be viable.
223639818|NCT04202107|OTHER|24 Hour food recall|Standardized and validated approach of collecting all foods, beverages, and supplements consumed during the past 24 hours
223639819|NCT02538224|DRUG|2.5%ketoprofen gel + 3 % doxycycline|"GroupA:(0.05cc, mixed gel) be put into the periodontal pocket using an insulin syringe.~Intervention category Treatment: drugs"
224227888|NCT05991661|DRUG|XKH001 Injection|100mg/ml，1ml/vial
224227889|NCT05991661|DRUG|XKH001 Placebo Injection|1ml/vial
224227890|NCT00928083|DRUG|OZ439 50mg API capsules|
224227891|NCT00928083|DRUG|OZ439 200mg API capsules|
224227892|NCT00928083|DRUG|OZ439 400mg aqueous dispersion|
224227893|NCT00928083|DRUG|OZ439 800mg aqueous dispersion|
224227894|NCT00928083|DRUG|OZ439 100mg API capsules|OZ439 100mg (2x50mg API capsules)
224227895|NCT00928083|DRUG|OZ439 400mg API capsules|OZ439 400mg (2x200mg API capsules)
224227896|NCT00928083|DRUG|OZ439 1600mg aqueous dispersion|
224227897|NCT00928083|DRUG|OZ439 800mg API capsules|OZ439 800mg (4x200 API capsules)
224227898|NCT00928083|DRUG|OZ439 1200mg API capsules|OZ439 1200mg (6x200mg API capsules)
224227899|NCT00928083|DRUG|Placebo|
224227900|NCT00928083|DRUG|OZ439 200mg aqueous dispersion|
224227901|NCT00118053|BIOLOGICAL|herceptin|
224227902|NCT00118053|DRUG|carboplatin|
224227903|NCT00118053|DRUG|docetaxel|
224227904|NCT00118053|PROCEDURE|conventional surgery|Modified radical mastectomy or lumpectomy and axillary node dissection
224227905|NCT00118053|PROCEDURE|radiation therapy|Whole breast or chest wall irradiation (as determined by radiologist)
224227906|NCT01601197|BEHAVIORAL|Tactile stimulation|Immunizer will rub the ipsilateral limb before, during and after immunization injection(s)
224227907|NCT00128453|DRUG|Colchicine (for 3 months)|Colchicine 0.5mg BID (patients\>70Kg) or 0.5mg once daily
224227908|NCT00128453|DRUG|Placebo|placebo
224227909|NCT00028665|BIOLOGICAL|filgrastim|Beginning 36-48 hours after the completion of cyclophosphamide, patients receive filgrastim (G-CSF) subcutaneously (SC) daily until blood counts recover. Patients receive G-CSF SC daily beginning 4 hours after completion of PBSC infusion and continuing until neutrophil engraftment.
224227910|NCT00028665|BIOLOGICAL|rituximab|rituximab IV over 2-5 hours on days 1, 8, and 15
224227911|NCT00028665|DRUG|carmustine|After completion of PBSC collection, patients receive high-dose chemotherapy comprising carmustine IV on days -7 to -3
224227912|NCT00028665|DRUG|cisplatin|After completion of PBSC collection, cisplatin IV for 3 days during days -7 to -3.
224227913|NCT00028665|DRUG|cyclophosphamide|cyclophosphamide IV over 3-6 hours on day 16.
224227914|NCT00028665|DRUG|etoposide|After completion of PBSC collection, etoposide IV for 3 days during days -7 to -3.
223639820|NCT02538224|DRUG|:2.5%ketoprofen gel|GroupB:2.5%ketoprofen gel which be inserted into the periodontal pocket using an insulin syringe .
223639821|NCT03413488|OTHER|kinesio taping|Apply exercise and kinesio taping for intervention
223639822|NCT03413488|OTHER|exercise|Apply only exercise intervention
223639823|NCT00193271|DRUG|Docetaxel|
223639824|NCT00193271|DRUG|Estramustine|
223639825|NCT05060029|DRUG|Lactobacillus Species|Lactobacilli containing suppositories have been successfully used in the past to maintain the vaginal environment and for treatment of infections like BV. Some of the Lactobacilli species that have been used include Lactobacillus acidophilus, Lactobacillus crispatus, Lactobacillus gasseri and Lactobacillus plantarum, none of which demonstrated any safety concerns. The investigational product, which contains a Lactobacilli complex as its main component, has already been marketed as a tool to maintain vaginal microbial balance, pH and the prevention of microbial infection, thus there are no additional safety concerns or risks involved in this clinical trial design.
223639826|NCT05060029|OTHER|Placebo|Coconut Oil Fatty Acids
223639827|NCT05731063|PROCEDURE|Computer guided simultaneous implant placement with tri-cortical ridge augmentation using chin cortical bone struts|fabrication of surgical guide to aid in chin bone harvesting and another guide to help for accurate placement and simultaneous placement in anterior maxillary defective area.
223639828|NCT03859310|DEVICE|SD-OCT|Spectral Domain Optical Coherence Tomography for non-invasive, light-based, cross-sectional imaging of ocular structures
223639829|NCT04106752|DIETARY_SUPPLEMENT|Caffeine|Provide caffeine supplements with or without meal before exercise
223639830|NCT04199988|DIAGNOSTIC_TEST|Posterior Shoulder Endurance Test|"Isometric posterior shoulder endurance test: In the prone position, the athlete's shoulder will be placed at horizontal abduction, and the time for maintaining this position will be recorded.~Isotonic shoulder endurance test: In the prone position, the athlete's shoulder will be placed at horizontal abduction and asked to perform horizontal adduction-abduction, and the athlete will horizontally abducted-adducted his/her arm to 90 degrees at a cadence of 30 beats per minute. The number of repetitions will be recorded."
223639831|NCT02850926|OTHER|Soccer head gear|Each head gear model consists of lightweight materials with a cross strap design that is fully adjustable or a single elastic headband. All models meet or exceed the American Society for Testing and Materials (ASTM) testing standards for soccer headgear and are approved by the National Federation of High Schools and The Fédération Internationale de Football Association (FIFA) for use by interscholastic soccer players. Players will be allowed to choose the brand of head gear to use and wear it for each practice and game during the soccer season.
223639832|NCT06030024|DEVICE|repetitive Transcranial Magnetic Stimulation|Magnetic pulses delivered to the Fz area of the brain in a low frequency (1 Hz) manner.
223639833|NCT03960996|PROCEDURE|dacryocystorinostomy|Dacryocystorinostomy is a surgical procedure indicated in patients with lacrimal duct obstruction.
224227915|NCT00028665|PROCEDURE|bone marrow ablation with stem cell support|Patients then undergo peripheral blood stem cell (PBSC) collection.
224227916|NCT00028665|PROCEDURE|peripheral blood stem cell transplantation|Arm I: Patients receive unmanipulated PBSCs on day 0. Arm II: Patients receive CD34 cell-enriched PBSC on day 0.
224227917|NCT00028665|RADIATION|radiation therapy|Patients may undergo involved-field radiotherapy to active or previously bulky (more than 5 cm) tumors daily for 7-10 days.
224227918|NCT04338867|RADIATION|Whole-brain radiotherapy|Patients were randomized 1:1 and allocated to either the control arm who received whole-brain radiotherapy (WBRT) or the experimental arm who received WBRT and the addition 36 mg of transdermal nitroglycerin (TN)
224227919|NCT00220701|DRUG|Lexapro (escitalopram)|antidepressant drug selective serotonin reuptake inhibitor (SSRI)
224227920|NCT01176448|DEVICE|Fractionated laser|Fractionated laser in the form of the Re:Pair CO2 laser manufactured by Solta Medical.
224227921|NCT01176448|DEVICE|Dermabrasion|Diamond Fraise Dermabrasion will be performed in standard fashion down to papillary dermis.
224227922|NCT01003132|OTHER|Acceptance and Commitment Therapy|Up to 10 sessions of a psychological therapy called Acceptance and Commitment Therapy
224227923|NCT01345032|OTHER|Home visit|Patients and their homecare helper will receive visits from a clinical dietician 1 week, 2 weeks and 4 weeks after discharge. The purpose of the visits is follow up on the individual diet plan distributed at discharge and supply dietary advice.
224227924|NCT01345032|OTHER|Telephone consultation|Patients and their homecare helper will be contacted on telephone from a clinical dietician 1 week, 2 weeks and 4 weeks after discharge. The purpose of the telephone contact is follow up on the individual diet plan distributed at discharge and supply dietary advice.
224323290|NCT06355414|DRUG|Psilocybin|Drug administration under supportive conditions
224323291|NCT06355414|DRUG|Methylphenidate|Drug administration under supportive conditions
224227925|NCT04365751|PROCEDURE|Percutaneous microwave ablation, Laparoscopic hepatectomy|For patients with hepatocellular carcinoma who meet the enrollment requirements, under the guidance of ultrasound, microwave ablation electrodes were implanted into the tumor tissues by percutaneous puncture, and the high-temperature heat energy was generated to cause coagulation necrosis of the tumor, so as to achieve the goal of local tumor treatment with minimally invasive technology.
224227926|NCT02171533|DRUG|dabigatran|
224227927|NCT02171533|DRUG|Verapamil|
224227928|NCT02171533|DRUG|Verapamil ER|
224227929|NCT00138905|DEVICE|UMTS mobile basestation radiation|
224227930|NCT01586247|DIETARY_SUPPLEMENT|Synbiotic|8g/day galacto-oligosaccharide + 10\^9 CFU/day B.lactis
224227931|NCT01586247|DIETARY_SUPPLEMENT|Placebo|8g/day maltodextrin
224227932|NCT01586247|DIETARY_SUPPLEMENT|Prebiotic|8g/day galacto-oligosaccharide
224227933|NCT01586247|DIETARY_SUPPLEMENT|Probiotic|10\^9 CFU/day B.lactis
224227934|NCT01199757|DRUG|Fluticasone furoate|cohort of patients receiving fluticasone furate
224227935|NCT01199757|DRUG|mometasone furoate|cohort receiving mometasone furoate
224227936|NCT01199757|DRUG|fluticasone propionate|cohort of patients on fluticasone propionate
224227937|NCT05665582|OTHER|Family program|A 4-day psychoeducational family program.
224227938|NCT05282160|DEVICE|Epino|The pregnant women will perform 10 sessions (twice a week for 5 weeks) of perineal preparation with the Epi-No device (pressure gauge connected to an inflatable soda that simulates the baby's head the vaginal canal). After the introduction of the deflated probe (only the first half of the device), it is minimally inflated until the perception in the vaginal canal. The first 5 minutes will be for perception of the pelvic floor with contraction and relaxation with the purpose of toning and maintaining muscular strength, followed by 15 minutes of perineal elongation respecting the tolerance of the pregnant woman. After 20 minutes in total, the pregnant woman relaxes so that the inflated device leaves gently of her vaginal cavity and the physiotherapist helps at that moment. After the device is removed, note the circumference reached on the day.
224227939|NCT00755326|DRUG|HLXL|Two daily dosages will be investigated. Huo-Luo-Xiao-Ling (HLXL) dose (10 capsules/day or 4,000mg/day) in the first 2 weeks to evaluate safety. If no adverse effects were observed, the dose was increased to 14 capsules per day (5,600 mg/ day) for the subsequent 6 weeks.
224227940|NCT03062566|OTHER|Blood sampling|Blood sampling from peripheral venous catheter routinely inserted in trauma patients during transportation
224319276|NCT04733261|OTHER|Diaphragmatic mobility|Therapist will manually make contact with Pisiform Hypothenar region and last three fingers among the underneath the costal cartilage of the 7th in the direction of 10 ribs. For the duration of participant's inhalation, the counselor drag softly within a upward course accompany the increase motion of the ribs. For the period of expiration, the counselor will deepens make contact with in the direction of the internal costal border. Taking place consequent breathing, the counselor wanted on the way to expand traction as well as slickly make deeper the contact.
224319277|NCT04733261|OTHER|Chest Physiotherapy|Patients allocated to the control group and interventional group received pulmonary rehabilitation two times a day beginning happening the day of entrance on the way to the intensive care unit. It consists of side-lying positioning with the head of the bed horizontal for at least 20 min with the most affected lung on chest x-ray positioned uppermost is also known as postural drainage, 4 sets of 6 cycles of expiratory chest wall vibrations , and airway suctioning at least three times through the endotracheal and tracheotomy tube disperse in the course of the management
224319278|NCT02458209|BIOLOGICAL|bococizumab PFS:Pfizer|150 mg bococizumab administered SC in a prefilled syringe using drug substance manufactured at Pfizer Andover
223639834|NCT05971082|OTHER|Follow-up|Follow-up study of progression/remission of liver disease
223639835|NCT05046561|DRUG|STRI Formula|STRI Formula is a combination of food based substances (botanicals, vitamins, minerals, and protein) with multiple, distinct, synergistic, direct and indirect antiviral effects against SARS-CoV-2
223639836|NCT05046561|DRUG|Placebo|Placebo oral capsule
224227941|NCT01102465|DRUG|losartan potassium hydrochlorothiazide|100 mg / 25 mg tablet
224227942|NCT05589935|DIETARY_SUPPLEMENT|Relief Study Product Usage|Participants instructed to use study product daily as directed for a period of 4 weeks
224227943|NCT00409890|DRUG|Hyoscine Butyl Bromide|
224227944|NCT02140957|BEHAVIORAL|Educational Intervention|Parents of children in both intervention and control groups received standardized counseling on healthy nutrition based on Canadian Paediatric Society guidelines. In addition, during the same 9-month doctors visit, parents of infants allocated to the intervention group were given a sip cup (Avent Magic CupTM) and shown how to use it. A trained research assistant told intervention group parents the risks of continued bottle use. They were also instructed to limit daily milk consumption to 16 ounces. Parents were also counseled to discontinue bottle use in the next 1 week using a step-wise protocol described on a handout to be placed on their refrigerator. Parents of infants allocated to the control group did not receive this information.
224227945|NCT04574310|OTHER|Collect retrospectively data on embryo implantation rate|Collect retrospectively data on embryo implantation rate
224227946|NCT04932733|OTHER|Exercises|The elderly participants in the experimental group underwent a single session of 5-minute quadriceps isometric exercise. The participant was asked to take a rest of 10 minutes before performing the exercise. After that, the exercise was performed from a long-sitting position.
223639837|NCT03071926|DRUG|Pegylated Liposomal Doxorubicin|20 mg, qw, first 6 weeks ,every 8 weeks
223639838|NCT04099199|DIAGNOSTIC_TEST|Click Sexual Health Test|The Click Diagnostics device is a single-use (disposable), fully integrated, rapid, compact, device containing a polymerase chain reaction (PCR)-based nucleic acid amplification test (NAAT) for accurate, qualitative detection and differentiation of deoxyribonucleic acid (DNA) for Neisseria gonorrhea (NG), Trichomonas vaginalis (TV), and Chlamydia trachomatis (CT) organisms.
223639839|NCT05684393|OTHER|frequency distribution type|One group is fitted using channel filterbank frequency distribution based on anatomy data extracted from post-OP CT measurements. The second (control) group is fitted with the standard frequency distribution used in MAESTRO 9 fitting software.
224319279|NCT02458209|BIOLOGICAL|bococizumab PFS: BIP|150 mg bococizumab administered SC in a prefilled syringe using drug substance manufactured at Boehringer Ingelheim Pharma.
224319280|NCT02458209|BIOLOGICAL|bococizumab PFP|150 mg bococizumab administered SC in a prefilled pen using drug substance manufactured at Pfizer Andover
223639840|NCT01635504|BIOLOGICAL|Botulinum toxin A|Botulinum toxin A 50 units per side of the posterior cheek enlargement, injected into the masseter muscle and parotid gland (10 units into 5 points of the posterior cheek enlargement per side, giving a total of 100 units per patient)
223639841|NCT00240396|DRUG|Narcotics alone|
223765132|NCT03738410|OTHER|Standard of Care Treatment|Standard of care (SOC) is defined as the usual care a licensed health care provider would give patients to treat HIV/AIDS. SOC associated procedures and policies may vary across clinical settings.
223765133|NCT07024810|OTHER|remote ischemic preconditioning|Participants randomized to the PIR intervention group will receive a hand-held blood pressure device (Welch Allyn DuraShock™ DS45, NY, USA) to self-administer PIR. The cuff will be placed around the upper arm and inflated to 220 mmHg for 5 minutes, followed by 5 minutes of deflation, and this cycle will be repeated another three times. This process will be performed 5 days a week for 3 months. The arm on which participants will apply the PIR is the left arm. Participants will be supervised during their first PIR session and every 15 days to ensure that it is performed correctly and, they will be free to perform the PIR at any time during the day and will record it in a diary to monitor compliance. Participants will be instructed to follow their normal routine and refrain from engaging in any new physical activity or changing their eating habits.
224227947|NCT04932733|OTHER|Young isometric exercise|The young participants in the experimental group underwent a single session of 5-minute quadriceps isometric exercise. The participant was asked to take a rest of 10 minutes before performing the exercise. After that, the exercise was performed from a long-sitting position.
224227948|NCT04954131|BIOLOGICAL|Candidate Vaccine, SCB-2019|30 μg of SCB-2019 antigen, and 1.5 mg CpG 1018 and 0.75 mg Alhydrogel as adjuvants
224227949|NCT04954131|OTHER|Placebo|Saline solution (0.9%)
224227950|NCT03256968|DRUG|Ataluren|ataluren
224227951|NCT03437759|BIOLOGICAL|exosomes derived from mesenchymal stem cells (MSC-Exo)|After air-liquid exchange, 50μg or 20μg MSC-Exo in 10μl PBS was dripped into vitreous cavity around MH, leaving 20% SF6 or air as tamponade .
224227952|NCT02076477|RADIATION|concurrent chemoradiotherapy|Radiation（image-guided radiotherapy）：（1）primary tumors≤3cm，Hypofractionated radiation therapy，accumulated dose BED ≥80Gy （central lung cancer），BED ≥100Gy（Peripheral lung cancer）.（2）primary tumors\>3cm，conventional fractionated radiotherapy，accumulated dose BED=60-66Gy/30-33f.（3） regional lymph node:conventional fractionated radiotherapy，accumulated dose BED=60-66Gy/30-33f.（4） Brain metastases： whole brain radiation therapy，36Gy/12f,Intracranial metastases，48Gy/12f.（5） bone metastasis：36 Gy/12f.
224227953|NCT02076477|DRUG|Docetaxel|Docetaxel:60mg/m2 d1,Given IV
224227954|NCT02076477|DRUG|pemetrexed|pemetrexed: 500mg/m2 d1,Given IV
224227955|NCT02076477|DRUG|Cisplatin|Cisplatin：25mg/m2 d1-3，Given IV
224227956|NCT04711525|BEHAVIORAL|Experimental Group: Interactive Malaysian Childhood Healthy Lifestyle Program (i-MaCHeL)|The preschool children in the experimental group will be received the i-MaCHeL program delivers through interactive classroom instruction, and their parents will have access to the i-MaCHeL Web-based program.
224227957|NCT04711525|BEHAVIORAL|Control Group: Standard health education|The children in the control group will be continued with standard health education only in the preschool setting, and their parents will be received general Web-based health newsletters.
224227958|NCT01460251|DRUG|DiaPep277|1.0 mg DiaPep277® administered every 3 months.For patients who just completed the 2-year 901 study, a 3-year extended treatment will be offered with 13 administrations; patients who completed the 2-year 910 extension study will be offered a 3rd year of treatment with 5 additional administrations.
223765134|NCT06879457|BEHAVIORAL|PCC-based mHealth-assisted self-care support intervention|Participants receive six bi-weekly WhatsApp video call sessions with a NCM over three months, using a person-centred care (PCC) approach.
224227959|NCT00636831|DRUG|Antibiotic: cefazolin Sodium|1g continuous IV at 30 minutes before starting operation
224227960|NCT04686136|DRUG|Atogepant 60 mg|Tablets containing 60 mg of Atogepant
224227961|NCT02946164|BEHAVIORAL|Stick To It|The intervention is a prize system linked to points earned through online and real-world activities designed to incentivize young MSM to test for HIV and STIs every three months. Participants receive points for pre-determined activities, such as: answering online quizzes, inviting friends to participate, and getting tested for HIV/STIs. Points are redeemable in person at two AIDS Healthcare Foundation Men's Wellness Centers, where participants will be able to exchange their points for gumballs from a gumball machine; different color combinations of gumballs correspond to prizes of different values. Participants are reminded to get tested regularly via SMS messages; in addition, they can check when their next test is due by checking their testing timer on the stick2it.org website.
223765135|NCT06879457|BEHAVIORAL|Provider-led mHealth-assisted self-care support intervention|Participants receive six bi-weekly WhatsApp video call sessions with a NCM over three months, based on the conventional provider-led model.
224227962|NCT00532597|PROCEDURE|On-line hemodiafiltration|
224227963|NCT00532597|PROCEDURE|Low flux hemodialysis|
224227964|NCT04035590|PROCEDURE|No drain|Mastectomy with flap fixation without low vacuum drainage
224227965|NCT04035590|PROCEDURE|With drain|Mastectomy with flap fixation with low vacuum drainage
224227966|NCT04122274|BEHAVIORAL|NCAA education sheet|A fact sheet that includes information about basic signs and symptoms of a concussion as well as steps to take if an individual sustains a concussion and reinforces the need to report the injury.
224227967|NCT04122274|BEHAVIORAL|Sham Intervention|An approximately 7-minute video that includes information about basic sports nutrition facts.
224323292|NCT04797286|DRUG|Sildenafil|Sildenafil 20 mg three times a day. This is the approved dose for the treatment of pulmonary arterial hypertension. It is being studied in this trial with a population who has mildly elevated pulmonary pressures.
223639842|NCT00240396|DRUG|Narcotics and NSAIDS|
223639843|NCT03200288|DEVICE|HL-01: high and low molecular weight hyaluronic acid|2 ml intra-articular single injection
223639844|NCT03200288|DEVICE|Placebo|2 ml intra-articular single injection
223639845|NCT03501849|DEVICE|Polypectomy using a cold snare|Polypectomy by cold-snare technique
224323293|NCT04797286|OTHER|Placebo|Oral pill placebo.
224323294|NCT04488133|DRUG|Nusinersen|Administered as specified in the treatment arm.
224323295|NCT06356337|DEVICE|Light goggles|Green light goggles worn for 1 hour each morning for two weeks
223639846|NCT03788252|DRUG|Renamezin|7 capsules once, three times a day, for 48 weeks
223639847|NCT06383533|DRUG|Disitamab Vedotin Plus Cadonilimab|Disitamab Vedotin: 2.0mg/kg，ivgtt，D1, every 2 weeks for a treatment cycle. Cardonilimab: 6mg/kg，ivgtt，D1, every 2 weeks for a treatment cycle.
223639848|NCT02200406|DRUG|Desvenlafaxine|All subjects will receive 50 mg of the medication during week 1 and 2, then 50-100 mg (based on the psychiatrist judgment) for the following 6 weeks. Subjects who experience significant adverse reactions with the 100mg dose during weeks 2 to 4 could return to the lower dose of 50 mg if judged clinically appropriate by the study psychiatrist.
223639849|NCT03318302|OTHER|Survey|Survey of the adult population in Israel
223639850|NCT03386383|BEHAVIORAL|Intervention|Individual session, physical activity tracker, online intervention
223639851|NCT02528552|DEVICE|LH80 PRO|
223639852|NCT02528552|DEVICE|Sham Device|
223639853|NCT05928962|DRUG|Recombinant Human Adenovirus Type 5 Injection|"1. Recombinant Human Type 5 Adenovirus Injection:~   This is expected to be administered prior to immunotherapy, i.e. scheduled for injection at C1D1 (C2D1, C3D1, C4D1). 1 treatment period every 2 weeks (3 day window) for a total of 4 cycles.~2. PD1 monoclonal antibody (Tremelimumab):~Administered intravenously within 48h of recombinant human adenovirus type 5 injection, scheduled at C1D2 (C2D2, C3D2, C4D2). 1 treatment period every 2 weeks (3 day window) for a total of 4 cycles."
223639854|NCT04808661|PROCEDURE|Thoracic endovascular aortic repair plus optimal medical therapy|Endovascular treatment (thoracic endovascular aortic repair) plus optimal medical therapy
223639855|NCT04808661|DRUG|Optimal medical therapy|Optimal medical therapy (strictly control of their blood pressure and heart rate)
223639856|NCT02404025|DRUG|Eltrombopag|Eltrombopag was provided as white round film-coated tablets containing 12.5 mg or 25 mg of eltrombopag free acid (SB-497115-GR, eltrombopag).
223639857|NCT02404025|DRUG|Rabbit ATG|Rabbit ATG, as an intravenous drip infusion, diluted by 500 mL of saline or 5% glucose injection was administered at a dose of 2.5 to 3.75 mg per kg per day as a slow intravenous infusion over 6 hours.
223639858|NCT02404025|DRUG|CsA|CsA as capsules, oral solution, or fine granule, was administered at a dose of 3 mg per kg twice a day.
223639859|NCT05078840|OTHER|Evaluation of first line treatment in patients with stage I and II LBCL|Evaluation of first line treatment in patients with stage I and II LBCL, without poor prognostic factors with treatment adapted to PET-CT after 3 R-CHOP
224227968|NCT04122274|BEHAVIORAL|Decision-based interactive concussive education platform|A platform grounded in theoretical frameworks including the socioecological model and theory of planned behavior. It includes a short video to provide an overview of key lessons, a short quiz, and additional resource links that conclude the module.
224227969|NCT03551249|DEVICE|Focused ultrasound (FUS)|FUS involves the application of acoustic energy at low frequencies from over 1000 individual transducers into distinct body targets.
223639860|NCT05808829|OTHER|Progressive Muscle Relaxation Exercise|University students did progressive muscle relaxation exercises at least 4 times a week for 6 weeks. Once a week, exercise was done with the researcher by online interview via Zoom.
223639861|NCT02061371|OTHER|virtual therapy|
223639862|NCT02061371|OTHER|conventional physiotherapy|
224227970|NCT05713500|OTHER|TCI|Temperament and character inventory
224227971|NCT05713500|OTHER|BPI|Brief Pain Inventory
224227972|NCT05713500|OTHER|CPAQ-8|Chronic Pain Acceptance Questionnaire-8
223639863|NCT01574092|DRUG|Combination of two marketed drugs (irinotecan and cisplatin)|Irinotecan and Cisplatin will be administered weekly ambulatory, intravenous (iv), until to reach a total of 16 cycles. Cisplatin is administered first and then Irinotecan. Cisplatin 30 mg/m2/d (iv) in one hour,followed by Irinotecan 65 mg/m2/d iv in one hour. There is a one-week rest period every 4 cycles. The total treatment length including 16 cycles + rest weeks is 19 weeks.
223639864|NCT02289261|DRUG|Morphine|Morphine, 0.02 mg/kg PCA bolus dose with 10 minutes lock-out interval
223639865|NCT02289261|DRUG|Morphine plus dexmedetomidine|Morphine 0.02 mg/kg plus dexmedetomidine 0.1 microgram/kg PCA bolus dose with 10 minutes lock-out interval
223639866|NCT03681314|OTHER|Umbilical Cord Milking|At delivery, the umbilical cord is grasped, and blood is pushed toward the infant 4 times before the cord is clamped. This procedure infuses a placental transfusion of blood into the infant and can be done in 10-15 seconds.
223639867|NCT05004441|DRUG|Fruquintinib Combined With mFOLFOX6/FOLFIRI|Fruquintinib (3mg) will be given p.o. daily
223639868|NCT02869880|OTHER|Enhanced Pre-Consent Discussion|The enhanced pre-consent discussion intervention is a tool that includes both textual and graphical information regarding the trial and an interactive component designed to initiate and facilitate conversations between all parties in the decision-parent, patient, healthcare provider and research staff.
223639869|NCT02869880|OTHER|Standard Pre-consent Discussion|Standard pre-consent discussion for a clinical trial
223639870|NCT00080535|BIOLOGICAL|LMB-2|30 micrograms/kg every other day (QOD) x 3 every 4 weeks
223639871|NCT02248519|PROCEDURE|Open Gastrectomy|Patients allocated to the 'Open Gastrectomy' group will receive distal or total gastrectomy via laparotomy. This group is considered the control group
223639872|NCT02248519|PROCEDURE|Laparoscopic Gastrectomy|Patients allocated to the 'Laparoscopic Gastrectomy' group will undergo distal or total gastrectomy via laparoscopy. If laparoscopic resection does not seem feasible during surgery, the procedure may be converted to an open gastrectomy.
223639873|NCT01484587|DRUG|CNTO 1959|CNTO 1959: type=range, unit=mg, number=10, 30, 100, 300, form=solution for injection, route=subcutaneous use, ascending dosing for 24 weeks
224227973|NCT05713500|OTHER|SF-MPQ|short-form McGill Pain Questionnaire
224227974|NCT05713500|OTHER|King's Parkinson's Disease Pain Scale (KPPS)|King's Parkinson's Disease Pain Scale
224227975|NCT05713500|OTHER|Hospital Anxiety and Depression scale (HAD) questionary|Hospital Anxiety and Depression scale
223639874|NCT01484587|DRUG|Placebo|Placebo: form=solution for injection, route=subcutaneous use, ascending dosing for 24 weeks
224227976|NCT05713500|OTHER|PCS|Pain Catastrophism Scale
224227977|NCT05713500|OTHER|ORT|Opioid Risk Tool
224227978|NCT05713500|OTHER|Social Support Questionnaire (SSQ6)|Social Support Questionnaire (SSQ6) (score of availability and score of satisfaction)
224227979|NCT05713500|OTHER|IPQ-R|Illness Perception Questionnaire Revised
224227980|NCT05713500|OTHER|WCC-R|Ways of Coping Checklist Revised
224323296|NCT06356337|BEHAVIORAL|Daily reminder test message|Participants will receive daily text message reminding them to use light goggles each morning
223639875|NCT02929394|DRUG|Trabectedin|Trabectedin 1.2 mg/m² through a central venous catheter as an IV infusion over 24 hours every 4 weeks until disease progression (RECIST 1.1) or unacceptable toxicity
224227981|NCT01480531|DRUG|Clevidipine|"Clevidipine administration begins in the ER or ICU~* Clevidipine is again administered post op when blood pressure control is required.~* Clevidipine will be administered by an infusion pump via either a central line or a peripheral IV as follows:~* Clevidipine will be initiated at an infusion rate of 0.4 μg•kg-1•min-1 and will be titrated as tolerated in doubling increments every 90 s up to 3.2 μg•kg-1•min-1.~* Infusion rates above 3.2 μg•kg-1•min-1 will be guided by the patient's response and permitted in serial increments of 1.5 μg•kg-1•min-1.~* Infusion rates between 4.4 and 8.0 μg•kg-1•min-1 will be administered for no longer than 2 h.~As blood pressure approaches goal, increase dose by less than double and lengthen time between does adjustments to every 5-10 minutes (a 1-2 mg/hr increase will generally result in a 2-4 mm Hg reduction in SBP)"
224227982|NCT01205607|DEVICE|ITPR -5 mm Hg then -9 mm Hg|the ITPR will be inserted in the ventilator circuit and activated to provide either -5 mm Hg or -9 mm Hg endotracheal tube pressure (ETP) Each subject will have all measurements recorded at both -5 \& -9 mm Hg
224227983|NCT01205607|DEVICE|ITPR -9 & then -5mm Hg|the ITPR will be inserted in the ventilator circuit and activated to provide either -5 mm Hg or -9 mm Hg endotracheal tube pressure (ETP) Each subject will have all measurements recorded at both -5 \& -9 mm Hg
224227984|NCT00195598|DRUG|VENLAFAXINE|
224227985|NCT00195598|DRUG|Paroxetine|
224227986|NCT01699581|DIETARY_SUPPLEMENT|Nestle Impact Advanced Recovery|dose of Nestle Impact Advanced Recovery orally three times a day beginning on the morning following stem cell transplant and continued until the day of hospital discharge.
224227987|NCT05417048|DIAGNOSTIC_TEST|Blood Sample|Up to 5mL of blood via venipuncture
224227988|NCT03291509|BEHAVIORAL|Video Conference Meetings|Individual video conferencing with a health educator using an iPad.
224227989|NCT03291509|BEHAVIORAL|In-person Meetings|Individual face-to-face (FTF) meetings with a health educator.
224227990|NCT03291509|BEHAVIORAL|Enhanced Stop Light Diet|Diet composed of healthy, pre-packaged meals, balance of fruits, vegetables, and low calories snacks, and shakes. Participants and study partners will be trained to use a color coded chart which categorize foods based on the Stop Light system (green, yellow, red) to assist in meal planning, grocery shopping, decisions regarding snack foods, and compliance with the diet in special situations such as eating away from home (restaurants, parties, etc.).
224227991|NCT03291509|BEHAVIORAL|Physical Activity|Participants will be asked to complete a set amount of time of moderate-to-vigorous physical activity each week. Participants in the Computer group will be asked to attend remote exercise sessions 2 times a week.
224227992|NCT00148915|DRUG|ibandronate|
224227993|NCT00148915|DRUG|Placebo|matching placebo
224227994|NCT00003078|DRUG|cisplatin|
224227995|NCT00003078|DRUG|fluorouracil|
223639876|NCT03938259|DRUG|Fentanyl|identification of respiratory parameter changes following administration of fentanyl in children with and without OSA
223639877|NCT00025688|DRUG|carboplatin|
223639878|NCT00025688|DRUG|paclitaxel|
223639879|NCT04881994|DRUG|Finerenone (BAY94-8862)|Single oral dose of finerenone given as 5 mg immediate release (IR) tablet.
223639880|NCT02004041|DRUG|VLY-686|
223639881|NCT02004041|DRUG|Placebo|
223639882|NCT03378986|PROCEDURE|Unilateral total hip arthroplasty|Replacement of one hip joint through a mininvasive surgical procedure
223639883|NCT03378986|PROCEDURE|Simultaneous bilateral total hip arthroplasty|Replacement of both hip joints through one-stage mininvasive surgical procedure
223639884|NCT04659876|DIAGNOSTIC_TEST|clinical features and laboratory values|Patients' age, gender, comorbidity, ABO and Rh blood groups, APACHE II, SOFA and KDIGO scores when first admitted to the ICU, performing hemogram (WBC, neutrophil, lymphocyte, neutrophil / lymphocyte ratio, hemoglobin, hematocrit, platelet count), blood gas information (pH, PO2, PCO2, HCO3, lactate), coagulation parameters PTZ and D-dimer, blood biochemistry results (CRP, LDH, CK, urea, creatinine, ALT, AST, total bilirubin, direct bilirubin and indirect bilirubin), procalcitonin and ferritin levels will be recorded. In addition, the number of days spent in the ICU and whether mortality develops or not will be recorded.
224227996|NCT00003078|RADIATION|brachytherapy|
224227997|NCT00003078|RADIATION|radiation therapy|
224227998|NCT04719000|DRUG|rhFSH+rhLH|300 IU of rhFSH and 150 IU of rhLH (Pergoveris®) GnRH antagonist: cetrorelix 0.25 mg (Cetrotide® - Merck) GnRH antagonist: cetrorelix 0.25 mg (Cetrotide® - Merck) Recombinant human chorionic gonadotropin (rhCG) 6500 IU (Ovitrelle® - Merck) micronized progesterone 90 mg (Crinone 8% ® - Merck)
224227999|NCT04719000|DRUG|rhFSH|300 IU rhFSH (Gonal-F®- Merck) GnRH antagonist: cetrorelix 0.25 mg (Cetrotide® - Merck) GnRH antagonist: cetrorelix 0.25 mg (Cetrotide® - Merck) rhCG 6500 IU (Ovitrelle® - Merck) micronized progesterone 90 mg (Crinone 8% ® - Merck)
224228000|NCT04191239|DEVICE|GE ventilator with two different modes|GE ventilator with two different modes
224228001|NCT04469608|BEHAVIORAL|acupuncture|Traditional Chinese medicine clinical daycare
223639885|NCT05950074|BEHAVIORAL|"It´s Up To You program"|The main goal of this program is to prevent substance use and engagement in addictive behaviors through enabling teenagers to make informed and responsible decisions. It seeks to support students in the anticipation of realistic choice situations and problems typically affecting this age group. It is based on social influences, considering the peer group influences (peer pressure) and the affective and cognitive factors that intervene at the time of decision-making and problem-resolution. This program is intended to be delivered by trained teachers in six sessions through six different modules.
223639886|NCT01143376|BEHAVIORAL|High intensity training|high-intensity intermittent sprinting (HIIS) (8 sec sprint:12 sec rest) for 12 weeks, 4 times a week
223639887|NCT01143376|BEHAVIORAL|short springs|short duration sprints (SDS)(8 sec sprint:12 sec rest) for 12 weeks, 4 times a week
223639888|NCT01143376|BEHAVIORAL|Moderate intensity exercise|
223639889|NCT05592106|DIAGNOSTIC_TEST|T1 mapping on gadoxetic acid-enhanced MRI|All subjects underwent 1.5T Gd-EOB-DTPA-enhanced MRI including pre-contrast and hepatobiliary-phase T1 mapping.
223639890|NCT01746901|DRUG|Placebo|Placebo solution + Placebo ALO-02 (intact)
223639891|NCT01746901|DRUG|intact ALO-02 60 mg/7.2 mg|Placebo solution + ALO-02 60 mg/7.2 mg (intact)
223639892|NCT01746901|DRUG|crushed ALO-02 60 mg/7.2 mg|crushed ALO-02 60 mg/7.2 mg in solution + placebo ALO-02 (intact)
223639893|NCT01746901|DRUG|crushed oxycodone IR 60 mg|crushed oxycodone immediate-release (IR) 60 mg in solution + placebo ALO-02 (intact)
223639894|NCT01746901|DRUG|crushed ALO-02 40 mg/4.8 mg|crushed ALO-02 40 mg/4.8 mg in solution + placebo ALO-02 (intact)
224228002|NCT00240682|DRUG|cetuximab|Dosage form: bottles of 50 ml, 2 mg/ml; Dosage:400 mg/m2 initial dose followed by 250 mg/m2 by infusion every week; Number of Cycles : until progression or unacceptable toxicity develops.
223639895|NCT01746901|DRUG|crushed oxycodone IR 40 mg|crushed oxycodone immediate-release (IR) 40 mg in solution + placebo ALO-02 (intact)
223639896|NCT00742495|DRUG|Forodesine|PK study
224228003|NCT03344367|BIOLOGICAL|JWCAR029|Subjects will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of JWCAR029. During JWCAR029 production, subjects will receive a conditioning chemotherapy regimen of cyclophosphamide and fludarabine for the purpose of lymphocytes depletion. After lymphodepletion, subjects will receive one dose treatment with JWCAR029 by intravenous (IV) injection.
224228004|NCT06384144|OTHER|Expectant Management of First Trimester Miscarriage|Expectant Management: Conservative management if miscarriage with follow-up booked in 2 weeks to determine whether complete miscarriage has occurred.
224228005|NCT06384144|OTHER|Medical Management of First Trimester Miscarriage|Medical Management: Misoprostol taken to manage first trimester miscarriage, with follow-up booked in 2 weeks to determine whether complete miscarriage has occurred.
223639897|NCT05750849|PROCEDURE|BLOOD COLLECTION FOR P4 DETERMINATION|Serum progesterone levels on the pregnancy test day
223639898|NCT03076151|DRUG|Tacrolimus monohydrate (ADOPORT®)|Pharmacokinetic of Tracrolimus (ADOPORT®) on 9 blood sampling by kinetics on 4 kinetics
223639899|NCT02683577|DRUG|telotristat etiprate|
223639900|NCT03594110|DRUG|Empagliflozin|Taken daily with or without food
223639901|NCT03594110|DRUG|Matching placebo|Taken daily with or without food
223639902|NCT06033248|DIAGNOSTIC_TEST|urine sample|urine sample will be collected
223639903|NCT05280067|COMBINATION_PRODUCT|ZetaMet™ (ZetaFuse™ Bone Graft)|ZetaMet™ (ZetaFuse™ Bone Graft) will be percutaneously implanted into the vertebral body defect(s) created by the lytic metastatic tumor.
223639904|NCT04857476|DIAGNOSTIC_TEST|Ultrasound scan|"Psoriasis epidemiology screening tool (PEST) score for completion Brief questionnaire about current psoriasis symptoms, current treatment and if any features associated with psoriatic arthritis.~One-off musculo-skeletal ultrasound Questionnaire at 2 years"
223639905|NCT05029362|BEHAVIORAL|SmokefreeSGM|Participants will have access to a text-based smoking cessation program tailored to sexual minority individuals (SmokefreeSGM). The text-based program will be beta-tested by these participants for a period of 2 weeks before and 10 weeks after their quit date. Messages originated from the text-based smoking cessation program will be sent by a fictitious quit coach who will offer evidence-based advice on quitting smoking based on real-life experiences of sexual minority individuals.
223639906|NCT06642220|DEVICE|Y-90 Selective Internal Radiation Therapy (SIRT)|Y-90 radioembolization will be performed using glass spheres to treat non-metastatic RCC within the kidney.
223639907|NCT05571605|BEHAVIORAL|Exercise|Participants randomized to this arm will exercise on a stationary bicycle.
223639908|NCT05571605|BEHAVIORAL|Stretching|Participants randomized to this arm will perform stretching and balance exercise.
223639909|NCT04851964|BIOLOGICAL|Experimental: Tezepelumab|Tezepelumab subcutaneous injection
223639910|NCT04851964|OTHER|Placebo|Placebo subcutaneous injection
223639911|NCT05955911|BEHAVIORAL|Exercise|20 minutes of Moderate intensity (40%-59% heartrate reserve) walking on a treadmill.
223639912|NCT05955911|BEHAVIORAL|Coloring|20 minutes of coloring in adult coloring book
223639913|NCT04780477|DIETARY_SUPPLEMENT|High Fiber Diet Featuring Legumes (HLD)|The high fiber diet featuring legumes (HLD) provides pre-portioned entrées for two meals per day in months 1-3, and one meal per day in months 4-6. Participants continue on the diet in months 7-12 but assume responsibility for food preparation. The HLD will contain approximately 250 grams (g) of legumes per day (\~1 ½ cups cooked legumes) in months 1-3 provided in two pre-portioned single serving entrées (i.e. \~125g in each serving). A study nutritionist provides in-person and written guidance for including side dishes that are nutritionally balanced with energy intake to lose 1-2 pounds of weight per week.
223639914|NCT04780477|DIETARY_SUPPLEMENT|Healthy American Diet|The healthy American diet provides pre-portioned meal replacement entrées with legumes replaced by lean chicken or meat. Participants continue on the diet in months 7-12 but assume responsibility for food preparation. A study nutritionist provides in-person and written guidance for including side dishes that are nutritionally balanced with energy intake to lose 1-2 pounds of weight per week.
223639915|NCT05081180|DRUG|Avelumab|Participants with primary CNS malignancies who have received at least 1 prior therapy will be enrolled into Dose Escalation Part 1 and will receive intravenous infusion at a flat dose or weight based dose of Avelumab, every 2 weeks (Q2W) until progression, unacceptable toxicity, or withdrawal of consent. Enrollment into part 1 of the study will end when Maximum tolerated dose (MTD) and/or a safe Recommended Dose for Expansion (RDE) for the expansion cohort is determined. Participants with defined CNS tumors will be enrolled into Dose Expansion Part 2 and will receive RDE in Part 2 until progression, unacceptable toxicity, or withdrawal of consent.
224228006|NCT04584125|DRUG|Riboflavin 5'-phosphate in 20% dextran ophthalmic solution) 0.146% with UV light|A wavelength of 365 nm ultraviolet A light will be used to direct 5.4 J/cm2 using a beam diameter of 9.5mm to treat the de-epithelialized corneal surface of a donor cornea for 30 minutes. Every 2 minutes, the UV light will be used while another drop of riboflavin is applied on top of the donor cornea.
224228007|NCT04584125|DRUG|Riboflavin 5'-phosphate in 20% dextran ophthalmic solution) 0.146% without UV light|The corneal tissue for the control arm will be treated the same as the crosslinked tissue except that it will not be exposed to ultraviolet light. The donor cornea will be placed on an artificial anterior chamber maintainer and the epithelium will be removed mechanically. Riboflavin solution (0.1% riboflavin and 20% dextran supplied in a sterile, single-dose container) will be applied to the cornea every 2 minutes for 30 minutes.
224228008|NCT03304509|OTHER|Telematic follow-up|Telematic follow-up by using a platform with videoconference
224228009|NCT04752436|BEHAVIORAL|Supra high intensity interval training|The exercise program will consist of eight 20-second all-out exercise bouts followed by 10 seconds of rest for a total of 4 minutes of total exercise duration. The intensity of exercise is all out. The exercise will be conducted 3 times a week for 8 weeks.
223639916|NCT05081180|DRUG|Lenvatinib|Participants with primary CNS malignancies who have received at least 1 prior therapy will be enrolled into Dose Escalation Part 1 and will receive daily oral escalated dose level of Lenvatinib until progression, unacceptable toxicity, or withdrawal of consent. Enrollment into part 1 of the study will end when MTD and/or a safe Recommended Dose for Expansion (RDE) for the expansion cohort is determined. Participants with defined CNS tumors will be enrolled into Dose Expansion Part 2 and will receive RDE of Lenvatinib in Part 2 until progression, unacceptable toxicity, or withdrawal of consent.
224319281|NCT04687683|OTHER|Post Isometric Relaxation Group|Athletes will be positioned in a modified cross-body position. They will be asked to actively bring their underlying arm in the direction of horizontal adduction up to the physiological barrier barrier. The participants will be asked to perform an isometric contraction for 5 seconds in the horizontal abduction direction with 20% of the maximum muscle strength. After the relaxation, the arm will be moved towards horizontal adduction and 15 seconds active-assistive stretching will be applied. Participants will be given a 5-second rest period between contractions. This stretching exercise will be applied in 5 repetitions for one session.
224319282|NCT04687683|OTHER|Isolytic Stretching Group|Athletes will be positioned in a modified cross-body position. They will be asked to actively bring their underlying arm in the direction of horizontal adduction up to the physiological barrier barrier. The participants will be asked to perform a contraction in the horizontal abduction direction with 20% of the maximum muscle strength. When the muscle contraction occurs, the arm will be moved quickly in 2-4 seconds towards horizontal adduction and 15 seconds active-assistive stretching will be applied. Participants will be given a 5-second rest period between stretches. This stretching exercise will be applied in 5 repetitions for one session.
223639917|NCT04449250|DRUG|Dexmethylphenidate|Subjects will be randomized to one of two sequences. Subjects will be dosed with 25 mg dose of CTx-1301 during each sequence. Subjects will serve as their own control.
224228010|NCT04041570|BIOLOGICAL|cAd3-EBO S vaccine|The recombinant chimpanzee adenovirus Type 3-vectored Ebola vaccine, VRC-EBOADC086-00-VP (cAd3-EBO S), is composed of a cAd3 vector that encodes Ebola Sudan wild type glycoprotein (WT GP).
224228011|NCT02980848|OTHER|Screening digital mammography|Screening with digital mammography alone
223639918|NCT02741063|BEHAVIORAL|screen low autistic subjects|screen subjects with low ASQ score
223639919|NCT02741063|BEHAVIORAL|screen high autistic subjects|screen subjects with high ASQ score
223639920|NCT02741063|DRUG|oxytocin|intranasal administration of oxytocin (24 IU)
224228012|NCT02980848|OTHER|Screening digital breast tomosynthesis|Screening with digital mammography plus digital breast tomosynthesis
224228013|NCT02980848|OTHER|Screening breast magnetic resonance imaging|Screening with digital mammography plus breast magnetic resonance imaging
224228014|NCT02980848|OTHER|Diagnostic mammography|Pre-operative diagnostic work-up with mammography alone
224228015|NCT02980848|OTHER|Pre-operative breast magnetic resonance imaging|Pre-operative diagnostic work-up with mammography plus breast magnetic resonance imaging
224228016|NCT01338636|DRUG|Ambrisentan|5 mg orally every day for 4 weeks. At Week 4, if ambrisentan 5 mg was tolerated, the dose was increased to 10 mg every day for the remainder of the 24-week period.
224228017|NCT01021436|DRUG|Amikacin inhalation solution (BAY41-6551)|Daily dose of 800 mg of aerosolized amikacin delivered in two divided doses of 400 mg per aerosol treatment 12 hour
224228018|NCT01697722|DRUG|Extra-fine hydrofluoroalkane-beclometasone dipropionate|Increase in the baseline BDP-equivalent dose of inhaled corticosteroid as HFA-BDP via pMDI or BAI
224228019|NCT01697722|DRUG|ICS / LABA via separate pMDI and / or BAI inhalers|A step-up from baseline ICS therapy via the addition of a separate long-acting beta-agonist with no change in baseline ICS drug or dose
224228020|NCT02185612|BEHAVIORAL|Savings program|The intervention is a web-based centralized savings account, which is a secure online account without fees. The account offers eligible savers nominal financial rewards for each deposit they make, as a financial incentive for savings.
224228021|NCT03122002|DRUG|Drug Therapy|For this observation research, anti platelet drugs, statins and ect. would be used as clinical guidelines as usal, and statical ananysis of the relationship between these drugs and the final outcomes
224228022|NCT03122002|DIAGNOSTIC_TEST|Routine Blood Test and Image Scan|Routine blood test(HCY, LDL and ect.) and image scan (DWI, DSA and ect.)
224228023|NCT03122002|OTHER|Intravascular therapy|Intravascular therapy including thrombectomy
224228024|NCT03122002|OTHER|Emergency Treatment|Emergency treatment including time to self-diagnosis of stroke, time to call for help, devices used to hospital and ect.
224228025|NCT03122002|OTHER|Medical history|Medical history including hypertension, diabetes, hyperlipemia and ect.
224228026|NCT02385526|DEVICE|Vagus Nerve Stimulation Therapy|Stimulation of the left tenth cranial nerve via VNS Therapy
224228027|NCT01054508|DRUG|nicotinic acid/laropiprant|Nicotinic acid/laropiprant (1g/20mg) daily for 4 weeks, then nicotinic acid/laropiprant (2g/40mg) daily for 8 weeks.
224228028|NCT03532009|DRUG|Sodium Zirconium Cyclosilicate|Oral use for approximately 3 months
224228029|NCT03532009|DRUG|Placebo|Oral use for approximately 3 months
224228030|NCT04725084|OTHER|Use of High Flow Nasal Cannula alone|Use of high flow nasal cannula oxygen therapy alone
224228031|NCT04725084|OTHER|Use of Non-invasive Ventilation|Use of non-invasive ventilation combined or not with high flow nasal cannula oxygen therapy
224228032|NCT04725084|OTHER|Use of Continuous Positive Airway Pressure|Use of continuous positive airway pressure combined or not with high flow nasal cannula oxygen therapy
224228033|NCT03758365|DRUG|MC2-01 Cream|Single application, visual evaluation of skin blanching and local tolerability, physical examination and safety evaluation
224228034|NCT03758365|DRUG|Clobetasol Propionate 0.05% Lotion|Single application, visual evaluation of skin blanching and local tolerability, physical examination and safety evaluation
224228035|NCT03758365|DRUG|Betamethasone Dipropionate 0.05% Cream|Single application, visual evaluation of skin blanching and local tolerability, physical examination and safety evaluation
224228036|NCT03758365|DRUG|Triamcinolone Acetonide 0.1% Cream|Single application, visual evaluation of skin blanching and local tolerability, physical examination and safety evaluation
224323297|NCT04533919|PROCEDURE|Biospecimen Collection|Undergo collection of dorsal root ganglia
224323298|NCT06581146|OTHER|No Intervention|No investigational drug will be administered to participants in this study.
224323299|NCT06801002|DRUG|JBZ-001|JBZ-001 Oral Capsule
223639921|NCT02741063|DRUG|placebo|intranasal administration of placebo (24 IU)
223639922|NCT00180778|DRUG|Low dose steroids|
223639923|NCT05994196|BEHAVIORAL|Optimum, a secondary prioritization software of patients in the pediatric emergency department (ED)|Optimum®'s purpose is to remove the mental load of prioritization from the Pediatric ED staff. The software first prioritizes the triage of new patients by the ED staff and the first evaluation of a new patient by the medical team. Optimum® then prioritizes blood sample collections and care (for nurses) and checks on imaging results, blood test results or an evaluation by a specialist (for physicians). Lastly, Optimum® prioritizes the final step in patient management by a senior physician, when appropriate.
223639924|NCT00217399|DRUG|sorafenib tosylate|Given orally
223639925|NCT00217399|DRUG|anastrozole|Given orally
223639926|NCT03869047|DRUG|Dexmedetomidine +bupivacaine|patients will receive combined general anesthesia and Quadratuslumborum block( transincisional ie before wound closure)with 19 mL of bupivacaine 0.20%plus 1 mic/kg of dexmedetomidine, total volume 20 ml
223639927|NCT03869047|DRUG|Bupivacaine|patients will receive combined general anesthesia and quadratus lumborum block (transincisional) with 20 ml of bupivacaine 0.20% .
224228037|NCT03758365|DRUG|Hydrocortisone Butyrate 0.1% Cream|Single application, visual evaluation of skin blanching and local tolerability, physical examination and safety evaluation
224228038|NCT03758365|DRUG|Desonide 0.05% Cream|Single application, visual evaluation of skin blanching and local tolerability, physical examination and safety evaluation
224228039|NCT03758365|DRUG|Vehicle|Single application, visual evaluation of skin blanching and local tolerability, physical examination and safety evaluation
224228040|NCT04421794|DEVICE|NMES|Neuromuscular Electrical Stimulation (NMES) is a non pharmacological intervention that sends electrical impulses to nerves leading to muscle contraction. The electrical stimulation can increase strength and is often used to re-educate or re-train muscles.
224228041|NCT04421794|DEVICE|TENS|Transcutaneous electrical nerve stimulation (TENS) is a nonpharmacological intervention that activates a complex neuronal network to reduce pain by activating descending inhibitory systems in the central nervous system to reduce hyperalgesia.
224228042|NCT02035137|RADIATION|131I-MIBG|
224228043|NCT02035137|DRUG|Vincristine|
224228044|NCT02035137|DRUG|Irinotecan|
224228045|NCT02035137|DRUG|Vorinostat|
224228046|NCT05639387|PROCEDURE|actual tVNS|Active tVNS (stimulation on cymba conchae --\> nervus vagus stimulation)
224228047|NCT05639387|PROCEDURE|sham tVNS|Sham tVNS (stimulation on earlobe --\> no nervus vagus stimulation)
224228048|NCT01288859|OTHER|free curcumin|free curcumin in bread, dosage 1g/100g, 200g/day per 1 day
224228049|NCT01288859|OTHER|encapsulated curcumin|encapsulated curcumin-enriched bread, 1g/100g bread, 200g bread/day
224228050|NCT01288859|OTHER|encapsulated curcumin + PQG|bread enriched with encapsulated curcumin plus piperine, quercetin and genistein, 1g/100g bread, 200g bread/day
224228051|NCT01288859|OTHER|free cocoa polyphenol|nut cream enriched with free cocoa polyphenols, 1,5 g/100g cream, 100g/day per 1 day
223639928|NCT00720915|OTHER|Discontinue anticoagulant therapy (Negative d-dimer)|Patients with negative d-dimer discontinue long-term anticoagulant therapy.
223639929|NCT00720915|OTHER|Continue on anticoagulant therapy (positive d-dimer)|Patients with positive d-dimer continue or re-start on anticoagulant therapy
223639930|NCT02631408|DRUG|Vancomycin|Locally, intrawound applied vancomycin powder
223639931|NCT03622489|DRUG|Acetaminophen|mentioned above
223639932|NCT03622489|DRUG|Ibuprofen 400 mg|mentioned above
223639933|NCT03622489|DRUG|Dipyrone|mentioned above
223639934|NCT03622489|DRUG|Tramadol|mentioned above
223639935|NCT03622489|DRUG|Morphine|mentioned above
223639936|NCT03622489|DRUG|Tramal|mentioned above
223639937|NCT05535725|DRUG|application of powdered vancomycin in the surgical wound as prophylaxis against the occurrence of surgical site infection|on the application of powdered vancomycin in the surgical wound as prophylaxis against the occurrence of surgical site infection at La Paix State University Hospital Haiti over 2 years.Both groups benefited from the same preoperative asepsis protocol. One hour before the incision, 1g of intravenous ceftriaxone is administered to the patients, this dose is maintained during the 48 hours postoperative every 12 hours. At discharged the two groups of patients received oral cloxacilin 500mg three times a day for one week. Patients are dressed every 2 days until the surgical wound has healed. Patients are seen in the outpatient clinic at 2, 4, and 6 weeks, then at one year. We selected 215 patients and retained 204.
223639938|NCT06278714|OTHER|Inspiratory muscle training|The subjects will perform deep inspirations against a threshold device with varying resistances
223639939|NCT03846336|OTHER|Upper extremity function|Upper extremity function was evaluated with 9-Hole Peg Test (9-HPT). The 9-HPT is a brief, standardized, quantitative test of upper extremity function. It consists of moving nine pegs into one of the nine holes on a peg board, then back into an open box. Both the dominant and non-dominant hands are tested twice.
224228052|NCT01288859|OTHER|encapsulated cocoa polyphenols|nut cream enriched with encapsulated cocoa polyphenols, 1,5 g/100g cream, 100g/day per 1 day
224228053|NCT01288859|OTHER|control nut cream|nut cream, cocoa polyphenols 0g/100g cream, 100 g/day per 1 day
224228054|NCT06543836|DRUG|Sintilimab|Sintilimab 200mg, d1, with a treatment cycle of 21 days, and efficacy assessment every 2 cycles.
224228055|NCT06543836|DRUG|Fruquintinib or Regorafenib|"The treatment regimen consists of the following options:~Option 1: Fruquintinib 5mg Qd, d1-21, Q4w, and efficacy assessment every 1.5 months.~Option 2: Regorafenib 160mg Qd, d1-21, Q4w, and efficacy assessment every 1.5 months."
224228056|NCT06543836|DRUG|Fruquintinib|Fruquintinib 5mg Qd, d1-14, with a treatment cycle of 21 days, and efficacy assessment every 2 cycles.
224228057|NCT02663089|DRUG|[14C]-GSK961081 solution for IV infusion|Subjects will receive 10 mL of solution equivalent to 4 mcg of \[14C\]-GSK961081 (approximately 6.2 kilobecquerel \[kBq\]) intravenously as a single dose over 1 hour.
224228058|NCT02663089|DRUG|[14C]-GSK961081 oral solution|Subjects will receive 10 mL of solution equivalent to 200 mcg of \[14C\]-GSK961081 (approximately 311 kBq) orally as a single dose with up to 250 mL of water.
223639940|NCT03846336|OTHER|Shoulder position sense|Shoulder position sense was evaluated with a Dualer IQTM digital inclinometer (J-TECH medical, Salt Lake City, UT, USA). The absolute error scores (in degrees) for shoulder abduction and flexion at 30° and 60° was calculated. The upper extremity of the participant was positioned with the arm in the scapular plane for the abduction movement and in the sagittal plane for the flexion movement. After returning to the starting position, participants attempted to repeat the previously attained angle. Participants indicated verbally when they felt they had reached the angle and held their position. The measurement was repeated 2 more times for a total of 3 trials for each limb (non-dominant and dominant), with a 30-second rest period separating trials.
224319283|NCT04687683|OTHER|Static Stretching Group Group|Athletes will be positioned in a modified cross-body position. They will be asked to actively bring their underlying arm in the direction of horizontal adduction up to the physiological barrier. Then, the arm will be moved towards horizontal adduction and 15 seconds active-assistive stretching will be applied. Participants will be given a 5-second rest period between stretching exercises. This stretching exercise will be applied in 5 repetitions for one session.
224323300|NCT04987879|BEHAVIORAL|Exercise|Aerobic exercise can be completed by walking, jogging or running or by using cardio equipment (e.g., recumbent bike). Each session will begin with a warm-up with walking (30-40% target HR for 5-min) and dynamic exercises (knee-to-chest, 10-yd lateral shuffle, bent over twist, calf sweeps, leg swings). A 5-min walking cool down will end the session (30-40% target HR).
224323301|NCT03616587|DRUG|AZD9833|Part A: AZD9833 monotherapy dose escalation.
223639941|NCT00495352|DRUG|Hihg-doseNRT, Low-dose NRT, bupropion|
223639942|NCT04946409|OTHER|no intervention|no intervention
223639943|NCT04252144|PROCEDURE|Dietary assessment|Dietary assessment is not within standards of care for patients with gastroesophageal reflux disease in Russia. Subjects enrolled to the study are to be interviewed on most common foods consumption in terms of frequency of use and sizes of portions.
223639944|NCT03423784|DEVICE|HA BPX V3.3|medical device containing HA
223639945|NCT03423784|OTHER|Dentinox-Gel N|Anaesthetic gel
223639946|NCT04402372|DEVICE|Novel bidirectional cannula (BiflowTM, LivaNova, Italy)|We are going to evaluate the safety and efficacy of the novel bidirectional cannula (BiflowTM, LivaNova, Italy) with specific design to ensure stable distal perfusion compared to conventional cannula with downstream line in patients undergoing femoral arterial cannulation for CPB during minimally invasive surgery
224228059|NCT02663089|DRUG|GSK961081 dry powder for inhalation|Subjects will receive single dose of 4 actuations of 300 mcg GSK961081 per actuation (1200 mcg GSK961081 total) as inhalation immediately after the start of infusion.
224228060|NCT00261729|DRUG|Paroxetine|paroxetine 20 mg
223639947|NCT01465555|BEHAVIORAL|Cognitive Behavioral Intervention|Counselors in this condition will work with the modified RecoveryTrack tested in the pilot study which has been altered to provide automated Clinical Alerts at either the intake, Month 1, or Month 2 CRM interview for High Risk patients. In addition, High Risk patients will be flagged in the counselor's caseload for discussion with clinical supervisors. Counselors in this condition will receive the Clinical Alert + Cognitive Behavioral Intervention (CBI) training, as well as monthly feedback from the Principal Investigator on their delivery of the CBI Months 1-3, with a booster session at Month 6.
223639948|NCT00694941|DRUG|ONO-2506PO|1200mg QD / 5 years
223639949|NCT03216772|DEVICE|Olympus PK Morcellator in PneumoLiner|Laparoscopic Supracervical Hysterectomy (LSH) or Total Laparoscopic Hysterectomy (TLH) using Olympus PK Morcellator in PneumoLiner containment device
224228061|NCT00261729|DRUG|Prazosin|Prazosin
224228062|NCT00261729|DRUG|placebo|placebo capsules
224228063|NCT04061564|DEVICE|Vagal nerve stimulation|The participant will be administered electrical stimulation at a level specifically set to their comfort. This will be performed using a TENS machine device.
224228064|NCT05610501|PROCEDURE|Ultrasound guided tru-cut biopsy|Tru-cut biopsies can collect tissue specimens via a needle of 18G A tru-cut biopsy can be performed under the guidance of different imaging modalities including ultrasound
224228065|NCT00568269|PROCEDURE|Open repair|Open repair is according to the Lichtenstein technique
224228066|NCT00568269|PROCEDURE|Laparoscopic repair|The TEP (Totally ExtraPeritoneal patch) repair is used as the laparoscopic repair
224228067|NCT02621515|DRUG|Nivolumab|All patients in this phase 2 trial will receive treatment with nivolumab, a monoclonal antibody against the PD1-receptor on T cells. Dosing will be based on patients' weight (3 mg/kg). It will be administered in an intravenous infusion every 2 weeks and for a maximum of 2 years.
224228068|NCT03840746|OTHER|Tomato, onion and lovage soup (TOL)|Soup
223639950|NCT01486719|PROCEDURE|Sensate Dorsal Digital Island Flap|This article reports repair of the finger pulp defect using the dorsal digital island flap. Both dorsal branches of the proper digital nerves (PDNs) were used for maximal sensory restoration.
223639951|NCT06266247|DIAGNOSTIC_TEST|Take blood samples|Tnf alpha, sirtuin and il-6 levels will be examined in patients with Behcet\&amp;#39;s disease using biological drugs and not using biological drugs
223639952|NCT04316845|DIAGNOSTIC_TEST|18F-fluorocholine PET/CT|Patients undergo both 18F-fluorocholine PET/CT and Single isotope dual phase Tc-99m sestamibi scan (both planar scan and SPECT/CT)
223639953|NCT00852449|OTHER|restrictive and liberal fluid therapy|In both group, when hypovolemia is suspected (peak aortic velocity variation \> 13%): fluid bolus (hydroxyethyl starch 130/0.4/6%) according to a predefined algorithm designed to maintain peak aortic velocity \< 13% and no further increases in SV
224228069|NCT03840746|OTHER|TOL soup with inulin|Soup
224228070|NCT00268710|DRUG|docetaxel|
224228071|NCT00603343|DRUG|Mictonetten 5 mg, coated tablet|propiverine 10 mg b.i.d. (17-27.9 kg BW) or propiverine 15 mg b.i.d. (28-45.0 kg BW)
224228072|NCT00603343|DRUG|placebo|placebo corresponding to body weight
224228073|NCT03588390|DRUG|BI 1323495|Low strength tablet
224228074|NCT03588390|DRUG|BI 1323495|Middle strength tablet
224228075|NCT03588390|DRUG|BI 1323495|High strength tablet
224228076|NCT03588390|DRUG|Placebo|Placebo to low strength tablet
224228077|NCT03588390|DRUG|Placebo|Placebo to middle strength tablet
224228078|NCT03588390|DRUG|Placebo|Placebo to high strength tablet
224228079|NCT03980379|DRUG|304 injection|Monoclonal antibodies, 100mg/10ml per injection
224228080|NCT03980379|DRUG|rituximab injection|100mg/10ml per injection ，manufactured by Roche
223639954|NCT00417417|DRUG|Rilonacept|Lyophilized rilonacept will be supplied by Regeneron Pharmaceuticals at 160 mg/vial and reconstituted with 2.3 mL of sterile water for injection by the Clinical Center Pharmacy Intravenous Admixture Unit. The formulation contains 80 mg/mL rilonacept, histidine, citrate, PEG 3350, polysorbate 20, glycine, arginine, and sucrose (pH 6.5). Matching placebo in the identical formulation will also be supplied, and also reconstituted with 2.3 mL of sterile water for injection. Each administration of study drug will consist of two syringes containing 2.0 mL in each syringe (320 mg total drug).
223639955|NCT00417417|DRUG|Placebo|Normal saline subcutaneously at each treatment visit.
223765136|NCT07034976|DEVICE|Active Radiofrequency (Capenergy C500 UpGradeC200)|"Non-ablative radiofrequency is applied using a Capenergy C500 device at a target tissue temperature of ≤ 45 °C, once a week for 6 consecutive weeks. Treatment is delivered through two channels simultaneously: a capacitive plate placed on the suprapubic area and an intracavitary vaginal probe. Each session lasts 20 minutes and is followed by 20 minutes of pelvic-floor muscle training guided by biofeedback. Participants will also follow a progressive home exercise programme and record adherence and events.~In addition, all participants will receive education on pelvic-floor anatomy and function, underlying mechanisms of pain after breast cancer, bladder and bowel retraining, respiratory pattern re-education, and-if interested-information on sexual health."
223765137|NCT07034976|DEVICE|Sham Radiofrequency (Capenergy C500 UpGrade C200 - Placebo Mode)|"Participants will receive one session per week for 6 weeks of sham (placebo) radiofrequency using the Capenergy C500 in Placebo Mode (no temperature increase), designed to simulate active treatment. The screen will display a simulated delivered energy value; temperature and energy readings will be hidden; LED indicators will activate sequentially; and a suprapubic capacitive plate and intracavitary probe will be used with the same protocol as in the intervention group. This will be followed by 20 minutes of pelvic-floor muscle training guided by biofeedback, identical to the intervention group. Participants will also follow a progressive home exercise programme and record adherence and events. All participants will receive education on pelvic-floor function, pain mechanisms after breast cancer, bladder/bowel retraining, breathing pattern correction, and-if interested-sexual health."
223765138|NCT06714513|BIOLOGICAL|QTP101|QTP101 consists of ID93 and GLA-SE. ID93 is a recombinant protein antigen comprising four antigens from Mycobacterium tuberculosis (Mtb). The adjuvant GLA-SE is a TLR4 agonist in a stable oil-in-water emulsion.
223765139|NCT06714513|BIOLOGICAL|Placebo|Sterile 0.9% normal saline
224228081|NCT03849365|DRUG|TOOKAD VTP|TOOKAD® VTP consists of the combination of a single, 10-minute IV infusion of TOOKAD® at the dose of 3.66 mg/kg, followed by the illumination of the zone to be treated with a 753-nm laser light delivered through transperineal interstitial optical fibers at a power of 150 mW/cm and light energy of 200 J/cm applied over 22 minutes and 15 seconds.
224228082|NCT06318650|BIOLOGICAL|Demineralized Dentin Matrix|"preparation of Allogenic Demineralized Dentin Matrix: Extracted teeth will be collected from the Departments of oral maxillofacial surgery and periodontics, Cairo university. Cleaning the teeth from any caries, Filings, cement, tartar, soft tissue debris and prosthetic components will be performed using a diamond bur under abundant irrigation with physiological water. Then it will be proceeded to the following steps~1\. (Washing with Distilled water ) 2. (Quick Freezing with liquid nitrogen, then Grinding to particle size of 300- 800 μm). 3.(Ultrasonic Cleaning cycles, 1st with Distilled water , 2nd with 5-7% Hydrogen Perioxide then 3rd with Distilled water for at 60-80 o) 4. (Defatting with Chloroform Methanol Solution1:0.5. 5. (Demineralization with0.5N HCL) 6. (Dehydration with Neutral Ethyl Alcohol then Defatting with Chloroform Methanol Solution 1:0.5 for ) 7. (Washing with Normal Saline \& Freeze Drying then Sterilization using Ethylene oxide gas)."
224228083|NCT06318650|BIOLOGICAL|Demineralized freeze-dried bone allograft (DFDBA)|combination allograft, is a particulate bone graft combining 70% mineralized ground cortical with 30% demineralized ground cortical Particle sizing: 250 - 1000um.
224228084|NCT05333250|DRUG|Modafinil|Modafinil
224228085|NCT05333250|OTHER|Placebo|Placebo
224228086|NCT02010723|PROCEDURE|surgery|crossectomy and avulsion of the varicose anterior accessory great saphenous vein (AAGSV) under local anesthesia
224228087|NCT02010723|DRUG|sclerotherapy with aethoxysclerol foam|foam sclerotherapy with aethoxysclerol foam
224228088|NCT06400849|DEVICE|cryotherapy alone of the upper or lower limbs|Self-controlled trial with only standard cryotherapy. Compression glove and foot sock will only be worn on one hand and one leg on the same side allocated by randomisation
224228089|NCT06400849|DEVICE|cryotherapy and crompression of the upper or lower limbs|Self-controlled trial adding compression to standard cryotherapy. Compression glove and foot sock will only be worn on one hand and one leg on the same side allocated by randomisation
224228090|NCT01675908|PROCEDURE|Stent Dysfunction|Rate of stent dysfunction (%) which includes persistent hyperbilirubinemia or cholangitis that warrant stent exchange by another ERCP.
224319284|NCT01346787|DRUG|CARFILZOMIB, CYCLOPHOSPHAMIDE, DEXAMETHASONE|Patients will start induction treatment with Cyclophosphamide given orally at the dose of 300 mg/m2 on days 1, 8, 15. Low dose Dexamethasone will be given orally at the dose of 40 mg on days 1, 8, 15, 22 or 20 mg on days 1-2, 8-9,15-16, 22-23. Carfilzomib = 20 mg/m2 IV once daily on days 1, 2, of cycle 1 only followed by 36 mg/ m2 days 8, 9, 15, 16 in cycle 1, then for all subsequent doses 36 mg/ m2 IV once daily on days 1, 2, 8, 9, 15, 16, followed by 13-day rest period (day 17 through 28). Each cycle will be repeated every 28 days for a total of 9 courses. MANTEINANCE PERIOD At the end of induction phase (9 courses), maintenance phase with Carfilzomib alone IV at 36 mg/ m2 IV on days 1, 2, 15, 16 will start, until progression or intolerance. For patients who show evidence of progression during maintenance phase, the frequency of Carfilzomib can be increased to days 1, 2, 8, 9, 15, 16 at the discretion of the investigator, or the patient may be removed from the study
224228091|NCT01675908|PROCEDURE|Complications|Rates of procedural complications (%) such as pancreatitis, perforation or hemorrhage during stent placement will be assessed.
224323302|NCT03616587|DRUG|AZD9833|Part B: AZD9833 monotherapy expansion.
224323303|NCT03616587|DRUG|AZD9833 with palbociclib|Part C: AZD9833 in combination with palbociclib dose escalation
223639956|NCT00684021|BIOLOGICAL|Adult stem cells|One time infusion of approximately 150 million total nucleated cells (TNC) in 30 ml of 5% HSA/saline solution
223639957|NCT00684021|BIOLOGICAL|Placebo|One time infusion of 30 ml of HSA (5%)
223639958|NCT01815970|BEHAVIORAL|Pulmonary Rehabilitation|8 weeks of Pulmonary Rehabilitation including exercise and COPD related education.
223639959|NCT05670886|PROCEDURE|uterine artery ligation|The peritoneum over the vesico-uterine pouch already being incised horizontally, the peritoneum over the uterine isthmus and cervix was dissected downwards, and this dissection was then extended laterally Lower uterine incision was done followed by fetal extraction and placental delivery . bilateral uterine artery ligation were done 2cm below the uterine incision.
223639960|NCT06151457|DRUG|Alpha-Agonist|An initial infusion dose of prophylactic norepinephrine (0.05 ug/kg/min) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 0.01 ug/kg/min of prophylactic norepinephrine according to the responses of previous patients according to the up-down sequential allocation.
223639961|NCT06151457|DRUG|α-adrenergic receptor agonist|An initial infusion dose of prophylactic norepinephrine (0.05 ug/kg/min) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 0.01 ug/kg/min of prophylactic norepinephrine according to the responses of previous patients according to the up-down sequential allocation.
223639962|NCT02808117|DIETARY_SUPPLEMENT|MNP|"Program that delivered MNP and implemented by an MFI in Haiti during 2011-2012.~One form of micronutrient supplementation proven to effectively combat micronutrient deficiency."
223639963|NCT04041414|OTHER|Proud & Empowered!|Proud \& Empowered! is a school-based intervention to decrease sexual minority stress and improve coping among LGBTQ students. It is administered by school counselors and trained social workers.
223639964|NCT05035381|DRUG|Pembrolizumab (PD-1 Inhibitor) Combined With Bevacizumab and FOLFIRI Regimen|MSI-H colorectal cancer, recurrence and metastasis within 1 year after surgery, or failure of first-line oxaliplatin and fluorouracil chemotherapy for advanced colorectal cancer, PD-1 inhibitors combined with bevacizumab and FOLFIRI regimen
223639965|NCT03317015|DRUG|triamcinolone XRG5029|"Pharmaceutical form: spray solution~Route of administration: nasal"
223639966|NCT03317015|DRUG|fluticasone|"Pharmaceutical form: spray solution~Route of administration: nasal"
223639967|NCT06961097|OTHER|Virtual Reality Group|control group
223639968|NCT02900378|DRUG|LCZ696 (Sacubitril/Valsartan)|LCZ696 (sacubitril/valsartan) was available in 24 mg/26 mg, 49 mg/51 and 97 mg/103 mg mg film-coated tablets
223639969|NCT02900378|DRUG|Placebo of LCZ696 (Sacubitril/Valsartan)|Placebo of LCZ696 (sacubitril/valsartan) was available to match 24 mg/26 mg, 49 mg/51 and 97 mg/103 mg mg film-coated tablets
223639970|NCT02900378|DRUG|Enalapril|Enalapril was available in 2.5 mg, 5 mg and 10 mg film-coated tablets
223639971|NCT02900378|DRUG|Placebo of Enalapril|Placebo of Enalapril was available to match 2.5 mg, 5 mg and 10 mg film-coated tablets
223639972|NCT01807624|DRUG|Tetracaine HCl 3% and Oxymetazoline HCl 0.05%|1 spray is 0.2mL is volume and contains 6mg Tetracaine HCl 3% and 0.1mg Oxymetazoline HCl (para-butylaminobenzoic acid or PABA is active metabolite)
223639973|NCT05465317|DRUG|Empagliflozin|Empagliflozin
223639974|NCT05465317|DRUG|Dipeptidyl Peptidate-4 inhibitors|Dipeptidyl Peptidate-4 inhibitors
223639975|NCT01690143|DRUG|Carfilzomib|Subjects will receive the appropriate dose of carfilzomib (according to assigned cohort in phase 1 and at the determined MTD in phase 2) on days -3 and -2. Carfilzomib will be infused over 30 minutes. Prophylaxis of chemotherapy induced nausea and vomiting will follow institutional guidelines and SOPs.
223639976|NCT01690143|DRUG|Melphalan|Subjects will receive 200 mg/m2 of intravenous melphalan on Day -2. Administered as an intravenous push or a fast infusion according to institutional standard operating procedure (SOP). Prophylaxis of chemotherapy induced nausea and vomiting will follow institutional guidelines and SOPs.
223639977|NCT00034177|DRUG|S-8184 Paclitaxel Injectable Emulsion|
223639978|NCT00034177|DRUG|Experimental Arm: TOCOSOL Paclitaxel|Doses of 80, 100 and 120mg/m2
223639979|NCT04351581|OTHER|Discontinuation of ACEi/ARB|Discontinuation of ACEi/ARB
223639980|NCT04351581|OTHER|Continuation of ACEi/ARB|Continuation of ACEi/ARB
223639981|NCT03167749|DIAGNOSTIC_TEST|Laboratory test|Semen analysis and reproductive hormonal assay (free and total testosterone, luteinizing hormone, follicle-stimulating hormone , estradiol and prolactin hormone) for both patients and control group
223639982|NCT00678782|DRUG|etanercept|etanercept 12.5mg, intraarticular injection administered once every two weeks for an eight week period
223639983|NCT00678782|DRUG|placebo|Placebo (NaCl) 0.5 ml intraarticular injection
223639984|NCT03841396|DRUG|Sodium chloride|All participants received a single dose of sodium chloride as placebo
223639985|NCT04263155|BEHAVIORAL|The Body Project|The Body Project is a 4-hour dissonance-based program designed to address body image concerns and prevent eating disorders. The curriculum consists of written, verbal, and behavioral exercises that provide participants with the opportunity to voluntarily and publicly critique the appearance ideal.
223639986|NCT01809600|OTHER|No intervention (observational study)|
223639987|NCT04886635|OTHER|Active surveillance|Patients will undergo two clinical response evaluations (CREs) after nCRT. During CRE-1 (5-6 weeks) patients will undergo oesophagogastroduodenoscopy (OGD) with bite-on-bite biopsies. During CRE-2 (10-12 weeks) patients will undergo positron emission tomography with computed tomography (PET-CT), endoscopy with bite-on-bite biopsies and endoscopic ultrasonography (EUS) plus fine-needle aspiration (FNA). If cancer is detected, surgery will be performed. Patients with cCR are eligible for active surveillance where regular CREs are performed to detect regrowth of cancer. Delayed oesophagectomy will be offered to patients with highly suspected or profen locoregional regrowth, without distant metastases. The safety and feasibility of active surveillance depends on several factors monitored in the SANO trial. So far, these stopping rules have not been met. In case one of the stopping rules is reached, further inclusion in the SANO-2 study will be stopped and surgical resection is offered.
223639988|NCT03852056|DRUG|MFP Fluoride toothpaste|Whole mouth brushing with a toothpaste, 2 times/day for 1 minute each time for the duration of the study,
223639989|NCT03852056|DRUG|Stannous fluoride toothpaste|Whole mouth brushing with a toothpaste, 2 times/day for 1 minute each time for the duration of the study,
223639990|NCT00563875|DRUG|acetylsalicylic acid|75 mg/d for 7 days (healthy volunteers) and continued treatment with 75 mg/d in patients taking daily aspirin.
223639991|NCT04125927|DRUG|Mercaptamine|Patients will be treated with 1 drop in each eye 4 times a day, at the same dose and regimen than the one indicated in adults and children from 2 years of age.
223639992|NCT04769934|DEVICE|Penguin RFA|to evaluate the peri-implant bone level changes (marginal bone level) around the implant platform.
223639993|NCT04351334|DRUG|Alectinib|Observational treatment based on physician choice
223639994|NCT02269969|DRUG|Tobramycin|
223639995|NCT01884467|DRUG|Gentamicin|Comparison of Gentamicin versus placebo
223639996|NCT01884467|DRUG|Placebo|
223639997|NCT01547923|GENETIC|Blood sample for phenotypic and pharmacogenetic analysis.|Prior to treatment by 5-FU, a DPD deficiency is identified thanks to just one blood sample (lithium heparinate).
223639998|NCT01547923|GENETIC|Blood sample for phenotypic and pharmacogenetic analysis.|Blood sample (lithium heparinate) will be taken prior to treatment but not analysed.
223639999|NCT00502476|PROCEDURE|Bathing with Chlorhexidine Impregnated Washcloths|
223640000|NCT04820569|PROCEDURE|Resection and chemotherapy|
223640001|NCT03125486|DRUG|SC belimumab 200 mg|Belimumab subcutaneous 200 mg will be supplied for compassionate use for the identified individual subject.
224228092|NCT04011969|DIAGNOSTIC_TEST|Score assessment|Asia Pacific Colorectal Screening (APCS) is a validated tool to predict the risk of colorectal cancer in asymptomatic Asian population. The scoring system comprises of three categories: low risk (score 0-1), moderate risk (score 2-3) and high risk (score 4-7). Patients with moderate and high risk will undergo further examinations.
223640002|NCT03141138|BIOLOGICAL|TDENV-PIV|Dosage: 0.5 mL of DENV serotypes 1-4 (4 µg / serotype) in alum adjuvant Mode of administration: intramuscular (IM) into the subject's upper arm, deltoid area of the subject's arm; vaccination will be given in the non-dominant arm whenever possible
223640003|NCT03141138|BIOLOGICAL|TDENV-LAV F17|Dosage: 0.5 mL of the post-transfection LAV F17 vaccine Mode of administration: subcutaneously into the upper-outer triceps/deltoid area of the subject's arm; vaccination will be given in the non-dominant arm whenever possible.
223640004|NCT03537755|OTHER|Observation|Examine thoughts and behaviors
223640005|NCT04232358|DRUG|Corticosteroid injection|Corticosteroid injections are administered ultrasound guided in the bursa adjacent to the achilles tendon insertion every 4 weeks until symptoms resolve with at maximum of 3 injections.
223640006|NCT04232358|DRUG|Local anesthesia injections|Local anesthesia injections are administered ultrasound guided in the bursa adjacent to the achilles tendon insertion every 4 weeks until symptoms resolve with at maximum of 3 injections.
223640007|NCT00000996|DRUG|Doxorubicin hydrochloride|
223640008|NCT01427764|DEVICE|manual and ultrasonic instruments|"The individuals were instructed regarding causes and consequences of periodontal disease as well as prevention techniques, including the sulcular brushing technique and flossing. The retention factors of plaque (caries cavities, excess supragingival restorations and calculus) were removed during the initial visits. Clinical parameters were initially assessed 30 days after initial therapy.~The quadrants were randomly assigned and a total of 28 teeth were examined and treated. One side was treated with Gracey curettes (Hu-Friedy™ - Chicago, IL, USA) - control group and the other side with ultrasonic instruments (Profi II Ceramic™, Dabi Atlante - Ribeirão Preto, São Paulo, Brazil) - the test group, using the tip for subgingival instrumentation Perio Sub (Dabi Atlante ®)."
223640009|NCT04362241|DRUG|Prednisolone Acetate 1% Ophthalmic Suspension [PRED FORTE]|Prednisolone Acetate 1% ophthalmic drops
223640010|NCT03104907|PROCEDURE|Prostatic Artery Embolization|The procedure is performed with the patient under local anaesthetic and if necessary sedation. We will be using a percutaneous transfemoral approach, super-selective catheterisation of small prostatic arteries is carried out using microcatheters. Embolisation will be done using microspherical embolic material.
223640011|NCT05666869|DRUG|Esketamine perfusion|Analgesic dose of ESKETAMINE via a 30 minutes.intravenous perfusion
223640012|NCT04355169|DRUG|Naldemedine|Oral tablet
223640013|NCT04355169|DRUG|Placebo|Oral tablet
223640014|NCT05798767|BEHAVIORAL|Neuropsychological tests|"Cognitive function screening (Mini-Cog; the Mini-mental State Examination, MMSE), depression screening (Patient Health Questionnaire-9, PHQ-9), sleep quality assessment (Pittsburgh Sleep Quality Index, PSQI), and pain assessment (Numeric Rating Scale, NRS) were performed the day before surgery.~The Short Confusion Assessment Method (CAM) was administered once per day on postoperative days 1 to 5 to evaluate delirium."
223640015|NCT03460795|BIOLOGICAL|MSC and Tregs|conventional plus MSC and Tregs or placebo treatment
223640016|NCT01621269|DRUG|Fingolimod|
223640017|NCT04466943|DEVICE|Neuromuscular transmission monitoring (NMT)|NMT is to monitor the depth of neuromuscular blockade intensity
223640018|NCT04046120|OTHER|Heel-free bandage|The bandage is made by leaving the heel uncovered.
224323304|NCT03616587|DRUG|AZD9833 with palbociclib|Part D: AZD9833 in combination with palbociclib expansion
224323305|NCT03616587|DRUG|AZD9833 with everolimus|Part E: AZD9833 in combination with everolimus dose escalation
224323306|NCT03616587|DRUG|AZD9833 with everolimus|Part F: AZD9833 in combination with everolimus dose expansion
223640019|NCT04488614|PROCEDURE|Breast Concervative or Meastectomy|National treatment guidelines in Norway
223640020|NCT04824339|BEHAVIORAL|Immediate Intervention Group|This study is a partial cross over study. The intervention is 8 weeks in duration. Participants will be randomized to immediate exercise or delayed exercise, and the delayed exercise group will cross over to the intervention after 8 weeks.
223640021|NCT04824339|BEHAVIORAL|Delayed Intervention Group|This study is a partial cross over study. The intervention is 8 weeks in duration. Participants will be randomized to immediate exercise or delayed exercise, and the delayed exercise group will cross over to the intervention after 8 weeks.
223640022|NCT01409707|BEHAVIORAL|Trauma-focused exposure therapy|cognitive behavioral therapy for PTSD
223640023|NCT01409707|BEHAVIORAL|Motivational enhancement + trauma-focused exposure therapy|Cognitive behavioral therapy for PTSD
223640024|NCT01409707|BEHAVIORAL|Healthy lifestyles sessions|
223640025|NCT02792686|DRUG|ABX464|Single Administration
223640026|NCT06380621|PROCEDURE|Totally Extra Peritoneal repair (TEP) repair|TEP repair
223640027|NCT05846243|BIOLOGICAL|VAC∆6 vaccine (10⁷ PFU)|"Live cell-based vaccine against smallpox and other orthopoxvirus infections (VAC∆6 vaccine) based on vaccinia virus (manufactured by FBRI SRC VB Vector, Rospotrebnadzor).~Batch: 08-10.19 (expiry date: 13.10.2021). Dosage: single intradermal dose of 10⁷ PFU/0.2 ml of vaccinia virus."
223640028|NCT05846243|BIOLOGICAL|VAC∆6 vaccine (10⁶ PFU)|"Live cell-based vaccine against smallpox and other orthopoxvirus infections (VAC∆6 vaccine) based on vaccinia virus (manufactured by FBRI SRC VB Vector, Rospotrebnadzor).~Batch: 08-10.19 (expiry date: 13.10.2021). Dosage: two intradermal doses of 10⁶ PFU/0.2 ml of vaccinia virus (given 28 days apart)."
223640029|NCT05846243|BIOLOGICAL|Live Smallpox Vaccine|"Live smallpox vaccine (Smallpox vaccine) (manufactured by the Federal State Unitary Enterprise NPO Microgen of the Ministry of Health of Russia).~Batch No. Т30 (expiry date: March, 2021). Dosage: Single 1x10⁶ PFU dose administered by multiple-pricking technique on the 30th/60th day after full series of vaccination with VAC∆6."
223640030|NCT05846243|OTHER|Placebo (Sodium chloride bufus, 0.9%)|"Sodium chloride bufus, a 0.9% solvent for the preparation of a dosage form for injections (manufactured by JSC Pharmaceutical manufacturing company Obnovlenie, Russia).~Batch: 391219 (expiry date: January, 2025)."
223640031|NCT04479995|BEHAVIORAL|Horizon Program|Telehealth videoconferencing sessions and questionnaires.
223640032|NCT04479995|BEHAVIORAL|Usual Care|Standard medical visits with additional paper or electronic booklet.
223640033|NCT01658436|DRUG|BEZ235 (Stage 1)|The investigational study drug used in this trial was BEZ235, which was supplied as 50mg, 200mg, 300mg, and 400mg solid dispersion sachets. Supply as 200mg and 50mg were provided for dose reduction. Patients were instructed to take the contents of one sachet of BEZ235 twice a day in the morning within 30 minutes after a light meal (breakfast).
223640034|NCT00686712|DRUG|1- Insulin glargine QHS|Insulin glargine at bedtime (dose titrated to maintain 50% of fasting glucose readings \<120 mg/dL)
223640035|NCT00686712|DRUG|2 - Insulin glargine QAM|Insulin glargine in AM (dose titrated to maintain 50% of pre-supper glucose readings \<120 mg/dL)
223640036|NCT00686712|DRUG|3 - NPH insulin QHS|NPH insulin at bedtime (dose titrated to maintain 50% of fasting glucoses \<120 mg/dL)
223640037|NCT06086717|OTHER|Kinesio Taping|"One Y-shaped strap with 25% stretch was applied from the mid third of the thigh over the rectus femoris, then its ends directed toward the tibial tuberosity by enwrapping the patella from lateral and medial sides. In 45° knee flexion one eye strap from medial to lateral was applied through the collateral medial and lateral ligaments.~For the facilitation of VMO 1 eye strap with 25% stretch from medial aspect of thigh to quadriceps tendon. Lastly, 1 eye strap with 25% stretch from tibial tuberosity to lateral aspect of thigh for inhibition of Vastus lateralis"
223640038|NCT06086717|OTHER|Dry Needling|"Following a protocol according to patient and limb, the tensor fasciae latae, hip adductors, hamstrings, quadriceps, gastrocnemius, and popliteus muscles were properly examined in each subject. These muscles are frequently involved in muscle-related knee pain.~Patients with knee OA who had at least one active MTrP that produced pain were recruited. Patients received a total of 8 DN sessions (2 sessions per week for 4 weeks) at all MTrPs of the lower limbs using the fast-in and fast-out technique (the needle was moved up and down within the muscle)."
223640039|NCT00044616|DRUG|Fluoxetine|
223640040|NCT00044616|DRUG|Lithium|
223640041|NCT03798951|OTHER|Prehabilitation|"The patients included in the treatment group will follow a prehabilitation program, based on a physiotherapist, nutritionist and psychologist evaluation. All the treatments will be tailored according the characteristics of each single patient.~The program will have a duration of, at least, 4 weeks."
223640042|NCT05251480|PROCEDURE|Standard of Care|debridement, wound dressings, offloading
223640043|NCT05251480|OTHER|DermGEN™|Decellularized human dermal matrix created from donated human skin
223640044|NCT05154786|OTHER|Early Mobilization and endurance training|The early mobilization and endurance training will be conducted with grading exercise level. In the course of endurance training. After achieving patient's active participation in sitting on the bed, the goal will be to train for at least 20 min. If this is accomplished, exercise level and training period increased until a maximum of 7 on modified RPE. If these are well-tolerated and no contraindications as per medical prescription exist, the treatment will be further advanced to mobilizing participants to the bedside. After being able to sit for at least 10 min on the side of the bed, regardless of whether support is needed, participants will be moved into a chair with an individually adapted transfer according to the individual's resources.While sitting, functional tasks and activities of daily living will be performed and gradually increased to standing and walking exercises.
223640045|NCT05154786|OTHER|Usual Care|The weaning protocols, bed exercise, positioning, respiratory therapy, and early mobilization.
223640046|NCT03987503|DRUG|Epclusa (SOF/VEL)|a trained physician will provide research participants with two-week supply of SOF/VEL. Treatment is: 1 tablet SOF/VEL (400 mg sofosbuvir/100 mg velpatasvir) daily x 12 weeks. The initial 2-week supply is provided by Gilead Sciences and will be dispensed to participants upon enrollment. Prescriptions and insurance prior authorizations for SOF/VEL will be submitted by the study pharmacist though the UCSF Specialty Pharmacy. The study team will be notified once insurance-authorized drug is available and will bring participants' medication in 2 supplies to the study site prior to study visits.
223640047|NCT03987503|DRUG|Standard of care|Standard of HCV care provided by medical care provider
223640048|NCT03987503|DEVICE|Fibroscan® 430 Mini Plus|"Trained research staff will measure participants liver stiffness using liver ultrasonographic elastography. Research staff place ultrasound gel directly on participant's skin on the area of the torso. Research staff will position the participant's body on the exam table to assure the liver can be located, placing the small probe on the body's surface (skin with gel) and begin recording images of the participant's liver.~The procedure will take 15-30 minutes, depending on the ease with which the research staff is able to accurately locate the participant's liver.~Results from the FibroScan will be discussed with a trained provider."
224228093|NCT04011969|DIAGNOSTIC_TEST|Blood sampling|"Blood samples will be taken before colonoscopy procedure to evaluate the level of serum CEA by ELISA method and to evaluate the presence of NF-ҡB by immunohistochemical method.~1. Carcinoembryonic antigen (CEA) is a well-known marker for colorectal cancer. A pre-treatment serum CEA level of ≥ 5 ng/mL is associated with poor prognosis in colorectal cancer patients.~2. NF-ҡB is a chronic inflammation marker found in colorectal cancer patients."
224228094|NCT04011969|DIAGNOSTIC_TEST|Fecal sampling|"Fecal samples will be taken before colonoscopy procedure to be tested for FIT and to evaluate the gut microbiome.~1. Fecal immunochemical test (FIT) is a recommended screening method for colorectal cancer. Detection of hemoglobin over a certain level in fecal samples indicated a positive FIT. Patients with positive FIT will undergo further examinations.~2. Gut microbiome examination will be conducted with next generation sequencing (NGS) method."
224323307|NCT03616587|DRUG|AZD9833 with abemaciclib|Part G: AZD9833 in combination with abemaciclib (± anastrozole) dose escalation
224323308|NCT03616587|DRUG|AZD9833 with abemaciclib|Part H: AZD9833 in combination with abemaciclib (± anastrozole) dose expansion
224323309|NCT03616587|DRUG|AZD9833 with capivasertib|Part I: AZD9833 in combination with capivasertib dose escalation
223640049|NCT00059462|DRUG|Interleukin-2 SA|HAART and Bay 50-4798
223640050|NCT00059462|DRUG|HAART|HAART alone
223640051|NCT05361707|DRUG|Tasimelteon Oral Capsule, Tasimelteon Liquid Suspension|Once Daily
223640052|NCT01706133|OTHER|Factors associated with the use of emergency departments|Participants who were assigned to the intervention will be evaluated jointly by the medical service by a medical specialist in geriatrics and a nurse trained in gerontology and geriatrics. The doctor will monitor the apparition and / or aggravation of any geriatric syndromes already established by the specialty in geriatrics, namely, polypharmacy, delirium, dementia, depression, risk of falls, etc.. The nurse will monitor and follow up in four areas I. medical issues (pressure ulcers, infusion, mobility); II. Mental and emotional state and coping strategies with hospitalization; III. functionality, and IV. Atmosphere (A. Service status, architectural difficulties for mobility, bathing etc. B. Support Network, caregiver, and C. hardship)
223640053|NCT00464633|DRUG|alvocidib|"1st dose: 30 mg/m2 as a 30-minute intravenous (IV) infusion followed by 30 mg/m2 as a 4-hour continuous infusion~Then, every treatment week, depending upon the patient's objective response to initial therapy:~* 30 mg/m2 over 30 minutes followed by 50 mg/m2 over 4 hours or~* 30 mg/m2 over 30 minutes followed by 30 mg/m2 over 4 hours."
223640054|NCT00655902|DIETARY_SUPPLEMENT|Trans fat (soy bean oil)|Industrially produced trans fatty acid from soy bean oil (15 g/d for 16 weeks). The fat (a total of 25 g/d) will be baked into buns.
223640055|NCT00655902|DIETARY_SUPPLEMENT|Control fat (sunflower oil)|Control fat from sunflower oil, with 60% oleic acid (in total 25 g/d for 16 weeks). The fat will be baked into buns.
224228095|NCT06467422|DEVICE|tTIS on dACC, theta frequency (5 Hz)|"Device: Transcranial electric stimulation device~The first pair of electrodes continuously outputs a current with a frequency of f1 = 2 kHz, while the second pair continuously outputs a current with a frequency of f2 = 2.006 kHz. According to the principle of time-domain coherence, an alternating electric field with a frequency of f2-f1 = 6 Hz can be generated in the target area. The experimental group receives a stimulation intensity of 2mA for 20 minutes. The optimal electrode position and current parameters are determined by using the MIDA head electric field model."
224228096|NCT06467422|DEVICE|tTIS on dACC, High frequency|The first pair of electrodes continuously outputs a current with a frequency of f1 = 2 kHz, while the second pair continuously outputs a current with a frequency of f2 = 2 kHz. The sham group receives a stimulation intensity of 2mA for 20 minutes. The optimal electrode position and current parameters are determined by using the MIDA head electric field model.
224228097|NCT03426930|OTHER|self-evaluation of the Body Mass Index|Evaluation of the Body Mass Index before and after the treatment
224228098|NCT03426930|OTHER|Cognitive-behavioral psychotherapies|Cognitive-behavioral psychotherapies before and after the treatment
223640056|NCT04418648|DRUG|Toripalimab|Toripalimab consolidation (240 mg) via iv infusion once every 3 weeks. Administration of toripalimab will commence on Day 1 following randomisation to toripalimab after confirmation of eligibility and will continue on a Q3W schedule for a maximum duration of 6 months.
224228099|NCT01006707|DRUG|Ondansetron|In this cross-over study, the blinded patient will receive saline placebo in one session and ondansetron in the other. The order is decided with a randomization table. If ondansetron is randomly chosen, an 8mg IV Bolus will be given at the start of the study for 30 minutes by the unblinded investigator.
223640057|NCT03223896|DRUG|Naloxone hydrochloride 20mg/ml|Nasal spray
223640058|NCT01929317|DRUG|Ropinirole CR 2mg tablet|Ropinirole CR 2mg tablets will be supplied as white oval film-coated tablets.
223640059|NCT01929317|DRUG|Ropinirole CR 8mg tablet|Ropinirole CR 8mg tablets will be supplied as white oval film-coated tablets.
223640060|NCT01929317|DRUG|Ropinirole CR matching Placebo tablet|Ropinirole CR matching Placebo tablet tablets (containing no active ingredients) indistinguishable in appearance from Ropinirole CR 2 mg tablets.
224228100|NCT00219661|PROCEDURE|drainage of subglottic secretions (HiLo Evac tube)|
224228101|NCT00976235|DEVICE|IMT - Implantable Miniature Telescope|Implantation of the telescope prosthesis (performed under the initial study)
224228102|NCT00974883|PROCEDURE|Ultrasound of temporal and axillary arteries|Standardised assessment of temporal arteries and axillary arteries using high resolution ultrasound to detect halo, stenosis or occlusion
224228103|NCT00974883|PROCEDURE|Temporal artery biopsy|Biopsy of temporal artery from symptomatic side
224228104|NCT02750306|DRUG|Suvorexant|10 mg tablet (may be increased to 20 mg tablet)
224228105|NCT02750306|DRUG|Placebo|Placebo to suvorexant
223640061|NCT05799885|OTHER|Neuro-vestibular-ocular group|Neuro-vestibular-ocular exercise group (30 footballers)will do the exercises given in addition to their training
224228106|NCT01115218|PROCEDURE|Trabeculectomy|Trabeculectomy with mitomycin C
224228107|NCT00704223|DRUG|biphasic insulin aspart|Start dose and frequency to prescribed by the physician as a result of a normal clinical evaluation
224228108|NCT02307383|DRUG|Lactitol|
224228109|NCT02307383|DRUG|Lactobacillus|
224228110|NCT04523805|BEHAVIORAL|Adapted judo programme|"The judo sessions were 75 minutes in duration and were held once a week. Two judo teachers led each session, and at least four volunteer judo instructors were present to lend support. The sessions were divided into warm-up, main exercise and cool-down activities. The main exercise content of the sessions included:~* Different types of movements and falling techniques (from walking in all directions to turning around, from stable movements to unstable movements).~* Judo techniques and games (building up body contact with games, teaching simplified movements, essential judo movements) (blinded for review).~* Ground control techniques and throws (gradually adding techniques to already known movements, scaffolding basic repetitive movements to assist in understanding to those more relevant for judo ).~* Repetition of different forms of foundational directional movements (pulling, pushing, holding, lifting)."
224228111|NCT05403411|OTHER|Distance education for nursing students on critical thinking|The students in the intervention group were trained with distance education method for the first 4 weeks, and in the following weeks, with theoretical and case presentations. Critical thinking techniques were used during the trainings. A total of 8 weeks of training was given. Training was given for the first 5 weeks without interruption, and for the next three weeks with a two-week break. Critical thinking disposition scale was applied in the pre-test and post-test.
224228112|NCT00942461|PROCEDURE|Laparoscopic colectomy|Laparoscopic colectomy. Epidural anaesthesia used
224228113|NCT00942461|PROCEDURE|Open colectomy|Open colectomy. Epidural anaesthesia used
223640062|NCT05799885|OTHER|Myofascial Release group|Manual myofascial release will be applied by the physiotherapist.(30 football players)
223640063|NCT03616028|DEVICE|left atrial appendage closure|Closure of the left atrial appendage (LAAC) is performed percutaneously. Implantation of the CLAAS device will be performed according to device specific instructions for use based on both TEE guidance, ICE and angiography, femoral access and inter-atrial septum crossing
223640064|NCT00100971|DRUG|autologous tumor cell vaccine|
223640065|NCT00100971|DRUG|therapeutic autologous dendritic cells|
223640066|NCT00100971|PROCEDURE|tumor cell-derivative vaccine therapy|
223640067|NCT01523756|DEVICE|test product 1: new ostomy base plate with Coloplast as manufacturer|test product 1 is tested first
223640068|NCT01523756|DEVICE|test product 2: new ostomy base plate with Coloplast as manufacturer|test product 2 is tested first
223640069|NCT00515619|DRUG|Lacosamide|50 mg and 100 mg tablets up to 800 mg/day as twice day (BID) dosing throughout the trial
223640070|NCT04407754|DIETARY_SUPPLEMENT|Inositol supplement|Inositol supplements given to inositol arm
223640071|NCT04407754|DIETARY_SUPPLEMENT|Placebo supplement|Placebo supplement given to placebo arm
223640072|NCT05227196|DRUG|Semaglutide D Dose 1|Tablet given orally
223640073|NCT05227196|DRUG|Semaglutide D Dose 2|Tablet given orally
223640074|NCT05227196|DRUG|Semaglutide D Dose 3|Tablet given orally
223640075|NCT05227196|DRUG|Semaglutide Dose 4|Tablet given orally
223640076|NCT05227196|DRUG|Semaglutide Dose 5|Tablet given orally
223640077|NCT05227196|DRUG|Semaglutide Dose 6|Tablet given orally
223640078|NCT01051895|OTHER|high risk HPV DNA testing|Specimens will be collected with a cervical cytobrush and cervical cells will be resuspended in 2 ml of Preservcyt® (Hologic LP), a liquid cytology preservation media. 75µl of processed sample will be hybridized with 25 µl of probe B mixture. The assay is completed as a standard enzyme immunoassay with the addition of a dioxetane-based chemiluminescent substrate. Specimens will be considered positive for HPV if the ratio of RLUs of the specimen to the mean RLUs of triplicates of positive control (at 1 pg per ml or 5000 copies of HPV genome per test) is at least one.
223640079|NCT01051895|OTHER|Active comparator: Routine colposcopy|Women will undergo colposcopy, with no standardized protocol; tests are left at the discretion of the treating physician, in order to document routine proactive. We will document all procedures (biopsies, endocervical curettage, cytology, etc) and their outcome.
223640080|NCT04073875|DIAGNOSTIC_TEST|18F-GP1|18F-GP1 PET-CT scan
223640081|NCT03025971|DEVICE|J-Valve Transcatheter Aortic valve replacement|Transapical Transcatheter Aortic Valve Replacement
224228114|NCT03787485|BEHAVIORAL|LINKS|The primary aim of LINKS is to create community-clinical linkages between three community health centers and their respective county health departments in southern Arizona. This study will also develop and evaluate a chronic disease and emotional well-being intervention that will connect clinic patients to community-centered, county-delivered, community health worker programs.
224228115|NCT03969459|BIOLOGICAL|breast milk collection|3 samples of 20 ml of breast milk will be collected between day 0 and day 4; between day 7 and day 15; and between day 21 and day 30 after childbirth.
224228116|NCT03969459|BIOLOGICAL|meconium collection|3 samples of 20 ml of meconium milk will be collected between day 0 and day 4; between day 7 and day 15; and between day 21 and day 30 after childbirth.
224228117|NCT03969459|BIOLOGICAL|newborn feces collection|3 samples of 20 ml of newborn feces will be collected between day 0 and day 4; between day 7 and day 15; and between day 21 and day 30 after childbirth.
224228118|NCT03969459|OTHER|questionary of pesticide exposure of the mother|maternal questionary of pesticide exposure of the mother
224228119|NCT00788190|PROCEDURE|Distal Radius Fracture Reduction|Surgical Intervention to Reduce Distal Radius Fracture
224228120|NCT00788190|OTHER|Conservative Management|Conservative management of Distal Radius Fractures
224228121|NCT03931096|OTHER|Quality of life questionnaire|Self and proxy PedsQL 4.0 questionnaires.
224228122|NCT04020107|OTHER|Compressive garment and Somatosensori Remediation|Each patient will benefit successively: from a classic care, over a period of 2 to 4 months, then will be treated with compressive or low compressive garments associated with specific proprioceptive physiotherapy program during the next 4 months. Finally, the 4 last months, patient will made adapted physical activity with both dance sessions strengthening the body diagram and stretching sessions
223640082|NCT06119308|OTHER|Benzodiazepine Medication Taper with Cognitive Behavioral Therapy|Brief Cognitive Behavioral Therapy to Enhance Benzodiazepine Deprescribing (led by pharmacist/clinician/psychologist) over a 10-week Trial.
223640083|NCT06585657|DEVICE|brain visual perception training group|Conduct brain visual perception training through a visual training system to improve binocular visual balance. Train 2 projects per day, each lasting 10 minutes.
223640084|NCT00289042|DRUG|Enoxaparin|
223640085|NCT06175884|OTHER|Video about pain neuroscience education with enhancing communication skills|Participants will watch a brief video on pain neuroscience in which physiotherapist will show evidence-based communication skills to effectively convey information to patients.
223640086|NCT06175884|OTHER|Video about pain neuroscience education without enhancing communication skills|Participants will watch a brief video on pain neuroscience in which physiotherapist will not show evidence-based communication skills to effectively convey information to patients.
223640087|NCT03626103|BEHAVIORAL|+ Brief ED Intervention (BI)|Brief ED Intervention (BI): A 20-minute Motivational Interviewing- and Cognitive Behavioral Therapy-based in-Emergency Department session delivered by a bachelors'-level Research Assistant
223640088|NCT03626103|BEHAVIORAL|+ Text|Text: 8 weeks of an automated, tailored, two-way text-message curriculum started after the ED visit, which reinforces cognitive reappraisal, emotional regulation, and self-efficacy skills. Those that do not show improvement in mood after 7 days will be randomized into LiveText.
223640089|NCT06275685|DEVICE|SeizureWise algorithm|An investigational algorithm which enables forecasting of future seizure probabilities based on the pattern and frequency of previous generalized tonic-clonic seizure (GTCS) events, as well as changes in physiological and behavioral variables
223640090|NCT06275685|DEVICE|Multi-day Visualizations|Multi-day visualizations of sensor derived data
223640091|NCT05667181|DEVICE|Surform|Da Vinci linear cutting stapler
224323310|NCT03616587|DRUG|AZD9833 with capivasertib|Part J: AZD9833 in combination with capivasertib dose expansion
223640092|NCT05104606|OTHER|TEE|"The intervention within the framework of the protocol will consist, for the needs of the study, in performing 2 TEE and 5 TTE in 24 hours after~For TEE:~* The first TEE will allow us to evaluate the right ventricle, to look for the existence of a acute cor pulmonale, to evaluate the patient's blood volume as recommended during the management of ARDS. If the patient is included in the study, our intervention will consist in leaving this TEE in place in order to perform measurements at H0, 30min, H1 and H2 after iNO administration.~* The second TEE will be performed at H24 to performed new measurements."
223640093|NCT05104606|OTHER|TTE|"For TTE:~• The TTEs will allow us to evaluate the anatomy of the right ventricle, to estimate the systolic pulmonary artery pressure, to calculate the cardiac output and to measure the conventional parameters of the right ventricular systolic function. This noninvasive examination will be repeated at 30 min, H1, H2, and H24 after iNO administration"
223640094|NCT06601114|DRUG|Paracetamol Group|Group A: Paracetamol Group will receive Oral form of paracetamol with dosage of 15mg/kg every 6 hours for 3 days
223640095|NCT06601114|DRUG|Ibuprofen group|Group B: Ibuprofen Group will receive oral form of ibuprofen at initial dosage of 10mg/kg followed by 5mg/kg after 24 hours and 48 hours.
223640096|NCT01588522|DRUG|Compound 31543 Calcitriol 5 μg/mL|5 μg/mL Topical Solution
223640097|NCT01588522|DRUG|Compound 31543 Calcitriol 10 μg/mL|10 μg/mL Topical Solution
223640098|NCT01588522|DRUG|Compound 31543 Calcitriol 20 μg/mL|20 μg/mL Topical Solution
223640099|NCT01588522|DRUG|Compound 31543 Calcitriol 40 μg/mL|40 μg/mL Topical Solution
223640100|NCT01588522|DRUG|Compound 31543 Calcitriol 60 ug/mL|60 ug/mL Topical Solution
224228123|NCT02224209|DEVICE|Abbott EPD systems (Accunet/Emboshield), a balloon, stent|"Standard method of endovascular interventional treatment:~Method of stage-1 angioplasty~1. The stent can be placed into the distal stenosis under Abbott EPD systems (Accunet/Emboshield) if distal filter cannot be used, balloon angioplasty can be performed under proximal protection device;~2. Use a balloon with diameter of 2mm × 2cm for stage-1 dilation until angiography shows residual stenosis \<70%.~Method of stage-2:~1. The stent systems (Acculink/Xact) can be placed into the distal stenosis under Abbott EPD systems (Accunet/Emboshield);~2. Use an Abbott balloon (diameter of 4 \~ 6mm) for pre-dilation or post-dilation;~3. After the placement of stent, the angioplasty is a success when residual stenosis is \<30%."
224228124|NCT02224209|DEVICE|a balloon, stent|"Routine stenting procedure:~1. The stent systems (Acculink/Xact) can be placed into the distal stenosis under Abbott EPD systems (Accunet/Emboshield);~2. Use an Abbott balloon (diameter of 4 \~ 6mm) for pre-dilation or post-dilation;~3. After the placement of stent, the angioplasty is a success when residual stenosis is \<30%."
223640101|NCT01588522|DRUG|Compound 31543 Calcitriol 80 μg/mL|80 μg/mL Topical Solution
223640102|NCT05500794|OTHER|MBSR (Mindfulness-Based Stress Reduction)|"MBSR (Mindfulness-Based Stress reduction) program : 1 weekly session of 2 hours and a half for 8 weeks, (first and last session: 3 hours) and an optional day of intensive practice of 6 hours, supervised by an MBSR instructor.~In each weekly session, the instructor creates a supportive environment in which:~* Guided meditation practices;~* Mindfulness stretching and yoga;~* Reflection and group discussion periods aimed at promoting mindfulness in daily life;~* Practice instructions and opportunity to ask questions;~* Instructions for home practice. Audio recordings and a manual are provided to support personal practice.~Audio recordings and a manual are provided to support personal practice"
223640103|NCT05027230|DRUG|STSP-0601 for Injection|A multiple-dose design to evaluate the safety,tolerability and efficacy of two doses of STSP-0601 for injection in patients with inhibitory hemophilia
223640104|NCT05027230|DRUG|STSP-0601 for Injection|A multiple-dose design to evaluate the safety,tolerability and efficacy of two doses of STSP-0601 for injection in patients with inhibitory hemophilia
223640105|NCT03667378|BEHAVIORAL|Expectations Survey (CanCORS)|Study assessments will be conducted at baseline (t0); at 3-6 weeks +/- 1 week from Day 1 of receiving investigational therapy, prior to sharing information on treatment response and before the first planned scan to evaluate extent of disease (t1); and at 8-12 weeks (the end of the 3 month total study time period) (t2).
223640106|NCT03667378|BEHAVIORAL|Values Survey (Serious Illness Care Program)|Study assessments will be conducted at baseline (t0); at 3-6 weeks +/- 1 week from Day 1 of receiving investigational therapy, prior to sharing information on treatment response and before the first planned scan to evaluate extent of disease (t1); and at 8-12 weeks (the end of the 3 month total study time period) (t2).
223640107|NCT03667378|BEHAVIORAL|Functional Assessment of Cancer Therapy-General (FACT-G)|Study assessments will be conducted at baseline (t0); at 3-6 weeks +/- 1 week from Day 1 of receiving investigational therapy, prior to sharing information on treatment response and before the first planned scan to evaluate extent of disease (t1); and at 8-12 weeks (the end of the 3 month total study time period) (t2).
223640108|NCT03667378|BEHAVIORAL|NCCN Distress Thermometer|Study assessments will be conducted at baseline (t0); at 3-6 weeks +/- 1 week from Day 1 of receiving investigational therapy, prior to sharing information on treatment response and before the first planned scan to evaluate extent of disease (t1); and at 8-12 weeks (the end of the 3 month total study time period) (t2).
223765140|NCT06876779|BEHAVIORAL|VR intervention|The intervention comprises six sessions of 60 minutes each. There are six VR scenarios such as a café, MTR, school scene, and classroom. The difficulty levels of these scenarios are determined by several factors: (1) the density and proximity of individuals present, as observed in a café or MTR setting, (2) the presence of familiar individuals, such as acquaintances or classmates who may be encountered and greeted in a school environment, and (3) the level of interaction required, such as engaging in a group discussion within a classroom. Participants have the flexibility to choose a different scenario for each session or repeat a previously selected one.
223765141|NCT06703021|DRUG|aleniglipron or placebo|Drug: aleniglipron administered orally; Drug: placebo administered orally
223765142|NCT06703021|DRUG|aleniglipron or placebo|Drug: aleniglipron administered orally; Drug: placebo administered orally
223765143|NCT06703021|DRUG|aleniglipron or placebo|Drug: aleniglipron administered orally; Drug: placebo administered orally
223765144|NCT06703021|DRUG|aleniglipron or placebo|Drug: aleniglipron administered orally; Drug: placebo administered orally
223765145|NCT06886230|DRUG|Placebo (Normal Saline)|Patients in this group will receive an intravenous (IV) injection of normal saline before surgery. This serves as a control group to compare the efficacy of active treatment groups in preventing postoperative nausea and vomiting.
224319285|NCT06423092|OTHER|Music therapy songwriting|"Session 1: The goal of the first music therapy session is to know the parents musically and to provide information about song creation. This is achieved by exploring their favorite songs. Options for creating a song (original song or song parody) are presented and possibilities for creating lyrics are discussed.~Sessions 2-7: The structure of the song will be created and discussed with the parents. Parents will also be invited to include written messages from other family members in the lyrics if they wish. In each session, the developing welcome song is sung together with the parents, accompanied by the music therapist, who provides vocal or instrumental support.~The final sessions (Sessions 8-9) are dedicated to singing the final version of the song with the parents and their infant. Should the parents desire, a final recording of the song will also be made and the digital songbook will be created."
224228125|NCT01032395|BIOLOGICAL|Focetria®|7.5 ug of HA antigen; adjuvanted; monovalent
224228126|NCT01032395|BIOLOGICAL|Fluad®|15 ug of HA antigen; adjuvanted; trivalent
224228127|NCT01032395|BIOLOGICAL|Begrivac®|15 ug of antigen; non-adjuvanted; trivalent
224228128|NCT03960697|BEHAVIORAL|walk out from operating room|After the surgery of laparoscopic total or partial nephrectomy， patients will be encouraged to walk out from the operating room and return to the ward by walking under the condition of stable physiological parameters, painlessness, clear consciousness and normal muscle strength of lower limb
224228129|NCT01953497|DRUG|URC102|
224228130|NCT01953497|DRUG|Placebo|
224228131|NCT04750005|OTHER|Listerine Cool Mint|Participants use 20 mL of Listerine cool mint mouth rinse for 30 sec after brushing twice a day.
224228132|NCT04750005|OTHER|Colgate Cavity Protection Toothpaste|Participants used Colgate cavity protection toothpaste for brushing teeth twice daily.
224228133|NCT04750005|OTHER|Reach Unflavored Waxed Dental Floss|Participants after brushing for 1 minute, rinse mouth with water and FLOSS once a day in first use.
224228134|NCT04750005|OTHER|American Dental Association (ADA) Ref Toothbrush|Participants will brush twice daily for 1 minute with the toothpaste and soft bristled toothbrush provided.
224319286|NCT00878176|PROCEDURE|First stage tined lead procedure|bilateral first stage tined lead placement
224319287|NCT00840489|DRUG|Ribavirin|Ribavirin 1000-1200 mg qd for 24 weeks
224319288|NCT00840489|DRUG|Colchicine|Colchicine 0.5 mg bd for 24 weeks
224319289|NCT00611260|BEHAVIORAL|Vipassana Meditation practice and instruction|2-3 instructed meditation sessions per week in addition to standard medical care.
224228135|NCT02701478|DRUG|N2O exposure|The aim of this study is to evaluate the nociceptive response to a standardized forearm electrical stimulus applied to patients under GA, during surgery, at different End-Tidal concentrations of N2O (ET-N2O: 0%-50%-25%-0%), and to see if ANI and NoL indices show less pain when inhaled N2O is higher.
224228136|NCT00992069|DRUG|Efavirenz (EFV)|Oral dose of 600 mg daily, taken in the evening
224228137|NCT00992069|DRUG|TMC207|Single oral dose of 400 mg in the morning
224228138|NCT03090984|DEVICE|PMMA (BKU)|At serial time points before, during and after each study hemodialysis session using a BKU dialyzer, blood samples will be drawn for coagulation activation analyses.
224228139|NCT03090984|DEVICE|PS (Phylter)|At serial time points before, during and after each study hemodialysis session using a Phylter dialyzer, blood samples will be drawn for coagulation activation
224228140|NCT03090984|DEVICE|AN69ST (Evodial)|At serial time points before, during and after each study hemodialysis session using an Evodial dialyzer, blood samples will be drawn for coagulation activation
224228141|NCT03713138|DIETARY_SUPPLEMENT|flaxseed powder|Three different quantities of flax seed powder were intervened to the subjects. One group was given 15 grams of flax seed a day. Second group was given 20 grams and third group was given 25 grams off lax seed a day.
224319290|NCT00611260|OTHER|Standard Medical Care|Standard medical care for patients with congestive heart failure plus implanted cardiac defibrillators.
224319291|NCT03577301|BEHAVIORAL|Clinic-based Delivery|A minimum of 2 community health workers (CHWs) will be trained to deliver clinic-based intervention sessions.
224228142|NCT02318121|PROCEDURE|Amniotomy first|rupture of membranes to augment labor
224228143|NCT02318121|PROCEDURE|Oxytocin first|Administration of oxytocin to augment labor
224228144|NCT02318121|PROCEDURE|Amniotomy and oxytocin|Rupture of membranes and administration of oxytocin to augment labor
224228145|NCT02318121|DRUG|Oxytocin|
224228146|NCT01502618|BEHAVIORAL|Focus Group|N/A. Protocol is the focus group
224228147|NCT01689259|DRUG|SL TNX-102 at 2.4 mg|1 TNX-102 SL Tablet at 2.4 mg held under the tongue until dissolution, without swallowing or chewing it.
224228148|NCT01689259|DRUG|SL TNX-102 at 4.8 mg|2 TNX-102 SL Tablet at 2.4 mg held under the tongue until dissolution, without swallowing or chewing them.
224228149|NCT01689259|DRUG|SL TNX-102-A at 2.4 mg|1 TNX-102-A SL Tablet at 2.4 mg held under the tongue until dissolution, without swallowing or chewing it.
224228150|NCT01689259|DRUG|Cyclobenzaprine tablets|1 x 5 mg cyclobenzaprine tablet, swallowed with 240 mL of room-temperature water
224228151|NCT05753384|DRUG|treatment of TKI in CML|continued treatment with TKI at randomization a then stopped treatment 12 months after randomization
224228152|NCT02806349|DIETARY_SUPPLEMENT|American Ginseng|herb
224228153|NCT02806349|DIETARY_SUPPLEMENT|Konjac-glucomannan fiber blend|Blend of 2 viscous fibers: konjac mannan and xanthan
224228154|NCT02806349|DIETARY_SUPPLEMENT|Control|Fiber matched control for intervention (corn starch and wheat bran)
224228155|NCT02737306|DRUG|PRO 140|PRO 140 is a humanized IgG4,κ monoclonal antibody (mAb) to the chemokine receptor CCR5.
224228156|NCT02737306|DRUG|Placebo|Placebo in parenteral solution.
224319292|NCT03577301|BEHAVIORAL|Remote Delivery|A minimum of 2 community health workers (CHWs) will be trained to deliver intervention sessions to the participant in a location remote from the clinic setting.
224319293|NCT03577301|BEHAVIORAL|Multi-modal Delivery|A minimum of 2 community health workers (CHWs) will be trained to deliver clinic-based or remote intervention sessions. First MI session is in person immediately after baseline. Sessions 2-4 can be delivered in person or remotely based on youth preference.
224319294|NCT02765763|DRUG|2-Minute Reveal Masque|
224319295|NCT02765763|DRUG|24/7 Barrier Repair Cream|
224319296|NCT02765763|DRUG|8-in-1 BioSerum|
224319297|NCT02765763|DRUG|Null Formula 2-Minute Reveal Masque|
224319298|NCT02765763|DRUG|Null Formula 24/7 Barrier Repair Cream|
224319299|NCT02765763|DRUG|Null Formula 8-in-1 BioSerum|
224228157|NCT04310410|COMBINATION_PRODUCT|combined radiotherapy and MR-HIFU|Following standard EBRT (single or multiple fraction), patients will receive one MR-HIFU treatment with the Profound Sonalleve MR-HIFU device on the most painful of their bone metastases. This treatment will take place in a short time frame of 3 hours to maximum 4 days. Patients will be followed up until 4 weeks after treatment. During follow-up they will be phoned around day 3, 7, 14, 21 and 28 to retrieve pain scores, pain medication and (serious) adverse events. At day 3 the patient's experience with the combined treatment will also be inquired.
224228158|NCT06138535|DEVICE|digital stabilizing splint|3D Printed stabilizing splint that has been digitally designed on a modern software
224228159|NCT05034731|DEVICE|Remote Fitting|Processors will be programmed using remote fitting application.
224228160|NCT05034731|DEVICE|In-Office Fitting|Processors will be programmed using standard Target CI application.
224228161|NCT03020602|OTHER|Laboratory Biomarker Analysis|Correlative studies
224228162|NCT03020602|OTHER|Pharmacological Study|Correlative studies
224228163|NCT03020602|DRUG|Ubidecarenone Injectable Nanosuspension|Given IV
224228164|NCT05317156|OTHER|Cold vapor|Before surgery, the socio-demographic data of the patients will be recorded. After surgery, patients will be evaluated in the recovery room for their suitability to participate in the study with the Ramsay sedation scale and the Modified Aldrete Scale. Cold vapor will be applied to the patients for 15 minutes in the recovery room during the postoperative period. The parameters to be set on the device for the cold vapor to be applied to the patients in the early postoperative period will be vapor intensity level 5, air blowing intensity 5, heater intensity 1 (+10C), and timer 15 minutes. The patients will be evaluated by the researchers in terms of sore throat, cough, hoarseness, and dysphagia before and 15 minutes after the cold vapor application in the recovery room and at the 6th,12th, and 24th hours after the cold vapor application in the postoperative service. In addition, the comfort levels of the patients will be evaluated at the 24th postoperative hour.
224228165|NCT03156166|PROCEDURE|fiberoptic bronchoscope|Distance from grille (the end of shaft in supraglottic airway) to glottis is measured using FOB
224228166|NCT01934296|DEVICE|Activa PC+S|Surgical implantation of Activa PC+S as one component of a therapeutic DBS system implantation
224228167|NCT05002907|OTHER|Questionnaire|After signing the informed consent sheet, a standardized face-to-face questionnaire will be conducted by the doctor, nurse or coordinator to collect socio-demographic data, lifestyle data, sex life and other potential risk factors and knowledge about viral hepatitis.
224228168|NCT05002907|OTHER|Biocollection|After answering the questionnaire, the nurse or the doctor will take a sample of capillary blood from the fingertip on the side of the distal phalanx of a middle or ring finger. The puncture site will be prepared by warming and massage to optimize blood flow and disinfected with a disposable 70% alcohol wipe. After drying, the puncture will be performed using a single use safety lancet. A total of 7 capillary blood spotswill be collected and deposited on the filter paper (each spot is about 50µL of capillary blood), 5 for the study and 2 for the biological collection.
224228169|NCT05002907|OTHER|Delivery of results|After receiving the individual biological analysis results, in coded form (results only identified by the anonymity number), at the investigation center and lifting the anonymity by the coordinator of the study in each study center (in Cayenne or Paramaribo depending the country where the inclusion took place) with the help of the correspondance list, the participants' results will be delivered to the referral doctor of each health centre and the infectious disease specialist responsible for each area of inclusion. All positive participants will be contacted if they do not spontaneously come to retrieve their results (within approximately 1 month after result's availability), and invited to come to the health centre to retrieve their results individually and be oriented towards the heathcare circuit.
224228170|NCT05002907|OTHER|Results and advices on transmission prevention methods|The results will be revealed by the health centre's doctor/infectiologist, individually and confidentially, with an explanation of the results and advices on transmission prevention methods.Non-immunized patients against HBV will be offered a status determination (Anti-HBs Ab quantification on whole blood sample) and if necessary a catch-up vaccination according to the national immunization schedule.
223765146|NCT06886230|DRUG|Ondansetron (Zofran)|Patients in this group will receive a single intravenous (IV) dose of Ondansetron 4 mg before surgery. Ondansetron is a selective 5-HT3 receptor antagonist commonly used to prevent nausea and vomiting associated with anesthesia and surgery.
223765147|NCT06886230|DRUG|Dexamethasone|Patients in this group will receive a single intravenous (IV) dose of Dexamethasone 8 mg before surgery. Dexamethasone is a corticosteroid with anti-inflammatory properties that has been shown to reduce the incidence of PONV by modulating inflammatory pathways and neuroreceptor activity.
223765148|NCT06749964|BEHAVIORAL|Internet-delivered, therapist-assisted, pain-focused CBT based on the psychological flexibility model for chronic pain|8-session intervention, twice weekly for the first 3 weeks and once weekly for the final 2 weeks (45-60 min each session) aimed at promoting psychological flexibility. Treatment involves a mixture of video and audiotaped presentations and homework activities for the participant.
223765149|NCT06900985|BEHAVIORAL|8-sessions CBT + App|It will consist of 8 one-hour sessions applied in group format once a week and participants will be followed at 3, 6, and 12 months. The sessions will be conducted by clinical psychology/general health psychology professionals and will be carried out using video calls. The smoking cessation treatment follows a cognitive-behavioral approach with components for anhedonia reduction, increased physical activity and positive social support, being a modified, multidisciplinary, and extended version of the original smoking cessation program (Becoña, 2007; Becoña et al., 2017). The treatment will be complemented with an App with active therapeutic components that participants will use during treatment and the one-year follow-up period.
224228171|NCT05002907|OTHER|Confirmation of results on a blood test (In the event of a positive result)|In case of a positive result, the doctor will explain the need to confirm these results on a blood test, prescribe the initial assessment and take an appointment with the infectious disease specialist. He will guide the patient towards accompaniment for the opening of medical coverage rights if necessary and support by an association if desired.
224228172|NCT05002907|OTHER|Information for care|A document with all contact information for a comprehensive and specialized care (professionals and associations for access to medical coverage and support, associations proposing support, general practitioners and specialists) will be given to positive participants. Patient monitoring and treatment will be carried out according to the national guidelines in each country.
223640109|NCT03667378|BEHAVIORAL|Hospital Anxiety and Depression Scale (HADS)|Study assessments will be conducted at baseline (t0); at 3-6 weeks +/- 1 week from Day 1 of receiving investigational therapy, prior to sharing information on treatment response and before the first planned scan to evaluate extent of disease (t1); and at 8-12 weeks (the end of the 3 month total study time period) (t2).
223640110|NCT03667378|BEHAVIORAL|Quality of Communication (QOC)|Study assessments will be conducted at baseline (t0); at 3-6 weeks +/- 1 week from Day 1 of receiving investigational therapy, prior to sharing information on treatment response and before the first planned scan to evaluate extent of disease (t1); and at 8-12 weeks (the end of the 3 month total study time period) (t2).
223640111|NCT03667378|BEHAVIORAL|visits with a supportive care clinician|Monthly visits with a supportive care clinician
224228173|NCT05002907|OTHER|Monitoring and treatment|Consequently, all positive participants will be able to be monitored and treated by a specialist of the disease. They will give post-test counselling and will conduct patient follow-up and treatment according to the usual standards of care of each country.
224228174|NCT00283686|DRUG|Lisinopril|Lisinopril titrated to 5mg, 10mg, 20mg, 40mg
224228175|NCT00283686|DRUG|Telmisartan|Telmisartan/Placebo titrated to 40mg and 80mg, as tolerated by participants
224228176|NCT00283686|DRUG|Placebo|Telmisartan/Placebo titrated to 40mg and 80mg, as tolerated by participants
224228177|NCT00283686|OTHER|Standard Blood Pressure Control|Achieve standard blood pressure control of 120-130/70-80 mm Hg using step dosing specified in protocol of lisinopril, study drug, hydrochlorothiazide, metoprolol, or non-dihydropyridine and dihydropyridine calcium channel blockers (diltiazem), clonidine, minoxidil, hydralazine at the discretion of the investigator
224228178|NCT00283686|OTHER|Low Blood Pressure Control|Achieve low blood pressure control of 95-110/60-75 mm Hg using step dosing specified in protocol of lisinopril, study drug, hydrochlorothiazide, metoprolol, or non-dihydropyridine and dihydropyridine calcium channel blockers (diltiazem), clonidine, minoxidil, hydralazine at the discretion of the investigator
224228179|NCT06381726|DIAGNOSTIC_TEST|Resting State Functional Magnetic Resonance Imaging (rs-fMRI)|rs-fMRI + neurological and neuropsychological evaluation at preoperative timepoint and 1-2 months postop, 3-4 months postop, 6-8 months postop, 12 months postop
224228180|NCT06381726|BEHAVIORAL|Up-front Motor Rehabilitation|personalized motor rehabilitation for 6 months + rs-fMRI + neurological and neuropsychological evaluation before starting motor rehabilitation, at 2-3 months during rehabilitation, 6-9 months during rehabilitation, before surgery (if surgery indicated by tumour board), 1 month postop, 2-3 months postop
224228181|NCT06381726|DRUG|Up-front Chemotherapy|Temozolomide at either 6 cycles consisting of 150-200 mg per square meter for 5 days during each 28-day cycle, or metronomic schedule, + rs-fMRI + neurological and neuropsychological evaluation before starting motor rehabilitation, at 2-3 months during rehabilitation, 6-9 months during rehabilitation, before surgery (if surgery indicated by tumour board), 1 month postop, 2-3 months Post
224319300|NCT03776149|DIETARY_SUPPLEMENT|Beetroot juice|Following randomization on day 1, subjects will consume either the nitrate or nitrate-free beverage for 7 days with outcome measurements performed on day 7. Following a 7 day washout, subjects will then consume the crossover beverage for 7 days with outcome measures performed on day 21.
224319301|NCT03776149|DIETARY_SUPPLEMENT|Black currant juice|Following randomization on day 1, subjects will consume either the nitrate or nitrate-free beverage for 7 days with outcome measurements performed on day 7. Following a 7 day washout, subjects will then consume the crossover beverage for 7 days with outcome measures performed on day 21.
224319302|NCT02897518|DEVICE|Imago V-Balde|the endotracheal intubation will be performed with videolaryngoscopes (imago V-Blade) according to the user manual
223640112|NCT04223479|DRUG|Probiotic Formula Capsule|The Probiotic will be coded in a specific label by a researcher who will not be in contact with the participants and administrated randomly based on gender in a double-blind manner. The patient will receive 2 bottles of the drug every 2 weeks and will be followed weekly for 6 weeks.
224228182|NCT05189561|OTHER|near-infrared scanner|"Tests to be administered: Near Infra-Red Scanning of the head at the bedside.~Time taken for testing: Two minutes~Biological samples collected: None~Frequency of testing/collection: Once~Risks for the participants while being tested: None"
224228183|NCT02970669|DRUG|sacubitril/valsartan (LCZ696)|sacubitril/valsartan tablet taken orally.
224228184|NCT02970669|DRUG|enalapril|Enalapril tablet taken orally.
224228185|NCT02970669|DRUG|matching placebo sacubitril/valsartan (LCZ696)|matching placebo sacubitril/valsartan tablet taken orally
224319303|NCT02897518|DEVICE|Glidescope|the endotracheal intubation will be performed with videolaryngoscopes (Glidescope) according to the user manual
224319304|NCT01114607|DRUG|GSK1605786 ChemoCentryx: formulation A|ChemoCentryx formulation A will be an opaque Swedish orange body, blue coloured capsule with size zero, administered 30 minutes after standard breakfast.
224319305|NCT01114607|DRUG|GSK1605786 GSK: formulation B|GSK1605786 formulation B will be an opaque Swedish orange body capsule with size 0, administered 30 minutes after standard breakfast.
224319306|NCT01114607|DRUG|GSK1605786 GSK direct-fill: formulation C|GSK1605786 formulation C will be an opaque Swedish orange body capsule with size 1, administered 30 minutes after standard breakfast.
224319307|NCT01114607|DRUG|GSK1605786 GSK modified-process: formulation D|GSK1605786 formulation D will be an opaque Swedish orange body capsule with size 0, administered 30 minutes after standard breakfast.
223640113|NCT04223479|DRUG|Placebos|The Placebos will be coded in a specific label by a researcher who will not be in contact with the participants and administrated randomly based on gender in a double-blind manner. The patient will receive 2 bottles of the placebo every 2 weeks and will be followed weekly for 6 weeks.
223640114|NCT03757546|OTHER|observational|The aim of the study is to describe extra-pulmonary complications due to influenza virus and RSV in hospitalized patients from November 2018 to April 2019 and November 2019 to April 2020 in a French university hospital.
223640115|NCT02449122|PROCEDURE|interventional therapy|Lung cancer patients received drug interventional therapy using the digital subtraction angiography（DSA.）
224228186|NCT02970669|DRUG|matching placebo enalapril|matching placebo enalapril tablet taken orally
224228187|NCT04253925|OTHER|Kegel exercises|global postural correction exercises
224228188|NCT04217668|DRUG|Isosorbide Mononitrate 60 MG|1 tablet Isosorbide Mononitrate 60 mg administrated orally.
224323311|NCT03616587|DRUG|AZD9833 with ribociclib|Part K: AZD9833 in combination with ribociclib (± anastrozole) dose escalation
223640116|NCT06649578|PROCEDURE|Metabolic-bariatric surgery|Our study is conducted in a predominantly high-risk Asian population that will be undergoing metabolic-bariatric surgery. The types of surgery can be divided into Laparoscopic Sleeve Gastrectomy (LSG), Roux-en-Y Gastric Bypass (RYGB) or One-Anastomosis Gastric Bypass (OAGB).
223640117|NCT06020521|OTHER|Three spectrometry differents technics|"Collection of expired air as follows:~* For online mass spectrometry techniques (PTR-MS and SICRIT)~* For offline mass spectrometry (GCxGC-MS)~Performing volatolome analyses:~* By PTR-TOF-MS (Ionicon) and SICRIT-HRMS (SICRIT module (Plasmion) coupled to a Q-exactive instrument (Thermofisher)) for online analyzes~* By two-dimensional gas chromatography coupled with mass spectrometry (Pegasus BT-4D, Leco) for the desorption tubes."
223640118|NCT04115761|BIOLOGICAL|autologous dendritic cells|The total 10 doses (1 mL/dose; 2±0.5 × 10\^7 cell/dose) of ADCV01 will be administered to patients assigned to the investigational group. The ADCV01 will be administered to the bilateral subaxillary subcutaneous regional lymph nodes (half of volume about 0.5 mL of ADCV01) once weekly for the first 4 doses, and the following 2 treatments will be administered bi-weekly. The last 4 treatments will be administered every 4 weeks.
223640119|NCT06503874|OTHER|Attention Training|The APT-3 is an evidence-based, standardized computer-based training program that was designed to improve attention skills that underlie higher level cognitive processes (e.g., executive functions and memory).
223640120|NCT06503874|OTHER|Music Group|This group will listen to a pre-determined playlist of music following the same dosing as the attention training group as stated in the arms.
223640121|NCT06978491|OTHER|Group C|Spinal anesthesia.
223640122|NCT06978491|OTHER|Group T|spinal anesthesia and at the end of the surgery, 20 ml 0.25% bupivacaine will be applied bilaterally between the transversus abdominis and internal oblique muscle.
223640123|NCT06978491|OTHER|Group W|spinal anesthesia and at the end of the surgery, 20 ml 0.25% bupivacaine will be applied to the wound site.
223640124|NCT06596421|OTHER|abdominal massage|abdominal massage
223640125|NCT05726578|OTHER|Lung recruitment|establishment of lung recruitment using high frequency ventilation and assessment with chest ultrasound and echocardiography
223640126|NCT06594484|OTHER|Ml Based Algorithm 1|The values in the ML algorithm were selected according to logistic regression analysis and the values used in the other six scores tested. The success rate of the constructed networks correct predictions was considered as the success rate of the algorithm. The usefulness of the test was determined through AUROC analysis. Two algorithms were tested in our study. In the first algorithm (ML1), the dependent variable was erythrocyte suspension (ES) consumption, and the independent variables included patients; demographic data, laboratory data, and operational data
223640127|NCT06594484|OTHER|Ml Based Algroithm 2|is an Ml algorithm created by combining commonly used bleeding scores
223640128|NCT06594484|OTHER|Bleeding Scores|ACTION CRUSCADE TRACK WILL-BLEED PAPWORTH TRUST ACTAPORT skores used to predict ES need
224228189|NCT03521999|BEHAVIORAL|AboutFace|AboutFace is an online peer-to-peer digital storytelling resource for Veterans with PTSD. Veterans will have access to AboutFace while they are enrolled in PTSD specialty care through the Charleston PCT.
224228190|NCT03521999|OTHER|Enhanced Usual Care (eUC)|Enhanced Usual Care (eUC) includes access to a PTSD educational brochure. Veterans will have access to the brochure information while they are enrolled in PTSD specialty care through the Charleston PCT.
223640129|NCT06588179|DRUG|SHR-1501+SHR-2005|SHR-1501, instillation；SHR-2005, instillation
223640130|NCT06599853|OTHER|Fever Education|Another aspect of this research that is different from other studies is that a retention test will be applied to the participants after the pre-test and post-test, and the long-term effect of the training given will be examined. In this direction, it is aimed to reduce the inappropriate use of emergency services, the use of unnecessary tests and the increasing health system costs. It is aimed to prevent crowding in the emergency department by reducing the inappropriate use of emergency services.
223640131|NCT06591702|OTHER|Questionnaire study|Questionnaire application
224228191|NCT00000372|DRUG|D-cycloserine|
224228192|NCT00000372|DRUG|Glycine|
224228193|NCT00000372|DRUG|Clozapine|
224228194|NCT00000372|DRUG|Placebo|
224228195|NCT00670475|DRUG|Piroxicam|In this interventional arm gel of piroxicam (manufactured by Iran najo co,Iran), repackaged in a 60 g anonymous tubes will be administered to the patients.
223640132|NCT06587438|DEVICE|Sinocare iCan I3 CGM|Real-time Continuous glucose monitoring
223640133|NCT06587438|DEVICE|Sinocare jinzhi+Blood glucose meter|Self-monitoring of blood glucose
223640134|NCT06591910|DRUG|Chemoimmunotherapy|Induction Serplulimab combined with chemotherapy
223640135|NCT06591910|PROCEDURE|Surgery|After induction chemoimmunotherapy, patients with tumors resectable after chemoimmunotherapy will receive surgical treatment in department of thoracic surgery.
223640136|NCT06591910|RADIATION|Radiation|After induction chemoimmunotherapy, patients with tumors still unresectable will receive radiotherapy or other therapy.
223765150|NCT06900985|BEHAVIORAL|4-sessions CBT+App|It will consist of 4 one-hour sessions applied in group format every two-weeks (8 weeks total duration) and participants will be followed at 3, 6, and 12 months. The sessions will be conducted by clinical psychology/general health psychology professionals and will be carried out using video calls. The 4 sessions will have the following content: 1) explanation of treatment rationale and components available in the App; 2) participants' progress monitoring, reinforcement of achieved goals, and analysis of difficulties; 3) cessation planning support; and 4) relapse prevention support. The treatment sessions will be protocolized in a treatment manual. The treatment will be complemented with the same App that the other conditions
224228196|NCT00670475|DIETARY_SUPPLEMENT|Olive Oil|"virgin olive oil prepared directly from olive fruit from olive gardens of north of iran, Gilan province will packaged in a 60 g anonymous tubes."
224228197|NCT04711629|OTHER|Clinical Tests|Respiratory function test, arterial blood gas analysis, six-minute walking test (6-MWT), mMRC Dyspnea Scale, St George Quality of Life Questionnaire and Hospital Anxiety Depression Scale
224228198|NCT02632656|OTHER|Monitoring on heart failure therapy|This is a prospective observational study where participants will have serial blood collection on medical therapy for heart failure.
224228199|NCT01842451|DRUG|VX-135|
224228200|NCT01842451|DRUG|Daclatasvir|
224319308|NCT01114607|DRUG|GSK1605786 GSK tablet: formulation E|GSK1605786 formulation D will be a pink coloured film coated tablet, administered 30 minutes after standard breakfast.
224228201|NCT01766674|BEHAVIORAL|Kyphosis spinal strengthening exercises|Investigator developed the intervention protocol (Kyphosis spinal exercises) of targeted spine exercises during our pilot study based upon the literature and clinical experience.We standardized the protocol with a written script and a video. Each exercise session will be preceded by light aerobic activity, ended with cool-down and stretching the neck, chest and all extremities. All participants will be carefully monitored to ensure that all exercises will be performed slowly, with correct body alignment and technique to minimize risk of injury.
224228202|NCT05498285|BEHAVIORAL|UPSCALER app|Usage of mobile app to guide rehabilitation after surgery
224228203|NCT00739856|PROCEDURE|Electroconvulsive Therapy|ECT was administered using the MECTA-SR1 apparatus. The current amplitude was 800 mA, pulse width was 1.5 ms, and pulse frequency was 50 Hz. Stimulus duration was increased as required to elicit an adequate seizure, defined as at least 25 s with EEG monitoring. The ECT course was fixed, and comprised 6 treatments administered with bitemporal electrode placement at a twice-weekly frequency
223640137|NCT06594692|DRUG|Node-Sparing Short-Course Radiotherapy Combined with CAPOX and Sintilimab|"Radiotherapy Protocol:~Short-course radiotherapy using three-dimensional conformal or intensity-modulated radiation therapy techniques. The radiation field will be limited to the tumor bed of the primary colon lesion, excluding surrounding draining lymph nodes and enlarged lymph nodes. The dose is fractionated as 5Gy per fraction, for a total of 25Gy over 5 fractions. Titanium clips will be placed on the proximal and distal ends of the colonic lesion via colonoscopy to guide radiation therapy positioning.~Chemotherapy Protocol (CAPOX Regimen):~1. Oxaliplatin: 130 mg/m², administered intravenously (ivgtt), on day 1 (d1).~2. Capecitabine: 1000 mg/m², orally (po), twice daily (bid), from day 1 to day 14 (d1-14).~Immunotherapy Protocol:~During preoperative treatment, Sintilimab (immune checkpoint inhibitor) will be administered concurrently with each chemotherapy cycle."
223640138|NCT06594692|DRUG|CAPOX Chemotherapy|Participants will receive 4 cycles of CAPOX chemotherapy followed by radical total mesorectal excision surgery, and then 4 additional cycles of postoperative CAPOX chemotherapy.
223640139|NCT06603740|DEVICE|Arthrex Nanoscope|Arthrex's all-in-one disposable, 2 mm, chip-on-tip camera system now allows surgeons to miniaturize their treatment solutions
223640140|NCT06603740|DEVICE|Conventional Arthroscopy without Arthrex Nanoscope|partial meniscectomy using conventional arthroscopy
223640141|NCT06600035|DEVICE|Gastric ultrasound|A curved array, low-frequency (2-5 MHz) transducer providing a scan depth up to 30 cm will be used. Patients will be scanned in the supine position followed by right lateral decubitus (RLD) position. The sonographic appearance of the gastric antrum will be classified as Grade 0,1 or 2, signifying empty antrum, fluid detected in RLD position only and antral fluid in both supine and RLD positions, respectively, based on the appearance in both the positions. Cross-sectional area (CSA) will be calculated by using two perpendicular diameters-anteroposterior (AP) and craniocaudal (CC) and the formula for area of an ellipse:CSA = (AP × CC × π)/4
223640142|NCT06591039|PROCEDURE|The study did not involve intervention in the patient's treatment regimen|This study is based on a prospective database platform to register the occurrence, treatment and prognosis of breast cancer in China, so there is no clear exposure factor. This study was a prospective cohort study, which did not intervene in exposure factors, but only assessed the occurrence, treatment, and prognosis of breast cancer in China.
223640143|NCT06602986|DIAGNOSTIC_TEST|TACE|"study was carried out in our setup for two major reasons. One was to decrease reliance on DSA since it is a costly investigation in our medical setups and the facility is not available except for a few centers of excellence which creates issues with treatments plan of patients admitted for treatment using TACE and subsequent follow-up visits to assess the presence or absence of HCC tumors. The mean age of patients in our treatment group was in the early sixties. This is in line with the median age of diagnosis for HCC globally as evidenced by studies done by Mc Glynn et al12 and Konyn et al13. Gender distribution was predominantly male in our study group in line with available literature14. The Child Pugh classification which quantifies severity of chronic liver disease by assessing clinical parameters was used in our study as well15. Since the inclusion criteria and procedural requirement required normal bilirubin levels, all subjects in the study protocol were in Class A16.~The prima"
223640144|NCT06601816|PROCEDURE|maxillary sinus lift with reamer|Lateral window created with specially designed burs for lateral sinus lift
223640145|NCT06601816|PROCEDURE|maxillary sinus lift with piezzo|lateral window was created using piezo surgery and surgical guide
223640146|NCT06601816|PROCEDURE|maxillary sinus lift with conventional burr|the lateral window was created with conventional rotary instrument burs
223640147|NCT06594224|DRUG|Ibuprofen|Patients were given 800 mg Ibuprofen in 200 cc normal saline intravenously at the time of arrival in the ward.
223640148|NCT06594224|DRUG|Nalbuphine|Patients received 20 mg nalbuphine in 200 cc normal saline IV at the time of arrival in the ward.
223640149|NCT06590506|DEVICE|Wearable|Continuous monitoring thought data recorded with wearable (Vivosmart Garmin bracelet)
223640150|NCT06595732|BEHAVIORAL|Pelvic floor and abdominal training|Participants in this group will undergo 12 weeks of in-person training, with supervision by a specialist physical therapist, in groups of up to four women. The training will take place after an initial evaluation and will consist of 24 sessions, held twice a week. Exercises will target both the pelvic floor muscles and the abdominal muscles. The exercises will be divided into three phases, with progressively increasing difficulty each month. The progression will be achieved by increasing the load, the number of repetitions, and the complexity of the exercises.
223640151|NCT06595732|BEHAVIORAL|Abdominal Hypopressive Technique Exercises|Participants in this group will perform Hypopressive Abdominal Gymnastics exercises as proposed by Marcel Caufriez (1997). The training will last 12 weeks and be conducted in person, with supervision by a specialist physical therapist, in groups of up to four women. The training will take place after an initial evaluation and will consist of 24 sessions, held twice a week. The exercises will be divided into three phases, with progressively increasing difficulty each month. Progression will be achieved by changing body positions, increasing the number of repetitions, and extending the duration of inspiratory apnea.
223765151|NCT06900985|BEHAVIORAL|Smoking cessation App|It will consist in the same App than the other two conditions. No therapeutic contact will be avaliable.
224228204|NCT00006381|BIOLOGICAL|trastuzumab|
224228205|NCT00006381|DRUG|celecoxib|
224228206|NCT02354378|DRUG|Dexmedetomidine|
224228207|NCT02354378|OTHER|Memory Test|
224228208|NCT02776761|BIOLOGICAL|Hantaan Vaccine:|DNA Vaccine 2.0 mg/1 mL phosphate-buffered saline
223640152|NCT06595732|OTHER|Pelvic floor muscle training|Participants in this group will undergo 12 weeks of in-person training, supervised by a specialist physical therapist, in groups of up to four women. Specific exercises targeting the pelvic floor muscles will be performed, with voluntary and maximal contractions, without involving other muscle groups. The exercises will be divided into three phases, with progressively increasing difficulty each month. Progression will be achieved by increasing the load (transitioning from gravitational to antigravitational positions), increasing the number of repetitions, and combining sustained and rapid contractions to enhance the difficulty of execution.
223640153|NCT06595433|OTHER|Experimental|In the PAPE 90% protocol, participants performed a general warm-up (e.g., jogging on a treadmill) for 5 minutes and a weightlifting-specific warm-up for 5 minutes, followed by 2 minutes of rest. After resting, they were asked to perform ten repetitions of dip squats with body weight and rested for 1 minute.Then, unlike the unloaded protocol, they performed three repetitions of dip squats with 90% of their one-repetition maximal dip squats and rested for 4 minutes. After resting, they performed a snatch to exhaustion with 75% of their maximum snatch weight. Then they rested for 2 minutes and performed one more repetition of the snatch to exhaustion. The maximum number of repetitions between sets was recorded.
223640154|NCT06595433|OTHER|Experimental|In the PAPE 50% protocol, 5 minutes of general warm-up (jogging on a treadmill) and 5 minutes of weightlifting-specific warm-up were followed by 2 minutes of rest as in the other protocols. After resting, they were asked to perform ten repetitions of body-weighted dip squats and rested for 1 minute. Then, unlike the unloaded and PAPE 90% protocols, they performed eight repetitions of bottom squats with 50% of their maximal bottom squats for one repetition and rested for 4 minutes. After resting, they performed snatches with 75% of their maximum snatch weight until exhaustion. Then they rested for 2 minutes and performed one more repetition of the snatch to exhaustion. The maximum number of repetitions was recorded for statistical analysis.
223640155|NCT06595433|OTHER|unloaded protocol|In the unloaded protocol, subjects performed a 5-minute general warm-up (e.g., jogging on a treadmill) and 5 minutes of weightlifting-specific warm-up followed by 2 minutes of rest. After resting, they performed ten repetitions of bottom squats with their body weight and then rested for 1 minute. After rest, they performed the snatch movement with 75% of their maximum snatch weight until exhaustion. Then, they rested for 2 minutes and again performed the snatch with 75% of their maximum snatch weight until exhaustion. The maximum number of snatch repetitions performed by the weightlifters was recorded for statistical analysis.
224228209|NCT02776761|BIOLOGICAL|Puumala Vaccine|DNA Vaccine 2.0 mg/1 mL phosphate-buffered saline
224228210|NCT02776761|BIOLOGICAL|Hantaan/Puumala Vaccine|DNA Vaccine 2.0 mg/1 mL phosphate-buffered saline
224228211|NCT06048900|DEVICE|ultrasound guided optic nerve sheath diameter measurement|First, both eyes were measured in a neutral position while awake and after intubation. Measurements were made at regular intervals until the end of the operation after the head-down position and in the neutral position after the operation.
223640156|NCT06588933|OTHER|completion of a questionnaire|completion of a questionnaire by participant
223640157|NCT06586333|DRUG|stress ulcer prophylaxis|In the EICU, patients were identified as part of the recruiting guideline group (GG), and in addition to receiving usual care, they were managed for SUP according to the ASHP SUP guidelines
224228212|NCT00646152|DRUG|Poly-ICLC|
224228213|NCT05584527|OTHER|Heat exposure (32°C)|"The participants will be exposed to heat (32°C) for 24 hours in a climatic apartment.~During the exposure,~* food intake and energy expenditure will be measured~* several physiological tests will be performed: hunger and thirst questionnaires, thermal sensations, skin temperature measurement, weighing, olfactory and gustatory capacities, food preference questionnaire, etc.~* sleep brain activity will be monitored using a headband~* urine and saliva samples will be collected."
224228214|NCT05584527|OTHER|Cold exposure (16°C)|"The participants will be exposed to cold (16°C) for 24 hours in a climatic apartment.~During the exposure,~* food intake and energy expenditure will be measured~* several physiological tests will be performed: hunger and thirst questionnaires, thermal sensations, skin temperature measurement, weighing, olfactory and gustatory capacities, food preference questionnaire, etc.~* sleep brain activity will be monitored using a headband~* urine and saliva samples will be collected."
224228215|NCT05584527|OTHER|Thermoneutral exposure (24°C)|"The participants will be exposed to a thermoneutral environment (24°C) for 24 hours in a climatic apartment.~During the exposure,~* food intake and energy expenditure will be measured~* several physiological tests will be performed: hunger and thirst questionnaires, thermal sensations, skin temperature measurement, weighing, olfactory and gustatory capacities, food preference questionnaire, etc.~* sleep brain activity will be monitored using a headband~* urine and saliva samples will be collected."
224228216|NCT01735058|DRUG|Sodium Hyaluronate|Ultrasound guided injection of sodium hyaluronate; Fermathron ™, 20 mg/2ml of Sodium Hyaluronate, 3 weekly injections.
224228217|NCT01735058|DRUG|Normal saline|Ultrasound guided injection of 0.9% normal sodium hyaluronate line solution, at 2 mL/syringe, 3 weekly injections.
224228218|NCT00989079|DRUG|Ertugliflozin|Ertugliflozin will be administered as an extemporaneously prepared suspension/solution for all doses within the initially planned range.
224228219|NCT00989079|DRUG|Placebo to Ertugliflozin|Correspondingly placebo doses to ertugliflozin will be administered as suspension/solution
223640158|NCT06591351|DRUG|Cilostazol 100 MG|Efficacy and safety of 200 mg cilostazol followed by 100 mg twice daily for three months and loading 300 mg aspirin and 75 mg aspirin maintenance will be assessed through NIHSS, mRS, duration of hospital stay, new ischemic stroke, and possible adverse effects,
223640159|NCT06591351|DRUG|Clopidogrel|Efficacy and safety of 300 mg clopidogrel followed by 75mg once daily for three months and loading 300 mg aspirin and 75 mg aspirin maintenance will be assessed through NIHSS, mRS, duration of hospital stay, new ischemic stroke, and possible adverse effects,
223640160|NCT06594887|DEVICE|SpaceOAR Vue|Peri-rectal hydrogel spacer consists of a layer of polyethylene-glycol gel (SpaceOAR vue) in order to outdistance the prostate from anterior rectal wall
224228220|NCT01195571|BIOLOGICAL|cmv vaccine|dose escalation study of 4 towne-toledo chimera vaccines
224228221|NCT04738279|DEVICE|Non-Invasive Continuous Remote Patient Monitoring|Continuous remote patient monitoring will consist of continuous collection of physiological data and patient status through a non-invasive wearable solution, connected to a structured cascading escalation management pathway
224228222|NCT04738279|OTHER|Affective Analysis of Participant Response to Continuous Remote Patient Monitoring|Survey and qualitative interviewing of participants
224228223|NCT04324879|DRUG|TQ-B3525|TQ-B3525 tablet administered 20mg orally, once daily in 28-day cycle.
224228224|NCT01128647|DIETARY_SUPPLEMENT|Fructose:glucose drink|
224228225|NCT01128647|DIETARY_SUPPLEMENT|glucose drink|
224228226|NCT00467584|DRUG|High Dose Aspirin (1300 mg/day)|1300 milligrams per day (the equivalent of 4 regular aspirin tablets) taken by mouth as two tablets, twice a day in the morning and at noon for 8 weeks
224228227|NCT00467584|DRUG|Low Dose Aspirin (162 mg/day)|162 milligrams per day (the equivalent of 2 baby aspirin tablets) taken by mouth as two tablets, twice a day in the morning and at noon for 8 weeks
224228228|NCT00467584|DRUG|Placebo|Placebo tablets matching the active aspirin tablets in appearance, taken as two tablets, twice per day for 8 weeks
224228229|NCT01597895|DRUG|Maraviroc|Maraviroc 150 mg BID x 5 days with food
224228230|NCT01597895|DRUG|Maraviroc + Boceprevir|Maraviroc 150 mg BID + Boceprevir 800 mg TID x 10 days with food
224228231|NCT01597895|DRUG|Maraviroc + Telaprevir|Maraviroc 150 mg BID + Telaprevir 800 mg TID x 10 days with food
224228232|NCT05442983|DRUG|PanCytoVir™ (probenecid)|Active drug
224228233|NCT05442983|DRUG|Placebo|Matching placebo
224228234|NCT03831633|DRUG|Akynzeo|"1 single oral dose of NEPA (capsule) on Day 1 to be administered approximately 1 hour prior chemotherapy (containing 300 mg netupitant and 0.5 mg palonosetron).~\- Dexamethasone 12 mg on Day 1 and 8 mg daily from Day 2 to Day 4"
224228235|NCT03831633|DRUG|Standard of Care|"* oral aprepitant 125mg (Day 1) and 80mg daily (on Day 2 and Day 3)~* IV ondansetron 8 mg on Day 1~* Dexamethasone 12 mg on Day 1 and 8 mg daily from Day 2 to Day 4"
224319309|NCT04774497|OTHER|Oxygen inhalation treatment group|Oxygen inhalation group: oxygen inhalation was started on the first day of chemotherapy, and the oxygen inhalation volume was 2 L / min, 8 hours / day for 3 consecutive days.
224319310|NCT04774497|OTHER|Control group|The control group was not given oxygen inhalation.
224319311|NCT05114278|DRUG|Ferinject|Experimental group will receive intravenous iron infusion (Ferinject©: 15 mg/kg in NaCl solution IV) at randomization, 2weeks after randomization, 4weeks after randomization, and then every month for a total of one year. Comparison group will not receive any intravenous treatment. Both experimental and comparison groups will receive an oral iron supplementation (100 mg/day).
224228236|NCT00877175|DRUG|1% tropicamide and 2.5% phenylephrine|For the eyes receiving lower conjunctival fornix packing (study group), one small piece of the cotton wool soaked with one drop of 2.5% phenylephrine and one drop of 1% tropicamide was packed in the lower conjunctival fornix. For the eyes receiving the instillation (control group), 2.5% phenylephrine and 1% tropicamide were alternately instilled every 5 minutes for two doses each.
224228237|NCT00494104|DIETARY_SUPPLEMENT|Vitamin D drops, 200 or 400 or 600 IU/day or 800 IU/day|Infants receive daily 0.5 ml of code labeled supplement
224319312|NCT05114278|DRUG|oral iron|All patients will receive an oral iron supplementation (100mg/day).
224319313|NCT01562860|PROCEDURE|Pronator Teres Release|Surgical release of median nerve compression
223765152|NCT07075094|PROCEDURE|Bladder stimulation|This stimulation consists of two stages. In the first maneuver, the bladder is stimulated by gentle tapping of the suprapubic area for 30 seconds. In the second maneuver, the paravertebral area is massaged in a circular motion for 30 seconds. The two stimulation maneuvers are repeated sequentially for 5 minutes.
223765153|NCT07075094|PROCEDURE|Subrapubic cutaneous stimulation|Circular rubbing movements will be made on the baby's suprapubic area with gauze soaked in cold salt water until micturition begins.
224228238|NCT01332110|DEVICE|Knee abduction moment-reducing footwear|Patients in each study group will be asked to run using their assigned footwear at least 3 times per week (minimum 15 km per week) for six weeks. Each patient will document their perceived knee pain each week throughout the six week intervention.
224228239|NCT01636297|BEHAVIORAL|Forced exercise|Exercise on a stationary cycle that was controlled by a motor, to augment voluntary cycling rate by 35%. Intervention was administered 3 times per week for 8 weeks
224228240|NCT01636297|BEHAVIORAL|Voluntary exercise|Exercise on a stationary cycle without motor assistance. Intervention was administered 3 times per week for 8 weeks
224228241|NCT02081261|PROCEDURE|Coronary artery bypass surgery|coronary artery bypass surgery
224228242|NCT00058279|BIOLOGICAL|aldesleukin|
224228243|NCT00058279|BIOLOGICAL|ipilimumab|
224228244|NCT01498484|BIOLOGICAL|EBV-specific T cells (EBV-CTLs)|EBV-CTLs are cytotoxic T lymphocytes that specifically kill cells presenting EBV protein antigens including EBV-transformed B lymphocytes responsible for EBV-associated lymphomas and lymphoproliferative disorders.
224228245|NCT00319956|DRUG|Azithromycin|Give 10 mg/kg IV/PO daily for first 7 days, then give 5 mg/kg IV/PO daily for 35 days.
224228246|NCT00319956|DRUG|Placebo|vehicle dose given daily, IV/PO, same volume that Azithromycin would be to equal 10 mg/kg for first 7 days, then 5 mg/kg for 5 weeks.
224228247|NCT01146132|DIETARY_SUPPLEMENT|Conventional diet +/- wine|usual eating habits
224319314|NCT01562860|PROCEDURE|dual compression release|Both the carpal tunnel compression and the pronator teres compression will be released on the same day.
224319315|NCT01562860|PROCEDURE|dual compression release|both procedures will be done on the same day
224319316|NCT01562860|PROCEDURE|median nerve release only|only the carpal tunnel compression is released
224319317|NCT05668546|DEVICE|isokinetic testing CSMI HUMAC NORM instrument|The strength (PT) of the bilateral knee flexors and extensors were tested with isokinetic test. Tests were performed under the guidance of a rehabilitation medicine specialist, and the system was calibrated prior to their commencement. The patients were seated in upright position and were fixed with pelvic and thigh belts. Concentric extension (PT\_E) and concentric flexion (PT\_F) were measured between the 0° and 90° knee ranges at angular velocities of 60°/s and 180°/s (60 PT\_E, 60 PT\_F, 180 PT\_E, and 180 PT\_F, respectively) The tests were repeated five times at each velocity, and the highest PTs were selected for statistical analysis. The participants performed repeated trials before sets, while a 20-second rest was provided between sets.
224319318|NCT00659958|DRUG|Zonisamide|300 mg tablet. Maintenance dosing period of 12 weeks, at the beginning of which, physicians will decide to keep the 300 mg dose from the titration period, lower it to 200 mg, or take it up to 400 mg.
224319319|NCT00137761|DRUG|ZD 1839|Taken orally once daily
224319320|NCT00137761|DRUG|Docetaxel|Given intravenously once weekly for 2 out of 3 weeks
224323312|NCT03616587|DRUG|AZD9833 with ribociclib|Part L: AZD9833 in combination with ribociclib (± anastrozole) dose expansion
223640161|NCT06594887|DEVICE|BioProtect Balloon Implant System|The balloon spacer is a biodegradable balloon made of poly (L-Lactide-co-caprolactone) which is a co-polymer of Poly Lactide acid and epsilon Caprolactone (BioProtect Balloon Implant System, BioProtect Ltd) inflated with saline, providing around 18 mm space height , and can be deflated and repositioned if needed, both laterally and along the distal /proximal planes, for optimal uniformity of spacing.
223640162|NCT05006352|DRUG|DNL343|Oral repeating dose
223640163|NCT05006352|DRUG|Placebo|Oral repeating dose
223640164|NCT05813574|OTHER|Observational patient reported outcomes|Of COVID-19 patients
223640165|NCT06979440|OTHER|No intervention|No intervention
223640166|NCT05464680|OTHER|blood sample and bronchoalveolar lavage|"These patients are put on VM as part of their care and present a suspicion of a 1st episode of PAVM for which a microbiological sample is taken and a probabilistic antibiotic therapy is started with the PIP-TAZ association (D0). A plasma PIP-TAZ assay will be performed 48 hours after the start of antibiotic therapy with PIP-TAZ. Blood urea will be measured and a mini-LBA (performed with a Combicatheter®) will be performed to measure PIP-TAZ and urea in the ELF.~On day 7 of the antibiotic therapy (last day of the planned antibiotic therapy), the same samples are taken and the same analyses are performed + bacteriology on the mini BAL. For patients for whom antibiotic therapy has been interrupted because of sterile samples, the samples taken at D7 will not be taken.~The clinical outcome of the patient will then be recorded until D60."
223640167|NCT06038669|DEVICE|Dried blood spot device|Patients will be asked to provide a dried blood spot sample
223765154|NCT07125261|DRUG|BHV-700|75 mg daily for the 4-week treatment period (dose which may be adjusted based on tolerability)
224228248|NCT01146132|DIETARY_SUPPLEMENT|Luxembourg variant of Mediterranean diet + physical activity +/- wine|"Walnuts, almonds, mustard and soy bean products as part of the Indo-Mediterranean diet could be recommended to ensure a variety of food constellation, as well as dark chocolate. This form of diet will be addressed to as Luxembourg variant of the Mediterranean diet"
224228249|NCT04616417|PROCEDURE|Investigational Oocyte Cryopreservation|Transvaginal oocyte retrieval under ultrasound guidance
224228250|NCT00256542|DRUG|Alkalinized Lidocaine-Heparin|
224228251|NCT02607800|DRUG|SOF/VEL/VOX|400/100/100 mg tablet administered orally once daily with food
224228252|NCT02607800|DRUG|SOF/VEL|400/100 mg tablet administered orally once daily with or without food
224228253|NCT00753714|DRUG|ZD6474, Vandetanib|100 mg as a once daily oral dose, from Day 1 until disease progression or unacceptable toxicity or consent withdrawal whichever occurs first
224228254|NCT00753714|DRUG|Placebo to Match ZD6474, Vandetanib|100 mg as a once daily oral dose, from Day 1 UNTIL disease progression or unacceptable toxicity or consent withdrawal whichever occurs first
224228255|NCT00753714|DRUG|Gemcitabine|administered intravenously at 1200 mg/m2 over 30 minutes on Days 1 and 8 of each 21-day cycle UP to 6 cycles or UNTIL disease progression or unacceptable toxicity or consent withdrawal whichever occurs first
224228256|NCT02549742|PROCEDURE|Electrochemotherapy|Electroporation by a device, Cliniporator, combined with chemotherapy, Bleomycin.
223640168|NCT06038669|OTHER|Healthcare professional interviews|Health care professionals only will be interviewed using the topic guide and asked about their experience of diabetes monitoring
223640169|NCT06985732|OTHER|Virtual Reality|Use of virtual reality to elicit positive emotions and improve the well-being of elderly patients hospitalized in SMR
223640170|NCT06602323|COMBINATION_PRODUCT|TMLI/Flu/Mel|Targeted total bone marrow and lymphoid irradiation (TMLI) conformal therapy administered in combination with a reduced-intensity regimen based on Fludarabine and Melphalan.
223640171|NCT06597890|BEHAVIORAL|educational content (sleep hygiene)|app-based sleep hygiene-related educational content
223640172|NCT06597890|BEHAVIORAL|sleep hygiene strategies|app-based self-selection of sleep hygiene strategies
223640173|NCT06597890|BEHAVIORAL|reminders|daily reminders sent via push notifications
223640174|NCT06597890|BEHAVIORAL|review of behavioural goal|app-based review of behavioural goal
223640175|NCT06597890|BEHAVIORAL|educational content (sleep guidelines)|app-based educational content on recommended sleep guidelines
223640176|NCT06597890|BEHAVIORAL|comparison of current behaviour to ideal behaviour|use of smartwatch/smartphone data to assess current behaviour and compare it to ideal behaviour
223640177|NCT06597890|BEHAVIORAL|goal setting|prompt participant to set a goal in relation to targeted behaviour
223765155|NCT06665100|DRUG|PUL-042|Pam2 : ODN (PUL-042) PUL-042 Inhalation Solution
223765156|NCT06665100|DRUG|Placebo|Sterile Saline for Inhalation
224228257|NCT02549742|DEVICE|Cliniporator|Electric pulses , duration 100 microseconds, about 400 V given at 5000 Hz.
224228258|NCT02549742|DRUG|Bleomycin|Administered intravenously or injected into the tumour before electroporation.
224323313|NCT03616587|DRUG|AZD9833 with anastrozole|Part M: AZD9833 in combination with anastrozole dose escalation
224323314|NCT03616587|DRUG|AZD9833 with anastrozole|Part N: AZD9833 in combination with anastrozole dose expansion
223765157|NCT03290456|DRUG|Prednisone 5mg/day extended of 12 additional months|Prednisone 5mg/day orally during 12 Month + 1 mg/week tapering until 0mg.
223765158|NCT03290456|DRUG|Placebo 5mg/day extended of 12 additionnal months.|1mg/week orally tapering Prednisone until Month 1 + Placebo orally 5mg/day until Month 13
223765159|NCT07087210|OTHER|Positron Emission Tomography (PET)|18F-TPP+ PET/CT imaging
224228259|NCT03256513|OTHER|model controlling|control blood pressure by statistical l model with anticipate lowest peri-procedure risk
224228260|NCT03256513|OTHER|conventional controlling|control blood pressure by conventional strategy
224228261|NCT03432195|DRUG|Donepezil TDS|Donepezil Hydrochloride Transdermal Delivery System
224228262|NCT02907112|BEHAVIORAL|Meat reduction|Advice, Motivational material and food products provided to participants
224228263|NCT02122081|RADIATION|radiation therapy|Undergo organ-sparing marrow irradiation BID on days -6 to -4
224228264|NCT02122081|DRUG|cyclophosphamide|Given IV over 1-2 hours every 24 hours on days -3 to -2.
224228265|NCT02122081|BIOLOGICAL|anti-thymocyte globulin|
224228266|NCT02122081|DRUG|tacrolimus|Given IV or PO
224228267|NCT02122081|DRUG|methotrexate|Given IV
224228268|NCT02122081|PROCEDURE|allogeneic bone marrow transplantation|Undergo allogeneic peripheral blood progenitor cell or bone marrow transplant on day 0
224319321|NCT06395805|DIAGNOSTIC_TEST|BREF, ADL, AIS.|"1. abbreviated version of the quality of life assessment questionnaire - The World Health Organization Quality of Life (WHOQOL) -BREF~2. scale I - ADL according to Lawton~3. the AIS questionnaire~4. the Zimet Multidimensional Scale of Perceived Social Support - the original version of the MSPSS"
224319322|NCT02197910|OTHER|Comparisons of two kind of pasta with low or high content of wheat bioactive peptides (sequence Low->High)|
224319323|NCT02197910|OTHER|Comparisons of two kind of pasta with low or high content of wheat bioactive peptides (sequence High->Low)|
224319324|NCT05065255|DEVICE|SpeediCath® catheters|Patients using SC catheters will be followed up in order to understand the major criteria in the choice of the catheter by the patients.
224319325|NCT04350450|DRUG|Hydroxychloroquine|400 mg tablet
223640178|NCT06597890|BEHAVIORAL|educational content (Vigorous Intermittent Lifestyle Physical Activity (VILPA))|app-based educational content on VILPA
223640179|NCT06597890|BEHAVIORAL|screentime breaks|repeated daily reminders to break up screentime
223640180|NCT06593990|DEVICE|echocardography|"Patients will be subjected to transthoracic echocardiography including, the following parameters will be measured:~* Left ventricular (LV) dimensions: end diastolic and systolic dimensions and LV ejection fraction (EF).~* Trans- mitral Doppler flow velocities including early (E) and late(A) diastolic velocities, E/A ratio.~* LA anteroposterior diameter measure from 2D parasternal long axis view targeted M-mode.~* LA superior-inferior and medio-lateral diameters measure from the apical 4 chamber view.~* LA volume included:~* Maximal LA volume measure at the end of systole~* Minimal LA volume will be measured at end diastole just at the closure of the mitral valve.~* Pre contractile LA volume ( LAV pre-A\] measured at P-wave onset on ECG just before atrial contraction."
223640181|NCT06593990|DEVICE|musculoskeletal ultrasonography|Ultrasound detected synovitis t
223640182|NCT06593990|DIAGNOSTIC_TEST|lipid profile test|The lipid profile typically includes measurement of total cholesterol, HDL-cholesterol (often called good cholesterol), LDL-cholesterol (often called bad cholesterol), and triglycerides.
223640183|NCT06593990|DIAGNOSTIC_TEST|C reactive protein|A c-reactive protein test measures the level of c-reactive protein (CRP) in a sample of your blood. CRP is a protein that your liver makes. Normally, you have low levels of c-reactive protein in your blood. Your liver releases more CRP into your bloodstream if you have inflammation in your body. High levels of CRP may mean you have a serious health condition that causes inflammation.
223640184|NCT06593990|DIAGNOSTIC_TEST|Complete blood count CBC|"A complete blood count, or CBC, is a blood test that measures many different parts and features of your blood, including:~Red blood cells, which carry oxygen from your lungs to the rest of your body. White blood cells, which fight infections and other diseases. There are five major types of white blood cells. A CBC test measures the total number of white cells in your blood. A different test called a CBC with differential measures the number of each type of these white blood cells.~Platelets, which stop bleeding by helping your blood to clot. Hemoglobin, a protein in red blood cells that carries oxygen from your lungs to the rest of your body.~Hematocrit, a measurement of how much of your blood is made up of red blood cells.~Mean corpuscular volume (MCV), a measure of the average size of your red blood cells."
223640185|NCT06593990|DIAGNOSTIC_TEST|Erythrocyte sedimentation rate (ESR).|An erythrocyte sedimentation rate (ESR) is a blood test that that can show if you have inflammation in your body. Inflammation is your immune system\&#39;s response to injury, infection, and many types of conditions, including immune system disorders, certain cancers, and blood disorders.
223640186|NCT06593990|DEVICE|x ray of the hand|The X-ray may show a hand with advanced rheumatoid arthritis. \&#34;Bone erosion\&#34; means cartilage and bone are worn away. \&#34;Bone displacement\&#34; means that a bone has moved out of its normal position. This X-ray shows how bone erosion and bone displacement can change the shape of the hand.
223640187|NCT06588764|PROCEDURE|modified deep lateral and/or medial wall decompression|Modified deep lateral orbital wall decompression is based on traditional outer wall decompression with combined abrasion of the deep outer orbital wall (including the greater pterygoid wing) to achieve adequate enlargement of the orbital cavity.
223640188|NCT06591650|DRUG|gemcitabine hydrochloride|800 mg/m\^2, intravenous (IV) over 30 minutes, Days 1,8, every 21 days.
223640189|NCT06591650|DRUG|Cisplatin|25 mg/m\^2, intravenous (IV) over 60 minutes, Days 1,8, every 21 days.
223640190|NCT06591650|DRUG|Nab-paclitaxel|100 mg/m\^2, intravenous (IV) over 30 minutes, Days 1,8, every 21 days.
223640191|NCT06591650|DRUG|Durvalumab|1500mg, intravenous (IV) over 30 minutes, Days 1, every 21 days.
223640192|NCT06589843|DIAGNOSTIC_TEST|Deep learning imaging enhancement|Conventional imaging or down-sampling imaging from CT or MR are enhanced by approved deep learning method.
223640193|NCT06586801|OTHER|Patient-reported outcome|"Patient-reported outcome data will be collected using the following instruments:EORTC QLQ-C30, EORTC QLQ-LC13, selected items from the PRO-CTCAE, EORTC-IL46.~The first collection of the information in questionnaires (EORTC QLQ-C30, EORTC QLQ-LC13, PRO-CTCAE \[select items\]), which defined as baseline- PROs, will be completed at Cycle 1, Day 1±7days prior to administration of study drug; then the rest times of collection will be completed at every two treatment cycle prior to administration of study drug (i.e., on Cycle 3, Day 1±7days; Cycle 5, Day 1±7days; Cycle 7, Day 1±7days; Cycle 9, Day 1±7days; Cycle 11, Day 1±7days; Cycle 13, Day 1±7days) . EORTC-IL46 will be completed at Cycle 3, Day 1±7days (baseline) prior to administration of study drug; then at every other study treatment cycle prior to administration of study drug (i.e., on Cycle 5, Day 1±7days; Cycle 7, Day 1±7days; Cycle 9, Day 1±7days; Cycle 11, Day 1±7days; Cycle 13, Day 1±7days)"
223640194|NCT06590246|BIOLOGICAL|Armored and GPC3-targeted autologous CAR T-cell|Armored and GPC3-targeted autologous CAR T-cells, single infusion intravenously.
223640195|NCT06598501|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|an open arm study of 10 gambling disorder subjects will be conducted to determine the efficacy and feasibility of a multimodalistic therapy of rTMS and Cognitive Behavioral Therapy (CBT) for gambling disorder in Indonesia.
223640196|NCT06590909|COMBINATION_PRODUCT|Fractional CO2 laser assisted PDT|Comparative split face study: participants will be treated with fractional co2 laser on the whole face then applying topical insulin on the right side of the face and topical platelet rich plasma on the left side of the face.
223765160|NCT05416489|DEVICE|C-MAC videolayngoscopy technique|Endotracheal tube will be removed before percutaneous tracheostomy using a C-MAC videolaryngoscopy.
223765161|NCT05416489|DEVICE|Laryngoscopy technique|Endotracheal tube will be removed before percutaneous tracheostomy using a laryngoscopy
223640197|NCT06590571|DEVICE|TRAcelet™|The group using TRAcelet™ after transradial angiography/intervention receives 2 hours and 15 minutes of compression from the device, followed by 3 stepwise releases every 15 minutes. There are two sizes of TRAcelet™ available, large and medium. Assuming that a Korean adult's wrist size is smaller than that of the Western population, we used a medium-sized TRAcelet™.
223640198|NCT06590571|OTHER|Gauze pad|Patients received radial artery compression by a gauze pad fastened with 3M™ Durapore™ surgical tape. An additional one hour of compression was applied when incomplete hemostasis or hematoma was identified.
223640199|NCT06594471|OTHER|Questionnaire on late-term physical effects|Patients will be asked to indicate any potential late-term physical effects following cancer treatment: neurocognitive, auditory, ocular, oral/dental, dermatologic, cardiovascular, pulmonary, gastro-intestinal, urinary tract, genital, endocrine/metabolic, musculoskeletal, neurological, immune disorders and occurrence of any subsequent malignant neoplasms.
223640200|NCT06594471|OTHER|Questionnaire on sexual and reproductive health outcomes|Patients will be asked to complete the following questionnaires: Body Appreciation Scale-2 (BAS-2), Body Image Scale (BIS), EORTC QLQ-SH22, Body Image Scale in Gynecological Cancer (SABIS-G). Patients who underwent a fertility-sparing procedure will be asked to fill out the Reproductive Concerns after Cancer (RCAC) and Decision Regret Scale (DRS), whereas those who experienced iatrogenic menopause will complete the MENQOL questionnaire to assess menopause-related quality of life.
223640201|NCT06594471|OTHER|Questionnaire on psychological outcomes|Patients will be asked to complete the following questionaires: EORTC QLQ-C30, Clinical outcomes in Routine Evaluation (CORE-OM), Ten Item Personality Inventory (TIPI), Hospital Anxiety and Depression Scale (HADS), General Self-Efficacy (GSE) Scale, Mini-Mental Adjustment to Cancer (Mini-MAC), Cancer Worry Scale (CWS), Multidimensional Scale of Perceived Social Support (MSPSS), the Patient Health Engagement scale and the Supportive Care Needs Survey-Short Form (SCNS-SF34).
223640202|NCT06594471|OTHER|Questionnaire on social outcomes|Patients will be asked to complete the following questionaires: Medical Consumption Questionnaire (iMCQ), Productivity Cost Questionnaire (iPCQ) and the Comprehensive Score for Financial Toxicity - Functional Assessment of Chronic Illness Therapy (COST-FACIT) questionnaire.
223640203|NCT06602505|PROCEDURE|Group A: Field Block Group|Patients received field block with 5ml of 2% Lignocaine using a 24 G hypodermic needle before institution of subarachnoid block using 27 G Quincke's spinal needle for lower segment Caesarean section.
223640204|NCT06596083|DIETARY_SUPPLEMENT|Placebo supplement|oral supplement containing: 16.4 grams of medium chained triglycerides, 1mM or sucrose octaacetate and water
223640205|NCT06596083|DIETARY_SUPPLEMENT|Ketone ester supplement|Oral supplement containing: 25 grams of pure (R)-3-hydroxybutyl-(R)-3-hydroxybutyrate ketone monoester drink
223640206|NCT06590311|DIAGNOSTIC_TEST|Heart Rate Variability|Heart rate variability evaluation through different domains
223640207|NCT06604182|OTHER|Community-based Simplified HCV Testing and Treatment Algorithm|The distinctive features of CBSA are: (i) community-based service provision, substantially lowering the threshold for HCV services and eliminating the need to visit health care facilities for the majority of patients; (ii) the use of simple, once-daily, pan-genotypic HCV treatment regimens; (iii) a minimum of required laboratory tests and assessments; (iv) task sharing of essential functions from physicians to the case-managers; (v) integration of HCV testing and treatment with existing harm reduction services, addressing multiple health needs and facilitating patient-centered care.
223640208|NCT04506411|DIETARY_SUPPLEMENT|Turmipure GOLD®|TPG: Turmipure GOLD® capsules - 4 capsules once daily- as prescribed
223640209|NCT04506411|DIETARY_SUPPLEMENT|Turmeric rhizome PE 95% curcuminoids|STE: Turmeric rhizome PE 95% curcuminoids - 4 capsules once daily- as prescribed
223640210|NCT04506411|DIETARY_SUPPLEMENT|Placebo|Placebo: Maltodextrin - 4 capsules once daily- as prescribed
223640211|NCT06663670|OTHER|Intraneural Facilitation Therapy|"* The initial hold, known as the facilitation hold, involves placing the contralateral joint in a maximal loose-pack position that will be comfortable for the patient. An illustration of this would be positioning the ankle joint on the contralateral side in full plantar flexion and inversion. Throughout the entire session, this position will be maintained using a stretch strap. It is crucial to emphasize that there is no muscle engagement in the joint where the facilitation takes place, only a slight stretch.~* Once the pressure elevation occurs, the subsequent phase known as the secondary hold will be initiated to direct the augmented flow of epineurial blood toward the transperineurial vessels connecting the epiperineum and the endoneurial capillaries of the target area.~* The final maneuver, the sub hold, leverages Bernoulli's principle to augment blood flow through the ischemic endoneurial capillaries experiencing heightened transmural pressure."
224228269|NCT02122081|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Undergo allogeneic peripheral blood progenitor cell or bone marrow transplant
224228270|NCT02122081|PROCEDURE|peripheral blood stem cell transplantation|Undergo allogeneic peripheral blood progenitor cell or bone marrow transplant
224228271|NCT02122081|OTHER|laboratory biomarker analysis|Correlative studies
224228272|NCT02353000|RADIATION|Stereotactic Radiosurgery|Stereotactic Radiosurgery for patients with 4 up to 10 brain metastases
224228273|NCT02353000|RADIATION|Whole Brain Radiotherapy|Whole Brain Radiotherapy for patients with 4 up to 10 brain metastases
224228274|NCT02486796|BIOLOGICAL|Reishi mushroom extract|Reishi mushroom preparation produced water-ethanol extraction.
224228275|NCT02486796|DRUG|Coenzyme Q10|Preparation of coenzyme Q10
224319326|NCT03484650|DRUG|Lidocaine Hydrochloride|Lidocaine bolus to be given 1 hour pre-operatively
224228276|NCT02486796|DRUG|Melatonin|Preparation of melatonin
224319327|NCT03484650|DRUG|Lidocaine Hydrochloride|Lidocaine infusion will be started after the bolus and be continued for 24 hours post-operatively
224319328|NCT03484650|OTHER|Placebo|Control patients will receive a placebo bolus and infusion of saline to match the experimental arm.
224228277|NCT05593198|PROCEDURE|Khoury technique|the bone block will be used following the principles of the Khoury technique to augment the bone volume.
224228278|NCT05593198|PROCEDURE|Guided bone regeneration|the membrane and the bone granules will be used to perform the guided bone regeneration technique.
224228279|NCT01513668|DRUG|Acetaminophen|Extended release Gel tabs 650 mg
224319329|NCT01918202|DRUG|20 mg PF-02545920|Subject will receive a single dose of 20 mg PF-02545920.
224319330|NCT01918202|DRUG|PF-02545920|"The dose will be selected based on the results obtained for Cohort 1. Dose options range from 30 mg to 10 mg, 5 mg, 2mg, 1 mg.~This cohort is optional."
223640212|NCT06663670|OTHER|Nerve Flossing Technique|"Tibial Nerve:~1. Passively flex the hip while dorsiflexing and everting the ankle to create tension; flex the knee to unload, then extend and plantarflex to reload.~2. Flex the hip, extend the knee, and dorsiflex and evert the ankle to induce tension; flex the hip to unload, then extend and plantarflex to reload.~3. Lift the leg, flex the hip, and extend the knee; dorsiflex and evert the ankle to induce tension, then plantarflex to unload.~Common Peroneal Nerve:~1. Passively flex the hip and plantarflex and invert the ankle to induce tension; flex the knee to unload, then extend and dorsiflex to reload.~2. Flex the hip, extend the knee, and plantarflex and invert the ankle to induce tension; flex the hip to unload, then extend and dorsiflex to reload.~3. Lift the leg, flex the hip, and extend the knee; plantarflex and invert the ankle to induce tension, then dorsiflex to unload."
223640213|NCT06596408|OTHER|optical coherence tomography angiography|OCTA will be used to evaluate the macular vascular density and to exclude patients with pathological myopic maculopathy
223640214|NCT06600529|DEVICE|Photo-Biomodulation|Application at acupuncture points for 20 seconds each week. using 810nm Laser probe
223640215|NCT06600529|BIOLOGICAL|Autologous PRP|IV injection of Autologous Plasma Rich Platelets (PRP) on Days 0, 15, 30, and 45.
223640216|NCT06600529|BIOLOGICAL|Exosome Therapy|IV injection of Umbilical Cord-Derived Exosomes at laser acupuncture points Umbilical Cord-Derived Exosomes
223640217|NCT06600529|OTHER|Standard Care (in control arm)|Routine conventional including Applied Behavioral Analysis (ABA) for Autism Spectrum Disorder (ASD)
223640218|NCT06592157|OTHER|NewEpi Plus Liquid Wound Dressing|"1. Hold the spray nozzle 7-10 cm away from the wound. Apply the product evenly over the wound, with a dosage of one spray (0.1 ml) per 10x10 cm² of wound area.~2. Wait for 2 minutes. It is not necessary to wait until the solution is completely dry; you can proceed with applying ointments and various types of dressings as directed by the physician.~3. Use once a day for 21 days. The frequency of use can be adjusted according to the physician\&#39;s instructions."
223640219|NCT06592157|OTHER|standard wound care|The standard wound care protocol aims to provide comprehensive and systematic care for patients to ensure smooth healing of surgical wounds. These care measures include regular cleaning, disinfection, dressing changes, and continuous observation and assessment of the wound condition. Through strict aseptic techniques and scientific care procedures, standard wound care effectively reduces the risk of infection and promotes wound healing.
223640220|NCT06588127|BEHAVIORAL|nudge|Nudge interventions are developed based on the scoping review and qualitative research by the research team, which involves commitment (behavioral contracts), norms (case and experience sharing), significance and framing effects (posters, health behavior identification posts), reminders, and incentives (arteriosclerosis detection). The content encompasses diet, physical activity, medication management, self-monitoring, and control of smoking and alcohol. From the viewpoint of bounded rationality in behavioral economics, and drawing on prior research that has pinpointed decision-making biases in patients' self-management behaviors, nudging strategies have been developed to assist individuals in overcoming these biases or to utilize the patterns of these biases to steer them toward making choices that are in line with their health.
224228280|NCT03697421|OTHER|Relationship Education|"We will provide the following 4 activities: 1) marriage and relationship education \[using a modified version of the empirically supported Loving Couples, Loving Children (LCLC); 2) pre-marital education and marriage skills; 3) marriage enhancement and marriage skills for married couples; and 4) divorce reduction and relationship skills.~All couples will be expected to participate in 24 hours of core relationship education workshops (including parenting education). Since parental financial support represents a core element of family stability, relationship education workshops will address motivation for providing financial support through employment for all couples (employed and unemployed) as well as how to manage conflicts over money. All couples will be invited to supplemental workshops (with couples from other cohorts) on topics of specialized interest, including employment services and financial literacy (i.e. budgeting, debt, etc.)."
224228281|NCT03697421|OTHER|Employment Services|For couples in need of job search, job retention, and career advancement services, we will provide employment services.
224228282|NCT01185288|BIOLOGICAL|Adalimumab|Adalimumab in pre-filled syringes
224228283|NCT01185288|DRUG|Methotrexate|Methotrexate capsule
224228284|NCT01200472|DRUG|Apremilast|Apremilast is supplied as 10 mg capsules for oral administration. After a 7-day titration phase patients will receive 20 mg PO BID apremilast.
224228285|NCT01200472|DRUG|Placebo|Placebo capsules identical to apremilast
224228286|NCT00513851|DRUG|OSI-930|Oral OSI-930 administered once daily at increasing doses until disease progression or unacceptable toxicity
224228287|NCT00513851|DRUG|OSI-930|Oral OSI-930 administered twice daily at increasing doses until disease progression or unacceptable toxicity
224228288|NCT05881148|OTHER|Carbon sprinting spiked-shoes|Trademarked Carbon Spiked-Shoes, from one Trademark only to ensure generalization concerns, is used alternatively with standard carbon-free spiked-shoes, for 8 repetitions of 30m-sprint each, separated by 10 minutes rest each.
224228289|NCT05881148|OTHER|Standard carbon-free sprinting spiked-shoes|cf
224228290|NCT03108105|DEVICE|AOS-C2001-B|A new 2-piece appliance composed with 2 parts: a base plate and an ostomy collection special pouch (1 base plate for 2 or 3 days and 1 to 4 collection special pouch per day)
224228291|NCT00278512|BIOLOGICAL|Autologous Stem Cell Transplant|Autologous Hematopoietic Stem Cell Transplant will be performed after conditioning
224228292|NCT00278512|BIOLOGICAL|Allogeneic Stem Cell Transplant|Allogeneic Stem Cell Transplant will be performed after conditioning
224228293|NCT00278512|DRUG|Cyclophosphamide|Causes prevention of the cell division
224228294|NCT00278512|DRUG|ATG (rabbit)|A rabbit polyclonal antibody to lymphocyte
224228295|NCT00278512|DRUG|G-CSF|Hematopoietic growth factor
224228296|NCT00278512|DRUG|Campath-1h|Humanized monoclonal antibody against CD52 antigen
224228297|NCT00278512|DRUG|Fludarabine|inhibits DNA synthesis or repair
224228298|NCT00278512|DRUG|Tacrolimus|immune suppressive drug
224228299|NCT00278512|DRUG|Mesna|Mesna is a drug used to protect the bladder from the effects of the chemotherapy drugs
224228300|NCT05240339|OTHER|Observation of minor phenomena|observation twice a year over 3 years
224228301|NCT00002719|BIOLOGICAL|filgrastim|
224228302|NCT00002719|DRUG|amsacrine|
224228303|NCT00002719|DRUG|carmustine|
224228304|NCT00002719|DRUG|cytarabine|
223640221|NCT06602115|OTHER|Observational study, no interventions involved|Observational study, no interventions involved
223640222|NCT06591585|RADIATION|Fracture Healing|"A-Clinical evaluation~1. Patients will be recruited for evaluation of documented short / long term complications:~   * subcutaneous haematoma~  * pin tract infection~  * surgical site infection~  * limb length discrepancy~  * arthritis of the hip and spine~  * SI joint pain or fusion~  * scoliosis~2. Visually assisted gait analysis B- Radiographic evaluation~1-Radiographic evaluation of pelvic integrity by plain X-ray ( Antero-posterior . inlet . outlet views) 2- Long film for limb length discrepancy 3- plain x ray whole spine Anterior -posterior \&amp; lateral for scoliosis"
223640223|NCT06601153|DIAGNOSTIC_TEST|Cardiac CT|Cardiac CT to characterize coronary atherosclerosis
223640224|NCT06993025|DRUG|Ivonescimab+chemotherapy|"Dosing Schedule:~1. Ivonescimab: 20 mg/kg, Day 1, intravenous infusion (ivgtt), every 3 weeks (Q3W).~2. Irinotecan Liposome: 70 mg/m², Day 1, intravenous infusion (ivgtt), every 3 weeks (Q3W).~3. Calcium Folinate (LV): 400 mg/m², Day 1, intravenous infusion (ivgtt), every 3 weeks (Q3W).~4. 5-FU: 2400 mg/m², Day 1, intravenous infusion (ivgtt), every 3 weeks (Q3W)."
223640225|NCT06991543|BEHAVIORAL|Community education and awareness, and personal lifestyle and cooling behavior modification|This component of the HAB will be achieved through community mobilization, which will encompass awareness and motivational activities throughout the intervention duration. Community groups (CGs) will be formed in each of the 11 clusters. Both male and female CGs will be formed separately and will be responsible for community mobilization activities, surveillance for primary outcome. Each CG will comprise of 6-8 members and will be a diverse group of people with varying qualifications, including local government members, local elders/elites, religious leaders, and prominent male and female members of the community. they could also name their respective CGs to enhance association, identity, and affiliation. These CGs will facilitate culturally tailored workshops, dissemination of early warnings regarding heat waves, awareness sessions, and door-to-door outreach focused on heat-health fundamentals. CGs will also maintain simple logbooks to track any incidence of heat related illness.
223640226|NCT06991543|OTHER|Participatory local structural and environmental heat mitigation solutions|"Participatory local structural and environmental heat mitigation solutions will be delivered through community participatory approach where the community and project will share the cost of intervention to improve ownership. This contribution can be monetary or non-monetary, for example, provision of labor or supplies. The modifications include:~1. Paints (Solar Reflective Paints, Lime Paints)~2. Shading (Façade, Roof)~3. Energy Sufficiency (Solar Panels with complete accessories)~4. Community Shading (Plantation, Street Shading, Field Shading space)~5. Ventilation (Windows, Wind catchers)"
223640227|NCT06991777|DEVICE|Precision sedation in intensive care using neurophysiologic and respiratory targets.|Sedation titration using EEG and ventilator parameters
223640228|NCT06993311|DEVICE|Xen Gel Stent implantation|Consecutive patients who underwent either stand-alone Xen stent insertion with MMC(mitomycin C) or combined phacoemulsification between 2018 and 2022
223640229|NCT06991374|PROCEDURE|combined burst mode|the combined burst mode is commonly used in cataract phacoemulsification. This study compares whether the two modes have different outcomes in hard nuclear cataract surgery.
223640230|NCT06991374|PROCEDURE|torsional mode|the toesional mode is commonly used in cataract phacoemulsification. This study compares whether the two modes have different outcomes in hard nuclear cataract surgery.
223640231|NCT06991647|DRUG|Intranasal dexmedetomidine|Intranasal dexmedetomidine at a dose of 2 mcg/kg body weight, diluted in 1 mL of 0.9% NaCl, administered using a 1 mL syringe connected to a Teleflex MAD Nasal device while in the supine position. The soft tip of the device will be gently placed into each nostril without applying pressure. The solution will be sprayed slowly to create a fine mist. The total dose will be divided equally, with 0.5 mL delivered into each nostril, administered approximately 30 minutes before intubation during induction.
223640232|NCT06991647|DRUG|0.9% NaCl solution|Participants will receive 1 ml of 0.9% NaCl solution administered intranasally using a 1 ml syringe connected to a Teleflex MAD nasal device while in the supine position. The soft tip of the Teleflex MAD nasal device is gently placed into each nostril without applying pressure. The solution is slowly sprayed to create a fine mist for patient comfort. The dose is divided equally, delivering 0.5 ml into each nostril, approximately 30 minutes before intubation during induction.
223640233|NCT06991998|PROCEDURE|Autogenous bone graft with enamel matrix derivative|Participants receive periodontal regenerative surgery using autogenous bone graft harvested from a secondary intraoral donor site (mandibular ramus or maxillary tuberosity) with a bone scraper. The bone graft is placed into the debrided intraosseous defect, and enamel matrix derivative (EMD) is applied to the root surface. Surgical access is performed using a single flap approach (SFA), and primary closure is achieved with microsurgical sutures.
223640234|NCT06991998|PROCEDURE|Autogenous tooth-derived graft with enamel matrix derivative|Participants receive periodontal regenerative surgery using autogenous tooth-derived particulate graft processed from an extracted tooth using a standardized protocol (Bonmaker® device and chemical decontamination), combined with enamel matrix derivative (EMD) applied to the root surface. The surgical site is accessed using a single flap approach (SFA), and graft material is placed into the non-self-contained intraosseous defect after debridement. Primary closure is achieved with microsurgical sutures.
223640235|NCT06991400|OTHER|Trans-Amniotic Suture Placement|Trans-Amniotic Suture placement
223640236|NCT06211361|OTHER|Cardiac rehabilitation|Physical exercise intervention within a cardiac rehabilitation program, lasting 2 months, 3 days per week. The intervention consists of a first part of warm up the large muscle groups, accompanied by breathing exercises, followed by a part of strength and muscular resistance training exercises (upper and lower limbs and abdominal muscles), another part of aerobic exercise part (continuous and interval), using a treadmill or cycle ergometer, and finally a part of stretching exercises and a cool-down phase.
223640237|NCT06598215|PROCEDURE|Duckett urethroplasty|hybrid duckett urethroplasty vs modified duckett urethroplasty
224228305|NCT00002719|DRUG|etoposide|
224228306|NCT00002719|DRUG|idarubicin|
224228307|NCT00002719|DRUG|mitoxantrone hydrochloride|
224228308|NCT00002719|PROCEDURE|peripheral blood stem cell transplantation|
224228309|NCT00781755|DRUG|varenicline|.5mg/day for 3 days then titrated to 1.0mg/day for 11 days. A total dosing regimen of 14 days.
224228310|NCT00781755|BEHAVIORAL|Adaptation of Motivational Interviewing|2 sessions of behavioral intervention designed to create ambivalence about quitting or plan for a quit attempt if the patient is ready.
223640238|NCT06999096|DIAGNOSTIC_TEST|Long-read whole genome sequencing|Pseudonymized blood samples will undergo high-molecular-weight DNA extraction, followed by long-read whole-genome sequencing (lrWGS) using Oxford Nanopore technology. Index cases will be sequenced at high depth (\>30X), while relatives will be multiplexed (\>15X). Sequencing data will be analyzed through a dedicated bioinformatics pipeline to detect SNVs, indels, structural variants, and repeat expansions. Results will be interpreted by expert teams and discussed in monthly clinical-genetic meetings. Variants of interest will be validated by appropriate molecular techniques, and family segregation will be assessed when relevant.
223640239|NCT06993207|DEVICE|Home Lab|The main goal is to comprehensively assess the cognitive and behavioral status of all participants, regardless of their assigned groups. Validated clinical tests (considered the gold standard) will be used, with measurements taken at participants' homes using a biosignal monitoring kit-the focal tool of the project. Whether in the control or specific groups, all participants will undergo an identical battery of tests in both the laboratory and home settings. The study design includes an introductory session for participants to understand the study's purpose and sign informed consent. Following consent, participants will have three sessions within a 3 to 6-week timeframe: one for autonomous technology use instruction and the other two for cognitive and functional evaluations.
223640240|NCT06405932|COMBINATION_PRODUCT|Mental Fitness Training Camp|The Mental Fitness Training camp employs and incorporates core learning content derived from Cognitive Behavioral Therapy and Mindfulness. The program comprises nine thought animations, emotional diary, daily breathing exercises, and pleasure lists.
223640241|NCT04949490|BIOLOGICAL|BNT162b2s01|intramuscular (IM) injection
223640242|NCT04949490|BIOLOGICAL|BNT162b2|IM injection
224319331|NCT01918202|DRUG|PF-02545920|The dose will be selected based on the results obtained for Cohort 1 and cohort 2.
223640243|NCT06590194|DRUG|PH009-1 tablet|PH009-1 will be administered in fasting state
223640244|NCT06595407|DIAGNOSTIC_TEST|Blood analysis for loss-of-Y chromosome|Analysis for the percentage of circulating leukocytes with loss-of-y chromosome
223640245|NCT06171009|BEHAVIORAL|Pain Coping Information|A 4-minute audio recording providing common pain coping techniques (e.g., ice, rest, medication, surgery).
224228311|NCT01202747|DEVICE|LipiFlow System|In-office treatment for meibomian gland dysfunction
224228312|NCT01620177|DRUG|Alcohol(oral) and placebo|Subjects will be dosed to an approximate peak BAC of 0.065%. Subjects will be tested on the decline such that subjects will be at or above the goal BAC (0.05%) throughout the drive
224228313|NCT01620177|DRUG|Cannabis(THC)(Inhaled) and Placebo|Cannabis vapor is produced from 500 mg either placebo (0% THC), approximately 2.5-3.5% THC (low dose), or approximately 6.0-7.5% THC (high dose) bulk cannabis plant material to yield doses of approximately 0, 12.5-17.5, or 30-37.5 mg THC
224228314|NCT00364403|BEHAVIORAL|Low glycemic load|Provision of foods and dietary counseling to promote a low glycemic load diet
224228315|NCT00364403|BEHAVIORAL|Low fat diet|Provision of foods and dietary counseling to promote a low fat diet
224228316|NCT00838474|OTHER|music|Each infant was randomized to receive music therapy or no music over 2 consecutive days
224228317|NCT05617859|DRUG|Lenvatinib mesylate capsule|Lenvatinib mesylate capsule, 8mg (body weight ≤60kg) or 12mg (body weight \>60kg), orally, once daily. Take the medicine about half an hour after meals (the time of taking the medicine should be the same as possible every day) and take it with warm water.
223640246|NCT06171009|BEHAVIORAL|Mindful Pain Management|A 4-minute audio recording consisting of a 1-minute introduction to mindfulness followed by a 1-minute and 30-second mindful breathing practice and a 1-minute and 30-second mindfulness of pain practice.
223640247|NCT05074979|OTHER|telerehabilitation|While telerehabilitation sessions will be applied to the participants in the telerehabilitation group for 6 weeks, home exercise program will be given to the home exercise program group and will be applied for 6 weeks.
223640248|NCT05074979|OTHER|home exercise program|While telerehabilitation sessions will be applied to the participants in the telerehabilitation group for 6 weeks, home exercise program will be given to the home exercise program group and will be applied for 6 weeks.
223640249|NCT05074979|OTHER|informed program|will informed after COVID 19
223640250|NCT05285371|DIAGNOSTIC_TEST|Urinalysis (UA)|Urinalysis will be performed twice daily starting on Postoperative Day 0.
223640251|NCT05285371|DIAGNOSTIC_TEST|Complete Metabolic Panel (CMP)|A CMP will be performed on Postoperative Day 2 and Postoperative Day 4.
224228318|NCT04041609|DRUG|LYR-210|A single administration of LYR-210 depot
224228319|NCT04041609|OTHER|Sham comparator|Sham comparator
224228320|NCT01268449|RADIATION|Low dose laser|5mv laser with a wavelength of 650nm
224228321|NCT01268449|RADIATION|Placebo|The act of radiating laser to the ear is done while the set is off.
224228322|NCT02729688|DEVICE|customized pressure guide bandage|"Investigators developed the customized pressure guide elastic bandage (CPG-EB). The experienced nurse applied the elastic bandages to each patient with sub bandage pressure monitoring. The target pressure was 35-45 mmHg. Measurements of the pressure applied by bandages was performed at point B1 corresponding to the height where the Achilles' tendon turns into the gastrocnemius muscle with Picopress (MicroLAB Elettronica, Ponte S. Nicolo, Italy). If the target pressure 35-45 mmHg was achieved, the circular ink stamp was applied into the entire bandages. The markers in CPG-EB had elliptical shape when they were not stretched. They turned into circular shape when they were stretched.~For the OEB, Bandaging was applied by spiral methods. Three EB were applied with 50 % stretching and 50% overlapping from foot to just below knee level."
224228323|NCT02729688|DEVICE|Ordinary elastic bandage|Bandaging was applied by spiral methods. Three ordinary elastic bandages were applied with 50 % stretching and 50% overlapping from foot to just below knee level.
224228324|NCT06209788|PROCEDURE|experimental group|The music intervention consists of two parts. The first part occurs during the surgical procedure, starting from the induction of anesthesia and continuing until the surgery over. The second part spans from the first day post-surgery to the fifth day (or until discharge), with the patient listening to music twice a day, each session lasting for 30 minutes. The planned times for the music sessions are expected to be at 11 a.m. and 8 p.m. Each day post-surgery, the music intervention must be completed, and measurements of respiratory rate, pulse rate, blood pressure, and pain score should be taken both before and after listening to the music. Other are routine post-operative care.
224319332|NCT01384903|DRUG|KW-3357|Intravenous infusion once a day
223640252|NCT05285371|DIAGNOSTIC_TEST|Glucose Stick Test (d-Stick)|A d-Stick will be performed twice daily except on Postoperative Day 2 and Postoperative Day 4 as the CMP includes serum glucose levels.
223640253|NCT05285371|OTHER|Medical Chart Review|A medical chart review will be performed for all subjects enrolled.
223640254|NCT05712330|OTHER|non invasive ventilation samples|machine samples for bacterial culture will be performed
223640255|NCT05712330|OTHER|patient samples|Patient samples for sputum culture
223640256|NCT05712330|OTHER|parent questionnaire|parent questionnaire
223640257|NCT03430297|BIOLOGICAL|JS001 240mg Q2W|"recombinant humanized anti-PD-1 monoclonal antibody injection (JS001) will be provided by the sponsor. Strength: 240mg/6ml/vial. 240mg, once every two weeks.~Control drug: dacarbazine (1000mg/m2, d1, intravenously, once every three weeks). The dose will be given intravenously over 180 minutes (the infusion time can be prolonged according to the institutional criteria), starting from Week 1, once every 3 weeks, until progression of disease."
224228325|NCT05499494|OTHER|Beautifil Flow Plus X F00 injectable composite|bioactive injectable composite
224228326|NCT05499494|OTHER|Tetric N ceram resin composite|Nano hybrid resin composite
224228327|NCT03083054|BIOLOGICAL|Autologous dendritic cells electroporated with WT1 mRNA|Production and application of autologous dendritic cells vaccines, 4 doses, biweekly
224228328|NCT01037166|DRUG|Entecavir|Tablet, P.O., 0.5 mg or 1mg, once daily, 52 weeks
224228329|NCT03869749|BEHAVIORAL|Learning to BREATHE Plus|Activities include psycho-education about stress and emotion regulation, and practices of body scanning, non-aerobic yoga, and meditation, which are designed to cultivate and provide opportunities to practice present-focused, non-judgmental attention.
224228330|NCT03869749|BEHAVIORAL|Health and wellness|The Health Education Wellness Program (modeled after Hey Durham) (Bravender, 2005) will provide didactic information on substance use, nutrition/body image, stress management, exercise, and signs of depression/suicide.
224228331|NCT01004692|DEVICE|Occlusal splints|The splint will be a hard acrylic-resin stabilization appliance to wear in the upper jaw. The OSS does not come in contact with the gums of the patient and does not act as an orthodontic device. The OSS will be used only for the three nights in a row, of the ambulatory-PSG recording with the OSS in situ.
224228332|NCT04597762|DRUG|Cyclosporin|Cyclosporin eyedrops
223765162|NCT06805318|BEHAVIORAL|Vocational Rehabilitation intervention for pwMS|"The VR intervention will cover three areas of intervention:~* Rehabilitation Area: this intervention has the goal of managing the work performance from a rehabilitative point of view.~* Reasonable accommodation area: this intervention has the goal of assessing the needs of reasonable accommodations, such has workspace modification, change in organization of the activities, management of work time, etc.., and propose it to the employer.~* Educational and Formative Area: this area is responsible for the implementation of educational intervention for the employees and the employers about multiple sclerosis and its impact on work performance, the rights and obligations of the employer and employee about disability management on the workplace."
224228333|NCT04597762|DRUG|Hydrocortisone|Hydrocortisone eyedrops
224228334|NCT02277873|BEHAVIORAL|pregnancy|Observational study in order to establish relationship between moon and births
224228335|NCT01348295|OTHER|Observation|No interventions are made. The purpose of the study is to find out current practices used in pediatric mechanical ventilation.
223765163|NCT06888609|OTHER|Back Extensor Strengthening Exercises|"1. Superman Exercise Sets/Reps: 2 sets × 10-12 reps, hold 5-10 sec~2. Prone Arm and Leg Raise Sets/Reps: 2 sets × 10-12 reps, hold 5-10 sec~3. Seated Row (Resistance Band) Sets/Reps: 2 sets × 12-15 reps, hold 3-5 sec~4. Wall Angels Sets/Reps: 2 sets × 10-12 reps, 3-5 sec per cycle"
223640258|NCT03430297|DRUG|Dacarbazine 1000mg/m2 Q3W|"The dose of DTIC will be calculated according to the following formula, where the 'X' represents the total mg dose of DTIC: X (mg) = \[body surface area (BSA) x (1000mg/m2)\].~The body surface area (BSA) is defined by Dubois formula: BSA (m2) = 0.007184\* (cm0.725) \* (kg0.425)"
223640259|NCT02017405|OTHER|Serum-derived bovine immunoglobulin protein isolate (SBI)|Serum-derived bovine immunoglobulin protein isolate is a specially formulated light-colored protein powder composed of immunoglobulin (IgG) and other serum proteins similar to those found in colostrum and milk. Serum-derived bovine immunoglobulin protein isolate does not contain any milk products such as lactose, casein, or whey. Serum-derived bovine immunoglobulin protein isolate is gluten-free, dye-free, and soy-free. Serum-derived bovine immunoglobulin protein isolate is manufactured in accordance with current Good Manufacturing Practice (cGMP) and FDA guidelines for medical food ingredients.
223640260|NCT02017405|OTHER|Matching Placebo|
223640261|NCT05383937|OTHER|Speech Therapy INTENS-DYS|During the six research month, children included in the intensive arm will benefit of two daily hours speech therapy during two weeks. Those one will be carried out between the second and the fourth month.
223640262|NCT06107036|DRUG|BI 1015550|BI 1015550
223640263|NCT06107036|DRUG|Moxifloxacin|Moxifloxacin
223640264|NCT06107036|DRUG|Placebo|Placebo-matching BI 101550
223640265|NCT06590012|DRUG|Placebo|Participants will take the placebo capsules in addition to standard treatment for a year.
223640266|NCT06590012|DRUG|Tertinat|Participants will take Tertinat capsules in addition to standard treatment for a year.
224228336|NCT00016926|DRUG|capecitabine|
224228337|NCT05283239|OTHER|Follow up|Participants will be followed up at 6th，12th, 18th and 24th months with HPV viral integration/genotyping tests, thinprep cytologic tests (TCT) for cervix and vaginal secretion tests. Colposcopy and biopsy will be conducted for participants if necessary.
224228338|NCT02879721|DRUG|Candesartan|Angiotensin II, type 1 receptor inhibitor, (candesartan) 8 mg once daily for
224228339|NCT02879721|DRUG|Enalapril|Angiotensin-converting enzyme (ACE) inhibitor (enalapril) 5 mg once daily
224228340|NCT05803278|OTHER|Online enhancement training|"Online enhancement training lasting 3 months, using the InTempo app system (Gea-Metaphonology-Athena-reading/Ermes-writing) three times a week for twenty minutes. The training will include: Metaphonological Enhancement; Reading Enhancement; Writing Enhancement."
224319333|NCT01384903|DRUG|Plasma-derived antithrombin|Intravenous infusion once a day
224319334|NCT00086593|DRUG|lamotrigine|
224319335|NCT04679493|DRUG|XC7 100 mg single|The volunteers will receive a single dose of the ID (1 capsule once, 100 mg)
224319336|NCT04679493|DRUG|XC7 200 mg single|The volunteers will receive a single dose of the ID (2 capsules once, 100 mg each)
223640267|NCT00811590|DRUG|Everolimus|"Everolimus is a novel derivative of rapamycin. Everolimus has been in clinical development since 1996 as an immunosuppressant in solid organ transplantation. Since 2003, RAD001 is approved in Europe (trade name: Certican) via the Mutual Recognition Procedure (MRP) for the prevention of organ rejection in patients with renal and cardiac transplantation. Certican is also approved in Australia, South Africa, the Middle East, Central and South America, the Caribbean and some Asian countries.~Everolimus is being investigated as an anticancer agent based on its potential to act~* directly on the tumor cells by inhibiting tumor cell growth and proliferation~* indirectly by inhibiting angiogenesis leading to reduced tumor vascularity (via potent inhibition of tumor cell VEGF production and VEGF-induced proliferation of endothelial cells."
223640268|NCT06589206|OTHER|modified design of twin block|Vacuum formed twin block appliance with sagittal blocks
223640269|NCT02864394|BIOLOGICAL|Pembrolizumab|Pembrolizumab administered IV at 2 mg/kg on Day 1 of each 21-day cycle for up to 35 doses (approximately 24 months).
223640270|NCT02864394|DRUG|Docetaxel|Docetaxel administered IV at 75 mg/m\^2 on Day 1 of each 21-day cycle as per the approved product label.
223640271|NCT06599801|PROCEDURE|Thoracodorsal artery perforator flap reconstruction surgery|Oral squamous cell carcinoma patients underwent reconstruction with thoracodorsal artery perforator (TDAP) flaps following tumor resection.
223640272|NCT06599801|PROCEDURE|Forearm flaps reconstruction surgery|Oral squamous cell carcinoma patients received the reconstruction with forearm flaps after tumor resection
223640273|NCT06599801|PROCEDURE|Anterolateral thigh flap reconstruction surgery|Oral squamous cell carcinoma patients received the reconstruction with anterolateral thigh flaps after tumor resection
223640274|NCT06599801|PROCEDURE|Fibula flap reconstruction surgery|Oral squamous cell carcinoma patients received the reconstruction with fibula flaps after tumor resection
223640275|NCT06599801|PROCEDURE|Forearm flap reconstruction surgery|Oral squamous cell carcinoma patients received the reconstruction with forearm flaps after tumor resection
223640276|NCT06633588|DRUG|Polyhexanide|Participants will apply Prontoderm® Nasal Gel and perform whole-body wash with Prontoderm® Foam daily for 5 days before surgery.
224228341|NCT02292238|DRUG|Benfotiamine|"* To test whether increasing brain thiamine by administering 600 mg per day (300 mg/morning and 300 mg/evening) of benfotiamine for one year can slow cognitive decline in these patients as measured with the Alzheimer's Disease Assessment Scale (ADAS-COG).~* To determine whether increasing brain thiamine availability with 600 mg (300 mg/morning and 300 mg/evening) per day of benfotiamine for one year can slow the decline in brain glucose metabolism in these patients as measured with Fluorodeoxyglucose Positron Emission Tomography(FGPET) in the posterior cingulate."
224228342|NCT02970643|DRUG|Olanzapine|Moderate risk chemotherapy induced nausea group in all cancer. D1 Olanzapine 10mg PO D2-3 Olanzapine 10mg PO
224228343|NCT02970643|DRUG|Palonosetron|Moderate risk chemotherapy induced nausea group in all cancer. D1 Palonosetron 0.25mg IV
224228344|NCT01251926|DRUG|EZN-2208|
224228345|NCT01251926|DRUG|Bevacizumab|
224319337|NCT04679493|DRUG|Placebo single|The volunteers will receive a single dose of the ID (1 or 2 capsules once)
223640277|NCT06633588|DRUG|Mupirocin and Chlorhexidine|Participants will apply Bactroban® Nasal ointment and perform whole-body wash with Lifo-Scrub® daily for 5 days before surgery.
223640278|NCT02938299|DRUG|L19IL2 + L19TNF|Mixture of L19IL2 and L19TNF once weekly
223640279|NCT02938299|PROCEDURE|Surgery|Surgical resection of melanoma tumor lesions
223640280|NCT06706401|DRUG|Vesanoid|Before (chemo)radiotherapy: D1 to D3: 150mg/m2/day, 1 week before radiotherapy. Post (chemo)radiotherapy: D1 to D3: 150mg/m2/day every 3 weeks for up to 4 cycles post (chemo)radiotherapy
223640281|NCT06706401|RADIATION|Standard radiotherapy|70 Gy in 35 fractions of 2 Gy over 6 (6 fractions per week) or hyperfractionated RT with a median therapeutic dose of 80.5 Gy delivered in 70 fractions of 1.15 Gy over 7 weeks.
223640282|NCT06706401|RADIATION|Tailored radiotherapy|70 Gy in 35 fractions of 2 Gy over 6 weeks (6 fractions per week) or hyperfractionated RT with a median therapeutic dose of 80.5 Gy delivered in 70 fractions of 1.15 Gy over 7 weeks.
223640283|NCT06706401|DRUG|Cisplatin|"Cisplatin is recommended for the following patients : Stage T1-T2/N2a-N2b and T3/N0-N1-N2a-N2b. concomitant chemotherapy is standard of care treatments and should be administered as per standard practice.~Chemotherapy will include one of the two cisplatin regimens specified in this protocol at the discretion of the participating centers. The centers must however treat all their recruited patients with one of the two regimens chosen before site activation. Chemotherapy should start the first day of radiotherapy. Cisplatin should be infused before radiation therapy delivery.~The 2 options are:~• Cisplatin 100 mg/m² i.v. on day 1 and 22 of radiotherapy (when 70 Gy are delivered in 6 weeks) or on day 1, 22 and 43 (when 70 Gy are delivered in 7 weeks).~or~• Cisplatin 40 mg/m² i.v. on day 1, 8, 15, 22, 29, 35 of radiotherapy (when 70 Gy are delivered in 6 weeks) or on day 1, 8, 15, 22, 29, 35, 42 of radiotherapy (when 70 Gy are delivered in 7 weeks)."
223765164|NCT06888609|OTHER|Core Stability Exercises|"1. Side Plank Sets/Reps: 3 sets, hold 10-60 sec per side~2. Dead Bug Exercise Sets/Reps: 3 sets × 6-15 reps per side~3. Bridging Exercise Sets/Reps: 3 sets × 10-20 reps, hold 2-5 sec~4. Bird-Dog Exercise Sets/Reps: 3 sets × 8-15 reps per side, hold 2-5 sec"
224228346|NCT03001609|DRUG|AC0010|Oral dose of 14C-labeled AC0010 suspension including 200 mg/83μCi\[14C\]
224228347|NCT01950988|DEVICE|Manual toothbrush reference|
224228348|NCT01950988|PROCEDURE|Measure of the dental plaque|
223640284|NCT06706401|DRUG|Cetuximab|"Cetuximab is recommended for the following patients : Stage T1-T2/N2a-N2b and T3/N0-N1-N2a-N2b. concomitant Cetuximab is standard of care treatments and should be administered as per standard practice.~Cetuximab therapy will be started with an intravenous loading dose of 400 mg/m2 one week before start of RT followed by six (radiotherapy over 6 weeks) or seven (radiotherapy over 7 weeks) weekly doses of 250 mg/m2."
224228349|NCT01950988|DEVICE|Manual toothbrush Broscyl®|
224228350|NCT03149588|DRUG|propofol|Using propofol and remifentanil as maintenance of general anesthesia during caesarean section.
224228351|NCT03149588|DRUG|sevoflurane|Using sevoflurane and remifentanil as maintenance of general anesthesia during caesarean section.
224228352|NCT01789320|DRUG|triamcinolone acetonide (Triesence®)|4 mg of TRIESENCE® (triamcinolone acetonide injectable suspension 40 mg/mL) administered as a single injection to the suprachoroidal space
224319338|NCT04679493|DRUG|XC7 200 mg multiple|The volunteers will receive multiple doses of the ID during 14 days (2 capsules daily, 100 mg each)
223640285|NCT06882902|BEHAVIORAL|habit formation training|Participants need to perform habit formation exercises for 4 consecutive days. During the exercises, participants will see a picture stimulus and need to learn the corresponding key press. Each day, participants will spend 30 minutes on the training.
223640286|NCT06705400|BEHAVIORAL|Multi-behavioural|The Bloom Study is implemented in an existing and highly accepted health service delivered by community health nurses. Beyond focusing on food, meals, motor skills and movement, the intervention also target sleep and family sense of security. The intervention commence in pregnancy and continues until the child is 2½ years old.
223640287|NCT06706024|OTHER|breathing exercise|Patients Under Hemodialysis
223640288|NCT06705699|PROCEDURE|Urethral mobilisation|Involves mobilizing the urethral tube proximally and advancing it distally to the glans. The urethra is repositioned and sutured at the neomeatal position.
223640289|NCT06705699|PROCEDURE|Mathieu|Utilizes a perimeatal-based flap, which is flipped up to create the neourethra.
223640290|NCT06705751|DIAGNOSTIC_TEST|Autonomic response in AAOCA|"Autonomic regulation sub-analysis: Autonomic control will be evaluated in a population prospectively recruited.~Thirty-eight subjects with Anomalous Aortic Origin of a Coronary Artery (AAOCA) will undergo an active standing test. For this prospective sample, demographic and clinical data, as well as DICOM images from previously conducted diagnostic CT angiographies (CTAs) for AAOCA, will also be collected. These data will be utilized to assess the final functionality of the online platform before its public launch.~The patients will be subjected to the active standing test to elicit an autonomic response, with results compared to reference normal values. During this examination, the following data will be collected: continuous ECG, non-invasive blood pressure, and respiratory measurements in both supine and prone positions."
223640291|NCT06706128|OTHER|reflex rolling technique|received reflex rolling technique for 20 min, 5 days a week, for 2 weeks.
223640292|NCT06706128|OTHER|lung squeezing technique|lung squeezing technique for 20 min, 5 days a week, for 2 weeks
223640293|NCT06705114|PROCEDURE|complete denture|Each patient received a newly constructed conventional complete denture with optimal denture extension and lingualized balanced occlusal concept
223640294|NCT06705114|PROCEDURE|implant overdenture|Two dental implants were inserted in the patient's mandibular arch at the canine region using guided surgery and a delayed loading protocol.After 3-4 months, the dental implants were exposed and ball abutments were screwed into the implants. The housing of the ball attachments were incorporated into the fitting surface of the mandibular denture using a direct pick-up technique (Fig. 1B). The mandibular overdenture was then inserted into the patient's mouth and occlusal adjustment was done using articulating paper to remove any occlusal interferences. Follow-up visits were scheduled.
223640295|NCT06743256|DEVICE|Surgical System|Levita Magnetic Surgical System
223640296|NCT06667687|DRUG|ABBV-291|Intravenous Infusion
223640297|NCT06004739|DRUG|Start Antibiotics / Continue Antibiotics for treatment of bacteriuria|Participants will be randomized to start or continue with antibiotics (with antibiotic duration determined by the Most Responsible Physician \[MRP\]). Antibiotics choice to be selected by the MRP.
223640298|NCT06004739|OTHER|No Antibiotics for treatment of bacteriuria|Participants will be randomized to no antibiotics
224228353|NCT04935827|OTHER|Season of Year|"We stratify patients into 4 groups based on the season of the year (between 12/1/2007-11/30/2017)~* Winter: December, January, February~* Spring: March, April, May~* Summer: June, July, August~* Fall: September, October, November"
224228354|NCT04935827|OTHER|Hospitalized 14 days prior to dialysis|"We further stratify patients into 3 groups based on whether they were hospitalized within 14 days prior to dialysis~* Group 1: No hospitalization prior to dialysis~* Group 2: Hospitalized within 14 days prior to dialysis for an acute infectious respiratory condition or one of the following acute cardiac conditions (arrhythmia, myocardial infarction, stroke, or fluid overload)~* Group 3: Hospitalized within 14 days prior to dialysis for a condition not in Group 2"
224228355|NCT00160030|DRUG|FOLFOX 4|total treatment of six 2-weekly cycles of FOLFOX 4, the first 3 cycles starting on D1, D15 and D29 concomitant with 5 weeks' radiotherapy.
224319339|NCT04679493|DRUG|Placebo multiple|The volunteers will receive multiple doses of the ID during 14 days (2 capsules daily)
223640299|NCT06775002|DIAGNOSTIC_TEST|Serum Raman spectroscopy intelligent diagnostic system|1\. Screening interested participants should sign the appropriate informed consent (ICF) prior to completion any study procedures. 2. The investigator will review symptoms, risk factors, and other non-invasive inclusion and exclusion criteria. 3. The following is the general sequence of events during the 3 months evaluation period. 4. Completion of baseline procedures Participants were assessed for 3 months and completed all safety monitoring.
223640300|NCT06757530|DIAGNOSTIC_TEST|AI|Using artificial intelligence models to distinguish between patients with lymph node metastasis and those without lymph node metastasis.
223640301|NCT06764407|OTHER|Patient preferential music|Patients will listen to their preferred music through the headphones before surgery and intraoperative period.
223640302|NCT06764407|OTHER|No Music|Patients will not listen to music.
224228356|NCT00160030|DRUG|5-FU / Cisplatin|two cycles of 5-FU / Cisplatin on week 1 and 5 of radiotherapy and two cycles of chemotherapy with 5-FU / Cisplatin on week 8 and 11 (one cycle each three weeks after the end of radiotherapy).
224319340|NCT03903211|DRUG|[18F]PI-2620|Imaging for evaluating the accumulation of abnormal tau protein in the brain
224319341|NCT05035277|DRUG|Acetylsalicylic acid|Acetylsalicylic acid 75 mg once daily is the current standard-of-care in TAVI patients without other indications for anticoagulation therapy.
224319342|NCT05035277|DRUG|Apixaban|Standard dose apixaban will be one of the options for the patients in the experimental arm.
224319343|NCT05035277|DRUG|Rivaroxaban|Standard dose rivaroxaban will be one of the options for the patients in the experimental arm.
223640303|NCT06778434|DRUG|Imipramine|10% imipramine
223640304|NCT06778434|OTHER|Control Vehicle|polyethylene glycol: dimethyl sulfoxide Solution
223640305|NCT04057664|BEHAVIORAL|Learning of Coping Strategies|Group sessions with psychotherapy and physiotherapy
224228357|NCT02048254|RADIATION|brachytherapy|
224228358|NCT02048254|RADIATION|IMRT|
224228359|NCT00310427|DRUG|LY686017|50 mg administered orally on a daily basis
224228360|NCT00310427|DRUG|Placebo|Administered on a daily basis
224319344|NCT05035277|DRUG|Edoxaban|Standard dose edoxaban will be one of the options for the patients in the experimental arm.
224319345|NCT02104115|OTHER|MRI scanners|
223640306|NCT06867328|PROCEDURE|Platelet-Rich Plasma (PRP) Dressing|"* PRP will be prepared by centrifugation of 20 mL venous blood with an anticoagulant.~* The extracted PRP will be applied twice weekly to the wound.~* A sterile gauze will be placed over the wound after PRP application.~* Treatment will continue for up to 6 weeks or until wound healing is achieved."
223640307|NCT06867328|PROCEDURE|Normal Saline Dressing|"Wound will be cleansed with normal saline and covered with sterile gauze.~* Dressing changes will be done twice weekly following wound debridement.~* Treatment will continue for up to 6 weeks or until wound healing is achieved."
223640308|NCT06818747|PROCEDURE|Best corrected monocular visual acuity|Assessed with the Monoyer scale and expressed in logMAR at 24 months after corneal transplantation
223640309|NCT06775015|DIAGNOSTIC_TEST|Serum Raman spectroscopy intelligent diagnostic system|Serum Raman spectroscopy intelligent diagnostic system Description: 1. Screening interested participants should sign the appropriate informed consent (ICF) prior to completion any study procedures. 2. The investigator will review symptoms, risk factors, and other non-invasive inclusion and exclusion criteria. 3. The following is the general sequence of events during the 3 months evaluation period: 4. Completion of baseline procedures Participants were assessed for 3 months and completed all safety monitoring.
223640310|NCT06466590|DIAGNOSTIC_TEST|Use of Measurement Instrument|Participants will complete the measurement procedure twice, with sessions scheduled one week apart, using the same instrument under standardized conditions. The results from both sessions will be compared to assess the instrument's consistency and accuracy
223640311|NCT06929299|DRUG|STSA-1301 subcutaneous injection|Subjects will receive the STSA-1301 on the dates specified in the protocol
223640312|NCT06929299|DRUG|Placebo|Subjects will receive the placebo on the dates specified in the protocol
224228361|NCT06271811|PROCEDURE|Flossing band|The application of flossing to the knee commences with a preliminary evaluation of the joint range of motion and pain perception. The band is wrapped around the knee, starting with an approximate tension of 50% for the first wrap and escalating to a tension of 60-80% in subsequent wraps. It\&#39;s essential to overlap the band with each wrap, moving from a distal to the proximal direction (bottom to top), which aids in enhancing drainage. Continuous monitoring of the patient is critical to ensure that excessive pressure is not being applied. This can be achieved by palpating the pulse on the dorsum of the foot or inner ankle, and observing if the skin regains its normal color after pressing the area with fingers. Should the patient experience strong tingling or pain, the bandage must be immediately removed. The duration of the band's application varies between 2 to 5 minutes, depending on patient tolerance, a methodology informed by existing research.
224228362|NCT06271811|OTHER|Conventional physiotherapy|"The intervention protocol is centered on neuromuscular training, targeting the strengthening of key muscle groups including the quadriceps, hamstrings, and hip abductors, which are vital for knee stabilization. This approach is supported by previous research, emphasizing the importance of these muscle groups in knee joint health. Complementing this, proprioceptive exercises, such as single-leg balances and controlled knee bends, were incorporated to enhance joint position sense, aligning with the guidelines set forth by Powers et al., 2010.~The intensity of these exercises is progressively increased, tailored to each patient's tolerance and improvement. The protocol stipulates two sessions per week over eight weeks."
223640313|NCT01704209|DRUG|Fibroblast Treatment|
223640314|NCT01704209|PROCEDURE|Vehicle|
224319346|NCT02104115|OTHER|VAS Symptom scores|
223640315|NCT06786676|DRUG|AS-S603|Oral administration of AS-S603 tablet
224228363|NCT01821027|DRUG|Simvastatin|One 40 mg tablet taken orally (by mouth) on Day 1 and Day 7.
224228364|NCT01821027|DRUG|Canagliflozin (JNJ-28431754)|One 300 mg dose (ie, one 100 mg and one 200 mg over-encapsulated tablet) taken orally (by mouth) on Days 2 through Day 7.
224319347|NCT00486031|DRUG|Balsalazide Disodium|
224319348|NCT06632574|DRUG|paclitaxel cationic liposomes|Paclitaxel cationic liposomes is a modified new drug. In this study, administration is performed through arterial catheter infusion.
224323315|NCT04695925|DRUG|Osimertinib|Osimertinib, 80mg, QD, p.o. until disease progression
224323316|NCT04695925|DRUG|Pemetrexed|pemetrexed 500 mg/m2 intravenously every 3 weeks until disease progression
224323317|NCT04695925|DRUG|Carboplatin|carboplatin area under curve 5 intravenously every 3 weeks for four cycles
223640316|NCT06786676|DRUG|Placebo|Oral administration of Placebo tablet
223640317|NCT06810609|PROCEDURE|surgery (any volume) and / or pharmaceuticals treatment initiated or planned or only dynamic observation, in accordance with current clinical guidelines|Surgical removal of the tumor in patients with resectable or borderline resectable NSCLC
223640318|NCT06810609|RADIATION|Chemoradiotherapy|Chemoradiotherapy
223640319|NCT06810609|DRUG|Immunotherapy|Immunotherapy (Durvalumab).
223640320|NCT06822257|DRUG|Alcohol beverage|moderate dose of alcohol
223640321|NCT06822257|OTHER|Non-alcohol beverage|No alcohol given
223640322|NCT03294707|DRUG|AG10 oral tablet|Active single ascending dose
223640323|NCT03294707|DRUG|Placebo Oral Tablet|Placebo single dose
223640324|NCT06911372|DRUG|Intradermal Microdialysis|A total of three microdialysis sites will be perfused with ringer's solution, L-NAME, or ketorolac (one drug per site). After a baseline period, all three sites will undergo tests of blood vessel function including an acetylcholine dose-response protocol and a test of maximal skin blood flow with sodium nitroprusside.
223640325|NCT06911372|OTHER|Brain Blood Flow Tests|Participants will complete CO2 breathing procedures to evaluate brain blood vessel health.
223640326|NCT06911372|OTHER|Local Heating|A dime-sized heater will be placed on the skin to evaluate cutaneous microvascular function
223640327|NCT06351124|BIOLOGICAL|Feasibility of beta-hydroxybutyrate supplementation to reduce inflammation in patients with Crohn's|Is Beta-hydroxybutyrate a supplement that can control symptoms and progression of Crohn's.
223640328|NCT06519942|DIAGNOSTIC_TEST|Blood sampling|Fasting blood samples will be obtained.
223640329|NCT06519942|DIAGNOSTIC_TEST|Electromyoneurography (EMNG)|Nerve conduction of sensory and motor nerves of the upper and lower limb will be performed, including F- and H-waves. Needle EMNG of the m. tibialis anterior, m. gastrocnemius (medial head), m. tensor fascia lata and m. gluteus maximus) will be performed.
224323318|NCT06475742|DRUG|Cenerimod|Film-coated tablets at a dose of 4 mg.
224228365|NCT00494806|OTHER|Rocking Chair Intervention|Patient out of bed rocking in a rocking chair at a constant rate of one rock cycle per second (back and forth), in ten to twenty minute increments, for at least sixty minutes per day or 3600 rock cycles and ambulate at least twice per day beginning the first postoperative day.
223640330|NCT06519942|PROCEDURE|Muscle biopsy|Muscle biopsy of the m. gastrocnemius will be performed under local anesthesia using the modified Bergström technique.
223640331|NCT06519942|RADIATION|Quantitative peripheral computed tomography (qPCT)|A qPCT scan of the calf will be performed.
223640332|NCT06519942|DEVICE|Mechanography|Single two leg jump, multiple one leg hopping, chair rise and sit to stand tests will be performed.
223640333|NCT06519942|DIAGNOSTIC_TEST|Electrocardiography (ECG)|A 15-minute resting ECG will be performed.
223640334|NCT06519942|OTHER|Questionnaires|Questionnaires will be performed to collect information on medical background (drug use, comorbidities, symptoms of peripheral neuropathy, ...) and lifestyle factors (ethyl consumption, food intake, physical activity, smoking).
223640335|NCT06519942|OTHER|Anthropometry|Length and hip:waist ratio will be measured. Furthermore, body weight and composition will be determined by bio-impedance measurement. Systolic and diastolic blood pressure (mean of 3 times) will be evaluated.
223640336|NCT05174221|DRUG|Mezagitamab|TAK-079 subcutaneous injection.
224228366|NCT01080430|OTHER|rehabilitation maneuver|rotation in the direction of the weak vestibular response, every 3-7 days over a period of a month. Each rotation lasts about 2 minutes and a total of 3-7 rotations are used per session.
224228367|NCT04985214|OTHER|Questionnaire|Questionnaire on the quality of life
223640337|NCT06827717|DRUG|irinotecan liposome (II) + temozolomide + fluzoparib|"Drug Irinotecan Hydrochloride Liposome Injection（II）56.5mg/m2, IV infusion administered on day 1 of every 28-day cycle until disease progression, unacceptable toxicity or death. Other names: HR070803.~Drug Fluzoparib 50mg PO bid, administered continuously until disease progression, unacceptable toxicity or death. 28 days as a treatment cycle. Other names: SHR-3162.~Drug Temozolomide 30mg/m2 PO qd, administered on day 1 to day 5 of every 28-day cycle until disease progression, unacceptable toxicity or death."
224228368|NCT05841381|DRUG|Pyrotinib|pyrotinib: 400mg orally daily for 1 year
224228369|NCT05841381|DRUG|Trastuzumab|8mg/kg iv load followed by 6mg/kg iv 3-weekly for a total of 17 cycles
224228370|NCT05841381|DRUG|Paclitaxel|80mg/m2 per week for a total of 12 weeks
223640338|NCT06412159|OTHER|Selective laser melting framework was fabricated using completely digital workflow|completely digital work flow Conventional technique versus complete digital technique
223640339|NCT06921551|DEVICE|ABLE Exoskeleton|Participants will undergo 60-min gait training sessions with the exoskeleton once a week for up to12 months
223640340|NCT06915142|DRUG|HRS-7058 + SHR-1316|HRS-7058 + SHR-1316
223640341|NCT06915142|DRUG|HRS-7058 + SHR-1316 + Platinum-containing doublet chemotherapy|HRS-7058 + SHR-1316 + Platinum-containing doublet chemotherapy
223640342|NCT06915142|DRUG|HRS-7058 + Cetuximab|HRS-7058 + Cetuximab
223640343|NCT06915142|DRUG|HRS-7058 + SHR-1826|HRS-7058 + SHR-1826
223640344|NCT06915142|DRUG|HRS-7058 + SHR-1826 + SHR-1316|HRS-7058 + SHR-1826 + SHR-1316
224228371|NCT00667927|DRUG|Busulfan|See Detailed Description section for description of treatment plan.
224228372|NCT00667927|DRUG|Cyclophosphamide|See Detailed Description section for description of treatment plan.
223640345|NCT06331819|DIAGNOSTIC_TEST|In-lab polysomnography|Patient's brainwaves are recorded overnight to diagnose sleep disorder.
223640346|NCT06331819|DEVICE|Continuous positive airway pressure|A machine that uses air pressure to keep breathing airways open while patients sleep.
223640347|NCT06331819|DIAGNOSTIC_TEST|Home sleep study device|Patient's brainwaves are recorded overnight to diagnose sleep disorder.
223640348|NCT06917287|DIETARY_SUPPLEMENT|Native CT-II® (undenatured type II collagen)|"Strength: 40 mg in 3 capsules~Dose Regimen:~3 yellow capsules containing MCC after breakfast with water 3 blue capsules containing 40 mg Native CT-II® \& MCC after dinner with water Route of administration: Oral"
223640349|NCT06917287|DIETARY_SUPPLEMENT|Glucosamine HCL + Chondroitin Sulphate (G+C) [Comparator]|2700 mg (1500 mg G + 1200 mg C) 3 yellow capsules containing G+C orally after breakfast with water \& 3 blue capsules containing G+C after dinner with water
223640350|NCT06917287|DIETARY_SUPPLEMENT|Placebo [Microcrystalline Cellulose (MCC)|2700 mg excipient 3 yellow capsules containing MCC orally after breakfast with water 3 blue capsules containing MCC after dinner with water.
223640351|NCT06936566|DRUG|Ruxolitinib|Ruxolitinib twice daily for 56 days followed by a short taper Given orally
223640352|NCT06936566|DRUG|Methylprednisolone|Starting dose 2 mg/kg/d for at least three days, then taper Given IV or orally
223640353|NCT02633059|DRUG|Dexamethasone|Given PO
224228373|NCT00667927|DRUG|Mesna|See Detailed Description section for description of treatment plan.
224228374|NCT02948322|DEVICE|CMRI|Myocardial Imaging (CMRI) will be performed in patients (at baseline and 6 month after treatment) and healthy volunteers (baseline)
224228375|NCT02948322|DRUG|Gadolinium|gadolinium injection will be performed during CMRI in patients and healthy volunteers.
224228376|NCT02948322|PROCEDURE|OGTT|Growth Hormon (GH) secretion and metabolic status of the acromegalic will be evaluated by an measure of plasma glucose, insulin and GH (OGTT), and insulin-like growth factor-1 (IGF-I) will be measured in patients and healthy volunteers.
224228377|NCT00497367|DEVICE|Percutaneous Coronary Intervention (PCI) TAXUS Petal|TAXUS Petal, paclitaxel eluting stent
224228378|NCT05834790|OTHER|Mobile Augmented Reality (MAR) for oral health education program|MAR application named MAKAR will be available to download and use for smartphones and tablets. Participants will need to scan QR code to access the content of oral health education program
224228379|NCT05834790|OTHER|Lecture-based oral health education program|The oral health education program that will be delivered by traditional lecture-based process
224228380|NCT04347590|DEVICE|Unblinded - CGM (Medtronic Guardian)|Data from device will be readable and alarms on
224228381|NCT04347590|DEVICE|Blinded - CGM (Medtronic Guardian)|Data from device will be blinded and alarms off
224228382|NCT02127996|DRUG|GLP-1|GLP-1 (7-36) amide infused at 1.2 pmol/Kg/min
224228383|NCT02127996|DRUG|placebo|Normal saline
224228384|NCT04890600|BEHAVIORAL|well-being assessment|exploration of emotional, cognitive and behavioural resources of healthcare professionals
224228385|NCT04318652|DRUG|Methylprednisolone eyedrops|instillation of methylprednisolone eye drops
223640354|NCT02633059|DRUG|Idasanutlin|Given PO
223640355|NCT02633059|DRUG|Ixazomib Citrate|Given PO
223640356|NCT02633059|OTHER|Laboratory Biomarker Analysis|Correlative studies
224228386|NCT04579874|DIAGNOSTIC_TEST|LIVERFASt|blood draw
224228387|NCT02088528|DEVICE|Aurolab glaucoma drainage device|Patients undergoing surgery will receive an implant
224228388|NCT02088528|PROCEDURE|Trabeculectomy with mitomycin-c|Trabeculectomy surgery augmented by application of mitomycin C (0.4 mg/ml) to the sclera in the region of the trabeculectomy site for a period of exactly 3 minutes.
224228389|NCT02539095|DEVICE|CartiZol|The product, CartiZol, which contains absorbable collagen, is applied on the cartilage defect to stimulate the neovasculization and cell penetration and to assist the natural wound healing process. It supplements the defective or damaged cartilage. Place the needle on the tip of the syringe and inject the product into the articular cavity.
223640357|NCT02633059|OTHER|Pharmacological Study|Correlative studies
224228390|NCT02539095|DEVICE|Normal saline|"1. Supplementation of fluid and electrolytes (sodium or chlorine deficiency)~2. Diluent for injection solution Place the needle on the tip of the syringe and inject the product into the articular cavity."
223640358|NCT06507774|DEVICE|3D Reconstruction Technology|Utilization of 3D reconstruction technology to assist in preoperative planning and surgical procedures for thoracic surgery patients.
223640359|NCT06507774|DEVICE|No 3D reconstruction is used|This group did not use 3D reconstruction for surgical navigation
223640360|NCT06819852|OTHER|Acute hospital care at home|Home visit for a serious illness conversation. Acute illness evaluation on demand. Acute hospital care at home as needed.
223640361|NCT06819852|OTHER|Standard medical treatment|Standard acute and emergency care delivered in a brick-and-mortar hospital setting.
223640362|NCT06952140|DIETARY_SUPPLEMENT|Ketone ester|Ketone ester: 3-hydroxybutyrate as enteral bolus (500 mg/kg)
223640363|NCT06952140|DIETARY_SUPPLEMENT|Placebo|Maltodextrin (isovolumic and isocaloric placebo) as enteral bolus
223640364|NCT05004129|DRUG|Tideglusib|Tideglusib dosing will be weight-adjusted at 400 mg, 600 mg, or 1000 mg dose levels, or weight banded fixed doses of 400 mg, 600 mg, 800 mg or 1000 mg, with each subject starting at a weight-adjusted 400 mg dose level for 2 weeks, then up titrating to a weight-adjusted 600 mg dose level for the next 2 weeks.
223640365|NCT04730804|DRUG|ALXN1830|ALXN1830 will be administered as SC infusion(s).
223640366|NCT04730804|DRUG|Placebo|Placebo will be administered as SC infusion(s).
223640367|NCT03330470|BEHAVIORAL|exercise|participants will be subjected to 4 months supervised exercise intervention
224228391|NCT02235233|DRUG|Technetium Tc 99M Mebrofenin|Each subject will be injected with \~2.5 mCi of Technetium Tc 99M Mebrofenin
224228392|NCT04603963|DEVICE|power breathe|respiratory muscle training 1 time a day with power breathe 3 sets of 10 repetitions
224228393|NCT04228341|OTHER|Glucose Reference 1|50 g of glucose dissolved in 250 ml of water (First glucose control visit)
224228394|NCT04228341|OTHER|Glucose Reference 2|50 g of glucose dissolved in 250 ml of water (Second glucose control visit)
224228395|NCT04228341|OTHER|Glucose Reference 3|50 g of glucose dissolved in 250 ml of water (Third glucose control visit)
224228396|NCT04228341|OTHER|Brown Rice|Unpolished brown rice containing 50 g of available carbohydrate was cooked using a rice cooker (Toyomi) at a ratio of rice to water of 1: 2
224228397|NCT04228341|OTHER|3 % polished rice|3% polished rice, containing 50 g of available carbohydrate was cooked using a rice cooker at a ratio of rice to water of 1: 2
224228398|NCT04228341|OTHER|6 % polished rice|6% polished rice, containing 50 g of available carbohydrate was cooked using a rice cooker at a ratio of rice to water of 1: 2
224228399|NCT04228341|OTHER|9 % polished rice|9 % polished rice, containing 50 g of available carbohydrate was cooked using a rice cooker at a ratio of rice to water of 1: 2
224228400|NCT04228341|OTHER|20 % Polished rice|White rice (20% polished rice), containing 50 g of available carbohydrate was cooked using a rice cooker at a ratio of rice to water of 1: 2.
224228401|NCT02044978|DEVICE|Zoledronate-coated dental implant|
224228402|NCT02529059|DRUG|Eviplera|A single-pill fixed dose combination of tenofovir 245mg, emtricitabine 200mg and rilpivirine 25mg once daily for 24 weeks.
224228403|NCT06484959|OTHER|Assigned Interventions|Assigned Interventions
224228404|NCT01129999|BEHAVIORAL|Cognitive-Behavioral Therapy|a cognitive-behavioral smoking cessation program; 6, weekly-held, group sessions (90 min each)
224228405|NCT01129999|BEHAVIORAL|Hypnotherapy|hypnotherapeutic smoking cessation program; 6, weekly-held, group sessions (90 min each)
224228406|NCT03184454|DEVICE|Medtronic Percept Deep Brain Stimulation|"Deep Brain stimulation involves bilateral stereotactic placement of stimulating leads into specific brain structures. Leads are attached to permanent subcutaneous wires and battery-powered implantable neurostimulators (INSs). Noninvasive INS programming can achieve a balance between maximal benefit (reduction in disabling OCD symptoms), while minimizing adverse effects (eg sensorimotor effects such as dysarthria or paresthesias; as well as behavioral side effects, e.g., hypomania, insomnia, or increased anxiety)."
224228407|NCT02072564|OTHER|Questionnaire|Questionnaire with 100 questions divided into different groups: general data, work, physical activity, character, hobbies, disease and diet.
224228408|NCT02587442|DRUG|RadProtect®|This study will evaluate RadProtect® at sequential, escalating dose levels. Once administration is given, study subjects will be followed during 24 hours of hospitalization according to the final injection timing. All subjects will need to return to the hospital for monitoring at 7+2 days after dosing, and follow-up visits by telephone at Day 3, Day 14+2, and Day 28+2 days will need to be conducted.
224228409|NCT05690568|OTHER|multimodal chiropractic care|functional movement score followed by intervention of multimodal chiropractic care including spinal/extremity manipulation and exercise recommendation
224228410|NCT03027336|DIETARY_SUPPLEMENT|Coleosoma|patients will take one tablet of 500mg daily for 12 weeks. No dose titration is foreseen.
224228411|NCT03027336|DIETARY_SUPPLEMENT|Placebo|patients will take one tablet daily for 12 weeks.
224228412|NCT03272256|DRUG|IM156|Sequential 3+3 design.
224228413|NCT06454500|OTHER|Clinical decision support|A 48 hour expiration on orders placed for indwelling urinary catheters.
223640368|NCT03330470|DIETARY_SUPPLEMENT|carnosine supplementation|participants will be instructed to take carnosine 2 times daily
223640369|NCT03330470|BEHAVIORAL|stretching|participants will be subjected to 4 months supervised stretching program
223640370|NCT03330470|DIETARY_SUPPLEMENT|supplementation with placebo|participants will be instructed to take placebo 2 times daily
223640371|NCT05825560|DRUG|OFA multimodal analgesia|Multimodal opioid free analgesia
223640372|NCT05825560|DRUG|Standard multimodal analgesia|Standard remifentanil analgesia
223640373|NCT04004364|OTHER|Coordinated Specialty Care (CSC)|CSC is an integrated and team-based treatment model for first episode psychosis elements include psychotherapy, supported employment and education, family education and support, and pharmacotherapy.
223640374|NCT04402567|OTHER|No Intervention|Not Apply
223640375|NCT04874246|DRUG|Vasopressin|During robot-assisted laparoscopic myomectomy, vasopressin diluted to different concentrations will be injected before uterine serosal incision.
223640376|NCT01516541|OTHER|Background care|Guidelines-based medical care
223640377|NCT01516541|DRUG|Placebo|Matching dalcetrapib placebo orally daily
224228414|NCT01911585|BEHAVIORAL|Prolonged Exposure Therapy|Prolonged exposure therapy (PE), a specific exposure therapy program for PTSD is a highly effective treatment for PTSD. The key components of PE are imaginal exposure to the traumatic event and processing it (revisiting of the traumatic memory in imagination) followed by processing of the revisiting experience, and in vivo exposure to avoided trauma-related situations and objects.
224228415|NCT04389879|OTHER|Bonding of either CAD/CAM or conventional multistranded stainless steel fixed retainer|Investigate and compare the clinical effectiveness of two types of fixed retainers; CAD/CAM vs. multistranded wire.
224228416|NCT01004211|PROCEDURE|Narrow band imaging transurethral resection|Transurethral resection of bladder lesion by mean of narrow band imaging
224228417|NCT01004211|PROCEDURE|Standard transurethral resection|Transurethral resection of bladder lesion by mean of standard white light
224228418|NCT01297010|DRUG|Dexamethasone and ondasetron|Patients will receive ondansetron (0.1 mg / kg dose of 4mg cap) associated with dexamethasone (0.15 mg / kg dose of 5mg ceiling) or dexamethasone (0.15 mg / kg) or placebo
224228419|NCT01297010|DRUG|Dexamethasone|Children were randomized to this group ni initiate proceedings with a 10ml syringe containing dexamethasone (0.15 mg / kg dose of 5mg ceiling)
223640378|NCT01516541|DRUG|dalcetrapib|600 mg orally daily
223640379|NCT00554216|DRUG|VI-0521|3.75 mg phentermine/23 mg topiramate
223640380|NCT00554216|DRUG|VI-0521|15 mg phentermine/92 mg topiramate
223640381|NCT00554216|DRUG|Placebo matched phentermine/topiramate|Placebo matched phentermine/topiramate
224228420|NCT01103505|DIAGNOSTIC_TEST|ForeseeHome AMD Monitoring Device|Earlier detection of progression from intermediate dry age-related macular degeneration to CNV between routine eye exams through home diagnostic testing with the ForeseeHome AMD Monitoring device
224228421|NCT05815381|OTHER|Questionnaires, quantitative sensory testing, blood sampling, skin biopsies, functional magnetic resonance imaging, magnetic resonance spectroscopy|se arm/group descriptions
223640382|NCT01933568|RADIATION|SABR|combined CFRT and SABR with concurrent cisplatin
223640383|NCT01933568|DRUG|Cisplatin|combined CFRT and SABR with concurrent cisplatin
223640384|NCT02559999|OTHER|Painful tonic stimuli|
223640385|NCT02559999|OTHER|non-painful stimuli|
223640386|NCT01570946|BEHAVIORAL|Lifestyle Modification|The mobile phone based intervention will use short messaging service (SMS or text messaging) to deliver education, treatment targets, advice, support and motivation.
223640387|NCT02446574|DRUG|Paclitaxel|starting dose 20mg/m2 qw
223640388|NCT02446574|DRUG|Cisplatin|dose 25mg/m2 qw
223640389|NCT02446574|RADIATION|Radiation|60Gy/2Gy/30f
223640390|NCT04775940|PROCEDURE|Perforated collagen membrane|Horizontal Bone Augmentation using Perforated Collagen Membrane
223640391|NCT04775940|PROCEDURE|Occlusive collagen membrane|Occlusive collagen membrane
223640392|NCT04674423|DRUG|Tenofovir Alafenamide|Tenofovir Alafenamide treatment for 144 weeks
223640393|NCT00110747|DRUG|S-Caine™ Peel (lidocaine and tetracaine topical cream 7%/7%)|S-Caine Peel comprising a 1:1 eutectic mixture of 7% lidocaine and 7% tetracaine was applied topically. A thin layer of the peel (approximately 1 mm in thickness) was applied and remained on the treatment area for 30 minutes (±2 minutes).
223640394|NCT00110747|DRUG|Placebo Peel|Peel was applied topically. A thin layer of the peel (approximately 1 mm in thickness) was applied and remained on the treatment area for 30 minutes (±2 minutes).
223640395|NCT06298799|GENETIC|DNA Sequencing and Analysis|DNA extracted from saliva / oral mucosa will be tested for diversities reported in the literature known to be associated with T2DM and Obesity and which may have a potential impact on the response to treatment with Semaglutide. In addition, the DNA will be screened for new diversities that have a potential impact on the response to treatment. working assumption of the study is that there can be 3 types of genetic variants that affect the drug's effectiveness and/or side effects.
223640396|NCT06298799|GENETIC|differential expression analysis with RNA-sequencing (RNA seq) experiments|Performing small RNA sequencing experiments on an Illumina Next-Generation Sequencing (NGS) machine to investigate microRNAs (miRNAs) or other small non-coding RNAs involves specific steps tailored to the unique characteristics of these molecules
223640397|NCT02331212|OTHER|Cytology Specimen Collection Procedure|Correlative studies
223640398|NCT02331212|OTHER|Laboratory Biomarker Analysis|Correlative studies
224228422|NCT01199432|DRUG|5-FU（intravenous infusion）+epirubicin+cyclophosphamide|5-FU 200mg/m2 per day from day 1 to day 28 （Continuous intravenous infusion）; epirubicin 65mg/m2 per day on day 1 and day 8 and cyclophosphamide 500mg/m2 per day on day 1 and day 8 ; every 28 days as a cycle. Total four cycles is needed
224228423|NCT01199432|DRUG|5-FU（intravenous bolus）+epirubicin+cyclophosphamide|5-FU 500mg/m2 per day on day 1 and day 8（intravenous bolus）; epirubicin 65mg /m2 per day on day 1 and day 8 and cyclophosphamide 500mg/m2 per day on day 1 and day 8 ; every 28 days as a cycle. Total four cycles is needed.
223640399|NCT03903237|OTHER|retrospective chart review|retrospective report review of HZ patients treated between 2005 and 2018 in the Department of Dermatology at the University Hospital Basel
223640400|NCT03458104|OTHER|Cone Beam Computed Tomography|Cone Beam CT of the larynx
223640401|NCT03458104|DIAGNOSTIC_TEST|Acoustic/Auerodynamic testing|Records and displays real-time sound pressure level intensity, intraoral pressure, airflow rate, and fundamental frequency
223640402|NCT03458104|DIAGNOSTIC_TEST|Laryngovideostroboscopy|Visualization of vocal cords in slow motion. It uses a stroboscopic lamp, which generates regular flashes of light. A flexible tube is inserted in the back of the mouth or through the nose and into the throat. Video pictures are then recorded while patients are making sound.
223640403|NCT03666663|DRUG|Lidocaine|Nasal application using the Sphenocath device- cleared by FDA
223640404|NCT03666663|DRUG|Bupivacaine|Nasal application using the Sphenocath device- cleared by FDA
223640405|NCT03666663|DRUG|Ropivacaine|Nasal application using the Sphenocath device- cleared by FDA
223640406|NCT03666663|DRUG|Placebo|Placebo Saline using the Sphenocath device- cleared by FDA
223640407|NCT01209416|DRUG|Acipimox|Tablet Acipimox 250 mg administered 4 times previous to and during the investigation day
223640408|NCT01209416|DRUG|Ghrelin|Ghrelin infusion 4.2 ng/kg/min throughout the investigation day
223640409|NCT01209416|OTHER|Placebo|placebo tablets or saline infusion
224228424|NCT01199432|DRUG|epirubicin+cyclophosphamide|epirubicin 65mg/m2 per day on day 1 and day 8 and cyclophosphamide 500mg/m2 per day on day 1 and day 8 ; every 28 days as a cycle. Total four cycles is needed.
224228425|NCT04773093|DRUG|Continous Intravenous Lidocaine Infusion|Patient will recieve intravenous Lidocaine dose 1.5 mg/kg at the time of induction and after that will receive maintenance by continous intravenous Lidocaine infusion dose 2 mg/kg/hour until the completion of surgery
223640410|NCT04822506|PROCEDURE|Routine perioperative management and PEA|Routine perioperative management： All patients were given perioperative fluid rehydration and nutritional support to correct acid-base imbalance, electrolyte disturbance, anti-infection, hemostasis and other symptomatic treatment； electroacupuncture protocol： Preoperation:RN 6 + RN 4 +ST30 + ST 36+ Hegu (bilateral),De qi, electroacupuncture, continuous wave, 5Hz, 30min before surgery at 19:00 PM Inoperatively: LI 4+ PC 6 + ST36 + GB 34 (bilateral) ,Deqi, electroacupuncture with density wave, 2/100Hz, 30 minutes before operation to the end of the operation Postoperative: LI 4 +SJ 6 + ST 6 + ST 37(Left);LI 4 +SJ 6 + ST 6 + ST 37(Right)(alternated on both sides per 12h) Deqi, electroacupuncture, continuous wave, 5Hz, 30min,19:00 on the left side and 07:00 on the next day after surgery,until to first flatus (FF)
223640411|NCT04822506|PROCEDURE|Routine perioperative management and postEA|Routine perioperative management： All patients were given perioperative fluid rehydration and nutritional support to correct acid-base imbalance, electrolyte disturbance, anti-infection, hemostasis and other symptomatic treatment； electroacupuncture protocol： Postoperative: LI 4 +SJ 6 + ST 6 + ST 37(Left);LI 4 +SJ 6 + ST 6 + ST 37(Right)(alternated on both sides per 12h) Deqi, electroacupuncture, continuous wave, 5Hz, 30min,19:00 on the left side and 07:00 on the next day after surgery,until to first flatus (FF)
223640412|NCT04490096|DRUG|[11C]-PBR28|"A dose of ≤ 20 mCi (approximate range for most studies is anticipated to be 5-20 mCi) of \[11C\]-PBR28 will be administered by IV injection to the patient under the direct supervision of a Nuclear Medicine Authorized User. A lesser activity may be injected if, in the opinion of a nuclear medicine authorized user complete imaging data could be generated.~Subjects will undergo an approximately 90 minute dynamic PET/CT scan over the brain starting at approximately the same time as the \[11C\]-PBR-28 injection. Scans will be acquired using a Philips PET/CT time-of-flight Ingenuity scanner (Philips Healthcare, Cleveland, OH, USA). At the end of the dynamic imaging the participant will be allowed to get off the scanner."
224228426|NCT04773093|DRUG|Placebo|Patient will recieve Placebo NaCl 0.9% continuous intravenous infusion until the completion of surgery
223640413|NCT05194735|BIOLOGICAL|Neoantigen specific TCR-T cell drug product|"Phase I:~Ascending dose, single Infusion of TCR+ Cells~Phase II:~Single infusion at the RP2D"
223640414|NCT05194735|BIOLOGICAL|Aldesleukin (IL-2)|To support growth and activation of TCR-T cell drug product
223640415|NCT06229275|DEVICE|Pap smear collection using the Personal Pap Smear (PPS) Device|Diagnostic Test: Use of PPS device to collect cervical cells during pap smear collection.
223640416|NCT06229275|DEVICE|Active Comparator: Pap smear collection using the Rovers Cervex-Brush|Diagnostic Test: Use of Rovers Cervex-Brush to collect cervical cells during pap smear collection.
224228427|NCT03083249|OTHER|Gardasil|None-data gathering only
223640417|NCT00479427|DRUG|GW842166|100 mg once daily
223640418|NCT00479427|DRUG|Placebo|once daily
223765165|NCT07096102|BEHAVIORAL|ENRICH Group|Participants will undertake a six-week programme to enhance their health information literacy. The specific details are as follows: (1) Capacity Building on Health Information Management via Health Education Based on the Health Empowerment Theory:①Strengthening skills related to Health Information Literacy; ②Training on Medication Management Skills;③ Practice of Self-Monitoring Skills;④Education on Diet and Exercise Management Knowledge. (2) Health Behavior Motivation Management Based on the Health Empowerment Theory:① Personalized Goal Setting;②Behavioral Incentives and Feedback;③Construction of Peer Support Networks;④Demonstration Effect of Role Models. (3) Health Management Support System Based on the Health Empowerment Theory:①Online Dynamic Monitoring;②Family-Community Collaborative Support;③Digital Monitoring Platform;④Continuous Supply of Resources.
223765166|NCT07096102|BEHAVIORAL|Routine Care Group|①Distribute 3-5 push publics on screening health information and health disinformation in the first week；②Distribute 3-5 push publics on medicine knowledge in the second week；③Distribute 3-5 push publics on self-monitoring knowledge in the third week；④Distribute 3-5 publics on exercise knowledge in week 4；⑤Distribute 3-5 push publics on dietary knowledge in week 5 and week 6.
224228428|NCT05783479|DRUG|estradiol|estradiol 0.5 mg in vaginal cream twice daily for 10 days pre-procedure
224228429|NCT05783479|DRUG|Hyaluronic acid|hyaluronic acid 5 mg in vaginal gel twice daily for 10 days pre-procedure
224228430|NCT00629616|DRUG|anastrozole|1 mg/day for either 4 months or 6 months depending on the clinical evaluation
224228431|NCT00629616|DRUG|fulvestrant|500mg at day 1, day 15 and day 29 500mg every 28 days for either 4 months or 6 months depending on the clinical evaluation
224228432|NCT01494688|DRUG|Paclitaxel|Paclitaxel, at a dose of 80 mg/m\^2 will be administered QW for up to 12 weeks.
224228433|NCT01494688|DRUG|RO5509554|RO5509554 will be administered Q2W, Q3W or initial biweekly followed by monthly maintenance as intravenous (IV) infusion until disease progression, unacceptable toxicity, death or participant refusal, whichever occurs first.
224228434|NCT01912105|DEVICE|Airway medix closed suction system|
224228435|NCT01912105|DEVICE|standard closed suctioning systems|
223640419|NCT05991297|OTHER|Deep sensory assisted rehabilitation|"A new PTR plan called deep sensory assisted rehabilitation was created: it was aimed to develop a sensory and deep sense in the adult age group by making use of sensory integration exercises, which are mostly applied in the childhood age group. Whether these exercises are effective on walking and balance will be evaluated. Patients will be dressed in a vest with an equally distributed weight of 4-6 kg according to their weight, and exercises will be done while walking and standing.~\- the so-called deep sensory pathway; The patients will be given standing and walking exercises on sand and stone floors, soft floors made of sponge, hard plastic floors with different sizes of grooves and shapes, and hot-cold floors formed by placing hot packs and cold packs."
223640420|NCT05991297|OTHER|classical rehabilitation|Muscle strengthening in all four extremities; strengthening of trunk and abdominal muscles; providing and maintaining joint range of motion; independent and safe standing, turning, and stepping; able to walk alone on flat ground and on different surfaces (such as sloping-handicapped-soil-stone-sand-grass-rough-stepped)
223640421|NCT04704596|DEVICE|anesthesia ventilator machine|dynamic lung compliance measurements will be used for detection of the optimum PEEP after alveolar recruitment
223640422|NCT04704596|DEVICE|lung ultrasound|lung ultrasound views will be used for detection of the optimum PEEP after alveolar recruitment
223640423|NCT00420771|DRUG|Gabapentin|For the first week, one 400 mg Gabapentin capsule taken 3 times per day. For the second week, two 400 mg Gabapentin capsules taken 3 times per day. For the third week through the eighth week, three 400 mg Gabapentin capsules taken 3 times per day. For the ninth and last week, two 400 mg Gabapentin capsules taken 3 times per day for 3 days, then one 400 mg Gabapentin capsule taken 3 times per day for 4 days. Placebo study medication appears identical to active medication and is prescribed with an identical dosing schedule.
223640424|NCT00420771|DRUG|Placebo|placebo comparator appears identical to active medication and is prescribed with an identical dosing schedule with a maximum dose of 400mg taken three times per day
223640425|NCT01271296|DIETARY_SUPPLEMENT|Liquorice|24 gram liquorice eq. to 150 mg glycyrrhizinic acid, taken orally, for three days.
223640426|NCT01271296|DIETARY_SUPPLEMENT|Grapefruit Juice|200 ml pink grapefruit juice three times a day, taken orally, for three days.
223640427|NCT04333719|OTHER|Type of sedations|Estimate the prevalence of deep sedations (i.e. with a -4 or -5 score at the Richmond scale at the induction time) for patients in terminal phase and receiving cares from a specialized palliative care facility
224228436|NCT02691806|OTHER|experimental protocol|"first day- VO2max test with the following measurements: anaerobic threshold, maximum oxygen consumption, heart rate and breathing indices.~second day- performing the same physical protocol of VO2max test with the measurements: leg muscles activity using a wireless EMG, hemodynamic measurements of oxygen levels in the skin and skin perfusion, the two latest using optic sensors."
223640428|NCT00463567|DRUG|Indacaterol|In the morning, Indacaterol once daily (o.d.) orally inhaled via a single dose dry powder inhaler (SDDPI).
223640429|NCT00463567|DRUG|Formoterol (12 µg b.i.d.)|Formoterol 12 µg twice daily (b.i.d.) in the morning and in the evening via an aerolizer.
224228437|NCT06206499|PROCEDURE|soft tissue augmentation|"Laterally Rotated Flap: A Split-thickness recipient bed on the buccal and mesial aspects of the implant was prepared, resulting in a firm attached bleeding area. The extension of the incisions towards the palate and the distance between them are dependent on the amount of keratinized tissue graft needed for each particular case. Habitually, the keratinized tissue is taken from the adjacent crest; however, if needed to displace more tissue, the incisions may be extended into the palatal tissue. The flap was prepared partial thickness, and released apically from the periosteum to allow passive displacement, and suturing without tension. It was latero-mesially displaced with a 90º rotation. The pedicle was sutured to the recipient bed.~Control group: The surgical procedure followed the design proposed by Sullivans \& Atkins 1968 for soft tissue augmentation around teeth and modified by for application around oseointegrated dental implants."
224228438|NCT03556917|COMBINATION_PRODUCT|iontophoresis + caffeine|we will use cafeislaine c (caffeine) +galvanic current
224228439|NCT00756847|DRUG|XL147 (SAR245408),|Gelatin capsules supplied in 25- and 100-mg strengths; daily dosing
224228440|NCT00756847|DRUG|paclitaxel|Intravenous injection dosed once every three weeks
224228441|NCT00756847|DRUG|carboplatin|Intravenous injection dosed once every three weeks
223640430|NCT00463567|DRUG|Tiotropium (18 µg o.d.)|Tiotropium 18 µg once daily (o.d.) dry powder capsules delivered via a SDDPI.
223640431|NCT00463567|DRUG|Placebo to Indacaterol|In the morning, Placebo to Indacaterol once daily (o.d.) orally inhaled via a single dose dry powder inhaler (SDDPI).
223640432|NCT00463567|DRUG|Placebo to Formoterol|In the morning and in the evening, placebo to formoterol delivered via Aerolizer.
223640433|NCT02721472|PROCEDURE|micro- and macro-circulatory vascular remodelling measures not practice in routine care|Vascular measures : reactive hyperaemia index (RHI) assessed by Endo-PAT, central aortic blood pressure, aortic augmentation index, carotid-femoral pulse wave velocity
223640434|NCT02721472|PROCEDURE|Biological measures not practice in routine care|Biological measures : Plasma DNA level, NETs (plasma nucleosome levels), Microparticules (MPs) (total, associated with red blood cells, neutrophils, platelets), haem (total and bound to MPs), Myeloperoxydase and elastase activity, neutrophils/DNA, Annexin A5, RNA and TSP1
223640435|NCT03296319|DEVICE|Echocardiography|Echocardiography guided fluid administration
223640436|NCT03063320|OTHER|Spice blend|Test spices include cardamom, coriander, cumin, ginger, paprika, red pepper, turmeric, cinnamon
223640437|NCT00186589|DRUG|90Y Ibritumomab tiuxetan|
223640438|NCT01429740|DRUG|PF-05180999|Ascending single oral doses of 0.1, 0.3, 1.0, 3, 10, 30, 100, and 250 mg oral solution or capsules
223640439|NCT01429740|DRUG|Placebo|Placebo oral solution or capsules
223640440|NCT00395668|DEVICE|TETRA (at lowest carrier freq, std TDMA pulse at 17,6 Hz).|
223765167|NCT06916039|OTHER|immediate verbal memory after high GI breakfast|Difference in immediate verbal memory after high GI breakfast at 150-180 minutes (i.e., in the late postprandial phase)
223765168|NCT06916039|OTHER|immediate verbal memory after low glycemic index breakfast|Difference in immediate verbal memory after low GI breakfast at 150-180 minutes (i.e., in the late postprandial phase)
224228442|NCT03645070|DEVICE|multipolar and self expandable thermometer|Will be evaluated if a multipolar and self expandable thermometer is superior to no probe or to single probe thermometer at prevention of esophageal thermal injury.
223640441|NCT02432755|BEHAVIORAL|home-based MTOT|The home-based MTOT group will receive 30 minutes of MT followed by 30 minutes of TOT per session. The intervention will take place in the participant's home environment. During the mirror practices, the patient will seat close to a table which the mirror box will be placed at the mid-sagittal plane. During MT, the participant will be encouraged to actively move their paretic arm and hand concurrently with the mirror reflection of the movement of the nonparetic arm and hand as possible as they can. If necessary, the therapist will assist the participant in moving the paretic hand to synchronize the movement with the nonparetic hand.
224228443|NCT03645070|DEVICE|Single probe thermometer|Will be evaluated if a single probe thermometer is superior to a multipolar and self expandable thermometer or to no probe thermometer at prevention of esophageal thermal injury
224228444|NCT01252628|DRUG|PX-866 (SCCHN)|PX-866 administered at the MTD/RD in combination in patients administered weekly on a 21 day cycle.
224228445|NCT01252628|DRUG|Cetuximab (SCCHN)|Cetuximab administered weekly on a 21 day cycle, as standard of care in patients.
224228446|NCT01252628|DRUG|PX-866 (CRC)|PX-866 administered at the MTD/RD in combination in patients administered weekly on a 21 day cycle.
224228447|NCT01252628|DRUG|Cetuximab (CRC)|Cetuximab administered weekly on a 21 day cycle in patients, as standard of care.
224228448|NCT03746678|OTHER|C-Care Mobile Application|C-care is a mobile application developed based on previous research at the IWK Health Centre. It contains topics relevant to Cesarean delivery and the recovery process, which the patient could access at anytime. Patient engagement with the application will be monitored anonymously for 30 days after delivery. On days one to five after delivery, patients will receive a short self-monitoring questionnaire (approximately 1 minute). At the end of two weeks (14 days), patients will complete an online survey regarding overall satisfaction, potential impact on care, usability and feasibility problems. At any point during the study, patients can email us to report any problems with the application.
224228449|NCT00948402|DRUG|Metformin|metformin 1250 mg three times daily
224228450|NCT00948402|DRUG|oral contraceptive|30 µg ethinylestradiol plus 30 mg drospirenone 21 day/month.
224228451|NCT00097019|DRUG|bevacizumab|
223640442|NCT02432755|BEHAVIORAL|hospital-based therapy|The control group will receive a dose-matched, individualized occupational therapy at a hospital. The participants will receive customary rehabilitation programs as usual performed at hospitals for 1 hour per session. The treatment protocol will include: (a) passive range of motion exercises, stretching of the affected limb, or facilitatory and inhibitory techniques, (b) fine motor or dexterity training, (c) arm exercises or gross motor training, (d) muscle strengthening of the affected upper limb, and (e) activities of daily living training or functional task practice.
224228452|NCT01626885|DRUG|MP-214|Patients who meet eligibility criteria will be administered a once daily oral fixed dose (3mg) of MP-214 for four weeks, then flexible dose (1.5-9 mg) of MP-214
224228453|NCT00367185|DRUG|Thalidomide|
224228454|NCT02141386|OTHER|PACR (Plasticity-based, Adaptive, Computerized Cognitive Remediation)|
224228455|NCT05092061|OTHER|Moderate-repetition resistance training|Will undertake resistance training with moderate loads, and moderate repetitions 3 times per week for 7 weeks.
224228456|NCT05092061|OTHER|High-repetition resistance training|Will undertake resistance training with low loads, and high repetitions 3 times per week for 7 weeks.
224228457|NCT02362906|DRUG|Xiyanping injection|ivd. 5 to 10 mg/(kg•d), plus 5% Glucose Injection, 80 to 100 ml, ivd. Once a day injection
224228458|NCT02362906|DRUG|wind-heat formula granules|children aged 6 months to 3-year old: 1/2 packet，orally taken two times daily or frequency; children aged 3 to 5-year old: 2/3 packet，orally taken two times daily or frequency; children aged 5 to 14-year old: 1 packet， orally taken two times daily or frequency
224228459|NCT02362906|DRUG|phlegm-heat formula granules|children aged 6 months to 3-year old: 1/2 packet，orally taken two times daily or frequency; children aged 3 to 5-year old: 2/3 packet，orally taken two times daily or frequency; children aged 5 to 14-year old: 1 packet， orally taken two times daily or frequency
224228460|NCT02362906|DRUG|Fu-xiong San|external application; 8-10 cm wide, 0.3-0.5 cm thick;10 mins for patient aged 1 to 3-year old; 15 mins for those aged 3 to 5-year old; once daily
224228461|NCT02362906|DRUG|second generation cephalosporin|
224228462|NCT02362906|DRUG|Erythromycin|ivd. 30 mg/(kg•d), plus 5% Glucose Injection, 80 to 500 ml, ivd. Once a day injection
224228463|NCT02362906|DRUG|Azithromycin|ivd. 10 mg/(kg•d), plus 5% Glucose Injection, 100 to 500 ml, ivd. Once a day injection
224228464|NCT02493725|DRUG|Eculizumab|
224228465|NCT02493725|DRUG|Placebo|
224228466|NCT04636749|DEVICE|Erbium laser|Vaginal laser therapy
224228467|NCT04636749|DEVICE|Sham laser|Sham laser therapy
224228468|NCT05725590|PROCEDURE|External pancreatic duct stent|All pancreaticoduodenectomies were performed by the same surgical team at our pancreatic center throughout the study period. According to the preoperative laboratory results, medical imaging data, and intraoperative conditions, the laparoscopic or open pancreaticoduodenectomy, or pylorus-preserving pancreaticoduodenectomy was performed at the discretion of the individual surgeon. The child's technique was implemented to achieve digestive tract reconstruction, and all patients underwent a duct-to-mucosa pancreaticojejunostomy. The external pancreatic duct stent left the other end exteriorized through the proximal jejunum via a small enterotomy that was fixed in the abdominal wall.
224228469|NCT05725590|PROCEDURE|Internal pancreatic duct stent|All pancreaticoduodenectomies were performed by the same surgical team at our pancreatic center throughout the study period. According to the preoperative laboratory results, medical imaging data, and intraoperative conditions, the laparoscopic or open pancreaticoduodenectomy, or pylorus-preserving pancreaticoduodenectomy was performed at the discretion of the individual surgeon. The child's technique was implemented to achieve digestive tract reconstruction, and all patients underwent a duct-to-mucosa pancreaticojejunostomy. The internal pancreatic duct stent, a silicone catheter with multiple side pores, was inserted into the main pancreatic duct and the other end was placed in the jejunum cavity.
224228470|NCT05645458|OTHER|mobile application ( PEG Assist )|The mobile application is used for PEG care. İt gives some information to caregivers related to PEG, PEG care, etc. Also, the researcher can monitor all feeding times with this application.
224228471|NCT03619161|OTHER|Bubbles|All bathrooms with showers or bathtubs will be cleansed with simple products (dilute bleach, dilute white vinegar, baking soda, and dilute Dawn dish soap)
223640443|NCT02432755|BEHAVIORAL|hospital-based MTOT|The hospital-based MTOT group will also receive 30 minutes of MT followed by 30 minutes of TOT per session at a hospital. The intervention will take place in the occupational therapy clinic. The treatment modalities in the hospital will be selected and provided for this group. Most of the treatment principles and components are the same as aforementioned in the home-based MTOT. However, the major differences between home-based and hospital-based MTOT are the treatment contexts, environments and functional modalities used.
224228472|NCT03619161|OTHER|Bleach and Bubbles|All bathrooms with showers or bathtubs will be cleansed with simple products (dilute bleach, dilute white vinegar, baking soda, and dilute Dawn dish soap).
224228473|NCT04053881|DRUG|Certolizumab pegol|Active Substance: Certolizumab Pegol Pharmaceutical Form: Prefilled syringe Concentration: 200 mg/ml Route of Administration: Subcutaneous injection
224319349|NCT03763474|COMBINATION_PRODUCT|Euglyca application|'Euglyca' is a mobile application developed by two of the authors (CC and DF). The application has a data base of 7000 foods and food products met in greek eating habits as well as the corresponding amount of carbohydrates and lipids for each of them. Subsequently, the amount of carbohydrates and lipids contained in a meal are calculated automatically by the application. By taking into consideration the amount of carbohydrates and lipids to be consumed, the preprandial and target post-prandial glycemia concentrations, the insulin correction factor for the patient, the carbohydrates and lipids factors and the active insulin (in case of CSII), 'Euglyca' calculates the required bolus dose of insulin.
224319350|NCT06498167|DRUG|Upadacitinib|Exposure to upadacitinib (Rinvoq™) in its different formulations approved by the Portuguese regulatory authority (15, 30, or 45mg extended-release tablets).
224319351|NCT00328848|BEHAVIORAL|Behavioral|Group Treatment(patient education, self management support, caregiver support)
223640444|NCT05028543|PROCEDURE|Conventional TLH|"Procedure: conventional Total laparoscopic hysterectomy the uterine artery will be identified close to the isthmus then coagulated at this level, close to the uterus , using bipolar diathermy. The utero-vesical fold will be dissected and the bladder will be pushed down done.. The vasculature of the uterus will now secured and this will be evidenced by the pale color of the fundus.~Using either bipolar diathermy , the cornual pedicles on one side will be desiccated and cut. Also, both the uterosacral and cardinal ligaments will be coagulated and cut. So that, the opposite side pedicles can be taken care of.. The infundibulopelvic ligaments will be coagulatd and cut if it is necessary to remove both ovaries. A vaginal cuff was inserted into the vagina to identify the vault, which will then cut laparoscopically using a monopolar hook, where the specimen will be completely detached."
223640445|NCT05028543|PROCEDURE|Clipping of utrine artery at its origin before bginning of TLH|"the uterine artery will be dissected using posteriorly and medially to the infundibulopelvic ligament, the ureter should be first identified. The surgeon may grab the obliterated umbilical artery at the anterior abdominal wall and retract it. The movement of the umbilical artery may be Seen at the ovarian fossa perpendicular to the ureter~The uterine vessels will be clipped at their origin from the hypogastric vessels using aclip applier which will be introduced through 10mm trocar. clipping of the artery will be performed through application of two 5 mm size metallic clips in continuity and complete the laparoscopic hysterectomy with the same steps of the conventional method."
224319352|NCT00328848|BEHAVIORAL|behavioral|patient education, self management support, caregiver support
224319353|NCT01499446|DRUG|GW685698X (fluticasone furoate) 100mcg Morning|GW685698X inhaled once daily in the morning plus placebo in the evening for 28 days
223640446|NCT01175577|DIETARY_SUPPLEMENT|Chlorophyll complex, Standard Process|One capsule, twice daily with meals for 28 days
223640447|NCT01175577|DIETARY_SUPPLEMENT|"Betatene, sold as Full Spectrum Carotenoid Complex"|One capsule per day with meals for 28 days
223640448|NCT01175577|OTHER|Small carotenoid-rich meals|Single carotenoid-enriched soup or salad serving eaten daily
223640449|NCT01175577|OTHER|Placebo|Safflower oil-filled capsules, one twice daily with meals
223640450|NCT06212336|DRUG|Favipiravir|Interventional Medicinal Product (IMP)
223640451|NCT06212336|DRUG|Ribavirin|Control arm
223640452|NCT06212336|DRUG|Dexamethasone|Interventional Medicinal Product (IMP)
223640453|NCT04889638|OTHER|Cessation Intervention|"1. Pharmacotherapy selection, prescription and monitoring of up to two types of cessation pharmacotherapies: Nicotine replacement therapy (gum, lozenge and transdermal patch) and non-nicotine replacement therapy (varenicline).~2. Remote video-conferencing and mobile phone-based, personalized motivational messaging"
223640454|NCT01096355|DRUG|gamma-secretase/Notch signalling pathway inhibitor RO4929097|
223640455|NCT01096355|OTHER|diagnostic laboratory biomarker analysis|
223640456|NCT01096355|OTHER|pharmacogenomic studies|
223640457|NCT01096355|OTHER|pharmacological study|
223640458|NCT05147363|DEVICE|Shockwave Intravenous lithotripsy with a Supera stent|Pre-dilation with the option of using a 2-3mm balloon to cross a lesion for lithotripsy with the shockwave device followed by placement of supera stent.
224228474|NCT03277781|OTHER|Screening|Screening for AAA
224228475|NCT02397681|OTHER|Autonomic Function Testing|Autonomic nervous system index assessed with Task Force Monitor (CNSystems Medizintechnik AG, Graz, Austria)
224228476|NCT05105165|DIAGNOSTIC_TEST|Enzyme linked immunosorbent assay|Determination of serum β 1-aa content
224228477|NCT06545422|OTHER|St. John's wort oil|To examine the effect of regularly applied St. John's Wort oil on skin moisture.
224228478|NCT06545422|OTHER|Barrier Cream|To examine the effect of regularly applied barrier cream on skin moisture.
224228479|NCT04326842|PROCEDURE|Carotid artery revascularization procedure|The patients with carotid artery stenosis will be examined before and after finishing the carotid artery revascularization procedure.
224228480|NCT04326842|DEVICE|Optical coherence tomography angiography|Examination will be performed using optical coherence tomography angiography. This device allows quantitative analysis, since it provides numerical data about flow area and flow density maps.
224228481|NCT01785784|DRUG|rhGM-CSF Gel|
224228482|NCT04165278|OTHER|hyperthermic baths|Taking hyperthermic baths
224228483|NCT01533428|DRUG|Capsaicin 8%|Capsaicin 8% transdermal delivery system
224228484|NCT01533428|DRUG|Placebo|Placebo Patch
224228485|NCT00004451|DRUG|Glucose|
224228486|NCT00094133|PROCEDURE|hot flashes attenuation|
224228487|NCT00094133|PROCEDURE|hypnotherapy|
224228488|NCT01692158|DRUG|Heparin, Low-Molecular-Weight|single subcutaneuous administration of 40 mg of the test drug and the comparator drug, according to randomization, in a crossover design, each administration separated by 6 days of washout.
224228489|NCT04309409|DRUG|Nivolumab|480 mg nivolumab fixed dose given as 60-minute iv infusion every 4 weeks for 12 doses over 1 year
224228490|NCT01364870|DEVICE|Placebo TENS|"Subjects randomized to the placebo group will use an EMPI TENS Select device that emits a current for 45 seconds then shuts off. They will be asked when they first feel the current, then the device will be turned down a half-point to provide treatment at a sub-sensory level. This unit displays an active indicator light suggesting to the subject that the unit is actively emitting current. At discharge, subject will be sent home with an adequate supply of batteries and asked to change batteries when the device goes below 4 bars, further suggesting that the device is actively working."
224228491|NCT01364870|DEVICE|Active TENS|High-frequency intense TENS provided with the EMPI Select TENS. The generator emits a balanced, asymmetrical, biphasic waveform and has buttons for variation of frequency and amplitude. A rate modulation frequency of 50pps and 150pps every 0.5 seconds will be used with a pulse width of 150 microseconds (μs).
224228492|NCT01999309|DRUG|Simvastatin|The lipid-lowering drug simvastatin is added to normal antipsychotic treatment. One 40 mg simvastatin tablet daily for the treatment period of one year.
224228493|NCT01999309|DRUG|Placebo|Placebo is added to normal antipsychotic treatment. One identical looking placebo tablet daily for the treatment period of one year.
224228494|NCT02834065|DEVICE|Cardiopulmonary bypass machine|Routinely used cardiopulmonary bypass machine (standard of care) will be used to initiate circulatory arrest
224228495|NCT03476915|OTHER|ultrasound examination of the hip joint|US examination by US machine , Midray model DP-2200 made in China , with a high frequency (5-10 MHZ) linear transducer using the previously described Graf method for assessment of both hip joints.
224228496|NCT02056730|DRUG|calcium sensing receptor agonist|For the Regpara those taking 25 mg per day to get the default dose and the dose is adjusted according to the levels of calcium and parathyroid hormone. By adjusting the dose of 25 mg every 3 weeks for a period of 12 weeks, the drug is between 25-75 mg dose, with a maximum dose of not more than 100 mg per day (weeks 3, 6, 9).
224228497|NCT02847533|PROCEDURE|blood sample|blood sample for concentration levels of inflammatory markers
224228498|NCT02847533|BEHAVIORAL|psychometric scales|Mini international interview MADRS, C-SSRS, QIDS-SR, BIS-10, BDHI, BART, ERD
224228499|NCT02666430|DRUG|Mylan's insulin glargine|
224228500|NCT02666430|DRUG|Lantus®|
224228501|NCT03828461|BEHAVIORAL|Facilitated group therapy with behavioral practice; 16 weeks|Facilitated group therapy for hoarding disorder with behavioral practice
224228502|NCT06144359|OTHER|specific MRI Acquisition (Diffusion Tensor Imaging) at 3T|"The imaging will be carried out on the technical stage of the 3T MRI Research of the University Hospital of Clermont-Ferrand with the following sequences:~\- For traumatized and healthy subjects: MRI 3 Teslas (3D T1, T2 axial TSE, T2\* axial, SWI axial, Sagittale cube FLAIR, DTI 20-direction sequence) The image processing will be carried out within the radiology department: morphological analysis and analysis of tractography and diffusion parameters (FA and ADC, diffusivity) on predefined and reproducible Regions of Interest (ROIs).~Regions Of Interest include: splenium of the corpus callosum, internal capsule, cortico-spinal tract, optic radiation."
224228503|NCT00576199|DRUG|Bevacizumab|Bevacizumab was supplied as a sterile liquid in single-use vials.
224228504|NCT00576199|PROCEDURE|Transarterial chemoembolisation (TACE)|"TACE was conducted by the transfemoral artery approach with selective cannulation of the artery supplying the tumor. Cisplatin mixed with Lipiodol in a 1 mg:1 mL ratio was infused intra-arterially up to a maximum dose of 30 mg, depending on tumor size, followed by embolization of the artery using Gelfoam particle until the blood flow slowed. Bilobar lesions were treated by separate catheterization of right and left hepatic arteries followed by injection of the cisplatin-Lipiodol mixture and embolization.~Patients with stable disease or a partial response after 4 TACE sessions could be given further TACEs upon the investigator's discretion until there was evidence of progressive disease or contraindication due to severe complication or technical failure to perform the TACE."
224228505|NCT02116413|PROCEDURE|Fluid challenge|The fluid challenge starts at minute 0 (T0) and consists of 500ml of crystalloids over 10 minutes.
224228506|NCT02116413|PROCEDURE|Cardiac ultrasound|Ultrasound measures are made at T0, T2, T4, T6, T8, T10, T20 and T30.
224228507|NCT06155799|DEVICE|Freehand zygomatic implant placement|Zygomatic implants will be placed without any guidance after preoperative virtual planning has been performed.
223640459|NCT06416124|DIAGNOSTIC_TEST|Anthropometric assessment|A total of 43 anthropometric variables (complete profile) will be assessed following the guidelines of the International Society for the Advancement of Kinanthropometry. All measurements will be taken on the right side of the body. The full anthropometric profile will be undertaken in duplicate to establish retest reliability. If the difference between duplicate measures exceeds 5% for skinfolds or 1% for all other variables, a third measurement will be taken, but only after the full profile has been completed in duplicate. The mean of duplicate or median of triplicate anthropometric measurements will be used for all subsequent analysis. The intra-evaluator technical error of measurement (TEM) was calculated according to the 1996 protocol of Pederson and Gore.
224228508|NCT03687099|OTHER|no intervention|Histological samples from 10 GBM removed from patients with long-term survival and 10 GBM removed from patients with short-term survival
224228509|NCT04434859|OTHER|No intervention|No intervention
224228510|NCT02867020|DRUG|Apalutamide|APALUTAMIDE 240-mg orally once daily (4 x 60-mg tablets) will be administered on a continual basis. For the purpose of scheduling the study assessments and treatment compliance a treatment cycle is defined as 28 days.
224228511|NCT02867020|DRUG|Abiraterone|Abiraterone acetate 1,000 mg (four 250 mg tablets) should be taken orally once daily, in combination with oral dose prednisone 5mg twice daily continuously. For the purpose of scheduling the study assessments and treatment compliance a treatment cycle is defined as 28 days
224228512|NCT02867020|DRUG|ADT|Dosing of goserelin (dose and frequency of administration) will be consistent with the prescribing information and should only be adjusted if clinically indicated to achieve and maintain subcastrate concentrations of testosterone (50 ng/dL or 1.7 nM).
224228513|NCT02867020|DRUG|Prednisone|Subjects will receive prednisone 10mg/day.
224228514|NCT01168128|OTHER|Tailored Change Strategy|e.g. Education, decision support tools
223640460|NCT05448196|OTHER|Coordinated Financial Navigation Program|Patients randomized to the intervention arm will be enrolled in a four-month coordinated financial navigation program. This program will take a more proactive, coordinated, and systematic approach and includes concrete action plans, and frequent and standardized follow-ups. All patients randomized to the intervention arm will meet with the nurse navigator (NN) for an intake. The NN will introduce navigation services and navigator's NN role and describe the financial navigation program (e.g., goals and expectations of the financial advocacy and social work programs). Next, the navigator will elicit from the patient their potential and current barriers to completing the diagnostic test or treatment. The navigator will then perform proactive outreach to these resources and coordinate an action plan with the patient.
223640461|NCT03570710|DRUG|intravenous tranexamic acid|1 gm tranexamic acid (2 ampoules of Capron 500 mg /5 ml; Amoun, Cairo, Egypt) intravenous just before skin incision plus110 ml normal saline IV just before skin incision plus topical application of 200 ml normal saline applied on the pelvic bed after Cesarean hysterectomy
223640462|NCT03570710|DRUG|Topical tranexamic acid|2 gm topical tranexamic acid ( 4 ampoules of Capron 500 mg/5 ml applied typically) in 200 ml normal saline applied on the pelvic bed after Cesarean hysterectomy plus110 ml normal saline IV just before skin incision plus topical application of 200 ml normal saline applied on the pelvic bed after Cesarean hysterectomy plus In topical tranexamic acid group gauze soaked with 2g tranexamic acid (20 ml) diluted in 200 ml of sodium chloride 0.9% or placebo (120ml of sodium chloride 0.9%.) applied on the pelvic bed after Cesarean hysterectomy. To ensure a sufficiently high concentration, the tranexamic acid was diluted only to a volume sufficient to moisten a large wound surface. 20 ml moisten at least 1500 cm2.
224228515|NCT02611999|BEHAVIORAL|Single median price information|Physicians in this Arm received a single median price in the electronic medical record at the time of ordering in addition to the paper memo.
224228516|NCT02611999|BEHAVIORAL|Paired inside/outside price information|Physicians in this Arm received two prices (the inside and outside price) in the electronic medical record at the time of ordering in addition to the paper memo.
224228517|NCT03804645|DRUG|Treatment A|Each subject will receive single dose of AZD9977 capsule under fasting condition in Part A. If the formulation chosen for Part B, each subject will receive one dose under fed condition and another dose under fasted condition.
224228518|NCT03804645|DRUG|Treatment B|Each subject will receive single dose of AZD9977 HDL capsule under fasting condition in Part A. If the formulation chosen for Part B, each subject will receive one dose under fed condition and another dose under fasted condition.
224228519|NCT03804645|DRUG|Treatment C|Each subject will receive single dose of AZD9977 ODL capsule under fasting condition in Part A. If the formulation chosen for Part B, each subject will receive one dose under fed condition and other dose under fasted condition.
223640463|NCT03570710|DRUG|Normal saline|110 ml normal saline IV just before skin incision plus topical application of 200 ml normal saline applied on the pelvic bed after Cesarean hysterectomy
223640464|NCT04764422|BIOLOGICAL|Normal Saline|0.9% normal saline for injection
223640465|NCT04764422|BIOLOGICAL|NDV-HXP-S vaccine|Vaccine NDV-HXP-S, manufactured by GPO with or without adjuvant CpG1018.
223640466|NCT01715324|DRUG|Adjuvant Growth Hormon|The treatment group will receive 2.5 mg of Saizen daily via subcutaneous injections, from the beginning of the ovarian reserve stimulation until the day of the ovulation triggering
224228520|NCT03804645|DRUG|Treatment D|Each subject will receive single dose of AZD9977 tablet under fasting condition in Part A. If the formulation chosen for Part B, each subject will receive one dose under fed condition and another dose under fasted condition.
224319354|NCT01499446|DRUG|GW685698X (fluticasone furoate) 100mcg Evening|GW685698X inhaled once daily in the evening fplus placebo in the morning for 28 days
224319355|NCT01499446|DRUG|GW685698X (fluticasone furoate) 250mcg Evening|GW685698X inhaled once daily in the evening plus placebo in the morning for 28 days
224319356|NCT01499446|DRUG|Placebo|Placebo inhaled twice daily (morning and evening) for 28 days
224319357|NCT04131348|PROCEDURE|botulinum toxin type A|From to December 2016 to December 2018, a single-center prospective comparative study was performed in 80 patients with LMIH at our tertiary center.
224228521|NCT03982056|OTHER|this is an observational study there are no interventions|development of an index to provide appropriate information on a person's ability to float, based on Physiological and anthropometric characteristics
224228522|NCT01208142|OTHER|standard of care treatment|weekly standardized physical therapy and daily wear of an AFO
224228523|NCT01208142|DEVICE|Ankle Flexion Dynasplint|Weekly standardized physical therapy, daily wear of an AFO and nightly wear of the ankle flexion Dynasplint
224228524|NCT05491174|BEHAVIORAL|DBT-Informed skills group|10 session group ran weekly by junior staff (P-BIFs) following a standardised manual-based protocol which can be delivered either face-to-face or via video-call. The groups will be skills-based, covering each of the four modules of DBT: Mindfulness, Distress Tolerance, Emotion Regulation and Interpersonal Effectiveness.
224228525|NCT00228462|DRUG|Seroquel (quetiapine)|
224228526|NCT02743442|DEVICE|da Vinci® Si™|
224228527|NCT01033344|BIOLOGICAL|Placebo|Intradermal injection 1x8 administrations 2 weeks apart
224228528|NCT01033344|BIOLOGICAL|Cat-PAD|Intradermal injection 1x8 administrations 2 weeks apart
224228529|NCT01033344|BIOLOGICAL|Cat-PAD|Intradermal injection, 1x8 administrations 2 weeks apart, alternating active and placebo
224228530|NCT01432132|BEHAVIORAL|Interview|Face-to-face audio recorded interview. It should take about 1 hour to complete.
224228531|NCT01432132|BEHAVIORAL|Questionnaire|Questionnaire about demographic information such as age and ethnicity.
224319358|NCT04335539|DRUG|Cefiderocol|Administered intravenously over 3 hours
224319359|NCT04335539|DRUG|Standard of Care|Standard of care antibiotics will be selected by the investigator based on the suspected or confirmed pathogen(s) for the infection in accordance with local standards.
224319360|NCT06488339|DIETARY_SUPPLEMENT|Protein and oil supplement|Take 1 sachet/day replaced dinner
224323319|NCT06184724|OTHER|Implementation Package for CGA|The Implementation Package will include a set of implementation strategies to improve the use of CGA before surgery. These strategies will be applied at the clinic-level to help increase the reach and adoption of the CGA.
224323320|NCT06184724|OTHER|Routine Clinical Care|Routine care may or may not include the use of the CGA before surgery. The use of CGA in clinical care is up to the medical and surgical healthcare providers.
224228532|NCT05974020|OTHER|Control|No intervention will be applied to the control group, and information will be given on general foot care instructions and the use of appropriate shoes.
224228533|NCT05974020|OTHER|Intrinsic Muscle Training|"In addition to general foot care instructions and briefings on the use of appropriate shoes, intrinsic muscle training including alternating toe movement, toes picking up sheets, opening and closing the toes, pinching the toe separators, toe transitions and short foot exercises will be implemented.~Additionaly, warm-up exercises, ankle exercises and functional exercises will be included in the program."
224319361|NCT02609438|BEHAVIORAL|Short breaks|Following baseline testing, participants will attend a 30-minute individual orientation session, during which they will complete a planning worksheet with a research assistant. They will identify specific strategies they will use to accomplish the pre-specified goal (i.e., to take a 1-minute active break every 30 minutes during the workday). They will also identify potential barriers they will face and devise strategies for overcoming them. The intervention will officially start the Monday after the orientation session and will last for 8 weeks. Participants will receive a weekly email containing tips related to reducing sitting time at work. All participants will complete daily activity logs indicating the time and duration of all breaks from sitting across the 8-week intervention.
223640467|NCT05132023|DRUG|Empagliflozin & Metformin (Test)|one tablet administrated according to a randomization scheme with 240 mL of a 20% glucose solution in water, followed by 60 mL of the glucose solution administered every 15 min for up to 4 hours after dosing.
223640468|NCT05132023|DRUG|Empagliflozin & Metformin (Reference)|one tablet administrated according to a randomization scheme with 240 mL of a 20% glucose solution in water, followed by 60 mL of the glucose solution administered every 15 min for up to 4 hours after dosing.
223640469|NCT01682889|DIETARY_SUPPLEMENT|Arginine|L-arginine-hydrochlorid (0.35 g/kg body weight) intravenously for 24 hours
223640470|NCT01682889|DIETARY_SUPPLEMENT|Placebo|NaCl 0.9% intravenously for 24h
223640471|NCT00135824|DRUG|Povidone K25 eye drops (povidone)|
223640472|NCT03252379|PROCEDURE|hepaticojejunostomy|"* Under general intubation anesthesia, a generous right subcostal incision is performed and could be extended on demand upward to the xiphoid process and/or to the left subcostal area. Thorough dissection and adhesiolysis is performed to reach the CBD and prepare the unaffected proximal part for anastomosis. The Roux jejunal loop is prepared and passed retrocolic to reach the porta hepatis.~* Then, the hepaticojejunostomy is done via end to side anastomosis using interrupted sutures of polyglactin of 3-0 or 4-0 size. The anastomosis is done 10-15 cm away from the free distal end of the Roux jejunum loop to allow anastomosis without tension to the stomach. A biliary stent may be optionally placed according to operative circumstances and is brought out through the anterior abdominal wall."
223640473|NCT03252379|PROCEDURE|modified hepaticojejunostomy with subcutaneous access loop|"In the subcutaneous access loop, the same steps are done for performing roux-en-Y hepaticojejunostomy.~The closed free end of roux loop is passed through the anterior abdominal wall in the right subcostal area and then fixed to the wall in a subcutaneous position using 3/0 polyglactin sutures. The limb between the hepaticojejunal anastomosis and the subcutaneous fixation should be short and straight.~Four Ligaclips are used to mark the jejunal loop by clipping the sutures holding the access loop in place."
223640474|NCT03252379|PROCEDURE|modified hepaticojejunostomy with gastric access loop|"* In the gastric access loop, the same steps are done for performing roux-en-Y hepaticojejunostomy.The end of the Roux jejunal loop taken up for hepaticojejunostomy is not closed but is anastomosed to the anterior wall of the gastric antrum near the pyloric orifice.~* All the enterogastrostomies and enteroenterostomies were in the form of single-layer continuous sutures of polyglactin of 3-0 size. An intraperitoneal drain was left in the hepatorenal pouch before closing the incision."
223640475|NCT02368587|BIOLOGICAL|WJMSCs Vs. placebo|WJMSCs Vs. placebo
223640476|NCT02368587|BIOLOGICAL|Placebo|WJMSCs Vs. placebo
223640477|NCT06051149|PROCEDURE|caudal adhesolysis using RACZ Catheter|caudal adhesolysis for patients with failed back surgery syndrome using RACZ Catheter under fluroscopy
223640478|NCT06051149|PROCEDURE|caudal adhesiolysis using NAVI Catheter|caudal adhesolysis for patients with failed back surgery syndrome using NAVI Catheter under fluroscopy
223640479|NCT05459896|BEHAVIORAL|Physical Activity Training|Participants who exhibit both physical and psychosocial distress will be recommended to receive physical activity intervention. An approach of adding game mechanics into an interactive environment that combines live action and an award system will be integrated into the intervention. The physical training involves 15-min resistance training and 30-min interactive cardio dancing each with beginner and advanced levels. Participants are recommended to start with the beginner level and do the exercises on regular intervals during the intervention period. The Light Detection and Ranging (LiDAR) motion sensor with tablet-based console and the full-body tracking sensor will be used to capture real-time data on participants' human body movements in order to enhance understanding of performance. Participants will get a commercial wearable sensor. Participants will be asked to wear the sensor at all times and sync the data with the Smart Health Platform to self-monitor daily condition.
224228534|NCT05974020|OTHER|Aerobic Exercise|In addition to general foot care instructions and information on the use of appropriate shoes, warm-up exercises, ankle exercises, functional exercises and intrinsic muscle training, the participants will be given a walking program for aerobic exercise.
224228535|NCT04317053|BEHAVIORAL|RELAY|Relay is a novel program that engages and intervenes with individuals in the ED following an opioid OD and for the next 90 days, with the goal of preventing subsequent OD events. Relay is delivered by trained peer navigators, who are DOHMH staff with lived substance use experience. Relay navigators provide counseling, linkage to services, and OD prevention education.
224228536|NCT06278402|DRUG|Tofacitinib|Oral tofacitinib 5mg twice daily for treatment of alopecia areata, totalis and universalis.
224228537|NCT04847609|DEVICE|GentleCath™ Air catheter|Patients
224228538|NCT06447454|RADIATION|radiotherapy|radiotherapy
224323321|NCT05343715|BIOLOGICAL|Agalsidase beta from Biosidus 1 mg/kg|Patients received an infusion of 1 mg/kg of Agalsidase Beta from Biosidus. Final infusion dose is achieved with lyophilized drug at concentration 35 mg and 5 mg
224228539|NCT06447454|DRUG|gemcitabine + cisplatin|Gemcitabine 1000mg/m² intravenous infusion over 30 minutes, cisplatin 25mg/m² intravenous infusion, on day 1 and day 8, every 3 weeks.
224228540|NCT06447454|DRUG|slulimumab|Slulimumab, 4.5mg/kg intravenous infusion, Q3W
223640480|NCT05459896|OTHER|Mindfulness-based Intervention|Participants who exhibit psychosocial distress will be recommended to receive mindfulness-based intervention which is designed based on the concept of validated Mindfulness-Based Stress Reduction (MBSR) combined with techniques from Mindfulness-Based Cognitive Therapy (MBCT). The intervention consists of 10 sessions, each session has different main themes and associated activities including body scan, mindful eating, abdominal breathing, chair yoga, awareness of breathing, mindful walking, breathing, body and emotions, yoga stretching, mindful listening and choiceless awreness. The materials will be delivered in the format of animation videos. Participants will be asked to complete one session per week.
224228541|NCT06324253|PROCEDURE|bilateral Erector spine block,A dose of 30 ml 0.125% Bupivacaine will be injected.|will receive bilateral Erector Spinae Block after induction of anesthesia
224228542|NCT06324253|PROCEDURE|Thoracic epidural analgesia|will receive Thoracic Epidural Block before induction of anesthesia .a bolus dose of 10 ml of 0.125% bupivacaine through epidural catheter followed by continuous infusion of 0.125% bupivacaine at the rate of 0.1 ml/kg/hour
224228543|NCT03571308|DRUG|R-CHOP + acalabrutinib|Patient will be given R-CHOP and acalabrutinib
224228544|NCT06398769|DEVICE|SecuFix UM|All surgeries were performed using Secufix UM.
224228545|NCT06398769|DEVICE|VCare UM|All surgeries were performed using VCare UM.
224228546|NCT02012647|PROCEDURE|Transcranial Magnetic Stimulation (TMS)|Participants sit in a chair that looks like one in a dentist's office. A magnetic coil will be placed on the scalp on one side of the head, overlying the brain's motor cortex to stimulate the brain's output to the muscles in the opposite hand. A second magnetic coil will be placed on the scalp of the opposite side. Recordings from both hands will be made using the magnetic coils placed on scalp. Results will be compared for participants with and without Parkinson's Disease.
224228547|NCT02012647|PROCEDURE|Motor Physiology Testing|Participants will be asked to move their upper and lower limbs while seated in a chair. Wireless EMG sensors placed on arm and leg muscles will record measurements during this procedure. Upper and lower limb testing will be performed separately.
224228548|NCT05016349|DRUG|All trans-retinoic acid|Vesanoid will be supplied orally at the total dosage of 45mg/m2/d (two daily administrations of 22.5 mg/m2 each). Treatment will last 28 days
224228549|NCT05016349|DRUG|13-Cis Retinoic Acid plus Tocopherol|13-Cis Retinoic Acid (50 mg/m2/d) Tocopherol (800 mg/day) supplied orally at the total dosage of 50 mg/m2/d (two daily administrations of 25 mg/m2 each). Treatment will last 28 days
224228550|NCT05016349|DRUG|Mifepristone|Mifepristone 200mg capsules daily for 28 days
224228551|NCT05016349|DRUG|Cannabidiol|Liquid taken orally for daily for 28 days
224228552|NCT05016349|DRUG|9 cis retinoic acid|9 cis retinoic acid will be supplied orally at the total dosage of 45mg/m2/d (two daily administrations of 22.5 mg/m2 each). Treatment will last 28 days
224228553|NCT05016349|DRUG|Tamoxifen|Patients will be given 10mg Tamoxifen twice a day. Treatment will last 28 days
224228554|NCT05016349|DRUG|Standard therapy|Patients will receive the approved standard therapy tamoxifen
224228555|NCT05188521|DRUG|Baricitinib (LY3009104) 2 mg|2 mg orally administered once daily for 16 weeks
224228556|NCT05188521|DRUG|Baricitinib (LY3009104) 4 mg|4 mg orally administered once daily for 12 weeks
224228557|NCT01341639|BIOLOGICAL|V419|V419 (Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus, Haemophilus b Conjugate \[Meningococcal Outer Membrane Protein Complex\], and Hepatitis B \[Recombinant\] Vaccine) 0.5 mL intramuscular injection at 2, 3, 4, and 12 months of age.
224228558|NCT01341639|BIOLOGICAL|INFANRIX™ hexa|INFANRIX™ hexa 0.5 mL intramuscular injection at 2, 3, 4, and 12 months of age.
224228559|NCT01341639|BIOLOGICAL|RotaTeq|RotaTeq (pentavalent combination live vaccine of 5 human-bovine reassortant rotavirus strains) 2 mL oral dose at 2, 3, and 4 months of age
224228560|NCT01341639|BIOLOGICAL|Prevenar 13|Prevenar 13 0.5 mL intramuscular injection at 2, 3, 4,and 13 months of age
224228561|NCT01341639|BIOLOGICAL|ProQuad™|ProQuad™ 0.5 mL subcutaneous injection at 12 and 13 months of age
224228562|NCT01657539|DIETARY_SUPPLEMENT|Yogurt containing probiotics|patients assigned to this group will use a yogurt containing Bifidobacterium animalis once a day during 14 days before evaluation of the outcomes.
224228563|NCT01657539|DIETARY_SUPPLEMENT|Placebo yogurt|Patients will use a yogurt without probiotics once a day during 14 days before evaluation of outcomes
224228564|NCT04582266|DRUG|Remdesivir|RDV was not provided as part of the study. Participants were administered RDV intravenously once daily for up to 10 days per clinical care.
224228565|NCT02872649|DRUG|Dabigatran|
224228566|NCT02872649|DRUG|Phenprocoumon|
224228567|NCT06234800|PROCEDURE|Removal of failed dental implants|Removal (with various techniques) of failed dental implants.
224228568|NCT03741413|OTHER|Gain-frame SMS|Emergency recruitment cell phone short messages that emphasizing donating blood can save patients' lives were sent to donors in this group.
224228569|NCT03741413|OTHER|Loss-frame SMS|Emergency recruitment cell phone short messages emphasizing that donating blood can prevent patients from death were sent to donors in this group.
224228570|NCT03741413|OTHER|Control SMS|Emergency recruitment cell phone short messages that only mentioning the low Rh-negative blood stockpile were sent to donors in this group.
224228571|NCT03879213|DIETARY_SUPPLEMENT|Active breakfast|freeze-dried red raspberry powder (12.5 g) in drink+ freeze-dried red raspberry powder (12.5 g) in buttermilk biscuit sandwich
224228572|NCT03879213|DIETARY_SUPPLEMENT|Control breakfast|Control drink + buttermilk biscuit sandwich
224228573|NCT04932356|OTHER|Therapeutic education by phone|The patients who participate in the intervention group, after their face-to-face visit, will undergo a fortnightly reinforcement by telephone of diabetes education (review of diet, physical exercise, doubts about insulin or oral medication and the registry of blood glucose controls). In addition, emotional support will be provided to the patient, along with a semester calendar with scheduled calls to carry out the intervention, at a specific time.
224228574|NCT04932356|OTHER|Therapeutical education traditional|The patients participating in the study will be visited in person every six months where the control group will follow the usual protocol of the health center in the face-to-face visits, with their respective analyzes and pertinent tests, together with health education and adherence to pharmacological treatment.
224228575|NCT01677559|DRUG|MLN8237|
224228576|NCT01677559|DRUG|nab-Paclitaxel|
223765169|NCT07134881|BEHAVIORAL|Careverse|Careverse is a digital psychoeducational website designed to assist caregivers and patients to clarify their values, end-of-life preferences, enable surrogates to further their understanding of the patient's wishes, and prepare surrogates for the role and responsibilities of a medical decision maker. The intervention consists of values elicitation tools, educational materials, and testimonies. The participants will receive guides on how to initiate/re-introduce discussions about end-of-life wishes with their loved ones and clinicians.
224228577|NCT03262181|OTHER|Isometric Exercise|5 sets of 45-seconds quadriceps contraction, each followed by 2-minutes of rest.
224228578|NCT03262181|OTHER|Sham Transcutaneous Electrical Nerve Stimulation|5 sets of 45-seconds intervals without quadriceps contraction, each followed by 2-minutes of rest.
224228579|NCT04643678|DRUG|Anakinra|Patient will receive Anakinra 100 mg SC injection every 12 hours for 3 days, then 100 mg once daily from day 4 to day 7 plus Standard of Care
224228580|NCT04643678|OTHER|Standard of Care|Patients will receive the Standard of Care therapy as per the local treatment protocol
224228581|NCT01502345|BIOLOGICAL|Vaccine/device combination for prevention of HFRS|PUUV DNA Vaccine, 2.0mg/ml TDS-IM injection HTNV DNA Vaccine, 2.0 mg/ml TDS-IM injection HTNV + PUUV Vaccine mixture, 1.0mg/mL + 1.0mg/ml TDS-IM injection
224228582|NCT05679765|DRUG|Greater Occipital Nerve Block with dexamethasone and lidocaine|Ultrasound guided Greater occipital nerve block on the side of headache
224228583|NCT05679765|DRUG|Greater Occipital Nerve Block with 0.9% saline|Ultrasound guided Greater occipital nerve block on the side of headache
224228584|NCT03281499|OTHER|da Vinci Surgical System Model IS4000|tailored radiotherapy regimen following transoral robotic surgery
224228585|NCT01209052|DRUG|GSK1325756|Drug will be orally administered in varying amounts over varying time periods as detailed in the 'arms' section.
224228586|NCT01209052|OTHER|Placebo|Placebo will be orally administered to at least 4 subjects in each treatment period of each cohort. In each sequence in each cohort, all subjects will receive one dose of placebo.
224228587|NCT00006470|BIOLOGICAL|monoclonal antibody 11D10 anti-idiotype vaccine|
224228588|NCT00006470|BIOLOGICAL|monoclonal antibody 3H1 anti-idiotype vaccine|
224228589|NCT00006470|RADIATION|radiation therapy|
224228590|NCT01241461|DRUG|LY2584702|"Dose escalation starting at 50 milligram (mg). On Day 1, subjects will receive a single oral dose. After a two-day observation period, subjects will receive oral doses twice daily for a 28-day cycle.~Patients may continue 28-day cycles of twice daily dosing until discontinuation criteria are met."
224228591|NCT01143025|DRUG|Ropivacaine 50 mg|Preoperative nebulization of 50 mg of Ropivacaine in the peritoneal cavity
224228592|NCT01143025|DRUG|Ropivacaine 100 mg|Preoperative nebulization of 100 mg of Ropivacaine in the peritoneal cavity
224228593|NCT01143025|DRUG|Ropivacaine 150 mg|Preoperative nebulization of 150 mg of Ropivacaine in the peritoneal cavity
224228594|NCT02036372|DRUG|Liraglutide|
223640481|NCT05459896|OTHER|Energy Conservation Techniques|Participants who exhibit physiological symptoms will be recommended to receive energy savings intervention which is co-developed by the local Occupational Therapy Association. The intervention consists of six session, each session has different topics and associated energy savings techniques related to particular circumstances, such as the six principle of energy conservation, application of energy conservation in the domains of self-care, household tasks, outdoor activities and work. The materials will be delivered in the format of animation videos. Participants will be asked to complete one session per week. Revision quiz will be given to understand the learning progress of participants.
223640482|NCT04558034|OTHER|cryotherapy|cryotherapy will be delivered
223640483|NCT01737437|DRUG|group C|0.9% normal saline was applied to trachea and laryngoscope blade
223640484|NCT01737437|DRUG|group L|10% Lidocaine was applied to the laryngoscope blade and 0.9% normal saline was applied to the trachea.
223640485|NCT01737437|DRUG|group V|0.9% normal saline was applied to the laryngoscope blade and 10% Lidocaine was applied on trachea.
223640486|NCT01737437|DRUG|group LV|10% Lidocaine was applied on laryngoscope blade and trachea.
223640487|NCT00692835|PROCEDURE|Total Thyroidectomy (Mini Video Assisted Thyroidectomy)|Immediate postoperative course of patients with Thyroidectomy
223765170|NCT07134881|OTHER|Usual Care|Caregivers in the comparator arm will receive a digital version of standard advanced care planning education material prepared by Agency of Integrated Care. The ACP Workbook is created by AIC to help individuals explore their values, care preferences, and end-of-life goals in a structured, reflective way.
224228595|NCT02036372|DRUG|Insulin bolus|
224228596|NCT02036372|DRUG|GIK infusion|continuous infusion
224228597|NCT01650922|PROCEDURE|phlebotomy|
224228598|NCT01650922|PROCEDURE|biopsy|
223640488|NCT00692835|PROCEDURE|Total Thyroidectomy (Classic Thyroidectomy)|Immediate postoperative course of patients with Thyroidectomy
223640489|NCT01295164|DEVICE|classic aberrometer and aberrometer AOVIS-1|"Measurement of aberrations in early stages (1 and 2) of keratoconus as compared aberrometer AOVIS-1 with a classic aberrometer."
224228599|NCT04493450|OTHER|Documentation of cancer treatment side effects|Standardized documentation of occurred side effects
224228600|NCT06324136|DIAGNOSTIC_TEST|Implementation of the diagnostic algorithm|Patients will be selected based on specific clinical criteria and referred to the tertiary center for genetic testing. All selected patients will undergo genetic testing by whole-exome sequencing (WES), followed by in silico analysis for an extended panel of genes associated with kidney diseases. The results of genetic testing will be evaluated by a multidisciplinary team of experts to establish conclusive diagnosis.
224228601|NCT00675649|BIOLOGICAL|CNTO 148 / Golimumab|100 mg sc injection every 4 weeks from week 0 to week 20
224228602|NCT00675649|BIOLOGICAL|placebo|placebo sc injection every 4 weeks from week 0 to week 20
224228603|NCT02565420|OTHER|Normal saline|Patients will be administered normal saline for intraoperative fluid management.
224228604|NCT02565420|OTHER|Lactated Ringer's solution|Patients will be administered Lactated Ringer's solution for intraoperative fluid management.
224228605|NCT01368523|DRUG|nilotinib|
224323322|NCT05343715|BIOLOGICAL|Fabrazyme (agalsidase beta) 1 mg/kg|Patients received an infusion of 1 mg/kg of Fabrazyme. Final infusion dose is achieved with lyophilized drug at concentration 35 mg and 5 mg
224323323|NCT05824728|DRUG|AGB101|low-dose levetiracetam, 220 mg, extended release tablet
224228606|NCT04326777|PROCEDURE|Ballon pulmonary angioplasty|Percutaneous vascular access for BPA is via the femoral vein using Seldinger technique. A 5Fr sheath is inserted into the vein, through which a 6Fr long introducer sheath is advanced into the pulmonary artery. Subsequently, a 6Fr guiding catheter is advanced into the pulmonary artery being treated. Generally, selective pulmonary angiography should be performed to evaluate lesion feature before BPA. Then a 0.014-inch guidewire is used to cross the lesion, a balloon catheter of an appropriate diameter is selected to dilate the lesion.
224228607|NCT00682305|PROCEDURE|Hematopoietic stem cell transplantation|"conditioning regimen:~* day -7: 12g/m\^2 Treosulfan~* day -6: 12g/m\^2 Treosulfan~* day -5: 12g/m\^2 Treosulfan~* day -4: 30mg/kg BW Etoposide~* day -3: 20mg/kg ATG Fresenius (OPTIONAL), 60mg/kg BW Cyclophosphamide~* day -2: 20mg/kg ATG Fresenius (OPTIONAL), 60mg/kg BW Cyclophosphamide~* day -1: 20mg/kg ATG Fresenius (OPTIONAL)~* day 0: SCT"
224228608|NCT05789277|OTHER|Conventional training program|"Conventional training program:~5-10 Repetitions ( 0.5-to 1-min rest);~1. Vertical jumps~2. Multiple forward jumps~3. Running exercises~4. Sprints alternating with slow jogging"
224228609|NCT05789277|OTHER|Eccentric hamstring training|Functional training along with specific eccentric hamstrings exercises i.e., prone hamstring curl, exercise ball (or glider) bridge with curl, Nordic hamstring curl, single leg deadlift. The exercise program comprises 3 sets of 15 repetitions once to twice per day for at least 12 weeks.
224228610|NCT03164395|PROCEDURE|Internal Cardioversion|Internal Cardioversion with device maximum output shock from RV coil to Can versus external cardioversion per institutional protocol
224228611|NCT03164395|PROCEDURE|External Cardioversion|External Cardioversion per institutional protocol
224228612|NCT02788422|OTHER|Video discharge instructions|Online video containing information on how to manage symptoms of acute otitis media and when to return to a health care professional.
224228613|NCT02788422|OTHER|Standard of Care|One page paper handout containing information on how to manage symptoms of acute otitis media and when to return to a health care professional.
224228614|NCT02619123|OTHER|Tailored screening according to breast density|Different interval of mammography screening according to breast density
224228615|NCT02619123|OTHER|Annual invitation to mammography|Annual interval mammography screening according to international guidelines for women younger than 50 years old
224228616|NCT01132118|DRUG|Hydroxychloroquine|Hydroxychloroquine comes in 200 mg tablets and is taken orally. The dose provided will be based upon a calculation of 6.5 mg/kg (subject's weight), which is the dose range commonly used to treat rheumatoid arthritis and lupus. Dosages will be rounded to the nearest 100 mg.
224228617|NCT03703713|DRUG|Sodium chloride|Treatment with Sodium chloride
224228618|NCT01557491|PROCEDURE|Straight Incision|The incision will be made at a 90 degree angle to the surface of the scalp
224228619|NCT01557491|PROCEDURE|Bevelled Incision|The Incision will be made at a 45 degree angle to the surface of the scalp.
223640490|NCT01295164|DEVICE|Aberrometer AOVIS-I|Measurement of aberrations in high stages (3 and 4) of keratoconus. Objective characterization of the optical quality of the patient eye by application of wave-front sensing technology in late stage keratoconus The complete procedure in one patient takes less than 5 minutes in only one consultation and is completely non invasive. The optical measurements only involve the use of low power infrared laser
223640491|NCT02494323|DEVICE|Functional Electrical Stimulation|Single channel and dual channel FES for balanced dorsiflexion for patients with dropfoot
223640492|NCT00693771|DRUG|Insulin Glargine|Once daily and up-titrate accordingly
223640493|NCT01962740|DEVICE|Drug-eluting stent implantation|
223640494|NCT00588835|DRUG|aprepitant|125mg on Day 1; 80mg on Day 2-3 during CE cycle. Dexamethasone is added as well.
223640495|NCT00588835|DRUG|Dexamethasone and Ondansetron during CE-treatment|Standard anti-emetic regimen during CE treatment
223640496|NCT01154257|PROCEDURE|Cleaning of teeth with a toothbrush|This is a split mouth study where patients will have one side of their mouth randomised for teeth cleaning with a toothbrush. Cleaning will be twice daily from recruitment until day seven.
223640497|NCT01154257|PROCEDURE|Cleaning of teeth with a foam swab|This is a split mouth study where patients will have one side of their mouth randomised for teeth cleaning with a foam swab. Cleaning will be twice daily from recruitment until day seven.
223640498|NCT04237597|DRUG|K-877|K-877 tablets
223640499|NCT04237597|DRUG|CSG452|CSG452 tablets
223640500|NCT02024919|DRUG|intracoronary administration of diltiazem|
223640501|NCT02024919|DRUG|intracoronary injection of 5 mL saline|
223640502|NCT00736762|OTHER|GPR|The subjects randomised to the GPR program will participate in posture retraining techniques of approximately forty minutes, one time a week for ten weeks.
223640503|NCT03071042|DRUG|Apatinib|Apatinib Mesylate Tablets 425mg (500mg，675mg or 750mg) po. qd continuous;
223640504|NCT03071042|DRUG|Docetaxel|Docetaxel 60mg/m2 ivgtt day 1, q21d Combined use of Docetaxel and Apatinib
223640505|NCT00565292|DRUG|MK0859|
223640506|NCT00751608|DRUG|APL180|
223640507|NCT00751608|DRUG|APL180|
223640508|NCT00751608|DRUG|Placebo|
223640509|NCT05684211|DRUG|Ametumumab|A recombinant fully human anti-EGFR monoclonal antibody
224228620|NCT04942379|OTHER|Asthma Link|Providers enroll patients in school nurse supervised daily controller asthma medication delivery
223640510|NCT05684211|DRUG|Anti-PD-1 monoclonal antibody|Toripalimab 3 mg/kg，Intravenous titration，Q2W
223640511|NCT05684211|DRUG|Cetuximab|Cetuximab 500 mg/m2 ，Intravenous titration，Q2W
223640512|NCT05684211|DRUG|FOLFIRI|Rinotecan hydrochloride，180mg/m2，intravenous titration，Q2W； 5 -Fluorouracil，400 mg/ m2, intravenous push, then 1200 mg/ m2 /day x 2 days, intravenous titration,Q2W; Calcium folinate,400mg/m2,intravenous titration，Q2W
223640513|NCT02871908|DRUG|Lactobacillus reuteri DSM 17938|Lactobacillus reuteri DSM 17938 twice daily 2 x 10\^8
223640514|NCT02871908|DRUG|Placebo|Placebo
223640515|NCT02199210|OTHER|Prompting forethought|Participants will be asked questions which elicit specific forethought elements related to the given clinical situation. These are elements that relate to strategic planning, goal setting, goal orientation, imagery, outcome expectation. These context specific questions will be determined in the Pilot study and validated in Study I.
224228621|NCT04942379|OTHER|Enhanced Usual Care|Providers counsel patients on behavioral strategies to improve medication adherence. Patients also receive an asthma workbook outlining behavioral strategies for asthma medication adherence.
224228622|NCT03384719|DIETARY_SUPPLEMENT|35 g protein (30% milk + 70% rapeseed)|"The daily amount of 35 g of protein is provided as a powder. The powder is packed in two separate sachets to be consumed in the morning and evening. Each sachet contains approximately 60 g of powder. The powder is mixed with liquid before intake.~Protein powder ingredients (all are food quality):~* Milk protein: Skimmed milk powder (Arla Foods, Viby, Denmark)~* Rapeseed protein isolate: Isolexx® (BioExx, Saskatoon, Canada)~* Other ingredients: lactose, sucrose, flavors, artificial sweeteners. The protein powders for each treatment group are standardized to contain the same amount of energy and lactose per day."
224228623|NCT03384719|DIETARY_SUPPLEMENT|35 g protein (54% milk + 46% rapeseed)|"The daily amount of 35 g of protein is provided as a powder. The powder is packed in two separate sachets to be consumed in the morning and evening. Each sachet contains approximately 60 g of powder. The powder is mixed with liquid before intake.~Protein powder ingredients (all are food quality):~* Milk protein: Skimmed milk powder (Arla Foods, Viby, Denmark)~* Rapeseed protein isolate: Isolexx® (BioExx, Saskatoon, Canada)~* Other ingredients: lactose, sucrose, flavors, artificial sweeteners. The protein powders for each treatment group are standardized to contain the same amount of energy and lactose per day."
224228624|NCT03384719|DIETARY_SUPPLEMENT|35 g protein (100% milk)|"The daily amount of 35 g of protein is provided as a powder. The powder is packed in two separate sachets to be consumed in the morning and evening. Each sachet contains approximately 60 g of powder. The powder is mixed with liquid before intake.~Protein powder ingredients (all are food quality):~* Milk protein: Skimmed milk powder (Arla Foods, Viby, Denmark)~* Other ingredients: lactose, sucrose, flavors, artificial sweeteners. The protein powders for each treatment group are standardized to contain the same amount of energy and lactose per day."
224228625|NCT03728842|OTHER|Blood collection for laboratory studies|Peripheral whole blood will be collected
224228626|NCT03728842|OTHER|Data collection from medical record|Clinical data such as demographics and cancer characteristics, history and treatment will be collected
224228627|NCT00171782|DRUG|VALSARTAN+HYDROCHLOROTHIAZIDE|
224228628|NCT00514995|DRUG|Sodium Oxybate|4.5 g/night - 9 g/night, liquid taken twice per night
224228629|NCT06051396|PROCEDURE|Right sided heart catheterization|Hemodynamic evaluation was performed in the supine position. RHC was performed using the modified Seldinger technique with an 8F sheath inserted in the jugular, basilic or cephalic vein . The Swan-Ganz catheter was a 7F, two-lumen, fluid filled, and pressure-measuring tipped catheter (Corodyn TD; Braun Medical, Bethlehem, PA, USA). The zero-level reference was determined at midthoracic line.(9)
224228630|NCT03004690|DEVICE|PPE Suit A|In this randomized study following good clinical practice guidelines nineteen study volunteers were recruited to wear one of two different types of randomly allocated PPE suits. Suit A has to be used by randomly selected participants to perform four different tests six times at 22°C on one day and four times at 28°C on another day in the local core facility clinical research center.
224228631|NCT03004690|DEVICE|PPE Suit B|Suit B has to be used by randomly selected participants to perform four different tests six times at 22°C on one day and four times at 28°C on another day in the local core facility clinical research center.
224228632|NCT06093256|DEVICE|Fixed orthodontic appliances|Taste sensation will be checked before and after fixed orthodontic therapy.
224228633|NCT00446498|DEVICE|CPAP and Non Invasive Ventilation|
224228634|NCT03705351|DEVICE|Tumor Treating Fields|Optune is intended as a treatment for adult patients (22 years of age or older) with histologically-confirmed glioblastoma multiforme (GBM). Treatment will begin approximately 1 week prior to start of radiation and temozolomide treatment and continue concurrently throughout the duration of the study.
224228635|NCT03705351|DRUG|Temozolomide|Patients will be given temozolomide according to routine treatment dosing and schedule.
224228636|NCT03705351|RADIATION|Radiation Therapy|Patients will be given radiation therapy according to routine treatment dosing and schedule.
224228637|NCT02780661|DEVICE|Denture Cleanser Daily Use Period|One denture cleansing tablet will be soaked in a cup of very warm water (150 ml) with dentures for Day 0 to Day 7 for 15 mins. Brush dentures for 30 seconds using the solution, rinse under running water for 10 seconds.
224228638|NCT02780661|DEVICE|Denture Cleanser Weekly Use Period|One denture cleansing tablet will be soaked in cup of very warm water (150 ml) from Day 0 to Day 6 for 15 mins; and in cup of very warm water (150 ml) with 1 denture cleansing tablet on Day 7 at site for 15 mins. Brush dentures for 30 seconds using the solution, rinse under running water for 10 seconds.
224228639|NCT02780661|OTHER|Water|A cup of very warm water will be used to soak one denture cleansing tablet and dentures for per day (Day 0 to Day 7) or weekly (Day 0 and Day 7) treatment regimen.
224228640|NCT03321747|RADIATION|Stereotactic Ablative Body Radiation (SABR)|Treatments shall not be delivered more frequently than every other day.
224228641|NCT05994456|DRUG|PD-1 inhibitor|240mg, Q3W. The opportunity for surgery was evaluated after 2 cycles of treatment and surgical treatment was performed after 2-4 cycles of treatment. Postoperatively, adjuvant therapy was continued according to the neoadjuvant regimen, and direct treatment met the criteria for termination of treatment.
224228642|NCT00494975|DEVICE|Narrow band UVB phototherapy , long wave UVA phototherapy|A UV irradiation cubicle (HOUVA II, National Biological Corporation, OH, U.S.A.) equipped with 24 UVA lamps (F72T12/BL9/HO UVA, National Biological Corporation, OH, U.S.A. ) and 24 UVB lamps (TL100W/01 311NB UVB, Philips Company, Eindhoven, The Netherlands).
224228643|NCT01806688|OTHER|gluten-free high protein snack #1|buckwheat groats 30g serving
224228644|NCT01806688|OTHER|gluten-free snack with similar energy density but 1/2 the protein as snack #1|32g serving of corn nuts
224228645|NCT01806688|OTHER|non-caloric control|water
223640516|NCT01715740|DRUG|Chinese Herbal Medicine (CHM)|Each CHM capsule, weighing 500mg, consists of XFS 250 mg and QSFFT 250 mg.
223640517|NCT01715740|DRUG|Placebo|Encapsulated powder with similar taste, color, odor to intervention Chinese herbal medicine
223640518|NCT01524796|OTHER|No intervention. Non-interventional study|No intervention. Non-interventional study
223640519|NCT01374438|DRUG|MSDC-0160|MSDC-0160 150 mg capsules given once daily for 90 days
223640520|NCT01374438|DRUG|Placebo|Placebo capsules given once daily for 90 days
223765171|NCT07134725|BIOLOGICAL|SpiN-Tec MCTI UFMG|Chimeric recombinant protein (SpiN) adjuvanted with CTVad1
223765172|NCT07134725|OTHER|Active Comparator: Covishield® vaccine|active comparator using vaccine approved by ANVISA (Brazilian Health Regulatory Agency)
223640521|NCT01595542|BEHAVIORAL|Modified Vaccine Consent Form|"Packet of written immunization materials for parents and students which includes the following:~1. Cover letter~2. Vaccine promotional flyer~3. Vaccine information sheets (one for adolescent vaccination and one for other vaccination)~4. Improved consent form~5. Note advertising a lottery for free movie tickets for returning the consent form~6. Self-addressed stamped envelope"
223640522|NCT05605002|DRUG|SSRIs|SSRIs antidepressants, including fluoxetine, paroxetine, sertraline, citalopram, etc., will be administered at oral doses determined by the psychiatrist. Once daily for 6 weeks.
223640523|NCT05605002|PROCEDURE|SIA|This study will select 4 acupoints (all taken bilaterally) commonly used to treat MDD, namely Taichong (LR3), Neiguan (PC6), Sanyinjiao (SP6) and Shenmen (HT7). The SIA will use the same size, colour and material as the AIA with a thin silicone pad in the middle instead of the needle body. SIA will be attached to the acupoints and retained for 72 hours, removed and rested for one day. A total of 10 sessions will be performed over a period of 6 weeks.
223640524|NCT05605002|PROCEDURE|AIA|This study will select 4 acupoints (all taken bilaterally) commonly used to treat MDD, namely Taichong (LR3), Neiguan (PC6), Sanyinjiao (SP6) and Shenmen (HT7). Depending on acupoints' location, a φ0.20\*1.5mm or φ0.20\*1.2mm AIA will be selected. Press the AIA to insert it vertically into the acupoint and retain it in the skin. AIA will be retained for 72 hours with a day's rest after removal. During the period of needle retention, participants will be instructed to press the AIA 3-4 times a day for approximately 1 minute each time, with as much stimulation as the patient can tolerate, at intervals of approximately 4 hours. A total of 10 sessions will be performed over a period of 6 weeks.
223640525|NCT05531292|DEVICE|Model C0002|Eligible subjects will be randomized in a 1:1 ratio to the investigational IOL Model C0002 in both eyes for the duration of the study.
223640526|NCT05531292|DEVICE|Model ZCB00/DCB00|Eligible subjects will be randomized in a 1:1 ratio to the control IOL Model ZCB00 in both eyes for the duration of the study.
223640527|NCT00956007|BIOLOGICAL|cetuximab|intravenously
223640528|NCT00956007|RADIATION|intensity-modulated radiation therapy|daily fractions
223640529|NCT06217510|DEVICE|Test Brace|Participants will be fitted with the Test Brace and will wear the brace for 30 minutes.
223640530|NCT03774576|DRUG|RO7017773|Single doses of RO7017773
223640531|NCT03774576|DRUG|Itraconazole|Multiple doses of Itraconazole
223640532|NCT06161389|DEVICE|Partially inflated mask|Manikin ventilation with a partially inflated mask
223640533|NCT06161389|DEVICE|Fully inflated mask|Manikin ventilation with a fully inflated mask
223640534|NCT02191735|DEVICE|RAMP 200|The RAMP® Reader is a general use fluorometer that analyzes results produced by immunoassays that use a fluorophore having an excitation wavelength at 560 nm and an emission wavelength of 610 nm. The RAMP® 200 is Response Biomedical's second generation reader. The RAMP® 200 is designed to process more tests with a smaller footprint.
223640535|NCT02191735|DEVICE|RAMP Reader|The RAMP® Reader is a general use fluorometer that analyzes results produced by immunoassays that use a fluorophore having an excitation wavelength at 560 nm and an emission wavelength of 610 nm. The RAMP® Reader is Response Biomedical's first generation reader instrument. Designed for use at near-patient/bedside or locations such as: laboratories, hospitals, on-site Emergency Response and Emergency Rooms.
223640536|NCT01253837|DRUG|L19TNFa|"Phase I: Sequential assignment of Patient cohorts to one of six dose levels of L19TNFa: 1.3, 2.6, 5.2, 7.8, 10.4, 13.0 µg/kg.~Phase II: The Recommended Dose (RD) of 13.0 µg/kg of L19TNFα determined in Phase I.~Schedule: Infusions of L19TNFα on days 1, 3 and 5 of each 21-day cycle. Patients may remain on treatment for a maximum of six 21-day cycles."
223640537|NCT04030910|OTHER|'LIFEView'|A prototype audiovisual technology in development by Motitech AS.
223640538|NCT00871416|DEVICE|NovoFine® needle 6 mm|
223640539|NCT00871416|DEVICE|NovoFine® needle 12 mm|
223640540|NCT06026917|DRUG|Toludesvenlafaxine hydrochloride sustained-release tablets|D1\~D6, 40mg/ tablet, 1 tablet per time, once a day, D7\~D10, 80mg/ tablet, 1 tablet per time, once a day, D11\~D42, 80mg/ tablet, 2 tablets per time, once a day. For subjects who cannot tolerate 160mg, the dose may be reduced to 80mg/ dose once daily. After the number of subjects receiving 160mg/ dose reached 6, the remaining subjects received D11\~D42, 80mg/ tablet, one tablet each time, once a day.
223640541|NCT00338845|BEHAVIORAL|Share Safer Sex program|The Share Safer Sex intervention will consist of a single, 30 to 40 minute, one-on-one counseling session designed to increase personal awareness of the participant's current unsafe behaviors and the associated risks, help her understand her motivation to change, and increase her knowledge about how to practice safe sex. Demonstrations and practice exercises will be used to improve participants' attitudes about, as well as intentions to practice, condom use. The counseling session will include the following activities: assessing readiness for change; building motivation for change; and performing exercises in decisional balance, identification of problem and problem-solving, and knowledge and skill-building.
223640542|NCT00338845|BEHAVIORAL|Standard didactic safer-sex counseling program|The standard counseling program will be based on a sexual risk reduction counseling program developed by the Centers for Disease Control and Prevention, and will focus on personal risk assessment and strategies for risk reduction. Additionally, it will incorporate risk reduction materials provided by CENSIDA, Mexico's National Center for AIDS Studies.
223640543|NCT02621450|BIOLOGICAL|standart dialysis|dialysate sodium consentration 140 mEq
223765173|NCT07134725|OTHER|Active Comparator: Comirnaty® vaccine|active comparator using vaccine approved by ANVISA (Brazilian Health Regulatory Agency)
224228646|NCT01806688|OTHER|gluten-free high protein and high fibre snack #2|buckwheat and pinto bean flour pita bread 50g serving
224228647|NCT01806688|OTHER|gluten-free snack with similar energy density, but less protein and fibre than snack #2|50g serving of rice bread
224228648|NCT05089994|PROCEDURE|US guided injection|using 2.5mg/kg of 0.25% bupivacaine diluted in a 20 mL syringe of normal saline , received ultrasound-guided quadratus lumborum.
224228649|NCT03642574|PROCEDURE|CNV|Embryo with euploid chromosome will transfer to uterus. The order of transfer is accroding to morphological grade.
224228650|NCT04298164|BEHAVIORAL|START programme|Acceptance and Commitment Therapy based programme for parents of children with Autism
224228651|NCT04298164|BEHAVIORAL|Treatment as Usual|Treatment as usual in outpatient within outpatient psychology services
224228652|NCT04776551|PROCEDURE|Percutaneous fixation of acute Scaphoid fractures|Percutaneous Trans-trapezial fixation of acute Scaphoid fractures by Herbert screw
224228653|NCT00084539|RADIATION|Radiation therapy|
224228654|NCT04123041|OTHER|JUUL ENDS, Combustible cigarette, comparator e-cigarette, Nicorette gum|JUUL ENDS and comparator e-cigarette will be used for 5 minutes ad libitum, one combustible cigarette will be used ad libitum, Nicorette gum will be used for 30 minutes ad libitum
224228655|NCT01717014|DEVICE|Covidien Radial Reload Stapler with Tri-Staple Technology|Case series of patients already selected to undergo an open LAR or proctosigmoidectomy using the Radial Reload Stapler
224228656|NCT03818490|OTHER|Bergamot Aromatherapy|Patients in this group inhaled bergamot essential oil for 15 minutes.
224228657|NCT05436821|DEVICE|Auricular vagus nerve stimulation|Autonomic nerve system regulation
224228658|NCT05436821|DEVICE|Sham Auricular Vagus Nerve Stimulation (AVNS)|Sham Auricular Vagus Nerve Stimulation (AVNS)
224319362|NCT02609438|BEHAVIORAL|Long breaks|Following baseline testing, participants will attend a 30-minute individual orientation session, during which they will complete a planning worksheet with a research assistant. They will identify specific strategies they will use to accomplish the pre-specified goal (i.e., to take two 15-minute activity breaks during each workday). They will also identify potential barriers they will face and devise strategies for overcoming them. The intervention will officially start the Monday after the orientation session and will last for 8 weeks. Participants will receive a weekly email containing tips related to reducing sitting time at work. All participants will complete daily activity logs indicating the time and duration of all breaks from sitting across the 8-week intervention.
224319363|NCT01890863|DRUG|Fluticasone Propionate / Salmeterol Xinafoate DISKUS|Fluticasone propionate and salmeterol xinafoate combination as a dry powder inhaler for oral inhalation with unit dose strength of 100/50 mcg (available in blister pack) administered via DISKUS (Ddpi) device.
224319364|NCT01890863|DRUG|Fluticasone Propionate / Salmeterol Xinafoate ROTACAP|Fluticasone propionate and salmeterol xinafoate combination as a dry powder inhaler for oral inhalation with unit dose strength of 100/50 mcg (available in blister pack) administered via ROTAHALER (Rdpi) device.
224319365|NCT00515918|DIETARY_SUPPLEMENT|iron|
223640544|NCT02621450|BIOLOGICAL|low sodium dialysis|dialysate sodium consentration will be reducer from 140 mEq to 137 mEq
223640545|NCT06198296|GENETIC|21.15.GPC3-CAR T cells|"Three different dosing schedules will be evaluated.~The following dose levels will be evaluated:~The following dose levels will be evaluated:~DL0: 3x10\^7/m2 DL1: 1x10\^8/m2 DL2: 3x10\^8/m2 DL3: 1x10\^9/m2"
223640546|NCT01471288|DRUG|Carum Cravi|40mg/kg of body weight
223640547|NCT01471288|DRUG|Placebo|Placebo
223640548|NCT00927953|BIOLOGICAL|MGAWN1|Humanized monoclonal to West Nile virus. Dose = 30 mg/kg actual body weight intravenous, one dose at Day 0.
223640549|NCT00927953|BIOLOGICAL|Placebo - normal saline|Normal Saline intravenous, volume same as active comparator, one dose at Day 0
223640550|NCT06025864|OTHER|Breastfeeding|"Over the 6 months of the intervention, 1 video per month was sent, a total of 6 videos, via the mobile application, with guidance on breastfeeding: the importance of maternal hydration; myths and truths about the mother's diet; practical guidance on breastfeeding; baby's gastric capacity; picking up and positioning the baby during breastfeeding and storing milk for the return to work. There were also 1 call per month, with an average duration of 15 minutes, with a breastfeeding consultant nutritionist, aiming to solve doubts and difficulties that month. In order to provide complete assistance, virtual groups were created via the WhatsApp application, with a nutritionist and a health academic to solve doubts, provide emotional support and exchange information when necessary.~According to the region or municipality of origin of the mother-baby dyad, when necessary, this study provided the loan of a breast pump during the follow-up period or 6 months."
223640551|NCT02633150|OTHER|Supplementation with red grapes polyphenol|
223640552|NCT00402948|DRUG|TPI ASM8|0.25mg, 0.5mg for 14 days, daily dosage
223640553|NCT00402948|DRUG|ASM8|inhalation 0.25mg daily for 14 days
223640554|NCT05871216|DIAGNOSTIC_TEST|Clinical tests and balance evaluation using the Delos Proprioceptive System|Each patient is evaluated using clinical tests (Time up and go test, 6 minutes walking test), scales (BORG scale, Beighton score), and the ''Delos Proprioceptive System'' to assess balance control and proprioception with bipodalic and monopodalic tests.
224228659|NCT04741100|OTHER|Ex-vivo analysis|Ex-vivo analysis
224228660|NCT02240407|GENETIC|Recombinant Adeno-Associated Virus Acid Alpha-Glucosidase|The dose selected for this study is a fixed dose of 4.6 x 10\^13 vg per TA muscle (range of 7.64 x 10\^11 vg/gm to 4.6 x 10\^11 vg/gm based on TA weight).
224228661|NCT02240407|DRUG|Rapamycin|Patients will receive Rapamycin (dose 0.6-2 mg/m\^2/day, adjusted to maintain a trough serum sirolimus level of 2-4 ng/mL.) every day starting from 7 days before first injection of AAV9 until four months after second injection.
224228662|NCT02240407|OTHER|saline|Same volume as rAAV9-DES-hGAA injection will be used.
224228663|NCT02240407|DRUG|Rituxan|Patients will receive Rituxan (dose: 750 mg/m\^2 twice) 21 and 7 day prior first AAV9 injection, with a Rituxan dose 375 mg/m\^2 on the day of the injection. Rituxan will be repeated 7 days prior to the 2nd injection of the vector. The maintenance dose of Rituxan will be 375 mg/m\^2.
224228664|NCT02240407|DRUG|Diphenhydramine|25-50mg will be provided before each Rituximab dose.
224319366|NCT05821335|OTHER|Leap motion assisted rehabilitation|Hand Therapy via leap motion sensor
224319367|NCT05821335|OTHER|Traditional program|Hand Therapy by physiotherapist via traditional methods
223640555|NCT00976924|DEVICE|blood glucose monitor|Blood glucose monitor is used to monitor the blood glucose level of the human-being.
223640556|NCT00235274|DRUG|Subcutaneous Secretin|
223640557|NCT02586740|PROCEDURE|Pulmonary artery rehabilitation|
223640558|NCT02987686|DRUG|Topical Infliximab|Aside from the standard treatment, patients will receive topical infliximab ( 10mg/ml) four (4) time per day for four (4) weeks.
223640559|NCT03490695|OTHER|Practice Facilitation|Community health nurses trained in implementing the evidence-based TASSH protocol will be employed as Practice Outreach Facilitators (POF) to train the CHPS community health officers to deliver TASSH. The POFs will be required to complete an intensive 12-week training course focused on adoption of TASSH protocol to identify patients at risk for uncontrolled HTN, initiate behavioral lifestyle counseling, and Refer patients to the community health centers for drug therapy. Over the course of 12 months, the POFs will provide support to their assigned CHPS zones to implement TASSH as part of routine patient care.The POFs will also work with CHPS directors to review current work flow and develop a plan of action for TASSH uptake at the CHPS zones.
224228665|NCT02240407|DRUG|Acetaminophen|We will provide 650 mg of tylenol before each dose of Rituximab.
223640560|NCT03490695|OTHER|Usual Care|Provide Ghana's National Health Insurance, behavioral counseling and referral for care through the usual care system for 12 months.
223765174|NCT06938724|OTHER|Omission of local therapies|"Omission of surgery (arm A) or radiotherapy (arm B) in those patients who have had the maximum response by neoadjuvant treatments. Maximum responders are those patients with no evidence of residual disease after neoadjuvant treatment at imaging -including mammography, US evaluation and contrast imaging procedures (MRI and/or CEM)-, confirmed by VABB on marked site of ascertained lesion.~This study is open to all patients with T1-2, N0-1, M0 HER2-positive or triple negative breast cancer, treated with neoadjuvant systemic treatment, irrespective of treatments delivered."
224228666|NCT02240407|DRUG|Lidocaine|Lidocaine will be used based on standard of care: Percutaneous infiltration, concentration 0.5-1%, 1-10 mL, 5-300mg total dose.
223640561|NCT05201300|DRUG|Remimazolam Besylate 6 mg/kg/hr|Patients will receive remimazolam at 6 mg/kg/hr by continuous infusion until loss of consciousness.
223640562|NCT05201300|DRUG|Remimazolam Besylate 12 mg/kg/hr|Patients will receive remimazolam at 12 mg/kg/hr by continuous infusion until loss of consciousness.
223640563|NCT05201300|DRUG|Propofol|Patients will receive propofol at a target controlled infusion 4 µg/ml until loss of consciousness.
223640564|NCT03693924|RADIATION|SRT-100|The SRT-100™ is a simple painless non-invasive in-office procedure that is approved by the U.S. Food and Drug Administration (U.S. FDA) to treat keloids caused by surgery or injury by delivering a precise, calibrated dose of Superficial Radiation Therapy (SRT) that only goes skin deep.
223640565|NCT02868632|DRUG|MEDI4736|anti-PD-L1 human monoclonal antibody
223640566|NCT02868632|DRUG|Tremelimumab|anti-CTLA4 human monoclonal antibody
223640567|NCT02868632|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|Stereotactic body radiation therapy (SBRT) will be administered at the standard dose of 6 Gy daily for 5 days.
223640568|NCT00686413|DRUG|AZD3480|single dose, oral
223640569|NCT00686413|RADIATION|2-[18F]-F-A85380|Single dose, IV
223640570|NCT04653077|OTHER|stem cells|Intravenous and Intrathecal transplantation of specific populations of purified bone marrow-derived stem cells and mesenchymal stem cells.
223640571|NCT05021406|DRUG|Carvedilol 12.5 MG|Carvedilol is started at a dose of 6.25 mg once per day, and will increase to a dose of 12.5 mg once per day after 1 week. Target dose will be maintained at 12.5 mg once per day if patients with systolic blood pressure not lower than 90 mm Hg and HR no less than 50 beats/min.
223640572|NCT01773044|DRUG|alkalinized lidocaine|recevied 0.05 mL/kg lidocaine with bicarbonate ( % 2 lidocaine 5 mL + 1 mL %8,4 NaHCO3+ 4 mL SF)
223640573|NCT01773044|DRUG|Lidocaine|0.05 mL/kg lidocaine (% 2 lidocaine 5 mL + 5 mL SF),
223640574|NCT01773044|DRUG|Placebo (for alcalinized lidocaine)|
223640575|NCT00594841|PROCEDURE|Open Reduction Internal Fixation of AC joint dislocation|"Definitive surgical treatment (i.e., ORIF) will be performed within 28 days of the injury. In all cases the procedure will be performed by an orthopedic staff surgeon with the assistance of a fellow/resident(s). The operating surgeon will determine the positioning of the patient for surgery. ORIF of the AC joint dislocation will be carried out as follows:~* Anatomic reduction of the AC joint~* Definitive fixation with a hook plate and screws"
223640576|NCT00594841|OTHER|Non operative treatment of AC joint dislocation (sling)|Standard protocol for conservative treatment will consist of the implementation of a sling, for shoulder support and patient comfort, for four weeks followed by physiotherapy. Pendulum exercises may be implemented at any time as dictated by the attending surgeon.
223640577|NCT03769519|BEHAVIORAL|ARICA|Personalized ARICA (AdheRence to Inhaled Corticosteroids in Asthma) intervention package.
223640578|NCT04014517|OTHER|Standard of Care|Standard of Care is represented by the best standard peri-operative treatment already planned for the study population: as for ERAS guidelines, it is represented by fast restoration of liquid and solid diet after surgery (approximately 24 hours after surgery) and pre-operative and post-operative dietary counselling whenever indicated by the surgeon or gastroenterologist
223640579|NCT04014517|DIETARY_SUPPLEMENT|Immunonutrition|Impact. Patients will be asked to consume 3 cartons/day of Nestle IMPACT for pre-operative 7 days and 1 carton/day of Nestle IMPACT for post-operative 30 days
223640580|NCT03854097|DEVICE|Active Intermittent Negative Pressure (INP)|Application of -40mmHg negative pressure on the lower limb
224228667|NCT02240407|DRUG|LMX 4 Topical Cream|Topical anesthesia cream will be used prior to gene therapy/saline injection.
224228668|NCT03097393|DIAGNOSTIC_TEST|measure Serum procalcitonin level|measuring procalcitonin level
223640581|NCT03854097|DEVICE|Placebo Intermittent Negative Pressure (INP)|Application of -10mmHg negative pressure on the lower limb
223640582|NCT02153749|BEHAVIORAL|Cognitive Regulation of Craving|"Regulation strategy practice: Participants will be trained to use a CBT-based cognitive regulation strategy. They will be asked to think of their individualized negative consequences for and thing of them when they see the instruction LATER during the task. Participants will practice using this strategy for multiple cigarette stimuli. High-Risk Situation Practice: Participants will identify 10 situations in which they usually smoke, or are likely to smoke in the next 48 hours. For each situation, they will be asked to practice using the strategy and to plan to use this strategy to regulate craving in daily life."
224228669|NCT00850902|OTHER|High Humidity (HH)|High Humidity Level
224228670|NCT00850902|OTHER|Moderate Humidity|Moderate Humidity Level
224228671|NCT00281619|DRUG|CellCept (mycophenolate mofetil)|
224228672|NCT00281619|BEHAVIORAL|Dietary Monitoring|
224228673|NCT00281619|BEHAVIORAL|Drug Diary|
224228674|NCT00281619|PROCEDURE|Blood Sampling|
224228675|NCT02398318|DEVICE|Bilateral Nucleus Accumbens DBS (Suzhou Sceneray)|High frequency stimulation applied using Suzhou Sceneray® DBS hardware (1120 electrode, 1180 (S) battery).
224228676|NCT02398318|DEVICE|Sham Bilateral Nucleus Accumbens DBS|DBS system switched off.
224319368|NCT01402635|DEVICE|point-of-care chemistry test(POCT) (Piccolo)|comprehensive chemistry POCT including ALB, ALP, ALT, AST, BUN, Ca, Cl-, Cre, Glu, K+, Na+, TBil, TCO2, TP It takes 12minutes to perform analyze.
224319369|NCT03209817|DIETARY_SUPPLEMENT|Red cherry tomato|300 grams of cherry tomatoes per day for four weeks (each)
224319370|NCT03209817|DIETARY_SUPPLEMENT|Yellow cherry tomato|300 grams of cherry tomatoes per day for four weeks (each)
223640583|NCT02153749|BEHAVIORAL|Mindfulness-Based Regulation of Craving|"Each training session in this condition will be identical to the CBT-based training session described, with the exception of the strategy being trained. Specifically, participants will be trained in using the MBT-based strategy (notice craving and accept the feeling without judgment or reaction). To do so, they will be asked to generate their own non- reactive responses to craving (e.g., I can just sit here and notice this. I can ask myself, 'can I be ok with this feeling?') Participants will then be instructed to think of those accepting and non-reactive responses when they see the instruction ACCEPT during the task. All other components will be identical."
224228677|NCT00782002|BIOLOGICAL|IMC-18F1|Cohorts 1-4 will receive IMC-18F1 intravenously for 4 weekly infusions, followed by a 2-week observation period. Cohort 5 will receive IMC-18F1 intravenously every other week for the first 6 weeks of therapy. Cohort 6 will receive IMC-18F1 every 3 weeks for the first 6 weeks for therapy. The starting dose in Cohort 1 will be 2mg/kg. The maximum dose of IMC-18F1 will not exceed 16mg/kg administered every week, 15mg/kg administered every other week, and 20mg/kg administered every 3 weeks. Dose escalation of 100% (2 x previous dose) if no dose limiting toxicities (DLTs) are observed in the first three patients within a cohort during the initial 6-week therapy period. Dose escalation increment will be reduced to 50% (1.5 x previous dose) following the occurrence of either grade 2 or higher AEs in 2 or more patients that are possibly, probably, or definitely-related to study medication or one DLT during the initial 6-week therapy period. No intrapatient dose escalation is allowed.
224228678|NCT01299038|DRUG|rosuvastatin|Taken orally once a day for 4 weeks
224228679|NCT03867903|DEVICE|Babysparks Application|mHealth application, BabySparks©, will be implemented for infant and toddler developmental activities through 24 months of age. (Currently, BabySparks is only designed to work on the developmental milestones through 24 months of age, and therefore the use of the application will no longer be applicable to the patient after reaching a developmental age of 24 months. If the subject has not reached a developmental age of 24 months at the time he/she is chronologically 24 months, the subject/family will be able to continue to utilize the application for a maximum of 24 months from the time they began to use the application or until reaching a study endpoint of reaching 24 months developmentally or death, whichever the infant reaches first.)
224228680|NCT03867903|OTHER|pre and post-test Redcap Survey|Prior to starting the use of the application, parents will be given a REDCap survey to complete to determine their current awareness and interventions being implemented with their child related to reaching developmental milestones. Data entered into application by the subject's caregivers will be stored by BabySparks.After completion of the use of the application (subject reaches a study endpoint), the caregivers will be asked to complete a REDCap survey asking them about their experience with the application.
224228681|NCT03562299|DEVICE|OrthoPure™ XT|A decellularized, sterile, single use, xenograft device for reconstruction of the anterior cruciate ligament
224228682|NCT00322556|DRUG|Immunoglobulins Intravenous (Human)|Liquid formulation; treatment schedule every 3 or 4 weeks using an individualized regimen with a dose of 0.2 - 0.8 g IgG per kg bw
224319371|NCT01931878|DRUG|incobotulinumtoxinA|The subject may be randomly assigned to receive incobotulinum toxinA (Xeomin) , a neurotoxin Which is approved for use by the FDA for certain conditions. This study has a double blind cross over design. Cross over means that you will have two sets of injections. If the first set of injections is Xeomin, the second injections after a three month interval will be the inactive placebo. Double blind means neither the investigators nor the subject knows which one of the two (Xeomin or placebo) is received with the first or second injections.
224319372|NCT01931878|DRUG|Placebo|The subject may be randomly assigned to receive Placebo which is an inactive test substance which has no active ingredient. In this protocol we use sterile salt water as placebo.This study has a double blind cross over design. Cross over means that you will have two sets of injections. If the first set of injections is placebo, the second injections after a three month interval will be active study drug. Double blind means neither the investigators nor the subject knows which one of the two (Xeomin or placebo) is received with the first or second injections.
223640584|NCT04588571|PROCEDURE|Endovascular recanalization with angioplasty and stenting with the biomimetic interwoven nitinol stent|"Under local anesthesia, a standard endovascular approach is performed and the affected arterial segment is visualized. Transluminal or subintimal recanalization of the occluded arterial segment is performed with a hydrophilic guidewire. Next, balloon angioplasty of the recanalized segment is performed. After control angiography, a biomimetic interwoven nitinol stent is placed throughout the lesion.~Drug therapy includes pre-procedure aspirin (160-300 mg/day), starting at least one day before, and intra-procedure heparin (100 U / kg body weight intravenously). After the procedure, all patients have prescribed aspirin (100 mg per day) for a long time and clopidogrel (75 mg per day) for 3 months."
223640585|NCT04588571|PROCEDURE|Femoropopliteal proximal bypass|"Under general anesthesia, 2 standard open surgical approaches are performed: first - to the common femoral artery, superficial femoral artery, and deep femoral artery; the second - to the first portion of the popliteal artery. After systemic heparinization, clamps are applied to the arteries. A longitudinal arteriotomy of the popliteal artery is performed, and a distal end-to-side anastomosis is formed between the artery and the shunt. Next, the shunt is passed into the groin wound. Longitudinal arteriotomy of the common femoral artery. A proximal end-to-side anastomosis is formed between the shunt and the common femoral artery. Surgical hemostasis wound drainage and layer-by-layer wound closure are performed.~Drug therapy includes pre-procedure aspirin (160-300 mg/day), starting at least one day before, and intra-procedure heparin (100 U / kg body weight intravenously). After the procedure, all patients have prescribed aspirin (75-100 mg per day) for a long time."
223640586|NCT02795702|DEVICE|tDCS|Transcranial direct current stimulation
223640587|NCT02795702|BEHAVIORAL|training|Cognitive training
223640588|NCT00767364|BIOLOGICAL|Oral, live, pentavalent rotavirus vaccine; RotaTeq(R)|Oral vaccine for prevention of rotavirus infection, 3 dose series
223640589|NCT05201313|DRUG|Lidocaine Hydrochloride|nebulization of 3 puffs of 10 mL Lidocaine hydrochloride 10% spray at a distance of 4-5 cm
223640590|NCT05201313|DRUG|Mepivacaine Injection|subcutaneous / submucosal infiltration depending on the type of perineal tear of 10 ml of 1% mepivacaine hydrochloride
223640591|NCT03429270|DEVICE|TDOC 5Fr|A Pivotal Study to Assess the Performance, Safety and Usability of a New 5 French Air-Charged Catheter for Performing Urodynamic Studies on Pediatric Subjects
223640592|NCT01035125|BEHAVIORAL|Self-management program|Participants will receive a one week inpatient self-management program
223640593|NCT00571493|DRUG|Bortezomib|Patients will receive bortezomib in four dose cohorts ( .8. 1.0, 1.3, 1.5 mg/m²). Patients will receive bortezomib on days -11, -8, -5, and -2 before infusion of autologous stem cells.
223640594|NCT00571493|DRUG|BEAM (carmustine (BCNU), etoposide, cytarabine, melphalan)|"All study patients will receive BEAM per the standard institution protocol:~BCNU (carmustine): 300 mg/m²on day -5 etoposide 100 mg/m² twice daily on days -5, -4, -3, and -2 cytarabine 100 mg/m² twice daily on days -5, -4, -3, -2 melphalan: 140 mg/m² on day -1 before infusion of autologous stem cells."
223640595|NCT04035148|DIAGNOSTIC_TEST|Cardiopulmonary exercise test|we prepared incremental treadmill exercise protocol in which the work rate increased at one-minute intervals.Transthoracic Echocardiography(TTE) : The first step non-invasive method to diagnose PHT.
223640596|NCT01249261|DRUG|Risedronate|5 mg/day
223640597|NCT01249261|DRUG|Placebo/Risedronate|placebo years 1-5 followed by 5 mg risedronate years 6 \& 7 and no drug year 8
223640598|NCT04098718|DRUG|Benralizumab|100mg sub cut once only
223640599|NCT04098718|DRUG|Prednisolone|30mg tablet daily for 5 days
223640600|NCT06462456|DEVICE|Verofilcon A spherical soft contact lenses|Silicone hydrogel contact lenses prescribed for single use, daily disposable wear (less than 24 hours while awake) for the correction of ametropia (myopia or hyperopia)
223640601|NCT06462456|DEVICE|Verofilcon A toric soft contact lenses|Silicone hydrogel contact lenses prescribed for single use, daily disposable wear (less than 24 hours while awake) for the correction of ametropia (myopia or hyperopia) with astigmatism
223640602|NCT00002013|DRUG|Zidovudine|
223640603|NCT00002013|DRUG|AS-101|
223640604|NCT02964143|DEVICE|Cellular Matrix / A-CP HA|Treatment with 2 injections of Cellular Matrix / A-CP HA Kit, administered 2 months apart; Cellular Matrix / A-CP HA Kit is designed for the safe, rapid and extemporaneous preparation of a cellular matrix of autologous PRP combined with HA. The Cellular Matrix / A-CP HA Kit is a single-use medical device including hematology tubes (A-CP HA tube), designed for blood collection and PRP/HA preparation after 5 min centrifugation. This tube contains a non-crosslinked hyaluronic acid (MW 1550 kDa) solution, a gel acting as a cell separator, and a sodium citrate acting as an anticoagulant. During centrifugation, the separator gel moves to form a barrier that separates red blood cells from other blood components. The HA, which migrates to the top of the gradient during centrifugation, can be mixed with PRP in order to give rise to a ready-to-use PRP/HA preparation.
223640605|NCT02964143|DEVICE|Ostenil® Plus|Treatment with 2 injections of Ostenil® Plus, administered one week apart; Ostenil® Plus is a solution of sodium hyaluronate obtained by fermentation, containing 0.5% mannitol, a free radical scavenger, which helps to stabilize the chains of sodium hyaluronate. The product is intended to be used for pain and restricted mobility in degenerative and traumatic changes of the knee joint.
223640606|NCT02964143|DEVICE|RegenKit-BCT-1|Treatment with 2 injections of RegenKit-BCT-1, administered 1 month apart; RegenKit-BCT-1 is designed for the safe, rapid and extemporaneous preparation of autologous platelet-rich plasma. RegenKit-BCT-1 is a single-use medical device including an hematology tube (Regen BCT tube), designed for blood collection and PRP preparation after 5 min centrifugation, and all necessary material for venipuncture and PRP injection. The Regen BCT tube contains a gel acting as a cell separator and a sodium citrate acting as an anticoagulant. During centrifugation, the separator gel moves to form a barrier that separates red blood cells from other blood components.
223640607|NCT01686399|BEHAVIORAL|Nutritional and Activity Promotion|Multi disciplinary nutritional and behavioral messages to improve diet and activity levels
224228683|NCT03417349|DEVICE|Sofia|The SOFIA™/ SOFIA™ PLUS Catheter will be used in removal/aspiration of emboli and thrombi following the CE marked Instructions For Use. Enrollment into the study does not change the routine care at the site provided to the patient requiring mechanical thrombectomy treatment.
223640608|NCT04347876|DIAGNOSTIC_TEST|Tuberculin test|Test the delayed hypersensitivity reaction and immunity to previous BCG vaccination
223640609|NCT03487237|BIOLOGICAL|Ddimer testing|Included patients will undergo a formal work up for pulmonary embolism: Ddimer testing, followed if positive by a computed tomography pulmonary angiogram or V/Q scan.
224228684|NCT04951128|DRUG|Tranexamic acid injection|Tranexamic acid (100 mg/mL concentration; 0.5 mL) will be added to local anesthetic mixture of 2% lidocaine with epinephrine (2.25 mL) and 0.5% bupivacaine with epinephrine (2.25mL).
224228685|NCT04951128|OTHER|Local anesthetic control|Local anesthetic mixture without tranexamic acid consisting of 2% lidocaine with epinephrine (2.5 mL) and 0.5% bupivacaine with epinephrine (2.5 mL).
224228686|NCT05349903|OTHER|Rice flour|Rice flour made into rice porridge will be tested for postprandial glycemic response, gut hormone levels, gastric emptying rate, appetitive response, and fermentability.
224228687|NCT05349903|OTHER|Alternanoligosaccharide 15|Alternanoligosaccharide 15 incorporated into rice porridge will be tested for postprandial glycemic response, gut hormone levels, gastric emptying rate, appetitive response, and fermentability.
224228688|NCT05349903|OTHER|Inulin|Inulin incorporated into rice porridge will be tested for postprandial glycemic response, gut hormone levels, gastric emptying rate, appetitive response, and fermentability.
224228689|NCT05349903|OTHER|Waxy potato starch|Retrograded waxy potato starch made into porridge meal will be tested for postprandial glycemic response, gut hormone levels, gastric emptying rate, appetitive response, and fermentability.
224228690|NCT05349903|OTHER|Waxy potato starch + epigallocatechin gallate (EGCG)|A combination of retrograded waxy potato starch and EGCG made into porridge meal will be tested for postprandial glycemic response, gut hormone levels, gastric emptying rate, appetitive response, and fermentability.
224228691|NCT05349903|OTHER|Chickpea flour + epigallocatechin gallate (EGCG)|A combination of chickpea flour and EGCG made into porridge meal will be tested for postprandial glycemic response, gut hormone levels, gastric emptying rate, appetitive response, and fermentability.
224228692|NCT00649025|DRUG|FlutiForm 250/10|SKP FlutiForm 250/10ug is a HFA pMDI that delivers 125ug of Fluticasone propionate per actuation and 5ug of Formoterol fumarate per actuation. Patients will take 2 actuations BID for 12 weeks.
224228693|NCT00649025|DRUG|SKP-Fluticasone|SKP Fluticasone 250 ug is a HFA pMDI that delivers 125ug of Fluticasone propionate per actuation. Patients will take 2 actuations BID for 12 weeks.
224319373|NCT02806115|PROCEDURE|acetic acid-enhanced endoscopy|Acetic acid-enhanced endoscopy combines conventional endoscopy with the instillation of acetic acid.
224319374|NCT02806115|DRUG|Acetic Acid|The concentration of acetic acid used in this study is 1.5%.
224228694|NCT00649025|DRUG|Flovent Fluticasone HFA|Flovent 250 ug HFA is a pMDI that delivers after priming 125ug of Fluticasone propionate per actuation. Patients will take 2 actuations BID for 12 weeks.
224228695|NCT03544320|DEVICE|Activity Monitoring-Wrist worn wearable|Participants wear an activity monitor on their wrist.
224228696|NCT03544320|DEVICE|Activity Monitoring-Waist-worn wearable|Participants wear an activity monitor on their waist.
224228697|NCT02924857|DEVICE|Chocolate Touch|The Chocolate Touch™ Paclitaxel Coated Balloon Catheter is indicated for balloon dilatation, after appropriate vessel preparation as needed, of lesions in native superficial femoral or popliteal arteries up to 18 cm in length that are appropriate for angioplasty with balloon diameters from 3.5 mm to 6.0mm.
224228698|NCT02924857|DEVICE|Lutonix Drug Coated Balloon|The Lutonix® 035 Drug Coated Balloon Catheter is indicated for improving luminal diameter for the treatment of obstructive de novo or non-stented restenotic lesions (≤ 18 cm in length) in native femoropopliteal arteries having reference vessel diameters of 4 mm to 6 mm.
224228699|NCT04612920|DRUG|Ibuprofen, acetaminophen, oxycodone|The timing of medications is the intervention.
224228700|NCT00108420|DRUG|Prazosin|
224228701|NCT02044471|OTHER|Remote Ischemic Conditioning (using Sphygmomanometer)|"Patients in experimental arm will have validated protocol of Remote Ischemic Conditioning (using Sphygmomanometer): 5 minutes with blood pressure cuff inflated at 200 mmHg, then deflated for 5 minutes; repeated for 3 cycles.~Patient in control group will not perform this."
224228702|NCT00003520|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Stage IV Kidney Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
224228703|NCT06393101|DRUG|BRC-002|BRC-002 is a non-scheduled cannabidiolic (CBD) formulation (\<.3% THC). The cannabinoids in BRC-002 are naturally biosynthesized within the Cannabis sativa L. plant as acidic forms of CBD (cannabidiolic acid; CBDA), THC (tetrahydrocannabinolic acid; THCA) and other minor cannabinoids.
224228704|NCT06393101|DRUG|BRC-002 Placebo|Oral solution of mono-, di-, and triglycerides
224228705|NCT00704418|DRUG|Bromfenac|sterile ophthalmic solution
224228706|NCT00704418|DRUG|Placebo|sterile ophthalmic solution
224228707|NCT00757913|DIETARY_SUPPLEMENT|n-3 enriched nutrition|
224228708|NCT02322879|DRUG|First Treatment Period|(duration: 14 days) Subjects will be randomized to receive either of the 2 interventions (4 grams of solid acetaminophen formulation for two weeks vs. 4 grams of solid acetaminophen formulation + 70 mg/kg/day of liquid propylene glycol)
224228709|NCT02322879|OTHER|Washout|(duration: 14 days) At the end of the First intervention period all participants will enter a washout period.
224228710|NCT02322879|DRUG|Second Treatment Period|(duration: 14 days) At the end of the washout period, participants will receive the alternative intervention.
224319375|NCT02806115|DEVICE|endoscope|This study using an EG-29-i10 endoscope (Pentax, Tokyo, Japan) and an EPK-i7010 processor (Pentax, Tokyo, Japan).
224319376|NCT01157988|DRUG|ibritumomab tiuxetan (Zevalin)|During Zevalin treatment, rituximab 250 mg/m2 will be administered with the same methods mentioned above on days 1 and 8. On day 8, within 4 hours following completion of the rituximab dose, 90Y Zevalin at a dose of 0.4 mCi/kg actual body weight for patients with a platelet count \> 150,000/L and 0.3 mCi/kg actual body weight for patients with a platelet count of 100,000 - 149,000/L will be injected intravenously over a period of 10 minutes. The maximum allowable dose of 90Y Zevalin is 32 mCi regardless of the patient's body weight. 90Y Zevalin should be administered within 4 hours after radiolabeling of Zevalin with 90Y.
224319377|NCT01662401|DRUG|Bupivacaine|The volume of 0.25% Bupivacaine at 0.075 ml/kg without epinephrine is a maximum of 3 ml for rectus sheath blocks and 4 ml for ilioinguinal blocks adding up to a total maximum dose of 14 ml.
223640610|NCT03060096|OTHER|Severe Anxiety/depression: High Intensity Stepped Care|The stepped-care Telehealth high intensity intervention is tailored to participants with severe anxiety and depression. Ppts randomized to this group will have 12 weekly psychotherapy sessions delivered by phone with a licensed therapist. Participants will also receive a CBT (cognitive behavioral therapy) workbook including daily exercises to supplement understanding.
223640611|NCT03060096|OTHER|Moderate Anxiety/depression: Low Intensity Stepped care|The stepped care Telehealth low intensity intervention is tailored to participants with moderate anxiety and depression. Ppts randomized to this group will receive a self-guided CBT workbook and biweekly (every 2 weeks) check-in calls from a research staff person to assess changes in symptom severity and need for treatment/support.
224228711|NCT02506647|DRUG|Gan & Lee insulin glargine followed by Lantus|0.4 IU/kg Gan \& Lee insulin glargine injection SC, Lantus 0.4 IU/kg injection SC
224228712|NCT02506647|DRUG|Lantus followed by Gan & Lee insulin glargine|Lantus 0.4 IU/kg injection SC, 0.4 IU/kg Gan \& Lee insulin glargine injection SC,
224228713|NCT02015091|BIOLOGICAL|PfSPZ Vaccine|The PfSPZ Vaccine is composed of radiation-attenuated Plasmodium falciparum sporozoites (PfSPZ) and is designed to prevent malaria in adults, children, and infants. It is formulated in phosphate buffered saline (PBS) with 1% human serum albumin (HSA). Sanaria Incorporated (Sanaria), Rockville, Maryland, developed and produced the PfSPZ Vaccine.
224228714|NCT02585882|OTHER|Fluoride table salt|
224319378|NCT01662401|DRUG|Bupivacaine|The volume of 0.25% Bupivacaine at 0.075 ml/kg without epinephrine is a maximum of 14 ml.
224228715|NCT02295774|PROCEDURE|standard white light colonoscopy-equivalent to placebo|standard white light colonoscopy
224228716|NCT02295774|DRUG|Methylene Blue MMX tablets|8x25mg methylene blue MMX tablets administered before a colonoscopy
224228717|NCT02103088|BEHAVIORAL|Sexual and urological intervention|Sexual and urological intervention consisting of: i) DVD instruction in pelvic floor muscle training ii) group instructions in pelvic floor muscle training by physiotherapist including three individually follow-up and ii) up to six couple sessions performed by a sexual nurse counselor.
224228718|NCT02352883|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
224228719|NCT02352883|PROCEDURE|Therapeutic Conventional Surgery|Undergo mastectomy
224228720|NCT02352883|PROCEDURE|Therapeutic Surgical Procedure|Undergo wide local excision
224228721|NCT02352883|RADIATION|Radiation Therapy|Undergo radiation therapy
224228722|NCT02352883|DRUG|Endocrine Therapy|Undergo endocrine therapy
224228723|NCT02352883|OTHER|Quality-of-Life Assessment|Ancillary studies
224228724|NCT02352883|OTHER|Laboratory Biomarker Analysis|Correlative studies
224228725|NCT02352883|OTHER|Cytology Specimen Collection Procedure|Correlative studies
224228726|NCT03845309|BEHAVIORAL|Self-Care Behavior|Limitations on liquid and sodium intake will be established in accordance with the NYHA functional classification, and patients will be provided with dietary assessments and nutrition advice according to personal characteristics such as age, physical activity level, and comorbidities. Additionally, suggestions on lifestyle changes were provided by referring to the advice for patients with heart failure from the American Heart Association.
224228727|NCT06456203|DIAGNOSTIC_TEST|AI|Artificial intelligence triage and reporting system
223640612|NCT03060096|OTHER|Enhanced Usual Care Control|"Participants with moderate to severe anxiety/depression that are randomized to Enhanced Usual Care Control (EUC) will receive information about referrals/resources in their local area (support groups, mental health providers), NCI materials (Facing Forward: Life after Cancer Treatment, self-help workbooks, copy of the CBT (cognitive behavioral therapy) workbook on completion of the study."
223640613|NCT00482053|PROCEDURE|Autologous hematopoietic stem cell transplantation (auto-HSCT)|Auto-HCT involves an intravenous infusion of a participant's previously collected and frozen white blood cells collected after treatment with mobilizing agents
224228728|NCT04485052|DRUG|IBI188|anti-CD47 Monoclonal antibody
224228729|NCT04485052|DRUG|Azacitidine|Demethylation drugs
224228730|NCT04485052|DRUG|Decitabine|Demethylation drugs
224228731|NCT01673009|DRUG|Gleevec|Gleevec® will be dosed orally 440 mg/m\^2/day (max 800 mg/day) for pediatric subjects and 800 mg/day for adult patients.
224228732|NCT05670054|DRUG|comparing both arms as regard the objective response rate, toxicity profile, quality of life, progression free survival|comparing both arms as regard the objective response rate, toxicity profile, quality of life, progression free survival
223640614|NCT00482053|PROCEDURE|Allogeneic hematopoietic stem cell transplantation (allo-HSCT)|Allo-HCT involves an intravenous infusion of a donor's white blood cells collected after treatment with mobilization with filgrastim (G-CSF)
224228733|NCT01349439|DRUG|Propranolol|1mg per Kg (participant weight)
224228734|NCT01349439|DRUG|Short acting + long acting propranolol + memory reactivation|After completing the double-blind phase of the study, participants will receive short acting propranolol 1mg/kg (patient weight) + long acting propranolol (1 or 1.5 mg/kg) followed by memory reactivation. Dose level for the long-acting propranolol will be randomly assigned across participants.
223640615|NCT00482053|PROCEDURE|Total lymphoid irradiation (TLI)|TLI is administered in 80cGy fractions on Days -11 to Day-7 relative to allo-HSCT
223640616|NCT00482053|DRUG|Rituximab|375 mg/m2 IV days 1 and 7 over 4 to 8 hours
223640617|NCT00482053|DRUG|Carmustine|"Based on body weight, unless its more than 15 kg greater than the idal body 15mg/kg (max dose 550 mg/m2) day -6 over 2 hours.~Males IBW = 50 kg + 2.3 kg/inch over 5 feet Females IBW = 45.5 kg + 2.3 kg/inch over 5 feet Adjusted IBW = IBW + 50% (actual weight - IBW)"
223640618|NCT00482053|DRUG|Etoposide|60 mg/kg over 4 hours day -4 and alternatively VP-16 2 Gm/m² may be used (for mobilization)
223640619|NCT00482053|DRUG|Filgrastim|10 µg/kg/day subcutaneous starting Day 9 until last day of apheresis. 5 ug/kg actual body weight per day will be started at Day +6 after allo-HCT until hematologic recovery
223640620|NCT00482053|DRUG|Anti-thymocyte globulin (ATG)|1.5 mg/kg/day for 5 days
223640621|NCT00482053|DRUG|Cyclosporine|5.0 mg/kg twice daily from day -3 until after day +56
223640622|NCT00482053|DRUG|Mycophenolate mofetil (MMF)|"250 mg (total) twice daily, oral~15 mg/kg po on day 0, at 5-10 hours after mobilized PBPC infusion is complete. On day +1 MMF is taken at 15 mg/kg po b.i.d. (30 mg/kg/day) if transplantation was using a matched related donor and 15 mg/kg po t.i.d if from a matched unrelated donor or a one antigen mismatched donor."
223640623|NCT00482053|DRUG|Cyclophosphamide|100 mg/kg will be administered over 2 hours on day -2
224228735|NCT02324972|DRUG|AQX-1125|Synthetic SHIP1 activator
224228736|NCT02324972|DRUG|Placebo|
224228737|NCT02623959|BEHAVIORAL|Questionnaires|Symptom and quality of life questionnaires completed at baseline and at 10 - 14 days after receiving Saline or Doxycycline.
224228738|NCT02623959|DRUG|Fentanyl Patch|Participant given a Fentanyl patch, 12 mcg/hour, which should be worn at follow up visit 5 days after IPC placement.
223640624|NCT00482053|DRUG|Acetaminophen|Pre-medication for rituximab and PBPC infusion. Administered at 650 mg by mouth 1 hour prior to infusion
223640625|NCT00482053|DRUG|Diphenhydramine|Pre-medication for rituximab and PBPC infusion. Administered at 50 mg intravenous 1 hour prior to infusion
223640626|NCT00482053|DRUG|Hydrocortisone|Pre-medication for the PBPC infusion. Administered at 100 mg intravenous 1 hour prior to infusion
223640627|NCT00482053|DRUG|Methylprednisolone|Anti-reaction medication for the ATG infusion. Administered at 1 mg/kg, Day-11 to Day-7
223640628|NCT00470886|DRUG|Telmisartan (Kinzal/Pritor, BAY68-9291)|Primary care clinic hypertensive patients for whom physician decided to start the treatment with telmisartan
223640629|NCT03114683|DRUG|PD1|IBI308 200mg/3 weeks
224228739|NCT02623959|DRUG|Fentanyl (IV)|Fentanyl 50 mcg given by vein prior to catheter draining.
224228740|NCT02623959|OTHER|Saline|Catheter is drained then Saline placed in the catheter. Catheter is capped for 1 hour and then drained again.
223640630|NCT05380180|OTHER|OneClick Social Engagement Intervention|Intervention group participants will receive the social engagement OneClick intervention for 8 weeks, and will complete a mid-assessment at week 4, and a post-assessment at week 8. Participants will use a computer or tablet to participate in two social engagement events per week. The intervention events will be delivered through the OneClick video conferencing platform. During each session participants will watch a short slideshow around a series of topics (e.g., nature, technology, hobbies) and get to engage in conversations surround the topics presented, which will be held in breakout rooms. Breakout room discussions will be set for 30 minutes, and participants will be provided with questions surrounding the topics to help stimulate conversation.
224228741|NCT02623959|DRUG|Doxycycline|Catheter is drained then Doxycycline 500 mg placed in the catheter. Catheter is capped for 1 hour and then drained again.
224228742|NCT02623959|BEHAVIORAL|Phone Calls|After the IPC is removed, participant is called one time each month by study staff to check on their status.
224228743|NCT02337933|DRUG|Ursolic acid|Ursolic acid capsules of 150 mg extracted from rosemary, once a day before breakfast
224228744|NCT02337933|DRUG|Placebo|Calcined magnesia capsules of 150 mg, once a day before breakfast
224228745|NCT05861726|BEHAVIORAL|Aerobic exercise|a moderate kind of physical activity with a heart rate between 65 \& 70% maximum heart rate
224228746|NCT05861726|OTHER|None (control group)|None (the control group)
224228747|NCT05896631|OTHER|7.5 mg hyperbaric bupivacaine|Spinal anesthesia with 7.5 mg hyperbaric bupivacaine after preoperative peng (pericapsular nerve group) block
224228748|NCT05896631|OTHER|5 mg hyperbaric bupivacaine|Spinal anesthesia with 5 mg hyperbaric bupivacaine after preoperative peng (pericapsular nerve group) block
224228749|NCT04318665|DIAGNOSTIC_TEST|CT Perfusion|Severe Traumatic Brain Injury patients will be undergoing CT perfusion test
224228750|NCT06020885|RADIATION|Split-course hypo-CCRT|"Split-course hypo-CCRT is administered at the following three dose levels:~* Level 1: DT 3000cGy/10 daily fractions/300cGy in the first course, DT 2000cGy/10 daily fractions/200cGy in the second course;~* Level 2: DT 2800cGy/7 daily fractions/400cGy in the first course, DT 2200cGy/10 daily fractions/220cGy in the second course;~* Level 3: DT 2500cGy/5 daily fractions/500cGy in the first course, DT 2500cGy10 daily fractions/250cGy in the second course."
223640631|NCT05380180|OTHER|OneClick Social Engagement Intervention Extension|Waitlist control group participants will receive no intervention for the first 8 weeks and will complete assessments at week 4 and week 8. Following the completion of the 8-week controlled portion, waitlist participants will be provided with the opportunity to participate in the OneClick social engagement intervention through the intervention extension. Waitlist participants will use a computer or tablet to participate in two social engagement events per week. The intervention events will be delivered through the OneClick video conferencing platform over the span of 8 weeks. Intervention effects will be measured at week 4 and week 8 of the intervention extension.
223640632|NCT01940796|DRUG|Brentuximab Vedotin|Up to five dose levels will be tested in cohorts of 3-6 participants each. Once the maximum tolerated dose (MTD) is established, 10 more participants will be treated at the MTD for analysis of efficacy.
223640633|NCT04497259|OTHER|Teleevaluation|Patients will answer to a questionnaire filled through a chatbot link
223640634|NCT04497259|OTHER|Teleconsultation|A teleconsultation (skype-like connection) at 6 and 9 months after surgery
223640635|NCT04497259|OTHER|Classical consultation|Patients in the consultation arm will benefit from a classical face to face consultation at 6 and 9 months after surgery.
223640636|NCT04043052|OTHER|Psychological evaluation|Psychological evaluation including: MINI (current diagnosis) ; HDRS ; MDQ ; GAD-7 ; PC-PTSD-5 ; Quality of Sleep (item 6 of the Pittsburgh Sleep Quality Index) ; CES-D ; BAI ; RRS-short form ; IES-R ; mYFAS2.0;
224228751|NCT06020885|DRUG|Induction chemo-immunotherapy|All patients receive 2-3 cycles of Abraxane 260mg/m2 d1+cisplatin 60mg/m2 d1+Toripalimab 240mg d1.
224228752|NCT06020885|DRUG|Concurrent chemotherapy|Concurrent capecitabine was administered orally at 1000mg/m2 twice daily within half an hour after meals concurrently with radiotherapy.
224228753|NCT02910609|DEVICE|Echocardiography|Echocardiography is a kind of ultrasound test that shows the inner structure and functions of the heart in both groups.
224228754|NCT00455052|DRUG|XMT-1001|XMT-1001 is administered as an IV infusion once every 21 days. This expansion of the Phase 1 study is to confirm the MTD.
224228755|NCT02551289|OTHER|Gluten free diet|Patients will follow a gluten free diet
224228756|NCT03106870|DRUG|Insulin Mixtard|"Insulin dose:~* 0.7 IU/Kg (at the second trimester of pregnancy).~* 0.8 IU/Kg (at the third trimester of pregnancy). Insulin dose was raised at a rate of 1 IU for every 10 mg/dl higher than the target blood glucose concentration."
224228757|NCT03106870|DRUG|Metformin|"Oral metformin at a dose of 1500 mg divided into three doses, were taken with meals, in addition to insulin.~If the target blood glucose concentrations were not attained, the dose of metformin was raised to 2000 mg per day."
224228758|NCT00533403|DRUG|MK0686|
224228759|NCT01632787|OTHER|Questionnaires and Optometrist Prism Challenge/Treatment|A Vertical Heterophoria Symptom Questionnaire (VHSQ) as well as Headache Disability Index (HDI) survey is used on all Emergency Department (ED) headache patients to assess medical history and symptom burden. Prism testing (or Prism Challenge) is performed by the study optometrist to identify those who have Vertical Heterophoria (VH). Prism Challenge is similar to prescription eyeglass testing, but with unique lenses that are meant to reduce strain on eyes that are misaligned. Follow-up questionnaires are then administered to assess any improvement in symptom burden.
224228760|NCT01617577|DRUG|G-CSF; filgrastim|The drug is administered s.c. at a dose of 10 microg/kg daily for 5 days
224228761|NCT01617577|DRUG|Placebo|vehicle (D5W or 5% dextrose solution) is administered subcutaneously daily for 5 days
224228762|NCT03936400|BEHAVIORAL|Couple-based intervention and and evaluation of effectiveness in increasing adjustment of sexuality and intimacy|Three face-to-face therapeutic conversations and an optional web-based evidence based information (about sexual consequences of cancer treatment)
224228763|NCT02287532|DEVICE|DIABEO software|DIABEO is an electronic diary system incorporating an immediate automatic aid to calculating the insulin dose according to the prescription given by the doctor, and a data processing, automated analysis message and secure internet data transfer system. DIABEO software could be combined with remote paramedical monitoring of data (telemonitoring)
224228764|NCT02605109|OTHER|Risk of MERS infection|HCPs, patients and layperson to closely or indirectly contact a case-patients
224228765|NCT02563509|BIOLOGICAL|HIV-specific CD8 cells|Based on HAART, receive HIV-specific CD8 cells transfuion.
224228766|NCT06125613|BEHAVIORAL|Experimental|"In reality, there will not be 200 trials but 40, and no painful stimulus will be delivered. The objective is only to make the subject afraid of making a movement when the red stimulus appears, and for us to compare the situation afraid to move to that where there is no reason to be afraid in terms of corticocortical influences. The subject will then be invited, during the second experimental series, to perform the movements previously described. Whether the preparatory signal for movement is red or green, it will be followed with a delay of 500ms by a test stimulus alone (ST) or by a doublet of SC+ST stimulation. This stimulation will therefore occur during the motor programming period during which it has been shown in the literature that the pIPS exerts a facilitatory action on the primary motor cortex at a latency of 4 ms. In total, 10 ST and 10 SC-ST doublets will be delivered during the experimental series for each of the two colors, i.e. 40 stimulations in total."
224319379|NCT06579235|DIAGNOSTIC_TEST|Proteomics|All samples of cases (with LNB) and controls (without LNB) will undergo proteomic analyses.
223640637|NCT04043052|OTHER|Functional evaluation|Functional evaluation including : EQ5-D ; MFI ; LUNS ; SSQ ; Physical activity (IPAQ)
223640638|NCT04043052|BIOLOGICAL|Biological assessment|Biological assessment : White and red blood cells count ; platelets count ; Haemoglobin ; CRPus ; Glycaemia ; Plasmatic HbA1c ; Plasmatic LDLc ; HDLc and triglyceride ; Creatinin clearance, Transaminases.
224228767|NCT04226911|BEHAVIORAL|S&SEs|"S\&SEs:~As many sugar-containing products in the diet as possible should be replaced with S\&SE-containing products.~To ensure that a certain amount of S\&SE products is consumed every day, a fixed minimum amount of units for each individual is planned."
224228768|NCT04226911|BEHAVIORAL|Sugar|"Sugar group:~In the sugar group it is allowed to consume up to a certain number of units of sugar-containing products each day, corresponding to \< 10 E% added sugar.~The sugar group is not allowed to consume any S\&SE products."
224228769|NCT02243956|OTHER|Flavanol rich food product|polyphenol rich test product
224228770|NCT03060005|DRUG|Tears Naturale Forte|This medication is used to relieve dry, irritated eyes
223640639|NCT04043052|OTHER|Ecological Momentary Assessment|During 3 months after inclusion, a 3 to 5 minutes daily interview will administer questions concerning mood symptoms, activities, stress experience, substance use, social relationships and medication intake, activities, social interaction, environmental conditions, experience of depressed mood, anhedonia, changes in weight, appetite, sleep, fatigue, feelings of worthlessness or inappropriate guilt, concentration or decision-making difficulty
223640640|NCT03271086|BEHAVIORAL|The StressEraser|The StressEraser is a handheld biofeedback device that measures heart rate variability (HRV). Heart rate increases during inspiration and decreases during expiration. The HRV, depicted on a miniature screen, essentially represents respirations. The investigator's prior study demonstrated that the device is easily mastered and acceptable to children above 6 years of age.
223640641|NCT03271086|BEHAVIORAL|Breathe2Relax|Breathe2Relax is a free mobile app, developed by the Dept. of Defense's National Center for Telehealth and Technology to help veterans with PTSD and others use breathing practice for stress management. This application guides users in relaxation breathing and is available for both android and iOS phones. It is adapted for children 6 years and up. For instance, the cycles can be shortened for children, there is a selection of quiet music and the user can choose backgrounds for personalization.
223640642|NCT03271086|BEHAVIORAL|Reminder text messages|Weekly texts will be sent out to parents in the technology-enhanced relaxation breathing group to as reminders to practice the daily relaxation breathing with their child.
223640643|NCT02415608|DRUG|Ibrutinib|Given orally in 28-day cycles
223640644|NCT02871934|GENETIC|SLCO1B1 Genotype|Polymerase chain reaction (PCR) assay for SLCO1B1 rs4149056, with possible results T/T, T/C, or C/C.
223640645|NCT01055197|RADIATION|Prophylactic Cranial Irradiation|Prophylactic Cranial Irradiation (PCI) to the brain in ten once-daily fractions of 2.5 Gy, five days per week, for a total of 25 Gy.
223640646|NCT01055197|RADIATION|Radiation Therapy|Radiation Therapy (RT) to locoregional and residual metastatic disease in 15 once daily fractions of 3.0 Gy, 5 days per week, for a total of 45 Gy
223640647|NCT02342028|BIOLOGICAL|OSA|This study aims to compare the difference in the number and function of regulatory T cells between OSA patients and controls. The investigators will draw peripheral venous blood samples from both groups and measure the number and function of their regulatory T cells. However, some, NOT ALL, of OSA patients may receive continuous positive airway pressure (CPAP) treatment-the standard therapy for severe-to-moderate OSA. Use of CPAP is based on physician's suggestion and patients' decision, but not for this study. The devices are provided by patients themselves and its type/brand is not limited or prespecified. For those with CPAP therapy, their blood sample will be re-collected 26 weeks later to repeat measurement for subgroup analysis.
223640648|NCT00840112|DIETARY_SUPPLEMENT|Vitamin E supplement|400 IU (268 mg) capsules of will be provided for the subjects. Subjects will be instructed to take one capsule with meals 2 times per day.
223640649|NCT03943654|OTHER|MotoMeds Healthline- illness assessment and treatment recommendation for non-emergent cases by telephone|The healthline uses a series of questions (based off of the WHO Integrated Management of Childhood Illness guidelines) asked to the parent of a sick child over the phone to remotely triage and assess the child's illness and then provide a treatment recommendation. MotoMeds is the accompanying motorcycle delivery service for basic medication delivery at nighttime.
223765175|NCT07146802|BEHAVIORAL|Metacognitive Training (MCT) for psychosis|MCT for psychosis is based on the theoretical foundations of the cognitive-behavioral model of schizophrenia, but it employs a somewhat different therapeutic approach. The program is comprised of ten modules targeting common cognitive errors, problem-solving biases as well as emotional problems in schizophrenia. These errors and biases may, on their own or in combination, culminate in the establishment of false beliefs to the point of delusions. The aim of the sessions is to raise the participants' awareness of these distortions and to prompt them to critically reflect on, expand upon, and change their current repertoire of problem solving. In addition to the sessions, the program includes homework tasks to reinforce the skills learned between sessions.
224228771|NCT03060005|DRUG|liposic|Liposic eye gel contain the active ingredient carbomer, which is a type of medicine known as an eye lubricant. It is used for the treatment of the symptoms of dry eye.
224228772|NCT00774358|DRUG|Interleukin-2|We propose to subcutaneously administer 0.5 MU/m2 of IL-2 daily to WAS subjects for 5 days. Research treatment will be repeated 2 and 4 months later. Inter-patient dose escalation will be employed to 1 MU/m2 and/or 2 MU/m2 based on safety as the primary endpoint.
224228773|NCT05825053|BEHAVIORAL|Gait adaptability training|Over a span of 1 year participants will receive 3 one hour, single sessions at 3, 6 and 9 months following baseline assessment, of gait adaptability training, using the C-mill (an instrumented treadmill with augmented reality). Several aspects of gait adaptability, such as obstacle avoidance, accelerating/decelerating and precision stepping, will be trained.
224228774|NCT05825053|BEHAVIORAL|Home-based exercise training|Participants will receive tailored exercise through an online platform targeting gait adaptability. Participants are instructed to train at a minimum of 60 minutes per week, with a frequency of 2 sessions per week. Participants will be supported through tele-consultations on a monthly basis for the first 3 months and bi-monthly for the remaining time of the study. These consultations are focused on technical support, on ways to ensure training progression and to encourage adherence to the program.
224228775|NCT00384033|DRUG|Desvenlafaxine Succinate Sustained-Release (DVS SR)|50 mg tablet, once daily dosing for 8 weeks
224319380|NCT06551818|OTHER|SesZen-Bio Low Dose 1 (350 mg extract)|"Mode of Usage: Swallow the capsule whole with a full glass of water without chewing, crushing, or opening it.~Dosage form: Capsule Frequency: One time daily after meal Rout of administration: Oral"
224228776|NCT00384033|DRUG|Desvenlafaxine Succinate Sustained-Release (DVS SR)|100 mg tablet, once daily dosing for 8 weeks
224228777|NCT00384033|DRUG|Placebo|Matching placebo tablets and capsules, once daily dosing for 8 weeks
224228778|NCT00384033|DRUG|Duloxetine 60 mg/day|60 mg capsule, once daily dosing for 8 weeks
224228779|NCT00290745|DRUG|letrozole|
224319381|NCT06551818|OTHER|SesZen-Bio Low Dose 1 (150 mg liposomal)|"Mode of Usage: Swallow the capsule whole with a full glass of water without chewing, crushing, or opening it.~Dosage form: Capsule Frequency: One time daily after meal Rout of administration: Oral"
224319382|NCT06551818|OTHER|SesZen-Bio High Dose 1 (500 mg extract)|"Mode of Usage: Swallow the capsule whole with a full glass of water without chewing, crushing, or opening it.~Dosage form: Capsule Frequency: One time daily after meal Rout of administration: Oral"
224319383|NCT06551818|OTHER|Placebo|"Mode of Usage: Swallow the capsule whole with a full glass of water without chewing, crushing, or opening it.~Dosage form: Capsule Frequency: One time daily after meal Rout of administration: Oral"
224319384|NCT04974749|BIOLOGICAL|REPLAGAL|REPLAGAL IV infusion.
224319385|NCT04775303|DRUG|Cyclosporine 0.1% (Ikervis®) eye drop|One drop of Cyclosporine 0.1% (Ikervis®) eye drop once daily for 12 weeks
224319386|NCT05044559|OTHER|Continuous Positive Air Way Group|CPAP between 10 and 12 cmH2O
223640650|NCT00538902|BIOLOGICAL|Placebo|Placebo administered subcutaneously (SC) every other week (eow) for 12 weeks, followed by adalimumab 40 mg SC eow for 92 weeks.
223640651|NCT00538902|BIOLOGICAL|Adalimumab 80 mg|Adalimumab 80 mg administered subcutaneously (SC) every other week (eow) for 12 weeks, followed by adalimumab 40 mg SC eow for 92 weeks.
223640652|NCT00538902|BIOLOGICAL|Adalimumab 40 mg|Adalimumab 40 mg administered subcutaneously every other week for 104 weeks
223640653|NCT00860093|OTHER|placebo|After SWL treatment subjects will be randomized to receive either MPC-5971 or placebo. Two tablets of MPC-5971 or placebo will be taken orally twice a day (bid). This will give a daily dosage equal to 40 mEq of potassium, 20 mEq of magnesium and 60 mEq of citrate. MPC-5971 or placebo will be taken bid for 90 days beginning immediately after SWL treatment.
223640654|NCT00860093|DRUG|MPC-5971|After SWL treatment subjects will be randomized to receive either MPC-5971 or placebo. Two tablets of MPC-5971 or placebo will be taken orally twice a day (bid). This will give a daily dosage equal to 40 mEq of potassium, 20 mEq of magnesium and 60 mEq of citrate. MPC-5971 or placebo will be taken bid for 90 days beginning immediately after SWL treatment.
223640655|NCT05647798|OTHER|Blood sugar check every 2 hours|Blood sugar check every 2 hours
223640656|NCT05647798|OTHER|Blood sugar check every 4 hours|Blood sugar check every 4 hours
223640657|NCT04425109|BEHAVIORAL|meal test response|soy fermented versus non fermented meal test
223640658|NCT03739203|DRUG|Cariprazine|Cariprazine supplied in capsules
223640659|NCT03739203|DRUG|Placebo|Placebo supplied in capsules
223640660|NCT03739203|DRUG|Antidepressant Therapy (ADT)|ADT as prescribed by the physician per standard of care in clinical practice.
223640661|NCT03193957|DRUG|Etanercept|Etanercept PFS and Autoinjector
223640662|NCT03193957|DEVICE|Autoinjector|Autoinjector
223640663|NCT02633098|DRUG|Artesunate 200mg|Artesunate 200mg PO OD for 14 days prior to colorectal resection surgery
223640664|NCT02633098|DRUG|Placebo|Matched placebo PO OD for 14 days prior to colorectal resection surgery
223640665|NCT02724891|OTHER|paper form|questionnaires in paper form
223640666|NCT02724891|OTHER|web/smartphone form|questionnaires in web/smartphone
223640667|NCT04043299|DRUG|100% Oxygen|High flow cylinder oxygen will be administered to women with fetal distress during labor
223640668|NCT04043299|DRUG|21% oxygen|High flow cylinder packaged medical air will be administered to women with fetal distress during labr
224228780|NCT00290745|DRUG|tamoxifen citrate|
224228781|NCT00290745|PROCEDURE|conventional surgery|
224228782|NCT00290745|PROCEDURE|neoadjuvant therapy|
224228783|NCT03381547|BIOLOGICAL|Pegilodecakin|Pegilodecakin Alone
224228784|NCT02887209|BEHAVIORAL|CBT-I|"Cognitive behavioural therapy for insomnia (CBT-I; Edinger \& Carney, 2008) is a standard 4-session cognitive behavioural therapy for insomnia administered biweekly in individual format. The first session involves presenting treatment rationale and introducing a behavioural treatment regimen consisting of a series of sleep habit parameters to follow, and determining a personalized time in bed prescription. The second session involves reviewing past-week sleep diary, discussing the role of cognitions in insomnia, and discussing constructive worrying techniques and the use of thought records. The third and fourth sessions are used to assist in adjusting time in bed prescriptions, to positively reinforce efforts, and to help problem-solve any problems they might have encountered."
224228785|NCT00297271|OTHER|Current treatment practice of each participating physician|Patients will be observed for the evaluation of current management strategies.
224228786|NCT01524042|PROCEDURE|Pants for colonoscopy|We divide the patients into group 1 and group 2. The group 1 wear a conventional single pants and group 2 wear a novel double pants.
224228787|NCT04232397|DRUG|Anlotinib|anlotinib 8mg qd po
224228788|NCT01857193|DRUG|ribociclib (LEE011)|LEE011 is taken orally once per day for 21 days of each 28 day cycle. LEE011 comes in 50 mg and 200 mg capsules.
224228789|NCT01857193|DRUG|Exemestane|Exemestane is taken orally once per day. Exemestane comes in 25 mg tablets.
224228790|NCT01857193|DRUG|Everolimus (RAD001)|Everolimus is taken orally once per day. Everolimus comes in 1 mg, 2.5 mg, 5mg, and 7.5 mg tablets
224228791|NCT03635853|DRUG|drug containing extract from cock's comb|a container containing 25 mg of ointment having extract from cock's comb as active ingredient two times daily for 3 months
224228792|NCT03263481|PROCEDURE|Intraductal secretin test (IDST)|If pancreatic duct entry incidentally occurs during the clinically scheduled ERCP and the pancreatic duct appears normal, an IDST will be performed for study purposes. An IDST consists of the administration of human secretin, after which pancreatic juice is collected intraductally. In this study, the fluid will be collected through continuous aspiration in 5 minute intervals for 30 minutes. Samples will be collected at 5, 10, 15, 20, 25, and 30 minutes after secretin administration (6 collections in total).
223640669|NCT05338346|DRUG|ATG-018|"Dose Escalation Phase:~For both dose escalation groups, subjects will receive a single dose of ATG-018 monotherapy on Cycle 1 Day 1 (C1D1) for single dose PK samples' collection. From the morning dose on Cycle 1 Day 2, twice daily dosing (except Dose Level 1: 5 mg QD) will be initiated. Subject(s) will receive intermittent dosing in a 3 days on/4 days off schedule in 21-day cycles until disease progression or unacceptable toxicity.~Dose Expansion Phase :~Dose Expansion Phase will begin at the defined MTD/RP2D for solid tumors and hematological malignancies groups, to further evaluate the safety, tolerability, and PDx profile of ATG-018. Subjects with solid tumors and hematological malignancies will be enrolled."
223640670|NCT04668755|DEVICE|Charcot Restraint Orthotic Walker 3d printed sole|"The Charcot Restraint Orthotic Walker (CROW) consists of anterior and posterior shells creating a total contact environment based on a rocker sole. the sole is manufactured by 3d printed Metamaterial .~Manufacture of the 3d printed sole of the CROW paths through two stages ;Computer aided designing (CAD) and computer aided manufacturing (CAM) ."
223640671|NCT04668755|DEVICE|Generic Charcot Restraint orthotic walker|It is a clamshell (two piece) design that provides complete/total contact over the shin, calf and foot. The CROW reduces all motion in the ankle and foot to reduce potential for further injury. It is fully padded on the inside, and the bottom is covered with a material similar to shoe soling. It is not worn with a shoe.
223640672|NCT01935206|DRUG|Naloxone (2 mg/kg)|
223640673|NCT01935206|DRUG|Placebo|
223640674|NCT00130572|DRUG|Pimecrolimus|
223640675|NCT02398890|OTHER|routine care|routine care
223640676|NCT02098785|DRUG|Caffeine citrate|Oral solution
223640677|NCT02416336|DEVICE|Sentinella Intraoperative imaging protocol|"There is a holding time of 15-20 minutes after the lymph node is removed during which the node is further dissected, examined and prepared for pathological analysis. This occurs before the procedure is completed in case the surgeon determines that further surgical exploration or tissue removal is required.~In this study, the investigators will use this holding time to collect images of the sentinel lymph node area using the Sentinella camera for this study. Therefore, participation in this study will not increase the subject's overall procedure time. However, if the Sentinella camera detects something that the standard imaging techniques have missed, such as an additional sentinel node, the surgeon will do further exploration and tissue removal as needed."
223640678|NCT01967940|DRUG|TAF|25 mg tablet administered orally once daily with food
223640679|NCT01967940|DRUG|Placebo|Tablets to match TAF administered orally once daily with food
224228793|NCT03361423|DEVICE|Nerivio Migra-1 active device|"The device is placed on the subject upper arm. when activated, stimulus is applied to influence the subject's perception of a painful stimulus, delivered (or originating) at a different location. Based on diffused noxious inhibitory control mechanism, sometimes referred to as pain inhibits pain principle, conditioned pain modulation evokes an endogenous analgesic mechanism. The modulatory effect is over the whole body, and can be induced anywhere in the body. This approach allows applying the conditioning stimuli away from the painful site."
224228794|NCT03361423|DEVICE|Nerivio Migra-1 Sham device|The device is placed on the subject upper arm. when activated, the stimulus is applied is not sufficient to influence the subject's perception of a painful stimulus.
224228795|NCT00464750|DEVICE|Pulmonary artery catheter|Four series of cardiac output measurements, each series consists of eight measurements using cold and eight measurements using tepid injectate. Randomized order of temperature at first series and crossover design.
224228796|NCT03147196|DRUG|Bicalutamide|Given PO
224228797|NCT03147196|OTHER|Laboratory Biomarker Analysis|Correlative studies
224228798|NCT03147196|OTHER|Questionnaire Administration|Ancillary studies
224228799|NCT03147196|DRUG|Raloxifene Hydrochloride|Given PO
224228800|NCT04459195|BEHAVIORAL|2 Minute Static Stretching|Stretching applications will be applied to the first group for 2 minutes. Static stretching exercise will be performed under the supervision of a physiotherapist as 30 seconds of stretching and 30 seconds of rest and and the individuals will be asked to participate in the exercise actively.
224228801|NCT04459195|BEHAVIORAL|5 Minute Static Stretching|Stretching applications will be applied to the first group for 5 minutes. Static stretching exercise will be performed under the supervision of a physiotherapist as 30 seconds of stretching and 30 seconds of rest and and the individuals will be asked to participate in the exercise actively.
223640680|NCT01967940|DRUG|E/C/F/TAF|150/150/200/10 mg STR administered orally once daily with food
223640681|NCT01967940|DRUG|Current failing ARV regimen|Participants will continue taking their current ARV regimen as prescribed in Part 1.
223640682|NCT01967940|DRUG|ATV|300 mg tablet administered orally once daily.
224228802|NCT01336894|PROCEDURE|therapeutic conventional surgery|Undergo surgery
224228803|NCT01336894|RADIATION|iodine I 125|Undergo seed implant radiotherapy
224228804|NCT01336894|RADIATION|stereotactic body radiation therapy|Undergo radiotherapy
224228805|NCT04642573|OTHER|non interventional|non interventional
224228806|NCT03821220|BEHAVIORAL|Motivational Interview support and Dietitian support|Three sessions of a structured motivational support intervention. Each patient will be required to set a SMART physical activity personal objective. The sessions will cover possible barriers and facilitators, enhancing self-efficacy, and feedback. In addition two sessions with a dietitian to discuss ways to improve current health habits.
224228807|NCT03821220|BEHAVIORAL|Activity tracker plus usual care|Each patient will receive their own activity tracker (vivofit 3) with instructions on use, in addition to usual care, and written handouts for pre-diabetic patients.
224228808|NCT03821220|BEHAVIORAL|Personalized physical activity prescription|Each patient will receive a personalized prescription of recommended physical activity including type of activity, duration and frequency.
224228809|NCT01171066|DEVICE|Tasman CPAP system|Participants will trial the Tasman CPAP system for a duration of 1 week in place of their current CPAP system.
224228810|NCT05673668|DEVICE|Endovascular Denervation System (Netrod)|The Netrod system is a percutaneous, catheter- based device which uses radiofrequency energy to denervate the sympathetic nerves surrounding the arteries
224228811|NCT00421096|DRUG|Gemcitabine|125 mg/m² at day 1, 8, 15, 21 and 28, 2 hours before radiotherapy.
224228812|NCT00421096|PROCEDURE|Radiotherapy|"45Gy (5 x 1,8Gy/week) on pelvic area +/- boost (10 to 15Gy)~+/- 45Gy (5 x 1,8Gy/week)on lumbo-aortic area"
224228813|NCT00421096|DRUG|Cisplatin|40 mg/m² at day 1, 8, 15, 21 and J28 before Gemcitabine and with a hyperhydration
223640683|NCT01588730|DEVICE|Ankle Dorsiflexion Dynasplint|Dynamic Splinting utilizes the protocols of Low-Load, Prolonged-Duration Stretch (LLPS) with calibrated, adjustable tension to increase the Total End Range Time (TERT) to reduce contracture. This unit is worn at night while sleeping (6-8 hours) and, this does not affect activities of daily living
224228814|NCT00622908|DRUG|ISV-403|0.6% TID, 5 days
224228815|NCT00622908|DRUG|Vehicle|Vehicle of ISV-403 TID, 5 days
224228816|NCT03937466|DEVICE|Cooling mattress pad|The cooling mattress pad is a commercially available pad designed to be placed between the top of a mattress and bed sheets. It allows for precise temperature regulation in one's bed.
224228817|NCT03658135|DRUG|BIIB092|BIIB092 is an investigational monoclonal antibody directed at tau protein
224228818|NCT03658135|OTHER|Placebo|Inactive ingredient
224228819|NCT01987622|PROCEDURE|Acupuncture|The patients in this group will receive individualized acupuncture prescribed by a certified Korean Medicine Doctor (KMD) with at least three years of clinical experience. The acupuncture formulas will be determined based on the individual patient's symptoms and at the KMD's discretion. The acupuncture treatment will be applied one to three times a week for six weeks (a total of 12 sessions and an additional four sessions are allowed). Acupuncture will be manually stimulated at first, and then electrical stimulation will be allowed at the KMD's discretion. Retention time will be equal to or less than 20 minutes. Examples of acupuncture points to be used might include LI4, LI11, TE5, SI3, TE3, ST36, SP6, SP9, LR3, GB34, Gb39, BL40, BL57, EX-B2, and BL23.
224228820|NCT01987622|PROCEDURE|Usual care|Usual care consists of patient education for a healthier lifestyle, including diet, exercise, self-management of symptoms, and the use of other treatments as needed. Participants will receive a three-page leaflet of patient education material. Optional regular physical therapies, including interferential current therapy (ICT) and local heat application, will be provided only for the control group at the participants' request . Physical therapy will be provided one to three times a week for six weeks (a total of 12 sessions and an additional four sessions are allowed). All kinds of conservative interventions for lumbar spinal stenosis, including analgesics and non-study physical treatments,will be allowed. However, surgical treatments, non-study acupuncture, or herbal medicine will not be allowed.
224228821|NCT06152913|BEHAVIORAL|HANDS-ON treatment|"The HANDS-ON treatment consists of three phases:~Phase I (preparatory phase, 3 weeks) entails motivation for and commitment to treatment (including meaning in life), collaboration with parents and school professionals, setting individual treatment goals, preparing related exposure exercises. Phase II (intensive phase, 4 weeks) contains intensive, therapist-assisted exposure in a child's natural environment. Phase III (consolidation, 2 weeks) consists of continuation of exposure and consolidation. In this phase, there are weekly sessions with the therapist."
224228822|NCT05528458|DRUG|Osimertinib 80Mg Tab|Subjects have a osimertinib (80 mg, orally, once daily) to suppress the progression of remaining GGN(s) in other lobes following surgical resection
224228823|NCT00113490|BIOLOGICAL|motavizumab (MEDI-524)|Patients will receive 15 mg/kg MEDI-524 administered IM every 30 days for a total of 4-5 injections.
224228824|NCT00113490|BIOLOGICAL|palivizumab 15 mg/kg|Patients will receive 15 mg/kg palivizumab administered IM every 30 days for a total of 4-5 injections.
224228825|NCT02310477|DRUG|regorafenib|regorafenib for all groups
224228826|NCT04837053|OTHER|Digital decision aid for physicians and patients|The intervention consists of three parts: (1) the EKIT tool provides a systematic presentation of individual patient and disease-specific information; (2) it visualizes the fulfilment of the indication criteria recommanded in corresponding german guideline; (3) it presents health information about total knee replacement.
224228827|NCT04837053|OTHER|Routine care|Care as usual within the included study sites.
223640684|NCT01588730|PROCEDURE|Commercially Available Static Night splint|A commericially avilable static night splint will be worn for 4-6 hours during rest.
223640685|NCT04706455|DEVICE|sodium hyaluronate 0.1%|Instillation of one drop sodium hyaluronate 0.1%
223640686|NCT04706455|DEVICE|sodium hyaluronate 0.3%|Instillation of one drop sodium hyaluronate 0.3%
223640687|NCT02725918|DRUG|Pemetrexed|500 mg/m2,iv,d1,q3w,until PD
223640688|NCT02725918|DRUG|Cisplatin|75 mg/m2,iv,d1,q3w,×4 cycles
223640689|NCT00232661|DRUG|ARIMIDEX (anastrazole)|
223640690|NCT00232661|DRUG|NOLVADEX (tamoxifen)|
223640691|NCT04046809|OTHER|Food for special medical purposes: Neurotidine®|"Each patient will be given the bottles for the first 3-month treatment period by the hospital pharmacist and will be asked to return them at the end of the period (3 months). Then the patients will be given the other bottles for the next phase of the study (3 months): these will contain placebo if the patient received Neurotidine® in the first phase of the study and vice versa. Again, the patients will be asked to return after 3 months with the study bottles and will be given the last set of bottles for the final phase of the study (3 months).~Administration at a dosage of 10 ml in the morning."
223640692|NCT04046809|OTHER|Placebo|"Each patient will be given the bottles for the first 3-month treatment period by the hospital pharmacist and will be asked to return them at the end of the period (3 months). Then the patients will be given the other bottles for the next phase of the study (3 months): these will contain placebo if the patient received Neurotidine® in the first phase of the study and vice versa. Again, the patients will be asked to return after 3 months with the study bottles and will be given the last set of bottles for the final phase of the study (3 months).~Administration at a dosage of 10 ml in the morning."
223640693|NCT03651570|DEVICE|PTSD Coach|PTSD Coach is a mobile mental health app that addresses the issue of mental health and stigma which can be used as a stand-alone education and symptom management and contains 4 modules: 1) Learn- Module, 2) Self- Assessment-Module, 3) Manage Symptoms-Module and 4) Find Support-Module.
223640694|NCT03651570|BEHAVIORAL|Game application|This control condition is important to control for distraction (attention on something pleasant or a task) and the human factor involved in usage prompting (i.e., same exposure time + contacts with personnel), since either distraction or the human contact with staff may, alone, lower anxiety
223640695|NCT00005080|DRUG|nelarabine|Given IV
223640696|NCT01663103|DRUG|Rilonacept|12 weeks of treatment with rilonacept (subcutaneous injection with a loading dose of 320 mg, followed by 160 mg/wk)
223640697|NCT01663103|DRUG|Placebo|Twelve weeks of treatment with placebo (subcutaneous injection of normal saline with a loading dose of 320 mg, followed by 160 mg/wk)
223640698|NCT05318352|DEVICE|Transcranial Direct Current Stimulation|Transcranial direct current stimulation (tDCS) is a noninvasive brain stimulation technique that modulates cortical activity. tDCS has been conducted to improve wide range of neurological impairments including sleep.
223640699|NCT03517397|BEHAVIORAL|Mobile Contingency Management|Participants will be offered 6 counseling sessions, nicotine replacement therapy, and a smartphone app that remotely verifies participant identity and smoking abstinence and automatically credits a gift card account for evidence of smoking abstinence.
223640700|NCT03659045|OTHER|scale of pain|The measurement is simple, reproducible, performed using a scale of pain rated from 0 to 10 (0 absence of pain, 10 maximum of pain felt)
223640701|NCT04008745|OTHER|Educational and home-based physical therapy by foot-related exercises|The booklet is divided in 2: educational and exercise protocol. The aim of the first part is to guide the individual for a change in his/her health behavior, and comprises info about diabetic neuropathy, foot care, shoes, and benefits of exercising. The second part is the foot protocol, composed by 6 exercises. The maximum duration of a session is 20min and should be performed 3 times/week. The subject should warm-up the foot-ankle and then start exercising in the order suggested by the booklet, filling a table with the effort perceived (effort likert scale). The foot exercises progresses from one set with 30 repetitions in a sitting position, to exercising standing, then performing the exercise on one foot only. Other progression criterion is to increase the number of sets performed. The effort scale regulates the individual effort for his/her progression, which is also registered by the participant in the monthly table at the booklet.
223640702|NCT05098834|DEVICE|ENLIGHT 2100 ventilatory electrical impedance tomograph|The ENLIGHT 2100 system will remain connected to the patient for data acquisition from immediately prior to initiation of the ERT until up to 24 hours following extubation.
223640703|NCT05094206|BIOLOGICAL|0.75x10^6 cells/kg CAR20.19.22 cells|"Dose escalation: CAR20.19.22 cells will be administered at one of three dose levels either fresh or thawed after cryopreservation by IV injection.~Dose expansion: The maximum tolerated dose intervention will be updated when it is determined. It will be one of four doses: 0.75x10\^6 cells/kg, 1x10\^6 cells/kg, 2.5x10\^6 cells/kg or 5x10\^6."
223640704|NCT05094206|BIOLOGICAL|1x10^6 cells/kg CAR20.19.22 cells|"CAR20.19.22 cells will be administered at one of four dose levels either fresh or thawed after cryopreservation by IV injection.~Dose expansion: The maximum tolerated dose intervention will be updated when it is determined. It will be one of four doses: 0.75x10\^6 cells/kg, 1x10\^6 cells/kg, 2.5x10\^6 cells/kg or 5x10\^6."
223640705|NCT05094206|BIOLOGICAL|2.5x10^6 cells/kg CAR20.19.22 cells|"CAR20.19.22 cells will be administered at one of four dose levels either fresh or thawed after cryopreservation by IV injection.~The maximum tolerated dose intervention will be updated when it is determined. It will be one of four doses: 0.75x10\^6 cells/kg, 1x10\^6 cells/kg, 2.5x10\^6 cells/kg or 5x10\^6."
223640706|NCT05094206|BIOLOGICAL|5x10^6 cells/kg CAR20.19.22 cells|"CAR20.19.22 cells will be administered at one of four dose levels either fresh or thawed after cryopreservation by IV injection.~The maximum tolerated dose intervention will be updated when it is determined. It will be one of four doses: 0.75x10\^6 cells/kg, 1x10\^6 cells/kg, 2.5x10\^6 cells/kg or 5x10\^6."
223640707|NCT05094206|BIOLOGICAL|Dose expansion: The maximum tolerated dose of CAR20.19.22 cells|Dose expansion: The maximum tolerated dose intervention will be updated when it is determined. It will be one of four doses: 0.75x10\^6 cells/kg, 1x10\^6 cells/kg, 2.5x10\^6 cells/kg or 5x10\^6 cells/kg.
223640708|NCT06540261|DRUG|ONO-7913|Specified dose on specified days
224228828|NCT01253720|BEHAVIORAL|PACE CALL/Fit4Life|"The Fit4Life E intervention will be designed to promote weight loss and subsequent weight loss maintenance through the adoption and maintenance of improved eating, physical activity and sedentary behaviors in at risk for overweight and overweight adolescent survivors of ALL and their parent/guardian. the Fit4Life intervention will incorporate elements of the Chronic Care Model, including frequent phone and mail interactions, an initial in-person encounter to provide encouragement and initial patient-tailored counseling for obesity management, family-centered skill development to achieve healthy behavioral modification via goal setting, self-monitoring, and problem solving.~The Fit4Life intervention includes:~Web-based weight loss program Text and Picture messages Counseling Calls Health Coach"
224228829|NCT03982966|DIETARY_SUPPLEMENT|Omega 3 fatty acids (fish oil) 1000 mg/day oral|Omega 3 fatty acids (fish oil) 1000 mg/day oral
223640709|NCT06540261|DRUG|ONO-4538|Specified dose on specified days
223640710|NCT06540261|DRUG|Fluorouracil|Specified dose on specified days
223640711|NCT06540261|DRUG|Oxaliplatin|Specified dose on specified days
223640712|NCT06540261|DRUG|Levofolinate|Specified dose on specified days
223640713|NCT06540261|DRUG|Bevacizumab|Specified dose on specified days
223640714|NCT06540261|DRUG|Cetuximab|Specified dose on specified days
223640715|NCT06577155|DRUG|Levobupivacaine|Regional anesthesia / analgesia
223640716|NCT06577155|DRUG|Levobupivacaine plus nalbuphine|Regional anesthesia / analgesia
223640717|NCT05395026|OTHER|electrical stimulation of vagus nerve|VNS electrical stimulation parameters (pulse duration, pulse amplitude, and pulse frequency) will be systematically changed to determine the effect on vagus nerve activation, laryngeal muscle contraction, and heart rate.
224228830|NCT03915938|DRUG|Ketamine|S-ketamine will be administered in precalculated infusion rates to obtain a plasmatic level of 60 ng/ml
223640718|NCT06201026|OTHER|Traditional exercise|Patients will perform aerobic and resistance exercises that are consistent with the exercise guidelines for MS patients at home
223640719|NCT06201026|OTHER|Individualized exercise|Patients will performed a mobile-app guided program at home designed to address identified individual disabilities such as loss of muscle strength or cardiorespiratory deconditioning.
223640720|NCT04352777|DRUG|Abemaciclib|50 - 150mg tablet BID as prescribed per standard of care
223640721|NCT04352777|DRUG|Fulvestrant|500mg as prescribed per standard of care
223640722|NCT04352777|DRUG|Aromatase Inhibitors|Letrozole, anastrozole as prescribed per standard of care
223640723|NCT05975684|DRUG|Baclofen|0.5 mg/kg/day up to 15 mg/day divided three times a day for 4 weeks
223640724|NCT05975684|DRUG|Placebo|Placebo three times a day for 4 weeks
224228831|NCT03915938|DRUG|Placebo|Administered in an identical way than ketamine.
224228832|NCT01776281|BEHAVIORAL|Kangaroo Mother Care|
224228833|NCT01776281|BEHAVIORAL|Standard Care|
224228834|NCT06109558|DRUG|LMV-12(HE003)|1 cycle was 28 days. LMV-12(HE003), 30mg or 60mg, continuously for 21 days, and the drug was discontinued for 7 days. Osimertinib, 80mg, continuously for 28 days.
224228835|NCT03467334|DIETARY_SUPPLEMENT|B. breve|Bifidobacterium probiotic strain at 1E+08 cfu/day
224228836|NCT03467334|DIETARY_SUPPLEMENT|B. breve plus L. fermentum|Probiotic combination at 2E+08 cfu/day
224228837|NCT03467334|DRUG|Simethicone 20 MG|Standard treatment for infant colic
224228838|NCT02462538|DRUG|Brentuximab vedotin|Brentuximab vedotin is given in a 21 day cycle intravenously starting at 1.8 mg/kg on day 1 of the first cycle and will be administered by IV infusion given over approximately 30 minutes on day 1 of each 21-day cycle.
224228839|NCT02462538|DRUG|Imatinib|Imatinib will be given orally at a dose of 100mg daily starting from day 1 of the first cycle. The dose will be increased to 200mg daily starting from day 1 of the second cycle if no DLT occurs during the first cycle and will be continued at 200mg for 48 weeks.
224228840|NCT02162758|DRUG|Dexlansoprazole|Dexlansoprazole delayed-release capsules
224228841|NCT02162758|DRUG|Dexlansoprazole Placebo|Dexlansoprazole placebo-matching capsules
224228842|NCT03336541|DRUG|Ketamine|Ketamine (0.5 mg/kg in 100 ml normal saline) will be administered by intravenous infusion in 40 minutes after childbirth during cesarean delivery.
223640725|NCT06038136|BEHAVIORAL|Decreased Neuro Checks overnight|If a patient is randomized to the intervention group, the team will discontinue neuro-checks between 8pm and 4am. They will otherwise receive the same care, including overnight vital signs. If the patient has a neurologic or hemodynamic change, the primary team may elect to restart the overnight neuro-checks.
223640726|NCT04195633|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic hematopoietic stem cell transplantation
223640727|NCT04195633|DRUG|Cyclophosphamide|Given IV
224228843|NCT03336541|DRUG|Placebo|Placebo (100 ml normal saline) will be administered by intravenous infusion in 40 minutes after childbirth during cesarean delivery.
224228844|NCT06057519|DRUG|Optimised dose rifampicin|Optimized dose of rifampicin
224228845|NCT06057519|DRUG|Standard dose rifampicin|Standard dose rifampicin
223640728|NCT04195633|DRUG|Cyclosporine|Given IV or PO
223640729|NCT04195633|BIOLOGICAL|Filgrastim|Given IV
223640730|NCT04195633|DRUG|Fludarabine|Given IV
223640731|NCT04195633|DRUG|Mycophenolate Mofetil|Given IV or PO
223640732|NCT04195633|DRUG|Mycophenolate Sodium|Given PO
223640733|NCT04195633|RADIATION|Total-Body Irradiation|Undergo total-body irradiation
223640734|NCT04195633|DRUG|Treosulfan|Given IV
224228846|NCT04471935|DEVICE|At home Speech Hero therapy app|Participants will be instructed to use the Speech Hero therapy app for three hours per week over a 4-week period.
224228847|NCT03356613|OTHER|Focus group|An researcher in psychology will lead focus group on research views for paramedical staff
224228848|NCT03356613|OTHER|test of the Geni tool|The GenI tool built on paramedic's view will be tested.
224228849|NCT02368613|DRUG|DW-3102|
224228850|NCT06274606|OTHER|Exercise Group|Previously sedentary adults awaiting bariatric surgery will be randomized to either an Exercise group (EX-group) or Standard care only group (SC-group) for 8 weeks. Outcome visits will occur before the exercise intervention, after the exercise intervention, and after surgery
224228851|NCT04886115|OTHER|Neuromuscular evaluation|"Before and after training.~Muscle function:~* voluntary maximal isometric force of the knee extensors~* evoked force in the knee extensors by double percutaneous electrical stimulation at 100 and 10 Hz~* level of voluntary activation~* voluntary maximum force in concentric and eccentric mode at an angular speed of 60°.s-1~* squat jump and counter-movement jump"
224228852|NCT04886115|OTHER|Assessment of aerobic capacity, muscle architecture and habituation to the eccentric pedaling task|"Before and after training.~Cardiovascular-respiratory function:~* Oxygen consumption during the incremental concentric pedaling test conducted to high effort perception.~* heart rate during pedaling tasks~Muscle architecture:~\- Pennation angle and thickness of vastus lateralis, rectus femoris, gastrocnemius medialis and lateralis muscles, before and after training.~Familiarization with eccentric pedaling"
224228853|NCT04886115|OTHER|Pedaling at 15 rpm|3 training sessions per week for 6 weeks
224228854|NCT04886115|OTHER|No pedaling, usual activity|Maintain usual physical activity and diet for a period of 6 weeks.
224228855|NCT04886115|OTHER|Pedaling at 60rpm|3 sessions per week of training for 6 weeks
224228856|NCT05040685|PROCEDURE|Axillary mapping reverse|At the time of performing the ALND associate the ARM, injecting between 2-5mL of indocyanine green subcutaneously in the ipsilateral upper extremity at the medial inter-muscular and massaged for 5 min. First, identify the ARM nodes by indocyanine green, then perform conventional axillary lymphadenectomy trying to preserve the ARM nodes. And, in a second time, extract ARM nodes for their individualized anatomopathological study.
224228857|NCT05343156|DRUG|Dexamethasone nanoparticles eye drops|DexNP 15 mg/mL eye drops 3 times a day (every 8 hours) for 12 weeks
224228858|NCT03065309|DRUG|Remifentanil|bolus dose
223640735|NCT04195633|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
223640736|NCT04195633|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
223640737|NCT04195633|PROCEDURE|Echocardiography|Undergo echocardiography
223640738|NCT04195633|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223640739|NCT04195633|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
223640740|NCT04195633|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
223765176|NCT07147036|PROCEDURE|Biodentine - Indirect Pulp Capping|"Caries removal under rubber dam isolation using round bur (#BR-45) and water spray~Tooth disinfection with 0.2% chlorhexidine~Mixing of Biodentine (Septodont, France) in an amalgamator (30 seconds at 4000 rpm)~Placement of Biodentine into the prepared cavity using an amalgam carrier and condensation~After 1 week: Placement of self-cure GIC (Fuji, Japan) as a base~Final restoration with light-cure composite resin~Follow-up at 2, 6, and 12 weeks"
224228859|NCT06159062|DRUG|162|The investigational product 162 is a novel monoclonal antibody targeting HBsAg.
224228860|NCT06159062|DRUG|Placebo|Placebo do not consist any active ingredients.
224228861|NCT02975089|DIETARY_SUPPLEMENT|"multi-nutrient supplement"|"1. 1.3g/d multivitamins \& minerals powder~2. Leaflet content (same as control)"
224228862|NCT02975089|DIETARY_SUPPLEMENT|"multi-nutrient & soy protein supplement"|"1. 1.3g/d multivitamins \& minerals powder~2. 16g/d isolated soy protein powder~3. Leaflet content (same as control)"
224228863|NCT02975089|DIETARY_SUPPLEMENT|Nutrition education on balanced diet & food supplement|"1. Nutrition education with a designed plate~2. 10g/d mixed nuts (cashews, pumpkin seeds, walnuts, macadamia, pine nuts, and almonds)~3. 25g/d milk powder (skimmed and calcium added)~4. Leaflet content (same as control)"
224228864|NCT04832113|OTHER|Adapted Physical Activity and Dietetic|session in addtion conventional management dietetic, hydratation and physical activity
224228865|NCT04832113|OTHER|conventional management|Dietary and hydratation advices according to the recommendations
224228866|NCT02397070|PROCEDURE|Jaw exercise program|The jaw exercise program will consist of three cycles: 1st CYCLE - simple opening and closing mouth, right and left lateral excursions with mechanisms of proprioceptive neuromuscular facilitation and muscle coordination; 2 ° CYCLE - opening and closing exercises, right and left lateral excursions with a counter-resistance force imposed by the participant, with reciprocal inhibition, stretching, and muscular endurance mechanisms; 3rd CYCLE - specific exercises to disk capture attempt in cases of disk displacement with reduction and acute disk displacement without reduction (mouth opening and closing in protrusion) or chronic disk displacement without reduction (forced mouth opening in order to push the disc), with remodeling articulate mechanisms. The conduct will be individualized according to the need and symptoms of patients, which will be monitored fortnightly. It will be proposed 3 times a day, lasting a minute and a half per turn, in front of the mirror, during three months.
224228867|NCT02397070|DEVICE|Occlusal Splint and counseling|The occlusal splints will be made from obtaining a plaster type IV model of upper arch using alginate and metal stock tray. A 2mm thick polyacetate blade will be adapted to the vacuum device plasticizer, heated and pressed over the previously cut U-shaped plaster model. After cooling, it will be added the self-curing acrylic resin on occlusal surface in order to increase the vertical dimension of occlusion in 2mm (anterior region). After polishing, the splints will be intraorally adjusted using carbon paper and clamp Muller, and installed obtaining maximum tooth contacts in centric relation. The splints will be flat and of full coverage for night use. Patients will be monitored every two weeks for the occlusal adjustment for three months. It will also be done counseling measures through a printed guide in relation to the daily care and the various contributing factors of TMD (diet, stress reduction, elimination of parafunctions and posture correction).
224228868|NCT06483659|DRUG|Oxytocin|Intravenous Oxytocin infusion
224228869|NCT06483659|DRUG|Placebo|0.9% Saline
224228870|NCT02730715|DRUG|Basiliximab|Periodic blood collection to monitor Treg cells
224319387|NCT05044559|OTHER|Control Group|"Day 1: Bed mobility chest physiotherapy, active assistive ROM 5 repetitions of upper and lower limb, ACBT cycle. ABGS was analyses at first minute of exercise and vital was record after exercise.~Day 2: Active range of motion exercise progress with 5 repetitions bed to chair mobility. same exercise progress with 5 repetition and 5 minute walk( day 3rd ).walking time will increase with 10 min at 4 day and at 5th day stair climbing the ABGS was record in ICU 3 days."
223640741|NCT05411393|OTHER|ADL-enhanced program|The ADL-enhanced program consists of six home visits delivered by a study occupational therapy staff. The study therapy staff will use the compensatory approach and the restorative approach during the visits to enhance patients' activity engagement. The compensatory approach uses strategies to reduce the activity demand to make every task easier. For example, using the sitting position to perform self-care tasks. The restorative approach uses strategies to increase the demand of the task to increase the patient's functional capacity. For example, carrying a full-load laundry basket versus an empty laundry basket.
223640742|NCT05411393|OTHER|Usual home health rehabilitation therapy|Usual home health rehabilitation therapy is prescribed by the home health agency. It often includes occupational therapy and physical therapy delivered in one to three home visits per week for one to two months.
223640743|NCT03982355|DEVICE|DRS probe|The Oxygenation measurements of the novel diffuse reflectance spectroscopy probe
223640744|NCT05806580|DRUG|Relma-cel|Patients who have undergone at least one disease assessment after initial Relma-cel treatment and have not achieved complete remission may receive a second treatment based on clinical practice. The specific dosage will be determined by the investigator according to the patient's condition and available dose reserves.
223640745|NCT03913533|DEVICE|Heart rate assessment using the Neonatal Resuscitation Program 6-sec assessment method|Heart rate assessment using the Neonatal Resuscitation Program 6-sec assessment method At birth, the clinical team will place the stethoscope on the infant chest and calculate heart rate by listening to the heart beat for 6-sec and then compute the heart rate of the newborn infant.
223640746|NCT03913533|DEVICE|Heart rate assessment using Tap-based smartphone application|At birth, the clinical team will place the stethoscope on the infant chest and calculate heart rate using a Tap-based smartphone application by tapping the screen for 3 beats at that time a heart rate will be displayed.
223640747|NCT04337970|DRUG|Talazoparib|"Dose Level 1: 0.5 mg PO daily Dose Level 2: 0.75 mg PO daily Dose Level 3: 1 mg PO daily~Phase II: MTD to be determined."
223640748|NCT04337970|DRUG|Axitinib|5 mg PO BID
223640749|NCT04752215|DRUG|BI 765049|BI 765049
223640750|NCT04752215|DRUG|ezabenlimab|ezabenlimab
223640751|NCT03113487|BIOLOGICAL|Modified Vaccinia Virus Ankara Vaccine Expressing p53|Given SC
223640752|NCT03113487|BIOLOGICAL|Pembrolizumab|Given IV
223640753|NCT03777982|DRUG|Prednisone|Taking advantage of the anti-inflammatory properties of the medication, corticosteroids are used to decrease the swelling around tumors.
223640754|NCT03777982|DRUG|Apalutamide|Apalutamide also prevents the androgens from working within the prostate cancer cells, and can ultimately lead to cancer cell death.
224228871|NCT02730715|DRUG|Thymoglobulin|Periodic blood collection to monitor Treg cells
224228872|NCT00526578|BEHAVIORAL|Questionnaire|Questionnaire taking about 30-40 minutes to complete.
224228873|NCT05945199|DEVICE|tDCS|"* 1 session/day for 5 consecutive days~* stimulation at an intensity of 2 mA for the active tDCS group and sham stimulation (using the device's sham mode) for the placebo group"
224228874|NCT05945199|BEHAVIORAL|Assessment of risk behaviours|Assessment of risk behaviours (retrospective exploration by the categorical rating of frequency: At least once a day - Several times a week several times a week - once a week - several times a month - once a month - less than once a month - never). times a month - Once a month - Less than once a month - Never)
223640755|NCT03777982|DRUG|Abiraterone Acetate|Abiraterone acetate interferes with an enzyme that is expressed in testicular, adrenal, and prostatic tumor tissues and is required as part of the body's androgen producing process. Because of this interference the amount of androgens produced are decreased. Abiraterone acetate, blocks androgen production at three sources; the testes, the adrenal glands, as well as from the tumor itself
224228875|NCT05945199|OTHER|Scales|EVA craving index for chemsex Maximum VAS craving in the week preceding assessment for chemsex, sexual practices and use of psychoactive substances, HAqII, CSBD-19, modified CCQ-brief, SDI, BDI-II
224228876|NCT01659567|DRUG|Pegylated Interferon Alfa-2a|Pegylated interferon alfa-2a will be administered according to the current standard of care and in line with current summaries of product characteristics/local labelling.
224228877|NCT01659567|DRUG|Ribavirin|Ribavirin will be administered according to the current standard of care and in line with current summaries of product characteristics/local labelling.
224228878|NCT01303562|OTHER|Whole grain oats and barley|One time dose of 48 g whole grain flour in 2 small muffins (24 g flour per muffin) per intervention
224228879|NCT04232462|DIAGNOSTIC_TEST|Endoscopists refer to AI for diagnosis|The AI will provide a clinical diagnosis during endoscopy.
224228880|NCT01409044|OTHER|Music|"Music listening for the treatment group. Music is from MusicCure selection Dreams. Outocmes are compared to control group who receives no music. Subjects are randomized Post-operatively."
224228881|NCT03019965|DRUG|Intermittent Piperacillin/tazobactam|Piperacillin/tazobactam administered in 30 minutes infusion.
224228882|NCT03019965|DRUG|Continuous Piperacillin/tazobactam|Piperacillin/tazobactam administered in 24 hours infusion.
224228883|NCT03019965|DRUG|Intermittent Imipenem|Imipenem administered in 60 minutes infusion.
224228884|NCT03019965|DRUG|Extended Imipenem|Imipenem administered in 6 hours infusion.
224228885|NCT03019965|DRUG|Intermittent Meropenem|Meropenem administered in 60 minutes infusion.
224228886|NCT03019965|DRUG|Extended Meropenem|Meropenem administered in 8 hours infusion.
224228887|NCT02846948|OTHER|Focused assessed echocardiography|Focused assessed transthoracic echocardiography is non-invasive, painless procedure. The transducer is placed on the chest at certain locations and angles to get the required information on patient's condition.
224228888|NCT02044172|PROCEDURE|Radical prostatectomy|radical prostatectomy
224228889|NCT02044172|RADIATION|Conformal radiation therapy|Conformal radiation therapy, external beam
224228890|NCT02044172|OTHER|Active monitoring|Active monitoring of Prostate specific antigen levels and disease surveillance
224228891|NCT03213210|DEVICE|easy-graft CLASSIC (beta-Tricalcium Phosphate)|easy-graft will be grafted to the bone defect supporting a dental implant and covered by polylactide membrane to facilitate regeneration of new bone and healthy attachment to stabilize the dental implant.
224228892|NCT02510716|BEHAVIORAL|SGR|
224228893|NCT02510716|BEHAVIORAL|Support message only|
224228894|NCT00219258|DRUG|Zoledronic acid|
224228895|NCT04582396|PROCEDURE|stellate ganglion block injection|A stellate ganglion block (SGB) is an injection of local anesthetic (numbing medicine) to block the nerves located on either side of the voice box in the neck. It will be administered in an inpatient monitored setting.
224228896|NCT04582396|PROCEDURE|Normal saline injection|An injection of normal saline will be injected into muscle on either side of the voice box in the neck. It will be administered in an inpatient monitored setting.
224228897|NCT04582396|BEHAVIORAL|Psychoeducation|"The session will be 30 minutes in duration, to be administered by a health professional with experience working with CA patients, the goal will be to establish rapport and help patient identify anxious situations, thoughts, and bodily feelings related their recent CA that could lead to avoidant behavior.~Explain how many of these feelings are common in CA survivors, and they are often unrelated to their risk of its recurrence. Explain how the body has a fight-or-flight system that is controlled in part by the stellate ganglion and explain how blocking the action of this part of the body can reduce the feelings of anxiety that commonly occur. Discuss how certain activities such as exercise can increase feelings of anxiety around bodily sensations, but continued engagement could reduce that fear and that exercise is helpful for recovering from CA"
224228898|NCT02521441|BIOLOGICAL|F-627|F-627 at doses of 10 mg/dose or 20 mg/dose, s.c. on Day 3 of each cycle for up to 4 cycles.
224228899|NCT02521441|BIOLOGICAL|Filgrastim|Filgrastim at dose of 5 mcg/kg/day for up to 2 weeks, s.c. start from Day 3 of each cycle for up to 4 cycles.
224228900|NCT01650324|DRUG|DBPR108|DBPR108 capsules in four doses beginning at 25 mg and rising to 600 mg.
224228901|NCT01650324|DRUG|matching placebo|Matching placebo capsules in four doses beginning at 25 mg and rising to 600 mg.
224228902|NCT04857619|OTHER|None (Observational study)|The data on different types of treatment received by the patients, socio-demographics, and clinico-pathological characteristics and healthcare resource utilisation will be extracted from patients' medical records (both alive and deceased).
224319388|NCT01134432|DRUG|prednisolone + mabthera|"Prednisolone: 1,5 mg/kg for two weeks with gradually reduced dosis over two months.~Mabthera: 375 mg/m2 once a week for four weeks"
224319389|NCT01134432|DRUG|Prednisolone|Prednisolone: 1,5 mg/kg for two weeks and then gradually reduced dosis over two months
224319390|NCT00052637|DRUG|hexaminolevulinate|
224228903|NCT05042141|DIETARY_SUPPLEMENT|KOVIR oral capsule|KOVIR is a hard capsule containing fine powder mixed medicinal herbs 600 mg
224228904|NCT05042141|DIETARY_SUPPLEMENT|Placebo oral capsule|Placebo
224228905|NCT00648518|DRUG|Metformin Hydrochloride ER Tablets 750 mg|750mg, single dose fasting
224228906|NCT00648518|DRUG|Glucophage® XR Tablets 750 mg|750mg, single dose fasting
224228907|NCT01333241|BEHAVIORAL|Lifestyle behavior interventon grop|
224228908|NCT01333241|OTHER|Placebo Comparator: Control group|
224228909|NCT02796235|OTHER|Venous Doppler ultrasound of the lower limbs|Venous Doppler ultrasound of the lower limbs at 6, 9 and 12 months of the initial injury
224228910|NCT00358384|DRUG|Pazopanib|Pazopanib will be available in dosing strengths of 0.1, 0.5 and 1 percent.
224228911|NCT00358384|DRUG|Pazopanib vehicle|Pazopanib vehicle will be given to subjects.
224228912|NCT00358384|DRUG|Betamethasone valerate|Betamethasone valerate ointment with 0.1 percent concentration will be given to subjects.
224319391|NCT00052637|PROCEDURE|biopsy|
224319392|NCT00052637|PROCEDURE|cystoscopy|
224319393|NCT01645787|DRUG|4-aminopyridine|10 mg/twice daily
223640756|NCT03777982|DRUG|LHRH Agonist or Antagonist|Luteinizing hormone-releasing hormone (LHRH) agonists (also called LHRH analogs or GnRH agonists) are drugs that lower the amount of testosterone made by the testicles
223640757|NCT06388512|DEVICE|prototype prone positioning device|The prototype prone positioning device will be used during neurosurgical procedures utilizing intraoperative MRI.
223640758|NCT06002269|COMBINATION_PRODUCT|Dietary and Exercise Intervention|Participants will receive food ingredients and recipes to be made and consumed for each meal, every day for a period of 3-6 weeks before surgery and 6-weeks after surgery. The menu is designed as a high protein, high calorie diet meeting targets for omega-3 fatty acids, vitamin A, and arginine (immunonutrition meal plan). In addition, participants will receive an individualized exercise prescription to be performed at home using theraband resistance bands.
223640759|NCT04473911|DRUG|FLUDARABINE|predetermined dose, intravenously, a predetermined times per cycle Given in both pre stem cell and post stem cell cycles
223640760|NCT04473911|DRUG|CYCLOPHOSPHAMIDE|◦Cyclophosphamide predetermined dose, predetermined number of times in Given in pre-stem cell Regimen #1 Cyclophosphamide predetermined dose, predetermined number of times in cycle, intravenous infusion
224228913|NCT00358384|DRUG|Calcipotriol|Calcipotriol ointment with 0.005 percent concentration will be given to subjects.
224228914|NCT05131906|DEVICE|gait task and activity of daily living task|use of lasers on shoes to potentially minimize freezing of gait
224228915|NCT02407379|PROCEDURE|PAPD+SRP|Photoablation of the gingival epithelium was performed with at 810 nm diode laser (1 W output power, continuous wave mode, 66.7 J/cm2, a 0.6 mm optical fiber). SRP was performed using curettes. The periodontal tissues and the dental root were rinsed with the photosensitizer agent methylene blue (0.3% w/v in water). After 5 min., the treated areas were irradiated with at 635 nm diode laser (100 mW output power, continuous wave mode, 0.6 mm optic fiber). The photodynamic treatment was repeated once weekly until normalization of the cytodiagnostic parameters (range: 4-10 applications).
224228916|NCT02407379|PROCEDURE|Sham-laser +SRP|Sham-treatment was similar to the previously described treatment but with switched off laser, followed by scaling and root planing
224228917|NCT01325207|RADIATION|Trastuzumab|Trastuzumab will be administered twice per week for 4 weeks, then once per week for 4 weeks, and then every 2 weeks
224228918|NCT02832856|BEHAVIORAL|Healthy Relationship Education|RS+ is a widely-implemented healthy relationship education curriculum that aligns with the Georgia Department of Education performance standards in health education. The full curriculum features 12 lessons covering such topics as healthy relationships, dating violence prevention, communication skills, conflict management, and decision making.
224228919|NCT02832856|BEHAVIORAL|Job Readiness Curriculum|"Beginning to Work it Out (BWIO) assists youth who are preparing for first-time employment. Topics include recognizing how personal beliefs and behaviors may be perceived in the workplace, as well as soft skills such as emotional self-management and problem-solving skills."
224228920|NCT00940056|PROCEDURE|Endoscopic ablation of AF|"The procedure is conducted in general anaesthesia. The right chest is entered with three working ports .~After a complete cycle of ablation creating a box lesion in the left atrium, conduction block is tested. A chest tube is placed through the most caudal port and the port incisions are closed. A Reveal loop recorder is then implanted subcutaneously. The patient is extubated and transferred to postoperative care."
224228921|NCT00940056|DRUG|Rate control|Anti-arrhythmic protocol The control group is using a rate-control strategy. All patients keep their anti-arrhythmic/beta-blocker/digoxin medication during the entire follow-up. No attempts are made to rhythm-control the patients, unless subjective symptoms make it necessary.
224228922|NCT02478307|OTHER|Cognitive Therapy|
224228923|NCT02478307|OTHER|Mindfulness Meditation|
224228924|NCT02478307|OTHER|Mindfulness-Based Cognitive Therapy|
224228925|NCT06090656|DRUG|Bevacizumab combined with Sintilimab|Bevacizumab combined with sintilimab, sindilizumab 200 mg IV d1, Q3W, combined with bevacizumab 15 mg/kg IV d1, Q3W treatment, treatment continued until disease progression, development of intolerable toxic reactions
224228926|NCT06090656|PROCEDURE|Transcatheter arterial chemoembolization|Transcatheter arterial chemoembolization, patients were treated with cTACE, and the efficacy was assessed by repeat CT/MRI 1 month after the initial treatment, and if the tumor still had arterial phase enhancement, TACE treatment could be supplemented until treatment failure and withdrawal of consent.
223640761|NCT04473911|RADIATION|TBI|Total body irradiation (TBI) once per cycle.
224228927|NCT00181922|DRUG|ziprasidone (Geodon)|
224228928|NCT00708422|DRUG|Travoprost ophthalmic solution 0.004% with SofZia® preservative system (TRAVATAN Z®)|Ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension, one drop a day, dosed topically for 12 weeks (84 days). Referred to as travoprost.
224228929|NCT00708422|DRUG|Latanoprost ophthalmic solution 0.005% (XALATAN®)|Ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension, one drop a day, dosed topically for 12 weeks (84 days). Referred to as latanoprost.
224228930|NCT00336310|DRUG|Repaglinide|
224228931|NCT04843163|BEHAVIORAL|NAMI Basics|NAMI Basics is a peer service program for caregivers of children with mental health needs. It was created by the National Alliance on Mental Illness (NAMI) and was adapted from their empirically supported model for caregivers of adult children with mental illness (Family-to-Family). The child-focused intervention, NAMI Basics, is a six-class curriculum focused on increasing caregiver knowledge about mental illness, empowering parents to advocate for their children across service systems, and introducing skills that assist in family problem-solving and communication (Brister et al., 2012). The program is currently available widely throughout the U.S. through certified trainers who volunteer with local NAMI affiliates and is provided free of charge to caregivers in a non-stigmatizing community setting (e.g., local school, church, community center). It is open to all caregivers, regardless of mental health diagnosis or time within a treatment system.
223640762|NCT04473911|DRUG|Melphalan|Melphalan, infusion, determined dosage, once per cycle
223640763|NCT04473911|DRUG|Sirolimus|Sirolimus: Predetermined dosage, predetermined number of time in cycle, oral: Please note that doses of sirolimus can be adjusted at the treating physician's discretion given the multiple drugs and other situations which affect its metabolism
223640764|NCT04473911|DRUG|Mycophenolate mofetil|◦Mycophenolate mofetil, oral or iv(predetermined dose or IV TID (based upon actual body weight), at predetermined times per cycle
223640765|NCT04473911|DRUG|RGI-2001|IV, predetermined dose, weekly to 6 total doses
223640766|NCT04473911|DRUG|CYCLOPHOSPHAMIDE|◦Given in Post Stem Cell cycle of Regimen #1 and #2 Cyclophosphamide predetermined dose, predetermined number of times in cycle, intravenous infusion
223640767|NCT05647408|DRUG|Dexamethasone|The nominal doses were similar, volunteers were randomly assigned to receive a single dose of DXM by IV bolus of 1.5 mL (equivalent to 6 mg of dexamethasone) or the same dose intranasally by using a Mucosal Atomization Device (MAD Nasal). allowing direct pharmacokinetic comparison without dose normalization. Venous blood samples were obtained via an indwelling catheter before administration and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 8, 12 and 24 h for DXM. Plasma was separated and frozen at -70 °C for further analysis.
223640768|NCT03675997|OTHER|HAD (Hospital Anxiety and Depression) scale|HAD (Hospital Anxiety and Depression) scale will be completed and reported by patients the first day of conditioning and then weekly from day 0 corresponding to the autograft, until their last day in the hematological department.
223640769|NCT01514799|PROCEDURE|gastric bypass|two techniques of gastric bypass for studying the effects of making a long BP-limb
223640770|NCT04266717|BEHAVIORAL|Baby Play Intervention|Baby Play Intervention involves teaching parents targeted ways they can handle, position, and play with young infants that aim to provide infants enhanced early opportunities to learn to control their bodies and interact with objects. These abilities are associated with future motor, cognitive, and language outcomes. Parents will be asked to perform the intervention activities 20 minutes daily and to log their activity performance weekly.
223640771|NCT04266717|BEHAVIORAL|Milestone Education|Parents in the Milestone Education Intervention group will receive information regarding milestones expected based on infants' CA. This information is based on forms from the Centers for Disease Control and Prevention (CDC) and The American Academy of Pediatrics (AAP). This will help parents understand the milestones typically observed at the their child's CA and reflects the education parents receive from healthcare providers. Parents will be asked to provide their infants opportunities to perform these milestone behaviors 20 minutes daily and to log their activity performance weekly.
223640772|NCT03184168|DRUG|[14C]lorlatinib|Extemporaneously compounded oral solution of \[14C\]lorlatinib (approximately 100 mg/100 µCi)
223640773|NCT02809001|PROCEDURE|Fat grafting|In the experimental group, liposuction will be performed and autologous fat graft will be harvest after washing with saline. Patients will receive autologous fat graft transplantation subdermally to expanded skin.
223640774|NCT03953352|OTHER|Helical intensity-modulated radiotherapy (IMRT)|Helical intensity-modulated radiotherapy (35 fractions, 5 fractions per week) will be administered during 7 weeks: 2 Gy per fraction on tumor and 1.6 Gy per fraction on bilateral lymph node areas.
223640775|NCT06104826|DRUG|Emicizumab|Emicizumab in Hemophilia A
223640776|NCT00940771|DRUG|Boosted Atazanavir|Boosted Atazanavir, once a day dose adjusted for child's weight for 6 months.
223640777|NCT00391586|DRUG|Erlotinib|"Erlotinib will be administered for at least 2 cycles (6 weeks) and for a maximum of 8 months.~Upon progression or intolerance to erlotinib, standard of care platinum-based chemotherapy (per the choice of the treating physician) is administered every 3 weeks. Physicians can adjust dose, schedule, or supportive care to the benefit of the patient"
223640778|NCT00391586|DRUG|Platinum-based chemotherapy|Intravenous chemotherapy combination per physician discretion every 3 weeks for at least 2 cycles
224228932|NCT01684358|DEVICE|Sino-implant (II)|Sino-implant (II) (Shanghai Dahua Pharmaceutical Co, Ltd.; Shanghai, China), a contraceptive implant with two rods each of which contain 75 mg of levonorgestrel.
224228933|NCT06485024|DEVICE|Modeling Resin|it is the application of Modeling liquid to make easier manipulation and sculpting the composite veneer and reflect on its physical properties and clinical performance
224228934|NCT00915057|DRUG|NRL972|Single dose of NRL972 administered at baseline, at 3-monthly intervals during treatment for up to 12 months (or the end of treatment) and at 3 and 6 months after the end of treatment.
224228935|NCT00244322|DRUG|LY450139 dihydrate|
224228936|NCT00244322|DRUG|placebo|
224228937|NCT04314739|DIETARY_SUPPLEMENT|Resveratrol|Participants will consume one of the treatment types daily for a period of four weeks.
224228938|NCT04314739|DIETARY_SUPPLEMENT|Placebo|Participants will consume one of the treatment types daily for a period of four weeks.
224228939|NCT04626999|PROCEDURE|Single Bundle ACL Reconstruction|"Arthroscopy Single Bundle ACL Reconstruction is a procedure to reconstruct the ACL using one bundle.~The procedure uses Hamstring (Gracillis muscle and Semitendinosus muscle) as a graft."
224228940|NCT04626999|PROCEDURE|Double Bundle ACL Reconstruction|"Arthroscopy Double Bundle ACL Reconstruction is a procedure to reconstruct the ACL using Two bundles (Double bundle).~The procedure uses Gracillis tendon as a Posterolateral bundle graft and Semitendinosus tendon as an Anteromedial bundle graft."
224228941|NCT00453570|BIOLOGICAL|Diphtheria, Tetanus, Polio, Acellular Pertussis and Hib|0.5 mL, IM
224228942|NCT00453570|BIOLOGICAL|Diphtheria, Tetanus, Polio, Acellular Pertussis and Hib|0.5 mL, IM
224228943|NCT00453570|BIOLOGICAL|Diphtheria, Tetanus, & Acellular Pertussis Combined, Absorbed|0.5 mL, IM
224228944|NCT03530956|DEVICE|Ankle Mimicking Prosthetic Foot prototype 4+|The amputee will walk with AMPfoot 4+, a novel bionic foot, designed and built by an engineer of department MECH (VUB, B)
224228945|NCT04998409|DEVICE|Monofocal lens|not applicable as patients are already implanted with the monofocal lens
224228946|NCT01254409|BIOLOGICAL|PRM-151|Intravenous PRM-151 administered over 30 minutes on study days 1, 3, 5, 8, and 15 at doses of 1.0, 5.0, or 10.0 mg/kg.
224228947|NCT01254409|OTHER|Placebo|Intravenous 0.9% normal saline administered over 30 minutes on study days 1, 3, 5, 8, and 15.
223640779|NCT00904982|BEHAVIORAL|Financial Incentive and Med-eMonitor|"Financial Incentives: Study participants are entered into a daily lottery. It includes a chance to win either $10 or $100 on any given day throughout the participant's duration in the study (6 months). Participants are assigned a number and each day a computer randomly draws a winning number. Participants whose number is drawn can only collect money if they have taken the medication correctly.~Med-eMonitor: The Med-eMonitor is a device used to measure medication compliance. The device has 5 drawers in which the participants' medication is placed. When a drawer opens, a message displays on the monitor, and asks the participant if he/she is taking his/her medication for the day. The device registers their answers and sends the compliance information via the participants' telephone line nightly to a central study server."
223640780|NCT00904982|DEVICE|2Med-eMonitor|Med-eMonitor is a device that subjects will be given that will monitor an individual's warfarin adherence.
223640781|NCT02072668|DRUG|rivaroxaban|Subject will receive rivaroxaban 20mg PO daily for 4 weeks and then matching placebo 1 PO daily for 4 weeks, with a 2-week wash out period in between the two treatment phases. Both of the two treatments will be in capsule form OR Subject will receive placebo 1 PO daily for 4 weeks, then rivaroxaban 20mg PO daily for 4 weeks, with a 2-week wash out period in between the two treatment phases. Both of the two treatments will be in capsule form.
223640782|NCT02072668|DRUG|placebo|Subject will receive rivaroxaban 20mg PO daily for 4 weeks and then matching placebo 1 PO daily for 4 weeks, with a 2-week wash out period in between the two treatment phases. Both of the two treatments will be in capsule form OR Subject will receive placebo 1 PO daily for 4 weeks, then rivaroxaban 20mg PO daily for 4 weeks, with a 2-week wash out period in between the two treatment phases. Both of the two treatments will be in capsule form.
224228948|NCT02297009|PROCEDURE|Buccal swab|Buccal swabs will be taken from the volunteers
224228949|NCT00868309|BIOLOGICAL|Anavip|Anavip, 10 vials Intravenous (IV) every 2 hours until initial control has been achieved; then 3 maintenance doses of 4 vials every 6 hrs
224228950|NCT00868309|BIOLOGICAL|CroFab|CroFab, 5 vials Intravenous (IV) every 2 hours until initial control has been achieved; then 3 maintenance doses of 2 vials every 6 hrs
224228951|NCT02053532|PROCEDURE|Positron emission tomography/magnetic resonance imaging|Positron emission tomography/magnetic resonance (PET/MR) imaging using 18-F-fluorodeoxyglucose (FDG) as radio tracer
224228952|NCT00299156|DRUG|Clofarabine|Starting dose 10 mg (Group 1) or 20 mg (Group 2) as tablets once a day for 5 days in a row and repeated every 4-8 weeks. Each 4-8 week period is a cycle.
224228953|NCT05307861|DEVICE|Pancreatic duct stenting with plastic stent|Plastic pancreatic duct stent placement (5fr x 4 cm) for patients in need of pancreatic duct stenting during ERCP.
224228954|NCT05307861|DEVICE|Pancreatic duct stenting with Biodegradable Stent|Biodegradable pancreatic duct stent placement (6fr x 4 cm or 6fr x 4 cm) for patients in need of pancreatic duct stenting during ERCP.
224228955|NCT00427128|DRUG|fluoxetine|10mg/day increased over 12 weeks to 20-80 mg/day; 20-80 mg/day maintained from week 13-36.
224228956|NCT00427128|DRUG|placebo|Week 13-36.
223640783|NCT01539161|DEVICE|Implantable Cardiac Monitor|9529 Reveal XT Implantable Cardiac Monitor as well as the use of 9539 Reveal XT Patient Assistant.
223640784|NCT01539161|PROCEDURE|Standard of Care|Standard of care arm including exam, ECG and Holter every 6 months, and an Echo, Chest X-Ray and Stress test every 12 months.
223640785|NCT04906811|DEVICE|AuraGen 1-2-3 with AuraClens system (BK190433)|Fat grafting to the breast in patients undergoing an aesthetic procedure without a breast implant. Device used: AuraGen 1-2-3 with AuraClens system
223640786|NCT04906811|DEVICE|Revolve System (K120902)|Fat grafting to the breast in patients undergoing an aesthetic procedure without a breast implant. Device used: Revolve System
223640787|NCT04701827|COMBINATION_PRODUCT|AWARE intervention|Comprehensive 360 degrees intervention. The intervention targets multiple aspects of the described enhancers of functioning based on on the ICF Brief Core Set. 1) ADL ability as a part of carrying out daily routines 2) Mood symptoms, medication and side effects 3) Social, relatives and network 4) Physical health, including BMI, biomarkers and exercise5) Cognition, circadian rhythm measured as sleep quality, and coping (stress reduction).
223640788|NCT00363259|DRUG|Peginterferon alfa-2b|
223640789|NCT00363259|DRUG|Ribavirin|
223640790|NCT02506088|BEHAVIORAL|Your Voice Your View|Session 1 of the intervention involves background information, an introduction to social norms, and bystander intervention skills training. Session 2 of the intervention establishes conditions for consent, types of abusive behavior and identifying abuse. Session 3 of the intervention addresses risk reduction strategies for girls. Session 3 of the intervention addresses false accusations, masculinity, and additional practice on identifying conditions for consent for boys. Session 4 of the intervention includes active practice of bystander intervention skills.
223640791|NCT05862077|DEVICE|Wearable Hip Assist Robot(EX1)|EX1 is a hip-type assist device developed by Samsung Electronics.
223640792|NCT05862077|BEHAVIORAL|Exercise Program 1|Exercise program 1 for fast walking by applying resistance and assist mode of EX1
223640793|NCT05862077|BEHAVIORAL|Exercise Program 2|Exercise program 2 for normal walking by applying resistance and assist mode of EX1
223640794|NCT05862077|DEVICE|Without Wearable Hip Assist Robot(EX1)|Overground walking without EX1
223640795|NCT03761992|DIETARY_SUPPLEMENT|Gingko Baloba|Tablets
223640796|NCT03761992|OTHER|Placebo|Tablets
223640797|NCT03150953|DEVICE|MRI-safe bore covering|
223640798|NCT03058146|BEHAVIORAL|Mobile Health Walking Condition|Physically inactive older adults in this condition will perform 3 months of prescribed brisk walking (to increase cardio respiratory fitness) in their real world environments, using mobile health (mHealth) devices during each exercise session to achieve and maintain a minimum of 150 minutes of moderate to vigorous physical activity (MVPA) per week.
223640799|NCT03058146|BEHAVIORAL|Healthy Aging Education Condition|The education control condition will provide participants with printed materials and homework assignments on issues related to successful aging, such as nutrition, social activity, cognitive and social engagement.
223640800|NCT02875236|DRUG|OctaplasLG®|"OctaplasLG is an donor plasma product pooled from approximately 1000 single donor units. It possesses unique features when compared to standard fresh frozen plasma, such as having standardized concentrations of natural pro- and anti-coagulation factors, a standardized volume as well as being pathogen free. The manufacturing method of OctaplasLG removes immune complexes and cells in several steps of microfiltration in addition to viral, bacterial and prion pathogen inactivation by immune neutralization. OctaplasLG should reduce the inflammatory hit on the endothelium, including the glycocalyx, by having standardized levels of coagulation proteins, which can give more sustainable support to the endothelial regeneration as compared to standard fresh frozen plasma."
223640801|NCT02875236|DRUG|Ringer-acetat|Crystalloid used as standard of care.
224228957|NCT03567109|OTHER|hand laterality judgment task|participants are asked to identify laterality of the hand presented on the screen
224228958|NCT00493571|DRUG|Gimatecan|Starting dose: 0.6 mg capsules administered orally once daily.
224228959|NCT04242771|BEHAVIORAL|Mindfulness|Subjects practice mindfulness before bedtime
224228960|NCT04132479|DRUG|Clarithromycin 500mg|1000mg taken orally every 12 hours for 5 days
224228961|NCT04132479|DRUG|Amoxicillin 500mg|1000mg taken orally every 12 hours for 5 days
224228962|NCT04132479|DRUG|Tinidazole 500mg|500mg taken orally every 12 hours for 5 days
223640802|NCT03533049|OTHER|myFAMI|Patients who are assigned to the myFAMI group will also have the smartphone application downloaded onto either the family member's smartphone or a study-provided smartphone. Following discharge from the hospital, participants will use the smartphone application to answer nine daily questions regarding tracking family coping, transplant symptoms, family management of child transplant symptoms, and family-management difficulty with medication and follow-up regimen daily for the first 30 days following discharge.
223640803|NCT00859196|DRUG|Dexpanthenol (BAY81-2996)|Test product and the respective placebo will be applied to previously wounded test areas and the surrounding skin (approx. 3 cm2). After a certain time the second skin biopsy will be taken from the treated test areas. The skin biopsies will be analysed via micro array.
223640804|NCT00859196|DRUG|Placebo|Test product and the respective placebo will be applied to previously wounded test areas and the surrounding skin (approx. 3 cm2). After a certain time the second skin biopsy will be taken from the treated test areas. The skin biopsies will be analysed via micro array.
224228963|NCT04132479|DRUG|Rabeprazole 20mg|20mg taken orally every 12 hours for 5 days
224228964|NCT04132479|DRUG|Clarithromycin 500mg|1000mg taken orally every 12 hours for 14 days
224228965|NCT04132479|DRUG|Amoxicillin 500mg|1000mg taken orally every 12 hours for 14 days
223640805|NCT02293694|DRUG|Sayana Press|Sayana® Press is a subcutaneous formulation of depot medroxyprogesterone acetate (DMPA) in a prefilled, auto-disabled injection system called Uniject
224228966|NCT04132479|DRUG|Tinidazole 500mg|500mg taken orally every 12 hours for 14 days
224228967|NCT04132479|DRUG|Rabeprazole 20mg|20mg taken orally every 12 hours for 14 days
224228968|NCT06546215|DRUG|Digoxin|Administer a single-dose (0.25mg) of either the reference or the test formulation of digoxin tablets.
224228969|NCT06485895|DIAGNOSTIC_TEST|test IGRA|BLOOD SAMPLES
224228970|NCT06485895|DIAGNOSTIC_TEST|TEST QUATIFERON TB Gold Plus|BLOOD SAMPLES
224228971|NCT01523964|OTHER|Testing with EIM|
224228972|NCT03871608|OTHER|Examination of functional etiologies on DTM Disorders|Evaluating functional etiologies accessible to rehabilitation, consists of 4 categories (Orofacial dyspraxia, parafunctions, posture, Chewing) and includes 11 items in total
224228973|NCT03871608|OTHER|Assessment of symptoms on DTM Disorders|Examining the symptoms of the patient, consists of 5 categories (Muscle examination, Areas of cellulalgic infiltrates, Mandibular kinetics, Joint sounds, Thrust)and includes 21 items
224228974|NCT00747175|DRUG|AZD1656|Dose titration to 3 (alt 4) increasing dose-steps with oral suspension, 8 days treatment
224228975|NCT00747175|DRUG|AZD1656|Dose titration of oral suspension to a tolerable dose, 1 month treatment
224228976|NCT02815878|BEHAVIORAL|Enhance Wellness|A 6-month health promotion intervention which pairs participants with a wellness coach to identify and pursue a health-related goal of their choosing.
224228977|NCT00963157|DRUG|AS03|AS03 adjuvant administered with 3.75, 7.5, or 15 mcg inactivated H1N1 vaccine.
224228978|NCT00963157|BIOLOGICAL|Influenza Virus Vaccine, Monovalent A/H1N1 A/California/7/2009 NYMC X-179A|Inactivated influenza H1N1 vaccine with AS03 adjuvant, delivered intramuscularly (IM) as 3.75, 7.5, or 15 micrograms per dose; and inactivated influenza H1N1 vaccine without adjuvant, delivered intramuscularly as 7.5 or 15 micrograms per dose. All doses of the vaccine with or without adjuvant will be administered as a single 0.5 mL IM injection in the deltoid muscle of the preferred arm.
224228979|NCT01166568|DEVICE|PresVIEW Scleral Implants|Subjects are implanted with the PresView Scleral Spacing Implants and followed for 24 months.
224228980|NCT02520557|OTHER|Blood or Saliva|To screen for HLA genotypes that may place patients at high risk of SCAR when they use ESL.
223640806|NCT04913077|OTHER|removal of submucosal gastric tumor preferably by Full Thickness Resection Device (FTRD)|FTRD (Ovesco company) in tumors up to 10 mm and predominantly intraluminal growth directly by sucking into the cap, at 10-20 mm and/or intramural/extramural growth by prior circumcision and lateral preparation, so that the lesions can be better pulled into the cap. The procedure depends on the endosonographic extent of the findings. The lesions are pulled into the cap with grippers and other instruments and, if necessary, with a snare and then resected with FTRD
224228981|NCT04868526|BEHAVIORAL|dietary intervention|Research participants will be assigned to two dietary conditions.
224228982|NCT03516383|DEVICE|PWVi|
224228983|NCT05805553|DRUG|Propranolol|2mg/kg/day in 3-4 dividd doses
224228984|NCT05805553|DRUG|Nandrolone Decanoate|1mg/kg weekly
224228985|NCT02647983|DRUG|Hyperpolarized Pyruvate (13C) Injection|Hyperpolarized Pyruvate (13C) Injection is a MRI contrast agent.
224228986|NCT01229085|DRUG|memotasone + salicylic acid|mometasone 0,1% + salicylic acid 5%.
224228987|NCT02548507|OTHER|observational study, no intervention|
224228988|NCT00996671|DRUG|GSK2256098|focal adhesion kinase inhibitor given as a single dose
224228989|NCT00996671|DRUG|Placebo|Placebo to be used as comparator for GSK2256098
224228990|NCT01720082|PROCEDURE|Single incision laparoscopic appendectomy|A multiport device will be introducted through a 2-2.5 transumbilical incision. Retraction of the appendix would be performed with a forceps. The mesoappendix will be divided with bipolar or monopolar cautery. The appendix stump will be ligated with suture loop or with an endo-stapler. The specimen will be delivered within a plastic bag or in any protected way (without any contact with the abdominal wall) via the umbilical port. Any fluid will be suctioned and washing performed if required. Fascial defects will be closed with 2-O polydioxanone sutures and skin closed with 4-O non-absorbable sutures. No pelvic drain will be inserted. A three-band dressing will be applied in the end.
224228991|NCT01720082|PROCEDURE|Multiport laparoscopic appendectomy|Three ports will be inserted as follows: One 10/12 umbilical port, one 5mm suprapubic (or right suprapubic)port, one 5mm or 10/12mm port in left iliac fossa (or left suprapubic). One additional trocar can be inserted following surgeons preference. Retraction of the appendix would be performed with a forceps. The mesoappendix will be divided with bipolar or monopolar cautery. The appendix stump will be ligated with suture loop or with an endo-stapler. The specimen will be delivered within a plastic bag or in any protected way (without any contact with the abdominal wall) via the umbilical port. Any fluid will be suctioned and washing performed if required. Fascial defects (10/12 trocars)will be closed with 2-O polydioxanone sutures and skin closed with 4-O non-absorbable sutures. No pelvic drain will be inserted. A three-band dressing will be applied in the end.
224228992|NCT03432013|BEHAVIORAL|CUD-AMT|Participants will be trained to manage their negative thoughts and emotions while also receiving treatment for cannabis misuse
224228993|NCT03432013|BEHAVIORAL|SUD-CBT|Participants will receive traditional cognitive behavioral therapy for substance use disorder
224228994|NCT01923077|DRUG|Simvastatin|usual care with Simvastatin
224228995|NCT01923077|DRUG|Rosuvastatin|rosuvastatin 80 mg as loading dose at randomization followed by rosuvastatin 40 mg daily.
224228996|NCT00684671|BIOLOGICAL|Twinrix|Intramuscular injection, single dose in left deltoid.
224228997|NCT00684671|BIOLOGICAL|Engerix-B|Intramuscular injection, single dose in left deltoid.
224228998|NCT00684671|BIOLOGICAL|Havrix|Intramuscular injection, single dose in right deltoid.
224228999|NCT00684671|BIOLOGICAL|HBVAXPRO|Intramuscular injection, single dose in the left deltoid.
224229000|NCT00684671|BIOLOGICAL|Vaqta|Intramuscular injection, single dose in right deltoid.
223640807|NCT03678493|BIOLOGICAL|Fecal Microbiota Transplant (FMT)|Oral Capsule
224229001|NCT00655577|BEHAVIORAL|Exercise|Supervised, mainly home-based balance, strength and jumping exercises
224229002|NCT03335371|DRUG|TTP399|Phase 1: Participants will receive TTP399 administered orally up to 1200 mg taken once daily for 7 days
224229003|NCT03335371|DRUG|TTP399|Phase 2: Participants will receive TTP399 administered orally 800 mg taken once daily for 12 weeks
224229004|NCT03335371|DRUG|Placebo Oral Tablet|Phase 2: Participants will receive Placebo oral tablets for 12 weeks
224229005|NCT00802802|DRUG|Efavirenz (EFV)|Participants will be administered oral EFV at a dose ranging from 50 mg to 800 mg once daily, based on weight and CYP 2B6 genotype. EFV capsules will be opened into a small amount of a compatible food or liquid vehicle; the smallest amount of food or liquid that will enable the child to swallow the capsule contents should be used (i.e., EFV should not be taken with a meal).
223640808|NCT03678493|OTHER|Placebo|Oral Capsule
223640809|NCT02551939|PROCEDURE|Autologous Fat Grafting|Autologous Fat Grafting
223640810|NCT01001026|BIOLOGICAL|Arepanrix|Adults: One dose Arepanrix vaccine given IM (0.5 mL)
223640811|NCT01001026|BIOLOGICAL|Arepanrix|Children: Two doses of Arepanrix vaccine given IM (0.25 mL) three weeks apart
223640812|NCT04027517|DRUG|JTZ-951|"Oral tablet~* Dose adjustments as maintenance dose is allowed according to the result of Hb level."
223640813|NCT04027517|DRUG|Darbepoetin Alfa|"Intravenous administration~* Dose adjustments as maintenance dose is allowed according to the result of Hb level."
223640814|NCT02382536|DEVICE|BD Scarlett Infusion set|Each subject will receive subcutaneous infusion from two investigational BD Scarlet infusion sets simultaneously, using a commercially available insulin pump to deliver insulin diluent (placebo) into the abdomen. Each infusion will run for approximately 4 1/2 hours.
223640815|NCT02382536|DEVICE|Medtronic QuickSet Infusion Set|Each subject will receive subcutaneous infusion from two Medtronic infusion sets simultaneously, using a commercially available insulin pump to deliver insulin diluent (placebo) into the abdomen. Each infusion will run for approximately 4 1/2 hours.
223640816|NCT03294252|DRUG|5-Fluorouracil|Presentation: Concentrated solution for concentrated infusion in vials containing 250 mg, 500 mg, 1 g and 5 g, in 5 ml, 10 ml, 20 ml and 100 ml respectively, providing a 50 mg / ml solution. Dosage: 400mg / m2. Administration: IV. Day of administration: between 1 h and 24 h before PIPAC.
223640817|NCT03294252|DRUG|L-Folinic acid|Presentation: lyophilisate for parenteral use, dosed at 25 mg, and in the form of a solution for injection by IM or IV dosed at 25 mg / 2.5 ml. Dosage: 20mg / m2. Administration: IV. Day of administration: between 1 h and 24 h before PIPAC.
223640818|NCT03294252|DRUG|Oxaliplatin|Concentrated solution for infusion dosed with 50 mg and 100 mg. Dosage: depending on the dose range assigned to inclusion (from 90mg / m2 to 300mg / m2). Administration: the solution is packaged in a syringe which is subsequently used for injection and not in a conventional bag. The product is administered in a high-pressure injector, during the PIPAC. Day of administration : J1 of PIPAC
223640819|NCT01297829|DRUG|Intravenous Ibuprofen|800 mg IV ibuprofen 30 minutes preoperatively
223640820|NCT01297829|OTHER|IV Placebo|IV normal saline
223640821|NCT05714410|DIETARY_SUPPLEMENT|PHGG|PHGG
223640822|NCT02757508|DIETARY_SUPPLEMENT|protein powder supplement|
223640823|NCT02757508|DIETARY_SUPPLEMENT|Vitamins/minerals|
223640824|NCT05849753|DEVICE|Advanced artificial pancreas closed-loop technology|Study is an observational capture of data in patients that qualify, before and after the use of any FDA-approved closed-loop system of Subject's/Family's choosing that uses a CGM that does not require fingerprick calibrations. Devices prescribed available through their insurance (including Medicaid).
224229006|NCT00802802|DRUG|Rifampin-containing anti-TB therapy|Treatment with rifampin-containing anti-TB treatment regimen. Treatment will last at least 24 weeks and up to 36 weeks.
224229007|NCT04303338|PROCEDURE|Masotherapy with neural tension and masotherapy with non-neural tension|To compare the effectiveness of masotherapy with neural tension and masotherapy with non-neural tension
224229008|NCT01759199|PROCEDURE|Pulmonary rehabilitation assessed with six-minute walk test and six-minute stepper test|
224229009|NCT00638599|DEVICE|LMA®|LMA® is placed after anesthesia induction and removed after the operation
224229010|NCT00638599|DEVICE|Endotracheal tube|Standard endotracheal tube is inserted after anesthesia induction and extubated after the operation
224229011|NCT00003237|DRUG|cisplatin|
224229012|NCT00003237|DRUG|paclitaxel|
224229013|NCT00003237|PROCEDURE|surgical procedure|
224229014|NCT01618799|DRUG|Lamotrigine Tablets 25 mg|2 x 25 mg tablet once a day
224319394|NCT01645787|DRUG|Placebo|Crossover study involving one trial with sugar pill (placebo)
224319395|NCT02473198|DRUG|Exparel|Prior to cementing of the prosthesis (minimum 20 minutes later), injection with mixture of 40 mL normal saline solution and 20mL 1.3% Exparel.
224229015|NCT01618799|DRUG|Lamotrigine|2 x 25 mg tablet once a day
224229016|NCT00977288|DRUG|anacetrapib|10, 40 or 100 mg tablet of MK0859 , once daily for 8 weeks
224229017|NCT00977288|DRUG|Comparator: atorvastatin|atorvastatin tablet, 10mg, once daily for 8 weeks
224229018|NCT00977288|DRUG|Comparator: Placebo|Placebo tablet, once daily for 8 weeks
224229019|NCT03629093|DRUG|General Anesthetics|General anesthesia required for surgery procedures or diagnostic interventions using either intravenous or inhalation anesthetics, or both.
224229020|NCT01964742|GENETIC|blood samples|
224229021|NCT05894161|OTHER|Exercise training program|"The designed exercise program will be distributed on everyone. The recommendations will be to train from 30 to 45 minutes, 3 days per week for 6 weeks in addition to walking 30 minutes on the ground surface daily.~1. Diaphragmatic Breathing Exercises: Diaphragmatic breathing (DBRT) or abdominal deep breathing is an expansion of the abdominal area rather than the thoracic area when breathing.~2. Progressive Muscle Relaxation (PMR): The physical element includes the tensing and relaxing of all muscle groups over the face, arms, trunk (abdomen \& chest) and legs.~3. A combination of stretching, stabilization and strengthening exercises of the pelvic-lumbar region:~4. Walking exercise: Walking on the ground surface for 30 minutes every day."
224229024|NCT01684553|BEHAVIORAL|Slow eating condition|The subjects were asked to eat their meal slowly during the slow eating condition
224319396|NCT02473198|DRUG|Femoral Nerve Block Bupivacaine|The patient will then undergo an ultrasound guided femoral nerve block in the preoperative area with bupivacaine 0.25% 20 cc. All patients will undergo unilateral TKR using a medial parapatellar approach. Intraoperatively prior to cementing of the TKR, patients will also receive a local anesthetic injection of a mixture of 30cc 0.25% bupivicaine with epinephrine, 30mg of toradol and 10 mg of morphine sulfate into the posterior capsule of the knee joint.
223640825|NCT01457508|BIOLOGICAL|DTPa-HBV-IPV/Hib (Infanrix hexa™)|Three doses administered intramuscularly
223640826|NCT01457508|BIOLOGICAL|DTPa-HBV-IPV (Infanrix penta™)|Three doses administered intramuscularly
223640827|NCT01457508|BIOLOGICAL|Hib (Hiberix™)|Three doses administered intramuscularly
223640828|NCT00845767|PROCEDURE|Forearm Vascular Study|"Forearm venous occlusion plethysmography during intraarterial infusion of L-NMMA (2-8 µmol/min) followed by co-infusion of sodium nitroprusside (90-900 ng/min) as a nitric oxide clamp. Forearm blood flow then measured during the clamp in response to infused vasodilators acetylcholine (5-20 mg/min), bradykinin (100-1000 pmol/min), verapamil (10-100 µg/min) and sodium nitroprusside (2-8 µg/min)."
223640829|NCT05105204|DEVICE|ArteVu|The study participants will concurrently undergo noninvasive blood pressure monitoring with the ArteVu finger clip applied to the same extremity that is being used to measure the radial artery pressure.
223640830|NCT01658319|DRUG|fludarabine phosphate|Given IV
223640831|NCT01658319|DRUG|methoxyamine|Given IV
223640832|NCT01658319|OTHER|laboratory biomarker analysis|Correlative studies
223640833|NCT01658319|OTHER|pharmacological study|Correlative studies
223640834|NCT01658319|GENETIC|western blotting|Correlative studies
223640835|NCT01658319|OTHER|mass spectrometry|Correlative studies
223640836|NCT01658319|GENETIC|DNA analysis|Correlative studies
223640837|NCT02231359|DRUG|Berodual® Respimat® solution for inhalation|
223640838|NCT01483261|BEHAVIORAL|Trauma-Focused Cognitive Behavioral Therapy|15 sessions of manualised, culturally modified trauma-focused cognitive behavior therapy
223640839|NCT06387121|DRUG|Vincristine|Anti-tumor alkaloids
223640840|NCT06387121|DRUG|Cyclophosphamide|Alkylating agent
223640841|NCT06387121|DRUG|Dexamethasone|Glucocorticoids
223640842|NCT06387121|DRUG|Venetoclax|Selective inhibitor of B-cell lymphoma 2 (Bcl-2)
223640843|NCT06387121|DRUG|Inotuzumab ozogamicin|A humanized monoclonal antibody-drug conjugate targeting CD22
223640844|NCT06387121|DRUG|Blinatumomab|Bi-specific anti-CD19/CD3 antibodies
223640845|NCT06387121|DRUG|6-mercaptopurine|Cell cycle-specific antitumor drug
223640846|NCT06387121|DRUG|Methotrexate|Antifolate antineoplastic drug
223640847|NCT06387121|DRUG|Cytarabine|Pyrimidine antimetabolites
223640848|NCT06387121|DRUG|Prednisone|Glucocorticoids
223640849|NCT01784224|PROCEDURE|Blom Low Profile Voice Cannula/Passty-Muir Speaking Valves|
223640850|NCT04500587|DRUG|ZN-d5|Oral agent; 25 mg or 100 mg formulation
223640851|NCT04616989|BEHAVIORAL|Psycho-education|Provide psycho-education to members of the community
223640852|NCT04616989|BEHAVIORAL|Comparator|Distribution of COVID-19 leaflets to members of the community
223640853|NCT01590355|RADIATION|Radiotherapy|Gross Tumour and Nodes: 70 Gy in 35 fractions over 7 weeks. High-risk nodal areas: 63 Gy in 35 fractions over 7 weeks. Low-risk nodal areas: 56 Gy in 35 fractions over 7 weeks
223640854|NCT01590355|PROCEDURE|Transoral Robotic Surgery + Neck Dissection|Transoral robotic excision will be carried out using the da Vinci surgical robot.
223640855|NCT03452969|OTHER|Implantation of multifocal intraocular lens|"Procedure/Surgery:~Bilateral implantation of a segmental refractive multifocal intraocular lens (MIOL) following cataract surgery."
223640856|NCT00771758|DRUG|oxycodone IR|maximum daily dose 450 mg
223640857|NCT00771758|DRUG|placebo|5 or 10 mg capsule every 4 - 6 hr as needed for up to 10 days
223640858|NCT00771758|DRUG|tapentadol IR|50 or 75 mg capsule every 4 - 6 hr as needed for up to 10 days
223640859|NCT03067077|PROCEDURE|SMILE|SMILE surgery
223640860|NCT03067077|PROCEDURE|LASIK|LASIK surgery
223765177|NCT07147036|PROCEDURE|Calcium Hydroxide - Indirect Pulp Capping|"Caries removal under rubber dam isolation using round bur (#BR-45) and water spray~Tooth disinfection with 0.2% chlorhexidine~Cavity dried with cotton pellet~Placement of a 0.5 mm layer of Calcium Hydroxide (Dycal)~After 2-3 minutes (setting time): Placement of self-cure GIC (Fuji, Japan)~After 1 week: Final restoration with light-cure composite resin~Follow-up at 2, 6, and 12 weeks"
224229025|NCT01684553|BEHAVIORAL|Fast eating condition|The subjects were asked to eat their meal quickly during the fast eating condition
224229026|NCT04894747|DIETARY_SUPPLEMENT|Bolus ingestion of protein|Ingestion of 25g of protein
224229027|NCT01820039|OTHER|FertiScreen|FertiScreen is an online application to assess whether referral is necessary or expectant management is indicated.
224229028|NCT06485375|DIAGNOSTIC_TEST|EMG|Disposable bipolar surface electrodes will be used. The patient's skin will be clean with cotton gauze soaked in alcohol before electrodes placement to reduce skin impedance. The operator will palpate the muscle belly while the patient clenches his teeth and will position surface electrodes in parallel to the muscular fibres. Doing so the position of the electrodes results as follows: Masseters electrodes will be fixed parallel to the exocanthion-gonion line and with the upper pole of the electrode under the tragus-labial commissural line. Temporalis electrodes will be positioned along the anterior margin of the muscle (corresponding to the frontoparietal suture). Suprahyoid muscles electrodes will be placed in the submental area nearly 1 cm posterior to the mental symphysis, paramedian to the midline and lightly diverging. A reference electrode will be applied to the forehead of the patient.
223640861|NCT02529072|DRUG|nivolumab|Nivolumab is a fully human monoclonal antibody that targets the programmed death-1 (PD-1) cluster of differentiation 279 cell surface membrane receptor. PD-1 is a negative regulatory molecule expressed by activated T and B lymphocytes. Binding of PD-1 to its ligands, programmed death-ligands 1 and 2, results in the down-regulation of lymphocyte activation. Inhibition of the interaction between PD-1 and its ligands promotes immune responses and antigen-specific T cell responses to both foreign antigens as well as self-antigens. Nivolumab is expressed in Chinese hamster ovary cells and is produced using standard mammalian cell cultivation and chromatographic purification technologies. The clinical study product is a sterile solution for parenteral administration.
223640862|NCT02529072|BIOLOGICAL|DC|DCs are potent immunostimulatory cells that continuously sample the antigenic environment of the host and specifically activate cluster of differentiation 4 positive (CD4+) and cluster of differentiation 8 positive (CD8+) T-cells and B-cells. They are at the crossroads of many of the elegant networks of the immune system, and DCs represent the most promising contemporary biologic entity for realizing the promise of immunotherapy. Potent immune responses and encouraging clinical results have been seen in Phase I and II human clinical trials in systemic cancers. Numerous animal studies and the investigator's institution's humans studies have demonstrated potent antitumor responses using DC-based immunotherapy against MGs.
223640863|NCT01632722|DRUG|Bevacizumab, mFOLFOX, FOLFIRI|"ArmA (postoperative arm)~Postoperative mFOLFOX or FOLFIRI regimen, every 2weeks for 12cycles Bevacizumab 5mg/kg IV, every 2weeks for 11cycles beginning with cycle 2"
223640864|NCT01632722|DRUG|Bevacizumab, mFOLFOX, FOLFIRI|"ArmB (perioperative arm)~Perioperative CTx mFOLFOX or FOFIRI regimen, every 2 weeks for 6 cycles Bevacizumab 5mg/kg IV, every 2 weeks for 5cycles (cycles 1-5)~Postoperative CTx mFOLFOX or FOLFIRI regimen, every 2weeks for 6 cycles Bevacizumab 5mg/kg IV, every 2weeks for 5cycles(cycles 8-12)"
223640865|NCT00935584|BEHAVIORAL|Physician training in patient-centered emr use|This intervention was performed in between the pre-intervention (Baseline) clinic visit and post intervention clinic visit.
223640866|NCT01113255|PROCEDURE|bench-evaluation, of three ventilators|to select in-VITRO the most appropriate ventilator for a given pathology.
223640867|NCT00687193|DRUG|Placebo|Placebo BID, 3 blinded tablets administered BID for 12 weeks
223640868|NCT00687193|DRUG|CP-690,550|10mg BID, 3 blinded tablets administered BID for 12 weeks
223640869|NCT00687193|DRUG|CP-690,550|15mg BID, 3 blinded tablets administered BID for 12 weeks
223640870|NCT00687193|DRUG|CP-690,550|1mg BID, 3 blinded tablets administered BID for 12 weeks
223640871|NCT00687193|DRUG|CP-690,550|3mg BID, 3 blinded tablets administered BID for 12 weeks
223640872|NCT00687193|DRUG|CP-690,550|5mg BID, 3 blinded tablets administered BID for 12 weeks
223640873|NCT00529438|DRUG|Bardoxolone methyl|
223640874|NCT04969939|DRUG|Semaglutide 2.4 mg and NNC0165-1875 2.0 mg|NNC0165-1875 will be co-escalated once-weekly subcutaneously with semaglutide every 2 weeks for the first 4 weeks, and every 4 weeks for the next 8 weeks until final target dose levels are reached.
223640875|NCT04969939|DRUG|Semaglutide 2.4 mg and placebo 2.0 mg|NNC0165-1875 placebo will be co-escalated subcutaneously once-weekly with semaglutide every 2 weeks for the first 4 weeks, and every 4 weeks for the next 8 weeks until final target dose levels are reached.
223640876|NCT04969939|DRUG|Semaglutide 2.4 mg and NNC0165-1875 1.0 mg|NNC0165-1875 will be co-escalated subcutaneously once-weekly with semaglutide every 2 weeks for the first 4 weeks, and every 4 weeks for the next 8 weeks until final target dose levels are reached.
223640877|NCT04969939|DRUG|Semaglutide 2.4 mg and placebo 1.0 mg|NNC0165-1875 placebo will be co-escalated subcutaneously once-weekly with semaglutide every 2 weeks for the first 4 weeks, and every 4 weeks for the next 8 weeks until final target dose levels are reached.
223640878|NCT06010160|BEHAVIORAL|Game Changers for Cervical Cancer Prevention|The peer advocacy training sessions focus on reduction of internalized stigma, disclosure decision making, education on cervical cancer facts and myths, and building skills for cervical cancer prevention advocacy.
223640879|NCT05830396|DRUG|Ambroxol Hydrochloride|Patients will either receive ambroxol or placebo. ambroxol will be given intially in a dosage of 600mg/day. After 1 week, this will be increased to 1200mg/day. After 2 weeks the maximum dosage of 1800mg/day will be given. In total, ambroxol will be administered for 48 weeks. This is followed by a 12 week washout period, after wich the final outcomes will be measured (week 60).
223640880|NCT05830396|DRUG|Placebo|Patients will either receive ambroxol or placebo. ambroxol will be given intially in a dosage of 600mg/day. After 1 week, this will be increased to 1200mg/day. After 2 weeks the maximum dosage of 1800mg/day will be given. In total, ambroxol will be administered for 48 weeks. This is followed by a 12 week washout period, after wich the final outcomes will be measured (week 60).
223640881|NCT04986904|BEHAVIORAL|SHUTi (Sleep Healthy Using the Internet)|Cognitive Behavioral Therapy for insomnia delivered online and metered out over 6 weeks in a fully automated, interactive, tailored web-based program
223640882|NCT00453141|DRUG|dosing of Betamethasone|
223640883|NCT06038110|DIAGNOSTIC_TEST|axillary ultrasound|usefulness of axillary ultrasound in predicting need for chemotherapy or upfront surgery
223765178|NCT06952426|OTHER|No intervention|Participants and their caregivers will report home reported outcomes (HRO) data on symptom burden to understand symptom variability and health-related quality of life (HRQoL).
224229029|NCT05129579|BEHAVIORAL|Mindfulness Based Stress Reduction Intervention|Mindfulness Based Stress Reduction intervention is a manualized course that includes meditation, relaxing movement, and breathing. A certified MBSR instructor will teach the courses in a group-based format for 90 minute sessions, once per week for eight weeks.
224229030|NCT05129579|OTHER|no intervention|No intervention will be made in the control group.
224229031|NCT03532685|PROCEDURE|Bariatric|withdrawing a part of the stomach and may or may not be combined with bowel deviation
224229032|NCT01042483|DEVICE|LaborPro device|monitoring labor progression by using a new device The LaborPro system (Trig Medical Inc) allows determination of fetal head station and position using ultrasound and position tracking system.
224229033|NCT01725451|DRUG|Testosterone|Administered topically to axillae
224229034|NCT01725451|OTHER|Deodorant Spray|Administered topically to axillae
224229035|NCT01725451|OTHER|Deodorant and Antiperspirant Combination Spray|Administered topically to axillae
224229036|NCT01725451|OTHER|Deodorant and Antiperspirant Combination Stick|Administered topically to axillae
224229037|NCT03308019|DEVICE|Photodynamic therapy|In groups 1 and 2, aPDT was performed after SRP. The protocol for aPDT is described elsewhere. Briefly, using a blunt needle, 0.005% of Methylene blue was applied into the periodontal pocket and left in place for 10 seconds. The dye was then irradiated with a diode laser (670 nanometers) at 150 milliwatts. In each dye filled periodontal pocket, laser irradiation was performed for one minute using a flexible tip. In the present study, aPDT was performed once, at baseline, by a trained dentist.
224229038|NCT03308019|PROCEDURE|Scaling and root planing (SRP)|In both groups, SRP was performed in one session under local anesthesia using handheld Gracey curettes No. 5/6. One trained dental hygienist blinded to the study groups and subgroups made 9 to 10 strokes in a vertical (apico-coronal) direction and the inclination between scaler tips and roots was maintained as zero. When the curved explorer indicated a smooth and hard dental surface, SRP was judged as completed. In all individuals, SRP was done in one session without any assigned time limit for completion.
224229039|NCT00854009|DRUG|BLI-489|
224229040|NCT00854009|DRUG|Placebo|
224229041|NCT04385446|PROCEDURE|Amniotic membrane transplantation|Amniotic membrane transplantation was used as covering material during pterygium surgery.
224229042|NCT04172298|OTHER|sham electroacupuncture (EA) session|The stainless steels acupuncture needles inserted into the subcutaneous layer of Zusanli (cathode) and Shangjuxu acupints (anion) , and the needles connected to EA stimulator, but no electric discharge for 30 min.
224229043|NCT04172298|OTHER|Zusanli session|The acupuncture needles inserted into Zusanli (cathode) and Shangjuxu acupoints (anion), and twisting obtain qi, and the needles then connected to EA stimulator, the frequency was 2 Hz, the duration was 30 min, and the intensity was visual slightly muscle contraction.
224229044|NCT04172298|OTHER|Shaohai session|The methods were identical Zusanli group, but Shaohai acupoint (cathode), and 3 cm below Shaohai (anion).
224229045|NCT04414956|DIAGNOSTIC_TEST|AFP-L3|AFP-L3 will be tested using serum sample every 6 months.
223640884|NCT01238367|DRUG|turoctocog alfa|Subjects will receive recombinant factor VIII (N8) at a dose of 50 +/- 5 IU/kg body weight. Intravenous administration as a single bolus injection.
223640885|NCT04334824|DRUG|Hydrochlorothiazide|Exposure to hydrochlorothiazide will be defined as a prescription for hydrochlorothiazide alone or in combination with non-ACE inhibitor antihypertensive drugs at cohort entry date.
223640886|NCT04334824|DRUG|Angiotensin-converting enzyme (ACE) inhibitors|Exposure to ACE inhibitors will be defined as a prescription for an ACE inhibitor alone or in combination with non-hydrochlorothiazide antihypertensive drugs at cohort entry date.
223640887|NCT03736863|DRUG|Apatinib+ SHR-1210（Camrelizumab）|Apatinib 250mg, q.d.po+SHR-1210（Camrelizumab）200 mg，Intravenous injection，q2W
223640888|NCT03736863|DRUG|Apatinib+ SHR-1316（Adebrelimab）|Apatinib 250mg, q.d.po+SHR-1316（Adebrelimab） 1200 mg，Intravenous injection，q2W
223640889|NCT03736863|DRUG|SHR-1316（Adebrelimab）+SHR-A2009|SHR-1316 was administered intravenously, 1200mg, Q3W; SHR-A2009 8mg/kg, iv, Q3W,
223640890|NCT05089825|OTHER|Receive routine instructions|Study subjects randomized to this arm will receive a mailed myLab Box kit with instructions on HPV self-collection and postage to be shipped directly to the commercial lab. It should take less than 5 minutes to collect the sample.
223640891|NCT05089825|OTHER|Telehealth-based instructional visit and receive routine instructions|"Study subjects randomized to this arm will similarly receive a mailed myLab Box kit and also undergo a brief 5-10 telehealth instructional visit via video conference."
223640892|NCT06553937|DRUG|Macitentan and Tadalafil|1 tablet of Macitentan and Tadalafil film-coated tablets 10 mg/40 mg
223640893|NCT06553937|DRUG|PrOpsynvi® Film-Coated Tablets|1 tablet of Macitentan and Tadalafil film-coated tablets 10 mg/40 mg
223640894|NCT04126135|DRUG|Cytisine|Subjects will take a 25-day course of Cytisine tablets started during the 4 days before the quit date. They will be asked to reduce smoking during this time.
223765179|NCT06952426|OTHER|Other treatment|Participants and their caregivers will report HRO data on symptom burden and treatment usage to understand symptom variability and HRQoL.
224229046|NCT04414956|DIAGNOSTIC_TEST|AFP|AFP will be tested using serum sample every 6 months.
224319397|NCT02473198|DRUG|Toradol|The patient will then undergo an ultrasound guided femoral nerve block in the preoperative area with bupivacaine 0.25% 20 cc. All patients will undergo unilateral TKR using a medial parapatellar approach. Intraoperatively prior to cementing of the TKR, patients will also receive a local anesthetic injection of a mixture of 30cc 0.25% bupivicaine with epinephrine, 30mg of toradol and 10 mg of morphine sulfate into the posterior capsule of the knee joint.
223765180|NCT06952426|OTHER|Iptacopan|Participants and their caregivers will report HRO data on symptom burden and treatment usage to understand symptom variability and HRQoL including those taking iptacopan.
223765181|NCT06952426|OTHER|Atrasentan|Participants and their caregivers will report HRO data on symptom burden and treatment usage to understand symptom variability and HRQoL including those taking atrasentan.
223765182|NCT04683679|DRUG|Pembrolizumab|Pembrolizumab 200 mg will be administered as a 30 minute IV infusion every 3 weeks for 3 doses
224229047|NCT04414956|DIAGNOSTIC_TEST|PIVKA-II|PIVKA-II will be tested using serum sample every 6 months.
224229048|NCT04414956|DIAGNOSTIC_TEST|Sonography|Sonography will be tested by experts every 6 months.
223765183|NCT04683679|DRUG|Olaparib|Olaparib will be administered twice daily continuously without breaks on a 21-day (3 week) cycle length, for a total of 2 cycles. Olaparib tablets will be administered bid (2 x 150 mg tablets twice daily; total 600 mg daily) on continuous days without interruption for 2 cycles. Each 3 week period constitutes one cycle.
223765184|NCT04683679|RADIATION|Radiation|The dose of radiation will be 8-9 Gy x 3 fractions. Radiation therapy will begin on C1D2-7. For tumors that are too large for this schedule, an accomodation of 30 Gy in 6 Gy per fraction is allowed, a schedule commonly used at MSK.
223765185|NCT07160036|DEVICE|RLRL(Model RS-200-2A, Eyerising; Suzhou Xuanjia Optoelectronic Technology Co., Ltd., Suzhou, China))|use RLRL twice a day
224229049|NCT04414956|DIAGNOSTIC_TEST|CT|Contrast-enhanced CT will be tested annually.
224229050|NCT03101943|BEHAVIORAL|Family Spirit Nurture (FSN)|The FSN intervention will be conducted over a 6-month period. Participants in the intervention group will receive 6- 45 minute lessons in their home or a private place of their choosing. The lessons focus on elimination or reduction of Sugar Sweetened Beverages (SSBs) among infants while teaching mothers complementary feeding and responsive parenting practices
224229051|NCT03101943|OTHER|Control Program|The control group will receive three home-based lessons with home safety information.Lessons will be delivered monthly (at 3, 4 and 5 months postpartum) in the same format as the FSN lessons, by trained FHCs in the home of the participant or in a private place of their choosing.
224229052|NCT03101943|OTHER|Water Delivery|Drinking water will be delivered to the household of each participant (both in the FSN intervention and control groups) from 6 to 9 months postpartum. The amount of water will be determined by the number of children and adults living in the household at the time of water delivery. The first delivery of water will occur at the time of the 6-month evaluation and the last delivery will occur at the time of the 9-month evaluation. Water will be delivered as often as weekly. Those families who do not need weekly water delivery (based on their preference and their usage of the first delivery of water) will receive water less frequently.
224229053|NCT02628340|OTHER|Ex-vivo analysis|
224229054|NCT02625415|DEVICE|Vitamin B6 cream|Topical Vitamin B6 cream
224229055|NCT02625415|DEVICE|Placebo Vitamin B6 cream|Placebo Vitamin B6 cream
224229056|NCT01564758|DRUG|Linezolid|"1. Vancomycin-resistant, E. faecium, including concurrent bacteremia: Linezolid for 600mg (IV or oral) every 12 hours for 14-28 days~2. Nosocomial infection, cSSTI: Linezolid for 600mg (IV or oral) every 12 hours for 10-14 days~3. Uncomplicated SSTI: Linezolid for 400mg oral every 12 hours for 10-14 days"
224229057|NCT04383990|OTHER|Timing of taking insulin|To take insulin Glargine early (6-7pm) or late (bedtime-10-12pm)
224229058|NCT02588625|DRUG|BMS-986020|
224229059|NCT02588625|OTHER|Placebo|
224229060|NCT02424981|DEVICE|Threshold inspiratory muscle training|Inspiratory muscle training
224229061|NCT00249821|DRUG|Saizen®|Saizen® \[somatropin (recombinant deoxyribonucleic acid \[rDNA\] origin) for injection\], a r-hGH, is indicated for the treatment of children with growth failure due to inadequate secretion of endogenous growth hormone.
224229062|NCT00249821|DRUG|Saizen®|Saizen® \[somatropin (rDNA origin) for injection\], a r-hGH, is indicated for the treatment of children with growth failure due to inadequate secretion of endogenous growth hormone.
223640895|NCT04126135|DRUG|Nicotine Replacement Therapy (NRT)|Subjects are asked to completely stop smoking on their quit day and use a daily NRT patch for 25 days.
223640896|NCT03435211|DEVICE|INVSENSOR00006|Noninvasive pulse oximeter sensor
223640897|NCT04537624|DRUG|Oral Semaglutide|Patients will be treated with commercially available oral semaglutide according to local label and to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available oral semaglutide has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician based on local label before and independently from the decision to include the patient in this study.
223640898|NCT04322890|DRUG|Osimertinib|Osimertinib 80mg, po, qd;
223640899|NCT04322890|DRUG|Alectinib 150 MG|Alectinib 600mg, po, qd; Lorlatinib, 100mg, po, qd;
223640900|NCT04322890|DRUG|Crizotinib 250 MG|Crizotinib 250 MG po bid.
223640901|NCT04322890|DRUG|Savolitinib, Crizotinib.|Savolitinib, 300mg po qd.
223640902|NCT04322890|DRUG|Chemotherapy|500mg, ivgtt, every 21day.
223640903|NCT06339099|OTHER|Conventional physical therapy program|This program included active resisted strengthening exercises for pelvis girdle and lower limb muscles, stretching exercises of tight muscles of lower limbs; hip flexors, hamstrings and calf muscle, balance activities from standing and walking and gait training exercises.
223640904|NCT06339099|OTHER|Loaded gait training|An extra weight was added around the distal legs during gait training in the intervention group. This weight began at 0.5 kg and was gradually increased every two weeks to a maximum of 2 kg
223640905|NCT04882202|DRUG|Acetaminophen|Acetaminophen 1g IV every 6 hours for a weight \> 50kg (maximum of 4g per 24 hours) or 15mg/kg every 6 hours for a weight \< 50kg (maximum of 75mg/kg per 24 hours)
223640906|NCT04882202|OTHER|Placebo|Normal saline 100 ml (equal amount of acetaminophen) IV every 6 hours
223640907|NCT03863080|DRUG|RVT-1401|Subcutaneous administration of RVT-1401
223640908|NCT03863080|DRUG|Placebo|Subcutaneous administration of Placebo
223640909|NCT02220543|OTHER|Back on Track intervention|Biopsychosocial primary care intervention based on multidisciplinary pain rehabiliation programs. The Back on Track intervention comprises 4 individual sessions and 8 group sessions.
223640910|NCT02220543|OTHER|Primary care as usual|Regular physical therapy in primary care. Physical therapists are recommended by their profession (the Royal Dutch Society for Physical Therapy) to work according to a profession-specific guideline for the treatment of patients with low back pain in primary care settings. Maximally 12 individual sessions (30 minutes each) for a maximum of 8 weeks.
223640911|NCT01342211|BIOLOGICAL|Placebo|Intravenous placebo monthly during treatment phase.
223640912|NCT01342211|DRUG|Statin|Single daily dose of atorvastatin (40 or 80 mg), rosuvastatin (20 or 40 mg) or simvastatin (40 or 80 mg) from Day 1 to Day 141/ET.
223640913|NCT01342211|BIOLOGICAL|PF-04950615 (RN316)|Intravenous 10mg/mL based on weight monthly during treatment phase.
223640914|NCT01342211|DRUG|Statin|Single daily dose of atorvastatin (40 or 80 mg), rosuvastatin (20 or 40 mg) or simvastatin (40 or 80 mg) from Day 1 to Day 141/ET.
224319398|NCT02473198|DRUG|Morphine Sulfate|The patient will then undergo an ultrasound guided femoral nerve block in the preoperative area with bupivacaine 0.25% 20 cc. All patients will undergo unilateral TKR using a medial parapatellar approach. Intraoperatively prior to cementing of the TKR, patients will also receive a local anesthetic injection of a mixture of 30cc 0.25% bupivicaine with epinephrine, 30mg of toradol and 10 mg of morphine sulfate into the posterior capsule of the knee joint.
224319399|NCT03509857|DEVICE|BUZZY(tm)|"Risks associated with the BUZZY(tm) device The intervention group will receive vibration only, with application of the BUZZY device just proximal to the intravenous infusion site immediately before and during propofol infusion.~There are no known risks for the use of the BUZZY(tm) device, which is registered as an FDA class III device (therapeutic massager)."
224319400|NCT03509857|OTHER|No Intervention|No intervention
224319401|NCT01537939|BEHAVIORAL|ASUKI Step Worksite Pedometer Intervention|The intervention required participants to accumulate 10,000 steps each day for six months, with a 3-month follow-up period. Steps were recorded onto a study-specific website. Participants completed a website-delivered questionnaire four times to identify socio-demographic, health, psychosocial and environmental correlates of study participation. One person from each team at each university location was randomly selected to complete physical fitness testing to determine their anthropometric and cardiovascular health and to wear an accelerometer for one week.
224319402|NCT01098630|OTHER|Medical Chart Review|Patients' medical record information is collected and staff complete the treatment review form
224229063|NCT02140450|DRUG|Timolol|2 drops of timolol, 10 minutes apart, 1-2 hours before intravitreal injection
224319403|NCT01098630|OTHER|Questionnaire Administration|Ancillary studies
224319404|NCT04902014|BEHAVIORAL|Motivational Interviewing|The individuals will be scheduled for and participate in six biweekly in person SDT based MI sessions. These sessions will take place in the HPCRL at CSU. The MI sessions will be conducted by a PhD student who has been trained by a MI practitioner. Participants will be provided a log book and will be asked to log their PA, with the goal of completing at least 150 minutes of PA per week. They will set biweekly PA goals, which will be discussed in the MI sessions. These participants will also receive general physical activity guidelines education and information on strategies to reach the recommended amount of activity per week during the initial baseline assessment meeting.
224319405|NCT04902014|BEHAVIORAL|Education|These participants will receive general physical activity guidelines education and information on strategies to reach the recommended amount of activity per week during the initial baseline assessment meeting. These participants will not do any other study related activities. At the conclusion of the study, these participants will be offered the chance to participate in one MI session.
224319406|NCT04902014|BEHAVIORAL|Wearable Fitness Trackers|Individuals assigned to this experimental condition will be given a wrist-worn WFT and will be instructed to wear it for the duration of the study. They will also download the corresponding mobile application on their smartphones. They will be trained by a member of our team on how to utilize the WFT and mobile application. The intended WFT tracks daily steps, miles traveled, kcals expended, and daily activity time. This device provides these data to the wearer via a small screen. Participants will be instructed to aim to complete at least 150 minutes of PA per week. Researchers will have the capability to track participant daily PA via the WFT and associated API. These individuals will be asked to set biweekly PA goals. These participants will also receive general physical activity guidelines education and information on strategies to reach the recommended amount of activity per week during the initial baseline assessment meeting.
223640915|NCT01342211|BIOLOGICAL|PF-04950615 (RN316)|Intravenous 10mg/mL based on weight monthly during treatment phase.
223640916|NCT01342211|DRUG|Statin|Single daily dose of atorvastatin (40 or 80 mg), rosuvastatin (20 or 40 mg) or simvastatin (40 or 80 mg) from Day 1 to Day 141/ET.
223640917|NCT01342211|BIOLOGICAL|PF-04950615 (RN316)|Intravenous 10mg/mL based on weight monthly during treatment phase.
223640918|NCT01342211|DRUG|Satin|Single daily dose of atorvastatin (40 or 80 mg), rosuvastatin (20 or 40 mg) or simvastatin (40 or 80 mg) from Day 1 to Day 141/ET.
223640919|NCT01342211|BIOLOGICAL|PF-04950615 (RN316)|Intravenous 10mg/mL based on weight monthly during treatment phase.
223640920|NCT01342211|DRUG|Statin|Single daily dose of atorvastatin (40 or 80 mg), rosuvastatin (20 or 40 mg) or simvastatin (40 or 80 mg) from Day 1 to Day 141/ET.
223640921|NCT05724277|BEHAVIORAL|Mindfulness Meditation|A 15-minute mindfulness meditation will be conducted by the meditation instructor researcher.
223640922|NCT05724277|BEHAVIORAL|Virtual Reality|A 10-minute virtual reality experience will be provided by using virtual reality glasses.
223640923|NCT01851642|PROCEDURE|History and physical exam.|At every study visit, participant's will be asked about their medical history and will have a physical exam.
223640924|NCT01851642|PROCEDURE|Blood draw.|At each study visit, participants will have an intravenous catheter (IV) placed in one of their veins and blood will be drawn from the IV for study testing.
223640925|NCT01851642|PROCEDURE|Pulmonary function testing.|At every study visit, participants will have their lung function assessed. This is done by blowing forcefully at least 3 times into a tube. Testing will be done two times; before and after the use of an Albuterol inhaler.
223640926|NCT01851642|DRUG|Albuterol inhaler.|At every study visit, participating subjects will take 2 puffs of an Albuterol inhaler after the first set of PFTs, but before the second set of PFTs. There will be at least a 30 minute period after the use of the Albuterol inhaler and the second set of PFTs.
223640927|NCT06543745|BEHAVIORAL|Low-Resistance Training|"The following 6 exercises will be performed in 3 sets of 15-15-15 repetitions, 3 times per week for 12 weeks:~Elbow Flexion, Elbow Extension, Lateral Hip Extensions, Hip Extensions, Knee Extensions, Wall push-ups"
224229064|NCT02140450|DRUG|Brimonidine|Brimonidine eyedrop, 2 drops 5 minutes apart, 1-2 hours before intravitreal injection
224229065|NCT02140450|DRUG|Acetazolamide|Acetazolamide tablet, 2 tabs, 2 hours before intravitreal injection
224229066|NCT02140450|DRUG|Mannitol|Intravenous mannitol, 1.5 gram/kg, 1 hour before intravitreal injection
224229067|NCT02140450|DRUG|Placebo|Artificial tears, 2 drops, 1-2 hours before intravitreal injection
224229068|NCT01775761|DRUG|Period 1|A comparison of less than or equal to 960 mg tafamidis, 400 mg moxifloxacin and placebo on the rate corrected QT interval.
224319407|NCT04902014|BEHAVIORAL|Wearable Fitness Tracker+|These individuals will be given the wrist-worn WFT, be instructed to wear it for the duration of the study AND be scheduled for six SDT based MI sessions. These participants will also be trained by a member of our team on how to utilize the WFT and associated application. They will be instructed to aim to complete 150 minutes of PA per week. These participants will be asked to set biweekly PA goals which will be discussed in MI sessions. Researchers will have the capability to track participant daily PA via the WFT and associated API. These participants will also receive general physical activity guidelines education and information on strategies to reach the recommended amount of activity per week during the initial baseline assessment meeting.
224319408|NCT00551512|DRUG|CBP501 and Cisplatin|CBP501 is given IV on Day 1 of each cycle (every 21 days). Dose escalation of CBP501 and cisplatin will be starting doses of 3.6 mg/m² CBP501 and 50 mg/m² cisplatin (Dose Level 1). Step 1, if during the first 2 cycles, at least 2 out of 3 to 6 patients experience Dose Limiting Toxicity (DLT) at 50 mg/m² cisplatin, then the cisplatin dose will be de-escalated to 30 mg/m². If no more than 1 out of 6 patients experiences DLT, cisplatin dose will be escalated to 75 mg/m². Step 2, dose escalation will be performed using the cisplatin MTD, with escalating CBP501 doses. CBP501 dose escalation will take place until the MTD has been defined or 74 mg/m² is reached.
224229069|NCT01775761|DRUG|Period 2|A comparison of less than or equal to 960 mg tafamidis, 400 mg moxifloxacin and placebo on the rate corrected QT interval.
223640928|NCT05558969|DRUG|pregnant women taking magnesium|The patient group who received magnesium as a 4-6 g loading and 2-3 g/h maintenance dose to prevent convulsions in preeclampsia. Pregnant will be operated under general anesthesia. Sugammadex 4mg/kg will be administered when TOF 0 response is seen at the end of surgery. The time from TOF 0 to TOF 0.9 will be recorded. Magnesium and calcium levels in the blood will be studied.
223640929|NCT05558969|DRUG|Placebo|Pregnant women who do not receive magnesium therapy and who will be operated under general anesthesia. Sugammadex 4mg/kg will be administered when TOF 0 response is seen at the end of surgery. The time from TOF 0 to TOF 0.9 will be recorded. Magnesium and calcium levels in the blood will be studied.
223640930|NCT01899521|PROCEDURE|Bronchoscopy|Involves flexible fiberoptic bronchoscopy with standardized bronchoalveolar lavage (BAL) technique (isotonic saline in a sub-segment of the right middle lobe or lingula) using standard conscious sedation techniques.
224229070|NCT01775761|DRUG|Period 3|A comparison of less than or equal to 960 mg tafamidis, 400 mg moxifloxacin and placebo on the rate corrected QT interval.
224229071|NCT01212783|BEHAVIORAL|In-Home Cognitive Behavioral Therapy|Adapted form of CBT that is delivered in the home setting, uniquely designed for young, low income new mothers, and is explicitly integrated with home visitation. IH-CBT is delivered by a masters level therapist. It consists of 15 weekly sessions and two monthly booster sessions provided after the 15th session.
224229072|NCT01212783|BEHAVIORAL|Present-Centered Therapy|Present-Centered Therapy is a supportive psychotherapy.
224229073|NCT05265195|OTHER|Mixed Methods study|Mixed Methods study
224229074|NCT02482571|DEVICE|Mild Hypoxia|During normoxia, the computer-controlled gas blender provides a gas mixture that generates pressures of expired O2 and CO2 similar to the resting values measured for each subject (32-35mmHg and 100-110 mmHg, respectively). During mild hypoxia, we will target the same expired CO2 of normoxia and a 60 mmHg reduction of expired O2 from the resting value (to a minimum limit of 50 mmHg), which is expected to reduce arterial oxygen saturation to 82-85%. In mild hypoxia, the fraction of inspired oxygen is reduced from \~21% (room air) to \~12% (equivalent to an altitude of 4000 meters). During both conditions of normoxia and mild hypoxia, the brain activity of subjects is monitored with functional magnetic resonance spectroscopy (fMRS) while they are presented with visual stimuli.
224319409|NCT01783912|BEHAVIORAL|Cognitive / Motivational Individual Sessions|Cognitive Motivational subjects will receive four evidence-based preparatory interventions (motivational interviewing, smoking reduction, practice quit attempt, and pre-quit use of nicotine replacement medication) (25 - 30 minutes each).
224229075|NCT04429451|BIOLOGICAL|4SCAR-PSMA T cells|Infusion of 4SCAR-PSMA T cells at 10\^6 cells/kg body weight via IV
223640931|NCT01899521|DIETARY_SUPPLEMENT|Zinc sulfate 220 mg once daily|
223640932|NCT01899521|DIETARY_SUPPLEMENT|S-adenosylmethionine 400 mg twice daily|
223640933|NCT01877070|BEHAVIORAL|assessments|
223640934|NCT06187025|OTHER|Alcohol, Smoking and Substance Involvement Screening Test (ASSIST)|Standardized clinical evaluations and screening of substance use using the World Health Organization Alcohol, Smoking and Drug Abuse Screening Test (ASSIST)
223640935|NCT06187025|OTHER|Ecological Momentary Assessment (EMA)|Daily EMA evaluations during 12 weeks
223640936|NCT05595707|OTHER|Expert-Guided Early Tracheostomy|Patients judged to be at moderate to high risk of prolonged ventilation(26, 27) were those who had chronic respiratory failure, advanced Effectiveness of an Expert-Guided Early Tracheostomy Pathway Page 6/27 age, thrombocytopenia or coagulopathy, persistent vasopressor shock, requirement for renal replacement therapy, an admission trauma diagnosis amongst other criteria, were included. In the absence of these criteria, a consensus for low risk of prolonged MV was reached. Early PDT, within the first 7 days from intubation, was recommended for patients with a moderate/high risk of prolonged MV (Early Group). Continued MV by ETT was recommend for low-risk patients with the potential for delayed PDT in the event of delayed weaning and liberation (Late Group).
223640937|NCT01367106|PROCEDURE|Euglycemic hyperinsulinemic clamp|Euglycemic hyperinsulinemic clamp will be performed at day 2
223640938|NCT06214689|OTHER|biomarkers analysis|IDH1 and OCT4 markers analysis of surgical specimens of high grade astrocytoma
223640939|NCT05063058|DRUG|Molecular guided therapy|Biomarker-driven therapy according to recommandations of the precision oncology tumor board including MEK Inhibitors (Trametinib 2 mg/d, Selumetinib 75 mg 2/d), MET Inhibitors (Crizotinib 250 mg 2/d, or Cabozantinib 60mg/d), RAS Inhibitor (Sorafenib 400 mg 2/d), Cell cycle Inhibitor (Palbociclib 125 mg/d) and Checkpoint Inhibitor (Nivolumab 240 mg every 2 weeks).
223640940|NCT02374528|PROCEDURE|Negative pressure wound therapy|Negative pressure wound therapy (NPWT) is the application of suction (negative pressure) to wounds with skin grafting.
223640941|NCT02374528|PROCEDURE|standard pressure bolster dressing|This method is traditional used in skin grafting wound.
223640942|NCT06967194|DRUG|Metoprolol (MET)|Administration of metoprolol 25 mg twice daily
223640943|NCT06967194|DRUG|Plcacebo|Administration of matching placebo
224229076|NCT01446913|DEVICE|Standard CPAP Intervention|
223640944|NCT06972121|BEHAVIORAL|Mindset Intervention|The mindset intervention includes 4 brief digital modules over 9 weeks (once every 3 weeks) via app or email, prior to the half-marathon race. The content introduces meta-mindsets (beliefs about how mindsets shape experiences and outcomes) and reframes non-severe physical symptoms (e.g., muscle soreness, fatigue) as signs of physiological adaptation. Modules cover: (1) what mindsets are and how they affect performance; (2) how to interpret normal training symptoms as positive signals; (3) how to maintain adaptive mindsets during peak training; and (4) race-day mindset preparation. Each module includes brief text, visuals, and reflection questions and takes approximately five minutes to complete.
223640945|NCT06972121|BEHAVIORAL|Marathon Performance Training|The marathon performance training intervention includes 4 brief digital modules over 9 weeks (once every 3 weeks) via app or email, prior to the half-marathon race. Content is based on publicly available half-marathon training guidance and excludes any mindset-related material. Modules cover: (1) setting race goals and structuring training plans; (2) training tips and best practices (e.g., pacing, injury prevention); (3) navigating peak training periods (e.g., distance increases, rest and recovery); and (4) practical race-day preparation strategies (e.g., pacing, fueling, warm-up routines). Each module includes concise text, visuals, and actionable tips designed to take approximately five minutes to complete.
223640946|NCT06972277|BEHAVIORAL|Commercial weight management program|Participants will receive evidence-based behavioral / lifestyle support from a commercial weight management program.
223640947|NCT05890664|DRUG|Colchicine|"Colchicine 0.5 mg (oral) once daily for 90 days. The chemical name for colchicine is (S)-N-(5,6,7,9-tetrahydro-1,2,3,10-tetramethoxy-9 oxobenzol\[a\]heptalen-7-yl) acetamide.~Colchicine consists of pale yellow scales or powder. It is soluble in water, freely soluble in alcohol, and slightly soluble in ether."
223640948|NCT05890664|DRUG|Placebo|Matched placebo. Both the active drug and placebo will look similarly. The route and mode of administration is also similar to the active group.
223640949|NCT01582269|DRUG|LY2157299 monohydrate|Orally administered as tablets
223640950|NCT01582269|DRUG|Lomustine|Orally administered as capsules
223640951|NCT01582269|DRUG|Placebo|Orally administered as tablets
223640952|NCT05631587|BEHAVIORAL|WExercise|A 10-weekly technology-based intervention delivered in a mobile application using the M-PAC framework to promote PA in post-treatment cancer survivors. Participants will be given individualised access to the app. Participants will be sent reminders (3 days apart) by WhatsApp/WeChat each time they have a class due.
223640953|NCT05631587|BEHAVIORAL|Control|A control group receiving an information sheet for self-directed exercise.
223640954|NCT06564519|DEVICE|Posture Biofeedback Device|Participants will wear a commercially available posture training device for a two-week tracking period and a two-week training period while performing laparoscopic procedures.
223640955|NCT04021654|PROCEDURE|Data collection|Data collection of growth, neuromotor, sensorial, behavioral, and cognitive development.
224229077|NCT01446913|BEHAVIORAL|Enhanced CPAP Intervention|
224229078|NCT05744609|OTHER|exposures of interest: epidemiological data, clinical characteristics, laboratory data, and chest radiographic reports|epidemiological data (e.g., age, sex, and residential area), clinical characteristics (e.g., fever, cough, and wheeze), laboratory data (e.g., white blood cell, c-reaction protein, and procalcitonin), and chest radiographic reports (e.g., X-ray, CT, and ultrasound)
223640956|NCT04310462|OTHER|New e-prescribing interface|The goal of this study is to conduct a pragmatic trial to assess the utility of a new e-prescribing (eRX) interface for prescriptions of hydroxychloroquine (HCQ). Through randomization of clinicians to the new interface, the investigators will measure the effectiveness of the system in reducing the number of individuals prescribed HCQ over current guidelines.
224229079|NCT04588428|DRUG|INO-4700|INO-4700 was administered ID.
224229080|NCT04588428|DRUG|Placebo|Sterile saline sodium citrate (SSC) buffer (SSC-0001) was administered ID.
223640957|NCT05481723|DRUG|noradrenaline and vascular filling|In the control group, the haemodynamic management of the patients is done according to usual practice by maintaining blood pressure with noradrenaline and optimising stroke volume with vascular filling.
223640958|NCT05481723|PROCEDURE|pulmonary ultrasound after vascular filling|In the interventional group, intraoperative haemodynamic management is based on an algorithm that includes measurement of the number of B-lines appearing on pulmonary ultrasound after vascular filling. Monitoring of the stroke volume will also be performed in this group in order to stop the vascular filling if the ESV does not increase by more than 10%.
223640959|NCT06482125|DRUG|Dexmedetomidine|Intervention group will receive Total Intravenous Dexmedetomidine as their anesthetic maintenance agent. Intravenous Dexmedetomidine 1.5ug/kg will be administered within 10 minutes and maintenance dose of 1.5ug/kg/hour continued as the sole anesthetic maintenance agent, thereafter.
224229081|NCT04588428|DEVICE|CELLECTRA™ 2000|EP using the CELLECTRA™ 2000 device was administered following ID drug administration
224229082|NCT06014437|DRUG|PLCL/Fg group|Routine ulcerated wounds were cleaned, and the test group was given an equal-sized PLCL/Fg dressing to cover the wounds.
223640960|NCT06482125|DRUG|Sevoflurane|Inhalation Sevoflurane will be administered as an anesthetic maintenance agent. Sevoflurane at 2 - 3 Vol% will be administered throughout the operative procedure.
223640961|NCT05353777|DEVICE|Levita Robotic Platform|Levita Robotic Platform
224229083|NCT06014437|DRUG|control group|Routine ulcerated wounds were cleaned and changed, and the control group was given an alginate dressing of equal size to cover the wounds
224229084|NCT04938778|OTHER|PNF|PNF Participants will engage in 8 weeks of 14 hours per night fasting
224229085|NCT03171714|DEVICE|Derma-Stent|The novel device will facilitate self removal by patients, as it has a narrower profile, and, as a nonabsorbent material, will not become saturated with bodily fluids. Although it will not absorb body fluids
224229086|NCT03171714|DEVICE|Usual care, cotton gauze packing|Standard gauze packing used to pack a drained abscess.
224229087|NCT03520283|OTHER|Interview|Ancillary studies
224229088|NCT03520283|OTHER|Questionnaire Administration|Ancillary studies
224229089|NCT03520283|BEHAVIORAL|System Support Mapping|Complete MAP
224229090|NCT06496919|DRUG|Recombinant Mutant Human Tumor Necrosis Factor|The patients who received rmhTNF intraperitoneal perfusion (intraperitoneal surgical field flushing perfusion or intraperitoneal thermal perfusion chemotherapy)
223640962|NCT05368753|OTHER|Blood sample|Lidocaine blood sample 30 min before the end of the surgery Lidocaine blood sample at the end of the infusion lidocaine and ropivacaine blood sample 2 h after the ropivacaine infusion of the TEA Ropivacaine blood sample 24h after the infusion of the TEA
223640963|NCT05368753|DRUG|Lidocain|Lidocaine will be injected during the anaesthetic induction and infused until the surgical closure (30 minutes before the end) The occurrence of adverse events will be monitor by a physical examination and blood samples of lidocainemia and ropivacainemia in the perioperative period.
223640964|NCT05368753|DRUG|ropivacaine|Lidocaine will be injected during the anaesthetic induction and infused until the surgical closure (30 minutes before the end), then ropivacaine will be injected in the TEA at the same time and infused during 24h. The occurrence of adverse events will be monitor by a physical examination and blood samples of lidocainemia and ropivacainemia in the perioperative period.
223640965|NCT04043195|DRUG|Nivolumab|240 mg every 2 weeks. Nivolumab will continue for up to 2 years.
223640966|NCT04043195|DRUG|Oxaliplatin|65 mg/m2 every 2 weeks. Oxaliplatin will continue for up to 12 cycles.
223640967|NCT04043195|DRUG|Ipilimumab|1 mg/kg every 6 weeks. Ipilimumab will continue for up to 4 cycles
224229091|NCT01323881|DEVICE|Intermittent theta burst stimulation|Intermittent theta burst stimulation with 1200 pulses or sham stimulation over the ipsilesional M1 hand region for 10 daily sessions in 2 weeks.
224229092|NCT01577511|BIOLOGICAL|Samples and follow up|"Samples: Peroperative blood sample plus primary and metastatic tumor biopsies.~Follow-up: disease outcomes assessed at 24 months"
224229093|NCT00334490|DRUG|Sildenafil|12.5 mg Sildenafil once with optional second dose
224229094|NCT00334490|DRUG|Sildenafil|12.5 mg orally once with optional second dose
224229095|NCT00334490|DRUG|Placebo|Oral Placebo in 5 mls distilled water
224319410|NCT01783912|BEHAVIORAL|Attention Control Individual Sessions|Attention control subjects will receive four placebo individual sessions (25-30 minutes each). The session content will reemphasize group discussion of the personal health risks from smoking.
224319411|NCT01783912|DRUG|Nicotine Patch|Cognitive Motivational subjects will be asked to take one 21 mg patch/day for 4 weeks.
223640968|NCT05932238|OTHER|Polyethylene glycol 400 and propylene glycol solution/drops - Preservative Free (PF)|commercially available eye drops
223640969|NCT05932238|OTHER|Polyethylene glycol 400 and propylene glycol solution/drops - Preserved|commercially available eye drops
223640970|NCT05174416|DRUG|Mavacamten|Mavacamten Capsules
223640971|NCT05174416|DRUG|Placebo|Matching PBO capsules during placebo controlled period，and mavacamten capsules during long term extension period
223640972|NCT05979311|DRUG|Dolutegravir|Dolutegravir will be administered once daily.
224229096|NCT01388023|DIETARY_SUPPLEMENT|herbal formula for fresh breath|composition of herbal ingridients in a palatal mucoadhesive patch to remove volatile solfur compounds and reducequantity of vsc creating bacteria
223640973|NCT05979311|DRUG|Lamivudine|Lamivudine will be administered once daily.
223640974|NCT05979311|DRUG|Bictegravir|Bictegravir will be administered once daily.
223640975|NCT05979311|DRUG|Emtricitabine|Emtricitabine will be administered once daily.
223640976|NCT05979311|DRUG|Tenofovir alafenamide|Tenofovir alafenamide will be administered once daily.
223640977|NCT04809987|OTHER|Virtual Gait|The subject will be stand up with a standing opposite a mirror (from the waist up) and a screen (from the waist down) where a video of treadmill gait of a person will be projected.
223640978|NCT04809987|OTHER|Physical Exercise|Specific gait exercise was conducted.
223640979|NCT04809987|OTHER|Documental projection|The subject will be stand up with a standing opposite a mirror (from the waist up) and a screen (from the waist down) where video without any type of animal or human movement was showed.
223640980|NCT06178055|DRUG|KUS121 high dose|Participants will receive KUS121 high dose intravitreal (IVT) injection once on each of 3 consecutive days (Day 1 through Day 3).
223640981|NCT06178055|DRUG|KUS121 low dose|Participants will receive KUS121 low dose intravitreal (IVT) injection once on each of 3 consecutive days (Day 1 through Day 3).
223640982|NCT06178055|DRUG|Sham procedure|Participants will receive a sham procedure that mimics an intravitreal (IVT) injection once on each of 3 consecutive days (Day 1 through Day 3).
223765186|NCT07164261|OTHER|progressive muscle relaxation training|Progressive muscle relaxation training will be performed twice a week, each session lasting 20-30 minutes, for a total of 12 sessions over 6 weeks.
224229097|NCT02975466|DEVICE|Insertion of AirQ Blocker and intubation through the device|Insertion of the SGA device and evaluation of easiness of endotracheal intubation
224229098|NCT02975466|DEVICE|Insertion of AuraGain and intubation through the device|Insertion of the SGA device and evaluation of easiness of endotracheal intubation
224229099|NCT02975466|DEVICE|Insertion of I-Gel and intubation through the device|Insertion of the SGA device and evaluation of easiness of endotracheal intubation
224319412|NCT01783912|BEHAVIORAL|Group Curriculum|Everyone to be put into the experimental or active comparator group will attend 2 group meetings over two weeks each of which lasts 40 minutes. Experience with the Kicking Butts program indicates that this duration is well tolerated by this population. The content of these two group meetings is based on the Kicking Butts program. The Kicking Butts program was initially developed as a cessation intervention, but consistent with the literature about the need to prepare this population to make a quit attempt, has evolved to emphasize preparation for quitting. Topics addressed include the health consequences of smoking, reasons to quit and methods of quitting.
224319413|NCT01493921|DRUG|SR-T100 gel|Patient will be instructed to self-apply approximately 0.3\~0.5g of SR-T100 gel on 25 cm squared treatment area (avoiding the periocular areas, lips, and nares) once daily with an occlusive dressing for 16 weeks treatment period.
224319414|NCT01493921|DRUG|Vehicle gel|Patient wil be instructed to self-apply approximately 0.3\~0.5g of vehicle gel (without active ingredient)per total of 25 cm squared treatment area (avoiding the periocular areas, lips, and nares) once daily with an occlusive dressing for 16 weeks treatment period.
224323324|NCT05859074|BIOLOGICAL|MQ719|Patients will receive either multidose monotherapy with MQ710 or multidose combination therapy with MQ710 and pembrolizumab. The applicable dose of MQ710 will be injected directly into the patient's tumor (intratumorally), and standard dosing of pembrolizumab (200 mg) will be administered intravenously at a 3-week interval.
223640983|NCT06970093|PROCEDURE|One Anastomosis Gastric Bypass|Participants will undergo One Anastomosis Gastric Bypass (OAGB), a laparoscopic bariatric procedure that creates a long narrow gastric pouch and anastomoses it to a loop of jejunum approximately 150-200 cm from the ligament of Treitz. This bypasses the compressed duodenum to relieve symptoms of SMAS while promoting weight gain or nutritional restoration in undernourished patients.
223640984|NCT06970093|PROCEDURE|Duodenojejunostomy|Participants will undergo Duodenojejunostomy (DJ), a standard surgical procedure to bypass the compressed segment of the duodenum. It involves creating an anastomosis between the duodenum and the jejunum distal to the point of compression, allowing normal food passage and relieving symptoms of Superior Mesenteric Artery Syndrome.
223640985|NCT02828826|OTHER|telephone coaching|
223640986|NCT02582775|DRUG|Thymoglobulin|0.5 mg/kg IV over 6 hours on day -9 and 2 mg/kg IV over 4 hours on day -8 and day -7 with premeds and solumedrol through day -2
223640987|NCT02582775|DRUG|Cyclophosphamide|14.5 mg/kg IV over 1 hour day -6 and -5 50 mg/kg IV over 2 hours with mesna 40 mg/kg IV day +2 and +3
223640988|NCT02582775|DRUG|Fludarabine|30 mg/m2 IV over 60 minutes days -6 through day -2
223640989|NCT02582775|RADIATION|Total Body Irradiation|See arm description for dosing.
223640990|NCT02582775|PROCEDURE|Bone marrow infusion|Bone marrow infusion on Day 0
223640991|NCT02582775|DRUG|Tacrolimus|Day +5 through day +100 with goals of 5-10 ug/L (not used for HLA-identical related donors). When used in non-MSD recipients, tapered over 6-8 weeks starting at day +100.
223640992|NCT02582775|DRUG|Mycophenolate Mofetil|15 mg/kg IV q8h (based upon actual body weight) with the maximum total daily dose not to exceed 3 grams. Day +5 through day 35
223640993|NCT02582775|BIOLOGICAL|Donor mesenchymal stem cell infusions|Day 60, 100 and 180 (collected during donor BM harvest for graft)
223640994|NCT02582775|DRUG|Busulfan|busulfan IV over 3 hours on days -3 and -2 for HLA-mismatched BM recipients only (Arms F and G)
223640995|NCT01648751|DRUG|Vaginal estrogen|1 gram vaginally for 7 days, followed by 1 gram vaginally twice weekly thereafter
224229100|NCT03708861|DRUG|maraviroc (300 mg QD) + atazanavir/ritonavir (300 and 200 mg /100 mg QD)|"Phase 1: switch from tenofovir disoproxil fumarate/emtricitabine (200/245 mg QD)+ atazanavir/ritonavir (300 /100 mg QD) to maraviroc (300 mg QD) + atazanavir/ritonavir (300 /100 mg QD).~Phase 2: switch from maraviroc (300 mg QD) + atazanavir/ritonavir (300 /100 mg QD) to maraviroc (300 mg QD) + atazanavir/ritonavir (200 /100 mg QD)"
224229101|NCT02262949|DEVICE|LifeStent Vascular Stent|PTA followed by implantation of the LifeStent Vascular Stent (stent length 250 mm) in the SFA or popliteal artery.
224229102|NCT02789111|DRUG|Alvimopan|Alviimopan 12 mg twice daily up to 15 doses
223640996|NCT01648751|DRUG|Placebo|1 gram vaginally for 7 days, followed by 1 gram vaginally twice weekly thereafter
223640997|NCT01885299|RADIATION|SRS/SBRT|Intervention varies by condition being treated.
224229103|NCT02789111|DRUG|Placebo|Placebo twice daily up to 15 doses
224229104|NCT06527989|DRUG|Ceftriaxone 2000 mg|antibiotic prophylaxis
224229105|NCT05678920|OTHER|patient-administered questionnaires|patient-administered questionnaires (MEOWS): Obstetric early warning systems are recommended to provide timely recognition, treatment and early referral of critically ill or developing patients. The development of early warning systems from simple bedside observation charts arose from the knowledge that physiological disturbances precede critical illness. Thanks to these charts, the fact that the patient's findings are in the risky value ranges allows the clinician to evaluate the patient earlier and in detail. MEOWS is a simple screening tool for maternal morbidity.
224323325|NCT05859074|DRUG|Pembrolizumab|Patients will receive either multidose monotherapy with MQ710 or multidose combination therapy with MQ710 and pembrolizumab. The applicable dose of MQ710 will be injected directly into the patient's tumor (intratumorally), and standard dosing of pembrolizumab (200 mg) will be administered intravenously at a 3-week interval.
223640998|NCT04720183|DRUG|Sulfasalazine|On Day 1, Day 5 and Day 9, a single oral dose of sulfasalazine tablets in fasted state.
223640999|NCT04720183|DRUG|GLPG3970|On Day 5 and Day 9, a single dose of GLPG3970 oral solution in fasted state.
223641000|NCT06573879|BEHAVIORAL|Eccentric Exercise|It was investigated whether volleyball athlete participants would develop muscle architecture, muscle strength and performance parameters differently from the control group by performing eccentric exercises in addition to their exercise routines.
223641001|NCT05964218|BEHAVIORAL|Food-Body-Mind Intervention|The Food-Body-Mind intervention includes 3 main components: 1) a school-based mindfulness component delivered by daycare teachers to equip preschoolers with knowledge and skills in mindful eating and movement (e.g., yoga, deep breathing exercises) to reduce emotional eating and increase F/V intake and physical activity; 2) a home-based mindfulness component to increase caregivers' skills in practicing mindful eating, movement, and parenting behaviors at home to foster a more positive, mindful, and healthy home environment; and 3) a preschooler school learning and caregiver home practice connection component to improve caregiver-preschooler relationships.
223641002|NCT02352896|DRUG|EPI-743|EPI-743 100 milligrams/milliliter (mg/mL) oral solution will be administered per dose and schedule specified in the arm.
223641003|NCT06510153|OTHER|Environmental Music Therapy|The music will consist of improvised music at a slow to moderate tempo, using free-flowing melodies, and simple chord progressions, focusing on creating moments of tension and resolution during approximately 20 minutes.
223641004|NCT06510153|OTHER|Pre-recorded music|The protocol for pre-recorded music is the same as for EMT.
223641005|NCT06510153|OTHER|Standard care only|Standard care in the emergency room waiting room as provided by each hospital without being exposed to EMT or pre-recorded music.
223641006|NCT03111121|DRUG|Sugammadex|receive reversal with sugammadex 4mg/kg
223641007|NCT03111121|DRUG|neostigmine|receive reversal with neostigmine 0.04 mg/kg
224229106|NCT05928728|DRUG|Colchicine|Colchicine 0.5 mg once daily
224229107|NCT05928728|DRUG|Placebo|Placebo once daily
224229108|NCT01166971|DEVICE|ReSTOR +3|Bilateral implantation of ReSTOR +3 Intraocular Lenses (IOLs) after cataract extraction
224229109|NCT01166971|DEVICE|Tecnis MF|Bilateral implantation of Tecnis Multifocal (MF) Intraocular Lenses (IOLs) after cataract extraction
224229110|NCT01861327|DRUG|CO2|carbon dioxide (CO2) as arterial contrast media
224229111|NCT01861327|DRUG|Iodine contrast media|Iodine as arterial contrast media
223641008|NCT03111121|DRUG|glycopyrrolate|receive reversal with glycopyrrolate (0.01 mg/kg)
223641009|NCT05387122|DEVICE|mandibular advancement device (MAD)|mandibular advancement device (MAD) is a removable oral appliance. It is an alternative therapy for patients of Obstructive Sleep Apnea who are non compliant to Continuous positive airway pressure(CPAP) which is the most accepted therapy for Obstructive Sleep Apnea.
223641010|NCT05997225|OTHER|opt out enrollment, tailored counseling, varenicline started prior to target quit date|Participants automatically enrolled in motivational counseling. Tailored counseling includes sharing results of Chest CT results and lung function spirometry tests with participants.
223641011|NCT05997225|OTHER|opt in enrollment, non-tailored counseling, varenicline started prior to target quit date|Participants must opt-in to receive counseling. Counseling does not include discussion of Chest CT or spirometry results.
223641012|NCT05893485|BEHAVIORAL|Music Therapy Intervention|Music Therapy Sessions. There will be 4 scheduled music therapy sessions, and a postpartum follow up.
223641013|NCT05060211|OTHER|Vancouver symptom score for dysfunctional elimination syndroms|Validated questionnaire concerning bladder and bowel symptoms
223641014|NCT05060211|OTHER|Magnetic resonance imaging|Known MRI results of the patient file
223641015|NCT02023463|DRUG|Enzalutamide|Given PO
223641016|NCT02023463|DRUG|Goserelin acetate|Given SC
223641017|NCT02023463|DRUG|Leuprolide acetate|Given IM or SC
223641018|NCT02023463|RADIATION|Radiation therapy|Undergo image-guided radiation therapy
223641019|NCT03013998|BIOLOGICAL|Samalizumab (BAML-16-001-S1)|300 mg/m2, IV, on days 1, 3, and 24; followed by 300 mg/m2, IV, every 21 days for 2 years in the absence of toxicity or disease progression. Dose may be de-escalated to 150 mg/m2 or escalated to 600 mg/m2 based on occurrence of dose-limiting toxicity.
223641020|NCT03013998|BIOLOGICAL|BI 836858 (BAML-16-001-S2)|20 mg/m2, IV, on days 9, 16, and 23 of a 28-day cycle; followed 20 by mg/m2, IV, on days 1, 8, 15 and 22 of each 28-day cycle for 2 years in the absence of toxicity or disease progression (reduced to monthly administration in event of complete response or complete response with incomplete blood count recovery). Dose may be escalated to a maximum dose of 320 mg/m2 or de-escalated to 10 mg/m2 based on occurrence of dose-limiting toxicity.
223641021|NCT03013998|OTHER|Laboratory Biomarker Analysis|Molecular genomic assessment to assign patients to targeted therapy (sub-study) based on their specific subtype of acute myeloid leukemia
224229112|NCT03417622|PROCEDURE|Bracketing|At the beginning of therapy, ultrasonographic examination is used to measure the tumor in three dimensions and bracket the tumor using 4-6 metal clips which will serve as markers for the initial tumor extent in case of tumor shrinkage in response to systemic treatment.
224229113|NCT03417622|DRUG|Neoadjuvant therapy|All patients will receive primary systemic therapy according to the current institutional guidelines. Drugs include cytotoxic chemotherapy, hormonal therapy and/or anti-HER2/neu therapy as indicated.
223641022|NCT03013998|DRUG|Daunorubicin (BAML-16-001-S1)|60 mg/m2, IV, on days 4, 5, and 6 of the induction cycle
224229114|NCT03417622|PROCEDURE|Post-treatment volume margin resection|The lumpectomy resection margin is planned according to the identifiable tumor at operation. The initial extent of the tumor at diagnosis is not taken in account. If there is complete clinical response to systemic therapy (i.e. no identifiable tumor), the center of the bracketed tissue is biopsied.
224229115|NCT03417622|PROCEDURE|Pre-treatment volume margin resection|The lumpectomy includes the whole bracketed tissue to take in account the initial tumor extent before systemic therapy.
223641023|NCT03013998|DRUG|Cytarabine (BAML-16-001-S1)|100 mg/m2, IV, on days 4 through 10 of the 24-day induction cycle; 1000 mg/m2, IV, on days 2, 4, and 6 of the consolidation cycle 1 and days 1, 3, and 5 of consolidation cycles 2 through 4
223641024|NCT03013998|DRUG|Azacitidine (BAML-16-001-S2)|75 mg/m2, IV, on days 1 through 7 of each 28-day cycle for 2 years in the absence of toxicity or disease progression
223641025|NCT03013998|DRUG|AG-221 (BAML-16-001-S3)|100 mg, oral, daily until time of intolerance or disease progression. Dose may be de-escalated to 50 mg based on occurrence of dose-limiting toxicity.
223641026|NCT03013998|DRUG|Azacitidine (BAML-16-001-S3)|75 mg/m2, IV or SC, on days 1 through 7 of each 28-day cycle starting with cycle 6 and ending after 12 cycles for patients not attaining complete remission or complete remission with incomplete blood count recovery after 5 cycles of monotherapy with AG-221
223641027|NCT03013998|DRUG|Entospletinib (BAML-16-001-S4)|200 mg, oral, twice daily for 5 years until time of intolerance or disease progression. Dose may be escalated to 400 mg.
223641028|NCT03013998|DRUG|Azacitidine (BAML-16-001-S4)|75 mg/m2, IV or SC, on days 1 through 7 of each 28-day cycle and continuing for 12 cycles. Treatment starts after 1 cycle of monotherapy with entospletinib for patients not attaining complete remission or complete remission with incomplete blood count recovery or after later cycles of monotherapy with entospletinib for patients with disease progression.
223641029|NCT03013998|DRUG|Entospletinib (BAML-16-001-S5)|400 mg, oral, twice daily for 2 years on study until time of intolerance or disease progression. Dose may be de-escalated to 200 mg twice daily or 200 mg once daily based on occurrence of dose-limiting toxicity.
223641030|NCT03013998|DRUG|Decitabine (BAML-16-001-S5)|20 mg/m2, IV, on days 1 through 5 or 10 of each 28-day cycle and continuing for up to 11 cycles. During the first induction cycle, and the 2nd and 3rd induction cycles if they are needed, administration occurs on days 1 through 10 of each 28-day cycle. During subsequent consolidation, decitabine is administered on days 1 through 5 of each 28-day cycle and continuing for up to 11 cycles. Duration may be reduced by 1 day based on occurrence of dose-limiting toxicity, and patients may switch to entospletinib monotherapy maintenance at any time if they develop toxicity or are unwilling to continue decitabine during consolidation therapy.
223641031|NCT03013998|DRUG|Entospletinib (BAML-16-001-S6)|400 mg, oral, twice daily for 2 years until time of intolerance or disease progression.
224229116|NCT05448716|DIAGNOSTIC_TEST|Left Atrial Strain Imaging|Two-dimensional, color Doppler, spectral Doppler recordings will be taken from parasternal, apical, subcostal, and modified sections using a Philips Epiq CVx echocardiography device and X5-1 probe. Conventional parameters, additional parameters, and strain analyzes will be performed with speckle tracking echocardiography from these recordings.
224229117|NCT05448716|DIAGNOSTIC_TEST|Electrocardiography|Electrocardiography will be taken at baseline and the follow-up periods
224229118|NCT03954561|PROCEDURE|endoscopist-administered abdominal compression|The endoscopist administers abdominal compression when loop formation encountered.
223641032|NCT03013998|DRUG|Daunorubicin (BAML-16-001-S6)|60 mg/m2, IV, on days 1-3 or 1-2 of each 28-day cycle for the first and second induction cycle, respectively
223641033|NCT03013998|DRUG|Cytarabine (BAML-16-001-S6)|100 mg/m2, IV, on days 1 through 7 or 1 through 5 of each 28-day cycle for the first and second induction cycle, respectively; then 1000 mg/m2 (patients ≥60 years) or 3000 mg/m2 (younger patients with creatinine clearance \>30 mL/min and \<50 mL/min), IV, every 12 hours on days 1, 3, and 5 of each 28-day cycle for up to 4 consolidation cycles
223641034|NCT03013998|DRUG|Pevonedistat (BAML-16-001-S9)|20 mg/m2, IV, on days 1, 3, and 5 of each 28-day cycle and continuing for 24 cycles in the absence of toxicity or disease progression
223641035|NCT03013998|DRUG|Azacitidine (BAML-16-001-S9)|75 mg/m2, IV or SC, on days 1 through 7 or days 1 through 5 and then 8 through 9 (based on institutional guidelines) of each 28-day cycle and continuing for 12 cycles in the absence of toxicity or disease progression
223641036|NCT03013998|DRUG|AG-120 (BAML-16-001-S16)|500 mg, oral, daily until time of intolerance or disease progression. Dose may be de-escalated to 250 mg based on occurrence of dose-limiting toxicity.
223641037|NCT03013998|DRUG|Azacitidine (BAML-16-001-S16)|75 mg/m2, IV or SC, on days 1 through 7 or days 1 through 5 and then 8 through 9 (based on institutional guidelines) of each 28-day cycle and continuing for 12 cycles in the absence of toxicity or disease progression
223641038|NCT03013998|DRUG|Gilteritinib (BAML-16-001-S8 Group 1)|"120 mg, oral, daily, with treatment continuing based on bone marrow results at 28 and 56 days. Patients with partial response at 28 days continue treatment for an additional 28 days. Patients with complete remission (CR) or complete remission with incomplete hematologic recovery (CRi) at 28 or 56 days continue treatment for 5 years until time of intolerance or disease progression. Patients with less than partial response at 28 days or partial response at 28 days followed by less than CR or CRi at 56 days proceed to combination treatment with decitabine or non-study alternative.~The combination dose is 80 mg, oral, daily, for 5 years until time of intolerance or disease progression (patients who do not achieve CR or CRi after 3 cycles will discontinue study treatment). The combination dose may be escalated to 120 mg daily or de-escalated to 80 mg daily given after decitabine rather than in combination with decitabine based on absence or occurrence of dose-limiting toxicity."
223641039|NCT03013998|DRUG|Decitabine (BAML-16-001-S8 Group 1)|20 mg/m2, IV, on days 1 through 10 of each 28-day cycle and continuing for up to 3 cycles. Treatment starts after 1-2 cycles of monotherapy with gilteritinib if patients do not attain complete remission (CR) or complete remission with incomplete hematologic recovery (CRi) with monotherapy. Patients who do not achieve CR/CRi after 3 cycles of combination therapy will discontinue study treatment. If CR or CRi is obtained with combination therapy after 3 cycles, decitabine will be administered on days 1-5 of each subsequent 28-day cycle until progression, intolerance, or patient desire to discontinue therapy.
223641040|NCT03013998|DRUG|AZD5153 (BAML-16-001-S10)|20 mg, oral, once daily during 7-day lead-in and then on days 1 through 21 of each 28-day cycle for up to 2 years or until allogeneic stem cell transplantation, time of intolerance, or disease progression \[if the continuous administration AZD5153 on Days 1-21 of a 28-day cycle is not tolerated, an alternative schedule of 2 weeks on and 2 weeks off (i.e. AZD5153 will be administered on Days 1-14 of a 28-day cycle) will be explored\]. Dose may be de-escalated to 10 mg or escalated to 30 mg based on occurrence of dose-limiting toxicity during phase 1 dose escalation. Starting with Cycle 2, patients may receive concomitant fluconazole, isavuconazole, or posaconazole and doses adjusted to 2, 5, or 8 mg daily. The Phase 1b expansion pharmacokinetics cohort will allow for posaconazole starting at Cycle 1 with AZD5153 dose adjusted from 10, 20, or 30 mg daily to 2, 5, or 8 mg daily. Phase 2 dose will be based on Phase 1 results.
223641041|NCT03013998|DRUG|Venetoclax (BAML-16-001-S10)|400 mg, oral, on days 1 through 21 of each 28-day cycle and continuing for up to 12 cycles (for Cycle 1, day 1 dose will be 100 mg, day 2 dose 200 mg, and days 3 onward 400 mg). Starting with Cycle 2, patients may receive concomitant fluconazole or isavuconazole and daily doses adjusted to 200 mg, or posaconazole and daily doses adjusted to 70 mg. The Phase 1b expansion pharmacokinetics cohort will allow for posaconazole starting at Cycle 1 with Venetoclax dose adjusted to 10 mg on day 1, 20 mg on day 2, 50 mg on day 3, and 70 mg on day 4 onward).
223641042|NCT03013998|DRUG|TP-0903 (BAML-16-001-S14)|37 mg, oral, once daily on days 1 through 21 of each 28-day cycle for up to 2 years to time of intolerance or disease progression. Dose may be de-escalated to as low as 12 mg or escalated to 50 mg based on occurrence of dose-limiting toxicity during Phase 1 dose escalation. Phase 2 dose will be based on Phase 1 results.
223641043|NCT03013998|DRUG|Decitabine (BAML-16-001-S14)|20 mg/m2, IV, on days 1 through 5 or 10 of each 28-day cycle and continuing for up to 2 years to time of intolerance or disease progression. During the first induction cycle, and the 2nd and 3rd induction cycles if they are needed, administration occurs on days 1 through 10 of each 28-day cycle. During maintenance, decitabine is administered on days 1 through 5 of each 28-day cycle. Patients may switch to TP-0903 monotherapy maintenance if they develop toxicity or are unwilling to continue decitabine during maintenance therapy.
223641044|NCT03013998|DRUG|Decitabine (BAML-16-001-S8 Group 2)|20 mg/m2, IV, on days 8 through 12 of the first 35-day induction cycle, then on days 1 through 5 of subsequent 28-day cycles and continuing for up to 60 cycles, disease progression, intolerance, or patient desire to discontinue therapy.
223641045|NCT03013998|DRUG|Venetoclax (BAML-16-001-S8 Group 2)|Oral dosing based on concurrent antifungal use. Dose without use of concomitant antifungal is 400mg, dose if on posaconazole is 70mg, dose if on voriconazole is 100mg, and dose if on moderate CYP3A inhibitors (ie fluconazole, isavuconazole) is 200mg continuing for up to 12 total cycles. For the 35-day induction cycle 1, dosing is days 2 through 28. For the 28-day induction cycle 2, if needed, dosing is days 1 through 21. For the 28-day consolidation cycles, dosing is days 1-15.
223641046|NCT03013998|DRUG|AZD5991 (BAML-16-001-S18)|150 mg, IV, on days 1, 4, 8, 11, 15, and 18 of three 28-day cycles; followed by 150 mg/m2, IV, on days 1, 4, 8, and 11 of twenty-one 28-day cycles; followed by 150 mg/m2 on days 1 and 4 of each 28-day cycle until time of progression, unacceptable toxicity, death, or 57 total cycles of treatment. Dose may be escalated to a maximum dose of 400 mg or de-escalated to 100 mg based on occurrence of dose-limiting toxicity.
223641047|NCT03013998|DRUG|Azacitidine (BAML-16-001-S18)|75 mg/m2, IV or SC, on days 1-7 or days 1-5 and 8 and 9 or days 1-2 and 5-9 (based on institutional guidelines) of each 28-day cycle until time of progression, unacceptable toxicity, death, or 57 total cycles of treatment
224229119|NCT03954561|PROCEDURE|assistant-administered abdominal compression|A assistant administers abdominal compression when loop formation encountered.
224229120|NCT01965561|DEVICE|CRoC|Use of Combat Ready Clamp (CRoC)
224229121|NCT01965561|DEVICE|AAJT|Use of Abdominal Aortic and Junctional Tourniquet (AAJT)
224229122|NCT01965561|DEVICE|JETT|Use of Junctional Emergency Treatment Tool (JETT)
224229123|NCT01965561|DEVICE|SJT|Use of SAM Junctional Tourniquet (SJT)
224229124|NCT04215055|DEVICE|vibraject|VibraJect; is a small battery-operated attachment that snaps on to the standard dental syringe. It delivers a high-frequency vibration to the needle which is strong enough for the patient to feel.
224229125|NCT01562795|DRUG|nonsteroid anti-inflammatory drops|nonsteroid anti-inflammatory drops plus artificial tear substitute
224229126|NCT01562795|DRUG|nonsteroid anti-inflammatory drops|nonsteroid anti-inflammatory drops plus artificial tear substitute
224229127|NCT01562795|DRUG|corticosteroids|corticosteroids plus artificial tear substitute
224229128|NCT01562795|DRUG|artificial tear substitute|artificial tear substitute alone
224229129|NCT05979181|PROCEDURE|Cesarean hysterectomy|Cesarean hysterectomy due to placenta previa percreta with no extrauterine disease (FIGO grade 3a) or with extrauterine disease (FIGO grades 3b and 3c)
224229130|NCT00717756|DRUG|lenalidomide|25 mg po qd x 21 days then 1 week off equals one cycle
224229131|NCT00673790|DRUG|Nebivolol with concomitant losartan or lisinopril|Encapsulated Nebivolol 5 mg, 10 mg, 20, mg, 40 mg total daily dosage, oral administration with concomitant treatment consisting of lisinopril 10 mg total daily dosage, oral administration or losartan 50 mg total daily dosage, oral administration.
224229132|NCT00673790|DRUG|HCTZ with concomitant losartan or lisinopril|Encapsulated Hydrochlorothiazide 12.5 mg or 25 mg total daily dosage, oral administration with concomitant treatment consisting of lisinopril 10 mg total daily dosage, oral administration or losartan 50 mg total daily dosage, oral administration.
224229133|NCT00673790|DRUG|Placebo with concomitant losartan or lisinopril|Placebo with concomitant treatment consisting of lisinopril 10 mg total daily dosage, oral administration or losartan 50 mg total daily dosage, oral administration.
223641048|NCT03013998|DRUG|SNDX-5613 (BAML-16-001-S17)|113 mg, oral, every 12 hours on Day 1-28 of each 28-day cycle, until time of progression, unacceptable toxicity, or death. Dose may be escalated to a maximum dose of 163 mg on days 1-28 or de-escalated to 113 mg on days 1-21 based on occurrence of dose-limiting toxicity. Other possible dose escalation and de-escalation would be 163 mg on days 1-21, 75 mg on days 1-21 and 75 mg on days 1-28. Following completion of induction, patients who do not require strong CYP3A4 inhibitor antifungals will have daily doses increased for doses in range of 113-226 mg (days 1-21 or days 1-28).
223641049|NCT03013998|DRUG|Azacitidine (BAML-16-001-S17)|75 mg/m2, IV or SC, on days 1-7 (during induction cycle/cycles) or can use alternative scheduled on days 1-5 and 8 and 9 or days 1-2 and 5-9 (based on institutional guidelines) during continued therapy cycles of each 28-day cycle until time of progression, unacceptable toxicity, or death.
223641050|NCT03013998|DRUG|Venetoclax (BAML-16-001-S17)|For Cycle 1 induction, day 1 dose is 10 mg, day 2 dose 20 mg, day 3 dose is 50 mg, and day 4 onward dose is 100 mg or 70 mg depending on concomitant antifungal treatment. For Cycles 2 and 3 inductions, daily doses are 100 or 70 mg depending on concomitant antifungal treatment. During continued therapy cycles, if not on concomitant strong CYP3A4 inhibitor antifungals, 400 mg, oral, on days 1 through 28 or days 1 through 14 of each 28-day cycle until time of progression, unacceptable toxicity, or death (patients on moderate CYP3A4 inhibitor antifungals should receive 200 mg/day).
224229134|NCT00374413|DEVICE|Artificial disk|Implant
224229135|NCT00374413|DEVICE|Artificial disc|Implant
224229136|NCT02234297|DRUG|BLZ-100|
224229137|NCT00935987|DRUG|CYT387|"For the Part 1 dose-escalation portion of the study, patients will be assigned to dose levels in successive cohorts starting with a dose in the first cohort of 100 mg/day. CYT387 will be orally self-administered as a single daily dose beginning on Day 1 of the study, and thereafter at approximately the same time each day of the 28-day cycle. It is recommended that all doses be preceded by a 2-hour fast from food and beverages, and be followed by a 1-hour post-dose fast from food and beverages.~Twenty additional patients will be assigned to a 150 mg BID (twice daily) dosing schedule. CYT387 will be orally self-administered twice-daily with doses approximately 10-12 hours apart beginning on Day 1 of the study, and thereafter at approximately the same times each day of the 28-day cycle.~For the Part 2 dose confirmation portion of the study, patients will be assigned to either 150 mg or 300 mg QD (once daily) dose groups."
224229138|NCT03247283|DRUG|BMS-986205|Carbon 14 tagged BMS-986205
224229139|NCT04032678|DEVICE|Schiller Defigard Touch 7 - DGT7, Schiller Medical, France|Cardioversion with a pulsed biphasic waveform
224229140|NCT04032678|DEVICE|LIFEPAK 15, Physio-Control Inc., Redmond, WA, USA|Cardioversion with a biphasic truncated exponential waveform
224229141|NCT01179633|DEVICE|OPLON active patch|
224229142|NCT01179633|DEVICE|Sham patch|
224229143|NCT03974633|COMBINATION_PRODUCT|Injection|All information is included in the Arm/group descriptions
224229144|NCT05442333|PROCEDURE|surgical resection with safety margin|"• The patients with preoperative radiotherapy:~1. will be assessed 3 weeks post radiation regarding wound signs of infection (redness, hotness or discharge).~2. 6 weeks post radiation for wound dehiscence~3. 3 months post radiation for local swelling or recurrence~4. 6 months post radiation for local recurrence, joint stiffness or pathological fractures.~The patients with postoperative radiotherapy:~1. will be assessed 3 weeks post radiation regarding wound signs of infection (redness, hotness or discharge).~2. 6 weeks post radiation for wound dehiscence~3. 3 months post radiation for local swelling or recurrence~4. 6 months post radiation for local recurrence, joint stiffness or pathological fractures."
224229145|NCT03753854|DIAGNOSTIC_TEST|polysomnography and oxygen saturation exam|Measurement of the Apnea/hypopnea index (AHI) and oxygen saturation
224229146|NCT03753854|BIOLOGICAL|calculation of VOC frequency between the first polysomnography and the end of the first year of continuous positive airway pressure treatment|calculation of VOC rate within the two previous years or between first polysomnography and one year of continuous positive airway pressure treatment
224229147|NCT03753854|BIOLOGICAL|Blood samples|Blood samples with measurements of hematological, hemorheological, inflammatory and blood coagulation markers
224229148|NCT03753854|OTHER|Physiological measurements|Evaluation of microvascular reactivity and autonomic nervous system activity
224229149|NCT03753854|OTHER|Continuous Positive Airway Pressure|Continuous Positive Airway Pressure during 1 year
224229150|NCT00627718|DEVICE|HRT screening for macula edema|HRT screening for macula edema at time of initial diagnosis of macular degeneration
224229151|NCT01869322|DEVICE|Sling and Swathe|Sling and Swathe immobilization of humeral shaft fracture.
224229152|NCT01869322|DEVICE|Coaptation Splint|Coaptation splint immobilization of humeral shaft fractures.
224229153|NCT01483872|DRUG|NAC/Tigecycline/Heparin combination lock solution|
224229154|NCT01483872|DRUG|Standard anticoagulant (Heparin or Citrate)|
224229155|NCT01492062|DEVICE|Multiple Model Predictive Controller|Use of closed loop algorithm in an inpatient environment while closely monitoring blood glucose levels.
224229156|NCT05254366|DRUG|Remimazolam Tosilate for Injection|Remimazolam Tosilate for Injection
224229157|NCT04217226|DEVICE|Perfusion index derived parameters|"The PVI and PI will be recorded in the supine position by an anaesthesiologist who was not involved in the further intraoperative monitoring of the patient using Masimo SET (MightySat 9900, Masimo Corporation, Irvine, CA, USA). This device allows bluetooth radio for transfer of parameter data to a smart device. The device will be applied on the index finger of the dominant hand of each patient. It will be applied on the hand that neither contains the venous line nor the blood pressure cuff. Three measurements of PVI and PI on one minute interval will be recorded. We will use the average of these readings.~Dicpleth is defined as the ratio of the height of the dicrotic notch to the height of the systolic peak, measured at end-expiratory time."
224229158|NCT00457522|BEHAVIORAL|Nurse/community health worker telephone intervention|
224229159|NCT02353065|PROCEDURE|Ultrasound imaging|Point of care ultrasound of fracture site during and post-reduction
224229160|NCT02353065|RADIATION|Bedside x-ray|Portable x-ray of fracture post-reduction
223641051|NCT03013998|DRUG|Gilteritinib (BAML-16-001-S8 Group 2)|Phase 1b induction: 80-120 mg, oral, daily for day 1 up to day 28 of the 35-day induction cycle 1; then 80-120 mg, oral, daily for day 1 up to day 28 of the 28-day induction cycle 2 (induction cycle 2 administered if needed after cycle 1 based on results bone marrow evaluation). Phase 1b consolidation: 80-120 mg, oral, daily for day 1 up to day 21 of the 28-day cycles, for a total of 12 total induction and consolidation cycles. Phase 1b induction and consolidation dose and duration may be escalated or de-escalated based on occurrence of dose-limiting toxicity. Phase 2 induction and consolidation dosage to be based on results of Phase 1b. Phase 1b and 2 maintenance: 120 mg, oral, daily for 28 days of the 28-day cycles until patient is minimal residual disease negative for FLT3 based on scheduled bone marrow biopsy, progression of disease, unacceptable toxicities, or desire to discontinue therapy.
223641052|NCT03013998|DRUG|Venetoclax (BAML-16-001-S12 Arm A)|400 mg, oral, on days 1 through 28 of each 28-day cycle for up to 2 cycles or until unacceptable toxicity or death. For Cycle 1, day 1 dose is 100 mg, day 2 dose 200 mg, and day 3 onward dose is 400 mg. (Dose adjusted by anti-fungal agent use per the package insert.)
223641053|NCT03013998|DRUG|Azacitidine (BAML-16-001-S12 Arm A)|75 mg/m2, IV or SC, on days 1-7 or days 1-5 and 8 and 9 or days 1-2 and 5-9 (based on institutional guidelines) of each 28-day cycle for up to 2 cycles or until unacceptable toxicity or death.
223641054|NCT03013998|DRUG|Venetoclax (BAML-16-001-S12 Arm B)|400 mg, oral, on days 1 through 14 of each 14-day cycle for up to 2 cycles or until unacceptable toxicity or death. For Cycle 1, day 1 dose is 100 mg, day 2 dose 200 mg, and day 3 onward dose is 400 mg. (Dose adjusted by anti-fungal agent use per the package insert.)
223641055|NCT03013998|DRUG|Azacitidine (BAML-16-001-S12 Arm B)|75 mg/m2, IV or SC, on days 1-7 or days 1-5 and 8 and 9 or days 1-2 and 5-9 (based on institutional guidelines) of each 14-day cycle for up to 2 cycles or until unacceptable toxicity or death.
223641056|NCT03013998|DRUG|ZE46-0134 (BAML-16-001-S21)|10 mg or 50 mg oral on Days 1-28 of each 28-day cycle for up to 24 cycles. On the first day of Cycle 1, a loading dose of 30 mg to 150 mg will be administered, after which the daily maintenance dose of 10 mg to 100 mg will be administered on days 2-28 of Cycle 1. Maintenance dose continues in subsequence cycles, for up to 24 cycles total.
223641057|NCT04327700|DEVICE|TheraBionic|Amplitude-modulated electromagnetic fields will be self-administered and given continuously to patients in three courses of 60-minute treatments per day, administered in the morning, at noon and in the evening at the patient's home, with the exception of the first 60-minute treatment, which will be delivered at the research site. Each 4 week treatment period will be considered a cycle of treatment.
223641058|NCT04327700|DRUG|Regorafenib|Patients will receive 160 mg regorafenib (four 40 mg tablets) orally once daily for the first 3 weeks of each 4-week cycle per approved prescribing information.
223641059|NCT05673876|DRUG|GDC-8264|GDC-8264 tablets will be administered as per the schedule specified in the respective arms.
223641060|NCT04050735|OTHER|Alcohol, ethyl, moderate dose|Moderate oral dose of ethyl alcohol
223641061|NCT04050735|OTHER|Placebo|Placebo beverage
223641062|NCT04574271|BEHAVIORAL|Intensive dietary advice and exercise prescription|Personalized dietary advice and exercise prescription according to nutritional status.
223641063|NCT04574271|BEHAVIORAL|Usual dietary advice and exercise prescription|Generalized dietary advice and excercise prescription in elder patients.
223641064|NCT05684757|BEHAVIORAL|Dietary Advice|Dietary Advice
223641065|NCT04401813|DRUG|IBI308 200mg|Received IBI310 combined with sintilizumab 200mg
223641066|NCT03361761|OTHER|Health education program|formalized/official Health education program
223641067|NCT03361761|OTHER|Health education program|non formalized/official Health education program
223641068|NCT04467437|OTHER|Gait Training|Training that targets rehabilitation of walking function
223641069|NCT04467437|DEVICE|Transcutaneous Spinal Stimulation|Non-invasive electrical stimulation of the spinal cord over the skin combined with gait training
223641070|NCT06342037|DRUG|Tiragolumab|600mg every 3 weeks (Q3W)
223641071|NCT06342037|DRUG|Atezolizumab|1200mg every 3 weeks (Q3W)
223641072|NCT06342037|DRUG|Ipilimumab|1 mg/kg, maximum of 4 cycles
223641073|NCT04504253|DIETARY_SUPPLEMENT|Creatine monohydrate|Creatine monohydrate loose powder
223641074|NCT04504253|DRUG|Placebo|Placebo control (dextrose 5mg) matched to creatine monohydrate loose powder
223641075|NCT05546879|DRUG|NP137|NP137 at 9 or 14 mg/kg IV will be administered every 21 days.
224229161|NCT01104519|DRUG|Niaspan|Oral doses of 2000 mg of Niaspan once daily for 7 days.
224229162|NCT01104519|DRUG|Comparator: Placebo|Oral doses of placebo once daily for 7 days.
224229163|NCT04043013|DEVICE|Mini-Taurus® (Rocky Mountain©) Brackets|
224229164|NCT04043013|DEVICE|Smart Clip® SL3 High Torque (3M Unitek©)|
224229165|NCT04043013|DEVICE|Tip-Edge Plus® (TP Orthodontics©)|
223641076|NCT05546879|DRUG|Atezolizumab|Atezolizumab will be administered by IV infusion at a fixed dose of 1200 mg on Day 1 of each 21-days cycle
223641077|NCT05546879|DRUG|Bevacizumab|Bevacizumab will be administered by IV infusion at a dose of 15 mg/kg on Day 1 of each 21-day cycle
223641078|NCT03205423|DRUG|Gabapentin|Maintenance medication under investigation for its ability to alter the subjective and reinforcing effects of experimenter-administered doses of oxycodone and alcohol.
223641079|NCT04930367|BEHAVIORAL|Radio Ads|Engaging radio mini shows that address community stigma and medical literacy through busting common myths with humor and building empathy with heartfelt storytelling.
223641080|NCT04930367|BEHAVIORAL|Community Sensitization Campaign|Large-scale, infographic billboards and posters located in public areas and secondary schools to address stigma, medical literacy and promote community support for AYAHIV.
224229166|NCT04043013|DEVICE|Victory® (3M Unitek©)|
224229167|NCT04203407|BEHAVIORAL|ACP game|Participants in the intervention group will be divided into groups of 4 participants to play a 1-hour culturally-sensitive theory-driven ACP board game with 15-minute debriefing delivered by facilitators. The ACP board game is developed by the principle investigator in a previous project.
224229168|NCT04203407|BEHAVIORAL|Usual care|Participants in the control group will receive a 1-hour board game about health lifestyle.
224229169|NCT04046042|OTHER|Conventional exercise|Virtual reality exercise performed during the first two hours of the hemodialysis session
224229170|NCT04046042|OTHER|Exercise during the last two hours of the hemodialysis session|Virtual reality exercise performed during the last two hours of the hemodialysis session
224229171|NCT00680875|BEHAVIORAL|Click City|School-based intranet delivery of tobacco use prevention program for 5th and 6th graders using interactive and engaging game-like multi-media technology.
224229172|NCT03387033|DEVICE|Relaxation response and virtual reality (VR) session|A 10-minute relaxation response (mindfulness and deep breathing) followed by 10-minute immersive VR session.
224229173|NCT00601484|DRUG|PF-04383119|PF-04383119 200 mcg/kg IV, single dose
224229174|NCT00601484|DRUG|Placebo|placebo IV, single dose
223641081|NCT04930367|BEHAVIORAL|Informational Posters|Large-scale, infographic posters located in clinic waiting areas to normalize HIV and build confidence in treatment.
223641082|NCT04930367|BEHAVIORAL|Motivation Walls|Interactive, patient-generated posters located in the consultation room where patients can post words and phrases about themselves and their futures.
223641083|NCT04930367|OTHER|Pill Container|A discreet pill container to support ART adherence.
223641084|NCT04930367|OTHER|CombinADO-specific training for healthcare workers|Comprehensive in-service training for healthcare workers focused on the needs of adolescents and young adults living with HIV
223641085|NCT04930367|OTHER|One Stop Shop Model of Care|Model of care that allows adolescents and young adults living with HIV to access a complete set of services, including HIV care, in one central location.
223641086|NCT04930367|OTHER|Treatment Toolkit|A guide to clinic visits and discussions on ART and viral load monitoring to help healthcare workers better communicate with patients.
223641087|NCT04930367|OTHER|Self-reflection Kit|A simple handout for healthcare workers to help patients reflect on their ART progress and understand the concept of viral load as a measure of ART success.
223641088|NCT04930367|BEHAVIORAL|Peer Support|Peer exposure to examples of adolescents and young adults openly living with HIV (AYAHIV) and; opportunities to share their experiences with HIV in one-on-one interactions with other AYAHIV during clinic visits.
223641089|NCT04930367|BEHAVIORAL|Informational and motivational Video|An informational and motivational video that in simple language with engaging graphics that a) demystifies and simplifies HIV, ART, and viral load and; b) emphasizes that people can live long, healthy lives.
223641090|NCT04930367|BEHAVIORAL|Support groups- caregivers of adolescents and young adults living with HIV|A learning, support, and empowerment group for caregivers of adolescents and young adults living with HIV (AYAHIV). Through monthly gatherings, the program aims to foster confidence, and equip caregivers with strategies to support AYAHIV adherence journey.
223641091|NCT04930367|BEHAVIORAL|Support groups- adolescents and young adults living with HIV|A peer-to-peer learning, support, and empowerment group to address loss of hope and improve medical literacy. Through biweekly gatherings, the program aims to foster belonging and confidence, equipping young people and caregivers with strategies to navigate the adherence journey.
223641092|NCT04930367|BEHAVIORAL|Mental health screening and linkage to adolescent-focused mental health support|HCWs will be trained in the use of a brief mental health screening tool focusing on depression, anxiety, and post-traumatic stress disorder. Mental health service providers at each facility will be trained and supported to provide diagnostic and mental health support to youth with positive screens who agree to further evaluation.
223641093|NCT02311621|BIOLOGICAL|Patient Derived CD171 specific CAR T cells expressing EGFRt (2nd generation T cells)|Intravenous infusion of autologous T cells transduced to express 4-1BB:zeta CD171CAR and EGFRt (2nd generation T cells)
223641094|NCT02311621|BIOLOGICAL|Patient Derived CD171 specific CAR T cells expressing EGFRt (3rd generation T cells)|Intravenous infusion of autologous T cells transduced to express CD28:4-1BB:zeta CD171CAR and EGFRt
223641095|NCT02311621|BIOLOGICAL|Patient Derived CD171 specific CAR T cells expressing EGFRt (long spacer 2nd generation T cells)|Intravenous infusion of autologous T cells transduced to express 4-1BB:zeta CD171CAR and EGFRt (long spacer 2nd generation T cells)
223641096|NCT04701762|DEVICE|GlideScope videolaryngoscope (Verathon, Bothell, Washington 98011)|After confirming adequate muscle relaxation, initial laryngoscopy will be performed using GlideScope videolaryngoscope with an appropriately sized blade (usually size 3 or 4). The GlideScope (Verathon, Bothell, Washington 98011) is an FDA-cleared commercially available portable videolaryngoscope.
223641097|NCT04701762|DEVICE|Direct laryngoscopy|After confirming adequate muscle relaxation, initial laryngoscopy will be performed using direct laryngoscopy with an appropriately sized Macintosh or Miller blade (usually size 3 or 4);
223641098|NCT01349608|BEHAVIORAL|Telephonic health coaching|Participants will be given a pedometer and activity log to use daily to track their physical activity accomplishments. Weekly, they will participate in a health coaching telephone session to discuss physical activity and set goals. The health coach is knowledgable in COPD care and will utilize a motivational interviewing approach to support the self-efficacy of the participants to be more active.
223641099|NCT02749422|DIAGNOSTIC_TEST|MagStim RapidStim2|Repetitive transcranial magnetic stimulation (TMS)
224229175|NCT01197313|OTHER|Home-based exercise|
224229176|NCT03966170|DRUG|Citicoline|Citicoline as neuroprotector
224229177|NCT03966170|DRUG|Placebo oral tablet|placebo drug
224229178|NCT00548288|DRUG|pamidronate|
223641100|NCT02386475|OTHER|placebo|In all cases, regardless of the assigned treatment group, will follow usual physiotherapy program and vascular risk factors, and treatment of stroke will be controlled according to current recommendations of the American Heart Association / American Stroke Association.
223641101|NCT02386475|DRUG|citalopram|In all cases, regardless of the assigned treatment group, will follow usual physiotherapy program and vascular risk factors, and treatment of stroke will be controlled according to current recommendations of the American Heart Association / American Stroke Association.
223641102|NCT02386475|DRUG|sinemet plus|In all cases, regardless of the assigned treatment group, will follow usual physiotherapy program and vascular risk factors, and treatment of stroke will be controlled according to current recommendations of the American Heart Association / American Stroke Association.
223641103|NCT04327804|DIAGNOSTIC_TEST|Odd/Even birth year intervention groups|The nostril used and order of testing will be different in each arm.
223641104|NCT04377659|DRUG|Tocilizumab|Participants will receive Tocilizumab 8 mg/kg i.v. at enrollment. Dose will be capped at 800 mg per infusion. If there is no improvement or toxicity, a second dose can be given 24 hrs to 5 days later.
223641105|NCT05097586|DEVICE|active tDCS|2mA of direct current delivered in 15 sessions lasting 30 minutes each over 3 weeks
223641106|NCT05097586|OTHER|workbook|Self-directed depression in pregnancy workbook completed during each session to control the in-session brain state
223641107|NCT05097586|DEVICE|sham tDCS|Sham stimulation in which the current turns off after 30 seconds in a slow ramp down that mirrors sensory adaptation in ongoing stimulation, delivered in 15 sessions lasting 30 minutes each over 3 weeks
223641108|NCT05786651|BEHAVIORAL|Experimental: Within-Subjects Attentional Information|Visual Search Information Type (target or distractor information) Participants will have information about targets, distractors, or neither in different trials of the intervention.
224229179|NCT03294278|OTHER|ablation plus ICD|Defibrillator, radio-frequency catheter ablation
224229180|NCT02864680|OTHER|Electroretinography|
224229181|NCT02864680|OTHER|Contrast sensitivity test during Electroencephalography|Stimuli are black and white grids, having different range of spatial frequencies, presented with different contrasts on a grey background thanks to a computer monitor, in a dark room. Participants are requested to maintain central fixation. During the test patients stay sit, head hold by chin strap. A pause can be asked by participant and done at every moment. This test lasts approximately 30 minutes.
223641109|NCT05937165|OTHER|Freeze-dried Blueberry Powder|Three day consumption of two doses of freeze-dried blueberry powder
223641110|NCT05083923|DRUG|Diroximel fumarate|Administered as specified in the treatment arm
223641111|NCT06108414|DRUG|low-dose rivaroxaban|Rivaroxaban 15mg q.d. (The dose should be reduced to 10mg q.d. in the following special populations: 1. Creatinine clearance \<50 mL/min; 2. Body weight ≤60kg; 3. Age ≥80 years old)
224229182|NCT02864680|OTHER|Visual simultaneity test during Electroencephalography|Two vertical bars are showed on a monitor, on the link and right of point of central fixation. Bars appear simultaneously or with a 10 to 200 ms asynchrony. Participants must determine whether stimuli are simultaneous or asynchronous and answer pressing the link button for simultaneity or right button for asynchrony. During the test patients stay sit, head hold by chin strap. A pause can be asked by participant and done at every moment. This test lasts approximately 30 minutes.
224229183|NCT02864680|OTHER|Face perception test during Electroencephalography|Faces filtered in different spatial frequence ranges are showed randomly on a monitor, in a dark room. Participants must maintain a central fixation thank to a fixation cross. During the test patients stay sit, head hold by chin strap. A pause can be asked by participant and done at every moment. This test lasts approximately 30 minutes.
224229184|NCT02864680|OTHER|CAST (cannabis abuse screening test)|
224229185|NCT02864680|OTHER|PANSS (Positive And Negative Symptoms Scale) test|
224229186|NCT02864680|OTHER|Delayed Matching to Sample (DMS) test|
224229187|NCT02864680|OTHER|Spatial Working Memory (SWM) test|
224229188|NCT02864680|OTHER|Rapid Visual Information Processing (RVP) test|
224229189|NCT02864680|OTHER|Test for attentional performance (TAP) / Divided Attention|
224229190|NCT02864680|OTHER|Collection of saliva sample|In case of specific consent of participant to ancillary study, for ancillary study
223641112|NCT06108414|DRUG|Standard-dose rivaroxaban|Rivaroxaban 20mg q.d. (The dose should be reduced to 15mg q.d. in the following special populations: 1. Creatinine clearance \<50 mL/min; 2. Body weight ≤60kg; 3. Age ≥80 years old)
224229191|NCT06356376|DEVICE|Heat Stimulation|Heat stimulation at a painful, but to the subject tolerable level.
223641113|NCT04390763|BIOLOGICAL|NIS793|anti-TGFb antibody. NIS793 2100 mg every 2 weeks by intravenous (i.v.) infusion.
224229192|NCT00376779|BIOLOGICAL|Infanrix hexa Vaccine|
224229193|NCT04125004|DEVICE|Samsung Virtual Reality Headset|Patients will pick a game or feature from the virtual reality headset to use during their procedure
224229194|NCT05359432|DRUG|Empagliflozin|Receiving allocated drug dosage as per clinical needs
223641114|NCT04390763|BIOLOGICAL|Spartalizumab|anti-PD-1 antibody. spartalizumab 400 mg every 4 weeks by i.v. infusion.
223641115|NCT04390763|DRUG|gemcitabine|SOC chemotherapy. Gemcitabine (1000 mg/m\^2 on Days 1, 8, and 15) i.v. given as per label.
224229195|NCT05359432|DRUG|Vildagliptin|Receiving allocated drug dosage as per clinical needs
224229196|NCT00352079|BIOLOGICAL|BCG vaccine|"Intravesical BCG:~Induction:~q weekly x 6 (cycle 1)~Maintenance:~q weekly x 3 at 3, 6, 12, 18, 24, 30, 36 months post- 2 randomization (cycles 2 - 8)"
224229197|NCT00352079|DRUG|gefitinib|Iressa® 250 mg PO Daily for 12 weeks starting on day 1 of each cycle of intravesical BCG therapy (cycles 1 - 8)
224229198|NCT00352079|PROCEDURE|quality-of-life assessment|Each cycle and at 3 and 6 months after treatment discontinuation
223641116|NCT04390763|DRUG|nab-paclitaxel|SOC chemotherapy. Nab-paclitaxel (125 mg/m\^2 on Days 1, 8, and 15) i.v. given as per label.
224229199|NCT01097356|DIETARY_SUPPLEMENT|probiotic drinkers|HPV+, LSIL patients in this arm will drink the probiotic study drink for a period of 6 months
224229200|NCT00745251|DRUG|VI-0521|15 mg Phentermine and 92 mg Topiramate
224229201|NCT00745251|DRUG|placebo|placebo
224229202|NCT02452645|BEHAVIORAL|Healthy Food and Physical Activity Environments|Tailored written materials, videos, telephone counseling, active toys
224229203|NCT02452645|BEHAVIORAL|Comparison Group|Written materials, videos, books, and telephone counseling.
224229204|NCT04954456|DRUG|QLS31901|QLS31901 is a bispecific antibody specifically targeting PD-L1 and TGF-β.In part 1,the QLS31901 will be administered in sequential cohorts on day 1 of every 21-day cycle (3 weeks) via IV infusion.In part 2,the QLS31901 will be administered in parallel cohorts(selected dose and dosing frequency ) on day 1 of every 2week or every 3week via IV infusion
224229205|NCT04883736|DRUG|Tretinoin Gel Microsphere, 0.1%|The study medication will be self-applied topically, on the affected areas of the face lightly, once daily in the evening, avoiding contact with the mouth, eyes, and other mucous membranes for 84 consecutive days.
223641117|NCT05030129|DRUG|5-Hydroxytryptophan|5-HTP will be over-encapsulated in identical size 00 capsules. During the 5-HTP Treatment Period (Period 3) and 5-HTP/EM Treatment Period (Period 2), subjects will take 1 capsule of 5-HTP 3 times per day.
223641118|NCT05030129|DRUG|Ergoloid Mesylates|Ergoloid mesylates 1 mg will be mixed with methyl cellulose and placed in a size 00 capsule. During the EM Treatment Period (Period 1) and 5-HTP/EM Treatment Period (Period 2), subjects will take 1 capsule of EM 3 times per day.
223641119|NCT05030129|DRUG|Matching placebo for Ergoloid mesylates|Matching placebo for Ergoloid mesylates will be ascorbic acid powder in identical size 00 capsules. During the 5-HTP Treatment Period (Period 3) and Placebo Treatment Period (Period 4), subjects will take 1 capsule of matching placebo for EM 3 times per day.
223641120|NCT05030129|DRUG|Matching placebo for 5-Hydroxytryptophan|Matching placebo for 5-Hydroxytryptophan will be ascorbic acid powder in identical size 00 capsules. During the EM Treatment Period (Period 2) and Placebo Treatment Period (Period 4), subjects will take 1 capsule of matching placebo for 5-HTP 3 times per day.
223641121|NCT06651944|DEVICE|Invisalign® System with mandibular advancement featuring occlusal blocks|Class II correction using the Invisalign® System with mandibular advancement featuring occlusal blocks
223641122|NCT06653075|PROCEDURE|mandibular advancement with acrylic splint Herbst Appliance|Mandibular advancement with acrylic splint Herbst Appliance
224229206|NCT04883736|DRUG|RETIN-A MICRO® (Tretinoin) Gel Microsphere, 0.1%|The study medication will be self-applied topically, on the affected areas of the face lightly, once daily in the evening, avoiding contact with the mouth, eyes, and other mucous membranes for 84 consecutive days.
224229207|NCT04883736|DRUG|Placebo Control|The study medication will be self-applied topically, on the affected areas of the face lightly, once daily in the evening, avoiding contact with the mouth, eyes, and other mucous membranes for 84 consecutive days.
223641123|NCT04240002|DRUG|gilteritinib|Administered orally.
223641124|NCT04240002|DRUG|fludarabine|Administered by intravenous (IV) infusion
223641125|NCT04240002|DRUG|cytarabine|Administered by intravenous (IV) infusion
223641126|NCT04240002|DRUG|granulocyte colony-stimulating factor (G-CSF)|Administered by subcutaneous injection
223641127|NCT06429696|DRUG|PD-L1 inhibitor combined with apatinib|Every 3 weeks (21 days) is a treatment cycle. After 4-6 cycles of induction therapy, patients whose efficacy is evaluated as CR, PR or SD (according to RECIST 1.1) will enter maintenance therapy until the disease progresses and becomes intolerable. Toxic and side effects, death, withdrawal of information or the investigator's decision to withdraw the subject from the study, non-compliance with study treatment or other reasons specified in the study procedures or protocol, or treatment for up to 2 years. Maintenance treatment: PD-L1 inhibitor + apatinib 250 mg po qd, maintained for up to 2 years. Note: The specific PD-L1 inhibitor is selected by the researcher, such as adebelimab 1200mg iv, q3w; or atezolizumab 1200mg iv d1, q3w; or durvalumab 1500mg iv d1, q3w . The selection of PD-L1 inhibitors in the maintenance phase is consistent with the first-line standard treatment in the induction phase.
223641128|NCT05874791|BEHAVIORAL|Goal Management training|metacognitive group intervention
223641129|NCT06038864|DIAGNOSTIC_TEST|2 clinical evaluations with 1 month in between|Patients will be evaluated twice with all evaluation methods selected by the international expert group (cfr. aim 1) showing sufficient reliability and feasibility in the patient group with LLL from aim 1
223641130|NCT06655376|DRUG|Aspirin|81-100 mg, oral
223641131|NCT06655376|DRUG|Warfarin|Warfarin dose will be adjusted per patient for a goal INR 2-3. The individualized daily dose could range anywhere from 0.5-2 mg to 5-7 mg. Oral.
223641132|NCT06655168|DEVICE|Video Laryngoscopy|orotracheal intubation by C-Mac ( Video laryngoscopy)
223641133|NCT06655168|DEVICE|Direct Laryngoscopy|Orotracheal intubation using Direct Laryngoscopy
223641134|NCT06654518|DIAGNOSTIC_TEST|Preoperative CBCT for Bone Density and Ridge Width Measurement|Participants in this arm underwent preoperative Cone Beam Computed Tomography (CBCT) scanning to evaluate bone density and alveolar ridge width. The CBCT scans provide high-resolution, 3D images, which was used to guide the planning and placement of dental implants. The primary goal of the intervention was to assess how well the measurements obtained from CBCT could predict the primary stability of the implants postoperatively.
223641135|NCT05743400|DRUG|Thymoglobulin 25 milligrams (mg) Injection|Patients will receive thymoglobulin between 5 and 20 milligrams/kilograms (mg/kg) as an intravenous infusion over a period of 2 to 5 days depending on the dose and the transplant package chosen by the physician.
223641136|NCT05743400|BIOLOGICAL|blood test|"Thymoglobulin® serum levels~Time frame : samples will be drawn at the following points :~* 1 after each end of perfusion ;~* 1 though concentration before each perfusion ;~* 3 blood samples in 3 different days during the first week;~* 1 weekly for 2 weeks post HSCT."
224229208|NCT00907309|BEHAVIORAL|iMET|Participants will receive the iMET intervention
224229209|NCT00907309|BEHAVIORAL|iMET/TE|Participants will receive the iMET intervention and also receive TEs (Technological Extenders)
224229210|NCT02928848|DEVICE|transcranial direct current stimulation|Transcranial direct current stimulation (tDCS) is a type of noninvasive brain stimulation that modulates the resting excitability of neuronal populations, thereby altering patterns of brain activity in potentially behaviorally relevant ways. The stimulation involves 20 minutes of constant stimulation at 1.5 mA.
224323326|NCT04982731|OTHER|Positive Assurance|"Positive assurance is a low-cost, non-pharmacological strategy commonly used by specialty clinics to manage anxiety in individuals with mTBI. Positive assurance is comprised of words of affirmation given to individuals with a medical condition by a healthcare provider that are centered on hope and positive recovery expectations (i.e., You will recover, This can be treated)."
223641137|NCT06589141|DRUG|MetFORMIN 500 Mg Oral Tablet|Metformin (500 to 2000 mg orally)
223641138|NCT06589141|DRUG|GlyBURIDE 2.5 MG Oral Tablet|Glyburide (2.5 mg to 20 mg orally)
223641139|NCT06597110|BEHAVIORAL|listened to ASMR|ASMR refers to a physiological sensation triggered by specific auditory stimuli.ASMR, characterized by low-frequency human voice and ambient sounds, has garnered significant attention across social media platforms, short and long-form video platforms, and podcasts, owing to its unique pleasurable and stimulating effects. listen to ASMR for 10mins.
223641140|NCT06597227|PROCEDURE|Proximal radical gastrectomy|Proximal radical gastrectomy : Dissection of lymph nodes No.1,2,3a,4sa,4sb,7,8a, 9, 11p, 11dare recommended. The tumor involved more than 3cm of esophagus and additional dissection No.19, 20, 110. Gastrointestinal reconstruction method: double channel anastomosis is recommended, and other anastomosis methods can be carried out according to the surgeon\&#39;s habit.
223641141|NCT06597227|PROCEDURE|Total radical gastrectomy|total radical gastrectomy : Dissection of lymph nodes No.1-7, 8a, 9, 11p, 11d, 12a are recommended. The tumor involved more than 3cm of esophagus and additional dissection No.19, 20, 110. Gastrointestinal reconstruction method: Roux⁃en⁃Y anastomosis is recommended
223641142|NCT06589076|DIAGNOSTIC_TEST|Clinical and Radiographic assessment + Questionnaires|"* Clinical and radiographic examination to assess oral health and apical periodontitis.~* Questionnaires to assess Anxiety and depression."
223641143|NCT06589349|BEHAVIORAL|Kangaroo Care|Physiological parameters will be measured in the Day (10:00) - Night (22:00) cycle for 3 days, just before being taken into kangaroo care in the experimental group, and when the kangaroo care is terminated, the baby will be measured in the mother's arms. Then, the mother and baby will be placed in kangaroo care for a minimum of 70 minutes
223641144|NCT06595485|BEHAVIORAL|online mindfulness based intervention|We anticipate the online MBI to be 10-20 minutes once daily, at least 5 days per week, for 8 weeks. Online MBI will be available free of charge on iOS and Android platforms. Participants will be instructed to download the app and use for practices. The online MBI group will be introduced to practice including mindful breathing (simple attention to the flow of the breath, inhalations, and exhalations), body scan (attention and awareness of different body parts) and practice of non-judgement of thoughts and emotions and guided meditation (sitting meditation). In addition, we anticipate participants in MBI group will have a group discussion via skype, 30 minute a week for 8 weeks. Moreover, we anticipate participants in MBI group to record how they practice in each day (attendance) as home assignment using online MBI application. For the details of mindfulness practice, we will develop based on data from interview and focus group
223641145|NCT06586840|OTHER|rescue analgesia|. If NRS is 4 or higher in the postoperative recovery room, 100 mg of intravenous tramadol will be administered as rescue analgesia
224229211|NCT03179475|DRUG|Oxycodone Naloxone Combination|"A flexible dosing schedule will be used in this study. The dose and schedule will be based on the minimal amount of medication required to manage pain related to spinal cord injury. The dose and/or frequency will be titrated to the individual's pain level at the discretion of their regular attending physician and/or investigator.~Oxycodone-Naloxone is available in the following oral dosages:~1. 5 mg oxycodone hydrocholoride / 2.5 mg naloxone hydrochloride~2. 10 mg oxycodone hydrocholoride / 5 mg naloxone hydrochloride~3. 20 mg oxycodone hydrocholoride / 10 mg naloxone hydrochloride~4. 40 mg oxycodone hydrocholoride / 20 mg naloxone hydrochloride"
224229212|NCT01200394|DRUG|PF-00489791|Tablet, 20 mg once daily for 12 weeks
224319415|NCT04637802|BEHAVIORAL|CBT (SurgeryPal)|The SurgeryPal intervention is a cognitive-behavioral program for youth undergoing major surgery. SurgeryPal is delivered in two 4-week phases: the pre-operative phase, and the post-operative phase. Each phase consists of 3 separate treatment modules for youth and parents, which teach cognitive and behavioral coping skills to target known psychosocial and behavioral risk factors (i.e. anxiety/distress and sleep disturbance) for poorer postsurgical outcomes, and provide training in pain self-management skills. Pre-operative modules include: 1) Preparing for surgery, 2) Coping with stress before surgery, and 3) Getting ready for the hospital. Postoperative modules include: 1) Coping at home after surgery, 2) Return to activities and school, and 3) Long-term recovery. Modules are self-guided and interactive, and focus on phases of preparation and recovery from surgery. The goal of the program is to reduce pain and enhance quality of life following surgery in youth.
223641146|NCT06586840|PROCEDURE|Adductor Canal Block|For Group I, after patients are placed in the supine position, a linear ultrasound probe (13-6 MHz) will be used to identify the superficial femoral artery in the short axis, lateral to the Sartorius muscle, and anterior to the adductor magnus muscle in the adductor canal. A 22-gauge × 100 mm needle (Braun® Stimuplex) will be inserted in-plane laterally to medially under sterile conditions, and 20 mL of 0.5% bupivacaine will be injected after negative aspiration.
223641147|NCT06586840|PROCEDURE|Adding an IPACK Block to the Adductor Canal Block|For Group II, 20 mL of 0.25% bupivacaine will be injected into the Adductor Canal after spinal anesthesia. With the knee flexed, a convex probe (3.5-6 MHz) will be placed in the popliteal region to identify the popliteal artery in the short axis. The ultrasound probe will be moved distally after the common peroneal and tibial nerves are identified. The probe will be gradually moved towards the popliteal fossa until the popliteal vessels are identified superficially. The ultrasound probe will be moved to the level where the femoral condyles merge with the femoral shaft. The popliteal artery, tibial and peroneal nerves will be visualized to identify the space between the femur and the popliteal artery. In the area known as iPACK, a 22-gauge × 100 mm needle (Braun® Stimuplex) will be inserted in-plane laterally to medially, and 20 mL of 0.25% bupivacaine will be injected after negative aspiration.
224229213|NCT01200394|DRUG|Placebo|Tablet, placebo once daily for 12 weeks
224229214|NCT05837364|OTHER|Development of an algorithm|Development of an algorithm to predict the risk of new onset Atrial Fibrillation
224229215|NCT02297906|DRUG|Ketorolac|Non-steroidal anti-inflammatory drug
224229216|NCT06102629|PROCEDURE|laparoscopy / laparotomy|"1. We will take both blood and ovarian tissue samples used to diagnosis.~2. We will take approximately 3 ml of blood which will be used from the blood sample collected for routine preoperative tests (surgical profile) before their planned surgery or for disease evaluation.~3. Small tissue samples (from ovary) will be taken from the tissue which is surgically excised as a part of treatment."
224323327|NCT05460468|DEVICE|Transcranial Magnetic Stimulation|Transcranial magnetic stimulation (TMS) is a noninvasive procedure that uses magnetic fields to stimulate nerve cells in the brain to improve a variety of cognitive conditions, and to probe the dynamics of normal brain function.
223641148|NCT06597825|DRUG|root canal irrigation solutions (NaOCl+EDTA, NaOCl+HEDP)|After cavity preparation with sterile burs, rubber dam components were applied to the tooth. The root canal filling material was removed via retreatment files. After the working length was determined, in all the groups, the canals were filled with distilled water. S1were taken from the canal after retreatment. Irrigation protocols were applied for 4 groups. S2 were taken from the canal. Intracanal medicament was placed in the root canal, the cavity was securely sealed. After 14 days,the medicament was removed with 10 mL of 17% EDTA and subsequently irrigated with 5 ml of distilled water, S3 was taken by sterile paper points. The final irrigation was performed according to the group to which the tooth belonged, and S4 was collected as before. the root canals were dried with sterile paper points and filled gutta-percha master cones and sealer.
223641149|NCT06598735|DRUG|HRS-4508|HRS-4508
224229217|NCT06102629|OTHER|NO INTERVENTION|".We will take both blood and ovarian tissue samples used to diagnosis. 2.We will take approximately 3 ml of blood which will be used from the blood sample collected for routine preoperative tests (surgical profile) before their planned surgery or for disease evaluation.~3\. Small tissue samples (from ovary) will be taken from the tissue which is surgically excised as a part of treatment."
224229218|NCT02460848|OTHER|Outpatient therapeutic program, counseling and cash transfer|"Each household will receive an unconditional cash transfer of $40 value every month during a 6 months' period.~The amount of cash per household per month was defined according to the results of the Household Economy Approach survey. This amount represents 70% of supplement to the monthly average household income characterized as very poor to meet their basic needs. This threshold corresponds to the total of food and income necessary to cover 100% of energy needs food (2100 kcal per day per person), the costs associated with the preparation and consumption of food (e.g. salt, soap, kerosene and / or firewood for cooking and basic lighting) and finally all expenses for access to water for human consumption."
223641150|NCT04139057|DRUG|EBV-specific TCR-T cell with anti-PD1 auto-secreted element|Patients were pre-conditioned with chemotherapy and infused with EBV-specific TCR-T cells with anti-PD1 auto-secreted element
223641151|NCT05509998|BEHAVIORAL|Screening Method (SM)|All consecutive incoming patients ages 12-30 entering mental health services will complete a self-report screener, the PQ-B on intake. The intake clinician will review the PQ-B and refer all patients who endorse 6 or more items for evaluation with the SIPS to determine whether the patient meets criteria for psychosis, CHR, or neither. Evaluating clinicians will meet with patients to discuss findings and make referrals to specialty care as appropriate.
223641152|NCT05509998|BEHAVIORAL|Screening and Communication Method (SCM)|Clinicians will be trained to discuss findings and provide referrals using the ComPsych model. ComPsych prepares clinicians to effectively communicate diagnostic, prognostic and treatment information about FEP and CHR with patients and families, using a model that instils realistic hope and provides information effectively to encourage shared decision making about treatment. All consecutive patients ages 12-30 entering mental health services will complete a self-report screener, the PQ-B on intake. The intake clinician will review the PQ-B and refer all patients who endorse 6 or more items for evaluation with the SIPS to determine whether the patient meets criteria for psychosis, CHR, or neither. Following the evaluation, the clinician will schedule a session with the patient, their family, and their treatment team (as applicable) and use the ComPsych model to discuss the findings of the evaluation, provide psychoeducation, and make referrals to specialty services, as appropriate.
223641153|NCT06601803|DRUG|sterile saline solution|The shoulder will be washed with normal sterile saline before and after placing the shoulder implant
223641154|NCT06601803|DRUG|Surgiphor|The shoulder will be washed with Surgiphor (Povidone Iodine) before and after placing the shoulder implant
223641155|NCT06601803|PROCEDURE|Sample Collection|During the surgical procedure, 4 swabs of the surgical wound will be taken at various times throughout the procedure
223641156|NCT06603610|OTHER|Intensive geriatric service worker model of care|"Participants in the intervention group will receive care from an intensive geriatric service worker (IGSW), who will help the participant:~(i) Coordinate community resources and actively support participants' instrumental activities of daily living (IADLs) (e.g., linking participants with Meals-on-Wheels, taking participants to appointments) (ii) Advocate for support from home care for completing activities of daily living (ADLs) (iii) Implement patients' prioritized treatment recommendations made by healthcare professionals (e.g., supporting patients to purchase and install home safety equipment because this aligns with their values and preferences)."
223641157|NCT06603610|OTHER|Information brochure and telephone follow-up support|Participants will be e-mailed or mailed a booklet containing information about locally available resources including (1) meal preparation, (2) grocery delivery, (3) housekeeping, (4) pharmacies that deliver medications, (5) home care, and (6) Wheel-Trans. Participants will receive a scripted phone call from the study research coordinator one and three months after study enrolment to see if they have questions about the booklet material.
224229219|NCT02460848|OTHER|Outpatient therapeutic program and counseling|
224229220|NCT06091800|OTHER|biochemical analysis|GCF and serum samples were collected from the participants for biochemical analysis.
224229221|NCT05469282|DEVICE|Blood circulation device|Blood circulation device of CGM MB-1701 (Ceragem Master V6)
224229222|NCT02729896|DRUG|Atezolizumab [TECENTRIQ]|"Atezolizumab will be administered by intravenous (IV) infusion at a flat dose of 1200 milligram (mg) every 3 weeks (Q3W) on Day 1 of Cycles 2-6, given in 21-day cycles during induction treatment.~NOTE: Atezolizumab treatment has been discontinued in all participants currently on study treatment."
224229223|NCT02729896|DRUG|Obinutuzumab|Obinutuzumab will be administered by IV infusion at a flat dose of 1000 mg on Days 1, 8, and 15 of Cycle 1, and on Day 1 of Cycles 2-6, given in 21-day cycles during induction treatment, and on Day 1 of every other month during maintenance treatment (1 cycle=21 days; infusion rate starts at 50 mg/hour (hr) and increases every 30 min to a maximum of 400 mg/hr).
224229224|NCT02729896|DRUG|Polatuzumab Vedotin|Polatuzumab vedotin will be administered by IV infusion. For relapsed or refractory FL either 1.4 mg/kilogram (kg) or 1.8 mg/kg (dose-escalation phase) and at RP2D (dose-expansion phase) on Day 1 of Cycles 1-6 will be given in 21-day cycles during induction treatment. For relapsed or refactory DLBCL, 1.8 mg/kg will be given during run-in phase and either 1.8 mg/kg or 1.4 mg/kg during the expansion phase (1 cycle=21 days; infusion rate starts with 90 min and decreases to 30 min).
224229225|NCT02729896|DRUG|Rituximab|Rituximab will be administered by IV infusion at 375 mg/m˄2 on Day 1 of Cycles 1-6 during induction treatment (1 cycle-21 days; infusion rate starts with 50 mg/hr and increases every 30 min to a maximum of 400 mg/hr).
224229226|NCT04057053|DRUG|Netarsudil 0.02% Ophthalmic Solution|Use of Netarsudil 0.02% ophthalmic solution daily after surgery
224229227|NCT00582309|PROCEDURE|Glucommander-Guided Intravenous Insulin Infusion|"Glucommander-Guided Intravenous Insulin Infusion.~* Prepare IV Insulin Drip: 250 units of glulisine (Apidra®) insulin with 250 ml NS (1.0 unit/ml). Piggyback insulin drip into IV fluids.~* During the infusion, enter glucose levels into the Glucommander and follow recommendations regarding infusion rate and time to measure next blood glucose levels."
224229228|NCT00582309|PROCEDURE|Standard Intravenous Insulin Infusion|"Standard Intravenous Insulin Infusion Standard Intravenous Insulin Infusion in the ICU setting Prepare IV Insulin Drip: 250 units of glulisine (Apidra®) insulin with 250 ml NS (1.0 unit/ml). Piggyback insulin drip into IV fluids.~Algorithm 1: Start here for most patients. Algorithm 2: For patients not controlled with Algorithm 1, or receiving glucocorticoids, or patient with diabetes receiving \>80 units/day of insulin as an outpatient.~Algorithm 3: For patients not controlled on Algorithm 2.No Patients Start Here."
224229229|NCT00582309|PROCEDURE|Simple Calculated Intravenous Insulin Infusion|If the patient was on insulin prior to this admission, 1/2 of the total insulin dose divided by 24 will be the initial insulin infusion rate. The amount of insulin given will be dependant upon blood sugar levels ( BG levels 80-120= 0.5 units/hr, 121-160=1.0 units/hr, 161-200= 2.0 units/hr, 201-240= 3.0 units/hr, 241-280= 4.0 units/hr, 281-320= 5.0 units/hr, 321-360=6.0 units, 361-400= 7.0 units, greater than 400= 8.0 units.
224229230|NCT04901000|PROCEDURE|Carotid endarterectomy|Carotid endarterectomy prior to CABG operations either under Local Anaesthetic or under General Anaesthetic.
224229231|NCT03123822|DEVICE|Glasses|Glasses traditionally prescribed for refractive error
224229232|NCT02214927|DRUG|BI 11634 tablet|
224229233|NCT02214927|DRUG|BI 11634 drinking solution|
224229234|NCT00545337|DRUG|Insuline glulisine|
224229235|NCT00060957|DRUG|Botulinum toxin type A|
224229236|NCT06301633|DEVICE|Intermittent Oro-esophageal Tube Feeding|The specific procedure was as follows: the infant was placed in a semi-recumbent or sitting position with the head fixed. Before each feeding, the infant's oral and nasal secretions were to be cleared. An intermittent oro-esophageal tube was appropriately lubricated with water on the head part. The professional medical staff held the tube and slowly inserted it through one side of the mouth into the upper part of the esophagus. The depth of insertion depended on the patient's age and height. After each feeding, the tube was immediately removed, and the patient was held upright for at least 30 minutes in case of reflux.
224229237|NCT06301633|DEVICE|Nasogastric Tube Feeding|Nasogastric Tube Feeding were used for feeding to provide nutritional support. Each feeding was administered by a nurse using the infant's mother's breast milk through the tube. The amount of each feeding varied from 20 to 100 ml depending on the age of the infant, with feedings given every 2 to 3 hours, approximately 10 times per day. The duration of each feeding procedure ranged from 10 to 20 minutes. The total daily intake ranged from 200 to 1000 ml. Each tube was kept indwelling for 5 to 7 days. When the tube needed to be replaced, it was removed after the last feeding of a day and a new tube was to be inserted through the other nostril on the following morning to continue the nutritional support.
224229238|NCT06301633|BEHAVIORAL|comprehensive rehabilitation therapy|Both groups were given comprehensive rehabilitation therapy. The main intervention measures included: 1) non-invasive ventilator treatment, generally at least once every night and typically not exceeding continuous daily usage.; 2) attention to feeding and sleeping positions, with a recommended sleeping position of lateral recumbent and the head of the bed raised by 20-30°; 3) swallowing function training, such as tongue muscle stretching training, assisted anterior jaw protrusion training, lemon ice stimulation to the soft palate, pharyngeal wall, etc., generally 5 days per week, twice per day, 5-20 minutes each time; 4) pulmonary ultrashort wave therapy, generally at least 2-3 times a week, and not more than once a day; 5) physical therapy, such as intensive training for gross motor functions including lifting the head, turning over, sitting, crawling, standing, etc., generally 3-5 days per week, 1-2 times per day, 5-20 min each time.
224229239|NCT02382471|DIETARY_SUPPLEMENT|Omega-3|4 cap 1 g Omega-3 per day for 2 months
224229240|NCT02382471|DIETARY_SUPPLEMENT|Placebo|4 cap 1 g Placebo(paraffin) per day for 2 months
224229241|NCT03847883|DRUG|Intravenous Solution Ateplase|Infusion Low dose 0.6 or 0.75 or 0.9 mg/kg Ateplase injection iv bolus 10% of total dose and infusion 90% of total dose in1 hour , with in 4.5Hr after onset of stroke
224229242|NCT05692921|OTHER|Remote Home Monitoring (RHM)|A Virtual platform will be used to provide education and support for ACS patients within the community after a patient is discharged home
224319416|NCT04637802|BEHAVIORAL|Education|The patient education website will serve as the active comparator. The purpose is to control for time, attention, and online usage. Youth and parents will be provided access to an education website containing information about pediatric surgery at the same time interval as the active intervention; however, there will be no exposure to cognitive and behavioral coping skills. Similar to the CBT condition, the presurgery period of Education will be administered for one month prior to surgery and the postsurgery period will be administered for one month after the post-discharge assessment.
224229243|NCT05692921|OTHER|Rapid Response Nursing|A Rapid Response Nurse will be used to provide education and support for ACS patients within the community after a patient is discharged home.
224229244|NCT02687477|PROCEDURE|Pulmonary Arterial Denervation|Contrast pulmonary artery （PA) angiography was performed to localize the pulmonary artery bifurcation level and calculate the PA diameter.Once the anatomy was deemed acceptable, the radiofrequency ablation catheter was introduced into the distal bifurcation area of the main PA.This was then maneuvered within the PA to allow energy delivery to ensure that the electrodes were tightly in contact with the endovascular surface. About two to three ablations at 1-15 W for 240 seconds each point were performed in the distal bifurcation area of the main PA.
224229245|NCT02687477|PROCEDURE|Sham procedure|patient in the sham group will receive sham procedure
224229246|NCT01589003|OTHER|Low Glycaemic index growing up milk|Low Glycaemic index growing up milk
224229247|NCT01589003|OTHER|High GI growing up milk|High glycaemic index growing up milk
224229248|NCT01463683|BIOLOGICAL|2XP HEPTAVAX™-II SC|
224229249|NCT01463683|BIOLOGICAL|1XP HEPTAVAX™-II SC|
224229250|NCT01463683|BIOLOGICAL|2XP HEPTAVAX™-II IM|
224319417|NCT01545518|DRUG|IVIG|IVIG 2 mg/kg in two divided doses with placebo crossover
224319418|NCT03893019|BIOLOGICAL|MB-CART20.1|MB-CART20.1 consists of autologous CD20 Chimeric Antigen Receptor (CAR) transduced CD4/CD8 enriched T cells targeting CD20.positive tumor cells
223641158|NCT06591507|DIETARY_SUPPLEMENT|BCAA Nutritional Intervention|Patients will receive BCAA nutritional supplements. The supplement is taken orally twice daily, with each sachet containing 10g of powder, of which 6g is BCAA, and the remainder consists of preservatives and fruit flavorings to enhance palatability. The morning dose is taken with breakfast, and the second dose is taken as a late evening snack after dinner. For critically ill patients, enteral nutrition is provided instead. During each follow-up visit, patients are required to retain and submit all empty and unused sachets to accurately assess compliance. Dietitians will adjust the type and amount of food for each patient according to the guidelines of the European Society for Parenteral and Enteral Nutrition to ensure a total caloric intake of 35-40 kcal/kg and a protein intake of 1.2-1.5 g/kg (including BCAA supplements).
223641159|NCT06591507|BEHAVIORAL|Muscle Rehabilitation Training|Phase 1: Resistance Training (During Hospital Stay, First Month) Phase 2: Resistance Training (Home-Based, From Hospital Discharge Until 3 Months Post-Surgery) Phase 3: Physical Activity Training (Post-Surgery, After 3 Months)
224229251|NCT00008099|BIOLOGICAL|MUC1 antigen/SB AS-2|
223641160|NCT06591507|DIETARY_SUPPLEMENT|Standard Nutritional Therapy|Standard Nutritional Therapy
223641161|NCT06587009|PROCEDURE|Shock wave therapy|Received shock wave therapy 7 times a week and functional exercise therapy intervention
223641162|NCT06587009|PROCEDURE|Conventional conservative treatment|Conventional conservative treatment and functional exercise were given
223641163|NCT06593561|OTHER|Breast Edema Questionnare|The Breast Edema Questionnaire, developed to evaluate breast edema in women undergoing breast cancer surgery, will be applied.
223641164|NCT06601881|OTHER|Experimental|"Thoracic mobilization exercises will include:~1. Thoracic Spine Extension exersice~2. Thoracic rotation exersice~3. Cat-Camel Exercise~4. Lateral Flexion of the Thoracic Spine~5. Muscules Psoas Stretching~6. Diaphragm Release Technique~Diaphragmatic Breathing Training will include:~1. Diaphragmatic Breathing~2. Crocodile Breathing Technique~3. Breathing with an exercise band~4. Pursed lip breathing"
223641165|NCT06601881|OTHER|Control (placebo) group|"Placebo Thoracic mobilization exercises will include:~1. Placebo Thoracic Spine Extension exersice~2. Placebo Thoracic rotation exersice~3. Placebo Cat-Camel Exercise~4. Placebo Lateral Flexion of the Thoracic Spine~5. Placebo Muscules Psoas Stretching~6. Placebo Diaphragm Release Technique~Placebo Diaphragmatic Breathing Training will include:~1. Placebo Diaphragmatic Breathing~2. Placebo Crocodile Breathing Technique~3. Placebo Breathing with an exercise band~4. Placebo Pursed lip breathing"
223641166|NCT06586450|DEVICE|Low level laser therapy|The participants will receive Low Level Laser on lumbo-pelvic region for 20 min/sessions,3 sessions / week for 12 weeks, with the following parameters: Wavelength: 808 nm, continuous mode, Output power: 160 mw, Penetration depth: 4 cm, Power density:0.16 J/cm2.
223641167|NCT06586450|DEVICE|Interferential current|All participants will receive interferential current on lumbopelvic region ( quadripolar technique) for 25 min/session, 3 sessions/week for 12 weeks, with the following parameters: carrier frequency of 4 KHZ and sweep frequency 95 HZ, intensity based on patient's tolerance without muscle contraction.
223641168|NCT06586450|OTHER|Core stability exercise|The participants will perform core stability exercises for 15 min 3 time/week in the form of Prone Gluteal Squeezes, Pelvic Bridging, Curl Up Exercise, and Double Knee to Chest Stretching Exercises.
223641169|NCT06595550|DIETARY_SUPPLEMENT|Whey protein|Powder milk
224229252|NCT01423838|DRUG|Solifenacin|5 mg, oral, once in a day
224229253|NCT01423838|DRUG|Oxybutynin|5 mg, oral, three times in a day
224229254|NCT03120702|DEVICE|Investigational Rainbow SpHb sensor|Investigational Rainbow SpHb sensor
224229255|NCT01816152|OTHER|Tailored Active intervention|Subjects experience a baseline for 1 week and an active intervention for 4 weeks. The active intervention is a bluish white light source delivering at least 300 lux at the eye of the patient during at least 2 hours daily.
224229256|NCT01816152|OTHER|Inactive intervention|Subjects experience a baseline for 1 week and an inactive intervention for 4 weeks. The inactive intervention is a yellowish white light source delivering at most 50 lux at the eye of the patient during at least 2 hours daily.
224229257|NCT05494905|OTHER|VR|In this project, the investigators focus on using our developed VR gaming platform called Super Pop VR, a VR system that can be individualized to the movement capabilities of the child. It consists of the Microsoft Kinect camera, a laptop, software, and TV screen. The research team will loan the system to the family. While engaged with the game, the child is immersed in a virtual world where virtual objects appear on the screen surrounding the child. Children are asked to move their arms to 'pop' as many virtual objects as possible in a certain amount of time. Playstation 2 EyeToy and EyeToy 2 games will also be used to increase children's motivation by playing a variety of different VR games.
224319419|NCT03545542|DIAGNOSTIC_TEST|Initial fecal microbiome|Stool sampling for fecal microbiome analysis by 16S rDNA pyrosequencing. Neuroblastoma group and Control group.
224319420|NCT03545542|DIAGNOSTIC_TEST|Initial fecal volatile organic compounds|Volatile organic compound analysis of stool samples by gas chromatography/mass spectroscopy Neuroblastoma group and Control group.
224319421|NCT03545542|DIAGNOSTIC_TEST|Initial breath volatile organic compounds|Breath sampling for organic compound analysis by gas chromatography/mass spectroscopy Neuroblastoma group and Control group.
224319422|NCT03545542|DIAGNOSTIC_TEST|Microbiome under chemotherapy|Stool sampling under chemotherapy of children in neuroblastoma group (1 sample 1 week after completion of each chemotherapy cycle). Chemotherapy according to Société Internationale d´Onclogie Pediatrique Neuroblastoma Group (SIOPEN) guidelines
224229258|NCT05494905|OTHER|FST|FST involves repetitive progressive resistance exercise during goal-directed functional activity with the children focus on the activity being performed. Children will be offered a pamphlet containing suggested functional arm exercises and these exercises are designed to move the more affected arm in overhead, outward, and across midline directions. Each exercise will be embedded in a game-like activity. Children will start with no resistance and gradually add on resistance using elastic bands or weight cuffs.
224319423|NCT03545542|DIAGNOSTIC_TEST|Fecal volatile organic compounds under chemotherapy|"Stool sampling under chemotherapy of children in neuroblastoma group (1 sample 1 week after completion of each chemotherapy cycle). Chemotherapy according to SIOPEN guidelines.~Neuroblastoma group"
224319424|NCT03545542|DIAGNOSTIC_TEST|Breath volatile organic compounds under chemotherapy|"Breath sampling under chemotherapy of children in neuroblastoma group (1 sample 1 week after completion of each chemotherapy cycle). Chemotherapy according to SIOPEN guidelines.~Neuroblastoma group"
224319425|NCT03545542|DIAGNOSTIC_TEST|Final microbiome|Stool sampling 3 weeks after completion of chemotherapy Neuroblastoma group
223641170|NCT06595550|DIETARY_SUPPLEMENT|no Whey protein|Powder milk
224229259|NCT01618305|DRUG|Lamivudine/zidovudine|"Participants received one lamivudine 150 mg/zidovudine 300 mg fixed-dose combination tablet twice a day from entry through delivery\*.~\* Participants may have received a locally supplied nucleoside reverse transcriptase inhibitor (NRTI) backbone in place of lamivudine/zidovudine with permission of the protocol team obtained prior to randomization."
224229260|NCT01618305|DRUG|Efavirenz|Participants received one 600 mg tablet of efavirenz each night from entry through delivery.
224229261|NCT01618305|DRUG|Raltegravir|Participants received one 400 mg raltegravir tablet twice a day from entry through delivery.
224229262|NCT03383393|DRUG|Intracoronary bolus of adenosine (adenocor), Integrilin (eptifibatide) or nitroglyzerin (nitronal)|intracoronary drugs
224229263|NCT03246698|OTHER|Isolytic Stretching group|In modified cross body position, isolytic stretching exercises will perform five times each for 15 seconds. After each stretching patient will rest for 5 seconds. When the patient contracts the agonist muscle group with 20% muscle force, the agonist muscle group is stretched at the same time for 2-4 seconds. Isolytic stretching exercises will perform four times a week for four weeks. It's obligatory to receive at least 15 sessions in total. They will also receive standard physiotherapy program four times a week for four week, 15 sessions in total.
224229264|NCT03246698|OTHER|Static Stretching group|In modified cross body position, active-assistive static stretching exercises will be performed 5 times each for 15 seconds. This stretching exercise is performed 5 times with 5 seconds intervals. Static stretching exercises will perform four times a week for four weeks. It's obligatory to receive at least 15 sessions in total. They will also receive standard physiotherapy program four times a week for four week, 15 sessions in total.
223641171|NCT06594653|OTHER|pre treatment assesment|All measurements will be obtained using an optoelectronic multicamera system for human motion analysis (with eight high-resolution cameras with infrared light and a sampling frequency of 60 Hz. The experimental protocol requires the positioning of markers (plastic spheres covered by reflecting film, 10 mm in diameter). Markers will be placed by clinical operators (physiotherapists with training in optoelectronic system for human motion analysis) after training and experience in recognition of the position of body landmarks.
223641172|NCT06594653|OTHER|post treatment assessment|All measurements will be obtained using an optoelectronic multicamera system for human motion analysis (with eight high-resolution cameras with infrared light and a sampling frequency of 60 Hz. The experimental protocol requires the positioning of markers (plastic spheres covered by reflecting film, 10 mm in diameter). Markers will be placed by clinical operators (physiotherapists with training in optoelectronic system for human motion analysis) after training and experience in recognition of the position of body landmarks.
223641173|NCT06591195|DEVICE|Distraction by use of kaleidoscope|"À kaleidoscope is an optical device consisting of mirrors that reflect images of bits of coloured glass in a symmetrical geometric design through a viewer.~A kaleidoscope was selected as the non-electronic method of distraction, because of its wide availability due to low costs, its evolving and colourful visual stimuli, the fact that is blocks out any visualisations from the environment when used properly, and because it requires active participation (i.e., greater attention) from the subject."
224229265|NCT03246698|OTHER|Control group|They will receive only standard physiotherapy program, four times a week for four weeks, 15 sessions in total.
224229266|NCT00918671|OTHER|No new specific intervention|No new specific intervention
224229267|NCT01816698|DRUG|Taurine granule|1 package(1.6g taurine granule) once a day after meals, 12 weeks
224229268|NCT01816698|DRUG|Placebo|Placebo: 1 package once a day after meals, 12 weeks
224229269|NCT06057298|PROCEDURE|Patient-tailored hyperthermic intraperitoneal chemotherapy (HIPEC)|"Patient-tailored HIPEC is performed by the closed-abdomen technique with the following drugs selected according to the results of the sensitivity tests on the organoid-based preclinical model:~* Oxaliplatin 360 mg/mq for 30 min.~* Oxaliplatin 200 mg/mq for 120 min.~* Mitomycin-C 35mg/mq for 60 min.~* Mitomycin-C 3.3 mg/mq/l of perfusate + cisplatin 25 mg/mq/l of perfusate for 60 min. (perfusate volume l. 4-6)"
224229270|NCT05286099|OTHER|Imaging examination and/or blood test|Imaging examination and/or blood test will be performed at a certain time
224229271|NCT01873638|PROCEDURE|Cholecystectomy|
224229272|NCT00902083|DRUG|p53 gene with surgery|pre-surgery p53 gene treatment: 10exp12 virus particles per 3 days for 5 times
224229273|NCT00902083|PROCEDURE|surgery|remove tumor surgery
224229274|NCT00902083|DRUG|p53 with chemotherapy|p53 gene treatment: 10exp12 virus particles per 3 days for 10 times Chemotherapy: standard chemotherapy
224229275|NCT00902083|DRUG|p53 gene therapy|p53 gene treatment: 10exp12 virus particles per 3 days for 10 times
224229276|NCT00798551|BEHAVIORAL|Risk counseling|cardiovascular risk counseling regarding elevated blood pressure
224229277|NCT00775697|DRUG|Montelukast|the arm will be treated with Montelukast 4 mg die for 4 weeks
224229278|NCT00775697|DRUG|Montelukast|montelukast 4 mg day for 4 weeks
224229279|NCT02346539|DRUG|Nicotine polacrilex|Single Acute dose
224229280|NCT05729633|OTHER|Robot mediated upper limb therapy|"The OR is classified as a Class A device with the Health Sciences Authority. The OR is capable of both delivering RMIT as well as RMTT. It can provide zero, partial, or full assistance to the patient to complete the movement or task. Its teach-and-follow mode allows a movement to be performed by the therapist, with the device then replaying the movement at either zero, partial, or full assistance, for the patient.~Impairment oriented training will focus on the following movements:~1. Diagonal movement~2. Shoulder abduction~3. Shoulder adduction~4. Shoulder flexion~5. Shoulder extension~6. Elbow flexion~7. Elbow extension~Task-specific training will focus on the following activities:~1. Picking up a cup/glass by the side and drink~2. Brushing hair~3. Cleaning unaffected upper limb (hand to arm)~4. Wiping table~5. Wiping wall~6. Sliding card on table to a designated location~7. Clipping a clothe peg"
224229281|NCT06537518|DRUG|Dexamethasone injection|Dexamethasone, a potent glucocorticoid, decreases the inflammatory response, tissue damage, and pain after surgical procedures; which can be injected locally or Intravenously.
224319426|NCT03545542|DIAGNOSTIC_TEST|Final fecal volatile organic compounds|Stool sampling 3 weeks after completion of chemotherapy Neuroblastoma group
224319427|NCT03545542|DIAGNOSTIC_TEST|Final breath volatile organic compounds|Breath sampling 3 weeks after completion of chemotherapy Neuroblastoma group
223641174|NCT00899132|GENETIC|in situ hybridization|Tumor tissue samples from paraffin-embedded tissue blocks are analyzed for TAB3 transcript and protein expression using in situ hybridization and immunostaining with TAB3 cRNA probe and antibody. Antibodies against the proteins involved in the NFkB signaling pathway (e.g., p65, TAK1, MyD88, and Akt) are used in the immunostaining assays.
223641175|NCT00899132|GENETIC|protein expression analysis|Tumor tissue samples from paraffin-embedded tissue blocks are analyzed for TAB3 transcript and protein expression using in situ hybridization and immunostaining with TAB3 cRNA probe and antibody. Antibodies against the proteins involved in the NFkB signaling pathway (e.g., p65, TAK1, MyD88, and Akt) are used in the immunostaining assays.
223641176|NCT00899132|OTHER|immunologic technique|Tumor tissue samples from paraffin-embedded tissue blocks are analyzed for TAB3 transcript and protein expression using in situ hybridization and immunostaining with TAB3 cRNA probe and antibody. Antibodies against the proteins involved in the NFkB signaling pathway (e.g., p65, TAK1, MyD88, and Akt) are used in the immunostaining assays.
223641177|NCT06987136|OTHER|Transversus thoracic muscle plane block|Patients will receive a transversus thoracic muscle plane block.
223641178|NCT06987136|OTHER|Erector spinae plane block|Patients will receive an erector spinae plane block.
223641179|NCT06987136|OTHER|Thoracic paravertebral block|Patients will receive a thoracic paravertebral block.
223765187|NCT07163117|OTHER|lumbar stabilization exercises|The participants required to be in a prone position with pillow under abdomen, first raise one leg then the other leg, raise one arm then the other arm, after that raise two legs together, then raise two arms together, raise right arm with left leg then left arm with right leg, then raise both arms and both legs together, every position hold for 20 seconds. Then they required to be in a half kneeling on standing for right leg hold for 20 second and repeat for other leg, do it again but their knees doesn't touch the ground. Finally they required to lie on their backs, and bend their knees at around a 90 degree angle. Place their hands to their sides and their feet flat on the floor at about shoulder width and asked to raise their hips off the floor, hold 20 second.
223641180|NCT06654908|PROCEDURE|resisted exercise using sand bags,resistance machines and elastic bands|Rehabilitative exercise training will be performed as previously described. All exercises will be performed using free weights, elastic bands and variable-resistance machines. Modifications to exercises will be made when appropriate depending on the patient injury characteristics. The load will be gradually increased from 50-60% of 3RM at the beginning of the program up to 80-85% of 3RM (repetitions maximum) at the end of the program. All exercise sessions will be preceded by a 5-minute warm-up at \&lt;50% VO2peak. No strength training activities will be permitted outside the supervised training session; however, both groups will be encouraged to maintain normal daily activities
223641181|NCT02538510|OTHER|Laboratory Biomarker Analysis|Correlative studies
223641182|NCT02538510|BIOLOGICAL|Pembrolizumab|Given IV
223641183|NCT02538510|DRUG|Vorinostat|Given PO or via PEG
223641184|NCT04531618|BEHAVIORAL|Emotional Exchange (EE)|These sessions, conducted by a trained study staff member through Zoom, will involve storytelling and discussing emotional experiences with the baby, with prompts like sharing about the pregnancy or reactions to the baby's smiles.
223641185|NCT04531618|OTHER|Newborn Care (NC)|Newborn Care (NC) is a teaching curriculum designed to provide mothers with developmentally appropriate information about newborn care. The curriculum is adapted from previously studied literature that increased maternal knowledge about both medical and developmental concerns.
223641186|NCT06588166|DIAGNOSTIC_TEST|Gut microbiome testing|Gut microbiome testing for the characterization of the patient gut microbiome
224229282|NCT06537518|DRUG|Bupivacaine 0.375% Injectable Solution|Isobaric bupivacaine (0.375%) is injected into the adductor canal deeply to the sartorius muscle around the saphenous nerve after ensuring negative aspiration space.
224229283|NCT06537518|DRUG|Bupivacaine 0.5% Injectable Solution|20 ml of Bupivacain 0.5% was mixed with dexamethasone 8 mg is injected into the adductor canal deeply to the sartorius muscle around the saphenous nerve after ensuring negative aspiration space.
224229284|NCT05434403|DEVICE|Vagus nerve stimulation|vagus nerve electrical stimulation through ear skin
224229285|NCT05434403|DEVICE|sham vagus nerve stimulation|sham vagus nerve electrical stimulation through ear skin
224229286|NCT00030173|DRUG|Epothilone D (KOS-862)|
224229287|NCT05071547|BEHAVIORAL|Guided internet-delivered acceptance and commitment therapy (ACT)|ACT builds on cognitive behavioral therapy (CBT), and includes methods for experiential learning and focus on psychological flexibility
224229288|NCT05071547|OTHER|Interdisciplinary Pain Rehabilitation Program (IPRP)|Multimodal treatment where physio therapists, occupational therapists, psychologists and physicians give synchronized treatments to raise physical and psychological function and promote return to work
224229289|NCT03058536|DEVICE|Arabin Pessary|The cervical pessary will be inserted at the randomization and removed during the 36 week of pregnancy, unless labour occurs sooner.
224229290|NCT03058536|DRUG|Vaginal Progesterone|Treatment with 400 mg micronized progesterone daily, until the day of randomization to 36 weeks of pregnancy.
224229291|NCT03058536|OTHER|Arabin Pessary and Progesterone|Arabin Pessary and Progesterone The cervical pessary will be inserted at the randomization and removed during the 36 week of pregnancy, unless labour occurs sooner. Treatment with 400 mg Micronized progesterone daily, until the day of randomization to 36 weeks of pregnancy.
224229292|NCT05660057|DEVICE|New computer monitor|The device to be studied is a newly designed computer monitor and will be compared with the standard computer monitor.
224229293|NCT02099266|DEVICE|Administration of hyperbaric oxygen|Hyperbaric oxygen at 2.5 atmospheres absolute (ATA) for a total of 2 hours
224229294|NCT01841606|DRUG|Ondansetron|4mg of IV ondansetron
224229295|NCT01841606|OTHER|Normal saline|10mL of IV normal saline
224229296|NCT02730065|BEHAVIORAL|Structured Aerobic Dance Training Group|Systematic physical activity
224229297|NCT02730065|BEHAVIORAL|Stretching plus education|Weekly group based stretching with psychoeducation and health education
224229298|NCT03152461|DIAGNOSTIC_TEST|Quantra System|Diagnostic device to monitor coagulation properties of a whole blood sample at the point-of-care.
224229299|NCT04895410|BIOLOGICAL|Lemzoparlimab|Intravenous (IV) infusion
224229300|NCT04895410|DRUG|Dexamethasone|Oral tablet or IV infusion/injection
224229301|NCT04895410|DRUG|Carfilzomib|IV infusion
224229302|NCT04895410|DRUG|Pomalidomide|Oral capsule
224229303|NCT04895410|BIOLOGICAL|Daratumumab|Subcutaneous (SC) injection
224229304|NCT01591031|DRUG|Sevoflurane|anesthesia induction with propofol, remifentanil and sevoflurane; afterwards tracheal intubation
224229305|NCT01591031|DRUG|Rocuronium|anesthesia induction with propofol, remifentanil and rocuronium; afterwards tracheal intubation
224229306|NCT02371967|DRUG|Vismodegib|Vismodegib therapy will be given in compliance with the physician's standard practice as per local label.
224229307|NCT01260480|OTHER|[18F]-ML-10 in conjunction with PET imaging|Subjects will receive two to three intravenous (IV) doses of \[18F\]-ML-10. The dose for each \[18F\]-ML-10 dose will be 5.50 MBq/Kg or 0.15 mCi/Kg but will not exceed 500.00 MBq (13.50 mCi) per administration.
224229308|NCT04133480|DRUG|GWP42003-P|oral solution of 100 milligrams per milliliter (mg/mL) cannabidiol (CBD)
223641187|NCT06604702|PROCEDURE|Autologous Fat Injection for Rectocele|In this procedure, autologous fat is harvested from the patient\&#39;s lower abdomen using a multiport cannula. The fat is then processed via centrifugation to separate the viable fat cells, which are emulsified into nanofat. This nanofat is injected into the submucosal layer of the rectocele through the posterior vaginal wall, using an anoscope for guidance. The procedure is intended to reinforce the rectovaginal fascia, alleviate rectocele symptoms such as obstructive defecation and vaginal bulge, and reduce prolapse recurrence.
224229309|NCT01026688|OTHER|Toolkit|Cardiovascular Disease Toolkit mailed by the Canadian Diabetes Association to family physicians, accompanying the Spring/Summer 2009 edition of the quarterly newsletter, Canadian Diabetes. (Mailed in June 2009.) The Toolkit includes a summary of selected sections of the practice guidelines targeted towards primary care physicians; a synopsis of the key messages pertaining to cardiovascular disease risk; a laminated card with a simplified algorithm for cardiovascular risk assessment and treatment; and a pad of tear-off sheets for patients with a cardiovascular risk self-assessment tool.
224229310|NCT01026688|OTHER|Control|The Spring/Summer 2009 issue of the quarterly newsletter, Canadian Diabetes, mailed on its own. The Cardiovascular Toolkit was mailed to Control arm physicians with the May 2010 issue of the newsletter.
223641188|NCT06587880|DRUG|Chlorhexidine Gluconate|Prescribed for 7 days period 2 times a day starting 24 hours post-extraction, the patient is instructed to pour 10 ml of the mouthwash into a measuring cup, rinse for 1 minute at an alternative time to teeth brushing. Do not eat or drink for 30 min after use.
223641189|NCT06587880|DRUG|Bone Bioactive Liquid|Prescribed for 7 days period 2 times a day starting 24 hours post-extraction.
223641190|NCT06587880|DRUG|Hyaluronic Acid mouthwash|Prescribed for 7 days period 3-4 times a day starting 24 hours post-extraction, the patient is instructed to pour 20 ml of the mouthwash into a measuring cup and rinse for 1 minute, at an alternative time to teeth brushing. Do not eat or drink for 30 mins after use.
223641191|NCT06587880|DRUG|Warm Saline Mouth Rinse|Prescribed for 7 days period 2 times a day starting 24 hours post-extraction.
223641192|NCT06589882|OTHER|Effectiveness of diagnostic and therapeutic and/or innovative endoscopic techniques|Evaluate the effectiveness of diagnostic and therapeutic and/or innovative endoscopic techniques practiced in French expert centers over the next 10 years with the rate of technical success (procedure completed) and clinical success (cure) of the digestive pathology presented by the patient who indicated endoscopy without recourse to a new intervention (endoscopic or surgical) within 30 days of the procedure.
223641193|NCT06591065|BEHAVIORAL|Yoga Flow|The study participants were subjected to an intervention comprising hatha yoga sessions conducted twicw weekly over an twelve weeks period, with each session lasting 60 minutes.
224229311|NCT00785122|DRUG|Endoxana, Leukine, IMA910|a single i.v. infusion of 300 mg/m2 Endoxana (Cyclophosphamide) and then 3 days later (visit 1) patients will start vaccination therapy with intradermal (i.d.) injections of 75µg GM-CSF followed by i.d. injections of 5.78 mg IMA90
224229312|NCT00785122|DRUG|Endoxana, Leukine, IMA910, Aldara|a single i.v. infusion of 300 mg/m2 Endoxana (Cyclophosphamide) and then 3 days later (visit 1) patients will start vaccination therapy with intradermal (i.d.) injections of 75µg GM-CSF followed by i.d. injections of 5.78 mg IMA90 followed by Aldara (Imiquimod)
224229313|NCT00508586|DRUG|PTC299|PTC299 orally administered twice per day given in combination with anastrozole (Arimidex®), letrazole (Femara®), or exemestane (Aromasin®)
224229314|NCT04345471|DRUG|Desvenlafaxine 100 mg|once daily dosing for 8 weeks
224229315|NCT04345471|DRUG|Desvenlafaxine 50 mg|once daily dosing for 8 weeks
223641194|NCT06591065|OTHER|Controlled|The control group did not receive any yoga training
223641195|NCT06594731|OTHER|Hip belt squat training|Hip belt squat training performed twice per week for 6 weeks
223641196|NCT06594978|DEVICE|dual-site anodal tDCS over the M1|M1: motor cortex
223641197|NCT06594978|DEVICE|dual-site anodal tDCS over the DLPFC|DLPFC: dorsolateral prefrontal cortex
223641198|NCT06594978|DEVICE|sham tDCS|sham stimulation
224229316|NCT04345471|DRUG|Placebo|once daily dosing for 8 weeks
224229317|NCT02373475|OTHER|Conventional ventilation|Conventional ventilation with TV of 10 mL/kg predicted body weight (PBW) without positive end-expiratory pressure (PEEP) during the surgery under general anesthesia
224229318|NCT02373475|OTHER|Protective lung ventilation|Protective lung ventilation with TV of 6 mL/kg PBW, PEEP of 6 cmH2O and recruitment maneuver during the surgery under general anesthesia
224229319|NCT05484271|PROCEDURE|Rotator cuff repair|The patients received the arthroscopic rotator cuff repair.
224229320|NCT05778149|DRUG|Aumolertinib,Anlotinib|Aumolertinib 110mg p.o QD; Anlotinib 12mg, oral for 2 weeks, three weeks a cycle, until disease progression.
224229321|NCT01672372|DIETARY_SUPPLEMENT|Max Stress B|Participants are to mix one vial per day of either placebo or actual supplement in 1 liter of water and drink over the course of the day
224229322|NCT01672372|DIETARY_SUPPLEMENT|Placebo Max Stress B|
224229323|NCT02525029|DRUG|Pregnyl®|"Standard of care immunosuppression, plus Pregnyl® at assigned dose subcutaneously every other day for up to 5 doses through day 7~Phase I: up to 7 dose levels of Pregnyl® will be tested; however dose levels -1 and -2 will be used only if dose level 1 proves too toxic. Study will use Continual Reassessment Method (CRM) to establish a maximum tolerated dose (MTD).~Step -2: 125 USP hCG/875 pg EGF/m2 Step -1: 250 USP hCG/1,750 pg EGF/m2 Step 1 (start): 500 USP hCG/3,500 pg EGF/m2 Step 2: 1,000 USP hCG/7,000 pg EGF/m2 Step 3: 2,000 USP hCG/14,000 pg EGF/m2 Step 4 (Arm 2b only): 3,500 USP hCG/24,500 pg EGF/m2 Step 5 (Arm 2b only): 5,000 USP hCG/35,000 pg EGF/m~Phase II: the dose of Pregnyl will be that identified as the MTD during phase I."
223641199|NCT06604507|DEVICE|non-pharmacological app|Amputees will be offered use of an app which offers a variety of non-pharmacological management techniques and exercises aimed at reducing the sensations and pain which are associated with amputation. These include: (1) offering information about the amputation, (2) augmented reality, this is a method for altering a person's perception about the real-world environment using computer simulation; (3) methods for reducing stress, also called 'Mindfulness-Based-Stress-Reduction' and (4) a method called 'Graded Motor Imagery' which aims to train the brain to address the changes which have occurred due to the amputation and which are related to pain and challenges with movement
223641200|NCT06597578|DEVICE|Extraction tools|The effect of different extraction tools on outcome parameters will be evaluated
223641201|NCT06591754|BEHAVIORAL|ISTDP|Both the individual therapy and the group therapy is based on ISTDP (Intensive Short-Term Dynamic Psychotherapy), an affect-focused psychodynamic therapy method. The therapy focus on the relationship between feelings, anxiety and dysfunctional emotion regulation (i.e. defenses). The purpose is to increase the capacity of anxiety regulation in the patient and to help the patient identify the dysfunctional patterns developed to avoid internal stress and then gradually approach previously warded of feelings. The individual therapy consists of 25 weekly sessions. The group treatment consists of 18 weekly sessions and is structured in three phases. Phase one: Psychoeducation about anxiety and exercises in anxiety regulation. Phase two: patients takes turn to observe their own anxiety and defenses together with a therapist. Phase three: Every session two patients will work with a chosen problem and identify defenses, anxiety and feelings together with a therapist in front of the group.
223765188|NCT07163117|OTHER|endurance training|"1. Back extensor endurance training exercise:~   The participants lay prone over the end of a treatment table with the anterior superior iliac spine supported on the bench edge. Their ankles were fixed by the researcher. They maintained the horizontal position for as long as possible, beginning timing when the horizontal unsupported position was achieved and ending when they dropped below the horizontal plane. The duration of holding was measured in seconds.~2. Back flexor endurance training exercise:~The participants asked to sit on the table with your arms crossed against their chest and their back against the wedge. Fix them to the table with a belt across the feet. They asked to remove the wedge from their back using the timing device to record how much time is accumulated until the original position can no longer be maintained."
223765189|NCT07163117|OTHER|Home based program|General and similar exercises for back muscles introduced for this group. They instructed to do knee to chest stretch, lower back rotational stretch, bridge exercise. The required measure data were obtained from the selected cases in this group before and after the end of rehabilitation program.
223765190|NCT07164950|DEVICE|Medical-grade compression stocking|A knee-high compression stocking providing 20-30 mmHg pressure will be applied to the assigned foot during the ADC treatment period to prevent chemotherapy-induced peripheral neuropathy (CIPN). Stockings will be worn daily, except during bathing.
223765191|NCT07171099|DRUG|Rengalin|Solution for oral administration
223765192|NCT07171099|DRUG|Placebo|Solution for oral administration
224229324|NCT00200005|DEVICE|Type: Implantable neurostimulator; InterStim|Treatment with InterStim Therapy: all patients meeting inclusion/exclusion criteria undergo test screening and those who have successful outcomes receive a permanent implant.
224229325|NCT05571085|OTHER|Core Stability Exercises|Core stabilization exercises will be performed based on the program recommended by Jeffrey. Each session will take 40-50 minutes. The program consists of a 5-minute warm-up, 40-minute main exercise and a 5-minute cool-down period.
224229326|NCT05571085|OTHER|PNF Exercise Program|PNF exercises will consist of a 5-minute warm-up, 40-minute main exercise and a 5-minute cool-down period, with each session lasting 40-50 minutes.
224229327|NCT03896490|BEHAVIORAL|Attention Control Training|Infants watch interactive cartoons that respond to infants' direction of gaze. An eye-tracker records the infant's eye movements in real time, relaying this information to the computer. These presentations trigger motivating stimuli (cartoon animations with child-friendly sounds) every time the infant fulfills the demands of a task (e.g. when the infant looks at a character on the screen avoiding to be distracted by other objects moving across the screen). The length of training sessions varies depending on infants' engagement with stimuli and time criteria.
224229328|NCT03896490|BEHAVIORAL|Control|The control procedure involves presentation of cartoons on a screen, while infants' gaze direction is recorded using the same eye-tracker and camera. The crucial difference is that the cartoons in this case are not interactive, thus do not change depending on infants' gaze direction. To ensure presentations in the control procedure are similar in length to those of the intervention group, infants in the control group are matched infant-by-infant and visit-by-visit with participants in the ACT treatment group: Infants in the control group see a replay of the session of the matched treated infant. Therefore, while the presentation is exactly the same (i.e. same length and same stimuli) for the treated and the control child, in the latter case the presentation is not interactive (i.e. not generated contingently on the infants' visual behaviour).
224229329|NCT02394132|DRUG|Imiquimod|
224229330|NCT02394132|RADIATION|Radiotherapy|
224229331|NCT05232578|RADIATION|Early salvage radiotherapy (eSRT)|"eSRT administered immediately after the confirmation of the biochemical relapse (PSA ≈ 0.2ng/ml).~66-70Gy will be delivered to the bed of prostate. Radiotherapy will be optionally accompanied by androgen deprivation therapy."
224229332|NCT05232578|RADIATION|Delayed Salvage radiotherapy (dSRT)|"dSRT administered if PSA levels increase to ≥ 0.4 ng/ml.~66-70Gy will be delivered to the bed of prostate. Radiotherapy will be optionally accompanied by androgen deprivation therapy."
223765193|NCT07163559|BEHAVIORAL|coping skills training|"CST aims to improve physical/mental health in chronic headache patients by reducing pain intensity, migraine attacks, and medication use. The program includes 8 sessions (2/week) covering:~Client-centered problem-solving \& migraine education (COPM-based), Activity pacing, stress management, and healthy habits, Energy conservation techniques, Social participation, Program evaluation. Session durations: Session 1 (45 min), Sessions 2-6 (60-75 min), Sessions 7-8 (60 min)."
224319428|NCT04315506|BEHAVIORAL|#EnufSnuff.TXT Intervention|The SGR program will reduce smokeless tobacco until you reach zero. The intent of this program is to reduce the number of times participants use smokeless tobacco down to zero. Participants will also receive text-based support messages.
224319429|NCT04315506|BEHAVIORAL|Enough Snuff Intervention|Participants will be sent the Enough Snuff cessation manual. One weeks after it is sent, participants will then receive text messages from the study team twice a week for ten weeks.
223641202|NCT06595355|DRUG|bevacizumab with oral curcumin|According to the recommendation of the American Association of Ophthalmologists, intravitreal injection of bevacizumab with a standard dose of 1.25mg/0.05ml in each group will be performed three times consecutively at one-month intervals. In the simultaneous intervention group, patients will take daily curcumin tablets (sinacurcumin product) at a dose of 40 mg twice a day for three months (at the same time as the start of bevacizumab intravitreal injection treatment).
223641203|NCT06595355|DRUG|bevacizumab with oral placebo|Intravitreal injection of bevacizumab with a standard dose of 1.25mg/0.05ml in each group will be performed three times consecutively at one-month intervals. In the control group, patients will be taking daily placebo tablets twice a day for three months (at the same time as the start of bevacizumab intravitreal injection treatment).
223641204|NCT06598995|PROCEDURE|Coronary artery bypass grafting or unroofing|Patients had an MB with \&gt;75% compression degree would receive coronary artery bypass grafting, and those who underwent unroofing may had a depth of MB \&lt; 5mm (whether deal with these MB with a depth \&lt;5mm depends on the surgeon and the period time of patients received a surgery).
223641205|NCT06587646|DIAGNOSTIC_TEST|Virtual Examination under Anaeastehtic - 3D reconstruction imaging|3D reconstruction of MRI imaging and review by patient and surgeon prior to surgical intervention.
224229333|NCT02260765|DEVICE|dTMS|The Brainsway H-Coil TMS device is intended for the treatment of depressive episodes in patients suffering from Major Depressive Disorder (MDD). The device technology is based on the application of deep TMS by means of repetitive pulse trains at a determined frequency
224229334|NCT02710461|DIETARY_SUPPLEMENT|Mixture of grape pomace and pomegranate pomace|Oral Glucose Tolerance Test
223641206|NCT06587646|DIAGNOSTIC_TEST|Standard Care - Written MRI report|A standard written MRI report will be provided to the surgeon and patient prior to surgical intervention.
223641207|NCT06599060|OTHER|Trinity Amputation and Prosthesis Experience Scale|Participants were administered a questionnaire.
224229335|NCT02710461|DIETARY_SUPPLEMENT|Mixture of grape pomace and pomegranate pomace|Oral Glucose Tolerance Test right after taking the mixture of grape and pomegranate polyphenols
223641208|NCT06588036|DRUG|Prebiotic|. The primary outcome measure will be the mean time from the initiation of treatment to the resolution of diarrhea symptoms. This objective seeks to provide evidence-based insights into the optimal management strategies for childhood diarrhea and inform clinical practice guidelines.
223641209|NCT06588036|OTHER|Duration|every participant is alloted a group based on RCT.
223641210|NCT06588036|DRUG|Smecta|Group 4 will be given smecta scahet
223765194|NCT07163858|PROCEDURE|passive leg raising for hemodynamic management during open-heart coronary bypass grafting|Passive leg raising will be used in the experimental group in order to manage hemodynamics: legs will be raised to an angle of approx. 45°
223765195|NCT07163858|PROCEDURE|Use of Noradrenaline only in control group|Noradrenaline will be used for hemodynamic management. Passive leg raising will not be used in this group
223765196|NCT07167992|PROCEDURE|Pleurodesis|Talc slurry pleurodesis is a chemical technique for managing recurrent pleural effusions and pneumothoraces. The procedure involves instilling a suspension of talc (4-5 grams) in sterile saline (50-100 mL) into the pleural space via a chest tube. This induces an inflammatory reaction, leading to fibrosis and fusion of pleural surfaces. The technique demonstrates 70-90% success rates in malignant pleural effusions and pneumothoraces, with efficacy comparable to talc poudrage. While generally safe, potential complications include pain, fever, and rarely, pneumonitis or empyema. Use of large-particle, asbestos-free talc and standardized protocols has improved its safety profile.
223765197|NCT07167992|PROCEDURE|pleurodesis|Talc insufflation, is a pleurodesis technique involving direct insufflation of dry talc powder into the pleural cavity during thoracoscopy. It allows visual inspection of the pleural space and concurrent diagnostic procedures. Success rates range from 85% to 93% for malignant pleural effusions and pneumothoraces, with efficacy comparable or potentially superior to talc slurry in some studies. The procedure typically requires general anesthesia and is more invasive than talc slurry. Common side effects include chest pain, fever, and dyspnea. The risk of severe respiratory complications has decreased with large-particle, asbestos-free talc. While effective, the choice between insufflation and slurry depends on patient factors, institutional expertise, and resource availability.
224229336|NCT02710461|DIETARY_SUPPLEMENT|Mixture of grape pomace and pomegranate pomace|Oral Glucose Tolerance Test ten hours after taking the mixture of grape and pomegranate polyphenols
224229337|NCT02688127|DRUG|Tranexamic Acid|tranexamic acid or placebo are given before cesarean section in patient with placenta previa
224229338|NCT01352559|DRUG|responders|Antidepressants administration for 6 weeks under therapeutic dose
224229339|NCT01352559|DRUG|non-responders|Antidepressants administration for 6 weeks under therapeutic dose
224229340|NCT06052371|DEVICE|VerioVue (Enhancements) blood glucose monitoring system|VerioVue meter with expanded haematocrit range
224319430|NCT00637494|DRUG|mifepristone|1200 mg (administered as four 300 mg tablets) once a day by mouth for the initial 7 days
224229341|NCT04083339|DRUG|AT-001|"AT-001 will be administered as 3 capsules twice daily, before breakfast and before dinner.~At present AT001 is the sole name for the active substance. No INN/genetic name is available to date"
224229342|NCT04083339|DRUG|Placebo|Matching placebo will be administered as 3 capsules twice daily, before breakfast and before dinner
224229343|NCT03773328|BIOLOGICAL|CK0801|CK0801 (Cord blood-derived T-regulatory cells)
224229344|NCT02277314|PROCEDURE|Manual Small Incision Cataract Surgery|This cost-effective solution for removing cataracts, also known as Manual Small Incision Cataract Surgery (MSICS), is a positive alternative when Phaco is not an option due to costs. The procedure takes approximately 30 minutes and involves a mid-size incision and an intraocular lens (IOL), or artificial lens, replacing the natural lens. Following the procedure, patients may need glasses, and most will need bifocals, but overall vision will be significantly improved.
224319431|NCT00637494|DRUG|placebo|Tablets of identical appearance to active drug, once a day by mouth for the initial 7 days
224319432|NCT06550960|DEVICE|Evaluation of two biopsy systems|Each subject will have prostate biopsy taken in 6 locations in one lobe of the prostate and then biopsy in 6 locations in the other lobe of the prostate
224319433|NCT02559180|DRUG|aflibercept|aflibercept 2mg given intravitreally every month until resolution of fluid in retina and then continued every 2 months for a total of 24 months of treatment
224323328|NCT04062552|OTHER|Behavioral, Psychological or Informational Intervention|Receive ENABLE palliative care information
223641211|NCT06588309|BEHAVIORAL|Eye movement desensitization and reprocessing (EMDR)|Integrated addiction and traumafocused treatment.
223641212|NCT06588309|BEHAVIORAL|CRA|CRA is a comprehensive cognitive behavioural treatment that focuses on helping people discover and adopt a pleasurable, social and healthy lifestyle that is more rewarding than a lifestyle including substance use.
223641213|NCT06599385|OTHER|Platelet transfusion if platelet count ≤ 10 G/L|Platelet transfusion as soon as platelet count falls ≤ 10 G/L
223641214|NCT06599385|OTHER|Platelet transfusion when platelet count ≤ 20 G/L|Platelet transfusion will be initiated immediately after randomisation
223641215|NCT06587815|OTHER|musical starry sky projector|Children in intervention group received musical starry sky projector during their sleep time
223641216|NCT06587971|PROCEDURE|Standard periodontal treatment protocol|Administering standard treatments for chronic periodontitis according to the current guidelines, including supragingival scaling, subgingival scaling, root planing, and periodontal flap surgery.
223641217|NCT06587971|BEHAVIORAL|Oral hygiene education|Providing guidance on proper brushing techniques, smoking cessation, dietary control, and blood sugar management.
223641218|NCT05848752|BEHAVIORAL|psychophysics|Subjects will be shown a pair of jars each filled with the same absolute number but different ratios of red/blue balls. Three blocks of trials exist, short-term inference (subjects must identify which of the equally likely jars is currently in use), long-term inference (subjects must predict the subsequent jar in use on the next trial, where jar switches are correlated across trials), or multi-timescale inference (subjects must both report the current jar and predict the subsequent jar, combining the short and longterm inferences). Subjects will draw balls as many balls as they wish with replacement (free response) during the short-term and multi-timescale blocks but will know the current jar in use for long-term inference.
223641219|NCT03397966|DRUG|recombinant human BNP(1-32)|Subjects will receive an IV infusion of recombinant human BNP(1-32) for 240 minutes at a rate of 10 ng/kg/minute for 240 minutes, preceded by an IV bolus of 100 ng/kg.
223641220|NCT03397966|DRUG|placebo (control, normal saline)|Subjects will receive an IV infusion of placebo (normal saline) at a rate of 10 ng/kg/minute for 240 minutes, preceded by an IV bolus of 100 ng/kg.
223641221|NCT05823480|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allo HCT per standard of care
223641222|NCT05823480|DRUG|Azacitidine|Given IV
223641223|NCT05823480|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223641224|NCT05823480|PROCEDURE|Bone Marrow Aspirate|Undergo bone marrow biopsy and aspirate
224229345|NCT03743428|DRUG|Apatinib Mesylate Tablets|Apatinib combinated with FOLFIRI regimen as the second-line chemotherapy for mCRC
223641225|NCT05823480|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy and aspirate
223641226|NCT05823480|PROCEDURE|Echocardiography|Undergo ECHO
223641227|NCT05823480|BIOLOGICAL|Magrolimab|Given IV
223641228|NCT05823480|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
223641229|NCT05823480|OTHER|Questionnaire Administration|Ancillary studies
223641230|NCT04215731|DRUG|Neoadjuvant chemotherapy with mFOLFOXIRI plus bevacizumab|Bevacizumab (5 mg/kg on day 1) plus mFOLFOXIRI (oxaliplatin 85 mg/m2, irinotecan 150 mg/m2, and folinic acid 400 mg/m2 followed by 5-fluorouracil 2400mg/m2 as a 46-hour continuous infusion on day 1) for 4 cycles and mFOLFOXIRI (oxaliplatin 85 mg/m2, irinotecan 150 mg/m2, and folinic acid 400 mg/m2 followed by 5-fluorouracil 2400mg/m2 as a 46-hour continuous infusion on day 1) for 2 cycles
223641231|NCT04215731|PROCEDURE|Restaging|Restaging by pelvic magnetic resonance imaging (MRI)
223641232|NCT04215731|RADIATION|Concomitant Chemoradiotherapy|Concomitant chemoradiotherapy (preoperative radiotherapy consisted of 50 Gy in 25 fractions, and concurrent with capecitabine at a fixed dose of 825 mg/m2 twice daily on days 1 to 5 for 5 weeks)
223641233|NCT04215731|PROCEDURE|Surgery|Radical surgery (TME or more extended surgery)
223641234|NCT04215731|RADIATION|Chemoradiotherapy (only when patients with MRF involved or ycT4a/b by restaging)|Chemoradiotherapy (preoperative radiotherapy consisted of 50 Gy in 25 fractions, and concurrent with capecitabine at a fixed dose of 825 mg/m2 twice daily on days 1 to 5 for 5 weeks)
223641235|NCT04215731|DRUG|Induction chemotherpay with FOLFOX|mFOLFOX6 (oxaliplatin 85 mg/m2, and folinic acid 400 mg/m2 followed by bolus 5-fluorouracil 400 mg/m2 and 5-fluorouracil 2400mg/m2 as a 46-hour continuous infusion on day 1) for 4 cycles
223641236|NCT06590844|DRUG|Injectable coenzyme I|On the first day, we will treat patients with Tybo Sulsintilimab ® 200mg IV and Dalutin ® Bevacizumab 15mg/kg IV every 21 days. The first to third days were treated with injectable coenzyme I, 100mg/day IV, every 21 days as a cycle.
223641237|NCT06992557|PROCEDURE|Biological drilling osteotomy protocol|"* Osteotomy site preparation through sequential biologic drilling in healed bony site with a pilot drill at 800 rpm with irrigation initiates the drilling process, which is then followed by drills of different sizes and shapes at low speeds at 150rpm without irrigation.~* The implant will be positioned in the osteotomy site and a healing collar will be placed."
223765198|NCT07168551|DIAGNOSTIC_TEST|*Lab Methods:* 1- Serum Uric Acid levels 2-Liver Function Tests 3- Lipid Profile . 4- Haemoglobin A1c level . 5- Serum glucose level .|Lab methods
223765199|NCT07168551|RADIATION|*Imaging Studies:* 1- Ultrasound 2 - FibroScan|Imaging
223765200|NCT07168551|DEVICE|Instruments:* 1- *Automated Analyzers*: Used for blood tests, such as serum uric acid and liver function tests.|Instrument
224229346|NCT03743428|DRUG|Bevacizumab Injection|Bevacizumab combinated with FOLFIRI regimen as the second-line chemotherapy for mCRC
224229347|NCT06542042|DIAGNOSTIC_TEST|NAS, NGS and Laboratory tests|Using three diffrent detection methods and comparing their efficiency
224229348|NCT00122850|DRUG|Duloxetine|
224229349|NCT00122850|DRUG|venlafaxine|
224229350|NCT00122850|DRUG|placebo|
224229351|NCT00003782|DRUG|cyclophosphamide|Arm 1: 600 mg/m2 IV every 21 days for 4 cycles; Arm 3: 500 mg/m2 IV every 21 days for 4 cycles
224229352|NCT00003782|DRUG|docetaxel|Arm 1: 100 mg/m2 IV every 21 days for 4 cycles; Arms 2 and 3: 75 mg/m2 IV every 21 days for 4 cycles
224229353|NCT00003782|DRUG|doxorubicin|Arm 1: 60 mg/m2 IV every 21 days for 4 cycles; Arms 2 and 3: 50 mg/m2 IV every 21 days for 4 cycles
224229354|NCT01204320|PROCEDURE|Paclitaxel-coated Balloon|POBA
224229355|NCT01204320|DEVICE|Paclitaxel-eluting Stent|Stenting
224323329|NCT04062552|OTHER|Educational Intervention|Participate in VLC group-based learning sessions
223641238|NCT06992557|PROCEDURE|Conventional drilling osteotomy protocol|"* Preparation for osteotomy site with conventional sequential drilling in healed bony site at 1200 rpm with irrigation.~* The implant will be positioned in the osteotomy site and a healing collar will be placed."
223641239|NCT06991829|PROCEDURE|HLA-matched pancreatic endocrine organoids transplantation|Islet cells are isolated from resected pancreatic tissue obtained from patients undergoing surgery, followed by ex vivo expansion and culture. Subsequent procedures include HLA typing, functional assessment of organoid-like structures, and biobanking. After matching for HLA, the cells are administered into patients with type 3c diabetes mellitus (T3cDM) via ultrasound-guided percutaneous transhepatic portal vein catheterization. A 52-week follow-up is conducted to evaluate the safety of the cell therapy and its clinical efficacy in glycemic control.
223641240|NCT06993441|BEHAVIORAL|Experimantal group|Participants in the experimental group listened to MusICure music via speakers for 30 minutes during each radiotherapy session. The intervention was administered concurrently with radiotherapy and aimed to reduce anxiety and emotional distress.
223641241|NCT06993441|BEHAVIORAL|control group|No intervention
223641242|NCT06992739|DRUG|Trilaciclib and Sacituzumab Tirumotecan|"Trilaciclib: 240 mg/m2 as a 30-min iv. infusion, completed ≤4h prior to sacituzumab tirumotecan.~Sacituzumab Tirumotecan: 5 mg/kg on days 1 \& 15 of a 28 day cycle via intravenous (IV) infusion until progressive disease or discontinuation."
223641243|NCT06991764|DEVICE|Non-Invasive Brain Stimulation (tDCS / tPCS / sham-tPCS)|This is a novel non-invasive brain stimulation technique that we hope to be investigating, and this technique will be compared with an active control (tDCS) and a control (sham-tPCS).
223641244|NCT06991959|OTHER|Educaton|Family Planning and Sexually Transmitted Diseases Training: The training program used a training module developed by UNFPA based on health belief theory, theory of reason-based behavior, social learning theory and transtheoretical model.
223641245|NCT06993259|DEVICE|Virtual Reality|Children in the virtual reality (VR) group watched a 360° Ice Age video via headset starting three minutes before and continuing throughout the allergy test. The video, selected by pediatric experts, was age-appropriate, visually rich, and emotionally neutral. VR provided immersive distraction to reduce pain, fear, and anxiety. After the test, children and parents rated pain (WBFPS), fear (CFS), anxiety (CAS-S), and satisfaction through structured forms.
223641246|NCT06993259|DEVICE|Serious game|Children in the serious game group played Subway Surfers on a tablet starting three minutes before and continuing throughout the skin prick test. The game was chosen by pediatric experts for its age-appropriateness and ability to sustain attention without overstimulation. As a fast-paced, interactive tool, it served as an effective distraction to reduce pain, fear, and anxiety. After the procedure, children and parents rated pain (WBFPS), fear (CFS), anxiety (CAS-S), and satisfaction using structured feedback forms.
223641247|NCT06993051|BEHAVIORAL|Social-HEROES Health-Promotion Program|"Six-month, cluster-level, stakeholder-co-created health-promotion programme delivered in preschool settings. The programme is developed through participatory innovation labs and includes:~* Educator training sessions (monthly)~* Classroom activities on healthy eating, active play and socio-emotional skills (weekly)~* Family workshops and take-home materials promoting 24-hour movement behaviour (diet, physical activity, reduced sedentary time, adequate sleep) (every 4-6 weeks)~* Community engagement events (beginning and end of intervention). Implementation period: 6 months; dosage approx. 20-24 contact hours per child."
223641248|NCT06991465|RADIATION|Radiation Therapy|High Dose Hypofractionated Radiotherapy 35 Gy over 5 fractions.
223641249|NCT06991465|DRUG|FOLFOX regimen|Radiosensitizing chemotherapy
223641250|NCT06991465|DRUG|Capecitabine|Radiosensitizing chemotherapy
223765201|NCT07152938|BEHAVIORAL|AVR Group (Chemotherapy + AVR)|the intervention group received AVR before they started treatment and during the session. The researcher administered the posttest questionnaire The questionnaire assessed immediately after finishing AVR. Participants informed not to discuss AVR with each other's, as the researcher explained to the participants the purpose of the study and their participation will not affect their care or treatment
223765202|NCT07141641|BIOLOGICAL|Acellular Tissue Engineered Vessel (ATEV)|
224229356|NCT01890707|PROCEDURE|General Anesthesia|Administer: Fentanyl:1mcg/kg prior to induction, additional doses to maintain blood pressure and heart rate within 20% of preoperative values, Propofol:2mg/kg,succinylcholine, 0.5mg/kg,to be followed with Rocuronium if necessary,bolus: 0.4mg/kg, Sevoflurane and oxygen to be titrated to maintain BIS value of 40-60.
224229357|NCT01890707|PROCEDURE|Deep Sedation|IV administration of Propofol,initial rate 100ug/kg/min, titrated to maintain BIS 65-75,Fentanyl,Ketamine,1mcg/kg,0.5mg/kg,additional 10mg increments for analgesia/movement.
224229358|NCT00152321|BEHAVIORAL|Patients (education, counseling) and Physicians (reminders,1-page guidelines).|
224229359|NCT00152321|BEHAVIORAL|Multifaceted intervention|Educational materials, counseling, opinion leader based guidelines, reminders
224229360|NCT00152321|OTHER|Usual Care|
224229361|NCT03017599|DEVICE|20-gauge ProCore FNB needle|"The investigators will prospectively collect data base including patients who underwent EUS-guided biopsy with the 20-gauge ProCore histology needle for the evaluation of Pancreatic solid mass.~EUS procedures will be performed under sedation with linear echoendoscopes. Once the lesion will be penetrated, the stylet will be removed, and suction will be applied for 10 to 20 seconds by using a 10-ml syringe while moving the needle to and fro. All samples will processed at the pathology departments for histological analysis with documentation."
224229362|NCT03362151|OTHER|Regular pasta|Regular pasta (Approximately 42 grams carbohydrate per meal)
224229363|NCT03362151|OTHER|High protein pasta|High protein pasta (Approximately 38 grams carbohydrate per meal)
224229364|NCT03362151|OTHER|White rice|White rice (Approximately 43 grams carbohydrate per meal)
224229365|NCT01082107|OTHER|Solar disinfection in transparent containers (plastic bottles)|Participants in the study drink solar disinfected (SODIS) water. Solar disinfected water is water (\> 3 L) that has been placed in direct sunlight for 6 hours. Participants are expected to drink SODIS treated water for the duration of the study.
224229366|NCT00000614|DRUG|warfarin|
224229367|NCT00717977|DEVICE|Continuous glucose monitor|Daily use of a continuous glucose monitor for 3-7 days
224319434|NCT03196245|OTHER|There is no intervention.|There is no intervention. This is a purely observational study. We enrolled pregnant women as they received a vaccine as part of their regular medical care; we did not administer the vaccine. We also enrolled pregnant women acutely infected with influenza.
223641251|NCT06993012|BEHAVIORAL|Mobile Health Stress Self Management System|FWD has been developed using proprietary machine-learning algorithms to detect physiological markers of stress/PTSD hyperarousal in veterans using a wearable smart watch sensor. Additionally, FWD includes a suite of self-management and monitoring tools through the smartphone app designed through several rounds of human factors design
224319435|NCT00919126|DRUG|Xenon|Maintenance of anaesthesia obtained with Xenon 50% and propofol infusion adjusted to depth of anaesthesia.
223641252|NCT06993012|BEHAVIORAL|Intensive Cycling Activity|The Project Hero Ride 2 Recovery is a unique event hosted by Project Hero where veterans participate in a week long cycling challenge where they cycle across the continental US about 50-70 miles per day for a total of over 350 miles within a group of peers.
223641253|NCT06595082|DIETARY_SUPPLEMENT|4-week lupins in brine consumption|Volunteers were asked to consume lupins in brine for 4 weeks.
223641254|NCT06595082|DIETARY_SUPPLEMENT|4-week lupins in brine consumption and dietary suggestion|Volunteers were asked to consume lupins in brine for 4 weeks and refrain to two servings per week of meat or processed meat or cheese.
223765203|NCT07172776|BEHAVIORAL|oral cancer communication tool|The overall goal is to determine if the OPC communication tool has potential to enhance Black-men's and dentists' comfort discussing oral and pharyngeal cancers in clinical-like settings. This communication tool will ideally help dentists communicate with their patients about oral cancer risk and treatment. The oral cancer screenings will occur in person. Participants will complete a pre-survey either on paper or online, engage with a dentist or dental student, then complete a post-survey
223765204|NCT07173738|DRUG|BIA 5-1058|During treatment period 1, a single oral dose of BIA 5-1058 (400 mg) will be administered on the morning of day 1, following an overnight fast of at least 10 h.
223765205|NCT07173738|DRUG|Furosemide|During treatment period 2, a single oral dose of furosemide (40 mg) will be administered on the morning of day 1, following an overnight fast of at least 10 h.
223765206|NCT07173738|DRUG|BIA 5-1058 and Furosemide|During treatment period 3, a single oral dose of both investigational medicinal product (IMPs) BIA 5-1058 (400 mg) concomitantly with furosemide (40 mg) will be administered on the morning of day 1, following an overnight fast of at least 10 h.
223765207|NCT07173309|DEVICE|Augmented reality|Augmented reality markers show the surgical trainee the expert's gaze location during the kidney exploration phase of surgery.
223641255|NCT06592287|DRUG|Adebrelimab + Apatinib + Lrinotecan liposome|"Adebrelimab 1200 mg, iv. q3w~Apatinib 250 mg po qd~Lrinotecan liposome 80mg/m2, iv. q3w~Continue medication until disease progression, toxicity intolerance, initiation of new anti-tumor treatment, withdrawal of knowledge, or continuous medication for at least 2 years."
223641256|NCT06604338|DIAGNOSTIC_TEST|Exome test|An exome will be performed on the participants of RPL group.
223765208|NCT07173270|OTHER|Oral health support|The intervention group will receive examination and treatment by a dental hygienist every 3 months starting 6 months after completion of RT/CRT up to 3 years. During visits to the dental hygienist, they will be asked about oral hygiene habits, fluoride use, dry mouth problems, and dietary habits (including intake of easily degradable carbohydrates). Oral dryness will be assessed using the Clinical Oral Dryness Scale. The stimulated salivary secretion and buffering capacity will be assessed, and the ability to open the mouth, cariological and periodontal status and registered plaque. Based on the results of the clinical examination, the patient will get individually tailored advice and recommendations on oral hygiene, fluoride use, dry mouth relief, and support in reducing the intake of food items and drinks with high sugar content. Professional oral care will be given, and fluoride applications when indicated.
224229368|NCT06002295|DRUG|Chlorhexidine Topical Cream|"After approval from the hospital ethical committee, neonates fulfilling inclusion and exclusion criteria were selected. Written informed consent was obtained from the parents. Full instructions to avoid confounding variables like maintaining temperature and hygiene of newborn, frequent diaper change, avoidance of herbal tonics and cow milk; are given to mothers.~In group A 4% chlorhexidine was applied generously over cord along with base of cord stump and surrounding skin thrice a day. In group B clean cotton swab dipped in methylated spirit was used to clean cord along with cord clamps and base thrice a day."
223641257|NCT06604338|DIAGNOSTIC_TEST|Microbiota analysis|A cervical microbiota analysis will be performed in the RPL and control groups.
223765209|NCT07172178|BIOLOGICAL|γδ T-PD-1 Ab cells|Patients will receive 6 cycles of ex-vivo expanded γδ T-PD-1 Ab cells treatments,at two-weeks' intervals.γδ T-PD-1 Ab cells are injected through the Ommaya device in a typical 3+3 dose-escalation design(Dose escalation, 1×10\^7, 3×10\^7, 1×10\^8).
224319436|NCT00919126|DRUG|Xenon|Maintenance of anaesthesia obtained with Xenon 70% and propofol infusion adjusted to depth of anaesthesia.
224319437|NCT00919126|DRUG|Medical Air in Oxygen|Maintenance of anaesthesia obtained with propofol infusion adjusted to depth of anaesthesia.
223641258|NCT06598020|BEHAVIORAL|Supportive Care|Competency-based training purposed to alleviate anxiety relief using a mind-body modality and improve pain with touch modalities (e.g., acupressure)
223641259|NCT06597162|BEHAVIORAL|education of patient safety|"For participants in the training group, data will be collected face to face in two stages: the pre-test phase and the post-training post-test phase.~A survey will be distributed to the control group simultaneously with the training group and will be collected as pre-test and post-test, but no training will be given to the control group. Only after the study ends will educational materials be shared with the control group."
223641260|NCT06594809|OTHER|PNF|Upper extremity PNF exercise is an exercise method that dynamically stabilizes the scapula and affect scapular muscles activity (Witt et al., 2011). Upper extremity PNF patterns consisted of four diagonal patterns (D1 flexion, D2 flexion, D1 extension, and D2 extension) and six key components manual contact, body position, verbal cues pattern of movement, timing of movement and resistance. Patient will be at sitting position with involved side up, head, spine, and scapula in neutral
224319438|NCT05125965|OTHER|additional time for the MRI|3 additional minutes to perform the MRI
224319439|NCT01485822|PROCEDURE|Trabecular Meshwork Tissue Collection|A minimum of two punches were used to remove tissue to form a sclerostomy. Tissue removed by the punch was collected for analysis. Alternatively, the tissue was collected by block excision of the meshwork with scissors at the time of sclerostomy.
224319440|NCT01485822|DRUG|Travoprost 0.004% ophthalmic solution|
224323330|NCT04062552|OTHER|Educational Intervention|Participate in consultation with ENABLE/TA expert
224323331|NCT04062552|PROCEDURE|Medical Examination Assessment|Undergo palliative care assessment
223641261|NCT06594809|OTHER|Traditional neck pain treatment|Cervical muscles stretch + Craniocervical retraction ex + Manual therapy
223641262|NCT06594809|OTHER|Traditional neck pain treatment + Blackburn scapular stabilization exercises|The patients will receive Traditional treatment of neck pain and Scapular stabilization exercises (Blackburn exercises). Blackburn exercises are one of the ways to treat scapular dyskinesia. Perform 2 sets of 20 repetitions of each exercise each session (3 sessions per week) for four weeks (panse et al .,2018). The exercise load will be 60% of the one-repetition maximum (1-RM) during the first week due to their first exposure to the exercises. The evaluation of one-repetition maximum (1-RM) will be every week for all exercises. From the second evaluation, more weight will be added (compare to the previous evaluation) to maintain the overload.
223765210|NCT07173582|DIAGNOSTIC_TEST|Serum samples will be collected at the time of registry enrollment, MMP 7 and 9 concentrations will be measured using enzyme-linked immunosorbent assays.|"All patients will be subjected to:~A- Complete medical history:~including demographic data (age, sex, disease duration, morning stiffness, joint involvement, smoking, habits of medical importance), articular and extra articular manifestations. Detailed respiratory manifestations.~B- Clinical examination:~* General and local rheumatologic examination.~* Local chest examination (inspection, palpation, percussion, auscultation).~* Assessment of RA disease activity using DAS 28 ESR.~C- Laboratory investigations:~CBC, C-reactive protein, erythrocyte sedimentation rate, antibody status.~D- Radiology and PFT:~PFTs and HRCT chest patterns will be done for patients.~E- MMP measurement:~MMP 7 and 9 concentrations will be measured using enzyme-linked immunosorbent assays.~F. The capillaroscopy procedure"
223765211|NCT07172789|OTHER|head down position|the patient is positioned at a -20° Trendelenburg
223765212|NCT07173946|OTHER|Standard of Care Anti-tumor Therapy|This is an observational cohort study. There is no intervention assigned by the study protocol. Treatment strategies (including but not limited to chemotherapy, immunotherapy, radiotherapy, and local interventional therapy) are determined solely by the treating physician based on clinical practice guidelines and individual patient circumstances.Patients will receive real-world anti-tumor treatments as prescribed by their physicians. Common treatments for extensive-stage small cell lung cancer (ES-SCLC) may include platinum-etoposide chemotherapy, immune checkpoint inhibitors (such as anti-PD-L1/PD-1 antibodies), radiotherapy, and other therapies per standard clinical practice. The study will observe and record these treatments and their outcomes.
224229369|NCT06002295|DRUG|Methylated Spirit|"After approval from the hospital ethical committee, neonates fulfilling inclusion and exclusion criteria were selected. Written informed consent was obtained from the parents. Full instructions to avoid confounding variables like maintaining temperature and hygiene of newborn, frequent diaper change, avoidance of herbal tonics and cow milk; are given to mothers.~In group A 4% chlorhexidine was applied generously over cord along with base of cord stump and surrounding skin thrice a day. In group B clean cotton swab dipped in methylated spirit was used to clean cord along with cord clamps and base thrice a day."
224229370|NCT05378087|RADIATION|Concurrent chemoradiation|Standard concurrent chemoradiation: A point/HCR-CTV D90 ≥80Gy (+20%) by using IMRT or TOMO technics. Patients with image-positive common iliac lymph nodes or para-aortic lymph nodes receive extended-field EBRT. Brachytherapy should begin after 15-20F external radiotherapy. A radiation dose for the image-positive nodes can range from 55Gy to 60Gy. Five cycles of concurrent platinum-containing chemotherapy (Cisplatin 40mg/m2 q1w or Carboplatin AUC=2 q1w, Window period one week) and CCRT should be completed within 56 days. CCRT one week later, if the cervix biopsy shows residual tumour and/or imaging (CT/MRI/PET/CT) indicates that there are still positive lymph nodes in the pelvic and abdominal cavity, three cycles of adjuvant chemotherapy (TP: Paclitaxel 135mg/m2, Cisplatin 50mg/m2, q3w or TC: Paclitaxel 135mg/m2, Carboplatin AUC=4, q3W; Window period 2 weeks) ± brachytherapy will be performed (A point/HR-CTV D90 ≤ 96Gy).
224319441|NCT03539263|DIETARY_SUPPLEMENT|Bifihappy|"During the six weeks of treatment, the experimental group will take daily doses of 2,5 g with a concentration of 4x109 CFU/sachet of a mixture of lyophilised probiotic strains of the following species:~* Lactobacillus fermentum~* Lactobacillus rhamnosus~* Lactobacillus plantarum~* Bifidobacterium longum"
224319442|NCT03539263|OTHER|Placebo|During the six weeks of treatment, the experimental group will take daily doses of 2,5 g of maltodextrin
224319443|NCT02904863|BIOLOGICAL|Extra blood draw samples|
224319444|NCT04291625|PROCEDURE|Levator muscle resection|"Surgery was performed under general anaesthesia. Two milliliters of 2% lidocaine with 1:100 000 epinephrine is injected subcutaneously. After the upper eyelid incision at the desired crease line, the orbital septum was opened and the preaponeurotic fat was identified and dissected off the levator aponeurosis. The aponeurosis was disinserted from the tarsus, and the complex of levator aponeurosis and Muller muscle was dissected free from the conjunctiva. The desired eyelid height was determined from the proposed formula.~Satisfactory Intraoperative lagophthalmos was defined as a difference of less than 1 mm between recommended by the formula and actual intraoperative lagophthalmos.~After permanent fixation, a caliper was used for precise measurement of lagophthalmos in a supine position. Additional sutures were placed on the medial and lateral sides for satisfactory eyelid contour. The redundant levator complex was excised. Eyelid crease was made by placing three interrupted sutures"
223641263|NCT06586203|DEVICE|Polygenic Risk Score|The Polygenic Risk Score (PRS) is a Class II software as a medical device (SaMD) that estimates a person's level of risk of developing a disease or associated complications before clinical signs appear. The device uses the genomic profile of the person in combination with some clinical data (i.e., age, sex, age of onset of diabetes) to compute this risk. This device further provides recommendations for personalized management of T2D for patients based on their risk score.
223641264|NCT06589232|OTHER|Food allergy|Threshold dose to pistachio
224319445|NCT06432855|OTHER|Blood collection|20 ml-blood sample
224319446|NCT06432855|OTHER|saliva collection|saliva sample
224319447|NCT00237523|DRUG|IoGen (molecular iodine)|
223641265|NCT06595901|OTHER|Actigraph|Participants will wear an Actigraph hip-worn accelerometer on their non-dominant hip during all waking hours, and on the wrist while sleeping
223641266|NCT06595901|OTHER|Questionnaires|"* Patient Health Questionnaire Anxiety and Depression Scale30 (PHQ-ADS), a validated composite of anxiety and depressive symptoms.~* Self-reported cognition will be assessed by the Functional Assessment of Cancer Therapy-Cognitive (FACT-Cog)."
223641267|NCT06595901|OTHER|BrainBaseline application|Objective measures of cognitive function will include those from the BrainBaseline application, a validated research tool developed by Digital Artefacts to remotely measure domains of cognition
223641268|NCT06595901|OTHER|Semi-structured interviews|Semi-structured individual interviews will be conducted with up to 15 healthcare stakeholders and 15-30 patients with breast cancer at any time during the study period, as determined by participant preference.
223641269|NCT06586749|OTHER|Group B: nurse-led education|Group B: nurse-led education No educational video, will be shown to this group of patients
224229371|NCT05378087|PROCEDURE|Open/minimally invasive para-aortic lymph node dissection followed by concurrent chemoradiation|Open/minimally invasive para-aortic lymph node dissection followed by concurrent chemoradiation. (height of lymph node dissection: At least the inferior mesenteric artery. Chemoradiation should be performed postoperatively within 28 days.) The chemoradiation is consistent with the image staging group, except for extended-field EBRT determined by pathological positive para-aortic lymph nodes.
224229372|NCT01056549|DRUG|exenatide|In each study, the subjects will receive s.c. injection of either exenatide or matched placebo, in the Metabolic Testing Center and 2 hours prior to the start of the lipoprotein turnover study. Subjects will be blinded with regard to the treatments.
223765213|NCT07171918|DRUG|Antibiotics, Vasopressors|Both groups are scored on REMS and NEWS2, and then observed closely for the period of hospital stay with regard to ICU stay duration, ventilator days, vasopressor dependent days and total hospital duration
224229373|NCT03414164|DIETARY_SUPPLEMENT|procyanidine|natural antioxidants
224229374|NCT00386672|DIETARY_SUPPLEMENT|Reduced energy (lite) OJ fortified with Calcium and Vitamin D|Three 240ml servings of lite OJ fortified with 350mg Ca and 100U VitD per day.
224229375|NCT00386672|BEHAVIORAL|Nutrition Counseling|Individual and group nutritional counseling by a registered dietician.
224229376|NCT00386672|DIETARY_SUPPLEMENT|Reduced energy (lite) OJ without Calcium and Vitamin D|Three 240ml servings of lite OJ without 350mg Ca and 100U VitD per day.
224229377|NCT03015090|DRUG|Theophylline|After oral theophylline 200mg per day for one week, blood sample will be collected for determining plasma concentrations of theophylline and it's metabolites and the genotypes of CYP1A2
224229378|NCT03516747|DIAGNOSTIC_TEST|pre operative parathyroid hormone level measurement|At the clinic, the participants will undergo ultrasound examination with fine needle aspiration. The aspirated material will be sent for parathyroid hormone level measurement.
224229379|NCT03516747|DIAGNOSTIC_TEST|pre operative parathyroid cytology|At the clinic, the participants will undergo neck ultrasound examination with fine needle aspiration. The aspirated material will be sent for cytology examination.
224229380|NCT03516747|DIAGNOSTIC_TEST|parathyroid hormone level measurement|At surgery, after the pathologic gland is excised , the gland will be aspirated. The material will be sent for parathyroid hormone level measurement.
224229381|NCT03516747|DIAGNOSTIC_TEST|parathyroid cytology|At surgery, after the pathologic gland is excised , it will be aspirated again for cytologic examination.
224229382|NCT01326026|DRUG|insulin degludec|Injected subcutaneously (under the skin) once daily. Dose individually adjusted.
224229383|NCT01326026|DRUG|insulin degludec|Injected subcutaneously (under the skin) once daily. Dose individually adjusted in a stepwise manner.
224229384|NCT03052166|DEVICE|QT Ultrasound scan|QT Ultrasound scan
224229385|NCT06217133|DEVICE|CPAP|"Conventional CPAP will be administered according to the unit's routine on ventilators of different brands and models according to service availability. Binary prongs, from brands available in the service, will be used as an interface without touching the nasal septum with the size recommended by the manufacturer and in accordance with the protocol established in the unit.~TThe CPAP bubbles will be administered using the CPAP NEONATAL BABYPAP® MODEL 1150 S equipment, which is an electromedical device for non-invasive ventilatory assistance for newborns that generates continuous pressure in the airways (CPAP) controlled by means of a column of water that bubbles, through a flow of heated and humidified medical gas mixture supplied by a breathing circuit to the patient's nasal passage."
224229386|NCT04541888|DRUG|CsA Ophthalmic Gel|The CsA eye gel of 0.3 g: 0.15 mg
224229387|NCT04541888|DRUG|Placebo|Placebo
224229388|NCT04541888|DRUG|Hypromellose Eye Drop|Hypromellose Eye Drops of 10ml：50mg, 3 times daily, 1-2 drop
224229389|NCT02941809|BEHAVIORAL|Open-Label Placebo (OLP)|We are designating this as a behavioral intervention for two reasons: (1) the placebo pill is physiologically inert and is not classified under FDA regulations; and (2) other studies have demonstrated that the efficacy of the placebo pill is strongly dependent on the participants' anticipation of an effect. We are presenting the pill's efficacy in an open and transparent way to the participants, but using a positive frame. We feel that this qualifies the placebo pill use as a behavioral intervention, in the same general category as exercise or relaxation.
224229390|NCT04390854|BIOLOGICAL|Blood clot scaffold|"Bleeding will be induced in the canal by passing a size 30 sterile K-file 3 mm beyond the apex with the goal of having the entire canal filled with blood to the level of the cemento-enamel junction. Bleeding will be stopped just below the cemento enamel junction.~Biodentine will be placed approximately 3-4 mm below the cementoenamel junction."
223641270|NCT06586749|OTHER|Group C: nurse-led education and implementation of teleinterventions|Group C: nurse-led education and implementation of teleinterventions An educational video, made for the purposes of the study only, will be shown to them. This is the difference between the two groups
223641271|NCT06586242|DRUG|Penpulimab;Anlotinib;albumin paclitaxel;oxaliplatin;lobaplatin|200mg, intravenous infusion, 30-60 minutes per infusion, once every 3 weeks, Penpulimab:administered on the first day of each cycle Anlotinib:Body weight \<60kg, 8mg Po, body weight ≥ 60kg, 10mg Po, D 1-14, q3w
223641272|NCT06589037|OTHER|shock wave treatment control group|The control group, consisting of 24 people, will receive shock wave treatment on the sole of the foot to treat plantar fasciitis. There will be 4 sessions and 4 data collections.
223641273|NCT06589037|OTHER|shock wave treatment experimental group|The experimental group, consisting of 24 people, will receive shockwave treatment on the back of the leg to treat plantar fasciitis. There will be 4 sessions and 4 data collections.
223641274|NCT06599515|PROCEDURE|robotic surgical platform|robot-assisted laparoscopic inguinal hernia repair (rTAR)
223765214|NCT07173699|PROCEDURE|root canal treatment|Standardized root canal treatment performed on asymptomatic mandibular molars. Procedures include local anesthesia, rubber dam isolation, access cavity preparation, cleaning and shaping with rotary instruments, irrigation with NaOCl and EDTA, and obturation using a standardized protocol. Saliva samples are collected prior to treatment for melatonin analysis. Postoperative pain and sleep quality are assessed using validated questionnaires.
223641275|NCT06993194|DRUG|Haloperidol|Haloperidol will be administered intravenously at a dose of 2.5 milligrams every eight hours over ten minutes. Treatment will begin 48 hours after admission to the intensive care unit and will continue for up to seven days or until delirium and agitation resolve. The need for additional sedation will be addressed with intravenous midazolam and fentanyl as required. The patient's clinical status will be monitored using standardized assessments including the Confusion Assessment Method for the Intensive Care Unit and the Richmond Agitation-Sedation Scale.
223641276|NCT06993194|DRUG|Dexmedetomidine|Dexmedetomidine will be administered by continuous intravenous infusion at a dose of 0.5 micrograms per kilogram. Treatment will begin 48 hours after admission to the intensive care unit and will be repeated every other day for up to seven days or until delirium and agitation resolve. Rescue sedation may be provided with intravenous midazolam and fentanyl as clinically indicated. Delirium and agitation will be assessed regularly using validated tools such as the Confusion Assessment Method for the Intensive Care Unit and the Richmond Agitation-Sedation Scale.
224319448|NCT05088135|DEVICE|Bilateral Auricular Vagus Nerve Stimulation will be performed with a device called VAGUSTIM.|It will be divided three groups as bilateral Auricular Vagus Nerve Stimulation (VSS). Auricular Vagus Nerve Stimulation will be performed with a device called VAGUSTIM. Auricular Vagus Nerve Stimulation will be performed for 20 minutes with a frequency of 10 Hz and a pulse width of 300 µs.
223641277|NCT06145321|DEVICE|G-CSF administration (bolus injection versus intravenous infusion)|Route of administration: intravenous infusion (with a 5 hours infusion period) or intravenous bolus (with an infusion period of less than one minute)
224323332|NCT04062552|OTHER|Quality-of-Life Assessment|Ancillary studies
223641278|NCT06145321|DRUG|G-CSF administration (bolus injection versus intravenous infusion)|Route of administration: intravenous infusion (with a 5 hours infusion period) or intravenous bolus (with an infusion period of less than one minute)
223641279|NCT06615206|GENETIC|HG204|The study will enroll up to 2 cohorts, evaluating a starting dose plus a higher or lower dose
223641280|NCT06993272|BEHAVIORAL|MIndful Jazz|Mindful Jazz Group: Participants in this group will watch an introduction to jazz appreciation and mindfulness training video, including the use of jazz for pain tolerance prior to the 4-week intervention. Participants in the Mindful Jazz Group will be informed that listening to music they are not comfortable with (i.e., jazz) can enhance long-term pain tolerance.
223641281|NCT06993272|BEHAVIORAL|Reggae Stereotypes|Reggae Stereotype Group: Participants in this group will be told about he stereotype of reggae in making people more calm. They will listen to reggae music over the 4 weeks.
223641282|NCT06993272|BEHAVIORAL|Traditional Mindfulness|Participants will listen to a traditional mindfulness practice over the 4 weeks
223641283|NCT06993272|BEHAVIORAL|Pain psychoeducation|Participants listen to an audio recording of the pain psychoeducation video they watch during training over the 4 weeks. Video: https://www.youtube.com/watch?v=azwEQXh5enA
223641284|NCT06992271|BEHAVIORAL|Fast Eccentric|Resistance training done quickly
223641285|NCT06992271|BEHAVIORAL|Slow Eccentric|Resistance training done slowly
223641286|NCT06991478|DRUG|SK-NK injection|In this stage, two dose groups are preset, namely 20×108 cells and 30×108 cells. Subjects who meet the inclusion criteria will receive intravenous infusion of SK-NK injection once a week for six consecutive times. After completing six consecutive infusions of SK-NK injection, the researchers evaluated that the patient benefited and could continue to receive six consecutive infusions of SK-NK injection. After completing twelve infusions, the decision on whether to continue the treatment subsequently could be made based on the patient's condition
223641287|NCT06991478|DRUG|SK-NK injection|Based on the dose selected from the results of the first stage, the clinical efficacy, safety, tolerability and pharmacokinetic characteristics of RP2D were further verified. The types of cancer and the number of cases enrolled in stage II are to be determined
223641288|NCT06991634|DRUG|Azvudine tablets|"Phase I: oral administration of 5 mg of Azvudine tablets on an empty stomach, single dose, 5 tablets per dose.~Phase II: oral administration of 5 mg of Azvudine tablets once a day on an empty stomach, 5 tablets once a day, for 7 consecutive days."
223641289|NCT06992921|OTHER|Dietary intervention|Iterventional dietary study using standardised meals with different fat content and carbohydrate quantity and quality or mixed meal tolerance test to predict for an individuals metabolic response.
223641290|NCT06536673|BEHAVIORAL|Intervention to reduce infectious complications of peritoneal dialysis|"* Before catheter placement: The nurse and doctor provide the patient and/or caregiver with a PD simulation.~* Initial training: from the placement of the catheter to the beginning of the technique at home, approximately 4 weeks, 6 and 7 sessions, duration 1-2 hours per session. Individualized learning taking into account learning abilities and education. It includes the explanation of the PD and the display of informational pictograms/capsules.~* Step-by-step teaching: peritoneal exchange, peritoneal orifice care, administration of intraperitoneal medication, recording of constants, detection of complications and risk behaviors.~* Nutritional education and water intake.~* Administration of the Objective Structured Assessment (OSA) checklist.~* Retraining: between the 1st and 3rd month of the start, after an episode of peritonitis and/or hospitalization, risk behaviors, functional/cognitive impairment, passivity/demotivation behaviors, and regularly once the year."
223641291|NCT06536673|BEHAVIORAL|Data collection from the patient's clinical history|Data collection from the patient's clinical history because this new standardized educational intervention was not used.
223641292|NCT06538896|DRUG|Tislelizumab + Nab-Paclitaxel|Tislelizumab, 200mg, intravenous, every 3 weeks
223641293|NCT06538896|OTHER|Rankl inhibitor|RANKL inhibitor determined by investigator is administered at a dose of 120 mg every 4 weeks, with dosing on Days 1, 8, and 15 during the first cycle.
223641294|NCT06992817|BEHAVIORAL|Hydration-Coach Encouragement|Athletes were encouraged by their coaches to consume fluids during the training session.
223641295|NCT06992817|BEHAVIORAL|Short Hydration Informative Session|Athletes were given a brief educational session related to importance of hydration before the exercise session.
223641296|NCT06992232|DRUG|Intense androgen deprivation therapy|Patients received ADT plus second-generation ARi (enzalutamide, apalutamide, darolutamide or rezvilutamide) for 2 years.
223765215|NCT07174245|DEVICE|continuous glucose monitor|All participants who wear CGM
223765216|NCT07172893|BIOLOGICAL|DermaBind TL|Full-Thickness Dehydrated Placental Allograft
224323333|NCT04062552|OTHER|Survey Administration|Complete surveys
224323334|NCT04062552|BEHAVIORAL|Telephone-Based Intervention|Receive monthly phone calls
223641297|NCT06992232|RADIATION|Radiation Therapy|Those allocated radiotherapy received 70Gy/2.8Gy/25f schedule for primary tumor and 70Gy/2.6-2.8Gy/25f or 37.5Gy/7.5Gy/5f for metastatic lymph nodes and bone lesions based on the size and location. Radiation should be finished within 2 years' systemic therapy.
223641298|NCT06992232|PROCEDURE|radical prostatectomy|Those allocated surgery received robot-assisted laparoscopic radical prostaectomy plus extended pelvic lymph node dissection for local treatment. Surgery should be finished within 2 years' systemic therapy.
223765217|NCT07173595|DRUG|QLS2309|initial dose - MTD; QW; intravenous infusion
223765218|NCT07172555|OTHER|Virtual Dietetic First-Appointment Webinar for Coeliac Disease|This intervention is a dietitian-led, pre-recorded on-demand webinar specifically designed for adults who have been newly diagnosed with coeliac disease. It acts as a patient's first formal dietetic appointment after diagnosis and provides comprehensive education about coeliac disease and the strict gluten-free diet required for its management. Unlike traditional approaches, which rely on face-to-face or telephone appointments with a dietitian-and which often involve significant waiting times-the webinar is available immediately online, allowing patients to access trusted, specialist information at their own pace and convenience, including the opportunity to re-watch as needed
223765219|NCT07172555|OTHER|Standard Dietetic Consultation (Face-to-Face or Telephone)|Participants in this group are allocated to receive the existing standard of care: an individual appointment with a specialist dietitian, delivered either in person (face-to-face) or by telephone. During the appointment, the dietitian provides a comprehensive overview of the gluten-free diet, strategies for avoiding cross-contamination, and advice on nutritional adequacy. As in the experimental arm, baseline assessment and validated questionnaires are administered pre- and post-intervention, with follow-up at 6 months to collect clinical, adherence, satisfaction, and quality of life data for direct comparison with the on-demand webinar intervention.
223765220|NCT07171996|OTHER|Dual-Simulation TPS + Biomechanical Planning|Combines TG-43-based TPS with a patient-specific FE biomechanical model to optimize needle paths and seed placement considering OAR limits, fracture risk, needle stability, and seed migration risk.
223765221|NCT07171996|OTHER|Conventional TPS Planning|Conventional TPS-driven plan per institutional practice; no biomechanical modeling.
223765222|NCT07173127|DRUG|Ryeqo treatment|Ryeqo treatment will be administered and hemostasis markers will be measured at T0 and T1
223765223|NCT07173777|DEVICE|Cardiac Waveform Generator|A pacing device that allows for programmable pulse waveforms to generate a predefined set of anodal biphasic waveforms. It possesses a battery-powered floating point gate array (FPGA) using software that allows flexibility in waveform configuration.
224229391|NCT04390854|BIOLOGICAL|Blood clot scaffold combined with PRF|Platelet-rich fibrin will be prepared by drawing the patient blood into a 10mL test tube without the addition of an anticoagulant. To prevent the blood from coagulating after coming in contact with the glass tube, it will be centrifuged immediately using a table top centrifuge\*\* at 400 g force for 12 minutes. Then platelet-rich fibrin membrane will be placed into the canal space to a level 3 mm below the cemento-enamel junction using hand plugger following the induction of apical bleeding by passing a number 30 sterile hand file 3 mm beyond the apex of the tooth. Biodentine cap will be placed over the platelet-rich fibrin scaffold.
224229392|NCT05296915|DEVICE|tVNS|An electric current with a frequency of 25 Hz (Figure 2) will be applied to the cymba conca of the left ear through a specific device (VITOS, Cerbomed, Germany; CE marking). The stimulation intensity will be customized between 0.1 and 5 mA according to the sensitivity threshold of each participant. Patients will be instructed to perform tVNS at home for 4 non-consecutive hours per day for 12 weeks, in accordance with the protocol reported in the literature for the treatment of major depression.
224229393|NCT05296915|DEVICE|rTMS|"The stimulation will be carried out with a TMS STM9000 system (Ates, Medica Device s.r.l., Italy) equipped with a 70 mm butterfly cooled coil. The stimulation protocol followed will be the one approved by the FDA for major depression, that is, a stimulation at the level of the left dorsolateral prefrontal cortex at an intensity equal to 120% of the motor threshold, at the frequency of 10hz. Each stimulation session will last 37.5 minutes, and will consist of 75 trains lasting 4 seconds, with a 26-second break between each train. During each session, a total of 3000 stimuli will be administered. The sessions will take place 5 days a week, from Monday to Friday, for 4 weeks, and for a total of 20 sessions of stimulation."
224229394|NCT05296915|BEHAVIORAL|CBT-E|Targeted cognitive-behavioral therapy following the CBT-E protocol (CG Fairburn - 2010. La terapia cognitivo-comportamentale dei disturbi dell'alimentazione. Firenze, Eclipsi; 2010.)
224229395|NCT04809181|DRUG|Azacitidine in Combination With Venetoclax|Azacitidine in combination with venetoclax
224229396|NCT04743258|PROCEDURE|MAXILLARY PREMOLAR EXTRACTION|Patients will undergo bilateral maxillary 1st premolar extraction before bonding followed by leveling \& alignment.
224229397|NCT04743258|PROCEDURE|DISTALIZATION|Maxillary arch will be distalized with the help Zygomatic miniplates will be placed bilaterally.
224229398|NCT03825458|OTHER|Blood sampling|Blood sampling at each clinical follow-up visit.
223641299|NCT06992154|DIETARY_SUPPLEMENT|Akkermansia Muciniphila, Clostridium Beijerinckii, Anaerobutyricum Hallii, Clostridium Butyricum, Bifidobacterium Infantis Probiotic Capsule|Probiotic capsule will contain Akkermansia Muciniphila, Clostridium Beijerinckii, Anaerobutyricum Hallii, Clostridium Butyricum, and Bifidobacterium Infantis
223641300|NCT06991595|PROCEDURE|cytoreductive resection of adenomyosis, myomectomy, resection of endometriosis|All women chosen for the study will be divided into the groups (AD, UF, DE, ETRS, CTRL) based on the inclusion/exclusion criteria (Table 2).A meticulous concern will be dedicated to patients´ education on advantages and disadvantages (including the eventual risks) of surgical and conservative management of AD and UF. These patients will be allocated into surgical or conservative arm of the study based on their inclinations: either to fertility saving surgical procedure (FSS) with subsequent IVF, or directly to IVF. This phenomenon of the importance of patients´ preferences in controversial clinical situations is the usual part of the management of infertile patients with AD or UF.
224229399|NCT05993338|DIAGNOSTIC_TEST|right heart catheterization (RHC).|Assessment of pulmonary artery pressure in COVID-19 survivors using right heart catheterization (RHC).
224229400|NCT01775592|DRUG|Arterakin (DHA-PPQ)|
224319449|NCT05088135|DEVICE|Unilateral-Right Auricular Vagus Nerve Stimulation will be performed with a device called VAGUSTIM.|It will be divided three groups as unilateral-right Auricular Vagus Nerve Stimulation (VSS). Auricular Vagus Nerve Stimulation will be performed with a device called VAGUSTIM. Auricular Vagus Nerve Stimulation will be performed for 20 minutes with a frequency of 10 Hz and a pulse width of 300 µs.
224319450|NCT05088135|DEVICE|Unilateral-Left Auricular Vagus Nerve Stimulation will be performed with a device called VAGUSTIM.|It will be divided three groups as unilateral-left Auricular Vagus Nerve Stimulation (VSS). Auricular Vagus Nerve Stimulation will be performed with a device called VAGUSTIM. Auricular Vagus Nerve Stimulation will be performed for 20 minutes with a frequency of 10 Hz and a pulse width of 300 µs.
223641301|NCT06991595|PROCEDURE|hysteroscopy|Sampling of endometrium (Hysteroscopy) The samples will be collected using hysteroscopy, scheduled into the secretory phase of endometrial cycle. During hysteroscopy, the uterine cavity will be observed and described in the surgical protocol (capacity, symmetry, presence of intrauterine pathologies, internal ostia of the tubes). The 3.2 mm wide hysteroscope will be used. Its usage usually does not require any anaesthesia. The endometrium will be taken using biopsy forceps (7 French / 2.3 mm) and immediately frozen on dry ice and stored at -80 °C until processing. Two pieces of endometrium per patient will be collected - one for isolation of RNA and bulk RNA-Seq and/or RT-qPCR and the second one for isolation of nuclei and snRNA-Seq or validation using snRT-qPCR. If some unexpected findings would be observed during hysteroscopy (especially some interfering with fertility), they would be hysteroscopically removed and endometrial sampling postponed.
223641302|NCT06991621|OTHER|Puzzle game|Scenario-based puzzle game sessions (group format)
223641303|NCT06991621|OTHER|Manual Education|Standardized death education manual distribution
223641304|NCT06586775|PROCEDURE|Pulpotomy|complete pulpotomy
223641305|NCT06586671|DRUG|Nemtabrutinib|Oral administration
223641306|NCT06599424|OTHER|Observational|Observational
223641307|NCT04721977|DRUG|Tucatinib|Tucatinib 300 mg administered BID via oral tablet
223641308|NCT04721977|BIOLOGICAL|Trastuzumab|Trastuzumab 8 mg/kg loading dose followed by 6 mg/kg maintenance dose, administered via IV infusion
223641309|NCT04721977|DRUG|Capecitabine|Capecitabine 1000 mg/m\^2 administered BID via oral tablet
223641310|NCT02086578|DEVICE|Breast MRI|
223641311|NCT02086578|BEHAVIORAL|Breast-Q© questionnaire|
223641312|NCT02086578|RADIATION|Multi-Beam IMRT|The radiation dose (50-50.4 Gy/25-28 fractions in approximately 5-6 weeks), treatment-planning and delivery aspects are according to departmental guidelines for breast IMRT.
223641313|NCT06592027|DRUG|PRECEDEX INJ★ 2ML|this group will receive single dose of dexmedetomidine 0.5 mcg /kg in 50 ml normal saline over 10 min IV infusion
223641314|NCT06592027|DRUG|PRECEDEX INJ★ 2ML|single dose of dexmedetomidine 1 mcg /kg in 50 ml normal saline over 10 min IV infusion
223641315|NCT06714682|PROCEDURE|Modified Pectoral Plane block group|The patient will lay supine with the ipsilateral arm abducted and externally rotated and the elbow flexed at 90 degrees. The probe will be placed transversely between the clavicle medially and above and the shoulder joint laterally. After identifying the pectoralis major and minor muscles and the plane between them, the probe will be pushed 1-2 cm caudally and medially. In a caudal tilt, within a biconvex space, the artery will be recognised. After that, the block needle will be inserted in an in-plane approach to the artery's location and 10 mL of 0.25% bupivacaine will be administered Then probe will be moved laterally and caudally towards the anterior axillary fold until the serratus muscle appears beneath the pectoralis minor muscle attaching to the underlying ribs. The needle will target the plane between pectoralis minor and serratus muscles at the level of the third rib, followed by negative aspiration into the fascial plane then injection of 10 mL of 0.25 bupivacaine.
223641316|NCT06714682|PROCEDURE|Erector spinae plane block group.|The block will be performed with the patient in a sitting position , The high-frequency linear probe will be placed in a longitudinal orientation 3 cm from the midline. Once the erector spinae muscle and the transverse processes identified, the block needle will be inserted in a caudad-to-cephalad direction until the tip lay in the interfacial plane deep to the erector spinae muscle, 20 mL of 0.25% bupivacaine will be administered for block performance.
224229401|NCT03889756|DRUG|Ketamine infusion|The dose of ketamine established in prior research (0.5 mg/kg over 40 minutes) will be used in this study to minimize risks. The maximum total single dose allowed in this study will be 40mg, corresponding to a weight of 80kg.
224229402|NCT03889756|DRUG|Midazolam infusion|The weight-based midazolam dosing established in prior ketamine trials in adults (0.045mg/kg) will be used to minimize risks, as this is considered a very low dose compared to the sedation literature. The maximum total dose allowed in this study will be 3.6mg per infusion, corresponding to a weight of 80kg.
224229403|NCT04107974|DEVICE|Gastropexy.|Two T-fasteners for G-tube insertion (gastropexy).
224229404|NCT04107974|PROCEDURE|Non-Gastropexy|Insertion of G-tube in absence of T-fasteners.
224229405|NCT03444116|DIAGNOSTIC_TEST|Motion Analysis|Gait and Motion Analysis, comprised of 3-dimensional kinematics and kinetics, electromyography, energy expenditure, and physical exam (range of motion, strength, spasticity, etc.)
224319451|NCT00150956|PROCEDURE|Daily home hemodialysis|
223641317|NCT06766201|DRUG|Metformin|Metformin mixed with propylene glycol
223641318|NCT06947408|DRUG|Placebo|Healthy participants and patients with asthma will receive matched placebo.
223641319|NCT06947408|DRUG|IBI3002|Healthy participants and patients with asthma will receive IBI3002 at the corresponding dose and dosing interval.
224319452|NCT03035578|DRUG|Morphine|Sampling blood for development of Morphine Pharmacokinetic/Pharmacodynamic Model for Neonatal Population
224319453|NCT03035578|DRUG|Morphine|Sampling saliva for development of Morphine Pharmacokinetic/Pharmacodynamic Model for Neonatal Population
224319454|NCT00852007|BIOLOGICAL|DC-Tn-MUC1: autologous dendritic cells expressing Tn-MUC1|1.2 x 10e7 dendritic cells per dose. One dose delivered intradermally (i.d.) and into a node (i.n.). Two weeks after this,two injections i.d. 2 weeks apart. Optional booster injections at 6 (i.d. and i.n.) and and 12 months (i.d.).
224319455|NCT00958893|DRUG|25 mg Proellex|one 25 mg capsules
224319456|NCT02032680|BEHAVIORAL|Web-based multi-family psychoeducational treatment|This intervention uses a website to provide multi-family psychoeducational treatment to Veterans and their family members or other supporters.
223641320|NCT05092100|BEHAVIORAL|Visual stimulus similarity|Visual stimulus similarity will be varied in order to test for effects on memory. Learning protocol (the order and frequency with which stimuli are learned) will also be varied.
223641321|NCT05092100|OTHER|fMRI|fMRI will be used to measure patterns of BOLD activity during learning.
223765224|NCT07172204|DRUG|Alternately treated with VA/low CHA regimen|"1. Induction Phase (4 alternating cycles):~   Participants will receive 4 cycles of alternating therapy:~  * VA Cycle:~     * Venetoclax 400 mg PO daily on Days 1-28~    * Azacitidine 75 mg/m² SC/IV daily on Days 1-7~  * Low-dose CHA Cycle:~     * Cladribine 5 mg/m² IV daily on Days 1-3~    * Homoharringtonine 1 mg/m² IV daily on Days 1-5~    * Cytarabine 20 mg SC every 12 hours on Days 1-10 Alternating sequence: VA → CHA → VA → CHA → VA → CHA → VA → CHA The interval between the VA to low-CHA is 2 weeks, and the interval between the two alternations (one alternation is VA plus low-CHA）is 4 weeks.~2. Maintenance Phase (24 months):~Following induction, participants will receive:~* Venetoclax 400 mg PO daily on Days 1-28~* Azacitidine 75 mg/m² SC/IV daily on Days 1-7 Repeated every 28 days for 24 cycles. The interval between the two cycles is 2 weeks."
223765225|NCT07173400|DEVICE|Active Transcutaneous Auricular Vagus Nerve Stimulation (TaVNS)|Active TaVNS delivered with the VagusStim® device (Vagus Medical Technologies, Istanbul, Türkiye). The bipolar electrode was placed on the left cymba concha. Stimulation was applied for 30 minutes per day, 5 days per week, for 4 weeks (20 sessions). Parameters included frequency 1-30 Hz, pulse width 50-250 μs, and current intensity individually adjusted (0.1-36 mA) to the participant's sensory threshold.
224229406|NCT03444116|DIAGNOSTIC_TEST|sterEOS Imaging of Lower Extremities|Bi-planar imaging of the lower extremities to evaluate femoral anteversion and hip dysplasia and subluxation.
224229407|NCT03444116|BEHAVIORAL|Surveys|9 surveys assessing function, activity, participation, pain, quality of life, and treatment history.
224229408|NCT05048303|PROCEDURE|Arthroscopic modified individualized flexible Latarjet procedure|The modifications were as follows: (1)the coracoid graft and conjoint tendon were prepared using a mini-open technique with an incision of 2.5 cm and coracoacromial ligament were preserved. A total of 2 bone tunnels were drilled. (2)The anterior (including part of the incision used for obtaining the graft), standard antelateral, and posterior portals were set. (3) The glenoid was marked at the 4-o'clock position, and then the subscapularis muscle was split. (4)The glenoid tunnel was drilled where the suture linked to the graft was passed, and the graft was pulled to the glenohumeral joint via the sutures. A knotless suture anchor for antirotation (PushLock; Arthrex) was fixed to the glenoid to prevent rotation of the graft.
224229409|NCT00929500|BEHAVIORAL|MAST program|MAST program: twice a week for 4 months
223641322|NCT05092100|BEHAVIORAL|Eye tracking|Eye tracking will be used to measure patterns of eye movements when viewing images.
223641323|NCT01582477|DRUG|EXPAREL 20 mL|EXPAREL 266 mg (undiluted)
223641324|NCT01582477|DRUG|EXPAREL 40 mL|EXPAREL 266 mg diluted with preservative-free 0.9% normal saline to 40 mL.
223641325|NCT00777153|DRUG|Cediranib|30 mg/day, oral, until progression
223641326|NCT00777153|DRUG|Cediranib|20 mg/day, oral, until progression
223641327|NCT00777153|DRUG|Lomustine Chemotherapy|110 mg/m2 / Q6W, oral, until progression
223641328|NCT00777153|DRUG|Placebo Cediranib|Oral, until progression
223641329|NCT04060927|DEVICE|SGRT|Surface Guided Radiation Therapy
223641330|NCT00809718|DRUG|Raltegravir and rifapentine|"Period 1- Raltegravir 400 mg q12h by mouth for 4 days~Period 2- Rifapentine 900 mg taken by mouth once per week for 3 doses and raltegravir 400 mg q12h by mouth for 4 days~Period 3- Rifapentine 600 mg taken by mouth once daily for 5 of 7 days per week for 10 doses and raltegravir 400 mg q12h by mouth for 4 days"
223641331|NCT05089786|DEVICE|Exablate Neuro Type 1.0 System with Echo Focusing|MR-Guided Focused Ultrasound
223641332|NCT03572660|BIOLOGICAL|Bone marrow derived mononuclear cells and G-CSF|Intra-coronary infusion
223641333|NCT04430816|PROCEDURE|double mesh modification of chevrel's technique|repair of midline incisional hernia by double mesh modification of chevrel's technique
223641334|NCT04430816|PROCEDURE|on lay mesh hernioplasty|repair of midline incisional hernia by online mesh hernioplasty
223641335|NCT02472470|DEVICE|rTMS|Participants will receive 10 active TBS rTMS sessions once daily on weekdays for 2 weeks.
223641336|NCT02079246|DRUG|Idalopirdine 60 mg|once daily, encapsulated tablets, orally
223641337|NCT06305832|DRUG|Rezvilutamide|Specifications of 80 mg; orally, once a day
223641338|NCT06305832|DRUG|Androgen deprivation therapy (ADT)|Androgen deprivation therapy (ADT), the ADT used by each subject will be determined by the investigator,and the dose and frequency of administration will be consistent with the prescription information
223641339|NCT06305832|RADIATION|SRT|SRT according to standard of care (66.6-72 grays will be delivered to the bed of prostate ,\~50.4 grays to the pelvis if needed)
223641340|NCT04730219|DRUG|Tislelizumab|Tislelizumab 200mg will be administered on Day 1 every 3 weeks for 3 cycles
223641341|NCT04730219|DRUG|Nab paclitaxel|Nab paclitaxel 200mg will be administered on Day 2 every 3 weeks for 3 cycles
223641342|NCT01484119|DRUG|ACT-129968|daily tablets
223641343|NCT01484119|DRUG|Placebo|matching placebo tablets and capsules
223641344|NCT01484119|DRUG|Cetirizine|daily capsules
223641345|NCT00208871|PROCEDURE|Stereoscopic Digital Mammography|screening digital 3D mammogram
223641346|NCT02645669|PROCEDURE|Study site|The probiotic is in the form of a lyophilized powder containing approximately 5 billion colony forming units (CFU) of the Saccharomyces boulardii. At the time of administration, the probiotic mixture was mixed with fructooligosaccharide in the ratio of 4:1 to induce growth and activity in S boulardii. This was applied after scaling and root planing.
223641347|NCT02645669|PROCEDURE|Control site|Only Scaling and Root planing was done.
223641348|NCT06061302|OTHER|Immediate yoga intervention|Subjects will complete 12 consecutive weeks of weekly 40 minute guided mindful yoga weeks 1-12.
223641349|NCT06061302|OTHER|Delayed yoga intervention|Subjects will complete 12 consecutive weeks of weekly 40 minute guided mindful yoga weeks 13-24.
223765226|NCT07173400|DEVICE|Sham Transcutaneous Auricular Vagus Nerve Stimulation|Sham stimulation delivered with the same VagusStim® device under identical conditions. The electrode was rotated and placed on the left earlobe, which lacks vagal innervation. Sessions lasted 30 minutes per day, 5 days per week, for 4 weeks (20 sessions). No effective vagus nerve stimulation was delivered, preserving participant blinding.
223641350|NCT05647148|BEHAVIORAL|Progressive Relaxation Exercises|"In the first part of this audio material, which consists of three parts; The definition of deep relaxation, its purpose and points to be considered during exercise are included.~The second part, consisting of an average of thirty minutes, includes the explanation of relaxation exercises with verbal commands accompanied by the sound of the stream.~In the last part, there is only relaxation music without any commands."
223641351|NCT02751190|PROCEDURE|Totally ExtraPeritoneal (TEP) repair|
223641352|NCT02751190|PROCEDURE|TransAbdominal PrePeritoneal (TAPP) repair|
223641353|NCT02751190|PROCEDURE|Open anterior mesh repair|
223641354|NCT02751190|PROCEDURE|Open Anterior Non Mesh|
223641355|NCT02751190|PROCEDURE|Combined anterior and posterior repair|
223641356|NCT02751190|PROCEDURE|Open preperitoneal mesh repair|
223641357|NCT02534740|DRUG|tafamidis|relative bioavailability
223641358|NCT02534740|DRUG|tafamidis|fasted
223641359|NCT02534740|DRUG|tafamidis|fed
223765227|NCT07174063|DRUG|JSB462|300 mg or 100 mg once a day (QD) with food
224229410|NCT01104207|DEVICE|repetitive transcranial magnetic stimulation (rTMS)|rTMS involves application of electromagnetic pulses through a coil to the subject's scalp. Some of the electromagnetic energy is transmitted to underlying neural tissue. The goal for this study: 1 Hz rTMS will suppress neural activity responsible for tinnitus perception.
224229411|NCT01104207|DEVICE|placebo rTMS|placebo rTMS
224229412|NCT05543148|OTHER|Questionnaire|Evaluate hearing loss and communication and conversation disabilities
224229413|NCT02268422|DRUG|Buprenorphine|7 day patch
224229414|NCT00020345|DRUG|fluorouracil|
224229415|NCT00020345|DRUG|gemcitabine|
224229416|NCT00003390|DRUG|irofulven|
223641360|NCT02823067|OTHER|Blood sample|One extra blood sample of 10 ml will be taken during a routine venapunction for immunoserology testing.
223641361|NCT04271397|OTHER|Multiple blood samples|Patients with active tuberculosis will have 5 research-specific blood samples: V1, (baseline) immediately before initiating anti-tuberculosis treatment, then 4 samples during anti-tuberculosis treatment and follow-up, i.e. at 48 hours (V2), 15 days (V3), 2 months (V4) and 6 months (V5) after initiation of treatment. The total volume of each sample will be 20 mL for a total of 100 mL.
223641362|NCT04271397|OTHER|Single blood sample|Patients with Latent tuberculosis infection will have a single specific sample of 14 mL.
223641363|NCT02763280|DIETARY_SUPPLEMENT|Ginseng extract 1g|Ginseng extract 1g, parallel design
223641364|NCT02763280|DIETARY_SUPPLEMENT|Ginseng extract 3g|Ginseng extract 3g, parallel design
223641365|NCT02763280|DIETARY_SUPPLEMENT|Placebo|placebo, parallel design
223641366|NCT03077412|DRUG|Filgotinib|Tablet(s) administered orally once daily
223641367|NCT03077412|DRUG|Placebo to match filgotinib|Tablet(s) administered orally once daily
223641368|NCT05117931|DRUG|Amivantamab|Patients will receive amivantamab weekly for the first cycle, and biweekly subsequently at a dose of 1050mg (\<80kg) or 1400mg (\>80kg). The first day of dosing is considered Cycle 1 Day 1. Each cycle is 28 days in duration. The initial dose will be administered over 2 days to prevent infusion reactions. For patients who weigh \<80 kg, amivantamab 350mg IV will be given on Cycle 1 Day 1, and the remaining 700mg IV will be given on Cycle 1 Day 2. Patients will continue to receive amivantamab 1050mg IV once a week during Cycle 1 then biweekly (Days 1 and 15) of each subsequent Cycle. For patients who weigh ≥ 80 kg, 350mg IV amivantamab will be given on Cycle 1 Day 1 and 1050mg IV will be given on Cycle 1 Day 2. Patients will continue to receive amivantamab 1400mg IV once a week during Cycle 1 then biweekly (Days 1 and 15) of each subsequent Cycle.
223641369|NCT06233136|DEVICE|Leg pedalling exercise|Each child in the experimental group will be positioned in inclined position and will cycle through the range of motion under the supervision of the researcher
223641370|NCT06233136|OTHER|The designed physical therapy program|"It applied for all participated children in both groups. It includes;~1. Flexibility exercises~2. Static and dynamic balance~3. Functional training exercises"
223641371|NCT04114318|OTHER|Dual-task cognitive-cycling training|Cognitive and cycling training simultaneously for dual-task cognitive-cycling training; stationary bicycle exercise training for single-task cycling training
223641372|NCT05178004|OTHER|Faecal and Urine sample collection|This is an observational study.
223641373|NCT05087004|BEHAVIORAL|Teen Council|Youth randomly selected for Teen Council attended weekly meetings for an entire school year to receive training on specific topics. In turn, they provided educational presentations to the community, which required that they miss school (about one day per month). The presentations Teen Council members offered in middle and high schools were most commonly on birth control methods; relationships; reproductive anatomy and physiology; sexual diversity; STDs/STIs; sexual consent; HIV/AIDS; and abstinence.
223641374|NCT02266888|BIOLOGICAL|Rituximab (Rituxan®)|2 Doses: 375 mg/m\^2 on Day 0 (within 12 hours of return to ICU following transplant) and Day 12 (+/-2 days).
223641375|NCT02266888|BIOLOGICAL|Placebo|Placebo for Rituximab (Rituxan®). 2 Doses: 375 mg/m\^2 on Day 0 (within 12 hours of return to ICU following transplant) and Day 12 (+/-2 days).
223641376|NCT04688008|DRUG|Hetrombopag|"Drug: Early phase hetrombopag olamine formulation single oral dose of 5 mg hetrombopag under fasting conditions~Drug: Late phase hetrombopag olamine formulation single oral dose of 5 mg hetrombopag under fasting conditions"
223641377|NCT02351856|DRUG|ARRY-371797, p38 inhibitor, oral|multiple dose, single schedule
223641378|NCT06456502|DEVICE|Non-invasive neuromodulation|The treatment plan of non- invasive neuromodulation will be applied for two months, with a frequency of 2 weekly sessions of one hour duration, until completing a total of 15 sessions for each patient. The sessions will always be applied in the same time slot of the day (to avoid influence on the measurements, specially cortisol).
224229417|NCT01312610|DIETARY_SUPPLEMENT|High flavanone orange juice|High flavonone orange juice drink.
224229418|NCT01312610|DIETARY_SUPPLEMENT|Control orange juice|Orange beverage, low flavanone content, matched for total carbohydrate content, individual sugar profile, vitamin C
224229419|NCT03940313|PROCEDURE|Prolotherapy|Musculoskeletal injection of lidocaine + 15% dextrose into damaged tissue
224229420|NCT04186390|OTHER|Simulation training in small bowel capsule endoscopy|Training in the evaluation of small bowel capsule endoscopies including evaluation, diagnostic and treatment in different cases.
224229421|NCT00909077|DRUG|Dexamethasone|Dexamethasone tablets: 40 mg/day for four days
224229422|NCT00909077|DRUG|Dexamethasone and Rituximab|Dexamethasone tablets: 40 mgs/day for four days Rituximab iv 375 mg/m\^2 weekly, a total of four times. Administered on day 2 (i.e. the patient has been treated with Dexamethasone for one day)
224229423|NCT03055533|BEHAVIORAL|Headsprout reading program|Headsprout is a commercially available, computer-based program reading intervention that can be tailored to meet the individual needs of each child. Participants will have treatment sessions with a trained therapist lasting one to two hours, two to four days a week, for approximately twelve weeks.
224229424|NCT02770183|DEVICE|Imacor|"In ICU, the doctors in charge places the probe in the esophagus, executing a series of morphological evaluations and semi-quantitative evaluations. Each image is saved as a video loop or a static image, to have a basic data for each patient and perform an off-line analysis. At the end of the first recording, the esophageal probe is left in the neutral position in the stomach, to eliminate any risk associated with a local increase of pressure.~During the stay in the intensive care unit until the end of the study, the esophageal probe will be left in the neutral position, to run every two hours a new echocardiographic assessment on the main window, similar to the first evaluation, always recording loop-video and photographs, to have a time course of recovery of cardiac contractile function. All images will be stored in a digital archive."
224229425|NCT05508451|PROCEDURE|Double jaw surgery|A type of orthognathic surgery
224229426|NCT01070641|DRUG|Carvedilol|Carvedilol 12.5mg QD
224229427|NCT01070641|PROCEDURE|Esophageal variceal band ligation|Each patient will undergo for variceal band ligation after 3 weeks till the eradication of varices
224229428|NCT03621800|OTHER|Menthol popsicle|The menthol popsicle composed of 0.05% menthol, 0.05% saccharin, 20ml ultrafiltered water and 2% cereal alcohol. The menthol popsicle was supported by a stick, allowing patients to taste more comfortably, with autonomy and safety
224229429|NCT01628120|BIOLOGICAL|Epoetin Hospira|Subcutaneous(SC) injection
224229430|NCT03404076|DIAGNOSTIC_TEST|Dual Energy CT|Dual Energy CT is performed for diagnostic evaluation in gastrointestinal stromal tumor (GIST) patients undergoing tyrosine kinase inhibitor (TKI) treatment
223641379|NCT06456502|OTHER|Placebo|The treatment plan of placebo will be applied for two months, with a frequency of 2 weekly sessions of one hour duration, until completing a total of 15 sessions for each patient. Participants will be attached to the neuromodulation machine, however, the cable will not be connected. Participants will not be able to see the machine connections. The sessions will always be applied in the same time slot of the day (to avoid influence on the measurements, specially cortisol).
223641380|NCT02132988|BIOLOGICAL|OPT-822/OPT-821|
223641381|NCT01707732|DRUG|Enoxaparin|Administration of Enoxaparin
223641382|NCT01560663|DRUG|Docetaxel- Carboplatin|Docetaxel 75mg/m2 day 1 and Carboplatin(AUC6)day 1, each 21 days for 6 cycles.
223641383|NCT01458392|BIOLOGICAL|Dalantercept|Subcutaneous dose of dalantercept once every 3 weeks.
223641384|NCT06200662|OTHER|Analgesic strategies during the S visit:|Analgesic strategies during the S visit: standard and recommended non-pharmacological analgesic strategies used by the CRI: administration of sugar solution, support for non-nutritive sucking with a dummy and wrapping in a nappy.
223641385|NCT06200662|OTHER|Analgesic strategies at visit M|Analgesic strategies at visit M: overall non-pharmacological analgesic strategies carried out by the mother: sucking on a sugar solution, supporting non-nutritive sucking with a dummy, contact, etc.
223641386|NCT03762993|BEHAVIORAL|Vocal rest and Controlled Phonation|Voice rest and semi occluded vocal tract voice exercises
223641387|NCT02202200|DRUG|PD- 0332991|"PD-0332991 Inhibitor of cyclin-dependant kinase (CDK) 8 schedules will be evaluated PD-0332991 PO QD either at 25 mg, 50 mg, 75 mg, 100 mg, 125 mg, 150 mg, 175 mg and 200 mg~All patients will receive vemurafenib as background therapy ,bid at 720mg bid for the first group (during the first 2 cycle then 960 mg bid if good tolerance) and 960mg bid for all other patients"
223641388|NCT03840018|OTHER|Letter by post to patients|Patients received an informative letter by post, in which their doctor invited them to seek an appointment for a medication review
223641389|NCT04698369|DEVICE|Vibration Massage Therapy|WearUL is a patent pending wearable rehabilitation technology that targets localized vibration massage therapy directly onto the body. The frequency and amplitude combinations to be delivered by WearUL are safe and effective in clinical and research settings based on previous studies on focal vibration.
223641390|NCT04244292|OTHER|Videolaryngoscopy|Patient will be intubated by using videolaryngoscope
223641391|NCT05264922|DRUG|Tisseel Injectable Product|Fibrin glue will provide an inert, biocompatible, viscous substance able to remain within the Rotator Cuff (RC) defect rather than injecting SVF cells in saline.
223641392|NCT05264922|BIOLOGICAL|Stromal Vascular Fraction Cells|Stromal Vascular Fraction cells are autologously harvested, processed and reinjected into the affected shoulder.
223641393|NCT00555698|DEVICE|Deep Brain Stimulations for Depression|Deep Brain Stimulations for Depression
223641394|NCT01263847|DIETARY_SUPPLEMENT|Galactooligosaccharide|Zero, 5 or 10 g/day of galactooligosaccharide will be administered in two yogurt drinks containing about 300 mg total calcium each per day for three weeks. During a clinical visit following three weeks of consumption, zero, 2.5 or 5 g of galactooligosaccharide will be administered in the same yogurt with the addition of 15 mg Ca-44 (calcium chloride). Participants will be given one of the above yogurts at breakfast in addition to intravenously receiving 3.5 mg Ca-43 (calcium chloride) in 4 ml saline one hour after breakfast consumption.
223641395|NCT02341677|PROCEDURE|SmartTarget - Biopsy|MRI to ultrasound fusion guided prostate biopsy
223641396|NCT01193244|DRUG|Orteronel|Orteronel will be administered orally twice a day continuously throughout the study. Patients will also receive concomitant gonadotropin-releasing hormone (GnRH) analogue therapy unless they have previously undergone orchiectomy and have a testosterone concentration of \<50 ng/dL.
223641397|NCT01193244|DRUG|Placebo|Placebo will be administered orally twice a day continuously throughout the study. Additionally, all patients will receive concomitant gonadotropin-releasing hormone (GnRH) analogue therapy unless they have previously undergone orchiectomy and a testosterone concentration of \<50 ng/dL.
223641398|NCT01193244|DRUG|Prednisone|Prednisone will be administered orally twice a day continuously throughout the study. Patients will also receive concomitant gonadotropin-releasing hormone (GnRH) analogue therapy unless they have previously undergone orchiectomy and have a testosterone concentration of \<50 ng/dL.
224319457|NCT02032680|BEHAVIORAL|In-persons Multi-Family Group Psycho-Education treatment|This intervention will provide the VA's evidence-based MFG. This intervention is delivered to Veterans and their families or other supporters using an in-person format.
223641399|NCT04731545|DEVICE|immediate implant placement|Minimally traumatic tooth extraction, immediate implant placement and hard tissue grafting. loading after 3 months.
224229431|NCT01259427|BEHAVIORAL|Ending Self Stigma (ESS)|Ending Self Stigma (ESS) is a 9-session small-group (4-8 persons) course designed to help individuals with serious mental Illness (SMI) develop skills to effectively cope with stigma and minimize the internalization of stigmatizing beliefs and stereotypes. Sessions combine in-class lecture, discussion of relevance to group members' personal experiences, review and practice of strategies and skills, and group sharing, support, and problem-solving. Each session is designed to focus on a specific strategy for addressing self-stigma.
224229432|NCT01259427|BEHAVIORAL|Health and Wellness Group|The Health and Wellness group is a 9-session small-group (4-8 persons) course designed for individuals with serious mental illness (SMI). Each session focuses on discussion of specific health and wellness related issues and education on ways to better manage health related concerns (e.g., physical activity/exercise, nutrition, managing fatigue/sleep, tobacco and other substance use, etc).
224229433|NCT00767117|DRUG|Etravirine; Lopinavir; Ritonavir|
224229434|NCT02958956|DRUG|Pioglitazone|Participants with diabetes who were members of the KPNC registry, and had received at least 2 prescriptions for pioglitazone within a 6-month period were followed up to 15.5 years (1997-2012) in this observational study 1.
223641400|NCT02909400|DRUG|KH176|
223641401|NCT02909400|DRUG|placebo|
223641402|NCT01129856|DRUG|Dexamethasone phosphate ophthalmic solution|Transscleral iontophoresis delivery of EGP-437 (dexamethasone phosphate formulated for ocular iontophoresis)
223641403|NCT01129856|DRUG|Sodium citrate buffer solution|Sodium citrate buffer solution 100 mM
223641404|NCT02678026|DEVICE|Cervical pessary|Cervical pessary is a medical device used to treat an incompetent (or insufficient) cervix (cervix starts to shorten and open too early). Early in the pregnancy a round silicone pessary is placed at the opening to the cervix to close it, and then remove late in the pregnancy when the risk of a preterm birth has passed.
223641405|NCT00689507|BIOLOGICAL|LY2127399|monoclonal antibody
223641406|NCT05324059|DRUG|Pregabalin 75mg/ Tramadol 50 mg|Pharmaceutical Form: Tablet Dosage: 75 mg / 50 mg Administration way: oral
223641407|NCT05324059|DRUG|Pregabalin 75mg|Pharmaceutical Form: Capsule Dosage: 75 mg Administration way: oral
223641408|NCT04605172|OTHER|hospitalization for premature birth|Number of inborn and outborn infants prematurely born during a specific period of time
223641409|NCT00384670|BIOLOGICAL|Dengue Vaccine Formulation 17|Tetravalent live attenuated DEN vaccine candidate. Containing dengue serotypes 1,2, and 3 vaccines produced at the Salk Institute and dengue serotype 4 produced at the WRAIR Pilot Bioproduction Facility. Dosage 1 mL administered via injection at Day 0 and Day 60.
223641410|NCT00384670|BIOLOGICAL|Licensed Japanese Encephalitis (JE) Vaccine|Produced by the Thailand GPO using a Beijing strain of JE in liquid form; dosed at 0.5 mL ot 7 and 7.5 months.
223641411|NCT00722943|OTHER|Developmental Massage Therapy|Tactile stimulation and massage will be done by a licensed therapist
223641412|NCT00722943|OTHER|no intervention|The infant will not be touched by the therapist.
223641413|NCT04766840|DRUG|CAR-T cells|Drug: IM73 CAR-T Cells Drug: Fludarabine Two days before cell infusion, patient will be treated with fludarabine for 3 days Drug: Cyclophosphamide: Two days before cell infusion, patient will be treated with Cyclophosphamide for 3 days
223641414|NCT03900091|DIAGNOSTIC_TEST|Multiplex PCR assay for meningitis|CSF from cases to be analysed with a FilmArray ME Panel
223641415|NCT03900091|DIAGNOSTIC_TEST|Multiplex vertical flow microarrray assay for meningitis|CSF from cases will also undergo analysis with a newly developed prototype for point-of-care diagnostic tool for CNS infections identification. The tool is a DNA-based vertical flow microarray technology printed on paper.
223641416|NCT03900091|DIAGNOSTIC_TEST|Profiling of blood proteins by multi-analyte Profiling technology|Blood from cases and controls to be analysed using Luminex technology to identify protein profiles associated with severe and non-severe infection. Myxovirus protein A (MxA) will also be analysed by the Luminex assay, to associate MxA levels with severe/non-severe infection.
223641417|NCT03900091|OTHER|Typing and whole genome sequencing|Pathogenic strains isolated from nasopharyngeal swabs from cases and controls will undergo whole genome sequencing (WGS) and typing .
223641418|NCT01232023|DRUG|Indobufen|Single Oral Dose of
223641419|NCT05791604|DIETARY_SUPPLEMENT|probiotics including B. lactis B420, B. lactis HN019, B. animalis Bb-12, L. rhamnosus GG|Take probiotics, 2g each time, twice a day, for 12 weeks
223641420|NCT05791604|DIETARY_SUPPLEMENT|Prebiotics with galactomannan and oligofructose|Take probiotics, 2g each time, twice a day, for 12 weeks Take prebiotics, 25g each time, twice a day, for 12 weeks
223641421|NCT05166772|DRUG|Donafenib|200 mg BID，oral administration will start before the first HAIC treatment.
223641422|NCT05166772|DRUG|Sintilimab|200 mg，Q3W，Intravenous infusion will performe before HAIC treatment.
223641423|NCT05166772|OTHER|HAIC|Q3W. The total number of HAIC treatments was determined by the investigator based on patient needs. Dose: Oxaliplatin 85 mg / m2 for 2h, Calcium folinate 400 mg / m2 for 2h, 5-FU 400 mg / m2 for 10min, followed by 5-FU 1200 mg / m2 for 23 hours);
223641424|NCT01173367|OTHER|Aggressive Fever Treatment|Patients assigned to the aggressive fever treatment protocol will receive acetaminophen 650 mg enterally every 6 hours for fever ≥ 38.3°C and external cooling will be initiated for temperatures ≥ 39.5°C. Acetaminophen and external cooling will be discontinued once core temperature is less than 38.3°C and 39.5°C respectively.
224229435|NCT04840407|BEHAVIORAL|SHARP coach intervention|The Coach provides guidance and support through four 45-60 minute in-home visits: Visit 1: to facilitate effective team communication, this visit is conducted, when possible, with the rehabilitation therapist, the patient/family, the direct care aide and the Coach, who jointly reviews the rehabilitation plan of care. Visits 2-4 include: discussion/observation of HHA/patient exercise repetition sessions, along with: 1) discussing falls prevention, signs of a recurrent stroke and when to call 911; 2) modeling motivation techniques, assessing adherence barriers and revising strategies for addressing them; and 3) identifying/ reporting signs of anxiety/depression. Additional coaching visits and calls may be scheduled as needed depending on the aide's progress in addressing barriers and the patient's progress toward rehabilitation goals.
223641425|NCT01173367|OTHER|Permissive Fever Treatment|Patients assigned to the permissive treatment strategy will not receive anti-pyretic therapy until the temperature reaches 40.0°C at which point they will receive acetaminophen 650mg every 6 hours. External cooling will be initiated for temperatures ≥ 40.5°C. Acetaminophen and external cooling will be discontinued once core temperature is less than 40.0°C and 40.5°C respectively.
223641426|NCT01394003|DRUG|LY2584702|administered orally
223641427|NCT03839160|PROCEDURE|Serratus anterior plane block|Serratus anterior plane block was applied in Group S. It was performed at the end of the operation following the skin closure, while the patient lay on his side with his arm above the head. After proper site cleaning, the first and second ribs were identified with a linear probe in the midclavicular line. The USG probe was advanced caudally in the sagittal plane, and the fourth and fifth ribs were visualized. The USG probe was then directed posteriorly and the serratus, latissimus dorsi and intercostal muscles were visualized. Bupivacaine 0.25% 30 mL was administered to the lower plane of the serratus muscle through an inserted catheter under the guidance of USG through the in-line technique. Afterwards, 0.12% bupivacaine hydrochloride was maintained at the rate of 0.1ml/kg/hr.
223641428|NCT03839160|DRUG|Intravenous patient-controlled-analgesia morphine|Morphine solution was prepared at a concentration of 0.5 mg/mL with the device programmed to 2 mg of bolus dose and 10 min of locking time.
223641429|NCT03763877|DRUG|PXL770|Oral capsule
223641430|NCT03763877|DRUG|Placebo Oral Capsule|Oral capsule
223641431|NCT03040336|BEHAVIORAL|Prehabilitation|The 6-week long prehabilitation intervention will include (1) strength and balance training; (2) inspiratory muscle training; and (3) nutritional coaching and supplementation.
223641432|NCT01686542|PROCEDURE|CPVI plus renal sympathetic modification|CPVI plus renal denervation to reduce atrial arrhythmia recurrence.
223641433|NCT01686542|PROCEDURE|CPVI|CPVI alone to reduce atrial arrhythmia recurrence.
223641434|NCT01262196|DRUG|MP4OX|4.3 g/dL pegylated hemoglobin in balanced lactate-electrolyte solution
223641435|NCT01262196|DRUG|Saline|Normal saline (0.9%) solution
223641436|NCT01601548|BEHAVIORAL|Mindfulness Based Cancer Recovery|Defined as practices or interventions that focus on the connection and integration of the mind and body and the ability for these connections to effect changes on physical, emotional and spiritual levels for the purpose of promoting health and well being. MBCR is a psycho-educational program developed by Dr. Linda Carlson. It is a step by step mindful-based stress reduction program (MBSR) designed to help cancer patients cope with their cancer diagnosis and treatment
223641437|NCT04570137|DIETARY_SUPPLEMENT|Dietary fiber supplementation|"1. 16g/day: mix of 70% wheat-bran arabinoxylan and 30% oat-derived fiber (ß-glucan)~2. 16g/day: mix of 50% inulin and 50% oligofructose from chicory"
223765228|NCT07172100|DRUG|Carica Papaya Leaf Extract Group|Carica papaya leaf extract syrup will be administered orally at a dose of 10 mL three times daily (TID) for a total of 3 days. Each 10 mL dose contains 1000 mg of papaya leaf extract. This intervention will be given in addition to standard supportive therapy for dengue fever
223765229|NCT07172100|OTHER|standard treatment|patients in this group will receive only the standard treatment for dengue fever
224229436|NCT03752593|OTHER|ET Tube|Patients with a BMI of greater than 30 or less than who are presenting to the hospital for any surgical procedure requiring general anesthesia
224229437|NCT03814109|DRUG|LENINGRADO association|1 coated sustained-release tablet, oral, once a day.
224229438|NCT03814109|DRUG|Indapamide SR 1.5 MG|1 coated sustained-release tablet, oral, once a day.
224229439|NCT03814109|DRUG|Levamlodipine 2.5/ 5 mg|1 tablet, oral, once a day.
224229440|NCT03814109|OTHER|Leningrado association Placebo|1 coated sustained-release tablet, oral, once a day.
224229441|NCT03814109|OTHER|Indapamide SR Placebo|1 coated sustained-release tablet, oral, once a day.
224229442|NCT03814109|OTHER|Levamlodipine placebo|1 tablet, oral, once a day.
224229443|NCT05304637|DEVICE|iTEAR100 treatment|Vibratory energy to the external nasal nerve
224229444|NCT04958083|DIAGNOSTIC_TEST|multiphase ECG-gated contrast-enhanced CT|Compared with current standard CT imaging, the dynamic CT protocol provides incremental functional information, which is potentially helpful to the individuals under study (such as early awareness for future complications and potential prediction of outcomes). Due to the nature of the acquisition, a wider R-R acquisition window will result in a higher radiation burden than a standard protocol. However, the study protocol will replace the standard routine CT image protocol as it contains both the routine anatomic information and incremental functional information. The time required for the image acquisition and associated radiation will be slightly higher; the additional information from multiple reconstructed phases will justify a slightly higher radiation burden in a usually elderly population. The estimated radiation dose for the standard imaging protocol is approximately 8 mSv. The estimated radiation dose for the modified dynamic CT image acquisition is approximately 18 mSv.
224229445|NCT05939661|RADIATION|Radiation|Neoadjuvant radiation therapy : 5Gyx5
223641438|NCT01735006|BIOLOGICAL|HPV Vaccine|3 doses at month 0,1 and 6
224229446|NCT05939661|DRUG|Chemotherapy|CAPOX (Oxaliplatin 130mg/m2, Capecitabine2000mg/m2/day, d1-14, 3week)x6cycles
224229447|NCT05939661|PROCEDURE|Surgery|Operation: Total methorectum excision wiht radical lymph node dissection
224229448|NCT02588183|DEVICE|ArticFont Advance ST Cryoenergy Balloon Catheter|PV isolation using the ArticFont Advance ST Cryoenergy Balloon Catheter
224229449|NCT06528483|DRUG|Sacituzumab Govitecan + Zimberelimab|"Sacituzumab Govitecan 7.5 mg/kg IV for 3 cycles Zimberelimab 360 mg IV for 16 cycles~Patients will be treated with Sacituzumab Govitecan 1,8q21 plus + Zimberelimab q21 for 3 cycles then radiological imaging and TURB will be repeated and patients with Stability of disease or down staging will continue Zimberelimab until disease progression, or unacceptable toxicities or completion of treatment (16 cycles). Patients with progressive disease after 3 cycles of study intervention will be treated as per clinical practice."
224229450|NCT04659733|DRUG|Anlotinib hydrochloride|Anlotinib are divided into 3 dosage levels, including 8mg, 10mg, 12mg; Oral administration of anlotinib was given, qd, D1-D14; taken on an empty stomach, Every 3 weeks is a cycle, a total of 2 cycles; Starting from the first level of anlotinib, the dose will be ramped up in sequence.
224229451|NCT05393947|OTHER|patient education|It is planned to provide education to patients about the side effects of chemotherapy.
223641439|NCT01735006|BIOLOGICAL|HEV vaccine|3 doses at month 0,1 and 6
223641440|NCT02026531|OTHER|3-Helium gas|3-Helium gas for MRI contrast
223641441|NCT04500899|DRUG|Mydfrin|A test dose of 20 mcg of Mydfrin will be administered through the peripheral intravenous line. BP will be monitored after each bolus of phenylephrine. Subsequent Mydfrin injections will then be administered in 50 mcg aliquots every 10-15 minutes, instead of 40 mcg, until the mean arterial blood pressure (MAP) increases by ≥ 20 mm Hg from the baseline MAP, however making sure not to exceed a MAP of 100 mmHg. Once a desired blood pressure has been achieved and maintained, echocardiographic evaluation of mitral regurgitation would be performed.
223641442|NCT03537404|DRUG|Narlaprevir|100 mg, film-coated tablets, taken as 200 mg per os daily
223641443|NCT03537404|DRUG|Ritonavir|100 mg, film-coated tablets, taken as 100 mg per os daily
223641444|NCT03537404|DRUG|Tenofovir Disoproxil Fumarate|300 mg, film-coated tablets, taken as 300 mg per os daily
223641445|NCT03537404|DRUG|Raltegravir|400 mg, film-coated tablets, taken as 400 mg per os daily
223641446|NCT03906448|COMBINATION_PRODUCT|TTFields with adjuvant temozolomide|Patients will begin study treatment with temozolomide and TTFields within 2 weeks of the baseline evaluation, and no later than 6 weeks from last dose of concomitant temozolomide or radiation therapy (the latter of the two). A minimum of 6 and a maximum of 12 cycles of adjuvant temozolomide will be given, depending on tolerability and toxicity.
223641447|NCT01765283|BIOLOGICAL|HepaStem|
223641448|NCT00001209|DRUG|vincristine, adriamycin and cytoxan, alternating with ifosfamide VP-16|
223641449|NCT04226755|DIETARY_SUPPLEMENT|Sodium chloride|1 gram tid (with every meal)
223641450|NCT00068692|RADIATION|Radiotherapy|Undergo external beam radiation therapy
224229452|NCT04354194|PROCEDURE|Conventional Physiotherapy|Conventional Physiotherapy consist of Hotpacks, TENS and US.The participants were positioned in sitting and supported with a pillow under the head, 20 min hot pack was applied. Therapatic Ultrason were applied with the frequency of 1 MHz, intensity of 1,5 watt/cm² and duration of 5 minute. TENS was applied to the cervical region with 2-channel, 4 surface electrodes at 60-120 Hz, and 50-100 pulse duration for 20 minutes.
223641451|NCT00068692|DRUG|Fluorouracil|Given IV
223641452|NCT00068692|DRUG|Leucovorin Calcium|Given IV
224229453|NCT04354194|PROCEDURE|Osteopathic Manupilative Treatment|Osteopathic Manupilative Treatment consist of stretching the fascia to the cervical region, soft tissue mobilization to the surrounding muscles, cervical manual traction, passive joint mobilization to the 7 cervical spine, passive joint mobilization to the 1st costa, passive joint mobilization to the clavicle and passive joint mobilization to the sternum mobilization in supine and prome positions.
224229454|NCT01075763|DRUG|Interferon beta-1a|Interferon (IFN) beta-1a \[Rebif® 22 microgram (mcg), three times per week (tiw)\] administered subcutaneously (sc)
224229455|NCT01075763|DRUG|Placebo|The inactive substance (placebo) looks the same as Interferon beta-1a (Rebif®), and is given the same way
224229456|NCT00586521|DRUG|Kogenate (BAY14-2222)|One group two treatment schedules, first on-demand then switch to prophylaxis
224229457|NCT06195670|DRUG|Experimental|SCRT: 5\*5Gy for 5 days, after a one-week rest, with fruquintinib plus sintilimab followed; Fruquintinib: qd po, 4mg/d, 2weeks on/1 week off, q3w; Sintilimab: intravenous infusion, 200mg, on day 1, q3w.
223641453|NCT00068692|DRUG|Oxaliplatin|Given IV
224229458|NCT06195670|DRUG|Active Comparator|Capecitabine: bid po, 1000mg/m², on days 1-14, q3w; Bevacizumab: intravenous infusion, 7.5mg/kg, on day 1, q3w.
224229459|NCT02337179|PROCEDURE|Voluntary medical male circumcision|Male Circumcision Under Local Anesthesia using the Forceps Guided Method
224229460|NCT03182179|DRUG|Ondansetron 4 MG|Ondansetron is taken orally BD
224229461|NCT03182179|DRUG|Placebo|Placebo is taken orally BD
224229462|NCT03517852|DEVICE|Human Intravital Microscopy|Intravital microscopy (IVM) allows real-time, direct visualization of microscopic blood vessels and calculation of blood flow.
224229463|NCT02841306|DRUG|Ursodeoxycholic Acid|
223641454|NCT00068692|DRUG|Irinotecan|Given IV
223641455|NCT00637455|DRUG|fexofenadine HCl|
223641456|NCT01222689|DRUG|erlotinib hydrochloride|Given PO
223641457|NCT01222689|DRUG|selumetinib|Given PO
223641458|NCT01222689|OTHER|laboratory biomarker analysis|Correlative studies
223641459|NCT03110523|DRUG|X0002|All subjects who provide informed consent will initiate the Screening Period of at least 14 (±3) days for the assessment of eligibility including radiographic evaluation of the lumbar spine. X-ray images must be collected within 4-11 hours after the subject wakes up. Those subjects who meet preliminary eligibility criteria will be treated with placebo in a subject-blind manner for 14(±3) days from Screening Visit to Day 1. Subjects with a placebo response exceeding 25% improvement in the average NPRS score over the previous 7 days will be excluded. Subjects with a Lane grading of 1 or 2 on their neutral lateral lumbar spine film per the central radiologist are eligible to be enrolled. At Day 1, eligible subjects will be randomly assigned to 1 of 2 treatment groups in a 1:1 ratio with a 1:1 ratio of active:placebo within each treatment group, and stratified evenly according to Lane Radiographic Grading Scale summary score (1 or 2) and gender.
223641460|NCT04790916|DRUG|RO7049665|RO7049665, subcutaneous injection, Q2W.
223641461|NCT04790916|OTHER|Placebo|RO7049665-matching placebo, subcutaneous injection, Q2W.
223641462|NCT03854266|DRUG|Low dose alteplase|Low dose alteplase is 4 milligram per pulmonary artery (maximum dose 8 milligram) infused in the pulmonary arteries over 2 hours
223641463|NCT03854266|DRUG|Unfractionated heparin|Unfractioned heparin is administered in a peripheral vein with an initial dose of 80 international units per kilo (IU/kg) bolus followed by 18 IU/kg as continuous infusion with dose adjustment every 6 hours and once daily when activated partial thromboplastin time (APPT) is 1.5-2.3 times control value.
224229464|NCT01442909|DRUG|Docetaxel and pemetrexed|docetaxel 60mg/m2 every 3 weeks for 4 cycles followed by pemetrexed 500mg/m2 every 3 weeks for 4 cycles; or in reverse sequence.
223641464|NCT03854266|DEVICE|Infusion catheter|A sidehole catheter (Unifuse, AngioDynamics, US) catheter will be advanced to the pulmonary arteries to facilitate the catheter directed thrombolysis
223641465|NCT04672668|DIAGNOSTIC_TEST|duplex ultrasound for the common femoral artery|duplex ultrasound for the common femoral artery before and after the angiography
223641466|NCT03278457|DIAGNOSTIC_TEST|Positron Emission Tomography|Positron Emission Tomography
224229465|NCT03145532|OTHER|tDCS plus robotic training|Children will first receive 20 min of tDCS (real or sham, see Arms), then will receive 1 hr of upper limb robotic therapy in which the child will use their impaired arm and hand to move a joystick controlling a cursor to a set of targets on a video screen in front of the child.
224229466|NCT00619632|BEHAVIORAL|Lactation Consultant|Lactation consultant- primary care based, meets with women pre-natally, in the hospital, and at home up to 6 months post-partum.
224229467|NCT00619632|BEHAVIORAL|Provider Prompt|Prompt in electronic prenatal record will appear 5 times throughout pregnancy re: up to 10 open-ended discussion points for provider to raise
224229468|NCT00619632|BEHAVIORAL|LC+ Provider Prompt|Participants in this group receive both the LC and Provider Prompt interventions.
224229469|NCT01022788|BEHAVIORAL|Home-based counselling|
224229470|NCT03654456|BIOLOGICAL|OSA|The diagnosis of OSA (obstructive sleep apnea) relies on polysomnographic data showing an apnea-hypopnea index at least 5/hr with compatible symptoms.
224229471|NCT03584737|DIAGNOSTIC_TEST|rapid in vitro diagnostic test|IVD for qualitative detection of 3 bacterial pathogens (Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae)
224229472|NCT03584737|DIAGNOSTIC_TEST|bacterial culture|Quantitative bacterial culture assay with isolate identification by MALDI-TOF.
224229473|NCT03584737|DIAGNOSTIC_TEST|PCR assay|Semiquantitative real-time PCR assay
224229474|NCT04253561|DRUG|Ipatasertib|Ipatasertib will be administered orally once a day, beginning on Cycle 1, Day 1 through Day 21 of each 28-day cycle.
223641467|NCT03530072|DIAGNOSTIC_TEST|Karius Test|Next Generation Sequencing
224229475|NCT04253561|DRUG|Trastuzumab|600 mg every 3 weeks
223641468|NCT00248040|DRUG|Reparixin continuous infusion|The Investigational Product was administered as an intravenous infusion into a (high flow) central vein or through an arterio-venous fistula, by an infusion pump adequate to provide reliable infusion rates, as per treatment schedule. Total infusion volume did not exceed 500 mL/24 hours. A dose of 2.772 mg/kg body weight/hour was to be administered for 12 hours. Placebo was volume/schedule matched saline.
223641469|NCT00248040|DRUG|reparixin intermittent infusion|A dose of 2.244 mg/kg body weight was to be administered over a 30-minute period, followed by a 1.5-hour interval. Twelve doses were to be administered over a total period of 22.5 hours. Placebo was volume/schedule matched saline.
223641470|NCT00248040|OTHER|placebo infusion|placebo was volume/schedule matched saline
223641471|NCT03221153|PROCEDURE|Simulation techique|The intervention group will be in a simulated case with mock scenarios and interaction by 'acting out' the clinical situation where knowledge and attitudes about safety in hospitalized patients will be assessed.
223641472|NCT05441748|OTHER|Walnuts|The intervention treatment will contain walnuts.
223641473|NCT05441748|OTHER|Walnut Oil|The intervention treatment will contain walnut oil.
224229476|NCT04253561|DRUG|Pertuzumab|420 mg every 3 weeks
224229477|NCT05702177|DRUG|Daridorexant 25 mg|A single-dose of daridorexant 25 mg will be administered in the evening 30 minutes prior to bedtime.
224229478|NCT05702177|DRUG|Daridorexant 50 mg|A single-dose of daridorexant 50 mg will be administered in the evening 30 minutes prior to bedtime.
224229479|NCT05702177|DRUG|Placebo|A single-dose of placebo matching daridorexant will be administered in the evening 30 minutes prior to bedtime.
224229480|NCT03480711|PROCEDURE|SST in group (A)|group (A) single surgeon, using retrobulbar anaesthesia with 2% lidocaine, will be performed in all surgeries. Following insertion of a lid speculum, a 10/0 silk bridle suture is inserted at superior limbus if required. In group (A) a conjunctival incision is made at the limbus to create a fornix-based conjunctival flap. A half thickness scleral flap (4 × 4 mm) are created and dissected into the clear cornea. A cellulose microsponge soaked in 0.3 mg/ml MMC solution (Mitomycin-C) is applied to the under surface of the scleral flap over a wide posterior area for 2 ml
224229481|NCT03480711|PROCEDURE|trabeculectomy with ESST in group (B)|group (B), another longitudinal scleral groove will be created in the center of the deep scleral bed area measured about 1.5 × 6 mm.In both groups, standard trabeculectomy of equal size (two bites aside) is created by a Kelly punch ( 1 mm)
224229482|NCT06057883|DIETARY_SUPPLEMENT|Probiotic|A blend of two probiotic strains. Participants will take 1 capsule daily at 3 billion Colony Forming Units (CFUs)
224229483|NCT03778047|DRUG|Enzalutamide|oral
224229484|NCT03778047|DRUG|HC1119|oral
224229485|NCT02261428|DEVICE|Catheter Tiemann|We tested the ability of Tiemann catheter to access trachea in order to aspirate bronchial secretions in ICU patients
224229486|NCT02261428|DEVICE|Suction catheter|We tested the ability of Suction catheter to access trachea in order to aspirate bronchial secretions in ICU patients
224229487|NCT05531266|OTHER|hUC-MSCs|Participants will be treated with hUC-MSCs at a dose of 1×10\^6 /kilogram (kg) actual body weight at Screening for twice per week in 1-2 weeks and once a week in 3-4 weeks after being rolled into this study. At the same time, patients will be treated with glucocorticoids according to patients' condition.
223641474|NCT05441748|OTHER|Control|The control treatment will contain corn oil.
223641475|NCT00512213|DIETARY_SUPPLEMENT|Immunonutrition for 5 days preoperative|Impact vs Meritene
223641476|NCT00512213|DIETARY_SUPPLEMENT|Standard enteral nutrition for 5 days preoperative|Impact vs Meritene
223641477|NCT03481595|DEVICE|HealthLoop mobile application|Patients will utilize the HealthLoop mobile application on their mobile device during the post-operative period in addition to standard, routine medical care.
223641478|NCT04724993|OTHER|Online Aerobic Dance Exercises|Online aerobic dance exercises will be performed with observance of physiotherapist. They will record their daily physical activity.
223641479|NCT04724993|OTHER|Physical Activity Counseling|Physical activity and exercise will ve explained to the participants.And they will record their daily physical activity.
223641480|NCT04324411|DRUG|sirolimus and ATRA|sirolimus (serum concentration 4-10ng/ml) and ATRA 20mg bid
223641481|NCT03403283|OTHER|15 subjects with Non Proliferative Diabetic Retinopathy(mild, moderate and severe). 15 subjects with Proliferative Diabetic Retinopathy|
223641482|NCT03403283|OTHER|Healthy Controls 15 age matched control subjects|
223641483|NCT03703427|DRUG|Capecitabine, Oral, 500 Mg|1250mg/m2，d1-d14，q3w
223641484|NCT03703427|DRUG|Vinorelbine Tartrate Oral|60mg/m2，d1；d8；q3w
224229488|NCT05531266|OTHER|glucocorticoids|Participants were treated with glucocorticoids only.
224229489|NCT03493126|DRUG|Estradiol|17β-estradiol vaginal cream
223765230|NCT07172126|DRUG|TQB3201 tablets|TQB3201 is an orally administered targeted protein chimera (PROTAC) drug in which one end of the drug is attached to a ligand that binds to AR and the other end to a ligand of E3 ligase (CRBN) via a linker. This product is effective against anti-androgen drugs (such as abiraterone, enzalutamide, etc.) resistance mutations, including AR amplification, point mutations (L702H, H875Y, T878A mutations, etc.), and can target the degradation of wild-type AR and AR ligand-binding domain mutants, especially L702H mutations, which is a new generation of AR-PROTAC.
223765231|NCT07172347|DRUG|VC005 tablets|VC005 groups repeat administration for 52 weeks
223765232|NCT07172347|DRUG|VC005 Tablets Placebo|VC005 Placebo groups repeat administration for 52 weeks
224229490|NCT03493126|OTHER|Placebo|Compounded placebo cream
224229491|NCT01095003|DRUG|Vinflunine plus Capecitabine|"Vinflunine 280mg/m² as a 20-minute i.v. infusion on day 1 of each cycle repeated every 3 weeks~Capecitabine 825mg/m² per os twice per day for 14 consecutive days starting day 1 of each cycle repeated every 3 weeks"
224229492|NCT01095003|DRUG|Capecitabine|Capecitabine 825mg/m² per os twice per day for 14 consecutive days starting day 1 of each cycle repeated every 3 weeks
224229493|NCT05414474|OTHER|Reference|Ferrum Hausmann 100 mg + 200 mL nanopure water with 3 mg 54Fe isotopes
224229494|NCT05414474|OTHER|Ascorbic acid (AA) 500 mg|Ferrum Hausmann 100 mg + 200 mL nanopure water with 3 mg 57Fe isotopes + 500 mg AA
224229495|NCT05414474|OTHER|Ascorbic acid (AA) 80 mg|Ferrum Hausmann 100 mg + 200 mL nanopure water with 3 mg 58Fe + 80 mg AA
224229496|NCT05414474|OTHER|Coffee|Ferrum Hausmann 100 mg + 200 mL nanopure water with 3 mg 54Fe isotopes + 150 mL coffee
224229497|NCT05414474|OTHER|Breakfast|Ferrum Hausmann 100 mg + 200 mL nanopure water with 3 mg 57Fe isotopes + 1 bread roll (\~100 g) with butter and honey + 1 cup of plain yoghurt (180 mL) + 1 cup of coffee (150 mL) + 1 glass of orange juice (250 mL)
224229498|NCT05414474|OTHER|Afternoon|Ferrum Hausmann 100 mg + 200 mL nanopure water with 3 mg 58Fe isotopes administered in the afternoon
224229499|NCT04809870|PROCEDURE|surgery|retrospective comparison of esophagectomy for esophageal cancer in patients with or without concomitant liver cirrhosis
224229500|NCT01903486|DRUG|Apo-Prednisone Cordorol, Detasone - Prednisone|Oral prednisone (study medication) at a dose of 40mg for 1 week, then 30mg for 1 week, then 20mg for 1 week, then 10mg for 1 week, and then stop the medication.
224229501|NCT05518942|BEHAVIORAL|sensorimotor rhythm neurofeedback training|In this study, baseline brain waves will be recorded for 5 minutes before each treatment, and the average value of SMR waves was used as the basis for setting the treatment threshold for the week. During the treatment, the subjects are arranged to sit in front of a computer screen with a game or animation playing. The individual focuses on the games or animations on the screen. The software will analyze the brain wave signals from the brain and convert them into visual and auditory feedback on the computer screen. Clients can learn to control brain activity and give visual and auditory feedback when a set threshold is reached
224229502|NCT03731182|BIOLOGICAL|V114|V114 pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19F, 19A, 22F, 23F, 33F (2 mcg each), and serotype 6B (4 mcg) in each 0.5 mL dose
224229503|NCT03731182|BIOLOGICAL|Prevnar 13™|Prevnar 13™ pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F (2.2 mcg) and 6B (4.4 mcg) in each 0.5 ml dose
224229504|NCT02007148|DRUG|capecitabine|twice a day
224229505|NCT02007148|DRUG|Docetaxel|cycles repeated every 3 weeks
223641485|NCT04172818|BEHAVIORAL|quality of life questionnaire|Since 10 years ago, diaries are used in intensive care unit to limit these symptoms after a coma.In analogy, the diary for patients with allogenic hematopoietic stem cell transplantation could be a mean to reduce the psychological adverse impact and long term consequences. The psychological impact of a diary on patients hospitalized for allogenic hematopoetic stem cell transplantation and on their relatives will be evaluated.
223641486|NCT06516380|DEVICE|Combined treatment of Cyberdyne HAL single joint with TecnoBody D-Wall and Walker View 3.0 SCX devices|HAL-SJ sessions were conducted 5 days a week for 3 months and 2 hours a day for a total of 60 sessions. HAL-SJ application was performed in cybernic voluntary control (CVC) mode for 90 minutes. In addition to each HAL-SJ session, balance exercises were performed with TecnoBody D-Wall for 30 minutes net.
223641487|NCT00753181|OTHER|Nutritional Formula|nutritional shake daily
223641488|NCT00753181|OTHER|Usual diet|usual dietary habits
223641489|NCT00753181|OTHER|Diabetes Meal Plan with experimental diabetes-specific nutritional shake, diabetes specific cereal, and diabetes specific snack bars.|nutritional shake, diabetes specific cereal and diabetes snack bar daily
223641490|NCT00842296|DEVICE|RF ablation (ClosureFAST)|Segmental RF Ablation with the CLF catheter
223641491|NCT00424892|DRUG|Desvenlafaxine Sustained Release|
223641492|NCT05170997|DIETARY_SUPPLEMENT|Cows' milk|Intervention groups will receive a free 12 week supply of cows' milk equating to a pint a day for study participants. Milk is provided by Lakeland dairies.
223641493|NCT05170997|OTHER|British Dietetic Association Iodine Fact Sheet.|All participants will receive the British Dietetic Association Iodine fact sheet which discusses the importance of iodine and the dietary sources.
223641494|NCT06311097|OTHER|Fermented dairy|Participants will consume 300g of yogurt daily for 4 weeks as an integral part of their habitual diet, substituting other food items.
223641495|NCT06311097|OTHER|Non-fermented dairy|Participants will consume 300g of milk daily for 4 weeks as an integral part of their habitual diet, substituting other food items.
223641496|NCT03041506|DRUG|Lidocaine|"Infiltration of local anesthetic agents around target nerves (C5, C6 nerve roots), US guidance, for shoulder pain relief and muscle relaxation.~Lidocaine 2%: 15 -20 ml."
223765233|NCT07174076|DRUG|cordyceps sinesis capsule|cordyceps sinesis capsule 4 capsules tid po for 12 months
223765234|NCT07174076|DRUG|cordyceps sinesis capsule placebo|cordyceps sinesis capsule placebo 4 capsules tid po for 12 months
223765235|NCT07174323|DIETARY_SUPPLEMENT|Peptide derived from collagen protein|Peptide derived from collagen protein
224229506|NCT01440530|BEHAVIORAL|Educational Intervention|Following randomization to TIDES (N=117) or usual care (N=49), TIDES group was oriented to the multimedia online intervention including a dosed sequence of learning via email, video, slideshows, food solutions, expert questions and answers, and quizzes.
224229507|NCT01440530|OTHER|Usual Care|Following randomization to TIDES (N=117) or usual care (N=49), TIDES group was oriented to the multimedia online intervention including a dosed sequence of learning via email, video, slideshows, food solutions, expert questions and answers, and quizzes.
224229508|NCT00720486|BEHAVIORAL|Juvenile Justice Anger Management (JJAM) for Girls|JJAM will include two 1.5-hour group treatment sessions per week for 8 weeks. JJAM sessions will be manual based and will be designed to help youth develop skills in the following areas: identifying different types of physical and relational aggression, recognizing early warning signs of anger, avoiding anger-provoking situations, managing anger to prevent aggression, solving problems, communicating about anger-related events, and repairing relationships damaged by anger-related behaviors.
223641497|NCT03041506|PROCEDURE|US guided ISCB|"Infiltration of local anesthetic agents around target nerves (C5, C6 nerve roots), US guidance, for shoulder pain relief and muscle relaxation.~Lidocaine 2%: 15 -20 ml."
223641498|NCT03041506|DRUG|Midazolam|IV administration up to a maximum dosage of 0.1 mg/kg (bolus of 1 mg by titration every 30-60 seconds) for sedation and pain relief.
223641499|NCT03041506|DRUG|Ketamine|IV administration up to maximum dosage of 100 mg IV (bolus of 25 mg by titration every 30-60 seconds) for sedation and pain relief.
223641500|NCT04558294|DRUG|Lysergic Acid Diethylamide|A moderate dose of 100 μg LSD will be administered.
223641501|NCT04558294|DRUG|Ketanserin Placebo|Mannitol capsules instead of capsules containing Ketanserin.
223641502|NCT04558294|DRUG|Ketanserin|A dose of 40 mg Ketanserin will be administered.
223641503|NCT02559804|OTHER|survival and late effects|survival and late effects
223641504|NCT01993797|OTHER|Lung US|
223641505|NCT05562219|DRUG|QA108 granules|Take the medication as required for 24 weeks
223641506|NCT05562219|DRUG|QA108 granules placebo|Take the medication as required for 24 weeks
223641507|NCT00990197|DRUG|Transdermal nicotine patch|Subjects will apply the nicotine patch on the morning of their treatment day and will keep it on for 24 hours.
223641508|NCT00711191|BIOLOGICAL|monoclonal antibody|CP-870,893 intravenous administration \[IV\] on day 3 of 4-week cycles
223641509|NCT00711191|DRUG|chemotherapy|gemcitabine 1000 mg/m\^2 intravenous administration \[IV\] q week \[wk\]x3 of 4-week cycles
223641510|NCT05053958|OTHER|superimposition of DICOM file from CBCT and STL file of Intraoral scanner|These files will be imported in implant planning software,and virtual implant planning will be performed.
223641511|NCT02001259|DRUG|epidural triamsinolone|add drugs into catheter at 48 hr after surgery
223641512|NCT02001259|DRUG|epidural lidocaine|add into catheter at 48 hr after surgery
223641513|NCT03125616|BIOLOGICAL|4CMenB Vaccine|The infants will receive an intramuscular injection of the 4CMenB vaccine at 2 months
223641514|NCT03125616|BIOLOGICAL|4CMenB Vaccine|The infants will receive an intramuscular injection of the 4CMenB vaccine at 3 months
223641515|NCT03125616|BIOLOGICAL|4CMenB Vaccine|The infants will receive an intramuscular injection of the 4CMenB vaccine at 4 months
223641516|NCT03125616|BIOLOGICAL|4CMenB Vaccine|The infants will receive an intramuscular injection of the 4CMenB vaccine at 12 months
223641517|NCT00602472|DRUG|linagliptin|active
223641518|NCT00602472|DRUG|placebo|placebo to linagliptin 5 mg
223641519|NCT03038880|DRUG|Faricimab|Faricimab was administered via IVT injections as specified during the treatment period.
223641520|NCT03038880|DRUG|Ranibizumab|Ranibizumab was administered via IVT injections as specified during the treatment period.
223641521|NCT03038880|DRUG|Sham Procedure|The sham was a procedure that mimicked an IVT injection and involved the blunt end of an empty syringe (without a needle) being pressed against the anesthetized eye. It was administered to participants in the faricimab treatments arms at applicable visits to maintain masking among treatment arms.
223641522|NCT05097040|BEHAVIORAL|acceptance and commitment therapy (ACT)|The intervention group will receive individual ACT sessions guided by a trained coach for one hour per week over 6 weeks through Zoom videoconferencing. Also, a one-time 1-hour booster session will be provided at 1-month follow-up to facilitate the maintenance of treatment effects.
223641523|NCT04493788|OTHER|Blood test, ultrasound and egg retrieval|Blood tests will be performed to determine free testosterone levels, anti-mullerian hormone (AMH) and lipid profile including fasting plasma glucose and insulin. Women from both PCOS and control groups will be minimally stimulated with gonadotrophins and cumulus-oocytes complexes (COCs) will be aspirated from small antral follicles (2-8mm) without any ovulation triggering. Specifically, administration of highly purified human menopausal gonadotropin (HP-hMG) will start on cycle Day 3 of the menstrual period or a withdrawal bleeding. A pelvic ultrasound scan will be performed in the morning of the last stimulation day to schedule the oocyte collection. Cumulus-oocyte complexes retrieved 42 hours after the last gonadotropin injection will be collected, washed, denuded and individually stored for further molecular characterization.
223641524|NCT00031317|DRUG|Paroxetine|
223641525|NCT00031317|DRUG|Clozapine|
223641526|NCT05337839|PROCEDURE|home exercises|stretching, balance and strengthening exercises
223641527|NCT00804921|DRUG|bevacizumab|
223765236|NCT07174323|DIETARY_SUPPLEMENT|Whey protein isolate|Whey protein isolate
224229509|NCT00720486|BEHAVIORAL|Treatment as usual|Treatment as usual will include standard activities in the female juvenile justice program.
223641528|NCT00804921|PROCEDURE|anterior chamber paracentesis|
223641529|NCT00804921|DRUG|acetazolamide|
223641530|NCT00804921|DRUG|brimonidine|
223641531|NCT04392180|OTHER|Qualitative Interview|There is no intervention as part of this study. Caregivers will participate in a qualitative interview over the phone or by video.
223641532|NCT00193544|DRUG|Arsenic Trioxide|
223641533|NCT00193544|DRUG|Thalidomide|
223765237|NCT07173933|GENETIC|GC310|GC310 is an adeno-associated virus 5 (AAV5) vector delivering a functional copy of the truncated human ATP7B gene
223765238|NCT07173075|DIAGNOSTIC_TEST|impedancemetry|impedancemetry by the InBody S10 device, during a visit, after stabilization of the patient's blood volume, within a limit of 7 days after inclusion
224229510|NCT00311779|DRUG|Spinosad Creme Rinse|
224229511|NCT02883790|DIETARY_SUPPLEMENT|Somnage|Melatonin 1mg, Zinc, Magnesium
224229512|NCT02883790|OTHER|Placebo|Placebo
224229513|NCT00582036|DRUG|Regular Insulin|Use of sliding scale insulin as per Appendix 1
224229514|NCT00582036|DEVICE|Deployment of the MiniMed Paradigm monitoring device|Automated insulin delivery system
224229515|NCT04110028|DRUG|Nicotinamide riboside|Nicotinamide riboside in different doses
223641534|NCT01002339|DRUG|Tacrolimus with rapid steroid withdrawal|"* Basiliximab induction (4 mg i.v., days 0 and 4).~* Corticosteroids: 0.5 gr of i.v. Methylprednisolone (MP) intraoperatively and 125 mg on the first day, followed by oral doses of prednisone rapidly tapered from 30 mg/day to complete discontinuation by postoperative day 7.~* Tacrolimus: 0.15 mg/Kg/day to achieve target trough levels of 8-12 ng/ml for the first month and then 5-8 ng/ml.~* Mycophenolate mofetil 1 gr b.i.d. for the first month and then 500 mg b.i.d."
224229516|NCT04110028|DRUG|Placebo|Placebo
224229517|NCT03354247|BEHAVIORAL|Lifestyle Intervention|Participants randomized to the Lifestyle Intervention will receive an intensive, state-of-the-art weight loss intervention based on a Mediterranean diet and physical activity. The intervention will focus on changing both eating and exercise habits with a goal of producing a 7-10% weight loss within the first 6 months and then maintaining this weight loss. Participants will be evaluate using validated questionnaires and adherence scores to assess food intake and physical activity, and will then be closely followed during the intervention period.
224229518|NCT04147754|PROCEDURE|Epidural anesthesia|Preoperative epidural anesthesia at physician discretion
223641535|NCT01002339|DRUG|Tacrolimus with steroids minimization|"* Basiliximab induction (4 mg i.v., days 0 an 4)~* Corticosteroids: 0.5 gr of i.v. MP intraoperatively and 60 mg on the first day, followed by oral doses of prednisone starting with 0.3 mg/Kg/day, and gradual weekly tapering to complete discontinuation over 6 months.~* Tacrolimus 0.15 mg/Kg/day to achieve target trough levels of 8-12 ng/ml for the first month and then 5-8 ng/ml.~* Mycophenolate mofetil 1 gr b.i.d. for the first month and then 500 mg b.i.d."
224229519|NCT04147754|PROCEDURE|Intrathecal morphine|Preoperative intrathecal morphine at physician discretion
224229520|NCT04147754|PROCEDURE|Erector spinae block|Preoperative erector spinae block at physician discretion
224229521|NCT02873390|BIOLOGICAL|HerinCAR-PD1 cells|herinCAR-PD1 cells transfusion: (1-5×107/kg herinCAR-PD1 + physiological saline + 0.25% human alloalbumin) 300ml for each infusion. IV (in the vein) for each infusion, 2 cycles, each cycle received one infusions on day 21, 43.
224229522|NCT05492591|DRUG|Peginterferon α1b|Injecting different doses of the peginterferon α1b into different groups of subjects.
224229523|NCT05492591|DRUG|Peginterferon α1b with valacyclovir|Both valacyclovir tablets and different dose of peginterferon α1b plan to be used in different groups of subjects.
223641536|NCT01002339|DRUG|CsA with steroid minimization|"* Basiliximab induction (4 mg i.v., days 0 an 4)~* Corticosteroids: 0.5 gr of i.v. MP intraoperatively and 60 mg on the first day, followed by oral doses of prednisone starting with 0.3 mg/Kg/day, and gradual weekly tapering to complete discontinuation over 6 months.~* CsA 5 mg/Kg/day to achieve target trough of 150-200 ng/ml the first month and then 100-150 ng/ml.~* Mycophenolate mofetil 1 gr b.i.d"
224229524|NCT05492591|DRUG|Valacyclovir|Valacyclovir is a positive control drug.
224229525|NCT03141489|DIETARY_SUPPLEMENT|Tubefeeding|NICE guidelines regarding refeeding syndrome, based on a very cautious refeeding regime reaching estimated calorie and protein needs within 7 days, compared to a protocol at Diakonhjemmet Hospital using a higher starting rate, reaching estimated needs within 3 days.
224229526|NCT03108365|DEVICE|Axiostat|"Axiostat® is a sterile, non-absorbable haemostatic dressing intended to control profuse bleeding within minutes of application by providing an active mechanical barrier to the wound site.~Axiostat® stops moderate to severe bleeding due to cuts, abrasions, lacerations, venous/arterial punctures and more. Mechanism of action is such that Axiostat® is an extremely positive dressing that becomes very sticky in the presence of negatively charged blood and thus seals the wound area."
223641537|NCT04959877|BEHAVIORAL|health education|data collect / Telemedicine
223641538|NCT00002696|DRUG|CAF regimen|
223641539|NCT00002696|DRUG|CMF regimen|
223641540|NCT00002696|DRUG|cyclophosphamide|
223641541|NCT00002696|DRUG|doxorubicin hydrochloride|
223641542|NCT00002696|DRUG|fluorouracil|
223641543|NCT00002696|DRUG|methotrexate|
223641544|NCT00002696|PROCEDURE|adjuvant therapy|
223641545|NCT00002696|PROCEDURE|conventional surgery|
223641546|NCT00002696|PROCEDURE|neoadjuvant therapy|
223641547|NCT00002696|RADIATION|radiation therapy|
223641548|NCT03708276|OTHER|My MS Toolkit|My MS Toolkit, a web-based self-management intervention designed to help persons with Multiple Sclerosis self-manage fatigue, pain, and depressed mood.
223641549|NCT02118961|BIOLOGICAL|Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed (DTaP vaccine, BK1301)|0.5 mL, subcutaneous injection
223641550|NCT02118961|BIOLOGICAL|Adsorbed Diphtheria-Tetanus Combined Toxoid (DT toxoid)|0.1 mL, subcutaneous injection
223641551|NCT00460083|DRUG|Elidel(R) (pimecrolimus 1%)|
223641552|NCT00460083|DEVICE|EpiCeram(R) -ceramide based barrier repair cream|
223641553|NCT05414058|DRUG|Apo-Methylphenidate ER|For inpatients, the study medication will be administered by unit nurses, alongside their other medications. For outpatients, the study medication will be dispensed to the participant by the research assistant during their weekly visit. Patients will continue their regular medications as per standard of care.
223641554|NCT05573997|DIAGNOSTIC_TEST|Investigation of clinical profile, laboratory and novel echocardiographic imaging biomarkers|Complete and comprehensive medical interview will be conducted in each eligible patient. In addition, patient's laboratory data will be recorded on admission and pre-discharge. Each patient will undergo a full echocardiographic examination with a specific protocol upon admission and pre-discharge. This will include among others 2-dimensional speckle-tracking analysis of all cardiac chambers, and non-invasive calculation of myocardial work indices of the left and right ventricle.
223641555|NCT03751917|DRUG|Arsenic Trioxide|This is an observational study. Patients who have received or are receiving all trans retinoic acid (ATRA) + Arsenic Trioxide will be followed and analyzed.
223765239|NCT07174284|OTHER|No Intervention: Observational Cohort|No intervention was applied to the patients within the scope of this study.
224229527|NCT03108365|DEVICE|Cotton Gauze|Size: 1 x 1 cm
223641556|NCT04055623|BIOLOGICAL|Monthly autologous Treg cells infusions + 3 times per week Interleukin-2 injections|For the first 6-months of the study: T-regulatory cells taken from a patient, increased in number in a lab, and returned through monthly intravenous (IV) infusions back to same patient + 3 times per week subcutaneous Interleukin-2 injections
223641557|NCT04055623|OTHER|Monthly placebo infusions + 3 times per week placebo injections|For first 6-months of study: monthly placebo infusions + 3 times per week subcutaneous placebo injections
223641558|NCT04055623|BIOLOGICAL|Monthly autologous Treg cells infusions + 3 times per week Interleukin-2 injections|For the second 6-months of the study: all participants will receive T-regulatory cells taken from the patient, that have been increased in number in a lab, and returned through monthly intravenous (IV) infusions back to same patient (Treg cell owner) + 3 times per week subcutaneous Interleukin-2 injections.
223641559|NCT01599624|BEHAVIORAL|Stress Resilience Training System (SRTS)|SRTS training provides both cognitive learning and training in a scientifically-designed stress resilience training approach designed to minimize the adverse effects of stress and also enhance its positive effects. In summary, the SRTS training comprises: (1) Cognitive rules and mental exercises based on expert knowledge and research; (2) Biofeedback stress control exercises based on proven HRV (Heart Rate Variability) algorithms developed by the Institute of HeartMath; and (3) E-Learning presentation of games and simulations to motivate younger trainees. The training is designed to familiarize participants with the iPad and the SRTS program. Participants will be told how to use the system and how often to use the system. SRTS program participants will each be assigned an iPad to take home with them and practice the techniques for a period of two months.
223765240|NCT06085313|BEHAVIORAL|CAI|Web App-based information and coaching/support program for cancer pain management with additional components for the individual optimization functionality
223765241|NCT06085313|BEHAVIORAL|CAPA|Web App-based information and coaching/support program for cancer pain management
224229528|NCT04401566|OTHER|Internal myofascial release|Internal myofascial trigger point release therapy consist of 30 minutes massage directly to the pelvic floor musculature by vaginally. Patients were instructed in internal myofascial relase techniques. Experienced pelvic health physiotherapist (A.B.) to use her fingers with a lubricated glove when the finger could easily reach internal trigger points and follows these steps: (a) finding internal and external trigger points associated with pelvic muscles, especially around sensitive areas of the vagina, anus, and/or pelvic floor; (b) releasing with the fingers the trigger point associated pelvic muscle tension by carefully pressing on the trigger point
224229529|NCT04401566|OTHER|External myofascial release|Eksternal myofascial trigger point release therapy consist 30 minutes massage to the abdominal wall, gluteal area and adductors and hamstring muscles. Pain in trigger points may exist at both locations of muscle insertion as well as in the belly and lower extremity of the muscle.
224229530|NCT04401566|OTHER|Control Group|The Control group will have a paper about exercises recommended in pelvic pain for 30 minutes. A physiotherapist will teach and show the exercises for pelvic pain. The home exercise for pelvic pain contains diaphragm breating, pelvic floor muscle stretching and releasing.
223765242|NCT05141591|OTHER|Anxiety level assessment|To investigate the impact of psychological variables e.g. pre-surgical anxiety on postoperative opioid consumption and pain level, the investigators will perform the STOA, APAIS, PCS and the VAS-A anxiety questionnaires before surgery.
224229531|NCT02304120|OTHER|Proprioceptive postural training|
224229532|NCT02304120|OTHER|Treadmill training|
224229533|NCT02304120|OTHER|Conventional physiotherapy|All participating patients will attend usual care according to their treatment plan (taking part in the study does not affect the treatment plan). A physiotherapy referral requests 9 treatments, each of which takes 30 minutes. These will take place twice a week for 4.5 weeks. The study protocol does not dictate the content of the physiotherapy sessions themselves, but detailed documentation of provided treatments is required (therapy documentation sheet). Additionally, the aim of the physiotherapy sessions should always include reduction of muscular imbalances and optimisation of posture.
223765243|NCT02870907|OTHER|Observation|no post operative chemotherapy
223765244|NCT02870907|DRUG|Etoposide|100 mg/m²/d, IV (in the vein) from D1 to D5.
223765245|NCT02870907|DRUG|Vincristine|1, 5 mg/m²/d, IV at D1.
223765246|NCT02870907|RADIATION|Orbital irradiation|45 Grays (Standard or external beam radiotherapy).
223765247|NCT02870907|DRUG|Carboplatin|160 mg/m²/d, IV from D1 to D5.
223765248|NCT02870907|DRUG|Vincristine|1,5 mg/m²/d, IV at D22 and D26
224229534|NCT04403048|PROCEDURE|Provisional DCB approach PCI procedure|Intervention is explained in detail in group description
224229535|NCT04403048|PROCEDURE|Standard provisional approach PCI procedure|Intervention is explained in detail in group description
224229536|NCT05755425|DEVICE|CPAP|CPAP will be delivered with a CPAP valve with venturi flow system with full-face mask. Treatment will start with CPAP set at 10cmH2O and FiO2 60% to target a SpO2 ≥90% or PO2 ≥60mmHg and then adjusted according to SpO2, respiratory distress and clinical tolerance
224229537|NCT05755425|DEVICE|HFNO|HFNO will be applied initially at maximal settings: 100% FiO2, flow rate 60 L/min and temperature 37C . Within 1 to 2 h, the HFNO settings should be titrated based on patients respiratory rate (\<25-30 per minute), SpO2 (92-96%) and comfort
224229538|NCT04161144|DRUG|sirolimus|Rapamycin (sirolimus) is administered in three 5mg oral capsules. This administration happens once during the first visit.
224229539|NCT04161144|DRUG|Placebo|Placebo is administered in three 5mg oral capsules. This administration happens once during the first visit.
224229540|NCT04954014|DRUG|Bevacizumab|Patients will receive best available treatment (BAT) for COVID-19 plus a single dose of bevacizumab calculated as 7,5 mg/kg diluted in 250cc of saline solution during 90 minutes.
224229541|NCT04954014|DRUG|BAT|Patients will receive best available treatment for COVID-19.
223765249|NCT02870907|DRUG|Cyclophosphamide|300 mg/m²/d, IV from D22 to D26.
223765250|NCT02870907|DRUG|Carboplatin|560 mg/m²/d, IV at D1.
223765251|NCT02870907|DRUG|Etoposide|100 mg/m²/d, IV from D1 to D5
223765252|NCT02870907|DRUG|Carboplatin|160 mg/m²/d,IV from D1 to D5
223765253|NCT02870907|DRUG|Thiotepa|15 mg, intrathecal Thiotepa injection at D1.
223765254|NCT02870907|DRUG|Vincristine|1,5 mg/m²/d), IV at D22
223765255|NCT02870907|DRUG|Cyclophosphamide|1000 mg/m²/d, IV from D22 à D24.
223641560|NCT01599624|BEHAVIORAL|Progressive Muscle Relaxation (PMR)|Progressive muscle relaxation is the systematic tensing and relaxing of 16 different muscle groups, starting with one's toes and ending with one's head (Jacobson, 1938; Conrad \& Roth, 2007). PMR users are instructed to inhale as they tense the muscles and exhale as they release the tension. Participants will participate in a two-hour PMR training. PMR participants will be given iPADs with a video recording that guides the user through working each muscle group while instructing them to focus on positive thoughts and feelings and breathing techniques. PMR program participants will each be assigned an iPad to take home with them and practice the techniques for a period of two months.
223641561|NCT04040348|BIOLOGICAL|Approximately 100 million cells allogeneic hMSC|Umbilical cord-derived, allogeneic hMSC administered intravenously at a dose of approximately 100 million cells per infusion.
223641562|NCT06483113|DEVICE|Delefilcon A spherical soft contact lenses|Silicone hydrogel contact lenses prescribed for single use, daily disposable wear (less than 24 hours while awake) for the correction of ametropia (myopia or hyperopia)
223641563|NCT06483113|DEVICE|Delefilcon A toric soft contact lenses|Silicone hydrogel contact lenses prescribed for single use, daily disposable wear (less than 24 hours while awake) for the correction of ametropia (myopia or hyperopia) with astigmatism
223641564|NCT06483113|DEVICE|Delefilcon A multifocal soft contact lenses|Silicone hydrogel contact lenses prescribed for single use, daily disposable wear (less than 24 hours while awake) for the correction of ametropia (myopia or hyperopia) with presbyopia
223641565|NCT06408649|DEVICE|Lehfilcon A spherical contact lenses|Silicone hydrogel contact lenses for the correction of ametropia (myopia or hyperopia)
224229542|NCT04473508|DRUG|Local administration of ropivacaine|Erector nerve block with local ropivacaine injection in addition with conventional anesthesia for spine surgery
224229543|NCT04473508|DRUG|Local administration of placebo (saline solution)|injection of saline solution in addition with conventional anesthesia for spine surgery
224229544|NCT03267342|BEHAVIORAL|One-on-one financial counseling|Clients will be given access to one-on-one financial counseling, provided by trained peer specialists, initially working under the guidance of the project director. The Consumer Financial Protection Bureau's Your Money, Your Goals: Financial Empowerment Toolkit for Social Services Programs (21) will be used as a reference during counseling sessions, with a view to developing a manual based on clients' existing experiences and coping strategies, such that the desired behavior change is manageable, realistic, and based on real-life possibilities rather than idealized circumstances which may be far from the reality of people's lives. Counseling will in all cases be responsive to clients' particular needs and concerns, rather than following a predetermined sequence.
224229545|NCT03267342|BEHAVIORAL|Peer support group|Support groups, facilitated by peer specialists and guided initially by the project director, will be offered for clients interested in specific financial issues such as budgeting, managing benefits, wise spending, planning and saving. The peer support groups will focus on enabling clients to share their own experiences with finances.
224229546|NCT03267342|BEHAVIORAL|Supported access to mainstream banking services|Interested clients will be helped to open bank accounts at banks of their choice, and to manage associated tools such as Automatic Teller Machine (ATM) cards and online bill pay. Clients will also be advised regarding use of non-bank financial products such as prepaid cards and check cashers. Representatives from both bank and non-bank providers will be invited to come in and talk with clients about the services they offer, and clients will also be invited to visit the facilities to be guided around the available services.
224229547|NCT03267342|BEHAVIORAL|A matched savings account|Clients will have the option of joining a savings club, which will combine group meetings, facilitated by a peer specialist under the initial guidance of the project director, and regular savings deposits towards specified goals. Clients will be offered a limited savings match as an incentive to achieve their savings goal (for example, the savings club will offer a 50% match on any money saved within a specified time period towards a specific goal, up to a maximum of a $100 match).
224319458|NCT02032680|OTHER|Treatment as usual (TAU)|Treatment as Usual (TAU) is considered the usual care at the VA. Participants assigned to be in the Treatment as Usual arm will complete assessments at all data collection time points, (baseline, 6, 12, and 15 months.) These participants will not receive any study treatment but will continue to receive their treatment as usual through the VA.
224319459|NCT03594760|DIAGNOSTIC_TEST|18F-DCFPyL IV injection|Patient will receive one injection of 18F-DCFPyL and undergo PET-CT imaging
224319460|NCT03619265|DIETARY_SUPPLEMENT|Prickly pear juice|3 ounces daily for 8 weeks.
224319461|NCT03619265|DIETARY_SUPPLEMENT|Pear-flavored juice|3 ounces daily for 8 weeks.
224319462|NCT02404116|OTHER|Metacognitive Therapy|Participants will receive treatment which focus's on helping reduce excessive thinking about health,
224319463|NCT02404116|OTHER|Wait List|Individuals are on a waiting list
223641566|NCT06408649|DEVICE|Lehfilcon A toric contact lenses|Silicone hydrogel contact lenses for the correction of ametropia (myopia or hyperopia) with astigmatism
223641567|NCT05912257|BEHAVIORAL|Structured perioperative nutrition and exercise|Nutrition counseling by a RD and prescribed a eucaloric diet with protein intake of 1.5 g/kg/d and at least 30 g high quality protein per meal. They will be provided 30 grams of high quality protein twice a day, Hydroxymethylbutyrate, and vitamin D3 and multi-vitamin. Participants will attend nutrition and exercise group classes 6-8 weeks. Following following discharge home, participants will be instructed to resume group classes and protein, HMB, vitamin-D and MVS regimen, and exercise classes will resume when cleared by surgical team.
223641568|NCT05912257|BEHAVIORAL|Nutrition and Exercise Counseling|nutrition counseling by study Registered Dietitian (RD) and prescribed a eucaloric diet with protein intake of 1.0 g/kg/d and a one a day multivitamin/multimineral supplement. They will be counseled on exercising three times per week and given access to exercise videos. Following following discharge home, participants will be instructed to resume protein recommendations and MVS, and exercise recommendations will resume when cleared by surgical team.
223641569|NCT04190862|DRUG|E-CEL UVEC|Injection of E-CEL UVEC
223641570|NCT02122328|PROCEDURE|Sequential laser photocoagulation of communicating vessels.|
224319464|NCT03086486|DRUG|Pretomanid|200mg tablets
224319465|NCT03086486|DRUG|Linezolid|Scored 600mg tablets
224319466|NCT03086486|DRUG|Bedaquiline|100mg tablets
224319467|NCT03086486|DRUG|Placebo Linezolid|Scored 600 mg tablets
224319468|NCT02207712|DEVICE|Noctura 400 Eye Mask|The intervention is the wearing of the eye mask
223641571|NCT02122328|PROCEDURE|Selective laser photocoagulation of communicating vessels|
223641572|NCT00661050|PROCEDURE|Alternative Medicine|
223641573|NCT00661050|PROCEDURE|Tai Chi instruction and class participation or walking exercise and sitting meditation|
223641574|NCT01087463|DEVICE|Quantum|Treatment of humerus fracture (according to the mentioned indications) with the Quantum Intramedullary Nailing System.
223641575|NCT00034502|DRUG|ALIMTA|
223641576|NCT00034502|DRUG|irinotecan|
223641577|NCT01185210|DIETARY_SUPPLEMENT|Placebo|Subjects will receive placebo (mix of sugar and salt) 20 minutes before consuming fructose.
223641578|NCT01185210|DIETARY_SUPPLEMENT|Alanine|Subjects will receive 12.5 grams of alanine 20 minutes before consuming fructose.
223641579|NCT01185210|DIETARY_SUPPLEMENT|Alanine|Subjects will receive 25 grams of alanine 20 minutes before consuming fructose.
223641580|NCT00608374|DRUG|chlorambucil|
223641581|NCT00608374|DRUG|fludarabine phosphate|
223641582|NCT00608374|PROCEDURE|quality-of-life assessment|
223641583|NCT05842902|BEHAVIORAL|mPRISM|PRISM is a brief, 1:1, skills-based resilience intervention delivered in-person by trained layperson coaches. PRISM's development was based on iterative research within the AYA oncology population, stress and coping theory, resilience theory, and successful cognitive-behavioral and mindfulness interventions. mPRISM is a digital version of the PRISM program with no in-person delivery. mPRISM includes coping skills modules: managing stress, goal-setting, cognitive reframing, and meaning-making.
223641584|NCT02324348|PROCEDURE|Deferred coronary stenting|Abciximab (0.25㎎/㎏) intracoronary injection will be performed to all possible patients after guidewire has passed culprit lesion. Additional manual thrombus aspiration or balloon angioplasty can be performed by operator to achieve TIMI Ⅲ flow. When TIMI Ⅲ flow is achieved after these procedures, patient will be randomized to immediate stenting or deferred stenting group. In deferred stenting group, second stage procedure (stent implantation) will be done at 5 to 7 days after TIMI Ⅲ flow has achieved.
224229548|NCT02442856|DEVICE|Thigh Cuff|
224319469|NCT02207712|DRUG|Ranibizumab|Standard ranibizumab treatment only
223641585|NCT02324348|PROCEDURE|Immediate coronary stenting|Abciximab (0.25㎎/㎏) intracoronary injection will be performed to all possible patients after guidewire has passed culprit lesion. Additional manual thrombus aspiration or balloon angioplasty can be performed by operator to achieve TIMI Ⅲ flow. When TIMI Ⅲ flow is achieved after these procedures, patient will be randomized to immediate stenting or deferred stenting group. In immediate stenting group, stenting will be done immediate after achieving TIMI III flow during initial procedure.
223641586|NCT02815501|BIOLOGICAL|blood samples|for the determination of thyroid hormones (TSH, FT3, FT4 ) and antibodies against the thyroid (anti TPO antibodies and anti thyroglobulin)
223641587|NCT01281800|PROCEDURE|Gemcitabine in long infusion|"TREATMENT A:~Day 1: Pemetrexed 500 mg/m2 Cisplatin 75 mg/m2 Cycle every 3 weeks. Supportive treatment: folic acid \[Tifol 400 mg tbl (350-1000 mg), beginning 7 days before CT, every day, till 3 week after the KT\], vitamin B-12 \[OH-B12 i.m., beginning in 7 days before CT, than at 3. + 6. cycles of KT + 9. week after the KT\], corticosteroids, hydration, antiemetic, LMW heparin as thromboprophylaxis.~In the absence of progression, 4 cycles of chemotherapy with pemetrexed and cisplatin will be given, followed by two additional cycles of pemetrexed as monotherapy.~TREATMENT B:~Days 1 and 8: gemcitabine 250 mg/m2 in 6 hours day 2: cisplatin 75 mg/m2 Cycle every 3 weeks. Supportive treatment: corticosteroids, hydration, antiemetics, LMW heparin as thromboprophylaxis.~In the absence of progression, 4 cycles of chemotherapy with gemcitabine and cisplatin will be given, followed by two additional cycles of gemcitabine alone as monotherapy."
223765256|NCT02870907|PROCEDURE|Cytapheresis|Cytapheresis for peripheral blood stem cells collection after the primary or the secondary courses of Vincristine- Cyclophosphamid.
223765257|NCT02870907|DRUG|Carboplatin|AUC : 7/d, IV from D-8 to D-6.
224229549|NCT00000909|DRUG|Aldesleukin|
224229550|NCT02207621|DRUG|AR-13324 Ophthalmic Solution 0.02%|1 drop once daily (QD), PM, OU
224229551|NCT02207621|DRUG|Timolol maleate Ophthalmic Solution 0.5% BID|1 drop BID, AM/PM, OU
224229552|NCT02207621|OTHER|Placebo|1 drop QD, AM, OU
224319470|NCT04736225|OTHER|Insulin Self-Titration Education Program|The program contents of instruction included blood glucose self-monitoring, types of insulin, insulin self-administration, insulin dose titration, hyperglycemia or hypoglycemia self-management, diet, and exercise.a 20-min one-on-one training session from a nurse on how to self-titrate the insulin dose. The participants were taught to monitor their before-breakfast and before-dinner blood glucose levels at home and adjust their insulin doses accordingly.
223641588|NCT06219408|BEHAVIORAL|CIH Stepped Care|"A mindfulness-based and meaning-based stepped care approach for treating co-occurring chronic pain and PTSD that will begin with less intensive treatment (e.g., psychoeducation) and, based on patient response and preference, will be stepped up to more intensive treatment when appropriate."
223641589|NCT03371043|OTHER|users of analgesic medications|Children and adolescents who are users of analgesic medications, 2012 to 2015
223641590|NCT02879409|DRUG|Metformin|Initial: 500 mg once daily; dosage may be increased by 500 mg weekly; maximum dose: 2,000 mg once daily
223641591|NCT02879409|DRUG|Gliclazide|"There is no fixed-dosage regimen for the management of diabetes mellitus with gliclazide. Dose will be individualized based on frequent determinations of blood glucose during dose titration and throughout maintenance. The 30 mg modified-release tablet equals the 80 mg immediate-release tablet.~Immediate-release tablet: Initial: 80 mg twice daily; titrate based on blood glucose levels. Usual dosage range: 80 to 320 mg/day (maximum dose: 320 mg/day); dosage of ≥160 mg should be divided into 2 equal parts for twice-daily administration.~Modified-release tablet: Initial: 30 mg once daily; titrate in 30 mg increments every 2 weeks based on blood glucose levels. Maximum dose: 120 mg once daily"
223765258|NCT02870907|DRUG|Etoposide|250 mg/m²/d, IV from D -5 to D-3.
223765259|NCT02870907|DRUG|Thiotepa|300 mg/m²/d, IV from D-5 to D-3.
223765260|NCT02870907|PROCEDURE|Peripheral bood stem cell transplantation|at D0
224229553|NCT02207621|DRUG|AR-13324 Ophthalmic Solution 0.02% BID|1 drop BID, AM/PM, OU
224229554|NCT00967642|DRUG|Intravenous Insulin|continuous intravenous insulin/24h guided by glycemia (Optium, Abbott) evaluated hourly, targeting values lower than 110 mg/dl
224229555|NCT00049036|BIOLOGICAL|rituximab|Given IV
224229556|NCT00049036|DRUG|etoposide|Given IV
223641592|NCT02879409|DRUG|Sitagliptin|Oral: 100 mg once daily
223641593|NCT02879409|DRUG|Liraglutide|SubQ: Initial: 0.6 mg once daily for 1 week; then increase to 1.2 mg once daily; may increase further to 1.8 mg once daily if optimal glycemic response not achieved with 1.2 mg daily.
223641594|NCT02879409|DRUG|Pioglitazone|"Oral, Monotherapy or combination therapy: 15-30 mg once daily~Patients with heart failure (NYHA Class I or II): Monotherapy or combination therapy: 15 mg once daily"
223641595|NCT02879409|DRUG|Dapagliflozin|5mg once daily increasing to 10mg once daily as required
223641596|NCT02879409|DRUG|human insulin|insulin dosage and administration according to physician
223641597|NCT00790842|DRUG|Lenalidomide|Given by mouth days 1-21 of a 28-day cycle. There is a 7 day rest (days 22-28). Continue until disease progression or unacceptable toxicity.
223641598|NCT00790842|DRUG|Dexamethasone|40 mg given by mouth days 1, 8, 15 and 22 of a 28-day cycle. Continue until disease progression or unacceptable toxicity.
223641599|NCT00790842|DRUG|Anticoagulants|Anticoagulation consisted of aspirin at either 81 mg/day or 325 mg/day at the physician's discretion. Heparin, low molecular weight heparin, or coumadin could be used if the patient was intolerant to aspirin.
223641600|NCT06499064|PROCEDURE|mHealth|"Follow-up and treatment of patients in the mHealth arm will be based on a comprehensive solution for the care and monitoring of chronic patients, modelled and tested in chronic HF patients. This is the PIRENe platform, previously described and evaluated in HF patients. It is a digital solution, external to the centre's information systems (external platform). However, it has some special features in its design in terms of remote monitoring, educational tools, among others, expressly conceived and designed for patients with ATTR-CM. This platform allows the provision of multichannel service and monitoring of patients through:~1. Patient monitoring of: Biometric data and symptom report.~2. Generation and management of warning alarms notified to the professionals assigned to each patient in case one of the following situations occurs.~3. Follow-up via videoconference."
223641601|NCT05462522|DRUG|RO7303509|RO7303509 will be administered as SC injection monthly, as specified in each treatment group.
223765261|NCT01532362|DRUG|Apricoxib|As part of the trial, forty eligible subjects will be randomly assigned to receive Apricoxib 400 mg orally once daily or no drug intervention for a 7 day period (Days 0-6) prior to surgical resection of the lung tumor but between the two surgeries.
224229557|NCT00049036|DRUG|doxorubicin hydrochloride|Given IV
223641602|NCT05462522|DRUG|Placebo|RO7303509 matching placebo will be administered as SC injection monthly, during the MAD stage.
223641603|NCT04022213|DRUG|131 I-omburtamab|Single dose of IP RIT administered through an IP catheter with 131 I-omburtamab at 80mCi/m2
223641604|NCT04022213|RADIATION|WAP-IMRT|Group A participants will receive WAP-IMRT approximately 2-4 weeks after completing IP RIT. A dose of 30 Gy will be delivered in 20 fractions of 1.5 Gy given once daily, 5 days per week over the course of approximately 4 weeks
223641605|NCT00419952|DRUG|Budesonide/formoterol (SYMBICORT) pMDI|Symbicort pMDI 160/4.5 ug x 2 actuations twice daily (BID)
223641606|NCT00419952|DRUG|Budesonide HFA pMDI|Budesonide HFA pMDI 160 ug x 2 actuations BID
223641607|NCT06221306|PROCEDURE|Dental implant: NDI|Placement of narrow diameter implants (NDI) (3.3) in the dentoalveolar ridge
223641608|NCT06221306|PROCEDURE|Dental implant: SDI|Placement of standard diameter implants (SDI) (4.1) in the dentoalveolar ridge with simaltenous bone augmentation
223641609|NCT06400693|OTHER|Endotracheal Intubation|Preparation of all necessary equipment for endotracheal intubation
223641610|NCT06400693|OTHER|Supraglottic Airway|Preparation of all necessary equipment for laryngeal mask
223641611|NCT06480201|DRUG|Ketamine|Ketamine infusion amount is dictated by BMI, sex, and age.
223765262|NCT01587326|DRUG|Escitalopram|escitalopram 10 mg/d to 20 mg/d
223765263|NCT04295538|DRUG|Elezanumab|Solution for infusion; Intravenous (IV)
223641612|NCT06480201|OTHER|Saline|Saline infusion amount is dictated by BMI, sex, and age.
223641613|NCT06184776|OTHER|Lumbar Stiffness Disability Index|The development and evaluation of the Turkish version of the Lumbar Stiffness Disability Index (LSDI) are planned. After ensuring the eligibility of adult participants included in the study, language validity will be established for the Turkish version of LSDI, and internal consistency will be assessed using Cronbach's alpha coefficient. Additionally, the test-retest reliability of the index will be evaluated by reapplying it to participants with a one-week interval. For external structure validity, LSDI scores will be correlated with Oswestry Disability Index, Functional Reach Test, and goniometric measurements. The study will include demographic data and measurements to examine the eligibility of individuals with specific medical conditions for the intervention.
224229558|NCT00049036|DRUG|vincristine sulfate|Given IV
224229559|NCT00049036|DRUG|prednisone|Given orally
224229560|NCT00049036|DRUG|cyclophosphamide|Given IV
223765264|NCT04295538|DRUG|Placebo|Solution for infusion; Intravenous (IV)
223765265|NCT02307552|DEVICE|UreScan|The TUUS Foley/catheter will be inserted into the urethra via the ultrasound visualization onto the apex prostate, and the ultrasound extended through the urethra until the bladder neck and stopped. This is recorded twice automatically, and this should take 5-10 minutes for completion, and the prostate ultrasound data stored in memory. The ultrasound/subject interaction is now complete, and the study should add 30-60 minutes to the preoperative visit. No local or general anesthesia is used. The subject will be given 500 mg of Ciprofloxacin as a preventative measure against a urinary tract infection.
224229561|NCT00049036|OTHER|laboratory biomarker analysis|Correlative studies
224229562|NCT03029533|DRUG|Leuprolide Acetate|DWJ108J, SC injection, once(Day1)
224229563|NCT03029533|DRUG|Leuprolide Acetate|Leuplin DPS Inj, SC injection, once(Day1)
224229564|NCT05287139|OTHER|Quality of Life|Assessment of patients' quality of life using the EORTC QLQ-C30 and EORTC-QLQ-BR 23 questionnaires
224229565|NCT01645800|DRUG|Lysozyme hydrochloride|LYL 90mg capsule: Three times daily for 52 weeks.
224229566|NCT01645800|DRUG|Placebo|Matching Placebo capsule: Three times daily for 52 weeks.
224229567|NCT01836848|PROCEDURE|measuring cerebral perfusion by NIRS with ICG|application of a bolus of 5mg indocyanine green (ICG) in 3ml saline 0,9% i.v. in 1 second and measuring the ICG turnover with the near-infrared-spectroscopy (NIRS)
223641614|NCT03126591|DRUG|Olaratumab|Administered IV
223641615|NCT03126591|DRUG|Pembrolizumab (KEYTRUDA®)|Administered IV
223641616|NCT01269021|DRUG|mycophenolate mofetil plus lower dose of Prednisone|MMF 1.0-1.5g/d\*6mons Prednisone 0.4-0.6 mg/kg/d
223641617|NCT01269021|DRUG|Prednisone in full dose|0.8-1mg/kg/d
223641618|NCT05651061|BIOLOGICAL|SS109|27 patients are enrolled in cohorts ,and will continue to be followed up until 28 days after SS109 administration for evaluating safety, PK/PD and immunogenicity.
223641619|NCT04277338|DRUG|SPECT|One single injection of 99mTc-HE3-G3, followed by gamma camera imaging directly postinjection and after 2, 4, 6 and 24 hours.
223641620|NCT02158546|DRUG|ALKS 5461|Sublingual tablet, taken once daily (in addition to open-label treatment with a commercially available antidepressant)
223641621|NCT02158546|DRUG|Placebo|Sublingual tablet, taken once daily (in addition to open-label treatment with a commercially available antidepressant)
223641622|NCT03863106|OTHER|Metastatic gastroenteropancreatic and lung neuroendocrine tumors|Patients with metastatic GEP and lung NETs will be selected via the Cancer Database on NEN of the Hospices Civils de Lyon. Data from this database will be matched with the French nationwide claims and hospitalization database (SNDS database), allowing access to the corresponding healthcare resources use and their related costs. Data regarding clinical and tumour characteristics and treatments patterns will be collected via the database between 1 January 1990 and 31 of December 2017.
223641623|NCT00244569|DRUG|13C-Methacetin|
223641624|NCT00244569|DEVICE|Breath ID Machine|
224229568|NCT03106090|OTHER|educational materials|The eSCP includes a treatment summary section, a section detailing follow-up and test recommendations, a section on anticipated and potential side effects, as well as additional information specific to their experience/concerns. They will receive a patient education notebook outlining symptoms and their management that is tailored to those that the subject may be likely to experience during their survivorship care trajectory.
224229569|NCT01758302|BEHAVIORAL|Simple physical task|Participants are asked to complete a 1-time simple physical task that is not challenging nor novel (moving small objects across a room).
224229570|NCT01758302|BEHAVIORAL|Complex physical task|Participants are asked to complete a 1-time physical task that is low intensity but somewhat complex (involves a novel request to move objects in a way that is challenging and requires some coordination).
224229571|NCT01758302|OTHER|Cookies|Participants are asked to taste test chocolate chip cookies
224229572|NCT01758302|OTHER|Vegetables|Participants are asked to taste test raw celery or radishes
224229573|NCT01758302|BEHAVIORAL|No physical task|As a control, for 2 of the arms, participants are not asked to engage in a physical task
224229574|NCT01775033|OTHER|Multicomponent intervention|Develop, implement and evaluate an organized system of regional pediatric emergency care in rural Western Pennsylvania using four pillars: education, community, protocolized triage and transport, and telemedicine.
223641625|NCT02351817|DEVICE|Test A|Ostomy appliance
223641626|NCT02351817|DEVICE|Test B|Ostomy appliance
224229575|NCT01090765|DRUG|TRC105|
224229576|NCT05372081|OTHER|Digital platform|Patients will be randomized (1:1) in the way they will receive or not any assistance from the digital platform.
224229577|NCT03260764|DEVICE|short term Multifocal Contact Lenses|wearing Multifocal Contact Lenses for one week
224229578|NCT03260764|DEVICE|short term Bifocal Spectacles|wearing Bifocal Spectacles for one week
224323335|NCT05639400|DEVICE|Thoraflex Hybrid|Thoraflex Hybrid is designed for the open surgical repair of aneurysms and/or dissections in the aortic arch and descending aorta with or without involvement of the ascending aorta. There are two types of Thoraflex Hybrid implants, namely the Plexus 4 and the Ante-Flo versions. Each patient receives one Thoraflex Hybrid device (either the Plexus 4 or Ante-Flo).
224229579|NCT03260764|DEVICE|long term Multifocal Contact Lenses|wearing Multifocal Contact Lenses for one year
224229580|NCT03260764|DEVICE|long term Bifocal Spectacles|wearing Bifocal Spectacles for one year
224229581|NCT02939274|DRUG|Verteporfin|
224229582|NCT02939274|DEVICE|Continuous Low-Irradiance Photodynamic Therapy (CLIPT)|
224229583|NCT00421174|DRUG|Etanercept|Etanercept will be given eight doses of study drug over a 4-week period. The initial dose of etanercept will be administered intravenously on Day 0, with subsequent doses administered subcutaneously (SQ). Dosing will be administered twice weekly over 4 consecutive weeks. Additionally, patients in both arms will receive corticosteroids (2 mg/kg/day) Day 0 through Day 7, with subsequent taper as clinically indicated.
224229584|NCT00421174|DRUG|Placebo plus corticosteroid|"Patients will receive a total of eight doses of placebo over a 4-week period. The initial dose of placebo will be administered intravenously on Day 0, with subsequent doses administered subcutaneously (SQ). Dosing will be administered twice weekly over 4 consecutive weeks. The placebo will be the inert diluent used for the etanercept formulation.~Additionally, patients in both arms will receive corticosteroids (2 mg/kg/day) Day 0 through Day 7, with subsequent taper as clinically indicated."
223641627|NCT02351817|DEVICE|Baseline|Ostomy appliance
223641628|NCT01194856|DRUG|Atazanavir/ritonavir|300 mg orally once daily with Ritonavir 100mg orally once daily for 96 weeks
223641629|NCT01194856|DRUG|Efavirenz|Maintain dosage - 600 mg orally QHS for 96 weeks
223641630|NCT02488915|DEVICE|EmboTrap® Revascularization Device|
223641631|NCT00998361|PROCEDURE|Allogeneic hemopoietic stem cell transplant|administration of 15 mg/kg of thiotepa + 140 mg/sqm of melphalan followed by infusion of allogeneic hemopoietic stem cell
223641632|NCT05370638|OTHER|Rounding on discharging patients first|Rounding on discharging patients meant that the attending physician and accompanying team (i.e. if they were working with advanced practice providers or learners) would prioritize seeing any patients that were going to discharge that day. The attending could break protocol if needed for patient care purposes and this was tracked each day.
223641633|NCT06277427|DRUG|PRG-1801 （CAR-T against BCMA）|Patients with refractory LN and ANCA-associated vasculitis will be treated with PRG-1801
223641634|NCT02726568|DRUG|Icotinib|375 mg Tid (1125 mg per day) until intracranial PD.
223641635|NCT02726568|RADIATION|SRS|If intracranial PD, then the subjects get stereotatic radiosurgery （30Gy/3f) combined with Icotinib 375mg Tid.
223641636|NCT01910363|DRUG|A2NTX|Intramuscular injection of the botulinum toxin preparation in 300 units (mouse LD50) into tibialis posterior and medial gastrocnemius muscles on the affected side.
223765266|NCT03969355|OTHER|Mortality|Patients who died during PICU stay
223765267|NCT01666340|OTHER|Exercise intervention|Group asked to perform exercise at a given moderate intensity for a set time
223765268|NCT01666340|OTHER|Exercise intervention|High intensity exercise
223765269|NCT01683591|PROCEDURE|High-resolution impedance manometry test|The test was performed as general guideline for high-resolution impedance manometry test. The parameter was obtained and analyzed using the Chicago classification for the liquid swallows with Takasaki's modification for pharyngeal function monitoring. Swallowing pattern and aspiration risk were defined using real-time assessment of high-resolution impedance manometry test.
223765270|NCT05484401|DRUG|Ibuprofen 200Mg Oral Cap|2 x 200mg Liquid Capsules once in 12 hours
224229585|NCT04572100|OTHER|Transoral Robotic Surgery (TORS) or Radiotherapy|Participants assigned to this group will receive transoral robotic surgery (TORs) or radiotherapy. Radiotherapy is given once a day for 5 weeks. A percentage of subjects who undergo surgery may need further radiotherapy with or without chemotherapy based on the results of the surgery. TORs is surgery in which a robot with arms is used to remove cancer from hard-to-reach areas of the mouth and throat.
224229586|NCT04572100|OTHER|Chemotherapy and Low-Dose Radiotherapy|Participants assigned to this group will receive 5 weeks of chemotherapy combined with low- dose radiotherapy.
224229587|NCT04572100|OTHER|Chemotherapy and High-Dose Radiotherapy|Participants assigned to this group will receive 7 weeks of chemotherapy combined with high- dose radiotherapy.
224229588|NCT04572100|DRUG|Paclitaxel|This drug will be combined with carboplatin during induction therapy for 9 weeks.
224229589|NCT04572100|DRUG|Carboplatin|This drug will be combined with paclitaxel during induction therapy for 9 weeks.
224229590|NCT02462824|BEHAVIORAL|Home-based exercise intervention|The home-based exercise intervention focuses on walking exercise and consists of two phases. Phase I (weeks 1-4) consists of four on-site visits to an exercise facility, where participants will meet the telephone coach, learn to use the Fitbit activity monitor, become familiar with the study website, learn behavioral skills necessary for long-term adherence to home-based exercise, and get started on their exercise program. Phase II (weeks 5-36) is entirely home-based and includes a) use of the Fitbit for self-monitoring; and b) regularly scheduled telephone calls from the study telephone coach to monitor and support participants' home exercise activity' c) use of the study website; d) optional group telephone calls.
224229591|NCT02380846|OTHER|White rice|Control - white rice
224229592|NCT02380846|OTHER|Rice with chicken breast|Treatment 1 - steamed white rice with steamed chicken breast
224323336|NCT05639400|DEVICE|RelayPro NBS|The RelayPro NBS Thoracic Stent-Graft System is an endovascular device intended for treatment of thoracic aortic pathologies such as aneurysms, pseudoaneurysms, dissections, penetrating ulcers and intramural hematoma.
223641637|NCT01910363|DRUG|BOTOX|Intramuscular injection of the botulinum toxin preparation in 300 units (mouse LD50) into tibialis posterior and medial gastrocnemius muscles on the affected side.
223641638|NCT05353270|BEHAVIORAL|Yoga|Yoga sessions will be completed 5 times per week for 4 weeks.
223641639|NCT05353270|BEHAVIORAL|Waitlist control|Waitlisted participants will maintain their normal exercise and diet for 4 weeks. After follow up testing at week 4, participants will be rerandomized to the yoga condition.
223641640|NCT05907863|OTHER|Use of intracardiac echocardiography|intracardiac echocardiography guided slow pathway ablation in patients with AVNRT
223641641|NCT01477398|DEVICE|QED-100|Use of the QED-100 results in mild hypercapnia during emergence
223641642|NCT04254003|DEVICE|DT1 Toric contact lenses|Delefilcon A contact lenses for the optical correction of astigmatism in people with healthy eyes with or without refractive ametropia (myopia or hyperopia)
223641643|NCT04254003|DEVICE|AO1DfA contact lenses|Senofilcon A contact lenses for the optical correction of astigmatism in people with healthy eyes with or without refractive ametropia (myopia or hyperopia)
223641644|NCT00264186|DRUG|LPS 2 ng/kg intravenous (IV) bolus|
223641645|NCT00264186|DRUG|rhSOD 82,000 IU (8.2 mg)/min intraarterially|
223641646|NCT00264186|DRUG|Norepinephrine 60, 120, 240 pmol/min intraarterially over 5 min/dose level (two times; pre-dose and +3.5 hrs)|
223641647|NCT00264186|DRUG|Acetylcholine 6.25, 12.5, 25 nmol/min intraarterially over 3 min/dose level (two times; pre-dose and +3.5 hrs)|
223641648|NCT00264186|DRUG|Glyceroltrinitrate (nitroglycerine) 4, 8, 16 nmol/min over 3 min/dose level (two times; pre-dose and +3.5 hrs)|
223641649|NCT02976038|DRUG|elamipretide|40 mg, subcutaneous injections (in the abdomen) daily for the shortest of the following: 260 weeks; regulatory approval and commercial availability of elamipretide in the subject's respective country; or termination of the clinical development for elamipretide in subjects with PMD.
223641650|NCT06267755|OTHER|Extracorporeal Shockwave therapy|the patients will receive Extracorporeal Shockwave therapy sessions by 600 impulses with 1.6 bar pressure at a frequency of 8 Hz on site of the upper trapezius
223641651|NCT06267755|OTHER|Traditional physical therapy|the patients will receive Traditional physical therapy in the form of Integrated neuro-muscular inhibition technique + posture correction and scapular stabilization exercises.
223641652|NCT03632889|BEHAVIORAL|GoToSleep Program|For the control group only the sleep hygiene handout will be given in this arm. For the computerized group a sleep hygiene handout along with assess to the GoToSleep online program.
223641653|NCT03228550|DIETARY_SUPPLEMENT|Efamol Active 50+|1000 mg docosahexaenoic acid, 160 mg eicosapentaenoic acid, 20 µg B12, 1 mg folic acid, 124 mg phosphatidylserine, 240 mg ginkgo biloba standardized leaf extract and 20 mg vitamin E
223641654|NCT03228550|BEHAVIORAL|Aerobic exercise|Static exercise cycle
223641655|NCT03228550|DIETARY_SUPPLEMENT|Placebo multinutrient|Placebo multinutrient supplement
223641656|NCT03755310|DRUG|Suvorexant|First week: 10 mg tabs; Second week: 10-20 mg tabs
223641657|NCT03755310|DRUG|Placebo|Equivalent dosage, route of administration and dose regimen
223641658|NCT01919502|DEVICE|Semi-quantitative urine pregnancy test|
223641659|NCT01046396|DRUG|adapalene cream 0.1% and adapalene lotion 0.1%|adapalene cream 0.1% - apply once daily on one side of the face for 3 weeks
223641660|NCT01046396|DRUG|adapalene lotion 0.1%|adapalene lotion 0.1% - apply once daily on the opposite side of the face for 3 weeks
223641661|NCT04396418|BEHAVIORAL|Education|Randomization between two groups at site level. One cluster with education and one without.
223641662|NCT02638194|OTHER|Active smoking of Tobacco Hookah for 2 hours|
223641663|NCT02638194|OTHER|Exposure to tobacco hookah second hand smoke|
223641664|NCT02638194|OTHER|Visit a win bar|Participants will visit a wine bar for food and/or drinks
223641665|NCT01208207|DRUG|Part I - etoricoxib 60 mg|etoricoxib 60 mg oral tablet once daily for 6 weeks
223641666|NCT01208207|DRUG|Part I - etoricoxib 90 mg|etoricoxib 90 mg oral tablet once daily for 6 weeks
223641667|NCT01208207|DRUG|Part I- naproxen 1000 mg|naproxen 500 mg oral tablet twice daily for 6 weeks
223641668|NCT01208207|DRUG|Part I - Placebo to naproxen 500 mg|Placebo to naproxen 500 mg oral tablet twice daily for 6 weeks
223641669|NCT01208207|DRUG|Part II- etoricoxib 60 mg|etoricoxib 60 mg oral tablet once daily for 20 weeks
223641670|NCT01208207|DRUG|Part II- etoricoxib 90 mg|etoricoxib 90 mg oral tablet once daily for 20 weeks
223641671|NCT01208207|DRUG|Part II- naproxen 1000 mg|naproxen 500 mg oral tablet twice daily for 20 weeks
223641672|NCT01208207|DRUG|Part I - Placebo to etoricoxib 60 mg|Placebo to etoricoxib 60 mg oral tablet once daily for 6 weeks.
223641673|NCT01208207|DRUG|Part I - Placebo to etoricoxib 90 mg|Placebo to etoricoxib 90 mg oral tablet once daily for 6 weeks.
224229593|NCT02380846|OTHER|Rice with fish|Treatment 2 - steamed white rice with steamed fish
224319471|NCT05501535|DEVICE|ND:YAG LASER|The standard therapy for PCO is now Nd: YAG laser posterior capsulotomy, which has a success rate of more than 95%. The neodymium: yttrium-aluminum-garnet (Nd:YAG) laser, with a wavelength of 1064 nm, is a solid-state laser that may destroy ocular tissues by achieving optical breakdown with a brief, high-power pulse .Ionization or plasma production occurs in the ocular tissue as a result of optical breakdown. This plasma production subsequently generates acoustic and shock waves, which destroy tissue. Because of its cost-effectiveness, speed, and lack of invasiveness, it is the chosen treatment option in PCO
223641674|NCT01208207|DRUG|Part II- Placebo to etoricoxib 60 mg|Placebo to etoricoxib 60 mg oral tablet once daily for 20 weeks.
223765271|NCT05484401|DRUG|Ibuprofen 200Mg Oral Tablet|2 x 200mg Tablets once in 12 hours
224229594|NCT02380846|OTHER|Rice with egg white|Treatment 3 - steamed white rice with egg white
224229595|NCT02380846|OTHER|Rice with beancurd|Treatment 4 - steamed white rice with steamed beancurd
224229596|NCT03763110|DEVICE|Photo Activated Disinfection|Photoactivated disinfection (PAD) is based on the interaction of a photosensitive antibacterial agent and a light source. It uses a nontoxic dye \[named photosensitizer PS\] and low-intensity visible light. In oxygen presentation, these combine to produce some cytotoxic species. The PS molecules attach to bacteria membrane
224229597|NCT03763110|DRUG|antibiotic paste|"An antibiotic mixture composed of ciproﬂoxacin, metronidazole, and minocycline, known as triple antibiotic paste (TAP) or 3mix, has been the most widely used medicament, This goes back to the studies by Hoshino et al.1996"
224229598|NCT02072759|DIETARY_SUPPLEMENT|Carnitine supplement|"Carnitine supplement (oral ingestion with meals)~Total dosage of 2g carnitine per day for 36 days.~* 1 carnitine supplement at breakfast (500mg)~* 1 carnitine supplement at lunch (500mg)~* 2 carnitine supplements at diner (2x 500mg=1000mg)"
224319472|NCT04957238|OTHER|ARBORea decision-making tool|Online ARBORea decision-making tool will guide the use of physical restraints in ICU patients based on objective information on neurological status, level of equipment related to critical illness, and patient's family presence and involvement in patient's surveillance.
224319473|NCT04979936|PROCEDURE|laparoscopic cholecystectomy|
223641675|NCT01208207|DRUG|Part II - Placebo to etoricoxib 90 mg|Placebo to etoricoxib 90 mg oral tablet once daily for 20 weeks.
223641676|NCT01208207|DRUG|Part II- Placebo to naproxen 500 mg|Placebo to naproxen 500 mg orally twice daily for 20 weeks.
223641677|NCT01469169|DRUG|Iloprost (Ventavis inhaled, BAYQ6256)|2.5 μg or 5.0 μg BAYQ6256 per inhalation session (Inhalation session is to be conducted 6 to 9 times per day with dosing intervals of at least 2 hours.)
223641678|NCT03086811|BEHAVIORAL|Mother Infant Feeding Interaction very early training|"weekly training meetings on 4 topics:~1. What - proper nutrition and supplements for solid feeding phase (dietitian); What - the meaning of feeding to mother and infant (social worker).~2. Who - feeding skills - knowledge and actual practices~3. From anxiety to serenity - knowledge concerning growth patterns and common physical and emotional issues troubling parents of infants 4-12 months old.~4. Prevention of obesity and emotional eating - practical advise and tips."
223641679|NCT01928212|DEVICE|Optical coherence tomography|
223641680|NCT00724698|DRUG|Desloratadine|Desloratadine 5 mg once daily
223641681|NCT04984746|DIETARY_SUPPLEMENT|No Intervention: (control group)|Lettuce without any biofortification was assigned to each participant belonging to the control group which ate 100gr every day for 10 days
223641682|NCT04984746|DIETARY_SUPPLEMENT|Experimental: intervention group|"Molybdenum Iodine group~Lettuces with Iodine and Molybdenum biofortification was assigned to each participant belonging to the intervention group which ate 100gr of each type of lattuce every day for 10 days"
223641683|NCT06371781|DIAGNOSTIC_TEST|Serum Netrin-4, Resistin and Sfrp-5 level measurement|Measurements of the levels of these molecules in the serum samples of the study group will be done with the ELISA kit.
223641684|NCT03193099|OTHER|Brain imaging|Volume, DWS and DTI
223641685|NCT03193099|OTHER|Neurological assessments|UHDRS
223641686|NCT03193099|BEHAVIORAL|Psychological assessments|STAI (Spielberger state and Trait Anxiety Inventory) A and B, BDI-II (Beck Depression Inventory), MINI (Mini-International Neuropsychiatric Interview) and MINI-SEA (mini Social cognitive and Emotional Assessment)
223765272|NCT05484401|OTHER|Placebo Liquid Capsule|2 x Liquid Capsules once in 12 hours
223765273|NCT05484401|OTHER|Placebo Tablets|2 x Tablets once in 12 hours
224229599|NCT02072759|DIETARY_SUPPLEMENT|Placebo|
224229600|NCT03476720|DEVICE|Pad positioning according to a manufacturer's diagram|Placement of defibrillation pads according to the diagram
224229601|NCT04835948|DRUG|single dose of Anti-thymocyte globulin|Used anti-thymocyte globulin (ATG) in a single dose of 3 mg/kg for immunosuppression induction in the immediate postoperative period
224319474|NCT04979936|PROCEDURE|percutaneous cholecystostomy|
224319475|NCT03959111|OTHER|Stimulation at Location 1|Stimulation parameters will include 1) density wave adjusted to 20Hz with less than 1 ms pulse width, 2) intensity adjusted based on the tolerance of the patient (moderate tolerable stimulation without pain), and 3) treatment will be applied 1 time per day, 5 times per week for four weeks (on-site tVNS treatment plus self-administration at home).
223641687|NCT03193099|BEHAVIORAL|Behavioural assessments|Computerized game
223641688|NCT03672708|DIAGNOSTIC_TEST|Cresyl violet|cresyl violet is applicated at the concentration of 0.15% via a spraying catheter to visualize cellular and tissue architecture in the pCLE
223641689|NCT03122509|DRUG|durvalumab|1500 mg durvalumab via IV infusion
224229602|NCT04868448|BIOLOGICAL|Covid-19 vaccines|Observation of individuals who received one or more doses of covid-19 vaccines.
224229603|NCT05394168|BIOLOGICAL|HLX53|There are 5 preset dose groups, namely 30mg/QW, 150mg/QW, 400mg/QW, 1000mg/Q3W and 2000mg/Q3W, administered by intravenous infusion.
224229604|NCT05313204|OTHER|Moderate-intensity cardiovascular exercise|The participant will be instructed to first rest quietly for 10 minutes wearing a heart rate monitor. The participant will then be instructed to exercise at an intensity of 60-70% heart rate reserve (HRR) for 20 minutes. The participant may choose any kind of cardiovascular exercise modality they prefer, as long as the exercise will meet the prescribed intensity. Following exercise, participants will rest quietly for 10 minutes wearing the heart rate monitor.
224229605|NCT02396381|OTHER|THS 2.2|Ad libitum use of THS 2.2 in an ambulatory setting for 26 weeks
224229606|NCT02396381|OTHER|CC|Ad libitum use of CC in an ambulatory setting for 26 weeks
224229607|NCT05583812|DRUG|FB2001 for inhalation|FB2001 once or twice daily inhalation
224229608|NCT05583812|DRUG|FB2001 for inhalation placebo|FB2001 placebo once or twice daily inhalation
224229609|NCT06461208|DRUG|Encapsulated FMT|Encapsulated Faecal Microbiota Transplant
224229610|NCT06461208|OTHER|Placebo|The placebo product contains microcrystalline methylcellulose. It is supplied as a size 0, Swedish Orange Delayed-Release capsule (DRCap) and provides a complete match with regards to the appearance (e.g., dimensions, colour) to the FMT capsules.
224229611|NCT03197064|DRUG|Fosaprepitant 150 mg|Antiemetic used to prevent nausea and vomiting after general anesthesia.
224229612|NCT00509964|DRUG|irinotecan|Patients will receive irinotecan 150 mg/m2 intravenously on day 1 every 2 weeks.
224229613|NCT00509964|DRUG|ILF|Patients will receive irinotecan 150 mg/m2 intravenously, in combination with leucovorin and 5-fluorouracil, on day 1 every 2 weeks.
224229614|NCT00356200|DRUG|Fluphenazine Decanoate|"Fluphenazine decanoate marketed by APP Pharmaceuticals (25 mg/mL, 5 mL vial) was used in this study. This was an ascending dose study with the first cohort of 5 subjects dosed at 10 µg/mL, followed by 5 subject dosed in the second cohort at 100 µg/mL. Note: APP Pharmaceuticals is the name of the pharmaceutical company; APP is not an acronym."
224229615|NCT00356200|DRUG|Placebo|The sterile placebo (sesame oil with 1.2% (w/v) benzyl alcohol) was prepared at the University of Iowa, Division of Pharmaceutical Services, a FDA registered pharmaceutical manufacturing facility.
224229616|NCT05857839|OTHER|Myofascial release|Patients will get myofascial release technique to sacroiliac joint area for up to 600 seconds and total treatment sessions will be 12 in 4 weeks
224229617|NCT05857839|OTHER|pelvic Support belt|The support belt will be worn for less than two to three hours at a time and it will be used 4 times a week
224229618|NCT03164603|DRUG|NLG802|Indoleamine 2,3-Dioxygenase (IDO) Inhibitor
224229619|NCT00628823|DIETARY_SUPPLEMENT|Gluten-free diet|Gluten containing foods removed from diet
224229620|NCT06367569|DIAGNOSTIC_TEST|Screening for trilateral retinoblastoma with MRI|The diagnostic accuracy of the screening program, baseline screening with MRI followed by follow-up of suspicious pineal glands in heritable retinoblastoma patients.
224229621|NCT06374030|PROCEDURE|Endotracheal intubation|All endotracheal intubations carried out in the emergency department of one of the participating hospitals in the time period 01-01-2019 - 31-12-2023
224229622|NCT06201273|BEHAVIORAL|High-Intensity Interval Training|This High-Intensity Interval Training (HIIT) program, structured to span 12 weeks, incorporates three sessions per week. Each session comprises 8 to 10 exercise intervals on a cycle ergometer. During these intervals, participants are required to reach an intensity level between 8 and 10 points, based on the modified Borg scale, which ranges from 1 to 10 points. A typical interval involves 1 minute of intensive pedaling, followed by a 2-minute rest period without any activity. To facilitate progressive development, the resistance of the cycle ergometer will be adjusted biweekly to increase the pedaling challenge. Despite these adjustments, participants should consistently maintain their effort intensity within the 8 to 10 point range on the modified Borg scale for each interval.
224319476|NCT03959111|OTHER|Stimulation at Location 2|Stimulation parameters will include 1) density wave adjusted to 20Hz with less than 1 ms pulse width, 2) intensity adjusted based on the tolerance of the patient (moderate tolerable stimulation without pain), and 3) treatment will be applied 1 time per day, 5 times per week for four weeks (on-site tVNS treatment plus self-administration at home).
224319477|NCT03536611|DRUG|dabigatran|dabigatran etexilate 110 mg bid + aspirin 100 mg qd + clopidogrel 75 mg qd for 1 month followed by dabigatran 110mg bid + clopidogrel 75mg/d for at least 5 months
223641690|NCT03122509|DRUG|tremelimumab|75 mg tremelimumab via IV infusion
223641691|NCT03122509|RADIATION|Radiotherapy (RT)|Radiotherapy (RT) will be performed using external beam ionizing radiation as standard therapy in accordance with institutional standard practice.
224319478|NCT03536611|DRUG|warfarin|warfarin (according to clinical routine monitoring of INR, maintain the therapeutic range at 2.0-3.0) + aspirin 100 mg qd + clopidogrel 75 mg qd for 1 month followed by warfarin + clopidogrel 75mg/d for at least 5 months
224319479|NCT00687830|DRUG|Polyethylene Glycol afternoon|Prescribed the standard dose of 4L or 1 Gallon Polythylene Glycol to be taken over a period of 4 hours with water. For Evening prep, between 5PM and 9PM
224319480|NCT00687830|DRUG|Polyethylene Glycol morning|Prescribed the standard dose of 4L or 1 Gallon Polythylene Glycol to be taken over a period of 4 hours with water. For Morning prep, between 6AM and 10AM
224319481|NCT04808973|DRUG|Dolutegravir plus lamivudine in a FDC|All participants will receive an ART regimen composed by Lamivudine plus Dolutegravir in a single pill (FDC)
224319482|NCT00426101|DRUG|Dexamethasone|"10 mg/m2 daily wk 1-2 5 mg/m2 daily wk 3-4 2.5 mg/m2 daily wk 5-6 1.25 mg/m2 daily wk 7 Steroids tapered wk 8~If continuation:~Pulses every 2nd wk, 10 mg/m2 for 3 days"
223641692|NCT03122509|PROCEDURE|ablation|Ablation will be performed percutaneously under image guidance as standard therapy at the discretion of the interventional radiologist in accordance with institutional standard practice.
223641693|NCT02769585|BEHAVIORAL|Self-hypnosis|Self-hypnosis
223641694|NCT02769585|BEHAVIORAL|CDE training|standard CDE training for an obese diabetic
223641695|NCT04458870|BEHAVIORAL|Acceptance and Commitment Therapy|Participants will receive 10 weekly individual acceptance and commitment therapy by a trained coach through zoom video-conferencing.
223641696|NCT02177032|BIOLOGICAL|Rabies vaccine|"12 doses of the PCEC rabies vaccine, administered ID (0.1mL for each injection) according to the 4-sites, 1-week regimen (i.e. 4 doses of vaccine; in both deltoids and anterolateral thigh areas, administered on days 1, 4, and 8)."
223641697|NCT02177032|BIOLOGICAL|Rabies vaccines + Rabies immunoglobulins|"12 doses of the PCEC rabies vaccine, administered ID (0.1mL for each injection) to adults only, according to the 4-sites, 1-week regimen (i.e. 4 doses of vaccine; in both deltoids and anterolateral thigh areas, administered on days 1, 4, and 8). HRIG will be administered on day 1 (before the first dose of the vaccine) in a dose of 20 IU/kg body weight intramuscularly into the gluteal muscle."
223641698|NCT02177032|BIOLOGICAL|Rabies vaccine|"8 doses of the PCEC rabies vaccine, administered ID (0.1ml for each injection) according to the 2-sites, TRC, updated Thai Red Cross regimen (i.e. 2 doses of vaccine; in both deltoids, administered on days 1, 4, 8, and 29)."
223641699|NCT02177032|BIOLOGICAL|Rabies vaccines + Rabies immunoglobulins|"8 doses of the PCEC rabies vaccine, administered ID (0.1ml for each injection) to adults only, according to the 2-sites, TRC, updated Thai Red Cross regimen (i.e. 2 doses of vaccine; in both deltoids, administered on days 1, 4, 8, and 29). HRIG will be administered on day 1 (before the first dose of the vaccine) in a dose of 20 IU/kg body weight intramuscularly into the gluteal muscle."
223641700|NCT02692521|DIETARY_SUPPLEMENT|Human Milk|
223641701|NCT00665652|DRUG|Lenalidomide|Subjects will receive lenalidomide 25 mg per day for days 1-21 followed by 7 days rest (28-day cycle) for 12 cycles.
223641702|NCT05960071|PROCEDURE|protective lung strategy with recruitment manoeuvre (RM) - steady PEEP|protective lung strategy with recruitment manoeuvre (RM) every 30 minutes and steady PEEP (10) cm H2o in between RM till end of surgery.
223641703|NCT05960071|PROCEDURE|protective lung strategy with recruitment manoeuvre (RM) - decreasing PEEP|protective lung strategy with recruitment manoeuvre (RM) every 30 minutes and decreasing PEEP (15, 10, and 5) cm H20 (10 minutes for each level) in between RM till end of surgery.
223641704|NCT04719078|DIAGNOSTIC_TEST|MRI of the chest|The study participants will obtain a MRI of the thorax with one of the institutions MR machines (Philips Achieva 1.5T, GE Discovery 3T, MRI Siemens Skyra 3T, and GE SIGNA Artist 1.5T). The study participant will be asked to lie in the MR scanner for about 30 minutes while the images will be acquired. The image acquisition with the above-mentioned MR machines is authorised in Switzerland and the application is done according to the product information.
223641705|NCT00378157|BEHAVIORAL|Joint attention intervention|Eight weeks with two daily sessions (20 minutes) with joint attention intervention in the pre-school.
223641706|NCT03862326|BEHAVIORAL|Exercise|From lying to sitting to active exercises with focus on the pelvic floor
223641707|NCT02321020|PROCEDURE|Radiofrequency maze procedure|Radiofrequency energy was used to create continous endocardial and epicardial lesions mimicking most of the left atrial incisions set as described in the Cox Maze III procedure. In the first 70 patients a monopolar technology was employed (Cardioblate Surgical Ablation Pen, Medtronic Inc, Minneapolis, MN, USA - cooled tip cardioblate pen, power ranging from 25 to 35 W), while in the subset of patients who underwent surgery after July 2005 a bipolar device was used (Cardioblate BP2 Irrigated RF Surgical Ablation System, Medtronic Inc, Minneapolis, MN, USA). The tip of both types of RF probe was irrigated with saline at room temperature at a flow rate of 4-6 ml/min.
223641708|NCT02321020|PROCEDURE|Transthoracic echocardiography|Contemporary to clinical follow up, all patients were evaluated with 2-dimensional transthoracic echocardiography by the same cardiologist at 3,6,12 and 24 months in order to specifically monitor left atrial contractility presence.
223641709|NCT01312103|BEHAVIORAL|Internet-based safety decision aid|"Participants will log into the the intervention website at baseline, 3 months, 6 months, and 12 months post baseline and receive:~* Setting of priorities for safety; a sliding bar allows participants to establish priorities by making pairwise comparisons of importance between factors.~* Danger Assessment; asks women to report on well-established risk factors for repeat violence and lethal IPV. A weighted scoring algorithm provides participants with their validated level of danger.~* Personalized action plan. Based on a participant's answers to the previous sections, a list of safety strategies with links to resources will be presented to her. The participant is given the option to print her results and the personalized plan."
224229623|NCT06201273|BEHAVIORAL|Resistance Training|"This training protocol, spanning a duration of 12 weeks, consists of three weekly sessions. In each session, participants will engage in Elastic Resistance Exercises (ERE) using Theraband CLX elastic bands. The focus will be on both concentric and eccentric contractions, maintaining an intensity level of 8 to 10 as per the OMNI-RES scale. Each exercise will be conducted for 1 minute, followed by a 2-minute rest period. Each exercise will be repeated three times within the session.~The specific exercises include bicep curls, seated horizontal rows, and wide squats. To ensure proper progression and adaptation, the exercise load will be adjusted biweekly. This adjustment will be based on the physiological adaptations of the subjects to the training, aiming to recalibrate the loads to new resistance thresholds and maintain a consistent intensity of 8 to 10 on the OMNI-RES scale for each exercise."
224229624|NCT04071600|DRUG|Neuropeptide Y|Intranasal
224229625|NCT04071600|OTHER|Placebo|intranasal
224229626|NCT02456532|DRUG|placebo|six months of nightly placebo
224229627|NCT02456532|DRUG|Zolpidem CR|six months of nightly zolpidem
224229628|NCT02456532|DRUG|Eszopiclone|
224229629|NCT01000337|DRUG|Sevoflurane|Sevoflurane concentration for induction of anesthesia 7-8%, for maintenance of anesthesia 2%.
224229630|NCT01000337|DRUG|Propofol|Propofol to induce anesthesia 2.5 mg/kg, for maintenance of anesthesia 6 mg/kg/h
224229631|NCT02173704|BIOLOGICAL|Bexsero®|Four doses administered in the anterolateral area of the right or left thigh.
224229632|NCT02173704|BIOLOGICAL|Routine vaccines|Infanrix-IPV + Hib®, Prevenar-13®, Engerix-B®, Priorix® and Varilrix® administered in the anterolateral area of the right or left thigh.
224229633|NCT03376594|DRUG|Benjakul Extract|30 patients taking Benjakul Extract dosage 100 mg capsule 3 times daily. before Breakfast, lunch and dinner for 42 days.
224229634|NCT03376594|DRUG|Loratadine|30 patients taking Loratadine dosage 10 mg capsule 3 times daily. before Breakfast, lunch and dinner for 42 days.
224229635|NCT04088214|PROCEDURE|Arthroscopic lateral soft tissue release|The arthroscopic lateral soft tissue release is performed using an inside-out approach via the 1MTPJ arthroscopy.
223641710|NCT01312103|BEHAVIORAL|Usual Care Safety Plan|"Participants will log into a control website at baseline, 3 months, 6 months and 12 months post baseline. Website will include the usual services provided to IPV survivors looking for safety planning resources on the internet. Participants will receive:~* Danger Assessment, will see risk factors associated with lethal violence, but will not receive a score or feedback.~* A brief emergency safety plan with links to national and state domestic violence resources as well as a suicide resource."
223641711|NCT01259414|OTHER|Solvent with specific gravity less than lipiodol|TACE with chemotherapy drugs (EADM 50mg, lobaplatin 50mg, and MMC 6mg)dissolved in distilled water and emulsified lipiodol followed embolization with polyvinyl alcohol particles (PVA)
223641712|NCT01259414|OTHER|Solvent with specific gravity equivalent to lipiodol|TACE with chemotherapy drugs (EADM 50mg, lobaplatin 50mg, and MMC 6mg)dissolved in water-soluble contrast medium and distilled water,then emulsified with lipiodol followed embolization with polyvinyl alcohol particles (PVA)
223641713|NCT03367520|BEHAVIORAL|StayQuit|StayQuit offers 3 meetings during hospitalization and up 13 telephone calls. StayQuit begins in the hospital with an assessment of motivation to remain quit after discharge and a brief intervention to develop discrepancy between values and behaviors and generate change talk. Participants are also encouraged to try nicotine replacement therapy during the hospitalization and after discharge. Telephone counseling is brief and focused on managing withdrawal from nicotine, coping with cravings, and supporting use of NRT. The investigators will work with hospital staff as needed to ensure that nicotine replacement therapy is offered to participants during the inpatient stay and prescribed at discharge.
223641714|NCT06116669|DIETARY_SUPPLEMENT|Iron supplementation|Iron supplements as 100 mg oral iron as FeSO4 given daily
223641715|NCT06116669|BIOLOGICAL|MenACWY vaccine|MenACWY vaccination given on day 28 to all participants
224229636|NCT05378906|DRUG|DRV/COBI FDC|Participants will receive a single oral dose of DRV/COBI FDC tablet dispersed in water as per assigned treatment sequence.
224319483|NCT00426101|DRUG|Etoposide|"150 mg/m2 iv twice/wk (wk 1-2) 150 mg/m2 iv once/wk (wk 3-8)~If continuation:~150 mg/m2 iv, every 2nd wk"
224319484|NCT00426101|DRUG|Cyclosporin|"WK 1-8:~\- Aim at around 200 microgram/L (trough value). Start: 6 mg/kg daily (divided in 2 daily doses) wk 1, if kidney function is normal.~If continuation:~\- Aim for around 200 microgram/L. Monitor GFR."
224319485|NCT00426101|PROCEDURE|Intrathecal therapy|"If at 2 wks there are progressive neurological symptoms or if an abnormal CSF (cell count and protein) has not improved, then give 4 wkly intrathecal inj. Be aware that some pat may have increased intracranial pressure.~Methotrexate: \<1 yr 6 mg, 1-2 yrs 8 mg, 2-3 yrs 10 mg, \>3 yrs 12 mg. Prednisolone: \<1 yr 4 mg, 1-2 yrs 6 mg, 2-3 yrs 8 mg, \>3 yrs 10 mg."
224319486|NCT00426101|PROCEDURE|Stem cell transplant|The SCT procedure is up to the treating physician. However, a suggested regimen is provided.
224319487|NCT02447601|DRUG|PEX168|200µg,injected subcutaneously,once a week.
223641716|NCT06116669|BIOLOGICAL|COVID-19 vaccine|Johnson \& Johnson COVID- 19 (JJ COVID-19) vaccination given on day 28 to all participants
223765274|NCT03945500|DEVICE|Investigational Mobile Medical Software Application & IT Dashboard Application, FDA approved Bluetooth spirometer, FDA approved pulse oximeter|"Standardized Home Spirometry (SHS) Method consists of an Investigational Mobile Medical Application embedded into an Android Tablet, an FDA approved Bluetooth spirometer, an FDA approved pulse oximeter. HIPAA compliant data will be sent to an Investigational IT dashboard maintained at the Central Monitoring Institute Server.~Volunteers will train in-center or remotely \& perform baseline testing with the SHS method along with a baseline laboratory-based spirometry test (if practicable).~Pre-Surveillance Phase: Daily home spirometry method testing for 4 to 10 weeks to enable normal range calibration.~Surveillance Phase: At least weekly home spirometry method testing for 2-10 months of participation. Volunteers will maintain a test log during study team directed SHS software pathway functionality testing."
223765275|NCT00634647|DRUG|Satraplatin|80 mg/m\^2 days 1-5 of every 35 day cycle
223765276|NCT00634647|DRUG|prednisone|5 mg twice daily every 35 days
224229637|NCT05378906|DRUG|COBI|Participants will receive a single oral dose of COBI tablet as per assigned treatment sequence.
224319488|NCT02447601|DRUG|Simvastatin|40mg,oral,two times
224319489|NCT03252730|OTHER|WO 4260 Cosmetic Product for Topical Use|Application on the hair scalp at least once a day over four weeks
224323337|NCT04993859|DIAGNOSTIC_TEST|Non-invasive Urodynamic Test (niUDS)|A noninvasive urodynamics is a simple test used to evaluate urinary flow.
223641717|NCT06116669|OTHER|Placebo|matching placebo capsules given daily
224229638|NCT05378906|DRUG|DRV|Participants will receive single oral dose of DRV suspension as per the assigned treatment sequence.
224229639|NCT01989520|DRUG|Phase IIb formulation|Single oral dose 45mg AZD5069
223641718|NCT06116669|BIOLOGICAL|Typhim Vi vaccine|Typhim Vi vaccination given on day 28 to all participants
223641719|NCT01749215|DRUG|Topiramate|Experimental study drug
223641720|NCT01749215|DRUG|placebo|Placebo comparator
223641721|NCT01749215|BEHAVIORAL|Medical Management|Brief alcohol counseling
223641722|NCT00672321|GENETIC|gene expression analysis|
223641723|NCT00672321|GENETIC|mutation analysis|
223641724|NCT00672321|GENETIC|polymorphism analysis|
223641725|NCT00672321|OTHER|laboratory biomarker analysis|
223641726|NCT00672321|OTHER|questionnaire administration|
223641727|NCT00494793|PROCEDURE|VAWC and mesh mediated fascial traction|"The first period of 2-5 days only the abdominal VAWC dressing is applied. On day 3-10 a polypropylene mesh is sutured to the fascial edges, between the two layers of the VAWC system, and tightened.~The VAWC dressing is changed and the mesh tightened every 2-3 days, resulting in gradual approximation of the fascial edges.~Finally the mesh is removed and the fascia is closed"
223641728|NCT04579107|COMBINATION_PRODUCT|Contrast Enhanced Mammography|A modality for examining breast conditions which is already approved and used but the evaluation of its role in a recalled screening population is limited. Intravenous iodine contrast is given prior to the mammogram.
224229640|NCT01989520|DRUG|Putative phase III formulation|Single oral dose 45mg AZD5069
224229641|NCT01989520|DRUG|Slow dissolution variant 1|Single oral dose 45mg AZD5069
224229642|NCT01989520|DRUG|Slow dissolution variant 2|Single oral dose 45mg AZD 5069
224229643|NCT01989520|DRUG|Test treatment E|Tablet formulation E, 45 mg (intermediate dissolution variant) of AZD5069
223641729|NCT02556177|PROCEDURE|MRI|MRI scanning
223641730|NCT01035801|DRUG|IN-105|Prandial Oral Insulin
223641731|NCT01035801|DRUG|Insulin Lispro Injection|Insulin Lispro Injection
223641732|NCT03739268|DRUG|Sevelamer|Sevelamer powder dissolved in water 1,600 mg three times a day for 17 days
223641733|NCT03739268|DRUG|Placebo|placebo powder dissolved in water 1,600 mg three times a day for 17 days
223641734|NCT04994288|BIOLOGICAL|Supaglutide injection|Supaglutide 1mg/0.5ml , 2mg/0.5ml ,3mg /0.5ml
223641735|NCT04994288|OTHER|placebo injection|placebo injection 0.5ml
223641736|NCT03262844|BEHAVIORAL|Conservative treatment|The conservative treatment group will be given diet and nursing guidance, then the drug treatment or physiotherapy will be given according to the conditions of patients. Patients with bladder dysfunction will be guided to perform routine intermittent catheterization with help of their parents.
223641737|NCT03262844|PROCEDURE|Capsule surgery|"In the multiple segments of the spine, articular facet joint and intervertebral disc will be resected to achieve the effect of decompression.~Specific surgical segments, osteotomy range, decompression degree of each patient needs to be designed individually."
223641738|NCT04852926|OTHER|Self-administered questionnaires|"6 self-administered questionnaires (EORTC-QLQ-C30, RSE, BIS, HAD, FSFI, DAS-4) completed by the patients at every usual follow-up consultation.~1 (FSFI) or 2 (MSHQ, PEP) self-administered questionnaires completed by the partner (respectively female or male) between every usual follow-up consultation.~Follow-up usual consultations :~* T0 (at inclusion) : before disease + since diagnosis~* C4 (chemotherapy course n°4)~* C6 (chemotherapy course n°6)~* M3 (3 months after chemotherapy)~* M6 (6 months after chemotherapy)~* A1 (1 year after chemotherapy)~* A2 (2 years after chemotherapy)"
223641739|NCT00951340|OTHER|Cognitive behavioral therapy (CBT)|15 weekly therapy sessions, the first hour of which will be devoted to standard CBT techniques
224229644|NCT03744416|OTHER|Counseling based on Epstein's active decision making|"Birth information leaflet. Based on the best evidence practice. Midwives' training on share decision making based on Epstein model. Pregnant intervention. The pregnant women will receive from the midwives the birth plan (BP) in the prenatal check at the health center, between the 24-28 weeks, to be completed at home. Later, on the visit between 29-33 weeks, the midwives will provide the birth information leaflet and carry out the counseling intervention based on shared decision making to the pregnant women. As well, midwives will deliver a second BP that pregnant woman will fill at home. On the prenatal check between 34 to 40 weeks, the midwife will save a copy of the latest BP. The midwife will instruct the woman to deliver the BP when she arrives to the hospital for birth."
224229645|NCT06141915|OTHER|Aerobic training|"patients will be engaged in aerobic training using treadmill three times per week, for 12 weeks. The exercise intensity will be 50-70% of each patient's maximum heart rate. Each exercise session will consist of three phases; five-minutes warming up phase in form of stretching exercises and walking on the treadmill at the slowest speed, 20-minutes conditioning phase in form of walking on the treadmill at 50% of participants' maximum heart rate in the first two weeks then progressed gradually to reach the 70% of maximum heart rate by the 12th weeks, and five-minutes cool down phase that will be constant as warming up phase. During the training, the patient's blood pressure, heart rate, and breathing pattern will be frequently monitored"
224229646|NCT06141915|OTHER|diet protocol|diet protocol
224229647|NCT00419926|DRUG|Enteric-coated mycophenolate sodium (Myfortic)|1440 mg/day for the standard dose. 2880 mg/day for the initial intensified dosage, reduced to standard level in two steps,i.e. reduction to 2160 mg/day after 2 weeks of treatment and to 1440 mg/day after 6 weeks of treatment.
224319490|NCT04812522|BEHAVIORAL|Clean Cut program|Clean Cut, is an adaptive, multimodal surgical infection prevention program that integrates perioperative process improvement and patient outcomes measurement using process mapping, training and improved management practices, and compliance with critical standards of surgical antisepsis
224319491|NCT02888730|DRUG|Tobramycin nebulized nasally|"Two sonic nebulizations per day will be realized by patients: morning and evening during 15 days. There should be a maximum of 12 hours between the 2 doses but shall not be less than 6 hours. The dosage should not be adjusted to body weight. All patients will receive one ampoule of tobramycin twice a dayAmpoules of tobramycin are filled by 5 ml containing 300 mg of tobramycin and 11.25 mg of sodium chloride. Bulb should be employed in nebulizer and administered by the inhalation route approximately 15 minutes to complete.Antibiotic retained for the study, tobramycin is manufactured by the Pharmacie à Usage Interne of the Henri Mondor Hospital. The study's product will be prepared with Base Tobramycin and excipients in accordance with TOBI's composition."
223641740|NCT00951340|BEHAVIORAL|Emotional processing and interpersonal therapy|15 weekly therapy sessions, the second hour of which will be devoted to interpersonal and emotional processing therapy techniques
223641741|NCT00951340|BEHAVIORAL|Listening therapy|15 weekly therapy sessions, the second hour of which will be directed by the participant's questions and discussion
224229648|NCT00419926|DRUG|Cyclosporine (Neoral)|cyclosporine microemulsion in galenic form capsules starting at twice a day for a dose of 8-10 mg/kg/day adjusted if necessary to achieve protocol specific target levels
223641742|NCT01526577|DRUG|LC23-1306|LC23-1306 10, 30, 100, 200, 400, 600 mg Placebo 10, 30, 100, 200, 400, 600 mg
223641743|NCT01526577|DRUG|placebo|LC23-1306 placebo
223641744|NCT01526577|DRUG|Ticagrelor|Ticagrelor 90mg
224229649|NCT00419926|DRUG|Prednisone|20 mg orally per day reduced according to center practice for a minimum dose of 5 mg/day.
223641745|NCT03008057|DIETARY_SUPPLEMENT|vitamin D|vitamin D supplement, 4000 IU tablet daily , one time a day, for 3 months
223641746|NCT03008057|DIETARY_SUPPLEMENT|vitamin D placebo|vitamin D placebo tablet (Containing starch powder), one time a day, for 3 months
223641747|NCT00458263|DRUG|Somatotropin growth hormone recombinant human|daily Sub Cutaneous injections
223641748|NCT03743181|OTHER|pharmaceutical care services|detection of drug therapy problems and investigation of the impact of clinical pharmacist interventions on the patient clinical outcome and quality of life
223641749|NCT00577304|DRUG|Nitroglycerin|Individual pouch applicators containing 0.5 grams of Topical AmphiMatrix with Nitroglycerin. Each dose contains 4.5mg of Nitroglycerin. Each dose is intended for topical usage on both hands up to five minutes before an anticipated Raynaud's attack or up to 5 minutes after the beginning of an actual Raynaud's attack. Limited to four applications per day; minimum of two hours between applications.
224229650|NCT03515395|BEHAVIORAL|Instruction to a computer game and motivation to use it|Patients who are willing to use the computer game and who have given written informed consent shall have three instruction sessions by a physiotherapist instructor. They will then asked to use the platform at least 3 times per week at their own discretion. The platform will be installed in the patient room, alternatively in a defined training room. The patient will be free to choose the time and duration of the gaming. This allows the patients to select times that do not interfere with their usual therapy schedule or visits (e.g. evening or weekends). Prior to discharge compliance with the platform will be monitored by analyzing the gaming data of each patient.
224229651|NCT01081561|DRUG|Riboflavin|Removal of the epithelium, riboflavin drops every 2 minutes for 30 minutes follow by UV light radiation and addition riboflavin drops every 2 minutes for 30 minutes. Some subjects will be randomized to recieve INTACS prior to treatment with riboflavin.
224229652|NCT02294656|DRUG|Ranibizumab,|Intravitreal injection of Ranibizumab as treatment for acute pseudophakic cystoid macular edema. Ranibizumab patients will receive three monthly Ranibizumab 0.5 mg/0.05 mL injections, followed by PRN dosing, as treatment for acute pseudophakic cystoid macular edema.
224229653|NCT02294656|DRUG|Triamcinolone acetonide|Intravitreal injection of Triamcinolone acetonide as treatment for acute pseudophakic cystoid macular edema. Triamcinolone acetonide patients will receive PRN Triamcinolone acetonide 4 mg/0.1 mL injections, every 3 months, as treatment for acute pseudophakic cystoid macular edema.
224229654|NCT02764008|DRUG|Bupivacaine|20 ml %0,25 bupivacaine
224229655|NCT02764008|DEVICE|Ultrasound|
224229656|NCT00004381|DRUG|tin mesoporphyrin|
224229657|NCT01695109|DRUG|Liraglutide|sc injections of 0.6 mg Liraglutide daily for three continuous days.
224229658|NCT01695109|DRUG|Placebo|0.9% NaCl, 0.2 ml
224229659|NCT04152928|DIAGNOSTIC_TEST|PET/MR scan|The patient will be positioned in the PET/MR with the field of view of the PET including the abdomen, and IV administration of 68Ga-DOTATATE will take place, with initiation of dynamic PET simultaneous with start of IV injection. Dynamic PET imaging will consist of 22 time frames of increasing durations (6 x 10, 3 x 20, 3 x 60, 5 x 180, and 5 x 300 s). The dynamic PET examination will be followed by a whole-body PET/MR scan ranging from the proximal femur to the base of the skull (3 min per bed position) starting at 60 min after injection. MR will be used for attenuation correction of the PET images of the abdomen/pelvis and whole-body. MR protocol will include three plane fast spin echo T2 weighted, DWI, DCE and ASL. The addition of PET/MR to the standard use of PET/CT adds no radiation exposure.
224229660|NCT05899790|OTHER|VR|"The first interview with the patients in the intervention group will be held in the afternoon, the day before the surgery. After completing the forms and scale the video containing information about the operating room environment will be applied to the patients through SG glasses and headphones.~Before the surgical intervention, patients admitted to the pre-operative waiting area from the clinic, the video containing information about the operating room environment will be watched by the patients through SG glasses and headphones."
224229661|NCT02374918|DEVICE|mTBI wavelength-1 bright light|6 weeks of daily light exposure, 30 minutes per morning
224229662|NCT02374918|DEVICE|mTBI wavelength-2 bright light|6 weeks of daily light exposure, 30 minutes per morning
224229663|NCT02374918|DEVICE|HC wavelength-1 bright light|30 minutes of light exposure
223641750|NCT00577304|DRUG|Topical AmphiMatrix|Individual pouch applicators containing 0.5 grams of Topical AmphiMatrix. Each dose is intended for topical usage on both hands up to five minutes before an anticipated Raynaud's attack or up to 5 minutes after the beginning of an actual Raynaud's attack. Limited to four applications per day; minimum of two hours between applications.
223641751|NCT05679752|OTHER|Facial PNF technique|Stimulation techniques used to facilitate the weak muscle groups
224229664|NCT02374918|DEVICE|HC wavelength-2 bright light|30 minutes of light exposure
223641752|NCT05679752|OTHER|Massage therapy|frictional massage to stimulate the weak muscle groups
224229665|NCT01968798|DRUG|Aspirin|100mg enteric-coated aspirin, taken daily
224229666|NCT01968798|DRUG|Placebo|100mg enteric-coated placebo, taken daily
224229667|NCT04842487|DRUG|R2-CHOP(Lenalidomide,Rituximab,cyclophosphamide，hydroxyldaunorubicin，Vincristine，Prednisone）)|Lenalidomide：25mg po QN,d1-10 Rituximab: 375mg/m2, ivdrip, d1 Cyclophosphamide: 750mg/m2, iv or ivdrip, d1 Hydroxyldaunorubicin: 50mg/m2, iv or ivdrip, d1 Vincristine： 1.4 mg/m2 , iv（max：2mg）, d1 Prednisone: 60mg/m2, po, d1-5 every 3 weeks was a course of treatment
224229668|NCT05751070|OTHER|Bowen Technique|"They would be receiving conventional treatment as follow:~Hot pack for 10 minutes TENS for 10 minutes Cervical isometrics 10 reps with 5 sec hold Additionally The Bowen treatment will be 15 to 20 Bowen moves with 2 mins gap between each set for total of 20 mins."
223641753|NCT02266511|DRUG|Flomax®, Norman II facility|
223641754|NCT02266511|DRUG|Flomax®, Nishine facility|
223641755|NCT02947789|PROCEDURE|Emergency surgery|Patients undergoing emergency surgery
223641756|NCT04186143|OTHER|Closed Cinetic Chain Exercises|Sit to stand, mini squat, anterior lunge, step up exercises are performed as Closed Cinetic Chain Exercises.
223641757|NCT04186143|OTHER|Open Kinetic Chain Exercises|Isometric quadriceps, isotonic quadriceps, hip extension and hip adduction exercises are performed as Open Kinetic Chain Exercises.
223641758|NCT04186143|OTHER|Control Group|Control Group was followed up by conservative treatment and home program for 12 weeks and they were asked to apply the home program three days in a week. Exercise brochure was handed out for home program. Quadriceps strength and harmstring stretch exercises were applied.
223641759|NCT03481686|DEVICE|Patients with injections of ESA|Patients will perform ASE injections themselves or by their spouses
223641760|NCT03619720|OTHER|Records|Respiratory records, Vocal records Video records Questionnaires
223641761|NCT01680471|DRUG|Midazolam 0.03mg/kg|"This group will be injected intravenous midazolam 0.03mg/kg five minutes before the end of surgery.~If emergence agitation is severe, the patients will be treated by psychological support from the parents or nurse and intravenous fentanyl 1㎍/kg."
223641762|NCT01680471|DRUG|Midazolam 0.05mg/kg|"This group will be injected intravenous midazolam 0.05mg/kg five minutes before the end of surgery.~If emergence agitation is severe, the patients will be treated by psychological support from the parents or nurse and intravenous fentanyl 1㎍/kg."
224323338|NCT04993859|DIAGNOSTIC_TEST|Urinary proteomic screen|Urine proteomics is a powerful platform to identify urinary excreted proteins and peptides in different stages of disease or therapy and to determine their quantity, functions, and interaction.
224319492|NCT02888730|DRUG|Physiologic serum nebulized nasally|"Two sonic nebulizations per day will be realized by patients: morning and evening during 15 days. There should be a maximum of 12 hours between the 2 doses but shall not be less than 6 hours. The dosage should not be adjusted to body weight. All patients will receive one ampoule of placebo (Nacl 0.9%) twice a day.Ampoules of placebo are filled by 5 ml containing of sodium chloride. Bulb should be employed in nebulizer and administered by the inhalation route approximately 15 minutes to complete. Placebo for the study is manufactured by the Pharmacie à Usage Interne of the Henri Mondor Hospital. Patients in placebo arm will receive 5ml of sodium chloride with the same color (light yellow transparent) as tobramycin"
224319493|NCT04944524|DRUG|Tofacitinib|"1. Tofacitinib 5mg twice a day for 12months;~2. Basic treatment with prednisone. (1) the initial dose of prednisone (or equivalent): 0.8mg/kg/day. (2) Glucocorticoids tapering: after two weeks' usage of initial glucocorticoids dose, glucocorticoids can be tapered if there's no disease activity (BVAS/WG=0) or at least 50% reduction of BVAS/WG and no new manifestations. Prednisone (or equivalent) was reduced to 10mg/d at the time of randomization."
224319494|NCT04944524|DRUG|Methotrexate|"1. Methotrexate (15 mg/week initially and progressively increased every week by 2.5 mg, to a maximum and optimal dose of 20 mg/week)~2. Basic treatment with prednisone. (1) the initial dose of prednisone (or equivalent): 0.8mg/kg/day. (2) Glucocorticoids tapering: after two weeks' usage of initial glucocorticoids dose, glucocorticoids can be tapered if there's no disease activity (BVAS/WG=0) or at least 50% reduction of BVAS/WG and no new manifestations. Prednisone (or equivalent) was reduced to 10mg/d at the time of randomization."
224319495|NCT04631536|DRUG|Atorvastatin + L-arginine + Folic acid + Nicorandil + Nebivolol|active Comparator: Endothelial dysfunction protocol + Standard of Care (dexamethasone, anticoagulation, vitamin c, zinc). Treatment to be continued until 14 days or discharge/death whichever occurs first. It includes: Nebivolol 5 mg PO daily, Sigmart 10 mg PO twice daily, Atorvastatin 40 mg PO daily, Folic Acid 5 mg PO daily, L-arginine 1000 mg PO 3 times daily.
223765277|NCT06271655|DEVICE|SPOTFIRE R Panel|The intervention involves the use of a rapid point-of-care multiplex PCR test (Spotfire) to identify etiology of patients with ARI. Specimen samples will be collected by research staff at the time of ED presentation. Upon collection, the sample will be promptly prepared for testing on the SPOTFIRE R Panel device. The device will be in the ED to facilitate testing and accelerate delivery of diagnostic results to clinicians. The time when the provider receives the results will be recorded to evaluate the incorporation of results in clinical decision making.
224229669|NCT05751070|OTHER|Graston technique|"They would be receiving conventional treatment as follow:~Hot pack for 10 minutes TENS for 10 minutes Cervical isometrics 10 reps with 5 sec hold Additionally The Graston treatment will be by using lubricant on the skin then a stainless steel instrument to relax the fascia and muscles. The frequency of the plastering and friction movements will be applied in 60 repetitions per minute for total of 20 mins."
224319496|NCT04631536|DRUG|Placebo|Placebo + Standard of Care (dexamethasone, anticoagulation, vitamin c, zinc)
224319497|NCT02708771|DRUG|Polyunsaturated fatty acids omega-3|4 daily capsules of polyunsaturated fatty acids omega-3, during 4 weeks. Each capsule contains: 460 mg eicosapentaenoic acid ethyl ester and 380 mg docosahexaenoic acid ethyl ester.
224319498|NCT02708771|DRUG|Placebo|4 daily capsules of similar appearance and flavor without active ingredient
223641763|NCT01680471|DRUG|Placebo|"This group will be injected intravenous normal saline five minutes before the end of surgery.~If emergence agitation is severe, the patients will be treated by psychological support from the parents or nurse and intravenous fentanyl 1㎍/kg."
223641764|NCT04454918|DRUG|TAK-906 Oral Capsule|TAK-906 capsule.
223641765|NCT04454918|DRUG|[14C]-TAK-906 Intravenous Infusion|\[14C\]-TAK-906 intravenous infusion.
223641766|NCT04454918|DRUG|[14C]-TAK-906 Oral Solution|\[14C\]-TAK-906 oral solution.
223641767|NCT06082362|OTHER|Collection of clinical and biological material|Collection of clinical and biological material (e.g., samples of semen, stool, urine, blood, buccal swab)
223641768|NCT04868786|DRUG|Mycophenolate Mofetil|Administer 15-20mg/kg of mycophenolate mofetil twice daily. Blood sampling for pharmacokinetics(PK) of mycophenolate mofetil will be performed in all patients who have taken the investigational drug for at least 3 days.
223641769|NCT02207777|PROCEDURE|Roux-en-Y gastric bypass surgery|A surgical procedure to help subjects lose approximately 16-18% (with a range of 16-25%) of their body weight.
223641770|NCT02207777|BEHAVIORAL|Low-calorie diet|Subjects will meet with a dietitian and/or behaviorist over approximately 6 months to lose approximately 16-18% (with a range of 16-25%) of their body weight.
223641771|NCT00649207|DRUG|ABT-888|Oral Capsules
223641772|NCT00649207|RADIATION|Whole Brain Radiation Therapy|15 fractions of 2.5 Gy over 3 weeks to a total dose of 37.5 GY or 10 fractions of 3.0 Gy over 2 weeks to a total dose of 30 Gy
223641773|NCT00389610|BIOLOGICAL|GVAX pancreas vaccine|Given intradermally
223641774|NCT04324437|OTHER|eRAPID online symptom monitoring in lung cancer|The eRAPID in lung cancer intervention is an online symptom monitoring system which provides tailored advice depending on the severity of symptoms reported. The system is integrated into the electronic medical record and results can be viewed by the medical team.
223641775|NCT03131570|DRUG|Secukinumab|Arms: Group 1 - Group 1 will receive Secukinumab at a dose of 300 mg with injections administered once weekly at baseline and at weeks 1, 2, 3, and 4 and then every 4 weeks for 6 months of period. In order to maintain the blind for the Group 2, Group 1 will receive placebo injections at weeks 13, 14, and 15. Group 1 will discontinue Secukinumab after 6 months of period being observed from week 25 to week 72 (48 weeks).
223641776|NCT03131570|DRUG|Placebo followed by Secukinumab|Arms: Group 2 - Group 2 will receive placebo injections corresponding to the Group 1 regimen until week 8 in order to maintain a double-dummy design until week 12. From week 12, Group 2 will receive Secukinumab with injections administered once weekly at week 12 and at weeks 13, 14, 15, and 16 and then every 4 weeks for 3 months of period. Group 2 will discontinue Secukinumab after 6 months of period being observed from week 25 to week 72 (48 weeks).
223641777|NCT05056233|OTHER|Systane Hydration lubricant eye drops|Sterile solution indicated for the temporary relief of burning and irritation due to dryness of the eye
223641778|NCT03405246|BEHAVIORAL|KIDFIT HEALTHY|KIDFIT Healthy intervention combines traditional in-person and electronic participant contacts.
223641779|NCT03405246|BEHAVIORAL|KIDFIT SAFE|KIDFIT Safe group will be referred to the KIDFIT Safe website for monthly Homestyles Safe Guides about safe home environments for raising children and related material emailed monthly to the moms.
223641780|NCT02288741|DRUG|Anthracycline/dexamethasone-based induction chemotherapy|4 cycles of anthracycline/dexamethasone-based chemotherapy
224229670|NCT01180244|DEVICE|Noninvasive cortical electrical stimulation|Subjects will receive 22 sessions of the intervention protocol, twice per week for a total of 11 weeks. The signal stimulation used in this study utilizes amplitude modulation to shape a high frequency carrier signal, nominally greater than 10 kilohertz, into the form of one or more low frequency components, nominally less than 40 hertz. Exact protocol is set in software and is the same for all participants in the active treatment arm.
223641781|NCT02288741|DRUG|Dexamethasone for control of symptoms|2 x 4 days of dexamethasone (day 1-4 and day 8-11: 40mg)
223641782|NCT02288741|DRUG|Tumor-reduction chemotherapy and stem cell mobilization|Ifosfamide (day 1-3: 1.900mg/m² iv), epirubicin (day 1: 75 mg/m² iv), etoposide (day 1-3: 120 mg/m² iv) and G-CSF (day 5 until end of apheresis: 5µg/kg sc)
224229671|NCT01180244|DEVICE|Sham treatment|Subjects in the placebo group will receive the exact same experience as those in the active treatment group. However, the device will not output any electrical stimulation signal.
224229672|NCT05713409|DIAGNOSTIC_TEST|Intestinal ultrasound|As part of the routine care, patients will undergo ileocolonoscopy at 6 months, IUS will be performed 3, 6, 12, 18, 24, 30 and 36 months (using B-mode and CDS) and at 3 and 6 months elastography will be performed on the neo-terminal ileum. Biomarkers (CRP and fecal calprotectine) will be measured according to routine care.
224229673|NCT04801966|DRUG|Trametinib|2 mg per day, continuous
224229674|NCT04801966|DRUG|Cobimetinib|60 mg/day for 21 days of a 28 day cycle
224229675|NCT04801966|DRUG|Binimetinib|45 mg/twice a day, continuous
224229676|NCT04801966|DRUG|Alpelisib|300 mg/day, continuous
224229677|NCT04801966|DRUG|Vemurafenib|960 mg/twice per day, continuous
224229678|NCT04801966|DRUG|Dabrafenib|150 mg/twicce per day, continuous
224229679|NCT04801966|DRUG|Encorafenib|450 mg/day, continuous
224229680|NCT04801966|DRUG|Palbociclib|125 mg/day, day 1-21 of a 28 day cycle
224229681|NCT04801966|DRUG|Olaparib|300 mg/twice per day, continuous
224229682|NCT04801966|DRUG|Ribociclib|600 mg/day, on day 1 -21 of a 28 day cycle
224229683|NCT04801966|DRUG|Abemaciclib|150 mg twice/day, continuous
224229684|NCT04801966|DRUG|Talazoparib|1 mg/day, on day 1 -28 of each 28 day cycle
224229685|NCT04801966|DRUG|Nivolumab|240 mg IV once every 2 weeks
224319499|NCT04189601|DIAGNOSTIC_TEST|Complement measurements|Blood and urine tests to assess the complement activation state
224229686|NCT04801966|DRUG|Atezolizumab|1200 mg IV on Day 1 of a 21 day cycle
224319500|NCT04947917|PROCEDURE|SpotTM Tattoo Ink|Ink injection
223641783|NCT02288741|PROCEDURE|Stem cell apheresis|stem cell apheresis in peripheral blood, sought amount of CD34-cells: 6 \* 10E6/kg
223641784|NCT02288741|DRUG|Tandem high-dose chemotherapy (melphalan)|Two cycles of high-dose melphalan (day -3 and day -2: 70mg/m²)
223641785|NCT02288741|PROCEDURE|Autologous peripheral blood stem cell transplantation|Two infusions of collected stem cells (day 0: 2\*10E6 CD34-cell/kg per transplantation)
223641786|NCT05579613|DEVICE|Interactive virtual reality device|The Kinect sensor is an infrared camera that can recognize the positions and motions of the player without the need for special controller. The console controls the various games .For the VR training, the Xbox Kinect, console, and monitor will set up in a dedicated space. The patient will placed 1.5-2 m away from the Kinect sensor.
223641787|NCT04569565|DEVICE|PleurX catheter|Placement of PleurX catheter for refractory cirrhotic ascites, with follow up monitoring
223641788|NCT00830440|DEVICE|EndoBarrier Device|NIH derived dietary, exercise and behavior modification 2005 guidelines. https://health.gov/dietaryguidelines/2005.asp and EndoBarrier Device for 12 weeks
223641789|NCT00830440|BEHAVIORAL|Diet & Lifestyle Counseling|NIH derived dietary, exercise and behavior modification 2005 guidelines. https://health.gov/dietaryguidelines/2005.asp
223641790|NCT03559374|OTHER|Vanadis NIPT system|A novel cost effective not NGS (next-generation sequencing) test, based on imaging single DNA molecules for high precision NIPT (non-invasive prenatal testing)
224229687|NCT04801966|DRUG|Pembrolizumab|200 mg IV on day 1 of a 21 day cycle
223641791|NCT01342861|DIETARY_SUPPLEMENT|Addition of protein (milky food in the breakfast)|The main purpose of this study is to evaluate the efficacy of additional protein (adding milky food to the breakfast) in order to deliver an optimized protein and energy intake of 15.75 g and 559 Kcal, respectively.
223641792|NCT04077216|DIETARY_SUPPLEMENT|Extra Virgin Olive Oil (EVOO)|This study used the FDA approved Doña Elena Extra virgin olive oil, which is readily available in local supermarkets. Its free acidity expressed as oleic acid was found to be 0.26%, comparable with the International food standards.15
223641793|NCT05513404|DIETARY_SUPPLEMENT|Honeyberry|To investigate changes in postprandial glucose and cognitive performance, after consumption of honeyberries grown in Scotland.
223641794|NCT05513404|DIETARY_SUPPLEMENT|Cherry|To investigate changes in postprandial glucose and cognitive performance, after consumption of cherries grown in Scotland.
224229688|NCT03353909|DEVICE|new crosslinked hyaluronan gel|At the end of the dilatation and curettage, new crosslinked hyaluronan gel was applied to the uterine cavity.
224319501|NCT04197778|DRUG|DDO-3055 tablet|DDO-3055 tablet, 2 single doses separated by 6 days.
223641795|NCT05513404|DIETARY_SUPPLEMENT|Raspberry|To investigate changes in postprandial glucose and cognitive performance, after consumption of raspberries grown in Scotland.
224229689|NCT00729859|DRUG|Acyline|Acyline 300 μg/kg injections every two weeks (2 doses) for 28 days + placebo Testosterone gel daily for 28 days + placebo oral anastrozole pill daily for 28 days
224229690|NCT00729859|DRUG|Acyline + Testosterone gel|Acyline 300 μg/kg injections every two weeks (2 doses) for 28 days + Testosterone gel 100 mg daily for 28 days + placebo oral pill 1 mg daily for 28 days
224229691|NCT00729859|DRUG|Acyline + testosterone gel + anastrozole|Acyline 300 μg/kg injections every two weeks (2 doses) for 28 days + Testosterone gel 100 mg daily for 28 days + oral anastrozole pill 1 mg daily for 28 days
224229692|NCT04646057|DEVICE|DuraSorb®|Monofilament Surgical Mesh
224229693|NCT01111110|DEVICE|anti-static then static|Albuterol using static chambers
224229694|NCT01111110|DEVICE|Static then anti-static chamber|albuterol with Static then anti-static chambers
224323339|NCT04993859|OTHER|Dysfunctional Voiding Symptom Score Survey (DVSS)|The Dysfunctional Voiding Symptom Score provides accurate and objective grading of voiding behaviors of children.
223641796|NCT03083834|DIAGNOSTIC_TEST|Cosyntropin stimulation test|At 0800h to 0900h, a 25 mm plastic intravenous line will be inserted in an antecubital vein. Then, 1 μg/ml ACTH aliquot stock solution will be pushed through, followed by 5 ml physiologic saline (0.9%). Serum cortisol and salivary free cortisol will measured just before ACTH administration and 30 minutes later.
223641797|NCT03699514|DEVICE|Brain Network Activation (BNA™) technology|"The BNA™ technology was developed and is utilized by ElMindA Ltd. The BNA Analysis System is cleared for use by qualified medical professionals for the post hoc statistical analysis of the human electroencephalogram (EEG), utilizing evoked response potentials (ERP'). This device is indicated for use in individuals 14 to 24 years of age. The BNA Analysis System is to be used with the auditory oddball task only."
223641798|NCT02622282|OTHER|Text Messages|Text messages will be sent one time per day. Text messages will include messages to motivate and inform participants on the importance of walking.
223765278|NCT05714527|DEVICE|Close-loop FiO2 controller|Close-loop FiO2 controller software option provides automated adjustment of the ventilator Oxygen setting to maintain the patient's SpO2 in a defined target range. When using the software option, the user defines the SpO2 target range, as well as the SpO2 emergency limits, and the device adjusts the FiO2 setting to keep the patient's SpO2 in the target range.
223765279|NCT05714527|DEVICE|Conventional|Conventional FiO2 adjustment by the clinician according to SpO2 values, by using the manual FiO2 knob.
224229695|NCT02623829|DRUG|Botulinum Toxin|50 units of botulinum toxin diluted in 1ml of normal saline will be administered.
224229696|NCT02623829|DRUG|Saline|1ml of normal saline will be administered
224229697|NCT03882164|DIAGNOSTIC_TEST|Blood-Bile Ratio of Tacrolimus|Diagnosis of early transplanted liver dysfunction to adjust Tacrolimus dose adminstered
224229698|NCT04195295|PROCEDURE|Regeneration of Intrabony Defects with Nano Hydroxyapatite Graft, Derived from Egg Shell along with Periosteum as Barrier Membrane|"* In group A, the full thickness mucoperiosteal flap will be elevated, which will be extended apically to expose sufficient amount of periosteum.~* Periosteal membrane will be separated from the full thickness mucoperiosteal flap and released by one vertical incision mesially and one horizontal incision apically.~* Posteriorly, the periosteum remained attached with the mucoperiosteal flap, so that blood supply could be maintained in the reflected periosteum.~* Then the graft material will be packed into the defect.~* Then periosteal membrane will be turned over the intrabony defect in such a way that the defect was completely covered by the periosteal membrane"
224229699|NCT04195295|PROCEDURE|Regeneration of intrabony defects using Egg shell derived nano hydroxyapatite (EnHA) as regenerative graft material|Full thickness mucoperiosteal flap will be raised and Vertical releasing incisions are used if necessary for better access to the surgical site. Then EnHA graft material will be placed into the defect before suturing the mucoperiosteal flap.
224229700|NCT04195295|PROCEDURE|Open flap debridement procedure in intrabony defects.|full thickness mucoperiosteal flap will be raised, entire granulation tissue will be removed from the defects, the pocket epithelium was curetted from the inner surface of the flap, and the roots were thoroughly scaled and planed by means of manual and ultrasonic instruments. Then the operative area will be irrigated with sterile saline. After that, the mucoperiosteal flaps will be sutured.
224229701|NCT03803566|OTHER|Pegboard practice|Practice of the grooved pegboard test
224229702|NCT03803566|OTHER|Force control practice|Practice performing steady muscle contractions
224229703|NCT01082653|BIOLOGICAL|autologous bone marrow-derived stem cells|All patients will receive a unique one-time intrathecal infusion of the cell product suspended in infusion medium.
224229704|NCT02197728|DEVICE|Use of the Colpo-Probe™ Vaginal Fornix Delineator or Hohl manipulator® during total laparoscopic hysterectomy|
224229705|NCT00479310|DRUG|Summers 5% L.A.|
224229706|NCT04546906|BIOLOGICAL|CD22 CAR-T|Biological: CD22 CAR-T; Drug: Cyclophosphamide,Fludarabine; Procedure: Leukapheresis
224229707|NCT04115449|DRUG|Dexmedetomidine|Injection dexmedetomidine 1 mcg /kg will be infused over a period of ten minutes
223641799|NCT02622282|OTHER|Phone Calls|Participants may receive a telephone call every two weeks for one month followed by once per month for two months.
223765280|NCT04293887|DRUG|Recombinant human interferon α1β|Saline needle 2ml + recombinant human interferon α1β10ug bid nebulization inhalation
223765281|NCT03345602|DIAGNOSTIC_TEST|serum S100B protein assay measurement|serum S100B protein assay measurement within the 3 hours after head trauma
223765282|NCT04705545|DEVICE|transpalatal arch group|transpalatal arch is a 1.0 mm stainless steel wire connecting the upper permanent first molar, with a U loop pointing posteriorly, soldered to the palatal side of the molar bands.
223765283|NCT04705545|DEVICE|Nance button|Nance button is a 1.0mm stainless steel wire connecting the upper permanent first molar, with a Nance button incorporated in the middle of the wire, soldered to the palatal side of the molar bands
224229708|NCT04115449|DRUG|normal saline|Normal Saline as a placebo will be infused over a period of ten minutes
224229709|NCT03349333|DRUG|pralatrexate|Pralatrexate will be administered at a dose of 30 mg/m2/week for 6 weeks followed by 1 week of rest in a 7-week cycle. Pralatrexate administration occurs once a week during week 1 through week 6 of each cycle.
224319502|NCT01006681|BIOLOGICAL|Focetria (Monovalent MF59-Adjuvanted vaccine)|"7.5 mcg Hemagglutinin H1/InfluezaA/California/7/2009 ,9.75 mg squalene MF59, 1.175 mg polysort80, 1.175 mg sorbitan trioleate~Intra muscular"
224319503|NCT01006681|BIOLOGICAL|Focetria (Monovalent MF59-Adjuvanted vaccine)|"7.5 mg Hemagglutinin H1/InfluezaA/California/7/2009, 9.75 mg squalene MF59, 1.175 mg polysirate 80, 1.175 mg sorbitan trioleate~Intramuscular injection"
224319504|NCT01006681|BIOLOGICAL|Focetria (Monovalent MF59-Adjuvanted vaccine)|Monovalent MF59-Adjuvanted vaccine
224319505|NCT05294250|DRUG|XC8|XC8 10 mg film-coated tablets, 3 discrete doses of 20 mg each separated by 7-day wash-out periods
224319506|NCT00801502|DIETARY_SUPPLEMENT|Oily fish consumption|Two portions of salmon per week from week 20 of pregnancy until giving birth
223641800|NCT02622282|OTHER|Handout|Handout includes information specific to participant's condition and ways to promote an active lifestyle.
223641801|NCT06029829|DRUG|Sintilimab|Any first-line treatment that includes immunotherapy、 Chemotherapy and Anti-angiogenesis Therapy
223641802|NCT04381364|DRUG|Ciclesonide Inhalation Aerosol|Ciclesonide 320 µg twice daily for 14 days.
223641803|NCT06131736|OTHER|Tabata Training|This training program, lasting about 20 minutes, was repeated three times a week for a total of 6 weeks.
223641804|NCT06131736|OTHER|Cluster Training|The movements were performed in 3 sets, each set containing 9 repetitions with 60-90 seconds of rest between each two sets.
223641805|NCT02307825|DRUG|Azithromycin|The drug will be taken three times a week for four months.
223641806|NCT02307825|DRUG|Placebo|The placebo will be taken three times a week for four months.
223641807|NCT00765206|DRUG|Omeprazole/sodium bicarbonate|Single dose of omeprazole/sodium bicarbonate per day for either 1 or 7 days.
223641808|NCT00765206|DRUG|omeprazole magnesium (20 mg equivalent)|Single dose of omeprazole magnesium per day for either 1 or 7 days.
223641809|NCT02416206|DRUG|BeEAM|BeEAM
223641810|NCT00942604|DRUG|PEP005 (ingenol mebutate) Gel|two day treatment
223641811|NCT00942604|DRUG|Vehicle gel|two day treatment
224229710|NCT03349333|DIETARY_SUPPLEMENT|Vitamin B12 and folic acid|The eligible subjects will receive vitamin supplementation at screening phase, at least 10 days prior to pralatrexate administration on cycle 1, dose 1. Vitamin supplementation will consist of vitamin B12 1 mg intramuscular (IM) q 8-10 weeks and folic acid 1.2mg by mouth (PO) once a day (QD). Once pralatrexate is permanently discontinued, vitamin supplementation should continue at least 1 month after the last pralatrexate dose, or longer at the discretion of the investigator.
224229711|NCT01961791|PROCEDURE|gastrectomy|gastrectomy with D1 + lymph node dissection for clinically early gastric cancer, and gastrectomy with D2 lymph node dissection for clinically advanced gastric cancer
224229712|NCT01851161|PROCEDURE|computed tomography|Undergo conventional CT scan in both supine and prone positioning
224229713|NCT01851161|PROCEDURE|4-dimensional computed tomography|Undergo 4D CT scan in both supine and prone positioning
224229714|NCT01851161|RADIATION|radiation therapy|Undergo radiation therapy
224229715|NCT03848585|DEVICE|Pilloxa Pillbox|A Pilloxa Pillbox is used for the prescribed immunosuppressants.
224229716|NCT03848585|OTHER|Non active Pilloxa Pillbox|A Pilloxa Pillbox with reminders disabled and without active mobile application is used for the prescribed immunosuppressants.
223641812|NCT01188343|BIOLOGICAL|Japanese encephalitis chimeric virus: Measles, mumps, and rubella live attenuated virus|0.5 mL each; Subcutaneous (SC)
223641813|NCT01188343|BIOLOGICAL|Japanese encephalitis chimeric virus: Measles, mumps, and rubella live attenuated virus|0.5 mL each, Subcutaneous (SC)
223641814|NCT01188343|BIOLOGICAL|Japanese encephalitis chimeric virus: Measles, mumps, and rubella live attenuated virus|0.5 mL each, subcutaneous (SC)
223641815|NCT00224822|DRUG|Aripiprazole|
224229717|NCT00783796|DEVICE|2.25 mm XIENCE V® Everolimus Eluting Coronary Stent System|Treatment of a maximum of two de novo native coronary artery lesions in small vessels.
224229718|NCT00710203|DEVICE|Pulsed dye laser|One lesion will be chosen for treatment with the pulsed dye laser with a 7 mm spot size. A single 10 J/cm2 pulse with 10 ms pulse duration will be used to treat the lesion.
224229719|NCT00710203|PROCEDURE|Curettage|A second lesion will be treated with curettage with or without anesthetic, depending on the patient's preference.
224229720|NCT00710203|PROCEDURE|Electrodesiccation|A third lesion will be treated with electrodesiccation after infiltration of 1% lidocaine with epinephrine.
224229721|NCT00710203|OTHER|No treatment|A fourth lesion will not be treated and will serve as a control.
223641816|NCT00212641|DRUG|ONO-5129|
223641817|NCT02846025|DIETARY_SUPPLEMENT|Folate and capsule of oil hazel|rich diet aministracao folate and capsule of oil hazel
223641818|NCT02846025|DIETARY_SUPPLEMENT|Folate and placebo|rich diet aministracao folate and placebo
224229722|NCT02823899|BIOLOGICAL|HL-OCV|Pharmaceutical company in Bangladesh is now producing HL-OCV, with technological support from MSD wellcome trust Hilleman pt. ltd, which meets international Good manufacturing practice( GMP) standards and WHO production guidelines.
224229723|NCT02823899|BIOLOGICAL|Shanchol|The vaccine is manufactured by Shantha Biotechnics in hyderabad, India and is prequalified by the WHO. Shanchol is available in a single dose. This vaccine is used as two dose regimen.
224229724|NCT02807142|BIOLOGICAL|NC 1 cell therapy|All patients will be treated with NC1
224229725|NCT03337178|BEHAVIORAL|Blinded Fitbit|Fitbit is worn for 3 months post-operatively with no activity feedback or step goals
224229726|NCT03337178|BEHAVIORAL|Fitbit|Fitbit is worn for 3 months post-operatively with feedback and step goals
223641819|NCT02846025|DIETARY_SUPPLEMENT|antioxidant and placebo|antioxidant diet (90μg folate) and placebo capsule
223641820|NCT01143246|DRUG|Terlipressin|Each 6 mL vial contains 1 mg lyophilized terlipressin acetate and 10 mg mannitol in sterile 0.9% sodium chloride solution.
223641821|NCT01143246|DRUG|Placebo|11 mg mannitol reconstituted with 5 ml of sterile 0.9% sodium chloride solution.
223641822|NCT01666028|DEVICE|FlorenceD or similar closed loop glucose control system|Subject's glucose level will be controlled by the FlorenceD or similar automated closed loop glucose control system. The system comprises of FreeStyle Navigator® Continuous Glucose Monitoring (CGM) System (Abbott Diabetes Care, Alameda, CA, USA), Dana R Diabecare subcutaneous insulin infusion pump (Sooil Corp. Seoul, South Korea)or similar insulin pump, and MPC-based glucose control algorithm running on a portable computer.
223641823|NCT01666028|DEVICE|CSII with real-time CGM|Subject glucose level controlled by usual insulin pump therapy in conjunction with real time continuous glucose monitoring (CGM)
223641824|NCT05510349|OTHER|Sonographic measure of placental elasticity and viscosity|Sonographic measure of placental elasticity and viscosity
223641825|NCT00613561|DRUG|Fludarabine, Busulfan, and Anti-Thymocyte Globulin|Patients on this study will receive 5 days of Fludarabine, 1 day of Busulfan Test Dose, 2 Days of Busulfan Regimen Dose, and 4 days of Anti-Thymocyte Globulin
223641826|NCT05567783|BIOLOGICAL|VIR-2482 (450 mg)|VIR-2482 450mg given by intramuscular injection
223641827|NCT05567783|BIOLOGICAL|VIR-2482 (1200 mg)|VIR-2482 1200 mg given by intramuscular injection
223641828|NCT05567783|BIOLOGICAL|Placebo|Sterile 0.9% (w/v) sodium chloride solution given by intramuscular injection
224229727|NCT05152342|BEHAVIORAL|Stigma Awareness Training for Legal System Staff|Multilevel intervention package addressing stigma associated with substance use and criminal involvement for staff and justice-involved clients enrolled in a diversion treatment program.
224229728|NCT05152342|BEHAVIORAL|Acceptance and Commitment Therapy for self-stigma|Multilevel intervention package addressing stigma associated with substance use and criminal involvement for staff and justice-involved clients enrolled in a diversion treatment program.
223641829|NCT06448676|DRUG|Botulinum toxin type A|Head-to-head comparison of all commercially available botulinum neurotoxin type A products
224229729|NCT01290393|OTHER|Data collection|Data collection from hard copy interview forms routinely used by the Organization of Teratology Information Specialists (OTIS).
224229730|NCT01362933|PROCEDURE|VTE treatment in cancer patient description|proportion of patients treated for evolutive VTE according to international recommendations
224229731|NCT03267264|DEVICE|BD Nano™ vs Nucleus|"Subjects will be randomized to~1. Nucleus pen needle for the first 15-day period, or current pen needle (BD Nano™) for the second 15-day period or~2. subject's current pen needle (BD Nano™) for the first 15-day period, Nucleus pen needle for the second 15-day period"
224229732|NCT03267264|DEVICE|NovoFine® vs Nucleus|"Subjects will be randomized to~1. Nucleus pen needle for the first 15-day period, or current pen needle (NovoFine®) for the second 15-day period or~2. subject's current pen needle (NovoFine®) for the first 15-day period, Nucleus pen needle for the second 15-day period"
224229733|NCT03267264|DEVICE|NovoTwist®/NovoFine® Plus vs Nucleus|"Subjects will be randomized to~1. Nucleus pen needle for the first 15-day period, or current pen needle (NovoTwist®/NovoFine Plus®) for the second 15-day period or~2. subject's current pen needle (NovoTwis®t/NovoFine® Plus) for the first 15-day period, Nucleus pen needle for the second 15-day period"
224229734|NCT03267264|DEVICE|Other Commercially Available Pen Needles (Unifine® Pentips®/Mylife Clickfine®) vs Nucleus|"Subjects will be randomized to~1. Nucleus pen needle for the first 15-day period, or current pen needle (Other Commercially Available Pen Needles) for the second 15-day period or~2. subject's current pen needle (Other Commercially Available Pen Needles) for the first 15-day period, Nucleus pen needle for the second 15-day period"
224229735|NCT02559050|OTHER|Customized 3D-printed nasal stent|Silicone stent with unconventional shape, 3D-printed based on patient's computed topographical images, to exactly fit newly made nasal cavity.
224229736|NCT05329636|BIOLOGICAL|Fecal Microbial Transplant (FMT)|FMT through capsules- patients will evacuate the bowel with 1 liter of Meroken solution 12 hours prior to the procedure and will fast from food for 12 hours prior to the procedure. Patients will swallow 30 frozen capsules on two consecutive days.
224229737|NCT05329636|OTHER|Placebo capsules|Patients will evacuate the bowel with 1 liter of Meroken solution 12 hours prior to the procedure and will fast from food for 12 hours prior to the procedure. Patients will swallow 30 frozen placebo-capsules on two consecutive days.
224229738|NCT05329636|BIOLOGICAL|Auto Fecal Microbial Transplant (FMT) via enema|3.FMT through enema- patients will evacuate the bowel prior to the procedure and will fast for 3 hours prior to the procedure . Patients will receive 80 ml of enema. Enemas will be administered with the assistance of the study nurse. Patients will be asked to hold the enema content for at least 15 minutes.
224229739|NCT02046421|DRUG|mifepristone|Given PO
224229740|NCT02046421|DRUG|carboplatin|Given IV
224229741|NCT02046421|DRUG|gemcitabine hydrochloride|Given IV
224229742|NCT02046421|OTHER|laboratory biomarker analysis|Correlative studies
224229743|NCT02046421|OTHER|pharmacological study|Correlative studies
224229744|NCT04884581|DEVICE|GI Genius CADx device|GI Genius System is an Intelligent Endoscopy Module designed to be an adjunct to video colonoscopy with the purpose of supporting the operating physician with artificial intelligence during colonoscopy. GI Genius CADx is the AI software that provides a histology prediction of framed polyps during real-time colonoscopy, with each polyp being classified as adenoma or non-adenoma.
224229745|NCT02476526|DRUG|Low Volume iso-osmolar non-ionic radio contrast medium|Intravenous injection of low volume (30 cc) iso-osmolar non-ionic radio contrast medium as part of the 64-MDCT Scanning procedure (intervention group only)
224229746|NCT02476526|DRUG|Acetylcysteine Inhalation|Mucomyst 1200 mg po BID x 48 hours starting the day prior to the CT scan (both experimental and control groups)
224319507|NCT00801502|OTHER|Control|No change to habitual diet from week 20 of pregnancy until giving birth
224319508|NCT02605915|DRUG|Atezolizumab|Atezolizumab 1200 milligrams (mg) or 840 mg (Cohort 1E only) flat dose administered via intravenous (IV) infusion on Day 1 of every 21-day cycle.
224319509|NCT02605915|DRUG|Carboplatin|Carboplatin will be administered at an initial target of area under the curve (AUC) of 6 milligrams per milliliter\*min (mg/mL\*min) via an IV infusion on Day 1 of every 21-days for 6 cycles.
223641830|NCT04916587|OTHER|Implementation Strategy of ACEs Screenings|We will use implementation mapping, guided by the EPIS framework, to promote a co-created process and refine the strategy comprised of online training videos, a customized ACEs algorithm and use of technology to improve workflow efficiency, implementation technical assistance/coaching, and written implementation protocols.
223641831|NCT04916587|OTHER|Usual Care|"The ACEs Aware policy goal is to equip providers with training and clinical protocols to screen children and adults for ACEs, detect ACEs early, and connect patients to interventions, resources, and other support to improve patient health and well-being. ACEs screenings are comprised of: a) a 2-hour on-line provider training; b) the Pediatric ACEs and Related Life-events Screener or PEARLS tool; c) an ACEs associated health conditions checklist; and d) complete a wellness exam. The primary care provider uses multiple sources of information to identify a child's need for follow-up services."
223641832|NCT03944577|DRUG|Evolocumab|Enrolled study participants will be treated with evolocumab (Repatha) 140 mg injected subcutaneously every 2 weeks for 52 weeks. All study participants will receive instruction on correct self-administration by research pharmacists. Study drug will be mailed to patients on a monthly basis for self-administration by patients. The evolocumab dose (140 mg every 2 weeks) will remain constant for the duration of the study. Side effects will be assessed on a quarterly basis. Serious adverse events considered related to treatment, death, and pregnancy will all result in immediate discontinuation of the study drug.
223641833|NCT05479019|BEHAVIORAL|Visual stimuli|Stimuli will be shown to participants and they will be asked to perform a visual task.
223641834|NCT04119414|BEHAVIORAL|Spear and Shield (S&S) Program|The S\&S Program is a comprehensive sexual risk reduction intervention consisting of 4 weekly 90-minute manualized group sessions conducted by a trained Community Health Center (CHC) facilitator.
223641835|NCT04119414|BEHAVIORAL|Like Father Like Son (LFLS) Program|The LFLS Program is a private 2 90-minute session conducted by a trained CHC facilitator. The sessions will be focused on exploring issues relevant to parental decision making related to voluntary medical male circumcision (VMMC) and early infant male circumcision (EIMC). Session 1 will be conducted antenatal and Session 2 will be immediately post-partum.
223641836|NCT03228823|PROCEDURE|Radiofrequency ablation|RFA to achieve PVC suppression will be performed using standard techniques and protocols similar to those patients that do not participate in this clinical study.
223641837|NCT03228823|DRUG|Amiodarone (Antiarrhythmic drug)|AAD therapy of choice is amiodarone. Amiodarone loading dose of 10 grams is recommended, followed by maintenance dose of 200-400mg daily to achieve successful PVC suppression. Alternatively, sotalol and/or propafenone could be considered at discretion of electrophysiologists (sotalol dose of at least 120mg twice daily, propafenone 150-300mg tid) if there is a significant concern of safety profile of amiodarone.
223641838|NCT02664896|OTHER|Knee Osteoarthritis|Questionnaire completion, strength testing, gait testing, pressure-pain threshold testing, proprioception testing, knee measurements, blood draw, and knee radiographs.
223641839|NCT02664896|OTHER|Healthy Control|Questionnaire completion, strength testing, gait testing, pressure-pain threshold testing, proprioception testing, and knee measurements.
223641840|NCT03842527|DEVICE|Ultrasound|Gastric ultrasound of the stomach antrum to assess contents 1 hour prior to C-section surgery. Scans will be completed in both supine (lying on back) and right lateral decubitus (positions) positions. The completion of both scans will take 5-10 minutes total
223641841|NCT01135173|BEHAVIORAL|Waterpipe smoking cessation|The main objective of this study is to compare two levels of intensity of a behavioral intervention for waterpipe smoking cessation, using a randomized controlled trial design. In this trial, brief motivational intervention with self-help materials will be compared with intensive behavioral counseling with four sessions, in order to test the efficacy of each of these interventions. This pilot testing will help us; 1) test the potential efficacy of the developed intervention, 2) fine-tune the intervention in terms of content and format, and 3) assess issues related to recruitment and retention. Thus, feedback from participants and intervention staff will form an essential part of this pilot study to assess the adopted approaches and suggest appropriate modifications.
223641842|NCT05915910|DIAGNOSTIC_TEST|Specimen Donation|blood donation
223641843|NCT01955135|DRUG|Ketamine|1mg/kg bolus intravenous, 0.25mg/kg/hour intravenous for maintenance of sedation
223641844|NCT01955135|DRUG|Sevoflurane|anesthesia was induced using 8% sevoflurane by inhalation with 50% nitrous oxide in oxygen; Anesthesia was maintained with sevoflurane (2%) and 50% nitrous oxide in oxygen
223641845|NCT01955135|DRUG|propofol|1 mg/kg propofol as a bolus for induction. The patients then received an infusion of 100-150 mcg/kg/min propofol
224229747|NCT02476526|DRUG|Sodium Bicarbonate Solution|Isotonic Sodium Bicarbonate 3 ml/kg/hr iv for 1 hour prior to the CT scan and for 6 hours after the CT scan (both experimental and control groups)
224229748|NCT02476526|PROCEDURE|64-MDCT Scanning|Both experimental and control groups will undergo 64-MDCT scanning over the thoracic area
223641846|NCT05680402|OTHER|Soft Tissue mobilization|mobilization of soft tissues of body
223641847|NCT05680402|OTHER|Piriformis Syndrome (Piriformis muscle stretching)|Stretching of Piriformis muscle
223641848|NCT00035243|DRUG|epothilone b|EPO906 administered intravenously at 2.5 mg/m2 as a 5 minute bolus infusion repeated every week for three weeks followed by one week off The final tables and data is not in yet, so I cannot give you info on safety issues.
223641849|NCT01915784|DEVICE|Genuair®|Inhaler with placebo only. Once daily, for 14 days.
223641850|NCT01915784|DEVICE|Breezhaler®|Inhaler with placebo only. Once daily, for 14 days.
223765284|NCT05544461|BEHAVIORAL|eNutri personalised nutrition advice|eNutri is a web-based app that administers an FFQ and delivers PN advice to the user. The advice is generated from their responses in the FFQ and considers their sex and dietary restrictions (such as whether they eat meat) so the reports are unique to each participant. This report (referred to as a 'healthy eating report') will also include an interactive component, allowing the participant to reflect on the advice received and set personal healthy eating goals to motivate behaviour change. The messages presented in the report have been developed by the eNutri Team, including a registered dietitian and registered nutritionist and are in line with UK dietary guidelines (primarily the EatWell Guide).
223765285|NCT04015219|DEVICE|Self retained cryopreserved amniotic membrane|PROKERA SLIM
224229749|NCT01766921|BIOLOGICAL|Adjuvanted H5N1 pandemic influenza vaccine|Comparison of two doses of aH5N1c vaccine
224229750|NCT01628081|DIETARY_SUPPLEMENT|Alga Dunaliella Bardawil placebo|"Dosage Regimen and Treatment Groups~* Daily oral administration of:~* Dunaliella, 6 capsules/day (3 capsules in the morning, 3 in the evening).~* Placebo, 6 capsules/day (3 capsules in the morning, 3 in the evening)."
224229751|NCT01628081|DIETARY_SUPPLEMENT|Dunaliella Bardawil|"Dosage Regimen and Treatment Groups~* Daily oral administration of:~* Dunaliella, 6 capsules/day (3 capsules in the morning, 3 in the evening).~* Placebo, 6 capsules/day (3 capsules in the morning, 3 in the evening)."
223765286|NCT04015219|OTHER|lifitegrast ophthalmic solution|Xiidra® (5% lifitegrast ophthalmic solution, Shire, Lexington, MA)
224229752|NCT01915732|DRUG|Duac™Once Daily Gel|1% clindamycin as clindamycin phosphate and 5% benzoyl peroxide
224229753|NCT01915732|DRUG|1% clindamycin phosphate gel|1% clindamycin as clindamycin phosphate
224229754|NCT04212039|DRUG|Saline Solution|0.5 ml/kg saline
224229755|NCT04212039|DRUG|Bupivacaine|0.5 ml/kg %0.25 bupivacaine
224229756|NCT01775020|DIETARY_SUPPLEMENT|L-arginine|
224229757|NCT02241603|BEHAVIORAL|Weight loss|Obese Veterans will undergo dietary education for weight loss or weight maintenance
224229758|NCT01654107|BEHAVIORAL|Persistence Targeted Smoking Cessation|"8-weeks of smoking cessation counseling (Persistence Targeted Smoking Cessation)"
224229759|NCT01654107|BEHAVIORAL|Clearing The Air|8-weeks counseling + 12-weeks nicotine lozenge based on NCI protocol, Clearing The Air
224229760|NCT01654107|DRUG|Nicotine lozenge|12-weeks 4mg nicotine lozenge
224229761|NCT05132309|COMBINATION_PRODUCT|enzyme replacement therapy|Correction of the previously prescribed dose of enzyme replacement therapy (ERT)/first time selection of ERT according to the severity of pancreatic exocrine insufficiency
224319510|NCT02605915|DRUG|Docetaxel|Docetaxel 75 mg/m\^2 administered via IV infusion on Day 1 every 21-days for 6 cycles.
224229762|NCT02744183|BEHAVIORAL|Exercise|Moderate intensity exercise
224229763|NCT02744183|BEHAVIORAL|Breakfast|Breakfast consumption
224229764|NCT02744183|BEHAVIORAL|Maintain habitual habits|Normal physical activity and dietary behaviors maintained
224229765|NCT04621409|BIOLOGICAL|Liver-enriched antimicrobial peptide 2|IV infusion of LEAP2, approximately 5 hours
223765287|NCT01008111|DRUG|Dermabond|On Day 0 patients will undergo bilateral inguinal surgery. One side will be dressed using a standard surgical dressing, while the other will use a combination hydrogen peroxide/baking soda gel placed over the wound and covered with a sealing dressing. The study team will determine which side gets assigned standard surgical dressing by the flip of a coin.
223765288|NCT01008111|DRUG|Hydrogen Peroxide Oxygen producing gel|On Day 0 patients will undergo bilateral inguinal surgery. One side will be dressed using a standard surgical dressing, while the other will use a combination hydrogen peroxide/baking soda gel placed over the wound and covered with a sealing dressing. The study team will determine which side gets assigned standard surgical dressing by the flip of a coin.
224229766|NCT04621409|BIOLOGICAL|Placebo|IV infusion of saline, approximately 5 hours
224229767|NCT04089709|BEHAVIORAL|Well-arm Exercise|Patients randomized to the treatment arm will perform these exercises on the contralateral arm once daily for 3 months: wrist flexion and extension, ball or sock squeeze, wrist curls and biceps curls. Participants allocated to this study arm will be provided a print out of the exercises with detailed explanations and pictures of each exercise.
224229768|NCT05743920|BEHAVIORAL|Self-help Forest Bathing|The self-help forest bathing includes two sessions (i.e., participants will perform the first intervention within week 1 to 3, and the second intervention within week 4 to 6) that are related to the following forest bathing activities : (a) forest meditation, (b) forest walking, (c) calling attention to sensory experiences of the forest, including seeing, hearing, touching, and smelling, and (d) building connection to the nature by partnership invitation. Each session will last for 45 minutes.
224229769|NCT01491620|DEVICE|532 nm KTP laser|Laser treatment sessions on the neck and/or chest
224229770|NCT00638365|BIOLOGICAL|KB001|Single-dose, 3mg/kg or 10mg/kg dose administered intravenously
224229771|NCT00638365|OTHER|Placebo|Placebo single-dose administered intravenously
224229772|NCT01569451|DRUG|Rituximab|intravenous (IV) infusion of 1000 mg of rituximab on study days 1 (baseline visit) and 15
224229773|NCT01569451|DRUG|Glatiramer Acetate|20 mg injected subcutaneously daily
224229774|NCT01569451|OTHER|Placebo|Subjects will receive an intravenous (IV) infusion of 1000 mg of rituximab or placebo (normal saline) on study days 1 (baseline visit) and 15 according to the rituximab infusion protocol. On study day 28, all subjects will initiate standard GA therapy, 20 mg injected subcutaneously daily.
224229775|NCT03749265|OTHER|Ultrasound test|patients need to undergo an ultrasound test for detecting the presence or abscence of peroneus tertius tendon
224229776|NCT05538884|PROCEDURE|Intertransverse process block|The ITPB block at T5-6 will be performed with a mixture of local anesthetic with MRI contrast 0.5% bupivacaine 10 ml and 0.5 ml contrast in concentration 3.09 mmol/l. Volunteers will be moved to MRI machine and imaged in a supine position for their whole thoracic spine. This process will last about 45-60 minutes.
224229777|NCT04216069|OTHER|Total 12 regimen|"The volunteers will be invited with their caregivers to a lecture administered with the aim of clarifying the importance of oral hygiene and motivating brushing among the volunteers. Written clarifications will also be given in the form of an illustrative pamphlet. The volunteers will be trained in the technique through supervised brushing in front of a mirror. Subjects from the Group 1 will use a regimen with Colgate Total 12 toothpaste + Plax mouthwash + Colgate Ultrasoft toothbrush. Subjects will be instructed to use only their assigned group during the study period. The treatment products will be re-supplied at regular intervals. Subjects will return with their assigned products to the study site before receiving new products.~There will be no restrictions regarding diet habits during the course of the study. Upon completion of the study, subjects will be instructed to return all used and used products."
224319511|NCT02605915|DRUG|Pertuzumab|Pertuzumab 840 mg loading dose then 420 mg administered via IV infusion on Day 1 of every 21-day cycle.
224319512|NCT02605915|DRUG|Trastuzumab|Trastuzumab 8 milligram per kilogram (mg/kg) loading dose, then 6 mg/kg administered via IV infusion on Day 1 of every 21-day cycle.
224319513|NCT02605915|DRUG|Trastuzumab emtansine|Trastuzumab emtansine 3.6 mg/kg administered via IV infusion on Day 1 of every 21-day cycle. Dose de-escalation may occur for trastuzumab emtansine, from the full trastuzumab emtansine dose at 3.6 mg/kg on Day 1 of every 21-day cycle, potentially to 3.0 mg/kg (Cohort 1C) or 2.4 mg/kg q3w (Cohort 1D).
224319514|NCT02605915|DRUG|Doxorubicin|Doxorubicin will be administered at 60 mg/m\^2 every 2 weeks as an IV bolus over 3 to 5 minutes or as an infusion over 15 to 30 minutes.
223641851|NCT00469599|DRUG|paricalcitol|3 microg 3 times a week. dosage is increased/decreased 50 % every second week according to iPTH, ionised s-calcium and phosphate
223641852|NCT00469599|DRUG|alfacalcidol|1 microg 3 times a week, dosage is titrated every second week according to iPTH, phosphate and ionised s-calcium.
223641853|NCT00168584|DRUG|Vitamin A|
223641854|NCT00999102|DRUG|Metoprolol|Metoprolol 50 mg, Metoprolol 100 mg,
223641855|NCT00999102|DRUG|Nebivolol|Nebivolol 5 mg, Nebivolol 10 mg.
223641856|NCT02871986|DRUG|Routine transdermal oestrogen patch|Transdermal oestrogen patch will be used with an incremental dose increase at 4 months
223641857|NCT04436952|DEVICE|H7 coil|The H7 coil arm will receive a medial prefrontal cortex (mPFC) DTMS 5 days a week for 8 consecutive weeks = 40 Sessions 20 Hz at 100% MT, 2 s on 20 s off intertrain interval, 50 trains, 2000 stimuli per session.
223641858|NCT04436952|DEVICE|Cool D-B80|The Cool D-B80 arm will receive dorsomedial prefrontal cortex (DMPFC) rTMS 5 days a week for 8 consecutive weeks = 40 sessions 10 Hz at 120% MT, 5 s on 10 s off intertrain interval, 60 trains, First 3000 pulses to the left DMPFC then 3000 pulses to the right DMPFC. TMS will be done at active state by provocation
223641859|NCT04436952|BEHAVIORAL|Exposure Response Prevention (ERP)|The ERP will be conducted for 2 hours on week 1 and week 8 and for 1 hour on Weeks 2 to 7 for a total of 10 hours
223641860|NCT03056222|DEVICE|Ablation catheter|Ablation of paroxysmal atrial fibrillation
223641861|NCT02431637|BIOLOGICAL|Administration of the malaria inoculum|Each participant in the cohort will be inoculated on Day 0 with \~2,800 viable parasites of Plasmodium falciparum-infected human erythrocytes (BSPC) administered intravenously. The threshold for commencement of treatment will be when PCR quantification of all participants is ≥ 5,000 parasites/mL.
223641862|NCT02431637|DRUG|Piperaquine Phosphate 480 mg|When PCR quantification of all participants is ≥ 5,000 parasites/mL, participants will receive a single dose of 480 mg Piperaquine Phosphate
223641863|NCT02643914|DRUG|Nicotine|
223641864|NCT02643914|DEVICE|MR Compatible Nicotine Delivery Device|
223641865|NCT01093157|DRUG|Adrenocorticotrophic hormone ACTH|There will be two arms to the study: one arm receive 40 units and the second arm 80 units of the ACTH gel subcutaneously both given in a dose escalating frequency beginning at once every two weeks escalating to a maximum of twice per week over a total of three months exposed.An ammendment(approved by Health Canada and the UHN IRB allows an additional 1 month of the perscribed therapy of ACTH )if there is an improvement in proteinuria at the end of the 3 month exposure.
223641866|NCT01352793|BIOLOGICAL|rLP2086 vaccine|120 mcg, 3 doses, at month 0, 2, and 6.
223641867|NCT01352793|BIOLOGICAL|control|HAVRIX: 720 EL.U. or 1440 EL.Ul, 2 doses, at month 0 and 6. Placebo: normal saline injection, 1 dose, at month 2.
223641868|NCT03203096|DIETARY_SUPPLEMENT|Magnesium|Magnesium citrate / Magnesium oxide
223641869|NCT03203096|DIETARY_SUPPLEMENT|Placebo|
223641870|NCT02743052|DRUG|Anticoagulation treatment.|Details of anticoagulation treatment information will be gathered including low molecular-weight heparin (enoxaparin 1 mg/kg) vs. NOAC (rivaroxaban 15 or 20 mg), vs. warfarin (target INR2.0-3.0) or no use of anticoagulation per physicians' decision and patients' conditions.
223641871|NCT00656448|DRUG|Procrit|40,000 units sq every week starting within two weeks (before or after) from the start of induction chemotherapy.
223641872|NCT00100269|DRUG|Menevit anti-oxidant|
223641873|NCT03146416|DRUG|Evinacumab|SC or IV administration of Evinacumab
223641874|NCT03146416|DRUG|Placebo|Matching placebo
223641875|NCT01838096|DEVICE|THA using 4th generation CoC|
223641876|NCT00335595|DRUG|XELOXA|XELOXA Bevacizumab: 7,5 mg/kg, day 1 Oxaliplatino: 130 mg/m2 ; day 1 Capecitabine: 1000 mg/m2 bid, oral, day 1-14 One cycle every 3 weeks
223641877|NCT00335595|DRUG|XELOXA-A|"XELOXA-A Bevacizumab: 7,5 mg/kg, day 1 Oxaliplatino: 130 mg/m2 ; day 1 Capecitabine: 1000 mg/m2 bid, oral, day 1-14 during 6 cycles followed by Bevacizumab until disease progression or premature drop out of study.~One cycle every 3 weeks"
224229778|NCT04216069|OTHER|Toothbrushing alone|"The volunteers will be invited with their caregivers to a lecture administered with the aim of clarifying the importance of oral hygiene and motivating brushing among the volunteers. Written clarifications will also be given in the form of an illustrative pamphlet. The volunteers will be trained in the technique through supervised brushing in front of a mirror. Group 2 will use Colgate Cavity Protection Toothpaste + Colgate Ultrasoft toothbrush. Subjects will be instructed to use only their assigned group during the study period. The treatment products will be re-supplied at regular intervals. Subjects will return with their assigned products to the study site before receiving new products.~There will be no restrictions regarding diet habits during the course of the study. Upon completion of the study, subjects will be instructed to return all used and used products."
224229779|NCT00211159|DRUG|EPAX 1050TG|
224229780|NCT04025788|DEVICE|Magmaris Resorbable Magnesium Scaffold (RMS)|Subjects will undergo a percutaneous coronary intervention for the implantation of the Magmaris scaffold in accordance with the standard of care and standard hospital practice. Maximum of two single de novo lesions in two separate major epicardial vessels are allowed.
224229781|NCT01507857|BIOLOGICAL|400U /0.5ml EV71 vaccine|inactivated vaccine (vero cell) against EV71 of 400U /0.5ml, two doses, 28 days interval
223641878|NCT01808456|BIOLOGICAL|influenza trivalent inactive vaccine|one time IM injection of standard influenza vaccine to measure immunogenicity, safety, and efficacy in organ transplant recipients
223641879|NCT01808456|BIOLOGICAL|influenza trivalent inactive vaccine high dose|one time IM injection of high dose influenza vaccine to measure immunogenicity, safety, and efficacy in organ transplant recipients
223641880|NCT03791814|DRUG|Zepatier|Patients screened as HCV positive will receive Zepatier for 12 weeks.
224229782|NCT01507857|BIOLOGICAL|0/0.5ml placebo|0/0.5ml placebo, two doses, 28 days interval
224229783|NCT00946257|DRUG|Otelixizumab|A humanized, aglycosyl, non-mitogenic, anti CD3 monoclonal antibody (MAb) directed against the ε domain of the human lymphocyte antigen CD3.
224229784|NCT04415125|DIAGNOSTIC_TEST|Applying on-ice and off-ice performance tests|The subjects were given a written description of study procedures and potential risks.The athletes'history of injury including previous injury site, type, number, date, surgical status, time to return to the field after the injury and the mechanism of injury were recorded. The subjects completed off-ice performance measures followed by on-ice testing with time allotted for warm-up before both the off-ice and on-ice testing.
223641881|NCT04071717|BEHAVIORAL|NIRS neurofeedback|Neurofeedback as a treatment for people which can be interpreted as a way to increase behavioral inhibition. A method to assess brain activity is functional near-infrared spectroscopy (NIRS), measuring hemodynamic correlates of neural activity.
223641882|NCT04071717|BEHAVIORAL|Sham NIRS neurofeedback|Sham NIRS neurofeedback
223641883|NCT05506124|DEVICE|airbag-type stretchable electrode array (ASEA) device|Propose a novel airbag-type stretchable electrode array (ASEA) device for electrical stimulation for training of the female pelvic floor muscle (PFM) for the treatment of UI
223641884|NCT05506124|DEVICE|two-channel hard electrode device|Propose a two-channel hard electrode device for electrical stimulation for training of the female pelvic floor muscle (PFM) for the treatment of UI
223641885|NCT01981408|DRUG|[^14C]-LY2801653|Administered orally
223641886|NCT05484752|DEVICE|Repetitive Peripheral Magnetic Stimulation|Repetitive Peripheral Magnetic Stimulation at knee joint 1 session
223641887|NCT05484752|BEHAVIORAL|Education|Conventional exercise and life style modification
223641888|NCT04586439|DRUG|JNJ-73763989|JNJ-73763989 will be administered (high or low dose) as single SC injection.
224229785|NCT00233857|PROCEDURE|Auricular acupuncture|
224229786|NCT02230397|OTHER|plantaricin a (active product)|Product application: 8 weeks (one on the right and one on the left face side randomly) twice a day, in the morning and in the evening, with a mild massage
224229787|NCT02230397|OTHER|placebo product|Product application: 8 weeks (one on the right and one on the left face side randomly) twice a day, in the morning and in the evening, with a mild massage
224229788|NCT05097872|OTHER|Diet|Diet excluding either trigger and sham nutrient in a blinded crossover fashion (CLE positive individuals with identified trigger) or wheat and soy in a blinded crossover fashion (CLE negative individuals without identified trigger)
224229789|NCT06141070|OTHER|Standard systemic therapy + radiotherapy|Combined systemic therapy + radiation
224229790|NCT06141070|DRUG|Standard systemic therapy|Chemoimmunotherapy or immunotherapy
223641889|NCT01198496|DRUG|Losartan, Losartan and HCTZ, Amlodipine , Spironolactone|\<Study drugs and treatment steps\> Step 1: Losartan 50 mg in principle (other ARB is usable) Step 2: Combination drug containing losartan 50 mg and hydrochlorothiazide 12.5 mg Step 3: Combination drug containing losartan 50mg and HCTZ 12.5mg + amlodipine 5 mg Step 4: Losartan 50 mg + combination drug containing losartan 50 mg and HCTZ 12.5 mg + amlodipine 5 mg Step 5: Losartan 50 mg + combination drug containing losartan 50 mg and HCTZ 12.5 mg + amlodipine 10 mg Step 6: Losartan 50 mg + combination drug containing losartan 50 mg and HCTZ 12.5 mg + amlodipine 10 mg + spironolactone 25 mg
223641890|NCT00800670|BIOLOGICAL|Ad5Ag85A|Single intra-muscular administration of 10\^8 pfu of recombinant-deficient human adenoviral TB vaccine (Ad5Ag85A)
223641891|NCT00800670|BIOLOGICAL|Ad5Ag85A|Single intra-muscular administration of 10\^9 recombinant-deficient human adenoviral TB vaccine (Ad5Ag85A)
223641892|NCT02877407|PROCEDURE|patient who undergo laparoscopic/robotic-assisted hysteropexy|
224229791|NCT02928913|OTHER|No intervention|
224229792|NCT01328275|DRUG|standard regimens according to the Thai Ministry of Public Health national guidelines|Participants may receive any of the standard regimens. These regimens are recommended in the Thai Ministry of Public Health National guidelines for the treatment of HIV in children. Change of treatment will be according to the treating physicians.
223641893|NCT02877407|PROCEDURE|patient who undergo vaginal hysterectomy|
223765289|NCT03215355|DRUG|Primovist|"Primovist is currently a drug marketed for MRI. In this study it will be administered intravenously at 4 times what it is quoted for MRI to enhance the different imaging modality (CBCT) to improve the accuracy of liver SBRT. Although liver SBRT usually consists of 5 treatments, contrast will only be administered during the first treatment.~Consulting Health Canada and Bayer HealthCare Canada (the drug manufacturer) deemed this use off label dosing which in Canada is at the discretion of the physician. Based on preliminary imaging testing, and a review of toxicity literature for this drug, the administration for this specific use was deemed appropriate to give adequate image quality, while simultaneously maintaining patient safety."
223765290|NCT01283048|DRUG|BKM-120 Bevacizumab|BKM-120 60, 80, 100 mg PO QD Bevacizumab 10 mg/Kg every 2 weeks
223765291|NCT00976898|RADIATION|Proton Beam Irradiation|Given once a day, 5 days a week, for 3 weeks
223765292|NCT05075876|DRUG|SP-01 manufactured by Site K (SP-01-K, Transdermal patch contained granisetron)|Single application for 6 days
223765293|NCT05075876|DRUG|SP-01 manufactured by Site A (SP-01-A, Transdermal patch contained granisetron)|Single application for 6 days
223765294|NCT04861506|PROCEDURE|endovascular treatment|All the patients are treated by endovascular therapy, through contralateral femoral artery approach, ipsilateral antegrade femoral artery approach or brachial artery approach. If the lesion is difficult to pass in antegrade approach, retrograde puncture at the distal artery of the lesion can be performed. Surgeons can choose treatment methods such as pharmacomechanical thrombectomy (PMT) and mechanical thrombectomy device (MTD) and/or pharmacomechanical thrombectomy (PMT）and/or percutaneous aspiration thrombectom (PAT) and/or CDT(catheter-directed thrombolysis) and/or percutaneous aspiration thrombectom (PAT) thrombolysis (CDT) for thrombus removal according to the characteristics of the lesions and hospital conditions.
223765295|NCT02755272|DRUG|Pembrolizumab|IV Infusion of 200 mg given on day one of each 21 day treatment cycle.
223765296|NCT02755272|DRUG|Carboplatin|IV infusion of a calculated dose (AUC 2 mL/min) given on days one and eight of each 21 day treatment cycle.
223765297|NCT02755272|DRUG|Gemcitabine|IV infusion of 800 mg/m\^2 given on days one and eight of each 21 day treatment cycle.
223765298|NCT04938362|OTHER|FDG-PET|\[18F\]Deoxyglucose-positron emission tomography at 0-10 years after brain abscess
223765299|NCT04938362|OTHER|EEG|Electroencephalography (EEG) at 0-10 years after brain abscess
223765300|NCT06013618|DRUG|Naxitamab monotherapy|Naxitamab is administered on days 1, 3, and 5
223765301|NCT06013618|DRUG|GM-CSF|Each treatment cycle is 28 days and is started with five days (days -4 to 0) of GM-CSF administered at 250 mcg/m2/day in advance of the start of naxitamab infusion. GM-CSF is thereafter administered at 500 mcg/m2/day on days 1 to 5.
224229793|NCT01654380|DRUG|LY2605541|LY2605541 is a solution. The concentration of LY2605541 is 100 units/milliliter (U/mL).
223641894|NCT03192735|DRUG|ApatinibMesylateTablets|Subject will be given ApatinibMesylateTablets 500mg/per day, from day1-day 21,per os; Oxaliplatin for Injection 130mg/m2 /per day，ivgtt，in day1; Gimeracil and Oteracil Porassium Capsules twice times a day,from day1-day 14,per os,and the dosage according body surface area:\<1.25m2, 40mg every time;1.25-1.5m2,50mg every time; \>1.5m2, 60mg every time.A course of treatment need 21days. Every subject need 2-5 courses accrding to tumor assessment by clinician. The last course stop ApatinibMesylateTablets.
223765302|NCT06013618|DRUG|Irinotecan|Each HITS treatment cycle is 21 days. Irinotecan intravenously (IV) at 50 mg/m2/day will be administered from Day 1-5 concurrently with temozolomide orally at 150 mg/m2/day or 100 mg/m2/day.
223765303|NCT06013618|DRUG|Temozolomide|Each HITS treatment cycle is 21 days. Irinotecan intravenously (IV) at 50 mg/m2/day will be administered from Day 1-5 concurrently with temozolomide orally at 150 mg/m2/day or 100 mg/m2/day.
223765304|NCT06013618|DRUG|Naxitamab in combination therapy|Naxitamab 2.25mg/kg IV will be administered on Days 2, 4, 8 and 10.
223765305|NCT06013618|DRUG|GM-CSF with combination regimen|GM-CSF 250 mcg/m2/day will be administered subcutaneously on Days 6-10.
223765306|NCT06013618|DRUG|Sintilimab|Sintilimab was administerd with 3mg/kg (max 200mg) on day 11 every 3 weeks.
224229794|NCT01654380|OTHER|Insulin glargine|Insulin glargine is a 100 U/mL solution in 10 milliliter (mL) glass vial.
224229795|NCT00347542|DRUG|Vitamin D|
224229796|NCT02101632|DIETARY_SUPPLEMENT|Bee Venom Ointment|2 weeks
224229797|NCT02101632|OTHER|Vaseline Ointment|2 weeks
223765307|NCT04575025|DRUG|Tabrecta tablets|There was no treatment allocation. Patients administered Tabrecta by prescription that had started before inclusion of the patient into the study were enrolled.
223765308|NCT01895751|PROCEDURE|Invasive management|Invasive management includes coronary and graft angiography (diagnostic imaging test) and coronary and/or graft revascularization with percutaneous coronary intervention (PCI) and/or coronary artery bypass graft (CABG), as clinically appropriate.
224229798|NCT01505257|BEHAVIORAL|END-DSD|Multi-component intervention including 1) Nursing education regarding detection and management of delirium superimposed on dementia; 2) Computerized decision support and EHR; 3) A unit champion nurse for promotion of delirium assessment and management; 4) Feedback to nursing staff
224229799|NCT01575522|OTHER|Laboratory Biomarker Analysis|Correlative studies
223641895|NCT02629900|BEHAVIORAL|Time restricted feeding|Participants will consume their daily calories only between 12:00 and 20:00 for 4 weeks
223641896|NCT04845282|DIETARY_SUPPLEMENT|Graded Protein plus Resistance Training|"Participants will be counseled to consume the specific level of dietary protein plus the protein supplement is MusclePharm Combat 100% Whey. Specific values per week are listed below:~Week 1: 25 g of protein supplement (0.8 g protein/kg body weight) Week 2: 25 g of protein supplement (1.0 g protein/kg body weight) Week 3: 50 g of protein supplement (1.2 g protein/kg body weight) Week 4: 50 g of protein supplement (1.4 g protein/kg body weight) Week 5: 50 g of protein supplement (1.4 g protein/kg body weight) Week 6: 75 g of protein supplement (1.6 g protein/kg body weight) Week 7: 75 g of protein supplement (1.8 g protein/kg body weight) Week 8: 75 g of protein supplement (2.0 g protein/kg body weight) Week 9: 75 g of protein supplement (2.2 g protein/kg body weight) Week 10: 100 g of protein supplement (2.2 g protein/kg body weight)"
223641897|NCT04845282|DIETARY_SUPPLEMENT|RDA Protein plus Resistance Training|Participants will be counseled to consume the RDA level of protein (0.8g/kg/day) utilizing only dietary protein.
223641898|NCT00086632|DRUG|oregovomab|
223641899|NCT02074501|OTHER|training capacity in caregivers|"The participants of the InCARE programme (intervention group) will receive, additionally, intervention based on: (i) empowering caregivers to put hands on caring, which will be the key-point of the pilot programme; (ii) training handling techniques: mobility, bathing, (un)dressing, transferring, positioning, eating and drinking using technical aids, after 1 week, 1 month and 3 months, post hospital discharge."
223641900|NCT00503763|DRUG|Simvastatin|
223641901|NCT01716234|DRUG|Posaconazole 12 mg/kg/day BID|Posaconazole oral suspension 12 mg/kg/day divided into 2 doses (BID) (maximum 800 mg/day)
223641902|NCT01716234|DRUG|Posaconazole 18 mg/kg/day BID|Posaconazole oral suspension 18 mg/kg/day divided into 2 doses (BID) (maximum 1200 mg/day)
223641903|NCT01716234|DRUG|Posaconazole 18 mg/kg/day TID|Posaconazole oral suspension 18 mg/kg/day divided into 3 doses (TID) (maximum 1200 mg/day)
223641904|NCT01716234|DRUG|Posaconazole 12 mg/kg/day TID|Posaconazole oral suspension 12 mg/kg/day divided into 3 doses (TID) (maximum 800 mg/day)
223641905|NCT06086769|DEVICE|High flow nasal canula|Measurement of diaphragm thickening fraction, respiratory rate and esophageal pressure swing with calculation of diaphragmatic pressure-time product without the use of HFNC and with the use of HFNC at 20 and 40 Liters per minute
223641906|NCT06379204|BEHAVIORAL|the maximum physiological value standardized group|10 kcal/kg/week for 1-6 weeks, 12.5 kcal/kg/week for 7-12 weeks, exercise frequency of 3d/week, exercise intensity calculated by CPET measurement and HRR heart rate reserve method, gradually increasing.
223641907|NCT06379204|BEHAVIORAL|the ventilatory threshold individualized group|10 kcal/kg/week for 1-6 weeks, 12.5 kcal/kg/week for 7-12 weeks, exercise frequency of 3d/week, exercise intensity calculated by CPET measurement and three zone threshold model, gradually increasing.
223641908|NCT04466319|OTHER|Rocking Chair|Patients in the experimental group were sat rocking chair three times a day in a rocking wooden chair in addition to their postoperative routine care by their nurses. After providing the rocking chair to the patients' room, the researcher gave the data collection form to be filled by the patient himself. It was the researcher's supervision that the patient sat in the rocking chair for the first time. The rocking chair movement continued to intervene until the patient released gas. After emitting gas, he continued to swing in the rocking chair until he made his first stools. The patient was visited every day until he was discharged. No special clothing or materials were required for the patients to sit in the rocking chair.
223641909|NCT01873872|DIETARY_SUPPLEMENT|Theralac probiotic|
223641910|NCT01873872|DIETARY_SUPPLEMENT|Culturelle probiotic|
223641911|NCT01873872|OTHER|placebo|
223641912|NCT03401619|COMBINATION_PRODUCT|Exercise，Nutrition，Bisphosphonates，Statins，Calcitonin,Vitamin D，et al.|The long-term effect of comprehensive treatment on health, especially for osteoporosis and neurodegenerative diseases, we hope to find association from epigenetics and provide clues for further exploration of its pathogenesis.
223641913|NCT01529567|BEHAVIORAL|Cognitive Behavioral Therapy without exposure|10 week internet-delivered cognitive behavioral therapy, including mindfulness training, education about the negative effects of excessive avoidance and control behaviors on IBS symptoms and quality of life, and guided behavioral change aiming to increase quality of life and flexibility.
223641914|NCT01529567|BEHAVIORAL|Cognitive Behavioral Therapy with exposure|10 week internet-delivered cognitive behavioral therapy, including mindfulness training, education about the negative effects of excessive avoidance and control behaviors on IBS symptoms and quality of life, guided behavioral change aiming to increase quality of life and flexibility, and systematic exposure to IBS symptoms and aversive situations.
223641915|NCT03351725|DEVICE|peripheral venous catheter (PVC)|No intervention is made only in situ swab from the PVC
223641916|NCT00702299|DRUG|cisplatin|IP cisplatin will be administered on day 2 of each cycle at 75mg per m2 and IP paclitaxel will be administered at 60mg per m2 on day 8 of each cycle. Courses will be repeated every 21 days for up to 6 cycles
224229800|NCT01575522|DRUG|Tivantinib|Given PO
224229801|NCT03155984|DRUG|Anti-CD20 antibody|All patients receiving anti-CD20 therapy (rituximab, ofanumumab, obinutuzumab) for hematological malignancies
223641917|NCT00702299|DRUG|paclitaxel|IP cisplatin will be administered on day 2 of each cycle at 75mg per m2 and IP paclitaxel will be administered at 60mg per m2 on day 8 of each cycle. Courses will be repeated every 21 days for up to 6 cycles
223641918|NCT00702299|DRUG|pemetrexed disodium|Escalate doses in groups of 3 patients to 60mg per m2, 120 mg per m2, 500 mg per m2, 750 mg per m2, 1000 mg per m2
223641919|NCT00702299|OTHER|biologic sample preservation procedure|Plasma samples will be collected on the 1st course at baseline, 30 minutes, 60 minutes, 2 hours, 4 hours, 6 hours (if possible) and 24 hours after the first IP Alimta® dose.
224229802|NCT02582970|DRUG|5-Fluorouracil|Intravenous 5-fluorouracil based chemotherapy will be administered until disease progression or until termination of the study. The chemotherapy regimen will be at the discretion of the prescriber and will not be provided by the sponsor.
224229803|NCT02582970|DRUG|Bevacizumab|Bevacizumab will be administered IV 5 mg/kg every 2 weeks until disease progression or until termination of the study.
224229804|NCT02582970|DRUG|Irinotecan|Irinotecan will be administered at the discretion of the prescriber until disease progression or until termination of the study.
223641920|NCT03901872|DEVICE|Contemporary endovascular venous intervention by Zelante pharmacomechanical thrombolysis|All patients will undergo ultrasound guided micro puncture venous access of the enrolled ipsilateral lower extremity popliteal vein followed by a diagnostic venogram to define thrombus burden and anatomic extent of DVT. Prior to and every 30 minutes during the endovascular procedure, an activated clotting time (ACT) will be obtained. Intravenous unfractionated heparin will be administered to keep the ACT between 250 - 300. A Zelante catheter will be utilised to perform pharmacomechanical thrombolysis of the enrolled lower extremity. If there is involvement of the popliteal and/or femoral vein, pharmacomechanical thrombolysis should also be performed of these veins. Venous stenting may be implemented to address areas of residual venous stenosis or outflow obstruction following pharmacomechanical thrombolysis. Stent placement in the common iliac, external iliac, and common femoral vein are routinely done to address inflow or outflow issues after pharmacomechanical thrombolysis.
223641921|NCT05581342|DIAGNOSTIC_TEST|Punch biopsy (3mm)|In case of suspicion of recurrence or a voluntary control biopsy; a punch biopsy (3mm) was obtained conform regular care.
224229805|NCT02582970|DRUG|Oxaliplatin|Oxaliplatin will be administered at the discretion of the prescriber until disease progression or until termination of the study.
224229806|NCT04419337|DRUG|Metformin plus Pioglitazone plus an SGLT2 inhibitor|Patients assigned to active group will stop their prior oral antidiabetic drugs and receive combination of metformin, pioglitazone, and an SGLT2 inhibitor (empagliflozin or dapagliflozin or canagliflozin) and dose will be adjusted by their physicians.
224229807|NCT01601678|PROCEDURE|Peroral Endoscopic Myotomy (POEM)|After lavage, measure gastro-esophageal junction (GEJ) in cm from mouth piece. Determine entry point 12-14cm above GEJ at the lesser curvature site, inject 10ml coloured saline, create entry point. Advance endoscope into the submucosa, dissect the submucosal tunnel up to 2-3cm into the cardia. Dissect the submucosa close to the muscularis and check endoluminally for the direction of the lesser curvature, sufficient extension onto the cardia and mucosal integrity. After tunnel completion flush with gentamycin and saline. Start myotomy from proximally to distally starting 4-5cm below the mucosal entry site; the inner circular muscle layer should be fully dissected especially at the cardia for good symptomatic results. It is vital that the mucosa of the tubular esophagus remains intact. Extend myotomy at least 2cm onto the cardia. After completion check for mucosal integrity and opening of the distal esophageal sphincter. Close the entry point with clips from distal to proximal.
224229808|NCT01601678|PROCEDURE|Laparoscopic Heller Myotomy (LHM)|Use five trocar technique with patient in the French position as for laparoscopic anti-reflux procedures. Establish 12-15 mm Hg pneumoperitoneum. Use left paramedian trocar for camera, two lateral trocars for elevating liver and retraction of stomach and two trocars for dissection and suturing. Use of robotic surgery devices is allowed. Divide phrenoesophageal ligament starting on the right and mobilize distal esophagus on the lateral and anterior side. Identify and spare anterior vagal nerve. Perform myotomy by dividing both muscle-layers extending at least 6 cm above gastroesophageal junction and at least 2-3 cm inferiorly over stomach. Perform extent downwards after dividing epiphrenic fat pad overlying cardia. Measure myotomy length. Peroperative endoscopy check is advisable. Perform anterior fundoplication according to Dor. Only if necessary mobilize fundus of the stomach by dividing short gastric vessels. Suture fundus to both cut edges of myotomy, using non-resorbable material.
224229809|NCT04033809|DIETARY_SUPPLEMENT|Multigrain powder (S)|A twice daily high fiber multigrain powder supplementation for 12 weeks
224229810|NCT05577793|OTHER|Mother's Voice|The audio recording was made to listen to the baby for 15 minutes during the nasal CPAP application. The NIPS and PICS scores were evaluated and recorded before, during and after the application.
224229811|NCT05577793|OTHER|Therapeutic Touch|Therapeutic touch was started 5 minutes before nasal prongs were placed, and was applied for 5 minutes during the application, and continued for another 5 minutes after the nasal prongs were placed. The method was applied for a total of 15 minutes as 5 minutes of hand resting, 5 minutes of gentle caressing and 5 more minutes of hand resting.The NIPS and PICS scores were evaluated and recorded before, during and after the application.
224229812|NCT05577793|OTHER|Mother's Voice +Therapeutic Touch|Both applications were applied together for 15 minutes.The NIPS and PICS scores were evaluated and recorded before, during and after the application.
224229813|NCT05577793|OTHER|Control|The premature babies in the control group did not receive any intervention other than the hospital procedure.The NIPS and PICS scores were evaluated and recorded before, during and after the application.
223641922|NCT00684931|OTHER|Imaging|neuropsychological evaluation and Imaging with magnetic resonance (MRI)
223641923|NCT02779101|DRUG|pembrolizumab|Pembrolizumab 200 mg every 3 weeks
223641924|NCT03533504|OTHER|Variability in individual PK|Multivariate hierarchical analysis will be performed on various factors (age, sex, weight, height, dose and type of factor administered (as total and IU/kg), blood group, baseline factor level, positive history of inhibitors, hematocrit, hemoglobin, and serum creatinine, laboratory methods used to measure factor VIII and factor IX) to explore sources of variability in patient outcome.
223641925|NCT00516360|DEVICE|3.15% chlorhexidine as daily antiseptic on needleless access port|3.15% chlorhexidine as daily antiseptic on needleless access port. 1 wipe used to cleanse port each time the port is accessed
223641926|NCT02643212|DRUG|Rivaroxaban|
224229814|NCT04132661|DRUG|Bisacodyl 5 milligram|one single dose
224229815|NCT04132661|DRUG|Placebo oral tablet|one single dose
224319515|NCT02605915|DRUG|Cyclophosphamide|Cyclophosphamide will be administered at 600 mg/m\^2 on Day 1 of each 21 day cycle as an IV bolus over 3 to 5 minutes or as an infusion, in accordance with local policy.
224319516|NCT05546437|DEVICE|Ion Endoluminal System|Ion Endoluminal dye marking procedure for pulmonary nodule
224319517|NCT05980845|BEHAVIORAL|Nature sounds|Nature sounds would be played for 30 minutes in three HD sessions for one week, starting from the beginning of the session. Afterwards, the patients were informed about the usage of the Mp3 player and in-ear headphones, they were demonstrated that they could adjust the volume to the level they desired, and it was stated that they should not detach the headphones until the 30-minute recording was over.
224319518|NCT03333265|DRUG|100mg Berberine hydrochloride|patients take the Berberine hydrochloride 100mg tablet by mouth, 2 times a day with 6 months
223641927|NCT02643212|DRUG|Placebo|
223641928|NCT02642016|BIOLOGICAL|CDX-0158 (formerly known as KTN-0158)|Single agent CDX-0158 until unacceptable toxicity or progressive disease
223641929|NCT03990792|BEHAVIORAL|e-predictD intervention|The intervention is based on validated risk algorithms to predict depression and includes: 1) Mobile applications as main user's interface; 2) a DSS that helps patients to develop their own personalized plans to prevent (PPP) depression; 3) eight intervention modules (the core of the system) including activities to prevent depression, to be proposed by the DSS and chosen by the patient. The intervention is biopsychosocial and multi-component, including the following modules: physical exercise, improving sleep, expanding relationships, problem solving, improving communication skills, assertiveness training, making decisions and managing thoughts. Patients will implement the recommendations and the tool will monitor these actions, offering feedback to improve their PPP at 3, 6 and 9 months. The intervention also includes an initial and single 15-minute face-to-face GP-patient interview.
223765309|NCT06034496|DEVICE|Active CES|Active CES group will receive a minimum of 250µA and up to 500µA depending on thresholding, once daily for 20 days (over the course of 4\~6 weeks), 20 minutes per day.
223765310|NCT06034496|DEVICE|Sham CES|Sham CES group will be identical to Active CES group with the exception of the device not administering any electrical current
223765311|NCT02909556|DEVICE|Transcatheter aortic valve replacement|Transcatheter aortic valve replacement via transfemoral access
223765312|NCT06577987|DRUG|CID-078 Monotherapy|Cyclin A/B-RxL inhibitor, twice-a-day in repeating 21-day treatment cycles until disease progression or discontinuation criteria.
223765313|NCT05952037|DRUG|Sonrotoclax|Administered orally as a tablet.
224229816|NCT06303999|DEVICE|Intermittent Oro-esophageal Tube|The group was given enteral nutritional support with IOE according to the following procedure: Before each feeding, inside and outside of the tube was cleaned with water. During feeding, the patient should maintain a semi-reclining or sitting position with mouth opened, and the tube was inserted slowly and smoothly into the upper part of the esophagus by medical staffs while the appropriate depth of intubation was checked with the calibration markings on the tube wall. The distance from the incisors to the head part of the tube should be between 22-25 cm. However, the specific depth should be evaluated based on patients' feedback and adjusted accordingly. After insertion, the tail part of the tube should be put into a container full of water and the absence of continuous bubbles indicated a successful intubation. Then, the feeding was to be conducted three times per day with 50 ml per minute and 400-600ml for each feeding.
224229817|NCT06303999|DEVICE|Nasogastric tube|Within 4 hours after admission, the placement of the feeding tube was conducted by professional medical staffs and after intubation, the tube was secured to the patient\&#39;s cheek with medical tape. The feeding was conducted once every 3-4 hours, with 200-300ml each time. The total feeding volume was determined based on daily requirements. The feeding content was formulated by the nutritionists based on the condition and relevant guidelines to reach the energy demand as 20-25 kcal/kg/day and protein supplementation of 1.2-2.0 g/kg/day for both two groups. For patients with limited tube feeding compliance, we made appropriate adjustments to ensure that they were not at risk of severe malnutrition as much as possible.
224229818|NCT05300984|OTHER|Topical Placebo Cream|cosmetic cream to be applied topically on face and forearms twice/daily using split/face design
224229819|NCT05300984|OTHER|Topical Cream with 0.5% Active|cosmetic cream to be applied topically on face and forearms twice/daily using split/face design
223765314|NCT05952037|DRUG|Zanubrutinib|Administered orally as a capsule.
223765315|NCT04593030|DRUG|Warfarin|Warfarin dispensing claim is used as the reference
224229820|NCT05300984|OTHER|Topical Cream with 1% Active|cosmetic cream to be applied topically on face and forearms twice/daily using split/face design
223765316|NCT04593030|DRUG|Apixaban|Apixaban dispensing claim is used as the exposure
223765317|NCT00215046|DRUG|Vinblastine|drug - dosage and frequency is based on size of patient and response to treatment.
223765318|NCT00215046|DRUG|Methotrexate|drug - dosage is based on size of patient and frequency and duration is based on response to treatment.
224229821|NCT04919928|DEVICE|Cochlear Implant and Hearing aid in bimodal solution|"Sixty adult participants with bilateral hearing aids (HA) referred for cochlear implantation (CI) will be included in the study. It will be patients who report limited benefit with appropriately fitted HAs in daily speech communication in quiet and in noise. The patients are depending on visual cues for successful communication.~All the referred patients have potential optimal fitted HAs that are no longer sufficient to treat their hearing loss and to improve the daily communication. All the patients will then receive new replacement HAs with the ability to corporate with a CI for one month trial period. One month is considered as a sufficient adaptation period to new replacement HAs according to current clinical practice.~Thirty individuals randomised to receive the intervention with CI to the poorest hearing ear."
224319519|NCT03333265|DRUG|300mg Berberine hydrochloride|patients take the Berberine hydrochloride 300mg tablet by mouth, 2 times a day with 6 months
223765319|NCT04961047|BEHAVIORAL|Digital neurotherapy (DNT) Treatment|The experimental group will have 8 weeks of DNT 4 times a week for 30 minutes in the participant's home. The computer-presented training will be done on the participants' tablets or personal computers with the Rejuvenate brain training program
223765320|NCT04961047|BEHAVIORAL|Wait list control group|Waiting-list control group participants will be offered 8 weeks of DNT training at the completion of the final outcome assessment.
223765321|NCT03892720|OTHER|Quality-of-Life Assessment|Ancillary studies
223765322|NCT03892720|OTHER|Questionnaire Administration|Ancillary studies
223765323|NCT03892720|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
223765324|NCT02786485|BIOLOGICAL|rivogenlecleucel|T cells transduced with iCasp safety switch
223765325|NCT02786485|DRUG|Rimiducid|administered to treat GVHD
223765326|NCT06214208|OTHER|Transcutaneous Spinal Stimulation|Transcutaneous spinal stimulation will be delivered for 30 minutes using biphasic pulses. A single cathode electrode will be placed over the skin of the back spine at the T11/T12 spinous interspace. Two reference electrodes will be placed over the stomach. Stimulation intensity will be set to 0.8x reflex threshold, as determined by posterior root muscle reflex testing before the intervention. Treatments will be a minimum of 72 hours apart.
223765327|NCT02377089|DEVICE|Trigeminal Nerve Stimulation|Subjects will be randomized to treatment with either active or sham TNS for a period of eight weeks. The programming will be set by an individual who has no contact with subjects to deliver TNS in a double-blind manner (n=37 in each group) at the active frequency of 120 Hz. TNS will be performed for approximately 8 hours each night, a protocol that subjects found acceptable in the pilot work.
223641930|NCT03990792|OTHER|Brief psychoeducational intervention|The intervention consists of an App that weekly send brief psychoeducational messages about physical and mental health (depression, anxiety, sleep hygiene, physical activity, etc.)
223641931|NCT00926718|DRUG|remifentanil infusion|rocuronium dose 0 mg/kg + remifentanil infusion of 2ng ml-1
223641932|NCT00926718|DRUG|rocuronium dose + remifentanil infusion|rocuronium dose 0.4 mg/kg+ remifentanil infusion of 2ng ml-1
223641933|NCT00926718|DRUG|rocuronium dose + remifentanil infusion|rocuronium dose 0.6 mg/kg+ remifentanil infusion of 2ng ml-1
223641934|NCT00926718|DRUG|remifentanil infusion|rocuronium dose 0 mg/kg + remifentanil infusion of 8ng ml-1
223641935|NCT00926718|DRUG|rocuronium dose + remifentanil infusion|rocuronium dose 0.4 mg/kg+ remifentanil infusion of 8ng ml-1
223641936|NCT00926718|DRUG|rocuronium dose + remifentanil infusion|rocuronium dose 0.6 mg/kg+ remifentanil infusion of 8ng ml-1
223641937|NCT00689039|DRUG|AZD1305|ER tablet, administered as single and repeated doses.
223641938|NCT00689039|DRUG|Placebo|Tablet, administered as single and repeated doses.
223641939|NCT01544205|OTHER|fMRI-based neurofeedback|5 sessions lasting one hour each
223641940|NCT03326713|BEHAVIORAL|Telephone Counseling & Navigation (TCN)|A health coach will conduct a 30-45 minute telephone counseling session with participants. Prior to the telephone session, participants will receive the same brochure that the TP arm receives. After the phone call, participants will receive a tailored follow-up letter which will include images tailored to the individual's age, self-identified ethnicity, and family composition.
223641941|NCT03326713|BEHAVIORAL|Mailed Targeted Print (TP)|Participants will be mailed an educational brochure within two weeks of completing the baseline survey that addresses important evidence-based theoretical targets: CGRA guideline (knowledge), threat appraisal (to validate or raise risk perceptions, HBOC seriousness), response efficacy (benefits and expectations about CGRA), self-efficacy messages (CGRA resources, insurance reimbursement, and assistance for those with financial challenges) and possible actions to take (make an appointment and discuss with provider). Both the targeted print and tailored intervention materials were developed using formative community engaged research methods.
224229822|NCT04919928|DEVICE|Bilateral hearing aids|Thirty individuals randomised to the control group will continue use of the new replacement HAs another three months, thus in total of four months of use.
223641942|NCT03326713|OTHER|Usual Care (UC)|A usual care arm is included to assess CGRA uptake in the absence of intervention as well as priming from the surveys for the primary outcome analysis.
223641943|NCT02612272|DRUG|Ketorolac|intra-articular ketorolac
223765328|NCT02377089|DEVICE|Placebo|Subjects will be randomized to treatment with either active or sham TNS for a period of eight weeks. The programming will be set by an individual who has no contact with subjects to deliver TNS in a double-blind manner (n=37 in each group) at the sham frequency of 0 Hz. TNS will be performed for approximately 8 hours each night, a protocol that subjects found acceptable in the pilot work.
223765329|NCT03277261|BIOLOGICAL|Ublituximab|Administered as an IV infusion.
223765330|NCT03277261|DRUG|Teriflunomide|Film-coated tablets administered orally.
223765331|NCT03277261|DRUG|Oral Placebo|Administered orally.
223765332|NCT03277261|DRUG|IV Placebo|Administered as an IV infusion.
224229823|NCT05485675|BEHAVIORAL|Stand & Move at Work|Web-based platform only.
224229824|NCT05485675|BEHAVIORAL|Stand & Move at Work+|Web-based platform and support from an expert facilitator
223641944|NCT02612272|DRUG|Betamethasone|intra-articular betamethasone
223641945|NCT04514861|DEVICE|Wireless Lumee Oxygen Platform|The Lumee Oxygen Platform is designed to monitor oxygen dynamics with a hydrogel placed in subcutaneous tissue
224229825|NCT05300932|DRUG|Baricitinib|Orally take Baricitinib 4mg everyday for 48 weeks
224229826|NCT05300932|DRUG|Cyclophosphamide|Subject received cyclophosphamide 400mg intravenous drip every 2 weeks combined with oral Prednisone 10-15 mg/d （standard of care）through the 24 weeks double blind period. Subsequently, subject were administered oral Baricitinib 4mg everyday through the 24-48 weeks open label period.
224229827|NCT04679870|DRUG|GB2064|GB2064 (formerly PAT-1251) is a high-affinity, selective, mechanism-based, small molecule inhibitor of LOXL2, administered twice a day
224229828|NCT02410512|DRUG|Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 [PD-L1] antibody|Atezolizumab will be administered intravenously.
224229829|NCT02410512|DRUG|MOXR0916, a humanized agonist anti-OX40 monoclonal antibody|MOXR0916 will be administered intravenously.
223641946|NCT03719079|DEVICE|SimpleSENSE|The Nanosense study is observational only. No interventions will be triggered by the SimpleSense device
223641947|NCT01624350|DEVICE|Permacol collagen paste|Collagen paste intended to reinforce soft tissue where filling is required such as to repair fistulas, including anal and rectal fistulas.
223641948|NCT00684918|DRUG|Obatoclax|A 3-hour IV infusion for 3 consecutive days or a 24-hour infusion for 3 consecutive days every 2 weeks for up to 6 cycles.
223765333|NCT04977323|OTHER|TICK-B group|These interventions will use as distraction techniques.
223765334|NCT02597010|DIETARY_SUPPLEMENT|Dietary nitrate|140ml of nitrate rich beetroot juice provides 12.9mmol nitrate and will be consumed on a daily basis during the intervention by the study subjects.
223765335|NCT02597010|DIETARY_SUPPLEMENT|Placebo|140ml of nitrate depleted beetroot juice provides 0.5mmol nitrate and will be consumed on a daily basis during the intervention by the study subjects.
223765336|NCT05944250|DEVICE|Spincare matrix|The Spincare device, developed by Nanomedic, is the first portable tool that delivers a non-invasive, non-therapeutic electrospun, nanofibrous matrix dressing to wounds to promote healing.
223765337|NCT00714246|DRUG|Bortezomib|Dose escalation using traditional Phase I - 3 x 3 design to establish MTD of bortezomib when administered in combination with carboplatin and docetaxel
223765338|NCT00714246|DRUG|Carboplatin|Establish MTD of bortezomib when administered in combination with carboplatin and docetaxel
224229830|NCT02167464|DRUG|Renin treatment-guided Therapeutics|Patients are treated based upon their renin levels according to an approved algorithm.
224229831|NCT02167464|OTHER|Referral Hypertension specialist|Patients are referred to a hypertension specialist.
224229832|NCT02167464|DRUG|Aldosterone Antagonist|Spironolactone 12.5 - 25mg daily
224229833|NCT02051881|OTHER|Taking intestinal biopsies|
224229834|NCT00143156|DRUG|pregabalin|
224229835|NCT02903056|OTHER|Rett Syndrome|Diagnosis of Rett Syndrome
223641949|NCT01135550|DRUG|High dose dexamethasone|"Subject will receive 5 mg/m2 po divided in two doses. Dexamethasone 4mg/mL solution will be compounded into a 1mg/mL dosage form.~If symptoms are well controlled over 2 weeks time, tapering of dexamethasone can be considered. It will be at the treating physician's discretion to decide the start of the tapering of dexamethasone. The weaning schedule will be the same in both intervention arms: halving the dose once weekly (week 1, week 2) while continuing to give two doses/day, one half morning dose at week 3 and every second day at week 4."
223641950|NCT01135550|DRUG|Low dose dexamethasone|"Subject will receive 1 mg/m2 po divided in two doses. Dexamethasone 4mg/mL solution will be compounded into a 1mg/mL dosage form.~If symptoms are well controlled over 2 weeks time, tapering of dexamethasone can be considered. It will be at the treating physician's discretion to decide the start of the tapering of dexamethasone. The weaning schedule will be the same in both intervention arms: halving the dose once weekly (week 1, week 2) while continuing to give two doses/day, one half morning dose at week 3 and every second day at week 4."
224229836|NCT05062850|OTHER|observation|Our study does not involve an intervention. Chronic diseases and geriatric syndromes of the participants will be studied.
223641951|NCT00434746|DRUG|ILV-094|Single, ascending doses of 5, 15, 50, 100, 300, and 600 mg IV or SC dose of ILV-094 or placebo
223641952|NCT04504825|DRUG|CAEL-101|The investigational product, CAEL-101, is formulated as a sterile liquid solution of protein plus excipients for dilution in a single-use, stoppered, glass vial. Each 10 mL vial contains 300 mg of CAEL-101 at a concentration of 30 mg/mL. CAEL-101 will be diluted with commercially available 0.9% Normal Saline.
223641953|NCT04504825|OTHER|Placebo|Commercially available 0.9% Normal Saline will be used as the placebo.
223641954|NCT04504825|DRUG|cyclophosphamide, bortezomib, and Dexamethasone (CyBorD) regimen|According to institutional standard of care.
223641955|NCT01781546|PROCEDURE|drug-eluting balloon (DEB)|The length of the DEB is chosen so that the lesion and 2mm from both ends are covered by the DEB. If needed, several DEBs can be used to cover the whole lesion. The diameter of the DEB and the pressure used is chosen so that the balloon-artery -ratio is 0.8-1.0. In case of a flow limiting dissection, significant recoil or coronary perforation, a provisional BMS is implanted (stent-artery -ratio 1.1) and the post dilatation is performed if indicated (the lesion length is \>20mm or stent malapposition is suspected).
223641956|NCT01781546|PROCEDURE|bare-metal stent (BMS)|The BMS is implanted after predilatation (stent-artery -ratio 1.1) to cover the whole lesion and the postdilatation is performed if indicated (the lesion length \>20mm or stent malapposition is suspected).
223641957|NCT05991271|DEVICE|Venus-Vitae Transcatheter Heart Valve System|The Venus-Vitae THV is comprised of balloon-expandable and radiopaque cobalt-chromium alloy frame, porcine pericardium tri-leaflet, porcine pericardium inner skirt, polyurethane outer skirt, PTFE assembly sutures, and three radiopaque gold markers (Figure 1). The valve utilizes Venus Endura technology and stored in a non-aqueous condition.
224229837|NCT03562806|DIAGNOSTIC_TEST|PET/MR image acquisition|Acquisition of PET and MR sequences on SIGNA PET/MR device.
223641958|NCT06110026|OTHER|Brunkow Exercise Program|The brunkow exercise program will be comprised of four exercise programs. Each exercise will be performed with two sets of 15 reps, 10 sec per rep 40 min per day, thrice per week for a total of four weeks.
223641959|NCT06110026|OTHER|Lumbar Stabilization Exercises|The lumbar stabilization exercises will be comprised of four exercise programs. Each exercise will be performed with two sets of 15 reps, 10 sec per rep 40 min per day, thrice per week for a total of four weeks.
223641960|NCT05674656|DRUG|Dolutegravir/Rilpivirine FDC|Dolutegravir/Rilpivirine will be administered.
223641961|NCT00636298|DRUG|Bevacizumab, cetuximab|"Cetuximab - 400 mg/m2 loading, then 250 mg/m2 weekly~Bevacizumab - 10 mg/kg every 2 weeks"
223641962|NCT04773535|DEVICE|3D Motion analysis|Motion analysis using DyCare® Lynx system with inertial based sensors as well as an optoelectronic motion analysis system based on infrared cameras (11x Vicon infrared high speed cameras)
224229838|NCT00341354|BEHAVIORAL|Prolonged Mechanical Ventilation|
224229839|NCT00482547|DEVICE|Hydrogel Silver Salts Coated Latex Urinary Catheter System|Silver-coated catheter
224229840|NCT00482547|DEVICE|Bard silicone elastomer coated latex catheter system|Silicone-coated catheter
224319520|NCT03333265|DRUG|Placebo Oral Tablet|patients take mmic Berberine hydrochloride tablet by mouth, 2 times a day with 6 months
224319521|NCT04552860|BEHAVIORAL|Emotional Awareness and Expression Therapy|Focus on emotions, writing about stress, assertiveness training, role playing new ways to handle relationships, and sharing feelings and experiences with others.
223641963|NCT05500144|OTHER|Not applicable- no intervention administered|Not applicable- no intervention administered
223765339|NCT00714246|DRUG|Docetaxel|Establish MTD of bortezomib when administered in combination with carboplatin and docetaxel
223765340|NCT01448018|DRUG|ranibizumab|3 monthly intravitreous injection as soon as possible after the inclusion
223765341|NCT01448018|PROCEDURE|hemodilution|hemodilution using erythrocytapheresis - target hematocrit: 35% - as soon as possible after the inclusion
223765342|NCT04920851|DEVICE|cytokine hemadsorption|to compare the laboratory and clinical results of cytokine hemadsorption as an immunomodulation therapy in COVID-19 ICU patients with or without sepsis.
224229841|NCT01576978|BEHAVIORAL|hatha yoga|The women's group of Yoga will participate in ten week sessions of Yoga once a week for an hour. The sessions will be taught by instructor of Hatha Yoga. For the intervention were chosen 37 postures, three breathing exercises. The sessions were divided into three stages: quieting the mind , breathing rate and the heating of the main joints, postures and breathing exercises, meditation and relaxation. At the beginning and end of each session, we evaluated the pain intensity.Pregnant women in the control group Postural orientations will receive a booklet containing guidelines postural figures and explanatory text on some possible changes in the curvatures of the spine during pregnancy suggestions for positioning of the spine for daily activities, lying postures, sitting and standing. After ten weeks the two groups will be scheduled for the final collection of data.
224319522|NCT03631316|DRUG|Generic Valganciclovir|900 mg daily during 4 days
224319523|NCT03631316|DRUG|Innovative Valganciclovir|900 mg daily during 4 days
224319524|NCT02396719|DEVICE|LenSx® Laser|Used for cornea incision, capsulotomy and lens fragmentation during cataract surgery
224319525|NCT00606632|DRUG|124-Iodine-cG250 (124I-cG250)|i.v. and PET/CT scan 4+/-2 days after administration
224319526|NCT00606632|PROCEDURE|CT|contrast enhanced CT scan
223641964|NCT03747562|DRUG|Gabapentin|Gabapentin will be administrated orally, with or without food, and should be swallowed with sufficient fluid intake (e.g. a glass of water). Since head and neck cancer patients frequently experience swallowing difficulties, gabapentin capsules will be provided to enable opening of the capsule and use of the contents for mixture with food or liquids. Moreover, gabapentin powder can be dissolved in water to enable injection of the drug into a percutaneous endoscopic gastrostomy tube.
223641965|NCT03747562|OTHER|Placebo|Placebo will be administrated orally, with or without food, and should be swallowed with sufficient fluid intake (e.g. a glass of water). Since head and neck cancer patients frequently experience swallowing difficulties, placebo capsules will be provided to enable opening of the capsule and use of the contents for mixture with food or liquids. Moreover, placebo powder can be dissolved in water to enable injection of the drug into a percutaneous endoscopic gastrostomy tube.
223641966|NCT05225090|OTHER|Smartphone App|"Medisafe is a Med\_App that is free and has been used in several studies evaluating medication adherence. Patients will receive individualized instruction and be followed for 12 weeks. The researcher will show the patients how to input current medication list, set up medication reminders and track if daily doses have been taken using the App (20 minute training session). After the participant has input their medication information into the app, the researcher will assist the participant in adding an optional Medifriend who will be alerted if the participant misses a dose as an option. The participant will also be provided with written instructions about the Medisafe app to take home for reference. At each office visit (4, 8, and 12 weeks) participants will complete a medication checklist and reconciliation form with the research staff. Participants will also be asked to send a medication status report through the Medisafe app."
223641967|NCT01394016|DRUG|Abemaciclib|Administered orally.
223641968|NCT01394016|DRUG|Fulvestrant|Fulvestrant is administered intramuscularly into the buttocks in Part G only.
223641969|NCT03534804|DRUG|Cabozantinib|Cabozantinib is administered at 40 mg oral daily
224229842|NCT01994603|BEHAVIORAL|Opt-in or Opt-out testing|Study participants will be offered a health screening onsite.
224229843|NCT01994603|BEHAVIORAL|Focus Group|Study participants will be invited to participate in a focus group discussion.
224229844|NCT02015793|BIOLOGICAL|Adalimumab|Adalimumab pre-filled syringe, administered by subcutaneous injection.
224229845|NCT02015793|BIOLOGICAL|Placebo for adalimumab|Placebo for adalimumab pre-filled syringe, administered by subcutaneous injection to maintain double-blind.
224229846|NCT01392898|DRUG|liraglutide|liraglutide 1.8 mg q.d.
224229847|NCT01392898|DRUG|Insulin|insulin dosed according titration scheme
224229848|NCT03892148|DRUG|Furosemide|Protocol for the use of diuretics
224229849|NCT03892148|DRUG|Hydrochlorothiazide|Protocol for the use of diuretics
224229850|NCT05555589|DRUG|RGN-259|A preservative-free, sterile eye drop solution containing Tβ4 for direct instillation into study eye(s), five times per day for 28 days
224229851|NCT05555589|DRUG|Placebo|It is composed of the same excipients as RGN-259 but does not contain Tβ4. Direct instillation into study eye(s), five times per day for 28 days
224229852|NCT00303992|BIOLOGICAL|trastuzumab|
224229853|NCT00303992|DRUG|irinotecan hydrochloride|
224229854|NCT01685970|DRUG|High volume split-dose PEG|High volume split-dose PEG 2L/2L 2 times before the day and at the day of colonoscopy
223641970|NCT03534804|DRUG|Pembrolizumab|Pembrolizumab will be administered at a fixed dose of 200mg intravenously every 3 weeks.
223641971|NCT06313112|OTHER|Observational study|Observational study
223641972|NCT00397501|BIOLOGICAL|trastuzumab|"Trastuzamab, 6mg/kg, within 48 hrs before BBBD~Then, Trastuzumab, 2mg/kg, weekly until next BBBD Then continue for 12 cycles"
223765343|NCT03898661|DRUG|Collagenase histiolyticum|local injection of collagenase histiolyticum into the esophageal stricture, 1 day before balloon dilation
223765344|NCT02365597|DRUG|Erdafitinib|8 mg orally once daily for 28 days on a 28 day cycle.
223765345|NCT02365597|DRUG|Midazolam|Participants who enrolled in DDI substudy will receive pretreatment with single dose of midazolam on Day -2 and single dose of midazolam on Day 13.
223765346|NCT02365597|DRUG|Metformin|Participants who enrolled in DDI substudy will receive pretreatment with single dose of metformin on Day -1 and single dose of metformin on Day 14.
223765347|NCT03409471|DEVICE|Flocked Swab|At the colposcopy clinic, vaginal self-sample will be collected with the Flocked Swab (Noble Bioscience, Inc., Korea).
224229855|NCT01685970|DRUG|2 sachets of picosulfate|2 sachets of picosulfate 2 times for bowel preparation at the day of colonoscopy
224229856|NCT05890456|BEHAVIORAL|Students with Involved Families and Teacher Program|The SWIFT Program is a 9-12 month intervention that includes four components: (a) behavioral progress monitoring, (b) clinical supervision of the intervention elements and coordination with the school, (c) parent support to promote parent engagement/collaboration with the school and study routines in the home, and (d) behavioral skills coaching for students.
224229857|NCT05890456|BEHAVIORAL|Services As Usual|The SAU students and families will continue to receive any services that they were receiving prior to their entry into the study. These may include school-based interventions and supports and related services as required in the student's Individualized Education Program.
224229858|NCT05084690|OTHER|Unilateral resistance training|Unilateral resistance training of the elbow flexors
224229859|NCT05084690|OTHER|Illusionary mirror visual feedback|Modified Ramachandran's mirror box
224229860|NCT05030090|BEHAVIORAL|Nutritional consultant|The control group is to be consulted by the dietitian using communication software (Line) or telephone to evaluate the nutritional requirement and guide the cancer diet principles before starting the project.
224229861|NCT05030090|DIETARY_SUPPLEMENT|Nutritional consultant + High-calorie, high-protein liquid nutrition supplement|At the beginning of the plan, the dietitian first calculates the patient's daily calorie intake and the ratio of the three macronutrients and guides the patients or their family members of the nutritional care plan group A to implement a daily diet with a concentrated high-calorie and high-protein liquid supplement (Commercial formula contains 425 kcal and 19.1 grams of protein).
224319527|NCT05167799|DEVICE|Cardiac Contractility Modulation (CCM)|Patients will be implanted with CCM device according to indications, to improve Heart Failure symptoms and then enrolled in the Registry if they fullfil Inclusion and Exclusion Criteria (First of all if they are diagnosed with TTR Amyloidosis)
223765348|NCT03409471|DEVICE|Cervical Brush|Physician collected cervical sample will be collected also at the colposcopy center with the Cervical Brush (Noble Bioscience, Inc., Korea).
223765349|NCT03409471|DIAGNOSTIC_TEST|HPV assay|The hrHPV assay used, will be the Roche Cobas® 4800 HPV test, Anyplex™ II HPV HR detection kit and Realtime HPV HR-S Detection kit.
223765350|NCT04698161|OTHER|Biological sample collection|Collection of faeces, coproculture examination, urine, saliva, PBMC and blood for biobanking, to evaluate the proteomic, metascriptomic, metabolomic, metagenomic, and metagenetic profile, and to perform routine screening. Analysis for the identification, quantification and characterization of health-promoting bacteria
223765351|NCT04698161|OTHER|Questionnaire|Anamnestic questionnaire, 3-day food questionnaire, Food Frequency Questionnaire
223765352|NCT04698161|OTHER|Medical examination|Blood pressure measurement, abdominal and thoracic physical examination
223765353|NCT04894045|OTHER|Personalized management|Intraoperative MAP will be maintained at least at the mean nighttime MAP (assessed using preoperative automated blood pressure monitoring). If the mean nighttime MAP is below 65 mmHg, intraoperative MAP will be maintained at least at 65 mmHg.
223765354|NCT03111654|DIAGNOSTIC_TEST|Compare the risk of a vascular event|"Collected in a post-stroke follow-up consultation, patient clinical outcome data, functional and cognitive disability, standardized, using validated scales.~Analysis of selected therapeutic options for the prevention of AF ischemic events."
224229862|NCT05030090|COMBINATION_PRODUCT|Nutritional consultant + Liquid supplement + Powdered supplement 1 and 2|At the beginning of the plan, the dietitian first calculates the patient's daily calorie intake and the ratio of the three macronutrients and guides the patients or their family members of the nutritional care plan group B to implement a daily diet with a concentrated high-calorie and high-protein liquid supplement (Commercial formula contains 425 kcal and 19.1 grams of protein). Meanwhile, nutrition care plan group B will be given powdered supplement 1 (containing β-glucan and gamma-aminobutyric acid) and nutritional products and powdered supplement 2 (contains water-soluble dietary fiber and probiotics).
224229863|NCT04853810|OTHER|CUTADIAB questionnaire|During a regular diabetes follow-up consultation, the patient is asked to complete the CUTADIAB questionnaire on a tablet, entirely dedicated to the study
224229864|NCT03935659|DEVICE|Negative Pressure Pressure Wound Therapy|Investigators will be using a Negative Pressure Wound Therapy Powered Suction Pump on primarily closed groin wounds after open common femoral artery exposure, The Negative pressure dressing will be applied in a sterile fashion in the operating room. The negative pressure dressing will be removed at day 5 postoperatively, or at discharge, whichever occurs first.
224229865|NCT03935659|PROCEDURE|Standard Wound Care|Standard sterile gauze coverage of the primarily closed groin wound.
224229866|NCT01682161|DRUG|Paliperidone palmitate|Paliperidone palmitate will be administrated in accordance with each product's information. Recommended initial loading doses are 150 mg equivalent on Day 1 and 100 mg equivalent on Day 8, followed by subsequent once-monthly administration with 75 mg equivalent or flexible dose between 25 mg and 150 mg equivalent.
223641973|NCT00397501|DRUG|carboplatin|200mg/m2/day x 2 days; total dose 400mg/m2 Infused i.a. over 10 mins in 200ml of normal saline after MTX infusion
223641974|NCT00397501|DRUG|methotrexate|2500 mg/day x 2 days; total dose 5000mg Infused over 10mins in 200ml saline beginning immediately after mannitol infusion
223641975|NCT00397501|DRUG|sodium thiosulfate|STS dose admin i.v. over 15mins @ 4hrs post carboplatin = 20gm/m2; STS dose admin i.v. over 15mins @ 8hrs post carboplatin = 16gm/m2
223641976|NCT05821127|BEHAVIORAL|Virtual Reality Assisted Neurodynamic Exercises and Patient Education with Telerehabilitation Method|A brochure showing the execution of median nerve and tendon gliding exercises and a wrist brace for night use will be provided. In addition, 2 sessions of patient education will be provided with videoconference calls, and with the mobile application to be installed on the phones of the patients as non-immersive virtual reality support, it will be possible to practice median nerve and tendon gliding exercises in the form of 5 repetitions and 6 sets every day with video support for 16 weeks. In this application, the user will use the front camera of phone as a sensor to detect hand movements. A screen on which exercises will be played at the top of the screen and a virtual image of the user's hand in the lower half of the screen will be displayed in the field of view of the camera. Each exercise position will take 5 seconds. Patient education will include neuroscience, etiology, pathophysiology and treatment options of carpal tunnel syndrome, ergonomics and posture education.
223641977|NCT05821127|BEHAVIORAL|Neurodynamic Exercises and Patient Education with Traditional Method|A brochure showing the execution of median nerve and tendon gliding exercises and a wrist brace for night use will be provided. Patients will be asked to do the exercises in the form of 5 repetitions and 6 sets every day and to wear the night splint every night for 16 weeks. Each exercise position will take 5 seconds. A brief verbal education will be given to the patients under the same topics as the intervention group, as in the outpatient clinic.
223641978|NCT05877924|DRUG|NBL-020 for Injection|NBL-020 for Injection, Q3W, i.v.
223641979|NCT03645824|DRUG|Pacritinib|Patients receive up to 4 cycles of pacritinib before allo-SCT
223641980|NCT05835284|DEVICE|Investigational Edge-on Silicon Photon Counting CT device|Administration of IV contrast material, if applicable, shall be done according to the hospital's SOC. Administration of oral contrast material, if applicable, shall also be done according to the hospital's SOC. Images will then be compared with the previously acquired CT conducted as standard of care. The investigational scan will take approximately 60-120 minutes.
223641981|NCT02718404|PROCEDURE|MR-HIFU Treatment|"The Philips MR-HIFU Sonalleve System integrates a high intensity phased array focused ultrasound transducer with a 3 Tesla Magnetic Resonance (MR) imaging system and electromechanical transducer positioning system to deliver spatially and temporally controlled ultrasound energy and thermal heat to tissues non-invasively.~At HIFU day (day 0) before treatment patient will be performed a bone lesion MRI and a functional brain MRI."
223641982|NCT02718404|DRUG|MR contrast media and medications|During the treatment procedure, an intravenous catheter will deliver MR contrast media and medications (such as sedation and analgesics if required) within the MR room.
223641983|NCT02718404|PROCEDURE|MR images|Following the MR-HIFU procedure, a set of MR images of the target region will be acquired with the use of a MR contrast agent, together with a functional brain MRI.
223765355|NCT00499603|DRUG|Paclitaxel|80 mg/m\^2 by vein once weekly over 1 hour on day 1(+/- 2 days) each week for 3 weeks and for 12 cycles.
223765356|NCT00499603|DRUG|5-Fluorouracil|500 mg/m\^2 by vein on day 1 every 3 weeks (+/- 7 days) for 4 cycles.
223765357|NCT00499603|DRUG|Epirubicin|100 mg/m\^2 by vein on day 1 every 3 weeks (+/- 7 days) for 4 cycles.
224229867|NCT01344408|PROCEDURE|Computer-training|"The computer-training program Move IT To Improve IT is a exercise program which is installed and used on a Apple Imac in the patients home to support vestibular rehabilitation"
224229868|NCT04648293|DEVICE|Starling|Starling is a portable, non-invasive, cardiac output detector system. The Starling monitor measures the cardiac output by employing electrical bioreactance that measures the electrical characteristics of a volume of tissue and fluid. In the case of cardiac output measurements, the relevant tissue includes the heart and the immediate surrounding volume of the thorax. The relevant fluid is blood. Baxter Healthcare's Starling electrode is a double electrode sensor. Within each sensor, one electrode is used to transmit a high frequency sine wave into the body, while the resulting voltage is measured at the adjacent electrode. Four electrodes are placed at specific areas of the thorax, the impedance to the current flow calculated, and the electrical bioreactance waveform constructed. This information is used to determine cardiac output, and measures and displays associated hemodynamic parameters based on calculations of measurements already incorporated into the Starling device.
224229869|NCT00510549|PROCEDURE|Modality: Peritoneal Dialysis|Peritoneal Dialysis: CAPD; Hemodialysis: 3 times/week
224319528|NCT06037005|OTHER|Cognitive Behavioral Therapy Group|Group intervention program based on cognitive behavioral approach of ten sessions; It was completed in approximately one and a half months (May-June 2022) in the Faculty of Nursing, by dividing the experimental group into two separate groups, two days a week for each group. Each session was held for approximately one hour. The last measurement was made three months after the last therapy session (September 2022).
224319529|NCT01933477|OTHER|MCH-focused ART services|Post-partum women who are breast feeding will be retained in the antenatal clinic to receive continued MCH-focused ART services until after the end of breastfeeding and once infants' final HIV status is determined.
224319530|NCT00711880|DRUG|Sativex®|containing THC (27 mg/ml):CBD (25 mg/ml), in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring. Maximum permitted dose was eight actuations in any three hour period and 24 actuations (THC 65 mg: CBD 60 mg) in 24 hours
224319531|NCT00711880|DRUG|Placebo|containing peppermint oil, 0.05% (v/v), quinoline yellow, 0.005% (w/v), sunset yellow, 0.0025% (w/v), in ethanol:propylene glycol (50:50) excipient.
224319532|NCT02779166|DRUG|Celecoxib|Received 400mg celecoxib prior to surgery
223641984|NCT05313971|OTHER|Self knowledge course|The online self-knowledge and communication course, created for the purpose of this clinical trial and taught by professionals with certified training in the area by the Shalom Enneagram Institute (https://iesh.pt/), consisted of providing volunteers with mechanisms for self-knowledge using the enneagram. Three modules were carried out between October and December 2020, spaced in time to allow participants to consolidate knowledge: there was 1 month between the first and second module, and between the second and third, 3 weeks.
223641985|NCT04214821|DRUG|Levofloxacin Ophthalmic Solution|Levofloxacin hydrate, an aqueous ophthalmic solution, to be given one drop at a time, 4 times daily for 3 days pre-operatively and one drop on the day of operation.
223641986|NCT04214821|DRUG|Moxifloxacin Ophthalmic Solution|Moxifloxacin hydrochloride, an aqueous ophthalmic solution, to be given one drop at a time, 4 times daily for 3 days pre-operatively and one drop on the day of operation.
223641987|NCT00174187|DRUG|Somatropin|liquid, daily, until final height Dosage: 0,46 mg/kg/week . The maximum dose should not exceed 50 µg/Kg/day
223641988|NCT02000206|DRUG|Propofol|
223641989|NCT02000206|DRUG|Ketamine|
223641990|NCT02000206|DRUG|Alfentanil|
223641991|NCT00344201|DEVICE|Tisseel fibrin adhesive|Intraoperative application to scleral bed and graft
223641992|NCT05142501|OTHER|Blood samples|Four consecutive blood sampling throughout the overall follow-up period of 12 months.
223641993|NCT05228951|DRUG|Pyrotinib maleate, dalpiciclib, Trastuzumab, letrozole|After providing written informed consent, the participants will undergo combined treatment of pyrotinib maleate, CDK4/6 inhibitor dalpiciclib, trastuzumab and letrozole. The effectiveness of the combined treatment will be evaluated by MRI every two treatment cycles. If the disease progresses, the participant will withdraw from the trial. If the combined treatment has identified effectiveness, the participant will undergo surgical treatment within 4 weeks (over 2 weeks) after termination of the neoadjuvant treatment. The patients will be followed up for 5 years.
223641994|NCT03453268|OTHER|STEP DOWN strategy|"reduction of the number of antihypertensive medication according to:~* the systolic blood pressure levels,~* co-morbidities"
223641995|NCT03453268|OTHER|Control|usual treatment
223641996|NCT04978675|DRUG|Fluorine F 18 rhPSMA-7.3|Given IV
223641997|NCT04978675|PROCEDURE|Magnetic Resonance Imaging|Undergo PET/MRI
223641998|NCT04978675|PROCEDURE|Positron Emission Tomography|Undergo PET/MRI
223641999|NCT06012916|DRUG|Esketamine nasal spray|This is an observational study. The Esketamine nasal spray is administered by the attending physician during a regular treatment appointment at the Interventional Psychiatry Clinic. Esketamine dosages may range between 28-84mg. The study does not interfere with the individual treatment plan in any way.
223642000|NCT04220307|BIOLOGICAL|AK104|Subjects will receive AK104 by intravenous administration
223642001|NCT04248634|PROCEDURE|Delayed colo-anal anastomosis|"Colo-anal anastomosis performed in two surgical steps:~\- Step one: the colon is exteriorized transanally and 5 cm of the colon is left outside without anastomosis creation.~Step two: after 7 days, the excess colon is resected and the colo-anal anastomosis is created."
223765358|NCT00499603|DRUG|Cyclophosphamide|500 mg/m\^2 by vein on day 1 every 3 weeks (+/- 7 days) for 4 cycles.
223765359|NCT00499603|DRUG|RAD001|30 mg by mouth weekly on Days 1, 8, \& 15 for 12 cycles.
223765360|NCT00262548|DRUG|Rosuvastatin; improvement of lipid profile|
223765361|NCT03524027|PROCEDURE|Posterior Vertebral Column Resection (PVCR)|Posterior Vertebral Column Resection (PVCR) Surgical Technique for Correction of Adolescent Thoracolumbar Congenital Kyphoscoliosis (CKS) Spinal Deformity
223765362|NCT01585142|OTHER|Test formula|Infant Formulas in powder in single-serve capsules (with a machine for dispensing, four consecutive formulas with customized composition
224319533|NCT02779166|DRUG|placebo|
223642002|NCT00759941|DRUG|Brinzolamide 1% ophthalmic solution (Azopt)|One drop three times a day in both eyes for 3 months
223765363|NCT00143611|DRUG|Resatorvid|Resatorvid 1.2 mg/kg, injection, subcutaneously for thirty minutes; then resatorvid 0.05 mg/kg/h (1.2 mg/kg/day), injection, subcutaneously over 96 hours.
224319534|NCT04341324|OTHER|It is an observational study.|
223642003|NCT00759941|DRUG|Placebo eye drops|One drop three times a day in both eyes for 3 months
223642004|NCT00759941|DRUG|Latanoprost 0.005% ophthalmic solution (Xalatan)|One drop once a day in both eyes for 3 months
223642005|NCT06104462|DEVICE|Intermittent theta burst stimulation (iTBS)|"The iTBS protocol consists of 20 trains of stimulation. Each train comprises ten 3-pulse bursts, delivered at an intra-burst frequency of 50 Hz, with a 5 Hz overall frequency, followed by 8 seconds of rest. A total of 600 pulses (10\*3\*20) will be administered in this 3-minute iTBS protocol. Concurrent TBS/fNIRS stimulation will be applied over the left DLPFC at an intensity of 90% of the resting motor threshold (RMT), which is considered appropriate to ensure compliance and elicit robust DLPFC activation.~Considering that the fNIRS optode beneath the coil increases the distance between the TMS coil and the skull by 10 mm, we will use the equation AdjMT% = MT + 2.8 \* (Dsitex - Dm1). Therefore, 2.8 \* 10 = 28% will be added to the normal intensity. The stimulation site over the DLPFC will be determined by the MNI coordinate (x-38, y+44, z+26) reported in previous studies."
223642006|NCT04760808|DIAGNOSTIC_TEST|Baseline Clinical Examination|Evaluations of Postural control; Subjective postural vertical; Subjective visual vertical; Verticality perception
223642007|NCT04760808|RADIATION|Initial 3T MRI of the Brain and Spine|Non-injected CSF flow MRI
223642008|NCT04760808|DIAGNOSTIC_TEST|6-month Follow-up Clinical Examination|Evaluations of Postural control; Subjective postural vertical; Subjective visual vertical; Verticality perception
223642009|NCT04760808|RADIATION|6-month Follow-up 3T MRI of the Brain and Spine|Non-injected CSF flow MRI
223642010|NCT05398172|DEVICE|MorpheusV Applicator|Eligible subjects will receive 3 treatments 4 weeks apart with the MorpheusV Applicator according to the study protocol
223642011|NCT06078124|BEHAVIORAL|Sibling Support for Adolescent Girls in Emergencies|"The Sibling Support for Adolescent Girls in Emergencies (SSAGE) intervention is a gender-transformative, 12-week program utilizing a whole family approach wherein an adolescent girl, her male sibling, and a male and female caregiver participate in sessions that are age- and gender-specific and combined with family-wide discussions of session learnings. The sessions are interactive, engaging, and promote self-reflection and discussion on topics such as power, gender, interpersonal communication, and healthy relationships. Given the whole-family approach, SSAGE addresses intersections between spousal relationships, caregiver-child relationships, and relationships between siblings, as they pertain to supporting the mental health and psychosocial well-being of adolescent girls."
223642012|NCT04017546|DRUG|CYC065|intravenous infusion
223642013|NCT04017546|DRUG|Venetoclax|oral capsule
223642014|NCT06135805|DRUG|Fluocinonide 0,05% oral gel|Application of Fluocinonide oral gel on oral syntomatic lesions
223642015|NCT06135805|DRUG|Placebo|Application of placebo oral gel on oral lesions
223642016|NCT04006587|DEVICE|incentive spirometer|patients were instructed how to use the IS in a seated or semi-seated position, and to maintain sustained maximal inspiration for 3-5 seconds before exhalation, ten times per hour, and for at least eight hours a day.
223642017|NCT04806685|BEHAVIORAL|Sleep education|Medical nutrition therapy plus behavior-based sleep education intervention
223642018|NCT04806685|BEHAVIORAL|Diet only|No sleep education
223642019|NCT01016249|DRUG|Treatment 1. (5% Hypertonic saline + Epinephrine)|Nebulization of 4ml 5% saline mixed with 1.5 ml of epinephrine on enrollment and every 4 hours thereafter until ready for discharge.
223642020|NCT01016249|DRUG|Treatment 3. (3% Hypertonic saline + Epinephrine)|Nebulization of 4ml 3% saline mixed with 1.5 ml of epinephrine on enrollment and every 4 hours thereafter until ready for discharge.
223642021|NCT01016249|DRUG|Treatment 2. (Normal saline + Epinephrine)|Nebulization of 4ml 0.9% saline mixed with 1.5 ml of epinephrine on enrollment and every 4 hours thereafter until ready for discharge.
223642022|NCT01198977|BEHAVIORAL|Brief telephone-based counseling|Brief telephone-based counseling using Motivational Interviewing and physical activity goal setting and problem solving
223642023|NCT01198977|OTHER|Education counseling|Mailed informational video of exercise programs
223642024|NCT03873077|PROCEDURE|local infiltration analgesia|10 mL ropivacaine 7.5 mg/mL and 10 mL lidocaine 10 mg/mL
223642025|NCT04951024|PROCEDURE|Thoracolumbar interfacial plane (TLIP) Block|TLIP Block: Bilateral 20 ml 0.25 % Bupivacaine injected between multifidus and longissimus muscle with Ultrasound guidance.
223642026|NCT04951024|PROCEDURE|Erector Spinae Plane (ESP) Block|ESP Block: Bilateral 20 ml 0.25 % Bupivacaine injected between the erector spinae muscles and transverse process with Ultrasound guidance.
223642027|NCT02368834|BEHAVIORAL|psychoeducation|The intervention included a presentation by a psychiatrist, with parent manual provided, and then two group sessions at the 2nd and 4th weeks to address further concerns of the parents
223642028|NCT04684277|DRUG|antidepressant treatment|depression recieve antidepressant treatment
223642029|NCT04684277|OTHER|antidepressant treatment combined with Internet-based interventions|depression recieve antidepressant treatment combined with Internet-based interventions
223642030|NCT01285557|DRUG|S-1 (Tegafur+Gimeracil+Oteracil) /cisplatin (investigational arm)|25 mg/m² body surface area (BSA) orally 2 times daily from Days 1 through 21 followed by a 7 day rest period, plus cisplatin 75 mg/m2 BSA on Day 1 each 28 day cycle Number of Cycles: until progression or unacceptable toxicity develops. Treatment with cisplatin is limited to a maximum of 8 cycles.
223642031|NCT01285557|DRUG|Fluorouracil/cisplatin (control arm)|"5-FU: 800 mg/m2 BSA/24 hours by continuous intravenous infusion (CIV) from Days 1 through 5 plus cisplatin 80 mg/m2 BSA on Day 1 each 21 day cycle.~Number of Cycles: until progression or unacceptable toxicity develops. Treatment with cisplatin is limited to a maximum of 8 cycles."
223642032|NCT06432296|DRUG|M701|Intra-peritoneal infusion of M701 in experimental group (M701 group\_
223642033|NCT06432296|PROCEDURE|paracentesis|Puncture and Draiange of ascites from the peritoneal cavity in both experimental group and control group
223642034|NCT06333860|DRUG|Risankizumab|Solution for Subcutaneous (SC) injection
224319535|NCT05392218|BEHAVIORAL|motivational interviewing|consisted of six sessions (twice each week) up to 30 minutes of individual sessions. Each session contained a different component and topic that included substance abuse, physical activity, healthy sleep, stress management, nutrition and social support. The components in order were randomized for each participant.
224323340|NCT05790252|DRUG|Buprenorphine Transdermal Matrix Patch|Buprenorphine transdermal patches will be applied at time of induction initiation and removed at 48 hours.
223642035|NCT06333860|DRUG|Deucravacitinib|Oral tablet
223642036|NCT05802212|DRUG|Metformin intervention for 12 weeks|PCOS patients were treated with metformin orally for 12 weeks, and various indicators related to fertility were observed.
223642037|NCT05927623|BEHAVIORAL|Multifaceted Virtual Fracture Prevention Program|"* Personalized exercise prescription: Comprised of muscle strengthening and balance exercises to perform three times a week, delivered and monitored remotely via the MisterFit app, a branded version of the secure commercially available Wibbi app (wibbi.com) and monthly virtual exercise consultations.~* Virtual nutrition counseling from a registered dietitian in months 2, 4 and 6: to encourage participants to meet daily targets for calcium and vitamin D (preferably from diet), and protein intake to support muscle accretion and target weight maintenance~* Virtual interactive information sessions in month 4 and 8: to education participants on topics identified as important by the Misterfit patient partner advisory committee."
223642038|NCT05927623|BEHAVIORAL|Attention Control|"* Encouraged to meet the 24-Hour Movement Guidelines for adults aged 65 years or older (https://csepguidelines.ca) with telephone contacts at the same frequency that the Misterfit online group receives virtual exercise consultations~* Nutritional fact sheets: sent by e-mail at the same frequency that the Misterfit online group meets with the research dietitian.~* Educational fact sheets: sent by e-mail at the same frequency that the Misterfit Online group has virtual interactive information sessions"
223642039|NCT00794716|DRUG|NRL972|Single dose of 2 mg NRL972 administered intravenously. Total volume 5mL.
223642040|NCT06117605|OTHER|Nurse SIRS alert|An electronic alert will display when a nurse opens the patient chart of a patient who meets SIRS criteria.
223642041|NCT06117605|OTHER|Prescribing clinician SIRS alert|An electronic alert will display when a prescribing clinician opens the patient chart of a patient who meets SIRS criteria.
223642042|NCT02835287|OTHER|Protocol-based integrated care|The protocol-based integrated care, which will provide a standardized, combined, multi-component intervention according to clinical guideline treatment algorithms for diabetes and comorbidities in community clinics, will be delivered by trained primary care physicians, health managers, and nurses supported by diabetes specialists.
224229870|NCT05293587|BEHAVIORAL|Physical Activity|Physical activity sessions will take place 3x/week over six weeks and will take between 45 and 60 minutes for each session. The sessions will be led by a Serenity Behavioral Health CPS as part of the PEERS program and will be supervised by research staff. Sessions will occur at public parks. Transportation to the park will be provided by Serenity Behavioral Health. Structured activities will include a warm-up, a mix of simple exercises requiring minimal supplies (such as walking, basic aerobic movements, and body weight resistance exercises), and cool-down. Sessions will be held in green park environments with shade, restrooms, and level walking paths.
224229871|NCT01538342|OTHER|3 Biopsies|3 biopsies: 2 lesional and 1 non-lesional
224229872|NCT01538342|OTHER|2 biopsies|
223642043|NCT01655459|PROCEDURE|Ultrasound exam of upper airway|LMA-position was evaluated with fiberoptic laryngoscopy. The ultrasound findings of pre- and post-LMA were compared.
224319536|NCT05392218|BEHAVIORAL|general health education|rceived the same amount of virtual session equivalent to MI form. However, the structure of the sessions consisted of brief advice to promote healthy lifestyle delivered by different therapists
223642044|NCT05569083|GENETIC|Genetic analysis of APOE and BDNF genes.|The three SNPs (rs429358, rs7412 and rs6265 on APOE and BDNF genes respectively) will be analyzed by the polymerase chain reaction (PCR) on genomic DNA and with the analysis of melting curves (HRMA) using the Rotor-Gene 6,000 (Rotor-Gene, Corbett Research, Mortlake, Australia).
223765364|NCT00143611|DRUG|Resatorvid|Resatorvid 1.2 mg/kg, injection, subcutaneously for thirty minutes; then resatorvid 0.1 mg/kg/h (2.4 mg/kg/day), injection, subcutaneously over 96 hours.
224229873|NCT01538342|OTHER|biopsy|1 biopsy ok healthy skin
224229874|NCT00525967|DRUG|Methadone plus Acetaminophen or Placebo|Methadone bid according to a established conversion morphine-to-methadone ratio plus Placebo or Acetaminophen qid
224229875|NCT00795561|PROCEDURE|Day care|Patients randomised to day care treatment of NVP will be instructed to present to the day services unit where they will receive a pre-agreed fluid and anti emetic regimen.
224229876|NCT00795561|PROCEDURE|Inpatient|Patients randomised to inpatient management of NVP will be admitted to hospital where they will receive a pre-agreed fluid and anti emetic regimen.
224229877|NCT01236833|DRUG|Lactated Ringer's Solution|2.5 ml per kg every 3 hours, via nasogastric tube, orogastric tube or orally, until the infant reaches 80 ml/kg/day of milk feeding or for a maximum of 14 days
224229878|NCT00601354|BEHAVIORAL|Emotion regulation group therapy|Emotion regulation guided self-help group therapy involves twelve 2-hour sessions of guided self-help group psychotherapy.
224229879|NCT00601354|DRUG|Orlistat/alli program|The orlistat/alli program involves taking 60 mg orlistat three times a day and participating in the alli program, a comprehensive behavioral weight loss program with online access.
223765365|NCT00143611|DRUG|Placebo|Resatorvid placebo-matching injection, subcutaneously for thirty minutes; then resatorvid placebo-matching injection, subcutaneously over 96 hours.
223765366|NCT04358497|DEVICE|Medtronic® Concerto® detachable coil system|coil embolization of the reflux pathways
223765367|NCT04358497|PROCEDURE|sclerosis|Pelvic varices sclerosis with polidocanol foam
223765368|NCT04358497|DRUG|Diosmin / Hesperidin|Best chronic medial treatment
223765369|NCT04358497|DRUG|Ibuprofen 400 mg|NSAID treatment
224229880|NCT05868109|DRUG|inhaled nitric oxide (iNO)|In patients randomized to the this arm, iNO will be delivered into the ventilator circuit through the endotracheal tube or tracheostomy. The dose will be 80 ppm during chest compressions and reduced to 20 ppm immediately following ROC. If the patient is enrolled following ROC, the dose will be 20 ppm. Dose modifications will occur if there is toxicity or if there is a clinical concern. The iNO or sham will be continued for 72 hours or until extubation.
224319537|NCT01657435|DEVICE|Ceramax Acetabular System|28mm Ceramic-on-ceramic Acetabular Cup System
224319538|NCT06581718|DEVICE|Eye Gaze Control|Eye Gaze Control - UGI and LGI endoscopy
224319539|NCT02289703|DRUG|Rivaroxaban 15 mg|Single oral dose of rivaroxaban 15-mg tablet on Day 1 of each of the treatment periods.
224319540|NCT02423421|OTHER|Faecal microbiota transplantation|Human Stool.
224323341|NCT05790252|OTHER|Sham patch|Bandage applied at time of induction initiation and removed at 48 hours.
224323342|NCT04668326|DEVICE|Manual Standing Wheelchair|Mobile in seated position; Not mobile in standing position
223642045|NCT05569083|DIAGNOSTIC_TEST|EEG recording|The EEG activity will be recorded continuously from 19 sites by using electrodes set in an elastic cap and positioned according to the 10-20 international system. The recording will be referenced to the common average of all electrodes, excluding Fp1 and Fp2. Re-referencing will be done prior to the EEG artifact detection and analysis. Data will be recorded with a band-pass filter of 0.3-70 Hz and digitized at a sampling rate of 512 Hz and analogue-digital precision was 16 bits (Gal-Nt, EbNeuro®, Florence, Italy). Horizontal and vertical eye movements will be detected by electrooculogram (EOG). Subjects will be sat in a reclined chair for approximately 20 min. Data will be collected at a sampling rate of 256 Hz, with a common mode rejection ratio of 105 dB (decibel), and the following band pass characteristics: 0.1 Hz high-pass filter, 100 Hz fifth order low-pass filter.
223642046|NCT05569083|DIAGNOSTIC_TEST|CSF collection and AD biomarker measurement|The CSF samples will be collected by lumbar puncture, immediately centrifuged and stored at -80 °C until performing the analysis. Aβ42, Aβ42/Aβ40 ratio, t-tau, and p-tau will be measured using a chemiluminescent enzyme immunoassay (CLEIA) analyzer LUMIPULSE® G600 (Fujirebio, Tokyo, Japan).
223642047|NCT05569083|DIAGNOSTIC_TEST|Neuropsychological evaluation|"For extensive neuropsychological evaluation the investigators will use the following tools: global measurements (MMSE, Information-Memory-Concentration Test), tasks exploring verbal and spatial short- and long-term memory (Digit Span, Corsi Tapping Test, Five Words and Paired Words Acquisition and Recall after 10 min and 24 hr, Short Story Immediate and Delayed Recall), prospective memory (Rivermead Behavioral Memory Test), attention (Trail Making Test A, Dual Task), language (Token Test, naming pictures, Category Fluency Task, Phonemic Fluency Task), constructional praxis (Copying Drawings and Rey-Osterrieth complex figure) and executive function (Trail Making Test B, Stroop Test, Frontal Assessment Battery, Weigl Test).~To assess independent living skills, the investigators will use two structured interview: Activities of Daily Living Scale (ADL) and Instrumental Activities of Daily Living Scale (IADL)."
223642048|NCT05569083|DIAGNOSTIC_TEST|Assessment of cognitive reserve, depression, personality traits and leisure activities|"In order to estimate premorbid intelligence, all cases will perform TIB test (Test di Intelligenza Breve), an Italian version of the National Adult Reading Test (NART).~To assess personality traits of the subjects, the investigators will use the Big Five Factors Questionnaire (BFFQ), that measures the five factors of emotional stability, energy, conscientiousness, agreeableness and openness to culture and experience.~For cognitive reserve. subjects will perform structured interviewed regarding participation in intellectual, sporting and social activities, in the course of their life.~The presence of depressive symptoms will be evaluated by means of the 22-item Hamilton Depression Rating Scale (HDRS)."
223642049|NCT05569083|DIAGNOSTIC_TEST|Clinical-neuropsychological follow-up|For follow-up assessment, each subject will perform a complete clinical evaluation, an extensive neuropsychological evaluation (27 test), assessment of independent living skills (ADL and IADL), estimation of premorbid intelligence (TIB test) and scale for depression (Hamilton Depression Rating Scale - HDRS).
223765370|NCT03444714|DRUG|RiMO-301|"Drug: RiMO-301 RiMO-301 will be administered by intratumoral route as slow injection~Radiotherapy Patients will receive 10 fractions of 3 Gy each over 2 weeks"
223765371|NCT04296812|BEHAVIORAL|Self-Love Model|"The model is a visual illustration shaped as a triangle.~* The bottom left line is title Zero Self-Love, moving upward are characteristics identified from zero self-love along the line.~* The bottom right side is titled Self-Love moving upward are characteristics identified from having self-love.~* At the top of the triangle is a circle with the letter R within for relationship.~* Two small lines project horizontally, from the circle, left and right.~* At the end of the Left line is a circle with the word break-up in the middle, surrounded by terms: drugs, alcohol, self-harming, suicide, and sex as the consequence of zero self-love.~* At the end of right line is a circle with the word break-up in the middle surrounded by terms: support system, coping skills, spirituality reflection as the consequences of having self-love.~The strategies being discussed:~* Exploring self-esteem strategies.~* Importance of self-worth in relationships.~* Importance of self-awareness."
223765372|NCT05244629|DEVICE|BMS vs. CS|Patients will be randomized to treatment with either BeSmooth (BMS, Bentley Innomed GmBh) or BeGraft (CS, Bentley Innomed Gmbh)
223765373|NCT01901380|DIETARY_SUPPLEMENT|Extensively hydrolyzed casein formula + LGG|
224229881|NCT05868109|DRUG|Sham|In patients randomized to sham, the iNO delivery device will be connected to the ventilator circuit or manual ventilation bag but flow of iNO will not be turned on. For the purposes of patient safety and to maintain blinding, the respiratory therapists (RTs) will continue checks of gas flow, flow adjustments and change iNO gas tanks at rates like routine clinical procedures on patients treated with iNO or sham.
224229882|NCT04592991|DIAGNOSTIC_TEST|Aortoiliac Occlusive Disease Group - PET-CT imaging with injection of 64Cu-DOTA-ECL1i|Patients from both genders, all ethnic groups, and between the ages of 45 and 75 will be considered for recruitment. We will recruit patients who have evidence of abdominal aortic aneurysm (AAA) as our study patient cohort. Patients with non-aneurysmal, atherosclerotic aortoiliac occlusive disease (n=3) will be enrolled in Aim 2A and undergo Cu-64 DOTA-ECL1i PET/CT.
224229883|NCT04592991|DIAGNOSTIC_TEST|AAA Group- PET-CT imaging with injection of 64Cu-DOTA-ECL1i|Patients from both genders, all ethnic groups, and between the ages of 45 and 75 will be considered for recruitment. We will recruit patients who have evidence of abdominal aortic aneurysm (AAA) as our study patient cohort. Patients with Abdominal aortic aneurysm (AAA) (n=5) will be enrolled in Aim 2B and undergo Cu-64 DOTA-ECL1i PET/CT and contrast-enhanced CT angiography between 7-14 days of their scheduled elective open repair surgery.
224229884|NCT01643369|BEHAVIORAL|Cognitive-Based Compassion Training|Eight-week training in compassion meditation, using a protocol developed by Geshe Lobsang Negi, Ph.D. of Emory University
224229885|NCT01643369|BEHAVIORAL|Adult Health Education Curriculum|Eight week training in health and wellness, using a curriculum developed specifically for this study.
224229886|NCT01643369|BEHAVIORAL|Mindful Attention Training|Eight week training in mindful attention, using a protocol developed by B. Alan Wallace, Ph.D.
224229887|NCT01862328|DRUG|MLN4924|"MLN4924 (intravenously \[IV\]) in participants in a 21-day cycle:~* MLN4924 on Days 1,3,5 of each cycle"
224229888|NCT01862328|DRUG|Paclitaxel|"Paclitaxel (IV) in a 21-day cycle:~* Paclitaxel on Day 1 of each cycle"
224229889|NCT01862328|DRUG|Gemcitabine|"Gemcitabine (IV) in participants in a 28-day cycle:~-Gemcitabine on Days 1,8,15 of each cycle"
224229890|NCT01862328|DRUG|Docetaxel|"Docetaxel (IV) in participants in a 21-day cycle:~\- Docetaxel on Day 1 of each cycle"
223642050|NCT05569083|DIAGNOSTIC_TEST|ERP recording|For ERP acquisition the same EEG system that was used for EEG data acquisition will be used. The participants will be administered an ERP test battery with concurrently recorded EEG consisting of a 3-choice vigilance task (3CVT) designed to evaluate sustained attention and standard image recognition memory task (SIR) designed to evaluate attention, encoding, and image recognition memory. In the SIR, images will be chosen as stimuli to distinguish short term from semantic memory loss and extend previous results of image recognition ERP effects.
223765374|NCT03808896|PROCEDURE|stylet-assisted epiglottic lifting|use stylet-equipped enodtracheal tube to lift the epiglottis and pass the endotracheal tube
223765375|NCT03808896|DEVICE|bougie-assisted intubation|use bougie as a introducer. Pass the bougie to the trachea and pass the tube via bougie guide.
223765376|NCT03410979|DRUG|GLPG2737 single dose|GLPG2737 oral suspension, single ascending doses
223765377|NCT03410979|DRUG|Placebo single dose|Placebo, oral suspension.
223765378|NCT03410979|DRUG|GLPG2737 multiple dose|GLPG2737 oral suspension, multiple ascending doses, daily for 14 days.
223765379|NCT03410979|DRUG|GLPG2737 multiple dose|Placebo, oral suspension, daily for 14 days
223765380|NCT00116389|DRUG|talabostat mesylate tablets|
223765381|NCT00116389|DRUG|gemcitabine|
223765382|NCT06320470|BEHAVIORAL|Educational Session|The initial session will last about 45 to 60 minutes. The subsequent 3 sessions are anticipated to take about 20-30 minutes.
223765383|NCT06207279|DIAGNOSTIC_TEST|rating|rating scales, test ANT
223765384|NCT03323099|BEHAVIORAL|N-of-1|Participants in the N-of-1 arm will use the Eureka mobile application and AliveCor device to tracking their AF episode frequency and severity and execute at least one N-of-1 trial with the goal of identifying and better controlling their AF triggers.
223765385|NCT03323099|BEHAVIORAL|Data Tracking|Participants in the data tracking arm will use the Eureka app and AliveCor device to record daily AF frequency and severity and daily AliveCor readings for a period of 10 weeks.
223765386|NCT06127134|PROCEDURE|peripheral angioplasty for tibial vessels|repair tibials blood vessels throughout two concepts using angioplasty ballooning
223765387|NCT06322719|DEVICE|Hyperangulated blade videolaryngoscope|For patients assigned to the Hyperangulated videolaryngoscope Group, the operator will use a Hyperangulated video laryngoscope on the first laryngoscopy attempt.
223765388|NCT06322719|DEVICE|Macintosh blade videolaryngoscope|For patients assigned to the Macintosh videolaryngoscope Group, the operator will use a Hyperangulated video laryngoscope on the first laryngoscopy attempt.
223765389|NCT05998109|DEVICE|PheCheck™|"Quantitative, single-use, rapid test Intended for home-based self-testing and monitoring of PKU.~1 fingerstick specimen collected at each study visit"
223765390|NCT05998109|DIAGNOSTIC_TEST|HPLC Amino Acid Analyzer|1 venous specimen collected at each study visit
223765391|NCT05998109|DIAGNOSTIC_TEST|Dried Blood Spot Cards|capillary blood specimen collected at each study visit
223765392|NCT03604692|DRUG|axatilimab|axatilimab is a high affinity antibody targeting the colony stimulating factor 1 receptor (CSF-1R). CSF-1R signaling has been demonstrated in nonclinical studies to be the key regulatory pathway involved in the expansion and infiltration of donor derived macrophages that mediate the disease processes involved in cGVHD.
223765393|NCT03466411|DRUG|Guselkumab Dose 1|Guselkumab will be administered by IV infusion.
223765394|NCT03466411|DRUG|Guselkumab Dose 2|Guselkumab will be administered by SC injection.
223765395|NCT03466411|DRUG|Guselkumab Dose 3|Guselkumab will be administered by IV infusion.
224229891|NCT01862328|DRUG|Carboplatin|"Carboplatin (IV) in participants in a 21-day cycle:~\- Carboplatin on Day 1 of each cycle"
223642051|NCT05686772|DRUG|Antipsychotic use|Use of first/second generation antipsychotics, use of third-generation antipsychotics, use of aripiprazole specifically
223642052|NCT05686772|OTHER|Psychiatric comorbidities|Substance use disorders, cluster B personality disorders, anxiety disorder, major depressive disorder, attention-deficit/hyperactivity disorder, tobacco smoking
223765396|NCT03466411|DRUG|Guselkumab Dose 4|Guselkumab will be administered by IV infusion.
223765397|NCT03466411|DRUG|Guselkumab Dose 5|Guselkumab will be by SC injection.
223642053|NCT05686772|OTHER|Sociodemographics/socioeconomic status|Age, gender identity, ethnicity, highest educational attainment, employment, at school, homelessness, in a relationship
223642054|NCT05686772|OTHER|Gambling history|Non-problematic gambling at the time of admission and/or previous 12 months
223765398|NCT03466411|DRUG|Guselkumab|Guselkumab will be administered by IV infusion and SC injection.
223765399|NCT03466411|DRUG|Ustekinumab|Ustekinumab will be administered by IV infusion and SC injection.
223765400|NCT03466411|DRUG|Placebo|Placebo will be administered as IV infusion.
223765401|NCT01026051|BIOLOGICAL|MKC1106-MT|Cancer Vaccine, Immunotherapy, Melanoma
223765402|NCT04911166|COMBINATION_PRODUCT|Atezolizumab and Interleukin-12 Gene Therapy|To determine the safety and tolerability of the atezolizumab and ADV/IL-12 gene therapy combination in patients with metastatic NSCLC who have disease progression after a prior line of either single agent immunotherapy or a regimen of chemoimmunotherapy.
223765403|NCT02375672|DRUG|Pembrolizumab|Pembrolizumab (MK-3475) 200mg IV over 30 minutes every 3 weeks
223765404|NCT02375672|DRUG|mFOLFOX6|"mFOLFOX6 Treatment D1 and D15 (Cycle = 28 days)~* Oxaliplatin 85 mg/m\^2 IV with~* Leucovorin 400 mg/m\^2 IV followed by~* 5FU 400 mg/m\^2 bolus and then 2400 mg/m\^2 via continuous infusion"
223765405|NCT02149433|DRUG|Prednisone|The steroid regime will be oral prednisone at 2 mg/kg for 7 days, then 1 mg/kg for 7 days, then 0.5mg/kg for 7 days for a total of 21 days.
223765406|NCT02149433|DRUG|Placebo|
223765407|NCT01486563|DRUG|Voluven (Hydroxyethyl starch 130/0,4)|7,5 ml/kg in the first hour and then 5 ml/kg
224229892|NCT00177112|PROCEDURE|clean patient preparation for cystoscopy|
224229893|NCT00177112|PROCEDURE|sterile patient preparation for cystoscopy|
224229894|NCT02959905|BIOLOGICAL|TSA-CTL|Patients will receive TSA-CTL iv over 20-30 minutes on day 0.
224229895|NCT02959905|DRUG|Cyclophosphamide|Cyclophosphamide 500 mg/m2/day iv on day -5 for one day.
224229896|NCT02959905|DRUG|Fludarabine|Fludarabine 25 mg/m2/day iv over 30 minutes on day -5 and -4 for two days.
224229897|NCT02959905|DRUG|Cyclophosphamide|Cyclophosphamide 500 mg/m2/day iv on day -5 and -4 for two days.
224229898|NCT01099384|BEHAVIORAL|Written self-help materials|Written materials to help adolescents stop tobacco use
223642055|NCT05686772|OTHER|Clinical variables|Main psychiatric diagnosis, history of psychiatric hospitalizations, severity of illness (CGI-S), functioning (SOFAS), concomitant psychotropic medications use
223765408|NCT01486563|DRUG|Sodium Chloride 9 mg/ml|7,5 ml/kg in the first hour and then 5 ml/kg
223765409|NCT04115358|PROCEDURE|Hyaluronic acid: Gengigel teething|Applying of 0,54% hyaluronic acid for one minute to the orifice of root canals of the primary molars, then sealing the chamber with zinc oxide eugenol cement and completing the restoration with stainless steel crowns and composite filling material.
224229899|NCT01099384|BEHAVIORAL|Group behavioral counseling|group behavioral counseling (2 day weekend program)
224229900|NCT00685971|DIETARY_SUPPLEMENT|5000 IU of cholecalciferol|5 drops taken once daily for 12 weeks
224229901|NCT00685971|DIETARY_SUPPLEMENT|placebo|5 drops once daily for 12 weeks
224229902|NCT03436628|DEVICE|MyT1DHero|A mobile phone application
224229903|NCT01443806|DRUG|Oseltamivir|75 mg, one time
224229904|NCT02404740|DEVICE|Pulse oximetry|Pulse oximetry
224229905|NCT04766918|PROCEDURE|Sono-guided injection with high molecular weight hyaluronic acid|Sono-guided injection with hyaluronic acid (Aragan Plus, 20 mg/2 ml, 3000kDa) between carpal tunnel and median nerve
224229906|NCT04766918|PROCEDURE|Sono-guided injection with low molecular weight hyaluronic acid|Sono-guided injection with hyaluronic acid (ARTZDispo, 25 mg/2 ml, 600-1200kDa) between carpal tunnel and median nerve
224229907|NCT04775784|DIAGNOSTIC_TEST|Determination of SARS-CoV2 presence in CNS|Brain tissue sampling
224229908|NCT00858000|OTHER|Retrospective analysis of already archived samples|RNA extracted from tissue samples already archived
223642056|NCT05030753|BEHAVIORAL|iSIPsmarter|iSIPsmarter is a technology-based behavioral and health literacy intervention. It is comprised of six Internet-delivered Cores, an integrated short message service (SMS) strategy to engage users in tracking SSB behaviors, and the incorporation of a cellular enabled scale for in-home weight tracking. Participants will be prompted (via email or text) to self-monitor their sugar-sweetened beverage intake. iSIPsmarter is a highly interactive, structured, and self-guided program that uses strategies previously proven to promote behavior change. iSIPsmarter also incorporates a stepped care approach to re-engage users who struggle to complete components.
223765410|NCT04115358|PROCEDURE|Formocresol Buckley formula: Formacresol|Applying of 1/5 diluted formocresol for one minute to the orifice of root canals of the primary molars, then sealing the chamber with zinc oxide eugenol cement and completing the restoration with stainless steel crowns and composite filling material.
224229909|NCT02027779|BIOLOGICAL|GreenGene™ F|"Prophylaxis safety and efficacy substudy:~intra venous infusion, 30 ± 10 IU/kg infusions 3 times per week with dose escalation to 45 ± 10 IU/kg if appropriate, for 50 exposure days"
223765411|NCT04115358|PROCEDURE|Ferric sulfate: ViscoStat|Applying of 20% ferric sulfate for one minute to the orifice of root canals of the primary molars, then sealing the chamber with zinc oxide eugenol cement and completing the restoration with stainless steel crowns and composite filling material.
223765412|NCT03023488|PROCEDURE|flexible ureteroscopy|Flexible ureteroscopy is an endourological procedure performed for kidney stones. The flexible ureteroscope is a device used to reach the renal cavities through the natural urinary tract in a retrograde fashion. During the operation, irrigation fluid is used to expand the cavities to provide space for movement of the device and also to provide clear vision.
223765413|NCT03023488|DEVICE|Doppler Ultrasound examination|peak systolic velocities (PSV) and end diastolic velocities (EDV) of the arteries will be measured and then resistive index (RI) and pulsatility index (PI) will be calculated.
223765414|NCT03023488|DEVICE|laser lithotripsy|The laser fiber extending into the cavities through the working channel of the ureteroscope is used to fragment the stones. Laser energy is generated by the laser machine and transmitted to the stones via the laser fiber.
224229910|NCT02027779|BIOLOGICAL|GreenGene™ F|"On-demand safety and efficacy substudy:~minor bleed = 20 ± 10 IU/kg moderate bleed = 30 ± 10 IU/kg major bleed = 30 - 50 IU/kg"
224229911|NCT01656889|BIOLOGICAL|HP-802-247|HP802-247 (fibrinogen solution \& thrombin solution containing living, irradiated, growth arrested keratinocytes and fibroblasts) 260 µL (130 µL, one spray, of each solution) containing 0.5 x 106 cells per mL every 14 days.
224229912|NCT01656889|BIOLOGICAL|Vehicle|(fibrinogen solution \& thrombin solution without cells)
223765415|NCT04065919|DRUG|Liposomal bupivacaine|20mL EXPAREL+40mL bupivacaine 0.25% infiltrated into 5th intercostal space
223765416|NCT04065919|DRUG|0.25% Bupivacaine with epinephrine|0.25% Bupivacaine with epinephrine at 1cc/kg total dose infiltrated into 5th intercostal space
224229913|NCT04576767|OTHER|anaesthetic|different states of consciousness
224229914|NCT00927121|DEVICE|Acoustic CR-Stimulator ANM//Technology: Acoustic coordinated reset|"The CR-stimulation was originally developed by Prof. Dr. Dr. Peter Tass for deep brain stimulation (DBS). The CR-stimulation through high frequency short pulses causes a neuronal reorganization in the stimulated brain area establishing a normal neuronal activity.~Based on intensive modeling studies, experimental proof of concept (POC) animal studies and a clinical POC, we proved that the pathologic activity can be recuperated to a desynchronized/healthy state with the acoustic CR-stimulation.~The acoustic CR-stimulation signal will be generated by the ANM CR-Stimulator and transmitted to the ears through a speaker system"
224229915|NCT01599208|DEVICE|TMS|TRANSCRANIAL MAGNETIC STIMULATION
224229916|NCT03857113|PROCEDURE|PSMA-radioguided surgery|PSMA-radioguided surgery
224229917|NCT02153307|DEVICE|Implantable loop recorders system Reveal ICM LINQ®,|
224229918|NCT05751681|OTHER|progestin primed ovarian stimulation protocol|progestin primed ovarian stimulation protocol
224229919|NCT05751681|DRUG|dydrogesterone (Duphaston, Abbott)|20 mg oral dose of dydrogesterone (Duphaston, Abbott)
224229920|NCT05751681|DRUG|Cetrotide|0.25 mg of Cetrotide (gonadotropin releasing hormone (GnRH) antagonist)
224229921|NCT06428708|DIAGNOSTIC_TEST|[18F] PSMA-1007 PET/CT|\[18F\] PSMA-1007 PET/CT scan
224229922|NCT05299268|BEHAVIORAL|Pain (hypertonic saline)|A bolus injection (1 ml) of hypertonic saline (5.8%) is injected into the dominant vastus medialis muscle 20 cm proximal from the basis of patella before performance of the 1x3 min Seated Isometric Knee Extension.
224229923|NCT05299268|BEHAVIORAL|No pain (Isotonic saline)|A bolus injection (1 ml) of isotonic saline (0.9%) is injected into the dominant vastus medialis muscle 20 cm proximal from the basis of patella before performance of the 1x3 min Seated Isometric Knee Extension
223642057|NCT05030753|BEHAVIORAL|Patient Education (PE)|he PE website will include scientifically accurate information that is typical of nutrition education websites and will include information about SSB recommendations, types of SSB and portion size, SSB-related health risks, energy balance information, identifying personal motivators and barriers to reducing SSB intake, interpreting SSB nutrition labels, and recognizing media influences and misclaims in SSB advertisements, as well as printable forms to track SSB and weight. Unlike iSIPsmarter, the content will not be tailored and will be presented all at once.
223642058|NCT01763697|BEHAVIORAL|taste acuity assessment|Quantitative measurement of for tasting detection and recognition thresholds, magnitude of perception and hedonic response.
223642059|NCT01763697|BEHAVIORAL|Recorded meal|
223642060|NCT06517160|OTHER|MedBook Portal|"Intervention Group (With MedBook Portal \&amp; MedBook Portal Notice)~1. MedBook Portal Notice in front of the patient home-based medical card~2. Discharge prescriptions are uploaded into MedBook Portal and can be retrieved by doctors \&amp; pharmacists.~MedBook portal (https://aplikasi.jknsarawak.moh.gov.my/medbook) is a webpage that enable sharing of patient medication records among healthcare facilities under Ministry of Health. Sarawak State Health Department owned and managed this portal. All the information is kept under their server. Doctors in the Health Clinics and Study Pharmacists will be given access to this portal whereby each of the healthcare providers shall log in using their Identification Number and the password created by them. Doctor shall log in to MedBook Portal to check on discharge medication list when reviewing the patient at health clinic. MedBook Portal can be accessed both using a smartphone or a computer."
223642061|NCT05818189|DEVICE|Personalized tactile cueing|We will use as an external cue, a system of tactile cueing with the purpose of enhancing proprioceptive inputs, in the form of real-time(synchronized to the gait heel strike), closed-loop tactile feedback signaling left and right stance times while walking. Also, the participants use the same system cueing in closed-loop feedback during daily life for one week.
223642062|NCT05818189|DEVICE|Fixed tactile cueing|We will use as an external cue, a system of tactile cueing with the purpose of enhancing proprioceptive inputs, in the form of real-time, open-loop(fixed rhythm) tactile feedback signaling left and right stance times while walking. Also, the participants use the same system cueing in open-loop feedback during daily life for one week.
223642063|NCT06250049|OTHER|Diabetic foot care protocol|Introduction of the diabetic foot care protocol in Primary Care in Salamanca, sensitization, and training of nursing professionals in Health Centers (HC).
223642064|NCT06250049|OTHER|Group education sessions for patients and/or caregivers|Conducting group education sessions for patients and/or caregivers on Diabetic Foot Care at the Health Centers.
223642065|NCT05759026|OTHER|Accompaing cares|"After signing the consent form, the patient will be randomised. The ones randomised in VR groups will choose their preferred environment (e.g. landscapes, animals...).~The participant will be managed during 1 care (one care in control condition (no material used), care with the VR headset, one care with the VR set and the prefered environnent of the patient) for an average of 30 minutes (including the completion of the scales and questionnaires)."
223642066|NCT03604783|DRUG|TP-1287|TP-1287 by oral administration
223642067|NCT05202119|DEVICE|Transcranial direct current stimulation|Transcranial direct current stimulation (tDCS) a non-invasive brain stimulation technique where a weak direct current (2 mA) is applied on the scalp through electrodes. The current modulates the underlying neural activity. The sessions are 30 minutes, 3-5 time a week.
223642068|NCT05202119|DEVICE|Sham Transcranial direct current stimulation|To blind the participants of the stimulation, a standardized sham protocol is used where the current ramped up and then down breifly in the beginning and end of each session to simulate active stimulation.
223642069|NCT06096922|OTHER|No intervention|No intervention
223642070|NCT05686356|DRUG|Sutezolid|Sutezolid will be given at a dose of 1200mg QD in arm 1 and at a dose of 1600mg QD in arms 2 and 3.
223765417|NCT02346240|BIOLOGICAL|Certolizumab Pegol|"* Active Substance: Certolizumab Pegol~* Pharmaceutical Form: Solution for injection in pre-filled syringe~* Concentration: 200 mg/ mL~* Route of Administration: Subcutaneous use"
223642071|NCT05686356|DRUG|N-acetyl cysteine|NAC will be given at a dose of 1800 mg BID in arm 3
223642072|NCT05686356|DRUG|Pretomanid|Pretomanid will be given at its approved dose
223642073|NCT05686356|DRUG|Bedaquiline|Bedaquiline will be given at its approved dose
223642074|NCT05686356|COMBINATION_PRODUCT|Rifafour|Fixed dose combination tablets for TB treatment will be given at approved doses
223642075|NCT03467750|DRUG|Ketorolac|Patients in this group will receive 0.5mg/kg of ketorolac, administered intravenously.
223765418|NCT02346240|BIOLOGICAL|Etanercept|"* Active Substance: Etanercept~* Pharmaceutical Form: Solution for injection in pre-filled syringe~* Concentration: 50 mg / mL~* Route of Administration: Subcutaneous use"
223765419|NCT02346240|OTHER|Placebo|"* Active Substance: Placebo~* Pharmaceutical Form: Solution for injection in pre-filled syringe~* Concentration: 0.9 % saline~* Route of Administration: Subcutaneous use"
224229924|NCT03742531|DRUG|oxytocin|one group will be treated with low dose oxytocin and the other group will be treated with high dose oxytocin for augmentation of labor induction.
224229925|NCT00065858|DRUG|BufferGel|
224229926|NCT01108900|DRUG|sildenafil|tables, 25,50,100 mg, on demand, 1 month
224229927|NCT02933593|DRUG|Labetalol|To determine which protocol recommended by ACOG for severe hypertension in pregnancy decreases central arterial pressure the fastest, and the most efficaciously.
224229928|NCT02933593|DRUG|Hydralazine|To determine which protocol recommended by ACOG for severe hypertension in pregnancy decreases central arterial pressure the fastest, and the most efficaciously.
224229929|NCT02933593|DRUG|nifedipine|To determine which protocol recommended by ACOG for severe hypertension in pregnancy decreases central arterial pressure the fastest, and the most efficaciously.
224229930|NCT04550949|DRUG|QL1206|The active ingredient of QL1206 is a recombinant human anti-RANKL monoclonal antibody ,subcutaneous injection of 120 mg (1.7ml)every 4 weeks for a maximum of 13 consecutive doses throughout the trial.
224229931|NCT04550949|DRUG|Xgeva|The active ingredient of Xgeva® is denosumab,subcutaneous injection of 120 mg (1.7ml)every 4 weeks for a maximum of 13 consecutive doses throughout the trial.
224229932|NCT02521948|DEVICE|MANTA Vascular Closure Device|The MANTA device developed by Essential Medical, Inc., is a vascular closure device (VCD) intended for use in catheterization laboratories following percutaneous cardiac or peripheral procedures that use the retrograde common femoral artery access route for large bore (10-18F) interventional devices.
224229933|NCT02496026|DEVICE|tDCS plus wrist robot therapy|Patients receive robotic rehabilitation session while tDCS stimulator is switched on
224229934|NCT02496026|DEVICE|Sham tDCS plus wrist robot therapy|Patients receive robotic rehabilitation session while tDCS stimulator is switched off.
223642076|NCT03467750|DRUG|Standard of Care|"All patients will undergo inhalational induction with nitrous oxide and sevoflurane. After intravenous (IV) placement, 1-3mg/kg of propofol and 1mcg/kg of fentanyl will be administered. After induction, 0.5mg/kg of dexamethasone and an IV infusion of 15mg/kg of acetaminophen will be administered. During surgery, 0.5mcg/kg of dexmedetomidine and 0.1mg/kg ondansetron will be given.~A rescue dose of 0.5-1mcg/kg of IV Fentanyl will be available for use at the end of the procedure. The decision to administer will be left to the discretion of the attending anesthesiologist. The choice to give this will be made based on variables including patient's condition and a 20% increase in the heart rate and blood pressure.~The PACU nurses, who will be blinded to ketorolac administration, will evaluate the patients using FLACC scores. For patients with a FLACC score of 6-10, morphine 0.05mg/kg will be administered. For patients with FLACC scores of 3-5, morphine 0.025mg/kg will be administered."
223642077|NCT06141226|DRUG|TQB2450 +Anlotinib+Docetaxel|"TQB2450 is a humanized monoclonal antibody targeting programmed death ligand 1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on the surface of T cells, restoring T cell activity and enhancing immune response. It has the potential to treat various types of tumors.~Anlotinib is a multi target receptor tyrosine kinase (RTK) inhibitor. It can inhibit VEGFR1, VEGFR2, VEGFR3, c-Kit, PDGFR β Activity.~Docetaxel is a taxane based anti-tumor drug."
223642078|NCT06141226|DRUG|TQB2450 +Androtinib Placebo+Docetaxel|"TQB2450 is a humanized monoclonal antibody targeting programmed death ligand 1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on the surface of T cells, restoring T cell activity and enhancing immune response. It has the potential to treat various types of tumors.~Androtinib Placebo Docetaxel is a taxane based anti-tumor drug."
223765420|NCT05676892|PROCEDURE|Laparoscopic cholecystectomy|"Method of operation~1. Surgery was started under general anesthesia~2. A trocar of 10 mm was placed on the navel, 5 mm under the blade, and a 5 mm trocar was placed on the right upper abdomen.~3. Pneumoperitoneum was performed using CO2 gas in the abdominal cavity.~4. Dissection started from Calot's triangle, and the operation was performed by retrograde cholecystectomy.~5. The excised gallbladder was placed in a laparoscopic pocket and extracted through the umbilicus.~6. The trocar was removed, and the skin was sutured"
223765421|NCT01573624|DRUG|FF/GSK573719|100/15.6
223765422|NCT01573624|DRUG|FF/GSK573719|100/31.25
223765423|NCT01573624|DRUG|FF/GSK573719|100/62.5
223642083|NCT05562999|DRUG|Rocuronium Bromide|Moderate NMB (TOF 1-2)
223642084|NCT05562999|DRUG|Rocuronium Bromide|Deep NMB (PTC 1-2)
223642085|NCT06515912|OTHER|Ketogenic Diet|A ketogenic diet with 5% carbohydrate, 18% protein, and 77% fat by percent kcal.
223642086|NCT04364867|DRUG|Exparel|Single shot Exparel 10cc (133mg) mixed with 10cc of 0.5% Bupivicaine
223642087|NCT04364867|DRUG|Pain Pump|Subject will receive an interscalene block with Ropivicaine 0.5% (20cc), and then a pain pump attached in the Post Anesthesia Care Unit infusing at 4cc/hr. The patient will go home with that device until it runs out.
223642088|NCT06193096|DIETARY_SUPPLEMENT|Experimental product|Probiotic mix (i3.1) comprising Pediococcus acidilactici KABPTM 021, Lactiplantibacillus plantarum KABPTM 022 and Lactiplantibacillus plantarum KABPTM 023 in a 1:1:1 ratio and with a total concentration of ≥3x10\^9 total colony forming units (CFU) per sachet (stick). Other ingredients are dextrose and maltodextrin as excipients, aroma, flavorings and silicon dioxide. Experimental product will be taken over 4 weeks.
223642089|NCT06193096|DIETARY_SUPPLEMENT|Control product|"Placebo product containing dextrose and maltodextrin, aroma, flavorings and silicon dioxide.~Control product will be taken over to weeks"
223642090|NCT01967849|DIAGNOSTIC_TEST|Oral Glucose tolerance test|
223642091|NCT05786924|DRUG|BDTX-4933|RAF inhibitor targeting all classes of oncogenic BRAF alterations (Classes I, II, and III) and constitutively active CRAF, KRAS or NRAS mutations
223642092|NCT03469037|DEVICE|Optiflow with an inspired fraction of oxygen of 100%|Respiratory gaz heated and humidified system of delivery with a fraction of oxygen inspired of 100%
223642093|NCT03469037|DEVICE|Optiflow with an inspired fraction of oxygen of 21%|Respiratory gaz heated and humidified system of delivery with a fraction of oxygen inspired of 21%
223642094|NCT06591624|OTHER|Prolonged Mechanical Ventilation|The neurosurgical patients who could extubated within 24 h after surgery
223642095|NCT06591624|OTHER|remain intubation after surgery|could not extubated after surgery and prolong mechanical ventilation for 48 hours
223642096|NCT06601400|COMBINATION_PRODUCT|Erythropoietin (EPO) with xenograft|After atraumatic extraction of the non-restorable tooth, Implant will be placed palatal and apical to osteotomy with at least 2mm gap junction between implant and buccal bone which will be grafted with xenograft and erythropoietin.
223642097|NCT06601400|OTHER|Xenograft alone|After atraumatic extraction of the non-restorable tooth, implant will be placed palatal and apical to osteotomy with at least 2mm gap junction between implant and buccal bone which will be grafted with xenograft alone.
223765424|NCT01573624|DRUG|FF/GSK573719|100/125
224229935|NCT02427607|DRUG|Perampanel|Perampanel 2 mg tablets. Doses of perampanel can be adjusted based on clinical judgment. A minimum perampanel dose of 2 mg per day is required to continue in the study. The maximum daily dose of perampanel permitted will be 12 mg per day.
224229936|NCT05508100|BIOLOGICAL|IO-108|IO-108, intravenously, on Day 1 of each 21-day cycle.
223765425|NCT01573624|DRUG|FF/GSK573719|100/250
223765426|NCT01573624|DRUG|FF|100
223765427|NCT01573624|DRUG|FF/VI|100/25
223765428|NCT05719428|OTHER|DRUID AI Program|Patients will begin single agent therapy within 4 weeks of enrolment and continue until disease progression, maximum safe cumulative dose reached (where applicable, per standard institution practice) or unacceptable toxicity as per physician's discretion.
223765429|NCT05188170|DRUG|Niclosamide|Niclosamide will be administered orally for 14 days. Each dose will be followed by backbone chemotherapy
224229937|NCT05508100|BIOLOGICAL|IO-108 + pembrolizumab|IO-108, intravenously, on Day 1 of each 21-day cycle. Pembrolizumab will be administered intravenously on Day 1 of each 21-day cycle.
224229938|NCT05508100|BIOLOGICAL|IO-108 + tislelizumab|IO-108, intravenously, on Day 1 of each 21-day cycle. Tislelizumab will be administered intravenously on Day 1 of each 21-day cycle.
223642098|NCT06986551|OTHER|5% NaF fluoride varnish|"Before the application of the varnish, teeth were cleaned using a prophylaxis polishing past with a low-speed cone brush in a contra angle low-speed handpiece. It will be dried with air and isolated using cotton rolls.~Package will be unpacked, and the application guide will be used to display the contents and mix to avoid the separation of sodium fluoride components. After isolation, a thin layer of the varnish will coat . The participants will be asked to keep their mouths closed to allow the varnish to set in the presence of saliva. Rinsing or suction was not allowed immediately after the application of the varnish.~The participants will be asked to avoid consumption of rough and viscid food or hot drinks for two hours after application of the varnish. For the rest of that day, participants will be asked to eat soft food and stop tooth brushing (Ezzeldin et al., 2024)."
223642099|NCT06986551|OTHER|PRG Barrier coat|"Before the application of the varnish, teeth were cleaned using a prophylaxis polishing past with a low-speed cone brush in a contra angle low-speed handpiece. It was then dried with air and isolated using cotton rolls.~\| P a g e 13 According to the manufacturer's instructions, the application of PRG barrier coat varnish a drop of the active will be mixed with the base using the attached brush. After isolation with cotton rolls, the brush will be used to smear the WSLs with the mix. I will be undisturbed for at least three seconds, then cured for 10 seconds using the visible-light curing unit (Ezzeldin etal.,2024).~And there will be no post operative instruction to patient after application (light cured resin material)."
223765430|NCT05493267|DRUG|Vγ2Vδ2 T lymphocyte-based immunotherapy|Intravenous injection of zoledronic acid, followed by a subcutaneous injection recombinant human interleukin. Zoledronic acid was administered 3 times and recombinant human interleukin was administered 10 times for a total of 6 months.
224229939|NCT04469738|DEVICE|SCS is switched off|Spinal cord stimulator is switched off for 12 hours
224229940|NCT04469738|DEVICE|SCS is switched on|Spinal cord stimulator is functioning
224229941|NCT00756028|DRUG|Patients receiving short protocol IVF/ICSI-treatment.|Injection s.c. Orgalutran® (Ganirelix)0.25 mg once daily from day 5 of FSH-stimulation until HCG-day
224229942|NCT00756028|DRUG|Long protocol|Patients receiving long protocol IVF/ICSI-treatment. Intervention pharmacon: GnRH-agonist (Synarela®:Nafarelin)
224229943|NCT00423800|DRUG|Combination of pegylated interferon alfa-2b (PEG) and ribavirin (RBV)|"1. Powder for Solution in Redipen® (pegylated interferon alfa-2b) (80, 100, 120, and 150 microgram strengths), subcutaneous, dose of 1.5 micrograms/kg, weekly for up to 24 or 48 weeks~2. 200 mg ribavirin capsules, oral, weight-based dose of 800, 1000, or 1200 mg, daily for up to 24 or 48 weeks"
224229944|NCT04164953|PROCEDURE|Surgical treatment|Surgical treatment of Dupuytren's disease. Average from 2 to 4 joints per hand operated on simultaneously
224319541|NCT01010243|DRUG|Lenalidomide, Pioglitazone, dexamethasone, treosulfan|"Phase I:lenalidomide dose ( 5 mg or 10 mg or 15 mg) will be determined for phase II on the basis of DLTs in the first 4 weeks for the phase II part.~Start Phase I part: lenalidomide 10 mg p.o. daily + pioglitazone 60 mg p.o. daily + treosulfan 250 mg p.o. bid + dexamethasone initially 40 mg p.o. d1-4 and d15-18, then 20mg d1 and d15. dexamethasone 1 mg p.o. continuously within the intervals of pulsed dexamethasone therapy"
224319542|NCT02756208|BIOLOGICAL|300 ug FLSC vaccine|FLSC vaccine 300 ug (1.0 mL) given by intramuscular injection into the arm on study Days 0, 28, 56, 168
224319543|NCT02756208|BIOLOGICAL|150 ug FLSC vaccine|FLSC vaccine 150 ug (0.5 mL) given by intramuscular injection into the arm on study Days 0, 28, 56, 168
224319544|NCT02756208|BIOLOGICAL|75 ug FLSC vaccine|FLSC vaccine 75 ug (0.25 mL) given by intramuscular injection into the arm on study Days 0, 28, 56, 168
224319545|NCT02756208|BIOLOGICAL|Placebo|Placebo sterile saline (0.25 - 1.0 mL) given by intramuscular injection into the arm on study Days 0, 28, 56, 168
224319546|NCT06106347|DEVICE|mfERG device (RETIscan; Roland Instruments, Wiesbaden, Germany)|physiological macular function
223642100|NCT06590662|DRUG|Solriamfetol|"Patient with a diagnostic of idiopathic hypersomnia (ICSD-3 criteria) will be randomized to receive solriamfetol or placebo for 7 weeks of treatment period. For the experimental arm, the dose will be progressively increased beginning at 75 mg to 300 mg according to tolerance to treatment.~Solriamfetol will be taken once a day upon awakening Schema of dispensation~1. One tablet of solriamfetol 75 mg per day for 1 week (week 1)~2. 150 mg of solriamfetol per day for 2 weeks (weeks 2 and 3)~3. According clinical judgment, Dose either maintained stable at 150 mg or increased to 300 mg per day for 2 weeks (weeks 4 and 5).~4. Prescription at week 5: Dose maintained at 150 or 300 mg or reduced at 150 mg per day according to benefit and safety for 2 weeks.~Treatment duration: 7 weeks treatment period."
223765431|NCT05493267|DRUG|Treatment regimens for MDR-TB|Treatment regimens was based on the principles of the WHO guidelines for the treatment of drug-resistant tuberculosis.
223765432|NCT02681302|DRUG|Ipilimumab|1 mg/kg; 6 doses Weeks 1, 4, 7, 10, 16, 22
223765433|NCT02681302|DRUG|Nivolumab|3 mg/kg; 12 doses Weeks 1, 4, 7, 10, 12, 14, 16, 18, 20, 22, 24, 26
223765434|NCT06033144|DIAGNOSTIC_TEST|Diagnosis of Tapia's Syndrome|"The diagnostic includes :~* Lingual clinical examination~* Nasofibroscopy~* Ultrasonography"
223765435|NCT06506461|DRUG|Plerixafor|Given Subcutaneous (under the skin)
223765436|NCT06506461|DRUG|Busulfan|Given Intravenous (IV)
223765437|NCT06506461|BIOLOGICAL|Gene-modified CD34+ cells|Given Intravenous (IV)
224229945|NCT05699707|DIETARY_SUPPLEMENT|(R)-3-hydroxybutyl (R)-3-hydroxybutyrate ketone monoester|Participants will consume a ketone monoester drink (0.75 k/kg body mass) with venous blood samples obtained before and after (30, 60 and 90 minutes) drink consumption.
224229946|NCT04000009|DRUG|Pimavanserin|Pimavanserin 34 mg (provided as 2×17 mg tablets) administered orally as a single dose once daily
224229947|NCT06334926|OTHER|no intervention, retrospective data analysis|not applicable, retrospective data analysis
224229948|NCT01181661|BEHAVIORAL|Full Group Contingency|This group (n = 20) will earn vouchers based only on team (n = 4) performance. Only if all members of the team submit a negative sample (CO ≤ 4 ppm), will they each earn a voucher.
224319547|NCT04258176|OTHER|Multidisciplinary outpatient pathway|Coordinators, assigned to improve the care flow, review and align the patient's appointments and tests in agreement with the patient's wishes. Outpatient consultations are arranged to take place the same day and schedules for care providers are coordinated. The patients' attendance in outpatient clinics are planned sequentially where the delivering specialty writes a summary to the subsequent specialty. Afterwards, the involved physicians and nurses attend an interdisciplinary conference, resulting in a joint treatment plan, with feedback and notice of modifications, which is delivered to the patient and general practice.
223642101|NCT06590662|DRUG|Placebo|"Patient with a diagnostic of idiopathic hypersomnia (ICSD-3 criteria) will be randomized to receive solriamfetol or placebo for 7 weeks of treatment period.~Placebo will be taken once a day upon awakening Schema of dispensation~1. One tablet of placebo per day for 1 week (week 1)~2. Two tablets of placebo per day for 2 weeks (weeks 2 and 3)~3. According clinical judgment, Either maintained stable with 2 tablets or increased to 4 tablets per day for 2 weeks (weeks 4 and 5).~4. Prescription at week 5: Dose maintained at 2 or 4 tablets or reduced at 2 tablets per day according to benefit and safety for 2 weeks.~Treatment duration: 7 weeks placebo period."
223642102|NCT06598969|DRUG|Total bone marrow and lymphoid irradiation/cyclophosphamide/etoposide|Evaluate the antileukemic activity of an total bone marrow and lymphoid irradiation/cyclophosphamide/etoposide conditioning regimen for allogeneic hematopoietic stem cell transplantation
223642103|NCT06600828|OTHER|Data collection|Data collected: Socio-demographic, hospital, clinical, biological, and imaging data
223642104|NCT06592456|BIOLOGICAL|Chickenpox Vaccines|The vaccines require reconstitution with the provided sterile water for injection nd should be shaken well before use. Each human dose (0.5 ml) contains at least 3.3 log PFU of VZV.
223642105|NCT06598488|DIETARY_SUPPLEMENT|Beetroot juice|Beetroot juice will be consumed 2 times a day for 4 days before testing plus one shot on experimental testing day 1,5 hours before arrival.
224229949|NCT01181661|BEHAVIORAL|Mixed Group Contingency|This group (n = 20) will earn vouchers based on both individual and team (n = 4) performance. If an individual submits a negative sample (CO ≤ 4 ppm), s/he will earn a voucher. Additionally, bonus vouchers will be earned if all team members submit negative samples.
223642106|NCT06598488|DIETARY_SUPPLEMENT|Beetroot juice placebo|Beetroot juice will be consumed 2 times a day for 4 days before testing plus one shot on experimental testing day 1,5 hours before arrival.
224229950|NCT01576588|DRUG|Rituximab|Rituximab (Rtx) antibody infusions will be administered on Day 1, 2, 3 (cycle 1) and Day 1 (cycles 2 to 4).
224229951|NCT01576588|DRUG|Glucocorticoid|Glucocorticoid (either Dexamethasone or Methyl-prednisolone) infusions will be administered on Days 1 to 3 (cycles 1-4(6)) and should precede the Rituximab infusion.
224319548|NCT04867343|DRUG|HR020602 injection|HR020602 injection
224319549|NCT04867343|DRUG|fentanyl injection ； remifentanil injection|fentanyl injection + remifentanil injection
224319550|NCT04641052|OTHER|Music listening|The music type will be chosen by the patients and researchers will not have any influence on their choices.
224319551|NCT01130662|DRUG|combination therapy using decitabine and midostaurin|"Cohort 1:~Decitabine 20mg/m2 IV daily on days 1-5 to be repeated every 28 days. Midostaurin 25mg bid days 8-21 of each cycle.~Cohort 2:~Decitabine 20mg/m2 IV daily on days 1-5 to be repeated every 28 days. Midostaurin 50mg bid days 8-21 of each cycle.~Cohort 3:~Decitabine 20mg/m2 IV daily on days 1-5 to be repeated every 28 days. Midostaurin 50mg bid x 28 days of each cycle."
224319552|NCT06291194|DRUG|AJU-S56 5%|After Randomization(Week 0), Participants will be administered with the durg, QID(4 times in a day, and 1 drop per each times) until end of trial(Week 24).
224319553|NCT06291194|DRUG|Placebo Group(Vehicle)|After Randomization(Week 0), Participants will be administered with the durg, QID(4 times in a day, and 1 drop per each times) until end of trial(Week 24).
224319554|NCT01972399|PROCEDURE|Laser|This is a surgery that the patient will undergo and the laser will be used to clean the surface of the implant.
224319555|NCT01972399|PROCEDURE|Mechanical debridement|This is a surgery that the patient will undergo to have the surface of the implant cleaned using hand instruments.
224319556|NCT05094661|PROCEDURE|BiPAP|The patient recives respiratory support with bilevel positive airway pressure system until treatment improves or fails (needs intubation/dies).
223642107|NCT02581241|DEVICE|tilt table|"Participating individuals will be instructed to rest supine for 10 minutes while repeat electrocardiograms are recorded. They will then be instructed to stand up quickly and remain standing still for 10 minutes.~Individuals with inability to stand up quickly will be tested with tilt table test used in our hospital"
223765438|NCT06506461|DRUG|Motixafortide|Given Subcutaneous (under the skin)
223765439|NCT02115282|PROCEDURE|Biospecimen Collection|Undergo collection of blood and archived tissue samples
223765440|NCT02115282|PROCEDURE|Computed Tomography|Undergo CT
223765441|NCT02115282|DRUG|Entinostat|Given PO
223765442|NCT02115282|DRUG|Exemestane|Given PO
223765443|NCT02115282|DRUG|Goserelin|Given PO
224229952|NCT05214807|DEVICE|KiOmedine® CM-Chitosan|KiOmedine® CM-Chitosan is a fluid implant intended for synovial fluid supplementation for the symptomatic treatment of osteoarthritis (OA). This Investigational Medical Device (IMD) is administered via intra-articular injection and is classified as a Class III Device under Council Directive 93/42/EEC (Annex IX, rule 8). A key component of the IMD is a soluble derivative of highly purified chitosan of non-animal origin, an exclusive natural linear glucosamine polysaccharide extracted from the edible white mushroom, Agaricus bisporus. KiOmedine® CM-Chitosan is sterile, non-pyrogenic, resorbable and composed of 2% (w:w) carboxymethyl chitosan (CM-chitosan).
224319557|NCT05094661|PROCEDURE|CPAP|The patient recives respiratory support with continuous positive airway pressure system until treatment improves or fails (needs intubation/dies).
224319558|NCT03338530|BEHAVIORAL|Comprehensive School-Based Intervention|School staff administered the 5 components during the school year. Social Skills Groups were conducted 2-3x/wk. for a total of 60-90 min./wk.; each group contained 3-6 students with social impairments. The Individual Daily Note was administered across the school day to reinforce new skills and reduce problem symptoms. Students' performance on targets was linked to home rewards. Mind Reading computer instruction targeting emotion recognition skills was conducted 3x/wk. for a total of 60 min./wk. Therapeutic Activities were conducted 2x/wk. for a total of 40-60 min./wk.; these cooperative activities were designed to practice targeted skills. Parent Training was conducted 1x/month for 60-90 min./session in order to increase home-school communication and integrate the CSBI across settings.
224323343|NCT04668326|DEVICE|Mobile Manual Standing Wheelchair|Mobile in BOTH seated and standing positions
224323344|NCT06566209|DEVICE|Fluorodeoxyglucose - Positron Emission Tomography (FDG-PET)|Receive 18F-FDG PET/CT
224323345|NCT06333015|DEVICE|enVista Beyond EY (EDF) IOL|enVista Beyond Extended Depth of Focus (EDF) Intraocular Lens (IOL) Model EY
224323346|NCT06333015|DEVICE|enVista MX60E monofocal IOL|enVista MX60E monofocal IOL
223765444|NCT02115282|DRUG|Goserelin Acetate|Given SC
223642108|NCT05163158|OTHER|Central vs brachial systolic blood pressure targeting|Participants will be randomized to either a central BP target (intervention) or a brachial BP target (standard care). For each group, the source of the BP (central or brachial) will be blinded and only the BP values will be provided to the attending Nephrologist. In both cases, the target SBP will be \<130 mmHg.
223642109|NCT06992986|OTHER|Investigating differences in the bladder microbiome|"Urine samples and tissue from radical cystectomy specimens will be analyzed for the assessment of the urinary microbiome.~The 16s rRNA gene will be amplified and the resulting amplicons analyzed by Illumina sequencing. To distinguish contaminants, DNA from the sample will be quantified by qPCR and compared to a known urine sample of E. coli. DNA will be extracted using the Quiagen kit and stored at -20 °C until PCR amplification. Bacterial DNA will be amplified with specific primers covering the V1-V3 hypervariable region of the 16S rRNA gene. Libraries will be prepared using the Illumina 16S microbiome sequencing protocol, and their quality will be verified by Bioanalyzer and quantity by qPCR. Sequencing will be performed in paired-end mode on Illumina sequencers. Alpha, beta diversity and species richness will be measured."
223642110|NCT03579251|BEHAVIORAL|Black Men's Care|12 weeks of behavioral intervention, including an in-person session and two-way SMS, to re-engage in HIV care HIV-positive Black men who have fallen out of care
223642111|NCT06070766|DRUG|Ketamine|The use of ketamine in chronic conditions.
223642112|NCT04922216|BEHAVIORAL|Core|Behavioral weight loss core includes behavioral lessons, activity tracker, daily self-weighing, weekly tailored feedback summary.
223642113|NCT04922216|BEHAVIORAL|Standard Diet Monitoring|Standard monitoring using smartphone tracking of all calorie intake.
223642114|NCT04922216|BEHAVIORAL|Simplified Diet Monitoring|Simplified diet monitoring using smartphone tracking of red foods using a traffic light approach.
223642115|NCT04922216|BEHAVIORAL|Adaptive Activity Goals (Daily)|Physical activity goals that adapt once each day using the participants' data derived from activity tracker.
223765445|NCT02115282|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
224229953|NCT05214807|DEVICE|Synvisc-One®|Synvisc-One (Hylan G-F 20) is a sterile, nonpyrogenic, elastoviscous fluid containing Hylan A and Hylan B polymers produced from chicken combs. Hylans are derivatives of hyaluronan (sodium salt of hyaluronic acid) and consist of repeating disaccharide units of N-acetylglucosamine and sodium glucuronate. Hylan A has an average molecular weight of approximately 6,000,000 daltons and hylan B is a hydrated gel. Hylan G-F 20 contains Hylan A and Hylan B (8.0 mg ± 2.0 mg per ml) in buffered physiological sodium chloride solution (pH 7.2 ± 0.3) and is unique in that the hyaluronan is chemically crosslinked.
224229954|NCT00712595|DRUG|Mifepristone|Oral administration of Mifepristone 10 mg daily for three months
224229955|NCT00712595|DRUG|Mifepristone|Oral administration of Mifepristone 5 mg, daily for three months
224229956|NCT02629549|DRUG|OTL38|Infusion of OTL38 prior to surgery
224229957|NCT03756753|DIAGNOSTIC_TEST|Results available to provider|Results of point of care testing are given to provider
224229958|NCT03406130|PROCEDURE|Orthodontic Procedure|"Damon self-ligating systems (Ormco) were used for all patients. The patients were allowed to choose between clear and metal brackets. The bonding method was standardized and applied according to the manufacturer's instructions. After bracket bonding, 0.014-in. copper nickel-titanium Damon arch forms were placed. The subjects returned every 2 wk, and the archwires were changed only when full bracket engagement were achieved. The sequence of archwires was the following: 0.018-in., 0.014 × 0.025-in., and 0.018 × 0.025-in. copper nickel-titanium archwires were used for alignment, while 0.019 × 0.025-in. stainless-steel archwires were used for fine-tuning. Following the alignment steps, impressions were taken, and a blinded senior orthodontist validated appliance removal or provided advice regarding further adjustments.~Alginate impressions were taken after the removal of the appliances, and fixed and removable retainers were placed."
224319559|NCT02566681|BIOLOGICAL|MSC construct for Osteonecrosis|"30 days before implanting the construct made with MSC + TP + DBM, bone marrow of patients diagnosed with osteonecrosis of the jaw included in the clinical trial is obtained. The bone marrow will be obtained according to standard practice for Hematologists of the Haematology University Hospital Virgen de la Arrixaca (HCUVA).~Mononuclear bone marrow cells were separated and cultured in GMP conditions (Good Manufacturing Practices). The cells are seeded on tricalcium phosphate and maintained in culture for 14 days.~The day when the implant is performed, the patient is prepared in the operating room. The area where the implant will be placed is cleaned. Mesenchymal cells seeded in tricalcium phosphate are mixed with demineralized bone matrix and It's coagulated with autologous platelet rich plasma and grafting is performed. Finally, the oral mucosa or skin will be sealingly closed by silk sutures."
224319560|NCT03632213|DRUG|Losartan|Losartan group: 15 patients, both sexes, will receive Losartan 0.4 to 1.4 mg/kg/day orally for 12 months.
223642116|NCT04922216|BEHAVIORAL|Adaptive Activity Goals (Weekly)|Physical activity goals that adapt once each week using the participants' data derived from activity tracker.
223642117|NCT04922216|BEHAVIORAL|Message Decision Points (Fixed)|Message timing is fixed and evaluated at specific times each day to determine message eligibility.
223642118|NCT04922216|BEHAVIORAL|Message Decision Points (Adaptive)|Message timing is adaptive and derived from individual user data to determine message eligibility.
224319561|NCT03632213|DRUG|Placebo|Placebo group: 15 patients, both sexes, will receive oral placebo for 12 months.
224319562|NCT05175235|DEVICE|CURATE.AI|Efficacy and toxicity measurements at the end of each two-/three- week dosing cycle, together with an information on given drugs and their doses, and other patient data, will be used by CURATE.AI to recommend the dose of nivolumab/pembrolizumab for the next cycle. The clinical investigators will decide whether or not to administer or prescribe the dose recommendation from CURATE.AI.
224323347|NCT06386263|DRUG|Trastuzumab deruxtecan|This is a non-interventional, observational study. Patients who are enrolled by their clinician will receive T-DXd per routine clinical practice through the PSP.
223642119|NCT04922216|BEHAVIORAL|Message Decision Rules (Standard)|Decision rules to determine eligibility to receive just-in-time messages consider participant's recent behaviors.
224323348|NCT05068102|DRUG|BI 765063|BI 765063
224323349|NCT05068102|DRUG|Ezabenlimab|Ezabenlimab
223765446|NCT02115282|OTHER|Placebo Administration|Given PO
223765447|NCT02115282|OTHER|Quality-of-Life Assessment|Ancillary studies
223765448|NCT05382208|DRUG|Doxycycline|Doxycycline 100 mg orally twice a day.
223765449|NCT05382208|DRUG|Placebo|Matching placebo orally twice a day.
223642120|NCT04922216|BEHAVIORAL|Message Decision Rules (Adaptive)|Decision rules to determine eligibility to receive just-in-time messages consider participant's recent behaviors and overall progress.
224229959|NCT03406130|PROCEDURE|Piezocision surgery|The piezocision surgery was performed 1 week after orthodontic appliance placement. The surgical protocol was performed as described by Dibart and al. (Dibart et al. 2009). However, to avoid bias, hard and soft tissue augmentations were not considered. The patients received local anesthesia in both arches; vertical interproximal microincisions were created below each interdental papilla. In cases of root proximity (i.e., \<2 mm of interdental bone), this procedure was not performed. These incisions were kept to a minimum (varying from 5 to 8 mm). Next, with a vertical piezoelectric device, 5-mm-long and 3-mm-deep corticotomies were made, and no subsequent sutures were required. The patients were advised to take analgesics (paracetamol) only if necessary and to record their daily intake for 1 wk. Anti-inflammatories were prohibited to avoid interference with the RAP.
223642121|NCT04922216|BEHAVIORAL|Message Choice (No)|Participant choice does not drive adaptation of 1) message type delivered or 2) lapse support provision
223642122|NCT04922216|BEHAVIORAL|Message Choice (Yes)|Participant choice drives adaptation of 1) message type delivered and 2) lapse support provision.
223642123|NCT06591546|DEVICE|Telescoping nail|"The implant used in this study is Fassier Duval type of telescoping nail.~The Fassier-Duval rod has certain advantages:~the design is dedicated to minimally invasive, ideally percutaneous, approaches sparing joint cartilage at implant positioning and removal. This reduces the risk of delayed growth and infection, with lower scar impact; instrumentation is much better than the very basic Dubow-Bailey instrumentation; maximum diameter is greater: 6.4 mm, compared to 5 mm for Bailey-Dubow; The length of the female part can be adapted, including intraoperatively. Precutting according to the surgeon's measurement can be adjusted intraoperatively with a dedicated circular saw with a diamond disc."
223642124|NCT06588543|DEVICE|Endovascular treatment|Endovascular treatment
223642125|NCT06596681|GENETIC|GA+clozapine|Patients were first given intracranial injections of GA and observed for 14-28 days, followed by a dose-climbing trial of clozapine medication, and finally, after the investigators had determined an effective dose of clozapine, the patients were given a fixed dose of clozapine orally for three months.
223642126|NCT06600516|BEHAVIORAL|CBTi: Stimulus Control Core|Stimulus control.45 People with insomnia may fail to associate the bedroom with sleep, and instead may associate it with worrying, planning, or recreation. Stimulus control includes the following instructions: (1) go to bed only when sleepy; (2) only use your bed or bedroom for sleep (or sex); (3) if you do not fall asleep quickly (i.e., 15 minutes), leave the bed, do something in another room, and return to bed only when you feel a strong sleep urge; (4) if you do not fall asleep quickly upon returning to bed, repeat instruction 3; (5) use your alarm to awaken at the same time every morning regardless of duration of sleep obtained; and (6) do not take long naps.
223642127|NCT06600516|BEHAVIORAL|CBTi: Sleep Restriction Core|Sleep restriction.46 People with insomnia often spend too much time awake in bed. Sleep restriction modifies the participant's sleep window so total time in bed is no more than 30 minutes beyond their average total sleep time to consolidate sleep, thus improving depth, continuity, and consistency. As the participant's sleep efficiency improves with treatment (i.e., the percentage of total time spent asleep within the sleep window), their sleep window is also increased. However, the shortened sleep window often causes increased anxiety.
223642128|NCT06600516|BEHAVIORAL|CBTi: Sleep Compression Core|Sleep compression.47,48 Sleep compression encourages time-in-bed restrictions. Unlike sleep restriction, sleep compression allows a gradual reduction in time-in-bed over the course of multiple weeks. Typically, average total sleep time and total time in bed values are calculated from one or more weeks of daily sleep diaries. The difference between these two values is then divided by the number of weeks remaining and the allotted time in bed duration is compressed by this calculated value weekly, by delaying bedtime or advancing wake time.
223642129|NCT06595199|OTHER|Online peer support|A closed online peer support group
223642130|NCT06603376|DRUG|FOLFIRI + Vemurafenib + Cetuximab|Liposomal Irinotecan Hydrochloride Injection (II): 60 mg/m², intravenous infusion over at least 90 minutes, on day 1; Leucovorin: 400 mg/m², intravenous infusion over 2 hours, on day 1; 5-FU: 400 mg/m², intravenous bolus; 5-FU: 2400 mg/m², continuous infusion over 46-48 hours, on day 1; Cetuximab: 500 mg/m², intravenous infusion over at least 2 hours, on day 1; Vemurafenib: 720 mg, orally twice daily. Repeat every 2 weeks.
223642131|NCT06603376|DRUG|FOLFIRI ± Bevacizumab|Liposomal Irinotecan Hydrochloride Injection (II): 60 mg/m², intravenous infusion over at least 90 minutes, on day 1; Leucovorin: 400 mg/m², intravenous infusion over 2 hours, on day 1; 5-FU: 400 mg/m², intravenous bolus; 5-FU: 2400 mg/m², continuous infusion over 46-48 hours, on day 1; Bevacizumab: 5 mg/kg, intravenous infusion, on day 1. Repeat every 2 weeks.
223642132|NCT06590363|OTHER|Listening to zen music|We conducted a quasi-randomized controlled clinical trial with two groups: Intervention Group (I), which corresponded to patients and doctors who underwent the period of musical listening in the office; and the Control Group (C), composed of patients and doctors who did not undergo the period of musical listening.
223642133|NCT06604000|BEHAVIORAL|GMT Usual|"Participants will receive Goal Management Training in groups of 4-6 patients, as implemented in a rehabilitation hospital setting (St. Olavs Hospital, Trondheim University Hospital). The standard treatment (GMT Usual) consists of 10 sessions, delivered as 2 sessions a day, one day per week, over 5 weeks."
223765450|NCT06468111|BEHAVIORAL|Animal Assisted Therapy|Blood and dental extraction will be performed according to the usual protocol of the health center in both groups; with the additional assistance of the therapy dog in experimental group.
224229960|NCT03935581|DEVICE|ExAblate|Auto Focusing (AF) echo imaging
224229961|NCT03772483|PROCEDURE|Local anesthesia with conventional syringe|"Buccal infiltration in posterior maxillary region with traditional technique. A 27 gauge short needle is inserted in the mucobuccal fold above the tooth to be anesthetized.~Local anesthetic infiltration speed 1ml/min. Drug: Local anaesthetic - Ubistesin - 4% Articaine with adrenaline 1: 200 000 1.7 mL"
224229962|NCT03772483|DEVICE|Local anesthesia with conventional syringe + VR device|"Virtual reality device (Noon VR, Gear FX) is placed on the face of the patient, playing a video of soothing and peaceful natural landscapes.~Buccal infiltration in posterior maxillary region with traditional technique. A 27 gauge short needle is inserted in the mucobuccal fold above the tooth to be anesthetized.~Local anesthetic infiltration speed 1ml/min. Drug: Local anaesthetic - Ubistesin - 4% Articaine with adrenaline 1: 200 000 1.7 mL"
223642134|NCT06604000|BEHAVIORAL|GMT Cuing|"The participants will receive extended cuing through a smartphone application (GMT Cuing) - intended to facilitate the effect of between-session tasks (homework) completed by the participants. These participants will, in addition to the standard treatment (as in GMT Usual), on a daily basis receive a message that says STOP as a reminder to do their home assignments. An sms with the the text STOP; as a reminder everyday from the third session until the fifth session. The message is pseudorandomly sent on different timepoints ranging from 11am to 8pm, including in weekends."
223642135|NCT06604000|BEHAVIORAL|GMT Boost|"After completion of the 10 GMT sessions and the first post-treatment assessment immediately after the main treatment period, the participants will receive an additional booster module (GMT Boost) 3 months after the last ordinary GMT module - intended to facilitate a prolonged treatment response."
223642136|NCT06590298|DRUG|Adjunctive Aripiprazole for improving Weight and Metabolic Outcomes in Females|The intervention group will be added 5 mg of aripiprazole as an adjunct with the usual antipsychotic treatment to the females on antipsychotic treatment
223642137|NCT06587724|OTHER|Questionnaire study|Questionnaire application
223642138|NCT05609487|OTHER|As usual|Patients included in the control phase, i.e. without intervention, will be asked not to oppose participation in the research, after having received the presentation of the study and the information notice. The data collection will be similar to the data collection during the intervention period.
223642139|NCT05609487|DEVICE|Protection plan|"The intervention consists of making the protection plan in a co-constructed process with the care user. This tool is built in 6 steps, is written and takes 20 to 40 minutes to complete.~These 6 steps allow to identify the first signs of a suicidal crisis and to identify different strategies to face it. They are constructed in an ascending order, with the aim of being used by the care user in an autonomous situation."
223642140|NCT06852313|PROCEDURE|Laparoscopic ovarian cyst surgery|Laparoscopic ovarian cyst surgery is any surgery with the goal of removal or drainage of an ovarian cyst. The exact surgical technique will be predefined by randomization.
223642141|NCT04900324|DEVICE|MRI guidance|Injections of botulinum toxin performed using MRI guidance
223765451|NCT05435885|OTHER|Pulmonary Tele-Rehabilitation|12 supervised training sessions via a specific mobile messenger during four weeks. (3 sessions/week)
223642142|NCT04900324|DEVICE|Ultrasound guidance|Injections of botulinum toxin performed using ultrasound guidance
223642143|NCT06526533|OTHER|Liberal RBC Transfusion|Liberal transfusion trigger group (patient receives RBC transfusion if Hb \<90g/L).
223642144|NCT06526533|OTHER|Restrictive RBC Transfusion|Restrictive transfusion trigger group (patient receives RBC transfusion if Hb \<70g/L).
223680643|NCT03455959|PROCEDURE|Airway Brushing|After completion of the BALs, endobronchial brushing of the airways will be performed using the airway brushings with a Conmed Harrell™ 4 mm unsheathed cytology brush. Upon completing the brushing the investigators remove the bronchoscope with the brush in place to avoid shearing off isolated cells. The brush will be gently glided back and forth on the airway epithelium 10 times in 2 different locations within the same airway. The brush is then placed in media and flicked to remove the cells. A second brush will then be introduced into an adjacent airway of the same lobe and gently glided back and forth on the airway epithelium 10 times in 2 different locations as was done with the first brush. The second brush will also be placed in media and flicked to remove the cells. There is some airway bleeding caused by the procedure, and participants are made aware that they may cough up small amounts of blood for 24-48 hours following the procedure.
223680644|NCT05502536|OTHER|Traditional rehabilitation programs with Individualized fairytales class|In addition to traditional rehabilitation programs, 30 minutes per week for 12 sessions of individualized fairytales classes by a child and educational teacher for three months, to preschool children with Attention Deficit Hyperactivity Disorder and developmental delays in regular traditional rehabilitation programs
223680645|NCT02383030|DRUG|Fulvestrant|After randomization patients will receive (Arm A, experimental Arm) fulvestrant as the following schedule: 500 mg i.m. on Days 0, 14, 28 followed by fulvestrant 500 mg im given every 28 days until progression disease. Study will start after 42 days from the last cycle of chemotherapy
223680646|NCT01425216|DRUG|Sorafenib|Treatment will be administered on an outpatient basis. All patients will keep a drug diary in order to record compliance with their drug regime. Sorafenib will be taken orally. Maximum length of treatment is 6 months. Starting dose of sorafenib is 200 mg three times per week for one month. In absence of Grade 2 toxicity, the dose will be increased on a monthly basis and will stop at 400 mg twice daily.
223680647|NCT03084627|BEHAVIORAL|Tailored dietary advice|The nutrient adequacy of the diet of each patient will be evaluated, at baseline, by a diet quality index: the PANDiet. Then, tailored dietary advice aiming at improving the nutrient adequacy of the diet will be generated for each patient in the arm #2. Patients will choose 3 tailored dietary advices among 3 options during three appointments with a research project team member (the first in person and the second and the third by phone). Each appointment will be spaced of 2 weeks. In total, each patient in the arm #2 will choose nine tailored dietary advice. Tailored dietary advices are of two kinds: substitution of a consumed food item by a food item in the same food subgroup or modification of the consumed amount (increase or decrease) of a food item. Tailored dietary advices cannot generate an increase of more than 190 kcal or a decrease as compared to the observed energy intake.
223680648|NCT06332638|DRUG|Tegoprazan 12.5mg|Oral administration of one tablet of Tegoprazan 12.5mg twice daily for 14 days.
223680649|NCT06332638|DRUG|Tegoprazan 25mg|Oral administration of one tablet of Tegoprazan 25mg once daily for 14 days.
223680650|NCT06332638|DRUG|Famotidine 20mg|Oral administration of one tablet of Famotidine 20mg twice daily for 14 days.
223680651|NCT06287606|DRUG|CTP0302-A|Subjects randomized into group CTP0302-A will take a bowel preparation from the evening until the following morning.
223680652|NCT06287606|DRUG|CTP0302-B|Subjects randomized into group CTP0302-B will take a bowel preparation on the Colonoscopy day
223680653|NCT06287606|DRUG|Conventional OST|Subjects randomized into group Conventional OST will take a bowel preparation from the evening until the following morning.
223680654|NCT04949919|OTHER|aerobic training by a cycle ergometer and Biodex system 4 pro|cyclic aerobic training in moderate-intensity and high-intensity interval training plus isokinetic resistance training prior to HD. 60 training sessions in 6 months.
223680655|NCT05719142|OTHER|Picture exposure|Participants are shown pictures for 15 minutes; 50 images in total, each shown for 6 seconds, and 3 times in total.
223642145|NCT04145349|DRUG|Ramucirumab|Administered IV
223642146|NCT04145349|DRUG|Cyclophosphamide|Administered orally
223642147|NCT04145349|DRUG|Vinorelbine|Administered IV
223642148|NCT05531734|DEVICE|NaoX Intra-Auricular Device (IAD) monitoring EEG data|Intrauaricular measurement tool developed by NaoX Technology to retrieve EEG type data.
223642149|NCT05531734|BEHAVIORAL|Simple psychometric tests|Associated with simple and self-managed psychometric tests.
223642150|NCT05628337|OTHER|Motivational texting|Health related information relevant to a subject's diagnosis and ongoing treatment
223642151|NCT05628337|OTHER|Control|Non-motivational text messages containing no specific health information
224229963|NCT03002649|DRUG|Tofacitinib|Tofacitinib comes as an extended-release (XR) (long-acting) tablet to take by mouth. The extended-release tablet is usually taken with or without food once daily.
224229964|NCT02444559|DRUG|Ropivacaine 20ml 5mg/ml+ Clonidine 150ug|
224229965|NCT02444559|DRUG|Ropivacaine 20ml 5mg/ml+ Placebo|
223642152|NCT05987930|DEVICE|bone lid technique|group I ten patients with mandibular lesion will be undergo excision of lesion using bone lid technique with piezo-electric device then reposition of buccal bone cortex
223642153|NCT05987930|DEVICE|standard technique|group II ten patients with mandibular lesion will be undergo excision of lesion using surgical bur to remove buccal cortex to get access to lesion
223765452|NCT05435885|OTHER|Control (Education)|Usual care with only one educational session.
223765453|NCT02610855|PROCEDURE|Spinal Fusion Surgery|Participants with severe scoliosis curves requiring spinal fusion surgery.
223765454|NCT02610855|OTHER|Bracing|Participants with scoliosis curves that require brace treatment for at least the next year. Braces include monitors to record hours of brace wear, as is current standard of care.
223765455|NCT02610855|DEVICE|Tri-axial Accelerometers|Four monitors are place on the participant (waist, thigh, both ankles), attached with straps. Periods of static and dynamic activity are measured based on accelerations in three orthogonal directions for 4 day's time while participating in regular daily activities.
224229966|NCT00679783|DRUG|AZD2281|PARP inhibitor Olaparib tablets, oral
224229967|NCT01536678|DRUG|Levothyroxine|Single dose of 600mcg of test formulation of levothyroxine administered in dosing period 1 or 2.
224229968|NCT01536678|DRUG|Levothyroxine|Single dose of 600mcg of reference formulation of levothyroxine administered in dosing period 1 or 2.
224229969|NCT00996528|BEHAVIORAL|Philani Intervention Program|Offered to pregnant women / mothers through mentor mothers, i.e. mothers in community who are selected because they are doing well. They are trained to conduct home visits, 2 times a months through pregnancy. After childbirth, visits are spaced depending on the perceived need. If the baby is thriving and mother is coping well with health risks, mentor mother will visit once a month.
224229970|NCT05248932|DRUG|Norepinephrine bolus|5 microgram bolus therapy
224229971|NCT05248932|DEVICE|cardiometry|cardiac output, stroke volume and fluid responsiveness monitoring
224229972|NCT05248932|DRUG|Norepinephrine infusion|2.5 microgram/min infusion
224229973|NCT05374863|DEVICE|Neuromuscular electrical stimulation (NMES) - Active|The NMES will be held for 20 minutes. Biceps musculature and bilateral wrist and finger flexors stimulated. For patients undergoing hemodialysis for fistula in the upper limb, NMES will be performed only in the limb without a fistula. points of points 4 electrodes in each, being 2 points of longitudinal position in the muscular belly of the biceps, and other 2 in the ventral region of the forearm. the parameters: frequency of 80 Hz, pulse frequency of 350 ms, time of 5 seconds and 10 seconds. The possibility will be greater for each patient who will have the contraction. Patients will be instructed to perform an isometric contraction of wrist and finger flexors during electrical stimulation.
223642154|NCT00755989|OTHER|None available|
223642155|NCT04424186|OTHER|'Rehabilitation for Life'|An empowerment-oriented cross-sectorial program including vital sign measurement and systematic progressive rehabilitation combined with convenient access for collaboration among professionals.
223642156|NCT04424186|OTHER|Usual care and rehabilitation|The care and rehabilitation usual provided to patients after hip fracture surgery
223642157|NCT00002330|DRUG|Ganciclovir|
223642158|NCT03365271|PROCEDURE|drainage|Applying a drain tube during TKA procedure
223642159|NCT03365271|PROCEDURE|non-drainage|No drain tube will be applied during TKA procedure
223642160|NCT04783493|DEVICE|Non-invasive magnetic stimulation of the spinal cord|Non-invasive transcutaneous magnetic stimulation of the dorsal spine will be applied by placing a circular magnetic coil (Magventure®️ MagPro®️ R20) on the skin, in the upper thoracic region (chest level T2-T3). The stimulation intensity will represent 100% of the motor threshold. The intermittent theta burst stimulation protocol will consist of 20 stimulation trains, with an interval of 8 seconds between trains, each train will have 20 bursts, and each burst will have 3 pulses at 50 Hz repeated at 5 Hz. In total, 1200 pulses will be applied for 3 minutes and 58 seconds
223642161|NCT04783493|OTHER|Coil will not be connected to the stimulation device|coil will not be connected to the stimulation device, and another active coil will be positioned about 15cm behind, far from its field of view, to provide idea from the sound stimulus that is being stimulated
223642162|NCT02553226|DRUG|Oxytocin|Both arms will initially receive routine treatment with oxytocin according to national guidelines. When active phase of labour is established both arms will have their infusion-set changed for a blinded infusion-set.
223642163|NCT02553226|DRUG|Placebo|Both arms will initially receive routine treatment with oxytocin according to national guidelines. When active phase of labour is established both arms will have their infusion-set changed for a blinded infusion-set.
223642164|NCT01035086|DIETARY_SUPPLEMENT|fabricated food|The subjects consumed a high-fibre diet containing 25 g fibre (citrus- or lupin fibre) per day and a low-fibre diet (placebo) for four weeks each. After a one-week run-in period, each volunteer had to pass all three periods (arms) in different order with a two-week wash-out period between each.
223765456|NCT02610855|OTHER|Shear Wave Elastography (SWUE)|SWUE is an ultrasound technique for noninvasively evaluating the mechanical properties (stiffness) of skeletal muscle tissue. A commercial ultrasound scanner (Aixplorer from Supersonic Imagine, France) with 2D real time SWUE will be used. The Aixplorer uses ultrasonic push beams to produce shear waves in tissue. The shear wave propagation speed is inherently related to tissue mechanical properties and is used to create a quantitative 2D elastogram of the tissue.
223642165|NCT04842812|BIOLOGICAL|TILs and CAR-TILs targeting HER2, Mesothelin, PSCA, MUC1, Lewis-Y, GPC3, AXL, EGFR, Claudin18.2/6, ROR1, GD1, or B7-H3|TILs and CAR-TILs injection: 1-10×10e7/kg cells for each treatment; 3 or more cycles.
223642166|NCT02061488|OTHER|open-loop night|During the open-loop night the patient is using his insulin pump as usual
223642167|NCT02061488|OTHER|closed-loop night|During the closed-loop night glucose values measured by the sensor are collected every 15 minutes. The data are entered into the SP-MPC controler that calculate the insulin dose to be delivered. A diabetologist validates the insulin dose before the infusion (manually bolus infusion)
223642168|NCT02786394|BEHAVIORAL|REACH|REACH is a lifestyle intervention program which aims to reduce sedentary behaviour, increase physical activity, and increase strength and balance. The REACH program is comprised of six sessions which include evidence-based education, behaviour change theory, and activity instruction. REACH also teaches goal setting techniques, mindfulness, and encourages active community engagement. In this study we are running the REACH program for women aged 55 and older alongside a supplementary optional walking program run by SportMedBC.
223642169|NCT02785549|DRUG|Ibuprofen|600 mg/8hours
223642170|NCT02785549|DRUG|Acetaminophen|1 g/8 hours
223765457|NCT06457373|PROCEDURE|Demineralized Dentin Allograft|20 sockets are randomly allocated to receive the Demineralized Dentin Allograft (split-mouth study)
224229974|NCT05374863|DEVICE|Neuromuscular Electrical Stimulation (NMES) - Sham|It will be performed in the same way as in the experimental group, however, the intensity of the actuality will only reach the sensitive threshold.
224229975|NCT05374863|DEVICE|Aerobic exercise with cycle ergometer|The exercise will be performed from the adaptation and positioning of a cycle ergometer (Mini Bike E5 Acte Sports®) in front of the hemodialysis chair. Each session will consist of three phases: duration (5 minutes), conditioning (20 minutes) and cool-down (5 minutes). During the development and cool-down phases, patients will be instructed to maintain a lower exercise intensity, with a level between 1 and 3 on the modified BORG scale. In the conditioning phase, patients will be instructed to slightly increase the intensity of the exercise, levels between 4 and 7 on the modified BORG scale. During exercise, patients will be asked every 5 minutes about the level of effort, and the load on the cycle ergometer will be possible to reach an intensity between 4 and 7 on the modified Borg Scale.
224229976|NCT03908255|DRUG|Branch Chain Amino Acid|Nutritional supplementation
224229977|NCT03908255|OTHER|maltodextrin|Placebo
224229978|NCT00121654|DEVICE|Spinal cord stimulation|Under sterile conditions and local anesthesia, the epidural space is punctured at the level of T5-T6 and a quadripolar electrode catheter is introduced and advanced under X-ray control into the epidural space. A suitable position for the electrode catheter is sought for, corresponding to the site where a prickling sensation (paresthesia) is felt and covers the area of radiation of angina pain under neurostimulation. The electrode catheter is connected to an internal pulse generator placed in a subcutaneous abdominal or gluteal pocket through an extension lead connected to the electrode by subcutaneous tunneling.
224229979|NCT01968733|DRUG|Solithromycin|
224229980|NCT01968733|DRUG|Moxifloxacin|
224229981|NCT00756964|DRUG|Rasburicase|Rasburicase (Dose: 7.5mg in 50ml of normal saline administered over 30 minutes) or identical placebo will be administered as an (dosage form)intravenous infusion preoperatively.
224229982|NCT00756964|DRUG|Placebo|Placebo drug (color-coded to appear identical to study drug) administered as an (dosage form) intravenous infusion preoperatively.
224229983|NCT03960918|BEHAVIORAL|aerobic exercise therapy|aerobic exercise therapy: All enrolled subjects will perform a CPET before the training initiation. After CPET, the patients in the experimental group need to perform an additional bicycle training program with the intensity of 60 % maximal workload in the previous CPET (five days per week, for four weeks with a total of 20 times).
224229984|NCT01754259|DRUG|Ranolazine|Subject will receive labeled bottles containing tablets with ranolazine 500 mg or a matching placebo provided by the sponsor. Each patient will receive both ranolazine and placebo for 4 weeks, but both the investigator and subject are blinded to the order.
224229985|NCT01754259|DRUG|Placebo|Subject will receive labeled bottles containing tablets with ranolazine 500 mg or a matching placebo provided by the sponsor. Each patient will receive both ranolazine and placebo for 4 weeks, but both the investigator and subject are blinded to the order.
224229986|NCT04403100|DRUG|Hydroxychloroquine Sulfate Tablets|Tablets of 400 mg: Loading dose of 02 tablets followed by one tablet of 400 mg orally on the following 09 days
224229987|NCT04403100|DRUG|Lopinavir/ Ritonavir Oral Tablet|tablets of 200/ 50 mg; Loading dose of 04 tablets twice a day on day 1 followed by two tablets twice a day on the following 09 days
224229988|NCT04403100|DRUG|Hydroxychloroquine Sulfate Tablets plus Lopinavir/ Ritonavir Oral Tablets|"Hydroxychloroquine Oral Tablet 400 mg: Loading dose of 02 tablets followed by one tablet of 400 mg orally on the following 09 days~plus~Lopinavir/ Ritonavir Oral Tablet of 200/ 50 mg: Loading dose of 04 tablets twice a day on day 1 followed by two tablets twice a day on the following 09 days"
224229989|NCT04403100|DRUG|Placebo|Placebo tablets - 01 tablet twice daily from day 01 through day 10.
224229990|NCT05268978|DEVICE|Medimonitor|A digital solution consisting of smartphone/tablet based application gathering data from medical and other devices provided to the patients. These devices are as follows: tablet, smartwatch, mobile ECG, blood pressure monitor, weight scales, pulse oximetry device.
224323350|NCT05068102|DRUG|[89Zr]Zr- BI 765063|\[89Zr\]Zr- BI 765063, specifically radiolabelled for immune-Positron Emission Tomography (PET)
224323351|NCT05068102|DRUG|BI 770371|BI 770371
223642171|NCT02785549|DRUG|Amoxicillin/clavulanic acid|875mg/125mg/8 hours
223642172|NCT05348343|BIOLOGICAL|Autologous platelet-rich plasma|PRP created using a commercially available system will be used for treatment. PEFA-PRP will be created by subjecting PRP to a pulsed electrical field in a specially designed instrument developed by sponsor. Two 9 cm2 contralateral regions of interest (ROI) on the scalp will be treated with approximately 6mL of either PRP or PEFA-PRP by subcutaneous injection.
223642173|NCT05784493|OTHER|Study group|Washing by heated saline group
223680656|NCT02821143|OTHER|usual palliative care|Residents in the control group will receive usual palliative care usually delivered in their nursing homes , according to the habits of the healthcare team and their physician.
223765458|NCT06457373|PROCEDURE|Demineralized Dentin Autograft|20 sockets are randomly allocated to receive the Demineralized Dentin Autograft (split-mouth study)
223642174|NCT02543957|PROCEDURE|Cholangioscopy|All patients will receive pre-procedural antibiotics per protocol. A blood culture will be drawn from patients prior to the procedure (before antibiotics administration), 5 minutes after the procedure and 30 minutes after the procedure. Patients will be followed up for 7 days after the procedure for fever and or sepsis.
223642175|NCT06834945|BEHAVIORAL|AYA SPARK|Intervention includes video conferencing based sessions to cover topics related to fertility-related information needs and concerns among female adult survivors of childhood cancer over a 6-8 week period.
223642176|NCT00504647|DEVICE|Biventricular Pacemaker|
223642177|NCT01964820|BEHAVIORAL|Positive Affect Skills Training|"Our intervention teaches 8 skills that research suggests lead to increased positive emotions, beginning with basic skills (recognizing and savoring positive events), and progressing to more complex ones such as goal- setting and acts of kindness. Established skills such as reappraising negative thoughts are also taught, in the context of cultivating positive emotions and coping with stress.~The skills are taught over 5 weeks, with one or more new skills introduced each week. A week consists of 1-2 days of didactic material and 5-6 days of real-life skills practice and reporting.~For a full description, see A positive affect intervention for people experiencing health-related stress: development and non-randomized pilot test (Moskowitz et al., 2012)."
223642178|NCT00942227|OTHER|Physical therapy rehabilitation|Extension oriented exercises. Subjects will be instructed in a progression of extension oriented exercises for the lumbar spine
223642179|NCT00942227|OTHER|Physical therapy rehabilitation|Mechanical lumbar traction will be applied with subjects in prone utilizing 40-60% of subject's body weight to create a distraction force in the lumbar spine. Following traction, subjects will be instructed in a progression of extension oriented exercises and manual therapy to increase extension as described for the comparator group.
223642180|NCT04279626|PROCEDURE|LETS-M|A 1.5-centimeter skin incision was made over the umbilicus, and the abdominal wall was opened layer by layer with an open method. A wound retractor (Alexis, 2-4 centimeter; Applied Medical Resources Corp., Rancho Santa Margarita, CA) was placed, and the glove port was set up, with a 10-millimeter trocar in the thumb over patient's right side, and a 5-millimeter trocar in the little finger over the left side. The pneumoperitoneum was established. A 10-millimeter rigid laparoscope was inserted via the 10-millimeter trocar and controlled by the assistant. The ancillary 5-millimeter port was made over the left lower abdomen under laparoscope inspection. The surgeon performed the surgery via the two 5-millimeter trocars.
223642181|NCT02306317|OTHER|Standard procedure|FiO2 manually controlled by nursing
223642182|NCT02306317|OTHER|Experimental procedure|FiO2 manually controlled by parents, after training.
223642183|NCT04828343|DRUG|rozanolixizumab|Study participants will receive a single dose rozanolixizumab subcutaneously administered by manual push or a syringe driver.
223642184|NCT04828343|OTHER|Placebo|Study participants will receive a single dose placebo subcutaneously administered by manual push or a syringe driver.
223642185|NCT01148979|DRUG|Lisdexamfetamine Dimesylate (Vyvanse)|Lisdexamfetamine Dimesylate (Vyvanse) capsules dose ranging from 20mg to 50 mg.
224229991|NCT05477329|DEVICE|Lenses|The test lens is manufactured in a standard FreeForm technology (exactly like a standard progressive addition lens which is similar in terms of the graduall power profile induced in both lens). It does not demand any special manufacturing processes.
224229992|NCT04813250|OTHER|ventilation mode setting|Ventilation strategies with 4 kinds of ventilator mode since weaning cardiopulmonary bypass (CPB), Four group were control EtCO2 between 35～45mmHg by adjusting respiratory rate, EIT Measurements were performed under supine position
224229993|NCT02363751|DRUG|Bevacizumab|"Patients will be treated for a maximum of 6 (21days) chemotherapy cycles (Gemcitabine+platinum salt+bevacizumab).~In case of disease control (complete, partial or stable disease) treatment with bevacizumab 15 mg/Kg monotherapy every 21 days will be continued until disease progression or until the end of the 24 months of follow-up."
224229994|NCT03664856|OTHER|interview|The patient will be asked to answer the questions that the interviewer will ask him.
224229995|NCT03849781|DEVICE|NeoBeat with a visible display|NeoBeat (Laerdal Medical) is a CE approved novel heart rate meter, able to detect heart rate in newborns within seconds of birth. The NeoBeat uses ECG dry-electrodes in a snug-fit abdomen-shaped buckle for rapid application around the newborn's abdomen or thorax. It allows healthcare providers to reliably assess heart rate of the newborn immediately after birth and continuously during resuscitation.
224229996|NCT05950724|DRUG|Etanercept Injection [Enbrel]|25 mg subcutaneous injection
224229997|NCT00638859|DRUG|Telithromycin (HMR3647)|
224323352|NCT05068102|DRUG|[89Zr]Zr- BI 770371|\[89Zr\]Zr- BI 770371, specifically radiolabelled for immune-PET
223642186|NCT01148979|DRUG|Placebo|Lisdexamfetamine Dimesylate (Vyvanse)-matched placebo capsules.
223642187|NCT05216809|BEHAVIORAL|Habitual Physical Activity|Participants will maintain habitual levels of physical activity (inclusive of structured physical activity). Participants will be required to maintain \>7,000 steps/day.
223642188|NCT05216809|BEHAVIORAL|Step-Reduction|Participants will be required to reduce their daily step-counts to \<2,000 steps/day. Further, they will be required to refrain from structured physical activity.
223642189|NCT04556799|PROCEDURE|computer-assisted surgery|derotation osteotomy with the aid of 3D osteotomy template and computer-assisted simulated surgery
223642190|NCT04556799|PROCEDURE|traditional osteotomy|traditional osteotomy without the aid of 3D osteotomy template
223642191|NCT00132470|DRUG|AX200 (G-CSF)|
223642192|NCT01341613|DIETARY_SUPPLEMENT|Cardioviva™ supplement capsule|Twice per day (BID), 9 weeks
223642193|NCT01341613|DIETARY_SUPPLEMENT|Placebo capsule|Twice per day (BID), 9 weeks
223642194|NCT00538668|DRUG|117Lu-J591|There will be 9 groups of patients. The first group will receive 20 units of test drug and the 9th group will receive 55 units of the test drug. The exact dose of the test drug will depend upon how many patients have been included in this protocol at the time of patient enrollment. Patients will receive 20-55 units (or millicuries) of radioactivity depending upon patient specific height and weight. The assignment of each patient for a specific dose level is purely based on the sequence of recruitment basis and does not depend on the clinical status of the patient.
224323353|NCT02942004|DRUG|Placebo|Intravenous infusion of matching placebo for either SAGE-547 60 μg/kg/h or 90 μg/kg/h.
224323354|NCT02942004|DRUG|SAGE-547 60 μg/kg/h|Intravenous infusion of SAGE-547.
224323355|NCT02942004|DRUG|SAGE-547 90 μg/kg/h|Intravenous infusion of SAGE-547.
224323356|NCT02446132|DRUG|AVP-786|
223642195|NCT01646125|DRUG|AUY922|AUY922 was to be given by i.v. once weekly at 70 mg/m2 until disease progression, death or any other reason for discontinuation from study treatment.
223642196|NCT01646125|DRUG|Docetaxel|Docetaxel was to be given i.v. once every 3 weeks at 75 mg/m2 until progression or unacceptable toxicity
223642197|NCT01646125|DRUG|Pemetrexed|Pemetrexed was to be given once every 3 weeks at 500 mg/m2 until progression or unacceptable toxicity
223642198|NCT05150119|DIAGNOSTIC_TEST|Evaluation of Synovial IL-6 in diabetic patients with gonarthrosis|To evaluate if there is a linear positive correlation between plasma glycated hemoglobin concentration HbA1c and synovial IL-6 in diabetic patients
223642199|NCT04440527|DEVICE|Preserflo / Innfocus Microshunt|The Microshunt features an 8.5-mm tube with an outer diameter of 350 µm and a 70-µm diameter lumen. Implantation creates a subconjunctival bleb and lowers intraocular pressure by increasing aqueous humor outflow.
223642200|NCT04440527|OTHER|Trabeculectomy|Trabeculectomy is the most commonly performed surgical procedure and is considered the gold standard.
223642201|NCT01302990|BIOLOGICAL|Dose given at Day 0|Dose given by intramuscular administration (0.5 mL)
223642202|NCT06094582|OTHER|questionnaire|Participants will have to fulfill a short questionnaire (10 minutes) concerning their use and knowledges about CBD.
223642203|NCT06522100|DRUG|Intravenous administration of Methylprednisolone|Patients will take intravenous administration of Methylprednisolone (500mg/100ml by IV over 30 minutes per day) for 3 days.
223642204|NCT06522100|DRUG|Oral Prednisone|After intravenous administration of Methylprednisolone patients will take by oral Prednisone 1mg/kg per day once a day (with a maximum dose of 90 mg per day for patients weighing \> 90kg) for 1 month, followed with a progressive decrease of 10 mg Prednisone every 15 days until a dose of 10mg per day during 15 days (= stop).
223642205|NCT06522100|DRUG|Perfusion of placebo|Patients will take perfusion of placebo (G5%: 100ml over 30 minutes per day) for 3 days.
223642206|NCT06522100|DRUG|Oral Prednisone placebo|After the perfusion of placebo, patients will take by oral Prednisone placebo once a day for the same duration as that required if the patient was in the investigational medicinal products group (1 month + progressive decrease).
223642207|NCT04147780|PROCEDURE|Sentinel node biopsy|Sentinel node biopsy, radiotracer (mandatory) and blye dye (optional). Scintigraphy.
224229998|NCT00814320|BIOLOGICAL|Recombinant human hyaluronidase (rHuPH20)+ immune globulin intravenous (IGIV)|"Comprises subjects previously participating in Study 160601, who now only complete Study Epoch 2 (subcutaneous \[SC\] infusions) as bioavailability/exposure for intravenous (IV) treatment was already obtained in Study 160601.~Study Epoch 2: Dose (calculated) of rHuPH20 followed by dose (calculated) of IGIV, 10% by SC infusion. Treatment intervals and doses are to be increased as defined, until treatment interval is the same as the pre-study treatment interval for IV treatment (ramp-up)."
224229999|NCT00814320|BIOLOGICAL|Recombinant human hyaluronidase (rHuPH20)+ immune globulin intravenous (IGIV)|"Comprises all other subjects.~Study Epoch 1: IV infusion of IGIV, 10% (same dose and frequency as pre-study) to determine pharmacokinetics.~Study Epoch 2: Dose (calculated) of rHuPH20 followed by dose (calculated) of IGIV, 10% by SC infusion. Treatment intervals and doses are to be increased as defined, until treatment interval is the same as the pre-study treatment interval for IV treatment (ramp-up)."
224230000|NCT00491504|DRUG|Mometasone Furoate Nasal Spray|Mometasone Furoate Nasal Spray: 2 sprays (50 mcg) each nostril (total 200 mcg)
224230001|NCT00491504|OTHER|Placebo|Placebo: 2 sprays in each nostril
224230002|NCT00425737|BIOLOGICAL|Rotarix|
223642208|NCT02132429|DRUG|AMG 333|Oral administration available in varying dose strength.
223642209|NCT02132429|DRUG|Placebo|Placebo containing no active drug
223642210|NCT02506348|DRUG|Diclofenac|
223642211|NCT02506348|DRUG|Nepafenac|
223642212|NCT06022692|DEVICE|Water-filtered infrared A radiation whole-body hyperthermia (HECKEL 3000MT-4T, Germany)|The patients were treated with whole-body hyperthermia (HECKEL 3000MT-4T, Germany)) on days 1 and 8 of each hyperthermia combined with immune checkpoint inhibitor treatment cycle along with administration of tislelizumab (BeiGene, China) 200 mg on day 2 (24 hours after the hyperthermia at day 1).
223642213|NCT06022692|DRUG|tislelizumab (BeiGene, China) combined with PD-1 inhibitor|The patients were treated with whole-body hyperthermia (HECKEL 3000MT-4T, Germany)) on days 1 and 8 of each hyperthermia combined with immune checkpoint inhibitor treatment cycle along with administration of tislelizumab (BeiGene, China) 200 mg on day 2 (24 hours after the hyperthermia at day 1).
224230003|NCT04056143|DIAGNOSTIC_TEST|Pharmacogenomics|Subjects enrolled in this study are providing blood samples for completing a set of laboratory testing and pharmacogenomic analyses. They are requested to comply a Pharmacist interview and complete of assisted questionnaires.
223642214|NCT04641208|DEVICE|mobile phone|The root mean square (RMS) of the signal will be calculated by using electromyography, and were normalized to the EMG data maximum voluntary isometric contraction (MVIC)
223642215|NCT04598802|DEVICE|covered stent|atherosclerotic aorto-iliac aneurysm
223642216|NCT00775190|DRUG|ortho tricyclen|brand name oral contraceptive
223642217|NCT00775190|DRUG|Trinessa|generic oral contraceptive
223642218|NCT00843596|PROCEDURE|cardiac surgery requiring ECC|the vacuum device is left on the 2 wounds (caused by the ECC cannulas) for 15 min (possible a second time of 15 min : 30 min max.)
223642219|NCT05504785|DEVICE|DexCom G6 continuous glucose monitor|Use of real-time DexCom G6 continuous glucose monitor (CGM or glucose sensor) trend data and an insulin-dosing algorithm to control the glucose levels of diabetic patients undergoing hip/knee orthopedic surgery at Thomas Jefferson University Hospital (TJUH).
223642220|NCT03710200|OTHER|Bologna 00+S. cerevisiae yeast|Bologna 00 bread made with yeast (portion corresponding to 50g available carbohydrates) +500 mL of water
223642221|NCT03710200|OTHER|Bologna 1+S. cerevisiae yeast|Bologna 1 bread made with yeast (portion corresponding to 50g available carbohydrates) +500 mL water
223642222|NCT03710200|OTHER|Bio2+S. cerevisiae yeast|Bio2 bread made with yeast (portion corresponding to 50g available carbohydrates) +500 mL water
223642223|NCT03710200|OTHER|ICARDA+S. cerevisiae yeast|Icarda bread made with yeast (portion corresponding to 50g available carbohydrates) +500 mL water
223642224|NCT03710200|OTHER|Bologna 1+sourdough|Bologna 1 bread made with sourdough (portion corresponding to 50g available carbohydrates) +500 mL water
223642225|NCT03710200|OTHER|Bio 2+sourdough|109g of Bio2 bread made with sourdough (portion corresponding to 50g available carbohydrates) +500 mL water
223642226|NCT03710200|OTHER|ICARDA+sourdough|Icarda bread made with sourdough (portion corresponding to 50g available carbohydrates) +500 mL water
223642227|NCT03710200|OTHER|Grossi+sourdough|Grossi bread made with sourdough (portion corresponding to 50g available carbohydrates) +500 mL water
223642228|NCT01965678|OTHER|Osteopathic Manipulative Treatment|
223642229|NCT02194478|BEHAVIORAL|Meditation|30 minute, 8 week meditation
223642230|NCT04791163|DEVICE|Socket evaluation|The subject will wear the socket for 4 weeks, and then reply questionnaires and achieve a 2-minute walking test
224230004|NCT03932266|DRUG|Endostar|Endostar, 15 mg/m2, continous intravenous infusion, 3 cycles during induction chemotherapy, 4 cycles during concurrent chemoradiotherapy.
224230005|NCT03932266|DRUG|Cisplatin|Cisplatin, 75 mg/m2, intravenous infusion, 3 cycles during induction chemotherapy; Cisplatin, 80 mg/m2, intravenous infusion, 2 cycles during concurrent chemoradiotherapy.
224230006|NCT03932266|DRUG|Docetaxel|Docetaxel, 75 mg/m2, intravenous infusion, 3 cycles during induction chemotherapy.
224230007|NCT03932266|RADIATION|Intensity Modulated Radiation Therapy (IMRT)|IMRT: 66 Gy, 2-2.2 Gy per fraction, a total of 33 fractions
224230008|NCT05476874|PROCEDURE|Open Mini-Laparotomy|A 5-cm paraumbilical skin is made, and the abdominal wall is incised in layers. The distal catheter tip is inserted into the peritoneal cavity in a craniocaudal direction, and the abdominal wound is sutured in layers.
224230009|NCT05476874|PROCEDURE|Abdominal Puncture|An about 0.5-cm paraumbilical incision made to allow introduction of a splitable trocar. The trocar is pierced through the abdominal wall into the abdominal cavity. Pull out the puncture cone, and adjust the trocar towards the pelvis. The distal catheter tip is inserted into the peritoneal cavity through the puncture cannula. Then the splitable puncture cannula is split apart and removed. The skin incision requires only one stitch.
224230010|NCT04170699|PROCEDURE|Port-a-cath replacement|Implantation of a subcutaneous venous port-a-cath
224230011|NCT04971057|OTHER|multimedia information program of renal biopsy|Multimedia information program is based on self-efficacy theory. The multimedia videos contain the information associated with renal biopsy, which including the purpose, indications, preparations for the examination, process, patient experience sharing, complications, precautions, home care and stress adjustment strategies.
224230012|NCT03197402|DIETARY_SUPPLEMENT|Leucine-enriched protein gel delivery system|Leucine enriched
224230013|NCT03197402|DIETARY_SUPPLEMENT|Milk protein gel delivery system|Non-leucine enriched
224230014|NCT05682495|DRUG|ARM A|Subjects will receive treatment SHR3824 10 mg+ SP2086 100 mg+ Metformin 500 mg XR\*2 followed by 7 days washout ，then receive treatment SHR3824 10 mg+ SP2086 100 mg+ Metformin 500 mg XR\*2 followed by 7 days washout and then receive treatment HR20031 FDC 10/100/1000 mg.
224230015|NCT05682495|DRUG|ARM B|Subjects will receive treatment HR20031 FDC 10/100/1000 mg followed by 7 days washout ，then receive treatment SHR3824 10 mg+ SP2086 100 mg+ Metformin 500 mg XR\*2 followed by 7 days washout and then receive treatment SHR3824 10 mg+ SP2086 100 mg+ Metformin 500 mg XR\*2.
224230016|NCT05682495|DRUG|ARM C|Subjects will receive treatment SHR3824 10 mg+ SP2086 100 mg+ Metformin 500 mg XR\*2 followed by 7 days washout ，then receive treatment HR20031 FDC 10/100/1000 mg followed by 7 days washout and then receive treatment SHR3824 10 mg+ SP2086 100 mg+ Metformin 500 mg XR\*2.
224230017|NCT05682495|DRUG|ARM D|Subjects will receive treatment SHR3824 5 mg\*2+ SP2086 50 mg\*2+ Metformin 500 mg XR\*3 followed by 7 days washout ，then receive treatment SHR3824 5 mg\*2+ SP2086 50 mg\*2+ Metformin 500 mg XR\*3 followed by 7 days washout and then receive treatment HR20031 FDC 5/50/750 mg\*2.
224230018|NCT05682495|DRUG|ARM E|Subjects will receive treatment HR20031 FDC 5/50/750 mg\*2 followed by 7 days washout ，then receive treatment SHR3824 5 mg\*2+ SP2086 50 mg\*2+ Metformin 500 mg XR\*3 followed by 7 days washout and then receive treatment SHR3824 5 mg\*2+ SP2086 50 mg\*2+ Metformin 500 mg XR\*3.
224230019|NCT05682495|DRUG|ARM F|Subjects will receive treatment SHR3824 5 mg\*2+ SP2086 50 mg\*2+ Metformin 500 mg XR\*3 followed by 7 days washout ，then receive treatment HR20031 FDC 5/50/750 mg\*2 followed by 7 days washout and then receive treatment SHR3824 5 mg\*2+ SP2086 50 mg\*2+ Metformin 500 mg XR\*3.
223642231|NCT02476539|DRUG|Hemay022|
223642232|NCT04188561|DRUG|Intra articular injection Group|"Patients included in the study had been received 2 ml high molecular weight (1.476 x 106 average Daltons) hyaluronic acid with concentration of 22mg/ml (OPTIVISC UK hyaluronic acid for intra articular injection). Platelet rich plasma is arranged by withdrawing 10 ml of patient's personal venous blood, anticoagulant is added, and centrifuged by duo-spin method, at the rate of 3500 rpm for five minutes then injected twice with 2 weeks interval. 3 distinct layers are produced by the end of the centrifugation: plasma, buffy coat (platelet) and RBCs, about 3 - 3.5 ml of PRP is produced~at the end with platelet concentration of 1.4 - 1.6 million/μl on average."
223642233|NCT04188561|DEVICE|Radiofrequency Group|Thermal radiation is done by Neurotherm 2000 (Neurotherm NT 2000 Radiofrequency (RF) Generator is a four electrode pain management (RF) generator for interventional pain management procedures. Neurotherm's newest system offers accurate independent controls of each electrode through the touch screen interface and output control knobs.), Patients from the radiofrequency (RF) group had been placed in the supine position and their knee will be supported by a small pillow placed beneath the popliteal fossa. Fluoroscopic images of knee joint had been obtained. Possible locations of genicular nerves had been determined on the lateral, medial aspects of the lower end of the femoral bone and on the medial aspect of the tibia, under fluoroscopic guidance.
223642234|NCT01608945|DRUG|Hydrocortisone sodium succinate|100mg/day
223642235|NCT02800629|DIETARY_SUPPLEMENT|Modified Citrus Pectin|MCP versus placebo
224230020|NCT03561506|DRUG|Ferric carboxymaltose|Ferinject®to be administered as IV drip infusion or undiluted bolus injection to consented patients with preoperative anemia before total knee arthroplasty.
224230021|NCT03561506|DRUG|0.9% Normal Saline|Placebo(0.9% Normal Saline) to be administered as IV drip infusion or bolus injection to consented patients with preoperative anemia before total knee arthroplasty.
223642236|NCT02800629|DIETARY_SUPPLEMENT|Placebo|
223642237|NCT00741182|DRUG|rhPTH(1-34)|Injection of 20 micrograms per day in eight weeks
224230022|NCT00977002|OTHER|Positive Pressure Noninvasive ventilation|Patients randomized to this group are submitted to positive pressure noninvasive ventilation for 12 hours or more. Children younger than one year use nasal prong and older than one year use nasal or facial mask. A blood gas is collected in the moment of intubation and one hour after.
223642238|NCT05306756|DIAGNOSTIC_TEST|Fetal Blood Sampling (FBS)|Vaginal examination, insert amnioscope through cervix, visualise fetal scalp, clean fetal scalp, apply ethyl chloride spray, wipe scalp with petroleum gel, small scalp scratch with sharp instrument, collect sample in heparinised capillary tube, analyse sample.
223642239|NCT05306756|DIAGNOSTIC_TEST|digital Fetal Scalp Stimulation (dFSS)|Vaginal examination, insert one or two fingers through cervix onto fetal scalp, rub fetal scalp digitally for approximately 30-60 seconds, withdraw fingers and observe CTG for 5-10 minutes.
223642240|NCT00510822|DRUG|Cimicoxib|50 mg per tablet, bid (total daily dose 100 mg)
223642241|NCT00510822|DRUG|Placebo|tablet
223642242|NCT02446119|DEVICE|EndoFLIP|Measurement of pyloric resistance and compliance
223642243|NCT02696967|DRUG|CLR325|CLR325 Concentrate for solution for infusion
223642244|NCT02696967|OTHER|Placebo|Normal saline
224230023|NCT00977002|OTHER|Inhalatory O2|Patients randomized to this group are submitted to inhalatory O2 using mask or nasal catheter. A blood gas is collected in the moment of intubation and one hour after.
224230024|NCT02184273|DRUG|Magnesium metamizol|
224230025|NCT02184273|DRUG|Placebo|
224230026|NCT03339037|DEVICE|Hyperbaric oxygen therapy|60 HBOT sessions at 2 ATA 100% oxygen
224230027|NCT03339037|DEVICE|Normobaric air SHAM|60 sessions at 1 ATA 21% oxygen (air)
224319563|NCT05175235|DRUG|Nivolumab, Pembrolizumab|Treatment with the selected regimen will take up to a maximum duration of 12 months, in two-/three- week cycles. CURATE.AI dose recommendations will be generated before each chemotherapy cycle; fixed throughout the cycle; Maximum total cumulative dose per cycle of nNivolumab/pembrolizumab in the predetermined safety range is set at 100% of standard starting dose (i.e. , 240 mg/m2 once every 2 weeks for single agent Nivolumab and 200 mg/m2 once every 3 weeks for single agent Pembrolizumab). Minimum total cumulative dose per cycle of nivolumab/pembrolizumab in the predetermined safety range is set at 30% of the standard starting dose (i.e. 8072 mg/m2 once every 2 weeks for single agent Nivolumab and 60 mg/m2 once every 3 weeks for single agent Pembrolizumab). Subject-specific dosing range may alter those numbers to suit the specific circumstances of the subject, thus giving the subject specific safe dosing range.
224319564|NCT01867892|DRUG|ICT of oxapliplatin, irinotecan, leucovorin, and fluorouracil and CCRT|oxapliplatin ,irinotecan ,5FU +leucovorin ,RT 5,040cGy in 28 fractions/5.5 wks and 5FU 450mg/m2 iv 30min weekly
223642249|NCT04610281|DEVICE|Inner Garden|"Care actions adapted to the intensity of the states of agitation (The child can be removed from the group while remaining in the same room on a chair with a caregiver. If the problems are too serious, the child can be accompanied to a soothing room where the carer will take care of him/her individually. In units equipped with Inner Garden, the child can use it under semi- supervision of nurses.)"
223642250|NCT04884464|DEVICE|Hyaluronic acid-based gel|Dosage: application of an even coat of 1mm thickness Frequency: 3 times/day (after main meals) Duration: 2 weeks
223642251|NCT04884464|DRUG|Chlorhexidine Gluconate|Dosage: application of an even coat of 1mm thickness Frequency: 3 times/day (after main meals) Duration: 2 weeks
224230028|NCT05241821|PROCEDURE|Mechanical thrombectomy|Percutaneous intervention aimed to retrieve/treat clot affecting the cerebral circulation.
224230029|NCT05241821|DRUG|Thrombolytic Agent|Drug aimed to dissolve thrombus affecting the cerebral circulation
224230030|NCT03919201|OTHER|Resistance band exercise intervention|Resistance band exercise intervention (12 weeks, 5x per week, 60 minutes per day)
224230031|NCT03919201|OTHER|No exercise intervention group|Control group: no exercise intervention
224319565|NCT01867892|DRUG|ICT of Gemcitabine,oxapliplatin, leucovorin, and fluorouracil + CCRT|Gem ,Oxa ,5FU +LV ,RT 5,040cGy in 28 fractions/5.5 wks and Gem 400mg/m2 iv 40min weekly
224319566|NCT03956940|DEVICE|Intplex test|Blood sample at baseline, 15 days, 4-8-16 weeks and then every 12 weeks
224319567|NCT02850692|OTHER|measure of endothelial function|Arterial tone index measured by EndoPAT®. Patient should neither eat nor drink at least 4 hours before exam and should neither smoke 3 hours before the exam.
223642252|NCT06093542|DRUG|AZD7053|Randomised participants will receive AZD7503 subcutaneously.
223642253|NCT06093542|DRUG|Placebo|Randomised participants will receive placebo subcutaneously.
223642254|NCT00940953|DRUG|Budesonide + Azelastine|nasal spray, one spray per nostril at time 0 plus one spray Placebo
223642255|NCT00940953|DRUG|Budesonide + Azelastine|nasal spray, one spray of each per nostril at time 0
223642256|NCT00940953|DRUG|Placebo|nasal spray, one spray per nostril from each of 2 bottles at time 0
223642257|NCT04412512|PROCEDURE|VATS approach|video-assisted thoracic surgery approach
223642258|NCT04412512|PROCEDURE|Thoracotomy approach|
223642259|NCT04165317|DRUG|PF-06801591|A monoclonal antibody (mAb) that blocks the interaction between PD-1 and PD-L1/PD-L2.
223642260|NCT04165317|DRUG|Bacillus Calmette-Guerin|Immunotherapy treatment approved by FDA for patients with high-risk non-muscle invasive bladder cancer
223642261|NCT05076162|DIAGNOSTIC_TEST|PAED|Delirium positive or negative
223642262|NCT05581550|RADIATION|FDG-PET|Patients will be fasted for 6 hours prior to intravenous injection of 370MBq +/- 10% (18)F-fluorodeoxyglucose. Scanning will be performed at an interval of at least 60 minutes following the injection.
223642263|NCT05581550|RADIATION|Galium-68 DOTATATE|200MBq +/- 10% Galium-68 DOTATATE will be injected intravenously. Scanning will be performed approximately 60 minutes after the injection.
224230032|NCT00619385|DRUG|Proellex|Proellex 25 mg capsules 100 mg, 150 mg or 200mg daily for 7 days
224230033|NCT00306748|DRUG|MD-1100 Acetate|
224230034|NCT00317161|BIOLOGICAL|DTPw-HBV/Hib-MenAC conjugate vaccine|
224230035|NCT05869942|DIAGNOSTIC_TEST|Light microscopic studies|Under complete sterile precautions, Skin biopsy will be taken from healthy volunteers of the control group via 3 mm disposable punches and two biopsies will be taken from patients with vitiligo, one from vitiligenous lesion and another from normal skin then will be rinsed in physiological saline and fixed in formalin for 24 hours. The preserved tissues will be trimmed for processing, then undergo dehydration with ethyl alcohol, clearing with xylene, infiltration and embedding with paraffin wax. Paraffin wax blocks will be sectioned at 5μ then mounted on glass slides. Sectioned slides will be stained with hematoxylin and eosin and other histological stains and mounted with (DPX). And examined by light microscope. The pathological changes in vitiligenous skin will be detected
223765459|NCT04515459|OTHER|Surgical prehabilitation program.|"This programme will include the practice of general physical activity and the implementation of nutritional and psychological support.~Each patient will have 8 Oncorehabilitation Transdisciplinary Evaluations (OTE):~* 2 OTE will be performed before the surgery,~* 6 OTE will be performed after the surgery.~During the program (at each OTE), patients will also be asked to complete the QLQ-C30 questionnaire."
223765460|NCT05572502|BEHAVIORAL|plant-based diet|For the duration of the study, this arm will: follow a low-fat vegan diet; weigh themselves weekly, and get fasting bloodwork before, during and after the study
224230036|NCT05869942|DIAGNOSTIC_TEST|Immunohistochemical studies|Monoclonal HMGB1 and active caspase 3 antibodies
223642264|NCT00112996|DRUG|alpha-lipoic acid|Oral two 300 mg ALA sustained release tablets initiated 4 days after last dose of platinum and discontinued 2 days before next scheduled platinum dose, continued for 24 weeks.
223642265|NCT00112996|OTHER|placebo|Given orally two similar color and sized placebo control tablets three times a day continued for 24 weeks.
224230037|NCT02190461|PROCEDURE|Early Respiratory Rehabilitation Program|
224230038|NCT02190461|PROCEDURE|Conventional Respiratory Rehabilitation Program|
224319568|NCT02850692|BIOLOGICAL|Blood sample|21 ml of blood to measure : hepatic workup, complete blood count (CBC), platelets, prothrombin time (PT), activated partial thromboplastin time (aPTT), C-reactive protein (CRP), lipid test, ionograms, creatinine, tissue plasminogen activator factor (tPA), plasminogen activator inhibitor-1 (PAI-1), tissue factor pathway inhibitor (TFPI), Willebrand factor, soluble thrombomodulin, blood levels of endoglin and syndecan. And level beta human chorionic gonadotropin (beta-HCG) for woman only.
224319569|NCT02850692|OTHER|Hepatic elastography|Hepatic elastography by Fibrocan®. Patient should neither eat nor drink at least 2 hours before exam. 10 successive measurements are made.
224319570|NCT02850692|DIAGNOSTIC_TEST|Injected abdominal CT|"Patient should neither eat nor drink at least 4 hours before exam.~The examination is not realized if an abdominal scan or an MRI was performed in the five years prior to the day of the visit."
223642266|NCT06328335|BEHAVIORAL|Comprehensive rehabilitation training|"Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training.~Pulmonary function training, including standing training, cough training, and diaphragm muscle training."
223642267|NCT06328335|BEHAVIORAL|Rise-bed Training|"gradually elevating the bed (head-up tilt) is one of the common methods to treat orthostatic hypotension. This treatment adjusts the patient's bed angle to gradually raise their body, promoting balanced blood distribution throughout the body and reducing orthostatic hypotension symptoms.~In head-up tilt treatment, the bed angle is usually gradually increased from a horizontal position, and the specific angle can be determined based on the patient's condition and tolerance. This treatment process is generally monitored and controlled by medical personnel to ensure safety and effectiveness.~The mechanism of head-up tilt treatment is to increase venous return by changing the body position and increasing the effect of gravity, thereby increasing cardiac preload, output, and blood pressure. This helps to reduce orthostatic hypotension symptoms such as dizziness, lightheadedness, and fatigue."
223642268|NCT00604487|DEVICE|ARD (Atad Ripener Device)|Atad double balloon ripener device
223642269|NCT00604487|DEVICE|AID (Atad double balloon Instillation Device)|Double balloon instillation device and continuous extra-amniotic instillation of NS 50 Ml/hour
224230039|NCT02535819|PROCEDURE|Subluxation|One pole of The nucleus is hydrodissected until it lilts above the capsular bag. The tilted nucleus is rotated to face the incision and remaining half nucleus is then tumbled and emulsification continues from the opposite equator outside in until complete
224230040|NCT02535819|PROCEDURE|Divide and Conquer|Cataract nucleus is fragmented into 4 pieces then aspirated by ultrasonic vibration
224230041|NCT00805298|DRUG|methylprednisolone|32 mg before surgery, 16 mg twice daily the day after surgery
224230042|NCT00805298|DRUG|placebo|two tablets before surgery, one tablet twice daily on the day after surgery
224230043|NCT00805298|DRUG|xyloplyin adrenalin|lidocaine local anaesthetic lidocaine 20 mg/ml, adrenalin 12,5 µg/ml maximum dosage 10 ml.
224319571|NCT02220517|DEVICE|MR-guided in-bore prostate biopsy|Patients of arm A receive a targeted MR-guided in-bore prostate biopsy. From each prostate lesion defined in the diagnostic multiparametric MRI two targeted biopsy cores will be taken.
224319572|NCT02220517|DEVICE|MRI/US fusion-guided prostate biopsy|Patients of arm B receive a targeted MRI/US fusion-guided prostate biopsy. From each prostate lesion defined in the diagnostic multiparametric MRI two targeted biopsy cores will be taken. Immediately after targeted biopsy patients undergo additional systematic TRUS-guided biopsy (12 biopsy cores)
224319573|NCT06579625|OTHER|Cancer education|Participants in the experimental group will receive cancer education.
224319574|NCT03417778|DRUG|Filgotinib|100 mg tablet administered orally
224319575|NCT01295320|PROCEDURE|Blood sample|Blood sample will be collected at Month 48, Month 60 and Month 72
223642270|NCT00604487|DEVICE|folly catheter|folly catheter (40 ml NS in the balloon) and continuous extra-amniotic instillation of NS 50 Ml/hour
223642271|NCT00712439|DRUG|Gabapentin Extended Release tablets|
223642272|NCT00712439|DRUG|Placebo|
223765461|NCT02886052|BEHAVIORAL|Therapist guided Internet-CBT for insomnia|
223765462|NCT02886052|OTHER|Active control|
223765463|NCT03612622|OTHER|transcranial magnetic stimulation|Intermittent Theta-Burst Transcranial Magnetic Stimulation
224230044|NCT00805298|DRUG|marcain adrenalin|bupivacaine local anaesthetic bupivacaine 5 mg /ml, adrenaline 5 µg/ml maximum dosage 10 ml
224230045|NCT02114307|DEVICE|REVITIVE IX|neuromuscular electrical stimulation device
224230046|NCT04784195|BEHAVIORAL|Observation|Verification of morfology and functionality of neck muscles
224230047|NCT01543100|OTHER|blood and bone marrow samples|"Specific tests of the study will be realized from :~* Blood samples: 2 EDTA tubes and 1 tube without anticoagulant per included patient.~* Bone marrow: 3 ml collected during of myelogram punction made for the diagnosis.~In all cases, no additional sampling will be performed."
224230048|NCT03788499|OTHER|Massage of Maxillofacial and Oral Cavity|Massage of Maxillofacial and Oral Cavity is performed five times a day, each part lasts 1-2 minutes, repeating 3 cycles. The maxillofacial and oral massage last from the first day of radiotherapy to three months after last radiotherapy.
223642273|NCT02812342|DRUG|Tofacitinib ointment|Patients with AA (with at least 2 patches of alopecia involving the scalp), AT or AU will be treated with tofacitinib ointment for a maximum of 6 months. During treatment, patients will be evaluated every 4 weeks and effectiveness of the medication will be measured by changes in hair growth.
223642274|NCT01837121|OTHER|the SMS reminder message|the SMS reminder message will sent to the SMS group patients 1 week and 3 day before there appointment,to remind them the exact time and address of the revisit appointment.
223765464|NCT03887481|DEVICE|"High-definition active tDCS (HD-tDCS) + Repeat After Me (RAM) Treatment"|"Device: Active HD-tDCS \& Repeat After Me (RAM) Treatment~Stimulation will be delivered by a battery-driven constant current stimulator. Electrical current will be administered to left supramarginal gyrus (L\_SMG). The stimulation will be delivered at an intensity of 2 milliamperes (mA) (estimated current density 0.04 mA/cm2; estimated total charge 0.048 Coulombs/cm2) in a ramp-like fashion for a maximum of 20 minutes.~Participants will receive RAM consisting of word span repetition span (increasing length, with/without response delay). Span tasks will be manipulated in terms of list length (single words, pair, triplets) and response delay (1 sec, 5 sec). Each list will consist of 10 spans. During each trial, participants will be asked to repeat words in the span after a response delay."
223642275|NCT05612620|DIAGNOSTIC_TEST|coulture|Samples from the vagina, fornix and cervical canal will be taken by introducing a flocked nylon swab to the vagina via a speculum and circular swabbing for 5-10 seconds before using any antiseptics.
223642276|NCT02532881|OTHER|Videos|Various videos showing four characteristic patient stories and five expert statements on special topics concerning inpatient psychosomatic rehabilitation.
223642277|NCT02532881|OTHER|Treatment as usual|Treatment as usual
223642278|NCT06118398|DRUG|Intravenous methylprednisolone (IVMP) and Efgartigimod|IVMP 800-1000mg/day for 3-5 days plus Efgartigimod (Efgartigimod: 10mg/kg IV on Day 1, Day 8, Day 15 and Day 22 after IVMP.)
223642279|NCT06118398|DRUG|IVMP|IVMP 800-1000mg/day for 3-5 days.
224230049|NCT04936997|BIOLOGICAL|SARS-COV2 Pfizer Vaccine|Vaccine for the prevention of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
224230050|NCT00332761|DRUG|Caduet|
223642280|NCT03754621|DIAGNOSTIC_TEST|Serum thyroid functions tests|Serum TSH, fT3, fT4 and anti-TPO
223642281|NCT02859571|DRUG|Oxytocin|
223642282|NCT00793897|DRUG|BMS-754807|Tablets, Oral, escalating doses starting at 10 mg, continuous or intermittent, until disease progression, unacceptable toxicity or at the subject's request
223765465|NCT03887481|DEVICE|"Sham + Repeat After Me (RAM) Treatment"|"Device: Sham Current will be administered in a ramp-like fashion but after the ramping phase the intensity will drop to 0 mA. Current under the Sham condition will last for a maximum of 30 seconds.~Participants will receive RAM consisting of word span repetition span (increasing length, with/without response delay). Span tasks will be manipulated in terms of list length (single words, pair, triplets) and response delay (1 sec, 5 sec). Each list will consist of 10 spans. During each trial, participants will be asked to repeat words in the span after a response delay."
223765466|NCT04583761|BEHAVIORAL|questionnaire|Mailed structured regarding current and former tobacco consumption and use of alternative nicotine delivery systems
224230051|NCT03160677|OTHER|Systolic blood pressure target < 130 mm Hg|Adaptation of antihypertensive treatments to reach the Systolic blood pressure target \< 130 mm Hg
224230052|NCT03160677|OTHER|Systolic blood pressure target < 185 mm Hg|Adaptation of antihypertensive treatments to reach the Systolic blood pressure target \< 185 mm Hg
224230053|NCT05933096|DIAGNOSTIC_TEST|Contrast-enhanced multispectral optoacoustic tomography|Ingestion of ICG-labeled food and 10 measurements with MSOT, 1 before ingestion of food, 8 afterwards, each after 60 minutes, 1 measurement 24 hours after ingestion
224230054|NCT03674008|DRUG|HSK3486|HSK3486 intravenous (iv) 0.4 mg/kg for induction, and 0.2 mg/kg top-ups for maintenance.
223642283|NCT00793897|DRUG|Paclitaxel|Vials, IV, 200 mg/m2, Day 1 of a 21-day cycle, until disease progression, unacceptable toxicity or at the subject's request
224230055|NCT03674008|DRUG|Propofol|Propofol iv 1.5 mg/kg for induction, and 0.75 mg/kg top-ups for maintenance.
224230056|NCT01672346|PROCEDURE|PVAI followed by adenosine provocation|All patients will undergo PVAI and ablation of the posterior wall of the LA using an open-irrigated ablation catheter and under general anesthesia. After PV isolation is achieved, all will undergo PVAI followed by adenosine provocation test with 24 mg of adenosine to check for PV reconnection. Upon identification, additional RF energy would be used to ablate those sites (that were revealed by adenosine-provocation).
224230057|NCT01127009|DRUG|bortezomib|Given IV
224230058|NCT01127009|DRUG|mitoxantrone hydrochloride|Given IV
224230059|NCT01127009|DRUG|etoposide|Given IV
223642284|NCT00793897|DRUG|Carboplatin|Vials, IV, 6 mg/mL.min, Day 1 of a 21-day cycle, until disease progression, unacceptable toxicity or at the subject's request
223642285|NCT05813600|DRUG|Nirmatrelvir/Ritonavir|Patients in both groups were given Lianhua Qingwen Capsule orally, 3 times/day, 6 g/time. oral antipyretic (ibuprofen suspension 10ml) and symptomatic supportive treatment for body temperature \>38.5 ℃. The study group was given Nirmatrelvir 300mg/Ritonavir 100mg orally, q12h, for 5 days, and the control group not given any antiviral drugs.
223642286|NCT02131506|DRUG|Lapatinib, Caelyx|Lapatinib, Caelix: Lapatinib is given at escalating doses orally and continuously on days 1-21. Caelyx is administered at escalating doses in a 60-minute i.v. infusion on day 1. Each cycle is defined as 21 days. Four dose levels are planned. Dose level -1, Caelyx 30 mg/mq \& Lapatinib 1000 mg die; dose level 1, Caelyx 30 mg/mq \& Lapatinib 1250 mg die; dose level 2, Caelyx 30 mg/mq \& Lapatinib 1500 mg die; dose level 3, Caelyx 40 mg/mq \& Lapatinib 1500 mg die
223642287|NCT04415203|DEVICE|Transcutaneous Auricular Vagus Nerve Stimulation (TAVNS)|Patients in TAVNS group will receive TAVNS and usual care. TAVNS will be performed on Erzhong and Xin (Auricular Acupuncture Point with vagus nerve distribution) for 6 weeks by using the Huato type SDZ-V stimulator; Usual Care: usual medicine treatment for PVCs.
224230060|NCT01127009|DRUG|cytarabine|Given IV
224230061|NCT01127009|OTHER|flow cytometry|Correlative studies
224230062|NCT02523456|BEHAVIORAL|Training|The staff will be trained on early detection and management of clinically deteriorating patients based on the EWS selected.
224230063|NCT02523456|BEHAVIORAL|Introduce EWS|An EWS that is appropriate for use in the study setting will be selected during the second components of the study. This EWS will then be adapted for this component.
223642288|NCT04415203|DEVICE|Sham Transcutaneous Auricular Vagus Nerve Stimulation (Sham-TAVNS)|Patients in sham-TAVNS group will receive sham-TAVNS and usual care. Sham-TAVNS will be also performed on Erzhong and Xin (Auricular Acupuncture Point with vegas nerve stimulation) for 6 weeks by using a special Huato type SDZ-V stimulator. We cut the inner electric wire of the stimulator; therefore, there is no current output. Usual Care: usual medicine treatment for PVCs.
224230064|NCT02264951|DIETARY_SUPPLEMENT|Tributyrin|a triglyceride containing three C4-acids
223642289|NCT02955173|PROCEDURE|Surgery|Laparoscopic or open surgery for resection of gastric or rectal cancer
223642290|NCT02549872|OTHER|This is not an intervention study|This study is based on the retrospective analysis of linked electronic health records.
223642291|NCT03208647|OTHER|AA or not|to study their risk factors
223642292|NCT06442878|OTHER|Belly Dance Program|All Belly Dance sessions comprised 5 phases: 1) opening ritual (5 min), in which participants will be welcomed and perceived how people were feeling. 2) warm-up (15 min), in which thinking and feeling are integrated during the movements, isolating each part of the body according to Laban's body organization. 3) main phase (30 min), will be proposed individual, pair and group activities, in order to achieve the objectives planned. This phase will end with a choreography composition or a challenge; 4) cool-down (5 min) with stretching and physiological parameters normalization; and 5) ending ritual (5 min), in which the participants will be invented to share their sessions' experience.
223642293|NCT03317184|PROCEDURE|Periumbilical incision|A periumbilical incision is made at the abdominal midline for hand-assisted laparoscopic donor nephrectomy.
223642294|NCT03317184|PROCEDURE|Pfannenstiel incision|Pfannenstiel incision is made as a slightly curved horizontal line just above the pubic symphysis for hand-assisted laparoscopic donor nephrectomy.
223642295|NCT05368246|DEVICE|UCon|The subjects self-administer electrical stimulation to the dorsal genital nerve (DGN) for 4 weeks using UCon
223642296|NCT01685502|DRUG|Glucobay ODT (Acarbose, BAYG5421)|Patients treated with Glucobay OD under practical manner
223642297|NCT04126941|OTHER|Serum calcium concentrations results|To compare serum calcium concentrations results in patients with hypoparathyroidism before and three months after initiation of teriparatide therapy
223765467|NCT04184674|OTHER|Pneumotachograph|"Measurements will be performed during the first three days of Acute Respiratory Distress Syndrome management :~* The first measurement will be performed 5 minutes after the initial ventilator settings.~* Measurements will be repeated systematically at 24 hours, 48 hours and 72 hours of evolution.~* An additional measure will be performed at each positive end-expiratory pressure modification (maximum 5 measures)."
223642298|NCT05812872|DRUG|Toothgraft|Particulate dentin
223765468|NCT04184674|OTHER|Esophageal catheter|"Measurements will be performed during the first three days of Acute Respiratory Distress Syndrome management~* The first measurement will be performed 5 minutes after the initial ventilator settings.~* Measurements will be repeated systematically at 24 hours, 48 hours and 72 hours of evolution.~* An additional measure will be performed at each positive end-expiratory pressure modification (maximum 5 measures)."
224230065|NCT02264951|DIETARY_SUPPLEMENT|C8-diet oil|a triglyceride containing 2 C8-fatty acids and one oleic acid at sn-2 position
224230066|NCT02264951|DIETARY_SUPPLEMENT|Olive oil|a triglyceride containing mostly three oleic acids
224230067|NCT02264951|DIETARY_SUPPLEMENT|Carrot|mainly water and glucose
224230068|NCT03678961|BEHAVIORAL|external rotation of leg|external rotation of leg by 45 degrees
223642299|NCT05812872|DRUG|Allograft|Mineralized corticocancellous allograft
223642300|NCT05812872|DRUG|Alloplast|Beta tri-calcuim phosphate
223642301|NCT04685044|DEVICE|IH 1Tx32Rx Head Array|BrainPET insert
223642302|NCT04899986|OTHER|Chlorhexidine and Biorepair gel and toothpaste application|Split-mouth application of chlorhexidine gel 1% (quadrants 1 and 4) and Biorepair Periogel (quadrants 2 and 3) after professional dental hygiene. Home oral care will be continued with chlorhexidine 0,12% gel and Biorepair Periogel in the same quadrants, for the following 15 days from the visits, together with the use of Biorepair Parodontogel toothpaste.
223642303|NCT04899986|OTHER|Standard oral hygiene|Use of standard toothpastes for home oral hygiene.
223642304|NCT04262154|DRUG|Atezolizumab|Atezolizumab 1200 mg IV over 60 minutes every 3 weeks
223642305|NCT04262154|DRUG|Abiraterone|Abiraterone 1000 mg daily
223642306|NCT04262154|DRUG|Prednisone|Prednisone 5 mg daily
223642307|NCT04262154|DRUG|GnRH analog|Any GnRH analog that is commercially available, injectable, and long acting analog of the native LHRH peptide and is administered to subjects via intramuscular injection. For this study, any GnRH analog can be used and thee manufacturer's instructions for dose and frequency should be followed.
223642308|NCT04262154|RADIATION|Stereotactic Body Radiotherapy (SBRT)|Intensity-modulated, image-guided, ultra-hypofractionated external beam radiotherapy (7.25-7.5 Gy x 5 to prostate and seminal vesicles QOD) will begin around 12 weeks (at Cycle 5 Day 1 (+/-5 days)
223642309|NCT04262154|DRUG|Enzalutamide|160 mg once daily
223642310|NCT04262154|OTHER|Follow up|Subjects who discontinue study treatment for reasons other than progression will be followed every 6 months (+/- 4 weeks) until a documented progression event (i.e., PSA, radiographic, or clinical progression). After a documented progressionevent (whether on treatment or during follow up), subjects will continue to be followed every 6 months (+/- 4 weeks) for overall survival via chart review and/or telephone call.
223642311|NCT06035913|DRUG|Dihydroergot mesylate|take medicine
224230069|NCT03678961|BEHAVIORAL|hip flexion and knee flexion|hip flexion by 15/45 degrees and knee flexion by 15/45 degrees
224230070|NCT01232673|PROCEDURE|BMAC application in Critical Limb Ischemia|Collection of 240ml from both illiac crests, followed by gradient density centrifugation, resulting in obtaining 40ml of BMAC (Bone-Marrow Aspiration Concentrate). BMAC is subsequently administered into the ischemic limb along calf vessels.
224230071|NCT03845946|BEHAVIORAL|angioedema|electronic tracking book
224230072|NCT02041702|DIAGNOSTIC_TEST|Non-Diagnostic Cardiac MRI scan|
224230073|NCT02809092|BIOLOGICAL|NK Cells + Chemotherapy Starting|"Drug: G-CSF G-CSF daily by vein starting on Day -7 until post nadir of absolute neutrophil counts (ANC) are equal or over 1000.~Other Names:~Filgrastim Neupogen Drug: Fludarabine monophosphate 30 mg/m2 by vein on Days -6, -5, -4, -3, and -2.~Other Names:~Fludarabine Phosphate Fludara Drug: Cytarabine 2 g/m\^2 by vein on Days -6, -5, -4, -3, and -2.~Other Names:~Ara-C Cytosar DepoCyt Cytosine arabinosine hydrochloride Procedure: Natural Killer (NK) Cell Infusion NK Cell infusion on Days 0 to 14 for 6 doses total according to dose escalation schema."
224319576|NCT00652340|DRUG|apricoxib/erlotinib|"apricoxib: 100 mg tablets, 400mg/day~erlotinib: per package insert"
224319577|NCT00652340|DRUG|erlotinib/placebo|"erlotinib: per package insert~placebo: 100 mg tablets, 400 mg/day"
223642312|NCT00307710|BIOLOGICAL|Trivalent Baculovirus-expressed Influenza HA vaccine|Receive either standard inactivated influenza vaccine or one of three doses of the experimental vaccine, vaccine dose 15, 45 or 135 μg HA per virus, intramuscular injection.
223642313|NCT00918255|BIOLOGICAL|adalimumab|Subcutaneous injection using prefilled syringe containing adalimumab 40 mg in 0.8 milliliters
223642314|NCT00918255|DRUG|Placebo|Subcutaneous injection using prefilled syringe containing 0.8 milliliters
223642315|NCT02510521|DEVICE|acute muscle exercise by NMES|
223642316|NCT02510521|DEVICE|daily workout sequence with NMES in one week|
223642317|NCT02510521|OTHER|rest situation|
223642318|NCT01849991|BIOLOGICAL|Lactobacillus reuteri|"Lactobacillus reuteri oil drops are a natural product containing Lactobacillus reuteri (LR), which has traditionally been used for the establishment of a well-functioning gastrointestinal (GI) microbiota and prevention and treatment of mild diarrhea associated with GI-tract infections, travel or antibiotic treatment.~The drug is a clear liquid when suspended in sunflower oil. The drug will be administered orally, 0.2cc once daily."
224230074|NCT01484405|PROCEDURE|posterior approach|Surgical approach for Total Hip Arthroplasty
224230075|NCT01484405|PROCEDURE|anterolateral approach|anterolateral surgical approach
224230076|NCT02177955|DRUG|7.5 mg Midazolam|7.5 mg midazolam 45 minutes before surgery
224230077|NCT02177955|DRUG|10 mg diazepam|10 mg midazolam 45 minutes before surgery
223642319|NCT01849991|BIOLOGICAL|Placebo|Placebo is sunflower oil (vehicle for LR). The placebo will be administered the same way as drug listed above.
223642320|NCT00001614|DRUG|Chicken type II collagen|
223642321|NCT03153943|DEVICE|HIP Mobile e-Monitoring support|3-month community-based extended-rehabilitation e-Monitoring and Coaching support program
223642322|NCT03153943|OTHER|Workbook support|Printed material support
223642323|NCT02263027|BIOLOGICAL|Vaccine|Licensed trivalent inactivated influenza vaccine
223642324|NCT05442788|BIOLOGICAL|HB0017 150mg or matching placebo|Each subject receive injection at week0(Day1), week 3(Day22), week 6(Day43) and week 9(Day64), respectively.
223642325|NCT05442788|BIOLOGICAL|HB0017 300mg or matching placebo|Each subject receive injection at week0(Day1), week 3(Day22), week 6(Day43) and week 9(Day64), respectively.
223642326|NCT05442788|BIOLOGICAL|HB0017 450mg or matching placebo|Each subject receive injection at week0(Day1), week 3(Day22), week 6(Day43) and week 9(Day64), respectively.
223642327|NCT01791712|PROCEDURE|On-line hemodiafiltration|pre-dilution 40% of blood flow rate blood flow rate 300-350 ml/min dialysate flow rate 800 ml/min
223642328|NCT01791712|PROCEDURE|High-flux Hemodialysis|blood flow rate 300-350 ml/min dialysate flow rate 800 ml/min
223642329|NCT03891381|DEVICE|Tetragraph quantitative monitoring|Neuromuscular monitoring will be guided by information provided by the Tetragraph
223642330|NCT01982097|DRUG|Sorafenib (Nexavar, BAY 43-9006)|The patients under routine treatment of metastatic RCC with Nexavar before and after cytoreductive nephrectomy meeting the criteria of inclusion.
223642331|NCT03557034|DEVICE|Kardia Monitoring|Kardia Mobile is an FDA approved device that allows one lead ECG recording for 30 seconds using the patient's smart phone. The device has a built-in algorithm that detects AF. KardiaPro is a secure platform that allows the physician to access the patient's recording at any time. The platform can also be programmed to send a notification to the healthcare provider if AF is detected by the software.
223642332|NCT05391672|PROCEDURE|we will do ACL augmentation surgery to the patients who have partial ACL tear|we will do ACL augmentation surgery to the patients who have ACL partial tear using hamstring graft and fixation of the graft to the femoral part by adjustable loop and tibial part with Bio or peak screws +\\- staples.
223642333|NCT04259996|PROCEDURE|PROGESTERONE AND ESTRADIOL SERUM CONCENTRATION MEASUREMENT|The only intervention will be a single determination of serum P and E2 levels immediately before the embryo transfer.
223642334|NCT04052633|RADIATION|intraoperative cholangiography|success or failure of cholangiography
223642335|NCT00719472|DRUG|Rituximab|During Cycle 1 rituximab was administered at an initial rate of 50 mg/hour. In the absence of infusion toxicity during Cycle 1, the infusion rate was escalated by 50 mg/h increments every 30 minutes to a maximum rate of 400 mg/hour. In case of infusion-related reactions, the infusion was interrupted or the infusion rate reduced. In case of Grade 3/4 infusion reactions, the rituximab infusion was discontinued and medical treatment provided. If the rituximab infusion in Cycle 1 was tolerated without a serious adverse event (AE) or Grade 3/4 infusion-related AE, as judged by the investigator, infusions in Cycle 2 onwards were administered as follows: 20% of the total dose was given over 30 minutes and the remaining 80% of the dose was given over the next 60 minutes, for a total infusion time of 90 minutes. Commercial preparations of rituximab were used.
224319578|NCT03682107|BIOLOGICAL|Andes virus DNA vaccine|A vaccine targeting the hantavirus pulmonary syndrome (HPS) causative agent Andes Virus (ANDV), with potential pan-hantavirus effect. The plasmid backbone, pWRG7077, is modified to produce the active ingredient of the vaccine, plasmid pWRG/AND-M (opt2), and includes the ANDV M gene responsible for encoding viral GnGc envelope glycoproteins. ANDV DNA vaccine will be administered intramuscularly at 2 mg or 4 mg doses using the PharmaJet Stratis Needle-Free Injection System.
224319579|NCT03682107|OTHER|Placebo|Normal saline injections will be administered intramuscularly as matching placebo using the PharmaJet Stratis Needle-Free Injection System
224319580|NCT03021681|OTHER|autologous bronchial basal cell transplantation|the investigators obtained extraction bronchial basal cells micro tissue from 3\~4 grade bronchus, then purified and selectively amplified bronchial basal cells to reserve . After a period of time, the basal lamina of the bronchial epithelial cells can be stored in the liquid nitrogen cell bank for a long time. Before applied to the patient, bronchial basal cells need to go through a series of strict examination. Then, bronchoscopy was performed again and the bronchial basal lamina suspension was injected directly into the lesion site .
224319581|NCT01863914|DRUG|Rosuvastatin|Arteriovenous fistula surgery was performed after 1-week treatment with placebo or Rosuvastatin (randomized, double blind). The intervention drug treatment continues for 3 more weeks after creation of AV fistula.
224319582|NCT04342819|DRUG|SGLT2 inhibitor|Sodium-Glucose Like Transporter 2 Inhibitor
224319583|NCT01101815|DRUG|Oral Naltrexone|50 mg/day-oral
223642336|NCT00719472|DRUG|CHOP (cyclophosphamide, hydroxydaunorubicin [doxorubicin], Oncovin [vincristine], prednisone)|Commercial preparations of CHOP were used. Prednisone was administered prior to rituximab infusion.
223642337|NCT00719472|DRUG|CVP (cyclophosphamide, vincristine, prednisone)|Commercial preparations of CVP were used. Prednisone was administered prior to rituximab infusion.
223642338|NCT00719472|DRUG|Analgesic/antipyretic and antihistamine drugs|An analgesic/antipyretic (eg, acetaminophen) and an antihistamine (eg, diphenhydramine) were administered 30 minutes before each infusion of rituximab.
223642339|NCT01244893|DEVICE|Acuvue Advance Plus prePQ|silicone hydrogel contact lens manufactured prior to equipment process qualification activities.
223642340|NCT01244893|DEVICE|Acuvue Advance Plus postPQ|silicone hydrogel contact lens manufactured after equipment process qualification activities.
223642341|NCT02117661|DIETARY_SUPPLEMENT|L-carnitine capsules|Oral
223642342|NCT02117661|DIETARY_SUPPLEMENT|Cellulose capsules|oral
224319584|NCT01101815|DRUG|Naltrexone Implant|monthly-implant
224319585|NCT01101815|BEHAVIORAL|Group Drug Counseling Manual Driven|Given to both groups biweekly, weeks 2 - 48. Counseling will consist of three components: 1) giving advice, support and clinical management aimed to maintain abstinence; 2) adherence enhancement to encourage keeping appointments, taking ART medications as prescribed and getting treatment for associated problems; and 3) reviewing behaviors that are likely to spread HIV and other infectious diseases, and counseling on how to stop them.
224319586|NCT02738710|PROCEDURE|transumbilical incision|incision within umbilicus
223642343|NCT04863469|BEHAVIORAL|B-POC high load intervention|aerobic exercise \[heartrate range (HRR) 70-75% of max HR, on treadmill\] and a computerized high-load task for 45 minutes, 3 times per week, for 6 weeks
223642344|NCT04863469|BEHAVIORAL|B-POC low load intervention|aerobic exercise \[heartrate range (HRR) 70-75% of max HR, on treadmill\] and a computerized low-load task for 45 minutes, 3 times per week, for 6 weeks
223642345|NCT00357552|DRUG|Emtricitabine/Tenofovir disoproxil fumarate|Once daily
223642346|NCT00357552|DRUG|Lopinavir/Ritonavir|Twice daily
223642347|NCT04910997|OTHER|Aerobic exercise training|Combination of supervised and home-based aerobic exercise training
223642348|NCT05338814|OTHER|scapular corrective exercises|40 minutes each, three times a week for six weeks
223642349|NCT05338814|OTHER|conventional neck exercises|40 minutes each, three times a week for six weeks
223642350|NCT00976404|BIOLOGICAL|DNA + HIV-rAd5 vaccine|4 mg subcutaneous injection at weeks 8 (DNA prime), 12 (DNA prime), 16 (DNA prime), and 32 (HIV-rAd5)
223765469|NCT04184674|OTHER|Transthoracic and / or transesophageal cardiac ultrasound|"The right ventricle systolic function will be assessed thanks to a transthoracic cardiac ultrasound in children, and a transthoracic of a transesophageal cardiac ultrasound in adults :~Measurements will be performed during the first three days of Acute Respiratory Distress Syndrome management :~* The first measurement will be performed 5 minutes after the initial ventilator settings.~* Measurements will be repeated systematically at 24 hours, 48 hours and 72 hours of evolution.~* An additional measure will be performed at each positive end-expiratory pressure modification (maximum 5 measures)."
223765470|NCT04184674|OTHER|Electrical impedance tomography (EIT) for pediatric patients|For pediatric patients: measurements will be performed during the first three days of Acute Respiratory Distress Syndrome management.
223642351|NCT00976404|DRUG|ART intensification (raltegravir)|raltegravir 400 mg PO BID for 56 weeks
223642352|NCT00976404|DRUG|ART intensification (maraviroc)|maraviroc 150, 300, or 600 mg PO BID (depending on PK interactions with other medications) for 56 weeks
223642353|NCT00850239|DRUG|dutogliptin|400 mg
223642354|NCT00850239|DRUG|placebo|
223642355|NCT03416543|OTHER|Puncture|Puncture necessary for daily practice in patients with acute arthritis of RA or Gout or osteoarthritis
224230078|NCT04958980|BEHAVIORAL|Specific and educational guidelines on care for pathology (diabetes mellitus) according to each profession involved in the research|"Physician: Guidance on pathology, sequelae and treatment, as well as guidance on the importance of medical monitoring.~Dental surgeon: guidance on oral health, demonstration of brushing techniques and daily flossing and periodontal changes resulting from diabetes mellitus.~Nurse: Guidance on pathology prioritizing pathophysiology, self-care and skin care and wound prevention (vascular sequelae).~Nutritionist: nutritional guidelines on diabetes mellitus and healthy eating habits.~Physiotherapist: guidance on prevention of falls and injuries and health promotion.~Physical educator: guidance on the importance of practicing physical activities for general health, encouraging self-care and body awareness and demonstrating basic physical activities that can be performed at home."
224230079|NCT00349505|PROCEDURE|hyper thermic chemo + surgery|
224230080|NCT03109366|BEHAVIORAL|Online patient-provider communication service|
224319587|NCT02738710|PROCEDURE|Infra umbilical incision|incision about 1 cm below umbilicus
224319588|NCT03908450|DEVICE|PTCA of coronary de novo lesion PCB|PTCA of coronary de novo lesion with drug coated balloon
224319589|NCT03908450|DEVICE|PTCA of coronary de novo lesion SCB|PTCA of coronary de novo lesion with drug coated balloon
224319590|NCT01004809|DRUG|Dutasteride|Basically there is no treatment allocation. Subjects who would be administered of dutasteride at their physicians' discretion will be enrolled. Dosage regimen will be recommended according to the prescribing information. Subjects will be enrolled consecutively.
224319591|NCT01569295|DRUG|Idelalisib|Idelalisib 150 mg administered orally twice daily
223642356|NCT02196948|OTHER|Electrolysis Percutaneous Therapeutic (EPTE)|
223642357|NCT02196948|OTHER|Eccentric exercise|
223642358|NCT02740101|DRUG|oxytocin treatment|intranasal administration of oxytocin (40 IU)
223642359|NCT02740101|DRUG|placebo treatment|intranasal administration of placebo (40 IU)
223642360|NCT01136083|BEHAVIORAL|Exercise training|Subjects in exercise group will undergo individualized high aerobic interval training on treadmill for 30 minutes under the supervision of an experienced physical therapist 3 times a week and home exercise twice a week with accelerometer.
223642361|NCT01136083|OTHER|Usual care|Subjects in control group will not undergo individualized high aerobic interval training on treadmill. They will receive usual care as normally does in hospital.
223765471|NCT06541457|DRUG|HRS-7249 injection|6 subjects for HRS-7249 injection
223765472|NCT06541457|DRUG|Placebo|2 subjects for placebo
223642362|NCT00876551|PROCEDURE|Endoscopic vacuum assisted closure|"1. Endoscopic debridement of wound using a regular biopsy forceps.~2. Introduction via the nose and oral exteriorization of a silicone duodenal tube (Freka Tube, 15 Ch, Fresenius Kabi, Bad Homburg v.d. H. Germany)~3. Fixation of a polyurethane foam (sponge, pore size 400-600 µm, KCI, Wiesbaden Germany) to the tip of the duodenal tube with a mersilene suture (0,35mm, Johnson \& Johnson, St-Stevens-Woluwe, Belgium).~4. Trimming of the sponge to the specific wound size.~5. Endoscopic placement of the sponge in the intrathoracic leak with a grasping forceps (Olympus, Germany)~6. Application of continuous suction of 125mmHg using vacuum pump (KCI, Wiesbaden Germany).~7. Sponge exchange twice a week until wound grounds are clean and closed"
223642363|NCT00882557|DRUG|daptomycin|intradialytic: 9 mg/kg during the last 30 minutes of dialysis
223642364|NCT00882557|DRUG|daptomycin|6 mg/kg administered after a hemodialysis session
223642365|NCT04581694|DIAGNOSTIC_TEST|TAVI without contrast|TAVI without contrast
223642366|NCT05322473|DRUG|Sonelokimab (M1095)|randomized treatment; parallel-group
223642367|NCT05322473|DRUG|Adalimumab|randomized treatment; parallel-group
223642368|NCT05322473|OTHER|Placebo|randomized treatment; parallel-group
223642369|NCT01908062|DRUG|Extended Release Naltrexone|
224230081|NCT02034331|DRUG|Insulin iontophoresis|For insulin iontophoresis, the cathode electrode will contain 0.2 ml of liquid insulin. For preparation and instrumentation, the arms will be uncovered below the elbow; the participant's lower extremities will be uncovered below knee for leg evaluations. The laser Doppler flowmetry (LDF) lead will be placed bilaterally, 2 inches proximal to the lateral malleolus over the peroneus longus muscle. For arm evaluations, a lead will be placed (and secured with dual-sided transparent tape) bilaterally, 2 inches distal to the lateral epicondyle over the flexor carpi ulnaris muscle along the midline with the ulnar process. Baseline and peak cutaneous blood flow responses to application of insulin iontophoresis will be determined for each LDF lead during the evaluation.
224230082|NCT02034331|DRUG|Placebo Iontophoresis|For placebo iontophoresis, the cathode electrode will contain 0.2 ml of preservative-free normal saline; the anode electrode will contain a medical grade adhesive for skin placement and last 20 minutes. Preparation, instrumentation and data collection for this intervention are the same as the insulin iontophoresis.
224230083|NCT02034331|DRUG|Acetylcholine Iontophoresis|For acetylcholine iontophoresis, the anode electrode will contain 0.2 ml of 1% acetylcholine chloride; the cathode electrode will contain a medical grade adhesive for skin placement and last 20 minutes. Preparation, instrumentation and data collection for this intervention are the same as the insulin iontophoresis.
224230084|NCT02034331|OTHER|Heat application|For the provocation with heat, an insulated thermal heat pack (\~106°F) will be applied to the exposed arm or leg for 18 minutes. The thermal heat pack is comparable to what is routinely used as a heat therapy in conventional rehabilitation settings. LDF leads and temperature sensors will be placed in the previously specified locations to evaluate the changes.
223642370|NCT01908062|OTHER|Treatment As usual|
223765473|NCT06513286|BIOLOGICAL|TherVacB (HEPLISAV B +/- HBcoreAg + MVA-HBVac)|Administration of the described combinations via the intramuscular route
223765474|NCT06513286|BIOLOGICAL|TherVacB (2xHEPLISAV B + HBcoreAg + MVA-HBVac)|Administration of the described combinations via the intramuscular route
223765475|NCT06540066|DRUG|BGB-B3227|Administered intravenously.
223765476|NCT06540066|DRUG|Tislelizumab|Administered intravenously.
224230085|NCT02499549|DRUG|cocamide diethanolamine|10% Cocamide DEA aqueous lotion is applied directly to dry hair and is washed off with water only
224230086|NCT04088578|OTHER|Training|Controlling movement of an object on computer screen by adjusting muscle activity.
224230087|NCT04088578|OTHER|Vagus Nerve Stimulation|Recruits the auricular branch of the vagus nerve which activates brain structures that release chemicals mediating cortical plasticity.
223642371|NCT03396263|BEHAVIORAL|Non-personalised advice|Provision of online non-personalised advice on dietary intake, weight and physical activity levels. Non-personalised dietary advice for improved food choice based on standard population health guidelines.
223642372|NCT03396263|BEHAVIORAL|Online personalised advice|Provision of online personalised advice on dietary intake, weight and physical activity levels. Personalised recommendations for improved food choice based on adherence to an 11-item modified US Alternative Healthy Eating Index (m-AHEI), for weight based on ideal BMI range and for physical activity based on the Baecke questionnaire/results.
223642373|NCT03396263|BEHAVIORAL|Face-to-face personalised advice|Provision of face-to-face personalised advice on dietary intake, weight and physical activity levels. Personalised recommendations for improved food choice based on adherence to an 11-item modified US Alternative Healthy Eating Index (m-AHEI), for weight based on ideal BMI range and for physical activity based on the Baecke questionnaire/results.
223765477|NCT06540066|DRUG|Chemotherapy|Administered in accordance with relevant local guidelines and/or prescribing information.
223765478|NCT05033028|OTHER|Smartphone app|SOAR (Smartphones for Opioid Addiction Recovery) system (battery + platform) as a tool for adjusting MOUD dosages to reduce treatment dropout.
223765479|NCT05518045|DRUG|LM-108|Administered intravenously
223765480|NCT05518045|DRUG|Toripalimab|Administered intravenously
223765481|NCT06015880|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223765482|NCT06015880|PROCEDURE|Computed Tomography|Undergo PET/CT
224230088|NCT04088578|OTHER|Sham Stimulation|Sub-threshold stimulation that does not activate neural structures.
224230089|NCT05668871|DRUG|Danning Tablet|3 times each day, 5 tablets each time, take orally after meals.
223765483|NCT06015880|DRUG|Lenalidomide|Given PO
223765484|NCT06015880|BIOLOGICAL|Mosunetuzumab|Given IV
223765485|NCT06015880|DRUG|Polatuzumab Vedotin|Given IV
223765486|NCT06015880|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
223765487|NCT02892981|OTHER|cardiopulmonary exercise test,hypoxia and hypercapnia test|class I and IV Pulmonary hypertension patients in stable haemodynamic status and optimized medical therapy underwent cardiopulmonary test and hypoxia and hypercapnia tests to evaluate the chemoreceptor sensitivity
224230090|NCT00134888|DRUG|Buprenorphine/naloxone|
224319592|NCT01569295|DRUG|Rituximab|Rituximab 375 mg/m\^2 on Day 1, then 500 mg/m\^2 every 28 days administered intravenously for a maximum of 6 infusions
224319593|NCT01569295|DRUG|Bendamustine|Bendamustine 70 mg/mg\^2/day on 2 consecutive days every 28 days administered intravenously for a maximum of 12 infusions
223642374|NCT02461277|OTHER|Fast-track protocol|Preoperatory management, epidural anesthetic management, avoiding the need opioid in postoperatory analgesia and use of an standardized postoperatory management protocol to an early oral intake and early mobilization. At the postoperative recovery room, after extubation and fully awake, patients started physiotherapy exercises, as physical exercises of moving up upper and lower extremities accompanied by deep breathing exercises. After than, the patients standed up beside the bed and if there was no complications, patients performed ambulation. The physiotherapist aided the patients during all period.
223642375|NCT03770767|DRUG|Faster-acting Aspart insulin Fiasp|Randomization to treatment with insulin Fiasp
223642376|NCT03770767|DRUG|Control (insulin Novorapid)|Randomization to standard treatment with insulin Novorapid
223642377|NCT03428035|OTHER|Package Insert|Modified package insert of Ibuprofen given postprocedural as pain medication
223642378|NCT04235751|BEHAVIORAL|Professional Coaching|6 individualized professional coaching sessions via phone
223642379|NCT02086500|DRUG|Tranexamic Acid|1 gram of prehospital Tranexamic Acid
223642380|NCT02086500|OTHER|Saline control|Saline Control
223642381|NCT00598676|DEVICE|biodegradable polymer Rapamycin-eluting stent|due to randomization, rapamycin-eluting stent with biodegradable polymer will be implanted
223642382|NCT00598676|DEVICE|permanent polymer rapamycin-eluting stent (Cypher)|due to randomization, rapamycin-eluting stent with permanent polymer will be implanted
224230091|NCT03455179|OTHER|Slow-speed traditional resistance training|The training session will consist in a general warm-up, 6 resistance exercises, including 2 upper limb exercises (elbow curl and chest press), 2 lower limb exercises (lunge and standing hip abduction), and 2 exercises combining both upper and lower limbs at the same time (squat plus upright rowing and squat plus shoulder press) and finally the cooldown routine.The participants will perform in each training session 6 submaximal repetitions equivalent to 85% of the one-repetition maximum (1RM) and 3-4 sets per exercise (high intensity training sessions).
224230092|NCT03455179|OTHER|High-speed resistance training|The participants will perform the same exercises than the TRADICIONAL group with12 submaximal repetitions equivalent to 40-50% 1RM (low-intensity) and 3-4 sets per exercise.
224319594|NCT01569295|DRUG|Placebo to match idelalisib|Placebo to match idelalisib administered orally twice daily
223642383|NCT00598676|DEVICE|permanent polymer everolimus-eluting stent (Xience, Promus)|due to randomization, everolimus-eluting stent with permanent polymer will be implanted
223642384|NCT05848999|BIOLOGICAL|UCLM802 Cell Injection (Anti-mesothelin CAR-T cells)|D0: 0.1×106/Kg ～ 2.0×106/Kg; Cells will be infused intravenously.
223642385|NCT00517088|DRUG|IPAQ|
223642386|NCT06103786|BEHAVIORAL|Assigned Interventions|"Ice hockey players did 12 weeks of on-ice high-intensity interval training. Their training included:~Repetitive sprint training Sprint interval training Long-pass tracking drills Chase-the-rabbit tracking drills High-intensity interval training in four types improved college ice hockey players' sports performance in 12 weeks."
223642387|NCT06103786|BEHAVIORAL|Random Interventions|"Ice hockey players did 12 weeks of traditional on-ice training. Their training included:~Varied pacing skating Dribbling and shooting Passing and catching drills 2-on-1 offensive tactics Traditional training in four types improved college ice hockey players' sports performance in 12 weeks.~A 12-week on-ice training program was conducted on college players to observe its effects on their physical fitness, skills, and tactical performance compared to an experimental and control group."
223642388|NCT01146717|BEHAVIORAL|Exercise|Patients with mild cognitive impairment will undergo moderate intensity endurance exercise training for one year.
223642389|NCT01146717|BEHAVIORAL|Balance training|A group of patients with mild cognitive impairment will perform flexibility and balance training for one year as a control group.
223642390|NCT00220285|DRUG|Zevalin (SH L 749 , BAY86-5128)|0,3mCi/kg
223642391|NCT00220285|DRUG|Zevalin (SH L 749 , BAY86-5128)|0,4mCi/kg
223642392|NCT02037308|DIETARY_SUPPLEMENT|Bread|
223642393|NCT01045837|DRUG|Prednisolone and Gluten free diet|Gluten free diet and Oral Prednisolone in a dose of 1 mg/ kg will be given for a period of 4 weeks, thereafter Gluten free diet alone will be continued
223642394|NCT01045837|BEHAVIORAL|Gluten free diet|Only gluten free diet will be given in this group
223642395|NCT02079961|DIETARY_SUPPLEMENT|Micronutrient-fortified yoghurt|A iron-fortified yogurt targeted to children 24-59 months old will be provided through the logistics of an existing value chain, to see if in return this can enhance the reliability of producers supply within this value chain.
223642396|NCT02079961|BEHAVIORAL|BCC|"Behavior Change Campaign (BCC)~A behavior change campaign will be conducted during all the duration of the intervention to increase knowledge about good infant feeding practices and health."
223642397|NCT04207762|DIAGNOSTIC_TEST|18F-AmBF3-TATE PET/CT|Blood pressure, heart rate, and oxygen saturation levels and EKG monitoring (vital signs) will be recorded prior to the injection and at three other stages of the scan visit. Each study subject will have an intravenous catheter inserted. Prior to the radiotracer injection an ultra low dose CT will be taken. Subjects are positioned supine, arms down. The subject will receive a bolus intravenous dose of the radiotracer from an approved study supplier site. A Dynamic PET scan will be taken of the heart. Then a serial whole body PET scan will be done. Vital signs will be taken again and the subject will have a bathroom break. The patient will return to the scanner bed for a standard low dose CT and whole body PET scan. Vital signs will be taken again, and subject will be allowed to use the washroom again. The subject will return to the scanner bed for the final time for an ultra low dose CT and whole body PET scan. A final set of vitals will be taken and the subject will be discharged.
223642398|NCT04207762|DIAGNOSTIC_TEST|Routine blood draw|Complete blood counts and routine clinical chemistry performed before and repeated within 18-72 hours after \[18F\]AmBF3-TATE administration.
223642399|NCT01817803|DRUG|furosemide/no spironolactone|furosemide (doubling previous furosemide dose)
223642400|NCT01817803|DRUG|metolazone/no spironolactone|metolazone (add 2.5mg qod)
223642401|NCT01817803|DRUG|furosemid/spironolactone|furosemide (doubling previous furosemide dose)+spironolactone (doubling previous spironolactone dose or add 12.5mg BID if previous non-user)
223642402|NCT01817803|DRUG|metolazone/spironolactone|metolazone (add 2.5mg qod)+ spironolactone (doubling previous spironolactone dose or add 12.5mg BID if previous non-user)
224319595|NCT04898686|BIOLOGICAL|Probiotic chewables|chewables containing Lacticaseibacillus rhamnosus GG
223642403|NCT03746158|DIETARY_SUPPLEMENT|curcumin|subjects will be assigned to consume one capsule of curcumin (330 mg of curcumin per capsule) three times a day (one capsule with each meal).
224230093|NCT03455179|OTHER|Multicomponent training|Participants will perform, in this order, balance exercises followed by resistance/coordination, aerobic/coordination and flexibility exercises in each session. The balance training will consist in static, dynamic and proactive balance exercises. In the resistance training block, the participants will perform 3-4 sets of 15 submaximal repetitions Participants will perform 2 resistance exercises (squat plus upright rowing and lunge) at traditional slow-speed (2s of concentric contraction and 2s of eccentric contraction).The intensity of the aerobic block will progress from 65 to 85% of the maximum heart rate over the training weeks.
224230094|NCT04740684|OTHER|Standardized diet|Standardized diet is prepared in a commercial kitchen and packaged in single serve portions to provide to participants to consume for 7 days
224230095|NCT05709106|DRUG|Rimegepant 75 MG|Migraine patients would take Rimegepant 75 MG to treat or prevent a migraine attack and patients would be followed up for 1 year
224230096|NCT00306384|DRUG|Alogliptin|Alogliptin tablets.
224230097|NCT04867161|DIAGNOSTIC_TEST|Inflammatory markers sampling|"Laboratory sampling:~Haematology: complete blood count, reticulocytes, IFP, PT, aPTT, fibrinogen, D-dimer Biochemical profile: urea, creatinine, bilirubin, ALT, AST, GGT, CK, LD, ferritin, troponin Inflammation markers IL-6, PCT (procalcitonin), CRP (C-reactive protein), PSP (presepsin)~BALF (bronchoalveolar lavage fluid) processing protocol:~1. microbiology: microscopic examination, standard cultivation test~2. biochemistry: albumin, total protein~3. Pathology: cytology~4. PCR:~a. Multiplex PCR b. SARS-CoV-2 RNA load"
224230098|NCT06190847|OTHER|regular chemoradiotherapy|regular chemoradiotherapy
224230099|NCT05263219|PROCEDURE|dTACE-HAIC|"For DEB-TACE, superselective catheterization is performed and CalliSpheres loaded with pirarubicin is use for chemoembolization. The embolization end point was blood stasis of the tumor-feeding arteries. In patients with huge or bilobar multiple lesions, in order to reduce the risk of complications, the embolization end point was not achieved in the initial TACE but in the second or third TACE session.~After each chemoembolization, the microcatheter is reserved at the proper/left/right hepatic artery. The FOLFOX-based regimen is intra-arterially administered.~During follow-up, the treatment will be repeated on demand (at a 4-6-week interval usually) based on the evaluation of the follow-up laboratory and imaging examination."
224230100|NCT05263219|PROCEDURE|HAIC|"HAIC treatment is divided into 3-week cycles. The microcatheter is advanced into the proper/left/right hepatic artery on day 1 in every cycle of treatment. After the patient returned to the ward, the FOLFOX-based regimen is intra-arterially administered though the microcatheter.~The treatment is repeated once every 3 weeks for up to six cycles."
224230101|NCT05263219|DRUG|dTACE-HAIC protocol|"CalliSpheres (100-300 µm) loaded with pirarubicin for transarterial chemombolization: Typically, one vial of the beads was loaded with 60 mg pirarubicin. If blushed tumors is still visible after the embolization with one vial of beads, regular microspheres (8spheres) with diameters of 100-700 μm are additionally injected.~FOLFOX-based regimen for hepatic arterial infusion chemotherapy: oxaliplatin, 85 mg/m2 infusion for 2 hours; leucovorin, 400 mg/m2 infusion for 2 hours; and 5-FU, 400 mg/m2 bolus infusion and then 2400 mg/m2 continuous infusion over 46 h."
224230102|NCT05263219|DRUG|HAIC protocol|FOLFOX-based regimen for hepatic arterial infusion chemotherapy: oxaliplatin, 85 mg/m2 infusion for 2 hours; leucovorin, 400 mg/m2 infusion for 2 hours; and 5-FU, 400 mg/m2 bolus infusion and then 2400 mg/m2 continuous infusion over 46 h.
224230103|NCT00990613|DRUG|Dimebon IR|A single, oral 10 mg dose of dimebon dihydrochloride (equivalent to 8.2 mg free base) immediate release will be administered.
224230104|NCT00990613|DRUG|Dimebon Transdermal|A single, transdermal 5 mg dose of dimebon free base solution will be applied to the back over a 24 hour period. A double-blinded vehicle (placebo) solution will be applied concurrently to a contralateral body site.
224319596|NCT04898686|BIOLOGICAL|Placebo chewables|chewables without probiotic strain. Ingredients: Xylitol, microcrystalline cellulose, stearic acid, natural orange flavor, silica, magnesium stearate, citric acid and malic acid.
224319597|NCT05778812|BEHAVIORAL|Full Sleep|"Daily lessons about sleep and skills that can help with sleep. Participants also record information about each night's sleep in their sleep log. Every seven nights, they also complete the Sleep Needs Questionnaire. At the beginning, middle, and end of the study, they complete the Insomnia Severity Inventory in the app. At the end of every week, a sleep schedule and weekly summary are calculated via automated formulas. The app also contains access to messaging a coach, for participants to ask questions about their daily lessons and application of the skills and to feel supported and accountable.~The REST device in the Full Sleep program uses radar to passively track sleep patterns and nighttime awakenings. It also offers white noise options and audio guidance for relaxation techniques and stimulus control."
223642404|NCT02724748|BEHAVIORAL|Educational intervention|Educational intervention for staff members will encourage collaboration between patients, relatives and staff members. Skills, intellectual resources, motivation and encouragement among staff members to make changes on the unit will be supported. More detailed content of the intervention to be used in each unit will be tailored based on preparatory phase of the study and individual needs of the unit. The educational intervention will be carried out beside usual care.
223642405|NCT02885025|DIETARY_SUPPLEMENT|Broccoli Sprout Extract|Broccoli Sprout Extract contains the antioxidant Sulforaphane which is the active ingredient being studies.
224230105|NCT00990613|DRUG|Dimebon Transdermal|A single, to be determined dose of dimebon free base solution will be applied to the back over a 24 hour period. The dose level chosen will be determined based on the pharmacokinetic/safety profile of the 5 mg dose. A double-blinded vehicle (placebo) solution will be applied concurrently to a contralateral body site.
224230106|NCT00990613|DRUG|Dimebon IR|A single, oral 10 mg dose of dimebon dihydrochloride (equivalent to 8.2 mg free base) immediate release will be administered.
223642406|NCT02885025|DRUG|fluticasone nasal|fluticasone is a nasal steroid that is currently approved for treatment of allergic rhinitis.
223642407|NCT02885025|DIETARY_SUPPLEMENT|broccoli sprout extract placebo|a tablet similar to the actual broccoli sprout extract though without BSE.
223642408|NCT02885025|DRUG|normal saline nasal spray|normal saline to replace nasal fluticasone in specific arms of the study
223642409|NCT03522311|PROCEDURE|Vitrectomy|
223642410|NCT03378271|DEVICE|Simultanious CGM/FGM|Patients will use both CGM and FGM and document their values as well as documenting a capillary blood glucose value.
223642411|NCT02013271|DEVICE|Lutonix Paclitaxel Drug Coated Balloon (DCB)|Patients exposed to the DCB as part of their routine care.
223642412|NCT02054104|BIOLOGICAL|H1299 cell lysates|H1299 cell lysate with iscomatrix adjuvant vaccine via subcutaneous injections once every cycle (cycle=28 days) for 6 cycles total. Additional 2 injections for patients with immunologic response and no clinical evidence of active disease (NED).
223642413|NCT02054104|DRUG|Cyclophosphamide|50 mg by mouth (PO) twice a day (BID) for 7 days prior to the first dose of vaccine and then on days 8 through 14, and 22 through 28 of each treatment cycle.
223642414|NCT02054104|DRUG|Celecoxib|400 mg by mouth (PO) twice a day (BID) for 7 days prior to the first dose of vaccine and then on days 1 through 28 of each treatment cycle.
223642415|NCT02054104|BIOLOGICAL|Iscomatrix adjuvant|H1299 cell lysate with iscomatrix adjuvant vaccine via subcutaneous injections once every cycle (cycle=28 days) for 6 cycles total. Additional 2 injections for patients with immunologic response and no clinical evidence of active disease (NED).
223642416|NCT03658590|DRUG|Dexamethasone|a prefilled syringe with two milliliters (8 mg) of dexamethasone intravenously
223642417|NCT03658590|DRUG|Distilled Water|a prefilled syringe with two milliliters of distilled water intravenously.
223642418|NCT04989868|PROCEDURE|Trans-Nasal Afferent Loop Decompression|A 14Fr silicon tube with multiple side holes within the range of 15 cm from the tip will be placed into the afferent jejunal limb with its end close to the pancreaticojejunostomy (\<3 cm) during the surgery. Continuous closed negative-pressure suction will be applied to that tube for 72 hours and after that the nasogastric tube will be removed. No nasogastric tube will be placed, or the nasogastric tube will be removed immediately after extubation.
223642419|NCT04989868|PROCEDURE|Without Trans-Nasal Afferent Loop Decompression|No decompression tube will be placed. No nasogastric tube will be placed, or the nasogastric tube will be removed immediately after extubation.
223642420|NCT05053204|OTHER||
224230107|NCT00990613|DRUG|Dimebon Transdermal|A single, to be determined dose of dimebon free base solution will be applied to the back over a 24 hour period. The dose level chosen will be determined based on the pharmacokinetic/safety profile of the 5 mg dose in Cohort 1. A double-blinded vehicle (placebo) solution will be applied concurrently to a contralateral body site.
224230108|NCT06265935|BEHAVIORAL|Experimental Group|It will be carried out as a randomized controlled experimental design to determine the fatigue and quality of life of pregnant women with gestational diabetes.
223642421|NCT03446196|DEVICE|Fluid replacement based on MOSTCARE up|Clinician will be able to read MOSTCARE parameters and to choose the best treatment to adequate hemodynamics considering that current literature suggests a fluid IV expansion only if PPV \> 12%
224230109|NCT06102967|BEHAVIORAL|delirium|Evaluation of delirium using the ICU Patient Ambiguity Assessment Form (CAM-ICU) 1 day, 2 days, 3 days, and 7 days after surgery
224230110|NCT02130206|OTHER|Caries Free|Gums will be examined. On some visits Saliva and plaque will be collected. Toothpaste assigned will include DenClude 1.5% Arginine.
224230111|NCT02130206|OTHER|Caries Active|Gums will be examined. On some visits Saliva and plaque will be collected. Toothpaste assigned will include DenClude 1.5% Arginine.
223642422|NCT02025413|DEVICE|Mesenchymal-marker based ferrofluid (N-cadherin or O-cadherin based)|
223642423|NCT01684865|DRUG|Rituximab|Due to observational nature of the study protocol does not specify any dosing schedule for rituximab.
223642424|NCT05820906|DRUG|Cadonilimab+Regorafenib+GC|Cadonilimab:10mg/kg, iv,q3w,D1 Regorafenib: 80mg, po, orally once daily Gemcitabine:1000 mg/m2, iv, Q3W，D1,D8 Cisplatin:25 mg/m2, iv, Q3W, D1,D8
223642425|NCT03110913|OTHER|dietary intakes|Four levels of methionine intakes will be provided by the reference protein drinks, 3 levels of methionine from lentils and 3 levels from lentils with rice.
223642426|NCT02896413|DRUG|Dexmedetomidine group|dexmedetomidine infusion (0.4 mcg/kg/h) from immediately after anesthetic induction to 24 h after surgery
223642427|NCT02896413|DRUG|Control group|0.9% saline infusion
223642428|NCT00569517|BEHAVIORAL|CBT|6-CBT based sesions
223642429|NCT00569517|OTHER|educational|subjects receive one hour of nutrition education and 5 weekly phone calls
223642430|NCT06140862|OTHER|calf muscle strengthening and streching|lumbar stabilization exercises, core strength training, myofascial release therapy for lower back, and stretching exercises for hamstring muscle.
223642431|NCT00084136|DRUG|Atazanavir|400 mg taken orally daily
223642432|NCT00084136|DRUG|Didanosine (enteric-coated)|400 mg taken orally daily
223642433|NCT00084136|DRUG|Efavirenz|600 mg taken orally daily
223642434|NCT00084136|DRUG|Emtricitabine|200 mg taken orally daily
223642435|NCT00084136|DRUG|Emtricitabine/Tenofovir disoproxil fumarate|200 mg/300 mg taken orally once daily
223642436|NCT00084136|DRUG|Lamivudine/Zidovudine|150 mg/300 mg taken orally twice daily
223642437|NCT00336596|PROCEDURE|transcranial ultrasound in patients treated with iv t-PA|
223642438|NCT03543878|DEVICE|Flicker|The Flicker intervention is delivered with the GammaSense Stimulation System by Cognito Therapeutics and involves viewing flickering lights at gamma frequency (like a strobe light but faster) to drive gamma oscillations in visual brain areas. The GammaSense Stimulation System is a device consisting of a pair of opaque glasses with a light-emitting diode (LED) illumination on the interior of the glasses. Headphones worn by the user during the stimulation session provide the auditory stimulation. When activated for the treatment session, the device will generate light and sound oscillations at 40 cycles per second (Hz) for 60 minutes. Participants will use the device daily during their active treatment period.
223642439|NCT05860972|DEVICE|Morpheus8 Applicator (with the 24 pin tip) in the treatment of primary axillary hyperhidrosis.|After subjects meet the eligibility criteria, they will be randomized with a 1:1 ratio to one of two treatment groups: Active or Sham. Subjects will receive two active or sham treatments, one month apart, with the InMode RF Pro System with the Morpheus8 Applicator and 24 pins tip and will return for three follow up visits: 4 weeks 12 weeks and 24 weeks post the second treatment
223642440|NCT03794336|DRUG|Alogliptin|"Pharmaceutical form: tablet~Route of administration: oral administration"
224230112|NCT02130206|OTHER|Caries Free - Placebo|Gums will be examined. On some visits Saliva and plaque will be collected. Marketed Toothpaste will be assigned.
223642441|NCT03794336|DRUG|Acarbose|"Pharmaceutical form: tablet~Route of administration: oral administration"
223642442|NCT03794336|DRUG|Metformin|"Pharmaceutical form: tablet~Route of administration: oral administration"
224230113|NCT02130206|OTHER|Caries Active - Placebo|Gums will be examined. On some visits Saliva and plaque will be collected. Marketed Toothpaste will be assigned.
224230114|NCT03350022|PROCEDURE|Sham Feeding|Sham feeding will be offered to participants.
224230115|NCT02442479|BEHAVIORAL|resistance training|
224230116|NCT01475383|DRUG|PF-03654746|20-day dose titration phase: all dosages in capsules starting at 0.25 mg qd x 5 d, then 0.5 mg qd x 5 d, then 1.0 mg qd x 5 d, then 2.0 mg qd x 5 d. If a subject has intolerable, severe, or serious AEs after taking 2 mg qd for 1 to 5 days of dosing, the dose will be decreased by the investigator to 1 mg qd. If, in the investigator's opinion, the subject is determined to be unlikely to tolerate continued dosing at a dose of 1 mg qd, the subject should be discontinued from the study. Subjects remaining in the study will proceed to the 3-week Stable Dosing Phase; doses will be 2 mg daily x 21 days or 1 mg daily x 21 days.
224230117|NCT01475383|DRUG|Placebo|once daily dosing of placebo capsules following the dosing scheme described in 1.1.
224230118|NCT01475383|DRUG|Placebo|once daily dosing of placebo capsules following the dosing scheme described in 1.1
224230119|NCT01475383|DRUG|PF-03654746|20-day dose titration phase: all dosages in capsules starting at 0.25 mg qd x 5 d, then 0.5 mg qd x 5 d, then 1.0 mg qd x 5 d, then 2.0 mg qd x 5 d. If a subject has intolerable, severe, or serious AEs after taking 2 mg qd for 1 to 5 days of dosing, the dose will be decreased by the investigator to 1 mg qd. If, in the investigator's opinion, the subject is determined to be unlikely to tolerate continued dosing at a dose of 1 mg qd, the subject should be discontinued from the study. Subjects remaining in the study will proceed to the 3-week Stable Dosing Phase; doses will be 2 mg daily x 21 days or 1 mg daily x 21 days.
224230120|NCT01475656|DRUG|levetiracetam|Infants in the both groups will receive 50 mg/kg IV levetiracetam after (continued) seizures are EEG confirmed.
224230121|NCT03419663|DIETARY_SUPPLEMENT|cereal or grain consumption|intake of cereal, whole grain, refined grain, and other grain of every day
224230122|NCT03262298|BIOLOGICAL|Anti-CD22-CAR-transduced T cells|a single dose of Anti-CD22-CAR-transduced T cells will be infusion after preconditioning.
224230123|NCT01680679|BIOLOGICAL|Inactivated Trivalent Influenza Vaccine (TIV)|
224230124|NCT01680679|BIOLOGICAL|Inactivated poliovirus vaccine (IPV), trivalent|
223642443|NCT03794336|DRUG|Aspirin|"Pharmaceutical form: tablet~Route of administration: oral administration"
223642444|NCT01041755|DRUG|L-ornithine-L-aspartate|a) Intravenous infusion of 20 g L-ornithine-L-aspartate (4 ampules of 10 mL each) in 250 mL sodium chloride solution administered daily in 4 hours for 3 consecutive days, plus the placebo b) Water enemas, 1000 mL of water and given as retention enema every 12 hours for 3 consecutive days.
224230125|NCT00046709|DRUG|Smoked Marijuana|
224230126|NCT02677909|DEVICE|AEGIS (Automated Evaluation of Gastrointestinal Symptoms)|Will place device on admission to SICU. Measure bowel sounds and await bowel function
224230127|NCT01027442|DEVICE|Mucosa-supported single-type guides|Compute generated Mucosa-supported single-type guides
224230128|NCT01027442|DEVICE|Bone-supported guides|Computer generated, Multiple type Bone-supported guides
224230129|NCT01027442|DEVICE|Dental Implants|Dental implants placed via conventional free-hand method
224230130|NCT02426619|DEVICE|SDF solution|around 1 mL of 30% silver diammine fluoride (SDF) solution is placed in a small disposable container and a small brush will be used to apply a very small quantity of the solution onto the surface of the dental caries lesion in the tooth
224230131|NCT02426619|DEVICE|NaF varnish|around 1 mL of 5% NaF (sodium fluoride) varnish is placed in a small disposable container and a small brush will be used to apply a very small quantity of the solution onto the surface of the dental caries lesion in the tooth
224230132|NCT03850509|DRUG|OPS-2071|OPS-2071 300 mg, tablets, orally, BID.
224230133|NCT03850509|DRUG|Placebo|OPS-2071-matched placebo, tablets, orally, BID.
223642445|NCT01041755|DRUG|Lactose|a) 20% Lactose enemas, 200 g Lactose diluted with 700 mL of water and given as retention enema every 12 hours for 3 consecutive days, plus intravenous placebo b)250 mL sodium chloride solution, infusion for 4 hours for 3 consecutive days.
223642446|NCT00836693|DRUG|tadalafil|5 milligrams (mg) administered orally once a day for 12 weeks
224230134|NCT00015106|DRUG|Lamotrigine|
224230135|NCT05178355|DRUG|KVD824|Active
224230136|NCT05178355|DRUG|Placebo to KVD824|Placebo
224230137|NCT03147170|DIAGNOSTIC_TEST|High and low salt diets|Effects of high and low salt diets on blood pressure in individuals with normal and elevated levels of NT-proBNP
223642447|NCT00836693|DRUG|placebo|tablet administered orally once a day for 12 weeks.
223642448|NCT02612779|DRUG|Elotuzumab|
223642449|NCT02612779|DRUG|Pomalidomide|
223642450|NCT02612779|DRUG|Dexamethasone|
223642451|NCT02612779|DRUG|Nivolumab|
223642452|NCT02741739|DRUG|REGN1033|
223642453|NCT06091202|BEHAVIORAL|CORPs Intervention|"Participants will be randomly assigned to the intervention or to the comparator arm. The follow-up period is 12 months. The primary outcome is a change in pain interference.~After the baseline assessment, participants will complete a masked telephone assessments with research staff at 3-, 6-, 9-, and 12-months.~A subset of individuals may be invited to participate in a qualitative interview at 12-month follow-up."
224230138|NCT06262711|DIETARY_SUPPLEMENT|Vitamin C|Vitamin C 500mg hydroxypropyl methylcellulose (HPMC) capsules (Solgar UK).
224230139|NCT06262711|DIETARY_SUPPLEMENT|Placebo|Vitamin C-matched placebo capsule. Placebo capsules manufactured using hydroxypropyl methylcellulose (HPMC) capsules and microcrystalline cellulose (MCC).
224230140|NCT02038478|BIOLOGICAL|Donor Stem Cell Transplantation|One day after they complete their radiation and Campath-1H treatments and have begun their Sirolimus, the donor blood stem cells described above are transfused through the central line. This process takes approximately 30 minutes to 2 hours and is normally completely without side effects.
224230141|NCT02880072|DIETARY_SUPPLEMENT|phosphate orally|4 different preparations of phosphate
224230142|NCT00969332|DRUG|Omegaven|0.5 g/kg/d intravenous every day for 2 days, then 1 g/kg/d intravenous everyday
224230143|NCT06545136|GENETIC|FLT201|FLT201 is a replication-incompetent single-stranded (ss) recombinant adeno-associated virus (AAV) vector. The vector is composed of a ss DNA genome packaged in an AAV-derived protein capsid.
223642454|NCT06091202|BEHAVIORAL|Minimally Enhanced Usual Care (MEUC)|"Participants will be randomly assigned to the intervention or to the comparator arm. The follow-up period is 12 months. The primary outcome is a change in pain interference.~After the baseline assessment, participants will complete a masked telephone assessments with research staff at 3-, 6-, 9-, and 12-months.~A subset of individuals may be invited to participate in a qualitative interview at 12-month follow-up."
223642455|NCT06370806|BEHAVIORAL|Weight loss and lifestyle intervention|Interdisciplinary intervention addressing weight loss and lifestyle change including nutritional behavior change, aerobic exercise, sleep hygiene, and alcohol and tobacco cessation combined with usual care (i.e., CPAP)
223642456|NCT05127733|BEHAVIORAL|Online Cognitive Behavioural Therapy|Interactive program utilizing cognitive behavioural therapy principles that guides users through its components and provides feedback, which facilitates behavior change (i.e., reduction in alcohol or substance use).
223642457|NCT05127733|BEHAVIORAL|Individual Peer Support|Weekly meetings with a trained peer support worker who guides participants through the BFO platform, reviews the platform's content with them, and supports them in the creation of an action strategy based on the platform's suggestions.
223642458|NCT05127733|BEHAVIORAL|Group Peer Support|Meetings with a group of peers led by a trained peer support worker/volunteer which will offer the participants an opportunity to discuss their experiences in a supportive and open environment.
223642459|NCT01957306|DIETARY_SUPPLEMENT|Dr. Tagliaferri's Menopause Formula|Administered as 2 grams PO BID
223642460|NCT00897494|GENETIC|protein expression analysis|Venous blood collection
223642461|NCT00897494|OTHER|laboratory biomarker analysis|Venous blood collection
224230144|NCT02437799|OTHER|Dicrotic wave analysis|We will download data from the pulse oximeter that is being used to monitor the patient during their surgery.
224230145|NCT04523142|DRUG|CyclASol Ophthalmic Solution|Cyclosporine A solution in vehicle
224230146|NCT01532245|OTHER|two lung ventilation (TLV)|During two-lung ventilation (TLV) and OLV 8 ml•kg-1 tidal volume was used.
224230147|NCT01532245|OTHER|one lung ventilation (OLV) without PEEP|During OLV, ventilation periods of ten minutes, with and without 5 cmH2O positive end-expiratory pressure (PEEP) were alternated.
224230148|NCT01532245|OTHER|One lung ventilation (OLV) with positive end-expiratory pressure (PEEP)|During OLV, ventilation periods of ten minutes, with and without 5 cmH2O positive end-expiratory pressure (PEEP) were alternated
224230149|NCT00630565|BIOLOGICAL|sargramostim|Given subcutaneously (SC) 10 μg/kg/day from day +3 until apheresis is completed
223642462|NCT00897494|OTHER|mass spectrometry|Venous blood collection
223642463|NCT00897494|OTHER|surface-enhanced laser desorption/ionization-time of flight mass spectrometry|Venous blood collection
223642464|NCT00074048|DRUG|BL22|Dosing via IV on Days 1,3, and 5.
223642465|NCT06046170|BEHAVIORAL|Cognitive Behavioral Therapy|Participants will receive cognitive behavioral therapy with elements of exposure in order to target anxious behaviors.
223642466|NCT06046170|OTHER|Treatment as Usual|Participants will receive treatment as usual at a community mental health center, including receiving skills training.
223642467|NCT00801177|BIOLOGICAL|IMC-11F8|"Cohort 1~100 mg I.V."
223642468|NCT00801177|BIOLOGICAL|IMC-11F8|"Cohort 2~200 mg I.V."
223642469|NCT00801177|BIOLOGICAL|IMC-11F8|"Cohort 3~400 mg I.V."
223642470|NCT00801177|BIOLOGICAL|IMC-11F8 I.V.|"Cohort 4~600 mg I.V."
223642471|NCT00801177|BIOLOGICAL|IMC-11F8|"Cohort 5~800 mg I.V."
223642472|NCT00801177|BIOLOGICAL|IMC-11F8|"Cohort 6~1000 mg I.V."
223642473|NCT00801177|BIOLOGICAL|IMC-11F8|"Cohort 1~100 mg I.V."
223642474|NCT00801177|BIOLOGICAL|IMC-11F8|"Cohort 2~200 mg I.V."
223642475|NCT00801177|BIOLOGICAL|IMC-11F8|"Cohort 3~400 mg I.V."
223642476|NCT00801177|BIOLOGICAL|IMC-11F8|"Cohort 4~600 mg I.V."
223642477|NCT00801177|BIOLOGICAL|IMC-11F8|"Cohort 5~800 mg I.V."
223642478|NCT00801177|BIOLOGICAL|IMC-11F8|"Cohort 6~1000 mg I.V."
223642479|NCT01147510|DRUG|Combination of low ICS and montelukast|Two puffs of Pulmicort ® turbuhaler 200µg/puff between 7 a.m. and 10 a.m and take orally a tablet of Singulair® 10mg one time per day.
223642480|NCT01147510|DRUG|Monotherapy of medium dose ICS|Two puffs of Pulmicort ® turbuhaler 200µg/puff between 7 a.m. and 10 a.m. and between 7 p.m. and 10 p.m. two times per day
223642481|NCT01567540|DRUG|Sitagliptin|100 mg Sitagliptin daily for 15 weeks
223642482|NCT01856959|DRUG|Magnesium Sulfate|2ml of 7.5% solution of isotonic magnesium heptahydrate, 150 mg
223642483|NCT01856959|DRUG|magnesium sulfate & albuterol|0.5ml of albuterol mixed with 2ml of isotonic magnesium sulfate,150mg+2.5mg
223642484|NCT01856959|DRUG|Albuterol|0.5ml of albuterol mixed with 1.5cc of normal saline, 2.5 mg
223642485|NCT05676177|DIAGNOSTIC_TEST|Ultra Low Dose CT|"* Two immediately consecutive scans with either one or two breath-holds~* First scan (ULD\_DECT\_1) 140 kilovolt peak (kVp) - fixed current 10 or 20 milliampere (mA) (if body mass index (BMI)\>30), that is 5 or 10 mAs~* Second scan (ULD\_DECT\_2) 80 kVp - fixed current 20 or 40 mA (if BMI\>30), that is 10 or 20 mAs"
224230150|NCT00630565|DRUG|busulfan|4 mg/kg po in 4 divided doses (.8 mg/kg/dose orally every 6 hours) on days -7 through -4.
224230151|NCT00630565|DRUG|cyclophosphamide|4 gm/m\^2 x 1 (day 0) and 60 mg/kg intravenous (IV) over 2 hours on days -3 and -2.
224230152|NCT00630565|DRUG|dexamethasone|20 mg/m\^2 x 4 doses every 12 hours given intravenously (IV) push before cytoxan on day 0 and then every 12 hours
224230153|NCT00630565|DRUG|etoposide|300 mg/m\^2/day x 2 days (day 0-1) over 3 hours intravenously (IV)
224230154|NCT00630565|PROCEDURE|bone marrow transplantation|Day 0 infusion of bone marrow cells
224230155|NCT00630565|PROCEDURE|hematopoietic stem cell transplantation|Stem cell infusion (\>48 hours after the last dose of cyclophosphamide)
224230156|NCT00630565|PROCEDURE|peripheral blood stem cell transplantation|Day 0 infusion of peripheral blood stem cells
224230157|NCT00630565|RADIATION|total-body irradiation|165 cGy/dose given twice a day on days -7 through -4.
224230158|NCT04780503|DIAGNOSTIC_TEST|Rapid Shallow Breathing Index|The RSBI is defined as the ratio of respiratory frequency to tidal volume.
224230159|NCT00162604|DRUG|Cefuroxime|
224230160|NCT05997056|DRUG|nab-sirolimus|Prospective phase 2 single arm, open-label, multi-institutional study to determine the efficacy and safety prospective of nab-sirolimus administered by IV infusion
223642486|NCT05676177|DIAGNOSTIC_TEST|Fat quantification MRI|Dual echo scans, as well as proton density fat fraction (PDFF) scans, will be performed to assess liver fat fraction
223642487|NCT00404222|DRUG|Hydrocodone/Acetaminophen Extended-Release|2 tablets x 1
223642488|NCT00404222|DRUG|Hydrocodone/Acetaminophen Immediate Release (NORCO®)|1 tablet q 4 hours x 3
223642489|NCT00404222|DRUG|Placebo|q 4 hours x 3
223642490|NCT05576454|DRUG|Mepolizumab Injection (BAT2606 Injection)|In this group, each subject will receive single subcutaneous injection of 100 mg BAT2606 Injection.
223765488|NCT06113419|PROCEDURE|Laparoscopic cholecystectomy|Laparoscopic cholecystectomy will be performed using the standard American 4-port technique, insufflation will be achieved using CO2 to 15mmHg of pressure. Calot's triangle will be dissected until the critical view of safety is reached, being careful to dissect above the R4U line. After reaching the critical view of safety, two proximal and one distal clip will be placed on both the cystic conduct and artery separately, cutting the clips and then dissecting the gallbladder in a cystfundic direction. When the critical view of safety is not reached, the surgeon may perform a fundus-first cholecystectomy, subtotal cholecystectomy, conversion to open procedure, intraoperative cholangiography or cholecystostomy to their own discretion. It will also be the surgeon's criteria to employ or not a drain system in the surgical site. The decision for theses interventions will be taken intraoperatively and will be according to findings during the procedure.
223765489|NCT06968845|DRUG|LTI-03|Caveolin-1-Scaffolding-Protein-Derived Peptide
223765490|NCT06968845|DEVICE|Dry Powder Inhaler|Plastiape Monodose RS01 Model 7
223765491|NCT06968845|DRUG|Placebo|Lactose powder
224230161|NCT03497533|BIOLOGICAL|TriCAR-T-CD19|A conditioning chemotherapy regimen of fludarabine and cyclophosphamide will be administered followed by a single infusion of CAR transduced autologous T cells administered intravenously at a target dose of 0.5-1 x 10\^6 CAR+ T cells/kg
224319598|NCT05778812|BEHAVIORAL|Path to Better Sleep|Path to Better Sleep is a self-management tool for insomnia. It is available as a web-based program at https://www.veterantraining.va.gov/apps/insomnia/index.html#dashboard. Path to Better Sleep is intended to be completed over six weeks, and includes weekly educational lessons about sleep which include videos, visual depictions, and interactive activities, in addition to sleep check-ins (e.g., knowledge checks, self reflections about sleep). It also includes sleep logging. Participants in this condition will be asked to share their sleep log weekly via email, as Stanford and Koko Labs do not receive access to the data.
224319599|NCT02366169|DEVICE|Medigus Ultrasonic Surgical Endostapler (MUSE) Procedure|The procedure is performed transorally under general anesthesia. The physicians staples the fundus of the stomach to the esophagus approximately 3cm superior to the Z-line in 2 or more locations. The procedural result is anatomically and functionally similar to standard anterior fundoplication (Dor-Thal operation). The staples are standard, 4.8mm titanium surgical staples. Each application of the device fires a quintuplet of staples (5) in three staggered rows. Anti-retching medications at the time of the procedure are essential.
223765492|NCT06099197|BEHAVIORAL|Brain CareNotes|The Brain CareNotes mobile telehealth app is used by unpaid caregivers for BPSD management. It includes remote communication with an external human support person-a care coach-as well as features for users to independently perform health-related activities.
223765493|NCT06099197|BEHAVIORAL|Dementia Guide Expert|"Dementia Guide Expert provides education only and no interactive BPSD management support, coaching, assessment, or external response. It contains evidence-based expert information on what dementia is, types, contributing factors, risks, symptoms, stages, diagnosis, tests, treatment, management, communication techniques, and links to resources and support services."
223765494|NCT06969196|OTHER|Written Communicatoin|ICU clinicians will be asked to edit AI-generated written summaries for content and clarity before they are delivered to families
223765495|NCT05774899|DRUG|CB-103|First-in-class pan-NOTCH inhibitor, capsule taken orally.
223765496|NCT05774899|DRUG|Abemaciclib|CDK4/6 inhibitor, tablet taken orally.
223765497|NCT05774899|DRUG|Lenvatinib|Per standard care, capsule taken orally.
223642491|NCT05576454|DRUG|Mepolizumab Injection (EU-licensed Nucala)|In this group, each subject will receive single subcutaneous injection of 100 mg Mepolizumab Injection (EU-licensed Nucala®).
223642492|NCT05576454|DRUG|Mepolizumab Injection (US-licensed Nucala)|In this group, each subject will receive single subcutaneous injection of 100 mg Mepolizumab Injection (US-licensed Nucala®).
223642493|NCT01672671|DRUG|Doxorubicin, Paclitaxel, Cisplatin|Doxorubicin 25 mg/m2, IV weekly. Number of Cycles: 8 Paclitaxel 100 mg/m2, IV weekly. Number of Cycles: 8. Cisplatin 30 mg/m2, IV weekly. Number of Cycles: 8.
223642494|NCT01657019|DRUG|Lisdexamfetamine dimesylate|50 or 70 mg administered orally, once a day for 52 weeks
223642495|NCT00041743|BEHAVIORAL|Group Cognitive Behavioral Therapy|
223765498|NCT01716728|OTHER|enzyme analysis|
223642496|NCT00104923|DRUG|fenretinide|Current dose level as an IV continuous infusion via central line over 5 days. Cycle is repeated every 3 weeks for up to 6 cycles
223642497|NCT01367990|DRUG|Norepinephrine|"The occipital scalp zone at risk for alopecia will be identified. The norepinephrine treatment site will be randomized to receive consistent treatment of one half of the scalp risk zone. Approximately 1.6 mL of a 400 mM norepinephrine solution will be applied topically to the norepinephrine site approximately 20 minutes prior to each radiation treatment, and placebo will be applied to the contralateral side (30-35 treatments)."
223642498|NCT04433988|DRUG|Pentoxifylline|Pentoxifylline 400 mg SR tablet
223642499|NCT04433988|DRUG|Placebo|Placebo tablet
223642500|NCT00473213|DRUG|Interferon Beta 1|
223642501|NCT02937324|DEVICE|CloudUPDRS smartphone software assessment|Smartphone software consisting of a series of tapping and tremor-measurement tests designed to measure a subset of the UPDRS.
223765499|NCT00123188|PROCEDURE|Ultrasound and Biopsy|Transvaginal ultrasound and Endometrial Biopsy
224230162|NCT02335970|OTHER|Training group|"After 1 week~* Chest expansions~* Static thoracic extension in prone~* Lateral flexion of the spine in standing~* Bilateral shoulder flexion~* Shoulder external rotation of shoulders~* Rotation of the thoracic spine in sitting~* Static back extensor strength in prone~After 1 month~* Thoracic extension, rotation and flexion abduction~* Hand in neck and in back~* Bilateral active flexion abduction~* Strength training of leg muscles~* Static back extensor strength~After 2 months~* Strength training of legs and back muscles~* Push-ups against a wall~* Thoracic extension in sitting and standing~* Thoracic rotation in lying~* Stretching of mm. pectoralis Training was performed daily with 10 rep of each exercise"
223642502|NCT02937324|OTHER|Clinical assessment|A clinician will assess the motor signs of the participant using the Unified Parkinson's Disease Rating Scale. The examination will be videoed and rated by 3 blinded examiners.
223642503|NCT05866952|DIAGNOSTIC_TEST|Computed Tomography of the Chest|Quantitative Computed Tomography of the chest in the inspiratory and expiratory phases will be performed to assess regional lung ventilation as well as pulmonary vascular volume and distribution
223642504|NCT00030732|DRUG|Gemcitabine + Capecitabine|Gemcitabine + Capecitabine
223642505|NCT00030732|DRUG|Gemcitabine alone|Gemcitabine alone
223642506|NCT03339752|DRUG|Rosuvastatin|10 mg tablet
223642507|NCT03339752|DRUG|ACT-541468|25 mg hard capsule
223642508|NCT02110836|DIETARY_SUPPLEMENT|Glucose ingestion|Glucose ingestion during exercise at 1.8 g/min
223642509|NCT02110836|DIETARY_SUPPLEMENT|Sucrose ingestion|Sucrose ingestion during exercise at 1.8 g/min
223642510|NCT05532306|DRUG|Ribavirin 400 mg film coated tablet (1*400mg)|an immediate release film-coated tablet containing 400 mg Ribavirin
223642511|NCT05532306|DRUG|Copegus® 200 mg film coated tablet (2*200mg)|an immediate release film-coated tablet containing 200 mg Ribavirin
223642512|NCT05538715|PROCEDURE|Split-thickness group|Following randomization, horizontal guided bone regeneration utilizing Bio-Oss (Geistlich, Wolhusen, Switzerland) and autogenous bone in combination with Bio-Gide membrane (Geistlich, Wolhusen, Switzerland). Surgery is performed with a split-thickness flap design in the posterior maxilla or mandible in partially edentolous patients.
224230163|NCT01261520|BEHAVIORAL|Culturally-tailored video|A 18 minute DVD made in Chinese language (i.e. Mandarin and Cantonese)
224230164|NCT01101009|DRUG|Perindopril + amlodipine + if necessary, hydrochlorothiazide|Two perindopril 4 mg tablets + 1 amlodipine 10 mg tablet + placebo tablet matching the olmesartan/amlodipine tablet. All tablets are taken once daily. The duration of administration of perindopril tablets and placebo is 24 weeks. The duration of administration of amlodipine tablets is 24-26 weeks. Hydrochlorthiazide tablets 12.5 mg or 25 mg, once daily, will be added, if necessary
224319600|NCT04839042|BIOLOGICAL|SC-Ad6-1|SC-Ad6-1, I.M., single or multiple-dose
224319601|NCT04839042|BIOLOGICAL|SC-Ad6-1|SC-Ad6-1, I.N., single or multiple-dose
224319602|NCT04839042|BIOLOGICAL|SC-Ad6-1|SC-Ad6-1, I.H., single or multiple-dose
224319603|NCT05638581|BIOLOGICAL|LTOWB|Participants will receive Low Titer O Whole Blood administered intravenously or intraosseously.
224319604|NCT05638581|BIOLOGICAL|Components|Participants will receive separated blood components (i.e., units of red cells, plasma, platelets, and cryoprecipitate) co-administered intravenously or intraosseously.
223642513|NCT05538715|PROCEDURE|Full-thickness group|Following randomization, horizontal guided bone regeneration utilizing Bio-Oss (Geistlich, Wolhusen, Switzerland) and autogenous bone in combination with Bio-Gide membrane (Geistlich, Wolhusen, Switzerland). Surgery is performed with a full-thickness flap design in the posterior maxilla or mandible in partially edentolous patients.
223642514|NCT02538913|BEHAVIORAL|Exercise training|Daily pelvic floor muscle training and individualized regular exercise training (aerobic and strength exercise) three days per week.
223642515|NCT02538913|PROCEDURE|Usual care|Patients randomized to the control group will receive standard care which does not include any pelvic floor muscle training or individualized exercise training
223642516|NCT04663659|OTHER|no intervention|no intervention
223642517|NCT05957380|DRUG|DA-2803|All participants are administered one tablet per day for 48 weeks
223642518|NCT05957380|DRUG|DA-2803-R|All participants are administered one tablet per day for 48 weeks
223642519|NCT05957380|DRUG|Placebo of DA-2803|All participants are administered one tablet per day for 48 weeks
223642520|NCT05957380|DRUG|Placebo of DA-2803-R|All participants are administered one tablet per day for 48 weeks
224319605|NCT05786560|BEHAVIORAL|BABE (Body Appreciation and Better Eating)|The participants will be randomized into either a treatment or control group. For the treatment arm, girls will participate in the Body Project for 30 minutes, then will be given a 30-minute self-compassion-based nutrition education lesson. Nutrition topics will cover the basic biochemistry of nutrition, nutrition needs for teenage girls, and ways to find balance in eating, framed in the constructs of self-compassion. The control group will receive the same 30-minute Body Project class and the same 30-minute nutrition education class; however, there will be no incorporation of self-compassion.
224319606|NCT05757375|OTHER|Mulligan Manuel Therapy Consept|Mulligan ankle taping is a noninvasive, painless, low-cost, and easily applicable technique of the Mulligan manual therapy concept. It is frequently used in cases of ankle instability. In healthy people, it is a method to prevent ankle sprains.
224319607|NCT03607487|DRUG|INCB054707|INCB054707 tablet administered orally once daily at the protocol-defined dose.
224319608|NCT03607487|DRUG|Placebo|Placebo tablet administered orally once daily.
224319609|NCT05853575|DRUG|Adagrasib|KRAS G12C inhibitor
224319610|NCT01884337|DRUG|Apixaban|
224319611|NCT02021513|DIETARY_SUPPLEMENT|Fish Oil|Fish Oil (2.25gm EPA and 2.25gm DHA total)
224319612|NCT02021513|DIETARY_SUPPLEMENT|Olive Oil|Placebo group
224319613|NCT02455518|DRUG|Oxycodone/acetaminophen|
224319614|NCT02455518|DRUG|Hydrocodone/acetaminophen|
223642521|NCT06286761|OTHER|endothelial cell collection|Participants may opt to have testing performed including blood sampling, intravenous catheter placement with endothelial cell collection, oral glucose tolerance test, consuming a test meal, having imaging performed such as MRI, DEXA, MRS to investigate use of different assays, different sample treatment approaches to determine optimal conditions that produce the most accurate and reproducible results, and/or repeat testing on different days or with different equipment that measures the same variable.
223642522|NCT06401239|OTHER|Dyadic expectations about the ARF survivor's perceived health 6 months after hospital discharge|Dyad members' expectations will be collected at baseline and at 3- month follow-up assessments using a visual analogue scale (VAS) ranging from 0 - 100, similar to the EQ-5D-VAS.
223765500|NCT00945022|DEVICE|wetting lips following surgery using anesthesia|The investigator will position the Lipsus device in accordance with the instructions for use
224230165|NCT01101009|DRUG|olmesartan/amlodipine + hydrochlorothiazide, if necessary.|olmesartan/amlodipine tablets 40 mg/10 mg, + placebo tablets matching the perindopril tablet and amlodipine tablet. All tablets are taken once daily for 24 weeks. Hydrochlorthiazide tablets 12.5 mg or 25 mg, once daily, will be added, if necessary
224319615|NCT02455518|DRUG|Codeine/acetaminophen|
223642523|NCT06401239|OTHER|Self-efficacy|Self-efficacy in both dyad members will be assessed at 3- and 6-month follow-up assessments using the Generalized Self-Efficacy Scale (GSE). The GSE has 10 items scored on a 4-point scale. U.S. adult population norms are available.
223642524|NCT06401239|OTHER|Concordant expectations/shared appraisal of ARF survivor's health 6 months after hospital discharge|Dyad members' expectations will be collected at baseline and at 3- month follow-up assessments using a visual analogue scale (VAS) ranging from 0 - 100, similar to the EQ-5D-VAS.
223642525|NCT03605485|DEVICE|Nasal Pillows CPAP mask|Investigative Nasal pillows Mask to be used for OSA therapy
223642526|NCT05283811|DEVICE|NEUROPACE RNS SYSTEM|This device is indicated as a therapy in reducing the frequency of seizures in individuals
223642527|NCT05283811|BEHAVIORAL|EMU|Patients are admitted to the Epilepsy Monitoring Unit for observation of seizure activity prior to further treatment
223642528|NCT04287036|DEVICE|JJVC Investigational Contact Lens|TEST
224230166|NCT01391182|OTHER|EACA|EACA 5 grams IV (mixed in NS) given in two doses: prior to incision (total hip arthroplasty) and repeated 4 hours later.
224230167|NCT01391182|OTHER|Placebo arm|Placebo (NS) IV given in two doses: prior to incision (total hip arthroplasty) and repeated 4 hours later.
224230168|NCT04890275|OTHER|Blood flow restricted resistance exercise (BFR)|Following a 5-minute low intensity warm-up, the BFR cuff will be placed at the most proximal portion of the leg inflated to 50% limb occlusion following standard BFR guidelines. Participants will then perform leg press including 1 set of 30 reps, then 3 sets of 15 reps at 20% 1RM. Rest for 5 minutes without cuff inflation. Cuffs will be re inflated and participants will perform knee extension including 3 x 15 repetitions at 20% 1RM.
224230169|NCT04890275|OTHER|Resistance exercise without blood flow restricted (NON-BFR)|Participants will follow the same exercise protocol as the blood flow restriction group but with out BFR.
223642529|NCT04287036|DEVICE|1-DAY ACUVUE® DEFINE® Radiant Sweet™|CONTROL
223642530|NCT05252533|DRUG|Ustekinumab|This study does not provide dosing instructions for ustekinumab but will engage participants who have been treated with ustekinumab by their corresponding HCPs independent of this study.
223642531|NCT05802225|DRUG|BCD-178|at an initial dose of 840 mg (1 cycle), then 420 mg
223642532|NCT05802225|DRUG|Perjeta|at an initial dose of 840 mg (1 cycle), then 420 mg
223642533|NCT00279487|DRUG|Gabapentin|
223642534|NCT00279487|DRUG|Placebos|
223642535|NCT05972317|OTHER|Low FODMAP dietary regimen|"intervention will include a guidance by a clinical dietitian about low FODMAP diet~The FODMAP diet has three phases:~1. Elimination - Avoidance from high-FODMAP foods (2-6 weeks)~2. Reintroduction -Structured challenges of specific food groups each time (6-8 weeks).~3. Maintenance - personalized diet, according to the response in step 2."
223642536|NCT06584474|DRUG|Azithromycin neubilization|"nebulized azithromycin (Xithrone, Amoun, Egypt) that will be initiated from day 7 of birth in a dose of 20 mg/kg/day in two divided doses for 3 weeks till the time of primary outcome assessment (at 28 days of age). Azithromycin solution for nebulization will be prepared from intravenous vials containing 500 mg lyophilized powder. First, each lyophilized powder vial will be prepared with 5 ml normal saline according to the manufacturer's instruction. The reconstituted solution will be diluted with 28.5 ml normal saline to make a final concentration of 17.5 mg/ml according to clinical pharmacy recommendation. For nebulization of azithromycin, 0.6 ml of final drug prepared solution will be taken for every~1 kg body weight of patient, then made up to 3 ml of normal saline and will be administered by Aerogen Jet Nebulizer every 12 hours using 8 liter/min of medical air or by face mask if not mechanically ventilated. According to the manufacturer's declaration, prepared azithro"
223642537|NCT06584474|DEVICE|Lung ultrasound|Device A mobile device (PHILIPS ® HD11 XE) with a 10-MHz linear probe will be used for chest ultrasound. It will be done at day 14 of postnatal life.
223765501|NCT03351764|DEVICE|Sham TMS|Subjects receive sham TMS via coil designed to produce the clicking sound of active TMS without delivering the magnetic field to the brain.
223642538|NCT00072839|DRUG|ALX-0600|teduglutide
223642539|NCT00072839|DRUG|placebo|placebo solution injected subcutaneously
223765502|NCT03351764|DEVICE|TMS|non-invasive transcranial magnetic stimulation is used to temporarily modulation ongoing cortical activity
224230170|NCT02431403|DRUG|ESHAP-Imatinib|After selection of the maximum-tolerated dose of the combination ESHAP with imatinib a phase 2 of the study will be performed in order to evaluate the ORR of ESHAP-imatinib.
224230171|NCT01565083|DRUG|Pertuzumab|Loading dose of 840 mg on Day 1 of first 21-day cycle, followed by 420 mg on Day 1 of each subsequent cycle.
224230172|NCT01565083|DRUG|Trastuzumab|Loading dose of 8 mg/kg on Day 1 of first 21-day cycle, followed by 6 mg/kg on Day 1 or 2 of each subsequent cycle.
224230173|NCT01565083|DRUG|Vinorelbine|A dose of 25 mg/m\^2 followed by 30-35 mg/m\^2 on Days 2 and 9 of the first 21-day cycle and on Days 1 and 8 (or Days 2 and 9) of each subsequent cycle.
223642540|NCT00072839|DRUG|teduglutide 0.05|0.05 mg/jg/d subcutaneous daily injection into thigh or abdomen
223642541|NCT00072839|DRUG|teduglutide 0.2 mg|0.2 mg/kg/d subcutaneously injected into thigh or abdomen
223642542|NCT00072839|DRUG|Teduglutide 0.05 dose|0.05 mg/kg/d subcutaneous daily injection into thigh or abdomen
223642543|NCT00072839|DRUG|teduglutide 0.1 mg dose|0.1 mg/kg/d daily subcutaneous injection into thigh or abdomen
223642544|NCT01807988|BEHAVIORAL|iCBT|Internetbased cognitive behavior therapy (iCBT) contains interventions that will help the participant to change her behavior to experience more positive reinforcement in daily life and also to challenge her negative patterns of thought. There are also information and exercices to improve sleep, increase physical activity, train mindfulness, handle anxiety and to learn about depression.
223642545|NCT04264936|DRUG|RC48-ADC and JS001|Recombinant Humanized anti-HER2(Human epidermal growth factor receptor-2) Monoclonal Antibody-MMAE(Monomethyl Auristatin E) Conjugate For Injection and JS001 Injection
224230174|NCT01106872|DRUG|Bevacizumab, Gemcitabine, Docetaxel and Valproic Acid|
224230175|NCT02212405|DEVICE|repetitive Transcranial Magnetic Stimulation|Each participant will participate in all three arms to receive sham, 1hz and 10hz rTMS as well as PET imaging.
224230176|NCT02212405|OTHER|repetitive Transcranial Magnetic Stimulation Sham|The sham coil is built in the same helmet of the active coil. The sham coil is has a circular shape and placed perpendicular to the scalp within the same helmet. This coil produces a similar sound and scalp sensation as the real coil.
224319616|NCT02455518|DRUG|Ibuprofen/acetaminophen|
223642546|NCT01750229|DEVICE|Sham|Frequency Setting - Sham
223642547|NCT01750229|DEVICE|1200 Hz|Frequency Setting - 1200 Hz
223642548|NCT01750229|DEVICE|3030 Hz|Frequency Setting - 3030 Hz
223642549|NCT01750229|DEVICE|5882 Hz|Frequency Setting - 5882 Hz
223642550|NCT02346721|DRUG|SOF/VEL|400/100 mg tablet administered orally once daily
223642551|NCT03439228|DEVICE|Lumbar brace|3 months of lumbar brace wear
223765503|NCT00003694|DRUG|omacetaxine mepesuccinate|Given IV
223765504|NCT00003694|DRUG|cytarabine|Given IV
223642552|NCT06410092|DRUG|FTL001|IV infusion every 2 weeks
223642553|NCT02941601|DRUG|Necitumumab|Administered IV
224319617|NCT02382861|DEVICE|Neurally adjusted ventilatory assist|In the NAVA group, the level of NAVA is daily adjusted to obtain Eadimax corresponding to 60 % of Eadimax of the patient during the SBT to obtain a good clinical and biologic tolerance, with a respiratory frequency between 15 and 30/min and a tidal volume at 6ml/kg.
223642554|NCT02941601|DRUG|Gemcitabine|Administered IV
223765505|NCT00003694|OTHER|laboratory biomarker analysis|Correlative studies
223765506|NCT03791658|OTHER|The 12-question TAI|The 12-question TAI (Test for the Adherence to Inhalers) yields a score indicating level of adherence (high, intermediate or poor). The TAI also provides some indication about the possible mechanisms of non-adherence (sporadic, deliberate or unconscious).
223765507|NCT03791658|OTHER|Information from patients file|Depending on which arm or group specific information will be gathered from the patients file after informed consent.
224230177|NCT02708277|DEVICE|loop-shaped intrauterine contraceptive device|Intrauterine contraceptive device can temporary protective layer between the endometrium wound during the most critical three weeks after the surgery to prevent adhesion reformation.
223642555|NCT02941601|DRUG|Carboplatin|Administered IV
223642556|NCT03440164|OTHER|Sylimarin and Sylibin|We compared the plasma levels of Silibinin after a dosage of Silibinin-phosphatidylcholine complex, equivalent to 45 mg Silybin oily-medium soft-gel capsules after the conventional 70-mg Silymarin tablets, in 23 healthy volunteers
223642557|NCT05919173|DRUG|Bupivacaine Hydrochloride 0.25% Injection Solution|Bupivacaine Hydrochloride 0.25% Injection Dose: 1mL/kg (milliliter per kilogram body weight)
223765508|NCT03791658|OTHER|The Asthma Control Test (ACT)|An international validated questionnaire on the symptoms an asthmatic experiences and the disease control in the patient. Only for the Asthmatics arm of the study
224230178|NCT02708277|DEVICE|intrauterine balloon (Cook Medical)|The balloons used in this study is heart- shaped that resembled the shape of the uterine cavity and could fully separate the two sides of the uterine wall and the corners of the uterus compare to loop-shaped intrauterine contraceptive device.
224230179|NCT01058421|PROCEDURE|intensive physical therapy|four week course of daily intensive physical therapy
224230180|NCT01058421|PROCEDURE|control group|four weeks of routine physical therapy
224319618|NCT02382861|DEVICE|Noninvasive pressure support ventilation|In the control group, the PSV is decreased of 2cmH2O daily or several times a day to obtain a good clinical and biologic tolerance, with a respiratory frequency between 15 and 30/min and a tidal volume at 6ml/kg.
224319619|NCT01313585|DRUG|Initiation of beclometasone via the Easibreathe device plus salbutamol via the Easibreathe device|
224319620|NCT01313585|DRUG|Initiation of beclometasone via the Easibreathe device plus salbutamol via and MDI device|
224319621|NCT01313585|DRUG|Increase of beclometasone via the Easibreathe device plus salbutamol via the Easibreathe device|
224319622|NCT01313585|DRUG|Increase of beclometasone via the Easibreathe device plus salbutamol via an MDI|
223642558|NCT05919173|DRUG|Bupivacaine Hydrochloride 0.25% Injection plus Dexmedetomidine 1 microgram/kg body weight|Bupivacaine HCL 0.25% Injection plus Dexmedetomidine 1micro/kg Dose: 1 mL/kg (milliliter per kilogram body weight)
223642559|NCT05039983|OTHER|EGCG|EGCG use various concentrations dissolved in 0.9% saline solution three times a day. A new batch is made up each time. For esophageal application, repeated swallowing of 30 ml of the EGCG solution is indispensable to assure the prolonged presence of drug the esophageal walls.
223642560|NCT00350415|DRUG|Mesalamine|"Asacol 400g/day (400 mg tablet), oral, for 6 weeks~OR~Asacol 4,8 g/day (800 mg table), oral, for 6 weeks"
223642561|NCT05969652|OTHER|Heavy slow resistance training|"Patients will perform the exercises in the concentric and eccentric phases with the maximum amount of weight tolerated at a rate of 3 seconds/repetition. The number of sets\*repetitions is given below. 2-3 minutes rest between sets will be given.~1st week 3\*15 2-3.week 3\*12 4th-5th week 3\*10 6th week 3\*8"
223765509|NCT03791658|OTHER|The COPD Assessment Test (CAT)|An international validated questionnaire on the symptoms a COPD-patient experiences and the disease control in the patient. Only for the COPD arm of the study
223765510|NCT04725461|DEVICE|Low cost lower limb prosthetic socket|"A pre-made 3D printed cylinder used as an outer shell is selected for each subject based on their measurements. The space between the residual limb and the outer shell will be filled with an expanding polyurethane foam (Foam IT 8, Smooth On Inc.) that conforms to the residual limb and bonds with the outer shell to form a strong and lightweight socket. The foam forms a smooth surface against the protective sheath; the socket is fully formed once the foam has hardened to the 3D printed cylinder.~A prefabricated supracondylar suspension cuff made of Dacron or nylon, or a commercially available suspension sleeve may be will be applied to the prosthetic socket to aid in suspension. Commercially available components, including the International Committee of the Red Cross (ICRC) transtibial polypropylene component system will be attached to the bottom of the socket to allow the patient to ambulate in the prosthesis."
223765511|NCT04209361|OTHER|Questionnaire|Data will be obtained through a printed questionnaire for assessment of knowledge, attitude and practice of dentists at military hospitals regarding child abuse and neglect. The collected data will be saved and tabulated on a computer and finally will be statistically analyzed.
223765512|NCT05012813|OTHER|Aromatherapy with Essential Oils|Participate in SFIT this is one intervention with aroma therapy with essential Forest oils
223765513|NCT01159964|BIOLOGICAL|Immunotherapeutic GSK2302032A, different formulations|Intramuscular administration
224230181|NCT03279679|PROCEDURE|costoclavicular infraclavicular block|Infraclavicular brachial plexus block will be performed through new costoclavicular space approach under realtime ultrasound guidance with 0.5% ropivacaine
224319623|NCT03852537|DRUG|Methylprednisolone|Methylprednisolone will be administered based on CRP-guided protocol outlined under 'Biomarker-adjusted steroid dosing'.
224319624|NCT03852537|OTHER|Usual Care|Usual care as determined by the patients treatment team.
223642562|NCT05969652|OTHER|Eccentric exercise training|"Among the patients in the eccentric exercise group, only the eccentric phase of the exercises in the HSR group, will be asked to actively engage with the affected party. The eccentric contraction rate will be set to 6 seconds. Each exercise will be done 3 sets of 15 repetitions. In the next week, progress will be made in exercise intensity according to tolerance and 500 g will be added to the previous weight.~will be continued. If patients cannot tolerate the new weight or there is an increase in pain, the same weight will be continued for another week."
223642563|NCT04341870|DRUG|Sarilumab|Sarilumab: 400 mg in a 1 hour - I.V. infusion on D1
224230182|NCT03279679|PROCEDURE|paracoracoid infraclavicular block|Infraclavicular brachial plexus block will be performed through traditional paracoracoid approach under realtime ultrasound guidance with 0.5% ropivacaine
223642564|NCT04341870|DRUG|Azithromycin|Azithromycin: oral administration, 500mg on D1 then 250mg QD on D2 to D5 (total duration 5 days)
223642565|NCT04341870|DRUG|Hydroxychloroquine|Hydroxychloroquine: oral administration, 600mg QD (200mg TID) from D1 to D10 (total duration 10 days)
223642566|NCT03879005|OTHER|renal scintigraphy|"99mTc-DTPA Scintigraphy Five mci of 99mTc-DTPA will be injected by IV route together with diuretic. Dose will be adjusted according to the age and weight of the patients. A total of 20 min dynamic imaging followed by calculation of GFR and SRF according to the built-in processing protocol Gate's method.~99mTc-DMSA scintigraphy Five mci of 99mTc- DMSA will be injected by IV route with adjustment according to age and weight. Static images will be acquired in the posterior, anterior, andposterior oblique projections for 60 s each."
223642567|NCT05125588|DRUG|"Reumoxicam® 15 mg tablets (PJSC Farmak, Ukraine)"|One tablet was administered orally and swallowed at once, without chewing, by study volunteers, followed by 200 ml of water, under fasting condition (after preliminary nocturnal fasting for 12 hours) in the morning at 8:00 hours on Day I Period I and Period II of the study.
223642568|NCT05125588|DRUG|"Movalis 15 mg tablets (Boehringer Ingelheim Ellas A.E., Greece)"|One tablet was administered orally and swallowed at once, without chewing, by study volunteers, followed by 200 ml of water, under fasting condition (after preliminary nocturnal fasting for 12 hours) in the morning at 8:00 hours on Day I Period I and Period II of the study.
223642569|NCT06438653|OTHER|No-intervenyion|No-intervenyion
223642570|NCT04513483|DEVICE|continuous positive airway pressure|CPAP treatment at night. Treat AF as cardiologist's discretion.
223642571|NCT04513483|DEVICE|Placebo|Observation. Treat AF as cardiologist's discretion.
223642572|NCT05778825|DRUG|Oral Minoxidil|minoxidil at a dose of 0.01 (\<40kg) and 0.02 (≥40kg) mg/kg/day
223642573|NCT05778825|OTHER|Placebo|placebo for 4 months
223642574|NCT03809104|OTHER|Virtual reality-based rehabilitation programs|A virtual reality (VR)-based rehabilitation program that lasts for 12 weeks, twice per week, 30 minutes per time. The program was combined with progressive resistant training and functional movement of dominant upper (UE) limb. The device of the VR including one computer, one oculus headset, and one hand-hold sensor. The rehabilitation secession contains 4 different VR games in total, including (1) Leap Motion Blocks (2) Slum Ball VR Tournament (3) VR Super Sports 10th Edition- Basketball (4) VR Super Sports 10th Edition- Soccer.
223642575|NCT06266091|DRUG|M701|Intra-peritoneal infusion of M701 combined with system therapy
223642576|NCT06266091|DRUG|paracentesis|paracentesis combined with system therapy
223642577|NCT02968004|DRUG|MOD-4023|Once weekly subcutaneous injection using pre-filled pen device.
223765514|NCT02165111|DRUG|Onabotulinumtoxin A|
223765515|NCT02165111|DRUG|sterile saline solution|
223765516|NCT02806479|OTHER|Observational: Arrhythmogenic Substrate|
223765517|NCT03080103|PROCEDURE|Laparoscopic or Open appendectomy|Laparoscopic three-port or single-port appendectomy; or conventional McBurney laparotomic appendectomy; or open appendectomy performed through midline incision
223765518|NCT03080103|DRUG|Antibiotic-first therapy|Patients treated with antibiotics as first-line approach
223765519|NCT05984277|DRUG|Volrustomig|Volrustomig
223765520|NCT05984277|DRUG|Pembrolizumab|Pembrolizumab
223765521|NCT05984277|DRUG|Carboplatin|Carboplatin
223765522|NCT05984277|DRUG|Paclitaxel|Paclitaxel
223765523|NCT05984277|DRUG|Pemetrexed|Pemetrexed
224230183|NCT03279679|DEVICE|Ultrasound|All the nerve blocks will be performed under realtime ultrasound guidance
224230184|NCT03279679|DRUG|Ropivacaine|0.5% ropivacaine will be used for the brachial plexus block in both groups.
224230185|NCT01960816|DEVICE|Procedure: thermal coagulation of tissue in the nasal airway|The Vivaer Stylus is used to deliver low-power, temperature-controlled, radiofrequency energy to tissues of the nasal airway to cause coagulation of soft tissues and submucosal tissue shrinkage.
224319625|NCT01038297|DRUG|EXC 001|Intradermal injections of EXC 001 and placebo given on various schedules.
224319626|NCT01038297|DRUG|Placebo|Intradermal injections of EXC 001 and placebo given on various schedules.
224319627|NCT02508935|DRUG|XARTEMIS XR|XARTEMIS XR \[7.5 mg oxycodone hydrochloride and 325 mg acetaminophen (APAP)\] Extended-Release Tablets
223765524|NCT03066765|DEVICE|Linguaflex Tongue Retractor|Tongue implant
223765525|NCT00448422|DRUG|prulifloxacin|Tablet
224230186|NCT04995978|DRUG|Pioglitazone 30 mg|"Subjects will self-administer a 30 mg pioglitazone oral tablet daily for 6 months.~For patient taking a diabetic regimen of gemfibrozil, the dose will be 15 mg daily."
224319628|NCT03203681|DRUG|Natesto|4.5% nasal testosterone. 11.0 mg testosterone administered per dose (2 pump actuations, 1 pump per nostril) applied intranasally three times a day.
224323357|NCT03836105|DRUG|cemiplimab|No investigational agents will be provided to enrolled patients by the sponsor as part of this study. Patients will have recently initiated or be planning to initiate treatment with commercially available cemiplimab for advanced CSCC or advanced BCC in a real-world setting according to respective label indications. In addition to cemiplimab, patients may receive other therapies as deemed necessary by their physicians for the treatment of CSCC or BCC or comorbid conditions.
223765526|NCT01485458|PROCEDURE|Early surgery|Surgery within 24 hours after admission
223765527|NCT01485458|PROCEDURE|Delayed surgery|Surgery more than 2 weeks after injury
223765528|NCT05137795|DRUG|ZYESAMI™ (aviptadil acetate)|Inhaled ZYESAMI™ (aviptadil acetate) 100μg 3x daily by mesh nebulizer
223765529|NCT05137795|DRUG|Placebo|Normal Saline Inhalation
223642578|NCT02968004|DRUG|Somatropin|Once daily subcutaneous injection of Genotropin using pre-filled pen device.
223642579|NCT06205628|DRUG|ADX-850|siRNA duplex oligonucleotide
223642580|NCT06205628|DRUG|Placebo|Saline
223642581|NCT04197921|DEVICE|Exablate Model 4000 Type 2.0/2.1|There are two treatment stages. In both stages, the subject will receive both the sham and active ExAblate treatment, and be evaluated for 90 days post-treatment for adverse events. During Stage 1 the subject will receive the moderate intensity Exablate LIFU procedure. During Stage2, the subject will receive the enhanced intensity ExAblate LIFU procedure. The subjects are blinded as to the order of the sham vs active treatment.
223642582|NCT05121064|BEHAVIORAL|Alcohol Brief Intervention|The alcohol brief intervention (BI) was based on CETA'S substance use module and was designed for one-on-one delivery. It is comprised of 6 elements (i.e. assessment, understanding impacts, exploring possibilities of change, goal setting, identifying reasons for alcohol use and skill building) including a 2-week alcohol timeline follow back assessment completed by provider. The alcohol brief intervention (BI) will be conducted by a trained counselor.
223642583|NCT05121064|BEHAVIORAL|Common Elements Treatment Approach|CETA is a multisession cognitive behavioral therapy (CBT)-based model. CETA consists of elements: engagement, safety assessment, psychoeducation, substance use reduction, behavioral activation, cognitive coping, relaxation, exposure and problem solving. During a weekly clinic meeting, newly enrolled participants who are assigned to get CETA will be assigned to a specific counselor. The counsellor, together with their supervisor, will design an individualized treatment plan including type and order of Common Elements Treatment Approach (CETA) for each participant. The counsellor will contact participants by phone or home visit to schedule CETA session. CETA sessions will begin with standardized clinical monitoring form to track progress of treatment and each session will last 45-90 minutes.
223642584|NCT05121064|BEHAVIORAL|Standard of Care|Standard of Care (SOC) at HIV clinics in Zambia consist of Antiretroviral Treatment (ART) adherence counselling. All participants will receive Standard of Care (SOC), but for participants in Arm C it will be the only alcohol treatment. The ART adherence counseling includes brief unstructured discussion of substance use and mental health issues with a focus on issues that reduce adherence and retention issues. ART adherence counseling is delivered in a one-on-one format between patient and counsellor and it usually lasts 5-10 minutes.
223642585|NCT05531201|PROCEDURE|collaboration general practitioner and physiotherapist|training general practitioner and physiotherapist
223642586|NCT06353893|DEVICE|Anika Integrity Implant System|The implant is a porous, flexible construct knitted using HYAFF® fibers and designed to support cell infiltration and regenerative healing. HYAFF is Anika's proven and proprietary esterified HA technology that resorbs over time as tissue remodels. Integrity is inherently strong and can be confidently manipulated arthroscopically, which offers a truly unique and differentiated solution for shoulder surgeons to treat rotator cuff tears.
223642587|NCT05766813|DRUG|Lenrispodun|Lenrispodun 30 mg tablets administered orally, once daily.
223642588|NCT05766813|DRUG|Placebo|Matching tablets administered orally, once daily.
223642589|NCT02115048|DRUG|Letrozole|
223642590|NCT02115048|DRUG|Afatinib|
223765530|NCT05137795|DEVICE|Nebulized administration of ZYESAMI™ or Placebo|Use of 510(k) cleared mesh nebulizer to deliver investigational product
223765531|NCT05896839|PROCEDURE|Biopsy Procedure|Undergo tumor biopsy
223765532|NCT05896839|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
224230187|NCT04995978|DRUG|placebo tablet|Subjects will self-administer an oral placebo tablet containing cellulose daily for 6 months.
224230188|NCT00042497|BIOLOGICAL|autologous dexosomes loaded with tumor-specific peptides|
224230189|NCT06294171|DEVICE|measurement of alveolar ridge width|the surgical procedure started with envelop flap reflection. A mucoperiosteal elevator was used to reflect the buccal and palatal flaps that were enough to expose the crestal part of alveolar ridge with clear visibility and accessibility. Measuring the width of the alveolar ridge 1 mm below the crest using bone caliber. Using piezoelectric surgery unit (Piezosurgery Ultrasonic® mectron, Italy), a horizontal crestal cut was produced along the crest of the bone. The cut depth extended into the same depth of the final dental implant to be inserted and then Versah Drills will be used in a successive manner and under copious irrigation with chilled sterile normal saline.We will measure the rate of ridge expansion by bone caliber to determine the efficacy of combining Versah drills with piezo surgery in expanding narrow alveolar bone.
224230190|NCT00748007|DRUG|Rivastigmine|Exelon (1.5mg/cap) 1.5 mg bid
224230191|NCT01118728|DRUG|Sarilumab|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
224230192|NCT00408733|OTHER|Medication Education Tool|Picture and Icon-based Customizable Educational Tool
223765533|NCT05896839|PROCEDURE|Computed Tomography|Undergo CT scan
223765534|NCT05896839|BIOLOGICAL|Ipilimumab|Given IV
223765535|NCT05896839|PROCEDURE|Kidney Biopsy|Undergo kidney biopsy
223765536|NCT05896839|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223765537|NCT05896839|BIOLOGICAL|Nivolumab|Given IV
223765538|NCT05896839|DRUG|Prednisone|Given PO
223765539|NCT05896839|DRUG|Sirolimus|Given PO
223765540|NCT02171598|DRUG|Clopidogrel|
223765541|NCT02171598|DRUG|Dabigatran high dose|
224230193|NCT02417090|DRUG|Insulin|Pregnant women who used insulin to treat gestational diabetes
224230194|NCT02417090|DRUG|Metformin|Pregnant women who used metformin to treat gestational diabetes
224230195|NCT04898985|DIAGNOSTIC_TEST|ImmunoSEQ|experiment assay
224230196|NCT03665571|DIAGNOSTIC_TEST|Receptor specific activation method|NK cell was incubated with P815-ULBP1+CD48 cells that trigger NK cell synergy via NKG2D and 2B4
224230197|NCT00274209|PROCEDURE|Chromoendoscopy with magnification|A blue dye (indigo carmine) will be sprayed prior to imaging the bowel lining using a zoom colonoscope. The dye is not absorbed and is safe for human use.
223765542|NCT02171598|DRUG|Dabigatran low dose|
223765543|NCT03594591|DRUG|Antidiabetic treatment by usual care|Observation of changes in the microcirculation after optimization of antidiabetic therapy by usual care.
223765544|NCT02569047|PROCEDURE|Atraumatic Restorative Treatment|No local anaesthesia will be used. Infected carious tissue will be removed with hand instruments, and the cavities restored with Glass Ionomer Cement (GIC).The cavity will be filled with GIC. After the press-finger technique, the excess of material will be removed.
223642591|NCT06132945|DRUG|Cabozantinib|Cabozantinib (40 mg PO daily)
223642592|NCT06132945|DEVICE|Nivolumab|Nivolumab (480 mg IV Day 1)
223642593|NCT06132945|RADIATION|Stereotactic Radiosurgery (SRS)|Radiation will be stereotactic radiosurgery, delivered over 1-5 fractions with a total dose of 18-30Gy depending on fractionation schedule per the discretion of the treating radiation oncologist.
223642594|NCT05327296|DRUG|Isoflurane|Inhaled isoflurane administered by Sedaconda ACD-S
223642595|NCT05327296|DRUG|Propofol|Intravenous infusion of propofol
223642596|NCT06526039|OTHER|a novel short regimen|An intensive phase consisting of isoniazid, bedaquiline, moxifloxacin and pyrazinamide for 2 months (9 weeks). A continuation phase consisting of isoniazid, bedaquiline, and levofloxacin for 4 months (17 weeks). Treatment may be extended for 3 months (13 weeks) in patients with severe disease or with delayed culture conversion, defined by culture positive at 4 months of treatment.
224230198|NCT03336983|DRUG|Zoledronic Acid|Prostate cancer patients with hormone sensitive metastatic bone disease will be treated with LHRH-A + Enzalutamide in the presence or absence of Zoledronic Acid
224230199|NCT03336983|DRUG|Enzalutamide|Patients from both arms will be treated with LHRH-A + Enzalutamide
224230200|NCT00385541|DRUG|Morphine PCA|Morphine 1mg/mL, dose 1mL, lockout 6 minutes, max 10mL
224230201|NCT00385541|DRUG|Hydromorphone PCA|hydromorphone PCA 0.2mg/lml, dose 1ml, lockout 6min, max 10ml
224230202|NCT00929708|DRUG|AZD3199|Dry powder for inhalation, o.d., 4 weeks
224230203|NCT00929708|DRUG|formoterol|Dry powder for inhalation, b.i.d., 4 weeks
224230204|NCT00929708|DRUG|Placebo|Dry powder for inhalation, b.i.d., 4 weeks
224230205|NCT01893138|OTHER|Placebo|Placebo control is the vehicle solution used for the study product.
224230206|NCT01893138|BIOLOGICAL|Iltamiocel|AMDC is the study product (autologous muscle-derived cells). The generic name is iltamiocel. Single intraurethral injection of 150 x 10\^6 cells.
224230207|NCT00824460|DRUG|1.25 g PA21 (250 mg iron)|Daily dose of 1.25 g PA21 (1 tablet/day) for 6 weeks. One PA21 tablet will be taken orally with the largest meal of the day.
224230208|NCT00824460|DRUG|5.0 g PA21 (1,000 mg iron)|Daily dose of 5.0 g PA21 (4 tablets/day) for 6 weeks. Two PA21 tablets will be taken orally with the largest meal of the day, and one PA21 tablet will be taken orally with each of the two smaller main meals of the day (3 meals per day).
224230209|NCT00824460|DRUG|7.5 g PA21 (1,500 mg iron)|Daily dose of 7.5 g PA21 (6 tablets/day) for 6 weeks. Two PA21 tablets will be taken orally with each of the three main meals of the day (3 meals per day).
224230210|NCT00824460|DRUG|10.0 g PA21 (2,000 mg iron)|Daily dose of 10.0 g PA21 (8 tablets/day) for 6 weeks. Four PA21 tablets will be taken orally with the largest meal of the day, and two PA21 tablets will be taken orally with each of the two smaller main meals of the day (3 meals per day).
224230211|NCT00824460|DRUG|12.5 g PA21 (2,500 mg iron)|Daily dose of 12.5 g PA21 (10 tablets/day) for 6 weeks. Four tablets will be taken orally with the largest meal of the day, and three PA21 tablets will be taken orally with each of the two smaller main meals of the day (3 meals per day).
224230212|NCT00824460|DRUG|Sevelamer hydrochloride|Daily dose of 4.8 g Sevelamer hydrochloride (6 tablets/day) for 6 weeks. Two Sevelamer tablets will be taken orally with each of the three main meals of the day (3 meals per day).
224323358|NCT03965481|RADIATION|Dynamic Enhanced CT|Undergo standard CECT
223642597|NCT04417517|DRUG|evorpacept|Fusion protein that blocks CD47-SIRPalpha pathway
223642598|NCT04417517|DRUG|azacitidine|Hypomethylating agent (HMA)
223642599|NCT02740023|DEVICE|Hearing Aid (Phonak Audéo V90-13)|Phonak's Receiver-In-the-Canal (RIC) hearing aid Audéo V90-13 will be fitted to the participants individual Hearing loss.
223642600|NCT02740023|DEVICE|Hearing Aid (Successor of Phonak Audéo V90-13)|The successor of Phonak's Receiver-In-the-Canal (RIC) hearing aid Audéo V90-13 will be fitted to the participants individual Hearing loss.
223642601|NCT03754777|PROCEDURE|Laparoscopic appendectomy|"Preoperative care in both arms. Crystalloid isotonic solutions and antibiotic prophylaxis 30 min prior to surgery.~Surgery. General anesthesia with strict control of fluid therapy and hemodynamic changes during surgery. Appendectomy with the use of monopolar coagulation by experienced surgeons following appendix stump ligation by two Roeder knots.~Postoperative care. Antibiotics for 3-5 days for patients with complicated appendicitis (Gomez ≥ 3A). The postoperative pain level evaluation in rest by VAS in 0 h (immediately after awakening), 2, 6, 12 and 24 h postop. The postoperative analgesic modality on demand: Ketorolac 30 mg for patients with VAS pain level ≥ 5 cm. Antiemetics in dyspepsia. No iv infusions postoperatively. Intestinal peristalsis evaluation by auscultation every 2 h after surgery."
223642602|NCT00664625|DRUG|BMS-791325|Capsules, Oral, Once Daily, Single Dose
223642603|NCT00664625|DRUG|Placebo|Capsules, Oral, Once Daily, Single Dose
223642604|NCT00093041|DRUG|Zalutumumab|Weekly infusion
224230213|NCT04786652|DEVICE|estimated stroke volume variation (esSVV, Nihon Kohden, Japan)|Assessment of the estimated stroke volume variation (esSVV, Nihon Kohden, Japan) in the early postoperative period after OPCAB
224230214|NCT04786652|DIAGNOSTIC_TEST|Assessment of fluid responsiveness in mechanically ventilated patients after OPCAB|In mechanically ventilated patients after OPCAB within two hrs after intervention: passive leg raising (PLR), increased PEEP, and mini-fluid load (mFL) tests will be followed by standard fluid load (sFL). Monitoring: SVVPCA, PPVPCA, esSVV, HLI, PVI, pre-ejection fraction (PEP, echocardiography), CIPCA, esCI and CISTD. Transthoracic echocardiography will be performed to assess the volume of heart chambers, ejection fraction and pre-ejection phase (PEP).
224230215|NCT04786652|DIAGNOSTIC_TEST|Assessment of fluid responsiveness in spontaneously breathing patients at 18 hrs of the postoperative period|2\) In spontaneously breathing patients at 18 hrs of the postoperative period: PLR, and mFL tests followed by sFL. Monitoring: SVVPCA, PPVPCA, esSVV, PVI, PEP, CIPCA, esCI and CISTD. Transthoracic echocardiography will be performed to assess the volume of heart chambers, ejection fraction and pre-ejection phase.
224230216|NCT00202449|DRUG|prazosin|taken by mouth, twice daily, titrated up to efficacy or a maximum of 5 mg at 10a and 25 mg at bedtime for duration of study
224230217|NCT00202449|DRUG|paroxetine|20 mg taken at 10a for duration of the study
224230218|NCT00202449|DRUG|Placebo|Placebo
224230219|NCT01604681|DIETARY_SUPPLEMENT|Placebo|6 capsules per day, thirty minutes before lunch and dinner, eating 3 capsules (3 g) at a time.
224323359|NCT03965481|PROCEDURE|Magnetic Resonance Imaging|Undergo PET/MRI scan
224323360|NCT03965481|PROCEDURE|Positron Emission Tomography|Undergo PET/MRI scan
223642605|NCT02446522|PROCEDURE|Open vein harvesting|Open vein harvesting was performed as a continuous incision under vision control. The GSV was identified two fingers proximal to the medial malleolus according to the standard practice. The vein was harvested using Metzenbaum scissors, and a continuous incision was made along the route of the vein. Care was taken not to traumatize the nerve, vein or its branches. Vein branches were ligated with titanium clips. The wound was closed in layers with continuous 2-0 Polysorb sutures and 3-0 skin sutures.
224230220|NCT01604681|DIETARY_SUPPLEMENT|Flaxseed Oil|6 capsules per day, thirty minutes before lunch and dinner, eating 3 capsules (3 g) at a time.
224230221|NCT05782790|BEHAVIORAL|Action Observation Theraphy Group|"In this method, patients will be seated in a comfortable chair in front of a 32-inch television placed approximately 2 meters away in a quiet room. On television, videos that will be used in swallowing rehabilitation prepared on realistic animations and/or real models will be shown to the patients. Patients will be asked to watch these exercise videos for 20 minutes with their full attention and concentrate on how the actions are done.~Evaluations to be made before starting the treatment program and finished; demographic information, Standardized Mini Mental Test, Turkish Eating Assessment Tool, Videofluoroscopic Swallowing Study (VFYC), Penetration Aspiration Scale (PAS), Evaluation of Swallowing Ability and Function, Surface Electromyographic Measurements of Suprahyoid Muscles, Swallowing Quality of Life Questionnaire, Beck Depression Scale."
224230222|NCT05782790|BEHAVIORAL|Classic Swallowing Exercise Group|Exercises include positioning, swallowing maneuvers, food modification, and swallowing exercises, which are sensory stimulation, oral motor exercises, head-neck mobilization, Shaker exercises, and neck region and tongue strengthening exercises, which are compensatory strategies according to the swallowing rehabilitation program accepted in the literature. Evaluations to be made before starting the treatment program and finished; demographic information, Standardized Mini Mental Test, Turkish Eating Assessment Tool, Videofluoroscopic Swallowing Study (VFYC), Penetration Aspiration Scale (PAS), Evaluation of Swallowing Ability and Function, Surface Electromyographic Measurements of Suprahyoid Muscles, Swallowing Quality of Life Questionnaire, Beck Depression Scale.
224230223|NCT01045590|DRUG|titration|Patients in the glibenclamide plus placebo treatment group Patients in the glibenclamide plus placebo treatment group who have FPG \< 270mg/dL after the glibenclamide 5mg om run-in will continue to receive glibenclamide 5mg om. At every subsequent visit, the glibenclamide dose will be titrated to achieve the target HbA1c level of \< 7%. If the HbA1c is \> 7%, the dose of glibenclamide will be escalated in the following sequence: from 5mg om, to 5mg om, 2.5mg on, to 5mg bd and 7.5mg om, 5mg on, to 7.5mg bd. The maximum total daily dose will not exceed 15 mg. A downward titration of glibenclamide using the above sequence in the reverse order can be used to maintain normoglycemia at any visit. Once the target HbA1c level of \< 7% is achieved, the dose of glibenclamide is maintained. If at the glibenclamide dose of 7.5mg bd, the HbA1c is \> 7% for 2 subsequent visits, the patient will be withdrawn from the study.
224230224|NCT01045590|DRUG|titration|Patients in the glibenclamide + rosiglitazone treatment group who have FPG \< 270mg/dL after the glibenclamide 5mg om run-in will receive glibenclamide 5mg om + rosiglitazone 4mg om. At every subsequent visit, the glibenclamide dose will be titrated to achieve the target HbA1c level of \< 7%. If the HbA1c is \> 7%, the dose of glibenclamide will be escalated in a similar fashion as above. The only exception is at visit 5 when the dose of rosiglitazone is increased (see next paragraph). Once the target HbA1c level of \< 7% is achieved, the dose of glibenclamide is maintained. If at the glibenclamide dose of 7.5mg bd, the HbA1c is \> 7% for 2 subsequent visits, the patient will be withdrawn from the study.
224230225|NCT02586103|DEVICE|MRI simulation|It is not a working MRI machine but sounds and feels just like the real machine.
223765545|NCT02569047|PROCEDURE|Hall Technique|It employs the cementation of preformed metal crowns (PMC) without the need of any prior teeth preparation or caries removal. No local anesthesia is used neither tooth preparation.Different sizes of PMCs will be tested until the smallest size that perfectly fit the tooth is achieved. The PMC will be loaded with the dental material glass ionomer cement (GIC) and placed. Child will asked to bite firmly on it, until it is fitted. The excess of GIC will be removed with hand instruments and dental floss.
224230226|NCT05228314|BIOLOGICAL|Candidate vaccine, SCB-2020S|a recombinant SARS-CoV-2 trimeric S-protein (from beta variant) subunit vaccine for COVID-19
224230227|NCT05228314|BIOLOGICAL|Candidate vaccine, SCB-2019|a recombinant SARS-CoV-2 trimeric S-protein subunit vaccine for COVID-19
224230228|NCT05228314|OTHER|Squalene based adjuvant|Squalene based adjuvant
224230229|NCT05228314|OTHER|CpG/alum adjuvant|CpG/alum adjuvant
224230230|NCT02689908|RADIATION|computed tomography|low dose protocol of thorax ct
224230231|NCT04983121|DRUG|Next-generation Site-specific human epidermal growth factor receptor 2 (HER2)-targeting Antibody-drug Conjugate (ARX788)|The subjects who sign an informed consent will enter the treatment period after screening. Each eligible subject will receive pyrotinib, 320 mg once a day, with 21 days as a session, for 6 sessions in total before operation. Next-generation Site-specific human epidermal growth factor receptor 2 (HER2)-targeting Antibody-drug Conjugate (ARX788) will be intravenously injected at a dose of 1.5 mg/kg, once every 3 weeks, with 21 days as a session, for 6 sessions before surgery. Breast MRI and other imaging examinations will be reviewed every 2 sessions to evaluate the curative effect, and the patient's baseline will be defined based on the imaging report at the time of enrollment. If a definite effect (complete response/partial response) is achieved, surgical treatment will be performed within 4 weeks (\> 2 weeks) after completion of 6 sessions of neoadjuvant therapy.
224230232|NCT02377336|DRUG|GS-6615|GS-6615 tablets administered orally
224230233|NCT02377336|DRUG|Placebo|Placebo to match GS-6615 tablets administered orally
224230234|NCT03604419|DRUG|PB-119 100 μg+ Glucophage®|Each patient will subsequently be randomized within the designated cohort to active drug or placebo
224319629|NCT05896735|PROCEDURE|Ultrasound-guided axillary vein catheterization|All axillary vein catheterizations were performed according to standard central venous catheterization procedures, which were performed under ultrasound guidance at the bedside. Before the operation, patients were placed in a supine position with the upper limb placed in a natural position, and the ultrasound probe and wires were wrapped with a sterile protective sheath. Ultrasound pre-scanning the axillary artery and axillary vein, and pay attention to using the minimum pressure to control the ultrasound probe to avoid crushing the blood vessels. The operator holds the ultrasound probe and puncture needle to puncture the axillary vein under the guidance of ultrasound. After drawing out of the dark red blood, the guide wire was inserted and the puncture needle was withdrawn. The three-lumen CVC catheter was then inserted using the Seldinger technique.
223642606|NCT02446522|PROCEDURE|Endoscopic vein harvesting|Endoscopic vein harvesting was performed through minimal incisions with use of Vasoview 6 system (Maquet Medical Systems, Wayne, NJ, USA.) The vein was identified through a 3 cm incision below the knee. The incision site was sealed using a balloon port to create a tunnel inside the leg. A second unit with cautery was inserted via the port to cut and seal the tributary branches. A 1 cm skin incision was made near the groin to ligate the distal end of the GSV and remove the vein, which was checked for leakage. The wound was closed with 3-0 skin sutures
223642607|NCT03397069|PROCEDURE|Peribulbar block (control)|"The Peribulbar block was performed by inserting the needle percutaneously at the area bounded by 1- The imaginary perpendicular line joining inferior lacrimal papilla to the inferior margin of the orbit, laterally 2- Lateral border of the nose, medially 3- Inferior lacrimal canaliculus, superiorly and 4- Inferior orbital margin, inferiorly. The needle was introduced in an anteroposterior direction to its half-length and then in an oblique direction to the optical foramen.~After negative aspiration, 6-8 ml of local anesthetic solution (lidocaine 2%, hyaluronidase 15 IU / ml ) was injected slowly over about 40 seconds or until the appearance of lid fullness. This was followed by a gentle digital massage to the eyeball to facilitate diffusion of the local anesthetic mixture."
223642608|NCT03397069|PROCEDURE|Peribulbar block(M1)|"The Peribulbar block was performed by inserting the needle percutaneously at the area bounded by 1- The imaginary perpendicular line joining inferior lacrimal papilla to the inferior margin of the orbit, laterally 2- Lateral border of the nose, medially 3- Inferior lacrimal canaliculus, superiorly and 4- Inferior orbital margin, inferiorly. The needle was introduced in an anteroposterior direction to its half-length and then in an oblique direction to the optical foramen.~After negative aspiration, 6-8 ml of local anesthetic solution (lidocaine 2%, hyaluronidase 15 IU / ml. plus midazolam 50 µg/ml ) was injected slowly over about 40 seconds or until the appearance of lid fullness. This was followed by a gentle digital massage to the eyeball to facilitate diffusion of the local anesthetic mixture."
223642609|NCT03397069|PROCEDURE|Peribulbar block(M2)|"The Peribulbar block was performed by inserting the needle percutaneously at the area bounded by 1- The imaginary perpendicular line joining inferior lacrimal papilla to the inferior margin of the orbit, laterally 2- Lateral border of the nose, medially 3- Inferior lacrimal canaliculus, superiorly and 4- Inferior orbital margin, inferiorly. The needle was introduced in an anteroposterior direction to its half-length and then in an oblique direction to the optical foramen.~After negative aspiration, 6-8 ml of local anesthetic solution (lidocaine 2%, hyaluronidase 15 IU / ml. plus midazolam 100 µg/ml ) was injected slowly over about 40 seconds or until the appearance of lid fullness. This was followed by a gentle digital massage to the eyeball to facilitate diffusion of the local anesthetic mixture."
223765546|NCT06534333|OTHER|Ultrasonography|musculoskeletal ultrasonography
224230235|NCT03604419|DRUG|PB-119 150 μg+ Glucophage®|Each patient will subsequently be randomized within the designated cohort to active drug or placebo
223765547|NCT02152995|PROCEDURE|Computed Tomography|Undergo iodine I-124 PET/CT
223765548|NCT02152995|OTHER|Iodine I 124|Undergo iodine I-124 PET/CT
224230236|NCT03604419|DRUG|PB-119 200 μg+ Glucophage®|Each patient will subsequently be randomized within the designated cohort to active drug or placebo
224230237|NCT03604419|DRUG|PB-119 placebo + Glucophage®|Each patient will subsequently be randomized within the designated cohort to active drug or placebo
223765549|NCT02152995|RADIATION|Iodine I-131|Given PO
223765550|NCT02152995|OTHER|Laboratory Biomarker Analysis|Correlative studies
223765551|NCT02152995|OTHER|Pharmacodynamic Study|Correlative studies
223765552|NCT02152995|PROCEDURE|Positron Emission Tomography|Undergo iodine I-124 PET/CT
223765553|NCT02152995|DRUG|Trametinib|Given PO
223765554|NCT04971850|OTHER|Sleep study|"Procedures added by research during PSG :~* SDB screening questionnaires~* Electromyography (EMG) of accessory and abdominal muscles~* Cerebral oxygenation~* Mandibular movements~* Sleep headband (pre-teens and teens) or other connected device~* Automatic PSG analyzes~* Psychological and neuropsychological assessment The recordings of the study will be repeated at one year if the patient needs a treatment (surgery or noninvasive ventilation) following the results of the PSG."
223765555|NCT03679871|OTHER|Questionnaire validation|"Participants will fill in the questionnaire Spiritual Resources and Distressplus additional questionnaires required for validation purposes. Three weeks later, a sub-sample will fill in the questionnaire one more time for consistency testing (test-retest)"
223765556|NCT00496847|DRUG|PERIOGEN|Implantation of rhPDGF-BB (0.3 mg/ml) + β-TCP (0.5 g)
223765557|NCT00496847|DRUG|Beta TCP alone|Implantation of β-TCP (0.5 g) alone
223765558|NCT00747968|DRUG|Byetta, Exenatide|Drug: Exenatide or placebo Dosage form: Infusion Dosage: Exenatide (Eli Lilly/Amylin Pharmaceuticals) 0.066 pmol\*kg-1\*min-1 Duration: 5 hours Frequency: Drug given once, placebo given once
223765559|NCT04123496|DEVICE|rTMS|Device: Repetitive Transcranial Magnetic Stimulation (rTMS) MagVenture MagPro TMS System would be utilized to deliver 3-minute sessions of intermittent theta burst to left dorsolateral prefrontal cortex.
223765560|NCT03728894|DRUG|Midazolam-hydroxyzine with 100% O2|Patients received Oral Sedatives with 100% O2 ,Behavior was assessed using the modified Houpt behavioral rating scale, by evaluating the videotapes of all patients at both the pretreatment and treatment phases.
223765561|NCT03728894|DRUG|Midazolam-hydroxyzine with 50% N2O/O2|Patients received Oral Sedatives with 50% nitrous ,Behavior was assessed using the modified Houpt behavioral rating scale, by evaluating the videotapes of all patients at both the pretreatment and treatment phases.
224230238|NCT03329027|DEVICE|Vibrating Capsule|Patients will receive vibrating capsule for 8 weeks of treatment (5 capsules/week)
224230239|NCT03329027|DEVICE|Sham capsule|Patients will receive vibrating capsule for 8 weeks of treatment (5 capsules/week)
224319630|NCT01973595|DIETARY_SUPPLEMENT|Almonds, Then no almonds|Whole, raw almonds with skin, or whole, raw almonds with skin that have been ground into a paste.
224230240|NCT01802502|DRUG|Rifampicin intravenous|
224230241|NCT01802502|DRUG|Oral rifampicin|
224230242|NCT04089982|DRUG|Varenicline|Chantix
224230243|NCT04089982|DRUG|Placebo oral tablet|Placebo
224319631|NCT01973595|OTHER|No Almonds, Then almonds|No almonds will be consumed by participants for 3 weeks.
224319632|NCT04581330|DEVICE|DEKA SmartXide C02 laser|One pass with a 1-mm spot density and a 60 micron depth will be performed followed by a 1-mm spot density and a 200 micron depth will be used
224319633|NCT02859753|OTHER|Percutaneous Radiofrequency Ablation|
223642610|NCT05108012|BIOLOGICAL|NK cell therapy|Activated NK cell injection in tumor cavity of patient with GBM (Glioblastoma Multiform)
223642611|NCT03408392|DRUG|Test formulation A|Test formulation: SKF101804 will be available as oral suspension supplied as powder for reconstitution (Off-white to cream coloured powder). Subjects will receive single dose of 5 mL of suspension thus receiving 200 mg dose of cefixime. The suspension is a white to off white viscous suspension with a fruit flavor and odor.
223642612|NCT03408392|DRUG|Reference formulation B|Reference formulation will be available as oral suspension supplied as powder for reconstitution (Off-white to cream coloured powder). Subjects will receive single dose of 5 mL of suspension thus receiving 200 mg dose of cefixime. The suspension is a white to off white viscous suspension with a strawberry flavor and odor.
223642613|NCT01082068|DRUG|XL147 (SAR245408)|given orally once daily as tablets
223642614|NCT01082068|DRUG|XL765 (SAR245409)|given orally twice daily as capsules
223642615|NCT01082068|DRUG|letrozole (Femara)|given orally once daily as tablets
223642616|NCT04668456|DRUG|Dexmedetomidine|the drug administered either subtenon ot iv
223765562|NCT03072485|DRUG|Sirolimus|Topical sirolimus applied to the skin
223765563|NCT03072485|DRUG|Metformin|Topical metformin applied to the skin
223765564|NCT03072485|DRUG|Diclofenac|Topical diclofenac applied to the skin
224230244|NCT02730078|BEHAVIORAL|VEMOFIT|The VEMOFIT intervention involves four biweekly two hours sessions over a period of about six weeks, and a booster at three months follow-up. It consists of a mixture of 1) exploring illness perceptions and personal meanings of diabetes, 2) cognition-focused education on diabetes and practical skills in self-management and 3) emotion-focused training on recognising emotions in the self and others. Each group will consist of 10 to 12 participants of equal representation by the patients and their significant others.
224230245|NCT02730078|BEHAVIORAL|Attention-meetings (AG)|Patients in the health clinics randomised to the AG, will receive the usual T2D care by the clinic doctors and education by the clinic paramedics based on the recommendations in the Malaysian clinical guidelines. At T1, T2 and T4, patients (not including their significant others) in AG will be gathered in groups of 10-12 people for the primary and secondary outcomes evaluation. This session will include general discussion on feeling about and coping with T2D, social support at home and satisfaction with treatment and care received at the respective clinics.
224230246|NCT01535326|PROCEDURE|air insufflation|insufflate air during the insertion of colonoscopy
224230247|NCT01535326|PROCEDURE|water immersion|infuse water during insertion, aspirate water during withdrawal
224230248|NCT01535326|PROCEDURE|water exchange|infuse and remove water during insertion phase of colonoscopy
224230249|NCT01806922|BEHAVIORAL|Yoga|
223642617|NCT04668456|DRUG|lidocaine 2%|subtenon injection
223642618|NCT04668456|DRUG|bupivacine 0.5%|subtenon injection
223642619|NCT04668456|DRUG|Normal saline|either subtenon or iv
223642620|NCT06300112|BEHAVIORAL|YOGA|Yoga will be applied to the experimental group for a total of 12 sessions, two sessions per week (90 minutes) for six weeks.
223642621|NCT03303976|BIOLOGICAL|Bioconjugate pneumococcal vaccine|Bioconjuagte vaccine against bacterial pneumococcal infection
223642622|NCT03303976|BIOLOGICAL|Multivalent plain polysaccharide vaccine|Multivalent plain polysaccharide vaccine against bacterial pneumococcal infection
223765565|NCT00145054|BEHAVIORAL|MoodHelper Internet program for Depression Self-Help|
223765566|NCT03334006|DRUG|Pentaglobin®/Standard of Care|Standard-of-Care treatment + Pentaglobin®
223765567|NCT06585137|OTHER|Web-Based Mind-Body Awareness Program|The program has been developed in line with peer-reviewed literature and expert opinions. It will incorporate a nursing approach based on the Meleis transition theory, education, mind-body awareness practices, and messages specific to women's health. Participants will be involved in an awareness program consisting of 3 sessions over an average of 2 weeks. Participants will be asked to complete their first final test one day after the egg retrieval (OPU) procedure, i.e., an average of 8-12 days after ovulation induction. There will be no intervention between the embryo transfer and the pregnancy test day. During this time period, interactive sessions between the researcher and participants will be conducted, and nursing care will be provided according to Meleis. The implementation phase of the study will be completed with 39 participants after the second final test following the pregnancy test.
223765568|NCT01952522|BEHAVIORAL|Weighted brace|People will have to wear all the day additional weights (between 2 and 4 kilograms) at the nonparetic ankle during 3 months
223765569|NCT01952522|BEHAVIORAL|Non weighted brace|People will be given a brace with no weight they will have to wear all the day during three months.
224230250|NCT02761980|DRUG|Ibuprofen 250 mg / Acetaminophen 500 mg|Ibuprofen 250 mg / Acetaminophen 500 mg
224230251|NCT02761980|DRUG|Ibuprofen 250 mg|Ibuprofen 250 mg
224230252|NCT02761980|DRUG|Acetaminophen 500 mg|1 APAP 500 mg caplet
223642623|NCT00885170|DRUG|Odanacatib|Odanacatib 50 mg tablets once weekly for 24 months
223642624|NCT00885170|DRUG|Placebo|Placebo to odanacatib 50 mg tablets once weekly for 24 months
223642625|NCT00885170|DIETARY_SUPPLEMENT|Vitamin D3|Vitamin D3, two 2800 IU tablets, taken once weekly for 24 months
223642626|NCT00885170|DIETARY_SUPPLEMENT|Calcium|Participants will receive calcium carbonate supplements as needed to ensure a daily calcium intake of 1200 mg.
223642627|NCT06204640|DRUG|Spironolactone|Spironolactone will be start at 25 mg per day initially then titrated to a maximum of 50 mg per day in the absence of contraindication at the 1-month study visit.
223642628|NCT03771664|DRUG|SAGE-217|Administered as capsules.
223642629|NCT03771664|DRUG|Placebo|Administered as capsules.
223642630|NCT03703284|OTHER|Treatments to reduce intracranial pressure|Drugs such as mannitol, glycerin fructose, etc and/or surgery
223765570|NCT05452447|DEVICE|Transfluthrin|Passive emanator with formulated transfluthrin
223765571|NCT05452447|DEVICE|Placebo|Passive emanator with formulated inert ingredients
224230253|NCT02761980|DRUG|Placebo|Placebo tablet
224319634|NCT02859753|OTHER|Percutaneous Microwave Ablation|
224319635|NCT01408602|DRUG|MRC375|MRC 375 (enteric coated Tetracycline) 75mg 3 times a day for 24 weeks.
224319636|NCT01408602|DRUG|Matching Placebo|Matching Placebo 3 times a day for 24 weeks. Early escape at week 16,20.
224319637|NCT01408602|DRUG|MRC375 150mg|MRC375 (enteric coated Tetracycline) 150mg 3 times a day for 24 weeks
224319638|NCT03901092|DRUG|flortaucipir F 18|No study drug will be administered.
223642631|NCT00783068|DRUG|GTS-21, [3-(2,4-dimethoxybenzylidene)-anabaseine dihydrochloride]|Subjects will receive GTS-21 or placebo 3 day before injection of LPS (150 mg tid) and a single oral dose of 150 mg of GTS-21 or placebo the morning of LPS injection (07:00 AM). Subjects will then receive an oral dose of 150 mg GTS-21 or placebo at 08:00 AM and another oral dose of 150 mg GTS-21 or placebo at 1 hour before LPS administration (t=0)
223642632|NCT00783068|DRUG|Placebo|Subjects will receive placebo 3 day before injection of LPS (150 mg tid) and a single oral dose of 150 mg of placebo the morning of LPS injection (07:00 AM). Subjects will then receive an oral dose of 150 mg placebo at 08:00 AM and another oral dose of 150 mg placebo at 1 hour before LPS administration (t=0).
223642633|NCT00783068|DRUG|Lipopolysaccharide E. Coli 113:H 10:K negative|Subjects will be randomized to oral pre-treatment with GTS-21 (150 mg tid 3 days before LPS injection and an oral dose of 150 mg GTS-21 on the morning of the day of the experiment (07:00 AM). Subjects will then receive an oral dose of 150 mg GTS-21 or placebo at 08:00 AM and another oral dose of 150 mg GTS-21 or placebo at 1 hour before LPS administration (t=0). One hour after ingestion of the last dosage of the study drug, purified LPS prepared from E coli O:113 (2 ng/kg iv) will be injected intravenously.
223642634|NCT03276338|BEHAVIORAL|HOLA|To increase condom use and HIV testing
223642635|NCT03207295|DRUG|Nesiritide|A standard dose of study drug was administered by a continuous infusion for ≥24 hours and ≤7 days after cardiac intensive care unit admission
223642636|NCT03207295|DRUG|Normal saline|Normal saline(2ml/h) is administered by a continuous infusion for ≥24 hours and ≤7 admission days after cardiac intensive care unit in postoperative children
223642637|NCT00561925|DRUG|nevirapine IR|200 mg BID
223642638|NCT00561925|DRUG|nevirapine XR|400 mg QD
223642639|NCT04941209|DEVICE|imPulse™ Una infrasound-to-ultrasound e-stethoscope|The imPulse™ System is an every/anywhere-point-of-care cardiopulmonary functional state assessment platform designed to capture normal and abnormal, audible and inaudible cardiopulmonary sounds, rhythms and patterns, via a real-time, intelligent, full-spectrum phonocardiogram obtained from direct to skin coupling or through a layer of clothing.
223642640|NCT04941209|DIAGNOSTIC_TEST|(PPA >95%) FDA EUA RT-PCR|Real-time RT-PCR that detects amplified SARS-CoV-2 genome in sputum, nasopharyngeal or oropharyngeal swabs, bronchoalveolar lavage fluid, nasal or nasopharyngeal aspirate, and lower respiratory tract aspirates.
223642641|NCT04941209|RADIATION|HR-CT-scan|High-resolution computer tomography, or CT/CAT, is an X-ray scan that produces images of the chest and is used as a confirmatory test in symptomatic patients that have a negative PCR test.
223642642|NCT00891904|BIOLOGICAL|cetuximab|Given IV
223642643|NCT00891904|RADIATION|stereotactic body radiation therapy|Undergoing Radiotherapy
223642644|NCT04871646|DRUG|CKD-314+SOC|CKD-314 is administered intravenously and standard of care is also performed.
223642645|NCT04871646|DRUG|CKD-314 Placebo+SOC|CKD-314 placebo is administered intravenously and standard of care is also performed..
224230254|NCT05404035|BEHAVIORAL|Family Connections for relatives of people with eating disorders and personality disorders|"The FC program (Fruzzetti and Hoffman, 2005) is divided into 7 modules:~1. Introduction to the intervention program. Program objectives, guidelines, criteria, and symptoms of ED and PD.~2. Psychoeducation on the development of ED and PD, explanatory theories, available treatments, comorbidity with PD.~3. Emotional regulation skills and awareness, and to decrease emotional reactivity.~4. Skills to improve the quality of relationships in family interactions (letting go of guilt and anger, acceptance skills in relationships).~5. Communication skills and effective self-expression, such as validation.~6. Problem management and making safe plans for crisis management.~7. Making new sense of my relationship with my family member, an opportunity to grow together.~All the modules include practice exercises, video viewing, and homework assignment."
224230255|NCT05404035|BEHAVIORAL|Optimized Treatment As Usual|"Family members with this condition will continue to receive the usual treatment provided by their referral care center. In addition, we will optimize the treatment, following the recommendations of the international guidelines for the treatment of ED (NICE, 2017). There will be 3 two-hour session in group format each week, with the following components: Up-to-date information and research on ED and PD; Psychoeducation on the development of ED and PD; Explanatory theories; Available treatments and comorbidity.~In both conditions, after each face-to-face session, the participant will be asked to review the contents addressed during the session as homework (independently of the homework corresponding to the specific module being addressed). All interventions carried out with family members will be performed by clinical psychologists or general health psychologists with at least a master's degree or a doctoral degree and previous training in the application of the programs."
224230256|NCT04820803|OTHER|ORAL INTERVENTION WITH CETYLPYRIDINIUM CHLORIDE|one mouthwash containing cetylpyridinium chloride (0.07%) for 60 seconds
224230257|NCT04820803|OTHER|PLACEBO|one mouthwash containing distilled (placebo) water for 60 seconds
224323361|NCT06417814|DRUG|Dato-DXd|Dato-DXd will be administered as IV infusion.
224323362|NCT06417814|DRUG|Osimertinib|Osimertinib will be administered orally.
223642646|NCT00598910|DRUG|Omacor|n-3 PUFA
223642647|NCT00598910|DRUG|Placebo|Placebo
223642648|NCT01042106|DRUG|DSP-8658|Ascending doses of DSP-8658 - 2.5, 10, 20, 40 mg orally once daily
223642649|NCT01042106|DRUG|Placebo|Placebo 2.5, 10, 20, 40 mg orally once daily
223642650|NCT01544010|BEHAVIORAL|Stage-Tailored Manual|Manual with 5 sections for each Stage of change delivered at baseline
223642651|NCT01544010|BEHAVIORAL|Stage Tailored Feedback Report|Tailored printed feedback reports based on assessments of stages of change were delivered at baseline, 6 months and 12 months.
223642652|NCT01544010|BEHAVIORAL|Moderate TTM-Tailored Feedback Report|Tailored printed feedback report based on assessment of stages of change, Pros, Cons, and Temptations were delivered at baseline, 6 months and 12 months.
223642653|NCT01544010|BEHAVIORAL|Full TTM-Tailored Feedback Report|Tailored print feedback report based on assessment of Stages, Pros, Cons, Temptations, 10 Processes of Change were delivered at baseline, 6 months and 12 months.
223642654|NCT01544010|BEHAVIORAL|Enhanced TTM+Addiction Tailored Feedback Report|Tailored print feedback report based on assessment of Addiction level (# cigarettes/day),Stages, Pros, Cons, Temptations, 10 Processes of Change were delivered at baseline, 6 months and 12 months.
223642655|NCT03006003|DRUG|Raloxifene|Raloxifene tratment more than 4 weeks
223642656|NCT03006003|DRUG|Alendronate|Alendronic acid 70mg with Colecalciferol 70mcg
223642657|NCT05537662|DEVICE|Standard of care neuromodulation therapy (SCS or DRG)|Standard SCS or DRG therapy
223642658|NCT05021978|DRUG|Part A: 20 and 40 mg PRAX-944|Once daily oral treatment
223642659|NCT05021978|DRUG|Part B: 120 mg PRAX-944|Once daily oral treatment with titration
223642660|NCT05021978|DRUG|Part B: 120 mg PRAX-944 and Placebo|Once daily oral treatment with titration followed by placebo
223642661|NCT03637738|RADIATION|RIOP-Intrabeam® system|The radiation source is inserted at the immediately on surgical resection bed after tumorectomy and started for 20 to 55 minutes to perform intraoperative radiotherapy precisely targeting the tissues that present the greatest risk of local recurrence. The applied dose will be 20 Gy on the applicator surface.
223642662|NCT03637738|RADIATION|conventional surgery +RTE|Conventional EBRT, 5 to 10 weeks after surgery, according to the usual recommendations, 2 Gy per session, 5 sessions per week, with a total dose on the mammary gland of 50 Gy + a boost of 16 Gy on surgical resection bed .
223642663|NCT01658033|DRUG|Avastin + mFOLFOX6|"mFOLFOX6 regimen, repeated every 2 weeks: Oxaliplatin 85 mg/m2，ivgtt； Leucovorin 400 mg/m2,ivgtt； 5-FU 400 mg/m2，iv，and then 2400 mg/m2，civ46h；~Avastin: Avastin 5mg/kg q2w or 7.5mg/kg q3w"
223642664|NCT04932486|DEVICE|Transcutaneous electrical stimulation|Transcutaneous electrical stimulation of the upper airway muscles
223642665|NCT03367988|DRUG|Opioid Anesthesia|"Doses/concentration of medications/agents used for the anesthetic management of the subjects enrolled in this trial may be adjusted when necessary to provide optimal subject care. Anesthesia will be induced with rocuronium, propofol, intravenous opioids, and other medication(s)/agent(s) at a concentration range/dose(s) based on the clinical need of the subject.~Depth of anesthesia will be measured with BIS-monitoring and a standard approaching 50% suppression will be maintained throughout the main duration of surgery. Reversal agent will be administered at a post-tetanic count of 1 or 2.~Anesthesia will be maintained with IV opioids, propofol and/or medication(s)/agent(s), including inhalation anesthetic agents, at a concentration range/dose(s) based on the clinical need of the subject.~Tracheal extubation will be performed at the end of anesthesia after administration of reversal agent. After extubation, the investigator will determine when the subject is OR discharge ready."
223642666|NCT03367988|DRUG|Opioid-free Anesthesia|"Doses/concentration of medications/agents used for the anesthetic management of the subjects enrolled in this trial may be adjusted when necessary to provide optimal subject care. Acetaminophen 1g will be given prior to induction. Anesthesia will be induced with rocuronium 1mg, propofol 3-6 mg/kg, and succinylcholine 1.5 mg/kg Depth of anesthesia will be measured with BIS-monitoring and a standard approaching 50% suppression will be maintained throughout the main duration of surgery. Reversal agent will be administered at a post-tetanic count of 1 or 2.~Anesthesia will be maintained with Sevoflurane, Magnesium, Lidocaine, Ketamine, Decadron, Ondansetron, and Ketorolac at a concentration range/dose(s) based on the clinical need of the subject.~Tracheal extubation will be performed at the end of anesthesia after administration of reversal agent. After extubation, the investigator will determine when the subject is OR discharge ready."
223642667|NCT01322620|OTHER|No treatment given|No treatment given. Participants are to complete a questionnarie in the study.
223642668|NCT03855488|BEHAVIORAL|Standard cognitive bias modification|Participants will be asked to repeatedly listen to descriptions of ambiguous scenarios that resolve positively and answer one question following each scenario that reinforces the positive interpretation; participants will listen to 60 scenarios/day for 7 days.
223642669|NCT03855488|BEHAVIORAL|Imagery enhanced cognitive bias modification|Participants will be asked to imagine themselves as though they are actively involved in the scenarios that they listen to. This condition will be required to answer two questions following each scenario; one that reinforces the positive interpretation and another that promotes engagement with imagery. Participants will listen to 60 scenarios/day for 7 days.
223642670|NCT03855488|BEHAVIORAL|Neutral Control Condition|Participants will be asked to listen to descriptions of neutral (i.e., non-emotional) scenarios. This condition will also be required to answer one comprehension question following each scenario. Participants will listen to 60 scenarios/day for 7 days.
224230258|NCT05891990|PROCEDURE|immediate implant augmented with sticky tooth|"* Topical anesthesia will be administered using an infiltration technique.~* Atraumatic extraction will be done with the aid of periotome and Luxators.~* The extraction socket will be debrided to remove any residual debris or granulation tissue.~* Full-thickness midcrestal incision and vertical releasing incision on the distal side will be made, and a vertical releasing incision on the mesial side will be made if necessary. The extraction socket and the labial bone defect will be exposed by buccal and palatal flap reflection.~* Implant insertion will be performed according to the manufacturer's instruction, and then the implant will be inserted 2mm apical to the alveolar bone crest with adequate primary stability.~* The gap between the implant and the defect of the facial bone will be filled with the sticky tooth to reach enough buccal bone supported and then will be covered with absorbable barrier collagen membranes.~* Finally, the flap will be repositioned and sutured."
224230259|NCT05891990|PROCEDURE|immediate implant augmented with autogenous tooth graft|"* Topical anesthesia will be administered using an infiltration technique.~* Atraumatic extraction will be done with the aid of periotome and Luxators.~* The extraction socket will be debrided to remove any residual debris or granulation tissue.~* Full-thickness midcrestal incision and vertical releasing incision on the distal side will be made, and a vertical releasing incision on the mesial side will be made if necessary. The extraction socket and the labial bone defect will be exposed by buccal and palatal flap reflection.~* Implant insertion will be performed according to the manufacturer's instruction, and then the implant will be inserted 2mm apical to the alveolar bone crest with adequate primary stability.~* The gap between the implant and the defect of the facial bone will be filled with the autogenous demineralized dentin graft to reach enough buccal bone supported and then will be covered with collagen membranes.~* Finally, the flap will be repositioned and sutured."
224230260|NCT01052116|DRUG|Soy isoflavone supplement|Oral soy isoflavone supplement (100 mg/day)
224230261|NCT01052116|DRUG|Placebo|Placebo
224230262|NCT03976713|DRUG|Bufei Yishen granule|Bufei Yishen granule will be administered twice daily for five days a week for 52 weeks.
224230263|NCT03976713|DRUG|Placebo Bufei Yishen granule|Placebo Bufei Yishen granule will be administered twice daily for five days a week for 52 weeks. The placebo granule consists of dextrin, bitter and 5% of the Bufei Yishen granule. The appearance, weight, color and odor of the preparation are the same as those of treatment group.
224230264|NCT03976713|DRUG|Tiotropium Bromide Powder for Inhalation|Tiotropium Bromide Powder for Inhalation will be used once daily (18 μg each time) for 52 weeks.
223642671|NCT04276896|BIOLOGICAL|Injection and infusion of LV-SMENP-DC vaccine and antigen-specific CTLs|Patients will receive approximately 5x10\^6 LV-DC vaccine and 1x10\^8 CTLs via sub-cutaneous injections and iv infusions, respectively.
224319639|NCT01513278|DRUG|APN201|"All patients receive APN201 and placebo at the same time. The irradiated region is divided vertically into two symmetric areas (left and right). One area is treated with APN201 (recombinant human superoxide dismutase (rhSOD) encapsulated in liposomal vesicles formulated as a hydrophilic gel; 1.6 mg rhSOD per mL), the other area is treated with placebo (empty liposomes formulated as a hydrophilic gel) in a double-blind fashion.~Study treatment (APN201 and placebo) starts on the day of initiation of radiation therapy and continues until the end of radiation therapy to the whole breast (25 or 28 daily fractions to a total dose of 50.0 Gy or 50.4 Gy, respectively). Study treatment is applied as a thin film on the irradiated area ≥10 minutes each day before radiation therapy (approximately 1 mL APN201 per 100 cm2 of the radiation field size and approximately 1 ml placebo per 100 cm2 of the radiation field size)."
223642672|NCT01128634|DRUG|GSK573719|13 days dosing with GSK573719, once daily dosing from day 1 to 13, concurrent dosing with verapamil from day 9 to 13.
224230265|NCT05284890|DRUG|CC-99677|Specified dose on specified days
224230266|NCT01768858|DRUG|Adalimumab|Adalimumab administered by subcutaneous injection, via pre-filled syringe or autoinjector pen
224230267|NCT03985670|DRUG|teripalimab plus chemotherapy|teripalimab 240mg d1 paclitaxel 150mg/m2 d1 cisplatin 70mg/m2 d1
224230268|NCT03985670|DRUG|chemotherapy plus teripalimab|paclitaxel 150mg/m2 d1 cisplatin 70mg/m2 d1 teripalimab 240mg d3
224230269|NCT01539915|DRUG|BCT194|Topically applied BCT194 cream (0.5%)
224230270|NCT02541526|DRUG|Mirtazapine|One capsule (15 mg) oral mirtazepine daily will be started on day six of treatment for a period of 3 days followed by two capsules (30 mg) daily for a period of four months
224230271|NCT02541526|DRUG|Placebo|Similar capsule containing placebo will be started on day six of treatment for a period of 3 days followed by two capsules of placebo daily for a period of four months
224319640|NCT01513278|DRUG|Placebo|"All patients receive APN201 and placebo at the same time. The irradiated region is divided vertically into two symmetric areas (left and right). One area is treated with APN201 (recombinant human superoxide dismutase (rhSOD) encapsulated in liposomal vesicles formulated as a hydrophilic gel; 1.6 mg rhSOD per mL), the other area is treated with placebo (empty liposomes formulated as a hydrophilic gel) in a double-blind fashion.~Study treatment (APN201 and placebo) starts on the day of initiation of radiation therapy and continues until the end of radiation therapy to the whole breast (25 or 28 daily fractions to a total dose of 50.0 Gy or 50.4 Gy, respectively). Study treatment is applied as a thin film on the irradiated area ≥10 minutes each day before radiation therapy (approximately 1 mL APN201 per 100 cm2 of the radiation field size and approximately 1 ml placebo per 100 cm2 of the radiation field size)."
224319641|NCT01776255|BEHAVIORAL|Healthy Children, Strong Families|"Healthy Children, Strong Families is a series of 13 lessons mailed to primary caregivers of preschool aged children that provide education and activities related to obesity prevention. The lessons cover topics related to nutrition, physical activity, stress, sleep, and the home environment. Lessons include printed materials and small items (for example, an apple sectioner) that support activities in the lessons. Social support components via a monitored Facebook group and approximately semiweekly text messages sent to caregivers are included. The intervention spans 1 year."
224230272|NCT01424839|RADIATION|craniospinal irradiation|"* Metastatic or incompletely staged pure germinoma 24 Gy (15 fractions) to craniospinal axis with a 16 Gy (10 fraction) boost to tumour bed and any intracra-nial metastases and spinal deposits (total tumour dose 40 Gy)~* Metastatic germinoma plus teratoma (incompletely resected) 24 Gy (15 fractions) to craniospinal axis ; 30.4 Gy (19 fraction) boost to tumour bed and 16 Gy (10 frac-tion) boost to metastases (total tumour dose 54.4 Gy)~* Patients with metastastic non-germinomatous disease at diagnosis After Chemotherapy: 30 Gy (20 fractions) to cranio-spinal axis with 24 Gy (15 fraction) boosts to tumour site and any intracranial metastases (total tumour dose 54 Gy) and 20.8 Gy (13 fraction) boosts to spinal deposits (total dose 50.8 Gy)"
224230273|NCT01424839|DRUG|Carboplatin, Etoposide, Ifosfamide|• Non-metastatic fully staged germinoma (± teratoma) Two courses (1 and 3) of Etoposide and Carboplatin, alternating with two courses (2 and 4) of Etoposide and Ifosfamide
224230274|NCT01424839|RADIATION|ventricular irradiation|"* Non-metastatic pure germinoma in PR/SD After Chemotherapy: 24 Gy (15 fractions) to whole ventricles with a 16 Gy (10 fraction) boost to tumour bed (total tumour dose 40 Gy)~* Non-metastatic germinoma in CR After Chemotherapy: 24 Gy (15 fractions) to whole ventricles~* Non-metastatic germinoma plus teratoma (incompletely resected) After Chemotherapy: 24 Gy (15 fractions) to whole ventricles; 30.4 Gy (19 fraction) boost to tumour bed (total tumour dose 54.4 Gy)"
224230275|NCT01424839|DRUG|Cisplatin, etoposide, Ifosfamide (standard)|Four courses of Etoposide, Cisplatin and Ifosfamide (standard treatment )
224319642|NCT01776255|BEHAVIORAL|Child Safety|The Child Safety intervention is an active control condition consisting of monthly two-page newsletters covering various topics relevant to child safety such as choking, car safety seats, bike and pedestrian safety. The intervention spans 1 year.
224319643|NCT04852029|OTHER|Low dose hCG|Patients will either maintain the current dose of have an increased dose prescribed based on randomization
224319644|NCT02984163|BEHAVIORAL|Exercise|Exercise sessions will include a combination of aerobic, resistance, balance, and flexibility exercises delivered in a circuit-type class setting or group personal training format.
224319645|NCT02293889|DIETARY_SUPPLEMENT|Vitamin D3 2000IU/daily 3 months|Vitamin D will be provided in the form of a daily capsule over 3 months containing 2000IU of Vitamin D3 suspended in oil (manufactured and provided by DSM) with the aim of raising 25OHD levels to sufficiency (\>50nmol/L) by 3 months.
224323363|NCT06417814|DRUG|Pemetrexed|Pemetrexed will be administered as IV infusion.
223642673|NCT01128634|DRUG|GW573719/GW573719|13 days dosing with GSK573719/GW573719, once daily dosing from day 1 to 13, concurrent dosing with verapamil from day 9 to 13.
223642674|NCT04074889|DIETARY_SUPPLEMENT|(Microbial cell preparation) Probiotics|Lactobacillus acidophilus (107mg), Lactobacillus casei subsp (107mg), Lactobacillus lactis (107mg), Bifidobacterium bifidum (107mg), Bifidobacterium infantis (107mg) and Bifidobacterium longum (107mg)
223642675|NCT04074889|OTHER|Placebo|Placebo sachet with no microbial cell preparation
223642676|NCT01054989|BIOLOGICAL|Fat/Inflammation effects|Fat infusion (Intralipid) over 6 hours Fat orally (Soy bean oil) single dose LPS infusion for 10 minutes Glycerol infusion over 6 hours
224230276|NCT01424839|DRUG|Cisplatin, Etoposide, Ifosfamide (high dose)|Two courses of standard Etoposide, Cisplatin and Ifosfamide, followed by two dose intensified courses of Etoposide, Cisplatin and Ifosfamide with stem cell support
224230277|NCT01424839|RADIATION|focal irradiation|• Patients with localised non-germinomatous disease at diagnosis After Chemotherapy: 54 Gy focal radiotherapy in 30 fractions
223642677|NCT04069702|BEHAVIORAL|VR Blue|VR Blue provides patients with an immersive computer-generated environment that can reduce pain, tension and distress.
223642678|NCT03597945|PROCEDURE|lidocaine with epinephrine|lidocaine with epinephrine in prehospital femoral nerve block for patient with diaphysial femoral fracture
223642679|NCT03597945|PROCEDURE|normal saline|normal saline as adjuvant to lidocaine with epinephrine in prehospital femoral nerve block for patient with diaphysial femoral fracture
223642680|NCT03597945|PROCEDURE|Magnesium sulfate|Magnesium-sulfate as adjuvant to lidocaine with epinephrine in prehospital femoral nerve block for patient with diaphysial femoral fracture
223642681|NCT04944004|OTHER|CogniPlus|The CBCT programmes proposed in this study is called CogniPlus. This software package offers training of scientifically proven trainable cognitive functions. According to the user manual, the lifelike interactive system and its automatic adaptability to client's ability level made CogniPlus feasible in community settings.
223642682|NCT04944004|OTHER|Training As Usual (TAU)|Training As Usual (TAU)
223642683|NCT01765933|DIETARY_SUPPLEMENT|DMAA|no placebo
223642684|NCT01644357|OTHER|Pharmaceutical care|Pharmacist intervention, focused on the optimization of drug therapy, identification and resolution of drug related problems, resulting in best asthma control and quality of life. Pharmacists document their initial and monthly follow up encounters using a specified form. An action plan for self management of these patients was prepared and discussed aiming at early identification and treatment of an exacerbation episode. Meetings will be held weekly with intervention team to discuss action plan and measure of outcomes of all problems identified.
223642685|NCT03096288|DRUG|Evolocumab|Patients will be randomly assigned to receive a single dose of either evolocumab 420 mg s.c. or placebo (0.9% sodium chloride s.c. injection).
223642686|NCT03096288|OTHER|Placebo|Patients will be randomly assigned to receive a single dose of either evolocumab 420 mg s.c. or placebo (0.9% sodium chloride s.c. injection).
223642687|NCT03702153|PROCEDURE|Abdominal wall reconstruction|The repair of abdominal wall defects with polypropylene mesh
223642688|NCT03721003|DEVICE|ICP monitoring|"4- Use the Touhy needle to tunnel under the scalp from the Burr Hole site to the desired MICROSENSOR exit site.~5- Place the tip of the MICROSENSOR in the Parenchyma through the puncture in the Dura"
223642689|NCT00588016|DRUG|Itraconazole|Topical application of Itraconazole in Sterile Water 100 mg/1000 ml, irrigating each nostril with 20 ml of solution twice daily for 7 days.
223642690|NCT00166777|PROCEDURE|exercise training|
223642691|NCT06316050|PROCEDURE|humeral retroversion|REVERSED SHOULDER ARTHROPLASTY IN TWO DIFFERENT GROUPS. Group 0 humeral retroversion, Group 30º humeral retroversion
223642692|NCT01394796|DIETARY_SUPPLEMENT|Epigallocatechin-3-gallate (EGCG)|EGCG normally works as a dietary supplement. EGCG administration in Down syndrome patients will result in an improvement of their cognitive performance.A a daily oral dose containing 9 mg/kg (range 6.9-12.7) of EGCG is given during three months.
223642693|NCT01394796|DRUG|Placebo|No active treatment is given.
223642694|NCT04683484|BIOLOGICAL|Nanocovax|Recombinant Protein spike (s) SARS-CoV-2 and adjuvant (0,5 mg Al PO4)
223642695|NCT04683484|BIOLOGICAL|Placebo|0,5 mg Al PO4
223642696|NCT06001073|OTHER|Observational; No Interventions were given.|Observational; No Interventions were given.
224230278|NCT02792413|DRUG|Denosumab|Patients will receive a subcutaneous injection of Denosumab every 6 months for the duration of the study. In addition, they will receive vitamin D and calcium (which is the normal treatment) for the duration of the study.
224230279|NCT02792413|DRUG|NaCl (placebo)|Patients will receive a subcutaneous injection of NaCl every 6 months for the duration of the study. In addition, they will receive vitamin D and calcium (which is the normal treatment) for the duration of the study.
224230280|NCT03346395|BEHAVIORAL|Problem solving based intervention|Problem solving based intervention
223642697|NCT01495403|DRUG|Hydroxychloroquine|daily dosing
224230281|NCT03346395|BEHAVIORAL|Care as usual|Medical treatment, or behavioral therapy or a coordination of behavioral therapy and medical treatment. Meeting with a rehabilitation coordinator.
224230282|NCT02516566|OTHER|PEEP|Mechanical ventilation with PEEP 8 cmH2O
224230283|NCT02742090|DRUG|Umbralisib|Umbralisib was administered as a tablet(s), orally once daily.
224230284|NCT01132599|DIETARY_SUPPLEMENT|C-11 choline|
224230285|NCT01132599|RADIATION|18F-fluoromethylcholine|
224230286|NCT04341740|PROCEDURE|Bone Marrow Aspirate|bone marrow aspiration
224230287|NCT05057156|BEHAVIORAL|cognitive rehabilitation|patients have to use an app with cognitive games
223642698|NCT02547818|DRUG|ALZT-OP1a|1\) Mast cell stabilizer, 2) Neuroinflammatory microglial modulator, 3) A-beta oligomerization inhibitor, and 4) anti-inflammatory
223642699|NCT02547818|DRUG|ALZT-OP1b|Anti-inflammatory
223642700|NCT02547818|OTHER|Placebo ALZT-OP1a|Non-active capsules
223642701|NCT02547818|OTHER|Placebo ALZT-OP1b|Non-active tablets
224230288|NCT01289509|DRUG|E5501|Lot P01010ZZA (test) single oral doses of 40 mg tablets.
224230289|NCT01289509|DRUG|Drug: E5501|Lot P97001ZZB (reference) single oral doses of 40 mg tablets.
224230290|NCT05954715|OTHER|Ischaemic Preconditioning|Four cycles of cuff inflation each lasting 5 min in duration followed by a 5-min period of cuff deflation will be applied.
224323364|NCT06417814|DRUG|Carboplatin|Carboplatin will be administered as IV infusion.
223642702|NCT02551887|BEHAVIORAL|Automated Reminder|Automated reminder shown to provider
223642703|NCT02551887|BEHAVIORAL|Automated Reminder Plus Script|Provider sees both reminder and script.
223642704|NCT02868593|OTHER|Pharyngeal swab|
223642705|NCT01703234|DRUG|Ramipril|ramipril 10 mg/day during 3 months
224230291|NCT05954715|OTHER|Sham|Four cycles of cuff inflation each lasting 5 min in duration followed by a 5-min period of cuff deflation will be applied.
224230292|NCT00996554|PROCEDURE|double layer-suture|Hand-sutured end-to-end or end-to-side anastomosis performed by double-layer continuous technique (monofil thread)
223642706|NCT04926987|OTHER|brain tissue single-cell sequencing|Using single-cell sequencing to study the brain tissue single-cell transcriptome difference in aging, epilepsy, and mental disorders
223642707|NCT04999540|DRUG|Tucidinostat|30 mg, administered orally twice per week (BIW)
223642708|NCT04999540|DRUG|Fulvestrant|Fulvestrant was supplied as a castor oil based solution in clear neutral glass pre-filled syringes. Each syringe will contain 250 mg of fulvestrant in 5 ml.
223642709|NCT04592887|RADIATION|FLASH Radiotherapy|FLASH radiotherapy is radiation treatment delivered at ultra-high dose rates compared to conventional radiation treatment.
223642710|NCT04639258|DEVICE|Medtronic Evolut™ PRO+ System|TAVR treatment with Medtronic Evolut™ PRO+ System
223642711|NCT00519753|DRUG|Travoprost 0.004%/timolol maleate 0.5% fixed combination ophthalmic solution (DuoTrav)|One drop in study eye(s) once daily in the evening (at 8:00 PM) for 12 weeks
223642712|NCT02346162|BEHAVIORAL|Weight management|Phone counseling for pre-pregnancy weight loss and weight maintenance when BMI \</=25, and when pregnant, weight gain within IOM guidelines.
223642713|NCT02346162|OTHER|Usual Care Control|Usual care control participants receive general dietary advice as it relates to planning for a healthy pregnancy (e.g. folate requirements, prenatal vitamins, smoking cessation, alcohol cessation, and prenatal food safety).
223642714|NCT02757209|DEVICE|Spiromax (budesonide/formoterol)|"DuoResp Spiromax 160 (160 micrograms budesonide/4.5 micrograms formoterol fumarate dihydrate), either one inhalation twice a day (morning and evening) or two inhalations twice a day (morning and evening), for 1 week.~Additional 8 weeks in one subgroup"
223642715|NCT02757209|DEVICE|Turbohaler (budesonide/formoterol)|Turbohaler® (160 micrograms budesonide/4.5 micrograms formoterol fumarate dihydrate)- Symbicort® 160/4.5. Dose of one inhalation twice a day (mornig and evening) or two inhalations twice a day (morning and evening), for 1 week. Additional 8 weeks in one subgroup
223642716|NCT02757209|DEVICE|Diskus(50mcg salmeterol &250/500 mcg fluticasone propionate)|Diskus® inhaler(50mcg salmeterol\&250/500mcg fluticasone propionate)-Seretide Diskus 50/250mcg® or 50/500mcg.Dose of 1inhalation twice a day for1 week.Additional 8 weeks in1subgroup
224230293|NCT00996554|PROCEDURE|Single-layer suture|Hand-sutured end-to-end or end-to-side anastomosis performed by single-layer continuous technique (monofil thread)
223642717|NCT02135913|DIETARY_SUPPLEMENT|Vitamin D|All subjects enrolled into the study will be prescribed standard of care Vitamin D
223642718|NCT04178668|OTHER|Oral mucosa and saliva samples|one oral mucosa sample and one saliva sample
223642719|NCT03566134|DRUG|DA-8010 Placebo|Participants receive placebo to match DA-8010 orally once a day.
223765572|NCT03384121|DRUG|Rifampin 150 mg, 300 mg capsules and 25 mg/mL oral suspension|Starting Dose (V2): 5 mg/kg/day (max 600mg/day) orally for 2 months followed by a 2 month washout period V4: After washout period, only Non-responders will escalate dose to 10 mg/kg/day (max 600mg/day) orally for 2 months
224230294|NCT02916173|DRUG|Recombinant Human Chorionic Gonadotrophin|250 unit intramuscular
224230295|NCT02916173|DRUG|human chorionic gonadotrophin + gonadotrophin releasing hormone agonist|250 unit intramuscular + 1 mg subcutaneous
224230296|NCT00631176|BEHAVIORAL|Just-In-Time Training|On-call pediatric residents from 7 south PICU (24 beds) will receive 20 minutes of just-in-time pediatric airway management training. This training will occur before their shift starts before the morning round. This training will cover direct laryngoscopy technique, orotracheal intubation technique, confirmation of the tube placement and recognition of associated events. This training will be done with or without high fidelity simulation function.
224230297|NCT02243020|DEVICE|Vagus Nerve Stimulation (VNS)|
223642720|NCT03566134|DRUG|DA-8010 2.5mg|Participants receive DA-8010 2.5mg orally once a day.
223642721|NCT03566134|DRUG|DA-8010 5mg|Participants receive DA-8010 5mg orally once a day.
223642722|NCT03566134|DRUG|Solifenacin 5mg|Participants receive solifenacin 5 mg orally once a day.
223642723|NCT03566134|DRUG|Solifenacin succinate placebo|Participants receive placebo to match solifenacin 5 mg orally once a day.
223642724|NCT04198558|DRUG|MEDI0618|MEDI0618 A novel human immunoglobulin antibody
223642725|NCT04198558|DRUG|Placebo|Placebo
223642726|NCT00017576|DIETARY_SUPPLEMENT|calcitriol|
223642727|NCT00017576|DRUG|carboplatin|
223642728|NCT04320316|DRUG|Crysvita (burosumab-twza) Treatment|KRN23 is a fully human IgG1monoclonal antibody that binds to and inhibits the activity of FGF23, leading to an increase in serum phosphorus levels. It is a potential therapeutic candidate for the treatment of XLH, Tumor-Induced Osteomalacia (TIO), and the rickets/osteomalacia resulting from Epidermal Nevus Syndrome (ENS). All of these conditions are diseases of bone hypomineralization, caused by urinary phosphate wasting due to elevated levels of FGF23.
223642729|NCT01887457|DRUG|VFEND|voriconazole will be administered in iv form
223642730|NCT01502826|DIETARY_SUPPLEMENT|standardized mixed meal|All participants will undergo a mixed meal test (300 kcal/m2 of body surface area, 53.8% carbohydrates, 29.5% lipids, 16.7% proteins) and will be monitored for 300 minutes thereafter.
223642731|NCT05695378|DRUG|KM-819|Subjects will receive KM-819 400 mg orally daily.
224230298|NCT00836927|DRUG|Ridaforolimus Tablet|Ridaforolimus 10 mg oral tablet
224230299|NCT00836927|DRUG|Ridaforolimus Intravenous (IV) Infusion|Ridaforolimus IV infusion administered once daily for 5 days every 2 weeks in a 28-day cycle (two 2-week courses equals 1 cycle).
224230300|NCT00001074|DRUG|Hydroxyurea|
223642732|NCT05695378|DRUG|Placebo|Subjects will receive Placebo orally daily.
223642733|NCT00755053|DRUG|Clotrimazole, vaginal ovule|Single intravaginal dose of 500 mg clotrimazole ovule at Visit 1 (Day 0).
223642734|NCT00755053|DRUG|Clotrimazole, vaginal tablet|Single intravaginal dose of 500 mg clotrimazole tablet at Visit 1 (Day 0).
223642735|NCT06165393|DIETARY_SUPPLEMENT|Slow-release CHO-AA|Slow-release CHO-AA, alginate encapsulated
224230301|NCT00001074|DRUG|Didanosine|
224230302|NCT05711030|PROCEDURE|Thoracic paravertebral block multiple (3) injections|already described in arm description
224230303|NCT05711030|PROCEDURE|Thoracic paravertebral block single injection|already described in arm description
224230304|NCT00004776|DRUG|topiramate|
224323365|NCT06417814|DRUG|Cisplatin|Cisplatin will be administered as IV infusion.
224323366|NCT05526248|DRUG|Darolutamide(BAY1841788, Nubeqa)|tablet, oral
224323367|NCT05526248|DRUG|Enzalutamide|tablet, oral
223642736|NCT06165393|DIETARY_SUPPLEMENT|Slow-release CHO|Slow-release CHO, alginate encapsulated
224230305|NCT02267096|BEHAVIORAL|Telephone Counseling|The TC arm includes a stepped care approach, 3-6 phone sessions, depending on each participant's needs. Within 1-2 days post-T1 assessment, the intervention will begin. Sessions 1-3 (15 min each) will occur approximately weekly over 3-4 weeks, scheduled at participants' convenience and at strategic therapeutic times (e.g., shortly pre/post-quit date). Continuing smokers or newly quit former smokers who would benefit from relapse prevention sessions will receive up to 3 additional sessions, to be completed within 3-4 weeks. The provision of 3-6 sessions is more intensive than several other telephone counseling interventions. A dose response relationship between quitting and number of sessions has been shown in non-volunteer smokers, and based on our pilot data, the investigators expect that a more intensive intervention will be needed for some participants.
224323368|NCT05681845|DRUG|NNC0365-3769 (Mim8)|Participants will receive a single dose of Mim8 subcutaneously in the abdomen.
223642737|NCT06165393|DIETARY_SUPPLEMENT|CHO|Carbohydrate-only, control
223642738|NCT03183297|DRUG|JMI-001|JMI-001, a combination product of naproxen and fexofenadine
223642739|NCT03183297|DRUG|Naproxen|Naproxen sodium 220mg
223642740|NCT03183297|DRUG|Fexofenadine|Fexofenadine 60mg
223642741|NCT03183297|DRUG|placebo|placebo comparator
223642742|NCT02217826|DRUG|DG3173|
223642743|NCT02217826|DRUG|Saline|
223642744|NCT02217826|DRUG|Octreotide|
223642745|NCT03672968|GENETIC|GS010|
223642746|NCT02819804|DRUG|Dasatinib|Given PO
223642747|NCT02819804|OTHER|Laboratory Biomarker Analysis|Correlative studies
223642748|NCT02819804|BIOLOGICAL|Nivolumab|Given IV
223642749|NCT02819804|OTHER|Pharmacological Study|Correlative studies
223642750|NCT01512238|OTHER|Pharmaceutical care|Information about medicine, sideeffect, adherence
223642751|NCT01170169|DRUG|Omeprazole|Omeprazole Delayed Release Capsules 40 mg
223642752|NCT01170169|DRUG|Prilosec|Prilosec® 40 mg of Merck \& Co.Inc.
223642753|NCT03004937|OTHER|Family Medicine Hearing Loss Best Practice Alert|A Best Practice Alert, or BPA, was created in the electronic medical record system, which fires when patients meet the inclusion criteria. It reminds providers to ask their patients if they think have a hearing loss and allows them to respond as needed (refer to audiology, add hearing loss to the problem summary list, or dismiss for one year).
223642754|NCT05133141|DEVICE|Echelon Contour|There is no intervention, beyond necessary clinical care, in this study. Echelon Contour is used for transection and resection in colorectal surgical procedures per its instructions for use (IFU).
223642755|NCT02633904|PROCEDURE|Osteotomy|Femoral osteotomy are applied in the open treatment of Developmental Dislocation of the Hip （DDH）.
223765573|NCT04102371|DRUG|Lactated Ringer|"LR is a sterile, nonpyrogenic balanced solution used for fluid and electrolyte replenishment via intravenous or intraosseous administration. Each 100 mL of LR contains 600 mg sodium chloride (NaCl), 310 mg of sodium lactate (C3H5NaO3), 30 mg of potassium chloride (KCl), and 20 mg of calcium chloride (CaCl2 · 2H20) with an approximate potential of hydrogen (pH) of 6.5 (6.0 to 7.5)."
223765574|NCT04102371|DRUG|Normal Saline|"Normal saline solution is an unbalanced crystalloid solution containing 154 mEq/L of sodium and 154 milliequivalent (mEq/L) of chloride."
223765575|NCT04102371|DRUG|Plasma-lyte|PL is a sterile, nonpyrogenic isotonic solution in a single dose container for intravenous administration. Each 100 mL contains 526 mg of Sodium Chloride, USP (NaCl); 502 mg of Sodium Gluconate (C6H11NaO7); 368 mg of Sodium Acetate Trihydrate, USP (C2H3NaO2•3H2O); 37 mg of Potassium Chloride, USP (KCl); and 30 mg of Magnesium Chloride, USP (MgCl2•6H2O). It contains no antimicrobial agents. The pH is adjusted with sodium hydroxide. The pH is 7.4 (6.5 to 8.0).
223642756|NCT02633904|PROCEDURE|Non-osteotomy|Femoral osteotomy are not applied in the open treatment of Developmental Dislocation of the Hip （DDH）.
223765576|NCT04944017|DRUG|Ketamine Infusion|Participants will receive 6 infusions of ketamine (0.5 mg/kg IV, up to 60 mg total) , administered over 40 minutes while on continuous cardiac monitoring and oximetry
223642757|NCT03657082|DEVICE|PEP-10|Bottle PEP with a water level of 10 cmH2O
223642758|NCT03657082|DEVICE|PEP-1|Bottle PEP with a water level of 1 cmH2O
224323369|NCT06402123|DRUG|zagociguat 15mg|Once-daily oral tablets
224323370|NCT06402123|DRUG|zagociguat 30mg|Once-daily oral tablets
224323371|NCT06402123|DRUG|Placebo|Once-daily oral tablets
223642759|NCT01287702|DIETARY_SUPPLEMENT|Delayed feeding|patients with acute bleeding varices arrested by EVL, will receive feeding 48 hours after EVL
223642760|NCT01287702|DIETARY_SUPPLEMENT|Dealyed feeding|patients with acute bleeding varices arrested by EVL, will receive feeding 48 hours after EVL
223642761|NCT01287702|DIETARY_SUPPLEMENT|Early feeding|patients receiving EVL will receive liquid diet since 4 hours after arresting of variceal bleedingpatients with acute bleeding varices arrested by EVL
223642762|NCT01782378|DEVICE|Real LED Treatment|"PhotoMedex Helmet: 12 Pods, 4.5 x 4.8cm (21.6 cm2); 20 diodes; 830nm; Power Output (PO) 665.3 mW; Power Density (PD)/LED 30.8 mW/cm2; CW; Time/session 28m 10s\*; Dose: Energy Density 26 J/cm2.~MedX Device: 1 Cluster Head/ear, 2 inch diameter (22.48 cm2); 870nm; PO 90 mW; PD/LED 4 mW/cm2; CW; Time/session 4m; Energy Density 4 J/cm2; 2 Vielight Intranasal Devices: Red, 633nm diode; PO 6.5 mW; PD/LED 7.6 mW/cm2; CW; Time/session 25m; Energy Density 11.4 J/cm2 and NIR, 810nm diode; PO 6.5 mW; PD/LED 7.6 mW/cm2; Pulse frequency 10Hz; Duty Cycle 50%; Time/session 25m; Energy Density 11.4 J/cm2 Thor Photomedicine Helmet: 10 Pods, 6cm diameter (28.3 cm2); 35 diodes; Wavelength 850nm; PO 1050 mW; PD/LED 50 mW/cm2; CW; Time/session 23m, 24s; Energy Density 26 J/cm2 2 Placement sets: 1) midline, 6 cluster heads; 2) L\&R side of head 12 cluster heads (14m, 5s, each set); 1) midline, 5 cluster heads; 2) L\&R side of head 10 cluster heads (11m, 42s, each set) CW, Continuous Wave"
223642763|NCT01782378|DEVICE|Sham LED Treatment|Intervention for Real and Sham are Identical, but sham has power output of 0, no photons emitted.
223642764|NCT02246790|PROCEDURE|Biatrial radiofrequency ablation and CABG|Coronary artery bypass (CABG) using cardio-pulmonary bypass (CPB) and occlusion. Concomitant biatrial RFA during CPB.
223642765|NCT02246790|PROCEDURE|Left atrial radiofrequency ablation and CABG|Coronary artery bypass (CABG) using cardio-pulmonary bypass (CPB) and occlusion. Concomitant left atrial RFA during CPB.
223765577|NCT04944017|OTHER|Placebo - Saline Infusion|Participants will receive 6 infusions of saline administered over 40 minutes while on continuous cardiac monitoring and oximetry
223765578|NCT06561217|OTHER|Chart review|Chart review
223642766|NCT05142813|DIAGNOSTIC_TEST|Diagnostic Test: Blood specimen collection|Diagnostic Test: Blood specimen collection Study samples must be collected within before treatment with antibiotics or antivirals.
223642767|NCT03865901|DIAGNOSTIC_TEST|Mellitus GCD59 Test|An ELISA for screening for the risk of gestational diabetes
223642768|NCT00201110|BEHAVIORAL|Problem Solving Skills|Intensive Intervention: CVD Risk Self-Management Education (1 session) + Intensive Health Problem-Solving Training (8 sessions)
223642769|NCT00201110|BEHAVIORAL|Problem Solving Skills|Brief Intervention: CVD Risk Self-Management Education (1 session) + Brief Problem-Solving Training (1 session)
223642770|NCT01553890|OTHER|Blood sample|blood sample, venous blood, about 10 ml will be drawn from participants
223642771|NCT05733832|OTHER|Transitional Liver Clinic (TLC)|Participants in this intervention receive additional attention from their Hepatology providers in terms of an additional call/telemedicine visit and more specific/additional attention from their Hepatology APP (advanced practice provider) based on individual patient needs
223642772|NCT05509140|OTHER|observation|investigate the clinical effectivity of intravenous methylprednisolone repeated intermittent pulse combined with mycophenolate mofetil in the treatment of newly diagnosed juvenile dermatomyositis
223642773|NCT03352609|DEVICE|Active rTMS with MagVenture MagPro double blind rTMS system|5 sessions of rTMS delivered with MagPro (MagVenture) double blind rTMS system delivered at 110% of resting motor threshold with 3000 pulses of 10hz stimulation (5s on, 10s off) per session.
223765579|NCT01591473|DRUG|Poly I:Poly C12U 50 ug|Poly I:Poly C12U 50 ug; 3 doses; nasal administration every 28 days
224230306|NCT02267096|BEHAVIORAL|Minimal Treatment|A list of self-help materials (print-, web-, phone-based), the national telephone quitline phone number, and local in person cessation resources will be given to all participants.
224230307|NCT02708290|OTHER|MITA Prefrontal Synthesis exercises - each activity adapts to deliver the exercise that is at the exact level of difficulty appropriate for a child at any given point in time|"Mental Imagery Therapy for Autism (MITA) is an early-intervention application for children with Autism Spectrum Disorder (ASD). MITA app uses adaptive-learning technologies, with fun, educational exercises that adapt to a child's abilities, resulting in a highly-customized learning experience. The MITA application is available for free in the Apple Store, Google Play, and Amazon App Store.~MITA verbal activities start with simple vocabulary-building exercises and progress toward exercises aimed at higher forms of language, such as noun-adjective combinations, spatial prepositions, recursion, and syntax. All exercises are deliberately limited to as few nouns as possible since the aim is not to expand a child's one-word vocabulary, but rather to teach him/her to integrate mental objects in novel ways by utilizing prefrontal synthesis (PFS). MITA activities outside of the verbal domain aim to provide the same PFS training visually through implicit instructions."
224230308|NCT00000464|DRUG|amiodarone|
224230309|NCT00000464|DRUG|imipramine|
224230310|NCT00000464|DRUG|mexiletine|
224230311|NCT00000464|DRUG|procainamide|
224230312|NCT00000464|DRUG|propafenone|
223642774|NCT03352609|DEVICE|Sham rTMS|Double blind MagPro system delivers sham condition by mimicking rTMS sound and delivering skin stimulus via TENS pads
223642775|NCT03815929|DRUG|Estradiol 100 Micrograms Patch|Standard
223642776|NCT03815929|DRUG|Estradiol Patch|Individualized
223642777|NCT05611788|BEHAVIORAL|Structure Learning Training|Participants will undergo 12 sessions of structure learning training lasting about 1 hour each along with 2 testing sessions interspersed within the 12 training sessions. Each session will be conducted in a remote-guided manner with an approximate 1-day gap in between sessions. The entire training will last around two weeks
223642778|NCT05189821|PROCEDURE|Radiofrequency Ablation|Ultrasound guided radiofrequency ablation
223642779|NCT02205736|OTHER|Breast Health Education|Small group breast health educational sessions for Latino women in home setting.
224230313|NCT00000464|DRUG|quinidine|
224230314|NCT00000464|DRUG|sotalol|
224230315|NCT03229252|DRUG|Placebo Inhalation Solution|Normal Saline Inhalation Solution
224230316|NCT03229252|DRUG|SPX-101|SPX-101 Inhalation Solution
224230317|NCT05170256|DRUG|Trastuzumab|Addition of trastuzumab to standard treatment (fluoropyrimidine/platinum doublet with pembrolizumab)
224230318|NCT01886274|DEVICE|Transcranial direct current stimulation|tDCS involves application of very low amplitude direct current via surface scalp electrodes. The applied current modifies the transmembrane neuronal potential and thus influences the level of excitability. Depending on the polarity of active electrodes tDCS can increase or decrease the cortical excitability. The cathodal tDCS decrease the excitability, in this study a constant current of 2 mA intensity was applied for 20 min.
223642780|NCT00305188|DRUG|Xaliproden (SR57746A)|oral administration
223642781|NCT00305188|DRUG|Placebo|oral administration
223642782|NCT00305188|DRUG|Oxaliplatin|IV administration
223642783|NCT00305188|DRUG|5-Fluorouracil|IV administration
223642784|NCT00305188|DRUG|Leucovorin|IV administration
223642785|NCT01071304|DRUG|Midazolam|A single oral dose of midazolam 2 mg (1 mL of 2 mg/mL syrup) was given on Day -2 and Day 5.
223642786|NCT01071304|DRUG|Ridaforolimus|Ridaforolimus 40 mg (4 x 10 mg tablets) oral once daily on Days 1 through 5.
223765580|NCT01591473|DRUG|Poly I:Poly C12U 200 ug|Poly I:Poly C12U 200 ug; 3 doses; nasal administration every 28 days
223642787|NCT03458819|DIAGNOSTIC_TEST|Isolation of peritoneal mesothelial cells|HPMCs will be isolated and stored at -80 degrees until analysis. Changes in the protein expression of EMT markers such as E-cadherin, a- SMA, Snail, and fibronectin in the HPMCs will be evaluated by Western blot analysis.
223642788|NCT02794909|DEVICE|Cardiopulmonary ultrasound exam|The cardiopulmonary ultrasound exam consists of a point-of-care ultrasound scan of the heart, lungs, peritoneal cavity, aorta, and femoral veins.
223642789|NCT03957577|OTHER|Prospective observational cohort study|Prospective observational cohort study
223765581|NCT01591473|DRUG|Poly I:Poly C12U 500 ug|Poly I:Poly C12U 500 ug; 3 doses; nasal administration every 28 days
223765582|NCT01591473|DRUG|Poly I:Poly C12U 1250 ug|Poly I:Poly C12U 1250 ug; 3 doses; nasal administration every 28 days
223765583|NCT01591473|DRUG|Placebo|Placebo; 3 doses; nasal administration every 28 days
223765584|NCT01591473|DRUG|FluMist|FluMist 0.2 ml; 3 doses; nasal administration every 28 days
223765585|NCT01133184|BIOLOGICAL|Sci B vac|Sci B vac
223642790|NCT05899426|OTHER|motor learning based clinical pilates|The exercises will be created as function and goal. At least one stimulus will be given during each exercise (visual, tactile, auditory or vestibular). 2 different levels were determined for 3 months of treatment, according to the months. As the level increased, the intensity of the exercise increased. In general, the exercise intensity was increased according to the against gravity and the decreasing in the support area.
224230319|NCT04799210|DEVICE|Eximis CS (Contained Segmentation) System|Containment, segmentation and extraction of uterine tissue in pre-menopausal women undergoing laparoscopic hysterectomy or myomectomy for non-cancer indications.
223642791|NCT05899426|OTHER|Conventional Physiotherapy|This exercise program will include strengthening, stretching, posture exercises, balance and gait exercises. Aim is to improve muscle strength and prevent shortness of muscles. Also, balance and gait exercise aim to improve walking capacity.
223642792|NCT06046118|DEVICE|Yellow and red light emitting diode photobiomodulation (Eye Light, Espansione Group, Bologna, Italy)|"Each session consists of:~* 1st phase: 300 seconds of continuous Yellow light (eyes closed) + 60 seconds of pulsed Yellow light (eyes opened)~* 2nd phase: 300 seconds of continuous Red light(eyes closed) + 60 seconds of pulsed Red light (eyes opened).~Cycle 1: 8 sessions (two PBM per week for 4 weeks); Cycle 2: 6 sessions (two PBM per week for 3 weeks)."
223642793|NCT06046118|DEVICE|Sham Mask|Low light emission mask (Sham Mask, Espansione group, Bologna, Italy)
223642794|NCT03777306|OTHER|ARM A EARLY INTERVENTION GROUP|"Post randomization, all patients will take baseline survey to assess their level of stress prior to starting the educational program During the educational interventions they will receive~* 1 video/picture/worksheet per week covering the topic to be covered.~* 1 phone/week by the Health Advisor, to discuss the topic for the week s/as their disease, stress and anxiety management, life organization, adherence skills, healthy eating and sleeping). Participant and the health advisor will also set up a Tiny Step to serve as a goal for the week .~* 3 emails/texts through the week, to remind about the topic covered, or to encourage them on their Tiny Step goal.~After 12 weeks on the program participants will re-take the surveys to assess the level of stress."
223642795|NCT03777306|OTHER|ARM B DELAYED INTERVENTION GROUP|The educational intervention is similar as in ARM A except that the participants will receive standard of care for the first 12 weeks post randomization and then begin the educational intervention
223642796|NCT02898181|DEVICE|Neuromodulation|Active LLTS will be performed by use of a transcutaneous electrical nerve stimulation Parasym neuromodulation system with electrodes attached to the ear. Neuromodulation will be applied continuously for 2 hours daily.
223642797|NCT03793946|OTHER|AB-assistant|The AB-assistant is an antimicrobial stewardship smartphone application that offers local antimicrobial guidelines to physicians currently assessed per website or paper/digital booklet.
223642798|NCT06463808|DRUG|Recombinant Human Brain Natriuretic Peptide|we divide our subjects into two groups;one is required to take recombinant human brain natriuretic peptide,the other is not required to take recombinant human brain natriuretic peptide
223642799|NCT03529695|BEHAVIORAL|Standard HVP Curriculum|Treatment in the control arm includes the content and services typically provided by the home visitation partner, which is focused on strengthening children's cognitive skills, early literacy skills, social/emotional and physical development.
223642800|NCT03529695|BEHAVIORAL|Obesity Prevention|Obesity prevention curriculum program targets 4 key behaviors (physical activity, increasing fruit and vegetable consumption, decreasing sugary beverages, and decreasing fried foods) aimed at reducing obesity risk in mothers and children. The module will also include weekly activity opportunities to develop social networks that foster healthy eating and physical activity.
223642801|NCT06582381|OTHER|Meal set A|morning meal: low carbohydrate, low protein, low fat afternoon meal: high carbohydrate, high protein, high fat
223642802|NCT06582381|OTHER|Meal set B|morning meal: low carbohydrate, high protien, low fat meal afternoon meal: high carbohydrate, low protein, high fat meal
223642803|NCT06582381|OTHER|Meal set C|morning meal: low carbohydrate, low protien, low fat meal afternoon meal: high carbohydrate, high protein, low fat meal
224230320|NCT05118321|DEVICE|Custom-made upper limb exosuit and hand exoskeleton|Participants go through 3 90-min sessions in a clinic setting and perform a series of functional tasks adapted from motor activity log and bilateral upper limb tasks with and without the device.
224230321|NCT06059170|BEHAVIORAL|LARS score/ EORTC QLQ C30|administering questionnaire
224230322|NCT01748500|DRUG|Pantoprazole|
223642804|NCT06582381|OTHER|Meal set D|morning meal: high carbohydrate, low protien, low fat meal afternoon meal: low carbohydrate, high protein, high fat meal
223642805|NCT05394324|DEVICE|Intervention|No study treatments will be administered during this retrospective study. However, data will be collected from medical records of patients who have been treated with subject devices of this study.
223642806|NCT02713893|DRUG|Econazole nitrate 1% plus Benzydamine HCl 0.12% intravaginal cream|
223642807|NCT02713893|DRUG|Placebo plus Econazole nitrate 1% intravaginal cream|
223642808|NCT02713893|DRUG|Placebo plus Benzydamine HCl 0.12% intravaginal cream|
223642809|NCT02713893|DRUG|Placebo intravaginal cream|
224230323|NCT04611659|BEHAVIORAL|Motivational Interviewing and Educational Training (MIET)|Women in the intervention arm will receive a motivational interviewing intervention coupled with education on contraception and the potential for neonatal abstinence syndrome.
224230324|NCT02192905|BEHAVIORAL|Diabetes Prevention Program Lifestyle Intervention|
224230325|NCT00004498|GENETIC|Adenoviral Vector-Mediated Gene Transfer|
224230326|NCT00002583|DRUG|cisplatin|50 mg/m2 IV
224230327|NCT00002583|DRUG|vinorelbine ditartrate|25 mg/m2 IV
224230328|NCT00221390|DRUG|Ropinirole (+ physical therapy)|
224230329|NCT00221390|DRUG|(vs.) Placebo + physical therapy|
224230330|NCT01693484|DRUG|ICG (Indocyanine Green)|Diagnostic drug used for visualisation of blood perfusion in various tissues.Administered intravenously, 2X: 1X prior to anesthesia, and 1X after tourniquet on operative extremity has been released for at least 15 minutes. When excited by laser light source, it subsequently emits at a near infrared frequency.
224319646|NCT02293889|BEHAVIORAL|PA intervention People with Osteoarthritis Walking Programme|The PA intervention will aim to increase levels of PA safely in our defined population. Participant are given a pedometer at the start of the intervention and encouraged to record their daily step counts and set step goals using the online system provided (POW: People with osteoarthritis walking programme).
224230331|NCT02435979|OTHER|hand therapy|Treatment can include stretching, motion, and strengthening exercises. As the patients endurance and strength increased the repetitions and/or resistance of these exercises will increase. Modalities for pain control and tissue mobility, and bracing or splinting if necessary. All treatments for the traditional hand therapy treatment group will occur seated at the hand therapy treatment table.
223642810|NCT02917096|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic HCT
223642811|NCT02917096|DRUG|Fludarabine|Given IV
223642812|NCT02917096|DRUG|Fludarabine Phosphate|Given IV
223642813|NCT02917096|OTHER|Laboratory Biomarker Analysis|Correlative studies
223642814|NCT02917096|DRUG|Melphalan|Given IV
223642815|NCT02917096|OTHER|Pharmacological Study|Correlative studies
223642816|NCT02917096|DRUG|Ruxolitinib|Given PO
223642817|NCT02917096|DRUG|Ruxolitinib Phosphate|Given PO
223642818|NCT02917096|DRUG|Sirolimus|Given PO
223642819|NCT02917096|DRUG|Tacrolimus|Given IV and PO
223642820|NCT06125041|DRUG|Adebelizumab+Carboplatin+Etoposide+Concurrent Radiotherapy|Eligible patients will receive the following treatment schemes: adebelizumab+carboplatin+etoposide, with one treatment cycle every three weeks. After 4-6 cycles, adebelizumab maintenance therapy combined with concurrent radiotherapy will be given, and conventional radiotherapy will be given to chest lesions (2Gy\*(20-30)f), brain (3Gy\*10f)/ bone (3Gy\*10f)/ adrenal gland. Immunotherapy is suspended during radiotherapy for chest lesions and lymph nodes in mediastinum, and immunotherapy is given 1-2 weeks after radiotherapy. Radiotherapy for other metastatic lesions can be carried out simultaneously with immunotherapy.
223642821|NCT04040205|DRUG|Abemaciclib|Abemaciclib 200 mg will be taken by mouth twice daily.
223642822|NCT06345690|OTHER|VIA Disc NP|VIA Disc NP - Allograft tissue injection
223642823|NCT01781728|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|Stereotactic Body Radiation Therapy (SBRT) which included 5 consecutive fractions of 25 to 33 Gy, following 3 months of multiagent chemotherapy.
224230332|NCT02435979|OTHER|Proximal Strengthening|Patients will perform a standardized proximal strengthening protocol consisting of cervical, periscapular, and shoulder strengthening exercises. Depending on the pace and guidance needed for these exercises 25-30 minutes will be spent on proximal strengthening exercises. As the patients endurance and strength increased the repetitions and/or resistance of these exercises will increase.
224230333|NCT05819008|DIAGNOSTIC_TEST|Neuropsychological Assessment|"To validate Mindmore Distance (MD), the following standard neuropsychological tests will be used in a testing session with a psychologist:~* Wordlist 1 and 2 from WMS-III (Wechsler, 1997). Equivalent to RAVLT in MD~* Coding from WAIS-IV (Wechsler, 2008). Equivalent to SDPT in MD~* Block Span from WMS-III (Wechsler, 1997). Equivalent to CBT in MD~* Trail Making Test from D-KEFS (Delis et al., 2001). Equivalent to TMT-Click in MD~* Color-Word Interference Test from D-KEFS. Equivalent to Stroop in MD~* Verbal fluency from D-KEFS. Equivalent to FAS in MD~All participants will complete some questionnaires: Hospital Anxiety and Depression Scale (Zigmond \& Snaith, 1983); Insomnia Severity Index (Bastien, Vallieres, \& Morin, 2001); Cognitive Failure Questionnaire (Broadbent, Cooper, FitzGerald, \& Parkes, 1982); Perceived Stress Scale (Levenstein et al., 1993); Multidimensional Fatigue Inventory (Smets, Garssen, Bonke, \& De Haes, 1995)."
224230334|NCT05304299|DIETARY_SUPPLEMENT|Cordyceps Cicadae Mycelia|Cordyceps Cicadae Mycelia will be given to test its potential for alleviation of high intraocular pressure.
224230335|NCT04820842|DRUG|TAK-994|TAK-994 tablets.
223642824|NCT05444530|BIOLOGICAL|VAC85135|Participants will receive VAC85135 as IM injection.
223642825|NCT05444530|DRUG|Ipilimumab|Participants will receive Ipilimumab as IV infusion.
223642826|NCT05615922|DEVICE|Transcranial Direct Current Stimulation (tDCS)|tDCS is noninvasive brain stimulation device that modulates brain activity by delivering a low-intensity electrical current (2.0 mA) through scalp sponge electrodes. The device is preprogrammed to ramp up to 2.0 mA (for 30 seconds), provide constant current throughout session (29 minutes), and then ramp down (for 30 seconds) at the end.
223642827|NCT05615922|BEHAVIORAL|Word-Naming Activity|During each tDCS session, the tDCS clinician will guide the participant in a word-naming exercise. Participants will be presented with photos of target items and prompted to verbally produce the names of the pictures.
223765586|NCT00480779|BEHAVIORAL|GLB Group|The Group Lifestyle Balance (GLB) program is a lifestyle change program adapted from the successful lifestyle intervention utilized in the Diabetes Prevention Program. For this arm, the intervention is delivered in face-to-face groups by a trained lifestyle coach.
223765587|NCT00480779|BEHAVIORAL|GLB DVD|The Group Lifestyle Balance (GLB) program is a lifestyle change program adapted from the successful lifestyle intervention utilized in the Diabetes Prevention Program. For this arm, the intervention is delivered via DVD and weekly telephone contact with a trained lifestyle coach.
223642828|NCT05378672|DRUG|Dasiglucagon|Dasiglucagon, 0.6 mg/0.6 mL or 0.3 mg/0.3 mL will be administered as an under the skin (subcutaneous, s.c.) injection by a prefilled syringe, into the buttocks.
223765588|NCT01763775|DEVICE|Transtek 125X|Measuring weight, total body water, body fat, muscle mass, and bone mass. Measure each participants by Transtek 125X (GBF-1251-B, BF-1255-B, BF-1256-B, GBF-1257-B).
224323372|NCT05791708|DRUG|Sutimlimab|CAD patients in Sutimlimab cohort must be treated according to routine clinical practice
223642829|NCT04410367|DRUG|18F fluciclovine|18F fluciclovine injection, 185 MegaBecquerel (MBq) (5 Millicurie (mCi)) ± 20%, delivered as an intravenous bolus
223642830|NCT03227913|OTHER|Two samples of saliva|"1. Without stimulation: the first will be used to measure the flow of naturally secreted saliva~2. With stimulation: the second will will be used to measure the flow and viscosity of the saliva secreted after stimulation"
223642831|NCT03227913|OTHER|Chewing behaviour|Measure the time taken by subjects to chew the food and the number of bites they use before swallowing
223642832|NCT03227913|OTHER|Study of the food bolus|"* Analysis by a compression and viscosity test~* Evaluation of the quantity of saliva incorporated by drying"
223642833|NCT01047488|DRUG|Imipramine|Tablet 25 mg, 3 tablets evening (extensive metabolizers) or 1 tablet evening (poor metabolizers), daily, 5 weeks
223642834|NCT01047488|DRUG|Pregabalin|Capsule 75 mg, 2 capsules twice daily, daily, 5 weeks
223642835|NCT01047488|DRUG|Imipramine, pregabalin|Imipramine: tablet 25 mg, 3 tablets evening (extensive metabolizers) or 1 tablet evening (poor metabolizers), daily, 5 weeks Pregabalin: capsule 75 mg, 2 capsules twice daily, daily, 5 weeks
223642836|NCT01047488|DRUG|Placebo|Placebo tablets to imipramine 25 mg, 3 or 1 tablet evening, daily, 5 weeks Placebo capsules to pregabalin 75 mg, 2 capsules daily, daily, 5 weeks
223642837|NCT02315742|BEHAVIORAL|Let's Move Program|Patients will walk 5 times per week for 12 weeks for a minimum of 30 minutes while using a heart rate monitor. After the first two weeks of walking, patients will attend four consecutive group meetings which a research team member will look at walking logs and download data from heart rate monitor to focus on progress. Patient will receive weekly phone calls to monitor progress and to change walking duration or intensity level.
223642838|NCT04305691|DRUG|Ixazomib Citrate|Given PO
223642839|NCT04305691|OTHER|Quality-of-Life Assessment|Ancillary studies
223765589|NCT01763775|DEVICE|Transtek 950D|Measuring weight, total body water, body fat, muscle mass, and bone mass. Measure each participants by Transtek 950D (GBF-950-D).
223765590|NCT06967584|OTHER|Kinesio Taping|"The Kinesio tape will be applied anteriorly and posteriorly along the subcostal region to facilitate the respiratory muscles. Anteriorly, an I-shaped Kinesio tape will be applied with the base anchored on the xiphoid process, stretched to 50-75% tension, applied only to the linea alba. The ends of the tape will be applied without tension toward the subcostal curvature. Posteriorly, a second I-shaped Kinesio tape will be applied. The base of the tape will be anchored on the spinous process of the 12th thoracic vertebra with 50-75% tension, and the tails will be applied without tension toward the ribs"
223765591|NCT06967584|OTHER|Sham Kinesio Taping|The Kinesio tape will be applied anteriorly and posteriorly along the subcostal region but without tension
223765592|NCT05682131|DRUG|Realgar Indigo naturalis formula|Realgar Indigo naturalis formula was used in the induction, consolidation and intensive treatment of patients in intermediate or high risk
223765593|NCT05682131|COMBINATION_PRODUCT|Conventional chemotherapy|conventional chemotherapy
224230336|NCT04820842|DRUG|Placebo|Placebo-matching tablets.
224230337|NCT00071552|DRUG|Qvar|Qvar (HFA-propelled beclomethasone dipropionate metered dose inhaler) 160 mcg twice daily for 12 weeks
224230338|NCT00071552|DRUG|Flovent Diskus|Flovent Diskus (fluticasone propionate multi-dose dry powder inhaler) 200 mcg twice daily for 12 weeks
224230339|NCT01917409|DEVICE|conventional laryngoscopy|the device is to assist nasotracheal intubation
224230340|NCT01917409|DEVICE|video-stylet|the device is to guide the nasotracheal tube into trachea
224230341|NCT01073306|BIOLOGICAL|Investigational Vaccine for Dengue Virus Subtype 2|Subcutaneous injection in upper arm of vaccine at dose of 10 plaque-forming units (PFU)
224230342|NCT01073306|OTHER|Placebo|Subcutaneous injection of placebo
223765594|NCT06971224|DIETARY_SUPPLEMENT|Nicotinamide Riboside (NR)|2000 mg NR daily.
224230343|NCT03164954|DIAGNOSTIC_TEST|automatic risk detection|automatic alert of the risk for CPSP, triggered by one of the following entries in the hospital information system: psychological risk factors (depression, anxiety, PTSD, catastrophizing, high pain anticipation), chronic use of benzodiazepines or opioids, intense postoperative pain or need of large opioid doses in the recovery room
224230344|NCT06543654|OTHER|Omnichroma|Each participants had two kinds of veneers
224230345|NCT06543654|OTHER|Ceram. X Spectra|Ceram. X Spectra
224230346|NCT04884659|OTHER|Time restricted feeding arm|80% of calories consumed before 2PM, remaining 20% consumed by 4PM. Fasting for 14-16 hours
223765595|NCT06971224|OTHER|Placebo|Placebo tablet identical in taste, shape and appearance to NR tablets.
224230347|NCT04884659|OTHER|usual feeding pattern arm|All meals consumed ad lib with 50% of calories consumed after 4PM
224230348|NCT04464694|DRUG|Ranibizumab|Patients will receive single intravitreal injection of Ranibizumab 0.5 mg 3\~7 days before vitrectomy.
224230349|NCT04464694|OTHER|Sham injection|Patients will receive single sham injection 3\~7 days before vitrectomy.
224230350|NCT04464694|PROCEDURE|Pars plana vitrectomy|Surgical procedure to remove the intravitreal hemorrhage and fibrosis membrane, and re-attach the retina, and perform endo laser photocoagulation on retina
224230351|NCT05083650|PROCEDURE|Macular hole closure with amniotic membrane with/without internal limiting membrane peeling|Pars plana vitrectomy with/without internal limiting membrane peeling, amniotic membrane, and air tamponade
224230352|NCT05688930|OTHER|PENMT (Experimental Group)|The neuromuscular injury prevention intervention protocol contains field work activities that involve proprioceptive exercises, flexibility, and specific and general muscle strength of the MMII and trunk soccer players.
224230353|NCT05688930|OTHER|FIFA 11+ (Control Group)|Treatment or experimental condition. 1: FIFA 11+ Program
224230354|NCT01493765|OTHER|Simulator training with expert scoring|Residents will be trained using surgical simulation
224230355|NCT00132002|DRUG|vorinostat|Given PO
224230356|NCT00132002|OTHER|laboratory biomarker analysis|Correlative studies
224230357|NCT00093964|DRUG|Cilengitide 500 mg|Subjects will receive 1-hour intravenous infusion of 500 mg cilengitide twice weekly on Day 1 and 4 of each week during every 4-week cycle, for a total of 8 infusions per cycle. Cycles were repeated without pause until progressive disease (PD), unacceptable adverse events (AEs), or withdrawal of consent.
224230358|NCT00093964|DRUG|Cilengitide 2000 mg|Subjects will receive 1-hour intravenous infusion of 2000 mg cilengitide twice weekly on Day 1 and 4 of each week during every 4-week cycle, for a total of 8 infusions per cycle. Cycles were repeated without pause until progressive disease (PD), unacceptable adverse events (AEs), or withdrawal of consent.
223642840|NCT04305691|OTHER|Questionnaire Administration|Ancillary studies
223765596|NCT04907032|DRUG|Mirabegron 50 MG|Posterior Tibial Nerve Stimulation with Mirabegron vs. Posterior Tibial Nerve Stimulation Plus Placebo
223765597|NCT04907032|DEVICE|Posterior Tibial Nerve Stimulation (PTNS)|Posterior Tibial Nerve Stimulation with Mirabegron vs. Posterior Tibial Nerve Stimulation Plus Placebo
223765598|NCT04182581|BIOLOGICAL|BCMA/CD19 Dual-Target CAR-T|BCMA/CD19 Dual-Target CAR-T target both BCMA and CD19. The subjects will receive CAR-T as one dose. The dosage ranges from 5×10\^4 to 3×10\^5 CAR+T/Kg.
223765599|NCT00876304|DRUG|PF-04802540|Multiple ascending doses for 10 days; planned doses include capsules totaling 5 mg and 20 mg every 12 hours, with additional doses determined based on accumulating data
223765600|NCT00876304|DRUG|Placebo|Placebo capsules every 12 hours for 10 days
224230359|NCT05824312|DRUG|Tyrosine kinase inhibitor drugs.|TKI drugs were used at least 8 weeks. Imaging exam would be taken every four weeks.
224323373|NCT03191149|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
223642841|NCT05589857|DEVICE|IPAD|Participants will play a game using the iPad's standard camera, which will show you your hospital room and the decal/stickers s as they appear in the real world.
223642842|NCT05589857|DEVICE|Augmented Reality|Participants will play a game through (device camera and application) that add virtual or digital characters and items that let participants view the real world.
223642843|NCT05233618|DRUG|Tagraxofusp|inpatient on days 1-3 of cycles 1-4 and days 1-2 of additional cycles
223642844|NCT06969066|BEHAVIORAL|Cognitive Remediation Therapy plus Sleep Hygiene Education (CRT+SHE)|Participants will receive Cognitive Remediation Therapy (CRT) combined with Sleep Hygiene Education (SHE). CRT includes structured training sessions targeting attention, memory, visuospatial skills, calculation ability, logical reasoning, and language abilities. Sessions will be conducted daily for 50 minutes over 6 weeks. Sleep Hygiene Education will cover standard recommendations to improve sleep behaviors.
223642845|NCT06969066|BEHAVIORAL|Sleep Hygiene Education Only (SHE)|Participants will receive Sleep Hygiene Education (SHE) only, including guidance on adjusting sleep schedules, maintaining healthy sleep environments, minimizing stimulant intake, and managing sleep-related behaviors, without any CRT intervention.
223642846|NCT06973486|BEHAVIORAL|psychometric scales|Perceived Stress Scale (PSS) Pain Tolerance Scale (PRS) Surgical Anxiety Scale
223642847|NCT03003325|DRUG|AOP2014|AOP2014 will be supplied to the patients as pre-filled auto-injection pens, containing 250 µg of active drug (0.5 ml solution for injection). One pen may be used twice within a time period of 4 weeks. Hence investigators will provide one prefilled pen at every monthly visit. AOP2014 will be self-injected subcutaneously by patients once every 14 days at the single doses of 100 µg (0.2 ml).
223642848|NCT03003325|PROCEDURE|Phlebotomies|According to current common clinical practice the regimen must be selected accordingly to maintain the recommended level of HCT\< 45%. Once normalization of the hematocrit has been achieved, blood counts at regular intervals (every 4 weeks) will establish the frequency of future phlebotomies. Sufficient blood should be removed to maintain the hematocrit below 45%.
223642849|NCT03003325|DRUG|ASA|100 mg/daily of ASA is recommended (when there are not contraindications) according with current guidelines for this risk class of patients
223642850|NCT06332521|OTHER|Acoustic signal analysis method|Evaluate at birth in 2 characterized populations of babies born at term or prematurely, the correlation between bioacoustic characteristic of a cry specific to each baby, with the neurodevelopmental data at 2 years.
223642851|NCT03173248|DRUG|AG-120|Tablets administered orally
223642852|NCT03173248|DRUG|Placebo|Tablets administered orally
223642853|NCT03173248|DRUG|Azacitidine|Administered SC or IV
223642854|NCT05777187|OTHER|Clinical Decision Support|The intervention will consist of clinical decision support alerts in the electronic health record directed towards anesthesiologists caring for patients with preexisting cognitive impairment. This intervention will alert towards delirium risk informed by history of cognitive impairment and promote 12 evidence based best practices during care for perioperative patients.
223642855|NCT06210724|DIAGNOSTIC_TEST|Faecal immunochemical test for haemoglobin, faecal calprotectin, faecal microbiome|Faecal samples to be collected by patients at home and delivered via post to a bowel cancer screening hub for analysis
223765601|NCT06974110|DRUG|MOMA-341|MOMA-341 administered orally
224230360|NCT00888810|DRUG|TOPOTECAN|IV administration on Day 1, day 8 and day 15, at the dose level of 3.2 mg/m² for 6 cycles of 28 days(up to 8 cycles)
224230361|NCT00888810|DRUG|LAPATINIB|Daily oral administration during all the study. 1250 mg/day
224230362|NCT01568008|DRUG|Bimatoprost 0.01% ophthalmic solution|Bimatoprost 0.01% ophthalmic solution eye drops at a dose and frequency as determined by the physician.
224230363|NCT05832255|DRUG|Psilocybin, 1.5 mg|Blister packs will contain five capsules of the study drug, Psilocybin 1.5mg. Subjects will be given blister packs with weekly doses at each visit including baseline (day 1), day 8, day 15, day 21, and day 28. Weekly blister packs will contain five doses (1-2 extra capsules depending on the week) to accommodate for flexibility in scheduling. Unused and open packages will be returned to study staff at each visit after baseline.
224230364|NCT00003213|DRUG|dexamethasone|4 mg Dexamethasone in the morning
224319647|NCT02293889|OTHER|Placebo capsule (Vitamin D): edible oil|Placebo capsules will be administered over 3 months, as daily capsules (identical to Vitamin D capsules) containing edible oil (manufactured and provided by DSM)
224319648|NCT05129605|DIAGNOSTIC_TEST|Prostate cancer screening|Physical exam (digital rectal exam), prostate-specific antigen (PSA) and PSA derivatives, and multiparametric MRI of the prostate
224319649|NCT01275430|DEVICE|Sherlock 3CG|Sherlock 3CG is indicated for central venous catheter guidance and positioning during catheter placement. The Sherlock 3CG provides real time catheter tip location information through the use of passive magnet and cardiac electrical signal detection.
223642856|NCT02833233|PROCEDURE|Cryoablation|
223642857|NCT02833233|DRUG|Ipilimumab|
223642858|NCT02833233|DRUG|Nivolumab|
223642859|NCT06575959|DRUG|Enlicitide|Oral tablet
223642860|NCT02991768|DRUG|Entocort|A corticosteroid that decreases levels of inflammatory cytokines.
223642861|NCT02991768|DRUG|Placebos|Placebo is matched to the study drug.
223765602|NCT06974110|DRUG|Irinotecan|Irinotecan administered by IV infusion
223765603|NCT06974110|DRUG|Immunotherapy|Immunotherapy administered by IV infusion
223765604|NCT03127891|BEHAVIORAL|pranayama yoga|providing short term pranayama yoga for 5 sessions before surgery patients under going cardiac surgery.
223765605|NCT03127891|OTHER|control group|no intervention should be given to patients allocated to this group
223765606|NCT02445027|DEVICE|MGH OCT Imaging Capsule|Imaging of the esophagus using the OCT Capsule and system.
223765607|NCT03549247|BEHAVIORAL|quality of life in healthy,gingivitis,periodontitis groups|a questionnaire form evaluating oral hygiene habits and oral hygiene consciousness levels, OHIP-14 scale was applied
224319650|NCT01275430|OTHER|Blind Placement|"PICCs will be placed blindly, without the use of any tip location/positioning device."
223765608|NCT05735561|DIAGNOSTIC_TEST|X-Ray|Consenting participants will be asked to come into the clinic for a single visit, during this visit they will be asked to complete an x-ray to check for evidence of avascular necrosis.
223765609|NCT01341886|DRUG|Metformin|in case group metformin is added to levothyroxine and levothyroxine is decreased by 30% .in control group levothyroxine is reduced by 30% and no metformin is added to the regimen.
223642862|NCT04979546|OTHER|Intensive Use of Patient Reported Outcome Measures and Open PROM Availability to Treating Neurologist|"Baseline, 6 months, and 12 months administration of HADS, EQ5D, MFIS, PDDS, PHQ-9 questionnaires in addition to Open ended text response to (limit 280 characters) What are the top 3 things you would like your MS Neurologist to know about you right now?~Additionally, the treating neurologist will be prompted to view the text response to the 3-item prompt in addition to the PROM questionnaire scores for participants in the interventional group."
224230365|NCT00003213|DRUG|granisetron hydrochloride|1 mg Granisetron in the morning
223642863|NCT04979546|OTHER|Conservative Use of Patient Reported Outcome Measures and Blinded PROM Availability to Treating Neurologist|"Baseline and 12 months administration of HADS, EQ5D, MFIS, PDDS, PHQ-9 questionnaires in addition to Open ended text response to (limit 280 characters) What are the top 3 things you would like your MS Neurologist to know about you right now?~Additionally, the treating neurologist will only be prompted to view the text response to the 3-item prompt, and will not be able to access the PROM questionnaire scores for participants in the control group."
223765610|NCT01946399|DRUG|Ozurdex implant|Intravitreal injection of Dexamethasone implant
223765611|NCT04738916|DEVICE|Whole-body vibration training|Whole body vibration (WBV) is a form of treatment that has been shown to have an important role in increasing neuromuscular performance, improving muscular strength, balance. The technique involves standing and holding positions, or performing prescribed exercises, on a platform that is vibrating at a programmed frequency, amplitude, and magnitude of oscillationWhole-body vibration (WBV) is a therapeutic method that exposes the entire body to mechanical oscillations while the patient stands or sits on a vibrating platform.
224230366|NCT00003213|DRUG|metoclopramide hydrochloride|20 mg Metoclopramide (1 x morning, 1 x afternoon, 1 x evening)
224319651|NCT05169632|DEVICE|Computerized Gaming Rehabilitation Program 1|Brain training games with physical exercise component.
223642864|NCT04940585|OTHER|ROSE Program|The program includes 6 group sessions and an individual session 4-6 weeks after birth. Each session will last 60 minutes and will be conducted over Webex. The key areas that will be discussed during the sessions include: Psychoeducation, Adjusting to life with baby, Effective communication, Asking for what you need, and Planning for the future.
223642865|NCT03052829|BEHAVIORAL|Physical activity counseling|Subjects in this arm will receive counseling on how to increase their physical activity level.
223642866|NCT03052829|BEHAVIORAL|Usual care|Subjects will undergo their usual care without intervention
223765612|NCT06267625|OTHER|Physical Evaluations of individuals|Participants will be evaluated on posture, cough strength, functional mobility and hand grip strength.They will be asked to answer the Standardized Mini Mental Test, Modified Medical Research Council Scale, Physical Activity Scale for the Elderly, Berg Balance Scale. The data to be obtained from all these evaluations are planned to be collected face to face from the participants at once and within a maximum of 1 hour.
223765613|NCT03179176|OTHER|High Frequence Ultrasound Doppler (HFUD) utilisation|Utilisation of HFUD will be done during on patients during an operation in waking condition. This procedure extends the usual procedure from 15 to 20 minutes.
223765614|NCT02325011|DRUG|Sativex® (Treatment A)|Each 100 uL actuation (spray) of Sativex contains 27 mg/mL THC and 25 mg/mL CBD plus peppermint flavouring. The study dosage of 10.8 mg THC and 10 mg CBD is delivered as four sprays to the oral mucosa.
223765615|NCT02325011|DRUG|Sativex® and fluconazole concomitantly (Treatment B)|"Each 100 uL actuation (spray) of Sativex contains 27 mg/mL THC and 25 mg/mL CBD plus peppermint flavouring. The study dosage of 10.8 mg THC and 10 mg CBD is delivered as four sprays to the oral mucosa.~Fluconazole 200 mg twice daily (BID) for two days, will be administered at the following time points relative to the Day 1 Sativex dose: 1 hour pre-dose, and approximately 11, 24, and 36 hours post-dose."
223765616|NCT00613509|BIOLOGICAL|ALVAC(2) Melanoma multi-antigen therapeutic vaccine|0.5 mL, 2 cycles
223765617|NCT00613509|BIOLOGICAL|Intron A, Interferon alpha -2b|0.5 mL, 5 times per week for 4 weeks
223765618|NCT03037528|BEHAVIORAL|diet and lifestyle program|Participants will be taught how to follow a very low carbohydrate, ketogenic diet, become more physically active, and get adequate sleep.
223765619|NCT03037528|BEHAVIORAL|positive affect informational materials|Participants will be taught about positive affect skills, such as gratitude, positive reappraisal, and personal strengths.
223765620|NCT03037528|BEHAVIORAL|mindfulness informational materials|Participants will be taught about mindfulness and mindful eating techniques.
223765621|NCT03037528|BEHAVIORAL|dietary tracking|Participants will be asked to track their diet consistently.
224230367|NCT01005836|BEHAVIORAL|Cognitive behavioral therapy for youth anxiety|
224230368|NCT01005836|OTHER|Usual clinic care|
224230369|NCT01005836|BEHAVIORAL|Cognitive behavioral treatment for youth depression|
224230370|NCT02688400|DRUG|Diacerein|
223765622|NCT01877629|DRUG|ACT-129968 500 mg tablet|ACT-129968, a tetrahydropyridoindole derivative, is a chemoattractant receptor homologous molecule expressed on T helper 2 cells (CRTH2) antagonist
224230371|NCT02688400|DRUG|Celecoxib|
224230372|NCT02688400|DRUG|Placebo|
224230373|NCT02259842|DRUG|BI 34021 FU2 solution|
224230374|NCT02259842|DRUG|BI 34021 FU2 tablet|dose group 4 only
224230375|NCT02259842|DRUG|Placebo|
224230376|NCT02259842|OTHER|High fat, high calorie breakfast|only for dose groups 3 and 5
224230377|NCT04886375|PROCEDURE|erector spina plane block|The investigators performed erector spina plane block to that patient group for postoperative analgesia
224230378|NCT04886375|PROCEDURE|modified pectoral nerve block|The investigators performed modified pectoral block to that patient group for postoperative analgesia
224230379|NCT05460442|PROCEDURE|Caudal Block group|Patients will be placed in the lateral decubitus position. After local sterilization with povidone-iodine, the sacral hiatus will be visualized at the level of the sacral Cornus by ultrasound. The needle will be advanced toward the upper third of the sacrococcygeal ligament. The needle advancement will be terminated immediately after penetrating the sacrococcygeal ligament. At this level, after confirming the absence of blood or cerebrospinal fluid on aspiration, bupivacaine 0.25% (0.5 mL/kg) will be injected over 1 minute
224319652|NCT05169632|DEVICE|Computerized Gaming Rehabilitation Program 2|Cognitive training games with physical exercise component.
224323374|NCT03191149|PROCEDURE|Computed Tomography with Contrast|Undergo CT with contrast
224323375|NCT03191149|PROCEDURE|Echocardiography Test|Undergo ECHO
223642867|NCT05745909|PROCEDURE|Laparoscopic or open low-anterior resection of the rectum with TME and created loop transverse colostomy|The loop transverse colostomy is matured without torsion using a plastic retainer. The stoma protrudes 2-3 cm. The loop of the transverse colon is sutured with interrupted sutures using an absorbable 3/0 polyglactin suture without piercing the intestinal wall. The intestinal lumen is opened through a transverse incision on the antimesenteric border.
223642868|NCT05745909|PROCEDURE|Laparoscopic or open low-anterior resection of the rectum with TME and created loop ileostomy|The loop ileostomy is matured 25-30 cm from the ileocecal angle without torsion and without a retainer, so that stoma protrudes 2-3 cm. The loop of the ileum is sutured with interrupted sutures using an absorbable 3/0 polyglactin suture without piercing the intestinal wall. The intestinal lumen is opened through a transverse incision on the antimesenteric border.
223642869|NCT03818854|BIOLOGICAL|Human Mesenchymal Stromal Cells|Immediately prior to administration, the study product will be thawed and diluted 1:1 with reconstitution media (1:1 mix of 5% human serum albumin and 10% Dextran 40). Additional reconstitution media is added to a final product volume of 300 mL.
223642870|NCT03818854|BIOLOGICAL|Cell Reconstitution Media|300 mL of reconstitution media (1:1 mix of 5% human serum albumin and 10% Dextran 40)
224230380|NCT05460442|PROCEDURE|Pericapsular nerve group block|Patients will receive ultrasound-guided Pericapsular nerve group block in the supine position after proper sterilization of the groin region. The needle will be inserted in-plane with the transducer. The Pericapsular nerve group block group will receive 0.5 mL/kg of (0.25%) bupivacaine after a negative aspiration
224230381|NCT05460442|PROCEDURE|Fascia iliaca group|Patients will receive Ultrasound-Guided fascia iliaca compartment block in the supine position after sterilization of groin area. The needle will be inserted in-plane with the transducer. The needle tip will be advanced through the fascia iliaca and inserted further cephalad just below the fascia iliaca into the iliacus muscle. 0.5 mL/kg of (0.25%) bupivacaine will be injected and visualized moving cephalad away from the needle tip
224230382|NCT05073575|PROCEDURE|Hyaluronic acid|"After local anesthesia, an access flap will be prepared. Scaling and root planning will be performed combining the use of metal curettes and power-driven instrumentation by means of ultrasonic scaler.~Hyaluronic acid gel will be applied to exposed roots surface, followed by a tension-free primary closure of the surgery wound by means of 5-0 monofilament (polypropylene) non-resorbable suturing material."
224230383|NCT05073575|PROCEDURE|No-hyaluronic acid|"An access flap will be prepared in order to perform scaling and root planning therapy with the use of metal curettes.~After intervention, a tension-free primary closure of the interdental papillae and of the mucoperiosteal flaps by means of 5-0 monofilament (polypropylene) non-resorbable suturing materia will be performed"
224230384|NCT01915056|OTHER|GA-driven Intervention|For patients assigned to the treatment arm, individuals will be offered the option of completing the GA during a visit with their primary oncologist, or attending an additional visit at the multidisciplinary geriatric oncology clinic. The intervention consists of providing results of geriatric assessment in a summary to oncologists.
224230385|NCT02935959|DRUG|nebulized ketamine|Drugs will be prepared in 3 mL of saline 0.9% before administration by a standard hospital jet nebulizer via a mouthpiece, with a continuous flow of 100% oxygen at 6 L/min for 10 to 15 minutes (30 minutes before GA). Treatment will be stopped when the nebulizer began to sputter.
224230386|NCT02935959|DRUG|nebulized Dexmedetomidine|
224230387|NCT02935959|DRUG|nebulized midazolam|
224230388|NCT00232115|DRUG|Pimecrolimus|Pimecrolimus cream 1 %
224230389|NCT00232115|DRUG|Placebo|Vehicle cream (placebo)
224230390|NCT01103037|DRUG|QAV680|QAV680 500 mg (5 x 100 mg capsules) four times per day
224230391|NCT01103037|DRUG|QAV680 Placebo|Placebo to QAV680 5 capsules four times per day
223642871|NCT04965025|PROCEDURE|Multi-stage urethroplasty with graft inlay in first stage|Herein, the graft will be used in the first stage and the second stage will solely consist of retubularizing the urethra.
223642872|NCT04965025|PROCEDURE|Multi-stage urethroplasty with graft inlay in second stage|Herein, the graft will be used in the second stage and the first stage will solely consist of opening the urethra longitudinally.
223642873|NCT06646185|OTHER|Menstrual Pads|Participants adopt menstrual pads to manage their menstruation during 2 menstrual cycles. For each menstrual cycle, participants will provide vaginal microbiome samples via self-sampled swabs at 3 points.
223642874|NCT06646185|OTHER|Menstrual Cups|Participants adopt menstrual cups to manage their menstruation during 2 menstrual cycles. For each menstrual cycle, participants will provide vaginal microbiome samples via self-sampled swabs at 3 points.
223642875|NCT06646185|OTHER|Tampons|Participants adopt tampons to manage their menstruation during 2 menstrual cycles. For each menstrual cycle, participants will provide vaginal microbiome samples via self-sampled swabs at 3 points.
223642876|NCT04500158|DRUG|Lidocaine|2% Lidocaine with 1:100,000 epi
224230392|NCT02465411|DEVICE|Dexcom G4 or later generation|Continuous glucose monitoring with DexCom G4 platina or later generations
224230393|NCT00968383|DRUG|Beta adrenergic blockers|Participants will receive beta adrenergic blockers.
224230394|NCT00968383|DRUG|Platelet inhibitors|Participants will receive platelet inhibitors.
224230395|NCT00968383|DRUG|Statins|Participants will receive statins.
224230396|NCT00968383|DRUG|ACE inhibitors and/or ARB and/or AA|Participants will receive ACE inhibitors and/or ARB and/or AA
224230397|NCT00968383|PROCEDURE|PCI with stenting|Participants will undergo percutaneous coronary intervention (PCI) and coronary stenting.
224230398|NCT03076177|OTHER|Taping application|Kinesio taping application will be applied for experimental group; non specific taping application for control
224230399|NCT06332547|OTHER|Restrictive Transfusion Strategy|Blood transfusion at HCT less than 21% or Hb less than 6.0g/dL during CPB, at HCT less than 21% or Hb less than 7.0g/dL in ICU or general ward after surgery
224230400|NCT06332547|OTHER|Liberal Transfusion Strategy|Blood transfusion at HCT less than 24% or Hb less than 8.0g/dL during CPB, at HCT less than 30% or Hb less than 10.0g/dL in ICU or general ward after surgery
224230401|NCT03467477|DRUG|Flortaucipir F18|370 megabecquerel (MBq) IV single-dose
224230402|NCT03467477|PROCEDURE|Brain PET Scan|positron emission tomography (PET) scan of the brain
224230403|NCT03853577|OTHER|TMS/EEG|navigated TMS/high-density(hd)-EEG to directly stimulate defined cortical areas and investigate quantitatively the level of consciousness in psilocybin-induced altered brain states
223642877|NCT04572815|DRUG|Placebo Administration|Given IV and SC
223642878|NCT04572815|OTHER|Quality-of-Life Assessment|Ancillary studies
224230404|NCT02497677|BEHAVIORAL|Circle of Security -Parenting|The COS-P manual and video material has been translated to Danish (Tryghedscirklen - Forældreprogrammet, manual, Lier, 2013). Based on standard video material of parent-infant interactions, parents are trained to see and understand infant attachment behavior and especially to learn about infant miscuing attachment signals. In the current study parents will attend 10 sessions of 1.5 hour duration
224230405|NCT02497677|BEHAVIORAL|Care as Usual|CAU are different in the three participating districts and vary in content and duration. All three districts offer (a) group interventions for mothers who experience postnatal depressive symptoms and/or (b) extra counselling home-visits by a health nurse. Number and content of extra home-visits vary in accordance with the families' specific needs, and will rarely exceed 12 extra visits per year.
223642879|NCT04572815|OTHER|Questionnaire Administration|Ancillary studies
223642880|NCT04572815|BIOLOGICAL|Ustekinumab|Given IV and SC
223642881|NCT02110069|DRUG|Vincristine|Vincristine dose dependent upon weight. Weekly for 2 months (Induction); Weekly 2 months; every 2 weeks for next 5 months; every 3 weeks for 5 months (Maintenance)
223642882|NCT02110069|DRUG|Sirolimus|Continuous dosing to maintain trough level of 10-15ng/ml.
223642883|NCT06651684|BEHAVIORAL|CanCEASE with Health Navigator|"CanCEASE is a digital intervention to identify parents who smoke, assess their motivation and willingness to quit, as well as to provide direct linkage to evidence-based smoking interventions, including effective behavioural and pharmacological resources that can be used alone or in combination.~Participants will have the choice to receive CanCEASE at three timepoints (0, 6 and 12 months). CanCEASE will be combined with an offer of support sessions with a Health Navigator.~Health Navigators will be research personnel hired specifically for this study and trained formally in health navigation, tobacco cessation counseling and strategies to address unmet social needs. The investigators will leverage knowledge and experience of two ongoing RCTs of HNs in pediatrics to inform training strategies."
223642884|NCT06651619|OTHER|Water|Prescribed amount of bottled water the evening prior and 2 hours prior to team practice
223642885|NCT06651619|OTHER|Hydration Education|30-60 minutes
224230406|NCT01497236|DIETARY_SUPPLEMENT|Dietary Supplement: Nutrition supplement with RUTF or MNP|"14 days nutritional supplementation with either~* a fortified high quality food(RUTF), 1 sachet/day, 500 kcal and multi micronutrients~* a multi micronutrient powder (MNP), 2 sachets per day, no calories, twice recommended daily intake~* a placebo (to MNP), 2 sachets per day , no calories, no micronutrients, containing micronutrient carrier"
224230407|NCT00423761|DRUG|midazolam|
224230408|NCT00423761|DRUG|GW876008|
224230409|NCT01053273|PROCEDURE|Caudal Epidural Injection|Group I will receive caudal epidural injections with catheterization up to S3 with local anesthetic, steroids, and 0.9% sodium chloride solution
224230410|NCT01053273|PROCEDURE|percutaneous adhesiolysis|Group II will receive percutaneous adhesiolysis with targeted delivery of lidocaine, 10% hypertonic sodium chloride solution, and non-particulate betamethasone.
224230411|NCT05326022|DEVICE|Microcurrent therapy|Microcurrent therapy
224230412|NCT05326022|DEVICE|Low Level Laser Therapy|Laser therapy
224230413|NCT05326022|OTHER|Medical therapy|Medical therapy
224230414|NCT02006706|DRUG|rituximab [MabThera/Rituxan]|1000 mg iv Days 1 and 15
224230415|NCT02006706|DRUG|methotrexate|10 - 25 mg/week
224230416|NCT02006706|DRUG|methylprednisolone|iv administration on Day 1 and 15 prior to MabThera/Rituxan infusion
224230417|NCT02145975|DRUG|Fentanyl|The nurse will administer 1 ug per kg during 5 seconds when the patient complain of pain (visual analog scale, VAS, ≥7). Immediately with the onset of drug administration a timer started; every 5 minutes the researcher assess the EVA and the drug will be administered if VAS \> 3, until the patient manifests as a lower pain VAS ≤ 3 (mild). The nurse in charge in the PACU will manage the drug and will take 100 ug of fentanyl which is diluted in 10 mL of normal saline leaving a 10μg per ml concentration, are not labeled and for the physical and chemical characteristics of both drugs (colorless) risks of unblinded is minimized.
224230418|NCT02145975|DRUG|Morphine|The nurse will administer 0,1 mg per kg during 5 seconds when the patient complain of pain (visual analog scale, VAS, ≥7). Immediately with the onset of drug administration a timer started; every 5 minutes the researcher assess the EVA and the drug will be administered if VAS \> 3, until the patient manifests as a lower pain VAS ≤ 3 (mild). The nurse in charge in the PACU will manage the drug and will take 10 mg of morphine which is diluted in 10 mL of normal saline leaving a 1 mg per ml concentration, are not labeled and for the physical and chemical characteristics of both drugs (colorless) risks of unblinded is minimized.
224230419|NCT01790022|DRUG|Methylprednisolone|
224230420|NCT04703946|OTHER|observacional|"Analyze the incidence of short sublingual frenulum in newborns of the Hospital Nostra Senyora de Meritxell of the Principat of Andorra.~1. Association or not of the AG with auxological parameters (weight, height, cranial perimeter) at birth.~2. Association or not of the AG with sex.~3. Association or not of the AG with gestational age.~4. Association or not of the AG with other minor and major malformations."
224230421|NCT04645095|DEVICE|Transcutaneous electrical nerve stimulation|All groups were administered hotpack for 20 minutes, different types of TENS therapy for 20 minutes, 5 days a week, total of 15 sessions.
224230422|NCT04645095|DEVICE|Hot pack|All groups were administered hotpack for 20 minutes, different types of TENS therapy for 20 minutes, 5 days a week, total of 15 sessions.
224230423|NCT04759508|DIETARY_SUPPLEMENT|Flax Oil Capsule|Flaxseed with brand name Flax Oil Capsule will be administered to subjects receiving antihypertensives.
223642886|NCT04080648|PROCEDURE|Venapuncture|Blood samples will be collected to determine the serum trough levels and anti-drug antibodies of guselkumab.
223642887|NCT04080648|OTHER|Patient questionnaires|The study participant will complete the dermatology quality of life index (DLQI) and EQ-5D-5L questionnaire at each study visit
223642888|NCT06589063|DEVICE|Transcatheter aortic valve replacement|Transcatheter aortic valve replacement with implantation of new-generation balloon-expandable or self-expandable bioprostheses
223642889|NCT06653959|DEVICE|active Transcranial Magnetic Stimulation|Based on each individual's MRI data, individualized stimulation targets will be found, and then this will be used for stimulation for 5 consecutive days.
223642890|NCT06653959|DEVICE|sham Transcranial Magnetic Stimulation|Based on each individual's MRI data, individualized stimulation targets will be found, and then this will be used for sham stimulation for 5 consecutive days.
223642891|NCT03583814|BEHAVIORAL|CASE Program|Controlling Asthma in Schools Effectively (CASE) provides school-based education and environmental assessments. This program takes place over the course of about 4 weeks and involves in-school or remote asthma education for school aged children, after-school or remote education sessions for their parents, asthma care training for school staff, and an evaluation of asthma triggers in the school.
223642892|NCT03583814|BEHAVIORAL|HARP Program|Home Asthma Response Program (HARP) is a home-visiting program consisting of 3 home visits or remote sessions (over about 6 weeks). HARP provides individualized asthma education, home-based environmental assessment, and strategies and supplies for controlling environmental asthma triggers.
223642893|NCT06818851|DRUG|Henggliflozin|Upon enrollment, at Visit 1 (baseline), overnight fasting blood and urine samples will be collected, and glucose levels will be monitored for 3-5 days using a continuous glucose monitoring (CGM) system (Medtronic MiniMed). After the preliminary assessment, participants will receiveHenggliflozin 10 mg once daily by oral administration for up to 16 weeks.
223642894|NCT06818851|OTHER|Placebo|Upon enrollment, at Visit 1 (baseline), overnight fasting blood and urine samples will be collected, and glucose levels will be monitored for 3-5 days using a continuous glucose monitoring (CGM) system (Medtronic MiniMed). After the preliminary assessment, participants will receive a placebo once daily by oral administration for up to 16 weeks.
223642895|NCT06655519|BIOLOGICAL|CAR-T（RD140 injection）|"This study is divided into two stages: dose escalation and dose extension. The dose escalation stage sampled the 3+3 dose-escalation design, and set up three dose-increasing dose groups of 1.0×10\^5 CART cells/kg, 3.0×10\^5 CART cells/kg and 6.0×10\^5 CART cells/kg, and subjects will receive a single infusion of RD140. Each dose group level will include 3-6 subjects.~In the dose expansion stage, 1\~2 dose groups were selected for expansion and 3\~6 subjects were included in each extended dose group, and the target dose was administered once."
223642896|NCT06596330|BEHAVIORAL|Validation of language model prompts in increasing short-term physical activity|"Aim 1: In preliminary data, the investigators have pre-trained an open-source language model, LLAMA, with expert-created coaching prompts based on the stages of change model for physical activity. Seven different prompts (for each day of an intervention week) will be generated, accounting for race/ethnicity, age, gender, and stage of change, to improve personalization. Using the existing MHC app, the investigators will perform a randomized crossover trial on mean daily steps across each intervention. The investigators will compare the interventions of a daily reminder to reach 10,000 steps (a neutral control) and AI-personalized interventions based on an individual's stage of change."
223642897|NCT06596330|BEHAVIORAL|Assessment of long-term changes to physical activity and glycemic control|"Aim 2: Using social accountability and the trained language model generating personalized coaching interventions, the investigators will conduct a long-term follow-up randomized, unblinded trial. Over a 24-week intervention period, participants will receive either a generic daily reminder to reach 10,000 steps or an AI-generated coaching prompt, with the AI group also being able to chat with the language model to ask for advice on maintaining their physical activity. The outcomes of this long-term trial will be change in: 1) daily steps over the intervention period, 2) weight (via HealthKit link to MHC), and 3) HbA1c (as derived from EMR records linked to the HIPAA-compliant MHC app)."
223765623|NCT01877629|DRUG|ACT-129968 250 mg capsule|ACT-129968, a tetrahydropyridoindole derivative, is a chemoattractant receptor homologous molecule expressed on T helper 2 cells (CRTH2) antagonist
224230424|NCT04759508|DIETARY_SUPPLEMENT|Placebo Soya Oil Capsule|Placebo capsule filled with soya oil and inert(inactive) substances will be administered to subjects remaining anti hypertensives.
224230425|NCT05936879|OTHER|Inspiratory muscle training|Group A: Intervention group will be treated with Inspiratory muscle training and early ambulation and routine physical therapy including ankle pumps,hand pumps isometrics of upper and lower limbs after surgery
224230426|NCT05936879|OTHER|physical therapy including ankle pumps, hand pumps isometrics of upper and lower limbs.|Group B: Control group routine physical therapy including ankle pumps, hand pumps isometrics of upper and lower limbs
224230427|NCT06542159|RADIATION|Online adaptive SBRT|Online adaptive SBRT (without PTV expansion margin). The total dose will be 45-50Gy/3-4 fractions, administered once daily. FBCT and 4DCT will be acquired.
224230428|NCT06542159|RADIATION|Conventional SBRT|SBRT with PTV expansion. The total dose will be 45-50Gy/3-4 fractions, administered once daily. CBCT will be acquired.
224230429|NCT06424899|DRUG|Adebrelimab|This product is administered by intravenously guttae. The recommended dose of subcutaneous injection is 20mg/kg, administered every 3 Weeks (Q3W).
224230430|NCT06424899|RADIATION|radical chemoradiotherapy|The total dose of radiotherapy was 60 Gy ± 10% (54 Gy - 66 Gy). The minimum technical standard for radiotherapy is the three dimensional conformal radiotherapy (3D-CRT) planned by CT.
223765624|NCT05222113|DRUG|Remdesivir|The patients, based on their clinical condition, got remdesivir OR favipiravir at least five days of treatment. The WHO ordinal scale was used to assess patients' clinical progress in the first and second weeks.
223765625|NCT00607282|DRUG|Udenafil|oral administration of Udenafil, prn(2hours before anticipated intercourse, 8 times/months)
224230431|NCT06424899|DRUG|Platinum based chemotherapy|Platinum based chemotherapy: Platinum drug must be one of cisplatin, carboplatin or nedaplatin; The other drug must contain one of the following: etoposide, vinorelbine, vinblastine, pemetrexed, taxanes (e.g., paclitaxel, docetaxel, albumin paclitaxel, paclitaxel liposomes) or gemcitabine (gemcitabine is not permitted in concurrent chemoradiotherapy regimens).
224230432|NCT00534625|DRUG|zileuton|Single injection of zileuton 150 mg
224230433|NCT00534625|DRUG|placebo|Single injection of placebo
224230434|NCT00534625|DRUG|zileuton|Single injection of zileuton 300 mg
224230435|NCT00958256|DRUG|Bortezomib|Bortezomib 1.3 mg/m\^2 given intravenously over 3-5 seconds at the end of infusion of Rituximab on Day 1 of every cycle, then on Days 4, 8 and 11 of every cycle.
224230436|NCT00958256|DRUG|Rituximab|375 mg/m\^2 given intravenously over 6-8 hours on Day 1 of every 21-day study cycle.
224230437|NCT00958256|DRUG|Cyclophosphamide|300 mg/m\^2 intravenously over 3 hours 2 times each day (6 hours total each day) on Days 2, 3, and 4 of every cycle
224230438|NCT00958256|DRUG|Mesna|600 mg/m\^2 intravenous continuous infusion (IVCI) over 24 hours daily for 3 days, 1 hour prior to Cyclophosphamide and complete by 12 hours after last dose of Cyclophosphamide.
224230439|NCT00958256|DRUG|G-CSF|5 micrograms/kg subcutaneously daily starting 24-36 hours for 7 days after last dose of Bortezomib until granulocytes are more than 4 x 103/dl.
223642898|NCT06599437|PROCEDURE|laparoscopic cholecystectomy|Early laparoscopic cholecystectomy in the same admission after atone clearance from the bile ducts via ERCP.
223642899|NCT06599437|PROCEDURE|Late laparoscopic cholecystectomy|Laparoscopic cholecystectomy is performed 6 weeks after clearance of stones from the common bile duct.
223765626|NCT03958240|OTHER|Blood samples, tumor biopsy specimens and ascites samples will be collected.|"Blood samples, tumor biopsy specimens and ascites samples will be collected at different time points (if feasible, according to the samples taken in the standard practice) for a maximum follow-up period of 5 years from baseline:~* at Baseline.~* at every surgical procedure or tumor biopsy.~* every 6 months (± 2 months) (only blood sample).~* at the time of the progression or recurrence, additional samples will be collected, and optionally at the time of the following progressions or recurrences (if applicable).~For patients undergoing a RT treatment, blood samples will be collected before the RT (i.e. at the time of planning CT-scan), at the last session of RT (± 2 days) and 3 months after the end of the RT (± 2 weeks)."
223642900|NCT06587828|PROCEDURE|Companion blood samples with procedure|Participants in all cohorts will have a companion blood sample obtained on or around the time of the procedure intended to obtain tissue or fluid.
223642901|NCT06603545|OTHER|Digital education for osteoporosis patients|DEOP is found on the Swedish health care system's dedicated website or app 1177, it takes approximately 60 minutes to complete and is composed of three modules: 1)Introduction: an animated video that shows the patient flow from having a fracture, being evaluated at the osteoporosis clinic, receiving information about osteoporosis, and being treated for osteoporosis. 2)Osteoporosis: basic information about osteoporosis; why it occurs, risk factors that the patient can affect (such as physical inactivity and smoking), and risk factors that cannot be affected (such as age and heredity). It provides information about typical osteoporotic fractures, and how a patient is evaluated according to clinical guidelines for osteoporosis care. 3)Treatment: information about the different kinds of pharmacological osteoporosis treatment, physical activity, balance control, lifting technique, risk of falling, and dietary advice, especially regarding calcium and vitamin D intake.
223765627|NCT00253578|DRUG|sorafenib tosylate|Given PO
223765628|NCT00253578|OTHER|laboratory biomarker analysis|Correlative studies
223642902|NCT06599892|OTHER|Intervention mapping|Intervention mapping is a model combining patient and professional questionnaires and a qualitative survey using individual interviews with patients and focus groups with professionals to identify the obstacles and levers to change at the level of patients, professionals and organisations.
223642903|NCT06586632|DEVICE|AID technology|Automated insulin delivery system combined with a CGM
223642904|NCT06586632|DEVICE|CGM|CGM alone
223642905|NCT06588985|BEHAVIORAL|Emotion Coaching Parent Training Workshop|Parents will attend a 3-hour online workshop that introduces the fundamentals of emotion coaching and the phone consultations will be used to help parents troubleshoot and brainstorm application of the workshop content.
223642906|NCT06588985|BEHAVIORAL|Waitlist Control|Parents will only receive the parent workshop and phone consultations after they have completed all the required questionnaires.
223765629|NCT01188603|DRUG|flibanserin 100 mg dose every evening|all subjects receive flibanserin
223765630|NCT06193681|OTHER|Pedi@ctivity Exercise Mobile Application Exercise Program|The first group of the study received a mobile application (Pedi@ctivity) based exercise program. With the Pedi@ctivity exercise mobile application, the selected exercises and exercise program will be offered personalized to each adolescent for 12 weeks. After 12 weeks, the effectiveness of the Pedi@ctivity mobile application-based exercise program on the evaluation parameters will be investigated.
224230440|NCT01769209|DRUG|Bortezomib|Administered subcutaneously (SC) at 1.3 mg/m², on Days 1, 4, 8, and 11.
224230441|NCT01769209|DRUG|Doxorubicin hydrochloride (HCl)|Administered intravenously (IV) over 15 min at 60mg/m², on Day 1.
224230442|NCT01769209|DRUG|PEG-Asparaginase|Administered intravenously (IV) or intramuscularly (IM) 2500 U/m² (maximum 3750 U), on Days 5 and 22.
224230443|NCT01769209|DRUG|Vincristine sulfate|Administered by intravenous (IV) push at 1.5 mg/m² (maximum 2 mg), on Days 1, 8, 15, and 22.
223642907|NCT06604351|DRUG|Sintilimab, Nab-Paclitaxel, and Carboplatin|Cryoablation received at least 2 or more depending on the mass, with 2-3 cycles；Sintilimab 200 mg Q3W plus Nab-Paclitaxel 260mg / m2(Day 1) Q3W + carboplatin AUC 4.25 or 5 (Day 1) Q3W, 4 cycles，until 24 months
223642908|NCT06090422|DRUG|Ketamine Hydrochloride|Four single-doses, given two times per week for two weeks Dose: 0,8 mg/kg body weight Route of administration: intravenous infusions over 40 minutes
223642909|NCT06090422|DRUG|Midazolam Hydrochloride|Four single-doses, given two times per week for two weeks Dose: 0,02 mg/kg body weight Route of administration: intravenous infusions over 40 minutes
223765631|NCT06193681|OTHER|Supervised Exercise Group|In the physiotherapist-supervised personalized exercise program, the exercises selected through the Pedi@ctivity exercise mobile application will be applied to adolescents under the supervision of a physiotherapist (2 sessions face-to-face, 1 session online/synchronous).
223765632|NCT02257736|DRUG|Apalutamide|Participants will receive 240 mg (4\*60 mg tablets) of apalutamide once daily orally.
223765633|NCT02257736|DRUG|Abiraterone acetate|Participants will receive 1000 mg (4\*250 mg tablets) of abiraterone acetate (AA) once daily orally.
223765634|NCT02257736|DRUG|Prednisone|Participants will receive 5 mg tablet of prednisone twice daily orally.
224230444|NCT01769209|DRUG|Dexamethasone|Administered orally (PO) at 10 mg/m², daily on Days 1 to 14.
224230445|NCT01769209|DRUG|Cytarabine|Administered intrathecally (IT) at 100 mg, on Day 1
224230446|NCT01769209|DRUG|Methotrexate|Administered intrathecally (IT) at 15 mg, on Day 15.
224230447|NCT03842943|DRUG|Pembrolizumab|Preoperative infusions
224230448|NCT03842943|DRUG|Talimogene Laherparepvec|Preoperative intralesional injection
224230449|NCT03777670|DIAGNOSTIC_TEST|Blood test|Drop of blood for RNA and metabolic analysis
224319653|NCT00710866|BIOLOGICAL|Inactivated Influenza Vaccine Trivalent Types A and B (Split Virion)|Arm 1 (experimental group) received two spaced injections of the 0.5 mL (full) dose while arm 2 (comparison group) received the currently recommended two spaced injections of 0.25mL (half) dose of trivalent inactivated split virion influenza vaccine (VAXIGRIP®) manufactured by Sanofi Pasteur, Lyon, France.
224323376|NCT03191149|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
224323377|NCT03191149|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
224323378|NCT03191149|DRUG|Osimertinib|Given PO
223642910|NCT05427422|DIAGNOSTIC_TEST|MRI recording|MRI imaging was performed using a 3 Tesla Siemens Prisma system with a 64-channel head/neck coil (Siemens Medical Systems, Erlangen, Germany). The MRI protocols included as follows: (i) Magnetization-Prepared 2 Rapid Acquisition Gradient Echoes: TR/TE/ TI1/TI2 = 5000/2.98/700/2500 ms, voxel size = 1.0 × 1.0 × 1.0 mm3, FOV = 256 × 240 × 176 mm3; (ii)Gradient-echo EPI: TR 720 ms, TE 33.1 ms, flip angle 52 deg, FOV 208x180 mm, Matrix 104x90, Slice thickness 2.0 mm; 72 slices; 2.0 mm isotropic voxels, Multiband factor 8, Echo spacing 0.58 ms, BW 2290 Hz/Px; (iii) DSI : TR/TE = 3300/73 ms, FOV = 220 × 220 × 60 mm3, voxel size = 2 × 2 × 2 mm3, 128 diffusion direction, b-max = 3000 sec/mm2, AT = 7:22 min); (iv) T2-weighted fluid-attenuated inversion recovery: TR/TE = 9000/84 ms, FOV = 270 × 320 × 22 mm2, voxel size = 0.72 × 0.72 × 6.6 mm3.
223642911|NCT05427422|DIAGNOSTIC_TEST|EEG recording|"EEG was performed using a BrainAmp MR 32 amplifier (BrainProducts GmbH, München, Germany). The EEG protocols included as follows: (i) EEG-fMRI fusion: Sampling rate: 5000 Hz, low cut off-high cut off: DC-1000Hz;(2) EEG-fMRI fusion: Sampling rate: 1000 Hz, low cut off-high cut off: DC-1000Hz.~In (i) an ECG channel would be used to collect artifact of pulse and not used in (ii)."
223642912|NCT06053671|GENETIC|Blood and nasal swab sampling|Genetic screening of DNA samples (blood, mucosal swab, brain tissue) from 60-100 patients with histologically confirmed diagnosis of FCDIIA/B identified from Epilepsy Surgery Databases.
223642913|NCT01704716|DRUG|Vincristine|given during Rapid COJEC and modified N7 therapy
223642914|NCT01704716|DRUG|Aldesleukin|Aldesleukin is given during MRD Treatment for patients randomised to the arm with IL-2
223642915|NCT01704716|DRUG|ch14.18/CHO|ch14.18/CHO antibody is given during MRD treatment
223642916|NCT01704716|DRUG|Carboplatin|Carboplatin is given during induction Treatment (R3 randomisation: Rapid COJEC arm)
223642917|NCT01704716|DRUG|Etoposide|Etoposide is given during Induction Treatment (both R3 randomisation arms)
223642918|NCT01704716|DRUG|Cisplatin|Cisplatin is given during Induction Treatment (both R3 randomisation arms)
224230450|NCT02266836|DEVICE|MyndMove|During a MyndMove therapy session, the patient is instructed to attempt to execute a task voluntarily. As the patient is attempting to perform the designated task, specific muscles in the arm are stimulated to generate contractions that produce the desired movement. After a brief interval of the patient attempting to initiate a movement the therapist activates the MyndMove stimulation protocol, which generates bursts of short electrical pulses, using surface electrodes, to produce muscle contractions enabling the patient to complete the desired/instructed task. Proper sequencing of the muscle contractions as per the MyndMove protocols are tailored to achieve a wide range of reaching and grasping functions. The technique stimulates non-damaged pathways of the central nervous system.
224230451|NCT04806009|BEHAVIORAL|'Mindful Living With Insomnia (MLWI)' Intervention via WeChat mini-program|The MLWI Intervention involves 12 sessions over 6 weeks course, 2 sessions a week and 0.5 hours per session. Two new sessions of online lessons will be updated weekly in the 6 weeks. Each session is consisted of theoretical lecture, mindfulness practices, sharing common difficulties and coping way during mindfulness practices and homework assignment in the form of video or audio. The Mindfulness practices embedded in the intervention include mindful breathing, mindful body scan, mindful dealing with thoughts and emotions, mindful meditation, mindful movement, and daily life mindfulness. In the intervention, the participants will also receive sleep hygiene education.Participants in the Intervention Group will receive the MLWI Intervention after follow the WeChat mini-program.
224230452|NCT04806009|BEHAVIORAL|'Cognitive Behavioral Therapy for insomnia (CBT-I)'via WeChat mini-program|The CBT-I involves 12 sessions over 6 weeks course, 2 sessions a week and 0.5 hours per session. Two new sessions of online lessons will be updated weekly in the 6 weeks. Each session is consisted of theoretical lecture, cognitive or behavioral regulation techniques, sharing common difficulties and coping way during mindfulness practices and homework assignment in the form of video or audio.Participants in the Control Group will receive CBT-I after follow the WeChat mini-program.
224230453|NCT02696811|DIETARY_SUPPLEMENT|White carrots|White carrots contain compounds called polyacetylenes, including falcarinol, falcarindiol and falcarindiol-3-acetate.
224230454|NCT02696811|DIETARY_SUPPLEMENT|Oat biscuits|The 3 oat biscuits contain the same amount of fibre and sugar as the white carrot but without the polyacetylenes.
224230455|NCT05602922|COMBINATION_PRODUCT|Liu-Zi-Jue Exercise|Combined with the actual situation of stroke patients, this Liu-Zi-Jue Exercise adopts the sitting position.
224230456|NCT05602922|OTHER|Basic treatment +Swallowing rehabilitation training|Basic treatment +Swallowing rehabilitation training
223642919|NCT01704716|DRUG|Cyclophosphamide|Cyclophosphamid is given during Induction Treatment (both R3 randomisation arms)
224319654|NCT06179563|OTHER|On-Demand Telemonitoring|Patients assigned to the on-demand intervention group do not have to use the app at set time intervals but will be asked to use the app at their own discretion, in case of symptoms. This implies that patients have full control over their monitoring activities. Patients have the option to reach out to the hospital whenever they feel the need.
223765635|NCT02257736|DRUG|Placebo|Participants will receive matching placebo to apalutamide once daily orally.
224319655|NCT03311750|DRUG|Panitumumab|6 mg/Kg will be administered intravenous over 1 hour on Day 1 every 2 weeks or 9 mg/Kg every 3 weeks.
223765636|NCT01686646|DRUG|paracetamol + caffeine|paracetamol with caffeine
223765637|NCT01686646|DRUG|paracetamol|paracetamol
223765638|NCT02319538|PROCEDURE|Total thyroidectomy performed|Surgery combined with standard thyroxine treatment
223765639|NCT02549508|DEVICE|AutoCPAP with SensAwake On|The comfort feature 'SensAwake' will be turned on
223765640|NCT02549508|DEVICE|AutoCPAP with SensAwake Off|The comfort feature 'SensAwake' will be turned off
223765641|NCT01220271|DRUG|LY2157299|Administered orally
223765642|NCT01220271|DRUG|Radiation|Administered as approved
223765643|NCT01220271|DRUG|Temozolomide|Administered orally
223765644|NCT00556842|DEVICE|Total hip arthroplasty|Proscribed approaches will include minimally invasive total hip arthroplasty (i.e., two incision approaches) and hinged prostheses or capture cups. Other surgical approach aspects, the use of cemented components, the implant manufacturer, and femoral head size will not be standardized. Surgeons will use the manufacturers' specific implant guidelines for insertion.
223765645|NCT00556842|DEVICE|Hemi-arthroplasty|Surgeons will use modern implants for hemi-arthroplasty, excluding non-modular, non-canal filling unipolar implants such as Moore's and Thompson's prostheses. The choice of modular unipolar versus bipolar hemi-arthroplasty will not be standardized. Whether implants are inserted with cement or a press-fit design will also not be standardized. Surgeons will use the manufacturers' specific implant guidelines for insertion.
223765646|NCT06362148|DIAGNOSTIC_TEST|Tumor- and plasma-informed, next-generation sequencing (NGS)-based patient-specific droplet digital (dd)PCR assay|Blood sampling for circulating tumor DNA analysis at baseline, cycle 2 day 1, cycle 3 day 1, mid-treatment, end of induction/end of treatment, 100 day follow-up, 6 month, 12 month, 18 month and 24 month follow-up. Blood sampling will also be done in case of relapsing/refractory disease at any point prior to the abovementioned time points.
224230457|NCT05303922|DIAGNOSTIC_TEST|Dual-energy CT|Dual-energy CT
223765647|NCT06362148|DIAGNOSTIC_TEST|18F-fludeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT)|FDG-PET/CT performed at baseline, mid-treatment, end of induction/end of treatment and 6 month, 12 month, 18 month and 24 month follow-up.
223765648|NCT02435251|DEVICE|dual energy X-ray absorptiometry|
224230458|NCT05303922|DIAGNOSTIC_TEST|MRI|MRI
224230459|NCT03036579|DEVICE|Celtra Duo|Full ceramic crowns will be made from the high strength ceramic, Celtra Duo.
224230460|NCT00993057|DRUG|Insulin|Adjustable insulin infusion scale with loading doses
224323379|NCT05911906|DRUG|Remdesivir|"Remdesivir is a prodrug that is intended to allow intracellular delivery of GS-441524 monophosphate and subsequent biotransformation into GS-441524 triphosphate, a ribonucleotide analogue inhibitor of viral RNA polymerase.~Participants will receive a single loading dose of 200 milligrams of Remdesivir in 250ml sodium chloride 0.9% bag via IV over 60 minutes on day 1, followed by, on days 2 - 5, a dose of 100 milligrams of Remdesivir in 250ml sodium chloride 0.9% bag via IV once daily over 30 minutes."
223642920|NCT01704716|DRUG|Doxorubicin|Doxorubicin is given during Induction Treatment (R3 arm modified N7)
223642921|NCT01704716|DRUG|G-CSF|G-CSF is given during Induction Treatment
223642922|NCT01704716|DRUG|Busulfan|In case i.v. busulfan is not available, the use of oral busulfan is permitted, although not recommended.
223642923|NCT01704716|DRUG|Melphalan|Melphalan is given during MAT treatment
223642924|NCT04983680|BEHAVIORAL|MBCT|Mindfulness-Based Cognitive Therapy (MBCT) is an 8-week group intervention (1.5-hour weekly sessions) that combines cognitive-behavioral therapy and mindfulness training. In this study, MBCT has been adapted to include education about cardiac health and fear of recurrence, and the intervention is delivered remotely via synchronous group videoconference. There is 15-20 minutes of daily mindfulness practice between sessions. Participants are provided a home practice record form and asked to submit the completed form to study staff each week.
223642925|NCT05304195|DIAGNOSTIC_TEST|Glucocerebrosidase|Blood sample (10ml) for GCase activity
223642926|NCT05304195|GENETIC|GBA gene|Blood sample (10ml) for variants or mutations of the GBA gene
223642927|NCT05304195|DIAGNOSTIC_TEST|Macrophage biomarkers|Blood sample (20ml) for macrophage biomarkers
223642928|NCT06992635|BEHAVIORAL|using non-processing screens|ask subjects to use non-processing screens
223642929|NCT06992635|BEHAVIORAL|using AR screens|ask subjects to use AR screens
223642930|NCT06992635|BEHAVIORAL|using AR+CP screens|ask subjects to use AR+CP screens
223765649|NCT03655678|BIOLOGICAL|CTX001|Administered by IV infusion following myeloablative conditioning with busulfan
223765650|NCT02296814|DRUG|Sinusitis Hevert SL Tablet|1st week: 6 times daily 2 tablets and 2nd week: 4 times daily 2 tablets
223765651|NCT02296814|DRUG|Placebo for Sinusitis Hevert SL Tablet|1st week: 6 times daily 2 tablets and 2nd week: 4 times daily 2 tablets
223765652|NCT01449578|DRUG|Dexpramipexole|Oral Tablet at varying doses
223765653|NCT01449578|DRUG|Dexpramipexole Placebo|Oral tablet at varying doses
223765654|NCT03941730|PROCEDURE|Biopsy|Undergo tissue biopsy
223765655|NCT03941730|PROCEDURE|Computed Tomography|Undergo CT
223765656|NCT03941730|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223765657|NCT03941730|PROCEDURE|Positron Emission Tomography|Undergo PET
223765658|NCT03941730|BIOLOGICAL|Therapeutic Estradiol|Given PO
224230461|NCT02503579|BEHAVIORAL|physical training|physical activity program, 30 minutes
224230462|NCT03604120|DEVICE|Preoxygenation with high flow therapy by nasal cannula|Preoxygenation during 4 minutes with High Flow Nasal Cannula (60l/min FiO2 = 1) before fiber-optic or laryngoscopic intubation. The device will be maintained in place throughout the intubation procedure in order to achieve oxygenation.
224230463|NCT03604120|DEVICE|Preoxygenation by standard Facial mask|"* For Fiber-optic intubation: patients will receive a 4 minutes FIBROXY facial mask preoxygenation with FiO2=100%. The FIBROXY facial mask will be maintained in place during the intubation procedure.~* For Laryngoscopic intubation: patients will receive a 4 minutes standard facial mask preoxygenation with FiO2=100%. The standard facial mask will be removed after crash induction to proceed to intubation."
223642931|NCT06991452|DIAGNOSTIC_TEST|Liquid biopsy|Serum protein profile, serum metabolic mass spectrometry, plasma cfDNA/cfRNA genomic and epigenomic assays, and serum tumor markers were performed. Patients were followed up for 3 years at a 3-month interval. Collect surgically removed colorectal cancer samples to construct PDX models if necessary.
223642932|NCT06992531|OTHER|Questionnaire and Physical Exam|Standardised participant questionnaires assessing neurological symptoms, including pain (NPSI, DN4, BPI), fatigue (Fatigue Severity Scale), depression and anxiety (PHQ9 and GAD7) and autonomic dysfunction (Malmo PoTS Score and COMPASS-31).
223642933|NCT06992531|DIAGNOSTIC_TEST|Nerve conduction studies|Measures how fast an electrical impulse moves through sensory and motor nerves. The test will be used to identify/rule out large fibre peripheral neuropathy.
224230464|NCT01518491|DRUG|NanoDOX Hydrogel|NanoDOX Hydrogel will be applied three time weekly to the wound for eight weeks along with VAC therapy
224230465|NCT01518491|OTHER|VAC Alone|Patients will receive VAC therapy three time weekly for eight weeks
224230466|NCT02848599|DRUG|morphine|
224230467|NCT02848599|DRUG|levobupivacaine|
224230468|NCT05624164|PROCEDURE|Lateralised microfracture|making microfracture(4 holes with 2mm diameter) at the lateral side of the footprint right after arthroscopy rotator repair.
223642934|NCT06992531|DIAGNOSTIC_TEST|Microneurography|Electrophysiological technique that can record action potentials from individual peripheral nerve axons in humans. The test will be used to identify/rule out small nerve fibre dysfunction.
223642935|NCT06992531|DIAGNOSTIC_TEST|Quantitative Sensory Testing|Measures psychophysical sensory perception in response to different types of stimuli, such as thermal, mechanical, pressure and vibration. The test will be used to identify/rule out nerve fibre dysfunction, by generating a quantitative sensory profile of different sensory modalities.
223642936|NCT06992531|DIAGNOSTIC_TEST|Skin biopsy|Safe and minimally invasive procedure to quantify intraepidermal nerve fibres density (IENFD). Reduced IENF density is associated with small fibre neuropathy.
223642937|NCT06992531|BIOLOGICAL|Blood Product|A blood sample of a maximum of 120ml will be collected from a superficial upper limb vein. Blood aliquots (50ml tubes) will then be centrifuged to separate serum from the peripheral blood cells.
223642938|NCT05056415|OTHER|Everyday Life Rehabilitation (ELR)|"Everyday Life Rehabilitation (ELR) is an intervention model for integrated occupational therapy in close collaboration with housing staff in sheltered and supported housing facilities (Lindström, 2007; 2011), aiming at personal recovery and engagement in meaningful everyday activities for persons with SPD. The mediators are: personcentred, motivational, recovery- and activity-based methods, negotiation of user goal priority and expected outcome; methods for training in real-life situations; devices for collaboration; support from staff on an everyday basis; and an educational package including web-sections, manuals, and collegiate tutorial.~The language and actions of professionals promote hope, self-discovery and shared-decision making, shaped in partnership with residents. The resident is also encouraged to access different resources outside of health and social care such as family, peer and social support, out-of-housing strategies, and sources in the open society."
223642939|NCT05056415|OTHER|Treatment as usual (TAU)|No standardized instructions about the efforts is given to staff at the accommodations. Usually, only short terms efforts are offered to residents, such as prescribing technical aids.
223642940|NCT06593080|OTHER|The comprehensive TDA based approach|"The intervention consists of implementing a comprehensive TDA-based approach for TB diagnosis and treatment decision-making, including shorter treatment for non-severe TB in children identified as TB presumptive cases through a CDSS. It will also include the management of high-risk groups. In practice, all sick children will be assessed using the WHO-suggested TDAs A with CXR (DH) and B without CXR (PHC). CLHIV and those hospitalised with SAM at DH will have further assessment and treatment decisions based on the PAANTHER and TB-Speed SAM TDAs, respectively.~Clinical and microbiological assessment data will be incorporated into a CDSS to help with the clinical decision to initiate TB treatment. The CDSS will incorporate specific features and test results for high-risk group children based on the PAANTHER TDA and the TB-Speed SAM TDA and will incorporate the results of the severity assessment to guide the choice of TB treatment duration once children are diagnosed with TB."
223642941|NCT06597461|OTHER|Myofascial release|Graston massage technique was used in the application. In the application, the participant was placed in a prone position and the feet were left slightly outside the massage table. The application was performed on the entire plantar surface between the calcaneal tuberosity and metatarsophalangeal joints in the form of multidirectional strokes at 30-60 degrees with the GT 4 graston tool. The total application took an average of 5 minutes for each foot. An average of 60-70 strokes were performed per minute and 10 seconds of rest was given every minute. The application was performed as a single session by an expert physiotherapist.
223642942|NCT06597461|OTHER|Placebo myofascial release|Graston massage technique was used in the application. In the application, the participant was placed in a prone position and the feet were left slightly outside the massage table. The application was performed on the entire plantar surface between the calcaneal tuberosity and metatarsophalangeal joints in the form of multidirectional strokes at 30-60 degrees with the GT 4 graston tool. The total application took an average of 5 minutes for each foot. An average of 60-70 strokes were performed per minute and 10 seconds of rest was given every minute. The application was performed as a single session by an expert physiotherapist. Since it was a placebo application, no pressure was applied to the tissues by the physiotherapist during the strokes.
223642943|NCT06603428|DEVICE|internal fixation by plate or screws|\- Patients more than 5 ml displacement of GT fracture (3ml in active highly demanded patient) are for internal fixation, others less this are for conservative management.
223642944|NCT06586814|OTHER|Suture|Wound Closure
223642945|NCT06586814|OTHER|Staple|Wound Closure
223642946|NCT06599944|DIAGNOSTIC_TEST|Negative Attitude Scale towards Immigrant Individuals and Cultural Intelligence Scale|Negative Attitude towards Immigrant Individual and Cultural Intelligence scales will be applied to the students in both groups included in the study. Thus, to measure the change in negative attitudes towards immigrant individuals and cultural intelligence as a result of the practice in the migrant health centre.
223642947|NCT06603701|DIAGNOSTIC_TEST|Bioimpedancemetry|"2\. Bioimpedancemetry at T1, T2, T3 ; the measurement will be~1. Squeletic mass (total and for each of the 4 limbs)~2. Angle phase (total and for each of the 4 limbs)"
223642948|NCT06603701|OTHER|Dynamometry|Dynamometry will be performed to assess the strength of each upper limb (deficient and non deficient) at T1, T2, T3
223642949|NCT06592326|DRUG|9MW2821|9MW2821, 1.25mg/kg, intravenous (IV) infusion
224230469|NCT06322927|OTHER|Patient Interview|Participants will be asked to take part in a 30-60 minute interview to understand their treatment experiences and preferences.
224230470|NCT05973227|DEVICE|use of the TRIDENT system|usage of Trident System v1.0, just before the final resection, to obtain some images of the tissue oxygenation.
224230471|NCT05873894|DEVICE|EEG|EEG recordings and analysis. Sensory evoked potentials analysis Motor evoked potentials studies
224230472|NCT02375126|PROCEDURE|Electroencephalography|Electroencephalography (EEG) is a relatively inexpensive measurement of basic brain activity. Traditional EEG techniques rely on the clinician to visually examine the electrical current waveforms to identify abnormal signal patterns and slowing. Abnormalities on EEG have been reported following CO poisoning, though the literature is scarce. While current EEG technologies record EEG signals digitally, rather than writing directly to paper, computer-assisted analysis of the data (quantitative EEG, or qEEG) has not been widely embraced, in part because clinicians are unsure what patterns revealed by computer-assisted analysis represent abnormal activity.
224230473|NCT01001065|PROCEDURE|Vascular ultrasound|RI ist predictive for arteriosclerosis
224230474|NCT00589095|OTHER|dynamic contrast enhanced magnetic resonance imaging|dynamic contrast enhanced MRI using contrast agent gadodiamide
224230475|NCT04700995|PROCEDURE|NiTi instruments|Root canal filling removal
224230476|NCT02401542|DRUG|Vofatamab|
223642950|NCT06592326|DRUG|Toripalimab|Toripalimab, 240mg, intravenous (IV) infusion
223642951|NCT06592326|DRUG|Gemcitabine|Gemcitabine: 1000mg/m2, intravenous (IV) infusion
223642952|NCT06592326|DRUG|Cisplatin/Carboplatin|Cisplatin: 70mg/m2 or Carboplatin: AUC=4.5/5, intravenous (IV) infusion.
223642953|NCT06591988|BEHAVIORAL|Lifestyle factors|introduction of environmental risk mitigation policies, from data and evidence from case studies (several European cities) with different levels of exposure to environmental, health, geographic, and socioeconomic factors.
223642954|NCT06992869|BEHAVIORAL|Group-based psychological therapy|Group-based psychological therapy for (1) adjusting to diagnosis; (2) Parkinson's anxiety and/or depression; and (3) Parkinson's-related cognitive decline
223642955|NCT06991907|PROCEDURE|125I seed implantation|125I seed implantation
223642956|NCT06991907|DRUG|PD-1 Inhibitors|PD-1 inhibitors (sintilimab/teriprizumab/camrelizumab) are administered intravenously at a dose of 200 mg once every three weeks. According to the manufacturer's guidelines, the dose is reduced or discontinued based on the severity of adverse effects.
223642957|NCT06992492|PROCEDURE|vojta therapy +conventional chest physical therapy|infants will receive reflex rolling technique along with conventional chest physical therapy (postural drainage, percussion and vibration) plus medical treatment with special emphasis on whether Surfactant therapy is given or not. This maneuver includes a slight rotation of the head towards the side from which the stimulus is delivered. The starting position for performing the first phase of reflex rolling is the asymmetric supine position, with the limbs freely lying on the resting surface. A digit pressure will exert on the chest area, where the mammillary line crosses the insertion of the diaphragm, either at the level of the 6th rib, or between the 5th and the 6th, or between the 6th and the 7th. Each treatment consists in delivering four stimuli, two to the left half of the chest (stimulations I and II) and two to the right half of the chest (stimulations III and IV). Each stimulus will be consisted of slight pressure, progressively oriented in dorsal, medial and cranial direct
223642958|NCT06992492|PROCEDURE|lung squeezing technique +conventional chest physical therapy|"infants will receive lung squeezing technique along with conventional chest physiotherapy (postural drainage, percussion and vibration) plus medical treatment with special emphasis on whether Surfactant therapy is given or not. Lung squeeze technique consists of 3- cumulative chest compressions lasting for 5 seconds, followed by a gentle low release phase, with the chest wall completely released; the second compressions are performed successively for5 minutes on one hemithorax, then 5 minutes on the other hemi thorax. The infant will be in supine position, and without body tilt, for a total of 10 minutes. Use both hands to perform the squeeze on one hemithorax at one time. Place One hand on the posterolateral aspect of the hemi thorax and the other hand covered the anterior chest extending from the lower ribs to above the clavicle of the infant."
223765659|NCT04275596|DRUG|2QR complex|Application of topical gel containing 2QR complex on the anal wound until complete wound healing
223765660|NCT04275596|DRUG|Placebo|Application of topical placebo on the anal wound until complete wound healing
223765661|NCT01664013|DRUG|Nuronox|Reconstituted Neuronox® is injected at a dose determined by the physician based upon his/her clinical experience with botulinum toxin.Actual dose and injection site should be adjusted individually considering the muscle mass, degree of spasticity, body weight, and response to any previous botulinum toxin injections.
224230477|NCT02401542|DRUG|Docetaxel|
224230478|NCT02401542|DRUG|Placebo|
223765662|NCT04029363|DEVICE|HighLife Transcatheter Mitral Valve Replacement|Transcatheter Mitral Valve Replacement
223765663|NCT03254238|OTHER|Monitoring prEscriptiondruG Abuse using DOctor Shopping bEhavior|development and identification of systems and tools able to detect earlier misuse phenomenon
223765664|NCT04797273|BEHAVIORAL|Internet-based cognitive behavior therapy|12 week Internet-based cognitive behavior therapy, delivered via an online treatment platform. The treatment includes components such as exercises in conducting recuperating activities, methods to improve sleep, exposure, and behavioral activation. The treatment content is provided through written texts, images and audiofiles in the treatment platform. The participant has access to a therapist who provides support throughout the treatment via asynchronous text messages.
224230479|NCT03057899|DRUG|TFG capsules (200 mg /capsule)|TFG capsules were prepared using extracts from Trigonella foenum-graecum seed and Lespedeza cuneata. During the study period, two capsules were taken daily for 8 weeks.
224230480|NCT03057899|DRUG|Placebo oral capsule|During the study period, two capsules were taken daily for 8 weeks. Placebo and TFG capsules were identical in shape, color, and taste.
224230481|NCT01790165|DRUG|TDT067 and Lamisil|Topical administration of TDT067 and single oral administration of 250 mg Lamisil tablet
224230482|NCT00992407|DRUG|Risperidone long acting injectables|Risperidone long acting injectables will be administered intramuscularly (given into the skin) at a flexible dose of 25, 37.5 or 50 milligram (mg) every 2 weeks up to Week 52. A supplementary oral antipsychotic will also be administered for 3-4 weeks after the initial dose of injection.
224230483|NCT00992407|DRUG|Risperidone tablets|Risperidone tablets will be administered orally as 0.5-10 mg daily up to Week 52.
224230484|NCT04204577|DRUG|Apatinib Mesylate|Evaluation of the efficacy and safety of simple local ablation, local ablation combined with apatinib, local ablation combined with apatinib and PD-1 antibody SHR-1210 for advanced liver cancer.
224230485|NCT02207309|DRUG|Pazopanib|
224230486|NCT02207309|DRUG|Placebo (for Pazopanib)|
224230487|NCT03473782|OTHER|Voiding Diary|A log kept by each patient to record frequency and volume of urine output and fluid input.
224230488|NCT03473782|OTHER|Urodynamics Correlation Study|Provides patho physiological data by assessing bladder sensation, bladder capacity, the presence of involuntary bladder contractions, bladder compliance and bladder outlet obstruction.
224230489|NCT00513968|GENETIC|a mixed plasmid DNA (HB-110)|HB-110 2mg (or 4mg or 8mg), im, every other week, from week 0 to week 22 (total 12 injections) and Adefovir(Adefovir dipivoxil 10mg), od, from week -10 to from week 48.
224230490|NCT00513968|DRUG|Adefovir|Adefovir(Adefovir dipivoxil)10mg, od, from week -10 to week 48.
224230491|NCT04653220|OTHER|Control 1|25g glucose dissolve in 250ml of water
224230492|NCT04653220|OTHER|Control 2|25g glucose dissolve in 250ml of water
224230493|NCT04653220|OTHER|Standard Crokao|Standard Crokao containing 25g of available carbohydrate
223642959|NCT06992492|PROCEDURE|conventional chest physical therapy|Conventional Chest Physical Therapy will be given for both the groups A and B and for group C in isolation manner with medical treatment with special emphasis on whether Surfactant therapy is given or not.it includes postural drainage, vibration, and percussion. Postural drainage will be applied to infants by elevating head of the infant at 30 degrees to prevent gastro esophageal reflex and aspiration. In neonates and infants 'tenting' (using the first three or four fingers of one hand with slight elevation of the middle finger). Chest percussion will be given with motion from the wrist. Vibration of the chest will be done manually by placing the fingers on the chest wall over the segment being drained and the wrist and the elbow remained immobile, isometrically contracting the muscles of the forearm and hand to cause a vibratory motion. The procedure will be performed for 5min. Chest percussion position lying down on the right side and on the left, with 5 min duration on each side
223642960|NCT06991790|DRUG|Sacituzumab Govitecan (SG)+Toripalimab|"Sacituzumab govitecan (Trodelvy): 10mg/kg, administered by intravenous infusion on day 1 and day 8.~Toripalimab: 240mg, administered by intravenous infusion on day 1."
223642961|NCT06992323|DIETARY_SUPPLEMENT|EPA + HT|Volunteers will consume during 12 weeks 2 g/d of EPA and 15 mg/d of HT, corresponding to 3 capsules. Additionally, they will consume a commercial olive oil with a minimal phenol content as their culinary oil that will be suplied by the research team for family use (1L/2 weeks)
223642962|NCT06992323|DIETARY_SUPPLEMENT|EPA|Volunteers will consume during 12 weeks 2 g/d of EPA corresponding to 3 capsules. Additionally, they will consume a commercial olive oil with a minimal phenol content as their culinary oil that will be suplied by the research team for family use (1L/2 weeks)
223642963|NCT06992323|DIETARY_SUPPLEMENT|Sunflower Oil|Volunteers will consume during 12 weeks 2 g/d of Sunflower Oil, corresponding to 3 capsules. Additionally, they will consume a commercial olive oil with a minimal phenol content as their culinary oil that will be suplied by the research team for family use (1L/2 weeks)
223642964|NCT06061003|OTHER|Clinical Anatomical Education with Fractured Bone Models|Participants will undergo a 2-hour training session, consisting of 60 minutes of theory and 60 minutes of practice. The theoretical lesson, supported by 2D images illustrating wrist anatomy, types of fractures, and rehabilitation based on fracture type, will be simultaneously delivered to both groups. Following this, the practical group will receive a 60-minute hands-on session using 3D-printed digital models of radius and ulna fractures. These training sessions will be scheduled in the morning hours, on a day when students have no other classes between 9 am and 12 pm, to minimize mental fatigue and exhaustion. In the practical session, anatomical structures, their relationships, and arrangements will be demonstrated to the practice group using a model of a fractured wrist.
223765665|NCT04797273|BEHAVIORAL|Internet-based structured treatment-as-usual|This is a 12-week treatment, delivered via an online treatment platform. The treatment components in this treatment are designed to be similar to what is typically provided in primary care to these patients and includes information about stress and how different factors such as eating habits, physical exercise, and alcohol can contribute to stress problems. The treatment content is provided through written texts, images and audiofiles in the treatment platform. The participant has access to a therapist who provides support throughout the treatment via asynchronous text messages.
223765666|NCT05828589|DRUG|BGB-21447|BGB-21447 will be administered orally
223765667|NCT04909086|PROCEDURE|Standard physical Therapy|Patients assigned to this group will receive a 40-min multimodal supervised physical therapy treatment comprised of warm-up (10-min cycling/walking), muscle stretching, neuromuscular control exercises, and ten-minute transcutaneous electrical nerve stimulation (TENS). Manual mobilization techniques may be applied as necessary according to the findings of the physical examination. Treating physical therapists will prescribe exercises based on a predetermined list of exercises.
224230494|NCT04653220|OTHER|Low sugar variant 1|Low sugar variant 1 containing 25g of available carbohydrate
224230495|NCT04653220|OTHER|Low sugar variant 2|Low sugar variant 2 containing 25g of available carbohydrate
224230496|NCT04653220|OTHER|Low sugar variant 3|Low sugar variant 3 containing 25g of available carbohydrate
224230497|NCT04653220|OTHER|Low sugar variant 4|Low sugar variant 4 containing 25g of available carbohydrate
224230498|NCT04653220|OTHER|Low sugar variant 5|Low sugar variant 5 containing 25g of available carbohydrate
224319656|NCT05056623|BEHAVIORAL|Dyadic pain management program|"Face-to-face part: The DPM will start with 20-30 minutes of physical exercise supervised by research assistant, followed by 20-minutes of pain management education. Communication skills regarding the practice of various pain management techniques by the participants and their caregivers will be taught. At the end of the session, the caregiver and research assistant will help the older adults to make portfolio entries on the activities of the day, to help them recall the various pain-relief methods learned in each class.~Home-based part: An exercise book will be given to guide them in performing exercises at home. It is recommended to perform 30 minutes of exercise, 3 times a week, at home and the more frequent the exercise time, the better.~All participants will join a WhatsApp group to receive teaching materials and videos of the physical exercises learned, for practice at home. The team will produce compact disc (CD) with the exercise video clips to the dyads for revision."
224319657|NCT05056623|OTHER|Usual care and pain management pamphlet|Usual care and pain management pamphlet
224230499|NCT01204580|DRUG|GLIMEPIRIDE + METFORMIN|Pharmaceutical form: film coated tablet Route of administration: oral Dose regimen: 1 tablet of 1/250 mg per day
224230500|NCT00043836|DRUG|ALT-711|
224230501|NCT00035087|DRUG|epothilone b|
224230502|NCT04648475|BIOLOGICAL|CD19 and CD22 targeted CAR-T cells|A single infusion of CD19 and CD22 CAR-T cells will be administered intravenously
224230503|NCT00006075|DRUG|Chlorhexidine gluconate|
224230504|NCT05927285|DIAGNOSTIC_TEST|Vexus|The VExUS group was considered the intervention group, where in addition to all the above, the decision for decongestant treatment was guided by the VExUS score until reaching a score that VExUS considered noncongestive, which was grade 0.
224230505|NCT05927285|OTHER|Control group|The control group is considered the conventional approach, where the treatment was guided by improvement in clinical data, imaging, or laboratory studies during the daily evaluation until categorized as decongested
224230506|NCT03665103|OTHER|Laser-assisted ICSI|Laser opening of the zona pellucida.
224230507|NCT05744973|OTHER|No intervention|This is an observational study
224230508|NCT02517801|DIETARY_SUPPLEMENT|Anthocyanin capsules|Chronic intake of 2 capsules for 30 days (2x daily). Capsules with 80 mg of anthocyanins.
223642965|NCT06061003|OTHER|Clinical Anatomical Education with Standard Bone Models|Participants will undergo a 2-hour training session, consisting of 60 minutes of theory and 60 minutes of practice. The theoretical lesson, supported by 2D images illustrating wrist anatomy, types of fractures, and rehabilitation based on fracture type, will be simultaneously delivered to both groups. Following this, the practical group will receive a 60-minute hands-on session using 3D-printed digital models of radius and ulna fractures. These training sessions will be scheduled in the morning hours, on a day when students have no other classes between 9 am and 12 pm, to minimize mental fatigue and exhaustion. The control group will receive the same practical session using a standard anatomical model.
223642966|NCT06602895|OTHER|Intensive short-term functional strength training|All players underwent a rigorous 2-week intensive short-term functional strength training program, with training sessions held for 5 days a week. One group engaged in intensive short-term functional strength training exercises, while the other group focused on balance training. The training regimen was then reversed for the two groups. Each daily training session lasted approximately 2 hours, with 1 hour of either intensive short-term functional strength training or balance training. Every intensive short-term functional strength training session spanned roughly 60 minutes, starting with a 10-minute warm-up followed by dynamic mobility exercises targeting key joints. During the 40-minute core segment of our intensive short-term functional strength training sessions, participants first engaged in stability exercises for 10 minutes, focusing on core stability and balance through plank variations and stability.
224230509|NCT02517801|DIETARY_SUPPLEMENT|placebo capsules|Chronic intake of 2 capsules for 30 days (2x daily). 2 capsules devoid of anthocyanins.
224230510|NCT03996486|DRUG|BAY1093884|Drug administered via subcutaneous injections once weekly for 6 weeks (= 6 doses)
224230511|NCT03656796|OTHER|Treadmill training with auditory cues|Participants should walk on the treadmill according to the rhythmic auditory cues (110% step frequency) for 30 min
224230512|NCT03656796|OTHER|Treadmill training without auditory cues|Participants should walk in comfortable speed on the treadmill for 30 min.
224230513|NCT03931863|DRUG|Ondansetron 4mg|Intravenous administration of ondansetron 4mg diluted in 100ml of normal saline 0.9 percent within 10 minutes prior to spinal anesthesia.
224230514|NCT03931863|DRUG|Ondansetron 8mg|Intravenous administration of ondansetron 8mg diluted in 100ml of normal saline 0.9 percent within 10 minutes prior to spinal anesthesia.
224230515|NCT03931863|DRUG|100ml normal saline 0.9 percent|Intravenous administration of 100ml of normal saline 0.9 percent within 10 minutes prior to spinal anesthesia.
224230516|NCT04302779|BEHAVIORAL|Solid Model|Cupcakes will be used, with the amount of protein varied to study the effect on perception of the products (using sensory methods rating drying and discrimination tests 'which is the stronger in drying'). Measuring mucoadhesion via protein content remaining in saliva samples following consumption of cupcakes.
224230517|NCT04302779|BEHAVIORAL|Liquid Model|To study the perception of whey protein beverages using repeated consumption sensory methods (e.g. rating mouthdrying over repeated sips of the drink).
224230518|NCT04605510|OTHER|Passive Cervical Joint Mobilization|It will be applied to the cervical spine, whose dysfunction is detected as a result of the evaluation. The participant will be in the prone position and Grade 3 Central Posterior-Anterior (CPA) passive joint mobilization with Maitland method will be applied for 3 sets, 30 seconds, to the segment to be treated.
224230519|NCT05637281|DRUG|Indometacin|Besides the conventional treatment, indomethacin will be given to the patients in the convention + indomethacin group.
223680830|NCT05057910|DIAGNOSTIC_TEST|SARS-CoV-2 IgG II Quant|3ml of blood samples are collected, contained in heparin-free tubes, and centrifuged. Blood serum samples are collected and stored at the -80 Celcius degree. SARS-CoV-2 IgG antibodies in human serum and plasma are detected using chemiluminescent microparticle immunoassay (CMIA) technology on the ARCHITECT I 1000r System. Quality Control procedures will take place once daily, with three levels: one negative control and two positive controls. Sample, SARS-CoV-2 antigen-coated paramagnetic microparticles, and assay diluent are combined and incubated. The SARS-CoV-2 IgG antibodies present in the sample bind to the antigen-coated microparticles. The resulting chemiluminescent reaction is measured as a relative light unit (RLU). There is a direct relationship between the titres of IgG antibodies to SARS-CoV-2 in the sample and the RLU detected by the system optics. Interpretation of Results: \< 50.0 AU/mL, Negative, ≥ 50.0 AU/mL, Positive
224230520|NCT05637281|OTHER|conventional treatment|All enrolled patients received conventional management according to AP guidelines of International Association of Pancreatology and the Chinese Society of Gastroenterology, including goal-directed fluid resuscitation, oxygen supply even mechanical ventilation, and nutritional support if necessary.
224230521|NCT01925755|OTHER|Rivaroxaban ( Xarelto, BAY59-7939)|Patients with prior stroke or TIA history and who have never taken anticoagulation treatment regarding AF before. One film-coated tablet contains Rivaroxaban 15 mg or 20mg
224230522|NCT02586766|BEHAVIORAL|Project Sync|A 30 minute private on-on-one brief motivational interviewing intervention given during emergency department care. The goal of the intervention was to reduce and prevention youth violence using techniques to change behavior in a respectful, non-confrontational, and non-judgmental manner. This one-on one counseling approach emphasizes individual choice and responsibility and differentiates between future goals/values and current behavior
224230523|NCT05549284|DRUG|Orelabrutinib,Rituximab and Methotrexate|Orelabrutinib, Rituximab combined with high-dose Methotrexate(RMO) as first line regimens in the treatments of newly diagnosed primary central nervous system lymphoma. The response will be evaluated every 2 cycles. Patients who achieved complete remission (CR) or partial remission (PR) will receive further treatment, and there are 6 cycles of RMO regimen for the induction. The patients with stable disease (SD) or progressed disease(PD) will withdraw from the trial and receive salvage regimens. After total 6 induction cycles, the investigators evaluate the efficiency again. After 6 cycles, the patients who receive CR or PR, can tolerate Autologous Hematopoietic Stem Cell Transplantation (AHSCT) will be candidates of high-dose chemotherapy and stem rescue. The patients who achieve CR or PR, cannot tolerate AHSCT will go to whole brain radiotherapy or Orelabrutinib maintenance. The patients with SD or PD will receive salvage regimen.
224230524|NCT05969470|DEVICE|Internal fixation with short intramedullary nails|Intramedullary nailing is a method of internal fixation used to treat fractures. An intramedullary nail is a metal rod forced into the marrow canal of a bone to stabilize and align fractures. Participants in this group will be fixed with a shorter intramedullary nail (defined as defined as less than 2/3 of the patient's femur) for proximal femoral (impending) pathological fractures.
223642967|NCT06602895|OTHER|Balance Training|Participants first engaged in stability exercises for 10 minutes, focusing on core stability and balance through plank variations and stability ball exercises. This was followed by 15 minutes of multi-joint strength exercises, where athletes performed compound movements like squats, deadlifts, push-ups or bench presses, and pull-ups or lat pull-downs, each for t sets of 8-10 repetitions. The session concluded with 15 minutes of agility and coordination drills, incorporating high-intensity activities such as lateral sprints and rope pulling, specifically designed to improve quickness and neuromuscular coordination, thereby enhancing overall athletic performance. The session concluded with a 10-minute cooldown involving flexibility exercises for the limbs and trunk. Exercise intensity was regulated to correspond with a 6-7 on the repetitions in the reserve-based Rating of Perceived Exertion (RPE) scale, where a s indicates that the exerciser feels they could perform approximately.
224230525|NCT05969470|DEVICE|Internal fixation with long intramedullary nails|Intramedullary nailing is a method of internal fixation used to treat fractures. An intramedullary nail is a metal rod forced into the marrow canal of a bone to stabilize and align fractures. Participants in this group will be fixed with a longer intramedullary nail (defined as greater than 2/3 of the patient's femur) for proximal femoral (impending) pathological fractures.
223680831|NCT04968054|DRUG|Arm I (Propofol)|Propofol group will be inducted and maintained total intravenous anesthesia with propofol 2% and remifentanil under Shinider and Minto target controlled infusion (TCI) model, respevtively.
223680832|NCT04968054|DRUG|Arm II (Remimazolam)|Remimazolam group started total intravenous anesthesia with remiamazolam at 6 mg/kg/h at the time of anesthesia induction, and maintained at 0.5-1.5 mg/kg/h.
223680833|NCT00083096|DRUG|lonafarnib|
224230526|NCT06373575|PROCEDURE|Lung and inferior vena cava ultrasound guidance|The lung and inferior vena cava ultrasound will be utilized as guidance for the development of a dialysis prescription for prolonged hemodialysis.
224230527|NCT06373575|PROCEDURE|Conventional protocol guidance|Fluid removal using conventional protocol including blood pressure and physical examination
224230528|NCT05632848|DRUG|Chidamide combined with Zimberelimab|Chidamide: 30mg each time, orally, biw; Zimberelimab, 240mg, IV, every 3 weeks.
224230529|NCT00344552|DRUG|Paclitaxel|Injection solution, IV, 100mg/sqm, once weekly, 7 weeks and over
223680834|NCT00083096|DRUG|temozolomide|
223680835|NCT00306332|PROCEDURE|T-cell and B-cell depletion|
223680836|NCT01455467|DEVICE|One iStent|Implantation of one iStent in conjunction with cataract surgery
224230530|NCT00519337|DRUG|Ascorbic acid|Ascorbic acid, 2 g p.o. the night before surgery followed by 500mg B.I.D. for 4 post-operative days
224230531|NCT00519337|DRUG|Placebo|Placebo capsule, 4 capsules the night before surgery followed by 1 capsule B.I.D. for 4 postoperative days
224230532|NCT01625637|BEHAVIORAL|AAT-experiment|This AAT condition trains kids to avoid cigarettes
224230533|NCT01625637|BEHAVIORAL|AAT-placebo|This AAT condition is a no contingency continued assessment version (50% approach-cigarettes, 50% avoid cigarettes).
224230534|NCT00635778|DRUG|dalotuzumab|Administered as an IV infusion over one to two hours
224230535|NCT02012309|BIOLOGICAL|PCV-13|
224230536|NCT02012309|BIOLOGICAL|PPSV-23|
224230537|NCT03615937|BEHAVIORAL|Child interactive intervention|The Child Interactive Intervention will be delivered through a Dialogic Reading Program, which is an individual/group level intervention component for both families and kindergartens. The original Dialogic Reading Program aims to enhance children's literacy and oral language skills by using the specific technique of shared book reading developed by Whitehurst and colleagues (1988). However, this project will expand from the original Dialogic Reading Program template to include alignment with local kindergarten curriculum and themed interactive activities that help build social competence and emotional maturity in children, in addition to cognitive skills.
224230538|NCT03615937|BEHAVIORAL|Family Empowerment|Family empowerment in this project can be conceptualized across three main pillars: 1) adaptive parenting; 2) adaptive extended family environment; and 3) familial resources. Typically, adaptive parenting is translated into positive parenting programs for primary caregivers, and the rest of the family environment involves extended caregivers. However, families from disadvantaged environments encounter many hurdles that hinder effective parenting and relationship nurturing, and parents' mental wellbeing are also consistently impacted by competing demands.
224319658|NCT04036110|DIETARY_SUPPLEMENT|Vitamin C 500 mg|500 mg tablet taken orally with one meal daily
223680837|NCT01455467|DEVICE|Two iStent|Implantation of two iStent in conjunction with cataract surgery
223680838|NCT03789617|BIOLOGICAL|EBViNT Cell|"1. Dosage: 1 bag containing 1.4x10\^9 cells/100mL~2. Administration: Inject intravenously over 30 minutes~3. Dosing schedule: Single dose"
223680839|NCT03047681|DIAGNOSTIC_TEST|venous blood withdrawl|patients will be asked for a venous blood sample
223680840|NCT02749526|DRUG|"Endostar"|30mg civ24h d0-6.A course of 3 weeks, after two course of chemotherapy the CT/MR/ultrasonic gastroscopy.
223680841|NCT02749526|DRUG|Liposo|135mg/m2 D1.A course of 3 weeks, after two course of chemotherapy the CT/MR/ultrasonic gastroscopy.
223680842|NCT02749526|DRUG|cisplatin|25mg/m2 D1-3.A course of 3 weeks, after two course of chemotherapy the CT/MR/ultrasonic gastroscopy.
223680843|NCT02749526|DRUG|Gimeracil and Oteracil Potassium （Tegafur）|40mg bid，D1-14.A course of 3 weeks, after two course of chemotherapy the CT/MR/ultrasonic gastroscopy.
223680844|NCT00841373|PROCEDURE|Panretinal Photocoagulation|Panretinal Photocoagulation treatment
223680845|NCT00841373|PROCEDURE|Panretinal Photocoagulation and intravitreal injection of ranibizumab|Panretinal photocoagulation and ranibizumab
223680846|NCT00880685|DRUG|Memantine|10-30mg, daily for 8 weeks
223680847|NCT03772860|OTHER|Pain stimulation|Pain will be simulated with an electric shock 25 mlAMP over the median nerve
223680848|NCT03772860|OTHER|Visual stimulation|Visual stimulation will be performed by a flicker of light on a computer screen at 15 Hrz for 0.3 seconds
223680849|NCT03772860|OTHER|Auditory stimulation|Auditory stimulation will be delivered through headphones with a sound at 500 Hrz at 85 decibels for 0.3 seconds
223680850|NCT03772860|OTHER|Mental stress|A mathematical challenge will be displayed on a computer screen that must be quickly solved
223680851|NCT01249118|DRUG|GDC-0973 IV Infusion|IV infusion.
223680852|NCT01249118|DRUG|GDC-0973 Oral Capsules|Oral dose.
223642968|NCT06601231|DIAGNOSTIC_TEST|GAAD score|In order to calculate the GAAD score an in-vitro diagnostic is used. The Elecsys GAAD assay by Roche Diagnostics is used to assess the GAAD score using on blood samples collected from patients during regular outpatient clinic visits. The Elecsys GAAD test combines the results of the Elecsys PIVKA-II and Elecsys AFP assays with gender and age (the GAAD score is calculated with PIVKA-II, AFP, gender and age).
223642969|NCT06594328|BEHAVIORAL|mHealth|participants of intervention group will receive text message reminder once a week on their mobile phones to brush and floss properly for the study duration
223642970|NCT06598111|OTHER|Amplified Benefits|Participants write a brief, detailed narrative describing a day in their future if they did not restrict their caloric intake and were not concerned about their body weight or shape.
223642971|NCT06598111|OTHER|Amplified Consequences|Participants complete the Pros and Cons of Anorexia scale to amplify the consequences of restrictive eating. They are also presented with blurbs about the consequences of restrictive eating.
223642972|NCT06598111|OTHER|Control|Participants write a brief narrative considering a future free of concern about finances.
223642973|NCT06861504|DEVICE|Femscope Calm Collect Device|The Femscope Calm Collect Device uses a patented brush for cervical cell collection.
224230539|NCT03615937|BEHAVIORAL|Access to Community Hub and its services|A new model of Community Hub will be implemented and there will be two hubs established in two respective districts. The Community Hubs act as an alternative venue to implement service delivery of intervention packages, such as activity sessions in the Child Interactive Intervention, Parenting Program, and mentor-mentee experience exchange, which provide families institutional flexibility and extended support while internalizing new practices. There will also be health education, consultation support and developmental assessments. The Hubs will play the roles of promoting and interweaving play-based learning into the lives of families frequently faced with competing demands and a lack of resources, and enable a protracted network for parents.
224230540|NCT03615937|OTHER|Enhancement to the kindergartens|This intervention package aims at providing a better physical and social kindergarten environment to maximize developmental reach and expedite timely interception and feedback without adding burden to teachers and frontline service professionals.
223642974|NCT02775786|OTHER|MRIs with and without intravenous contrast (up to 2)|Participants will undergo up to two MRIs with and without intravenous contrast. The first MRI will be performed using an extracellular contrast agent and the second 1-14 days later, with a macromolecular contrast agent. If patient cannot undergo the second MRI for any reason eg. not enough time before surgery, one MRI with either contrast agent will still be used for analysis.
223642975|NCT04801420|BIOLOGICAL|VLA15|a multivalent recombinant Outer Surface Protein A (OspA) based vaccine candidate
223642976|NCT04801420|BIOLOGICAL|Placebo|PBS (Phosphate Buffered Saline)
223642977|NCT04774094|DRUG|Zavicefta, Ceftazidime-Avibactam|Participants will receive CAZ-AVI (2000 mg of ceftazidime and 500 mg of avibactam) administered by IV infusion in a volume of 100 mL at a constant rate over 2 hours.
224230541|NCT03615937|OTHER|Health education, screening, and support|Health seminars and interactive workshop will be provided to the families. Screen for common child health problems (e.g. dental and visual) will also be conducted. A support hotline and website will be established for the participants.
224230542|NCT01739283|OTHER|GIP|
224230543|NCT01739283|OTHER|GLP-1|
224230544|NCT01739283|OTHER|Saline|
224230545|NCT04120428|OTHER|Aquatic exercise training program|The intervention will be performed in a pool in which the water surface line will remain in the imaginary line of the xiphoid process. Each season will last 50 minutes and will be divided in 3 phases as (1) warm-up (15 minutes), (2) main part (30 minutes) and (3) cool-down (5 minutes).
224230546|NCT05780879|DRUG|Venetoclax|Venetoclax administered orally once daily on days 3-16.
224319659|NCT04036110|DIETARY_SUPPLEMENT|Vitamin C 1000 mg|1000 mg tablet taken orally with one meal daily
224319660|NCT04036110|OTHER|Placebo|1 tablet taken orally with one meal daily
224319661|NCT03946280|PROCEDURE|conventional X-ray based Fluoroscopy|catheter tracking via conventional X-ray based Fluoroscopy
224319662|NCT03946280|PROCEDURE|low X-ray 3D navigation technique|catheter tracking via low X-ray 3D navigation technique
223642983|NCT05130528|BEHAVIORAL|Sensorimotor Intervention|Infants in the experimental group will receive 2 sensorimotor intervention sessions in the Neonatal Intensive Care Unit (NICU) and 8 sensorimotor intervention sessions in the home or in a clinic (parent choice) at 1, 3, 5, 8, 11, 15, 20, 26 weeks post NICU discharge. The 2 intervention sessions in the NICU will consist of collaborating with parents to recognize their infant's cues to engage in interaction, readiness for sensory exposures, and anticipatory guidance on the transition to home. The 8 intervention sessions in the home will focus on supporting the parents to read their infant's cues to identify the ideal times for interaction and provide 20 minutes of daily intervention addressing four key principles: encourage 1) self-initiated movement, 2) movement variability, 3) visual and manual object interaction, and 4) social interaction. Parents are encouraged not to impose movement on the infant but to encourage movement through environmental enrichment
223642984|NCT06638190|OTHER|100% Orange juice|250 mL of commercial 100% orange juice containing 25 g of total sugars (glucose, fructose, saccharose).
223680853|NCT05565885|OTHER|Sampling|4 blood sampling per patient and an additional one in case of relapse
223680854|NCT05776797|PROCEDURE|Atrioventricular junction ablation in patients with cardiac resynchronization therapy (CRT)|Ablation of the atrioventricular (AV) node is a procedure used to disrupt or break the electrical connection between the upper heart chambers (the atria) and the lower heart chambers (the ventricles).
223680855|NCT05776797|DRUG|Optimal medication treatment in patients with cardiac resynchronization therapy (CRT)|Optimal medication therapy according to the prescription of the physician.
223680856|NCT05819684|DRUG|SHR-4602 for injection|be administered via intravenous (IV) infusion
223680857|NCT04564118|DRUG|Retrospective analysis of assigned treatment|analysis of treatment assigned by physicians within routine clinical practice
223680858|NCT04179890|DRUG|Afatinib (Gi(l)otrif®)|Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI) as first or second-line therapy.
223680859|NCT04179890|DRUG|Erlotinib (Tarceva®)|Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI) as first or second-line therapy.
223680860|NCT04179890|DRUG|Gefitinib (IRESSA®)|Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI) as first or second-line therapy.
223642985|NCT06638190|OTHER|50% Orange juice|250 mL of 50% diluted orange juice (100% orange juice) plus added sugars to attain the same concentration and composition of sugars (glucose, fructose, saccharose) as the 100% orange juice
223642986|NCT06638190|OTHER|0% Orange juice|250 mL of water plus added sugars to attain the same concentration and composition of sugars (glucose, fructose, saccharose) as the 100% orange juice
223642987|NCT06638190|OTHER|Glucose|250 mL of water with 25 g of glucose. To determine the glycemic index of the different drinks and to characterize the glucose and insuline response of the participants
223642988|NCT06638190|OTHER|100% Orange juice Rep|Repetition of the 100% orange juice intervention
223642989|NCT06638190|OTHER|0% Orange juice Rep|Repetition of the 0% orange juice intervention
223642990|NCT04098237|DRUG|Pancrelipase|Pancrelipase delayed-release capsules
223642991|NCT03088735|PROCEDURE|Blastocyst-stage embryo transfer strategy|Intra-uterine transfer of blastocist if in cleavage embryo stage the oocyte recipient has a mínimum of 3 availables embryos with at least one of good quality to transfer and also the inta-uterine transfer of cleavage embryo (day 3) when the recipient doesn't have the previous criteria.
223642992|NCT03088735|PROCEDURE|Cleavage-stage embryo transfer strategy|Inta-uterine transferring of cleavage embryo transfer (day 3 of develpment) in oocyte recipients
223642993|NCT00412919|DRUG|Azacitidine|
223642994|NCT02784691|DEVICE|Feeligreen patch|
223642995|NCT06233396|OTHER|Extra 4DCT scan|Extra 4DCT scan after routine simulation
223642996|NCT03365089|PROCEDURE|Collateral vein ligation|Collateral venous flow will be interrupted by ultrasound-guided ligation of venous side branches.
223642997|NCT01999257|OTHER|Online pre-test genetic education tool|See Arm Descriptions above.
223642998|NCT05973617|DIAGNOSTIC_TEST|Measurement of corneal biomechanical properties|Measurement of corneal biomechanics
223642999|NCT05217316|BEHAVIORAL|Supervised Virtual Toothbrushing|"A supervised virtual toothbrushing performed once a week for all students by dental hygienist that will be performed through a prescheduled virtual appointment for each child. All virtual appointments will be conducted using the collaboration of two national platforms. Mawid, a Ministry of health (MOH) Central Appointment System, to be used by the subjects. And ANAT system, a Saudi Commission for Health Specialists (SCHS) application for the hygienists to use for their virtual supervision."
223643000|NCT01376804|DRUG|valganciclovir [Valcyte]|Oral, daily for up to 200 days.
223643001|NCT01691222|DEVICE|Double lumen endotracheal tube tracheostomy|"Percutaneous tracheostomy in this study will be performed with the use of a dedicated double-lumen endotracheal tube.~The dedicated double-lumen endotracheal tube (Deas S.R.L, Italy) has an upper and a lower lumen. The upper one will be occupied by flexible fiberoptic bronchoscope while the lower one is exclusively dedicated to patient ventilation during the procedure. The lower lumen has a a semi-elliptical cross section. This tube will be placed in the patient airway with a direct laryngoscopy. After this intubation, a percutaneous dilatational tracheostomy will be performed with the standard techniques recognised in the literature."
224230547|NCT05780879|DRUG|FLAG or CLAG Protocol|FLAG consists of daily infusions of Fludarabine (30mg/m2/day over 30 minutes) and Ara-C (2g/m2/day over 4 hours) for 5 days with daily subcutaneous injections of G-CSF until count recovery. Tbo-filgrastim will be administered as follows: WBC count \>50,000 - 5mcg/kg; WBC count \<50,000 - hold Tbo-filgrastim. Given the national shortage of Fludarabine, Cladrabine (5mg/m2/day IV over 2 hours) has been substituted (CLAG) with similar toxicity profile.
223643002|NCT00093704|DRUG|bortezomib + ganciclovir|Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8 and 11. Patients also receive ganciclovir IV twice daily on days 1-14. Treatment repeats every 21 days for a maximum of 3 courses.
223643003|NCT00750503|BEHAVIORAL|Behavioural and Pharmacotherapy for tobacco cessation|Professional help in the form of health awareness sessions, focus group discussion, one to one counseling and pharmacotherapy was provided to the employees by a team of doctors and counselors from Tata Memorial Hospital. Self reporting of tobacco history was validated with Rapid Urine cotinine test. Naked eye examination of oral cavity of all employees for detection of oral pre-cancers and cancers was conducted. Nursing staff and Doctors attached to the industry and from the local referral hospital were invited to participate as trainees during the active intervention sessions for local manpower development.
223643004|NCT01694498|DRUG|A: Desmopressin 25 µg|
223643005|NCT01694498|DRUG|B. Desmopressin 50 µg|
223643006|NCT01694498|DRUG|Placebo|
223643007|NCT00492635|DRUG|Levitra (Vardenafil, BAY38-9456)|9 months DAILY dosage (double blind) 2 months single-blind placebo wash-out period (subject only is blinded) 2 months open-label PRN treatment with active medication
223643008|NCT00492635|DRUG|Levitra (Vardenafil, BAY38-9456)|9 months PRN dosage (double blind) 2 months single-blind placebo wash-out period (subject only is blinded) 2 months open-label PRN treatment with active medication
223643009|NCT00492635|DRUG|Placebo|9 months placebo (double blind)2 months single-blind placebo wash-out period (subject only is blinded)2 months open-label PRN treatment with active medication
223680861|NCT04179890|DRUG|Osimertinib (Tagrisso®)|Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI) as first or second-line therapy.
223680862|NCT04179890|DRUG|Afatinib (Gi(l)otrif®)|As first line therapy.
223680863|NCT04179890|DRUG|Osimertinib (Tagrisso®)|In the case the T790M resistance mutation was developed (second line therapy).
223680864|NCT04211805|DRUG|Tenofovir Alafenamide 25 MG for arm (A)|Tenofovir Alafenamide (TAF) will be provided, 25 mg Per Oral daily.
223680865|NCT04211805|DRUG|Tenofovir Disoproxil Fumarate 300mg for arm (B)|Tenofovir Disoproxil Fumarate (TDF) will be provided, 300 mg Per Oral daily.
223680866|NCT01665612|DEVICE|Contact lens care solution|Comparison of clinical and subjective performation of the contact lens care solutions used with two types of contact lenses
223680867|NCT05380999|DIAGNOSTIC_TEST|Methylation tests of nucleic acids extracted from mature red blood cells (RBCs)|Up to 15 ml of peripheral blood will be collected from each subject, and the blood specimen will be processed to isolate mature red blood cells and extract the DNA and RNA from RBCs. DNA and RNA methylation will be tested by next-generation sequencing (NGS).
223680868|NCT03566069|DRUG|Intranasal Oxytocin|32IU (16IU\*2) of OT, Sorbitol, Benzyl, alcohol glycerol, distilled water.
223643010|NCT02005861|PROCEDURE|bone marrow cells transplantation on collagen scaffold|"120 ml of venous blood will be collected for the platelet gel production. The day of the surgery, 60 ml of bone marrow will be aspirate from the posterior iliac crest and concentrated. a standard ankle arthroscopy will be performed, with the patient in the supine position. The lesion will be detected and cleaned.~An equine collagen type 1 scaffold (IOR-G1, Novagenit, Mezzolombardo, TN, Italy) will be loaded with 2 ml of bone marrow concentrate and cut into an appropriate shape to fit the lesion.~After the scaffold implantation 2 ml of platelet gel will be loaded on the top of implant, in order to provide growth factors and to improve the stability of the implant."
223643011|NCT02942459|OTHER|Music therapy|25 Weekly Hours of Music Therapy by an Educated Music Therapist
223643012|NCT02942459|OTHER|Music Listening|25 weekly Hours of Being Together with an unknown Care Staff Member
223643013|NCT03074552|DIETARY_SUPPLEMENT|LactoLevure|The probiotic preparation will consist a combination of four probiotics: Lactobacillus acidophilus LA-5 1.75 × 109 CFU, Lactobacillus Plantarum 0.5 × 109 CFU, Bifidobacterium lactis BB-12 1.75 × 109 CFU και Saccharomyces boulardii 1.5 × 109 CFU per capsule (LactoLevure, UniPharma, Athens, Greece).
223643014|NCT03074552|OTHER|Placebo|Placebo will consist of identical capsules of powdered glucose polymer
223643015|NCT02482818|DRUG|Pregabalin|Increasing dose regimen depending on tolerability followed by decreasing dose regimen.
223643016|NCT02482818|DRUG|Control-Placebo|A control substance, Lactose is administered in place of Pregabalin.
223643017|NCT05611294|DEVICE|Topography Guided LASIK Surgery|LASIK surgery, using corneal topography data in treatment profile, to correct myopia or myopia with astigmatism refractive error.
223643018|NCT05611294|DEVICE|Small Incision Lenticule Extraction Surgery|Corneal lenticule formation using a femtosecond laser, with subsequent lenticule extraction, to correct myopia or myopia with astigmatism refractive error.
223643019|NCT01357850|DRUG|GSK716155|GSK716155
223643020|NCT01357850|DRUG|Placebo|Placebo
223643021|NCT06611553|PROCEDURE|Biospecimen Collection|Undergo collection of cervical sample by clinician
223643022|NCT06611553|PROCEDURE|Cervical Biopsy|Undergo cervical biopsy conducted by clinician
223643023|NCT06611553|PROCEDURE|Colposcopy|Undergo colposcopy conducted by clinician
223643024|NCT06611553|OTHER|Electronic Health Record Review|Ancillary studies
223643025|NCT06611553|PROCEDURE|Endocervical Curettage|Undergo endocervical curettage conducted by clinician
223643026|NCT06611553|PROCEDURE|Excision|Undergo cervical excisional procedure conducted by clinician
223643027|NCT06611553|PROCEDURE|HPV Self-Collection|Undertake self-collection of vaginal sample
224230548|NCT02679677|DEVICE|Whole Body Vibration|The principle of the Galileo vibration platform is a side alternating motion similar to a childrens seesaw. Both the amplitude of movement and the frequency of movement may be altered. Frequency may be controlled on the device and settings range from 5Hz to 30Hz. Amplitude of movement is set by spreading one's legs further apart from the midline. Control arm participants remain fixed at 5Hz through the 6 week training period, while intervention arm participants steadily increase their frequency to a maximum of 28Hz.
224319663|NCT01471730|DRUG|Fibrinogen|All the patients randomized and not withdrawn will be tested 20 minutes before removal of aortic cross clamping with a Thromboelastometric fibrinogen test FIBTEM (Rotem) . They will all receive either human fibrinogen concentrate (according to the formula: (22 \[mm\] - MCF \[mm\]) \* body weight \[kg\] / 140 \[m\] = whole g fibrinogen to be dosed as HFC) (treatment group) or placebo (control group). Study drug or placebo has to be administered after protamine.
224319664|NCT01471730|DRUG|Saline solution|Normal saline will be administered to control patients.
223643028|NCT06611553|PROCEDURE|Human Papillomavirus Test|Undergo HPV testing of self-collected vaginal sample and cervical sample
223643029|NCT06611553|OTHER|Questionnaire Administration|Ancillary studies
223643030|NCT06611553|OTHER|Survey Administration|Ancillary studies
224230549|NCT00812253|DRUG|Intravenous insulin|Half of subjects will receive insulin through the intravenous route while the other half will receive 4 injections per day.
223643035|NCT02789293|DEVICE|EyeOP1 device|Ultrasound Ciliary Plasty (UCP procedure) using Focused Ultrasound
223643036|NCT06322654|PROCEDURE|Robotically Assisted Locomotion|"* Motor control training~* Locomotion and motor control training with elements of balance and coordination~* Verticalization training: standing frame device and vibration platform~* Cognitive therapy"
223643037|NCT06322654|PROCEDURE|Robotically Assisted Verticalization|"* Motor control training~* Verticalization training with Standard Frame Devices~* Locomotion and motor control training with elements of balance and coordination~* Cognitive therapy"
223643038|NCT02911584|PROCEDURE|Laparoscopic procedure|
223643039|NCT04939714|BEHAVIORAL|Psychoeducational Intervention|The intervention is an online course providing education and training to caregivers over an 8 week period. The self-paced course provides information on caregiving for a PLWD during a pandemic, navigating the health care system for a PLWD, and managing daily life (including self-care).
223643040|NCT04963647|DIAGNOSTIC_TEST|Adult subjects diagnosed with IS or TIA|From the moment the person decides to participate, the patient will undergo the first 24-hour cycle of monitoring with a high-resolution 12-lead Holter. The following day, the Holter report generated will be analyzed by an expert electrocardiographic. After the removal of the first Holter, the study subject will undergo a second monitoring with a 3-lead Holter device for a duration of 6 days, followed by decontamination of the device and archiving of data The electronic data relating to the monitoring periods with Holter will be analyzed with various high-sensitivity AF detection algorithms in order to identify the outcome of the study.
223643041|NCT02564003|DRUG|Oxycodone|oxycodone 0,1 mg/kg iv
223643042|NCT05626868|DEVICE|Intra abdominal pressure measurement|Device: Biometrix - Intraabdominal pressure monitoring set Intraabdominal pressure monitoring with the intended set in values of milimeters of mercury (mmHg) in real time.
223643043|NCT03800147|DRUG|"Mutaflor Suspension (E. coli Nissle 1917)"|"Inoculation of Mutaflor Suspension (E. coli Nissle 1917)"
223643044|NCT03800147|OTHER|Blood samples|Blood samples will be collected and analyzed at different study time points
223643045|NCT03800147|OTHER|Stool samples|Stool samples will be collected and analyzed at different study time points
223643046|NCT03800147|OTHER|Clinical information|Clinical information will be collected at different study time points using questionnaires
223643047|NCT00753506|DIETARY_SUPPLEMENT|Artemisinin|100 mg of artemisinin twice per day for 10 weeks
224230550|NCT00812253|DRUG|Subcutaneous insulin|Half of subjects will receive insulin through the intravenous route while the other half will receive 4 injections per day.
224230551|NCT04073147|DRUG|Venetoclax|Venetoclax per os
224230552|NCT04073147|DRUG|Obinutuzumab|ObintuzumabIV
224230553|NCT04289545|DIETARY_SUPPLEMENT|Functional bread|Postprandial effects of bread containing galactomannan
224230554|NCT05012345|PROCEDURE|Below Elbow cast|below-elbow cast ( 4 or 6 weeks )
224230555|NCT01827007|OTHER|Volume expansion with gelofusine|
224230556|NCT01884025|BEHAVIORAL|Get Moving and Get Well|Walking Class
224230557|NCT01884025|BEHAVIORAL|Health and Humor Class|Class about the role of humor in health
224230558|NCT05883176|DRUG|Bevacizumab Biosimilar QL 1101|TACE + Bevacizumab (15mg/kg, intra-arterial infusion, Q3W) for 4 cycles, followed by maintenance therapy with Bevacizumab (15mg/kg, intravenously, Q3W) to a maximum total cycle of 18 unless any evidence of disease progression or unacceptable side effects.
224230559|NCT01153048|OTHER|Intensification of education|The main objective is to assess impact of the establishment of involved patients (peer educators) network in Mali. Peer educators and persons targeted by the project will be recruited through Post-Test Club on diabetes (PTC). PTC will be a social support club that provides on going prevention counseling, education and support services to people who have diabetes. PTC represents an important link between patients, educators and general medical services. PTC will be defined as clubs, which are facilitated by well-trained peer educators, and will have 3 objectives: to provide social and emotional support to diabetic patients, to provide assistance in daily management and living with diabetes and to provide linkage to clinical care. To lead the sessions, in clubs, we will use a very innovative methodology for peer education: the learning nests method. To evaluate, we propose a classical randomized controlled experimental (RCT) design, with randomization at the person-level.
224230560|NCT01902680|RADIATION|Focal brachytherapy|Focal brachytherapy with permanent I125 localized implant.
224230561|NCT05398822|DIAGNOSTIC_TEST|MRI|Texture analysis (TA) is a novel imaging biomarker that can assess heterogeneity in MRIs by measuring grey-level intensities distribution. This study hypothesizes that TA of MRI is an imaging biomarker that can predict local recurrence and distant metastasis.
224230562|NCT05176977|BEHAVIORAL|Peer Support-Whole Health Coaching|Participants will meet with a Peer Specialist for 18 sessions over a period of 24 weeks. The essential elements of this intervention include 1) general support provided via the core functions of a Peer Specialist and 2) a structured Whole Health Coaching curriculum.
224230563|NCT03286582|DRUG|AC-203 1% Topical Ointment|AC-203 1% ointment BID (twice daily)
224230564|NCT03286582|DRUG|Clobetasol 0.05% Topical Ointment|Clobetasol 0.05% Topical Ointment BID
224230565|NCT02918162|DRUG|Pembrolizumab|Pembrolizumab dosed IV at 200mg every 21 days per cycle.
223643048|NCT00753506|DIETARY_SUPPLEMENT|Identical looking placebo capsule|Identical looking placebo twice per day for 10 weeks
223643049|NCT03689621|DEVICE|Transcutaneous vagus nerve stimulation (tVNS)|
223643050|NCT02178150|DIETARY_SUPPLEMENT|Magnesium Oxide|This is a double-blind randomized clinical trial which will be started at June 2014 and end on June 2015 in Isfahan city. Serum insulin level is considered as a key variable and the sample size was calculated to be 70 persons (35 persons for control group and 35 persons for patient group). Patient group will receive magnesium supplement (250 milligram) and the other group will receive placebo which is similar to the magnesium tablets in color, odor and appearance both for 8 weeks. All subjects will complete 4 physical activity and 4 dietary records. Outcome measurements including metabolic and inflammatory profiles,sex hormone levels will be measured at the beginning and end of the study as well as anthropometric measurements.
223643051|NCT02178150|DIETARY_SUPPLEMENT|Placebo|
223643052|NCT00936767|DRUG|Artemisone/Mefloquine (AmiM3)|Artemisone 4 mg/kg/day for 3 days plus mefloquine 15mg/kg on day 3 and 10mg/kg on day 4
223643053|NCT00936767|DRUG|Artesunate|Artesunate 4mg/kg/day for 3 days plus mefloquine 15mg/kg on day 3 and 10mg/kg on day 4
223643054|NCT04380285|DEVICE|Custom heel pads and modified soft molded orthotics|
223643055|NCT04380285|DEVICE|Custom hard orthotic|
223643056|NCT02528981|DRUG|Probiotic|Lactobacillus GR-1 and RC-14
223643057|NCT02528981|DRUG|Placebo|
223643058|NCT03227120|OTHER|Prehabilitation exercise|"Three times weekly exercise program of strengthening, balance and functional activities.~Weekly evaluation and progression with daily use of the Borg Rating of Perceived Exertion (RPE) supplemented with Heart Rate (HR) and Blood Pressure as needed to target the moderate intensity training level (40-60% HR Max) or above as appropriate to each individual."
223643059|NCT04147663|OTHER|describe the management of the adult population suffering from suspected seizure by the emergency structures|For 3 consecutive days, all patients with suspected epileptic seizures (assessed by the Emergency medical assistance service ( SAMU), paramedical team and the emergency unit) will be included in the study. With the use of questionnaries, information will be collected from patients or witnesses by the SAMU, the paramedical team or physicians of the emergency unit. A 7-day follow-up will be carried out by the principal investigator (PI) of each center.
223643060|NCT05434286|DIAGNOSTIC_TEST|Echocardiographic assessment|POC-Echocardiography to assess dynamic changes in cardiac output to assess therapeutic responses with albumin and terlipressin
223643061|NCT03995602|DIETARY_SUPPLEMENT|Dragon fruit juice drink|Dragon fruit drink containing 24 g of freeze-dried dragon fruit powder dissolved in low nitrate water.
223643062|NCT03995602|DIETARY_SUPPLEMENT|Placebo|Drink with macro- and micro-nutrient matched against the intervention drink.
223680869|NCT03566069|OTHER|Intranasal Placebo|32IU (16IU\*2) of Sorbitol, Benzyl, alcohol glycerol.
223680870|NCT05631288|GENETIC|Sampe collection|Unstimulated crevicular fluid samples are collected using two sized 35 paper cones per subject, both used in the sampling process. The DNA is extracted from the samples through multiplex PCR at the Egas Moniz Applied Microbiology Laboratory (LMAEM).
223680871|NCT00119873|BIOLOGICAL|VRC-HIVADV014-00-VP|
224230566|NCT02918162|DRUG|Standard of care chemotherapy regimen|"Standard regimen containing at least a platinum and Fluorouracil (5-FU) agent (per National Comprehensive Cancer Network guidelines) - such as Doublet or Triplet chemotherapy with capecitabine, oxaliplatin, and epirubicin (optional) (21 day cycle). Epirubicin can be excluded at the discretion of the treating physician.~Example:~Oxaliplatin dosed IV at 130 mg/m2 every 21 days per cycle. Capecitabine dosed orally at 625mg/m2 twice a day daily."
223643063|NCT05204004|DEVICE|Sunrise|"Sunrise (Sunrise SA, Belgium) is a novel integrated digital medicine solution for the diagnosis of OSA allowing the detection of respiratory disorders from the analysis of mandibular movements optimised by an artificial intelligence algorithm machine learning. It is composed of a unique innovative sensor, placed on the chin during the night, connected via Bluetooth to a mobile application which guides the patients for the implementation and allows the transfer of the data collected by the sensor to a certified health host guaranteeing the security and confidentiality of medical data. The analysed data is integrated and automatically transferred into a detailed report made available to doctors via a secure website the day after the test."
223643064|NCT05204004|DEVICE|Polygraphy|Polygraphy (Apnoealink-Air, ResMed, Australia) is a commercially available, limited-channel sleep study device which can be used in the home. Many sleep services in the UK already use the ApneaLink Air for routine screening. It is a portable device which consists of a nasal cannula to measure nasal flow and snoring, oximeter to measure pulse and blood oxygen levels, and a chest band to measure respiratory effort. It contains software which allows for the scoring of apnoeas, hypopnoea and arousals.
223643065|NCT01600716|BIOLOGICAL|OnabotulinumtoxinA|OnabotulinumtoxinA 100 U is administered into the detrusor at Day 1 in the onabotulinumtoxinA 100 U arm. After a minimum of 12 weeks, patients in both the onabotulinumtoxinA 100 U arm and the placebo arm could request/qualify for an onabotulinumtoxinA injection.
223643066|NCT01600716|DRUG|Placebo (Normal Saline)|Placebo (normal saline) is administered into the detrusor at Day 1.
223643067|NCT00779155|DEVICE|The Resonator|active magnetic field therapy
223643068|NCT00779155|DEVICE|The Resonator control|inactive magnetic field therapy with placebo fields
223643069|NCT02698553|DRUG|Bupropion HCl XL tablet 150mg|The 150 mg of tablet will be given to subject once daily orally. Subject will be instructed to swallow whole tablet with 240 ml of water, without crushed, divided or chewed.
223643070|NCT02698553|DRUG|Bupropion HCl XL tablet 300mg|The 300 mg of tablet will be given to subject once daily orally. Subject will be instructed to swallow whole tablet with 240 ml of water, without crushed, divided or chewed.
224230567|NCT03146091|OTHER|Nonantibiotic treatment of uncomplicated diverticulitis|Patients randomized to this arm will be treated without antibiotics in the outpatient setting. Pain will be managed with appropriate analgesia as per protocol.
224230568|NCT03146091|OTHER|Antibiotic treatment of uncomplicated diverticulitis|Patients randomized to this arm will be treated with antibiotics in the outpatient setting. Pain will be managed with appropriate analgesia as per protocol.
224230569|NCT04060368|PROCEDURE|Endoscopic Sleeve Gastroplasty (ESG) with OverStitch® system + Lifestyle modifications|Endoscopic technique defined as a gastric restriction by means of continuous sutures of the entire gastric wall of the antrum and body, transmurally, in order to simulate a gastric sleeve, in the same way as sleeve gastrectomy surgery. Gastroplasty is performed using an endoscopic suture system (OverStitch, Apollo Endosurgery Inc., Austin, Texas, USA) inserted into a dual-channel endoscope (GIF-2T160, Olympus Medical Systems Corp., Tokyo, Japan).
224230570|NCT04060368|PROCEDURE|Laparoscopic Sleeve Gastrectomy (LSG) + Lifestyle modifications|Minimally invasive surgical technique defined as a gastric restriction by means of an excision approximately 80% of the stomach along the greater curvature.
224230571|NCT00215462|DRUG|Vinorelbine|
224230572|NCT00314938|DRUG|PHA-794428|
224230573|NCT02382666|DRUG|Rolapitant|
224230574|NCT00395226|DRUG|zinc sulfate|zinc sulfate 220 mg bis for 90 days
224230575|NCT00395226|DRUG|placebo|placebo bid for 90 days
224230576|NCT05105373|BEHAVIORAL|Parenting for Respectability|"The programme addresses main challenges of Parenting and builds skills in 4 main areas~1. Poor parental bonding and child attachment;~2. Harsh parenting~3. Inequitable socialisation by gender~4. Parental conflict."
224230577|NCT04245566|PROCEDURE|Prostatic Artery Embolization (PAE)|Prostatic artery embolization will be performed under local anesthesia according to well established and standardized techniques.
224230578|NCT04245566|DRUG|Pharmacotherapy|Pharmacotherapy will be performed using α1-blockers and 5α-reductase inhibitors in accordance with the EAU recommendations
224319665|NCT01471730|DRUG|Prothrombin complex|After 15min from study drug administration and in presence of ongoing microvascular bleeding, we run a CT EXTEM. In case of prolonged CT time at EXTEM as long as 80 seconds \[M1\] , they will receive coagulation factors concentrates (Confidex) at a weight-based dose of 7 U/kg b.w. (treatment group) or placebo.
224319666|NCT04252092|OTHER|Sensory training|15 session,20 minutes sensory training program
224319667|NCT04252092|OTHER|Electrical stimulation|15 session,20 minutes electrical stimulation program
223643071|NCT04510818|DRUG|Capecitabine, Camrelizumab|This is a single-arm study with all patients receiving these two drugs.
223643072|NCT05115071|BEHAVIORAL|Childbirth preparation education|"Purpose: The aim of the birth preparation education is to eliminate the fears and concerns of pregnant women about birth and to prepare them for birth during the Covid-19 Pandemic process.~Education hours: The education will be completed in total two weeks and eight hours, consisting of two days and four hours each week.~Method: The education will be given online through the Microsoft Teams application. Each training day will consist of two lessons. Each lesson will last 45 minutes. There will be a 15-minute break between the two lessons. The first lesson will be conducted in the form of a question and answer session with a power-point presentation.In the second lesson, relaxation exercises will be applicated and evaluations will be taken at the end of the lesson.~The group that will receive the education: Healthy pregnant women between 24-34 weeks of gestation will be included in the training. Trainings will continue with closed groups."
223643073|NCT05982418|DEVICE|3D Printed Models (3D printing facilities at GSTT)|3D patient-specific printed models are given to the surgeon before the start of RARP on a given patient. These 3D models are generated using automatic segmentation in MONAI followed by validation by a radiologist, and then post-processed for 3D printing.
223643074|NCT05982418|DEVICE|3D Virtual Models (Innersight Labs)|3D patient-specific virtual models loaded into Innersight Labs platform are given to the surgeon before the start of RARP on a given patient. These 3D models are generated using automatic segmentation in MONAI followed by validation by a radiologist, and then post-processed for 3D visualisation.
223643075|NCT02601248|DRUG|Theliatinib|Theliatinib is a tablet in the form of 25 mg ,10mg and 100 mg,oral,once daily
223643076|NCT02441296|OTHER|Formula with lactose|
223643077|NCT02441296|OTHER|Formula with maltodextrins|
223643078|NCT00955916|DRUG|CLAG Regimen|The CLAG regimen consisted of: Cladribine, 5 mg/m\^2 administered via 2 hour IV daily for 5 consecutive days starting on day 2; Cytarabine, 2 mg/m\^2 administered through a 4 hour IV starting 2 hours after the ignition of Cladribine for 5 days starting on day 2; granulocyte colony-stimulating factor (G-CSF): 300 mcg subcutaneous (SC) for 6 days starting 12-24 hours (Day 1) before the first dose of Cladribine.
223643079|NCT00955916|DRUG|Gleevec®|Imatinib mesylate 400 mg orally twice daily was administered on day 2 to day 15. Re-induction was allowed if participant had partial response (PR).
223643080|NCT04896515|DIETARY_SUPPLEMENT|Supplemental parenteral nutrition|Supplemental parenteral nutrition OLIMEL N12E (Baxter Healthcare Corporation)
223643081|NCT02600039|OTHER|ELTGOL|Individuals will be placed in the lateral decubitus position and instructed to perform slow expirations with an open glottis through a nozzle attached to the mouth from the residual functional capacity to residual volume. Concurrently, a trained and subsequently positioned relative to the voluntary physical therapist will perform a manual compression of the abdominal region dependent and the rib cage to enhance contralateral lung deflation. This intervention is performed so that the time is homogeneous between each repetition interval of one minute between each set. To this end, three sets of ten repetitions will be performed on each lateral decubitus (left and right)
223643082|NCT02600039|DEVICE|Acapella|Participant should be comfortably seated and with his elbows on a table. The mouthpiece is attached properly to not allow leaks. The resistance load will be one in which the individual is able to maintain uninterrupted expiration of 3 seconds. Then the patient will be instructed to inhale slowly and deeply, with lung volumes between the residual volume and total lung capacity. The air exhaled by Acapella is directed toward an orifice which opens and closes periodically, promoting oscillations in the air stream throughout the expiratory phase. The expiration is always performed to the VR, and without performing the active contraction of the abdominal muscles. Still prompted an inspiratory pause of 2 seconds for the end of the inspiratory phase. This procedure will be performed in 4 sets of 5 minutes with interval of 1 minute between the series.
223643083|NCT02538393|DRUG|Sorafenib (BAY43-9006) Film-coated tablet|Subjects received a single oral dose of 400 mg sorafenib marketed tablets (2 \* 200 mg) in fasting state in Treatment A
223643084|NCT02538393|DRUG|Sorafenib (BAY43-9006) Oral suspension|Treatment C: Subjects received a single oral dose of 200 mg sorafenib tablets for oral suspension (2 \* 100 mg) in fasting state in the second intervention period; Treatment B: Subjects received a single oral dose of 400 mg sorafenib tablets for oral suspension (4 \* 100 mg) in fasting state in the third intervention period; Treatment D: Subjects received a single oral dose of 400 mg sorafenib tablets for oral suspension (4 \* 100 mg) after a high-fat, high-calorie breakfast (fed state) in the fourth intervention period.
223643085|NCT06383728|DRUG|Osimertinib|Patients with resectable stage II-IIIB EGFR-mutated lung squamous cell carcinoma will receive Osimertinib ( 80mg/d, ≥9 weeks).
224230579|NCT01365429|DEVICE|XPS™ with Steen Solution™|The XPS™ System is an integrated cardiac bypass system comprised of various components such as a Maquet CardioHelp centrifugal pump (K102726), the HicoVariotherm Heater/Cooler, the Hamilton C2 ICU (intensive care unit) pressure- controlled ventilator (K092148), the perfusate gas monitors, and the display monitors. The XPS™ System is responsible for housing the organ for preservation, providing the normothermic environment, and perfusing the organ with the STEEN Solution™. Donor lungs that meet inclusion criteria are placed on the XPS™ and rewarmed and perfused with STEEN Solution™ and ventilated for 3-6 hours. If the lungs meet transplant suitability, they are cooled down and transplanted into a consented recipient that meet's trial criteria.
224230580|NCT04613830|DRUG|Bupivacaine Hydrochloride|The patient will be placed in a sitting position under complete aseptic condition and a cover sheath will be used for the ultrasound probe with an appropriate amount of lubricating gel applied on the probe, a high-frequency linear ultrasound transducer will be placed in a longitudinal orientation 3 cm lateral to the L3 spinous process. This should reveal three muscles superficial to the hyperechoic transverse process shadow as follows: trapezius, rhomboid major, and erector spinae. then injecte bupivacaine hydrochloride
224230581|NCT04613830|DRUG|Tramadol hydrochloride|Patients in group Tramadol will intravenously administrate dose of 1 mg/kg/8hr tramal to be increased upon patient needs up to 2mg/kg/6hr as rescue analgesic
224230582|NCT00414531|DRUG|Atorvastatin|20 to 80 mg per day
224230583|NCT05103722|OTHER|Combined Aerobic and Resistance Exercise Training|Participants receive personalized exercise plan for home-based two days of aerobic exercises (20-30-minutes) and two days of resistance exercises per week for 12 weeks. After completion of study intervention, participants will be assessed at the of study visit at Week 24.
224230584|NCT00361322|DRUG|clindamycin phosphate|
224230585|NCT00361322|DRUG|salicylic acid|
224230586|NCT05822401|BEHAVIORAL|Blood flow restriction (BFR)|Blood flow restricted training integrated into the daily work tasks for 8 weeks.
224230587|NCT05822401|BEHAVIORAL|Usual care (control)|Will continue their work as usual
223643086|NCT03926611|DRUG|LOU064 Arm 1|10 mg LOU064 orally in the morning (once daily) and matching placebo in the evening from Day 1 to 85
223643087|NCT03926611|DRUG|LOU064 Arm 2|35 mg of LOU064 orally in the morning (once daily) and matching placebo in the evening from Day 1 to 85
223765668|NCT04909086|PROCEDURE|Closed Kinetic Chain|Patients assigned to this group will receive a 40-min multimodal supervised physical therapy treatment comprised of warm-up (10-min cycling/walking), three sets of 10 repetitions of 60% of one-repetition maximum (1RM) of seated leg press and partial squat exercises, neuromuscular control exercises, and ten-minute transcutaneous electrical nerve stimulation (TENS). Manual mobilization techniques may be applied as necessary according to the findings of the physical examination. Treating physical therapists will prescribe exercises based on a predetermined list of exercises.
224230588|NCT00280267|DRUG|Testosterone gel|
224230589|NCT05893550|DIETARY_SUPPLEMENT|Smartfish Omega|Fruit juice drink containing Omega-3: the experimental condition
224230590|NCT05893550|DIETARY_SUPPLEMENT|Smartfish Fruit Juice Only|this is a fruit juice drink with no omega-3 added. it is the placebo condition
224230591|NCT02384616|OTHER|Oxygen|Delivery of high concentration of oxygen at induction, maintenance and extubation of children under general anesthesia.
224230592|NCT00295958|BIOLOGICAL|LMB-2 immunotoxin|
224319668|NCT04775615|DRUG|DDO-3055 tablets；Placebo|Low dose：DDO-3055 tablets for 7 days or Placebo for 7 days
224319669|NCT04775615|DRUG|DDO-3055 tablets；Placebo|Medium dose：DDO-3055 tablets for 7 days or Placebo for 7 days
224230593|NCT00295958|BIOLOGICAL|MART-1 antigen|
224230594|NCT00295958|BIOLOGICAL|gp100 antigen|
224230595|NCT00295958|BIOLOGICAL|incomplete Freund's adjuvant|
224230596|NCT04842058|OTHER|Mobilisation procedure|A standardized mobilization procedure was performed preoperatively \~ 1h before surgery and was repeated 6h and 24h after surgery. The mobilization procedure included patient supine rest (5 minutes), followed by 45° passive leg raise (PLR) (3 minutes), supine rest (5 minutes), sitting on the edge of the bed with feet resting on the floor (3 minutes) followed by standing using a walker while the patient was encouraged verbally to stand on toes and shift body weight from one leg to the other (3 minutes) and finally rest in supine position (5 minutes). The procedure was terminated prematurely in any position if patients experienced unbearable symptoms of OI or upon a decrease of systolic arterial pressure (SAP) \> 30 mmHg.
224230597|NCT04172363|DRUG|Octenisept and Serasept|Swab probes of wounds will be taken upon study inclusion and analysed for resistance on Octenisept and Serasept. If the patient indicates resistance on one of the antiseptics, he/she will receive the other antiseptic for wound dressings
224230598|NCT00096395|DRUG|gemcitabine hydrochloride|Given IV
224230599|NCT00096395|DRUG|sorafenib tosylate|Given orally
223643088|NCT03926611|DRUG|LOU064 Arm 3|100 mg of LOU064 orally in the morning (once daily) and matching placebo in the evening from Day 1 to 85
223643089|NCT03926611|DRUG|LOU064 Arm 4|10mg bid of LOU064 orally, twice daily from Day 1 to 85
223643090|NCT03926611|DRUG|LOU064 Arm 5|25 mg bid of LOU064 orally, twice daily from Day 1 to 85
223643091|NCT03926611|DRUG|LOU064 Arm 6|100 mg bid of LOU064 orally, twice daily from Day 1 to 85
223643092|NCT03926611|DRUG|Placebo arm|Matching placebo, orally, twice daily from Day 1 to 85
223643093|NCT05317325|BIOLOGICAL|OCDC vaccine; NeoDC vaccine|OCDC vaccine and NeoDC vaccine are administered in a prime-boost regimen by subcutaneous injection.
223643094|NCT05457439|BEHAVIORAL|Sustainable diet promotion through behavioral change intervention|15 weeks digital intervention to promote sustainable diets through workshops, and behavioral change techniques in a mobile application, to decrease environmental impact of diets and improve health.
223643095|NCT01088698|RADIATION|UVB-311nm radiation|UVB-311nm radiation given 3 times a week to one randomized body-half
223643096|NCT03134703|DRUG|Methadone|Infants in the Methadone Treatment Group will receive the study drug, methadone, instead of morphine to treat withdrawal symptoms from Neonatal Abstinence Syndrome (NAS)
223643097|NCT03134703|DRUG|Morphine|Infants in the Comparison Group will receive standard of care narcotic (morphine) to treat withdrawal symptoms from Neonatal Abstinence Syndrome (NAS)
223643098|NCT04295824|DIAGNOSTIC_TEST|Skin imaging and Skin biopsy|"Imaging includes:~* Structural Optical Coherence Tomography (OCT) - Skin thickness/roughness.~* Angiographic OCT- Vessel depth/morphology.~* Polarisation-sensitive OCT - Tissue birefringence / collagen index.~* Skin biopsies will be taken from the same volar forearm site as the imaging is performed."
223643099|NCT02230670|DRUG|IDN-6556|25 mg BID
223643100|NCT02230670|DRUG|Placebo|
223643101|NCT05406674|DRUG|Cisplatin 100 mg/m2|Cisplatin 100 mg/m2 milligram(s)/square meter
223643102|NCT05406674|DRUG|Cisplatin 40 mg/l|Cisplatin 40 mg/I milligram(s)/litre
223643103|NCT03722238|DRUG|Ibuprofen 600 mg Immediate Release/Extended Release Caplet|Ibuprofen 600 mg Immediate Release/Extended Release Tablet to be adminstered orally (i.e., one caplet every 12 hours, not to exceed 2 caplets per day) for pain.
223643104|NCT02451982|DRUG|Cyclophosphamide|200 mg/m2 IV
223643105|NCT02451982|BIOLOGICAL|GVAX pancreatic cancer|5x10\^8 cells intradermal injection
223643106|NCT02451982|DRUG|Nivolumab|480 mg IV
223643107|NCT02451982|DRUG|Urelumab|8 mg IV
223643108|NCT02451982|DRUG|BMS-986253|2400 mg IV
223643109|NCT03898544|DEVICE|Group primary TKA|"Assessment by gait kinematics analysis The total knee arthroplasty will be performed as usual with the dedicated instrumentation.~The gait kinematics analysis will be performed with the KneeKG system on a treadmill, with infrared sensors (IR) on the leg. This system is not invasive. The IR sensors are positioned on the pelvis, the distal femur and the tibial crest. This system records the flexion/extension, the varus/valgus and the rotation during the walking (1 minute of walking)."
223643110|NCT03898544|DEVICE|Group TKA revision|"Assessment by gait kinematics analysis The total knee arthroplasty will be performed as usual with the dedicated instrumentation.~The gait kinematics analysis will be performed with the KneeKG system on a treadmill, with infrared sensors on the leg. This system is not invasive. The IR sensors are positioned on the pelvis, the distal femur and the tibial crest. This system records the flexion/extension, the varus/valgus and the rotation during the walking (1 minute of walking)."
223643111|NCT05330286|DRUG|LMI070|oral solution
223643112|NCT05330286|DRUG|LMI070|Oral solution
223643113|NCT05330286|DRUG|LMI070|Oral solution given in fasted state
223643114|NCT05330286|DRUG|LMI070|Oral solution given in fed state
223643115|NCT03457896|DRUG|Trastuzumab|Patients with HER2 amplified tumors with prior anti-EGFR therapy and/or HER2 mutated colorectal cancer with/or without prior anti-EGFR therapy will receive 4 mg/kg IV loading dose; then 2 mg/kg IV weekly until disease progression. Neratinib: 240 mg taken by mouth daily until disease progression.
223643116|NCT03457896|DRUG|Cetuximab|Patients with HER2 WT or HER2 amplified with no prior anti-EGFR therapy: 400 mg/m2 IV loading dose; then 250 mg/m2 IV weekly. Neratinib 240 mg taken by mouth daily until disease progression.
224230600|NCT00096395|OTHER|laboratory biomarker analysis|Correlative studies
224230601|NCT03190746|DIAGNOSTIC_TEST|TaqMan SNP analysis|TaqMan SNP analysis of the YWHAH gene
224230602|NCT01396681|DRUG|gemcitabine and cisplatin|The study consists of three phases; Induction chemotherapy phase:Starting 4\~8 weeks after R0 resection of pancreatic cancer. Gemcitabine: 1200mg/㎡ (Day 1, 8), cisplatin 60mg/㎡ (Day 1) every 3 weeks for 2 cycles. Chemoradiotherapy phase: Starting 1-2 weeks after completion of induction chemotherapy (within 5 weeks after D1 of 2nd cycle of induction chemotherapy), no later than 16 weeks after operation. Gemcitabine 300mg/㎡ weekly for 5 weeks throughout RT period. Radiotherapy: 50.4Gy at 1.8Gy/Fx, for 28 Fx (Field reduction at 45Gy) for 5.5 pweeks. Maintenance chemotherapy phase: Within 4 weeks after completion of chemoradiotheray, no later than 6 weeks after completion of chemoradiotherapy Gemcitabine: 1200mg/㎡ (Day 1, 8) every 3 weeks, for 4 cycles
224230603|NCT03082781|DIETARY_SUPPLEMENT|NCDsport|Negative Calorie Diet supplemented with exercise
224230604|NCT03082781|DIETARY_SUPPLEMENT|LCDsport|Low-Calorie diet with exercise
223643117|NCT03457896|DRUG|Neratinib|240 mg taken by mouth daily until disease progression.
223643118|NCT03457896|DIAGNOSTIC_TEST|Guardant360 Diagnostic Test|Prior to assignment to Arm 1, the Guardant360 diagnostic test will be conducted in blood to confirm known HER2 status for select patients.
223643119|NCT02372188|OTHER|water|Control
223643120|NCT02372188|DIETARY_SUPPLEMENT|caffeine|
223643121|NCT02372188|DIETARY_SUPPLEMENT|caffein + homoeriodictyol sodium salt|
223643122|NCT02372188|DIETARY_SUPPLEMENT|homoeriodictyol sodium salt|
223643123|NCT04958473|DRUG|Sintilimab|PD-1 inhibitor，Sintilimab 200mg IV, every 3 weeks.
223643124|NCT04958473|DRUG|Axitinib|Tyrosine kinase inhibitor，licensed for use in treatment of renal cell carcinoma. Oral treatment Axitinib given 5 mg PO BID.
224230605|NCT05451459|OTHER|12-week FMS Intervention|4 virtual workshops (2-3 hours each) covering topics of 1) Sensory Integration, 2) Communication, 3) Physical activity, and 4) Sports (during intervention)
224230606|NCT05451459|BEHAVIORAL|Physical Activities & Activity Booklets (via FitFamilies app)|expected to engage in physical activity at least 3 hours per week, virtual workshops provide them with resources to engage in Physical activity
224230607|NCT02873988|OTHER|bronchial epithelial cell culture|
224230608|NCT04800653|PROCEDURE|Stellate ganglion block|Find the position of the stellate ganglion under ultrasound guidance, and inject 0.375% ropivacaine near the stellate ganglion to block the sympathetic nerves in the upper chest and head and neck
224230609|NCT02142244|PROCEDURE|Near infra red sentinel node biopsy|Explicated in the protocol arm
224230610|NCT02142244|DRUG|Indocyanine green|Explicated in the protocol arm
223643125|NCT02835248|OTHER|Fall Detection|All participants will wear a device configured to detect falls.
223643126|NCT03430102|DIAGNOSTIC_TEST|Indicor|Calculation of LVEDP via analysis of PPG waveform with Valsalva
223643127|NCT02254070|DRUG|BIBT 986 BS|
223643128|NCT04551482|DRUG|Oxytocin nasal spray|24 IU nasal spray, 4 times per day for 12 weeks
224230611|NCT02142244|DEVICE|Intraoperative Near-Infrared Imaging System|Explicated in the protocol arm
224230612|NCT00001776|DEVICE|Cadwell Rapid Rate Magnetic Stimulator|
224230613|NCT05733247|OTHER|Copenhagen adductor exercise|Week 1 - 1 session per week consisting of 2 sets of 5 reps of the exercise Week 2 - 2 sessions per week consisting of 2 sets of 6 reps of the exercise Week 3 -3 sessions per week consisting of 3 sets of 6 reps of the exercise Week 4 - 3 sessions per week consisting of 3 sets of 8 reps of the exercise Weeks 5 and 6 - 3 sessions per week consisting of 3 sets of the exercise.
224230614|NCT05733247|OTHER|The adduction and abduction partner exercise|Week 1 - 1 session per week consisting of 2 sets of 5 reps of the exercise Week 2 - 2 sessions per week consisting of 2 sets of 6 reps of the exercise Week 3 -3 sessions per week consisting of 3 sets of 6 reps of the exercise Week 4 - 3 sessions per week consisting of 3 sets of 8 reps of the exercise Weeks 5 and 6 - 3 sessions per week consisting of 3 sets of the exercise.
224230615|NCT02642666|BEHAVIORAL|Children's Yoga|"Trained children's yoga instructors will guide the children through 30 minute yoga classes (in-person and on the yoga video), using a manualized curriculum from If I Was a Bird Yoga ™ with child centered themes. Each class will have a similar structure, set of poses, and breathing exercises, but the theme of the class will change every two weeks. The themes for the classes are ocean yoga adventure, jungle yoga adventure and outer space yoga adventure. The study participants will spend two weeks practicing the same theme at home and at school before moving on to the next theme."
224230616|NCT04502069|DRUG|Opaganib|500 mg Q12 hours orally
224230617|NCT05229757|OTHER|Physiotherapy and rehabilitation treatment in a special education and rehabilitation center.|Routine physiotherapy and rehabilitation practice was performed 2 days a week for 8 weeks in the special education and rehabilitation center.
224230618|NCT05229757|OTHER|Family-based home exercise.|Home exercise was applied by the families every day of the week for 8 weeks.
224230619|NCT03736109|GENETIC|Soluble and genetic biomarkers measurements|Insulin-Like Growth Factor-1 and Coll2-1 gene expression will be measured by real time PCR. In addition, syndecan 4, hyaluronic acid, substance P and nitric oxide will be measured in plasma by ELISA
223643129|NCT04551482|DRUG|Placebo|24 IU nasal spray, 4 times per day for 12 weeks
223643130|NCT05324514|PROCEDURE|Split-thickness skin grafting|Harvesting for split-thickness skin grafting will be performed at the specified donor site using a pneumatically powered dermatome with a setting of 10 /1000th inch and meshed 2:1.
223643131|NCT05324514|DEVICE|High density microscopic skin tissue column grafting|MSTC harvest will be conducted using the ART system (Medline Industries) in accordance with the manufacturer's instructions and distributed at high density (300-360 columns/50cm2).
223643132|NCT05324514|DEVICE|Low density microscopic skin tissue column grafting|MSTC harvest will be conducted using the ART system (Medline Industries) in accordance with the manufacturer's instructions and distributed at low density (150-180 columns/50cm2).
223643133|NCT02928614|DRUG|Liraglutide 3 mg (Saxenda)|
223643134|NCT02928614|DRUG|Liraglutide 3 mg placebo|
223643135|NCT05819151|DIAGNOSTIC_TEST|HbA1c Test|HbA1c Test is required. No other interventions. The researchers will only take photos of the subjects' tongues, and ask them to fulfil a questionnaire.
223643136|NCT02004093|DRUG|pertuzumab|Loading dose of 840 mg IV, followed by 420 mg IV every 3 weeks
223643137|NCT02004093|DRUG|paclitaxel|175 mg/m2 IV every 3 weeks for 6 cycles
223643138|NCT02004093|DRUG|gemcitabine|1000 mg/m2 IV Day 1 and 8 of each cycle for 6 cycles
223643139|NCT02004093|DRUG|carboplatin|Target AUC of 5 following paclitaxel or AUC of 4 following gemcitabine IV every 3 weeks for 6 cycles
223643140|NCT01411891|DEVICE|Chlorhexidine impregnated patch (Biopatch)|Patients assigned to the intervention group will have a chlorhexidine impregnated patch placed at the femoral nerve catheter insertion site.
223643141|NCT05498714|DRUG|PEG+lactulose|On the day before colonoscopy , Patients took 50mL lactulose solution at 7:00 PM. And then Patients began to drink 1 L of PEG at 8:00 PM. On the day of the procedure, patients took 50 mL lactulose solution and the remaining 2 L of PEG 4-6 hours before colonoscopy.
223643142|NCT05498714|DRUG|CSP＋lactulose|On the day before colonoscopy , Patients took 50mL lactulose solution at 7:00 PM. And then Patients began to drink 150 mL of CSP at 8:00 PM ,followed by 2000ml of clarified liquid. On the day of the procedure, 4-6 hours before colonoscopy, patients took 50 mL lactulose solution and the remaining 150mL of CSP ,then followed by 750ml of clarified liquid .
224230620|NCT02475083|OTHER|Virtual Reality|Rehabilitation with virtual reality, using Football games, Boxe, Bambolê and Tennis.
224230621|NCT02475083|OTHER|Conventional|Stretching exercises in limbs, trunk mobilization in the three planes, balance training in standing position, training of balance reactions and gait training.
224230622|NCT03602326|OTHER|Neurodevelopmental Therapy-Bobath group|Neurodevelopmental Therapy-Bobath (NDT-B) is one of the most commonly used models for therapeutic management and treatment in patients with stroke. The basic philosophy underlying this approach is that; lesions in the central nervous system cause impairments in the coordination of movement and posture combined with problems in muscle tone which lead directly to functional limitations. According to the NDT-B approach, practice has a great role in treatment due to the fact that more practice leads to better motor learning and increases neural plasticity. According to NDT-B, the duration of treatment should not be limited to rehabilitation sessions, but should be designed to be implied throughout the day and should be adapted to the patients' daily life.
224230623|NCT03602326|OTHER|Standart Rehabilitation Group (SR group)|Standard Rehabilitation for Stroke consists of the hospitals' physiotherapy and rehabilitation routine.
224230624|NCT00279721|PROCEDURE|IMRT|
224230625|NCT00231868|DRUG|Carboplatin and Paclitaxel and Pelvic Radiation Therapy|Paclitaxel 175 mg/m2/3 hour \& Carboplatin (AUC=6.5) Repeat q 21 days x 3 cycles followed by RT followed by Paclitaxel 175 mg/m2/3 hour \& Carboplatin (AUC=5.0)Repeat q 21 days x 3 cycles
224230626|NCT00231868|PROCEDURE|Carboplatin and Paclitaxel and Pelvic Radiation Therapy|Paclitaxel 175 mg/m2/3 hour \& Carboplatin (AUC=6.5) Repeat q 21 days x 3 cycles followed by RT followed by Paclitaxel 175 mg/m2/3 hour \& Carboplatin (AUC=5.0)Repeat q 21 days x 3 cycles
224230627|NCT00231868|DRUG|Carboplatin and Paclitaxel and Radiation Therapy|Paclitaxel 175 mg/m2/3 hour \& Carboplatin (AUC=6.5) Repeat q 21 days x 3 cycles followed by RT followed by Paclitaxel 175 mg/m2/3 hour \& Carboplatin (AUC=5.0)Repeat q 21 days x 3 cycles
224230628|NCT05253560|DIAGNOSTIC_TEST|The investigators aim to identify prodromal PD in a cohort of carriers of Gaucher disease.|Tests to help identify prodromal PD in a cohort of carriers of Gaucher disease
224230629|NCT05412407|OTHER|Questionnaire|description of analgesic self-medication in the context of acute pain using a questionnaire evaluating the drug taken, the dosage, the duration of treatment, the type of pain, its intensity, the origin of the drug, the source of information consulted and the factors that prompted the patient to self-medicate
224230630|NCT06157307|DEVICE|Aortic compression|Aortic compression with four different methods on each participants
224230631|NCT06460974|OTHER|stress ball|A stress ball was applied to the patients in the during chemotherapy treatment.
224319670|NCT04775615|DRUG|DDO-3055 tablets；Placebo|High dose：DDO-3055 tablets for 7 days or Placebo for 7 days
224319671|NCT03382587|DRUG|Aflibercept (Eylea, BAY86-5321)|"Intravitreal aflibercept injections used in a routine treat and extend regimen, under which the intervals between the injections are extended if disease stability is maintained and no signs of worsening disease are observed on the injection day"
224319672|NCT03190811|BIOLOGICAL|Anti-PD-1 plus DC-CIK|"Anti-PD-1 antibody treatment: Patients will receive pembrolizumab 100mg every three weeks until disease progression, unacceptable toxicity or patient refusal.~DC-CIK Immunotherapy: Mononuclear cells were collected aseptically with blood cell separator composition apheresis, and cultured DC-CIK cells for 10-14 days. Cells were infused back to the patients in 3 times via intravenous infusion .Patients will received at least 2 cycles of DC-CIK Immunotherapy along with 4 dosage of anti-PD-1 antibody treatment. If the evaluation of the treatment is partial response or stable disease, additional cycles were eligible."
224319673|NCT03190811|BIOLOGICAL|Anti-PD-1 alone|Anti-PD-1 antibody treatment: Patients will receive pembrolizumab 100mg every three weeks until disease progression, unacceptable toxicity or patient refusal.
224319674|NCT02077361|GENETIC|rAAV2.REP1 vector|No additional details needed.
223643143|NCT02445898|DRUG|Methylprednisolone|Comparison of preoperative single high dose of Methylprednisolone 125 mg iv. and isotonic Sodium Chloride (placebo)
223643144|NCT02445898|DRUG|Isotonic Sodium Chloride|Placebo
223643145|NCT02253862|DRUG|Tadalafil|administered days 1, 8 and 16
223643146|NCT02253862|DRUG|Tipranavir|administered days 8-18
223643147|NCT02253862|DRUG|Ritonavir|administered days 8-18
223643148|NCT00414596|DEVICE|DRX9000™|Device is designed to apply spinal decompressive forces.
223643149|NCT03498898|OTHER|Chronic use of Beta adrenergic receptor blocker|Chronic use of Beta adrenergic receptor blocker
223643150|NCT03232697|DIAGNOSTIC_TEST|Full version of the Montreal Cognitive Assessment|Patients or subjects will be submitted to the full version of the MOCA
223643151|NCT03232697|DIAGNOSTIC_TEST|5 minutes version of the Montreal Cognitive Assessment|The same patients and subjects will be submitted to the 5 minutes version of the MOCA through a phone call
223643152|NCT00003523|DRUG|aminocamptothecin colloidal dispersion|
223643153|NCT02824341|DEVICE|fMRI|
223643154|NCT00203099|DRUG|Glatiramer Acetate, N-Acetylcysteine|Subcutaneous glatiramer acetate 20 mg and concomitant oral administration of N-Acetylcysteine divided into two 2.5 g doses.
223643155|NCT00126243|DRUG|rituximab|
223643156|NCT00126243|DRUG|CHOP|
223643157|NCT03930082|OTHER|Frailty Index Scale|We will evaluate the frailty with a Frailty Index Scale in elderly patients undergoing gastrointestinal surgery.
223643158|NCT06960382|DRUG|ALUTARD SQ® Felis domesticus|The drug is approved for use in Switzerland for subcutaneous injections. I this study, we will test the intralympahtic injection
223643159|NCT02558296|DRUG|Bexagliflozin|20 mg, tablet
223643160|NCT02558296|DRUG|Placebo|20 mg tablet to match active comparator
223643161|NCT00297258|DRUG|pazopanib|oral tablet
223643162|NCT02874989|DRUG|Dasatinib + Quercetin|
223643163|NCT02874989|DRUG|Placebo|
223643164|NCT01967329|DRUG|Standard Triple|Oral twice-daily doses of rabeprazole (20 mg), amoxicillin (1 g) and clarithromycin (500 mg)
223643165|NCT01967329|DRUG|Sequential|Oral twice-daily doses of rabeprazole (20 mg) and amoxicillin (1 g) on days 1-5, and on days 6-10, rabeprazole (20 mg), metronidazole (500 mg) and clarithromycin (500 mg)
223643166|NCT01967329|DRUG|Quadruple|Oral doses of rabeprazole (20 mg) twice daily, metronidazole (500 mg) three times daily, bismuth subsalicylate (Pepto-Bismol) (2 tablets) four times daily and tetracycline (500 mg) four times daily
223643167|NCT04846738|DEVICE|Transcranial Doppler|This device measures Mean Systolic Velocity (VMS), Tele-Diastolic Velocity (TDV) and Pulsatility Index (PI),
223643168|NCT04846738|DEVICE|Pupillometry.|This device measures the photomotor reflex (basic pupil diameter, percentage of variation, latent and slope of the standard photomotor reflex)
223643169|NCT00485095|BEHAVIORAL|Intake of plant sterols|
223643170|NCT06516016|RADIATION|PET|\[18F\]DPA-714 will be injected intravenously as a 1 minute intravenous bolus injection and dynamic PET acquisition will last 90 min. The aim is the quantification of the neuroimmune reaction during neuroinflammation process.
223643171|NCT06516016|OTHER|MRI 3T|Brain MRI will aim at providing imaging biomarkers which will allow evaluating brain structure, microstructure, iron load, myelin, neurodegeneration of the substantia nigra and locus coeruleus, functional connectivity, brain perfusion and the glymphatic system.
223643172|NCT06516016|OTHER|Oculomotricity assessment|Recording eye movements in a controlled environment (requiring no specific room or area) in binocular vision at a frequency \> 500Hz, while retaining infrared video footage of eye movements for high-quality clinical monitoring.
223643173|NCT06516016|OTHER|Magnetoencephalography assessment|Recording brain magnetic activity using the Elekta Neuromag® TRIUX Magnetoencephalograph ; The participant will be comfortably seated in an adjustable-height chair. The device is enclosed in a shielded room isolated from external electric and magnetic fields to measure the extremely weak magnetic activities produced by the brain.
223643174|NCT06516016|OTHER|Body posture and gait assessment|The acquisition of kinematic gait parameters will be achieved ; markers are positioned on the different segments of members, recognized by a camera system positioned on the walls. Neurophysiologic muscular activity of the lower limbs will also be recorded.
223643175|NCT06516016|OTHER|Voice recording|Participants will be recorded during a single session at every visit upon baseline with a professional quality head mounted microphone.
223643176|NCT06516016|OTHER|Video-polysomnography|Participants will complete standard sleep questionnaires before the visit and perform neurophysiological tests including cognitive tasks before and after the sleep recording.
223643177|NCT06516016|BIOLOGICAL|Blood sampling, skin biopsy, excreta sampling, lumbar puncture|Experimental analyses, genetic and multi-OMIC analyses for biomarker research.
223643178|NCT05679258|DRUG|HLX15|A single dose (8 mg/kg) of HLX15 via intravenous infusion.
223643179|NCT05679258|DRUG|US-sourced DARZALEX®|A single dose (8 mg/kg) of US-sourced DARZALEX® via intravenous infusion.
223643180|NCT05679258|DRUG|CN-sourced DARZALEX®|A single dose (8 mg/kg) of CN-sourced DARZALEX® via intravenous infusion.
223643181|NCT05679258|DRUG|EU-sourced DARZALEX®|A single dose (8 mg/kg) of EU-sourced DARZALEX® via intravenous infusion.
223643182|NCT03920319|DRUG|Bupropion|Bupropion 150 mg sustained release
223643183|NCT03920319|OTHER|Placebo|
223643184|NCT03405597|DRUG|Commercial Hepatitis B vaccine|Commercial Hepatitis B vaccine (Engerix B) 20 microgram subcutaneous injection at month 0, 1, 6
223643185|NCT03405597|OTHER|Standard Treatment|HBsAg, HBsAb test Ultrasound upper abdomen every 6 months
223643186|NCT01441076|DRUG|Anakinra|Anakinra/Kineret\[registered\] is a recombinant, non-glycosylated form of the human interleukin-1 receptor antagonist (IL-1Ra)
223643187|NCT01385293|DRUG|BKM120|BKM120 at the maximum tolerated dose (MTD) of 100mg orally daily
224230632|NCT01531465|OTHER|Pulmonary Function Testing & esophageal pressure monitoring|Infants who are currently on NCPAP will have pulmonary function testing (PFTs)and esophageal pressure performed while on 2 different settings of NCPAP. These infants will then be transitioned HFNC and will undergo PFTs and esophageal pressure while on different HFNC settings. The infant will then be returned to NCPAP at the same settings they were on prior to any study interventions.
224230633|NCT01531465|OTHER|Pulmonary function testing and esophageal pressure|Infants who are currently on HFNC will have pulmonary function testing (PFTs) and esophageal pressure performed while on 2 different settings of HFNC. These infants will then be transitioned NCPAP and will undergo PFTs and esophageal pressure while on 2 different NCPAP settings. The infant will then be returned to HFNC at the same settings they were on prior to any study interventions.
224319675|NCT04272424|PROCEDURE|laparoscopic mesh fixation|laparoscopic mesh fixation by non fixation,tacker and histoacryl
224319676|NCT02884570|OTHER|Auto-Questionnaires|Consents and questionnaires will be sent to the parental home or filled in an interview with an investigator (or telephone consultation).
223643188|NCT00346697|DRUG|Omega-3 fatty acid administration|LOVAZA 1 gram capsules, 4 capsules daily
223643189|NCT00346697|DRUG|Placebo|Corn-oil placebo
223643190|NCT02895893|BEHAVIORAL|PrEP Smart|Men who have sex with men and already prescribed and taking oral PrEP will use an application on their smart phone for 4 weeks.
223643191|NCT04670978|DRUG|albumin-bound paclitaxe combined with bevacizumab biosimilar|albumin-bound paclitaxe, 260mg/m2, every 3 weeks, 6cycles, bevacizumab biosimilar, 10mg/kg, every 3 weeks, continue until PD or unaccceptable toxicity
223643192|NCT00002080|DRUG|Rifabutin|
223643193|NCT01672580|BEHAVIORAL|exposure to vitamin use|"Seed individuals in village are given daily adult multivitamin, with training on use and general nutrition information, along with coupons to distribute to others in village"
223643194|NCT01672580|BEHAVIORAL|exposure to water chlorination|"Seed individuals in village are given Clorox bleach for water purification, with training on use and general information on water hygiene, along with coupons to distribute to others in village"
223643195|NCT01672580|BEHAVIORAL|high in-degree|"Seed individuals for starting intervention are chosen on the basis of high (social network) in-degree"
223643196|NCT01672580|BEHAVIORAL|nominated by random|"Seed individuals for starting intervention are chosen on the basis of being named as a friend/alter of a randomly selected individual"
223643197|NCT02567578|DRUG|YH12852 0.1 mg|
223643198|NCT02567578|DRUG|YH12852 0.25 mg|
223643199|NCT02567578|DRUG|YH12852 0.5 mg|
223643200|NCT02567578|DRUG|Placebo|
223643201|NCT05851261|DRUG|PA3670|Placebo as control
223643202|NCT04182828|DRUG|Lidocaine|both the drugs will be prepared in same volume, color, consistency and appearance
223643203|NCT04467372|DIETARY_SUPPLEMENT|Tart cherry juice concentrate|Two 8oz bottles of tart cherry juice concentrate daily for 30 days
223643204|NCT04467372|DIETARY_SUPPLEMENT|Juice placebo|Two 8oz bottles of placebo juice daily for 30 days
223643205|NCT04467372|DIETARY_SUPPLEMENT|Freeze dried tart cherry powder|Two freeze dried tart cherry powder capsules daily for 30 days
223643206|NCT04467372|DIETARY_SUPPLEMENT|Capsule placebo|Two placebo capsules daily for 30 days
223643207|NCT03032978|OTHER|Calcium hydroxide|Pulp capping material
223643208|NCT03032978|OTHER|Calcium silicate|Pulp capping material
223643209|NCT02566421|OTHER|Laboratory Biomarker Analysis|Correlative studies
223643210|NCT02566421|OTHER|Quality-of-Life Assessment|Ancillary studies
224230634|NCT05241236|DEVICE|Image Fusion (MR/US) Software Registration Guided Laser Ablation of Prostate Cancer|Subjects diagnosed by a transperineal fusion or random transperineal or random transrectal prostate biopsy. Laser treatment plan generated by biopsy results +/- MRI is uploaded into the device. In procedure suite, a transperineal anesthetic block is conducted following by Bianco - USPTO PCT/US18/24404. On lithotomy a transrectal ultrasound probe is advanced, the prostate scanned. The images are acquired by fusion device. Co-registration is performed by surgeon delimiting boundaries of prostate. Medical device delivers real-time fusion guidance outlining prostate contours, ablation goals and laser introduce location. Surgeon executes plan or adjust as needed. Surgeon activates laser device, performs ablation monitored by medical device in real-time. The fusion device will deliver great perspective between the ablation areas and critical anatomical landmarks such as: NVB, membranous urethra, etc. Patient is dismissed to the recovery room and discharged afterwards
223643211|NCT02566421|OTHER|Targeted Therapy|Receive treatment based on genomic sequencing
223643212|NCT05903768|OTHER|Mobilization|"Hot Pack for 5mins,Active range of motion exercises (10 reps x 3 sets),Home plan include: wand exercises, wall-walking exercises, pendulum exercises,towel stretch exercises, Cross Body Adduction (10reps x 2 sets, each)Cold pack for 5 mins.~Maitland's Mobilization: Inferior glide (10x3), posterior glide, (10 reps x 3 sets), anterior glide (10 reps x 3 sets)"
223643213|NCT05903768|OTHER|Cyriax capsular stretching|"Hot Pack for 5mins,Active range of motion exercises (10 reps x 3 sets),Home plan include: wand exercises, wall-walking exercises, pendulum exercises,towel stretch exercises, Cross Body Adduction (10reps x 2 sets, each)Cold pack for 5 mins.~Anterior, Posterior and inferior capsular stretching would be performed. Each stretch should be held15-30 seconds and repeated 2 to 4 times."
223643214|NCT02290249|DEVICE|Glidescope|Manikin was intubated by different novice personal with glidescope videolaryngoscope
223643215|NCT02290249|DEVICE|Airtraq|Pediatric manikin was intubated by novice personal with airtraq
223643216|NCT04609176|DRUG|Camrelizumab plus Apatinib and SOX|Camrelizumab 200mg, day1; Apatinib 250mg qd p.o.;Oxaliplatin 130 mg/m2 day1; S-1 40-60 mg (calculated according to the body surface area) bid day1-14. 3 weeks for one cycle.
223643217|NCT04609176|DRUG|Camrelizumab plus Apatinib|Camrelizumab 200mg, day1; Apatinib 250mg qd p.o. 3 weeks for one cycle.
223643218|NCT04772612|DRUG|sitravatinib|sitravatinib
223643219|NCT02062840|DEVICE|High intensity whole-body infrared heating|The Whole Body Hyperthermia system uses water-filtered infrared-A (wIRA) heat radiation. The rise in the body's core temperature is correspondingly rapid and well-tolerated. There are two phases of the thermal challenge, 1) Irradiation phase during which the patient lies recumbent with his/her head positioned outside the tent. The wIRA irradiators are arranged above the exposed upper part of the body; and 2) Heat retention phase during which the patient lies in the chamber with the walls of the tent positioned to retain heat. Core body temperatures will be raised to those comparable to a mild fever 37.8-38.5°C.
223643220|NCT02062840|DEVICE|Low intensity whole-body infrared heating|Attenuated heating using only heating coils at the bottom of the Heckel device. This results in only a minor increase in skin temperature and no increase in core body temperature. The participant will still feel heat and will see similar lighting and hear similar sounds as those occurring during actual WBH, and will be in the chamber for the same period of time.
223643221|NCT02062840|DEVICE|Functional Magnetic Resonance Imaging (fMRI) and electrocardiogram (EKG)|A standard magnetic resonance imaging (fMRI) machine will be used to take images of the brain. An standard EKG (compatible with the fMRI machine) will be used to take measurements of cardiac vagal control.
223643222|NCT02062840|OTHER|Questionnaires|Weekly questionnaires to assess changes in depression, mood, perceptions of self and quality of life will be administered.
223643223|NCT03248206|BEHAVIORAL|lifestyle changes|Providing a home-based exercise program supervised by therapists can be an acceptable strategy with the characteristics of convenience and inexpensiveness to promote neuromuscular and functional component for the patients with diabetes mellitus.
224230635|NCT01134081|BIOLOGICAL|CelTx™|CelTx™ is a living bilayered cell therapy product. CelTx™ is constructed of Type I bovine collagen (extracted from bovine tendons and subsequently purified) and viable allogeneic human fibroblasts and keratinocytes isolated from human neonatal foreskin. This is applied once in the oral cavity.
224230636|NCT01134081|PROCEDURE|Free Gingival Graft|Harvested tissue from palate
224230637|NCT04026464|DRUG|Intravenous Ibuprofen|The control monotherapy group will receive 10 mg/kg intravenous ibuprofen followed by 5 mg/kg 24 and 48 hours subsequently.
224319677|NCT03323242|DEVICE|LigaSure|The dissection of the small blood vessels and the connective tissue in the hepatoduodenal ligament is carried out with LigaSure
223643226|NCT06516978|DRUG|Polatuzumab vedotin|Polatuzumab vedotin IV infusion will be administered as per the schedule specified in the respective arm.
223643227|NCT06516978|DRUG|Rituximab|Rituximab IV infusion will be administered as per the schedule specified in the respective arm.
223643228|NCT06516978|DRUG|Cyclophosphamide|Cyclophosphamide IV infusion will be administered as per the schedule specified in the respective arm.
223643229|NCT06516978|DRUG|Doxorubicin|Doxorubicin IV infusion will be administered as per the schedule specified in the respective arm.
223643230|NCT06516978|DRUG|Vincristine|Vincristine IV infusion will be administered as per the schedule specified in the respective arm.
223643231|NCT06516978|DRUG|Prednisone|Prednisone PO will be administered as per the schedule specified in the respective arm.
223643232|NCT06516978|DRUG|Orelabrutinib|Orelabrutinib PO will be administered as per the schedule specified in the respective arm.
223643233|NCT06516978|DRUG|Venetoclax|Venetoclax PO will be administered as per the schedule specified in the respective arm.
223643234|NCT06516978|DRUG|Chidamide|Chidamide PO will be administered as per the schedule specified in the respective arm.
223643235|NCT06516978|DRUG|Penpulimab|Penpulimab IV infusion will be administered as per the schedule specified in the respective arm.
223643236|NCT06516978|DRUG|Lenalidomide|Lenalidomide PO will be administered as per the schedule specified in the respective arm.
223643237|NCT04200599|OTHER|duration of initiation of oxytocin|mode of delivery
223643238|NCT01308437|BIOLOGICAL|Wosulin (N or 70/30 with R)|Basal bolus conventional Insulin viz. Wosulin (N or 70/30 with R) to be injected subcutaneously.
223643239|NCT01308437|BIOLOGICAL|Novolin® (N or 70/30 with R)|Basal bolus conventional Insulin viz. Novolin® (N or 70/30 with R) to be injected subcutaneously.
223643240|NCT02676141|OTHER|Manual Therapy|The treatment the patients receive is not specifically set up for the study. Participants will already be seeing a practitioner before the participants are included in the study.
223643241|NCT03236636|DRUG|Icaritin|Icaritin：600mg/time, 6 capsules/time(6×100mg/capsule), 2 times/day(30 minutes after breakfast, lunch and dinner), take orally, continuous administration until reach the standard of termination.
223643242|NCT03236636|DRUG|HUACHANSU PIAN|HUACHANSU PIAN:Take orally 4 tablets/time(0.3g/tablet), 3 times/day(30 minutes after breakfast, lunch and dinner), continuous administration until reach the standard of termination.
223643243|NCT02352155|PROCEDURE|epinephrine injection or heater probe or hemoclips|Elective Second look endoscopy in the following morning with re-treatment to the bleeding vessel using epinephrine injection or heater probe or hemoclips
223643244|NCT02352155|OTHER|Observation only|Observation for rebleeding, unscheduled endoscopy only when rebleeding criteria fulfilled
223643245|NCT05196295|DRUG|Hydrogen|Participants take either 1 (n=5), 3 (n=5) or 6 (n=5) capsules every day for one month.
223643246|NCT04607538|OTHER|No intervention is made|No intervention is made. This i an observational study.
223643247|NCT01036048|DEVICE|drug eluting stent|pts with cabg disease treated with drug eluting stent
224230638|NCT04026464|DRUG|Intravenous Ibuprofen + Oral Acetaminophen|The combined treatment group will receive 10 mg/kg intravenous ibuprofen followed by 5 mg/kg 24 and 48 hours subsequently and will in addition receive 15 mg/kg oral acetaminophen \[160 mg/5ml concentration\] every 6 hours for a total of 12 doses.
224230639|NCT03342495|OTHER|Patient Navigator|Social worker/Patient Navigator will be assigned to follow youth in adult care for up to 24 months to assist youth adapt and attach to adult delivered healthcare
224319678|NCT03323242|DEVICE|Harmonic Ultrasonic dissector|The dissection of the small blood vessels and the connective tissue in the hepatoduodenal ligament is carried out with Harmonic Ultrasonic dissector
223643248|NCT01036048|DEVICE|bare metal stent|pts with cabg disease treated with bare metal stent
223643249|NCT04522284|DEVICE|CURATE.AI|Efficacy and toxicity measurements at the end of each dosing cycle, together with an information on given drugs and their doses, and other patient data, will be used by CURATE.AI to recommend the dose of capecitabine and Ibrutinib for the next cycle. The clinical investigators will decide whether or not to administer or prescribe the dose recommendation from CURATE.AI.
223643250|NCT04522284|DRUG|Capecitabine|Treatment with the selected regimen will take up to a maximum duration of 12 months, in 3-week cycles. CURATE.AI dose recommendations will be generated before each chemotherapy cycle; fixed throughout the cycle; and within 1) the predetermined safety range (50% to 100% of dose used in standard of care treatment) and 2) subject-specific dosing range. Maximum total cumulative dose per cycle of capecitabine in the predetermined safety range is set at 100% of standard starting dose (i.e. , 1250mg/m2 twice daily for single agent capecitabine regimen). Minimum total cumulative dose per cycle of capecitabine in the predetermined safety range is set at 50% of the standard starting dose (i.e. 625mg/m2 twice daily for single agent capecitabine). Subject-specific dosing range may alter those numbers to suit the specific circumstances of the subject, thus giving the subject specific safe dosing range.
223643251|NCT04522284|DRUG|XELOX|Treatment with the selected regimen will take up to a maximum duration of 12 months, in 3-week cycles. CURATE.AI dose recommendations will be generated before each chemotherapy cycle; fixed throughout the cycle; and within 1) the predetermined safety range (50% to 100% of dose used in standard of care treatment) and 2) subject-specific dosing range. Maximum dose of capecitabine in the predetermined safety range is set at 100% of standard starting dose (i.e. 1000 mg/m2 twice daily for XELOX regimen). Minimum dose of capecitabine in the predetermined safety range is set at 50% of the standard starting dose (i.e. 500 mg/m2 twice daily for XELOX regimen). Subject-specific dosing range may alter those numbers to suit the specific circumstances of the subject, thus giving the subject specific safe dosing range. The doses of other drug in the XELOX regimen (oxaliplatin) will be held constant or adjusted at the clinical investigator's discretion, as per standard of care.
223643252|NCT04522284|DRUG|XELIRI|"Treatment with the selected regimen will take up to a maximum duration of 12 months, in 3-week cycles. CURATE.AI dose recommendations will be generated before each chemotherapy cycle; fixed throughout the cycle; and within 1) the predetermined safety range (50% to 100% of dose used in standard of care treatment) and 2) subject-specific dosing range. Maximum dose of capecitabine in the predetermined safety range is set at 100% of standard starting dose (i.e. 1000 mg/m2 twice daily for XELIRI regimen). Minimum dose of capecitabine in the predetermined safety range is set at 50% of the standard starting dose (i.e. 500 mg/m2 twice daily for XELIRI regimen). Subject-specific dosing range may alter those numbers to suit the specific circumstances of the subject, thus giving the subject specific safe dosing range.~The doses of other drug in the XELIRI regimen (irinotecan) will be held constant or adjusted at the clinical investigator's discretion, as per standard of care."
224230640|NCT03342495|OTHER|Usual Care|Whatever processes are in place in a variety of clinics to support transfer from pediatric to adult care in the pediatric clinics
224230641|NCT05150509|DIAGNOSTIC_TEST|Oral Squamous Cell Carcinoma|To identify the association of elevated level of specific amino acids in OSCC by Liquid Chromatography Mass Spectrometry
224323380|NCT06956547|DRUG|nogapendekin-alfa inbakicept|1.0mg nogapendekin-alfa inbakicept (NAI) administered by subcutaneous injection no less than every 3 weeks and no more frequently than every 2 weeks between doses in combination with the standard of care schedule of chemotherapy, immunotherapy, and/or radiation therapy. Patients who are known HIV+ will be dosed with NAI at 0.5 mg
223643253|NCT04522284|DRUG|Ibrutinib|"Treatment with the selected regimen will take up to a maximum duration of 12 months, in 4-week cycles. CURATE.AI dose recommendations will be generated before each chemotherapy cycle; fixed throughout the cycle; and within 1) the predetermined safety range (50% to 100% of dose used in standard of care treatment) and 2) subject-specific dosing range.~Maximum total cumulative dose per cycle of Ibrutinib in the predetermined safety range is set at 100% of standard starting dose (i.e. 420 mg once daily for 4 weeks, which constitutes the total of 11760 mg per cycle). Minimum total cumulative dose per cycle of Ibrutinib in the predetermined safety range is set at 50% of the standard starting dose (i.e. 280 mg once daily on alternative days with 140 mg once daily, which constitutes the total of 5880 mg per cycle). The dosing range may be altered to suit the specific circumstances of the participant, thus giving the participant-specific safe dosing range."
223643254|NCT05467306|BEHAVIORAL|Nurse-Navigator Enhanced PrEP Support|Pharmacies randomized to the nurse-navigator model will receive tailored support counseling, in addition to receipt of standard PrEP services. Support counseling by nurse-navigators will provide educational messaging tailored to AGYW and actionable advice targeting PrEP persistence and adherence and/or FP topics, and will address participants' questions related to the content. Counseling will include adherence encouragement (IMB domain: motivation), PrEP efficacy and safety (IMB domain: information), self-efficacy for prevention of HIV, support for potential PrEP side effects, behavioral skills (tips for remembering PrEP medications, IMB domain: behavioral skills) and strategies for remembering PrEP refill schedules. During enrollment, the nurse-navigator will explain that support counseling is voluntary and that the nurse will also be available at the pharmacy to address concerns or questions whenever they arise outside of scheduled visits.
223643255|NCT00624598|BEHAVIORAL|SMART|Use of measured resting metabolic rate from indirect calorimetry for personalized diet program and use of a computer application for journalizing food and exercise.
223643256|NCT04067817|DRUG|norepinephrine|patient who was received the treatment of norepinephrine
223643257|NCT04067817|DRUG|Phenylephrine|patient who was received the treatment of phenylephrine
223643258|NCT03745014|DIAGNOSTIC_TEST|Accelerate Pheno|The Accelerate Pheno™ system and PhenoTest™ BC Kit is a fully-integrated in vitro diagnostic system. It is FDA-cleared to perform ID of bacteria and yeast in less than 90 minutes and AST in less than 7 hours, on average, directly from positive blood culture.
223643259|NCT03745014|DIAGNOSTIC_TEST|Standard of Care|Standard blood culture work up as determined by the site's microbiology lab.
223643260|NCT00334048|DRUG|Ropinirole (Requip)|1 mg extended release formulation given once per day to a maximum of 4 per day
223643261|NCT04788329|BEHAVIORAL|"Prepare for Surgery, Heal Faster Program"|This NYU program teaches patients how to feel calmer before surgery. Patients are taught relaxation techniques by phone or in person by trained NYU personnel. The program uses five steps to ease stress-related symptoms prior to surgery and improve help recovery time. By practicing deep relaxation, it is possible to reduce anxiety and promote a feeling of calmness. The patient swill be enrolled in the course preoperatively and will be ask to continue these meditations for ten weeks.
224230642|NCT05221580|DRUG|Ryzodeg®|Patients will be treated with commercially available Ryzodeg® in a prefilled device (FlexTouch®) or in a penfill according to the label and routine clinical practice at the discretion of the treating physician
224230643|NCT05638503|OTHER|Left ventricular hypertrophy|Hypertension with normal left ventricular geometry and left ventricular concentric remodeling
224230644|NCT05638503|OTHER|Left ventricular non-hypertrophy|Hypertension with left ventricular concentric hypertrophy and left ventricular eccentric hypertrophy
224230645|NCT01455753|OTHER|Functional Proximity|Using each employee's building entry/exit swipe card data, we test whether functional proximity-the likelihood that the employee walks by the clinic for reasons other than vaccination-predicts whether the employee gets vaccinated at the clinic.
224230646|NCT01455753|OTHER|Base Proximity|We also test whether base proximity-the inverse of walking distance from the employee's desk to the clinic-predicts vaccination probability.
224230647|NCT01384695|DRUG|Fluorescein|fluorescent contrast agent, Fluorescein 5ml
223643262|NCT04788329|BEHAVIORAL|Wim Hof Method|Patients will be enrolled in Wim Hof Method, a breathing/meditation program. This is a free online program, developed by a man named Wim Hof and his techniques. On this website, he explains the origins and methods behind his teachings ( https://www.wimhofmethod.com/iceman-wim-hof. ). Patients in this group will take the online free course provided by the Wim Hof Method. The patients will be introduced to the online course preoperatively. The three pillars of the WHM are 1) breathing/meditation, 2) stretching exercises and 3) gradual cold exposure. The patients will be told to concentrate on the breathing and meditation component, they may not be able to participate in the cold exposure (cold showers, ice baths) in the immediate post op period because of the open wounds.
224230648|NCT01384695|DRUG|Proflavine hemisulfate|3 ml of 0.01% proflavine (derived from dissolving 10mg proflavine hemisulfate USP in 100ml sterile water)
224230649|NCT03741608|BEHAVIORAL|High blood pressure management education|The 7-part education series includes 5 sessions focused on mindfulness and breathing techniques for stress reduction. One session will focus on choosing healthy, low salt foods and will provide resources for smoking cessation. The final session will include a grocery store tour to teach participants how to read food labels and to purchase healthy food.
224230650|NCT03741608|BEHAVIORAL|Home blood pressure measurement|Participants will be taught to use an automated blood pressure cuff and will be asked to provide monthly blood pressure readings to study staff.
224230651|NCT05955352|PROCEDURE|Perineal warm compression Technique|There will be two groups. Interventional group will receive perineal warm compression and control group will receive standard care to asses the pain intensity and perineal tear
224230652|NCT01497483|DRUG|Pravastatin alone|Pravastatin 40 mg with placebo.
224230653|NCT01497483|DRUG|Pravastatin and Cyclosporine|Pravastatin 40 mg co-administered with 200 mg of cyclosporine.
224230654|NCT03081715|OTHER|PD-1 Knockout T Cells|Programmed cell death 1(PD-1) gene will be knocked out by CRISPR Cas9
224230655|NCT05911373|OTHER|group serratus plan block|preoperativelly, Superficial Serratus Block performed with 30 ml %0.25 Bupivacaine and Parasternal Block performed with 10 ml saline
224230656|NCT05911373|OTHER|group serratus and parasternal plan block|preoperativelly, Superficial Serratus Block performed with 30 ml %0.25 Bupivacaine and Parasternal Block performed with 10 ml %0.25 Bupivacaine
224230657|NCT04210895|OTHER|Ginger powder footbath|40 ± 2 ° C warm water footbath with an additive of dried ginger powder reaching up to mid-calf level
223643263|NCT06110130|DRUG|Empagliflozin 10 MG|Take Empagliflozin 10 mg orally daily for 4 months
223643264|NCT06110130|DRUG|Placebo|Take Placebo 10 mg orally daily for 4 months
223643265|NCT04800809|OTHER|This study does not entail offering any intervention; all data collected will be based on standard of care.|This study does not entail offering any intervention; all data collected will be based on standard of care.
223765669|NCT04909086|PROCEDURE|Open Kinetic Chain|Patients assigned to this group will receive a 40-min multimodal supervised physical therapy treatment comprised of warm-up (10-min cycling/walking), three sets of 10 repetitions of 60% of one-repetition maximum (1RM) of Quadriceps seated strengthening and Hamstring curl-up exercises, neuromuscular control exercises, and ten-minute transcutaneous electrical nerve stimulation (TENS). Manual mobilization techniques may be applied as necessary according to the findings of the physical examination. Treating physical therapists will prescribe exercises based on a predetermined list of exercises.
223765670|NCT00308711|DRUG|Misoprostol vaginal insert 100 mcg|Hydrogel polymer intravaginal insert with retrieval system. One insert is to remain in the posterior fornix of the vagina until removed for one of the following conditions: onset of active labor; maternal/fetal complication, e.g. non-reassuring fetal heart rate. Record if the insert falls out prior to meeting one of the first two criteria. In no case is the insert to remain in place longer than 24h.
224230658|NCT04210895|OTHER|Warm water only footbath|40 ± 2 ° C warm water footbath without any additive reaching up to mid-calf level
224230659|NCT01834521|OTHER|Web-based screening and tailored support|
224230660|NCT05520424|DIETARY_SUPPLEMENT|The Daily Supplement|"The ingredient list of the product includes the following:~400mg of curcumin (Longvida) 300mg of lemon balm extract (Cyracos) 200mg of American ginseng (Cereboost) 50mg of epigallocatechin gallate derived from green tea Organic oat milk powder Phosphatidylserine (SerinAid) (active) B6 (in the form of P5P) Folate (Quatrefolic) B12 Silica (non-active)"
224230661|NCT02520271|BEHAVIORAL|Behavioral Activation|BA consists of at least 4 intervention sessions with a focused, active working style by the therapist. The therapy initiation includes a focused interview targeting at determining 1-2 main problems, on which the therapy will be focused. Specific therapeutic methods for BA include the use ABC analysis, targeting at hitting the negative consequences of current problematic behavior and motivating for change. Further, recognizing the obstacles for change (TRAP) is the next method to be used. The therapist encourages the client for active behavioral monitoring through assigned homework during the therapy process. The final step and method used is strengthening the gained change (ACTION).
224230662|NCT02520271|BEHAVIORAL|Motivational Interview|"Motivational interview (MI) is a therapeutic intervention that focuses on resolving client ambivalence towards changing problematic behavior. MI involves a client-centered approach that encourages the client to develop his or her own motivation. The therapeutic alliance in MI is predominantly a partnership, rather than an expert/client dynamic.~MI has been studied primarily in addiction problems, but there are numerous reports of its efficacy in several chronic somatic conditions, and lifestyle problems."
224230663|NCT01807871|DRUG|nicotine patch, experimental use|nicotine patch-transdermal, continue during lapses Nicotine patches are used according to normal package label, except if the participant lapses and smokes, they will continue to use the patch.
224230664|NCT01807871|DRUG|nicotine patch, labeled use|nicotine patch-transdermal, discontinue during lapses Participants will use the nicotine patch while abstinent, but will remove the patch if there is a lapse and smoking resumes. This is the use indicated on current FDA approved labeling.
224230665|NCT00376571|PROCEDURE|Percutaneous coronary intervention|"Comparing treatment of either no side branch treatment versus stenting of main vessel and side branch treatment"
224230666|NCT02720003|DEVICE|LTX DCB|Treatment with a drug-coated balloon
223643266|NCT02030652|PROCEDURE|Intermittent nasal positive pressure positive ventilation.|
223643267|NCT02030652|PROCEDURE|CPAP|Nasal continuous positive airway pressure
223643268|NCT00734539|DRUG|fluconazole|6mg/kg IV/PO twice weekly for a total of up to 12-13 doses
223643269|NCT00734539|DRUG|placebo|normal saline (IV) or 3 parts Ora Plus oral suspension vehicle and 1 part simethicone suspension (PO): will be given twice weekly PO/IV for a total of up to 12-13 doses
223643270|NCT00847210|DRUG|Dexlansoprazole MR|Dexlansoprazole MR 30 mg, capsules, orally, once daily for up to 7 days.
223643271|NCT00847210|DRUG|Dexlansoprazole MR|Dexlansoprazole MR 60 mg, capsules, orally, once daily for up to 7 days.
223643272|NCT05902247|RADIATION|Radionuclide Therapy|To evaluate the tolerability and safety of 225Ac-PSMA I\&T in patients with metastatic prostate cancer
223643273|NCT05352503|DEVICE|Watching videos with nature images accompanied by nature sounds with virtual reality glasses|The video with nature images accompanied by the sounds of nature with virtual reality glasses will be watched 3 times a day for at least 5 minutes for 2 days.
223643274|NCT04000633|DRUG|Lidocaine 2%|the patients of this group will recieve nebulization of 5 ml of 2% lidocaine prior to induction of general anesthesia
223643275|NCT04000633|DRUG|Normal saline|Normal saline
223643276|NCT01187355|DEVICE|FID 114675A Multi-Purpose Disinfecting Solution (MPDS)|Investigational multi-purpose disinfecting solution used by subjects as specified in use instructions provided for the care of study contact lenses, 30 days.
223643277|NCT01187355|DEVICE|renu fresh Multi-Purpose Solution (MPS)|Commercially available multi-purpose solution used by subjects as indicated for care of study contact lenses, 30 days.
223643278|NCT01187355|DEVICE|Contact lenses|Contact lenses per subject's habitual brand and power worn for 30 days on a daily wear basis.
223643279|NCT05510388|DEVICE|High-flow nasal cannula oxygenation|The patients receive oxygen flow of 6L/min for preoxygenation with an high-flow canular oxygenation device before losing of conscious. Then, the oxygen flow is adjusted to 60L/min with the oxygen concentration of 100% and the temperature of 37℃ until the end of procedure.
223643280|NCT05510388|DEVICE|Regular nasal cannula oxygenation|The patients receive an oxygen flow of 6L/min for preoxygenation with a disposal regular nasal cannula until the end of procedure.
223643281|NCT02504151|DRUG|Cannabidiol|
223643282|NCT02504151|DRUG|Placebo|
223643283|NCT03005158|OTHER|Validation Phase|Standard care across all sites during the validation phase will rule out myocardial infarction in those with presentation troponin below the 99th centile with greater than 6 hours of symptoms at the time of blood sampling. In those with less than 6 hours of symptoms, a second test will be measured 6- 12 hours after presentation.
223643284|NCT03005158|OTHER|Randomization Phase|Standard care or HighSTEACS pathway.
223643285|NCT03005158|OTHER|Implementation Phase|Implementation of the HighSTEACS pathway to rule out myocardial infarction in patients with suspected acute coronary syndrome. Myocardial infarction will be ruled out if presentation cardiac troponin concentrations are \<5 ng/L in those with at least 2 hours of symptoms at the time of blood sampling. In patients with less than two hours of symptoms, or where cardiac troponin concentrations are between 5ng/L and the 99th centile, repeat testing will be recommended at 3 hours. Myocardial infarction will be ruled out at 3 hours if cardiac troponin concentrations are unchanged (\<3 ng/L change) and remain ≤99th centile on retesting. Those remaining ≤99th centile on retesting but demonstrating a significant change will require admission for further testing at 6-12 hours.
223643286|NCT05867238|OTHER|Training stress management|The stress management training included 1 day and a half day. It was given by a therapist trained in transactional analysis and a trainer from the nurse anaesthetist school. The training was based on cognitive behavioural stress management training and the use of stress management exercises: cardiac coherence, mindfulness meditation, muscle relaxation, mental imagery.
224230667|NCT05017584|DRUG|Hyperbaric bupivacaine|"The dose for the first subject (A#X) will be 12 mg 0.75% hyperbaric bupivacaine. Two possible outcomes will be recorded: satisfactory or unsatisfactory anesthesia which is determined by occurrence of intraoperative pain and the need for intraoperative analgesia supplementation. Satisfactory analgesia will be defined as a sensory block to the T8 dermatome and the patient shall require no further supplementation for discomfort during her procedure. Unsatisfactory analgesia will be defined as a block not achieving a T8 dermatomal level or when a patient requests additional medication for discomfort at any time during her procedure.~The dose for the next (A#X+1) will be adjusted based on the outcome from previous subjects respectively using up-down sequential allocation method with a biased-coin design. This process will continue in similar fashion with dose adjustments for next subjects to be based on outcome from subjects immediately prior."
224230668|NCT01314690|OTHER|Caloric transition|6 week low calorie diet followed by 6 week stabilization period
224230669|NCT02782624|DRUG|Empagliflozin|5 days of treatment with 5 mg BI 10773 bid until steady state
224230670|NCT02782624|DRUG|Empagliflozin|5 days of treatment with 10 mg BI 10773 qd until steady state
224230671|NCT01616732|DRUG|Testosterone|TU im
224230672|NCT01616732|DRUG|placebo|placebo im
224230673|NCT05409677|OTHER|This was a retrospective study with no intervention other than normal treatment|This was a retrospective study with no intervention other than normal treatment
224230674|NCT02540356|BIOLOGICAL|BAX69 Single-Route Arm|Intraperitoneal (IP) only
224230675|NCT02540356|BIOLOGICAL|BAX69 Double-Route Arm|Intravenous (IV) infusion + intraperitoneal (IP) infusion
224230676|NCT03614377|DIAGNOSTIC_TEST|Device interrogation|All devices are interrogated at every follow-up, and two questionnaires are performed 2 years after enrollment.
224230677|NCT01513148|DEVICE|Superluminous light diode|900W, 880nm, 1.6 J/cm2 for 30sec
224230678|NCT03056274|DRUG|Metformin|Metformin Hydrochloride (HCl) Tablets, is an oral antihyperglycemic drug used in the management of type 2 diabetes
223643287|NCT05038982|DRUG|Abrocitinib|During the study period, subjects will take one Abrocitinib 200 mg tablet once daily orally. Subjects will be directed to take doses of Abrocitinib at approximately the same time of day.
223643288|NCT05855707|BIOLOGICAL|WJ-MSC infusion|cellular therapy
223643289|NCT00304551|DRUG|peginterferon alfa-2a 180μg|180μg（s.c.）/week for 48 weeks
223643290|NCT00304551|DRUG|peginterferon alfa-2a 90μg|90μg(s.c.)/week for 48 weeks
223643291|NCT00304551|DRUG|ribavirin|600, 800, or 1,000 mg X 2(p.o.)/day
223643292|NCT04948372|DRUG|Terlipressin treatment|Patients in the terlipressin group received a fixed dose of terlipressin added to usual care. Terlipressin was intravenously pumped at a fixed dose of 1.3μg/kg/hour for 24 hours.
223643293|NCT04948372|DRUG|Usual care|Patients in the usual care group were treated with standard care, according to the international guidelines for the management of sepsis and septic shock.
223643294|NCT02125669|PROCEDURE|Laser treatment|Pulsed dye laser 595nm
223643295|NCT02125669|DEVICE|SHAM-Treatment|using the pulsed dye laser (PDL) laser without releasing a pulse
223643296|NCT01942694|DIETARY_SUPPLEMENT|Vitamin D (Cholecalciferol)|Vitamin D (Cholecalciferol) 4000 IU, administered as 1 soft-gel pill daily by mouth.
223643297|NCT01942694|OTHER|Placebo|Administered as one soft-gel pill daily by mouth
223643298|NCT01774396|DRUG|Emervel® Touch|Emervel® Touch will be injected only in the intervention group.
223643299|NCT01774396|DRUG|Emervel® Volume Lidocaine and Emervel® Deep Lidocaine|Emervel® Volume Lidocaine and Emervel® Deep Lidocaine will be injected in the group #2.
224230679|NCT03056274|DRUG|Ursodeoxycholic Acid|Ursodeoxycholic acid (UDCA) is used to treat gallstones and primary biliary cirrhosis. UDCA is also used to treat obstetric cholestasis (OC), a liver condition that occurs specifically in pregnancy.
223643300|NCT04530214|OTHER|Blood collection|Blood collection at enrollment (before surgery) and at Visit 1 (45-60 days following surgery)
223643301|NCT04530214|OTHER|Saliva collection|Saliva collection at enrollment (before surgery) and at Visit 1 (45-60 days following surgery)
223643302|NCT04530214|OTHER|Electrocardiography (ECG)|Electrocardiography (ECG) at enrollment (24-72h following surgery) and at Visit 1 (45-60 days following surgery) to assess heart rate variability
223643303|NCT04530214|BEHAVIORAL|Questionnaires|Mental health assessment through questionnaires at enrollment (24-72h following surgery), at Visit 1 (45-60 days following surgery), at Visit 2 (7 months following surgery) and at Visit 3 (12 months following surgery)
223643304|NCT01948596|DIETARY_SUPPLEMENT|Omega-3 polyunsaturated fatty acids|
223643305|NCT00472576|DRUG|MK-0657|Daily double-blind administration of the NR2B antagonist MK-0657 (4-8 mg/day)
223643306|NCT00472576|DRUG|Placebo|Daily double-blind administration of placebo
223643307|NCT01957007|DRUG|Docetaxel|Docetaxel will be administered IV.
223643308|NCT01957007|DRUG|vantictumab|Vantictumab will be administered intravenously
224230680|NCT01652365|BEHAVIORAL|RDT Training and Subsidy Offered|
224230681|NCT01652365|BEHAVIORAL|Information/Education Campaign|
224230682|NCT01323764|DEVICE|ShuntCheck test|Non-invasive, thermal dilution test for CSF shunt flow compared to radionuclide shunt patency testing
224230683|NCT05291078|DEVICE|A transcutaneous trigeminal nerve stimulator: High Frequency|30min/day, at least 5 to 7 times a week
224230684|NCT05291078|DEVICE|A transcutaneous trigeminal nerve stimulator: Low Frequency|30min/day, at least 5 to 7 times a week
224319679|NCT05017961|DEVICE|Autograft|An autograft bone will be harvested from proximal tibia or posterior superior iliac crest. First the bony landmarks of the posterior iliac crest or proximal tibia are palpated. The skin is then injected down to and including the periosteum with 1% lidocaine without epinephrine. After 1 cm skin incision and gentle dissection of subcutaneous soft tissue, the bone harvesting device inserted through the skin and subcutaneous tissues until it reaches the cortical bone. Then, manual pressure is used to position the bone harvesting device against the dense cortical bone. A battery-powered power instrument is then will be used to drill the harvesting device into the medullary cavity. After the harvesting device insertion the cancellous strips of bone will be harvested and applied to the fracture site gap.At the conclusion of autograft bone harvesting procedure, the wound will be closed with 3-0 Nylon and a sterile dressing will be applied to the harvest site.
224319680|NCT05017961|DEVICE|Allograft only|The jar containing allograft tissue and cryopreservation solution will be placed in a sterile basin containing a warm (35°C to 39°C; 95°F to 102.2°F) sterile irrigant (Normal saline or 5% Dextrose in Lactated Ringer's Solution). The jar containing the allograft will remain in this solution until the contents of the jar flows freely upon inversion. The jar will be removed from the warm solution once free-flowing. Sterile gauze or the optional strainer will be used to decant the cryopreservation solution into a waste container. 5% Dextrose in Lactated Ringer's Solution will be added to the indicated fill line to immerse the allograft tissue. The cap will be replaced and inverted twice to suspend tissue until ready for use. 5% Dextrose will be decanted in Lactated Ringer's Solution prior to use. Implant will be used within 2 hours of thawing.
224230685|NCT05291078|DEVICE|A transcutaneous trigeminal nerve stimulator: Sham|30min/day, at least 5 to 7 times a week
223643309|NCT04690049|OTHER|Neuromuscular resistance exercise program|This neuromuscular resistance exercise program will be organized in 5 stages, distributing the different phases in 2, 4, 4, 2 and 2 weeks respectively, with a frequency of 3 sessions/week. In addition, 2 weekly sessions of aerobic work with cycloergometer will be developed. The duration of each session will last 30 minutes. The parameters of load and execution speed will be modified as the exercise program progresses along the phases, with the goal of have an impact on the different aspects of the neuromuscular system.
223643310|NCT04690049|OTHER|Control exercise program with elastic band|"This program is based on previous literature so that it remains comparable to the experimental program.~The parameters will consist in 3 sets of 10 repetitions, 2 times/day, 3 times/week, for a total of 6 weeks."
223643311|NCT01826019|OTHER|Intervention|In intervention communities, management plans will be developed by the NPHW for all enrolled participants. The NPHWs will educate participants about CVD, HT treatment, lifestyle modifications and initiate therapy according to the modified WHO CVD risk-management algorithm, including referral of high-risk patients to physicians and safety monitoring where appropriate. Participants in intervention communities will have support from family or friends (treatment supporters) and will receive educational materials and treatment reminders using text-messaging, email, and printed materials, as appropriate for the participant and the community setting. Evidence-based CV medications will be made available to the NPHWs and supervising physicians for participant treatment.
224230686|NCT05291078|DEVICE|Sound Therapy|Notch Therapy at least 30min/day, at least 5 to 7 times a week
224230687|NCT02175797|DEVICE|MRI|at least 6 weeks after the implantation of the pacemaker a MRI exam is performed
224230688|NCT02473211|DRUG|Sofosbuvir|Sofosbuvir 400 mg tablet administered once daily
224230689|NCT02473211|DRUG|Daclatasvir|Daclatasvir 60mg tablet administered once daily
224230690|NCT03806036|DRUG|Vitamin D|300.000 I.U single dose of VIT D IM injection
224230691|NCT03806036|DRUG|Clomiphene Citrate|100mg daily for 5 days starting from third day of menstruation
224323381|NCT06819176|DRUG|Lenacapavir|Lenacapavir (Sunlenca) is a prescription drug approved by the Food and Drug Administration (FDA) for the treatment of people living with multidrug-resistant HIV. Lenacapavir is always used as part of a combination ART regimen. Participants will receive lenacapavir at 927 mg by subcutaneous injection (2x1.5 mL injections) on day 0 and 600 mg orally (2x300 mg tablets) on days 0 and 1, followed by 927 mg by subcutaneous injection (2x1.5 mL injections) at weeks 24 and 48.
224323382|NCT05898399|DRUG|ART6043|ART6043 will be given orally.
224323383|NCT05898399|DRUG|Olaparib|Olaparib will be given orally.
224323384|NCT03866382|PROCEDURE|Biospecimen Collection|Undergo blood and urine sample collection
224230692|NCT04433390|DRUG|Naloxegol|one naloxegol 12.5 mg tablet will be administrated 2 hours before surgery. One 25 mg naloxegol tablet per day will be administrated from 24h post-surgery until bowel movement; for maximum 5 days.
224230693|NCT04433390|DRUG|inert tablet|one inert tablet will be administrated 2 hours before surgery. One inert tablet per day will be administrated from 24h post-surgery until bowel movement; for maximum 5 days.
224230694|NCT00585780|DRUG|Prazosin Tablet|Target medication dosing was three times/day (t.i.d. dosing) with 5 mg in the morning, 5 mg in the afternoon and 6 mg at night reached at the end of the 2-week period, and maintained at this or their highest tolerated dose until week 11, followed by a 5-day taper in week 12, as in previous research.The titration schedule was as follows: 1 mg dose at bedtime for 2 nights, followed by a 1mg dose morning and night (8 AM/8 PM) on day 3, then 2 mg dose t.i.d., on days 4-6, 3 mg dose (2 pills each) morning and afternoon, and 4 mg dose (2 pills) at night for days 7-9, increased to 4 mg dosing t.i.d. on days 10-13, and from day 14 through week 11, 5 mg (1 pill) each in the morning and afternoon, and 6 mg for the night (2 pills) dose. This was followed by a 5-day taper in week 12. Patients were initiated on study medication upon presenting with a negative breathalyzer without any minimum pre-treatment alcohol abstinence period prior to medication initiation.
224230695|NCT00585780|DRUG|Placebo Tablet|Placebo tablets identical in appearance and dosing schedule as the active study medication was utilized
224230696|NCT03050593|DIAGNOSTIC_TEST|MRI scan, Echo scan|
224323385|NCT03866382|PROCEDURE|Bone Scan|Undergo bone scan
224323386|NCT03866382|DRUG|Cabozantinib S-malate|Given PO
223643312|NCT01826019|OTHER|Usual Care|At initial screening, eligible participants will be provided with a brief information booklet/leaflet (customized to the community or region) regarding lifestyle modification and be advised to see their usual physician for care that is considered appropriate. No structured interventions will be employed.
223643313|NCT01046487|DRUG|Imatinib mesylate, Cyclophosphamide (Dosing level 1 )|"CYCLE 1 (42 days):~* Day 1 to 14 Imatinib mesylate : 400 mg/day, per os~* Day 15 to 42 Cyclophosphamide : 50 mg x 2/day, per os Imatinib mesylate : 400 mg/day, per os~NEXT CYCLE (28 days):~Cyclophosphamide : 50 mg x 2/day, per os Imatinib mesylate : 400 mg/day, per os"
223643314|NCT01046487|DRUG|Imatinib mesylate, Cyclophosphamide (Dosing level 2)|"CYCLE 1 (42 days):~* Day 1 to 14 Imatinib mesylate : 600 mg/day,(300 mg in the morning and 300 mg in the evening) per os~* Day 15 to 42 Cyclophosphamide : 50 mg x 2/day, per os Imatinib mesylate : 600 mg/day,(300 mg in the morning and 300 mg in the evening) per os~NEXT CYCLE (28 days):~Cyclophosphamide : 50 mg x 2/day, per os Imatinib mesylate : 600 mg/day,(300 mg in the morning and 300 mg in the evening)per os"
223643315|NCT01046487|DRUG|Imatinib mesylate, Cyclophosphamide (Dosing level 3)|"CYCLE 1 (42 days):~* Day 1 to 14 Imatinib mesylate : 800 mg/day,(400 mg in the morning and 400 mg in the evening) per os~* Day 15 to 42 Cyclophosphamide : 50 mg x 2/day, per os Imatinib mesylate : 800 mg/day,(400 mg in the morning and 400 mg in the evening) per os~NEXT CYCLE (28 days):~Cyclophosphamide : 50 mg x 2/day, per os Imatinib mesylate : 800 mg/day,(400 mg in the morning and 400 mg in the evening)per os"
224230697|NCT04536259|BEHAVIORAL|Video Default|"The case and response options participants in this group will be asked to consider is provided below.~Imagine that a hospital clinician you have been seeing for over a year tells you that that upon reviewing your patient notes they would like you to attend your next consultation by video.~Consider each of the response options below, and select the one that best describes how you would respond to your clinician.~A) Yes, I would be happy to attend a video consultation. B) If possible, I would rather attend the appointment in person."
224230698|NCT04536259|BEHAVIORAL|In-Person Default|"The case and response options participants in this group will be asked to consider is provided below.~Imagine that a hospital clinician you have been seeing for over a year tells you that that upon reviewing your patient notes they would like you to attend your next consultation in person.~Consider each of the response options below, and select the one that best describes how you would respond to your clinician.~A) Yes, I would be happy to attend an in-person consultation. B) If possible, I would rather attend the appointment by video."
224230699|NCT04536259|BEHAVIORAL|Active Choice|"The case and response options participants in this group will be asked to consider is provided below.~Imagine that a hospital clinician you have been seeing for over a year tells you that that upon reviewing your patient notes they would like you to attend a consultation by video or in person.~Consider each of the response options below, and select the one that best describes how you would respond to your clinician.~A) I would prefer a video consultation. B) I would prefer an in-person consultation."
224230700|NCT04168476|OTHER|Interscapular muscle release or scapular mobilization technique as described by Travell and Simons.|"Patient is sidelying with the testing side up. The auditor stands in front of the patient, reaches over the patient's shoulder to grasp the upper portion of the vertebral border of the scapula, and the other arm reaches under the patient's humerus to grasp the lower portion of the vertebral border of the scapula.~The auditor then slowly moves the scapula into elevation/depression, internal/external rotation/abduction and adduction.~To standardize the technique and be able to reproduce it in each participant, a set of 10 repetitions for each movement was performed in the same order."
224230701|NCT04168476|OTHER|Calcaneus abduction and adduction mobilization technique|Abduction and adduction mobilization of the calcaneus is carried out in the opposite side of the upper extremity measured.
224230702|NCT00091598|DRUG|Ambrisentan|
224230703|NCT02314377|DRUG|Bevacizumab|Bevacizumab dosing of 5mg/kg q 2 weeks for 12 weeks (2.5 mg/week).
224230704|NCT03857022|DEVICE|Enhanced External Counterpulsa|The EECP therapy was given as a 1-hour session, once daily, for a total of 35 sessions. The daily urine amount, blood pressure, time for taper off positive inotropic agents, length of hospital stay, and will be monitored daily in the hospital stay. Patients will be followed-up if he or she can be released from hospital and the mortality, readmission for heart failure, and 6-minute walking distance will be checked at the end of 6th month. Plasma natriuretic peptide (BNP) or N-terminal pro-brain natriuretic peptide (NT-pro-BNP) levels will be checked at enrollment, day 35, and 6th month.
224230705|NCT02777060|PROCEDURE|Exergame|Subjects will perform progressive and computerized foot and ankle exercises which include weight shifting, ankle reaching task while standing, and virtual obstacle crossing task (i.e. balancing on single leg) using wearable sensors technology (Exergaming) equipment). Subjects will perform these exercises for 4-6 weeks, twice per week. The duration of exercise per session is anticipated to be 30-45 minutes.
224230706|NCT02777060|PROCEDURE|Home based balance training|Subjects in the control group will ask to perform a standard home based balance program for 4-6 weeks. The home based program includes similar exercise components as proposed in the experimental group, however without computerized feedback and Exergaming equipment.
224230707|NCT00617526|DRUG|RDEA806 400 mg|
224230708|NCT00617526|DRUG|Placebo|Placebo
224230709|NCT00617526|DRUG|RDEA806 1000 mg|
224230710|NCT00617526|DRUG|RDEA806 600 mg|
224230711|NCT00617526|DRUG|RDEA806 800 mg|
224230712|NCT03295058|DRUG|Non ATG Conditioning regimen|50% of the patients will receive Fludarabine + cyclophosphamide (F-araA 120 mg/m2 total dose for 3 days (d-3,-2,-1) over 1 h infusion and cyclophosphamide 25 mg/kg/d (d-5 to d-2) for 4 days over 1-h infusion prior to hematopoietic cell transplantation , then post transplant cyclophosphamide dose 50 mg/kg on days +3 and +4
224230713|NCT03295058|DRUG|GVHD Prophylaxis|Cyclosporine A (CsA 3 mg/kg) start day +5
224230714|NCT03295058|PROCEDURE|Allogenic Stem Cell Transplantation|using peripheral blood stem cells
224230715|NCT03295058|DRUG|ATG conditioning regimen|the other 50% of the patients will receive Cyclophosphamide + ATG
224230716|NCT00437281|DRUG|Placebo|Placebo
224230717|NCT00437281|DRUG|Pregabalin|Orally-administered pregabalin
224230718|NCT06482866|OTHER|Cottle's septoplasty and radiocoagulation conchoplasty|Cottle's septoplasty and radiocoagulation conchoplasty Study group - added nasal splits; Control group - nasal splits weren't used.
224230719|NCT05621486|BIOLOGICAL|B4T2-001 Autologous CAR T cells|Each subject will receive infusion with B4T2-001 autologous CAR T Cells
224230720|NCT03309891|DRUG|GX-H9|subcutaneous injection (weekly or twice-monthly)
224319681|NCT05017961|DEVICE|Allograft combined with BMAC|A bone marrow aspiration kit will be used for bone marrow aspiration. First the bony landmarks of the posterior iliac crest and sacroiliac joint are palpated. The skin is then injected down to and including the periosteum with 1% lidocaine without epinephrine. Then, the bone marrow aspiration trochar and needle are percutaneously inserted through the skin and subcutaneous tis- sues until it reaches the posterior iliac crest. The trajectory of the needle will be parallel to the iliac crest, or perpendicular to the Anterior Superior Iliac Spine (ASIS) or Posterior Superior Iliac Spine (PSIS), depending on the harvest site used. After the trochar is inserted into the posterior iliac crest but prior to aspiration, 1 mL of heparin (1,000 U/mL) will be preloaded into the syringe. Approximately 60 mL of bone marrow will be aspirated, which requires the use of two 30-mL syringes. At the conclusion of BMAC harvesting, a sterile dressing will be applied to the harvest site.
224319682|NCT00420732|BIOLOGICAL|HyperAcute-Lung Cancer Vaccine|300 million cells given intradermally every 3 weeks for up to a total of 12 vaccinations
223643316|NCT01046487|PROCEDURE|Blood sampling|"ONLY FOR CYCLE 1, at day 15 and day 28 :~11 sampling for dosing level 1 (pre-dose, imatinib mesylate + 30 min, +1, +2, +3, +4, +6, +10, +12 , +24 hours, cyclophosphamide + 12 hours) 10 sampling for the next dosing level (pre-dose, imatinib mesylate + 30 min, +1, +2, +3, +4, +6, +10, +12,cyclophosphamide + 12 hours)"
224230721|NCT03309891|DRUG|Genotropin|subcutaneous injection (daily)
224319683|NCT01669603|DIETARY_SUPPLEMENT|Bifidobacterium lactis Bl-04|The study product will be a 2\*109 cfus of probiotic Bifidobacterium lactis Bl-04 mixed with 1g of sucrose as a carrier.
224319684|NCT01669603|DIETARY_SUPPLEMENT|Placebo|Placebo will be 1g of sucrose that has identical appearance, smell, and taste with the study product.
224319685|NCT01669603|BIOLOGICAL|Rhinovirus|rhinovirus for experimental challenge
224319686|NCT03394157|OTHER|metabolic surgery|operation to cure type2 diabetes
224319687|NCT06281444|DEVICE|ESWT|"All patients in both groups will be applied with a home-based exercise program around for 30-minutes per day for four weeks. The exercises that mentioned in the research content are knee range of motion and strengthening exercises for the knee. It will be checked by phone on a weekly basis. Also, each patient in group 1 will receive shockwaves of continuous frequency and intensity (1000 shocks, 2.0 to 3.0 bar,10 Hz and 0.08-0.25mJ/mm2 energy range), while the second group of patients will receive sham-ESWT.~ESWT application will be applied to the medial part of the knee area on the side where the pain is described, or at the patellofemoral and tibiofemoral borders of the affected knee, and will be given in four sessions in total once a week."
224319688|NCT06281444|DEVICE|Sham-ESWT|Sham ESWT application will be set to 1000 pulses, 2-3 bar pressure, 10 Hz frequency and 0 mJ/mm2 energy to be sham.
224230722|NCT03074526|OTHER|Amniotic Fluid|Amniotic Fluid
224230723|NCT03074526|OTHER|Saline Placebo|Saline Placebo
224230724|NCT03994445|BEHAVIORAL|Mobile Phone-Based Intervention|"We propose our intervention based on social cognitive behavior theories and the stages of the change model.~The program will be carried out using the word Mettle, it will help ex-smokers stay off cigarettes through advices generated to promote the health from religious concepts and culture perspectives ."
224230725|NCT01818570|DRUG|PPC-5650|A dose of 2.5 mg PPC-5650 in a 100 ml solution will be administered to the esophagus with an infusion rate of 7ml/min in one out of three visit days.
224230726|NCT01818570|DRUG|Placebo|A 100 ml placebo solution will be administered to the esophagus with an infusion rate of 7ml/min in one out of three visit days.
224319689|NCT00537511|DRUG|Pomalidomide|
224319690|NCT00537511|DRUG|Cisplatin|
224319691|NCT00537511|DRUG|Etoposide|
224319692|NCT00396565|DRUG|ER OROS paliperidone|Type= exact number, unit= mg, number= 3, form= tablet, route= oral use. Two tablets once daily for 6 weeks.
224319693|NCT00396565|DRUG|Placebo|Form= tablet, route= oral use. Two tablets once daily for 6 weeks.
223643317|NCT04170608|DEVICE|FARAPULSE Endocardial Multi Ablation System|Ablation using the FARAPULSE Endocardial Multi Ablation System
224230727|NCT02509000|OTHER|air purifier|filtration units randomly allocated to active- and sham-mode in 20 recruited households for four weeks
224230728|NCT00947427|DRUG|canakinumab (anti IL-1beta)|canakinumab subcutaneous injections given at 2.0mg/kg dose on monthly basis for 12 months
224230729|NCT00947427|DRUG|Placebo|Placebo subcutaneous injections
224230730|NCT02848430|DIETARY_SUPPLEMENT|Humulus lupulus|Extract of spent hops standardized to xanthohumol, isoxanthohumol, 6-prenylnaringenin, and 8-prenylnaringenin
224230731|NCT03617484|DRUG|Bortezomib|Bortezomib will be administered subcutaneously at a dose of 1.3 mg/m\^2 on days 1, 4, 8, and 11 of each 21-day cycle.
224230732|NCT03617484|DRUG|Ibrutinib|Ibrutinib will be administered orally at a dose of 560 mg daily for each 21 day cycle.
224230733|NCT03939169|OTHER|Installation of a naso-gastric feeding tube|Insertion of the feeding tube with skin-to-skin contact or whilst being held in the mother's arms, or by using the four hands technique or by performing positional support with appropriate equipment
224230734|NCT02703077|PROCEDURE|Spyglass|Endoscopic direct view of the bile ducts
223643318|NCT04840693|BIOLOGICAL|Biological samples|blood, urine, saliva
223643319|NCT04840693|OTHER|Complications|bone mineral density, diabetes, hypertension, quality of life (quality of life questionnaire SF-36)
223643320|NCT00993577|OTHER|Stretching exercises|Treatment consisted of eight individual sessions (once a week), over two months. At the first 10 minutes of sessions, patients rested (supine position) with all limbs relaxed. Manual therapy maneuvers were made as described by Bienfait,17 associated to breathing exercises, in order to stretch the fasciae that recover the shoulders, as well as the cervical spine muscles. After that, stretching treatment (global or static) was conducted for another 30 minutes.
224230735|NCT02703077|PROCEDURE|Balloon dilation of the papilla|Using a hidrostatic balloon the major papilla will be dilated to facilitate the stone removal
224319694|NCT00396565|DRUG|Olanzapine|Type= exact number, unit= mg, number= 2.5, form= tablet, route= oral use. Four tablets once daily for 6 weeks.
224319695|NCT06257251|OTHER|Histological slides digitization|Histological slides of the capsule samples taken during surgery will be collected for analysis and digitized. Using the NDPview2 software, the investigators will manually count the silicone particles present in the peri-prosthetic capsule and measure the surface area of the capsule to estimate the silicone particle density.
224323387|NCT03866382|PROCEDURE|Computed Tomography|Undergo CT and/or PET/CT scan
224323388|NCT03866382|PROCEDURE|Echocardiography Test|Undergo echocardiography
224323389|NCT03866382|BIOLOGICAL|Ipilimumab|Given IV
223643321|NCT00993577|DEVICE|Stretching exercises|Treatment consisted of eight individual sessions (once a week), over two months. At the first 10 minutes of sessions, patients rested (supine position) with all limbs relaxed. Manual therapy maneuvers were made as described by Bienfait,17 associated to breathing exercises, in order to stretch the fasciae that recover the shoulders, as well as the cervical spine muscles. After that, stretching treatment (global or static) was conducted for another 30 minutes.
223643322|NCT00993577|DEVICE|Exercises|Treatment consisted of eight individual sessions (once a week), over two months. At the first 10 minutes of sessions, patients rested (supine position) with all limbs relaxed. Manual therapy maneuvers were made as described by Bienfait,17 associated to breathing exercises, in order to stretch the fasciae that recover the shoulders, as well as the cervical spine muscles. After that, stretching treatment (global or static) was conducted for another 30 minutes.
223643323|NCT01916954|DRUG|3-day artemether-lumefantrine|
223643324|NCT01916954|DRUG|5-day artemether-lumefantrine|
223643325|NCT02080715|DRUG|Tolcapone|2 x 100mg Tolcapone compared to placebo (randomized, double-blind, cross-over)
223643326|NCT02080715|DRUG|Placebo|
223643327|NCT02557139|DRUG|Belumosudil Tablet|
223765671|NCT00308711|DRUG|Misoprostol vaginal insert 50 mcg|Hydrogel polymer intravaginal insert with retrieval system. One insert is to remain in the posterior fornix of the vagina until removed for one of the following conditions: onset of active labor; maternal/fetal complication, e.g. non-reassuring fetal heart rate. Record if the insert falls out prior to meeting one of the first two criteria. In no case is the insert to remain in place longer than 24h.
223765672|NCT00308711|DRUG|Dinoprostone vaginal insert (Cervidil)|Hydrogel polymer intravaginal insert with retrieval system. One insert is to remain in the posterior fornix of the vagina until removed for one of the following conditions: onset of active labor; maternal/fetal complication, e.g. non-reassuring fetal heart rate. Record if the insert falls out prior to meeting one of the first two criteria. In no case is the insert to remain in place longer than 24h.
223765673|NCT02167256|DRUG|AZD0530 100mg daily|All patients in experimental group (50%) will be started on 100mg AZD0530 daily
223765674|NCT02167256|DRUG|AZD0530 125mg daily|Patients with plasma drug level \<100ng/ml after 2 weeks of 100mg AZD0530 daily will receive 125mg daily of AZD0530.
223765675|NCT02167256|DRUG|Placebo|50% of patients will receive placebo treatment for the duration of the study.
223765676|NCT02311751|DEVICE|Repetitive Transcranial Magnetic Stimulation|rTMS is a non-invasive procedure involving the use of magnetic fields to stimulate nerve cells.
223765677|NCT06082102|DRUG|Orelabrutinib|Orelabrutinib Tablets
223765678|NCT06082102|DRUG|Rituximab|Rituximab Injection
223765679|NCT06082102|DRUG|Lenalidomide|Lenalidomide Capsules
223643328|NCT02557139|DRUG|Belumosudil Capsule|
223643329|NCT00985764|PROCEDURE|cesarean delivery|
223643330|NCT04495023|PROCEDURE|Left elective colectomy|Open or laparoscopic left elective colectomy with colo-rectal anastomosis
223643331|NCT02622126|DRUG|hydroxyethyl starch (6% 130/0.4)|preloaded prior to spinal anesthesia with 500 mL hydroxyethyl starch (6%130/0.4) (Voluven).
223643332|NCT02622126|DRUG|Hyperbaric bupivacaine|Sub arachnoid 10-12 mg hyperbaric bupivacaine
223643333|NCT02622126|DRUG|Morphine|Sub arachnoid 200 meg morphine
223643334|NCT02622126|DRUG|Isotonic 0.9 sodium chloride (NaCl) solution|10 ml/kg of isotonic 0.9 sodium chloride (NaCl) solutions will be used as co loading during the duration of the operation
223643335|NCT02622126|DRUG|Ephedrine|If severe hypotension (fall of \> 20% of mean arterial pressure from baseline) occurred, vasopressors, 6 mg ephedrine (per dose) will be used.
223643336|NCT02622126|DRUG|Atropine|Bradycardia (fall of \>30% of heart rate from baseline or \<50 beats /minute and when associated with hypotension) will treated with 0.5 mg of atropine intravenous.
223643337|NCT01454102|BIOLOGICAL|Nivolumab|
223643338|NCT01454102|DRUG|Gemcitabine|
223643339|NCT01454102|DRUG|Cisplatin|
223765680|NCT06082102|DRUG|Rituximab|Rituximab Injection
223765681|NCT02163928|OTHER|Food-based intervention; increased fruits and vegetables|4-6 cups of fruits and vegetables daily for 8-weeks
223765682|NCT03389711|COMBINATION_PRODUCT|DMARD´s and multidisciplinary treatment|"At study enrollment, medical history, disease-specific autoantibodies, ACR 1987 classification criteria for RA were applied. Medical evaluations were standardized and included at least 66 swollen and 68 tender joint counts, acute reactant-phase determinations , patient and physician reported outcomes, comorbidity established by record review, and treatment assessments (name, dose and schedule of all drug they were taking) along with an evaluation of persistence, at six-month intervals.~Patients were evaluated by a single rheumatologist every two months during the first two years of follow-up, and every two, four or six months thereafter.~Also the following scores: Michigan Hand Outcome Questionnaire (MHQ), Disabilities of the Arm, Shoulder and Hand Outcome Measure (DASH),Mayor Depressive Episodes (MDE) was defined using the Mini International Neuropsychiatric Interview and the severity of depressive symptoms was assessed with the Beck Depression Inventory (BDI-II)."
224323390|NCT03866382|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
224323391|NCT03866382|BIOLOGICAL|Nivolumab|Given IV
223643340|NCT01454102|DRUG|Pemetrexed|
223643341|NCT01454102|DRUG|Paclitaxel|
224323392|NCT03866382|PROCEDURE|Positron Emission Tomography|Undergo PET/CT scan
223643342|NCT01454102|DRUG|Carboplatin|
223643343|NCT01454102|DRUG|Bevacizumab|
223643344|NCT01454102|DRUG|Erlotinib|
223643345|NCT01454102|BIOLOGICAL|Ipilimumab|
223643346|NCT03356041|OTHER|Diabetic patients with neuropathy|Lifestyle modification will be assessed using summary of diabetes self-care activity
223643347|NCT01378871|DRUG|IMTOX-25|"This agent is supplied as a sterile solution at 0.5 mg/ml. Thus a vial with 5 mL contains 2.5 mg IMTOX-25~IMTOX-25 is an immunotoxin. It is an antibody that is bound to a piece of the poison ricin. This antibody have been shown to bind to leukemia cells and kill them because of the ricin.~15 mg/m²/cycle IV. The calculated total dose for the cycle will be divided by four and given on Days 1, 3, 5 and 7."
223643348|NCT04355143|DRUG|Colchicine Tablets|COLCRYS (colchicine, USP) tablets for oral administration, containing 0.6 mg of the active ingredient colchicine USP, administered po every 12 hours x 30 days.
223643349|NCT04355143|OTHER|Current care per UCLA treating physicians|Current care
223643350|NCT04892381|DIAGNOSTIC_TEST|Skin Biopsy|"* Skin biopsy will be taken under local anesthesia :~* From each normal control; a 3 mm punch skin biopsy from a sun protected area will be taken and preserved in PBS and kept frozen at -80 degrees Celsius for ELISA study.~* From each LP patient; two punch skin biopsies will be taken and preserved in PBS and kept frozen at -80 degrees Celsius for ELISA study:~  i. The first biopsy will be a 3 mm punch biopsy from the center of LP lesional skin of sun protected area ii. The second biopsy will be a 3 mm punch biopsy from non lesional skin at least 15 cm away from the edge of any existing LP lesion of sun protected area~* The level of PD1 and PD-L1 will be detected using ELISA technique.~* The lesional biopsy will be assessed by routine hematoxylin and eosin (H\&E) to confirm the diagnosis of LP"
223643351|NCT02148874|BIOLOGICAL|influenza virus vaccination|comparison of immune responses to the flu vaccine in obese and non-obese populations
223643352|NCT04647188|OTHER|Robotic assisted surgery with IDR data capture|Robotic assisted surgery with digital point of care data capture using Intuitive Data Recorder (IDR) technology
223643353|NCT02592798|DRUG|Abatacept|Abatacept IV administered on Day 1, 15, 29 and then every 28 days
223643354|NCT02592798|OTHER|Normal Saline|Normal Saline administer on Day 1, 15, 29 and then every 28 days
223643355|NCT02592798|OTHER|D5W|Dextrose 5% in Water (D5W) administered on Day 1, 15, 29 and then every 28 days
223643356|NCT03470389|PROCEDURE|HVPG measurement|Each patient's computed tomography, blood tests, Doppler ultrasound and HVPG measurement will be performed within 30 days and treatments that may affect HVPG value will be avoided during this period.
223643357|NCT03455595|PROCEDURE|Endoscopic exams|Coloscopy
223643358|NCT05715099|DRUG|Saffron|Dietary Supplement: saffron supplement for IBD
223643359|NCT05715099|DRUG|Placebo|Dietary Supplement: placebo for IBD
223643360|NCT00705016|DRUG|Cilengitide 2000 mg once weekly|Cilengitide 500 milligram (mg) will be administered as an intravenous infusion over 60 minutes, daily from Day 1 to 4 of the first week of each 3-week cycle, subsequently followed by 2000 mg dose of cilengitide on Day 8 and 15 of every cycle for a total of 6 cycles (18 weeks) or until PD, unacceptable toxicity or withdrawal for any other reason. After 6 cycles, participants received cilengitide 2000 mg once weekly until PD, unacceptable toxicity or withdrawal for any other reason.
223643361|NCT00705016|DRUG|Cilengitide 2000 mg twice weekly|Cilengitide 2000 mg will be administered as an intravenous infusion over 60 minutes, twice weekly on Day 1, 4, 8, 11, 15, and 18 of each 3-week cycle for a total of 6 cycles (18 weeks) or until PD, unacceptable toxicity or withdrawal for any other reason. After 6 cycles, participants will receive cilengitide 2000 mg once weekly until PD, unacceptable toxicity or withdrawal for any other reason.
223643362|NCT00705016|DRUG|Cetuximab|Cetuximab will be administered as 250 milligram per square meter (mg/m\^2) as infusion (initial starting dose of 400 mg/m\^2) on Day 1, 8 and 15 of each 3-week treatment cycle. Cetuximab will be administered for a total of 6 cycles (18 weeks) or until PD, unacceptable toxicity or withdrawal for any other reason. After 6 cycles, participants received Cetuximab 250 mg/m\^2 once weekly until PD, unacceptable toxicity or withdrawal for any other reason.
223643363|NCT00705016|DRUG|5-fluorouracil (5-FU)|5-FU will be administered as an intravenous continuous infusion at a dose of 1000 mg/m\^2 daily from Day 1 to 4 of each 3-week treatment cycle. 5-FU will be administered for a total of 6 cycles (18 weeks), or until PD, unacceptable toxicity, or withdrawal for any other reason, whichever occur first.
223643364|NCT00705016|DRUG|Cisplatin|Cisplatin will be administered as an intravenous infusion over 60 minutes, at a dose 100 mg/m\^2 on Day 1 of each 3-week treatment cycle. Cisplatin will be administered for a total of 6 cycles (18 weeks), or until PD, unacceptable toxicity, or withdrawal for any other reason, whichever occur first.
223643365|NCT02233517|BEHAVIORAL|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy provides patients with the skills to 1) identify and challenge maladaptive cognitions that are contributing to self-destructive behaviors; and 2) implement techniques such as relaxation training, communication skills, and relaxation training to address physiological and environmental barriers to effective functioning.
223643366|NCT02233517|BEHAVIORAL|Present Centered Therapy|"Present Centered Therapy utilizes interpersonal process, supportive techniques, identification of response options, encouragement of adaptive reactions, and focus on the here-and-now to support patients in their efforts to improve functioning."
223643367|NCT00588107|OTHER|Web Intervention|Receives pharmacotherapy and access to an interactive Web site (Web condition). The Web site will offer tailored intervention messages and strategies in an interactive format that is much less labor-intensive and costly than the prior PFH peer telephone counseling intervention.
223643368|NCT00588107|BEHAVIORAL|print materials|tailored print materials designed to aid in smoking reduction and cessation
223643369|NCT04042948|DRUG|Tylenol|when we decide to remove the drainage tube, we ask the patient to take a pill of tylenol, and another pill in 12h later
223643370|NCT06437041|DRUG|Ornidazole|Patients will receive three consecutive enemas of ornidazole 0.5g+50ml saline through the TET tube, followed by WMT treatment once daily for a duration of 3 days.
223643371|NCT06437041|DRUG|Placebo|Patients will receive three consecutive enemas of placebo of equal volume through the TET tube, followed by WMT treatment once daily for a duration of 3 days
223765683|NCT01420081|DRUG|PF-05212384|154mg IV weekly
223765684|NCT01420081|DRUG|PF-05212384|154mg IV weekly
223765685|NCT01420081|DRUG|PF-05212384|154mg IV weekly
224230736|NCT02703077|PROCEDURE|EHL (electrohydraulic lithotripsy)|With a probe a direct view lithotripsy will be performed
224230737|NCT02703077|PROCEDURE|ERCP (Endoscopic retrograde cholangiopancreatography)|Endoscopic procedure to identify and treat biliary diseases
224230738|NCT02597543|DRUG|Regadenoson|For use in stress myocardial perfusion imaging.
224230739|NCT02597543|DRUG|Gadolinium|For use in both perfusion imaging and late gadolinium enhancement.
224230740|NCT02597543|PROCEDURE|Cardiac MRI|Cardiac MRI will be the imaging modality for perfusion imaging, late gadolinium enhancement and obtaining mean T1 segmental values of the heart.
224319696|NCT06141343|DIETARY_SUPPLEMENT|Veillonella atypica FB0054|Veillonella contains Veillonella atypica FB0054 as the active ingredient with microcrystalline cellulose and hypromellose as excipients. The two doses are 15 billion cfu (high dose) and 7.5 billion cfu (low dose). Placebo capsules contain microcrystalline cellulose and hypromellose. Both Veillonella and placebo are encapsulated in acid-resistant capsules to improve delivery to the large intestine, which participants will take orally at home on a daily basis for four weeks.
224319697|NCT06141343|OTHER|Placebo|Placebo will be given as the non-active study control
224319698|NCT00103714|DRUG|denufosol tetrasodium (INS37217)|
224319699|NCT00004338|DRUG|zinc acetate|
224319700|NCT01252277|DRUG|Lovaza™|4 capsules daily for 6 months
223643372|NCT03365349|OTHER|"participating in a session of living theatre"|"participating to a session of living theatre which consists in writing a story about life with diabetes, which is then transformed to a script to be played by professional actors co-directed by the patient with the support of the Director to create a short play"
223643373|NCT03365349|OTHER|writing workshop|"one session consisting for the patient of writing a Letter to his/her own diabetes and then to read it to the group of patients and the healthcare providers."
223643374|NCT06239818|DEVICE|Photobiomodulation therapy (PBMt)|Participants will be asked to use the photobiomodulation (PBM) device for 20 minutes, daily (e.g., Monday - Sunday) for a total of 30 days. The device will be preprogrammed and automatically switched off after 20 minutes.
223643375|NCT06239818|OTHER|Standard of Care|The patient is provided with verbal and written education including what a mild traumatic brain injury (mTBI) is, favorable expectations for recovery, and advice about how to manage specific symptoms. Relative rest for the first 24-48 hours after an mTBI is recommended as the main goal is to alleviate symptoms and reduce demands on the brain. After an initial period of relative rest and symptom stabilization, patients are encouraged to gradually resume normal daily activities as tolerated. Physical and cognitive activities can be progressively resumed at a pace that does not worse existing or create new symptoms. Education, return to activity advice, and symptom management are all reviewed in subsequent visits as needed.
223643376|NCT04636684|DIAGNOSTIC_TEST|Proteomic analysis|Proteomic analysis based on mass spectrometry on the sample of valve tissues.
223643377|NCT03853109|DRUG|AMG 404|AMG 404 will be examined for safety, tolerability, PK, and PD of AMG 404 in subjects with advanced solid tumors.
223643378|NCT06480591|OTHER|Blood Draw|The amount of blood that will be collected for this is 50 mL(milliliters), or about 3 ½ tablespoons.
223643379|NCT00385216|DRUG|Nicotine|Nicotine nasal spray 3mg x 1 before surgery
223643380|NCT00385216|OTHER|Placebo|Placebo nasal spray 0mg x 1 before surgery
223643381|NCT06540417|DEVICE|External trigeminal nerve stimulation|The stimulation parameters were set to 120Hz, 250μs, 30s ON-30s OFF, with the intensity adjusted for patient comfort.
223643382|NCT05610059|OTHER|Blood Pressure Technology System M|Participants will be provided the blood pressure technology system M. The study staff will teach the participants how to use the system on their personal cell phones with instruction guides. Participants will be asked to use the system for 6-months.
223643383|NCT05610059|OTHER|Blood Pressure Technology System E|Participants will be provided the blood pressure technology system E. The study staff will teach the participants how to use the system on their personal cell phones with instruction guides. Participants will be asked to use the system for 6-months.
223643384|NCT05005182|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223643385|NCT05005182|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow biopsy and aspirate
223643386|NCT05005182|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy and aspirate
223643387|NCT05005182|DRUG|Hydroxyurea|Given PO
223643388|NCT05005182|BIOLOGICAL|Luspatercept|Given SC
223643389|NCT05005182|OTHER|Questionnaire Administration|Ancillary studies
223643390|NCT06800794|BEHAVIORAL|Behavioral Skill Training|7 sessions including: Hunger and fullness, eating on a budget, traffic light eating plan, menu planning, creating alternatives to food, financial planning, and changing the environment.
223643391|NCT06800794|OTHER|Meal Provisioning|3 meals a day consisting of low energy dense, nutrient rich, ready to eat, low GI, foods delivered to the participants' homes.
223643392|NCT06411561|BEHAVIORAL|SLEEP + COG|Combination of SLEEP and COG interventions
223643393|NCT06411561|BEHAVIORAL|COG|Daily 30-minute session of computerized cognitive training
223643394|NCT06411561|BEHAVIORAL|SLEEP|Nighttime use of both ear plugs and eye masks
223643395|NCT06411561|BEHAVIORAL|AC|Educational modules on cognitive and sleep health
223643396|NCT05863559|BEHAVIORAL|Super Chef: Family Fun in the Kitchen!|Two-phase intervention: in the online phase, a professional chef will demonstrate cooking strategies to help families modify existing recipes to be consistent with the Mediterranean Dietary pattern. Effective food parenting practices will also be integrated into the intervention. The intervention is guided by theory - Family Systems, Social Cognitive, and Self Determination - and gamification techniques. At the end of the online phase, dyads will set a goal to use the cooking strategy and make a plan to facilitate goal attainment. In the home phase, the dyad will work together to use the plan to meet the goal. Dyads can also participate in bonus activities. Prior to viewing the next session, dyads will report whether the goal was attained and any bonus activities completed. Collectively, this will determine level of Super Chef status the family achieves at the end of the program (Session 4).
223643397|NCT01088178|DEVICE|Levonorgestrel Intrauterine System (LNG-IUS: Mirena, Bayer)|Placement of Mirena at given intervals during the postpartum period
223643398|NCT04431817|DEVICE|KinetiGait|This device is an Intel RGB depth camera that relays video to gait analysis software. The images will be taken from amputees walking at a self-selected pace on a treadmill.
223643399|NCT06475976|DIAGNOSTIC_TEST|Chest computed tomography (CT) with angiography|A CT scan uses a doughnut-shaped machine to take x-rays in a circle around the body. CT scans help doctors learn about the structure of the lungs, heart, and blood vessels in the chest. A CT scan provides more information than regular x-rays. CT w/angiography - injection of intravenous contrast during the CT to image the blood vessels within the chest.
224319701|NCT02192398|DRUG|Guanfacine|"Subjects will be randomized into 1 of the following 3 treatment groups:~1. guanfacine (2mg)~2. guanfacine (1mg)~3. placebo~To compare pain threshold, pain tolerance, and wind up, as measured by QST, throughout 4 weeks of drug treatment (guanfacine or placebo)."
224319702|NCT02192398|DRUG|Placebo|"Subjects will be randomized into 1 of the following 3 treatment groups:~1. guanfacine (2mg)~2. guanfacine (1mg)~3. placebo To compare pain threshold, pain tolerance, and wind up, as measured by QST, throughout 4 weeks of drug treatment (guanfacine or placebo)."
224319703|NCT00030472|DRUG|pegylated liposomal doxorubicin hydrochloride|
224319704|NCT00457483|DRUG|hydrochlorothiazide|12.5 mg once-a-day
224319705|NCT00457483|DRUG|valsartan, 80 mg once-a-day|80 mg once-a-day
223643400|NCT06475976|DIAGNOSTIC_TEST|Bronchoscopy with bronchoalveolar lavage|During a bronchoscopy, a lung doctor inserts a small flexible camera into the breathing tube and main branches of the airways within the lungs. During the test, a small amount of sterile fluid is placed into the lung and then retrieved (lavage). This fluid is tested for evidence of infection.
223643401|NCT06475976|DIAGNOSTIC_TEST|Echocardiography|An echo uses sound waves to create computer pictures of the heart.
223643402|NCT06475976|DIAGNOSTIC_TEST|"24 hour esophageal pH (potential of hydrogen) - multichannel intraluminal impedance (MII) monitoring (reflux testing)"|24 hour pH/MII testing is used to measure gastroesophageal reflux. A small feeding tube like catheter is passed through the nose or mouth into the esophagus. The catheter is used to measure the frequency and acidity of reflux episodes during a 24 hour monitoring period.
223643403|NCT06464991|DRUG|Equecabtagene Autoleucel Injection|dosage form: injection, dosage: 1.0×10\^6 CAR-T/kg, frequency: single dose.
223643404|NCT06464991|DRUG|Daratumumab|"dosage form: Injection dose level:16mg/kg frequency: 28days/cycle for DPd regimen~* Cycle1-2：D1, D8, D15, D22；~* Cycle3-6：D1, D15；~* above Cycle7：D1"
223643405|NCT06464991|DRUG|Pomalidomide|dosage form:capsule. doseage form: capsule. dose level: 4mg/d. frequency: every cycle: D1-D21 for DPd regimen, D1-D14 for PVd regimen.
223643406|NCT06464991|DRUG|Bortezomib|dosage form: subcutaneous injection. dose level: 1.3mg/m2. frequency: 21days/cycle for PVd regimen cycle 1-8: D1,D4, D8, D11； above cycle 9: D1, D8.
223643407|NCT06464991|DRUG|Dexamethasone|dosage form: oral or intravenus injection. dose level:20mg/d. frequency: for DPd: every cycle, D1, D2, D8, D9, D15, D16, D22, D23； for PVd: Cycle1-8：D1, D2, D4, D5, D8, D9, D11, D12; above Cycle 9: D1, D2, D8, D9.
223643408|NCT04307329|BIOLOGICAL|Monalizumab|Monalizumab 750 mg every two weeks
223643409|NCT04307329|BIOLOGICAL|Trastuzumab|Trastuzumab 4 mg/kg every two weeks
223643410|NCT03323346|DRUG|Disulfiram|"Patients will take one pill of disulfiram (Antabus) daily at a dose of 400 mg continually during the treatment phase (from day 0 till End of treatment Visit). In case of intolerance, lower dose up to 200 mg per day is allowed.~Copper supplementation will be given separately from disulfiram; in the morning with patients´breakfast. Patients will take one pill of copper dietary supplement (for instance Copper Star, STARLIFE) corresponding to 2 mg of elementary copper."
223643411|NCT06303388|OTHER|Bruegger,s Exercise|Bruegger's Exercise protocol along with conventional Physiotherapy.
223643412|NCT06303388|OTHER|Egoscue Exercise|Egoscue Exercise along with conventional Physiotherapy.
223643413|NCT04345120|DRUG|SY-008|The subjects were admitted to the clinical trial center two days before the administration period (D-2), fasted for 10 hours overnight on the day before the Administration (D-1), and banned water for 1 hour before the administration. Take sy-009 test drug or placebo immediately before meal (QD is before breakfast, bid is before breakfast and dinner) in the morning of the first day of administration, and deliver it with not more than 200ml warm boiled water. From the day 2 (D2) to the day 7 (D7) before dinner, the oral cavity of the subjects was checked for residual drugs after each administration.
223643414|NCT04345120|DRUG|SY-008 matching placebo|SY-008 matching placebo
223643415|NCT02317471|BIOLOGICAL|autologous gp96 vaccination|"Vaccination of gp96 derived from autologous tumor tissue. Treatment will be started between 3-6 weeks after the surgery.~gp96 of 25ug in 1mL normal saline s.c. on days 1 of each cycle, up to a maximum of 10 doses (1 cycle= 7 days). 200-400mg cyclophosphamide i.v. 1-3 days before each gp96 infusion."
224319706|NCT03140787|DRUG|Nasal Spray of Lidocaine HCL|This spray consists of lidocaine hydrochloride-epinephrine hydrochloride
223643416|NCT02317471|DRUG|Oxaliplatin+S-1|"Treatment will be start at the 5th week after the surgery.~S-1: 40\~60mg bid，d1\~14 q3W; oxaliplatin:130mg/m2，iv drip for 2h，d1,q3W 6 cycles."
223643417|NCT01721044|DRUG|Placebo|Administered orally
224230741|NCT04104568|BEHAVIORAL|iSupport for dementia - European-Portuguese version|iSupport for dementia, European-Portuguese version consists in an online self-help training and support program developed by the World Health Organization to to provide education, skills training and support to informal caregivers of people with dementia and culturally adapted to Portugal by the Institute of Biomedical Sciences Abel Salazar and CINTESIS. Framed as a multi-component intervention, iSupport is grounded in problem-solving and cognitive behavioral therapy techniques. The program comprises 23 lessons on dementia and caregiver support distributed by 5 modules: 'Introduction to dementia'; 'Being a carer'; 'Caring for me'; 'Providing everyday care' and 'Dealing with behavior changes'. The education plan can be personalized by the caregiver and each lesson includes interactive exercises with immediate feedback; and positive messages as well as 'skills certificates' are displayed when lessons are completed.
224319707|NCT03140787|DRUG|Infiltration injection of Lidocaine HCL|This is the ordinary method of establishing anesthesia for patients undergoing dental treatment for caries.
224319708|NCT02771470|DRUG|Probiotics|Microbial composition using probiotic
224319709|NCT02771470|DRUG|placebo|Microbiota modulation using placebo
224319710|NCT04535687|DRUG|Fluzoparib|Fluzoparib
224319711|NCT02802904|OTHER|Diet: Palm olein IV64|Each subject received a palm olein-based run in diet for 2 weeks, followed by random assignment test fat Palm Olein IV64 which was incorporated into daily snacks (\~50g of test fats, brownies (\~15g test fat each) for breakfast and 4 pieces cookies (\~5g test fat each) with low fat palm olein based background diet daily.
223643418|NCT01721044|DRUG|Baricitinib|Administered orally
223643419|NCT01721044|DRUG|cDMARD|Participants will continue to take background cDMARD therapy throughout study.
223643420|NCT01623453|BIOLOGICAL|Autologous adipose derived stem cells(low dose group)|low dose group: 1x10e7 cells/mL At 6 weeks after first stem cell injection, fistula closing was assessed. If it is not completely closed, second injection would be applied in 2 weeks. Additional dosage would be doubled to first dosage.
223643421|NCT01623453|BIOLOGICAL|Autologous adipose derived stem cells(high dose group)|high dose group: 2x10e7 cells/mL At 6 weeks after first stem cell injection, fistula closing was assessed. If it is not completely closed, second injection would be applied in 2 weeks. Additional dosage would be doubled to first dosage.
223643422|NCT05361668|DRUG|Randomized: 40 mg Paltusotine|Two 20 mg tablets QD (Potential post-randomization dose escalation based on efficacy and acceptable tolerability: up to 80 mg)
223765686|NCT06331793|DEVICE|Active AlgoCare|Device that emits Pulsed Electromagnetic Fields
223765687|NCT06331793|DEVICE|Non-active AlgoCare|Device that doesn't emit Pulsed Electromagnetic Fields
223765688|NCT01723228|DRUG|Rasagiline|
224230742|NCT04104568|OTHER|e-book (comparator)|The e-book contains information on relevant topics for dementia and caregiving, including basic information about dementia; practical tips on managing dementia; the changing needs of a person with dementia; dealing with care provision; caring for oneself (the caregiver) and finding emotional support; dealing with the death of the care receiver; relevant legislation (e.g. advance directives); how to get help; and how to reach the national Alzheimer's Association.
224230743|NCT02920411|OTHER|Pediatopic Treatment Cream|Applied twice a day minimum.
223643423|NCT05361668|DRUG|Randomized: 80 mg Paltusotine|Four 20 mg tablets QD (Potential post-randomization dose escalation based on efficacy and acceptable tolerability: up to 120 mg)
224230744|NCT02920411|OTHER|Pediatopic Body lotion|Applied at libitum.
223643424|NCT03824249|DIAGNOSTIC_TEST|Indirect Calorimetry|Performance of indirect calorimetry in Canopy mode.
223643425|NCT02144896|OTHER|Ankle splinting|Ankle dorsiflexion splinting will be performed 30 minutes per day, 5 days per week for 4 weeks.
223643426|NCT00997308|DRUG|AZD1446|Solution, oral, for 4 weeks
223643427|NCT00997308|DRUG|Placebo|
223643428|NCT02048670|DEVICE|Balance Belt|Vestibular habituation therapy worn under the clothes around the waist that uses sensitive motion detectors and vibrates against the skin at four locations to provide information about posture and gait
223643429|NCT04032093|BIOLOGICAL|RSV vaccine|RSV vaccine
223643430|NCT04032093|BIOLOGICAL|Placebo|Normal saline solution for injection (0.9% sodium chloride injection)
223643431|NCT03394820|DRUG|Dexamethasone|The intervention is the time when dexamethasone is administered
224230745|NCT01519128|DRUG|Treatment A: Digoxin|Type=exact number, unit=mg, number=0.5, form=tablet, route=oral. Digoxin administered on Day 1.
223643432|NCT01258686|DRUG|Silymarin|700mg thrice daily
223643433|NCT01258686|DRUG|Placebo|Placebo 700mg thrice daily
223643434|NCT00722072|DRUG|fulvestrant|Loading dose for cycle 1: 500 mg intramuscular(IM) on Day 1;250 mg IM on Day 15 Upon completion of the loading dose, a fixed dose of fulvestrant 250 mg IM will be administered on day 1 of the next 28 day cycle and every consecutive cycle until tumor progression or until unacceptable toxicity occurs requiring discontinuation of study therapy
223643435|NCT00722072|DRUG|sorafenib tosylate|Subjects will take sorafenib 800 mg/day administered as 400 mg bid (twice daily) each morning and evening approximately 12 hours apart. Treatment will begin on Day 1 of the study and continue daily until tumor progression or until an unacceptable toxicity occurs which would require delay, modification or discontinuation of study therapy
223643436|NCT00005804|DRUG|cyclophosphamide|
223643437|NCT00005804|PROCEDURE|allogeneic bone marrow transplantation|
223643438|NCT00005804|RADIATION|radiation therapy|
223643439|NCT02787902|BEHAVIORAL|Communication|Behavioral weight management program adapted for mother-daughter dyads with communication skills training
224230746|NCT01519128|DRUG|Treatment B: TMC278|Type=exact number, unit=mg, number=25, form=tablet, route=oral. TMC278 administered for 16 days, with digoxin administered in the morning on Day 11.
223643440|NCT02787902|BEHAVIORAL|Standard|Behavioral weight management program adapted for mother-daughter dyads without communication skills training
223643441|NCT04957875|DEVICE|emergency endoscopic therapy|When cirrhotic patients presented with AVB to the emergency department, emergency physicians consulted gastroenterologists on duty to assess the patient for suitability for endoscopy, usually after initial stabilization. Performance of endoscopy and its timing was at the discretion of the gastroenterologist on call. Therapeutic endoscopy for AVB was performed within 24 hours after consultation by an experienced attending endoscopist, using standard forward-viewing upper gastrointestinal video endoscopes at individual centers. Written informed consent for endoscopy was obtained before each procedure. The standard of care at all hospitals was to administer a vasoactive agent and antibiotics upon the patient's presentation. Packed red blood cells were transfused at the discretion of the attending gastroenterologist.
223643442|NCT03782246|BEHAVIORAL|MBCT|Mindfulness- based Cognitive Therapy
223643443|NCT03782246|BEHAVIORAL|CBT|Cognitive Behavioral Therapy
223643444|NCT04987333|DRUG|Efavaleukin alfa|Administered as a single dose SC injection.
223643445|NCT04114760|DEVICE|patchy-type wireless ECG|This device consists of a single patchy and save the ECG result as a Potable Document Format. Also can transfer to hospital using wifi-network.
223643446|NCT04114760|DEVICE|defibrillator ECG|This device is essential equipment in ambulance. For 12-lead ECG examination the connector need to replace for specific cable.
223643447|NCT03129568|BIOLOGICAL|CDC infusion|Injection of CDCs (0.3 million per kg of body weight).
223765689|NCT01723228|DRUG|Placebo|
224230747|NCT02832609|OTHER|Supine|measurements after 30 minutes in complete supine position
224230748|NCT00593879|DRUG|Mecamylamine|2.5mg mecamylamine Hcl, tablet form taken twice a day (total of 5.0mg). For 7.5 mg dose group, 2 tablets taken morning, one tablet evening. At 10.0mg, 2 tablets taken twice daily.
224230749|NCT02752945|OTHER|One-day CBT workshop|One-day long CBT workshop, with between 4-15 participants, facilitated by clinical psychologists. Following introductions, ice breakers and an explanation of the CBT model, CBT techniques are then introduced and practised using a variety of methods. One week after the workshop, any personal goals set during the workshop are reviewed with one of the workshop facilitators in a 'telephone goal review.'
224230750|NCT02752945|OTHER|Usual care|Usual care afforded by local CAMHS services
224230751|NCT01411995|DRUG|2% lidocaine gel|3-5cc of 2% lidocaine gel will be applied to the lip of the cervix and within the endocervical canal prior to Intrauterine device insertion
224230752|NCT01411995|DRUG|Water based lubricant|3-5cc of water based lubricant will be applied to the lip of the cervix and within the endocervical canal prior to intrauterine device insertion
224230753|NCT03214718|DIAGNOSTIC_TEST|Measurement level of myeloid derived suppressor cells in CML patients treated with imatinibe 400 mg/day|"For each patient these investigation will be done:~\- Complete blood count,bone marrow aspirate and bone marrow biopsy Measure BCR-ABL GENE Level by FISH at diagnosis and every 3 months till one year .~Measurement Level of myeloid derived suppressor cells both granulocytic and monocytic cells by flowcytometry ."
224323393|NCT06295965|OTHER|Non-Interventional Study|Non-interventional study
224323394|NCT06961006|BIOLOGICAL|V940|IM injection
224323395|NCT06961006|BIOLOGICAL|Pembrolizumab|IV infusion
224323396|NCT06961006|OTHER|Placebo|IM injection
224230754|NCT03214718|DIAGNOSTIC_TEST|Measurement level of myeloid derived suppressor cells in CML patients treated with nilotinib 600 mg/day|"For each patient these investigation will be done:~\- Complete blood count,bone marrow aspirate and bone marrow biopsy Measure BCR-ABL GENE Level by FISH at diagnosis and every 3 months till one year .~Measurement Level of myeloid derived suppressor cells both granulocytic and monocytic cells by flowcytometry ."
223643448|NCT00613873|PROCEDURE|Colonoscopy and Questionnaire|Pt is asked to complete attitude and belief questionnaire then have a Colonoscopy. Then within 6 weeks post colonoscopy a final telephone interview.
223643449|NCT05127954|DRUG|Ubrogepant|Oral Tablet
223643450|NCT04205877|DEVICE|Transcatheter PDA Closure|Device utilized for closure of PDA, study is to help assure continued safety and effectiveness of FDA approved Amplatzer Piccolo Occluder device as well as other devices used off label for PDA closure in premature infants less than 2 kg at the time of device implant.
223765690|NCT05263661|PROCEDURE|LIFT|Ligation of fistula tract between external and internal sphincter
223765691|NCT05263661|PROCEDURE|FLAP|Creation of a partial wall rectal flap to close internal opening of fistula tract
223765692|NCT00862784|BIOLOGICAL|IMC-1121B (ramucirumab)|8 milligrams/kilogram (mg/kg) IMC-1121B (ramucirumab) infusions every 2 weeks
223765693|NCT00862784|DRUG|Oxaliplatin|85 milligrams/square meter (mg/m²) intravenous infusion over 2 hours on Day 1
223765694|NCT00862784|DRUG|Folinic acid|400 mg/m² intravenous infusion over 2 hours on Day 1
223765695|NCT00862784|DRUG|5-FU|400 mg/m² intravenous bolus injection over 2-4 minutes, immediately following folinic acid infusion
223765696|NCT00862784|DRUG|5-FU|2400 mg/m² intravenous continuous infusion over 46 hours immediately following bolus 5-FU on Days 1 and 2
223765697|NCT06972732|DRUG|Metformin|The dosage and dose frequency are maintained as they were before the screening.
223765698|NCT06972732|DRUG|Dapagliflozin/Pioglitazone|Dapagliflozin 10mg/Pioglitazone 30mg QD
223765699|NCT06972732|DRUG|Dapagliflozin/Sitagliptin|Dapagliflozin 10mg/Sitagliptin 100mg QD
223765700|NCT05681429|DRUG|Lignocaine, Dexmedetomidine, Sevoflurane, Paracetamol, Parecoxib|To compare the recovery outcome of patients who undergo supratentorial craniotomy with opioid-based anaesthesia and opioid-free anaesthesia
223765701|NCT06108817|OTHER|Information material|The intervention consists of the distribution of a poster for the waiting room and flyers to be given to patients aiming to inform both patients and GPs with respect to the correct indications for treatment of dyspepsia. After signing up, practices assigned to the intervention group received a package containing 60 flyers and one waiting room poster to use during consultations. The flyer and poster provide a short description of the correct indications for treatment of dyspepsia. Additionally, both the flyers and posters contained a QR-code linking to a decision aid explaining the correct indications and causes of dyspepsia.
224230755|NCT03715270|DEVICE|Image surgical area|Image surgical area
223765702|NCT06108817|OTHER|No Intervention|These practices do not receive information material
223765703|NCT06533189|DEVICE|Enhanced Diffusion Software|Application of specific sequences with the use of Enhanced Diffusion Software during Patient MRI
223643451|NCT02015260|DRUG|Topical NO|Varying doses of sodium nitrite and citric acid co-applied to warts
223643452|NCT02015260|DRUG|Placebo|Placebo
223765704|NCT01313429|DRUG|Cyclophosphamide|50 mg PO BID for 7 days prior to the first dose of vaccine and then on days 8 through 14, and 22 through 28 of each treatment cycle.
223765705|NCT01313429|BIOLOGICAL|Allogenic tumor Cell Vaccine (K562)|4 vaccines consisting of approximately 2.5E7 cells each will be delivered IM every 4 weeks for 6 months. If immune response is detected after first 6 vaccinations, 2 more may be given at 3 month intervals.
223765706|NCT01313429|DRUG|Celecoxib|400 mg PO BID for 7 days prior to the first dose of vaccine and then on days 1 through 28 of each vaccine cycle.
223643453|NCT05679869|OTHER|Masking Sound|Prerecorded environmental noise and masking sounds played from headphones
223643454|NCT05679869|OTHER|No masking sound|Prerecorded environmental noise but no masking sounds played from headphones
223765707|NCT05093426|OTHER|Stage 2 Digital sleep diary app|Participants in Stage 2 will be asked to download a digital sleep diary app and complete a sleep log every day for 21 days.
223765708|NCT06343077|DRUG|Poly-ICLC intramuscular (IM) injection|1.5 mg IM (week 1), followed by paired 1.5 mg IM weekly from weeks 3-through10, and at weeks 14, 18, 22, 26, 30, 34, 38, 42 and 46 with a 4-week rest period between IM injections.
223765709|NCT06343077|DRUG|Poly-ICLC, Intertumoral (IT) injection|1 mg IT once (week 2)
223765710|NCT01451424|DRUG|Proellex|vaginal suppository, daily, for 12 weeks
223765711|NCT02147808|DRUG|Telotristat etiprate|All subjects will receive two 250 mg telotristat etiprate tablets three times daily.
223765712|NCT02147808|DRUG|Midazolam|All subjects will receive 3 mg (1.5 mL oral syrup \[2mg/mL\]).
223765713|NCT06561347|DRUG|Zanubrutinib|A potent, specific, and irreversible Bruton tyrosine kinase (BTK) inhibitor
223765714|NCT06561347|DRUG|Bendamustine|Alkylating agent
223765715|NCT06561347|DRUG|Rituximab|Monoclonal antibody
223765716|NCT01895738|BEHAVIORAL|WrapAround Care|Wraparound care is an established care model that starts with linking an individual with a support￼￼￼ worker who works with them to address risk factors and enable the individual to make positive choices. It is hypothesized that by working with youth to address the risk factors in their control, the likelihood of future violence is reduced.
223765717|NCT00841438|DRUG|Clotinab|Clotinab: IV bolus 0.25 mg per Kg and a 12-hour IV infusion 0.125 μg per kg
223765718|NCT00841438|DRUG|Clotinab|Clotinab: IV bolus 0.25 mg per Kg and a 12-hour IV infusion 0.125 μg per kg
223765719|NCT00243516|DEVICE|PREtest Consult|
224230756|NCT04748211|PROCEDURE|Infraclavicular Block|USI and neurostimulator guided infraclavicular block, 10 ml 2% lidocain and 10 ml 0.05% marcaine was administered for local anetshesia. After the block was administered MAP, HR, TAV, BAD, BAA, BF, PI and rSO 2 values were measured and recorded at the 10th, 20th, and 30th minutes.
224230757|NCT04748211|PROCEDURE|Interscalen Block|USI and neurostimulator guided interscalen block, 10 ml 2% lidocain and 10 ml 0.05% marcaine was administered for local anetshesia. After the block was administered MAP, HR, TAV, BAD, BAA, BF, PI and rSO 2 values were measured and recorded at the 10th, 20th, and 30th minutes.
224230758|NCT04685421|DRUG|Bupivacaine liposome|Liposomal Bupivacaine PKs collections up to 96 hours on children from 2 to 17 years in pediatric cardiac surgeries.
223643455|NCT05067725|OTHER|CarePath|During an in-clinic patient encounter with a primary care provider (PCP) in any one of the intervention CMSL sites, the BPA is fired when any type of headache or migraine is entered as a diagnosis or chief complaint. The purpose of the headache assessment questionnaire is to assist the PCP in characterizing patients' headache. The Express Lane will help guide PCP decision-making for prescribing medications, lab/image ordering, and referrals. The Ask-a-doc button will provide timely access to a virtual treatment and diagnosis consult with a neurologist.
223643456|NCT04971434|DEVICE|laser stimulation for acupoints|In fatty liver patients (30 patients), a daily application of 4-minute laser (for one month, except Fridays) on acupoint number 25,40,36 of stomach meridian, acupoint number 3 of liver meridian, acupoint number 6 of spleen meridian,acupoint number 9,12,4 of conception vessel meridian, acupoint number 14 of governor vessel meridian, acupoint number 4, 11 of large intestine meridian, acupoint number 34 of gall bladder meridian
223643457|NCT04971434|OTHER|cupping with scarification|In fatty liver patients (30 patients),every-two-week applied cupping (with scarification) session within one month on back of upper thorax
223643458|NCT02271672|DEVICE|XP1000 RF|Treatment of adipose tissue within the fat layer with XP1000 RF.
223643459|NCT02271672|DEVICE|sham XP1000 RF|Treatment of adipose tissue within the fat layer with XP1000 RF.
223643460|NCT03530982|OTHER|Intensive goal training|Intensive goal training : 30 hours during 2 weeks
223643461|NCT01654302|DRUG|Synera|70 mg lidocaine/ 70 mg tetracaine topical patch applied once for 12 hours
223643462|NCT01654302|DRUG|Inactive patch|placebo patch applied once for 12 hours
223643463|NCT01481844|DRUG|Lansoprazole , Tab Amoxycillin , Tab Clarithromycin ,Tab Tinidazole|use of Sequential therapy as second line treatment for eradication H pylori currently Sequential therapy is indicated as first line treatment for H pylori eradication
223643464|NCT01481844|DRUG|Lansoprazole, Bismuth Subsalicylate, Metronidazole, Tetracycline|this combination is standard of care as H pylori second line treatment
223643465|NCT00570986|DRUG|Placebo|Two injections at weeks 0 and 4. One injection at week 8. At week 12, arm is rerandomized to placebo every 4 weeks.
223643466|NCT00570986|BIOLOGICAL|ABT-874|200mg at week 0 and week 4. 100mg at week 8. On week 12, arm is rerandomized to 100mg every 4 weeks.
223643467|NCT00570986|BIOLOGICAL|ABT-874|100mg every 12 weeks.
224230759|NCT05358873|DEVICE|Human IgG1 anti-SARS-CoV-2 antibody cocktail|Hypromellose-based nasal spray solution containing human IgG1 anti-SARS-CoV-2 antibody cocktail
224230760|NCT05358873|DEVICE|Placebo|Normal saline
224230761|NCT00936975|RADIATION|Fluorine F 18 Sodium Fluoride|Undergo fluorine F 18 sodium fluoride PET scan
224319712|NCT02802904|OTHER|Diet: Cocoa butter|Each subject received a palm olein-based run in diet for 2 weeks, followed by random assignment test fat cocoa butter which was incorporated into daily snacks (\~50g of test fats, brownies (\~15g test fat each) for breakfast and 4 pieces cookies (\~5g test fat each) with low fat palm olein based background diet daily.
223643468|NCT00828594|DRUG|RAD001|
223643469|NCT00828594|DRUG|RAD001, sorafenib|
223643470|NCT05397925|BEHAVIORAL|ADSProgram - Self management for substance dependence program|GENERAL STRUCTURE OF THE MODEL - 8 sessions: One initial - assessment; 1 to 6 Intermediates - empowerment (Flexible number of intermediate sessions according to the person's need and accessibility, interlude 1 week minimum, up to a maximum of 3 weeks); 1 Final - autonomy; Duration of sessions: 20-60 min; Context: Outpatient specialized addictions unit. Private room needed; Preferred approach: Individual, face-to-face or virtual consultation. Complementary approach: In groups of up to 4 people, when peer support or sharing feelings are needed: Clinical focus 1 - Concerning the problematic use of substances, 2 - Related to health knowledge in general, 3 - Related to health-seeking behavior and adherence, 4 - Related to self-knowledge and well-being, 5 - Related to social role and personal dignity, 6 - Related to the family process.
223643471|NCT05397925|BEHAVIORAL|Treatment as usual - Regular nursing consultation on a medication-based program|Regular individual assessment on: substance used (kind of substance, consumption way, frequency), way of living, social relationship, health status nursing diagnoses. To support on this, therapeutic interventions, medication delivery and management support.
223643472|NCT00514839|BEHAVIORAL|Motivational Interviewing|Two sessions of Motivational Interviewing (after baseline assessment and 4 weeks later) plus one individualized feedback based on the Transtheoretical Model of Behavior Change (8 weeks after baseline assessment)
223765720|NCT01698229|OTHER|Group 1|Collecting a small amount of cerebrospinal fluid (5 mL) from healthy children, ages 2 yrs - 8 yrs, who are already undergoing a lumbar puncture procedure at New York Presbyterian Hospital for clinical or diagnostic purposes.
224230762|NCT01832805|OTHER|Theta burst stimulation.|In each session, subjects will receive 54 Theta burst trains of 2 seconds duration, separated by an intertrain interval of 18 seconds, delivered on the left dorsolateral prefrontal cortex (DLPFC). The treatment protocol of in total 20 Theta burst sessions will be spread over 4 days, yielding a total of 32400 stimuli. On each stimulation day, a given patient shall receive 5 sessions with a between session delay of 10 to 15 minutes.
224230763|NCT01592799|PROCEDURE|Throat swab and/or nasopharyngeal swab|Samples will be tested to quantify the inpatient and ER visits burden of laboratory-confirmed influenza.
224230764|NCT01592799|OTHER|Data collection|Log Sheet will be used to collected data on a monthly basis for the following age groups: \< 6 months; 6-23 months; 24-59 months; \> 5 years.
224323397|NCT06023238|PROCEDURE|Treatment of Chronic TKA PJI|Patients will all undergo standard of care treatment for a chronic total knee arthroplasty prosthetic joint infection.
223643473|NCT00043862|DRUG|topotecan|
223765721|NCT05361681|OTHER|Electromagnetic Field Exposure|All participants were exposed to the electromagnetic field of 4-5 different high power charging systems, charging 4-5 different, commercially available full electric cars
223765722|NCT03660410|OTHER|Anamnesis|A detailed anamnesis should be carried out in order to know the habits, the presence of systemic pathologies, the use of medication
224230765|NCT04104646|DRUG|CHF6563|Sublingual CHF6563 administration at starting dose of 10 µg/kg q8
224230766|NCT04104646|DRUG|Morphine|Oral morphine administration at starting dose of 0.07 mg/kg q4
224230767|NCT04104646|DRUG|CHF6563 matched placebo|Sublingual CHF6563 matched placebo administration
224230768|NCT04104646|DRUG|Morphine matched placebo|Oral morphine matched placebo administration
223643474|NCT03136510|DRUG|Apixaban 5 mg|"Bood collection for biological analyses at:~* inclusion visit~* follow-up visit at 1 month~* end of research at 3 month"
223643475|NCT06044779|PROCEDURE|Transversus Abdominis Plane Block using 0.25% Bupivacaine|TAP block regional anesthesia with ultrasound guidance with administration of 20 mL of 0.25% Bupivacaine in the abdominal wall before the operation is completed. The patient was also fitted with a morphine PCA device with a background dose of 5 µg/kgBW/hour and a rescue dose of 1 mg with a lockout interval of 10 minutes.
223643476|NCT06044779|PROCEDURE|Erector Spinae Plane Block using 0.25% Bupivacaine|Regional anesthesia ESP block under ultrasound guidance with 20 mL of 0.25% bupivacaine at the tip of the transverse process at the T9 level before completion of surgery. The patient was also fitted with a morphine PCA device with a background dose of 5 µg/kgBW/hour and a rescue dose of 1 mg with a lockout interval of 10 minutes.
223643477|NCT00088088|DRUG|Paclitaxel|
223643478|NCT00088088|DRUG|Carboplatin|
223643479|NCT00088088|DRUG|STA 4783|
223643480|NCT06177548|PROCEDURE|Minimally invasive Bentall procedure|The minimally invasive Bentall procedure is performed through a small incision in the right intercostal space.
223643481|NCT04941677|OTHER|no intervention|no intervention in this study
223643482|NCT02203968|DRUG|Fibrinogen concentrate|Six grams of fibrinogen concentrate (RiaSTAP™) will be administered intravenously as a single 300ml rapid infusion (less than 3min) via level I automated pressure pump within one hour of hospital admission.
223643483|NCT02203968|DRUG|Placebo Comparator|Placebo Comparator: Normal saline Placebo (normal saline) will be administered intravenously as a single 300ml rapid infusion (less than 3min) via level I automated pressure pump within one hour of hospital admission.
223643484|NCT00434291|DRUG|TG-873870(Nemonoxacin)|
224230769|NCT03133442|DEVICE|Somnomat V4|Vestibular stimulation is provided using an innervated bed platform. This robotic device consists of a standard single bed, mounted on a moving mechanism. It was developed and produced by the ETH Zürich and approved for use in this study by Swissmedic.
224230770|NCT01790620|OTHER|CVVHD|CVVHD will be used during 72 hours with a prescribed dose of 30 ml/Kg/h Prismasol® 4 as dialysate fluid. Blood flow of 200-250 ml/min, to achieve 12 - 15 L/h will be prescribed. Isovolemic CRRT will be encouraged during this 72 hours if volume overload status is not present. After 72 hours, CVVHD will be continued and dialysate dose (ml/kg/h) will be adjusted to achieve creatinine levels between 80-120 umol/L until patient recovers urine output and / or tolerates intermittent hemodialysis.
224230771|NCT01790620|OTHER|CVVH|CVVH will be used during 72 hours with a prescribed dose of 30 ml/Kg/h Prismasol® 4 as reposition fluid. Blood flow of 200-250 ml/min, to achieve 12 - 15 L/h will be prescribed adjusting the adequate percentage of prefilter reinfusion to maintain a theorical filtration fraction between 18-22%. Isovolemic CRRT will be encouraged if volume overload status is not present. After 72 hours, CVVH will be continued and filtration dose (ml/kg/h) will be adjusted to achieve creatinine levels between 80-120 umol/L until patient recovers urine output and / or tolerates intermittent hemodialysis.
224230772|NCT03158142|DRUG|Atropine Sulfate 1% Oph Soln|Atropine sulphate 1% ophthalmic solution is both a mydriatic and cycloplegic
223643485|NCT01771289|DRUG|docetaxel/cisplatin|weekly docetaxel/cisplatin combined with radiation
223643486|NCT01771289|RADIATION|Radiation|chemoradiation
223643487|NCT03410706|DRUG|Rivaroxaban(Xarelto, BAY 59-7939)|The dosage and the anticoagulation duration is decided by investigators. As list in product information, the PE treatment dosage of rivaroxaban is 15mg bid for first 21 days and then 20mg qd. If CrCl is 30-49 ml/min and bleeding risk is over VTE recurrence risk, 20mg qd can be replaced with 15mg qd.
223643488|NCT02354898|DRUG|BBI503|
224230773|NCT04570566|PROCEDURE|horizontal alveolar ridge augmentation|evaluate the potential application of resorbable pericardium membrane to augment localized alveolar ridge defects in esthetic zone, from histological, radiographical and clinical aspects in comparison with titanium mish for the subsequent placement of dental implants
224230774|NCT00284297|PROCEDURE|History taken and clinical examination|History is taken and clinical examination is followed
223643489|NCT02354898|DRUG|Sorafenib|Sorafenib 400mg twice daily (800mg total daily dose)
223643490|NCT05323227|DIAGNOSTIC_TEST|Coronary CTA|Patients receive coroanry CTA at the discretion of the physicians in charge. And parameters including plaque burden, minimal lumen area, diameter stenosis, total plaque volume, high-risk plaque characteristics, fractional flow reserve, pullback pressure gradient, fat attenuation index will be analyzed.
223765723|NCT03660410|OTHER|Oral clinical examination|Clinical examination should be carried out evaluating the presence of caries, tooth loss, periodontal condition, occlusal factors
223765724|NCT03895320|BEHAVIORAL|Sexual Health Risk Assessment|The self-assessment ('Sexual Health Risk Assessment'), will pertain to sexual and reproductive health. The self-assessment, will include a valid clinical prediction tool, established to predict STI positivity.
224230775|NCT03144856|DRUG|Apatinib|Apatinib 500mg, po, qd, every 4 weeks.
224230776|NCT02405507|DIETARY_SUPPLEMENT|wheat bread with wheat germ|
224230777|NCT02405507|DIETARY_SUPPLEMENT|wheat bread without wheat germ|
223643491|NCT03563014|DRUG|Radium-223 (Xofigo, Bay88-8223)|Follow the physician's prescription in routine clinical practice.
223643492|NCT03429114|OTHER|Magnetic resonance imaging|We will conduct MRI and fMRI brain scans to compare brain function between groups.
223643493|NCT02134496|PROCEDURE|assessment of motorfunction in PACU|assessment of motorfunction in PACU after spinal anesthesia
223643494|NCT05613140|DRUG|sacubitril/valsartan|Two study cohorts were constructed to include adult HFrEF patients who newly initiated sacubitril/valsartan (Cohort 1) and adult CHF patients who newly initiated sacubitril/valsartan (Cohort 2).
224230778|NCT03586336|DEVICE|ReDS-Guided|ReDS measurements will be shared with the treating clinicians who can use the information to guide diuresis and determine the appropriate timing of discharge
224230779|NCT03586336|DEVICE|Usual Care|ReDS measurements will not be shared with the treating clinicians, who will guide diuresis using standard clinical criteria
224230780|NCT06026982|DIETARY_SUPPLEMENT|probiotic and pickle|probiotic formula by Rugby Health that has Bacillus Coagulans spores 1billion CFU and inulin 250mg along with a pickle
224230781|NCT00003536|DRUG|antineoplaston A10|
224230782|NCT00003536|DRUG|methotrexate|
224230783|NCT00003536|PROCEDURE|alternative product therapy|
224230784|NCT00003536|PROCEDURE|biological therapy|
224230785|NCT00003536|PROCEDURE|biologically based therapies|
223643495|NCT05663658|OTHER|Intravenous morphine patient control device|24-hour morphine consumption will be recorded
223643496|NCT05663658|OTHER|External oblique intercostal plane block|External oblique intercostal plane block will be administered before the surgery.
223643497|NCT03524508|DRUG|Onivyde|The recommended dose and regimen of Onivyde is 70 mg/m2 intravenously over 90 minutes, followed by dl-LV 400mg/m2 or l-LV 200mg/m2 intravenously over 30 minutes, followed by 5-FU 2400 mg/m2 intravenously over 46 hours, administered every 2 weeks.
223643498|NCT03524508|DRUG|5-FU/LV|The recommended dose and regimen of dl-LV 400mg/m2 or l-LV 200mg/m2 intravenously over 30 minutes, followed by 5-FU 2400 mg/m2 intravenously over 46 hours, administered every 2 weeks
224230786|NCT00003536|PROCEDURE|cancer prevention intervention|
224230787|NCT00003536|PROCEDURE|chemotherapy|
224230788|NCT00003536|PROCEDURE|complementary and alternative therapy|
224230789|NCT00003536|PROCEDURE|differentiation therapy|
224230790|NCT06464809|OTHER|kinesio taping (KT)|
224230791|NCT03149913|DEVICE|SequentPlease OTW paclitaxel coated balloon catheter|PTA with SequentPlease OTW paclitaxel coated balloon catheter
224230792|NCT03149913|DEVICE|conventional uncoated balloon for BTK endovascular therapy|PTA with uncoated balloon for BTK endovascular therapy
223643499|NCT00225316|PROCEDURE|Acupuncture|See Detailed Description.
223643500|NCT06120400|DRUG|Whole Egg|Whole Large, Grade A Egg
223643501|NCT00746382|DRUG|Roflumilast cream|Roflumilast cream 0.5% versus Placebo cream
223643502|NCT00746382|DRUG|Placebo cream|Placebo cream
223643503|NCT03257059|OTHER|Breakfast|Glutinous rice (75 grams of available carbohydrate)
224230793|NCT02942303|DRUG|Dysport|
224230794|NCT02942303|PROCEDURE|lateral orbicularis injection|
224230795|NCT02942303|PROCEDURE|Lateral orbicularis + corrugator injection|
224230796|NCT05980988|DIETARY_SUPPLEMENT|Probiotic|The experimental phase of this study had last 84 days, and each patient will make 4 visits (d1, d28, d56, d84).
224230797|NCT05980988|DIETARY_SUPPLEMENT|Placebo|Placebo
224230798|NCT02974153|BIOLOGICAL|ALD403 (Eptinezumab)|
224230799|NCT02974153|BIOLOGICAL|Placebo|
223643504|NCT03257059|OTHER|No Breakfast|No food to be served in the morning
223643505|NCT04275362|DEVICE|DJO Empowr PS Knee System|Patients will receive a DJO Empowr PS Knee System total knee replacement
223643506|NCT04275362|DEVICE|Stryker Triathlon Total Knee System|Patients received a Stryker Triathlon Total Knee System total knee replacement
223643507|NCT04275362|DEVICE|Biomet Vanguard Complete Knee System|Patients received a Biomet Vanguard Complete Knee System total knee replacement
223643508|NCT04275362|DEVICE|Control|No total knee replacement
223643509|NCT02765516|OTHER|Plant sterols|2.0g/day of plant sterols incorporated into margarine to be consumed for 28 days
223643510|NCT02765516|OTHER|Placebo|Identical margarine without additional plant sterols to be consumed for 28 days
223643511|NCT01455701|DRUG|Tocilizumab|Tocilizumab will be administered as indicated in the arm description.
223643512|NCT03327662|OTHER|Active CTC Assessment|CTC Counts used to guide treatment switch
223643513|NCT05839301|BIOLOGICAL|Investigational live attenuated varicella vaccine (lot 1)|0.5ml/vial
223643514|NCT05839301|BIOLOGICAL|Investigational live attenuated varicella vaccine (lot 2)|0.5ml/vial
223643515|NCT05839301|BIOLOGICAL|Investigational live attenuated varicella vaccine (lot 3)|0.5ml/vial
224230800|NCT04432948|OTHER|PHQ-9 Depression Scale|It involves a 9-question scale that detects depression
224230801|NCT04432948|OTHER|GAD-7 General anxiety disorder scale|It involves a 7-question scale that detects general anxiety disorder
224230802|NCT04432948|OTHER|38-questions questionnaire|It involves a 38 question questionnaire that aims to detect any association between the Covid-19 pandemic, the psychological impllications and anaesthetic practice
224230803|NCT02277769|DRUG|Dupilumab|Subcutaneous injection alternated among the different quadrants of the abdomen, upper thighs and upper arms.
224230804|NCT02277769|DRUG|Placebo (for Dupilumab)|Subcutaneous injection alternated among the different quadrants of the abdomen, upper thighs and upper arms.
223643516|NCT05506033|PROCEDURE|rapid GCs taper|After a complete response was achieved, the GCs dose was halved from the original dose.
223643517|NCT01167504|OTHER|Saliva sample collection|Collection of either whole mouth saliva or parotid saliva. Whole mouth saliva is collected through stimulation by inert gum. Parotid saliva is collected by using a Lashley cup placed over the parotid duct and stimulated by a fruit sweet.
223643518|NCT01246596|PROCEDURE|dental root planing|The objective of root planing, otherwise known as conventional periodontal therapy, non-surgical periodontal therapy, or dental prophylaxis is to remove or eliminate the etiologic agents which cause inflammation: dental plaque, its products and calculus,\[1\] thus helping to establish a periodontium that is free of disease.\[2\]
223643519|NCT01246596|PROCEDURE|dental root planing|The objective of root planing, otherwise known as conventional periodontal therapy, non-surgical periodontal therapy, or dental prophylaxis is to remove or eliminate the etiologic agents which cause inflammation: dental plaque, its products and calculus, thus helping to establish a periodontium that is free of disease.
223643520|NCT01246596|PROCEDURE|dental root planing|The objective of root planing, otherwise known as conventional periodontal therapy, non-surgical periodontal therapy, or dental prophylaxis is to remove or eliminate the etiologic agents which cause inflammation: dental plaque, its products and calculus, thus helping to establish a periodontium that is free of disease.
224230805|NCT06328283|OTHER|measure of Glutamine synthetase and BCLFAF1|compare Glutamine synthetase and BCLFAF1 in cases and controls
224230806|NCT00391690|DRUG|Zoledronic acid|In case of bone metastases: Zoledronic acid every 4 weeks for 3 months.
224230807|NCT04529642|DIAGNOSTIC_TEST|Inertial Measurement Unit evaluation|An IMU was worn by the subjects during the execution of the 6MWT, to assess the kinematic parameters of gait.
224230808|NCT05462288|DEVICE|Entia Liberty|Home monitoring blood analyser
224230809|NCT03730103|OTHER|Same day discharge|Patients will be discharged home from the hospital on the day of her surgery.
224323398|NCT05663320|OTHER|virtual educational based transition intervention self-paced|study intervention is a standardized, virtual educational video on CAH that will be delivered self-paced
224323399|NCT06511141|DEVICE|Axonics SNM System|To assess clinical outcomes of the Axonics SNM System in the male OAB population.
223643521|NCT02982980|PROCEDURE|Physiotherapy Guidance|Pre and postoperative assessment and orientation, guidelines for lymphedema prevention and self drainage, follow-up for rehabilitation or maintenance of joint amplitude of shoulder movements and functional return.
223643522|NCT02982980|PROCEDURE|Physiotherapy Muscle strengthening|The exercises performed were active-free, with the aid of a stick or resistance by elastic bands and dumbbells for flexion, extension, adduction, abduction, external and internal rotation of the shoulder, and elbow flexion and extension, besides activities to enable movements Functional. The mode of execution of the exercises was isotonic, done slowly and within the joint amplitude reached by the patient, using resistance according to the muscular capacity of each patient.
224230810|NCT04645290|BEHAVIORAL|"Intervention group: Educational Intervention KARER"|"Multicomponent and interdisciplinary intervention on the care ability and burden of family caregivers. It consists of:~Virtual componet~* Module 0: the introduction~* Module 1: called Identifying my role as a caregiver~* Module 2: called Strategies to strengthen care~* Module 3: called Strengthening my caring skills~Face-to-face componed - Two seasons of 4 hours each~Simulation component~\- One season of practices abilities of 4 hours."
224230811|NCT04387110|DRUG|Ocrelizumab|Receiving either 1infusion (600mg) or 2 infusions (300mg).
224230812|NCT01488578|DRUG|Tolterodine tartrate|Detrusitol Capsule 2mg and 4mg, depending on the Investigator prescription.Frequency and duration are according to Package Insert as follows.
224230813|NCT00672828|BEHAVIORAL|Non-tailored CRC screening brochure|Patients receive written educational material about colorectal cancer and prompting to talk to their doctor about getting tested.
224230814|NCT00672828|BEHAVIORAL|Interactive computer intervention|
224230815|NCT02308111|DRUG|Obeticholic Acid (OCA)|"Non-cirrhotic and classified as CP Class A: 5 mg tablet of OCA once daily titrating up to a maximum of 10 mg OCA once daily based on tolerability at 3 months for the duration of the study (majority of participants).~Cirrhotic and classified as CP Class B and C: 5 mg tablet of OCA once weekly for at least 3 months, subsequently titrating up to a maximum dose and frequency of 10 mg OCA twice weekly based on tolerability and biochemical response for the duration of the study."
224230816|NCT02308111|DRUG|Placebo|One tablet daily (or a lower frequency depending on CP score) for the remainder of the study
224230817|NCT02592694|DRUG|cocktail|Cocktail (tirofiban, bivalirudin, tenecteplase) will be given in addition to thrombus aspiration
224230818|NCT02592694|DEVICE|thrombus aspiration|manual thrombus aspiration
224230819|NCT01342679|DRUG|dasatinib|100mg QD
224230820|NCT04405934|OTHER|Use of virus (Covid-19) genome sequence report to inform infection prevention control procedures|Rapid or standard (time to return to sites) receipt of virus (Covid-19) genomic sequencing reports
223643523|NCT03075514|OTHER|MKD|Modified ketogenic diet
223643524|NCT03075514|OTHER|MCT|Medium chain triglyceride ketogenic diet
223643525|NCT03000608|DRUG|SAN021 Serum|SAN021 is a serum containing 10% East Indian Sandalwood Oil. It is packaged in an amber glass bottle with a dropper top. The dose is 5 drops per 1% BSA involvement twice daily.
223643526|NCT03000608|DRUG|SAN021 Placebo|SAN021 Placebo is a serum that does not contain East Indian Sandalwood Oil however, does contain a synthetic sandalwood fragrance. It is packaged in an amber glass bottle with a dropper top. The dose is 5 drops per 1% BSA involvement twice daily.
223643527|NCT00651690|BIOLOGICAL|Botulinum Toxin Type A|200 U to 360 U of botulinum toxin Type A on Day 0. Patients who met retreatment criteria received a second treatment (open-label) at Week 12 or Week 18
223643528|NCT00651690|BIOLOGICAL|Placebo|Saline injection on Day 0
223643529|NCT03133793|DRUG|CoQ10|Participants will take 300 mg capsules two times daily, 1 taken in the morning and 1 taken in the evening, for up to 12 weeks.
223643530|NCT03133793|DRUG|D-Ribose Oral Powder|Participants will mix 15 grams D-Ribose powder, mixed with non-carbonated liquid, one time per day for up to 12 weeks.
223643531|NCT03133793|OTHER|Placebo pills|Participants will take matched placebo pills that are 300 mg capsules, two times daily, 1 taken in the morning and 1 taken in the evening, for up to 12 weeks.
223643532|NCT03133793|OTHER|Placebo powder|Participants will mix 15 grams placebo powder, mixed with non-carbonated liquid, one time per day for up to 12 weeks.
223643533|NCT04002232|DEVICE|CPP-ACP-NaF varnish|calcium phosphate containing fluoride releasing varnish to prevent caries
223765725|NCT03895320|BEHAVIORAL|Sexual Health Score|The results of the 'Sexual Health Risk Assessment' will produce a score ('Sexual Health Score'). The 'Sexual Health Score' will be presented as a number (0/10) and will be organized by category: Low, Medium or High Risk.
223643534|NCT04477096|DRUG|HS-10234|HS-10234
223643535|NCT04477096|DRUG|Emtricitabine|Emtricitabine
223643536|NCT02751853|DEVICE|Conductance catheter|Continuous online measurements of left ventricular pressure and volume using conductance catheters
223643537|NCT02480387|DRUG|Ledipasvir/Sofosbuvir FDC|
224230821|NCT01561183|PROCEDURE|Indirect pulp capping (IPC)|"Procedure: IPC~The IPC will be performed as follow:~* Anesthesia~* isolation the tooth~* access to the lesion~* incomplete removal of carious tissue from the cavity walls~* indirect pulp capping with ≈2 mm layer calcium enriched mixture cement~* permanent filling with sandwich technique"
224230822|NCT01561183|PROCEDURE|Direct pulp capping (DPC)|"Procedure: DPC~The DPC will be performed as follow:~* Anesthesia~* isolation the tooth~* access to the lesion~* complete removal of carious tissue from the cavity walls result in pulp exposure~* preparation of clot-free pulpal mound~* direct pulp capping with ≈2 mm layer calcium enriched mixture cement~* permanent filling with sandwich technique"
224230823|NCT01561183|PROCEDURE|Miniature pulpotomy (MP)|"Procedure: MP~The MP will be performed as follow:~* Anesthesia~* isolation the tooth~* access to the lesion~* complete removal of carious tissue from the cavity walls result in pulp exposure~* intentionally removal of pulp horn (≈1 mm)~* preparation of clot-free pulpal mound~* direct pulp capping with ≈2 mm layer calcium enriched mixture cement~* permanent filling with sandwich technique"
223643538|NCT01859624|DRUG|Albuterol|Albuterol 4 mg
223643539|NCT02839200|DRUG|ACT-541468 5 mg|Capsule for oral administration containing ACT-541468 at a strength of 5 mg
223643540|NCT02839200|DRUG|ACT-541468 10 mg|Capsule for oral administration containing ACT-541468 at a strength of 10 mg
223643541|NCT02839200|DRUG|ACT-541468 25 mg|Capsule for oral administration containing ACT-541468 at a strength of 25 mg
223643542|NCT02839200|DRUG|Zolpidem|Over-encapsulated zolpidem tablet at a strength of 10 mg
223643543|NCT02839200|DRUG|Placebo 1|Placebo capsules matching ACT-541468 capsules
223643544|NCT02839200|DRUG|Placebo 2|Placebo capsules matching over-encapsulated zolpidem
223643545|NCT05279677|DRUG|Fecal microbiota transplantation plus Sintilimab and Fruquintinib|"Microbiota capsules containing 1g gut microbiota, po d1-3 before anti-tumor treatment, total for 8 cycles.~Sintilimab 200mg iv, q3w. Fruquintinib 5mg po d1-14, q3w."
223643546|NCT02952820|DRUG|lemborexant|
223643547|NCT02952820|DRUG|Placebo|
223643548|NCT06237985|PROCEDURE|ProTaper Gold file system|According to the manufacturers ' instructions, root canal treatments will be conducted with the ProTaper Gold rotary file system up to F2 for mesial canals.
223643549|NCT06237985|PROCEDURE|OneShape file system|According to the manufacturers ' instructions, root canal treatments will be conducted with the OneShape rotary file system up to 25/.06 for mesial canals.
223643550|NCT06237985|PROCEDURE|TruNatomy file system|According to the manufacturers ' instructions, root canal treatments will be conducted with the TruNatomy rotary file system up to 26/.04 for mesial canals.
223643551|NCT04764708|BEHAVIORAL|Compassion and Metacognition Based Therapy|The intervention is a Third Wave Cognitive Therapy targeting metacognitive dysfuctions (through Metacognitively Oriented Psychotherapy) and self-criticism (through Compassion Focused Therapy).
223643552|NCT04764708|BEHAVIORAL|Cognitive Behavioral Therapy|Standard Cognitive Behavioral Therapy for Personality Disorders plus Standard Psychopharmacological Treatment.
223643553|NCT03310918|OTHER|Palliative Care|Specialized medical care for people with serious illness. This type of care is focused on providing relief from the symptoms and stress of a serious illness. The goal is to improve quality of life for both the patient and the family
223643554|NCT03310918|OTHER|Standard Leukemia care|Standard care per the hospital guideline
224230824|NCT01561183|PROCEDURE|Full pulpotomy (FP)|"Procedure: FP~The FP will be performed as follow:~* Anesthesia~* isolation the tooth~* access to the lesion~* complete removal of carious tissue from the cavity walls result in pulp exposure~* pulpotomy~* preparation of clot-free pulpal mound~* direct pulp capping with ≈2 mm layer calcium enriched mixture cement~* permanent filling with sandwich technique"
224230825|NCT03277183|DRUG|Low dose erythropoietin|Subjects randomized to this arm will receive low-dose of EPO administered thrice weekly
224230826|NCT03277183|DRUG|High dose erythropoietin|Subjects randomized to this arm will receive the same cumulative dose of EPO administered as a high-dose of EPO every 2 weeks
224230827|NCT03271528|DRUG|Lacosamide|Lacosamide titration was done to a target dose of 300mg. Participants took 100 mg of lacosamide once on day 1, 100 mg twice per day from day 2 through day 6 (200 mg daily total), on day 7 the lacosamide dose was increased to 150 mg twice daily (300 mg daily total), and on day 8 the participant took one dose of 150 mg.
223643555|NCT03074240|PROCEDURE|TAPB Group|Subjects allocated to the TAPB group will be monitored for instances of intraoperative local anesthetic supplementation, analgesic administration, or conversion to general anesthesia will be compared.
223643556|NCT03074240|PROCEDURE|RSB Group|Subjects allocated to the RSB group will be monitored for instances of intraoperative local anesthetic supplementation, analgesic administration, or conversion to general anesthesia will be compared.
223643557|NCT03074240|PROCEDURE|conversion to general anesthesia|For those who do not respond to TAPB or RSB to allow for completion of the intended procedure.
223643558|NCT05803239|PROCEDURE|EBUS-TBNA|Participants with lymphadenopathy would receive EBUS-TBNA attempts to conduct diagnoses.
223643559|NCT05803239|PROCEDURE|EBUS-TBMC via a tunnel|Participants with lymphadenopathy would receive EBUS-TBMC via a tunnel attempts to conduct diagnoses.
223643560|NCT02876432|DEVICE|Electroacupuncture|"The acupuncture points selected were ST36, BL25, GB30, BL40, GB34 the needles were inserted into acupoints and the depth of needle insertion depended of the acupoints selected to achieve Deqi sensation, which is characterized as a numb, heavy, sore and/or distending sensation.~Electrical stimulation was delivered at 4 Hz. The stimulator (ITO EST-160) was then switched on, and the intensity was gradually increased to reach a strong but comfortable level the sensation of EA which is characterized for numbness, tingling and a light muscle cramp. For 15 minutes"
223643561|NCT02876432|DRUG|Diclofenac sodium|100 mg Diclofenac sodium was administrated orally every 12 hours for 5 days.
223643562|NCT02876432|OTHER|Sham electroacupuncture|The investigators use 1.0 cm outside point of the real electroacupuncture, the depth of needle insertion was superficial to avoid Deqi sensation, the cables wasn't connected to the electro stimulator and was then switched on for 15 minutes. The participants were threaded separately to avoid sharing experiences about the electroacupuncture sessions
223643563|NCT04139018|DRUG|Timolol Gel|Timolol nasal gel 0.1% will be prepared with a poloxamer gel (combination of poloxamer 188 and 407; pH adjusted to 4.5-6.5) and 0.5 ml applied to each nostril twice daily. The total daily dose would amount to 2 mg.
223643564|NCT04139018|DRUG|Placebo Gel|Placebo gel is prepared with poloxamers and no active ingredients.
223643565|NCT02077452|DRUG|HMS5552|
223643566|NCT02077452|DRUG|Placebo|
224230828|NCT03271528|DRUG|Placebo oral capsule|Participants took a placebo oral capsule once on day 1, twice per day from day 2 to day 7, and once on day 8.
224230829|NCT04184310|OTHER|Modified perineal linear stapler resection for external rectal prolapse|After anesthesia and patient position, the prolapse was pulled out Two vertical incision were made in both the inner and outer walls of the prolapse (at 3and 9 o'clock)1-2 cm in size approximately 2 cm above the dentate line. We used a reloadable linear cutter stapler (GIA 100mm Covidien, Mansfield, Mass., USA) passing through the tunnel to cut the anterior aspect of the prolapse . Then, after reload the stapler by the new cartridge, we used it to do the same for posterior wall and the prolapsed rectum was completely transected . We ensure that the stapler did not fire at the dentate line to avoid post-operative pain. Multiple 3-0 PDS intermittent full thickness sutures were done for hemostasis. The prolapsed rectum falls back into place spontaneously.
224230830|NCT00873210|DRUG|Sutent|50 mg per day for 4 consecutive weeks, followed by 2 weeks treatment pause
224230831|NCT06546579|DIAGNOSTIC_TEST|Skin sampling|All individuals will self-collect skin samples and swabs and fill in a questionnaire. Subsequently, all individuals will see a professional. The professional will collect skin samples and swabs as well.
224323400|NCT04267848|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
224323401|NCT04267848|DRUG|Carboplatin|Given IV
224323402|NCT04267848|DRUG|Cisplatin|Given IV
224323403|NCT04267848|PROCEDURE|Computed Tomography|Undergo CT
223765726|NCT03895320|BEHAVIORAL|Sexual Health Messaging|After the score ('Sexual Health Score') the participant will receive personalized messaging ('Sexual Health Messaging') that relates to their score and risk level (i.e. Low, Medium or High). Short messages that indicate key steps the person can take to lower their risk for STIs will be displayed on the screen that correspond to their 'Sexual Health Score.'
223765727|NCT03895320|BEHAVIORAL|Water SSB Quiz|The self-assessment ('Water SSB Quiz') will pertain to consumption of water, soda and sugar sweetened beverages. There will not be a comparable clinical prediction tool in the control self-assessment ('Water SSB Quiz).
223765728|NCT03895320|BEHAVIORAL|Water SSB Score|The results of the 'Water SSB Quiz' will produce a score ('Water SSB Score'). The 'Water SSB Score' will be presented as a number (0/10).
223765729|NCT03895320|BEHAVIORAL|Water SSB Messaging|After the score ('Water SSB Score') the participant will receive personalized messaging ('Water SSB Messaging') that relates to their score. Short messages that indicate key steps the person can take to meet the recommended daily intake for water and sugar sweetened beverages will be displayed on the screen that correspond to their 'Water SSB Score.'
223765730|NCT03895320|BEHAVIORAL|STI Screening|All participants regardless of group, will be offered a STI screening kit immediately after receipt of their respective program (intervention or control). Participants will have the option of completing the kit at the first study visit, taking it with them after the first study visit is over, or receiving it later from one of our staff either at our local project office or the kit can be dropped off at a location the participant chooses. Completed kits can be returned to our office or picked up by a study staff. (NOTE: while the STI screening kit will be available to all participants should they request it at subsequent study visits, e.g. the 3- and 6-month follow-ups, the STI screening kit will only be explicitly offered by the study team at the first study visit immediately after participants complete their respective quiz).
224319713|NCT02802904|OTHER|Diet: Virgin olive oil|Each subject received a palm olein-based run in diet for 2 weeks, followed by random assignment test fat virgin olive oil which incorporated into daily snacks (\~50g of test fats, brownies (\~15g test fat each) for breakfast and 4 pieces cookies (\~5g test fat each) with low fat palm olein based background diet daily.
223643567|NCT03233581|BEHAVIORAL|Fitbit + Facebook + Coaching Group|Participants will use the FitBit device to track their physical activity (PA). Participants will receive and post messages and receive badges on the Facebook group. Weekly a research staff member will call them to provide brief health coaching. Participants will select an adult family member or friend to also receive a Fitbit during the intervention period to provide support.
223643568|NCT03233581|BEHAVIORAL|Fitbit only|Participants will receive a Fitbit device only, and will not receive health coaching, join the Facebook group, or select an adult family member or friend to receive a Fitbit to provide them with support.
223643569|NCT02633514|DRUG|Cisplatin|25mg/m2,iv gtt,d1-3
223643570|NCT02633514|DRUG|Etoposide|75mg/m2,iv gtt,d1-3
223643571|NCT02633514|RADIATION|radiotherapy|60Gy/30Fx
223643572|NCT01730482|DRUG|[14C] AT1001|150 mg of \[14C\] labelled AT1001 will be administered as a solution (prepared by weighing 150 mg of AT1001 powder and dissolving in 100 mL of water). The entire solution will be swallowed orally. After ingestion of study medication, the dosing bottle will be rinsed with 50 mL of water and this will be ingested by the subject. This rinse procedure should be performed twice. Following the second rinse ingestion, the subjects should be instructed to drink additional water to bring the total volume ingested to 240 mL.
223643573|NCT00411684|DRUG|CDB-2914|
223643574|NCT02243995|OTHER|Physical training|
223643575|NCT02243995|BEHAVIORAL|Physical training|
223643576|NCT02484885|OTHER|Hyperpolarized Xenon MRI|Hyperpolarized noble gas imaging using Xenon-129 has been used to explore structural and functional relationships in the lung in patients with lung disease and healthy controls. In contrast to proton-based MRI imaging, 129Xe gas is used as a contrast agent to directly visualize the airways, and thus ventilation. Whereas the normal density of gas is too low to produce an easily detectable signal, this is overcome by artificially increasing the amount of polarization per unit volume using optical pumping.
223765731|NCT02084628|DRUG|Gadoxetate disodium (Eovist/Primovist, BAY86-4873)|Participants to receive single dose of Eovist/Primovist as a manual injection at a dose of 0.1 milliliter per kilogram (mL/kg) body weight (BW) (0.025 millimole \[mmol\]/kg BW), followed by a flush of at least 5 mL saline (sodium chloride 0.9 percent \[%\] solution) manually.
223765732|NCT00578500|PROCEDURE|ovarian transplantation|Patients will undergo laparoscopic oophorectomy, aspiration of oocytes and maturation followed by cryopreservation. In case of ovarian failure and approval by treating physicians, restoration of fertility will be attempted by thawing of oocytes or by transplantation of ovarian cortex to induce ovulation and obtain oocytes for fertilization and embryo transfer.
223765733|NCT00219375|DRUG|Sivelestat sodium hydrate|0.2 mg/kg/hr continuous i.v. infusion - up to 14 days
223765734|NCT00219375|DRUG|Sivelestat sodium hydrate|0.2 mg/kg/hr continuous i.v. infusion - up to 14 days
223765735|NCT00204256|DRUG|Iron sucrose|
223765736|NCT05639270|DEVICE|use of an auricular electrode|Use of the auricular electrode throughout the duration of the study (30minutes/day) combined with assessment of pain, tolerance, vagal tone.
223765737|NCT00494572|DRUG|Montelukast|10 mg rapid dissolving granule in sterile water orally once
223765738|NCT00494572|OTHER|sterile water|sterile water
224319714|NCT04317092|DRUG|Tocilizumab Injection|Tocilizumab 8 mg/kg (up to a maximum of 800mg per dose). A second administration (same dose) can be given after 12 hours if respiratory function has not recovered, at discretion of the Investigator.
224319715|NCT02447146|OTHER|Resistance Training|The TG performed the RT program using weight machines. Before the training period, participants underwent three weeks with eight familiarization sessions to ensure proper technique execution. The protocol aimed to workout major muscle groups and involved the following exercises: chest press, knee extension, hamstrings curl, leg press, and seated row. Training sessions lasted approximately 50-60 minutes with 2 sets of 10-12 repetitions until fatigue.
223643577|NCT00002476|BIOLOGICAL|bleomycin sulfate|
223643578|NCT00002476|DRUG|fluorouracil|
223643579|NCT00002476|DRUG|leucovorin calcium|
223643580|NCT00002476|DRUG|methotrexate|
223643581|NCT00002476|DRUG|vincristine sulfate|
224319716|NCT02447146|OTHER|Lectures on the disease|The control group attended an orientation program with lectures on health, quality of life and scientific update on disease.
224230832|NCT00625690|OTHER|questionnaire administration|Subjects will be asked to complete an additional detailed questionnaire regarding personal information about themselves, their medical history, their diet and lifestyle habits, any past or current environmental exposures and to re-create their family tree for any cancers that have occurred in any of their family members.
224230833|NCT00625690|PROCEDURE|computed tomography|The baseline and repeat screening CT scans will be performed with a multi-slice helical CT scanner (8 or more rows), at a low-dose setting (120kVp, 40-80mA, slice thickness of 1.25 mm or less). In a single breath-hold, contiguous slices from the thoracic inlet to the adrenal glands will be obtained. Contrast material will not be used. Multi-slice scanners will be used because they provide higher-resolution images. Diagnostic studies, including HRCT will be performed with a multi-slice helical CT at diagnostic settings (120kVp, 140-300mA, slice thickness of 1.25 or less) with the nodule retrospectively reconstructed at a 15cm field of view.
224230834|NCT00625690|PROCEDURE|evaluation of cancer risk factors|When the CT scan at baseline does not lead to the diagnosis of malignancy, repeat screening will be scheduled 12 months later. If the initial scan led to further evaluation, the repeat scan will be performed 12 months after the most recent scan. The subjects will be allowed to add relevant health information to their record in the web-based database as it develops. Similarly, when in the first repeat screening malignancy is not diagnosed; the second repeat screening will be scheduled 12 months later for a total period of 5 years.
224230835|NCT00625690|PROCEDURE|study of high risk factors|When the CT scan at baseline does not lead to the diagnosis of malignancy, repeat screening will be scheduled 12 months later. If the initial scan led to further evaluation, the repeat scan will be performed 12 months after the most recent scan. The subjects will be allowed to add relevant health information to their record in the web-based database as it develops. Similarly, when in the first repeat screening malignancy is not diagnosed; the second repeat screening will be scheduled 12 months later for a total period of 5 years.
224230836|NCT03818958|OTHER|blood sampling|blood sampling
223643582|NCT00002476|RADIATION|low-LET cobalt-60 gamma ray therapy|
223643583|NCT00002476|RADIATION|low-LET photon therapy|
223643584|NCT00002476|RADIATION|radiation therapy|
223643585|NCT02247986|DRUG|Methylphenidate Hydrochloride|Bold signal changes by methylphenidate on DBD
223643586|NCT03486834|BIOLOGICAL|V160|V160 was administered as a 0.5 mL (100 Units/0.5 mL dose with Merck aluminum phosphate adjuvant \[MAPA\], 4°C stable formulation) IM injection.
223643587|NCT03486834|DRUG|Placebo|Saline solution administered as a 0.5 mL IM injection
223643588|NCT04476797|DRUG|GC4711 +SBRT|15 minute IV Infusion prior to SBRT
223643589|NCT04476797|DRUG|Placebo +SBRT|15 minute IV infusion prior to SBRT
223643590|NCT00255489|DRUG|Gefitinib|
223643591|NCT00255489|PROCEDURE|palliative thoracic radiotherapy|
223643592|NCT02364570|OTHER|Glucose (100g)|Ingestion of glucose (100g)
223643593|NCT02364570|OTHER|Glucose (75g)|Ingestion of glucose (75g)
224230837|NCT06483958|BEHAVIORAL|palliative care protocol|"1. Symptom management~2. Respect for patient and family autonomy.~3. Respectful management of clinical information.~4. Provision of holistic care and support."
224230838|NCT00929357|DRUG|DMARDs or Biologics|
224230839|NCT00026104|DRUG|gemcitabine hydrochloride|Given IV
224230840|NCT00026104|DRUG|paclitaxel|Given IV
224230841|NCT00026104|DRUG|tipifarnib|Given orally
224230842|NCT00026104|RADIATION|radiation therapy|Undergo radiation therapy
224230843|NCT05914519|PROCEDURE|Ejaculatory Preserving Transurethral resection of prostate|Transurethral resection of prostate with preservation of 1cm safety area above verumontanum and without paracollicular digging
224230844|NCT05914519|PROCEDURE|Standard Transurethral Resection of prostate|Transurethral resection of prostate including whole adenoma till the capsule.
224230845|NCT02957279|DRUG|Antibiotics|In the sepsis group, antibiotics were used when needed.
224230846|NCT01873859|DRUG|Metformin|Incidence of lactic acidosis in diabetic patients receiving contrast media in the presence of metformin.
224230847|NCT00870909|PROCEDURE|active tDCS|Intensity 2 mA during 20 minutes, 2 times per day
224230848|NCT00870909|PROCEDURE|sham tDCS|sham condition as delivered by the stimulator
224230849|NCT01144884|OTHER|Procedure (education and exercise)|education/exercise
224230850|NCT04258241|PROCEDURE|Local infiltration analgesia with local anesthetic|The orthopedic surgeon will perform local infiltration analgesia at the end of the surgery. The knee joint capsule, periarticular and subcutaneous tissues will be infiltrated with 150 mg of bupivacaine, 0.3 mg of epinephrine and 90 ml of normal saline.
224230851|NCT04258241|PROCEDURE|Local infiltration analgesia without local anesthetic|The orthopedic surgeon will perform local infiltration analgesia at the end of the surgery. The knee joint capsule, periarticular and subcutaneous tissues will be infiltrated with 0.3 mg of epinephrine and 120 ml of normal saline.
223643594|NCT02364570|OTHER|Whole Eggs|Ingestion of 1.5 whole eggs
223643595|NCT02364570|OTHER|Egg Whites|Ingestion of 7 egg whites
224230852|NCT04258241|DEVICE|Needle|18-gauge 40 mm Sterican needle (B. Braun Medical Inc., Melsungen, Germany) will be used to perform local infiltration analgesia.
224323404|NCT04267848|PROCEDURE|Echocardiography Test|Undergo ECHO
223643596|NCT02364570|OTHER|Egg Yolks|Ingestion of 2 egg yolks
223643597|NCT00264732|DRUG|Amolimogene|1-dose amolimogene Group: Two intramuscular (IM) injections (100 micrograms ZYC101a per injection), one in each quadriceps, at Treatment Initiation. Single IM placebo injections (approximately 1 mL 0.9% sterile saline) at Weeks 3 and 6 in alternating quadriceps.
223643598|NCT00264732|DRUG|Amolimogene|3-dose amolimogene Group: Two IM injections (100 micrograms ZYC101a per injection), one in each quadriceps, at Treatment Initiation. Single IM injections of 100 micrograms ZYC101a at Weeks 3 and 6 in alternating quadriceps.
223643599|NCT00264732|OTHER|Placebo|Placebo Group: Two IM placebo injections at Treatment Initiation (1 injection in each quadriceps). Single placebo injections at Weeks 3 and 6 in alternating quadriceps. Each placebo injection consists of approximately 1 mL 0.9% sterile saline.
223643600|NCT03614156|DRUG|Rapastinel|Rapastinel 450 mg or 225 mg (prefilled syringe, weekly intravenous IV administration) or Rapastinel 450 mg or 225 mg (prefilled syringe, clinically driven schedule IV administration, variable interval, placebo on intervening weeks)
223643601|NCT03614156|DRUG|Placebo|Placebo (prefilled syringe, weekly IV administration)
224230853|NCT04258241|DRUG|Solution with local anesthetic|Solution of 150 mg of bupivacaine, 0.3 mg of epinephrine and 90 ml of normal saline will be used to perform local infiltration analgesia.
224230854|NCT04258241|DRUG|Solution without local anesthetic|Solution of 0.3 mg of epinephrine and 120 ml of normal saline will be used to perform local infiltration analgesia.
224230855|NCT05493696|DEVICE|Antigravity treadmill|Alter G training for 30-minute, 3 times/week, 75% body weight
224230856|NCT05493696|OTHER|Traditional physical therapy program|applied 3 times/week for 12 weeks
224230857|NCT03977584|DRUG|Crenezumab|Crenezumab will be administered subcutaneously (every 2 weeks) or IV (every 4 weeks) for at least 260 weeks.
224230858|NCT03977584|DRUG|Placebo|Placebo matched to crenezumab will be administered subcutaneously (every 2 weeks) or IV (every 4 weeks) for at least 260 weeks.
224230859|NCT03977584|OTHER|[^18F]GTP1|IV \[\^18F\]GTP1 will be administered up to three times. The first primary \[\^18F\]GTP1 tau PET scan will occur during any visit in the main protocol NCT01998841 (GN28352) from Week 130 to Week 224 and the second \[\^18F\]GTP1 tau PET scan from Week 248 to Week 260. The third and optional \[\^18F\]GTP1 tau PET scan will supplement the two primary scans.
224230860|NCT03358459|OTHER|non|non
224230861|NCT03232203|DRUG|STRIMVELIS|It is the Autologous cluster of differentiation (CD) 34+ enriched cell fraction that contains CD34+ cells transduced with retroviral vector that encodes for the human ADA complementary Deoxyribonucleic acid (cDNA) sequence. HCP who have previously referred a patient for STRIMVELIS treatment or a parent's/carer's child who previously received treatment with STRIMVELIS will be recruited to the study
223643602|NCT01040910|DRUG|smoking of cannabis|smoking of cannabis, 2 cigarettes a day, equivalent to about 50 mg THC
223643603|NCT01040910|DRUG|smoking cigarettes with placebo|smoking cigarettes with cannabis that was chemically treated so that most active ingredients were removed
223643604|NCT00036985|DRUG|cyclophosphamide|
223643605|NCT00036985|DRUG|doxorubicin hydrochloride|
223643606|NCT00036985|PROCEDURE|conventional surgery|
224230862|NCT02172248|DRUG|BI 10773|
224230863|NCT02172248|DRUG|Metformin|
224230864|NCT01042366|BIOLOGICAL|Vaccination|Subjects will receive as an outpatient 4 weekly ultrasound-guided intra/peri-lymph nodal administrations of the autologous tumor dendritic cell vaccine. The dose of the autologous tumor cell dendritic cells/vaccine will be 1-5 X 106.
224230865|NCT02220465|BEHAVIORAL|PA+ Smoking Cessation (LMPA)|
224230866|NCT02220465|BEHAVIORAL|Standard Care Smoking Counseling (SCC)|
224230867|NCT02634060|DEVICE|Home Based Fecal Calprotectin|Home Based Fecal Calprotectin measurement at weeks 0, 4 and 8
224230868|NCT06094374|BEHAVIORAL|observation of physical activity behavior|"An observational study will be conducted to gather data on multiple levels aiming to identify diverse digital phenotypes related to PA behavior among community-dwelling older adults.~A hybrid approach will be employed, combining both cross-sectional and longitudinal data collection methods. The overall aim is to employ data analysis to identify patterns of PA - behavior (referred to as phenotypes) and to pinpoint prognostic factors that affect PA outcomes.~This integrated strategy will be complemented by four distinct measurement approaches, ensuring a comprehensive assessment of the research objectives. These measurement approaches include:self-reporting, clinical, ecological momentary and time series assessment."
224230869|NCT05346549|BEHAVIORAL|High energy preload|Tests the extent to which participants reduce their food intake at a meal following ingestion of a high energy preload drink.
224230870|NCT05346549|BEHAVIORAL|Low energy preload|Tests the amount participants eat at a meal following ingestion of a low energy preload drink
224230871|NCT02277457|RADIATION|PET-Adaptive RT|All patients will be treated with response-driven PET-adaptive RT. The radiation dose will be delivered in greater than or equal to 2.2 Gy per daily fraction to FDG-PET/CT-guided target volumes with the treatment duration limited to 30 fractions and total radiation dose limited to 66-80.4 Gy.
224230872|NCT02277457|DRUG|Erlotinib|150 mg once daily
224230873|NCT02277457|DRUG|Crizotinib|250 mg twice daily
224230874|NCT00002174|DRUG|Thalidomide|
224230875|NCT05925790|DIAGNOSTIC_TEST|IL1RA Antibody Assay|-The measurement of anti-interleukin-1 receptor antagonist (IL1RA) antibodies will be performed using the ELISA (Enzyme-Linked Immunosorbent Assay) method,as previously described \[Thurner, L., et al., IL-1RA Antibodies in Myocarditis after SARS-CoV-2 Vaccination. N Engl J Med, 2022. 387(16): p. 1524-1527\].
224230876|NCT05925790|DIAGNOSTIC_TEST|suPAR Testing|"-The quantitative determination of soluble urokinase plasminogen activator receptor (suPAR) levels in blood will be conducted using the commercially available CHORUS suPAR Extended kit (cod. 81414, DIESSE Diagnostica Senese S.p.A., Siena, Italy), based on the principle of the sandwich ELISA method."
224230877|NCT00496184|DRUG|Nifedipine cream topical application|
223643607|NCT00036985|PROCEDURE|neoadjuvant therapy|
223643608|NCT00036985|PROCEDURE|thermal ablation therapy|
223643609|NCT02535806|DRUG|Velcade|4 doses of study drug will be given.
223643610|NCT02535806|DRUG|Methotrexate|Intrathecal dose For CNS negative patients, Day 1 and Day 8
223643611|NCT02535806|DRUG|Methotrexate / Hydrocortisone / Cytarabine|Intrathecal dose for CNS positive patients, Day 1, 8, 15, 22
223643612|NCT02535806|DRUG|Dexamethasone|Days 1-5 and 15-19
223643613|NCT02535806|DRUG|Mitoxantrone|Days 1 and 2
223643614|NCT02535806|DRUG|Vincristine|Days 1, 8, 15, 22
223643615|NCT02535806|DRUG|Pegaspargase|Days 3 and 17
223643616|NCT02936596|DRUG|Ursodeoxycholic acid combination of immunosuppressive agents|Ursodeoxycholic acid combination of immunosuppressive agents(methylprednisolone with or without azathioprine)
223643617|NCT02936596|DRUG|Ursodeoxycholic Acid|Ursodeoxycholic Acid
223643618|NCT00646048|DEVICE|TriVascular Stent-Graft System|TriVascular Stent-Graft System
223643619|NCT01473901|DRUG|BKM120 + temozolomide|The investigational drug, BKM120, will be supplied as 10-mg and 50-mg hard gelatin capsules. BKM120 will be administered on a once daily dosing schedule at a dose of 40 mg, or 60 mg, or 80 mg, or 100 mg (p.o.), in combination with the approved dosing of temozolomide and SoC delivery of cranial irradiation for GBM. The patient will be dosed with BKM120 on a flat scale of mg/day and the dose of BKM120 will not be adjusted to body weight or body surface area. Patients should not eat for 2 hours after the administration of BKM120. Temozolomide in 5 mg, 20 mg, 100 mg, 140 mg, 180 mg or 250 mg capsules will be administered in combination with the investigational drug BKM120.
223765739|NCT04774510|OTHER|Diagnostic Test: optimized C-Arm Cone Beam Computed Tomography|Optimized C-ARM CBCT using new geometry and a novel software can rapidly and accurately detected brain abnormalities and hemorrhagic complications for critical patients with acute stroke. This rapid assessment would eliminate the need for the patient to be imaged in another scanner and be subsequently transported again to another room; all anatomic and physiologic imaging would occur in the neuro angiography suite (NAS).
223765740|NCT06265402|PROCEDURE|Tab block versus retrolaminar block in abdominal plastic surgery|i inject 20ml bupivacine either 4mg dead in each side
223765741|NCT04376034|BIOLOGICAL|Convalescent Plasma 1 Unit|"Each adult recipient will receive 1 units of plasma, each unit will consist of about 200 to 250 mL.~Each pediatric recipient will receive 10mL/kg up to 1 unit of plasma."
223765742|NCT04376034|BIOLOGICAL|Convalescent Plasma 2 Units|"Those that meet severe or critical criteria will be given 2 units if available or 1 unit if 2 units are not available.~Those that are given 1 unit may receive the second unit (or the remainder of the maximum pediatric weight calculated amount of plasma up to 1 additional unit) if they progress to severe or critical condition or if already in severe or critical condition but only received 1 unit secondary to shortages.~Each pediatric recipient will receive 10mL/kg up to 2 units of plasma."
223765743|NCT04376034|OTHER|Standard of Care|Those that meet mild severity will be allowed to enroll in the study, but will not receive plasma unless there is progression of illness into the moderate/rapid progression or greater category.
224230878|NCT01933828|PROCEDURE|OPEN lobectomy|Lobectomy and mediastinal lymph node dissection by thoracotomy with rib-spreading.
223643620|NCT01473901|DRUG|BKM120 +temozolomide with/without radiotherapy|The investigational drug, BKM120, will be supplied as 10-mg and 50-mg hard gelatin capsules. BKM120 will be administered on a continuous once daily dosing schedule at a dose of 40 mg, or 60 mg, or 80 mg, or 100 mg (p.o.), in combination with the approved dosing of temozolomide and SoC delivery of cranial irradiation for GBM. The patient will be dosed with BKM120 on a flat scale of mg/day and the dose of BKM120 will not be adjusted to body weight or body surface area. Patients should not eat for 2 hours after the administration of BKM120. Temozolomide in 5 mg, 20 mg, 100 mg, 140 mg, 180 mg or 250 mg capsules will be administered in combination with the investigational drug BKM120.
223643621|NCT00638014|DEVICE|Rapid Sternal Closure System|Sternal talons will be used and supplemented with wires
223643622|NCT00638014|DEVICE|Conventional wire closure|Conventional wire closure of sternum
223643623|NCT02405832|DIETARY_SUPPLEMENT|Zinc|Oral administration of a 40 mg elemental zinc (in the form of zinc sulfate) lozenge, with sweetener and citrus flavor
223643624|NCT02405832|DIETARY_SUPPLEMENT|Placebo|Placebo lozenge, with sweetener and citrus flavor, administered orally
223643625|NCT04287517|DEVICE|Capacitive-Resistive Therapy|Capacitive-resistive diathermy therapy heats deep tissues by transferring energy through radiofrequency waves.
223643626|NCT05181436|DIAGNOSTIC_TEST|measuring Total Haemoglobin (SpHb) using Masimo Rad-67.|To determine the prevalence of Malaysian children aged ≥ 6 to ≤ 36 months at risk of anaemia by measuring Total Haemoglobin (SpHb) using Masimo Rad-67.
223643627|NCT01021891|DRUG|Technosphere®/Insulin|
223643628|NCT04771117|BEHAVIORAL|Fear of Covid-19 Scale|"The Fear of Covid-19 Scale (FCV-19S) is a questionnaire that evaluates fear of the global pandemic caused by the SARS-CoV-2. The FVC-19S consists of seven items, such as It makes me uncomfortable to think about coronavirus-19, I am afraid of losing my life because of coronavirus-19, and When watching news and stories about coronavirus-19 on social media, I become nervous or anxious, each with a five-point Likert scale of options. The participant is instructed to choose the option that best represents their perception about the statement presented. The maximum possible total is 35 points. The scale's authors indicate that the higher the score is, the higher is the level of the participants' fear of COVID-19."
223643629|NCT01786577|OTHER|Magnetic Resonance Imaging|Both groups will undergo two MRIs at baseline and within 48 hours after surgery/non-surgery.
223643630|NCT01786577|BEHAVIORAL|Cognitive assessment testing|Both groups will undergo in-person baseline assessment of cognitive functioning as well as assessments at three weeks, three months and one year.
223643631|NCT04404491|DRUG|Procedural death 1|200mg,d1,15,29,43,57,I.V
223643632|NCT04404491|DRUG|Capecitabine|Capecitabine: 625mg/m2, bid d1-5; q1w, po,6 weeks in total.
223643633|NCT04404491|RADIATION|Radiotherapy|radiotherapy： 50-50.4Gy ，1.8-2 Gy/d，5d/w.
223643634|NCT04404491|DRUG|Placebo|placebo: 200mg,d1,15,29,43,57,I.V
223643635|NCT04515472|DRUG|Botnia Clamp|This clamp technique is designed to obtain independent measures of insulin secretion and insulin sensitivity during the same test. In brief, 0.3g/kg body wt of a 20% glucose solution is given at time 0. Blood samples for the measurement of plasma glucose and serum insulin are obtained at -10, 0, 2, 4, 6, 8, 10, 20, 30, 40, 50, 60, 120, and 180 min.
223643636|NCT04515472|OTHER|Withdrawal of Gender Affirming Hormone Therapy (GAHT)|GAHT, either estrogen or testosterone therapy will be withdrawn after the Botnia Clamp.
223643637|NCT03070964|DRUG|plitidepsin|
223643638|NCT02899468|DEVICE|BrightBrainer Virtual Reality (BBVR) Rehabilitation System|During the active treatment stage (3 sessions per week x 6 weeks), each BBVR therapy session will consist of a series of custom games targeting one or several cognitive domains of executive function, attention, short-term memory, working memory and language comprehension. In addition, the BBVR device incorporates uni- and bi-manual activities by having the subject manipulate hand-held devices, which are programmed to measure in real time the subject's 3D hand movement and index flexion/extension. Therefore, in addition to completing the cognitive tasks, subjects must manipulate virtual hands through a hand-held interface to also enhance visual-motor perception, hand-eye coordination, and upper limb function. In addition, wrist weights can be added to increase upper limb strength training.
223643639|NCT05808231|DRUG|Standard of Care + Quinine Sulfate|Standard of Care + Quinine Sulfate
223643640|NCT05808231|DRUG|Standard of Care|Standard of Care for COVID-19 mild and moderate symptom
223643641|NCT03420599|PROCEDURE|splenectomy|Traumatic patients who performed total splenectomy
223765744|NCT03651791|COMBINATION_PRODUCT|USPIO labeled MSC injection|USPIO labeled MSC injection
223765745|NCT05854875|PROCEDURE|Laparoscopic Roux en Y gastric bypass|Laparoscopic RYGBP included the creation of a small gastric pouch, with a 200cm biliopancreatic limb and a 150cm alimentary limb.
224230879|NCT01933828|PROCEDURE|VATS lobectomy|Thoracoscopic minimally invasive lobectomy with thoracoscopic mediastinal lymph node dissection without rib-spreading.
223643642|NCT01131832|DIETARY_SUPPLEMENT|Plant sterol|
223643643|NCT01131832|DIETARY_SUPPLEMENT|Placebo|
223643644|NCT00965861|OTHER|Tissue Registry Study|If a patient consents to allowing the use of their tumor tissue sample(s) for testing/analysis at a future date, their name and information will be stored electronically in a registry that will be managed by SCRI. SCRI may then use the information contained in this registry (such as disease indication, demographic information, etc.) at any time in the future to select tissue samples on which to perform testing/analyses.
223643645|NCT06112353|DRUG|Neostigmine Injectable Solution|Examine GI-2 recovery
224230880|NCT01933828|DEVICE|ROBOT-assisted lobectomy|Robot-assisted lobectomy with mediastinal lymph node dissection (Robot group as clinical assignment in prospective Cohort).
224230881|NCT06085482|DRUG|LY3502970|Administered orally
223643646|NCT06112353|DRUG|Sugammadex injection|Examine GI-2 recovery
223643647|NCT05160181|OTHER|Yogatherapy|Description: Retrospective study on medical file of patients seen in consultation for chronic pain with prescription of Yogatherapy
223643648|NCT04985123|DEVICE|Pre-Formed Penile Silicone Block Implant|Implantation of Pre-Formed Penile Silicone Block Implant
223643649|NCT01094119|DEVICE|heated blanket|heated blanket
223643650|NCT01094119|DEVICE|heated pad|patients will be warmed with a heated pad during surgery.
223643651|NCT05024019|DRUG|Nimotuzumab|The study group received nimotuzumab (200mg, weekly, for 6 weeks) in combination with radiotherapy.
223643652|NCT01352000|BEHAVIORAL|Smoking Cessation|Approximately 3400 quitline clients will be randomized to one of three conditions at the point of their 2-week follow-up call.
223643653|NCT00002786|BIOLOGICAL|aldesleukin|
223643654|NCT00002786|BIOLOGICAL|therapeutic tumor infiltrating lymphocytes|
223643655|NCT00148096|DEVICE|Mechanical Heat Recovery Ventilation|De-humidification without loss of heat
223643656|NCT03612752|DIETARY_SUPPLEMENT|CMI-168|Dietary supplement
223643657|NCT03612752|OTHER|Placebo|Placebo
224230882|NCT06085482|DRUG|[14C]-LY3502970|Administered IV
224230883|NCT06178679|DRUG|ST-100 (vezocolmitide)|ST-100 (vezocolmitide) Ophthalmic Solution 60 μg/ml
224230884|NCT06178679|DRUG|Vehicle|Vehicle Ophthalmic Solution
224230885|NCT03504852|DRUG|secukinumab 150 mg|sub-cutaneous secukinumab prefilled syringe 150 mg
223643658|NCT02708186|DRUG|Nelotanserin|once daily, oral, 20-mg tablets
223643659|NCT02708186|DRUG|Placebo|once daily, oral, matching tablets
223643660|NCT00041561|DRUG|Nitrogen gas|Nitrogen gas will be given at 5ppm until Day 28 or extubation
223643661|NCT00041561|DRUG|inhaled nitric oxide|inhaled nitric oxide will be given at 5 ppm until day 28 or extubation
223643662|NCT02851472|DRUG|Inhaled Nitric Oxide|Nitric oxide gas will be added to the inhaled gas mixture that the patient was already receiving at baseline, using standard of care gas delivery systems adapted specifically for this study.
223643663|NCT02851472|DRUG|Placebo|Placebo gas (nitrogen) will be added to the inhaled gas mixture that the patient was already receiving at baseline, using standard of care gas delivery systems specifically adapted for this study.
223643664|NCT00854399|PROCEDURE|Staging surgery or debulking surgery|Staging surgery or debulking surgery
223643665|NCT04125472|DRUG|Lumasiran|Lumasiran administered as a subcutaneous (SC) injection
223643666|NCT05599867|BEHAVIORAL|quality of life|to assess quality among patients with patients with IBD
223643667|NCT02629263|DIETARY_SUPPLEMENT|Viscous Fiber|Meta- analysis of Randomized Controlled Trials
223643668|NCT03309735|DRUG|Micronized progesterone|Utrogestan, 200 mg orally thrice a day until acute symptoms of the threat of termination of pregnancy (scarlet discharge from the genital tract, pain in the abdomen) and then Utrogestan vaginally 200 mg twice a day and 200 mg orally once a day before bed
223643669|NCT03309735|DRUG|Micronized progesterone|Utrogestan vaginally 200 mg twice a day and 200 mg orally once a day before bed
223643670|NCT03309735|DRUG|Dydrogesterone|Duphaston, orally 40 mg once, then 10 mg every 8 hours until the symptoms disappear
223643671|NCT01281904|BEHAVIORAL|Relaxation Acupressure|Apply pressure on 9 relaxatory acupressure points for 3 minutes each once daily for a 6 week period, followed by a 4 week wash-out period.
223643672|NCT01281904|BEHAVIORAL|Stimulating Acupressure|Apply pressure on 10 excitatory acupressure points for 3 minutes each once daily for a 6 week period, followed by a 4 week wash-out period.
223643673|NCT03638037|DIAGNOSTIC_TEST|Vitamin D measurement|Maternal serum 25- hydroxyl vitamin D level
223643674|NCT01020240|BEHAVIORAL|Avolition|\- avolition for cesarean discomforts
223643675|NCT01020240|BEHAVIORAL|Orientation|"* avolition of cesarean discomfort~* physiotherapy orientation"
223643676|NCT01020240|BEHAVIORAL|Guide|"* avolition of cesarean discomfort~* physiotherapy orientation~* guide orientation"
223643677|NCT00834093|BIOLOGICAL|Epstein-Barr Virus Specific Immunotherapy|
223643678|NCT00248768|DEVICE|Transcranial magnetic Stimulator|a device which produces intense magnetic fields in the brain and activates cerebral neurons
223643679|NCT05914337|BEHAVIORAL|exercise|A program consisting of strengthening and stretching exercises 2 days a week was applied to the study group for 8 weeks. One day a week, 30 minutes of mild moderate walking was requested.
223643680|NCT05914337|BIOLOGICAL|gene expressions of miRNA|In the samples taken, gene expressions of miRNA-146a, miRNA-155, miRNA-16, miRNA-145 were determined by real-time polymerase chain reaction method.
223643681|NCT02745119|DRUG|Lampalizumab|Lampalizumab 10 mg will be administered every 4 or 6 weeks according to the frequency given during participation in the parent study.
223643682|NCT05322382|PROCEDURE|A-line|Subjects breathe air mixtures containing reduced amounts of oxygen to produce the desired level of hypoxemia.
223643683|NCT02721329|DEVICE|APAP|Automatic Continuous Positive Airway Pressure
224230886|NCT00727454|DEVICE|CPAP|Continuous Positive Airway Pressure (CPAP) during sleep for 3 months.
224230887|NCT00727454|DEVICE|No treatment|No treatment
224230888|NCT01066052|DRUG|r-hGH|Subcutaneous administration.
224230889|NCT01835145|DRUG|Cabozantinib S-malate|Given PO
224230890|NCT01835145|DRUG|Dacarbazine|Given IV
224230891|NCT01835145|OTHER|Laboratory Biomarker Analysis|Correlative studies
224230892|NCT01835145|DRUG|Temozolomide|Given PO
224230893|NCT05152641|DRUG|BGE-117, 4mg|BGE-117, 4mg Capsules
224323405|NCT04267848|DRUG|Gemcitabine Hydrochloride|Given IV
223643684|NCT02721329|DEVICE|APAP with SensAwake|Automatic Continuous Positive Airway Pressure with SensAwake enabled. SensAwake is a pressure relief technology that detects the transition from sleep to wake, and promptly reduces the pressure during wakeful periods.
223643685|NCT02973750|PROCEDURE|Baseline Biopsy|Baseline biopsy (and ascites fluid sampling if applicable). This is done during the normal work-up procedures.
223643686|NCT02973750|PROCEDURE|Tissue Collection|Tissue collection during debulking surgery.
223643687|NCT02973750|PROCEDURE|Blood Draws|Blood samples for paclitaxel and carboplatin plasma levels will be collected in the study. Paclitaxel will be measured on cycle 1 day 1 at predose and then at the end of the infusion, followed by 1, 2, 4, 8 hours after the end of infusion, then on cycle 1 day 2 at 24 hours after the end of infusion. Carboplatin will be sampled for on cycle 1 day 1 at predose and then at the end of the infusion, followed by 0.5, 1.5, 3.5, 7.5 hours after the end of infusion, then on cycle 1 day 2 at 23.5 hours after the end of infusion.
223643688|NCT01587924|DRUG|GSK1278863|tablet
223643689|NCT01587924|DRUG|rhEPO|injection
224230894|NCT05152641|DIETARY_SUPPLEMENT|Ferrous Sulfate|Ferrous Sulfate, 325mg Tablets
224230895|NCT05152641|OTHER|Matching Placebo|Matching Placebo to BGE-117 Capsules
224230896|NCT05152641|DRUG|BGE-117, 12mg|BGE-117, 12mg Capsules
224230897|NCT03846921|DIAGNOSTIC_TEST|Laboratory blood test|Laboratory blood test will be analyzed to determine whether there is a rise in alpha-defensin
224230898|NCT03724110|OTHER|Telestroke|Telestroke is an audiovisual communication network that allows for coordination of stroke care from a distant 'hub' site (the telestroke provider location) to an originating 'spoke' site (patient location) in a HIPAA compliant fashion. In TELECAST-TIA, inpatient telestroke rounding will be used to oversee the urgent diagnostic TIA evaluation, secondary stroke prevention, and stroke education in patients admitted with TIA.
224230899|NCT02177097|BIOLOGICAL|Blood samples|4 x 10 ml blood samples.
224230900|NCT06234852|BEHAVIORAL|Glucocorticoid withdrawal group|Gradual withdrawal of daily 5-mg prednisolone to daily 0-mg prednisolone over 20-24 weeks
223643690|NCT03561480|DRUG|Ferric carboxymaltose|Ferinject®to be administered as IV drip infusion or undiluted bolus injection with a minimum administration time of 15minutes (for 1000mg single administration) for body weight ≥50 Kg or 6 minutes (for 500mg single administration) for body weight \<50Kg .
223643691|NCT03561480|DRUG|0.9% Normal Saline|Placebo will be in the form of normal saline administered over same time period as equivalent Ferinject® administration. IV drip infusion or undiluted bolus injection with a minimum administration time of 15 minutes (200mL as infusion or 20mL as bolus injection) for body weight ≥50 Kg or 6 minutes (100mL normal as infusion or 10mL as bolus injection) for body weight \<50 Kg.
223643692|NCT02444078|OTHER|Exercise|Exercise training will take place in the NH, twice weekly, around 60 minutes per session (session duration can be shorter during the first weeks of intervention according with participants' physical capacity), during 6 months; interval between two exercise sessions will be of at least 48 hours. The exercise program will be a multicomponent training, with exercises specifically developed to improve participants' flexibility (10 minutes), coordination and balance (10 minutes), muscle toning (10 minutes), and cardiorespiratory capacity (25 minutes). The exercise intensity targeted will be moderate. All exercise sessions will be accompanied by music.
223643693|NCT02444078|OTHER|Social Activity|Interventionists will be health professionals external to the NH, preferentially psychologists. Interventions will take place in the NHs, at the same frequency and duration than the exercise intervention (twice weekly, 60 minutes per session, during 6 months).
223643694|NCT00432172|DRUG|Epirubicin|
223643695|NCT00432172|DRUG|Cyclophosphamide|
223643696|NCT00432172|DRUG|Docetaxel|
223643697|NCT00432172|DRUG|Exemestane|
223643698|NCT00432172|DRUG|Goserelin|
223643699|NCT00432172|DRUG|Carboplatin|
223643700|NCT00404469|PROCEDURE|peritendinous corticosteroid injections|1 ml of40mg/ml methylprednisolone acetate at 0 and 4 weeks. 2 week observational
223643701|NCT00404469|PROCEDURE|eccentric decline squat training|eccentric decline unilateral squats performed twice daily. for 12 weeks
223643702|NCT00404469|PROCEDURE|heavy slow resistance training|Heavy slow resistance training for knee extensors. 3/week. total of 12 weeks
223643703|NCT03214848|BEHAVIORAL|Contraceptive education prior to abortion|Contraceptive education script will be delivered over the phone prior to abortion visit.
223643704|NCT06414629|OTHER|Simulation Based Mentorship Program|"In this program, local level mentors were developed to provide regular mentorship on low-dose high-frequency approach in contrast to one-time coaching in a long gap. This program combined the existing package of the continuum of care along with Helping Babies Survive (HBS) \& Helping Mothers Survive (HMS) guidelines, adopting a simulation-based onsite mentoring and coaching approach. The mentors provided monthly mentorship on following seven modules topics to the nurses of the intervention birthing centers:~1. Infection prevention~2. Antenatal care and counseling~3. Essential care of labor and birth~4. Helping babies breathe~5. Bleeding after birth~6. Essential care of labor and birth~7. Postnatal care and counseling~Every monthly session was followed by four weekly practice sessions. The nurses from intervention birthing centers were also called mentees."
224230901|NCT06234852|BEHAVIORAL|Glucocorticoid maintenance group|Daily 5-mg prednisolone over 24 weeks
223643705|NCT05876715|DRUG|Lurbinectedin|This is an open label, dose-seeking phase 1/2 study using escalating doses of LURBINECTEDIN administered intravenously with fixed doses of IPILIMUMAB and NIVOLUMAB administered intravenously.
223643706|NCT02791672|BEHAVIORAL|Discharge within 24 hours|If both the physician and patient have no concerns within 24 hours of a Latissimus Dorsi Flap breast reconstruction the patient will be discharged home and enrolled in the cohort group.
223643707|NCT00460616|DRUG|Cabergoline|According with our previous studies, in the patients with microprolactinoma and in those with non-tumoral hyperprolactinemia, cabergoline treatment was administered orally at a starting dose of 0.25 mg twice weekly for the first two weeks and then 0.5 mg twice weekly. After 2 months of treatment, dose adjustment was carried out every 2 months on the basis of serum PRL suppression.
224230902|NCT02066584|OTHER|Sibling oocyte incubation|
224319717|NCT04603326|PROCEDURE|Lumbar Puncture|Lumbar Puncture for collection of Cerebrospinal Fluids
224319718|NCT04324021|BIOLOGICAL|Emapalumab|I.v. infusion every third day
224319719|NCT04324021|BIOLOGICAL|Anakinra|Daily i.v. infusion
224323406|NCT04267848|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223643708|NCT03399188|PROCEDURE|Fecal microbiome transplantation|Fecal microbiota transplantation will be performed through colonoscopy to the IBD patients. Donor feces will be extensively screened for other diseases. Colonoscopy will be done at FMT center of Severance Children's Hospital twice with a month of duration. Recipients will be admitted the day before colonoscopy, and they will be discharged after a day of observation.
224230903|NCT04987177|OTHER|Workload of Manual Wheelchair Propulsion|Participants will complete 20 one-minute manual wheelchair propulsion bouts. Each one minute propulsion bout will be followed by a 2 minute rest period. Each propulsion bout will be at a different workload. After every 10 propulsion bouts, participants will be provided with an extended rest period (5 to 30 minutes). For each participant, the maximum workload to be tested is based on their estimated maximum workload. Estimate maximum workload is based on the HR-Workload relationship documented during a prior sub maximal test to 80% of age adjusted maximum heart rate.
224230904|NCT02494245|OTHER|STARFISH|The intervention group will take part in a four month physical activity intervention using the STARFISH app with the aim of increasing physical activity by 3000 steps per day. Participants will be provided with a smartphone for the intervention. Participants will work in groups of four but each participant will have their own individualised step count target, based on their baseline step count. If the participant reaches their step count target on at least five days of the week, then their target will be increased by 5% for the following week, up to a maximum increase of 3000 steps above baseline. Where a participant fails to reach their step count target, it remains unchanged for the following week.
224230905|NCT05297747|DIAGNOSTIC_TEST|Apical periodontitis|Radiography of the patients were taken. Blood samples were collected from those patients.
224230906|NCT05297747|DIAGNOSTIC_TEST|Chronic periodontitis|Radiography of the patients were taken. Blood samples were collected from those patient
224230907|NCT04753736|PROCEDURE|Intrauterine administration of hCG-activated peripheral blood mononuclear cells|Intrauterine administration of hCG-activated peripheral blood mononuclear cells
224230908|NCT00028353|DRUG|GTX-006 (Acapodene)|
224230909|NCT00367588|BEHAVIORAL|Low bacterial diet|
224230910|NCT04771819|DEVICE|SWIS|Bilateral experimental blister wounds on each forearm. The wound on one arm is rinsed with experimental solution (SWIS) and the contralateral wound on the other arm is rinsed With Saline as a comparator.
224230911|NCT01104857|PROCEDURE|diaphragm muscle biopsy|Biopsy is obtained for biochemical analysis
224230912|NCT01104857|PROCEDURE|Diaphragm muscle biopsy|Biopsy is obtained for biochemical analysis
224230913|NCT03750474|DIAGNOSTIC_TEST|magnetic resonance elastography and shear wave elastography|magnetic resonance elastography and shear wave elastography of the back muscles
224230914|NCT00004812|BEHAVIORAL|Exercise|
224230915|NCT03405285|DEVICE|Connected Catheter|The Connected Catheter is a fully internal, urethral-indwelling urinary prosthesis designed for improved bladder management in males with urinary retention disorders requiring catheterization, including neurogenic lower urinary tract dysfunction (NLUTD - e.g. due to spinal cord injury). The CoCath is a sterile, single-extended-use device that resides fully internally to the male lower urinary tract (urethra + bladder neck) for an intended service life of up to 29 days per Catheter.
224230916|NCT05164809|DEVICE|Application of novel electrodes|Application of novel electrodes since 2017 for the dissection of extremity tumors in tumororthopedics
224230917|NCT05269654|DEVICE|injectable poly-L-lactic acid|Injectable biostimulant for volume loss
224230918|NCT05269654|OTHER|Normal Saline|Sham Comparator
224230919|NCT00698425|OTHER|EyeGate II® Drug Delivery System|Transscleral iontophoresis using citrate buffer delivered by EyeGate II® Drug Delivery System
224230920|NCT00698425|DRUG|Citrate buffer|Transscleral iontophoresis using citrate buffer delivered by EyeGate II® Drug Delivery System
224230921|NCT01050231|DEVICE|Functional/ Multi-joints activities|Subjects participated in 4 weeks of robotic training with the device: BONES (Biomimetic Orthosis Neurorehabilitation for Elbow and Shoulder), 3 days per week, 1 hour per day with the robotic exercise program focusing on functional tasks such as cleaning the windows, driving a steering wheel, grocery shopping, etc.
224230922|NCT01050231|DEVICE|Individual Joint Training|Subjects participated in 4 weeks of training with the robotic device BONES, 3 days per week, 1 hour per day with a robot-assisted exercise program. The robotic exoskeleton assists in arm and hand movements focusing on one joint at a time.
224230923|NCT03859609|PROCEDURE|Spinal Fusion|Spinal alignment was evaluated according to two different score-systems
224323407|NCT04267848|OTHER|Observation Activity|Undergo observation
223643709|NCT02425943|DEVICE|injectable poly-L-lactic acid Sculptra Aesthetic|
223643710|NCT05294458|DRUG|cotadutide solution for injection|cotadutide solution for injection
223643711|NCT00585026|DEVICE|D-28 bifocal lenses and frame|
223643712|NCT00585026|DEVICE|Progressive addition computer lenses and frame|
223643713|NCT04843657|BEHAVIORAL|Observation for symptom distress|Observation for symptom distress
223643714|NCT04833218|DRUG|Propranolol|Test of catecholamines level in moderate traumatic brain injury
223643715|NCT05397158|PROCEDURE|single administration of low dose polyethylene glycol|"Patients in single administration of low dose polyethylene glycol (PEG) group: Take 30ml lactulose and 2L PEG.~Patients in control group: Take 4L PEG."
223643716|NCT05172908|DRUG|Dexamethasone|"5 mg dexamethasone in a 50 ml syringe containing normal saline will be infused within 15 minutes.~The syringe will be prepared by a nurse outside the research team and the Study participants, care providers, and data collectors will be blinded to the allocation throughout the study.~Global Quality of Recovery- 15 score and standard pain follow-up scores will be noted."
223643717|NCT05172908|DRUG|Saline|"A 50 ml syringe containing normal saline will be infused within 15 minutes. The syringe will be prepared by a nurse outside the research team and the study participants, care providers, and data collectors will be blinded to the allocation throughout the study.~Global Quality of Recovery- 15 score and standard pain follow-up scores will be noted."
223643718|NCT03714880|DRUG|Mifepristone 200 MG|Ingestion of study medication vs placebo
223643719|NCT03714880|DRUG|Placebo Oral Tablet|Ingestion of study medication vs placebo
223643720|NCT05614596|OTHER|CT guided and Flouroscopic guided injection of corticosteroid and local anathesia|Patients will be grouped into two groups, the first group (Group A) included patients who were subjected to fluoroscopic guided injection, and the second group (Group B) will include patients who were subjected to CT guided injections.
223643721|NCT05103046|DRUG|UCT-03-008|Orally available kinase inhibitor
223643722|NCT03207061|DIAGNOSTIC_TEST|3D Ultrasound|A 3D ultrasound will be performed for all patients presenting to the clinic for suspected endometrial cancer (in addition to routine standard of care)
223643723|NCT05275504|DRUG|TT-01488|TT-01488 tablet will be administered orally once daily per protocol defined schedule.
223643724|NCT00531544|DRUG|SU011248|SU011248 Expanded Access Protocol for Systemic Therapy
223643725|NCT02612519|DEVICE|Alfapump|Implantation of Alfapump
223643726|NCT02612519|DEVICE|TIPS|Implantation of TIPS
223643727|NCT01811966|OTHER|Volume|
223643728|NCT01811966|OTHER|Control|
223643729|NCT00530972|DRUG|Peginterferon alfa-2a plus ribavirin adjusted to body weight|PegInterferon 180 mcg/week, Adjusted body weight Ribavirin (1000 mg \<75 kg, 1200 mg \>75 kg)
223643730|NCT03507569|DRUG|RO7017773|RO7017773 will be administered orally. The doses to be tested will be determined by review of PET scan, PK, and safety results from the previous dose level.
223643731|NCT03507569|OTHER|[11C] Ro15-4513|At the start of each PET scan, participants will receive an intravenous dose of the radiolabeled tracer \[11C\]Ro15-4513.
223643732|NCT05765578|BIOLOGICAL|Moderna COVID-19 Vaccine|Sterile liquid for injection. Intervention not administered through this study.
223643733|NCT05765578|BIOLOGICAL|Moderna mRNA1273.222 Booster|Sterile liquid for injection. Intervention not administered through this study.
223643734|NCT05765578|BIOLOGICAL|Pfizer COVID-19 Vaccine|Sterile liquid for injection. Intervention not administered through this study.
223643735|NCT05765578|BIOLOGICAL|Moderna 2023 Updated COVID-19 vaccine (XBB.1.5)|Sterile liquid for injection. Intervention not administered through this study.
223643736|NCT05765578|BIOLOGICAL|Pfizer 2023 Updated COVID-19 vaccine (XBB.1.5)|Sterile liquid for injection. Intervention not administered through this study.
223643737|NCT01050504|OTHER|Cytology Specimen Collection Procedure|Correlative studies
223643738|NCT01050504|OTHER|Laboratory Biomarker Analysis|Correlative studies
223643739|NCT03313037|BIOLOGICAL|Multivalent|Pneumococcal conjugate vaccine
223643740|NCT03313037|BIOLOGICAL|Prevnar 13|Pneumococcal conjugate vaccine
223643741|NCT03313037|BIOLOGICAL|PPSV23|Pneumococcal polysaccharide vaccine
223643742|NCT03313037|OTHER|Saline|Placebo
223643743|NCT04664127|DRUG|Kagocel+Valacyclovir|"Group 1-patients with simple severe herpes (HSV-infection orolabial and / or genital localization) treatment \[Valacyclovir + Kagocel ° \] (n= 25).~Treatment: Valacyclovir, 1000 mg orally (2 tablets of 500 mg): 1 time per day for at least 4 months continuously (the rate of suppressive therapy). \* Kagocel®, 24 mg orally (2 tablets of 12 mg): 3 times per day, 5 days continuously.~\* - During the study the minimum duration of Valacyclovir suppressive therapy in instruction for medical use that drag was changed from 4 (what was using in our reserch) to 6 months, and the optimal duration of continuous antiviral therapy with PG was changed from 6 to 12 months"
223643744|NCT04664127|DRUG|Valacyclovir|"Group 2 -patients with simple severe herpes (HSV-infection orolabial and/or genital localization) receiving treatment \[Valacyclovir\] (n= 20).~Scheme of treatment: Valacyclovir, 1000 mg orally (2 tablets of 500 mg): 1 time per day for at least 4 months continuously (a course of suppressive therapy)\*.~\* - During the study the minimum duration of Valacyclovir suppressive therapy in instruction for medical use that drag was changed from 4 (what was using in our reserch) to 6 months, and the optimal duration of continuous antiviral therapy with PG was changed from 6 to 12 months."
223643745|NCT03806764|DIAGNOSTIC_TEST|Blood sampling|Blood sampling from prospective study participants will be taken for immune functions measurements
223643746|NCT06413082|DRUG|Torasemide|The assignment to each drug will be carried out randomly in each genotypic group with the aim of reaching the same number of patients treated with the two drugs in the different genotypic groups
223643747|NCT06413082|DRUG|Spironolactone|The assignment to each drug will be carried out randomly in each genotypic group with the aim of reaching the same number of patients treated with the two drugs in the different genotypic groups
223765746|NCT05854875|PROCEDURE|Laparoscopic Roux en Y gastric bypass with fundus resection|Laparoscopic RYGBP included the creation of a small gastric pouch, with a 200cm biliopancreatic limb and a 150cm alimentary limb. Fundus resection is further applied in this arm.
223765747|NCT06347081|PROCEDURE|Nd- YAG laser at 532nm wavelength|Nd-YAG laser at 532nm wavelength every 2 weeks for 14 sessions. patients will also receive standard medical care, nursing, physiotherapy
223765748|NCT02282696|OTHER|Questionnaire, focus group participation|participants of the quantitative part of the study are asked to fill in a questionnaire, participants of the qualitative part are asked to participate in a focus group interview.
224230924|NCT02286518|DRUG|TAK-114 10 mg capsule|
223643748|NCT00000258|DRUG|Nitrous oxide 10% & placebo|
223643749|NCT00000258|DRUG|Nitrous oxide 20% & placebo|
223643750|NCT00000258|DRUG|Nitrous oxide 30% & placebo|
223643751|NCT00000258|DRUG|Nitrous oxide 40% and placebo|
223643752|NCT02379091|DRUG|Namilumab|Namilumab subcutaneous injection
223643753|NCT02379091|DRUG|Placebo|Namilumab placebo-matching subcutaneous injection
223643754|NCT02379091|DRUG|Methotrexate|Methotrexate tablets
223643755|NCT02379091|DRUG|Folic/folinic acid|Folic/folinic acid tablets
223643756|NCT06503263|DRUG|Zanubrutinib plus Lenalidomide as Maintenance Therapy|Patients were treated by Zanubrutinib(160mg po bid d1-28) plus Lenalidomide(25mg po qd d1-14) as maintenance therapy until 2 years post chemotherpay
223643757|NCT06373965|BEHAVIORAL|Online to offline counseling|"* Online registration and risk assessment: Users complete an onboarding process comprised of creating an account, entering demographic data, customizing settings, and completing the baseline risk assessment.~* HIVST kit order, management, and monitoring: The platform will allow users to request HIVST kits via standard mail or self-pickup at user-preferred sites (e.g., LGBT-friendly clinics). After completing the mandatory section of the questionnaire and selecting a delivery option, a random personal identification number will be assigned by the system, which will be used to track future HIVST requests, collect HIVST results, and monitor subsequent linkage to further testing and HIV care.~* eHIVST and O2O linkage to HIV clinical services: After unsealing the test kit, participants will find a reminder card to schedule their O2O pre- and post-test e-counseling appointment."
224230925|NCT02286518|DRUG|TAK-114 matched placebo|
224230926|NCT01824251|DRUG|NPB-01|
224230927|NCT03650933|BIOLOGICAL|G-CHOP|6 cycles(each cycle is 3 weeks)
223643758|NCT05610345|PROCEDURE|Placental Blood Drainage|Immediately after vaginal delivery following delayed cord clamping and cutting of the cord, the cord will be unclamped and blood will be drained from the placenta until cessation of flow.
223643759|NCT05610345|PROCEDURE|Placenta Blood Not Drained|Placenta Blood Not Drained
223643760|NCT06188637|DRUG|Ozanimod Oral Capsule|open label ozanimod
223643761|NCT03964831|DEVICE|P200TxE|The P200TxE ophthalmoscope provides widefield scanning laser ophthalmascope (SLO) fundus imaging.
223643762|NCT03964831|DEVICE|P200DTx|The P200DTx ophthalmoscope provides widefield scanning laser ophthalmascope (SLO) fundus imaging.
223643763|NCT05056935|DRUG|LB1148|A total of 700 mL of LB1148 will be administered orally as a split dose before surgery.
223643764|NCT05056935|DRUG|Placebo|A total of 700 mL of placebo will be administered orally as a split dose before surgery.
224230928|NCT03650933|BIOLOGICAL|R-CHOP|6 cycles(each cycle is 3 weeks)
223643765|NCT03623165|DEVICE|Cordella™ Heart Failure System|The Cordella™ Heart Failure System electronically transfers communications and data from a set of medical devices in a heart failure patient's home to a database for storage, retrieval, and display to healthcare providers.
223643766|NCT00763880|DRUG|Lidocaine|2% Lidocaine (no epinephrine) in the dose of 2.5 mg/kg to a maximum of 10mL will be instilled once into the fracture site in the form of a hematoma block.
223643767|NCT00763880|DRUG|Saline|Volume of normal saline equivalent to providing 2.5mg/kg of 2% lidocaine, to a maximum of 10mL.
223643768|NCT04335006|DRUG|Carelizumab|Participants receive SHR-1210 intravenously (IV)
223643769|NCT04335006|DRUG|Nab-paclitaxel|administered intravenously every 4-week cycle
223643770|NCT04335006|DRUG|Apatinib|administered orally every 4-week cycle
223643771|NCT03656289|DRUG|Etonogestrel 68Mg Implant|Participants will have an etonogestral contraceptive implant (NEXPLANON) placed sub-dermally just under the skin at the inner side of the non-dominant upper arm.
223765749|NCT00170079|BEHAVIORAL|Smoking Cessation Intervention|"A common approach to increasing long-term adherence and control of chronic medical problems such as hypertension in both general and preventive medicine is the concept of step care. The purpose of this study is to evaluate the long-term efficacy of a step care model for smoking cessation that is disseminable in primary care settings. With that introduction, we propose the following specific aims:~Aim 1: To enroll approximately 400 adult cigarette smokers recruited mainly from primary care settings;~Aim 2: To randomize these participants to: 1) State of the Art Smoking Cessation + Recycling or 2) State of the Art Smoking Cessation + Step Care; and~Aim 3: To evaluate the long-term (24 months post-randomization) relative success of the interventions. It is predicted that long-term cessation rates will be significantly higher in the step care condition."
224230929|NCT05770258|DEVICE|The novel electrolyzed water spray|Study staff will use the novel electrolyzed water spray device and spray for approximately 5 minutes on the participant's diseased area until half a bottle (200ml) of water is used. The patients use electrolyzed water to treat the diseased area, two times a day, for 10 days. The trial consists of 10 study visits (day 1-day 10). The relief of mild periodontitis evaluation and adverse event assessments will be performed at each visit. Safety analysis will be assessed based on the reports of adverse events during the study.
224230930|NCT05705583|OTHER|Other: Blood and Urine Collection|Blood and Urine Collection
224230931|NCT01983020|DRUG|Lidocaine|
223643772|NCT00633113|PROCEDURE|MPPA|\- Medial Parapatellar Arthrotomy
223643773|NCT00633113|PROCEDURE|SV|\- Subvastus Technique
223643774|NCT05261646|DRUG|Hetrombopag|"Stage 1： Hetrombopag lower dose； Hetrombopag higher dose~Stage 2:~Hetrombopag X mg (dose to be determined based on Stage 1 results)"
223643775|NCT05261646|DRUG|Matching placebo|Matching placebo（Stage 1；Stage 2）
223643776|NCT02530515|BIOLOGICAL|Ex Vivo-activated Autologous Lymph Node Lymphocytes|Given IV
223643777|NCT02530515|OTHER|Laboratory Biomarker Analysis|Correlative studies
223643778|NCT05294549|OTHER|Caring Contact|The Caring Contact intervention is an email with messages of hope, support and resource information sent to patients post-discharge from psychiatric hospitalization.
223643779|NCT06125600|OTHER|Clustering of people living with obesity using behavioural questionnaires|In a cross-sectional analysis using the online Aviitam® platform, a cluster analysis was carried out in overweight/obese adults. The following questionnaires were studied: Hospital Anxiety and Depression Scale (HADS), Perceived Stress Scale (PSS), Epworth Sleepiness Scale, Morin's Insomnia Scale, Intuitive Eating Scale-2 (IES-2), Binge Eating Scale (BES), Ricci/Gagnon Physical Activity questionnaire and EQ-5D Quality-of-Life questionnaire.
223643780|NCT04013477|DRUG|DA-5207|DA-5207 Transdermal Delivery System
223643781|NCT04013477|DRUG|Donepezil Hydrochloride|donepezil HCl 10mg QD
223643782|NCT04161157|BEHAVIORAL|Pathways|Goal-setting intervention to help patients identify personal values, value-consistent goals, and ways to pursue goals and address goal obstacles. Although potential refinements may occur based on aim 1 (refining procedures and content with 6 patients), Pathways is designed to consist primarily of 2 in-person sessions (\~30-60 minutes) delivered when patients are in clinic for cancer treatment, with supporting phone calls and contact in between sessions.
223643783|NCT06231589|DEVICE|Sperm Selection|Sperm selection using physiological intracytoplasmic sperm injection (PICSI dish) or magnetic-activated cell sorting (MACS) for selecting sperm with high-quality, better morphology and lower DNA fragmentation.
223643784|NCT00361348|DRUG|Palifermin|
223643785|NCT00361348|DRUG|Heparin|
223643786|NCT00658385|GENETIC|GCSF, Central venous line placement, Stem cell Collection (leukapheresis)|"Daily injections under the skin of a GCSF. This is done for 5 to 6 days. On days 1, 3,5, and if need on day 6. To collect stem cells, we need good access to this blood. If the patient has good veins, we do this by placing an IV on each one of their arms. The peripheral blood stem cell collection is usually an outpatient procedure and takes about 3 to 4 hours. You will have blood work and a physical exam on days one, three, and five while you are getting GCSF.~These will be done again 24 hours after your stem cells are collected."
224230932|NCT01983020|DRUG|Ketamine|
224230933|NCT01983020|OTHER|Saline|
224230934|NCT00588393|DRUG|FolateScan (Technetium Tc 99mEC20)|0.1 mg. of EC20 labeled with 20-25 mCi of technetium-99m followed by FolateScan
224323408|NCT04267848|DRUG|Paclitaxel|Given IV
224323409|NCT04267848|BIOLOGICAL|Pembrolizumab|Given IV
224323410|NCT04267848|DRUG|Pemetrexed Disodium|Given IV
223643787|NCT02885701|OTHER|No Splint|The no splint group received a soft dressing consisting of an occlusive petroleum gauze strip (Xeroform, Mansfield, MA) over the wound, one folded 4x4 gauze, and a single wrap of roll gauze around the hand, and the wrist was placed and secured by a Coban wrap (3M, St. Paul, MN). The dressing permitted wrist and finger motion. Patients were further instructed to remove the dressing at five days and place an adhesive bandage (Band-Aid, Johnson \& Johnson, New Brunswick, NJ) over the incision.
223643788|NCT02885701|OTHER|Removable Splint|The removable splint group received a V-strap Wrist support (Medical Specialties, Inc., Charlotte, NC) placed over the identical soft dressing that was placed on the no splint group. The cock-up wrist splint was designed to keep the wrist fixed in a 20 degree extended wrist position. Patients were instructed to wear the splint for comfort as needed during day and night. While the patient was wearing the cock-up splint, only finger motion was permitted. Wrist motion was permitted when the cock-up splint was removed.
223643789|NCT02885701|OTHER|Non-removable Splint|The plaster non-removable splint group received an occlusive petroleum gauze strip placed over the wound, followed by a 4X4 gauze, and a Webril cotton roll wrap (Covidien, Inc., Covidien, Ireland). A 4- inch, 15-layer thick plaster splint was placed across the volar wrist and molded to keep the wrist in approximately 20 degrees of extension allowing full digital range of motion (ROM). The splint was to be kept dry and not removed by the patient.
223643790|NCT03752567|OTHER|Follow up|like group descriptions
223643791|NCT02012413|DEVICE|PST - Pulsed Signal Therapy|PST application is a painless over-the-skin eletromagnetic field application. 9 sessions of application of electromagnetic therapy - PST - during 60 minutes
223643792|NCT02012413|DEVICE|Placebo - Sham PST|"Placebo PST will be performed by applying the same device over the patient knee. The machine is not applying the PST but it appears to be on. In this way, patients are blinded to the intervation.~9 sessions of application of Sham PST - during 60 minutes"
223643793|NCT02864290|DRUG|ASP1235|intravenous (IV) infusion
223643794|NCT04815824|BEHAVIORAL|Exercise Mode|Stationary cycling or treadmill walking
223643795|NCT05864391|DRUG|AZD7503|Each participant is expected to be in the study for approximately 24 weeks, including a screening period of up to 28 days, a 12-week study intervention period, and a follow-up visit at week 18 (10 weeks following the final dose). Participants will be randomly assigned in a 3:1 ratio to receive AZD7503 or placebo. Study intervention will be administered via subcutaneous injection.
223643796|NCT06654154|DIAGNOSTIC_TEST|variation of serum level vitamine B12|"There will be no specific visit to the study. Follow-up in consultation will be done by your referring doctor. A determination of the serum level of vitamin B12 will be carried out at inclusion, during a consultation where the pathology is in remission (during the classic assessment of follow-up under tocilizumab, left to the discretion of the patient's referring doctor. ). It will also be necessary to carry out, in addition to the classic assessment left to the discretion of the patient's doctor, a determination of the serum level of vitamin B12 in the event of clinical suspicion of infection or an outbreak of MAI/I.~The determination of serum vitamin B12 requires the collection of an additional tube of 300 μl of venous blood but no additional venipuncture"
223643797|NCT06586034|BEHAVIORAL|Impacto (Mobile App)|This is the mobile app to be developed and evaluated in this project. It is designed for both English and Spanish languages and is culturally tailored for Hispanic/Latino/Latinx individuals who smoke. Impacto will be developed for both iOS and Android platforms. The mobile app aims to aid smoking cessation by targeting elevated anxiety sensitivity.
223643798|NCT06594458|PROCEDURE|Observation of newborn with respiratory distress in the delivery room|Newborn manifesting tachypnea or respiratory distress at birth (that responds to supplementary oxygen with FiO2 \<30% and without the need for mechanical ventilation) are placed in a preheated incubator with the required oxygen concentration (if necessary) and carefully monitored by medical and nursing clinicians. A clinical evaluation will be carried out every 15 minutes, with the detection of vital parameters. In case of clinical improvement and suspension of oxygen therapy, the newborn will be transferred to the Neonatal Observation Ward to perform multiparameter monitoring of vital signs up to 6 hours of life and then be reunited with the mother. In case of clinical worsening, a bedside thoracic ultrasound will be carried out and depending on the result and the lung ultrasonography score, it will be evaluated whether to continue the observation in the delivery room or to admit the newborn in the Neonatal Care, Neonatal Sub-Intensive Care or Neonatal Intensive care Units
223643799|NCT06600984|DEVICE|whole body vibration|On a vibration platform, the children went into a complete squat. The device was calibrated at a frequency of 30 Hz, an amplitude of 2 mm, and a duration of 5 minutes. After the vibration was turned on, the children were told to stay in the squatting position and to report any discomfort that could occur. The vibration automatically shut off after five minutes. The children then rested for a minute. Next, under the identical conditions as for the squatting position, they were instructed to stand on the vibration platform for five minutes with the therapist\&#39;s assistance. Consequently, WBV was applied for a total of 10 minutes during each session.
223643800|NCT06600984|OTHER|designed physiotherapy program|structured therapeutic exercise program that included neurodevelopmental approaches, balance exercises, milestone facilitation, stretching exercises, and postural reaction facilitation. The program was conducted for one hour each day, three days a week.
223643801|NCT06589336|OTHER|Dietary changes via Instacart vouchers|Instacart will provide consumers with the dignity of choice to shop at preferred retail stores, which is key for our behavioral change strategy. Delivery and service fees will be waived for patients, so 100% of the vouchers will be applied to groceries (all food products excluding alcohol and tobacco). The investigators will use a custom study store front with an integrated website and email option.
223765750|NCT05390203|DIAGNOSTIC_TEST|Penile duplex study, Hormonal Assay (Total Testosterone, Prolactin and E2)|we will do penile duplex and hormonal profile preoperatively and 6 months postoperatively.
223765751|NCT04001569|DRUG|AZD8186 in combination with paclitaxel|"Phase 1b is planned for a 4-stage dose level and the traditional 3+3 design is applied. The RP2D will be determined based on the MTD and toxicity profiles.~In phase 2 part, RP2D from the phase 1b part will be applied.~* AZD8186 ( )mg po bid, 5 days on, 2 days off~* Paclitaxel ( )mg/m² on D1,8,15 every 4 weeks"
223765752|NCT00279565|DRUG|buprenorphine|
223765753|NCT00279565|DRUG|methadone|
223765754|NCT00279565|DRUG|pegylated interferon alfa-2b plus ribavirin|
223765755|NCT05495412|OTHER|Rebound therapy|Exercise therapy delivered twice weekly for 6 weeks, during Phase B of an ABA single case study design.
224323411|NCT04267848|OTHER|Questionnaire Administration|Ancillary studies
223765756|NCT05880433|DEVICE|NIRS(INVOS 5100; Covidien Somanetics, Troy, MI|NIRS (Near Infrared Spectroscopy) is a non-invasive, bedside device that measures the concentration of oxygenated and deoxygenated hemoglobin in tissue, providing information about tissue oxygenation. Its working mechanism is based on the ability of light with wavelengths between 700-1000 nm to penetrate up to 8 cm into the skin and brain tissue. It offers continuous information about tissue oxygenation in different regions using probes attached to the skin. While pulse oximeters indicate arterial oxygen saturation, they are insufficient in detecting tissue-level hypoxia. Therefore, NIRS, being a painless method, is frequently used in the monitoring of newborns in the intensive care unit.
223643802|NCT06589336|OTHER|Dietary changes via access to Mid-Ohio Farmacy|Mid-Ohio Farmacy will provide healthy food provisions through a network of food banks with fresh produce and other items.
223643803|NCT06589336|OTHER|Behavior changes via access to Health Impact Ohio Hub|Health Impact Ohio Hub is a regional coordination entity that has connections with community care agencies that employ community health workers to assess social needs and make connections to resources to address social needs. The community health workers will conduct an initial needs assessment, and guide the participant through appropriate care pathways to address social needs.
223765757|NCT04204018|OTHER|Experimental Arm|"* First, these providers will receive educational materials (e.g. a slide deck) meant to mimic what physicians will receive in the real-world market as they learn about the Progenity technology.~* Second, within each of their four cases, intervention-arm physicians only will receive simulated test results from the Progenity PE test at the clinically-appropriate point in each case."
223765758|NCT03736824|PROCEDURE|endoscopy|All endoscopy was performed by qualified gastroenterologists or endoscopic physicians in Renji hospital,Shanghai Jiaotong University School of Medicine.
223643804|NCT06589336|OTHER|Behavioral nutrition counseling|All dietary recommendations will be individualized and informed by existing guidelines to improve diet quality and cardiovascular health through the Mediterranean Diet.
223643805|NCT06589336|OTHER|Cooking classes|Registered dietician nutritionists will also lead cooking demonstrations every 2 weeks, focused on culinary education and building engagement among SUSTAIN participants.
223643806|NCT06589336|OTHER|Dietary changes to Delivery fees|Delivery fees will be supported for SUSTAIN participants.
223643807|NCT06590545|DRUG|KYV-101, an autologous fully-human anti-CD19 CAR T-cell immunotherapy|A dosage of 1x10\^8 KYV-101 CAR+ T cells will be administered intravenously as a single infusion.
223643808|NCT06614881|DRUG|Dexmedetomidine Injection [Precedex]|Dexmedetomidine (Precedex, 100 µg/ml) was provided as an intravenous (IV) loading dose of 1 µg/kg over 10-min
223643809|NCT06614881|DRUG|Dexmedetomidine in 0.9 % NaCl 1,000 Mcg/250 mL (4 Mcg/mL) INTRAVEN INFUSION BOTTLE (ML)|Dexmedetomidine infusions were prepared to provide 0.5 µg/kg/h
223765759|NCT04936958|OTHER|patients having had an osteomyelitis since 2017|description of osteomyelitis and their management
223765760|NCT00064246|BIOLOGICAL|rituximab|Given IV
224230935|NCT06121869|DIETARY_SUPPLEMENT|Placebo|Participants will supplement daily for 10 weeks with 2 grams rice flower placebo in capsule form. On training days, participants will consume their assigned supplement within 60 minutes of completing their workout. On non-training days, participants will consume their assigned supplement with their first meal of the day. All doses will be consumed with 8-12 ounces of water.
224230936|NCT06121869|DIETARY_SUPPLEMENT|Leucine|Participants will supplement daily for 10 weeks with 2 grams leucine in capsule form. On training days, participants will consume their assigned supplement within 60 minutes of completing their workout. On non-training days, participants will consume their assigned supplement with their first meal of the day. All doses will be consumed with 8-12 ounces of water.
223643810|NCT06614881|DRUG|Dexmedetomidine in 0.9 % NaCl 1,000 Mcg/250 mL (4 Mcg/mL) INTRAVEN INFUSION BOTTLE (ML)|Dexmedetomidine infusions were prepared to provide 0.7 µg/kg/h
223643811|NCT06614881|DRUG|Dexmedetomidine in 0.9 % NaCl 1,000 Mcg/250 mL (4 Mcg/mL) INTRAVEN INFUSION BOTTLE (ML)|Dexmedetomidine infusions were prepared to provide 1.1 µg/kg/h
223643812|NCT06614881|DRUG|Normal saline|loading dose of saline was injected 10-min before induction of anesthesia.
223643813|NCT03375788|DRUG|Tesamorelin|Tesamorelin F4 formulation 1.4mg daily
223765761|NCT00064246|RADIATION|indium In 111 ibritumomab tiuxetan|Given IV
224230937|NCT06121869|DIETARY_SUPPLEMENT|Dileucine|Participants will supplement daily for 10 weeks with 2 grams dileucine (RAMPS, Ingenious Ingredients, TX, USA) in capsule form. On training days, participants will consume their assigned supplement within 60 minutes of completing their workout. On non-training days, participants will consume their assigned supplement with their first meal of the day. All doses will be consumed with 8-12 ounces of water.
223765762|NCT00064246|RADIATION|yttrium Y 90 ibritumomab tiuxetan|Given IV
223765763|NCT04174313|DIAGNOSTIC_TEST|CT scan|"Mechanical variables and PaO2/FiO2 were registered daily for 14 days or until initiating assisted ventilation. These data were obtained in passive mechanical conditions.~Ventilator-induced lung injury vortex was defined as a progressive increase in driving pressure (ΔP) as Vt remained constant or even decreased.~Refractory hypoxemia was defined as PaO2/FiO2 \<100 despite the optimization of mechanical ventilation and prone positioning."
224230938|NCT01309919|DEVICE|IUD|Placement of the IUD after delivery (vaginal or cesarean birth), either immediately (within 10 minutes of placental delivery) or delayed (within 48 hours of delivery). Subjects will also keep a bleeding diary for three months postpartum.
223765764|NCT05183685|PROCEDURE|telecare consultation|Participants will use zoom to communicate with the doctors in clinic.
223765765|NCT05183685|PROCEDURE|Usual face to face consultation|Participants will have face-to-face communication with the doctors in clinic.
224230939|NCT01309919|OTHER|Diary|Subjects will keep a bleeding diary for three months
224230940|NCT01018888|DEVICE|Auro KPro (Keratoprosthesis)|Front plate with optical cylinder, a back plate and a titanium ring to hold the complex together
223643814|NCT03375788|DRUG|Identical Placebo|Placebo injection daily
223643815|NCT06993454|OTHER|Magnetic Resonance Liver Assessment|Liver fat will be measured by MR imaging to assess level of hepatic steatosis.
223643816|NCT06993454|OTHER|Bike Exercise VO2max|Maximal fitness measured by cycle ergometer.
223643817|NCT06993454|OTHER|DEXA|Measure body composition (fat and lean body mass).
223643818|NCT06992245|DIAGNOSTIC_TEST|DW-MRI|Predict changes in ovarian diffusion using DW-MRI scan
223643819|NCT06590155|DRUG|Erythropoietin|the role of erythropoietin in improving neonatal hypoxic ischemic encephalopathy
224230941|NCT06347497|DRUG|Zonisamide 50 MG|The arm will include 300 migraine patients diagnosed according to ICHD3-beta criteria. We will assess The change in migraine days per 28 days, the number of migraine days after three months of treatment, and the percentage of patients who achieved ≥ 50% reduction in the monthly headache days frequency compared to the baseline frequency (14). HIT-6 score reduction in each group after three months of treatment. The safety of zonisamide was evaluated by monitoring and documenting treatment-emergent adverse events (TEAE) in patients through regular follow-up procedures for three months.
224230942|NCT06347497|DRUG|Topiramate 50 MG|The arm will include 300 migraine patients diagnosed according to ICHD3-beta criteria. We will assess The change in migraine days per 28 days, the number of migraine days after three months of treatment, and the percentage of patients who achieved ≥ 50% reduction in the monthly headache days frequency compared to the baseline frequency (14). HIT-6 score reduction in each group after three months of treatment. The safety of topiramate was evaluated by monitoring and documenting treatment-emergent adverse events (TEAE) in patients through regular follow-up procedures for three months.
224230943|NCT04875234|DEVICE|Clear-K Low Vision Aid Treatment|A Clear-K Low Vision Aid Device is used to produce small corneal shape and refraction changes in order to redirect light onto functional areas of the retina.
224230944|NCT00319449|DRUG|Ezetimibe|10 mg ezetimibe, orally, daily for 6 weeks, added to ongoing treatment with 10 mg atorvastatin
224230945|NCT00319449|DRUG|Placebo|10 mg/day matching placebo to ezetimibe, orally, daily for 6 weeks, added to ongoing 10 mg atorvastatin
224230946|NCT00319449|DRUG|Atorvastatin 10 mg|10 mg/day atorvastatin, orally, (ongoing treatment in participants)
224230947|NCT02102490|DRUG|Abemaciclib|Administered orally
223643820|NCT06588959|OTHER|validity and reliability study|Determination of strength, endurance and exercise capacity of the upper extremities is an important issue in scleroderma management. 6PBRT, which is one of the tests serving this purpose, has been found to be valid and reliable in patients with chronic obstructive pulmonary disease and asthma, but when the literature is reviewed, it is seen that 6PBRT has not been studied in patients with scleroderma. This study was planned as a non-interventional safety study. The study will investigate the validity and reliability of 6PBRT in patients with scleroderma. In this context, the test will be performed 2 times with a 1-hour rest break. Dyspnea and fatigue will be assessed using the Borg scale and muscle oxygenation, heart rate and blood pressure will be recorded before and after 6PBRT. The level of dyspnea and fatigue and baseline values of heart rate will be checked before the second trial to ensure patients are stable. All assessments will be performed by the same physiotherapist.
223643821|NCT05156385|BIOLOGICAL|Blood sample for the determination of antihypertensives or their metabolites.|15 ml of Blood sample for the determination of antihypertensives or their metabolites
223643822|NCT05156385|BEHAVIORAL|Questionnaire on sexual activity|Questionnaire on sexual activity in women
223643823|NCT05156385|BEHAVIORAL|Scale on hospital anxiety and depression|Scale on hospital anxiety and depression to detect anxious and depressive symptoms (14 questions)
223643824|NCT05156385|BEHAVIORAL|Morisky Questionaire|anti-hypertensive medication compliance questionnaire
223643825|NCT06991985|DIAGNOSTIC_TEST|Enzyme-linked immunosorbent assay|Serum STN and C4 levels were detected
223643826|NCT06527950|OTHER|no intervention|observational study , no intervention
223643827|NCT06585852|DRUG|RGD|Study group main material
223643828|NCT06585852|DRUG|Xenograft|Scaffold material of choice
223643829|NCT06585852|PROCEDURE|Split crest technique|Piezoelectric surgery
223643830|NCT04819542|DEVICE|Bandage|Bandage
223643831|NCT04819542|DEVICE|No bandage|No bandage
223643832|NCT05485896|DRUG|Pembrolizumab plus Lenvatinib|Patients will receive treatment with Pembrolizumab in combination with Lenvatinib every 3 weeks for 3 cycles in the preoperation. Additional 17 cycles of Pembrolizumab were needed for patients with high risk of recurrence (tumor stage 2 with nuclear grade IV or sarcomatoid differentiation, tumor stage 3 or higher, regional lymph-node metastasis, or stage M1 with no evidence of disease residual).
223643833|NCT03941236|DRUG|dasiglucagon|Glucagon analog
223643834|NCT05790551|DEVICE|Addinex|Medication dispensing system for Suboxone
223643835|NCT06088069|OTHER|Virtual reality|Patients will be virtually immersed into a natural universe and soft music for 15 minutes preoperatively and during surgery.
223643836|NCT03278249|OTHER|Modified Atkins Ketogenic Diet|Less than 20 grams of carbohydrates per day
223643837|NCT06601049|DIETARY_SUPPLEMENT|ResArgin|Resveratrol-based supplement
223643838|NCT04493008|BEHAVIORAL|Experimental: Educational session|Each patient will receive educational session consisting of face-to-face interview, administration of posters, brochures and pamphlets.
223643839|NCT04454216|OTHER|No intervention|This is an observational study that consists of data abstraction from patient medical records.
223643840|NCT04988477|BEHAVIORAL|Study 3: Chronic care management|Quarterly brief provider intervention (the 5As) and 3 quarterly outreach calls over 9 months.
223643841|NCT04988477|BEHAVIORAL|Study 2: Pilot trial|Providers trained in brief provider intervention and 1 outreach call over 3 months.
223643842|NCT02455830|BIOLOGICAL|Autologous cord blood cell therapy|The neonates receive their own non-cryopreserved volume- and red blood cell-reduced cord blood cells. The cord blood cells are divided into 3 doses and intravenously infused at 12-24, 36-48, and 60-72 hours after the birth.
223643843|NCT00084513|BIOLOGICAL|trastuzumab|
223643844|NCT00084513|DRUG|imatinib mesylate|
223643845|NCT03307876|OTHER|autologous PPP injection|autologous platelet poor plasma (PPP) injection taken from the participants own blood is injected in to all patients.
223643846|NCT01872390|OTHER|Combination Intervention Package|CIP will contain programmatic, structural and psychosocial components including: 1) nurse training and mentorship in TB/HIV cotreatment using a clinical algorithm; 2) reimbursement of transportation costs to monthly clinic visits for patients and treatment supporters; 3) health education using a TB and HIV treatment literacy curriculum for patients and treatment supporters; and 4) real-time adherence support using short message service (SMS) text messaging and trained village health workers (VHW). These components were selected for their promise, practicality, and feasibility of implementation and scale-up in HIV programs in diverse settings - in addition to SOC.
223643847|NCT01872390|OTHER|Standard of Care|Usual procedures for management of HIV-infected TB patients will be followed: Three I's training, ART provision to TB patients in integrated clinics, and treatment supporter for TB treatment.
223643848|NCT04675008|DRUG|Dacomitinib|Secondary generation EGFR-tyrosine kinase inhibitor (TKI) (Dacomitinib) for EGFR mutant NSCLC patients with non irradiated brain metastasis
223643849|NCT01071798|DRUG|Rituximab|As prescribed by physician
223643850|NCT02841514|DEVICE|The Y10 Tooth Whitening system including the Y10 toothpaste and the Y10 device|
223643851|NCT02841514|OTHER|OTC toothpaste and an unoperated Y10 device|
223643852|NCT00641667|DRUG|Fentanyl|Fentanyl 1-day application transdermal patch releasing the drug at the rate of 12.5 microgram per hour (mcg/hr) to 100 mcg/hr applied once daily, and maintained for 2 days. Dose escalation or reduction is as per Investigator's discretion (maximum applied dose is 300 mcg/hr) up to Day 7 and then dose is fixed for next 3 days that is Day 10 (end of treatment period).
223643853|NCT04141904|DRUG|Tofacitinib 5 MG [Xeljanz]|Tofacitinib 5mg capsules twice a day for 7-10 days
223643854|NCT04141904|OTHER|Placebo|Placebo capsules twice a day for 7-10 days
223643855|NCT00256672|DEVICE|Thoraco-Lumbar-Sacral-Orthoses (TLSO) / Flex-Foam|TLSO back brace, Flex-Foam (Posterior Opening)
223643856|NCT02606201|OTHER|Peri sphincter injection Autologous myofibers|"The first step of the procedure consists to harvest a muscle fragment from the lower part of the rectus abdominis muscle of the abdomen approached by a short incision. Injectable myofiber cores will be prepared by hydrodissection of the muscle biopsy.~All myofibers cores will be suspended in autologous serum prepared by centrifugation before the incision.~During the second step of the procedure, the myofibers will be injected percutaneously into the peri-sphincter region under endoscopic and radiographic control."
223643857|NCT05373407|OTHER|aerobic exercise|participants will perform different dosage of the same intervention, one group will perform moderate intensity and the other will perform low intensity aerobic training
224230948|NCT00618969|OTHER|haploidentical allogeneic PBSC transp|"Days -5 and -4: IV busulfan 3.2 mg/kg/dose daily for 2 days~Day -3: IV melphalan 100 mg/m2 as a single dose~Days -2 and -1: IV alemtuzumab 30 mg/dose daily for 2 days~Day 0: Transplantation of haploidentical related allogeneic peripheral blood stem cells (PBSCs)- target cell dose 10 x 106 donor CD34+ cells per kilogram of recipient weight"
224230949|NCT00897442|OTHER|Laboratory Biomarker Analysis|Correlative studies
224230950|NCT00129779|BEHAVIORAL|Intermediate care package|
223643858|NCT03202602|OTHER|Telemonitoring of CPAP treatment|Telemedicine technology allows for monitoring of CPAP pressure, air leaks, apnea-hypopnea index (AHI) and compliance on a daily basis.
223643859|NCT03202602|OTHER|Standard care|Office visits and monitoring of CPAP treatment at each visit.
223643860|NCT04613037|BIOLOGICAL|Fecal Microbial Transplantation|Fecal Microbial Transplantation in adults with Atopic Dermatitis
223643861|NCT03349034|DRUG|Ropivicaine|Patients will be randomized to receive a local continuous infusion of 6 ml/hr of 0.2% Ropivacaine via On-Q infusion pump, at the donor site, for the first 48 hours of the postoperative period.
223643862|NCT03349034|DRUG|Local Saline Infusion|Patients will be randomized to receive a local continuous infusion of 6 ml/hr of 0.9% normal saline via On-Q infusion pump, at the donor site, for the first 48 hours of the postoperative period.
223643863|NCT02565368|DRUG|Duvie Tab. 0.5mg, Glucophage XR Tab. 1000mg|single oral administration
223643864|NCT02565368|DRUG|CKD-395 0.5/1000mg|single oral administration
223643865|NCT04922632|BEHAVIORAL|Transcendental Meditation (TM)|TM is a mind-body program that allows the participant to experience progressively quieter, less excited states of mental activity, with growing experience of restful alertness in mind and body.
223643866|NCT04922632|BEHAVIORAL|Experience Resolution Methodology (ERM)|ERM is a specific, protocolized coaching method that aims to maximize an individual's performance, professional development and well-being by recognizing and resolving subjective stress associated with specific situations, circumstances, events or experiences.
223643867|NCT04922632|BEHAVIORAL|Transcendental Meditation (TM) and Experience Resolution Methodology (ERM)|TM + ERM is an integrative method using both TM and ERM coaching with ERM with the aim of achieving an overall restful, alertness in mind and body and maximizing performance, professional development and well-being.
223643868|NCT04922632|BEHAVIORAL|Treatment As Usual (TAU)|TAU is the existing Duke Health \& Well-being services, such as the availability of acupuncture, integrative health coaching, integrative nutrition and weight management, personal exercise training, massage therapy, yoga therapy, mindfulness-based stress reduction (MBSR), experiencing mindfulness, group fitness classes, gentle yoga, or chair yoga, as well as additional resources such as Personal Assistance Services (PAS).
223643869|NCT00658125|PROCEDURE|Bilateral fornix DBS implantation,|Fornix DBS for Alzheimer Disease
223765766|NCT00682019|DRUG|Levitra (Vardenafil, BAY38-9456)|5mg, 10mg or 20mg taken 8 hours before sexual intercourse
223765767|NCT00682019|DRUG|Placebo|matching placebo
223643870|NCT05510596|OTHER|Magnetic Resonance Imaging with contrast injection|Magnetic Resonance Imaging with contrast injection
223643871|NCT05510596|OTHER|Blood withdrawal|Blood withdrawal : serum, plasma, cytokine assay
223643872|NCT05510596|OTHER|Neuropsychological tests|Neuropsychological tests
223643873|NCT06129708|OTHER|Aquatic Exercise|The aquatic exercises included 5 minutes of warming up in form of walking and running in water, 20 minutes of aerobic and strengthening exercises of pelvis, abdominal and thigh muscles (Double-leg Squat, lunge, knee flexion and extension, hip flexion and
223765768|NCT01611324|DRUG|Mepivacaine chlorhydrate 2% in Sodium Bicarbonate 1.4%|4 mL mepivacaine chlorhydrate 20 mg/mL with epinephrine 5 mcg/mL diluted with 16 mL sodium bicarbonate 1.4%
223765769|NCT01611324|DRUG|Mepivacaine chlorhydrate 2% with epinephrine in NS 0.9%|4 mL mepivacaine chlorhydrate 20 mg/mL with epinephrine 5 mcg/mL diluted with 16 mL sodium chloride 0.9%
223765770|NCT00019474|BIOLOGICAL|filgrastim|
223765771|NCT00019474|BIOLOGICAL|recombinant interferon alfa|
223765772|NCT00019474|DRUG|fluorouracil|
223765773|NCT00019474|DRUG|hydroxyurea|
223765774|NCT01879696|DEVICE|ECSPRESS catheter with active vacuum|
224230951|NCT02289924|DRUG|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|Administration by intravitreal injection
224230952|NCT00062309|RADIATION|radiation therapy|
224230953|NCT01346410|RADIATION|Stereotactic Body Radiotherapy|Suggested fractionation is 20-25 Gy / 1 fraction OR 30-36 Gy / 3 fractions (10-12 Gy per fraction) OR 40-45 Gy / 5 fractions (8-9 Gy per fraction)
224323412|NCT06507748|DEVICE|AlgometRx Nociometer|Novel objective pain measurement device
223643874|NCT06129708|OTHER|Aerobic Exercise|The exercise protocol consists of 5 minute warm up, 35 min aerobic exercise and 5 minute cool-down. Exercises high-intensity treadmill-based treatment for primary dysmenorrhea for three days a week ,The Borg Rating of Perceived Exertion (RPE) Scale from 6 ('no exertion at all') to 20 ('maximal exertion') was used to regulate the exercise intensity on the treadmill. Participants were encouraged to increase the speed of the treadmill until they perceived their RPE to be between 14 and 16. or at a perceived exertion of 11.0 (Borg scale) for the first five minutes (warm-up period), followed by aerobic exercise at 70-85% of maximum heart rate (MHR) (16.0-18.0 Borg scale) for 30 minutes. At the end of the exercise session, women completed a 5-minute cool-down (11.0 Borg scale).
223643875|NCT02352389|OTHER|Blood sample|Blood samples will be drawn and analyzed at Day 0, 7, 14, 21, and 28
223765775|NCT01778166|DRUG|Immuno-enhanced|Immediately drip 37°C saline 20 ml/h and exchange to drip 37°C enteral nutrition fluid concerning omega-3-unsaturated fatty acids 20 ml/h at postoperative 6 h via jejunostomy tube or nasogastric tube
223765776|NCT01778166|DRUG|Standard early enteral nutrition|Immediately drip 37°C saline 20 ml/h and exchange to drip 37°C standard enteral nutrition fluid 20 ml/h at postoperative 6 h via jejunostomy tube or nasogastric tube
224230954|NCT06528262|DRUG|Enavogliflozin|Patients hospitalized at Severance Hospital for atrial fibrillation catheter ablation, or those who had the procedure within the last three months, will be randomly assigned to receive either 0.3 mg of enavogliflozin once daily or a placebo for 360±30 days
223765777|NCT00352612|DRUG|clindamycin|clindamycin suspension or tablets, 20mg/kg/day, given by mouth, divided TID, for 7 days
223765778|NCT00352612|DRUG|cephalexin|cephalexin suspension or tablets, 40mg/kg/day, given by mouth, divided TID, for 7 days
223765779|NCT04949438|DRUG|AZD4831|Participants will receive a single dose of AZD4831 administered with 240 mL of water after an overnight fast of at least 10 hours.
224230955|NCT06528262|DRUG|Placebo|Patients hospitalized at Severance Hospital for atrial fibrillation catheter ablation, or those who had the procedure within the last three months, will be randomly assigned to receive either 0.3 mg of enavogliflozin once daily or a placebo for 360±30 days
224230956|NCT04638985|BIOLOGICAL|sIPV+DTaP+MMR|sIPV+DTaP+MMR at the age of 18 month old
224319720|NCT02454855|DRUG|melatonin|"Oral supplementation with melatonin (tablets) will be administered for 3 months once daily , 1-2 hours before bedtime. It will start on the day of the first administration of the new line of anticancer treatment (or no later on the day of the second administration of the new line of anticancer treatment).~Melatonin supplementation is achieved by the administration of (Circadin) at a dose of 2 mg / day according to its MA form of prolonged-release tablet of 2 mg."
223643876|NCT02352389|OTHER|Nasal swab|Obtained on Day 0, 7, 14, 21 and 28.
223643877|NCT02352389|OTHER|Oropharyngeal swab|Obtained on Day 0, 7, 14, 21 and 28.
223643878|NCT02352389|OTHER|Stool sample|Obtained on Day 0, 7, 14, 21 and 28.
223643879|NCT02352389|OTHER|Symptom checklist|Obtained on Day 0, 7, 14, 21 and 28.
223643880|NCT06081816|OTHER|carie|Caries lesions were assessed by visual tactile examination and periodontal disease through two probing sites around third molar, considering the presence of periodontal pathology when at least one periodontal probing depth was greater than 4 mm, and both were evaluated by radiograph diagnostic methods. The assessment of oral health related quality of life by Oral Health impact Profile questionary (OHIP-14), applied as an interview. The evaluation of the position of the third molars was made by clinical and panoramic radiographs according to the classification of Pell and Gregory and Winter
223765780|NCT01000246|BIOLOGICAL|influenza virus vaccine (influvac or vaxigrip)|one i.m. dose of 0.5 mL
223765781|NCT04335344|OTHER|Observation of suPAR plasma and salivary levels|Evaluation of suPAR plasma level and correlation of plasma suPAR levels with periodontal and cardiovascular disease
223765782|NCT00528528|DRUG|Telaprevir|Oval tablets containing 375 mg of telaprevir for oral administration.
223643881|NCT05306535|PROCEDURE|Occlusal reduction|Occlusal reduction of the experimental single rooted tooth after root canal completion will be done to evaluation reduction in postoperative pain and sensitivity to percussion
223765783|NCT00528528|DRUG|Peg-IFN-alfa-2a|Solution containing Peg-IFN alfa2a for subcutaneous injection in a pre-filled syringe.
223765784|NCT00528528|DRUG|Peg-IFN-alfa-2b|Powder containing Peg-IFN-alfa-2b and solvent for solution for subcutaneous injection in a pre-filled pen.
223765785|NCT00528528|DRUG|Ribavirin (RBV) tablet|Tablets containing 200 mg RBV for oral administration.
223765786|NCT00528528|DRUG|Ribavirin (RBV) capsule|Capsules containing 200 mg RBV for oral administration.
223765787|NCT01321801|DRUG|Pregabalin|Preoperative administration of pregabalin 600mg
223765788|NCT01321801|DRUG|placebo|Preoperative administration of a matching placebo
223765789|NCT06518668|BIOLOGICAL|NKX019|NKX019 is an investigational allogeneic CD19-Directed CAR NK. NKX019 will be administered at a dose of 1 × 109 CAR NK cells (dose normalized for weight for subjects ≤ 50 kg) administered IV.
223765790|NCT06518668|DRUG|Cyclophosphamide LD|"Cy dose of 1 g/m2 administered IV over 30 to 60 minutes for the purpose of Lymphodepletion Therapy. Cyclophosphamide will help prepare your body to receive the treatment by decreasing the cells from your immune system to make space for the NKX019 cells.~(non-experimental)"
224230957|NCT04638985|BIOLOGICAL|sIPV|sIPV at the age of 18 month old
224230958|NCT04638985|BIOLOGICAL|DTaP|DTaP at the age of 18 month old
224230959|NCT04638985|BIOLOGICAL|MMR|MMR at the age of 18 month old
224230960|NCT00979628|DRUG|sliding scale regular insulin (SSRI)|four-time daily in patients with T2DM admitted to general medicine and surgery wards.
224230961|NCT00979628|DRUG|Basal Bolus|glargine once daily plus glulisine before meals (plus corrective doses of glulisine as needed)
224230962|NCT00979628|DRUG|Basal Plus|glargine once daily plus corrective doses of glulisine before meals and bedtime as needed
224319721|NCT02454855|DRUG|placebo|Oral supplementation with placebo (tablets) will be administered for 3 months once daily , 1-2 hours before bedtime. It will start on the day of the first administration of the new line anticancer treatment (or no later on the day of the second administration of the new line of anticancer treatment).
224323413|NCT05256225|PROCEDURE|Biospecimen Collection|Undergo blood and urine sample collection
224323414|NCT05256225|DRUG|Carboplatin|Given IV
224323415|NCT05256225|PROCEDURE|Computed Tomography|Undergo CT
224323416|NCT05256225|PROCEDURE|Echocardiography Test|Undergo ECHO
223643882|NCT06299059|DEVICE|Intermittent Oro-esophageal Tube Feeding|The observation group was given enteral nutritional support with Intermittent Oro-esophageal Tube according to the following procedure: Before each feeding, inside and outside of the tube was cleaned with water. During feeding, the patient should maintain a semi-reclining or sitting position with mouth opened, and the tube was inserted slowly and smoothly into the upper part of the esophagus by medical staffs while the appropriate depth of intubation was checked with the calibration markings on the tube wall. The distance from the incisors to the head part of the tube should be between 22-25 cm.
223643883|NCT06299059|DEVICE|Nasogastric Tube Feeding|The control group was given enteral nutritional support with Nasogastric Tube Feeding according to the relevant guidelines. Within 4 hours after admission, the placement of the feeding tube was conducted by professional medical staffs and after intubation, the tube was secured to the patient's cheek with medical tape. The feeding was conducted once every 3-4 hours, with 200-300ml each time.
223643884|NCT04359316|DRUG|Hydroxychloroquine|This Drug will be used in all arms as mandated by our governmental guidelines.
223643885|NCT04359316|DRUG|Azithromycin|This will be drug only used in the intervention arm of our study, designed mainly to assess the additional efficacy and safety of Azithromycin in COVID-19 patients.
223643886|NCT06188143|COMBINATION_PRODUCT|Ibuprofen-Paracetamol|Ibuprofen 40mg and Paracetamol 500mg per oral, single dose each, in study group 30minutes before hysteroscopic procedure
223643887|NCT02425852|DRUG|Azathioprine|Azathioprine alone versus Azathioprine and IFX
223643888|NCT02425852|DRUG|Infliximab|
223643889|NCT02425852|DRUG|Prednisolone|
223643890|NCT02425852|DRUG|Hydrocortisone|
223643891|NCT03261752|DIAGNOSTIC_TEST|blood sample|Total genomic DNA will be extracted DNA extraction kit using a QIAamp DNA Blood Mini kit .Genetic analysis of both SPG20 \&STK31 by RTPCR.
223643892|NCT06431152|BIOLOGICAL|UC-MSC sEV|Small extracellular vesicles derived from allogenic mesenchymal stromal cells, single dose
223643893|NCT00865566|BIOLOGICAL|DNA plasmid vaccine|4-mg injection administered as 1 mL intramuscularly (IM) via Biojector® in either deltoid
223643894|NCT00865566|BIOLOGICAL|Recombinant adenoviral serotype 5 (rAD5) vector vaccine|1 x 10\^10 particle units (PU) administered as 1mL IM by needle and syringe in either deltoid
223643895|NCT00865566|BIOLOGICAL|DNA vaccine placebo|1 mL IM via Biojector® in either deltoid
223643896|NCT00865566|BIOLOGICAL|HIV-1 recombinant adenovirus vaccine placebo|1 mL administered IM by needle and syringe in either deltoid
223643897|NCT02905227|DRUG|CVT-427 (zolmitriptan inhalation powder)|Each subject received 2 self-administered doses of 3.0 mg CVT-427 (zolmitriptan inhalation powder), 2 hours apart.
223643898|NCT01898260|DEVICE|Ultrafilcon B contact lens|Silicone hydrogel contact lens CE-marked for daily disposable wear. Private-label versions may be used.
224230963|NCT06527963|PROCEDURE|Endovascular therapy|Endovascular therapy is a minimally invasive interventional approach that utilizes the vascular system as a pathway to access and treat various pathological conditions within the body. By employing specialized catheters and devices, endovascular techniques enable precise delivery of therapeutic agents or interventional procedures directly to the target site, without the need for conventional open surgery.
224230964|NCT00912418|BIOLOGICAL|autologous tumor cells plus GM-CSF-in Adjuvant|"Autologous tumor cells plus 225 ug GM-CSF in-adjuvant: The autologous tumor cells will be administered intradermally. Subjects will be vaccinated over at least a 6 week period (at weeks 0, 1, 2, 4, 5, 6), with responders vaccinated every 4 weeks thereafter for a maximum of 9 vaccinations (up to week 18). Systemic low-dose interleukin-2 will also be administered daily for 6 weeks following the second vaccination at week 1.~Concurrent with the first three of these vaccinations, each patient will also receive an additional set of 3 vaccinations in a different site, the response to which will be evaluated at the draining lymph node. This node will be harvested using lymphatic mapping and sentinel node biopsy methods."
224230965|NCT06526845|OTHER|Video-Conference based rehabilitation|"All exercises in the brochure will be performed by patients via telerehabilitation. The exercises included in the exercise package are as follows:~* Post-isometric relaxation exercise and relaxation exercise with diaphragmatic breathing~* Neck Exercises: 5 neck exercises including cervical isometric flexion, extension, right and left lateral flexion and chin tuck exercises.~* Soft tissue-friction massage: It will be applied to the area where myofascial pain develops due to TMJD.~* Mandibular mobility exercises: opening and closing the mouth slowly and rhythmically, lateral movements, protrusion movement, hold-relax technique, jaw isometric exercises~* Stretching exercises: Stretching exercises for chewing muscles (masseter muscle stretching, temporalis muscle stretching, pterygoid muscle stretching)."
224323417|NCT05256225|RADIATION|High-Dose-Rate Vaginal Cuff Brachytherapy|Undergo vaginal brachytherapy
224323418|NCT05256225|DRUG|Hyaluronidase-zzxf/Pertuzumab/Trastuzumab|Given SC
223643899|NCT01898260|DEVICE|Stenfilcon A contact lens|Silicone hydrogel contact lens CE-marked for daily disposable wear. Private-label versions may be used.
223643900|NCT02596932|OTHER|Standard Protocol for intrapartum glucose management|Tight glucose control protocol: Goal maternal blood glucose 70-100, q 1 hour blood glucose checks, insulin treatment started with single maternal blood glucose level \> 100mg/dL or \< 60mg/dL
223643901|NCT02596932|OTHER|Experimental Protocol for intrapartum glucose management|Less Tight: Goal maternal blood glucose 70-120, q 4 hour blood glucose checks (unless symptomatic), insulin treatment started with single maternal blood glucose \> 120 mg/dL or \< 60 mg/dL
223643902|NCT03098732|DEVICE|Magnetically Enhanced Diffusion (MED)|Treatment of Acute Ischemic Stroke with IV tPA and the adjunctive Magnetically Enhanced Diffusion (MED) System Procedure.
223643903|NCT03098732|DEVICE|MED Workstation Magnet Sham Control|Treatment of Acute Ischemic Stroke with IV tPA and Sham use of the MED Workstation only, without the injection of MED MicroBeads.
223643904|NCT01202968|PROCEDURE|Transcutaneous neuro-muscular electrical stimulation|Neuro-muscular electrical stimulation with two pairs of surface electrodes was applied to submental area. One paired electrodes to be placed horizontally was attached on the anterior half of area between mandible and hyoid bone. The other was affixed to posterior half of the same area far laterally. Bipolar electrical stimulation with pulse rate of 80-Hz, duration of 700 µs and intensity to evoke visible muscle contraction was performed for 60 minutes a day until one day before extubation.
223643905|NCT01565824|OTHER|web-based support|
223643906|NCT00815659|DRUG|rosuvastatin|medication start dose is 10mg. After 6 weeks of treatment will be force-titrated to 20mg.
223643907|NCT00936923|DRUG|furosemide|patients will take furosemide 60 or 120mg oral per day for 1 years .
223643908|NCT03847896|COMBINATION_PRODUCT|Budesonide/albuterol sulfate metered dose inhaler / BDA MDI 160/180 μg (high dose)|Budesonide/albuterol sulfate pressurized metered dose inhaler (BDA MDI) 160/180 micrograms (μg), given as 2 inhalations of BDA MDI 80/90 μg, four times a day (QID)
223643909|NCT03847896|COMBINATION_PRODUCT|Budesonide/albuterol sulfate metered dose inhaler / BDA MDI 80/180 μg (low dose)|Budesonide/albuterol sulfate pressurized metered dose inhaler (BDA MDI) 80/180 micrograms (μg), given as 2 inhalations of BDA MDI 40/90 μg, four times a day (QID)
223643910|NCT03847896|DRUG|Budesonide metered dose inhaler / BD MDI 160 µg|Budesonide pressurized metered dose inhaler (BD MDI) 160 micrograms (μg), given as 2 inhalations of BD MDI 80 μg, four times a day (QID)
223643911|NCT03847896|DRUG|Albuterol sulfate metered dose inhaler / AS MDI 180 μg|Albuterol sulfate pressurized metered dose inhaler (AS MDI) 180 micrograms (μg), given as 2 inhalations of AS MDI 90 μg, four times a day (QID)
223643912|NCT03847896|OTHER|Placebo metered-dose inhaler / Placebo MDI|Placebo pressurized metered dose inhaler (Placebo MDI), given as 2 inhalations of Placebo MDI, four times a day (QID)
223643913|NCT02395471|DEVICE|Cytosponge™ Cell Collection Device|Cytosponge™ Cell Collection Device is indicated for use in the collection and retrieval of surface cells in the esophagus.
223643914|NCT05224999|DRUG|nivolumab|nivolumab 3mg/kg (every 2 weeks)
223643915|NCT01977989|DRUG|Vancomycin Powder|For surgeries involving 3 contiguous spinal segments or less, 500mg of vancomycin will be applied topically. For surgeries involving more than 3 contiguous spinal segments, 1gm of vancomycin will be applied topically to the surgical site.
223643916|NCT05859503|OTHER|Closure Strategy with Perclose-Proglide system|Patients who have required Perclose-Proglide system in Percutaneous Interventional Procedure
223643917|NCT05859503|OTHER|Closure Strategy with figure-of-8|Patients who have required the manual compression with figure-of-8 in Percutaneous Interventional Procedure
223643918|NCT01980537|PROCEDURE|Magnetic wire navigation|
223643919|NCT01980537|PROCEDURE|Conventional wire navigation|
223643920|NCT01216826|DRUG|Everolimus|Everolimus will be administered every day, initial dose 5 mg/m²/dia, in 28 days cycles. Maximum dosis: 10 mg/day. The cycles will be repeated till progression disease or untolerable toxicity.
223643921|NCT03847051|DIAGNOSTIC_TEST|MRI|Brain MRI without intravenous contrast
223643922|NCT05838118|DRUG|Fecal Microbiota Transplantation|Biologically active human fecal fluid (donor stool) is provided in fluid form.
223643923|NCT05838118|OTHER|Standard of Care for Chronic Kidney Disease|Patients accepted oral drug or dialytic therapy like they used to be to treat CKD.
224230966|NCT06526845|OTHER|Home-Based rehabilitation|"Patient education will be provided by showing all exercises in practice. Brochures will then be given to patients so they can apply them at home. The exercises in the brochure are as follows;~* Post-isometric relaxation exercise and relaxation exercise with diaphragmatic breathing~* Neck Exercises: 5 neck exercises including cervical isometric flexion, extension, right and left lateral flexion and chin tuck exercises.~* Soft tissue-friction massage: It will be applied to the area where myofascial pain develops due to TMJD.~* Mandibular mobility exercises: opening and closing the mouth slowly and rhythmically, lateral movements, protrusion movement, hold-relax technique, jaw isometric exercises~* Stretching exercises: Stretching exercises for chewing muscles (masseter muscle stretching, temporalis muscle stretching, pterygoid muscle stretching)."
224230967|NCT06529198|DEVICE|NeuroGyn Genital Neuromodulation System|Genital Neuromodulation
224230968|NCT04224090|DIAGNOSTIC_TEST|Echocardiographic assessment of coronary arteries origin and proximal course|Echocardiographic assessment of CAA utilizing 4 specific echocardiographic acoustic windows: parasternal short-axis (PSAX), parasternal long-axis (PLAX), apical 4/5-chambers views.
224230969|NCT04119661|DEVICE|Max-i-Probe|Using Max-i-Probe as endodontic needle during syringe irrigation
224323419|NCT05256225|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
224323420|NCT05256225|DRUG|Paclitaxel|Given IV
223643924|NCT03891849|DRUG|Octreotide Injection|Patients admitted in intensive care unit after variceal hemorrhage treated with norepinephrine perfusion will received an additional octreotide perfusion during one hour.
223643925|NCT02978781|DRUG|SAGE-217|SAGE-217 Oral Solution
223643926|NCT02978781|DRUG|SAGE-217|SAGE-217 Capsules
223643927|NCT02978781|DRUG|Placebo|SAGE-217 matching placebo capsules
223643928|NCT01777113|OTHER|High intensity aerobic training|The mode of the training will be uphill treadmill walking in 4x4 minute intervals at 85% and 95% of Heart Rate Peak (HRpeak) precede by 10-minute warm-up period on the treadmill at self-selected speed and inclination. Between the 4-minute intervals, 3-minute active breaks walking at approximately 50% of HRpeak will be applied. The training sessions will be terminated by a 3-minute cool-down period at 50% to 70% HRpeak. To compensate for increased VO2peak, the speed and/or inclination will be gradually adjusted during 3-month intervention to make sure that the target HR will be between 85% and 95% of HRpeak during the high-intensity intervals.
223643929|NCT01777113|OTHER|High Intensity Strength Training|Five warm-up repetitions will be completed at approximately 50% of 1 repetition maximum before the main session of four sets of four repetitions unilaterally at 85%Y95% of 1 repetition maximum for both leg press and plantarflexion. When subjects will be able to complete a fifth repetition, the weight will be increased by 1.25 to 2.5 kg, dependent on subjective feelings of capability. They will be encouraged to focus of an explosive concentric movement and a controlled eccentric movement such that the time on each phase will be in the ratio 1:2. The subjects will be regularly reminded to focus on breathing during the contraction, preventing the valsalva maneuver and high rises in blood pressure. The session will finish with a minimum 5-min warm down the treadmill device.
223765791|NCT05950581|DEVICE|Modified Twin-Block Appliance with Clear Plates.|Clear plates technique A group of patients in which participants will be undergo to clear plates treatment will be applied to the upper and lower arch 17 hours daily
224230970|NCT04119661|DEVICE|NaviTip|Using NaviTip as endodontic needle during syringe irrigation
224230971|NCT02758366|DRUG|Doxorubicin|
224230972|NCT02702206|DRUG|corticosteroids|under US guidance, 2ml triamcinolone (1ml/10mg), 0.5ml distilled water and 1ml 1% lidocaine
224230973|NCT02702206|DRUG|hyaluronic acid|under US guidance, 2.5ml HA (ARTZ, 1% sodium hyaluronate solution, 10mg/mL, molecular weight 0.9x106Da) and 1ml 1% lidocaine
224323421|NCT05256225|OTHER|Survey Administration|Ancillary studies
223643930|NCT01777113|OTHER|Mixed Training|Conventional training consisted of group mobility, balance and stretching exercises. Mobility training included treadmill and cycloergometer training for 10 minutes at self selected speed. Exercises at the parallel bars included weight shift from leg to leg, half-squat, turn in place, leg-trunk flexion, and extension exercises. Finally seated upper- and lower-limb stretching exercises will focus on range of motion, including trunk mobility.
223643931|NCT03168776|DEVICE|BuMA Supreme DES|Implant BuMA Supreme stent only
223643932|NCT03168776|DEVICE|Xience or Promus DES|Implant XIENCE family or Promus family only
223643933|NCT03543228|DIAGNOSTIC_TEST|MyoStrain|MyoStrain quantifies myocardial contraction to detect changes in heart function during chemotherapy.
223643934|NCT00785785|DRUG|Nilotinib (AMN107)|
223643935|NCT00785785|DRUG|imatinib (STI571)|
223765792|NCT05950581|DEVICE|Traditional Twin-Block appliance|Traditional Twin-Block appliance A group of patients in which participants will undergo to the Traditional Twin-Block appliance Treatment, appliances will be applied to the upper and lower arch 17 hours daily
223765793|NCT04325828|DRUG|Apalutamide|Apalutamide 240 mg (4\*60-mg tablets) will be administered orally once daily with or without food.
224230974|NCT02702206|DRUG|normal saline|under US guidance, 2.5ml normal saline (placebo group). 0.5ml distilled water and 1ml 1% lidocaine
224230975|NCT02768142|OTHER|Natural cesarean delivery|Natural cesarean delivery
224230976|NCT02768142|OTHER|Standard cesarean delivery|Standard cesarean delivery
224319722|NCT03097991|BEHAVIORAL|Focused Coparenting Consultation|Six 90-minute sessions completed within 10 weeks address importance of coparenting for child development; overcoming challenges to coparenting collaboratively; anger and conflict management and communication skills. Parents develop a coparenting plan to support one another's involvement as parents to the baby. A 90-minute booster session one month after the baby's birth reinforces lessons learned in the 6-session intervention.
224319723|NCT05107648|BEHAVIORAL|Gardner GOALS|12 lesson curriculum focusing on healthy eating, increased physical activity and decreased screen time
224319724|NCT06147648|DRUG|Tacrolimus Sustained-release Capsules|Transition from Immediate-release tacrolimus to prolonged-release tacrolimus at 3 months after liver transplantation
224319725|NCT00002704|BIOLOGICAL|filgrastim|
223643936|NCT02453321|PROCEDURE|Continuous Femoral Nerve Block|A 27g plastic catheter placed below the inguinal crease to perform a conduction blockade of the sensory components of the femoral nerve in order to decrease pain in the knee after total knee arthroplasty
224319726|NCT00002704|DRUG|asparaginase|
224319727|NCT00002704|DRUG|cyclophosphamide|
223643937|NCT02453321|PROCEDURE|Nerve Block, Continuous Adductor Canal|A 27g plastic catheter placed on the anterior medial thigh midway between the groin and knee to provide a local anesthetic conduction blockade of the sensory components of the femoral nerve in order to decrease pain in the knee after total knee arthroplasty
223643938|NCT02453321|PROCEDURE|Continuous Sciatic Nerve Block|A transgluteal approach to the sciatic nerve is use to place a 27g catheter. It will only be dose postoperatively after verifying sciatic nerve function still intact. The infusion will be 0.003% bupivacaine at 2ml/hr. This is not the intervention of interest, but our institution's predominant practice is to include the sciatic nerve block as part of the analgesic regimen for total knee arthroplasty.
223643939|NCT02453321|DRUG|Bupivacaine|The concentration of the continuous infusion of bupivacaine though the peripheral nerve catheters will be 0.0625% for the femoral and adductor canal blocks and the concentration for the sciatic continuous catheter will be 0.03%.
223643940|NCT02763501|PROCEDURE|closure of mesenteric defects|Closure of mesenteric defects by use of non-absorbable running sutures in RCT; and according to the choice of the surgeon in the non-RCT
223643941|NCT02763501|PROCEDURE|non-closure of mesenteric defects|Mesenteric defects are left open
223765794|NCT04325828|DRUG|GnRH Agonist|A stable regimen of goserelin 3.6 mg will be administered as a GnRH agonist.
223765795|NCT00827892|DRUG|Pioglitazone|Escalating doses for 3 days, then 30 mg orally daily for the duration of the study as determined by MRI
224230977|NCT02938494|DRUG|IDP-123 Lotion|Lotion
224230978|NCT02938494|DRUG|Tazorac Cream|Cream
224230979|NCT02938494|DRUG|Vehicle Lotion|Lotion
224230980|NCT02938494|DRUG|Vehicle Cream|Cream
224230981|NCT04330300|DRUG|Thiazide or Thiazide-like diuretics|Anti-hypertensive (Active Arm)
224230982|NCT04330300|DRUG|Calcium Channel Blockers|Anti-hypertensive (Active Arm)
224230983|NCT04330300|DRUG|ACE inhibitor|Anti-hypertensive (Control Arm)
224230984|NCT04330300|DRUG|Angiotensin receptor blocker|Anti-hypertensive (Control Arm)
224230985|NCT06113796|OTHER|Surgery|Robotic rectal resection, either sphincter preserving or extirpation
224230986|NCT02676219|OTHER|RS01|Oral Care product containing sodium monofluorophosphate and sodium fluoride
224230987|NCT02676219|OTHER|Water|
224230988|NCT03281421|OTHER|Manual Therapy|The manual therapy intervention, through the technique of mobilization with movement in the ankle joint (following the specific sense direction of the group), will be performed in a protocol that consists of four sets of five repetitions, with rest time between series of one minute.
224319728|NCT00002704|DRUG|daunorubicin hydrochloride|
224319729|NCT00002704|DRUG|dexamethasone|
224319730|NCT00002704|DRUG|etoposide|
224319731|NCT00002704|DRUG|leucovorin calcium|
224319732|NCT00002704|DRUG|liposomal cytarabine|
224319733|NCT00002704|DRUG|mercaptopurine|
224319734|NCT00002704|DRUG|mesna|
224319735|NCT00002704|DRUG|methotrexate|
224319736|NCT00002704|DRUG|therapeutic hydrocortisone|
224319737|NCT00002704|DRUG|thiotepa|
224319738|NCT00002704|DRUG|vincristine sulfate|
224319739|NCT00002704|RADIATION|low-LET electron therapy|
224319740|NCT00002704|RADIATION|low-LET photon therapy|
224319741|NCT00246324|DRUG|Interferon beta 1a, oral doxycycline|Patients took intramuscular interferon beta 1a, 30 micrograms, for 3 months then added oral doxycycline, 100 daily with the interferon for 4 months.
224319742|NCT02547688|DEVICE|Nasal High Flow|
224319743|NCT02006732|DRUG|olodaterol|fixed dose combination
224319744|NCT02006732|DRUG|tiotropium|fixed dose combination
224319745|NCT02006732|DRUG|placebo|
224323422|NCT05256225|DRUG|Trastuzumab/Hyaluronidase-oysk|Given SC
223643942|NCT03024476|BEHAVIORAL|Behavioral intensification|"Suggested algorithm for behavioral intensification:~* If frequency of BP measurement ≤5 in a week, send a texting message~* If frequency of BP measurement ≤3 in a week, make a telephone contact by research nurse~* Target range of home-systolic blood pressure: 110 - 135~* If rate of outlier exceeds 50% in a week (based on ≥5 measurements in a week), make a telephone contact by research nurse (applied at least 2 weeks after randomization). A call for breakthrough visit may be issued when clinically required (decided by the institutional investigator)~* If frequency of BP measurement ≥ 10 in a week and frequency of outlier = 0 in a week, send a texting message to encourage and compliment on excellent BP management"
223643943|NCT03024476|DRUG|Pharmacological intensification based on olmesartan|"* Study drug will be provided from the roll-in period.~* Step I:~  * Use olmesartan 20 mg only if mean systolic blood pressure ≤150 mm Hg during the immediate past 2 days~ * Use olmesartan 40 mg if mean systolic blood pressure \>150 during the immediate past 2 days~* Step II: olmesartan 20 mg or 40 mg + amlodipine 5 mg~* Step III: olmesartan 20 mg or 40 mg + amlodipine 10 mg~* Step IV: olmesartan 20 mg or 40 mg + amlodipine 10 mg + hydrochlorothiazide 12.5 mg~* If blood pressure profile showed high degree variability to evoke clinical concern, consider discontinuation of hydrochlorothiazide or reduction of olmesartan dose.~* Use of beta-blockers is permitted if clinically indicated.~* At each clinic visit regardless of regular or breakthrough visit, follow the pharmacological intensification rule."
223643944|NCT03024476|DEVICE|Bluetooth-equipped sphygmomanometer|"* Participants will be given a wireless Bluetooth-equipped sphygmomanometer system, which is connected to the main server through the participants' own smartphone. (Identical for both intervention and control groups)~* Every blood pressure and heart rate measured will be encrypted and stored in the main server. (Identical for both intervention and control groups)"
223643945|NCT00025519|BIOLOGICAL|therapeutic allogeneic lymphocytes|
223643946|NCT00025519|DRUG|fludarabine phosphate|
223643947|NCT00025519|DRUG|mycophenolate mofetil|
223643948|NCT00025519|DRUG|tacrolimus|
223643949|NCT00025519|DRUG|thalidomide|
223643950|NCT00025519|PROCEDURE|peripheral blood stem cell transplantation|
223643951|NCT00025519|RADIATION|radiation therapy|
223643952|NCT04417699|DRUG|TAS 102|Oral medication over Days 1-5
223643953|NCT04417699|DRUG|Oxaliplatin|Administered by intravenous infusion over 2 hours on day 1
223643954|NCT01887483|DIETARY_SUPPLEMENT|Vetal Laban active|Dairy product with probiotic
223643955|NCT01887483|DIETARY_SUPPLEMENT|Placebo|Dairy product without probiotic
223643956|NCT06047418|PROCEDURE|Blepharoplasty|This is an cross-sectional, retrospective observational study, to evaluate the clinical characteristics and surgical outcome of blepharoptosis patients who undergone the surgery
223643957|NCT04527770|DRUG|Dexamethasone|Ultrasound guided median nerve hydrodiseection using dexamethasone or midazolam
223643958|NCT04527770|DRUG|Midazolam injection|intracarpal injection of midazolam and bupivacaine 0.5%
223643959|NCT01796366|DRUG|insulin 338 (GIPET I)|Each subject will be allocated to one of three dosing periods only. The subject will receive oral insulin 338 and placebo, administered subcutaneously (s.c., under the skin) once daily for 10 days at fixed dose levels.
223643960|NCT01796366|DRUG|placebo|S.c placebo administered in combination with insulin 338
223643961|NCT01796366|DRUG|insulin glargine|Each subject will be allocated to one of three dosing periods only. The subject will receive insulin glargine for s.c. administration and oral placebo once daily for 10 days at fixed dose levels.
223643962|NCT01796366|DRUG|placebo|Oral placebo administered in combination with s.c. insulin glargine
224230989|NCT02495597|OTHER|no intervention - just observational|
224230990|NCT04730557|BEHAVIORAL|Weight Loss|Each participant receives a calorie (kcal) prescription derived from calculations of estimated total energy expenditure (TEE) based on weight, height, sex, age, and activity level using equations developed by the Institute of Medicine \[29\]. Prescribed kcal levels are adjusted downward from the TEE to achieve a weekly weight loss of 1 to 2 pounds, generally a deficit of 500-1000 kcal/day. Weekly intervention sessions and activities will be delivered virtually using Microsoft Teams, Duke ZOOM or Duke Webex and led by Registered Dietitians.
224319746|NCT04936711|DEVICE|Resteck Shiatsu Neck and Back Massager|back massager device sold on the market that can readily be purchased online or in store
224319747|NCT04936711|DRUG|Marcaine|Marcaine spray at incision site after closure
223643963|NCT02497170|BEHAVIORAL|Education of goal setting and achievement|Education of American Association of Diabetes Educations 7 behavioral goals and how to achieve them
223643964|NCT00157989|PROCEDURE|Controlled tidal volume resuscitation|
223643965|NCT00521404|DRUG|CS-1008 (humanized anti-DR5 antibody)|CS-1008: 8mg/kg loading dose followed by 3mg/kg weekly.
223643966|NCT00521404|DRUG|gemcitabine|Gemcitabine - 1000mg/meter sq
223643967|NCT04600661|OTHER|Traditional exercise therapy|Neuromuscular training
223643968|NCT06088784|DRUG|ATH-399A|Orally administered drug in capsule form.
223643969|NCT06088784|DRUG|Placebo|Orally administered drug in capsule form.
223643970|NCT04342533|PROCEDURE|Thulium fiber laser enucleation of the prostate|enucleation of the BPH according to standard procedure protocol
223643971|NCT04342533|PROCEDURE|Holmium laser enucleation of the prostate|enucleation of the BPH according to standard procedure protocol
223643972|NCT02301416|DRUG|Phentermine/topiramate|Minimum of 3 months on Qsymia (7.5/46 mg) prior to scheduled weight loss surgery and continuance of up to 24 months of Qsymia after scheduled weight loss surgery.
223643973|NCT02301416|OTHER|low calorie diet|The low-calorie diet will be individually tailored based on initial resting metabolic rate measurement and co-morbid conditions.
223643974|NCT00967837|PROCEDURE|Pulsatile Intravenous Insulin Therapy|Diabetic pts that meet trial criteria referred by an endocrinologist are given Pulsatile intravenous insulin therapy on a weekly basis. Weekly orders for insulin dosage is based upon pt response to therapy monitored by RQ and insulin resistance.
224323423|NCT06066138|DRUG|Atezolizumab|Atezolizumab administered via IV at either 1,200 mg q3 weeks, or 1,680 mg q4 weeks for the first 2 doses followed by 840mg q2 weeks or q6 weeks.
223643975|NCT01295437|DEVICE|Vypro II mesh|partly absorbable mesh
223643976|NCT01295437|DEVICE|Premilene LP|lightweight mesh
223643977|NCT01295437|DEVICE|Premilene mesh|A conventional polypropylene mesh (82 g/m2)
223643978|NCT04951635|DRUG|Almonertinib|"The initial dose of Almonertinib 110 mg daily can be reduced to 55 mg daily under specific conditions.~Treatment can continue until disease progression, unacceptable toxicity or other discontinuation criteria are met. The 2:1 ratio (Almonertinib to placebo)."
223643979|NCT04951635|DRUG|Placebo Almonertinib|"The initial dose of Placebo Almonertinib 110 mg daily can be reduced to 55 mg daily under specific conditions.~Treatment can continue until disease progression, unacceptable toxicity or other discontinuation criteria are met. The 2:1 ratio (Almonertinib to placebo)."
223643980|NCT02282605|DRUG|XF-73 nasal gel|
223643981|NCT02282605|DRUG|Placebo nasal gel|
223643982|NCT02282605|OTHER|Chlorhexidine gluconate 2% topical cloths|
223643983|NCT02791503|PROCEDURE|Irreversible electroporation (IRE)|IRE is based on permeabilization of the cell membrane through electrical pulses leading to apoptosis. Theoretically, IRE only affects viable tumor tissue, leaving surrounding vital structures relatively intact. It is therefore considered to cause less morbidity than thermal ablative strategies.
224319748|NCT01436630|OTHER|Step Test and Six Minute Walk.|The 6 Minute Walk Test (6MWT) was conducted in a level corridor 30 meters long and 5 meters wide. Before and after testing were measured O2 saturation (SatO2) and heart rate (HR), respiratory rate (RR), blood pressure (BP), the Double Product (DP), a measure of myocardial oxygen consumption, was calculated as the product of HR and systolic BP, and the sensation of dyspnea and fatigue of the lower limbs using the Borg scale, and performing the record turns traveled, each 30 meters is considered a covered back. To calculate the predicted distance, the investigators use the formula described by American Thoracic Society (ATS) knowing the weight, age and height of participants. The Step Test (ST) was conducted in six minutes for it to be compared to the 6MWT.
223643984|NCT02791503|PROCEDURE|Stereotactic ablative radiotherapy (SABR)|Stereotactic ablative radiotherapy (SABR) is a form of external beam radiation that has important advantages over conventional radiotherapy such as a more precise and greater biological dose delivery and hence less toxicity and presumably better outcome.
223643985|NCT04816552|BEHAVIORAL|CHoBI7 mHealth program Arm|We will start delivery of this intervention with a pictorial module delivered in the home during two 30 minute visits on cholera transmission and prevention after enrollment. Households will be provided a handwashing station, a covered water vessel, and chlorine tablets. Households will then receive the CHoBI7 WASH mHealth program voice and text messages on handwashing with soap and water treatment bi-weekly.
224230991|NCT01314755|DIETARY_SUPPLEMENT|IMPACT|IMPACT (Nestlé Healthcare Nutrition, Minnetonka, MN, USA) an 'immune-enhancing' feed which contains supplemental L-arginine (1.25 78 g/L), dietary nucleotides (1.2 g/L) and omega-3 fatty acids in the form of 79 eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) (EPA/DHA 1.7 g/L) 80 as its active ingredients.
224230992|NCT01314755|DIETARY_SUPPLEMENT|An iso-caloric, iso-nitrogenous control feed|
224230993|NCT04485247|PROCEDURE|Transumbilical Laparoscopic-Assisted Appendectomy|appendectomy performed extracorporeally through umbilical port
224230994|NCT04485247|PROCEDURE|3-port laparoscopic appendectomy|appendectomy performed intracorporeally with 3-port
224230995|NCT06369337|DIAGNOSTIC_TEST|Ultrasound|The physical function variables will be analyzed through the Medical Research Council (MRC) and Functional Status Score (FSS), as well as swallowing function variables through the Volume-Viscosity Swallow (VVS-T) and Functional Oral Intake Scale scales. (FOIS) and Gugging Swallowing Screen (GUSS). The ecographic measurements will be made of the thickness and echogenicity of the submental and tonue muscles, as well as hyolaryngeal kinematics. These measurements will be performed 48 hours from the start of the orotracheal intubation episode, 7 days and 14 days of mechanical ventilation. To enable the correlation of clinical and ultrasound variables, one more independent measurement will be performed within the first 24 hours after authorization of oral tolerance in the patient.
224230996|NCT05994781|DEVICE|EasyDew MD regen cram|No intervention
224230997|NCT00211783|PROCEDURE|fMRI|there is no intervention
224319749|NCT00690066|DRUG|PROCHYMAL®|Intravenous infusion of ex vivo cultured adult human mesenchymal stem cells
224319750|NCT00690066|DRUG|Placebo|Intravenous infusion of excipients of PROCHYMAL®
223643986|NCT04816552|BEHAVIORAL|general message on oral rehydration solution (ORS)|general message on oral rehydration solution (ORS)
223643987|NCT01293656|OTHER|No intervention.|There is no study intervention. Participants will be treated locally per site standards.
223643988|NCT00575640|DRUG|Hydralazine|Dose Level 1: 150 mg/d 50 mg PO TID Dose Level 2: 200 mg/d 50 mg PO QID Dose Level 3: 225 mg/d 75 mg PO TID
223643989|NCT04823013|OTHER|high power pain threshold ultrasound which the dose was kept constant|Participants in HPPT-US 1 group received the HPPT-US treatment. The intensity was gradually increased from 0.5 W/cm² to the pain threshold level at which the patient verbally reported the pain. The therapist kept the intensity at that level for 5 s, and then moved the US transducer in a circle without the change of the intensity for 15 s. The procedure was repeated 3 times. The patients were asked whether serious pain or any abnormal sensation was felt during HPPT-US. The intensity was varied from 0.5 to 1.2 W/ cm².
223643990|NCT04823013|OTHER|high power pain threshold ultrasound which the dose reduced to one half|Participants in HPPT-US 2 group also received the HPPT-US treatment. The intensity was gradually increased from 0.5 W/cm² to the pain threshold level at which the patient verbally reported the pain. The therapist kept the intensity at that level for 5 s, then reduced the dose half and moved the US transducer in a circle for 15 s. The procedure was repeated 3 times. The patients were asked whether serious pain or any abnormal sensation was felt during HPPT-US. The intensity was varied from 0.5 to 1.2 W/ cm².
223643991|NCT04823013|OTHER|ischemic compression|Participants in IC group received ischemic compression therapy. The technique was applied in the sitting position to participants. Ischemic compression was performed by compressing trigger points identified by palpation with tolerable intensity using thumb. The duration for each trigger points was 1 minute. Then the muscle containing the trigger point was applied intramuscular stretching for 30 seconds by therapist
223643992|NCT00345748|DRUG|Abatacept|Injection, IV Infusion, Day 1, 15, 29 and every 28 days for 24 weeks
223643993|NCT00345748|DRUG|Placebo|Injectio, IV Infusion, Day 1, 15, 29 and every 28 days for 24 weeks
223643994|NCT04250909|DEVICE|Passeo-18|POBA
223643995|NCT04250909|DEVICE|Passeo-18 Lux|DCB
223643996|NCT00916331|PROCEDURE|subcutaneous indwelling|vacuum drainage is indwelled in subcutaneous layer
223643997|NCT00916331|PROCEDURE|intraarticular indwelling|vacuum drainage is indwelled in intraarticular space
223643998|NCT02253446|DRUG|Piroxicam|20 mg of piroxicam (Feldene ampoule-Pfizer-France) intramuscularly (IM) was given 200 patients,
223643999|NCT02253446|DRUG|Diclofenac Sodium|Second Group: Diclofenac sodium 75mg (Miyadren ampoule-bulb-Yavuz Istanbul) intramuscularly (IM) was given 200 patients.
223644000|NCT03584789|OTHER|Clinical Decision Support|A clinical decision support system designed to assist dentists in providing optimal pain management for patients without resorting to opioids when a non-opioid alternative would suffice. It provides pertinent clinical information to the dentist, including point-of-care access to the Prescription Drug Monitoring Program.
223644001|NCT03584789|OTHER|Patient education|Patient education regarding pain management before and after dental extraction, including information about the risks and benefits of various strategies.
223644002|NCT05550493|BEHAVIORAL|Cognitive Behavioral Therapy|The cognitive behavioral therapy program consisted of eight interactive sessions, each requiring approximately 15 minutes to complete. Each ICBT session includes interactive multimedia modules (videos, pictures, and texts), the contents of which were based on the community reinforcement approach. The ICBT sessions covered the following topics: (1) introduction to digital therapeutics and CBT, (2) recognizing the triggers of craving, (3) coping with craving, (4) refusing skills/assertiveness, (5) problem-solving skills, (6) changing thoughts about drugs, (7) seemingly irrelevant decisions, and (8) HIV risks and prevention.
223644003|NCT05550493|BEHAVIORAL|Counseling|Counseling provided by social workers and psychotherapists on topics including work, family, stress management, and drug craving suppression.
223644004|NCT05550493|BEHAVIORAL|Approach Bias Modification|In an ApBM session, users were instructed to swipe upward (downward) when they saw portrait (landscape) format images. A shrinking (growing) animation comes after swiping upward (downward) to simulate the visual effect of moving away (moving towards). The images were related to methamphetamine usage (methamphetamine crystals, powders, and paraphernalia) or healthy lifestyles (wealth, sports, gourmet, family activities, etc.). Each ApBM session was composed of presenting each one of the healthy lifestyle (methamphetamine) cues 12 times in landscape (portrait) and once in portrait (landscape).
223644005|NCT05550493|BEHAVIORAL|Cognitive Training|The DTx application incorporated a game-based cognitive function training module for improving working memory. In this game, a matrix of squares is displayed at the center of the screen. Between 3 and 5 target symbols are randomly placed in the matrix and displayed for 2 seconds. Next, the symbols disappear, and the matrix randomly rotates. The participants were asked to click the correct locations of the target symbols within the prescribed time limit. The game becomes more difficult as the size of the matrix, the number of target symbols, and the complexity of the matrix rotation change at each level. Each cognitive function training session lasted between 3 and 5 minutes.
223644006|NCT05295069|BEHAVIORAL|A nursing care program was applied for the intervention group under the guidance of Levine's conservation model.|Face-to-face training and training booklets were provided in home visits. As of the fourth home visit, Pilates exercises were performed.
223644007|NCT05023668|OTHER|No intervention|No intervention
223644008|NCT05526482|DEVICE|mobile app|preoperative respiratory exercises and thoracic surgery with a mobile application
223644009|NCT02035267|DRUG|Deoxycholic Acid|Formulated as an injectable solution containing deoxycholic acid at a concentration of 10 mg/mL.
223644010|NCT02035267|DRUG|Placebo|Phosphate buffered saline placebo for injection.
223644011|NCT00808652|OTHER|Measurement of flow mediated dilation of brachial artery.|"Flow-mediated brachial artery reactivity will be measured and flow-mediated vasodilatation will be assessed with the subject's arm using a 15 MHz linear array ultrasound.~Study Phases:~1. Flow-mediated (endothelial-dependent) vasodilatation (FMD): Following a 2-minute baseline period, a longitudinal image of the artery will be obtained. A tourniquet placed around the forearm proximal to the target artery will be inflated to a pressure 50 mmHg higher than the subject's systolic blood pressure and held for 5 minutes. Cuff will be then deflated. A continuous scan will be performed at deflation, 60 and 90 seconds after cuff deflation, with frozen and Doppler measurements recorded at similar intervals to the baseline phase.~2. NTG-induced (non-endothelial-dependent) vasodilatation (NTG): After vessel recovery, sublingual 375 mg of isosorbide dinitrate spray will be administered, and scanning will be performed continuously for 5 minutes thereafter."
223644012|NCT04509219|DRUG|Methylprednisolone Injection|methylprednisolone pulse therapy, 30mg/kg, with maximal dose of 1000mg/day, for continue 3 days.
223644013|NCT04803396|DRUG|DF2755A|"DF2755A was planned to be administered in two different parts:~Part A: Single oral dose administration on D1 according to the randomization (50, 150, 300 and 300 mg oad).~Part B: was planned (100 mg bid, 200 mg bid or 300 mg bid) but not performed (repeated oral administration from Day 1 to Day 14)."
223644014|NCT04803396|OTHER|Placebo|Single oral dose administration on D1
223644015|NCT04827680|DEVICE|Venus Viva MD|The Venus Viva™ MD fractional RF device has been shown in clinical studies to improve various skin conditions related to aging and alter collagen structures such as wrinkles, rhytids, and scars. Beginning with the Baseline visit (Visit 1), subjects will receive a total of 3 treatments approximately 3-5 weeks apart.
223644016|NCT00614731|BIOLOGICAL|KLH carrier-protein|KLH carrier-protein vaccination containing no other protein or antibodies
224230998|NCT03542136|DEVICE|VibrosSense Meter®|A multi frequency tactilometry device to evaluate the vibrotactile sense to indicate the underlying (Oxaliplatin induced poly neuropathy) OIPN and then compare the results with the results of CTCAE (Common toxicity criteria of adverse events) assessment tool evaluation.
223765796|NCT00827892|DRUG|Placebo Control|Lactose Capsule administered by mouth daily for the duration of the study as determined by MRI
223644017|NCT04755686|PROCEDURE|Fast-tracking|
223765797|NCT06428500|DRUG|QTX3046|QTX3046 will be administered at protocol defined dose.
223765798|NCT06428500|COMBINATION_PRODUCT|Cetuximab|Cetuximab will be administered at protocol defined dose.
223765799|NCT06731218|BIOLOGICAL|RGB-5088|Transplantation under the anterior rectus sheath
224230999|NCT02669680|DRUG|G-CSF|G-CSF subcutaneously, 5 μg/kg daily on day 0-4, then every 3rd day over 26 days (days 7, 10, 13, 16, 19, 22, 25) = 12 doses
223644018|NCT05457010|BIOLOGICAL|SPRX002|"SPRX002 is a soluble protein with a TAG region to which ARC-T cells bind and a binding region targeting CD123"
223644019|NCT05457010|BIOLOGICAL|ARC-T Cells|"ARC-T Cells is a genetically modified autologous T-cell product. The T cell has a binding domain chimeric antigen receptor (CAR), which specifically binds to the TAG protein of the soluble protein antigen-receptor x-linker (sparX; specifically, SPRX002). When ARC-T cells bind to a TAG and the SPRX protein is bound to its target (in this case CD123), ARC-T cells are capable of activation, expansion, and killing (based on preclinical experiments)."
223644020|NCT04917016|DIAGNOSTIC_TEST|Plasma B-HCG levels|Blood sample
223644021|NCT01416324|DRUG|placebo|Vehicle used to dilute the powder for oral administration.
223644022|NCT01416324|DRUG|0.1 mg GSK2330672|GSK2330672 is available as a white to almost white solid powder diluted in vehicle for oral administration.
223644023|NCT01416324|DRUG|0.3 mg GSK2330672|GSK2330672 is available as a white to almost white solid powder diluted in vehicle for oral administration.
223644024|NCT01416324|DRUG|1 mg GSK2330672|GSK2330672 is available as a white to almost white solid powder diluted in vehicle for oral administration.
223644025|NCT01416324|DRUG|3 mg GSK2330672|GSK2330672 is available as a white to almost white solid powder diluted in vehicle for oral administration.
223644026|NCT01416324|DRUG|10 mg GSK2330672|GSK2330672 is available as a white to almost white solid powder diluted in vehicle for oral administration.
223644027|NCT01416324|DRUG|30 mg GSK2330672|GSK2330672 is available as a white to almost white solid powder diluted in vehicle for oral administration.
223644028|NCT01416324|DRUG|60 mg GSK2330672|GSK2330672 is available as a white to almost white solid powder diluted in vehicle for oral administration.
223644029|NCT03678220|DEVICE|LapAR|LapAR system will be used for guidance during laparoscopic hepatectomy and laparoscopic liver thermal ablation
223644030|NCT01718405|OTHER|Cognitive function after exercise test|The individual subjects will participate in 3 sessions of either aerobic exercise, resistance exercise or rest, in a random order. Before and after each session, the subject will take computerized cognitive tests.
223644031|NCT01718405|GENETIC|Blood sample analysis|In the first evaluation session blood samples will be taken from each subject and will be analysed for genetic polymorphism.
223644032|NCT03807921|DRUG|Warfarin|Oral anticoagulation
223644033|NCT03807921|DRUG|Aspirin|Antiplatelet treatment
223644034|NCT01823913|DRUG|Test formulation|A single oral dose of a combination tablet of amlodipine orotate 10mg and valsartan 160mg
223644035|NCT01823913|DRUG|Reference formulation|A single oral dose of a combination tablet of amlodipine besylate 10mg and valsartan 160mg
223644036|NCT04097964|BEHAVIORAL|brief intervention|1 minute or less of anticipatory guidance will be provided for adolescents reporting no use in the past year, a 3-5 minute abbreviated brief intervention including raising the subject, asking more questions, and correcting misinformation will be provided for adolescents reporting substance use once or twice in the past year, and a 5-10 minute full brief intervention will be provided, including the above steps as well as assessing readiness and negotiating change and scheduling a follow-up to potentially include a referral to treatment will be provided to adolescents reporting monthly to weekly use in the past year.
223644037|NCT04097964|BEHAVIORAL|treatment as usual|standard care conducted by primary care providers during clinic visits
223644038|NCT02345993|DRUG|Extra fine Formoterol/Beclomethasone|"standard treatment consisting in: Albuterol 2.5 mg via nebulizer at baseline (0), 20, 40 minutes + Systemic steroid (methylprednisolone 60 mg) at the moment of evaluation~\+ formoterol/beclomethasone, 3 puffs administered via aerochamber at baseline (0), 20, 40, 60 minutes"
223644039|NCT04446104|DRUG|Hydroxychloroquine Sulfate Tablets|Hydroxychloroquine tablet 400mg loading dose, followed by 200mg daily for 42 days
223644040|NCT04446104|DRUG|Ivermectin 3mg Tab|Ivermectin tablet 12mg single dose
223644041|NCT04446104|DRUG|Zinc|Zinc tablet 80 mg/vitamin C 500mg daily for 42 days
223644042|NCT04446104|DRUG|Povidone-Iodine|Povidone-iodine throat spray (3 times daily) for 42 days
223644043|NCT04446104|DIETARY_SUPPLEMENT|Vitamin C|Vitamin C tablet 500mg daily for 42 days
223644044|NCT00224991|PROCEDURE|Intensive systematic information (osteoporosis school)|
223644045|NCT01359085|DRUG|Pregabalin|Pregabalin 75 mg will be given orally as premedication at the night before surgery (at bedtime). Pregabalin 150 mg will be administered orally at 1h preoperatively and at 12h and 24h postoperatively.
224231000|NCT02669680|OTHER|Standard therapy|
224231001|NCT01094444|OTHER|Vitamin K3|Lotion containing 1.5 mM Vitamin K3
224231002|NCT03449043|OTHER|Real care course|Evaluate the rate of adequacy between the request made by the general practitioner and the response to emergencies
224231003|NCT02154529|DRUG|Tesevatinib|
224231004|NCT02154529|DRUG|Trastuzumab|
224231005|NCT00468533|DRUG|Aripiprazole|
223644046|NCT01359085|PROCEDURE|ISBPB - interscalene brachial plexus block|ISBPB will be performed by an anesthesiology consultant experienced in performing the procedure, after the induction of GA. Block will be performed under sterile conditions by injection of 40ml 0.5% bupivacaine with epinephrine 1:100,000 to the plexus sheath through a 5-cm, 23-gauge short-beveled needle.
223644047|NCT06067217|DRUG|Tranexamic acid 250 mg oral tablet|Compare between tranexamic acid and progynova to stop abnormal uterine bleeding in DMPA users
224231006|NCT01412671|DRUG|Sorafenib (Nexavar, BAY43-9006)|Patients who have received Nexavar for unresectable or advanced RCC.
224231007|NCT05866757|OTHER|Discontinuation of maintenance treatment|The discontinuation of maintenance treatment in multiple myeloma. Classed as interventional due to treatment being taken away.
224231008|NCT00974142|DRUG|Cyclosporine|Fifteen patients will receive cyclosporine at an initial dosing of 3.0 mg/kg/day.
224231009|NCT00974142|DRUG|Placebo|Fifteen patients will receive will receive placebo.
224231010|NCT02081326|BIOLOGICAL|Bacillus Calmette-Guérin|2 BCG vaccinations spaced 4 weeks apart during the first year and then 1 vaccination every year for the next 4 years
224231011|NCT02081326|BIOLOGICAL|Saline injection|2 injections spaced 4 weeks apart during the first year, then 1 injection per year for the next 4 years
224231012|NCT02322528|DRUG|Administration of Lotemax|An FDA approved drug (Lotemax) will be administered to induce an inflammatory mediated response in both eyes.
224231013|NCT00458302|DRUG|darunavir (DRV, TMC114)|800 mg qd (2 x 400 mg tablet) + 2 NRTI for 144 weeks
223644048|NCT06067217|DRUG|Progynova 1 mg oral tablet|Compare between tranexamic acid and progynova to stop abnormal uterine bleeding in DMPA users
223644049|NCT01981018|OTHER|Imagery-focused Cognitive Therapy (ImCT - psychotherapy based on CBT principles)|"ImCT Therapy is carried out by a team of 2 co-therapists and comprises of:~* Mapping: Therapists and patient collaboratively map out difficulties and pinpoint a treatment focus, with regards to imagery symptoms and anxiety co-morbidity that impact on bipolar mood instability. This leads to an individualised formulation of the patient's current problem.~* Target: Follows the rationale, timing and objectives identified collaboratively in Mapping. It is structured around imagery-based techniques, such as imagery rescripting, which are used to address problematic imagery, to promote management of mood and boost self-care. This results into the acquisition of imagery-based mood- and anxiety-regulating strategies to be integrated into the patient's already existing coping strategies.~* Consolidation: Consist of fine tuning the strategies devised during Target based on experience gained after testing them out in real life situations and includes a video blue print."
223644050|NCT00194532|DRUG|Cefpodoxime|Cefpodoxime 100mg twice a day(BID)for 3 days
223644051|NCT00194532|DRUG|Ciprofloxacin|Ciprofloxacin 250mg twice a day (BID)for 3 days
223644052|NCT01470950|PROCEDURE|Motionmaker|3 times per week, FES Training on the Motionmaker device, for 6 months
223644053|NCT00823615|DEVICE|Lotrafilcon B multifocal contact lens|Silicone hydrogel, soft, multifocal contact lens for daily wear use
223644054|NCT00823615|DEVICE|Senofilcon A multifocal contact lens|Silicone hydrogel, soft, multifocal contact lens for daily wear use
223644055|NCT01801228|DRUG|Eplerenone|
223644056|NCT00098813|DRUG|romidepsin|Given IV
223644057|NCT00098813|OTHER|laboratory biomarker analysis|Correlative studies
223644058|NCT00098813|PROCEDURE|positron emission tomography|Correlative studies
223644059|NCT03967613|DEVICE|Functional eletrical stimulation|Aplication of functional eletrical stimulation on contralesional upper limb during functional tasks
223644060|NCT04834622|BEHAVIORAL|Melodies for Mums|Melodies for Mums (M4M) is an intervention that was developed and tested as part of a collaboration between the Royal College of Music, Imperial College London and University College London from 2015-2017. The programme involved weekly singing classes for mothers and their babies delivered in groups of 8-12 in Children's Centres for 10 weeks. A trained artist delivers 1-hour long singing sessions to mothers with postnatal depression (and their babies) for a period of 10-weeks. The sessions are aimed at the mothers, with songs ranging from sound baths to folk songs and songs created by the mothers themselves. Mothers randomised to the intervention will be prompted via text message, each week before the session, to attend these singing sessions.
223644061|NCT04834622|BEHAVIORAL|Control Community Sessions|Group mother-baby interventions in the community (i.e. baby play, baby reading sessions, baby massage, etc). A list of these activities will be collected from the activities on offer in the community. All the mothers randomised to the control group will be pointed towards these activities, prompted by text messages in line with the prompts received by the mothers in the intervention group. Mothers will be encouraged to attend these non-music based community activities once a week with their babies.
223644062|NCT05842161|BEHAVIORAL|QUIT-AD|An adapted, six-session cognitive behavioral therapy intervention for smoking cessation and treatment adherence
223644063|NCT05842161|OTHER|Enhanced Treatment as Usual|Standard treatment for HIV/TB with one session of psychoeducation.
223644064|NCT00436514|BEHAVIORAL|diet and absorption of ColoPEG|4l of PEG during 2 days
223644065|NCT00436514|PROCEDURE|Colonoscopy with colic videocapsule|2x 10mg Motilium, 2 Fleet Phospho soda (one is facultative) and 1 dulcolax (facultative)
223644066|NCT00436514|PROCEDURE|Standard colonoscopy|1l of PEG the morning just before colonoscopy
223644067|NCT01588392|BEHAVIORAL|Short bouts of structured physical activity|Short bouts of structured physical activity preschools will be asked to implement age-appropriate 10 minute structured physical activity routines within the classroom setting followed by 20 minutes of usual unstructured playtime activities. Intervention will be implemented for a total of 30 minutes during both morning and afternoon gross motor playtime 5 days/week for 6 months.
223644068|NCT01588392|BEHAVIORAL|Unstructured physical activity|Unstructured physical activity intervention will consist of 30 minutes of supervised unstructured free playtime twice. intervention will be delivered during both morning and afternoon gross motor playtime for 5 days/week for 6 months.
223644069|NCT00004669|DRUG|hydrocortisone|
223644070|NCT02894736|DEVICE|Soterix tDCS machine|Soterix tDCS machine - miniCT supervised neuromodulation system
223644071|NCT04946981|DIETARY_SUPPLEMENT|Turmipure Gold®|TPG: Turmipure GOLD® - 1 capsule per day - as prescribed
223644072|NCT04946981|DIETARY_SUPPLEMENT|Placebo|Placebo: colored acacia gum - 1 capsule per day - as prescribed
223644073|NCT03669497|RADIATION|Hypo fractionated whole breast radiotherapy|Hypo fractionated radiotherapy to the whole breast and SCF to a dose of 26 GY in 5 fractions with simultaneous integrated boost in advanced incurable breast cancer
223644074|NCT02154698|OTHER|22-gauge Standard Needle|Acquisition of lymph nodes samples using the 22-gauge Standard Needle, following subject-sedation and the introduction of an EBUS scope into the airway.
223644075|NCT02154698|OTHER|22-gauge ProCore Needle|Acquisition of lymph nodes samples using the 22-gauge ProCore Needle, following subject-sedation and the introduction of an EBUS scope into the airway.
223644076|NCT01926262|BEHAVIORAL|Specific Strength Training|Specific Strength Training for the Neck and Shoulder Muscles
223644077|NCT06096571|DRUG|Aterixen|A single dose of R or T drug in each of 2 periods of the study in fasted conditions
223644078|NCT05965544|DRUG|Bupivacain (preoperative)|After the patients are in the supine position and aseptic conditions are provided in the preoperative period, the fascia on the iliacus muscle will be determined with the help of an 8-12 MHz linear probe and a block will be applied with the in-plane technique. During the block, 0.2% bupivacaine concentration 0.5 mL/kg is routinely used in patients.
223644079|NCT05965544|DRUG|Bupivacaine-fentanyl|The patient will be placed in the lateral decubitus position with the fractured side up. After the spinal anesthesia method was provided with aseptic conditions, 10 mg 0.5% bupivacaine + 20 mcg Fentanyl injection will be applied using a 26 Gauge pencil point needle through the L3-L4 or L4-L5 intervertebral space
224231014|NCT00458302|DRUG|darunavir (DRV, TMC114)|800 mg qd (2 x 400 mg tablet) monotherapy for 144 weeks
224231015|NCT02201498|PROCEDURE|Pulpotomies with Formocresol/OZE and Biodentine|
224319751|NCT07134283|PROCEDURE|Preoperative and Postoperative Cold Therapy with Gel Cold Pack|Cold therapy was applied using a conventional gel cold pack , pre-cooled at -17°C for at least 2 hours. In the intervention group, cold application was performed three times before surgery (20 minutes per session with 40-minute intervals), and continued postoperatively for 24 hours with the same frequency. This protocol aimed to reduce pain, swelling, bleeding, and improve functional outcomes after total knee arthroplasty.
224319752|NCT07134283|PROCEDURE|Postoperative Cold Therapy with Gel Cold Pack|Cold therapy applied only in the postoperative period, for 24 hours, using the same method as the intervention group (20-minute applications with 40-minute breaks.
224319753|NCT07134218|DRUG|serplulimab、bevacizumab|short-course radiotherapy 25 Gy in 5 fractions → 2-week break → 2 cycles of FOLFOX + serplulimab + bevacizumab → 2 cycles of FOLFOX + serplulimab.
223644080|NCT05965544|DRUG|Bupivacain (Postoperative)|After the patients are in the supine position and aseptic conditions are provided in the postoperative period, the fascia on the iliacus muscle will be determined with the help of an 8-12 MHz linear probe and a block will be applied with the in-plane technique. During the block, 0.2% bupivacaine concentration 0.5 mL/kg is routinely used in patients.
223644081|NCT02670239|PROCEDURE|normothermic ex vivo lung perfusion|
223644082|NCT00140582|DRUG|Rituximab|rituximab 375 mg/m2 every 8 weeks for 24 months (12 injections) or control with no treatment
224319754|NCT07134218|OTHER|neoadjuvant chemoradiation therapy|short-course radiotherapy 25 Gy in 5 fractions → 2-week break → 4 cycles of FOLFOX alone.
224319755|NCT06854757|BEHAVIORAL|RIVER|RIVER is a peer grief support process intervention developed by Peer Support Community Partners.
224319756|NCT06854757|BEHAVIORAL|Enhanced care as usual|The enhanced care as usual condition involves a psychoeducational booklet developed by What's Your Grief, as well as a list of local grief resources.
223644083|NCT00921375|DRUG|TULY|TULY (rasburicase) 0.20 mg/kg body weight intravenously for 4 days
223644084|NCT00893438|BEHAVIORAL|FitNet treatment|web-based cognitive behavioural treatment for adolescents with CFS
223644085|NCT00893438|OTHER|Usual care|Usual care treatment for adolescents with CFS
223644086|NCT04567992|PROCEDURE|superficial cervical plexus block|ultrasound guided injection of local anaesthesia in the superficial cervical plexus
223644087|NCT02987790|OTHER|C-reactive protein|PCR assays shall be performed daily on serum obtained from blood collected for routine intensive care examinations up to 2 days after antibiotic withdrawal. In the PCR group, antibiotic suspension will be encouraged when levels of this marker are \<35mg / L (if peak PCR below 100mg / L); or reduce 50% of the highest value (if PCR peak\> 100mg / L), with a limit of seven days, if there is clinical improvement.
223644088|NCT00072319|BIOLOGICAL|filgrastim|
223644089|NCT00072319|DRUG|cyclophosphamide|
223644090|NCT00072319|DRUG|epirubicin hydrochloride|
223644091|NCT00072319|DRUG|paclitaxel|
223644092|NCT00072319|PROCEDURE|adjuvant therapy|
223644093|NCT00072319|PROCEDURE|neoadjuvant therapy|
223644094|NCT01464437|DRUG|AMG 151|Drug: AMG 151 50 mg BID
223644095|NCT01464437|DRUG|Placebo|Placebo
223644096|NCT01464437|DRUG|Metformin|Subjects will remain on their metformin regimen throughout the study. The metformin dose must be ≥ 850 mg/day for at least 2 months immediately prior to randomization.
223644097|NCT01464437|DRUG|AMG 151|Drug: AMG 151 100 mg BID
224319757|NCT06983639|DIAGNOSTIC_TEST|Fecal occult blood testing|Fecal testing for blood as surveillance efter polyp removal
224319758|NCT06983639|DIAGNOSTIC_TEST|Colonoscopy|Colonoscopy after polyp removal according to guidelines
224319759|NCT06981598|BEHAVIORAL|Cognitive Behavioral Coaching Training|Behavioral technicians will engage in a structured, deliberate-practice-based training program designed to enhance competence in evidence-based interventions (EBIs) over a 10-week period. The program begins with an initial seminar that provides an overview of the training framework, key research supporting deliberate practice, and specific intervention techniques. Each participant is assigned a coach-either a clinical psychologist or a licensed MSW with expertise in the EBI Toolkit-who will provide individualized guidance throughout the training. During the weekly coaching sessions, participants will review session notes, engage in structured practice exercises, and work toward mastering the skills and competencies necessary for effective intervention delivery. Weekly homework assignments will allow participants to practice each tool as though they were working with an SM client, followed by self-reflections that will be discussed in coaching sessions.
224319760|NCT04489719|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
223644098|NCT01464437|DRUG|AMG 151|Drug: AMG 151 200 mg BID
223644099|NCT01464437|DRUG|AMG 151|Drug: AMG 151 100 mg QD
223644100|NCT01464437|DRUG|AMG 151|Drug: AMG 151 200 mg QD
223644101|NCT01464437|DRUG|AMG 151|Drug: AMG 151 400 mg QD
223644102|NCT00445926|DEVICE|deep TMS H-coil|
223644103|NCT00462995|DRUG|Erlotinib|150mg once a day for 28 days
223644104|NCT00462995|DRUG|Erlotinib|28 days of Erlotinib before surgery in patients with stage I-IIb NSCLC
223644105|NCT05434416|OTHER|mobile app|mobile app self-guided psychological interventions
223644106|NCT00566761|DRUG|bevacizumab and triamcinolone|three applications monthly administrated of bevacizumab 2.5mg for group 1 and bevacizumab 2.5 mg + triamcinolone 4mg first dose followed by two of bevacizumab alone for the group 2
223644107|NCT05488535|DEVICE|cochlear implant headpiece|investigational cochlear implant headpiece
223644108|NCT06521333|DRUG|Resveratrol-Based gel|The Resveratrol-Based gel will be applied using a sterile plastic syringe, and the palatal wound will be immediately covered by an acrylic resin stent. Three days postoperatively, the patients will be recalled, the stent will be removed for evaluation and the Resveratrol gel will be reapplied.
223644109|NCT06521333|DRUG|Hyaluronic acid gel 0.2%|The 0.2% Hyaluronic acid gel will be applied using a sterile plastic syringe, and the palatal wound will be covered by an acrylic resin stent. Three days postoperatively, the patients will be recalled, the stent will be removed for evaluation, and the Hyaluronic acid gel will be reapplied.
223644110|NCT06521333|DEVICE|Stent|The palatal wound will be immediately covered by acrylic resin stent three days postoperatively, the patients will be recalled, and the stent will be removed for evaluating the healing of the palatal wound and then recover with stent.
223644111|NCT03705338|DEVICE|Electroencephalography|Measure the appearance and disappearance of frontal alpha wave with EE, when them loss and recovery of consciousness under general anesthesia with propofol.
223644112|NCT03705338|DRUG|Propofol|Recorder the loss and recovery of consciousness in children under general anesthesia with TCI of propofol intravenous. Induction will be started with 20 mg/kg/hr of propofol up to UMSS level 4. Then will be titrated leading anesthesiologist criteria.
223644113|NCT00892099|DRUG|Ergocalciferol|50,000 IU tablet given weekly
223644114|NCT00892099|DRUG|Ergocalciferol|50,000 IU tablet given monthly
223644115|NCT00892099|OTHER|Placebo|Placebo equivalent of ergocalciferol, given weekly as one tablet
223644116|NCT06341478|DRUG|various neoadjuvant therapies|Radical cystectomy, Sacituzumab Govitecan (SG), SG + pembrolizumab, nivolumab+abraxane
223644117|NCT04129567|OTHER|Humidified oxygen|Delivering humidified oxygen at 15 liters per minute through the nose in a blinded fashion using a nasal cannula.
223644118|NCT04129567|OTHER|Dry oxygen|Delivering dry oxygen at 15 liters per minute through the nose in a blinded fashion using a nasal cannula.
223644119|NCT04129567|OTHER|Humidified air|Delivering humidified air at 15 liters per minute through the nose in a blinded fashion using a nasal cannula.
223644120|NCT04129567|OTHER|Dry air|Delivering dry air at 15 liters per minute through the nose in a blinded fashion using a nasal cannula.
223644121|NCT02376699|DRUG|Intravenous (IV) SEA-CD40|Given intravenously; schedule is cohort-specific.
223644122|NCT02376699|DRUG|Pembrolizumab|Given intravenously; schedule is cohort-specific.
224231016|NCT04849845|COMBINATION_PRODUCT|Afrezza Dose 1|The first dose of Afrezza will be based on the dose of subcutaneous rapid-acting analogue (RAA) insulin that the subject would normally take for the standardized meal, converted according to the guidelines provided in the current Afrezza U.S. prescribing information.
224231017|NCT04849845|COMBINATION_PRODUCT|Afrezza Dose 2|The second dose of Afrezza will be based on the dose of subcutaneous rapid-acting analogue that the subject would normally take for the standardized meal, converted by multiplying their RAA dose by 2 and rounding down to the nearest Afrezza cartridge size.
224231018|NCT03712657|COMBINATION_PRODUCT|ERAS|"1. preoperative pain control;~2. avoiding application of ureter;~3. avoiding application of gastric tube;~4. avoiding application of irrigation;~5. avoiding application of drainage;~6. early exercising postoperatively;~7. early oral feeding postoperatively;~8. early discharging."
224231019|NCT05147051|DRUG|Meglumine Sodium Succinate|500 ml of 1.4% solution IV at a rate of at least 4 ml and not more than 10 ml per minute
223644123|NCT02376699|DRUG|Subcutaneous (SC) SEA-CD40|Given subcutaneously on Day 1 every 3 weeks
223644124|NCT02376699|DRUG|Gemcitabine|1000 mg/m\^2 given intravenously on Day 1, 8, and 15 of each 28-day cycle
223644125|NCT02376699|DRUG|Nab-paclitaxel|125 mg/m\^2 given intravenously on Day 1, 8, and 15 of each 28-day cycle
223644126|NCT00217607|DRUG|paclitaxel|
223644127|NCT03352037|DIAGNOSTIC_TEST|PET scan|Patients with known pancreatic cystic lesions requiring MR imaging for lesion characterization for clinical evaluation will be recruited to undergo 18F-FDG PET/MR imaging after written informed consent.
223644128|NCT01167413|DEVICE|Evaluation by manual Dolorimeter|Patients will be examined by a manual Dolorimeter
223644129|NCT01167413|OTHER|SIJ imaging|Patients will undergo imaging of the Sacroiliac joint by plain x-ray or MRI and sacroileitis will be documented
223765800|NCT03889119|RADIATION|Stereotactic Body Radiation Therapy (SBRT) radiation for prostate cancer utilizing the Elekta Versa or Agility System.|SBRT uses advanced imaging techniques to deliver targeted radiation to a tumor. The Elekta Versa and Agility Systems are approved by the Food and Drug Association (FDA) for SBRT treatment of cancer.
223644131|NCT02481661|PROCEDURE|segmentectomy|segmentectomy in Arm I and lobectomy in Arm II
223644132|NCT06144112|BIOLOGICAL|fresh frozen plasma|transfusion of fresh frozen plasma
223644133|NCT06144112|BIOLOGICAL|prothrombin complex concentrate|prothrombin complex concentrate administration
223644134|NCT04396639|BIOLOGICAL|Moroctocog-alfa (AF-CC)|Moroctocog-alfa (AF-CC) is indicated for the control and prevention of hemorrhagic episodes and for routine and surgical prophylaxis in patients with hemophilia A (congenital factor VIII deficiency or classic hemophilia).
224231020|NCT05147051|DRUG|Placebo|Ringer's solution, 500 ml IV at a rate of at least 4 ml and not more than 10 ml per minute
224231021|NCT02331537|BEHAVIORAL|Internet-based cognitive-behavior therapy|Internet-based cognitive-behavior therapy on a safe internet platform. Treatment is divided into seven modules, each containing homework assignments . The participants will be assigned a therapist that they can contact through a message system in the platform and expect answer within 24 hours.
224231022|NCT02957656|BIOLOGICAL|H7N9 pLAIV|10\^7.0 fluorescent focus units (FFU); delivered by an Accuspray device
224231023|NCT02957656|BIOLOGICAL|H7N9 pIIV|Administered by intramuscular injection in the deltoid.
224231024|NCT02957656|BIOLOGICAL|AS03 adjuvant|Mixed with H7N9 pIIV vaccine; administered by intramuscular injection in the deltoid
224231025|NCT01813656|DRUG|Aripiprazole|Aripiprazole group,5mg/pill,10mg/day non-forced titration method,last 12weeks
224231026|NCT01813656|DRUG|placebo|placebo group,5mg/pill,10mg/day non-forced titration method,last 12 weeks
223644135|NCT00892476|DIETARY_SUPPLEMENT|Calcium Supplementation|"Ca-gluconate powder (molar weight 430.4 g) will be measured with household measuring spoons and added to the feeding mixtures as follows:~Amount of feeding Actual Weight \< 1000 g Actual Weight \< 1000 g~25 ml ¼ tsp 1/8 tsp~50 ml ½ tsp ¼ tsp~100 ml 1 tsp ½ tsp~200 ml 2 tsp 1 tsp"
223644136|NCT00892476|OTHER|Standard of Care|Infants are feed breast milk with fortifier or 24 cal/oz formula per standard of care
223644137|NCT04285970|OTHER|cycle detection|6-minute test on a treadmill at pedestrian speed (5km/h) with 2 instruments (dynamometric wheel and inertial centre) on a standardised wheelchair
223644138|NCT04285970|OTHER|detection of effort intensity|6-minute test on an urban course with 2 instruments (dynamometric wheel and inertial units) on a wheelchair
223765801|NCT06079164|DRUG|KITE-197|A single infusion of CAR-transduced autologous T cells administered intravenously
224231027|NCT04578743|DEVICE|Graded Exercise Therapy: ClearPlay(TM)|ClearPlayTM; a novel therapeutic intervention, downloadable to an Apple i-touch or i-phone device, that provides a telemetry-based graded exercise program that enables remote monitoring of symptoms.
224319761|NCT04489719|OTHER|Questionnaire Administration|Ancillary studies
224319762|NCT04489719|DRUG|Radium Ra 223 Dichloride|Given IV
223644139|NCT04749004|BEHAVIORAL|Promotion of physical activity|Provision of motivational stimuli (commitment contracts, nudges, financial incentives) to increase amount of steps taken
223644140|NCT00965172|OTHER|Caphosol|Oral rinse of calcium phosphate solution five times daily beginning on day one of chemotherapy.
223644141|NCT00965172|OTHER|Baking Soda|Oral rinse of baking soda solution as per standard of care five times daily beginning on day one of chemotherapy.
223644142|NCT02052518|BEHAVIORAL|Experimental|These participants will receive the enhanced intervention including decision support and problem solving skills in addition to the standard of care for the individuals in the Nuturing Family Network Home Visition Program
223644143|NCT02229669|PROCEDURE|Horizontal incisions|Performed by using horizontal interdental incisions. An initial horizontal incision was made slightly coronal to the CEJ from the distal to the mesial papilla of the teeth with the recessions. A second incision, 1 to 2 mm apart and parallel to the first incision, was made apically. A sulcular incision was made to link the second incisions and the blade was inserted (2 to 3 mm) extending beyond the mucogingival junction (MGJ), to create a uniform split-thickness flap. The tissue between the two incisions was partially removed to obtain a uniform receptor site that permitted primary closure. Approximation sutures to place the edge of the flap at the base of the remaining papilla were performed. Passive closure of the wound margins without tension was achieved with interrupted coaptation.
223644144|NCT02229669|PROCEDURE|Oblique incisions|Coronally advanced flap was performed by using oblique incisions in interdental areas, according to the technique proposed by Zucchelli \& De Sanctis (2000). Oblique submarginal interdental incisions were performed and continued with the intrasulcular incisions at the recession defects, resulting in a envelop flap that was raised with a split-full-split approach in the coronal-apical direction. During coronal advancement, each surgical papilla was dislocated with respect to the de-epithelized anatomic papilla by the oblique incisions. Interrupted sutures were performed to stabilize single surgical papilla over the interdental connective tissue bed.
223644145|NCT05427188|BEHAVIORAL|Stress paradigm|HV will receive mental arithmetic challenges, together with social evaluative threat components from the program and/or the investigator
223644146|NCT05427188|BEHAVIORAL|Sham paradigm|HV will receive mental arithmetic challenges where threat components from the program and/or the investigator are absent
223644147|NCT00297518|DEVICE|PerioWave|
223644148|NCT00297518|PROCEDURE|Scaling and Root Planing|
223644149|NCT02641782|DRUG|antibody ch14.18|17.5mg/m²d 10-20h i.v, d4-7 in cycles 1,3,5 and d8-11 in cycles 2,4.
223644150|NCT02641782|DRUG|GM-CSF|250µg/m²xd, d1-14 s.c. or i.v (2h) in cycles 1,3,5
224231028|NCT03070249|BEHAVIORAL|Professional Quality of Life (ProQoL) scale|COMPASSION SATISFACTION AND COMPASSION FATIGUE (PROQOL) measures how compassion for those who are cared for can affect providers in positive and negative ways. Questions about experiences, both positive and negative, as a provider reflecting the frequency experiences within the last 30 days. 1=Never 2=Rarely 3=Sometimes 4=Often 5=Very Often
223644151|NCT02641782|DRUG|IL-2 i.v.|3.0 mio U/m²xd d1-4 continuous infusion i.v. and 4.5 mio U/m²xd d8-11 continuous infusion i.v. in cycles 2,4
223644152|NCT02641782|DRUG|IL-2 s.c.|0.06 mio U/m² i.v. test dosis for 30min. i.v. at least 2h before first subcutaneous (s.c.) application. 6 mio U/m²xd d1-5 and 8-12 s.c. in cycles 2,4
223644153|NCT02641782|DRUG|Retinoic acid|160mg/m²xd b.i.d.oral d 11-24 in cycles 1,3,5,6 and d15-28 in cycles 2,4
223644154|NCT06092593|DEVICE|Upper endoscopy|Evaluation of upper gastrointestinal tract lesions in ulcerative colitis patients
223644155|NCT04028219|DIAGNOSTIC_TEST|Online surveys|Psychometric measures within 14 online surveys, which is one at each assessment point (before and 3, 6, 9, 12, 24, 36, 48, 60, 72, 84, 96, 108, 120 months after hormonal therapy).
223644156|NCT05866315|DRUG|Remimazolam|Administer remimazolam
223644157|NCT05866315|DRUG|Desflurane|administer desflurane
223644158|NCT05866315|DRUG|Remifentanil|administer remifentanil
223644159|NCT00042315|PROCEDURE|Chemotherapy|
223644160|NCT00042315|DRUG|tariquidar + vinorelbine|
223644161|NCT00042315|DRUG|placebo + vinorelbine|
223644162|NCT05847816|OTHER|Experimental group: infrared vascular imaging|"Experimental group - infrared vascular imaging;Before PIVC, infrared light will be directed to the vein area and the procedure will be started after vein visibility is achieved.~Experimental group - isometric hand exercise; Stress balls will be given to patients 10 minutes before the PIVC procedure and they will be asked to perform hand-clamping exercises with both hands. Processing will then begin."
223644163|NCT05933382|OTHER|Corticosteroid Group|Conventional exercise and corticosteroid injection
223644164|NCT05933382|OTHER|Mulligan Group|Conventional exercise and mulligan mobilization
223644165|NCT01752777|BEHAVIORAL|Infectiousness Risk Reduction|Behavioral counseling conducted in one office session followed by 4 cell-phone-based sessions. Counseling is based on models of behavioral self-management and cognitive decision making with the primary aim to increase antiretroviral adherence, engagement in HIV care, and reduction of sexual risk behaviors for HIV transmission.
223644166|NCT01752777|BEHAVIORAL|General Health Improvement|Educational counseling to help link participants to social serves and health related strategies.
223644167|NCT01895556|OTHER|Information|
223644168|NCT01895556|OTHER|Control|
223644169|NCT03565094|DRUG|Lu AF28996 solution|"Oral solution (0.1-0.2 mg/mL)~Following each cohort, a dosing conference will be held where tolerability, safety and preliminary PK results from the previous cohorts will be reviewed before deciding on the next doses"
223644170|NCT03565094|DRUG|Lu AF28996 capsule|hard capsule orally QD: one dose lower than the highest dose level in part A
223644171|NCT00584636|DRUG|pulmicort respules|pulmicort respules 0.5 mg twice a day for 28 days versus placebo
223644172|NCT06169059|DRUG|JLP-2004|administration of JLP-2004(COX-2 inhibitor)
223644173|NCT06169059|DRUG|JC-013|administration of JC-013(COX-2 inhibitor))
223644174|NCT06238258|BEHAVIORAL|SPECTROM Training|Training regarding treatment of behavioral challenges in adults with intellectual disability
223644175|NCT05488665|DEVICE|Crush technique|Treatment for bifurcation with the Crush technique
223644176|NCT05488665|DEVICE|Culotte technique|Treatment for bifurcation with the culotte technique
223644177|NCT00253318|DRUG|Docetaxel|40 mg/m\^2 IV over 1 hour on Day 1.
223644178|NCT00253318|DRUG|RAD001|30 mg orally on Days 1 and 8.
223644179|NCT00253318|DRUG|Dexamethasone|8 mg orally twice daily for 3 days, starting 24 hours prior to the administration of Docetaxel.
223644180|NCT02694484|OTHER|Blood and stool samples|Blood sample at Day 1 and blood and stool sample at the next visit
224231029|NCT03801161|BIOLOGICAL|Pentavalent vaccine. It is a combination of five different antigens (Hepatitis B (HBV)/ Haemophilus influenzae type b (HiB) / Tetanus-Diphtheria-whole cell Pertussis (TDwP)).|Pentavalent vaccine is being recommended to provide infants at 6wk, 10wk and 14wk of age. This vaccine also induces plasma CRP \>5 mg/L in infants within 24 hours of immunization.
223765802|NCT06079164|DRUG|Cyclophosphamide|Lymphodepleting chemotherapy administered intravenously
223765803|NCT06079164|DRUG|Fludarabine|Lymphodepleting chemotherapy administered intravenously
224231030|NCT01026961|DRUG|Phenylephrine HCL|Phenylephrine HCL 10mg
224231031|NCT01026961|DRUG|Phenylephrine HCL/Acetaminophen/Dimethindene Maleate|Phenylephrine HCL 10mg/Acetaminophen 500mg/Dimethindene Maleate 1mg
224231032|NCT02010047|DEVICE|ALK qPCR assay|72 IHC ALK-negative and 72 IHC ALK-positive FFPE samples will tested with FISH and qPCR to determine the sensitivity and specificity of the ALK qPCR assay.
223644181|NCT06344221|DEVICE|Dextrain Manipulandum and haptic feedback device|Assessment of key components of manual dexterity in addition to vibrotactile stimulation on the fingers and wrist.
223644182|NCT03107871|DRUG|Valganciclovir|Valganciclovir is supplied as a powder for reconstitution into an oral solution. The reconstituted solution formulation comprises the following excipients: Povidone K30, fumaric acid, sodium benzoate, saccharin sodium, mannitol, flavor, and purified water.
223644183|NCT03107871|DRUG|Simple Syrup|Simple Syrup contains sucrose 85% weight by volume, purified water, and methyl paraben as a preservative along with natural preservatives. It will be flavored to match the flavor of valganciclovir.
223644184|NCT04135274|DIAGNOSTIC_TEST|Neutrophil to lymphocyte ratio|Neutrophil to lymphocyte ratio
223644185|NCT05162963|OTHER|fixed implant denture|Patients will receive four or six dental implants, four in the mandible or six in the maxilla, depending on the arch to be treated. After an osseointegration phase of 4 to 6 months, two implant prostheses will be made for each patient, one removable, the other fixed. According to the randomization, during an initial period of 6 months, half of the patients will be using the removable prosthesis, the other half the fixed prosthesis. A 15-day washout will be performed. Then, during a second period of 6 months, the patients will be using the second prosthesis.
223644186|NCT05162963|OTHER|removable implant denture|removable implant denture
223644187|NCT05518097|OTHER|Conventional physical therapy program|Patients with knee osteoarthritis underwent a total of 15 sessions of conventional physical therapy program including hotpack, US, TENS, and exercise 5 days a week, for 3 weeks. Hot pack was applied for 10 minutes, ultrasound was applied continuously at 1 MHz, 1.0 W/cm2 for 10 minutes, and TENS was applied for 30 minutes according to the patient's tolerance. The exercise program consisted of an active, active-assisted range of motion and isometric quadriceps strength training.
223644188|NCT04931368|DRUG|Experimental Treatment: one course Rituximab/HD-Methotrexate, two courses of MATRix|De-escalated induction treatment with R/HD-MTX and two courses of MATRix
223644189|NCT04931368|DRUG|Control intervention: four courses of MATRix|Patients receive four courses of MATRix as induction treatment.
223644190|NCT01532986|OTHER|Coordinated care management for Parkinson's disease|Nurse care managers will use standardized assessment tools and care coordination protocols to address unmet needs of Veterans with PD, and collaborate with these Veterans and their families, providers, and community partners to manage PD care.
223644191|NCT01532986|OTHER|Educational handout|"To minimize potential bias from participants' awareness of randomization arm assignment, the investigators will provide to all study participants (intervention arm and usual care arm) on enrollment a brief educational handout on Parkinson's disease that is available in the VA's Healthwise for Life handbook (page 273). This information includes a definition of PD, its symptoms, and several suggestions for managing PD such as medications and regular exercise."
224231033|NCT06464328|BEHAVIORAL|Tai Chi Combined with Music Therapy Intervention|Tai Chi combined with music therapy Intervention, the effect was achieved by replacing the school's physical education classes with Tai Chi of the researchers' choice, and then by playing music of the researchers' choice during class; twice a week for twelve weeks
224319763|NCT04603547|DEVICE|Transcutaneous Carbon Dioxide Monitoring|Once an infant is identified as being eligible for TH treatment and hypothermia was initiated according to the department clinical practice guidelines, and written informed consent was obtained from one of the parents, tcPCO2 monitoring can be started. Transcutaneous CO2 will be measured by SenTec Digital Monitor (software version SW-V07.00; MPB SW-V05.00.12) with V-Sign™ Sensor (SenTec AG, Thervil, Switzerland). Also, we will use small blood samples (0.2 ml) from clinical blood draws up to 4 times following starting transcutaneous CO2 monitoring for measuring blood gas for research purposes.
223644192|NCT00265603|PROCEDURE|Extracorporeal Photochemotherapy With Transimmunization|The photopheresis apparatus and procedure will be identical to that currently used. Patients will receive intravenous 8-MOP (UVADEX®) directly into the photopheresis apparatus, to yield a concentration of 50-200 ng/ml of drug. The blood will be leukapheresed to obtain a buffy coat and will then be passed through the contiguous closed circuit ultraviolet A exposure device, delivering the desired 1-2 joules/cm2 of ultraviolet A energy. In this manner 2-4 molecules of 8-MOP will be induced to bind covalently to thymines of the leukocyte DNA. At that point, the single variation from the standard treatment will be initiated. Instead of returning the patient's cells and the saline to the patient, the bag will be detached from the apparatus. KLH (depyrogenated, endotoxin-free; Calbiochem-Novabiochem Corp., San Diego, CA) will be added at a concentration of 10 g/ml to the DC-rich leukocyte culture prior to overnight culture.
223644193|NCT06374563|OTHER|group 1 received topical Bee venom gel|Group 1 received a topical application of Bee Venom gel, 3 times per weeks. The wound dressing changed day after day and was cleaned every time with normal saline.
224231034|NCT06464328|BEHAVIORAL|Music intervention only|Music only (120-130 bpm) The effect was achieved by playing music selected by the researchers during originally physical education classes in school; twice a week for twelve weeks
224231035|NCT06464328|BEHAVIORAL|Tai Chi intervention only|Tai Chi intervention only The effect was achieved by replacing the school's originally physical education classes with Tai Chi of the researchers' choice; twice a week for twelve weeks
223644194|NCT06374563|OTHER|Group 2: Phonophoresis of Bee Venom gel|group 2 received phonophoresis of Bee Venom gel using low frequency ultrasound, 3 times per weeks
223644195|NCT03650231|OTHER|Serological giagnosis|The serological diagnosis of EBV infection was performed in the Amiens University Hospital virology laboratory (France). 91 routinely collected samples were analyzed by Immulite, Architect, and Liaison Blood samples were centrifuged for 15 min at 2500g at room temperature. Sera were aliquoted and first analyzed by Immulite. All samples were tested for EBV VCA IgG, EBV VCA IgM and EBV EBNA IgG in order to determine infection status (primary EBV infection, past infection, absence of infection and indeterminate status).
223644196|NCT02994446|DEVICE|Saline-Enhanced Radiofrequency Catheter and Ablation System|Ablation of ventricular tachycardia with a saline-enhanced radiofrequency ablation catheter
223644197|NCT05204277|OTHER|Opalescence™ boost™ PF 40%|40% hydrogen peroxide in-office bleaching
223644198|NCT05204277|OTHER|Opalustre™|6.6% hydrochloric acid and silicon carbide microparticles microabrasion paste
223644199|NCT05204277|OTHER|MI-Paste Plus®|casein phosphopeptide amorphous calcium fluoride phosphate (CPP-ACFP) remineralizing tooth crème
223644200|NCT01052337|DRUG|anaesthetics: sevofluorane|0.5%of sevofluorane with air
223644201|NCT00078598|DRUG|Rituximab or Iodine I 131 Tositumomab Therapy|
223644202|NCT04444453|DEVICE|Wearable Pedometer|Pedometer worn on wrist
224231036|NCT06378983|DRUG|Oral isotretinoin|Oral isotretinoin
224231037|NCT06378983|OTHER|Oral isotretinoin combined with microneedle radiofrequency therapy|Oral isotretinoin combined with microneedle radiofrequency therapy
224231038|NCT01625156|OTHER|Laboratory Biomarker Analysis|Correlative studies
224231039|NCT01625156|OTHER|Pharmacological Study|Correlative studies
224231040|NCT01625156|DRUG|Temsirolimus|Given IV
223644203|NCT06359730|OTHER|LARS score questionnaire|LARS score questionnaire is filled by the patient after anterior resection for rectal cancer to study the quality of life
223765804|NCT05122897|DEVICE|Rings made of PA (test)|Rings made of PA (test) 0.2mm in thickness are pushed on the conical titanium base (abutment) of implant crowns and are removed and replaced after 48h, 2 weeks and 3 months for quantification of the bacterial biofilm. Test rings are applied in a split-mouth design provided that 2 implants are present (total of 4 months study period), or one after the other when only 1 implant is present (total of 8 months study period).
223765805|NCT05122897|DEVICE|Rings made of TAN (control)|Rings made of TAN (control) 0.2mm in thickness are pushed on the conical titanium base (abutment) of implant crowns and are removed and replaced after 48h, 2 weeks and 3 months for quantification of the bacterial biofilm. Control rings are applied in a split-mouth design provided that 2 implants are present (total of 4 months study period), or one after the other when only 1 implant is present (total of 8 months study period).
223765806|NCT04753840|OTHER|Antihypertensive drugs|One of ACEI / ARB, beta blocker, calcium channel blocker, diuretic
223765807|NCT04753840|OTHER|remote ischemic preconditioning（RIPC）|40 minutes per day, 10 minutes as a cycle (cuff inflated to 200 mmHg and maintained for 5 minutes, then deflated for 5 minutes to start the next cycle)， a total of 4 cycles.
223765808|NCT04753840|BEHAVIORAL|lifestyle intervention|Such as changing dietary habits, smoking cessation and alcohol restriction, exercise and so on.
223765809|NCT05754684|BIOLOGICAL|Natural killer cell|Natural killer cells isolated from HLA-haploidentical relative donor
223765810|NCT05754684|DRUG|Dinutuximab beta|Dinutuximab beta iv for 5 days
224231041|NCT01625156|DRUG|Tivantinib|Given PO
224231042|NCT02178709|DRUG|FOLFIRINOX|"FOLFIRINOX consists of the following combination of drugs:~1. Oxaliplatin, 85 mg/m2, IV over 2 hours prior to irinotecan, administered on days 1 and 15 of each 28 day cycle~2. Leucovorin, 400 mg/m2, IV over 2 hours with irinotecan, administered on days 1 and 15 of each 28 day cycle~3. Irinotecan, 180 mg/m2, IV over 90 minutes with leucovorin, administered on days 1 and 15 of each 28 day cycle 4.5 FU, 400 mg/m2, IV bolus over 2 minutes after irinotecan, administered on days 1 and 15 of each 28 day cycle.~5.5FU, 2400 mg/m2, IV infusion over 46 hours after 5FU bolus injection, administered on days 1 and 15 of each 28 day cycle."
224231043|NCT04143113|OTHER|Decision Aid|Shared decision making tool
224231044|NCT03562442|BEHAVIORAL|Smoking cessation|Smoking cessation with or without professional / medical support
224231045|NCT02224456|DRUG|Tenofovir disoproxil fumarate|"White, almond-shaped, film-coated tablet containing 300 mg of TDF, debossed with GILEAD and 4331 on one side of the tablet."
224231046|NCT02946385|BIOLOGICAL|Meningococcal ABCWY Vaccine|Intramuscular injection of one booster dose at Day 1 to follow-on subjects in the ABCWY\_ 0\_2 Group, ABCWY\_ 0\_2\_6 Group and ABCWY\_ 0\_6 Group, primed with 2 or 3 doses of the study vaccine and 2 doses at Days 1 and 61 to naïve subjects in the ABCWY naïve group.
223644204|NCT00631072|BIOLOGICAL|INKT|Administered in 3 equal doses by intravenous infusion on days 1, 15 and 29.
223644205|NCT00631072|DRUG|GM-CSF|Given subcutaneously once daily for 10 days beginning the second day of the second and third infusion
223644206|NCT05689996|DRUG|Ozone-Based Agent|Ozone-based eye drops as adjuvant therapy in microbial keratitis
223644207|NCT03473054|OTHER|Web-based Mindfulness Course|"The intervention is a therapist led, web-based MBI course, delivered asynchronously via a series of online videos. The Be Mindful course is a four-week mindfulness course based on the Mindfulness-Based Stress Reduction and Mindfulness-Based Cognitive Therapy courses. The course has been positively evaluated and shown to reduce stress, anxiety, and depression for participants.~Participants complete ten online interactive videos (30 minutes each), twelve daily practice assignments (with supportive emails), five audio downloads, and online tools for reviewing progress. The minimum time to complete the course is four weeks, but people can take longer if they wish and will still have access to the resources."
223644208|NCT02046577|DIETARY_SUPPLEMENT|Vitamin D3|Cholecalciferol administration
223644209|NCT02046577|DIETARY_SUPPLEMENT|Placebo|Placebo liquid
223765811|NCT05754684|DRUG|Interleukin-2|Interleukin-2 sc alternate day for 6 doses
223765812|NCT05754684|DRUG|Granulocyte-Macrophage Colony-Stimulating Factor|Granulocyte-macrophage colony-stimulating factor sc daily till ANC \>2,000/mm3
223765813|NCT05754684|DRUG|Spironolactone|Spironolactone po three time daily
223765814|NCT05754684|DRUG|Naxitamab|Naxitamab iv for 4 days (as alternative for dinutuximab)
223644210|NCT01907035|BEHAVIORAL|A cognitive-behavioral intervention|Evaluate the effectiveness of a cognitive-behavioral intervention by psychologists in collaboration with MF plus routine therapy in the field of APS in anxiety-depressive patients mild to moderate, with respect to standardized usual care by physicians, improve quality of life of these people, producing at least ten-point increase in the level of overall quality of life (SF-36)
223644211|NCT01907035|OTHER|Usual care|
223644212|NCT06256796|OTHER|fresh frozen plasma|repeated doses of fresh plasma over 3 days in organophosphate poisoned patients
223644213|NCT00043979|DRUG|F-18 Fluorodeoxyglucose|
223644214|NCT00043979|BIOLOGICAL|therapeutic allogeneic lymphocytes|Lymphocyte cells are collected from a healthy donor by apheresis and infused into the patient with a central venous catheter.
223644215|NCT00043979|DRUG|cyclophosphamide|"Induction - 750 mg/m\^2 intravenous (IV) infusion over 30 minutes x 1 dose. Day 5.~Transplant - 1200 mg/m\^2 per day IV infusion over 2 hours daily for 4 days; days -6, -5, -4, -3."
223644216|NCT00043979|DRUG|cyclosporine|6 mg/kg per dose orally every other day (no day 9 dose).
223644217|NCT00043979|DRUG|doxorubicin hydrochloride|Induction - 10 mg/m\^2 per day continuous intravenous (IV) infusion over 24 hours daily for 4 days. Days 1, 2, 3, 4.
223644218|NCT00043979|DRUG|etoposide|50 mg/m\^2 per day continuous intravenous (IV) infusion over 24 hours daily for 4 days. Days 1, 2, 3, 4.
223644219|NCT00043979|DRUG|fludarabine phosphate|"Induction - 25 mg/m\^2 per day intravenous (IV) infusion over 30 minutes daily for 3 days. Days 1, 2, 3.~Transplant - 30 mg/m\^2 per day IV infusion over 30 minutes daily for 4 days; days -6, -5, -4, -3."
223644220|NCT00043979|DRUG|melphalan|Transplant - 100 mg/m\^2 per day intravenous (IV) infusion over 15 minutes for 1 day; day -2.
223644221|NCT00043979|DRUG|prednisone|Induction - 60 mg/m\^2 per day in 2-4 divided doses by mouth daily for 5 days; days 1, 2, 3, 4, 5.
223644222|NCT00043979|DRUG|sirolimus|Initiated on day +3. Patients \>40kg, the initial dose will be 2 mg every 24 hours orally. Patients \<40 kg, the initial dose will be 1 mg/m\^2.
224231047|NCT02946385|BIOLOGICAL|Meningococcal B Recombinant vaccine|Intramuscular injection of one booster dose of the rMenB+OMV vaccine to subjects in the B\_0\_2 group, primed with 2 doses of the vaccine and intramuscular injection of 2 doses at Days 1 and 61 in the deltoid area of the non-dominant arm to naïve subjects in the rMenB+OMV Naïve group.
224231048|NCT05123456|PROCEDURE|Radiography|Comparative X-ray of the single knee at 30 ° flexion.
224231049|NCT00966225|DIETARY_SUPPLEMENT|LIP-01|comparison of different dosages of natural health product
224231050|NCT04059601|DIAGNOSTIC_TEST|Magnetic resonance cholangiography|preoperative MRCP in acute cholecystitis before cholecystectomy
224231051|NCT04059601|DIAGNOSTIC_TEST|Intraoperative cholangiography|Intraoperative cholangiography in acute cholecystitis during cholecystectomy
224231052|NCT02206204|DRUG|selexipag|
224231053|NCT02206204|DRUG|placebo for selexipag|
224231054|NCT02206204|DRUG|moxifloxacin|
224231055|NCT02206204|DRUG|moxifloxacin-matching placebo|
224231056|NCT05411770|DEVICE|Thoracic kyphosis and lumbar lordosis angle assessment|Thoracic kyphosis and lumbar lordosis angle assessment was performed with the reliable Baseline Bubble Inclinometer®.
224231057|NCT05411770|DEVICE|Temporomandibular range of motion|TMJ range of motion, maximum mouth opening amount (MAAM), right and left lateral movements of the mandible (laterotrusion), anterior movement of the mandible (protrusion), and backward movement of the mandible (retrusion) were measured with a millimetric ruler, while the adolescent was seated on a chair.
224231058|NCT05411770|DEVICE|Measuring the cervical joint range of motion|Cervical joint flexion, extension, lateral flexion and rotation ranges of motion were measured with a universal goniometer while the adolescent was sitting in a chair.
223644223|NCT00043979|DRUG|tacrolimus|Day -1 at least 24 hours before the stem cell infusion at a dose of 0.03 mg/kg/day as a continuous infusion. Twelve hours later oral dose initiated at a dose of 0.1-0.15 mg/kg/day in two divided doses every 12 hours.
224231059|NCT05411770|DEVICE|Craniovertebral angle measurement|Head posture of the adolescent was evaluated by craniovertebral angle (CVA) method. Adolescents sat on a chair with back support in an upright position and turned sideways to the worker. The pivot point was accepted as the seventh cervical vertebra, and the angle between the head (tragus) and the horizontal plane was measured with a goniometer and recorded in degrees.
223644224|NCT00043979|DRUG|vincristine sulfate|Induction - 0.4 mg/m\^2 per day continuous intravenous (IV) infusion over 24 hours daily for 4 days; 1, 2, 3, 4.
223644225|NCT00043979|PROCEDURE|peripheral blood stem cell transplantation|Stem cells from a healthy donor are collected and transplanted into the patient using a central venous catheter.
223644226|NCT00043979|DRUG|Filgrastim|
223644227|NCT00043979|PROCEDURE|Peripheral Blood Stem Cell donation|
223644228|NCT03904914|OTHER|TOCI|TOCI staging evaluated
223644229|NCT02690948|BIOLOGICAL|Pembrolizumab|Given IV
224231060|NCT05411770|DEVICE|Tragus-to-wall distance measurement|Tragus-to-wall distance was measured using a tape measure and recorded in cm.
224323424|NCT06274749|DIETARY_SUPPLEMENT|Urolithin A|Urolithin A (UA) is a widely available dietary supplement devoid of any known sided effects that is reported to improve mitochondrial function. The UA substance used in this investigation is regulated under Generally Recognized as Safe (GRAS) by the US FDA (GRN No. 000791) (https://www.fda.gov/media/120300/download) and is being advertised and sold as an oral supplement. The daily dose (1 gram) and duration (8 weeks) have already been tested in previous clinical trials.
223644230|NCT02690948|DRUG|Vismodegib|Given PO
223644231|NCT02783807|DEVICE|Eyenez Retinal Camera v200|
223644232|NCT02783807|DEVICE|Volk Pictor Ret 1|
223644233|NCT00658359|DRUG|Cyclosporine|Standard of care
223644234|NCT00658359|DRUG|CP-690,550|CP-690,550 tablets dosed BID Months 12-72
223644235|NCT00658359|DRUG|CP-690,550|CP-690,550 tablets dosed BID Months 12-72
223644236|NCT02754440|DEVICE|Trima Accel System with Version 7.0 Software|Platelet Apheresis Procedure
223644237|NCT02832115|DRUG|Topical Nitroglycerine|Topical nitroglycerine is applied to wrist prior to transradial cardiac catheterization to dilate radial artery and reduce spasm in study arm patients
223644238|NCT02832115|DRUG|Topical Lidocaine|Topical Lidocaine is applied to wrist prior to transradial cardiac catheterization in both study and control arms
223644239|NCT01189032|DRUG|DE-089 ophthalmic solution|
224231061|NCT05411770|DEVICE|Scoliosis angle assessment|Scoliosis angle assessment was done with a scoliometer.
223644240|NCT01189032|DRUG|DE-089 ophthalmic solution|
223644241|NCT01189032|DRUG|Placebo ophthalmic solution|
223644242|NCT00464776|DRUG|Aliskiren|
223644243|NCT00464776|DRUG|Aliskiren|
224231062|NCT02156648|OTHER|Feasibility study|All participants will have blood draws for biomarkers during the course of the study at visit 1, 2, 3, 4, 5, 6, 7 and 8. they will also have the speckle tracking echocardiogram at visit 1, 4, 5, 6, 7 and 8. For women 45 an over a cardiac PET scan will be performed at visit 1 and 5.
224319764|NCT06066957|DRUG|Letermovir 480 MG [Prevymis]|"Letermovir for CMV prophylaxis in thoracic organ transplant recipients.~Letermovir will be administered by oral administration, as per study protocol. The intended duration of therapy will be up to 365 days, depending on organ transplanted and donor and recipient CMV status. However, treatment may discontinued as discussed in Section 7.~Letermovir is dosed at 480mg daily for patients with CrCl \>10. Dose adjustment, as per package insert, is recommended in setting of co-administration of cyclosporine, with dose reduction of letermovir to 240mg daily. Missed doses of letermovir will not be made up."
223644244|NCT00464776|DRUG|Aliskiren|
223644245|NCT00464776|DRUG|Aliskiren|
223644246|NCT01585376|GENETIC|mutation analysis|
223644247|NCT01585376|GENETIC|nucleic acid sequencing|
223644248|NCT01585376|OTHER|laboratory biomarker analysis|
223644249|NCT03308370|BIOLOGICAL|Platelet rich plasma|10 ml of blood will be drawn from the patients on an anticoagulant then it will be centrifuged to get platelet rich plasma that will be injected in the melasma lesions of the patients after its activation with calcium chloride.
223644250|NCT05469659|DRUG|Tofogliflozin|Tofogliflozin 20 mg is orally administered once daily for 104 weeks before or after breakfast.
223644251|NCT05469659|DRUG|Metformin|Metformin is started at 500 mg daily and orally administered in 2 to 3 divided doses immediately before or after meals. The dose during the maintenance period is determined by observing the effect, but is usually 750 to 1,500 mg daily. Metformin is orally administered for 104 weeks throughout post-start period. The dose may be adjusted according to the patient's condition, but the maximum daily dose should be 2,250 mg.
223644252|NCT04883372|OTHER|continuous glucose monitoring|a continuous glucose monitoring CGM system through the ETAPES telemedicine program
224319765|NCT06856213|DRUG|Cetuximab|Cetuximab 250 mg/m2 will be administered as an intravenous infusion over 60 minutes. Cetuximab loading dose is 400 mg/m2 infusion and will be administered over 120 minutes. During maintenance, cetuximab at 500 mg/m2 will be administered as an intravenous infusion over 120 minutes.
224319766|NCT06856213|DRUG|Paclitaxel|Paclitaxel at a dose of 80 mg/m² will be administered after cetuximab as an intravenous infusion over 60 minutes weekly.
224319767|NCT00093119|DRUG|ABI-007|
224319768|NCT03563651|PROCEDURE|Biopsy|Undergo biopsy
223644253|NCT03755349|DEVICE|Placement of burr-hole covers|Placement of a burr-hole cover (Stryker® UN3 BURR HOLE COVER, 20mm, W/TAB, Item code 53-34520) fixed with 2 screws (Stryker® UNIII AXS SCREWS, SELF-DRILLING, 1.5 x 4MM, Item code 56-15934) on each of two burr-holes
223644254|NCT03755349|OTHER|No placement of burr-hole covers|In the control group, none of the burr-holes is covered, representing our current standard of care. In patients with bilateral cSDH, none of the burr-holes on the control side are covered with burr-hole covers.
223644255|NCT05064137|DRUG|Monomeric self - assembling peptide P11-4|Monomeric self - assembling peptide P11-4 ( Curodont Repair ) is a remineralizing agent applied on tooth surface after treating it with 3% sodium hypochlorite for 20 seconds then etching it with 37% phosphoric acid for 20 seconds followed by rinsing then dryness.
224319769|NCT03563651|PROCEDURE|Biospecimen Collection|Undergo collection of blood, urine, and stool
224319770|NCT03563651|OTHER|Laboratory Biomarker Analysis|Correlative studies
223644256|NCT05064137|DRUG|Tricalcium phosphate fluoride varnish, 5% F-|Tricalcium phosphate fluoride varnish, 5% F- ( Clinpro White Varnish ) is a remineralizing agent applied on tooth surface after mixing it with a brush onto the dosage guide.
223644257|NCT05064137|DRUG|fluoride varnish (5% sodium fluoride)|fluoride varnish (5% sodium fluoride) ( Voco-profluorid ) is a remineralizing agent applied on tooth surface then area is allowed to become wet (either by gentle rinsing or natural salivary flow) to ensure setting of VOCO Profluorid Varnish.
223644258|NCT01282762|BIOLOGICAL|HEPLISAV|"0.5 mL administered intramuscularly (IM) at Week 0, Week 4 and Week 24.~HEPLISAV booster injection = one dose of 0.5 mL volume when needed."
223644259|NCT01282762|BIOLOGICAL|Engerix-B|"2.0 mL administered intramuscularly (IM) at Week 0, Week 4, Week 8 and Week 24.~Engerix-B booster injection = one dose of 2.0 mL volume when needed"
223644260|NCT04876469|PROCEDURE|Pulsed Radiofrequency treatment of the lumbar dorsal root ganglion|Using radiocontrast media or not for the pulsed radiofrequency treatment of the lumbar dorsal root ganglion
223644261|NCT01963078|DRUG|Oxytocin|
223644262|NCT01963078|DRUG|Placebo|
223644263|NCT03388164|DRUG|Escitalopram + RT2CK17|Participants randomized to active or placebo condition will be prescribed medication over the course of 8 weeks, with in-person follow-up visits at weeks 0, 2, 4 and 8, with follow-up phone calls on weeks 1, 3 and 6.
223644264|NCT03388164|DRUG|Escitalopram + Placebo|Participants randomized to active or placebo condition will be prescribed medication over the course of 8 weeks, with in-person follow-up visits at weeks 0, 2, 4 and 8, with follow-up phone calls on weeks 1, 3 and 6.
223644265|NCT02359097|PROCEDURE|Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging|Undergo MRI including DSC or DCE-CBV mapping
223644266|NCT02359097|DRUG|Ferumoxytol|Given IV
223644267|NCT02359097|DRUG|Gadoteridol|Given IV
223644268|NCT02359097|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI including SS-CBV
223644269|NCT02314819|DRUG|fruquintinib|fruquintinib is a capsule in the form of 1mg and 5mg, orally, once daily, 3 weeks on/ 1 week off
223644270|NCT02314819|DRUG|placebo|fruquintinib placebo is a capsule in the form of 1mg and 5mg, orally, once daily, 3 weeks on/ 1 week off
224231063|NCT00169533|DRUG|GW572016 oral tablets|Lapatinib either at 750, 1000, 1250 or 1500 mgs
224231064|NCT05348109|OTHER|Well finished cases|To decide whether extraction or non-extraction decision will be made for each case
224231065|NCT05861648|DRUG|Folic Acid Oral Tablet|Dietary Supplement: Folic acid 2.5mg/day
224231066|NCT05861648|DIETARY_SUPPLEMENT|Placebo|Dietary Supplement: Placebo
224231067|NCT00178581|DRUG|Glutamine|
224231068|NCT03500848|DRUG|Tacrolimus|Tacrolimus will be started between 3 and 7 days post-transplantation and continued after randomization at a dose of 1.0 mg twice a day (bid, 2 mg daily dose). The tacrolimus trough level is measured twice a week for 1 month, followed by trough level once a month thereafter. Tacrolimus trough levels are targeted to be maintained at 8-15ng/ml until Month 6. After Month 6, the dose will be adjusted over time to maintain steady-state tacrolimus trough blood levels of approximately 5-10 ng/mL.
223644271|NCT04587661|BEHAVIORAL|off-the-shelf digital CBT|Cognitive behavioral therapy for depression and anxiety
223644272|NCT04587661|BEHAVIORAL|adapted digital CBT|Cognitive behavioral therapy for depression and anxiety for individuals from a minority group with SCD
223644273|NCT01538095|PROCEDURE|Dynamic Contrast-Enhanced Magnetic Resonance Imaging|Correlative studies
223644274|NCT01538095|OTHER|Laboratory Biomarker Analysis|Correlative studies
223644275|NCT01538095|OTHER|Pharmacological Study|Correlative studies
223644276|NCT01538095|BIOLOGICAL|Trebananib|Given IV
224231069|NCT03500848|DRUG|Tacrolimus (Tacrolimus elimination)|Tacrolimus will be started between 3 and 7 days post-transplantation at a dose of 1.0 mg twice a day (bid, 2 mg daily dose) for 30 (± 5) days and eliminated when randomization is done.
224231070|NCT03500848|DRUG|Sirolimus|Within 24 hours of randomization, sirolimus will be started at a dose of 2.0 mg once a day. The sirolimus trough level is measured twice a week for 1 month, followed by trough level once a month thereafter. The dose will be adjusted over time to maintain steady-state sirolimus trough blood levels of approximately 4-10 ng/mL.
224319771|NCT03563651|OTHER|Questionnaire Administration|Ancillary studies
223644277|NCT05375760|BIOLOGICAL|AZD7442 (tixagevimab [AZD8895] + cilgavimab [AZD1061])|"Arm A - Day 1:~600 mg AZD7442 administered sequentially as a 3 mL IM injection containing 300 mg tixagevimab (AZD8895) and a 3 mL IM injection containing 300 mg cilgavimab (AZD1061), one injection in each gluteal region.~Arm A - Days 92, 183, 274, 365:~300 mg AZD7442 administered sequentially as a 1.5 mL IM injection containing 150 mg tixagevimab (AZD8895) and a 1.5 mL IM injection containing 150 mg cilgavimab (AZD1061), one injection in each gluteal region."
224319772|NCT00751556|DRUG|Naproxen Sodium 660mg|Extended release Naproxen Sodium (660mg) administered once a day
224319773|NCT00751556|DRUG|Commercial Aleve 220 mg|Immediate release commercial Aleve (220 mg) administered in a 2 (440 mg) plus one (220 mg) dosing schedule, 660 mg total
223644278|NCT05375760|BIOLOGICAL|AZD7442 (tixagevimab [AZD8895] + cilgavimab [AZD1061])|"Arm B - Day 1:~1200 mg AZD7442 (600 mg tixagevimab \[AZD8895\] and 600 mg cilgavimab \[AZD1061\]) administered by IV infusion.~Arm B - Days 183, 365:~600 mg AZD7442 administered sequentially as a 3 mL IM injection containing 300 mg tixagevimab (AZD8895) and a 3 mL IM injection containing 300 mg cilgavimab (AZD1061), one injection in each gluteal region."
223644279|NCT00232752|DEVICE|4.0 CYPHER Sirolimus-Eluting Coronary Stent|4.0 CYPHER Sirolimus-Eluting Coronary Stent
223644280|NCT00363480|DRUG|Salmeterol/Fluticasone 50/250 mcg|Participant received salmeterol/fluticasone combination 50/250 mcg using DISKUS™ powder inhalers.
223644281|NCT00363480|DRUG|Salbutamol 100 mcg|This medication was provided in metered dose inhalers containing at least 200 puffs of 100 mcg salbutamol.
224231071|NCT03500848|DRUG|MMF and/or steroids|For patients in both groups, MMF and/or steroids are initiated at or prior to the time of liver transplantation according to local practice. Steroids reduction is encouraged by 3 months post liver transplantation.
224231072|NCT00002965|BIOLOGICAL|Recombinant Interferon Alfa (INF alpha)|Subcutaneous injection Monday through Friday for 8 weeks.
224231073|NCT05108623|DRUG|agenT-797|agenT-797 is an off-the-shelf cell therapy consisting of ≥ 95% allogeneic human unmodified iNKT cells isolated from 1 healthy donor mononuclear cell apheresis unit and expanded ex vivo.
223644282|NCT00363480|DEVICE|DISKUS™ powder inhalers|Participant received salmeterol and fluticasone using DISKUS™ powder inhalers.
224231074|NCT05108623|DRUG|Approved ICIs|Nivolumab and pembrolizumab
224319774|NCT02567240|OTHER|Carbon monoxide-bubbled mediums|Islets will be harvested with carbon monoxide bubbled mediums
224319775|NCT01739660|DRUG|Pegloticase|a single 8 mg iv (in the vein) dose before hemodialysis session
224319776|NCT07133971|OTHER|skin care product（Cerave Neuroceramide Moisturizing Repair Body Lotion）|All study participants will use Cerave Neuroceramide Moisturizing Body Lotion during the trial period, applying it every night to dry skin areas. If topical medications are used, they should be applied first to dry skin areas, followed by the product.
224319777|NCT04591951|BEHAVIORAL|I2-ART|Based on the Parent Empowerment Program model, I2-ART will use methods of adult learning, direct instruction to share knowledge or techniques for practice, modeling, vicarious learning, and practice opportunities (i.e., role rehearsals). The research team will provide the family navigators with 3 months of I2-ART training, including 40 hours of didactic and interactive sessions (10 sessions of 4 hours each). Following training, the family navigators will implement the 3-month I2-ART intervention with the caregivers, including a 2-hour face-to-face meeting, at least three monthly in-person meetings, and intermittent contact between in-person meetings by phone calls, texts or emails, as determined by the family navigator-caregiver dyad.
224319778|NCT04591951|OTHER|Usual care|Care as usual
223644283|NCT01457703|DRUG|Cetrorelix|Abolishes pituitary sensitivity to GnRH.
223644284|NCT01457703|DRUG|Gonadorelin-GnRH|GnRH is used to stimulate the pituitary gland to produce LH and FSH.
223644285|NCT01457703|DRUG|Recombinant LH|Used to stimulate ovarian function in women.
223644286|NCT01457703|DRUG|Letrozole|An aromatase inhibitor.
223644287|NCT00949702|DRUG|vemurafenib|960 mg b.i.d. continuous oral dosing
223644288|NCT02139007|DRUG|Alendronate|
223644289|NCT04968275|BEHAVIORAL|CHAMPS|CHAMPS provides personalized feedback on participants' cannabis use behaviors and supports strategies to change such behaviors. It comprises six modules measuring the use of cannabis protective behavioural strategies, exploring the possible benefits of changing cannabis practices and setting and monitoring the reach of a SMART cannabis use goal.
223765815|NCT04209946|PROCEDURE|Less Invasive Surfactant Administration LISA|Laryngoscopy with insertion of a small 16 gauge angiocatheter to administer FDA approved Surfactant, during spontaneous respirations.
223765816|NCT04209946|PROCEDURE|Continuous Positive Airway Pressure CPAP|Infant will remain on CPAP Therapy during spontaneous respirations
223644290|NCT06394141|BEHAVIORAL|Real-time triggers|The first intervention group (n= 30 professional drivers) will receive real-time triggers related to acute stress and sleepiness/fatigue. The real-time feedback involves giving relevant triggers when exceeding some critical stress values or detecting events of \&#39;energy-takers\&#39; based on accurate measurements of mental energy in a fully automated way. The selected triggers will be based on the co-creation workshops with drivers (e.g., auditive, visual) in order to select the most efficient (type or combination of) trigger(s) for the real-time feedback. The warning messages will be tailored to the preferences of the driver (e.g., personalized comfort- and safety-related settings) and aim to generate a warning message/signal meant to alert drivers and prevent they might end up with high stress levels
223644291|NCT06394141|BEHAVIORAL|Personalized tailored feedback|The second intervention group (n= 30 professional drivers) will receive personalized tailored feedback to reduce chronic stress and sleepiness/fatigue. The advice involves personalized (semi-)automatic feedback to drivers about a reduced stress level via the mobile app with automatic reports, as well as post-intervention during the next work break or at the end of the workday, based on the preferences of the driver. The (semi-)automatic feedback is based on the theory of Stages of Change, by which a driver will only receive relevant feedback based on their attitude and willingness during daily life.
223644292|NCT06394141|BEHAVIORAL|Real-time triggers + Personalized tailored feedback|The third intervention group (n= 30 professional drivers) will receive both real-time feedback related to acute stress and sleepiness/fatigue, as well as personalized tailored feedback related to chronic stress and sleepiness/fatigue, similar as in the first and second intervention groups.
223644293|NCT06394141|BEHAVIORAL|App-supported exercise therapy|The fourth intervention group (n= 30 professional drivers) will receive app-supported exercise therapy. The intervention will be based on principles of high-intensity training exercises that focus on the improvement of cardiorespiratory exercise capacity, as well as on the reduction of stress levels during work. Participants will receive instructions via the app to do some short, vigorous exercises adapted to their work environment at regular intervals, e.g., bending-and-stretching exercises with a weight in their hands, walking up and down the stairs of their vehicle for a few minutes, etc.
223644294|NCT06394141|BEHAVIORAL|Conventional intervention|The active control group (n= 20 professional drivers) will get a conventional intervention to reduce stress, e.g., mindfulness.
223644295|NCT00003439|BIOLOGICAL|recombinant interleukin-12|
223644296|NCT06042855|OTHER|Placebo|Each study arm will contain a placebo comparator. Placebo will look similar to study drug and will be administered via the same route of administration and dose. However, placebo will be an inactive substance, containing no study drug.
223644297|NCT06042855|DRUG|Metformin|Metformin IR tablets contain the active metformin hydrochloride and inactive ingredients including povidone and magnesium stearate. Commercially available metformin 500 mg tablets will be provided.
223644298|NCT05164991|BEHAVIORAL|Visuo-tactile stimulations of the right hand|Participants lay down in the magnetic resonance (MR) scanner are presented with visual stimuli (videos of the virtual rubber hand - visual stroking) simultaneously in real time with tactile stimuli (robotic stroking of the participant's hand - tactile stroking). An MR-compatible robot systematically provides the tactile stroking on the participant's hand. MR-compatible goggles show the visual stroking. Patterns of long and short robotic movements will be provided.
223644299|NCT00485784|OTHER|Blood test|Blood test
223644300|NCT01783691|DRUG|NKTT120|
223644301|NCT01767090|DRUG|ASP1707|Oral
223644302|NCT01767090|DRUG|Placebo|Oral
223644303|NCT01767090|DRUG|Leuprorelin acetate|subcutaneous
223644304|NCT02165098|DRUG|Cariprazine prolonged release tablet A|Cariprazine prolonged release tablet A - fasted
223644305|NCT02165098|DRUG|Cariprazine prolonged release tablet B|Cariprazine prolonged release tablet B - fasted
223644306|NCT02165098|DRUG|Cariprazine capsule|Cariprazine capsule - fasted
223644307|NCT02165098|DRUG|Cariprazine PR tablet A|Cariprazine Prolonged Release tablet A - fed
223644308|NCT02165098|DRUG|Cariprazine PR tablet B|Cariprazine Prolonged Release tablet B - fed
223644309|NCT04834102|DIAGNOSTIC_TEST|Blood Tests|Evaluation of blood ferritin, hemoglobine, serum iron and serum iron binding capacity
223644310|NCT03545958|BEHAVIORAL|High-intensity Interval Training (HIT)|Following the mind-motor training component, participants in the experimental group will then continue in the 45-minute HIT intervention, which will be composed by a 10-minute warm-up, a 25-minute core activity, and a 10-minute cool down. The 25-minute core activity will be carried out based on a 4 x 4 minutes aerobic interval training model. The intensity in each cycle will be prescribed at an individual level, and training heart rates will be determined via a sub-maximal excise testing at baseline and monitored during exercise using a wrist-based heart rate monitor (Suunto). In order to ensure progression in aerobic training over the 6-month intervention, training heart rates will be recalculated at the intervention midpoint (i.e., 3 months), where a new sub-maximal exercise test will be performed. Participants will exercise 60 minutes/day, 3 days/week for 6 months.
223644311|NCT03545958|BEHAVIORAL|Moderate-intensity Continuous Training (MCT)|After the mind-motor training component, participants in the comparison/control group will then continue in the 45-min MCT intervention, which will be composed by a 10-minute warm-up a 25-minute moderate-intensity continuous aerobic exercise training, and a 10-minute cool down. The exercise intensity will be prescribed at an individual level, and training heart rates will be determined via a sub-maximal excise testing at baseline and monitored during exercise using a wrist-based heart rate monitor (Suunto). In order to ensure progression in aerobic training over the 6-month intervention, training heart rates will be recalculated at the intervention midpoint (i.e., 3 months), where a new sub-maximal exercise test will be performed. Participants will exercise 60 minutes/day, 3 days/week for 6 months.
223765817|NCT04175210|RADIATION|Radiation therapy - 3 weeks|Patients randomized to ARM 1 will receive whole breast radiotherapy of 4050cGY and a concomitant boost to the tumor bed of 4800cGY in 15 fractions
223765818|NCT04175210|RADIATION|Radiation therapy - 2 weeks|Patients randomized to ARM 2 will receive whole breast radiotherapy of 3200cGY and a concomitant boost to the tumor bed of 4200cGY in 10 fractions.
223765819|NCT04436640|DRUG|Bimekizumab|Subjects will receive bimekizumab at prespecified time-points.
224231075|NCT01379781|BEHAVIORAL|Behavioral Intervention for PPD|We will select a sample of pregnant women at risk for PPD, teach parenting skills to increase infant nocturnal sleep and reduce fuss/cry behavior to half of the sample during 3 perinatal visits.
223644312|NCT03208946|OTHER|High-CML diet|Participants will be randomly assigned to either a high-CML or to a low-CML diet for 5 days, and they will receive the 5 corresponding meals (breakfast, lunch, snacks and dinner) during the 5 days of the intervention. These preparations will be elaborated by a catering company with indications and supervision by the research group. The intervention will be based on an isocaloric diet with a distribution of 55 to 63% carbohydrates, 12 to 15% protein, 25 to 30% lipids and less than 10% saturated fat and it macro and micronutrients will be similar in both diets. The only difference will be the CML content.
223644313|NCT03208946|OTHER|Low-CML diet|Participants will be randomly assigned to either a high-CML or to a low-CML diet for 5 days, and they will receive the 5 corresponding meals (breakfast, lunch, snacks and dinner) during the 5 days of the intervention. These preparations will be elaborated by a catering company with indications and supervision by the research group. The intervention will be based on an isocaloric diet with a distribution of 55 to 63% carbohydrates, 12 to 15% protein, 25 to 30% lipids and less than 10% saturated fat and it macro and micronutrients will be similar in both diets. The only difference will be the CML content.
223644314|NCT04015544|DIETARY_SUPPLEMENT|Watermelon|Pureed whole (100%) watermelon
223644315|NCT04457882|BEHAVIORAL|Intraperitoneal Laparoscopic Radical Prostatectomy Without Drainage Tube|No place the drainage tube after the intraperitoneal Laparoscopic Radical Prostatectomy
223644316|NCT04457882|BEHAVIORAL|Intraperitoneal Laparoscopic Radical Prostatectomy With Drainage Tube|Place the drainage tube after the intraperitoneal Laparoscopic Radical Prostatectomy
223644317|NCT00404612|DRUG|Placebo|PO BID
223644318|NCT00404612|DRUG|LX211|0.2 mg/kg, twice a day (BID)
223644319|NCT00404612|DRUG|LX211|0.4 mg/kg, twice a day (BID)
223644320|NCT00404612|DRUG|LX211|0.6 mg/kg, twice a day (BID)
223644321|NCT03210194|BEHAVIORAL|Standard Neonatal Resuscitation Training|Theoretical and practical training on basic and advanced neonatal resuscitation skills, directed to personnel from remote health centers using Standard Training
223644322|NCT03210194|BEHAVIORAL|MP-ICT Neonatal Resuscitation Training|Theoretical and practical training on basic and advanced neonatal resuscitation skills, directed to personnel from remote health centers using Information and Communication Technologies
223644323|NCT02562677|DEVICE|Transcutaneous Trigeminal Nerve Stimulation|
223644324|NCT06234761|DRUG|Dupilumab|Patient who start to take dupilumab will be followed. This study is only observational
223644325|NCT03933007|DRUG|Colchicine,|"the day of phenotyping assay~* Colchicine : 1.5 mg over 1 hour (1 mg + 0.5 mg 1 hour later)"
223644326|NCT03933007|DRUG|midazolam,|Midazolam 1 mg
223644327|NCT03933007|DRUG|fexofenadine|Fexofenadine 120 mg
223644328|NCT01724099|DRUG|Euiiyin-tang|Korean medicinal herbal drug
223644329|NCT01724099|DRUG|Placebo|Placebo drug, same odor and formula as Euiiyin-tang
223644330|NCT02061410|DEVICE|Neuromuscular Electrical Stimlation (NMES)|The intervention was performed with subjects seated on a regular chair (hip and knee angles maintained at approximately 908), 3 times/week for a period of 8 weeks. NMES parameters included: rectangular biphasic symmetric current, pulse duration of 400 ms and stimulation frequency of 80 Hz.
223644331|NCT01886053|DRUG|Faropenem（high dose group）|dosage form: Injection dosage:2400 mg frequency: Three times a day
223644332|NCT01886053|DRUG|Faropenem（low-dose group)|dosage form: Injection dosage:2400 mg frequency: twice a day
223644333|NCT01886053|DRUG|Ertapenem|dosage form: Injection dosage:1000 mg frequency: once a day
223644334|NCT02939911|DEVICE|Residual neuromuscular blockade measurement|Just prior extubation in OR and at the arrival to PACU the residual neuromuscular blockade will be measured by accelerometry
223644335|NCT05433207|DRUG|Eldecalcitol soft capsules|0.75 μg orally once a day during the intensive monitoring period. (The dose can be appropriately reduced to 0.5 μg according to symptoms, once a day.)
223644336|NCT04844398|OTHER|Clown visits by RED NOSES Clowndoctors Austria|Participants will receive one clown visit per week over four weeks in a group setting. The visits will take place in at least two different wards of each participating psychiatric care facility. In each ward, max. 10 participants will be targeted. The visits are carried out routinely by two professional clown artists from RED NOSES Clowndoctors Austria. The duration of the visits and the specific artistic sequences will take place according to internally organized routines. The essence of the clown visit is to catch the patient's attention proactively and reach the highest level of engagement possible. The specific artistic sequences are implemented spontaneously according to the situational atmosphere and current mood of participants. One clown visit will last between 1 and 2 hours depending on age and number of participants. Each participant will be engaged between 5 and 10 minutes by the clown. The clown artists are not involved in any study-related research activities.
223644337|NCT01516021|DIETARY_SUPPLEMENT|intake of high or low fat yoghurt|intake of 500 ml of a high fat yoghurt on one day and intake of 500 ml of a low fat yoghurt on the other day
223644338|NCT00196482|DRUG|changing of fortifier|
223644339|NCT01524575|DRUG|gemcitabine and oxaliplatin|Excision repair cross-complementation group 1 (ERCC1) protein and mRNA expression predicts response to oxaliplatin - patients whose cancers make small amounts of ERCC1 are much more likely to respond to cisplatin than those whose tumors produce large amounts.
223644340|NCT02951377|OTHER|Exercise (MDT approach)|Postural or movement exercises of the lower back that aim to centralise and reduce pain intensity.
223644341|NCT02951377|DRUG|Transforaminal epidural steroid injection (20mg dexamethasone 0.5cc lidocaine 2%)|An epidural steroid injection (20mg dexamethasone 0.5cc lidocaine 2%), under guidance of fluoroscopy is used to reduce inflammation at a lumbar spinal nerve root(s).
223644342|NCT00084071|DRUG|Tifacogin|
223644343|NCT03230461|BEHAVIORAL|Compression depth|
223644344|NCT02546388|DRUG|Indium-111 Pentreotide|
223644345|NCT02546388|DRUG|Gallium-68 DOTATATE|
223644346|NCT00699114|DRUG|Placebo|Lactose as powder in gelatine capsules, single dose
223644347|NCT00699114|DRUG|Ibuprofen 400 mg|Ibuprofen 400 mg as powder in gelatine capsules, single dose
223644348|NCT00699114|DRUG|Ibuprofen 600 mg|Ibuprofen 600 mg as powder in gelatine capsules, single dose
223644349|NCT00699114|DRUG|Ibuprofen 800 mg|Ibuprofen 800 mg as powder in gelatine capsules, single dose
223644350|NCT00699114|DRUG|Paracetamol (acetaminophen) 500 mg|Paracetamol (acetaminophen) 500 mg as powder in gelatine capsules, single dose
223644351|NCT00699114|DRUG|Paracetamol (acetaminophen) 1000 mg|Paracetamol (acetaminophen) 1000 mg as powder in gelatine capsules, single dose
223644352|NCT00699114|DRUG|Paracetamol (acetaminophen) 1000 mg + codeine 60 mg|Paracetamol (acetaminophen) 1000 mg + codeine 60 mg as powder in gelatine capsules, single dose
223644353|NCT00252096|DEVICE|Nucleic acid amplification test|
223644354|NCT01982656|OTHER|Massage|twenty minute massage intervention prior to bedtime (1900-2100), to be started after day 3 of admission for a minimum of 5 consecutive days and up to fourteen days. The massage will be conducted by an RN trained in massage technique that is not caring for the patient in a direct nursing role.
223644355|NCT05826938|DEVICE|Virtual reality technology|Participants who are randomized to group 1 will receive the Virtual Reality glasses on the day of oocyte retrieval in the recovery room. The participant chooses which animation she wants to experience.
223644356|NCT00967070|DRUG|Nicotine Patch|25 mg nicotine patch applied on the assigned marked sites on the lower back. Induction phase (21 days): left side, six treatment applications for 48 or 72 h. Challenge phase (five days): right side, one treatment application for 48 h.
223644357|NCT00967070|DRUG|Placebo Patch|Placebo patch applied on the assigned marked sites on the lower back. Induction phase (21 days): left side, six treatment applications for 48 or 72 h. Challenge phase (five days): right side, one treatment application for 48 h.
223644358|NCT00040989|DRUG|BAY 56-3722|
223644359|NCT00040989|PROCEDURE|enzyme inhibitor therapy|
223644360|NCT02490865|DRUG|RNS60|RNS60, 4 ml dose nebulized twice daily
223644361|NCT02490865|DRUG|Normal saline|Normal Saline, 4 ml dose nebulized twice daily
223644362|NCT02936804|DEVICE|Low Dose Computed Tomography|LDCT was performed at baseline and 2 rounds of biennial repeated LDCT. The abnormal nodules were defined as noncalcified nodules (NCN) larger than 4 mm. The management of abnormal nodules including precision diagnosis by endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA), electromagnetic navigation bronchoscope (ENB) and peripheral biomarkers, and precision therapy by intraoperative frozen section guided lung resection and ENB radiofrequency ablation.
223644363|NCT00437229|DRUG|Casopitant (GW679769) Oral Tablets|Casopitant (GW679769) tablets will be available as white, film-coated tablets containing 50 mg of GW679769 as the mesylate salt for oral administration.
223644364|NCT00437229|DRUG|dexamethasone|Dexamethasone will be available as 4 mg tablets for oral administration and injection for IV administration.
223644365|NCT00437229|DRUG|ondansetron|Ondansetron for oral use will be available as 8 mg tablets to be taken with 240 milliliters (mL) of water on an empty stomach. For IV use, ondansetron 32 mg will be infused intravenously over a period of 15 minutes.
223644366|NCT04200846|BEHAVIORAL|Exercise intervention|Subjects in this group will be asked to exercise 5 days a week. Two days on-site with an Exercise Physiologist and the other 3 days at home.
223644367|NCT02529969|DIETARY_SUPPLEMENT|curcumin|
223644368|NCT02529969|DIETARY_SUPPLEMENT|Placebo|
223644369|NCT01662765|PROCEDURE|Surgery|modified umbilectomy
223644370|NCT01662765|OTHER|conservative|this treatment will include conservative procedures under local anesthesia for patient comfort.
223644371|NCT00119184|PROCEDURE|External cephalic version|7.5 mg bupivacaine intrathecally
223644372|NCT00119184|DRUG|spinal anesthesia|spinal anesthesia
223644373|NCT02129699|DRUG|Denosumab|Denosumab: 120 mg, s.c. every 3-4 weeks (in cycle 1 additional dose on day 8) until unacceptable toxicity, patient refusal or patient's death (max. 4 years 3 months).
223644374|NCT02129699|OTHER|None, standard chemotherapy only|"Possible standard chemotherapies (3 weeks cycles, duration: 4 - 6 cycles):~Cisplatin 75 mg/m2 as an infusion on day 1 Gemcitabine 1250 mg/m2 as an infusion days 1 and 8 or Carboplatin AUC 5 as an infusion on day 1 Gemcitabine 1000 mg/m2 as an infusion days 1 and 8 or Cisplatin 75 mg/m2 as an infusion on day 1 Pemetrexed 500 mg/m2 as an infusion on day 1 or Carboplatin AUC 5 as an infusion on day 1 Pemetrexed 500 mg/m2 as an infusion on day 1"
223644375|NCT00387504|DRUG|fenretinide|4-HPR (Fenretinide) is given as a continuous intravenous infusion (CIV) for five consecutive days. Cycle is repeated every 3 weeks, if PR, CR or stable disease for 6 cycles.
223644376|NCT00387504|OTHER|pharmacological study|samples drawn per protocol
223644377|NCT04257929|DRUG|Pitolisant oral tablets|Pitolisant 4.45 mg or 17.8 mg tablets
223644378|NCT04257929|DRUG|Placebo oral tablet|Matching placebo tablets
223644379|NCT05378191|DRUG|COMIRNATY|One dose of COMIRNATY
223644380|NCT03710577|BEHAVIORAL|Yoga|1 session
223644381|NCT03710577|BEHAVIORAL|Quiet Rest|1 session
223644382|NCT00525161|DRUG|sorafenib|400 mg PO (orally) twice daily for 12 months from study enrollment or until disease progression, whichever occurs first.
223644383|NCT00002999|DRUG|cisplatin|
223644384|NCT00002999|DRUG|fluorouracil|
223644385|NCT00002999|RADIATION|radiation therapy|
223644386|NCT02790411|DEVICE|Imaging devices|technological adjustment tests
223644387|NCT02790411|DEVICE|New Non Invasive Devices|Tests with REX BIONICS Exoskeleton
223644388|NCT05422898|BEHAVIORAL|Gist messages on COVID-19 vaccination|Participants will receive gist-based messages on COVID-19 vaccines and have their concerns addressed by a group moderator
223644389|NCT05422898|BEHAVIORAL|COVID-19 vaccine information|Participants will receive a link to the Facebook COVID-19 Information Center via a private Facebook Group
223644390|NCT01607255|DRUG|Indigo carmine|0.008% indigo carmine in water is used as a surface contrast agent to enhance visualization of diminutive polyps (adenoma) during screening colonoscopy
223644391|NCT01607255|PROCEDURE|water (exchange) method|Residual pocket of air will be suctioned. Water is infused using a peristaltic pump to facilitate scope advancement until the cecum is reached. Dirty water will be suctioned and clean water is infused. Air will not be insufflated until the cecum is reached. Residual water is suctioned and air insufflated on scope withdrawal to facilitate biopsy and removal of lesions.
223644392|NCT01607255|PROCEDURE|water (exchange) plus dye method|Residual pocket of air will be suctioned. Water with 0.008% indigocarmine is infused using a peristaltic pump to facilitate scope advancement until the cecum is reached. Dirty water will be suctioned and clean water is infused. Air will not be insufflated until the cecum is reached. Residual water is suctioned and air insufflated on scope withdrawal to facilitate biopsy and removal of lesions
223765820|NCT04635241|DRUG|Unfractionated heparin|Inhaled nebulised 6 hourly
223765821|NCT03726177|DRUG|aspirin 162 mg|Aspirin 81mg two tablet once a day from recruitment until 37 weeks or labor whichever comes first
224231076|NCT05777538|OTHER|hydrotherapy|Hydrotherapy will be performed by immersing the women's foot in a container filled with 3 liters water with a temperature of 30-32°C. The water level must cover the women's feet up to ankle. During the immersion the therapist will ask the women to perform exercise with legs being fully supported, then alternatively stretch and flex the ankle for 30 times. which will be followed by circling each foot at ankle in clock wise and anticlock wise direction, 30 times each. The duration of water immersion session will be (30 min) for 5 consecutive days.
224231077|NCT05777538|OTHER|foot exercises|The therapist will ask the women to perform exercise with legs being fully supported, then alternatively stretch and flex the ankle for 30 times. which will be followed by circling each foot at ankle in clock wise and anticlock wise direction, 30 times each.
224231078|NCT03665181|OTHER|use or non-use of dose modulator and bismuth mask|For each child for who the eligibility criteria are met, the CT exam is perfomed with or without dose modulator associated to with or without bismuth mask
224231079|NCT02492490|OTHER|SVFderived MSC transplantations|"infusion of autologous SVF derived MSC to the recipients of DCD kidney transplant.~Subjects with uremia in the intervention group will undergo puncture to collect SVF, then SVF will be cultured to abstain MSC, and the abstained MSC will be infused to the recipients during kidney transplant operation and on 7, 14, and 21 POD. And the induction therapy of control group will be Basiliximab."
223644393|NCT01607255|PROCEDURE|air method|The colonoscope is inserted gently and advanced slowly using minimal air insufflation, if necessary, the assistant will provide abdominal compression or the patient's position will be changed to facilitate scope passage. The scope is inserted until the cecum is reached. Air is insufflated on scope withdrawal for visualization and water irrigation is used to remove any adherent feces covering the mucosa. Biopsy or polypectomy is performed where indicated.
223644394|NCT01173094|DEVICE|Percutaneous Transluminal Angioplasty|Before operation, take aspirin 100mg every day. During the operation, balloon is delivered by a catheter and positioned through the narrowing in the artery. Then expand the balloon against the wall of the blood vessel to provide a wider channel for blood.
223644395|NCT01173094|DEVICE|below-knee arterial bypass|Before operation, take aspirin 100mg every day. Perform bypass to below-knee(posterior tibial，anterior tibial or peroneal)arteries, saphenous vein graft with end to side anastomoses
223644396|NCT01898559|OTHER|Switch to smoking only little cigars|Participants smoke only little cigars for 15 days.
223644397|NCT03208829|OTHER|Rehabilitation exercises|Patients in group 1 will participate in a physical exercise protocol supervised by a physiotherapist. The sessions will focus on the rehabilitation of muscle strength and the exercises will be performed with increased external load.
223644398|NCT03208829|OTHER|Postoperative guidance|Group 2 will receive only guidelines regarding postoperative care.
223644399|NCT04382352|BIOLOGICAL|Humanized Anti-HER2 Monoclonal Antibody Compound for Injection .R&D code: B002.|Usage: intravenous infusion; B002, doses 2, 6, 12, 16, 20 mg / kg, intravenous drip. The infusion time was 120 ± 10 minutes for the first time; if the patient was tolerated, the follow-up time was adjusted to 60 ± 10 minutes. Pre-treatment was performed using phenergan (25 mg, intramuscular) within 30 minutes prior to each study drug infusion. The dosing cycle is administered once every 3 weeks for one cycle and can be administered continuously until the disease progresses or is intolerable.
223644400|NCT03646097|PROCEDURE|Angio-PCI|PCI only with angiography and without OCT findings
223644401|NCT03646097|PROCEDURE|OCT-PCI|PCI with OCT-measurements but no transfer of landingzone-markers to angiography
223644402|NCT03646097|PROCEDURE|ACR-PCI|PCI with OCT-measurements and transfer of landingzone-markers to angiography
223644403|NCT02735811|DEVICE|Assesment of long-term outcome of ICD patients|Evaluation during follow-up of the occurrence of complications related to ICD implantation and of death
223644404|NCT03250715|OTHER|Low Level Laser Therapy|For application of the LLLT in the quadriceps muscle the patient will be in dorsal decubitus, with the legs extended and will be defined by the palpation of the muscle belts six points of application: two points in the distal region of the vastus medialis muscle, two points of the distal region of the vastus lateral muscle and two points of the central region of the rectus femoris muscle. For the application of LLLT in the gastrocnemius muscle the patient will remain in the supine position, but will be oriented to keep the hips and knees flexed at 90º and 45º respectively. Two application points will be defined, one in the lateral ventricle and the other in the medial ventricle, but both in the distal region of the muscle.
223644405|NCT04057417|OTHER|Urban Trail|A newly built urban trail that was part of a large policy/infrastructure investment from the city/province to enhance the built environment for active transport and recreational physical activity in the city of Winnipeg, Manitoba Canada between 2010 and 2012.
223644406|NCT00516516|DIETARY_SUPPLEMENT|L-Carnitine|L-Carnitine, 1g orally, twice daily
224231080|NCT02492490|DRUG|Basiliximab|induction with Basiliximab before kidney transplantation and on POD 4
224231081|NCT03041766|BIOLOGICAL|Sm14|Three 0.5 mL intra-muscular injections of the vaccine solution (50µg Sm14) will be administered on D0, W4, W8 (D = day, W = week).
224231082|NCT03041766|DRUG|GLA-SE solution|Two (2) adjuvant concentrations will be made and packaged at 0.4 mL/vial, per GMP standards. One lot at the concentration of 10µg/mL for injection in the first cohort at 2.5µg GLA-SE/injection and one lot at the concentration of 20µg/mL for the second cohort intended to receive 5.0µg of GLA-SE/injection
223644407|NCT00516516|DIETARY_SUPPLEMENT|Placebo|Placebo, similar in appearance to study tablets, given orally, twice daily.
223644408|NCT00308490|DRUG|iron sucrose|
224231083|NCT02815969|OTHER|vena punction|vena punction and urine collection
224231084|NCT00439790|PROCEDURE|Microneurography|Microneurography
223644409|NCT01088724|DRUG|fludarabine, cyclophosphamide, doxorubicin, rituximab|Fludarabine i.v.(30 mg/sqm/day,day 1,2,3); Cyclophosphamide i.v.(750 mg/sqm, day 1); Doxorubicin i.v.(30 mg/sqm, day 1); Rituximab i.v. (375 mg/sqm, day 4).
223644410|NCT02447003|BIOLOGICAL|Pembrolizumab|IV infusion of 200 mg.
223644411|NCT01939418|DRUG|RAD001|Afinitor 5mg qd. po.
223644412|NCT01939418|DRUG|Gemcitabine|gemcitabine 800mg/m2 iv. D1 and D8 every 3 weeks
223644413|NCT01939418|DRUG|Cisplatin|cisplatin 30mg/m2 iv. D1 and D8 every 3 weeks
223644414|NCT04516447|DRUG|ZN-c3|Investigational drug
223644415|NCT04516447|DRUG|Carboplatin|Carboplatin is an approved drug
223644416|NCT04516447|DRUG|Pegylated liposomal doxorubicin|Pegylated liposomal doxorubicin (PLD) is an approved drug
223644417|NCT04516447|DRUG|Paclitaxel|Paclitaxel is an approved drug
224231085|NCT00214279|DRUG|Corticosteroid withdrawal|prednisone withdrawal, with maintenance mycophenolate mofetil therapy and either cyclosporine or tacrolimus
224231086|NCT03839706|DEVICE|PET MRI|18F-Fluorodeoxyglucose Positron Emission Tomography combined with Primovist MRI
224319779|NCT07010887|OTHER|Short Interval|A standardized and reliable soccer heading protocol will be used for the experiment. Participants perform 16 headers or kicking with 1 header per 30 seconds. The sessions (twice per week for 4 weeks) will be separated by 24 hours.
223644418|NCT04516447|DRUG|Gemcitabine|Gemcitabine is an approved drug
223644419|NCT04516447|BIOLOGICAL|Bevacizumab|Combined with azenosertib
223644420|NCT02677883|OTHER|Manometry-guided thoracentesis|Arm I will undergo a standard of care therapeutic thoracentesis procedure, and in addition include pleural pressure monitoring (via an FDA-approved digital manometer) which is also standard of care but left at the discretion of physicians as per expert recommendations. In this group, the procedure will be stopped when the patient develops symptoms or when all the fluid has been removed, and will also be stopped if the pressure begins to fall quickly in the fluid collection.
223644421|NCT02677883|OTHER|Symptom-guided thoracentesis|Arm II will undergo a standard of care therapeutic thoracentesis procedure. In this group, the procedure but will be stopped when the patient develops symptoms or when all the fluid has been removed.
224319780|NCT07010887|OTHER|Long Interval|A standardized and reliable soccer heading protocol will be used for the experiment. Participants perform 16 headers or kicking with 1 header per 30 seconds. The sessions (twice per week for 4 weeks) will be separated by 72 hours.
223765822|NCT03726177|DRUG|aspirin 81 mg|Aspirin 81mg one tablet once a day from recruitment until 37 weeks or labor whichever comes first
223765823|NCT03726177|DRUG|placebo|placebo one tablet once a day from recruitment until 37 weeks or labor whichever comes first
224231087|NCT01644890|DRUG|NK105|IV, Weekly
224231088|NCT01644890|DRUG|Paclitaxel|IV, Weekly
224231089|NCT01583777|DRUG|Belinostat|"On Day 1, a single dose of 14C-labeled belinostat (approximately 94 to 105 µCi, 1500 mg) will be administered to the patient as a 30-minute IV infusion.~After Cycle 1 evaluations are completed, and if it is in the best interest of the patient, patients may receive additional cycles of non-radiolabeled belinostat until disease progression, unacceptable toxicity, or initiation of new anticancer therapy. After Cycle 1, Day 21, non radiolabeled belinostat will be administered IV as a 30 -45 minute infusion of 1000 mg/m2 on Days 1 through 5 every 21 days."
224231090|NCT00238069|DEVICE|CPAP machine as a result of sleep study|
224319781|NCT03431142|DRUG|Clopidogrel|Additional 9 months of clopidogrel monotherapy after 9-12 months of DAPT (aspirin+clopidogrel)
224319782|NCT03431142|DRUG|Clopidogrel+aspirin|Additional 9 months of clopidogrel plus aspirin after 9-12 months of DAPT (aspirin+clopidogrel)
224319783|NCT03946553|OTHER||No intervention
224319784|NCT05500950|OTHER|CDU and CT-DCG or CT examination|patients with space occupying lesions in the lacrimal sac area completed CDU and CT-DCG or CT examination before surgery
224319785|NCT06697626|DIETARY_SUPPLEMENT|Inulin, B-vitamins and vitamin D|"Intervention twice daily with:~10g chicory inulin 100µg folic acid 5µg vitamin B12 5mg vitamin B6 2.5mg riboflavin 5µg vitamin D"
224319786|NCT06697626|DIETARY_SUPPLEMENT|Placebo group|A twice daily placebo drink with similar energy content but without the additional nutrient provision
223644422|NCT03848728|OTHER|SEARCH Youth combination intervention|"* Administration of life-stage assessment tool~* Structured choice clinic access~* Rapid feedback of VL results~* Provider e-collaboratives with chat groups for discussions of challenging cases using de-identified information"
223644423|NCT06273995|OTHER|Behavioral Activation|All participants will undergo behavioral activation treatment for 8-10 weeks
223644424|NCT05720312|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|Patterned pulsed magnetic stimulation delivered using an electromagnet. We will use a MagVenture rTMS device and a Cool-B65 coil.
223644425|NCT00630838|DRUG|VSL#3|"Dosing will be based on patient weight. For those infants greater or equal to 5 kg, one gram (360 billion bacteria or 4 sachets) of VSL#3 will be administered into 3 ounces of either expressed breast milk or formula daily. For patients under 5 kg, 0.5 gm (180 billion bacteria or 2 sachets) daily in the same amount of formula or breast milk.~E.2.6. Time of start of probiotics: Probiotic vs. placebo will begin once the infant has reached full oral feeding."
223644426|NCT00630838|DRUG|Placebo|Dosing will be based on patient weight. For those infants greater or equal to 5 kg, one gram (4 sachets) of placebo will be administered into 3 ounces of either expressed breast milk or formula daily. For patients under 5 kg, 0.5 gm (2 sachets) daily in the same amount of formula or breast milk Initiation: within one week of pullthrough Duration: 3 months
223765824|NCT04791748|DIAGNOSTIC_TEST|Vestibular tests|Screening vestibular test for patients without chronic vestibular deficits Complete vestibular test if not done yet in care of patients with chronic vestibular deficits
223765825|NCT04791748|OTHER|Virtual reality|Virtual reality protocol : doing tasks involving hand-eye coordination, in virtual reality, and in different sensory situations
223765826|NCT05160337|DIAGNOSTIC_TEST|Biomarker based IVD tests|Biomarker based IVD tests
223765827|NCT04602624|DRUG|SAGE-718|SAGE-718 oral tablets.
224231091|NCT01824758|DRUG|Lidocaine|Group L lidocaine (0.5 mg/kg), (rocuronium) (0.05mg/kg).
224231092|NCT01824758|DRUG|Esmolol|Group E: esmolol (1 mg/kg), (rocuronium) (0.05mg/kg)
224231093|NCT01824758|DRUG|rocuronium|0.05 mg/kg rocuronium
224231094|NCT01824758|DRUG|Placebo|Group C: Placebo (NaCl 0.9%, 5 ml), (rocuronium) (0.05mg/kg)
224231095|NCT03482063|DIETARY_SUPPLEMENT|Swisse Ultiboost Memory + Focus|"B vitamins help energy release, help with metabolism of food into energy, assist energy production and vitality.~Vitamin B5 helps support normal mental performance. Brahmi, Ginkgo, Vitamin B12 and B3 help support brain function. Ginkgo helps maintain healthy circulation and delivery of oxygenated blood to the brain.~Brahmi supports memory function and recall. Vitamin B5, B6 are important for adrenal function, assist adrenal glands during stress periods.~Vitamin B2, B3, B5, B6, B12 help relieve tiredness and fatigue."
224231096|NCT03482063|OTHER|Placebo|riboflavin (2.2mg)
224231097|NCT01586858|OTHER|Observational|Observational study of subjects previously enrolled in the RAVE trial
224231098|NCT00704795|OTHER|Oral glucose tolerance test|50 g of waterfree glucose dissolved in 300 ml water is ingested over 5 minutes following a 10-h fast including liquids and medication (if any).
223644427|NCT03723642|DIAGNOSTIC_TEST|Initial serum malondialdehyde level|"Blood sample (0.4ml) will be obtained within 5 minutes before induction of general anaesthesia.~Samples will be obtained in both groups (LAE and OAE)"
223644428|NCT03723642|DIAGNOSTIC_TEST|Final serum malondialdehyde level|Blood sample (0.4ml) will be obtained within 5 minutes after wound closure. Samples will be obtained in both groups (LAE and OAE)
223644429|NCT03723642|DIAGNOSTIC_TEST|Initial differential white blood cell count|"Differential blood counts (microscopic) will be obtained during pre-operative routine work-up.~Samples will be obtained in both groups (LAE and OAE)."
223644430|NCT03723642|DIAGNOSTIC_TEST|Final differential white blood cell count|"Differential blood counts (microscopic) will be obtained 24h after the first sample (Initial differential blood count).~Samples will be obtained in both groups (LAE and OAE)."
223765828|NCT04832477|BEHAVIORAL|Stigma counseling for PrEP use|This counseling consists of a single-session (45 minute) delivered by trained peer counselors. The primary aims and relevant content areas for counseling are: (1) Assessing and discussing factors known to be drivers of emotional barriers to accessing health care. This counseling aim has two main sub-components: (a) participants will be asked about their prior experiences with accessing health care and their concerns regarding future access, and (b) the counseling will focus on creating personal agency around needing to prioritize one's health. (2) Evaluating concerns around discussing PrEP with health care providers. The counseling combines motivational interviewing with medical decisional balance, which focuses on points to consider when evaluating PrEP. (3) Promoting resiliency beliefs and positive adaptation. For this objective the counselor works with the participant to establish PrEP use goals and problem-solving strategies.
223765829|NCT04754282|OTHER|Position of labouring women for epidural analgesia catheter placement : Traditional Sitting Position (TSP)|"Labouring women admitted to the delivery room of Necker Enfants Malades hospital, requesting an epidural analgesia for labour, and willing to participate in our study will be randomized in the Traditional Sitting Position (TSP) group on odd days or in the Cross-legged Sitting Position (CSP) group on even days.~Patients in the TSP group seat on the edge of the bed, their feet laid on a support set next to the bed. Patients in the CSP group also seat on the edge the bed, but in a so-called tailor position, their knees bent, their hips flexed and in abduction, their feet under each contralateral thigh.~The epidural catheter will be placed according to standard local practice in either of the groups."
223765830|NCT04754282|OTHER|Position of labouring women for epidural analgesia catheter placement : Cross-legged Sitting Position (CSP)|"Labouring women admitted to the delivery room of Necker Enfants Malades hospital, requesting an epidural analgesia for labour, and willing to participate in our study will be randomized in the Traditional Sitting Position (TSP) group on odd days or in the Cross-legged Sitting Position (CSP) group on even days.~Patients in the TSP group seat on the edge of the bed, their feet laid on a support set next to the bed. Patients in the CSP group also seat on the edge the bed, but in a so-called tailor position, their knees bent, their hips flexed and in abduction, their feet under each contralateral thigh.~The epidural catheter will be placed according to standard local practice in either of the groups."
223765831|NCT04084769|BIOLOGICAL|Meningococcal polysaccharide (serogroups A, C, Y, and W) tetanus toxoid Conjugate vaccine MenACYW Conjugate vaccine|Pharmaceutical form: Solution for injection Route of administration: IM
223765832|NCT04084769|BIOLOGICAL|Meningococcal Group B vaccine (Trumenba®)|Pharmaceutical form: Suspension for injection in pre-filled syringe Route of administration: IM
223765833|NCT04084769|BIOLOGICAL|Meningococcal group B vaccine (Bexsero®)|Pharmaceutical form: Suspension for injection in pre-filled syringe Route of administration: IM
223765834|NCT03390504|DRUG|Erdafitinib|Participants will swallow erdafitinib tablets orally at a starting dose of 8 mg.
223644431|NCT03723642|DIAGNOSTIC_TEST|Initial c-reactive protein serum level|"C-reactive protein levels will be obtained during pre-operative routine work-up.~Samples will be obtained in both groups (LAE and OAE)."
223765835|NCT03390504|DRUG|Vinflunine|Participants will receive vinflunine 320 mg/m\^2 as a 20-minute intravenous infusion.
223765836|NCT03390504|DRUG|Docetaxel|Participants will receive docetaxel 75 mg/m\^2 as a 1 hour intravenous infusion.
223765837|NCT03390504|DRUG|Pembrolizumab|Participants will receive pembrolizumab 200 mg as a 30-minute intravenous infusion.
223765838|NCT03390504|DEVICE|Fibroblast Growth Factor Receptor inhibitor Clinical Trial Assay (FGFRi CTA)|FGFRi CTA will be used to determine molecular eligibility.
224231099|NCT00704795|OTHER|Isoglycemic iv glucose infusion|The plasma glucose curve obtained during a 50 g-OGTT (performed on a separate day) is copied using an adjustable iv glucose infusion (20% w/v) performed following a 10-h fast including liquids and medication (if any). The iv catheter is inserted into a peripheral vein in the hand/forearm.
224231100|NCT05889338|DRUG|adalimumab and methotrexate|Adult patients (\> 18 years) with severe psoriasis who will start treatment with either adalimumab or methotrexate
224231101|NCT01462214|DRUG|Everolimus|Patients will be treated with low-dose oral cyclophosphamide (8 different dose levels and schedules) in combination with fixed dose (10 mg) everolimus in patients with mRCC.
224323425|NCT06274749|DIETARY_SUPPLEMENT|Placebo|The placebo will consist of methylcellulose and will appear identical to the active supplement. The placebo will be provided by the manufacturer of Urolithin A.
223644432|NCT03723642|DIAGNOSTIC_TEST|Final c-reactive protein serum level|"C-reactive protein levels will be obtained 24h after the first sample (initial c-reactive protein level).~Samples will be obtained in both groups (LAE and OAE)."
223644433|NCT03723642|DIAGNOSTIC_TEST|Initial VOC|Volatile organic compound sampling (2 samples within 5 minutes) within 10 minutes before induction of general anesthesia
223644434|NCT03723642|DIAGNOSTIC_TEST|VOC 5min|Volatile organic compound sampling (2 samples within5 minutes) within 5 minutes after endotracheal intubation before skin incision.
223644435|NCT03723642|DIAGNOSTIC_TEST|VOC 15min|Volatile organic compound sampling (2 samples within 5 minutes) 15 minutes after skin incision.
223644436|NCT03723642|DIAGNOSTIC_TEST|VOC 30min|Volatile organic compound sampling (2 samples within 5 minutes) 30 minutes after skin incision.
223644437|NCT03723642|DIAGNOSTIC_TEST|VOC 45min|Volatile organic compound sampling (2 samples within 5 minutes) 45 minutes after skin incision.
223644438|NCT03723642|DIAGNOSTIC_TEST|Final VOC|Volatile organic compound sampling (2 samples within 5 minutes) within 5 minutes after skin closure.
224231102|NCT00006250|DRUG|chlorambucil|
224231103|NCT00006250|DRUG|dexamethasone|
224231104|NCT00006250|DRUG|fludarabine phosphate|
224231105|NCT00006250|DRUG|mitoxantrone hydrochloride|
224231106|NCT00386464|DEVICE|noninvasive positive pressure ventilation|
223644439|NCT06306807|OTHER|Exercise program including active cervical range of motion, strengthening, and posture correction exercises and ergonomic modifications|Active cervical range of motion exercise program consists of the general range of movement for flexors, extensors, both sides flexors, and rotator neck muscles. Participants were instructed to perform exercises in a sitting position, but they were allowed to perform exercises in supine and prone lying if they had problems with sitting position. Strengthening exercises were planned for weak, lengthened, inhibited muscles e.g. Longus colli, and longus capitis. Chin tucks, chin tucks against gravity, and chin nod exercises were selected. Ergonomic modifications while using a smartphone were taught such as taking breaks and changing positions frequently while using a smartphone, avoiding cradling the phone between your ear and shoulder, choosing a smartphone that fits your hands properly, holding the smartphone near chest level rather than waist level, and using features including predictive text or auto-complete tools
223644440|NCT06306807|OTHER|PNF exercise program|The contract-relax technique for the neck extension pattern and the replication technique for the scapular posterior elevation pattern were used.
223644441|NCT04606602|DRUG|SLN360|SLN360 for subcutaneous (s.c.) injection
223644442|NCT04606602|DRUG|Placebo|Sodium chloride for subcutaneous (s.c.) injection
223644443|NCT03726580|DRUG|Sevoflurane|Assess the effect of isoflurane, sevoflurane, propofol and regional anesthesia on the olfactory threshold, olfactory identification and endocrine regulation of associative memory in the postoperative period in old age group.
223644444|NCT02581410|BIOLOGICAL|GSK Biologicals Herpes Zoster subunit (HZ/su) vaccine (GSK 1437173A)|2 doses administered by intramuscular (IM) injection into the deltoid muscle of the non-dominant arm.
223644445|NCT01393392|BEHAVIORAL|Intensive, tailored intervention|Eight, 45 minute counseling sessions, tailored to the individual and based on the Information-Motivation-Behavioral Skills model of behavior change. Incorporates motivational interviewing, education, cognitive-behavioral skills training. 12 week course of nicotine replacement patches provided. Nicotine lozenges also provided.
223644446|NCT01393392|BEHAVIORAL|NJ Quitline Referral|Participants will receive a facilitated referral to the NJ Quitline (i.e. fax to quit).
223644447|NCT06268275|PROCEDURE|Scalp block|Receive 30 ml of 0.25% bupivacaine with 1% lidocaine (1:1) with adrenaline 1:200,000 infiltration for 10 minutes before skull pins application.
223644448|NCT06268275|DRUG|Esmolol|Receive Intravenous esmolol 1 mg/kg bolus over 1 minute before skull pins application
223644449|NCT00222300|BEHAVIORAL|Strength training program|
223644450|NCT05488041|PROCEDURE|Performing anorectal manometry|"Anorectal manometry is a safe, low-risk procedure and is unlikely to cause any pain, colorectal perforation is very rare. Seven cases have been published in four reports.~* Anorectal Manometry - NY Gastroenterology Associates n.d. https://www.gastroenterologistnewyork.com/preparing-for-procedure/anorectal-manometry/ (accessed July 14, 2021).~* Bionda M, Lenglinger J, … AH-J of E, 2020 undefined. Closure of Large Rectal Iatrogenic Perforation by Endoscopic Suture Device: Go for it. BorisUnibeCh 2020;01:13-5. https://doi.org/10.48350/151165."
223644451|NCT02689037|PROCEDURE|Percutaneous transluminal angioplasty and stenting|Surgeons will plant stents after vascular angioplasty in target ICAS vessels within 5 days after randomization.
223644452|NCT02689037|DRUG|Aspirin plus clopidogrel|aspirin 100mg daily and clopidogrel 75mg daily for 90 days
223644453|NCT00670748|BIOLOGICAL|Anti-NY ESO-1 T-cell receptor PBL|Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of anti-NY ESO-1 T-cell receptor (TCR) peripheral blood lymphocytes (PBL) and high dose aldesleukin. On day 0,cells (1x10e8 to 1x10e11)will be infused intravenously on the Patient Care Unit over 20-30 minutes.
223644454|NCT00670748|DRUG|aldesleukin|Aldesleukin 720,000 IU/kg intravenous (IV) (based on total body weight)over 15 minutes every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 5 days(maximum of 15 doses)
223644455|NCT00670748|DRUG|Cyclophosphamide|Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml dextrose 5% in water (D5W) with Mesna 15 mg/kg/day X 2 days over 1 hr.
223644456|NCT00670748|DRUG|fludarabine phosphate|Fludarabine 25 mg/m2/day intravenous piggyback (IVPB) daily over 30 minutes for 5 days.
223644457|NCT00670748|BIOLOGICAL|ALVAC NY ESO-1 vaccine|Approximately two hours prior to cell infusion, patients will receive 0.5 mL containing a target dose of 10e7 cell culture infectious dose 50 (CCID50) (with a range of approximately 10e6.4 to 10e7.9 / mL) of the ESO-1 ALVAC virus S.C. in each extremity (total of 4 x 10e7 CCID50/2 mL.
223644458|NCT05589467|OTHER|DASH-FP|Dash diet with only fried potatoes
224231107|NCT01526538|DRUG|d-cycloserine|50 mg d-cycloserine
223644459|NCT05589467|OTHER|DASH-NFP|Dash diet with only non-fried potatoes
223644460|NCT05589467|OTHER|Control|Dash diet with no potatoes
223644461|NCT01424072|OTHER|auriculotherapy by needles|The chinese auriculotherapy is a intervention used by Chinese Traditional Medicine in order to balance the body energy and to treat several kind of diseases using semi-permanent needles in specific points of the auricular pavilion.
223644462|NCT01424072|OTHER|auriculotherapy by seeds|We used the three points Shenmen, Kidney, and Brain Stem with mustard seeds, 1 time per week for 8 sessions.The subjects were instructed to stimulate the points three times a day.
223765839|NCT03527420|OTHER|Exercise training|Twelve weeks of aerobic exercise training
223765840|NCT03546686|DRUG|Pembrolizumab|Pembro will be administered 1-20 days before the cryoablation date per SOC and q3 weeks after surgery for 9 cycles per SOC.
223765841|NCT03546686|PROCEDURE|Core Biopsy/Cryoablation|US-guided core biopsy and cryoablation 7-10 days prior to surgery.
223765842|NCT03546686|PROCEDURE|Breast Surgery|Standard-of-care definitive surgery.
223765843|NCT03546686|DRUG|Ipilimumab|ipilimumab 1mg/Kg IV is administered 1-5 days prior to cryoablation.
224231108|NCT01526538|DRUG|sugar pill|placebo
224231109|NCT05216536|OTHER|No intervention|No intervention
224231110|NCT03296475|PROCEDURE|Abdominal Wall Closure Force (N).|This measurement will be recorded for both the right and left anterior rectus sheath. We will measure this force at three anatomical points 1) at the level of the umbilicus and 2) at the halfway point between the pubic symphysis and the xiphisternum and 3) at the point of maximal hernia defect width.
224323426|NCT05652478|DRUG|Tenofovir alafenamide|25mg tenofovir alafenamide (TAF) one tablet orally once a day for 8 days.
223644463|NCT02390193|PROCEDURE|Hemodialysis|"Daytime haemodialysis was standardised. It was performed 3 times per week, with a 4-h session duration, 250-mL/min blood flow, and 500-mL/min dialysate flow, using bicarbonate buffered dialysate with 1.25 mmol/L ionised calcium concentration, dialysate temperature of 36.5°C.~The ultrafiltration amount for each haemodialysis session was decided by individual dry weight, which was fixed during the trial. In addition, the patients were not permitted to change their medication or start new drugs, especially antiplatelet agents, angiotensin-converting enzyme inhibitors, angiotensin II receptor antagonists, calcium-channel blockers, and β-blockers.~The patients who required a change in medication for medical reasons were subsequently excluded from the study."
223644464|NCT04633265|DEVICE|ECG-I Mapping of Atrial Fibrillation|Catheter ablation of Atrial Fibrillation guided by ECG-I
223644465|NCT03307499|OTHER|NeoPatch|NeoPatch as an adjunct to foot and ankle tendon revision/repair surgery
223644466|NCT03172988|DRUG|Dexamethasone|Dexamethasone 10 mg is administered before anesthesia induction.
223644467|NCT03172988|DRUG|Normal saline|Normal saline 2 ml is administered before anesthesia induction.
223644468|NCT03172988|DRUG|Flurbiprofen axetil|Flurbiprofen axetil 50 mg is administered before the start of surgery. Postoperative analgesia is provided with a patient-controlled analgesia pump, which is established with 100 ml of 1.25 μg/ml sufentanil and 2 mg/ml flurbiprofen axetil, programmed to deliver a 2 ml bolus with a lockout interval of 6-8 min and a background infusion of 1 ml/h.
223644469|NCT03172988|DRUG|Lipid microsphere|Lipid microsphere 5 ml is administered before the start of surgery. Postoperative analgesia is provided with a patient-controlled analgesia pump, which is established with 100 ml of 1.25 μg/ml sufentanil and 20 ml lipid microsphere, programmed to deliver a 2 ml bolus with a lockout interval of 6-8 min and a background infusion of 1 ml/h.
224231111|NCT05129852|OTHER|Sage oil group|Sometimes called muscatel. Made by steam or water distillation of Salvia sclarea flowering tops and foliage. Yields range from 0.7 to 1.5%. A pale yellow to yellow liquid with a herbaceous odor and a winelike bouquet. Produced in large quantities in France, Russia and Morocco. The oil contains linalyl acetate, linalool and other terpene alcohols (sclareol), as well as their acetates.
224231112|NCT05129852|BEHAVIORAL|Reiki group|Within complementary and integrative health practices, Reiki is an ancient practice of Japanese origin widely used worldwide. Through the touch or approximation of the hands, an enabled therapist applies this technique to eliminate toxins, to balance the organism, and to favor the full functioning of the organism, to reestablish the flow of vital energy. Reiki as bioenergy therapy works with the energy that leads the human body to a calmer state that is linked to health and cure. Reiki therapists conduct the curing energy that enters the top of the head and leaves through the hands.
224231113|NCT01060670|DEVICE|Integra® Dermal Regeneration Template|Application of Integra® Dermal Regeneration Template in diabetic foot ulcer
224231114|NCT01060670|OTHER|Conventional Wound Therapy|Conventional Wound Therapy
224231115|NCT01643837|OTHER|Osteopathic Manipulative Treatment|OMT - Sacral Ligamenotus Articular Release; OMT - Lumbar Spine (L1-L2) and Lower Thoracic Spine (T10-12) Ligamentous Articular Release; OMT - Upper Thoracic Spine Ligamentous Articular Release (T1-T8); OMT - Cervical Spine Ligamentous Articular Release (C5-C7); OMT - Suboccipital Myofascial Release; OMT - Clavicular Ligamentous Articular Release; OMT - First Rib Ligamentous Articular Release; OMT - Ribs 2-8 Ligamentous Articular Release; OMT - Pectoral Pull; OMT - Sternal Ligamentous Articular Release; OMT - Direct Myofascial Release of the Diaphragm; OMT - Thoracic Lymphatic Pump; OMT - Fascial Release of Breast Tissue
223644470|NCT05986695|BEHAVIORAL|Alert|Interruptive alert. The prototype alert is in the form of a chart note with evidence-based practice guidelines that will actively display in the clinician's list of daily alerts (like an inbox) that must be cleared daily. It is interruptive because can only be dismissed from the clinician's inbox list after signing the note
223644471|NCT05986695|BEHAVIORAL|Peer comparison report|Clinicians will receive an email describing their recent SGLT2 and MRA prescribing performance relative to their peers.
224231116|NCT01643837|OTHER|Osteopathic Manipulative Light Touch Protocol (LT)|LT - Sacral Region; LT - Lumbar Spine and Lower Thoracic Region; LT - Upper Thoracic Spine Region; LT - Cervical Spine Region; LT - Suboccipital Region; LT - Clavicles; LT - First Ribs; LT - Ribs 2-8; LT - Pectoralis Muscles; LT - Sternum; LT - Respiratory Diaphragm; LT - Upper Thoracic Cage; LT - Lower Thoracic Cage
223644472|NCT05069948|OTHER|HeadOn|HeadOn is a web application which takes the participant through a 5-stage CBT programme including: (i) understanding post-concussion symptoms; (ii) sleep after a concussion; (iii) lifestyle habits and exercise; (iv) managing negative thought patterns and (v) returning to baseline. The programme is delivered through a combination of weekly tasks (such as completing symptom diary, setting exercise goals and setting up a sleep time routine), audio/video media and reading material.
223644473|NCT03810924|BEHAVIORAL|Trier Social Stress Test|Test to induce high levels of acute social stress, including actors and a faked exam situation
223644474|NCT03810924|BEHAVIORAL|Ergometer|Riding ergometer
224323427|NCT05652478|DRUG|Dolutegravir|50mg dolutegravir (DTG) one tablet orally once daily for 8 days.
223644475|NCT03810924|BEHAVIORAL|Barlab-Exposure|Participants are exposed to a bar situation with different sorts of alcohol available. They sniff at water and at one alcoholic drink.
223644476|NCT03810924|BEHAVIORAL|Reading Newspaper|Participants read newspaper
223644477|NCT04854187|DEVICE|N95 Mask/Indoor air purifier: Including sham|Participants will be using indoor air purifier and N95 mask (control arm with sham filters). The effect will be studied on blood pressure and blood glucose levels.
223644478|NCT06851052|OTHER|sample collection|Samples could include blood, skin biopsy, urine, plucked hair.
223644479|NCT06851052|OTHER|Seeking consent|
224231117|NCT01880970|OTHER|starter infant formula with pro and prebiotics|
224231118|NCT01880970|OTHER|Placebo comparator|
224231119|NCT02596503|DRUG|Eribulin|Intravenous eribulin administered on days 1 and 8 of a 21-day cycle.
224231120|NCT02596503|DRUG|Irinotecan|Irinotecan will be administered orally at a fixed dose of 90 mg/m2/day on days 1 -5 of a 21-day cycle.
224231121|NCT02596503|OTHER|Cefixime|Cefixime will be given to all patients to reduce irinotecan-associated diarrhea. It will be administered Day -1 through Day 8 of each cycle.
224323428|NCT05714085|DRUG|Vericiguat tablet|2.5 mg or 5 mg or 10 mg vericiguat administered orally once daily in tablet form
224323429|NCT05714085|DRUG|Vericiguat suspension|0.2 mg/mL or 1 mg/mL vericiguat administered orally once daily in suspension form
223644480|NCT06851052|OTHER|Sample Collection: Surgical|Excess surgical tissue (diseased tissue or tissue being removed for a clinical reason).
223644481|NCT04113447|OTHER|observational|observational
223644482|NCT02283853|DRUG|dimethyl fumarate|administered orally
223644483|NCT02283853|DRUG|Interferon β-1a|administered by intramuscular injection
223644484|NCT03670056|DRUG|Combination immunotherapy with Ipilimumab and Nivolumab|Patients will be treated with nivolumab 1 mg/kg and ipilimumab 3 mg/kg, starting on Day 1. Patients will receive 4 doses of each nivolumab and ipilimumab and then will receive nivolumab 240 mg starting week 13 (day 85) every 2 weeks until progression, unacceptable toxicity, withdrawal of consent, or the study ends, whichever occurs first.
223644485|NCT01200771|PROCEDURE|TEP|Intravenous injection of glucose labeled Fluor 18. The patient remains fasted at least 6 hours before the start of the examination. The review lasted 1 hour, during wich the patient should not move.
223644486|NCT02376127|PROCEDURE|Dynamic contrast enhancement MRI|
223644487|NCT05135663|DRUG|NS-089/NCNP-02|The same dose administered in as Part 2 of Study NCNP/DMT02 (40 mg/kg) will be administered once weekly for 288 weeks (The total treatment period is 312 weeks including Part2 of Study NCNP/DMT02).
223644488|NCT05135663|DRUG|NS-089/NCNP-02|The same dose administered in as Part 2 of Study NCNP/DMT02 (80 mg/kg) will be administered once weekly for 288 weeks (The total treatment period is 312 weeks including Part2 of Study NCNP/DMT02).
223644489|NCT02874521|OTHER|Intra-dialytic LF-EMS|Electrical muscle stimulation during haemodialysis
223644490|NCT02874521|OTHER|Intra-dialytic cycle training|Cycle training during haemodialysis
223644491|NCT02706106|DEVICE|Knee brace|Patients will be prepared to receive the device of knee brace with or without a hole in the sit position. This intervention will be blinded. Patients will receive a mask covering their eyes and the knee brace will be placed by the researchers, then the knee area will be covered with a dark clothing bag, so the patient will not be able to guess which type of brace is wearing (with or without a hole). Patient will perform the tests without the mask covering their eyes and only the dark clot bag on their knee.
224231122|NCT03237819|DRUG|Sulfate, Magnesium|"Magnesium sulphate will be administered at a dose of 6g over 20 min intravenously followed by a continuous infusion of 6g / 24h for 3 days.~For each day of treatment, 4 ampoules of 10 ml will be distributed to the nurse in charge of the patient (4 ampoules of 1,5g of magnesium sulfate)"
224231123|NCT03237819|DRUG|Placebo - Concentrate|For each day of treatment, 4 ampoules of 10 ml will be distributed to the nurse in charge of the patient (4 ampoules of glucose 5% as placebo)
224231124|NCT05780541|DRUG|PF-07304814|PF-07304814 is a phosphate ester prodrug of PF-00835231 (active moiety), a potent and selective inhibitor of the SARS-CoV-2 3CLpro.
224231125|NCT05780541|DRUG|Placebo|Commercially available 0.9% sodium chloride solution
224231126|NCT05780541|BIOLOGICAL|Remdesivir|Antiviral agent
224231127|NCT06162923|BEHAVIORAL|On-site video group|Each participant will receive standard oral hygiene reinforcement verbally, followed by watching a pre-recorded oral hygiene instruction video on a tablet
224231128|NCT06162923|BEHAVIORAL|Remote video group|After receiving normal oral hygiene reinforcement verbally, each participant will be sent a video link Whatapps instant message, which they are required to watch at home
224231129|NCT04442776|BEHAVIORAL|D-AIP|Intervention on change motivation, insight, medication adherence, drug consumption abstinence or reduction, therapeutic alliance, hopelessness and anxiety
223644492|NCT05599893|OTHER|Tele physical therapy|Before commencing training, warm-up exercises involving upper and lower extremity joint movements were performed for 10 times. During the first and second weeks, the third and fourth weeks, the fifth and sixth weeks and the seventh and eighth weeks, the exercises were performed 10-15, 15-20, 20-25 and 25-30 times per session, respectively. Each session lasted for 10 minutes of warm up, 60 minutes of training and 10 minutes of cool down phase. The participants in the TPG received training four times a week, for 8 weeks, each session lasted for 60 minutes.
223644493|NCT05599893|OTHER|Patient educationa and Conventional exercises|They were informed to do their normal daily activities, avoid a sedentary lifestyle, perform regular physical activities such as household activities, maintain a balanced diet and have 6-8 hours of sleep per day.
223644494|NCT03976219|OTHER|ECAPS Closed Loop SCS|The purpose of this study is to determine the feasibility of recording evoked compound action potentials (ECAPs) and somatosensory evoked potentials (SSEPs) from the spinal cord (SC) and Dorsal root ganglions (DRG), and their suitability as feedback signals.
223644495|NCT04722419|OTHER|Probe meal|The probe meal will be served in 112 Kcal portions (16 g white bread, 10 g cheese, 10 g jam, 3.25 g butter, and 50 mL orange juice) up to the level of maximal satiation.
223644496|NCT06555549|DRUG|DEH113|tablets
224231130|NCT00252980|BEHAVIORAL|Psychotherapy|
223644497|NCT06555549|DRUG|Placebo|tablets
223644498|NCT03636100|DEVICE|Cryoballoon ablation|Cryoballoon ablation using standard equipment and techniques
223644499|NCT04151303|PROCEDURE|Cervical cerclage|Cervical cerclage and cervical cerclage removal
223644500|NCT01913496|OTHER|ebalance|using the ebalance application for 14 weeks
223765844|NCT03546686|DRUG|Nivolumab|nivolumab 240mg IV flat dose is administered 1-5 days prior to cryoablation and 240mg IV every 2 weeks ± 3 days starting 3 (+/-1) weeks after surgery.
224231131|NCT00620490|DRUG|ropivacaine|Ropivacaine 0.5% 0.1 ml/kg per hour
224231132|NCT00620490|OTHER|nacl 0,9%|saline 0.9% 0.1 ml/kg per hour
224231133|NCT04849988|DRUG|ABP-450|ABP-450 (prabotulinumtoxinA) contains a 900kDA botulinum toxin type-A complex produced by the bacterium Clostridium botulinum.
224231134|NCT04849988|DRUG|Placebo|0.9% sodium chloride, sterile, unpreserved, USP/Ph.Eur.
224231135|NCT03185065|DRUG|Amantadine|100 mg of amantadine increased to 200 mg of amantadine, if tolerated
224231136|NCT03185065|DRUG|Modafinil|100 mg of modafinil increased to 200 mg of modafinil, if tolerated
224231137|NCT03185065|DRUG|Methylphenidate|5 mg of methylphenidate uptitrated to max of 20 mg of methylphenidate, if tolerated
224231138|NCT03185065|DRUG|Placebos|1 placebo capsule increased to max of 2 capsules twice daily
224231139|NCT01418157|DRUG|Acetazolamide|125 mg twice daily until 4380 meters altitude
224231140|NCT01418157|DRUG|Placebo|Twice daily
224231141|NCT02684682|BEHAVIORAL|Frequency of mechanical control of plaque (12h)|Performing oral hygiene 12 in 12 hours, with tooth brush and interdental device.
224231142|NCT02684682|BEHAVIORAL|Frequency of mechanical control of plaque (24h)|Performing oral hygiene 24 in 24 hours, , with tooth brush and interdental device.
224231143|NCT02684682|BEHAVIORAL|Frequency of mechanical control of plaque (48h)|Performing oral hygiene 48 in 48 hours, , with tooth brush and interdental device.
224231144|NCT03400930|OTHER|Severe Acute Malnutrition|
224231145|NCT00826930|DRUG|Trans Sodium Crocetinate (TSC)|Single bolus intravenous administration in a superficial vein of the arm over a period of up to 2 minutes.
224231146|NCT04055402|OTHER|Ecological momentary assessments|The staff will help the participants in the EMA group to install and set up the EMA App. The briefing will also emphasise the role of EMA participants that they should perform their normal activities as usual instead of finding out the alcohol advertisements and PADC intentionally. Within 2 weeks after completing the baseline survey, participants in EMA group will complete 5 EMAs prompted regularly every day for 14 consecutive days. The participants will then be contacted for a follow-up survey 2 weeks after the completion of EMA.
224231147|NCT04055402|OTHER|Control|Completion of a baseline questionnaire and a 1-month follow-up survey.
224231148|NCT04640103|OTHER|No interventions|No interventions
223644501|NCT06337630|DRUG|PLX038 + Tuvusertib|"Dose escalation will be conducted on the grid defined by the 4 doses of PLX038 (800 mg/m², 1000 mg/m², 1300 mg/m² and 1700 mg/m² IV every 21 days D1=D22) and 3 doses of Tuvusertib (90 mg, 130 mg and 180 mg QD for 10 days from D3, D3-12). Premedication with anti-emetic agents is not required prior to the initial infusion, but may be used for an individual patient, as needed.~All included patients will receive PLX038 + Tuvusertib until progression of disease, unacceptable toxicity, patient withdrawal of consent, investigator decision, lost to follow-up, death, patient non-compliance, or study termination by Sponsor."
223644502|NCT06150066|OTHER|Recruiting samples|The GCF, plaque, and saliva samples will recruited from participants.
223644503|NCT06027788|DEVICE|CardioGard Embolic Protection Cannula|The CardioGard embolic protection cannula is a device that combines the function of a standard aortic cannula with an added suction mechanism to capture debris that may result from cardiac surgery. The device is comprised of 2 hollow tubes. The first tube is the standard main forward-flow tube to return oxygenated blood to the patient's aorta. The second tube attached to an existing bypass vent port, is a novel element located posteriorly to the main tube; its function is to facilitate blood and particle suction by directing the blood back to the reservoir of the coronary bypass machine, while the retrieved embolic debris is eliminated through the filter of the venous reservoir.
223644504|NCT06027788|DEVICE|Standard Aortic Cannula|An aortic cannula is a device that is used routinely during cardiac surgery to return oxygenated blood from the cardiac bypass machine into the patient's aorta.
223644505|NCT05668481|BEHAVIORAL|Transdiagnostic sleep and circadian intervention (TranS-C)|TranS-C is a psychosocial treatment that helps people who have sleep and circadian problems to improve their sleep health.
223644506|NCT05136703|BEHAVIORAL|Cognitive-Behavioral Therapy for Adherence and Depression (CBT-AD)|CBT-AD is a behavioral intervention administered either in person or via Zoom. Each session lasts approximately 50 minutes. Participants will receive up to 12 individually delivered sessions over 4 months. Participants receive up to three individually delivered booster sessions through 6 months.
223644507|NCT05136703|BEHAVIORAL|Antiretroviral Therapy (ART) Adherence Counseling|"This treatment involves a single session integrating CBT for depression with CBT for adherence following our Life-Steps approach."
223644508|NCT06563102|COMBINATION_PRODUCT|Albuterol/Budesonide|Oral Inhalation. Rescue medication. Unit dose strength of 80 μg budesonide and 90 μg albuterol per actuation
223644509|NCT06563102|COMBINATION_PRODUCT|Albuterol|Oral Inhalation. Rescue medication. Unit dose strength of 90μg albuterol per actuation.
223644510|NCT06083506|DEVICE|NOVALOC TiN retained maxillary overdenture|4 implants immediately loaded by means of a NOVALOC TiN retained maxillary overdenture
223644511|NCT05934877|BEHAVIORAL|PrEP navigation + text messaging|Using a client-centered approach, the PrEP navigator works to link participants into SUD treatment and other ancillary behavioral health and support services, according to their unique barriers, with the ultimate goal of PrEP initiation, adherence, and persistence; services may include mental healthcare, counseling for intimate partner violence, food insecurity, housing instability, hormone therapy. Text-messaging support includes once weekly text message.
223644512|NCT05934877|BEHAVIORAL|Standard of Care|The SOC arm provides PrEP education, information, and referrals. Those randomized to the SOC arm receive an approximate 20-30-minute educational session on PrEP, and will be given a PrEP pamphlet and list of clinics that provide PrEP in LAC.
223644513|NCT05934877|BEHAVIORAL|Contingency Management|Non-responders in the ASK-PrEP arm will be stepped and re-randomized (1:1) to Contingency Management (CM), either in concert with ASK-PrEP or alone. CM is a progressive contingency schedule. Participants submit a thrice weekly urine sample. Participants will receive a voucher-based escalating reinforcement schedule. Successive urine samples that are nonreactive for the metabolites of their identified SUD will escalate their voucher point value. Each three consecutive nonreactive urine samples will receive bonus voucher points. A reactive urine sample will place the participant at the initial voucher point value; however, a rapid reset procedure allows participants to return to their place in the escalating schedule following three consecutive nonreactive urine samples. Voucher points can be redeemed at any time during the study for goods or services that promote a pro-social and healthy lifestyle.
223644514|NCT05269238|OTHER|performing lumbar punctures by students with standard training|performance of the puncture by the student have been previously trained with standard training
223765845|NCT06368492|DRUG|Psilocybin|Each participant will receive 2 different doses of psilocybin (5mg and 10mg) and a matching placebo on three separate occasions.
224231149|NCT05533502|DIETARY_SUPPLEMENT|Combined Plant-Based Protein and Marine-Based Multi-Mineral Supplement|Ingestion of the Test Product at 07.00am - Fava-bean protein concentrate dosed at 0.33 g/kg body mass and Aquamin F dosed at 800mg in 500 ml water volume. Supplied by Marigot Limited, Strand Farm Currabinny, Co. Cork, Ireland
224231150|NCT05533502|DIETARY_SUPPLEMENT|Placebo Control|Ingestion of the Control Product at 07.00am - 500ml water volume.
224231151|NCT04303988|DRUG|SHR-1316|IV
224231152|NCT04303988|DRUG|Bevacizumab|IV
224231153|NCT04303988|DRUG|Cisplatin/Carboplatin|IV
224231154|NCT05701371|OTHER|Biological samples collection|blood drawing + feces collection in a dedicated device
224323430|NCT05714085|DRUG|Placebo tablet|Placebo for vericiguat administered orally once daily in tablet form
223644515|NCT05269238|OTHER|training students augmented reality simulator|performance of the puncture by the student have been previously trained using the augmented reality simulator
223644516|NCT05403424|OTHER|Evaluation of pain|The severity of pelvic girdle pain will be evaluated with the Visual Analog Scale (VAS).
223644517|NCT05403424|DIAGNOSTIC_TEST|Application of pelvic girdle diagnostic tests|Pelvic girdle pain diagnostic tests will be applied.
223644518|NCT05403424|OTHER|Evaluation of biomechanics and viscoelastic properties of thoracolumbar fascia|The biomechanical and viscoelastic properties of the thoracolumbar fascia will be measured in the prone position and measurements will be taken from three different points
223644519|NCT05403424|OTHER|Evaluation of activity limitation|Pelvic Girdle Questionnaire will be filled
223644520|NCT03313778|BIOLOGICAL|mRNA-4157|IM injection
223644521|NCT03313778|BIOLOGICAL|Pembrolizumab|Intravenous infusion
223644522|NCT03313778|BIOLOGICAL|SoC Treatment|Intravenous infusion
223644523|NCT06577610|BEHAVIORAL|Feedback from colonoscopy monitoring program|Adenoma detection rate feedback from colonoscopy monitoring programs
223644524|NCT05889546|PROCEDURE|Biospecimen Collection|Lung, liver, skin, subcutaneous metastases, and blood specimens may be collected via rapid autopsy within 10 hours of expiration.
224231155|NCT00613470|DRUG|citalopram and escitalopram|"escitalopram tablets starting at 10 mg, increase to 20 mg at 4 weeks if QIDS-C16 \> 5, keep at same dose if QIDS-C16 \< 5.~citalopram tablet or solution starting at 2o mg, increase to 40 mg at 4 weeks if QIDS-C16 \> 5, keep at same dose if QIDS-C16 \< 5."
224231156|NCT02199548|OTHER|Interview|This study involves teen participants taking part in one private interview with the study team. Interviews last less than one hour and are scheduled at the participant's convenience. Interviews will be audio/digital recorded. Participants may answer any or all of the questions.
224231157|NCT02146430|DRUG|DS-5565|DS-5565 15 mg tablet for oral administration
224231158|NCT02146430|DRUG|Pregabalin|Pregabalin 150 mg capsule for oral administration
224231159|NCT02146430|DRUG|Placebo tablet|Placebo tablet (matching DS-5565) for oral administration
224231160|NCT02146430|DRUG|Placebo capsule|Placebo capsule (matching pregabalin) for oral administration
224319787|NCT07133321|BEHAVIORAL|Husband Group Health education.|The community-based husband group health education will target expectant fathers with pregnant partners. It will focus on reshaping gender-related attitudes and beliefs, promoting caregiving best practices, preventing violence against women, and improving men's involvement in maternal health. The intervention will comprise group sessions with 20 participants each, conducted over three sessions lasting 2.5 hours each, with a 15-day interval between sessions. The sessions will cover key topics, including recognizing obstetric danger signs, preparing for childbirth, fostering men's engagement in maternal health, advocating nonviolence and shared responsibility, and encouraging joint decision-making.
223644525|NCT05609916|BEHAVIORAL|Cognitive Behavioral Therapy|"During Phase I, participants will receive open label (no blinding) CBT during their study participation for 12 to 18 weeks.~During Phase II, participants will continue receiving CBT maintenance sessions every two weeks for the first 4 weeks, followed by sessions every four weeks. They will also meet with the study physician every 2 weeks via telepsychiatry appointments for clinical and scalar assessment."
223644526|NCT05989217|DEVICE|Occlusal Splint|Occlusion Splint
223644527|NCT05989217|RADIATION|Laser Therapy|Laser Therapy
223644528|NCT05989217|RADIATION|Acupuncture Laser Therapy|Acupuncture Laser Therapy
223644529|NCT04258800|DEVICE|Music during colonoscopy|Music during colonoscopy
223644530|NCT04260802|DRUG|OC-001|Administered IV.
223644531|NCT04260802|DRUG|Drug: OC-001 in Combination with Avelumab|Administered IV.
223644532|NCT03529422|DRUG|Durvalumab|Durvalumab 1500mg IV every 3 weeks for 6 cycles
223644533|NCT03529422|RADIATION|Intensity Modulated Radiotherapy Treatments|Total dose will be 60 Gray (Gy) at 2Gy per fractions for 30 fractions delivered Monday through Friday for 6 weeks
223644534|NCT02000115|DEVICE|Portico transcatheter aortic valve|St. Jude Medical transcatheter Portico aortic valve
223644535|NCT02000115|DEVICE|Commercially available transcatheter aortic valve|Commercially available transcatheter aortic valve
223644536|NCT05704764|BEHAVIORAL|Ending Self Stigma for Persons living with HIV and Use Substances|One-on-one intervention based on principles of cognitive behavioral therapy and social cognitive theory designed to reduce internalized stigma related to HIV and/or drug use.
223644537|NCT05006573|BIOLOGICAL|Benralizumab|Benralizumab active solution in a single accessorized prefilled syringe (APFS) will be administered subcutaneously (SC), 1 mL fill volume
223644538|NCT05006573|BIOLOGICAL|Placebo to Benralizumab|Matching placebo solution in a single accessorized prefilled syringe (APFS) will be administered subcutaneously (SC), 1 mL fill volume
223644539|NCT05783037|OTHER|New Organic Infant Formula|New organic infant formula fed daily ad libitum
223644540|NCT05783037|OTHER|Commercial Organic Infant Formula|Commercially available organic infant formula fed daily ad libitum
223644541|NCT05028556|DRUG|Cohort 1 of Y101D|Y101D, 1mg/kg, Q2W, intravenous infusion
223644542|NCT05028556|DRUG|Cohort 2 of Y101D|Y101D, 3mg/kg, Q2W, intravenous infusion
223644543|NCT05028556|DRUG|Cohort 3 of Y101D|Y101D, 10mg/kg, Q2W, intravenous infusion
223644544|NCT05028556|DRUG|Cohort 4 of Y101D|Y101D, 20mg/kg, Q2W, intravenous infusion
223644545|NCT05028556|DRUG|Cohort 5 of Y101D|Y101D, 30mg/kg, Q2W, intravenous infusion
223644546|NCT06653361|PROCEDURE|Green laser|Green Laser
223644547|NCT06978946|PROCEDURE|Deep Cervical Lymphaticovenous Anastomosis(DLVA)|This surgery will enhance the drainage of cerebral lymphatic fluid by surgically establishing a connection between lymphatic vessels and veins in the neck
223644548|NCT04400643|DEVICE|INTELLiVENT-ASV|INTELLiVENT-ASV is software accessory that automatically adjust ventilation and oxygenation variables to keep the patient within clinician-set target ranges.
223644549|NCT04400643|DEVICE|Non-automated ventilation|In conventional ventilation modes, clinicians adjust and modify the oxygenation and ventilation parameters manually.
223644550|NCT04475146|OTHER|video vizualisation|video vizualisation
223644551|NCT06655350|OTHER|MRI|Morphological data on the tendon (appearance) will be collected on the harvested side and on the healthy side from an MRI analysis carried out systematically after Haemi-Castaing-type surgery.
223644552|NCT06655350|OTHER|Measure|Morphological data on the tendon (diameter) will be collected on the harvested side and on the healthy side from an MRI analysis carried out systematically after Haemi-Castaing-type surgery.
223644553|NCT04353258|BEHAVIORAL|Behavioral Economics intervention (BE mHealth)|Participants will receive a 12-month behavioral weight loss intervention delivered primarily via mobile phone (mHealth) that includes behavioral economics components.
223644554|NCT04353258|BEHAVIORAL|Standard mHealth intervention (mHealth)|Participants will receive a 12-month behavioral weight loss intervention delivered primarily via mobile phone (mHealth).
224231161|NCT05942703|OTHER|saliva samples|Saliva samples, which are part of the usual treatment, will be carried out before and after the non-surgical periodontal treatment
224231162|NCT01894711|DRUG|Trastuzumab|Treatment with trastuzumab in HER2 positive patients
224323431|NCT05714085|DRUG|Placebo suspension|Placebo for vericiguat administered orally once daily in suspension form
223644555|NCT06588569|DEVICE|Multi-mode tumor treatment system|The intervention for this arm involves the use of a novel multi-mode tumor treatment system, developed by Shanghai MAaGI Medical Technology Co., Ltd. The system combines cryoablation and radiofrequency ablation in a single device. During the treatment, the tumor tissue is rapidly frozen to create an ice ball larger than the lesion by 5mm, followed by thawing and rewarming. Subsequently, the lesion is treated with radiofrequency ablation according to conventional procedures to ensure complete ablation within a safety margin of 5-10mm around the tumor.
223644556|NCT06588569|DEVICE|Radiofrequency ablation therapeutic apparatus|The intervention for this arm involves the use of conventional radiofrequency ablation equipment, which is developed by MedSphere International (Shanghai) Co., Ltd.. During the treatment, the tumor is ablated using predefined power and time settings to ensure complete ablation within a safety margin of 5-10mm around the tumor.
223644557|NCT06599398|OTHER|Jeroen Pit Huis|The JPH is a unique and innovative Transitional Care Unit (TCU) situated in close proximity of the AUMC. In this TCU, patients and their family reside in separate private home-like apartments. The families can stay while practising in, and adapting to, their new reality until they are ready to transition home. A multidisciplinary team of healthcare experts (nurses, psychosocial care workers, family counsellors, and paediatricians) are gradually guiding parents towards taking on the role of their child's primary caregiver. This process is guided by a newly developed seven phase care path.One condition for staying in the JPH is that one parent is always present. In this form (24/7 parental stay and nursing care directly available under the supervision of pediatricians) the JPH is unique in the Netherlands.
223644558|NCT06603584|RADIATION|Chest x- Rays|prebronchial Thicknening - Right upper lobe Patches suggesting Aspiration -Collapsing lobe
223644559|NCT06603792|BEHAVIORAL|EEG-neurofeedback|Traditional neurofeedback uses one or two electrodes to modulate activity within a specific frequency band. Standardized Weighted Low Resolution Electromagnetic Tomography (swLORETA) analyzes the 3D distribution of intracortical brain electrical activity based on surface EEG recordings, enabling real-time brainwave imaging with a spatial resolution under one cubic centimeter. This divides the brain into over 12,000 voxels, offering localization similar to fMRI while maintaining EEG's faster temporal resolution. Source-localized NF can target specific, deeper brain regions, multiple Brodmann areas simultaneously, and provide feedback on connectivity between neural sources, enabling the training of specific neural networks. swLORETA metrics are compared to a normative database of neurotypical brains to produce z-scores for each area and metric. We will use the NeuroGuide normative database, FDA-approved and validated in peer-reviewed studies, widely used in clinical NF.
223644560|NCT05522153|DRUG|Arista|hemostatic powder
223644561|NCT06597812|PROCEDURE|Sevoflurane|Depending on the anesthesia maintenance protocol, total intravenous anesthesia (TIVA) or sevoflurane anesthesia, patients were divided into group T (TIVA) and group S (sevoflurane).
223644562|NCT06596993|OTHER|IMU-based balance training|Leveraging AI technology to identify motion deficiencies, the experimental group will undergo IMU-based balance training
223644563|NCT06596993|OTHER|general health education or exercise training|general health education or exercise training
223644564|NCT06600009|DRUG|Secukinumab|Patients had received secukinumab per their dosing regimens prior to this observational study.
223644565|NCT06600009|DRUG|Adalimumab|Patients had received adalimumab per their dosing regimens prior to this observational study.
223644566|NCT06589401|DRUG|INP12|Oral paclitaxel
223644567|NCT06597630|OTHER|Tissue specimens were stained by histopathology of hematoxylin-eosin|Whole slide images were created by scanning the complete histologic slide to produce high-resolution digital files of the histopathology of hematoxylin-eosin and CYP11B2 immunostained sections.Tissue sections of all blocks from each resected adrenal were evaluated by hematoxylin and eosin and CYP11B2 immunostaining and adrenal specimens were categorized as classical or nonclassical histopathologic findings of unilateral PA according to the HISTALDO consensus; Genotyping was performed using CYP11B2 (aldosterone synthase)-guided sequencing
223765846|NCT06368492|BEHAVIORAL|Hypnosis script|All participants will receive a brief hypnotic induction aimed at producing analgesia before the second administration of CPT
224231163|NCT01893905|DRUG|CS+SG|Chondroitin sulfate+glucosamine sulfate orally administered once a day for 24 weeks.
224231164|NCT01893905|DRUG|Placebo|Placebo of chondroitin sulfate+glucosamine sulfate orally administered once a day for 24 weeks.
224231165|NCT02441972|DRUG|18F-Al-NOTA-PRGD2 PET/CT|18F-Al-NOTA-PRGD2(PET imaging agent) given by vein before PET scans.Perform PET/CT for each enrolled volunteer or patient at 60-90min.
224231166|NCT06451861|DRUG|Chidamide|Induction Therapy
224231167|NCT06451861|DRUG|Venetoclax|Induction Therapy
224231168|NCT06451861|DRUG|azacitidine|Induction Therapy
224231169|NCT06451861|DRUG|Anthracyclines or anthraquinones|Induction Therapy
224231170|NCT06451861|DRUG|cytarabine|Induction Therapy
224323432|NCT06830798|DRUG|Ravulizumab|Participants will receive ravulizumab via intravenous (IV) infusion.
224323433|NCT06830798|DRUG|Placebo|Participants will receive placebo via intravenous (IV) infusion.
224323434|NCT05058651|BIOLOGICAL|Atezolizumab|Given IV
224323435|NCT05058651|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
224323436|NCT05058651|DRUG|Carboplatin|Given IV
224323437|NCT05058651|DRUG|Cisplatin|Given IV
224323438|NCT05058651|PROCEDURE|Computed Tomography|Undergo CT scan
224323439|NCT05058651|DRUG|Etoposide|Given IV
223644568|NCT06603922|BEHAVIORAL|Psychological treatment (P-MCT)|Personalization will be performed according to the results obtained from the platform. Both the classic MCT and personalized MCT will be the same with regard to specific modules that are offered to patients. However, the personalized MCT will have personalized homeworks that target specific factors, in which patients have deficits. For instance, patients with deficits in self-esteem (based on the results from the platform) will be provided with homework addressing this aspect. We identified five domains that will be personalized: 1. self-esteem; 2. cognitive insight; 3. delusions; 4. positive symptoms; 5. completion.
223644569|NCT06603922|BEHAVIORAL|Psychological treatment (MCT)|"Metacognitive training is a cognitive approach to the treatment of positive symptoms in psychosis.~Metacognitive training consists of ten modules referring to common cognitive issues and biases in solving problems in schizophrenia. The topics of MCT include the following: attribution blaming and taking credit (module 1), jumping to conclusions (modules 2 \& 7), changing beliefs (module 3), deficits in theory of mind and social cognition (modules 4 and 6), overconfidence in (memory) errors (module 5), mood (module 8), self-esteem (9) and stigma (10).~Each session lasts 45-60 min and follows a protocol defined in the 'Metacognitive Training for Psychosis (MCT)' manual.~The MCT for Schizophrenia programme will be applied to the group (6-12 persons) applied by therapists in each center. The training format (online or in-person) as well as the frequency (1 or 2 times per week) will vary depending on the center."
223644570|NCT06599541|BEHAVIORAL|Hypopressive Exercise|A hypopressive exercise program will be carry out.
223644571|NCT06599541|BEHAVIORAL|Pilates Exercise|A pilates exercise program will be carry out.
223644572|NCT06590259|DEVICE|Multi-mode tumor treatment system|All subjects are treated using the multi-mode tumor treatment system (Shanghai MAaGI Medical Technology Co., Ltd), with the treatment procedure conducted according to the temperature control mode for tumor ablation. Complete ablation of intrahepatic lesions is achieved to realize an intrahepatic no-evidence-of-disease (NED) state. For lesions that could not be ablated in a single session, two treatments are performed to achieve NED within the liver.
223644573|NCT06590259|DRUG|Sintilimab+mFOLFOX6 or FOLFIRI+bevacizumab or cetuximab|Systemic therapy including PD-1 inhibitor starts on the 7th day after ablation (sintilimab 200 mg IV D1 + mFOLFOX6 or FOLFIRI + bevacizumab or cetuximab (determined according to the subject's first-line chemotherapy regimen), Q3W, chemotherapy for 4-6 cycles. Sintilimab continues until disease progression, not exceeding a maximum of 2 years.）
223644574|NCT06591312|DRUG|Ticagrelor 90 MG|The ticagrelor arm will receive (a 180mg loading dose of cilostazol during the first 24 hours of stroke onset, followed by 90mg once daily from the 2nd day to the 90th day) and an open-label loading 300 mg aspirin, followed by a maintenance dose of 75 mg aspirin.
223644575|NCT06591312|DRUG|Clopidogrel|The clopidogrel arm will receive (a 300 mg loading dose of clopidogrel during the first 24 hours of stroke onset, followed by 75 mg once daily from the 2nd day to the 90th day) and open-label loading 300 mg aspirin, followed by a maintenance dose of 75 mg aspirin.
223644576|NCT06602154|OTHER|Resin modified glass ionomer|"The product will be stored by investigators at room temperature in lock and key.~Product: Riva light cure RMGIC (HV) Composition: 18 mg orthodontic bonding paste and 6 ml enamel bond resin. Storage: Stored at room temperature and protected from humidity.~Usage: Steps for Resin-modified glass ionomer cement composite bonding:~1. Prepare all teeth with oil-free pumice, and rinse thoroughly for 15 seconds with water.~2. Wash thoroughly.~3. Etch enamel surface with 37% phosphoric acid for 15 seconds.~4. Rinse the etched surface for 20 seconds to remove the acid and precipitates that might have formed during the etching procedure.~5. Activate the capsule and immediately mix in an amalgamator. Do not click with applicator before you mix.~6. Immediately place into capsule applicator and click trigger until paste is seen through the nozzle~7. Light cure each increment for 20 seconds."
223644577|NCT04791735|PROCEDURE|Laparoscopy|"* Installations of the patient: the position of the patient will depend on both extent of resection and location of the lesion.~* Absence of laparotomy with the exception of the extraction of the resected specimen and absence of costal retractors.~* Use of laparoscopic specific devices:~  * Use of multiple (3-7) ports depending on the operator's preference and technical difficulty (mainly 5-6 ports for major liver resection).~ * Use of a laparoscopic camera system with 0° or 30°~ * Use of a dedicated laparoscopic ultrasound probe.~ * Use of specific laparoscopic devices for coagulation, parenchymal transection and sealing.~* Placement of the resected specimen in a plastic bag and extraction without fragmentation, depending on the surgeon's preferenceand the diameter of the resected specimen"
223765847|NCT06019988|OTHER|Early Point-of-Service Social and Behavioral Determinants of Health (SBDOH) Screening|All patients who participate in the trial will receive one of three social and behavioral determinants of health (SBDOH) screening instruments (AHC-HRSN, Health Leads, or NCCN DT + PL). Any patients who do not complete the screening within 48 hours of its administration will be randomized to receive the same screening via one of two modality arms (Chatbot or IVR System)
224231171|NCT04347746|BEHAVIORAL|stretching physiotherapy|"A booklet with images and a description of all movements to be performed during therapy will be offered to patients. The booklet illustrates the movements for stretching the upper limbs divided as follows: three movements for the neck, three movements for the arms and forearms and four movements for the hands.~The therapy will be carried out twice a week at the Unopar research center, under the guidance of a physiotherapist trained in technique and supervision by a senior therapist. At the end of each movement, the individual is instructed to maintain the position for 40 seconds.~Patients will be instructed to appear in comfortable clothes and the environment will have favorable conditions."
224319788|NCT07133321|BEHAVIORAL|Helping Mothers Survive + RMC|"The Helping Mothers Survive training is designed by Jhpiego, an affiliate of Johns Hopkins University, in collaboration with global health partners, including the World Health Organization (WHO), Laerdal Global Health, and the International Confederation of Midwives (ICM) for healthcare professionals involved in childbirth care focusing on saving lives at birth in low-resource settings. This on-site training will use realistic simulations to enhance skills in identifying and managing key causes of maternal mortality, such as postpartum hemorrhage and preeclampsia, starting with essential labor care. The program employs the MamaNatalie birthing simulator, a low-tech realistic tool for hands-on practice developed by Laerdal Global Health. MamaNatalie features a model uterus with a neonate, placenta, and umbilical cord, enabling simulations of postpartum hemorrhage, breech delivery, vacuum-assisted birth, and normal labor."
224323440|NCT05058651|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
224323441|NCT05058651|OTHER|Patient Observation|Undergo observation
224323442|NCT06618287|DRUG|BMS-986507|Specified dose on specified days
223644578|NCT04791735|PROCEDURE|Laparotomy|"* Installation of the patient: patients will be placed in supine position, the surgeon operating on the right side of the patient and the assistant standing on the left side.~* Incision: the type of incision will depend on both the nature of the resection and the operator's preference. Various incisions such as bi subcostal incision, J-shaped incision, right subcostal incision and midline incision can be used.~* Use of open surgical instruments and devices for coagulation and parenchymal transection. These may include the crush-clamp technique or ultrasonic dissection for parenchymal transection, bipolar coagulation, clips, sutures or open vascular stapler for hemostasis and biliostasis.~* Methylene blue injection through the cystic drain to rule out biliary leakage will be performed depending on the surgeon's preference."
223644579|NCT05415072|DRUG|DYP688|Single agent DYP688
223644580|NCT06655259|PROCEDURE|TURP|Participants will undergo Transurethral Resection of the Prostate (TURP), a surgical procedure performed to relieve symptoms of urinary obstruction caused by the prostate tumor
223644581|NCT06655259|DRUG|Standard Medical Therapy|Participants will receive Standard Medical Therapy, which includes ADT, typically with an LHRH agonist or antagonist, to reduce testosterone levels, a key driver of prostate cancer progression. In addition to ADT, participants may be treated with second-generation anti-androgen drugs such as Abiraterone or Enzalutamide. These medications block androgen receptor signaling and further inhibit the cancer\&#39;s ability to grow.
223644582|NCT06666218|BEHAVIORAL|Behavioral Intervention|Complete the HOPE intervention workshop
223644583|NCT06666218|OTHER|Electronic Health Record Review|Ancillary studies
224231172|NCT04347746|BEHAVIORAL|Myofascial therapy|Myofascial therapy will be performed on the upper limbs, pectoral and dorsal regions with the aid of hooks (instrument assisted soft-tissue mobilization). In the supine position, the pectoral muscles will be manipulated (infracromial, external, axillary-claviculopectoral fossa), biceps brachii (short head, long and forearm insertion), round pronator, anterior forearm musculature (compartment of the radial extensor of the long carpus and brevis, finger extensor and ulnar carpal extensor). In lateral decubitus the deltoid muscle in the anterior, middle and posterior portions. In the prone position, the trapezius muscle (in its cervical, scapular and nuchal insertions), scapular levator muscle, great dorsal muscle (in its lateral insertions) and triceps brachii muscle. The hook manipulation time is two minutes of execution for each muscle mentioned above, making a total time of each section of forty minutes. There will be two weekly sessions with an interval between forty-eight hours.
224231173|NCT03093324|DRUG|ALKS 8700|Administered as specified in the treatment arm.
224231174|NCT03093324|DRUG|Dimethyl Fumarate|Administered as specified in the treatment arm.
224231175|NCT01139255|BEHAVIORAL|Podcasting + mobile media|Use of a weight loss podcast designed with health behavior theory
224231176|NCT01927536|DEVICE|White LED Flashlight|white light setting
224231177|NCT01927536|DEVICE|Red/Green Green Dominant LED Flashlight|Green LED light dominant setting
224231178|NCT03923179|DRUG|Pyrotinib|Pyrotinib, 400mg qd
223644584|NCT06666218|OTHER|Interview|Complete an interview
223644585|NCT06666218|OTHER|Survey Administration|Complete a survey
223644586|NCT06666218|OTHER|Survey Administration|Ancillary studies
223644587|NCT06389955|DRUG|TP 3654|TP 3654 is an investigational orally delivered drug
223644588|NCT03493464|DRUG|BR55|A novel targeted ultrasound contrast agent
223644589|NCT06589323|PROCEDURE|Coronary artery bypass graft|All patients included will undergo coronary artery bypass graft surgery. During surgery, every graft will be evaluated through transit time flowmetry (TTFM) and intraoperative ultrasound control (HFUS).
223644590|NCT06587672|DEVICE|Micra AV implantation|Patients received Micra AV implantation
223644591|NCT06592612|RADIATION|SBRT and second-line systemic therapy|Patients in the SBRT arm will receive second-line systemic therapy combined with SBRT. The choice and stipulations for second-line systemic therapy drugs are the same as those for the control arm.SBRT will be administered to all oligoprogressive lesions and must begin within 2 weeks after the start of second-line therapy. Systemic therapy will not be paused during SBRT. Patients who do not withdraw from the study will not receive crossover treatment; however, if a patient in the control group withdraws from the study due to tumor progression and is assessed as suitable for SBRT, salvage SBRT will be administered promptly.
223644592|NCT06592612|DRUG|Second-line systemic therapy|Patients in the control arm will receive second-line systemic therapy. The following stipulations apply to the second-line treatment drugs: for patients who received bevacizumab combined with atezolizumab/sintilimab as the first-line treatment, lenvatinib or regorafenib will be used for second-line treatment; for patients who received lenvatinib with or without PD-1 antibody as the first-line treatment, regorafenib combined with another PD-1 antibody will be used for second-line treatment.
223644593|NCT06602440|PROCEDURE|The indwelling length of epidural catheter is 3 centimeters.|When performing Dural Puncture Epidural technique with Programmed Intermittent Epidural Bolus（PIEB） mode for labor analgesia, According to different indwelling lengths of epidural catheters as variables, patients are divided into three treatment groups（3cm group 、5cm group and 7cm group）
223644594|NCT06602440|PROCEDURE|The indwelling length of epidural catheter is 5 centimeters.|When performing Dural Puncture Epidural technique with Programmed Intermittent Epidural Bolus（PIEB） mode for labor analgesia, According to different indwelling lengths of epidural catheters as variables, patients are divided into three treatment groups（3cm group 、5cm group and 7cm group）
224231179|NCT03923179|DRUG|Etoposide|Etoposide, 50mg，qd,d1-21,Q4W
224231180|NCT03362437|DRUG|BMS-986177|Form A
224231181|NCT03362437|DRUG|BMS-986177|Form B
224231182|NCT02643901|BIOLOGICAL|GW003|single SC injection
224231183|NCT01201746|PROCEDURE|Delayed treatment|Scaling, Root Planing and oral hygiene instruction
224231184|NCT01201746|PROCEDURE|Periodontal therapy|Scaling, root planning and oral hygiene instructions
224231185|NCT04064229|DEVICE|ivWatch Model 400 with SmartTouch Sensor|The ivWatch Model 400 with SmartTouch Sensor monitored the site during the course of the infiltration and issued red and/or yellow notifications if an infiltration was detected.
224231186|NCT04064229|DEVICE|ivWatch Model 400 with Fiber Optic Sensor|The ivWatch Model 400 with Fiber Optic Sensor monitored the site during the course of the infiltration and issued red and/or yellow notifications if an infiltration was detected.
224231187|NCT04193631|DRUG|Cannabidiol (CBD)|A single dose of Cannabidiol (CBD) when patients experience musculoskeletal pain in the trial.
224323443|NCT06618287|DRUG|Osimertinib|Specified dose on specified days
223644595|NCT06602440|PROCEDURE|The indwelling length of epidural catheter is 7 centimeters.|When performing Dural Puncture Epidural technique with Programmed Intermittent Epidural Bolus（PIEB） mode for labor analgesia, According to different indwelling lengths of epidural catheters as variables, patients are divided into three treatment groups（3cm group 、5cm group and 7cm group）
224231188|NCT01992289|DRUG|EDI200|Long-term follow-up study of subjects that received EDI200 as part of protocol ECP-002
224231189|NCT05943925|OTHER|No intervention|no intervention
224231190|NCT05943925|DIETARY_SUPPLEMENT|Probiotic supplement|A total of 60 Alzheimer Disease (AD) patients will be recruited, 30 will ingest the probiotic mixture and 30 will ingest placebo (randomized assignment to the groups will be done). The experimental group will take the probiotic ingest daily: Lactobacillus acidophilus, Lactobacillus casei, Bifidobacterium bifidum, and Lactobacillus fermentum (2 × 109 colony forming units (CFU)/g of each). This mixture of bacteria has been showed to have positive results with 12 weeks treatment.
224231191|NCT02518230|DEVICE|Neurally Adjusted Ventilatory Assist|The subject will be crossed over from the baseline ventilator mode to Neurally Adjusted Ventilatory Assist
224319789|NCT00707382|GENETIC|(1) Genotyping for CYP4502D6 and 2C19 polymorphisms|"In this study arm (1), the genotype information is given to the physician in charge of treatment and can be used to direct the pharmacological treatment according to local guidelines. In the guidelines the genotype is translated to the clinical designation normal, slow or fast metabolizer of CYP2D6 or normal or slow metabolizer of CYP2C19. Different treatment options for the different genotypes are described."
223644596|NCT06603389|OTHER|Psychiatric Non-Suicidal Self-Injury Risk Assessment Scale|sacles or questionnaires
223644597|NCT06593782|DRUG|HSK21542|"1. HSK21542 injection was administered day 1;~2. Placebo to match Dorasetron was administered on day 1;~3. Aprepitant injection was administered on day 1;~4. Dexamethasone tablets was administered on day 1 to day 4;"
223644598|NCT06593782|DRUG|HSK21542|"1. HSK21542 injection was administered day 1;~2. Placebo to match Dorasetron was administered on day 1;~3. Aprepitant injection was administered on day 1;~4. Dexamethasone tablets was administered on day 1 to day 4;"
223644599|NCT06593782|DRUG|Dolasetron|"1. Placebo to match HSK21542 injection was administered day 1;~2. Dorasetron injection was administered on day 1;~3. Aprepitant injection was administered on day 1;~4. Dexamethasone tablets was administered on day 1 to day 4;"
223644600|NCT06599229|DIAGNOSTIC_TEST|myocardial contrast echo|Vasodilator stress myocardial contrast echocardiography will be performed at baseline and within 4 months of reaching target dose of a cardiac myosin inhibitor.
223644601|NCT06600139|BEHAVIORAL|The Collaboration-Screening-Referral (SSH) model|The SSH aims to identify parents in need of mental health support and to strengthen social workers' competence in addressing mental illness. The SSH includes three components: 1) Collaborating - establishing collaboration with local services offering support to adults with mental illness, 2) Screening - using screening instruments for depression (the Patient Health Questionnaire - PHQ-9) and anxiety (GAD-7) to identify symptoms of mental illness among parents, and 3) Referral - Discussing the results of the screening with parents and referring to appropriate services. Techniques from motivational interviewing are included. Social workers receive training and material to administer the screening and refer parents in need of support.
223644602|NCT05156567|DIAGNOSTIC_TEST|Deep Learning System|The multitask DLS with five algorithms detecting spine metastases and evaluate features (bone lesion quality, posterolateral involvement, and vertebral body collapse)
223644603|NCT06590519|OTHER|Date Seed Extract|"Intervention group participants will undergo a three-month intervention program. The Health Belief Model (HBM) will be the underlying theory to facilitate behaviour change.~The intervention group will receive a capsule of date-seed-powder. Each person should consume 5 grams (two capsules of date-seed powder)twice daily after meals for three months.~Assessments are carried out at the beginning of the study, one month and two months after the intervention on the effect of date-seed on glycaemic control,risk of cardiovascular, physical activity, daytime sleepiness and anthropometric measurements. Participants will be contacted twice a week to ensure that they are adhering to the rules."
223644604|NCT06591416|PROCEDURE|minimally invasive surgical technique|minimally invasive surgical technique
223644605|NCT06591416|PROCEDURE|minimally invasive surgical technique with granulation tissue preservation|minimally invasive surgical technique with granulation tissue preservation
223644606|NCT06591637|BEHAVIORAL|Fertility supportive behavior education based on Watson's Theory of Human Care|In this study, Watson's Theory of Human Caring guided the development of a care framework and nursing intervention for women with infertility. The researchers adapted the theory and focused on six of the ten carative factors : 1) Adopting values of humanity and devotion; 4) Developing supportive care relationships; 6) Using problem-solving methods for informed decisions; 7) Tailoring teaching to individual needs; 8) Creating a comfortable, peaceful environment; 9) Assisting with basic needs. The nursing care program, integrated with IVF treatments (14-18 days), involved four transpersonal interviews lasting 45-90 minutes each. These interviews were recorded in notes, used to individualize future sessions. The approach included active listening, empathy, and support, with participants encouraged to keep diaries for discussion. Communication was maintained in person, by phone, or email.
223644607|NCT06591637|PROCEDURE|Routine nursing care|"Routine nursing care during IVF treatment includes:~Pre-Treatment Counseling: Providing information and addressing patient questions.~Monitoring and Assessment: Regular checks of health, hormone levels, and ovarian function.~Medication Administration: Giving prescribed fertility drugs and other medications.~Assisting with Procedures: Preparing and assisting with egg retrieval and embryo transfer.~Emotional Support: Offering emotional and psychological support. Education: Instructing on medication use, self-care, and recognizing complications.~Follow-Up Care: Scheduling and managing follow-up appointments to monitor progress"
224231192|NCT02518230|DEVICE|Synchronized Interm. Mandatory Assist|The subject will be crossed over from the baseline ventilator mode to Synchronized Intermittent Mandatory Assist with Pressure Support
224231193|NCT01548781|BEHAVIORAL|Impairment-based robotic intervention for reaching function|All participants will undergo 8 weeks of reaching practice in the ACT3D. Frequency and duration will be matched at three 1.5-hour sessions per week. All reaching practice will include abduction (gravity) loading standardized to the participant's motor abilities. The experimental group intervention will also include a horizontal viscous resistant element similar to pushing the arm through molasses.
224231194|NCT00614055|DRUG|insulin degludec/insulin aspart|Formulation 1: Treat-to-target dose titration scheme, injection s.c., once daily
224231195|NCT00614055|DRUG|insulin degludec/insulin aspart|Formulation 2: Treat-to-target dose titration scheme, injection s.c., once daily
223644608|NCT06591637|DEVICE|"The booklet Fertility-Supporting Health Training"|This booklet was prepared in line with the relevant literature and contained educational content aimed at improving healthy lifestyle behaviours . The training booklet included information on the effects of factors such as obesity, weakness, exposure to environmentally harmful substances, smoking and caffeine use on fertility and the methods of coping with these factors. In addition, information on how to use proper nutrition, develop exercise habits and cope with stress was provided. The booklet was distributed to the women at at the onset of the study.
223644609|NCT06595771|DEVICE|continuous positive airway pressure|continuous positive airway pressure is a form of positive airway pressure ventilator, which applies mild air pressure on a continuous basis to keep the airways continuously open in people who are able to breathe spontaneously on their own, but need help keeping their airway unobstructed
223644610|NCT06595771|DEVICE|Polysomnography|"Polysomnography measures Apnea-hypopnea index (Minutes)~Classify and identify Obstructive Sleep Apnea Syndrome (OSAS):~1. Apnea-hypopnea index: 5-14.9 olan; mild OSAS~2. Apnea-hypopnea index: 15-29.9: moderate OSAS~3. Apnea-hypopnea index ≥30: severe OSAS measures duration and percentage of time oxygen saturation dropped below 90% the total minutes of sleep"
223644611|NCT06591832|OTHER|Exercise|Virtual reality based progressive relaxation exercise
223644612|NCT06603454|RADIATION|Preoperative CT|Preoperative contrast enhanced CT
223644613|NCT06591611|OTHER|PEEK reinforced fixed all-on-four prosthesis|Fabricating a fixed prosthesis for patients with completely edentulous mandibles reinforced with PEEK
223644614|NCT06588023|OTHER|Observational study to evaluate professional practices|"It consists of collecting data prospectively on all pre-eclamptic patients undergoing a non-urgent cesarean section.~The objective is to observe the management of hemodynamics and calculate the prevalence of complications such as maternal hypotension and/or hypertension through the implementation of non-invasive monitoring (ClearSight)."
223644615|NCT06597669|PROCEDURE|Placement of stainless steel crowns on primary molars|Preformed metal crowns have been placed to treat caries in primary molars
223644616|NCT06592131|DRUG|BF844|BF844, a small molecule developed by Usheriii Initiative to prevent or delay the progressive hearing and vision loss in patients with Usher syndrome type 3.
223644617|NCT06594835|BEHAVIORAL|Better Together|Better Together (BT) is a 90-min, age-appropriate, culturally relevant prevention intervention to prevent substance use among Black youth experiencing household challenges (ages 11-13) by addressing the multilevel influences of substance use.
223644618|NCT06594835|BEHAVIORAL|Youth In the Media (YM)|Delivered in eight in-person, 90-minute sessions concurrently with BT sessions, the YM program was designed to (1) increase participants' awareness of and access to the different types of media and free resources available at the participants local libraries, (2) discuss different types of media that center stories and experiences of Black youth, and (3) expose participants to careers in media.
223644619|NCT06591325|OTHER|exercise|The RT program was performed in the morning and in groups, three days per week (Mondays, Wednesdays, and Fridays), in the University fitness facility over 12 weeks. Participants were personally supervised by Physical Education professionals (1-2 supervisors per exercise session) with substantial RT experience to ensure consistent and safe exercise performance. Throughout the intervention period, the RT program was carried out on machines and free weights (Ipiranga Fitness, Presidente Prudente, SP, Brazil). The training program was carried out in groups. Participants performed four exercises for the trunk and upper limbs (chest press, seated row, triceps pushdown, preacher curl) and four exercises for the lower limbs (horizontal leg press, leg extension, lying leg curl, seated calf raise) in three sets of 10-15 repetitions based on previous guidelines (9,22).
223644620|NCT06591325|OTHER|Control|maintaining the daily routine
223644621|NCT06593730|DRUG|NRL001 cream 0.5%w/w|
223644622|NCT06593730|DRUG|NRL001 cream 0.75%w/w|
223644623|NCT06593730|DRUG|NRL001 cream 1.0%w/w|
223644624|NCT06593730|DRUG|NRL001 cream 1.5%w/w|
223644625|NCT06593730|DRUG|NRL001 cream 2.0%w/w|
223644626|NCT06593730|DRUG|NRL001 cream 2.5%w/w|
223644627|NCT06595524|BEHAVIORAL|online mindfulness-based intervention|The mindfulness-based intervention (MFU-Mindful-application) consists of 8 topics, one topic per week. Moreover, we will assign participants (experimental group) to continuously practice using guided meditation approximately 10 minutes daily at least 5 days a week for 3 months via MFU-Mindful application
223644628|NCT06600893|DEVICE|Low intensity shockwave therapy (LiSWT)|The Urogold100™ uses electrohydraulic technology to generate low intensity shockwave energies in ranges of 0.1 - 0.18 mJ/mm2 (using 0.9 - 0.12 mJ/mm2 in this study) associated with biologic activities of stimulation of mechanosensors, activation of neo-angiogenesis processes, recruitment and activation of stem cell progenitor cells, improvement of microcirculation, nerve regeneration, remodeling of erectile tissue with increase in the muscle/collagen ratio and reducing inflammatory and cellular stress responses. The device uses the parabolic applicator OP 155 that generates a plasma-driven detonation resulting in a shockwave with a broad and widely-stretched 5 megapascal therapeutic volume. Due to the absence of a concentrated focus, a 14 mm wide shockwave is delivered to the erectile tissue with up to 30 mm penetration. LiSWT is delivered to Active Arms 1 and 2 per protocol. After unblinding at the first follow up visit, participants in Sham Arms 1 and 2 receive active LiSWT treatment
223644629|NCT06600893|DEVICE|Sham|With the Urogold 100 turned on and with the participant wearing headphones and blinded by a pulled curtain the applicator is applied in a similar manner to when it is active treatment and the sound of shockwave playing in a blue tooth speaker the participant believes he is receiving active treatment but zero energy is delivered.
223644630|NCT06595797|DRUG|HRS9531|HRS9531
223644631|NCT06595797|DRUG|HRS9531placebo|HRS9531placebo
224231196|NCT00614055|DRUG|insulin glargine|Treat-to-target dose titration scheme, injection s.c., once daily
224231197|NCT00614055|DRUG|metformin|Tablets, 1500-2000 mg/day
224231198|NCT04138849|DRUG|BBT-877 single dose|Oral capsule, single dose.
224231199|NCT04138849|DRUG|Placebo single dose|Oral capsule, single dose.
224231200|NCT00208390|DEVICE|Summit Tapered Hip System|A cementless, tapered femoral component for use in total hip replacement
224231201|NCT06539364|DIAGNOSTIC_TEST|Quality of life surveys were conducted|Quality of life surveys were conducted with OHIP-14, OHRQoL-UK and VAS
224323444|NCT06618287|DRUG|Pembrolizumab|Specified dose on specified days
224231202|NCT05157321|DEVICE|Repetitive Transcranial Magnetic Stimulation|TMS device will deliver repetitive trains of magnetic pulses using Magstim Rapid 2 with angulated figure of eight shaped coil. The device comprised two-channel Neuro-EMG-MS digital system for determining the motor threshold of the patients that will be used for establishing the threshold intensity for stimulation. The figure of eight-shaped coil generated a magnetic field of up to 4 Tesla that penetrates the cranium, enters into the soft tissue of the brain and henceforth stimulates the motor neurons.
224231203|NCT05157321|DEVICE|Sham Repetitive Transcranial Magnetic Stimulation|Sham Repetitive Transcranial Magnetic Stimulation
224231204|NCT02072356|RADIATION|yttrium Y 90 glass microspheres|Given Interartrial
224323445|NCT06618287|DRUG|Nivolumab|Specified dose on specified days
223644632|NCT06591871|OTHER|Self-management educational program for post mastectomy lymphedema women|"The researcher created this program in response to the identified needs of post mastectomy lymphedema women to provide them with essential knowledge and self-care practices concerning post-mastectomy lymphedema. It was designed as a straightforward Arabic booklet written in simple language and supplemented with colorful illustrations and images to accommodate women of varying educational levels. It was consisted of two sections:~Theoretical section included the following (A brief overview of anatomy and physiology of the lymphatic system, definition, causes, signs and symptoms, risk factors , stages, diagnosis and complications of post mastectomy lymphedema, also instructions about general practices for preventing and managing infection, hand and arm care ,a healthy nutrition and when you call your physician ).~Practical section included (use of compression bandages, garments and their care, upper extremity lymphedema exercises, Manual Lymphatic Drainage (MLD) massage)."
223644633|NCT05042414|BEHAVIORAL|High intensity interval training|Four times four minutes treadmill interval training
223644634|NCT05042414|BEHAVIORAL|Moderate intensity training|Moderate intensity treadmill training
223644635|NCT05042414|BEHAVIORAL|Resting|No training
223644636|NCT03123731|BEHAVIORAL|Control Arm|Wearing Physical Activity Monitor
223644637|NCT03123731|BEHAVIORAL|iSTEP|Physical Activity Intervention
223644638|NCT03123731|BEHAVIORAL|iSTEP|Physical Activity and Diet Intervention
223644639|NCT06992375|OTHER|Manual therapy|This technique involves a low-amplitude, high-velocity push on the shoulder joints with an additional two-second tension
223644640|NCT06992375|OTHER|Placebo|This technique involves a low-amplitude, high-velocity push on the shoulder joints with an additional two-second tension
223644641|NCT06992375|OTHER|Exercise|The following exercise will be performed:push-ups
223644642|NCT06857864|DEVICE|Test myopia control lenses (BSL)|Test spectacle lenses will be provided to the subjects throughout the 1 year clinical trial.
223644643|NCT06586983|DRUG|Tenofovir Disoproxil Fumarate|300 mg po OD
223644644|NCT06592625|DRUG|SHR-A1811|SHR-A1811
223644645|NCT06592625|DRUG|Adebrelimab|Adebrelimab
223644646|NCT06603896|OTHER|Aromatherapy|Aromatherapy and placebo patches will be used
223644647|NCT06603857|DRUG|CE Ferulic|CE Ferulic serum regimen combined with laser treatment
223644648|NCT06603857|DRUG|Sham Comparator|Vehicle serum regimen combined with laser treatment
223644649|NCT06603857|DEVICE|1927nm (Clear and Brilliant Perméa®)|non-ablative fractional diode laser
223644650|NCT04515810|OTHER|Internet-Based Intervention|Use smartphone application
223644651|NCT04515810|OTHER|Best Practice|Engage in standard care
223644652|NCT04515810|OTHER|Questionnaire Administration|Ancillary studies
223644653|NCT06613789|BIOLOGICAL|426c.Mod.Core-C4b|self-assembling nanoparticle expressing up to 7 molecules of the 426c.Mod.Core envelope immunogen.
223644654|NCT06613789|BIOLOGICAL|3M-052-AF|3M-052-AF is an aqueous formulation (AF) of a lipidated small molecule imidazoquinoline that is a Toll-like receptor (TLR)7/8 and inflammasome agonist. To be administered as 0.3 mcg, 0.75 mcg, or 1.5 mcg admixed with 426c.Mod.Core-C4b, with Alum
223644655|NCT06613789|BIOLOGICAL|Aluminum hydroxide suspension (Alum)|Aluminum hydroxide suspension (Alum) to be administered as 250 mcg (aluminum content) admixed with 426c.Mod.Core-C4b with 3M-052-AF.
223644656|NCT06613789|BIOLOGICAL|Placebo and Diluent|Tris-NaCl buffer.
223644657|NCT06259916|OTHER|Alcohol|Participants in this condition will receive the standard alcohol dose
223644658|NCT06259916|OTHER|Cannabis|Participants in this group will self-administer legal-market flower cannabis
223644659|NCT03837041|OTHER|Reconditioning Proprioception|Proprioceptive training using Delos Postural Proprioceptive System
223644660|NCT06543199|PROCEDURE|local application of hyaluronic acid agent to the wound site|Evaluation of the effect of local use of hyaluronic acid agent on wound healing
223644661|NCT06543199|PROCEDURE|Local application of hypericum perforatum L to the wound site|Hyperıcum perforatum L ajanının lokal kullanımının yara iyileşmesine etkisinin değerlendirilmesi
223644662|NCT06543199|PROCEDURE|wound healing monitoring|Doctor visit on days 3, 7, 14, 21 and 28
223644663|NCT06602687|DEVICE|PICSI|The PICSI® dish is a CE marked medical device containing dots of a HA hydrogel (Cooper Surgical).
224231205|NCT02072356|OTHER|laboratory biomarker analysis|Alpha-fetoprotein assay
224231206|NCT02072356|DRUG|TheraSphere|TheraSphere is delivered into the liver tumor through a catheter placed into the hepatic artery.
224231207|NCT01001897|DRUG|Misoprostol|400 micrograms of misoprostol or placebo inserted buccally or vaginally prior to IUD insertion
224231208|NCT01001897|DRUG|Placebo|400 micrograms of misoprostol or placebo inserted buccally or vaginally prior to IUD insertion
224231209|NCT03417128|BEHAVIORAL|Peer support|Participants residing in the location selected to be intervene will to form at minimum 4 peer groups. This group will receive a continuous three-months, peer-led nutrition and lifestyle behaviour intervention through a series of peer gathering. Two participants from each peer group will be selected as the peer leader (PL). PL will be trained to deliver the content of PERSUADE modules and will be responsible to run a weekly peer gathering with their respective groups for the following three months.
224323446|NCT05652465|DEVICE|Intermittent theta burst repetitive transcranial magnetic stimulation (iTBS)|Device described in protocol
223644664|NCT06591130|BEHAVIORAL|Youth culturally adapted manual assisted psychological intervention (Y-CMAP)|YCMAP (Youth culturally adapted manual assisted psychological intervention) is based on CBT principles. It comprises of 8-10 sessions delivered individually over 3 months (weekly for 1 month then fortnightly), lasting for 60 minutes. The intervention includes psycho-education and a comprehensive cognitive behavioural assessment of the self-harm attempt using virtual stories of four young people. Therapists and young person choose from a list of techniques those which are most relevant to the young person's problems. Therapy is therefore adapted to fit with the young person's problems and primarily utilises problem solving, CBT, and dialectical therapy strategies to bring about change. To help determine the most appropriate coping strategy a coping tree is designed. Training in assertiveness and anger management are offered to help the young person to develop resilience to cope with stress.
224231210|NCT06015373|DRUG|supress the night dose of carvedilol|already described
223644665|NCT06597318|OTHER|Hospitalization|The investigators collect PROMs amongst up to 1000 patients in general internal medicine divisions of all five Swiss university hospitals
223644666|NCT06112509|OTHER|Vestibular exam|Interrogation, videonystagmoscopy, videonystagmography, video-head-impulse-test
223644667|NCT05543330|DRUG|M701 pleural infusion|M701 pleural infusion on Days 1,4,7 and 10.
224231211|NCT03972982|DRUG|Simplified intensive insulin therapy regimen|Short-term continuous subcutaneous insulin infusion to maitain near normoglycemica for 1 week, thereafter basal insulin and metformin were subsequently used. Wearable devices and smart apps will be used for lifestyle modification.
224231212|NCT03972982|DRUG|Traditional Short-term Intensive insulin therapy|Short-term continuous subcutaneous insulin infusion will be initiate to maitain near normoglycemica for 2 weeks, then patients will be ordinarily follow-up
224231213|NCT01501799|DRUG|adapalene 0.1% and benzoyl peroxide 2.5% topical gel|Dosage form: topical gel Dosage: A pea-sized amount was applied to each affected area of the face Frequency: once daily in the evening Duration: 12 weeks
224231214|NCT01501799|DRUG|EPIDUO|EPIDUO (adapalene 0.1% and benzoyl peroxide 2.5%) Gel
224231215|NCT01501799|DRUG|Placebo (Vehicle Gel)|Vehicle Gel
224231216|NCT02132299|BIOLOGICAL|PfSPZ Vaccine|Aseptic, purified, vialed, metabolically active, non-replicating (live, radiation attenuated) cryopreserved Plasmodium falciparum sporozoites (PfSPZ)
224231217|NCT02132299|BIOLOGICAL|Normal Saline (Placebo)|
223644668|NCT05543330|PROCEDURE|Pleural drainage|Pleural effusion drainage via Ultra-sound guidance on Day 1.
223644669|NCT05543330|DRUG|Cisplatin pleural infusion|Cisplatin pleural infusion (30-50mg/m2) on Day 1.
223644670|NCT06770543|OTHER|Inclisiran|There is no treatment allocation. Patients administered Leqvio by prescription that have started before inclusion of the patient into the study will be enrolled.
223644671|NCT06587425|DRUG|LM-302+Candonilimab+Capecitabine|LM-302: 1.8mg/kg ivgtt d1, q2w; Canonilimab: 6mg/kg ivgtt d1, q2w; Capecitabine: 1000mg/m\^2 po bid d1-10, q2w.
223644672|NCT06588270|BEHAVIORAL|Virtual Reality Therapy for the Negative Symptoms of Schizophrenia|VRTNSS is a 12-session therapy using psychological intervention principles. Each therapy session will involve engaging with different VR based tasks where participants can experience different activities.
223644673|NCT06588270|BEHAVIORAL|Sham- VR|Patients will attend to VR sessions without the software created activities for treatment (sham-VR).
223644674|NCT06596278|DEVICE|Memesto|Memesto wearable audio player
223644675|NCT06867588|DIAGNOSTIC_TEST|PSMA PET|patients included in the study will perfom a PSMA PET
223644676|NCT06679062|DRUG|Suvorexant|Suvorexant is described chemically as: \[(7R)-4-(5-chloro-2-benzoxazolyl) hexahydro-7-methyl-1H-1,4-diazepin-1-yl\]\[5-methyl-2-(2H-1,2,3-triazol2-yl)phenyl\]methanone. SUV's empirical formula is C23H23ClN6O2 and the molecular weight is 450.92. Each film coated tablet contains 10mg or 20mg of suvorexant.
223644677|NCT06679062|OTHER|Placebo|Film coated tablet to match the active drug.
223644678|NCT06321263|OTHER|Peripheral Muscle Training and step aerobics training|First 5-minute warm-up in the protocol (calisthenic exercises); 30-40 minutes of resistance exercises and step aerobic exercises and the last 5 minutes cooling (stretching exercises) period will be applied.
223644679|NCT06321263|OTHER|Inspiratory Muscle Training and step aerobics training|First 5-minute warm-up in the protocol (calisthenic exercises); 30-40 minutes of resistance exercises and step aerobic exercises and the last 5 minutes cooling (stretching exercises) period will be applied.
223644680|NCT03012503|DRUG|BioFreeze|The estimated surface area of the average adult's neck is 350cm and the standard dose of Biofreeze® to achieve a clinically significant effect has been sited to be 1ml/200cm2 of skin surface area. Using this data approximately 1.75 ml of the assigned gel was applied to each participant's neck (posterior, anterior, left lateral and right lateral) by the same member of the research team, 5 minutes prior to an independent practitioner performing cervical manipulation on the participant.
223644681|NCT03012503|DRUG|Placebos|control gel with a similar packaging, texture, and scent as Brand X but without the active ingredient of menthol
224231218|NCT02132299|BIOLOGICAL|PfSPZ Challenge|Live, infectious, aseptic, purified, vialed, cryopreserved Plasmodium falciparum sporozoites (PfSPZ) for CHMI
224231219|NCT00332293|DRUG|Moxifloxacin Alternative Formulation Ophthalmic Solution 0.5%|1 drop into the conjunctival sac of both eyes 3 times a day for 3 days
224231220|NCT00332293|DRUG|Moxifloxacin hydrochloride ophthalmic solution 0.5% as base|1 drop into the conjunctival sac of both eyes 3 times a day for 3 days
224231221|NCT01797471|RADIATION|Lattice Extreme Ablative Dose (LEAD) Radiation Therapy|A single fraction of LEAD RT, dose of 18 Gy will be delivered to subjects on day 1
224231222|NCT02303561|BEHAVIORAL|CHAMP|Families assigned to this arm will receive tailored asthma education and behavioral skills focused on improving asthma and weight management.
224231223|NCT02303561|BEHAVIORAL|Health education|Families assigned to this arm will receive tailored asthma education and general health education on a variety of topics.
224231224|NCT04579328|BEHAVIORAL|Exposure to Growth Mats|see arm/group descriptions for description of intervention
224231225|NCT01419106|DEVICE|Ultrasound (A point of care ultrasound protocol)|Bedside ultrasound will be used to view any intraperitoneal bleeding, pleural fluid, cardiac abnormalities, or structural abnormalities of major blood vessels. The results of this test will then be used to determine the best course of treatment for the patient.
224231226|NCT01558141|OTHER|Aspiration without flushing follicles with culture media|Aspiration without flushing follicles with culture media.
223644682|NCT06586047|DIAGNOSTIC_TEST|PET imaging|Imaging with FDG PET/CT and Pyl PET/CT
223644683|NCT04780932|DRUG|Macitentan 10mg|Macitentan 10 mg will be initiated at Day 8 (+/- 3 days) until week 42 (+/- week). The recommended dose is 10 mg once daily by oral administration
223644684|NCT04780932|DRUG|Placebo|Placebo 10 mg will be initiated at Day 8 (+/- 3 days) until week 42 (+/- week). The recommended dose is 10 mg once daily by oral administration
224231227|NCT01558141|OTHER|Follicular Flushing|Flushing follicles with embryo culture media prior to aspiration.
224231228|NCT01959256|BEHAVIORAL|Visual perceptual learning|24 times of training for visual perceptual learning
224231229|NCT04023565|DRUG|perindopril + moxonidine|"After 14 days of wash-out period perindopril 10 mg + moxonidine 0.4 mg a day will be prescribed.~If target BP is achieved after 4 weeks, the dosage will remain unchanged (perindopril 10 mg + moxonidine 0.4 mg a day (given as two divided doses).~If target BP is not achieved after 4 weeks, the dosage will increase up to perindopril 10 mg + moxonidine 0.6 mg a day (given as two divided doses)."
224231230|NCT05694325|OTHER|peripheral blood and bone marrow withdrawal|samples evaluation
224231231|NCT02461368|PROCEDURE|Glenohumeral triamcinolone injection by anterior approach|Glenohumeral steroid injection is performed under ultrasound-guidance by anterior approach. The injection mixture was: 1 mL triamcinolone, 4 mL lidocaine, 4 mL normal saline, and 3 mL Omnipaque (Iohexol, General Electronics Healthcare).
224231232|NCT02461368|PROCEDURE|Glenohumeral triamcinolone injection by posterior approach|Glenohumeral steroid injection is performed under ultrasound-guidance by posterior approach. The injection mixture was: 1 mL triamcinolone, 4 mL lidocaine, 4 mL normal saline, and 3 mL Omnipaque (Iohexol, General Electronics Healthcare).
224231233|NCT02463617|OTHER|magnetic resonance imaging|
224231234|NCT03749655|BEHAVIORAL|Physical Activity Promotion|The physical activity (PA) promotion intervention will be provided only to the intervention group, and will include: 1) a step-counter with a digital display, 2) an interview discussing motivational issues, favourite daily activities and strategies to become more physically active; and 3) a tailored physical activity coaching plan including an Individualised activity goal (in steps/day) revised twice weekly through consultation sessions (16 sessions in total). Patients' targets will be revised twice weekly during the consultation sessions which will be incorporated into the Pulmonary rehabilitation sessions. The aim is to increase physical activity by 10% each week. The goal can be altered if required.
224231235|NCT01537484|PROCEDURE|Massage Therapy|Swedish Massage for 1 hour for 8 weeks, Light Touch Bodywork for 1 hours for 8 weeks.
224231236|NCT00268502|OTHER|study of socioeconomic and demographic variables|
224231237|NCT00268502|PROCEDURE|fatigue assessment and management|
224231238|NCT00268502|PROCEDURE|management of therapy complications|
223644685|NCT06578650|DEVICE|Synthetic Electrospun Fiber Matrix|Patients who are eligible for enrollment will be treated with Synthetic Electrospun Fiber Matrix immediately after surgical resection to the resulting wound
223644686|NCT06109636|OTHER|Pentacam, Corvis ST and Casia2|scleral and ciliary muscle thickness were obtained by Casia2, biomechanical parameters were obtained by Pentacam and Corvis ST
223644687|NCT03118401|OTHER|Ritual of stool|During the first 4 weeks, data will be collected on an individual stool diary with usual care of the resident After randomization will start the implementation period of ritual of stool. From the stool diary: - will be determined the stool profile of each resident over 1 week and application of the ritual of stool the following week At the end of this second period, data will be collected on an individual stool diary in for 4 weeks
223644688|NCT03118401|OTHER|Usual practice|"During the first 4 weeks, data will be collected on an individual stool diary with usual care of the resident After randomization will start 2 weeks without data collection. Patient will be follow in usual practice.~At the end of this second period, data will be collected on an individual stool diary in for 4 weeks"
224231239|NCT00268502|PROCEDURE|psychosocial assessment and care|
223644689|NCT02264236|BIOLOGICAL|P10s-PADRE vaccine|"P10s-PADRE vaccine combined with MONTANIDE™ ISA 51 VG Chemotherapy Subcutaneous injection at weeks 2, 3, 5, and 6. 3-Week Interval Immunotherapy Subcutaneous injection at weeks 2, 3, and 4. 2-Week Interval Immunotherapy Subcutaneous injection at weeks 3, 4, and 5."
223644690|NCT00791505|DRUG|ciprofloxacin|1500 mg a day for 10 days
223644691|NCT00791505|DRUG|trimethoprim-sulfamethoxazole|2000 mg a day for 10 days
223644692|NCT02080598|BEHAVIORAL|2 cigarettes in 15 minutes|
223644693|NCT06464822|PROCEDURE|Bariatric Surgery|weight control procedures, including intragastric balloon (IGT) \[5\], laparoscopic adjustable gastric banding (LAGB) \[6\], laparoscopic gastric bypass (LGB) operation and laparoscopic sleeve gastrectomy (LSG)
224231240|NCT00268502|PROCEDURE|quality-of-life assessment|
224231241|NCT01998321|OTHER|Patient specific instrument|A special software with the ability to perform 3D planning including sizing, alignment, bone cutting, positioning of implants, simulation \& PSI designing and PSI production
224231242|NCT01998321|OTHER|conventional technique for TKA|
224231243|NCT05602090|DRUG|4 IU of recombinant GH (Somatotropin )|4 IU of recombinant GH
224231244|NCT01691859|DRUG|Mepolizumab|100 mg of mepolizumab will be injected subcutaneously (SC) once every 4 weeks
224231245|NCT06366256|BEHAVIORAL|Traditional ultrasound biofeedback|"Participants use a B-mode ultrasound device to view their tongue movement on a screen. The participant sees the ultrasound image of their tongue moving in sagittal plane on the screen. The speech-language pathologist working with the participant also views participant's tongue movement and provides verbal instruction on how the participant should move their tongue to produce a perceptually correct r sound in simple syllables (CV, VC), as well as evaluative statements about accuracy. Participants practice moving their tongue along with these instructions, practicing the simple syllable (CV, VC) words.~VC=vowel consonant syllables (ex. or) CV=consonant vowel syllables (ex. ra)"
224323447|NCT06133348|BEHAVIORAL|Promoting Resilience in Stress Management Intervention|"PRISM is a manualized, brief, skills-based intervention targeting four resilience resources; PRISM is delivered by trained intervention staff (called coaches within the PRISM program). Session 1, Stress-Management. Session 2, Goal setting. Session 3, Cognitive Restructuring. Session 4, Meaning-Making. Session 5 (optional), Coming Together. Session 6 (optional) involved advance care planning to discuss."
224323448|NCT04036032|OTHER|Exercise program|Encourage to work out 4 to 5 times a week for 3 months. Patient chooses what exercise they would like to do. At YMCA visit for fitness assessments they provide exercise support
223644694|NCT04285619|OTHER|Positive expectation|"After heating, the physiotherapist will apply the bandage with flossing on both ankles, using 2 Voodoo Floss Bands (Power Guidance model). The distal to proximal bandage will begin with a tension of 50-70% and each lap of the bandage will cover 50% of the previous lap. There will be 3 figures of 8 that will cover the hindfoot and the distal third of the leg.~With the bandage applied on both feet, the runners will perform plantar flexion and active dorsal flexion movements in a range of complete joint movement with both ankles, at a constant rate of 2 seconds of plantar flexion, followed by another 2 of dorsal flexion, during A period of 2 minutes. Next, the therapist will remove the bandages and the athlete will walk barefoot for a minute, to restore normal blood flow.~During the first application of the bandage, the investigator will induce the positive expectation through a standardized phrase for all subjects"
224231246|NCT06366256|BEHAVIORAL|Simplified ultrasound biofeedback|"Participants use a B-mode ultrasound device that captures the movement of their tongue and software that transforms the movement of their tongue into gamified objects on a screen. The participant sees a game object (a character) move on the screen towards goals; the movement of the game object represents the movement of the tongue and the goals are representative of tongue movements that correlate with an acoustic percept of accuracy. The speech-language pathologist working with the participant views the movement of the game object and provides verbal instruction on how the participant should move the game character in order to reach the goals when saying simple syllable words (CV, VC) as well as evaluative statements about accuracy. Participants practice moving their tongue along with these instructions, practicing the simple syllable (CV, VC) words.~VC=vowel consonant syllables (ex. or) CV=consonant vowel syllables (ex. ra)"
224231247|NCT03561259|DRUG|131I-MIBG|Subjects will receive 18 mCi/kg of 131I-MIBG administered over 1.5 to 2 hours on Day 1 either a central line or a peripheral intravenous catheter. The maximum absolute dose of 131I-MIBG is determined by institution therapeutic limits and will not exceed 1,000 mCi. Subjects with an overall response of stable disease or better as assessed by the Investigator, and who meet certain protocol predefined criteria, may receive a second 18 mCi/kg 131I-MIBG treatment no sooner than 6 weeks following the first treatment.
224231248|NCT03561259|DRUG|131-MIBG + Vorinostat|Subjects will receive vorinostat 180 mg/m2/dose (maximum dose 400 mg) once daily by mouth, NG, or G-tube on days -1 to +12 (14 total doses) for 14 days continuously. The 131I-MIBG treatment will be administered on day 1 via either a central line or a peripheral intravenous catheter over 1.5 to 2 hours. On day 1 of therapy, vorinostat should be taken 1 hour prior to the start of the 131I-MIBG infusion. Subjects with an overall response of stable disease or better, as assessed by the Investigator and who meet certain predefined criteria, may receive a second course of 18 mCi/kg 131I-MIBG combined with vorinostat (180 mg/m2) no sooner than 6 weeks following the first therapeutic 131I-MIBG treatment.
224231249|NCT05492071|DEVICE|Local Vibration Application Following Flow Mediated Dilation|Flow mediated dilatation will be induced via 5 min cuff inflation below left elbow at suprasystolic pressures (50mmHg above preapplication systolic pressure). Vibration is applied with a commercially available vibration plate to forearm at 20 hz and 3 mm of vertical amplitude for 5 minutes, 30 minutes after termination of FMD.
224231250|NCT05492071|OTHER|Flow mediated dilation|Flow mediated dilatation will be induced via 5 min cuff inflation below left elbow at suprasystolic pressures (50mmHg above preapplication systolic pressure).
224231251|NCT02110771|BEHAVIORAL|GAÏA - facial affect recognition targeted|"2 sessions of one hour per week with therapist. Intervention proposes 3 stages : 1)discovering and learning facial affects recognition and discrimination criterions for joy, sadness and anger (photos exercises); 2) facial affect recognition training (computer based and role game exercises); 3) generalization to other emotions (photos, role games and computer based exercises).~The therapist chooses the change of stages; 5 sessions or more are proposed for the generalization stage."
224231252|NCT02110771|BEHAVIORAL|RECOS - attentional process targeted|2 sessions of one hour per week with therapist the first of those two session is allocated to paper and pen exercises (search and validation of strategies to resolve cognitive training exercises or functional problems). the second session is allocated to computer based exercises.
224231253|NCT01296932|DRUG|BI 836826|Monotherapy with BI 836826 at escalating dose levels administered as an intravenous infusion.
224231254|NCT02796027|OTHER|BRIDGE|"BRIDGE, enhanced HIV service integration package, has three components:~1. peer driven recruitment using a Social Network Strategy (SNS) -- which has been designated as a high impact and highly effective strategy by the CDC for reaching out and engaging PWID in HIV testing~2. HCT using CTR with Rapid Testing~3. ARTAS -- a CDC case management strategy for linking HIV-positive PWID to HIV care that addresses specific barriers and gaps in HIV service delivery in NSPs"
224231255|NCT02725944|DEVICE|Implantation of ICRM|All patients will be implanted with ICRM in order to detect an occult PAF.
224231256|NCT03949556|OTHER|Videos and/or SMS|Participants assigned to one of the intervention programmes will watch videos on a website for two months then will receive SMSs for four months.
224231257|NCT04001608|DRUG|Seraprevir|Subjects will receive oral tablets of Seraprevir 100 mg, twice a day from Day 1 up to Week 12
224231258|NCT04001608|DRUG|Sofosbuvir|Subjects will receive oral tablet of sofosbuvir 400 mg, once a day from Day 1 up to Week 12
224231259|NCT02117583|DRUG|Oxycodone|One capsule of 40 mg PF-00345439 Formulation K, taken whole, single dose, under fasting conditions
224231260|NCT02117583|DRUG|Oxycodone|One capsule of 40 mg PF-00345439 Formulation K, taken whole, single dose, under fed conditions
224231261|NCT02117583|DRUG|Oxycodone|One capsule of 40 mg PF-00345439 Formulation K, Chewed, single dose, under fasting conditions
224231262|NCT02117583|DRUG|Oxycodone|One capsule of 40 mg PF-00345439 Formulation K, Chewed, single dose, under fed conditions
224231263|NCT04641429|BEHAVIORAL|Qigong exercise|Participants in the experimental group receive 12-week group-based Qigong exercise training.
224231264|NCT04641429|BEHAVIORAL|Stretching exercise|Participants in the control group receive 12-week group-based stretching exercise training.
223765848|NCT05182385|DRUG|Blinatumomab|"All patients with hematological relapse will additionally receive Blinatumomab immunotherapy (first cycle: 9 ug/d c.i.v. on d1 until d7 and 28 ug/d c.iv. on d8 until d28; second cycle: 28 ug/d c.iv. on d1 to d28) in six-week cycles (4 weeks on Blinatumomab, 2 weeks off Blinatumomab).~All patients with molecular relapse will additionally receive Blinatumomab immunotherapy at 28 ug/d c.iv. on d1 until d28 in six-week cycles (4 weeks on Blinatumomab, 2 weeks off Blinatumomab.)~Patients eligible for a second cycle shall not receive Blinatumomab starting dose independent from relapse type."
224231265|NCT06124430|OTHER|ECOX box|For the ECOX approach, they will have the various ECOX grids and a stopwatch at their disposal in the 2 units of the emergency department. There will be around thirty evaluation grids at their disposal. Students will choose the ECOX grid corresponding to a starting situation. Once the time limit has elapsed, they must compare their answers with the grid's expectations. Each completed grid will be returned to a drawer in the box, to assess adherence to the tool and suggestions for grid modifications, as well as any comments. Students will be able to use them as many times as they wish during the course and before the service ECOS.
224231266|NCT06302231|BEHAVIORAL|Dietary and Exercise Approaches|Intermittent fasting plus energy restriction combined with aerobic exercise performed in a fasted state.
223644695|NCT04285619|OTHER|Neutral expectation|"After heating, the physiotherapist will apply the bandage with flossing on both ankles, using 2 Voodoo Floss Bands (Power Guidance model). The distal to proximal bandage will begin with a tension of 50-70% and each lap of the bandage will cover 50% of the previous lap. There will be 3 figures of 8 that will cover the hindfoot and the distal third of the leg.~With the bandage applied on both feet, the runners will perform plantar flexion and active dorsal flexion movements in a range of complete joint movement with both ankles, at a constant rate of 2 seconds of plantar flexion, followed by another 2 of dorsal flexion, during A period of 2 minutes. Next, the therapist will remove the bandages and the athlete will walk barefoot for a minute, to restore normal blood flow.~During the first application of the bandage, the researcher will not induce any expectations to the athletes."
223644696|NCT04499313|DRUG|Dexamethasone|Injectable solution
223644697|NCT04499313|DRUG|Methylprednisolone|Injectable solution
224231267|NCT06302231|BEHAVIORAL|Dietary and Exercise Approaches|Intermittent fasting plus energy restriction combined with aerobic exercise performed in a fed state.
223644698|NCT05647603|OTHER|data collection|Information about contraception
223644699|NCT01771224|DIETARY_SUPPLEMENT|Palmitoleic acid|Palmitoleic acid and 5-ASA
223644700|NCT02334540|DIETARY_SUPPLEMENT|purses|food intake
223644701|NCT02334540|DIETARY_SUPPLEMENT|a calorie/protein matched smoothie|
223644702|NCT00373997|PROCEDURE|Esophageal and Laryngeal biopsies|one day procedure
223644703|NCT00373997|PROCEDURE|egd with biopsy|standard of care procedure with biopsy
223644704|NCT05188833|DEVICE|Deep Transcranial Magnetic Stimulation|Deep TMS, unlike traditional TMS, is a treatment method that provides stimulation of lower parts of the brain and larger brain volume, in addition to drug treatment and psychotherapy approaches, in addition to localized brain regions magnetic stimulation is a treatment method where disease symptoms are addressed.
223644705|NCT05188833|DRUG|Paroxetine|Paroxetine is a type of antidepressant known as an SSRI (selective serotonin reuptake inhibitor). It's often used to treat depression.
223644706|NCT03063034|OTHER|PD21864AA|A king size menthol cigarette.
224231268|NCT06302231|BEHAVIORAL|Dietary Approach|Intermittent fasting plus energy restriction without aerobic exercise training.
224231269|NCT06544317|BEHAVIORAL|physical training|All children received a series of 90-minute sessions 3 times a week for 8 weeks of after-school physical training. Each session began with a warm-up (20 min), three or four tasks related to the skill to be developed (aerobic training, resistance training, other activities designed to improve motor skills and balance, stretching and flexibility activities and core strength and posture exercises; 60 min) and a cool-down (10 min). Children were divided into six groups, with the number of children in each group ranging from eight to twelve.
224231270|NCT02352337|DRUG|FOLFIRINOX|Perfusion :oxaliplatine, Irinotecan ,folinic acid, 5FU bolus and continue
224231271|NCT02352337|DRUG|LV5FU2|Perfusion: Folinic Acid,5FU Bolus,5FU continue
224231272|NCT02352337|DRUG|FOLFIRI.3|Perfusion :Irinotecan,Acide folinique ,5FU continue
223644707|NCT03063034|OTHER|PD21864AB|A king size menthol cigarette.
223644708|NCT00178776|BEHAVIORAL|Transtheoretical Model Group Therapy|
223644709|NCT00178776|BEHAVIORAL|Education & Advice|
223644710|NCT04463459|DRUG|Vitamin C, Vitamin E|Vitamin C (500mg) twice daily and Vitamin E (400mg) once daily
223644711|NCT03967353|BEHAVIORAL|New management mode intervention|"Patients in routine treatment group use TB assistant APP. Medical staff strengthen health promotion of the patients,including, infection control, doctor-patient communication, etc."
223644712|NCT04922567|DRUG|Lenalidomide|25mg po on day 1-10
223644713|NCT04922567|DRUG|Cyclophosphamide|750mg/m² iv on day1
223644714|NCT04922567|DRUG|Doxorubicin|50mg/m² iv on day 1
223644715|NCT04922567|DRUG|Vincristine|1.4mg/m² iv on day 1
223644716|NCT04922567|DRUG|Prednisone|100mg po on day1-5
223644717|NCT05814172|OTHER|no intervention|no intervention
223644718|NCT02232906|DRUG|intravenous ferric carboxymaltose|Ferric carboxymaltose (FCM) dose of 1,000 mg iron, followed by a 6-month ESA/FCM maintenance regimen (target: Hemoglobin 120 g/L, transferrin saturation \>20%)
223644719|NCT05462756|DRUG|Insulin Efsitora Alfa|Administered SC
224231273|NCT02352337|DRUG|Gemcitabine|Gemcitabine perfusion
224231274|NCT02458638|DRUG|Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 (PD-L1) antibody|Atezolizumab will be given as IV infusion over 60 minutes on Day 1 of Cycle 1, then over 30 minutes (as tolerated) on Day 1 of each subsequent 3-week cycle.
224231275|NCT05116020|OTHER|Usual chiropractic care|Usual chiropractic care in Switzerland can include spinal manual therapy, soft-tissue therapy, use of electric therapeutic modalities (low level laser therapy, therapeutic ultrasound, interferential current), acupuncture, prescription medication, exercise, education and reassurance.
224231276|NCT02296580|DEVICE|Nativis Voyager RFE Therapy|Nativis Voyager Radiofrequency Energy Therapy
224231277|NCT03495648|BEHAVIORAL|walking group led by a community organizer|Subjects will walk 1 kilometer from a pre-determined point to a local farmer's market.
224231278|NCT04409665|DRUG|Ketamine|Patient will be sedated using Ketamine 2 minutes before the LISA procedure. 10 minutes prior the procedure and during the procedure the patient's pain and/or discomfort will be evaluated using COMFORT and FANS scales
224231279|NCT04409665|DRUG|Glucose|Patient will be sedated using Glucose 2 minutes before the LISA procedure. 10 minutes prior the procedure and during the procedure the patient's pain and/or discomfort will be evaluated using COMFORT and FANS scales
223644720|NCT05462756|DRUG|Insulin Lispro (U100)|Administered SC
223644721|NCT05462756|DRUG|Insulin Glargine (U100)|Administered SC
223644722|NCT02336529|DRUG|Bupivacaine|
223644723|NCT02336529|DRUG|NaCl|
224231280|NCT04177264|PROCEDURE|Occipito-Atlantal Decompression (OA DC)|The participant lies supine in a relaxed state while the investigator cradles the patient's head with their hands, middle finger pads along the inferior aspect of inion, reaching to the occipito-atlantal joint. The investigator then applies gentle posterior and cephalad traction to the occiput, while bringing the elbows together. This results in supination of the hands and separation of the middle fingers, creating a posterior-lateral force vector to either side of the foramen magnum. The pressure is maintained until softening of the underlying structures is felt. The procedure is applied for 10 minutes.
224231281|NCT04177264|PROCEDURE|Sham Occipito-Atlantal Decompression (Sham OA DC)|The participant lies supine in a relaxed state while the investigator applies light touch to the patient's head with their hands.
224231282|NCT04177264|PROCEDURE|Splenic Lymphatic Pump Technique (SpLPT)|With the participant supine, the investigator places a posterior hand along the left lower ribcage, and a superior hand over the left costal arch, encompassing the spleen. The investigatory compresses and releases the spleen at a rate of 20 compressions/min for 3 min.
224231283|NCT04177264|PROCEDURE|Sham Splenic Lymphatic Pump Technique (Sham SpLPT)|With the participant supine, the investigator places a posterior hand along the left lower ribcage, and a superior hand over the left costal arch, encompassing the spleen. The investigator will maintain light touch at these positions for 3 minutes. No compressions are performed.
224231284|NCT04177264|DEVICE|Transcutaneous Auricular Vagus Nerve Stimulation (taVNS)|A bipolar clip electrode is attached to the auricle at the location of the cymba conchae. Electrical stimulation (30 Hz stimulation frequency, 300 μs pulse width) is applied for 10 min. The stimulation current is determined individually for each participant by slowly increasing the stimulation current until the participants feel a mild tingling sensation at the site of the electrode. Then the current is gradually reduced until the tingling sensation disappears. This current will then be used for taVNS. A TENS 7000 or EMS 7500 device (510(k): K080661) is used.
224231285|NCT04177264|DEVICE|Sham Transcutaneous Auricular Vagus Nerve Stimulation (Sham taVNS)|A bipolar clip electrode is attached to the auricle at the location of the cymba conchae but no electrical current is applied to the electrode.
224231286|NCT06126081|DEVICE|LBBP+GDMT|LBBP is a procedure that the pacing lead is placed at the left bundle branch to achieve electrical and mechanical synchronization by pacing the left bundle branch area with stable pacing parameters.
223644724|NCT00812019|BIOLOGICAL|Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 3.75_0%MF59|Two vaccinations of Cell Culture-Derived H5N1 3.75 µg Subunit Influenza Vaccine containing 0% of MF59.
223644725|NCT00812019|BIOLOGICAL|Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 3.75_25%MF59|Two vaccinations of Cell Culture-Derived H5N1 3.75 µg Subunit Influenza Vaccine containing 25% of MF59.
223644726|NCT00812019|BIOLOGICAL|Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 3.75_50%MF59|Two vaccinations of Cell Culture-Derived H5N1 3.75 µg Subunit Influenza Vaccine containing 50% of MF59.
223644727|NCT00812019|BIOLOGICAL|Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 3.75_100%MF59|Two vaccinations of Cell Culture-Derived H5N1 3.75 µg Subunit Influenza Vaccine containing 100% of MF59.
223644728|NCT00812019|BIOLOGICAL|Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 7.5_0%MF59|Two vaccinations of Cell Culture-Derived H5N1 7.5 µg Subunit Influenza Vaccine containing 0% of MF59.
223644729|NCT00812019|BIOLOGICAL|Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 7.5_25%MF59|Two vaccinations of Cell Culture-Derived H5N1 7.5 µg Subunit Influenza Vaccine containing 25% of MF59.
223644730|NCT00812019|BIOLOGICAL|Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 7.5_50%MF59|Two vaccinations of Cell Culture-Derived H5N1 7.5 µg Subunit Influenza Vaccine containing 50% of MF59.
223644731|NCT00812019|BIOLOGICAL|Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 7.5_100%MF59|Two vaccinations of Cell Culture-Derived H5N1 7.5 µg Subunit Influenza Vaccine containing 100% of MF59.
223644732|NCT00812019|BIOLOGICAL|Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 15_0%MF59|Two vaccinations of Cell Culture-Derived H5N1 15 µg Subunit Influenza Vaccine containing 0% of MF59.
223644733|NCT00812019|BIOLOGICAL|Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 15_25%MF59|Two vaccinations of Cell Culture-Derived H5N1 15 µg Subunit Influenza Vaccine containing 25% of MF59.
223644734|NCT00812019|BIOLOGICAL|Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 15_50%MF59|Two vaccinations of Cell Culture-Derived H5N1 15 µg Subunit Influenza Vaccine containing 50% of MF59.
223644735|NCT00812019|BIOLOGICAL|Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 15_100%MF59|Two vaccinations of Cell Culture-Derived H5N1 15 µg Subunit Influenza Vaccine containing 100% of MF59.
223644736|NCT04090359|DEVICE|Dual Mobility Implant|Patients in this intervention will receive a dual mobility implant
223644737|NCT04090359|DEVICE|Conventional, single-bearing implant|Patients in this intervention will receive a conventional, single-bearing implant
223644738|NCT00089401|DRUG|isolated perfusion|
223644739|NCT00089401|DRUG|melphalan|
223644740|NCT00089401|PROCEDURE|conventional surgery|
223644741|NCT04678219|OTHER|Dietary Intervention|Subjects will be placed on 1 of 2 diets for a treatment period of 8 weeks with the support of dietitians; it will then be evaluated whether they can continue this diet on their own for 4 weeks.
223644742|NCT02259335|DEVICE|Extracorporeal CO2 removal device|A device able to remove CO2 using a dedicated device connected to the patient via a double lumen catheter inserted in the femoral vein
223644743|NCT00990704|DRUG|paricalcitol|Intravenous administration 3 times a week immediately before completion of dialysis
223644744|NCT00990704|DRUG|maxacalcitol|Intravenous administration 3 times a week immediately before completion of dialysis
223644745|NCT04040933|DEVICE|Marketed Adhesive Bandage #1|On the randomized wound site, a marketed adhesive bandage will be applied.
223644746|NCT04040933|DEVICE|Marketed Bandage #2|On the randomized wound site, a marketed adhesive bandage will be applied.
223644747|NCT04040933|DEVICE|Non-Marketed Bandage #1|On the randomized wound site, a non-marketed adhesive bandage will be applied.
224231287|NCT06126081|DRUG|GDMT|GDMT is defined as the drug strategy for treatment of heart failure according to the current guidelines.
224231288|NCT01479881|DRUG|tacrolimus|a single 2-mg dose of tacrolimus (on Day 1 in treatment C and on Day 7 in treatment D).
224231289|NCT01479881|DRUG|TMC435|TMC435, 150 mg daily for 12 days (Days 1 to 12 in treatment D).
224231290|NCT01479881|DRUG|cyclosporine|A single 100-mg dose of cyclosporine (on Day 1 of treatment A and on Day 7 of treatment B).
224231291|NCT01479881|DRUG|TMC435|TMC435, 150 mg daily for 10 days (Day 1 - 10 in treatment B).
224231292|NCT00390312|DRUG|Intranasal Placebo|Intranasal placebo
224231293|NCT00390312|DRUG|Intranasal Morphine 15 mg|Intranasal Morphine 15 mg
224231294|NCT00390312|DRUG|Immediate Release Oral Morphine 60 mg|Immediate Release Oral Morphine 60 mg
223644748|NCT04040933|DEVICE|Non-Marketed Bandage #2|On the randomized wound site, a non-marketed adhesive bandage will be applied.
223644749|NCT04040933|DEVICE|Non-Marketed Adhesive Bandage #3|On the randomized wound site, a non-marketed adhesive bandage will be applied.
223644750|NCT04040933|DEVICE|Non-Marketed Adhesive Bandage #4|On the randomized wound site, a non-marketed adhesive bandage will be applied.
223644751|NCT04040933|DEVICE|Non-Marketed Adhesive Bandage #5|On the randomized wound site, a non-marketed adhesive bandage will be applied.
223644752|NCT02029248|OTHER|Quality of life questionnaire|
223644753|NCT03734380|BEHAVIORAL|Laboratory-based gait retraining (LGR)|Subjects in the LGR group will be encouraged to modify the gait pattern (e.g. adjusting foot progression angle, performing medial knee thrust, and/or lateral trunk lean) to lower their KAM to 80% of respective average baseline KAM obtained during normal unmodified gait. Real-time auditory feedback will be delivered using stereo speakers from both sides of the staircase. A middle C (261.6 Hz) tone and a high-pitched C (4186.0 Hz) of equal intensity will be generated at a footfall below and above the targeted 80% value, respectively. They will be advised to maintain their new gait pattern during their daily living after training.
223644754|NCT03734380|BEHAVIORAL|Sensor-based gait retraining (SGR)|Subjects in the SGR group will receive training similar to LGR, except the KAM measurement is based solely on inputs from IMUs embedded in the shoes. In addition, the auditory feedback will be delivered through a pair of earphones connected to a smartphone, which has been pre-installed with an app for KAM measurement. They will be advised to maintain their new gait pattern during their daily living after training.
223644755|NCT03734380|BEHAVIORAL|Walking exercise control (Ctrl)|Subjects in the Ctrl group will walk on the same instrumented staircase at a self-selected pace without any guidance on gait modification. The training period and training time per session will be identical to the other two groups. They will not be given any instructions for out-of-lab activities.
223644756|NCT03959267|BEHAVIORAL|Telephone Genetic Counseling|A genetic counselor fluent in Spanish (see letter of support) will conduct the TGC. The TGC intervention consists of two sessions. Prior to the sessions the investigators will mail participants the education materials with information to be reviewed prior to the genetic counseling session and a set of visual aids that the counselor will refer to during the session to facilitate the understanding of the information conveyed in the session.
223644757|NCT02897440|PROCEDURE|Full Repairng of soft tissue surrounding the hip|Full repairing soft tissue surrounding the hip damaged during the procedure of hip dislocation and prosthesis implanting.
223644758|NCT02897440|PROCEDURE|Partial Repairng of soft tissue surrounding the hip|Partial repairing soft tissue surrounding the hip damaged during the procedure of hip dislocation and prosthesis implanting.
223644759|NCT01079052|DRUG|Famotidine|Tablets
223644760|NCT04754659|DEVICE|Stentgraft|Stentgraft treatment for AAA. Comparison between supra vs infrarenal fixation.
223644761|NCT05350397|OTHER|How Important Is Acupress Applyıng In Atrıal Fıbrılatıon Treatment?|The acupressure wristband was correctly attached to the Experimental Group and acupressure was applied. The placebo group was fitted with an inverted and loose acupressure wristband. No intervention was applied to the control group.
223644762|NCT02409277|OTHER|Experimental: Standard vs Intensive e-AT Intervention|Patients will be self-monitoring their symptoms weekly using the e-AT, either the Standard or Intensive versions of the e-AT, completing the Asthma Control Test. As patients complete their assessments each week, the clinics will be able to see how each patient is doing, and follow-up when a patient is showing high symptoms for that week, potentially avoiding Emergency Room visit, and/or hospitalization.
223644763|NCT03204734|DRUG|Capecitabine|Capecitabine will been given as a sequential treatment who are got benefit in capecitabine-base chemotherapy.
223644764|NCT03204734|DRUG|endocrine therapy|endocrine therapy will been given as a sequential treatment who are got benefit in capecitabine-base chemotherapy.Endocrine therapy is determined by the doctor, including any kind of letrozole, anastrozole, exemestane, fulvestrant, tamoxifen, toremifene, combined with or without drugs or surgery in the inhibition of ovarian function.
223644765|NCT03993652|BEHAVIORAL|Kids FIRST|family- and school-based intervention to reduce unhealthy screen-time and snacking
223644766|NCT06101589|DIETARY_SUPPLEMENT|25 hydroxy cholecalciferol (Vitamin D) /25(OH)D3.|5 mg (200,000 IU) vitamin D3 in 1 ml ethyl oleate Pharmaceutical form: Solution of vitamin D3 in ethyl oleate, 0.75% w/v. three doses will be given orally every a month apart.
224231295|NCT00390312|DRUG|Intravenous morphine|Intravenous morphine 7.5 mg
224231296|NCT00390312|DRUG|Intranasal morphine 7.5 mg|Intranasal morphine 7.5 mg
224231297|NCT00390312|DRUG|Oral placebo|Oral placebo
224231298|NCT00390312|DRUG|Intravenous placebo|Intravenous placebo
224231299|NCT05056181|OTHER|Physical Activity|Physical activity
224231300|NCT05209646|DIETARY_SUPPLEMENT|Bee honey|patients will receive honey for 8 weeks in a dose of 30 ml undiluted honey per day divided as 5 ml honey 30 minutes before each meal six times daily. The honey will be kept in a closed glass container and away from light until the time of use. Each patient will be provided with a well-sealed container containing 210 ml honey each week. The honey used in the study will be a raw, unprocessed Clover honey collected from AL Mahala-Gharbia governorate, Egypt. The honey will be supplied directly from a beekeeper without heating or gamma irradiation.
224231301|NCT00648323|DRUG|Doxazosin mysylate GITS|Subjects initiated on 4 mg doxazosin GITS once daily at Visit 1 for four weeks. At Visit 2 (Week 4) increased to 8 mg Doxazosin GITS if efficacy response criteria not met.
224231302|NCT03528408|DRUG|Nivolumab|Nivolumab 240 mg IV over 30 minutes given Day 1, 15 and 29 of each Cycle
224231303|NCT03528408|DRUG|Ipilimumab|Ipilimumab 1 mg/kg IV over 60 minutes given Day 1 of each Cycle
224231304|NCT00185523|PROCEDURE|Allogeneic hematopoietic cell transplantation|
224231305|NCT05785455|OTHER|COGMO Intervention|Group sessions in which each patient, after motivational interviewing sessions will follow a goup education in pain neuroscince program followed by a cognition targeted exercise therapy
224231306|NCT05785455|OTHER|Usual Care|Usual Primary Care health education and treatment for patients with chronic neck pain
224231307|NCT01986036|DIETARY_SUPPLEMENT|Protein|Milk-Protein
224231308|NCT01986036|DIETARY_SUPPLEMENT|Calcium|Soluble calcium powder.
224231309|NCT01986036|DIETARY_SUPPLEMENT|Porridge-based breakfast.|Oats and water.
224231310|NCT01829464|DRUG|Placebo|TAK-875 placebo-matching tablets
224231311|NCT01829464|DRUG|TAK-875|TAK-875 tablets
224231312|NCT01829464|DRUG|TAK-875|TAK-875 tablets
224231313|NCT02743702|OTHER|RESPIRATORY PHYSIOTHERAPY|"The protocol designed was composed of the following exercises:~* supine position: inhalation and exhalation with abdominal and thoracic pressures. 5 times~* lateral decubitus, with incentive spirometer lung inflation are made on right/left sides. 3 sets on each side~* sitting position, with the body leaning slightly forward, head and shoulders bent inwardly directed. It inspire called for 3 times, sent off in air through the mouth, after that the child was coughing~* diaphragmatic breathing in a sitting position: after a slow exhalation requested, child should steam a mirror with his mouth slightly open. 3 replications~* in a sitting position, with help of an ambu bag, we made inflations. Repeated 3 times~* exercises of upper member coupled to respiratory rhythm: shoulder flexion and extension was carried out during the inspiratory phase and the extension and adduction of them during expiration. 3 times"
224231314|NCT02743702|OTHER|USUAL THERAPIES|
224231315|NCT00274703|DRUG|mepolizumab|
224231316|NCT02229890|DRUG|alteplase|
223644767|NCT06101589|DIETARY_SUPPLEMENT|Placebo|Olive oil in 1 ml ethyl oleate with no vitamin D3 content
223644768|NCT00846092|DEVICE|Warp 10 LED Device|Study Subjects will take the Warp 10 (LED) home and treat twice per day for three months
223644769|NCT00846092|DEVICE|Near-infrared light (NIR)|"* Subjects will be exposed to light emitted from LED's at wavelengths of 670 nm (+/-15nm) with a minimum exposure of 4 J/cm2 (4.0 - 7.68J/cm2). This is accomplished by applying the 50 mW/cm2 (50 - 80 mw/cm2) LED-generated light to the study eye.~* Treatments involve application of the LED-generated light for 80 seconds, twice daily."
223644770|NCT05884827|DEVICE|EMG|Measure the electrical activity of the muscle and nerve
223644771|NCT04553380|DRUG|basic insulin|"1. Initial dose of basic insulin: 0.2U/kg/d.~2. Dose titration regimens: the dose is titrated by increments of 0.07U/kg daily until the fasting blood glucose（FBG）≤7 mmol / L, and if the FBG≤ 3.9mmol/L, the 0.07U/kg is reduced.~3. Injection time: subcutaneous injection before going to bed every night."
223644772|NCT00560196|OTHER|Observation|
223644773|NCT03723304|PROCEDURE|Bridging followed by transplant|Trans-arterial chemoembolization or percutaneous alcohol injection or radio-frequency ablation during the waiting time followed by liver transplant
223644774|NCT03723304|PROCEDURE|Direct liver transplant|Direct liver transplant (no neoadjuvant approaches during the waiting time period)
223644775|NCT04670367|BEHAVIORAL|Walk 30mins|aerobic exercise
223644776|NCT04670367|BEHAVIORAL|Walk plus Baduanjin|Walk 30mins then Baduanjin 12mins per day, 5 times per week.
223644777|NCT04670367|OTHER|usual care|routine care
223644778|NCT04670367|BEHAVIORAL|Baduanjin|Baduanjin exercise is moderate in intensity and short in duration (a set of Baduanjin takes about 12 minutes). Baduanjin consists of the sitting and standing practicing form. The sitting Baduanjin exercise conforms to the aspects of low-intensity and long-term aerobic activity, which is suitable for the rehabilitation training of patients who are in stable condition during hospitalization. The standing Baduanjin is more suitable for patients with sequential rehabilitation after discharge and can be adjusted based on the patient's condition
223644779|NCT00538018|DRUG|Telithromycin|
223644780|NCT01235741|DRUG|Pramlintide+Metreleptin|Group A: Subcutaneous Injection once a day (QD): Pramlintide 360 mcg+Metreleptin 5.0 mg for 1 week followed by Pramlintide 360 mcg+Metreleptin 5.0 mg twice a day (BID) for 15 weeks.
223644781|NCT01235741|DRUG|Placebo|Group B: Subcutaneous Injection-twice a day (BID): Placebo equivalent volumes to active doses.
223644782|NCT01794767|DRUG|0,9% NaCl flush|Normal Saline solution
224231317|NCT00783406|DRUG|PF-00610355|dry powder inhaler, 1472 mcg, single dose
223644783|NCT01794767|DRUG|Heparin 50U/ml|Heparin solution
223644784|NCT00462813|DRUG|oral microencapsulated diindolylmethane|
223644785|NCT00462813|GENETIC|polymerase chain reaction|
223644786|NCT00462813|OTHER|cervical Papanicolaou test|
223644787|NCT00462813|OTHER|cytology specimen collection procedure|
223644788|NCT00462813|PROCEDURE|colposcopic biopsy|
223644789|NCT00959985|DEVICE|Compression Sleeve|Worn for a minimum of 12 hours per day
223644790|NCT00959985|DEVICE|Short-Stretch Compression Bandage|Worn overnight at least 5 nights of the week
223644791|NCT00451633|DRUG|E2007|
223644792|NCT00004567|DRUG|Mycophenolate Mofetil|
223644793|NCT00904033|DRUG|Calcitriol|Calcitriol tablet taken once per week.
223644794|NCT00904033|BEHAVIORAL|Exercise|Exercise consisting of progressive walking and resistance band training
223644795|NCT00904033|DIETARY_SUPPLEMENT|Multivitamin|
223680872|NCT04243109|DRUG|Pomalidomide + Cyclophosphamide + Dexamethasone|"Treatment Phase: Combination of Pomalidomide, Cyclophosphamide and Dexamethasone, days 1-21 every 4 weeks (28 day cycles), up to a total of 8 cycles:~* Pomalidomide: Treatment with Pomalidomide 4 mg / day 1-21 days in 28-day cycles is started. Dose reductions will be made based on the evaluation of hematological and non-hematological toxicity.~* Cyclophosphamide: Cyclophosphamide will be administered 15 mg / day, days 1-28 in 28-day cycles.~* Dexamethasone: Dexamethasone will be administered 40 mg / day, days 1, 8, 15 and 22 in 28-day cycles. In patients older than 75 years the dose will be reduced to 20 mg / day in the same previous schedule.~Maintenance Phase: Combination of Pomalidomide and Dexamethasone. The last doses prescribed in the previous cycle will be maintained."
224231318|NCT00783406|DRUG|PF-00610355|dry powder inhaler, 736 mcg, single dose
224231319|NCT00783406|DRUG|PF-00610355|dry powder inhaler, 368 mcg, single dose
224231320|NCT00783406|DRUG|Placebo|Placebo
224231321|NCT02295709|PROCEDURE|SNR steroid (dexamethasone) injection|"deliver steroids (dexamethasone) into spinal nerve root with the guidance of ultrasound.~Device: Ultrasound (S-Nerve; SonoSite, Bothell, Wash), Probe 9L (6 MHz, SonoSite, Bothell, Wash)"
224231322|NCT02295709|PROCEDURE|CTF steroid (dexamethasone) injection|"deliver steroids (dexamethasone) into spinal epidural space with the guidance of ultrasound.~Device: Ultrasound (S-Nerve; SonoSite, Bothell, Wash), Probe 9L (6 MHz, SonoSite, Bothell, Wash)"
224231323|NCT02295709|DRUG|Dexamethasone|One of the most efficient steroids
224231324|NCT02295709|DEVICE|Ultrasound|Ultrasound (S-Nerve; SonoSite, Bothell, Wash), Probe 9L (6 MHz, SonoSite, Bothell, Wash)
223644796|NCT05758636|BEHAVIORAL|Emotional Freedom Technique|"Before starting the EFT session, the participants were asked to identify the problem that aroused their anxiety. After the common point of the problems was determined, the ORDS level of all participants was determined. Next, the EFT session explained traditional acupressure meridian points on the head, face, neck, chest, and hands. Next, they were asked to repeat the phrase, Even though I have this feeling of stress and anxiety, I accept myself deeply and completely, while gently applying to the acupuncture points with their index and middle fingers. While using this expression, the participants hit each acupuncture area seven times. After the first round of hits accompanied by this phrase, participants were asked to abbreviate this feeling of anxiety, stress with another short phrase. The participants then repeated rounds of this process until they noticed that their anxiety had decreased"
223644797|NCT05940220|OTHER|Acetazolamide|Acetazolamide placebo add-on a standard therapy of iv furosemide in one day and oral furosemide during three consecutive days will be used for the comparator arm
223644798|NCT05940220|OTHER|placebo|placebo
224231325|NCT02295709|RADIATION|C arm|the needle position will be re-confirmed by C arm C arm (Philips Healthcare, Best, the Netherlands）
224231326|NCT02270788|DRUG|Crenolanib|"Day 1 of Course 1: once followed by pharmacokinetic analysis. Days 2-28 of cycle 1: 3 times per day Crenolanib dose will not be adjusted unless the participant experiences side effects.~All subsequent courses: 3 times per day on Days 1-28. At least 50% of participants in each dose level must be ≤ 18 years old."
224231327|NCT02270788|DRUG|Sorafenib|"Days 8-28 of course 1: given orally once each day.~All subsequent courses: given orally on days 1-28 once per day~This is a dose-finding study for the use of sorafenib in combination with crenolanib. Different doses will be given to several participants, with the first participants receiving a lower dose than typically used in children as a single agent. If the drug does not cause serious side effects, it will be given to other study participants at a higher dose. If side effects occur, the dose will be lowered."
224231328|NCT02270788|DRUG|methotrexate, hydrocortisone and cytarabine with leucovorin|Triple IT therapy includes methotrexate, hydrocortisone and cytarabine with leucovorin rescue given on day 8. All participants will receive one IT chemotherapy on Day 8 of the first cycle. If they do not have leukemia cells in their spinal fluid, they will receive only one IT chemotherapy per cycle. If leukemia cells are present in their spinal fluid, they will receive IT chemotherapy weekly during the course. Triple IT therapy will be repeated on Day 1 of Cycle 2 and with each subsequent cycle in all participants.
224231329|NCT04872907|DEVICE|adhesive system|adhesive system G-BOND. It will be applied to healthy temporary anterior and posterior teeth The adhesive system (on side defined by randomization) will be renew at 6, 12, 18 months, on all three sides due to the physiological wear of the temporary teeth (and therefore the wear of the material).
223644799|NCT03531346|OTHER|Daily-disposable soft contact lens|Subjects were refitted with Silicone-Hydrogel (Delefilcon A) or Hydrogel (Omafilcon A) daily-disposable soft contact lenses based on their fit, reported comfort and tear film surface quality.
223644800|NCT01870518|DEVICE|Bilateral GPi DBS|
223644801|NCT01870518|DEVICE|Bilateral STN DBS|
223644802|NCT06119932|PROCEDURE|Evacuation for subdural hematoma by one burrhole|Evacuation for subdural hematoma by one burrhole
223644803|NCT00090207|DRUG|MK0869, aprepitant / Duration of Treatment: 3 days|
223644804|NCT00090207|DRUG|Comparator: ondansetron / Duration of Treatment: 4 days|
223644805|NCT02592590|BEHAVIORAL|Group A|"This condition receives three study components:~1. The base-level of the smartphone app, which contains health-related educational content (i.e., weekly videos, additional resources, quiz questions), activity tracking, and graphical feedback.~2. The guided goal-setting module within the app that utilizes participant activity preferences and experiences, as well as performance within the program to guide the setting of high-quality short and long-term physical activity goals. These goals form the basis of the physical activity prescription.~3. The points-based feedback module. For each action in the app (e.g., setting goals, achieving goals, viewing weekly videos, answering quiz questions, tracking activity), a number of program points is awarded. These are weighted by task difficulty, and accumulate to earn levels. Levels accumulate to earn badges depicting an avatar becoming increasingly healthy and active. Badges accumulate to earn titles (e.g., expert exerciser)."
223644806|NCT02592590|BEHAVIORAL|Group B|"This condition receives two study components:~1. The first is the base-level of the smartphone app, which contains health-related educational content (i.e., weekly videos, additional resources, brief quiz questions), behavioral tracking, and instantaneous graphical feedback.~2. The second is the guided goal-setting module within the app that utilizes participant activity preferences and experiences, as well as performance within the program to guide the setting of high-quality short and long-term physical activity goals. These goals form the basis of the physical activity prescription."
223644807|NCT02592590|BEHAVIORAL|Group C|"This condition receives two study components:~1. The first is the base-level of the smartphone app, which contains health-related educational content (i.e., weekly videos, additional resources, brief quiz questions), behavioral tracking, and instantaneous graphical feedback.~2. The second is the points-based feedback module. For each action in the app (e.g., viewing weekly videos, answering quiz questions, tracking activity), a number of program points is awarded. These are weighted by task difficulty, and accumulate to earn levels. Levels accumulate to earn badges depicting an avatar becoming increasingly healthy and active. Badges accumulate to earn titles (e.g., expert exerciser). As the intervention is goal drive, these participants will also receive printed goal setting worksheets."
223680873|NCT00891111|BEHAVIORAL|Direct Payment|$25 gift card given upon completion of Health Risk Assessment
224231330|NCT04872907|DEVICE|fluoride varnish|The reference drug is a fluoride varnish at 22,600 ppm of the brand Duraphat 50 mg / ml, dental suspension. The varnish is applied to healthy temporary anterior and posterior teeth, on the three sides of the teeth. The reference treatment (on side defined by randomization) will be renew at 6, 12, 18 months, on all three sides due to the physiological wear of the temporary teeth (and therefore the wear of the material).
223765849|NCT05182385|DRUG|Venetoclax|"In phase I of the study all eligible patients will receive increasing doses of Venetoclax on days -7 to -1 (Venetoclax dose-titration) in the first cycle and continuous dosing of Venetoclax at a pre-specified target dose (TD, p.o., once daily, d1 to d42) in six-week cycles for a maximum of two cycles.~In phase II of the study all eligible patients will receive the recommended phase 2 dose (RP2D) of Venetoclax in six-week cycles for a maximum of two cycles. RP2D will be MTD.~Patients eligible for a second cycle shall not receive Venetoclax dose-titration independent from relapse type."
224231331|NCT04872907|DRUG|flowable composite|"Composite Essentia HiFlo. It will be applied on healthy temporary molar grooves (on side defined by randomization).~Complete or partial renewal of the fluid composite in the grooves of the molars in the event of total or partial loss at 6, 12, 18 months"
224231332|NCT01904500|DRUG|Pre-operative cefazolin|
224231333|NCT02046928|DRUG|A6|A6 is self-administered subcutaneously two times a day for 6 cycles (1 cycle = 28 days).
224231334|NCT01947777|DRUG|IPI-145|25 mg oral capsule
224231335|NCT01947777|DRUG|Rifampin|2x 300 mg oral capsule
224231336|NCT00898482|OTHER|This is a non-intervention study for all groups.|This is a non-intervention study.
224231337|NCT00898482|OTHER|study of socioeconomic and demographic variables|Non-intervention study.
223644808|NCT02592590|BEHAVIORAL|Group D|This condition receives only the base-level smartphone app. This contains health-related educational content (i.e., weekly videos, additional resources, brief quiz questions), behavioral tracking, and instantaneous graphical feedback. As the intervention is goal drive, these participants will also receive printed goal setting worksheets.
223644809|NCT05505617|OTHER|Single-breath nitric oxide lung diffusing capacity measurements according to type of device in random order.|"Device: Jaeger Masterscreen TM (PFT Pro, Vyaire, Hoechberg, Germany)~Device: HypAir Medisoft (Medisoft, Dinant, Belgium)"
223644810|NCT02298010|DRUG|Capecitabine, oxaliplatin|
223644811|NCT05447884|OTHER|A zero impedance mode, controlling a wearable bilateral hip exoskeleton|The bilateral hip exoskeleton has two degrees of freedom to enable the hip joint extension and flexion movement on both left and right sides. The zero impedance mode will not provide any assistance or resistance to the hip joints.
223644812|NCT05447884|OTHER|A personalized optimal assistance mode, controlling a wearable bilateral hip exoskeleton|The personalized optimal assistance mode includes both individualized hip flexion and hip extension assistance, which is determined by using the reinforcement learning-based automatic control parameters tuning during walking tasks. Therefore, the personalized optimal assistance will be able to improve the walking gait performance and reduce the energetic consumption.
223644813|NCT05447884|OTHER|A free walking mode, without wearing a wearable bilateral hip exoskeleton|The free walking mode will not include the usage of the wearable bilateral hip exoskeleton, and the human walking subjects will conduct pure natural walking tasks.
223644814|NCT01748513|OTHER|preoperative venous return optimizing|Preoperative transthoracic echocardiography (TTE) was performed in the awake state before and after volume challenge based on 6ml colloids /kg ideal body weight.
223644815|NCT01177397|DRUG|CC-223|Part A: (closed to enrollment) Dose level starts with 7.5mg daily taken by mouth in cycles of 28 days. Level increases for different patient cohorts in 100% or 50% increments until optimal dose level is established for further study. Treatment continues for as long as patient benefits (i.e., until disease progression or unacceptable toxicity). Part B: (closed to enrollment) Optimal dose is administered in 28 day cycles until disease progression.
223644816|NCT05985252|PROCEDURE|Virtual ileostomy|Laparoscopic or robotic surgery with virtual ileostomy
223644817|NCT05985252|PROCEDURE|Diverting ileostomy|Laparoscopic or robotic surgery with diverting ileostomy
223644818|NCT02734459|DRUG|cataract surgery|"the patient will be dosed with the study drug into the V pocket is formed between the eye ball and the lower eyelid during cataract surgery."
223644819|NCT04632836|OTHER|quality of life questionnaires|responses for quality of life questionnaires (WHOQOL-BREF questionnaire, study specific questionnaire, PSQI index, HADS scale)
223644820|NCT01912170|DIETARY_SUPPLEMENT|Fish oil|
223644821|NCT01912170|DIETARY_SUPPLEMENT|Flaxseed oil|
223644822|NCT00804076|BIOLOGICAL|NP2|Intradermal injection of NP2 at doses ranging from 10e7 to 10e9 pfu at the site of pain.
223644823|NCT00118417|DRUG|Clonazepam|Participants will receive clonazepam.
223644824|NCT00118417|DRUG|Sertraline|Participants will receive sertraline.
223644825|NCT00118417|BEHAVIORAL|Cognitive behavioral therapy|Participants will receive cognitive behavioral therapy
223644826|NCT01090661|DRUG|mipomersen sodium|200 mg of mipomersen intravenous (IV) (single dose)
223644827|NCT01090661|DRUG|mipomersen sodium|200 mg of mipomersen subcutaneous (SC) (single dose)
223644828|NCT01090661|DRUG|moxifloxacin hydrochloride (Avelox®)|400 mg of moxifloxacin intravenous (IV) single dose
223644829|NCT01090661|DRUG|placebo|placebo intravenous (IV) single dose
223644830|NCT01090661|DRUG|placebo|placebo subcutaneous (SC) single dose
224231338|NCT05271474|DEVICE|ANNE ONE Platform|ANNE ONE is one most advanced digital platforms that are gradually becoming more available to enable providers to help patients manage their condition. It integrates soft and flexible sensors for comprehensive vital signs monitoring. This platform creates objective transparency by automatically recording data from the sensor on the patient, lessening the need for patients to consciously track their COPD exacerbation events, enabling providers to proactively manage their patients' condition, and creating actionable reports for providers to review with their patients.
224231339|NCT00617448|PROCEDURE|diathermy haemorrhoidectomy under espinal anesthesia|For surgery: conventional haemorrhoidectomy with diathermy (Milligan-Morgan).For anesthesia: lidocaine 2% at doses of 50-70 mg was used for spinal anaesthesia.
224231340|NCT00617448|PROCEDURE|diathermy haemorrhoidectomy under local anesthesia|For surgery: conventional haemorrhoidectomy with diathermy (Milligan-Morgan). For anesthesia: pudendal nerve block, infiltration of the right and left pararectal spaces, anterior and presacral regions with ropivacaine (150 mg of ropivacaine \[20 mL, 7.5 mg/mL\] diluted in 50 mL of 0.9% physiological saline). Ten minutes before local anaesthesia, patients were sedated with i.v. remifentanil 0.05-0.15 μg·kg-1
224231341|NCT00617448|PROCEDURE|Ligasure haemorrhoidetomy under spinal anestesia|For surgery: ligasure haemorrhoidectomy For anesthesia: lidocaine 2% at doses of 50-70 mg was used for spinal anaesthesia.
224231342|NCT00617448|PROCEDURE|Ligasure haemorrhoidectomy under local anesthesia|For surgery: haemorrhoidectomy with Ligasure For anesthesia: pudendal nerve block, infiltration of the right and left pararectal spaces, anterior and presacral regions with ropivacaine (150 mg of ropivacaine \[20 mL, 7.5 mg/mL\] diluted in 50 mL of 0.9% physiological saline). Ten minutes before local anaesthesia, patients were sedated with i.v. remifentanil 0.05-0.15 μg·kg-1
224231343|NCT00761592|BIOLOGICAL|Botulinum Toxin Type A 900kDa|6 to 16 injections, with maximum of 21, at a dose of ≥20U/eye (≥40U total dose)
224231344|NCT00761592|BIOLOGICAL|Botulinum Toxin Type A 150kDa|6 to 16 injections, with a maximum of 21, at a dose of ≥20U/eye (≥40U total dose)
224231345|NCT01290263|DRUG|Amgen 386|"For Cohort A, AMG 386 will be administered intravenously at 30 mg/kg every week.~For Cohort B Phase I, AMG 386 will be administered intravenously at beginning at starting dose level of 15 mg/kg every week.~For Cohort B Phase II, AMG 386 will be administered intravenously at the maximum tolerated dose determined in the Phase I portion of the study every week."
224231346|NCT01290263|DRUG|Bevacizumab|The dose of bevacizumab will be 10 mg/kg and will be administered intravenously every other week.
224231347|NCT05273619|DRUG|XC8, film-coated tablets, 10 mg|80 mg/day: 4 tablets (40 mg) twice a day
224231348|NCT05273619|DRUG|Placebo|4 tablets twice a day
224231349|NCT02707536|PROCEDURE|Socket grafting with PRF|Extraction with socket grafting using PRF.
224231350|NCT02707536|PROCEDURE|Socket grafting with bone graft|Extraction with socket grafting using bone graft.
224231351|NCT04700449|DRUG|Double-Blind 0.2mg CBP-307|0.2 mg capsule oral administration
224231352|NCT04700449|DRUG|Double-Blind Placebo|Placebo capsule oral administration
224231353|NCT04700449|DRUG|Open-label CBP-307|0.2 mg capsule oral administration
223644831|NCT05353153|OTHER|hypnosis|Hypnosis-based intervention with two sessions of hypnosis (focusing on the treatment of anxiety)
223644832|NCT05353153|OTHER|standart care|no intervention no hypnosis
223644833|NCT04769388|DRUG|Osimertinib|Pemetrexed (500 mg/m2) plus carboplatin (AUC5) on Day 1 of 21day cycles (every 3 weeks) for up to 6 cycles, followed by Osimertinib daily with pemetrexed maintenance (500 mg/m2) every 3 weeks.
223644834|NCT04769388|DRUG|Pemetrexed/Carboplatin|Pemetrexed (500 mg/m2) plus carboplatin (AUC5) on Day 1 of 21day cycles (every 3 weeks) for up to 6 cycles, followed by Osimertinib daily with pemetrexed maintenance (500 mg/m2) every 3 weeks.
223644835|NCT03894683|DRUG|Melatonin 10 mg|Melatonin tablets (10 mg)
223644836|NCT03894683|DRUG|Placebo Oral Tablet|Placebo tablets manufactured the same as melatonin tablets
223644837|NCT06373952|BEHAVIORAL|Online to offline counseling|"* Online registration and risk assessment: Users complete an onboarding process comprised of creating an account, entering demographic data, customizing settings, and completing the baseline risk assessment.~* HIVST kit order, management, and monitoring: The platform will allow users to request HIVST kits via standard mail or self-pickup at user-preferred sites (e.g., LGBT-friendly clinics). After completing the mandatory section of the questionnaire and selecting a delivery option, a random personal identification number will be assigned by the system, which will be used to track future HIVST requests, collect HIVST results, and monitor subsequent linkage to further testing and HIV care.~* eHIVST and O2O linkage to HIV clinical services: After unsealing the test kit, participants will find a reminder card to schedule their O2O pre- and post-test e-counseling appointment."
223644838|NCT00082225|BIOLOGICAL|CD45 antibodies|The antibody solution is administered by a syringe pump in incremental doses, 0.2-0.8 mg in the first hour and up to 10 mg/hr thereafter, for a maximum infusion time of 8 hrs.
223644839|NCT00082225|BIOLOGICAL|EBV specific T cells|"The following dose levels will be evaluated: Each patient will receive 1 injection, according to the following dosing schedules:~2 x 10e7 cells/m2 5 x 10e7 cells/m2~1 x 10e8 cells/m2"
223644840|NCT04268381|OTHER|Biochemical analysis|aMMP-8 is measured by immunofluorometric assay (IFMA).
223680874|NCT00891111|BEHAVIORAL|Regret Lottery|Entered into a lottery upon completion of Health Risk Assessment
224231354|NCT04700449|DRUG|Double-Blind 0.1mg CBP-307|0.1 mg capsule oral administration
224231355|NCT03738332|DEVICE|Low-Level Laser|Low-level laser therapy
224231356|NCT03377400|DRUG|Durvalumab|concurrent radiotherapy
224231357|NCT03543956|BEHAVIORAL|Questionnaire|Questionnaire
224231358|NCT02336737|DEVICE|SiennaXP|Sub-cutaneous injection of SiennaXP magnetic marker, followed by lymph node localization using the SentiMag handheld magnetic probe
224231359|NCT02336737|DRUG|Technetium Tc99m Sulfur Colloid|Injection of a single dose of radioisotope (Technetium Tc99m Sulfur Colloid)
224231360|NCT02336737|DRUG|Isosulfan blue dye|Injection of a single dose of isosulfan blue dye
224231361|NCT00027807|BIOLOGICAL|Aldesleukin|Subcutaneous injections of IL-2 (3.0 × 105 IU/m2/day) starting 3 days before the 1st armed ATC infusion and ending 7 days after the last armed ATC infusion.
224231362|NCT00027807|BIOLOGICAL|Sargramostim|GM-CSF Injections will be given SQ GM-CSF (250 μg/m2/twice weekly), to start 3 days before the first ATC infusion and ending 1 week after the last ATC infusion.
224231363|NCT00027807|BIOLOGICAL|therapeutic autologous lymphocytes|The time for armed-ATC infusions will vary from patient to patient, but the dose of armed-ATC (up to 40 billion) will be given over 30 min.
224231364|NCT00356798|BIOLOGICAL|an inactivated whole virion H5N1 vaccine, adjuvanted|
224231365|NCT01190969|DIETARY_SUPPLEMENT|Nutritional Supplement (Ensure Plus)|Subjects will be provided with 2 to 3 serves of Ensure Plus (complete nutritional beverages) and to be taken between meals
224231366|NCT06483945|DEVICE|Dexcom CGM G6/G6 Pro/G7|Dexcom CGM G6/G6 Pro/G7 device
224231367|NCT03312062|OTHER|Foam Rolling Exercise|Foam rolling exercise will be performed actively. Participants will use a foam roller for exercise. They will position the foam roller on the chair. Afterwards, they will use their body weights to rub the elbow area (biceps brachii muscle) with this foam. There will be 2 sets and each set will be 1 minute. Single set contains 10 repetitions in 1 minute with 30 seconds resting period between sets.
224231368|NCT02228382|DRUG|Bosutinib|100 mg and 500 mg tablets, once daily dosage up to 4 years duration
224231369|NCT00200122|DEVICE|Spinal Cord Stimulation|
223644841|NCT03992248|BEHAVIORAL|Time restricted feeding|Eating within a time frame of 10hrs during the day. Outside of this time frame, participants need to refrain from food and energy containing drinks.
224231370|NCT02934750|BEHAVIORAL|Pursed lip breathing|"Pursed lip breathing will be taught to the participants following the chronic obstructive pulmonary disease (COPD) Foundation recommendations:~1. Breathe in through your nose (as if you are smelling something) for about 2 seconds.~2. Pucker your lips like you're getting ready to blow out candles on a birthday cake.~3. Breathe out very slowly through pursed-lips, two to three times as long as you breathed in.~4. Repeat."
224231371|NCT02470559|BIOLOGICAL|Aldesleukin|Given SC
224231372|NCT02470559|BIOLOGICAL|HER2Bi-Armed Activated T Cells|Given IV and IP
224231373|NCT02470559|OTHER|Laboratory Biomarker Analysis|Correlative studies
224231374|NCT02470559|BIOLOGICAL|Sargramostim|Given SC
224231375|NCT04072588|PROCEDURE|vaginal cuff prolapse surgery|Different surgical methods for the treatment of vaginal cuff prolapse in patients who have previously undergone hysterectomy for benign causes
224231376|NCT02035709|DRUG|Hydromorphone|Hydromorphone is given by PCA or TCI-PCA. The TCI-PCA System steer the hydromorphone infusion pump to achieve plasma concentrations of hydromorphone in predefined increasing steps on patient request and in predefined decreasing steps on lack of patient request within predefined plasma concentration range, lock times and infusion speed.
224231377|NCT05773183|DRUG|Testosterone|In OBS1 20 men will be started on Testosterone replacement therapy as per routine clinical practice. Data collection will occur prior initiating therapy, and 6 months post
224231378|NCT05773183|DRUG|GnRH|20 men in OBS2 planned for GnRH analogue therapy will undergo data collection prior, and 3 months post initiation of GnRH analogue therapy
224231379|NCT04682041|DIETARY_SUPPLEMENT|Bovine Plasma-Derived Immunoglobulin Concentrate|EnteraGam® 10.0 g, containing 5.0 g of serum-derived bovine immunoglobulin/protein isolate (SBI) BID (every 12 hours) for 2 weeks.
224231380|NCT04682041|OTHER|Standard of care|Standard of care PSMAR protocol for COVID-19 patients.
224231381|NCT03213119|PROCEDURE|Non-invasive brain stimulation of the vestibular system through caloric vestibular stimulation.|Caloric vestibular stimulation (CVS) involves the irrigation of cold or warm water into the external ear canal, and induces a temperature gradient across the semicircular canals stimulating the vestibular nerve. It is commonly used in both otolaryngology to assess vestibular function and neurology to test brain stem function.
224231382|NCT03213119|PROCEDURE|Non-invasive brain stimulation of the vestibular system through caloric vestibular stimulation.|Caloric vestibular stimulation (CVS) involves the irrigation of cold or warm water into the external ear canal, and induces a temperature gradient across the semicircular canals stimulating the vestibular nerve. It is commonly used in both otolaryngology to assess vestibular function and neurology to test brain stem function.
224231383|NCT03213119|PROCEDURE|Non-invasive brain stimulation of the vestibular system through caloric vestibular stimulation.|Caloric vestibular stimulation (CVS) involves the irrigation of cold or warm water into the external ear canal, and induces a temperature gradient across the semicircular canals stimulating the vestibular nerve. It is commonly used in both otolaryngology to assess vestibular function and neurology to test brain stem function. The SHAM condition uses body-temperature water, and thus does not result into vestibular unbalance.
224231384|NCT02531984|DRUG|Azithromycin|
224231385|NCT00095381|DRUG|forodesine hydrochloride (BCX-1777)|
224231386|NCT03651323|DEVICE|Left atrial appendage closure with Watchman device|Percutaneous left atrial appendage closure using Watchman device
224231387|NCT05779449|DIETARY_SUPPLEMENT|Prebiotics and Probiotics supplementation|"From the 1st day to the 15th day (included) patients with MS in the Pre-Pro group will receive daily:~1 capsule of Probactiol Duo, Metagenics (6 billions of Saccharomyces boulardii and 8,5 billions of probiotics including Bifidobacterium lactis Bi-07®, Bifidobacterium lactis Bl-04, Lacticaseibacillus paracasei Lpc-37, Lactobacillus acidophilus NCFM®)~1. packet of Probactiol Stips, Metagenics (4 g inulin enriched with oligofructose)~   From the16th day to the 365th day (included) patients with MS in the Pre-Pro group will receive daily:~2. capsules of Probactiol HMO Combi, Metagenics (7,5 billions of Lactobacillus acidophilus NCFM®, 7,5 billions of Bifidobacterium lactis Bi-07®, 2,5 ug Vitamine D3, 320 ug Vitamine A, 100 mg Threonine, 250 mg 2'-Fucosyllactose)."
224231388|NCT05779449|DIETARY_SUPPLEMENT|Placebo supplementation|1-year supplementation with two placebo capsules/day containing starch, the probiotic bacteria carrier.
223644842|NCT03992248|BEHAVIORAL|Control|Eating for at least 14hrs per day.
223644843|NCT00958906|DRUG|Infliximab (intravitreal, 2.0mg/0.05ml)|One injection of intravitreal infliximab (2.0mg/0.05ml).
224231389|NCT05779449|PROCEDURE|peripheral blood withdrawal|40 ml of blood for the isolation of Peripheral Blood Cells (PBMCs) and T cells.
224231390|NCT05779449|PROCEDURE|Transcranial Magnetic Stimulation (TMS)|Intermittent theta burst stimulation (iTBS) protocol
224231391|NCT02324465|DEVICE|King Vision Video Laryngoscope|Intubation via King Vision Video Laryngoscope
224231392|NCT02324465|DEVICE|Glidescope Video Laryngoscope|Intubation via Glidescope Video Laryngoscope
224231393|NCT00263809|DEVICE|Pathogen Reduction Technology|
224231394|NCT01580878|DRUG|Butenafine Hydrochloride Cream, 1%|Butenafine Hydrochloride Cream, 1% applied twice daily for 7 consecutive days
224231395|NCT01580878|DRUG|Lotrimin Ultra®|Lotrimin Ultra® (Butenafine Hydrochloride Cream, 1%) applied twice daily for 7 consecutive days.
224231396|NCT01580878|DRUG|Butenafine Vehicle|Butenafine Vehicle applied twice daily for 7 consecutive days.
223644844|NCT03310853|DIETARY_SUPPLEMENT|Probiotic|Dosing regimen of one capsule daily for a maximum of 18 weeks
223644845|NCT03310853|OTHER|Placebo|Dosing regimen of one capsule daily for a maximum of 18 weeks
223644846|NCT01383356|DRUG|Metformin Single Tablet|Metformin medium doseTablet
223644847|NCT01383356|DRUG|Linagliptin/Metformin Combo|Fixed dose combination
223644848|NCT01383356|DRUG|Linagliptin Single Tablet|Linagliptin Single medium dose Tablet
223644849|NCT02796183|DRUG|Subconjunctival bevacizumab (Altuzan)|Subconjunctival injections of Altuzan 3.75mg were applied in order to eliminate the macular edema.
223644850|NCT05147090|DRUG|Empagliflozin 10 MG|Empagliflozin 10mg daily
223644851|NCT05147090|DRUG|Placebo pills|Identical in appearance to empagliflozin 10mg daily
223644852|NCT03727256|OTHER|ultrasound therapy|Group 1, ultrasound therapy ;1 watt/cm² dose, 1 MHz, 5 minutes
224231397|NCT02059993|DEVICE|continuous positive airway pressure|mean continuous positive airway pressure use was at least 4 hours per night;continuous positive airway pressure group received fixed-level continuous positive airway pressure titration using an automated pressure
224231398|NCT06236737|OTHER|Sensorimotor Exercise|The sensorimotor group was given oculomotor, gaze stability and postural stability exercises. Each session lasted 40 minutes in total.
224231399|NCT06236737|OTHER|Yoga Exercise|A flow was created for the yoga group. Each session lasting 40 minutes was included ocular motor, balance, meditation and stretching. Practices illustrated in table one were repeated for the eight weeks. Beginning of each session was focused on breathing exercises and the yoga flow is designed. Weeks 1-2. were prepared by focusing mostly on sagittal plane asanas. While 3-5. tweeks were focused on frontal plane asanas, 6-8. weeks were focused on transvers plan. Each session commenced with a 5-minute practice of a three dimensional breathing technique. This was followed by a 25-minute yoga asana flow, concluding with a 10-minute meditation in shavasana, also known as Corpse Pose. NDY was taught by an academician physiotherapist who has completed graduation in yoga therapy.
224231400|NCT05159609|DEVICE|Closed loop auditory stimulus|50ms of low volume pink noise delivered during slow wave sleep
224231401|NCT01226056|DRUG|RAD001 in combination with sorafenib|"Phase I / Dose escalation: during the first cycle RAD001 (2.5-10 mg/day) will be administered alone, once a day, on days 1-14 to allow PK-profiling of the drug. From day 15 sorafenib administration (400-800 mg/day) twice a day will be added.~The cycle 1 will last 6 weeks, subsequent cycles will last 4 weeks (the 2 drugs administered in combination from day 1 to day 28).~Phase II: The drugs will be administered at the Recommended Dose and each treatment cycle will last 4 weeks."
224231402|NCT03665909|OTHER|Remote activity monitoring system|The home-based sensor technology of eNeighbor relies on multiple, non-invasive and safe remote monitors (up to 6 sensors) that can alert family caregivers and/or health professionals to potentially negative situations that lead to adverse outcomes (e.g., wandering, falls, incomplete activity of daily living tasks). The technology platform of eNeighbor relies on wireless infrastructure that allows for remote monitoring via alerts that are communicated to the family caregiver's or nurse care manager's personal computers or handheld devices. The Alerts that are generated from the sensors detected abnormal motion or activity are sent to the family caregiver as well as a nurse care manager that monitors the real-time information generated by the eNeighbor sensors.
223644853|NCT03727256|OTHER|neuromuscular electrical stimulation application|Group 2, neuromuscular electrical stimulation application;20 mins/session
224231403|NCT03868137|DRUG|Ibuprofen|3 doses of Ibuprofen 800 mg
224231404|NCT03868137|DRUG|Placebos|Placebo
224231405|NCT02655237|DRUG|Relugolix|Relugolix tablets
224231406|NCT02655237|DRUG|Relugolix Placebo|Relugolix placebo-matching tablets
224231407|NCT02655237|DRUG|Leuprorelin|Leuprorelin injection
224231408|NCT02655237|DRUG|Leuprorelin Placebo|Leuprorelin placebo-matching injections
224231409|NCT00207337|DEVICE|Exhale Drug-Eluting Stent|
224231410|NCT06496737|BEHAVIORAL|Moderate-Intensity Interval Training (MIIT)|Moderate-Intensity Interval Training (MIIT) is developed by university badminton coaches, three times a week for 12 weeks
223644854|NCT04424264|DRUG|Phase 1: Tenofovir disoproxil fumarate/Emtricitabine/Efavirenz coadministered with Rifampicin/Isoniazid|TDF/FTC/EFV 300/200/600 mg once daily plus RIF/INH 600\*/300 mg daily from screening until enrolment (days -15 to 0)
223644855|NCT04424264|DRUG|Phase 2: Tenofovir alafenamide/Lamivudine/Efavirenz coadministered with Rifampicin/Isoniazid|TAF 25 mg + 3TC 300 mg + EFV 600 mg once daily plus RIF/INH 600/\*300 mg daily (days 1 to ≤ 56)
223644856|NCT04424264|DRUG|Phase 3: Tenofovir disoproxil fumarate/Emtricitabine/Efavirenz|TDF/FTC/EFV 300/200/600 mg once daily. RIF/INH 600mg \<70kg, 750mg \>70kg
223644857|NCT02807584|DEVICE|ELECT|
223680875|NCT03578770|DEVICE|Hot Axios stent|Hot Axios stent
223680876|NCT03915522|PROCEDURE|Single adductor canal block|The operated leg is slightly externally rotated and prepared for a block with 2% chlorhexidine and sterile dressing. The adductor canal is identified using ultrasound image at the mid-thigh level and after a subcutaneous injection of 2 ml of 1% lidocaine a total of 20 ml of 0'5% ropivacaine is injected into the canal using a 22 gauge ultrasound-visible needle. In the end, a sterile apposite is placed at the puncture site
223680877|NCT03915522|PROCEDURE|Simulated adductor canal block|The operated leg is slightly externally rotated and prepared with 2% chlorhexidine and sterile dressing. The adductor canal is identified using ultrasound image at the mid-thigh level and at this leve a subcutaneous injection of 2 ml of 1% lidocaine . After, a sterile apposite is placed at the puncture site.
223680878|NCT00001115|DRUG|Acyclovir|
223680879|NCT03319290|GENETIC|BRCA1 and BRCA2|Genetic breast and ovarian cancer testing
223680880|NCT05513131|DRUG|Venetoclax；Azacitidine；Homoharringtonine|A cycle every 28 days Treatment with Venetoclax 100mg d1，200mg d2，400mg d3\~d14； Azacitidine 75mg/m2/d，d1\~d7 Homoharringtonine 2mg/d d1\~d7
223680881|NCT06063707|OTHER|Taking peripheral blood|Taking peripheral blood of no more than 3ml
223680882|NCT02520128|RADIATION|Intensity modulated radiotherapy (IMRT)|Intensity modulated radiotherapy (IMRT) is an advanced radiotherapy technique that is able to deliver a highly conformal dose to a target with improved sparing of the surrounding normal tissues from moderate to high radiation doses. IMRT is likely to be of particular benefit for tumours that have complex shapes, or those in close proximity to sensitive normal tissues and critical organs. Reducing the dose to normal tissues may in turn reduce the acute and late side effects of treatment. IMRT can be delivered from multiple fixed beam angles or through rotational arc applications such as volumetric modulated arc therapy (VMAT) and tomotherapy. The radiotherapy is delivered using multiple small beams (beamlets) of non-uniform intensity.
223680883|NCT00095238|DRUG|Irbesartan|Tablets, Oral, titration from 75 to 300 mg, once daily up to 6 years
223680884|NCT00095238|DRUG|Placebo|Tablets, Oral, titration from 75 to 300 mg, once daily up to 6 years
223680885|NCT00075673|DRUG|celecoxib|Patients receive oral celecoxib twice daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
223680886|NCT00075673|DRUG|vinorelbine ditartrate|Patients receive oral vinorelbine on days 7, 14, and 21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
224231411|NCT06496737|BEHAVIORAL|High-Intensity Interval Training (HIIT)|High-Intensity Interval Training (HIIT) is developed by university badminton coaches, three times a week for 12 weeks
224231412|NCT00153283|DRUG|Gabapentin|
224231413|NCT00039611|DRUG|FOLFOX regimen|
224231414|NCT00039611|DRUG|fluorouracil|
224231415|NCT00039611|DRUG|leucovorin calcium|
224323449|NCT06813872|BIOLOGICAL|ABRYSVO Vaccination|"The primary exposure of interest for the TND study is maternal history of vaccination with Pfizer's ABRYSVO vaccine during pregnancy with the infant who presented for care. Infants will be considered exposed to ABRYSVO if their birth parent has documented evidence of receiving ABRYSVO ≥14 days before the date of the infant's birth, during the licensed gestational age window of 32 0/7 to 36 6/7 weeks."
223644858|NCT04367623|OTHER|Brain computer interface based therapy|Participants who decide to take part will be assigned to a treatment or a control group. Both groups will have the same assessments and the same number of therapy sessions. Therapy group will have a training that consists of Brain Computer Interface controlled Functional Electrical Stimulation followed by a physical practice of the dominant upper limb, while the control group will have a physical practice only. One experimental session will last about 60 min for both groups (including setup and therapy) and participants in each group will receive 20 sessions, about 3 times per week. The expected time needed for completion of 20 sessions is 7 weeks
223644859|NCT02182752|DRUG|Ropivacaine - Tramadol|Interscalene block using ropivacaine plus tramadol
223644860|NCT02182752|DRUG|Ropivacaine|Interscalene block using ropivacaine
223644861|NCT04287296|BEHAVIORAL|Wakey!|Everyone who has downloaded the app will receive a 9-minute morning show as an alternative to an alarm clock every Mon-Fri for 12 weeks. The show is presented by a cast of presenters who appeal to the target demographic. The intervention content is theory and evidence led, drawing on approaches from cognitive and third-wave psychotherapies, positive psychology interventions (such as those based on resilience training and growth mindset), and lifestyle mental health interventions. Additional content will be provided on the app to support the theory and techniques that are covered in the show. Fun content will also be posted in an ad-hoc manner that complement the shows or relate to cultural dates and aim to increase engagement. Wakey! will avoid any polarising topics such as politics, religion and folk science. There are several features beside the show itself: a moderated live chat between 6-9AM, feedback for users (e.g. how many days they have seen the show, current energy levels).
223644862|NCT02538978|BIOLOGICAL|Autologous Bone Marrow Concentrate (aBMC)|"Aspirated bone marrow will be processed by centrifugation, separating out a concentrate (aBMC) comprising primarily white blood cells and platelets. These cells will be injected i.m. to loci determined by the operating physician using imaging and vascular flow criteria.~Device: SurgWerks-CLI Kit~Device: VXP System"
223644863|NCT02538978|BIOLOGICAL|Placebo Control (diluted autologous peripheral blood)|Diluted peripheral blood prepared in a blinded fashion to resemble bone marrow will be injected intramuscularly per the same procedure used for the Experimental Device Arm.
223644864|NCT06297811|DRUG|Trilaciclib Injection|Experimental: trilaciclib group Intervention: Drug: Trilaciclib Injection \[Cosela\] 240 mg/m\^2, intravenous drip over 30 min within 4 hours before chemotherapy administration on the same day
223644865|NCT06297811|DRUG|Paclitaxel|Drug: Paclitaxel 175 mg/m\^2, intravenous drip over ≥ 3 hours , d1, Q3W, at least 6 cycles.
223644866|NCT06297811|DRUG|Carboplatin|area under curve(AUC) 5\~6, intravenous drip over ≥ 1 hours, d1, Q3W, at least 6 cycles.
223644867|NCT02518295|OTHER|Positive control|200ml milk containing 18g lactose
223644868|NCT02518295|OTHER|Probiotic S. thermophilus|200ml milk containing 18g lactose + probiotic S. thermophilus
223644869|NCT02518295|OTHER|Probiotic B. longum|200ml milk containing 18g lactose + probiotic B. longum
223644870|NCT02518295|OTHER|Negative control|200 ml of UHT Lactose free milk
223644871|NCT05169359|BEHAVIORAL|Speak Up! Video|Once a clinic begins active implementation (is ready to show the video) patients will view the Speak Up! Video intervention prior to their visit. The 10-minute video program will be provided to patients for viewing on an iPad (or a portable DVD player, computer or TV as appropriate to the site based on PDSA activities during implementation planning). The clinic staff will set patients up with comfortable headphones.
223644872|NCT02713282|DRUG|Paliperidone palmitate 3 month formulation (PP3M)|Participants will receive intramuscular injection of Paliperidone Palmitate 3-Month Formulation (PP3M) on Day 1 at a starting dose of 175 milligram equivalent (mg eq) up to 525 mg eq based on last Paliperidone Palmitate 1-Month Formulation (PP1M) dose (at a dose of 3.5-fold multiple of the participant's last PP1M dose). Subsequent PP3M injections will be given at Month 3, Month 6, and Month 9 and dose can be adjusted flexibly in increments within the range of 175 to 525 mg eq.
223644873|NCT03352102|PROCEDURE|Electrical stimulation|Neuromuscular electrical stimulation therapy was performed
223644874|NCT00998296|DRUG|BIBW 2992|EGFR inhibitor
223644875|NCT00998296|DRUG|BIBF 1120|VEGF inhibitor
223644876|NCT02350296|DRUG|KSL 40 mg|Ketoprofen lysine salt (KLS) immediate release oral tablets 40 mg, corresponding to 25 mg of ketoprofen free acid. Ketoprofen lysine salt was administered according to the randomisation list and the cross-over design. One (1) tablet of test formulation was administered to the subjects in the morning with 240 mL of still mineral water. Afterwards, no fluid intake was permitted for 2 h. All subjects were under fasting conditions from the evening before investigational product administration (i.e. for at least 10 h, overnight).
224231416|NCT00039611|DRUG|oxaliplatin|
224231417|NCT02132247|DRUG|Diclofenac hydroxyethylpyrrolidine|
224231418|NCT00928954|DRUG|gabapentin|increasing to 1200 mg/day
224231419|NCT00928954|DRUG|memantine|increasing to 40 mg/day
224231420|NCT02932254|DRUG|Magnesium Sulfate|After 90% of baseline T4 / T1, are injected intravenously magnesium sulfate 60 mg/kg over 10 minutes (100 mL solution).
224231421|NCT02932254|DRUG|Saline|After 90% of baseline T4 / T1, are injected intravenously saline solution over 10 minutes (100 mL solution).
224231422|NCT00437242|DRUG|Odiparcil|
224231423|NCT01911494|BEHAVIORAL|Community Engagement|The primary objective of the community engagement activities in CLIP will be to create awareness and action around the prevention of maternal morbidity and mortality due to pre-eclampsia/eclampsia. Community engagement involves the collective action of individuals, families, religious leaders, policy makers,
224323450|NCT06836063|DRUG|Ropanicant|Tablet dosage form, twice a day
224323451|NCT06836063|DRUG|Placebo|Matching placebo tablets, twice a day
224231424|NCT01911494|DEVICE|PIERS on the Move mHealth decision aid|This mHealth application is to be used by community health workers in intervention clusters to guide collection of relevant clinical data during antenatal visits. This clinical data is used to generate a risk estimate for any women with hypertension based on the miniPIERS (Pre-eclampsia Integrated Estimate of Risk) clinical risk prediction model. This risk estimate in combination with other pre-defined treatment triggers (severe hypertension (\>160mmHg systolic) or proteinuria (\>3+ dipstick); absence of fetal movements for greater than 12 hours; signs of recent stroke of seizure) are collected in the app and based on this data recommendations for care of the woman are provided.
224231425|NCT01911494|DRUG|Magnesium Sulfate|Women identified in intervention clusters by the community health worker during a study visit as being at high risk of- or having recently experienced- an eclamptic seizure will be given 10 g intramuscular magnesium sulfate prior to transfer to a nearby facility for further care.
223644877|NCT02350296|DRUG|OKi® 80 mg|"OKi® 80 mg granules for oral solution (bipartite sachets: each half sachet containing 40 mg of KLS corresponding to 25 mg of ketoprofen free acid). Ketoprofen lysine salt was administered according to the randomisation list and the cross-over design.~The content of half sachet of the reference formulation was dissolved in 190 mL of still mineral water. The subject drank the entire solution immediately. Then the glass was rinsed with 50 mL of still mineral water and the subject drank the rinse immediately. Afterwards, no fluid intake was permitted for 2 h. All subjects were under fasting conditions from the evening before investigational product administration (i.e. for at least 10 h, overnight)."
223644878|NCT01452841|OTHER|Grapefruit|1.5 Rio Red Grapefruit consumed daily for 6 weeks
223644879|NCT01452841|OTHER|Control|Participants followed a diet low in bioactive rich fruits and vegetables and avoided citrus for six weeks
223644880|NCT01544335|OTHER|Bioimpedance Spectroscopy|BIS used to measure fluid in arm
223644881|NCT02231905|DRUG|BI-Sifrol®|
223644882|NCT01717027|DRUG|Oxycodone|One capsule of 40 mg PF-00345439 Formulation A, single dose, taken whole and under fed conditions
223644883|NCT01717027|DRUG|Oxycodone|One capsule of 40 mg PF-00345439 Formulation J, single dose, taken whole and under fed conditions
223644884|NCT01717027|DRUG|Oxycodone|One capsule of 40 mg PF-00345439 Formulation K, single dose, taken whole and under fed conditions
223644885|NCT01717027|DRUG|Oxycodone|One capsule of 40 mg PF-00345439 Formulation J or K, single dose, chewed and under fasted conditions
223644886|NCT00031278|DRUG|CPG 7909|Each 0.01 mg/kg CPG 7909 treatment will consist of a monitored 2-hour infusion given once weekly until disease progression or a maximum of 24 weeks.
223644887|NCT00031278|DRUG|Herceptin®|Herceptin® will be administered at a dose of 2 mg/kg IV according to the Herceptin® package insert
223644888|NCT00031278|DRUG|CPG 7909|Each 0.04 mg/kg CPG 7909 treatment will consist of a monitored 2-hour infusion given once weekly until disease progression or a maximum of 24 weeks.
223644889|NCT00031278|DRUG|Herceptin®|Herceptin® will be administered at a dose of 2 mg/kg IV according to the Herceptin® package insert
223644890|NCT00031278|DRUG|CPG 7909|Each 0.16 mg/kg CPG 7909 treatment will consist of a monitored 2-hour infusion given once weekly until disease progression or a maximum of 24 weeks.
223644891|NCT00031278|DRUG|Herceptin®|Herceptin® will be administered at a dose of 2 mg/kg IV according to the Herceptin® package insert
223644892|NCT00031278|DRUG|CPG 7909|Each 0.32 mg/kg CPG 7909 treatment will consist of a monitored 2-hour infusion given once weekly until disease progression or a maximum of 24 weeks.
223644893|NCT00031278|DRUG|Herceptin®|Herceptin® will be administered at a dose of 2 mg/kg IV according to the Herceptin® package insert
223644894|NCT03219528|DRUG|Rifaximin 550 MG|Rifaximin 550 mg three times daily for 14 days
223644895|NCT03219528|OTHER|Low FODMAP Diet|Low FODMAP dietary intervention for 4 weeks
223644896|NCT05432440|BEHAVIORAL|The digital asthma education program|The intervention group receives the digital asthma education program (MIRACLE program). It consists of an asthma interactive narrative, a serious game, and an asthma action plan. It mainly covers asthma self-management and asthma attack prevention, such as asthma definition, asthma triggers and how to prevent asthma triggers exposures, asthma medications, proper inhaler technique, and asthma written action plan.
223644897|NCT05050227|BEHAVIORAL|cCBT Enhanced Collaborative Care|"Computerized CBT (cCBT) will be delivered supported by a depression care manger who will facilitate access to cCBT, promote and monitor cCBT use, reinforce CBT concepts (during outside CBT session homework), and monitor mental health symptoms for each participant."
223644898|NCT05050227|BEHAVIORAL|Usual Care|Primary Care Provider supported usual care typically includes medication prescription and referrals to specialty mental health, including Primary Care - Mental Health Integration services.
223644899|NCT03501498|DRUG|Loperamide|Alters intestinal transit time.
223644900|NCT03501498|DRUG|Senna|Alters intestinal transit time.
223644901|NCT02120898|DRUG|Imiquimod|Cream, generic formulation of the brand product.
224231426|NCT01911494|DRUG|Methyldopa|Women identified in intervention clusters as having severe hypertension (systolic greater than 160 mmHg) by the community health worker during a study visit will be given 750 mg of oral methyldopa prior to transfer to a nearby facility for further care.
223644902|NCT02120898|DRUG|Zyclara®|Cream, brand product.
223644903|NCT02120898|DRUG|Vehicle Cream|Vehicle cream in the same image of the generic imiquimod. Has no active ingredient.
223644904|NCT06359353|DRUG|Pitavastatin|"Pitavastatin 2 mg or 4 mg once daily~\* The dosage is determined based on cholesterol levels and the physician's decision."
223644905|NCT05606445|BEHAVIORAL|Elbow movement|The behavioral paradigm consist of a passive and active movement condition. Both conditions consist of arm movements along the entire range of motion by moving the distal segment of the arm towards the proximal segment and back under varying conditions. In the 'passive' condition, this arm movement will be performed by researcher at 3 different velocities in sinusoidal (continuous) and linear (non-continuous) fashions whereas in the 'active' condition, the participant will be instructed to move the arm in one velocity under internal and external focus of attention.
223644906|NCT03913520|OTHER|Outcome research|patients will undergo an evaluation of their outcome at 30 days postoperatively
223644907|NCT03218046|BEHAVIORAL|EMDR|Eye Movement Desensitisation and Reprocessing
223644908|NCT05945342|DRUG|Escitalopram|The US Food and Drug Administration(FDA) has only approved fluoxetine and escitalopram for the treatment of adolescent depression
224231427|NCT01241968|DEVICE|Cardiac Extracorporeal Shockwave Therapy generator (Cardiospec)|Energy Density - 0.09 mJ/mm2
224231428|NCT01241968|DEVICE|Placebo|Placebo
224231429|NCT05075603|DRUG|Efineptakin alfa|NT-I7 is administered via an intramuscular injection after CAR-T infusion on Day 21.
224231430|NCT05075603|DRUG|Tisagenlecleucel|Administered as standard of care as described in the package insert on Day 0.
224231431|NCT05075603|DRUG|Axicabtagene ciloleucel|Administered as standard of care as described in the package insert on Day 0.
224231432|NCT05075603|DRUG|Lisocabtagene Maraleucel|Administered as standard of care as described in the package insert on Day 0.
224231433|NCT06436196|DEVICE|Video Laryngoscope|Use of Video laryngoscope to secure airway
224231434|NCT06436196|DEVICE|Direct laryngoscope|Macintosh or Miller's laryngoscopes used to secure paediatric airways
223644909|NCT05945342|OTHER|Interpersonal Psychotherapy for Adolescent|Interpersonal Psychotherapy for Adolescent(IPT-A), A modified version of interpersonal psychotherapy, is shorter than the standard therapy duration (12-16 sessions), with a total of eight sessions, retaining the structure of the standard IPT but employing a series of strategies to extract the most important components to speed up the time process.
223644910|NCT05945342|OTHER|Escitalopram combined with psychotherapy|The subjects received adolescent interpersonal psychotherapy for adolescent(IPT-A) while taking medication
223644911|NCT05945342|OTHER|Escitalopram combined with rTMS|The subjects received Robotic navigational repetitive transcranial magnetic stimulation while taking medication
223644912|NCT05945342|DRUG|Escitalopram combined with sham rTMS|The subjects received sham Robotic navigational repetitive transcranial magnetic stimulation while taking medication
223644913|NCT06127849|DIETARY_SUPPLEMENT|Resistance Training + Placebo (Capsule) + Placebo (Sachet)|"* Placebo sachet of 20 gms dissolved in 200-300 ml water. One sachet to be taken in the Morning and one in the evening.~* One Placebo capsule to be taken 30 minutes after sachet in the morning."
223644914|NCT06127849|DIETARY_SUPPLEMENT|Resistance Training + Whey protein (40 gms) + Placebo (Capsule)|"A sachet of 20 gms of Whey protein isolate (WPI) dissolved in 200-300 ml water. One sachet to be taken in the Morning and one in the evening.~\- One Placebo capsule to be taken 30 minutes after whey protein in the morning"
223644915|NCT06127849|DIETARY_SUPPLEMENT|Resistance Training + Whey protein (40 gms) + EB-PA (500 mg)|"* A sachet of 20 gms of Whey protein isolate (WPI) dissolved in 200-300 ml water. One sachet to be taken in the Morning and one in the evening.~* One capsule of EB-PA to be taken 30 minutes after whey protein in the morning"
223644916|NCT05060367|DIETARY_SUPPLEMENT|Liposomal multivitamin/mineral|Two-capsule dose of liposomal multivitamin/mineral that is nutrient-matched to the standard multivitamin/mineral.
223644917|NCT05060367|DIETARY_SUPPLEMENT|Standard multivitamin/mineral|Two-capsule dose of standard multivitamin/mineral that is nutrient-matched to the liposomal multivitamin/mineral.
223644918|NCT04295278|DIAGNOSTIC_TEST|MicroKine Dx system|Biomarker concentrations will be determined using the MicroKine Dx system and results will be compared to measurements taken using standard immunoassays.
223644919|NCT06064214|PROCEDURE|u/s guided intermediate cervical plexus block|The patient will be placed in supine position,u/s probe is placed on the lateral neck, overlying the sternomastoid muscle at the level of its midpoint , Once the SCM has been identified, the transducer is moved posteriorly until the tapering posterior edge is positioned in the middle of the screen.cervical plexus is visible as a small collection of hypoechoic nodules ( immediately superficial to the prevertebral fascia the needle is passed through the skin, platysma, and investing layer of the deep cervical fascia, and the tip is placed adjacent to the plexus,bupivicaine 0.25% (5-15 mL) is administered to envelop the plexus
223644920|NCT00290316|PROCEDURE|Endoscopy ultrasound|
223644921|NCT02454088|OTHER|Calcium Hydroxylapatite and Triamcinolone acetate|Combination Therapy Triamcinolone acetate and Calcium Hydroxylapatite
223644922|NCT02454088|DEVICE|Calcium Hydroxylapatite and Placebo|Calcium Hydroxylapatite and Placebo
223644923|NCT04916691|PROCEDURE|EPSB for rib fractures|EPSB for rib fractures
223644924|NCT04916691|DRUG|Ropivacaine|Standard of care weight-based optimal Ropivacaine dosing for ESPB
223644925|NCT05855811|DRUG|Dostarlimab|Dostarlimab should initiated within 6 months after the end of treatment for FPC.
223644926|NCT01584375|OTHER|Flat midline head position|"Infant's chin will be kept at a 90±5 degree angle to the bed (the chin and nose being in line with the sternum) throughout the first 168 hours of life.~\--------------------------------------------------------------------------------"
224231435|NCT01906541|GENETIC|ex-vivo gene-therapy|transplantation autologous CD34+ cells, transduced with a SIN gammaretroviral vector
224231436|NCT00520741|DRUG|Lacosamide|50 mg and 100 mg tablets provided for 200 mg twice daily dosing for up to 20 weeks.
223644927|NCT01584375|OTHER|Right flat lateral head position|Infant's head will be tilted 85-90 degrees to right side (approximately the entire chin beyond the right nipple line) throughout the first 168 hours of life.
224231437|NCT00520741|DRUG|Lacosamide|50 mg and 100 mg tablets provided for 150 mg twice daily dosing for up to 20 weeks.
224231438|NCT00359086|DRUG|MGCD0103|MGCD0103 given orally three times per week
224231439|NCT03679741|DEVICE|CONTROL Lens|Acuvue OASYS
224231440|NCT03679741|DEVICE|TEST Lens|senofilcon A
224231441|NCT00348010|DRUG|Tramadol HCl ER|
224231442|NCT01117610|DRUG|Placebo (one of medication)|patients in Group C will receive none of medication preoperatively and intraoperatively
224231443|NCT01117610|DRUG|Ropivacaine (epidural injection)|patient in group I will receive epidural injection of 0.1% ropivacaine 10ml before skin incision.
224231444|NCT03935269|DEVICE|Cereset Research Wearable|CRW is a stress-relaxation device where participants listen to sounds that help to balance brain rhythms. Participants will be asked to come to an office for 5 days over 1-2 weeks, on your their schedule. Sessions will take approximately one (1) hour to complete.
224231445|NCT03935269|PROCEDURE|Stress management therapy|Undergo Cereset research office intervention
224231446|NCT03935269|OTHER|Questionnaire administration|Ancillary studies
224231447|NCT03935269|OTHER|Quality of Life Assessment|Ancillary studies
224231448|NCT05380635|DRUG|Hypericin|HyBryte is synthetic hypericin formulated as a 0.25% hypericin ointment.
224323452|NCT04590326|DRUG|REGN5668|Administer per the protocol
224323453|NCT04590326|DRUG|Cemiplimab|Administer per the protocol
224323454|NCT04590326|DRUG|Ubamatamab|Administer per the protocol
224231449|NCT01913990|DRUG|Dexamethasone, Ondansetron, Aprepitant|Arm B participants will be given doses of anti-emetics based on the emesis risk calculation. Doses will vary depending on the which level they fall into level 0, level 1, 2 or 3 based on the participant's diary.
224231450|NCT01913990|OTHER|Arm A: Standard Anti-emetic regimen|Treating physician's discretion for type of anti-emetic to be prescribed.
224231451|NCT05111821|PROCEDURE|Magnetic Resonance Imaging (MRI)|Quantification of iron will be performed through Magnetic Resonance Imaging
224319790|NCT00707382|OTHER|(2) Intense clinical monitoring|In this study arm (2) the genotype information is not revealed. The intervention consists of an intensified clinical monitoring of treatment effect, side effects and patient perspective. Staffpersonnel is trained in the use of a clinical manual that builds on a selection of validated questions from the Scale for the Assessment of Positive Symptoms (SAPS), Side effect score (Udvalg af Kliniske Undersøgelser (UKU) and Rating of Medical Influences (ROMI). The manual has to be used at least once in a quarter (every third month), which is monitored by the study personnel. Data registered by the patients primary contact person are not used as outcome measures in the study but only as intervention tool for the optimisation of the medical antipsychotic treatment.
224319791|NCT00707382|OTHER|(3) Control|In this studyarm (3), (Control) treatment followed usual local practice. The genotype information was not revealed.
224231452|NCT05111821|DRUG|Deferiprone treatment|Patients receiving Deferiprone during 6 months. Oral deferiprone for 6 months at a dose of 30 mg/kg/d
224231453|NCT04910490|OTHER|No interventions - retrospective data collection|No new/additional patients will be enrolled within this project.
224231454|NCT04858100|PROCEDURE|Surgical excision of the lesion|"The surgical removal of the lesion, performed within 3 months from the final diagnosis, will follow these steps:~* local anesthesia~* excision of the lesion with surgical blade or laser, according to the clinical case, paying attention to having at least 2 mm-free margins~* silk or resorbable suture for wound closure~The patient will be recall after 14 days for assessing the wound healing and after 30 days for providing and explaining him the histopahtological exam.~The patient will receive a 3-6 month follow-up according to the clinical and histopathological case."
224319792|NCT03052127|DRUG|Light-activated AU-011|Study treatment
224319793|NCT03052127|DEVICE|Laser Activation|Study treatment
224323455|NCT04590326|DRUG|Sarilumab|Administer per the protocol
224323456|NCT04590326|DRUG|Cemiplimab + Fianlimab [Fixed Dose Combination (FDC)]|Administer per the protocol
224323457|NCT06496178|DRUG|Petosemtamab|MCLA-158
224323458|NCT06496178|DRUG|Investigator's Choice|Cetuximab
224323459|NCT06496178|DRUG|Investigator's Choice|Methotrexate
224323460|NCT06496178|DRUG|Investigator's Choice|Docetaxel
223644928|NCT00780312|OTHER|physiotherapy|50 patients in this group get the existing hospital treatment: A 10 minute instruction in mouth opening exercises by a nurse. Furthermore they receive in all 6-7 sessions of physiotherapy treatment for a 5-6 weeks period with sessions of approximately 45 minutes. 2 months after having completed radiotherapy treatment they receive a final physiotherapy treatment. The treatment consists of instruction in active and passive exercises for mouth opening, stretching exercises for the neck and shoulder region, tongue exercises, mimic exercises, self administered lymph drainage and softening of fibrotic tissue.
223644929|NCT00506363|PROCEDURE|pulsed dye laser therapy|Each scar will be divided into 3 equal parts. One part will be randomly allocated to be treated with pulsed dye laser and dynamic cooling device on the day of suture removal. Another part will be treated with pulsed dye laser and dynamic cooling device 2 months after suture removal. Only dynamic cooling device will be used for remaining part serving as control. Treatment will repeat for 6 sessions at 3 weeks intervals.
223644930|NCT03328091|OTHER|Traditional pre-test genetic counseling|Participant meets with a genetic counselor at the Center for Cancer Genetics and Prevention and traditional pre-test cancer genetic counseling is provided
223644931|NCT03328091|OTHER|Pre-test video education|The video is designed to mirror the educational components of a traditional genetic counseling visit
223644932|NCT02579304|PROCEDURE|transbronchial lung cryobiopsy|bronchoscopic sampling
223644933|NCT01929746|BIOLOGICAL|BIIB019 subcutaneous injection|participants will be randomized to receive a single subcutaneous injection of BIIB019, 75 mg or 150 mg per dose group
223644934|NCT00589199|PROCEDURE|Placement and use of the device|Surface electrodes currently used for peripheral muscle stimulation by other groups will be applied to the abdominal wall and over the posterior lower thoracic rib cage. Between two and three pairs (anodic and cathodic) of electrodes will be used in combination to activate the expiratory muscles. Electrodes will be positioned at various points over the abdominal wall and the posterior thoracic rib cage to ascertain optimal placement for airway pressure and expiratory airflow generation. The electrical stimulators to be used (EMPI and NeuroMedic) are powered by 9-volt batteries. These stimulators are currently in clinical use to stimulate other skeletal muscles and are known to be quite safe.
223644935|NCT01412684|PROCEDURE|Distal pancreatectomy with partial splenectomy|Distal pancreatectomy with partial splenectomy
223644936|NCT06214273|DEVICE|Low level diode laser|diode laser with a wave length range of 800-980 n m and power less than 500 ml
223644937|NCT06214273|DRUG|Chamomile|Chamomile 3% mucoadhesive gel
223644938|NCT06214273|DRUG|Ibuprofen analgesic and anti-inflammatory oral gel and miconazole anti fungal oral gel|Topical anti-inflammatory, topical analgesic and topical antifungal
223644939|NCT06286488|DRUG|Vaxigrip|Evaluation of immunogenicity and tolerance of quadrivalent influenza vaccine in groups at risk of severe influenza, including obese adults, as well as in pregnant women (with assesment of antibodies in cord blood).
223644940|NCT01119378|OTHER|Dual isotope technique|Dual isotope technique using stable isotopes
223644941|NCT04085289|DRUG|Galcanezumab|Administered SC
223644942|NCT04085289|DRUG|Placebo|Administered SC
223644943|NCT02097264|DRUG|NNC0109-0012|Solution for injection administered subcutaneously (s.c. - under the skin). 240 mg NNC0109-0012 will be administered weekly for 12 weeks
223644944|NCT02097264|DRUG|Adalimumab|Solution for injection administered subcutaneously (s.c. - under the skin). Administered every other week for 12 weeks; Each active treatment involves 1 (one) s.c. injection of adalimumab 40 mg/0,8 mL solution for injection for paediatric use (Humira®)
224323461|NCT06303193|DRUG|pacritinib|Pacritinib will be administered orally on a continuous basis for 28 day cycles without a rest period between cycles. Dose assigned by dose level/phase.
224231455|NCT04858100|OTHER|Wait and see approach|"The patient will receive a 3-6 month follow-up according to the clinical and histopathological case, with periodical incisional biopsy every 4 control visit.~In case of OSCC onset during the first 3 months after the final diagnosis, the patient will be excluded since the oral cancer occurence will be considered as a misdiagnosis, more than a true malignat progression."
224319794|NCT06550973|PROCEDURE|pre-cut biliary sphincterotomy/fistulotomy, double guide wire (DGW) technique|Rescue techniques, such as pre-cut biliary sphincterotomy/fistulotomy, double guide wire (DGW) technique, wire-guided cannulation over a pancreatic stent and transpancreatic biliary sphincterotomy, will be used at the discretion of the endoscopist \[12\]. After deep cannulation, a cholangiogram to better define the characteristics of the stenosis will be done. The stent will then be inserted over a guidewire and deployed across the stenosis. All stents will be fully covered SEMSs or partially covered SEMSs of 10 mm diameter. The length of the stent will be chosen at the discretion of the endoscopist performing the procedure. A prophylactic pancreatic stent will be placed in patients who will be thought to be at high risk of post-procedure pancreatitis at the discretion of the treating endoscopist.
224319795|NCT05451992|DIETARY_SUPPLEMENT|Placebo|The group will have to consume a jar every day (approx. 75 ml) which contain (water, malt-dextrins, 0.1% starch, 0.1% guar gum, flavorings and colorants)
224319796|NCT05451992|DIETARY_SUPPLEMENT|SuperFood|The group will have to consume a jar of superfood (vegetable smoothie) every day. The jar will be filled with approx. 75 ml which corresponds to about 75 g. The superfood formulated by the University of Bolzano on the basis of the results and evidence acquired in collaboration with the Istituto Superiore di Sanità. Composition: pomegranate, walnuts, moringa, broccoli, according to the proportions indicated in Annex 2. This mixture has been analyzed by an external laboratory and authorized for human use
224319797|NCT01118286|DRUG|Nifedipine (Adalat, BAYA1040)|Previously untreated hypertensive adult patients starting with combination therapy containing nifedipine or insufficiently controlled hypertensive patients receiving nifedipine as an add-on to existing non-CCB containing antihypertensive therapy. The decision of including the patient as well as decision on dosage and duration is taken by the investigator.
223644945|NCT02097264|DRUG|placebo|"Solution for injection administered subcutaneously (s.c. - under the skin).~1 active adalimumab injection and 2 placebo injections per active treatment (every other week), and 3 placebo injections on placebo visits (alternative weeks)."
223644946|NCT03848026|OTHER|Middle ear fluid viscosity|The patients were subdivided into two groups according to median viscosity level
224319798|NCT04549103|OTHER|Baduanjin exercise program|Baduanjin (BDJ), also known as Eight-Section Brocades, is one of the forms of traditional Chinese Qigong exercises, characterized by symmetrical physical posture, movements, mindfulness, and breathing. Its primary focus is on the release of 'Qi' or internal body energy with the intent of improving health outcomes. BDJ encompasses eight simple movements involving combinations of postures, meditation, slow relaxing movements, and breathing exercises. It is a low intensity exercise, which have been found to improve range of motion, strength and general health. The simplicity and low intensity level is ideal for older adults to practice at home using instructional videos.
223644947|NCT03848026|OTHER|Tympanostomy tube extrusion time|Tympanostomy tube extrusion time of the all patients recorded prospectively.
223644948|NCT01924949|DRUG|LDV/SOF|Ledipasvir (LDV)/sofosbuvir (SOF) 90/400 mg FDC tablet administered orally once daily
223644949|NCT04648397|OTHER|Low glycaemic load, high fibrous product|Test-lunch of 370 grams of chickpeas, seasoned with a herb- and spice mix to increase palatability. Glycaemic load 18.5. Consumed in duplicate.
223644950|NCT04648397|OTHER|High glycaemic load, low fibrous product|Test-lunch of 257 grams of brown rice, seasoned with rice-oil and a herb- and spice mix to increase palatability. Glycaemic load 44.9. Consumed in duplicate.
223644951|NCT05174403|OTHER|Cerebral and spinal cord magnetic resonance imaging|"Cerebral and spinal cord magnetic resonance imaging (without injection of contrast medium).~Patient's data will be compared to calibrated data from the commercially available medical software Brain Quant (licence BT-BQ-001-START, market CAIH, CE12331)."
223644952|NCT03994848|BEHAVIORAL|Spirometry Group|Patients that are provided the incentive spirometer pre-operatively and instructed to use it for 4 cycles of 10 spirometry attempts on the day prior to surgery
223644953|NCT04178603|OTHER|Exercise, insulin infusion|Trial A: Acute one-legged exercise Trial B: Insulin infusion 4 hours after one-legged exercise
224323462|NCT06058377|PROCEDURE|Biospecimen Collection|Undergo optional collection of tissue and/or blood
224323463|NCT06058377|DRUG|Cyclophosphamide|Given IV
224323464|NCT06058377|DRUG|Doxorubicin|Given IV
223644954|NCT06096961|BEHAVIORAL|Baby smell|Mothers in the experimental group will be given baby clothes that their babies will wear for 12 hours and will be asked to smell these clothes during the milking process.
223644955|NCT03292796|DRUG|Prostaglandins|
223644956|NCT05199103|DRUG|rabbit anti-thymocyte globulin|0.8 - 1.0 mg/kg of rATG (cumulative dose of 150-200 mg given intravenously in two or three divided doses, 24 hours apart) after premedication with methylprednisolone i.v. (in total dose of 375 mg), 1 mg of antihistaminic agent clemastine and 1000 mg paracetamol i.v.
223644957|NCT04572789|DIETARY_SUPPLEMENT|Omega-3 polyunsaturated fatty acids|All participants will complete a set of outcome measures at baseline and the follow-up visits before and after 12 weeks of omega-3 PUFAs intervention (EPA, 1.8 g/day) and a series of blood tests for neurotransmitter, neurotrophic and neuroinflammation. The clinical efficacy and the peripheral blood biomarkers, will be analyzed at baseline and the end of the intervention.
223644958|NCT04572789|DIETARY_SUPPLEMENT|omega-6 PUFAs|All participants will complete a set of outcome measures at baseline and the follow-up visits before and after 12 weeks of placebo omega-6 PUFAs intervention and a series of blood tests for neurotransmitter, neurotrophic and neuroinflammation. The clinical efficacy and the peripheral blood biomarkers, will be analyzed at baseline and the end of the intervention.
223644959|NCT00897234|OTHER|Mass Spectrometry|Levels of Cathepsin D (CD) and fatty acid synthase (FAS) will be measured using isobaric tag labeling coupled with mass spectrometry. RNA concentration will be measured using spectrophometer and purity will be analyzed.
224231456|NCT03711409|OTHER|Soft tissue biased manual therapy group|It includes hot pack and muscle release technique of pectoralis major, pectoralis minor, teres major, teres minor, infraspinatus and posterior deltoid muscles. Subjects are supine on the bed. The muscle release technique is applied at the end available range and the acceptable intensity. The time of muscle release intervention is about 30 min and hot-pack about 15 min.
224231457|NCT03711409|OTHER|Conventional physical therapy group|It includes modality (electrotherapy, ultrasound and low-level laser therapy) and GH joint mobilization. GH joint mobilization includes anterior to posterior glide, caudal glide and distraction. The intensity of joint mobilization is grade III to IV. The time of joint mobilization is about 30 min and hot-pack for 15 min.
224231458|NCT00726700|BIOLOGICAL|pegfilgrastim|Given subcutaneously
224231459|NCT00726700|BIOLOGICAL|rituximab|Given IV
224231460|NCT00726700|DRUG|cyclophosphamide|Given IV
224231461|NCT00726700|DRUG|doxorubicin hydrochloride|Given IV
224231462|NCT00726700|DRUG|prednisone|Given orally
224231463|NCT00726700|DRUG|vincristine sulfate|Given IV
224323465|NCT06058377|BIOLOGICAL|Durvalumab|Given IV
223644960|NCT02217202|DEVICE|Aquacel Ag dressing|Participants will have their knee arthroplasty wound dressed using the Aquacel Ag dressing instead of the standard Aquacel dressing.
223644961|NCT00076635|DRUG|Interferon gamma-1b|200 mcg, SQ, 3x per week
223644962|NCT00606606|OTHER|Clinical Decision Support|
223644963|NCT01000792|DRUG|Levocetirizine|The study drug is Xyzal® 5 mg (API: levocetirizine dihydrochloride). 28 film tablets will be dispensed. Oral intake should be performed once daily (administration in the evening).
223644964|NCT01000792|DRUG|Levocetirizine|Levocetirizine
223644965|NCT02722993|DIETARY_SUPPLEMENT|Probiotics|
223644966|NCT02722993|DIETARY_SUPPLEMENT|Placebo|
223644967|NCT02067481|BEHAVIORAL|Weight loss intervention|This single-arm pre-post study, that involved one-hourly weekly diet sessions delivered by a dietician and 75-minute bi-weekly Physical Activity (PA) sessions of moderate-to-high intensity led by PA monitors, was offered to overweight and obese BC survivors shortly after treatment. Before and after the intervention, anthropometry, dietary information, Quality of Life (QoL) and cardiorespiratory fitness (CRF) were collected.
223644968|NCT00455182|PROCEDURE|Acupuncture|Standard medical care plus a single true acupuncture treatment.The needles are strategically inserted into the scalp, trunk, arms or legs (not near the surgical site) and manipulated. The needles are withdrawn between 5 minutes and 30 minutes after insertion.
223644969|NCT00455182|PROCEDURE|Sham Acupuncture|Standard medical care plus sham acupuncture. A single treatment, using a maximum of 9 sham needles, which adhere to the skin but do not penetrate it. The sham needles are strategically placed on the scalp, trunk, arms or legs (not near the surgical site)
223644970|NCT00455182|PROCEDURE|Standard medical care|Standard medical care at Woodwinds Hospital includes guided imagery, essential oils and massage.
223644971|NCT06441240|DIAGNOSTIC_TEST|MRI|Breast MRI
223644972|NCT01531569|OTHER|BeneFlax - 38% secoisolariciresinol diglucoside (SDG)|0.8g of BeneFlax (contains 300mg SDG) given once by mouth
223644973|NCT02694016|PROCEDURE|Remote ischemic preconditioning|A blood pressure cuff is placed around the right leg on the level of the thigh. Randomization is performed after this, using sealed envelopes with covariate balancing for age and sex. Regardless of the outcome of the randomization the cuff is left in place so as not to give any indication of which group the patient belongs to. If the patient is randomized into the remote ischemic preconditioning group (RIPC) then four (4) cycles of five (5) minute inflation are given after induction. Each cycle is followed by a five (5) minute interval of reperfusion. Cuff pressure should be 200mgHg at least (RRsyt + 100mmgHg) during the inflation periods.
223644974|NCT01666041|DRUG|placebo|
223644975|NCT01666041|DRUG|fenofibrate/omega|
224231464|NCT04332978|DRUG|Fluticasone Propionate|
224231465|NCT04596956|DRUG|sodium bicarbonate Ringer injection|Used in surgery
224231466|NCT04596956|DRUG|Lactated Ringer's solution|Used in surgery
223644976|NCT01666041|DRUG|fenofibrate|
223644977|NCT03033095|DRUG|Etanercept ® 50 mg|The etanercept is not the experimental study drug. Etanercept is a treatment justifying the inclusion of patients and is used in accordance with its marketing authorization.
224231467|NCT01079637|PROCEDURE|Surgery with Midfoot Fusion Bolt|Surgery with Midfoot Fusion Bolt
224231468|NCT01079637|PROCEDURE|Cast treatment|Cast treatment
224231469|NCT03235778|DRUG|Felbinac Trometamol Injection|Felbinac Trometamol Injection will be infused IV as a single dose in 100 mL normal saline,in a 30-minute period using a programmable pump
223644978|NCT03674853|DRUG|Wuling Capsule|take Wuling Capsule in experiment group for 2 months
223644979|NCT03674853|DRUG|Oryzanol|take oryzanol in active comparator group for 2 months
223644980|NCT02919995|DRUG|RPL554|RPL554 suspension administered using a nebuliser
223644981|NCT02919995|DRUG|Placebo|Placebo solution administered using a nebuliser
223644982|NCT03066947|BIOLOGICAL|SV-BR-1-GM|See above
223644983|NCT03066947|DRUG|Cyclophosphamide|Low dose pre-treatment to reduce regulatory T cells
223644984|NCT03066947|BIOLOGICAL|Interferon-alpha-2b|Low dose given in the vaccine site to boost the immune response
224231470|NCT03235778|DRUG|Placebo|Normal saline will be infused IV as a single dose in 100 mL normal saline,in a 30-minute period using a programmable pump
224231471|NCT02750761|DRUG|Tedizolid Phosphate (IV)|200 mg/vial powder for injection
224231472|NCT02750761|DRUG|Tedizolid Phosphate (oral suspension)|Powder for oral suspension 20 mg/mL following reconstitution
224231473|NCT02715947|DRUG|Methotrexate|During The first week: 7.5mg per week, oral; The second and third weeks: 10mg per week, oral; The fourth and fifth weeks: 12.5mg per week,oral; The sixth week:15mg per week, and maintain this dose, oral.
224231474|NCT01451853|DRUG|SPI-1005 Low Dose|"Oral capsules, 200 mg ebselen, twice daily, 3 days for each cycle of chemotherapy~Arms: Low Dose~Other Names:~200 mg Ebselen"
224231475|NCT01451853|DRUG|SPI-1005 Middle Dose|Oral capsules, 400 mg ebselen, twice daily, 3 days for each cycle of chemotherapy
224231476|NCT01451853|DRUG|SPI-1005 High Dose|Oral capsules, 600 mg ebselen, twice daily, 3 days for each cycle of chemotherapy
224231477|NCT01451853|DRUG|Placebo|Oral capsules, 0 mg ebselen, twice daily, 3 days for each cycle of chemotherapy
224231478|NCT04834245|PROCEDURE|Hydrogel/nano silver-based dressing|compare the effectiveness of using hydrogel/nano silver-based dressing vs. traditional dressing on diabetic foot wound healing.
224231479|NCT02842697|PROCEDURE|HVPG measurement|HVPG obtained by means of catheterization of a hepatic vein with a balloon catheter
224323466|NCT06058377|OTHER|Genetic Testing|Undergo MammaPrint testing
224323467|NCT06058377|PROCEDURE|Mammography|Undergo mammography
223644985|NCT02717923|OTHER|maintenance treatment with capecitabine plus cetuximab|Using a maintenance treatment strategy of capecitabine plus cetuximab as a treatment option in mCRC after first-line 5-FU-based chemotherapy plus cetuximab
223644986|NCT00002127|DRUG|Thalidomide|
223644987|NCT01364844|DRUG|DS-7423|oral capsule 1mg, 8mg, 48mg, and 80mg strengths administered once daily
223644988|NCT04568616|DRUG|Letrozole 2.5mg|Aromatase Inhibitor
223644989|NCT03212781|DRUG|Iron dextran|total dose infusion
223644990|NCT03212781|DRUG|Ferrous Fumarate|oral tablets
223644991|NCT00445913|BIOLOGICAL|Diabetes-suppressive dendritic cell vaccine|The dendritic cells will be treated ex vivo with the antisense oligonucleotides and cryopreserved in aliquots for subsequent intradermal administration into sites closest to the physical location of the pancreas inside the body. Physiologic, biologic and immunologic responses to the dendritic cell vaccine will be evaluated over the period of the trial. The first group of volunteers will receive autologous dendritic cells without any ex vivo treatment (7/15) and the second group will be administered iDC (8/15). If there is no evidence of toxicity or adverse events associated with the dendritic cell vaccine, and only upon FDA and IRB approval we will initiate a new study comparing efficacy of control DC and iDC in improving glycemia and reversing autoimmunity in new-onset patients.
223644992|NCT00445913|BIOLOGICAL|control dendritic cells|The dendritic cells will be treated ex vivo with vehicle and cryopreserved in aliquots for subsequent intradermal administration into sites closest to the physical location of the pancreas inside the body. Physiologic, biologic and immunologic responses to these control dendritic cells will be evaluated over the period of the trial. The first group of volunteers will receive autologous dendritic cells without any ex vivo treatment (7/15) and the second group will be administered iDC (8/15). If there is no evidence of toxicity or adverse events associated with the dendritic cell vaccine, and only upon FDA and IRB approval we will initiate a new study comparing efficacy of control DC and iDC in improving glycemia and reversing autoimmunity in new-onset patients.
223644993|NCT04663009|DEVICE|AutoPulse|A band circumflex of the chest that provide chest cage compressions.
223644994|NCT02560558|DRUG|Belatacept|Belatacept is an immunosuppressive medication and will be given as an intravenous infusion at a dose of 5 mg/kg at 4-weekly or 8-weekly intervals.
223644995|NCT01540552|OTHER|medical chart review|
223644996|NCT01540552|PROCEDURE|computed tomography|
223765850|NCT03508219|DEVICE|BiOSS LIM C|"The BiOSS LIM C (Bifurcation Optimization Stent System, Balton, Warsaw, Poland). The BiOSS LIM C is a dedicated bifurcation stent covered with a mixture of a biodegradable polymer and the antiproliferative substance sirolimus. BiOSS LIM C will be used for treatment of the Left-Main bifurcation, according to its instructions for use.~The Alex-Plus cobaltchromium sirolimus eluting stent (Balton, Warsaw, Poland) will be used for treatment of distal left-main side branches according to its instructions for use (i.e. proximal segments of the left anterior descending and left circumflex arteries as well as the ramus intermedius if the latter vessel is part of a trifurcation).~All other lesions (other than left-main bifurcations) will be treated with XIENCE family everolimus-eluting coronary stent systems."
223765851|NCT06310707|DEVICE|ePatch ® Extended Wear Holter (EWH)|"Diagnostic Test: Extended ECG investigation~• An ambulatory ECG recordings with a duration of 7 days using Philips ePatch (https://www.myheartmonitor.com/device/epatch/) will be applied"
223765852|NCT04563884|OTHER|Questionnaires|"Children 12 months to 5 years old will receive PEACH alone, children 5 years old to 11 years old will receive PEACH and SSQ-P, and children and adolescents over 11 years old will receive SSQ-P and SSQ-C (even between 11 and 13 years old, the PEACH also).~Questionnaires will be completed twice, 15 days apart."
223765853|NCT04694196|DEVICE|Dentulous subjects|Determine the occlusal plane using CN in anterior border of ramus
223644997|NCT01540552|PROCEDURE|computer-aided detection/diagnosis|
223644998|NCT02245217|DEVICE|PET/CT scan to assess treatment efficacy|
223644999|NCT00176917|PROCEDURE|Stem Cell Transplant|The purpose of hematopoietic cell transplantation is to introduce hematopoietic cells from a normal donor that contains the enzyme able to get rid of the substances that have accumulated in the body of patients with storage diseases. Hematopoietic cells can come from bone marrow, peripheral blood (i.e., the blood circulating in our body's blood vessels) or umbilical cord blood (i.e. blood taken from the umbilical cord after a baby is born and umbilical cord is cut).
223645000|NCT00176917|DRUG|Busulfan, Cyclophosphamide, ATG|"Prior to transplantation, subjects will receive BUSULFAN intravenously (IV) via the Hickman line twice daily for 4 days, CYCLOPHOSPHAMIDE intravenously via the Hickman line once a day for 4 days, and ANTI-THYMOCYTE GLOBULIN IV via the Hickman line twice daily for three days before the transplant. These three drugs are being given to help the new marrow take and grow. METHYLPREDNISOLONE will be given as a pre-medication for the ATG."
223645001|NCT00533117|DRUG|Fluoxetine|Fluoxetine is administered in standard dosing 20, 40, 60, 80 mg increased monthly if tolerated
223645002|NCT00533117|BEHAVIORAL|Dialectical Behavior Therapy|Dialectical Behavior Therapy is a form of CBT originally developed to treat suicidal and self injuring individuals with borderline personality disorder. Treatment consists of 2 sessions/week: individual psychotherapy and skills training group.
223645003|NCT00533117|BEHAVIORAL|Supportive psychotherapy|Supportive therapy is a manualized form of psychotherapy designed to enhance individual's strengths and coping mechanisms while reducing distress.
223765854|NCT05480566|OTHER|Functional strength training|Functional strength training will include lower limb (e.g. rising from chair, heel rises) and upper limb (e.g. push-ups from the chair and against the wall) exercises for 15 min/day. Target levels of dyspnoea and/or perceived exertion will be 4 to 6 in the modified Borg scale.
223765855|NCT05480566|DEVICE|NMES|For neuromuscular electrical stimulation, electrodes will be placed longitudinally on the vastus intermedius and vastus medialis and a symmetric biphasic pulse waveform, with a pulse duration of 400ms, a frequency of 50Hz, in cycles of 8s of contraction and 20s of rest, will be used for 30min/day. The highest intensity tolerated by the patient will be used and intensity will be increased every time the patient feels comfortable with increasing the intensity. The device Compex Pro Rehab (CE-0473) will be used.
223645004|NCT02910479|DEVICE|E-Celsius thermometer|comparison of temperature between e-celsius and thermometer, rectal thermometer, esophageal thermometer, vital sense capsule thermometer
223645005|NCT02910479|DEVICE|Rectal thermometer|
223645006|NCT02910479|DEVICE|Esophageal thermometer|
223645007|NCT02910479|DEVICE|Vital sense capsule thermometer|
224231480|NCT02842697|PROCEDURE|CTA|Three-dimensional hepatic vein-portal vein model constructed with CTA images
224231481|NCT02842697|PROCEDURE|Doppler ultrasound|Portal vein velocity measured by Doppler ultrasound
224231482|NCT06101654|DEVICE|Pulse oximeter|Devices (4) were placed on the finger and the fingertip of both index fingers. Blood samples were taken at each stable level of oxygenation.
224231483|NCT06496763|DEVICE|Vision-700|OCT machines used for diagnostic purposes
224231484|NCT05875818|DIAGNOSTIC_TEST|In-clinic Rehabilitation|Effects of In-clinic Rehabilitation for Upper Limb Motor Function in Chronic Stroke Patients
224231485|NCT05875818|DIAGNOSTIC_TEST|Tele-rehabilitation|Effects of Tele-rehabilitation for Upper Limb Motor Function in Chronic Stroke Patients
224231486|NCT05832463|DIETARY_SUPPLEMENT|Carbohydrate blocking supplement (CBS)|"The CBS is composed of a Hypromellose outer shell, and filled with mulberry leaf extract, berberine HCl, cinnamon bark powder, and cinnamon bark essential oil.~Mulberry leaf extract (Reducose) - 250 mg Berberine HCl (97%)(Berberis aristata root extract)- 25 mg Organic cinnamon powder (Cinnamon (Cinnamomum loureirii) bark powder) - 20 mg Essential oil blend (Grapefruit (Citrus paradisii) peel oil, Lemon (Citrus limon) peel oil Peppermint (Mentha piperita) aerial (leaf/stem) oil), Ginger (Zingiber officinale) root oil, Cinnamon (Cinnamomum zeylanicum) bark oil) - 5 mg"
224231487|NCT05832463|DIETARY_SUPPLEMENT|Placebo capsule|The placebo is composed of a Hypromellose outer shell filled with extra virgin olive oil.
224231488|NCT01860976|DRUG|Abatacept|
224231489|NCT01860976|DRUG|Placebo|
224231490|NCT06269276|BEHAVIORAL|Caregiver Contribution to Self-Care in Ostomy Patient Index|This study was conducted to evaluate the Turkish validity and reliability of the Caregiver Contribution to Self-Care in Ostomy Patient Index, to evaluate the relatives of patients with stoma who contribute to their self-care in Turkish society, and to contribute to the nursing literature of the measurement tool.
224231491|NCT02227862|DRUG|Mylan's insulin glargine|All patients will be shifted from their current mealtime insulin to insulin lispro at the start of the run-in period, and will continue on this for the complete trial. During the 6 week run-in period the doses of Lantus® and insulin lispro will be titrated (if required) to ensure diabetes control. After the run-in period, patients will be randomized to receive either Mylan's insulin glargine (in place of Lantus®), or to continue on Lantus®. During the period from 12 to 24 weeks dose titration will be kept to a minimum.
224231492|NCT02227862|DRUG|Lantus®|All patients will be shifted from their current mealtime insulin to insulin lispro at the start of the run-in period; and will continue on this for the complete trial. During the 6week run-in period the doses of Lantus® and insulin lispro will be titrated (if required) to ensure diabetes control. After the run-in period, patients will be randomized to receive either Mylan's insulin glargine (in place of Lantus®), or to continue on Lantus®. During the period from 12 to 24 weeks dose titration will be kept to a minimum.
224231493|NCT06220292|BEHAVIORAL|Conventional Care|"Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training.~Pulmonary function training, including standing training, cough training, and diaphragm muscle training."
224231494|NCT06220292|DEVICE|Intermittent Oral-esophageal Tube Feeding|The observation group was given enteral nutritional support with Intermittent Oro-esophageal Tube according to the following procedure: Before each feeding, inside and outside of the tube was cleaned with water. During feeding, the patient should maintain a semi-reclining or sitting position with mouth opened, and the tube was inserted slowly and smoothly into the upper part of the esophagus by medical staffs while the appropriate depth of intubation was checked with the calibration markings on the tube wall. The distance from the incisors to the head part of the tube should be between 22-25 cm. However, the specific depth should be evaluated based on patients' feedback and adjusted accordingly. After insertion, the tail part of the tube should be put into a container full of water and the absence of continuous bubbles indicated a successful intubation. Then, the feeding was to be conducted three times per day with 50 ml per minute and 400-600ml for each feeding.
224323468|NCT06058377|DRUG|Paclitaxel|Given IV
224323469|NCT06058377|OTHER|Quality-of-Life Assessment|Ancillary studies
224323470|NCT06392711|BIOLOGICAL|Mesenchymal Stromal Cells (MSC) Dose Level 0|10 (8-12) x 10\^6 MSCs
223645008|NCT02037399|DRUG|intravenous dexamethasone|"Patients were enrolled in outpatient settings after evaluating appropriate ESD indications. A single study coordinator performed a randomization process by using a table of random numbers. The patients were allocated to receive intravenous dexamethasone (0.15 mg/kg) immediately after ESD. The patients with an odd number were assigned into DEXA group, and the patients with an even number were assigned into placebo group. The syringe including dexamethasone was completely covered with a paper sticker to mask treatment assignment. The operator and assisting nurse were also blinded to the study.~At the day and next day of ESD, intravenous proton pump inhibitor was routinely administered to prevent complications including bleeding. At 3rd day of ESD, all patients started to take 40mg oral lansoprazole once a day and sucralfate suspension 3 times a day for 28 days."
223645009|NCT02037399|DRUG|intravenous normal saline|"Patients were enrolled in outpatient settings after evaluating appropriate ESD indications. A single study coordinator performed a randomization process by using a table of random numbers. The patients were allocated to receive intravenous normal saline as placebo immediately after ESD. The patients with an odd number were assigned into DEXA group, and the patients with an even number were assigned into placebo group. The syringe including placebo was completely covered with a paper sticker to mask treatment assignment. The operator and assisting nurse were also blinded to the study.~At the day and next day of ESD, intravenous proton pump inhibitor was routinely administered to prevent complications including bleeding. At 3rd day of ESD, all patients started to take 40mg oral lansoprazole once a day and sucralfate suspension 3 times a day for 28 days."
223645010|NCT05445791|DRUG|Metformin Hydrochloride|Metformin 500 mg twice daily until disease progression.
223645011|NCT05445791|OTHER|Placebo|Placebo 500 mg twice daily until disease progression
223645012|NCT02837770|DRUG|Diclofenac Eye Drops|One drop of Diclofenac 0.1% will be instilled 45' prior to the IVI.
223645013|NCT02837770|DRUG|Pacebo pill|Pacebo pill will be administered 4 hours before the IVI.
223645014|NCT02837770|DRUG|Oral Diclofenac|One Diclofenac Sodium sustained-release 75mg tablet administered per os 4 hours prior to the IVI.
223645015|NCT02837770|DRUG|Diclofenac Eye Drops|One drop of Diclofenac 0.1% will be instilled 45' prior to the IVI.
224319799|NCT01396915|DIETARY_SUPPLEMENT|Dietary Protein Intake|Dietary Protein Intake This is a 12-week randomized,prospective study incorporating a dietary intervention in which subjects will consume either higher protein(HP:1.4g protein•kg-1•d-1) or normal protein diet (NP:.8g protein•kg-1•d-1)
224319800|NCT01166165|DRUG|Cholecalciferol|3 tablets of 1000 IU daily for 20 weeks
224319801|NCT01166165|DRUG|Placebo|3 placebo tablets daily for 20 weeks
224319802|NCT03694327|DEVICE|CT-101-M|Mobile Application
223645016|NCT02837770|DRUG|Pacebo pill|Pacebo pill will be administered 4 hours before the IVI.
223645017|NCT02837770|DRUG|Artificial Tears|One drop Artificial Tears will be instilled 45' prior to the IVI.
223645018|NCT03109496|OTHER|Collection of body fluids/swabs|Middle ear, ear duct, anterior nare, nasopharynx, adenoids. Niches depend on accessibility for each individual participant.
223645019|NCT02454517|BEHAVIORAL|Behavioral Dietary Intervention|Undergo DPP lifestyle intervention
223645020|NCT02454517|BEHAVIORAL|Exercise Intervention|Undergo DPP lifestyle intervention
223645021|NCT02454517|OTHER|Informational Intervention|Receive oral and written guidelines and meet with dietician
223645022|NCT02454517|OTHER|Laboratory Biomarker Analysis|Correlative studies
223645023|NCT02454517|OTHER|Quality-of-Life Assessment|Ancillary studies
223645024|NCT02454517|OTHER|Questionnaire Administration|Ancillary studies
223645025|NCT04641182|OTHER|Prone position|Prone position as indicated by the treating physician as specified in the institutional protocol
223645026|NCT00809952|PROCEDURE|recombinant FSH|
223645027|NCT06232824|BEHAVIORAL|Tele-rehabilitation|The whole program is constituted of preoperative education and postoperative rehabilitation (in hospital and out of hospital). All the participants received the same preoperative education through the mobile phone application and oral communication. Participants in the intervention group get the multicomponent supervised tele-rehabilitation, while participants in the control group get the home-based self-rehabilitation. All the postoperative rehabilitation programs are presented and executed through the mobile phone application.
223645028|NCT00473382|DRUG|Ranibizumab|Sterile solution for intravitreal injection.
223645029|NCT00473382|DRUG|Sham injection|
223645030|NCT03849508|DRUG|Norepinephrine|"Drug: Norepinephrine Norepinephrine tartrate variable infusion with a starting rate of 0,1μg/kg/min (equivalent to norepinephrine base of 0.05 μg /Kg/min).~Other name: Noradrenaline~Drug: Hyperbaric Bupivacaine will be injected in the subarachnoid space with a dose of 8 to 12 mg adjusted according to height~Drug: Sufentanil will be injected in the subarachnoid space with a dose of 2,5μg~Drug: Morphine will be injected in the subarachnoid space with a dose of 100 μg"
223645031|NCT03849508|DRUG|Phenylephrine|"Drug: Phenylephrine variable infusion with a starting rate of 0,5μg/kg/min~Drug: Hyperbaric Bupivacaine will be injected in the subarachnoid space with a dose of 8 to 12 mg adjusted according to height~Drug: Sufentanil will be injected in the subarachnoid space with a dose of 2,5μg~Drug: Morphine will be injected in the subarachnoid space with a dose of 100 μg"
223645032|NCT04924881|DRUG|COVID Rehab Formula granules|COVID Rehab Formula granules once daily for 8 weeks
223645033|NCT04924881|OTHER|Placebo granules|Placebo granules once daily for 8 weeks
223645034|NCT05738304|PROCEDURE|Retrograde intrarenal surgery with external ureteral catheter|The retrograde fURS sheathless technique will be used in all cases, including (a) cystourethroscopy with the introduction of a guidewire into the ipsilateral ureter up to the collecting system; (b) Semi-rigid ureteroscopy (using 9.5 Fr, Karl Storz, semi-rigid ureteroscope) for visualization of the ureter for any abnormalities, the introduction of the second guidewire and hydrophilic ureteral dilation; (c) introduction of the flexible ureteroscope (8.6 Fr, single-use digital flexible ureteroscope, OUT Medical Inc.) over the guidewire up to the kidney; (d) removal of the working guidewire after visualization of the stone; and (e) fragmentation of the stone using a holmium YAG laser device. All procedure steps will be performed under direct visualization and fluoroscopy guidance. At the end of the procedure, an external ureteral catheter will be placed for 24 hours.
223645035|NCT05738304|PROCEDURE|Retrograde intrarenal surgery with double J internal ureteral stent|The retrograde fURS sheathless technique will be used in all cases, including (a) cystourethroscopy with the introduction of a guidewire into the ipsilateral ureter up to the collecting system; (b) Semi-rigid ureteroscopy (using 9.5 Fr, Karl Storz, semi-rigid ureteroscope) for visualization of the ureter for any abnormalities, the introduction of the second guidewire and hydrophilic ureteral dilation; (c) introduction of the flexible ureteroscope (8.6 Fr, single-use digital flexible ureteroscope, OUT Medical Inc.) over the guidewire up to the kidney; (d) removal of the working guidewire after visualization of the stone; and (e) fragmentation of the stone using a holmium YAG laser device. All procedure steps will be performed under direct visualization and fluoroscopy guidance. At the end of the procedure, a double-J internal ureteric stent will be placed for 2 weeks.
223645036|NCT04365608|PROCEDURE|Direct laryngoscopy|standard laryngoscope with Macintosh blade
223765856|NCT05480566|DRUG|Daily medical treatment (e.g., oxygen, medrol, duovent, azitromycine)|Patients will be treated with daily medication prescribed by the physician, which can include oxygen, medrol, duovent, azitromycine or other medications that physicians consider that are needed.
223765857|NCT05480566|OTHER|Routine physiotherapy|Daily sessions of approximately 15 minutes consisting of airway clearance techniques and breathing exercises upon indication, mobilization, and low-intensity daily walking/cycling exercise (5 to 10 minutes) according to patients' tolerance.
224319803|NCT03694327|DEVICE|QuitGuide|Mobile Application
224319804|NCT03354767|PROCEDURE|Aortic and aortic valve surgery|
224319805|NCT02202863|DIETARY_SUPPLEMENT|Red wine grape pomace flour (WGPF)|Pomace, a byproduct from wine production, was obtained from red wine grapes, Cabernet Sauvignon, vintage 2011, Maipo Valley, Chile, after alcoholic fermentation. The wine grape pomace was dried and grounded to obtain the flour. Intervention group ate 20 g per day of this flour, which contained 10 g of dietary fiber and an antioxidant capacity of 7,258 ORAC units.
224319806|NCT00611481|BEHAVIORAL|Tai Chi|a set of pre-designed Tai Chi Movements
224319807|NCT00611481|BEHAVIORAL|Strength training|Lower-extremity strength training exercises
224319808|NCT00611481|BEHAVIORAL|Low-Impact Exercise Control|a set of chair-based low-impact exercises
224319809|NCT00357084|DRUG|methotrexate|
224319810|NCT00357084|DRUG|methylprednisolone|
224319811|NCT00357084|DRUG|prednisone|
224319812|NCT00421980|DRUG|Etanercept|
224319813|NCT00097396|BIOLOGICAL|rF1V vaccine|
224231495|NCT06220292|DEVICE|Nasogastric tube|Besides, the control group was given enteral nutritional support with Nasogastric tube according to the relevant guidelines. Within 4 hours after admission, the placement of the feeding tube was conducted by professional medical staffs and after intubation, the tube was secured to the patient's cheek with medical tape. The feeding was conducted once every 3-4 hours, with 200-300ml each time. The total feeding volume was determined based on daily requirements. The feeding content was formulated by the nutritionists based on the patient's condition and relevant guidelines to reach the energy demand as 20-25 kcal/kg/day and protein supplementation of 1.2-2.0 g/kg/day for both two groups. For patients with limited tube feeding compliance, we made appropriate adjustments to ensure that they were not at risk of severe malnutrition as much as possible.
223645037|NCT04365608|PROCEDURE|Vie Scope laryngoscopy|Vie Scope with dedicated bougie stylet
223645038|NCT01134055|DRUG|pazopanib eye drops|A tyrosine kinase inhibitor of multiple receptors including vascular endothelial growth factor receptors and platelet-derived growth factor receptors.
223645039|NCT01134055|DRUG|placebo|placebo eye drops
223645040|NCT01134055|BIOLOGICAL|ranibizumab intravitreal injection|Humanized recombinant monoclonal antibody fragment targeted against human vascular endothelial growth factor A
223645041|NCT00275509|DRUG|Thymoglobulin|
223645042|NCT00275509|DRUG|Daclizumab|
223645043|NCT00275509|OTHER|Plasmapheresis|Following each plasmapheresis session, 100 mg/kg of Cytogam (CMVIg) (Cytogam, CSL Behring, King of Prussia, PA) was administered
223645044|NCT00275509|DRUG|Mycophenolate mofetil|2 gm/day. Standard of care
223645045|NCT00275509|DRUG|Tacrolimus|To achieve serum level of 8-10 ng/ml.
223645046|NCT00275509|DRUG|Dexamethasone|100 mg intra-operatively, and 25 mg every 6h post-operatively for six doses
223645047|NCT00275509|DRUG|Prednisone|Taper over three months to 5 mg daily
223645048|NCT00275509|DRUG|Cytogam|Following each plasmapheresis session, 100 mg/kg of Cytogam (CMVIg) (Cytogam, CSL Behring, King of Prussia, PA) was administered
223645049|NCT06246461|DRUG|capecitabine|The control group was treated with 2,500 mg/m2 capecitabine, with 2,000 mg/m2 capecitabine for the medium-dose group and 1,500 mg/m2 capecitabine for the low-dose group.
223645050|NCT02640534|DRUG|Enzalutamide|Enzalutamide 160 mg od until disease progression
223645051|NCT02640534|DRUG|Metformin|850 mg bid until disease progression
223645052|NCT02422667|OTHER|Patient Registry|Orthopedic Data Registry
223645053|NCT06522490|OTHER|Virtual discrete trial training|VDT was given to Experimental group.
223645054|NCT06450483|DEVICE|Auricular vagus nerve stimulation|"Auricular vagal nerve stimulation using TPN dual channel TENS will be used for the study.The device used to stimulate is a conventional TENS. The stimulation is by applying a clip electrode placed on the tragus of the left ear and a second electrode applied on the left upper trapezius of the participant which will then stimulate the vagus nerve.Auricular vagus nerve stimulation session will be applied for 15 minutes. Participant is seated and relaxed.After the first session ended; heart rate will be measured and recorded once again to see the effect of the VNS.~Before the last AVNS session started; heart rate will be measured and recorded. The participants' vagus nerve is then stimulated for 15 minutes."
223645055|NCT04239391|DRUG|Triferic|Ferric Pyrophosphate Citrate
223645056|NCT04287790|BEHAVIORAL|audit and feedback, educational meetings, and academic detailing to promote medication receipt|Our implementation intervention will incorporate the following strategies: 1) Formation of an alcohol-related care working group. This voluntary working group will consist of members of the research team and volunteer health professionals from YNHH. The group with supervise and support the other intervention components. 2) We will develop medication for alcohol use disorder marketing (posters and buttons) materials and educational (pamphlet) materials and distribute these materials to health professionals. 3) Building on the existing infrastructure and collaboration, the research team will assist in revising existing alcohol-related care daily monitoring systems to support auditing and feedback on the adoption of medications for alcohol use disorder at YNHH. 4) The research team will hold educational meetings and educational outreach visits (academic detailing) when invited during regular noon conferences and team meetings.
223645057|NCT04287790|DRUG|Acamprosate, naltrexone, or disulfiram|Increased receipt of medications for alcohol use disorder facilitated by the implementation intervention.
223645058|NCT05741671|OTHER|Questionnaire|Extra in the context of the study are questionnaires which last a maximum of 5-15 minutes. The treatment considering the fibroid(s) is independent of this research. the Also the outcome measures include vaginal ultrasound, questionaires and a hemoglobin test. These measurements are applied in daily practice, as standard care.
223645059|NCT03811704|DEVICE|Laparoscopic surgical navigation system|We will use this navigation system to guide de liver resection.
223765858|NCT04674969|DEVICE|Any eligible commercially available Boston Scientific Corporation (BSC) drug-eluting device.|Ranger™ Paclitaxel-Coated Percutaneous Transluminal Angioplasty (PTA) Balloon Catheter; ELUVIA™ Drug-Eluting Vascular Stent System
224231496|NCT02457429|DEVICE|Experiemental diagnostic procedure: Dx-pH measurement system|"The Dx-pH Measurement system (Dx-pH; Respiratory Technology Corp., San Diego, CA) is a sensitive and minimally invasive transnasal device for detection of aerosolized extra-oesophageal acid reflux in the posterior oropharynx.~The sterile single use Dx-pH catheter will be passed trans-nasally into the same nostril as the same nostril as the other catheter. The internal pH value of the oesophagus is then continuously measured and recorded onto a small ambulatory device. The 2 catheters are connected to the ambulatory recording devices and recording commences. The duration of the investigation is 24 hours."
224319814|NCT01464931|DRUG|Denosumab|Adminstered by subcutaneous injection
223645060|NCT03811704|DRUG|Indocyanine Green|ICG was administered 24 hours before the operation or intravenously after clamping the Glissonian sheaths flowing in the cancer-bearing hepatic segment, or directly into the portal branches supplying blood flow to the tumor-bearing hepatic segment, after puncturing of the target segments under intraoperative ultrasonography guidance.
223645061|NCT02198378|DRUG|MEOPA and paracetamol|The patient will be equipped with a facemask after he/she has been informed. The facemask is adapted to the patient. The patient breathes normally in the mask which is held in place by a member of the SMUR team who has received previous training in use of MEOPA. The gas flow received by the patient is adapted to his/her ventilation.
223645062|NCT02198378|DRUG|Morphine|Bolus of 2 mg intravenously if EN = 4 or 5 and 3 mg bolus if EN\> 6 followed by reinjection of 2mg every 5 minutes until effective analgesia.
223645063|NCT04100252|OTHER|AFI via transabdominal ultrasonography|AFI via transabdominal ultrasonography was performed at the time of diagnosis.
223645064|NCT00594815|DRUG|Cytarabine, Leucovorin, Methotrexate, Procarbazine, Rituximab, Vincristine|Immunochemotherapy
223645065|NCT02102178|OTHER|Tapestry|"A gauze screen, wool thread appropriate for tapestry and a large needle were used.~The entire screen was filled with a striped pattern made of embroidered half-stitches in the individuals' preferred colors. To fill the screen with half-stitches, the needle was always worked in diagonal movements, point to point. The stitches were started keeping a distance of three points from the four edges."
223645066|NCT02102178|OTHER|Regular occupation therapy|All the patients were followed up daily for 10 days by a single occupational therapist for around 30 minutes, during which they received guidance regarding how best to perform their ADLs, i.e. how to position themselves when sitting down and standing up, dressing and undressing, feeding themselves, performing personal hygiene and undertaking leisure activities, with the aim of protecting their joints, reducing the pain and expending less energy.
223645067|NCT02102178|OTHER|Weaving a scarf on a nail frame|"Weaving a scarf on a nail frame: this activity used a rectangular wooden frame (30 cm x 10 cm), with an empty space in the middle and nails distributed at 1 cm intervals along all sides, together with a crochet needle and wool thread.~Procedure: The thread was measured out on the frame and all the fringes were cut to the same length. After this, each thread was knotted, leaving a loop that was placed over each nail. A wool thread was tied to the nail at the corner and a zigzag pattern was woven between alternate nails. On the return, the zigzag weave went via the nails that had initially been missed out. Using the crochet needle, the loop of the fringe was pulled across on top of the zigzag. The scarf went on coming out from under the frame. The zigzag sequence and the needle movement were repeated until the scarf reached the desired length."
223645068|NCT02102178|OTHER|Domino game|"Each player received seven dominos and kept them concealed from the adversaries' eyes. The player with the double-six (domino with the number six at both ends) started the game. If this domino had not been dealt out to any player, the one with the highest double domino started. Following on from this first player, in clockwise direction, each subsequent player placed one domino at one of the ends of the chain that was formed as the dominos were played. If a player did not have a domino that could be played, he would go to the pile and keep on picking up dominos until getting one that would fit. If no such domino existed, the player would then pass his turn on to the next player. The first player to get rid of all his dominos was the winner. If the game became blocked, i.e. there was no longer any possibility of adding dominos to the chain, the points in each player's hand were counted and the winner was the one with the lowest number of points in his hand."
223645069|NCT00071630|BEHAVIORAL|Cognitive Behavioral Therapy|
223765859|NCT07130058|DIETARY_SUPPLEMENT|GI Product Form - Control|Participants will use their GI Health Product Form - Control as directed for a period of 6 weeks
223765860|NCT07130058|DIETARY_SUPPLEMENT|GI Health Product Form - Active|Participants will use their GI Health Product Form - Active as directed for a period of 6 weeks
224231497|NCT02457429|OTHER|Peptest assay|A saliva sample of 0.5-1 ml will then be taken for pepsin assay (Peptest). The saliva sample will be drawn into a micro-centrifuge tube (0.5ml) and centrifuged. 80 microlitres is taken from the supernatant layer, vortex mixed, then applied to the assay test strip. The result is obtained after 15 minutes. The saliva sample will then be securely disposed.
224231498|NCT02457429|OTHER|GORD symptom questionnaire|A validated 7 domain GORD symptom questionnaire (GSQ-YC) to quantify the GORD related symptoms their child suffers with is to be completed prior to any intervention.
224231499|NCT01774474|DRUG|Bromfenac|
224231500|NCT01774474|DRUG|Dexamethasone|
224231501|NCT01774474|DRUG|Bevacizumab|
223645070|NCT04221867|PROCEDURE|Stricture dilation with CRE balloon|Esophageal stricture is treated by dilation therapy.
223765861|NCT06343363|BEHAVIORAL|Early discharge protocol|Patients admitted for transcatheter edge-to-edge repair to either mitral or tricuspid valve and then discharged within 36 hours
224231502|NCT01774474|DRUG|Triamcinolone Acetonide|
224231503|NCT01610466|PROCEDURE|Laparoscopic bariatric surgery ex-vivo training curriculum|The training curriculum will consist of a cognitive, technical and non-technical components. Cognitive component will consist of self-directed readings and a faculty-led seminar. Technical component will consist of training to proficiency on cadaveric porcine laparoscopic jejunojejunostomy and gastrojejunostomy models. Non-technical component will consist of an introductory lecture on non-technical skills in surgery and a simulated crisis scenario with a debriefing session.
224231504|NCT00719966|DRUG|anastrozole|Patients receive aromatase inhibition therapy.
224231505|NCT00719966|DRUG|exemestane|Patients receive aromatase inhibition therapy.
224231506|NCT00719966|DRUG|letrozole|Patients receive aromatase inhibition therapy.
224231507|NCT00719966|PROCEDURE|assessment of therapy complications|Endothelial function is measured
224231508|NCT00964626|DRUG|cisplatin|
224231509|NCT00964626|DRUG|paclitaxel|
224231510|NCT05770726|DIETARY_SUPPLEMENT|Probiotics administration|A total of 10 grams of probiotics was administered in both group, but the routes were different. One group were per colonoscopic spray, and the other was per oral.
224231511|NCT03799666|OTHER|Pulmonary Rehabilitation|Patients will be treated with daily medication prescribed by the physician. Additionally patients will participate in a 12-w.eek community-based pulmonary rehabilitation programme, with two exercise training sessions per week and six psycho-education sessions, managed by a multidisciplinary team, once every two weeks. Patient's families will be invited to participate in the psychoeducational component
224231512|NCT03799666|OTHER|Daily medication|Patients will be treated with daily medication prescribed by the physician and will continue to receive the standard care from the primary care centre team.
224231513|NCT06371248|BEHAVIORAL|Steady Feet|Steady Feet is a three-month progressive exercise-based single-component intervention spanning twenty-four sessions, with a focus on enhancing balance, mobility, and strength among community-dwelling older adults at risk of falls.
224231514|NCT06371248|OTHER|Usual care for fall prevention|CGH's usual care for fall prevention, which include fall prevention materials and advice.
224319815|NCT06186180|OTHER|inspiratory muscle training|They will perform 5 sets of 10 repetitions with a 1-minute rest between sets, 5 days a week, using a specific respiratory muscle training device
224319816|NCT02936180|BIOLOGICAL|HD-TIV|
224319817|NCT02936180|BIOLOGICAL|SD-QIV|
223645071|NCT04221867|PROCEDURE|Autologous fat grafting|Autologous fat graft is gathered and injected to stricture
223645072|NCT03553355|DEVICE|Infrared Laser Moxibustion|We will use SX10-C1 laser moxibustion devices (Shanghai Wonderful Opto-Electrics Tech Co Ltd, Shanghai, China) for the ILM and SILM groups. Four laser probes will be synchronously aligned with 4 points (tST36 (bilateral), CV4, and CV6 acupoints) and we will irradiate each acupoint 2 cm away from the skin surface for 20 minutes. Each patient will receive this treatment twice per week for six weeks (12 sessions total).
223645073|NCT03553355|DEVICE|Sham Infrared Laser Moxibustion|The sham laser moxibustion instrument appears to be identical as the real one.
223645074|NCT00215839|DRUG|Peginterferon a-2a plus Ribavirin|
223645075|NCT00131248|DRUG|Metaclopramide|
223645076|NCT00131248|DRUG|Ranitidine|
223645077|NCT00131248|DRUG|placebo|
223645078|NCT04950621|DRUG|remimazolam|Remimazolam will be administered during induction and maintenance for general anesthesia.
223645079|NCT04950621|DRUG|propofol|Propofol will be administered during induction and maintenance for general anesthesia.
223645080|NCT02296645|DRUG|ZuraPrep|Apply topically.
223645081|NCT02296645|DRUG|ChloraPrep|Apply topically.
223645082|NCT06252688|BEHAVIORAL|Ambulatory cares in a day-hospital (Lapeyronie, Montpellier) specialized in the evaluation of eating disorders.|"All patients assessed in the day-hospital will permormed the same evaluation :~* Blood sampling~* Calorimetry~* Osteodensotometry~* Psychiatric assement~* Endocrinologic assessment~* Dietetic assessment~* Neuropsychological assessment~* Self-questionnaires~With the patient agreement, a biological collection will be constituted. The objective is the subsequent study of biological factors involved in eating disorders (in particular genetic factors)"
223645083|NCT02784899|DRUG|iloprost|"20μg(2ml) of inhaled iloprost (Ventavis®)~When anesthesia induction finishes, change patients' position from supine to lateral position and measure arterial blood gas analysis (ABGA), venous blood gas analysis (VBGA) while two lung is ventilated. After 20 minutes of applying one lung ventilation, measure ABGA. Apply iloprost or normal saline inhalation for each iloprost and control group and measure ABGA at the time of 20 min and 40 min after iloprost (or normal saline) inhalation has finished."
223645084|NCT02784899|DRUG|normal saline|"20μg(2ml) of inhaled normal saline~When anesthesia induction finishes, change patients' position from supine to lateral position and measure ABGA, VBGA while two lung is ventilated. After 20 minutes of applying one lung ventilation, measure ABGA. Apply iloprost or normal saline inhalation for each iloprost and control group and measure ABGA at the time of 20 min and 40 min after iloprost (or normal saline) inhalation has finished."
223645085|NCT02903329|OTHER|Detoxification|Two ways of composing the detoxification protocol
223645086|NCT01130480|DEVICE|Accu-Chek Integra Glucometer|
223645087|NCT04310371|BEHAVIORAL|3-month lifestyle intervention|"Adolescents from the intervention group will be enrolled at the obesity center for the whole school year (i.e., 10 months). The physical activity program consists of two training sessions (aerobic and resistance training) per week.~There will be two measurement time: one at baseline (Day 0) and one at three months after the beginning of the lifestyle intervention (M3). The controls will be evaluated at baseline only."
224231515|NCT05994222|OTHER|Assessment Group|Evaluation forms will be applied to the participant who meets the inclusion criteria by face-to-face interview method. The sociodemographic information of the participants and the time taken to answer the questions in the questionnaires will vary according to each participants but will take approximately 45 minutes. The second interview will be conducted with the patients for test-retest application at 1-week intervals.
224323471|NCT06392711|BIOLOGICAL|Mesenchymal Stromal Cells (MSC) Dose Level 1|20 (16-24) x 10\^6
223645088|NCT01174719|DRUG|volume replacement|Hydroxyethylstarch up to 50mL/kg/24 hrs
223645089|NCT01174719|DRUG|Humanalbumin 5%|Humanalbumin 5% up to 50 mL/kg/24 hours
223645090|NCT01174719|DRUG|volume replacement|up 10 50mL/kg/24 hours
223645091|NCT03023397|BIOLOGICAL|Der f|Nasal administration of Dermatophagoides farinae with 100 allergen units (AU), 500 AU, and finally 1000 AU
223645092|NCT03705689|OTHER|validation of Bitts|No intervention, observation of photographs of stool
223645093|NCT04341246|DEVICE|LiverMultiscan|The Livermultiscan is a quick, 15 minute contrast free MRI scan that provided metrics to quantify liver health namely fat, iron and fibro-inflammation
223645094|NCT02387502|DEVICE|Intubation- Macintosh laryngoscope|Difficult intubation was simulated by using rigid neck collar. Then patients were intubated according to the assigned laryngoscopes. In Macintosh group, tip of the laryngoscope blade was placed in the vallecula and epiglottis was lifted. After visualization of the vocal cord, patients were intubated.
223645095|NCT02387502|DEVICE|Intubation- MacCoy laryngoscope|In MacCoy group, tip of the laryngoscope blade was placed in the vallecula and lever was pressed to flex the tip. After visualization of the vocal cord, patients were intubated.
223645096|NCT02387502|DEVICE|Intubation- Airtraq laryngoscope|In Airtraq group, the laryngoscope was loaded with endotracheal tube. Airtraq laryngoscope was inserted through midline and after visualization of image of vocal cord through its eyepiece, endotracheal tube was passed.
223645097|NCT05805917|DEVICE|Neoviderm Skin Emulsion medical device|Neoviderm Skin Emulsion will be applied twice daily, to cover the entire cutaneous surface interested by burns, followed by a gentle massage to spread the product evenly of all the affected skin.
223645098|NCT05805917|DRUG|Connettivina 0.2% Cream|Connettivina 0.2% Cream will be applied twice daily, to cover the entire cutaneous surface interested by burns, followed by a gentle massage to spread the product evenly of all the affected skin.
223645099|NCT02466893|OTHER|Adapt/Standard Stent Retriever (SR) Group|If the patient is randomized to mechanical thrombectomy, the groin puncture to initiate the procedure should occur within 1 hour of the clinical imaging used to determine trial candidacy. An introducer sheath will be placed in the femoral artery. Diagnostic angiography is initially performed via the transfemoral approach with catheterization of the carotid artery appropriate to the patient's presenting symptoms. Once thrombus in the appropriate vessel is identified, the thrombectomy procedure will be initiated.
223680887|NCT04476823|OTHER|Activity|The questionnaire had requested information on the biosafety organization, impact of the COVID-19 crisis on the clinical and molecular pathology and the biobanking activity in thoracic pathology, on the research activity associated with the COVID-19, and on the educational and training organization. It requested the different needs planned by the different laboratories following the COVID-19 crisis and finally the consequence of this latter on the health and virological status of the staff members.
223680888|NCT02643758|DEVICE|Bifocal soft contact lenses|
223680889|NCT06097013|OTHER|Routine clinical rehabilitation|Routine clinical rehabilitation
224231516|NCT02498548|BEHAVIORAL|Trained SCI Knee or Trained SCI Hip|Individuals with SCI will perform downhill walking training 3 times a week for 12 wks with a 4 wk follow-up period. This intervention will be delivered by trained therapists. In order to focus on rehabilitation of knee control or hip control, members of this group will be trained at slow to moderate gait speeds.
224231517|NCT05331222|DRUG|JT-1|JT-1 is a physiological salt with recently detected pharmacological properties that warrant testing for its therapeutic potential in chronic rhinitis and chronic sinusitis.
224231518|NCT00795665|DRUG|bevacizumab|Bevacizumab (10 mg/kg) will be given intravenously every other week starting one week before the first dose of BCNU. Treatment with both BCNU and bevacizumab for 6-months, after which the participant may continue to receive bevacizumab every 2 weeks for a maximum of one year and three additional cycles of BCNU.
224231519|NCT00795665|DRUG|carmustine|BCNU (200 mg/m2), will be given over 4 hours as a continuous intravenous infusion every 8 weeks. Treatment with both BCNU and bevacizumab for 6-months, after which the participant may continue to receive bevacizumab every 2 weeks for a maximum of one year and three additional cycles of BCNU.
224231520|NCT01263158|OTHER|Expectancy of standard oxytocin treatment|
224231521|NCT01612000|BIOLOGICAL|PanBlok|Intramuscular injection
224231522|NCT01612000|BIOLOGICAL|rHA adjuvant|Intramuscular injection
224231523|NCT01798459|DRUG|Methylphenidate|
224231524|NCT00377052|DRUG|bortezomib|1.0 mg/m2 IV; injection bolus (3-5 sec) Twice weekly x 2 weeks every three weeks
224231525|NCT00377052|DRUG|gemcitabine hydrochloride|1000 mg/m2 IV; injection 30 minute infusion Once weekly x 2 weeks every three weeks
224231526|NCT05142436|OTHER|Product A: Non-Combusted Cigarette Variant 42001402 and product use Mode B|42001402, A Heated Tobacco Product using a Non-Combusted Cigarette Variant and product use Mode B
224231527|NCT05142436|OTHER|Product B: Non-Combusted Cigarette Variant 42001399 and product use Mode B|42001399, A Heated Tobacco Product using a Non-Combusted Cigarette Variant and product use Mode B
224231528|NCT05142436|OTHER|Product C: Non-Combusted Cigarette Variant 42001401 and product use Mode B|42001401, A Heated Tobacco Product using a Non-Combusted Cigarette Variant and product use Mode B
224231529|NCT05142436|OTHER|Product D: Non-Combusted Cigarette Variant 40007386 and product use Mode B|40007386, A Heated Tobacco Product using a Non-Combusted Cigarette Variant and product use Mode B
224231530|NCT05142436|OTHER|Product E: Non-Combusted Cigarette Variant 42001402 and product use Mode A|42001402, A Heated Tobacco Product using a Non-Combusted Cigarette Variant and product use Mode A
224231531|NCT00310258|BEHAVIORAL|Drug use prevention intervention|
224231532|NCT03847376|DRUG|Rilpivirine Long Acting (RPV LA)|Participants will receive RPV LA injectable suspension containing 300 milligram per milliliter (mg/mL) of RPV by intramuscular (IM) injection. A starting dose of 900 milligram (mg) RPV LA (3 milliliter \[mL\] suspension) will be administered with subsequent doses of 600 mg RPV given at 4-week intervals.
224231533|NCT01336829|DRUG|ETR/telaprevir|Treatment A: ETR 200 mg twice a day from Day 1 to Day 10 + a single dose in the morning on Day 11. Treatment B: telaprevir 750 mg every 8 hours from Day 1 to Day 17 + 2 doses (morning and afternoon) on Day 18, and ETR 200 mg twice a day from Day 8 to Day 17 + a single dose in the morning on Day 18.
224231534|NCT01336829|DRUG|TMC278/telaprevir|Treatment C: TMC278 25 mg once day from Day 1 to Day 11. Treatment D: telaprevir 750 mg every 8 hours from Day 1 to Day 18, and TMC278 25 mg once daily from Day 8 to Day 18.
223680890|NCT02827565|OTHER|KRAS, NRAS et BRAF mutation analysis from circulating plasma DNA|10 ml blood sample
223680891|NCT02352922|DRUG|Liposomal Bupivacaine|pre-incision infiltration with liposomal bupivacaine
223680892|NCT02352922|DRUG|Bupivacaine HCl|pre-incision infiltration with bupivacaine HCl
223680893|NCT02869061|PROCEDURE|Liposuction|
224231535|NCT01336829|DRUG|telaprevir/ETR|Treatment A: ETR 200 mg twice a day from Day 1 to Day 10 + a single dose in the morning on Day 11. Treatment B: telaprevir 750 mg every 8 hours from Day 1 to Day 17 + 2 doses (morning and afternoon) on Day 18, and ETR 200 mg twice a day from Day 8 to Day 17 + a single dose in the morning on Day 18.
224231536|NCT01336829|DRUG|telaprevir/TMC278|Treatment C: TMC278 25 mg once day from Day 1 to Day 11. Treatment D: telaprevir 750 mg every 8 hours from Day 1 to Day 18, and TMC278 25 mg once daily from Day 8 to Day 18.
223680894|NCT02869061|PROCEDURE|Transurethral bladder neck resection.|
223680895|NCT02869061|BIOLOGICAL|ADRC|Injection of ADRC suspension will be performed endoscopically into the bladder neck close to the site of resection.
223680896|NCT02869061|OTHER|ADRC isolation|ADRC will be isolated according to patent pending technology based on enzymatic digestion, washing and concentration of cell pellet in up to 9.5 ml of normal saline.
223680897|NCT04585152|DRUG|Rituximab Biosimilar|for dosage between 100 and 250 mg Rituximab will be diluted in 100 ml of normal saline and administered at 2 ml/h for the first 30'; 3 ml/h for the second 30'; 6 ml/h for the third 30'; 15 ml/h until the end. For dosage between 260 and 500 mg Rituximab will be diluted in 250 ml of normal saline and administered at 6 ml/h for the first 30'; 9 ml/h for the second 30'; 18 ml/h for the third 30'; 36 ml/h until the end. For dosage between 510 and 1000 mg Rituximab will be diluted in 500 ml of normal saline and administered at 9 ml/h for the first 30'; thereafter, the infusion rate can be doubled every 30 minutes up to a maximum of 72 ml/h.
224231537|NCT01390363|OTHER|Parent Only Phone Call|A telephone call will be made to the parent/guardian informing them that the adolescent has not received one or more vaccines (Td/Tdap in the past 5 years, the MCV4 vaccine, or the 2nd VZV vaccine). The phone call will include a brief informational statement about the vaccine(s) that the adolescent has not yet received. Up to 4 telephone calls will be attempted. As part of the phone call, we will offer to schedule an appointment for the adolescent to receive the missing immunization(s). We will also ask them to mail or fax to the Adolescent/Young Adult Medicine clinic records of immunizations given at other sites.
224319818|NCT01982812|DRUG|Oral Levetiracetam|liquid, 40 mg/kg loading dose and 30mg/kg every 12 hours via nasogastric tube for 3 days
224319819|NCT01982812|DRUG|Standard AED|Active comparitor, Standard AED
224323472|NCT04386993|RADIATION|Intensity modulated radiation therapy|Radiation should be delivered over the course of 1-2 weeks (allowing for weekends/holidays).
224323473|NCT05549258|DRUG|Inebilizumab|Inebilizumab administered intravenously (IV) over a total of 28 weeks.
224231538|NCT01390363|OTHER|Parent and Adolescent Phone Call|A telephone call will be made to the parent/guardian informing them that the adolescent has not received one or more vaccines (Td/Tdap in the past 5 years, the MCV4 vaccine, or the 2nd VZV vaccine). The phone call will include a brief informational statement about the vaccine(s) that the adolescent has not yet received. Up to 4 telephone calls will be attempted. As part of the phone call, we will offer to schedule an appointment for the adolescent to receive the missing immunization(s). We will also ask them to mail or fax to the Adolescent/Young Adult Medicine clinic records of immunizations given at other sites. We will also ask permission to speak with the adolescent as well, and if granted, will make up to 4 phone calls to the adolescent to convey the same message.
224231539|NCT05814081|PROCEDURE|Position/Ventilation|Positioning and ventilation mode adjustments were made to the patients.
224231540|NCT00012714|BEHAVIORAL|Case management services|
224231541|NCT01270750|DRUG|BOSENTAN|TWICE DAILY PERORAL BOSENTAN, 125 MG DAILY DIVIDED IN TWO DOSES DURING THE FIRST MONTH AND 250 MG DAILY DIVIDED IN TWO DOSES SUBSEQUENTLY.
224231542|NCT03745625|DRUG|HSK3486|"First-stage:after an initial dose of 1mg/kg/h, If the BIS is in the range of 80 to 60 and the continuous RASS score = 3 or one time RASS score ≤ -4, the 0.4 mg/kg/h maintenance dose is administered. The total infusion time was 4h.~Second-stage: a single loading dose of 0.2 mg/kg given over 1 minute, then a continuous infusion of maintenance dose 0.35 mg/kg/h for a total infusion time of 12h."
224231543|NCT03745625|DRUG|Propofol|"First-stage: after an initial dose of 5mg/kg/h, If the BIS is in the range of 80 to 60 and the continuous RASS score = 3 or one time RASS score ≤ -4, the 0.4 mg/kg/h maintenance dose is administered. The total infusion time was 4h.~Second-stage: loading dose of 1mg/kg given over 1 minute, then a continuous infusion of maintenance dose 1.75 mg/kg/h for a total infusion time of 12h."
224231544|NCT00904020|DRUG|Lidoderm|Patients participated in a 2-week treatment period. Commercially available Lidoderm (lidocaine patch 5%) was provided to patients with up to four patches applied topically once daily (q24h) to the area of maximal peripheral pain.
224231545|NCT05629949|DRUG|QL1701|8 mg/kg administered intravenously over 90 minutes as a loading dose on Day 1, Cycle 1 then 6 mg/kg every 3 weeks for subsequent cycles.
224231546|NCT05629949|DRUG|Herceptin®|8 mg/kg administered intravenously over 90 minutes as a loading dose on Day 1, Cycle 1 then 6 mg/kg every 3 weeks for subsequent cycles.
224231547|NCT05629949|DRUG|Docetaxel|The recommended dose is 75mg/m2 and the infusion time is approximately 70min (±20min) (or adjusted according to clinical experience at each study center). The drug was administered once every 3 weeks for a treatment cycle of 3 weeks, with the exception of the second day of the first cycle, followed by the first day of each cycle for at least 8 cycles
224323474|NCT04557124|BEHAVIORAL|USS|social cognitive training
224323475|NCT04557124|BEHAVIORAL|MovingForward|problem solving training
224323476|NCT05382442|DRUG|AK112|AK112 via intravenous (IV) infusion until disease progression or unacceptable toxicity
224323477|NCT05382442|DRUG|AK117|AK117 via intravenous (IV) infusion until disease progression or unacceptable toxicity
223645100|NCT04434443|OTHER|trunk exercise on unstable exercise|Participants would receive exercises on unstable surface. Started from supine position, participants had abdominal drawer-in maneuver with soft foam under the pelvic. Lower trunk rotation, bridging and abdominal muscles isometric contraction exercises were also used in this exercise during supine position, with different unstable surfaces used. Including soft foam under the feet, then progressed to BOSU ball under the feet, then progressed to the a BOSU ball under the feet combined with pelvic on soft foam. During sitting, BOSU ball and Swiss ball were used as unstable surface. Pelvic anterior-posterior tilt, lateral tilting, rotation, lifting, and stepping with arm swing were used in this position.
223645101|NCT04434443|OTHER|Upper limb range of motion exercise|Upper limb range of motion exercise with trunk fully supported
223645102|NCT04708561|BEHAVIORAL|Speech and language therapy|"The intervention focuses on understanding the thoughts of the characters. Twenty written stories will be used, which end with statements that can be interpreted literally, ironically, as a lie, a request or a faux-pas (maladroitness). At the end of each story, the participant should explain what the characters want to mean by their statement.~To help the participant in his understanding of the character's intention, he will be asked:~1\) To mention as many intentions as possible that can be associated with the target statement presented out of context (eg: it's hot here that can be interpreted literally, ironically, as a lie or a request) and to imagine contexts in connection with interpretation; 2. Analyze the relevant elements of the context (environment, the relationship between the characters, knowledge of the characters); 3. To judge the probability of the possible interpretations (pt 1) by justifying using the elements of the context analyzed previously (pt 2)."
223645103|NCT03171961|BEHAVIORAL|online visit group|subjects has online visit with dietitian every 2 weeks+diet
223645104|NCT03171961|BEHAVIORAL|Clinic visit group|Clinic visit group ,subjects has every 2 weeks in person visit at clinic+diet
223645105|NCT03171961|BEHAVIORAL|self-directed group|self-directed group receives nutritional information via web and their energy needs for weight loss
223645106|NCT03177655|OTHER|Guided Imagery|Guided Imagery meditation
223645107|NCT03177655|OTHER|Journaling|Keeping a journal
223645108|NCT04601961|DRUG|Propofol|"Monitoring and other anaesthetic procedures including the management of hypertension and hypotension will be the same as SEVO group. Induction and maintenance of general anaesthesia will be conducted using total intravenous infusion of propofol. Sevoflurane will not be used, and oxygen and air would be given to provide a FiO2 of 30-50%.~Target controlled infusion (TCI) with a modified Marsh effect site model (Fresenius Kabi) will be used for induction and maintenance of general anaesthesia and titrated to effect. The usual effect site concentration is 1.5-3 mcg.ml-1 and BIS monitoring will also be used to produce a value of between 40-60. As with patients in the SEVO group, remifentanil will be infused at a rate of between 0.1-0.3 mcg.kg.min-1."
223680898|NCT05109052|DRUG|PXS-5505 and Atezolizumab and Bevacizumab|Open label safety and tolerability assessment of PXS-5505 incorporating first-line combination therapy Atezolizumab and Bevacizumab
223680899|NCT00638807|DRUG|Celecoxib|200 mg oral capsule once daily with morning meal for 6 weeks
223680900|NCT00638807|OTHER|Placebo|Matched oral placebo for 6 weeks
223680901|NCT04393298|DRUG|ginisortamab|Study participants will receive predefined doses of ginisortamab (UCB6114) administered intravenously at pre-specified time points.
224323478|NCT05382442|DRUG|Oxaliplatin|Oxaliplatin via IV infusion
224231548|NCT02030184|DRUG|Rhenium Re 188-P2045|Topotecan at 1.0 mg/m2 or 1.5 mg/m2 for 3 days, followed by single dose of Rhenium Re 188-P2045, at one of the following dosage levels based on the Phase I Maximum Tolerated Dose (MTD): 40% of MTD; 50% of MTD; 75% of MTD; 85% of MTD or 100% of MTD.
224231549|NCT04908566|DRUG|PD-1 antibody combined with FOLFIRINOX regimen|Give 240 mg of PD-1 antibody before each cycle of chemotherapy, d1; Chemotherapy regimen: irinotecan 150mg/m2, d1; fluorouracil 2400 mg/m², d1-2, continuous pumping for 46 hours; leucovorin 200 mg/m², d1; oxaliplatin 65 mg/m², d1; PD-1 antibody repeats once every 3 weeks; Chemotherapy is repeated every 2 weeks. 4 cycles before surgery. 4 cycles after operation。
223645109|NCT04601961|DRUG|Sevoflurane|Propofol 1.5-3mg/kg, remifentanil 1mcg/kg, and rocuronium 0.6-1mg/kg or atracurium 0.5mg/kg will be used intravenously for induction of general anaesthesia. Intubation would be performed after induction of general anaesthesia. General anaesthesia monitoring will be used. Sevoflurane, air and oxygen will be used for maintenance of general anaesthesia. FiO2 will be kept between 35-50%. BIS monitoring will be applied and level of anaesthetia will be titrated to maintain a BIS value of between 40-60. Intravenous remifentanil infusion between 0.1-0.2 mcg/kg/min will be given and this will be titrated to provide optimal haemodynamic parameters.
223645110|NCT01146795|DRUG|Carboplatin|Carboplatin will be administered at a concentration-time curve (AUC) of 5-6 (at the discretion of the physician) day 1 every 3 weeks in combination with Paclitaxel and Bevacizumab.
223645111|NCT01146795|DRUG|Paclitaxel|Paclitaxel 175 mg/m2 over 3 hours day 1 every 3 weeks in combination with Carboplatin and Bevacizumab.
223645112|NCT01146795|DRUG|Bevacizumab|Bevacizumab 15 mg/kg day 1 every 3 weeks in combination with Paclitaxel and Carboplatin.
223645113|NCT02930512|PROCEDURE|DXA scan|
223645114|NCT02930512|PROCEDURE|pQCT scan|
223645115|NCT04580979|GENETIC|Mutation analysis|The investigators will sequence DNA samples from the patients or their families.
223645116|NCT05156034|DRUG|SRK-001|Participants will receive IV doses of SRK-001.
223645117|NCT05156034|DRUG|Placebo|Participants will receive IV doses of placebo.
223645118|NCT01973764|PROCEDURE|Ultrasound guided ventricular drain insertion|Ventricular puncture and insertion of the intraventricular catheter is performed under ultrasound guidance.
223645119|NCT01973764|PROCEDURE|landmark-based ventricular drain insertion|Ventricular puncture and insertion of the intraventricular catheter is performed without any guiding devices and is based on anatomical landmarks.
223645120|NCT01812863|PROCEDURE|Supraclavicular nerve block|"Following injection of morphine, an ultrasound-guided supraclavicular nerve catheter (Angiocath) will be placed in Group 2. All catheters will be placed by one of the anesthesiologist trained in regional pain control using a 25 mm linear US probe in a sterile fashion.~If the examination is unchanged from preoperative assessment, an injection block using 5 ml of 0.25% bupivacaine with 1:200,000 epinephrine will be administered. Bupivacaine is a long acting local anesthetic that prevents nerve conduction and action potential initiation by decreasing the permeability of the neuronal membrane to sodium. We use a maximum dose of 5 mL of 0.25% bupivacaine, and we usually base the dose on a ml/kg (0.2 ml/kg) with a maximum dose not to exceed 2.5 mg/kg. This will be well below toxic levels."
223645121|NCT05816447|BEHAVIORAL|interview|Interview patient's perception
223645122|NCT03350594|BEHAVIORAL|Systemic Family Therapy|Patient will have 10 sessions of Systemic Family Therapy during 12 months with his/her family.
223645123|NCT03350594|BEHAVIORAL|Multiple Family Therapy|Patient and his/fer family will have 10 sessions of Multiple Family Therapy during 12 months.
223645124|NCT04311021|OTHER|No intervention|No intervention
223645125|NCT06459206|DEVICE|Pulse oximeter|Devices (4) were placed on the finger base and the fingertip of two right or left fingers and placed in motion for the duration of the study. Devices (3) were placed on the contralateral side and maintained motionless for the duration of the of study. Blood samples were taken at each stable level of oxygenation.
223645126|NCT04313062|BEHAVIORAL|Educational Intervention|"An educational intervention based on the PM ACTIVAS' model and a  Falling Prevention Kit , both in a home visit by the trainees. Also, a telephone follow-up and a last house call 12 months after recruiting to assess the changes implemented by the person and their family, to conduct the final survey and to ask for the  Falls and Events Calendar  ."
223645127|NCT05064215|PROCEDURE|anatomical examination|After injection of dye, its distribution along lymphatic clearance paths was investigated
223645128|NCT05086107|DRUG|BV100|Rifabutin for infusion
224231550|NCT04908566|DRUG|PD-1 antibody combined with SOX program|"Give 240 mg of PD-1 antibody before each cycle of chemotherapy, d1; Chemotherapy regimen: oxaliplatin 130 mg/m², d1, ticgio 40-60mg bid, d1-14 q3w;Repeat once every 3 weeks.~2-4 cycles before surgery. The perioperative period was 8 cycles."
224231551|NCT03256799|DRUG|Ivacaftor/Ataluren|Both drugs were given in combination for 48 week study period
223645129|NCT04529902|DRUG|Tumor Necrosis Factor Inhibitors|TNFi claim is used as the reference group.
223645130|NCT04529902|DRUG|Abatacept|Abatacept claim is used as the exposure group.
223645131|NCT04343742|DRUG|chlorine dioxide 3000 ppm|"Each patient will receive the 3,000 ppm chlorine dioxide base preparation with written and precise instructions on how to prepare and take the dilutions.~: 10 ml of 3000 ppm chlorine dioxide are added to 1 liter of water, per day. One part is taken every hour, until the content of the bottle is finished (8 to 12 shots)."
223645132|NCT05690802|DRUG|Palonosetron hydrochloride capsules|"This protocol only stipulates Palonosetron capsule containing hydrochloric acid protocol, and does not make uniform provisions on the treatment course, and does not interfere with the actual clinical usage and dosage."
223645133|NCT01840982|DIETARY_SUPPLEMENT|Mixed grain 1|All test foods contained 50 g available carbohydrate from the test food products. A glass of 200 ml water was served together with the clinical trial food, and the participants were instructed to ingest the breakfast with 15 min.
223645134|NCT01840982|DIETARY_SUPPLEMENT|Mixed grain 2|All test foods contained 50 g available carbohydrate from the test food products. A glass of 200 ml water was served together with the clinical trial food, and the participants were instructed to ingest the breakfast with 15 min.
223645135|NCT01840982|DIETARY_SUPPLEMENT|White rice|All test foods contained 50 g available carbohydrate from the test food products. A glass of 200 ml water was served together with the clinical trial food, and the participants were instructed to ingest the breakfast with 15 min.
223645136|NCT01840982|OTHER|Glucose solution|All test foods contained 50 g available carbohydrate from the test food products.
223645137|NCT05812066|PROCEDURE|all ceramic single-retainer resin bonded fixed partial denture|The intervention will be all ceramic single-retainer RBFPD using the upper canine as abutment with minimum preparation on the lingual surface within the enamel providing maximum area for the retainer bonding, to replace the upper lateral incisor and will be compared with the control/comparator group which is the all ceramic single-retainer RBFPD using the upper central incisor.
223645138|NCT04646421|BEHAVIORAL|Motivational telephone intervention|Motivational telephone intervention to high-risk gamblers, aiming to stimulate them to reduce gambling, quit gambling, or to seek peer support or treatment.
223645139|NCT02911844|DRUG|Fulvestrant|Fulvestrant 500 mg administered intramuscularly into the buttocks slowly as two 5 mL injections, one in each buttock, on days 0, 14, 28 and 56. Fulvestrant 250 mg (one 5 mL injection) will be used in patients with Child-Pugh Class B liver disease.
223765862|NCT06642818|OTHER|protocolized interview and prevention messages|This care consists of a consultation carried out by an environmental health expert (midwife, environmental health engineer) from the PREVENIR platforms. This consultation is carried out through a protocolized interview already developed which allows the identification of exposure to risk factors on reproduction. During the interview, prevention messages targeted at the exposures identified during the interview are delivered.
224231552|NCT02892500|DRUG|bupivacaine hydrochloride and betamethasone sodium phosphate|5ml of 0.25% bupivacaine hydrochloride and 2 ml of 3mg/ml betamethasone sodium phosphate one injection into the inferior tibiofibular ligament
224231553|NCT02892500|DRUG|bupivacaine hydrochloride|5ml of bupivacaine hydrochloride into the tibiofibular ligament
224231554|NCT02863302|OTHER|Reflexology treatment|All patients will receive reflexology (a specialized foot therapy) from a certified reflexologist twice weekly from the beginning of chemotherapy treatment.
224231555|NCT02354586|DRUG|Niraparib|
224231556|NCT00346086|DRUG|AIC (Amb a 1 Immunostimulatory Conjugate)|
224231557|NCT04981899|DRUG|Nivolumab|6 infusions of nivolumab at a fixed dose of 40 mg, 14 days apart, and infusion of nivolumab on day 0 of the NICE-40.
224231558|NCT04981899|DRUG|Ifosfamide|5000 mg / m2, 24-hour infusion on day 2 of the NICE-40.
224231559|NCT04981899|DRUG|Carboplatin|Optimized to get AUC = 5 (max. 800 mg) on day 2 of the NICE-40.
224231560|NCT04981899|DRUG|Etoposide|100 mg / m2 intravenously on 1-3 days of the NICE-40.
224231561|NCT00575406|DRUG|Rituximab|i.v., 375 mg/m2, d0 or d1 of each treatment cycle
224231562|NCT00575406|DRUG|Cyclophosphamide|i.v., 750 mg/m2, d1 of each treatment cycle
223645140|NCT01569607|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|Training sessions for 5 days in a row
223645141|NCT01569607|DEVICE|Sham stimulation|Sham stimulation
223645142|NCT02753504|DRUG|CKD-519|
223645143|NCT02753504|DRUG|placebo|
223645144|NCT01356277|BEHAVIORAL|Action-focused problem-solving|"* Adherence Support Team (patient, parent, Coach)~* standardized education on immunosuppressive medications~* identification of adherence barriers~* 'Action-Focused Problem-Solving' to address barriers selected as most important by the patient"
223645145|NCT01356277|DEVICE|Electronic pillbox monitoring, dose reminders, and feedback|"* Electronic adherence monitoring with feedback of past 3 months of electronic monitoring data at 3-month intervals~* text message, email, or visual cue dose reminders"
223645146|NCT03790202|DEVICE|VistaCare®|Controlled atmosphere wound healing device
223645147|NCT02056587|DRUG|Everolimus|All patients with metastatic renal cell carcinoma progressing on prior treatment with bevacizumab ± interferon enrolled into this study will receive everolimus in the dose of 10 mg daily until the disease progression or unacceptable toxicity.
223645148|NCT00378365|PROCEDURE|Arsenic trioxide|Arsenic trioxide
223765863|NCT03945981|DRUG|Dolutegravir + Lamivudine FDC|Dolutegravir + Lamivudine FDC is available as white oval film-coated tablets which are packed in high density polyethylene (HDPE) bottles with induction seals and child-resistant closures. Each 60 milliliter (mL) bottle contains 30 tablets
223765864|NCT06980636|DRUG|Shengmai Liquid|The Shengmaiyin treatment group will be given the traditional Chinese medicine Shengmaiyin oral liquid (produced by Jilin Aodong Yanbian Pharmaceutical Co., Ltd., with the approval number Z41021384. Ingredients: Codonopsis pilosula, Ophiopogon japonicus, Schisandra chinensis, excipients: sucrose, sodium benzoate, ethylparaben, specification 10m1/bottle), taken orally at a dose of 10ml per time, three times a day
224231563|NCT00575406|DRUG|Doxorubicin|i.v., 50 mg/m2, d1 of each treatment cycle
224231564|NCT00575406|DRUG|liposomal Doxorubicin|i.v., 50 mg/m2, d1 of each treatment cycle
224231565|NCT00575406|DRUG|Vincristin|i.v., 2mg, d1 of each treatment cycle
224231566|NCT00575406|DRUG|Prednisolone|p.o., 100mg, d1 - d5 of each treatment cycle
224231567|NCT02115906|OTHER|1H/31P Magnetic Resonance Spectroscopy|The 31P-MRS examinations will be performed in a 7 T MR system (Siemens Healthcare, Erlangen, Germany) using a double-tuned (31P/1H) surface coil (Rapid Biomedical Ltd, Rimpar, Germany), with a diameter of 10 cm. Participants will be investigated lying in lateral position with the right lobe of the liver positioned over the coil.
224231568|NCT02115906|OTHER|oral glucose tolerance testing|"In patients without overt diabetes, glucose tolerance will be assessed by an oral glucose tolerance test, routinely performed at the outpatients clinic. The test will be performed in the morning after an overnight fast of at least 8 hours. Blood will be drawn via a catheter placed in an antecubital vein of one arm. Blood samples for the assessment of glucose, insulin, C-peptide, free fatty acids and growth hormone will be drawn at baseline as well as 30, 60, 90 and 120 minutes after ingestion of 75g glucose in a solution.~Concentrations of glucose, insulin and C-peptide will be used to derive parameters of insulin secretion and insulin sensitivity by mathematical modelling."
224231569|NCT02115906|OTHER|Thyroid sonography|In acromegalic patients thyroid morphology will be assessed at the outpatient clinic of the Division of Endocrinology and Metabolism, using standard ultrasound technique. Measurements will be performed by a well- experienced physician at baseline and at each follow up examination in an out-patient care setting.
224231570|NCT03988270|OTHER|Exercise|Participant randomized to an exercise protocol using a hand grip device that is used on a daily basis. Participant will be encouraged to increase the number of repetitions used by the hand grip device during the course of the trial
224231571|NCT02490488|DRUG|Masitinib|
224231572|NCT02490488|DRUG|Gemcitabine|
224231573|NCT02490488|DRUG|Placebo|
223645149|NCT00378365|PROCEDURE|ATRA|ATRA
223645150|NCT06276829|DIAGNOSTIC_TEST|LDH/albumin ratio|LDH/Albumin ratios of patient and control groups were recorded.
223645151|NCT04539795|DRUG|Alvelestat|oral tablet
223645152|NCT04539795|DRUG|Placebo|oral tablet
223645153|NCT01577888|DEVICE|Shockwave System Treatment|Shockwave System Treatment during vascular disease intervention.
223645154|NCT03549182|DRUG|ATD treatment|oral administration of ATD (100g)(Acute Tryptophan Depletion)
223645155|NCT03549182|DRUG|placebo treatment|oral administration of placebo (102.3g)
223645156|NCT01599637|DRUG|IGE025|Study medication will be supplied as a lyophilized, sterile powder in a single-use, 5-mL vial.
223645157|NCT01599637|DRUG|placebo|Study medication will be supplied as a lyophilized, sterile powder in a single-use, 5-mL vial.
223645158|NCT03460249|OTHER|BP measurement|the BP will be measured in the chair position followed by the table position and also in the reverse sequence
223645159|NCT04763369|BIOLOGICAL|Injection of stem cells in sub-tenon space of eye for the management of retinitis pigmentosa|Cultured stem cells will be injected in the sub-tenon space of eye and patients will be monitored and evaluated for outer retinal thickness, early treatment of diabetic retinopathy study visual acuity, visual field sensitivity, fundus photography, amplitudes of multifocal electroretinogram and implicit times of multifocal electroretinogram at baseline (day 0) and days 30, 60, 90, 180, 270 and 360.
223645160|NCT04763369|BIOLOGICAL|Injection of stem cells in suprachoroidal space of eye for the management of Retinitis Pigmentosa|Cultured stem cells will be injected in the suprachoroidal space of eye and patients will be monitored and evaluated for outer retinal thickness, early treatment of diabetic retinopathy study visual acuity, visual field sensitivity, fundus photography, amplitudes of multifocal electroretinogram and implicit times of multifocal electroretinogram at baseline (day 0) and days 30, 60, 90, 180, 270 and 360.
223645161|NCT06125717|BIOLOGICAL|H1 influenza antigen|Either 7.5 μg or 15 μg of the H1 influenza antigen
223645162|NCT00973635|OTHER|Web-based education|"Patients of subjects who were required to complete 10 web-based, independent learning modules. Each subject given a course packet which includes 13 required core articles pertaining to handoff skills. Each subject receives immediate feedback to each web-case with correct answers and suggested readings. Each subject given individualized feedback on their scores for summaries, instructions, and sign outs."
223645163|NCT02963285|OTHER|Nasopharyngeal temperature probe|Nasopharyngeal temperatures will initially be recorded 30 minutes after induction of anesthesia. Nasopharyngeal probes will then be withdrawn at the designated increment for each age group and will be equilibrated for 3 minutes before the temperature is recorded. Thereafter, the nasopharyngeal withdrawal sequence will be repeated.
223645164|NCT01483521|OTHER|Clinical home visitation|Clinical Home visitation consisted of once a month visits to families on the experimental group. During those visits home visitors facilitated developmentally appropriate play guidance and co-construction tasks for the dyad.
223645165|NCT01377337|DRUG|sodium bicarbonate|"1 mEq/kg sodium bicarbonate administered intravenously immediately following the administration of the first epinephrine dose during advanced CPR. Dose may be repeated every 5-10 minutes up to 3 doses.~Note: The Placebo Arm receives 1 ml/Kg of 0.9% NaCl (in a blinded fashion)."
223645166|NCT02124785|PROCEDURE|Blood sampling|At Years 21 to 25 after their second vaccine dose.
223645167|NCT04724109|DRUG|Equfina|Equfina oral tablets.
223645168|NCT02721966|BIOLOGICAL|Secukinumab|Anti IL-17a monoclonal antibody
223645169|NCT02721966|DRUG|Secukinumab and Placebo|Placebo matching AIN457
223645170|NCT05908019|OTHER|Web-based health care program|"According to the participants' feedback and recommends, we will modify this program to make it more suitable.~In the second and third years, we will conduct a parallel-group, double blind, and block randomization, experimental design study to examine the effectiveness of the Pulmonary Hypertension Web-Based Care Program on the improvements of patients' social support, self-care ability, active tolerance, symptom distress, depression, anxiety and quality of life in patients with PAH."
223645171|NCT03857867|DEVICE|Tactile Stimulation Glove|A glove device produces non-painful sensory (tactile) vibratory stimulation to the fingertips of Parkinson's patients.
223645172|NCT05740501|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
223645173|NCT05740501|OTHER|Electronic Health Record Review|Medical records are reviewed
223645174|NCT05740501|OTHER|Questionnaire Administration|Ancillary studies
223645175|NCT03367637|OTHER|Standard palliative care|Standard care includes regular follow-up phone calls and home visits by the RPCHO staff for all advanced cancer patients at RPCHO, though the timing of these calls is variable and is selected by the discretion of the team. In addition, patients can contact providers on a landline number available during business hours and staffed by an on-call palliative care provider as and when needed. For after-hours emergency assistance, patients have the option of contacting the on-call palliative-care physicians for assistance.
223645176|NCT03367637|OTHER|Smart Phone based symptom evaluation application|In addition to the standard palliative care currently provided at the RPCHO, patients will receive biweekly reminders to fill out the African Palliative Care Outcomes Scale (APCA POS) on the new smartphone application on their phones. It is a short symptom assessment questionnaire with responses on 5-point severity scale. In addition to bi-weekly frequency, patients can complete the symptom assessment at any time they feel their symptoms are poorly controlled. The team at RPCHO will be able to track all enrolled patients on a desktop dashboard. Any score of 2 or higher will be flagged. The providers at RPCHO will respond to such patients during business hours via call or text and will advise the patients as indicated or triage to a fellow team member.
223645177|NCT02157883|PROCEDURE|Pharmacokinetic sampling|Blood samples taken pre and post dosing with AZD9291+/- itraconazole
223645178|NCT02157883|DRUG|AZD9291|AZD9291 tablets: Part A 80mg od, days 1 and 10 only. Part B 80mg od for 12 months.
223645179|NCT02157883|DRUG|Itraconazole|Itraconazole tablets: 2x100mg bd, Part A days 6 to 19 only
223645180|NCT03229785|BIOLOGICAL|Human Umbilical Cord Blood Plasma|Plasma collected from human umbilical cord blood
224323479|NCT05382442|DRUG|Capecitabine|Capecitabine via oral,The total daily dose was 2000mg/sqm, Each cycle was administered for 2 consecutive weeks, followed by a week of rest, with a treatment cycle every 21 days
224323480|NCT05382442|DRUG|Irinotecan|Irinotecan via IV infusion
223645181|NCT00101673|DRUG|vildagliptin|
223645182|NCT02728687|DRUG|Mannitol|Apply cream as needed up to 4 times daily to the painful foot and leg
223645183|NCT02728687|DRUG|Menthol|Apply cream as needed up to 4 times daily to the painful foot and leg
223645184|NCT03810105|DRUG|Olaparib|Olaparib 300mg twice daily (600mg total daily dose)
223645185|NCT03810105|DRUG|Durvalumab|Durvalumab 1500mg IV monthly
223645186|NCT05701501|DRUG|Vitamin B5 Tablets|The experimental group was given Vitamin tablets (5mg/tablet) based on the standard IBD treatment.
223645187|NCT05701501|DRUG|placebo|The control group was given placebo tablets of the same type based on the standard IBD treatment.
223645188|NCT04948359|OTHER|Group I (The patients intubated with cuffed ETT of ID number 4.5)|Groups are classified according to endotracheal tube ID numbers. Inflating the endotracheal tube cuff with more than normal volume leads to decreased capillary blood flow and mucosal damage, while inflating the endotracheal tube cuff with less than normal volume leads to insufficient ventilation of the patient and an increase in the risk of pulmonary aspiration. The cuff pressure safety range is recommended between 20-30 cmH2O to prevent gas leakage and the risk of aspiration. We aimed to determine the optimal cuff volume that ensures airway safety in pediatric patients intubated with a 4.5 size inner diameter (ID) endotracheal cuff tube. Choosing the appropriate tube for endotracheal intubation is of great importance, especially in children. In our study, the transverse diameter of the subglottic airway will be measured by USG for the selection of the appropriate ETT to be used for each patient (the formulas for the selection of ETT in the literature will be used)
223645189|NCT04948359|OTHER|Group II (The patients intubated with cuffed ETT of ID number 5.0)|Groups are classified according to endotracheal tube ID numbers. Inflating the endotracheal tube cuff with more than normal volume leads to decreased capillary blood flow and mucosal damage, while inflating the endotracheal tube cuff with less than normal volume leads to insufficient ventilation of the patient and an increase in the risk of pulmonary aspiration. The cuff pressure safety range is recommended between 20-30 cmH2O to prevent gas leakage and the risk of aspiration. We aimed to determine the optimal cuff volume that ensures airway safety in pediatric patients intubated with a 5.0 size inner diameter (ID) endotracheal cuff tube. Choosing the appropriate tube for endotracheal intubation is of great importance, especially in children. In our study, the transverse diameter of the subglottic airway will be measured by USG for the selection of the appropriate ETT to be used for each patient (the formulas for the selection of ETT in the literature will be used)
223645190|NCT04948359|OTHER|Group III ( The patients intubated with cuffed ETT of ID number 5.5)|Groups are classified according to endotracheal tube ID numbers. Inflating the endotracheal tube cuff with more than normal volume leads to decreased capillary blood flow and mucosal damage, while inflating the endotracheal tube cuff with less than normal volume leads to insufficient ventilation of the patient and an increase in the risk of pulmonary aspiration. The cuff pressure safety range is recommended between 20-30 cmH2O to prevent gas leakage and the risk of aspiration. We aimed to determine the optimal cuff volume that ensures airway safety in pediatric patients intubated with a 5.5 size inner diameter (ID) endotracheal cuff tube. Choosing the appropriate tube for endotracheal intubation is of great importance, especially in children. In our study, the transverse diameter of the subglottic airway will be measured by USG for the selection of the appropriate ETT to be used for each patient (the formulas for the selection of ETT in the literature will be used)
223645191|NCT01607684|DEVICE|Magnetic Marker Imaging (MMI) with Magma 3D system|Magnetic Marker Imaging (MMI). It comprises of a high-resolution three-dimensional detector system, that detects passively and continuously the magnetic field of a magnetic marker capsule (1g, 6x12mm), which is taken orally by the subject. Changes in frequency, intensity and duration of oscillating marker movements allow us to delineate migrating gastric motor complexes. The Magnetic Marker Imaging takes up to 4 h in which the patient lies in a bed. Short interruptions (e.g. to visit the restroom) during this 4 h period are possible.
223645192|NCT06492525|DRUG|Ensartinib|225 mg oral dose on day 1 in period 1 and on day 18 in period 2
223645193|NCT06492525|DRUG|Rifampicin|600 mg QD from day 9 to day 22 in period 2
223645194|NCT06492525|DRUG|Itraconazole|200 mg QD from day 9 to day 19 in period 2
223645195|NCT06492525|DRUG|Ensartinib|100 mg oral dose on day 1 in period 1 and on day 12 in period 2
223645196|NCT02790190|OTHER|Radiotherapy dose|
223645197|NCT03725891|DRUG|Aspirin 162 mg|Aspirin 81mg two tablet once a day from recruitment until 37 weeks or labor whichever comes first
223645198|NCT03725891|DRUG|Aspirin 81 mg|placebo one tablet once a day from recruitment until 37 weeks or labor whichever comes first
223645199|NCT03725891|DRUG|placebo|placebo one tablet once a day from recruitment until 37 weeks or labor whichever comes first
223645200|NCT02544581|OTHER|Soberlink combined with aftercare services|Soberlink Alcohol Breath Analyzer System combined with aftercare services
223765865|NCT06980636|OTHER|Placebo|A simulated Shengmaiyin oral liquid (provided by Jilin Aodong Yanbian Pharmaceutical Co., Ltd., with main ingredients water, brown sugar, flavoring agents, etc., specification 10m/bottle), 10ml per time, three times a day. The treatment course for Shengmaiyin or placebo will be 8 weeks (56 days), with follow-up continuing until 30 days after the end of the treatment course.
224323481|NCT05382442|DRUG|Leucovorin|Leucovorin via IV infusion
223645201|NCT01106248|DRUG|Eribulin Mesylate|1.4 mg/m\^2 intravenous (IV) bolus given over 2-5 minutes on Days 1 and 8 every 21 days.
223645202|NCT00357903|BIOLOGICAL|Etanercept|Adult Rheumatoid Arthritis (RA) patients on etanercept (TNFR:Fc) with well controlled arthritic symptoms will continue on the etanercept (TNFR:Fc) dose administered in their original protocol of enrollment. All other adults will receive 50 mg per week as two 25 mg subcutaneous (SC) injections at separate sites, either on the same day or 3 or 4 days apart. Pediatric patients ages 4 to 17 years will receive a 0.8 mg/kg per week dose (up to a maximum of 50 mg per week).
223765866|NCT02598180|DEVICE|VergenixTM Flowable Gel|The VergenixTM Flowable Gel is supplied as powder contained in a syringe that will be hydrated with saline.
223765867|NCT05849467|DRUG|89 Zr-Df-crefmirlimab|"an 80 kDa minibody (Mb) with high~affinity to CD8 glycoprotein (binding EC50 = 0.4 nM) that is conjugated with deferoxamine (Df)~and radiolabeled with the positron emitting radionuclide, Zr-89 (T1/2 78.4 hours)."
223765868|NCT05764564|DIAGNOSTIC_TEST|Positive or negative pressure|Positive or negative pressure is applied via a closed chamber.
224323482|NCT05382442|DRUG|5-fluorouracil|5-fluorouracil via IV infusion
223645203|NCT00606593|DRUG|ACT-078573 oral capsules at 25 and 100 mg and matching placebo|5-period, 5-treatment crossover: sequences: ABECD, BCADE, CDBEA, DECAB, EADBC DCEBA, EDACB, AEBDC, BACED, CBDAE Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
223645204|NCT00606593|DRUG|ACT-078573 and matching placebo|ACT-078573 oral capsules at 25 and 100 mg and matching placebo 5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
223645205|NCT00606593|DRUG|ACT-078573 and matching placebo|ACT-078573 oral capsules at 25 and 100 mg and matching placebo 5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
223645206|NCT00606593|DRUG|ACT-078573 and matching placebo|ACT-078573 oral capsules at 25 and 100 mg and matching placebo 5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
223645207|NCT00606593|DRUG|ACT-078573 and matching placebo|ACT-078573 oral capsules at 25 and 100 mg and matching placebo 5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
223645208|NCT00606593|DRUG|ACT-078573 and matching placebo|ACT-078573 oral capsules at 25 and 100 mg and matching placebo 5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
223645209|NCT00606593|DRUG|ACT-078573 and matching placebo|ACT-078573 oral capsules at 25 and 100 mg and matching placebo 5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
223645210|NCT00606593|DRUG|ACT-078573 and matching placebo|ACT-078573 oral capsules at 25 and 100 mg and matching placebo 5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
223645211|NCT00606593|DRUG|ACT-078573 and matching placebo|ACT-078573 oral capsules at 25 and 100 mg and matching placebo 5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
224231574|NCT05102279|DIETARY_SUPPLEMENT|Giving subjects different phosphorus diets at different stages of the trial|Ordinary phosphorus diet: Phosphorus content 1500mg High phosphorus diet: Phosphorus content 2500mg (inorganic phosphorus is added to the ordinary phosphorus diet) Low phosphorus diet: Phosphorus content 500mg (Protein content is achieved through chicken albumen and addition of low-phosphorus whey protein powder) The ratio of plant protein and animal protein is the same as the other two diets. In addition, calcium-magnesium tablets and potassium chloride salt are added to achieve the same calcium, magnesium and potassium content as the other two diets.) There are 2 recipes for each diet. Ensure that the energy, protein, fat, carbohydrate, calcium, magnesium, sodium, potassium, oxalic acid content, vegetable protein and animal protein ratio are basically the same: Energy: 2100kcal (30kcal/kg, standard body weight 70kg) Protein: 110g Fat: 55-60g Carbohydrate: 300g Calcium: 600-700mg Magnesium: 350-400mg Sodium: 4600mg Potassium: 2500mg
223645212|NCT00606593|DRUG|ACT-078573 and matching placebo|ACT-078573 oral capsules at 25 and 100 mg and matching placebo 5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
224231575|NCT00747188|BEHAVIORAL|PBL|
223645213|NCT03181529|DRUG|Psilocybin|Participants will receive a moderately high psilocybin dose in the first session and will receive either a moderately high or high psilocybin dose in the second session.
223645214|NCT04618107|PROCEDURE|Wide awake surgery|Wide awake local anaesthesia was used to perform tendon repair surgeries.Local anaesthetic injections given using 27 gauze needle in subcutaneous tissue plane.Tendon repair performed using modified Kessler repair.Outcome of surgery assesed at sixth postoprative week.
223645215|NCT04618107|PROCEDURE|General anaesthesia|Tendon repair performed under general anaesthesia using modified Kessler repair.Outcomes of surgery assesed at sixth post operative week
223645216|NCT05828329|BEHAVIORAL|Guided visualization of exams through immersive virtual reality|During 4 weeks (twice per week), students will visualize a 30-minutes 360º video that simulates the experience of an exam, from first person perspective.
223645217|NCT05828329|BEHAVIORAL|Guided visualization of exams through traditional method|During 4 weeks (twice per week), students will listen a 30-minutes audio that explains the experience of an exam from first person.
223645218|NCT02064257|BEHAVIORAL|Listening Project Protocol|The intervention will consist of listening to computer-altered acoustic stimulation, designed to modulate the frequency band of vocal music passed to the participant. The frequency characteristics of the acoustic stimulation are selected to emphasize the relative importance of specific frequencies in conveying the information embedded in human speech. Modulation of the acoustic energy within the frequencies of human voice, similar to an exaggerated vocal prosody, are hypothesized to recruit and modulate the neural regulation of the middle ear muscles and to functionally reduce sound hypersensitivities and improve auditory processing.
223645219|NCT03333278|DRUG|Vitamin C|Ascorbic acid 1.5g every 6 hours i.v. while in ICU, until shock resolution for a maximum of ten days
223645220|NCT03333278|DRUG|Thiamine|Thiamine 200mg every 12 hours i.v. while in ICU, until shock resolution for a maximum of ten days
223645221|NCT03333278|DRUG|Hydrocortisone,|Hydrocortisone 50mg every 6 hours i.v while in ICU, until shock resolution or for a maximum of 7 days, then tapered or stopped.
223645222|NCT03586557|DEVICE|Corticosteroid & Plasma exchange|High-dose intravenous methylprednisolone 1000mg 3\~5 days and subsequent taper, combined simultaneous plasma exchange 5 times in all
223645223|NCT03586557|DRUG|Corticosteroid|High-dose intravenous methylprednisolone 1000mg 3\~5 days and subsequent taper
223645224|NCT05803733|OTHER|Blood flow restriction (BFR) with low load resistance training|Combination of low load resistance exercise in the upper limb.
223645225|NCT05803733|OTHER|Routine strength training|range of motion exercises and strength training
223645226|NCT00501917|DRUG|G-CSF with/without darbepoetin, peripheral blood stem cell infusion|
223645227|NCT04921072|BEHAVIORAL|Constant practice conditions|CG will be practicing only one specific pattern of step isometric contractions (SPSIC) scheme. It means that 90 trials in all training sessions will consist only of SPSIC 1.
223645228|NCT04921072|BEHAVIORAL|Variable practice conditions|VG will practice three SPSIC's (1-3). Each SPSIC will be practiced 30 times per session, which means that each session will consist of 90 SPSIC like CG.
223645229|NCT02952404|PROCEDURE|Educational workshop|The educational workshop for improved perineal support during vaginal delivery
223645230|NCT00231569|DRUG|ISIS 301012 or Placebo|30 mg subcutaneous injection on days 1, 8, 10, 12, 15, 22, and 29
223645231|NCT00231569|DRUG|ISIS 301012 or Placebo|100 mg subcutaneous injection on days 1, 8, 10, 12, 15, 22, and 29
223645232|NCT00231569|DRUG|ISIS 301012 or Placebo|200 mg subcutaneous injection on days 1, 8, 10, 12, 15, 22, and 29
223645233|NCT00231569|DRUG|ISIS 301012 or Placebo|300 mg subcutaneous injection on days 1, 8, 10, 12, 15, 22, and 29
223645234|NCT00231569|DRUG|ISIS 301012 or Placebo|400 mg subcutaneous injection on days 1, 8, 10, 12, 15, 22, and 29
223645235|NCT00231569|DRUG|ISIS 301012 or Placebo|200 mg subcutaneous injection on days 1, 8, 10, 12, 15, 22, 29, 36, 43, 50, 57, 64, 71, 78, and 85
223645236|NCT00231569|DRUG|ISIS 301012 or Placebo|300 mg subcutaneous injection on days 1, 8, 10, 12, 15, 22, 29, 36, 43, 50, 57, 64, 71, 78, and 85
223645237|NCT06402656|DEVICE|Customized facemask|The customized face mask will be fabricated from a 3D digital image of the patient's face obtained by means of a 3D scanner. Such a scanner consists of 6 digital SLR cameras and software capable of processing a 3-D image of the patient's face exportable as an stl file.
223645238|NCT06402656|DEVICE|Standard facemask|The standard facemask is the commercially available Petit standard facemask
223645239|NCT00507780|DRUG|GnRH antagonist|
223645240|NCT02694289|DRUG|Metformin|Treatment/continuation of metformin therapy during admission
223765869|NCT03553875|DRUG|Memantine Hydrochloride|Participating children and adolescents with Non-Verbal Learning Disorder and related conditions (NVLD-RC) who meet the eligibility criteria will be randomly assigned to memantine for the course of the 12-week randomized controlled trial (RCT).
224231576|NCT00634907|GENETIC|Pharmacogenetic-based warfarin dosing|"Prior to elective joint replacement surgery a blood sample is collected for genetic information(genotyping)which was used for calculating warfarin doses for patients randomized to the cytochrome arm. Outcomes in terms of efficacy, safety, and management of warfarin were compared between this group and the group in which warfarin doses are determined per usual care.~NOTE: Standard of care for elective knee and hip replacement at our institution is to receive post-operative warfarin thromboprophylaxis. Administration of warfarin was not specific to this study, nor was the duration of prophylaxis, however, warfarin dosing was influenced by the study arm as noted above."
224231577|NCT00634907|OTHER|Usual care warfarin dosing|"For patients in arm 2, the control group, warfarin dosing is per usual care. Outcomes in terms of safety, efficacy, and warfarin management was compared to that of patients in the other arm, who receive warfarin dosing based on genotyping.~NOTE: Standard of care for elective knee and hip replacement at our institution is to receive post-operative warfarin thromboprophylaxis. Administration of warfarin was not specific to this study, nor was the duration of prophylaxis, however, warfarin dosing was influenced by the study arm as noted above."
224231578|NCT01261078|DRUG|Placebo|intrathecal 8 mg of bupivacaine only
224231579|NCT01261078|DRUG|epinephrine 25|intrathecal 8 mg of bupivacaine mixed with 25 mcg of epinephrine
224231580|NCT01261078|DRUG|Epinephrine 50|intrathecal 8 mg of bupivacaine mixed with 50 mcg of epinephrine
224231581|NCT01261078|DRUG|epinephrine 100|intrathecal 8 mg of bupivacaine mixed with 0.1 mg of epinephrine
224231582|NCT01261078|DRUG|Epi 200|intrathecal bupivacaine 8 mg with 200 mcg of epinephrine
223765870|NCT03553875|DRUG|Placebo|Participating children and adolescents with Non-Verbal Learning Disorder and related conditions (NVLD-RC) who meet the eligibility criteria will be randomly assigned to placebo for the course of the 12-week randomized controlled trial (RCT).
223765871|NCT06808828|BEHAVIORAL|Health and coping skills|An occupational therapist and occupational therapy graduate capstone student will lead in-person sessions. Subjects will participate in an occupational therapy program that meets 2x/week x 4 weeks for eight sessions. Topics will include sleep hygiene, physical activity, healthy cooking, self-management, coping skills, self-esteem, mindfulness, and goal setting. Subjects will receive education as well as actively engage in activities related to the topic. Subjects will be provided with a personal journal to complete homework involving reflections on the topics discussed in the sessions.
223765872|NCT06806267|DEVICE|Virtual reality exposure therapy|Exposure therapy applied through virtual reality goggles, controlled by a clinician
223645241|NCT02694289|DRUG|Subcutaneous (sliding scale) Insulin|Discontinue Metformin and be placed on subcutaneous sliding scale insulin during admission
223645242|NCT02863120|DRUG|liposomal bupivacaine|
223645243|NCT02863120|DRUG|bupivacaine HCl|
223645244|NCT02863120|DRUG|Ropivacaine|
223645245|NCT02863120|DRUG|Saline|
223645246|NCT06409546|DRUG|Tocopherol and pentoxifilline topical gel|Oral gel applied locally on the MRONJ related lesions or post-extraction sockets
223645247|NCT06409546|DRUG|Placebo|Oral gel applied locally on the MRONJ related lesions or post-extraction sockets
223645248|NCT02119377|OTHER|questionnaire|
223645249|NCT05037929|DRUG|Astegolimab|Participants will receive SC astegolimab Q2W or Q4W.
223645250|NCT05037929|DRUG|Placebo|Participants will receive SC placebo Q2W.
223645251|NCT06494826|OTHER|colonoscopy procedure|"Candidates for a medically-indicated colonoscopy due to suspected new-onset CD or non-specific GI complaints or routine screening for colorectal cancer as part of primary prevention.~colonoscopy will not be done for research purposes only ."
223645252|NCT02809235|DIETARY_SUPPLEMENT|coconut oil|3 tablespoons per day of supplemental coconut oil
223645253|NCT05318313|OTHER|Telerehabilitation|The TR PT evaluation and follow-up visits will be performed via Zoom software
223645254|NCT06595667|PROCEDURE|Pulse pressure variation|Fluid administration during posterior fossa surgery in the parkbench position is guided by the PPV value.
223645255|NCT06595667|PROCEDURE|Central venous pressure|Fluid administration during posterior fossa surgery in the parkbench position is guided by the CVP value.
223645256|NCT06603480|BEHAVIORAL|Exercise|Aerobic exercise (moderate intensity) at 50-70% of maximum heart rate for 60 minutes, 3 days a week for 12 weeks
223645257|NCT06603480|OTHER|Metformin|Patients who started Metformin 2\*1
223645258|NCT06600399|DIAGNOSTIC_TEST|glioblastoma|All patients underwent conventional MRI, ASL perfusion imaging and 68Ga-PSMA-11 PET/CT examinations within 1 week interval
223645259|NCT06591000|PROCEDURE|tricuspid valve replacement|Complete or partial tricuspid valve replacement with mitral allograft/ complete tricuspid valve replacement with biological prosthesis
224231583|NCT01645306|DRUG|Revacept|single intravenous injection
224231584|NCT01645306|DRUG|Placebo|single intravenous injection
224231585|NCT03445195|DRUG|Sulbactam-ETX2514|The ETX2514SUL regimen of 1 g ETX2514/1 g sulbactam infused over 3 hours q6h.
224231586|NCT03445195|DRUG|Placebo|Matching 1g IV solution.
224231587|NCT03445195|DRUG|Imipenem-cilastatin|All patients will receive background therapy with 500 mg IV imipenem/cilastatin q6h.
223645260|NCT06591156|PROCEDURE|Root coverage|"Treatment of gingival recession, Miller\&#39;s Class I or Cairo\&#39;s RT1, which is the most predictable group to receive interventions without any impairment or problem for the patients.~After local anesthesia, a horizontal incision was made, delimitating the coronal part of the flap. This horizontal incision of the envelope flap consists of an oblique submarginal incision in the interdental areas that creates a surgical papilla. The incisions continue with the intrasulcular incision in the recession defects and are extended to form an envelope flap between the central and molar. This design facilitates the planned coronal repositioning of the flap tissue on the exposed root surfaces.~The apical gingival tissue at root exposures is raised to a full thickness to provide the critical part of the flap for root coverage with more thickness. Finally, the most apical portion of the flap is elevated in a split-thickness to facilitate coronal displacement of the flap."
223645261|NCT06591156|PROCEDURE|control group|Coronally advanced flap without any graft or biomaterial
223645262|NCT06591247|DEVICE|Double Baloon Catheter|A double Baloon Catheter will be inserted for 12 hours to one of the arms of the study
223645263|NCT06591247|PROCEDURE|Membrane Stripping|Stripping will be considered as 3-5 rotations of separating the amniotic sac from the cervix and will be perfomed twice (every 4-6 hours)
223645264|NCT04895644|OTHER|No Hard Collar|The patient in the intervention arm will not wear a Hard Collar for 12 weeks post injury
223645265|NCT06299475|OTHER|Online counseling and invitation|"Online counseling - An educational video including contraceptive models, four key questions and an effectiveness chart (the LOWE intervention material).~Invitation to a clinic - access by weblinks to a regional or national website"
223645266|NCT06372691|OTHER|Subparaneural Injection (Grup S), Block|Comparison of two different methods in terms of various features
224231588|NCT05709509|DRUG|Colchicine|Colchicine: A major alkaloid from Colchicum autumnale L. and found also in other Colchicum species. commonly used as anti-inflammatory drugs.
224231589|NCT05709509|PROCEDURE|Percutaneous Coronary Intervention|Percutaneous Coronary Intervention: a family of minimally invasive procedures used to open clogged coronary arteries (those that deliver blood to the heart)
224231590|NCT05709509|OTHER|Optimal medical treatment including statin, aspirin, P2Y12 inhibitor, and nitrate.|The subjects just received optimal medical treatment including statin, aspirin, P2Y12 inhibitor, and nitrate.
224231591|NCT01787136|DRUG|Dextromethorphan|added on therapy
224231592|NCT05180006|DRUG|Atezolizumab Injection|Patients randomized to an atezolizumab arm will receive atezolizumab 840 mg IV on D1 (15 days +/- 48 h before the surgery date or the biopsy prior to the start of standard of care neoadjuvant systemic treatment.).
224231593|NCT05180006|DRUG|Bevacizumab|Patients in the atezolizumab plus bevacizumab arm will receive a unique dose of bevacizumab as 10 mg/kg administered by IV infusion over 60 mins on day 1 cycle 1 (15 days before surgery +/- 48 h), the same day as atezolizumab.
224231594|NCT05180006|DRUG|Pertuzumab|Patients in the atezolizumab plus trastuzumab plus pertuzumab arm will receive single doses of pertuzumab on day 1 administered IV. Pertuzumab will be administered IV at a loading dose of 840 mg.
223645267|NCT06372691|OTHER|Interneural Injection (Grup I), Block|Comparison of two different methods in terms of various features
223645268|NCT06992947|OTHER|Healthy food subsidy: $27/household/week|Participants receive 16 weeks of coupons valued at $27/week to purchase healthy foods at BC farmers' markets. Eligible foods include vegetables, fruits, dairy, meat, poultry, fish, eggs, nuts, vegetable and fruit plants, honey and herbs.
223645269|NCT06992947|OTHER|Healthy food subsidy: $54/household/week|Participants receive 16 weeks of coupons valued at $54/week to purchase healthy foods at BC farmers' markets. Eligible foods include vegetables, fruits, dairy, meat, poultry, fish, eggs, nuts, vegetable and fruit plants, honey and herbs.
223645270|NCT06992947|OTHER|Healthy food subsidy: $81/household/week|Participants receive 16 weeks of coupons valued at $81/week to purchase healthy foods at BC farmers' markets. Eligible foods include vegetables, fruits, dairy, meat, poultry, fish, eggs, nuts, vegetable and fruit plants, honey and herbs.
224231595|NCT05180006|DRUG|Trastuzumab|Patients in the atezolizumab plus trastuzumab plus pertuzumab arm will receive single doses of Trastuzumab on day 1 administered IV. Trastuzumab will be given at a loading dose of 8 mg/kg.
224231596|NCT04982146|DRUG|Bromelin|0.5mg per mL of total tumor volume calculated, administered percutaneously
224319820|NCT05962762|BIOLOGICAL|Human Umbilical Cord Mesenchymal Stem Cells|"The trial was conducted sequentially from the low dose group to the high dose group, with 3-6 subjects enrolled in each dose group. The trial was conducted on a case-by-case basis in the high dose group, with each subject in the high dose group being enrolled in subsequent subjects only after completion of at least 7 days of post-dose safety observation. Each subject received only one corresponding dose. All subjects received experimental drugs and conventional treatment during the study period.~All subjects in each test dose group will complete a 4-week (28-day) dose-limiting toxicity (DLT) After the observational evaluation period, a decision will be made by the investigator and sponsor based on a discussion of relevant safety data whether to start the next dose group."
223645271|NCT06992947|OTHER|Nutrition skill-building|Participants are eligible, but not required, to attend optional nutrition skill-building activities (e.g. cooking and gardening classes).
223680902|NCT04393298|DRUG|trifluridine/tipiracil|Study participants will receive predefined doses of trifluridine/tipiracil (TFD/TPI) administered as film-coated tablets at pre-specified time points.
224231597|NCT04982146|DRUG|N-Acetylcysteine|20mg per mL of total tumor volume calculated, administered percutaneously
224231598|NCT00425815|DRUG|Org 24448|Org 24448 is a moderate-potency selective AMPA positive modulator that enhances the glutamate system in the brain.
224231599|NCT00425815|OTHER|Placebo|Placebo comparison
224231600|NCT02204371|DRUG|Pazopanib|Pazopanib is available as 50 mg and 200 mg tablets to be administered orally once daily in the morning at least one hour before or two hours after a meal for 12 weeks
224231601|NCT02204371|DRUG|Placebo|Pazopanib matching placebo is available as tablets to be administered orally once daily in the morning at least one hour before or two hours after a meal for 12 weeks
224231602|NCT01447264|PROCEDURE|Land exercises|3 times a week. 50 minutes in every session. Performed by educational professor
224231603|NCT01447264|PROCEDURE|Water exercises|3 times a week. 50 minutes in every session. Performed by educational professor
224231604|NCT02419313|DRUG|incobotulinumtoxinA|Subjects randomized to the active drug intervention arm will receive incobotulinumtoxinA (Xeomin). A series of rating scales and examinations will take place prior to treatment and for 24 weeks after treatment. At 12 weeks the subjects will cross over to the placebo (saline) arm.
224231605|NCT02419313|DRUG|Saline|same volume as injected for incobotulinum toxin A into forearm muscles under EMG guidance.
223765873|NCT06806267|DEVICE|transcranial direct current stimulation|transcranial direct current stimulation applied to the vmpfc, 2mA
223765874|NCT06806267|BEHAVIORAL|Imaginal exposure therapy|Imaginal exposure therapy
223765875|NCT06581263|DEVICE|Meta Quest 3|Meta Quest 3 is a virtual reality headset device
223765876|NCT04466891|DRUG|ZW25 (Zanidatamab)|Administered intravenously
223765877|NCT06978621|BIOLOGICAL|Inactivated hepatitis A vaccine (I-HAV)|"A formaldehyde-inactivated hepatitis A virus (HM175 hepatitis A virus strain)~Dose and administration: 0.5 mL intramuscular injection for participants age \<=18 years, and 1.0 mL intramuscular injection for participants age 19 years and above."
224231606|NCT03097042|PROCEDURE|Embryo transfer any further manipulation|The catheter will be pulled back slowly and without rotation with the plunger still pushed forward
224231607|NCT03097042|PROCEDURE|Embryo transfer with catheter Manipulation|catheter rotation during withdrawal
224231608|NCT01158365|DRUG|LACTIC ACID (Dermacid)|Route of administration: local
224231609|NCT01158365|DRUG|Glycerine Vegetal Soap Granado Traditional|Route of administration: local
224231610|NCT03972566|DRUG|INOMAX|INOMAX + PBM
224319821|NCT00307437|DRUG|Placebo; Ustekinumab (CNTO 1275) 45 or 90 mg|Placebo at Weeks 0 and 4 and blinded SC injections of ustekinumab, 45 or 90 mg, at Weeks 12 and 16; followed by a dosing regimen to be determined by patient's response status for Weeks 28 to 52; followed by unblinded dosing that may be adjusted at the investigator's discretion for Weeks 52 to 264
223645272|NCT05104112|OTHER|The M.E.R. program|"The M.E.R program is a therapeutic education intervention for mothers of children with ASD during a new pregnancy. This program, which is a pilot in France and in Europe, involves several dimensions, both pedagogical and behavioral (strategies for stimulating the baby, use of specific communication and interaction tools) and psychological (reduction of stress, anxiety, etc. in the mother).~It includes 8 individual interviews of 1h30 every 15 days. The first and the last one are for evaluation purposes, the 6 intermediate sessions constitute the accompaniment. The structure of the program and the sessions are based on what is recommended in therapeutic education. The sessions can take place on the hospital site or at home."
223645273|NCT06601361|DEVICE|Fibroscan|Fibroscan (transient elastography ) is a non-invasive imaging method that evaluates steatosis and fibrosis by measuring liver stiffness using ultrasonographic sound waves. It is an acceptable alternative to liver biopsy and is fast , reliable, and reproducible, enabling screening and disease follow-up.11 It is now widely used to assess liver fibrosis in various liver diseases; however, currently there is no data on Fibroscan assessment regarding hepatic involvement in SLE patients. The aim of this study was to evaluate fatty liver and liver fibrosis in SLE patients using fibroscan and determine associated factors such as immunosuppressive medications.
223765878|NCT00004078|DRUG|irinotecan hydrochloride|Given IV
223765879|NCT04063033|DRUG|IV iron - Sodium Ferric Gluconate Complex|IV Iron will be administered 125 mg each day, to 3-5 days during hospitalisation.
224231611|NCT05705713|RADIATION|chest computed tomography (CT)|Within the first 12 hours of suspected inhalation lung injury, fiberoptic bronchoscopy was done to confirm the diagnosis. After confirming the diagnosis, an initial chest CT in the first 24 hrs through which the radiologist score (RADS) together with bronchial wall thickening (BWT) was done.
224231612|NCT04581005|BEHAVIORAL|Prehabilitation|Endurance and Resistance Exercise, Nutrition therapy, reducing intervention during the whole preoperative period
223765880|NCT05403710|DRUG|Botulinum toxin|Administration of botulinum toxin (50 units/100cm2 injected intradermally) into lesional skin
223765881|NCT03203902|OTHER|Psychoeducation and Therapeutic Touch|6-week, 1-hour psychoeducation group followed by 30-minute therapeutic touch
223765882|NCT07000994|DRUG|Dobutamine|In patient assigned to dobutamine administration, dobutamine (concentration: 5 mg mL-1) will be administered with an infusion rate of 3 µg kg-1 min-1 (ideal body weight).
223765883|NCT07000994|OTHER|Routine care|In patients assigned to routine care, intraoperative hemodynamic management will be in accordance with routine care.
223765884|NCT07024212|DRUG|DR10624 Injection|Drug: DR10624 injection
223765885|NCT07024212|DRUG|Placebo|Drug: Placebo
223765886|NCT06881472|DRUG|Glucose-dependent Insulinotropic Polypeptide (GIP)|GIP
223765887|NCT06881472|DRUG|alanine|Alanine
224231613|NCT04351009|PROCEDURE|sentinel lymph node mapping|Through on-table colonoscopy indocyanine green solution will be injected in the submucosa at 2-4 points around the tumor for laparoscopic surgeries. Dye will be injected in the subserosa at 2-4 points for open surgeries. Lymphatic flow from the tumor will be mapped in real time with near-infrared fluorescence imaging scope and sentinel lymph nodes will be identified.
224231614|NCT03196999|BEHAVIORAL|Personalized Attention Bias Training|This self-help program will aim to reduce neurobiological threat sensitivity with the ultimate goal of developing a low-cost and highly scalable self-help tool to alleviate symptoms of PTSD. The app can be used on an iOS compatible phone and involves a training program that aims to directly reduce threat sensitivity by modifying attention. The contents of the app will be personalized for each user.
223765888|NCT06881472|DRUG|Saline (NaCl 0,9 %) (placebo)|Placebo
224231615|NCT03196999|BEHAVIORAL|Neutral Attention Training Condition|This self-help program is a placebo control program that will be used on an iOS compatible phone. The placebo will contain only neutral words.
224231616|NCT03196999|BEHAVIORAL|Non-Personalized Attention Bias Training|This self-help program administered on an app will aim to reduce neurobiological threat sensitivity with the ultimate goal of a low-cost and highly scalable self-help tool to alleviate symptoms of PTSD. The app can be used on an iOS compatible phone and involves a training program that aims to directly reduce threat sensitivity by modifying attention. The contents of the app will be the same for each user.
224231617|NCT03439163|DEVICE|MRI scan|All participants underwent the MRI scan
224231618|NCT00120900|DRUG|GW406381|
223645274|NCT06598917|DRUG|S-1|"Treatment schedule At 4 to 8 weeks after chemotherapy and radiotherapy ended, maintenance S-1 was administered for up to 12 cycles. A cycle was 3 weeks, with S-1 administrated on days 1 to 14 in each cycle.~The initial dose of S-1 was determined according to the body surface area (BSA): 40 mg twice a day for BSA \&lt; 1.25 m2; 50 mg twice a day for 1.25 m2⩽ BSA \&lt; 1.5 m2; and 60 mg twice a day for BSA ⩾1.5 m2.~Maintenance chemotherapy with S1 was administered for 12 cycles or terminated earlier if there was disease progression, intolerable toxicity, or at the patient's request."
223645275|NCT06600256|BEHAVIORAL|Viz HCM ECG Review|Viz HCM will auto-alert relevant users to ECGs the algorithm has deemed as suspicious for HCM. Following review of this alert and the patient\&amp;#39;s Medical/Clinical History, the reviewer will take the next Standard of Care action they deem appropriate.
223645276|NCT06600256|BEHAVIORAL|Baseline Effectiveness Cohort|A review of the timing and clinical details of the diagnostic process for patients diagnosed with HCM before the site began using Viz HCM.
223645277|NCT06991413|DEVICE|PMS App|The PMS App helps to implement multimodal self help measures in the daily lives of PMS patients through various functions such as symptom diary and interactive exercises.
223645278|NCT06588465|DEVICE|On-venous Laser Irradiation of Blood|The treatment will take place three times a week, over six weeks. The On-venous Laser will placed in the body for 60 minutes. A total of 15 laser heads (15 acupoints, bilaterally) will be used in each session.
223645279|NCT06588465|DEVICE|low dose On-venous Laser Irradiation of Blood|The treatment will take place three times a week, over six weeks. The low dose On-venous Laser will placed in the body for 60 minutes. A total of 15 laser heads (15 acupoints, bilaterally) will be used in each session.
223645280|NCT06599294|PROCEDURE|Digital scanning|. For each patient three digital files will be obtained: One reference scan, one conventional IOS scan, and one IPS scan. All the STL files will be imported to dental CAD software, and scan bodies will be converted to implant multi-unit ti-base using a digital library. The updated STL files will be imported to inspection software Mimics for trueness assessments. The three-dimensional discrepancy between 2 STL files will be evaluated in terms of linear and angular deviation. A central point \&amp; central axis of the virtual MUA ti-base was used for deviation measurements. Linear deviations will be assessed for each MUA tibase on the three-space axis (X longitudinal, Y lateral, and Z vertical) using the center of the ti-base heads for the deviation measurement. Angular deviations were assessed as the angles formed by the two lines passing perpendicularly through the centers of the test image and the reference image of each ti-base.
223680903|NCT04393298|DRUG|mFOLFOX6|Study participants will receive predefined doses of oxaliplatin, Leucovorin and 5-fluorouracil as part of the mFOLFOX6 chemotherapy regimen administered as intravenous (iv) infusion at prespecified time points.
223765889|NCT06889246|DIETARY_SUPPLEMENT|Anvitra Gastric Suspension|Anvitra Gastric Suspension is provided as a liquid oral preparation, designed with a pleasant flavor to ensure compliance in patients. The intervention involves administering 1 packet (15 ml) per dose three times daily, taken orally 30 minutes after meals, for a duration of 14 days. The supplement is intended to alleviate symptoms of GERD (heartburn, regurgitation, and dyspepsia). Anvitra Gastric Suspension has been widely used in clinical and community settings, with a favorable safety profile and reported effectiveness in GERD treament.
224231619|NCT01093209|DEVICE|Interferential Laser Therapy|PROCEDURE: Interventional group: Two independents and identical probes. Energy dose per point and per probe: 5 J. Continuous emission. Treatment time:8 minutes. Sessions: 10. Frequency of the sessions: daily. Irradiation technique: handily, in contact and at 7 points over distal pathway of median nerve.Control group: Sham laser:650 nm.Scanning mode.Outpout power:1 mW.
224231620|NCT03706989|PROCEDURE|EEG|EEG samples will be recorded before and during the cardiac surgery in order to perform spectral and coherence analyses
224231621|NCT03706989|GENETIC|Apolipoprotein genotype|APOE genotyping will be performed for each patient
224319822|NCT00307437|DRUG|Ustekinumab (CNTO 1275) 45 mg|Ustekinumab, 45 mg, at Weeks 0 and 4 and every 12 weeks for Weeks 16 to 28. Followed by a dosing regimen to be determined by patient's response status for Weeks 28 to 52; followed by unblinded dosing that may be adjusted at the investigator's discretion for Weeks 52 to 264
224231622|NCT03706989|BIOLOGICAL|Serum NfL measurements|5 perioperative blood samples will be taken to measure the evolution of NfL in the serum (before and until postoperative day 5)
224231623|NCT03706989|OTHER|Preoperative neurocognitive evaluation|Each patient will benefit from a complete neurocognitive evaluation before surgery (battery of validated cognitive tests)
224231624|NCT03072680|BEHAVIORAL|BPS PAST|"Participants think about themselves in a past when they displayed their best self. Then, they visualize this with the help of audio instructions.~They will practice within a mobile app."
224231625|NCT03072680|BEHAVIORAL|BPS FUT|"Participants think about themselves in the future after everything has gone as well as it possibly could. Then, they visualize this with the help of audio instructions.~They will practice within a mobile app."
224231626|NCT03072680|BEHAVIORAL|DAILY ACTIVITIES|"Participants think about the activities they did during the last 24 hours. Then, they visualize this with the help of audio instructions.~They will practice within a mobile app."
224231627|NCT01159548|DRUG|Promethazine|
224231628|NCT01159548|DRUG|Promethazine|
224231629|NCT00906425|DEVICE|Straumann Bone Level Implant|Straumann Bone Level Implant, SLActive surface, diameter 4.1, length 8, 10, 12, and 14 mm
224231630|NCT02339766|PROCEDURE|Quadratus Lumborum Block|Quadratus Lumborum Block with Ropivacaine 0.5% will be done.
224231631|NCT02339766|PROCEDURE|Sham Block|Sham block of Quadratus Lumborum will be done with Saline.
224231632|NCT02339766|DRUG|Intrathecal Morphine|Intrathecal Morphine 150 mcg will be co-administered with the spinal anesthetic.
224231633|NCT02339766|DRUG|Intrathecal Saline|Intrathecal Saline 0.15 mL will be co-administered with the spinal anesthetic.
224231634|NCT00620763|OTHER|High Meat - High Potential Renal Acid Load (PRAL) diet|Menu high in meat protein
224231635|NCT00620763|OTHER|Low Protein - Low Potential Renal Acid Load (PRAL) diet|Menu low in meat protein
224231636|NCT06078163|OTHER|supplementation|daily pharmacological therapy with Alpha Lipoic Acid 600 mg, L-acetylcarnitine 1000 mg, Resvelatrol 50 mg, vit D3 800UI for 30 consecutive days in combination with a rehabilitation protocol lasting 20 sessions
224231637|NCT06078163|OTHER|rehabilitation|rehabilitation protocol lasting 20 sessions.
223645281|NCT06599294|PROCEDURE|Two digital impressions will be recorded, one with a conventional intra-oral scanner and another one with an intra-oral photogrammetry scanner.|. For each patient three digital files will be obtained: One reference scan, one conventional IOS scan, and one IPS scan. All the STL files will be imported to dental CAD software, and scan bodies will be converted to implant multi-unit ti-base using a digital library. The updated STL files will be imported to inspection software Mimics for trueness assessments. The three-dimensional discrepancy between 2 STL files will be evaluated in terms of linear and angular deviation. A central point \&amp; central axis of the virtual MUA ti-base was used for deviation measurements. Linear deviations will be assessed for each MUA tibase on the three-space axis (X longitudinal, Y lateral, and Z vertical) using the center of the ti-base heads for the deviation measurement. Angular deviations were assessed as the angles formed by the two lines passing perpendicularly through the centers of the test image and the reference image of each ti-base.
223645282|NCT06614959|DEVICE|Oscillatory Positive Expiratory Pressure (OPEP) Therapy|The smart OPEP device is a standard OPEP device equipped with an additional detachable sensor that collects diagnostic information on the total elapsed time of OPEP use, the pressure generated during use, frequency and amplitude of pressure oscillations, respiratory information (inhalations/exhalation number/time), and sum of all oscillations with a pressure over 1 centimeter of water (cmH2O), all of which will inform the duration and quality of home use.
223645283|NCT06073938|DRUG|NHWD-870|The base dosage administered is 2.0 mg/dose/day, and the frequency and dose of administration may be adjusted based on safety data.
223645284|NCT06993090|DEVICE|Kinesio Tape|A thin, flexible, and elastic therapeutic tape intended for skin application to provide support for muscles and joints. This tape may help decrease pain, swelling, and inflammation while permitting movement. It is commonly utilized to enhance athletic performance and facilitate injury recovery. The tape functions by elevating the skin, which can enhance blood and lymph circulation, and is believed to engage the nervous system through proprioceptive feedback.
223645285|NCT04757168|DEVICE|NOGA TM probe|"Each subject will be his own witness since the linear local shortening (LLS) will be measured successively in all patients before, then after stimulation of the scar zone (comparison of LLS measured in sinus rhythm then during stimulation in the scar zone for each patient.~Each subject being his own witness and the two recordings being made a few minutes apart, during the same procedure."
223645286|NCT06673238|DRUG|ABBV-722|Oral Capsule
223645287|NCT06673238|DRUG|Placebo|Oral Capsule
223645288|NCT05455879|OTHER|Impact of antenatal corticosteroid therapy on surfactants use postnatal|Intervention Description: Retrospective study on preterm infants to evaluate the impact of antenatal corticosteroid therapy on surfactants use postnatal
223645289|NCT06993298|DEVICE|Augmented Reality Ergonomics Training (ARPE)|Participants in this arm will receive an interactive training module using Augmented Reality (AR) delivered via the MAKAR XR app. The module aims to enhance ergonomic knowledge, self-prevention, and self-evaluation related to work-related musculoskeletal disorders (WMSDs)
223765890|NCT06724965|BEHAVIORAL|Trans STAIR|Skills Training in Affect and Interpersonal Regulation (STAIR) is a transdiagnostic evidenced-based mental health treatment for individuals who have experienced multiple traumas. STAIR is based in cognitive-behavioral principles and delivered in a flexible manner over 8 group sessions, with demonstrated efficacy for the treatment of PTSD and other mental health symptoms. This trial will adapt and pilot test the STAIR intervention to be culturally appropriate and acceptable for TGD persons, adding content related to TGD health and wellness, coping with minority stress, responding to stigma and microaggressions, social support, and community connectedness, self-compassion, celebrating trans joy, trans advocacy, sexual health and PrEP use.
223765891|NCT06724965|BEHAVIORAL|PrEP Well|"This pilot trial will leverage PrEP Well, a multi-level implementation strategy for providing PrEP in TGD-serving contexts by integrating peer-led PrEP navigation with programming that addresses other social and structural needs of the TGD community (e.g., housing, legal, employment, gender-affirmation, primary care)"
223765892|NCT07045168|OTHER|risk-scoring model|This system classifies +1q NDMM patients into low, intermediate, and high-risk groups based on coexisting ISS stage III, hypercalcemia, high LDH, and t(14;16).Patients with ISS stage III, elevated LDH, hypercalcemia, and t(14;16) were assigned scores of 1 point, 1 point, 2 points, and 3 points, respectively. According to the tertiles of their scores,the patients with +1q were classified into low- (0 point),intermediate- (1-3 points), and high-risk (4-7 points) groups.
223765893|NCT06889857|BIOLOGICAL|The study drug is SHED-CM manufactured by U-Factor|This study will involve informed consent, a 12-week observation period, a 12-week study drug administration period, and a 4-week follow-up period.
223765894|NCT06890026|DRUG|Faricimab Injection [Vabysmo]|The procedures were carried out according to the local standard protocol, which involved applying 2-3 drops of topical tetracaine anesthesia, using an eye speculum, disinfecting with 5% povidone-iodine, employing a 33G needle, marking the injection site 3.5 mm posterior to the limbus with calipers in either the superotemporal or inferotemporal quadrant, applying a sterile cotton tip for tamponade after needle removal, and omitting post-procedure antibiotics.
223765895|NCT06744465|DEVICE|NearWave monitoring|NearWave optical molecular monitoring
223765896|NCT06737718|OTHER|Eye tracking|"The eye-tracking session will take place in the Pediatric Radiology department of Necker Hospital. The child will be seated in front of a computer screen. Films and images with social and/or non-social content will be shown to the children. The session will be unique, will last approximately 15 minutes and will not involve any constraints for the child.~Eye tracking allows to measure where and how a person looks. An infrared light is emitted towards the subject's eye. It is reflected there and a camera records the reflections generated, allowing a real-time calculation of the position of the gaze. The technique is harmless and non-invasive."
224231638|NCT03256110|BEHAVIORAL|Improving Communication about Serious Illness-AI/AN|A one-page summary of patient-specific preferences, barriers and facilitators for engaging in patient-provider communication about advance care planning, provided to patient and provider prior to a clinical encounter with prompts for initiating and/or improving the quality of communication about advance care planning.
224231639|NCT05559996|DEVICE|Injectable form of multifractional intercalated cross-linked hyaluronic acid (Armonia®, Regenyal, Italy)|2 mL of Armonia was injected into the vaginal wall with a standardized injection technique called Cannulated Intravaginal Injection Technique®. In this technique, Armonia® was injected as drops at 40 different points on the entire vaginal wall using 8 different entry points
224231640|NCT00725439|DRUG|Talarozole|Oral Dose 1.0 mg once daily
223645290|NCT06993298|BEHAVIORAL|Conventional Ergonomics Training|Participants in this arm will receive conventional ergonomic training based on the Department of Occupational Safety and Health (DOSH) guidelines for manual material handling (MMH) workers. The training includes lectures, printed materials, and standard instructional content focused on safe lifting techniques, proper posture, risk factor identification, and strategies to prevent work-related musculoskeletal disorders (WMSDs). This training is delivered in a one-time session with follow-up reminders, simulating current standard practices in workplace safety education.
223645291|NCT06594211|BIOLOGICAL|ACT-001 CAR-NK cell|Subjects were distributed into three dosage groups, each receiving a single dose of CAR-NK cells at levels of 1×10\^8, 3×10\^8, and 9×10\^8 cells, respectively.
223645292|NCT06591299|DRUG|Cilostazol 100 MG|Efficacy and safety of 200 mg cilostazol followed by 100 mg twice daily for three months and loading 300 mg aspirin and 75 mg aspirin maintenance will be assessed through NIHSS, mRS, duration of hospital stay, new ischemic stroke, and possible adverse effects,
223645293|NCT06591299|DRUG|Clopidogrel 75mg|Efficacy and safety of 300 mg clopidogrel followed by 75mg once daily for three months and loading 300 mg aspirin and 75 mg aspirin maintenance will be assessed through NIHSS, mRS, duration of hospital stay, new ischemic stroke, and possible adverse effects,
224231641|NCT03797664|DRUG|CDX-6114|CDX-6114 will be administered as a single, oral dose solution at dose levels of 7.5, 15.0 and 22.5g
223645294|NCT06588452|OTHER|RECTIFIER - a generative artificial intelligence screening tool|RECTIFIER is a large-language model based, generative artificial intelligence-enabled inclusion and exclusion criteria assessment tool.
223645295|NCT06588452|OTHER|Manual clinical trial screening by study staff|The current gold standard - study staff manually review potentially eligible patients through chart review.
223645296|NCT06587373|OTHER|Assessment of the quality of mother-child dyadic relationships|Filling out questionnaires
223645297|NCT06542835|BEHAVIORAL|Video text message|Video text messages tailored to the Latinx population to educate and motivate patients to complete CRC screening.
223645298|NCT06542835|BEHAVIORAL|In-clinic CRC screening promotion|Stool-test orders, colonoscopy referrals.
223645299|NCT06542835|BEHAVIORAL|Mailed FIT|Mailed FIT kits.
223765897|NCT06737718|OTHER|Data collection from patients' medical files|"Data collection from patients' medical files:~* Brain imaging data if this examination was carried out as part of the patient's care,~* Angelman syndrome genotypes."
224231642|NCT03797664|DRUG|Placebo|Phosphate Buffer Diluent oral solution
224231643|NCT01747603|OTHER|Specialized LPTB clinic|50% of enrolled infants will be randomized to the specialized LPTB follow-up clinic.
224231644|NCT00325533|BEHAVIORAL|Baseline BP Screening|Barbers in the barbershops in the experimental arm will be trained to accurately measure and interpret blood pressure (BP). Each barber will offer a BP check to customers with each haircut, complete an encounter form after each haircut, discuss the BP reading with the customer, identify customers with elevated BP, and refer customers with elevated BP to a regular physician or other primary provider for long-term BP management. Each time a customer with elevated BP goes to a regular medical provider, he receives a free haircut, and the referring barber receives a monetary bonus.
224231645|NCT00325533|OTHER|Intensive 10-week Blood Pressure Screening|Intensive 10-week Blood Pressure Screening
224231646|NCT04602104|BIOLOGICAL|low dose hMSC-Exos|basic treatment and 7 times aerosol inhalation of hMSC-Exos (2.0\*10\^8 particles at Day 1, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7)
224231647|NCT04602104|BIOLOGICAL|medium dose hMSC-Exos|basic treatment and 7 times aerosol inhalation of hMSC-Exos (8.0\*10\^8 particles at Day 1, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7)
224231648|NCT04602104|BIOLOGICAL|high dose hMSC-Exos|basic treatment and 7 times aerosol inhalation of hMSC-Exos (16.0\*10\^8 particles at Day 1, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7)
224231649|NCT04602104|BIOLOGICAL|Dosage 1of hMSC-Exos|basic treatment and 7 times aerosol inhalation of hMSC-Exos (a quarter of MTD/day at Day 1, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7)
224231650|NCT04602104|BIOLOGICAL|Dosage 2 of hMSC-Exos|basic treatment and 7 times aerosol inhalation of hMSC-Exos (MTD/day at Day 1, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7)
224231651|NCT04602104|BIOLOGICAL|No hMSC-derived exosomes|basic treatment and 7 times aerosol inhalation of normal saline (at Day 1, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7)
224231652|NCT01141725|DRUG|bendamustine hydrochloride|Given IV
224231653|NCT01141725|DRUG|idarubicin|Given IV
224231654|NCT03855475|BEHAVIORAL|Aerobic exercise|Participants will complete 12 weeks of supervised aerobic exercise, 3 times per week, on a treadmill or stationary bicycle
224231655|NCT03855475|BEHAVIORAL|Stretching|Participants will complete 12 weeks of supervised stretching, 3 times per week
224231656|NCT04682275|OTHER|Psychological measurements|A questionnaire test (Beck depression Inventory) for depression was performed.
224231657|NCT00368966|BIOLOGICAL|13-valent Pneumococcal Conjugate Vaccine|
224231658|NCT00368966|BIOLOGICAL|7-valent Pneumococcal Conjugate Vaccine|
224231659|NCT02866175|DRUG|Edoxaban|Edoxaban 60 mg once-daily or 30 mg once-daily in selected subjects
224231660|NCT02866175|DRUG|Clopidogrel|Clopidogrel 75 mg once-daily
224231661|NCT02866175|DRUG|Prasugrel|prasugrel 5mg or 10 mg once-daily
223765898|NCT04459806|PROCEDURE|intracranial pressure monitoring|Invasive monitoring of intracranial pressure by using CereLink monitor.
223765899|NCT07052786|BEHAVIORAL|Infants will receive group care based on individualized developmental care according to the guide.|A guide to implementing group care based on individualized developmental care will be developed, and nurses working in the NICU will be trained in group care practices and how to use the guide.
224231662|NCT02866175|DRUG|Ticagrelor|ticagrelor 90 mg twice-daily
224231663|NCT02866175|DRUG|Vitamin K antagonist|VKA once-daily dosing for target international normalized ratio between 2.0 and 3.0, inclusive
224231664|NCT02490709|PROCEDURE|Local excision|Local excision for rectal cancer with good response
224231665|NCT06460714|OTHER|Shock wave therapy, stretching and orthosis|Shortwave therapy, stretching and orthotics will be provided to Group A. Shock wave session will be provided for 20 minutes thrice a week. Five days in a week provided five minutes with 30 seconds sustained stretch will be provided and than orthotics will be used to obtained the sustained effect.
224231666|NCT06460714|OTHER|Stretching, strengthening and orthosis|In Group B spastic diplegic children just given stretching with strengthening and orthotics. We provide sustained 30 seconds stretch with 30 seconds rest for 5 minutes and followed with forty repetition of hip flexor and knee flexors and range will be maintained by applying orthosis.
223645300|NCT06542835|BEHAVIORAL|Social needs navigation|Patient navigation to address social needs.
223645301|NCT06542835|BEHAVIORAL|Reminders|Centralized text and/or telephone reminders for ordered tests.
223645302|NCT06587477|OTHER|Hormonal profile|Blood for FSH, LH, testosterone
223765900|NCT07052786|BEHAVIORAL|Standard care|Nurses working in the NICU will continue to provide standard care. After the study is completed, nurses in the control group will also receive the same training as the other group.
223645303|NCT06587477|OTHER|Semen analysis|Semen analysis
223645304|NCT06587477|OTHER|Questionnaire|The European Male Ageing Study (EMAS) questionnaire
223645305|NCT05934565|BEHAVIORAL|Mindful Steps|Integrated website, activity tracker, and mind-body training
223645306|NCT05514886|DEVICE|Gene Expert molecular Point-of-Care (POC) (Xpert® Xpress SARS-CoV-2/Flu/RSV test|POC viral load (VL) assay in improving the availability of SARS-CoV-2 detection for COVID-19 patient management in decentralized healthcare facilities of resource-constrained settings in Tanzania, DR Congo and Burkina Faso.
223645307|NCT05320445|BEHAVIORAL|Supportive Expressive Group Therapy|The SEGT is a six-module program where each session is approximately one hour, and is held twice a week over a three-week period. It is framed within social cognitive theory, whereby resilience to adversity (NMSK trauma in this instance) relies on personal enablement. Enablement serves to equip the individual with the personal resources to cultivate their self-efficacy and mastery and to select and construct environments that promote successful adaption.
223645308|NCT03075072|RADIATION|Whole brain radiation|Treatment of the whole brain with radiation. When possible the hippocampus will be spared from radiation.
223645309|NCT03075072|RADIATION|Stereotactic radiation (SRS)|Focused radiation to each individual brain metastasis without treatment of the remainder of the brain.
223645310|NCT06474832|OTHER|High-intensity interval training|Training on a stationary bike and integrated with exergame (Jbike, JACFIT, USA), the exercise games connect to a map in the app through sensors, allowing players from different countries to ride together and complete the map, thus increasing the diversity of the training, including a warm-up and cool-down at 30% HRR for 5 minutes each. Perform HIIT with 5 intervals at 80% heart rate reserve (HRR), each interval lasting 4 minutes, with 3-minute intervals at 40% HRR between each interval.
223645311|NCT06474832|OTHER|Moderate intensity continuous training|Training on a stationary bike and integrated with exergame (Jbike, JACFIT, USA), the exercise games connect to a map in the app through sensors, allowing players from different countries to ride together and complete the map, thus increasing the diversity of the training, including a warm-up and cool-down at 30% HRR for 5 minutes each. Perform continuous exercise at 59% HRR for 35 minutes.
223645312|NCT06874803|PROCEDURE|Acupuncture and Moxibustion (AM)|Acupuncture and moxibustion group (AM): Acupuncture at Shuifen (CV9), bilateral Yinlingquan (SP9), bilateral Zhongliao (BL33), and bilateral Weiyang (BL39), combined with moxibustion at Shuifen (CV9) and Zhongliao (BL33).
223645313|NCT06874803|PROCEDURE|Sham Acupuncture and Moxibustion (Sham-AM)|Sham acupuncture and moxibustion group (sham-AM): Acupuncture at non-acuipoints of bilateral Hegu (LI4) and bilateral Zusanli (ST36), with fake moxibustion at Shuifen (CV9) and bilateral Zhongliao (BL33).
224231667|NCT01694485|BIOLOGICAL|Abrilumab|Administered by subcutaneous injection.
224231668|NCT01694485|DRUG|Placebo|Placebo matching to abrilumab administered by subcutaneous injection
224231669|NCT00004096|DRUG|carboplatin|
224231670|NCT00004096|DRUG|vinorelbine ditartrate|
224231671|NCT03987152|DRUG|Sirolimus|Daily intake of Sirolimus during Challenge and Rechallenge phase
224231672|NCT01595009|DRUG|Everolimus (RAD001)|Everolimus was supplied as tablets of 5mg strength.
223645314|NCT03868995|PROCEDURE|Sham injection|Dextrose water injection to subcutaneous layer at tender point
223645315|NCT03868995|PROCEDURE|Tendon injection|Dextrose water injection to injured tendon
223645316|NCT06592391|OTHER|educational innovation dynamic school day|Schools will form a community of practice, and will be supported with regular workshop to develop a dynamic school day that matches the local context.
223645317|NCT06592391|OTHER|e-learning on a dynamic school day|Schools will form a community of practice, and will develop a dynamic school day that matches their local context using e-learning materials
223645318|NCT06592391|OTHER|expert schools|Schools that have developed a local dynamic school day without additional support
224231673|NCT00506909|DRUG|Oxytocin|20 IU BID or 40 IU BID
224231674|NCT00506909|DRUG|Placebo|20 IU BID or 40 IU BID
224231675|NCT02907203|DEVICE|Drug Coated Balloon|Prospective, multi-center, single-arm study characterizing outcomes in subjects with Peripheral Artery Disease (PAD) lesions treated with percutaneous transluminal angioplasty (PTA) using the GORE® DCB Catheter.
223645319|NCT05625490|DRUG|Ga-68 Galmydar|Intravenous injections of the PET radiotracer \[68Ga\]Galmydar.
224231676|NCT04956666|DRUG|Lyophilized S95014|"Each patient was administrated, over 1 to 2 hours, every 2 weeks Lyophilized S95014 intravenously at the dose of 1000, 2000 or 2500U/m2, as per investigator's judgement.~In total, 9 infusions of lyophilized S95014 were administrated (at week 7, 9, 11, 15, 17, 19, 23, 25 and 27).Patients received other backbone chemotherapy agents as per ALL-MB 2015."
224231677|NCT03129269|PROCEDURE|MRI and PET scan|Neuroimaging with MRI and PET scan Amyloid tracer : For PET-scans, 4 MBq/kg of \[18F\]AV-45 will be injected into each subject in an intravenous bolus.
224231678|NCT05095909|DEVICE|Cryo-compression|Programmable intermittent compression with integrated cryo-therapy.
224231679|NCT05095909|OTHER|Cryo-therapy|Subjects are fitted with gel ice packs and wraps.
224231680|NCT03172780|DRUG|Diclofenac sodium gel 1%|Diclofenac Sodium Topical Gel, 1%. 4 gm, 4 times a day for 4 weeks
224231681|NCT03172780|DRUG|Voltaren® Gel (Diclofenac Sodium Topical Gel) 1%|Diclofenac Sodium Topical Gel, 1%. 4 gm, 4 times a day for 4 weeks
224231682|NCT03172780|DRUG|Placebo gel|Vehicle Gel 4 gm, 4 times a day for 4 weeks
224231683|NCT05023213|BEHAVIORAL|Warna-Warni Waktu|Six videos and eighteen reinforcer activities
224231684|NCT00748293|OTHER|Low-residue diet|Commercialized (not yet marketed)low-residue diet
223645320|NCT05625490|DRUG|13N-ammonia|Two intravenous injections of PET radiotracer \[13N\]Ammonia.
223645321|NCT05755516|DEVICE|Self-expanding Intracranial Stent (Tonbridge)|Stent assisted coiling with Self-expanding Intracranial Stent (Tonbridge).
223645322|NCT05755516|DEVICE|LVIS and LVIS Jr. (MicroVention)|Stent assisted coiling with LVIS and LVIS Jr. (MicroVention).
223645323|NCT07022353|PROCEDURE|Bilevel erector spinae plane block|Block will be performed unilaterally with the patient in the sitting position leaning forward. The block will be done using a high frequency linear probe (6-13 MHz). The block area will be adequately sterilized and draped, then the ultrasound probe will be placed 2-3 cm laterally from the midline at the level of the T3 spinous process using a sagittal approach to identify the hyperechoic transverse process shadow deep to the trapezius, rhomboid major, and erector spinae muscles. Then, the needle will be inserted craniocaudally in-plane to reach the transverse process deep to the erector spinae muscle. Correct positioning of the needle will be confirmed through real-time visualization of 2-mL saline hydro dissection. After confirmation of needle position, 15 mL of bupivacaine 0.25% will be injected at each level. The same procedure was repeated for the second level T5 spinous process. block failure defined as the presence of full sensation after 30 minutes, patients will be excluded .
223645324|NCT07022353|DRUG|Placebo Oral Capsule|One hour prior to anesthesia induction, the patients will recieve oral placebo capsule that will have the same color, smell, and size as tizanidine.
223645325|NCT07022353|DRUG|tizanidine oral capsule|One hour prior to anesthesia induction, the tizanidine group will receive a 4 mg tizanidine oral capsule.
223645326|NCT04207788|OTHER|HIP-REP|HIP-REP programme is an add on to usual care which includes 5 add on individual activity-focused interventions that will be tailored to the need of elderly with hip fracture in a liaison with the health care professionals. Home visits and follow-up phone call will be a part of programme.
223645327|NCT04207788|OTHER|Usual care|The elderly in the control group will receive usual rehabilitation. with a focus on mobilization within 24 hours postoperative as an in-patient. In the municipality physiotherapy is offered twice a week for approximately 12 weeks postoperative focusing on neuromotor control over hip, activation and strengthening of muscles as well as increase mobility. When relevant, the elderly receives a home visit by an occupational therapist who assess ADL behaviours, the use of assistive devices and the environmental hazards, preparing and adapting the home environment to prevent falls.
223765901|NCT06893380|DRUG|Gemcitabine, Cisplatin, Nab-paclitaxel, and Tislelizumab.|Tislelizumab: IV 200mg on Day 1 of every 3-week cycle Nab-paclitaxel: IV 75mg/m2 on Days 1 and 8 of every 3-week cycle (up to 16 cycles) Gemcitabine: IV 800mg/m2 on Days 1 and 8 of every 3-week cycle Cisplatin: IV 25mg/m2 on Days 1 and 8 of every 3-week cycle (up to 8 cycles)
223765902|NCT07053566|BEHAVIORAL|Rotator Cuff Strengthening Exercises|Progressive exercise program focused on rotator cuff muscles
224231685|NCT00662025|DRUG|Capecitabine|Capecitabine 1000 mg/m2, twice daily, for 2 consecutive weeks, followed by a 1-week rest period and given as 3-week cycles
224231686|NCT00662025|DRUG|Sunitinib|Sunitinib 37.5 mg daily, continuous dosing
224231687|NCT00000391|DRUG|Peptide T|
224231688|NCT02010762|DRUG|Vitamin D|25.000 IU oral drops
224231689|NCT02010762|DRUG|Placebo|placebo oral drops
224231690|NCT05400876|DRUG|TQB2618 injection|TQB2618 injection is an inhibitor of T cell immunoglobulin and mucin domain-containing protein 3 (TIM3)
224231691|NCT05400876|DRUG|Penpulimab injection|Penpulimab is an inhibitor of programmed cell death protein 1 (PD-1)
224231692|NCT06367400|DIAGNOSTIC_TEST|Pediatric Sleep Questionnaire|Questionnaire with 22 questions of symptoms of OSDB
224231693|NCT01165671|RADIATION|Carbon Ion Radiotherapy|Carbon ion Radiotherapy up to 18 Gy E in 3 Gy E fractions to the macroscopic tumor
223765903|NCT07053566|BEHAVIORAL|Latissimus Dorsi Strengthening Exercises|Progressive exercise program targeting the latissimus dorsi muscle
223765904|NCT06787066|DRUG|Propranolol Hydrochloride|Examine how IV propranolol impacts sympathetic transduction
223765905|NCT06787066|DRUG|Phentolamine Injection|Examine how IV phentolamine impacts sympathetic transduction
223765906|NCT07057323|DEVICE|Coronary Sinus Reducer|Subjects will have the Coronary Sinus Reducer implanted in their coronary sinus during a right heart catheterization procedure.
224231694|NCT01165671|RADIATION|Proton Radiotherapy|Proton Radiotherapy up to 10 Gy E in 2 Gy E fractions to the macroscopic tumor
224231695|NCT05521750|PROCEDURE|Transforaminal Percutaneous Endoscopic Lumbar Decompression|TPELD is procedure of percutaneous lumbar discectomy done under endoscopic setting
224231696|NCT02925065|OTHER|Non-traditional group guitar instruction|A 6-week curriculum for non-traditional training in finger-style guitar has been developed with rhythmic and goal oriented upper extremity and finger movements. Guitar group intervention will be implemented at the Towson campus of the Peabody Preparatory. Intervention approaches will include rhythmic digital grip with finger isolation, goal directed rhythmic reach on the fret-board and rhythmic alternating tap-like digit and hand movements on the guitar. Participants will be provided with the instruments in the group setting without expectation of practice at home.
224231697|NCT00095290|DRUG|Ramipril + Irbesartan|Tablets + Capsules, Oral, 10mg Ramipril + 300mg Irbesartan target dose, Once daily, 20 weeks.
224231698|NCT00095290|DRUG|Ramipril + Placebo|Tablets + Capsules, Oral, 10mg Ramipril + 300mg Placebo target dose, Once daily, 20 weeks.
224231699|NCT03824522|BIOLOGICAL|ADYNOVATE|Pegylated recombinant human factor VIII
224231700|NCT00418483|BIOLOGICAL|Plasmin (Human) 25 mg|Plasmin (Human) 25 mg delivered via an infusion catheter into the thrombus over approximately 5 hours.
224231701|NCT00418483|BIOLOGICAL|Plasmin (Human) 50 mg|Plasmin (Human) 50 mg delivered via an infusion catheter into the thrombus over approximately 5 hours.
224231702|NCT00418483|BIOLOGICAL|Plasmin (Human) 75 mg|Plasmin (Human) 75 mg delivered via an infusion catheter into the thrombus over approximately 5 hours.
224231703|NCT00418483|BIOLOGICAL|Plasmin (Human) 100 mg|Plasmin (Human) 100 mg
224231704|NCT00418483|BIOLOGICAL|Plasmin (Human) 125 mg|Plasmin (Human) 125 mg delivered via an infusion catheter into the thrombus over approximately 5 hours.
224231705|NCT00418483|BIOLOGICAL|Plasmin (Human) 150 mg|Plasmin (Human) 150 mg delivered via an infusion catheter into the thrombus over approximately 5 hours.
224231706|NCT00418483|BIOLOGICAL|Plasmin (Human) 175 mg|Plasmin (Human) 175 mg delivered via an infusion catheter into the thrombus over approximately 5 hours.
224231707|NCT06449079|OTHER|Machine learning|Analysis of data with machine learning methods
223645328|NCT07025317|OTHER|Perceptual-cognitive|"The intervention is to determine the effectiveness of NeuroTracker for treating cognitive deficits associated with a prior history of concussion. NeuroTracker has a virtual cloud-based platform (NeuroTrackerX), which has been validated for use in research. This online platform allows participants to complete the interventions from home and greatly increases the accessibility of the program. Participants will have two 30-minute training sessions per week over the course of the 6-month intervention. Each session will consist of 3 blocks of 20 trials. For each trial in a block, participants sit upright, approximately 20 away from a standard computer or laptop screen, and wear anaglyph 3D glasses while focusing on the center of a standard 20 computer screen."
223645329|NCT04429256|OTHER|data collection|retrospective analysis of perioperative data collected from patient medical charts and from a telephone enquiry
223645330|NCT07024758|BEHAVIORAL|Parent Coached Exposure Therapy|Parent-based cognitive behavioral therapy with guidance from a therapist
223645331|NCT07024758|BEHAVIORAL|Family Based, Internet-Based Cognitive Behavioral Therapy|Family-based cognitive behavioral therapy employing internet-delivered modules and videos
223645332|NCT04008160|DEVICE|ProTex|Non invasive measurement of pressure, temperature, humidity, perfusion, and oxygenation
223645333|NCT06705452|OTHER|Additional 4D Flow MRI or additional 4D Flow sequence|Additional 4D Flow MRI or additional 4D Flow sequence
223645334|NCT06704165|PROCEDURE|Orthodontic treatment using double slot bracket wire in high level slot|patients will receives the new treatment therapy by using Double slot bracket with the wire in low level for the treatment of anterior deep bite .
223645335|NCT06704165|PROCEDURE|Orthodontic treatment using double slot bracket with wire in low level slot|patients will receives the new treatment therapy by using Double slot bracket with the wire in high level for the treatment of anterior deep bite .
223645336|NCT02374450|PROCEDURE|Blood collection|For all hospitalised children suspected of having an AESI or meningitis, a sample of 5 ml of whole blood was collected and the serum was stored.
223645337|NCT06706999|OTHER|PREVAIL model of care|"Components 1, 2, and 3 are essential components that all participants will receive. Components 4 and 5 are based on the results of either the DAPS tool or the PT consultation call.~1. Screening tool (DAPS) completed at baseline to determine current level of limitation with valued life activities.~2. Recommendation to rheumatology clinician based on screening results to provide exercise resource and/or recommend a PT consult call during routine visit.~3. Exercise resource (PREVAIL website) provided to all participants by their rheumatology clinician at their routine visit.~4. Brief consultation call with a study physical therapist to determine level of priority for PT referral. Only applicable for those with/at risk for limitation with valued life activities.~5. Referral to PT. Only applicable if determined by study physical therapist to meet priority requirements."
223645338|NCT06053775|DEVICE|Transcranial Direct Current Stimulation|tDCS+OCT
223645339|NCT06053775|DEVICE|Transcranial Alternating Current Stimulation|tACS+OCT
223645340|NCT06053775|DEVICE|tES sham|tES sham + OCT
223765907|NCT06836609|DRUG|ALN-CIDEB|Administered per the protocol
224231708|NCT00760383|DIETARY_SUPPLEMENT|Essential amino acids|Subjects will ingest 20 grams of essential amino acids (EAA) daily for 7 days prior to total knee arthroplasty (TKA) surgery and for 14 days after surgery daily. On the days they are seen by physical therapy (PT) they will ingest the EAA supplement 30 minutes after the end of each PT rehabilitation session.
224231709|NCT00760383|DIETARY_SUPPLEMENT|Alanine|Subjects will ingest 20 grams of non-essential amino acid (NEAA) daily for 7 days prior to total knee arthroplasty (TKA) surgery and for 14 days after surgery daily. On the days they are seen by physical therapy (PT) they will ingest the NEAA supplement 30 minutes after the end of each PT rehabilitation session.
224231710|NCT03943251|DRUG|HEC113995PA•H2O tablet|2.5-、5-、10-、20-、40-、60-、80mg HEC113995PA•H2O tablet in day1.
224231711|NCT03943251|DRUG|Placebo tablet|2.5-、5-、10-、20-、40-、60-、80mg Placebo tablet in day1.
224231712|NCT00626925|DRUG|topiramate|up to 200mg/day orally (over 12 weeks during which the dosage is gradually increased up to 200 mg orally and then maintained, and 1 week of medication taper)
224231713|NCT00626925|DRUG|placebo|placebo (12 weeks during which the dosage of study medication is gradually increased up to 200 mg orally and then maintained, and 1 week of medication taper)
224231714|NCT01000740|GENETIC|EGFR Mutation Test|Explore the EGFR mutation status from both tumour tissue sample and the free DNA in the peripheral blood using appropriate method(s) which may include ARMS assay, ME-PCR coupled sequencing and regular sequencing.
224231715|NCT01000740|GENETIC|Ki-67 protein expression|Ki-67 protein expression in tissue will be analysed by IHC method.
224231716|NCT01606566|DRUG|Amphinex induced PCI of bleomycin|Intravenous administration of 0.25 mg/kg Amphinex (day 0) followed by intravenous administration of bleomycin (15000 IU/m2, day 4) and laser light application (3 hours (+/- 1 hour) after bleomycin administration).
224231717|NCT00897897|DEVICE|Philips MRI-guided HIFU system|HIFU is the use of focused ultrasound energy to penetrate through soft tissue and causes localized high temperatures (55°C to 70°C) for a few seconds within the target producing well defined regions of protein denaturation, irreversible cell damage, and coagulative necrosis.
224231718|NCT04665076|BIOLOGICAL|Auto CAR-T|Biological: Auto CAR-T
224231719|NCT04665076|DRUG|Cyclophosphamide,Fludarabine|Drug: Cyclophosphamide,Fludarabine
224231720|NCT04665076|PROCEDURE|Leukapheresis|Leukapheresis
224231721|NCT00102362|BEHAVIORAL|Behavior Therapy|
224231722|NCT01696591|BIOLOGICAL|NEUROSTEM®-AD|NEUROSTEM®-AD was administered to eligible subjects in the early part of the Phase I clinical study. In this follow-up study, no intervention will be performed.
224231723|NCT01076803|DRUG|Lanreotide (acetate)|Deep subcutaneous injection into the upper external quadrant of the right or the left buttock.
224231724|NCT02959775|BIOLOGICAL|60 µg dose hepatitis B vaccine|three-dose, 60 µg per dose
223645341|NCT06053775|DEVICE|Online Cognitive Training|OCT
223645342|NCT03694938|DEVICE|Magnetic resonance imaging|Annually magnetic resonance imaging
223645343|NCT06706687|DIAGNOSTIC_TEST|DISBAND protocol|For each participant blood samples will be collected, processed and studied to analyse microRNA expression, more specifically investigating non-coding RNA (ncRNA). Each participant will undergo a multimodal neuroimaging session, composed of structural MRI, 1H-MRS and PET.
223765908|NCT06836609|DRUG|Placebo|Administered per the protocol
224231725|NCT02959775|BIOLOGICAL|20 µg dose hepatitis B vaccine|three-dose, 20 µg per dose
223645344|NCT07059624|PROCEDURE|"Modified Dynamic Needle Tip Positioning, Short-Axis, Out-Of-Plane (MDNTP-SAOP)"|Patients will have their femoral arterial line inserted using the MDNTP-SAOP technique.
223645345|NCT07059624|PROCEDURE|"Conventional, Short-Axis, Out-Of-Plane (C-SAOP)"|Patients will have their femoral arterial lines inserted using the C-SAOP technique.
223645346|NCT02819011|DEVICE|MBB AFO|Subjects will be provided with a pair of New Balance 813 shoes plus a custom made MBB AFO
223645347|NCT02819011|OTHER|Control|Subjects will be provided with a pair of New Balance 813 shoes
223765909|NCT06747091|PROCEDURE|Catheter Ablation|This is a prospective randomized clinical trial. Patients will undergo catheter ablation for persistent AF using a lattice-tip catheter that can switch between RFA and PFA energy. Enrolled patients will be randomized to one of three ablation strategies:
223765910|NCT07049068|DRUG|Oral Nicotinamide|"Participants from group 1 received 120 capsules of 500 mg nicotinamide and a tube of placebo cream at each visit. . All participants were instructed to take 1 capsule every 12 hours and to apply the cream to their entire face twice a day.~Participants were unaware of which group they were allocated to and participants in both groups received either capsules (active or placebo, which looked identical) or a tube of cream (active or placebo, which looked identical). In follow-up visits participants returned empty tubes to the responsible pharmacist.~At the initial assessment and at 6 months photographs of the participants' faces were taken."
224231726|NCT01215942|DRUG|LY2127399|Administered Subcutaneously
224231727|NCT02678910|PROCEDURE|Ovarian Cryopreservation|The ovarian tissue will be removed at a UK Healthcare facility and evaluated for gross disease by a pathologist, embryologist, andrologist or REI physician. The ovarian cortex will be dissected from the medulla and cut into strips in culture/holding media, washed to remove blood cells, and cryopreserved. Cryopreservation will be performed using modifications of the techniques described by Gosden et al. (1994) or will be vitrified using a modification of the techniques of Kuwayama et al., 2007.
224231728|NCT06087874|DIETARY_SUPPLEMENT|Vivomixx®|The probiotic group participants will receive 1 sachet of probiotic product daily from 36weeks of gestation up to 7th day of postpartum while placebo groups will 1 sachet placebo prepared with the same colour, taste, and packaging with Vivomixx® daily for the same duration of probiotic groups. Vivomixx® is a non-genetically modified (GMO), gluten-free, high potency microbiotic food supplement, containing eight strains (Streptococcus thermophilus DSM24731® / NCIMB 30438, Bifidobacterium breve DSM24732® / NCIMB 30441, Bifidobacterium longum DSM24736® / NCIMB 30435, Bifidobacterium infantis DSM24737® / NCIMB 30436\*, Lactobacillus acidophilus DSM24735® / NCIMB 30442, Lactobacillus plantarum DSM24730® / NCIMB 30437, Lactobacillus paracasei DSM24733® / NCIMB 30439, Lactobacillus delbrueckii subsp. bulgaricus DSM24734® / NCIMB 30440) of live bacteria (450 billion bacteria per sachet).
224231729|NCT06087874|DIETARY_SUPPLEMENT|Placebo|A maltose- containing product with a similar phenotype with Vivomixx®.
224231730|NCT01220349|DEVICE|Echocardiographic 2D strain analysis|Conventional transthoracic echocardiography with acquisitions for strain analysis by speckle tracking (2D strain)
224231731|NCT00930865|DRUG|Bumetanide|Tablets, Oral, 1 mg, Single Dose, 7 Days
223645348|NCT07065253|OTHER|blood ponction|blood ponction
223645349|NCT07065253|OTHER|urines collection|urines collection
223645350|NCT07065253|OTHER|hair collection|hair collection
223645351|NCT07065253|OTHER|saliva collection|saliva collection
223645352|NCT07065253|OTHER|stools collection|stools collection
223645353|NCT07074340|DEVICE|occlusal stabilization splint manufactured with a conventional workflow|Heat-cured acrylic resin occlusal stabilization splint
223645354|NCT07074340|DEVICE|occlusal stabilization splint manufactured with Fully-digital workflow|3D printed occlusal stabilization splints
223645355|NCT07075562|DRUG|Bevacizumab Arterial Perfusion plus TACE|The intervention consists of a combination treatment. Patients undergo transcatheter hepatic artery chemoembolization (TACE), a procedure involving localized delivery of chemotherapy and embolization of the tumor-feeding arteries. This is combined with a targeted arterial perfusion of bevacizumab, a monoclonal antibody that inhibits vascular endothelial growth factor (VEGF).
224231732|NCT00930865|DRUG|Dapagliflozin|Tablets, Oral, 10 mg. Single Dose, 7 Days
224231733|NCT03866850|BEHAVIORAL|Phase duration|We will vary the phase duration in the stimulation, and examine detection threshold, spatial spread of neural excitation, and speech recognition as the outcomes.
224231734|NCT06099314|DRUG|Fruquintinib+PD-1 inhibitors|Third-line treatment with fruquintinib combined with PD-1 inhibitors. Fruquintinib: 5mg,Oral once daily,2 weeks on/1 week off,Q3W； PD-1 inhibitor：for example, Sintilimab,iv,200mg, Q3W.
224231735|NCT06099314|DRUG|Fruquintinib+TAS-102|Fourth-line treatment with fruquintinib combined with TAS-102 . Fruquintinib: 3-5mg(Depending on the patient's physical condition), Oral once daily,3 weeks on/1 week off,Q4W； TAS-102:orally, 35mg/m2 twice daily (maximum dose 80mg in a single dose) for days 1-5, repeated every 14 days.
224231736|NCT03305055|DRUG|ketamine|Information included in arm descriptions
223645356|NCT07075562|PROCEDURE|Conventional Therapy|Patients in the control group received conventional therapy, which typically consists of TACE alone for this patient population. This involves the selective catheterization of hepatic arteries supplying the tumor, followed by the infusion of chemotherapeutic agents and an embolic agent to induce tumor necrosis.
223645357|NCT06895031|DRUG|JYP0015|JYP0015 is an orally bioavailable pan-RAS inhibitor designed to target the active (ON) form of wild-type and mutant RAS across KRAS, NRAS, and HRAS isoforms. The drug will be administered orally, with dosing determined by the study protocol in the dose-escalation and indication-expansion phases.
223645358|NCT07074496|DRUG|ThisCART19A|ThisCART19A is a new type CAR-T therapy for patients with ph+ ALL.
223645359|NCT07074496|DRUG|Fludarabine|Fludarabine is used for lymphodepletion.
223645360|NCT07074496|DRUG|Cyclophosphamide|Cyclophosphamide is used for lymphodepletion.
223645361|NCT07074496|DRUG|Olverembatinib|a third-generation TKI
223645362|NCT07074652|DRUG|Escitalopram|Participants received 2-3 weeks of escitalopram.
224231737|NCT03305055|DRUG|Fentanyl|Information included in arm descriptions
224319823|NCT00307437|DRUG|Ustekinumab (CNTO 1275) 90 mg|Ustekinumab, 90 mg, at Weeks 0 and 4 and every 12 weeks for Weeks 16 to 28. Followed by a dosing regimen to be determined by patient's response status for Weeks 28 to 52; followed by unblinded dosing that may be adjusted at the investigator's discretion for Weeks 52 to 264
223645363|NCT07074652|DRUG|Placebo|Participants received 2-3 weeks of placebo, matched in colour and size to the escitalopram.
223645364|NCT07074834|DRUG|Metoprolol Succinate Sustained-Release Tablets|Oral administration. Dose was 23.75 mg once daily for the first two weeks, then increased to 47.50 mg once daily.
223645365|NCT07074834|DRUG|Trimetazidine|Oral administration. Dose was one tablet twice daily.
223645366|NCT07074834|DRUG|Routine Drug Therapy|Included oral nitroglycerin tablets (0.5 mg twice daily), aspirin enteric-coated tablets (0.1 g once daily), and rosuvastatin calcium tablets (10 mg three times daily).
223645367|NCT07075107|PROCEDURE|Blood collection|Blood is collected in order to perform transcriptomic sequencing from blood
223645368|NCT07075107|PROCEDURE|skin biopsy|A biopsy of skin is performed in order to perform transcriptomic sequencing on fibroblasts obtained from the biopsy
223645369|NCT07075393|OTHER|full renal workup|full renal workup (biology and echography)
223645370|NCT07074171|BEHAVIORAL|Text message-based education intervention|The intervention consisted of enhanced behavioral and educational text messages, up to three messages each week, providing updates on COVID-19 testing and vaccination. The text messages included digitally delivered intervention content such as a video with low-literacy instructions for administering the rapid antigen tests, guidance if they tested positive (e.g., quarantine, notify contacts, wearing a mask), and other relevant strategies and content focused on increasing COVID-19 testing and vaccination.
223645371|NCT07075575|DRUG|Nicotine Polacrilex Gum (2 mg)|"Participants chew 2 mg nicotine gum according to a tapering 12-week schedule: Weeks 1-6: 1 piece every 1-2 hours; Weeks 7-9: 1 piece every 2-4 hours; Weeks 10-12: 1 piece every 4-8 hours. Max 24 pieces/day. Gum is distributed every 2 weeks during study visits.~Arm(s) Used In:~NRT Gum Only CBGT + NRT Gum"
223645372|NCT07075575|BEHAVIORAL|Cognitive Behavioral Group Therapy (CBGT)|"Participants attend six weekly sessions of group-based cognitive behavioral therapy focused on smoking cessation. Sessions include education on cravings, relapse prevention, stress management, and self-efficacy building.~Arm(s) Used In:~CBGT Only CBGT + NRT Gum"
223645373|NCT07075549|OTHER|Maintenance phase of Decongestive Lymphatic Therapy|Patients with lower limb lymphedema in the maintenance phase of decongestive lymphatic therapy (with compression garments) were included
223645374|NCT07075549|OTHER|Intensive phase of Decongestive Lymphatic Therapy|Patients with lower limb lymphedema who are treated in the intensive phase of Decongestive Lymphatic Therapy (with multilayer bandages) were included
223645375|NCT07074457|DRUG|Induction therapy-3 cycles of BvC (Brentuximab vedotin plus Chidamide)|"3 cycles of BvC treatment for all enrolled patients.~Brentuximab vedotin; Specification: 50mg per vial; 1.8mg/kg qd d1 every 3 weeks, ivgtt.;~Chidamide; Specification: 5mg per tablet; 20mg biw for 2 weeks every 3 weeks, po.;"
223645376|NCT07074457|DRUG|Consolidation therapy- 3 or 6 cycles of BvC(Brentuximab vedotin plus chidamide)|"Consolidation therapy( For patients who achieved CR after induction therapy, 3 cycles of additional BvC treatment; For patients who achieved PR after induction therapy, 6 cycles of additional BvC treatment).~Brentuximab vedotin; Specification: 50mg per vial; 1.8mg/kg qd d1 every 3 weeks, ivgtt.;~Chidamide; Specification: 5mg per tablet; 20mg biw for 2 weeks every 3 weeks, po.;~Maintenance therapy chidamide (20mg biw for 2 weeks every 3 weeks, po.) for ≥2 years"
223645377|NCT07074457|DRUG|Maintenance therapy-chidamide|Chidamide (20mg biw for 2 weeks every 3 weeks, po.) for ≥2 years
223645378|NCT07074509|OTHER|Manual therapy|Patients were treated by manual therapy in the form of nerve gliding, soft tissue release, and carpal bone mobilization, three sessions per week for 4weeks.
223645379|NCT07074509|OTHER|Extracorporeal shock wave therapy|Patients were treated by extracorporeal shock wave therapy. 4 sessions, one week apart, 2000 pulses per session, intensity 1.6 mj/mm, and frequency 8Hz.
223645380|NCT07073573|PROCEDURE|Vital pulp therapy|Vital pulp therapy was performed using a calcium silicate-based material after caries removal and coronal pulp exposure. Hemostasis was achieved using sodium hypochlorite before placing the material. Permanent restoration was completed in the same session. Pulpal fluid samples were collected before the intervention to assess biomarker levels. The relationship between biomarker expression and the clinical success or longevity of the treated teeth was evaluated over time
223765911|NCT07049068|DRUG|topical nicotinamide|"Participants from group 2 received a tube of 5% nicotinamide cream and 120 placebo capsules. All participants were instructed to take 1 capsule every 12 hours and to apply the cream to their entire face twice a day.~Participants were unaware of which group they were allocated to and participants in both groups received either capsules (active or placebo, which looked identical) or a tube of cream (active or placebo, which looked identical). In follow-up visits participants returned empty tubes to the responsible pharmacist.~At the initial assessment and at 6 months photographs of the participants' faces were taken."
223645382|NCT07073989|DEVICE|Afferent stimulation|Stimulation applied through mechanical vibration or low-intensity electric currents
223645383|NCT07074860|BEHAVIORAL|Peer to peer video to raise awareness about substance use|A total of 4 short, animated videos will be created using design concepts and language created by the VT RAYS. Each video will be \<2 minutes in length and address a specific topic including e-cigarette, cannabis, alcohol and other substance use. These videos will be curated online and shown to study participants during their scheduled primary care visits. The video will be followed by a short online survey available immediately after viewing to collect feedback on the content.
223645384|NCT07075055|OTHER|Metapaste Calcium Hydroxide|To compare the effect of calcium hydroxide and Bio-C Temp as intra canal medications on postoperative pain via VAS and periapical healing via CBCT
223645385|NCT07075055|OTHER|Bio C-Temp|Bio C-Temp
223765912|NCT06895499|DRUG|HB0043|Low dose
223765913|NCT06895499|DRUG|HB0043|Medium dose
223765914|NCT06895499|DRUG|HB0043|High dose
224319824|NCT05895955|BIOLOGICAL|TetraFluvac TF vaccine|"The vaccine is a seasonal quadrivalent inactivated split virion influenza vaccine \[A/Sydney/5/2021(H1N1) pdm09-like virus and A/Darwin/9/2021 (H3N2)-like virus and B/Austria/1359417/2021 (B/Victoria Lineage)-like virus and B/Phuket/3073/2013 (B/Yamagata lineage)-like virus\] produced by The Government Pharmaceutical Organization (GPO), Thailand.~Each prefilled dose of TetraFluvac TF contains a total of 60 micrograms (μg) hemagglutinin (HA) per 0.5 ml dose (15 μg HA per strain per dose), to be administered by intramuscular (IM) injection."
223765915|NCT06083519|BEHAVIORAL|White Noise|This is the control condition. Listening to white noise -- participants listen to white noise for 24 minutes
223645386|NCT07075744|OTHER|Intraoperative Heart Rate Monitoring|This is a non-interventional observational analysis of intraoperative heart rate metrics, including minimum, maximum, average, and time-weighted average heart rate recorded during non-cardiac surgery. The study also includes duration-based metrics such as time spent below or above specific heart rate thresholds. These variables were retrospectively analyzed for their association with 30-day postoperative mortality. No clinical intervention or treatment was administered as part of this study.
224231738|NCT00186914|BIOLOGICAL|Marrow stromal cell infusion|"This is a pilot study of infusions of ex vivo expanded, gene marked donor bone marrow stromal cells following allogeneic bone marrow transplantation. The study is a within patient dose escalation safety evaluation. It is believed that this patient population may benefit from these donor stromal cell infusions.~As the stromal cells will be obtained from the original stem cell donor, no conditioning is required.~Patients will receive two infusions of mesenchymal cells (MSC) approximately 14 to 21 days apart unless there is unacceptable toxicity after the first infusion. The first dose of cells to be given will be 1x10\^6 MSC/kg and the second dose of cells will be 5x10\^6 MSC/kg. The patients will be followed for approximately 28 days following the second infusion for any toxicity. Only after all six patients have safely completed both infusions will we consider 5 x 10\^6 MSC/kg a safe dose of allogeneic mesenchymal stem cells for infusion."
224231739|NCT01490281|BEHAVIORAL|water-based exercise|Interventions will consist of aerobic, muscular strength and flexibility exercises in the water
224231740|NCT01490281|BEHAVIORAL|land-based exercise intervention|Interventions will consist of aerobic, muscular strength and flexibility exercises in the land
224231741|NCT05572411|OTHER|GAITRite Electronic Walkway|Participants will be asked to walk across the electronic walkway to record information relating to their gait pattern. Depending on the age and compliance of the participant, they will be asked to complete 3 passes at 3 speeds, preferred, fast and slow.
224231742|NCT02829671|OTHER|Clinical and biological assessment|Blood sample, clinical assessment with questionnaires
224231743|NCT04845061|DRUG|Nebivolol Tablets|cardio selective beta-1 blocker
223645387|NCT07075224|DRUG|IMP 08P2002F0|Fixed combination of 0.34 % tropicamide and 2.5 % phenylephrine Hydrochloride (HCl) Eye drop Solution.
223645388|NCT07075224|DRUG|Mydriasert® insert|0.28 mg tropicamide and 5.4 mg phenylephrine hydrochloride
223645389|NCT07074106|DRUG|Carboplatin and a Taxane|"All patients will receive Carboplatin and a Taxane for 4 cycles.~* Patients who achieve a complete radiological response will proceed directly to surgery.~* Patients without a complete radiological response will receive Doxorubicin and Cyclophosphamide, with or without Pembrolizumab, for an additional 4 cycles before surgery."
223645390|NCT07074418|DRUG|Empagliflozin 10 MG then Placebo|Taking Empagliflozin first
223645391|NCT07074418|DRUG|Placebo then Empagliflozin 10 MG|Taking the Empagliflozin in second
223645392|NCT07073937|OTHER|Retrospective chart review|Retrospective study; a total of approximately 100 subjects have been identified to have had minimum 36 months follow-up.
223645393|NCT07075952|BEHAVIORAL|Food-specific inhibitory control training delivered through the FoodTraining App|"Participants will complete one training session per day for the first week and three sessions per week for the following three weeks (4 weeks in total). Each session lasts about 5 minutes and includes 3 blocks of stimuli presentation. In each block, 32 images (8 low-energy-dense foods, 8 high-energy-dense foods, 16 neutral objects) are presented for 1500ms with a 500ms interstimulus interval. One-hundred ms after the image presentation, a red or green circle appears. Participants will have to tap the image when a green circle appears (go trials) and inhibit a response when a red circle appears (no-go trials). Low-energy-dense foods are always paired with go trials, high-energy-dense foods with no-go trials, and neutral objects with either go or no-go trials. After each block, participants receive feedback on mean accuracy and reaction time. Participants can personalise the training by selecting up to three categories of high-energy-dense foods to include."
223645394|NCT07075952|BEHAVIORAL|Waiting list|Participants allocated to the control condition will not have access to the FoodTraining App during the active phase of the study (8 weeks), but will be offered the opportunity to access the app at the end of the 8-week follow-up period. This ensures that all participants, regardless of group allocation, will have the chance to benefit from the intervention once data collection is complete.
223645395|NCT07075536|BEHAVIORAL|My Health, My Choice Web-Based Contraceptive Decision Tool|"The My Health My Choice decision tool is a web-based interactive tool designed to educate patients with health conditions about their contraceptive options, elicit their personal preferences and contraceptive concerns, and help them prepare for a contraceptive discussion with their clinician. Patients can compare features of different contraceptive methods side-by-side and grouped by medical risk according to the Center for Disease Control and Prevention U.S. Medical Eligibility Criteria (US MEC). The tool generates an individualized Birth Control Summary for each patient user that records their contraceptive favorites and their questions for the clinician. Clinicians can use the Clinician Version of the tool to review the patient's Birth Control Summary and their medical eligibility for different contraceptive methods per the US MEC guidelines."
223645396|NCT07075536|BEHAVIORAL|Usual Contraceptive Care|Participants will attend clinic visits per routine. Clinicians proceed with usual contraceptive care. All study activities and incentives for participants in the usual contraceptive care arm are the same as for participants in the intervention arm except for those related to the intervention itself.
223645397|NCT07074405|OTHER|Questionnaire and Physical Exam|This is an online questionnaire that the patients fill in
223645398|NCT07075133|OTHER|Antidiabetic diet (control)|Standard antidiabetic diet
223645399|NCT07075133|OTHER|eTRE diet|eTRE for a total duration of 12 weeks. During the eTRE, volunteers will have to eat and drink (meals + snacks, medication) exclusively during an 8-hour period which will extend between 6 a.m. (flexible: or 7 a.m. or 8 a.m.) in the morning and 2 p.m. (depending on the chosen start time: or 3 p.m. or 4 p.m.), which corresponds to a fasting period of 16 hours per day
223645400|NCT07075133|OTHER|Physical activity in the morning|Physical exercise will consist of 3 weekly morning sessions that will combine aerobic and resistance exercises
223645401|NCT07075133|OTHER|Physical activity in the afternoon|The physical exercise will consist of 3 weekly afternoon sessions that will combine aerobic and resistance exercises.
223765916|NCT06083519|BEHAVIORAL|Music and Auditory Beat Stimulation|Listening to music and auditory beat stimulation. The VIBE app (LUCID) incorporates theta-band (4 Hz) auditory beat stimulation and an auditory music recommendation system. Participants will listen to this music with theta auditory beat stimulation for 24 minutes.
223645402|NCT07074639|OTHER|Personalized, home-based motor-cognitive exergame training|"The simultaneous cognitive-motor training in this study will be delivered using the exergame platform Senso Flex by Dividat (Dividat AG, Schindellegi, Switzerland), which is a pressure-sensitive foldable mat that connects to standard televisions (or any big screen). Games will be allocated across three primary domains: cognition (consisting of five sub-domains), balance (consisting of four sub-domains) and endurance. The five sub-domains of cognition are visuospatial orientation (Cognition A), memory (Cognition B), response inhibition (Cognition C), choice reaction time (Cognition D) and task switching (Cognition E). The four sub-domains of balance are mediolateral weight-shifting (Balance A), multidimensional weight-shifting (Balance B), free walking/stepping (Balance C) and mediolateral stepping (Balance D). The training sessions will be personalized in terms of difficulty level."
223765917|NCT03091192|DRUG|Savolitinib|600 mg (400 mg if \<50 kg) by mouth (PO) with a meal once daily (QD), continuously
224231744|NCT04384172|DEVICE|Tibial e-stim|For tibial nerve stimulation, the two electrodes will be placed just above the medial malleolus and the ipsilateral calcaneus on one leg near the ankle.
223645403|NCT07074639|OTHER|Otago Exercise Program|Participants in the CG will receive the evidence-based OEP on fall prevention. The OEP was selected as an active control to mirror usual care in real-world clinical settings and support the pragmatic nature of our study design. The program will be implemented in the form of a booklet, designed to provide a comprehensive guide for improving balance, strength, and overall physical function. Specifically tailored for older adults, the program includes a variety of exercises targeting key areas such as lower limb strength, balance, and flexibility. It features step-by-step instructions, illustrations, and tips to ensure exercises are performed safely and effectively.
223645404|NCT07074561|DRUG|CBZ placebo|Patients received oral administration of one 100 mg placebo tablet three times daily (TID) after meals for four consecutive weeks.
224231745|NCT04384172|DEVICE|Genital e-stim|For dorsal genital nerve stimulation, two electrodes will be placed on either side of the clitoris.
223645405|NCT07074561|DRUG|CBZ|In the EA + CBZ + placebo group, patients received oral carbamazepine (CBZ) at a dosage of 100 mg per tablet three times daily (TID) after meals for 4 consecutive weeks. In the sham EA + CBZ group, patients were administered oral CBZ at 200 mg per dose TID after meals for the same 4-week duration.
223765918|NCT03091192|DRUG|Sunitinib|50 mg by mouth (PO) once daily (QD), with or w/o food, 4 weeks on/2weeks off
224231746|NCT06154863|DRUG|RAI|Radioactive iodine
224231747|NCT03565809|OTHER|Incidence analysis|Incidence analysis between the 2 groups (ADRS/non ADRS). For each pair, an index date was defined as the ADRS identification date. In both groups, a 5-year period free of these three ADRS criteria was required before the index date, to ensure incident ADRS cases.
223765919|NCT07060573|BEHAVIORAL|Parental Oral Stimulation Protocol|This intervention consists of a structured oral stimulation protocol composed of 4 extraoral and 4 intraoral exercises designed to improve oral motor function in preterm neonates. Exercises include perioral massage, stimulation of sucking reflex, and non-nutritive sucking using a pacifier. The protocol is administered once daily for 14 consecutive days. In this study arm, the intervention is performed by parents, previously trained and supervised in the neonatal unit.
224231748|NCT01415466|DRUG|Cresto|tablet, 20mg
224231749|NCT01415466|DRUG|Olmetec|tablet, 40mg
224231750|NCT01415466|DRUG|Cresto, Olmetec|tablet, 20mg and 40mg
224231751|NCT00751946|BEHAVIORAL|Trauma Adaptive Recovery Group Education and Therapy|"Trauma Affect Regulation: Guidelines for Education and Therapy (TARGET; Ford \& Russo, 2006) is a manualized gender-specific treatment for PTSD. The 12-session individual therapy version in the present study is being adapted for adolescent girls based on a parallel version for young mothers and a group version that has been field tested with more than 20 adolescent girls.~TARGET teaches a practical 7-step sequence of skills for processing and managing trauma-related reactions to current stressful experiences. The skills are designed in a sequence mirroring the three phases of complex traumatic stress disorder treatment (Ford, Courtois, Van der Hart, Nijenhuis \& Steele, 2005), summarized by an acronym FREEDOM. TARGET also uses creative arts activities: personalized lifelines via collage, drawing, poetry, and writing."
224231752|NCT00751946|BEHAVIORAL|Enhanced Treatment As Usual|Enhanced Treatment as Usual (ETAU) is a 12-session supportive therapy adapted from the Present Centered Therapy co-developed by the first author (McDonagh-Coyle, Friedman, McHugo, Ford, Mueser, \& Sengupta, 2005). In ETAU therapists invite the participant to talk about goals or problems that are important to her. The therapist's focus is on providing the core conditions of client centered psychotherapy (nonjudgmental acceptance, empathy, interpersonal warmth) and engaging the participant in a strengths-based solution-focused reflection on how she is successful (or has been in the past) in managing stressors, handling problems, achieving personal goals, and developing healthy relationships with peers, family, and other community members.
223765920|NCT07060573|BEHAVIORAL|Physiotherapist-led Oral Stimulation|This intervention consists of a structured oral stimulation protocol composed of 4 extraoral and 4 intraoral exercises designed to improve oral motor function in preterm neonates. Exercises include perioral massage, stimulation of sucking reflex, and non-nutritive sucking using a pacifier. The protocol is administered once daily for 14 consecutive days. In this study arm, the intervention is performed by a licensed physiotherapist.
223765921|NCT07059728|DEVICE|Oxygen therapy during sedation provided via high nasal cannulae (60L/min at 60% FiO2)|Intervention group: Oxygen therapy during sedation provided via high nasal cannulae (60L/min at 60% FiO2)
223765922|NCT07059728|DEVICE|Oxygen therapy during sedation delivered via nasal cannulae at 5L/min|Control group: Oxygen therapy during sedation delivered via nasal cannulae at 5L/min
223765923|NCT05262023|DRUG|DNL593|Ascending single doses (for healthy participants) and multiple doses (for participants with FTD)
223765924|NCT05262023|DRUG|Placebo|Ascending single doses (for healthy participants) and multiple doses (for participants with FTD)
223765925|NCT05677360|BEHAVIORAL|HPV MISTICS -Provider Level|The HPV MISTICS (Multilevel Intervention Strategies Targeting Immunization in Community Settings) provider-level intervention for all clinical staff (e.g., physicians, nurses, medical assistants) includes a 1-hour online training session on the Announcement Approach (i.e., presumptive recommendation) to recommend adolescent vaccinations.
223765926|NCT05677360|BEHAVIORAL|HPV MISTICS - Parent Level|The HPV MISTICS (Multilevel Intervention Strategies Targeting Immunization in Community Settings) parent-level intervention includes a low literacy pre-visit HPV vaccine notification post card in the parent's preferred language.
224231753|NCT05530356|DRUG|Aminohippurate Sodium Inj 20%|Diagnostic aid/agent used to measure effective renal plasma flow (ERPF)
223645406|NCT07074561|PROCEDURE|Electroacupuncture|The primary acupoints selected were the affected side's Sibai (ST2), Xiaguan (ST7), and Dicang (ST4). Based on the affected nerve branch, additional acupoints were chosen: for the ophthalmic branch, Tongziliao (GB1); for the maxillary branch, Quanliao (SI18); and for the mandibular branch, Jiache (ST6). Distal acupoints included bilateral Hegu (LI4) and Waiguan (SJ5). Electroacupuncture was applied based on the affected nerve branch. For the ophthalmic branch, the local acupoints selected were Xiaguan + Tongziliao; for the maxillary branch, Xiaguan + Quanliao; and for the mandibular branch, Xiaguan + Jiache. The distal acupoints selected were Hegu + Waiguan. A sparse-dense wave, 2/100Hz, was used, with a treatment duration of 60 minutes. The intensity of the electrical current was adjusted according to the patient's tolerance. Acupuncture was administered 3 times per week (with 1-2-day intervals between sessions) for 4 consecutive weeks, totaling 12 sessions.
223645407|NCT07074561|PROCEDURE|Sham electroacupuncture|In this group, superficial needling (0.5-1 mm depth) was performed at non-meridian points located 1 cm lateral to: (1) primary local acupoints ST2 (Sibai), ST7 (Xiaguan), and ST4 (Dicang) on the affected side; (2) branch-specific supplementary points GB1 (Tongziliao) for ophthalmic branch involvement, SI18 (Quanliao) for maxillary branch involvement, and ST6 (Jiache) for mandibular branch involvement; and (3) bilateral distal points LI4 (Hegu) and TE5 (Waiguan). Local acupoint pairs (ST7 adjacent +GB1 adjacent or ST7 adjacent +SI18 adjacent or ST7 adjacent +ST6 adjacent) and distal pairs (LI4 adjacent +TE5 adjacent) were connected to a modified electroacupuncture device with severed output wires (preventing current flow while maintaining indicator function), followed by 60-minute needle retention after parameter adjustment. Acupuncture was administered 3 times per week (with 1-2-day intervals between sessions) for 4 consecutive weeks, totaling 12 sessions.
223645408|NCT07073911|BEHAVIORAL|Exercise|Les Mills Thrive is a 45-minute class that consists of flexibility, strength, and coordination exercises. This program aims to improve sensorimotor control and strength via functional weight-bearing exercises and floor exercises to isolate targeted hip and core muscles. In each class (whether in person or online), a certified Les Mills Thrive instructor will provide options to either increase or decrease the intensity of each exercise to cater to varying fitness levels and fluctuating symptoms. Each exercise has an assisted (using a chair for balance), body weight, and resisted (weight or exercise tubing) option. Participants will have the option to attend group fitness classes or do the classes asynchronously at home using a link to access a recorded class.
223645409|NCT07074912|OTHER|Prescription for weight-based dosing of antipyretic|The intervention group (n=220) will receive prescription with weight-based dosing for acetaminophen (also prescribed and known as Tylenol) and ibuprofen (also prescribed and known as Motrin).
223645410|NCT07074912|OTHER|Standard discharge instructions|The control group (n=220) will also receive standardized printed discharge instructions but no prescription. The discharge instructions include the appropriate dose of acetaminophen (also known as Tylenol) and ibuprofen (also known as Motrin).
223645411|NCT07074626|OTHER|transrectal ultrasound|"A- Complete history was taking (personal, past, medical, surgical and family history) with careful attention to abdominal examination and suspected cause of pelvic pathology B- Through physical examination (general and abdominal examination). C- Investigations.~* Trans-rectal ultrasound will be conducted to all the virgin patients as the standard US examination to detect the pelvic pathology~* Patient anticipation for pain will be documented before the exam according to pain visual analogue scale (VAS)~* Lidocaine gel will be used on the probe during TRU~* The intensity of pain during trans-rectal US based on the pain visual analogue scale (0-10 ) points and the adverse events like extreme pain, inability to complete the examination and inability to detect the pathology will be reported.A Visual Analogue Scale (VAS) is one of the valided pain rating scales used for the first time in 1921 by Hayes and Patterson."
223765927|NCT05677360|BEHAVIORAL|HPV MISTICS- HPV Vaccine Champion Level|The HPV MISTICS (Multilevel Intervention Strategies Targeting Immunization in Community Settings) system-level intervention involves training an HPV Vaccine Champion at each FQHC on the provider and parent EBIs to monitor and share clinic HPV initiation and completion rates with providers, and to implement reminder/recall systems for subsequent vaccine doses
224231754|NCT05530356|DRUG|Iohexol Inj 300 MG/ML|Diagnostic aid/agent used to measure glomerular filtration rate (GFR)
224231755|NCT05530356|DRUG|Dextran 40|Diagnostic aid/agent used to measure glomerular size selectivity
224231756|NCT05530356|PROCEDURE|Renal Biopsy|Minimally invasive outpatient procedure in interventional radiology to obtain renal tissue cores.
224323483|NCT03456128|OTHER|CAPABLE|It involves up to 10 in-home tailored interventions of approximately 60 minutes duration each over a 5-month period. The assessment driven interventions are delivered by an Occupational Therapist (OT) (≤ 6 home visits for ≤ 1hour), a Registered Nurse (RN) (≤ 4 home visits for ≤ 1hour), and a handyman (HM) team.
224231757|NCT05530356|RADIATION|Positron Emission Tomography|Imaging study performed to study renal oxidative metabolism
224231758|NCT05092490|PROCEDURE|Combined serratus anterior plane block and transversus thoracis plane block|The study group will receive a combined plane block by a dedicated anesthesia team prior to their procedure. 20 mL of local anesthetic (0.25% bupivacaine) will be injected for the Serratus anterior plane block and another 20 mL of local anesthetic (0.25% bupivacaine) will be injected in transversus thoracis plane block
224231759|NCT05092490|PROCEDURE|Standard local infiltration technique|Local anesthetic infiltration of the incision sites will be performed by the cardiologist prior to, and as, necessary during the procedure. The amount of local anesthetic used will be determined intraoperatively by the cardiologist according to the patients' requirements.
224231760|NCT03891719|PROCEDURE|Unilateral cleft lip rhinoplasty|"* Perform marking with methylene blue tattoo marks~* Inject Local anesthetic solution with epinephrine~* Harvest auricular cartilage~* Make the incisions parallel the lip scar, extende into the marginal incision and encompass any alar webbing. The incisions outline the entirety of the lower lateral cartilage and create sliding chondrocutaneous flap. This flap combines with reverse U incision.~* Harvest septal bony cartilaginous unit for grafting the caudal septum and suspend the medial crural cartilages~* Create dome symmetry at the cartilage level and reconstruct nasal tip with other grafts (shield-type tip graft, cap graft, alar batten graft)~* Dorsal augmentation~* Lip reconstruction and alar base repositioning.~* Closure and repair vestibular deficiency with the reverse-U component of the chondrocutaneous flap at the alar rim."
223645412|NCT07075172|OTHER|Instrumented-assisted soft tissue mobilization|Instrumented-assisted soft tissue mobilization of the posterior leg and Achilles tendon region
223645413|NCT07075458|BEHAVIORAL|Magic Rope Trick|Children will be distracted using a magic rope trick during local anesthesia administration.
223645414|NCT07075458|BEHAVIORAL|Magic Thumb Sleeves|Children will be distracted using light-up magic thumb sleeves during local anesthesia administration
224231761|NCT04484337|DRUG|Cabotegravir sodium (Oral Lead In)|CAB will be available as 30 mg tablets for oral administration.
224231762|NCT04484337|DRUG|Cabotegravir 400 mg/mL|CAB 400 mg/mL will be available for administration by IM injection or SC Injection.
224231763|NCT04484337|DRUG|Cabotegravir 200 mg/mL|CAB 200 mg/mL will be available for administration by IM injection or SC Injection.
224231764|NCT04484337|DRUG|Topical non-steroidal anti-inflammatory drug|Non-steroidal anti-inflammatory drug will be available for topical application
224231765|NCT04484337|DRUG|Topical steroid|Steroid will be available for topical application
224231766|NCT04484337|DRUG|Placebo creams/gels|Placebo creams/gels will be available for topical application
224231767|NCT04484337|DRUG|Recombinant human hyaluronidase PH20 (rHuPH20)|rHuPH20 will be available for administration by SC Injection
224231768|NCT03309449|DEVICE|Syringe and needle|Intramuscular administration of simulated naloxone
224231769|NCT03309449|DEVICE|Intranasal mucosal atomization device|Intranasal atomizer administration of simulated naloxone
224231770|NCT03309449|DEVICE|Nasal spray|Nasal spray administration of simulated naloxone
224231771|NCT06046027|DEVICE|Accupressure band|The accupressure band and wirst band will be place 20 minutes prior to induction of anaesthesia. The induction and maintenance of anaesthesia performed at the discretion of the supervising anaesthesiologist. The maintenance of anaesthesia was achieved by administering sevoflurane at a minimum alveolar concentration (MAC) range of 1 to 1.2. A fresh gas flow rate of 2 L/min comprising a 50:50 concentration mixture of oxygen and air were employed. The patients will be ventilated and maintain end-tidal carbon dioxide (ETCO2) levels within the range of 35-40mmHg. All patients were administered intravenous dexamethasone at a dosage of 0.1mg/kg as a conventional prophylaxis for postoperative nausea and vomiting (PONV) following the induction of anaesthesia. Additionally, intravenous morphine was administered at a dosage of 0.05mg/kg and suppositories containing paracetamol were given at a dosage of 30mg/kg for analgesic purposes. Patients will be extubated at the end of surgery
224231772|NCT05567380|OTHER|Observation|Observation of Rheumatoid arthritis disease response to JAK inhibitors and TNF inhibitors after definite timepoints from the initialization of treatment in comparison to the current standard of care of therapy with conventional DMARDs.
223645415|NCT07075458|BEHAVIORAL|Tell-Show-Do (TSD)|Children will receive the conventional Tell-Show-Do behavior management technique during local anesthesia administration
223645416|NCT07075939|OTHER|No Intervention: Observational Cohort|Observational data collection only
223645417|NCT07074548|DIETARY_SUPPLEMENT|Placebo|Placebo oral capsule identical in appearance to hydroxytyrosol supplement, administered once daily for 4 weeks.
223645418|NCT07074548|DIETARY_SUPPLEMENT|Hydroxytyrosol|Hydroxytyrosol is a natural polyphenol with antioxidant and anti-inflammatory properties, derived from olives. In this study, hydroxytyrosol 10 mg will be administered orally once daily for 4 weeks to assess its effects on blood pressure and inflammatory biomarkers in hypertensive pregnant women.
223645419|NCT07075419|DRUG|JDB153|JDB153 is administered orally at doses of 600 mg twice daily (1200 mg total daily dose) or 500 mg twice daily (1000 mg total daily dose) based on safety and tolerability assessment.
223645420|NCT07075419|DRUG|Penpulimab|Penpulimab is administered by intravenous infusion at a dose of 200 mg once every 3 weeks (Q3W).
223645421|NCT07075003|DEVICE|nociceptive level|remifentanil infusion dose adjustment according to the changes of nociceptive level
223645422|NCT07074808|DEVICE|aiTriage risk score|Risk score generated by AI App aiTriage for chest pain patients
224231773|NCT01621464|DEVICE|Pacemaker with Closed Loop Stimulation (CLS sensor)|Crossover: 1 year at control group and 1 year at CLS group (randomized which group goes first)
224231774|NCT02833038|DRUG|Magnesium Sulfate|adminstration of intravenous magnesium as bolus of 50 mg/kg, followed by continuous infusion at rate of 10 mg/kg/h
224231775|NCT02833038|DRUG|Normal saline|the same bolus and infusion volumes of normal saline
224231776|NCT01450709|DIETARY_SUPPLEMENT|Kibow Biotics|6 month, double-blind, cross-over, wash-out, placebo controlled study in an outpatient setting. Each patient takes two capsules, three times a day (180 CFU/day).
224231777|NCT00208988|PROCEDURE|Educational handout about prostate cancer screening|
224231778|NCT00208988|PROCEDURE|Simple cue for patient to talk to doctor|
224231779|NCT04652453|OTHER|Geriatrics Bundle|Enrolled participants in the intervention arm will receive all 3 bundle components: occupational therapy (in addition to physical therapy) upon enrollment in the ICU, a portable amplifying device upon enrollment in the ICU, and a de-prescribing intervention by the ICU pharmacist (in conjunction with the medical team) upon ICU-to-floor transfer.
224231780|NCT03061409|DIETARY_SUPPLEMENT|Pharmavite Nature Made Multi for Him 50+|To examine whether one tablet a day of Pharmavite Nature Made Multi for Him 50+ will increase micro-nutrient status in older people taking multiple medications as compared to placebo
224231781|NCT03061409|DIETARY_SUPPLEMENT|Placebo|served as placebo
224231782|NCT03820583|PROCEDURE|Whipple Procedure|Patients underwent Whipple procedure for pancreatic tumors. The procedure commenced with rooftop incision. then layers of abdomen dissected to reach the peritoneum. Then Duodenum dissected out along with pancreas and common bile duct. After rescetion of these structures the anatomy of the tract restored with three anastomosis namely pancreaticojejunostomy, gastrojejunostomy and choledochojejunostomy/hepaticojejunostomy.
224231783|NCT04079907|DIETARY_SUPPLEMENT|Ketone|This intervention will take their respective supplement for 14 days, then will be followed for up to 1 year during routine clinic visits.
224231784|NCT04079907|DIETARY_SUPPLEMENT|Placebo|This intervention will take their respective supplement for 14 days, then will be followed for up to 1 year during routine clinic visits.
224231785|NCT00343980|DRUG|rosiglitazone|Tablets, 4 mg once or twice a day.
224231786|NCT00343980|DRUG|inhaled human insulin|Treat-to-target dose titration scheme, pre-prandial, inhalation.
224231787|NCT00343980|DRUG|glimepiride|Tablets, 4 mg/day.
223645423|NCT07076017|BEHAVIORAL|Dry-land strength and conditioning programme|Participants in the experiment group will be asked to complete two supervised gym sessions per week for 10 weeks. Each session will include a variety of plyometric and strength exercises, selected for their relevance to start and turn performance in swimming.
223645424|NCT07076017|BEHAVIORAL|Active control condition|The control group will complete their usual swimming training which comprises of several pool-based session and one land-based session each week.
223645425|NCT07074873|OTHER|Descriptive information form|The age, gender, height, weight, body mass index, age at menarche, time of initial diagnosis, how it was detected (medical history), family history (genealogy), dominant hand use, exercise habits (type of sport and duration), and corset use of individuals participating in the study will be recorded.
223645426|NCT07074873|OTHER|Health-Related Quality of Life Assessment|The Paediatric Quality of Life Inventory is a valid and reliable health-related quality of life questionnaire used for children. This inventory, which has been adapted into Turkish, consists of two forms for children and families. Both forms include sections on physical functioning (8 items), emotional functioning (5 items), social functioning (5 items), and school functioning (5 items). Scoring is done on a scale of 0-5 for each question (0 = Never causes a problem, 1 = Rarely causes a problem, 2 = Sometimes causes a problem, 3 = Often causes a problem, and 4 = Always causes a problem). The total score of the inventory ranges from 0 to 100 points (0 = 100, 1 = 75, 2 = 50, 3 = 25, 4 = 0). A high score indicates better health-related quality of life. Since our study population is aged 10-18, the inventories developed for the 8-12 and 13-18 age groups will be used.
223645427|NCT07074873|DIAGNOSTIC_TEST|Trunk rotation angle|The Adam's Forward Bend Test is used as the primary assessment test in the clinical examination of scoliosis patients. In our study, the scoliometer assessment will be performed on the study group while the subjects are standing with equal weight on both feet. Patients will be asked to bend forward so that their shoulder level is aligned with their hip level (body parallel to the ground), and measurements will be taken with the scoliometer, with the highest degree recorded. The Baseline Scoliometer will be used for evaluations.
224231788|NCT03465566|DIAGNOSTIC_TEST|IDS;MMSPE;CDI 2;CBCL;tests of facial expression evaluation|Five pictures (including nonfacial features; i.e., hairs) were used for each emotion, giving a total of 25 trials.Stimuli consist of pictures of facial affect taken from the Ekman and Friesen series.
223645428|NCT07074873|DIAGNOSTIC_TEST|Cobb angle measurement|The Cobb angle allows for the evaluation of deformity in the frontal plane in scoliosis. It is obtained by measuring the lateral flexion angle of scoliosis from a standing spinal X-ray taken in the posterior-anterior direction. The angle between the perpendicular lines connecting the parallel line drawn from the upper edge of the uppermost vertebra (upper vertebra) involved in the curvature and the parallel line drawn from the lower edge of the lowest vertebra (lower vertebra) gives the Cobb angle. In our study, the Cobb angle will be recorded from the spinal X-ray.
223645429|NCT07074873|DIAGNOSTIC_TEST|Pelvic floor muscle activation measurement|The physiotherapist will position the child in a supine position with the knees flexed at 140 degrees, the soles of the feet in contact with the bed, and the thighs and feet approximately 30 centimetres apart. Two surface electrodes will be placed at the 3 and 7 o'clock positions on the perineal region, and a 30×30 mm single-use electrode will be placed on the right thigh as a reference electrode. Children will be taught to contract the correct pelvic floor muscles to move in the ventral and cranial directions. The 'Work-Rest Assessment,' lasting a total of 55 seconds, will be applied to each child using the same device. First, children will be asked to relax their pelvic floor muscles. Then, 5 seconds of contraction (work) and 5 seconds of relaxation (rest) will be performed, and a total of 10 cycles of contraction and relaxation of the pelvic floor muscles will be requested. The device provides a report of the data in graphical and numerical form at the end of the measurement.
223765928|NCT06787222|DRUG|tretinoin 0.025% + Z. officinale patch|Material used for patch formulation were 3,15 grams of polyvinyl alcohol, 4,2 grams of polyvinyl pyrrolidone, 12,6 ml distilled water, and 1,05 grams of Z. officinale extract.
224231789|NCT04740021|DRUG|LP002|10 mg/kg administered as IV infusion on Day 1 of each 21-day cycle.
224231790|NCT04740021|DRUG|Carboplatin|AUC 5 administered as IV infusion on Day 1 of each 21-day cycle.
224231791|NCT04740021|DRUG|Etoposide|100 mg/m\^2 administered as IV infusion on Day 1, 2 and 3 of each 21-day cycle.
224231792|NCT05079009|DEVICE|ECCO2R pulsatile configuration|Use of the pulsatile extracorporeal blood flow configuration.
224231793|NCT06138379|OTHER|Experimental: 1st Experimental Group|Individuals will be sent relevant educational videos after liver transplantation and asked to watch them.
224231794|NCT06138379|OTHER|Experimental: 2nd Experimental Group|Individuals will be sent relevant educational videos after liver transplantation and asked to watch them.
224231795|NCT04769466|OTHER|LifeBio Memory|LifeBio Memory is a digital reminiscence therapy platform designed to collect the life stories of older adults to generate personalized life storybooks that capture their unique narratives and social histories. Life story booklets, summaries, and materials are also developed as mechanisms for sharing this story and for staff to provide enhanced person-centered care.
224231796|NCT03284775|DEVICE|Intraoperative ultrasound|Patients will undergo transsphenoidal surgery in the usual manner except that an intraoperative ultrasound device will be available for use to better visualise the tumour and surrounding neurovascular structures.
223765929|NCT06787222|DRUG|tretinoin 0.025% cream|no Z. officinale patch applied after tretinoin 0.025% application
224231797|NCT00967538|DRUG|etanercept 50 mg|All patients will receive etanercept 50 mg twice a week for 12 weeks followed by 50 mg once a week for an additional 12 weeks.
224231798|NCT05137080|DRUG|Dexamethasone|24mg dexamethasone
224231799|NCT05137080|DRUG|Isotonic saline|Isotonic saline
224231800|NCT05889871|DRUG|Standard endocrine therapy plus Apatinib|Standard endocrine therapy plus Apatinib
224231801|NCT00855842|DEVICE|osmotic dilator insertion|osmotic dilators are placed in the cervix to cause cervical dilation
224319825|NCT05895955|BIOLOGICAL|Vaxigrip vaccine|"Vaxigrip vaccine is commercially available seasonal quadrivalent inactivated split virion influenza vaccine \[A/Sydney/5/2021(H1N1) pdm09-like strain and A/Darwin/9/2021 (H3N2)-like strain and B/Austria/1359417/2021-like strain and B/Phuket/3073/2013-like strain, manufactured by Sanofi Pasteur, Ltd. France.~Each prefilled dose of Vaxigrip vaccine contains a total of 60 micrograms (μg) hemagglutinin (HA) per 0.5 ml dose (15 μg HA per strain per dose), to be administered by intramuscular (IM) injection."
224231802|NCT04997343|OTHER|Neurophysiological assessment|EMG will be recorded from the Abductor pollicis brevis muscle (APB) with surface electrodes. EEG will be recorded with a 32-channel elastic cap via a TMS compatible system. TMS will be performed using a Magstim 200 stimulator with a 90 mm figure-of-eight coil localized on motor and non-motor areas using a neuronavigation system together with an optical tracking system. Coordinates for neuronavigation will be calculated in the MNI space and fit of each participant's anatomical MRI. Three minutes of continuous-EEG will be recorded with subjects at rest. Single-pulse neuronavigated TMS (sp-TMS) will be delivered at rest below the resting motor threshold intensity (RMT) over the APB hotspot on M1 during concurrent EEG recording. In a final block, the subject will maintain a voluntary muscle contraction (50% of the maximal voluntary contraction) of the left APB, and sp-TMS will be delivered at 130% RMT over the ipsilateral APB hotspot in order to record the lpSP.
224231803|NCT04997343|OTHER|clinical assessment|"Clinical evaluation, performed at each time point, will include:~* The assessment of clinical disability using EDSS score~* The multiple sclerosis functional composite (MSFC), a three-part quantitative objective measure of neurologic function, measuring lower limbs (timed 25-foot walk \[T25FW\]), upper limbs (nine-hole peg test \[9HPT\]) and cognitive (three-second paced auditory serial addition test \[PASAT3\]) function.~In order to reduce inter-rater variability, the same physician/technician with adequate training will administer all three tests. The patient should feel comfortable with the situation. Examiner should explain the instructions in a professional but friendly way and let the patient ask any questions before starting the tests. Examiner should write down the test results, as well as any situation that disturbs the performance of patient. Examiner should not provide direct feedback to the patient about his/her performance"
223645430|NCT07075120|DRUG|Ipilimumab and Nivolumab|Immunotherapy combination (Ipilimumab and Nivolumab) targeting CTLA-4 and PD-1 pathways to enhance immune response.
223645431|NCT07075120|RADIATION|Stereotactic Body Radiotherapy (SBRT)|High-dose radiation therapy delivered in 3-5 fractions for local control of tumors in combination with immunotherapy. Radiation dosages are based on the RTOG 1112 trial guidelines to minimize normal tissue exposure.
223645432|NCT07075601|BIOLOGICAL|Take 1 ml of blood|Take 1 ml of blood
223645433|NCT07075601|BIOLOGICAL|DNA sequencing|DNA sequencing
223645434|NCT07075601|PROCEDURE|Valve collection (healthcare waste)|Valve collection (healthcare waste)
223645435|NCT07075601|OTHER|Collection of serious post-operative complications|Collection of serious post-operative complications
223645436|NCT07075692|OTHER|Physiotherapy|Physiotherapy program will include patient education, lifestyle recommendations (fluid intake, diet, correct urination/defecation position, weight control, etc.), breathing exercises, pelvic floor muscle training, and stabilization exercises. The treatment program will last for a total of 8 weeks
223645437|NCT07075289|DRUG|DLBS1033|Participants would get oral lumbrokinase DLBS1033 (490 mg, DISOLF film-coated tablet, Dexa Medica b.i.d.) for a 14-day prospective observation period.
223645438|NCT07075289|DRUG|Betahistine Mesylate tablet|Patients would get betahistine mesylate (12 mg, MERTIGO SR tablet, Dexa Medica b.i.d.) for a 14-day prospective observation period.
223645439|NCT07074028|DIAGNOSTIC_TEST|Medical Research Council sum score (MRC-SS) test|Medical Research Council (MRC)-sumscore evaluates global muscle strength. Manual strength of six muscle groups (shoulder abduction, elbow flexion, wrist extension, hip flexion, knee extension, and ankle dorsiflexion) is evaluated on both sides using MRC scale
223645440|NCT07074028|DIAGNOSTIC_TEST|Handgrip test combined with surface electromyography (sEMG)|Handgrip test combined with surface electromyography (sEMG) of the flexor digitorum superficialis
223645441|NCT07074028|DIAGNOSTIC_TEST|Electrical activity during maximal voluntary contraction of the rectus femoris|Surface EMG amplitude (RMS) during maximal voluntary contraction measured by surface electromyography (sEMG) of the rectus femoris
223645442|NCT07074028|DEVICE|Musculoskeletal Ultrasound|Measurement of the cross-sectional area (CSA) of the rectus femoris by ultrasound
223645443|NCT07074028|DEVICE|Diaphragmatic ultrasound|Diaphragmatic ultrasound is a non-invasive technique that allows for sequential assessment of diaphragm mobility (excursion) and contraction (thickening) in mechanically ventilated patients
223645444|NCT07074028|BIOLOGICAL|blood sampling|Blood samples are collected from a radial or femoral arterial catheter, which is part of the routine care of the patients. These samples are taken with the aim to: 1) describe the inflammatory profile (plasma measurements of CRP, IL-1, IL-6, TNFα, IL-10, fibrinogen, ferritin, cortisol), 2) assess organ dysfunction and calculate the SOFA score (arterial blood gases, lactate levels, liver function tests, complete blood count, and blood electrolyte panel)
223645445|NCT07074028|DEVICE|Electroneuromyogram|Analysis of peripheral neurogenic and myogenic components involved in intensive care unit-acquired muscle dysfunction through the performance of an electroneuromyogram
223645446|NCT07074028|DIAGNOSTIC_TEST|6-minute walk test|The 6-minute walk test (6MWT) is a simple test that requires a quiet, indoor, flat 30-meter course, ideally in a straight rectangular hallway
223645447|NCT07074028|DIAGNOSTIC_TEST|Montreal Cognitive Assessment (MoCA)|The Montreal Cognitive Assessment (MoCA) is the most sensitive rapid assessment test and assesses cognitive functions most broadly (attention, concentration, executive functions, memory, language, visual-constructive abilities, abstraction, calculation, orientation).
223645448|NCT07074028|BEHAVIORAL|MNA-SF|The MNA-SF (Short Form) is a simplified version that allows us to determine whether the elderly person is well nourished, at risk of malnutrition or malnourished.
223645449|NCT07074600|DEVICE|Electroacupuncture Therapy|Participants in the experimental group will receive daily electroacupuncture therapy over a standardized 14-day therapeutic course. Comprehensive functional and neurological assessments will be conducted at pre-intervention (baseline) and post-intervention timepoints. Acupoint selection will target anatomical domains spanning the cranial, upper limb, and lower limb regions.
223645450|NCT07074600|DEVICE|Sham electroacupuncture intervention|Participants in the control group will receive daily sham electroacupuncture therapy over a standardized 14-day therapeutic course. Comprehensive functional and neurological assessments will be conducted at pre-intervention (baseline) and post-intervention timepoints. Sham electroacupuncture procedures will target non-acupoint locations outside recognized cranial, upper limb, and lower limb anatomical domains.
223765930|NCT06767514|BIOLOGICAL|Ivonescimab Injection|Subject will receive ivonescimab as an IV injection
223765931|NCT06767514|BIOLOGICAL|Pembrolizumab Injection|Subject will receive Pembrolizumab as an IV injection
223765932|NCT06448481|PROCEDURE|Intra-dermal purse-string closure|Sutures are placed below the skin surface around a circular surgical wound, and the ends are cinched together like a coin purse.
223765933|NCT06448481|PROCEDURE|Transcutaneous purse-string closure|Sutures are placed through the skin surface around a circular surgical wound, and cinched together like a coin purse.
223645451|NCT07075809|DEVICE|The laser acupuncture|The intervention group in this study receives laser acupuncture therapy using a laser Micropad GL2+ device with an infrared wavelength of 880 nm. The laser acupuncture is applied to specific acupuncture points, namely GV14, LI4, ST36, and SP6 on the body, as well as ear points including MA-TF1 Shenmen, MA-SC5 Liver, MA-IC3 Endocrine, MA-IC8 Spleen, and MA-SC6 Kidney. Treatment is administered once daily for a total of six sessions during the chemotherapy treatment period.
223765934|NCT06773845|DEVICE|TheraSphere|The multicompartment MIRD model (a.k.a. partition model) based on diagnostic CT/MRI and 99mTc-MAA SPECT-CT will be used to plan a targeted dose of 700 Gy (± 50%) to the tumor. Given the high tumor burden, a scheduled second radioembolization within 120 days from the initial treatment will be permitted at the discretion of the operators provided the cumulative lung dose remains below 50 Gy. A scheduled second radioembolization may be considered when the largest tumor diameter exceeds 8 cm, or the estimated lung dose reaches 30 Gy while the tumor absorbed dose remains below the target dose of 700 Gy. The radioactive microsphere delivery device used will be glass-based (TheraSphere; Boston Scientific, MA, USA), in which Y90 is an integral constituent of the biocompatible glass matrix. Dosimetry planning will be made by personalized dosimetry software (Simplicit90y; Boston Scientific).
224231804|NCT02978326|DRUG|SAGE-217 15/20 mg Oral Solution|SAGE-217, 15 mg oral solution, BID for Days 1 to 2 followed by 20 mg oral solution BID for Days 3 to 14. If not tolerated, 15 mg for the rest of study (Days 3 to 14).
224231805|NCT02978326|DRUG|Placebo|SAGE-217 matching placebo, capsules, orally, once daily, for up to 14 days.
223645452|NCT07075809|DEVICE|Sham Laser acupuncture|The Control group in this study receives sham laser acupuncture therapy using a laser Micropad GL2+ device with deactivation mode. The sham laser acupuncture is applied to specific acupuncture points, namely GV14, LI4, ST36, and SP6 on the body, as well as ear points including MA-TF1 Shenmen, MA-SC5 Liver, MA-IC3 Endocrine, MA-IC8 Spleen, and MA-SC6 Kidney. Treatment is administered once daily for a total of six sessions during the chemotherapy treatment period.
224231806|NCT02978326|DRUG|SAGE 217 30 mg Capsules|SAGE-217, 30 mg, capsules, orally, once daily, for up to 14 days.
224231807|NCT03317613|DRUG|Qutenza|Patients suffering from neuropathic pain will receive patch of capsaicin (qutenza) on the painful zones. Three months after the first application, patients will be allowed to receive another patch if necessary. They will be able to receive one every three months. They will be followed in the study during one year after the first patch application.
224231808|NCT05710978|OTHER|Work Protocol|Participants will complete 4 hours of walking and cycling to a work:rest ratio of 3:1.
224231809|NCT01048437|BEHAVIORAL|Transplant education with video|1 hour standard transplant module is replaced with the Explore Transplant presentation and 20 minute video featuring transplant patients and donors
224231810|NCT01048437|BEHAVIORAL|Transplant education with speakers|1 hour standard transplant module is replaced with the Explore Transplant presentation and 3 live speakers: 1 deceased donor recipient, 1 living donor recipient and 1 living donor
224231811|NCT03588325|DIAGNOSTIC_TEST|CBC-DIFF with MDW, PCT, CRP|Tests will be run to determine early identification of sepsis and added value of the combination of tests. Results will not be used to manage patients
224231812|NCT04449159|DIETARY_SUPPLEMENT|Vinh Wellness Collagen|Vinh Wellness Collagen is hydrolyzed collagen
224231813|NCT04449159|DIETARY_SUPPLEMENT|Placebo|Placebo
224231814|NCT03607006|PROCEDURE|Patient specific PEEK sheets|Computer aided sheet design
224231815|NCT03607006|PROCEDURE|Autogenous bone shell|autogenous retromolar/chin bone graft
224231816|NCT02566135|DEVICE|Tracheal Intubation using I-gel and ventilating bougie|Following general anaesthesia I-gel was inserted. After proper placement . ventilating bougie was inserted. Once it's placement is confirmed I-gel was removed keeping the ventilating bougie in situ. Then appropriate sized endotracheal tube was railroaded over ventilating bougie then it (v.bouggie) was removed . Proper placement of endotracheal tube was confirmed by bilateral equal chest excursion and air entry on auscultation, absence of gastric insuffflation sound over epigastrium and 'sine' wave on capnography. Maximum 3 attempts were allowed for I-gel, ventilating bougie and endotracheal tube.
224231817|NCT02566135|DEVICE|Tracheal Intubation using C-LMA and ventilating bougie|Following general anaesthesia C-LMA was inserted. After proper placement of C-LMA, ventilating bougie was inserted. It's placement was confirmed and C-LMA was removed after deflation of cuff keeping the ventilating bougie in situ. Then appropriate sized endotracheal tube was railroaded over ventilating bougie. It's placement was confirmed by bilateral equal air entry and chest excursion, absence of gastric insufflation sound over epigastrium and 'sine' wave on capnography. Maximum 3 attempts were allowed for C-LMA , ventilating bougie and endotracheal tube.
224319826|NCT05920512|DRUG|Sodium valproate extended-release tablets|Sodium valproate extended-release tablets 0.5g/day; sirolimus tablets 1mg/day and calcitriol capsules 0.25μg/day.
224319827|NCT03450252|DEVICE|Active pacing|Ventricular pacing via the invasive haemodynamic study-defined optimal pacing site in order to relieve pressure gradient across the mid-cavity obstruction in mid-cavity obstructive variant hypertrophic cardiomyopathy.
224231818|NCT03945565|OTHER|Fraction of inspired oxygen level|A fraction of inspired oxygen level during off-pump coronary artery bypass grafting will be set differently between the study groups: 0.3 vs 0.8.
224319828|NCT03450252|DEVICE|Back-up pacing|Back-up pacing. The pacemaker is set-up to sense and pace only in the right atrium (AAI) without any pacing capacity in the ventricle.
224319829|NCT02598947|OTHER|Manual therapy|Exercise, behaviour change interventions and manual therapy
224319830|NCT03909269|DEVICE|Continuous glucose monitoring|Continuous glucose monitoring five times over 17 weeks
224319831|NCT03909269|DIAGNOSTIC_TEST|Glycaemic markers|Measurement of HbA1c by immunoassay (Roche) and chromatography (TOSOH), including glycated albumin and fructosamine.
224319832|NCT03909269|RADIATION|Erythrocyte life span|Erythrocyte life span measured by Crom-51 labelling over 4 weeks
224319833|NCT03909269|DEVICE|Carbon monoxide (CO)-rebreathing method|Measurement of total blood volume, plasma volume and erythrocyte volume
223645453|NCT07074262|DRUG|Ketamine|to compare the effect of Ketamine versus Dexmedetomidine on postoperative cognitive dysfunction and delirium in all cardiac patient undergoing low risk non-cardic surgery.
223645454|NCT07076043|DRUG|Multiple Product PrEP Program|In the intervention phase, clinics will offer a multi-product PrEP program, which includes daily oral PrEP and other forms of PrEP that are available. To start, the dapivirine vaginal ring will be included among the other forms of PrEP that are available. Others will be added as they become available in Kenya.
223645455|NCT07074743|OTHER|community-based PI care bundle|"The PI care bundle follows the aSSKINg model and is delivered in addition to routine care. Key components include:~Assessment Pre-discharge evaluation Ongoing skin, nutrition, and hydration monitoring Caregiver training for home assessment Equipment and Resources~Customized provision of necessary devices based on needs:~Sliding sheets Repositioning cushions Skin barriers Moisturizers Pressure-relieving overlays Alternating air mattresses Implementation Caregivers demonstrate device usage competency Documentation checklist for monitoring Regular follow-up by community nurses Professional Support Community nurses trained by PI specialists Standardized care protocols Regular effectiveness assessment~All participants receive routine care including:~Pre-discharge nutrition assessment Dietician referral if needed Educational materials Basic wound care referrals Hospital-to-home team support for complex cases The intervention provides structured, comprehensive support beyond standard care."
223645456|NCT07074743|OTHER|Wait-list|"During hospitalisation:~Patient's nutritional status assessed. Referred to a dietician before discharge if needed. Nurse assesses caregiver training needs and arranges training if required.~At discharge:~Patients receive PI educational pamphlets (hardcopy or softcopy). Emphasis on regular repositioning, skin inspection, proper nutrition, and hydration.~Patients with PI wounds:~Referred to home nursing or polyclinics for wound care. Only those with complex PI (stage \>3) receive up to two follow-ups by the H2H care team.~H2H team supports general care transition, not PI-specific follow-up alone. Any signs of PI deterioration will be monitored weekly throughout the waiting period for safety and ethical considerations.~If the index PI advances to a higher stage and reports increased pain after a week, the investigator will refer them to a community wound care nurse and record this as a deterioration and will start PI care bundle"
223645457|NCT07074951|DRUG|Immunosuppressive treatment|"Patients will be able to receive the corticosteroid (CS) monotherapy or CS in combination with other immunosuppressive drugs (e.g. cyclophosphamide, mycophenolic acid) by a decision of treating physician.~CS treatment will start with intravenous or oral induction. In the first case, methylprednisolone will be administered intravenously for 1-3 days at the dosage of 500-1000 mg. Oral prednisolone will be initiated at a dose of 0.5 to 1.0 mg/kg body weight, not exceeded 60 mg/day (week 1) with a rapid decrease by 5 mg each subsequent week until a maintenance dose of 5 mg/day will be reached. Patients will receive maintenance dose for 6 to 12 months."
223645458|NCT07074951|PROCEDURE|Tonsillectomy|Tonsillectomy will be done in accordance with local clinical practice. TE has to be performed no earlier than 12 months before and no later than 12 months after the initiation of IST.
223645459|NCT07075965|DRUG|Amlodipine|Evaluating 2 different doses of amlodipine, after an initial titration phase (2.5 mg daily), amlodipine is increased to the target doses of 5 mg and 10 mg
223645460|NCT07075783|DRUG|MgSO4 plus Ropivacaine|1ml 50% MgSO4 added to 0.375% Plain Ropivacaine plus 5 mcg/ml adrenaline for scalp block
223645461|NCT07075783|OTHER|Plain Ropivacaine|0.375% Plain Ropivacaine plus 5 mcg/ml adrenaline and 1 ml of 0.9% NaCl
223645462|NCT07074795|PROCEDURE|Inhalation of Nitrous Oxide (N₂O) during Office Operative Hysteroscopy|Inhaled nitrous oxide
223645463|NCT07074795|PROCEDURE|inhalation of ambient air during office hysteroscopy|inhalation of ambient air
223645464|NCT07075666|DIAGNOSTIC_TEST|PSA|Prostate-Specific Antigen test, a blood test used to measure the level of PSA in a man's blood. PSA is a protein produced by the prostate gland, and elevated levels can indicate various conditions, including prostate cancer, benign prostatic hyperplasia (BPH), or prostatitis.
223645465|NCT07075666|DIAGNOSTIC_TEST|DRE|A digital rectal exam (DRE) is a procedure where a doctor inserts a lubricated, gloved finger into the rectum to check for abnormalities.
223645466|NCT07075731|OTHER|No intervention|Observational study
223645467|NCT06902766|DEVICE|Active telemonitoring using real-time data from digital inhalers.|"Telemonitoring system relying on the use of 2 digital inhalers FindAir ONE for pMDI, one for the controller the other for the reliever treatment.~Active telemonitoring using real-time data from digital inhalers.~Investigators will be alerted by email if a child:~1. fails to take his or her controller treatment for 4 continuous days and/or~2. uses \> 4 doses of reliever treatment over 24 hours~3. uses \< 12 doses of reliever treatment over 3 months (indication to decrease the controller treatment)~In these cases, investigators will be asked to schedule a teleconsultation within 2 working days with the family and to adapt treatments as needed. They may ask the family to use the portable spirometer and oximeter if necessary.~No systematic consultation will be planned."
223645468|NCT06902766|OTHER|Standard|Standardized care + passive recording of asthma treatment use (controller and reliever treatments) using digital inhalers
223645469|NCT06497543|DRUG|Intrathecal Pemetrexed|Intrathecal pemetrexed(50mg) twice a week for 1 week (day 1 and day 5) as induction treatment, then once monthly until progressive disease.
223645470|NCT02434406|BEHAVIORAL|internet-What Am I Worried About|This web-based intervention consists of three sections: 1) Is this for me? 2) Practice 3) Understanding. The three main sections are divided up into nine sessions. Participants will get access to the program for eight weeks and can access the sessions more than once. Sessions are made up of multimedia presentations and worksheets that are completed online.
223645471|NCT07074067|PROCEDURE|Laparoscopic surgery|the laparoscopic (LPC) arm, 21 patients will be assigned to conventional LPC and another 21 to robotic surgery, consecutively.
223645472|NCT07074067|PROCEDURE|surgery via v-NOTES|surgery via v-NOTES
224231819|NCT02454270|DRUG|Part 1 (Dose Escalation): Duvortuxizumab|Participants currently enrolled in the study will continue to receive duvortuxizumab every 14 days (biweekly dosing) in each 28 -day cycle as an intravenous infusion. In the priming dose regimen, a priming dose will be administered on Day 1 followed by full doses on Day 8 and Day 22, of a 35-day Cycle 1, and then every 14 days in each subsequent 28-day cycle. The cohorts will be opened where participants will receive duvortuxizumab every 7 days (for investigating weekly dosing schedule) in each 28-day cycle as an intravenous infusion. In the priming dose regimen, a priming dose will be administered on Day 1 followed by full doses on Day 8, Day 15, Day 22, and Day 28 of a 35-day Cycle 1, and then every 7 days in each subsequent 28-day cycle.
224231820|NCT02454270|DRUG|Part 2 (Dose Expansion): Duvortuxizumab|Participants will receive intravenous infusion of duvortuxizumab at the recommended Phase 2 dose (RP2D) defined in Part 1 for their disease type either with or without a priming dose.
223765935|NCT07066722|DRUG|VH4524184|VH4524184 will be administered.
223765936|NCT07066722|DRUG|Itraconazole|Itraconazole will be administered.
223765937|NCT07066722|DRUG|Rifabutin|Rifabutin will be administered.
223765938|NCT07066722|DRUG|Phenytoin|Extended phenytoin sodium will be administered.
224319834|NCT01593943|BEHAVIORAL|CHARM|CHARM will be conducted via three 30-minute counseling sessions delivered in the rural setting, with the first session required and the 2nd and 3rd sessions optional. The first two CHARM sessions will be for men only to build family planning (FP) and gender equity (GE) awareness and investment, and the third session will be for the couple with an emphasis on FP services, shared decision-making and marital communication. The three sessions can occur anytime within a 3 month timeframe but with a minimum of 1 week between sessions. All sessions and FP services (pill, condom, EC) will be provided at no cost to patients.
224319835|NCT00338728|DRUG|Imatinib Mesylate|Given PO
224319836|NCT00338728|DRUG|Letrozole|Given PO
223645473|NCT06907446|DIAGNOSTIC_TEST|Comparison of Biopsy Needle Types for Prostate Biopsy|Each patient will undergo a standard of care prostate biopsy according to the clinical indication alternating between the SureCore and standard Bard needle
223645474|NCT01811992|BIOLOGICAL|Dose Escalation of Ad-hCMV-TK and Ad-hCMV-Flt3L|"Two adenoviral vectors will be used, each to deliver one of the therapeutic genes. Both vectors are human serotype 5, replication-defective, first generation adenoviral vectors deleted in E1a and E3 viral encoding regions. Each vector will constitutively express their respective therapeutic transgene (i.e. HSV1-TK or Flt3L) under the control of the human cytomegalovirus promoter (hCMV). Valacyclovir treatment will begin 1-3 days after vector administration at a dose of 2 grams given orally 3X per day for 14 days. A second course of valacyclovir will be given beginning Week 10.~Radiation and chemotherapy will be administered as per standard of care."
223645475|NCT03422900|DIETARY_SUPPLEMENT|Diabetes-Specific enteral formula|Complete enteral formula normocaloric hyperproteic with fiber (80% SOLUBLE)
223645476|NCT03422900|DIETARY_SUPPLEMENT|Standard formula|Complete enteral formula normocaloric hormoproteic without fiber
223645477|NCT06016114|DIAGNOSTIC_TEST|HIV Latency Diagnostic Sampling|This intervention involves the collection of blood, lymph node, colon biopsy, and placental samples from individuals living with HIV (HIV controllers) and healthy controls. The goal is to investigate HIV latency by analyzing these biological samples to gain insights into the mechanisms and characteristics of latent HIV reservoirs. The sampling procedures will be conducted using minimally invasive techniques where appropriate, and the collected samples will undergo laboratory analysis for further study.
223645478|NCT01161095|DEVICE|LNG-IUS|Mirena (Bayer)- Levonorgestrel-Intrauterine System
223645479|NCT06910670|OTHER|Standard developed materials|Participants will be given the option to receive different types of results from genomic sequencing. The choices available to them will be explained by research staff following a script that describes what each type of result means. Participants will be able to choose to receive: (1) no results, or any combination of (2) biomarker information from cancer cells, (3) inherited mutations related to cancer, and (4) inherited mutations related to other medical issues. These choices will be presented to them via a discussion with study staff with accompanying paper information
223645480|NCT06910670|OTHER|Genetics Advisor Decision Aid|Participants will be given the option to receive different types of results from genomic sequencing. The participants will be given access to a web-based decision aid that elicits participants' values and preferences for receiving results from cancer genomic sequencing to guide them making a decision about what types of results they would like to receive. Participants will be able to choose to receive: (1) no results, or any combination of (2) biomarker information from cancer cells, (3) inherited mutations related to cancer, and (4) inherited mutations related to other medical issues.
223645481|NCT07074665|BIOLOGICAL|5µg R21/50µg Matrix-M|R21/Matrix-M is a vaccine against P. falciparum malaria, which has WHO prequalification and policy recommendation in children over 5 months old in malaria endemic areas. The standard paediatric dose is 5µg R21/50µg Matrix-M.
223645482|NCT07074665|BIOLOGICAL|10µg R21/50µg Matrix-M|R21/Matrix-M is a vaccine against P. falciparum malaria, which has WHO prequalification and policy recommendation in children over 5 months old in malaria endemic areas. 10µg R21/50µg Matrix-M is the standard adult dose.
223765939|NCT07066722|DRUG|Metformin|Metformin will be administered.
223765940|NCT04953442|BEHAVIORAL|Fit 24|This 12-week goal-setting intervention will test the feasibility of using a Fitbit watch and motivational text messaging to improve physical activity and sleep in Hispanic youth (14-16 years of age) with obesity. Youth will be prompted to set weekly steps per day and hours of sleep per night goals. Text messages will be grounded in the Self-Determination Theory and will provide evidence-based strategies, support, and motivation to encourage youth to meet their goals.
223765941|NCT06811116|PROCEDURE|Biospecimen Collection|Undergo blood collection
223765942|NCT06811116|DRUG|Cabozantinib S-malate|Given PO
223765943|NCT06811116|PROCEDURE|Imaging Procedure|Undergo imaging scans
223765944|NCT06811116|DRUG|Sapanisertib|Given orally (PO)
223765945|NCT07069751|DIETARY_SUPPLEMENT|diet rich in fiber|Enrolled and eligible patients will be encouraged to consume a balanced diet rich in fiber for the entire duration of the trial (i.e., 12 weeks). Patients will also be encouraged to prolong plant-based diets beyond week 12. Free outpatient medical visit will be performed at enrollment and at week 12, and nutritional counseling will be given at the time of enrollment, one month later and on demand. Dietary measurements will be conducted along the entire duration of the nutritional regimen by questionnaires. In particular, the patient will write for each day of the trial the number associated to the chosen diet plan or food.
224231821|NCT03539315|BEHAVIORAL|ARCHES|Addressing Reproductive Coercion within Healthcare Settings (ARCHES) is a clinic-based intervention developed in the U.S., and involves training existing health providers to identify RC and IPV during standard family planning clinic-based counselling interactions. The intervention seeks to empower women with harm reduction strategies that minimize their risk for unintended pregnancy by offering a wide range of contraceptive options, providing counseling on correct and consistent use of contraception, and counseling on contraceptive methods that are difficult for a male partner to detect or block such as injectables or IUDs. ARCHES also facilitates access to violence support and counselling services by connecting women with community-based IPV services.
223765946|NCT06606847|DRUG|Oleclumab|Oleclumab IV (intravenous infusion)
223645483|NCT07074431|PROCEDURE|EYE 1 SURGERY BY CATAPULSE TECHNIC|In arm 2: 1st eye operated by high-frequency pulsed vacuum technology / 2nd eye operated by phacoemulsification
223645484|NCT07074431|PROCEDURE|EYE 2 SURGERY BY CATAPULSE TECHNIC|In arm 1: 1st eye operated by phacoemulsification / 2nd eye operated by high-frequency pulsed vacuum technology
223645485|NCT07075029|DIAGNOSTIC_TEST|NP swabs|Nasopharyngeal (NP) swabs will be collected from all participants for respiratory pathogen detection using point-of-care testing (POCT) and/or centralized laboratory analysis.
223765947|NCT06606847|DRUG|Durvalumab|Durvalumab IV (intravenous infusion)
223765948|NCT04487080|DRUG|Amivantamab|Participants will receive amivantamab intravenously.
223765949|NCT04487080|DRUG|Osimertinib|Participants will receive osimertinib capsules orally.
223765950|NCT04487080|DRUG|Lazertinib|Participants will receive lazertinib tablets orally.
223765951|NCT04487080|DRUG|Placebo|Participants will receive matching placebo orally.
224231822|NCT03360201|BEHAVIORAL|"Tuko Pamoja, We are Together in Kiswahili"|"Tuko Pamoja, We are Together in Kiswahili; This intervention, delivered by lay counselors and through existing community social structures, focuses on improving family relationships and mental health with content derived from evidence-based practices; these include solution-focused family therapy and cognitive behavioral strategies. It is components based, with modules delivered based on need. Tuko Pamoja includes a smart phone component to support psychoeducation components and data collection. The content and structure has been adapted in both content and implementation model based on formative research in this context."
224231823|NCT05753657|DRUG|Pioglitazone|hyperinsulinemia and hyperglycemia
224231824|NCT02763111|DRUG|BCD-085|
223645486|NCT05169060|DRUG|Fish Oil Concentrate, 1000 Mg Oral Capsule|Oral capsules, 2 grams or 4 grams per day.
223645487|NCT05169060|DRUG|Salsalate Oral Tablet|Oral tablets, 1.5 gram or 3.0 gram per day.
223645488|NCT06923618|BIOLOGICAL|Blood samples|Blood samples (5 ml) during surgery
223645489|NCT05585905|DEVICE|Virtual Reality|The VR system will be worn for approximately 5-10 minutes during dental sealant application
223645490|NCT05585905|BEHAVIORAL|Basic Behavior Guidance Techniques|Basic behavior guidance techniques will be used as a distraction technique when the VR system is not used during the dental sealant application
223645491|NCT05228587|DRUG|Indocyanine green|Indocyanine green will be injected in all donor
223645492|NCT05387239|DRUG|VL-PX10 and VL-P22 plus standard care|The treatment consists of administration of VL-P22 and VL-PX10 plus standard care
223645493|NCT05387239|DRUG|Placebo|Saline plus standard care
223765952|NCT06848868|PROCEDURE|Ambulatory flexible ureterorenoscopy|Ambulatory flexible ureterorenoscopy (experimental)
223645494|NCT06938061|DEVICE|3D Imaging|The Derma Monitor device is a handheld, battery powered camera incorporating polarized LED illumination, a high-resolution CMOS color image sensor and a 3D depth sensor, allowing for the imaging and mapping of a patient's skin.
223645495|NCT06413121|BIOLOGICAL|Hexavalent (DTwP-HepB-IPV-Hib) Vaccine Containing Reduced Dose IPV|Hexavalent (DTwP-HepB-IPV-Hib) Vaccine Containing Reduced Dose IPV for active immunization of infants as 3 dose regimen (6, 10 \& 14 weeks) for primary vaccination and booster dose at the age of 12-24 months.
223645496|NCT06413121|BIOLOGICAL|Hexavalent (DTwP-HepB-IPV-Hib) Vaccine Containing Full Dose IPV|Hexavalent (DTwP-HepB-IPV-Hib) Vaccine Containing Full Dose IPV for active immunization of infants as 3 dose regimen (6, 10 \& 14 weeks) for primary vaccination and booster dose at the age of 12-24 months.
223765953|NCT06540144|DRUG|rozanolixizumab|rozanolixizumab solution for injection
223765954|NCT07086833|OTHER|Low Cysteine Diet|A diet low in cysteine, about 1.4 g/1000 kcal.
224231825|NCT02763111|OTHER|Placebo|
224231826|NCT00092859|DRUG|MK0557|
224231827|NCT03841032|DRUG|Coppertone, BAY1183345|Lotion, for 4 weeks
224231828|NCT00951288|DIETARY_SUPPLEMENT|Saffron|Saffron 20 mg/day supplementation
224231829|NCT00951288|DIETARY_SUPPLEMENT|Placebo|Placebo
224231830|NCT06428448|COMBINATION_PRODUCT|REMEDY Spectrum IM Spacer Nail|"The REMEDY SPECTRUM IM Spacer Nail is a single-use implant made of polymethylmethacrylate (PMMA) which is internally reinforced with a stainless-steel core (ASTM F138, ISO 5832-1). The PMMA of the REMEDY SPECTRUM IM Spacer Nail is laden with gentamicin and vancomycin.~The nail has a slot at the distal end and can be combined with the surgeon's choice of fixation to prevent migration depending on the anatomy of the patient. The REMEDY SPECTRUM IM Spacer Nail is available in two lengths (150mm and 300mm) to accommodate variations in patient anatomy. The distal end has a threaded recess for mating with the optional distal cap, as well as the insertion and removal tools."
224231831|NCT01937364|DRUG|Baclofen|Baclofen 10 mg every 8 hours for 72 hours (9 doses) as an inpatient, or until discharge if before 72 hours.
224231832|NCT01937364|DRUG|Placebo|Identical appearing placebo every 8 hours for 72 hours (9 doses) as an inpatient, or until discharge if before 72 hours.
223645497|NCT00093626|OTHER|Laboratory Biomarker Analysis|Correlative studies
223645498|NCT00093626|DRUG|Sorafenib Tosylate|Given orally
223645499|NCT06002724|OTHER||
223765955|NCT07086833|OTHER|High Cysteine Diet|A diet high in cysteine, about 3 g/1000 kcal.
223765956|NCT07085871|OTHER|Fish Powder|This RCT aims to test the effectiveness of fish powder (produced from dried fish from Lake Malawi - Lake Malawi sardine) used to fortify school meals. The intervention meal will be the normal school meal, however substituing 3-5g of ingredients (such as soya flour, maize flour or groundnut flour) for 3-5g of fish powder.
224231833|NCT00803842|DRUG|doxycycline|Doxycycline (the study drug) will be provided to all subjects as 100 mg tablets. They will be allocated enough doxycycline to last them until their next scheduled visit. The doxycycline tablets should be taken orally (only) at a dosage of 100 mg every 12 hours. Administration of adequate amounts of fluid along with capsule and tablet forms of drugs in the tetracycline class is recommended to wash down the drugs and reduce the risk of esophageal irritation and ulceration. The doxycycline tablets should not be taken with foods that contain calcium. The absorption of doxycycline is reduced when taking bismuth subsalicylate. Duration of study period if 14 days
223765957|NCT07085078|BEHAVIORAL|progressive relaxation exercises|Participants with menopausal symptoms received progressive relaxation exercise training, led by the responsible researcher who assigned them to the experimental group.
223645500|NCT01408173|DRUG|NPC-11 for intravenous or oral administration.|NPC-11, Each vial (3mL) contains 60 mg caffeine citrate (equivalent to 30mg caffeine).
224231834|NCT05330507|OTHER|Wellinks|"30-day post-discharge period: virtual respiratory therapist sessions twice per week with synchronous virtual pulmonary rehabilitation and educational materials; at-home use of connected spirometer and pulse oximeter; at-home use of mobile app.~12-week intensive period: virtual health coaching sessions once every two weeks; asynchronous virtual pulmonary rehabilitation program; ongoing access to connected devices (spirometer and pulse oximeter) and mobile app."
224231835|NCT02089490|DEVICE|NEVELIA® implantation|Skin substitute implantation followed by ultra-thin epidermal graft
224231836|NCT03841383|DIAGNOSTIC_TEST|Echo stress dipyridamole|Echo stress dipyridamole
224231837|NCT06469879|DRUG|TQB2450+Anlotinib|"TQB2450 injection test group, 1200 mg/time, strength: 600mg/20 mL, intravenous drip, day 1, every 3 weeks. Anlotinib hydrochloride capsules: 8 mg/time, strength: 10mg/capsule, 8mg/capsule, 6mg/capsule., 1 time a day (QD), continuous use for 2 weeks and stop for 1 week.~TQB2450 Injection Placebo (control group): 0 mg/time, strength: 0mg/20 mL, Intravenous Drip, Day 1, every 3 weeks. Anlotinib hydrochloride capsule placebo: 0 mg/time, strength: 0mg/capsule, 1 time a day (QD), continuous use for 2 weeks and stop for 1 week."
224231838|NCT06469879|DRUG|TQB2450 placebo + Anlotinib placebo|No drug substance is contained
224231839|NCT00581620|BIOLOGICAL|pneumococcus conjugate vaccine|Infants from 1 to 6 months: 3 doses at 2; 4; 6 m and booster from 12 to 15 months.
224231840|NCT04458077|BEHAVIORAL|Discover Learning (SEIL)|This mobile-phone-based intervention will assess the effectiveness of 10 SEIL sessions conducted at the household level with VYAs. Activities were designed to be done individually, with siblings/peers, and with parents/caregivers. This intervention will look at how household composition and types of practice that can enhance SEIL learning.
224231841|NCT00000359|BEHAVIORAL|Canalith repositioning maneuver (Epley maneuver)|Standard passive motion of the head: Dix-Hallpike maneuver, turn head to opposite side, roll over, sit up.
224231842|NCT00000359|BEHAVIORAL|Semont maneuver|Sidelying maneuver, flip over 180 deg, sit up.
223645501|NCT06286202|BEHAVIORAL|Cognitive Remediation: Adapted Neuropsychological and Education Approach to Remediation (NEAR)|NEAR consists of computer-assisted cognitive exercises to restore cognitive functioning through rehearsal and strategy learning. Based on the results of the baseline assessments, the therapist will complete the Cognitive Remediation Treatment Plan, to outline targeted cognitive domains and functional goals. During the cognitive games sessions, the Multicontext Treatment Approach will be used, where error patterns are identified. The participants will work on metacognition and use of strategies to overcome challenges faced during the computer games sessions. Bridging groups may include activities for participants to utilize strategies learnt during the computer game sessions to everyday living. Participants will also learn about cognitive impairments and how lifestyle modifications, mood regulation etc can affect cognitive performance. In addition, they will learn about metamotivation and build awareness about their motivation levels through self- reflection and self-monitoring.
223645502|NCT06286202|BEHAVIORAL|Standard Psychiatric Rehabilitation at Anglican Care Centers|Participants in the control arm will attend their usual psychiatric rehabilitation activities. These activities may include vocational training, community living skills training, psychoeducation, social skills training and peer support etc. These activities are also undertaken by participants in the experimental arm.
223645503|NCT05153694|PROCEDURE|Cystectomy|Removal of the urinary bladder
223645504|NCT05490927|BEHAVIORAL|Microaggression Recall and Relapse Analogue Task|Participants will engage in a microaggression recall task followed by the McKee Experimental Relapse Analogue Task
223645505|NCT05251558|OTHER|Telerehabilitation|The telerehabilitation platform is used to deliver the home exercise program.
223645506|NCT05251558|OTHER|Conventional Education Program|The patient is given education about the points to be considered for the disease and the exercises to be applied.
223645507|NCT01442103|DEVICE|Normlgel Ag|Normlgel Ag dressing will be changed together with planned investigation visits. Dressing changes between visits will be performed at home on Day 3 or 4 of each week by subject or caregiver and documented in a dressing log.
223645508|NCT00902590|OTHER|saliva sample and questionaire|"Urothelial Cancer Registry- Patients will complete a family history and urothelial cancer risk questionnaire, and will provide a buccal sample for germline DNA. If the cases have undergone germline sequencing as part of Protocol 12-245, they will not need to provide a buccal sample. If the cases have previously completed athe the Urothelial Baseline Questionnaire, in an MSKCC urology clinic they will not need to complete the urothelial cancer risk questionnaire."
223645509|NCT00902590|OTHER|saliva sample, questionaire|Urothelial Cancer Registry- These participants will be requested to complete the risk factor questionnaire and to provide a saliva sample for DNA extraction.
223645510|NCT03713658|DRUG|Risperidone 3 mg|Participants will receive 3 mg oral risperidone tablets once daily for up to one Week.
223765958|NCT07087028|DEVICE|SleeperOne™|Computerized intraosseous anesthesia was delivered using the SleeperOne™ (Dental HiTec, France) device with a 30 G × 9 mm Effitec needle at a 15° angle to the mucosa. A total of 2 mL 2% articaine with 1:100,000 epinephrine was administered per site.
223645511|NCT03713658|DRUG|Paliperidone Palmitate 50 mg eq.|Participants will receive 50 mg eq. PP1M intramuscular injection for 17 Weeks.
223645512|NCT03713658|DRUG|Paliperidone Palmitate 75 mg eq.|Participants will receive 75 mg eq. PP1M intramuscular injection for 17 Weeks.
223645513|NCT03713658|DRUG|Paliperidone Palmitate 100 mg eq.|Participants will receive 100 mg eq. PP1M intramuscular injection for 17 Weeks.
223645514|NCT03713658|DRUG|Paliperidone Palmitate 150 mg eq.|Participants will receive 150 mg eq. PP1M intramuscular injection for 17 Weeks.
223645515|NCT03713658|DRUG|Paliperidone Palmitate 175 mg eq.|Participants will receive 175 mg eq. PP3M intramuscular injection for 24 Weeks.
223645516|NCT03713658|DRUG|Paliperidone Palmitate 263 mg eq.|Participants will receive 263 mg eq. PP3M intramuscular injection for 24 Weeks.
223645517|NCT03713658|DRUG|Paliperidone Palmitate 350 mg eq.|Participants will receive 350 mg eq. PP3M intramuscular injection for 24 Weeks.
223645518|NCT03713658|DRUG|Paliperidone Palmitate 525 mg eq.|Participants will receive 525 mg eq. PP3M intramuscular injection for 24 Weeks.
224231843|NCT00000359|BEHAVIORAL|Brandt-Daroff exercises|Active exercise. Sidelying to involved side, sidelying to uninvolved side, sit up.
224231844|NCT00000359|BEHAVIORAL|Vestibular habituation exercises|Head shaking exercises in pitch, roll, yaw and circumduction. Titrating from 2 repetitions per exercise to 20 repetitions per exercise, as tolerated.
223765959|NCT07087028|OTHER|Conventional Infiltration Anesthesia|The intervention for the Conventional Infiltration Anesthesia involves the manual administration of a local anesthetic using a standard dental syringe with a fine-gauge needle.
224231845|NCT00000359|BEHAVIORAL|ShamManeuver|Passive movement of the head
224231846|NCT00134836|BEHAVIORAL|Preventive Primary Care Outreach|Nurse home visit at baseline, 6 months, 12 months, including comprehensive assessment using MDS HC, care planning, referral to appropriate services
224319837|NCT01897038|DRUG|Onartuzumab|Onartuzumab intravenous infusion at a starting dose of 10 or 15 milligram per kilogram body weight administered every 3 weeks (Q3W) until disease progression or unacceptable toxicity occurs (maximum up to 31 months).
223645519|NCT06653348|DRUG|Ticagrelor 60 + Aspirin|Ticagrelor 90 mg BID plus ASA 80 mg daily for 1 month and then ticagrelor 60 mg BID plus ASA 80 mg daily until the end of month 6.
223765960|NCT07085156|DRUG|Fludarabine; melphalan; busulfan|The conditioning regimen includes fludarabine, busulfan, and melphalan, with a transplant conditioning intensity of 3.0. The RIC is used in the allo-HCT in the MDS patients.
223765961|NCT07087106|DRUG|[F-18]FDG|PET radiopharmaceutical
224231847|NCT01851070|DRUG|Allogeneic Mesenchymal Precursor Cells|
224231848|NCT01851070|DRUG|Normal Saline|
224231849|NCT06396520|OTHER|No intervention, observational|No intervention, observational
223645520|NCT06653348|DRUG|Ticagrelor 90 + aspirin|ticagrelor 90 mg BID plus ASA 80 mg daily for 1 month.
223645521|NCT06257511|BEHAVIORAL|Simulation-Based Mastery Learning of the Non-technical skills|Participants will participate in a simulation-based mastery learning of the non-technical skills.
223645522|NCT02202759|DRUG|MLN0264|MLN0264 IV infusion
223645523|NCT01987453|DRUG|LDV/SOF|Tablet(s) administered orally once daily
223645524|NCT01987453|DRUG|RBV|"Tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)~Participants in the LDV/SOF+RBV 24 weeks group will dose adjust RBV according to hemoglobin and renal status as stated in the RBV package insert."
223645525|NCT04259099|OTHER|Testing the Quality of Life Questionnaire of the European Foundation for Osteoporosis-31(QUALEFFO-31)|Administer the questionnaires to 150 participants to classify their status of quality of life.
223645526|NCT00213434|DEVICE|Herbst oral appliance|
223645527|NCT05141890|DIETARY_SUPPLEMENT|Lactobacillus Plantarum|Dietary Supplement: Lp299v. Lp299v is a commercially available probiotic supplement manufactured and distributed by Next Foods.
223645528|NCT04748354|BEHAVIORAL|Otago Exercise Program|An individualized and home-based program of progressive strength and balance training exercises delivered by a physical therapist
223645529|NCT04748354|OTHER|Usual Care|Clinical care provided by a geriatrician.
223645530|NCT00013416|PROCEDURE|Hearing|
223645531|NCT02064582|DRUG|Enzalutamide|160mg by mouth each day
223645532|NCT02064582|DRUG|Leuprolide acetate|22.5 mg intramuscular every 3 months or 45mg intramuscular every 6 months
223645533|NCT02064582|RADIATION|radiation|External beam radiation will be delivered as per standard radiation therapy protocol
223645534|NCT00456859|DRUG|Kremezin|
223645535|NCT01590888|DRUG|PBT2|250mg capsules administered orally once per day for 26 weeks
223645536|NCT01590888|DRUG|PBT2|100mg capsules administered orally once per day for 26 weeks
223645537|NCT01590888|DRUG|Placebo|Matching capsules administered orally once per day for 26 weeks
223645538|NCT05868434|PROCEDURE|Medial Patellofemoral Ligament Reconstruction (MPFLR) With Fascia Lata Allograft, Based on Isometry Assessment Combined With Elmslie-Trillat Tibial Tuberosity Osteotomy.|Medial Patellofemoral Ligament Reconstruction (MPFLR) With Fascia Lata Allograft, Based on Isometry Assessment Combined With Elmslie-Trillat Tibial Tuberosity Osteotomy. Management of any accompanying patellofemoral lesions will be performed as well.
223645539|NCT01937832|DRUG|Faropenem|dosage form: Injection dosage:1200 mg frequency: Three times a day
223645540|NCT01937832|DRUG|Ertapenem|dosage form: Injection dosage:1000 mg frequency: once a day
223645541|NCT05012384|OTHER|Vergence exercises (Orthoptic exercises)|Vergence exercises as described by the Convergence Insufficiency Treatment Trials Group (CITT)
223645542|NCT05012384|GENETIC|Placebo|Generic management plan with non-visual elements
223645543|NCT01378585|DRUG|DLBS1033|3 x 490 mg DLBS1033 daily
223645544|NCT01378585|DRUG|Placebo|3 x 1 tablet daily
223645545|NCT04953728|DEVICE|Transcutaneous Electrical Acustimulation (TEA)|Each participant will undergo 5 sessions total at two different frequencies (25 Hz and 100Hz) with electrodes placed at two different locations (wrist and knee) and a placebo session.
223645546|NCT00532610|DRUG|GSK189075|
223645547|NCT00056069|OTHER|questionnaire administration|Participants complete questionnaires regarding caregiver demands and family information over 25-30 minutes within 3-4 months of the initiation of the child's treatment and at the completion of the first year of the child's treatment.
223645548|NCT02923297|OTHER|Blood sampling|blood sampling for determine and compare the expression patterns of GALIG gene
223645549|NCT04070872|PROCEDURE|3D laparoscope|For laparoscopic camera system, a 10-mm ENDOEYE FLEX 3D Deflectable Videoscope (Olympus Corp., Germany) was used in the 3D group.
223645550|NCT04070872|PROCEDURE|2D laparoscope|For laparoscopic camera system, a 10-mm 30º IDEAL EYES Laparoscope (Stryker, Kalamazoo, MI, USA) camera was used in the 2D group.
223645551|NCT01512511|PROCEDURE|nitrous oxide use for pneumoperitoneum creation|use nitrous oxide for create pneumoperitoneum in laparoscopic cholecystectomy
223645552|NCT02554461|OTHER|advise for exercices given by team staff|"To respond to questions asked:~it is not the investigator who decides on the intervention, but the daily team staff (e.g. trainer, coach, PT,.....). So no predetermined intervention is provided"
223645553|NCT01685515|DRUG|Oral Decitabine and Tetrahydrouridine|Oral Decitabine and Oral Tetrahydrouridine (THU) given 1-2 hours apart on 2 consecutive days over 8 weeks
223645554|NCT01685515|DRUG|Placebo|Plain water will be dispensed at a similar volume and in the same containers as study drug. The water placebo has a similar appearance and taste to the study drug, since the study drug is highly diluted in water.
223645555|NCT05932667|DRUG|Milademetan|The study treatment, including a combination of milademetan and fulvestrant, is administered into two successive parts: a safety run-in part followed by a phase II part. Once GATA3 mutational status confirmed, patients will continue to receive study drug treatment until progression of disease, unacceptable toxicity, patient withdrawal of consent, Investigator decision, lost to follow-up, death, patient non-compliance, or study termination by Sponsor.
223645556|NCT05932667|BEHAVIORAL|Patient Reported Outcomes (PROs) and Health-Related Quality of Life (HRQOL)|Measure of interest is the mean difference in the change from baseline to different specific visit (each disease radiological assessment, disease progression and/or treatment discontinuation) in total/subscale scores of the 5 Dimension 5 Level (EQ-5D-5L) scale and the EORTC-QLQ-C30 questionnaire
223645557|NCT05536596|PROCEDURE|Orthognathic Surgery|Prognathism/Retrognathism correction through surgical procedures
223645558|NCT05536596|DRUG|Melatonin 10 MG Oral Tablet|Group B will receive the pharmacology treatment with 10 mg Melatonin. One capsule orally at night for 60 days.
224231850|NCT04810923|PROCEDURE|i-PRF|intra-articular i-PRF injection after arthrocentesis
224231851|NCT04810923|PROCEDURE|Arthrocentesis|Arthrocentesis procedure with 2 to 3 mL saline solution to lavage the superior compartment of temporomandibular joint.
224231852|NCT00203307|DRUG|Olanzapine during first intervention period and placebo during second intervention period|Olanzapine (5-10 mg) daily during first intervention period, then placebo(matching)druing second intervention period (after a washout period)
223645559|NCT05536596|DRUG|Hydroxycobalamin|Group C will receive the pharmacology treatment with 1 mg hydroxycobalamin (vitamin B12). One capsule daily for 60 days.
223645560|NCT05536596|DRUG|Centrum|Groups A will receive the pharmacology treatment with 1.5 mg uridine triphosphate, 2.5 mg cytidine monophosphate and 1 mg hydroxycobalamin (Citoneuron). One capsule orally three times a day for 60 days as suggested by the manufacturer for patients with trauma - compressive peripheral neural disorders.
223645561|NCT03780296|DEVICE|Real-time action observation with augmented Kinect|Participants will receive 30 minutes of the augmented kinect software in real-time undergoing an exercise protocol involving seated upper extremity exercises, seated lower extremity exercises and standing upper extremity exercises.
223645562|NCT02105662|DRUG|Grazoprevir 100 mg/Elbasvir 50 mg fixed-dose combination tablets|MK-5172A FDC tablet: MK-5172 (100 mg)/MK-8742 (50 mg)
223645563|NCT00554632|DRUG|Ethinyl estradiol and norgestimate|Oral contraceptive
223645564|NCT00554632|DRUG|Ethinyl estradiol and norelgestromin|Transdermal hormonal contraceptive changed weekly
224231853|NCT00203307|DRUG|Placebo during first intervention period, then olanzapine during second intervention period|Placebo (matching) during first intervention period, then olanzapine (5-10 mg. daily) during the second intervention period (after a washout phase).
223645565|NCT02118441|DEVICE|Ultrasound-guided Radial Artery Catheter Insertion|
223645566|NCT02118441|DEVICE|Direct Palpation-guided Radial Artery Catheter insertion|
223645567|NCT04695717|BIOLOGICAL|IVACFLU-S|"The Seasonal Inactivated, Split Virion, Trivalent Influenza Vaccine (TIV) were purified by the method of super centrifugation to create gradient segments in sucrose sugar produced by IVAC, or placebo produced by IVAC. Vaccines are produced on eggs, inactivated with formaldehyde. The dose of the vaccine tested was 15 mcg of HA for each antigen component in 0.5 ml.~The influenza virus strains used to produce the 2020-2021 seasonal vaccine will also be provided by the NIBSC, which will be used according to WHO's recommendation, which is expected to include the following Southern Hemisphere strains:~Influenza A / H1N1 strain: Recombinant strain IVR-190 44250 E12 of the strain (A / Brisbane / 02/2018).~Influenza strain A / H3N2: strain IVR-197 (H3N2) 44850 E14 recombinant strain (A / South Australia / 34/2019).~Flu strain B (B / Washington / February 2019)."
223645568|NCT05813041|DEVICE|BioCaptis|The BioCaptis is a medical device intended to capture cell-free DNA from peripheral blood for use in liquid biopsy. When used as a cartridge filter during an apheresis procedure in which plasma is passed through the device, the BioCaptis binds cfDNA which can be eluted, concentrated, and used as an input for cancer diagnostic tests.
223645569|NCT02997241|BIOLOGICAL|OncoCare|Personalized monitoring
223645570|NCT02997241|DRUG|chemotherapy for colorectal carcinoma|chemotherapy for colorectal carcinoma
223645571|NCT01915836|OTHER|web-based video game (Quit IT)|
223645572|NCT01915836|BEHAVIORAL|Questionnaires|
223645573|NCT01915836|BEHAVIORAL|Evaluation Interview|
223645574|NCT06252324|OTHER|Prime taper implant + cover screw|tissue level implant placement with the addition of a cover screw
223645575|NCT06252324|OTHER|Prime taper implant + healing screw|bone level implant placement with the addition of a healing screw
223645576|NCT02109185|DRUG|Mometasone Furoate Monohydrate Nasal Spray, 50 μg/act.|
223645577|NCT02109185|DRUG|Nasonex® Nasal Spray, 50 μg/actuation|
223645578|NCT02109185|DRUG|Nasonex® Nasal Spray Suspnsn, 50 μg/actuation|
223645579|NCT02109185|DRUG|Placebo Nasal Spray, 50 μL/actuation|
223645580|NCT02331277|DRUG|BI 655064|subcutaneous injection
223645581|NCT02331277|DRUG|Placebo|Placebo
223645582|NCT03978117|DIETARY_SUPPLEMENT|Freeze Dried Watercress Preparation|Freeze dried watercress containing gluconasturtiin, which when added to provided water with flavor powder, will result in a total target dose of up to 40 mg/day of 2-phenethyl isothiocyanate (PEITC). Preparation consumed at breakfast, lunch and dinner 3x daily for 2 weeks.
224231854|NCT06033066|BEHAVIORAL|Financial Incentives|Small financial incentive or prize incentive
223645583|NCT03978117|DIETARY_SUPPLEMENT|Placebo Preparation|Maltodextrin added to provided water with flavor powder. Preparation consumed at breakfast, lunch and dinner 3x daily for 2 weeks.
223645584|NCT00000991|DRUG|Pentamidine isethionate|
223645585|NCT00000991|DRUG|Sulfamethoxazole-Trimethoprim|
223645586|NCT00000991|DRUG|Dapsone|
223645587|NCT00000991|DRUG|Zidovudine|
223645588|NCT02392819|DIETARY_SUPPLEMENT|Panax ginseng|Pananx ginseng is provided prior to a standardised breakfast, effects on test variables are determined at fasting and repeatedly postprandially the breakfast
224231855|NCT06033066|BEHAVIORAL|Message|Message inviting participant to enroll
224323484|NCT05018585|BIOLOGICAL|Recombinant human glutamic acid decarboxylase (rhGAD65) formulated in Alhydrogel®|Recombinant human glutamic acid decarboxylase (rhGAD65) formulated in Alhydrogel®
223645589|NCT02392819|DIETARY_SUPPLEMENT|Placebo|
223645590|NCT00322660|DRUG|Adrenaline|
223765962|NCT07085897|BEHAVIORAL|Web-based Single-session Intervention of Mindset on Intelligence, Failure, and Emotion (We-SMILE) for allied health practicum trainees|The intervention is structured into three video-and-exercise sessions. Part one focuses on students' mindsets in coping with practicum-related challenges and their attitudes towards setbacks, encouraging them to shift from a 'fear-of-failure' mindset to a 'failure-is-enhancing' mindset. Part two introduces the nature and concept of neuroplasticity to promote students' understanding of effective learning. Part three centers on providing guidance for students on strategies to cope with stress and emotional turbulence with growth mindset regarding emotion.
223645591|NCT04375085|DEVICE|Percutaneous Coronary Intervention|Percutaneous Coronary Intervention
223645592|NCT02042274|DIETARY_SUPPLEMENT|Fish oil supplement|Participants are instructed to consume fish oil supplements on a daily basis for a 3-month period.
223645593|NCT04475887|DRUG|Iron Carboxymaltose|see above
223645594|NCT04475887|DRUG|Placebo|see above
223645595|NCT01757925|BEHAVIORAL|weight managment program|a comprehensive peditric weight management program consisting of 16 weekly group sessions
223645596|NCT01757925|OTHER|Active Gaming|partcipants will be given a gaming device and 2 games (1 at baseline and 1 at week 8)
223645597|NCT02707822|OTHER|Clinical and genetic factors|
223645598|NCT01549418|DRUG|Aspirin (ASA)|Usage or withdrawal of aspirin (75mg daily per os) 7 days before and 14 days after polypectomy
223645599|NCT01549418|DRUG|Placebo|
223645600|NCT05687669|DRUG|Glyceryl trinitrate vs phentolamine for prophylaxis against renal impairment|Glyceryl trinitrate vs phentolamine for prophylaxis against renal impairment
223645601|NCT04422678|DRUG|Imatinib Mesylate|Adding treatment by imatinib oral tablet into the standard treatment for moderate to severe COVID-19 pneumonia.
223645602|NCT04422678|DRUG|Standard of Care|Standard of Care for the Moderate to Severe COVID-19 Pneumonia as per the Egyptian National Protocol by the Ministry of Health.
223645603|NCT01074593|BIOLOGICAL|Interferon beta-1a|12.000UI - single dose
223645604|NCT01074593|BIOLOGICAL|Interferon beta-1a|12.000UI - Single dose
223645605|NCT03078218|DIAGNOSTIC_TEST|Pulse oximetry|The tool evaluated will be the assumption of peripherical arterial oxygen saturation by pulse oximetry. The pulse oximetry will identify hypoxemic CCHD and hypoxemic non-cardiac disease before discharge.The test will be realised before 24 hours of life in a newborn aged at least of 35 weeks of gestation.
223645606|NCT05446818|DIETARY_SUPPLEMENT|Cocoa flavanol (CF)|2 times per day 750 mg cocoa flavanols (each delivered in 6 CocoaVia capsules)
223645607|NCT05446818|OTHER|Placebo (P)|2 times per day 0 mg cocoa flavanols calorically matched control (delivered in 6 identical capsules)
223645608|NCT03202771|DEVICE|Home Biofeedback Therapy|Patients will be taught how to use the home-trainer in a single lab session. Then we will place a reusable, dual sensor, probe into their rectum. The probe is connected to a hand- held pressure monitor displaying the patient's response. Next, the clothed patient will be asked to sit on a commode, and attempt 15 bearing down maneuvers. When the anal sphincter pressure decreases more lights go on. If the patient cannot relax then fewer lights go on. Thus, the number of lighted lights gives instant feedback about their performance. Patients will get a 20-minute tape recording for home use. Patients will be asked to insert the probe at least twice daily and each time practice at least 15 bearing down maneuvers; a daily log will be kept. At 4 and 8 weeks, they will return for follow up. Based on their progress, new targets will be set by adjusting the device's sensitivity.
223645609|NCT03202771|OTHER|Office Biofeedback Therapy|A monitor screen will provide visual feedback by showing changes in pressure activity. First patients will be taught abdominal muscle coordination exercise to improve the pushing effort during defecation. Here, patients are taught how to distend the abdomen by inhaling slowly and then holding their breath for at least 15 seconds and to practice this for 20 minutes, twice a day. Thereafter, patients will be asked to attend the motility laboratory, biweekly for up to 6 training sessions. Biofeedback Therapy (BT) will be performed by a 3-sensor manometry probe. The clothed patient will be seated on a commode in front of a monitor. The physician/nurse therapist will give verbal feedback by either complimenting the patient for performing a correct maneuver or rectifying any errors. Each 60 minute treatment session will comprise of the following maneuvers:
223645610|NCT00277654|DRUG|Risperidone|risperidone 0.5mg up to 4mg daily vs. placebo
223645611|NCT03518255|OTHER|Nature video|After signing the Informed Consent Form, the participants will respond to a demographic questionnaire to characterize the sample and then they will watch nature videos. After that, will be applied a scale questionnaire about the physical and psychological symptoms of chemotherapy in the positive and negative mood of that patient.
223645612|NCT03679507|PROCEDURE|Low Intensity Ultrasound Therapy|Subjects suffering from chronic pain due to osteoarthritis of the knee will be recruited for this study, and randomly assigned to two groups. One-half of these Subjects (Group A) will receive ultrasound therapy as detailed below on the affected joint; the other half (Group B) is a placebo group.
223645613|NCT03679507|OTHER|Enhancing CBD oil penetration into joints by sonophresis|High CBD oil will be applied to the affected knee of one-half of the recruited subjects.
223645614|NCT03323281|OTHER|Neuropsychological assessments|Maintenance of approximately 1h30 with a neuropsychologist or a physician trained in neuropsychological assessments in Diabetic Type 1 or Type 2 with foot wound hospitalization and Diabetic Type 1 or Type 2 without a foot wound or antecedent Of foot wound (podological risk grade 0 to 2, including foot of Charcot)
223645615|NCT05885399|DRUG|Penpulimab|Penpulimab will be administered intravenously at a dose of 200 mg every 3 weeks. Treatment continued until the patient exhibited radiographic or clinical disease progression or unacceptable adverse events.
223645616|NCT06168448|OTHER|Oral and written information|Legal oral and written information given by physicians concerning additional examinations
223645617|NCT06168448|OTHER|Video information|Explanatory video applied after physician's formal information
223645618|NCT01795170|DIETARY_SUPPLEMENT|Lysine Restricted Diet|Daily lysine intake will be managed to maintain a plasma lysine level of 50-80 µmol/L (normal range: 52-196 µmol/L). Diet prescriptions will be based on international guidelines for glutaricaciduria type I, another inborn error of lysine catabolism. In order to meet the recommended daily protein intake (DRI) \[23,24\], the diet may include commercially available lysine-free amino acid formulas approved for use in conditions affecting lysine metabolism, as well as commercially available low-protein products based on the participant's taste.
223645619|NCT01795170|DRUG|Pyridoxine|All participants will be on 15-30 mg/kg/day of pyridoxine therapy up to a maximum of 500mg/day divided in 2-3 doses enterally
223645620|NCT02386644|OTHER|PAMG-1 Immunoassay|Immunoassay for presence of placental alfa microglobulin-1(PAMG) in vaginal fluids.
223645621|NCT02386644|DEVICE|Ultrasound transperineal assessment|Transperineal ultrasound assessment of vaginal canal for pooling of amniotic fluid.
223645622|NCT02386644|DEVICE|Ultrasound amniotic fluid index measurement|Calculation of amniotic fluid index in millimetres via ultrasonography by measuring four deepest pockets in four quadrants.
223645623|NCT02386644|OTHER|Speculum examination|Sterile speculum examination to evaluate vaginal pooling of amniotic fluid pooling.
223645624|NCT02386644|OTHER|Nitrazine test|To assess acid , alkaline status of pooled fluid in vagina.
223645625|NCT02653417|DRUG|RAD1901|RAD1901
223645626|NCT02653417|OTHER|Placebo|Placebo
223645627|NCT01640392|BEHAVIORAL|MyLife MyStyle group-level intervention|Three 1.5-hour HIV behavioral risk-reduction group sessions conducted with up to 12 young African American/Black men (ages 18-29 years) over a 1-3 week period.
223645628|NCT06815536|DIAGNOSTIC_TEST|Investigational Reflex Test 1|Investigational Reflex Test 1
223645629|NCT06815536|DIAGNOSTIC_TEST|Investigational Reflex Test 2|Investigational Reflex Test 2
223645630|NCT06815536|DIAGNOSTIC_TEST|Investigational Reflex Test 3|Investigational Reflex Test 3
223645631|NCT01527097|DRUG|Atorvastatin|Drug: Atorvastatin 80 mg for 6 months following by 40 mg for additional 6 months once daily.
223645632|NCT01527097|DRUG|Atorvastatin placebo|Atorvastatin 80mg during 6 month and 40mg in additional 6 month period once daily.
223645633|NCT03931369|DRUG|Tolvaptan 15 MG|Single administration of one pill of 15 MG tolvaptan
223645634|NCT04213248|DRUG|Umbilical Mesenchymal Stem Cells derived Exosomes|Participants will receive artificial tears for 2 weeks to get the normalized baseline, followed by UMSC-exo 10ug/drop, four times a day for 14 days. The follow-up visit will be 12 weeks.
223645635|NCT01241201|DIETARY_SUPPLEMENT|Priobiotic supplement VSL#3|four weeks, twice daily two sachets of VSL#3, a priobitics mixture
224231856|NCT04701957|BEHAVIORAL|Ketogenic diet|The Atkins 2: 1 diet as prescribed for the participants of our intervention group (N = 35) is based on a diet moderately rich in protein (meat, fish, cheese, eggs, vegetable proteins) and without restriction of fats, provided they are balanced, but limiting the carbohydrate intake (bread, pasta, rice) to 50 grams / day. The ratio calories from fat / calories from protein + carbohydrates will be 3 to 1
223645636|NCT01528969|DIETARY_SUPPLEMENT|xylitol|Subjects will chew 2 pieces of xylitol chewing gum (1,5 g/pellet) three times a day in the experimental group for a five-week period.
223645637|NCT01528969|DIETARY_SUPPLEMENT|sorbitol|Subjects will chew 2 pieces of sorbitol chewing gum (1,5 g/pellet) three times a day in the control group for a five-week period.
223645638|NCT03123952|DRUG|ABT-414|ABT-414 will be administered by intravenous infusion
223645639|NCT05029778|DIETARY_SUPPLEMENT|L-arginine 3g + L-Citruline 2 g|receive L-arginine 3g + l-Citruline 2 g PO, for 24 h, until birth.
223645640|NCT05029778|DRUG|Placebo|receive placebo 3g PO, for 24 h, until birth.
223645641|NCT02919579|DRUG|Placebo (Intranasal)|Participants will receive intranasal placebo in Part A (as per the treatment sequence in period 1,2 and 3) and Part B.
223765963|NCT07085455|DIETARY_SUPPLEMENT|Early Supplemental Parenteral Nutrition (SPN)|SPN is initiated on ICU day 4 if enteral nutrition remains \<50% of the target caloric requirement. Nutrition support is guided by protocol
223765964|NCT07085455|DIETARY_SUPPLEMENT|Late Supplemental Parenteral Nutrition (SPN)|SPN is initiated on ICU day 8 if enteral nutrition remains \<50% of the target caloric requirement. Nutrition support is guided by the same protocol as in the early SPN group.
224231857|NCT01463540|DEVICE|A 20 Fr gastrostomy tube, placed using push/pull techniques.|In this group a 20 Fr gastrostomy tube will be placed, of the type in use at each centre, using the push or the pull method. Positioning of the gastrostomy tube will be carried out endoscopically in sedated patients, after antibiotic prophylaxis. Single dose ampicillin/sulbactam 1g/500 mg will be infused intravenously 30 minutes before positioning. In patients just receiving antibiotic therapy, as treatment of concomitant disease, the current therapy will be continued and antibiotic prophylaxis with ampicillin/sulbactam will be not given.
223645642|NCT02919579|DRUG|Esketamine|Participants will receive intranasal esketamine in Part A (as per the treatment sequence in period 1,2 and 3) and Part B.
223645643|NCT02919579|OTHER|Alcohol|Participants will receive oral alcohol in Part A (as per the treatment sequence in period 1,2 and 3).
223645644|NCT02919579|DRUG|Placebo (Oral)|Participants will receive oral placebo in Part A (as per the treatment sequence in period 1,2 and 3).
223645645|NCT04562818|DIAGNOSTIC_TEST|Diagnosis|Determine the number of center that are able to process PCR or FISH/Karyotype for PML/RAR or t(15;17)
223645646|NCT04562818|DIAGNOSTIC_TEST|Molecular and Karyotype|To realize the need of having more center we the technology to perform all of these tests
223645647|NCT04562818|DIAGNOSTIC_TEST|Leucocytes|
223645648|NCT01203969|PROCEDURE|Single port laparoscopic surgery|laparoscopic surgery in which all the instrument was entered into the abdominal cavity through the single port in the umbilicus
223645649|NCT01203969|PROCEDURE|Conventional laparoscopic surgery|laparoscopic surgery in which each of the instrument were entered into the abdominal cavity through the multiple port in multiple quadrants of abdomen
223645650|NCT01106690|DRUG|Placebo|One matching placebo capsule orally (by mouth) once daily for 26 weeks with stable doses of metformin and pioglitazone.
224319838|NCT01897038|DRUG|Sorafenib|Sorafenib 400 milligram (mg) tablets (2 tablets of 200 mg each) orally once daily or twice daily depending on the cohort assigned until disease progression or unacceptable toxicity occurs (maximum up to 31 months).
224319839|NCT05705765|OTHER|Suspension training|Training with suspension devices. 12 sessions of 40-45 min in four weeks.
224319840|NCT05705765|OTHER|Instability training|Training on unstable surfaces. 12 sessions of 40-45 min in four weeks.
224319841|NCT04928079|PROCEDURE|deep brain stimulation|performing deep brain stimulation if needed
223645651|NCT01106690|DRUG|Canagliflozin|One 100 mg or 300 mg over-encapsulated tablet orally once daily for 52 weeks with stable doses of metformin and pioglitazone.
223645652|NCT01106690|DRUG|Sitagliptin|One 100 mg over-encapsulated tablet orally once daily beginning at Week 26 until Week 52 with stable doses of metformin and pioglitazone.
224231858|NCT01463540|DEVICE|A 20 Fr balloon type tube, placed after gastropexy.|In this group a 20 Fr balloon type gastrostomy tube will be placed endoscopically, after gastropexy performed using the Kimberly Clarke MIC Introducer kit, according to the instructions suggested by the manufacturer. The kit includes 4 T-fasteners (only 3 are usually placed in clinical use) and a serial 24 Fr dilator with a pell-away sheath. All commercially available brands of balloon type gastrostomy tubes will be allowed for use in the study. Positioning of the gastrostomy tube will be carried out in sedated patients, after antibiotic prophylaxis (Single dose ampicillin/sulbactam 1g/500 mg ev.). In patients just receiving antibiotic therapy, as treatment of concomitant disease, the current therapy will be continued and antibiotic prophylaxis will be not given.
224231859|NCT02259751|DRUG|KUC 7483 CL|
224231860|NCT02259751|DRUG|Placebo|
224231861|NCT06148909|OTHER|Small Talk Motivational Interviewing|Combining small talks and skills on Motivational Interviewing in the smoking cessation services
223645653|NCT01106690|DRUG|Metformin|The patient's stable dose of metformin background therapy should be continued throughout the study.
224231862|NCT00002387|DRUG|Indinavir sulfate|
224231863|NCT00002387|DRUG|Efavirenz|
224231864|NCT03810430|BEHAVIORAL|health promotion|health promotion on water, sanitation and hygiene and child feeding along with hygiene kits were delivered to the mothers in the intervention arm
224231865|NCT02717247|DEVICE|Active tRNS|"The intervention consists in active tRNS stimulation with cathode above the left dorsolateral prefrontal cortex (DLPFC) which corresponds to the F3 location given by the 10-20 system. Anode is above the right dorsolateral prefrontal cortex (F4).~100Hz-650Hz, 2mA, 30min, twice daily, 5 days"
224231866|NCT02717247|DEVICE|Sham tRNS|The intervention consists in placebo or sham tRNS stimulation electrode are above F3 and F4. Voltage will be ramped at the begin and end of a stimulation for 30 seconds. Placebo stimulation will consist of just applying the ramps at the begin and end of the stimulation.
224231867|NCT00110968|DRUG|Itopride hydrochloride|
224231868|NCT05172375|BEHAVIORAL|Shared Care Model|The Shared Care model consists of the following key elements: Shared care is a collaboration between general practice and mental health services and enables a 'best of both worlds' scenario with the opportunity to provide holistic care of high quality to support the recovery process of people with mental health difficulties.
224319842|NCT04928079|DRUG|Anti-Parkinsonian Drugs|Using anti-parkinsonian drugs if needed
223645654|NCT01106690|DRUG|Pioglitazone|The patient's stable dose of pioglitazone background therapy should be continued throughout the study.
223645655|NCT00506974|DRUG|sodium oxybate|3.5 g of sodium oxybate or placebo on two of the five overnights.
223645656|NCT00489658|DRUG|Eflornithine plus Nifurtimox combination therapy|
223765965|NCT07086508|BEHAVIORAL|e-CHECKUP TO GO (eCTG)|A brief, web-based program designed by San Diego State University to reduce high-risk drinking by providing personalized normative feedback regarding alcohol use, risk factors, and risks associated with drinking and accurate information about alcohol.
223765966|NCT07086508|BEHAVIORAL|e-Parent Intervention and eCTG (eCTG+)|The eCTG+ is a combination of the eCTG and the e-Parent Intervention, which is an electronic handbook developed by Rob Turrisi to guide parents in discussing drinking, behaviors, and consequences with their teens.
223765967|NCT07084896|DRUG|Belantamab mafodotin|Belantamab mafodotin will be administered.
223645657|NCT04682054|PROCEDURE|ocular surgery|surgery to remove the pathological eye tissue
223765968|NCT07084896|DRUG|Nirogacestat|Nirogacestat will be administered.
223765969|NCT06901570|DRUG|Kuangxiong Aerosol|Patients in the intervention group will receive Kuangxiong Aerosol for eight weeks, in addition to guideline-recommended medications. The aerosol will be administered sublingually (under the tongue), with a dosage of two sprays per dose, three times daily.
224231869|NCT02333370|DRUG|LEE011|LEE011 as 50 mg and 200 mg hard gelatin oral capsules as individual patient supply packaged in bottles. LEE011 will be taken QD - days 1-21 of each 28 days cycle.
224231870|NCT02333370|DRUG|Letrozole|25mg
224231871|NCT02333370|DRUG|Tamoxifen|20 mg
224231872|NCT02333370|DRUG|Fulvestrant|500 mg
224231873|NCT02333370|DRUG|goserelin|
224231874|NCT05769530|DRUG|Nalbuphine，dexmedetomidine|According to the drug use, the subjects were divided into group A, which was continuously injected with normal saline during the operation, and intravenously injected with 5 mL normal saline 30 minutes before the end of the operation. In group B, DEX 0.5μg/kg was injected intravenously during the operation, which was completed in 10 min, and Nalbuphine 0.20 mg/kg (5 mL) was injected intravenously 30min before the end of the operation. After the operation, all anesthetic drugs were stopped and the patient was transferred to PACU with intubation.
224231875|NCT04714658|OTHER|Therapeutic Education|"Each patient will participate in 1 to 3 PTE sessions.~1. st group collective workshop : allow the patient to better understand autoimmune~2. nd workshop : fatigue and techniques that enable its best management.~3. rd workshop : improving the management of the emotions generated by myasthenia. It allows patients to express their experiences of the disease in front of a group, to talk about their difficulties in their relationships and mobilize their resources to promote exchanges."
224231876|NCT02929979|BEHAVIORAL|Cognitive Training|Participants will complete 22.5 hours of cognitive training exercises over 6-weeks (training 5 times a week) using an app-based program, BrainHQ (BPI/Posit Science, San Francisco). BrainHQ is based on a previous neuroscience-based cognitive training program shown to improve cognition in several different randomized controlled studies with other clinical populations. The investigators will use a suite of BrainHQ exercises designed to target and ameliorate cognitive disruptions in 4 cognitive domains (see main outcome). The investigators will employ basic exercises that focus on increasing processing efficiency in the auditory and visual perceptual and working memory domains, as well as exercises that target impulsivity and cognitive biases. Exercises will be packaged into 4 modules (attention skills, memory skills, executive functioning skills, cognitive control skills) comprised of 4 exercises each. All participants will progress through the same fixed schedule of modules.
224319843|NCT01562561|DRUG|repaglinide|2 mg at each main meal
224319844|NCT01562561|DRUG|insulin NPH|Administrated subcutaneously (s.c., under the skin) either at bedtime or twice daily at breakfast and before dinner.
224319845|NCT04820205|DRUG|Intranasal dexmedetomidine and ketamine|Intranasal administration of dexmedetomidine (2mcg/kg) and ketamine (3mg/kg) to increase the success rate of adequate pediatric procedural sedation (pediatric sedation state scale = 1,2,3)
223645658|NCT03385980|OTHER|Proteomic analysis|Proteomic analysis of tissues collected from all sites of disease, guided by either imaging performed prior to the patient's death or post-mortem findings. Peripheral blood mononuclear cells (PBMC) will be collected with the purpose of identifying somatic changes occurring specifically in the tumor cells and not in normal DNA of the same patient.
223645659|NCT05234697|DRUG|Remifentanil|Remifentanil was used for maintenance of anesthesia.
223645660|NCT00124514|DRUG|Triptorelin pamoate|IM injection given monthly
223645661|NCT00124514|DRUG|Triptorelin Pamoate|IM injection given monthly
223765970|NCT06901570|DRUG|Placebo Drug|Patients in the control group will receive a placebo version of Kuangxiong Aerosol for eight weeks, alongside guideline-recommended medications. The placebo will be administered sublingually (under the tongue), with a dosage of two sprays per dose, three times daily.
223765971|NCT06903442|BEHAVIORAL|Co-designed cardiovascular brief intervention|Patients will be randomised to a brief intervention where they will be informed of their high-sensitivity cardiac troponin value and cardiovascular risk.
224231877|NCT02929979|BEHAVIORAL|Cognitive training placebo control|Participants will play a rotating set of commercial computer games at the same dose and frequency as the cognitive training. The investigators selected this control activity because it mirrors the game-like properties of the cognitive training and it will be used to control for contact with research personnel and for the non-specific effects of participant motivation and engagement with daily computerized activities. It also allows for a double blind study design. Games from the website Sporcle will be used and an online account can be created for each participant.
224231878|NCT01130688|DRUG|Zileuton|Imatinib combined with Zileuton
224231879|NCT02427685|DEVICE|Pulse Co-Ox|Comparison of pulse co-oximeter to blood gas analyzer.
223765972|NCT06903650|PROCEDURE|bilateral salpingectomy, ovarian arter doppler ultrasonography|The effect of salpingectomy operation on ovarian reserve
224231880|NCT00101582|DRUG|Placebo|
223645662|NCT00124514|DRUG|Triptorelin Pamoate|IM injection given monthly
223645663|NCT00124514|DRUG|Triptorelin Pamoate|IM injection given monthly
223765973|NCT06928506|DEVICE|Hi-OxSR device|The Hi-OxSR device consists of the Hi-Ox mask connected to a portable oxygen concentrator, with added tubing serving as a reservoir for rebreathed exhaled breath.
223765974|NCT06928506|DEVICE|Hi-Ox device|The Hi-Ox mask is connected to a portable oxygen concentrator.
223765975|NCT07085429|BIOLOGICAL|Blood and tissue sampling|"Tissue samples (tumor tissue and healthy tissue) frozen and secured in paraffin collected during surgery.~During the blood samples taken for diagnosis and / or treatment when possible. Additional samples for research purposes will be carried out, these blood samples will be collected:~* before any therapeutic intervention (T1) for a total volume of 36mL,~* prior to surgery (T-Surg) for a total volume of 24mL,~* at each progression (T2a, b, c…) for a total volume of 24mL,~* at the end of follow-up (T3) for a total volume of 24mL."
223765976|NCT07087262|DRUG|SNH-119014|study drug
224231881|NCT00101582|DRUG|palifermin|
224231882|NCT00101582|DRUG|cisplatin chemotherapy|Commercially available cisplatin was administered as an intravenous infusion at a dose of 100 mg/m\^2 on Days 1, 22, and 43.
224231883|NCT00101582|RADIATION|Radiotherapy|Radiotherapy was delivered in 200 cGy daily fractions, 5 days a week.
224231884|NCT03370068|OTHER|ICSI|Oocytes retrieved from one ovary will undergo insemination by ICSI.
224231885|NCT03370068|OTHER|Conventional IVF|Oocytes retrieved from the second ovary will undergo insemination by conventional IVF
224231886|NCT06486480|PROCEDURE|Using robot assisted endoscopy to clear intraventricular hemorrhage|More advanced surgical auxiliary instruments are used to improve surgical accuracy
223765977|NCT07087262|DRUG|Placebo|placebo
223645664|NCT00124514|OTHER|placebo|placebo 0.9% normal saline IM injection
223645665|NCT04655794|DRUG|3HP|all patients taking 3HP under directly observed preventive therapy (DOPT) program
223645666|NCT03298906|DRUG|Esketamine|Participants will self-administer one intranasal spray of 14 mg esketamine at Time 0 and again 5 minutes later on Day 1, a total dose of 56 mg in Treatment Period 1 and 2.
224231887|NCT00056160|DRUG|CC-5013|Subjects in the CC-5013/Dex treatment group took 25 mg of lenalidomide orally once daily on Days 1 to 21 and a matching placebo capsule once daily on Days 22 to 28 of each 28-day cycle.
223645667|NCT03298906|DRUG|Ticlopidine|Participants will receive 250 mg ticlopidine tablets orally twice daily on Day -9 through Day 1 in Treatment Period 2.
223645668|NCT01325636|OTHER|Cell therapy|"Injection of specific T cell by intravenous way with a posology of 1000 to 5000 CD3 IFN γ+ / kg.~A second injection could be made at day 21"
223645669|NCT04384692|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo HSCT
223645670|NCT04384692|DRUG|Busulfan|Given IV
223645671|NCT04384692|DRUG|Cyclophosphamide|Given IV
223645672|NCT04384692|DRUG|Fludarabine|Given IV
223645673|NCT04384692|DRUG|Melphalan|Given IV
223645674|NCT04384692|DRUG|Methotrexate|Given IV
223645675|NCT04384692|DRUG|Mycophenolate Mofetil|Given IV or PO
223645676|NCT04384692|DRUG|Ruxolitinib|Given PO
223645677|NCT04384692|DRUG|Tacrolimus|Given IV and PO
223645678|NCT04384692|RADIATION|Total-Body Irradiation|Undergo TBI
223645679|NCT04384692|PROCEDURE|Computed Tomography|Undergo CT scan
223645680|NCT04384692|PROCEDURE|Echocardiography|Undergo echocardiography
223645681|NCT04384692|PROCEDURE|Bone Marrow Aspiration and Biopsy|Undergo bone marrow aspiration and biopsy
223645682|NCT04384692|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223645683|NCT04384692|PROCEDURE|Ultrasound Imaging|Undergo ultrasound imaging
223645684|NCT03458247|DRUG|Abiraterone acetate standard dose|1000 mg/day
224231888|NCT00056160|DRUG|Dexamethasone|Subjects in the CC-5013/Dex and Placebo/Dex treatment groups took 40 mg of dexamethasone orally once daily on Days 1 to 4, 9 to 12, and 17 to 20 of each 28-day cycle for the first 4 cycles of therapy. Beginning with Cycle 5, the dose of dexamethasone was reduced to 40 mg orally once daily on Days 1 to 4 for the remaining cycles.
224319846|NCT04820205|DRUG|Oral chloral hydrate|Oral chloral hydrate (50mg/kg) administration to induce adequate pediatric procedural sedation (pediatric sedation state scale = 1,2,3)
224319847|NCT00525798|DRUG|SMC021 Oral calcitonin|0.8mg SMC021 - oral calcitonin, once daily
224319848|NCT00525798|DRUG|SMC021 Placebo|SMC021 - Placebo, once daily
224231889|NCT04898296|OTHER|Questionnaire, Interview|During the stay, a study visit is arranged with the patient after the 6-minute walk test has been performed. This consists of filling out the questionnaire and an interview, which lasts about 45-60 minutes. This is carried out by the investigator on at least 5 subjects. After each interview, a list of influencing factors is kept. If new aspects continue to appear in the 5th interview, the interviews are continued (up to a maximum of the 10th subject). If no new aspects appear in the interviews from number 6 onwards, the interviews are discontinued and no further patients are recruited. The conversations are recorded with an audio recording.
224231890|NCT04898296|OTHER|Focus Group|The focus group is carried out first in order to identify influencing variables that may be relevant for the interview (duration 60-90 minutes).
224231891|NCT01551095|DEVICE|PEGJ tube|The self-propelled PEGJ feeding tube
224231892|NCT05436002|DEVICE|With Cross-linked Hyaluronic Acid|Without Cross-linked Hyaluronic Acid
223645685|NCT03458247|DRUG|Abiraterone acetate escalated dose|2000 mg/day
223645686|NCT01923636|OTHER|detection of CMV|Clinical, radiological and laboratory (virological and immunological) standardized reports
223645687|NCT05598801|DEVICE|VersaWrap|VersaWrap is applied to the affected tendon to allow post-operative gliding.
223645688|NCT05761548|DIAGNOSTIC_TEST|ultrafast ultrasound power Doppler imaging|ultrafast ultrasound power Doppler imaging for neonatal brain microvessels
223645689|NCT01544257|OTHER|osteopathic manipulative treatment|Patients from this group received osteopathic treatments twice a week for the entire length of stay in the unit.
223645690|NCT01544257|PROCEDURE|Usual care|Patients from control group received standard care plus osteopathic evaluation only, according to the same schedule as the study group.
223645691|NCT05585450|DEVICE|Electroacupuncture|"BL32 and BL33 will be inserted by needles of 0.30×75mm size at an angle of 45°, inward and downward, to the depth of 60-70mm. BL35 will be inserted by needles of 0.30×75mm size, slightly outward and upward, to the depth of 60-70mm. SP6 will be inserted by needles of 0.30×40mm to the depth of 25-30mm. The needles will be lifted, thrust, and twisted evenly three times after insertion to induce the sensation of deqi.~The electronic acupuncture apparatus (Yingdi KWD 808I electro pulse acupuncture therapeutic apparatus, Changzhou Yingdi Electronic Medical Device Co., Ltd) will be connected to the four pairs of needles transversally, with a continuous wave of 5 Hertz (Hz) and an electric current of 2-6.5 milliampere (mA) for BL32, BL33 and BL35, and 0.5 mA-2mA for SP6."
223645692|NCT05585450|DEVICE|Sham electroacupuncture|"The four pairs of acupoints will be inserted by needles of 0.30×25mm or 0.30×40mm size to a depth of 2-3mm till the needles can stand still. No manipulations will be conducted, and the sensation of deqi will not be induced.~The electronic acupuncture apparatus (Yingdi KWD 808I electro pulse acupuncture therapeutic apparatus, Changzhou Yingdi Electronic Medical Device Co., Ltd) will be connected to the four pairs of needles transversally, with a continuous wave of 5 Hz and a minimal electric current (ideally at a degree which participant can just percept). In about 30 seconds, the electric current will be turned down, leaving the indicator light and ticking sound on."
223645693|NCT02559024|DRUG|MEDI6469|MEDI6469 0.4 mg/kg IV x 3 doses over 5-6 days
223645694|NCT04001322|OTHER|Community engagement|The government will conduct a cascade of sensitization meetings with traditional leaders at all levels to promote newborn line listing (birth registration), reconciliation of child's vaccination status and defaulter tracking (home-based follow up of children who have missed their vaccination doses) by health providers and community leaders
223645695|NCT04001322|OTHER|IRISS advert for opt-in|A module to advertise and demonstrate how individuals can opt-in to IRISS to receive the messages will be included in the community engagement sensitization meetings.
223645696|NCT04001322|OTHER|One-time SMS broadcast on immunization|General broadcast of SMS messages on the importance of immunization to all active mobile phone subscribers in the intervention LGAs
223645697|NCT04001322|OTHER|Scheduled weekly SMS reminder of health facility RI schedule to community leaders|"Traditional and religious leaders who have a phone or access to a phone and have been registered on IRISS will receive SMS messages on the immunization session schedule of the health facilities in their communities, so they can disseminated the information through their town announcers to inform parents and caregivers. For example, Ribah clinic is holding a vaccination session tomorrow from 8am to 2pm. Please take your child there to vaccinate them and encourage your neighbors to vaccinate their children."
223645698|NCT04001322|OTHER|Scheduled bi weekly RI messages to community leaders|"Traditional and religious leaders who own or have access to a phone and have been registered on IRISS will receive SMS messages on immunization, to share same with community members. The message categories are: 1) Educational messages that provide facts and increase knowledge, e.g. Have you heard of Penta vaccine? It protects against 5 diseases: they are diphtheria, whooping cough, tetanus, HiB and Hepatitis B. 2) Informative messages that dispel myths about immunization, e.g. Getting more than one vaccine at the same time does not harm a child. It is very important to completely receive all vaccine doses for full protection. 3) Normative messages to promote positive norms, e.g. Our religious leaders have immunized their children, what are we waiting for? 4) Motivational messages to inspire action, e.g. Each visit to the health center for vaccination will reap many health benefits. Say YES to good health, be on time and complete your child's vaccination."
223765978|NCT07086729|OTHER|CT-Based Morphologic and Attenuation Scoring|Retrospective analysis of CT images to extract morphological and Hounsfield Unit (HU) parameters for development of a predictive scoring model (TSMAS). No clinical or therapeutic intervention was performed.
224231893|NCT03382002|DIAGNOSTIC_TEST|TCL|evaluation of oxidative status
224231894|NCT03528200|OTHER|Contrast|"The scan requires that the patient lie still on a hard surface for about 5-10 minutes. Before the scan, they will have a special fluid called contrast dye injected through the IV in their arm. This contrast dye helps to see the blood in the arteries using x-ray pictures.~After the IV dyna CBV is completed, they will have their routine conventional angiography to evaluate the lesion for embolizable arteries as part of routine clinical care. If the patient undergoes embolization of the lesion (as part of the standard of care), a post embolization Dyna CBV will be performed."
224231895|NCT01436032|DRUG|N1539|IV
224231896|NCT01436032|DRUG|N1539|IV
224231897|NCT01436032|DRUG|N1539|IV
224231898|NCT01436032|DRUG|Ketorolac Tromethamine|IV
224231899|NCT01436032|DRUG|Placebo|IV
224319849|NCT00003445|DRUG|docetaxel|
224323485|NCT05018585|DIETARY_SUPPLEMENT|Colecalciferol 2000 IU|Colecalciferol (vitamin D3) 2000 IU (equivalent to 50 microgram vitamin D3).
223645699|NCT04001322|OTHER|Responsive individualized child vaccination schedule reminder to caregivers who opt-in|"Parents and caregivers who voluntarily registered their child's information into IRISS will receive a reminder, a day before, about their child's due vaccines and the schedule of vaccination sessions in the health facilities within their locality (wards), e.g. Greetings! Amina is due for Penta 1 tomorrow, kindly visit Ribah clinic. They vaccinate on Mondays and Thursdays."
223645700|NCT04001322|OTHER|Responsive one-time SMS message on hand washing to those that erroneously register on IRISS|"If individuals from control LGAs encounter IRISS adverts inadvertently and erroneously register into IRISS expecting a message, to avoid a loss in trust if no message is sent, they will receive a one-time general message about the importance of hand-washing, e.g. Wash your hand with soap and water every time you finish from to the toilet, to maintain clean hands and avoid germs that make you sick."
223765979|NCT07084844|DEVICE|WaveLigh Plus LASIK|Wavelight plus LASIK is an advanced laser eye surgery technology designed to enhance visual outcomes through personalized treatment plans. This system integrates comprehensive diagnostics, including biometry, tomography, and wavefront measurements, to create a tailored ablation profile for each patient.
224231900|NCT04882332|OTHER|sampling for diabetes control parameters|Intravenous blood withdrawal for a sample of fasting blood glucose (FBG), 2 hr postprandial blood glucose (2 hr -PPG), fasting lipids {total cholesterol (TC), triglycerides (TAG), low density lipoprotein cholesterol (LDL-C), high density lipoprotein cholesterol (HDL-C)}, glycosylated hemoglobin (Hb A1c) ,fasting insulin level and Vitamin B 12 levels
224231901|NCT04882332|OTHER|Sampling for vitamin B12 level|Intravenous blood sampling for a sample of vitamin B12 level
224319850|NCT02933255|BIOLOGICAL|PROSTVAC-V/F|PROSTVAC-V (vaccinia) will be administered subcutaneously in an extremity (e.g., thigh) at a dose of 2x10\^8 infectious units. PROSTVAC-F (fowlpox) will be administered subcutaneously in an extremity (e.g., thigh) at a dose of 1x10\^9 infectious units.
224319851|NCT02933255|DRUG|Nivolumab|Nivolumab is to be administered as a flat dose over approximately 30-minutes via intravenous (IV) infusion.
223645701|NCT01121770|DRUG|fondaparinux sodium injection|1.5mg subcutaneously every day
223645702|NCT02145377|BIOLOGICAL|PXVX0200 10E8|Oral dose of PXVX0200 10E8
223645703|NCT02145377|BIOLOGICAL|PXVX0200 10E9|Oral dose of PXVX0200 10E9
223645704|NCT02145377|BIOLOGICAL|Placebo|Oral dose of sodium bicarbonate buffer
223645705|NCT02145377|BIOLOGICAL|Shanchol|Licensed comparator
223645706|NCT04721886|PROCEDURE|Ultrasonsgraphy|Undergo ultrasonography
223645707|NCT04721886|DRUG|Perflutren Lipid Microcpheres|Given IV
223645708|NCT04721886|PROCEDURE|Contrast - Enhanced Ultrasound|Undergo CEUS
223645709|NCT04029402|OTHER|RNA sequencing|Transcriptomic analysis of kidney biopsy tissue, and linking with slope of eGFR decline
223645710|NCT05565625|OTHER|Sunscreen A|Participants will topically apply Sunscreen A at Visit 1.
223645711|NCT05565625|OTHER|Sunscreen B|Participants will apply Sunscreen B at Visit 1.
223645712|NCT05565625|OTHER|Sunscreen C|Participants will apply Sunscreen C at Visit 1.
223645713|NCT05565625|OTHER|Sunscreen D|Participants will apply Sunscreen D at Visit 1.
223645714|NCT05565625|OTHER|Sunscreen E|Participants will apply Sunscreen E at Visit 1.
223645715|NCT05565625|OTHER|Sunscreen F|Participants will apply Sunscreen F at Visit 1.
223765980|NCT07085663|OTHER|Exergame-assisted simultaneous motor-cognitive training|Exergame-assisted simultaneous motor-cognitive training
223645716|NCT03863158|OTHER|No intervention|No intervention / medical records only
223645717|NCT00482248|DRUG|Omalizumab|
223645718|NCT04614974|DRUG|Famotidine|Famotidine will be prescribed based on patients' weight. Caregivers will purchase this medication and dosage will be given to families in easy-to-understand language.
223645719|NCT04614974|OTHER|Speech Language Therapy|Speech Language Therapy (feeding therapy) will be provided by a speech language pathologist to assess feeding and swallowing.
223645720|NCT01635153|DIETARY_SUPPLEMENT|Protein calorie supplement|Fortified porridge with 1062 kcal and 40 gm protein
223645721|NCT01635153|DIETARY_SUPPLEMENT|Micronutrient|Dar-vite Multivitamin
223645722|NCT04193995|BEHAVIORAL|Intermittent fasting|There are two 36h fasting periods (FP) every week, over a 12week period. Free access to water is allowed; two cups of tea or coffee are also allowed. Each 36h FP begins after the last meal, which is consumed no later than 2000h on the preceding nights. Fasting days are Sunday and Wednesday, and fasting is terminated at 0800 on Monday and Thursday. Medications may be adjusted as needed during these visits, and this is reconsidered and may be further adjusted after the receipt of the blood tests results later during the day. Adjustments based on lab results are discussed with the patients during the clinic visit or later on the same day. Also, dietary needs are addressed by the physician and /or the dietician, during the clinic visit. As of week 3 through week 12, clinic visit is reduced to once a week, on Thursdays.
223645723|NCT02196844|BEHAVIORAL|Hatha Yoga|5-6 weeks of a couple-based yoga program, three sessions per week (up to 15 sessions) during radiation treatment.
223765981|NCT07085624|DRUG|ceftazidime|ceftazidime loading dose and maintenance dose
224231902|NCT05532332|DRUG|Fluoxetine 10 mg capsules|an immediate release hard gelatin capsule containing Fluoxetine hydrochloride equivalent to Fluoxetine 10 mg
224231903|NCT05532332|DRUG|Prozac® 10 mg capsules|an immediate release hard gelatin capsule containing Fluoxetine hydrochloride equivalent to Fluoxetine 10 mg
224231904|NCT05268432|PROCEDURE|Surgery with intraoperative imaging|laparoscopic, robot-assisted or other intraoperative imaging (ultrasound, CT, MRI)
224231905|NCT03519828|OTHER|No intervention has been conducted|It is an observational study, and no intervention has been conducted
224231906|NCT01366508|OTHER|High calorie lunch|Subject fed a standard high calorie lunch at 1pm
224319852|NCT02933255|PROCEDURE|Prostatectomy|Participants in the neoadjuvant cohort will undergo a radical prostatectomy in week 9. (If surgery is scheduled earlier than 9 weeks after initial dosing, the 6 and 8 week dosing may be skipped, and surgery may be done as early as week 5.)
224319853|NCT02933255|PROCEDURE|Biopsy|A baseline biopsy is performed for participants in the neoadjuvant cohort that do not have a previous collection of biopsy material.
224319854|NCT02933255|DRUG|Tylenol|Participants who experience aches or fever after vaccination may take Tylenol as directed.
224319855|NCT00368017|DRUG|pioglitazone|30 mg once a day for 12 weeks
224319856|NCT00368017|DRUG|placebo|1 pill once a day for 12 weeks
224231907|NCT01366508|OTHER|Breakfast|At approximately 09:00 the subject will be given breakfast. After this, no food will be served until study procedures for the day are over. However, a 330 ml bottle of still water at room temperature will be given at \~11:00 and at \~13:00. During this period the subject will be required to remain in the unit.
224231908|NCT03207581|BEHAVIORAL|Professional Coaching|Professional, individualized coaching
224231909|NCT03312530|DRUG|Cobimetinib|Cobimetinib will be administered as per the schedule specified in the respective arm.
224231910|NCT03312530|DRUG|Venetoclax|Venetoclax will be administered as per the schedule specified in the respective arm.
224231911|NCT03312530|DRUG|Atezolizumab|Atezolizumab will be administered as per the schedule specified in the respective arm.
224319857|NCT05251610|DRUG|20mg oral propranolol and oxytocin|Participants will receive 20mg of oral propranolol 10minutes prior to initiation of augmentation or induction of labor with oxytocin
224319858|NCT05251610|DRUG|Oxytocin only|Participants will have outright augmentation or induction of labor with oxytocin
224231912|NCT04329208|DEVICE|Transcranial doppler|"TCD examination was performed using DWL-EZ-Dop machine Compumedics GmbH, Singen, Germany. TCD utilizes low-frequency pulsed insonation (2 MHz) to measure blood flow velocity within proximal cerebral arteries, obtaining systolic and diastolic peaks and mean flow velocities (MFV). MFV is defined as (systolic + diastolic)/3 + diastolic velocities, according to Alexandrov et al..~Initial TCD examination was done after admission serving as a baseline state for cerebral circulation. Follow-up TCD examinations was done at fixed intervals on the first, third, fifth, seventh and tenth days of the onset of SAH."
224231913|NCT00868400|DIETARY_SUPPLEMENT|commercially available high-carbohydrate beverage|800 ml before the day of surgery, and additional 400 ml two hours prior to surgery
224231914|NCT00868400|DIETARY_SUPPLEMENT|flavored water|will be given in doses equal to those of high-carbohydrate beverage
224231915|NCT00909493|OTHER|Network Access|Primary Care Physicians in this treatment group will have access to a pain specialist at the Pain Management Unit.
224231916|NCT04505033|DRUG|HB0017|HB0017 at 100 mg/mL (1 mL/vial) in 2 mL glass vial with a rubber stopper. HB0017 will be administered in the abdominal area by a subcutaneous injection in the mornings. A maximum volume of 1 mL is injected per site.
224231917|NCT04505033|DRUG|placebo|A matching injection solution containing a specific volume of normal saline (0.9%, Sodium Chloride Injection USP) and no active substance will be prepared for the subjects who will be assigned to placebo according to the dose schedule.
224319859|NCT00591981|BEHAVIORAL|TOGA Tools|ADL's, Zubrod, IADL's, BFI, MMS, MNS, GDS
224319860|NCT00049179|DRUG|cytarabine|ind and consol: 200 mg/m2/d continuous IV days 1-7
224319861|NCT00049179|DRUG|gemtuzumab ozogamicin|ind and consol: 6 mg/m2 IV over 2 hrs day 1, 4mg/m2 IV over 2 hrs day 8
224319862|NCT06111261|DRUG|Albumin solution|200ml of 20% Human Serum Albumin
223645724|NCT02196844|BEHAVIORAL|Questionnaires|10 questionnaires completed before first radiation treatment, each week during radiation, 5 questionnaires halfway through radiation treatment schedule. at radiation treatment completion, and again 3 months later.
223645725|NCT02196844|OTHER|Walk Test|6-minute walk test performed at baseline, at the end of radiation therapy, and 3 months after radiation therapy.
223645726|NCT03332706|OTHER|observation|after the subjects are included into the groups,they are asked to do a questionaire.Then,we just observe the outcomes of pregnancy
223645727|NCT01662570|BEHAVIORAL|Beverage Choice and Lifestyle Modification|The family-based BCLM intervention trained children and parents in self monitoring of sugar sweetened beverage intake and goal-setting, incorporated feedback and reinforcement, and provided water bottles and water filters to promote a reduction in sugar sweetened beverages and overall energy intake. 16 sessions were provided over a 6-month period.
223645728|NCT01662570|OTHER|Nutrition Education (NE)|This treatment for parents and children addressed a variety of topics in nutrition including benefits of fruits and vegetables, the food pyramid, vitamins, benefits of eating a variety of foods, and healthy beverage selections. No behavioral change training component was included. 16 sessions over 24 weeks was provided.
223645729|NCT00831480|DRUG|everolimus|everolimus 10 mg PO once daily for 3-5 weeks followed by removal of the kidney. Everolimus will begin again between 2 to 4 weeks after surgery.
223645730|NCT01312740|OTHER|LC-P-LGI diet|a hypocaloric diet low in lipids (25%) which is compensated by proteins (35%) with no change in carbohydrate content.
223645731|NCT01312740|OTHER|LC-CONV|4-week CONV period consisted in the subjects' consumption of 1200 Kcal/ day (25% protein, 31% lipids, 44% carbohydrates).
223645732|NCT02231931|DRUG|Digoxin|single dose, fasted
223645733|NCT02231931|DRUG|Rosuvastatin|single dose, fasted
223645734|NCT02231931|DRUG|Digoxin, Furosemide, Metformin hydrochloride, Rosuvastatin|fasted
223645735|NCT02231931|DRUG|Digoxin, Furosemide, Metformin hydrochloride, Rosuvastatin|fasted
223645736|NCT02231931|DRUG|Metformin hydrochloride|single dose, fasted
223645737|NCT02231931|DRUG|Digoxin, Furosemide, Metformin hydrochloride, Rosuvastatin|fasted
223645738|NCT02231931|DRUG|Furosemide|single dose, fasted
223645739|NCT01032122|DRUG|rituximab|induction phase: 375mg/m² qw, 4wks; followed by maintenance phase: 375mg/m², every 8 wks; duration: 2 years.
223645740|NCT05984576|RADIATION|Reirradiation|Reirradiation recurrent rectal cancer
224231918|NCT01452451|DRUG|HM11260C|1, 2, and 4 mg for 8 weekly subcutaneous injections for cohorts W1, W2 and W3. 8, 12 and 16 mg for 3 monthly subcutaneous injections for cohorts M1, M2 and M3
224231919|NCT01452451|DRUG|Placebo|Placebo for 8 weekly subcutaneous injections for cohorts W1, W2 and W3. Placebo for 3 monthly subcutaneous injections for for cohorts M1, M2 and M3
224319863|NCT06111261|DRUG|Balanced crystalloid solution|Balanced crystalloid solution
224319864|NCT03526783|PROCEDURE|Roux en Y gastric bypass|Laparoscopic Roux en Y gastric bypass (150 cm alimentary limb, 50 cm biliopancreaty limb)
224319865|NCT03526783|PROCEDURE|Mini/One anastomosis gastric bypass|Laparoscopic Mini/One anastomosis gastric bypass (200 cm biliopancreatic limb)
224319866|NCT04803305|DRUG|PF-06946860|subcutaneous injection
224319867|NCT04803305|DRUG|Placebo for PF-06946860|subcutaneous injection
224319868|NCT05289297|PROCEDURE|Karydakis Flap Procedure|Pilonidal sinus surgery will be performed with the Karydakis Flap procedure.
224319869|NCT05289297|PROCEDURE|Burow's Triangle Advancement Flap Procedure|Pilonidal sinus surgery will be performed with the Burow's Triangle Advancement Flap procedure.
223645741|NCT06367140|DEVICE|EMG-triggered CIMCT device|The study tested an EMG-triggered CIMCT device for stroke rehab, involving EMG sensors, a stationary bike, and a control unit displaying muscle activity. The protocol included warm-up, therapist-guided exercises, and cool-down, performed under supervision.
223645742|NCT06367140|DEVICE|general cycling training|The training aimed to improve overall physical fitness and potentially aid in stroke recovery through regular cycling activity, conducted under supervision to ensure participant safety and adherence to the protocol.
223765982|NCT07085624|BIOLOGICAL|plasma ceftazidime dosage|"plasma ceftazidime dosage kinetics will be performed according to an optimal D- sampling plan (4 measurements per subject: T0+5min, T0+3h, T0+6h, T0+24h, PFIM software).~T0 corresponds to the time to administer the ceftazidime loading dose."
223765983|NCT07085286|DEVICE|Continous IAP measurement|Continuous IAP measurement via existing Foley bladder catheter - allowing continuous APP, MPP and RPP calculation
224231920|NCT05367388|DRUG|APL-101|"APL-101 (Vebreltinib) is an orally available small molecule, which is a tyrosine kinase inhibitor (TKI) for the mesenchymal epithelial transition protein tyrosine kinase receptor (c-Met) with high selectivity and potency.~The treatments to be administered in this study include:~• Treatment A (reference): Two 100 mg APL-101 (Vebreltinib) capsules (200 mg dose), manufactured for Apollomics, Inc."
224231921|NCT05367388|DRUG|PLB-1001|"PLB-1001 (Bozitinib) is a chemical drug category 1.1 innovative drug. It is a highly effective and highly selective c-Met tyrosine kinase inhibitor.~The treatments to be administered in this study include:~• Treatment P (test): Two 100 mg PLB-1001 (Bozitinib) capsules (200 mg dose), manufactured for Beijing Pearl Biotechnology Co., Ltd."
224231922|NCT05064462|OTHER|Collection of EDTA blood sample (5 to 7 ml)|"For all the patients included in the study, the samples to measure the viral load will be taken during the transplantation, then at each of the consultations planned as part of the usual care during the first year post-transplant (at minimum once and maximum twice a month).~These samples will be taken at the same time as those taken as part of standard care."
224231923|NCT04629404|DRUG|LY03003|Firstly, intramuscularly inject 14 mg of the study drug once, continue intramuscularly inject 28 mg of the study drug once after being observed for 1 week to confirm safety, continue intramuscularly inject 42 mg of the study drug once after being observed for 1 week to confirm safety, and prepare to enter the maintenance period of 56 mg dose after being observed for 1 week to confirm safety. During the dose maintenance period, 56 mg of the test drug was intramuscularly injected once a week for a total of 4 consecutive doses.
224231924|NCT04629404|DRUG|Placebo|Firstly, intramuscularly inject 14 mg of the study drug once, continue intramuscularly inject 28 mg of the study drug once after being observed for 1 week to confirm safety, continue intramuscularly inject 42 mg of the study drug once after being observed for 1 week to confirm safety, and prepare to enter the maintenance period of 56 mg dose after being observed for 1 week to confirm safety. During the dose maintenance period, 56 mg of the test drug was intramuscularly injected once a week for a total of 4 consecutive doses.
224231925|NCT03343522|BEHAVIORAL|Exercise|A multimodal exercise training program (aerobic, strength and flexibility exercises) for 6 months (60-min sessions performed 3 times/week with moderate intensity).
224231926|NCT04119349|BEHAVIORAL|Extra counseling|Participants will be given an extra 15-minute prenatal counseling before their first-trimester scan. The extra counseling, which is the intervention in the experimental group, consists of an explanation of all screening techniques for chromosomal abnormalities, including the first trimester combined test, cfDNA testing, invasive testing, and no screening at all.
224231927|NCT06543264|DEVICE|Cryotherapy|Cryotherapy is a pain treatment that uses a method of localized freezing temperatures to deaden an irritated nerve. Cryotherapy is also used as a method of treating localized areas of some cancers (called cryosurgery), such as prostate cancer and to treat abnormal skin cells by dermatologists
224319870|NCT00753662|DEVICE|1Hz TMS with H2 coil|1Hz TMS with H2 coil to prefrontal and parieto-temporal cortex
224319871|NCT00753662|DEVICE|10Hz TMS with H2 coil to prefrontal and parieto-temporal cortex|10Hz TMS with H2 coil to prefrontal and parieto-temporal cortex
223645743|NCT02424877|PROCEDURE|SandRA|SandRA software sends SMS messages to a patient asking questions about the usage and adverse effects of prescribed drugs and about the severity of rheumatoid arthritis. The answer messages are interpreted automatically.
223645744|NCT06317740|OTHER|green management intervention program|The program activities focused on integrating green management concepts into both theory and practice learning
223645745|NCT02386540|BEHAVIORAL|Health Coaching|The Alameda County Health Coach program pairs patients with a language-concordant health coach for six months following an ED visit. Health coaches are young adults from the local community employed through Alameda County and trained for three months in topics such as self-management support and motivational interviewing. Health coaches work one-on-one with participants in order to develop an action plan in order to achieve patient-identified health goals. Communication between the health coach and participant includes text messages (weekly), phone calls (twice a month), face-to-face visits (at least once), and accompaniment to a primary care visit (at least once). Health coaches may also assist participants in accessing community resources as related to the individualized action plan.
223645746|NCT02847052|OTHER|Non interventional study|
223645747|NCT01915589|DRUG|Refametinib (BAY86-9766)|All patients who meet the entry criteria will receive refametinib 50 mg (2x20 mg + 1x10 mg capsules or 50 mg tablet) bid.
223645748|NCT00070967|PROCEDURE|Acupuncture|
223645749|NCT01059435|DRUG|Romosozumab|Administered subcutaneously or intravenously
223645750|NCT01059435|DRUG|Placebo|Administered subcutaneously or intravenously
223645751|NCT01443052|OTHER|Gait analysis|walking on an electronic walkway GAITRite® at self-selected speed
223645752|NCT03228225|BEHAVIORAL|Tele Cardiac Rehabilitation|Comprehensive intervention according to the secondary prevention goals
223645753|NCT02660372|DRUG|Imonogas|Simethicone 120 mg in gel capsules
223645754|NCT02660372|DRUG|Espumisan|Simethicone 40 mg in gel capsules
223765984|NCT06923046|OTHER|Standard of Care|Multidisciplinary team based care every 3 months.
223645755|NCT03677557|DRUG|16,5% Cutaquig|Participants with primary or secondary immunodefiiciney disease and who do not tolerate other immunoglobulin treatments will be asked to use 16.5% Cutaquig
223765985|NCT06923046|BEHAVIORAL|Shared Medical Appointments|Participants will attend 4 quarterly appointments. In additionto time with their clinician, they will also have groupactivities that address relevant topics.
223645756|NCT05369741|OTHER|TIME™ at Home|"Components of each 1.5-hour session:~1. Pre-class social time (15 min): Unstructured - introductions, safety, and technology troubleshoot, and social interactions if time allows~2. Exercise video (1 hour pre-recorded): a) 10-minute seated warm up; b) 40-minute functional exercises in standing, with standardized progressions and variations. Exercises are selected from the original, in-person TIME™ program and are deemed safe to perform at home by rehabilitation experts; and c) 10-minute seated cool down~3. Post-class social time (15 min): Structured and unstructured social interactions~4. Facilitators: A live virtual facilitator assisted by a co-facilitator to stream video, provide verbal encouragement and technology support~5. Healthcare partner e-visits: A registered healthcare professional will make 2-3 e-visits. They will observe the class and engage with participants during the post-class social time and debrief with facilitators."
223645757|NCT04926389|OTHER|low-level laser therapy applied on days 0, 3,7,14 & every 2 weeks|one side of the maxillary arch will randomly receive LLLT on days 0, 3, 7, 14, and every 2 weeks thereafter and the contralateral side will serve as the controls.
223645758|NCT04926389|OTHER|low-level laser therapy applied every 3 weeks|one side will also be randomly chosen to receive LLLT every 3 weeks and the contralateral side will serve as the controls.
223645759|NCT04550884|DIAGNOSTIC_TEST|neuromascular ultrasound|neuromascular ultrasound of foot and ankle
223645760|NCT01263197|DRUG|LY2216684|administered orally
224231928|NCT04583579|DEVICE|DMV inserter (DMV® MagicTouch™) with an open end|This is a device used to help apply scleral lenses.
224231929|NCT04583579|DEVICE|DMV inserter (DMV® MagicTouch™) with a closed end|This is a device used to help apply scleral lenses.
224231930|NCT04583579|DEVICE|Three fingers (Patient's Hand)|This is a device used to help apply scleral lenses.
223765986|NCT07078812|BEHAVIORAL|Mirror Therapy|Mirror Therapy involves placing a mirror in the patient's midsagittal plane to reflect movements of the unaffected upper limb, creating a visual illusion of movement in the paretic limb. Patients perform bilateral symmetrical movements while focusing on the mirror reflection, helping to stimulate motor cortex activation and promote neuroplasticity. Sessions last 30 minutes, 5 days per week, for 6 weeks. This intervention is delivered in addition to standard stroke rehabilitation.
224231931|NCT04583579|DEVICE|O-ring (Hardware Store Product)|This is a device used to help apply scleral lenses.
224231932|NCT04583579|DEVICE|Tea light candle (Generic Deparment Store Product) with DMV inserter (DMV® MagicTouch™)|This is a device used to help apply scleral lenses.
224231933|NCT00928837|DIETARY_SUPPLEMENT|Flavocoxid 500 mg|flavonoid mixture
224231934|NCT00928837|DRUG|Naproxen|non-steroidal anti-inflammatory drug
224231935|NCT00928837|OTHER|Placebo|Placebo
224231936|NCT00928837|OTHER|flavocoxid 250 mg|Medical food product
223645761|NCT01263197|DRUG|albuterol|administered orally
223645762|NCT01263197|DRUG|propranolol|administered orally
223645763|NCT01263197|DRUG|placebo for LY2216684|administered orally
223645764|NCT01263197|DRUG|placebo for albuterol|administered orally
223645765|NCT01263197|DRUG|placebo for propranolol|administered orally
223645766|NCT06170294|DRUG|TCR-MAGE-A4 T-Cells|"* Preconditioning with fludarabine, cyclophosphamide, based chemotherapy regimen at sub-clinical doses~* MAGE-A4-directed T cell receptor-engineered T Cells"
223645767|NCT03524976|DEVICE|Squid|"SQUID™ is injected into the vascular site to be treated, under fluoroscopic control. DMSO dissipates in the blood and causes precipitation of EVOH in which the tantalum powder is trapped. It then forms a consistent spongy embolus.~This embolus solidifies from the outside inwardly while moving distally in the vessel. The non-adhesive character of the embolus allows slow and controlled injections while leaving in place the microcatheter."
223645768|NCT03319147|DIETARY_SUPPLEMENT|Active|4g of essential amino acids
223645769|NCT03319147|DIETARY_SUPPLEMENT|Placebo|4g of maltdextrin
223645770|NCT02476461|DRUG|xiapex|
223645771|NCT02476461|PROCEDURE|percutaneous needle fasciotomy|
223645772|NCT02542319|DIETARY_SUPPLEMENT|Mablet 360 mg|
223645773|NCT02542319|DIETARY_SUPPLEMENT|Placebo|
223645774|NCT05104177|PROCEDURE|conservative tecchniques in management of PAS|"Meticulous complete dissection of the urinary bladder from the lower uterine segment.~* Transverse uterine incision above the visible vascular bulge if visible in cases with anterior PAS, otherwise a transverse lower uterine segment incision is performed in the same site of previous CS scar.~* Delivery of the baby, clamping of the cord and administration IV 10 IU oxytocin.~* Bilateral uterine artery ligation at one or two levels below the lowermost part of the placenta.~* Removal of the separable part of the placenta from above downwards, until the adherent part is encountered.~* A decision is taken to either resect a wedge of the myometrium above the adherent placenta (in case the adherent area is small and anterior), or removing all the adherent placenta then inserting a rubber or plastic catheter inside the cervical canal then identifying and closing the placental pouch. Care is given to rapidly perform this step to decrease the blood loss after removing the placenta"
223645775|NCT04306341|BEHAVIORAL|real time fMRI neurofeedback|Participants will use real time feedback about their amygdala activity to learn to decrease amygdala activity.
223645776|NCT03903588|DEVICE|Optical Coherence Tomography|Imaging of the Retina
223645777|NCT02892448|OTHER|Cardiac magnetic resonance imaging (CMR)|Cardiac MRI is used to assess cardiac function in patients at risk of cardiotoxicity. In addition, Cardiac MRI enables imaging of inflammation, and fibrosis in the heart which may provide more specific information about the mechanism of injury in patients with high ion blood levels. Patients in all three groups (Unilateral hip resurfacing, bilateral hip resurfacing, and non-metal on metal total hip arthroplasty) will undergo a Cardiac MRI.
223645778|NCT02350140|OTHER|Text messaging from beginning|"Registered women will then receive up to 14 text messages as follows: weeks 28, 30, 32, 34, 36, 38, 39, and 40 during the third trimester of pregnancy; weeks 1, 2, 3, 4, 5, and 6 after delivery.Participants at facilities receiving TextIT will have the option to call or send text messages to a designated clinic phone, to which a clinic nurse will respond. Participants will also have an option to request a call from the clinic by sending a free call back text message to the designated clinic phone at any time."
223645779|NCT02350140|OTHER|Text messaging after 6 months of control|After six months of standard care, women at control clinics will be registered to receive the text messaging intervention with up to 14 text messages as follows: weeks 28, 30, 32, 34, 36, 38, 39, and 40 during the third trimester of pregnancy; weeks 1, 2, 3, 4, 5, and 6 after delivery.
223645780|NCT03143062|DIAGNOSTIC_TEST|NEWS|NEWS
223765987|NCT07078812|BEHAVIORAL|Action Observation Therapy|Action Observation Therapy consists of observing video demonstrations of functional upper limb movements, followed by the patient imitating the observed actions. Each session includes 15 minutes of watching goal-directed tasks and 15 minutes of active execution. This therapy aims to activate the mirror neuron system and enhance motor recovery. The protocol is administered 5 days per week for 6 weeks and is combined with routine stroke rehabilitation practices.
224319872|NCT00753662|DEVICE|SHAM TMS with H2 coil|SHAM TMS with H2 coil to prefrontal and parieto-temporal cortex
224231937|NCT00278200|BIOLOGICAL|Inactivated EBV-infected vaccine|
224319873|NCT05449860|PROCEDURE|Radiofrequency ablation using combined bipolar and monopolar energy deliver with Twin Cooled-Wet electrodes|Radiofrequency ablation will be performed by using twin cooled-wet electrodes. Two electrodes will be places on the tumor under ultrasonography (US)-computed tomography (CT)/magnetic resonance (MR) fusion tool guidance. The electrodes will be cooled with saline, and radiofrequency (RF, bipolar mode and switching monopolar mode) will be applied to two electrodes at the same time for about 6 to 30 minutes depending on the tumor size. The temperature will be maintained at 90-100 °C. The RF energy will be delivered by using the 200 watts single generator.
224319874|NCT00877162|BEHAVIORAL|Controlled crying and routines|Behavioural (teaching and support)
223645781|NCT00499083|BIOLOGICAL|therapeutic autologous dendritic cells|injected into the primary breast mass or palpable axillary node, one week after the first, second and third T treatments. If, after a cycle(s) of chemotherapy, no tumor can be localized by ultrasound, the DCs will be injected where the tumor bed was localized by the clip or marker.
223645782|NCT00499083|DRUG|aromatase inhibition therapy|Adjuvant hormone therapy for patients having tumors with estrogen and/or progesterone receptors. Premenopausal patients will be treated with tamoxifen. Post or perimenopausal women may receive tamoxifen or an aromatase inhibitor (AI) or those drugs in sequence as determined by the treating oncologist. Hormone therapy will be given for at least 5 years.
223645783|NCT00499083|DRUG|cyclophosphamide|600 mg/m2 IV day 1 every 2 weeks for 4 cycles
223645784|NCT00499083|DRUG|doxorubicin hydrochloride|60 mg/m2 IV day 1 every 2 weeks for 4 cycles
223645785|NCT00499083|DRUG|paclitaxel|175 mg/m2 intravenously (IV) over at least 3 hours day 1 every 2 weeks for 4 cycles.
223645786|NCT00499083|DRUG|tamoxifen citrate|Adjuvant hormone therapy for patients having tumors with estrogen and/or progesterone receptors. Premenopausal patients will be treated with tamoxifen. Post or perimenopausal women may receive tamoxifen or an aromatase inhibitor (AI) or those drugs in sequence as determined by the treating oncologist. Hormone therapy will be given for at least 5 years.
223645787|NCT00499083|GENETIC|gene expression analysis|IHC for CEA and Survivin with appropriate controls will be done on the tumor biopsy material (preferably from the initial diagnostic biopsy).
223645788|NCT00499083|GENETIC|protein expression analysis|Tumor biopsymaterial (preferably from the initial diagnostic biopsy) will be stained by IHC with appropriate controls for COX-2, VEGF A, T cell and Dendritic Cell infiltration.
223645789|NCT00499083|GENETIC|reverse transcriptase-polymerase chain reaction|delta Ct (quantitative real time- reverse transcription-polymerase chain reaction (qRT-PCR)) of COX-2 and VEGF will be divided into the upper or lower median and Fisher Exact test used to assess the difference in response.
223645790|NCT00499083|OTHER|immunoenzyme technique|"Estrogen and progesterone receptor, Her2/neu testing: Tumor biopsy material (preferably the initial diagnostic biopsy if tissue is available) will be examined by Immunohistochemistry (IHC) with appropriate controls for estrogen, progesterone receptors and Her2/neu. If the IHC is 2+ or in the indeterminate range, further testing of over-expression of Her2/neu by fluorescent in situ hybridization (FISH) will be done . If this has already been done and reported by the referring hospital, it will not be repeated. These tests are standard of care.~CEA and Survivin testing: IHC for CEA and Survivin with appropriate controls will be done on the tumor biopsy material (preferably from the initial diagnostic biopsy).~COX-2 and VEGF A , T cell and Dendritic Cells: Tumor biopsymaterial (preferably from the initial diagnostic biopsy) will be stained by IHC with appropriate controls for COX-2, VEGF A, T cell and Dendritic Cell infiltration."
223765988|NCT07085598|DIETARY_SUPPLEMENT|Vitamin D|15 male epileptic patients with hypovitaminosis D will be enrolled. They will be supplemented with Vitamin D orally 50,000 IU/week for 8 weeks
223765989|NCT07087301|OTHER|subtherapeutic concentration risk group|The second model (for subtherapeutic concentration risk prediction) defined low concentration as trough \<10 mg/L and target as 10-20 mg/L to analyze predictors of target concentration attainment.
223765990|NCT07087301|DRUG|subtherapeutic concentration risk group|The second model (for subtherapeutic concentration risk prediction) defined low concentration as trough \<10 mg/L and target as 10-20 mg/L to analyze predictors of target concentration attainment.
223765991|NCT07085143|DRUG|Compound Ciwujia Granules|Take Compound Ciwujia Granules or placebo twice daily for 8 weeks; Continue concomitant SSRI medication therapy throughout the treatment period;
223765992|NCT07085143|DRUG|placebo|"1. Take placebo twice daily for 8 weeks;~2. Continue concomitant SSRI medication therapy throughout the treatment period;"
224231938|NCT03968471|BEHAVIORAL|Scoring tool in Chemotherapy-induced necrosis in Ewing sarcoma|"The aim of the present study is to evaluate which is the best scoring tool to determine the histological response to chemotherapy in localized Ewing sarcoma of bone.~The study will exam all the different systems to evaluate the histological necrosis after neo-adjuvant chemotherapy in all patients with localized Ewing sarcomas of bone surgically treated between 1982 and 2012."
224231939|NCT01142037|DIETARY_SUPPLEMENT|Cooked parsnips with parsley|Beginning on Day 9 participants will be given cooked parsnips with parsley at a dose of 2 grams total apiaceous vegetable/kilogram body weight for period 1, and 4 gram/kilogram body weight for period 2.
224319875|NCT06432374|BEHAVIORAL|WET|"The five weekly WET sessions were delivered online via Canvas. Five session modules were created, each containing writing instructions for the respective session and an assignment feature for participants to upload their narratives. All sessions included 30 minutes of writing. Following instructions, participants wrote about a specific work-related trauma event in detail and described the emotions and thoughts experienced during the event. While all sessions were self-paced, participants were advised to complete each subsequent session within one week. Participants had the option to self-administer sessions or participate in Zoom office hours for live writing sessions with a facilitator who had completed WET training providing the writing instructions."
224319876|NCT02349867|DRUG|Gemcitabine|Given IV
224319877|NCT02349867|DRUG|Sorafenib|Given PO
223645791|NCT00499083|OTHER|immunohistochemistry staining method|"Estrogen and progesterone receptor, Her2/neu testing: Tumor biopsy material (preferably the initial diagnostic biopsy if tissue is available) will be examined by Immunohistochemistry (IHC) with appropriate controls for estrogen, progesterone receptors and Her2/neu. If the IHC is 2+ or in the indeterminate range, further testing of over-expression of Her2/neu by fluorescent in situ hybridization (FISH) will be done . If this has already been done and reported by the referring hospital, it will not be repeated. These tests are standard of care.~CEA and Survivin testing: IHC for CEA and Survivin with appropriate controls will be done on the tumor biopsy material (preferably from the initial diagnostic biopsy).~COX-2 and VEGF A , T cell and Dendritic Cells: Tumor biopsymaterial (preferably from the initial diagnostic biopsy) will be stained by IHC with appropriate controls for COX-2, VEGF A, T cell and Dendritic Cell infiltration."
223645792|NCT00499083|OTHER|laboratory biomarker analysis|"Estrogen and progesterone receptor, Her2/neu testing: Tumor biopsy material (preferably the initial diagnostic biopsy if tissue is available) will be examined by Immunohistochemistry (IHC) with appropriate controls for estrogen, progesterone receptors and Her2/neu. If the IHC is 2+ or in the indeterminate range, further testing of over-expression of Her2/neu by fluorescent in situ hybridization (FISH) will be done . If this has already been done and reported by the referring hospital, it will not be repeated. These tests are standard of care.~CEA and Survivin testing: IHC for CEA and Survivin with appropriate controls will be done on the tumor biopsy material (preferably from the initial diagnostic biopsy).~COX-2 and VEGF A , T cell and Dendritic Cells: Tumor biopsymaterial (preferably from the initial diagnostic biopsy) will be stained by IHC with appropriate controls for COX-2, VEGF A, T cell and Dendritic Cell infiltration."
224231940|NCT00974493|DRUG|Antibiotics|"The trial protocol does not specify individual antibiotics, as the trial question is one of strategy (i.e. oral vs intravenous route) rather than individual antibiotics.~Within allocated strategy (i.e. oral or intravenous) antibiotics will be selected by a clinician with reference to the subject's clinical condition, microbiological data and local guidelines."
224231941|NCT01468051|BIOLOGICAL|four doses of Euvax B vaccine|40 μg (2 ml) four doses of Euvax B vaccine
223645793|NCT00499083|PROCEDURE|adjuvant therapy|Hormone manipulation Adjuvant hormone therapy for patients having tumors with estrogen and/or progesterone receptors. Premenopausal patients will be treated with tamoxifen. Post or perimenopausal women may receive tamoxifen or an aromatase inhibitor (AI) or those drugs in sequence as determined by the treating oncologist. Hormone therapy will be given for at least 5 years.
223645794|NCT00499083|PROCEDURE|biopsy|Two tumor biopsies will be performed. The first tumor biopsy will be performed before apheresis for diagnostic purposes, and again after completion of the first four chemotherapy treatments. Patients will undergo local anesthesia with lidocaine and 1% epinephrine followed by 1-2 core biopsies of the breast primary and/or palpable axillary node with a 14 gauge, 16 cm. Bard needle or other similar needle. The procedure may be done under ultrasound guidance. If a metal clip or marker has not been previously placed in the tumor, it will be placed before treatment.
223645795|NCT00499083|PROCEDURE|conventional surgery|Definitive breast surgery Surgery will occur two to four weeks after the last course of chemotherapy. Modified radical mastectomy or lumpectomy and standard axillary dissection could be performed and the specific procedure will be decided by the patient and physician team. If a sentinel node dissection was done prior to chemotherapy and was negative, no further node dissection is necessary. A standard node dissection will be necessary if no node assessment was done prior to chemotherapy or if the pre- chemotherapy sentinel node was positive.
223645796|NCT00499083|PROCEDURE|neoadjuvant therapy|Chemotherapy: Paclitaxel (T) 175 mg/m2 intravenously (IV) over at least 3 hours day 1. Repeat every 2 weeks for 4 cycles. IT DCs will be injected into the primary breast mass or palpable axillary node, one week after the first, second and third T treatments.
223645797|NCT00499083|RADIATION|radiation therapy|Radiation therapy Radiation is started two to four weeks after surgery for all patients receiving lumpectomy and those patients after mastectomy that the physician feels chest wall radiation is warranted (example: T3 or T4 breast lesion, four or more axillary nodes etc.). The exact doses and methods of administration will be determined by the treating radiation therapist, but should be standard breast radiotherapy and not partial breast or investigational methods.
223645798|NCT02731235|OTHER|High-intensity training|high intensity training 5 days a week for 12 weeks
223645799|NCT02731235|DRUG|prophylactic stroke medication|Usual care medication for stroke prophylaxis
223645800|NCT02731235|BEHAVIORAL|Recommendations for lifestyle changes|Advise on diet, alcohol, smoking and exercise
223645801|NCT06152393|DIAGNOSTIC_TEST|Measure of an antibody index for intrathecal synthesis of specific anti-Treponema pallidum IgG by ELISA.|"Paired CSF/serum samples from all patients were blind tested for anti-T. pallidum IgG with an ELISA containing recombinant T. pallidum proteins (Euroimmun).~The AI was calculated conforming to Reiber's method (PMID 11239944) and as previously described in Alberto et al. (PMID 35138118)."
224231942|NCT01468051|BIOLOGICAL|20 μg (1 ml) three doses of Euvax B vaccine|20 μg (1 ml) three doses of Euvax B vaccine (recombinant hepatitis B surface antigen adsorbed on aluminium hydroxide adjuvant- LG Chem, Korea)
224231943|NCT02505854|DIETARY_SUPPLEMENT|Probiotic|Hypocaloric diet associated with capsule containing 1billion UFC Bifidobacterium lactis and sache of maltodextrin
224231944|NCT02505854|DIETARY_SUPPLEMENT|Symbiotic|Hypocaloric diet associated with capsule containing 1billion UFC Bifidobacterium lactis and sache of fructooligosaccharide
224231945|NCT02505854|DIETARY_SUPPLEMENT|Placebo|Hypocaloric diet associated with capsule containing 50g of gelatin and sache of maltodextrin
224319878|NCT02349867|DRUG|Vorinostat|Given PO
224319879|NCT02349867|RADIATION|3-Dimensional Conformal Radiation Therapy|Undergo 3D CRT
224319880|NCT02349867|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
224319881|NCT02349867|OTHER|RosetteSep|Circulating tumor cells (CTCs) will be captured and analyzed, when detected. Pancreatic cancer has been a difficult tumor in which to detect CTCs (41). Utilization of techniques that do not require cell surface marker expression will be explored. Samples will either be analyzed by negative-selection techniques (RosetteSep). Peripheral blood samples will be collected at several time-points for CTC enumeration and to evaluate CD95 density.
224323486|NCT05018585|BIOLOGICAL|Placebo|Placebo for Diamyd, Alhydrogel® only
224323487|NCT03573947|DRUG|Nivolumab|360 mg intravenously every 3 weeks
224323488|NCT03573947|DRUG|Ipilimumab|1 mg/kg intravenously over 30 minutes
224323489|NCT03573947|DRUG|Paclitaxel|80 mg/m2 on days 1 and 8 of every 21-day treatment cycle
223645802|NCT01902095|DEVICE|Tooth powder|Each participant was handed over a sealed pack containing a teeth cleaning kit that included tooth powder (test) or toothpaste (control) and a new soft toothbrush along with written and verbal instructions of usage. They were advised to brush their teeth twice a day with the given dentifrices and tooth brush for two weeks.
223645803|NCT01902095|DEVICE|Tooth paste (control)|Active Comparator
223645804|NCT02094924|DRUG|GSK587323|Single dose of FDC tablet formulation to be taken orally.
223645805|NCT02094924|DRUG|FDC of candesartan cilexetil 16 mg and HCTZ 12.5mg|Single dose of FDC tablet formulation to be taken orally
223645806|NCT03860493|PROCEDURE|Perfusion evaluation with indocyanine green|"1\. At least 10 minutes before surgery, will receive a weight-scaled dose of indocyanine green by IV and the time of administration and any adverse reactions will be recorded. The Surgeon/researcher will visualize and record the images given by the KARL STORZ VITOM II ICG System and the IC-Flow camera.~3\. The surgery will proceed as planned pre-operatively. The surgeon will conduct the surgery under white light and will categorize initial visualization of the organs."
223645807|NCT00704119|DRUG|RhuDex®|"* Treatment A.1: 31.65 mg RhuDex® once N=12~* Treatment A.2: 63.33 mg RhuDex® once N=12~* Treatment A.3: 126.63 mg RhuDex® once N=12~* Treatment A.4: 253.26 mg RhuDex® once N=12~* Treatment B.1: 31.65 mg RhuDex® once N=12~* Treatment B.2: selected dose of RhuDex® once N=12~* Treatment C: selected dose of RhuDex® once N=12~* Treatment D: selected dose of RhuDex® twice daily for 6 days N=12"
223765993|NCT07085884|BEHAVIORAL|The Static-Dynamic Balance Training Combined with Reminiscence Therapy|The intervention group received a 12-week SDBT-RT program, conducted twice weekly: 40-minute reminiscence therapy plus 50-minute balance training in odd weeks, and 50-minute balance training alone in even week.
223765994|NCT07086950|DEVICE|Body Brain Trainer software|Patients will engage in cognitive and physical exercises with the training software Body Brain Training (BBT) for 4 consecutive weeks. Participants will be asked to complete 3 sessions per week for a length of \~1h per session.
223765995|NCT07086950|DEVICE|RehaCom software|Patients will engage in exercises with the cognitive training software RehaCom (Hasomed®), which is a proxy to the standard of care, for 4 consecutive weeks. Participants will be asked to complete 3 sessions per week for a length of \~1h per session.
223645808|NCT01877395|BIOLOGICAL|Purified Vero Rabies Vaccine (VRVg)|0.5 mL, Intramuscular
223765996|NCT07086755|DRUG|Vadadustat 900mg|Participants will receive 900mg vadadustat (as oral tablets) for 14 days or until the date of discharge, whichever comes first, at approximately the same time each day without regard for timing of meals.
223765997|NCT07086755|DRUG|Vadadustat 1200mg|Participants will receive 1200mg vadadustat (as oral tablets) for 14 days or until the date of discharge, whichever comes first, at approximately the same time each day without regard for timing of meals.
224231946|NCT00976664|DEVICE|Shoe orthotic|Shoe orthotics are devices worn in the shoe to modify the patient's stance and gait.
224231947|NCT00976664|DEVICE|Shoe Orthotic Wait Group|This group receives the custom-made shoe orthotics at week 6 of the 12 week treatment program rather than week 1.
224231948|NCT05945394|OTHER|No intervention|This is an obvertional study, and there is no intervention.
224231949|NCT04330248|DRUG|Erdafitinib|Participants will receive single oral dose of erdafitinib tablets on Day 1 in Period 1 and on Day 28 in Period 2.
224231950|NCT04330248|DRUG|Carbamazepine|Participants will receive an oral dose of carbamazepine tablets from Day 15 to 35 in Period 2.
224231951|NCT02174939|DRUG|Cilostazol|One tablet (100 mg) twice per day for 12 weeks
224231952|NCT02174939|DRUG|Dummy Placebo|One tablet twice per day for 12 weeks
224231953|NCT03651115|DIAGNOSTIC_TEST|therapeutic drug monitoring|To monitor the blood concentrations of gentamicin and vancomycin
224231954|NCT02062047|PROCEDURE|FMSRP|FMSRP in a maximum of 24 hours.
224231955|NCT02062047|DRUG|Chlorhexidine|Application and irrigation of chlorhexidine, rinsing chlorhexidine solution during 60 days
224231956|NCT02062047|PROCEDURE|PMSRP|Scaling and root planing in 4-6 sessions in a maximum of 2 weeks
224231957|NCT02062047|OTHER|Placebo|Application and irrigation of placebo, rinsing placebo solution during 60 days
224231958|NCT01190683|DRUG|Cholecalciferol|60,000 IU/week for ist eight weeks followed by 60,000 IU every 15 days for four months
224231959|NCT01190683|DRUG|Calcium Carbonate|two tablets of calcium carbonate daily containing 1 gm of elemental calcium for six months
224231960|NCT01190683|DRUG|cholecalciferol and calcium carbonate|60,000 IU of cholecalciferol for first eight weeks and then 60,000IU for next four months along with 1 gm of elemental calcium daily for six months
224231961|NCT01190683|OTHER|lactose placebo|similar number of granules and tablets as active group
224231962|NCT01190683|OTHER|lactose granules and tablets|one sachet every week for eight weeks followed by two sachets every month along with two lactose tablets daily
224231963|NCT00759447|DEVICE|Genesis and Gemini|3 dimensional breast mammography system
224319882|NCT02349867|OTHER|DEPfff|Circulating tumor cells (CTCs) will be captured and analyzed, when detected. Pancreatic cancer has been a difficult tumor in which to detect CTCs (41). Utilization of techniques that do not require cell surface marker expression will be explored. Samples will either be analyzed by with the ApoStream dielectrophoretic field-flow fractionation (DEPfff) enrichment device. Peripheral blood samples will be collected at several time-points for CTC enumeration and to evaluate CD95 density.
223645809|NCT01877395|BIOLOGICAL|Imovax® Rabies: inactivated rabies vaccine|1.0 mL, Intramuscular
223645810|NCT00686686|BIOLOGICAL|Infliximab|Intravenous infliximab 5 mg/kg given over a 2-hour period at Weeks 0, 2, and 6 and possibly at week 12.
223645811|NCT05419778|DEVICE|Osteogen plug®|A type I bovine Achilles tendon collagen with bioactive resorbable calcium apatite crystals (CCAC)
223645812|NCT05419778|DEVICE|MInerOss®|A cortico-cancellous bone chips mix with polytetrafluoroethylene (dPTFE)(Cytoplast) barrier membrane.
223645813|NCT03650283|OTHER|monitoring|The bispectral index (BIS) and skin conductance (SC) monitors will be connected when patient will be positioned on the operating table. A BIS value greater than 60 will be considered an indicator of light anaesthesia. The SC monitoring will be achieved using the MEDSTORM AS 2005 monitor. Number of fluctuations in mean skin conductance (NFSC) of \>0.1 s-1 in a period of 15 s might be counted as a significant change and indicates an increase in the sympathetic outflow. General anaesthesia will be performed and laryngeal mask will be inserted. Blood pressure, heart rate, BIS, SC, and PRST (pressure, rate, sweating, tears) score will be recorded.
223645814|NCT01012440|DEVICE|PEM Flex Solo II PET Scanner|Subjects will receive bilateral (both sides) breast and axillary PEM scans.
224231964|NCT00759447|DEVICE|Investigational 3D Mammography system|3 dimensional breast mammography system
224231965|NCT04584268|BEHAVIORAL|mindfulness|in person and smart phone application mindfulness practice
224231966|NCT04584268|OTHER|standard medical education|standard medical education / control
224319883|NCT02963233|PROCEDURE|Closed reduction and percutaneous pinning and immobilization|
223645815|NCT01012440|DEVICE|MRI scan|Subjects will receive bilateral (both sides) breast and axillary MRI scans.
223645816|NCT00206817|DEVICE|Triage CardioProfilER (Troponin I, Myoglobin, CK-MB, BNP)|
223645817|NCT06225713|DEVICE|focused power ultrasound mediated inferior perirenal adipose tissue modification|"This novel focused power ultrasound is an externally delivered, completely noninvasive focused therapeutic ultrasound device. It is capable of focusing the resulting ultrasound beam to a small cigar-shaped volume and monitoring the temperature of the target area, which leads to the rapid elevation of the peri-renal adipose tissue temperature and the destruction of target tissue eventually."
223645818|NCT06225713|DEVICE|sham-control group|Participants will receive the sham control therapy (including peri-renal fat ultrasonic measurement and localization, focused ultrasound treatment parameters setting), however, without initiating the focused ultrasound equipment.
223645819|NCT01278212|RADIATION|accelerated hypofractionated radiotherapy (AHF-RT)|30 Gy in 5 fractions once a week for 5 weeks, followed by optional boost of 10-16 Gy
223645820|NCT00515762|DEVICE|elasto-gel cap|scalp cooling cap
223645821|NCT06517589|OTHER|Process-based Cognitive Behavioral Therapy (PBT)|PBT (20 sessions), intervention planning based on the use of EMA data, feedback of dynamic network analysis and matching of interventions to central nodes of the network.
223645822|NCT06517589|OTHER|Cognitive Behavioral Therapy (CBT)|CBT (20 sessions), intervention planning as usual based on manual.
223645823|NCT01559857|DRUG|Pioglitazone|30mg once daily for 12 weeks
223645824|NCT01559857|DRUG|Sugar Pill|Placebo
223645825|NCT02912689|DEVICE|Neurally Adjusted Ventilator Assist|NAVA during Non-invasive ventilation
223645826|NCT02912689|DEVICE|Pressure support ventilation|PS during Non-invasive ventilation
223645827|NCT00742261|DRUG|GSK1363089|Two-part study to evlauate the relative bioavailability of GSK1363089 from a free base formulation (GSK1363089G) compared with the biophosphate salt formulation (GSK1363089A) (Part 1) and to assess the safety of the GSK1363089 biophosphate formulation when administered three times a week until disease progression (Part 2).
224319884|NCT02963233|PROCEDURE|Non-operative reduction and immobilization|
224319885|NCT04874805|OTHER|Measurement of oxygen saturation|Measurement of oxygen saturation by pulse oximetry once a day, at 6 a.m., for a minimum of 3 days, thanks to three pulse oximeters (1 measurement point per device/day), in parallel with a synchronous sampling, programmed as part of the usual care, of arterial gasometry.
224319886|NCT03782051|PROCEDURE|combined phacoemulsification and viscocanalostomy|phacoemulsification with viscocanalostomy
223645828|NCT05568303|BEHAVIORAL|CBT techniques|through CBT sessions , the participants apply problem solving process in managing their stressors . examining the role of cognitions, emotions, and behaviors to form cause and effect relationship of participants psychological distress
223645829|NCT00210743|DRUG|epoetin alfa|
223645830|NCT02900040|OTHER|kidney transplantation|
223645831|NCT00560001|BEHAVIORAL|MD.2 Medication Dispenser|For those subjects receiving an MD.2 Medication Dispenser, the machine organizes medications and provides verbal and auditory explicit reminders for individuals to take their medications. At the scheduled time, the patient gets a series of reminders. The patient is then expected to push a single button to dispense a pre-filled medication cup. An automatic record is kept of the subject's medication adherence. Interviewer-administered surveys of the Geriatric Depression Scale, SF-12 Health Status Inventory, self-reported medication compliance and recent hospitalizations and emergency room visits will be given. Caregivers will complete the Caregiver Burden Interview.
223645832|NCT00379691|DRUG|phenylephrine|
223645833|NCT03254758|BIOLOGICAL|Mesenchymal stem cell|"Phase1 The dose of AD-MSCs are escalated from low to mid and high step by step. Each administration is one time via intravenous infusion for one hour.~Phase2 The recommended dose of ADR-001 is administrated once a week 4 times. The administration route and time is same method with Phase 1."
223645834|NCT02222948|DRUG|Vatelizumab|"Pharmaceutical form: solution for infusion~Route of administration: intravenous"
223645835|NCT02222948|DRUG|Placebo (for Vatelizumab)|"Pharmaceutical form: solution for infusion~Route of administration: intravenous"
223645836|NCT02112071|BEHAVIORAL|Exercise|Blended supervised-home based walking program 3-4 times per week for at least 30 minutes.
223645837|NCT01760252|DRUG|Capecitabine, Oxaliplatin and Irinotecan (CAPOXIRI)|Neoadjuvant CAPOXIRI chemotherapy is an innovative strategy that builds on the advancement associated with FOLFIRINOX chemotherapy in patients with metastatic disease
223645838|NCT04029077|OTHER|NA: intervention is not part of the study|NA: it is not an interventional study
223645839|NCT00593190|DRUG|Gas SF6 (Sulfur Hexafluoride)|ONCE
224231967|NCT01167920|OTHER|Virtual Hypertension Clinic|In the VHC group, patients will be ask to regularly measure blood pressure with the Stabil-o-Graph so that these readings are transmitted to Virtual Hypertension Clinic. The data will be reviewed weekly and the patient will receive feedback and intervention if needed at every 2 week interval to achieve blood pressure goal. Once they reach goal, the feedback will be less intense and given at four week intervals until the end of the study.
224231968|NCT03407859|BIOLOGICAL|Sequential Treatment With different CART|Sequential Treatment With CD20/CD22/CD10-CART After CD19-CART Treatment in Relapsed/Refractory B-ALL
224231969|NCT01319656|BEHAVIORAL|Support, management, educational, counselling, follow-up|The project offers a range of activities (educational, counselling, follow-up) by several professionals. The varied range of services is spread out over six months and may include individual or group meetings with professionals. Informational documents and follow-up tools are provided to patients based on their condition, to facilitate the acquisition and maintenance of knowledge, self-management, and changes in risk behaviour.
224231970|NCT02105376|DEVICE|Trigeminal Nerve Stimulation (TNS)|Trigeminal Nerve Stimulation (TNS)
224231971|NCT00487344|PROCEDURE|Non-Personalized Meal Planning|
224231972|NCT00487344|PROCEDURE|Personalized Meal Planning and Dietetic Consultation|
223645840|NCT01724632|BEHAVIORAL|Lifestyle Counseling|Participants receive instructions for making healthy changes to their diet and physical activity habits.
223645841|NCT01254422|BIOLOGICAL|Live, attenuated, recombinant dengue serotypes 1, 2, 3, and 4 virus|0.5 mL (at 0, 6, and 12 months), Subcutaneous suspension
223645842|NCT01254422|BIOLOGICAL|Placebo: NaCl 0.9%|0.5 mL (at 0, 6, and 12 months), Subcutaneous suspension
223645843|NCT05242120|OTHER|Survey to access the impact of COVID 19 on anesthesia residency|This is a cross-sectional study using an online survey will be conducted on 75 anesthesia residents in Cairo University hospitals. Invitations were sent to residents' groups on WhatsApp. Study objectives were clearly explained at the beginning of the survey, and the participants were encouraged to roll out the survey to as many physicians as possible. This survey contains 62-question, divided into four main sections
223645844|NCT04986514|OTHER|Bio-banking without genetic analysis|For patients included in SCLERO-BIOBANK study, 2 blood samples will be collected at each SSc evaluation (usually once a year), in addition to the routine care blood collection.
223645845|NCT00450268|PROCEDURE|blood draw, skin shave biopsy|
223645846|NCT06090136|DRUG|TPN171H|5 mg TPN171H tablets，single dose,oral
223645847|NCT00643162|DRUG|Lexapro|5mg-10mg of lexapro, daily, for 9 weeks for all study participants.
223645848|NCT00643162|BEHAVIORAL|Light touch|Light touch twice a week, for 8 weeks
223645849|NCT00643162|BEHAVIORAL|Massage|Massage twice a week, for 8 weeks.
223645850|NCT03551561|DRUG|CSAAC|Skin preparation with 4% chlorhexidine-based soap for a period of 5 minutes, followed by a sterile and soaked with 70% alcohol compress. After removing the chlorhexidine-based soap excess, antisepsis was performed with alcoholic chlorhexidine and surgical drapes and gowns.
223645851|NCT03551561|DRUG|CSAC|Skin preparation with 4% chlorhexidine-based soap for a period of 5 minutes and the of a simple, dry and sterile compress to remove the excess. After removing the excess, antisepsis was performed with alcoholic chlorhexidine and surgical drapes and gowns.
223645852|NCT00046462|DRUG|Lantus (insulin glargine [rDNA origin] injection)|
223645853|NCT00046462|DRUG|Metformin|
223645854|NCT00046462|DRUG|Glyburide|
223645855|NCT00046462|DRUG|Thiazolidinedione|
223645856|NCT02347137|OTHER|step-reduction|reduce daily physical activity to less than 1500 steps per day
223645857|NCT02347137|OTHER|step-reduction plus resistance exercise|reduce physical activity to less than 1500 steps per day with thrice weekly low-load, high effort resistance exercise
223645858|NCT00483769|DRUG|Glargine|
223645859|NCT00382759|PROCEDURE|stem cell transplant|
223645860|NCT03798769|OTHER|Supportive Oncology Care at Home|"Entails the following:~1. patient-reported symptoms, vital sign, and weight monitoring with appropriate triggers to phone calls and home visits by Medically Home based on a clinician-derived algorithm;~2. scheduled nursing visits for intravenous (IV) hydration during the course of chemotherapy;~3. regular communication with oncology clinicians regarding care delivered at home to ensure continuity of care."
223645861|NCT02691507|DEVICE|EpiCeram Skin Barrier Emulsion|EpiCeram Skin Barrier Emulsion
223645862|NCT02691507|DRUG|Experimental Product 1% Colloidal Oatmeal Balm|Experimental Product 1% Colloidal Oatmeal Balm
223645863|NCT00541385|DRUG|pyronaridine artesunate|The strength of the granule formulation is 60:20 mg pyronaridine artesunate per sachet. Depending on their body weight, patients will receive between 1 to 3 pyronaridine artesunate sachets per day, for 3 consecutive days The actual dose-range covered by this regimen is 7.0:2.3 mg/kg to 13.3:4.4 mg/kg pyronaridine artesunate, which has shown to be effective and safe in the phase II studies conducted in children and adults.
223645864|NCT00541385|DRUG|arthemeter lumefantrine|The strength of the tablet is 20 mg artemether and 120 mg lumefantrine. Depending on their body weight, patients will receive either 1 or 2 crushed tablets twice a day (≥5 to \<15 = 1 tablet, 15 to \<25 kg = 2 tablets), for 3 consecutive days.
223765998|NCT07086755|DRUG|Placebo|Participants will matching placebo (as oral tablets) for 14 days or until the date of discharge, whichever comes first, at approximately the same time each day without regard for timing of meals.
223765999|NCT07085481|DRUG|room temperature Bupivacaine|bupivacaine will be on a sterile shelf in the operating room at 23°C. The empty syringes and needles will be also on the same shelf before their use.
223645865|NCT04717219|OTHER|Blood drawing|Blood will be drawn after inclusion of the participants.
223645866|NCT03468140|DRUG|Eculizumab|Eculizumab will be given at a dose of 1200mg diluted in 0.9% sodium chloride (NaCl) to 5mg/mL for a total volume of 240 mL administered by IV infusion over 25-45 minutes in the anhepatic-phase during the transplant procedure, and a second dose of 900mg diluted in 0.9% NaCl to 5mg/mL for a total volume of 180 mL administered by IV infusion over 25-45 minutes will be given 24 hours following the first dose.
223645867|NCT03468140|OTHER|No intervention|Historical control arm
223645868|NCT04288726|BIOLOGICAL|CD30.CAR-EBVST cells|The dose is based on the number of CD30.CAR-expressing cells. In our previous study the highest dose was 2 × 10\^8 cells/m2 and we did not reach an MTD. This will be administered as a single infusion of the full dose for each level, which was already shown to be safe in the first 3 patients treated at dose level 3. Since we have not observed any dose limiting toxicities at the current dose level (Dose Level 3 as of June 2022), we propose to include a new higher dose level (8 × 10\^8).There will be a gap of 4 weeks between the first and second patient, and between the second and the third patient, on each dose level.
223645869|NCT05126953|DEVICE|samfilcon A Lenses with EPG01 Packaging Solution|samfilcon A Lenses with EPG01 Packaging Solution
223645870|NCT05126953|DEVICE|Commercially Available B+L Ultra Lenses|Commercially Available B+L Ultra Lenses
223645871|NCT06346769|OTHER|Polyethylene Fiber|In the restoration of the endodontically treated posterior teeth, polyethylene fiber was placed in different directions ('O' shape, mesiodistal I shape, buccolingual I shape) according to the amount of remaining tooth tissue and cavity preparation.
223766000|NCT07085481|DRUG|warm Bupivacaine|bupivacaine will be warmed to 37◦C for 20 minutes. The empty syringes and needles, in their packaging, will be held at the same temperature for at least 2 hours before initiating the block.
223766001|NCT06773936|DRUG|Induction Phase|Asciminib, Dasatinib, Prednisone, and Methotrexate
223766002|NCT06773936|DRUG|Re-Induction Phase|Blinatumomab, Dasatinib, Methotrexate, and Dexamethasone
223766003|NCT06773936|DRUG|Post-Remission|Blinatumomab, Dasatinib, Methotrexate and Dexamethasone
223766004|NCT06773936|DRUG|Maintenance|Asciminib, Dasatinib, Prednisone, and Methotrexate
223645872|NCT03313622|BEHAVIORAL|Beads Task|Participants will be asked to make a series of decisions that involve combining information about the value and probability of potential rewards. Subjects will sit in front of a computer monitor and place their hand over a box with orange and blue button that they will be asked to press based on their idea of which one will be the majority in a jar full of orange and blue beads. This task should take 15-20 minutes to complete, not including EEG setup.
223645873|NCT03313622|BEHAVIORAL|PROVOC Tasks|Three tasks will be developed collaboratively with the participant and independent evaluator that involve the participant being exposed to triggers that are considered by him/her impossible to confront without ritualizing. There will also be a similar process involving objects that should not cause any distress to be used as a control. Sessions will be videotaped with AFAR system concurrent to recording of LFPs from VS and scalp EEG.
223645874|NCT06463249|BEHAVIORAL|CORE Helpline|All participants will receive the Core Helpline program (CORE) for 2 months, which includes written weight loss material, use of a smartphone app, weekly text messages and email reminders and 1 optional participant-initiated coaching call per month.
223645875|NCT06463249|BEHAVIORAL|Extended Helpline|Those who achieved 2% weight loss at 2-month, will continue to Extended Helpline, where the participants can continue receiving all CORE resources including1-on-1 coaching through 1 optional participant-initiated call per month for 6 months.
223645876|NCT06463249|BEHAVIORAL|Enhanced Helpline|Those who do not reach 2% weight loss at the end of 2 months will be randomized. Participants will continue to receive all CORE resources plus 1 optional participant-initiated call/month for 6 months. Additionally, the participants will receive 2 individualized coach-scripted feedback emails per month, and the option to receive daily text message reminders.
223645877|NCT06463249|BEHAVIORAL|Intensive Helpline|Those who do not reach 2% weight loss at the end of 2 months will be randomized. Participants will continue to receive all CORE resources plus 2 scheduled coaching calls/month for 6 months. Additionally, the participants will receive 2 individual coach-scripted feedback emails per month, and the option to receive daily text message reminders.
223645878|NCT06800092|DRUG|Sildenafil|Sildenafil, 50mg, daily
223645879|NCT04139798|DRUG|NOV03|100% Perfluorohexyloctane
223645880|NCT04139798|DRUG|Placebo|Saline solution (0.6% sodium chloride solution)
223645881|NCT06124807|DRUG|LY3305677|Administered SC
223645882|NCT06124807|DRUG|Placebo|Administered SC
223645883|NCT05286775|OTHER|Clinical treatment and Knee educational program|"Three weekly medical interventions, according to the patient's need as observed at baseline.~1. 3ml paraspinal infusion of 1% Lidocaine (segmental spinal level);~2. 5,000 impulses of Radial Shockwave Therapy (pneumatic generator, 0.16mJ/mm² of energy and 20Hz of frequency) at the most painful spot of the knees;~3. \*6,000 pulses of Focused Shockwave Therapy (electromagnetic generator) at four sites of the painful knee.~   For those with knee pain of 7 or above in Visual Analogue Scale after the treatments above, the interventions below will be delivered in the order they appear:~4. Ultrasound guided genicular nerve block: infusion of up to 10ml 0.50% Levobupivacaine without vasoconstrictor;~5. Hydrodissection of superficial and deep plane nerves: infusion of 10ml 5% dextrose diluted in water (D5W);~6. Intra-articular Infusion of Hyaluronic Acid: ultrasound guided infusion of 2.5ml of sodium hyaluronate at the knee joint.~   * Four weekly applications."
223645884|NCT05286775|OTHER|Knee educational program|"Three weekly 60-minute educational program sessions with the following services:~Stretching and strengthening exercises for specific muscle groups (hip flexors, extensors, and abductors; knee flexors and extensors; plantar flexors; and abdominal muscles), using one's own body and gravity resistance. Patients will be encouraged to practice them at home at least twice a week after the end of the sessions.~Nutritional guidance: Instructions on the importance of adequate weight management, healthy food consumption, and the adequate intake of nutrients.~Physical activities: Counseling on home-based physical activities, according to their physical capacities, to protect knee joints.~General health: psychology counseling, encouraging participants to apply strategies and self help conduct to improve their general health; Occupational Therapy: Activities of Daily Living strategies to protect knee joints; Nursing: Counseling on strategies for improving healthy sleeping habits."
223766005|NCT05637775|OTHER|EEG-based BCI system for (hands) Motor Imagery training|For the purposes of this study we adapted an available BCI-supported motor imagery (MI) training station, equipped with a computer, a commercial wireless Electroencephalography (EEG)/ Electromyography (EMG) system, a screen for therapist feedback and a screen for the real-time ecological feedback to patient - a custom software program that provides a for (personalized) visual representation of the patient's own hands. This software allows the therapists to create an artificial reproduction of patient's hands/forearms by adjusting a digitally created image in shape, size, skin colour and orientation to match as much as possible the real patient hands/forearms. Training consists of the MI tasks of both hands, grasping or finger extension in separate runs. The trial length will include a constant baseline period of 4 sec and a task period of maximally 10 sec for BCI intervention group. Each training session will consist of 4 runs (20 trials each).
224231973|NCT05210023|OTHER|NUTRIGENETIC DIET INTERVENTION|"Weekly, personalized meal plans (menus) will be provided, prepared based on the anthropometric needs of the patients, with a caloric reduction (-500 kcal). These weekly menus (Sunday to Monday) consist of 5 meal times (breakfast, snack, lunch, snack and dinner). The distribution of the macronutrients: carbohydrates, proteins and fats, as well as the percentages of polyunsaturated, monounsaturated and saturated fatty acids, will be established according to certain nutrigenetic recommendations identified in the reference bibliography.~Participants included in this group will receive remote (virtual) nutritional counseling every 15 days."
224319887|NCT03782051|PROCEDURE|combined phacoemulsification and viscocanalostomy and ologen|phacoemulsification with viscocanalostomy with ologen
224319888|NCT02217254|PROCEDURE|Atrial fibrillation catheter ablation using the Medtronic Arctic Front Ablation System|
224319889|NCT04246827|BEHAVIORAL|Enhanced Lifestyle Weight Management|The Enhanced Lifestyle Weight Management program was a 12-week protocol in which training in coping skills to increase self-efficacy and decrease the impact of RA pain on behavioral (e.g., activity, eating) and psychosocial (e.g., mood, relationships) weight loss factors were integrated into a lifestyle behavioral weight loss intervention.
224319890|NCT04011163|DEVICE|VPIA pump|The pump is a specially designed and manufactured infusion syringe pump for intravenous analgesia. It incorporates the VPIA study regimen to meet the specific requirements of the clinical trial. It is intended to be used only for delivering drugs intravenously.
224323490|NCT06213818|DRUG|INCB160058|Oral; Immediate release solid tablet
223766006|NCT05637775|OTHER|Control - MI intervention|Training consists of MI tasks of both hands, grasping or finger extension in separate runs. MI training will be delivered with a dose/setting regimen equivalent to EXP intervention. The trial length will include a constant baseline period of 4 sec and a task period of maximally 4 sec. Each training session will consist of 4 runs (20 trials each).
223766007|NCT07085195|GENETIC|gene therapy|Six participants are planned to be divided into three dose groups in the dose escalation principle. The dose escalation principle is as follows: After the first sentinel subject receives 1×10¹² vg virus vectors, the research team will evaluate the safety, tolerability, and efficacy of the current drug dose after 4 weeks. If this sentinel does not experience dose-limiting toxicity, another sentinel subject will receive a 2×10¹² vg dose; if this sentinel develops dose-limiting toxicity (DLT), this dose will be defined as an intolerable dose, and the Data Review Committee will determine whether to select a lower dose for exploration or terminate dose escalation based on the existing data. If this sentinel subject doesn't experience dose-limiting toxicity, another participant will receive a 4×10¹² vg dose as a new sentinel subject. If this sentinel subject doesn't experience DLT, all of the next three subjects will receive a 4×10¹² vg dose.
223766008|NCT07085195|DRUG|clozapine|Clozapine ramp-up will be performed four weeks after neurosurgery, when the participants have recovered, and the participants will be treated orally with clozapine. Clozapine is 25mg per tablet, and the oral dose is 1/32, 1/16, and 1/8 tablet twice a day, in the morning and at noon, respectively, with each dose repeated for 3 days for a total of 9 days. If no DLT develops during this time, the participants will continue to take 1/8 pill orally twice a day as a maintenance dose, and they will be monitored for 12 months.
223766009|NCT07086924|DRUG|Methotrexate|Assessing the response of psoriasis and psoriatic arthritis to Methotrexate. and also Assessing the pharmacogenetic association between TRAF3IP2 ( rs13190932 ) gene Polymorphism in psoriatic and psoriatic arthritis patients taking Methotrexate.
224231974|NCT05210023|OTHER|CONVENTIONAL DIET INTERVENTION|"Weekly, personalized meal plans (menus) will be provided, prepared based on the anthropometric needs of the patients, with a caloric reduction (-500 kcal). These weekly menus (Sunday to Monday) consist of 5 meal times (breakfast, snack, lunch, snack and dinner). The distribution of the macronutrients: carbohydrates, proteins and fats, as well as the percentages of polyunsaturated, monounsaturated and saturated fatty acids, will be in accordance with the recommendations made by the WHO (World Health Organization), the AHA (American heart association) and the NOM (Official Mexican Standards) for the treatment of obesity and dyslipidemias.~Participants included in this group will receive remote (virtual) nutritional counseling every 15 days."
224231975|NCT06041464|OTHER|cell culture|isolation of cell culture
224231976|NCT00133770|DRUG|pantoprazole|The continuous IV pantoprazole compared to the once a day IV pantoprazole for 72 hours in the treatment of severe erosive esophagitis
224231977|NCT04100499|DEVICE|ESAR (Endosutured Aneurysm Repair)|EndoAnchors adjunctive therapy for EVAR and TEVAR
224231978|NCT06036758|DIAGNOSTIC_TEST|VIDAS® NEPHROCLEAR™ CCL14 Test|Urine samples previously collected from persons with stage 2/stage 3 AKI will be tested using the VIDAS® NEPHROCLEAR™ CCL14 Test
224231979|NCT03085446|BEHAVIORAL|PDM nutritional intervention|personalized, diet-induced alterations in microbiota (PDM) for six months. (1) A 14-day running-in, no-treatment baseline assessment of all outcomes (T0); (2) A 6-month intervention period, with repeated assessments of all outcomes during the last two weeks of months 3 (T1) and 6 (T2). (3) A 12 month follow up (T3).
224231980|NCT03085446|BEHAVIORAL|General information on nutrition and health|General information on nutrition and health for six months: (1) A 14-day running-in, no-treatment baseline assessment of all outcomes (T0); (2) A 6-month intervention period, with repeated assessments of all outcomes during the last two weeks of months 3 (T1) and 6 (T2). (3) A 12 month follow up (T3),
224231981|NCT03513393|DRUG|velpatasvir|Test 1
224231982|NCT03513393|DRUG|velpatasvir|Test 2
224323491|NCT06213818|DRUG|Placebo|Oral; Tablet
223645885|NCT06292078|BEHAVIORAL|Instructional Skill-Building Learning Approach (ISLA)|The Inclusive Skill-building Learning Approach (ISLA) is a school-wide, multi-component, instructional and restorative alternative to exclusionary discipline that begins with universal prevention grounded in positive, preventative classroom strategies for all students, and layers on additional supports for students in need.
223645886|NCT06193356|OTHER|Learning tool|Video based learning tool about detection of endoscopic resection scars and recurrence.
223645887|NCT06422819|OTHER|Heart rate variability Biofeedback [HRV-BFB]|"Biofeedback (BFB), sometimes referred to as biological feedback technique, is a non-invasive and non-pharmacological approach based on physiological recordings that provide real-time feedback enabling people to learn how to control their physiological processes, which are typically unconscious and beyond their control. HRV-BFB specifically targets heart rate variability (HRV), which can help regulate the autonomic nervous system (including vagal tone and sympathetic-parasympathetic balance) as well as emotional states. HRV-BFB has been clinically and experimentally validated as a physiological intervention and has demonstrated its effectiveness. However, it has never been studied in an adult FND population."
224231983|NCT03513393|DRUG|velpatasvir|Reference
224231984|NCT04592354|DIETARY_SUPPLEMENT|Oxaloacetate Medical Food/Dietary Supplement|500 mg Anhydrous Enol-Oxaloacetate BID
223645888|NCT06422819|OTHER|Pseudo HRV-BFB|The pseudo HRV-BFB intervention aims to implement the same HRV BFB methods with no specific effect on HRV.
223645889|NCT03841279|DIAGNOSTIC_TEST|MRI|Magnetic resonance imaging (MRI) produces detailed images of the body's internal structures without relying on radiation. It is used to diagnose and also gauge efficacy of treatment.
223645890|NCT05107336|DRUG|AZD2693|Participants will receive subcutaneous injection of AZD2693, once per month.
223645891|NCT05107336|DRUG|Placebo|Participants will receive subcutaneous injection of placebo (volume matching to AZD2693 injection \[0.9% saline solution\]), once per month.
223645892|NCT03844399|DEVICE|Ablation|The medical device will passively record image data during the standard care ablation
223645893|NCT03844399|DEVICE|Biopsy|The medical device will passively record image data during the standard care biopsy
223645894|NCT04072900|DRUG|Peptide|4 x 3 mg all the peptides given on days 84，87，91，98，105，133，and 161
223645895|NCT04072900|DRUG|Anti-PD-1|3mg/kg, ivgtt, Q2w
224231985|NCT02512354|OTHER|Sample of a fragment of fetal tissue|
224231986|NCT02512354|OTHER|Parent's blood samples|
224323492|NCT06213818|DRUG|Esomeprazole|Oral; Delayed-release capsule or tablet
224231987|NCT02616692|DRUG|Hepatocellular Cancer (HCC) treatments including oral anti-cancer therapy [Nexavar (Sorafenib, BAY43-9006)]|Oral anti-cancer therapy (Sorafenib, an multiple kinase inhibitor), repeated transarterial chemoembolization (TACE) procedures, and hepatic arterial infusion chemotherapy (HAIC)
224231988|NCT04963348|OTHER|convolutional neural networks (CNNs)|CNN architecture named U-Net architecture
224231989|NCT05063461|DEVICE|Tetanic stimulation|For each participant, record the first concentration that ANI≥50 after the tetanic stimuli, as the sufficient concentration.
224319891|NCT04011163|DRUG|Morphine|Intravenous medication used is morphine diluted in normal saline to a concentration of 1mg/ml. This is a standard dilution and are routine drugs used as standard of care.
224319892|NCT05185765|OTHER|Bread|Samples will be provided one by one labeled with an unique code. The mastication and expectorated sample will be given in replicate.
224319893|NCT03763006|PROCEDURE|Eyelid cleaning|This is a pure hypochlorous acid that kills many microbes, but remain very friendly and non-toxic for the ocular surface.
223645896|NCT04072900|DRUG|rhGM-CSF|3μg/kg given on Days 81，82，83，95，96，97，102，103，104，130，131，132，158，159，and 160
223645897|NCT04072900|DRUG|Imiquimod 5% Topical Cream|topical application on the injection site 6 hours before each NeoAntigen peptides injection
223645898|NCT02572908|OTHER|Sourdough wheat bread|
223645899|NCT02572908|OTHER|Regular yeast baked toast bread|
223645900|NCT02572908|OTHER|Gluten-free diet|Gluten-free diet excluding even oats and buckwheat. Rice, quinoa, corn and potato allowed as grains/pseudo-grains
223645901|NCT00120302|DRUG|Pimecrolimus|Pimecrolimus cream 1 %
223645902|NCT00120302|DRUG|Placebo|Matching vehicle cream
223645903|NCT00760032|DRUG|Ciprofloxacin|Ciprofloxacin oral, 500 mg capsules, one capsule per day during four weeks.
223645904|NCT00760032|DRUG|Placebo|Placebo capsules, one capsule per day during four weeks.
223645905|NCT01281514|DRUG|everolimus|Given PO
223645906|NCT01281514|DRUG|carboplatin|Given IV
223645907|NCT01281514|DRUG|pegylated liposomal doxorubicin hydrochloride|Given IV
223645908|NCT01281514|OTHER|laboratory biomarker analysis|Correlative studies
223645909|NCT03155841|BEHAVIORAL|Life Skills Coaching|The investigators designed the intervention to help participants increase their HIV risk awareness, promote self-appraisal and increase motivation for engaging in prevention services, problem solving barriers to accessing care, and locating culturally-sensitive providers. Intervention content is customized based on participants' socio-demographic characteristics and geographic location.
223645910|NCT03155841|BEHAVIORAL|Community Resources|The investigators will provide a resource locator as the attention-control condition. The resource locator provides a list of health (e.g., HIV testing) and social (e.g., support groups) resources across study regions.
223645911|NCT02353975|DRUG|SHR3824|SHR3824 tablet,10mg, fasting conditions and high fat, high calorie breakfast.
223645912|NCT04202601|DRUG|Sintilimab|"Arms 1: Neoadjuvant therapy group 20 patients Drug: Sintilimab Weight\<60Kg: 3mg/kg Q3W Weight\>=60Kg:200 mg Q3W on Day 1 by IV infusion; Intervention：Perioperative Sintilimab+IBI310 are administered for 1-3 (6-18 weeks) cycles followed by 4 postoperative cycles (12 weeks) with Sintilimab monotherapy .~Arms 2: first-line therapy group, 30 patients Drug: Sintilimab Weight\<60Kg: 3mg/kg Q3W Weight\>=60Kg:200 mg Q3W on Day 1 by IV infusion; Intervention：Sintilimab + IBI310 are administered for 1-3 (6-18 weeks) cycles followed by Sintilimab monotherapy for up to 2 years.~Arms 3: ≥second-line therapy group, 30 patients Drug: Sintilimab Weight\<60Kg: 3mg/kg Q3W Weight\>=60Kg:200 mg Q3W on Day 1 by IV infusion; Intervention：Sintilimab + IBI310 are administered for 1-3 (6-18 weeks) cycles followed by Sintilimab monotherapy for up to 2 years."
223645913|NCT04202601|DRUG|IBI310|"Arms 1: Neoadjuvant therapy group, 20 patients Drug: IBI310 1 mg/kg Q6W on Day 1 by IV infusion. Intervention：Perioperative Sintilimab+ IBI310 are administered for 1-3 (6-18 weeks) cycles followed by 4 postoperative cycles (12 weeks) with Sintilimab monotherapy .~Arms 2: first-line therapy group, 30 patients Drug: IBI310 1 mg/kg Q6W on Day 1 by IV infusion. Intervention：Sintilimab + IBI310 are administered for 1-3 (6-18 weeks) cycles followed by Sintilimab monotherapy for up to 2 years.~Arms 3: ≥second-line therapy group, 30 patients Drug: IBI310 1 mg/kg Q6W on Day 1 by IV infusion. Intervention：Sintilimab + IBI310 are administered for 1-3 (6-18 weeks) cycles followed by Sintilimab monotherapy for up to 2 years."
223645914|NCT01966016|PROCEDURE|Pacing|"In this study we intend to include patients that have indication to and are intended to undergo CRT implantation with an additional electrode on LV, that have inclusion criteria and have signed an informed consent.~In this study we will include 20 patients for each study arm (overall 100)- each patient will have both treatment configurations and these two will be compared"
223645915|NCT00281242|OTHER|blood draw|All subjects undergo blood draws at study visits and at the time of COPD exacerbation visits.
223645916|NCT05464342|BEHAVIORAL|Evening LGI Carbohydrate Consumption Group|Participants will receive in the evening food with low glycemic index
223645917|NCT05464342|BEHAVIORAL|Evening HGI Carbohydrate Consumption|Participants will receive in the evening food with high glycemic index
223645918|NCT05464342|BEHAVIORAL|Evening NO-CHO Carbohydrate Consumption|Participants will receive in the evening a meal with no carbohydrates at all.
224231990|NCT05063461|PROCEDURE|Skin incision|Infuse the sufficient concentration for at least 5min of the steady-state period, then surgical stimulus is applied. The surgical stimulus is defined as the first skin incision to establish pneumoperitoneum.
224231991|NCT01309009|DRUG|Nepadutant oral solution|Oral administration once daily for 7 days
224231992|NCT01309009|DRUG|Placebo matching Nepadutant oral solution|Oral administration once daily for 7 days
224231993|NCT01309009|DRUG|Nepadutant oral solution|Oral administration once daily for 7 days
224231994|NCT03519256|BIOLOGICAL|Nivolumab|Specified dose on specified days
224231995|NCT03519256|BIOLOGICAL|BCG|Specified dose on specified days
224231996|NCT03519256|DRUG|BMS-986205|Specified dose on specified days
224231997|NCT05431153|DRUG|Single dose of PF-07104091 as Tablet Formulation A (Treatment A)|A single dose of PF-07104091 as Tablet Formulation A administered under fasting conditions.
224231998|NCT05431153|DRUG|Single dose of PF-07104091 as Tablet Formulation B (Treatment B)|A single dose of PF-07104091 as Tablet Formulation B administered under fasting conditions.
224231999|NCT05431153|DRUG|Single dose of PF-07104091 as Tablet Formulation C (Treatment C)|A single dose of PF-07104091 as Tablet Formulation C administered under fasting conditions.
223766010|NCT07085936|BEHAVIORAL|Video-based orientation program|The intervention group will receive a structured video-based orientation program developed for first-degree relatives of psychiatric inpatients. The program consists of four sessions (each 45-60 minutes) delivered over one week by psychiatric nurses. Topics include an introduction to the psychiatric unit, understanding stigma, basic information on mental illnesses, and strategies for coping with stigma. Educational videos support learning and discussion. Unlike the control group, this intervention emphasizes stigma awareness and emotional support. Pre- and post-tests are used to assess perceived stress and stigma.
224232000|NCT05431153|DRUG|Single dose of PF-07104091 as Tablet Formulation D (Treatment D)|A single dose of PF-07104091 as Tablet Formulation D administered under fasting conditions.
224232001|NCT05431153|DRUG|Single dose of PF-07104091 as Tablet Formulation C (Treatment E)|A single dose of PF-07104091 as Tablet Formulation C administered under fed conditions.
224232002|NCT04828161|DRUG|ensovibep|IV on day 1 only.
224232003|NCT04828161|DRUG|Placebo|IV on day 1 only.
224232004|NCT05480397|OTHER|TENS, Distractive techniques, cryotherapy|"Group (1): Will receive (TENS , cryotherapy and conventional physical therapy ) Massage with ice was done by the researcher over the AVF puncture site . After that, the TENS electrodes will be applied by the researcher 6 centimeters apart closely up and down the skin area for insertion of the needle.~* Group (2): Will receive (Distraction techniques ,cryotherapy and conventional physical therapy ) Initially five minutes before starting hemodialysis, Distraction techniques will be applied. Natural and eye-catching images were broadcasted through a video display device on a laptop monitor in a manner that was easy for the older patient to watch while they were lying on the bed. Massage with ice was done by the researcher over the AVF puncture site~* Group (3): Will receive (cryotherapy and conventional physical therapy )"
224232005|NCT04488575|DRUG|EDP1815|EDP1815 is an orally administered monoclonal microbe
224232006|NCT04488575|DRUG|Placebo|Placebo oral capsule
224232007|NCT01224132|DRUG|probiotic ® pur|daily, four types of probiotic bacteria ( Bifidobacterium bifidity, Lactobacillus acidophilus, Lactobacillus casei and Lactobacillus salivarium) 2 bags (two billion bacteria) (probiotic ® pur) for a total of 8 (eight) weeks
224232008|NCT03250533|DEVICE|Light emitting diodes (LED)|The light-emitting diode (LED) device consists of a soft 15 x 15 cm blanket, which allows the body segment curvature of the cutaneous lesion to be monitored. The LEDs are fixed equidistant to obtain uniform irradiation over the entire ulcer. The wound site will be surrounded by a PVC film (polyvinyl chloride), to avoid contamination, for posterior positioning of the LED device, applying light directly and perpendicularly, with energy density of 6 J / cm². All LEDs will be calibrated prior to the start of applications in the Laboratory of Photobiophysics of the Faculty of Sciences and Letters of Ribeirão Preto, University of São Paulo, in which the wavelengths will be checked, the angle of radiation, power and power density.
224232009|NCT03250533|DEVICE|Fixed diphasic current|The electrical stimulation treatment will be performed with the fixed diphasic current of the Dualpex 071 equipment (Quark®, Piracicaba, SP, Brazil), with the monopolar technique, 100 Hz, maximum intensity of 1 mA / cm² of lesion for 10 minutes. Autoclave sterilized aluminum electrodes will be used, one on the lesion (negative pole) and the other transversal to the segment (positive pole). The size of the electrode will be proportional to the extension of the lesion, having as a means of contact between the electrode and the ulcer, sterile gauze moistened with 0.9% saline solution.
224232010|NCT06029036|DRUG|Darolutamide+ADT|"Drug: Darolutamide~Darolutamide 600 mg, (two 300 mg tablets) administered orally twice daily. Swallow tablets whole. Take Darolutamide with food.~Drug: ADT GnRH agonist per physicians' choice, orchiectomy is excluded"
224232011|NCT04194866|OTHER|receiving operation during the day or at night|120 patients scheduled for elective laparoscopic abdominal surgeries under general anesthesia were randomly assigned to receive operation in the Day Group (8:00-12:00) and in the Night Group (18:00-22:00)
224232012|NCT01274416|BEHAVIORAL|Acceptance and Commitment Therapy|The stated goal of this intervention is to increase willingness to experience difficult thoughts, feelings, and bodily sensations in order to engage in flexible action.
224232013|NCT01274416|BEHAVIORAL|Parent Skills Training|Skills Training for parents that provides psychoeducation for eating disorder and skills in behavior management, self-regulation, and emotion regulation.
224232014|NCT03386422|BEHAVIORAL|MSC|Mindfulness and Self-Compassion training
224232015|NCT03386422|BEHAVIORAL|CBT|Cognitive-behavioural techniques training
224232016|NCT01908127|BEHAVIORAL|tell- show- do|Children came in the operation room. Tell-Show-Do, prophylaxis with paste and rubber cap and fluoride therapy was performed by the dentist for each participant to increase their familiarity with dental procedures. The duration of the appointment was about 20 minutes and constant for all children.
224232017|NCT01908127|BEHAVIORAL|film modelling|the children were directed to a quiet and comfort room to watch a film presented by a dental assistant. The film showed that the same procedure consisted of Tell-Show-Do, prophylaxis with paste and rubber cap and fluoride therapy was performed on a 5-years-old child model with a time of 20 minutes. The child in the film was cooperative and was reinforced by a reward at the end of the procedure.
224232018|NCT01908127|DRUG|injection of local anesthesia solution|A topical anesthesia and injection of local anesthesia solution using mandibular alveolar nerve block technique was performed by the dentist
224232019|NCT01908127|PROCEDURE|occlusal cavity preparation|the occlusal cavity was prepared for pulpotomy and restoration of the teeth
224232020|NCT04617665|OTHER|One-handed mask ventilation|Using one-handed mask ventilation techniques during induction of general anesthesia
224232021|NCT04617665|OTHER|Two-handed mask ventilation|Using two-handed mask ventilation techniques during induction of general anesthesia
224232022|NCT02215694|DIETARY_SUPPLEMENT|dual probiotics|2g of powder daily containing dual probiotics(Lactobacillus curvatus HY7601 and Lactobacillus plantarum KY1032)
224232023|NCT02215694|DIETARY_SUPPLEMENT|placebo|2g of powder daily without probiotics
224232024|NCT03408366|PROCEDURE|Laparotomy|Laparotomy via vertical midline incision and after the planned surgical procedure is complete.
224232025|NCT03408366|OTHER|ICG|ICG will be injected intravenously ICG is a fluorescent iodide dye.
224232026|NCT03408366|OTHER|Spectrum NIR imaging system|The Spectrum NIR imaging system uses a handheld camera that emits light in the NIR range.
224232027|NCT01290939|BIOLOGICAL|bevacizumab|
224232028|NCT01290939|DRUG|lomustine|
224232029|NCT01290939|GENETIC|DNA methylation analysis|
223645919|NCT00454324|DRUG|Carboplatin|Carboplatin will be given at a dose of target area under the concentration versus time curve in mg/mL•min (AUC)=6, on Day 1 of a 21 Day Cycle
223645920|NCT00454324|DRUG|Abraxane|"Abraxane will be given at a dose of 240mg/m2 on Day 1 of a 21 Day Cycle (Arm A)~Abraxane will be given at a dose of 80mg/m2 on Days 1, 8, and 15 of a 21 Day Cycle (Arm B)"
223645921|NCT02699749|DRUG|TAK-931|TAK-931 oral capsules.
223645922|NCT05755321|OTHER|Skin biopsy|Skin biopsy performed during surgery.
223645923|NCT00453219|PROCEDURE|Screening evaluation|A detailed history will be taken and a physical examination performed along with a blood sample to verify ovulatory status in women with regular cycles and determine cause of anovulation in women with irregular or absent menstrual cycles.
223645924|NCT00453219|PROCEDURE|Meal Response|The investigators are interested in how nutrition and metabolism can influence reproduction and they will look at how the body senses hunger and how it responses to food. Blood samples will be collected and questionnaires given to assess responses and feeling about hunger and food.
223766011|NCT07085520|DRUG|Microneedle with 0.24mg Denosumab|This intervention uses microneedle patches loaded with 0.24mg of denosumab. The patch is made of a biocompatible material, polyvinyl pyrrolidone (PVP), and is applied to the skin around the knee. It aims to evaluate the skin safety and tolerability of the microneedle patch at this specific dose. Participants will apply 4 microneedle patches around their knee and avoid behaviors that may affect skin condition during the study.
223766012|NCT07085520|DRUG|Saline Microneedle Patch|This intervention involves the use of a microneedle patch loaded with saline. The patch is made of a biocompatible material, polyvinyl pyrrolidone (PVP), and is applied to the skin around the knee. It serves as a control to assess the skin safety of the microneedle patch without the active drug. Participants will apply 4 microneedle patches around their knee and avoid behaviors that may affect skin condition during the study.
224232030|NCT01290939|OTHER|laboratory biomarker analysis|
224232031|NCT01290939|PROCEDURE|cognitive assessment|
224232032|NCT01290939|PROCEDURE|quality-of-life assessment|
224319894|NCT07059585|BEHAVIORAL|CGA|Participants will come once in person for the standard of care surgery. After the surgery, participants will receive delirium assessment questionnaires twice daily in the hospital for a duration of up to 7 days after surgery and, up to two sensory aids if required, one pair of eyeglasses as well as frequent orientation of physical and occupational therapy. On postoperative day 14, the subjects will be assessed for the same, whether at home or in-patient. The assessment completion could take up to an hour.
224319895|NCT07059585|OTHER|control|Participants will come once in person for the standard of care surgery. After the surgery, participants will receive assessment questionnaires regarding perioperative delirium, twice daily in the hospital for a duration of up to 7 days after surgery. On postoperative day 14, the subjects will be assessed for the same, whether at home or in-patient. The assessment completion could take up to an hour.
224319896|NCT07134270|PROCEDURE|MDRO Rectal Screening|Repeated rectal swab collection for screening digestive colonization with multidrug-resistant organisms (MDRO), performed at admission (or within 14 days prior), on day 7, weekly during hospitalization, and at discharge.
223645925|NCT00453219|GENETIC|Blood Collection|A blood sample will be collected and used to check for genetic markers of stress vulnerability.
224232033|NCT00154024|DRUG|atorvastatin|
224232034|NCT00154024|DRUG|irbesartan|
223645926|NCT00453219|PROCEDURE|Functional MRI|research participants will have an functional MRI scan of their brain while reviewing word lists associated with body image and emotions. This procedure will last about 1 hour.
223645927|NCT00453219|PROCEDURE|Endocrine Assessment|research participants will have a 30 hour inpatient hospital admission with every 15 minute blood sampling for 24 hours. Hormone measures of stress, reproduction, and appetite will be obtained.
224232035|NCT06141096|DRUG|MB07133|Evaluate the effectiveness and safety of different doses of MB07133
224232036|NCT05197712|BIOLOGICAL|25 Baiya SARS-CoV-2 Vax 2|Intramuscular injection in the deltoid region of 0.5 mL/dose of Baiya SARS-CoV-2 Vax 2 (recombinant SARS-CoV-2 receptor-binding domain fused with FC region of human IgG1 vaccine)
224232037|NCT05197712|BIOLOGICAL|50 Baiya SARS-CoV-2 Vax 2|Intramuscular injection in the deltoid region of 0.5 mL/dose of Baiya SARS-CoV-2 Vax 2 (recombinant SARS-CoV-2 receptor-binding domain fused with FC region of human IgG1 vaccine)
223645928|NCT05021861|DRUG|Cyproterone Acetate, Ethinyl Estradiol Drug Combination|FEMALE PATIENTS WITH PCOS ON CPA/EE DRUG REGIMEN FOR ATLEAST 6 MONTHS
223645929|NCT05021861|DIAGNOSTIC_TEST|FEMALE PATIENTS WITH PCOS|FEMALE PATIENTS WITH PCOS( NEWLY DIAGNOSED) ,NOT ON ANY MEDICATION,
223645930|NCT05021861|DIAGNOSTIC_TEST|Control group|SYSTEMICALLY HEALTHY FEMALES
223645931|NCT00405600|PROCEDURE|Device used in surgery with or without instrumentation|Infuse Bone Graft BMP-2, Large Kit will be used in all surgeries. Spine surgeries will be either instrumented or uninstrumented.
223645932|NCT04869826|DEVICE|Pulsewave Health Monitor (PAD-2A) Device|This is an observational, comparison study of blood pressure measurements. The objective of this study is to calibrate the blood pressure measurements of the Pulsewave Health Monitor (PAD-2A) device to be within 5±8 mmHg of the average of the dual-observer auscultatory blood pressure measurements via an aneroid sphygmomanometer (reference device), as per the ISO 81060-2: AMD\_2020 universal protocol.
224232038|NCT00600795|OTHER|CSF collection|CSF collection at time of VPS insertion
224232039|NCT03711955|OTHER|Exercise|Two types of training exercises, AET and IRT, will be used as the interventions in this study. Participants will either be assigned to the AET group or the IRT group, where they will participate in the respective training intervention group for 8 consecutive weeks.
224232040|NCT05760664|OTHER|Group Experimental/Fascial Fitness|Participants will receive twelve treatment sessions, twice a week, for six weeks, lasting 30 minutes per session. The interventions will be applied by a physiotherapist with previous experience and training in the proposed protocols.
224232041|NCT05760664|OTHER|Group Sham/Static stretching exercise|Participants will receive twelve treatment sessions, twice a week, for six weeks, lasting 30 minutes per session. The interventions will be applied by a physiotherapist with previous experience and training in the proposed protocols.
224232042|NCT05760664|OTHER|Control Group/Placebo|The placebo intervention will be performed using ultrasound turned off in the thoracolumbar region for 15 minutes followed by rest for 15 minutes for 6 weeks, twice a week. Participants will be evaluated on the first day, fourth week and sixth week of intervention.
224232043|NCT00399113|DRUG|188Re-PTI-6D2|monoclonal antibody
224232044|NCT02236338|PROCEDURE|Ablation of the Incompetent Greater Saphenous Vein|For each patient, the Greater Saphenous Vein (GSV) will be accessed just below the knee. After liberal use of anesthesia, the patient will undergo an ablation of the GSV. Half the patients will have this procedure performed using the Laser Ablation device and half will be treated using the Radiofrequency Ablation device. They will be randomly assigned to treatment.
224232045|NCT02236338|DEVICE|ClosureFAST radiofrequency catheter|
224232046|NCT02236338|DEVICE|EVLT 980nm diode laser system|
224232047|NCT05095064|DRUG|Onivyde® + 5-FULV|Nanoliposomal irinotecan (Onivyde®) in combination with 5-fluorouracil and leucovorin (5-FU/LV)
224232048|NCT01645384|DRUG|Atorvastatin Calcium Tablets, 40 mg|Atorvastatin Calcium Tablets, 40 mg of Dr. Reddy's Laboratories Limited
224232049|NCT02966379|DEVICE|cochlear implantation|"Surgery is standardized in order to have the same procedure for all patients and to preserve a maximum of residual hearing:~* Corticosteroïds (1mg/kg solumedrol) at anesthetic induction ,~* mastoidectomy + posterieur tympanostomy ,~* insertion through round window,~* stop at the first resistance point"
223645933|NCT03154411|DRUG|ABY-029|A minimum of 6 and a maximum of 12 adult patients with a diagnosis of primary soft-tissue sarcoma will be enrolled. Initial diagnostic biopsy specimens will be analyzed for EGFR positivity (an EGFR pathology score ≥ 1) by immunohistochemistry following routine diagnostic processing by Pathologist. Patients will be administered a single intravenous dose of ABY-029 1-3 hours before surgery.
223645934|NCT03052075|OTHER|Retrospective Data Review|Retrospective, uncontrolled pre- and post-test design in a case series of approximately 250 patients who underwent parathyroidectomy at MD Anderson Cancer Center (years 1990 - 2013 ) and had bone density measures recorded at baseline and at one year post-surgery. Data extracted from the surgical oncology database for bone mineral density measures for each patient at multiple sites including the lumbar spine, total hip (right/left), femoral neck (right/left), and distal 1/3 radius. All measures recorded from two time points: presurgical (baseline) and postsurgical (all follow-up available dates beginning at 1 year post-parathyroidectomy).
223645935|NCT03780140|DRUG|Cefiderocol|Cefiderocol for intravenous infusion
223645936|NCT00734500|DRUG|Anidulafungin|Intravenous form. Loading Dose: 3 mg/kg/dose. Maintenance dose: 1.5 mg/kg/dose. Treatment duration: 5 days total.
223645937|NCT04982263|DIAGNOSTIC_TEST|Blood coagulation profile|Venous blood sample for measurement of blood coagulation profile
223645938|NCT06037902|DEVICE|CPAP|patients undergo simulation twice, with and without CPAP
223645939|NCT02728167|DEVICE|Pre-coagulation of the liver parenchyma with HIFU|6 to 10 (or more if necessary) side-to-side 40-seconde HIFU treatments
223645940|NCT05702606|OTHER|Radial extracorporeal shock wave therapy (rESWT)|Radial shock waves are ballistic waves generated by injection of compressed air inside an applicator that fires a projectile into the itself and impacts against the application head
223645941|NCT04784572|OTHER|first injection delay and second injection delay|"During the first injection, the patient will make END scale for 5 seconds, EVAF scale for 10 seconds and insight scale for 5 minutes.~The second injection the patient will make END scale for 5 seconds and EVAF scale for 10 seconds and then a maintenance."
223645942|NCT03522896|OTHER|control|balancing sugars and organic acids
223645943|NCT03522896|OTHER|test meal 1|orange juice plus hesperidin low dose
223645944|NCT03522896|OTHER|test meal 2|orange juice plus hesperidin higher dose
223645945|NCT03522896|OTHER|test meal 3|diluted orange juice plus hesperidin low dose
223645946|NCT04151576|OTHER|aromatherapy massage|aromatherapy massage
224232050|NCT02577159|DRUG|Dapagliflozin|Dapagliflozin is orally administered for 8 weeks in the dose of 5mg per day by adding the conventional treatment if there is no serious event included in termination criteria. If the effect for improving diabetes is insufficient, it is allowed to raise its dose up to 10mg/day.
224232051|NCT01202006|OTHER|Training of general practitioners in an uptitration protocol.|The general practitioners randomly allocated to the intervention group will be trained in the practical appliance of the Dutch GP's 'heart failure' guideline. They will receive detailed instructions on initiating diuretics with ACE-inhibitors and uptitration of ACE-inhibitors and beta-blockers.
224232052|NCT03169959|DRUG|2.5 mg Saxagliptin tablet|A competitive dipeptidyl peptidase-4 (DPP-4) inhibitor, slows the inactivation of the incretin hormones, thereby increases their bloodstream concentrations and reduces fasting and post-prandial glucose concentrations in a glucose-dependent manner in subjects with Type 2 diabetes mellitus (T2DM).
224319897|NCT07134270|OTHER|30-Day Telephone Follow-Up|Structured phone interview conducted 30 days post-discharge, using a standardized questionnaire assessing new infections, rehospitalizations, antibiotic use, and self-rated health status.
224319898|NCT07134582|OTHER|Hippotherapy 1x/week|This group will perform hippotherapy once per week for 12 weeks
223645947|NCT05425472|DRUG|HR070803|HR070803
223645948|NCT03186742|DRUG|Eplerenone 50 mg Tab|Eplerenone 50 mg Tab once a day
223645949|NCT00212589|DRUG|Capecitabine|
223645950|NCT00212589|DRUG|Fluorouracil + folinic acid|
223645951|NCT02550834|OTHER|Wheelchair indoors curling training|8x 90 minutes of training and playing indoors curling in 4 weeks
223645952|NCT04455256|OTHER|x box binding protein|Serum value (pg / mL) of x box binding protein (XBP-1), which is one of the unfolded proteins indicating endoplasmic reticulum stress, is measured.
223645953|NCT02633202|RADIATION|IMRT|Intensity modulated-radiotherapy (IMRT) is given as 2.0-2.30 Gy per fraction with five daily fractions per week for 6-7 weeks to a total dose of 66 Gy or greater to the primary tumor
223645954|NCT02633202|DRUG|Cisplatin|concurrently with cisplatin 100 mg/m² every 3 weeks for 3 cycles during IMRT
223645955|NCT06057467|DRUG|Anticoagulation Agents|Anticoagulation agents includes rivaroxaban, dabigatran, apixaban, and edoxaban.
223645956|NCT06023017|BEHAVIORAL|Prone Position Training|All patients were admitted to our hospital at least 3 days before surgery. Patients in the intervention group (PPT group) received the prone position training daily in the hospital, three times a day, and about 1 hours every times, for at least 3 days before surgery. On the day of admission to the hospital, the patients in the PPT group were instructed to perform prone position training by nurses who were previously trained by prone position training.
223645957|NCT06023017|BEHAVIORAL|standard perioperative care without any prone position training|Patients in the control group (C group) received standard perioperative care without any prone position training.
224319899|NCT07134582|OTHER|Hippotherapy 2x/week|This group will perform hippotherapy twice per week for 12 weeks
224319900|NCT07078630|DIETARY_SUPPLEMENT|Placebo|Participants instructed to intake the placebo capsule along with the ferrous sulphate tablet, separated from food, tea or coffee, at the same time of the day.
223645958|NCT04350957|DIAGNOSTIC_TEST|Low-dose Imaging|"We are comparing MRI image quality for diagnostic purposes. We hope to learn whether using a lesser dose (25%) of the FDA approved contrast agent, Gadavist®, is just as effective as a standard or full dose (100%) of the same contrast in a breast MRI.~This research is being done because breast MRI's have repeatedly been shown to represent the most reliable imaging method for breast cancer screening and diagnosis, regardless of personal risk for breast cancer and radiographic breast density. However, there are growing concerns about getting frequent breast MRI examinations due to the deposition of gadolinium, a metal ion that is found in all breast MRI contrast agents. The FDA states that this deposition and retention is not known to have any long term side effects on patient. However, the researchers at the University of Chicago Medicine would like to further investigate this using a lesser dose of contrast agent than the recommended dose for breast MRI examinations."
223645959|NCT00183313|BEHAVIORAL|Nurse case management|Nurse case management is a population-based medical case management program to improve the delivery of primary medical care to patients with serious mental illness in a Community Mental Health Center (CMHC) in Atlanta GA. The treatment draws on elements from the primary care, nursing case management, chronic disease, health behavior change literature, and from the study team's experience in integrating primary care services for patients with serious mental illnesses.
223645960|NCT00183313|BEHAVIORAL|Usual care|Usual care includes standard mental health services.
224319901|NCT07078630|DIETARY_SUPPLEMENT|HydroCurc®|Participants instructed to intake the HydroCurc® capsule along with the ferrous sulphate tablet, separated from food, tea or coffee, at the same time of the day.
224319902|NCT07078630|DIETARY_SUPPLEMENT|Ferrous sulphate 200mg oral tablet providing 65 mg of elemental iron|Participants instructed to intake the ferrous sulphate tablet along with the HydroCurc® or the placebo together, preferably and separated from food, tea or coffee, at the same time of the day.
224319903|NCT07082244|PROCEDURE|Dental implant placement|Participants will have a dental implant placed at a toothless site
223645961|NCT02497352|DIETARY_SUPPLEMENT|flaxseed|
223645962|NCT02497352|BEHAVIORAL|lifestyle modification|
223645963|NCT02460419|DRUG|capecitabine|capecitabine 1250mg/m2 bid, oral, for 14 days, every 3 weeks. Number of Cycles: until progression or unacceptable toxicity develops.
224232053|NCT03169959|DRUG|5 mg dapagliflozin / 1000 mg metformin XR tablet|"Dapagliflozin - An inhibitor of sodium-glucose co-transporter 2 (SGLT-2), reduces re-absorption of filtered glucose and lowers the renal threshold for glucose, and thereby increases urinary glucose excretion.~Metformin - Lowers both basal and post-prandial plasma glucose by decreasing hepatic glucose production and intestinal absorption of glucose; improves insulin sensitivity by increasing peripheral glucose uptake and utilization."
224232054|NCT03169959|DRUG|Triple FCDP - 2.5 mg saxagliptin / 5 mg dapagliflozin / 1000 mg metformin XR|"Saxagliptin - A competitive dipeptidyl peptidase-4 (DPP-4) inhibitor, slows the inactivation of the incretin hormones, thereby increases their bloodstream concentrations and reduces fasting and post-prandial glucose concentrations in a glucose-dependent manner in subjects with T2DM.~Dapagliflozin - An inhibitor of SGLT-2, reduces re-absorption of filtered glucose and lowers the renal threshold for glucose, and thereby increases urinary glucose excretion.~Metformin - Lowers both basal and post-prandial plasma glucose by decreasing hepatic glucose production and intestinal absorption of glucose; improves insulin sensitivity by increasing peripheral glucose uptake and utilization."
224232055|NCT03169959|DRUG|5 mg saxagliptin|A competitive dipeptidyl peptidase-4 (DPP-4) inhibitor, slows the inactivation of the incretin hormones, thereby increases their bloodstream concentrations and reduces fasting and post-prandial glucose concentrations in a glucose-dependent manner in subjects with T2DM.
224319904|NCT07082244|PROCEDURE|Guided bone regeneration with collagen membrane|Participants will receive guided bone regeneration at a toothless site with bone substitute and a collagen membrane.
224319905|NCT07082244|PROCEDURE|Guided bone regeneration with acellular dermal matrix.|Participants will receive guided bone regeneration at a toothless site with bone substitute and an acellular dermal matrix.
224319906|NCT07080229|DRUG|Intranasal dexmedetomidine|Intranasal dexmedetomidine (1 mcg/kg ideal body weight) will be diluted to a total volume of 1 ml and will be administered via a mucosal atomization device (MAD) 30 minutes before surgery. The dose will be divided evenly, with 0.5 mL sprayed into each nostril while the patient is in a semi-recumbent position.
224319907|NCT07080229|DRUG|Intranasal normal saline|Intranasal normal saline (1 ml) will be administered via mucosal atomization device (MAD) 30 minutes before surgery. The dose will be divided evenly, with 0.5 mL sprayed into each nostril while the patient is in a semi-recumbent position.
224319908|NCT03023176|BIOLOGICAL|Fluzone® standard IIV3|Influenza Virus Vaccine Suspension (0.5ml) for Intramuscular Injection
224319909|NCT03023176|BIOLOGICAL|Fluzone® standard IIV3 Pediatric Dose|Influenza Virus Vaccine Suspension (0.25ml) for Intramuscular Injection
224319910|NCT00256399|DRUG|Alfuzosin 10 mg|
224319911|NCT01807286|DRUG|Pomalidomide|"Phase I: Starting dose of Pomalidomide 1 mg/day by mouth on days 1-21 of a 28 day cycle.~Phase II: Starting dose of Pomalidomide maximum tolerated dose from Phase I."
224319912|NCT01807286|DRUG|Melphalan|Phase I and II: 9 mg/m2 by mouth on days 1-4 of a 28-day cycle.
224319913|NCT01807286|DRUG|Dexamethasone|Phase I and II: 40 mg/day by mouth on days 1-4 of a 28 day cycle.
224319914|NCT01807286|BEHAVIORAL|Questionnaires|Questionnaires about the feeling in hands and quality of life completed at different time points during the study.
224319915|NCT06389682|DRUG|68Ga-NYM005 injection|he radiation dose is about 2-7 mCi for a single patient.Using a syringe to withdraw 68Ga-NYM005 injection, the dose will be administered via an intravenous injection and the injection time will be about 45-60 seconds.
224319916|NCT07134816|OTHER|Cognitive and behavioral therapy for auditory hallucinations|Consists of 16 one-hour individual sessions (one session per week over a 16-week period) of cognitive behavioral therapy, divided into three types of interventions (modules) that have been independently proven to be effective in the management of auditory hallucinations.
224323493|NCT06213818|DRUG|Famotidine|Oral; Tablet
224323494|NCT03237377|DRUG|Durvalumab|1500mg via IV infusion every 4 weeks for up to 3 doses/cycles
224323495|NCT03237377|DRUG|Tremelimumab|75mg via IV infusion every 4 weeks
224232056|NCT03169959|DRUG|10 mg dapagliflozin / 1000 mg metformin XR tablet|"Dapagliflozin - An inhibitor of SGLT-2, reduces re-absorption of filtered glucose and lowers the renal threshold for glucose, and thereby increases urinary glucose excretion.~Metformin - Lowers both basal and post-prandial plasma glucose by decreasing hepatic glucose production and intestinal absorption of glucose; improves insulin sensitivity by increasing peripheral glucose uptake and utilization."
224319917|NCT07134816|OTHER|Usual treatment|Consists of an antipsychotic medication treatment (including dosage changes and molecule changes.), regular consultation with a psychiatrist (once a month on average), and if necessary, one-off psychological support or family interventions not including specific CBT for positive symptoms
224319918|NCT05792696|BEHAVIORAL|PPI guided strategies|For targeted MAP or lower, if PPI\<1, more fluid therapy. if PPI\>3, vasoconstriction therapy. For MAP\<65mmHg and 1\<=PPI\<3, test bolus of 250 ml crystalloid fluid.
223645964|NCT02460419|OTHER|Best supportive care (BSC)|Best supportive care and following-up every 6-8 weeks
223645965|NCT02794532|PROCEDURE|High-flow nasal cannula|Oxygenation will be done via a high-flow nasal cannula
223645966|NCT00327600|DRUG|imexon|
223645967|NCT00327600|DRUG|DTIC|
223645968|NCT00888940|DRUG|Ecallantide|2.25 mg/L pump prime, 0.13 mg/kg loading dose, 2.25 mg/L constant infusion
223645969|NCT00888940|DRUG|Cyklokapron(R)|1000-mg loading dose followed by a continuous infusion of 400 mg/hr with an additional 500 mg added to the pump prime
223645970|NCT05151276|BEHAVIORAL|mobile phone-based distance video education group|Following the first interview, diabetes education videos created previously were sent to the mobile phones of the individuals in two episodes a week fashion. Video submission was completed in a total of four weeks. In the second interview, three months after the video submission had been completed, data collection forms were re-administered to the individuals, and blood analysis results were recorded.
223645971|NCT04809480|DIAGNOSTIC_TEST|Fungal rhinosinusitis|Pathology examination
223645972|NCT01202032|DRUG|Association of Bevacizumab (BVC)+ Pazopanib (PZP)|"Treatment is administered in 28-day cycles, during which patients received BVC intravenously every 2 weeks and oral PZP once daily from days 1 to 28. For the first cycle, PZP is administered alone from days 1 to 14.~The starting dose for dose escalation is BVC at 7.5 mg/kg in combination with PZP 400 mg (level 1).~The therapy regimens for each dose level are respectively:~BVC 7.5 mg/kg + PZP 600 mg (level 2) BVC 10 mg/kg + PZP 600 mg (level 3) BVC 10 mg/kg + PZP 800 mg (level 4). Patients who experience grades 3 to 4 adverse events have dose adjustments to one or both drugs. Dose reductions affect in priority the administration of PZP. Doses reductions to PZP are made in 200-mg decrements and to BVC to 2.5-mg/kg decrements.~Patients with toxicities that warrant reductions at either PZP 400 mg or BVC 7.5 mg/kg are withdrawn from the study."
223645973|NCT03931252|DIETARY_SUPPLEMENT|Boost VHC|8 ounce can liquid meal, calories 530kcal, Carbohydrate 46g, Protein 22g, Fat 30g
223645974|NCT03931252|DIETARY_SUPPLEMENT|Ensure High Protein|8 ounce can liquid meal, calories 160kcal, Carbohydrate 13g, Protein 16g, Fat 2g
223645975|NCT01578486|DRUG|salsalate|open-label trial of salsalate 3g/day for 12 weeks.
223645976|NCT02751489|OTHER|Bain De Soliel - Solid|0.05 gm/cm2 of each test product is applied to duplicate skin sites (approximately 2 x 2 cm each) on the lower or mid-back. After the test articles have dried for 5 to 15 min, the sites are covered by the appropriate patch.
223645977|NCT02290769|DEVICE|Short guide wire rapid exchange|Use of short guide wire rapid exchange to guide the cannulation during primary ERCP
223645978|NCT02290769|DEVICE|Long guide wire|Use of long wire to guide the cannulation during primary ERCP
223645979|NCT05060601|PROCEDURE|Gracey micro-curettes|Mechanical debridement will be performed by means of ultrasonic scalers with specific thin tips and micro-curettes, in order to minimize trauma for gingival tissues.
223645980|NCT05060601|PROCEDURE|Standard Gracey curettes|After local anaesthesia, non surgical subgingival debridement will be performed by standard Gracey curettes
223645981|NCT06330558|PROCEDURE|laparoscopic right adrenalectomy|adrenalectomy
223645982|NCT01915069|DRUG|Cilostazol|
223645983|NCT05254704|OTHER|TEX-Q-F before scheduled surgery|"The TEX-Q-F questionnaire (French version of the breif version of the TEX-Q) contains 15 questions to assess the patient's overall expectations concerning the surgery.~The first 11 questions concern the patient's expectations regarding the postoperative period: pain and functional recovery. The last 4 questions focus on the patient's hopes for the outcome of the surgery. Each item is scored from 0 to 10, according to the intensity of the level of expectation."
223645984|NCT05158764|DEVICE|Venous compression system of the lower limbs stage C6 / C6r of the CEAP classification|Etiological treatment of venous disease of the lower limbs stage C6 / C6r
223645985|NCT05716282|OTHER|Accuracy of neuromuscular recovery estimation|"Accuracy of the estimation of neuromuscular recovery will be measured as:~* Correct attribution of the patients to the groups slow, intermediate or fast recovery~* Real speed of recovery falls between 95 confidence interval of the estimated speed of recovery"
223645986|NCT05601895|DRUG|Sorafenib|The initial dose of sorafenib is 400 mg orally twice daily and is adjusted in case of suspected toxicity or resistance (dose range, 200-800 mg daily).
223645987|NCT05366062|DRUG|ERC1671|ERC1671 is an autologous and allogeneic cells and lysates suspension generated from human glioblastoma (GBM) tumors harvested from patients undergoing surgery for glioblastoma. For each patient the treatment is composed of three allogeneic cells vaccine and lysates vaccine (ERC1671 A, B, C) plus from one autologous cells and lysate (ERC1671D).
223645988|NCT05366062|DRUG|GM-CSF|Sargramostim (Leukomax®, Leukine®); yeast-derived, recombinant human granulocyte-macrophage colony stimulating factor (rhu GM-CSF)
223645989|NCT05366062|DRUG|Cyclophosphamide|Cyclophosphamide is an alkylating agent, used for immunopotentiation. This drug is FDA approved and is being used off-label for the condition of hematopoietic stem cell transplant conditioning as an antineoplastic and immunosuppressant agent to modulate immunity.
223645990|NCT05366062|DRUG|Pembrolizumab|A therapeutic antibody that binds to and blocks PD-1 located on lymphocytes. The receptor is generally responsible for preventing the immune system from attacking the body's own tissues - it is an immune checkpoint inhibitor.
223645991|NCT05083286|DRUG|OnabotulinumtoxinA|Injection of glabellar rhytids
223645992|NCT05185713|OTHER|This project is a clinical observational study. No additional medication or surgical interventions are performed on the subjects.|This project is a clinical observational study. No additional medication or surgical interventions are performed on the subjects.
223645993|NCT02536963|DEVICE|Pediatric Vision Scanning device|The Pediatric Vision Scanner (PVS) performs a 3-second, non-invasive scan of both eyes simultaneously while a child looks at a single target. The scan will measure the frequency of the light waves that reflect off of the participants' eyes to determine the fixation state of the eye.
223645994|NCT02536963|OTHER|Reference examination|Reference examination of the eyes will be performed by a fellowship-trained pediatric ophthalmologist.
223645995|NCT05069493|PROCEDURE|simple suturing|Hiatal hernia repair by simple suturing of the diaphragmatic
223645996|NCT05069493|PROCEDURE|mesh|Hiatal hernia repair by tension-free mesh closure
223645997|NCT05451901|PROCEDURE|Immediate necrosectomy|"Endoscopic ultrasonography (EUS)-guided drainage will be conducted within 72 hours from randomization. A convex-type echoendoscope is advanced to the stomach or duodenum, and the walled-off necrosis (WON) is visualized and punctured under EUS guidance. A lumen-apposing metal stent (LAMS), such as Hot AXIOS system (Boston Scientific Japan, Tokyo, Japan), is recommended for the initial EUS-guided drainage.~For the immediate necrosectomy group, endoscopic necrosectomy (EN) will be performed in the same session of EUS-guided drainage using a gastroscope. The endoscope is inserted into the WON cavity through the LAMS, and necrotic tissue is removed using biopsy forceps, snare, or basket catheter. The EN procedures will be repeated until clinical improvement."
223645998|NCT05451901|PROCEDURE|Step-up approach|"Endoscopic ultrasonography (EUS)-guided drainage will be conducted within 72 hours from randomization. A convex-type echoendoscope is advanced to the stomach or duodenum, and the walled-off necrosis (WON) is visualized and punctured under EUS guidance. A lumen-apposing metal stent (LAMS), such as Hot AXIOS system (Boston Scientific Japan, Tokyo, Japan), is recommended for the initial EUS-guided drainage.~For the step-up approach group, an additional interventional procedure will be withheld for 72-96 hours after initial EUS-guided drainage. In cases without clinical improvement after 72-96 hours, additional drainage will be permitted, which includes increasing the number of stents, additional EUS-guided drainage, and performing percutaneous drainage (step-up treatment). Insufficient improvement even after two times of step-up treatment allows subsequent endoscopic necrosectomy (EN)."
223645999|NCT05503823|DEVICE|tACS or tRNS and TMS|A light electrical current will be applied to the scalp of the participants via 2 electrodes. The resting and active motor threshold will be measured before, right after, after 30 minutes, and after 1 hour of receiving the tACS or tRNS.
224232057|NCT03169959|DRUG|Triple FCDP - 5 mg saxagliptin / 10 mg dapagliflozin / 1000 mg metformin XR|"Saxagliptin - A competitive dipeptidyl peptidase-4 (DPP-4) inhibitor, slows the inactivation of the incretin hormones, thereby increases their bloodstream concentrations and reduces fasting and post-prandial glucose concentrations in a glucose-dependent manner in subjects with T2DM.~Dapagliflozin - An inhibitor of SGLT-2, reduces re-absorption of filtered glucose and lowers the renal threshold for glucose, and thereby increases urinary glucose excretion.~Metformin - Lowers both basal and post-prandial plasma glucose by decreasing hepatic glucose production and intestinal absorption of glucose; improves insulin sensitivity by increasing peripheral glucose uptake and utilization."
224232058|NCT02659852|PROCEDURE|side by side|Stenting generally begins with selective guidewire cannulation into the left and right intrahepatic bile ducts. Self-expandable metallic stent(SEMS) deployment is the conventional method and parallel SEMS can be inserted. SEMS deployment can be performed serially or simultaneously.
224232059|NCT02659852|PROCEDURE|stent in stent|After first SEMS deployment, contralateral placement of a second SEMS through the mesh of the first deployed stent was done and it looks like a Y configuration.
224232060|NCT01521442|BEHAVIORAL|Mindful Yoga Therapy|Veterans will participate in twice weekly Mindful Yoga Therapy, which includes meditation, breathing practices, mindful movement, and guided rest (yoga nidra), as well as daily home practice.
223646000|NCT03586466|DEVICE|BupreCare|"Subjects will receive their medication in a MedicaSafe device. Medication will be dispensed in accordance with the programmed treatment plan for each subject. Subjects will complete a Check-In remotely each week with their device."
223646001|NCT03586466|DRUG|Buprenorphine/naloxone|Subjects will be given buprenorphine/naloxone as a component of Medication Assisted Treatment (MAT).
223646002|NCT03586466|OTHER|MEMS|Subjects will receive their medication in a MEMS pill bottle.
223646003|NCT00012844|DEVICE|Redesigning patient handling tasks using equip: Arjo Bianca Overhead Lift, Hill-Rom Resident Transfer Device, TranSit Chair, Total Care Bed|
224232061|NCT01521442|BEHAVIORAL|Wait-list Control|Participants will receive Mindful Yoga Therapy intervention after 12 weeks from being enrolled. Veterans will participate in twice weekly Mindful Yoga Therapy, which includes meditation, breathing practices, mindful movement, and guided rest (yoga nidra), as well as daily home practice.
224232062|NCT00949299|DRUG|buprenorphine|intradermal injection
224232063|NCT06454006|DEVICE|Placebo PBMT-sMF|Placebo, without therapeutic dose.
224232064|NCT06454006|DEVICE|Active PBMT-sMF|Active with a dose of 31.50 J per site.
224232065|NCT00006052|DRUG|imatinib mesylate|
224232066|NCT00135707|DRUG|Dietary Supplement/Vitamins|Vitamin C (1000 mg) and Vitamin E (400 IU) per capsule, two capsules daily between randomization (at 9 - 16 weeks gestation) up to delivery.
224232067|NCT00135707|DRUG|Placebo for Vitamin C and Vitamin E|Placebo two capsules daily between randomization (at 9 - 16 weeks gestation) up to delivery.
224232068|NCT04184037|BEHAVIORAL|Mindfulness meditation delivered via a mobile app|"This is a six-week intervention that requires completing daily meditation sessions at home using a mobile app while wearing a four-channel EEG device (Muse,RRID:SCR\_014418) and headphones. Participants are asked to increase their session duration from 5 to 15 minutes over the first 10 sessions, and continue with 15 minutes thereafter. Meditation sessions in both intervention arms consist of listening to a calm soundscape while focusing one's attention on the present moment.~Prior to starting the intervention, participants are familiarized with the mobile device, EEG headband, and the study app during an onboarding session. In this session, participants listen to four different meditation exercise instructions (e.g., focusing attention on their breath, counting breaths, thinking of meditation akin to training a puppy) that offer them techniques to use during meditation.The transcript of these exercises and a basic guide on how to use the study app and headband are provided."
223646004|NCT00012844|PROCEDURE|Redesigned patient handling tasks using work practice controls: setting bed height at correct level; applying anti-embolism stockings from foot of bed|
224232069|NCT01918878|DRUG|Aflibercept (EYLEA)|INTARAVITREAL INJECTION OF AFLIBERCEPT
223646005|NCT01070017|OTHER|DOT-HAART|For 8 months, DOT-HAART of all doses in the participant's home or alternate location. DOT worker ensures that HIV medications are taken as indicated and witnesses ingestion of all medications including other medications prescribed by physician. The worker will be trained to identify, triage and notify providers of any psychosocial and medical problems/complications. Transition to self-administration begins in months 9-12 when DOT will be tapered and greater participation of treatment supporter to prepare patients for self-administration.
223646006|NCT00904592|DRUG|Qi ming granula|Qi ming granula Usage:4.5g，po，tid. duration:12 months/ arise Endpoint Event
223646007|NCT00904592|DRUG|Placebo Comparator|"Control group: Basic therapy ＆ placebo~1. Therapy for DM: To control blood glucose, blood pressure, and serum lipid through drug, dietary management , exercise and education.~2. placebo,Usage: 4.5g，po，tid"
223646008|NCT02817048|DEVICE|chest tube|
223646009|NCT02817048|PROCEDURE|VATS without chest tube placement|Patient received Video-Assisted Thoracic Surgery (VATS) wedge resection for peripheral lung nodule without chest tube placement (Tubeless)
223646010|NCT02817048|PROCEDURE|VATS with chest tube placement|
223646011|NCT05404932|DRUG|Aliquoted allogeneic donor plasma in patient's conjunctiva|1-2 drops of allogenic aliquoted plasma to affected eye every 1-5 hours per day based on disease severity to be weaned down based on clinical response Administration period: Two to Six months. This may be repeated based on recurrence/worsening of conjunctivitis
223646012|NCT02354053|DRUG|Switch to Triumeq|
223646013|NCT02354053|BEHAVIORAL|Adherence support + current ART|
223646014|NCT00309348|OTHER|Weekly measurement of graft flow|
223646015|NCT00936780|DEVICE|Infinnium-Core™ Paclitaxel eluting Coronary Stent|Infinnium-Core™ Coronary Stent System consisting of the Coronnium® coronary stent (CE approved) having Biodegradable Polymeric Matrix on a Co-Cr alloy Platform. Drug concentration is 1.36 µg/mm2.
223646016|NCT02763670|OTHER|PRETICARD patient care management|"A standardized and specialized network to take care of the severe cardiac insufficiency:~* An initial assessment and consultations with health professionals specialized in severe cardiac insufficiency during the hospitalization for cardiac insufficiency~* At 1 months, consultations and acts realized by health professionals specialized (one hospital day care)~* At 2 months, a therapeutic education program for heart failure patients, approved by the Rhône-Alpes regional public health authorities (week hospital: two days and one night).~* At 6 and 18 months, one cardiology consultation~* At 12 and 24 months, consultations and acts realized by health professionals specialized (one hospital day care)"
223680904|NCT04833829|BEHAVIORAL|CHIMES Intervention|"There are six components to the intervention:~1. Posters and other print materials to prompt providers and patients to discuss MH care engagement.~2. Brief verbal scripts to help HIV providers facilitate patient MH engagement and discuss barriers to MH utilization.~3. Expanded MH screening procedures, including at initial intake.~4. Case management, emphasizing MH care engagement.~5. Interactive trainings for all HIV providers on MH needs, screening/treatment, and barriers to MH service utilization specific to YB-GBMSM.~6. Regular case review meetings."
223680905|NCT04833829|BEHAVIORAL|Standard of Care|The standard of care practices of referring patients to mental health services of the clinic during Months 1 - 12 of the study.
223680906|NCT03754972|DIAGNOSTIC_TEST|Sagittal plane shear index (SPSI)|Report SPSI to surgeon after surgeon records an initial surgical plan, and determine whether the objective spinal stability metric influences a change in the surgical plan.
223680907|NCT02311582|BIOLOGICAL|MK-3475|Patients currently on pembrolizumab beyond the 2 year/35 cycle limit at the time of the approval of Amendment 13 (approved 07/28/2021) may continue to receive pembrolizumab unless there is progression, toxicity or agreement by the patient and PI to come off therapy. Participants who discontinue pembrolizumab after receiving 35 doses are eligible for retreatment with pembrolizumab if they progress during follow-up provided they meet the requirements. Participants may receive an additional 17 cycles (12 months) of pembrolizumab during the Second Course Phase (Retreatment).
224232070|NCT03129477|PROCEDURE|Telemonitoring in noninvasive ventilation|Compare telemonitoring to conventional monitoring to optimize Ventilation
224232071|NCT03093454|DRUG|Lavender Essential Oil|Lavender essential oil will be applied topically and by inhalation to the lavender group.
224232072|NCT02353130|DRUG|Memantine-XR|Participants will begin with 7mg Memantine XR® daily for a minimum of one week before increasing to an optimal dose of 14 mg daily. It is suggested that participants be titrated to the optimal dose by week 2 so that they may remain on 14mg for at least 6 weeks. Morning dosing is suggested, but can be flexible.
224232073|NCT00100165|DRUG|Placebo|Placebo by mouth twice a day for 4 weeks
224232074|NCT00100165|DRUG|3-(2,4 dimethoxybenzylidene anabaseine) 150 mg|3-(2,4 dimethoxybenzylidene) 150 mg by mouth twice a day for 4 weeks
224232075|NCT00100165|DRUG|3-(2,4 dimethoxybenzylidene anabaseine) 75 mg|3-(2,4 dimethoxybenzylidene) 75 mg by mouth twice a day for 4 weeks
224232076|NCT00278694|DRUG|Oxaliplatin|
224232077|NCT00278694|DRUG|Chemoradiation|
224232078|NCT00278694|DRUG|5-FU|
224232079|NCT00278694|RADIATION|Preoperative chemoradiation|
224232080|NCT00278694|PROCEDURE|Pelvic surgery|
224232081|NCT00278694|DRUG|Neoadjuvant oxaliplatin|
224232082|NCT05522010|PROCEDURE|Cervical spine surgery|A standard anterior approach was made with discectomy sparing the cartilage, and with foraminal decompression. Complete excision of the posterior longitudinal ligament was routinely performed to complete neural decompression. Trial inserters were used to identify the proper implant size. Device under sizing may lead to poor ﬁxation and implant migration. The largest possible device that can be safely placed should be selected to maximize device- endplate contact and to gain support from the apophyseal rim. The teeth of the implant were optimally ﬁxated to the endplate via Caspar pin compression following device insertion. The device may be replaced or changed using the same insertion instrument if ﬁnal imaging demonstrated suboptimal positioning. Rinsing the implanted disc space removes rests of blood and bone dust, all potentially promoting HO
224232083|NCT04540497|DRUG|Inebilizumab|Inebilizumab is a monoclonal antibody that depletes B cells.
224232084|NCT04540497|OTHER|Placebo|Placebo
224319919|NCT05792696|BEHAVIORAL|Empirical strategies|Fluid therapy or vasoconstriction depended on experiences of anesthetic staffs.
224319920|NCT05538910|OTHER|Placebo Nicotine Patch|Comparator
224319921|NCT05538910|DRUG|Nicotine Patch|Study drug: 7.5 mg Nicotine Patch which will be administered in a double blind, randomized manner
224319922|NCT06829563|DRUG|RZ-629|Administered orally
223646017|NCT02763670|OTHER|"As usual  patient care management"|"Conventional management of heart failure patients is defined in the guide HAS (Haute Autorité de Santé) care course. Patient follow-up, however, is defined by the patient's physician and / or cardiologist at the waning of his hospitalization, according to the usual practice for patients with stage II, III or IV NYHA.~According to these recommendations, the patient should see his cardiologist at least once a year.~Usual practices are:~* An initial assessment and consultations with health professionals specialized in severe cardiac insufficiency during the hospitalization for cardiac insufficiency~* At 12 months, a cardiologic consultation. For the study, three evaluation points are programmed: two by phone at 6 and 18 months, two by a consultation at 24 months. This interview aimed to evaluate the number of hospitalization, consultations and acts realized by health professionals specialized (the information in the logbook)."
223646018|NCT02668393|DRUG|Docetaxel|
223646019|NCT02668393|DRUG|Nintedanib|Low Dose
223646020|NCT02668393|DRUG|Nintedanib|Medium dose
223646021|NCT02668393|DRUG|Nintedanib|High dose
223646022|NCT02668393|DRUG|Nintedanib|Continuous high dose
224232085|NCT02850068|DEVICE|Geniculate Artery Embolization|Geniculate artery embolization (GAE) is a new procedure that is being used to reduce pain and disability (resulting from pain, stiffness and difficulty performing daily activities) caused by knee osteoarthritis (OA). Embolization is a procedure where physicians intentionally block the blood vessels to specific areas of the body to prevent blood flow to that region. By doing this, the decrease in blood flow will decrease the size of the area of interest. In this case, the goal is to decrease the size of inflammatory tissue around the knee, resulting in improvement of pain, stiffness and difficulty performing daily activities from OA.
224232086|NCT02042391|DRUG|Rituximab sc|All patients will receive 4 courses of rituximab on days 1, 8, 15 and 22. Rituximab will be administered as a single therapeutic agent at a standard dosage of 375 mg/m2 infused intravenously at day 1. Three subsequent single therapeutic agent applications of rituximab will be administered subcutaneously at a fixed dose of 1400 mg once a week for 3 weeks at days 8, 15 and 22.
223766013|NCT07085520|DRUG|Microneedle with 1.2mg Denosumab|This intervention uses microneedle patches loaded with 1.2mg of denosumab. The patch is made of a biocompatible material, polyvinyl pyrrolidone (PVP), and is applied to the skin around the knee. It aims to evaluate the skin safety and tolerability of the microneedle patch at this specific dose. Participants will apply 4 microneedle patches around their knee and avoid behaviors that may affect skin condition during the study.
223766014|NCT07085520|DRUG|Microneedle with 6mg Denosumab|This intervention uses microneedle patches loaded with 6mg of denosumab. The patch is made of a biocompatible material, polyvinyl pyrrolidone (PVP), and is applied to the skin around the knee. It aims to evaluate the skin safety and tolerability of the microneedle patch at this specific dose. Participants will apply 4 microneedle patches around their knee and avoid behaviors that may affect skin condition during the study.
224232087|NCT02042391|DRUG|Rituximab sc consolidation|Patients considered low-risk will receive four more single therapeutic agent applications of rituximab administered subcutaneously at a fixed dose of 1400 mg once every three weeks at days 50, 71, 92 and 113.
224232088|NCT02042391|DRUG|Rituximab sc combined with CHOP chemotherapy|Patients considered high-risk will receive four more applications of rituximab administered subcutaneously at a fixed dose of 1400 mg combined with CHOP chemotherapy every 3 weeks at days 50, 71, 92 and 113. CHOP chemotherapy will be administered at standard doses: cyclophosphamide 750 mg/m2, adriamycine 50 mg/m2, vincristine 1.4mg/m2 (maximum total dose: 2mg) and prednisone 100mg (at day 1 to 5 of each cycle). Cyclophosphamid, adriamycine and vincristine will be infused intravenously. Prednison will be administered orally in a single dose. At day 3-4 of each treatment cycle either a single dose of 6 mg Peg-GCSF or repetitive doses of 5 µg/kg GCSF until recovery of WBC will be applied subcutaneously, as per institutional practice.
224232089|NCT02042391|DRUG|Rituximab sc combined with alternating chemotherapy with CHOP and DHAOx|Patients considered very high-risk will receive six more applications of rituximab sc at a fixed dose of 1400 mg combined with chemotherapy every 3 weeks. Chemotherapy is CHOP at days 50, 92 and 134 (cyclophosphamide IV 750 mg/m2, adriamycine IV 50 mg/m2, vincristine IV 1.4mg/m2 (maximum total dose: 2mg) and prednisone PO 100mg (at day 1 to 5 of each cycles). Chemotherapy is DHAOx at days 71, 113 and 155 (oxaliplatin (130 mg/m2, day 1) and cytarabine (ARA-C, 2x 1000 mg/m2 at day 2) dexamethasone PO (40 mg/m2, day 1)), as per institutional practice. At day 3-4 of each treatment cycle either a single dose of 6 mg Peg-GCSF or repetitive doses of 5 µg/kg GCSF until recovery of WBC will be applied subcutaneously, as per institutional practice.
224232090|NCT06547580|OTHER|Group-based PFMT|Under the supervision of an experienced physiotherapist, group-based pelvic floor muscle training was applied for 12 weeks, 2 sessions per week, 30-45 minutes each session.
224232091|NCT06547580|OTHER|Individualized PFMT|Under the supervision of an experienced physiotherapist, individualized pelvic floor muscle training was performed using the Emg Biofeedback device, 2 sessions a week, 30-45 minutes each session, in 12 weeks.
224232092|NCT02287168|PROCEDURE|pre-gastrectomy peritoneal washing cytology|sampling of peritoneal washing fluid before gastrectomy
224232093|NCT02287168|PROCEDURE|post-gastrectomy peritoneal washing cytology|sampling of peritoneal washing fluid after gastrectomy
224232094|NCT02287168|PROCEDURE|post-lavage peritoneal washing cytology|sampling of peritoneal washing fluid after peritoneal lavage
224232095|NCT04325074|OTHER|Mental practice|During each of the 12 treatment sessions, the patient was asked to select two tasks from a list of MP activities, graded by level. Once the task was selected, patients received the specific visual or audio instructions and subsequently performed the task. The recording was viewed three times and the audio instructions were repeated two times. To listen to the audio instructions, the participants were requested to close their eyes in order to aid concentration. After listening to the recordings, the patient was asked to perform the task once again, practicing what had been learnt. After the process was completed, the participant completed a questionnaire and scored each task.
223646023|NCT05569278|DRUG|GE200486 0.5M Injection|Single administration by intravenous (IV) hand injection without dilution, followed by a 5mL saline flush
223646024|NCT06367530|DIAGNOSTIC_TEST|Incidence and survival of trilateral retinoblastoma and the differences globally|The detection and survival of trilateral retinoblastoma around the world and for instance differences between high- and low-income countries in terms of incidence and survival.
223646025|NCT01521793|DRUG|QLT091001|oral QLT091001 administered once daily for 7 days
223646026|NCT01694797|DRUG|Metoprolol Succinate|
223646027|NCT04433416|DIAGNOSTIC_TEST|hypertension|If the patient has two or more blood pressure values ≥140/90mmHg in a calm state, he is included in this group
223646028|NCT03068585|DRUG|Neovasculgen (Cambiogeneplasmid)|treatment
223646029|NCT04607018|DEVICE|PMA-zeolite|"subjects received boxes containing PMA-zeolite powder for supplementation for a total of 28 days.~Dosage for PMA-zeolite (100% zeolite; 1 ML - spoon for dosage = ca. 3 g zeolite):1 spoon of the powder stirred 2 times daily (morning and evening) in water (1 glass)."
223646030|NCT04256083|BIOLOGICAL|Biological analysis|Two blood samples of 4 ml each (total: 8 ml) for IGFBP1 assay and metabolic phenotyping and proteomic analysis.
223646031|NCT02843516|OTHER|No intervention|No intervention
223646032|NCT04207632|DRUG|Botulinum toxin type A injection|Ultrasound-guided BoNT-A injection in biceps brachii or brachialis
223646033|NCT03651297|OTHER|Balance training with Fall-Arrest harness|This study will analyze the subjects' responses to balance training protocols with two types of harness support. The protocol will involve balance training, initially of low intensity and then advanced by an algorithm based on subjects' responses to the prior repetition of balance activity. For this intervention, the subjects will be using a standard Fall-Arrest harness for safety throughout, but no other external support. This will allow comparison of postural control, slip responses, motor learning, reliance on the harness and confidence with the system between the two harness types.
223646034|NCT03651297|OTHER|Balance training with Adjustable harness|This study will analyze the subjects' responses to balance training protocols with two types of harness support. The protocol will involve balance training, initially of low intensity and then advanced by an algorithm based on subjects' responses to the prior repetition of balance activity. For this intervention, the subjects will be using a motorized harness in which the support provided is adjustable. This will allow comparison of postural control, slip responses, motor learning, reliance on the harness and confidence with the system between the two harness types.
223646035|NCT05612828|BEHAVIORAL|Conventional versus simulation manikin training|Two approaches to training Combat Life Savers will be employed and performance of participants will be evaluated.
223646036|NCT02141204|BIOLOGICAL|HRV Liquid|Two doses administered orally according to a 0, 1-month schedule.
223646037|NCT02141204|BIOLOGICAL|HRV Lyophilized|Two doses administered orally according to a 0, 1-month schedule.
223646038|NCT05695508|DRUG|Teclistamab (Tec)|Subcutaneous administration of Teclistamab
223646039|NCT05695508|DRUG|Daratumumab|Subcutaneous administration of Daratumumab
223646040|NCT05695508|DRUG|Dexamethasone|administered i.v. or orally
224319923|NCT06829563|DRUG|Placebo|Administered orally
224319924|NCT06829563|OTHER|Fasted|Participants will be treated with RZ-629 in fasted or fed condition and then cross over after washout
223646041|NCT05695508|DRUG|Lenalidomide|Administration oral
223646042|NCT05695508|DRUG|Bortezomib|Subcutaneous administration
224319925|NCT06829563|OTHER|Fed|Participants will be treated with RZ-629 in fasted or fed condition and then cross over after washout
224319926|NCT05919160|DEVICE|DBC (Diagnostic Biochips) Deep Array microelectrode; Intan Electrophysiology recording system; Matlab response recording to behavioral task|Devices listed are components of a single intervention that includes: Record neuronal activity (Intan) from electrodes (DBC), record and analyze patient responses (Matlab)
224319927|NCT05825573|DRUG|Vitamin K antagonist|VKA study medications (Warfarin, Fluindione and Acenocoumarol) will be prescribed and supplied in the usual setting of patient care with respect of the international guidelines and recommended dose protocols and will not be specifically supplied for the trial. Anticoagulant treatment will be prescribed for 6 months. The recommended INR target will be \[2-3\] and \[2-2.5\] for patients treated with concomitant antiplatelet therapy. Biological monitoring will be performed at discretion of physicians as usual care.
223646043|NCT05695508|DRUG|Talquetamab|Subcutaneous administration of Daratumumab
224232096|NCT04325074|OTHER|Mental practice + skill training|In this option, six sessions of MP were alternated with six sessions of skills training (ST). The MP protocol was the same as in group A: selecting, performing, visualizing, listening to and scoring the selected tasks. The activities performed in the skills training were based on the Kamm et al. (2015) protocol and bimanual tasks. After the performance of each task, the patients were allowed to rest for 1 or 2 minutes to avoid the appearance of fatigue.
224232097|NCT04325074|OTHER|Control group|The control group only received their usual physical therapy and occupational therapy treatments provided by their association. The treatment mainly consisted of the application of the Bobath concept and the Vojta method, dry needling, myofascial induction therapy, passive mobilizations, training of gross and fine motor coordination of the upper limbs, resistance training and static and dynamic balance training.
224232098|NCT03688230|DRUG|abituzumab|1000 mg IV
224232099|NCT03688230|COMBINATION_PRODUCT|Placebo + Cetuximab + FOLFIRI|400 mg/m2 over 120 min followed by 250 mg/m2 weekly 60 min or 500 mg/m2 every two weeks, initially 120 min followed by 60 to 90 min
224232100|NCT05166330|DRUG|Ketofol equal ratio|5mg/ml10 mL propofol (100 mg) will be mixed with 2 mL ketamine (100 mg) and then diluted to a total volume of 20 mL to have a final concentration of 5 mg/mL propofol and 5 mg/mL ketamine
224323496|NCT03237377|RADIATION|Thoracic Radiation|5 days per week in once daily fractionation, 1.8-2.0 Gy per fraction
224323497|NCT03237377|PROCEDURE|lobectomy|patients may proceed to surgery post drug and radiation intervention for lung lobectomy
223766015|NCT07086365|DEVICE|Immersive virtual reality|Virtual reality with hand tracking and immersive environment
223766016|NCT07086365|DEVICE|Immersive Virtual Reality|Immersive virtual reality is a digital therapeutic approach to enhance neuroplasticity using virtual environment and hand tracking for functional motion in upper extremity
223766017|NCT06619379|OTHER|Retention time of speculum|"According to the randomization, the speculum can be extracted :~1. just after the transfer catheter is withdrawn~2. 60 seconds after the transfer catheter is withdrawn~3. 420 second (7 minutes) after the catheter is withdrawn"
223646044|NCT00713518|DRUG|0.5 mg ranibizumab|
223646045|NCT00713518|DRUG|3 mg PF-04523655|
223646046|NCT00713518|DRUG|1 mg PF-04523655|
223646047|NCT05345652|PROCEDURE|deep anterior lamellar keratoplasty|DALK is a partial-thickness corneal transplant which involves only the donor stroma, leaving the recipient's own Descemet's membrane and endothelium
223646048|NCT04879251|OTHER|No intervention|No intervention
223646049|NCT00121615|DRUG|etanercept|
223646050|NCT02653599|DRUG|TTP273|
223646051|NCT02653599|DRUG|Placebo|
223646052|NCT00176267|RADIATION|Radiotherapy|50 cGy on days 1, 2, 8, 15, 22, 23, 29 \& 36 of chemotherapy
223646053|NCT00176267|DRUG|Paclitaxel|75 mg/m2 intravenously over one hour on Days 1, 8, 15, 22, 29 and 36
223646054|NCT00176267|DRUG|Carboplatin|AUC of 6 on Days 1 \& 22
223646055|NCT00607373|DRUG|mipomersen|200 mg mipomersen administered once a week for 26 weeks as a 1 mL subcutaneous injection. Subjects weighing less than 50 kg received a lower dose of 160 mg (0.8mL) mipomersen.
223646056|NCT00607373|DRUG|Placebo|1 mL subcutaneous injection once a week for 26 weeks. Subjects weighing less than 50 kg received 0.8 mL subcutaneous injection.
223646057|NCT02186418|GENETIC|ARU-1801|"Autologous CD34+ hematopoietic stem cells transduced ex-vivo with a gamma-globin lentiviral vector~* Subjects with sickle cell anemia will undergo hematopoietic stem cell procurement by bone marrow harvest or apheresis after mobilization with plerixafor~* Reduced intensity chemotherapy conditioning with single dose melphalan will be used to facilitate engraftment of ex-vivo transduced cells."
223646058|NCT02765646|DEVICE|Coronary stent procedure (CSP)|
223646059|NCT00243438|DEVICE|Multilink Vision™ Stent (CE-labeled)|Patients who have diabetes and/or complex lesions and who have had a Multilink Vision™ Stent placed.
223646060|NCT00276341|DRUG|EGb 761® (Tanakan®)|
223646061|NCT04197596|BIOLOGICAL|BK CTL|"Patient with refractory BK infection and a HLA Matched Related Donors: BK specific CTLs (2.5 x 104 CD3/kg) infused intravenously on day 0 and may be additionally reinfused at a minimum of every two weeks (depending on safety and efficacy) for a maximum of five total infusions (maximum 12.5 x 104 CD3/kg).~Patients with refractory BK virus and a HLA Mismatched Related Donors: BK specific CTLs (0.5x104 CD3/kg) infused intravenously on day 0 and may additionally be reinfused at a minimum of every two weeks (depending on safety and efficacy) for a maximum of five total infusions (maximum 2.5 x 104 CD3/kg)."
223646062|NCT02170077|DRUG|BIA 2-093|BIA 2-093 (tablets) administered at increasing daily doses of 400 mg, 800 mg and 1200 mg once-daily or twice-daily, oral route
223646063|NCT02170077|DRUG|Placebo|Placebo tablets administered orally
223646064|NCT03568227|PROCEDURE|Hypnosis|The hypnosis intervention consists of two elements: A hypnotic induction and a hypnotic deepening. The induction aims at guiding the participant into the first hypnotic state (state 1). The participants will remain in this state for 10 minutes, the duration of the fMRI-scan. The hypnotic deepening guides the participants into a very deep hypnotic state (state 2). Participants also remain in this state for 10 minutes, during which their brain activity is measured using fMRI
223646065|NCT03568227|PROCEDURE|Control|The control intervention consists of texts corresponding to the induction and deepening of the hypnosis intervention. They are matched in duration and consist of textually matched excerpts from www.wikipedia.org. Control induction will be presented, resulting in the control state 1 (10 min). Then the control deepening will be performed, leading to the control state 2 (10 minutes). During both control states the brain activity will be recorded using fMRI.
223646066|NCT04546672|DRUG|Sugammadex|At the end of the surgical procedure at a depth of neuromuscular blockade after the reappearance of T2 on the train-of-four, Sugammadex will be dosed once at 2 mg/kg actual body weight through an intravenous line with brisk flow
223646067|NCT04546672|DRUG|Neostigmine|At the end of surgical procedure at a depth of neuromuscular blockade after the reappearance of T2 on the train-of-four, Neostigmine will be dosed once at 0.07 mg/kg actual body weight to a maximum of 5 mg through an intravenous line with brisk flow. Glycopyrrolate will be coadministered with Neostigmine at a dose of 0.2 mg of Glycopyrrolate per 1.0 mg of Neostigmine administered
224232101|NCT05166330|DRUG|Ketofol 1:3 ratio|15 mL propofol (150 mg) will be mixed with 1 mL ketamine (50 mg) and then diluted to a total volume of 20 mL to have a final concentration of 7.5 mg/mL propofol and 2.5 mg/mL ketamine).
224319928|NCT05825573|DRUG|Direct oral anticoagulant|DOA study medications (Apixaban, Rivaroxaban and Dabigatran) will be prescribed and supplied in the usual setting of patient care and will not be specifically supplied for the trial. The usual doses of DOA will be prescribed: dabigatran 150mg twice a day, apixaban 5mg twice a day and rivaroxaban 20mg once a day. The adjusted doses (dabigatran 110mg twice a day, apixaban 2.5mg twice a day and rivaroxaban 15mg once a day) will be prescribed according to clinical practice treatment guidelines.
224319929|NCT05133726|OTHER|Text4Support|Daily supportive text messages
223646068|NCT05271877|PROCEDURE|Laparoscopy|Diagnostic/operative laparoscopic procedure
223646069|NCT05932823|OTHER|Laminary airflow|A ventilation system that reduces the number of bacteria in the air compared to conventional ventilation.
223646070|NCT05107726|BEHAVIORAL|TRE Group|This group will practice time-restricted eating
223646071|NCT03171363|BEHAVIORAL|Gaze-contingent feedback|Participants will receive gaze-contingent feedback according to their viewing patterns
223646072|NCT02070536|OTHER|sRAGE|
223646073|NCT01355952|DIETARY_SUPPLEMENT|Alpha Lipoic Acid|600mg three times per day (1800mg total) daily for 10 weeks
223646074|NCT01986426|DRUG|LTX-315 consecutive lesions|"Dose escalation:~Cohort 1: 2 mg twice per day (4 mg) Cohort 2: 3 mg twice per day (6 mg) Cohort 3: 4 mg twice per day (8 mg)"
223646075|NCT01986426|DRUG|LTX-315|"Dose escalation:~Cohort 1: 3 mg per injection Cohort 2: 4 mg per injection Cohort 3: 5 mg per injection"
223646076|NCT01986426|DRUG|LTX-315 + ipilimumab|Cohort 1: 3 mg per injection + 3 mg/kg ipilumumab Cohort 2: 4 mg per injection + 3 mg/kg ipilumumab Cohort 3: 5 mg per injection + 3 mg/kg ipilumumab
223646077|NCT01986426|DRUG|LTX-315 + pembrolizumab|Cohort 1: 3 mg per injection + 200 mg pembrolizumab Cohort 2: 4 mg per injection + 200 mg pembrolizumab Cohort 3: 5 mg per injection + 200 mg pembrolizumab
223646078|NCT06218966|DEVICE|intracochlear catheter|intracochlear administration of steroids through the intracochlear catheter INCAT
223646079|NCT06008990|DRUG|Buprenorphine|Pregnant mother must be taking Buprenorphine
223646080|NCT06008990|DIAGNOSTIC_TEST|Maternal Brain MRI|Maternal Brain MRI obtained between 24-32 week gestation
223646081|NCT06008990|OTHER|Blood Samples|During the MRI visit blood samples will be drawn: one hour prior to MRI, immediately before MRI, and one hour post MRI to test for Buprenorphine levels.
223646082|NCT06008990|BEHAVIORAL|Questionnaires|Participants will answer questionnaires about their medical history, pregnancy, and substance use.
223646083|NCT04994847|DRUG|Amyloid and Tau PET|NAV4694 and MK6240 PET scans completed every two years
223646084|NCT01780974|DRUG|Lipoic Acid plus Omega-3 Fatty Acids|alpha lipoic acid (racemic) and fish oil concentrate
223766018|NCT07086014|BEHAVIORAL|Cognitive Reappraisal|an emotion-regulation strategy while being asked to complete cognitive tasks.
224232102|NCT03845920|COMBINATION_PRODUCT|tdcs (sham/anodal) + drug (placebo/tyrosine)|"tDCS= A DC Stimulator Plus (neuroConn, Germany) with one 5 cm x 7 cm rubber electrode (anode) and a 10 cm x 10 cm (cathode; reference electrode), encased in saline soaked sponges will be used. The anode will be positioned over the left dlPFC, centered on F3 in the 10e20 electroencephalography (EEG) system, while the cathode on the contralateral supraorbital ridge (Fp2).Current will be delivered at 1.5mA for 20 min plus 30 s fade in/fade out periods.For sham stimulation, the current will be faded in over 30 s, at 1.5mA and then will be switched off.~Drugs= 2.0 g of L-Tyrosine and 2.0 g of the placebo microcrystalline cellulose will be dissolved in 400ml of orange juice as per previously published protocols."
224232103|NCT01456182|DRUG|AFX-2|Dose level 1
224232104|NCT01456182|DRUG|AFX-2|Dose level 2
224232105|NCT01456182|DRUG|AFX-2|Dose level 3
224232106|NCT01456182|DRUG|AFX-2|Dose level 4
224232107|NCT01456182|DRUG|AFX-2|Dose level 5
224232108|NCT05263648|OTHER|Virtual Reality Session|"VR-based education sessions will be used to influence patients' perceived emotional and social distress while undergoing radiation therapy (RT).~Emotional and social distress levels will be evaluated using questionnaires at baseline (prior to the first VR experience), at completion of RT, and at 30-60 days post RT."
224232109|NCT01681030|BIOLOGICAL|EVARREST™|EVARREST™ Fibrin Sealant Patch is a sterile bio-absorbable combination product consisting of two constituent parts- a flexible matrix and a coating of two biological components (Human Fibrinogen and Human Thrombin).
224232110|NCT01681030|BIOLOGICAL|Topical hemostat|Equine collagen with Human Fibrinogen and Human Thrombin
224232111|NCT01681030|OTHER|Standard of Care|SoC is a composite of techniques/methods typically used by the surgeon to control bleeding after conventional methods (i.e. suture, ligation, cautery) are ineffective or impractical.
224232112|NCT00000563|DRUG|dexamethasone|
224232113|NCT00760058|DEVICE|AcrySof® IQ IOL|Replacement of natural crystalline lens in cataract surgery
223646085|NCT01780974|DRUG|Placebo|placebo capsules
223646086|NCT03276624|PROCEDURE|CABG|surgical revascularization of stenosed coranary arteries using arterial and venous grafts.
223646087|NCT01580163|DRUG|JITAI Combined with psychological intervention|tablet，Each tablet weight 0.4g
223646088|NCT01580163|DRUG|Methadone|Oral Solution，1mg/ml
224232114|NCT00760058|DEVICE|Tecnis® Aspheric intraocular lens|Replacement of natural crystalline lens in cataract surgery
223646089|NCT01580163|DRUG|Traditional Chinese Medicine JITAI|tablet，Each tablet weight 0.4g
223646090|NCT05570669|DRUG|(Macrogol 4000 52,500 g + Sodium sulphate anhydrous 3,750 g + Simethicone 0,080 g) full dose|Taking the colonoscopy preparation drug (Clensia) in a single administration
223646091|NCT05570669|DRUG|(Macrogol 4000 52,500 g + Sodium sulphate anhydrous 3,750 g + Simethicone 0,080 g) split dose|Taking the colonoscopy preparation drug (Clensia) in two stages of administration
223646092|NCT06390748|DRUG|esmolol|The primary intervention is the administration of Esmolol. Esmolol was specifically used to evaluate its immunomodulatory effects in patients with sepsis in the study. The dosage was tailored to achieve optimal heart rate control, an integral part of the therapeutic strategy aiming to mitigate the hyperadrenergic state often seen in sepsis. Alongside Esmolol, daily electrocardiogram (ECG) monitoring was incorporated to observe any changes in the QT interval, ensuring cardiac safety due to the known potential cardiac effects of beta-blockers.
224232115|NCT00760058|DEVICE|Akreos® MI60 intraocular lens|Replacement of natural crystalline lens in cataract surgery
224232116|NCT04566835|OTHER|Standart Care given during normal examination|This is the standart education given by doctor. The child and his/her parents come to the doctor for normal examination. They take their asthma diagnosis or other information about their condition. and then the doctor explain them about what is asthma, what are the drugs or how should they use them. This is the implementation using for the control group.
224232117|NCT04566835|BEHAVIORAL|Health Promotion Program with cartoon education for Children with Asthma|First of all, the child and their parents take the routine examination as the same as the control group. Then they take the experimental education called Health Promotion Program with cartoon education for Children with Asthma. The children with asthma were educated within the scope of the program in order to demonstrate the effect of the program on asthma management. Children with asthma were educated with the program, which consisted of 4 units, each of 10 minutes, prepared in the light of the literature and with the current guidelines. Each child received the education in a total of 40 minutes. Every unit has its own cartoon video and comic book material. To sum up The Principal Investigator first give the education about asthma management, then makes them watch the Iggy and the Inhalers videos developed for each unit, and does a colouring activity with comic books at the end of each unit.
224232118|NCT00003696|DRUG|carboplatin|
224232119|NCT00003696|DRUG|cyclophosphamide|
223646093|NCT01724346|DRUG|Ibrutinib|Ibrutinib 420 mg (3 x 140-mg capsules) is administered orally once daily
223766019|NCT06906614|BEHAVIORAL|Simulation-Based Communication Training|"In our study, the intervention is more of an experimental situation - a scenario.~High-fidelity scenarios include patients played by real actors displaying anxiety, aggression, silence, and emotional distress in various clinical situations such as delivering serious news or frustration for waiting for physicians. The average time of each simulation is 12 minutes."
224232120|NCT00003696|DRUG|doxorubicin hydrochloride|
224232121|NCT00003696|DRUG|etoposide|
224232122|NCT00003696|DRUG|paclitaxel|
224232123|NCT02524379|DRUG|Glyburide|3 day drug regimen beginning 8 hours after acute traumatic spinal cord injury.
224232124|NCT03996603|DRUG|Conjugated Estrogens Cream|0.625mg/1g cream, 1g applied vaginally nightly for 2 weeks then 2x/week for 8 weeks
224232125|NCT00003584|DRUG|estramustine phosphate sodium|
224232126|NCT00003584|DRUG|prednisone|
224232127|NCT00003584|DRUG|vinorelbine tartrate|
224232128|NCT01269970|OTHER|18-FDG-PET-CT|
224232129|NCT00197275|BIOLOGICAL|Hib-MenAC mixed with Tritanrix™-HepB|
224319930|NCT05133726|OTHER|Peer support|Meeting with peers who have lived experiences with similar diagnoses but are in recovery
223646094|NCT01724346|DRUG|Next-line ibrutinib|Ibrutinib 420 mg (3 x 140-mg capsules) is administered orally once daily
223646095|NCT06071689|DEVICE|screw retained prosthesis|all-on-4 screw-retained prosthesis.
223646096|NCT05120401|DEVICE|presbyopia glasses|fogging for glasses for far and intermediate
223646097|NCT00598793|DRUG|biphasic insulin aspart|
224232130|NCT04241159|BIOLOGICAL|Allogeneic Young Plasma|"The experimental dosing will consist of once weekly administration of PF24 over a period of 8 consecutive weeks (8 total doses over 56 days). 250 mL single units of PF24 will be obtained from the South Texas Blood Bank and processed by the WFBH Blood Bank.~1 unit (250 mL) PF24, will be infused at 1 mL/kg/hr, once weekly for 8 consecutive weeks."
223646098|NCT00598793|DRUG|insulin glargine|
224232131|NCT01390883|DRUG|Fondaparinux Sodium|
224232132|NCT04172389|PROCEDURE|vesico-vaginal fistula robot assisted laparoscopic repair|realization of O'conor technique or extra-vesical technique for vaginal vesico fistula repair in robot assisted coelioscopy
224232133|NCT01855724|DRUG|Gemcitabine-Pazopanib|
224232134|NCT04954950|OTHER|no intervention|no intervention
223646099|NCT00598793|DRUG|metformin|
223646100|NCT00598793|DRUG|pioglitazone|
223646101|NCT00397865|BEHAVIORAL|Educational booklet|Parental perception of educational booklet and evaluating any change in child's weight.
223646102|NCT00996853|OTHER|Safety follow up|Collection of reactogenicity data from diary cards, reporting of medically-attended adverse events, reporting of serious adverse events and adverse events of special interest, reporting of pregnancy outcomes and fatalities.
224232135|NCT04448665|DIAGNOSTIC_TEST|microbiological investigation|a microbiological tests, including isolation of the pathogen and analysis of their susceptibility/resistance to antimicrobial agents
224232136|NCT01521559|PROCEDURE|Macular Laser Photocoagulation|
224232137|NCT01521559|DRUG|Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321)|
224232138|NCT06408909|BEHAVIORAL|Clinical Pharmacist Intervention Group|Group to which the clinical pharmacist makes recommendations The drugs administered to patients during scheduled hospital visits will be recorded. A detailed medication review will be conducted by the clinical pharmacist. As a result of a comprehensive evaluation, recommendations were made to doctors regarding drug-related problems and were recorded.
224232139|NCT03558477|DRUG|YYD601 1|YYD601 1
224232140|NCT03558477|DRUG|YYD601 2|YYD601 2
224232141|NCT03558477|DRUG|YYD601 3|YYD601 3
224232142|NCT03558477|DRUG|Nexium|Nexium
224232143|NCT04447638|PROCEDURE|Tracheostomy with aerosol box in COVID-19 positive patients|Patients who underwent percutaneous tracheostomy with aerosol box in COVID-19 positive patients. The patients age, gender, hospitalization diagnosis, number of intubated days, anesthetic agents used during the procedure, neck ultrasonography data before and during the procedure, and complications were recorded.
224232144|NCT06003920|BEHAVIORAL|Process group|The medical student process group served as a space for students to gain increased self-awareness through guided exploration of the psychodynamic processes.
224232145|NCT00315874|DRUG|Buprenorphine transdermal delivery system|
223646103|NCT03237455|DIAGNOSTIC_TEST|Thoracic spine x-rays+whole spine MRI|PA radiographs of the thoracic spine and MRI of the whole spine and sacroiliac joints
223646104|NCT03237455|DIAGNOSTIC_TEST|blood tests|blood chemistry including total cholesterol, LDL HDL, CBC, HbA1C, fasting glucose, TG, and insulin levels, HLA-B27, 2 vials of frozen serum for future studies.
223646105|NCT03237455|OTHER|constitutional and demographic data collection|demographics, concomitant diseases (in particular type 2 DM, hypertension, hyperlipidemia) concomitant medications, height and weight (BMI), waist circumference
223680908|NCT02311582|DEVICE|MRI-guided laser ablation|MLA is a minimally invasive laser surgery, which employs a small incision in the scalp and skull, through which a thin laser probe is inserted and guided by MR imaging to the core of the tumor mass where it delivers hyperthermic ablation from the core to the rim.
223680909|NCT04811196|DRUG|Selinexor|Selinexor
223680910|NCT03703570|DRUG|KW-6356|Oral administration
223680911|NCT03703570|DRUG|Placebo|Oral administration
223680912|NCT04691284|OTHER|Blood, urine and stool sampling|Sampling of blood and urine for miR and chemokine detection. Sampling of stool for for microbiome studies.
224232146|NCT04360031|DRUG|Tacrolimus|Tacrolimus and Mycophenolate Mofetil are given in accordance with patient's current regimen
224232147|NCT02337465|DEVICE|Cone-Beam Computed Tomography|Undergo kilo-voltage cone beam computed tomography
224232148|NCT02337465|RADIATION|3-Dimensional Ultrasound-Guided Radiation Therapy|Undergo ultrasound-guided radiation therapy
224232149|NCT04154748|DEVICE|Argon Plasma Coagulation 90W power|
224232150|NCT04154748|DEVICE|Argon Plasma Coagulation 60W power|
224232151|NCT04154748|DRUG|Omeprazole 120 mg|
224232152|NCT04154748|DRUG|Omeprazole 40 mg|
224232153|NCT02407444|OTHER|Physiotherapy treatment & leg cycling|"All patients receive comprehensive care as part of routine rehabilitation program : individual physical therapy treatment, gym's training and balance training in virtual reality, occupational therapy treatment, strengthening and range of motion exercises as a group.~In addition each patient in this group will train with stationary leg cycle ergometer for 20 minutes under physical therapist's supervision . Cycling exercise intensity subjectively determined by the patient using RPE Borg scale . Maximal intensity level determined as 14 in Borg scale."
224232154|NCT02407444|OTHER|Physiotherapy treatment & music listening|"All patients receive comprehensive care as part of routine rehabilitation program : individual physical therapy treatment, gym's training and balance training in virtual reality, occupational therapy treatment, strengthening and range of motion exercises as a group.~In addition each patient in this group will listen to music with earphone for 20 minutes while sitting under physical therapist supervision.~Overall treatment session will last 50 minutes."
224232155|NCT03726463|PROCEDURE|Kidney transplantation|Bilateral nephrectomy of polycystic kidneys are routinely performed during kidney transplantation in ADPKD patients
224232156|NCT05883410|OTHER|Exercise|It is important for the therapist to organize a home exercise program to provide edema and pain control. The exercise program should be specific and clear to the patient. The exercise program will be taught to the patient and given as a home program
224323498|NCT03237377|DRUG|Standard of care adjuvant chemotherapy|patients may or may not proceed to adjuvant chemotherapy post trial drug and radiation intervention and surgery
223646106|NCT03262480|OTHER|stroke volume optimization|"Hemodynamic variables including stroke volume (SV), stroke volume variation (SVV), stroke volume index (SVI), cardiac output (COP), cardiac index (CI), systemic vascular resistance (SVR), systemic vascular resistance index (SVRI), thoracic fluid content (TFC), corrected flow time (FTC), index of contractility (ICON), systolic time ratio (STR), oxygen delivery (DO2) and oxygen delivery index (DO2I) will be measured by Cardiac output non-invasive monitor (ICONTM, OSYPKA medical cardiotronic GMBH, Elixir, Germany). Heart rate (HR), mean arterial blood pressure (MAP), central venous pressure (CVP) and arterial oxygen saturation (Sao2) will be measured using HP monitor.~If mean arterial blood pressure(MAP) drops below 65 mmHg despite achievement of SVopt and CVPmax in both groups, a bolus dose of 5 mg ephedrine will be given and repeated as needed .Norepinephrine will be given for persistent hypotension.Dobutamine 5 mic/kg/min will be started if cardiac index less than 2.5 l/m2."
223646107|NCT05880186|DIETARY_SUPPLEMENT|Acute caffeine supplementation|To evaluate the influence of the time of the day (i.e., morning vs evening) on the effect of caffeine on maximal fat oxidation in women.
223646108|NCT01025518|OTHER|Resistance training|12 weeks of resistance training in combination with protein and creatine or placebo ingestion
223646109|NCT01025518|DIETARY_SUPPLEMENT|Protein and creatine|30 g of protein with each training session, 5 g of creatine pr day
223646110|NCT01025518|DIETARY_SUPPLEMENT|Placebo|Maltodextrine
223646111|NCT04416841|BEHAVIORAL|Tai Chi Chuan|Participants would take 24-form simplified Tai Chi Chuan 1 hour/session, 3sessions/week for 24 weeks. There were 10 minutes warm-up, 40 minutes Tai Chi Chuan lesson and 10 minutes cool-down exercises in the Tai Chi Chuan training. Besides, they would also take standard diabetic care education 0.5hour/session, 2 sessions/month for 6 months.
223646112|NCT04416841|BEHAVIORAL|Fitness Walking|Participants would take fitness walking training 1 hour/session, 3sessions/week for 24 weeks. There were 10 minutes warm-up, 40 minutes fitness walking and 10 minutes cool-down exercises in the fitness walking training, the exercise intensity was 50% to 70% of the maximum heart rate. Besides, they would also take standard diabetic care education 0.5hour/session, 2 sessions/month for 6 months.
223646113|NCT04416841|BEHAVIORAL|Standard Diabetic Care Education|Participants would take standard diabetic care education 0.5hour/session, 2 sessions/month for 6 months.
223646114|NCT02073058|DEVICE|No treatment|
224232157|NCT05883410|OTHER|PNF Technique|While the limb is in the agonist pattern, the patient is instructed to perform isometric contractions for 5-8 seconds against maximum resistance without movement at the limiting point. After maximum isometric contraction, the patient is instructed to actively relax.Participants in the second group will be applied 10 repetitions of isometric contractions for 8 seconds at the limitation points of the movement with the PNF techniques, the hold and relax active movement technique in the direction of wrist flexion and extension.
224232158|NCT05883410|OTHER|Mulligan Mobilization|In thw Mobilization with movement technique; the patient is expected to perform painless ROM. After obtaining painless movement in the patients participating in the study, this application will be applied to the patient with the painless active movement technique in 10 repetitions and 2-3 sets. Rest time between sets will be 15-20 seconds. Patients will be taught self-mobilization to ensure the continuity of painless movement. Self-mobilization will be applied by the patient at home with 10 repetitions every two hours (29).
224232159|NCT04826510|DRUG|Perospirone hydrochloride tablets|The dosage of perospirone hydrochloride tablets was 16-36 mg / D for 8 weeks.
224232160|NCT04826510|DRUG|Lithium carbonate + perospirone hydrochloride|The stable blood lithium concentration was 0.5-1.2 mmol / L, and the dose of perospirone hydrochloride tablets was 16-36 mg / D for 8 weeks.
224232161|NCT04826510|DRUG|Lithium Carbonate Pill|Lithium carbonate treatment, stable blood lithium concentration 0.5-1.2 mmol / L, course of 8 weeks.
224232162|NCT01521195|DEVICE|Extracorporeal blood flow via ECMO machine|"Extracorporeal Membrane Oxygenation (ECMO) machine can provide complete support of heart and lung function.~Extracorporeal blood flow will be given at baseline rate, increased by 25% and decreased by 25%"
224232163|NCT03382366|DIAGNOSTIC_TEST|Blood sampling, risk of fall evaluation, and MR acquisition.|Data will be collected on 1) bone/muscle metabolism through blood sampling, 2) risk of fall through OAK device; 3) muscle quality through MR acquisition.
224232164|NCT00275002|DRUG|O6-benzylguanine|Dosing is based on the body surface area (BSA) calculated at the beginning of each course of therapy. O6-Benzylguanine, 120 mg/m\^2, will be administered as a one-hour intravenous (IV) infusion, daily for 5 days. Four consecutive weeks will constitute one course. Courses will be repeated every 4 weeks for up to 12 courses of therapy.
224232165|NCT00275002|DRUG|temozolomide|Dosing is based on the body surface area (BSA) calculated at the beginning of each course of therapy. Temozolomide, 75 mg/m\^2 (rounded to the nearest 5 mg, the size of the smallest capsule) will be given orally, 30 minutes following the completion of each infusion of O6-Benzylguanine. Four consecutive weeks will constitute one course. Courses will be repeated every 4 weeks for up to 12 courses.
224232166|NCT04749602|DRUG|Nivolumab|40 mg of the nivolumab will be used intrapleurally (once).
224323499|NCT06215820|DRUG|MR-107A-02|tablet
224323500|NCT06215820|DRUG|Tramadol|over-encapsulated tablet
224323501|NCT06215820|DRUG|Placebo|over-encapsulated tablet and/or tablet
224323502|NCT06215820|PROCEDURE|Bunionectomy|Primary unilateral bunionectomy with first metatarsal osteotomy under regional anesthesia
224323503|NCT05559580|DRUG|Avenciguat (BI 685509)|Avenciguat (BI 685509)
224323504|NCT05559580|DRUG|Placebo|Placebo
224323505|NCT06850623|COMBINATION_PRODUCT|Acoustic Cluster Therapy|Drug: PS101; Device: Ultrasound
224323506|NCT06850623|DRUG|Modified FOLFIRINOX|Chemotherapy
223646115|NCT00131261|DRUG|PXD101|
223646116|NCT00131261|DRUG|Dexamethasone|
223646117|NCT05975203|PROCEDURE|skin-to-skin contact|Immediately after delivery the infant will receive skin-to-skin contact with the mother.
223646118|NCT04501770|DRUG|Chort 1 of M802|Cohort 1, subjects will be administered M802 via intravenous infusion on Day 1, Day 8, Day 15, and Day 22 of each 28-day treatment cycle at dose levels. The starting dose is 2 μg, and the maintenance dose during core treatment period and extended treatment period is 5 μg.
223680913|NCT04670224|OTHER|QLB anesthesia|The QLB is a bilateral locoregional anesthesia technique, performed after surgery, under general anesthesia and in right and then left lateral decubitus.
224323507|NCT06308978|DRUG|FT819|FT819 will be administered as intravenous (IV) infusion at planned dose levels.
224323508|NCT06308978|DRUG|Fludarabine|Fludarabine will be administered as an IV infusion at planned dose levels.
223646119|NCT04501770|DRUG|Chort 2 of M802|Cohort 2, subjects will be administered M802 via intravenous infusion on Day 1, Day 8, Day 15, and Day 22 of each 28-day treatment cycle at dose levels. The starting dose is 5 μg, and the maintenance dose during core treatment period and extended treatment period is 10 μg.
223646120|NCT04501770|DRUG|Cohort 3 of M802|Cohort 3, subjects will be administered M802 via intravenous infusion on Day 1, Day 8, Day 15, and Day 22 of each 28-day treatment cycle at dose levels. The starting dose is 10 μg, and the maintenance dose during core treatment period and extended treatment period is 20 μg.
223646121|NCT04501770|DRUG|Cohort 4 of M802|Cohort 4, subjects will be administered M802 via intravenous infusion on Day 1, Day 8, Day 15, and Day 22 of each 28-day treatment cycle at dose levels. The starting dose is 20 μg, and the maintenance dose during core treatment period and extended treatment period is 50 μg.
223646122|NCT04501770|DRUG|Cohort 5 of M802|Cohort 5, subjects will be administered M802 via intravenous infusion on Day 1, Day 8, Day 15, and Day 22 of each 28-day treatment cycle at dose levels. The starting dose is 50 μg, and the maintenance dose during core treatment period and extended treatment period is 100 μg.
223646123|NCT04501770|DRUG|Cohort 6 of M802|Cohort 6, subjects will be administered M802 via intravenous infusion on Day 1, Day 8, Day 15, and Day 22 of each 28-day treatment cycle at dose levels. The starting dose is 100 μg, and the maintenance dose during core treatment period and extended treatment period is 150 μg.
223646124|NCT04501770|DRUG|Cohort 7 of M802|Cohort 7, subjects will be administered M802 via intravenous infusion on Day 1, Day 8, Day 15, and Day 22 of each 28-day treatment cycle at dose levels. Dose on D1 is 150 μg, and on D8, D15, D22 is 225 μg.
223646125|NCT04501770|DRUG|Cohort 8 of M802|Cohort 8, subjects will be administered M802 via intravenous infusion on Day 1, Day 8, Day 15, and Day 22 of each 28-day treatment cycle at dose levels. The starting dose is 225 μg, and the maintenance dose during core treatment period and extended treatment period is 300 μg.
223646126|NCT00645346|BIOLOGICAL|GBS glycoconjugate vaccine|Study subjects will receive either GBS conjugate vaccine or placebo. Total study size is 65. Study subjects will be followed for a total of 12 months after their last vaccination.
223766020|NCT06902779|OTHER|Support of the hospital pharmacist for the medication management at hospital discharge|1\) The hospital pharmacist calls the community pharmacy the day before discharge to order unusual or specific medications 2) The day of discharge, the hospital pharmacist performs a medication reconciliation in collaboration with the hospital physician 3) Once completed, the discharge prescription is sent to the community pharmacy before the patient is discharged. 4) The hospital pharmacist calls the community pharmacy to provide additional information about the patient and the prescription and to answer any questions. Additional information will help the community pharmacist to understand the prescription : administrative data, clinical data, medication-related information, patient follow-up and patient concerns.
224232167|NCT01627275|BIOLOGICAL|Naive T Cell Depleted Donor Lymphocyte Infusion|A single naive T-cell depleted donor lymphocyte infusion will be administered through a peripheral or central venous catheter greater than or equal to 60 days post allogeneic hematopoietic stem cell transplant.
224232168|NCT01819636|OTHER|sparkling highly mineral bicarbonated sodium water|1,25 liter a day at the mealtimes
224323509|NCT06308978|DRUG|Cyclophosphamide|Cyclophosphamide will be administered as an IV infusion at planned dose levels.
223646127|NCT00645346|BIOLOGICAL|Placebo|Subjects will receive one dose of placebo
223646128|NCT03978546|DIAGNOSTIC_TEST|Humphrey Visual Field Test|SITA Standard and 24-2 and 10-2 visual field tests
224323510|NCT06308978|DRUG|Bendamustine|Bendamustine will be administered as an IV infusion at planned dose levels.
223646129|NCT03978546|DIAGNOSTIC_TEST|Optical Coherence Tomography (OCT) Scan|Circle and Wide Angle Scans
223646130|NCT03978546|DIAGNOSTIC_TEST|Smart Perimetry - Henson 9000|24+10-2 Smart Supra test
223646131|NCT00776074|DRUG|Leuprorelin (GF)|Leuprorelin (GF) 3.75 mg injection, subcutaneously, once every 4 weeks for up to 12 weeks.
223646132|NCT00776074|DRUG|Leuprorelin (GC)|Leuprorelin (GC) 3.75 mg injection, subcutaneously, once every 4 weeks for up to 12 weeks.
223646133|NCT00787644|DRUG|Pioglitazone|Pioglitazone tablets; 30 mg/day for 2 weeks; then increased to 45 mg/day until week 12 (approximately 3 months)
223646134|NCT00787644|DRUG|Placebo|Matching placebo (inert tablet)
223646135|NCT01930006|DRUG|MGCD265|
223646136|NCT04078425|DRUG|Aldosterone Antagonists|aldosterone antagonist will be applied to patients of heart failure with preserved ejection fraction, level of the drug will be sampled before administration of the drug and follow up will be sampled after one month
223646137|NCT01619280|DRUG|Sodium Nitroprusside|Each subject will receive one of five possible dosages of nebulized sodium nitroprusside. The dosage will be determined by the 3 + 3 dose escalation design. Only a maximum of six patients will be given a particular dosage. Arterial blood gases will be drawn at 0 min, 15 min, 30 min and 45 min during nebulized sodium nitroprusside administration. Vitals signs will be recorded every five minutes. No changes to ventilator settings or vasopressor dosage or fluid administration will be allowed.
223646138|NCT00569400|DRUG|human insulin|
223646139|NCT02177565|BIOLOGICAL|carrier plus in vitro expanded autologous BMSCs|The non-unions of fractures were stabilized with internal or external fixation devices. The non-union site was clearly exposed and decorticated to introduce sub-periosteal bone graft. Depending on the surgical approach, the site was partitioned in either medial/lateral or anterior/posterior sides. The contents of each universal container were mixed individually with a carrier by the surgeon, who was blinded to the contents of the container
223646140|NCT06418802|PROCEDURE|STN-DBS surgery|bilateral subthalamic nucleus deep brain stimulation surgery
223646141|NCT06418802|DEVICE|pulse width|a short pulse width (30s)
223646142|NCT06418802|DEVICE|frequency|frequency parameters of STN-DBS (60,100, and 130HZ)
223766021|NCT07092150|OTHER|School meals|Daily mid-day meals sourced locally and supplemented by school gardens.
224232169|NCT06123507|BEHAVIORAL|Student practitioner perspective-taking intervention|This intervention compares the outcomes where some learn about and practice perspective-taking and others do not. All participants received at least a partial intervention through getting video-feedback on their dialogue with a client actor.
224232170|NCT05198804|DRUG|ZN-c3|ZN-c3 will be administered.
223646143|NCT02264249|OTHER|Esophagogastroduodenoscopy and colonoscopy split dose prep|"Patients undergoing a combined EGD (esophagogastroduodenoscopy) and a colonoscopy receive the Split dose colonoscopy prep~split dose colonoscopy preparation- ½ evening before and ½ early AM (4L volume or 2L volume bowel preparation)"
223646144|NCT02264249|OTHER|Esophagogastroduodenoscopy and colonoscopy Evening before colonoscopy prep|Patients undergoing a combined EGD (esophagogastroduodenoscopy) and a colonoscopy receive Evening before (4L, 2L or miralax bowel preparation)
223766022|NCT07092150|OTHER|School gardens|A school vegetable garden to grow green leafy vegetables on school grounds.
223766023|NCT07092150|DIETARY_SUPPLEMENT|IFA and Deworming|Weekly iron and folic acid supplements and annual deworming.
223766024|NCT07092150|BEHAVIORAL|Nutrition education|Nutrition education, led by trained teachers, that will cover health, agriculture, and WASH topics.
224232171|NCT05198804|DRUG|Niraparib|Niraparib will be administered.
224232172|NCT03408379|OTHER|Collection of blood sample in aneurysm|"In case of an endovascular treatment :~* A blood sample (venous or arterial) of 10 ml will be taken at the beginning of the procedure, an intra aneurysmal blood sample (1mL) will be taken during the procedure and a blood sample (arterial) of 1 mL will be taken at the end of the procedure.~* Iterative blood samples (arterial) of 10 mL will be taken at each follow up visit.~In case of a surgery treatment :~* A blood sample (venous or arterial) of 10 ml will be taken at the beginning of the surgery.~* A Tissue sample will be taken during the surgery~* Iterative blood samples (arterial) of 10 mL will be taken at each follow up visit."
224232173|NCT04567602|DRUG|PAH medication|There will be no specific interventions.
224232174|NCT06250595|OTHER|Collection of clinical and laboratory data from EHR.|Observational sutdy
224232175|NCT05431881|PROCEDURE|Binaural beat|Different frequencies are transmitted in both ears, causing beats. The low frequency sound generated by beats induces brainwaves entrainment.
224232176|NCT05431881|PROCEDURE|Silent|Apply a wave file which is created in silence.
224232177|NCT02494765|DEVICE|I-gel TM|Airway management with I-gel
224232178|NCT02494765|DEVICE|Ambu AuraOnce (AO)|Airway management with Ambu AuraOnce (AO)
223646145|NCT02264249|OTHER|Esophagogastroduodenoscopy and colonoscopy Same day prep colonoscopy preparation|Patients undergoing a combined EGD (esophagogastroduodenoscopy) and a colonoscopy receive Same day prep (4L volume or 2L volume or Miralax bowel preparation)
224319931|NCT06795815|OTHER|Go Wish Game|"The Go Wish Game (GWG) provides a simple tool, composed by 35 cards to identify individual priorities. GWG is welcomed as a first step in clarifying values and personal thoughts linked to the end of life. The GWG discussion will be divided into two meetings. During the first one, the physician instructs the patients and their caregivers on how the GWG works. The patient will be invited to divide the cards into three sets, labeling the content of the cards within each set as: Very important;more or less important and not important.~This will be the base for the second meeting. During the second meeting - scheduled within one week - each category of card sets will be discussed with patients and their caregivers. The identification of the most relevant wishes or priorities of each patient will be incorporated into the individual therapeutic plan and the patient will be offered the option to make a formal ACP in the following 4 weeks."
224319932|NCT05520567|DRUG|Gilteritinib|Oral
223766025|NCT07092150|BEHAVIORAL|Women's workshops|Community workshops that will engage mothers or female guardians in gardening, nutrition, and entrepreneurship, offering support and training for small businesses and homestead gardens.
224232179|NCT02909140|DRUG|Topical phenylephrine 2.5%|
224232180|NCT02909140|DRUG|Topical cyclopentolate 1%|
224319933|NCT05520567|DRUG|Venetoclax|Oral
224319934|NCT05520567|DRUG|Azacitidine|Subcutaneous injection or intravenous infusion
223646146|NCT05528315|DRUG|ABX-002|ABX-002
224319935|NCT06790004|PROCEDURE|Laparotomy|Open Surgery
223646147|NCT05528315|DRUG|Placebo|Placebo
224319936|NCT06790004|PROCEDURE|Laparoscopy|Minimally invasive surgery
224319937|NCT05714657|RADIATION|Shortened Course Adjuvant Radiotherapy Following TORS|Shortened Course Adjuvant Radiotherapy Following TORS
223646148|NCT01642589|BIOLOGICAL|Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (Menactra®)|0.5 mL, Intramuscular
223646149|NCT01642589|BIOLOGICAL|Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed|0.5 mL, Intramuscular
223766026|NCT07090018|BEHAVIORAL|Empowered Relief|The participants will attend a pain relief skills intervention (Empowered Relief). The two-hour session is delivered by a certified instructor and includes pain neuroscience education, 3 core pain management skills, experiential exercises, completion of a personalized plan for empowered relief. Participants download a binaural relaxation audio file for daily use.
223766027|NCT06594159|DRUG|LY4065967|Administered orally
223766028|NCT06594159|DRUG|Placebo|Administered orally
223766029|NCT06594159|DRUG|Rosuvastatin|Administered orally
223766030|NCT06302296|DEVICE|injectable form of PRF|A group of patients in which participants will be undergo to orthodontic treatment will be received a 0.9 ml injection of PRF after 1st premolar extraction.
223766031|NCT06302296|BEHAVIORAL|Placebo injection|A group of patients in which participants will be undergo to traditional orthodontic treatment will be received a Placebo injection after 1st premolar extraction.
224232181|NCT02909140|DRUG|Intracameral Lidocaine 1%|
224232182|NCT02909140|DRUG|Intracameral 0.2- 0.3ml of epinephrine 1:10,000|
224232183|NCT02580630|BEHAVIORAL|Reduction in running and jumping|Advocate to avoid running and jumping sports for the first 3 months, thereafter slowly progressing to normal sport activity.
224232184|NCT02580630|OTHER|Training|Patients are instructed to carry out strengthening exercises for the diseased achilles tendon 3 times a week. Physiotherapist will instruct all patients in these heavy slow resistance exercises. First time one week after the first injection, and then week 3, 6, 10. The patient will register all training on a diary and on an App.
224319938|NCT06958328|PROCEDURE|Biopsy Procedure|Undergo tumor tissue biopsy
224319939|NCT06958328|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
224319940|NCT06958328|DRUG|Capecitabine|Given capecitabine
224319941|NCT06958328|PROCEDURE|Computed Tomography|Undergo CT
224319942|NCT06958328|RADIATION|Dose-escalated Radiation Therapy|Undergo dose-escalated radiation using intensity-modulated radiation therapy treatment planning
224319943|NCT06958328|DRUG|Fluorouracil|Given fluorouracil
223646150|NCT00359645|PROCEDURE|Screening by head and neck clinical examination with a fiberoptic nasolaryngoscopy and an oesopharyngeal brush biopsy annually during 3 years|
223646151|NCT06498076|DRUG|Norepinephrine|injection of prophylactic norepinephrinebolus after spinal anesthesia induction. If hypotension at any time during surgery, administration of rescue bolus of the same vasopressor to each patient.
224232185|NCT02580630|DRUG|Ultrasound guided injection with Glucocorticosteroid|Ultrasound guided injection in Kagers triangle underneath the thickest part of the achilles tendon with 1ml Lidocain 5 mg/ml and 1 ml methylprednisolone 40mg/ml. Injection is given every months until the tendon pain is markedly reduced (VAS morning pain: 0-20, and VAS training pain: 0-40, and Global recovery rating scale (-5 to +5) is +3 to +5 ). (max 3 injections).
224232186|NCT02580630|DRUG|Ultrasound guided injection with local anaestethic|Ultrasound guided injection in Kagers triangle underneath the thickest part of the achilles tendon with 1ml Lidocain 5 mg/ml and 1 ml of intralipid (for blinding). Injection is given every months until the tendon pain is markedly reduced (VAS morning pain: 0-20, and VAS training pain: 0-40, and Global recovery rating scale (-5 to +5) is +3 to +5 ). (max 3 injections).
224319944|NCT06958328|DRUG|Gemcitabine|Given gemcitabine
223646152|NCT06498076|DRUG|Ephedrine|injection of prophylactic ephedrine If hypotension at any time during surgery, administration of rescue bolus of the same vasopressor to each patient.
223646153|NCT01703767|BEHAVIORAL|Provider Education Workshop|Educational resources for physicians regarding the needs of GW1V patients.
223646154|NCT02211846|DRUG|Mirabegron|oral
224232187|NCT03318692|PROCEDURE|spondylodesis|Dorsal instrumentation with transpedicular screws (spondylodesis)
224232188|NCT03318692|PROCEDURE|CT|CT of operated area is performed within 7 days of surgery
224232189|NCT01964664|BEHAVIORAL|Mindfulness Meditation Training|6-week, one-on-one meditation training. 90-minute home study visit once per week with research assistant. Learn Mindfulness-Based Cognitive Therapy curriculum and mindfulness techniques, and are asked to practice guided meditations 30-45 minutes each day.
224232190|NCT01964664|BEHAVIORAL|Audio Group|Listen to 30-minute podcasts on a daily basis, and discuss podcasts with research assistant at 90-minute weekly home visits. 6 weeks total.
224232191|NCT05557786|DEVICE|Transcranial Alternating Current Stimulation|Cerebellar Transcranial Alternating Current Stimulation（tACS）
224232192|NCT04607239|PROCEDURE|Telemonitoring|"* A weekly telephone call by the CRA for the collection of home blood pressure measurements (which the patient measures twice a day everyday), for therapeutic education, and for treatment compliance assessment.~* A monthly call by the attending physician for treatment titration and side effects check."
224232193|NCT04607239|PROCEDURE|Usual Care without Telemonitoring|"* Attending the follow up visits after inclusion at Day 90 (D-90) \& Day 180 (D-180) for face to face consultation with the attending physician.~* Usual care without any phone calls for therapeutic education, treatment compliance assessment, treatment titration or side effects check."
224232194|NCT04790084|OTHER|no intervention|no intervention
224232195|NCT03363295|DRUG|Moxifloxacin Injection|One group will receive moxifloxacin injection (0,03ml) in the anterior chamber by the end of phacoemulsification surgery
224232196|NCT02624843|DRUG|Benzyl Alcohol Lotion 5%|White topical lotion
224232197|NCT02624843|DRUG|Ulesfia (benzyl alcohol lotion) 5%|White topical lotion
224232198|NCT02624843|DRUG|Placebo|White topical lotion
224232199|NCT00576381|DRUG|Dexmedetomidine|Dosage Level 1=0.25mcg/kg loading dose, 0.2 mcg/kg/hr infusion Dosage Level 1A= 0.35mcg/kg loading dose, 0.3 mcg/kg/hr infusion Dosage Level 2= 0.5mcg/kg loading dose, 0.4 mcg/kg/hr infusion
224232200|NCT01747850|BEHAVIORAL|Motivational Enhancement/Cognitive Behavioral Therapy|All participants will receive a combination of pharmacotherapy (Sativex or Placebo) associated with a weekly intervention of combined Motivational Enhancement Therapy and Cognitive Behavioral Therapy.
224232201|NCT01747850|DRUG|Sativex|Study subjects will gradually increase the maximal allowed dose of Sativex starting at five sprays per day for the first two days and increasing of five sprays per day until reaching the max number of 42 sprays maximal per day at end of week 2 (Day 11). The target quit date will be set at Day 21 (but subjects will be allowed to stop using cannabis before if they are willing and able to). The medication treatment phase will then be continued for an additional 9 weeks (the last week will be a reduction phase with the use of Spray that will be decreased by 50% to avoid abrupt withdrawal). Then exposure to medications will be stopped (so there will be a total of 12 weeks medication treatment exposure).
224319945|NCT06958328|DRUG|Irinotecan Hydrochloride|Given irinotecan hydrochloride
224319946|NCT06958328|DRUG|Irinotecan Sucrosofate|Given liposomal irinotecan
224319947|NCT06958328|DRUG|Leucovorin Calcium|Given leucovorin calcium
224319948|NCT06958328|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
224319949|NCT06958328|DRUG|Nab-paclitaxel|Given nab-paclitaxel
224319950|NCT06958328|OTHER|Observation Activity|Undergo observation
224319951|NCT06958328|DRUG|Oxaliplatin|Given oxaliplatin
224319952|NCT06958328|OTHER|Questionnaire Administration|Ancillary studies
223646155|NCT01334450|DEVICE|TMS , H2-coil|Trans cranial magnetic stimulation with H2-coil
223646156|NCT05689372|DRUG|Semaglutide|Participants will receive Ozempic (solution for injection 1.34 mg/ml (Semaglutide s.c.) according to routine clinical practice conditions for 26 weeks. The physician will determine the dose of Ozempic in accordance with the K-PI.
223646157|NCT00298558|BEHAVIORAL|Cognitive Training|Memory, Reasoning, or Speed of Processing cognitive training interventions
224319953|NCT06958328|RADIATION|Radiation Therapy|Undergo standard radiation therapy
224319954|NCT04329247|OTHER|Median nerve neural mobilization|Manual therapy maneuver performed in the upper limb.
224319955|NCT05833139|DRUG|Zongertinib|Zongertinib
224319956|NCT05833139|DRUG|Itraconazole|Itraconazole
224319957|NCT06160973|OTHER|Feed the Household|Medically tailored meals will be provided for the enrolled individual, with additional meals provided as needed for others living the same household
223646158|NCT04302077|OTHER|virtual doctor visit|interactive live-video feed at home through EPIC
223646159|NCT04302077|OTHER|Standard care doctor's visit|In person visit as per standard of care
223646160|NCT02638454|PROCEDURE|Acute Resistance Exercise|1 bout of high-intensity resistance exercise at 80% of the individuals 1 repetition maximum
223646161|NCT06266143|DRUG|Y101D|Intravenous infusion of Y101D at day1, combined with Gemcitabine and Nab-Paclitaxel IV infusion at day1, 8, a 21-day cycle. After 6 cycles, Y101D and Gemcitabine infusion is applied as the maintenance treatment.
223646162|NCT06383481|OTHER|Mobile based education|"Control Group Patients in the control group will be provided with standard patient care and information. No application will be made.~Experimental group The mobile application will be downloaded to the phones of patients who can use the mobile application. The mobile application will be available to the patient. Patients will be informed about daily monitoring of the mobile application, following the training steps, and that they can reach the researcher with consultancy services whenever they need. The mobile application will be made available to patients within a 12-week period and patient follow-up will be provided."
223646163|NCT04002102|OTHER|OLP treatment|Receive two open-label placebo pills twice a day after randomization. Will receive for 21 days and then stop. It will include educational materials and positive expectancy.
223646164|NCT04002102|OTHER|Usual care|Remain in standard care after randomization and educational materials.
223646165|NCT04002102|OTHER|Expectancy Group|Educational materials and positive expectancy orientation via Zoom or telephone
223646166|NCT00057720|DRUG|TLK286 HCl for injection|
223646167|NCT00057720|DRUG|topotecan hydrochloride for injection|
223646168|NCT00057720|DRUG|doxorubicin HCl liposome injection|
223646169|NCT00752778|OTHER|pet-scan FDG-F18|
223646170|NCT01538758|OTHER|Us guided needling|"Us guided needling is a therapeutical technique treating calcifying tendinitis of the shoulder. Calcifications in the rotator cuff tendon are visualised with ultrasound. Under ultrasound guidance a 20 gauge needle is inserted in the calcification. Lidocaine 1% in a 1cc syringe is injected in the calcification and aspirated. The calcification is flushed until the fluid is clear. Sometimes it is not possible to flush the calcification. In this case the calcification will be fragmented.~After flushing or fragmentation of the calcification, 20 mg triamcinolone with 1cc lidocaine 1% will be injected in de subacromial bursa under us guidance."
223646171|NCT01538758|OTHER|corticosteroid injection|Us guided subacromial bursa injection with 20 mg triamcinolone with 1cc lidocaine 1%.
223646172|NCT04494802|BEHAVIORAL|lower pressure|During the operation, cuff pressure of LMA flexible is maintained to 30cmH2O
223646173|NCT04494802|BEHAVIORAL|higher pressure|During the operation, cuff pressure of LMA flexible is maintained to 50cmH2O
223646174|NCT01073111|DEVICE|zotarolimus-eluting stent (ENDEAVOR®)|zotarolimus-eluting stent
223646175|NCT01073111|DEVICE|sirolimus-eluting stents (CYPHER SELECT® PLUS)|sirolimus-eluting stents
223646176|NCT01073111|DEVICE|everolimus-eluting stents (PROMUS®)|everolimus-eluting stents
223646177|NCT03767413|PROCEDURE|PNF|proprioceptive neuromuscular facilitation training
223646178|NCT03767413|PROCEDURE|PNFMP|proprioceptive neuromuscular facilitation training and mental practice technique
223646179|NCT01880138|OTHER|watching animated cartoon before general anesthesia|
223646180|NCT01880138|OTHER|not watching animated cartoon beofre general anaesthesia|
223646181|NCT04154774|DRUG|Apalutamide|Apalutamide will be administered orally.
223646182|NCT01298986|PROCEDURE|Pulmonary vein isolation ablation procedure for atrial fibrillation|The catheters will be introduced to the right atrium using the femoral vein as an access. Following a trans-septal puncture, ablation catheters will be placed in the left atrium under appropriate imaging and anticoagulation conditions (Standard of care). Following the positioning of the ablation catheters in the left heart cavity ablation to achieve PVI and left atrial isthmus line are going to be performed. Following the appropriate protocol of mapping and AF induction the right sided isthmus is going to be ablated to achieve a flutter line ablation as well. Following the procedure and following the appropriate standard of care protocols, the catheter are going to be retrieved and the procedure will be concluded. The left atrial appendage will be managed surgically. All ablation lines will be placed according to their current standard of practice using radiofrequency ablation technology and based on CARTO mapping.
224232202|NCT01747850|DRUG|Placebo spray|Study subjects will gradually increase the maximal allowed dose of Placebo starting at five sprays per day for the first two days and increasing of five sprays per day until reaching the max number of 42 sprays maximal per day at end of week 2 (Day 11). The target quit date will be set at Day 21 (but subjects will be allowed to stop using cannabis before if they are willing and able to). The Placebo treatment phase will then be continued for an additional 9 weeks (the last week will be a reduction phase with the use of Placebo Spray that will be decreased by 50%). Then exposure to Placebo will be stopped (so there will be a total of 12 weeks Placebo treatment exposure).
224232203|NCT00972881|BIOLOGICAL|cetuximab|
224232204|NCT00972881|DRUG|capecitabine|
224232205|NCT00972881|DRUG|irinotecan hydrochloride|
223646183|NCT01298986|PROCEDURE|Hybrid procedure for ablation of atrial fibrillation|The endoscope will be passed though a small port in the right thoracic cavity to the beating heart. The pericardium will be opened, the coronary sinus transected. The ablation catheters will pass underneath the SVC and IVC establishing access to the transverse and oblique sinuses. A box lesion will be epicardially placed around the pulmonary veins using cryothermia. An additional lesion line will be placed from the box lesion to the left atrial appendage. The ablation catheter will be left in place to guide the EP physicians in placing the right and left atrial flutter lines using radiofrequency. Electromagnetic mapping using a CARTO system and measuring for conduction block of the pulmonary veins will be conducted by the EP's. A second small port will then placed in the left thoracic cavity and the pericardium on the left side will be opened and the left atrial appendage will be ablated with the use of a clip placed around the left atrial appendage and tightened.
223680914|NCT04670224|OTHER|Intravenous anesthesia without QLB|only intravenous anesthesia
223680915|NCT01053936|DRUG|Bardoxolone methyl (amorphous dispersion)|Oral, once daily
223680916|NCT05966337|PROCEDURE|CPAP|Use of non-invasive ventilation in patients in group 2 with CPAP.
223680917|NCT05966337|PROCEDURE|BIPAP|Use of non-invasive ventilation in patients in group 3 with BIPAP.
223680918|NCT05966337|PROCEDURE|Usual care in phisicaltherapy|Patients undergoing usual physiotherapy treatment, consisting of a kinesiotherapy protocol
223680919|NCT06251479|BEHAVIORAL|behavioral 1|verbal and non verbal tasks
224232206|NCT00972881|PROCEDURE|neoadjuvant therapy|
224232207|NCT00972881|PROCEDURE|therapeutic conventional surgery|
224232208|NCT00972881|RADIATION|radiation therapy|
223646184|NCT01298986|PROCEDURE|The Cox Maze Procedure for Ablation of Atrial Fibrillation|A 7-cm incision is placed and the chest is entered through the 4th or 5th intercostal space. The femoral artery and femoral vein are cannulated. The pericardium is opened. Cardiopulmonary bypass is instituted. The right sided lesions are applied using 3 purse-strings that are placed over the right atrial free wall. The right and left atrial lesions are done using cryoablation using either nitrous oxide or Argon. Next the left atrium is entered through a standard atriotomy placed in the interatrial groove. The base of the left atrial appendage is cryoablated and connected to the left upper pulmonary vein. All four pulmonary veins are then encircled using multiple application of cryo. An endocardial cryolesion is then placed posteriorly down to the level of the mid-mitral valve annulus and an epicardial cryolesion is placed on the coronary sinus directly across the atrial wall from the endocardial lesion. The left atrial appendage is then surgically managed.
223646185|NCT01298986|PROCEDURE|Hybrid Procedure for Left Atrium >5 cm but < 6.1 cm|The endoscope will be passed though a small port in the right thoracic cavity to the beating heart. The pericardium will be opened, the coronary sinus transected. The ablation catheters will pass underneath the SVC and IVC establishing access to the transverse and oblique sinuses. A box lesion will be epicardially placed around the pulmonary veins using cryothermia. An additional lesion line will be placed from the box lesion to the left atrial appendage. The ablation catheter will be left in place to guide the EP physicians in placing the right and left atrial flutter lines using radiofrequency. Electromagnetic mapping using a CARTO system and measuring for conduction block of the pulmonary veins will be conducted by the EP's. A second small port will then placed in the left thoracic cavity and the pericardium on the left side will be opened and the left atrial appendage will be ablated with the use of a clip placed around the left atrial appendage and tightened.
223646186|NCT02876601|DRUG|Defibrotide|6.25mg/kg bodyweight over 2h infusion
223646187|NCT02876601|DRUG|Placebo (0.9% sodium chloride)|(0.9% sodium chloride) infusion over 2h infusion
223646188|NCT02876601|DRUG|Lipopolysaccharide|bolus infusion of 2ng/kg bodyweight lps
223646189|NCT02876601|DRUG|Placebo (0.9% sodium chloride bolus)|(0.9% sodium chloride) bolus infusion
223646190|NCT03959176|DRUG|Brimonidine|2 drops administered once in the left eye in both study arms
223646191|NCT03959176|DRUG|Tropicamide|1 drop administered at two different times points in both eyes in both study arms
223646192|NCT03959176|DRUG|Phenylephrine Ophthalmic Product|1 drop administered at two different time points in both eyes in both study arms
223646193|NCT00256997|DRUG|Risperidone long-acting injection (LAI)|Risperidone LAI 25 milligram (mg), 37.5 mg or 50 mg intramuscular (injection of a substance into a muscle) injection will be administered every 2 weeks as per Investigator's discretion. An oral atypical antipsychotic will also be administered in the first 3 weeks following the dose increase. Duration of treatment will be 24 months.
223646194|NCT00256997|DRUG|Oral atypical Antipsychotic|Oral atypical antipsychotic will be administered as per local label practice for 24 months. Participants will be switched to another atypical oral therapy as per Investigator's discretion.
223646195|NCT02739061|BEHAVIORAL|cognitive behavioral group therapy|"Establish closed every collection of six or so patients structured group. Each group patients were treated for 12 times, once a week, 120 minutes at a time.~Treatment for 1 to 3 times to obsessive-compulsive disorder and cognitive behavioral therapy as the theme of psychological education; 4 to 6, 8 to 10 times exposed step by step and reaction treatment and prevention of training;7 and 11 times invite patients family members or other caregivers, make education about obsessive-compulsive disorder cognitive behavioural therapy, to promote patients exposed response prevention homework completion and social support; The 12th time treatment is self assessment and treatment guidelines for a long time."
224232209|NCT04357275|OTHER|ICU treatment|ICU treatment according to standard of care
224232210|NCT01031537|BIOLOGICAL|FSME-IMMUN 0.5ml Baxter|Vaccine
223646196|NCT02739061|DRUG|sertraline, fluvoxamine|Select specified drugs (sertraline, fluvoxamine)
223646197|NCT02739061|OTHER|cognitive behavioral group therapy and drug therapy|Select specified drugs (sertraline, fluvoxamine) and start group cognitive behavior therapy for 12 weeks at the same time
223646198|NCT00354432|DIETARY_SUPPLEMENT|oral soy protein/isoflavones powder|Soy protein powder (20gm) orally 160 mg of total isoflavones isocaloric supplement of casein protein
224232211|NCT05123937|OTHER|BOBATH technique|In group A (BOBATH) one session per day for three days lasting 1 hour for 3 months. Position transitions such as turning from supine to prone or from prone to supine from sitting to standing are facilitated according to the needs. Balance reflexes are attempted to stimulate by using a CP ball. Ambulation training appropriate to the child's motor development. Additionally, passive stretching of spastic muscle reduces spasticity and facilitates the motor function
223646199|NCT00354432|DRUG|Venlafaxine|Patients receive oral venlafaxine 75mg.
223646200|NCT00354432|DIETARY_SUPPLEMENT|Placebo Powder|Placebo powder (20gm casein protein) orally 0 mg of total isoflavones
223646201|NCT00354432|DRUG|Placebo Pill|Patients receive oral placebo pill.
224232212|NCT05123937|OTHER|Task training|In group B (task training) will be applied for 60 minutes per day, 3 times per week for 3 months the individual session lasted roughly 10 minutes for each activity. Standing from a seated situation; (ii) reaching for an object high up, which required ankle plantarflexion from the standing position, and go back to the starting position with the heel leaning on the floor; (iii) stepping on and off a bench; (iv) walking up and downstairs. (10) (v) Drinking water hold the cup stable and drink it by lifting it at an appropriate speed and power (vi) Moving a rubber ball, the task involved taking a 6.5 cm diameter rubber ball and placing it in a basket with a diameter of ten cm (the basket location was moved in various directions).
224232213|NCT00099528|DRUG|REN-1654|
224232214|NCT01189825|BEHAVIORAL|Exercise|Moderate to intense cardiovascular exercise on a treadmill for 20 minutes
224232215|NCT00658398|BEHAVIORAL|Interactive Computer Program to prevent alcohol misuse.|Interactive Computer Program with questionnaires, video and informations
224319958|NCT06160973|OTHER|Dedicated Driver|Medically tailored meals will be delivered each week by a driver who is an employee of Community Servings
224319959|NCT06160973|OTHER|Feed the Individual|Medically tailored meals will be provided for the enrolled individual
224319960|NCT06160973|OTHER|Commercial Shipper|Meals will be delivered by a commercial shipping organization
224319961|NCT04819464|DRUG|Cenerimod|A single oral dose of 0.5 mg.
224319962|NCT04450251|OTHER|Data Collection|Collect observational fetal electrocardiogram (ECG) readings with a novel wearable device.
224232216|NCT06109103|PROCEDURE|telerehabilitation-based motor imagery training|"Motor imagery is defined as the mental thinking of a movement without actual movement being revealed. Many of the currently available physiotherapy and rehabilitation approaches are designed to stimulate damaged motor neural connections through neuroplasticity.~based on real movements. Studies have shown that similar brain regions are activated during motor imagery and real movement. By repeatedly visualizing the same movement, people can improve their motor activity skills such as lifting weights, playing the piano or performing surgery. These findings suggest that motor imagery provides motor learning by strengthening synaptic connections depending on activity."
223646202|NCT02736578|DRUG|Cetuximab-IRDye800|Administered intravenously (IV) at 50 or 100 mg
223646203|NCT02736578|DRUG|Cetuximab|Administered as a 100 mg IV loading dose
223646204|NCT00002150|DRUG|Celgosivir hydrochloride|
223646205|NCT05395975|DEVICE|Oxygen Reserve Index|It is a new non-invasive and continuous measurement parameter that aims to provide information about the oxygen status of patients in the moderately hyperoxic range (100 mmHg\< PaO2 ≤ 200 mmHg).
223646206|NCT04819607|OTHER|model of care|Multidisciplinary model of care for BMFS patients.
223646207|NCT05012917|OTHER|Patient/Proxy-SSPedi|"SSPedi and Mini-SSPedi: SSPedi is a symptom assessment scale for children 8-18 years of age that includes 15 symptoms considered most important by children receiving cancer treatment or HSCT, their parents and healthcare professionals. Each symptom is rated on a 5-point Likert scale consisting of 0=not at all bothered, 1=a little, 2=medium, 3=a lot and 4=extremely bothered. The recall period is yesterday or today.~Mini-SSPedi was developed for children 4-7 years of age and is comprised of the same 15 symptoms. Mini-SSPedi has a recall period of today with a 3-point Likert scale consisting of 0=not at all bothered, 2=medium and 4=extremely bothered'. So, the anchors and mid-point are identical to SSPedi. A faces-type scale accompanies the response options and the symptom descriptions are simplified.~Proxy-SSPedi: Proxy-SSPedi is identical to SSPedi except that the leading question refers to your child rather than you. It is designed for children 2-18 years of age."
223646208|NCT05012917|OTHER|Co-SSPedi|"Co-SSPedi: Co-SSPedi is based upon either SSPedi (age 8-18) or mini-SSPedi (age 4-7).~Co-SSPedi is meant to be completed by both child and parent together. The format and wording is identical to self-report SSPedi and mini-SSPedi (depending on child age) to maximize the ability of the child to participate in symptom reporting.~The approach uses written instruction that asks the dyad who will hold the device and enter the agreed-upon scores. The instruction then asks one member to read the leading question, each symptom and response options out loud. The child answers how bothered they are by that symptom out loud. The parent then states if they agree or they can offer a different answer. If the answer is different, the instruction asks the dyad to discuss until they agree upon an answer. The agreed-upon answer is then entered into co-SSPedi. This process is repeated for the remaining 14 symptoms."
223646209|NCT04640610|OTHER|Storage of operating waste|Storage of operating waste of adenoidectomy / tonsillectomy
223646210|NCT03452657|DRUG|Ranibizumab|Participants in arm Ranibizumab will receive ranibizumab injection every 4 weeks for the first 3 months, followed by re-injections every 3 months until 1year
223646211|NCT03452657|PROCEDURE|No drug|Participants in arm Sham-injection will receive sham injection every 4 weeks for the first 3 months, followed by re-injections every 3 months until 1year.
224232217|NCT06109103|PROCEDURE|telerehabilitation-based physiotheraphy training|The telerehabilitation application will be carried out by video conference method, one of the image-based telerehabilitation technologies. The telerehabilitation-based physiotherapy program will be administered to both Group 1 and Group 2 children by a physiotherapist experienced in the physiotherapy of neuromuscular diseases, excluding the researchers who performed the randomization and evaluations.
224232218|NCT02404948|OTHER|Diagnostic algorithm|Validation of a diagnostic algorithm used to detect coronary artery disease and/or myocardial ischemia based on pulse wave analyses.
224232219|NCT04736992|OTHER|No intervention involved|No intervention involved
224232220|NCT05184049|DRUG|Epalrestat,Mecobalamin|Epalrestat will be taken orally at a dose of 50mg 3 times a day before meals. In addition, conventional hypoglycemic and oral mecobalamin treatment 0.5mg/ time, 3 times/day, before meals.
224232221|NCT05184049|DRUG|Mecobalamin|Subjects takes mecobalamin 0.5mg orally, 3 times a day.Regular hypoglycemia.
224232222|NCT03784664|DIAGNOSTIC_TEST|Arterial blood gas|arterial blood sample with puncture of the radial artery
224232223|NCT03784664|DIAGNOSTIC_TEST|Veinous blood gas|veinous blood sample using peripheral venepuncture
224232224|NCT03627936|DRUG|Lorcaserin manufactured at Zofingen|Lorcaserin XR tablets manufactured at Zofingen.
224232225|NCT03627936|DRUG|Lorcaserin manufactured at Kawashima|Lorcaserin XR tablets manufactured at Kawashima.
224232226|NCT05004428|OTHER|No intervention|Retrospective population-based study utilizing administrative data without any intervention.
223646212|NCT00567099|DRUG|Aripiprzole|"Dosage form, dosage, frequency and duration:~Aripiprazole 5-30 mg tabs po qday x 3 months"
224232227|NCT02627742|DEVICE|MetaNeb® System|The treatment protocol used for Respiratory Care during the CHANGE IN PRACTICE period of the Study will be that prescribed by the patient's health care team in the routine standard care of each patient. With the exception of standard airway clearance and lung expansion procedures, other components of the patients respiratory care regimen will remain the same as during the standard therapy period, however the CHANGE IN PRACTICE will incorporate the use/treatment with The MetaNeb® System as an alternative to usual airway clearance and lung expansion procedures. Use of The MetaNeb® System will follow the labeling of the device.
224232228|NCT01208558|BEHAVIORAL|Diet A|"Prudent diet without grains. Written advice and 17-20 group sessions. Subjects are advised to avoid cereal grains as much as possible. Apart from that, the recommendation is to follow Nordic Nutrition Recommendations (NNR) for overweight people (www.slv.se), i.e. to eat much fruit, vegetables, fish, and to choose low-fat meat, and low-fat dairy products, and to avoid candy, ice cream, snacks, cakes, pastries, chocolate, potato chips, beer, soft drinks and juice. In order to match carbohydrate intake between the intervention arms, a high intake of potatoes, root vegetables, fruit and other carbohydrate-rich foods is recommended.~Guideline: 200-400 g of potatoes, 300-500 g of root crops, 400-600 g of vegetables, 200-300 g of beans, peas and corn, and 600 g of fruit and berries per day."
223646213|NCT05287620|DEVICE|Emerald device|The Emerald device is a wireless sensor that can track the motion, breathing, and sleep of participants without touching or requiring any interaction with the participants, allowing them to go about their normal lives. The Emerald device operates by transmitting and receiving low power radio signals that reflect off of the participant and return back to the device. The power of these signals is 1,000 times lower than what a typical Wi-Fi device transmits. The ability of the device to monitor gait, breathing, sleep, and other metrics has been validated and documented. Studies of the Emerald device in individuals with Parkinson's disease, Alzheimer's disease, and rare diseases have demonstrated the feasibility of monitoring at home and the ability to characterize gait, breathing, and sleep in these populations specifically. In this study, the Emerald device will be used to characterize the mobility, breathing and sleep of the participant.
223646214|NCT02086253|DRUG|BQ-788 and/or BQ-123|
223646215|NCT01815697|DEVICE|Enhanced External Counterpulsation|Enhanced external counterpulsation (EECP) is mainly used in cardiovascular and cerebrovascular diseases, which has been proven to be able to improve microcirculation and endothelial function. EECP therapy is done by sequential inflation of 3 sets of cuffs wrapped around the lower extremities during diastole and deflation of the cuffs during systole. The systolic deflation/ Diastolic inflation sequence of EECP leads to systolic unloading and diastolic augmentation, resulting in increased blood flow in a pulsatile manner. The patients will receive 35-36 hours EECP intervention, 1-hour session every day over a 7-week period.
223646216|NCT06315582|PROCEDURE|Removal of uterine septum with hysteroscopic scissors without electrosurgery.|Hysteroscopic septoplasty utilizing scissors without electrosurgery followed by hysteroscopic morcellation of residual tissue
223646217|NCT06315582|PROCEDURE|Hysteroscopic septoplasty utilizing bipolar electrosurgery|Hysteroscopic septoplasty utilizing bipolar electrosurgery
223646218|NCT02641028|DRUG|CERC-501|CERC-501
223646219|NCT02641028|DRUG|Placebo|Placebo
223646220|NCT04800276|OTHER|muscle strengthening targeted on ischemic areas|muscle strengthening targeted on ischemic areas
223646221|NCT04800276|OTHER|global muscle strenghtening|global muscle strenghtening
223646222|NCT06666270|DRUG|SYN818|Patients will orally receive SYN818
223646223|NCT04325321|OTHER|Stress reactivity test|"The protocol consists of Resting Baseline (BL), Emotion Recall (ER), followed by a Recovery Phase (RP). Heart rate and blood pressure are measured at baseline and then every 5 minutes during ER and RP.~Resting Baseline (BL - 10 min). The participant is instructed to rest quietly.~Emotion Recall (ER - 5-10 min). The participant is instructed to think about the incident associated with the onset of their cardiac event and bring to mind details of the incident. When the participants have the incident clearly in mind, they are instructed to relate the incident and their experience out loud; frequent questions to re-elicit the emotion are asked.~Recovery Phase (RP - 20 min). Upon completion of RP, the catheter is removed and participants are de-instrumented. Blood samples for plasma catecholamines, assessments of heart rate variability, and echocardiograms are performed 10-min into BL, 10-min into ER, and 18 minutes into RP."
223646224|NCT01065987|DRUG|Tizanidine|Tizanidine HCl Tablets 4 mg
223646225|NCT04673643|DEVICE|Transcutaneous Auricular Vagus Nerve Stimulation|"taVNS device (Elmmedicare, EC100, Shenzhen, China) was used to apply stimulation for patients.~Stimulation parameters comprised an electrical current of 1 mA at a frequency of 20 Hz, with a waveform width of 1 ms. Repurposed off-the-shelf devices were utilized for this purpose, with the stimulator generating single square-wave pulses lasting 1 ms each. Enhancing conductivity was achieved by wiping the ear with tap water. The electrodes were placed on the cymba conchae and concha around the affected ear, which is the region of rich vagus nerve branch distribution. Patients in control group were applied using the same stimulator, stimulation parameters and same sessions. However, the electrodes were placed on the antihelix around the affected ear, which is the region of few vagus nerve branch distribution."
223646226|NCT04673643|DRUG|Hyaluronic acid eye drops|Participants in both groups received hyaluronic acid eye drops (HYLO COMOD® eye drops, Ursapharm, Ltd., Germany) with the treatment of 3 times a day.
223646227|NCT06486064|DIETARY_SUPPLEMENT|heat-treated Limosilactobacillus fermentum|one capsule daily for 8 weeks
223646228|NCT06486064|DIETARY_SUPPLEMENT|Placebo|one capsule daily for 8 weeks
223646229|NCT06212726|BEHAVIORAL|InjureFree|The InjureFree software is a commercialized injury incident management platform for organizations working in sports and athlete care and is focused on providing administrators and caregivers' technology to enhance coordination of care. InjureFree will be utilized to track concussion management and communication following SRRC at Buchholz and Gainesville High Schools. This will not modify the current standard of practice for healthcare delivery, it will only modify the communication between members of the concussion management team
223646230|NCT04163016|DRUG|Pharmacokinetics of certolizumab pegol|"The collection of blood samples for pharmacokinetics (PK) is considered interventional. Blood samples will be drawn at enrollment, predose every 4 weeks (Q4W), postdose every 8 weeks (Q8W) and postpartum predose and postdose.~Study participants will be responsible for obtaining and administering commercially available approved dosing regimens of certolizumab pegol (CZP) as prescribed by each study participant's own physician."
223646231|NCT01967238|BIOLOGICAL|IM Pneumococcal, meningococcal, or flu vaccine|Volunteers given one of the 3 vaccines
223646232|NCT05011097|DRUG|Y150|Subjects will receive an intravenous infusion of Y150 in a dose escalation once a week for a 28-day treatment cycle until confirmed progression, unaccepted toxicity, or any criterion for withdrawal from the study.
223646233|NCT05992753|OTHER|Questionnaire application|The research data were collected from 455 mothers admitted to the postpartum and lactation unit of a city hospital in Istanbul between September and November 2022. The mothers to be included in the study sample were determined according to the non-probability sampling method, considering the inclusion criteria of the study. The research data were collected by the researchers face-to-face through a questionnaire that lasted about 10-20 minutes.
224319963|NCT05621616|DRUG|mirabegron|"Participants will receive mirabegron prolonged-release microgranula-based oral suspension once daily. The initial dose of mirabegron will be based on the participant's weight.~The initial low dose will be up-titrated to a higher dose at weeks 2, 4 or 8 unless the participant is determined to be effectively treated with the low dose, based on urodynamics and the participants'e-diary."
224319964|NCT04255277|DRUG|Combined oral contraceptives (COC)|A commercially available COC consisting of 0.1mg levonorgestrel and 0.02 mg ethinylestradiol will be used and administered open-label.
223646234|NCT06597357|PROCEDURE|Arthroscopy &amp; saline irrigation alone|the meniscus scaffold is aimed at replacing partial meniscus defect with a synthetic device.
223646235|NCT06508385|OTHER|Breathing exercise|"Breathing exercises will include;~1. Correct posture and sitting~2. Nose opening techniques~3. Diaphragmatic breathing, which consists of continuous and deep nasal inspiration with movement of the abdominal region and diaphragm~4. Main Breathing exercise (during 5 minutes)=inspiration (during 5 seconds) + expiration (during 15 seconds)."
223646236|NCT03897777|BEHAVIORAL|Exercise Training effect on Hypertension and Gut Dysbiosis|the proposed research will: 1) Characterize gut microbial community structure in AA with hypertension in two important compartments that make up the overall gut bacteria in the colon (fecal and colon mucosa); 2) Quantify the relationship between aerobic exercise training and gut bacteria to identify SCFA microbes that adapt to exercise and benefit BP.
223646237|NCT06593340|BEHAVIORAL|Messenger 1|The first type of messenger (specific details TBD) that will be used to deliver the environmental sampling results.
223766032|NCT06748274|DEVICE|Transcranial Magnetic Stimulation (TMS)|Transcranial Magnetic Stimulation (TMS) is a sophisticated neuromodulation technique that involves the use of a magnetic coil placed against the scalp to generate brief magnetic pulses. These pulses induce electric currents in the cortical neurons, leading to depolarization or hyperpolarization depending on the parameters of the stimulation.
223766033|NCT06748274|DEVICE|High-definition transcranial direct current stimulation (HD-tDCS)|Transcranial Direct Current Stimulation (tDCS) is a non-invasive brain stimulation technique that involves applying a low-intensity electrical current to specific areas of the scalp. The electric current induces alterations in the membrane potentials of underlying neuronal networks. The application of tDCS with concentric ring electrodes is a more targeted form of tDCS, allowing for more precise modulation of cortical activity compared to traditional tDCS methods.
223766034|NCT07086469|DRUG|Neoadjuvant immunochemotherapy|Albumin-bound paclitaxel 260 mg/m² on day 1, cisplatin 25 mg/m² on days 1-3, and toripalimab 240 mg on day 1 of each 3-week cycle (q3w), for a total of 2 cycles.
223646238|NCT06593340|BEHAVIORAL|Messenger 2|The second type of messenger (specific details TBD) that will be used to deliver the environmental sampling results.
223646239|NCT06593340|BEHAVIORAL|Format 1|The first type of format (specific details TBD) that will be used to deliver the environmental sampling results.
223646240|NCT06593340|BEHAVIORAL|Format 2|The second type of format (specific details TBD) that will be used to deliver the environmental sampling results.
223646241|NCT06594965|DRUG|HS-20106|HS-20106 administered subcutaneously every 4 weeks for up to 6 cycles. Eligible participants may be able to continue to receive subcutaneously administered HS-20106 after completing 6 cycles in the extended treatment period.
223646242|NCT06592118|OTHER|Different Pathological Types (FTC vs PTC)|Comprehensive Comparison of Pediatric and Adolescent Follicular Thyroid Carcinoma and Papillary Thyroid Carcinoma Patients
223646243|NCT06591923|OTHER|No Interventions|No interventions.
223766035|NCT07086469|DRUG|Surufatinib Administration|Surufatinib 200 mg orally once daily (po, qd) on days 1-14, administered concurrently with immunochemotherapy. During radiotherapy, surufatinib will be administered at the start of each radiotherapy phase.
223766036|NCT07086469|DRUG|Concurrent Chemotherapy|Toripalimab 240 mg on day 1 of each 3-week cycle (q3w), starting one day prior to the initiation of radiotherapy. Weekly administration of albumin-bound paclitaxel 50 mg/m² and cisplatin 25 mg/m² on day 1 during the radiotherapy course.
223766037|NCT07086469|RADIATION|Radiotherapy|All patients will undergo thoracic intensity-modulated radiotherapy (IMRT), delivered once daily, 5 days per week, at a total prescribed dose of 50 Gy.
223766038|NCT05054686|OTHER|Stretching and Aerobic Exercise at Clinic|In this group of knee osteoarthritis patients will be applied both stretching and 30 minutes bicycle exercises in the same session, strengthening exercises and 30 minutes walking will be given in seperate days as home program.
223766039|NCT05054686|OTHER|Strenghthening and Aerobic Exercise|In this group of knee osteoarthritis patients will be applied both strengthening and 30 minutes bicycle exercises in the same session, 2 days strecthing exercises and 30 minutes walking will be given in seperate days as home program.
223766040|NCT05054686|OTHER|Strengthening, Stretching and Aerobic Exercises at clinic|In this group of knee osteoarthritis patients will be applied all stretching, strengthening and 30 minutes bicycle exercises in the same session, only 30 minutes walking will be given as home program.
223766041|NCT05645432|DRUG|Brexanolone|Brexanolone IV infusion
223766042|NCT03195478|DRUG|Nivolumab|Specified dose on specified days
223766043|NCT03195478|DRUG|Ipilimumab|Specified dose on specified days
224232229|NCT01208558|BEHAVIORAL|Diet B|Prudent diet with whole grains. Written advice and 17-20 group sessions. An exchange of regular cereal grains for whole grains is recommended. A daily intake of 7-8 portions of whole grain products is recommended, and a list of recommended cereal products (brands, names) is provided. Apart from that, the recommendation is identical to Diet A: to follow Nordic Nutrition Recommendations (NNR) for overweight people (www.slv.se; in Swedish), i.e. to eat much fruit, vegetables, fish, and to choose low-fat meat, and low-fat dairy products, and to avoid candy, ice cream, snacks, cakes, pastries, chocolate, potato chips, beer, soft drinks and juice. The goal is that carbohydrate intake, as a proportion of total energy intake, should not differ between the groups.
223646244|NCT05929300|BEHAVIORAL|Yoga|The yoga program includes up to 4 weeks of pre-habilitation yoga and 8 weeks of post-surgery yoga. The yoga program includes basic yoga poses and breathing exercises.
223646245|NCT05929300|OTHER|Usual Care|"This consists of usual care patients. It is current practice for all patients to: 1) receive a handout that covers Kegel exercises; and, 2) instruction from a nurse who teaches the patient how to perform the exercises. There is no referral to a physical therapist unless progression indicates a need for it."
223646246|NCT06597877|RADIATION|CT|Patients with unilateral ear pathology will be randomly assigned to do CT temporal bone, The presence of five variants was determined. These variants were: a high dehiscent jugular bulb, an anteriorly located sigmoid sinus, a deep sinus tympani, an enlarged cochlear aqueduct, and an enlarged internal auditory meatus (IAM). A GE LightSpeed 16, four-slice, helical CT scanner (Fairfield, Connecticut, USA) was used for all patients. The scan parameters were as follows: 1 mm slices, smart Ma (50-250 Ma), 120 kV, 0.8-second rotation time, 0.562:1 pitch factor, and 5.62 mm rotation speed. All scans covered an area from 1 cm inferior to the mastoid tip to 1 cm superior to the petrous temporal bone.
223766044|NCT07140380|DRUG|IVW-1001 Ophthalmic Eyelid Wipe|Dry eye treatment
224232230|NCT01208558|BEHAVIORAL|Physiotherapy|Twelve physiotherapy-led, charged, 2-hour sessions of structured group training for increased cardiorespiratory fitness. A pedometer sold at the start. Physical activity on prescription (FaR) at the end.
223646247|NCT06591845|DRUG|Ziresovir 125 mg|Active Substance: Ziresovir, Pharmaceutical Form: Suspension, Route of Administration: Oral
223646248|NCT06591845|DRUG|Ziresovir 500 mg|Active Substance: Ziresovir, Pharmaceutical Form: Suspension, Route of Administration: Oral
223646249|NCT06591845|DRUG|Placebo|Active Substance: Placebo, Pharmaceutical Form: Suspension, Route of Administration: Oral
223646250|NCT06591845|DRUG|Moxifloxacin hydrochloride tablet 400 mg|Active Substance: Moxifloxacin hydrochloride Pharmaceutical Form: Tablet Route of Administration: Oral
223646251|NCT07033052|BEHAVIORAL|Improvisation + Wellness|Theatrical improvisation exercises, the theatrical art of performance and storytelling without a script, will be combined with wellness techniques
223646252|NCT07033052|BEHAVIORAL|Improvisation|Theatrical improvisation exercises (the theatrical art of performance and storytelling without a script) will be completed in this arm. These exercises will be fairly similar to that from the improvisation + wellness but without the wellness techniques.
223646253|NCT07033052|BEHAVIORAL|Social Craft|Participants assigned to the Social Craft group will engage in arts and crafts projects and activities
223646254|NCT06709222|OTHER|robotic rehabilitation|robotic rehabilitation
223646255|NCT06709222|OTHER|exercise|dual-task exercises
223646256|NCT04167878|DEVICE|3D printed biodegradable cervical fusion cage|ACDF with 3D printed biodegradable cervical interbody fusion cage for spinal fusion procedure at one level (C2 to T1) of the cervical spine.
224232231|NCT04207281|DIETARY_SUPPLEMENT|Raw Honey|Canada #2 white raw honey (1.5 tablespoons) supplied by SweetHeart Pollinators (Janeil Enterprises, Eatonia, SK) administered for 7 days
224232232|NCT04207281|DIETARY_SUPPLEMENT|Comparator|Honey comparator(1.5 tablespoons) administered for 7 days
224232233|NCT02584140|BEHAVIORAL|Text Messaging|All participants assigned to the iTAB intervention will receive daily dosing reminders that will be sent for the first 6 weeks and then continue with reminders for the duration of the study.
224232234|NCT02584140|BEHAVIORAL|Adherence Counseling|All participants assigned to the counseling intervention will receive sexual health and medication adherence counseling at each study visit. Participants with suboptimal adherence (TFV-DP levels of \<1050 fmol/punch (representing fewer than mean 6-7 daily doses per week)) will trigger a targeted iNSC session. Participants with two TFV-DP levels of \<1050 fmol/punch will trigger PrEP Steps, a higher intensity adherence counseling intervention consisting of four 50-minute counseling sessions and 2 booster counseling sessions.
224232235|NCT02584140|DRUG|Daily Oral PrEP|All participants will be offered daily oral emtricitabine/tenofovir disoproxil fumarate for Pre-exposure Prophylaxis.
224232236|NCT01243554|BEHAVIORAL|Exercise|Exercise training at the hospital
224232237|NCT04259177|OTHER|Scale|This test is divided into 3 sections: neurological examination, developmental motor boundary stones and behavioral status, and consists of a total of 37 items. The first part consists of 26 items such as cranial nerve functions, posture, quality, amount of movements, muscle tone, reflex and reactions. The second part evaluates motor development boundary stones consisting of 8 items. The third part refers to the behavioral condition consisting of 3 items. These items can be easily scored. It can be rated as optimal or inadequate. Each item is scored separately (as 0, 1, 2, 3) and the final total score is calculated. The total score ranges from 0-78. The total score shows the global optimal scores.
223646257|NCT04167878|DEVICE|PEEK cage|ACDF with PEEK cage for spinal fusion procedure at one level (C2 to T1) of the cervical spine.
223646258|NCT06708520|DRUG|Rupatadine|10 mg tablets
223646259|NCT05715931|DRUG|Toripalimab|Toripalimab, 240 mg IV infusion on Day 1 of each 21 day cycle for 3 cycles prior to surgery and 3 cycles after surgery.
223646260|NCT05715931|DRUG|Trastuzumab|Trastuzumab, 8 mg/kg IV loading dose at 1st administration and then 6 mg/kg IV on Day 1 of each 21 day cycle for 3 cycles before surgery and 3 cycles after surgery. The first administration of trastuzumab after surgery should also be given at the loading dose of 8 mg/kg.
223646261|NCT05715931|DRUG|5-FU, leucovorin, docetaxel, oxaliplatin (FLOT)|"Pre-operative treatment 4 cycles and post-operative treatment 4 cycles:~Docetaxel 50 mg/m², IV on day 1 of each 14 day cycle; Oxaliplatin 85 mg/m² , IV on day 1 of each 14 day cycle; Leucovorin 200 mg/m² or Levoleucovorin 100 mg/m², IV on day 1 of each 14 day cycle; 5-FU 2600 mg/m², IV over 24 h on day 1 of each 14 day cycle."
223646262|NCT06725888|DEVICE|Vagitab -T vaginal tablets. Components: tyndallized probiotic L. plantarum HA-119, lactic acid, and xylo-oligosaccharides, lauryl glucoside, and macrogol 3350:|"Vagitab -T will be used for 3 monthly cycles of 10 days each. Metronidazole will be used for 1 cycle of 7 days at the start of the study~Metronidazole will be administered as follows:~500 mg intravaginally once per day for 7 days or 500 mg orally 2 times/day for 7 days"
223646263|NCT07043972|DRUG|Gemcitabine|IV over 30 minutes given on days 1 and 8 of a 21 day cycle
223646264|NCT07043972|DRUG|Carboplatin|IV over 30 minutes given on day 1 of a 21 day cycle
223646265|NCT03672578|OTHER|loss-frame|loss frame label
223646266|NCT03672578|OTHER|gain-frame|gain frame label
223766045|NCT05570409|DRUG|Mycophenolate Mofetil|Mycophenolate mofetil 1g bid for 6 months
223766046|NCT05570409|DRUG|Prednisolone|initially 1mg/kg in a step-down regime for 6 months
223766047|NCT05570409|DRUG|Mycophenolate Mofetil Placebo|MMF matching Placebo
223766048|NCT05570409|DRUG|Prednisolone Placebo|Prednisolone matching placebo
223646267|NCT03672578|OTHER|text-only|text-only label
223646268|NCT03672578|OTHER|icon|label with icon and text
223646269|NCT03672578|OTHER|attribution|label with attribution
223646270|NCT03672578|OTHER|no attribution|label with no attribution
223646271|NCT03672578|OTHER|No label|No label
223646272|NCT06704685|DRUG|Butylphthalide|Subjects who were initially diagnosed with STEMI and scheduled for PCI were randomly assigned to one of two groups in a 1:1 ratio: a butylphthalide group and a placebo group.
223646273|NCT06704685|DRUG|Butylphthalide placebo|Butylphthalide placebo
224232238|NCT00633282|BEHAVIORAL|Life style intervention|"calorie limited diet: to subtract 500 kcal from daily mean calorie intake when entering the treatment~activity: medium intensity aerobic exercise for more than 150 min per week with heart rate around 50-70% of the maximal heart rate; or higher-intensity aerobic exercise for more than 90min per week with heart rate around 70% of the maximal heart rate"
223646274|NCT05232682|DIETARY_SUPPLEMENT|Seed DS-01 Daily Synbiotic|Daily administration of Seed DS-01 Daily Synbiotic (dietary supplement)
223646275|NCT06377033|BEHAVIORAL|Behavioral nudge|Comparison of genetic rates among individuals for whom it may make a difference in their care across study arms.
223646276|NCT07045363|BEHAVIORAL|Cognitive Intervention|Participants in the intervention arm will receive a personalized one-page Heart Age report based on data from their government-funded annual health check. The report is delivered by trained physicians using a standardized communication script during a routine follow-up visit. The control group receives usual chronic disease care without structured risk communication.
223646277|NCT03002870|OTHER|Questionnaires|Patients will receive questionnaires yearly to follow their QOL
223646278|NCT07051746|BEHAVIORAL|Metacognitive Training (MCT), Traditional Chinese version|The intervention is a culturally adapted version of Metacognitive Training (MCT) for psychiatric populations in Taiwan. The program consists of 8 group sessions over 4 weeks. Each session includes psychoeducation, cognitive exercises, and group discussion to help participants recognize and reduce cognitive biases.
223646279|NCT03387085|DRUG|Aldoxorubicin HCl|Aldoxorubicin hydrochloride
223646280|NCT03387085|BIOLOGICAL|N-803|Recombinant human super agonist interleukin-15 (IL-15) complex
223646281|NCT03387085|BIOLOGICAL|ETBX-011|Ad5 \[E1-, E2b-\]-CEA
223646282|NCT03387085|BIOLOGICAL|ETBX-051|Ad5 \[E1-, E2b-\]-Brachyury vaccine
223646283|NCT03387085|BIOLOGICAL|ETBX-061|Ad5 \[E1-, E2b-\]-MUC1
223646284|NCT03387085|BIOLOGICAL|GI-4000|Vaccine derived from recombinant Saccharomyces cerevisiae yeast expressing mutant Ras proteins
223646285|NCT03387085|BIOLOGICAL|GI-6207|Vaccine derived from recombinant Saccharomyces cerevisiae yeast expressing mutant CEA proteins
223646286|NCT03387085|BIOLOGICAL|GI-6301|Vaccine derived from recombinant Saccharomyces cerevisiae yeast expressing mutant Brachyury yeast proteins
223646287|NCT03387085|BIOLOGICAL|haNK for Infusion|NK-92 \[CD16.158V, ER IL-2\]
223646288|NCT03387085|BIOLOGICAL|avelumab|Recombinant human anti-PD-L1 IgG1 monoclonal antibody
223646289|NCT03387085|BIOLOGICAL|bevacizumab|Recombinant human anti-VEGF IgG1 monoclonal
223646290|NCT03387085|DRUG|Capecitabine|5'-deoxy-5-fluoro-N-\[(pentyloxy) carbonyl\]-cytidine
223646291|NCT03387085|DRUG|Cisplatin|cis-diamminedichloroplatinum(II)
224232239|NCT00633282|DRUG|pioglitazone|pioglitazone tablet,15mg qd ,30 minutes before breakfast,for 16 weeks
224232240|NCT00633282|DRUG|berberine|berberine tablet 0.5g tid,30 minutes before each meal,for 16 weeks
223646292|NCT03387085|DRUG|Cyclophosphamide|2-\[bis(2-chloroethyl)amino\]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
224232241|NCT06227975|DRUG|[14C]-BMS-986368|Specified dose on specified days
224232242|NCT00442910|DRUG|3% SPL7013 Gel (VivaGel)|3% vaginal gel
224232243|NCT00442910|DRUG|Placebo Gel|Placebo for SPL7013 gel
224232244|NCT00442910|DRUG|HEC Placebo Gel|HEC Placebo gel intravaginally bd for 14 days
224232245|NCT02309125|PROCEDURE|immediate progressive loading using gingival formers|"Implant placement will be 1 mm subcrestally, and it will receive transmucosal healing using gingival former.~The gingival former will be replaced every 2 weeks by consequent larger size gingival former (at surgery time group A will receive 2 mm height gingival former which will be swapped by,3 mm, 4 mm and the last is 5 mm)."
224232246|NCT02309125|PROCEDURE|submerged healing|the implant placement will be 1 mm subcrestally, and it will receive unloaded healing.(submerged healing)
223646293|NCT03387085|DRUG|5-Fluorouracil|5-fluoro-2,4 (1H,3H)-pyrimidinedione
223646294|NCT03387085|DRUG|Leucovorin|L-Glutamic acid, N-\[4-\[\[(2-amino-5-formyl-1,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)methyl\]amino\]benzoyl\]-, calcium salt
223646295|NCT03387085|DRUG|nab-Paclitaxel|Benzenepropanoic acid, β-(benzoylamino)-α-hydroxy-(2aR, 4S, 4aS, 6R, 9S, 11S, 12S, 12aR, 12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a, 3, 4, 4a, 5, 6, 9, 10, 11, 12, 12a, 12b-dodecahydro-4,11-dihydroxy-4a, 8, 13, 13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca\[3,4\]benz\[1,2-b\]oxet-9-y1ester,(αR,βS)-(9CI) bound to albumin
223646296|NCT03387085|PROCEDURE|SBRT|Stereotactic Body Radiation Therapy
223646297|NCT07063862|DRUG|Psilocybin|Participants randomized to the psilocybin microdosing intervention will take 2mg (if participant weighs \<55kg) or 3mg (if participant weighs ≥55 kg) of psilocybin daily on Monday, Tuesday, Thursday, and Friday for two consecutive weeks.
223646298|NCT07063862|DRUG|Placebo|Participants randomized to the placebo intervention will take 2mg (if participant weighs \<55kg) or 3mg (if participant weighs ≥55 kg) of placebo daily on Monday, Tuesday, Thursday, and Friday for two consecutive weeks.
224232247|NCT02031848|OTHER|Diet Intervention|
224232248|NCT02031848|OTHER|Assessments and Diet Intake|
224232249|NCT00732290|DRUG|Clopidogrel then fluoxetine+clopidogrel|D1 : clopidogrel (Plavix) 600mg (8 tablets) one time D45 to D48 : Fluoxetine (Fluoxetine EG 20mg) 20mg (1 tablet) per day D49 : 20mg Fluoxetine + 600mg Clopidogrel
224232250|NCT00732290|DRUG|Fluoxetine+clopidogrel then clopidogrel|D1 to D4 : Fluoxetine (Fluoxetine EG 20mg) 20mg (1 tablet) per day D5: 20mg Fluoxetine + Clopidogrel (Plavix) 600mg (8 tablets) one time D49 : Clopidogrel 600mg one time
224232251|NCT00752323|DRUG|aminolevulinic acid|Given orally
223646299|NCT07067190|DEVICE|Conventional Bar Attachment|A rigid cast bar attachment fabricated and screwed onto three mandibular implants (placed at the midline and canine areas). The bar connects the implants to provide splinting and retention for a mandibular overdenture without the use of additional retentive components such as OT Caps. The overdenture is adjusted to fit passively over the bar and picked up intraorally.
223646300|NCT07067190|DEVICE|Bar with OT Cap Attachment|A cast bar attachment fitted with two OT Cap attachments, which are designed to improve prosthesis retention and load distribution. This bar system is installed on three mandibular implants (midline and canine regions). The mandibular overdenture is relined to incorporate the female retentive caps that snap onto the OT Caps. This system combines the splinting benefits of the bar with the resilient retention of stud attachments.
224232252|NCT00752323|PROCEDURE|Surgical Resection|Surgical resection - 6 biopsies from 3 fluorescent regions
224232253|NCT05852548|BEHAVIORAL|Parent-Mediated Intervention|Children with ASD will participate in a 6-month parent-mediated intervention that will include direct intervention and parent education.
224232254|NCT03653195|OTHER|urine metabolomics|We aim to determine of a specific urine metabolomic biomarkers can diagnose concussion.
223646301|NCT01008540|BIOLOGICAL|depistage|Virus isolation from urine, blood, or any suitable sample in case of CMV disease Resistance phenotype to antivirals UL97 and UL54 genes sequencing from blood, urines or any suitable samples for resistance mutations detection and polymorphism study
223646302|NCT07068152|BEHAVIORAL|Preoperative telenursing|The role of Nursing in Telenursing includes Nursing Consultation, Interconsultation, Consulting, Monitoring, Health Education and Reception of Spontaneous Demand mediated by Information and Communication Technologies. In this research, the researcher will make a telephone call the day before surgery to patients scheduled in the surgical map in order to guide them on immediate preoperative care.
223646303|NCT07068347|COMBINATION_PRODUCT|VR + lifestyle modification|"VR + lifestyle modification (Warm up,In VR kinetic sports I Bowling, Darts,Golf,Boxing,Beach Volleyball ,Table Tennis,Fruit Ninja)Passive glenohumeral joint mobilization,Scar tissue massage.In lifestyle modification walking at home for 30 min in 3-5 days /week. Dietry habits will be given according to American Institute for cancer Research.~In sleep habits Recommended Sleep Hours 7-9 hours per night,Establish a Consistent Sleep Schedule,Create a Comfortable Sleep Environment,Limit Screen Time Before Bed,Engage in Relaxation Techniques,Limit Caffeine and Alcohol Intake,Manage Nighttime Discomfort,Maintain a Pre-Sleep Routine,Address Emotional Health,Avoid Daytime Naps.Deep breathing exercise for stress management"
223646304|NCT07068347|COMBINATION_PRODUCT|VR only|VR only (Warm up,In VR kinetic sports I Bowling, Darts,Golf,Boxing,Beach Volleyball ,Table Tennis,Fruit Ninja)Passive glenohumeral joint mobilization,Scar tissue massage.
223646305|NCT07068347|COMBINATION_PRODUCT|Conventional physical therapy + lifestyle modification|Conventional physical therapy + lifestyle modification In Conventional physical therapy(Pumping exercise for upper limb,Pendulum exercises ,Shrugs for shoulder and rotations,In sitting position arms up with clasped hands ,Shoulder rotation (arms on sides-arms in abduction),Arms up with hands clasped again but in lying position ,Wand exercises ,M. pectoralis major-M. Pectoralis Minor stretches in supine and standing positions,Snow angels,Front and lateral climbing on wall ,Trunk rotation in standing position (in sitting position, if not tolerated)
223646306|NCT07068347|COMBINATION_PRODUCT|Conventional physical therapy only|Conventional physical therapy only((Pumping exercise for upper limb,Pendulum exercises ,Shrugs for shoulder and rotations,In sitting position arms up with clasped hands ,Shoulder rotation (arms on sides-arms in abduction),Arms up with hands clasped again but in lying position ,Wand exercises ,M. pectoralis major-M. Pectoralis Minor stretches in supine and standing positions,Snow angels,Front and lateral climbing on wall ,Trunk rotation in standing position (in sitting position, if not tolerated) ,Trunk lateral flexion with arms in 90 degrees abduction in standing position,Theraband (flexion-extension-abduction, adduction and internal-external rotation),Muscles of upper limb strengthening ,Mobilization for passive glenohumeral joint ,Tissue massage for scars.
223646307|NCT07064915|BEHAVIORAL|Medical-Financial Partnership Support|"The Medical-Financial Partnership (MFP) intervention will include (at minimum):~1. A relationship with a trained MFP intervention team member~2. Establishment of financial and social goals in the initial meeting, with connection to public anti-poverty programs, employment opportunities, and other income supports, among others, as tailored to participant goals~3. Establishment of an action plan to reach short, medium and long-term goals in core MFP domains~4. Co-designing with the participant to identify and refine goals and action steps longitudinally~5. A standard toolkit for access to financial services and public benefits"
223646308|NCT07068386|OTHER|Early intervention with telerehabilitation|"All premature infants aged 3 to 5 months included in the study were assessed for motor development using the General Movements Assessment (GMs) and the Alberta Infant Motor Scale (AIMS), based on videos submitted by their parents. Following the video evaluations, parents were contacted via video call. An intervention program was developed in collaboration with the parents, guided by the video-based assessments.~The intervention program focused on the acquisition of age-appropriate motor development and included components such as massage, positioning, trunk control, movement selectivity, and anti-gravity activities. It was delivered to parents through synchronous. Parents were advised to implement the program for 30 minutes per day, 4 days a week, over a 12-week period. After the intervention, the infants were re-evaluated using the AIMS via video call."
223646309|NCT07071675|DRUG|Calcium Hydroxide Intracanal medication|Treated using calcium hydroxide based material as an intracanal medicament
223646310|NCT07071675|DRUG|bioceramic based intracanal medication|treated using bio-ceramic based material as an intracanal medicament
224232255|NCT05586425|BEHAVIORAL|Emotion Regulation Skills + Treatment as Usual|ERS has been updated to be friendlier to youth and involves learning skills for how to: (1) be more present in the moment, (2) effectively manage and respond to emotional experiences, (3) communicate your needs to others, and (4) increase your ability to tolerate distress.
224232256|NCT05586425|BEHAVIORAL|Treatment as Usual|Treatment as Usual entails psychiatric medication management, psychiatric management, individual support from peer mentors, drop-in activity groups, etc.
223646311|NCT07069192|BEHAVIORAL|Counselling|Received structured caregiver counseling - weekly sessions for 1 month and biweekly for the next 2 months.
223766049|NCT07161115|RADIATION|Reduced-field short-course radiotherapy|A dose of 25 Gy in 5 fractions was delivered as short-course radiotherapy, with one fraction per day, completing treatment within one week. The target volume was delineated using both CT and MRI. Compared to conventional radiotherapy fields, the irradiated volume was significantly reduced to include only the primary tumor and any metastatic lymph nodes as identified on MRI and CT.
223766050|NCT07161115|DRUG|Immunotherapy combined with chemotherapy|After completion of radiotherapy, chemotherapy with the XELOX regimen (oxaliplatin 130 mg/m² on day 1 plus capecitabine 1500 mg/m² on days 1-14, every 3 weeks) was initiated in combination with sintilimab immunotherapy (200 mg every 3 weeks) for 4 cycles.
223766051|NCT07161115|RADIATION|Standard short-course radiotherapy|"Patients in the standard short-course radiotherapy group will receive 25 Gy in 5 fractions, once daily. Target volumes will be delineated according to the 2023 Guidelines for Target Volume Delineation and Planning of Rectal Cancer (National Cancer Center/National Cancer Quality Control Center), including the primary tumor, mesorectal region, and internal iliac and obturator lymph node drainage areas."
224232257|NCT00536900|BEHAVIORAL|Advisor-Teller Money Manager|The acronym for the functions of ATM are TTT-- Teller (storing patient funds), Training patients by making and reviewing monthly budgets, and Treatment-Linked Spending in which weekly behavioral contracts link disbursement to completion of abstinence-related activities
224232258|NCT00536900|BEHAVIORAL|FIT|FIT (finance instruction therapy) involves review of a financial workbook and budgeting sheets
223646312|NCT06849037|DRUG|zinacef tretment|prophylactic antibiotic treatment with zinacef
223646313|NCT06849037|OTHER|Placebo|I.V SALINE 100 CC X3/d
223646314|NCT07075263|OTHER|Questionnaire|A self-administered structured questionnaire
223646315|NCT07074821|DRUG|Taurolidine citrate 4% and heparin 500|Taurolidine ,citrate 4% and heparin 500 units per ml used as lock solution in tunneled hemodialysis catheter
223646316|NCT07075250|DRUG|Realgar-Indigo Naturalis Formulation Combined with Anlotinib|"RIF: Oral administration after meals, 6 tablets each time, three times daily (tid), from day 1 to day 14 (d1-14), every 3 weeks (q3w), continuous dosing.~Anlotinib : Oral administration before breakfast, 10 mg each time, once daily (qd), from day 1 to day 14 (d1-14), every 3 weeks (q3w), continuous dosing.~Subjects will continue the study treatment until meeting the protocol-defined discontinuation criteria. The total treatment duration should not exceed 18 months."
223646317|NCT07075770|DEVICE|Combined iTBS-tACS|The iTBS-tACS will be applied over the precuneus and last for 190 s, with the tACS electrode positioned on the scalp and the iTBS coil positioned just above it. The iTBS protocol will consist of 600 pulses, delivered in 20 trains of 10 bursts with an interval of 8 seconds between each train. Each burst consists of three pulses at 50Hz, repeated at 5Hz. The total duration will therefore be 190 seconds. iTBS and tACS will be synchronized using a BrainTrigger and SIGNAL Software so that both stimulations will start simultaneously
223646318|NCT07075770|DEVICE|iTBS-sham tACS|"The iTBS-tACS will be applied over the precuneus and last for 190 s, with the tACS electrode positioned on the scalp and the iTBS coil positioned just above it. The iTBS protocol will consist of 600 pulses, delivered in 20 trains of 10 bursts with an interval of 8 seconds between each train. Each burst consists of three pulses at 50Hz, repeated at 5Hz. The total duration will therefore be 190 seconds.~For the tACS sham condition, the electric current will not be applied, but there will be a 2 s 1 mA ramp up and 2 s 1 mA ramp down, to give the participant real stimulation feelings."
223646319|NCT07075770|DEVICE|sham iTBS- sham tACS|"The iTBS-tACS will be applied over the precuneus and last for 190 s, with the tACS electrode positioned on the scalp and the iTBS coil positioned just above it. The iTBS protocol will consist of 600 pulses, delivered in 20 trains of 10 bursts with an interval of 8 seconds between each train. Each burst consists of three pulses at 50Hz, repeated at 5Hz. The total duration will therefore be 190 seconds.~For the iTBS sham condition, stimulation was delivered with the coil angled at 90°, with only the edge of the coil resting on the scalp..~For the tACS sham condition, the electric current will not be applied, but there will be a 2 s 1 mA ramp up and 2 s 1 mA ramp down, to give the participant real stimulation feelings."
223646320|NCT07074717|PROCEDURE|Buccal Mucosal Graft (BMG) Urethroplasty|Urethroplasty using a buccal mucosal graft harvested from the inner cheek. The graft is dorsally onlaid to reconstruct the strictured urethral segment. The procedure is conducted under spinal or general anesthesia.
223646321|NCT07074717|PROCEDURE|Penile Skin Graft (PSG) Urethroplasty|Urethroplasty using a penile skin graft harvested from the ventral surface of the penis. The graft is applied dorsally after excision of the fibrotic urethral segment. The surgery is performed under spinal or general anesthesia.
223646322|NCT07074899|OTHER|Multi-component HIV testing and linkage-to-services intervention|"The intervention includes two core components:~1. HIV testing offered at sex-on-premises-venues \[SOPVs\];~2. mHealth-supported linkage to treatment/prevention services (enrollment in a two-way text messaging application adapted from the WelTel platform).~In this trial, the specific format of HIV testing offered will differ according to intervention arm."
223646323|NCT07074210|DEVICE|non invasive ventilation|Non invasive mechanical ventilation pressure support
223646324|NCT07074678|DIAGNOSTIC_TEST|Functional MRI (fMRI)|Research MRI, which will include both structural and functional sequences, will either be collected independently, or in conjunction with clinically-indicated sequences. Functional MRI captures the blood oxygen level dependent (BOLD) signal that reflects brain activity. A subset of the PREDICT study fMRI will include sequences with auditory and/or noxious stimulation. Noxious stimulation will be delivered with an MRI-compatible device that delivers intermittent nailbed pressure under computerized control. Additionally, the BOLD signal will be captured at rest to investigate functional neural networks.
223646325|NCT07074587|BEHAVIORAL|Pelvic floor muscle exercises|Pelvic floor muscle exercises will be taught with an innovative approach based on the principles of finding, feeling, forcing, following and functional training of the pelvic floor muscles. Pelvic floor muscle exercises will be applied as 3 sets in the first 2 weeks, 4 sets in the 3rd and 4th weeks, 5 sets in the 5th and 6th weeks, and finally 6 sets in the 7th and 8th weeks. Individuals will continue their pelvic floor muscle exercises as a home program.
223646326|NCT07074587|BEHAVIORAL|Spinal stabilization exercises focusing on the pelvic floor + Pelvic floor muscle exercises|This program consists of 3 phases: 30 minutes of spinal stabilization exercises focusing on the pelvic floor, 5 minutes of warm-up and 5 minutes of cool-down exercises.The exercises will consist of 3 phases: static, dynamic and functional phases. Individuals will perform static phase exercises for the first 2 weeks, then dynamic phase exercises in the 3rd and 5th weeks and finally functional phase exercise in the 6th and 8th weeks. Individuals will be asked to maintain neutral spine position and abdominal bracing during pelvic floor muscle contraction during all exercises. Individuals will maintain the contraction for 5-10 seconds for 10 repetitions in each position in all phases.
223646327|NCT07075211|DEVICE|MARPE (mini-screw assisted rapid palatal expansion)|MARPE (mini-screw assisted rapid palatal expansion) with two min screws in post-pubertal patients
223646328|NCT07074847|OTHER|Measure QFR|Collect blood samples from 100 patients with normal coronary angiography or stenosis less than 50%, centrifuge and collect plasma, and then send them for further metabolomics testing to analyze the test results.
223646329|NCT07075978|BEHAVIORAL|Remote patient monitoring|The usual interprofessional program activities are delivered via remote patient monitoring kits. The kit includes a tablet for virtual visits with the Mobile Health and Wellness Team and access to educational videos, as well as at-home monitoring devices for blood pressure, blood sugar if diabetic, pulse ox if COPD, and/or weight scale.
223646330|NCT07075978|BEHAVIORAL|Telephone|The usual interprofessional program activities are delivered via telephone visits without any at-home monitoring devices.
223646331|NCT07074093|COMBINATION_PRODUCT|app+smartband+education|"Intervention:~Behavioral: Health education~Device: AirVisual App~Device: Amazfit Band 5"
223680920|NCT06251479|BEHAVIORAL|behavioral 2|verbal and non verbal tasks with other partecipants
223646332|NCT07074132|BEHAVIORAL|Combined Aerobic and Muscle-Strengthening Training Program|A combined training program including both aerobic and muscle-strengthening physical activities within the same session, conducted over a period of 8 months. Aerobic training is performed at an intensity of 50-70% of heart rate reserve (HRR), and strength training at 60-70% of one-repetition maximum (1-RM). The training is conducted three times per week.
223646333|NCT00458172|BEHAVIORAL|Assessment of beliefs and attitudes|
223646334|NCT02462135|BEHAVIORAL|Virtual interactive memory training|Training sessions of the VIMT group are divided into initial training and booster training. Each training session is 45 minutes/day, 3 sessions/week, for 12 weeks for both initial training and booster training (36 sessions each). The training content of the four memory training include: (1) spatial encoding memory training task, (2) updating-spatial memory training task, (3) updating-visual memory training task, and (4) rehearsal-visuospatial memory training task.
223646335|NCT02462135|BEHAVIORAL|Passive information activities|The active control group (Passive information activities) only accepts the initial training phase, which training content of the two types to include: (1) listening to audio books, and (2) reading online newspaper.
223646336|NCT01136980|DEVICE|TIF Transoral Fundoplication|A novel surgical technique that creates a gastric fundoplication and restores competency of the gastroesophageal valve now exists for patients who have limited anatomic defects (small hiatal hernia). This technique is performed transorally using the EsophyX device (EndoGastric Solutions, Inc. Redmond, WA, USA) recreates a gastric fundoplication at the gastroesophageal junction by creating a flap valve at the intersection of the stomach and the esophagus by deploying polypropylene SerosaFuse fasteners (EndoGastric Solutions)
224232259|NCT06046664|DIAGNOSTIC_TEST|ONCOTYPE DX DCIS test|"The Oncotype DX DCIS score, comprised of 12 of the 21 genes of the Oncotype DX Recurrence score, has been developed by Genomic Health Inc.~Two clinical utility studies have now been performed in USA, assessing the value of the Oncotype DX DCIS to clinical decision making (18,19) The first study by Alvarado et al. evaluated the influence of the test in 10 centres and in 115 patients (18). The DCIS score led to a change in the treatment recommendation in 36 patients (31.3%; 26 patients had a change to no radiation and 10 patients had a change to recommend radiation). The second study similarly showed change in recommendations following the Oncotype DX DCIS test in 26.4% of cases. It is unclear what the impact of the DCIS score test would be in the UK."
224232260|NCT05608356|BIOLOGICAL|injectable platelet rich fibrin(i-prf)|I-prf is a second-generation PRP where autologous platelets and leukocytes are present in a complex fibrin matrix and can be obtained from blood using low-speed centrifugation without adding anticoagulants.
223646337|NCT01136980|OTHER|Sham placebo procedure|The Sham Procedure (control) will consist of an upper GI endoscopy that will be conducted under general anesthesia in an operating room. The surgical team will follow the same steps before, during, and after the sham procedure similar to the TIF procedure, except they will never insert the EsophyX device into the patient. The endoscope will be manipulated for 30-45 min as if the device were around it to simulate the effect of many rotations and manipulations on the esophagus.
223646338|NCT02103673|DRUG|DAOIB|Intervention drug: DAOIB. Dosage: 250-1500 mg/day by mouth. Duration: 6 weeks
224232261|NCT05608356|DRUG|Sham Injection|Sham injection as a placebo injection
224232262|NCT03486977|PROCEDURE|Evaluation of disease and follow-up|Correspondence medical consultation with specific device
224232263|NCT02724683|DEVICE|Ascites drainage with vascular catheter.|In case of symptomatic malignant ascites, the procedure of vascular catheter insertion into abdominal cavity will be performed, followed by slow, systematic drainage, on patient's demand.
224232264|NCT02724683|BEHAVIORAL|Interview.|Interview with patients will be performed according to attached chart. The aim is to collect data concerning patient's symptoms, co-morbidity, and basic clinical data about the primary malignancy and treatment status.
224232265|NCT02724683|BEHAVIORAL|Quality of life.|Quality of life questionnaire (QLQ). Patients will be asked to complete QLQ at two time points: 1. immediately before the procedure, 2. one or two weeks after the procedure.
224232266|NCT02724683|DEVICE|Quality of procedure.|Patients will be asked to complete quality of procedure questionnaire at one time point: one or two weeks after the procedure.
224232267|NCT02724683|OTHER|Nutritional status|Risk of malnutrition and ability to feed normally will be assessed with specific questionnaire at two time points: 1. immediately before the procedure, 2. one or two weeks after the procedure.
224232268|NCT00436358|OTHER|Not applicable: none|Please refer to the detailed description section
224232269|NCT01495377|DRUG|Remifentanil|Powder for injection/ infusion fluid solution, 1 mg Infusion TCI 3 ng/ml 60 min ( 0,15 ug/kg/min)
224232270|NCT01495377|DRUG|Placebo|Infusion fluid, solution 9 mg/ml ( hydrogenic solution )
224232271|NCT01495377|DRUG|Technetium|37-40 MBq( effective dose 0,7 mSv) 99Tc albumin colloid in a volume of 6 ml, infusion velocity 0,1 ml/min via a transnasal catheter
224232272|NCT01495377|DEVICE|Dynamometer (Jamar)|portable hydraulic hand dynamometer to assess grip strength.
223646339|NCT02103673|DRUG|Placebo|Intervention drug: placebo by mouth. Duration: 6 weeks
223646340|NCT03240549|DRUG|bevacizumab|The patients in conventional group continued the previous chemotherapy,and the patients in experimental group received adding bevacizumab to previous chemotherapy regimen.
223646341|NCT02941718|BEHAVIORAL|Sleep Advancement Counseling|Participants will receive cognitive behavioral counseling on achieving adequate sleep duration.
223646342|NCT02941718|BEHAVIORAL|General Health Information|Participants will receive educational information on general health topics including diet, physical activity, skin protection, oral health and cancer screenings.
223646343|NCT02561468|DRUG|Nefopam|
223646344|NCT02561468|DRUG|Saline|
223646345|NCT04791306|OTHER|supervised exercise training|Participates perform once a week for 4 months an in-house supervised endurance and strength training.
224232273|NCT01919632|BEHAVIORAL|health-behavior seminar and endurance exercise|The initial stage of the program consists of a health-behavior seminar and six weeks (twice a week for 90 minutes) of supervised endurance exercise (i.e. jogging, nordic walking, cycling or swimming) in groups. In the second phase of the program, the participants receive a recommendation to continue exercise regularly unsupervised for one year, and receive monthly supervised exercise training sessions.
224232274|NCT00355628|DRUG|KW-2246 (fentanyl citrate)|KW-2246
224232275|NCT00029679|DRUG|Gingko biloba|
224232276|NCT00029679|DRUG|Borage oil|
223646346|NCT04791306|OTHER|home-based exercise training|Participants are provided with an application for planning and documentation of their physical activity, together with an expert participants plan their physical activities for their home-based training to reach at least 150 min physical activity per week.
223646347|NCT00245752|DEVICE|acupuncture|acupuncture in points bilaterally: BL 67, LI 4, SP6, one in GV20.
223646348|NCT03383016|OTHER|Lifestyle questionnaires|
223646349|NCT03383016|DIAGNOSTIC_TEST|Prostate Biopsy|Possible follow-up by an urologist at 1 year and 2 years after recruitment. After 2 years, proposal for a 2-year end-of-study prostate biopsy to assess the presence or absence of prostate cancer.
223646350|NCT03136848|DRUG|Normothermic ex-vivo kidney perfusion Solution -Toronto|"The perfusion device will circulate warmed, oxygenated blood-based perfusate (Normothermic ex-vivo kidney perfusion solution-Toronto) through the kidney."
223646351|NCT00306319|DRUG|moxifloxacin|
223646352|NCT06186193|BEHAVIORAL|MyP|see above: attention exercise based on phone app
223646353|NCT00529867|DRUG|Artemether/lumefantrine tablets|"Artemether/lumefantrine tablets containing 20mg artemether and 120mg lumefantrine~Dosage: 5 - 14.9 kg: 1 tablet and 15 - 24.9 kg: 2 tablets~Administered at 0, 8, 24, 36, 48, and 60 hours on days 0, 1, and 2"
223646354|NCT00529867|DRUG|Artemether/Lumefantrine suspension|"Artemether/lumefantrine suspension containing 15mg artemether and 90mg lumefantrine per 5ml suspension~Dosage: 5.0 - 7.4 kg = 7 ml, 7.5 - 9.9 kg = 10 ml, 10 - 12.4 kg = 14 ml, 12.5 - 14.9 kg = 17 ml, 15 - 17.4 kg = 20 ml, 17.5 - 19.9 kg = 24 ml, 20 - 22.4 kg = 27 ml and 22.5 - 24.9 kg = 30 ml~Administered once daily at 0, 24, and 48 hours on days 0, 1 and 2"
223646355|NCT05832229|DRUG|Rosuvastatin|Patients meeting all eligibility criteria will be assigned to a randomization arm prior to initiation of a 4-week lead-in phase of the study. All participants will undergo a 4-week, open-label active run-in phase to evaluate initial safety and adherence to rosuvastatin. During this active run-phase, all participants will receive target dose rosuvastatin-- 20 mg daily (10 mg daily for participants of East-Asian ancestry or on a protease inhibitor). After the active run-in phase, all participants will continue with their pre-assigned randomization (1:1) treatment of rosuvastatin 20 mg daily (10 mg daily for participants of East-Asian ancestry or on a protease inhibitor) or matching placebo.
223646356|NCT01610778|DIETARY_SUPPLEMENT|Placebo|
223646357|NCT01610778|DIETARY_SUPPLEMENT|5-aminolevulinic acid phosphate|
223646358|NCT03743857|PROCEDURE|Manual Therapy|AP ankle mobilization
223646359|NCT00003518|DRUG|gemcitabine hydrochloride|
223646360|NCT00003518|DRUG|paclitaxel|
223646361|NCT01118000|PROCEDURE|limb ischemia preconditioning|limb ischemic preconditioning consists of three 5-min cycles of left upper limb ischemia induced by a blood pressure cuff placed on the left upper arm and inflated to 200 mmHg,with an intervention 5-min of reperfusion during which the cuff was deflated.
223646362|NCT02212951|DRUG|BIOD-531|
223646363|NCT02212951|DRUG|Humalog Mix 75/25|
223646364|NCT02212951|DRUG|Humulin R U-500|
223646365|NCT03536416|BEHAVIORAL|My Asthma in School|The intervention will include three arms. During the theatre workshop, the children will watch a theatre performance, and engage in a discussion at the end of the play, about what they have watched. The self-management workshops will cover a range of topics identified as barriers to self-management in our earlier study, and will be delivered to children with asthma only. The control group will receive usual care during the intervention.
223646366|NCT03766152|DEVICE|Adhesive bone conduction hearing aid (ADHEAR - Med El)|Patients are asked to wear an adhesive bone conduction hearing device which is attached to the mastoid with an adhesive adapter
223646367|NCT05480267|PROCEDURE|surgical treatment for lumbar spondylolisthesis|There are two surgical treatments for lumbar spondylolisthesis; one is UBE, and another is MIS-TLIF
223766052|NCT07161115|RADIATION|Standard long-course radiotherapy|Patients in the standard long-course radiotherapy group will receive 50 Gy in 25 fractions, once daily, five days per week, with concurrent oral capecitabine chemotherapy. Target volumes will be delineated according to the 2023 Guidelines for Target Volume Delineation and Planning of Rectal Cancer (National Cancer Center/National Cancer Quality Control Center), including the primary tumor, mesorectal region, and internal iliac and obturator lymph node drainage areas.
223766053|NCT07161115|DRUG|Chemotherapy|Two weeks after the completion of radiotherapy, patients will receive four cycles of CAPOX chemotherapy.
223646370|NCT04129008|DRUG|Indobufen and aspirin mimetic|Day 1 to 84±7: The first time: indobufen 100mg + aspirin mimetic; The second time: indobufen 100mg
224232277|NCT00118105|BIOLOGICAL|bevacizumab|Preoperative: 7.5 mg/kg, IV, Day 1 of cycles 1,2,3 Postoperative: 7.5 mg/kg, IV, Day 1 of cycles 1,2,3,4
223646371|NCT04129008|DRUG|Aspirin and indobufen mimetic|Day 1 to 84±7: The first time : aspirin 100mg+ indobufen mimetic; The second time: indobufen mimetic
223646372|NCT06840262|OTHER|Questionnaire Administration|Ancillary studies
223646373|NCT06840262|PROCEDURE|Regenerative Peripheral Nerve Interface Surgery|Undergo regenerative peripheral nerve interface surgery
223646374|NCT06840262|PROCEDURE|Targeted Muscle Reinnervation|Undergo targeted muscle reinnervation
223646375|NCT06789172|DRUG|OKN4395|OKN4395 oral dosing twice per day
223646376|NCT06789172|COMBINATION_PRODUCT|Pembrolizumab|200 mg IV every 3 weeks
223646377|NCT06789172|OTHER|Fasting|Fasting before first dose of OKN4395
223646378|NCT06789172|OTHER|Fed|Food provided to patient before first OKN4395 dose
223646379|NCT06789172|DRUG|H2 Receptor Antagonist|Famotidine 20 mg IV (as a slow push over 2 minutes) administered 3 hours prior to OKN4395
223646380|NCT06736028|BEHAVIORAL|Diet Therapy|Participants will be provided food to meet the ketogenic diet prescription for the 6-week weight maintenance phase.
223646381|NCT06736028|BEHAVIORAL|Calorie Restriction|Participants will follow a commercial low-energy diet and be provided with meal replacements for 4 weeks aiming to achieve a minimum of 5% weight loss.
223646382|NCT06736028|BEHAVIORAL|Behavioral Support|Participants will meet weekly with a registered dietitian, for a 20-minute consultation throughout the entire study period (10 weeks) to increase engagement and improve adherence and retention.
223646383|NCT06736028|BEHAVIORAL|Diet Therapy|Participants will have food provided to meet the standard low-fat diet prescription for the 6-week weight maintenance phase.
223646384|NCT03249402|DRUG|Ethinyl Estradiol + Levonorgestrel|Participants will receive one OC tablet containing EE 0.03 mg and LN 0.15 mg once daily on Days 1 to 21 in cycles 1 and 2.
223646385|NCT03249402|DRUG|JNJ-42847922|Participants will receive 40 mg of JNJ-42847922 once daily on Days 14 to 21 in cycle 2.
223646386|NCT06551116|DIAGNOSTIC_TEST|CE-10-IVD|Leftover tumor tissue from a routine biopsy will be sent for analysis.
223646387|NCT00751517|DRUG|Methotrexate|
223646388|NCT00751517|DRUG|Cyclophosphamide|
223646389|NCT00880919|DRUG|quetiapine extended-release|Seroquel XR 150mg/day vs Seroquel XR 300mg/day vs Placebo
223646390|NCT00880919|DRUG|Placebo|Seroquel XR 150mg/day vs Seroquel XR 300mg/day vs Placebo
223646391|NCT03745521|OTHER|no intervention|no intervention
223646392|NCT06255431|DRUG|Ezerra cream|"The research subjects were divided into 2 groups: group A (intervention cream on the right side of the face and control cream on the left side of the face) and group B (intervention cream on the left side of the face and control cream on the right side of the face).~The test material consists of a cream containing a mixture of spent grain wax extract, shea butter, and argan oil, along with a vehicle cream. Vehicle cream was prepared by the Pharmacy Department of Faculty of Medicine Universitas Indonesia and has similar consistency, color, and scent as the intervention cream.The creams are applied to the face twice daily (0,5 FTU), immediately after washing, in equal amounts on each side of the face. The creams are applied for 7 days, and participants are instructed to use appropriate sunscreen."
223646393|NCT03085602|BEHAVIORAL|Cognitive behavioral therapy|Therapy focused on explaining the physiological and psychological effects of nicotine. Training is focused on adherence to smoking instructions, physiological and psychological effects of nicotine, reviewing reasons for quitting, and coping with smoking urges. Smokers will be asked to begin smoking on a set schedule leading up to their quit day.
223646394|NCT03085602|BEHAVIORAL|Health education|Therapy that provides health education on the importance of healthy eating. Participants will be instructed to smoke as usual.
223646395|NCT00578825|DRUG|Lopinavir / Ritonavir plus Ribavirin|
223646396|NCT05641259|DRUG|LP-108|Oral administration for 21 or 28 days on a 28-day cycle
224232278|NCT00118105|DRUG|capecitabine|Pre \& Post Operative: 1,700 mg/m\^2/day, PO at 12 hr interval, Days 1-14 of cycles 1,2,3,4
224232279|NCT00118105|DRUG|oxaliplatin|130 mg/m\^2, IV, Day 1 of cycles 1,2,3,4
224232280|NCT00118105|PROCEDURE|conventional surgery|Resection
224232281|NCT01506947|DRUG|Paricalcitol|"Paricalcitol was administered by intravenous bolus. The initial dose was calculated according to the following formula:~\[Paricalcitol (µg) = iPTH (pg/mL) / 80\]. Subsequent doses were determined based on iPTH, calcium and phosphorus levels."
223646397|NCT05641259|DRUG|Azacitidine|Subcutaneous administration for 7 days on a 28-day cycle at the dose of 75mg/m2 2-2.5h hours after LP-108.
224232282|NCT01506947|DRUG|Darbepoetin alfa|Routine darbepoetin alfa use was allowed when transferrin saturation (TSAT) was ≥ 20% and ferritin ≥ 200 μg/L, and hemoglobin level \< 11.5 g/dL. The initial dose was 0.25 to 0.75 µg/kg/week, and the maintenance dose was 0.13 to 0.35 µg/kg/week. Target hemoglobin level was between 10 to 11.5 g/dL.
223646398|NCT03646552|DRUG|THX-110|"Participants will receive THX-110 in the following regimen:~Dronabinol will be slowly titrated in the first 10 days of the study and PEA will be given in a constant dose of 800mg per day for the entire duration of the study.~Patients will be followed for a total of 30 days."
223646399|NCT01576809|DRUG|IFF flavor 316 282, Paracetamol , Phenylephrine, Guaifenesin|Single dose syrup containing a warming flavor IFF flavor 316 282, in a syrup containing Paracetamol 500 mg + phenylephrine 10mg + Guaifenesin 200 mg per 30 ml syrup
223646400|NCT02015637|DRUG|Delafloxacin|single dose
223646401|NCT02015637|DRUG|Ceftriaxone|single dose
223646402|NCT00619814|PROCEDURE|Double-contrast Barium enema, colonoscopy|This is a blinded cohort study comparing double contrast barium enema (DCBE) and colonoscopy in detecting polyps and/or cancer in patients with positive FOBT. Initial evaluation consisted of complete clinical history and physical examination. A DCBE and a colonoscopy were performed in all patients. All polyps identified during colonoscopy were removed and classified by histology. Sensitivity and specificity of DCBE for polyp and/or cancer detection was determined. Tolerability and grade of satisfaction with study procedures was assessed.
224232283|NCT05865639|BEHAVIORAL|Aerobic Exercise|Three weekly, supervised exercise sessions with aerobic exercise. Each session will last for 60-65 minutes, each period will be consist of 5 min warm up, 45 min formal training and 5-10 min relaxation training. Intervention period will be eight weeks.
224232284|NCT05865639|BEHAVIORAL|Time Restricted Fasting|Restricted daily window of caloric intake to maximum 8 hours. Intervention period will be eight weeks.
224232285|NCT03791749|OTHER|Breastfeeding Support|12-minute simple technique
224232286|NCT00677196|DEVICE|The stonebreaker arm (LMA Stonebreaker)|The interventional device name is the LMA Stonebreaker pneumatic handheld lithotriptor.
224232287|NCT00677196|DEVICE|Pneumatic Lithotripsy (Swiss LithoClastR)|Pneumatic lithotripsy, the Swiss LithoClastR during percutaneous nephrolithotripsy (PNL)
224232288|NCT01421706|DRUG|Sibutramine-clopidogrel|Sibutramine-clopidogrel
224232289|NCT01421706|DRUG|sibutramine-Clarithromycin|sibutramine-Clarithromycin
224232290|NCT04179045|DEVICE|The Bioheart Rapamycin Drug-Eluting Bioresorbable Coronary Stent System|Subjects enrolled will be treated with Bioheart Rapamycin Drug-Eluting Bioresorbable Coronary Stent.
224232291|NCT02820922|PROCEDURE|Orthopedic|anesthesia techniques with regard to age, sex, ASA score, anaesthesia technique, comorbidities, surgery diagnosis, length of surgery, complications and admission to intensive care unit after surgery
224232292|NCT00528242|DRUG|SLx-2101|
224232293|NCT00528242|DRUG|Placebo|
224232294|NCT02503943|DRUG|"Liraglutide and Mitiglinide"|"Liraglutide(1.2mg/d) and Mitiglinide (50mg, 3/d)"
224232295|NCT02503943|DRUG|"Metformin and Mitiglinide"|"Metformin(500mg, 3/d) and Mitiglinide(50mg, 3/d)"
224232296|NCT02503943|DRUG|"Mitiglinide"|"Mitiglinide (50mg, 3/d)"
224232297|NCT05364827|DIAGNOSTIC_TEST|CTCA|CTCA performed in intervention arm patients prior to CTO PCI
224232298|NCT03131180|OTHER|Rapid Learning Healthcare System|The investigators created a Rapid Learning Healthcare System that integrates pre-specified data elements and validated surveys within the clinical workflow in order to operationalize automated research data collection and integrate predictive analytics into the electronic health record (EHR). Patients, caregivers, and physicians access data in order to make informed, shared decisions about care and align expectations about outcomes.
224232299|NCT04782648|PROCEDURE|transit bipartition|transit bipartition as revisional bariatric surgery for weight regain after sleeve gastrectomy
224232300|NCT04540640|DEVICE|Kidney perfusion pump|The pulsatile perfusion device will circulate room temperature oxygenated perfusion solution through the donor kidney ex vivo.
224232301|NCT00496444|DRUG|Azacitidine|Starting Dose 20 mg/m\^2 administered subcutaneously (under the skin), daily, for ten days (Days 1 -10) of every 4 Week Cycle.
224319965|NCT04255277|DRUG|Moxifloxacin 400mg|A commercially available formulation of moxifloxacin 400 mg will be used and administered open-label. All tablets will be from the same batch.
224319966|NCT04255277|DRUG|Cenerimod 0.5 mg|This will be administered orally as a film-coated tablet in the morning.
224319967|NCT04255277|DRUG|Cenerimod 4 mg|This will be administered orally as a film-coated tablet in the morning.
224319968|NCT04255277|OTHER|Charcoal, activated|Granules for oral suspension will be used and administered open-label.
224319969|NCT04255277|DRUG|Matching Placebo|Cenerimod matching placebo tablets will be administered once daily orally in the morning.
223646403|NCT05298553|DEVICE|Group A|Participants will be asked to perform a simultaneous 30-seconds 12-lead ECG and single-lead ECG for each wearable device: Skylab CART-I ring followed by Apple Watch.
224319970|NCT05200208|DIETARY_SUPPLEMENT|Citicoline supplement|Participants with AD will receive a dietary citicoline supplement. Subjective sleep measures will be measured via the Pittsburgh Sleep Quality Index (for measurement of sleep quality) and Epworth Sleepiness Scale (for measurement of sleepiness). Cognition will be measured by Rey Auditory Verbal Learning Test (RAVLT), Trail Making Test (TMT) Parts A \& B, and the Montreal Cognitive Assessment (MOCA). Participants will complete all questionnaires at baseline and at follow-up at 3 months.
223646404|NCT05298553|DEVICE|Group B|they will be asked to perform a simultaneous 30-seconds 12-lead ECG and single-lead ECG for each wearable device: Apple Watch followed by the Skylab CART-I ring.
223646405|NCT03085264|BEHAVIORAL|Community Health Worker|Community Health Workers calls, texts and visits patient to support them in pre-established care plans as well as medication compliance/appointment attendance
223646406|NCT02354196|PROCEDURE|CCTA|CT of heart to assess coronary disease
224232302|NCT00496444|DRUG|Valproic Acid|Starting Dose 10 mg/Kg once daily by mouth, every day of 4 Week Cycle.
223646407|NCT01855061|PROCEDURE|Biopsy|"Histological biopsy of the index lesion (a radiological measurable lesion on which biopsy is performed) at baseline, as well as when showing progressive disease. Histological biopsies will be subjected to DNA sequencing to assess the mutational profile, as well as to analysis of carboxylesterase activity."
224232303|NCT01648010|DEVICE|TC-3 gel|One intravesical instillation of 40 cc of TC-3 hydrogel is instilled using catheter.
224232304|NCT01648010|DEVICE|TC-3 gel mixed with Mitomycin C (MMC)|One intravesical instillation of 40 cc of TC-3 gel mixed with 40 mg MMC will be instilled using catheter
224232305|NCT00257712|DRUG|TH9507 human growth hormone releasing hormone (GHRH)|1mg subcutaneous injection given daily for 20 weeks
224319971|NCT05200208|OTHER|Placebo|Participants with AD will receive a placebo supplement. Subjective sleep measures will be measured via the Pittsburgh Sleep Quality Index (for measurement of sleep quality) and Epworth Sleepiness Scale (for measurement of sleepiness). Cognition will be measured by Rey Auditory Verbal Learning Test (RAVLT), Trail Making Test (TMT) Parts A \& B, and the Montreal Cognitive Assessment (MOCA). Participants will complete all questionnaires at baseline and at follow-up at 3 months.
224319972|NCT06311838|BEHAVIORAL|Motivational Interviewing/Community Reinforcement Approach (MI/CRA)|MI/CRA includes two Motivational Interviewing sessions and twelve 1-hour Community Reinforcement Approach sessions.
224319973|NCT06311838|BEHAVIORAL|Strengths-Based Outreach and Advocacy (SBOA )|The number of Strengths-Based Outreach and Advocacy sessions participants will receive are flexibly determined based upon youth needs.
224319974|NCT06311838|BEHAVIORAL|Services as Usual (SAU)|Participants assigned to this group will receive the standard services provided to all youth involved with the drop-in center.
223646408|NCT01855061|PROCEDURE|Blood samples|Blood samples will be taken at baseline to determine patient's genetic background variation (germline DNA).
223646409|NCT01855061|PROCEDURE|Pharmacokinetics|Blood samples will be taken for pharmacokinetic analysis of the active irinotecan metabolite (SN-38).
223680921|NCT06251479|DEVICE|neuromodulation 1|registration with neurophysiological tecniques during verbal and non verbal tasks
224232306|NCT01700621|BIOLOGICAL|Rotarix vaccine|one 1.0 ml dose of oral rotavirus vaccine at 9 months of age
224232307|NCT01700621|BIOLOGICAL|measles-rubella vaccine|one 0.5 ml subcutaneous dose of live attenuated measles-rubella vaccine
224232308|NCT03282838|DRUG|DFN-15 (fasted)|DFN-15 administered to fasted subjects
224232309|NCT03282838|DRUG|DFN-15 (fed)|DFN-15 administered to fed subjects
224232310|NCT03282838|DRUG|Comparator Celebrex® (fed)|Comparator (Celebrex®) administered to fed subjects
224232311|NCT05389943|DRUG|Oral administration of vitamin D3|the effect of oral supplement in postmenopausal women.
224232312|NCT05389943|DRUG|Vitamin D3 50000 UNT Oral Capsule|In postmenopausal women with BMD less than 32 ng/ml
224232313|NCT05389943|DIETARY_SUPPLEMENT|milk, Dietary and life style modifications.|Postmenopausal women with BMD greater than 32 ng/ml
224232314|NCT03923764|DIETARY_SUPPLEMENT|High protein and energy diet|Intervention group receives nutritional counseling to increase protein and energy in their diet to reach their estimated protein need (1.3 g/kg). Kontrol group continues their usual diet.
224232315|NCT03923764|OTHER|Habitual Diet|Patients continue their usual diet
224232316|NCT03487055|BIOLOGICAL|TK006|Subcutaneous injection in the upper arm
224232317|NCT05770752|PROCEDURE|Elevated pressure ventilation|Elevated pressure ventilation is defined as a raise in PIP and PEEP by 10 cmH2O from each patients original pressure setting, although never higher than a PIP of 30 cmH2O.
224232318|NCT02210715|DRUG|Isentress.|28 subjects will change from their normal cART treatment to Raltegravir, which will be given at the standard dose of 400 mg p.o. b.i.d. for 24 months.
224232319|NCT02210715|OTHER|Continue usual antiretroviral therapy|28 subjects will continue with their normal cART treatment, as prescribed by their treating physician.
224232320|NCT03332693|OTHER|Exercise|Leg weight raising
223646410|NCT01855061|PROCEDURE|Midazolam clearance test|Patients who are being treated in Rotterdam will be subjected to blood draws for validation of the earlier developed midazolam phenotyping test (midazolam clearance test), which may be an indicator for pharmacokinetics of irinotecan.
223646411|NCT05542719|OTHER|application|"Through the application, determine if the patient is out of LDL-C goals for referral and treatment review.~Show the usefulness of the application in achieving dyslipidemia treatment goals in patients with high and extremely high cardiovascular risk"
223646412|NCT01695304|OTHER|Ceramic water filter|In total, 120 households with a child 4-10 months old will receive a Cera Maji ceramic water filter for treatment of drinking water at initial entry into the study (intervention group), and 120 households with a child 4-10 months old at initial entry into the study will not receive a ceramic water filter (control group). The study duration will be 6 months. All households in the control group will receive a Cera Maji ceramic water filter when the study ends.
223646413|NCT05821062|OTHER|standard Aspirin (ASA) + clopidogrel (CLP) therapy|ASA100mg + CLP 75mg daily
223646414|NCT05821062|OTHER|standard Aspirin (ASA) + Ticagrelor (TCG) or Prasugrel (PSG) therapy|ASA 100 mg + TCG 90mg/b.i.d or PSG10mg daily
223646415|NCT05821062|OTHER|standard ASA therapy|ASA 100 mg daily
223646416|NCT02122003|DRUG|Sorafenib|Sorafenib 400 mg bid
223646417|NCT05155267|OTHER|Biomonitoring study to detect MNPLs in biological samples and study of their health effects|Determination of MNPLs levels, genotoxic damage and immunological effects
223646418|NCT05590078|DEVICE|Virtual reality session|The 20-minute virtual reality session, in the outpatient department before surgery, immerses the patient in calm environments combined with music therapy and breathing exercises to relax and reduce anxiety.
223646419|NCT05590078|OTHER|State Trait Anxiety Inventory|"The State Trait Anxiety Inventory (State anxiety) is a questionnaire given to adults that shows how strong a person's feelings of anxiety are right now, just now. The score is measured on arrival in the outpatient department and just before going into the intervention room (= after the virtual reality session for the experimental group)"
223646420|NCT05590078|OTHER|Virtual Reality Satisfaction Score|Likert scale satisfaction questionnaire to collect the patients' satisfaction regarding virtual reality session
224232321|NCT03332693|OTHER|No exercise|Volunteers will not participate in exercise
224232322|NCT05757011|PROCEDURE|pre-sacral nerve block (bupivacaine injection into both uterosacral ligaments at the end of laparoscopic hysterectomy.|pre-sacral nerve block (bupivacaine injection into both uterosacral ligaments at the end of laparoscopic hysterectomy.
224232323|NCT02166697|DRUG|candesartan cilexetil|candesartan cilexetil tablets
223646421|NCT05590078|OTHER|Perioperative care satisfaction score|Likert scale satisfaction questionnaire to collect the patients' satisfaction regarding perioperative care
223680922|NCT06251479|DEVICE|neuromodulation 2|registration with neurophysiological tecniques during verbal and non verbal tasks with other partecipants
223680923|NCT00475475|BEHAVIORAL|Fructose|25% of energy intake in the form of a fructose-sweetened beverage (arm 1), a glucose-sweetened beverage (arm 2), or an isovolumetric amount of a beverage sweetened with a non-caloric sweetener
224232324|NCT00939653|DRUG|Clofarabine|40 mg/m2/day IV over 2 hours (given at hours 0 to 2) on days 1 through 5.
224232325|NCT00939653|DRUG|Etoposide|100 mg/m2/day IV over 2 hours (given at hours 2 to 4) on days 1 through 5.
224232326|NCT00939653|DRUG|Cyclophosphamide|440 mg/m2/day IV as a 30-60 minute infusion (given at hours 4 to 5) on days 1 through 5.
224232327|NCT00939653|DRUG|Filgrastim|Administered in Courses 1 and 2 only. 5 micrograms/kg/day IV or SC will begin on Day 6 and end when the ANC is \> 1000 x 2 days.
224232328|NCT00939653|DRUG|Cytarabine|"Given intrathecally on day 1 at the dose defined by age below:~30 mg for patients age 1-1.99 50 mg for patients age 2-2.99 70 mg for patients \>3 years of age"
224232329|NCT00515645|OTHER|Head-down tilt and immersion|Head-down tilt -6° at inclusion, head-down tilt -15° at week one and Water Immersion at week two
224232330|NCT03622658|BIOLOGICAL|Placebo|Placebo solution for subcutaneous injection.
224232331|NCT03622658|BIOLOGICAL|Namilumab|Namilumab solution for subcutaneous injection
224232332|NCT02720510|DRUG|Revlimid|Revlimid was used with dexamethasone to treat patients with multiple myeloma
224232333|NCT02720510|DRUG|Velcade|Velcade was a proteasome inhibitor indicated for treatment of patients with multiple myeloma
224232334|NCT02720510|DRUG|dexamethasone|Dexamethasone was a steroid used to treat patients with multiple myeloma.
224232335|NCT02720510|DRUG|Farydak|FARYDAK® (panobinostat) capsules was a prescription medicine used, in combination with bortezomib and dexamethasone, to treat adults with a type of cancer called multiple myeloma after at least 2 other types of treatment have been tried.
224232336|NCT01208012|DRUG|Victoza®|Patients taking Metformin at individual dose and Liraglutide 0.6 mg once daily for the 1st week, 1.2 mg daily for another 5 weeks, 1.8 mg daily for another 6 weeks. When arrived at the dosage of 1.8 mg daily and the dose is not tolerated by the patient, the dose of Liraglutide can be decreased.Liraglutide is injected in the subcutaneous tissue once daily
224232337|NCT05585996|BIOLOGICAL|CD19 CAR-T and CD19 CAR-DC|Intravenously injected CAR DC cells and followed by CAR T cells 4 hours later
224232338|NCT00983710|BEHAVIORAL|PC-PEP - Prostate Cancer Patient Education Program|Men in the intervention group will receive a new patient education intervention to help them manage side-effects related to treatment for localized prostate cancer. The intervention will be delivered by phone and by mail and is targeted to me with low health literacy. The intervention consists of written materials, audio materials, and telephone-based problem-solving education.
224232339|NCT00983710|BEHAVIORAL|Usual care|Booklet on coping with localized prostate cancer
224232340|NCT02869646|PROCEDURE|Procedure: Acupuncture|Acupuncture is a general term indicating the insertion and stimulation of needles at one or more prescribed points in order to effect the biology of the individual.
223680924|NCT00475475|BEHAVIORAL|glucose|25% of energy intake in the form of a fructose-sweetened beverage (arm 1), a glucose-sweetened beverage (arm 2), or an isovolumetric amount of a beverage sweetened with a non-caloric sweetener
223646422|NCT02223858|BEHAVIORAL|Positive Activities (PA) Program|6-week program of at-home activities (1 per week) that have been shown to increase positivity. Activities were delivered via activity booklets and oral instructions provided during weekly telephone calls from trained interventionists. Interventionist oriented participants to the booklets and reviewed the first activity at the end of an in-person baseline visit. Booklets contained all instructions patients needed to complete the full program. Interventionists also provided support via weekly calls in which they assessed completion of the previous week's activity, reviewed instructions for the next activity, and helped participants trouble-shoot anticipated barriers.
223646423|NCT02223858|BEHAVIORAL|Attention Control (AC) Program|6-week program of at-home activities (1 per week) based on affectively neutral activities from control conditions in studies of positive activities interventions. Activities were delivered via activity booklets and oral instructions provided during weekly telephone calls from trained interventionists. Interventionist oriented participants to the booklets and reviewed the first activity at the end of an in-person baseline visit. Booklets contained all instructions patients needed to complete the full program. Interventionists also provided support via weekly calls in which they assessed completion of the previous week's activity, reviewed instructions for the next activity, and helped participants trouble-shoot anticipated barriers.
223646424|NCT01829906|BEHAVIORAL|Multidisciplinary outpatient programme|
223646425|NCT01829906|BEHAVIORAL|Inpatient lifestyle programme|
223646426|NCT03529591|DEVICE|Selective laser trabeculoplasty (SLT)|In this study, treatment naive patients with bilateral ocular hypertension or primary open angle glaucoma are treated with 180 degrees SLT in one eye and 360 degrees SLT in the contralateral eye. The primary outcome measure is assessing the response to SLT in both eyes and comparing the intraocular pressure outcomes between the two eyes of each patient.
223646427|NCT03529591|PROCEDURE|Selective laser trabeculoplasty|In this study, treatment naive patients with bilateral ocular hypertension or primary open angle glaucoma are treated with 180 degrees SLT in one eye and 360 degrees SLT in the contralateral eye. The primary outcome measure is assessing the response to SLT in both eyes and comparing the intraocular pressure outcomes between the two eyes of each patient.
223646428|NCT04936087|OTHER|The World Health Organization 8 steps for manual wheelchair service delivery|"All study participants were provided with a new wheelchair, a wheelchair cushion, and wheelchair services, delivered by trained wheelchair service providers, according to the WHO 8-step wheelchair service delivery process including assessment, fitting, and a 30-minute individual or group training on 7 wheelchair skills, device care, and pressure injury prevention techniques. Additionally, wheelchair maintenance reminders were sent through a text message service (SMS) to a sub-cohort of participants.~Wheelchair users were provided with one of three different, International Standards Organization (ISO) tested, wheelchair models according to the users' needs and availability: standard, active, and all-terrain models. All wheelchairs were provided with a basic contour cushion made of polyurethane foam. However, whenever a risk of pressure injury was identified for a study participant, wheelchair providers fabricated a pressure-relief cushion."
223646429|NCT04733859|DIETARY_SUPPLEMENT|placebo group|subjects drank 50 ml , 1 bottle a day for 8 week
223646430|NCT04733859|DIETARY_SUPPLEMENT|red djulis drinks|subjects drank 50 ml , 1 bottle a day for 8 week
223646431|NCT00971152|DRUG|menotropins for injection|comparison of different dosages
223646432|NCT00971152|DRUG|urofollitropin for injection|comparison of different dosages
223646433|NCT04455815|DRUG|Camostat|Patient to receive treatment with camostat tablets, 200mg four times daily (qds) for 14 days.
223646434|NCT00004114|BIOLOGICAL|filgrastim|
223646435|NCT00004114|DRUG|cyclophosphamide|
223646436|NCT00004114|DRUG|cytarabine|
223646437|NCT00004114|DRUG|fludarabine phosphate|
223646438|NCT00004114|PROCEDURE|peripheral blood stem cell transplantation|
223646439|NCT03458195|OTHER|bio-banking collection|blood samples, biopsies, and surgical specimen collected in addition to usual practice
223646440|NCT00218218|DRUG|Transdermal Nicotine Patch|42 mg transdermal nicotine
224232341|NCT02869646|PROCEDURE|Procedure: Sham acupuncture|Sham acupuncture is a general term indicating the use of needles, whether inserted or not, at points on the body that are not expected to have a clinically significant biological effect.
224232342|NCT02063295|DRUG|ZGN-440 sterile diluent|ZGN-440 sterile diluent/placebo
224232343|NCT02063295|DRUG|ZGN-440 for injectable suspension|
224232344|NCT01992055|BEHAVIORAL|Goal Management Training|Participants will be randomly assigned to the GMT Treatment. The GMT cognitive rehabilitation intervention program will be administered in group format, consisting of 8 sessions, including structured psychoeducation, relaxation training, and stepwise learning of GMT.
224232345|NCT01992055|BEHAVIORAL|Education & relaxation training|The Education \& Relaxation Training Control Group program will also be administered in group format, consisting of two sessions, including structured psychoeducation and relaxation training. Participants assigned to the Control condition will be offered the opportunity to complete the full GMT program following the completion of the study.
224232346|NCT02780336|OTHER|No intervention.|Participants will complete questionnaires and interviews as well as have a neurological exam that will be video recorded. For this exam they will do simple movements (like looking at the camera, squeezing your eyes closed, moving your head, and writing).
224232347|NCT03003338|DRUG|OBV/PTV/r and DSV|OBV/PTV/r (12.5 mg/ 75 mg/ 50 mg) in combination with DSV (250 mg): Two tablets of OBV/PTV/r in the morning and one tablet of DSV in the morning and one tablet of DSV in the evening orally with a meal without regard to fat or calorie content.
224232348|NCT03003338|DRUG|Placebo to match OBV/PTV/r and DSV|Placebo to match OBV/PTV/r and DSV
223646441|NCT00218218|DRUG|21 mg transdermal nicotine|
223646442|NCT00218218|DRUG|placebo patch|
223646443|NCT04106206|DRUG|LY3372689|Administered orally
223646444|NCT04106206|DRUG|Placebo|Administered orally
223680925|NCT00475475|BEHAVIORAL|non-caloric sweetener|25% of energy intake in the form of a fructose-sweetened beverage (arm 1), a glucose-sweetened beverage (arm 2), or an isovolumetric amount of a beverage sweetened with a non-caloric sweetener
223680926|NCT03621618|DIAGNOSTIC_TEST|dobutamine|evaluation of effects of dobutamine on dynamic arterial elastance in cardiac failure
223680927|NCT03621618|DIAGNOSTIC_TEST|norepinephrine|evaluation of effects of norepinephrine on dynamic arterial elastance in sepsis
223646445|NCT02747498|PROCEDURE|Procedure with circumferential pulmonary vein isolation|We will compare circumferential pulmonary vein (PV) isolation (CPVI) alone and posterior box isolation in addition to CPVI in patients with AF recurrence after de novo ablation procedures and with PV reconnections with 1:1 randomization. We will conduct ablation procedures by 3D electroanatomical mapping guidance and confirm bidirectional blocks of each ablation lines by differential pacing. For posterior box isolation, we will ablate remaining atrial potentials with point by point ablation to avoid the risk of esophageal injury at posterior inferior line. In all patients, mapping and ablation for non-pulmonary vein foci will be done with isoproterenol infusion at the end of the procedure. We will compare procedure time, ablation time, procedure related complication rates, and clinical recurrence rate of AF during follow-up period.
224232349|NCT05045118|OTHER|Digital Structured Patient Education Material|Participants of home-based Cardiac Rehabilitation Program that are included in this research will be provided with a digital Structured Patient Education Material at the beginning of the program, and will be followed up for 12 weeks duration
224319975|NCT03922529|BEHAVIORAL|MACRO-I|MACRO-I coaches engage with patients regularly while they are still inpatients, and then by telephone once they are discharged. Coaching incorporates innovative techniques for holistic risk assessment (medical, functional, psychosocial), guidance to initiate CR in a format aligned with each patient's risks and preferences (i.e., CR as either site-based, home-based, or in a hybrid format \[site transitioning to home\]), behavioral prompts based on their personal goals of care, and de-prescribing of sedating medications.
223646446|NCT02747498|PROCEDURE|Procedure with linear ablation in addiction to pulmonary vein isolation|We will compare circumferential pulmonary vein (PV) isolation (CPVI) alone and posterior box isolation in addition to CPVI in patients with AF recurrence after de novo ablation procedures and with PV reconnections with 1:1 randomization. We will conduct ablation procedures by 3D electroanatomical mapping guidance and confirm bidirectional blocks of each ablation lines by differential pacing. For posterior box isolation, we will ablate remaining atrial potentials with point by point ablation to avoid the risk of esophageal injury at posterior inferior line. In all patients, mapping and ablation for non-pulmonary vein foci will be done with isoproterenol infusion at the end of the procedure. We will compare procedure time, ablation time, procedure related complication rates, and clinical recurrence rate of AF during follow-up period.
223646447|NCT04593199|BEHAVIORAL|Gamified Smartphone App|The primary objective was to determine the acceptability and satisfaction of the Draco app among children. Secondary objective was to evaluate if the Draco app could improve physical activity levels (steps, and moderate-to-vigorous physical activity) and intrinsic motivation for physical activity in children. The gamified smartphone app, Draco, is a virtual pet simulator where you care for a pet by exercising, walking, and answering healthy lifestyle questions.
223646448|NCT04593199|BEHAVIORAL|Physical activity tracking app|Participants were asked to use the Fitbit app to track and sync their daily physical activity.
223646449|NCT04063007|OTHER|Ketogenic diet|The patients follow the ordinary treatment protocol for ketogenic diet
223646450|NCT02106390|BIOLOGICAL|Meningococcal group B Vaccine, rMenB+OMV NZ|4 doses administered intramuscularly on Days 1, 61, 121 and 301 with blood draw visits at Days 1, 151, 301 and 331 and who will receive reminder calls at 2 and 4 days after each vaccination visit and safety calls on Days 201 and 251.
224232350|NCT05043636|DEVICE|Vagus|Cardiovascular autonomic neuropathy (Vagus) both resting heart rate variability and cardiovascular reflex tests The examination consists of 4 measures, all aimed at measuring heart rate. Measurements are taken for 5 minutes rest, change of position from lying to standing position, during deep breathing and by Valsalva (by breathing in a mouthpiece with a 40 mmHg resistance).
224232351|NCT05043636|DEVICE|HeartsTrends|• Cardiovascular autonomic neuropathy (HeartTrends®) measurers 60-minutes heart rate variability via a chest belt electrode (a Holter monitor) and an external data acquisition device.
224232352|NCT05043636|DEVICE|Sudoscan|Peripheral small-fiber sympathetic function (Sudoscan), measuring sudomotor function by electrochemical skin conductance in hands and feet
224232353|NCT05043636|DEVICE|UllMeter|• Pressure pain sensitivity of the chest bone is recorded (with a device which has the size and shape as a pen)during rest as a measure for sympathetic autonomic activity of the brain (UllMeter®) (www.stressmeter.org)
224232354|NCT05043636|DEVICE|DPN-check|Nerve conduction velocity and amplitude of the Sural nerves by DPN-check
224232355|NCT05043636|DEVICE|Rolltemp|Cold and warm sense of foot and lower leg
224232356|NCT05043636|DEVICE|Dexcom G6 Device|"Insertion of continuous glucose monitor ( The Dexcom G6 Device)~After 10 days in the study the patient will return the glucose monitor and diary by prepaid mail.~Glycemic variability and hypoglycemia duration will be calculated from CGM data. Glycemic variability will be assessed by standard deviation (SD) and Coefficient of Variance (CV). We define normo-glycemic range as sensor glucose between 4.0 and 10.0 mmol/L. Hypoglycemia will be defined in two ranges as SG ≤3.9 mmol/L or SG ≤3.0 mmol/L). An episode of hypoglycemia will be defined as at least 15 minutes with SG below 3.9 mmol/L or 3.0 mmol/L, respectively. CGM recordings with less than 72 hours of data will be excluded from analysis."
224232357|NCT04005664|DRUG|Phenylephrine|Prophylactic phenylephrine infusion as part of fluid coload
224232358|NCT03886090|BEHAVIORAL|aerobic exercise|Single-bout of moderate intensity aerobic exercise on a cycle ergometer following motor skill practice
224232359|NCT03886090|BEHAVIORAL|rest|Seated rest following motor skill practice
224319976|NCT03922529|OTHER|Usual Care|Participants will receive usual care that is recommended by their providers. MACRO study personnel will follow the participant for the course of the study to assess endpoints in comparison to the MACRO-I arm.
224319977|NCT02506153|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
224319978|NCT02506153|PROCEDURE|Computed Tomography|Undergo CT scan
224319979|NCT02506153|BIOLOGICAL|Ipilimumab|Given IV
224232360|NCT03886090|BEHAVIORAL|motor learning|Motor learning task on a stability platform (Stabilometer). Participants try to keep the tiltable platform in a horizontal position.
224232361|NCT01719406|BEHAVIORAL|Intervention, behavioral lifestyle education|Twenty interactive weekly sessions that are scripted curriculum and peer led.
224232362|NCT04216043|DIETARY_SUPPLEMENT|RUSF skimmed milk powder|ready-to-use supplementary foods 75 kcal/kg/day (314 kJ/kg/day) and full daily doses of vitamins and micronutrients
224319980|NCT02506153|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
224319981|NCT02506153|BIOLOGICAL|Pembrolizumab|Given IV
223646451|NCT02106390|BIOLOGICAL|Meningococcal ACWY Conjugate Vaccine, MenACWY|4 doses administered intramuscularly on Days 1, 61, 121 and 301 with blood draw visits at Days 1, 151, 301 and 331 and who will receive reminder calls at 2 and 4 days after each vaccination visit and safety calls on Days 201 and 251.
223646452|NCT03198507|DRUG|RHB-105|"The intended dose of RHB-105 (12.5 mg rifabutin, 250 mg amoxicillin, and 10 mg omeprazole capsules) 4 capsules every eight hours, is equivalent to a total daily dose of:~* Rifabutin 150 mg~* Amoxicillin 3000 mg~* Omeprazole 120 mg~One 50mg Riboflavin tablet to be taken once daily to maintain the blind."
223646453|NCT03198507|DRUG|Active Comparator|"The intended dose of the Active Comparator (250 mg amoxicillin, and 10 mg omeprazole capsules) 4 capsules every eight hours, equivalent to a total daily dose of:~* Amoxicillin 3000 mg~* Omeprazole 120 mg~One 50mg Riboflavin tablet to be taken once daily to maintain the blind."
224232363|NCT04216043|DIETARY_SUPPLEMENT|RUSF milk protein concentrate and sucrose|ready-to-use supplementary foods 75 kcal/kg/day (314 kJ/kg/day) and full daily doses of vitamins and micronutrients
224319982|NCT02506153|PROCEDURE|Positron Emission Tomography|Undergo PET scan
224319983|NCT02506153|OTHER|Quality-of-Life Assessment|Ancillary studies
224319984|NCT02506153|BIOLOGICAL|Recombinant Interferon Alfa-2b|Given IV and SC
223646454|NCT04516889|PROCEDURE|Doubled sutured SFIOL|Recruited subjects would undergo implantation of SFIOL with the modified technique under either local or general anesthesia. The surgeon would mark the sclerotomies as per routine sutured SFIOL at 2mm behind the nasal and temporal limbus, followed by passage of 2 pairs of prolene sutures. The intraocular lens with islets would be implanted into the posterior chamber and sutured to the sclera as per single suture SFIOL.
223646455|NCT03348228|DIETARY_SUPPLEMENT|Hydroxycitrate (HCA)|Hydroxycitrate supplements are available over the counter and are primarily promoted as a weight loss supplement. Each subject will be given 42 capsules of Swanson super citrimax (hydroxycitrate) Details of the product are provided above. The subjects will be asked to take the capsules over a seven period (6 capsules per day).
223646456|NCT02180776|OTHER|Summit 456 TLSO|Thoracolumbarsacral orthosis
223646457|NCT02980861|PROCEDURE|Laparoscopic total gastrectomy|When the participants with advanced proximal gastric cancer are randomized in the laparoscopic totalgastrectomy (LATG) group, they will received LTG with spleen-preserving splenic hilum lymph nodes dissection.
223646458|NCT02980861|PROCEDURE|Open total gastrectomy|When the participants with advanced proximal gastric cancer are randomized in the open total gastrectomy(OTG) group, they will received OTG with spleen-preserving splenic hilum lymph nodes dissection.
223646459|NCT03007693|DRUG|JNJ-61393215|Participants will receive JNJ-61393215 for 7 days.
223646460|NCT03007693|DRUG|Placebo|Participants will receive JNJ- 61393215 matching placebo for 7 days.
223646461|NCT01910935|BEHAVIORAL|Physical activity prescription to develop program in group.|Overall the intervention involves a medical reference in primary care (PHC) to hypertensive patients (during routine consultation) to assist the sports facilities of the same Institute, to develop a group program of physical activity which will last 24 weeks. Led by the trained staff in physical activity to patients with chronic diseases.
223646462|NCT04857632|DRUG|Statin|atorvastatin 20mg per day for 7 days
223646463|NCT05543642|BIOLOGICAL|Hepatitis A vaccine|Vaccination series administered to prevent hepA infection.
223646464|NCT05543642|BIOLOGICAL|Diphtheria, pertussis, and tetanus booster vaccine|Vaccination booster administered to prevent diphtheria, pertussis, and tetanus
223646465|NCT06667141|DRUG|ACR-2316|ACR-2316 is an experimental drug
224319985|NCT06572683|DEVICE|Transcranial Magnetic Stimulation|Transcranial magnetic stimulation (TMS) is a noninvasive procedure that uses magnetic fields to stimulate nerve cells in the brain to improve symptoms of depression. Using pulsed magnetic fields, transcranial magnetic stimulation therapy stimulates the part of the brain thought to be involved with mood regulation. These magnetic fields do not directly affect the whole brain; they only reach about 2-3 centimeters into the brain directly beneath the treatment coil.As these magnetic fields move into the brain, they produce very small electrical currents. These electrical currents activate cells within the brain, causing them to rewire, a process called neuroplasticity.
223646466|NCT05382949|OTHER|SilverBills Financial and Legal Tech Tool for Caregivers|All subjects will be receiving the Silverbills financial and legal tech tool and a pre-post analysis will be conducted.
223646467|NCT04781751|DRUG|insulin injection|Carpal tunnel syndrome sonagraphic injection
223646468|NCT06169826|DRUG|l-Histidine|In the outpatient setting, one chewable tablet multivitamin (Zn and folic acid containing) plus a titrated dosing of L-histidine powder or capsules starting at 2g consumed before noon escalating every 2 weeks up to 4, 6, then 8 g per day as tolerated for up to 3 months.
223646469|NCT06169826|OTHER|Control|Control
223646470|NCT02811250|RADIATION|Stereotactic radiotherapy 4 x 8 Gy|
223646471|NCT02811250|RADIATION|Stereotactic radiotherapy 5 x 8 Gy|
223646472|NCT02811250|RADIATION|Stereotactic radiotherapy 4 x 10 Gy|
223646473|NCT02811250|RADIATION|Stereotactic radiotherapy 4 x 12 Gy|
223646474|NCT05218655|DRUG|Vatiquinone|Vatiquinone will be administered per dose and schedule specified in the arm description.
223646475|NCT06549348|RADIATION|Measure average procedure fluoroscopy time using LumiGuide and conventional fluoroscopy guidance|Fenestrated Endovascular Aortic Repair (FEVAR) procedure done with either LumiGuide or conventional fluoroscopy guidance
223646476|NCT06012136|DRUG|VH4004280|VH4004280 will be administered.
223646477|NCT06012136|DRUG|Placebo|Placebo will be administered.
223646478|NCT06012136|DRUG|VH4011499|VH4011499 will be administered.
224232364|NCT04216043|DIETARY_SUPPLEMENT|RUSF soy protein and whey permeate|ready-to-use supplementary foods 75 kcal/kg/day (314 kJ/kg/day) and full daily doses of vitamins and micronutrients
224232365|NCT04216043|DIETARY_SUPPLEMENT|RUSF soy and sucrose|ready-to-use supplementary foods 75 kcal/kg/day (314 kJ/kg/day) and full daily doses of vitamins and micronutrients
224232366|NCT02834000|DEVICE|LiDCO rapid™ CNAP monitoring|LiDCO rapid™ CNAP monitoring allows through analysis of the arterial blood pressure trace to acquire information about CO, HR variability, SVR, SV and BIS during general anaesthesia.
224232367|NCT04631770|PROCEDURE|Systemic mediastinal lymph node dissection|Systematic hilar and mediastinal lymph node dissection.
223646479|NCT06337175|DRUG|Alteplase|Following the guidelines set by the American Heart Association/American Stroke Association (AHA/ASA), inclusion and exclusion criteria for alteplase were established; 0.9 mg/kg of alteplase up to a maximum dose of 90 mg was administered intravenously to eligible individuals within 4.5 hours of the beginning of their clinical manifestations (10% bolus, 90% infusion in 1 hour). After receiving IV-alteplase, all patients continued their management and rehabilitation in the stroke unit.
223646480|NCT06337175|DRUG|Alteplase|Following the guidelines set by the American Heart Association/American Stroke Association (AHA/ASA), inclusion and exclusion criteria for alteplase were established; 0.9 mg/kg of alteplase up to a maximum dose of 90 mg was administered intravenously to eligible individuals within 4.5 hours of the beginning of their clinical manifestations (10% bolus, 90% infusion in 1 hour). After receiving IV-alteplase, all patients continued their management and rehabilitation in the stroke unit.
223646481|NCT03599765|OTHER|Best Practice|Receive routine therapy
223646482|NCT03599765|PROCEDURE|Local Consolidation Therapy|Receive LCT
224232368|NCT04631770|PROCEDURE|Spared mediastinal lymph node dissection|Mediastinal lymph node is spared in this group.
224232369|NCT05944107|OTHER|Activated Clotting Time measurements combined with heparin concentration monitoring|In the HC group, the initial heparin dose is calculated using the HepCon HMS Plus . Except for ACT, heparin concentration is measured to maintain target heparin levels during CPB. The protamine dose for reversal is computed based on actual measured heparin levels using the device. ACT is also performed in all instances.
224319986|NCT06105645|DEVICE|DIXI Medical Microdeep® Micro- Macro Depth electrodes|It is a deep intracerebral electrode used in the pre-surgical diagnosis of certain drug-resistant epilepsies. It consists of micro- and macro-contacts and is designed for Stereo-ElectroEncephalography (SEEG) recording via the macro-contacts or micro-contacts and brief stimulation via the macro-contacts.
224319987|NCT06105645|DEVICE|Standard electrodes|Standard electrodes used usually during the SEEG
223646483|NCT05024968|DRUG|Sintilimab|Given by IV
223646484|NCT05957068|BEHAVIORAL|Exercise Programme|Aerobic exercise consists of 20-minute brisk walks or jogs (5-6 km/h) on the treadmill each session, reaching a heart rate corresponding to 50%-70% of the patient's VO2max (VO2max is determined before embarking on the exercise programme). Study participants are expected to aim for 50% VO2max at the start of the exercise programme, and gradually increasing to 70% VO2max in subsequent exercise sessions. Strength training comprises a series of circuit resistance exercises targeting the major muscle groups. Patients will perform 2-4 sets of these exercises each session, 8-10 repetitions per set. Both aerobic exercise and strength training are done in the same session. With warm-up and cool-down, each session is estimated to take up 1 hour.
223646485|NCT05957068|BEHAVIORAL|Control|Usual care group.
223646486|NCT04007029|BIOLOGICAL|Chimeric Antigen Receptor T-Cell Therapy|Given Autologous anti-CD19/anti-CD20 CAR-expressing naive/memory T cells IV
223646487|NCT04007029|DRUG|Cyclophosphamide|Given IV
223646488|NCT04007029|DRUG|Fludarabine Phosphate|Given IV
223646489|NCT04007029|BIOLOGICAL|Tocilizumab|Given IV
223646490|NCT02962063|BIOLOGICAL|durvalumab|Durvalumab can be given irrespective of CBC, at the discretion of the treating physician.
223646491|NCT02962063|DRUG|carboplatin AUC 2/paclitaxel|
223646492|NCT02962063|RADIATION|External beam radiation (EBRT)|Radiation will be delivered starting on a Monday or Tuesday between Days 29-30, based on the first induction durvalumab dose administered on Day 1. Patients will be treated 5 days/week at 1.80 Gy/day, to a total planned dose of 41Gy in 23 fractions. Induction Day 15 has a -1/+2 day window, and Day 29 has a -1/+1 day window.
223646493|NCT02962063|PROCEDURE|esophagogastrectomy|Patients undergo surgical resection 6-10 weeks after the completion of chemoradiation.
223646494|NCT02962063|DRUG|Tremelimumab|Tremelimumab will be administered once at 300 mg on Day 29 prior to chemoradiation only.
223646495|NCT00241839|DRUG|Allopurinol|Allopurinol (300 mg capsule) was given for 8-10 weeks compared to placebo group after initial baseline testing. After two weeks on the Allopurinol, a serum uric acid level was obtained. If the uric acid level was greater than 5.5, the Allopurinol dosage was increased to 600mg (two 300 mg capsules)for the duration of the trial, 6-8 weeks.
223646496|NCT00241839|DRUG|Placebo|Placebo capsule (matched in appearance for Allopurinol and labeled 300mg) was given for 8-10 weeks compared to the Allopurinol group after initial baseline testing. After two weeks on the placebo, a serum uric acid level was obtained. If the uric acid level was greater than 5.5, the placebo dosage was increased to 600mg (two 300 mg capsules)for the duration of the study, 6-8 weeks.
223646497|NCT00241839|DRUG|Chlorthalidone|Chlorthalidone 25 mg was given daily for 5 weeks before baseline visit for testing and continued through out the study.
223646498|NCT00241839|DRUG|Potassium chloride|Potassium Chloride 40-50meq was given daily for 5 weeks before baseline visit for testing and continued through out the study.
223646499|NCT04031014|DEVICE|BTL EMSELLA Active treatment|BTL EMSELLA delivers high intensity focused electromagnetic technology to induce pelvic floor muscle contractions up to maximum intensity of 100% for active treatment
224232370|NCT05944107|OTHER|Activated Clotting Time|The target ACT for procedures other than Coronary Artery Bypass Grafting (CABG) is 400s when Minimally Invasive Extracorporeal Circulation is used. A bolus of 300 International Units(IU)/kg heparin are administered to reach this target and initiate cardiopulmonary bypass (CPB). Repeated ACT measurements guide further heparin dose to maintain adequate anticoagulation. Then, at the end of the CPB, 0.75 mg of protamine are administered for every 100IU of the initial heparin bolus.
224232371|NCT02780570|PROCEDURE|Small Volume Plasma Exchange|Six sessions will be done daily for consecutive 8 days (total 48 sessions). 7 ml/body weight blood will be drawn at each session and will be separated into plasma and blood cells. Blood cells will be infused back to the patients and plasma will replaced by equal volume of fresh frozen plasma and colloid solution. At the end of each day 1200 ml plasma (total 9600 ml in 48 sessions) will be removed.
224319988|NCT04294160|DRUG|Dabrafenib|Capsule for oral use
224319989|NCT04294160|DRUG|LTT462|Capsule for oral use
224319990|NCT04294160|DRUG|Trametinib|Tablet for oral use
224319991|NCT04294160|DRUG|LXH254|Tablet for oral use
224319992|NCT04294160|DRUG|TNO155|Capsule for oral use
224319993|NCT04294160|BIOLOGICAL|Spartalizumab|Liquid in vial (Concentrate for solution for infusion) for intravenous use
224319994|NCT04294160|BIOLOGICAL|Tislelizumab|Liquid in vial (Concentrate for solution for infusion) for intravenous use
224232372|NCT03140007|DEVICE|single operator cholangioscopy|If patient is randomized to the Study arm, then the procedure will consist of the following in order: Cannulation and sphincterotomy per standard of practice. POCS with recording of POCS-based impression of malignancy (yes/no/indeterminate). POCS will be performed using the Spy DS system. POCS-guided biopsies will be collected, consisting of 6 macroscopically visible biopsies. The POCS-guided biopsy forceps will be the SpyBite forceps.
224319995|NCT05562388|DEVICE|Somnodent Classic|The efficacy of the device will be evaluated in regards to the response of nocturia. Once patients report an average of voiding per night of less than 2 in the preceding 2 weeks of the follow up they will be classified as responders in term of nocturia and will be evaluated with a second sleep study. Efficacy of MAD will be assessed by comparing the apnea hypopnea index (AHI) values of pre and post sleep study with MAD, and they will be classified as responders if they have 50% improvement in AHI.
224319996|NCT03917251|DIAGNOSTIC_TEST|Coronary flow and pressure measurement in patients with ventricular pacing|Coronary flow and pressure measurement in patients with ventricular pacing
224319997|NCT02017015|DRUG|nab-paclitaxel|nab-paclitaxel at 125 mg/m\^2, by IV infusion over 30 to 40 minutes (maximum infusion time not to exceed 40 minutes)
224319998|NCT02017015|DRUG|Gemcitabine|Gemcitabine at 1000 mg/m\^2 IV infusion over 30 to 40 minutes given once weekly for 3 weeks (Days 1, 8 and 15) followed by a week of rest (28 day cycle).
224319999|NCT02989909|DEVICE|CATS tonometer prism|demonstrate that not more than 5% of the paired differences between the reference tonometer (CATS prism) reading and the test tonometer (Goldmann prism) reading for each pressure range
224320000|NCT02989909|DEVICE|Goldmann tonometer prism|demonstrate that not more than 5% of the paired differences between the reference tonometer (CATS prism) reading and the test tonometer (Goldmann prism) reading for each pressure range
224320001|NCT02864576|BEHAVIORAL|Cognitive Remediation_Aerobic Exercise|"Cognitive Remediation:~The REHACOP program consists of: Attention unit training sustained, selective, alternant and divided attention; Memory unit focusing on visual and verbal learning, recall and recognizing memory; Language unit including grammar, syntax, vocabulary, verbal fluency, verbal comprehension, abstract language; Executive functions unit training cognitive planning, proverbs, analogies; and Social cognition unit exercising theory of mind, social reasoning and moral dilemmas.~Aerobic Exercise:~12 weeks of systematic aerobic exercise program. Patients will walk with a moderate intensity 10 minutes the first week and will increase gradually up to 30 minutes-walk with a moderate intensity. Patients will also perform 5 minutes of warm-up and stretching."
224320002|NCT02864576|BEHAVIORAL|Cognitive Remediation_Health Promotion|"Cognitive Remediation:~The REHACOP program consists of: Attention unit training sustained, selective, alternant and divided attention; Memory unit focusing on visual and verbal learning, recall and recognizing memory; Language unit including grammar, syntax, vocabulary, verbal fluency, verbal comprehension, abstract language; Executive functions unit training cognitive planning, proverbs, analogies; and Social cognition unit exercising theory of mind, social reasoning and moral dilemmas.~Health Promotion:~12 weeks of health promotion sessions. These sessions will be carried out by a specialized/trained nurse."
224320003|NCT05889624|BEHAVIORAL|CBT|"During an 8-week active treatment, participants will receive 6 telehealth CBT sessions, followed by a maintenance phase (16 weeks) when participants will receive 3 booster CBT sessions. The sessions will be conducted by teletherapists from the Clinical Coordinating Center at Cincinnati Children's using a standardized treatment manual. A parent/legal guardian will be included in 2 sessions teaching ways to be active coaches, encouraging use of effective coping skills and refraining from reinforcement of maladaptive coping. Each session will be about 45 minutes."
224320004|NCT05889624|DRUG|Amitriptyline|During an 8-week active treatment, participants will begin taking a daily pill (amitriptyline) prescribed and managed clinically by the site headache provider. Amitriptyline will be taken once a day before bedtime. The weight based dosage will gradually be increased based on tolerability and a standardized titration protocol during the 8 week active treatment. The participant will remain on a maximum tolerated dose for the final 16 weeks (maintenance).
224320005|NCT02303795|DRUG|Rivaroxaban|Patients assigned to rivaroxaban will receive oral rivaroxaban, 20 mg od. Patients with a calculated creatinine clearance of 30 to 49 mL/min per 1.73 m2 received a reduced dose of rivaroxaban of 15 mg od.
223646500|NCT04031014|DEVICE|BTL EMSELLA Sham Treatment|BTL EMSELLA delivers high intensity focused electromagnetic technology to induce pelvic floor muscle contractions up to maximum intensity of 5% for sham treatment
224320006|NCT02303795|DRUG|Warfarin|"Patients will take the warfarin once daily (q.d.). The individual doses will be titrated as needed to maintain a target INR of 2.0-3.0.~Patients with 65 \> years old, should take warfarin (2,5mg/day) and all others patients should take 5mg/day."
224320007|NCT02076087|PROCEDURE|Liposuction/lipectomy|Subcutaneous adipose tissue will be obtained from liposuction/lipectomy to determine the types of immune cells
223646501|NCT05865431|DRUG|Zinc Oxide and Avobenzone|Zinc Oxide is applied to one area of the forearm, Avobenzone is applied to another area of the forearm.
223646502|NCT05615038|PROCEDURE|Contact aspiration Thrombectomy|Contant aspiration is an approach that utilizes the advantages of large-bore aspiration catheters that can be easily tracked and introduced into the cerebral circulation to directly remove the thrombus via negative pressure aspiration.
223646503|NCT05615038|PROCEDURE|Stent retriever thrombectomy|Stent retriever thrombetomy is an approach that utilize sself-expandable stent for thrombectomy. The stent retriever is expanded to capture the thrombus, which immediately may restore blood flow.
223646504|NCT05204641|BIOLOGICAL|Fecal Microbiota Transfer provided by Human Biome Institute|Fecal Microbiota Transfer with colonoscopy
223646505|NCT03859687|BIOLOGICAL|Vitamin A supplementation|liquid oral vitamin A supplementation
223646506|NCT03859687|BIOLOGICAL|No vitamin A supplementation|No vitamin A supplementation
223646507|NCT04394234|DRUG|Direct oral anticoagulant (DOACs)|Data of participants newly exposed to individual DOACs that is rivaroxaban, apixaban, dabigatran from 19-Oct-2010 to 31-Dec-2018 will be assessed. No study drug treatment will be administered as part of this observational study.
224232373|NCT03140007|DEVICE|ERCP guided brushing and biopsy|• If patients are randomized to the Control arm, then they will undergo an ERCP. ERCP-based impression of malignancy (yes/no/indeterminate) will be recorded. ERCP-guided brushing and ERCP-guided biopsy will be performed.
224232374|NCT00189709|DRUG|Micafungin|IV
224232375|NCT00189709|DRUG|fluconazole|IV
223766054|NCT07163546|BEHAVIORAL|Lifestyle intervention|"A lifestyle intervention is an occupational therapy intervention program that aims to help individuals change their lifestyle by encouraging greater engagement in meaningful activities. This program aims to help participants develop healthy routines and habits. It offers a perspective that combines various approaches such as patient education, occupational self-analysis, problem-solving, and building motivation to prevent and manage chronic health problems. Participants gain self-analysis and problem-solving skills while experiencing positive lifestyle changes and developing healthy routines.~The lifestyle intervention was planned as a total of 8 sessions, 2 sessions per week."
223646508|NCT04394234|DRUG|Warfarin|Data of participants newly exposed to warfarin from 19-Oct-2010 to 31-Dec-2018 will be assessed. No study drug treatment will be administered as part of this observational study.
223646509|NCT05575830|BIOLOGICAL|Recombinant Zoster Vaccine|Shingrix® vaccine will be administered in two vaccinations on Day0 and Day60
223646510|NCT06284681|BEHAVIORAL|Weight-focused health coaching|Following the definition of structured lifestyle interventions within the current obesity clinical practice guidelines, the weight-focused health coaching intervention will be delivered as a multi-component behavior change intervention intended to produce clinically-important weight loss through consuming a healthy, energy-restricted diet and increasing physical activity.
224232376|NCT01504737|OTHER|Aerobic Exercise Training|12 weeks of endurance training, 40 minutes, 3 times per week on ergometer bicycle.
223646511|NCT06284681|BEHAVIORAL|Weight-neutral health coaching|Dietary and physical activity prescriptions for the weight-neutral health coaching intervention will be similar to the weight-focused intervention except the diet prescription will be designed to fully meet daily estimated energy requirements rather than creating a negative energy balance and producing weight loss. Health coaches will not emphasize changes in body weight as an explicit goal or as a mediator of improved cardiometabolic health. Rather, health coaches will emphasize achieving diet and exercise behavioral goals as a direct means to improving cardiometabolic health independently of changes in body weight.
223646512|NCT06284681|BEHAVIORAL|Intensify lifestyle approach|Participants identified as non-responders to initial health coaching interventions may be re-randomized to receive a 4-month membership to the local YMCA and health coaches will assist participants in identifying and enrolling in at least 2 weekly group fitness classes at the YMCA.
223646513|NCT06284681|OTHER|Augment with enhanced medical management|Participants identified as non-responders to initial health coaching interventions may be re-randomized to meet with the primary care provider and health coach to consider additional or revised medication plans to address their weight and weight-related chronic conditions.
223646514|NCT03405441|DRUG|JNJ-55375515 Dose Level 1|Participants will receive JNJ-55375515 orally at a Dose level 1 in Part 1 of study.
223646515|NCT03405441|DRUG|JNJ-55375515 Dose Level 2|Participants will receive JNJ-55375515 orally at a Dose level 2 in Part 1 of study.
223646516|NCT03405441|DRUG|JNJ-55375515 Dose Level 3|Participants will receive JNJ-55375515 orally at a Dose level 3 in Part 1 of study.
224232377|NCT01504737|OTHER|Physical Activity Recommendations|Written and verbal information on minimal level of physical activity recommended.
224232378|NCT00930488|DRUG|Avelox (Moxifloxacin, BAY12-8039)|Patients with a diagnosis of acute bacterial sinusitis who take moxifloxacin
223646517|NCT03405441|DRUG|JNJ-55375515 Dose Level 4|Participants will receive JNJ-55375515 orally at a Dose level 4 in Part 1 of study.
223646518|NCT03405441|DRUG|JNJ-55375515 Dose Level 5|Participants will receive JNJ-55375515 orally at a Dose level 5 in Part 1 of study.
223646519|NCT03405441|DRUG|JNJ-55375515 Dose Level 6|Participants will receive JNJ-55375515 orally at a Dose level 6 in Part 1 of study.
223646520|NCT03405441|DRUG|Placebo|All participants will receive matching placebo orally in Part 1 and Part 2 of the study.
223646521|NCT03405441|DRUG|JNJ-55375515|Participants will receive JNJ-55375515 as per the assigned treatment in Part 2.
223646522|NCT06113861|DIAGNOSTIC_TEST|Quantiferon Gold|Test for TB infection
223646523|NCT06113861|DIAGNOSTIC_TEST|HIV serology|Test for HIV infection
223646524|NCT06113861|DIAGNOSTIC_TEST|Respiratory secretion culture (sputum or gastric aspirate_|TB culture by MODS
223646525|NCT06113861|DIAGNOSTIC_TEST|Chest radiograph|Chest imaging test by traditional X ray
223646526|NCT06113861|DIAGNOSTIC_TEST|Lung ultrasound|Chest imaging test by ultrasound
223646527|NCT06113861|DIAGNOSTIC_TEST|cell free DNA test|Blood test for TB infection
223646528|NCT03292601|DEVICE|NYRC Brace Scoliosis Monitor|Scoliosis Monitor is a system that allows the continuous monitoring of the scoliosis brace use compliance and posture. This product includes a brace wearable that enables the monitoring of the scoliosis brace. The wearable device is able to communicate with a companion mobile application which stores and processes the collected data and is responsible for data synchronization.
223646529|NCT03852160|DRUG|Esketamine 28 mg|Participants will receive 28 mg esketamine as nasal spray (Initial dose for elderly participants with 65-74 years of age on Day 1 and then uptitrated to 56 mg on Day 4).
223646530|NCT03852160|DRUG|Esketamine 56 mg|Participants will receive 56 mg esketamine as nasal spray (Initial dose for participants with 18-64 years of age) on Day 1. The dose may be increased/may remain same based on the efficacy and tolerability. Participants with 65 to 74 years of age will receive esketamine 56 mg from Day 4 onwards.
224232379|NCT03179345|DRUG|Gabapentin|
224232380|NCT03179345|DRUG|Pregabalin|
224232381|NCT03179345|OTHER|Placebo|
224232382|NCT00820625|PROCEDURE|pulmonary vein isolation|common pulmonary vein isolation procedure
224232383|NCT00820625|PROCEDURE|pulmonary vein isolation with additional ablation of fragmented potentials|common pulmonary vein isolation with additional but also common ablation of fragmented potentials
224232384|NCT02841826|OTHER|IUD|
224232385|NCT02841826|OTHER|Uterine sounding|
224232386|NCT02841826|RADIATION|Transvaginal ultrasound|
224232387|NCT02585700|BIOLOGICAL|Influenza vaccine, split inactivated|Seasonal trivalent inactivated influenza vaccine (TIV), inactivated split virion, purified by sucrose gradient ultracentrifugation. The vaccine is produced in hen's eggs, and inactivated with beta-propiolactone.
224232388|NCT02585700|OTHER|Placebo|0.5 mL of phosphate buffered saline
224232389|NCT05685979|PROCEDURE|Robotic-assisted laparoscopic prostatectomy in deep Trendelenburg position.|After general anesthesia induction, the patients were placed in the deep Trendelenburg position (at least 25°-45° upside down).
223646531|NCT03852160|DRUG|Esketamine 84 mg|Participants may receive 84 mg (maximum uptitrated esketamine dose). The dose may be decreased/may remain same based on the efficacy and tolerability.
223646532|NCT03852160|DRUG|Placebo|Participants will receive matching placebo as nasal spray.
223646533|NCT03852160|DRUG|Escitalopram|Escitalopram can be selected as the oral antidepressant medication based on investigator's discretion. The initial dose for escitalopram is 5 mg once daily (for elderly participants) and 10 mg once daily (for adults). The dose may be increased to 10 mg (for elderly participants) and 20 mg (for adults) once daily at the discretion of treating physician/investigator.
223646534|NCT03852160|DRUG|Sertraline|Sertraline can be selected as the oral antidepressant medication based on investigator's discretion. The initial dose for sertraline is 50 mg once daily and may be increased up to 200 mg once daily.
223646535|NCT03852160|DRUG|Duloxetine|Duloxetine can be selected as the oral antidepressant medication based on investigator's discretion. The initial dose for duloxetine is 60 mg once daily and may be increased to 120 mg once daily.
223646536|NCT03852160|DRUG|Mirtazapine|Mirtazapine can be selected as the oral antidepressant medication based on investigator's discretion. The initial dose for mirtazapine is 15 to 30 mg once daily and may be increased to 45 mg once daily.
223646537|NCT03852160|DRUG|Agomelatine|Agomelatine can be selected as the oral antidepressant medication based on investigator's discretion. The initial dose for agomelatine is 25 mg once daily and may be increased to 50 mg once daily after 2 weeks.
223646538|NCT03852160|DRUG|Bupropion|Bupropion can be selected as the oral antidepressant medication based on investigator's discretion. The initial dose for bupropion is 150 mg once daily and may be increased to 300 mg once daily after 4 weeks.
224232390|NCT05575414|BEHAVIORAL|Didactic dietary sessions|Three one-hour online nutrition group classes will be scheduled at 17, 21 and 29 weeks gestation (± 1 week). Nutrient dense foods and beverages and limiting the intake of added sugars, sodium and saturated fat will be encouraged, as well as reading the nutrition facts label, individual goal setting and self-monitoring. Physician recommended physical activity will be encouraged. Food and beverage intake data will be measured by 24-hour dietary recalls collected on three non-consecutive days. Data will be collected by telephone interview by a registered dietitian or dietary technician on four separate occasions: 16, 20 and 28 weeks gestation (± 1 week) and 36 weeks of gestation. Details on portions consumed will be estimated using standard measuring cups and household utensils. Nutrient intake will be generated using Vision Software Nutrient Analysis Software and the United States Department of Agriculture Food Composition Database, Food Data Central.
224232391|NCT05575414|BEHAVIORAL|Education Tool|The standard patient education tool will take the form of a leaflet which will include 1. A definition of body mass index 2. A list of measures to be taken to limit weight gain in pregnancy. 3. A description of the major nutrients required in pregnancy (folate, iron, calcium, vitamin D and protein). and 4.A description of the six food groups with recommendations for the number of servings per day.
223646539|NCT03852160|DRUG|Trazodone Prolonged Release|Trazodone prolonged release can be selected as the oral antidepressant medication based on investigator's discretion. The initial dose for trazodone prolonged release is 75 to 150 mg once or twice daily and may be increased up to 450 mg (adults) and 300 mg (elderly).
223646540|NCT04808778|DRUG|Hydroxyurea therapy per standard care|Moderate-dose of 20mg/kg/day
224232392|NCT03104205|BEHAVIORAL|Evaluate home-based MOWI|MOWI will be delivered via video-conferencing in the subject's home in a 3x per week, 26-week program from the coordinating center. It will include an individual dietician-led weekly nutrition session; 2x/week physical therapist-led group exercise session; and remote fitness device monitoring. We plan 5 cohorts of 8 subjects (n=40). In-person Research Assistant-led assessments will occur at 0, 8, 16 and 26 weeks. Recruitment, screening, selection criteria, and usability parallel Aim 2 (NCT03104192).
224232393|NCT04155983|DRUG|Ropivacaine|The drug will be administered in the same dosage in both arms. The location of the injection will vary by arm.
224232394|NCT04873674|OTHER|ASD diagnosis|Autism Diagnostic Interview-revised (ADI-R) and Autism Diagnostic Observation Scale (ADOS)
224232395|NCT04873674|OTHER|Psychiatric diagnosis|Kiddie Schedule for Affective Disorders \& Schizophrenia (K-SADS) for DSM-5
224232396|NCT01618266|DRUG|dexamethasone intravitreal implant|dexamethasone intravitreal implant 700 μg administered into the eye according to physician judgment.
224232397|NCT02985151|DEVICE|Syneron-Candela CO2RE Laser|This fractionated ablative laser will administer energy at either a high intensity setting or a low intensity setting to subjects randomized into a particular treatment group. It will be operated by the principle investigator, who has extensive experience with laser therapy.
223646541|NCT04516057|DRUG|Nabilone|After the screening period, participants randomized to the nabilone arm will receive nabilone for 8 weeks. Participants will then be followed for 8 weeks following completion of the study treatment.
223646542|NCT04516057|OTHER|Placebo|After the screening period, participants randomized to the placebo arm will receive placebo capsules for 8 weeks. Participants will then be followed for 8 weeks following completion of the study treatment.
224232398|NCT00838318|BEHAVIORAL|Interview|Audiotaped Phone Interview/Survey, 30 - 45 minutes.
224232399|NCT02623790|OTHER|Test meal (butter)|Subjects will eat one meal test containing 33g of lipids from butter (percent of total caloric intake: 15.0% from proteins; 53.0% from carbohydrates; 32.0% from fat).
224232400|NCT02623790|OTHER|Test meal (cheddar cheese)|Subjects will eat one meal test containing 33g of lipids from cheddar cheese (percent of total caloric intake: 15.0% from proteins; 53.0% from carbohydrates; 32.0% from fat).
224232401|NCT02623790|OTHER|Test meal (cream cheese)|Subjects will eat one meal test containing 33g of lipids from cream cheese (percent of total caloric intake: 15.0% from proteins; 53.0% from carbohydrates; 32.0% from fat).
224232402|NCT04735419|OTHER|No intervention|No intervention
224232403|NCT02226796|DEVICE|Transcranial direct current stimulation|Transcranial direct current stimulation (tDCS) is a non-invasive neuromodulation tool that presents a low current that induces bi-directional polarity-dependent changes in the cortex to facilitate focal, prolonged shifts in cortical excitability at or around the time stimulation is provided. Anodal tDCS (a-tDCS), in which the positively charged electrode is placed over the targeted cortical region, has been shown to increase cortical excitability (upregulation), similar to long-term potentiation (LTP). Combining a-tDCS with behavioral-based approaches has been suggested to enhance the learning process and increase the likelihood of retention.
224232404|NCT00195299|DRUG|Temsirolimus|
223646543|NCT05837039|BEHAVIORAL|Healthcare Provider|Questionnaires
223646544|NCT05837039|BEHAVIORAL|Caregiver Perception|Questionnaires
223646545|NCT06144645|DEVICE|tVNS, intermittent stimulation|transcutaneous vagus nerve stimulation, intermittent stimulation
223646546|NCT06144645|DEVICE|tVNS, continuous stimulation|transcutaneous vagus nerve stimulation, continuous stimulation
223646547|NCT05786794|BEHAVIORAL|Patient Navigation Program for Hearing Health Care|Patients presenting for routine office visits will be invited to participate in the study and informed consent procedures and study enrollment will be conducted by a research assistant. Participants will then undergo baseline assessment. Following baseline measures, participants who screen positive for hearing loss will be contacted by the Patient Navigator (PN) to begin the intervention. The navigator will contact participants every 2 weeks to focus on addressing key aspects of Hearing Health Care (HHC): education, screening, diagnosis, and treatment. PNs will assist the patient to undergo a formal audiogram with the 12 months following enrollment. Each PN session will likely last between 10-30 minutes. Post-intervention data collection also administered by a trained interviewer, will occur following a diagnostic audiogram with an audiologist or at 12 months following enrollment.
223646548|NCT05811286|PROCEDURE|Hysteroscopic morcellation 19 Fr. intrauterine BIGATTI Shaver for uterine intracavitary lesions|"With the shaver, the lesion is removed in the OR. We will include endometrial polyps, FIGO 0-1 myomas and retained products of conception.~We will assess the completeness of hysteroscopic resection, operation time, need for cervical dilation, adverse events, pain, operator satisfaction; quality of tissue for histological examination, postoperative complications and pain."
223766055|NCT07166640|DRUG|Propofol|The initial dose is 1.5 mg/kg, adjusted in increments or decrements of 0.1 mg/kg according to the modified Dixon's up-and-down method. Additional rescue doses of 0.25-0.5 mg/kg is titrated if insertion is unsuccessful.
224232405|NCT02300025|DRUG|cobimetinib|single oral 10-mg dose of cobimetinib
224232406|NCT04693065|OTHER|ponseti|Standard of care, treatment by ponseti method
224232407|NCT05921058|DRUG|Secretome|Mesenchymal stem cell secretome obtained from Kalbe Pharma Company
223646549|NCT00831181|DRUG|5-FU|5-FU: continuous infusion via portable pump during all RT (approximately 33 days)
223646550|NCT00831181|DRUG|Oxaliplatin|Oxaliplatin: 50mg/m2 weekly dosing during RT (Day 1)
223646551|NCT00831181|DRUG|leucovorin|Folinic Acid (Leucovorin): 400 mg/m2; 2-hour IV infusion simultaneously with oxaliplatin
223646552|NCT00831181|PROCEDURE|mesorectal excision|mesorectal excision
224232408|NCT05921058|DRUG|Placebo|NaCl 0,9% infusion
224232409|NCT00450996|DRUG|Topical Steroids|
224232410|NCT05391009|DIAGNOSTIC_TEST|PNF|PNF exercise twice daily five days per week for 8 weeks. D1 and D2 flexion and extension pattern for upper limb. In D1 Flexion-adduction -external rotation d1, extension -abduction-internal rotation and in D2 flexion-abduction-external rotation, extension-adduction-internal rotation
224232411|NCT05391009|DIAGNOSTIC_TEST|TRT|The duration of a TRT session Will be 60 min. Each session started with warm-up exercises for 10 min followed by 50 min of TRT. Each task will be repeated approximately 10 to 20 times, for 1 to 5 sets, or alternatively for 2 to 5 min. A 2 min rest period after every 15 min of practice will be allowed. Before commencing the exercise session, tasks will be demonstrated to each patient using the non-affected UE.
224320008|NCT05326204|OTHER|Home blood glucose monitoring|Self monitoring of capillary blood glucose
224320009|NCT05014282|DRUG|Nicotine patch|Participants will be provided with a 10-week supply of nicotine patches
224320010|NCT05014282|BEHAVIORAL|Counseling|Phone counseling with the state tobacco quitline.
224320011|NCT05014282|DRUG|Nicotine lozenge|Participants will be provided with a 10-week supply of nicotine lozenges
224320012|NCT05014282|BEHAVIORAL|Smartphone-delivered automated treatment|An interactive smartphone-based intervention that comprises content delivered via audio/video clips and text content automatically each week to the participant
223646553|NCT01062932|DRUG|Cycloserine|Oral administration of cycloserine medication (50 mg administered prior to each exposure treatment) on Day 1, 4, 7, and 10 of the study
224320013|NCT06236061|DRUG|LCZ|LCZ 200 mg
224320014|NCT06236061|DRUG|LCZ/AML 200 mg/2.5 mg|LCZ/AML 200 mg/2.5 mg
223646554|NCT01062932|DRUG|Placebo|Oral administration of matching placebo pill on Days 1, 4, 7, and 10
223646555|NCT00629070|OTHER|Traditional strength training|Performed 3 x week for 8 weeks on an isokinetic dynamometer (knee extension exercise)at 30 degrees/second; 6 sets of 5 maximum-effort concentric actions
223680928|NCT02916238|DRUG|Fluoxetine|Fluoxetine prescribed and dispensed beginning at 10 mg daily; side effects and symptoms monitored biweekly; dosage increased to 20 mg., then by 20 mg. increments according to protocol algorithm based on PHQ-9 score to a maximum dose of 60 mg.
223680929|NCT02916238|BEHAVIORAL|Enhanced Usual Care|Depression symptoms monitored at 3 month intervals; results from PHQ-9 available to ART clinic physicians.
223766056|NCT07161830|DEVICE|Omeza® Complete Matrix|OCM Application, Surgical sharp debridement, offloading (TCC gold standard, fixed ankle-walker alternative), and proper moisture balance
223766057|NCT07161830|OTHER|Standard of Care|Surgical sharp debridement, offloading (TCC gold standard, fixed ankle-walker alternative), and proper moisture balance
224232412|NCT04902274|OTHER|Transcranial Direct Current Stimulation|The Halo Sport (Halo Neuroscience, San Francisco, CA) is a commercial off-the-shelf tDCS device that delivers a 2.2 mA current to the motor cortex through three elastomer foam scalp pads with a 24 sq. cm surface area (see https://www.haloneuro.com/). The tDCS is controlled through the Halo Sport App where the therapist and patient are blind to an actual or sham treatment. Patients in the tDCS group will complete a 20-minute tDCS session while performing the warm-up.
224320015|NCT06236061|DRUG|LCZ/AML 200 mg/5 mg|LCZ/AML 200 mg/5 mg
224320016|NCT06236061|DRUG|LCZ/AML 200 mg/10 mg|LCZ/AML 200 mg/10 mg
224320017|NCT06236061|OTHER|Placebo|Matching placebo of Amlodipine.
224323511|NCT03022825|DRUG|N-803 and BCG|BCG and N-803 will be mixed together (with saline) and administered via intravesical instillation weekly for 6 consecutive weeks (induction). After the first disease assessment, eligible patients will receive either a 3-week maintenance course or a 6-week re-induction course (second treatment period) at Month 3. Eligible patients will continue to receive maintenance treatment in the third treatment period at Months 6, 9, 12, and 18. Eligible patients have the option to receive maintenance treatment in the fourth treatment period at Months 24, 30, and 36.
223646556|NCT00629070|OTHER|Velocity-enhanced training|Performed 3 x week for 8 weeks on an isokinetic dynamometer (knee extension exercise). Subjects will perform 2 sets of 5 concentric exertions at 30°/second. The following 4 sets of 5 repetitions will be performed at a faster speed, starting at 60° /second. The velocity will be increased weekly in 15° /second increments up to a maximum of 120°/second.
223646557|NCT01749332|OTHER|Perihepatic Phlebotomy|
223766058|NCT07168863|DEVICE|EUS-guided FNB|EUS-guided FNB from the lesions in the pancreatobiliary tract
223766059|NCT07163429|DRUG|Flurbiprofen 8.75 MG|Topical administration of flurbiprofen 8.75 mg spray applied directly to the tracheal and bronchial cuffs of the double-lumen endobronchial tube before intubation. A total of three sprays will be applied: one spray to the bronchial cuff and two sprays to the tracheal cuff, immediately before intubation.
223766060|NCT07163429|DRUG|Saline spray|Topical administration of placebo spray (0.9% normal saline) applied in the same manner as the active intervention, with one spray to the bronchial cuff and two sprays to the tracheal cuff of the double-lumen tube before intubation.
223766061|NCT07168616|DIAGNOSTIC_TEST|Ga-68 PSMA11 PET/CT|delayed (120-minute) Ga-68 PSMA PET/CT and will be evaluated by using Istanbul PSMA PET/CT Criteria (IPPC)
223766062|NCT07167823|PROCEDURE|Decortication|removal of fibrinous infected material from pleural cavity and thick fibrous entrapping peel over the lung resulting in full expansion of lung.
223766063|NCT07167823|PROCEDURE|Decortication|removal of fibrinous infected material and thick fibrinous entrapping peel over the lung
223766064|NCT07168369|DIETARY_SUPPLEMENT|protein and energy-rich supplement|The nutritional supplements were provided in the form of ready-to-drink liquid solutions rich in protein and energy. Patients without diabetes received one 235 ml bottle per day of Ensure® Protéine Max (Abbott Nutrition, Montreal, Canada), which contained 350 kcal, 20 g of protein, 11 g of fat, 44 g of carbohydrates, 1.5 g of calcium-HMB and other essential micronutrients. Patients diagnosed with diabetes prior to LT received one 237 ml bottle per day of Boost® Diabetic (Nestlé, Montreal, Canada), which provided 190 kcal, 16 g of protein, 7 g of fat, 17 g of carbohydrates, and other essential micronutrients. Patients were instructed to consume the supplement in four equal doses of \~60 ml each, taken daily with breakfast, lunch, dinner, and as a bedtime snack, totaling one full bottle per day. The supplementation lasted for 12 weeks, beginning once solid oral feeding was initiated.
224232413|NCT04902274|OTHER|Sham Transcranial Direct Current Stimulation|The Halo Sport (Halo Neuroscience, San Francisco, CA) is a commercial off-the-shelf tDCS device that delivers a 2.2 mA current to the motor cortex through three elastomer foam scalp pads with a 24 sq. cm surface area (see https://www.haloneuro.com/). The tDCS is controlled through the Halo Sport App where the therapist and patient are blind to an actual or sham treatment. Patients in the sham tDCS group will complete a 20-minute sham-tDCS session while performing the warm-up, but the app will discontinue the treatment after 30 seconds.
224232414|NCT04902274|OTHER|Physical Therapy|After the tDCS session is complete, the patient will complete treatment consistent with the standard of care for rehabilitation of acute ankle inversion sprain. The rehabilitation program will be standardized among all patients and will consist of therapeutic exercises, manual physical therapy, and other modalities. Rehabilitation sessions will be performed 2x weekly and sessions will last approximately 45 to 60 minutes. Patients will also perform a standardized home exercise program that reinforces the in-clinic treatment.
224232415|NCT00780026|DRUG|insulin|bolus or infusion 80 to 110 mg/dl
224232416|NCT05067257|DRUG|Resiniferatoxin|Resiniferatoxin is a compound purified from natural sources
224232417|NCT05067257|DRUG|Placebo|Vehicle solution
224320018|NCT04687176|DRUG|Oral Arsenic Trioxide Formulation|"Patients will be recruited to oral arsenic trioxide, all-trans-retinoic acid, ascorbic acid (AAA) based-induction for 42 days. Daunorubicin or idarubicin will only be used during induction in patients \<65 with presenting white blood cell count (WBC) ≥ 10 x 10\^9/L. In patients not receiving daunorubicin, hydroxyurea if WBC ≥ 5 x 10\^9/L within the first 14 days of induction. A reassessment bone marrow aspirate will be performed on day 28 of induction for assessment of morphologic remission.~Four weeks after the completion of induction phase, all patients, regardless of initial WBC, will receive two cycles of chemotherapy-free AAA consolidation (14 days every 28 days).~Four weeks after completion of consolidation, all patients will receive 12 cycles of chemotherapy-free AAA maintenance (14 days every 8 week)."
223646558|NCT00675272|DRUG|hydrocortisone|hydrocortisone 50mg iv. every 6 hours
223646559|NCT00675272|DRUG|sodium chloride|sodium chloride every 6 hours iv
223646560|NCT03475147|DEVICE|eyeFusion|Smartphone app based flicker fusion test.
223646561|NCT02282098|DRUG|Colchicine|Colchicine 0.6mg twice daily
223646562|NCT02282098|DRUG|Placebo|Placebo Colchicine
223646563|NCT02863419|DRUG|semaglutide|Oral semaglutide once-daily.
223646564|NCT02863419|DRUG|liraglutide|Subcutaneous (s.c.) injection once-daily.
223646565|NCT02863419|DRUG|placebo|Placebo once-daily.
223646566|NCT05335226|PROCEDURE|Combined haploidentical and umbilical cord blood allogeneic stem cell transplantation|Patients will receive umbilical cord blood allogeneic stem cell transplantation at the same day as the haploidentical stem cell transplantation. (HLA 6-10/10, TNC≥1-3×10-7/Kg)
223646567|NCT05335226|PROCEDURE|haploidentical hematopoietic stem cell transplantation|Receive haploidentical hematopoietic stem cell transplantation (HLA 6-10/10)
223646568|NCT01371357|DRUG|TEST 1|2.4 g/day of guanidinoacetic acid
223646569|NCT01371357|DRUG|TEST 2|2.4 g/day of guanidinoacetic acid + 3.0 g/day of choline dihydrogencitrate + 5 µg/day of B12 + 10 mg/day of B6 + 600 µg/day of folic acid
223646570|NCT01371357|DRUG|TEST 3|2.4 g/day of guanidinoacetic acid + 1.6 g/day of betaine HCl + 5 µg/day of B12 + 10 mg/day of B6 + 600 µg/day of folic acid
223646571|NCT01371357|DRUG|TEST 4|2.4 g/day of guanidinoacetic acid + 5 µg/day of B12 + 10 mg/day of B6 + 600 µg/day of folic acid
223766065|NCT07173374|RADIATION|SCART Dose Escalation Arm|Patients will receive SCART with escalating dose cohorts (10 Gy, 13 Gy, 16 Gy, and 19 Gy per fraction within the SCART region) using a standard 3+3 design. All patients will also receive background SBRT (25 Gy in 5 fractions) to the gross tumor volume and margin.
224232418|NCT03341065|DEVICE|exoskeleton type robot|
224232419|NCT03341065|DEVICE|end-effector type robot|
223646572|NCT05240027|BEHAVIORAL|Vape use survey|pre \& post test surveys
223646573|NCT03029871|BIOLOGICAL|Ad5-yCD/mutTKSR39rep-ADP Adenovirus|oncolytic adenovirus
223646574|NCT05386771|DIETARY_SUPPLEMENT|Whey/collagen protein blend|Ingestion of 30g of protein dissolved in 300ml water consumed after an exercise session
223646575|NCT05386771|BEHAVIORAL|Resistance exercise|A single resistance exercise session of the leg press and leg extension exercise
223646576|NCT04048356|DRUG|Vaginal scrub, to be applied vaginally and perineally immediately prior to surgery.|Vaginal scrub, to be applied vaginally and perineally immediately prior to surgery.
223646577|NCT05682196|DRUG|Rituximab added to standard of care treatment|Rituximab with standard of care treatment
223646578|NCT05682196|DRUG|standard of care treatment alone|Standard of care treatment alone
223646579|NCT00196313|DRUG|levonorgestrel/EE 0.15/0.03 and EE 0.01 mg tablets|1 tablet daily by mouth
223646580|NCT00196313|DRUG|Placebo tablet|1 tablet daily by mouth
223646581|NCT03760042|DRUG|Within-Subject Active vs Placebo Topical Applications|Crisaborole 2% ointment (right side) and Placebo vehicle ointment (left side)
224232420|NCT02320357|DRUG|Treatment by clopidogrel|Peripheral blood will be obtained during the study
223766066|NCT07171788|OTHER|low level laser therapy|patients will receive LLT. The LLLT system used in the study (ASA LASER M6) delivered 1.0 W in continuous wave at a wave length in the near infrared of 808 nm. The incident power density will be 670 mW/cm2.The probe head will held with light pressure in contact with the skin over the course of median nerve on the dysfunctional limb for 15 minutes. Protective goggles will be used to prevent direct eye contact of the laser beam. plus selected phyiscal therapy program
224232421|NCT03613350|DIAGNOSTIC_TEST|Pad test|20-minutes pad test and urodynamic study (including uroflowmetry, filling and voiding cystometry, and urethral pressure profile) were conducted to every patient.
224232422|NCT01142843|DRUG|green propolis mouthwash|The subjects were instructed to brush their teeth as usual and to rinse with the 10mL of Mouthwash contain 5% Green Propolis, twice a day, for one minute, right after their meals in the morning and at night. The treatment was performed during three months
224232423|NCT04104958|GENETIC|qRTPCR (mRNA level).|RNA extraction and RT-qPCR Protein extraction and western blotting ELISA assay
224232424|NCT04669665|DRUG|SLS-002|Intranasal racemic ketamine hydrochloride 90 milligrams (mg)
223646582|NCT03760042|DRUG|Within-Subject Active vs. Placebo Topical Applications|Crisaborole 2% ointment (left side) and Placebo vehicle ointment (right side)
223646583|NCT03071107|BEHAVIORAL|Multi-disciplinary intervention|Participants in the intervention group will receive a multifactorial, interdisciplinary, treatment program intended to target pre-frailty for a 4-month period following randomization (physical meetings at 2-monthly time points with telephone consultations between meetings). The interventions will be individually tailored to each participant based on their frailty characteristics at baseline and amended if other problems are identified during the intervention program. This intervention team will consist of a renal dietitian and physiotherapist, both of whom will be trained and accredited in behavioural therapy intervention skills, and will focus on improving nutritional status and physical strength through resistance exercise training. They will be supported by a Clinical Research Fellow who will provide additional medical assessment to determine any reversible medical causes of frailty.
223646584|NCT04485390|OTHER|Basic life support witn use of an AED before EMS|BLS performance with use of an AED before arrival of EMS
223646585|NCT01460693|DRUG|Imatinib|Oral Imatinib 100mg daily
223646586|NCT01460693|DRUG|Dasatinib|Oral Dasatinib 100mg daily
223646587|NCT05824780|OTHER|Exercise training|4-week weightlifting strength training
223646588|NCT03516188|DRUG|Alginate-antacid group|Participants will be given 10 mL of alginate-antacid preparation (Gaviscon-Advance®, Reckitt-Benckiser, United Kingdom)
223646589|NCT03516188|DRUG|Non antacid alginate group|Participants will be given 4 mL of magnesium tri-silicate which has equivalent strength and component with Gaviscon-Advance® except it is alginate-free.
223646590|NCT04382040|DRUG|ArtemiC|Treatment will be sprayed orally twice a day for the first 2 days in the treatment period
223646591|NCT04382040|DRUG|Placebo|Treatment will be sprayed orally twice a day for the first 2 days in the treatment period
223646592|NCT06054074|BEHAVIORAL|Positive Appreciation of Body Functionality Induction|The positive induction takes place in a virtual environment of a dressing room and includes the following methods to induce positive appreciation of body functionality: 1) a narrative that aims to take the participants back to a time in the past when they held a higher positive body image. 2) A green virtual costume, representing their body at that time in the past and the positive attitude and feelings towards their body. 3) Five daily life tasks involving the use of the lower back, accompanied by auditory reminders and visual cues (green costume) to preserve the induction effect.
223646593|NCT06054074|BEHAVIORAL|Negative Appreciation of Body Functionality Induction|The negative induction takes place in a virtual environment of a dressing room and includes the following methods to induce a lower appreciation of body functionality: 1) a narrative that aims to take the participants back to a time in the past when they held a lower positive body image. 2) A red virtual costume, representing their body at that time in the past and the negative attitude and feelings towards their body. 3) Five daily life tasks involving the use of the lower back, accompanied by auditory reminders and visual cues (red costume) to preserve the induction effect.
223646594|NCT00168857|DRUG|telmisartan|
223646595|NCT00168857|DRUG|losartan|
223646596|NCT03805152|DRUG|Neuronox(R)|Injection botulinum toxin intramuscular for affected neck muscle
223646597|NCT03805152|DRUG|Dysport (R)|Intramuscular injection
224232425|NCT04669665|DRUG|Placebo|Intranasal placebo
224232426|NCT04669665|OTHER|Standard of care|Standard of care treatment will be determined by the treating physician(s) based on clinical judgement and practice guidelines
224232427|NCT04669665|DEVICE|Intranasal device|Device to deliver intranasal solution
224232428|NCT00762957|DRUG|TAK-559 and metformin|TAK-559 16 mg, tablets, orally, once daily and metformin stable dose orally, once daily for up to 26 weeks.
224232429|NCT00762957|DRUG|TAK-559 and metformin|TAK-559 32 mg, tablets, orally, once daily and metformin stable dose, orally, once daily for up to 26 weeks.
224232430|NCT00762957|DRUG|Metformin|TAK-559 placebo-matching tablets, orally, once daily and metformin stable dose, orally, once daily for up to 26 weeks.
224232431|NCT04744740|DEVICE|in-home sleep recording|in-home, nightly, zero-burden objective quantification of sleep scheduling and sleep heart rate via a mattress-top sensor (Sleepace RestOn) + ad lib quantification of blood SaO2 via a ring-based sensor (Bodimetrics Circul) + ad lib quantification of sleep and waking activity and heart rate via a wrist-worn sensor (Garmin Vivosmart 4)
224232432|NCT05396820|OTHER|Experimental pain|Experimental pain will be induced by capsaicin 1% on intact, non-irritated and dry shoulder's skin. For the purposes of this study, we will remove this patch before the recommended application time in order to generate a pain. The participant will be seated on a chair facing a table so that his or her dominant forearm rests on the table. Markers will be placed at the table and chair legs as well as on the table, corresponding to the two support points of the elbow and the index finger, in order to standardize the starting position. The target of the pointing movement will be placed at 80% of this maximum distance. The investigator will tell the participant to stand by, and then, within 4 to 10 seconds, an audible signal will indicate to the subject that he/she should perform the pointing movement. The procedure will repeat after a 4-10 second pause. For each session, 30 pointing movements reaching the target will be performed.
223646598|NCT05302726|DRUG|Estrogen|Transdermal and oral estrogen both as substitution therapy
223646599|NCT03798353|COMBINATION_PRODUCT|PeriCord: Expanded and cryopreserved allogeneic umbilical cord Wharton´s jelly-derived adult mesenchymal stem cells colonized on human pericardial matrix.|A matrix-cell construct (PeriCord) will be placed on the ischemic area of the non-candidate revascularization area during a surgery by sternotomy to perform the surgical revascularization of the arteries candidates for revascularization.
223646600|NCT03798353|PROCEDURE|Surgery by sternotomy|The patient will undergo surgery by sternotomy to perform the surgical revascularization of the arteries candidates for revascularization. No additional procedure will be performed only the by-pass.
223646601|NCT03751930|OTHER|Samples|Urinary and faecal samples
223646602|NCT06400381|BEHAVIORAL|Mindfulness|There are many mindfulness-based interventions protocol that can be implemented and practice by healthcare organization. In the current study, the intervention protocol the investigators will use is based on Smiths version of mindfulness meditation (Smith, 2005). This version is compromised of several components includes being mindful of breathing, thought, sounds, taste, body scan, and sitting. The initial educational session by power point presentation will be given to the participant to explain the intervention rationale and procedure of mindfulness in daily life. In addition to giving opportunity for the participant to ask questions during the educational session.
223646603|NCT02590224|DRUG|Ferrous bis-glycinate|
223646604|NCT02590224|DRUG|Ferrous glycine sulphate|
223646605|NCT00560170|DRUG|Simvastatin (Zocor)|40mg of Simvastatin (n=20) orally per-day for 28 days
223646606|NCT00560170|DRUG|10mg/10mg of Ezetimibe/Simvastatin (Vytorin)|10mg/10mg of Ezetimibe/Simvastatin (n=20) orally per-day for 28 days
223646607|NCT06356896|BEHAVIORAL|diaphragmatic breathing exercise|Each patient's relative should not be in the room, the curtains/screens around the patient bed should be closed, and interventions should be applied in a comfortable environment care will be taken to ensure that the room is quiet and calm. During the first 5 minutes, researchers will explain with pictures how the exercise is done and show it to the patient. The patient will then be asked to perform the exercise for 10 minutes under the supervision of the researchers. If the patient has performed the DBE correctly, the procedure will be discontinued. Otherwise, the patient will be asked to practice for another 5 minutes. If at the end of this period the patient still cannot perform the exercise correctly, he will be removed from the sample. DBE will be performed according to Cleveland Clinic guidelines.
223646608|NCT05479357|DRUG|Oxytocin|10 iu will be given intravenously.
223766067|NCT07171788|OTHER|selected physical therapy program|patient will receive standard physical therapy program for wrist flexors spasticity post-stroke typically includes the following components: Passive stretching: Passive static or dynamic stretching of the wrist flexorss is the mainstay to reduce spasticity and Physical therapy exercises in form of specific techniques of proprioceptive facilitation, relaxation techniques, passive and self-passive motions, and proper limb positioning. plus sham low level laser therapy
224232433|NCT02625831|OTHER|Biological analysis|"Biological analysis :~* ficolin-3~* anti-ficolin 3 antibodies~* anti-C1q antibodies"
224232434|NCT03960320|OTHER|questionnaire|questionnaire to assess the quality of life of children using KINDL, SDQ and SF-36
224232435|NCT03522948|BEHAVIORAL|Brief intervention with text messaging to reduce sexual risk and heavy drinking among MSM|Combines a brief in-person motivational intervention with personalized cognitive counseling elements and 4 weeks of personalized text messaging to support goals related to sexual risk behavior and alcohol use
224320019|NCT03663452|BEHAVIORAL|Targeted Assessment and Context-Tailored Implementation of Change Strategies (TACTICS)|TACTICS begins with a mixed methods assessment (using data from medical records, staff surveys, and staff interviews) to identify barriers and facilitators of PE use in each clinic. From a menu of implementation strategies that can be matched to local conditions, an implementation plan is developed in collaboration with clinic personnel and deployed to address specific barriers and leverage strengths at each clinic site over a 5-month period.
223646609|NCT05479357|DRUG|Carbetocin|100 micrograms will be given intravenously.
223646610|NCT02670096|DRUG|Acetazolamide|Two single dose administrations of acetazolamide (once before daytime testing, and once before nighttime testing)
223646611|NCT04491318|OTHER|Observational|Hemophilic arthropathy patients who will not receive any intervention. The dependent variables (frequency of hemarthrosis, pain, joint state and range of movement) in the joints will be evaluated: elbows, knees and ankles.
223646612|NCT00491634|DRUG|treosulfan|12 g/m2 x 3 days
223646613|NCT00491634|DRUG|Treosulfan|12 g/m2 x 3
223646614|NCT02889952|DEVICE|Near infrared camera (NIR)|"Surgical field was examined with NIR, during a few minutes (\<5') with room lights switched off, to avoid parasite lights, then conventional open thyroidectomy was resumed conventionally. Real-time images, evocative of autofluorescent parathyroids, were checked visually.~NIR consisted of a 750 nm class 1 laser excitation, with a power \<20mW/cm2 (5 times less than the limit of 100mw/cm2, fixed by the international norm IEC 60601-2-41). It was provided by the Fluobeam® camera, which was inserted into a sterile cover and hold at a 15-20 cm distance from the patient. The system has an FDA 510(k) authorization for clinical use in parathyroid surgery and a European Community certification (Class 1 device)."
224320020|NCT03663452|BEHAVIORAL|Prolonged exposure training|Providers will receive a 2-day workshop training in the delivery of prolonged exposure, followed by weekly phone clinical consultation.
224320021|NCT05179928|PROCEDURE|Erector Spinae Plane Block (ESPB)|Postoperative Bilateral Ultrasound-guided ESPB
223646615|NCT05103137|OTHER|Questionnaire|Questionnaires concerning assesment of quality of life with 3 different questionnaires ( SF36, HAQ and pre-established questionnaire for the study) during a phone interview
223646616|NCT05133310|DRUG|Simvastatin|Combination of Simvastatin with Standard Chemotherapy scheme for acute lymphoblastic patients.
223646617|NCT04943653|DRUG|Paclitaxel|"intraperitoneal paclitaxel~20mg/BSA(Body Surface Area), 40mg/BSA, 60mg/BSA (phase I)~recommended dose (phase II)"
223646618|NCT03311243|PROCEDURE|Non surgical periodontal therapy|
223646619|NCT03311243|DRUG|Chemical plaque control|
223646620|NCT02559375|OTHER|Survey|
223646621|NCT02577718|DRUG|Nitroglycerin-citrate-ethanol (NiCE)|Lock solution instilled in catheter lumens for 2 hours then flushed. Administration for up to 30 days, daily as in-patient or once weekly as out-patient
223646622|NCT04587427|DRUG|Radium 223 dichloride (Xofigo, BAY88-8223)|Prescribed by physicians.
223646623|NCT03903406|DRUG|ixazomib in combination with lenalidomide and dexamethasone|Patients with RRMM who have received at least one prior therapy will receive Ixazomib in combination with lenalidomide and dexamethasone within the routine clinical practice in accordance with prescription. Duration of therapy - until disease progression or unacceptable toxicity.
223646624|NCT05423561|PROCEDURE|exchange nailing with larger, thicker nail crossing corticalization|exchange nailing with larger, thicker nail crossing corticalization
223646625|NCT01967576|DRUG|Axitinib (AG-013736)|5 mg twice a day on a 28-day cycle.
223646626|NCT05237076|DIAGNOSTIC_TEST|Hyperinsulemic-Euglycemic Clamp & Hypoxic Ventilatory Response (HVR)|Hyperinsulemic-Euglycemic Clamp as described by deFronzo et al.
223646627|NCT00768456|DRUG|Ropivacaine 0.5 %|Local Infiltration with Ropivacaine 0.5 %
223646628|NCT00768456|DRUG|Isotonic NaCl|Local Infiltration with NaCl
223646629|NCT04640220|PROCEDURE|Intra-articular steroid injection|Ultrasound-guided Gleno-humeral joint steroid (Triamcinolone 40mg with 0.5% lidocaine ) injection
223646630|NCT03515330|OTHER|mHealth Intervention|The mHealth application will allow liver transplant recipients to see their medication regimen, record a video of themselves taking every dose, report side effects or symptoms, visualize their treatment progress, and access educational content. This information is encrypted and transmitted to a HIPAA-secure web portal for providers to review.
223646631|NCT03196349|DRUG|Warfarin|Will be randomized to receive open label warfarin daily to achieve a target INR of 2-3
223646632|NCT03196349|DRUG|Apixaban 2.5 MG|Will be randomized to receive open label apixaban of 2.5 mg twice daily
223646633|NCT03196349|DRUG|Rivaroxaban 10 MG|Will be randomized to receive open label rivaroxaban of 10mg daily
223646634|NCT05654818|DRUG|Vitamin D|100,000 UI
223646635|NCT05654818|DRUG|Placebo|The placebo is identical in appearance to the active treatment: a drinkable solution in ampoules that is clear, yellowish in color with a slightly lemony odor and an oily, slightly sweet, lemony taste.
223646636|NCT04084691|OTHER|Physical exercice - moderate intensity|standardized physical activity (moderate intensity) lasting 30 minutes and having a warm-up portion of 5 minutes
223646637|NCT04084691|OTHER|Physical exercice - high intensity|standardized physical activity (high intensity) lasting 30 minutes and having a warm-up portion of 5 minutes
223646638|NCT04084691|OTHER|Physical exercice - workout|standardized physical activity (bodybuilding) lasting 30 minutes and having a warm-up portion of 5 minutes
223646639|NCT04084691|OTHER|Normal meal|\- Hyperlipidic meal Energy supply: 800 kcal Distribution of macronutrients: proteins: 15% +/- 5; carbohydrates: 40% +/- 5; lipids: 45 +/- 5 Choice of foods determined with the dietician taking into account the patient's tastes and products available on the market The same meal will be taken before the 3 sessions concerned.
223646640|NCT04084691|OTHER|Normalized meal|"\- Hyperglucidic meal Energy supply: 800 kcal Macronutrient distribution: protein 15% +/- 5; carbohydrates 60% +/- 5; lipids 25 +/- 2 Choice of foods determined with the dietician taking into account the patient's tastes and products available on the market.~The same meal will be taken before the 3 sessions concerned."
223646641|NCT04084691|OTHER|Fasting|non meal in the hour before exercise
223646642|NCT03967444|DEVICE|Hyaluronic acid|Injectable gel for lip augmentation
223646643|NCT03967444|DEVICE|Hyaluronic acid|Injectable gel. Lip Augmentation and other wrinkles/folds
223646644|NCT00655200|DRUG|insulin detemir|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
223646645|NCT05242380|OTHER|Kettlebell Exercise|"The exercise training plan for this group consists of 4 stages. Each stage lasts 2 weeks and consist of 5 kettlebell (KB) exercises. These exercises will continue from basic (single movement training) to advanced (comprehensive movement training) and is geared towards functional training. Participants will perform 2 sets of 12 repetitions of each exercise. Each training session is planned to last 45 minutes.~The following exercises will be used in KB training: biceps curl, triceps extension, kettlebell swing (two-handed), kettlebell dead lift, kettlebell goblet squat, suitcase carry, waiter carry, bottoms up carry, farmer's walk, overhead carry, lunge, kettlebell row."
223646646|NCT03775135|OTHER|Questionnaires|Different questionnaires about identity development and psychosocial functioning will be administered
223646647|NCT02210039|DEVICE|SECM Probe|Imaging of the esophagus using SECM probe and system.
223646648|NCT03441815|DRUG|XC8|
223646649|NCT03441815|DRUG|Placebo|
223646650|NCT04355039|DRUG|Pomalidomide|4 mg Days 1-21
223646651|NCT04355039|DRUG|Dexamethasone|40 mg Days 1, 8, 15 and 22
224320022|NCT05179928|PROCEDURE|Rectus Sheath Block (RSB)|Postoperative Bilateral Ultrasound-guided RSB
224320023|NCT04158245|DRUG|18F-fluciclovine PET Scan|The use of 18F-fluciclovine PET scanning will allow a more sensitive assessment of mCRPC patients at the initiation of systemic therapy and changes observed in 18F-fluciclovine PET will correlate better with the serologic changes in PSA, allowing superior disease monitoring, as compared to conventional imaging modalities. In addition, 18F-fluciclovine PET will detect heterogeneity in disease response and thus identify potential lesions amenable to targeted therapy.
224232436|NCT04181450|OTHER|Determination of the Cut-off Scores of Biodex Balance System|Based on the findings of the Sherafat et al. (Sherafat, S., Salavati, M., Takamjani, I. E., Akhbari, B., Mohammadirad, S., Mazaheri, M., \& Negahban, H. (2013). Intrasession and intersession reliability of postural control in participants with and without nonspecific low back pain using the Biodex Balance System. Journal of manipulative and physiological therapeutics, 36(2), 111-118.) related to intrasession and intersession reliability of BBS in patients with NSLBP12, in the present study, one stability level (Level 5; ICC ≥0.70) and two conditions (eyes-open and eyes-closed) will be selected as testing procedure. All postural assessments will be performed during bilateral stance for a period of 30 seconds.
224232437|NCT03198013|DRUG|Prednisolone|Specified dose on specified days
224232438|NCT03198013|DRUG|BMS-791826|Specified dose on specified days
224232439|NCT03198013|DRUG|Placebo|Specified dose on specified days
224232440|NCT05743218|OTHER|electropuncture|"Electroacupuncture (EA) is a method of treating diseases by inserting a needle (usually a filiform needle) into the skin or tissue of a patient at a certain Angle, and then passing through the needle (sensing) micro-current waves of human bioelectricity to stimulate specific parts of the human body (acupoints).~1. Disposable sterile acupuncture filiform needle (0.16mm×13mm, 0.30mm×25mm, 0.30mm× 40mm), Guizhou Andi Medical Equipment Co, LTD, Guizhou Food and Drug Supervision and Equipment Production Xu 20170011.~2. Electroacupuncture apparatus: SDZ-Ⅱ electroacupuncture apparatus of Huatuo brand, Suzhou Medical Supplies Factory Co., LTD., Registration No. : 20172270675."
224232441|NCT00084084|DRUG|Agalsidase alfa|0.2 mg/kg agalsidase alfa administered by IV infusion over 40 (+/- 10) minutes every other week for 52 weeks, with periodic reassessments for study continuation beyond 52 weeks
224232442|NCT01802879|DRUG|Panobinostat|Panobinostat was provided as 5, 10 and 20 mg hard gelatin capsules to be taken orally. Patients started on dose from parent protocol and dose modifications were at the discretion of the investigator based on guidance provided in the protocol and IB.
223646652|NCT04355039|DRUG|INCB053914 50 mg bis in die (BID)|Dose level 0: 50 mg BID
223646653|NCT04355039|DRUG|INCB053914 65 mg BID|Dose level 1: 65 mg BID
223646654|NCT04355039|DRUG|INCB053914 80 mg BID|Dose level 2: 80 mg BID
223646655|NCT02064101|PROCEDURE|Spinal Fusion|The investigators are studying the use of triggered EMG via the IPC POWEREASE screwdriver (Product Codes HBE, HWE, GWF) during spinal fusion surgery in adolescent idiopathic scoliosis by comparing it to the traditional triggered EMG OrthoMon probe system (Product Codes GWF, IKN).
223646656|NCT02369796|DRUG|TAK-448|TAK-448 solution for subcutaneous injection
223646657|NCT03330301|OTHER|D-tect|"1. This study is based on a unique Danish social experiment that took place during a well-defined period between 1937 and December 1985, when it was mandatory to fortify all margarine with vitamin D (1.25 μg/100 g). This well-defined vitamin D fortification period makes it possible to investigate the impact of fetal exposure to extra vitamin D from food fortification on the risk of developing diseases later on. This study is possible due not only to the well-defined adjacent time window but also to the complete registration of every citizen via a civil registration number. This number can be linked, on an individual level, to Danish birth, patient and medical registries; social and ethnic registries; and clinical and other large databases~2. Case-cohort study: vitamin D measurements from dried blood spots and the risk of diseases later on"
223646658|NCT01821118|BIOLOGICAL|Ponezumab|Infusion of Ponezumab (Day 1=10mg/kg; Day 30 and Day 60 dose = 7.5mg/kg) or placebo (saline); administered via infusion for a total infusion time of 20 minutes.
223646659|NCT01821118|OTHER|placebo|placebo (saline)- given via infusion total infusion time of 20 minutes
223646660|NCT00642083|DEVICE|Viabahn stent-graft|The viabahn stent-graft is a combined ePTFE-Nitinol self-expanding stent-graft preloaded on a catheter-based delivery system. It was originally designed for improving blood flow in patients with symptomatic peripheral arterial disease in superficial femoral artery lesions with reference vessel diameters ranging from 4.8 to 7.5 mm. This device is also increasingly used for the exclusion of popliteal aneurysms. Its flexibility might make the device ideal for the treatment of recurrent outflow stenosis in AV loop-fistula.
223646661|NCT01605799|BEHAVIORAL|IOK Killing Treatment|The IOK Killing Treatment is based on Cognitive Behavioral Therapy theory and principals and target maladaptive cognitions related to killing in war.
223646662|NCT01605799|BEHAVIORAL|Wait list control group|Participants in this group will not receive treatment; however, at the end of 6 weeks, they will be offered the option of receiving treatment.
223646663|NCT03805282|DRUG|Lidocaine|Continuous infusion, variable dose of lidocaine.
223646664|NCT04549129|BEHAVIORAL|Breastfeeding education video|"An introductory video (15 minutes) gives an overview of these ABCs (video titled Term baby which are further taught through brief text summaries (150-200 words) and short instructional videos (2-6 minutes)."
223646665|NCT04549129|BEHAVIORAL|Breastfeeding website|"The website firstdroplets.com is designed for prenatal education, focusing on the ABCs of breastfeeding that come before D (delivery) - attachment (latch), breastmilk production, and calories (transfer of milk to baby)."
223646666|NCT04549129|BEHAVIORAL|Usual breastfeed education|The usual breastfeed education includes brief counseling by study staff and provision of handouts on latch/positioning and common first week breastfeeding advice
223646667|NCT00345358|BIOLOGICAL|Synflorix|1, 2, 3 or 4 Intramuscular injections, depending on age group
223646668|NCT00345358|BIOLOGICAL|Infanrix IPV/Hib|4 intramuscular injections
223646669|NCT02202941|OTHER|Procalcitonin guided treatment|Patients who will be randomized to arm will receive antibiotics therapy based on procalcitonin measurement on day 1, 3, 5, 7, 9, 11 and 13.
223646670|NCT02202941|OTHER|Conventional treatment|Patients who will be randomized to this arm will receive antibiotic therapy based on conventional practice.
223646671|NCT01099462|DRUG|Ibuprofen|Ibuprofen (10mg/kg BW) will be given orally if the temperature on presentation is higher than 38.0OC according to the decision of the attending physician.
223646672|NCT06379815|OTHER|Sodium Lactate|See arm/group description.
223646673|NCT06379815|OTHER|Sodium Chloride|See arm/group description.
223646674|NCT05346419|DRUG|Risedronate|Participants received risedronate 35 mg once a week for 6 months.
223646675|NCT05346419|DRUG|Vitamin D|Participants received 2,800 IU of vitamin D once a week, with additional daily supplementation of 4,000 IU of vitamin D
224232443|NCT06484946|OTHER|aquatic occupational therapy|Each week, the children participated in a 45-minute aquatic occupational therapy group that consisted of warmup on land, 30 mins of sensory activities in the water, and 10 mins of social activity in the water
223766068|NCT07174050|DEVICE|King Vision Channeled Video Laryngoscope|King Vision Videolaryngoscope (KVVL) is one of the new indirect laryngoscopes with disposable (either with channeled or non-channeled) blades .Both designs include an anti-fog lens coating . The channelled KVVL has a rigid blade with an integrated channel for introducing the endotracheal tube. The height and width of the standard non-channeled and channeled blades are 13 mm and 26 mm vs 18 mm and 29 mm, respectively. The KVVL has a unique design and high-quality image . It has a camera that enables a clear view of the glottis. It is a solid, portable, battery-operated device with an organic LED display for video laryngoscopy . It allows better glottis visualization and Cormack Lehane score than DL. Compared with Airtraq, the KVVL has wide field of view (160° vs 80° respectively) and potentially shortens the time to tracheal intubation .
223766069|NCT07174050|DEVICE|Macintosh Laryngoscopy|In clinical practice, direct laryngoscopy (DL) with either a curved (Macintosh) or straight (Miller) blade is a well-known and reliable technique in the hands of an experienced operator.
223766070|NCT07172802|DRUG|GI-108|Dose level will be escalated from 0.1mg/kg to 0.6 mg/kg and Recommended phase 2 dose (or RP2D) of GI-108 will be administered via IV infusion Q3W upto 2 years (approximately 35 years)
224232444|NCT05498246|PROCEDURE|laparoscopic partial nephrectomy|Operations were done under general anesthesia. Patients were positioned in modified lateral kidney position for trans-peritoneal procedures. Pneumoperitoneum using the Veress needle technique and trocar placement . Dissection to the renal hilum for good and sufficient exposure of the renal vessels. Good exposure of the tumor and marking the excision site with electro cautery. Clamping of renal vessels using laparoscopic Bulldog appliers. Excision of the renal mass using visual assessment to determine the suitable depth of normal parenchyma to be excised in order to achieve a negative surgical margin. Unclamping was done and re-assessment of the hemostasis to secure residual bleeding points. Approximation of the edges of renal parenchyma using suturing in both groups. The specimen was placed in an EndoCatch bag and removed through pfannenstiel incisionsurgical drain was placed in the paracolic gutter
224232445|NCT01105650|DRUG|Fludarabine|Administered intravenously, 25 mg/m\^2, days -6 through -2 (5 days).
224232446|NCT01105650|DRUG|Cyclophosphamide|Administered intravenously, 60 mg/kg, days -5 and -4.
224320024|NCT05848115|DEVICE|Bi-level Positive Airway Pressure|An appropriately sized vented BiPAP face mask with a good seal will be applied and monitored by trained respiratory therapists. Patients will be started on an inspiratory peak airway pressure (IPAP) of 10 cm of water and expiratory positive airway pressure (EPAP) of 5 cm of water per Children's Hospital Colorado (CHCO) clinical pathway. BiPAP pressures will be titrated to effect per the treating physician, using assessment of physical examination, vitals, and asthma score per institutional clinical pathway. Study participants will remain on BiPAP for four hours or until weaned off continuous beta-agonist therapy by the treating clinician. After the four-hour intervention period, it is at the discretion of the treating clinician regarding the ongoing use of BiPAP or not.
223646676|NCT03917953|DEVICE|Transcutaneous Electrical Acupoint Stimulation|"Patients in the experimental group will be treated for 20 min TEAS, twice a week, for a total of 4 weeks of treatment.The same intervention was performed in the sham group (electrode patches were attached at corresponding acupoints without electrical stimulation).~Acupoint selection: baihui (GV 20), taichong (LR 3), taixi (KI 3)."
223646677|NCT00342108|BEHAVIORAL|cross-modal sensory stimulation|comparison of participant response to unimodal visual stimulation and to bimodal sensory stimulation
223646678|NCT05418205|OTHER|Families with FGP support|Non-randomized controlled trial with four points of measurement ( in 18 months)
223646679|NCT06523920|DEVICE|University of Wisconsin solution + cold storage|Preservation of the free flap with UW solution and cold storage during ischemia time
223646680|NCT06523920|OTHER|Unperfused free flap under warm ischemia|Traditional processing of the free flap: no perfusion of the flap and warm ischemia (room temperature conservation during ischemia time
223646681|NCT06198582|OTHER|Virtual Reality Exercises|In addition to conventional treatment, patients in the study group underwent a virtual reality-based task-specific exercise program in a computer-based virtual reality station. Two different virtual reality games that fit the definition of task-specific exercise were selected for our study. In order for the patient to complete the task in the game, the patient was asked to extend the upper extremity and hand to touch the virtual object through the reflection on the screen and to first grasp the object in the virtual environment by making active flexion with all fingers and to move it from one place to another on a certain plane without disturbing the grasping posture of the hand. These virtual reality exercises selected in our study were practiced under the supervision of the researcher 3 days a week for 15 minutes each for a total of 4 weeks. These sessions consisted of three sets of 2.5 minutes each for each game, with 15-second breaks between sets.
223646682|NCT04189887|BEHAVIORAL|aerobic exercise (cycling)|People who perform aerobic exercise will ride on a stationary bike for 20 minutes after motor skill learning
223646683|NCT04189887|BEHAVIORAL|Implicit sequence learning|All participants will practice the serial reaction time task (SRTT) on the first day, and retention performance will be assessed immediately, on the 2nd day, and on the 7th day of study.
223646684|NCT00477386|DRUG|decitabine|"Decitabine dose will be escalated as follows.~Dose level 1: 10mg/m2 IV QD X 5 days Dose level 2: 20mg/m2 IV QD X 5 days Dose level -1: Carboplatin AUC 4."
223646685|NCT02207452|DEVICE|He-3 MRI|Hyperpolarised helium-3 Magnetic Resonance Imaging (MRI) scan pre-bronchodilator and 1 hour post-bronchodilator (after 1 hour post-bronchodilator assessments/procedures completed).
223646686|NCT02207452|DRUG|Salbutamol|Salbutamol 5mg nebulised single dose
223646687|NCT02207452|DRUG|Ipratropium|Ipratropium 500mcg nebulised single dose
223646688|NCT02207452|DEVICE|MRI|Proton Magnetic Resonance Imaging (MRI) scan pre-bronchodilator and 1 hour post-bronchodilator (after 1 hour post-bronchodilator assessments/procedures completed).
223646689|NCT02207088|DRUG|ombitasvir/paritaprevir/ritonavir|tablet
223646690|NCT02207088|DRUG|dasabuvir|tablet
223646691|NCT02207088|DRUG|Ribavirin|tablet
223646692|NCT01166880|DEVICE|Laser Speckle Imaging|Laser Speckle Imaging Infant Head Blood flow
223646693|NCT00724087|OTHER|5.5-hour bedtime|16 days with sleep allowed only during a 5.5-hour bedtime period at night
224232447|NCT01105650|DRUG|Cyclosporine|Administered intravenously, CsA 1.5 mg/kg for target dose range of 150-250 ng/mL day -3 through day +14
224323512|NCT03022825|DRUG|N-803|N-803 will be administered via intravesical instillation weekly for 6 consecutive weeks (induction). After the first disease assessment, eligible patients will receive either a 3-week maintenance course or a 6-week re-induction course (second treatment period) at Month 3. Eligible patients will continue to receive maintenance treatment in the third treatment period at Months 6, 9, 12, and 18. Eligible patients have the option to receive maintenance treatment in the fourth treatment period at Months 24, 30, and 36.
223646694|NCT00724087|OTHER|8.5-hour bedtime|16 days with sleep allowed only during a 8.5-hour bedtime period at night
223646695|NCT05711212|DIETARY_SUPPLEMENT|micellar solubilized Xanthohumol|single administration of 4 soft gelatine capsules each containing 43 mg micellar solubilized Xanthohumol
223646696|NCT05711212|DIETARY_SUPPLEMENT|Placebo|single administration of 4 soft gelatine capsules containing only micelles
223646697|NCT03768934|OTHER|1X airtime incentive|An incentive given in the form of airtime.
223646698|NCT03768934|OTHER|2X airtime Incentive|An incentive given in the form of airtime.
223646699|NCT03768934|OTHER|Lottery airtime incentive|An incentive given in the form of airtime.
223646700|NCT04522232|PROCEDURE|conventional Total laparoscopic hysterectomy|"the ascending branch of the uterine artery was identified close to the isthmus then ligated at this level, close to the uterus or coagulated, using bipolar diathermy. The utero-vesical fold was dissected and the bladder was pushed down done, thus moving the ureters laterally, which decreases the risk of including them in a suture. The vasculature of the uterus is now secured and this is evidenced by the pale color of the fundus.~Using either bipolar diathermy or the harmonic ultracision, the cornual pedicles on one side were desiccated and cut. Also, both the uterosacral and cardinal ligaments were desiccated and cut. So that, the opposite side pedicles can be taken care of, the direction of manipulator was changed. The infundibulopelvic ligaments were desiccated and cut if it is necessary to remove both ovaries. A vaginal cuff was inserted into the vagina to identify the vault, which was then cut laparoscopically using a monopolar hook, where the specimen was completely detached."
223646701|NCT04522232|PROCEDURE|Total laparoscopic hysterectomy with prior uterine artery ligation at its origin|"the uterine artery was dissected using the lateral approach; where dissection begins from the anterior leaf of the broad ligament. The triangle enclosed by the round ligament, external iliac artery, and infundibulopelvic ligament was opened. The areolar space was dissected and the origin of the uterine artery from the internal iliac and the ureter was identified. The uterine artery was then isolated from the surrounding structures and ligated by Hem-o-lok clips.~then same steps as conventional Total laparoscopic hysterectomy"
223646702|NCT01574469|OTHER|1-Low fat fermented dairy product enriched with plant sterol esters (0,8 g equivalent as free sterols) (test)|1 = Intervention 1 (2 test products / day)
223646703|NCT01574469|OTHER|2-Low fat fermented dairy product (control)|2 = Intervention 2 (2 control products/day)
223646704|NCT02516137|PROCEDURE|Dry needling|Dry needling will be performed on two points over the hamstring muscles on the randomly determined side. Points 2 cm distal to the ischial tuberosity and halfway between the ischial tuberosity and popliteal crease within the medial and lateral muscle bellies will be identified and the skin cleansed with rubbing alcohol. A Seirin L- type 50 mm needle will be inserted into each of the two points to a depth no greater than three-quarters length of the needle into the hamstring muscle for 30 seconds using a vertical pistoning technique and then statically up to 10 minutes.
223646705|NCT02516137|PROCEDURE|Sham needling|Sham dry needling will be performed on two points over the hamstring muscles on the randomly determined side. Points 2 cm distal to the ischial tuberosity and halfway between the ischial tuberosity and popliteal crease within the medial and lateral muscle bellies will be identified and the skin cleansed with rubbing alcohol. The plastic tube of a Seirin L- type 50 mm needle will be placed against the skin and the needle will be tapped once so that it is inserted subcutaneously no deeper than 5 mm for 30 seconds using a vertical pistoning technique and then statically up to 10 minutes in each location.
223646706|NCT02516137|PROCEDURE|Blunt needle placement|Blunt needle placement will be performed on two points over the hamstring muscles on the randomly determined side. Points 2 cm distal to the ischial tuberosity and halfway between the ischial tuberosity and popliteal crease within the medial and lateral muscle bellies will be identified and the skin cleansed with rubbing alcohol. A blunt needle handle is inserted into a plastic tube which will be placed over the identified points for 30 seconds and then for an additional 10 minutes each. The blunt needle handle only touches the skin without puncturing it.
223646707|NCT02516137|OTHER|Standard hamstring stretching exercise|Subjects will be instructed to stretch the back of their thighs, once a day for 3 repetitions, holding for 30 seconds each time performed bilaterally.
223646708|NCT01812252|DRUG|Azacitidine (AZC)|Given IV or SC
223646709|NCT01812252|DRUG|Decitabine|Given IV or SC
223646710|NCT01812252|OTHER|Quality-of-Life Assessment|Ancillary studies
223646711|NCT05766046|DIAGNOSTIC_TEST|early lung cancer detection|standard treatment for early lung cancer detection with LDCT at one or two years interval
223646712|NCT05766046|OTHER|blood test|blood analysis for microRNA and other biomarkers detection
223646713|NCT02864784|DRUG|Amorphous calcium carbonate|Subjects in this arm of the study will receive standard treatment with ZA or Denosumab (4 mg once every 4 weeks for ZA and 120mg (1.7ml injection) every 4 weeks for Denosumab) as well as AMOR-1 tablets, containing 200 mg elemental calcium per tablet, individually titrated up to the maximum level which does not induce grade 2 hypercalcemia.
224232448|NCT01105650|BIOLOGICAL|Natural killer cells|Administered by infusion over less than 1 hour, no more than 8.0 x 10\^7 cells/kg will be given.
223646714|NCT02864784|OTHER|Placebo|microcrystalline cellulose
224232449|NCT01105650|DRUG|IL-2|Will be given subcutaneously at 9 million units 3 times a week for a total of 6 doses, beginning 4 hours after NK cell infusion. (For patients weighing less than 45 kilograms, will be given at 5 million units/m\^2 3 times per week for 6 doses).
224232450|NCT01105650|DRUG|Methylprednisolone|Administered intravenously (IV) 10 mg/kg Days -2 to +4 and 1 mg/kg Days +5 to +9
224232451|NCT01105650|DRUG|Methylprednisolone|Administered intravenously (IV) 1 mg/kg Days -2 to +9
223646715|NCT01249079|OTHER|No intervention would be provided in this research|No intervention would be provided in this research,but need to draw blood
223646716|NCT04603599|DIAGNOSTIC_TEST|serum soluble L1CAM (sL1CAM)|blood sample
223646717|NCT02284243|DRUG|Intranasal Dexmedetomidine|
223646718|NCT02284243|DRUG|Intranasal Placebo|
223646719|NCT01655485|OTHER|Patient teaching|The Social script application is an story book on the iPAD with photos and script explaining the steps of getting a medical image such as a CAT scan from the perspective of the child.
223646720|NCT01227993|DRUG|Finasteride|
223646721|NCT05637580|DRUG|Timing of drug administration|The effect of drug administration timing on tumor and lymph node responses was observed.
223646722|NCT04615052|OTHER|Exercise training|A 16 weeks parallel-group randomised controlled trial will be performed, in which covid-19 survivors patients will complete a telemonitored home-based exercise training program, 3 times per week. The training program will involve strength, aerobic, balance and flexibility exercises.
223646723|NCT04387604|DRUG|Ranibizumab 0.5 MG/0.05 ML Intraocular Solution [LUCENTIS]|"PRN regimen. Treatment Schedule Repeat injections at every 4-week visit if eye improves or worsens (defined as ≥5 letter change from last injection or ≥10% CST change on OCT from last injection or CSF\>300 μm at any timepoint).~Defer injections if either BCVA of 85 letters and OCT CSF normal (CSF≤300 μm and non-existent intra- or sub-retinal fluid); or OCT CSF normal (CSF≤300 μm) and stable BCVA (defined as \< 5 letters change from last injection) after two consecutive injections during the first 24 weeks, or after one injection if the initial stability period has already been achieved (OCT CSF normal and stable BCVA).~Resume injections if BCVA or OCT worsens."
223646724|NCT01099332|OTHER|Gastro-retentive zinc cysteine tablet|Oral, one tablet, once daily with water for 6 months.
223646725|NCT01099332|OTHER|Tablet identical physically to active comparator containing some lactose|Oral, once daily, with water, 6 months.
223646726|NCT02869464|OTHER|Imaging-Ultrasound|Abdominal Ultrasound
223646727|NCT02869464|OTHER|Imaging-MRA|Non-contrast Enhanced Magnetic Resonance Angiogram
223646728|NCT02869464|GENETIC|DNA, RNA testing|To test for the co-prevalence of shared genetic markers in afflicted populations.
223646729|NCT03381638|DEVICE|Blink Reflexometer|The device uses 5 light puffs of air to the side of the eye causing a blink reflex that is captured by the high-speed camera tracking the eyelids.
223646730|NCT03838432|DEVICE|Steep Pulse Device|Applying the steep pulse to treat the patients with Prostate cancer
223646731|NCT04269889|DRUG|Eltrombopag|"Eltrombopag will be administered to participants 12 years of age an above will receive the adult dose of 150 mg by mouth daily. Participants between ages of 6 and 11 years old will start at 75 mg by mouth daily, and children 2 and 5 years of age will start at 2.5 mg/kg, not to exceed 75 mg by mouth daily.~To adjust for the higher expected exposure in participants of East Asian and South East Asian ancestry, the starting dose for East Asian and South East Asian participants 12 years of age and above will be 75 mg by mouth once daily. For East Asian and South East Asian participants between 6 and 11 years of age, the starting dose will be 37.5 mg once daily by mouth, and for children between 2 and 5, the starting dose will be 1.25 mg/kg by mouth."
223646732|NCT04513509|DRUG|Atenolol, Bisoprolol, Metoprolol, Nebivolol, Propranolol, Diltiazem, Verapamil, digoxin|Start with empirical lower dose for 3 months, and then titrate up
223646733|NCT00095888|DRUG|triapine|Given IV
223646734|NCT00095888|DRUG|gemcitabine hydrochloride|Given IV
223646735|NCT00095888|OTHER|laboratory biomarker analysis|Correlative studies
223646736|NCT00095888|OTHER|pharmacological study|Correlative studies
223646737|NCT00042822|DRUG|romidepsin|
223646738|NCT04634253|DRUG|Placebo|Given IV
223646739|NCT04634253|DRUG|LY3462817|Given IV
223766071|NCT07173023|PROCEDURE|Transnasal Puncture with Mitomycin C application|"* Performed under general anesthesia.~* Nasal cavities decongested with oxymetazoline.~* Atretic plate perforated using serial dilators under direct visualization.~* Additional removal of bony/membranous tissue including the posterior nasal septum as possible.~* Topical mitomycin C (0.5 mg/mL) applied to the edges of the newly created choana for 2 minutes using cotton pledget in a transparent tube , followed by irrigation with saline.~* syndromatic patients and patients requiring less time UGA will be included in this group"
223766072|NCT07173023|PROCEDURE|Endoscopic Crossover Flap Repair|"* Performed under general anesthesia using a 0° 4 mm endoscope.~* Elevation of mucosal crossover flaps to cover exposed bone following resection of the atretic plate where one flap is inferiorly based and the other is superiorly based.~* Precise removal of the posterior vomer and lateral bony plates as needed using cold steel instruments and possible nasal drill.~* Flaps will be repositioned to minimize exposed bone and promote mucosal healing preventing restenosis."
223646740|NCT02134158|DEVICE|anodal tDCS and sham tDCS stimulations|"Two conditions will be tested in randomized order: 2 arms in the first one anodal tDCS and then sham tDCS. In the other arm sham tDCS and then anodal tDCS.~All the investigations will associate with clinical, functional and 3D motion analysis assessments."
224232452|NCT01105650|DRUG|Interleukin-2|Will be given subcutaneously at million units 3 times a week for a total of 3 doses, beginning 4 hours after NK cell infusion. (For patients weighing less than 45 kilograms, will be given at 3 million units/m\^2 3 times per week for 6 doses).
223646741|NCT05533736|OTHER|Community based strategy to follow-up pactientes with Cutaneous Leishmaniasis|Community Health leaders follow patients using the Guaral+ST app at final of treatment, and on days 90 and 180 after initiating the treatment.
224232453|NCT00263107|PROCEDURE|telerounding versus bedside rounding|
224232454|NCT02180308|DEVICE|PET/MRI|Simultaneous PET/MRI (3T system)
224232455|NCT01784042|DRUG|Placebo|placebo
223646742|NCT01499355|BIOLOGICAL|BIIB023|
223646743|NCT01499355|BIOLOGICAL|Placebo|
223646744|NCT01499355|DRUG|mycophenolate mofetil|titrated to a target daily dose of 2 g (1 g twice daily)
223646745|NCT01499355|DRUG|oral corticosteroids|oral corticosteroids (prednisone or equivalent) at a target prednisone dose of 10 mg/day
223646746|NCT01526733|DRUG|Sham Injection|
223646747|NCT01526733|DRUG|Recombinant human hyaluronidase PH20|
223646748|NCT01526733|DRUG|Insulin aspart|
223646749|NCT01526733|DRUG|Insulin lispro|
223646750|NCT06508190|BEHAVIORAL|continuous positive airway pressure|continuous positive airway pressure therapy for a period of 12 weeks, all patients with in this group are required to utilize the CPAP machine for at least 4 hours each night
223766073|NCT07173608|BEHAVIORAL|Inner Engineering Program|"The intervention is a comprehensive secular training called Inner Engineering (IE), offered by the international non-profit Isha Foundation. This program combines cognitive reappraisal and emotion regulation strategies, breath-based meditation and simple yoga practices. The training provides precise, step by step and easy to follow instructions on how to perform the practices. No previous experience of yoga and meditation is required. By fostering health, exuberance and awareness, one can engineer their inner climate the way they want it to lead a joyful, fulfilling life. Previous research shows improved wellbeing, mindfulness, joy, sleep, relationships, psychological capital, and work engagement, compassion, and parent-child relationships. Evidence suggest it may promote enhanced Heart Rate Variability and Sympathovagal balance."
223766074|NCT07174024|DEVICE|Narrow Band UVB Treatment|type of phototherapy
223766075|NCT07174024|DEVICE|blue light emitting diode|type of diode
223766076|NCT07173881|DIETARY_SUPPLEMENT|Fortified powder milk|Super 1.000 Mamá It's made up of milk with added vegetable oils, fish oil, carbohydrates from corn, prebiotic fiber (inulin), vitamins, and minerals, with specifically defined proportions. It has medium energy content, is balanced in protein, fats, and carbohydrates, and provides a significant content of both polyunsaturated fatty acids, such as omega-6, and omega-3, and the added docosahexaenoic acid, as recommended by international organizations. The reconstituted 200 ml serving delivers between 20 and 40% of the Daily Reference Intake in critical nutrients for this particular group of people, which include minerals such as calcium, iron, zinc, iodine, and vitamins such as A, D, C, B12 and folic acid. The rest of the vitamins, and minerals are also at the same level, allowing those who consume it to incorporate a large amount of nutrients regularly. Addvance SA, an SME dairy company from the Province of Santa Fe, will carry out the production of this milk.
224232456|NCT01784042|DRUG|Lovaza|
223766077|NCT07173647|DEVICE|Electrical Muscle Stimulation (EMS)|Electrical Muscle Stimulation (EMS) will be applied to the quadriceps muscles of children with cerebral palsy during stationary cycling sessions as part of the Pediatric Endurance and Limb Strengthening (PEDAL) program. EMS will be delivered using clinically approved portable stimulators at parameters appropriate for muscle strengthening and endurance training (frequency 35-50 Hz, pulse width 200-400 μs, duty cycle on/off as tolerated). EMS will be administered simultaneously with cycling to enhance muscle activation and improve motor outcome
223766078|NCT07173647|BEHAVIORAL|Pediatric Endurance and Limb Strengthening (PEDAL) Program|The PEDAL program is a structured exercise intervention designed for children with cerebral palsy. It includes 60-minute sessions of stationary cycling, warm-up, endurance and limb strengthening exercises, and cool-down stretching. Sessions are conducted three times per week for four weeks under therapist supervision. This program is used in both arms of the trial, with or without adjunct Electrical Muscle Stimulation (EMS).
223766079|NCT07172087|OTHER|Baduanjin for patients with enterostomy|Modified Baduanjin exercise: a standardized, low-to-moderate intensity qigong regimen consisting of eight sequential movements combined with diaphragmatic breathing. The program excludes any additional resistance or aerobic training and is compared with routine walking exercise only.
223766080|NCT07173452|OTHER|vaginal examination|pelvic dimensions measured via vaginal examination.
223766081|NCT07173452|OTHER|physical body measurements|Anthrometric measurements of the participants were made
223766082|NCT07173452|DIAGNOSTIC_TEST|transvaginal ultrasonographic|intrapartum pelvic evaluations were performed by transvaginal ultrasonography
224232457|NCT01784042|OTHER|Dietary energy restriction|
224232458|NCT00193778|PROCEDURE|Surgery for breast cancer|This group will receive standard loco-regional treatment i.e. surgery (modified radical mastectomy (MRM)/ Simple SMAC/BCT) +/- radiotherapy
224232459|NCT00193778|OTHER|No Loco-regional treatment|This group will not receive any loco-regional treatment
224232460|NCT01816477|DEVICE|ON-Q soaker catheter system|"ON-Q soaker catheter system with Ropivicaine at 7 cc per hour placed by a single surgeon in the operating room. 7.5 catheters will be tunneled subcutaneously in the anterior axilla bilateral and secured with steri-strips and dressing. ON-Q systems will be primed with 750 cc and refilled accordingly to provide for 6 days of analgesia. Catheters will be removed by the surgeon in the hospital or clinic on the 6th post operative day. Patients may request removal of the catheter prior to the 6th day and this will not be considered a withdrawal from the study or complication and will be included in overall analysis, but noted accordingly."
224232461|NCT01816477|DRUG|Epidural (ropivicaine 0.25%)|Thoracic epidural with Ropivicaine 0.25% placed pre-operatively by the anesthesiologist. Epidurals will remain in place for 72 hours and discontinued by the anesthesia pain management team.
224232462|NCT01948505|DRUG|Intravenous acetaminophen|
224232463|NCT01948505|DRUG|Placebo for IV acetaminophen|
223646751|NCT06508190|BEHAVIORAL|free walking exercise and continuous positive airway pressure|patients will receive continuous positive airway pressure therapy for a period of 12 weeks, all patients with in this group are required to utilize the CPAP machine for at least 4 hours each night. Also, patients will perform walking exercise for 30 mint, daily for 12 weeks
223646752|NCT01795053|BEHAVIORAL|Experimental: playtraining|playtraining is a play based intervention that includes techniques of behavioral management as: structuring of play situation, detailled play planning, definition of behavioral tasks, positive reinforcement, token economy. The intervention is designed to enhance play-persistence and -intensity and thereby reduce ADHD symptoms
223646753|NCT01795053|BEHAVIORAL|Placebo open play session|
223646754|NCT02080806|DEVICE|Mechanical Insufflation Exsufflation|Mechanical Insufflation Exsufflation -Each patient received daily treatments by means of a light-weight, elastic oronasal mask. Treatments were divided between morning and afternoon and were carried out 5 times a week. A total of 20 sessions were carried out by a a trained respiratory therapist.
223646755|NCT01642784|DEVICE|Primary PCI of culprit lesion in IRA with drug eluting stent (DES)|Primary PCI of culprit lesion in IRA with drug eluting stent (DES)
223646756|NCT01642784|DEVICE|Primary PCI of culprit lesion in IRA with drug eluting stent (DES) and PCI of the other critical lesion in IRA with another DES|Primary PCI of culprit lesion in IRA with drug eluting stent (DES) and PCI of the other critical lesion in IRA with another DES
223646757|NCT04772274|DRUG|Ustekinumab|45 mg, single-dose
223646758|NCT05653869|DRUG|APS03118|Participant received APS03118 orally until evidence of unacceptable toxicity, progressed disease, consent withdrawal or with drawl from the study at the discretion of the investigator.
224232464|NCT02368847|DEVICE|Diagnostic tests|C Reactive Protein (CRP) measurement on capillary blood using a point-of-care test to determine C Reactive Protein level in the blood
224232465|NCT02368847|DEVICE|Diagnostic tests|Uricult dipslide: Easy-to-perform bacterial culture test for dectecting urinary tract infections in point of care settings
224232466|NCT04861545|OTHER|Soy|"Isolated soy protein food sources are foods that include isolated soy protein in different forms and matrix (e.g. soy beverage and meat analogue).~Non-isolated soy protein food sources of soy protein are foods made with soy (e.g. Tofu, tempeh, edamame)."
224232467|NCT03299153|OTHER|barberry juice|
224232468|NCT01047345|BIOLOGICAL|V503|V503 (9vHPV) vaccine given as a 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6 of the Base Study or the Study Extension
224232469|NCT01047345|BIOLOGICAL|Placebo to V503|Placebo to V503 (saline) given as a 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6 of the Base Study
224232470|NCT05265182|PROCEDURE|virtual reality|Create an immersive technology system for managing the behavioral and psychological symptoms of dementia and determine its acceptability, usability, and safety in the healthy adult population initially, using semi-Cave or head-mounted display.
224232471|NCT00819247|DRUG|Degarelix|Given as a subcutaneous injection.
224232472|NCT00865553|BEHAVIORAL|computer-assisted smoking cessation intervention|
224232473|NCT00865553|OTHER|cancer prevention|
224232474|NCT00865553|OTHER|educational intervention|
224232475|NCT00865553|OTHER|survey administration|
224232476|NCT04716660|OTHER|Sensory block level check|Patients will have their sensory block level checked multiple times following administration of their epidural bolus for labor analgesia.
223646759|NCT03754998|BEHAVIORAL|Intervention Group|The participating dyads in intervention communities were invited to consume veo soup/meal (HSM) three times a week and provided weekly supply of iodized salt (450 g) for the household usage as well as being engaged in dry season container gardening. The veo soup/meal is a local Ghanaian soup/meal mainly made of Hibiscus Sabdarifa leaves. It is a soup when prepared a bit watery and consumed with 'tou zaafi' (millet or corn based cooked paste). It is also a meal when prepared thick and eaten by itself. The Hibiscus Sabdariffa leaves meal (HSM) used in the present study was made of 18 kg Hibiscus Sabdariffa leaves, 8 kg groundnut, 1.1 kg dawadawa (fermented African locust beans), 3 kg dried fish plus 0.045 kg iodized salt, cooked with about 23 L (23 kg) water to yield 52.5 kg HSM. In each community, groups of ten women took turns to share the cooking activities, washing of bowls, and making water available for cooking. No treatment provided in our control communities.
223646760|NCT01875094|OTHER|Self-Management / MTM using Health IT|
223646761|NCT00065078|PROCEDURE|Home dispensing of contraception|
223646762|NCT01626469|DRUG|Captopril|25mg Captopril
223646763|NCT01626469|DRUG|placebo|placebo
223646764|NCT02874378|DRUG|Dexmedetomidine|
223646765|NCT02874378|DRUG|0.9%NaCl solution|
223646766|NCT02873416|DRUG|Chemotherapy|Cisplatin：60mg/m2，Gemcitabine：1g/ m2,Physiological saline 100ml:IV (in the vein) once a week with a total of six times.
223646767|NCT02873416|BIOLOGICAL|Precision Cells|Precision Cells DC cell suspension (1×10\*7 DC+physiological saline + 0.25% human bloodalbumin)1ml for each infusion, subcutaneous injection for each infusion, 3 cycles, each cycle received two infusions on day 19, 20; 40, 41; 61, 62. Precision Cell suspension (1-6×109 PNAT + physiological saline + 0.25% human bloodalbumin) 300ml for each infusion, IV (in the vein) for each infusion, 3 cycles, each cycle received one infusions on day 21, 42, 63.
223646768|NCT02640287|BIOLOGICAL|Blood or bone marrow samples|
223646769|NCT01887535|DRUG|JNJ-54861911 3 mg|JNJ-54861911 3 mg will be administered as an oral suspension formulation.
223646770|NCT01887535|DRUG|JNJ-54861911 10 mg|JNJ-54861911 10 mg will be administered as an oral suspension formulation.
223646771|NCT01887535|DRUG|JNJ-54861911 30 mg|JNJ-54861911 30 mg will be administered as an oral suspension formulation.
223646772|NCT01887535|DRUG|JNJ-54861911 80 mg|JNJ-54861911 80 mg will be administered as an oral suspension formulation.
223646773|NCT01887535|DRUG|JNJ-54861911 25 mg|JNJ-54861911 25 mg will be administered as a solid dose formulation.
223646774|NCT01887535|DRUG|Placebo|Matching placebo will be administered as an oral suspension formulation.
223646775|NCT06150391|DEVICE|Visionary: computer exercises using dichoptic Gabor Patches and band-filtered noise masks|Visionary exercises are computer gammified activities that run on a computer with internet connection to facilitate home therapy. Patient must wear anaglyph glasses. Visual stimuli consists in dichoptic Gabor Patches presented to the amblyopic eye. Frequency is adjusted to actual patient visual acuity, and contrast to actual patient performance (contrast sensitivity). A band-filtered noise mask at the same frequency than the Gabor patch is presented to the fellow eye in certain ocassions.
223646776|NCT06150391|DEVICE|Patching|PEDIG (Pediatric Eye Disease Investigator Group) recommended amblyopia treatment. Consist on covering a child's better-seeing eye with a patch for 2 hours per day for mild and moderate amblyopia or 6 hours per day for severe amblyopia
224232477|NCT04702620|DEVICE|Ventica® device from Revenio|Measurement of expiratory flow variability for the detection of bronchospasm in infants
224232478|NCT04708795|DRUG|AP701|Preparation of Cannabis flowers (Cannabis flos)
224232479|NCT02187042|OTHER|Best supportive care|BSC may include medications and supportive measures deemed necessary to palliate disease related symptoms and improve quality of life
224232480|NCT02187042|OTHER|call center|Nurses from a call center will call the patients at regular time to help patients in the management of their cancer, with some dietetic advices, medical advices etc.
224232481|NCT00108732|DRUG|Bicalutamide|Given orally
224232482|NCT00108732|DRUG|Goserelin Acetate|Given SC
224232483|NCT00108732|BIOLOGICAL|Recombinant Fowlpox-PSA(L155)/TRICOM Vaccine|Given SC
224232484|NCT00108732|BIOLOGICAL|Recombinant Vaccinia-TRICOM Vaccine|Given SC
224232485|NCT00108732|BIOLOGICAL|Sargramostim|Given SC
224232486|NCT00670956|DRUG|Betamethasone|12 mg intramuscularly x 2 doses 24 hours apart
224232487|NCT00670956|DRUG|Placebo|PLACEBO: IM x 2 doses 24 hours apart
224232488|NCT02779309|PROCEDURE|Home Care/RAI-HC Assessment|Home care recipients who have received a comprehensive health assessment using the Resident Assessment Instrument for Home Care (RAI-HC).
224232489|NCT04965571|GENETIC|genetic test|Sanger sequencing and multiplex ligation-dependent probe amplification (MLPA)
223646777|NCT03698877|DIAGNOSTIC_TEST|Brain Natriuretic Protein (BNP) and Procalcitonin (PCT) blood tests|"For patients with suspected infection, PCT levels will be drawn at the time of suspected infection and again at the start of the next HD treatment.~For patients with shortness of breath, PCT and BNP levels will be drawn at the time of the complaint and again at the start of the next HD treatment."
223646778|NCT03382444|PROCEDURE|Cognitive Assessment|Each patient with have a 2 hour cognitive assessment at baseline, 3months after starting renal replacement therapy and 12 months after starting renal replacement therapy
223646779|NCT03382444|DIAGNOSTIC_TEST|Depression and Quality of Life Assessment|Each patient with have a 2 hour depression and QOL assessment at baseline, 3months after starting renal replacement therapy and 12 months after starting renal replacement therpay
223646780|NCT01310075|DEVICE|Alloderm|6 x 12 cm piece or 6 x 16 cm piece is trimmed into a semicircle and sewn into the inframammary fold using vicryl. The smooth side is placed against the implant.
223646781|NCT01310075|DEVICE|Surgimend|10 x 15 cm piece of fenestrated material is sewn to the fold, curved side along the fold, using vicryl suture.
223646782|NCT05349071|DRUG|methylprednisolone|a single preoperative dose of 500 mg of methylprednisolone diluted in 250 mL of physiological saline 2 hours before surgery as a 30-minute infusion.
223646783|NCT05349071|DRUG|physiological saline|a single preoperative dose of 250 mL of physiological saline 2 hours before surgery as a 30-minute infusion.
223646784|NCT03450122|BIOLOGICAL|Aldesleukin|Given SC
223646785|NCT03450122|BIOLOGICAL|Autologous NY-ESO-1-specific CD8-positive T Lymphocytes|Given IV
223646786|NCT03450122|DRUG|Cyclophosphamide|Given IV
223646787|NCT03450122|BIOLOGICAL|Dendritic Cell-targeting Lentiviral Vector ID-LV305|Given ID
223766083|NCT07174193|DEVICE|Piezosurgery|Initially introduced in the field of implantology, piezosurgery has gained increasing popularity in orthognathic surgery in recent years (7-9). This technique utilizes ultrasonic vibrations ranging from 60-210 μm/s at frequencies between 24-29 kHz to cut bone, thereby minimizing trauma to surrounding soft tissue (10). Although numerous studies have been conducted, many clinical investigations have been limited by small sample sizes and insufficiently described methodologies (17, 18). Furthermore, the lack of standardized assessment tools hinders reliable comparisons of outcomes across studies (19). While surgeons increasingly recommend the use of piezosurqical instruments in orthognathic surgery, robust evidence from the literature remains insufficient to support the change in surgical technique.
223766084|NCT07174193|DEVICE|Conventional techniques|In the control group a Lindemann burr will be used to perform the horizontal and vertical osteotomies and the cut at the lower border of the mandible. A reciprocal saw will then be used to connect the horizontal and vertical osteotomies in the sagittal plane.
223766085|NCT07173725|DRUG|Octenidine dihydrochloride 0.1%|Final intracanal irrigant (aqueous solution); single administration during the final irrigation phase. Sonic activation performed in three 20-second cycles; solution refreshed with 2 mL between cycles (approximate total 6 mL per canal). Delivered through a side-vented needle positioned short of the working length.
224232490|NCT05029583|OTHER|routine screening|routine screening for advanced NASH
224232491|NCT05029583|OTHER|physician-driven screening|physician-driven screening for advanced NASH
224232492|NCT00820456|OTHER|DCE-MRI|Participants will receive two (2) dynamic contrast enhanced magnetic resonance imaging (DCE-MRI) prior to chemotherapy and one (1) DCE-MRI after the first cycle of chemotherapy. Participants will be followed for up to 2 years after the initiation of chemotherapy or until disease progression.
224232493|NCT04084756|BEHAVIORAL|Couples Crisis Response Plan|The CCRP is a single session therapist-facilitated suicide prevention intervention conducted with a dyad
224232494|NCT04084756|BEHAVIORAL|Mental Health Education|The Mental Health Education session is a single session therapist-facilitated mental health psychoeducation session conducted with a dyad
224320025|NCT05848115|DEVICE|Sham Bi-level Positive Airway Pressure|The sham BiPAP will have pressure attenuated using an orifice restrictor as described in previous double blinded studies using sham non-invasive ventilation. With this set-up pressures no greater than 2 cm of water have been documented at the location of the face mask. This will ensure that the patient is not receiving positive pressure with any effectiveness or deleterious effects. Study participants will remain on sham BiPAP for four hours or until weaned off continuous beta-agonist therapy by the treating clinician. After the four-hour intervention period, it is at the discretion of the treating clinician regarding the use of BiPAP or not.
223646788|NCT02778789|DRUG|Tocilizumab|Patients will be treated with either i.v. Tocilizumab every 4 weeks or s.c. Tocilizumab weekly according to the label
223646789|NCT02778789|DRUG|TNF-alpha Inhibitor|Patients will be treated with TNF-Inhibitors either i.v. or s.c. according to the label
223646790|NCT00770172|BIOLOGICAL|filgrastim|Given subcutaneously
223646791|NCT01123902|DEVICE|hand-held fan|Patients are instructed to direct the hand-held fan towards the face around the central part of the face, the sides of the nose and above the upper lip. The hand-held fan has three soft rotor blades and an unfoldable rotor unit.
223646792|NCT01123902|DEVICE|wristband|Patients are instructed to wear the wristband continually and pull it regularly at short intervals when breathless or during breathlessness attacks.
223646793|NCT04617704|BIOLOGICAL|GC012F injection|GC012F injection is a autologous dual CAR-T targeted BCMA and CD19. A single infusion of CAR-T cells will be administered intravenously.
223646794|NCT02395081|DIETARY_SUPPLEMENT|600 IU Vitamin D3 in prenatal vitamin|Women will receive 600 IU 25(OH)D in prenatal vitamin.
223646795|NCT02395081|DIETARY_SUPPLEMENT|2000 IU Vitamin D3 in prenatal vitamin|Women will receive 2000 IU 25(OH)D in prenatal vitamin.
223646796|NCT02395081|DIETARY_SUPPLEMENT|4000 IU Vitamin D3 in prenatal vitamin|Women will receive 4000 IU 25(OH)D in prenatal vitamin.
223646797|NCT01876017|BIOLOGICAL|Intravenous transfer of Autologous (BMMNCs)|Intervention therapy , Total 3 doses ,in 30 days ,in 7days interval Intravenous transfer of Autologous (BMMNCs)
223646798|NCT03835806|OTHER|Elastikon|This randomized controlled trial will compare the traditional method of treating blisters with a multi-step approach of percutaneous drainage, paper tape, spray adhesive and then Elastikon which is our traditional blister treatment approach.
223646799|NCT03835806|OTHER|Rocktape|This randomized controlled trial will compare the traditional method of treating blisters with a multi-step approach of percutaneous drainage, paper tape and then Rocktape which is our novel blister treatment approach.
223646800|NCT04097574|DRUG|NPO-13: l-menthol|20 mL/site
223646801|NCT04171843|GENETIC|PBCAR269A|Allogeneic anti-BCMA CAR T-cell
223646802|NCT04171843|DRUG|Fludarabine|Fludarabine is used for lymphodepletion.
223646803|NCT04171843|DRUG|Cyclophosphamide|Cyclophosphamide is used for lymphodepletion.
223646804|NCT04171843|DRUG|Nirogacestat|Allogeneic anti-BCMA CAR T-cell
223646805|NCT05807620|OTHER|Gentle Cleansing Lotion|Facial cleansing lotion to be used by study participants (morning and evening, 2x daily).
223646806|NCT05807620|OTHER|Facial Moisturizer|Anti-aging facial moisturizer to be used by study participants after anti-aging daily serum before sunscreen (morning and evening, 2x daily).
223646807|NCT05807620|OTHER|Sunscreen SPF 30|"Neutrogena Ultra Sheer Dry Touch SPF 30. Sunscreen to be applied after application of the facial moisturizer in the morning. Participants were asked to reapply every 2 hours.~Per FDA this intervention is an over the counter"
223646808|NCT02099955|DRUG|Vitamin D3|4000 IU/day or 2000 IU/day for 12 weeks
223646809|NCT00926861|DEVICE|ultrasound|A-scan and B-scan ultrasound at baseline and month 6,12,24
223646810|NCT00926861|DEVICE|OCT|Volume scans of spectralis OCT at baseline and month 6,12,24
223646811|NCT01223781|BEHAVIORAL|Biofeedback-based motor learning for PD|Prior to freezing episodes, auditory stimulation is triggered
223646812|NCT02779946|DEVICE|Fibro Scan|
223646813|NCT02779946|GENETIC|PNPLA3|
223646814|NCT02991040|DEVICE|Revanesse Ultra+ (with lidocaine)|Bilateral nasolabial fold trial to compare the safety and efficacy profiles of Revanesse® Ultra + (with lidocaine) to Revanesse® Ultra (comparator)
223646815|NCT02991040|DEVICE|Revanesse Ultra|Comparator without lidocaine
223646816|NCT00102817|DRUG|somatropin|
223646817|NCT02395159|DEVICE|Prevena™ IMS|"Prevena™ IMS is intended for the management of the surgical incision environment and surrounding healthy skin in patients with a risk of postoperative complications such as infections. This entails the maintenance of a closed environment around the incision by applying a negative pressure wound therapy system.~The corresponding dressing is known under the name Prevena™ Dressing. The layer closest to the skin comprises silver foil, which reduces the microbial colonisation of cells."
223646818|NCT02395159|OTHER|sterile plaster dressings|standard wound management method of sterile plaster dressings
223646819|NCT04615026|DIAGNOSTIC_TEST|duplex sonography|all patients with consent receive a duplex ultrasound, blood test, cognitive test and test of smelling
223646820|NCT02295618|DEVICE|Standard tracheal tube|Intubation using Macintosh laryngoscope and standard tracheal tube
223646821|NCT02295618|DEVICE|ETView VivaSight SL|Intubation using ETView VivaSight SL
223646822|NCT01869764|DRUG|omega-3 fatty acid|Given PO
223646823|NCT01869764|OTHER|placebo|Given PO
223646824|NCT01869764|OTHER|laboratory biomarker analysis|Correlative studies
223646825|NCT05303311|DRUG|Bupivacaine Hydrochloride|intrathecal injection of bupivacaine alone
223646826|NCT05303311|DRUG|Pethidine plus Dexamethasone|Intrathecal injection of pethidine plus dexamethasone
223646827|NCT06190704|DEVICE|caIMR|Coronary angiography-derived IMR (caIMR) is a novel and accurate alternative that can enable the assessment of coronary microvascular function easier, and more efficiently and does not require pressure wire or adenosine.
223646828|NCT00380783|DRUG|AGN 203818|
223646829|NCT01286480|BEHAVIORAL|Clinic-based Educational Intervention|This will involve a 60 minute interaction between the teen and an advanced practice nurse (APN) in the cardiology clinic. A MyHealth passport will be created covering the name of the teen's cardiac condition, previous cardiac interventions, and name and purpose of the teen's medications. Potential late cardiac complications and contact names and location of local adult CHD cardiologists will also be reviewed. Three scenarios regarding adolescent risk taking behaviors (written in the 3rd person) will be presented to the teen who will be asked what advice he/she would offer to the teen in each of those scenarios. The teen will be given a study email address and encouraged to contact the APN by email or text messaging with follow-up questions. If no contact is initiated after 1 week, the APN will email or text (based on preference) the youth, to discuss additional questions.
223646830|NCT01626872|DRUG|MP-214 3mg|In the double-blind period (before Week 6), participants continue in the same arm they were on in core trial A002-A4 (except placebo arm starts 3mg or 6mg of MP-214). In the open-label period (after Week 6), patients will be rerandomized to 3mg or 6mg of MP-214. After the fourth week of the open-label treatment period, they will be received MP-214 at flexible doses (3mg or 6mg or 9mg).
223646831|NCT01626872|DRUG|MP-214 6mg|In the double-blind period (before Week 6), participants continue in the same arm they were on in core trial A002-A4 (except placebo arm starts 3mg or 6mg of MP-214). In the open-label period (after Week 6), patients will be rerandomized to 3mg or 6mg of MP-214. After the fourth week of the open-label treatment period, they will be received MP-214 at flexible doses (3mg or 6mg or 9mg).
223646832|NCT01626872|DRUG|MP-214 9mg|In the double-blind period (before Week 6), participants continue in the same arm they were on in core trial A002-A4 (except placebo arm starts 3mg or 6mg of MP-214). In the open-label period (after Week 6), patients will be rerandomized to 3mg or 6mg of MP-214. After the fourth week of the open-label treatment period, they will be received MP-214 at flexible doses (3mg or 6mg or 9mg).
223646833|NCT01626872|DRUG|Risperidone 4mg|In the double-blind period (before Week 6), participants continue in the same arm they were on in core trial A002-A4. In the open-label period (after Week 6), patients will be rerandomized to 3mg or 6mg of MP-214. After the fourth week of the open-label treatment period, they will be received MP-214 at flexible doses (3mg or 6mg or 9mg).
223646834|NCT05724537|PROCEDURE|Quadrangular resection and annular plication|Mitral regurgitation is treated removing the redundant tissue of the posterior leaflet, which is then reconstructed by sutures and plicating the posterior annulus
224320026|NCT03785600|DEVICE|Morning Bright Light Therapy|Morning bright light: Sitting in front of a lightbox for 60 minutes every morning within 90 minutes of waking up.
223646835|NCT02979548|DRUG|Aprepitant|Aprepitant is a non peptide, selective, Neurokinin type 1 (NK 1) receptor antagonist. Group A will receive Aprepitant as an add-on anti-emetic therapy in addition to ondansetron.
223646836|NCT02979548|DRUG|Ondansetron|Ondansetron is 5HT3 Receptor antagonist used to treat and prevent chemotherapy induced nausea and vomiting
223646837|NCT02979548|DRUG|Metoclopramide|Dopamine receptor antagonist , acts at CTZ. Rescue medication, injection metoclopramide 0.5 mg/kg body weight/day.
223646838|NCT05275283|OTHER|PEEP|6 cmH2O of PEEP
223646839|NCT00960999|RADIATION|Single-fraction stereotactic body radiation therapy (SBRT)|34 Gy in 1 fraction to the prescription line at the edge of the planning target volume (PTV). The maximum dose must exist within the PTV, and the prescription isodose surface must be ≥ 60% and \< 90% of the maximum dose. 99% of the PTV must receive a minimum of 90% of the prescription dose. The maximum dose to any point ≥ 2 cm away from the PTV in any direction must be at least \< 50% of the prescription dose. The percent of the lungs (excluding PTV) receiving 20 Gy or more must be \< 10%.
223646840|NCT00960999|RADIATION|Multiple-fraction stereotactic body radiation therapy (SBRT)|48 Gy in four 12 Gy fractions to the prescription line at the edge of the planning target volume (PTV). Treatments are given on 4 consecutive calendar days, but at least 18 hours apart. The maximum dose must exist within the PTV, and the prescription isodose surface must be ≥ 60% and \< 90% of the maximum dose. 99% of the PTV must receive a minimum of 90% of the prescription dose. The maximum dose to any point ≥ 2 cm away from the PTV in any direction must be at least \< 50% of the prescription dose. The percent of the lungs (excluding PTV) receiving 20 Gy or more must be \< 10%.
223646841|NCT05114252|DEVICE|Vivid Vision Home|The study intervention consists of playing serious games (Vivid Vision, San Francisco, USA) embedded in a virtual reality headset in a home environment 5 days a week for 30 minutes over 8 weeks (20 h of total gaming).
223766086|NCT07173725|DRUG|Chlorhexidine 2%|Final intracanal irrigant (aqueous solution); single administration during the final irrigation phase. Sonic activation performed in three 20-second cycles; solution refreshed with 2 mL between cycles (approximate total 6 mL per canal). Delivered through a side-vented needle positioned short of the working length.
223766087|NCT07172321|DRUG|PF-08049820 MR1|Administered orally
223766088|NCT07172321|DRUG|PF-08049820 MR2|Administered orally
223766089|NCT07172321|DRUG|PF-08049820 IR|Administered orally
223766090|NCT07174011|DRUG|Roflumilast|Phosphodiesterase-4 (PDE4) inhibitor assigned to arm A
223766091|NCT07174011|DRUG|intralesional steroid|intralesional injection of corticosteroid
223766092|NCT07172698|OTHER|multicomponent training with an emphasis on muscle power|Group 1 will perform an exercise protocol that includes warm-up, mobility, muscle strength, and flexibility. Group 2 will perform the same exercise protocol, with the caveat that, whenever feasible, exercises will be executed in the muscle power modality (at the highest possible speed). This latter training is characterized by a lower number of repetitions and a higher movement speed, guided by the therapists assisting. The progression of muscle power exercises will occur at 35%, 40%, 45%, 50%, 55%, and 60% of 1RM over the 12 weeks, distributed in 2 sets of 6 to 8 repetitions, with rest times of 60 to 120 seconds.
223766093|NCT07172698|OTHER|traditional multicomponent training|Group 1 will perform an exercise protocol that includes warm-up, mobility, muscle strength, and flexibility
223766094|NCT07172165|DIAGNOSTIC_TEST|Expert double-blind evaluation|Expert reading will be using TCDPlayer and will be blinded to clinical data, source information, and other assessments. They will manually annotate six predefined signal features: characteristic audible signal increase, characteristic wave-like of raw Doppler signals, Emboli-to-Background Ratio, Emboli-to-Mirror Ratio, signal duration, and average velocity of maximum intensity. Analysis will be completed within 90 days.
223766095|NCT07173920|DEVICE|repetitive Transcranial Magnetic Stimulation|"Patients will receive rTMS treatment for a total of 14 days. Prior to treatment, patients will undergo an MRI scan; the images will be preprocessed to construct a structural network, and precise localization of the pre-SMA (preSupplementary Motor Area) region and the SCAN (Somatosensory-Cognitive-Action Network) will be performed based on coordinates.~Participants will receive two treatment sessions per day, with an interval of at least 1 hour between each session. Each treatment session consists of 3 cTBS (Continuous theta-Burst Stimulation) treatments, and the interval between each cTBS treatment is at least 15 minutes. Each cTBS treatment lasts 40 seconds, comprising 3 pulses at 50 Hz, repeated every 200 ms (equivalent to 5 Hz), totaling 600 pulses per cTBS treatment. Accordingly, patients receive a total of 3,600 pulses per day, and a cumulative total of 50,400 pulses are delivered throughout the entire treatment period."
223766096|NCT07173062|DIETARY_SUPPLEMENT|Spirulina Arthrospira platensis (microalgae)|Spirulina Arthrospira platensis (4 x \~500mg), taken twice daily as 2 capsules in the morning + 2 capsules in the evening
224232495|NCT01601509|DRUG|Nasal tramazoline with dexamethazone|Every patient will undergo four assessments. Every assessment will consist of an overnight polysomnography with concomitant measurement of breathing route pattern (oral, nasal, oro-nasal breathing epochs) as previously described \[7\], along with a nasal resistance measurement. After baseline assessment and randomization patients of the first group will undergo a one-week therapy with nasal tramazoline and dexamethazone, while the patients of the second group will undergo a one-week therapy with nasal placebo (sodium chloride, 0.9% solution). The second assessment will take place at the end of this one week regimen. A washout period of two weeks will follow. Subsequently, the third assessment will take place and next the patients of the first group will undergo a one-week therapy with nasal placebo (sodium chloride, 0.9% solution), while the patients of the second group will undergo a one-week therapy with nasal tramazoline and dexamethazone. Fourth assessment will then follow.
224232496|NCT01601509|DRUG|Nasal placebo|Every patient will undergo four assessments. Every assessment will consist of an overnight polysomnography with concomitant measurement of breathing route pattern (oral, nasal, oro-nasal breathing epochs) as previously described \[7\], along with a nasal resistance measurement. After baseline assessment and randomization patients of the first group will undergo a one-week therapy with nasal tramazoline and dexamethazone, while the patients of the second group will undergo a one-week therapy with nasal placebo (sodium chloride, 0.9% solution). The second assessment will take place at the end of this one week regimen. A washout period of two weeks will follow. Subsequently, the third assessment will take place and next the patients of the first group will undergo a one-week therapy with nasal placebo (sodium chloride, 0.9% solution), while the patients of the second group will undergo a one-week therapy with nasal tramazoline and dexamethazone. Fourth assessment will then follow.
223766097|NCT07173062|DIETARY_SUPPLEMENT|Gelidium corneum|Gelidium corneum (4 x \~500mg), taken twice daily as 2 capsules in the morning + 2 capsules in the evening
224232497|NCT02116803|DRUG|dovitinib|Dovitinib was available in two formulations: capsules of 100 mg strength, and tablets of 100 mg strength and taken orally.
224232498|NCT02116803|DRUG|fulvestrant|Fulvestrant is generally available as solution for injection in pre-filled syringes containing 250 mg of fulvestrant in 5 mL solution.
224232499|NCT04256265|DRUG|Risdiplam|Risdiplam will be administered orally once daily
224232500|NCT01060592|DEVICE|EndoFLIP device (FDA Device Listing Number : D091203)|The EndoFLIP balloon catheter will be introduced to the band and used to permit the band stoma size to be adjusted to 7mm.
224232501|NCT00698685|DRUG|Pentostatin|Days - 8 through -6: pentostatin 4 mg/m2/24 hr as a continuous intravenous infusion (CIVI) (total cumulative dose, 12 mg/m2 over 3 days)
224232502|NCT00698685|BIOLOGICAL|Alemtuzumab|Days - 5 through - 1: alemtuzumab 20 mg per dose intravenously over 8 hours daily for 5 doses (total cumulative dose, 100 mg)
224232503|NCT00698685|PROCEDURE|Allogeneic hematopoietic stem cell transplantation|Infusion of related or unrelated donor peripheral blood progenitor cells on day 0.
224232504|NCT00282256|DRUG|tacrolimus modified release (MR)|Oral
224232505|NCT00282256|DRUG|tacrolimus|Oral
224232506|NCT05100758|DIETARY_SUPPLEMENT|Active Hexoses Correlated Compound|Active Hexose Correlated Compound was isolated from basidiomycetes which comprise polysaccharides and amino acids.
224232507|NCT02879019|OTHER|Stretching exercise group|In each stretching class, approximately 20 exercises will be performed. The total duration of the session will be approximately 30 minutes.
224232508|NCT02879019|OTHER|Walking training group|Patients will perform two walking session per week, each consisting of 15\*2-min walking bouts, with 2-min of rest in between. The intensity will be set at heart rate corresponding to the pain threshold.
224232509|NCT03252470|PROCEDURE|Laparoscopic Roux-en-y Gastric Bypass Surgery|Laparoscopic Roux-en-y Gastric Bypass Surgery
224232510|NCT04844177|OTHER|conditioning with TLI|"Total lymphoid irradiation 4 Gy (days -7, -6) in combination with:~* Fludarabine 150 mg/m2 (days-6, -5, -4, -3, -2)~* Cyclophosphamide 120 mg/kg (days -5, -4, -3)~* Thymoglogulin (Genzyme) 5 mg/kg (days -5, -4)~* Melphalan 180 mg/m2 (day -2)~* Rituximab 100 mg/m2 (day -1)~* Hematopoietic stem cell graft infusion after TCRab/CD19 depletion - day 0"
224232511|NCT02901899|DRUG|Guadecitabine|Given SC
224232512|NCT02901899|OTHER|Laboratory Biomarker Analysis|Correlative studies
224232513|NCT02901899|BIOLOGICAL|Pembrolizumab|Given IV
224232514|NCT03196947|DRUG|APO010|APO010 is given iv on D1, D8 and D15 followed by a one-week drug rest (cycle duration 4 weeks).
224232515|NCT03920137|BEHAVIORAL|UP-ST Therapy|Phase 1 analyses will focus primarily on demonstrating feasibility and utility of the new UP-ST intervention. Feasibility will be determined by examining the proportion of individuals who 1) complete each module of the UP-ST treatment, 2) complete a full course of the UP-ST treatment, and by 3) benchmarking participant ratings of treatment credibility, expectancy, and satisfaction with corresponding ratings from our previous clinical trials examining the UP or ST interventions. The investigators will include and examine outcomes on the same measures that will be used in phase 2, but due to the sample size our analyses for Phase 1 will focus on intraindividual effect sizes (with 95% CI) for continuous smoking, anxiety, and depression outcomes
224232516|NCT03920137|BEHAVIORAL|Standard Therapy|In the control group therapists will hold standard smoking cessation therapy sessions.
224232517|NCT03920137|DEVICE|Nicotine Patch|Nicotine patches will be worn in tandem with UP-ST therapy
224232518|NCT06159270|OTHER|Blood sample|Venuous blood sampling
224232519|NCT03239132|BEHAVIORAL|Breath-based meditation|The experimental group will receive 4 group sessions of breath-based meditation over 4 weeks.
224232520|NCT03239132|BEHAVIORAL|Meditation educational materials|Meditation educational materials
224232521|NCT05602688|DIETARY_SUPPLEMENT|Lemon Balm Supplement|Oral 200 mg Lemon Balm supplement tablet Twice a day for three-weeks
223646842|NCT05114252|BEHAVIORAL|Refractive error correction|The control intervention will be refractive error correction that consists of wearing the lenses with the prescribed correction for 2 months.
223646843|NCT01696188|DEVICE|interscalene nerve catheter|
223646844|NCT01267500|PROCEDURE|Non surgical therapy|patching or fusion exercises
223646845|NCT01024413|DRUG|erlotinib|study arm.erlotinib 150 mg oral till disease progression
223646846|NCT01024413|DRUG|gefitinib|study arm.gefitinib 250 mg oral till disease progression
223646847|NCT00302367|DRUG|OROS methylphenidate hydrochloride|
223646848|NCT00302367|DRUG|immediate release methylphenidate hydrochloride|
223646849|NCT05704582|OTHER|Avatar Intervention|8 weekly sessions of 60 minutes. Possibility of 4 additional sessions.
223646850|NCT05704582|OTHER|Addiction supportive intervention|8 weekly sessions of 60 minutes. Possibility of 4 additional sessions.
223646851|NCT00063765|DRUG|Ciliary Neurotrophic Factor Implant NT-501|
223646852|NCT01091220|BIOLOGICAL|Certolizumab pegol|400 mg certolizumab pegol in 2 x 200 mg/mL, prefilled syringes, administered once, subcutaneously
223646853|NCT01091220|BIOLOGICAL|Placebo|2 x prefilled syringes containing 0.9% saline, administered once, subcutaneously
223646854|NCT06009848|DRUG|Cadonilimab|Cadonilimab (10 mg/kg, administered on the first day of each cycle, Q3W, until there is no clinical benefit)+Nab-Paclitaxel(200 mg/m2, Q3W ,6 cycles), every 3 weeks (21 days) is a treatment cycle.
223646855|NCT03869697|DRUG|SCB-313|5 mg or 20 mg lyophilized powder in a single-use glass vial
223646856|NCT04610593|BEHAVIORAL|Mindfulness-based Intervention|A mindfulness-based intervention will be developed for chronic hemodialysis patients to be performed during hemotherapy sessions. This is an integrative mind-body program, which is based on the MBRP (Bowen et al., 2014) and BMT (T. Russell, 2015) protocols. The program will be conducted in eight weeks, with a weekly individual session of up to 60 minutes facilitated by an instructor, at the bedside during the HD session. The program aims to develop awareness of bodily sensations, emotions and thoughts, with an attitude of openness, curiosity, kindness and non-judgment. During the sessions will be worked four main techniques of mindfulness meditation: mindfulness in breathing, body scanning, conscious movements and practice of compassion. Participants are invited and encouraged to practice Mindfulness using audios made available during the other HD sessions they undergo during the week, in addition to daily home practice.
223646857|NCT00601393|BEHAVIORAL|Cognitive behavioral therapy (CBT)|CBT treatment is delivered via the Internet. Adaptations to the CBT program will include the addition of content of particular relevance to mothers of young children and the incorporation of instructional design principles to promote self-learning. The treatment program will take advantage of the unique properties of the Internet, including multimedia presentations and interactive components with professional and moderated peer social support.
224232522|NCT05602688|DIETARY_SUPPLEMENT|Matched Placebo|Matched placebo tablet Twice a day for three-weeks
224232523|NCT01709032|DRUG|Deferasirox and deferiprone|
223766098|NCT07173062|OTHER|Placebo|Microcrystalline cellulose, silicon dioxide and dicalcium phosphate (4 x \~500mg), taken twice daily as 2 capsules in the morning + 2 capsules in the evening
223766099|NCT07172737|OTHER|Respiratory Muscle Training|Respiratory Muscle Training with Telerehabilitation
224232524|NCT01457053|DRUG|Loop diuretics (furosemide, torsemide, bumetanide)|"Patients with ADHF and hypervolemia will be enrolled in a prospective, randomized fashion.~Subjects will be randomized with a computer generated random number function to either ultrafiltration or diuretic therapy within 24 hours of hospitalization for the management of fluid overload.~Patients randomized to diuretic therapy will be treated with intravenous loop diuretics (e.g. furosemide, bumetanide, torsemide). The selection of diuretic, dose and frequency of diuretic administration will be determined by the treating physicians based upon clinical assessment of volume status, response to medication, and perceived safety."
224232525|NCT01457053|OTHER|Ultrafiltration|"Subjects will be randomized with a computer generated random number function to either ultrafiltration or diuretic therapy within 24 hours of hospitalization or outpatient heart failure clinic for the management of fluid overload. If randomized to the ultrafiltration arm, on admission to the hospital patients will be initiated on ultrafiltration therapy for 2-5 days.~Patients randomized to UF will be treated using the Aquadex System 100 ultrafiltration device (CHF Solutions, Minneapolis, MN). The selection of ultrafiltration rate (fluid removal rate)will be determined by the treating physicians based upon clinical assessment of volume status and perceived safety."
224232526|NCT04730505|DEVICE|MyHOPE™ for Multiple Myeloma|The MyHOPE for MM Platform is designed to provide patients with tools and resources to support them in their overall experience with MM. Patients can share their data through a PDF or by showing their device to their care team at clinic visits.
224232527|NCT04730505|DEVICE|MyHope HCP Portal|Is designed to provide HCPs with the ability to view patient data and symptom notifications (Cohort 1 only) to provide support between clinic visits and to facilitate dialogue during clinic visits.
224232528|NCT04894994|DRUG|FLX475|Tablet
223646858|NCT00601393|OTHER|Treatment as usual (TAU)|Participants receiving TAU will be offered the CBT treatment after a wait-list period. During the wait-list period, participants will be offered facilitated referrals to treatment provided in the community.
223646859|NCT06042062|DEVICE|Novel spacer|After diagnosis of infection and informed consent, patients will be taken to the operating room. After anesthetization, patients will be randomized to either a United Cellbrick spacer (United Orthopedic Corporation, Taiwan) or an articulating full-cement spacer. Randomization will be performed by prepared opaque envelopes administered by a nonparticipant in the study. After a complete debridement of devitalized tissue, explantation of the infected components and any associated cement, either a Cellbrick spacer or an articulating spacer will be placed. As for the United Cellbrick spacer, antibiotic loaded bone cement (ALBC) will be molded into the designed holes (fenestrations). The ALBC will be formed from an antibiotic mixture of Vancomycin and Gentamicin with bone cement (Stryker, Simplex P).
223646860|NCT06042062|DEVICE|Spacer|After diagnosis of infection and informed consent, patients will be taken to the operating room. After anesthetization, patients will be randomized to either a Cellbrick spacer (United Orthopedic Corporation, Taiwan) or an articulating full-cement spacer. Randomization will be performed by prepared opaque envelopes administered by a nonparticipant in the study. After a complete debridement of devitalized tissue, explantation of the infected components and any associated cement, either an United Cellbrick spacer or an Articulating Spacer will be placed. The Articulating Spacer will be hand-made to fit the femoral and tibial exposed metaphyses as a solid block with associated antibiotic loaded bone cement (ALBC). The ALBC will be formed from an antibiotic mixture of Vancomycin and Gentamicin with bone cement (Stryker, Simplex P).
223646861|NCT03487705|OTHER|electromyographic essential tremor|"* Making a recording electromyographic recording of the essential tremors in each child included at prospective.~* Collect an electromyographic recording of essential tremors already made in each child included at retrospective."
223646862|NCT01103752|OTHER|no intervention, descriptive study|no intervention, descriptive study
223646863|NCT01918306|DRUG|cisplatin|"In Arm I patients receive cisplatin IV over 1 hour on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients may crossover to Arm II upon disease progression.~In Arm II patients receive cisplatin as in Arm I and PI3K inhibitor GDC-0941 orally (PO) one time a day (QD) on days 2-6, 9-13, 16-20, and 23-27. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~\--------------------------------------------------------------------------------"
223646864|NCT01918306|OTHER|laboratory biomarker analysis|correlative studies
223646865|NCT01918306|OTHER|pharmacological study|correlative studies
223646866|NCT01918306|PROCEDURE|dynamic contrast-enhanced MRI, diffusion-weighted MRI & chemical exchange saturation transfer MRI|correlative studies
223646867|NCT01918306|DRUG|GDC -0941|Patients receive cisplatin as in Arm I and PI3K inhibitor GDC-0941 PO QD on days 2-6, 9-13, 16-20, and 23-27. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity
223646868|NCT02053376|DRUG|Regorafenib|regorafenib (120 mg) (160 mg for second and subsequent treatment cycles)orally once daily 21 days (3 weeks) on and 7 days (1 week) off in the 28-day (4-week) cycle.
223766100|NCT07172646|DRUG|SRSD216 injection|Administered SC.
223766101|NCT07172646|DRUG|Placebo|Administered SC.
223766102|NCT07172048|DIAGNOSTIC_TEST|Foot pressure Distribution test|"This study is observational and does not involve any therapeutic or experimental intervention. Participants will be divided into two groups based on their scoliosis curve pattern:~Group 1: Adolescents with a major thoracic curve. Group 2: Adolescents with a major lumbar curve.~Each participant will undergo non-invasive assessments including:~Baropodometric foot pressure analysis during static standing to evaluate pressure distribution in both coronal and sagittal planes.~Radiographic evaluation to classify curve patterns using Cobb's angle, Central Sacral Vertical Line, and Plumb Line."
223766103|NCT07172373|PROCEDURE|antegrade flexible ureteroscopy-assisted PCNL|antegrade flexible ureteroscopy-assisted PCNL
223766104|NCT07172373|PROCEDURE|single PCNL|single PCNL
224232529|NCT04894994|DRUG|Ipilimumab|IV infusion
224232530|NCT06355739|DEVICE|CAR T cell injection|intravenous injection
224232531|NCT06022133|BEHAVIORAL|Dietary sodium restriction|Selfemployed dietary sodium restriction
224232532|NCT00151294|DRUG|escitalopram oxalate antidepressant|
224232533|NCT04217408|DEVICE|Deep brain stimulation|Active continuous deep brain stimulation of the ventral capsule/ventral striatum
224232534|NCT03050632|BEHAVIORAL|N-back|The N-back task is a measure of working memory in which individuals need to make a response to targets which are repeated letters either in a row (i.e., one-back) or in every-other-letter format (i.e., two-back).
223646869|NCT02504593|DEVICE|mHealth platform employing Fionet Deki Readers to ensure quality of community-based malaria diagnosis|The investigators propose to implement a new mobile interface that automatically reads and troubleshoots malaria rapid diagnostic test (RDT) cassettes. This device, called a Deki reader (DR), will allow the investigators to establish an extensive quality assurance program of malaria diagnosis performed by trained community health volunteers (CHVs). To ensure high-quality diagnosis by CHVs, the study team will deploy 10 Fionet DRs and rotate them amongst 200 CHVs who have been trained to do RDTs. In the first phase, each CHV will use the device for 10 successive clients presenting themselves for malaria diagnosis to the CHV, and then the device will be rotated to another CHV.
223646870|NCT01673542|DRUG|Lidocaine-Prilocaine 5%|
223646871|NCT01673542|DRUG|DEXERYL|
223646872|NCT02756286|OTHER|NAT electroencephalography (EEG) test|Individuals in both groups are asked to perform standard behavioral tests and an electroencephalography (EEG) test.
223646873|NCT01184157|BEHAVIORAL|Home screening|
223646874|NCT01184157|BEHAVIORAL|Clinic screening|
223646875|NCT04838470|OTHER|cardiac rehabilitation|multidisciplinary disease management program
223646876|NCT00344409|DRUG|darbepoetin alfa|
223646877|NCT05703711|BEHAVIORAL|mHealer|MHealer is a software application installed on smartphones that provides psychosocial treatment support and patient condition tracking.
224232535|NCT03050632|BEHAVIORAL|White Bear Task|For this thought suppression task, participants are instructed to inhibit thoughts of a white bear, and to indicate with a pencil mark every time the thought of the white bear occurs to them.
224232536|NCT02003495|BIOLOGICAL|MCV-ACYW135 Vaccine Group|0.5ml, intramuscular
224232537|NCT02003495|BIOLOGICAL|MPV-ACYW135 Vaccine Group|0.5ml, intramuscular
224232538|NCT02003495|BIOLOGICAL|MPV-A Vaccine Group|0.5ml, intramuscular
223646878|NCT01017302|DRUG|Placebo|Subcutenaous once weekly for 4 weeks
223646879|NCT01017302|DRUG|Placebo|Single subcutaneous dose in week 5
223646880|NCT01017302|DRUG|RO5095932|Escalating subcutaneous doses once weekly over a 4 weeks period
223646881|NCT01017302|DRUG|RO5095932|Single subcutenaous dose in week 5
223646882|NCT01958164|DRUG|Actilyse|Actilyse 2mg/2ml will be given if the CVAD has not been restored at time 120min.
223646883|NCT01958164|DRUG|Saline solution|Instil Saline solution 2 ml into the disfunctional CVAD once at time O only for patients enrolled in Group II
223646884|NCT01958164|DRUG|Actilyse|Instil Actilyse 2 mg/ 2 ml into the dysfunctional CVAD at time O.
224232539|NCT02003495|BIOLOGICAL|MCV-AC Vaccine Group|0.5ml, intramuscular
224232540|NCT02003495|BIOLOGICAL|Hib Vaccine Group|0.5ml, intramuscular
224232541|NCT05058742|DEVICE|AuriStim|Auricular vagal nerve Stimulator, which Targets the auricular branches of the vagal nerve
224232542|NCT01919879|DRUG|Cetuximab + Afatinib|Afatinib taken orally, cetuximab administered intravenously
224232543|NCT01919879|DRUG|Cetuximab|Cetuximab administered intravenously
224232544|NCT03556371|DRUG|N-Acetylcysteine|In each patient recruited, assignation to placebo or N-Acetylcysteine group treatment wil be performed, after he/she has signed the informed consent. In the first visit, the evaluation by the psychiatrist and with the nurse team (structured evaluation, which includes the CCQ-N-10, CSSA, general health evaluation, urine drug test and basal blood screening), will be carried out. The nurse team will supervise the drug intake and they will observe 2 hours late the ADRs and general health status of patient, who will be responsible for the intake of the following medication doses. Each patient will be asked to attend twice week to his/her treatment center, during four weeks and each patient visit the clinical team will record the primary and secondary outcome.
224232545|NCT03556371|DRUG|Placebo oral capsule|In each patient recruited, assignation to placebo or N-Acetylcysteine group treatment wil be performed, after he/she has signed the informed consent. In the first visit, the evaluation by the psychiatrist and with the nurse team (structured evaluation, which includes the CCQ-N-10, CSSA, general health evaluation, urine drug test and basal blood screening), will be carried out. The nurse team will supervise the drug intake and they will observe 2 hours late the ADRs and general health status of patient, who will be responsible for the intake of the following medication doses. Each patient will be asked to attend twice week to his/her treatment center, during four weeks and each patient visit the clinical team will record the primary and secondary outcome.
223646885|NCT01958164|DRUG|Actilyse|Second dose of Actilyse 2mg/2ml will be given if CVAD has not been restored at time 120min.
223646886|NCT02930863|OTHER|pulse oximetry software|This pulse oximetry software will utilize automated verbal prompts that direct the patients to breathe when their pulse oximetry reading falls at or below 93%.
223646887|NCT02930863|BEHAVIORAL|Brief post-PACU stay survey.|Complete a brief post-PACU stay survey focused around their satisfaction and experience during their time in the PACU.
223646888|NCT03830541|OTHER|Oral care delivery analysis in participants with ASD|The analysis of oral health status, tooth loss, oral rehabilitation, characteristics of routine dental treatment and treatment in general anaesthesia in persons with ASD
223646889|NCT05999357|DRUG|JDQ443|JDQ443 tablets, orally administered
223646890|NCT04330404|BEHAVIORAL|Cognitive strategy training|The Cognitive strategy training, including awareness enhancement, cognitive-related education, discussion of everyday cognitive difficulties, generation of cognitive strategies, cognitive strategy practice, and homework assignments
223646891|NCT04330404|BEHAVIORAL|group interactive game|The active control group will receive group interactive game, including table games and games using songs, balloons, newspapers and so on.
223646892|NCT05241990|BEHAVIORAL|Practice Facilitation|A practice coach will offer tools, resources, hands-on guidance, and content expertise to assist sites in offering a stepped care model of alcohol treatment to patients with unhealthy alcohol use.
223646893|NCT05241990|BEHAVIORAL|Alcohol Stepped Care|Based on severity of alcohol use, individuals receive brief alcohol intervention delivered in person or by computer, cognitive behavioral therapy by person or computer, or pharmacotherapy for alcohol use disorder
223646894|NCT02019095|OTHER|Bronchoscopy for the sampling of bronchoalveolar lavage (BAL) fluid|
223646895|NCT02453308|DRUG|ACT|"1. Artemether-lumefantrine for 3 days~2. Dihydroartemisinin-piperaquine for 3 days.~3. Artesunate-mefloquine for 3 days"
223646896|NCT02453308|DRUG|TACT|"1. Artemether-lumefantrine for 3 days plus Amodiaquine for 3 days.~2. Dihydroartemisinin-piperaquine for 3 days plus Mefloquine hydrochloride for 3 days.~3. Dihydroartemisinin-piperaquine for 3 days plus Mefloquine hydrochloride for 3 days."
224232546|NCT02255513|DRUG|HLD200|
223646897|NCT00066157|DRUG|Transdermal estradiol|50 micrograms (low-dose) or 100 micrograms (high-dose) transdermal 17-ß-estradiol patch, changed every 3 days, for 12 months
223646898|NCT00066157|DRUG|Medroxyprogesterone|2.5mg tablet daily for 12 months
223646899|NCT00066157|DRUG|Placebo Patch|Transdermal placebo patch, changed every 3 days, for 12 months
223646900|NCT00066157|DRUG|Placebo|Placebo tablet daily for 12 months
223646901|NCT02963506|OTHER|Placebo|
223646902|NCT02963506|DRUG|Bimekizumab|Bimekizumab in different dosages.
223646903|NCT03503032|PROCEDURE|Extracardiac Fontan|Extracardiac Fontan (Total cavo-pulmonary connection) will be constructed with a tube graft from the inferior vena cava to the pulmonary artery \[applied to both arms\]
223646904|NCT03503032|PROCEDURE|Fontan fenestration|Fontan fenestration created as a single 3 to 6mm communication between fontan channel and pulmonary venous atrium \[Fenestrated arm\]
223646905|NCT05796934|BEHAVIORAL|Moments that Matter (MTM) Program|"MTM aims to empower caregivers, enhance nurturing care practices, and ultimately improve early child development (ECD). MTM will be targeted to primary caregivers of children aged 0-3 years and implemented over an 18 month period. The primary program delivery agent will be local volunteers (ECD promoters) who will facilitate monthly peer group sessions and conduct monthly home visits to participants residing in their village. The MTM curriculum covers topics relating to responsive caregiving, early learning, and child security \& safety, and gender equality. Faith leaders will also be trained to promote nurturing care and ECD within their sermons and Bible study groups. ECD committees will be also formed among leaders across various sectors (e.g., health, education, faith institutions) to promote nurturing care and ECD at the community level and coordinate MTM activities with program staff, delivery agents, and other existing service providers (e.g., community health volunteers)."
223646906|NCT06520917|DEVICE|Locator-Positioner (LOPO) Guide Device|Patients underwent temporomandibular joint arthroscopy with the aid of the LOPO guide device
223646907|NCT00905866|OTHER|PAS and SF-36 questionnaires|Patients who agree to participate in this study will be asked to fill out a translated PAS questionnaire and a Taiwan version of SF-36 before and after surgery
224232547|NCT02255513|DRUG|Placebo|
224232548|NCT02626949|BEHAVIORAL|MBSR Course|Formal mindfulness meditation methods taught in the MBSR course include: Body Scan Meditation (a supine meditation), Gentle Hatha Yoga (practiced with mindful awareness of the body), Sitting Meditation (mindfulness of breath, body, feelings, thoughts, and emotions), and Walking Meditation. Informal Mindfulness Meditation Practices (mindfulness in everyday life) include: 1) awareness of pleasant and unpleasant events, and, 2) deliberate awareness of routine activities and events such as eating, weather, walking, and interpersonal communication. Daily home assignments include a minimum of 30 minutes daily formal mindfulness practices and 5-15 minutes informal practice, 6 days per week for the entire duration of the course. Course sessions will consist of discussions oriented around weekly homework assignments, including an exploration of obstacles, and development of self-regulatory skills and capacities.
223646908|NCT02212782|DRUG|Linagliptin 5mg|Linagliptin 5mg once daily for 7 days
223646909|NCT02212782|DRUG|DW1029M 1200mg and Linagliptin 5mg|Linagliptin 5mg 1 tablet once daily and DW1029M 300mg 2 tablets b.i.d for 7 days
223646910|NCT04336917|DRUG|Rhomboid Intercostal and Subserratus Plane Block with local anesthetic|Local anesthetic will be injected in the tissue planes between the rhomboid and the intercostal muscles and the serratus anterior and external intercostal muscles with ultrasound guidence.
223646911|NCT06204198|OTHER|No intervention|No intervention
223646912|NCT05486806|DRUG|18F-PBR06|TSPO-PET (translocatior protein, positron emission tomography) scan
223646913|NCT05486806|RADIATION|18F-PBR06|TSPO-PET (translocatior protein, positron emission tomography) scan
223646914|NCT06514066|DRUG|Cannabidiol Oil|The study intervention involves the administration of high purity Cannabidiol (CBD) in vegan soft gel capsule form. Dosing will range between 200 mg and 400 mg and will be administered twice daily. The CBD capsule is water-soluble to improve its bioavailability and absorption in the body.
224232549|NCT02626949|BEHAVIORAL|HEP Course|HEP is an active control that matches MBSR in non-specific factors, such as the amount of time participants interact, but does not include mindfulness practice as an active component. HEP instructors will be selected from experts in the areas covered: music, nutrition education, and, functional movement. The study's RC will coordinate HEP sessions and monitor attendance. Following the 8-week HEP protocol, subjects will meet monthly in 1.5-hour educational sessions to match the booster sessions of MBSR participants.
224232550|NCT03744260|DIAGNOSTIC_TEST|Patients undergo ultrasound and lumbar MRI|Patients undergo ultrasound, physical therapy exam and MRI before and after the radiofrequency ablation procedure that they are getting as part of their regular care.
223646915|NCT02999204|DRUG|Vitamin D3|Two different doses of Vitamin D3
223646916|NCT00710697|DRUG|Picoplatin|IV 150 mg/m2, IV (in the vein) on day 1 of each 21 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
223646917|NCT04258267|PROCEDURE|Early mobilization|Patients will wear an adduction sling to immobilize the shoulder during the first 4 weeks post-operative
223646918|NCT04258267|PROCEDURE|Delayed mobilization|Patients will wear an abduction sling to immobilize the shoulder during the first 4 weeks post-operative, followed by an adduction sling for 2 weeks.
223646919|NCT00904137|PROCEDURE|Cast|
223646920|NCT00904137|PROCEDURE|Splint|
223646921|NCT00904137|PROCEDURE|Tape|
223646922|NCT02173899|BIOLOGICAL|varicella-1|Give the second varicella vaccine (a single 0.5 ml) and get blood samples at 0, 35-42 day
223646923|NCT02173899|BIOLOGICAL|varicella-3|Give the second varicella vaccine (a single 0.5 ml) and get blood samples at 0, 35-42 day
223646924|NCT02173899|BIOLOGICAL|varicella-5|Give the second varicella vaccine (a single 0.5 ml) and get blood samples at 0, 35-42 day
223646925|NCT01397968|DRUG|YKP3089|Capsule, dose to be titrated Tablet, dose to be titrated
223646926|NCT01397968|DRUG|Placebo|Placebo capsule Placebo tablet
223646927|NCT00332176|DRUG|Celgosivir|400mg qd + standard of care for 12 weeks
223766105|NCT07173530|DEVICE|Three 15-minute low-level light therapy sessions using Light Emitting Diodes of wavelength 633nm (Essilor epi-c plus).|A mask with Light Emitting Diodes wavelength 633nm will be placed over closed eyes for 15 minutes.
223766106|NCT07174180|OTHER|Exercise-heat stress with no hijab|Participants perform exercise in the heat with no hijab
223646928|NCT00332176|DRUG|Celgosivir|600mg qd + standard of care for 12 weeks
223646929|NCT00332176|DRUG|Peginterferon alfa 2b + ribavirin|Standard of care for 12 weeks
223646930|NCT01698580|OTHER|On-site exercise|The program will consist of progressive balance, including postural orientation and anticipatory postural adjustments sensory-motor activities, and strengthening exercises to enhance balance and postural control and reduce falls. Exercises in the standing position will be prioritised in order to target balance control.Exercises will be both static and dynamic, and will get progressively more challenging, in order to reach the individual optimal level of balance and strength functional status.
223646931|NCT01698580|OTHER|home-based exercise|Participants will be provided with a detailed booklet containing safety precautions, instructions and photographs of exercises for use in exercise sessions at home and will be instructed to do the exercises preferably under the supervision of a relative or caregiver, in a suitable place (with good lighting and ventilation) and using proper support (close to a table or chair, or the corner of a wall). In the first four weeks of intervention the patients will stay for 30 minutes after the therapy sessions in order to learn the home exercises. The exercises will be reviewed, if necessary, after each session till the last week of intervention. All necessary equipment to undertake the exercise program will be provided.
223646932|NCT01698580|OTHER|Educational and behavioural|Sessions will address specific environmental and behavioural risk factors delivered by trained health professionals,lasting for 30 minutes and will use appropriate language for lay people.Each meeting will be consisted of a brief introduction on the core day topic with supporting audio-visual or graphic material, followed by group discussion in order to identify the beliefs and attitudes of participants regarding falls and any major restriction or barrier for the implementation of preventive strategies. Participants will be encourage to report their own experiences and beliefs. The activity will always end with the reinforcement of the core message of the session.
223766107|NCT07174180|OTHER|Exercise-heat stress with a hijab|Participants perform exercise in the heat with a hijab
223766108|NCT07172061|OTHER|PSV + sigh (Clinical PEEP and Clinical PEEP + 3 cmH₂O)|Each patient undergoes two sequential 15-minute steps: 1) pressure support ventilation at the clinical PEEP and 2) the same settings with PEEP increased by 3 cmH₂O. A ventilator-delivered sigh is programmed as one sustained inflation at 30 cmH₂O for 3 seconds every minute. All other ventilator parameters (trigger sensitivity, pressure support level, mandatory breath timing) remain unchanged. At the end of each step, inspiratory and expiratory holds are performed to collect respiratory mechanics and arterial blood gases; compliance during the sigh is calculated once flow is zero and airway pressure is stable.
223766109|NCT07173426|DEVICE|Bioimpedance analysis|"Bioimpedance analysis involves electrodes attached to the patient's limbs which measures the resistance in the body to an imperceptible high-frequency, low-amplitude alternating electrical current. BIA measurements will include total body water (TBW), intracellular water (ICW), extracellular water (ECW), and the derived parameter dry weight. Results are available at the bedside within 2 minutes."
223766110|NCT07173036|OTHER|metabolic and auxological outcomes|Evaluation over a three-year period following the initiation of treatment with daily recombinant human growth hormone (rhGH)
223766111|NCT07173036|OTHER|metabolic and auxological outcomes|Evaluation over a three-year period following the initiation of treatment with weekly long-acting growth hormone (LAGH).
223766112|NCT07172607|DIETARY_SUPPLEMENT|Avance eZZe drink|25 mL liquid sachet, 1 sachet/day, consume 1 sachet of the sample 1 hour before sleep daily
223766113|NCT07172607|DIETARY_SUPPLEMENT|Avance eZZe drink (without liposomal)|25 mL liquid sachet, 1 sachet/day, consume 1 sachet of the sample 1 hour before sleep daily
223766114|NCT07172607|DIETARY_SUPPLEMENT|Placebo drink|25 mL liquid sachet, 1 sachet/day, consume 1 sachet of the sample 1 hour before sleep daily
223766115|NCT07173842|OTHER|Biobanking and Phenotypic Data Collection|This intervention involves the systematic collection of blood samples (EDTA tubes for DNA extraction) and detailed phenotypic/clinical data using the NeuroCybe Data Collector software. All biospecimens are processed and stored at the RTSGD-NeuroPsyBiT Biobank under ISO-compliant procedures. Data are entered into a secure on-premises server infrastructure (GDPR/KVKK compliant) for long-term use in genomic and epigenomic studies. No therapeutic intervention is applied; all activities are non-invasive and focused on sample and data acquisition.
224232551|NCT01097161|BEHAVIORAL|speech therapy with the assistance of an acoustical analysis program|Two weekly speech sessions realized on individual basis for three months period
223766116|NCT04186416|OTHER|Mostcare® device|The Moscare® system is connected to the patient monitoring devices. Data are collected just before and 5 minutes after the vascular filling.
224232552|NCT04559295|BIOLOGICAL|Bone Marrow Concentrate|The intradiscal delivery of bone marrow concentrate (BMC) into discs, facet , epidural space, and sacroiliac joints
224320027|NCT03785600|DEVICE|Negative Ion Generator|Negative ion generator: Sitting in front of a modified negative ion generator for 60 min every morning within 90 minutes of waking up.
223646933|NCT01698580|OTHER|Management of modifiable risk factors|Postural hypotension: review of medications that may contribute to postural hypotension;Visual impairment: Participants identified as having visual problems will be referred to an ophthalmologist. The use of four or more medications or the use of psychotropic medication: A review of the risk-benefit of using specific medications will be undertaken, especially psychotropic and anti-hypertensive drugs; Foot problems and shoes: Guidance on the use of proper footwear, nail care and the treatment of cutaneous mycoses will be given; Undernutrition: Participants with a BMI lower than 22 kg / m2 and or a leg calf under 31cm will be oriented to increase their protein and calorie intake and will be referred to a nutritionist.
223646934|NCT01698580|OTHER|Usual care|The control group will receive a baseline assessment to identify risk factors for falls and will be referred to their clinicians with a report of individual modifiable risk factors to be managed without any specific guidance: referral to routine services, treatments or any specific orientation will be at the discretion of their primary clinicians. So, further management of each participant in the control group will be individualized, with no specific protocol. Interventions will be recorded. Participants will receive a leaflet with basic orientations for fall prevention.
223646935|NCT02716480|BEHAVIORAL|Mobility coaching|"The intensive follow-up for the patients of Mobility Coaching  arm will consist on a monthly remote coaching of 20 to 30 minutes led by a Mobility coach. The web platform allows self-administration of a questionnaire to establish patient's diagnosis of mobility to enable personalized coaching. The web platform can also track the parameters collected by connected devices (pedometer and connected scale), organize appointments with patients and ensure the traceability of exchanges with patients. A smartphone application tracks different modes of locomotion used."
223646936|NCT02716480|BEHAVIORAL|Diet coaching|"The intensive follow-up for the patients of Diet Coaching  arm will consist on a monthly remote coaching of 20 to 30 minutes led by dietitian trained in the care of patients undergoing bariatric surgery."
223766117|NCT04186416|OTHER|Transthoracic cardiac ultrasound|Transthoracic cardiac ultrasound before and 3 minutes after the vascular filling.
223646937|NCT05043662|DIAGNOSTIC_TEST|UroCAD assay, CTU examination and urine cytology|The extracted DNA from morning urine will be analyzed by UroCAD to determine the level of CNV. CTU and cytology will be performed according to the routine of clinical practice.
223646938|NCT04129463|DEVICE|Subscleral Trabeculectomy (SST) with Iris incarceration|Subscleral Trabeculectomy with Iris Incarceration using iris forceps and scissors
223646939|NCT04129463|DEVICE|Conventional trabeculotomy|Conventional trabeculotomy in Buphthalmous using rigid Hans trabeculotome
223766118|NCT03890367|BIOLOGICAL|Meningococcal polysaccharide (serogroups A, C, Y, and W) tetanus toxoid Conjugate vaccine|Pharmaceutical form: Liquid solution for injection Route of administration: Intramuscular
223766119|NCT03890367|BIOLOGICAL|Meningococcal polysaccharide group A, C, W-135 and Y Conjugate vaccine|Pharmaceutical form: Powder and solvent for suspension for injection Route of administration: Intramuscular
223766120|NCT03890367|BIOLOGICAL|Meningococcal group C polysaccharide Conjugate vaccine adsorbed|Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
223766121|NCT04527068|DRUG|Bevacizumab|7.5 mg/kg intravenously every 3week
223766122|NCT04527068|DRUG|Tripleitriumab|240mg intravenously every 3week
224232553|NCT05436158|OTHER|Implant placement in the safe angle position in the anterior maxilla|After assessing the CBCT of patients, the immediate implants will be assessed if they were placed in the safe zone. the safe zone is described as; that there is an angle between the intersection of the incisal long axis perpendicular to the palate or the occlusal plane, and the long axis of the root. When this relation is shifted more palatal, where the incisal plane line will be at the cingulum position or slightly palatal to it, it is named the safe angle position. The more palatal relocation to the cingulum is performed according to the availability of palatal bone, the occlusion with the opposing dentition, the type of the restoration (screw vs cemented).
224232554|NCT03580343|DRUG|tofacitinib|tofacitinib extended release, 11mg, daily, oral
224232555|NCT01117883|OTHER|Application of two different sternal weights|Two separate weights (first 10% of body weight, then 20% of body weight) will be placed on the sternum and changes in central hemodynamic measurements and intrathoracic pressure will be recorded and documented.
224232556|NCT05912686|DRUG|Atorvastatin 80mg|The test group will undergo high-dose atorvastatin treatment (80mg/day) for the first 3 days after the procedure, transitioning to a standard dose (20mg/day) of atorvastatin thereafter.
224232557|NCT05912686|DRUG|Atorvastatin 20mg|The control group will receive a consistent standard dose (20mg/day) of atorvastatin.
224232558|NCT03820154|DIAGNOSTIC_TEST|Skin Prick Test|Skin Prick Testing with inhalant allergens
224232559|NCT03820154|DIAGNOSTIC_TEST|Skin Prick Test TAPE|Skin Prick Testing with a Tape, integrating the allergens and needles
224232560|NCT03013933|DRUG|Brentuximab Vedotin|Given IV
224232561|NCT03013933|DRUG|Cyclosporine|Given PO
223646940|NCT05326490|DRUG|PB-201|PB-201: 100 mg each time, orally in the morning and evening respectively
223646941|NCT05326490|DRUG|PB-201 matched placebo|PB-201 matched placebo: One tablet each time, orally in the morning and evening respectively
223646942|NCT05326490|DRUG|Metformin hydrochloride|The dosage and administration of metformin hydrochloride remain unchanged before screening
223646943|NCT02702791|BEHAVIORAL|Telecoaching|Pedeometer based goals and telecoaching support
223646944|NCT02702791|OTHER|pulmonary rehabilitation|Conventional pulmonary rehabilitation along the ATS-ERS guidelines, total duration 6 months.
224232562|NCT03013933|OTHER|Pharmacokinetic Study|Correlative studies
223646945|NCT04609670|DRUG|[14C]-ALXN2050|A single dose of 200 milligrams (\~85 microcuries) \[14C\]-ALXN2050 will be administered orally.
223646946|NCT00828204|DEVICE|single-use autoinjector with a prefilled liquid Avonex syringe|
223646947|NCT00828204|DEVICE|Avonex prefilled syringe via manual IM injection|
223766123|NCT01501812|BEHAVIORAL|Generalization pattern|"During evaluation a conditioning of a tone (conditioning stimulus) and aversive sound (metal scratch) will conduct (another tone which will be un-conditioning stimulus for control). Generalization patterns will be evaluated, by measuring the differentiation capability between different tones (neutral and aversive) before and after the conditioning, and after extinction phase. The generalization will also be measured by the generalization curve that plotted from displaying tones, different from the original tones, and asked the subject whether the current tone is original or new"
223766124|NCT05597527|DRUG|Fluzopari and apatinib|Fluzopari was used as 100mg capsules orally twice a day (one time in the morning and one time in the evening), every four weeks as a cycle, a total of 3-4 cycles. Apatinib was used as 250 mg orally once a day, every 4 weeks as a cycle, 2-3 cycles in total, and stop 4 weeks before operation.
223646948|NCT00828204|DRUG|BG9418 (interferon beta-1a)|
223646949|NCT00337480|BEHAVIORAL|education|education of acute coronary syndrome patients, mostly about nicotinic weaning, weight loss and physical activity
223646950|NCT03100552|DIAGNOSTIC_TEST|Endoscopic imaging|Analysis of the presence of dysplasia within sessile serrated polyps (SSP) using endoscopic imaging (high definition white light +- narrow band imaging)
223766125|NCT04414384|OTHER|Abdominal Binder|Abdominal Binder placement
223766126|NCT04414384|OTHER|Step Counter|step counter to track steps
223766127|NCT03826329|OTHER|observational study|this is an observational study, there is no intervention in this study
223766128|NCT04176770|PROCEDURE|ESP Block|ESP block: bilateral injection of 20 ml of isobaric Bupivacain 0,375% in the paraverebral space T5.
223766129|NCT04176770|PROCEDURE|TAP Block|TAP block: bilateral injection of 15 ml of Isobaric Bupivacain 0,5%
223646951|NCT02641288|DRUG|Ropivacaine irrigation|Using a standard irrigation device (no specific device is being used), 300 mg total of ropivacaine in 200ml normal saline will be instilled into the abdomen after surgical dissection, just before abdominal wall closure. Under direct visualization, the solution is delivered over the oesophageal hiatus, over both anastomoses and in both subdiaphragmatic spaces.
223646952|NCT02641288|DRUG|Normal saline irrigation|Using a standard irrigation device (no specific device is being used), 200ml normal saline will be instilled into the abdomen after surgical dissection, just before abdominal wall closure.
223646953|NCT03254797|OTHER|Stepping training with feedback|Subjects stand in a step standing position with placing one leg on the load cells of the device and the other leg at the posterolateral direction to the trained leg outside the load cells, look at the displayed section which will be positioned at their eye level. Then subjects will be instructed to shift/take their body-weight onto the trained leg until the green zone of the displayed section is lightened. When the subjects can take a proper level of their body-weight onto the trained leg, the beep sound will be alarmed to trigger the subjects and therapist that the subjects can step the other leg forward to the marker. Then they have to do the same when steps the leg backward.
223646954|NCT03254797|OTHER|Stepping training without feedback|Subjects stand in a step standing position with placing one leg on the load cells of the device and the other leg at the posterolateral direction to the trained leg outside the load cells. Then subjects will be instructed to shift/take their body-weight onto the trained leg as most as they can. If the subjects can take a proper level of their body-weight onto the trained leg, the subjects can step the other leg forward to the marker. Then they have to do the same when steps the leg backward.
223646955|NCT04657393|PROCEDURE|mechanical ventilation|change of ventilation frequency
223646956|NCT00395031|DRUG|Ziprasidone|Ziprasidone dose of between 40 mg po bid to 160 mg po bid for 8 weeks
223646957|NCT00518765|DRUG|Aliskiren|
223646958|NCT00518765|DRUG|Aliskiren plus placebo|
223646959|NCT00518765|DRUG|Aliskiren|
223766130|NCT02533921|OTHER|Interdisciplinary outpatient palliative care|Interdisciplinary outpatient palliative care is an approach to caring for individuals with life-threatening illnesses that addresses potential causes of suffering including physical symptoms such as pain, psychiatric symptoms such as depression, psychosocial issues and spiritual needs. Palliative care approaches have been successfully applied to improve patient-centered outcomes in cancer as well as several chronic progressive illnesses including heart failure and pulmonary disease.
223646960|NCT00518765|DRUG|Aliskiren plus placebo|
223646961|NCT02792530|OTHER|Dietary consultation|Dietary consultation for sodium restriction to decrease dietary intake to 2 grams/day less than the patients consume currently
223646962|NCT04087850|BEHAVIORAL|Making Socially Accepting Inclusive Classrooms|Using a consultation model, study staff members met with teachers approximately twice per month and observed them an additional two times per month. The goal was to help teachers implement practices that create a socially accepting classroom climate for children.
223646963|NCT04431440|OTHER|silver nanoparticles|effect silver nanoparticles will be examined on multidrug resistant bacteria
224232563|NCT03013933|DRUG|Verapamil|Given PO
223646964|NCT00654771|OTHER|urine collection|clean catch urine collection and catheterized urine collection
223646965|NCT02970162|DRUG|Amifampridine Phosphate|
223646966|NCT02970162|DRUG|Placebo Oral Tablet|
223646967|NCT03495089|DIAGNOSTIC_TEST|dermal electrochemical conductance (DEC)|The patient will undergo DEC quantification using the Sudoscan® device.(Sudoscan®, Impeto Medical, France)
223646968|NCT03495089|DIAGNOSTIC_TEST|Monofilament testing|Monofilament testing by Semmes-Weinstein 5:07 MFT (10 g),
223766131|NCT02533921|OTHER|Standard of Care|Usual care defined as including both a PCP and neurologist
223766132|NCT06342440|DIAGNOSTIC_TEST|DENEB|A panel of circulating microRNA, whose expression level is tested in cell-free and exosome-derived samples.
223766133|NCT04346615|DRUG|Zavegepant (BHV-3500)|10 mg intranasal (IN) for 14 days
224232564|NCT03013933|DRUG|Verapamil Hydrochloride|Given PO
224232565|NCT03917628|DRUG|SCT630|SCT630 single s.c. injection
224232566|NCT03917628|DRUG|adalimumab-EU source|adalimumab-EU source single s.c. injection
223646969|NCT03241901|DRUG|Artemether-Lumefantrine Tab 20-120mg|Artemether-Lumefantrine Tablet 20-120mg
223646970|NCT03241901|DRUG|Primaquine Phosphate 0.25 mg/kg|Primaquine Phosphate 0.25 mg/kg
223646971|NCT03241901|OTHER|Placebo|Aqueous solution prepared to mimic the taste of the intervention drug.
223646972|NCT00612248|OTHER|Splint|Patients in the study group received the splint on the day of the first evaluation and took it with them for use during activities of daily living and patients in the control group only used the splint during the evaluations
223646973|NCT06039111|PROCEDURE|ICG alone|SLNs will be detected with ICG alone, labelled as such, and subsequent to that tested with Gamma probe for accuracy
223646974|NCT02340364|BEHAVIORAL|Education + Patient Navigation|208 patients randomized to self-care Education+ Patient Navigation-delivered self-care plan.
223646975|NCT02340364|BEHAVIORAL|Self-care Education|208 patients randomized to self-care education alone.
223646976|NCT00923572|DRUG|EE30/DRSP (Yasmin, BAY86-5131)|Patients in daily life clinical practice treatment receiving Yasmin according to indication on the label.
223766134|NCT04346615|DRUG|Placebo|Placebo Q8h for 14 days
223766135|NCT03447327|PROCEDURE|single burr hole|patients with CSDH operated by single burr hole craniostomy under local anaesthesia
223766136|NCT04268342|OTHER|Resistance guided treatment for gonorrhoea infection|For cases of gonorrhoea infection treated at the return visit, a nucleic acid assay will be used to determine individual eligibility for ciprofloxacin treatment
223766137|NCT01122199|DRUG|RAD001 + AMG479|Escalating doses of RAD001 + AMG479. Starting cohort will be 5 mg RAD001 once daily, continuous + AMG479 12 mg/kg on Day 1 and 15 of each 28 day cycle.
224232567|NCT05420428|DEVICE|supraglottic airway device|under general anesthesia, patients received supraglottic airway device
224232568|NCT05420428|DEVICE|endotracheal intubation|under general anesthesia, patients received endotracheal intubation
224320028|NCT06508307|BIOLOGICAL|A Phase I Clinical Study of Intratumoral Injection Oncolytic Vaccinia Virus GC001 in Patients With Advanced Solid Tumors|The maximum number of lesions that each participant is allowed to inject at one time is two.
224320029|NCT06496542|BEHAVIORAL|Daily caloric restriction|Weight loss based on daily caloric restriction and increased physical activity
223646977|NCT03760861|DEVICE|Prototype Microcapsule Treatment|The subject will be sedated and using an endoscope, a prototype microcapsule will be placed into the gastric corpus. Then, an external handheld magnet will be applied to inflate the balloon encapsulated in the microcapsule. Upon ascertaining the full inflation based on the endoscopic visualization, the investigator will wait another 10 minutes after that to observe how the subject feels before manually puncturing the balloon with needle knife, and retrieving the punctured balloon with the RothNet through the mouth.
223646978|NCT00750438|DIETARY_SUPPLEMENT|Propionate ester|The subject will take propionate ester at the dose specified by the dose finding study, three times a day for 24 weeks
223646979|NCT00750438|DIETARY_SUPPLEMENT|Inulin|The subjects in this group will take inulin at a comparable dose, three times a day for 24 weeks
223646980|NCT00750438|DIETARY_SUPPLEMENT|Cellulose|The subjects in this group will take the non fermentable carbohydrate, cellulose, at a comparable dose for 24 weeks.
223646981|NCT03603262|DRUG|SH-1028|Starting dose 60mg,oral administered once daily.If tolerated subsequent cohorts will test increasing doses (100mg,200mg,300mg,400mg) of SH-1028.
223646982|NCT05221957|DRUG|Iron(III)isomaltoside|Individual weight and hemoglobin dependent dosage
223646983|NCT05453591|DEVICE|Colli-Pee UAS devices|Colli-Pee UAS device variants will be evaluated during this study
223646984|NCT05002296|PROCEDURE|upper cervical manipulation|rotatory upper cervical manipulation to both sides. The treatment program was conducted for twelve sessions (three sessions per week). Assessment procedures were performed before and after treatment through visual analogue scale (VAS)
223646985|NCT04960657|DRUG|glibenclamide|Oral administration of glibenclamide/placebo. To investigate the role of PACAP38 on cranial arteries in healthy volunteers after glibenclamide/placebo administration .
223646986|NCT04960657|DRUG|PACAP38|PACAP38 infusion
223646987|NCT04139213|DRUG|buprenorphine/naloxone oral product|To treat opioid use disorder, buprenorphine/naloxone will be provided by a study pharmacist under a collaborative pharmacy practice agreement on a weekly or monthly basis, unless the care plan specifies greater frequency of pharmacy visit. The median expected dose of buprenorphine/naloxone (sublingual film or tablet) is 8 to 24 mg daily, and may be adjusted per the collaborative pharmacy practice agreement.
223646988|NCT04139213|DRUG|injectable naltrexone|To treat opioid use disorder, injectable naltrexone will be provided by a study pharmacist under a collaborative pharmacy practice agreement on a monthly (injectable naltrexone) basis. The expected dose of injectable naltrexone will be approximately 380 mg. Injectable naltrexone will be dispensed and prepared by the pharmacist but administered by nursing staff for the pilot study.
223646989|NCT04139213|OTHER|Pharmacy maintenance addiction care|Patients randomized to the pharmacy study arm and on a stable dose of buprenorphine/naloxone or naltrexone will receive maintenance care at the pharmacy for up to three months. Patients will visit for check-ins with a pharmacist on a monthly, weekly, or more frequent basis, depending on the individual treatment plan. Patients on buprenorphine/naloxone will be dispensed their medication at study visits, whereas patients taking injectable naltrexone will be dispensed it monthly by the pharmacist. All patients will visit the pharmacy at least monthly for addiction care (assessment, toxicological testing).
223646990|NCT04139213|DRUG|oral naltrexone|To augment care for patients receiving injectable naltrexone for the treatment of OUD and treat cravings that may arise before their scheduled injection, patients prescribed injectable naltrexone may be provided a several day supply of oral naltrexone by a study pharmacist under a collaborative pharmacy practice agreement. The expected dose of oral naltrexone will be approximately 25-50 mg daily.
223646991|NCT01568242|DEVICE|Phacoemlsification|Transurgical measurement of temperature
223646992|NCT01651637|DRUG|synthetic surfactant (CHF5633)|CHF5633 100 mg/kg; CHF5633 200 mg/kg synthetic surfactant sterile suspension in 3.0 ml glass vials with a total concentration of 80 mg/ml for intratracheal administration. Single administration
223646993|NCT01173237|PROCEDURE|Use tracheal intubation for surfactant therapy|Surfactant endotracheal administration after tracheal intubation
223646994|NCT01173237|PROCEDURE|Use of Proseal laryngeal mask airway for surfactant therapy|Surfactant use by proseal laryngeal mask airway
223646995|NCT01260402|DEVICE|Resynchronization using a transeptal approach|"Cardiac resynchronization with one in the right ventricle and one in the left ventricle via a transeptal puncture.~Devices used for procedure : Medtronic C304 or 6227DEF, Nykanen RF Wire, RADI PressureWire"
223646996|NCT01260402|DEVICE|Resynchronization using a coronary sinus approach|"Cardiac resynchronization with one in the right ventricle and one in the left ventricle via the coronary sinus.~Devices used for procedure : RADI PressureWire, routine catheters chosen by operator"
223646997|NCT00590265|DEVICE|Northern Light Technology (SADelite lamp) bright light-therapy|10 000 lux for 30 minutes
223646998|NCT00590265|DEVICE|Northern Light Technology (SADelite lamp) Dim light-therapy|\<100 lux for 30 minutes
223646999|NCT04017195|DRUG|EVRA patch (NGMN+EE) (Treatment A) (Reference)|A single transdermal contraceptive patch of EVRA (NGMN + EE) will be applied to the buttock (right or left) of participants on Day 1 of each Treatment period and is removed 7 days after patch application, that is, on Day 8.
223647000|NCT04017195|DRUG|High molecular weight polyisobutylene (HMW PIB) patch (NGMN+EE) (Treatment B) (Test)|A single transdermal contraceptive HMW PIB (NGMN + EE) patch will be applied to the buttock (right or left) of participants on Day 1 of each Treatment period and is removed 7 days after patch application, that is, on Day 8.
223766138|NCT04124549|OTHER|Usual care with sham intervention|Patients in the control group received usual care and were advised to do sham exercise such as stretch legs and arms about 15 minutes during the first 2 HD hours.
224232569|NCT03641898|PROCEDURE|FFR-guided PCI|After the angiographic screening for lesions with 40%-90% diameter stenosis, FFR will be performed according to standard protocol using the s5 console and PrimeWire Prestige PLUS coronary pressure wire (Volcano Corporation, San Diego, California). FFR is calculated as the ratio of mean distal intracoronary pressure measured by the pressure wire, and the mean arterial pressure measured through the coronary guiding catheter. An FFR ≤0.8 or \>90% diameter stenosis should result in a treatment decision for revascularization by PCI and lesions with FFR \>0.80 are defined as FNLs and should result in deferral of PCI.
224320030|NCT06496542|OTHER|Standard advice control|Initial nutrition consultation without subsequent counseling
224320031|NCT04210219|DRUG|JNJ-64264681|JNJ-64264681 capsule will be administered orally.
224320032|NCT06358001|DEVICE|EchoTip AcuCore|Using endoscopic ultrasound guided needle to collect biopsies
223647001|NCT06332664|COMBINATION_PRODUCT|Early Nutrition Intervention|This involves a multidisciplinary team intervention, including oncologists, nutritionists, and nurses. Additionally, the intervention introduces a team-developed mobile application (APP) for the purpose of regular patient follow-ups to identify nutritional risks promptly and facilitate timely interventions. Patients identified as at risk through the app follow-up will be referred to the nutrition clinic for consultation to address nutritional concerns. For advanced-stage cancer patients undergoing monthly chemotherapy hospitalizations, comprehensive assessments encompassing nutrition, psychological aspects, and other facets will be conducted during hospital stays. When deemed necessary, patients will receive dietary guidance and nutritional support.
223647002|NCT01926561|OTHER|Interscalene brachial plexus block|After sterile draping around interscalene groove with povidone, a nerve stimulating needle connected to a nerve stimulator is inserted through the interscalene groove. Following involuntary contraction of shoulder, arm, forearm, or hand muscles with 0.5 milliamperes at 1 Hz using the nerve stimulator, 30 to 40 ml of mixture of 1% mepivacaine 20 ml and 0.75% ropivacaine 20 ml are injected.
223647003|NCT06159777|DRUG|Polyethylene Glycol 3350|\*Polyethylene glycol 3350 (PEG) will be used within it's FDA indication and dosing for constipation. Each 17-gram dose of PEG is to be mixed in 8oz of liquid.
223647004|NCT02284035|DRUG|Raltegravir/3TC|MK0518B (Raltegravir/3TC) (300mg/150mg) twice daily, administered orally in the 300/150 mg film-coated tablets according to instructions in the prescribing information.
223647005|NCT02284035|DRUG|EFV/TDF/FTC|standard combination therapy
223647006|NCT02284035|DRUG|ATV/r + TDF/FTC or DRV/r + TDF/FTC|
223647007|NCT02284035|DRUG|DTG+ABC/3TC DTG+TDF/FTC EVG/cobi/TDF/FTC RAL+TDF/FTC|
223647008|NCT02284035|DRUG|EFV plus ABC/3TC or RPV/TDF/FTC|
223766139|NCT04124549|OTHER|Intradialytic Combined Exercise|Each session consisted of a 5-minute warm-up, cool-down and 30-minute cycling at a Rating of Perceived Exertion (RPE) of 12-14. The machine has two exercise types including aerobic exercise and resistance exercise. Patients were asked to perform aerobic exercise 20-min and resistance exercise 10-min in the first stage. Every four weeks is divided into a stage. And the time of aerobic exercise and resistance exercise were personally adjusted per stage to maintain the personalized target RPE. In the following stages, aerobic exercise was continued 15-min for the second stage, 10-min for the third and the forth stage, 15-min for the fifth stage and 20-min for the last stage. And the time for resistance exercise was adjusted for the total exercise time. The resistance of exercise also progressive increased in order to adapt the target RPE. It was accessible to patients of different ages, gender, cultures and ethnicities.
224232570|NCT03641898|DIAGNOSTIC_TEST|Intravascular ultrasound|After the successful FFR-guided PCI, IVUS will be performed in all FNLs with the ultrasound Imaging Catheter Atlantis™ SR Pro (40 MHz, mechanical-type transducer, 3.2 F, Boston Scientific Corporation, Natick, MA, USA). Quantitative analyses of grayscale IVUS include contouring external elastic membrane (EEM) and luminal borders and the measurement of EEM cross-sectional area (CSA), luminal CSA, plaque and media CSA, plaque burdenand remodeling index. Virtual assessment of plaque is performed with iMap software (QIvus 2.0; Medis Medical Imaging Systems, Leiden, The Netherlands). Plaque components are categorized as dense calcium, necrotic core, fibrofatty, and fibrous tissue and reported as absolute area and proportion of total plaque area.
224232571|NCT01305083|DRUG|Udenafil|Placebo-control
223647009|NCT02284035|DRUG|ATV/r plus ABC/3TC|
223647010|NCT02284035|DRUG|DRV/r + ABC/3TC or LPV/r + ABC/3TC or LPV/r + TDF/FTC|
223647011|NCT02284035|DRUG|RAL plus ABC/3TC|
223647012|NCT02284035|DRUG|Other ART regimens|
223647013|NCT04832997|DIAGNOSTIC_TEST|Prostate biopsy systematic random prostate biopsy (TRUS-Bx) + eventual MRI-targeted biopsy (MRI-TBx) + eventual microUS-targeted (Micro-US-TBx)|Patients with both positive mpMRI and Micro-US, defined as the presence of one or more lesions with PI-RADS \>= 3 and PRI-MUS \>= 3 respectively, will receive a 12-core TRUSBx in addiction to MRI-TBx and Micro-US-TBx. Patients with both negative mpMRI and Micro-US will receive a 12-core TRUSBx. Patients with only positive mpMRI will receive MRI-TBx and 12-core TRUSBx. Patients with only positive Micro-US-TBx will receive Micro-US-TBx and 12-core TRUSBx.
223647014|NCT04845568|BEHAVIORAL|Virtual Reality Experience|"The virtual reality experience includes psychoeducation content about healthy eating and consideration of future consequences. It includes a game where participants are in a go kart and pick up healthy or unhealthy foods on the road. Participants play in the present and in the future."
223647015|NCT00928408|DRUG|Cinacalcet|
224232572|NCT01305083|DRUG|Placebo|Placebo
224232573|NCT04476082|OTHER|No intervention - observational study only|No intervention - observational study only
223647016|NCT00923793|DEVICE|Titanium implant (CranioConstruct™)|One to three weeks before operation the skull defect is well defined using Computer tomography. Based on these results the Titanium implant is ordered.
224232574|NCT06179966|OTHER|Dance group|The application will be taught to the participants' spouses by the researcher after they are admitted to labor, and the spouses will be asked to do it to the participants at regular intervals.
223647017|NCT00923793|DEVICE|Hydroxylapatite (CustomBone)|Six to eight weeks before operation the skull defect is well defined using Computer tomography. Based on these results the Hydroxylapatite implant is ordered.
223647018|NCT00536744|DEVICE|acoustical pulse energy (extracorporeal shockwave)|Acoustical pulse energy (extracorporeal shockwave) + Standard of care wound dressing.
223647019|NCT00536744|OTHER|Sham|Non-energized (inactive - Sham) application + standard of care
223647020|NCT06491485|DRUG|Group M (lidocaine with Magnesium sulfate)|a total volume 200 ml normal saline 0.9% at a temperature of 37°c including 3mg/kg of 1% lidocaine with magnesium sulfate 50 mg/kg (maximum 2g) will be sprayed by the surgeon through the laparoscopic port to wash the incisions and anastomosis.
223647021|NCT06491485|DRUG|Group B (lidocaine with Sodium bicarbonate)|a total volume 200 ml normal saline 0.9% at a temperature of 37°c including 3mg/kg of 1% lidocaine with 50 ml 4.2% sodium bicarbonate will be sprayed by the surgeon through the laparoscopic port to wash the incisions and anastomosis.
223647022|NCT06491485|DRUG|Group C (lidocaine with saline)|a total volume 200 ml normal saline 0.9% at a temperature of 37°c including 3mg/kg of 1% lidocaine will be sprayed by the surgeon through the laparoscopic port to wash the incisions and anastomosis.
224232575|NCT06179966|OTHER|Massage group|After admission to travaya, the researcher will teach the pregnant woman's husband practically and the spouses will massage the participants' backs at certain intervals.
224232576|NCT00329602|DRUG|Placebo|Matching Placebo
223647023|NCT06516536|OTHER|MBI (Mindfulness-Based Intervention)|"Breath-Focused Meditation Approach (5-7 minutes):~They will be guided to observe the flow of air in and out of the nose, noting sensations in the abdomen or chest.~Body scan (7-8 minutes):~Students will be guided through a careful exploration of their body. You'll start with your toes and slowly work your way toward your head, paying attention to the physical sensations in each part of your body.~Simple yoga poses (5-7 minutes):~Students will stand and follow instructions to perform a series of simple poses, such as mountain pose, tree pose, and cat-cow pose."
223647024|NCT05858723|DIAGNOSTIC_TEST|ROAT|Repeated Open Application Test
223647025|NCT01039740|DRUG|Mirtazapine|Mirtazapine administration for 6 weeks under therapeutic dose
223647026|NCT02827877|RADIATION|Copper Cu 64-DOTA-Trastuzumab|Given IV
223647027|NCT02827877|OTHER|Laboratory Biomarker Analysis|Correlative studies
223647028|NCT02827877|BIOLOGICAL|Pertuzumab|Given IV
223766140|NCT00881309|DRUG|Tripterygium|TW 90mg/d
223766141|NCT01135810|BEHAVIORAL|Hypnosis|
223766142|NCT01135810|BEHAVIORAL|Meditation|
223766143|NCT06504030|DRUG|modified-DEP|"For non-EBV-HLH patients: Liposomes doxorubicin, 25 mg/m2 d1, etoposide 100 mg/m2 d1, methylprednisolone 1 mg/kg d1-3, then tapering according to patients condition, fully stop with d7 to d10; ruxolitinib, 15 mg bid. Emapalumab, if needed.~For EBV-HLH patients: PD-1 monoclonal antibody, 2 mg/kg (maximum dose, 200 mg) d-3, liposomes doxorubicin, 25 mg/m2 d1, etoposide 100 mg/m2 d1, methylprednisolone 1 mg/kg d1-3, then tapering according to patients condition, fully stop with d7 to d10; ruxolitinib, 15 mg bid. Emapalumab, if needed."
224232577|NCT00329602|DRUG|Ropinirole|Ropinirole IR 0.25mg/day to 4mg/day for RLS
224232578|NCT04683822|OTHER|Telerehabilitation|Patients will attend telerehabilitation sessions
224232579|NCT02779816|DEVICE|Pen device|Adaptive pen device
223647029|NCT02827877|PROCEDURE|Positron Emission Tomography|Undergo PET
223647030|NCT02827877|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
223647031|NCT02827877|BIOLOGICAL|Trastuzumab|Given IV
223647032|NCT01685762|DRUG|Metformin|850 mg of metformin taken once daily by mouth for 4 weeks (weeks 1-4) and then twice daily by mouth for 8 weeks (weeks 5-12).
223647033|NCT05206773|DRUG|Venglustat (GZ402671)|Pharmaceutical form: Tablet Route of administration: Oral
223647034|NCT05206773|DRUG|Placebo|Pharmaceutical form: Tablet Route of administration: Oral
223766144|NCT00513422|DIETARY_SUPPLEMENT|Glucosamine sulphate and chondroitin|"Glucosamine: Two 750mg capsules once daily for two years;~Chondroitin: Two 400mg capsules once daily for two years."
223766145|NCT00513422|DIETARY_SUPPLEMENT|Glucosamine sulphate|"Glucosamine: Two 750mg capsules once daily for two years;~Placebo Chondroitin: Two capsules once daily for two years."
223766146|NCT00513422|DIETARY_SUPPLEMENT|Chondroitin sulphate|"Chondroitin sulphate: Two 400mg capsules once daily for two years;~Placebo glucosamine: Two capsules once daily for two years."
224232580|NCT03885102|BEHAVIORAL|Intradialytic exercise intervention|50% aerobic exercise, 50% resistance training thrice a week for 60 min per dialysis session, and health literacy counselling
224232581|NCT03885102|BEHAVIORAL|Usual Care|Usual care with no exercise intervention or health literacy counselling
224232582|NCT03812068|BEHAVIORAL|Long-distance developmental behavioral intervention|Long-distance learning program combined parent-mediated developmental behavioral intervention
223766147|NCT00513422|DIETARY_SUPPLEMENT|Placebo capsules for glucosamine and chondroitin|"Two placebo glucosamine capsules once daily for two years;~Two placebo chondroitin capsules once daily for two years."
224232583|NCT03812068|BEHAVIORAL|Developmental behavioral intervention|Parent-mediated developmental behavioral intervention
223766148|NCT04516161|DRUG|Radium-223 dichloride (Xofigo, BAY88-8223)|Receiving Ra-223 either alone or in combination with other cancer therapies at any time after diagnosis of mCRPC
223647036|NCT06174363|DRUG|Maxigesic|For postoperative analgesia, 50 mcg of fentanyl was administered 15 minutes before the end of surgery, and IV-PCA (fentanyl 1.0 mcg/kg, ramosetron 0.3 mg, total 250cc, infusion rate 5cc/h, bolus 0.5 cc, lock-out time 15min) is started. Additionally, in the Maxigesic group, one vial of Maxigesic (acetaminophen 1000mg/ ibuprofen 300mg) is administered 15 minutes before the end of the surgery, and 2 vials of Maxigesic are added to the IV-PCA.
223647037|NCT06174363|DRUG|0.9% saline solution|For postoperative analgesia, 50 mcg of fentanyl was administered 15 minutes before the end of surgery, and IV-PCA (fentanyl 1.0 mcg/kg, ramosetron 0.3 mg, total 250cc, infusion rate 5cc/h, bolus 0.5 cc, lock-out time 15min) is started. Additionally, in the control group, the same amount of 0.9% saline solution with Maxigesic is administered.
223766149|NCT00795691|BEHAVIORAL|low-carbohydrate diet|ketogenic low-carbohydrate diet in patients with type 2 diabetes
223766150|NCT00795691|BEHAVIORAL|low-fat diet|low-fat diet in patients with type 2 diabetes
224232584|NCT05128188|OTHER|No intervention will be given in this study|No intervention will be given in this study
224232585|NCT05657093|DIETARY_SUPPLEMENT|Beetroot Juice|The swimmers drank 3 hours before the test, mL70 of BJ (containing mmol6.4 of NO-3) (Beet-It-Pro Elite Shot, James White Drinks Ltd., Ipswich, UK) or PLA (0.04 mmol of NO-3)
224232586|NCT05657093|COMBINATION_PRODUCT|Placebo|The swimmers drank 3 hours before the test, mL70 of BJ (containing mmol6.4 of NO-3) (Beet-It-Pro Elite Shot, James White Drinks Ltd., Ipswich, UK) or PLA (0.04 mmol of NO-3)
224232587|NCT00215982|DRUG|capecitabine|Capecitabine will be administered at a dose of 825 mg/m2 PO BID, for a total daily dose of 1650 mg/m2. Capecitabine will be administered on days 1-14 followed by 7 day treatment free rest period and days 21-35 followed by a 7 day treatment-free rest period, every six weeks (42 days) of treatment is considered one cycle.
224232588|NCT00215982|DRUG|Oxaliplatin|Oxaliplatin will be administered at a dose of 130 mg/m2 IV over 120 minutes in 250-500 ML D5W on day 1, every 42 days.
224232589|NCT00215982|DRUG|Irinotecan|Irinotecan will be administered at a dose of 180mg/m2 IV over 90 minutes on day 21 every 42 days.
224232590|NCT02304575|OTHER|Questionnaires|"Questionnaires:~For examinee: European Organization for Research and Treatment of Cancer quality of life questionnaire of 30 items and testicular cancer module of 26 items (EORTC QLQ-30 + QLQ-TC-26), Multidimensional Coping Inventory, The Meaning Test for cognitive function, cognitive orientation questionnaires.~For partner: Multidimensional Inventory of quality of life (QoL) for Adults, Multidimensional Coping Inventory."
224232591|NCT02304575|OTHER|Hormonal Function measurement|Plasma levels of: follicular stimulating hormone (FSH), luteinizing hormone (LH), thyroid-stimulating hormone (TSH), prolactin, free androgen index.
223766151|NCT05281367|PROCEDURE|Breast milk odor group|The researcher applied the breast milk that dripped on the pad for 3 minutes before the heel stick for 36 premature newborns in the breast milk odor group. About three cc breast milk dripped onto a sterile pad and placed at a distance of 10 cm from the nose of the newborn. It continued until 3 minutes after the invasive procedure. Heart rate, arterial oxygen saturation, and respiration rate were recorded in this group before the study. Then, to evaluate the pain in the infants, a video camera was placed on the incubator. The infants in each group were filmed from three minutes before the procedure to three minutes after. Neonatal pain was measured at 1, 2, and 3 minutes before, during, and at 1, 2, and 3 minutes after the procedure by two researchers independently using the new version Premature Infant Pain Profile (PIPP).
223766152|NCT05281367|PROCEDURE|Facilitated tucking group|The Facilitated tucking position was given to 36 premature newborns in the Facilitated tucking group, from 3 minutes before to 3 minutes after the heel stick procedure. Premature newborns were kept in the facilitated tucking position by the investigator using the incubator windows without opening the incubator cover to prevent heat loss of the newborn. Heart rate, arterial oxygen saturation, and respiration rate were recorded in this group before the study. Then, to evaluate the pain in the infants, a video camera was placed on the incubator. The infants in each group were filmed from three minutes before the procedure to three minutes after. Neonatal pain was measured at 1, 2, and 3 minutes before, during, and at 1, 2, and 3 minutes after the procedure by two researchers independently using the new version Premature Infant Pain Profile (PIPP).
223647038|NCT06589089|DRUG|autologous hematopoietic stem cell|Intervention were given myelosuppression occurring that cannot be controlled with other drugs as judged by the investigators
223647039|NCT02357771|DRUG|Probiotic (L. brevis CD2 lozenges)|Each Lactobacillus brevis CD2 lozenge contains not less than 1 billion Colony Forming Unit of L. brevis CD2
223647040|NCT02357771|DRUG|Placebo|Each placebo lozenge contains all excipients except the active constituent (Lactobacillus brevis CD2)
223647041|NCT06603688|DRUG|esomeprazole|Esomeprazole 40mg, twice daily for 14 days.
223647042|NCT06603688|DRUG|Bismuth|Bismuth 220mg, twice daily for 14 days.
223647043|NCT06603688|DRUG|Amoxicillin|Amoxicillin 1000mg, twice daily for 14 days.
223647044|NCT06603688|DRUG|clarithromycin|clarithromycin 500mg, twice daily for 14 days.
223647045|NCT06603688|DRUG|Berberine|Berberine 500 mg, twice daily for 14 days
223647046|NCT06603688|DRUG|Minocycline|Minocycline 100 mg, twice daily for 14 days
223647047|NCT06588374|PROCEDURE|lateral internal sphincterotomy|Hemorrhoidectomy versus Hemorrhoidectomy with lateral internal sphincterotomy
223647048|NCT06654427|BEHAVIORAL|Obstetric Trauma Informed Care Toolkit|The OB-TIC toolkit will include provider and staff training on trauma- informed care and information on trauma-related perinatal concerns; trauma assessment tools; trauma-informed procedure modifications; clinical language guides; patient-facing resources including birth strategies, referral resources, and education; and clinical language. The OB-TIC intervention will utilize the toolkit to integrate trauma-informed care into clinical practice. Implementation strategies will be assessed to determine the most effective method for integrating OB-TIC content into practice.
223647049|NCT06655597|DIETARY_SUPPLEMENT|REDS Powder|Dietary supplement powder
223647050|NCT06313307|COMBINATION_PRODUCT|topical H2R antagonist|Topical H2RA (2% famotidine solution solved in double-distilled water (containing poloxamer 407, glycerol, lauryl alcohol polyether-4, polyethylene glycol-8, and propylene glycol)) was applied topically twice per day in the morning and the evening for 16 weeks.
223647051|NCT06313307|DEVICE|Thulium 1927-nm Fractional Laser|1927nm fractional laser (South Korea, WONTECH, Lavieen) was performed with 4-week interval (Week 0, 4, 8, 12 and 16) for a total of 4 treatments. The parameter of 1927nm fractional laser was as follows: duration 600-800um, 10w, density 0.8mm, 1 pass.
223647052|NCT03812757|DIAGNOSTIC_TEST|Supraclavicular fossa US scanning|As previously stated.
223647053|NCT04372381|DEVICE|Transcatheter aortic valve replacement (Edwards Sapien Ultra or Medtronic Evolut Pro|Treatment of aortic valve stenosis using transcatheter aortic valve replacement
223647054|NCT06984354|BEHAVIORAL|Pain education and clinical hypnosis delivered via a mobile app|Pain education and clinical hypnosis will be delivered via a mobile app. The 8-week intervention includes daily sessions on pain education and clinical hypnosis for managing back pain (5 minutes of education, 15 minutes of listening to hypnotherapy audio and engaging in physical/social activities for 5 minutes). The first six weeks will be semi-standardised, with participants following a set program with the option to repeat sessions. The last two weeks will be flexible, allowing participants to choose a specific program or self-paced continuation of the intervention. Adherence will be monitored by tracking the number of days participants complete sessions, as recorded by the mobile app.
224232592|NCT00455533|DRUG|Ixabepilone|Intravenous Solution, intravenous (IV), 40mg/m², Day 1 every 21 days, 12 Weeks
224232593|NCT00455533|DRUG|Paclitaxel|Intravenous Solution, IV, 80mg/m², Weekly, 12 Weeks
224232594|NCT00455533|DRUG|Cyclophosphamide|Intravenous Solution, IV, 600mg/m², Day 1 every 21 days, 12 Weeks
223647055|NCT06984354|BEHAVIORAL|Guideline-informed factsheet|A single guideline-informed factsheet for back pain delivered via a webpage. Participants will be informed that the factsheet intends to provide reassurance for their back pain and encourage reflections on treatments and self-management options.
223647056|NCT06589973|OTHER|Study Cohort|Clinical records (files) of patients with a diagnosis of admission of alcohol withdrawal syndrome (AAS) who have been treated in the Department of Internal Medicine for 5 years.
223647057|NCT06604559|OTHER|Discharge using Apollo application|Discharge using Apollo application
223647058|NCT06604559|OTHER|Regular discharge|Discharge with the regular process
223647059|NCT06601023|BEHAVIORAL|Psychosocial intervention|The PM+MiLE is a low-intensity intervention. The intervention will cover relevant aspects of brief mindfulness, legal education, awareness of human rights and challenges of complaint, including support. The problem management ambit will include understanding adversity, managing stress, managing problems, getting going and keep doing, strengthening social support and staying well and looking forward, including positive behaviour modification.The intervention will also incorporate child development and building positive parenting interactions with children.
224232595|NCT00455533|DRUG|Doxorubicin|Intravenous Solution, IV, 60mg/m², Day 1 every 21 days, 12 Weeks
224232596|NCT00600626|DRUG|biphasic insulin aspart|
224232597|NCT00600626|DRUG|insulin NPH|
224232598|NCT00600626|DRUG|insulin aspart|
223647060|NCT06593028|BEHAVIORAL|Veggie Vouchers pilot|This intervention aims to increase awareness and use of a Supplemental Nutrition Assistance Program (SNAP) fruit and vegetable incentive program in South Carolina among families with young children experiencing food insecurity. To do so, brief education about this SNAP program is delivered by pediatricians to caregivers during well-child visits. Subsequently, caregivers are given 3 free produce boxes as a free trial of this program to incentivize first time use.
223647061|NCT06596161|DRUG|Iron sucrose|Receving iron
223647062|NCT06596161|DRUG|Placebo|Placebo
223647063|NCT06594861|OTHER|No intervention|No intervention.
223647064|NCT06593808|PROCEDURE|Weaning from the incubator to open coat at a weight greater than or equal to 1400 grams|They will be dressed in a woolen hat and dress, wrapped in a blanket and placed in crib with preheated mattress.Vital signs will be monitored daily.Axillary temperature will be measured every 3 hours for the first 12 hours, if above or equal to 36.5°C it will be measured every 6 hours for the next 36 hours. If normothermia for 48 hours, the preheated mattress will be turned off and temperature monitoring will be continued every 3 hours for 24 hours.If greater than or equal to 36.5°C, thermal control will be continued every 8 hours for 48 hours, at the end of which time, if normothermic, care will be confirmed.If not it will be placed back in the crib with heated mattress.If temperature still below 36.5°C, an additional blanket will be placed and it will be rechecked after 2 hours.If it remains below 36.5°C, the infant will be placed under a radiant lamp and the temperature will be checked after 3 hours.If hypothermia persists, the infant will be transferred back to the incubator.
223647065|NCT06599905|OTHER|Episodic Migraine (EM)|Three stimulus offset trials (OT) and three constant temperature trials (CT) applied to the forehead based on the individual heat pain threshold (HPT).
223647066|NCT06599905|OTHER|Chronic Migraine (CM)|Three stimulus offset trials (OT) and three constant temperature trials (CT) applied to the forehead based on the individual heat pain threshold (HPT).
223647067|NCT04370210|BEHAVIORAL|Questionnaires|Child of both groups enrolled, and their parents, must complete online questionnaires
223766153|NCT05281367|PROCEDURE|Non-nutritive sucking group|36 premature newborns who were in the non-nutritive sucking group were given a silicone pacifier suitable for the week of the baby's mouth from 3 minutes before to 3 minutes after the heel stick. Heart rate, arterial oxygen saturation, and respiration rate were recorded in this group before the study. Then, to evaluate the pain in the infants, a video camera was placed on the incubator. The infants in each group were filmed from three minutes before the procedure to three minutes after. Neonatal pain was measured at 1, 2, and 3 minutes before, during, and at 1, 2, and 3 minutes after the procedure by two researchers independently using the new version Premature Infant Pain Profile (PIPP).
224232599|NCT03594877|DIETARY_SUPPLEMENT|Sublimated mare milk|The dietary supplement mare milk product, which is obtained from fresh (few hours) through sublimation process. This product is first mixed with warm water (37-38 degrees of Celsius) and then will be given to participants.
224232600|NCT02785172|DRUG|IDP-118 Vehicle Lotion|Vehicle
224232601|NCT02785172|DRUG|IDP-118 Vehicle Cream|Vehicle
224232602|NCT02785172|DRUG|IDP-118 Lotion|Lotion
224232603|NCT02785172|DRUG|Ultravate Cream|Cream
224232604|NCT05077852|DIAGNOSTIC_TEST|Urethrocystoscopy|Patients diagnosed with a primary bladder cancer at the base, trigone or neck of the bladder with USG in the urology clinic will be evaluated with urethrocystoscopy. With urethrocystoscopy, patients definitive diagnosed with bladder cancer and IPP.
223647068|NCT04852172|DRUG|L-citrulline|L-citrulline is a naturally occurring amino acid. It is produced by, and normally present in, the human body.
223647069|NCT04852172|OTHER|D5 1/2NS|Saline
223647070|NCT06991504|BEHAVIORAL|Cervical Stabilization Exercises|The main goal of this training is to increase the strength and endurance of the deep cervical flexor and extensor muscles.
223647071|NCT06991504|BEHAVIORAL|vestibular exercises|Vestibular exercises are a training used in individuals with migraine to ensure balance and coordination.
223647072|NCT06991504|BEHAVIORAL|Classic cervical/ neck exercises|Classic cervical neck exercises including stretching and strengthening
223647073|NCT06669845|PROCEDURE|Ultrasonography, Pelvic|Ultrasound measurements will be taken before and after bladder emptying. The axes of the uterine body, cervix and vagina will be marked out by tracing the 3 corresponding lines on the image.
223647074|NCT06993077|OTHER|environment Exposure|No special intervention
223647075|NCT06992479|DEVICE|high-flow nasal cannula oxygen therapy (HFNC) combined with sequential non-invasive ventilation (NIV)|"The control group was treated with NIV routine treatment. During non-invasive ventilation, patients in both the intervention group and the conventional group will receive NIV through a full mask or nasal mask using any of the existing ventilators in the hospital. Usually, the ventilator was set to the pressure support ventilation mode, and the inspiratory pressure was adjusted to the maximum tolerance to obtain the ideal body weight of 6 \~ 8mL / kg of exhaled tidal volume, and the PEEP was set at 3 \~ 5cmH2O. FiO2 in both groups was set to maintain 88% -92% peripheral blood oxygen saturation.~The study group was treated with nasal high-flow oxygen therapy combined with sequential non-invasive ventilation. Patients will receive high-flow oxygen therapy ventilator during the day and in the morning and evening awake time (manufacturer: Hunan Mingkang Zhongjin Medical Technology Co., Ltd., registration number: Xiangji Zhuzhun 20192080049, model: OH60A) treatment. At night (from 10 p.m. to 6"
223647076|NCT06992479|DEVICE|NIV routine treatment|Usually, the ventilator was set to the pressure support ventilation mode, and the inspiratory pressure was adjusted to the maximum tolerance to obtain the ideal body weight of 6 \~ 8mL / kg of exhaled tidal volume, and the PEEP was set at 3 \~ 5cmH2O. FiO2 in both groups was set to maintain 88% -92% peripheral blood oxygen saturation.
224232605|NCT00901368|DRUG|FOSTER|CHF1535 (beclometasone dipropionate 100 µg plus formoterol 6 µg) pMDI aerosol via HFA-134a propellant 2 inhalations b.i.d. (daily dose 400 µg + 24µg)
224232606|NCT00901368|DRUG|Seretide|Fluticasone 250 µg + salmeterol 50 µg DPI (Seretide® Diskus®) 1 inhalation b.i.d. (daily dose 500+100 µg)
224232607|NCT00800059|RADIATION|Total Marrow Irradiation|Total Marrow Irradiation delivered by chemotherapy delivered to cohorts of patients in a dose escalation. The initial cohort will receive 14 Gy. If tolerated subsequent cohorts will receive an additional 2 Gy until the maximum tolerated dose or 28 Gy is reached.
224320033|NCT02567435|DRUG|Cyclophosphamide|Given IV and PO
224320034|NCT02567435|BIOLOGICAL|Dactinomycin|Given IV
224320035|NCT02567435|DRUG|Irinotecan Hydrochloride|Given IV
224320036|NCT02567435|OTHER|Laboratory Biomarker Analysis|Correlative studies
223766154|NCT05281367|PROCEDURE|Control group|"The control group will consist of 36 premature newborns who are routinely applied in the clinic. In the clinic where the research was conducted, no attempt is made to reduce pain during heel stick. Heart rate, arterial oxygen saturation, and respiration rate were recorded in this group before the study.~Then, to evaluate the pain in the infants, a video camera was placed on the incubator. The infants in each group were filmed from three minutes before the procedure to three minutes after. Neonatal pain was measured at 1, 2, and 3 minutes before, during, and at 1, 2, and 3 minutes after the procedure by two researchers independently using the new version Premature Infant Pain Profile (PIPP)."
223766155|NCT03370341|DEVICE|active anodal tDCS|active anodal tDCS with behavioral tasks to assess IA
223766156|NCT03370341|DEVICE|sham tDCS|sham tDCS with behavioral tasks to assess IA
223766157|NCT02449356|DEVICE|prone position endotracheal tube(PPT)|some special kind of endotracheal tube,including traditional air tube ,fixed device, fixed rope, and two through holes
223766158|NCT01636141|DRUG|OLT1177 Gel|OLT1177 Gel - 3% or 5% administered topically to a defined area of one knee
223766159|NCT01636141|DRUG|Placebo gel|
223766160|NCT04486287|DRUG|Sintilimab|"Sintilimab 200mg IV, every 3 weeks, until progressive disease (PD), intolerable toxicity, or at a maximum of 12 months.~Before enrollment, patient should undergo Stereotactic Ablation Brachytherapy. Sintilimab shall be started no later than 4 weeks after Stereotactic Ablation Brachytherapy."
223766161|NCT02078739|BEHAVIORAL|Yoga Program at home using internet technology|
223766162|NCT04913493|PROCEDURE|Cytocam-IDF|Patients receive an extra medical imaging test perioperatively with the Cytocam-IDF
224232608|NCT06528717|PROCEDURE|Carotid graft interposition|In patients with extensive atherosclerotic carotid disease, when endarterectomy isn't feasible, replacement of the carotid artery with a graft is needed. Graft interposition can be performed either by end-to-end proximal and distal anastomoses in the undiseased common and internal carotid artery with ligation of the external carotid artery, or by side-to-end proximal anastomosis on the origin of the internal carotid artery and end-to-end distal anastomosis on the internal carotid artery with flow preservation in the external carotid artery.
224232609|NCT02576990|BIOLOGICAL|Pembrolizumab|IV infusion
224232610|NCT05017233|DEVICE|Spectral CT|Using Spectral CT to scan Breast
224232611|NCT04450290|DEVICE|CIDEXEL implant|The newly developed MED-EL Cochlear Implant incorporates the anti-inflammatory agent dexamethasone (DEX) into the electrode array. The passive elution of DEX during the post-implantation period has the purpose of counteracting the increase of the post-operative impedance induced by the insertion trauma.
224232612|NCT04650100|PROCEDURE|ultrasound-guided PENG bloc realized before surgery|ultrasound-guided PENG block realized before surgery. The PENG block, described by Giron-Arebgi is made in the supine position. The ultrasound probe used is a 5 MHz high frequency linear probe placed parallel to the line delimited by the anterior-inferior iliac spine (lateral) and the pubis (medial). The needle used is an 80 mm, 22G, needle inserted in the ultrasound plane. The slow and fractioned injection of 20 ml of Ropivacaine 4.75 mg/ml is performed in the fascia between the psoas tendon and the iliopubic eminence under ultrasound guidance.
224232613|NCT00762671|DRUG|Ebselen|150 mg BID for 2 weeks
224232614|NCT00762671|DRUG|Placebo|Placebo 1 po BID for 2 weeks
224232615|NCT02907008|OTHER|Polysomnography|
224232616|NCT02415959|DRUG|Creon IR|
223647077|NCT06518057|PROCEDURE|Biospecimen Collection|Undergo CSF sample collection
223647078|NCT06518057|PROCEDURE|Computed Tomography|Undergo PET/CT and/or CT
223647079|NCT06518057|OTHER|Electronic Health Record Review|Ancillary studies
223647080|NCT06518057|PROCEDURE|Lumbar Puncture|Undergo lumbar puncture
223647081|NCT06518057|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223647082|NCT06518057|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
223647083|NCT06518057|RADIATION|Proton Beam Craniospinal Irradiation|Undergo proton CSI
223647084|NCT06518057|OTHER|Survey Administration|Ancillary studies
223647085|NCT06518057|RADIATION|Volume Modulated Arc Therapy|Undergo photon VMAT CSI
224232617|NCT02415959|DRUG|Creon® (DR/GR)|
223647086|NCT06518057|PROCEDURE|Hippocampal-Avoidance Craniospinal Irradiation|Undergo HA
223647087|NCT06612788|DEVICE|Exablate Model 4000 Type 2.0/2.1|There are two treatment stages. In both stages, the subject will receive both the sham and active ExAblate treatment, and be evaluated for 90 days post-treatment for adverse events. During Stage 1 the subject will receive the moderate intensity Exablate LIFU procedure. During Stage2, the subject will receive the enhanced intensity ExAblate LIFU procedure. The subjects are blinded as to the order of the sham vs active treatment.
223647088|NCT04574960|DRUG|Gemcitabine|Gemcitabine 1000 mg/m\^2, IV infusion on days 1 and 8 of each 3-week cycle
223766163|NCT00960700|DEVICE|Visual Acuity|Assessment of visual acuity
223766164|NCT00960700|DEVICE|Contrast sensitivity|Assessment of contrast sensitivity
223766165|NCT00960700|DEVICE|Reading Speed|Assessment of reading speed
223766166|NCT00960700|PROCEDURE|Eye Health|Examination of eye health through use of a slitlamp/ photography. Assessment of Intraocular Pressure.
223766167|NCT01072487|PROCEDURE|Capnography|Monitoring of the capnography curve for early detection of apnea
223766168|NCT06108856|DEVICE|Hemodialysis machine|machine by which people undergo dialysis on it.
223766169|NCT01707004|DRUG|decitabine|Given IV
223766170|NCT01707004|DRUG|fludarabine phosphate|Given IV
223766171|NCT01707004|DRUG|busulfan|Given IV
223766172|NCT01707004|DRUG|cyclophosphamide|Given IV
223766173|NCT01707004|DRUG|tacrolimus|Given PO or IV
223766174|NCT01707004|DRUG|mycophenolate mofetil|Given PO
223766175|NCT01707004|BIOLOGICAL|filgrastim|Given SC
223766176|NCT01707004|RADIATION|total-body irradiation|Undergo total-body irradiation
223766177|NCT01707004|PROCEDURE|allogeneic bone marrow transplantation|Undergo allogeneic bone marrow transplantation
223766178|NCT01707004|OTHER|laboratory biomarker analysis|Correlative studies
223766179|NCT03488576|PROCEDURE|Complete Macular Peeling|A complete peeling of the internal limiting membrane was performed
223766180|NCT03488576|PROCEDURE|Macular Peeling with Foveal Sparing|A partial peeling of the internal limiting membrane was performed, sparing the fovea.
224232618|NCT04433481|DRUG|Dabigatran|T. Dabigatran 150 mg twice a day
224232619|NCT04433481|OTHER|Placebo|placebo
224232620|NCT01881399|DEVICE|Fluorescence cholangiography (da Vinci surgical system)|Patients will received IV injection of ICG intra-operatively, allowing surgeons to view bile ducts under fluorescence imaging using the da Vinci surgical system with fluorescence Imaging system.
224232621|NCT01881399|OTHER|Virtual cholangiography|Images from virtual cholangiography will be superimposed in real time on images obtained with fluorescence.
224232622|NCT01881399|PROCEDURE|Conventional IOC|Patients will undergo conventional intraoperative cholangiography (with use of radio-opaque dye), allowing surgeons to view bile ducts under Rx imaging.
224232623|NCT03342703|DIAGNOSTIC_TEST|Ultrasound|Patients will undergo a standard liver US protocol for approximately 15 minutes.
224232624|NCT05728632|DRUG|Nebivolol|Nebivolol, capsule, 5 mg once daily, for 12 months
224232625|NCT05728632|DRUG|Placebo|Placebo, capsule, once daily, for 12 months
224232626|NCT02484820|DEVICE|Silicone pessary|Silicone pessary is used between 24 weeks of pregnancy and up to 6 weeks after the date of the term (maximum 6 months)
224232627|NCT00911859|DRUG|Siltuximab11 mg/kg|Participants will receive siltuximab 11 mg/kg as a 1-hour intravenous infusion every 3 weeks in Part 1.
224232628|NCT00911859|DRUG|Siltuximab 8.3 mg/kg or 11 mg/kg|Participants will receive siltuximab 8.3 mg/kg or 11 mg/kg as a 1-hour intravenous infusion every 3 weeks for 9 cycles of treatment in Part 2, Arm A and in maintenance period.
224232629|NCT00911859|DRUG|Velcade (bortezomib)|Participants will receive Velcade 1.3 mg/m2 as an intravenous bolus injection according to the current approved package insert in Part 1.
224232630|NCT00911859|DRUG|Velcade (bortezomib)|Participants will receive Velcade 1.3 mg/m2 as an intravenous bolus injection for 9 cycles of the treatment period in Part 2. It will be administered twice weekly for first 4 cycles (on Days 1, 4, 8, 11, 22, 25, 29, and 32, followed by a 10-day rest period) and once weekly for next 5 cycles (on Days 1, 8, 22, and 29, followed by a 13-day rest period)
224232631|NCT00911859|DRUG|Melphalan|Participants will take melphalan 9 mg/m2 will be administered orally on Days 1 to 4, followed by a 38-day rest period in Part 1.
224232632|NCT00911859|DRUG|Melphalan|Participants will receive melphalan according to currently approved package inserts. Melphalan 9 mg/m2 will be administered orally for 9 cycles of treatment period in Part 2, Arm A.
224232633|NCT00911859|DRUG|Prednisone|Participants will take prednisone 60 mg/m2 will be administered orally on Days 1 to 4, followed by a 38-day rest period in Part 1.
224232634|NCT00911859|DRUG|Prednisone|Participants will take prednisone 60 mg/m2 orally for 9 cycles of treatment period in Part 2, Arm A.
223647089|NCT04574960|DRUG|Cisplatin|Cisplatin 70 mg/m\^2, IV infusion on day 1 of each 3-week cycle
223647090|NCT04574960|DRUG|Carboplatin|Carboplatin AUC 5-6 calculated using the Calvert formula on day 1 of each cycle
223647091|NCT06175104|BEHAVIORAL|HeartGPS|"HeartGPS includes three key components:~1. Sessions with a psychologist trained to deliver the intervention using attachment-based and trauma-informed therapy techniques, coupled with mind-body skills. The intervention can be delivered in-person or via telehealth, in accordance with participants' preferences.~2. Educational resources, including a series of modules to complement the sessions and evidence-based tools to support psychological adjustment and coping, parent-infant bonding and attachment, and parent-clinician communication.~3. A personalized care plan, charting mental health care needs, goals, and preferences, with evidence-based strategies to support longer-term wellbeing."
223647092|NCT06707493|DRUG|Ivosidenib|Ivosidenib tablets are supplied as 50 mg, 200 mg, and 250 mg strengths, to be taken orally.
223647093|NCT06707493|DRUG|Placebo|Placebo tablets are taken orally.
223647094|NCT06716866|DEVICE|temporally-interfering electric field stimulation|Temporally-interfering electric field stimulation is a candidate non-invasive means to stimulate and modulate the nervous system. We do not know of any other trials of this method in epilepsy patients.
223647095|NCT05560607|DRUG|AZD7503 Intervention|"Part A: Participants will be screened for histologic evidence of NAFLD or NASH and all eligibility criteria in part A prior to enrollment in part B.~Part B: Participants consented to part B will be administered the study drug over the course of 31 days. At the end of the study a liver biopsy will be collected to measure for endpoints."
223647096|NCT07040917|DRUG|CAR-T cell|CAR-T cell
223647097|NCT06720220|DRUG|Dexmedetomidine Hydrochloride|"procedural sedation by I.V. infusion of dexmedetomidine. It was prepared as 200 ug (2 ml) of dexmedetomidine added to 48 ml of 0.9% saline.~A loading dose of dexmedetomidine 0.5 to 1 ug/kg was given over 10- 20 minutes, followed by 0.2-0.7 ug/kg/hr as a continuous infusion by a syringe pump. During the dexmedetomidine infusion, a spontaneous respiratory pattern was maintained, and the level of sedation achieved to a point of semi-sleep but responds to commands (equivalent to Modified Ramsay Sedation Scale score of 3)."
223647098|NCT06720220|OTHER|Nebulization|nebulization session through a face mask nebulizer attached to an oxygen source. The nebulizer chamber was filled with 10 ml of 2% lidocaine (200 mg). The oxygen flow was adjusted at a rate of 8-10 L/min for 10-15 minutes.
223647099|NCT06720220|OTHER|Atomization|"Airway topicalization by atomization (through a modification of McKenzie technique). This modification utilizes a 10-Fr suction catheter instead of 20-gauge cannula. This suction catheter was attached to oxygen tubing with a three-way stopcock. The oxygen tubing was attached to an oxygen source, which delivers a flow of 2-4 L/min. A 10-ml syringe filled with 10 ml of lidocaine 2% was attached to top port of the three-way stopcock.~Local anesthetic was injected via the syringe forming a jet- like spray for topicalization of the nasal and oral mucosa"
223766181|NCT02042976|BEHAVIORAL|Mindfulness-based cognitive therapy|
223766182|NCT02042976|BEHAVIORAL|Pulmonary rehabilitation|
223766183|NCT04865822|BEHAVIORAL|Single session pain education class|Pain education classes will be provided in person group or virtual settings
223766184|NCT03132597|BEHAVIORAL|Mindfulness training|six weeks of 2 hours class of mindfulness training and orientations for home training
223766185|NCT02188368|DRUG|POM|
223766186|NCT02188368|DRUG|Steroids|
223766187|NCT02188368|DRUG|PLD|
223766188|NCT02188368|DRUG|CFZ|
223766189|NCT02188368|DRUG|BTZ|
223766190|NCT02188368|DRUG|CLA|
223766191|NCT02188368|DRUG|CY|
223766192|NCT06028867|PROCEDURE|Non-surgical periodontal treatment|Subgingival biofilm ultrasonic debridement
224232635|NCT00911859|DRUG|Velcade (bortezomib)|Participants will receive Velcade 1.3 mg/m2 as an intravenous bolus injection according to the current approved package insert.
224232636|NCT00911859|DRUG|Melphalan|Participants will take melphalan 9 mg/m2 orally according to currently approved package insert.
224232637|NCT00911859|DRUG|Prednisone|Participants will take prednisone 60 mg/m2 orally according to the package insert.
224232638|NCT03880279|BIOLOGICAL|TAC01-CD19|Dose-escalating cohorts plus expansion groups
224232639|NCT00200031|DEVICE|Interstim therapy|
224232640|NCT00021502|DRUG|pyridoxalated hemoglobin polyoxyethylene conjugate (PHP)|
224232641|NCT01048333|DRUG|Formoterol|Formoterol Turbuhaler 9 μg and Placebo Diskus
224232642|NCT01048333|DRUG|Salmeterol|Salmeterol Diskus 50 μg and Placebo Turbuhaler
224232643|NCT01048333|DRUG|Placebo|Placebo Diskus and Placebo Turbuhaler
224232644|NCT01396044|OTHER|Electronic checklist|Electronic checklist for process of care issues implemented in our institution. Training on a regular basis of the electronic checklist arm to use the electronic checklist. Process of care issues on the electronic checklist include several that are under investigation: antibiotics and mechanical ventilation.
224232645|NCT01396044|OTHER|Verbal prompting|Prompting by study investigators of physicians on the verbal prompting arm. Prompting will include questions related to antibiotic utilization and mechanical ventilation weaning.
224232646|NCT01403883|BEHAVIORAL|Standard Care|Psychological \& enterostomal therapy clinics on demand only
224232647|NCT01403883|BEHAVIORAL|Optimal care (Psychological and enterostomal therapy clinics)|Psychological clinics at D-45, D0, D45, D60, D90 enterostomal therapy clinics at D-45, D0, D45, D60
224232648|NCT04784117|OTHER|Dispatcher protocol change|In the beginning of 2019 dispatcher protocol was changed to shorten the time of death detection
224232649|NCT04582227|DEVICE|Ambu aura-i LMA|The ETT or the LMA will be inserted with the patient's head position is aided either by pins or head rest, and either the head will be in neutral position or tilted as long as the airway device is successfully placed.
224232650|NCT01962883|OTHER|Osteopathic treatment|"The following treatment protocol is an outline only; structures will be treated only if the dysfunction was present during the evaluation.~Week 1: Venous Sinuses, diaphragms, major cranial compactions, sphenobasilar symphysis normalization and dural release~Week 2 Non-Physiological without respect of axis dysfunction in cranium, spine, pelvis, ankle. Non-physiological with respect of axis dysfunctions in the cranium. Temporal and orbital sutures.~Week 3 Non-Physiological with respect of axis dysfunction lesions within the spine, pelvis and ankle. Visceral tissues: kidneys, liver, spleen, heart. Cerebral hemisphere and lateral ventricles.~Week 4 Physiological dysfunctions within the cranium, spine, pelvis, and ankle. Myofascial restrictions and muscles of the jaw and eye."
224232651|NCT02456909|DEVICE|Patient-Controlled Analgesia pump with Cues|The end of the lockout period will be cued via the PCA pump
223647100|NCT06720220|OTHER|Spray-As-You-Go|airway topicalization method using the fiberoptic bronchoscope itself. The fiberoptic bronchoscope, preloaded with a 6.5 or 7 mm endotracheal tube, was passed under direct vision through the nose into the pharynx. Then 10-ml syringe containing 10 ml Lidocaine 2%, was attached to the working channel, and thus the local anesthetic was sprayed towards the mucosa of postnasal space and back of throat, while advancing the fiberscope. At the level of the epiglottis and around the vocal cords 2-4 ml of lidocaine 2% were sprayed toward these structures as the patient takes a deep breath to achieve sufficient anesthesia to the laryngeal inlet. The patient was asked to take another deep breath as the scope was passed through the vocal cords and 2 ml of lidocaine 2% is sprayed to the trachea and the scope was advanced further until the carina was visualized.
223647101|NCT06877377|BIOLOGICAL|hDNAgr Therapy|A novel investigational therapy that uses fragmented therapeutic double-stranded DNA, designed to correct or replace locally damaged genomic regions in hematopoietic stem cells and elongate telomeres. The hDNAgr therapy is administered according to the study protocol schedule (Visits at Day 0, 14, 28, 60, 90, and 180), with blood draws and safety evaluations at each time point to assess hematological parameters, telomere length, and potential impacts on biological aging.
223647102|NCT06877377|OTHER|Placebo|An inactive formulation identical in appearance to the hDNAgr therapy but lacking the active DNA fragments. It is administered under the same schedule and conditions as the experimental intervention to maintain blinding and enable comparison of safety and efficacy outcomes.
223647103|NCT06718452|DIETARY_SUPPLEMENT|PEA-LUT 1 sachet|1 dose day to be absorbed sublingually
223647104|NCT06718452|DIETARY_SUPPLEMENT|PEA-LUT 2 sachet day|1 sachet two times a day to be sublingually absorbed
223647105|NCT06718452|DIETARY_SUPPLEMENT|Placebo|Same administration of PEA-LUT
223647106|NCT07046221|DRUG|Tislelizumab|200mg，d1，q3w，1years
223647107|NCT07046221|DRUG|Albumin-Bound Paclitaxel|125mg/m2，d1，d8，q3w，2cycles
223647108|NCT07046221|DRUG|cis-platinum|75mg/m2，d1，q3w，2cycles
223647109|NCT07046221|PROCEDURE|Surgery|Radical resection of esophageal cancer
223647110|NCT07046221|RADIATION|Radiation|50.5Gy/28f
224232652|NCT02456909|DEVICE|Patient-Controlled Analgesia pump without Cues|The PCA pump will be programmed such that no cues will be provided to the end of the lockout period.
224232653|NCT02456909|DRUG|Morphine|Morphine will be administered for post-operative pain in both the Cues and Non-Cues groups
224232654|NCT01250158|DEVICE|Liver-PILP kit|"Device: Liver-PILP kit The Liver-PILP kit (three devices) is composed of percutaneous, disposable (single-use), catheter-based devices for targeted, isolated, organ specific (liver), drug delivery and perfusion with high dose drugs.~1. The Portal Vein Device (PVD): balloon catheter to occlude the portal vein and allow aspiration through a central lumen for portal veno-venous bypass.~2. The Hepatic Artery Device (HAD): balloon catheter to occlude arterial flow to the liver.~3. The Vena Cava Device (VCD): catheter based device to isolate and access hepatic outflow to vena cava by creating a closed chamber in vena cava at ostia of the hepatic veins while maintaining central vena cava blood flow from lower extremities to right atrium through reduced central lumen."
224232655|NCT04604639|DIAGNOSTIC_TEST|NEWS2 score|Patients seen by ambulance crews within the preceeding 48 hrs of their cardiac arrest will have a NEWS2 score performed to assess the level of physiological deterioration at the time of thei intial assessment.
224320037|NCT02567435|OTHER|Questionnaire Administration|Ancillary studies
223647111|NCT07046221|DRUG|Nedaplatin|80-100mg/m2，d1，q3w，2cycles
223647112|NCT07046221|DRUG|Carboplatin|AUC=5，d1，q3w，2cycles
223647113|NCT06736262|DRUG|Briquilimab|No additional details needed
223766193|NCT04657159|OTHER|Pain rehabilitation program|Effect on health related quality of life och health-care consumption after rehabilitation
224232656|NCT04464135|OTHER|acetic acid staining|The water exchange colonoscopy is used during insertion procedure, in which the water contains 1% acetic acid, and the liquid is absorbed during the withdrawal process for observation.
224232657|NCT04464135|OTHER|Water exchange colonoscopy|The water exchange colonoscopy is used during insertion procedure, and the liquid is absorbed during the withdrawal process for observation.
224232658|NCT04203680|DRUG|HTK cardioplegic solution|30 ml/kg of HTK cardioplegic solution at 4°C through an antegrade fashion at an initial perfusion pressure of 80-100 mmHg
224232659|NCT04203680|DRUG|blood cardioplegia|one liter of blood cardioplegia was given with the antegrade route at 30°C, or lower. Blood maintenance cardioplegia was repeated every 30-45mins
224232660|NCT06354244|DEVICE|Electroacupuncture of 2 sessions per week|Acupoints including bilateral BL23, BL32, BL33, BL35 and SP6 are inserted with acupuncture needles(size 0.30 × 40 mm and 0.30 × 75 mm or 0.40 × 100 mm,Hwato Brand). Bilateral BL32 and BL33 are needled to a depth of 70-95 mm with an angle of 60°-75° inward and downward, into the second and third sacral foramen. Bilateral BL35 are needled to a depth of 60-70 mm in a slightly superolateral direction. Bilateral BL23 and SP6 are vertically needled to a depth of 25-30 mm. After deqi is evoked, electric stimulators with a 5Hz continuous wave (5-10 mA intensity) are separately connected to bilateral BL32, BL33,BL35 and SP6. Current intensity is adjusted according to the patients' individual tolerance. During each session, electroacupuncture(EA) is retained for 30 minutes. The patients receive EA 2 sessions per week for 2-24 weeks.EA can be terminated if the patient acquire satisfactory spontaneous urination.
224320038|NCT02567435|RADIATION|Radiation Therapy|Undergo RT
224320039|NCT02567435|DRUG|Temsirolimus|Given IV
223647114|NCT06428006|BEHAVIORAL|Cognitive behavioral therapy for insomnia|"The general sessions outlines are as follows with each session:~Session 1: determine treatment plan, set up sleep schedule and stimulus control, discuss strategies for how to stay awake to prescribed hour and what to do if wake up in middle of night, sleep hygiene education Session 2: continue upward titration of total sleep time, review sleep hygiene; introduce diaphragmatic breathing Session 3: continue upward titration of total sleep time, introduce mindfulness Session 4: continue upward titration of total sleep time, introduce progressive muscle relaxation Session 5: continue upward titration of total sleep time, discuss negative sleep beliefs Session 6: assess global treatment gains, discuss relapse prevention"
223647115|NCT06428006|BEHAVIORAL|Sleep and lifestyle education|"The general sessions outlines are as follows with each session:~Session 1: Basic sleep education, stretching exercises Session 2: Sleep hygiene education (environmental factors \& sleep positions), stretching exercises Session 3: Sleep hygiene education (lifestyle factors), stretching exercises Session 4: Diet recommendations, stretching exercises Session 5: Exercises recommendations, stretching exercises Session 6: Discus maintaining achievements \& preventing relapses, stretching exercises"
223647116|NCT06891001|DEVICE|Unilateral neutral shoe insert|In the treatment group, subjects will undergo the addition of a neutral shoe insert to the involved lower extremity according to manufacturer guidelines at the initial visit. These subjects will also undergo a once-weekly 12-week course of physical therapy according to the established standardized protocol.
223647117|NCT06891001|DEVICE|Bilateral Shoe Insert|For subjects placed in the sham group, subjects will undergo the addition of a neutral shoe insert to both lower extremities according to manufacturer guidelines at the initial visit. These subjects will also undergo a once-weekly 12-week course of physical therapy according to the established standardized protocol with guidelines .
223647118|NCT06891001|OTHER|Physical Therapy|For subjects placed in the control group, subjects will undergo a once-weekly 12-week course of physical therapy according to the established standardized protocol.
223647119|NCT06891417|BIOLOGICAL|Chlamydia mRNA Vaccine|"Pharmaceutical Form: Suspension for injection~Route of Administration:~Intramuscular injection"
223647120|NCT06891417|OTHER|Placebo|"Pharmaceutical Form:~Solution for injection~Route of Administration:~Intramuscular injection"
223647121|NCT06743958|OTHER|Exercise intervention|Specific strength and balance training intervention during neoadjuvant chemotherapy, twice per week for 30 min, progression according to individual status
223647122|NCT06740747|DEVICE|Intermittent theta-burst stimulation|Intermittent theta-burst stimulation, applied sequentially to the cerebellar vermis and the left dorsolateral prefrontal cortex
223647123|NCT06740747|DEVICE|Sham intermittent theta-burst stimulation|Sham intermittent theta-burst stimulation, applied sequentially to the cerebellar vermis and the left dorsolateral prefrontal cortex
223647124|NCT06746116|DRUG|Durvalumab + Chemotherapy phase|Durvalumab (IV) with SoC (carboplatin + paclitaxel chemotherapy: patients should receive at least 4, but preferably 6 cycles) every three weeks.
223647125|NCT06746116|DRUG|Durvalumab + Olaparib phase|durvalumab (IV) with olaparib (tablets) every four weeks until progression.
223647126|NCT06845566|BEHAVIORAL|Compensation Based Problem Solving Therapy|"Compensation-Based Problem Solving Therapy (CB-PST) is a therapeutic approach based on the occupational adaptation model. It entails the implementation of compensatory strategies with the objective of enhancing the performance of both extremities in daily life activities. The therapy encompasses the implementation of problem-solving training. The occupational problem is defined. The development of compensation-focused strategies is based on the personal factors and occupational environment identified as relevant to the problematic occupation, as determined according to the principles of the occupational adaptation model. Once a compensatory strategy has been selected, the next step is to apply it and evaluate its efficacy, with the expectation that an adaptive response will be observed, and that the resulting adaptation will be reflected in improved occupational performance, as guided by the occupational adaptation model."
223647127|NCT06845566|BEHAVIORAL|standard rehabilitation|The standard rehabilitation program is provided to all individuals in the inpatient service on an equal basis. The program allows individuals to utilize the physiotherapy and occupational therapy units on a weekly basis, with access available on weekdays. These units are staffed by physiotherapists and occupational therapists. All individuals included in the study received the same service from the same therapists at the same times in a homogeneous manner. All individuals received physiotherapy, electrotherapy, and hydrotherapy as part of this service. In the physiotherapy unit, the first intervention was 25 minutes of electrotherapy for the upper extremity. This was followed by 40 minutes of physiotherapy exercises, conducted with the assistance of a physiotherapist. The final component of the physiotherapy unit programme was 15 minutes of hydrotherapy. In the occupational therapy unit, a standard 40-minute occupational therapy was completed
224232661|NCT06354244|DEVICE|Electroacupuncture of 3 sessions per week|Acupoints and electroacupuncture (EA) procedures are the same as in the group of EA of 2 sessions per week, but the patients receive EA 3 sessions per week for 2-24 weeks in this group.EA can be terminated if the patient acquire satisfactory spontaneous urination.
224232662|NCT06354244|DEVICE|Electroacupuncture of 4 sessions per week|Acupoints and electroacupuncture (EA) procedures are the same as in the group of EA of 2 sessions per week, but the patients receive EA 4 sessions per week for 2-24 weeks in this group.EA can be terminated if the patient acquire satisfactory spontaneous urination.
224232663|NCT02367495|DEVICE|PCB|PCB with Citrate-based excipient
224232664|NCT03923595|OTHER|Adherence intervention research|dedicated management
224232665|NCT03482713|DRUG|Gefapixant 45 mg|Gefapixant 45 mg (film-coated tablet) to be administered orally BID
224232666|NCT03482713|DRUG|Placebo|Placebo (film-coated tablet) matching gefapixant to be administered orally BID
224232667|NCT06087809|BEHAVIORAL|Education and feedback|"Clinicians within practices assigned to the Education/Feedback group received a personal email from one of the authors at the outset of the project explaining that the Committee on Infectious Diseases of the American Academy of Pediatrics (the Red Book Committee) recommends limiting the duration of antibiotic treatment for uncomplicated CAP to 5 days and for uncomplicated SSTI to 5-7 days. The email also shared data on the performance of the individual PCC and their practice for CAP and SSTI for the baseline period and the goals for each-50% for CAP and 67% for SST. An infographic was also attached to the email which could be printed and displayed in the PCC's work area. One month and two months into the project period, each PCC in the Education/Feedback group received an email reminding them of the recommendations and updating them on their performance since the previous email."
224232668|NCT06087809|BEHAVIORAL|Clinical decision support|"Clinicians within practices assigned to the CDS group did not receive education or any performance feedback relative to the initiative. If they prescribed an antibiotic linked to a diagnosis of CAP with a duration of greater than 5 days, or to a diagnosis of SSTI with a duration greater than 7 days, they received a pop-up advisory when they attempted to sign the prescription alerting them to the relevant recommendation (eFigure 3). The alert was a hard stop, meaning that the prescriber was required to respond in some way to continue their work. Options included altering the prescription to comply with the recommended duration or acknowledging the alert and sending the prescription with the originally selected duration."
224320040|NCT02567435|DRUG|Vincristine Sulfate|Given IV
224320041|NCT02567435|DRUG|Vinorelbine|Given IV
224320042|NCT05802797|OTHER|Algae Oil Fortified Soymilk|Flavored soymilk beverage fortified with 0.4% algae oil with both EPA and DHA
224320043|NCT05802797|DIETARY_SUPPLEMENT|Algae Oil Capsule|Algae oil capsules with EPA and DHA
223647128|NCT05298956|OTHER|Low-level laser therapy (LLLT)|"Sham Comparator: Participants will receive 8 counts of 60 seconds of the same laser to the right forehead, however the laser power will be turned off and will be 0 Watts.~Transcranial infrared laser stimulation: Participants will receive 8 counts of 60 seconds of transcranial infrared laser stimulation to the right forehead. The wavelength will be 1064 nm and the laser power will be 3.4 Watts."
223647129|NCT07054723|BEHAVIORAL|Mobile Daily Diary|This study will include a 14-day daily diary survey in which participants will be expected to complete morning (\~5 minutes) and night (\~10 minutes) assessments using mobile phones provided by the research team.
223647130|NCT06420999|OTHER|Diaphragmatic ultrasound and data collection|At the inclusion visit, anamnestic data available in the medical record and clinical data (vitals, chest X-ray) will be collected. At the same time, a diaphragmatic ultrasound will be performed in the half-seated position to measure diaphragmatic excursion and the thickening fraction of the right hemi-diaphragm at rest. A follow-up visit will be made on the day of discharge from intensive care, during which diaphragmatic ultrasound will be performed At D90 (+/- 15 days), the following information will be collected by consulting the electronic medical record, or by telephone if the information is not available in the record: date of discharge from hospital, date of death, date and reason for readmission to hospital or intensive care, possible introduction of long-term non-invasive ventilation, new respiratory complication after discharge from intensive care (pneumonia, atelectasis).
224232669|NCT06463964|DIAGNOSTIC_TEST|Serum Creatinine|Laborataries for prediction of AKi in patients with ADHF
224232670|NCT01497938|DEVICE|Medtronic MMT-754 Veo Insulin pump testing Low Glucose Suspend (LGS) feature|Automatic suspension of insulin delivery when glucose is low.
224232671|NCT01497938|DEVICE|Medtronic (NO LGS FEATURE ) using Paradigm® Revel™2.0 Pump|No Automatic suspension of insulin delivery when glucose is low.
224232672|NCT02210403|DEVICE|transcranial direct current stimulation (tDCS)|
224232673|NCT01823003|RADIATION|34 Gy in a single fraction|34 Gy in a single fraction in case of Distance to chest wall \> 1 cm, tumour size \< 2 cm and distance to the main bronchus \> 2 cm. STEREOTACTIC ABLATIVE RADIOTHERAPY (SABR) will be administered with volumetric modulated arcs, with photon beam energy of 6-10 MV. The number of arcs and their ballistic is left undefined in order to allow for optimization of the dose distribution. Bolus is not allowed.
224232674|NCT01823003|RADIATION|54Gy 18Gy/fr. x 3 fractions|54Gy administered in 3 fractions of 18Gy in case of distance to chest wall \> 1 cm, tumour size between 2 and 5 cm and distance to the main bronchus \> 2 cm. STEREOTACTIC ABLATIVE RADIOTHERAPY (SABR)will be administered with volumetric modulated arcs, with photon beam energy of 6-10 MV. The number of arcs and their ballistic is left undefined in order to allow for optimization of the dose distribution. Bolus is not allowed.
224320044|NCT02091791|PROCEDURE|Traction sessions|
224320045|NCT03765788|DRUG|Secukinumab 300 mg, s.c.|Secukinumab 300 mg was administered by subcutaneous (s.c.) injections using 1 mL pre-filled syringes (PFSs) throughout the study.
224320046|NCT03765788|DRUG|Prednisolone|Prednisolone was provided as tablets (1 mg, 5 mg, 10 mg, 20 mg tablets) for daily administration as tapered regimen from a dose of 25 mg to 60 mg at Baseline to 1 mg at Week 26 (last dose)
224320047|NCT03765788|DRUG|Placebo|Placebo 300 mg was administered by subcutaneous (s.c.) injections using 1 mL pre-filled syringes (PFSs) throughout the study.
224320048|NCT01534169|DRUG|Dexamethasone|The course of treatment will be last for 3 months. The intrathyroid injection of dexamethasone will be performed using a 25-gauge (0.25-mm) needle under ultrasound guidance. The injection will be performed in both lobes of the thyroid. The dosage of dexamethasone is 5mg (1.0 ml) in each lobe, twice a week during the first month of the treatment. The treatment strategy will be changed to once a week in the second month and twice a month in the third month; the dosage of dexamethasone is the same as in the first month.
223647131|NCT06132373|BEHAVIORAL|Peer delivered problem solving therapy|PST uses a straightforward approach amenable to use in new settings given its focus on idiographic problems, therefore session content is driven by the adolescent's presenting problem causing the most distress or impairment. We will use the standardized, core steps of PST and existing manualized protocols including from the Friendship Bench study and the WHO protocol for Problem Management Plus. The peers will deliver PST through 5 structured counseling sessions of 30-60 minutes over a 4-6 week period. There are 5 core components of PST which including problem listing and identification, problem exploration, developing an action plan, implementation, and follow up. The components will be introduced in the first session and be reviewed in an iterative process across the session to help participants use this model for different problems.
223647132|NCT06535516|BEHAVIORAL|Trauma-Focused Cognitive Behavioral Therapy (TF-CBT)|TF-CBT is a well-established trauma treatment for children ages 3-17 years that demonstrates improved outcomes relative to other active treatments. Originally developed for treatment of childhood sexual abuse, evidence from numerous randomized clinical trials (RCT) demonstrates that TF-CBT is one of the most effective treatments for children with PTSD and/or depression resulting from many forms of child abuse and neglect as well as other traumatic experiences.TF-CBT is rated by California Evidence-Based Clearinghouse for Child Welfare as highly relevant for child welfare and well-supported in improving children's outcomes, including reduced PTSD symptoms, behavior problems, depression, and shame, and improving parental support related to their children's experiences.
223647133|NCT06535516|BEHAVIORAL|Trauma-Focused Cognitive Behavioral Therapy (TF-CBT) augmented with Socialization (S)|The study will compare standard TF-CBT with TF-CBT augmented with Socialization enhancements. TF-CBT+S includes enhancements to address socioecological stress and trauma and provide coping strategies to support positive socialization.
223647134|NCT07057882|BEHAVIORAL|Health Belief Model-based Education|The intervention is a structured educational program based on the Health Belief Model (HBM), developed to improve health perception and reduce risky behaviors among international university students. The program includes six weekly sessions lasting approximately 45 minutes each, delivered face-to-face in small groups. The training content is tailored to address perceived susceptibility, severity, benefits, barriers, and self-efficacy related to health behaviors. Interactive discussions, visual materials, and culturally sensitive examples are used. Participants in the intervention group receive this training in addition to usual care or routine university services..
224320049|NCT02147964|DRUG|Testosterone 1% Gel|Testosterone 1% gel 5g daily for 4 months \[all subjects\]
223647135|NCT07059637|OTHER|Multidisciplinary clinic evaluation|The goal is to use evidence-based strategies to diagnose and treat sarcopenia due to COPD. The investigators anticipate that the approach will improve clinical outcomes for COPD patients with sarcopenia as compared to standard of care visits in ambulatory COPD clinics. The investigators will determine if the approach improves skeletal muscle mass and function, and also improves clinical outcomes related to frequency of hospitalizations, COPD exacerbations, or mortality. The approach is different than standard of care COPD treatment because it is informed by quantifying muscle mass and strength (through handgrip strength and bio-impedance) and have strong collaborations with nutrition and pulmonary rehabilitation.
223647136|NCT07059637|OTHER|COPD standard of care|Standard COPD care treatment in an ambulatory post-hospital follow up clinic
224320050|NCT02147964|DRUG|Acyline|Acyline 300 ug/kg SQ injections every 2-weeks for 4 months \[all subjects\]
223647137|NCT07069101|OTHER|Erector spinae block|Patients will receive continuous ipsilateral erector spinae plane block.
223647138|NCT07069101|OTHER|Edge of lamina block|Patients will receive continuous ipsilateral edge of laminar block.
223647139|NCT07068594|DEVICE|Virtual Reality Goggles|A device consisting of glasses placed on the head of patients in the intervention group and earphones attached to the glasses
223647140|NCT07069621|BEHAVIORAL|Triple p level parenting program|An evidence-based program with self-agency strategies enhances trust and confidence in managing children's ADHD behaviors
223647141|NCT07063563|OTHER|ambiant air|Standard ambiant air will be breathed during endurance training. ambiant air
223647142|NCT07063563|OTHER|Oxygen|SSOT and sham air (5l/min) will be applied with the oxygen concentrator EverFloTM via nasal cannula during training
223647143|NCT07063563|OTHER|ambiant air|Standard ambiant air will be breathed during endurance training. ambiant air
223647144|NCT07064928|BEHAVIORAL|Adapted Project Accept's Post-Test Support Services (PTSS) Module 3|Adapted Project Accept's Post-Test Support Services (PTSS) Module 3 for the Ghanaian context, and among pregnant and/or postpartum women living with HIV
223647145|NCT07068555|BIOLOGICAL|Immunomodulatory DC vaccines to target prostate cancer|1 to 2 injections, with an interval of one month, of 1\~2x10\^7 DC vaccine administered subcutaneously
223647146|NCT07072611|DRUG|SOF-SKN 0.25%|cream for topical application
223647147|NCT07072611|DRUG|SOF-SKN 0.5%|cream for topical application
223647148|NCT07072611|DRUG|SOF-SKN 1%|cream for topical application
223647149|NCT07072611|DRUG|SOF-SKN 2%|cream for topical application
223647150|NCT07072611|DRUG|Placebo|cream for topical application
223647151|NCT07069647|OTHER|VeriSee AI-assisted screening tools for diabetic retinopathy and age-related macular degeneration|VeriSee DR is an AI-assisted diagnosis screening tool for diabetic retinopathy, the software received medical device license approval from the TFDA in 2020 (MOHW-MD-No.006966). VeriSee AMD is an AI-assisted diagnosis screening tool for age-related macular degeneration, the software also received medical device license approval from the TFDA in 2022 (MOHW-MD-No.007652).
223647152|NCT07069647|OTHER|Standard fundus photography with physician interpretation|The control group will undergo the fundus photography without AI-functionality, with reports interpreted solely by physicians. Participants must schedule a follow-up visit to receive their results.
223647153|NCT07074002|DRUG|BP1.4979|Selective dopamine D3 partial agonist
223647154|NCT07074002|DRUG|Placebo|Matching placebo of BP1.4979 tablet
224320051|NCT02147964|DRUG|Dutasteride|Dutasteride 2.5 mg (day 1) followed by 0.5 mg daily for 4 months
224232675|NCT01823003|RADIATION|60Gy (12 x 5 fr.s)|50Gy administered in 5 fractions of 12 Gy for Peripheral Nodes in case of distance to chest wall \< 1 cm, tumour size \< 5 cm and distance to main bronchus \> 2 cm. STEREOTACTIC ABLATIVE RADIOTHERAPY (SABR) will be administered with volumetric modulated arcs, with photon beam energy of 6-10 MV. The number of arcs and their ballistic is left undefined in order to allow for optimization of the dose distribution. Bolus is not allowed.
224232676|NCT01823003|RADIATION|60Gy (7.5Gy x 8fr.)|60 Gy administered in 8 fractions of 7.5 Gy for mediastinal nodes in case of tumour size \< 5 cm and distance to the main bronchus \< 2 cm. STEREOTACTIC ABLATIVE RADIOTHERAPY (SABR)will be administered with volumetric modulated arcs, with photon beam energy of 6-10 MV. The number of arcs and their ballistic is left undefined in order to allow for optimization of the dose distribution. Bolus is not allowed.
224232677|NCT04546607|OTHER|Nuvastatic TM (C5OSEW5050ESA) 1000 mg|Nuvastatic TM is a patented polymolecular botanical medicine made from Lanctos 75TM which is a proprietary high potency herbal standardized extract.
224232678|NCT05895253|DEVICE|vibrotactile ground-contact feedback|Suralis®, Saphenus Medical Technology (Baden, Lower Austria, Austria)
224232679|NCT00024453|BIOLOGICAL|teicoplanin|
224232680|NCT04165538|PROCEDURE|Thrombelastograph and surgical timing|Patients in the TEG group will undergo a Thrombelastograph test after admission, and the timing of operation will be determined according to the results of the test, that is, 1 day, 3 days and 5 days later respectively for patients with ADP-induced platelet-fibrin clot strength (MAADP) of \> 50 mm, 30-50 mm and \< 30 mm. For Non-TEG patients, the drug withdrawal time is determined by the doctor in charge according to the clinical routine, generally about one week.
224232681|NCT04810819|DRUG|Methylprednisolone 40 MG Injection;Dihydroxypropyltheophylline;|Before anesthesia induction, 80 mg methylprednisolone and 100 ml saline were given intravenously, and 0.25 g dihydroxypropyltheophylline and 100 ml normal saline were given intravenously.
224232682|NCT04810819|DRUG|Placebo|Placebo
224232683|NCT01152203|DRUG|Bendamustine|Starting dose of 70 mg/m\^2 by vein on Days 1 and 2 of a 28 day cycle
224232684|NCT01152203|DRUG|Bevacizumab|10 mg/kg by vein on Days 1 \& 15 of every 28 day cycle
224232685|NCT05200858|DEVICE|TENS - high-dose|Subjects will receive a functional TENS device (delivers 100% of the dose) to wear for 3-5 hours per day.
224232686|NCT05200858|DEVICE|TENS - low-dose|Subjects will receive a placebo TENS device (delivers 10% of the dose) to wear for 3-5 hours per day.
224232687|NCT01914315|BEHAVIORAL|Cardiac Rehabilitation|Patients will participate in a 6-month cardiac rehabilitation program, consisting of structured, 60-minutes, bi-weekly exercise training sessions according to a predefined protocol. Institutional activity will be complemented by 120 minutes weekly home exercise prescribed by specialist in cardiac rehabilitation. Exercise prescription will be based on a symptom limited exercise test when clinically feasible and according with the patients' functional capacity, medical history and physiological values obtained prior to exercise. Target heart rate will be set initial as 50-60% of heart rate reserve and gradually increased up to 80% of HRR. Aerobic exercise will be complemented by resistance training of low intensity.
224232688|NCT01914315|OTHER|Internal Medicine|Following discharge, patients will return to the IM outpatient clinics at 2-4 weeks, 3, and 6 months for consultation. These scheduled consultations will comprise of history taking, recording of any new events, physical examination and recommendations as clinically indicated. Target values for blood pressure and glucose control will be in accordance with current guidelines and special emphasis given to management of fluid retention.
224232689|NCT00190554|DRUG|Surgery +(Cisplatin 80 mg/㎡+5FU 800mg/㎡×5days)×2|
224232690|NCT00190554|DRUG|(Cisplatin 80 mg/㎡+5FU 800mg/㎡×5days)×2＋Surgery|
224232691|NCT02546908|OTHER|No Intervention|This is an observational study. No study medication is provided will be provided as part of participation. Participants disease status, overall survival (OS), PFS, MFS, SRE-free survival, and time to castration (TTC) will be analyzed according to treatments prescribed while enrolled in the registry. All treatment decisions will be made at the discretion of the investigator or treating physician.
224232692|NCT02368405|BEHAVIORAL|Control|Participants in the control group will receive the standard nutrition lecture currently given at Carolinas Rehabilitation to all inpatients with spinal cord injuries. This one lecture is what is required by Commission on Accreditation for Rehabilitation Facilities (CARF)
224232693|NCT02368405|BEHAVIORAL|Eat Smart, Live Better|Intervention participants will participate in a series of six, 60-minute small group sessions of interactive nutrition education discussions led by a Registered Dietitian delivered over 3 weeks. They will also have one follow-up comprehensive nutrition education session approximately 3 months after receipt of the Eat Smart, Live Better curriculum. In order to help us assess the effectiveness of the nutrition education program, we will assess nutrition behavior and knowledge at this time as well. Community participants in the treatment group will attend the sessions at Carolinas Rehabilitation (CR). The control participants from the community will come to CR for the one standard nutrition lecture. Caregivers and spouses of all of the participants will be encouraged to attend the sessions.
224320052|NCT02147964|DRUG|Ketoconazole|ketoconazole 400 mg PO daily for 4 months
224320053|NCT02147964|DRUG|HCG|HCG 60 IU injection Subcutaneously, every other day for 4 months
224320054|NCT02147964|DRUG|placebo dutasteride|placebo oral dutasteride PO daily for 4 months
224320055|NCT02147964|DRUG|placebo ketoconazole|placebo ketoconazole daily for 4 months
223647155|NCT07075796|DEVICE|GLUCUBE system|A non-invasive system to monitor and measure the blood glucose compared to the standard glucometer in a group subjects
224320056|NCT04856930|BIOLOGICAL|Imsidolimab|Humanized Monoclonal Antibody
224320057|NCT04856930|BIOLOGICAL|Placebo|Placebo
224320058|NCT00678210|DRUG|CP-690,550|tablets, 2 mg BID for 12 weeks
223647156|NCT07075328|OTHER|Drug:5-ALA, Device:Photodynamic system|"\[Phase I part\] Patients will receive 5-ALA administered orally once. After administration of 5-ALA, patients will receive Photodynamic system once.~Dosage of 5-ALA: 10 mg/kg (1st cohort), 20 mg/kg (2nd cohort), 40 mg/kg (3rd cohort), 60 mg/kg (4th cohort) \[Phase II part\] Patients will receive 5-ALA and Photodynamic system once a week for 6 months."
223647157|NCT07074522|PROCEDURE|Single-layer closure|Patients who underwent single-layer closure of the transverse lower segment during cesarean section.
223647158|NCT07074522|PROCEDURE|Double-layer closure|Patients who underwent double-layer closure of the transverse lower segment during cesarean section.
224320059|NCT00678210|DRUG|CP-690,550|tablets, 5 mg BID for 12 weeks
224232694|NCT01737177|DRUG|Bendamustine, Lenalidomide, Rituximab|"INDUCTION PHASE (COURSE 1-4)~* Bendamustine: 70 mg/m2 on day 2 and 3 every 28~* Lenalidomide: 10 mg/daily on day 1 to 14 of a 28 days course~* Rituximab: 375 mg/m2 on day 1 every 28 days; only for the first cycle in the induction phase will start on day 8~CONSOLIDATION PHASE (courses 5-6)~Patients in CR and PR at the end of the induction phase~* Lenalidomide: 15 mg/daily on day 1 to 21 of a 28 days course.~* Rituximab: 375 mg/m2 on day 1 every 28 days~MAINTENANCE PHASE (courses 7-24)~Patients in CR or PR at the end of the consolidation treatment with Lenalidomide until disease progression or unacceptable toxicity up to 18 months (from month 7 to month 24)~\- Lenalidomide: 15 mg/daily on day 1 to 21 of a 28 days"
224232695|NCT03248856|DRUG|Triamcinolone Acetonide|Intratympanic administration
224232696|NCT00944970|DRUG|binodenoson|30-second intravenous injection (bolus) of binodenoson (1.5 mcg/kg) and a 6-minute intravenous infusion of placebo
224232697|NCT00944970|DRUG|adenosine|30-second intravenous injection (bolus) of placebo and a 6-minute intravenous infusion of adenosine (140 mcg/kg/minute)
224232698|NCT05111470|OTHER|Arm throws with his dominant arm|Seated patient with different sensors on his naked torso. Patients will throw a ball with their dominant arm. The trajectories will be recorded by Vicon MX-40
224232699|NCT00564525|DRUG|Amitriptyline|Medication taken for 4 weeks
224232700|NCT00564525|DRUG|Placebo|Medication taken for 4 weeks
224320060|NCT00678210|DRUG|CP-690,550|tablets, 15 mg BID for 12 weeks
224232701|NCT04762056|OTHER|Chelsea Critical Care Physical Assessment Tool|Chelsea Critical Care Physical Assessment Tool is a bedside assessment tool firstly reported in 2013 to measure physical morbidity in the critical care population, consisting of 10 items (respiratory function, cough, moving within the bed, supine to sitting on the edge of bed, dynamic sitting, standing balance, sit to stand, transferring from bed to chair, stepping, and grip strength) rated on a 6-point scale from complete dependency (level=0) to independency (level=5). Therefore, the CPAx sum score ranges from 0 (worst condition) to 50 (best functioning/independence)
224232702|NCT00488748|DEVICE|Thymatron|Right unilateral placement, 6x seizure threshold, 3 times per week until clinically appropriate to stop (approximately 2-6 weeks)
224232703|NCT00488748|DEVICE|Magstim Theta|100% power, vertex placement, 3 times per week, until clinically appropriate to stop (approximately 2-6 weeks)
224232704|NCT00160407|DRUG|Orlistat (Xenical)|
224232705|NCT00160407|BEHAVIORAL|1400 kcal diet (30% fat)|
224232706|NCT01581970|DRUG|Cyclophosphamide|Patients will be given oral cyclophosphamide 50 mg twice daily to be self-administered starting the first day of therapy with weekly cetuximab for 12 weeks or until disease progression.
224320061|NCT00678210|DRUG|Placebo|tablets, BID for 12 weeks
224320062|NCT01981902|DEVICE|Non-Invasive Optical Spectroscopic|Non-Invasive Optical Spectroscopic
224232707|NCT01581970|DRUG|Cetuximab|The initial dose of cetuximab 400 mg/m\^2 is administered over 120 minutes followed by weekly infusions of cetuximab 250 mg/m\^2 intravenously (IV) over 60 minutes.
224232708|NCT00584298|DRUG|SMS995|
224232709|NCT00584298|DRUG|Placebo|
224320063|NCT04825912|BEHAVIORAL|Self System Therapy for Older Adults with Advanced Lung Cancer (SST-LC) Resilience|The SST-LC is a brief structured intervention deliverable by video conference. The SST-LC Resilience protocol will incorporate behavioral strategies designed to meet the needs of older adults with lung cancer, including examining individual and shared expectations for lung cancer care, identifying discrepancies between expectations and realistic possibilities, and modifying stress-exacerbating behaviors. The focus will be to test measures of resilience during the intervention period.
224232710|NCT05067361|PROCEDURE|Aerobic Exercise|Jogging was performed for 20 minutes. Jogging was performed by experimental group for 3 weeks and 4 sessions per week.
224232711|NCT05067361|PROCEDURE|Ball Exercises|Ball exercises like stability ball roll, stability ball hug, stability ball catching, ball throwing and ball tapping exercises were for 10 minutes. Ball exercises was performed by both groups for 3 weeks and 4 times per week .
224232712|NCT01361802|DRUG|Ambroxol Spray|low dose Ambroxol Spray
224232713|NCT01361802|DRUG|Ambroxol Spray|medium dose Ambroxol Spray
224320064|NCT06230042|OTHER|Types of catheters|One type of catheters were used for patients
224320065|NCT04442399|BEHAVIORAL|Family Connections|Ten intervention sessions were covered, ranging form understanding HIV and to handling stigma and discrimination.
224320066|NCT02394470|OTHER|Deuterium oxide dilution|Reference standard for total body water: deuterium oxide dilution by mass spectrometry
223647159|NCT07074925|OTHER|Video assisted informed consent|The 2-minute video (available in English or Spanish) will use animation to explain the neonatal LP procedure, benefits, and risks.
224232714|NCT01361802|DRUG|Ambroxol Spray|high dose Ambroxol Spray
224232715|NCT01361802|DRUG|Placebo Spray|Placebo Spray
224320067|NCT02394470|OTHER|Bioimpedentiometry|Bioimpedentiometry: measurement of whole body and thoracic resistance and reactance
224320068|NCT02394470|OTHER|Lung and subcutaneous ultrasound|Ultrasound: semiquantitative scoring of lung congestion (B lines) and peripheral edema (subcutaneous echography of the ankle)
224320069|NCT00251329|DRUG|neoadjuvant chemotherapy|
224320070|NCT03550911|OTHER|Biological Collection From Samples From The Gut Microbiota|The aim of this study is just to constitute a biological collection from samples from the Gut microbiota in patients having a bone or joint infection treated by a suppressive subcutaneous antibiotherapy with betalactamine. No analysis will be done for instance.
223647160|NCT07074925|OTHER|Standard consent|The standard consent group will receive usual procedure description and consent.
223647161|NCT07075913|OTHER|Subcostal transverse abdominis plane block|Patients received an ultrasound-guided subcostal transverse abdominis plane block with injection of 10 ml bupivacaine 0.25 %, 5ml lignocaine 2 % plus 0.5 μg/kg dexmedetomidine in a 20 ml volume.
223647162|NCT07075913|OTHER|Erector spinae plane block|Patients will receive an ultrasound-guided erector spinae plane block (ESPB) with injection of 10 ml bupivacaine 0.25%, 5 ml lignocaine 2 % plus 0.5 μg/kg dexmedetomidine in a 20 ml volume.
224232716|NCT01691508|DRUG|Mepolizumab|Mepolizumab is a fully humanised Immunoglobulin G antibody (IgG1, kappa) with human heavy and light chain frameworks.
224232717|NCT01691508|DRUG|Placebo|Will be available as an equivalent volume of 0.9% sodium chloride.
224232718|NCT01691508|DRUG|OCS (prednisone/prednisolone)|Oral Corticosteroid (prednisone/prednisolone)
223647163|NCT07074119|DEVICE|wearable-based adjustment therapy|"* Patients will wear the BWS for 7 days prior to each of the visit : baseline (V1) at week 0, V2 at week 4 (phone call at 1 month), V3 at week 12 (3 months visit) and V4 at week 24 (6 months).~* Data extracted from each session of monitoring with the BWS will be made available to the neurologist (only in the experimental group) prior to V1 (W0), V2 (W4), V3 (W12) and V4 (W24) respectively~* Treatment adjustment will be guided by the current consensus guidelines for treatment adjustment for motor fluctuations in PD using reports from BWS data. Reports will be screened by neurologists before the patient's visit so the groups blinding is correctly observed"
223647164|NCT07074613|DEVICE|Traditional Treadmill Walking|Participants walked on a traditional treadmill with standard time, speed, and distance tracking, no AR features.
223647165|NCT07074613|DEVICE|JOHNSON 8.1T treadmill with Passport AR system|Participants walked on an AR-integrated treadmill with immersive virtual environments and real-time feedback.
223647166|NCT07075042|DEVICE|Training with PRC|All participants will receive in-person training with an onsite study prosthetist for the assigned controller strategy. The purpose of the training will be to instruct users on the care of the device formally and to achieve a basic level of functional performance. Training will be individualized according to clinical discretion consistent with clinical practice. Training will consist of up to four sessions to facilitate participants' use of the assigned controller system. The number of sessions will be competency-based (i.e., determined by the ability of each participant to explain or perform specified tasks). A standardized protocol and training checklist have been developed by clinical subject matter experts (i.e., upper limb prosthetists and occupational therapists).
224232719|NCT03432247|BEHAVIORAL|Interactive Music Therapy|Six 45-minute individual interactive music therapy (IMT) sessions delivered by a board-certified music therapist. Sessions start with music-guided breathing, imagery, or humming. The music therapist then engages the participant in singing of familiar songs and co-created vocal or instrumental music improvisations based on patient needs. Discussion about the meaning assigned to songs and emotions expressed through the improvisations follow. The IMT experiences are aimed at facilitating emotional expression, offering support through interactive music making, and strengthening inner resources of creativity. In addition, each week the participant learns music-based techniques for self-management of anxiety, stress, mood, and pain.
224232720|NCT03432247|BEHAVIORAL|Verbal support|Six 45-minute individual sessions delivered by a master's level clinician with training in counseling. The sessions are focused on patient-initiated conversations about their pain, life stressors and the impact on their daily life. The intervener provides nondirective, supportive care by offering supportive, validating statements and reflective listening. The intervener refrains from employing active suggestion, problem-solving or behavioral or cognitive therapy techniques. The verbal support sessions are aimed at providing an empathic, therapeutic environment to facilitate emotional expression and sharing of worries and fears.
224232721|NCT03700944|OTHER|Yoga training|Complete protocol with yoga training for a period of 8 weeks, 60 minutes, 3 times a week.
224232722|NCT00159302|PROCEDURE|Induced Sputum|
224232723|NCT00159302|PROCEDURE|Exhaled Nitric Oxide|
224232724|NCT00159302|PROCEDURE|Nasal Nitric Oxide|
224232725|NCT00159302|PROCEDURE|Blood Tests|
224320071|NCT01469728|PROCEDURE|Non-awake VATS talc pleurodesis|Thoracoscopic talc pleurodesis performed through sole general anesthesia and one-lung ventilation
224320072|NCT01469728|PROCEDURE|Awake VATS talc pleurodesis|Thoracoscopic talc pleurodesis performed in awake patients through sole thoracic epidural anesthesia.
224320073|NCT00477048|DRUG|Saquinavir|SQV/r 1000/100 BID + NNRTI or SQV/r 1600/100 OD + 2 NRTI
224320074|NCT00974922|DRUG|Aliskiren|150 mg once daily for 2 weeks, then titrated to 300 mg once daily for 4 weeks
223766194|NCT04661176|DIAGNOSTIC_TEST|miR Sentinel™ PCC4 Assay|This study is a prospective clinical utility study. Urine samples will be collected from participants for the miR Sentinel™ PCC4 Assay, which interrogates the expression profile of 442 small non-coding RNAs to classify disease status as having no molecular evidence of prostate cancer (NMEPC) or molecular evidence of low-, intermediate- or high-risk prostate cancer.
223766195|NCT00533949|BIOLOGICAL|Cetuximab|Loading dose: 400 mg/m2, IV, one week prior to start of radiation therapy (RT). Then, beginning day 1 of RT, 250 mg/m2, IV, weekly; for 60 Gy arm for 15 weeks, for 74 Gy arm for 16 weeks.
223766196|NCT00533949|DRUG|Carboplatin|"Concurrent: AUC=2, IV, days 1, 8, 14, 22, 29, and 36 of radiation therapy; for 74 Gy arms, on day 43 as well.~Consolidation, 3 weeks after completion of RT, AUC=6, IV, days 1 and 22."
223766197|NCT00533949|DRUG|Paclitaxel|"Concurrent: 45 mg/m2, IV, days 1, 8, 14, 22, 29, and 36 of radiation therapy (RT); for 74 Gy arms, on day 43 as well.~Consolidation, 3 weeks after completion of RT, 200 mg/m2, IV, days 1 and 22."
223766198|NCT00533949|RADIATION|60 Gy RT|Radiation therapy (RT) in once-daily, 2 Gy fractions, given in 30 fractions over the course of 6 weeks.
223766199|NCT00533949|RADIATION|74 Gy RT|Radiation therapy (RT) in once-daily, 2 Gy fractions, given in 37 fractions over the course of 7.5 weeks.
224232726|NCT00159302|PROCEDURE|24hr Urine Samples|
224232727|NCT00159302|PROCEDURE|Exhaled Breath Condensate|
224320075|NCT00974922|DIETARY_SUPPLEMENT|Cholecalciferol|3000 I.U. once daily for 6 weeks
224232728|NCT00159302|PROCEDURE|Spirometry|
224232729|NCT01016028|BEHAVIORAL|Questionnaire|3 questionnaires to collect information about any pain and/or symptoms experienced, general well-being, and personal information such as age and marital status. One (1) will be a symptom assessment questionnaire where asked to rate symptoms on a scale of 0-10.
224232730|NCT01016028|BEHAVIORAL|Sensory Tests|Test of sensitivity to things such as cold and touch, involve feeling cold objects, feeling bumps on a rectangular board, and putting pegs into holes on a board; and marking on computerized drawings areas experience pain, numbness, and/or cold sensitivity.
224320076|NCT00974922|DIETARY_SUPPLEMENT|Placebo|Placebo for two weeks
224320077|NCT02712723|DRUG|Letrozole|Nonsteroidal aromatase inhibitor
224320078|NCT02712723|DRUG|Ribociclib|Oral cyclin-dependent kinase (CDK) inhibitor
224320079|NCT02712723|DRUG|Placebo|Placebo for ribociclib
224320080|NCT04820738|OTHER|Sensorimotor training exercises|Sensorimotor training exercises include wall slides , core exercises (Planks, leg raises, crunches, bridging) balance exercises (single leg side lift, leg lift with dumble, balance on stability ball) on unstable surface for 50-60 min (3 sets of 10 rep) of exercises and gait training (different patterns of walking
223647167|NCT07075042|DEVICE|Training with DC|All participants will receive in-person training with an onsite study prosthetist for the assigned controller strategy. The purpose of the training will be to instruct users on the care of the device formally and to achieve a basic level of functional performance. Training will be individualized according to clinical discretion consistent with clinical practice. Training will consist of up to four sessions to facilitate participants' use of the assigned controller system. The number of sessions will be competency-based (i.e., determined by the ability of each participant to explain or perform specified tasks). A standardized protocol and training checklist have been developed by clinical subject matter experts (i.e., upper limb prosthetists and occupational therapists).
223647168|NCT07075042|DEVICE|PRC Device use in community and home|After the training sessions, all subjects will use the PRC device in their homes, just in a different order.
223647169|NCT07075042|DEVICE|DC Device use in community and home|After the training sessions, all subjects will use the DC device in their homes, just in a different order
223647170|NCT04379414|BEHAVIORAL|YES portal|A web-based portal designed for access by smartphone, tablet, or laptop/desktop. The portal is designed to help monitor cancer related issues and to share self-management information, resources and potential research opportunities. The portal is also designed to create a community among participants through the yeschat.org discussion board.
223647171|NCT06956040|PROCEDURE|Low-dose computed tomography of the chest|Baseline low dose Ct acquisition, then at 1 year to depict suspicious lung nodules
223647172|NCT05784844|DRUG|Meropenem|Carbapenem antibiotic
223647173|NCT05784844|DRUG|Micafungin|Echinocandin antifungal
223766200|NCT01668095|OTHER|Laboratory Biomarker Analysis|Correlative studies
223766201|NCT00727194|DRUG|eculizumab|eculizumab 600 mg IV weekly for 4 doses followed by eculizumab 900 mg IV every two weeks for 7 doses
224232731|NCT01016028|BEHAVIORAL|Interview|First 5 patients receiving platinum agents, taxanes, and bortezomib (15 patients total) will be asked to describe their symptoms in an open-ended, semi-structured 20-30 minute interview.
224232732|NCT02915679|OTHER|Blood sample for genetic purpose, psychiatric assessment and pain investigation|"All the participant will performed the same evaluation and blood analysis:~* A clinical assessment by psychiatrics assessing psychiatric disorder and suicidal behavior~* Thermal stimulation for pain assessment~* Computer game named Cyberball: test of social exclusion~* Self report questionnaire for the assessment of reject sensitivity, relationship style, impulsivity, childhood trauma.~* Routine blood sampling"
224232733|NCT02472678|OTHER|Web-based tailored information and support system|Access to the web-based tailored information and support system (with a username/password)
224232734|NCT02472678|OTHER|Standard care|The control group will receive standard care.
224320081|NCT04820738|OTHER|Without Sensorimotor training exercises|Cut back on high-fat foods. Drink plenty of water Use sugar and salt in moderation. Eat fruits and vegetables Get enough calcium Pump up your iron. Get enough fiber
224320082|NCT01808547|DRUG|ISV-303|0.075% bromfenac in DuraSite dosed BID
224320083|NCT01808547|OTHER|DuraSite Vehicle|DuraSite vehicle dosed BID
224320084|NCT05190445|DRUG|Cinrebafusp alfa (PRS-343) in combination with ramucirumab and paclitaxel|HER2/4-1BB
224320085|NCT05190445|DRUG|Cinrebafusp alfa (PRS-343) in combination with tucatinib|HER2/4-1BB
224320086|NCT05823688|DEVICE|Electrical Impedance Tomography|Measure of regional ventilation by Electrical Impedance Tomography (EIT) before and during pneumoperitoneum
223647174|NCT00124553|BEHAVIORAL|Intensive dietary advice|
223647175|NCT06517004|BIOLOGICAL|JWCAR201|Autologous CD19/CD20-directed CAR-T cells, single infusion intravenously
223647176|NCT00145808|DEVICE|Given® Diagnostic System|
223647177|NCT05760469|OTHER|Screening|Clinical nurse (CN) notifies research coordinator (RC) about patients with rashes. RC assesses eligibility criteria of patient based on inclusion criteria. RC provide CN with appropriate documentation tool (DT), smart device (SD), standardized red adhesive label (SRAL), and adhesive QRcode. Intervention: With written informed consent, demographic information will be collected. QRcode adhesive will be placed in the DT to track subject documentation throughout the study. Baseline live photograph (LP) of the rash will be taken with SD at day 0. LP will be taken daily. A SRAL, and a QR adhesive code will be included in the LP. LP will be automatically saved in a secure file on the cloud server under the QR code. CN will complete the DT for all rashes included in the study. Treatment of the rash will be at the discretion of the clinical team; the treatment regimen will be recorded daily. The procedure will be repeated daily for all rashes during the patient stay to a maximum of 7 days.
223647178|NCT04528966|OTHER|Whole-Body Vibration|Whole-Body Vibration Treatment for 3 sessions in a week for 8 weeks. Each sessions takes 15 minutes.
223647179|NCT04528966|OTHER|Conventional Physiotherapy|conventional physiotherapy for 2 sessions in a week for 8 weeks. Each sessions takes 45 minutes.
223647180|NCT00913952|DRUG|Geneva 25 mg Clomipramine Hydrochloride Capsules Under Fasting Conditions|
223647181|NCT00913952|DRUG|Geneva 25 mg Clomipramine Hydrochloride Capsules Under Fed Conditions|
223647182|NCT00913952|DRUG|Basel (Anafranil) 25 mg Clomipramine Hydrochloride Capsules Under Fed Conditions|
223647183|NCT02675673|PROCEDURE|GJ-Tube|Insertion of a GJ tube either prior to the start of radiotherapy or within the first 2 weeks after the first dosage.
223647184|NCT02675673|PROCEDURE|G-Tube|Insertion of a G-tube either prior to the start of radiotherapy or within the first 2 weeks after the first dosage.
223647185|NCT04004195|DRUG|BAY2327949|A single oral dose of 30 mg BAY2327949 given as one 30 mg IR tablet (dose might be reduced to 15 mg for group 4 according to safety assessment team decision)
223647186|NCT01571687|DIETARY_SUPPLEMENT|antioxidant supplements|Intake of 6 tablets daily containing: 800 I.E. Vitamin E, 1000mg Vitamin C, 200000 I.E. Vitamin A, 600mg Acetylcystein.
223647187|NCT01571687|DIETARY_SUPPLEMENT|Placebo|Intake of 6 identically appearing tablets daily containing placebo
224320087|NCT03965689|DRUG|Carboplatin|Given IV
224320088|NCT03965689|DRUG|Paclitaxel|Given IV
224320089|NCT03965689|DRUG|Pevonedistat|Given IV
224320090|NCT06139822|OTHER|Experimental Group|Hamstring stretching is the main intervention which is being used along with convention protocol for plantar fasciitis.
224320091|NCT06139822|OTHER|Control Group|Control group included Cold pack for 7 to 10 mins. Followed by stretching of plantar fascia .
224320092|NCT03022084|DEVICE|Desyncra|This group will use the sound-therapy device, Desyncra™ for Tinnitus Therapy System.
223766202|NCT00727194|DRUG|Placebo|Placebo IV weekly for 4 doses then every two weeks for 7 doses
223647188|NCT01732718|DRUG|Atorvastatin|40 mg tablet by mouth daily for 6 weeks
223647189|NCT01732718|DRUG|Placebo|Matching placebo tablet by mouth daily for 6 weeks
223647190|NCT02111759|PROCEDURE|knee flexion angle 1|0 degrees of knee flexion during ACL graft fixation
223647191|NCT02111759|PROCEDURE|knee flexion angle 2|30 degrees of knee flexion during ACL graft fixation
223766203|NCT00072345|DRUG|lomustine|
224232735|NCT05344183|DEVICE|Low-level laser|A laser will be used in the quadriceps and gluteus medius muscles with the following parameters described for muscle recovery: dose of 40 J for the gluteus medius muscle, 180 J for the quadriceps muscle; power from 50 to 200 mW per diode (for single probes), 10 to 35 mW per diode (for cluster probes). The full power of the device cannot lead to thermal effects; Wavelengths of 950 nm (infrared).
224232736|NCT01584661|BEHAVIORAL|Dietary recommendations|
224232737|NCT00275483|DEVICE|Vital-band (R)|
224232738|NCT01752348|OTHER|Endotoxin, US standard reference E.coli|
224320093|NCT03022084|OTHER|Cognitive Behavioral Therapy|Standard of Care
224320094|NCT04667000|OTHER|Forced Air Warming|We will use Forced Air Warming for cesarean patient
224320095|NCT05005052|DRUG|Vessel|Sulodexide has protective effect on the endothelium, antithrombotic, fibrinolytic and anti-inflammatory effects. In the last 20 years, it has been well established in the common practice and its efficacy and safety have been demonstrated notably in the treatment of venous diseases such as post-thrombotic syndrome of the lower extremities, secondary prevention of deep and superficial venous thrombosis, supportive treatment of leg venous ulceration, ischemic disease of the lower limbs; symptomatic therapy of intermittent claudication, treatment of diabetic ulcers and microcirculation disorders of various aetiology. Patients with CVD were shown to respond quickly to sulodexide therapy in single arm observational studies. Sulodexide seems to provide both symptomatic and causal therapy.
223766204|NCT00072345|DRUG|temozolomide|
224320096|NCT05005052|DRUG|Placebo|Placebo and no compression or venopharmaceutical regimen
223766205|NCT00072345|DRUG|thalidomide|
223766206|NCT01360034|DRUG|Nifedipine|Nifedipine: 20 mg as a single dose upon admission and then 10 mg vo every 8 hours for 48 hours.
223766207|NCT01360034|DRUG|Indomethacin|Indomethacin: 50 mg vo as a single dose upon admission and then 25 mg vo every 6 hours for 48 hours.
223766208|NCT05063734|DRUG|THR-687 dose level 1|3 intravitreal injections of THR-687 dose level 1, 1 month apart
223766209|NCT05063734|DRUG|THR-687 dose level 2|3 intravitreal injections of THR-687 dose level 2, 1 month apart
223766210|NCT05063734|DRUG|THR-687 selected dose level|3 intravitreal injections of THR-687 selected dose level, 1 month apart, possibly followed by a 4th intravitreal injection with the same dose level of THR-687 at Month 3, or Month 4, or Month 5, if any of the PRN criteria are met.
223766211|NCT05063734|DRUG|Aflibercept|3 intravitreal injections of aflibercept, 1 month apart, possibly followed by a 4th intravitreal injection with aflibercept at Month 3, or Month 4, or Month 5, if any of the PRN criteria are met.
223766212|NCT01455883|DRUG|ITCA 650 60 mcg/day|exenatide in DUROS
223766213|NCT01455883|DRUG|glimepiride|oral glimepiride does-escalated,if tolerated, to 8 mg/day
224232739|NCT04125628|BEHAVIORAL|Exercise with cooling|The exercise training session involved head cooling and neck wraps. Participants followed a 40-minute continuous cycling where they performed an incremental sub-maximal exercise protocol beginning at 45 W, increasing 10 W every 10 min for a total of four stages on a semirecumbent cycle ergometer in a 20oC room. Before and after the completion of the condition each participant performed a variety of functional ability tests. The evaluation of the core temperature and the assessment of the patient's quality of life also was performed
224320097|NCT02579473|DRUG|SER-214|SER-214 is a poly(2-ethyl-oxazoline) (POZ) polymer conjugate of the potent dopamine agonist rotigotine that is designed to provide continuous drug delivery following a single weekly injection
224320098|NCT03474666|PROCEDURE|Strict Glycemic Control Group|The strict protocol adopted to conduct the study was proposed by Keegan e Cols.(2010) to be used among adult LT recipients that consist of a continuous intravenous insulin infusion. The targeted blood glucose range is 80-130 mg/dL. The procedure must be stopped when the patient can ingest at least 50% of liquid diet or receive bolus tube feedings.
224320099|NCT03474666|PROCEDURE|Standard Glycemic Control Group|"The targeted blood glucose range is 130-180 mg/dL~* Blood glucose reading: ≤ 180 mg/dL - subcutaneous insulin dose: 0~* Blood glucose reading: ≥181 mg/dL and ≤250 mg/dL - subcutaneous insulin dose: 5 IU~* Blood glucose reading: ≥251 mg/dL and ≤300 mg/dL - subcutaneous insulin dose: 10 IU~* Blood glucose reading: ≥301 - subcutaneous insulin dose: 15 IU"
223647192|NCT02569749|OTHER|Berlin and Epworth questionaries|
223647193|NCT02569749|OTHER|Sleep apnea monitoring in those patients in whom a pacemaker with monitoring apnea system has been implanted.|
223647194|NCT02569749|OTHER|Night polygraph / Polysomnography|
223647195|NCT01734603|PROCEDURE|experimental rehabilitation program|"Duration training = 40 min : 5 cycles of 6 min each Week 1 speed of the walking exercise fixed at 70% of the max walking test's speed done on the initial walking test speed of the walking recovery fixed at 40% Walking slope : 0% Increase of the speed = 0.1 km/h after each training without pain.~* Week 2 Walking speed = average of the walking speeds done on week 1 Walking slope = 1% Recovery slope = 0% Increase of the slope = 0.5% after each training without pain.~* Week 3 Walking speed = 70% of the maximal walking test's speed Recovery speed = 40 % of the maximal walking test's speed Slope = average of the slopes done on week 2 Increase of the speed = 0.1 km/h .~* Week 4 Speeds = average of the walking speeds done on week 3 Walking slope = 1% Recovery slope = 0% Increase of the slope is 0.5% ."
223766214|NCT00948805|DRUG|GnRH agonist|3,6mg of goserelin acetate, 250mg of hCG, FSH variable dose according to the number of days required for appropriate ovarian stimulation
223766215|NCT00948805|DRUG|Control|250mg of hCG, Zoladex, FSH variable dose according to the number of days required for appropriate ovarian stimulation
223766216|NCT03853707|DRUG|Atezolizumab|Given IV
223766217|NCT03853707|DRUG|Capecitabine|Given PO
223766218|NCT03853707|DRUG|Carboplatin|Given IV
223766219|NCT03853707|DRUG|Ipatasertib|Given PO
223766220|NCT03853707|DRUG|Paclitaxel|Given IV
223766221|NCT03853707|OTHER|Quality-of-Life Assessment|Ancillary studies
223647196|NCT01734603|PROCEDURE|conventional rehabilitation program|"Duration of the training 40 minutes (time excluding rest and warm up)~Initial intensity = 3.2 km per hour and slope at 0% Walking until pain 3/5, then stop until pain completely subsides.Resume of walking as soon as possible.~Increase :~Week 1: if the walking is possible during 8 minutes, increase of the slope of 0.5% in each training until 10% Week 2 :if the walking is possible during 8 minutes, increase of the speed 0.2 mile per hour until 3 mph Week 3 :if the walking is possible during 8 minutes, increase of the slope 2% at each training until 15% Week 4 : if the walking is possible during 8 minutes, increase the speed 0.2mph at each training as long as it is possible."
223647197|NCT06405724|DRUG|Liposomal bupivacaine|133mg LB 20mL thoracic paravertebral nerve block
223647198|NCT06405724|DRUG|Ropivacaine|0.5% ropivacaine 20mL thoracic paravertebral nerve block
223647199|NCT04115865|DEVICE|Endotracheal sonde or laryngeal mask|Healthy subjects ; requiring general anesthesia with endotracheal or endobuccal device
224232740|NCT04125628|BEHAVIORAL|Exercise without cooling|The exercise session performed without cooling. Participants followed a 40-minute continuous cycling where they performed an incremental sub-maximal exercise protocol beginning at 45 W, increasing 10 W every 10 min for a total of four stages on a semirecumbent cycle ergometer in a 20oC room. Before and after the completion of the session each participant performed a variety of functional ability tests. The evaluation of the core temperature and the assessment of the patient's quality of life also was performed.
224232741|NCT01827722|DRUG|Ozurdex|Intravitreal injection of Ozurdex
224232742|NCT01827722|DRUG|Ranibizumab|Intravitreal Injection of Ranibizumab
224232743|NCT01827722|DRUG|Combination Ozurdex with Ranibizumab PRN|Intravitreal Injection of combination medication Ozurdex and Ranibizumab
224320100|NCT01173120|DEVICE|Abatacept combination product (ACP)|Abatacept Solution, Subcutaneous, 125 mg/device, Weekly, 3 months
224320101|NCT02380326|PROCEDURE|Advanced endoscopic imaging modalities|Virtual bronchoscopic navigation, confocal laser endomicroscopy, micro CT
223647200|NCT04052152|DRUG|Anlotinib and Sintilimab injection|Patients will be treated with Anlotinib and Sintilimab injection
223647201|NCT02617472|DEVICE|Pelvic floor exerciser|Daily exercise using the study device
223647202|NCT06119139|DRUG|3.6 ml 4% Articaine hydrochloride|3.6 ml 4% articaine buccal infiltration
223647203|NCT06119139|DRUG|1.8 ml 4% Articaine hydrochloride|1.8 ml 4% articaine buccal infiltration
223647204|NCT03485872|OTHER|Self-Screening and Referral Information|Urinary incontinence self-screening questionnaire, fact sheet and self-referral information will be provided by mail or email.
223647205|NCT03485872|OTHER|Standard Care|Demographic and quality of life questionnaires; standard care provided by participants' GPs
223647206|NCT01041963|DRUG|Enalapril|Patients with hypertension will take 20-40mg enalapril per day, antihypertensive agents other than ACE inhibitors and ARBs and spironolactone will be allowed. Doses are adjusted appropriately to achieve and maintain the target blood pressure of 130/80 mmHg
223647207|NCT01041963|DRUG|Enalapril plus Losartan|Patients with hypertension will take 20-40mg enalapril plus 25-50mg losartan per day, antihypertensive agents other than ACE inhibitors and ARBs and spironolactone will be allowed. Doses are adjusted appropriately to achieve and maintain the target blood pressure of 130/80 mmHg
223647208|NCT01041963|DRUG|Placebo|Patients in the control group will administer antihypertensive agents, except ACE inhibitors and ARBs and spironolactone. Doses are adjusted appropriately to achieve and maintain the target blood pressure of 130/80 mmHg
223647209|NCT00809302|DRUG|aplindore MR tablets or Placebo|aplindore MR tablets administered BID for about 13 weeks
223647210|NCT00145158|BIOLOGICAL|8 HLA-A2-restricted peptides and Montanide ISA51|
223647211|NCT00145158|BIOLOGICAL|8 HLA-A2-restricted peptides and CpG 7909|
223647212|NCT06333119|DIAGNOSTIC_TEST|modified rankin scale|"Modified Rankin Scale: The functional status of individuals with stroke is determined by this scale.~Modified Ashworth Scale: It allows determining the severity of spasticity. Tinetti Balance and Gait Scale: This scale helps determine the risk of falling by evaluating balance and gait.~Danish Prostatic Symptom Score: It allows to evaluate the storage and urinary functions of the bladder."
223647213|NCT04652219|BIOLOGICAL|gucy2c cart cells|Patients with advanced malignant gastrointestinal tumors were injected with CART cells
223647214|NCT02695563|DRUG|Lactoferrin|
223647215|NCT03252925|DRUG|N-Acetylcysteine|50mg/Kg.d, oral
223647216|NCT03252925|DRUG|Placebo Oral Tablet|50mg/Kg.d, oral
223647217|NCT04986319|DIAGNOSTIC_TEST|Serum vitamin D assay|"Trained phlebotomists will collect 10 cc of a Blood sample. Specimen will be preserved at -40ºc for batch analysis.~S Vitamin D, S iPTH, S Calcium, S Alkaline Phosphatase, S PO4, S Mg, S Albumin and S Creatinine will be done in BIRDEM laboratory. Vitamin D will be assayed by The ARCHITECT 25-OH Vitamin D assay system: Vitamin D will be assayed by The ARCHITECT 25-OH Vitamin D assay system: The ARCHITECT 25-OH Vitamin D assay is a chemiluminescent micro-particle immunoassay (CMIA). This technology is used for the quantitative analysis of 25(OH) D and aid in the assessment of vitamin D sufficiency."
223647218|NCT04531930|PROCEDURE|surgery|Colorectal surgery, mainly total proctocolectomy.
223647219|NCT04531930|PROCEDURE|enhanced colonoscopy|Colonoscopic treatment and surveillance in every 3 months.
223647220|NCT04531930|OTHER|self choosed methods|A patient chooses a method for himself other than surgery.
223647221|NCT00499616|DRUG|carboplatin|Given IV
223647222|NCT00499616|DRUG|cyclophosphamide|Given IV
223647223|NCT00499616|DRUG|doxorubicin hydrochloride|Given IV
223647224|NCT00499616|DRUG|etoposide|Given orally
223647225|NCT00499616|DRUG|topotecan hydrochloride|Given IV
223647226|NCT00499616|DRUG|Isotretinoin|Given orally
223647227|NCT00499616|PROCEDURE|Surgery|With the exception of patients with INSS 4S disease, patients undergo surgery to remove as much of the primary tumor and involved lymph nodes as can safely be accomplished.
223647228|NCT00499616|DRUG|Filgrastim|Administered subcutaneously or by IV beginning 24-48 hrs after the last dose of chemotherapy \& continuing daily until the ANC is greater than or equal to 1500 following the myelosuppressive nadir . Supportive care given to stimulate neutrophil recovery following chemotherapy and to shorten the duration of chemotherapy-induced neutropenia. On ANBL0531 the use of filgrastim was required for patients less than 60 days of age and was optional for other patients.
224232744|NCT05639842|OTHER|Pain in competitive athletes with physical disabilities. Techniques for its management, support received and perceived difficulties.|A total of 413 athletes with physical disabilities participated in the study, 157 Spanish athletes and 260 Latin American athletes. The athletes were contacted through different sports federations, Paralympic Committees and sports teams of people with disabilities.For the distribution of the questionnaire, the researcher made an initial telephone contact with the Spanish Paralympic Committee and the Spanish Sports Federation for People with Physical Disabilities, to explain the objectives of the study and ask for their collaboration in the dissemination. Subsequently, the information was officially sent to them by email.
224232745|NCT05022836|DIAGNOSTIC_TEST|four-limb blood pressure measurements|Four-limb blood pressures were measured by certificated nurses at admission.
223647229|NCT02569788|RADIATION|Carbon ion radiotherapy (CIRT)|Five dose levels (55GyE, 57.5GyE, 60GyE, 62.5GyE, 65GyE) are planned within the Phase I part. Daily fraction of 2.5 GyE will be delivered for all dose levels. After the recommended dose (RD), i.e., MTD, is determined or if the treatments to 65 GyE are safely delivered, the recommended dose (or 65 GyE) will be the prescribed dose in the Phase II part of the study. Ninty-five percent (95%) of the isodose line should cover the GTV+3\~5mm.
223647230|NCT04409080|DRUG|REGN7257|Administered by intravenous (IV) infusion, in Part A and B.
223647231|NCT00487656|DRUG|ART-123|6mg/ml ampule solution for injection @ .01mg/kg
223647232|NCT00487656|DRUG|placebo|6 mg/ml ampule solution for injection at .01mg/kg
223647233|NCT00123422|BEHAVIORAL|Breathing retraining|exercise training with computerized training program
223647234|NCT00123422|BEHAVIORAL|Heliox|exercise training with a helium oxygen combination
223647235|NCT00123422|BEHAVIORAL|Exercise|exercise training
223647236|NCT00067730|DRUG|Drotrecogin Alfa (activated)|
223647237|NCT04233723|OTHER|peripheral blood samples|venous puncture
223647238|NCT05452343|BIOLOGICAL|CM310|600 mg (first doing) + 300 mg (subsequent dosing), once every two weeks
223647239|NCT04555616|BEHAVIORAL|Standard Environmental Design|Participants' caregivers will receive set script of physical environmental modifications (i.e., declutter living space, reduce background noise, increase natural light), and social environment training script will include caregiving techniques: training for calming demeanor (emotional contagion), needs-driven care to decrease behavioral disruption, and accepting and accommodating approach to behavioral disruption. A pre-selected sensory stimulation kit will be provided to each participants' caregiver for administration throughout the day.
223647240|NCT04555616|BEHAVIORAL|Individual Environmental Design|Participants' caregivers will receive set script of physical environmental modifications and social environment training script in a standard protocol. Following initial assessments, individualized sensory stimulation kits will be developed using subjects' preferred sensory stimuli (as determined by the Adult Sensory Profile assessment and informant report) and will be provided via caregiver administration throughout the day to promote maintained behavioral regulation.
223647241|NCT04555616|BEHAVIORAL|Placebo|Participants' caregivers will receive a set script of placebo modifications.
223647242|NCT03089281|DEVICE|CRT-D|Commercially approved quadripolar Boston Scientific Cardiac Resynchronization Therapy Defibrillator (CRT-D) devices and future generations of BSC X4 CRT-D devices approved by the appropriate regulatory bodies will be included in the trial. All devices utilized in the study will include SmartDelay™ and must be capable of providing SmartDelay recommendations for both biventricular pacing (BiV) and Left Ventricular (LV) only pacing. All enrolled subjects with implanted BSC X4 CRT-D system and identified with an RV-LV delay of ≥70ms were 1:1 randomized. Randomization occurred in the electronic data capturing system.
223647243|NCT02796313|BEHAVIORAL|DASH Groceries + Weekly Sessions|Intervention group participants will receive 1 hour of in-person nutritional counseling and a personalized prescription for the low-salt DASH diet based on estimated calorie needs at baseline, followed by weekly 20-minute phone calls in weeks 1-8 to provide extra support.
223647244|NCT02796313|BEHAVIORAL|Groceries + Brochure|Control group participants will receive a printed brochure about the health benefits of a low-salt diet. They will place an unrestricted $35 grocery order for 8 weeks.
223647245|NCT00045617|BIOLOGICAL|monoclonal antibody 11D10 anti-idiotype vaccine|
223647246|NCT00045617|BIOLOGICAL|monoclonal antibody GD2 anti-idiotype vaccine|
223647247|NCT00045617|DRUG|cisplatin|
223647248|NCT00045617|DRUG|etoposide|
223647249|NCT00045617|RADIATION|radiation therapy|
223647250|NCT01938716|DRUG|Gemcitabine|500 mg/m2 at a fixed dose rate of 10 mg/m2/min by vein for the first 5 patients during pancreatic surgery. Next 15 subsequent patients receive 750 mg/m2 by vein at a fixed dose rate of 10 mg/m2/min.
223647251|NCT00697138|DRUG|d-Amphetamine; Atomoxetine|Dexedrine (0-60 mg/day); Strattera (0-80 mg/day)
223647252|NCT02817568|OTHER|Drawing Blood|Drawing Blood for genetic analysis
223647253|NCT00426244|OTHER|Osteopathic Manipulative Treatment|OMT is a complementary and alternative body-based treatment method in which the patient is evaluated and treated including the musculoskeletal system to improve physiologic functioning and remove impediments to optimal health and functioning.
223647254|NCT00426244|OTHER|Placebo Ultrasound|"In addition to controlling for physician attention during the treatment visit, the SUT used a nonfunctional ultrasound therapy unit that was modified for research purposes to provide both visible and auditory cues that could potentially elicit a placebo response. The physician provided the SUT by placing the applicator head over the subject's clothing and applying sufficient pressure for tactile stimulation of the skin and underlying tissues in the same anatomical distributions as would generally be addressed if the subject were being treated with OMT.~The subjects assigned to the UOBC only group did not receive any study treatments beyond conventional obstetrical care; however, they were expected to complete data collection forms on the same schedule as all other trial subjects."
223647255|NCT04395742|OTHER|Data collection|Only data collection
223647256|NCT01358721|DRUG|BMS-936558 (Anti-PD-1)|Solution, Intravenous infusion, 0.3 mg/kg, Every 3 weeks, Indefinitely depending on response
223647257|NCT01358721|DRUG|BMS-936558 (Anti-PD-1)|Solution, Intravenous infusion, 2 mg/kg, Every 3 weeks, Indefinitely depending on response
223647258|NCT01358721|DRUG|BMS-936558 (Anti-PD-1)|Solution, Intravenous infusion, 10 mg/kg, Every 3 weeks, Indefinitely depending on response
223647259|NCT01908803|DRUG|AL-60371/AL-817 otic suspension|
224232746|NCT01812421|OTHER|Hypertension Health Education Protocol (HHEP)|
224232747|NCT01183000|PROCEDURE|Closure of the peritoneum at cs|Injection of 5 mg Marcaine (anesthetic solution) to the leg
224232748|NCT00721877|DRUG|resveratrol|Given orally
224232749|NCT00721877|OTHER|pharmacological study|Correlative studies
224232750|NCT00721877|OTHER|laboratory biomarker analysis|Correlative studies
224232751|NCT01596647|DRUG|caffeine|single dose of the probe drug cocktail contains: caffeine, diclofenac, omeprazole and midazolam
224232752|NCT01596647|DRUG|diclofenac|single dose of the probe drug cocktail contains: caffeine, diclofenac, omeprazole and midazolam
224232753|NCT01596647|DRUG|omeprazole|single dose of the probe drug cocktail contains: caffeine, diclofenac, omeprazole and midazolam
224232754|NCT01596647|DRUG|midazolam|single dose of the probe drug cocktail contains: caffeine, diclofenac, omeprazole and midazolam
224232755|NCT01596647|DRUG|TKI258|dovitinib, 5 days on / 2 days off dose schedule
224232756|NCT01350063|DRUG|Sodium dichloroisocyanurate (NaDCC) tablet (Aquatab)|One tablet should be added to 10L container, resulting in a free chlorine dose of 2 mg/L.
224232757|NCT01350063|DEVICE|Water storage container (Jerry can)|Shallow tubewell water should be stored in 10L container.
224232758|NCT01350063|OTHER|No intervention|
224232759|NCT02574052|BEHAVIORAL|participants' food choices|just recorded the participants' food choices in the school cafeteria
224232760|NCT02574052|BEHAVIORAL|menu labelling without nutrition education|The investigators provided every participant with a menu labeling without any interpretation and recorded their dietary selections
224232761|NCT02574052|BEHAVIORAL|menu labelling with nutrition education|The investigators not only sent a menu labeling to every participant, but also delivered nutrition education to participants by providing them with nutrition and health knowledge through WeChat daily.
223647260|NCT01908803|DRUG|Ciprofloxacin 0.3%/dexamethasone 0.1% otic suspension|CIPRODEX®
223647261|NCT00184301|BEHAVIORAL|inpatient treatment|inpatient treatment during 1 year
223647262|NCT00184301|BEHAVIORAL|outpatient treatment|intensive outpatient treatment consisting of two-weekly group sessions during 1 year
223647263|NCT00867815|DRUG|Diagnostic procedures|The patients will not receive any study drug in this study. The patients will have ophthalmological (eye) examinations, blood work and will complete an interview
223647264|NCT00120419|DRUG|mycophenol mofetil (MMF, Cellcept®) 500 mg BID|
223647265|NCT02840591|DRUG|Ramelteon|
223647266|NCT02840591|DRUG|Citicoline|
223647267|NCT04980144|DRUG|3% Diquafosol tetrasodium|3% Diquafosol tetrasodium eye drops will be used to assess its usefulness in diabetic dry eye symptoms
223647268|NCT04980144|DRUG|0.1% hyaluronate|0.1% hyaluronate eye drops will be used to assess its usefulness in diabetic dry eye symptoms and compared to 3% Diquafosol tetrasodium eye drops.
223647269|NCT01043367|DIETARY_SUPPLEMENT|Deprexil|One 600 mg Deprexil tablet (Orally administered) half an hour after each meal (breakfast, lunch and dinner), for 24 weeks. A 20 minutes relaxation psychotherapy will also be provided once a week.
223647270|NCT01043367|DIETARY_SUPPLEMENT|Placebo|One Placebo tablet (Orally administered) half an hour after each meal (breakfast, lunch and dinner), for 24 weeks. A 20 minutes relaxation psychotherapy will also be provided once a week.
223647271|NCT04441918|COMBINATION_PRODUCT|JS016 (anti-SARS-CoV-2 monoclonal antibody)|JS016 (anti-SARS-CoV-2 monoclonal antibody)
223647272|NCT05653076|DIETARY_SUPPLEMENT|Hibiscus sabdariffa extract|Daily supplementation with 520 mg of Hibiscus sabdariffa extract for 10 days.
223647273|NCT00710580|BIOLOGICAL|ABT-874|SQ injection 200 mg Weeks 0 and 4; 100 mg Week 8
223647274|NCT00710580|BIOLOGICAL|etanercept|SQ injection 50 mg BIW
223647275|NCT00710580|DRUG|placebo|SQ placebo injections for ABT-874 and etanercept
223647276|NCT04884178|DEVICE|Trifocal Preloaded IOL Delivery System|UV and blue-light filtering foldable trifocal IOL with a +2.2 diopter (D) addition power of intermediate visual acuity and a +3.3 D addition power of near visual acuity. This device is approved in Taiwan.
223647277|NCT04946279|OTHER|Best Practice|Receive usual/standard of care
223647278|NCT04946279|OTHER|Informational Intervention|Receive conversation tool
223647279|NCT04946279|OTHER|Questionnaire Administration|Ancillary studies - Baseline and follow-up questionnaires
223647280|NCT05408442|OTHER|No intervention|No intervention
223647281|NCT03893942|OTHER|Questionnaires administration|Psychological and quality of life questionnaires
223647282|NCT03893942|OTHER|Langer Mindfulness Scale (LMS)|The LMS is a 21-item questionnaire, assessing four domains associated with mindful thinking: novelty-seeking, engagement, novelty producing, and flexibility.
223647283|NCT03893942|OTHER|Mindful Attention Awareness Scale (MAAS)|The MAAS is a 15-item questionnaire, designed to assess a core characteristic of dispositional mindfulness, namely, open or receptive awareness of and attention to what is taking place in the present
223647284|NCT03893942|OTHER|Cognitive Flexibility Scale (CFS)|The CFS is 12-item self-report test assessing awareness.
223647285|NCT03893942|OTHER|Life Orientation Test (LOT)|The LOT is a 10-item, self-administered scale assessing generalized expectancies for positive versus negative outcomes.
223647286|NCT03893942|OTHER|Mini Locus of Control test (MLS)|The MLS is a 6-item questionnaire that includes 3 factors : chance, powerful others, and internality.
223647287|NCT03893942|OTHER|Hospital Anxiety and Depression Scale (HADS)|The HADS is a 14-items rated on a four-point Likert scale. The questionnaire was designed to screen for the presence and severity of depression (HADS-D) and anxiety (HADS-A) in people with a physical symptomatology
223647288|NCT03893942|OTHER|Perceived Stress Scale (PSS)|The PSS is 14-item self-report tool commonly used to provide a global measure of perceived stress in daily life.
223647289|NCT01501877|BEHAVIORAL|Acceptance and Commitment Therapy|The intervention is based on Acceptance and Commitment Therapy and will be tailored to smokers with Type 2 diabetes.
223647290|NCT01501877|BEHAVIORAL|Standard smoking cessation intervention|Standard smoking cessation intervention based on clinical practice guidelines.
224232762|NCT01636856|BEHAVIORAL|Oropharyngeal exercises|Oropharyngeal exercises (derived from speech language pathology) to the soft palate, tongue and facial muscles exercises as well as stomatognathic functions.
224232763|NCT01636856|BEHAVIORAL|Respiratory exercises, nasal dilator, nasal lavage|Respiratory exercises, nasal dilator, nasal lavage
223647291|NCT01432925|PROCEDURE|surgical intervention on Buruli ulcer|Can the need for surgical intervention be avoided by delay of the decision on surgical intervention, comparing the need on surgical intervention from time points of week 8 and week 14 (number of weeks after start of antibiotic treatment with streptomycin/rifampicin).
223647292|NCT00001213|DRUG|Cysteamine|
223647293|NCT05297981|PROCEDURE|Erector spinae plane block|The patient will be placed in lateral decubitus position. A high frequency linear probe of a transportable Fuji M-Turbo ultrasound system will be placed on the spinous process at T8 level on the parasagittal plane and then slide 2.5-3 cm laterally to visualize the transverse process and erector spinae muscle. Using the inplane technique,then 0.5 ml/kg of 0.25% bupivacaine will be injected between the muscle and transverse process. The same procedure will be performed bilaterally.
223647294|NCT05297981|PROCEDURE|Quadratus lumborum block|The patient will be placed in the lateral decubitus position. A low frequency curved probe of a transportable Fuji M-Turbo ultrasound system will be placed horizontally in the anterior axillary line midway between the subcostal margin and the iliac crest to identify the triple abdominal muscle layers.A 22-G, 80-mm needle echogenic needle will be inserted in plane relative to the US probe, into the posterior aspect of the QL muscle (between QL and erector spinae muscle); this is known as QLB type 2. Then, 0.5 ml/kg of 0.25% bupivacaine will be injected behind the muscle as a bolus dose. The block will be performed bilaterally.
223647295|NCT00149318|OTHER|Biochemical analyses.|Biochemical analyses.
223647296|NCT04673019|BEHAVIORAL|Nurse AMIE (Addressing Metastatic Individuals Every day)|Supportive Care Platform (behavioral interventions that are offered based on answers to daily symptom rating questions). Interventions offered include walking, balance, strength exercise, guided relaxation, CBT, DBT, soothing music.
223647297|NCT01554241|DIETARY_SUPPLEMENT|D3 2000 IU/day|2000 IU/day D3
223647298|NCT01554241|DIETARY_SUPPLEMENT|D3 4000 IU/day|vitamin D3 4000 IU/day
223647299|NCT01554241|DIETARY_SUPPLEMENT|D3 50,000 IU weekly|vitamin D3 50,000 IU/week
223647300|NCT01554241|DIETARY_SUPPLEMENT|vitamin D3 800 IU/day|vitamin D3 800 IU/day
223647301|NCT06104436|BEHAVIORAL|Individualized music playlist|Individualized music playlist composed of preferred music genres sequenced according to the ISO-Principle. It will be played at the state of agitation.
223647302|NCT06104436|BEHAVIORAL|Preferred music|Preferred music is composed of the genres selected by the participants, and to be played at random sequence.
223647303|NCT06104436|BEHAVIORAL|Usual care|Usual technique for calming agitated older adults with dementia
223647304|NCT05272501|BEHAVIORAL|Calming Touch|The calming treatment consists of deep pressure massage and gentle facilitation. The therapist works with the vertical axis, center, respiration, body boundaries and the feet.
223647305|NCT03404752|DRUG|Peg-Filgrastim|
223647306|NCT04030117|PROCEDURE|ACTIVA Bioactive restoration|Removal of Class II decay in second primary molars and placement of ACTIVA restoration.
223647307|NCT04030117|PROCEDURE|Compomer restoration|Removal of Class II decay in second primary molars and placement of Compomer restoration.
223647308|NCT00077415|DRUG|gemcitabine hydrochloride|
223647309|NCT00077415|DRUG|triapine|
223647310|NCT05591313|BEHAVIORAL|LI-40|Participants were asked to complete a volume-matched light-intensity exercise for 30-min. The exercise volume was pre-determined based on the energy expenditure (kcal) calculated with 5-min warm-up stage, 20-min main exercise stage (i.e., moderate intensity as 50%-60 % heart rate reserve, HRR), and 5-min cool-down stage.
223766222|NCT03853707|OTHER|Questionnaire Administration|Ancillary studies
223766223|NCT06454981|DEVICE|Hemodiafilter|"The enrolled patients were randomly divided into the experimental group and the control group, using the hemodiafilter (experimental device) produced by Shinva Medical Instrument Co.,Ltd."
223647311|NCT05591313|BEHAVIORAL|MI-30|Participants were asked to complete a volume-matched moderate-intensity exercise for 20-min. The exercise volume was pre-determined based on the energy expenditure (kcal) calculated with 5-min warm-up stage, 20-min main exercise stage (i.e., moderate intensity as 50%-60 % heart rate reserve, HRR), and 5-min cool-down stage.
223647312|NCT05591313|BEHAVIORAL|HI-16|Participants were asked to complete a volume-matched high-intensity exercise for 16-min. The exercise volume was pre-determined based on the energy expenditure (kcal) calculated with 5-min warm-up stage, 20-min main exercise stage (i.e., moderate intensity as 50%-60 % heart rate reserve, HRR), and 5-min cool-down stage.
223647313|NCT04468997|DRUG|Drug 601|Recombinant humanized anti-VEGF monoclonal antibody, drug 601(0.375mg), Vitreous injection, injection once;
223647314|NCT04468997|DRUG|Drug 601|Recombinant humanized anti-VEGF monoclonal antibody, drug 601(0.75mg), Vitreous injection, injection once;
223647315|NCT04468997|DRUG|Drug 601|Recombinant humanized anti-VEGF monoclonal antibody, drug 601(1.25mg), Vitreous injection, injection once;
223647316|NCT04468997|DRUG|Drug 601|Recombinant humanized anti-VEGF monoclonal antibody, drug 601(2.5mg), Vitreous injection, injection once;
223647317|NCT04468997|DRUG|Drug 601|Recombinant humanized anti-VEGF monoclonal antibody, drug 601(1.25mg), Vitreous injection, injection once every 4 weeks, three times continuously, then injection as needed within 9 months.
223647318|NCT04468997|DRUG|Drug 601|Recombinant humanized anti-VEGF monoclonal antibody, drug 601(2.5mg), Vitreous injection, injection once every 4 weeks, three times continuously, then injection as needed within 9 months.
223647319|NCT00933452|DRUG|duloxetine|30mg, oral administer; step 1: single dose; step 2: multiple dose, 7 days
223647320|NCT00933452|DRUG|duloxetine|15mg, oral administer
223647321|NCT00933452|DRUG|duloxetine|60mg, oral administer; step 1: generic duloxetine; step 2: Innovator duloxetine
223766224|NCT06454981|DEVICE|Fresenius Medical Care AG & Co.KGaA|The enrolled patients were randomly divided into the experimental group and the control group, using the FX 800HDF hollow fiber hemodialysis/filter (control device) produced by Fresenius Medical Care AG \& Co.KGaA (registered agent: Fresenius Medical Care (shanghai) Company Limted).
223766225|NCT04898218|OTHER|Exercise|The exercises were performed for 12 weeks, for the maximum of 6 days/week for Osteoanabolic group, 5 days/week for aerobic group and 3 days/ week for a resistance group as per ACSM, FITT protocol.
223766226|NCT03111992|DRUG|PDR001|Anti-PD1 antibody
223766227|NCT03111992|DRUG|CJM112|Anti-IL-17A antibody
223766228|NCT03111992|DRUG|LCL161|Oral small molecule SMAC-mimetic
223647322|NCT03835832|OTHER|The participants do not receive any intervention for this study|The participants do not receive any intervention for this study
223647323|NCT06288100|OTHER|Observation|"1. Measure changes in tibial slope after medial opening wedge High tibial osteotomy in Skeletally mature patient with unicompartmental osteoarthitis and genuvarus knee~2. Evaluate the effect of tibial slope angle change on the clinical outcome at 1 year ."
223647324|NCT04316819|OTHER|Packed Promise Demonstration Benefits|Monthly: Home-delivered food box, nutrition education handout, and $15 monthly voucher for fruits and vegetables
223647325|NCT01614392|BEHAVIORAL|High velocity low force Power Training|Lower Extremity high velocity power training performed at lower external resistance (40% of the 1 repetition maximum muscle strength). Leg and knee extension exercises were performed twice per week (3 sets of each exercise consisting of 10 repetitions).
223647326|NCT01614392|BEHAVIORAL|Low velocity high force Power Training|Lower extremity low velocity power training performed at high external resistance (70% of the 1 repetition maximum muscle strength). Leg and knee extension exercises were performed twice per week (3 sets of each exercise consisting of 10 repetitions).
223647327|NCT01657240|DRUG|PRO-118|instill one drop in each eye once a day for 21 days
223647328|NCT01657240|DRUG|Olopatadine Hydrochloride|instill one drop in each eye once a day for 21 days
223647329|NCT05597488|DEVICE|EUS guided portal pressure gradient measurement|EUS-guided PPGM is performed under monitored anaesthesia. The linear array echoendoscope is passed from the mouth into the stomach and duodenum, as with a standard exam. Under endoscopic ultrasound guidance, a 25 gauge EUS needle (Echotip, Cook Medical, USA) primed with heparin 100 USP/ml is then placed across the stomach or duodenal wall and through the liver parenchyma into the portal vein (Figure 3). A pressure measurement is then obtained from the compact pressure transducer attached to the handle of the needle (Figure 4). Three separate measurements are made with re-priming of heparin (less than 0.5 ml). The needle is then removed from the portal vein and liver, if necessary. The process is repeated for the hepatic vein (Figure 5). The EUS - PPG is calculated by subtracting the average of the three hepatic vein pressure measurements from the average of the 3 direct portal vein pressure measurements.
223647330|NCT04441086|BEHAVIORAL|eMotion|Content is delivered within the context of emotion provoking situations common in those recovering from a first MI and in maintaining MVPA. The new on-demand access to asynchronous content sessions provides didactic presentation of video and written material based on weekly needs assessments. Weekly scheduled synchronous video chat sessions, led by a nurse interventionist, will provide further individualization and application of content materials.
223647331|NCT04441086|BEHAVIORAL|Healthy Living Active Control|The attention control group will receive their usual cardiac rehabilitation and a comparable dose matched (to that of the eMotion intervention) of healthy living web content and video chat with a nurse.
223647332|NCT01993121|OTHER|Supervised Exercise Training|All subjects will perform three months of supervised exercise training.
223647333|NCT03683459|DEVICE|FemFlow Drug-Eluting Peripheral Balloon Catheter|Medical devices will be applied to the enrolled subjects. The arterial pathway was established, followed by lower limb arteriography, and the auxiliary equipment was selected according to the stenosis of the subject's target lesions, followed by pre-dilation. Patients with residual stenosis ≤70% after pre-dilation and suitable for simple balloon dilation catheter treatment can be enrolled. Select the appropriate size of the experimental drug balloon for expansion, then radiography was used to observe the expansion effect, if necessary, multiple expansion can be conducted, and finally withdraw the instrument and suture the puncture point.
223647334|NCT00372593|DRUG|asparaginase|Given intramuscularly
223647335|NCT00372593|DRUG|cytarabine|Given IV
223647336|NCT00372593|DRUG|daunorubicin hydrochloride|Given IV over 6 hours
223647337|NCT00372593|DRUG|etoposide|Given IV over 1-4 hours
223647338|NCT00372593|DRUG|gemtuzumab ozogamicin|Given IV over 2 hours
223647339|NCT00372593|DRUG|mitoxantrone hydrochloride|Given IV over 1 hour
223647340|NCT01380821|RADIATION|Myocardial SPECT|Myocardial SPECT according to clinical standards for patients with a clinical indication to undergo this imaging test.
223647341|NCT01994824|DRUG|rabbit antithymocyte globulin|Thymoglobulin, 3 mg/kg, will be given on day 8 posttransplant to patients at high risk of significant GVHD per day 7 IL15 and IL2Ra levels.
223647342|NCT03623529|DRUG|LJPC-501 (angiotensin II)|Angiotensin II is a peptide hormone naturally produced by the body that regulates blood pressure via vasoconstriction and sodium reabsorption.
223647343|NCT03623529|DRUG|Placebo|Placebo Arm
223647344|NCT00433004|DRUG|Plan B (Levonorgestrel)|PP TEENS ARE RANDOMIZED TO PLAN B + ROUTINE CONTRACETIVE CARE VS. ROUTINE CARE ALONE. QUESTIONNAIRES ON HEALTH STATUS, SEXUAL HISTORY, AND CONTRACEPTIVE USE ARE COMPLETED AT STATED INTERVALS.
223647345|NCT05048095|OTHER|AI cancer detection system|The use of AI as a third reader and as a decision support system during consensus meeting
223647346|NCT03180918|PROCEDURE|testicular tissue biopsy|testicular tissue biopsy during general anesthesia
223647347|NCT05522348|PROCEDURE|Stability of a two piece PSI deign in splintless maxillary orthognathic surgery|two patient fitted custom made plates will be used for the fixation of the maxilla following le fort 1 osteotomy for the correction of the dentofacial deformity and the postoperative stability will be measured using postoperative xrays
223647348|NCT05522348|PROCEDURE|Stability of a one piece PSI deign in splintless maxillary orthognathic surgery|one patient fitted custom made plate will be used for the fixation of the maxilla following le fort 1 osteotomy for the correction of the dentofacial deformity and the postoperative stability will be measured using postoperative xrays
223647349|NCT03534180|OTHER|Laboratory Biomarker Analysis|Correlative studies
223647350|NCT03534180|DRUG|Romidepsin|Given IV
223647351|NCT03534180|DRUG|Venetoclax|Given PO
223647352|NCT04786535|PROCEDURE|Expanded Hemodialysis|"* Single-use Theranova 400 Dialyzer~* Blood flow (Qb) minimum of 300 mL/min~* Dialysis flow (Qd) 500 mL/min~* Minimum therapy time of 4 hours~* Ultrafiltration necessary to achieve dry weight"
223647353|NCT04786535|PROCEDURE|High-flux Conventional Hemodialysis|"* Single-use high-flux hemodialyzer~* Blood flow (Qb) minimum of 300 mL/min~* Dialysis flow (Qd) 500 mL/min~* Minimum therapy time of 4 hours~* Ultrafiltration necessary to achieve dry weight"
223766229|NCT05943444|PROCEDURE|Parks technique|compare different operational styles of low rectal cancer
223766230|NCT05943444|PROCEDURE|Bacon technique|Bacon technique
223647354|NCT04786535|PROCEDURE|Hemodiafiltration|"* Single-use high-flux hemodialyzer~* Post-dilution mode~* Minimum convective volume of 23 L~* Blood flow (Qb) minimum of 300 mL/min~* Dialysis flow (Qd) 700 mL/min~* Minimum therapy time of 4 hours~* Ultrafiltration necessary to achieve dry weight"
223647355|NCT03353519|OTHER|Primary care model|"Specifically, the intervention will comprise the following components:~1. Structured review of patient needs;~2. A self-management programme (MLAS) for stroke survivors and their carers;~3. A direct point of contact for stroke survivors and carers at the GP surgery;~4. Optimised communication between General Practice staff and specialist services;~5. Service mapping for stroke related needs;~6. Training for General Practice staff."
223647356|NCT01744080|OTHER|Regular Wait Time|Surgery will take place no earlier than 9 months and no later than 12 months after the sport medicine physician consult.
223647357|NCT01744080|OTHER|Early Surgery|Patient will proceed to have rotator cuff repair surgery within 3 months of the initial consult with the sport medicine physician.
223647358|NCT04517175|DIAGNOSTIC_TEST|Flow cytometry|Flow cytometric immunophenotyping and determination of proliferative activity by means of Ki-67.
223647359|NCT01169818|DRUG|Insulin Glargine|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous~Dose regimen: initial: once a day in the evening at bedtime. Titration will occur each time the middle FPG (Fasting Plasma Glucose) value is above target"
223647360|NCT00220636|DRUG|Aripiprazole|Aripiprazole dose ranging from 5 to 30 mg/day, augmenting antidepressant treatment. Aripiprazole is used as an augmenting medication on an open label basis for patients on antidepressant medication who continue to have depressive symptoms. This is an open label case series in which all subjects receive aripiprazole augmentation. There is no comparator group.
223647361|NCT06465407|DIETARY_SUPPLEMENT|Collagen|Participants will consume two 30-g amount of collagen peptides derived from bovine hide (commercially available as Vital Proteins or Peptan) mixed in 300 ml of orange gatorade zero.
223647362|NCT06465407|DIETARY_SUPPLEMENT|Maltodextrin|Participants will consume two 30-g amount of pure maltodextrin mixed in 300 ml of orange gatorade zero.
223647363|NCT00330967|DRUG|20% Intralipid|lipid infusion
223647364|NCT01119209|DRUG|Ropivacaine|Approved by the Danish Medicines Agency
223647365|NCT01119209|DRUG|Saline|Approved by the Danish Medicines Agency
223647366|NCT01970098|DRUG|KPS-0373, High dose|28 weeks
223647367|NCT01970098|DRUG|KPS-0373, Low dose|28 weeks
223647368|NCT01970098|DRUG|Placebo|28 weeks
223647369|NCT05828485|DRUG|MY008211A tablets|A single dose of MY008211A tablet was administered after fasting and high-fat, high-calorie feeding
223647370|NCT00539942|DRUG|Arixtra (fondaparinux sodium)|Treatment will consist of daily injections of pharmacy prepared syringes of Arixtra (fondaparinux sodium) 2.5mg. Treatment will continue for 21 consecutive days to end on post-operative day 22.
223647371|NCT00539942|DEVICE|Intermittent compression devices (ICD)|All patients will receive intermittent compression devices (ICD's) during the patient's entire hospitalization after the operative procedure. Patients randomized to the standard of care management will receive ICD's only. This represents the current standard of care at our institution at the time of initiation of the trial.
223647372|NCT02616588|BEHAVIORAL|Veteran Patient Navigator and Social Work Intervention|Each study participant will receive a veteran patient navigator intervention which consists of five study visits consisting of advance care planning, pain/symptom management, and education about hospice and palliative care. When clinically indicated, patients will be referred to a social work intervention providing psychosocial care and support.
223647373|NCT05167643|DRUG|Enituzumab injection+Abesili tablets+Anastrozole tablets|According to the current clinical guidelines combined with clinical practice, the treating physicians recommended the treatment plan to the subjects, and decided to enroll HR+/HER2+ advanced breast cancer patients treated with H combined with CDK4/6 inhibitor + AI±OFS into this study
223647374|NCT01719497|DRUG|[C-11]OMAR|PET radioligand
223647375|NCT00892983|BEHAVIORAL|FAB|Standard well child care plus 7 extra parent contacts for augmented education and support around breast feeding, food and activity with 1 before birth and then at 1-2 weeks, and 3, 4, 7, 9, 13, and 18 months post-partum.
223647376|NCT00892983|BEHAVIORAL|Sleep|"Standard well child care plus 2 extra contacts focussed on Sleep with 1 before birth (anticipatory guidance), and sleep problem prevention at 3 weeks. A sleep problem intervention starting at 6 months was possible for those indicating their child had a sleep problem at 6 months of age. Main prevention advice focussed on placing baby to sleep awake, maximising night-day differences and use of sleep place in parents bedroom for first 6 months. Intervention after 6 months uses preferentially a technique called parental presence, and if this does not fit family a technique called camping out and finally, if neither of the first two fit family, controlled crying."
223647377|NCT06108232|DRUG|Obinutuzumab|Given by IV (vein)
223647378|NCT06108232|DRUG|CC-99282|Given by PO
223647379|NCT01977872|BEHAVIORAL|A worksite activity-diet intervention|
223766231|NCT03384446|OTHER|Tooth-borne treatment|Titanium curettes
223766232|NCT03384446|OTHER|Implant-specific treatment|Implant brush
223766233|NCT06392555|DEVICE|Device-Aided performances|Determination of the presence of the 8 findings suspicious of CHD by readers, aided by the device
223647380|NCT03448913|PROCEDURE|PECS block|It consists in injection of 20-30 ml of local anesthetic between pectoral minor, pectoral major, and serratus muscles.
223647381|NCT02370108|DEVICE|electrical muscle stimulation|electrical muscle stimulation at hand muscle for reduction tremor
223680930|NCT03422627|DRUG|Efavaleukin Alfa|"Phase 1: This study will be conducted as a multiple ascending dose (MAD) study. Each dosing cohort will consist of between 3 and 6 subjects who will receive efavaleukin alfa subcutaneously (SC) either every week or every 2 weeks plus protocol permitted background therapy for 52 weeks. At the discretion of the Sponsor, following discussion and agreement between the principal investigator and medical monitor, subjects responding to efavaleukin alfa (as assessed by the end of week 50), who wish to continue treatment, may continue to receive efavaleukin alfa treatment at their current dosing regimen for up to an additional 208 weeks through an extended dosing period. All subjects who continue to receive efavaleukin alfa during the extended dosing period will be reevaluated every 6 months for their response to treatment.~Phase 2: All subjects will receive the recommended phase 2 dose (RP2D) of efavaleukin alfa for 52 weeks."
223766234|NCT06392555|OTHER|Device-Unaided performances|Determination of the presence of the 8 findings suspicious of CHD by readers, unaided by the device
224232764|NCT04126356|PROCEDURE|mobilization of the larynx|Check the intubation conditions during laryngoscopy without external mobilization of the larynx, with Sellick manoeuvre or with low paratracheal esophagal compression.
224232765|NCT03185897|OTHER|Non-treatment, seroprevalence|Non-treatment study examining the prevalence of preexisting immunity to adeno-associated virus (AAV)
224232766|NCT00003145|DRUG|Fludarabine Phosphate|Given IV
224232767|NCT00003145|RADIATION|Total-Body Irradiation|Undergo TBI
224232768|NCT00003145|PROCEDURE|Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic PBSCT
224232769|NCT00003145|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo allogeneic PBSCT
224232770|NCT00003145|DRUG|Cyclosporine|Given PO or IV
224232771|NCT00003145|DRUG|Mycophenolate Mofetil|Given PO or IV
223647382|NCT05466864|DEVICE|Belun Sleep platform|BSP(Belun Technology Company Limited) is a novel wearable system using a neural network algorithm that consists of a patented wearable device (Belun Ring), a charging cradle, and cloud-based software. The Belun Ring, an FDA-cleared pulse oximeter, acquires signals from the radialis indicis artery of the proximal index finger. The Belun Ring total sleep time can be derived from features extracted from accelerometer, SpO2, and PPG signals, whereas Belun Ring AHI can be derived from Ring-TST and features extracted from HRV and SpO2 changes. The BSP proprietary OSA detection algorithm was using neural network. BSP performance can be improved by training the algorithm through continual data collection. To our knowledge, BSP is the only validated sleep platform using a medical-grade wearable pulse oximeter, actigraphy, and artificial intelligence algorithm that has the capability to identify sleep stages, detect OSA events, and monitor autonomic nervous system activity changes during sleep.
223647383|NCT04065737|DRUG|Sintilimab|"Sintilimab is a type of immunotherapy. Immunotherapy works by encouraging the body's own immune system to attack cancer cells.~other name: IBI308"
223647384|NCT06211959|BEHAVIORAL|Approach Bias Modification with Implementation Intentions|Participants in each experimental condition will perform different variants of the Approach-Avoidance Task (i.e., a task that is widely used in the litterature to assess and modify the approach bias toward alcohol - the relative ease to approach alcohol rather than to avoid it). Participants in the classical Approach Bias Modification conditions will perform a version of this task which will train them to (almost-)systematically emit an avoidance response toward alcohol ; Participants in the Approach Bias Modification with Implementation Intentions condition will perform the same version of the task but will additionnaly have to complete a planning intervention (i.e., implementation intentions) to help them avoiding alcohol; Participants in the Sham-training condition will perform a version of this task which require them to approach alcohol as often as they have to avoid it (i.e., no real training).
223647385|NCT00257257|DRUG|Rimonabant (SR141716)|
223647386|NCT01210040|DIETARY_SUPPLEMENT|Folic Acid|2.8mg
223647387|NCT01210040|DIETARY_SUPPLEMENT|Folic Acid and Iron|60mg Iron and 2.8mg Folic Acid
223647388|NCT01149668|DRUG|PCI-24781|Subjects enrolled in this study will receive PCI-24781 administered orally at the schedule and dosage from their prior protocol.
223647389|NCT03680846|DEVICE|HF10 Therapy|Senza 10 kHz Spinal Cord Stimulation
223647390|NCT03680846|OTHER|CMM|Conventional Medical Management
223647391|NCT02029300|OTHER|Fiberoptic Intubation through the nasal route|
223647392|NCT02029300|OTHER|Fiberoptic intubation through the oral route|
224232772|NCT00003145|BIOLOGICAL|Therapeutic Allogeneic Lymphocytes|Given IV
224232773|NCT00003145|OTHER|Laboratory Biomarker Analysis|Correlative studies
224232774|NCT00836836|OTHER|Modified Atkins diet|"Modified Atkins Diet administration~1. Carbohydrates intake will be restricted to 10 grams/ day. (Carbohydrate values of various food items will be explained in detail, and exchange lists provided. Four 2.5 grams carbohydrate exchange items will be allowed in a day.)~2. Fats (e.g. cream, butter, oils, ghee) encouraged.~3. Proteins (cheese, fish, eggs, chicken, soya products) unrestricted.~4. Clear carbohydrate-fluids not restricted.~5. Calcium and multivitamin supplementation will be provided."
224232775|NCT06205719|DRUG|ciprofol|sedation
223647393|NCT05045378|DRUG|Midazolam (active placebo)|Arm1: Two 0.045mg/kg midazolam infusions at Day1 and Day3。
223766235|NCT03944122|DEVICE|ultrasound|therapeutical ultrasound were applied to the patients
223766236|NCT02864641|BEHAVIORAL|Planet K|Planet K is a mobile and web-based technology infrastructure specifically designed to (a) enhance youths' chronic kidney disease- and treatment-related knowledge through interactive and game-based educational materials; (b) support adherence to the treatment regimen through customized task prompts via mobile and web-based delivery; and (c) promote patient-provider communication through real-world data collection and feedback loops.
224232776|NCT06205719|DRUG|Remazolam|sedation
224232777|NCT06205719|DRUG|Flumazenil|antagonism
224232778|NCT06205719|DRUG|Remifentanil|2ug/kg Remifentanil
224232779|NCT03491449|PROCEDURE|Group A|Maintaining a systolic blood pressure ≥ 140 and ≤ 160mm Hg for 72 hours.
224232780|NCT03491449|PROCEDURE|Group B|Maintaining a systolic blood pressure \<185mm Hg for 72 hours.
224232781|NCT04222036|OTHER|Translating the Questionnaire into Turkish and Related Processes|The first step is the translation from the original language to the other language. The ideal target in the translation phase is to use people who are familiar with the structure of the original language and who are familiar with the language. Two forward translation and one reverse translation methods will be applied after obtaining the written permission of the authors. After the completion of this phase, the terminological differences arising from the translators in the translation process from the original language to Turkish will be collected and discussed on the questions. The cultural adaptation study will be terminated by determining the equivalence between the Turkish version of the index and the English original. The final version of the questionnaire and the necessary changes will be arranged specific to the investigator's society and the authors of the original questionnaire will be consulted and the questionnaire will be finalized.
224232782|NCT04222036|OTHER|Validity|The scale will be applied by face-to-face technique and convergent (moderate-high correlation with optimism measure) and distant (low correlation with depression and anxiety measures) validity will be evaluated.
224232783|NCT04222036|OTHER|Reliability|The reliability of the materials will be tested with Cronbach alpha.
224232784|NCT06009913|OTHER|online teaching|teaching of subject was done using online system only
224232785|NCT06009913|OTHER|In class teaching|subjects were explained in normal class room
224232786|NCT01246375|DEVICE|Dual energy X-ray absorptiometry|Device which measures bone density
224232787|NCT04316273|OTHER|colonic surgery|resection of duplicated colon
224232788|NCT02234609|DEVICE|modified ART class IV|Carious tissue was removed with an excavator until a sound probing was obtained. Restorations were performed using a mechanically improved glass-ionomer cement for ART. The modified class IV ART restoration was inserted into the cavity using a spatula. By these restoration technique, the cavity was (i) sealed to stop further caries progression. The cavity was (ii) capped to protect the vital dentin-pulp-complex from external stimuli. The modified class IV ART was aimed at conserving the carious incisor for prospective functional use and for prolonging tooth preservation rather than at anatomical reconstruction of the tooth form for cosmetic reasons.
224232789|NCT00175357|DRUG|Methadone|The dose of the drug will be determined by a physician. The oral drug will be administered 1 dose per days, 7 days per week.
224232790|NCT00175357|DRUG|Diamorphine hydrochloride|The dose of the drug will be determined by a physician. The injected drug will be administered up to 3 doses per day, 7 days per week.
224232791|NCT04496635|OTHER|Implementation of a bundle of care|
224232792|NCT06153121|OTHER|Physical performance test - Closed Kinetic Chain Upper Extremity Stability Test (CKCUEST)|The test is performed in a pushup position with the hands placed 91.4 cm apart on strips of athletic tape. The person reaches with alternating hands across the body to touch the piece of tape under the opposing hand. The number of cross-body touches performed in 15 seconds is recorded. In total, three 15-s test trials were performed, with 45 s rest between each trial.
224232793|NCT06153121|OTHER|Physical performance test - modified Closed Kinetic Chain Upper Extremity Stability Test (m-CKCUEST)|The test is performed in a pushup position with the hands one half-arm span apart on strips of athletic tape. The person reaches with alternating hands across the body to touch the piece of tape under the opposing hand. The number of cross-body touches performed in 15 seconds is recorded. In total, three 15-s test trials were performed, with 45 s rest between each trial.
224232794|NCT06153121|OTHER|Physical performance test - Seated Seated Single Arm Shot Put Test (SSASPT)|Set up requires that the subject is placed in a seated position with their back against the wall, and a 2kg medicine ball held in a shot put position. When ready, the subject will perform a shot put motion to project the medicine ball as far as possible. The average of three trials is recorded for each arm.
224232795|NCT06153121|OTHER|Physical performance test - Upper Limb Rotation Test (ULRT)|Participants starts in a modified (on elbows) push-up position. Participants are positioned next to a wall in order to allow the shoulder, the elbow epicondyle, the greater trochanter and the lateral malleolus of the ankle to touch the wall. Participants are asked to perform a trunk rotation, coupled with an external rotation of the shoulder in a 90°-90° position (90° abduction, 90° external rotation) touching the tape placed vertically on the wall as quickly as possible for 15 s. Finally, three 15-s test trials were performed, with 45 s rest between each trial.
224320102|NCT00113763|OTHER|Best supportive care|Best supportive care as site routine excluding: antineoplastic chemotherapy, investigational agents, anti-EGFr(Epidermal growth factor receptor) targeting agents other than ABX-EGF(Panitumumab), experimental or approved anti-tumor therapies (e.g. Avastin), chemotherapy, radiotherapy (with the exception of radiotherapy for pain control limited to bone metastases).
224320103|NCT00113763|DRUG|Panitumumab|Intravenous infusion at a dose of 6 mg/kg once every 2 weeks.
224320104|NCT01207583|OTHER|Non-interventional observational study|Non-interventional observational study
224320105|NCT03757351|DRUG|DNL747|Repeating oral dose
224320106|NCT03757351|DRUG|Placebo|Repeating oral dose
223647394|NCT05045378|DRUG|Ketamine and Midazolam (active placebo)|Arm2: First 0.045mg/kg midazolam infusion and Second 0.5mg/kg ketamine infusion。
223647395|NCT05045378|DRUG|Ketamine|Arm3: Two 0.5mg/kg ketamine infusions。
223647396|NCT05835687|DRUG|B7-H3-CAR T cells|Autologous T cells transduced with a lentiviral vector expressing a B7-H3-CAR with a CD28z signaling domain and 41BB ligand (B7-H3-CAR T cells). Four (4) infusions of B7-H3-CAR T cells will be locoregionally administered via CNS reservoir catheter.
223647397|NCT06249867|DRUG|Darifenacin 7.5 MG Extended Release Oral Tablet|During the first two weeks (titration period), patients in the treatment arm will receive a daily dose of 7.5 mg darifenacin extended-release tablet. After the titration period, the dose will be increased to 15 mg once daily, which consists of two 7.5 mg tablets together for a period of 22 weeks.
223647398|NCT06249867|DRUG|Placebo|During the first two weeks (titration period), patients in the placebo arm will receive a daily dose of 1 placebo tablet. After the titration period, the dose will be increased to two placebo tablets taken together, for a period of 22 weeks.
223647399|NCT05752760|OTHER|Lactobacillus Plantarum 299v Freeze Dried Capsule|The intervention is a probiotic lactobacillus that is contained in food products in the US
223647400|NCT05752760|OTHER|Freeze Dried Potato Starch Capsule|The intervention is potato starch that is freeze dried designed to mimic the lp299v capsule.
223647401|NCT01858025|RADIATION|Pencil Beam scanning Radiation|
223647402|NCT01858025|DRUG|5-fluorouracil|
223647403|NCT01858025|DRUG|Mitomycin-C|
223647404|NCT05035706|PROCEDURE|Biopsy|Undergo biopsy
223647405|NCT05035706|PROCEDURE|Biospecimen Collection|Undergo blood and tissue sample collection
223647406|NCT05035706|OTHER|Electronic Health Record Review|Medical records reviewed
223647407|NCT05035706|OTHER|Photography|Photographs taken
223647408|NCT04533529|DRUG|Seltorexant|Seltorexant tablet will be administered orally once daily.
223647409|NCT04533529|DRUG|Placebo|Matching placebo tablet will be administered orally once daily.
223647410|NCT05592002|DEVICE|Genio System|The Genio® IS electrode placement does not require an extensive surgical manipulation of the hypoglossal nerve, it requires only a single incision site and does not require battery replacements as those are external components. Whereas UPPP surgery and other similar upper airway enlargement surgeries are much more extensive, are irreversible and tend to have more complications and modest long-term results in reducing OSA severity and symptoms. In summary, the solution offered by the Genio System to treat OSA patients with CCC using bilateral HGNS has a favorable risk-benefit ratio, as demonstrated by evidence from 2 studies.
223647411|NCT05084833|BEHAVIORAL|Control|Electronic educational materials
223680931|NCT01393028|OTHER|Cardiac CT|Cardiac CT: calcium scan and CT coronary angiography
223680932|NCT01393028|OTHER|Standard care|Standard care according to international guidelines
223647412|NCT05084833|BEHAVIORAL|Patient activation|Interactive text messages with links to videos (e.g. colorectal cancer screening options, cost of colorectal cancer screening, perspective from a cancer survivor, why regular appointments are important for cancer survivors) and resources (e.g. helpful websites) are sent to participants
223647413|NCT05084833|BEHAVIORAL|Primary care provider activation|Faxed educational materials (e.g. current colorectal cancer screening recommendations, frequently asked questions, insurance letter template, cover letter with overview of patient's cancer treatment history) sent to primary care providers
223647414|NCT03014544|DEVICE|Computer- administered test battery|Participants in this observational study will only undergo sequential cognitive performance evaluations by computer- administered cognitive test battery.
223647415|NCT03014544|DEVICE|Examiner- administered test battery|Participants in this observational study will only undergo sequential cognitive performance evaluations by examiner- administered cognitive test battery.
223766237|NCT02954913|PROCEDURE|Simultaneous Resection|Resections of 3 or more segments of the liver will be considered a major liver resection.(Reddy) The anesthetic technique and the order of liver resection or rectal resection will be determined by each surgeon's standards. It is recommended that a low central venous pressure be maintained in order to decrease intraoperative blood loss (Chen; Hughes) and that liver resection be performed prior to colorectal resection in order to keep a low central venous pressure during that part of the case.
223647417|NCT05201014|DIAGNOSTIC_TEST|NT-pro-BNP|Blood draw
223647418|NCT05201014|DIAGNOSTIC_TEST|Electrocardiogram|electrodes are placed on certain spots and a reading obtained to measure the voltage of the heart
224232796|NCT06153121|OTHER|Physical performance test - Shoulder endurance test (SET)|Participants were instructed to stand up straight with their back against a wall. The tested arm was placed in a 90°forward flexion holding a 1-m long thera-band® fixed at shoulder height on a graduated stick. Participants were asked to pull the thera-band® from the starting position 90°forward flexion-to a 90° external rotation and 90° abduction (90°90°position) at an alternated cadence given by a metronome. Males are asked to pull a green thera-band (2.1 kg) and females a red thera-band (1.7 kg). Repetitions are performed until the participant is fatigued.
224232797|NCT06153121|OTHER|Physical performance test - Posterior shoulder endurance test (PSET)|The participant is positioned prone, with the test shoulder off the table and the arm perpendicular to the floor. A bar on a stick is adjusted for each patient and fixed at the point that the participant's shoulder reaches 90° of horizontal abduction, the point at which the participant was to hold the arm at the top of the arc of motion for 1 second. The participant held a weight equal to 2% of his body weight (rounded to the nearest 0.5 kg). Starting with the arm perpendicular to the floor, the participant horizontally abducted his arm to 90 degrees at a cadence of 30 beats per minute. Repetitions are performed until the participant is fatigued.
224232798|NCT06153121|OTHER|Analytical test - Shoulder Strength|shoulder external rotation and internal rotation measured with a hand held dynanometer
224232799|NCT06153121|OTHER|Analytical test - Hand Grip Strength|Hand grip strength measured with a JAMAR Hand Dynamometer
224232800|NCT06153121|OTHER|Analytical test - Shoulder Range of Motion (ROM)|Passive external rotation in supine position with arm in 90° abduction - passive internal rotation in supine position with arm in 90° abduction.
224232801|NCT06153121|OTHER|PROM - Kerlan-Jobe Orthopedic Clinic Shoulder and Elbow Score (KJOC-SES)|The KJOC-SES survey is composed of ten 10-point questions to evaluate specifically the performance of overhead athletes, with the highest performance score of 100.
224232802|NCT06153121|OTHER|PROM - Competitive State Anxiety Inventory-2 (CSAI-2)|The Competitive State Anxiety Inventory scale contains 27 items. It a psychometric scale that asks the volunteer to rate, on a 4-point Likert scale, their coping skills for sports performance.
224232803|NCT06153121|OTHER|PROM - General elf-efficacy scale (GSES).|The GSES measures (10 statements) how a person deals with stressors/difficult situations in life. The scale is about a person's self-confidence that his or her actions are responsible for successful outcomes or, in other words, that one has control over challenging demands imposed by the environment.
224232804|NCT01751152|DRUG|NNC0114-0006|A single i.v. (intravenous, into the vein) dose. At week 12 the possibility to administer an additional open-label dose of NNC0114-0006 will be provided to all subjects irrespective of initial treatment allocation as long as they are not in need of rescue medication, as judged by the clinical investigator.
224232805|NCT01751152|DRUG|placebo|A single i.v. (intravenous, into the vein) dose. At week 12 the possibility to administer an additional open-label dose of NNC0114-0006 will be provided to all subjects irrespective of initial treatment allocation as long as they are not in need of rescue medication, as judged by the clinical investigator.
223647419|NCT05201014|DIAGNOSTIC_TEST|Echocardiogram|medical imaging of the heart
223647420|NCT05816850|DIAGNOSTIC_TEST|EZH2 mutations/CNAs by droplet digital PCR (ddPCR)|Test of EZH2 mutations/CNAs by droplet digital PCR (ddPCR) in peripheral blood and in unsorted bone marrow aspirate samples at enrolment
223647421|NCT05816850|DIAGNOSTIC_TEST|EZH2-derived gene expression signature by RNA-Seq|Test of EZH2-derived gene expression signature by RNA-Seq in a subset of diagnostic FFPE samples
223647422|NCT06315010|DRUG|Repotrectinib|"Repotrectinib is administered orally in capsule form, with each capsule containing size 0 hard gelatin 40 mg of the active compound in bottles containing 30 capsules.~Repotrectinib is administered orally in the form of capsules. The capsules are taken by mouth and swallowed intact (without chewing, crushing, or opening) with water or another suitable liquid."
223647423|NCT01950130|PROCEDURE|Preoperative IABC|IABP-Insertion upon inclusion into the trial and admission to the ICU
223647424|NCT02685332|RADIATION|Stereotactic Radiation|"Stereotactic Body Partial Breast irradiation Step No. Fractions Dose per fraction~-1 1 20 0 (starting) 1 22.5~1. 1 26.5~2. 1 30"
223647425|NCT05868239|DEVICE|Aerosol box|The aerosol box is a transparent, plastic cube covering the patient's head and shoulders, with circular access ports on the front of the box allowing for access to manage the airway. An additional four access holes (i.e. two on either side of the box) allow for airway assistants to access the patient airway.
223647426|NCT06783686|DRUG|NV701|eye drop
223647427|NCT06783686|DRUG|Pilocarpine 1.25% Eye drop|eye drop
223647428|NCT06784063|DEVICE|Clareon Vivity Extended Vision IOL|Extended vision intraocular lens implanted in the capsular bag of the eye during cataract surgery. IOLs are intended for long term use over the lifetime of the cataract patient.
223647429|NCT03438461|DRUG|Seltorexant 40 mg|Seltorexant 40 mg as two tablets of 20 mg will be administered as Formulation 1, 2 and 3 orally in Part 1.
223647430|NCT03438461|DRUG|Seltorexant 20 mg|Seltorexant as a tablet of 20 mg will be administered as Formulation 1, 2 and 3 orally in Part 2.
223647431|NCT05658913|DRUG|AV-1451|This is a cross-sectional study using the radiotracer AV-1451 to determine the relationship of tau pathology to other biomarker data of MPC participants.
223647432|NCT05460000|DRUG|3 cycles chemotherapy instead of 6 cycles chemotherapy|We hypothesise that recurrence free survival in patients receiving 3 cycles of chemotherapy followed by maintenance with niraparib is not inferior to 6 cycles of chemotherapy followed by niraparib in advanced HRDpositive high-grade ovarian cancer patients with no residual tumor mass following primary tumor debulking.
223647433|NCT05460000|DRUG|6 cycles chemotherapy|Standard chemotherapy as comparator
223647434|NCT05661409|DRUG|Sugammadex|"Sugammadex is a FDA-approved drug that is in routine clinical use for NMB reversal.~Patients will be randomized to six groups: 2 mg/kg (the lowest dose approved by the FDA), 1 mg/kg, 0.5 mg/kg, 0.25 mg/kg, 0.125 mg/kg of sugammadex and placebo. Doses would be based on actual body weight. The time taken to reach a TOF ratio of 0.9 thereafter would be measured. If the patient fails to achieve this goal by 10 minutes, sugammadex would be given in 2 mg/kg increments until the patient reaches this threshold and can be safely extubated."
223647435|NCT05661409|DRUG|Placebo|Normal saline will be used as placebo. The inclusion of a placebo group would allow us to examine if patients may recover spontaneously over that time without needing any sugammadex at all, and what parameters may predict that subset of patients. It will also improve the dose response modelling, in that randomization has been weighted so that patients who are least likely to need sugammadex (i.e. if they achieved a TOF count of 4 twitches without fade) are more likely to be in the placebo group or at the lowest dose of sugammadex that is being tested.
223647436|NCT05753046|DRUG|Early TAP Block|For treatment delivery, subjects will receive 60 mL of 0.25 percent ropivacaine with 4 mg of dexamethasone at the initiation of the procedure (immediately following placement of the robotic / laparoscopic camera port). The TAP block will be performed with 15 mL 2 finger breadths subcostal at the mid-clavicular line and then 15 mL at the level of the umbilicus along the mid-axillary line on each side. Laparoscopic / robotic camera will be used as a visual aid to confirm positioning between the internal oblique and transversus abdominis muscles for the goal of pain relief.
224232806|NCT06115005|BIOLOGICAL|Plasma rich in growth factors ( PRGF )|"Plasma rich in growth factors (PRGF) is characterized by a moderate concentration of platelets, in the absence of leukocytes.~This absence of leukocytes is based on the fact that they synthesize matrix metalloproteinases, free radicals, and proinflammatory cytokines, which do not contribute and even impair the altered tissue regeneration"
224232807|NCT02103283|DRUG|Teprotumumab|Teprotumumab 20mg/kg administered by intravenous infusion every 3 weeks for 3 infusions
224232808|NCT02687048|BEHAVIORAL|Otago Exercise program|The Otago exercise program (OEP) is an evidence-based falls prevention home-based program. The participants will be instructed by a physiotherapy to do muscle strengthening and balance exercises (to be done 3x/week). The physiotherapist will progress these exercises during 5 home visits to each participant.
224232809|NCT02687048|BEHAVIORAL|Mindful meditation|Mindful meditation aims to reorient the individual to the present and broaden self awareness by promoting attention to internal experiences such as bodily sensations, thoughts, emotions, sights or sounds. The participants will be instructed in mindful meditation during 6 hour-long education sessions and will be expected to practice with audio meditations 30 minutes 5 times per week.
224232810|NCT00392639|PROCEDURE|Comparison of 2 cooling procedures|Comparison of 2 cooling procedures
224232811|NCT04384549|BIOLOGICAL|BCG GROUP|One intradermal injection of 0.1 ml of BCG vaccine (AJ Vaccine).Each 0.1 ml vaccine contains between 2 to 8 x 105 colony forming units.
224232812|NCT04384549|OTHER|PLACEBO GROUP|One intradermal injection of 0.1ml NaCl
224232813|NCT03130764|DRUG|Durvalumab|1500 mg, IV over 1 hour Every 4 weeks for 1 year
223647437|NCT05753046|DRUG|Late TAP Block|For treatment delivery, subjects will receive 60 mL of 0.25 percent ropivacaine with 4 mg of dexamethasone at the conclusion of the procedure (immediately proceeding removal of the robotic / laparoscopic camera port). The TAP block will be performed with 15 mL 2 finger breadths subcostal at the mid-clavicular line and then 15 mL at the level of the umbilicus along the mid-axillary line on each side. Laparoscopic / robotic camera will be used as a visual aid to confirm positioning between the internal oblique and transversus abdominis muscles for the goal of pain relief.
223647438|NCT05132608|OTHER|Social media-based Health education program|The social media-based health education program consist of 16 minute PNC video in Nepali language guided by Health Belief Model. The video provided general information on postnatal care including frequency, timing, and place providing postnatal care; danger signs of mother and newborn; different services provided at each PNC visit, and the importance of PNC visit. The researcher sent PNC videos through instant messaging (IM) software applications such as Viber, What's App, and Facebook messenger to the intervention group.
223647439|NCT02229344|OTHER|No Intervention|Participants with newly diagnosed moderate to severe ulcerative colitis in a tertiary referral hospital within 4 weeks before prior to enrollment will be observed.
224232814|NCT03130764|DRUG|Tremelimumab|75 mg, IV over 1 hour Every 4 weeks for 4 doses
224232815|NCT02786238|BEHAVIORAL|Standard Behavioral Treatment (SBT)|See description of treatment arm.
224232816|NCT02786238|BEHAVIORAL|Acceptance-Based Treatment (ABT)|See description of treatment arm. \*\*Cherokee Nation members receive only the ABT intervention as they are in an open, feasibility trial and are not randomized.\*\*
224232817|NCT02815852|OTHER|Women under 40 years old with histological diagnosis of breast cancer|Evaluation of imaging characteristics (ultrasound, mammography and mammary MRI if available) of breast cancer with the corresponding histological reports and assess whether in women \<40 years the typical imaging presentation pattern of malignancies observed in women\> 40 years are confirmed.
224320107|NCT01899339|OTHER|submassive PA treatment with Ekosonic endo device|Ultra Sound energy along with tPA to treat submassive pulmonary embolism
224320108|NCT03309761|OTHER|Blood test|6ml blood sample taken
224320109|NCT04862221|DRUG|High-dose methylprednisolone|Subjects in the high-dose methylprednisolone arm will receive an initial dose of methylprednisolone IV 10 mg/kg/day for 3 days and 5 mg/kg/day on Day 4. Normal saline will be used as placebo pre-medications and infusions given at the same volume and duration as the eATG infusions.
224232818|NCT05366959|OTHER|Trunk Muscle Endurance test|"Trunk flexors endurance test: Participants will be positioned with trunk flexed to 60º, knees and hips to 90º flexion. The evaluator fixes the feet on the ground by supporting them from the toes. When the 60º trunk flexion is broken, the test will be terminated and the time it maintains this position will be recorded in seconds.~Modified Biering-Sorensen test: With this test, the endurance of trunk extensors is evaluated. The subjects are positioned in the prone position with the pelvis, hips and knees on the bed. The subjects are asked to extend their upper body straight forward from the edge of the table and the time they maintain this position will be recorded in seconds.~Lateral bridge test: During the test, the subjects were asked to lie on their side, raise their bodies on their forearms and toes and maintain this position, and the time they held the position would be recorded in seconds. The test will be done on both sides."
224232819|NCT05366959|OTHER|Fatigue Severity Scale|"Fatigue Severity Scale was used to evaluate the fatigue level of the participants. This scale consists of a 7-point Likert scale. 1 point means strongly disagree, 7 means strongly agree. High scores are associated with increased fatigue. Evaluates the effects of fatigue on physical function, motivation, family and social life. Turkish validity and reliability was established."
224232820|NCT05366959|OTHER|Roland Moris Scale|"The Roland Moris Scale will be used to evaluate the participants for low back pain assessment. The Roland Morris Inquiry Form was designed to evaluate the functional disability of the patient. The total score ranges from 0 (no disability) to 24 (severe disability). The higher the total score, the lower the patient's functionality. It is a questionnaire filled by the patient, which evaluates the functionality of 24 items questioning the patient's mobility, self-care and sleep status. Each item marked as 'Yes' is given 1 point, and answers marked as 'No' are given 0 points. Turkish validity and reliability was established."
224232821|NCT05366959|OTHER|Physical Activity Levels|The physical activity level of the participants will be measured with the International Physical activity scale: MET values will be calculated according to this scale, which has Turkish validity and reliability.
224232822|NCT03238677|BEHAVIORAL|Speech Motor Chaining without Biofeedback|These procedures target sound sequences (consonant-vowel, consonant-consonant, or vowel-consonant). Sessions begin with Pre-practice to elicit the target sounds, with verbal cueing and shaping strategies. The Practice component then includes chaining that is response-contingent. Participants practice in blocks of 6 consecutive trials beginning at the syllable level. If 5/6 are correct, the participant advances to monosyllabic word practice, then multisyllabic word practice, phrase practice, and sentence practice (with the target syllable embedded within each level of complexity). If fewer than 5/6 trials are correct, a different syllable with the target sound pattern is practiced next. Verbal feedback is faded from 5 of 6 trials at the syllable level to only 3 of 6 trials at the sentence level. For more description, see http://speechproductionlab.syr.edu/Resources%20for%20Researchers.html
223647440|NCT02316106|DRUG|daratumumab|16 mg/kg administered by intravenous (IV) infusion once every week in Cycle 1, every other week in Cycle 2 and Cycle 3, every 4 weeks in Cycle 4 to Cycle 7, and from Cycle 8 to Cycle 20 on Day 1 of each cycle. If, as per investigator discretion, there is a positive benefit/risk ratio, absence of Grade greater than or equal to (\>=) 3 treatment related toxicity, and at least stable disease has been achieved, treatment can be extended and given every 8 weeks after Cycle 20. For participants participating in treatment extension, the duration of infusion may be shortened to a 90-minute infusion or can switch to daratumumab 1800mg subcutaneous (Q8w).
223647441|NCT02316106|DRUG|daratumumab|16 mg/kg administered by IV infusion once every week in Cycle 1, and then on Day 1 of each cycle from Cycle 2 to Cycle 20, and every 8 weeks after Cycle 20. If, as per investigator discretion, there is a positive benefit/risk ratio, absence of Grade greater than or equal to (\>=) 3 treatment related toxicity, and at least stable disease has been achieved, treatment can be extended and given every 8 weeks after Cycle 20. For participants participating in treatment extension, the duration of infusion may be shortened to a 90-minute infusion or can switch to daratumumab 1800mg subcutaneous (Q8w).
223647442|NCT02316106|DRUG|daratumumab|16 mg/kg administered by IV infusion once every week in Cycle 1 only. Treatment cycles are 8 weeks in length.
223647443|NCT06016270|DRUG|hSTC810 400 mg + Paclitaxel|"hSTC810 400 mg and paclitaxel 175 mg/m2 will be administered as an intravenous (IV) infusion~Paclitaxel: 175 mg/m2 will be administered as an IV infusion"
223647444|NCT06016270|DRUG|hSTC810 800 mg + Paclitaxel|hSTC810 800 mg and paclitaxel 175 mg/m2 will be administered as an IV infusion
223647445|NCT05316948|OTHER|self-questionnaire|Quantitative survey with self-administered questionnaire offered to all patients attending psychiatry study care during the month of the assessment.
223647446|NCT04439136|DRUG|Afatinib Dimaleate|Given PO
223647447|NCT02429245|OTHER|Retrospective study|
223647448|NCT06236048|PROCEDURE|MRI scan|7 Tesla MRI scan
223647449|NCT06236048|PROCEDURE|PET-MR scan|18F-fluorodeoxyglucose PET-MR scan
223647450|NCT05350878|OTHER|Implementation Intervention|Virtual and in-person implementation support
223647451|NCT00433082|BEHAVIORAL|Ramadan Fasting|
223647452|NCT04333576|DRUG|Elagolix|Tablet:Oral
223647453|NCT04333576|DRUG|Placebo|Tablet:Oral
223647454|NCT04333576|DRUG|Combined Oral Contraceptive|Tablet:Oral
223647455|NCT06167733|DEVICE|VERTICA Active device|VERTICA device with a therapeutic RF energy level
223647456|NCT06167733|DEVICE|VERTICA Sham device|VERTICA device with a low, non-therapeutic RF energy level
223647457|NCT01291732|DRUG|Matching placebo|single dose of matching placebo
223647458|NCT01291732|DRUG|BI 135585 XX|single dose of low, medium or high dose of BI 135585 XX
223647459|NCT03968562|DRUG|2% Doxycycline Cream in Generic Aquaphor or Generic Aquaphor|2% Doxycline Cream in Generic Aquaphor or Generic Aquaphor will be applied topically twice during the study visit: first for 30 minutes, then for 6 hours duration.
223647460|NCT00408200|DRUG|propafenone; flecainide; sotalol; dofetilide|Above drugs prescribed per established guidelines for treatment of AF
223647461|NCT00408200|DEVICE|Radiofrequency catheter ablation|A special catheter that delivers radiofrequency (heat) energy is advanced into the heart and used to destroy small areas of heart tissue responsible for causing atrial fibrillation. All catheters / devices used in the study are FDA approved for human use and currently being used to perform the AF ablation procedure in the United Sates.
223647462|NCT02578706|DRUG|Clopidogrel|Clopidogrel 75mg
223647463|NCT02578706|DRUG|Aspirin|81 mg
223647464|NCT02578706|DRUG|Placebo|
224232823|NCT03238677|BEHAVIORAL|Biofeedback|Real-time images of the tongue are made available using ultrasound placed beneath the chin. Participants practice speech movements and can be cued to modify their tongue shape or position to achieve clearer speech. Practice structure is similar to the Speech Motor Chaining procedures, but with the addition of a visual reference.
223647465|NCT03105752|OTHER|Questionnaire of understanding|"The study involved 12 clinical trials conducted in the Clinical Research Center Paris Est. Twenty participants per trial were offered to answer the Qualité de Compréhension des Formulaires d'information et de consentement questionnaire (QCFic) at the inclusion visit after receiving the information by the investigator and signed or refused to sign the form of consent.~Participants filled out the questionnaire in an isolated location, with no possibility of re-reading the information contained in the consent form. The questionnaire was immediately retrieved."
223647466|NCT03630445|OTHER|Isomaltooligosaccharides (IMOs)|Isomaltooligosaccharides (IMOs) incorporated into yogurt were tested for gastric emptying rate, glycemic response, appetitive response, and fermentability.
223647467|NCT03630445|OTHER|Xtend® sucromalt|Xtend® sucromalt incorporated into yogurt was tested for gastric emptying rate, glycemic response, appetitive response, and fermentability.
224232824|NCT03238677|BEHAVIORAL|Distributed Practice|2 sessions per week for 10 weeks
224232825|NCT03238677|BEHAVIORAL|Massed --> Distributed Practice|Week 1: 10 hours of treatment Week 2: 3 hours of treatment Week 3: 3 hours of treatment Week 4: 2 hours of treatment Week 5: 2 hours of treatment
224232826|NCT03650777|OTHER|Warfarin Telehealth Education|Patients received education on warfarin through a video on an iPad, and were assessed on knowledge pre and post video, and at follow up visit
224232827|NCT00011297|DRUG|gabapentin (Neurontin)|
224232828|NCT00011297|DRUG|lorazepam (Ativan)|
224232829|NCT00724568|DRUG|Lenalidomide|Patients will be treated with Revlimid on days 1-14 in 3-week cycles for 4-8 cycles.
224232830|NCT00724568|DRUG|Bortezomib|Patients will be treated with Velcade at 1.3 mg/m2 on days 1, 4, 8, and 11
224232831|NCT00724568|DRUG|Dexamethasone|Patients will be treated with Dexamethasone at 20 mg orally on days of Velcade and the day after for all dose levels.
224232832|NCT00724568|DRUG|Doxil|Patients will be treated with Doxil on day 4.
224232833|NCT00066131|PROCEDURE|Periodontal scaling and root planing|Hard and soft tisse deposits (plaque and calculus) are removed from the tooth and tooth root using hand and ultrasonic instruments.
223647468|NCT03630445|OTHER|Combination of IMOs and Xtend® sucromalt|A combination of IMOs and Xtend® sucromalt incorporated into yogurt was tested for gastric emptying rate, glycemic response, appetitive response, and fermentability.
223647469|NCT03630445|OTHER|Raw corn starch|Raw corn starch incorporated into yogurt was tested for gastric emptying rate, glycemic response, appetitive response, and fermentability.
223647470|NCT03630445|OTHER|Maltodextrin|Maltodextrin incorporated into yogurt was tested for gastric emptying rate, glycemic response, appetitive response, and fermentability.
223647471|NCT03644004|OTHER|frequency of diabetes mellitus, type 2, diagnosis in patients with medical history of gestational diabetes.|"Patients will be contacted by mail with sending of the information notice to ask them to participate in the study.~If they don't reply, the subjects will be called by phone by the investigator to collect their non opposition of participation at the study.~During this call, the investigator will be able to answer all the questions about the study.~The report of this telephone conversation will be register in the medical file of the patient.~Then, we will collect informatic data from the hospital concerning the patients.~After that they will be contacted by phone to answer a survey. Beside, another secure survey will be send by email to each patient's family doctor.~To finish, crossing data between those of the patients and the family doctor and anonymisation of the data."
223647472|NCT02961829|DRUG|Maraviroc|antiretroviral intensification
223647473|NCT02961829|DRUG|Dolutegravir|antiretroviral intensification
224232834|NCT00066131|PROCEDURE|Scaling and root planing|Delivered using hand and powered scalers and with topical or local (injected) anesthetics as needed. Procedures performed over 1 to 4 90-minute visits.
224232835|NCT01242280|DEVICE|Stent|Self-expandable esophageal stent (SX-Danis, Czesc Republic).
224232836|NCT01242280|DEVICE|Tamponade|Sengstaken-Blakemore tube
223647474|NCT02961829|BIOLOGICAL|Dendritic Cell Vaccine|Therapeutic vaccination
223647475|NCT02961829|DRUG|Auranofin|purging
223647476|NCT02961829|DRUG|Sirtuin Histone deacetylase inhibitor|latency disruption
223647477|NCT00087867|DRUG|SCIO-469|two 30-mg capsules three times daily
223647478|NCT00087867|DRUG|SCIO-469 and bortezomib|In addition to SCIO-469, patients with disease progression will receive bortesomib 1.0 mg/m2 intravenously as a bolus injection on Days 1, 4, 8, and 11 of a 21-day cycle, followed by a 10-day rest period
224232837|NCT01434966|OTHER|Lumbopelvic Manipulation|The lumbopelvic joint manipulation (Grade V mobilization) will be performed on the ipsilateral side of the test limb. The participant will be passively side-bent towards and rotated away from the selected lumbopelvic region which is followed by the delivery of a posterior/inferior force through the opposite anterior superior iliac spine. If a cavitation is not heard or felt by the patient or clinician, the technique will be repeated. If the second attempt does not produce cavitation the procedure will be repeated on the contralateral side using similar methods. If cavitation is not heard or felt by the participant or clinician following the second attempt on the contralateral side, the participant will proceed with the assessment of quadriceps strength and activation as usual.
224232838|NCT01434966|OTHER|TENS- Spine|The TENS electrodes will be applied lateral to L1 and L2 and lateral to S5 and S1. The TENS unit will be set to deliver a continuous TENS biphasic pulsatile current at 150 Hz, with a phase duration of 150 microseconds. The TENS unit will be worn during all exercise testing and for the first 30 minutes of quadriceps force output and activation testing. After the 30 minute post-intervention measures (Post30) are obtained, the TENS unit will be turned off.
224232839|NCT01434966|OTHER|TENS- Knee|The TENS electrodes will be applied on the medial and lateral superior, as well as the medial and lateral inferior, borders of the patella. Care will be taken not to place TENS electrodes on the quadriceps muscles or muscles of the anterior leg. The TENS unit will be set to deliver a continuous TENS biphasic pulsatile current at 150 Hz, with a phase duration of 150 microseconds. The TENS unit will be worn during all exercise testing and for the first 30 minutes of quadriceps force output and activation testing. After the 30 minute post-intervention measures (Post30) are obtained, the TENS unit will be turned off.
223647479|NCT06186843|BEHAVIORAL|Plant-based diet|A two week training program will be completed which consists of information, resources and activities that will help participants transition to a plant-based diet. Each day of the program, participants will engage with material that provides information about how a plant-based diet can improve health outcomes, how to cook plant-based meals, what to shop for when eating plant-based, and other information that will help participants become comfortable with this dietary change. In addition, each participant will have a virtual, weekly check-in with one of the investigators. Finally, participants will be encouraged to attend a once monthly group session with all participants.
223647480|NCT02922647|DEVICE|suprapubic catheterization|Experimental Arm: Suprapubic catheterization after rectal resection with low anastomosis for cancer in males
223647481|NCT02922647|DEVICE|transurethral catheterization|Active comparator: Transurethral catheterization after rectal resection with low anastomosis for cancer in males
223647482|NCT04203186|DRUG|atovaquone-proguanil|Malaria standard treatment regimen
223647483|NCT04211909|DRUG|SOF/VEL|400/100 mg FDC tablet orally once daily.
223647484|NCT04211909|DRUG|SOF/VEL/VOX|400/100/100 mg FDC tablet orally once daily.
223647485|NCT05676580|PROCEDURE|cross-linking surgery or intra corneal ring|After keratoconus diagnosis the patient was assigned to surgery
223647486|NCT05676580|OTHER|abstention|No surgery
223647487|NCT06296316|DEVICE|Restorelle Polypropylene Mesh|"The Coloplast Restorelle® Polypropylene Mesh is a Class III, implantable, permanent, non-absorbable, single use device indicated to restore female pelvic floor anatomy by providing anatomical support and suspension as a bridging material to support deficient fascia that resulted in descent of the female pelvic organs (pelvic organ prolapse).~Restorelle mesh is a synthetic, macroporous mesh constructed of medical grade knitted, monofilament polypropylene."
223647488|NCT05436743|DRUG|K-Y Jelly, Topical Gel soaked packs|Topical Gel used as lubricant
224232840|NCT05471674|DRUG|Nivolumab|3 mg/kg on Day 1 of each 2-weekly cycle for 3 doses
224232841|NCT05471674|PROCEDURE|Hepatectomy|Hepatectomy will be performed approximately 2 weeks after the 3rd dose of nivolumab
224232842|NCT05153265|OTHER|Survey|There will be no interventions for study participants. Participants will be asked to complete a survey.
223647489|NCT05436743|OTHER|Water soaked packs|Water soaked packs for reduction of postoperative sore throat
223647490|NCT00545259|DRUG|AEB071|
223647491|NCT06203847|DRUG|Combination group|Combination of epinephrine (Adrenaline® 1mg/vial) every 3 minutes, vasopressin (Pitressin® 20Unints/vial) every 3 minutes up to 4 vials (a total of 80Units), methylprednisolone (Solu-Medrol® 40mg/vial)
223647492|NCT06203847|DRUG|Standard group|standard doses of epinephrine (Adrenaline® 1mg/vial) every 3 minutes
223647493|NCT04288661|PROCEDURE|No drain placement|The need of perianastomotic drain placement after Roux-en-Y reconstruction in total gastrectomy operations is investigated. As intervention, no drain placement is considered, according to the criteria stated above
223647494|NCT01719510|OTHER|Samples|"At time of delivery we will performed vaginal swabs in two groups: women tested positive for GBS at 35-37 weeks and women with risk of neonatal infection.~For both groups:~* one swab for GBS detection by real-time PCR~* the second swab for GBS detection by conventional bacteriological techniques and sent to the bacteriology laboratory.~For all women included will be achieved in the delivery room:~1. To the mother: A blood sample of 5 ml at the time of the implementation of the IV line.~2. A sampling of umbilical cord blood.~Newborns of mothers included (group 1 and 2) will have a search for GBS (standard culture) in the stools and the pharynx prior to return home.~For mothers, the collection of 3-5 ml of milk when breastfeeding."
223647495|NCT06053502|OTHER|filtering facepiece respirator|Graded exercise test with filtering facepiece respirator
223647496|NCT04631250|DRUG|5-Aminolevulinic Acid-Containing Product in Cutaneous Dose Form|5-Aminolevulinic Acid was applied to both sides of the face.
223647497|NCT05245617|DEVICE|JuniOrtho™ Plating System™|The patient underwent surgery for the application of JPS for treatment of deformity or traumatic fracture.
223647498|NCT01465919|DRUG|Mirtazapine|Mirtazapine will be administered at baseline, 1-week, 2-week, 4-week, 6-week, and 8-week, dosing between 7.5mg/day and 45mg/day, in patients with interferon induced depression.
223647499|NCT01465919|OTHER|Supportive psychotherapy|Supportive psychotherapy will be administered at baseline, 1-week, 2-week, 4-week, 6-week, and 8-week in patients with interferon induced depression.
223647500|NCT00872443|OTHER|Data collection|"Collection of characteristics of interauricular septum, characteristics of the CVA, and headache history.~Collection of anamnesis data, surgical past history, especially at the moment of the implement of prothesis, collection of dtat of transthoracic echography, transcranial echodoppler, holter ECG, cerebral MRI."
223647501|NCT03470610|DRUG|Progesterone|6 mg estradiol and vaginal and rectal progesterone
223647502|NCT01662102|DRUG|Zevalin|Zevalin administered intravenously.
223647503|NCT01662102|DRUG|Rituximab|Rituximab administered intravenously.
223647504|NCT05336591|OTHER|Covid-19 pandemic|All participants worked during the Covid-19 pandemic in the preventive or curative healthcare for children with overweight and obesity. We will ask all professionals about their experiences during and after the pandemic.
224232843|NCT05539820|OTHER|Reiki|Reiki is based on the belief that disease occurs when an energy center is blocked, and that the energy is transmitted through touch. In distant Reiki, Reiki practitioners followed the traditional Usui Reiki protocol for distant healing. Reiki practitioners first undertake the name of students and then send the healing energy to the students.
224232844|NCT03824626|DIAGNOSTIC_TEST|TEVAR patients|Computed Tomography Angiography (CTA) will be performed using a 16-slice unit before and after intravenous administration of 100 mL of iodinated contrast material. Phase contrast-Magnetic Resonance (pc-MRI) will be performed using a 1.5-T unit with 40-mT/m gradient power and a four-channel cardio-thoracic coil. ECG-triggered, free-breathing through plane, and in-plane pc-MRI sequences will be performed for phase-velocity mapping of aortic and branches flow. Ad hoc processing of preoperative CTAs, based on 3D multiplanar reconstruction, will be performed with 3Mensio Vascular software 8.0® (3Mensio Medical Imaging B.V.), which provides specific functions for automatic measurements.
224232845|NCT03409757|DRUG|Velphoro|4 weeks
224232846|NCT03409757|OTHER|saliva collection|2 samples
224232847|NCT03409757|OTHER|Supragingival biofilm collection|2 samples
224232848|NCT03409757|OTHER|stool collection|2 samples
224232849|NCT03409757|OTHER|blood collection|2 samples
223647505|NCT05072236|PROCEDURE|bronchoscopic insertion|After intravenous anesthesia is stabilized with BIS levels between 50-70, Intravenous lidocaine 1.5 mg/kg, or alfentanil 10 ug/kg, or 5 mL normal saline will be injected. Bronchoscopic insertion will be started 1 minute later. After seeing the vocal cords, local spraying of 2% will be initiated from vocal cords, trachea, and bilateral bronchial trees.
223647506|NCT02586298|OTHER|Autologous mitochondria with ICSI|Autologous mitochondria during the intracytoplasmic sperm injection (ICSI) process will be added to this randomized group of oocytes.
223647507|NCT02586298|OTHER|STANDARD ICSI PROCEDURE|STANDARD ICSI PROCEDURE
223647508|NCT03802292|BIOLOGICAL|YQ23|Single dose of YQ23 delivered via intravenous route. Ascending dose levels will be evaluated
224232850|NCT03305029|DRUG|SCNT-hES-RPE Cells|Pars Plana Vitrectomy and Sub-retinal Transplantation of Human Somatic cell nuclear transfer Embryonic Stem Cell Derived Retinal Pigmented Epithelial(SCNT-hES-RPE) Cells in Patients with Advanced Dry Age-related Macular Degeneration
224232851|NCT03499938|DEVICE|Structured Light Plethysmography|Non-invasive non-contact measurement of tidal breathing during hospital admission
224232852|NCT02439398|BIOLOGICAL|Allogeneic human cardiac stem cells (CSCs)|Allogeneic human CSCs is a new cell medicine based on cells isolated from human heart biological samples (right atrium appendage of donors) and expanded in vitro.
223647509|NCT03802292|BIOLOGICAL|Matching Placebo|Single dose of the matching placebo delivered via intravenous route.
223647510|NCT03645720|DEVICE|Plastic cannula|puncture using plastic cannula
223647511|NCT01440894|DEVICE|Comparison test|"Reference Device: Transtek Glass Body Analyzer, GBF-950, accuracy: ±0.1kg and range: 0-180kg.~DUT(Device Under Test): Transtek Glass Body Fat Analyzer, Model: GBF-733-W1, GBF-1012, BF-1039, BF-1041-A, and GBF-950-D."
223647512|NCT00645996|DIETARY_SUPPLEMENT|Probiotics (L.acidophilus and B.lactis)|2.1 X 109 L.acidophilus and B.lactis
223647513|NCT00645996|DIETARY_SUPPLEMENT|Cornflor|Cornflour 2 gram daily
223647514|NCT01219881|DRUG|Desflurane|5.4 to 7.4% desflurane
223647515|NCT01219881|DRUG|Sevoflurane|1.4 to 2.5% Sevoflurane
223647516|NCT00004428|DRUG|CPX|
223647517|NCT02314559|DRUG|Manual titration of propofol|One group will be sedated with a manual titration technique: here the titration of propofol is done manually by the anesthetist. Dosages may range between 50 and 400mg, given by boluses of 20-50mg.
223647518|NCT02314559|DRUG|Target controlled infusion of propofol|The other group will be sedated with a target controlled infusion technique (pump, marsh or Schneider). The anesthetist can titrate indirectly by adjusting the target controlled infusion to achieve adequate sedation. The concentrations of propofol may vary between 2 and 6 µg/ml, achieved by increments of 0.5-1.5 µg/ml.
223647519|NCT01904994|PROCEDURE|POC (point-of-care) CD4+ (cluster of differentiation 4) Count|Each HIV testing and counseling (HTC) site will be equipped with POC CD4+ testing using PIMA™ Analyser (Inverness), test strips, and reagents. Study staff will obtain 25 microliters of blood via finger prick and process the POC (point-of-care) CD4+ (cluster of differentiation 4) Count' test immediately following the baseline interview. Test results will be recorded on study forms including a referral form that has multiple copies, one copy to be given to the participant, the second sent to the affiliated HIV (Human immunodeficiency virus)care clinic in the study unit, and the third kept by study staff in a locked cabinet with other confidential material. All participants, regardless of the CD4+ result, will be encouraged to enroll in HIV care as soon as they can.
223647520|NCT01904994|PROCEDURE|Accelerated ART (antiretroviral therapy) Initiation|"Accelerated ART initiation for patients with POC CD4+ \< 350 cells/uL (micro-liter) within 1 week from testing.~2 counseling sessions (one at time of HTC and other at first HIV clinic visit), and collection of blood for other baseline lab tests, but initiation prior to return of results for patients who do not meet criteria for waiting"
223647521|NCT01904994|BEHAVIORAL|Basic Care and Prevention Package|Basic care and prevention package (BCPP) provided approximately every three months that includes: condoms; soap, pill box and pictorial education about use of materials and HIV, such as family testing tools and information. Information on BCPP contents and review the educational materials will be provided. An example of educational materials is a family-testing tool to encourage the participant to have all family members tested for HIV. All BCPP items will be replenished every 3 months for all participants, regardless of ART status, beginning at linkage to HIV care.
223647522|NCT01904994|BEHAVIORAL|Cellular Appointment Reminders and Follow-Up|"SMS (short messaging service) appointment reminders for follow-up appointments.~Telephone call within 7 days of missed appointment for all patients."
223647523|NCT01904994|OTHER|Financial Incentive|Participants will receive a series of financial incentives to support linkage into care within 1 month and retention in care at 6 months and 12 months after testing HIV positive. The value of the financial incentive (FI) will be 80 Swaziland Rand, calculated based on the associated financial costs of traveling to clinic. These incentives will be distributed by through mobile airtime. Participants without mobile phones will be given an alternative incentive of equal value, such as a store voucher.
223647524|NCT00500513|PROCEDURE|CT Scans|CT scan performed weekly to measure how much the tumor moves + additional pulmonary function measurements.
223647525|NCT00500513|PROCEDURE|Implanted markers|Implanted radio-opaque fiducial markers, diameter of 1.0 - 2.0 mm, inserted through a catheter at several chest locations using a flexible bronchoscope
224232853|NCT02439398|OTHER|Human Serum Albumin-HSA 5%|Human Serum Albumin (HSA) is a well-known physiologic protein widely used in clinical practice and without known toxicity after parenteral administration.
223647526|NCT00500513|RADIATION|Radiation Treatment (RT)|Radiotherapy incorporating respiratory treatment delivery
223647527|NCT02988895|RADIATION|episcleral brachytherapy|The study intervention is an outpatient, ambulatory procedure performed under local anesthesia with anesthesia assist.
223647528|NCT02531672|DRUG|11C-choline|
223647529|NCT02531672|DEVICE|PET/CT Scan|
224232854|NCT04963426|BEHAVIORAL|Behavioral interventions targeting multiple risk behaviors as well as protective factors|Depending on the baseline data and prioritization of actions, behavioral interventions related to the following topics will be implemented: alcohol use, dietary behaviors, drug use, hygiene, mental health, physical activity, protective factors, sexual behaviors, tobacco use, violence and unintentional injury.
224320110|NCT04862221|DRUG|Equine anti-thymocyte globulin|Subjects will receive eATG IV 40 mg/kg/day on Days 1- 4. Day 1 eATG infusion is run over 8 hours and Day 2-4 infusions are run over 4 hours.
224232855|NCT04963426|OTHER|School-level interventions targeting the school environment and system|Depending on the baseline data and prioritization of actions, and based on the Global Standards for Health Promoting Schools, school-level interventions related to the following will be implemented: school policies and resources, school governance and leadership, school and community partnerships, school curriculum, school social-emotional environment, school physical environment, school health services
223647530|NCT02700906|DRUG|Corticosteroid|triamcinolone (10mg/ml) 1 ml will be injected to the lateral epicondyle of the affected elbow.
224232856|NCT00623103|DRUG|Rivastigmine capsule|Rivastigmine capsules orally twice a day. Target dose 12 mg/day.
224232857|NCT00623103|DRUG|Rivastigmine transdermal patch|Rivastigmine patch once a day in the morning, worn for 24 hours. Target dose 10 cm\^2/day delivering 9.5 mg over a 24 hour period.
224232858|NCT04784000|DRUG|Period 1: AT-527 550 mg|AT-527 550 mg tablet (1 x 550 mg tablet, in the morning) on Day 1
224232859|NCT04784000|DRUG|Period 2: carbamazepine|Carbamazepine 100 mg twice daily (BID) Days 3 to 6, 200 mg BID on Days 9 to 11, 300 mg BID on Days 12 to 25
224232860|NCT04784000|DRUG|Period 3: AT-527 550 mg + carbamazepine|AT-527 550 mg tablet (1 x 550 mg tablet, in the morning) on Day 26 plus carbamazepine 300 mg BID on Day 26
224232861|NCT04784000|DRUG|Period 3: AT-527 1100 mg + carbamazepine|AT-527 1100 mg tablet (2 x 550 mg tablets, in the morning) on Day 26 plus carbamazepine 300 mg BID on Day 26
224232862|NCT02401282|BEHAVIORAL|Attention Bias Modification|This is a modification of the dot-probe task (placebo task) designed to train attention away from threat
224232863|NCT02401282|BEHAVIORAL|Dot-probe task|This is the active control placebo condition that simply measures levels of attention to threat
224232864|NCT02468739|DRUG|Ganglioside-monosialic acid|Ganglioside-monosialic sodium is added into to 250 ml of 0.9% sodium chloride injection, which is given once a day via intravenous drip infusion for 3 days. The first dose is given at 1 day before the start of the chemotherapy.(day -1, day 1 and day2). The dosages of GM1 are 80mg per day.
224232865|NCT02468739|DRUG|placebo|Placebo is added into to 250 ml of 0.9% sodium chloride injection, which is given once a day via intravenous drip infusion for 3 days. The first dose is given at 1 day before the start of the chemotherapy.(day -1, day 1 and day2).
224232866|NCT01138072|DRUG|GSK2248761|200mg once daily
224232867|NCT01138072|DRUG|Simvastatin|20 mg Simvastatin single dose
224232868|NCT01138072|DRUG|Atorvastatin|20 mg atorvastatin single dose
224232869|NCT01138072|DRUG|Rosuvastatin|10 mg rosuvastatin single dose
224320111|NCT04862221|DRUG|Prednisolone|"Subjects will receive prednisolone 1 mg/kg on Days 5-13 followed by a gradual taper with discontinuation at 42 Days as indicated below.~Days 5 - 13 Prednisolone PO 1 mg/kg/day (max 50 mg/day)~Days 14- 20 Prednisolone PO 0.5 mg/kg/day (max 25 mg/day)~Days 21 - 27 Prednisolone PO 0.3 mg/kg/day (max 15 mg/day)~Days 28 - 34 Prednisolone PO 0.1 mg/kg/day (max 5 mg/day)~Days 35 - 41 Prednisolone PO 0.1 mg/kg every OTHER day (max 5 mg every other day)~Day 42 Discontinue"
223647531|NCT02700906|DRUG|Lidocaine|For lidocain injection, 1ml 1% lidocain will also be peppered on the same area.
223647532|NCT01019083|DRUG|Placebo|Placebo will be given according to randomization list
223647533|NCT01019083|DRUG|Placebo|Placebo will be given according to randomization list
223647534|NCT01019083|OTHER|Control|Control will be selected from the Arsenic non contaminated Area
223647535|NCT01019083|DRUG|Zinc Sulphate|Zinc Sulphate will be given according to randomization list
223647536|NCT01019083|DRUG|Albendazole and Secnidazole|Albendazole and Secnidazole will be given according to randomization list
223647537|NCT01019083|OTHER|Arsenic|Participant will be selected from the Arsenic Contaminated Area
223647538|NCT00503815|DRUG|BLI-800|
223647539|NCT00503815|DRUG|Polyethylene glycol 3350 based bowel preparation|
223647540|NCT01980667|DRUG|lurbinectedin (PM01183)|lurbinectedin (PM01183) is presented as powder for concentrate for solution for infusion with two strengths, 1-mg and 4-mg vials.
223647541|NCT01980667|DRUG|Cisplatin|vials containing 1 mg/ml concentrate for solution for infusion
223647542|NCT02196636|DRUG|Placebo|Matching placebo, administered orally with approximately 240 mL of buffer
223647543|NCT02196636|DRUG|RO6806127|Administered orally with approximately 240 mL of buffer
223647544|NCT05417919|OTHER|Solution-oriented Nursing in Violence Against Women (SONVAW)|The Personal Information Form was filled in by the students themselves before the program. İSKEBE was filled before, after the program and at the follow-up 3 months later. 3 days were determined for the program for the students in the experimental group, and the program was applied for 60 minutes a day for 6 weeks, allowing the students to participate in the program on a suitable day
223647545|NCT02849899|DRUG|Vildagliptin|"Galvus is prescribed as recommended by the marketing authorization. In adults, the recommended dose of Galvus is 100 mg per day (one tablet in the morning and another in the evening).~In patients with moderate or severe kidney problems, the recommended dose is 50 mg once daily (one tablet in the morning).~Patients with creatinine clearance greater than 50 ml/min the vildalgliptin dose will be 100 mg/day. For those whose clearance is less than 50 ml/min, the daily dose is 50 mg. The creatinine clearance will be measured each week.~The treatment duration will be 3 months, divided into 2 months of complete treatment and one month of cessation treatment with half dose of vildagliptin."
223647546|NCT02849899|DRUG|Placebo|The placebo is the same as Galvus (packaging, shape, color, registration) but will contain only excipient. The given dose will also be identical.
223647547|NCT00787358|DRUG|ZT-031|80 ul subcutaneous injection per day
223647548|NCT00787358|OTHER|placebo|80 ul daily subcutaneous injection of vehicle only
223647549|NCT00863226|DEVICE|Resonator Device|Application of Magnetic Fields Using the Resonator Device
223647550|NCT01995838|DRUG|E2006|E2006 1 mg, 2.5 mg, 5 mg, 10 mg, 15 mg, or 25 mg, in tablet form, taken orally, 30 minutes prior to bedtime, each night for 15 consecutive nights
223647551|NCT01995838|DRUG|Placebo|E2006-matched placebo in tablet form, taken orally, 30 minutes prior to bedtime, each night for 15 consecutive nights
223647552|NCT05902806|DIETARY_SUPPLEMENT|Upgraded tube feed|Total duration of study: 4 weeks; 1 week on current tube feed followed by 2 weeks on upgraded tube feed comparable in energy density and fiber content as their current tube feed. The tube feeding regimen is similar to pre study feeding regimen. There will then be a one week follow up period.
224232870|NCT02096419|DRUG|Clopidogrel dose adjustment|"Patients in the interventional arm will receive clopidogrel dose adjustment to maintain optimal platelet reactivity determined by Multiplate function analyzer (19-46U).~They will undergo platelet function testing on day 1,2,3,7,30 and month 2,3,6,9 and 12.~On first two measurements patients will receive up to 2 additional clopidogrel loading doses (600 mg) and put on 150 mg and 75 mg a day if platelet reactivity \>18U and \<18U, respectively. Maintenance dose will be determined on following measurements - increased by 75 mg if \>46U; not changed if 19-46U; decreased by 75 mg if \<19U. Minimal dose - 75 mg; maximal dose 300 mg (for patients \>70 years 150 mg)"
224232871|NCT03272139|DRUG|Bupivacaine|Anesthetic that will help treat pain and sensation after shoulder arthroscopy
224232872|NCT03272139|DEVICE|Ultrasound|Ultrasound will help guide the anesthesiologist in performing the different nerve blocks
224232873|NCT01985802|OTHER|Pacing|
224232874|NCT05867355|PROCEDURE|surgical fixation|compare implant removal rates between surgical fixation techniques.
224232875|NCT01568164|DEVICE|PliCath HF System|This study is a multi-center, prospective, single-armed, study designed to evaluate the safety and efficacy of the BioVentrix PliCath HF System for left ventricular volume restoration in patients with ischemic cardiomyopathy.
224232876|NCT05936749|GENETIC|Pre-implantation genetic testing|
224232877|NCT03955536|OTHER|Group A: Group routine cardiac rehabilitation program (RCRP)|"Patient education, Chest Physiotherapy, Abdominal and chest breathing, Bronchial hygiene techniques, Segmental breathing exercises, Triflow, exercise and mobilization,graduated exercise, positioning, active joint movement, moving inside bed, sitting at the edge of the bed, transfer from bed to chair, standing walking program, up and down stairs.~Evaluations for each patient (preoperative and just before discharge) Spirometric measurements Intraoral pressure measurementDyspnea assessment (BORG), Pain assessment (VAS), Evaluation of anxiety and depression (HAD) Evaluation of functional capacity (6 minutes walking test) Quality of Life (MacNew Heart Disease Specific Quality of Life Questionnaire)"
224232878|NCT03955536|OTHER|Group B: Group RCRP and inspiratory muscle training|"use of additional virtual reality goggles in the routine cardiac rehabilitation program Virtual reality glasses installed in the patient will feel the best way to feel an environment.~Virtual reality glasses are planned to be used 15 minutes by increasing the usage period.~Evaluations for each patient (preoperative and just before discharge) Spirometric measurements Intraoral pressure measurementDyspnea assessment (BORG), Pain assessment (VAS), Evaluation of anxiety and depression (HAD) Evaluation of functional capacity (6 minutes walking test) Quality of Life (MacNew Heart Disease Specific Quality of Life Questionnaire)"
224232879|NCT03955536|OTHER|Group C: Group RCRP and virtual reality application|"nspiratory muscle training with Threshold for routine cardiac rehabilitation Training intensity~\- 30% of the maximum measured inspiratory pressure per week (15 min.). Every 10 breaths after rest.~Evaluations for each patient (preoperative and just before discharge) Spirometric measurements Intraoral pressure measurementDyspnea assessment (BORG), Pain assessment (VAS), Evaluation of anxiety and depression (HAD) Evaluation of functional capacity (6 minutes walking test) Quality of Life (MacNew Heart Disease Specific Quality of Life Questionnaire)"
224232880|NCT00063206|DRUG|DVS-233 SR|
224232881|NCT05201690|DRUG|VV116 200 mg Group|Drug: VV116 9 subjects will receive VV116 200 mg, orally, QD12h, 5.5 days ;
224232882|NCT05201690|DRUG|VV116 400mg Group|Drug: VV116 9 subjects will receive VV116 400 mg, orally, QD12h, 5.5 days ;
224232883|NCT05201690|DRUG|VV116 600mg Group|Drug: VV116 9 subjects will receive VV116 600 mg, orally, QD12h, 5.5 days ;
224232884|NCT00008736|DRUG|metoclopramide|
224232885|NCT04103177|OTHER|Chair based exercises in the dialysis environment|"Each participant will be given an educational / information booklet. It will include when the right time to engage in Physical Activity. The Chair-based Exercise Program will be the focus of the exercise intervention with written step- by-step instructions with demonstrative image of the exercises. Further details included in this booklet will include, information regarding the benefits of exercise including walking and safety measures in undertaking the exercises.~Sports Exercise Instructor led Chair-based Exercise Programme Patients will be given Sports Exercise Instructor led training on how to perform the chair-based exercises, for 6 weeks. This will be delivered during one of the patients' dialysis sessions. The Instructor will deliver a short 10 minute session to patients and deliver safety instruction.~Motivational interviewing Motivational interviewing will consist of discussion to encourage the participant without coercion and help them develop goals."
224232886|NCT03683407|OTHER|Next-Genernation Sequence|Tumor Mutation burden will be evaluated using NGS after 2-cycle chemotherapy, 4-cycle chemotherapy, or at progressive disease
224232887|NCT03319420|DRUG|LO2A eye drops|Sodium hyaluronate
224232888|NCT03319420|DRUG|Systane Ultra UD|Active Ingredients; Polyethylene Glycol Propylene Glycol
223647553|NCT04301804|DRUG|SHR6390|a selective small-molecule CDK4/6 inhibitor
223647554|NCT05611320|OTHER|Awareness campaign - communications campaign|"How this concept would work in a full deployment:~1. Develop a set of images of healthy meals with local produce. The meals will be child-friendly and easy to prepare.~2. Develop educational content to accompany the images, on the importance of shopping for local produce, and seasonality (when to use what). Optionally work with farmer associations to inform the seasonal options.~3. Package the materials as posters and/or digital infographics. The materials include a link to the campaign website, which has more information about nutrition, local produce and recipes to inspire parents.~4. Partner with government agencies (e.g., ministry of health) to deploy the posters in local supermarkets, and in newspapers and on social media. Make the materials available to the farmer associations for their dissemination as well."
223647555|NCT05611320|OTHER|Online shopping|Provide information on an online shopping site where the parents can shop for local produce online, and have it delivered to their homes, to disrupt their current ingredient-selection habits. Working backwards from a potential broad implementation, here we identify key risks along the path, and examine how to use the pilot to de-risk those areas.
223647556|NCT00992472|DRUG|Prochlorperazine suppositories, 25mg|
223647557|NCT00992472|DRUG|Compazine® suppositories, 25mg|
223647558|NCT04254172|DEVICE|Activity Monitor|Wrist and ankle sensors to be worn continuously for 2-week intervals.
223647559|NCT01437566|DRUG|Fulvestrant|Participants will receive fulvestrant 500 mg as 2 IM injections of 250 mg on Days 1 and 15 of Cycle 1 and on Day 1 of each subsequent cycle, each cycle of 28 days until disease progression, intolerable toxicity, elective withdrawal from the study, study completion or termination.
224232889|NCT06497322|OTHER|Exercise intervention - High intensity interval training on a cycle-ergometer|The experimental group starts with 5 minutes of unloaded cycling, followed by 3 × 3-minute HIIT training sequences alternating between: i) 30 seconds at 90% of maximal PO (70 rpm for 30 seconds) and ii) 30 seconds of light pedaling at 20% of PO). Recent work suggests that this high-intensity approach to aerobic exercise is feasible and safe, even during acute oncology treatment. The HIIT sequences are interspersed with two 3-minute cycling sessions at moderate intensity. The training session will be concluded with a 5-minute cool-down by cycling (light pedaling) and stretching. This protocol will be performed twice a week throughout the study, and all patients who reach an 80% adherence threshold for the exercise intervention will be included in the final analysis.
224232890|NCT03422926|BEHAVIORAL|Social marketing campaign|Messaging campaign designed to help mothers in choosing healthful options when dining out.
224232891|NCT01164943|PROCEDURE|Stimulation with human FSH|Human FSH
224232892|NCT01164943|PROCEDURE|Stimulation with recombinant FSH|Recombinant FSH
224232893|NCT02598102|DRUG|Diclofenac sodium|Diclofenac for pain relief
224320112|NCT04862221|DRUG|Placebo for prednisolone|"Subjects will receive 1 mg/kg/day of oral placebo for prednisolone on days 5-13 followed by a gradual taper to discontinuation at 42 days as indicated below. Subjects receiving oral placebo will be given a solution that closely resembles the treatment drug.~Days 5 - 13 Placebo for Prednisolone PO 1 mg/kg/day (max 50 mg/day)~Days 14- 20 Placebo for Prednisolone PO 0.5 mg/kg/day (max 25 mg/day)~Days 21 - 27 Placebo for Prednisolone PO 0.3 mg/kg/day (max 15 mg/day)~Days 28 - 34 Placebo for Prednisolone PO 0.1 mg/kg/day (max 5 mg/day)~Days 35 - 41 Placebo for Prednisolone PO 0.1 mg/kg every OTHER day (max 5 mg every other day)~Day 42 Discontinue"
223647560|NCT01437566|DRUG|GDC-0941|Participants will receive GDC-0941 260 mg (Part II) or 340 mg (Part I) QD orally from Day 1 or Day 15 of Cycle 1 until disease progression, intolerable toxicity, elective withdrawal from the study, study completion or termination.
223647561|NCT01437566|DRUG|GDC-0941 Matching Placebo|Participants will receive GDC-0941 matching placebo QD orally from Day 1 or Day 15 of Cycle 1 until disease progression, intolerable toxicity, elective withdrawal from the study, study completion or termination.
223647562|NCT01437566|DRUG|GDC-0980|Participants will receive GDC-0980 30 mg (Part I) QD orally from Day 15 of Cycle 1 until disease progression, intolerable toxicity, elective withdrawal from the study, study completion or termination.
223647563|NCT01437566|DRUG|GDC-0980 Matching Placebo|Participants will receive GDC-0980 matching placebo QD orally from Day 15 of Cycle 1 until disease progression, intolerable toxicity, elective withdrawal from the study, study completion or termination.
223647564|NCT00409734|BEHAVIORAL|Children with pyloric stenosis|Both cohorts' feeding habits will be observed and recorded for the purposes of comparison
223647565|NCT00409734|BEHAVIORAL|Children without pyloric stenosis|Both cohorts' feeding habits will be observed and recorded for the purposes of comparison
223647566|NCT03449667|DEVICE|Cryoneurolysis|Cryoneurolysis of the femoral and sciatic nerves (or their distal counterparts) in the residual limb: The cryoneurolysis device will be triggered using 3 cycles of 2-minute gas activation separated by 1-minute defrost periods. For active probes, the nitrous oxide will be deployed to the tip where a drop in temperature to -70°C will result in cryoneurolysis.
223647567|NCT03449667|DEVICE|Sham Comparator|Sham cryoneurolysis of the femoral and sciatic nerves (or their distal counterparts) in the residual limb: The cryoneurolysis device will be triggered using 3 cycles of 2-minute gas activation separated by 1-minute defrost periods. However, for sham probes, the nitrous oxide is not deployed to the tip and therefore there is no drop in temperature resulting in cryoneurolysis.
223647568|NCT06035757|DRUG|Bridion 200 MG in 2 ML Injection|Sugammadex is administered at the end of surgery after assessment of the level of neuromuscular blockade is done. The dosage of each reversal agent is determined with response to TOF or PTC.
223647569|NCT06035757|DRUG|Pyridostigmine Bromide 5 MG/ML|Pyridostigmine is administered at the end of surgery after assessment of the level of neuromuscular blockade is done. The dosage of each reversal agent is determined with response to TOF.
223647570|NCT04651062|DEVICE|endocuff|Endocuff is a relatively new device which is intended to be attached to the end of the colonoscope.
223647571|NCT04651062|PROCEDURE|no endocuff|colonoscopy is performed without endocuff.
223647572|NCT03135964|DEVICE|filler dressing of NPWT|a dressing or filler material is used to fit to the contours of a wound (which is covered with a non-adherent dressing film) .
223647573|NCT02760953|PROCEDURE|Cryoablation|Using a novel cryoablation unit to perform transurethral cryoablation on the tumor base after transurethral resection
223647574|NCT02760953|DRUG|Epirubicin|Epirubicin instillation should be give within 24 hours after initial TUR, this is accord with current guideline.
223647575|NCT04830319|OTHER|Pilates Method|includes exercises in soil, that associate the correct respiratory movement with muscular strengthening and control, stretching from the eccentric movement, selective upper and lower trunk movements. There will be used accessories described by the method for their realization. Participants will perform the first week of awareness and body alignment exercises for 10 minutes, 10 minute breath perception, 10 minute proximal muscle accuracy and control, and 10 minute stretches; from the second week will be included selective trunk movements, with muscle strengthening of lower limbs. Rest intervals will be performed between exercises.
224232894|NCT02598102|DRUG|Placebo|Placebo for comparison
224232895|NCT06375590|DEVICE|Transcatheter Aortic Valve Implantation|Transcatheter treatment of bicuspid stenosis with the Navitor platform
224232896|NCT05220670|OTHER|HIIT|It will be carried out after a 10-minute warm-up period with joint mobility exercises and dynamic stretching. The intervention will consist of a training in which intense work intervals and active rest periods are combined using a cycle ergometer. The session will be divided into 4 intervals of 4 minutes duration at an intensity of 85-95% of the maximum heart rate \[MHR\], individually controlled during all sessions (Polar Team pro®), followed by active rest intervals of 3 minutes duration at 50-70% FCM. After training, a 10-minute cool-down of gentle pedaling and joint range exercises will be carried out.
224232897|NCT05220670|OTHER|MICT|Heating phase identical to the previous one. Subsequently, the participants will perform training on the cycle ergometer with an intensity close to 70% FCM maintained for 40 minutes and will be individually controlled (Polar Team pro®). The session will conclude with a cool-down phase identical to the previous one.
224232898|NCT00317499|OTHER|Placebo|Placebo
224232899|NCT00317499|DRUG|Etanercept|Etanercept
223647576|NCT04830319|OTHER|task-oriented training protocol|The control-test group (CTG) will initiate the task-oriented training protocol. The task-oriented training protocol will include functional exercise drills, such as sit-up and workout, obstacle course workout, speed-and-direction workout, balance workout, work-up and downhill workout, each tasks performed for eight minutes, with two minutes of rest between them. The difficulty in carrying out the tasks will be progressively adjusted. At all times, individuals will be instructed to contract the pelvic floor musculature. After 20 sessions, the patients will be reassessed and will remain for a period of one month without any intervention, and at the end of this period will be reevaluated again. Next, the CTG group will perform 20 sessions of Pilates exercises.
223647577|NCT03444636|DRUG|Ropivacaine/Fentanyl|Ropivacaine 0.2% with Fentanyl 5 µg/ml; flow rate of 0.1 ml/kg/hr
223647578|NCT03444636|DRUG|Bupivacaine/Fentanyl|Bupivacaine 0.125% with Fentanyl 5 µg/ml; flow rate of 0.1 ml/kg/hr
223647579|NCT04814004|DRUG|hCD19.IL15.CAR-iNKT|Universal hCD19.IL15.CAR-iNKT cells by a single infusion intravenously will be given in escalating doses.
223647580|NCT00380367|BIOLOGICAL|Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine|Quadrivalent HPV vaccine (6, 11, 16, 18) given intramuscularly on Day 1, Month 2, and Month 6.
223647581|NCT03281200|DRUG|L - Antineoplastic and immunomodulating agents|L - Antineoplastic and immunomodulating agents
223647582|NCT03281200|DRUG|L01 - Antineoplastic agents|L01 - Antineoplastic agents
223647583|NCT03281200|DRUG|L01X - Other antineoplastic agents|L01X - Other antineoplastic agents
223647584|NCT03281200|DRUG|L01XE - Protein kinase inhibitors|L01XE - Protein kinase inhibitors
223647585|NCT03281200|DRUG|L01XE31 - Nintedanib|L01XE31 - Nintedanib
223647586|NCT05109143|DRUG|Indomethacin suppository|100mg Indomethacin Suppository administered at the time of Induction
223647587|NCT05109143|OTHER|Standard Medical Treatment|Standard Medical Treatment
223647588|NCT01155518|DRUG|testosterone|intramuscular every 2 weeks
223647589|NCT01155518|DRUG|clomiphene|thrice a week
223647590|NCT01155518|DRUG|placebo|intramuscular saline injections every 2 weeks
223647591|NCT01155518|DRUG|placebo|oral
223647592|NCT04981990|PROCEDURE|Single lung ventilation by double lumen endotracheal tube|Single lung ventilation using double lumen endotracheal tube and isolation of the operated lung during surgery to create ideal surgical field
223647593|NCT04981990|PROCEDURE|Two lung ventilation by conventional single lumen endotracheal tube|Intermittent two lung ventilation so that no significant hypoxia occurs with creating optimum surgical field
223647594|NCT00439517|DRUG|UFOX + Cetuximab|"* Cetuximab infusion (400 mg/m\^2 on day 1 of cycle 1 and 250 mg/m\^2 at each subsequent day 1, as well as on days 8, 15 and 22)~* Oxaliplatin infusion (85mg/m\^2) on days 1 and 15 (every 2 weeks)~* Oral UFT® (250mg/m\^2 tegafur + 560 mg/m\^2 uracil in 3 daily doses rounded to the nearest number of whole capsules) on days 1-21~* Oral Folinic Acid (90 mg in 3 daily divided doses) on days 1-21"
223647595|NCT00439517|DRUG|FOLFOX4 + Cetuximab|"* Cetuximab infusion (400 mg/m\^2 on day 1 of cycle 1 and 250 mg/m\^2 at each subsequent day 1, as well as on days 8, 15 and 22)~* Oxaliplatin infusion (85 mg/m\^2) on days 1 and 15 (every 2 weeks)~* 5-FU bolus + infusions (400 mg/m\^2) on days 1, 2, 15 and 16~* Folinic Acid infusions (200 mg/m\^2) on days 1, 2, 15 and 16"
223647596|NCT01684813|DRUG|Prasugrel.|Patients in this group will receive a loading dose of 60 mg prasugrel (6 x 10 mg tablets) followed by at least dose of 10 mg prasugrel (1 x 10 mg tablet). Beyond the second day after PCI, these patients will receive double antiaggregation therapy according to their physician´s criteria.
223647597|NCT01684813|DRUG|Clopidogrel|Patients in this group will receive the standard dose of clopidogrel, a daily dose of 75 mg. Beyond the second day post-PCI, these patients will receive double anti aggregation therapy according to their physician's criteria.
223647598|NCT02058303|DRUG|Exparel Forearm block|20-30 mL Mepivacaine will be used for the supraclavicular block following the forearm block.
223647599|NCT02058303|DRUG|Bupivacaine supraclavicular block|20-30mL 0.5% bupivacaine
223647600|NCT05377255|COMBINATION_PRODUCT|16 mg naloxone AP003|4 doses of 4 mg each (total: 16 mg) of naloxone through the AP003 device
223647601|NCT05377255|COMBINATION_PRODUCT|8 mg naloxone NARCAN Nasal Spray|2 doses of 4 mg each (total: 8 mg) of the naloxone through the NARCAN Nasal Spray device
223647602|NCT03463928|BIOLOGICAL|donor-derived CD19/22 bispecific CAR-T cells or CD19-directed CAR-T cells; donor-derived-HSCT|The allo-CAR-T cells will be infused in a fractionated manner, 1/3 on day 0, 2/3 on day 1.The allo-HSCT will be infused on day 2.
223647603|NCT03171571|OTHER|Coaching procedure|"In this study, the volunteers will be followed during one year. The wellbeing will be followed with :~* survey like FFQ, SF36, dietary habits.~* actimetry measurement~* one year follow-up of weight, waist measurement~* nutritional biomarkers"
223647604|NCT01185665|DEVICE|TENS|Transcutaneous Electrical Nerve Stimulator
223647605|NCT01185665|DEVICE|Sham-TENS|TENS without electrical output, from the outside not different from a normal TENS
223647606|NCT00554489|BEHAVIORAL|exercise intervention|participation in physical activity intervention program weeks 2 through 5
223647607|NCT01907711|DEVICE|Acupuncture.|"Who tried the insertion and manipulation between 8 - 12 needles with guide applied at different points of the body, individually selected and customized, after the insertion, the acupoint stimulation is done through manipulation of de needle sleeve to achieve at each point the sensation known as De Qi."
223647608|NCT02905799|DRUG|oral resveratrol|Resveratrol will be administered orally, at the dose of 40 mg (2 caplets) twice a day for one week, then at the dose of 20 mg (1 caplet) twice a day, for a total duration of 6 months.
224232900|NCT04664842|OTHER|Diaphragmatic Stretch Technique|Diaphragmatic stretch technique is an intervention intended to indirectly stretch the diaphragmatic muscle fibers. This will help to decease tension generated by trigger points, normalizing muscle ﬁber length, and improve muscle contraction.
224232901|NCT04664842|OTHER|Breathing Exercise Training|During diaphragmatic or abdominal breathing training, inhalation will caused diaphragm contract downwards, inflating the lungs. This filling of the lungs pushes the abdominal organs down leading to expansion of the abdomen. Subjects are required to do few repetitions during the intervention.
224232902|NCT05214742|OTHER|Diagnostic Test|Molecular diagnosis carried out in the context of care
223766238|NCT02984501|RADIATION|Radiation|Radiotherapy target volumes are established by CT scan and PET-CT scan. Radiotherapy is delivered with a total dose of 54-59 Gy with fractionation of 1.8 Gy daily for 5 days a week. The Planning Target Volume (PTV) is defined by CTV with a safety margin of 1cm in all directions to include organ motion and set-up errors. Organs at risk for radiation-induced side effects are contoured on the dose planning CT and dose volume histograms (DVH) are calculated. All treatments are delivered with a 15-MV linear accelerator (Varian Medical System) with a multifield isocentric technique using a multileaf collimator. A quality-control protocol are applied for all patients with periodical digital portal images to evaluate the precision of the set-up.
223766239|NCT02984501|DRUG|Chemotherapy|The induction phase of the treatment plan is designed to administer gemcitabine 1000 mg/mq and oxaliplatin 100 mg/mq every 14 days for four doses. Chemotherapy concurrent to conformal radiation therapy is gemcitabine at the dose of 600 mg/mq weekly.
224232903|NCT02583542|DRUG|AZD2014|AZD2014 is a dual inhibitor of both mTORC1 (rapamycin-sensitive) and mTORC2 (rapamycin insensitive); compared to rapalogues, AZD2014 has a broader range of growth inhibitory activity in preclinical models based on a more profound mTORC1 inhibition and the additional inhibition of mTORC2. AZD2014 is currently in phase 2 studies in renal cell cancers and metastatic breast cancer.
224232904|NCT02583542|DRUG|AZD6244|Selumetinib (AZD6244, ARRY-142886) is an orally available, potent, selective, non-ATP competitive inhibitor of MEK1/MEK2 kinases. Selumetinib has demonstrated clinical efficacy in pre-treated KRAS-mutant NSCLC, leading to a significantly improved progression-free survival in combination with docetaxel compared to docetaxel alone.
224232905|NCT00007878|DRUG|bortezomib|Given IV
224232906|NCT00007878|DRUG|fluorouracil|Given IV
224232907|NCT00007878|DRUG|leucovorin calcium|Given IV
224232908|NCT00007878|OTHER|pharmacological study|Correlative studies
224232909|NCT00007878|OTHER|laboratory biomarker analysis|Correlative studies
224232910|NCT00625807|BEHAVIORAL|RR|A well-validated 8 week stress reduction course. Classes meet once a week for 1.5 hours. Participants will be asked to perform stress reduction techniques each night for 20 minutes throughout the entire 8-week course. Stress reduction techniques use meditative techniques that focus primarily on inducing relaxation
224232911|NCT00625807|BEHAVIORAL|MBSR|A well-validated 8 week stress reduction course. Classes meet once a week for 1.5 hours. Participants will be asked to perform stress reduction techniques each night for 20 minutes throughout the entire 8-week course. Stress reduction techniques use meditative techniques that focus primarily on inducing mindfulness
223647609|NCT02905799|DRUG|oral placebo|Placebo will be administered orally : 2 caplets twice a day for one week, then 1 caplet twice a day, for a total duration of 6 months
223647610|NCT00199212|DRUG|Combination of trastuzumab and PS-341|Trastuzumab and velcade are used according standard procedure
223647611|NCT02403648|DRUG|BIOD-961|BIOD-961 is a lyophilized glucagon formulation.
223647612|NCT02403648|DRUG|Lilly Glucagon|
223647613|NCT02403648|DRUG|Novo Glucagon|
223647614|NCT04767984|DRUG|Atorvastatin Calcium|Given PO
223647615|NCT04767984|PROCEDURE|Biopsy of Colon|Undergo colonoscopy with biopsy
223647616|NCT04767984|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
223647617|NCT04767984|DRUG|Placebo Administration|Given PO
223647618|NCT04767984|OTHER|Questionnaire Administration|Ancillary studies
223647619|NCT00272311|DRUG|Aspirin|Dosage
223647620|NCT04399785|OTHER|Camrelizumab and SBRT|Camrelizumab: 200mg every 3 weeks; SBRT
223647621|NCT01538667|DRUG|Ciprofloxacin (Cipro Inhale, BAYQ3939)|50 mg single powder dose of 99mTc labeled ciprofloxacin PulmoSphere inhalation powder inhaled by healthy subjects
223647622|NCT01538667|DRUG|Ciprofloxacin (Cipro Inhale, BAYQ3939)|50 mg single powder dose of 99mTc labeled ciprofloxacin PulmoSphere inhalation powder inhaled by healthy subjects under charcoal block
223647623|NCT01538667|DRUG|Ciprofloxacin (Cipro Inhale, BAYQ3939)|50 mg single powder dose of 99mTc labeled ciprofloxacin PulmoSphere inhalation powder inhaled by COPD patients
223647624|NCT01538667|DRUG|Ciprofloxacin (Cipro Inhale, BAYQ3939)|50 mg single powder dose of 99mTc labeled ciprofloxacin PulmoSphere inhalation powder inhaled by bronchiectasis patients
223647625|NCT01168037|DEVICE|Endovascular aortic repair with branched/fenestrated stent-graft|Insertion via bilateral femoral access, stent-graft deployment under fluoroscopic guidance, complementary stenting of visceral arteries, control angiogram
223647626|NCT01168037|PROCEDURE|Open Surgical Repair|aortic replacement with revascularization of visceral arteries
223647627|NCT00580307|PROCEDURE|Septoplasty|Surgical straightening of nasal septum
223647628|NCT00580307|PROCEDURE|Septoplasty and endoscopic contact point correction|Septoplasty (as previously described). Contact point correction: structures of the lateral nasal wall that impinge on the nasal septum are mobilized to a more lateral position under endoscopic guidance.
223647629|NCT05996133|DRUG|Bupivacaine Hcl 0.25% Inj|30 mL of 0.25% bupivacaine + 0.5 mL (5 mg) preservative-free dexamethasone + 0.1 mL epinephrine 1:400,000.
223647630|NCT05996133|OTHER|Normal saline|3 mL normal saline
223647631|NCT05267522|OTHER|Egg diet|30% fat \[6% saturated fat\], 20% protein, 40% carbohydrate, 600 mg cholesterol
223647632|NCT05267522|OTHER|Egg-free Diet|30% fat \[12% saturated fat\], 25% protein, 40% carbohydrate, 300 mg cholesterol
223647633|NCT05267522|OTHER|Control Diet|30% fat \[12% saturated fat\], 25% protein, 40% carbohydrate, 600 mg cholesterol
223647634|NCT04319588|PROCEDURE|Parasternal Block+ Infiltration with local anesthetic of access to thoracic drainage|After induction of general anesthesia we will perform an ultrasound-guided Parasternal Block in association with infiltration with local anesthetic of access to thoracic drainage at the end of the intervention.
223647635|NCT04319588|PROCEDURE|Infiltration with local anesthetic of access to thoracic drainage|Infiltration with local anesthetic of access to thoracic drainage at the end of the intervention.
224232912|NCT02473978|DEVICE|INVOS Cerebral Oximetry|Participants will be connected to INVOS Cerebral Oximetry Cerebral Oximetry preoperativly and intraoperativly to ascess there cerebral perfusion throughout cesarean sections.
224232913|NCT01474278|DRUG|Placebo|Single dose
224232914|NCT01474278|DRUG|RO5028442|Single dose
224232915|NCT00116935|DRUG|imatinib mesylate|imatinib 400 mg/day orally qd for 12 months
224232916|NCT00116935|DRUG|imatinib|imatinib 400 mg/d orally qd for 36 months
224232917|NCT00116935|DRUG|imatinib|imatinib 400 mg/d orally qd for 36 months
223647636|NCT04251130|DRUG|2-(2-([18F]fluoro)pyridin-4-yl)-9H-pyrrolo[2,3-b:4,5-c']dipyridine|A small molecule aimed for binding and PET-imaging of aggregated tau protein in the human brain.
223647637|NCT05884541|OTHER|TipsbyText Messages|Texts sent to caregivers meant to increase parent child interaction around math and literacy, sent to participants 4x a week for 8 months
223647638|NCT00647959|DRUG|Doxycycline Tablets, 150mg|150mg, single dose fasting
223647639|NCT00647959|DRUG|Adoxa Tablets 150 mg|150mg, single dose fasting
224232918|NCT02224391|BEHAVIORAL|Computer-Assisted Smoking Cessation Intervention|Receive ABM training via a smartphone
224232919|NCT02224391|OTHER|Laboratory Biomarker Analysis|Correlative studies
224232920|NCT02224391|DRUG|Nicotine Patch|Given via transdermal patch
224232921|NCT02224391|OTHER|Questionnaire Administration|Ancillary studies
224232922|NCT02224391|OTHER|Sham Intervention|Undergo sham training
224232923|NCT00379457|BIOLOGICAL|dactinomycin|
224232924|NCT00379457|DRUG|carboplatin|
224232925|NCT00379457|DRUG|cyclophosphamide|
224232926|NCT00379457|DRUG|doxorubicin hydrochloride|
224232927|NCT00379457|DRUG|etoposide|
224232928|NCT00379457|DRUG|ifosfamide|
223647640|NCT04169074|DRUG|Abemaciclib|Treatment will consist of a single neoadjuvant cycle of 10-21 days (+7 days). Abemaciclib will be administered from days 1-21. Abemaciclib may be continued for an additional 7 days, or up to 28 days, for delays in planned surgery.
223647641|NCT03397810|RADIATION|low dose radiotherapy|10 Gy in 5 fractions of 2 Gy on 5 consecutive days
223647642|NCT04529018|COMBINATION_PRODUCT|[18F]CETO|\[18F\]CETO is a PET radiotracer used to diagnose and visualise the cause(s) of primary aldosteronism
224232929|NCT00379457|DRUG|topotecan hydrochloride|
224232930|NCT00379457|DRUG|vincristine sulfate|
224232931|NCT00379457|DRUG|vinorelbine tartrate|
224232932|NCT00379457|PROCEDURE|conventional surgery|
224232933|NCT00379457|RADIATION|radiation therapy|
224232934|NCT00280436|DRUG|GW679769|
224232935|NCT02354300|DEVICE|TCD Ultrasound|Transcranial doppler ultrasound monitoring will occur during flow diverter placement.
224232936|NCT05613699|BEHAVIORAL|Exercise - Social Media|The supervised online-social media exercise intervention took place once per week at a fixed, pre-scheduled time, via an online video conference platform. The training sessions lasted for 60 minutes and included a holistic workout with different focuses (e.g. resistance training for lower extremities, sensorimotor training, home-based endurance training). Patients were further recommended independent physical activity like walking or cycling, 1-2 times per week or to maintain the current volume of physical activity.
224232937|NCT05613699|BEHAVIORAL|Exercise - App|Exercise program in the online-app were personalized and focused on a combination of endurance and resistance training, 2-3 times a week, depending on patient's needs. Additional types of exercise (e.g. sensorimotor training) were added if therapy-related side effects were present. If necessary, exercise trainers conducted one introductory training session as video conference to check for exercise techniques and answer any individual questions.
224232938|NCT05613699|BEHAVIORAL|Exercise - closed to patients residence|The supervised exercise program close to patient's home was executed in a certified exercise facility of the network OnkoAktiv and supervised by special qualified exercise trainers. The weekly recommendation was to participate in a personalized in-person exercise program 1-2 per week, plus independent physical activity (or to maintain current level of physical activity)
224232939|NCT00322478|BEHAVIORAL|Automated informatics driven education and social networking|The patient uses a self-contained wireless accessory to a standard blood glucose meter. This device manages the meter to ensure accurate time stamps and transmits the data to a centralized data management system. The system is then configured to assess the data and take automated steps to derive relevant diabetes education and/or send reports to a registered and authorized team.
224232940|NCT00322478|BEHAVIORAL|Blood Glucose Notifications to Remote Caregivers|When children with type 1 diabetes are at school they will connect their blood glucose meter to the GlucoMON appliance. The data from the meter is then transmitted to the central system followed by the most recent blood sugar being sent to the primary caregiver's email address(es) as a plain text message. The investigator is interested to better understand the behaviors that accompany the expectation of the message and actions taken subsequent to receipt of the message by the patient-centric team.
224232941|NCT00322478|BEHAVIORAL|Frequency of Pattern Management|The behavioral intervention being studied involves the assessment of frequency of self-care in relation to the primary and secondary outcomes including overall blood sugar control and patient satisfaction.
224232942|NCT00991588|PROCEDURE|PCL, posterolateral reconstruction|The operative procedures involve either a single- or double-strand PCL graft which is usually harvested from the patient's knee. In cases of multiple ligament procedures, allograft tissues may be used which are obtained from tissue banks certified by the American Associate of Tissue Banks and that have passed FDA inspection. The posterolateral structures, including the fibular collateral ligament (FCL), are reconstructed with one or two grafts, depending upon the severity of damage encountered at surgery.
223647645|NCT05744817|BEHAVIORAL|Inspiratory muscle strength training|30 breaths/day against a set resistance
223647646|NCT02324101|DEVICE|Hsp90|Detect plasma Hsp90α concentration
223647647|NCT06404385|PROCEDURE|Static computer-assisted guided surgery with analogic guide|coDiagnostix9® planning software
223647648|NCT06404385|PROCEDURE|Static computer-assisted guided surgery with CAD-CAM surgical guide|coDiagnostix9® planning software
223647649|NCT00210951|OTHER|No Intervention|Participants will not receive any intervention in this study. Participants with chronic renal disease receiving treatment with epoetin alfa or other recombinant erythropoietins will be prospectively observed to monitor incidence of pure red cell aplasia and/or antibodies to erythropoietin. Participants will receive standard-of-care treatment for their chronic renal (or other) disease from their individual Investigators.
223647650|NCT00973804|DRUG|EPOCH-F/R|
223647651|NCT00973804|DRUG|FLAG|
223647652|NCT00973804|DRUG|Transplant Preparative Regimen (Flu/Cy/Mes)|
223647653|NCT00973804|DRUG|GVHD Prophylaxis (tacrolimus and sirolimus)|
224320113|NCT04862221|DRUG|Placebo for infusions|Subjects randomized to the supportive care alone arm will receive normal saline in place of all study treatments (skin test, premedication and IV infusions) on Days 1-4 given at the same volume and duration as the eATG infusions.
224232943|NCT03112057|DIAGNOSTIC_TEST|harmonic generation (HGM) microscopic methods.|a frequency-dependent optical microscopy system with a near-infrared light source with a wavelength of 1230 nm was used to detect the diseased site and normal skin.Use erbium-Jacob (Er-YAG) laser exfoliation. the participants need to lie down, wear goggles. The lens sucker device to help fix the skin examination site. Based on the experience of the past 118 subjects, the participants did not discomfort. The total time of the laser irradiation on the same skin is no more than 30 minutes, the maximum laser power is no more than 0.15 watts, irradiation in the skin of the total energy of the laser does not exceed 270 joules. After the experiment, the investigators immediately check the skin for the participants
224232944|NCT06158321|DEVICE|M1 or DLPFC sham stimulation|Participants receiving M1 or DLPFC sham stimulations will complete the same procedures as those in the active groups. The sham coil, with the same stimulation parameters, will provide auditory and sensory effects similar to the active coil without delivering active stimulation.
223647654|NCT00973804|PROCEDURE|Double Cord Blood Transplantation|
223766240|NCT04585334|DRUG|Tricortin 1000|Tricortin 1000 \[2 mL ampoules containing 12 mg of phospholipids and 1 mg of Vitamin B12 (Cyanocobalamin)\] will be administered intramuscular on the gluteus, once daily (24 hours apart), for 15 days starting from the evening of Day 0 (visit 2) plus Diclofenac sodium medicated plaster placebo will be applied twice daily (12 hours apart) for 15 days starting from the evening of Day 0 (visit 2), i.e. 30 applications.
223766241|NCT04585334|DRUG|Itami|Diclofenac sodium 140 mg medicated plaster (Itami®) will be applied twice daily (12 hours apart) for 15 days starting from the evening of Day 0 (visit 2), i.e. 30 applications plus Tricortin 1000 placebo (2 mL ampoules) will be administered intramuscular on the gluteus, once daily (24 hours apart), for 15 days starting from the evening of Day 0 (visit 2).
223766242|NCT04585334|DRUG|Placebo|Tricortin 1000 placebo (2 mL ampoules) will be administered intramuscular on the gluteus, once daily (24 hours apart), for 15 days starting from the evening of Day 0 (visit 2) plus Diclofenac sodium medicated plaster placebo will be applied twice daily (12 hours apart) for 15 days starting from the evening of Day 0 (visit 2), i.e. 30 applications.
224232945|NCT06158321|DEVICE|M1 rTMS|The stimulation parameter of the active M1-rTMS is a 10 Hz stimulation frequency with a total of 1500 stimulation pulses.
224232946|NCT06158321|DEVICE|DLPFC rTMS|The stimulation parameter of the active DLPFC-rTMS is a 1 Hz stimulation frequency with a total of 1500 stimulation pulses.
224232947|NCT01974895|BIOLOGICAL|FluLaval® Quadrivalent|1 or 2 doses administered intramuscularly (IM) in deltoid region of non-dominant arm (for subjects ≥12 months of age) or anterolateral region of left thigh (for subjects \<12 months of age) on Day 0 (primed subjects) and on Day 0 and Day 28 (unprimed subjects), respectively.
224232948|NCT01974895|BIOLOGICAL|Fluzone®|1 or 2 doses administered IM in deltoid region of non-dominant arm (for subjects ≥12 months of age) or anterolateral region of left thigh (for subjects \<12 months of age) on Day 0 (primed subjects) and on Day 0 and Day 28 (unprimed subjects), respectively.
224232949|NCT00699504|DRUG|cangrelor|IV bolus 60 mcg/kg; 8 mcg/kg x 3 hrs
224232950|NCT00699504|DRUG|cangrelor|30 mcg/kg bolus; 4 mcg/kg/min x 3 hrs. Oral placebo capsule
224232951|NCT00699504|DRUG|cangrelor|60 mcg/kg bolus; 8 mcg/kg/min x 3 hrs. Oral placebo capsule
223766243|NCT05514834|DEVICE|Cellular Matrix TM BCT-HA Kit (ref. BCT-HA-3)|Injections with platelet-rich plasma and hyaluronic acid
223766244|NCT05514834|OTHER|PRP Only|platelet rich plasma without hyaluronic acid
224232952|NCT00699504|DRUG|moxifloxacin|400 mg orally. Placebo IV bolus and infusion.
223647655|NCT02546206|DIETARY_SUPPLEMENT|Probiotic Yoghurt|Probiotic yoghurt consumption
223766245|NCT05514834|OTHER|Placebo|Neither PRP nor hyaluronic acid
224232953|NCT00699504|DRUG|placebo|placebo IV and oral
224232954|NCT01984242|DRUG|Atezolizumab (MPDL3280A), an Engineered Anti-PD-L1 Antibody|Atezolizumab will be administered according to the dosage schedule mentioned in the arm description.
223647656|NCT02546206|DIETARY_SUPPLEMENT|Natural Yoghurt|Natural yoghurt consumption
224232955|NCT01984242|DRUG|Bevacizumab|Bevacizumab will be administered according to the dosage schedule mentioned in the arm description.
224232956|NCT01984242|DRUG|Sunitinib|Sunitinib will be administered according to the dosage schedule mentioned in the arm description.
224232957|NCT01357603|BIOLOGICAL|Glargine|dosage form: Subcutaneous injection
224232958|NCT01346852|DRUG|Asthma treatment with an asthma-related medication and at least one asthma controller medication|participants with an asthma diagnosis who also had at least one dispensing event of an asthma-related medication and had at least one asthma controller medication (inhaled corticosteroids containing inhalers, methylxanthines, leukotriene receptor antagonists, cromolyn sodium) or albuterol.
224232959|NCT02983708|BIOLOGICAL|Peripheral blood mononuclear cells (mPBMC)|
224232960|NCT02983708|DRUG|G-CSF|
224232961|NCT02983708|DRUG|Placebo|
224232962|NCT03712553|BEHAVIORAL|Opt-Out|Opt-In messaging prompts participants to contact their primary care provider to receive Hepatitis C screening whereas Opt-Out messaging includes a signed laboratory order for Hepatitis C screening.
224232963|NCT03712553|BEHAVIORAL|Letter|Participants receive messaging prompting them to contact their primary care provider to receive Hepatitis C screening, either as a letter or an electronic message on the MyPennMedicine patient portal.
224232964|NCT03712553|BEHAVIORAL|Behavioral Economic Messaging|Participants receive standard messaging about HCV and ways to get screened and messaging that incorporates behavioral economic principles such as norms, reciprocity, anticipated regret, and pre-commitment to get screening.
224232965|NCT03712553|BEHAVIORAL|Usual Care Messaging|Participants receive standard messaging about HCV and ways to get screening.
224232966|NCT06346210|PROCEDURE|Tracheostomy|Surgery for tracheostomy
223647657|NCT04786717|OTHER|core muscle training|The intervention of this group will focus on training the endurance of the core muscle.
223647658|NCT04786717|OTHER|movement control training|Based from the initial test, the subjects will receive either lumbar flexion control exercise or lumbar extension control exercise. They will perform each lumbar movement control exercise in different position. Starting from the lying position, then progressing to sitting, standing with support, and the last level will be standing without support. Each set of movement will be practiced 10 times, totally 10 sets. It will take approximately 5\~8 minutes to finish each movement. The subjects will learn 5\~8 types of the movement every week.
223647659|NCT04786717|OTHER|combined imagery and movement control training|The intervention of this group is mostly same as the movement control training group. The different part is that the first 3 times of the movement will be practiced through image training, so the subjects will not have any real movement, and the last 7 times they will perform the lumbar motor control exercise literally. Each set of movement will be practiced 10 times, totally 10 sets. It will take approximately 5\~8 minutes to finish each movement. The subjects will learn 5\~8 types of the movement every week.
223647660|NCT01184963|DIETARY_SUPPLEMENT|High protein diet|High protein diet (30% protein, 40% carbohydrate, 30% lipid)
223647661|NCT01184963|DIETARY_SUPPLEMENT|Normal protein diet|Normal protein diet (15% protein, 55% carbohydrate, 30% lipid
223647662|NCT01177371|DRUG|busulfan|Given orally
223766246|NCT06536218|BEHAVIORAL|CONSCIOUS AWARENESS STRESS REDUCTION PROGRAM APPLICATION|CONSCIOUS AWARENESS STRESS REDUCTION PROGRAM APPLICATION Conscious Awareness Based Stress Reduction (BFTSA) intervention consists of seven sessions in total and is planned to be completed in a total of seven weeks, with one session per week and each session being 45 minutes. After the results of the PSG patients are determined according to the randomization criteria, they receive certain points from the sleep scale, it is planned to call the patients by phone and explain the meaning and importance of the study, the applications to be performed in the study and its duration. It is planned to hold online individual interviews with patients who agree to participate in this study.
223766247|NCT04269161|DEVICE|Automatic control of inspired oxygen|A device will be used to automatically adjust the blend of oxygen and air with the ability to return to manual control as needed.
223766248|NCT00268528|BEHAVIORAL|Compliance Monitoring|Receive an electronic pill monitoring system comprising an empty MEMS medication bottle with TrackCap
223766249|NCT00268528|OTHER|Laboratory Biomarker Analysis|Correlative studies
223766250|NCT00268528|DRUG|Mercaptopurine|Given PO
224232967|NCT04543136|DEVICE|SpeediCath® Standard male|Intermittent catheterization through the urethra draining the bladder, using SpeediCath® Standard male.
224232968|NCT04543136|DEVICE|New intermittent Variant 1 catheter for males|Intermittent catheterization through the urethra draining the bladder, using the new Variant 1 catheter.
224232969|NCT04543136|DEVICE|New intermittent Variant 2 catheter for males|Intermittent catheterization through the urethra draining the bladder, using the new Variant 2 catheter.
224232970|NCT03219398|PROCEDURE|Pneumoperitoneum pressure|Subjects were set to 8- 10 mmHg pressure during laparoscopic surgery; Subjects were set to 12-14 mmHg pressure during laparoscopic surgery
223647663|NCT01177371|DRUG|cyclophosphamide|Given IV
223647664|NCT01177371|PROCEDURE|allogeneic bone marrow transplantation|Patients undergo allogeneic bone marrow transplant IV over 2-3 hours on day 0.
223647665|NCT01177371|DRUG|methylprednisolone|Given IV or orally
223647666|NCT01177371|DRUG|methotrexate|Given IV
223647667|NCT01177371|DRUG|cyclosporine|Given IV or orally
223647668|NCT05866809|DRUG|HK-660S|Administered orally
223647669|NCT05866809|DRUG|Placebo|Administered orally
223647670|NCT02135796|OTHER|Echocardiography|
223647671|NCT00867672|DRUG|Decitabine|i.v. Decitabine 20 mg/m² over 1h, 5 days (total dose 100 mg/m²), repeated every 4 weeks
223647672|NCT00867672|DRUG|VPA|VPA starting on day 6 of first cycle continuously throughout all treatment cycles
223647673|NCT00867672|DRUG|ATRA|ATRA (45 mg/m² p.o.) from day 6 to day 28 of each treatment cycle
223647674|NCT01702649|DRUG|RPX2003 (Biapenem)|"Six (6) cohorts of 3 active or 8 subjects of 6 active are planned for evaluation.~Single dose followed by multiple dose, three times a day."
223647675|NCT01702649|DRUG|Placebo|"Six (6) cohorts of 1 placebo or 8 subjects of 2 placebo are planned for evaluation.~Single dose followed by multiple dose, three times a day."
223647676|NCT00406484|BEHAVIORAL|Standard drug counseling|Individual drug counseling
223647677|NCT00406484|BEHAVIORAL|BDRC|Behavioral Drug and HIV Risk Reduction Counseling, individual once or twice weekly sessions
223647678|NCT04058964|BIOLOGICAL|Pegylated Recombinant Human Hyaluronidase PH20|Given SC
223647679|NCT04058964|BIOLOGICAL|Pembrolizumab|Given IV
223647680|NCT00002002|DRUG|Trimethoprim|
223647681|NCT00002002|DRUG|Sulfamethoxazole|
223647682|NCT00002002|DRUG|Leucovorin calcium|
223766251|NCT00268528|DRUG|Methotrexate|Given PO
223766252|NCT00268528|OTHER|Questionnaire Administration|Ancillary studies
223766253|NCT00268528|OTHER|Study of Socioeconomic and Demographic Variables|Receive an electronic pill monitoring system comprising an empty MEMS medication bottle with TrackCap
223766254|NCT00260923|DRUG|aliskiren|
223766255|NCT01509859|DEVICE|PFNA proximal femur nail device (Synthes)|"synthes PFNA proximal femur nail device"
223766256|NCT01509859|DEVICE|INTERTAN proximal femur nail device (Smith&Nephew)|"Smith\&Nephew INTERTAN proximal femur nail device"
223766257|NCT03058731|DEVICE|Matristem|Paraesophageal hernia repair with MatriStem Surgical Matrix
223766258|NCT03058731|DEVICE|Control|Paraesophageal hernia repair with other biologic mesh
224232971|NCT00424658|PROCEDURE|SAHS diagnosis|
224232972|NCT00794183|DEVICE|CRT device settings|Comparision of A-V delay settings
224232973|NCT02259556|BIOLOGICAL|CART30|Cells will be infused 1 day after the completion of conditioning regimen.
224232974|NCT02573909|DRUG|Oxycodone intravenously|Oxycodone intravenously 0,1mg/kg
224232975|NCT02573909|DRUG|Oxycodone epidurally|Oxycodone 0,1 mg epidurally
224232976|NCT01520948|BEHAVIORAL|Exercise-based behavioral therapy|Pelvic floor muscle exercise training, bladder training, fluid management, constipation management
224232977|NCT01520948|BEHAVIORAL|Behavioral control|Mirrored star drawing
224232978|NCT06321081|DRUG|irinotecan, cetuximab, envafolimab|rechallenge treatment
224232979|NCT00546390|DEVICE|Blood Pressure Cuff|The blood pressure cuff will be inflated for 5 minutes and then deflated for 5 minutes. This will be done 4 times in a row.
224232980|NCT03785236|RADIATION|68Ga-NODAGA-exendin PET/CT|68Ga-NODAGA-exendin PET/CT
224232981|NCT02991547|OTHER|Observational|
224232982|NCT04287881|GENETIC|Methylenetetrahydrofolate reductase (MTHFR) deficiency|To investigate the incidence of MTHFR deficiency in patients with adult-onset epileptic seizures and diagnosed ischemic stroke
224232983|NCT03682952|DRUG|Alprostadil Injection|Participants are given alprostadil injection 10ug intravenously once a day for 2 weeks.
224320114|NCT04862221|DRUG|Diphenhydramine|Subjects in the eATG arm will receive pre-treatment medication diphenhydramine IV 1 mg/kg prior to start of eATG infusion.
224232984|NCT03682952|DRUG|Beraprost sodium tablets|Participants are given alprostadil injection 10ug intravenously once a day for 2 weeks ,then they take beraprost sodium tablets 40ug orally three times perday for 3 months.
223647683|NCT03417154|DRUG|Nivolumab|3mg/kg IV (or if prior alloHSCT, 1 mg/kg) over 30 minutes every 14 days on Days 1 and 15 for up to four 28-day courses.
223647684|NCT03417154|DRUG|Low dose Cyclophosphamide (CTX) Daily|Oral cyclophosphamide 50mg + nivolumab 3 mg/kg IV every 2 weeks for up to 4 courses of treatment
223647685|NCT03417154|DRUG|Low dose Cyclophosphamide (CTX) Every 7 Days|Oral cyclophosphamide 350 mg every 7 days + nivolumab 3mg/kg IV every 2 weeks for up to 4 courses of treatment
223766259|NCT03095300|PROCEDURE|Prone position|Patients are rotated from the supine to the prone position for a period of 2 hours.
223766260|NCT04788732|DEVICE|ECG and EEG monitoring|the ECG and EEG will also be monitored during the entire period that the patients remain anesthetized with various anesthetics drugs and will later be used to compose the DoA score based on HRV.
224232985|NCT05713591|BEHAVIORAL|Transition care model|The transition care model (TC) consists in multidisciplinary standardized interventions to educate and support adolescents with congenital heart disease, representing a key element in the adequate delivery of care to these individuals during their transition from childhood to adulthood. This model encompasses three main pillars previously described.
224232986|NCT04229849|DRUG|Anrotenib plus Toripalimab|Anrotenib: 10 mg on day 1-14 orally repeated every 21 days; Toripalimab: 240 mg on day 1 intravenously repeated every 21 days.
224232987|NCT04229849|DRUG|Toripalimab|Toripalimab: 240 mg on day 1 intravenously repeated every 21 days.
224232988|NCT01626079|DEVICE|MitraClip System|Percutaneous mitral valve repair using MitraClip System
224320115|NCT04862221|DRUG|Methylprednisolone|Subjects in the eATG arm will receive pre-treatment medication methylprednisolone IV 1 mg/kg prior to start of eATG infusion.
223766261|NCT01677195|DRUG|ACCS100|ACCS100 is not absorbed. The dose is estimated based on the volume of the gastrointestinal tract. We estimate that the average human intestinal tract has a volume of approximately 4 liters. In the high dose group, the effective concentration in the gut is 0.75 milligrams per milliliter. In the low dose, the effective concentration in the gut is 0.375 milligrams per milliliter. The test article is made by filling gelatin capsules with 500 milligrams of ACCS100. There are no excipients used in the manufacturing process of the test article.
224232989|NCT03466957|OTHER|3D printed applicator|add-on cap for oblique needles, 3D printed Vienna-like applicator, individual vaginal cylinder for intracavitary/interstitial application
224320116|NCT04812470|DRUG|Autologous Tumor Infiltrating Lymphocytes|Administered via hepatic arterial infusion
224320117|NCT04812470|DRUG|Melphalan|Melphalan will be administered once as an intravenous infusion.
224320118|NCT04812470|DRUG|Interleukin-2|After TIL infusion, Interleukin-2 will be administered subcutaneously once daily for up to 14 days.
223647686|NCT05429957|OTHER|Muscle Energy Technique|"Muscle energy technique (Post Isometric relaxation) three times per week for 8 weeks.~* MET of the Iliopsoas~* MET of Piriformis muscle~* MET of Quadratus Lumborum muscle~* MET of Erector Spinae muscle"
223647687|NCT05429957|OTHER|Aerobic Exercises|"Aerobic exercise (treadmill walking) three times per week for 8 weeks~* Warm-up phase: in which each patient alternately steps their legs forward, backward, and sideways in each direction for 5 min~* Active phase: Treadmill speed was 3km/hour for 5 weeks and progress to 4km/hour after 5 weeks for 20 min.~* Cool down phase: During a cool down period take a deep breath with both arms overhead and exhale while bringing the arms down, shaking out the legs and arms for 5 min."
223647688|NCT02644655|BIOLOGICAL|CD19-specific chimeric antigen receptor|Cyclophosphamide 500 mg - 2000 mg/m2 (day 2) with or without Fludarabine 30 mg/m2 /day, 4 days (day 6, 5, 4, 3); nCAR19-T transfusion：day 0(5×105/kg，1×106/kg，3×106/kg).
223647689|NCT03859934|DRUG|Melatonin|Melatonin treatment
223647690|NCT03859934|DRUG|Placebo Oral Tablet|Placebo treatment
223647691|NCT01736995|BEHAVIORAL|Functional Family Therapy|
223647692|NCT01736995|BEHAVIORAL|Motivational Enhancement Tx/Cognitive Behavioral Tx|
223647693|NCT01736995|BEHAVIORAL|Contingency Management|
223647694|NCT01519921|DRUG|peginterferon alfa-2a [Pegasys]|Peginterferon alfa-2a (Pegasys) 180 mcg subcutaneously once a week for 48 weeks
223647695|NCT02426203|PROCEDURE|Pulmonary endarterectomy|Echocardiographic assessment right ventricular function prior to, during, and following Pulmonary Endarterectomy surgery.
223647696|NCT03585738|DIETARY_SUPPLEMENT|Inositol + Folic acid|"Daily oral supplementation before spontaneous conception until delivery:~Myo-Inositol: 1100 mg D-chiro-inositol: 27.6 mg Folic acid: 400 mcg"
223647697|NCT03585738|DIETARY_SUPPLEMENT|Folic acid|"Daily oral supplementation before spontaneous conception until delivery:~Folic acid: 400 mcg"
224232990|NCT01215448|DIETARY_SUPPLEMENT|Wheatgrass juice|110 CC daily od frozen wheatgrass juice in the intervention arm
224232991|NCT02010411|DRUG|Prolastin (drug)|Outcomes compared to saline or no intervention in each subject.
224232992|NCT06165900|DRUG|adebrelimab plus stereotactic radiotherapy followed by adebrelimab plus chemotherapy (nab-paclitaxel + carboplatin)|Adebrelimab plus radiotherapy phase: radiotherapy was started on the day of the second cycle of adebrelimab administration every other day for 3 fractions; Adebrelimab plus chemotherapy phase: starting within 3-5 weeks after completion of radiotherapy, every 3 weeks for 6 cycles.
224232993|NCT06165900|DRUG|adebrelimab plus chemotherapy (nab-paclitaxel + carboplatin)|adebrelimab plus chemotherapy (nab-paclitaxel + carboplatin)
224232994|NCT00006264|BIOLOGICAL|aldesleukin|
224232995|NCT00006264|DRUG|ganciclovir|
224232996|NCT00006264|DRUG|zidovudine|
224232997|NCT00559481|DRUG|dexamethasone|
224232998|NCT00559481|DRUG|ketoconazole|
224232999|NCT00559481|DRUG|therapeutic hydrocortisone|
224233000|NCT00559481|PROCEDURE|pharmacological study|
224233001|NCT02519413|DRUG|dimethyl fumarate|delayed release capsules
224233002|NCT02430870|DRUG|TAK-648|TAK-648 solution
224233003|NCT02430870|DRUG|Placebo|TAK-648 placebo-matching solution
224233004|NCT01958463|PROCEDURE|Fecal Microbiota transplantation.|Fecal Microbiota transplantation during colonoscopy.
224233005|NCT01713309|DRUG|Filgrastim|Filgrastim 300 ug daily for 7 days, subcutaneously.
223647698|NCT01553968|OTHER|Cycling|30 minutes of cycling at 50% of predetermined maximal performance
223647699|NCT02864459|OTHER|Muscular ultrasound|Muscular ultrasound is done before extubation
223647700|NCT06361069|OTHER|distraction cards, kaleidoscope and finger puppet|"A kaleidoscope, characterized by vibrant patterns visible through rotation of its cylinders, operates on the principle of light refraction, producing dynamic and ever-changing visual displays.~Distraction cards feature an array of images and shapes, each measuring approximately 5-8 cm in length. These intricate designs are discernible only upon careful examination of the cards.~Puppets, as a therapeutic intervention tool, significantly influence children's personal, social, and emotional development, facilitating their comfortable expression of emotions."
223647701|NCT00424684|PROCEDURE|collection of blood sample|
223647702|NCT05322395|DIAGNOSTIC_TEST|ESC 0/1 hour troponin pathway|randomisation to 0/1 versus 0/3 hour pathway
223647703|NCT04204889|DRUG|Oxaloacetic Acid|The first 3 patients will receive 500 mg twice daily, and subsequent cohorts will increase by 500 mg per dose to a maximum of 2500 mg twice daily.
223647704|NCT02611583|DEVICE|TENS|Transcutaneous Electrical Nerve Stimulation
223647705|NCT05099952|PROCEDURE|Biospecimen Collection|Undergo collection of cheek cell and blood samples
223647706|NCT05099952|OTHER|Counseling|Meet with therapist
223647707|NCT05099952|OTHER|Educational Intervention|Participate in BBT-CI sessions
223647708|NCT05099952|OTHER|Electronic Health Record Review|Medical records are reviewed
223647709|NCT05099952|OTHER|Medical Device Usage and Evaluation|Wear actigraphy watch
223647710|NCT05099952|OTHER|Questionnaire Administration|Ancillary studies
223647711|NCT04803552|DEVICE|Overnight sleep study with Sleepiz One and a respiratory polygraphy|"Participants will undergo a screening night with Sleepiz One. and with a cardiorespiratory polygraphy device (Miniscreen, Heinen-Löwenstein).~Measurements (Miniscreen, Heinen-Löwenstein)~* Thoracic respiratory effort: respiration frequency (BR), respiration curve~* Airflow: respiration frequency (BR), respiration curve~* Body movement: body position~* Blood oxygen saturation (SpO2)~* Pulse~Measurements (Sleepiz One):~• Movement originating from breathing and heart contractions"
223647712|NCT06440681|OTHER|Providing nutritional counselling|"Dietary counseling and monitoring:~Reduce fat intake (30% of total energy and saturated fat 10% of total energy) and increase fiber intake (15 g/1000 kcal) in the diet.~Participants will receive individual, detailed, ongoing nutritional counseling by the study dietitian every two weeks."
223647713|NCT06440681|OTHER|counseling on physical activity|"Physical activity:~Participants will also be encouraged to participate in physical activities. moderate exercise (150 minutes/week)"
223647714|NCT05950815|DRUG|CD73 Antigen|subjects will be administered with PM1015 via intravenously (IV) Q2W pemetrexed until progression or accepted other treatment.
223647715|NCT03511937|BEHAVIORAL|Sugar-Sweetened Beverage Health Warning Label|Labels with a health warning will be applied to the front-of-package of all sugar-sweetened beverage containers in the mock store. Investigators developed the text and design of these labels based on previous research and on designs described in US and international legislation.
223647716|NCT03511937|OTHER|Neutral Label|Neutral labels will be applied to the front-of-package of all sugar-sweetened beverage containers in the mock store. Investigators developed the design of these labels.
223647717|NCT03727308|BEHAVIORAL|Medical abortion pills sourced from pharmacies|One cohort using medical abortion pills sourced from pharmacies
223647718|NCT03727308|BEHAVIORAL|Medical abortion pills sourced from health clinics|One cohort using medical abortion pills sourced from health clinics
223647719|NCT01339143|DRUG|Galvus (vildagliptin)|50mg BID, PO, for 16 weeks
223647720|NCT01339143|DRUG|pioglitazone|15mg, QD, PO, 16 weeks
223647721|NCT01684293|BEHAVIORAL|Occupational therapy-based cognitive rehabilitation|Occupational therapy-based cognitive rehabilitation
223647722|NCT01684293|BEHAVIORAL|Psychoeducation/games|Psychoeducation/games
223647723|NCT02346058|DRUG|Esarin Gel|
223647724|NCT00088764|BEHAVIORAL|Coping skills training|8 sessions of pain and stress coping skills training
223647725|NCT00088764|BEHAVIORAL|Written emotional disclosure|4 sessions of writing about stress
223647726|NCT00088764|BEHAVIORAL|Arthritis education|8 sessions of learning about rheumatoid arthritis
223647727|NCT00088764|BEHAVIORAL|Health behavior writing|4 sessions of writing about various health behaviors
223647728|NCT04782479|PROCEDURE|hand position|For tracheal intubation with a stylet for a manikin, one time, the position of the hand holding the tube was placed in the air, and the other time, the position of the hand holding the tube was placed on the cheek of the patient, while the assistant pulling back the stylet.
223647729|NCT04378543|BIOLOGICAL|ART352-L|recombinant human Wnt3a protein delivered on liposomes to local autologous bone graft during posterolateral fusion procedures
223647730|NCT00060840|DRUG|Nitric Oxide|40 ppm of Nitric Oxide continuously administered for 48 hours
223647731|NCT00060840|DRUG|Nitrogen|Nitrogen (N2) administered at 40 ppm for 48 hours
223647732|NCT04923282|BIOLOGICAL|single 1-hour IV infusion of 0.8 mg/kg recAP|Intravenous infusion
223647733|NCT04923282|BIOLOGICAL|single 1-hour IV infusion of 1.6 mg/kg recAP|Intravenous infusion
223647734|NCT04923282|BIOLOGICAL|single 1-hour IV infusion of 3.2 mg/kg recAP|Intravenous infusion
223647735|NCT04923282|BIOLOGICAL|1-hour infusions of 1.6 mg/kg recAP on Days 1, 2 and 3|Intravenous infusion
223647736|NCT04923282|BIOLOGICAL|Placebo|Intravenous infusion
223647737|NCT02768857|BEHAVIORAL|Sensorimotor reeducation programs|
223647738|NCT04148846|DRUG|Dypirone|Dipyrone 2g, 6 / 6h for 7 days, orally or intravenous
223647739|NCT04148846|PROCEDURE|Sphenopalatine block|The sphenopalatine block will be performed with the patient in the supine position, with neck extended. Following topical anesthesia of the nasal vestibules with one application of 10% lidocaine spray and one application of 2% lidocaine gel in each nostril, two long cotton swab applicators embedded in 2% lidocaine jelly, one in each nostril, will be introduced. They will be advanced at a 45-degree angle to the floor of the nose until resistance is encountered, indicating that the swab is in the posterior nasopharyngeal wall, superior to the middle nasal concha. It will be held in this position for 5 minutes and then removed. Thereafter, a 14 gauge, non-cutting, teflon blunt catheter will be introduced into each nostril at a 45 ° angle to the hard palate until it touches the posterior wall of the nasopharynx. For it will be applied 2ml of 0.375% Ropivacaine, on each side, slowly.
223647740|NCT04148846|DRUG|Ketoprofen|Ketoprofen 100 mg, 12 / 12h for 5 days, orally or intravenous
223647741|NCT04148846|DRUG|Gabapentin|Gabapentin 300 mg 8 / 8h for 7 days orally
223647742|NCT04148846|DRUG|Dexamethasone|Dexamethasone 4mg 8 / 8h for 48h orally
223647743|NCT04148846|DRUG|Theophylline|Theophylline 200mg, 12 / 12h, for 5 days, orally
223647744|NCT04148846|DIETARY_SUPPLEMENT|Espresso coffee|Espresso coffee 20ml, 5x / day, for 7 days
223647745|NCT05080335|OTHER|Short videos|"As an educational RCT, the didactic content will be the same across the four arms, but its deliver will vary by:~1. TRANS- vs CIS-gender female instructors~2. With or without short videos of transgender youth embedded into the didactic \[TV or CV\]; for the group with no embedded videos \[NV\], the same videos will be shown AFTER completion of the post measures)~3. No-intervention control, in which TV will be delivered \*after\* collection of pre/post measures."
223647746|NCT02983552|OTHER|iPad®|Binocular therapy using a Dig Rush application on an iPad®
223647747|NCT02983552|OTHER|Spectacle correction|Spectacle correction for all waking hours, 7 days per week
223647748|NCT02627976|DEVICE|Compression vest, Thuasne|Wearing a compression 4 days/weel with a minumum of 6 hours per day
223647749|NCT00694642|BIOLOGICAL|Selected CD 133+ cells|Endothelial progenitor cell CD 133
223647750|NCT06353555|DRUG|Euthyrox|Upon discovering low T3 or low T4 levels, administer oral levothyroxine sodium tablets daily. If accompanied by a decrease in TSH, the regimen is 100μg qd (for individuals weighing \<75kg) or 150μg qd (for individuals weighing \>75kg). If not accompanied by a decrease in TSH, the regimen is 50μg qd. However, if thyroid function does not significantly improve within 3 days of medication, the regimen is adjusted to 100μg qd. Treatment should continue until transfer out of the NICU or discharge, with a minimum duration of 7 days.
223647751|NCT06353555|DRUG|Euthyrox|Patient will not receive the oral levothyroxine sodium tablets.
223647752|NCT02740452|DEVICE|ligamys technique|Ligamys technique (device) or standard technique
223766262|NCT01677195|DRUG|Placebo|Placebo is calcium carbonate, USP. This calcium mineral does not absorb mycotoxins, specifically aflatoxin and fumonisin. This mineral has approximately the same physical appearance as active test article.
223766263|NCT00461903|DRUG|Perindopril|Perindopril 4 mg or matching placebo , 1 tablet administrated once daily for the first 2 weeks. If tolarable, dosage increased to 8mg/day until the end of the study (
223766264|NCT05104398|DEVICE|Efferon CT|extracorporeal adsorbers containing mesoporous styrene-divinylbenzene copolymer to remove pro-inflammatory 6-60 kD molecules
223766265|NCT06346977|DRUG|Pemetrexed|Intrathecal injection of pemetrexed
223766266|NCT05924464|OTHER|Group Preconception Care|Groups of 6-10 patients to initiate biweekly virtual group care sessions on a rolling basis, with completion of enrollment and the virtual curriculum within a year.
223766267|NCT05884437|PROCEDURE|Chiropractic adjustment|Participants will receive 6 weeks of chiropractic care. The frequency of care will be determined by the field clinician. Participants will have their spine assessed for the presence of vertebral subluxations per their clinician's normal and customary procedures. The adjustment technique(s) utilized by the field clinician will be at their discretion.
223766268|NCT04368429|BIOLOGICAL|Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine (MenACYW Conjugate Vaccine)|Pharmaceutical form: Liquid solution Route of administration: IM
223766269|NCT04368429|BIOLOGICAL|Meningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine|Pharmaceutical form: Liquid solution Route of administration: IM
223766270|NCT06174441|DIETARY_SUPPLEMENT|Investigational product 1 (CPMSM)|Test group 1 will receive investigational product 1 (CPMSM: daily dose 25 mL contains: Hydrolyzed fish collagen 5 g, methylsulphonylmethane (MSM) 1,5 g, Biotin 150 μg, Vitamin B6 1,6 mg, Zinc 2 mg, Vitamin C 120 mg).
223766271|NCT06174441|DIETARY_SUPPLEMENT|Investigational product 2 (HC+)|Test group 2 (TG2) will receive investigational product 2 (HC+: daily dose 25 mL contains: Niacin 16 mg, Pantothenic acid 6 mg, Biotin 500 μg, Vitamin B6 1,4 mg, Folic acid 200 μg, Zinc 2 mg, Pea sprout extract 100 mg, Horsetail aerial parts extract 70 mg, Ashwagandha root extract 40 mg, Saw palmetto fruit extract 40 mg, Nettle leaves extract 30 mg, Grape seed extract 10 mg).
223766272|NCT06174441|DIETARY_SUPPLEMENT|Placebo|Placebo group (PG) will receive placebo product without any of the active ingredients (PL, daily dose 25 mL: no active ingredients).
224233006|NCT04468256|OTHER|COVID-19 experience surveys|Serial online surveys recording experiences of the COVID-19 pandemic.
223766273|NCT04702633|OTHER|Results obtained by biopsy and MRI results.|Results obtained by biopsy and MRI results.
223766274|NCT04702633|OTHER|Clinical data|Clinical data
223766275|NCT04071457|DRUG|Lenalidomide|Commercially available intervention
223766276|NCT04071457|DRUG|Daratumumab/rHuPH20|SWOG-Held IND
223766277|NCT05250505|DEVICE|eShunt Implant|The eShunt System consists of endovascular delivery componentry and a permanent implant intended to shunt cerebrospinal fluid from the intracranial subarachnoid space to the venous system in adults.
223766278|NCT05027945|PROCEDURE|Allogeneic HSCT|stem cell transplant on day 0
223766279|NCT05027945|DRUG|Busulfan test dose|0.8 mg/kg IV over 2 hours. May be skipped if real-time PKs are done during conditioning.
224233007|NCT00624871|DRUG|Ascorbic acid (vitamin C)|IV, 100 mg/kg/day, every day, for 3 days
224233008|NCT00624871|DRUG|Ibuprofen|PO, 10 mg/kg on day 1, 5 mg/kg/day on days 2 and 3 of life
224233009|NCT00624871|DRUG|Placebo|
223647753|NCT02740452|OTHER|standard technique (anatomic reconstruction)|Ligamys technique (device) or standard technique
223647754|NCT03783832|OTHER|OCT ANGIOGRAPHY DATA|Follow-up of diabetic macular edema treated by Aflibercept (EYLEA®) with OCT angiography
223647755|NCT00691834|BIOLOGICAL|Intracoronary delivery of unfractionated bone marrow mononuclear cells|Maximal intracoronary cell dose: 50 x 10e7 cells diluted in 10 ml Maximal intracoronary volume: 10 ml (diluted in plasma and culture medium)
223647756|NCT00691834|BIOLOGICAL|Placebo|Plasma and culture medium (10 ml)
223647757|NCT03339843|DRUG|Abemaciclib|Subjects will receive 200 mg of abemaciclib orally, two times a day, during cycles of 28 days each. An early FDG-PET/CT will be performed at cycle 1 day 14 to search for any new lesions.
223647758|NCT05380817|OTHER|Remote Monitoring Program|Participants receive remote monitoring while engaging in a theory-based, multi-component, multi-level, multi-setting (MMM) community team sports program designed specifically for children
223647759|NCT05724888|BEHAVIORAL|Peer mentorship and physical activity|Participants will be asked to participate for 12 weeks, attending 3 sessions per week (if in the intervention arm). Session 1 will be a group session that will be about 90 minutes, session 2 will be an individual session with a peer mentor for 20-30 minutes, and session 3 will be a virtual check in with the peer mentor about 15 minutes. The intervention will focus on increasing physical activity through the circle of courage.
223647760|NCT00553891|DRUG|mometasone furoate nasal spray|One spray (50 mcg per spray) in each nostril once daily (100 mcg daily) for 3 months.
223647761|NCT00553891|DRUG|placebo nasal spray|One spray in each nostril once daily for 3 months.
223647762|NCT03570099|DRUG|Naloxone Nasal Spray|Naloxone Nasal Spray will be distributed at the addiction centres.
223647763|NCT03570099|OTHER|Historical control cohort|Historical data will be retrieved from quality registries.
223647764|NCT02293317|BIOLOGICAL|M-001|A recombinant epitope based universal vaccine against seasonal and pandemic influenza
223647765|NCT02293317|DRUG|TIV|HA based seasonal influenza vaccine, for 2014/15 seson
223647766|NCT02293317|OTHER|Saline|Placebo
224233010|NCT06452810|DIETARY_SUPPLEMENT|Experimental: Sahajan Golden Glow Balm|Participants will apply the Sahajan Golden Glow Balm twice daily (morning and night) to the periorbital area following the specified instructions.
224320119|NCT04675099|BEHAVIORAL|pCARE|"Mothering from the Inside Out is an evidence-based intervention delivered in substance use treatment settings that helps mothers with substance use disorders foster parent-child attachment, cope with stressful parenting situations, and promote their child's healthy development. This 3 month counseling intervention both improves parent-child attachment and decreases rates of drug relapse among mothers. The proposed mechanism of action targeted by the intervention is a change in parental reflective functioning, defined as the capacity to recognize and make sense of mental states (especially emotional states) and understand how they influence behavior and relationships."
224320120|NCT04675099|OTHER|Standard Early Intervention services|The state of Massachusetts provides voluntary early childhood development services to substance-exposed infants through a system of Early Intervention programs. These programs offer coordinated services to all infants and toddlers with disabilities and those at risk for developmental delays in homes and child centers beginning at birth.
224320121|NCT04541537|DIAGNOSTIC_TEST|Sorbstar®|Thermodesorption method coupled with full two-dimensional gas chromatography and mass spectrometry
224320122|NCT04541537|DIAGNOSTIC_TEST|Dog Detection|Analysed by the dogs of Curie Institute at the training centers
223647767|NCT04152941|DRUG|Olaparib|Patients with histologically confirmed ovarian cancer, primary peritoneal cancer and / or fallopian-tube cancer treated with olaparib in a real life-setting, between May 2014 to March 2017, whatever the line of therapy
223647768|NCT02356861|DEVICE|Photomedex Sham Helmet with Red/Near-Infrared Light-Emitting Diodes (LEDs) that are not turned on|"The LED helmet from Photomedex, Montgomeryville, PA will be used.~18 LED pods are in the helmet. Each LED pod:~Pod size: 19 cm2 Power output: 692.5 mW Power density: 36.5 mW/cm2~20 NIR diodes, 830 nm and 4 red diodes, 633 nm.~1 J/cm2 = 30.4 sec"
223647769|NCT00889161|DRUG|Curcumin|Initial dosage of 500mg twice a day for 3 weeks. Using the forced dose titration design, dose will be titrated up to 1g twice a day at Week 3 for a total of three weeks and then titrated again to 2g twice a day at Week 6 for three weeks.
223647770|NCT02842489|PROCEDURE|left lateral tilt-down position|patients will be positioned on their left side and at an angle of 20 degree
223647771|NCT02842489|PROCEDURE|left lateral horizontal position|patients will be horizontally positioned on their left side
223647772|NCT01216189|RADIATION|Preoperative radiotherapy|Preoperative radiotherapy (RT) was administered as either short course (5Gy x5) or long-course (2Gy x25 or 1.8 Gy x25 with or without 3 fractions of boost to the primary tumor and radiologically malignant lymph nodes) treatment with or without concomitant or sequential chemotherapy. Oncological treatment was decided at a multidisciplinary team conference.
223647773|NCT04844411|DRUG|JNJ-67835989|JNJ-67835989 will be administered orally.
223647774|NCT04844411|DRUG|Placebo|Matching placebo will be administered orally.
223647775|NCT05459883|PROCEDURE|splenic artery ligation|We identified portal hyperperfusion as a cause of potential small-for-size liver remnant dysfunction and we applied splenic artery ligation as a technically simple procedure to manage the situation
223647776|NCT00888732|DRUG|Insulin Aspart, BIAsp 70, BIAsp50, Human Insulin|0.2 U/IU/kg subcutaneous injection, single dose
223647777|NCT04536558|DRUG|olanzapine plus fosaprepitant-based triple regimen|olanzapine 5mg p.o. on day 1-day 5, fosaprepitant 150mg i.v. on day 1 before undergoing chemotherapy. Patients received ondansetron hydrochloride(8mg, i.v. day 1-day 3) and dexamethasone(6mg, oral, day 1-day 5) at the same time, before undergoing chemotherapy.
224233011|NCT01372787|PROCEDURE|Assessment of Therapy Complications|Ancillary studies
224233012|NCT01372787|OTHER|Medical Chart Review|Ancillary studies
223647778|NCT04536558|DRUG|placebo plus fosaprepitant-based triple regimen|placebo p.o. on day 1-day 5, fosaprepitant 150mg i.v. on day 1 before undergoing chemotherapy. Patients received ondansetron hydrochloride(8mg, i.v. day 1-day 3) and dexamethasone(6mg, oral, day 1-day 5) at the same time, before undergoing chemotherapy.
223647779|NCT00125164|DRUG|rhIGF-1 (mecasermin, Tercica, Inc.)|Twice Daily Injection
223647780|NCT05633758|DRUG|Placebo|All patients will receive standard heart failure therapy, including but not restricted to diuretics, digoxin, angiotensin converting enzyme inhibitors or angiotensin II receptor blockers, beta blockers, aldosterone antagonists, hydralazine, and/or nitrates, at the discretion of the treating physician. After informed consent is obtained, patients will be randomized 1:1 to the treatment arm or placebo arm. The first placebo dose is given within six hours of administration of first dose of intravenous diuretic. The second placebo dose is given at 24-hours after the first dose.
223766280|NCT05027945|DRUG|Mycophenolate mofetil (MMF)|Mycophenolate mofetil (MMF): 15 mg/kg IV over 2 hours BID starting on day +5 until approximately day +35 (+/-2 days)
223766281|NCT05027945|DRUG|Tacrolimus|Starting on day +5, start at 0.02 mg/kg IV continuous infusion over 24 hours until day +180 and titrated to trough levels of 5-15 mg/ml.
224233013|NCT01372787|OTHER|Quality-of-Life Assessment|Ancillary studies
224233014|NCT01372787|OTHER|Questionnaire Administration|Ancillary studies
224233015|NCT02958657|OTHER|Exercise Training|Supervised exercise training program that includes two workouts per week for three months at a rehabilitation unit.
223647781|NCT05633758|DRUG|Metolazone|All patients will receive standard heart failure therapy, including but not restricted to diuretics, digoxin, angiotensin converting enzyme inhibitors or angiotensin II receptor blockers, beta blockers, aldosterone antagonists, hydralazine, and/or nitrates, at the discretion of the treating physician. After informed consent is obtained, patients will be randomized 1:1 to the treatment arm or placebo arm. The first dose of metolazone is given within six hours of administration of first dose of intravenous diuretic The second dose of metolazone is given 24-hours after the first dose.
223647782|NCT05005117|PROCEDURE|Laparoscopic operation|Operation
223647783|NCT05005117|PROCEDURE|Open operation|Operation
223647784|NCT00175396|PROCEDURE|Androgen suppression, radiotherapy|Total of 12 months of androgen suppression. 8 months after the start of androgen suppression 4.2-5 weeks external beam radiation (46 Gy in 23 equal fractions) followed by an external beam radiation boost lasting 3.2-4 weeks (32 Gy in 16 equal fractions).
223766282|NCT05027945|DRUG|Busulfan|AUC Targeted Dose based on busulfan test dose PKs, IV infusion over 3 hours once daily (3.2 mg/kg IV per day will be the default dose) per the below time frame: For 8/8 Matched Related or Unrelated Donor Busulfan dose will be on days -6, -5, and -4 For 7/8 Matched Related or Unrelated or Haploidentical Donor Busulfan dose will be on days -4 and -3
223766283|NCT05027945|RADIATION|Total Body Irradiation (TBI)|For 7/8 Matched Related or Unrelated or Haploidentical Donor, 200cGy on day -1
223766284|NCT05027945|DRUG|Fludarabine|40 mg/m2 IV over 30 mins daily For 8/8 Matched Related or Unrelated Donor Fludarabine dose will be on days -6, -5, -4, and -3 For 7/8 Matched Related or Unrelated or Haploidentical Donor Fludarabine dose will be on days -6, -5, -4, -3, and -2
223766285|NCT05027945|DRUG|Cyclophosphamide (CY)|For 7/8 Matched Related or Unrelated or Haploidentical Donor, prior to transplant 14.5 mg/kg IV daily on days -6 and -5
223766286|NCT05027945|DRUG|Post-Transplant Cyclophosphamide (PTCY)|Post-Transplant Cyclophosphamide: 50 mg/kg IV daily over 2 hours on days +3 and +4, dosed according to ideal body weight
223766287|NCT03015077|DIETARY_SUPPLEMENT|oral glutamine|L-Glutamine and maltodextrin are both nutritional supplements. In the glutamine arm: 10 g L-Glutamine and 5 g maltodextrin. The patients take their supplements three times a day during the period: 7 days before radiotherapy to 14 days after radiotherapy.
223766288|NCT03015077|DIETARY_SUPPLEMENT|placebo|in the placebo arm: 15 g maltodextrin. The patients take their supplements three times a day during the period: 7 days before radiotherapy to 14 days after radiotherapy.
223766289|NCT03015077|RADIATION|Radiotherapy|All patients undergo radiotherapy. 5 days a week. All patients had a dental evaluation for good oral hygiene prior to computed tomography simulation for radiotherapy. Post-operative patients received planned course of adjuvant treatment of 60 to 66 Gy in 2-Gy fractions to the surgical bed. The course of radiation was initiated no more than 6 weeks after resection. Patients without operation received definitive treatment to 70 Gy in 2-Gy fractions.
223766290|NCT00208429|DEVICE|Pinnacle Acetabular System|
223766291|NCT01706952|DRUG|Cocaine|Pledgets soaked in 4% cocaine hydrochloride solution were placed intranasally (one side).
223647785|NCT00175396|PROCEDURE|Androgen suppression, radiotherapy, iodine 125 brachytherapy|Total of 12 months of androgen suppression. 8 months after the start of androgen suppression 4.2-5 weeks external beam radiation (46 Gy in 23 equal fractions) followed by iodine 125 brachytherapy carried out 14-25 days after the last external beam treatment.
223647786|NCT00843219|PROCEDURE|PET/CT Scan|PET/CT scan performed with elastic belt around lower chest/upper abdomen to track breathing motion.
224233016|NCT03982433|BEHAVIORAL|Motivation and Cognitive Behavioral Management for Alcohol and Pain|Behavioral intervention that includes motivational, cognitive, and behavioral intervention strategies to reduce heavy drinking and chronic pain interference
224233017|NCT04059666|OTHER|Investigational|Cow's milk-based Infant Formula with whey protein-lipid concentrate
223647787|NCT00518102|DRUG|REGRANEX (becaplermin)|A cohort of REGRANEX (becaplermin) users (ie, patients treated with REGRANEX (becaplermin), a topical medication used to treat non-healing neuropathic foot ulcers in patients with diabetes).
223766292|NCT01706952|DRUG|Adrenaline|Pledgets soaked in 1/1000 adrenaline solution were placed intranasally (one side).
223766293|NCT05132075|DRUG|JDQ443|JDQ443 tablets, orally administered
223766294|NCT05132075|DRUG|docetaxel|docetaxel concentrated solution for infusion, intravenously administered
223766295|NCT05978700|DEVICE|Video-game|The video-game has three games: (1) Game One - Lip Exercise; (2) Game Two - Tongue Exercises; (3) Game Three - Lower Jaw Exercise. The whole training will take about once a day for 30 min per session, 5 times a week for 4 weeks.
223766296|NCT05978700|BEHAVIORAL|Conventional therapy|The control group used the conventional swallowing function training. The lip exercise consisted of the following specific movements: opening mouth, closing mouth, drumming cheeks, left drumming cheeks, and right drumming cheeks; the tongue exercise consisted of the following specific movements: extending the tongue, tongue up, tongue down, tongue left, and tongue right. Each specific movement in the steps lasts 2-3s, repeat 15 times and continue with the next movement. The lower jaw movement contains the following specific movements: keep the head as low as possible, and squeeze the rubber ball placed on the neck for 2-3 seconds, repeat 15 times.
223766297|NCT04253171|DEVICE|Lithoplasty|"The lithoplasty balloon should be utilized as early as possible. If it is necessary for passage of the lithoplasty balloon, the lesion may first be predilated with an undersized conventional balloon, non-compliant or semi-compliant. If passage of the lithoplasty balloon is still not possible, it is recommended to perform rotational atherectomy with a small burr size.~The lithoplasty balloon is sized 1:1 to reference diameter. Lithoplasty is performed with the balloon dilated at 4 atmospheres, and 10 shocks are delivered, after which the balloon is expanded to 6 atmospheres for 30 seconds, and then deflated. Up to 8 series of balloon expansion/deflation can be delivered in this manner if necessary, and several balloons may be used for long lesions."
224233018|NCT04059666|OTHER|Control|Cow's milk-based Infant Formula
224233019|NCT00865709|DRUG|Sorafenib (Nexavar, BAY43-9006) + mFOLFOX6 (5-FU, levo-leucovorin, oxaliplatin)|Subjects will receive oral Sorafenib 400 mg twice daily (BID) continuously and intravenous (IV) mFOLFOX6 (5-FU 400 mg/m\^2 bolus and 2400 mg/m\^2 for 46-48 hrs; levo-leucovorin 200 mg/m\^2; 85 mg/m\^2 oxaliplatin) every 14 days until progressive disease (PD)
224233020|NCT00865709|DRUG|Matching placebo + mFOLFOX6 (5-FU, levo-leucovorin, oxaliplatin)|Subjects will receive oral matching placebo 2 tablets BID continuously and IV mFOLFOX6 (5-FU 400 mg/m\^2 bolus and 2400 mg/m\^2 for 46-48 hrs; levo-leucovorin 200 mg/m\^2; 85 mg/m\^2 oxaliplatin) every 14 days until progressive disease
223647788|NCT00518102|OTHER|REGRANEX (becaplermin) comparators|A cohort of REGRANEX (becaplermin) nonusers (ie, patients who are not treated with REGRANEX \[becaplermin\]) but are similar in characteristics to patients in the REGRANEX \[becaplermin\] user cohort)
223647789|NCT03773276|DRUG|Norepinephrine boluses|"On portal vein declamping, We will inject NE boluses in the C.V.P port of the pulmonary artery catheter with 5 ml saline flushing after each. After reperfusion, we will start bolus noradrenaline 20 µg if mean arterial blood pressure (mABP) decreases by 10 % or more of the basal reading (immediately before portal vein declamping after ensuring withholding of the surgical manipulation). Additional NE boluses will be given as follow;~* If mABP rises to 65 mmHg (lowest target level), we will hold NE boluses.~* If mABP remains constant or begins to rise but did not reach 65 mmHg, we will give 20 µg after 10 seconds from the previous bolus~* If mABP continues to drop, we will add 10 µg to the previous dose after 10 seconds and can be repeated.~* If mABP remains below 65 mmHg more than 1 minute, we will give the scheduled bolus NE with adding 10 µg adrenaline boluses."
223647790|NCT02127697|DRUG|NVA237|NVA237 capsules for inhalation, delivered via Concept1 once daily
223647791|NCT02127697|DRUG|Placebo to NVA237|Placebo to NVA237 delivered via Concept1 once daily
223647792|NCT02127697|DRUG|salbutamol/ albuterol|Taken as rescue medication
223647793|NCT02869568|OTHER|Data collection|
223647794|NCT01339052|DRUG|BKM120|
223766298|NCT04253171|DEVICE|Conventional|Lesion preparation is performed starting with conventional balloons, non-compliant or semi-compliant. Unless fully satisfactory dilatation is achieved with conventional balloons, it is recommended to also use modified balloons (scoring balloons, cutting balloons). If balloons cannot be passed or if dilatation is inadequate, the lesion may first be predilated with an undersized conventional, non-compliant, or semi-compliant balloon. If necessary, rotational atherectomy with a small burr size can be used to facilitate adequate balloon preparation.
224233021|NCT04488640|PROCEDURE|Thyroid biopsy with ultrasound|Patients with thyroid nodules who underwent ultrasound-guided core needle biopsy with a 20 gauge core needle biopsy apparatus were included in the study.
224233022|NCT02686216|DRUG|F-18 THK-5351|Totally 24 subjects age 20-90 including 12 healthy cognitively intact subjects and 12 probably AD patients with NINCDS-ADRDA criteria. For disease subjects, caregiver should be able to report activities of daily living and their mental status. Patient should be able to give informed consent or have a caregiver give consent with subject assent.
224233023|NCT01548872|DRUG|HTK solution|50 ml/kg bolus in 2 minutes
223647795|NCT01339052|PROCEDURE|Surgery|Surgery
223647796|NCT02528812|DEVICE|TheraBand Roller Massager|The roller massager was moved proximal to distal at a slow pace (2 seconds up and 2 second downs) over the muscle belly. Participants in the Sham group received very light pain-free cutaneous strokes of rolling massage with the same pace of rolling as performed for the Ipsi-R and Contra-R groups. The Control group did not receive any treatment.
223647797|NCT02528812|OTHER|Manual Massage|A massage therapist massaged the participant
223647798|NCT02637037|DRUG|dapagliflozin/metformin XR 5/500 mg test drug (Mount Vernon)|single fixed-combination dose tablets
223647799|NCT02637037|DRUG|dapagliflozin/metformin XR 5/500 mg reference drug (Humacao)|single fixed-dose combination tablets
223647800|NCT02637037|DRUG|dapagliflozin/metformin XR 10/1000 mg test drug (Mount Vernon)|single fixed-dose combination tablets
223647801|NCT02637037|DRUG|dapagliflozin/metformin XR 10/1000 mg reference drug (Humacao)|single fixed-dose combination tablets
223647802|NCT00513916|DIETARY_SUPPLEMENT|soy isoflavones|High or low dose of soy isoflavones in the diet.
223647803|NCT00338585|DRUG|alfimeprase|
223647804|NCT03702283|OTHER|Penicillin Allergic Risk Stratification Best Practice Alert|Providing best practice information on a patient's penicillin allergy risk and how to manage different levels of risk.
223647805|NCT05179356|DRUG|Dapagliflozin 10 MG [Farxiga]|Dapagliflozin 10 mg given once daily for three months
223647806|NCT05179356|DRUG|Placebo|Matching placebo
223647807|NCT00034580|DRUG|olanzapine|
223766299|NCT06477315|OTHER|survey|telephone surveys
223766300|NCT04406896|DRUG|Selatogrel|A single subcutaneous injection of 16 mg.
224233024|NCT01548872|DRUG|crystalloid cardioplegia solution|30 ml/kg bolus in two minutes
224233025|NCT00429923|DRUG|Difluprednate|
224233026|NCT00429923|DRUG|Difluprednate|
224233027|NCT00429923|DRUG|Placebo|
223647808|NCT00034580|DRUG|risperidone|
223647809|NCT04472832|DRUG|Placebo for Treatment A|6 tablets matched to mitapivat tablet
223647810|NCT04472832|DRUG|Mitapivat 100 mg|Two 50-mg tablets
224233028|NCT05024461|DIAGNOSTIC_TEST|Salivary test for COVID19|"Results of nasopharyngeal and salivary samples taken at the Cayenne hospital and the Caen university center,~* Pre-analytical particularities and analytical particularities~* Cycle threeshold~* Demographic variables~* Clinical variables~* Clinical criteria~* Questionnaire on the perception of the 2 sampling methods"
223647811|NCT04472832|DRUG|Placebo for Treatment B|4 tablets matched to mitapivat tablet
223647812|NCT04472832|DRUG|Mitapivat 300 mg|Six 50-mg tablets
223647813|NCT04472832|DRUG|Placebo for Treatment C|4 tablets matched to mitapivat tablet
224233029|NCT00365261|DRUG|Eszopiclone|eszopiclone 2 to 3 mg po at bedtime
224233030|NCT00365261|DRUG|Placebo|placebo 2 to 3 mg po at bedtime
224233031|NCT04292106|DIETARY_SUPPLEMENT|Red Spinach Extract (RSE)|Oral capsules containing 2g of Red Spinach Extract will be consumed daily for 7 days
224233032|NCT04292106|DIETARY_SUPPLEMENT|Placebo|Oral placebo capsules will be taken consisting of maltodrextrin daily for 7 days
223647814|NCT04473677|DIAGNOSTIC_TEST|The new qFIT and colonoscopy with pathological examination|Detect hemoglobin in stool by the new qFIT before colonoscopy, detect colon lesion using colonoscopy and pathological examination.
224320123|NCT01383707|DRUG|5-Fluorouracil (5-FU)|Participants will receive 5-FU 400 mg per meter-squared (mg/m\^2) IV dose on Day 1 of each 2 weeks' cycle followed by 2400 mg/m\^2, continuous infusion over 46 hours up to 12 cycles.
224320124|NCT01383707|DRUG|Bevacizumab|Participants will receive 5 mg/kg bevacizumab IV dose on Day 1 of each 2 weeks' cycle up to Cycle 5 and thereafter cycles 7 to 12; followed by maintenance therapy of 5 mg/kg IV every 2 weeks up to 52 weeks (26 cycles).
224320125|NCT01383707|DRUG|Levofolinic acid|Participants will receive levofolinic acid 200 mg/m\^2 IV infusion over 2 hours on Day 1 of each 2 weeks' cycle up to 12 cycles.
223766301|NCT06335329|BEHAVIORAL|Discussion of point-of-care ultrasound lung findings|"The investigator will obtain point-of-care ultrasound images to assess the lung findings in 12 lung fields. These 12 lung fields will include the standard protocol of the upper and lower halves of the anterior, lateral, and posterior chest bilaterally. Subjects' ultrasound images will be scored using a modified lung ultrasound score (LUS). Each of the 12 lung fields will be scored from 0-5, with a total score of 0-60 (noted below). The participants will watch their ultrasound being performed, looking at their lungs in real time. Then, the ultrasound findings will be discussed with the participant.~Modified LUS 0: No B-lines present~1. 1 well-defined B-line~2. 2-3 well-defined B-lines~3. \>3 B-lines~4. Confluent B-lines~5. Lobar consolidation~   * C: Noted if subpleural consolidation present~  * E: Noted if pleural effusion present"
223766302|NCT06056063|DEVICE|Halcyon 4.0|This Halcyon 4.0 is a new imaging hardware recently developed by Varian and approved by the FDA.
223766303|NCT05666310|DRUG|Denosumab|Half of study participants will randomly receive denosumab 60 mg subcutaneous injection at month 0 and 6 with zoledronic acid placebo at month 0.
223766304|NCT05666310|DRUG|Zoledronic Acid|Half of study participants will randomly receive zoledronic acid 5 mg intravenous infusion at month 0 with denosumab placebo at month 0 and 6. All forty participants will receive zoledronic acid 5 mg intravenous infusion at month 12.
223766305|NCT05666310|OTHER|Denosumab Placebo|Half of study participants who will randomly receive zoledronic acid 5 mg intravenous infusion at month 0 will also receive denosumab placebo at month 0 and 6.
223766306|NCT05666310|OTHER|Zoledronic Acid Placebo|Half of study participants who will randomly receive denosumab 60 mg subcutaneous injection at month 0 and 6 will also receive zoledronic acid placebo.
223766307|NCT06831019|DIAGNOSTIC_TEST|Oxidative stress markers|We will measure markers of oxidative stress in the follicular fluid, semen, and blood and correlate this with IVF and reproductive outcomes
224233033|NCT03963570|BEHAVIORAL|Safe Step - digital exercise program|"After receiving the Safe Step application the participants view an instruction movie on how to use the application to create and progress their own individual exercise program. The exercises, presented in video format, are organized into 10 predetermined groups with a main focus to improve balance (3 groups), increase lower-limb strength (4 groups), and improve gait/step (3 groups). The participants choose an exercise suitable for their needs from each group to compose a program of ten exercises.~They can use the app to plan their exercises, set reminders, register their exercise, and view statistics of their progress. A virtual physiotherapist deliver motivational messages and feed-back. At the end of every month, of the 1 year intervention period, the participants will receive an email asking them to report any falls during the past month by answering a short digital survey. This message will provide a new video each month with general falls prevention information besides exercise."
224233034|NCT03963570|BEHAVIORAL|Control group|Participants randomized to the control condition will only be given information. They will receive exactly the same email messages as the intervention group with falls prevention information and a request to report any falls. At the end of the 12 month intervention we will, in addition to the other questions, ask if they have started to do any exercises during the intervention period. After the 12 month follow-up assessment the control group will be offered the Safe Step application.
224233035|NCT00697775|BIOLOGICAL|HBV-MPL vaccine Formulation A|Single dose (when extemporaneously co-administered with Engerix™-B) or 2-dose (when administered alone) intramuscular injection
224233036|NCT00697775|BIOLOGICAL|HBV-MPL vaccine Formulation B|2-dose intramuscular injection
224233037|NCT00697775|BIOLOGICAL|Engerix™-B|Single dose (when extemporaneously co-administered with HBV-MPL) or 3-dose (when administered alone) intramuscular injection
224233038|NCT00991198|DRUG|Topical oxygen|0.5% concentration of Topical oxygen
224233039|NCT00991198|DRUG|Topical oxygen|0.25% concentration topical oxygen
224233040|NCT00991198|DRUG|placebo|no O2
223766308|NCT06352177|OTHER|Noom Weight Application|This commercially available program (Noom Weight) promotes clinically significant body weight loss and behavior change in multiple populations. The program is delivered through a smartphone application and includes self-monitoring and feedback features for diet, physical activity, and body weight, as well as digital access to a 1:1 behavior change coach, a support group facilitated by a health coach, and a curriculum delivered via daily articles focused on nutrition, physical activity, and sustainable behavioral change.
223766309|NCT04026503|OTHER|Live Long Walk Strong rehabilitation program|Live Long Walk Strong is a rehabilitation program that focuses on impairments known to contribute to mobility decline that are not considered standard of care in rehab and addresses behavioral change within the context of rehabilitation.
223766310|NCT04789239|DRUG|Sodium zirconium cyclosilicate|SZC is an approved drug in Sweden and subsidized for patients with chronic kidney disease in stages 3 to 5, with or without chronic heart failure, for whom treatment with Resonium is not suitable and for patients with chronic heart failure without con-comitant chronic kidney disease
223766311|NCT04789239|OTHER|Placebo|Treatment with the same dose of placebo medicine as they would have received had they been treated with the interventional drug (SZC).
224233041|NCT01456611|DRUG|Diclofenac|Diclofenac Sodium Gel 1%
223647815|NCT01497496|DRUG|High Dose Methylprednisolone (HDMP)|1000 mg/m\^2 on Cycle 1: Day 1, 8, 15, 22; Cycle 2: Day 1, 15; Cycle 3: Day 1, 15
223647816|NCT01497496|DRUG|Ofatumumab|Ofatumumab infusion will be administered immediately after HDMP. 300 mg on Cycle 1 Day 1. 2000 mg on Cycle 1: Day 8, 15, 22; Cycle 2: Day 1, 15; Cycle 3: Day 1, 15; Cycle 6: Day 1; Cycle 8: Day 1; Cycle 10: Day 1: Cycle 12: Day 1
223647817|NCT01497496|DRUG|Lenalidomide|The lenalidomide treatment will start with cycle 4. 5-10 mg pd Days 1-28 as per Creatinine Clearance (CrCl)
223647818|NCT03532204|RADIATION|SBRT|"Patients will received 2 courses of chemotherapy before SBRT if no hepatic or extra-hepatic progression identified.~All liver metastases will be irradiated. 4 doses prescription are allowed (according to the center, and the technique uded and the dosimetric constraints): 3x15 Gy, 4 x 15 Gy, 5 x10 Gy or 5 x 8 Gy.~The remaining courses of chemotherapy 2 to 3 weeks after completion of SBRT will be administered"
223647819|NCT03532204|DRUG|Chemotherapy|At investigator's discretion
223766312|NCT02472756|DRUG|Chemotherapy|The choice of the chemotherapy regimen will be established on a per center basis, according to the standard in use in the country and in the center. Protocol does not specify any particular chemotherapy regimen.
224233042|NCT01456611|DRUG|Placebo|Placebo Topical Gel
223647820|NCT06255613|DEVICE|Belun Ring|The Belun Ring sensor should be placed on the palmar side of the proximal phalanx of the index finger and the sensor should be placed along the radial artery such that the accuracy of the device will be minimally affected by skin color. The Ring has 7 adjustable arms for different finger sizes. Each device is reusable after thorough cleaning with an alcohol swab.
224233043|NCT04516850|GENETIC|Expression of receptors and activating proteases|Level of expression of the mRNA of the genes encoding ACE2, TMPRSS2, TMPRSS4 and AR along with reference genes (beta-actin and EPCAM) in nasopharyngeal swabs taken from patients tested for COVID-19
223647821|NCT06255613|DEVICE|Belun Cor|"The Belun Cor body sensor accessory is composed of an accelerometer, a temperature sensor, and a lithium battery. It will be placed immediately below the xiphoid process in the upper abdomen with a medical adhesive to detect the body temperature, body posture, respiratory rate, and respiratory efforts."
223647822|NCT02124993|OTHER|Questionnaire|Dr. Ballanger's office will administer a FPQ upon approval of an informed consent. Subjects will be asked to complete the questionnaire at a pre-operative visit and six weeks post-operatively.
223647823|NCT00485810|DRUG|Olanzapine Hydrochloride|
223647824|NCT03330249|DRUG|Split Cisplatin|25 mg/m2/day IV infusion at D1 to D4, at D22 to D25, at D43 to D46 during the radiotherapy.
223647825|NCT03330249|DRUG|Cisplatin|100 mg/m2/day IV infusion at D1, D22 and D43 during the radiotherapy.
223647826|NCT03330249|RADIATION|Radiotherapy|70 Gy in 35 fractions of 2 Gy in non-operated patients and 66 Gy in 33 fractions in post-operative.
223647827|NCT00675610|BEHAVIORAL|communication training|providers are trained to communicate with patients about adherence and patients are coached to discuss adherence with providers
223647828|NCT04900727|OTHER|No intervention|No intervention
223647829|NCT01469377|DRUG|Placebo|Placebo was supplied in capsules
223647830|NCT01469377|DRUG|Cariprazine|Cariprazine was supplied in capsules.
223647831|NCT05330299|BEHAVIORAL|COMPASS|Participants will be treated with an online CBT program that is specifically tailored to illness-related distress in the context of long-term conditions. It consists of 11 online modules and is therapist-supported.
223647832|NCT01733680|DRUG|amiloride|Subjects will take either amiloride hydrochloride or placebo for 8 weeks.
223647833|NCT01733680|BEHAVIORAL|Behavioral|Each week of the study, subjects will complete the AISRS, BRIEF-A, and CGI to measure symptom improvement
223647834|NCT05208099|BIOLOGICAL|Blood tests|"For patients, it will be performed:~* a collection of blood samples (3 tubes of 5 mL) according to the usual medical management, in order to search for cardiovascular comorbidities associated with HS,~* A collection of 3 EDTA tubes and 2 additional dry tubes of 5 mL each according to the needs of the study."
223647835|NCT05208099|PROCEDURE|exeresis|"For patients, it will be performed:~\- 6 tissue samples from the total excision specimen: two samples from the acute inflammatory zone (nodule, abscess, fistula) of 1 cm3; two samples from the chronic lesion zone (scar) of 1 cm3 and two samples from the peri-lesion zone (in the margin) of 1 cm3 on fresh tissue."
223647836|NCT05208099|PROCEDURE|abdominoplasty|"For the controls, 6 fresh skin samples of 1 cm3 each will be taken from the abdominoplasty operation:~* four in the center,~* two in the margin"
223647837|NCT06520293|OTHER|Sweet Beverage|A beverage containing different sweet ingredients.
223647838|NCT02681978|DRUG|Ivabradine|Ivabradine 5 mg twice daily
223647839|NCT02681978|DRUG|Standard medical therapy|Standard medical therapy for patients with coronary artery disease undergoing percutaneous coronary interventions
223647840|NCT06344962|DEVICE|Absorbable Suture|3-0 V-Loc
223647841|NCT06344962|DEVICE|Non-absorbable Suture|3-0 Prolene
223647842|NCT04542837|BIOLOGICAL|KN046|Subjects enrolled in the study will be intravenously administered KN046 5mg/kg every 3 weeks (Q3W), until disease progression, or unacceptable toxicity, or withdrawal of consent, or lost to follow-up, or died, or treatment for 2 years, or the investigator decides to terminate.
223766313|NCT02472756|DRUG|Rituximab|The choice of the rituximab regimen will be established on a per center basis, according to the standard in use in the country and in the center. Protocol does not specify any particular chemotherapy regimen.
224233044|NCT04516850|GENETIC|Polymorphism of the HSD3B1|Formalin-fixed paraffin embedded tissue blocks will be amplified using polymerase chain reaction (PCR) based experiments followed by direct sequencing (Sanger sequencing)
223647843|NCT04542837|DRUG|Lenvatinib|Subjects enrolled in the study will receive lenvatinib 12 mg (BW≥60 kg) or 8 mg (BW\<60 kg) orally once a day (QD) ,until disease progression, or unacceptable toxicity, or withdrawal of consent, or lost to follow-up, or died, or treatment for 2 years, or the investigator decides to terminate.
223647844|NCT04903613|DRUG|Ligelizumab|Ligelizumab 120 mg s.c every 4 weeks
223647845|NCT06237504|DEVICE|SaCoVLM™|Patients will receive general anesthesia with their airways maintained with the SaCoVLM, which is a newer supraglottic airway device with a video port to directly visualize the upper airway.
223647846|NCT06237504|DEVICE|Ambu®Auragain™|Patients will receive general anesthesia with their airways maintained with the Ambu Auragain, which is a conventional 2nd generation supraglottic airway device.
223647847|NCT00080236|DRUG|IDN-6556|
223647848|NCT00080236|DRUG|Placebo|
223647849|NCT05966688|DRUG|SPR720|Multiple oral doses of SPR720 capsules.
223647850|NCT05966688|DRUG|Azithromycin|Multiple oral doses of azithromycin.
223647851|NCT05966688|DRUG|Ethambutol|Multiple oral doses of ethambutol.
223647852|NCT02666625|PROCEDURE|saliva samples|
223647853|NCT02666625|PROCEDURE|blood samples|
223766314|NCT01234129|DRUG|zoledronic acid|zoledronic acid, 4 mg,standard dose,at monthly interval, by 2 years
224233045|NCT01978678|DRUG|Pulmicort|ACQ and FeNO
224233046|NCT00098709|DEVICE|Fetal pulse oximeter|
224233047|NCT00257296|OTHER|Screening and Intervention|Screening for intimate partner violence and providing a multi-faceted intervention which depends on the needs of the patient
224233048|NCT00257296|OTHER|Usual Care|Screening for intimate partner violence and provide enhanced usual care which includes providing resource list, educating medical staff and partner violence and instructing physicians to help all patients regardless of assigned arm.
224233049|NCT02276677|DRUG|Oxytocin|Single dose, intranasal
224233050|NCT02276677|DRUG|Placebo|Single dose, intranasal
224320126|NCT01383707|DRUG|Oxaliplatin|Participants will receive oxaliplatin 85 mg/m\^2 IV infusion over 2 hours on Day 1 of each 2 weeks' cycle up to 12 cycles.
223647854|NCT01792752|BEHAVIORAL|Enhanced HIV Care Access and Retention Intervention|Through the Enhanced HIV Care Access and Retention Intervention, the five neighborhoods will receive the 4 components of the intervention: 1) HIV Testing Campaign; 2) Treatment Re-engagement Campaign; 3) Patient Navigator Linkage to Care and Substance Abuse Treatment Team; and 4) Mobile Care Clinic. In addition to these intervention components, study participants will receive screening and access to treatment for other physical and mental co-morbidities, general primary health care, and social/psychosocial services addressing unstable housing, food insecurity, interpersonal violence, legal issues. All HIV-positive IDUs identified either through the HIV Testing Campaign or the Treatment Re-engagement Campaign will be enrolled in the HIV Care Cohort. The HIV Care Cohort will be comprised of the HIV-positive injectors who are receiving direct services in the Mobile Care Clinic. The 4 intervention components are detailed below:
223647855|NCT01792752|BEHAVIORAL|HIV Testing Campaign|When the intervention is initiated in a neighborhood, HIV rapid testing will begin and continue in a particular neighborhood from the time that the neighborhood's intervention begins until the end of the study period. Anyone testing HIV positive will be seen and counseled by a member of the Patient Navigator Team.
223647856|NCT01792752|BEHAVIORAL|Treatment Re-engagement Campaign|Simultaneously with the introduction of the HIV Testing Campaign, a patient navigator team will approach HIV-positive IDUs identified as not having seen their HIV care provider in the last 6 months. In addition, known HIV-positive IDUs within the designated neighborhoods will be approached for service enrollment and meet with a patient navigator.
223647857|NCT01792752|BEHAVIORAL|Patient Navigator Linkage to Care and Substance Abuse Treatment Team|The patient navigator team will provide informational support to the HIV-positive injectors, motivate them to attend HIV care visits and engage in substance abuse treatment, encourage their use of and adherence to antiretroviral therapies, and work with them to overcome any barriers to attendance at HIV care visits and substance abuse treatment. All clients of the patient navigator will become part of the HIV Care Cohort; they will have been identified either in the HIV Testing Campaign or the Treatment Re-Engagement Campaign.
224233051|NCT02369042|DEVICE|Kyma Device u-Cor System|The Kyma uCor system externally measures thoracic fluid content, heart rate, respiratory rate, posture and movement. The system includes a flat antenna that is attached to the patient's torso with a bandage-like sticker. The antenna transmits radio waves and receives their reflections from the body for several seconds every few hours throughout the day.The data is recorded and collected then compared to traditional clinical parameters.
224233052|NCT02204969|DIETARY_SUPPLEMENT|Lithia water|"* Experimental: Lithia spring water Lithia water (active) for 4 weeks then placebo water for 4 weeks Intervention: Dietary Supplement: Lithia water~* Placebo Comparator: Natural spring water Placebo water for 4 weeks then lithia water (active) for 4 weeks Intervention: Dietary Supplement: Natural spring water with negligible lithium levels"
224320127|NCT03104400|DRUG|Adalimumab|Administered by subcutaneous injection
224320128|NCT03104400|DRUG|Upadacitinib|Oral tablet
224320129|NCT03104400|DRUG|Placebo to Upadacitinib|Oral tablet
224320130|NCT03104400|DRUG|Placebo to Adalimumab|Administered by subcutaneous injection
224320131|NCT05551715|DEVICE|Software development for individualized refractive surgery|Software development for individualized refractive surgery
223647858|NCT01792752|BEHAVIORAL|Mobile Care Clinic|Participants who choose to receive services in the study mobile HIV care clinic will receive an initial appointment and the patient navigator will ensure that the client attends it. At the initial visit, clients will have a medical history taken, be examined and have blood drawn to measure CD4 and viral load. The mobile care clinic doctor will also prescribe medications for the client at the subsequent visit which will be scheduled as soon as lab results are available and interpreted, approximately one week later. The mobile HIV care clinic van will provide health services to the general IDU population within each intervention neighborhood to avoid any stigmatization of the HIV positive clients.
223647859|NCT00776516|DRUG|mirabegron|oral
223647860|NCT00776516|DRUG|rifampin|oral
223647861|NCT05882708|DRUG|Ivabradine|After randomization, the starting dose of ivabradine, 5mg, is given via the gastrointestinal tract every 12 hours. Heart rate control ranged from 70 to 94 bpm. Ivabradine was maintained until 96 hours after initiation of therapy. Beyond this period, the decision to continue ivabradine is left to the discretion of the treating intensivist. During the drug intervention period, heart rate is assessed before each dose. Ivabradine is tapered or discontinued if the heart rate is lower than the target rate; If the heart rate remains ≥95 bpm after 48 hours, the dose is increased to 7.5mg. If a heart rate of 95 or more bpm recurs after discontinuation during the intervention period, treatment with ivabradine can be resumed. Furthermore, Ivabradine is also discontinued at any time in the presence of severe liver impairment, malignant arrhythmia, cardiac conduction block, allergy, the need to take drugs with potentially harmful effects of ivabradine.
223647862|NCT04176484|OTHER|Survey|Women age 25 and above who are scheduled for an abdominal procedure and were seen in the General Surgery Clinic will be called and asked to complete a 5-10 minute verbal survey prior to their date of surgery. Some additional information will be gleaned from the medical record during the interview.
223647863|NCT06581549|OTHER|Translation analysis|Bulk GEP analysis, Spatial whole transcriptome analysis, mIF analysis of tumors
223647864|NCT03942120|DRUG|Ustekinumab|Participants treated with ustekinumab under real world clinical practice will be observed in this study. No study drug will be administered as a part of this study.
223647865|NCT06358313|DRUG|Atorvastatin 40mg|The atorvastatin group consisted of 300 patients who received 40 mg daily atorvastatin for 3 months, and open-label clopidogrel at a loading dose of 300 mg and then 75 mg daily till the end of the 3 months.
223647866|NCT06358313|DRUG|Rosuvastatin 20mg|The rosuvastatin group consisted of 300 patients who received 40 mg daily rosuvastatin for 3 months, and open-label clopidogrel at a loading dose of 300 mg and then 75 mg daily till the end of the 3 months.
223647867|NCT03674047|DRUG|ruxolitinib|Ruxolitinib blocks certain proteins called tyrosine kinases. Specifically, it blocks tyrosine kinases called JAK2. it's believe that ruxolitinib may lower the rate of GVHD through its ability to block the JAK2 pathway since this pathway can lead to inflammation in the body
224320132|NCT04725396|DEVICE|Mandibular Reconstruction (MR) with Preoperative Virtual Planning (PVP).|PVP-assisted mandibular reconstruction includes the production of the surgical cutting guides required for mandibular resection and fibula free-flap conformation and of the preformed plates for flap osteosynthesis (for all patients, PVP will be done by the same laboratory).
224233053|NCT02204969|DEVICE|Transcranial Magnetic stimulation|All participants will receive standard medical therapy for AD. In addition, patients recruited for the study will receive 16 sessions of TMS with the H2 coil over 8 weeks. The first group will receive excitatory stimulation of 10 Hz over the prefrontal and parietal cortex, the second group will receive inhibitory stimulation of 1 Hz over similar brain areas and control patients will receive the same amount of Sham sessions. Patient will receive 3 treatments per week in the first 3 weeks and then 1 treatment per week for additional 4 weeks.
223647868|NCT05745493|BEHAVIORAL|Social Engage Coaching (S-ENG)|Social Engage Coaching (S-ENG) involves 10 individual coaching sessions focused on increasing social connection. S-ENG is a stepped, modular intervention that was developed to allow personalization to a given subject's needs, preferences, and individualized barriers to social connection. Early sessions include psychoeducation on the importance of social connection; a values clarification exercise on aspects of connection most important to subjects; and assessment of current social networks and social activities. Together, the coach and subject create a conceptualization of reasons for loneliness and identify personalized activities most likely to impact loneliness. The primary activity is 'action planning,' which involves selecting a social goal for the week, brainstorming ways to meet the goal, identifying barriers, and selecting specific actions to take before the next session. The first 8 sessions are offered weekly and the final two are monthly booster sessions.
223647869|NCT05670301|DIAGNOSTIC_TEST|cytokine and lipidomic profiling|"* FEBRIS Cytokine Profile Assay (quantification of inflammatory cytokines)~* Serum amyloid A~* Biobanking of leftover sample for future analyses and specific immunofunctional assay in selected cases~* Lipidomics"
223647870|NCT02754752|PROCEDURE|Electroacupuncture Therapy|Undergo electroacupuncture therapy
223647871|NCT02754752|PROCEDURE|Electroacupuncture Therapy|Undergo modified electroacupuncture therapy
223647872|NCT02754752|OTHER|Laboratory Biomarker Analysis|Correlative studies
223647873|NCT02754752|OTHER|Quality-of-Life Assessment|Ancillary studies
223647874|NCT02754752|OTHER|Questionnaire Administration|Ancillary studies
223647875|NCT03476330|DRUG|Quercetin (dietary supplement)|Quercetin will be administered twice daily at an adjusted dose based on weight for a maximum total daily dose of 4000mg/day. If the patient is 70 kg or more, the dose will automatically be assigned at the maximum dose of 4000mg/day.
223647876|NCT02812420|BIOLOGICAL|Durvalumab|Given IV
224320133|NCT04725396|DEVICE|Conventional Mandibular Reconstruction (MR without PVP)|Conventional Mandibular Reconstruction
224320134|NCT05693259|DEVICE|Electrolyzed Alkaline Reduced Water (EARW) generated from electrolyzed ionizer|Patient will be allocated randomly to two groups: EARW and PW groups. For 6 weeks, patients drink water (10mL/kg body weight/day ) generated from the device installed in the house before starting intervention. Patients will be instructed to drink in empty stomach, and to drink immediately after generation of water. The total amount that the patient drank the day before will be monitored by a researcher using survey form of mobile phone everyday.
223647877|NCT02812420|PROCEDURE|Therapeutic Conventional Surgery|Undergo cystectomy with pelvic lymph node dissection
223647878|NCT02812420|BIOLOGICAL|Tremelimumab|Given IV
223647879|NCT06479213|BEHAVIORAL|REACH Peer Coaching Program|The REACH Peer Coaching Program consists of weekly coaching calls conducted over video teleconference. Coaches will use motivational interviewing to help participants formulate and work towards movement goals.
223647880|NCT06479213|BEHAVIORAL|REACH Mobile Health Application|Participants will use the the REACH mobile health application to set weekly movement goals and log physical activity.
223647881|NCT06404021|OTHER|interventional cardiology procedures with proctoring system|Interventional procedures are performed by utilizing a monitoring platform that provides real-time support without engineer in the electrophysiology laboratory
223647882|NCT06404021|OTHER|interventional cardiology procedures with engineer in the electrophysiology laboratory|Biomedical engineers supervise the performance of interventional cardiology procedures in the electrophysiology laboratory.
223647883|NCT05699538|BEHAVIORAL|Minimal-Dose Home-Based Resistance Exercise|8-week home-based resistance exercise performed one day per week.
224320135|NCT05827614|DRUG|BBI-355|Oral CHK1 inhibitor
223647884|NCT04030507|DEVICE|MRI|MRI (which stands for magnetic resonance imaging) provide imaging of the brain which help look for brain metastases (spread of the breast cancer to the brain).
223647885|NCT05197504|DRUG|atezolizumab plus bevacizumab|1200 mg of atezolizumab plus 15 mg/kg of body weight of bevacizumab intravenously every 3 weeks
223647886|NCT05293197|DEVICE|SonoCloud® (9 transducers)|SonoCloud®, sonication: dose escalation 6 cycles of sonication
223647887|NCT04187781|DEVICE|external microphone|External microphone is developed for direct transmission of speech into the hearing aids for better speech intelligibility, especially in noise.
223647888|NCT03916913|RADIATION|Local radiation therapy|Local radiotherapy on all sites of disease including primary and metastatic lesions
223647889|NCT05414084|DIETARY_SUPPLEMENT|Oral (poly)phenol challenge test (OPCT)|Nutritional challenge with standardized (poly)phenol-rich tablets
223647890|NCT05766800|DRUG|Serplulimab|Specified dose on specified days
223647891|NCT05766800|DRUG|Carboplatin|Specified dose on specified days
223647892|NCT05766800|DRUG|Pemetrexed|Specified dose on specified days
223647893|NCT05766800|DRUG|Nab-paclitaxel|Specified dose on specified days
223647894|NCT05766800|DRUG|Liposomal paclitaxel|Specified dose on specified days
223647895|NCT05766800|PROCEDURE|Surgery|Patients with stage IIIB-IIIC non-small cell lung cancer are treated with nab-paclitaxel/pemetrexed plus carboplatin and serplulimab for 4 cycles. Those with downstaged and resectable tumors after chemoimmunotherapy are randomised into surgical treatment arm and radiotherapy arm, and those with tumors still unresectable after chemoimmunotherapy will receive non-surgical treatment in department of medical oncology in the third arm.
224320136|NCT05827614|DRUG|Erlotinib|EGFR Inhibitor
224320137|NCT05827614|DRUG|Futibatinib|FGFR1-4 Inhibitor
224320138|NCT05827614|DRUG|BBI-825|Oral RNR Inhibitor
224233054|NCT03025607|DEVICE|JOOL Health Mobile Phone Application|JOOL Health is a mobile phone-based application that aims to increase autonomous motivation to prevent T2DM by helping individuals make connections between certain health behaviors and the energy and willpower needed to achieve personal goals. On a daily basis, JOOL Health users chart the following health behaviors: Sleep, Presence, Activity, Creativity, and Eating. On a weekly basis, JOOL Health users are asked to record how well they lived according to their purpose and values. Through the integration of user-entered information with contextual data, JOOL Health provides tailored messaging and daily predictions of individuals' energy and willpower.
224233055|NCT01448083|OTHER|Standard of care diagnostic MIBG scan for neuroendocrine tumor diagnosis.|Each subject will receive a 370 MBq (10 mCi ) (±10%) injection of I- 123 MIBG. Myocardial I-123 MIBG uptake will be quantitatively measured over time via planar imaging acquired at 15 minutes, one, two, four, and at 24 hours (the standard of care time point for NET patient imaging) post I-123MIBG injection.
224233056|NCT00642538|DRUG|MKC253 Inhalation Powder|Inhalation Powder, prandial
224233057|NCT00642538|DRUG|Technosphere Inhalation Powder|Inhalation Powder, prandial
224233058|NCT00642538|DRUG|subcutaneous injection|10µg Exenatide, prandial
224233059|NCT03080181|DRUG|Pasireotide 0.6 MG/ML|The aim of the study was to evaluate the effect of pasireotide on β -cell and adipose function in patients with Cushing's disease (CD).
224233060|NCT03902275|OTHER|Quantra-Algorithm|Hemotherapy based on Quantra-Algorithm
224233061|NCT03902275|OTHER|ROTEM-Algorithm|Hemotherapy based on Basic-Algorithm
224233062|NCT06203275|DRUG|Paroxetine|intervention group n=22 Patients with type 2 diabetes treated with metformin based combined oral hypoglycemic ( metformin plus DDP4 inhibitor or metformin plus sulfonylureas or metformin plus GLP-1 analogues) plus paroxetine 12.5 mg daily
223647896|NCT05766800|RADIATION|Radiotherapy|Patients with stage IIIB-IIIC non-small cell lung cancer are treated with nab-paclitaxel/pemetrexed plus carboplatin and serplulimab for 4 cycles. Those with downstaged and resectable tumors after chemoimmunotherapy are randomised into surgical treatment arm and radiotherapy arm, and those with tumors still unresectable after chemoimmunotherapy will receive non-surgical treatment in department of medical oncology in the third arm.
223647897|NCT02981446|DRUG|DE-117|DE-117 ophthalmic solution will be taken one drop, once daily for 3 months in both eyes.
223647898|NCT02981446|DRUG|Latanoprost ophthalmic solution|Latanoprost ophthalmic solution will be taken one drop, once daily for 3 months in both eyes.
224233063|NCT06203275|DRUG|Placebo|Patients with type 2 diabetes treated with metformin based combined oral hypoglycemic ( metformin plus DDP4 inhibitor or metformin plus sulfonylureas or metformin plus GLP-1 analogues) plus placebo daily
224233064|NCT04509609|OTHER|Exon 3 truncating mutation|Any patient affected by LGMD 2E with a genetic diagnosis carrying the truncating mutation c.377\_384duplCAGTAGGA on exon 3, both in homozygosis and in heterozygosis
224233065|NCT04509609|OTHER|Any other mutation in SGBC gene|Any patient affected by LGMD 2E with a genetic diagnosis other than the truncating mutation c.377\_384duplCAGTAGGA on exon 3, both in homozygosis and in heterozygosis
224233066|NCT00119613|DRUG|placebo|placebo
224233067|NCT00119613|DRUG|darbepoetin alfa|darbepoetin alfa
224323513|NCT06850298|OTHER|Pasteurized milk contaminated with killed A(H5) virus|Milk to be used in the study will be obtained from the CDC. Pasteurized commercial milk likely to contain detectable A(H5N1) particles will be obtained from a source such as a recently affected dairy farm. The CDC Influenza Division laboratory (Viral, Surveillance, and Diagnosis Branch) will test the milk to confirm the presence of viral A(H5) RNA using a protocol developed and validated by the US FDA Agricultural Research Service. The US Food and Drug Administration (FDA) has indicated that the consumption of commercial pasteurized dairy products in the US is safe.
223647899|NCT02826317|PROCEDURE|preoperative and postoperative setting|Preoperative assessment will consist on collecting demographic data as well as the presence preoperative chronic pain and its localization, preoperative opioid, gabapentin or pregabalin consumption. In postoperative, we will collect the following data: type of anesthesia, intra operative ketamine administration, type and total dose of opioid administered during surgery. Pain will be evaluated at least 2 hours after the surgery within the same day (D0) and then at day 2 (D2), 1 (M1) and 2 months (M2) after the surgery. Pain will be assessed using a 10-point NPS. If NPS \>0, neuropathic pain will be diagnosed on the basis of DN4 questionnaire. NCPSP is defined by NPS \>0 and positive DN4 (DN4 ≥ 4 /10) (11). APSNP and CPSNP are defined by D0/D2 DN4≥ 4/10 and M1/M2 DN4≥ 4/10, respectively.
224233068|NCT02534779|OTHER|Placebo Vaginal Insert|Placebo insert
224233069|NCT04373577|PROCEDURE|erector spinae plane block|the patient will be placed in the lateral position with the surgical side up for performing erector spinae plane block. After skin preparation, superficial (5-12 MHz) ultrasound transducer will be placed in a longitudinal orientation 1-2cm lateral to the midline at the sacral level. The L2 level will be identiﬁed by counting upward from the sacrum. Following identiﬁcation of the erector spinae muscle (ESM) and transverse process, a 21 G needle will be inserted deep to the erector spinae muscle (ESM) in a cranio-caudal direction. After negative aspiration, the correct needle position will be conﬁrmed with the administration of 0.5-1ml LA. A total volume of 0.5 mL/kg local anesthetic solution will be injected interfascial plane between erector spinae muscle and transverse process for block performance.
224233070|NCT04373577|PROCEDURE|pericapsular nerve group block|the patient will be in supine position. The ilio-pubic eminence (IPE), the iliopsoas muscle and tendon, the femoral artery, and pectineus muscle will be visualized using a linear ultrasound probe. A 22-gauge, 50-mm needle will be introduced in a lateral to medial fashion in an in-plane approach to place the tip of the needle in the musculofascial plane between the psoas tendon anteriorly and the pubic ramus posteriorly. Following negative aspiration, a total volume of 0.5 mL/kg local anesthetic solution will be injected.
224233071|NCT04153253|DRUG|Aflibercept Injection [Eylea]|"Three monthly based intravitreal injections were given followed by PRP if the hemorrhage was sufficiently cleared.Intravitreal injection was done in sterile operating room, after sterilization and toweling with application of sterile speculum, Betadine 5% drops was instilled into the conjunctiva and kept for two minutes followed by wash with balanced salt solution. Injection of 2mg /0.05m aflibercept was given 4 mm from the limbus in phakic eyes and 3.5 mm in pseudophakic with compression by sterile cotton tip on the site of injection, Paracentesis was done in cases of very high IOP following injection. At the end of procedure check of visual acuity was done (to be at least light perception).~PRP was done if the hemorrhage is sufficiently cleared after the third injection."
224233072|NCT04153253|PROCEDURE|Vitrectomy|Was done under local peribulbar anesthesia. After sterilization and toweling, wash with diluted betadine 5% was done. Insertion of three 23 valved cannulas beginning with the lower temporal one for infusion, clearance of anterior vitreous was done followed by core vitrectomy, peripheral vitrectomy , removal of posterior hyaloid aided by triamcinolone staining , trimming and removal of any vascular epicenters followed by vitreous base shaving with 360 scleral indentation, endolaser treatment was done for all eyes followed by fluid air exchange, 20% SF6 was used only if there is active significant bleeding during surgery or if there is intraoperative retinal tears, removal of cannulas was done at the end of surgery. All eyes received combination of topical steroid and antibiotic eye drops as postoperative treatment.
224233073|NCT03772639|OTHER|Shared decision making|Decision-making processes focused on the knowledge of the disease for set up adjusted care management about their necessities and engaging in recommended health behaviors
224233074|NCT03075137|DEVICE|External counter pulsation (ECP)|standard ECP protocol involves 35 one-hour sessions (once per day, 5 days a week) and continuous for 7 weeks. ECP consists of three sets of pneumatic cuffs attached to each of the patient's legs at the calf and lower and upper thigh. The inflation of the cuffs is triggered by a computer, and timing of the inflation is based on the R wave of the electrocardiogram. The ECP therapist adjusts the inflation and deflation timing to provide optimal blood movement per a finger plethysmogram waveform reading.
224233075|NCT03357783|OTHER|Macroscopic deciduosis|Deciduosis is a benign lesion during pregnancy that is not correlated with obstetrical complications. Our study has shown that this physiological phenomenon is more frequent that originally thought, being present in 10% of the Cesarean sections, and is associated with abdominal pain during pregnancy.
224233076|NCT03922477|DRUG|Atezolizumab|Atezolizumab will be administered to participants by IV infusion at a fixed dose starting on Day 22 of Cycle 1. In subsequent cycles (Cycles 2 and beyond), IV atezolizumab will be given every 2 weeks (Q2W) on Days 8 and 22 of each 28-day cycle.
224233077|NCT03922477|DRUG|Hu5F9-G4|Two priming doses of 1 mg/kg of Hu5F9-G4 will be administered to participants by continuous IV infusion on Days 1 and 4 of Cycle 1, followed by loading doses of 15 mg/kg IV on Day 8 and 30 mg/kg IV on Day 11. Starting on Day 15 of Cycle 1, Hu5F9-G4 maintenance will be given by IV infusion at a dose of 30 mg/kg once a week (QW) of each 28-day cycle. Dosing for de-escalation, if needed: Hu5F9-G4 will be given as two priming doses of 1 mg/kg IV on Days 1 and 4, followed by loading doses of 10 mg/kg IV on Day 8 and 15 mg/kg on Day 11. Starting on Day 15, maintenance treatment with Hu5F9-G4 will be given by IV infusion at a dose of 15 mg/kg once a week (QW).
224233078|NCT00440596|BEHAVIORAL|Mindfulness based stress reduction|8 weeks group MBSR
224233079|NCT00440596|BEHAVIORAL|Progressive Muscle Relaxation|8 weeks PMR in group format
224233080|NCT02362477|BEHAVIORAL|Cognitive Processing Therapy in-person|Cognitive Processing Therapy is delivered to female veterans and civilians, who have been diagnosed with PTSD, in-person.
224233081|NCT02362477|BEHAVIORAL|Cognitive Processing Therapy through videoteleconference|Cognitive Processing Therapy is delivered to female veterans and civilians, who have been diagnosed with PTSD, through videoteleconference.
224233082|NCT02133755|DRUG|Bromocriptine|Three month administration of bromocriptine. Baseline ultrasound and laboratory parameters measured. Repeat measures at discontinuation of drug at 3 months.
224233083|NCT01004770|DRUG|GE-145 (AN113111) Injection|40 healthy volunteers (10 per treatment group) will receive AH113111 320 mg I/mL at 1 of 4 possible doses (300, 450, 600, or 900 mg I/kg) as a single intravenous (IV) administration.
224233084|NCT01004770|DRUG|Visipaque (iodixanol) Injection|An additional 10 subjects will receive Visipaque (iodixanol) 320 mg I/mL) at a dose of 450 mg/kg.
224233085|NCT03158337|BEHAVIORAL|Aerobic exercise|
224233086|NCT02277652|DEVICE|The Miller Laryngoscope|Direct laryngoscopy
224233087|NCT02277652|DEVICE|The Bonfils intubation fibrescope|Optical laryngoscopy
224233088|NCT02277652|DEVICE|The GlideScope Ranger|Videolaryngoscopy
224233089|NCT02277652|DEVICE|The Supraglottic Airway Laryngopharyngeal Tube (SALT)|Blind intubation
223647900|NCT03102437|DEVICE|Optimizer Smart System|The Optimizer Smart System delivers non-excitatory cardiac contractility modulating (CCM) electrical signals to the heart muscle. Treatment group subjects receive five non-contiguous one-hour periods of CCM signals per day.
223647901|NCT03265314|BEHAVIORAL|LeadHer|The 30-hour curriculum is delivered for five hours per week, either split over multiple after school sessions or one five-hour-long session conducted at AFG headquarters or a community-based partner site.
223647902|NCT03265314|BEHAVIORAL|Sassy Science|The 30-hour curriculum is delivered for five hours per week, either split over multiple after school sessions or one five-hour-long session conducted at AFG headquarters or a community-based partner site.
223647903|NCT04308291|DEVICE|MiniMed™ 780G System|Subject enrolled in the study will start using the MiniMed™ 780G pump in Auto Mode after a run-in period of two weeks in Manual Mode (with no SmartGuard™ functions). Study phase in Automode will follow a 6 and 12 months follow- up as per standard of care.
224233090|NCT05662553|PROCEDURE|ENB guided MWA combined with VATS|"ENB guide MWA combine ENB, microwave ablation and 3D reconstruction technology, and guide the probe in the airway to the target lesion for ablation therapy, which is safe and effective. For patients with synchronous bilateral multiple primary pulmonary nodules, ENB guide MWA combined with VATS treatment can not only avoid the risk of bilateral surgery, but also complete the one-stop treatment, which is a new treatment mode."
224233091|NCT05662553|PROCEDURE|sequential surgery|Bilateral surgery is a traditional treatment, but it will lead to increased intraoperative risk and postoperative complication rate, and more likely to lead to postoperative complications such as decreased quality of life and cardiopulmonary dysfunction.
224233092|NCT03028272|OTHER|Skye Barrier|Substrate derived from amniotic tissue that is FDA-approved for human implantation
224320139|NCT06068491|OTHER|Vet-CALD|Vet-CALD Participants will receive the standard of care from their usual VA healthcare provider, plus they will participate in 5 monthly 60-minute care counselor sessions over a period of 6 months via VA Video Connect (VVC) or by telephone. The purpose of care counselor visits is to assess and cultivate the patient's understanding of their illness and identify personal healthcare goals. The counselor will be part of a centralized research care team (hepatologist and supportive care physician) and will work with each patient's usual VA care providers to help tailor treatment plans and education to better align with each patient's understanding of their disease prognosis and their healthcare goals and priorities.
224233093|NCT03028272|OTHER|Fascia|Autologous donor substrate. Examples include tragal cartilage, perichondrium, temporalis fascia, and temporoparietal fascia
224320140|NCT05132244|PROCEDURE|Endocrinologist-directed target blood glucose level 4-10 mmol/L using data from a continuous glucose monitor (CGM)|Standard anti-hyperglycemic treatment given as directed by an endocrinologist to maintain blood glucose level within 4-10 mmol/L based on data from a continuous glucose monitor (CGM) and standard blood work drawn prior to each cycle of chemotherapy. Participants will have access to their glucose data from the CGM.
224320141|NCT05132244|OTHER|Standard Care|Standard anti-hyperglycemic treatment given only if blood glucose level is greater than 15 mmol/L as measured from standard blood work drawn prior to each cycle of chemotherapy. Participants will wear a continuous glucose monitor (CGM) but will not have access to their glucose data. Participants may be referred to an endocrinologist at the discretion of their medical oncologist.
224320142|NCT04948333|DRUG|ABL001 40mg BID|One tablet of 40 mg will be taken orally twice a day (BID)
224320143|NCT04948333|DRUG|ABL001 80mg QD|Two tablets of 40 mg will be taken orally once a day (QD)
224320144|NCT04948333|DRUG|ABL001 200mg QD|Five tablets of 40 mg will be taken orally once a day (QD)
224320145|NCT05504837|BIOLOGICAL|KB407 (Nebulization)|Nebulized solution of KB407, a replication-defective HSV-1 expressing full length human CFTR
224320146|NCT05927571|DRUG|Cevostamab|Cevostamab solution for infusion will be administered as IV as specified in each treatment arm.
224320147|NCT05927571|DRUG|Elranatamab|Elranatamab solution for injection will be administered SC as specified in each treatment arm.
224320148|NCT05927571|DRUG|Tocilizumab|Tocilizumab will be used as rescue medication for participants who experience a cytokine release syndrome (CRS) event.
224320149|NCT05674097|OTHER|no intervention|no intervention
224320150|NCT04410419|DIETARY_SUPPLEMENT|Pre-operative carbohydrate drink|Carbohydrate drink containing 40g of carbohydrate to be consumed three hours prior to surgery
223647904|NCT01523912|DEVICE|Radiofrequency ablation of dysplastic mucosa (HALO)|Gastric ablation is performed using the HALO Ablation System (BÂRRX Medical Inc., Sunnyvale, CA, USA). A HALO90 ablation catheter, which is mounted on the tip of an endoscope, is used. Radiofrequency energy is delivered at 40 W/cm2 and 15 J/cm2 via a 13 x 20 mm electrode. All patients will have two RFA sessions 8 weeks apart with the same area being ablated in consecutive endoscopies. The precise area to ablated in the second RFA session is determined by referring to careful measurements that utilized gastric landmarks (a typical notation may specify that the lesion extends from 2 to 5 cm proximal of the pylorus in the 5 o'clock position and is 4 cm wide) as well as to digital image recordings that are taken during the first RFA.
223647905|NCT05924217|OTHER|Survey questionnaire|This survey aims to explore the perception that transgender men have of cervical cancer screening and to identify the challenges they face, the obstacles and the levers to access this prevention program.
223647906|NCT01970293|OTHER|Introduction to AA volunteer|In-person, in jail introduction to an AA volunteer, who will offer assistance in attending 2 AA meetings.
223647907|NCT03052062|DIETARY_SUPPLEMENT|Lipidrive|LipiDrive, 4 to 8 capsules per day, oral administration. Dose 1: 2.6 g Lipidrive per day Dose 2: 5.2 g Lipidrive per day
223647908|NCT06007950|BEHAVIORAL|Time-restricted eating 10-hr|Time-restricted eating is a form of intermittent fasting. In this study, 10-hr TRE will be employed, where eating duration is limited to 10 hours. Participants are allowed to consume non-caloric beverages during fasting period.
223647909|NCT02275234|OTHER|Psychological intervention|Psychological support via clinic visit, helpline and telephone calls
223647910|NCT04613648|DIAGNOSTIC_TEST|Imaging|Ultrasonographic imaging of the shoulder
223647911|NCT03121053|DRUG|sodium bicarbonate|
223647912|NCT03121053|DRUG|hypotone saline|
223647913|NCT01871935|DRUG|Remifentanil|Anaesthesia with remifentanil/propofol.
223647914|NCT01871935|DRUG|Sufentanil|Anaesthesia with sufentanil/propofol
223647915|NCT02565108|DRUG|GWP42003-P 20 mg/kg/Day Dose|GWP42003-P was an oral solution containing 25 mg/mL cannabidiol (CBD) or 100 mg/mL CBD dissolved in the excipients sesame oil and anhydrous ethanol (79 mg/mL) with added sweetener (0.5 mg/mL sucralose) and strawberry flavoring (0.2 mg/mL).
223647916|NCT02565108|DRUG|Placebo|Placebo oral solution contained the excipients sesame oil and anhydrous ethanol (79 mg/mL) with added sweetener (0.5 mg/mL sucralose) and strawberry flavoring (0.2 mg/mL).
223647917|NCT02565108|DRUG|Clobazam|Participants were already on a stable dose of CLB at Baseline and continued to take a stable dose of CLB for the duration of the blinded phase of the study. CLB was administered either once or twice daily in line with the physician's preferred dosing regimen for the CLB for each participant.
223647918|NCT05136014|OTHER|Collection of surgical waste|collection of a fragment of healthy and tumorous lung tissue taken as part of the operating theatre procedure and normally destined to be destroyed
223647919|NCT01312532|DEVICE|fixed-bearing (P.F.C.® Sigma)|P.F.C.® Sigma, DePuy, Johnson \& Johnson, Leeds, UK
224233094|NCT00545558|DRUG|Efavirenz|600 mg tablet taken orally daily
224320151|NCT05015426|BIOLOGICAL|Gamma Delta T-Cell Infusion|Donor cells will be processed in a laboratory, where T-cell subtype called γδ (gamma delta) T-cells will be isolated and expanded in number. These T-cells expanded in a laboratory will be infused in participants who are otherwise at high risk of AML recurrence after alloHCT.
224320152|NCT05543408|BEHAVIORAL|EXERCISE|individualized, progressive, exercise program
224320153|NCT02366429|BEHAVIORAL|ICBT for antenatal depression|Participants receives active therapist support via the internet to go through a 10-week self-help treatment on a secure web platform
224320154|NCT02366429|OTHER|TAU|Treatment as usual provided at antenatal clinics and other health care instances
224233095|NCT00545558|DRUG|Emtricitabine/Tenofovir disoproxil fumarate|200 mg emtricitabine/ 300 mg tenofovir disoproxil fumarate tablet taken orally daily
224233096|NCT02272868|BIOLOGICAL|Fecal Microbial transplant|Pretransplant regimen(rifaxamin+omeprazole+miralax) + Donor feces transplant
224233097|NCT02272868|DRUG|Normal Saline|Pretransplant regimen(rifaximin+omeprazole+miralax) +Normal Saline
224233098|NCT02272868|DRUG|rifaximin+omeprazole+miralax|
224233099|NCT03387098|DRUG|Aldoxorubicin HCl|Aldoxorubicin hydrochloride
224320155|NCT03004339|DRUG|SOR007 Ointment 2.0%|
224320156|NCT03004339|DRUG|SOR007 Ointment 1.0%|
224320157|NCT03004339|DRUG|SOR007 Ointment 0.3%|
224320158|NCT03004339|DRUG|SOR007 Ointment 0.15%|
224233100|NCT03387098|BIOLOGICAL|ALT-803|Recombinant human super agonist interleukin-15 (IL-15) complex
224233101|NCT03387098|BIOLOGICAL|ETBX-011|Ad5 \[E1-, E2b-\]-CEA
224233102|NCT03387098|BIOLOGICAL|GI-4000|Vaccine derived from recombinant Saccharomyces cerevisiae yeast expressing mutant Ras proteins
224233103|NCT03387098|BIOLOGICAL|haNK for infusion|NK-92 \[CD16.158V, ER IL-2\]
224233104|NCT03387098|BIOLOGICAL|avelumab|Recombinant human anti-PD-L1 IgG1 monoclonal antibody
224233105|NCT03387098|BIOLOGICAL|bevacizumab|Recombinant human anti-VEGF IgG1 monoclonal
224233106|NCT03387098|DRUG|Capecitabine|5'-deoxy-5-fluoro-N-\[(pentyloxy) carbonyl\]-cytidine
224233107|NCT03387098|DRUG|Cyclophosphamide|2-\[bis(2-chloroethyl)amino\]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
224320159|NCT03004339|DRUG|SOR007 Ointment Placebo|
224320160|NCT03004339|DRUG|Taclonex® Ointment|
224320161|NCT05151289|BIOLOGICAL|Blood test at time of inclusion for sFlt-1/PlGF ratio|As part of the research, a blood sample is taken to measure the sFLT-1 and PlGF ratio at the inclusion visit.
224320162|NCT05151289|BIOLOGICAL|Follow-up blood test 2 to 4 weeks after inclusion|As part of the research, a blood sample is taken to measure the sFLT-1 and PlGF ratio at the follow-up visit (about 2-4 weeks after inclusion). This second sample is not mandatory for the evaluation of the study's main endpoint.
224320163|NCT05151289|DIAGNOSTIC_TEST|Placenta analysis for all included patients, even in case of normal birthweight|"After delivery, the placenta of each included patient is sent to anatomo-pathology (even in case of normal weight of the baby at birth). An anatomopathologist referent, designated for the study in each center, performs an analysis (aware of the clinic but not of the sFLT-1/PlGF ratio results), according to the benchmark criteria grid. Local analysis will classify the placenta as vascular IUGR or nonvascular IUGR."
224320164|NCT01133457|DRUG|Finasteride|Finasteride tablets 1 mg
223647920|NCT01312532|DEVICE|mobile-bearing (P.F.C.® Sigma)|P.F.C.® Sigma, DePuy, Johnson \& Johnson, Leeds, UK
223647921|NCT02453711|DRUG|semaglutide|Once-daily subcutaneous (s.c., under the skin) administration with dose escalation.
223647922|NCT02453711|DRUG|liraglutide|Once-daily subcutaneous (s.c., under the skin) administration with dose escalation.
223647923|NCT02453711|DRUG|placebo|Once-daily subcutaneous (s.c., under the skin) administration.
223647924|NCT02774629|OTHER|prick and patch test|The cases are pricked and patched with local food allergen extract at different storage times (0, 3 and 6 months after preparation)
223647925|NCT06462599|GENETIC|Gene polymorphism from blood samples|"Blood samples will be collected from stroke patients within 24 hrs of stroke and normal volunteers.~Two samples will be collected serum and plasma; five ml whole blood from patients and normal volunteers and centrifuge serum samples at 1500 rpm 10 min then will be stored at - 80 °C until the day of the analysis.~Plasma samples will be stored at - 80 °C until the day of the analysis without centrifugation"
223647926|NCT03172416|DRUG|Oxaliplatin|This study started as a prospective, single arm phase I trial in a 3 + 3 dose escalation evaluating the safety and tolerability of PIPAC using oxaliplatin in patients with peritoneal carcinomatosis.
223647927|NCT03172416|DRUG|Oxaliplatin & Nivolumab|PIPAC oxaliplatin 90mg/m2 has been well tolerated in our Cohort 1 study. Hence, we added a second cohort (Cohort 2) which combines PIPAC oxaliplatin at 90mg/m2 every 6 weeks with IV nivolumab at 240mg every 2 weeks to evaluate the safety and tolerability of combination therapy.
223647928|NCT03863769|OTHER|Lumbar Spinal Stenosis|Posture and Performance testing: ABC-6 Scale, low back pain NRS, buttock or leg pain NRS, five times sit-to-stand, timed up-and-go, PGIC, eyes open force plate assessment (30 seconds), and eyes closed force plate assessment (30 seconds).
223647929|NCT04241562|OTHER|Injection of Nerve Growth Factor|Injection of Nerve Growth Factor to the right masseter
223647930|NCT01578369|OTHER|Exercise classes with pelvic floor muscle training|Supervised exercise classes which included pelvic floor muscle training. 3 sessions per week. 55-60 min per session, with 10 minutes of pelvic floor muscle training. At least during 22 weeks.
223647931|NCT00992797|DRUG|Cholecalciferol|Cholecalciferol 200.000 IU pr ampoule, 400.000 IU given at randomization day, followed by additionally 200.000 IU at week 5 if serum 25(OH)D \< 100 nmol/L. If serum 25(OH)D \> 100 placebo will be given. The cholecalciferol will be given in orange juice.
223647932|NCT00992797|OTHER|Orange juice|Orange juice at randomization day and at week 5.
223647933|NCT05824195|OTHER|Bread products|Four intervention products were included in the study. Three experimental breads (quinoa 1, quinoa 2, quinoa 3) were developed, and consisted of white wheat breads substituted with the differrent quinoa types. The reference product included was a white wheat bread without quinoa. All intervention products contain 50 g available starch.
223766315|NCT04342832|PROCEDURE|Cryoballoon ablation|If a patient is randomized to early invasive treatment, the ablation is performed within 3 months by an experienced cardiac electrophysiologist using CE-certified equipment. Via the femoral vein a guiding catheter is advanced through the inferior vena cava to the right atrium and into the left atrium via transseptal puncture. Then, the cryoballoon is advanced, inflated, and placed against one of the four PVs. PV occlusion is assessed by selective contrast injection. When adequate PV antral seal is confirmed, ablation of the tissue in contact with the balloon is performed using pressurized liquid nitrous oxide. The cold inflated balloon thus creates circular lesions around the PV. The balloon and tissue interface are then allowed to reach normal temperatures. Depending on local practice, the freeze-thaw cycle may be repeated twice. Electrical isolation is assessed and when it is confirmed, the next PV is treated in the same way. The procedure ends when all PV's are isolated.
223766316|NCT01885442|DEVICE|In-bed leg cycle ergometry|Patients will receive 30 minutes of in-bed leg cycling in addition to routine physiotherapy, 6 days per week, for the duration of their ICU stay (to a maximum of 28 days).
224233108|NCT03387098|DRUG|Fluorouracil|5-fluoro-2,4 (1H,3H)-pyrimidinedione
224233109|NCT03387098|DRUG|Leucovorin|L-Glutamic acid, N-\[4-\[\[(2-amino-5-formyl-1,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)methyl\]amino\]benzoyl\]-, calcium salt
224233110|NCT03387098|DRUG|nab-Paclitaxel|Benzenepropanoic acid, β-(benzoylamino)-α-hydroxy-(2aR, 4S, 4aS, 6R, 9S, 11S, 12S, 12aR, 12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a, 3, 4, 4a, 5, 6, 9, 10, 11, 12, 12a, 12b-dodecahydro-4,11-dihydroxy-4a, 8, 13, 13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca\[3,4\]benz\[1,2-b\]oxet-9-y1ester,(αR,βS)-(9CI) bound to albumin
224320165|NCT03719651|BEHAVIORAL|LOCI|LOCI includes training of leaders in general leadership, implementation leadership, and implementation climate.
223647934|NCT02353624|BEHAVIORAL|Cycling|Cycling distance of 2880 km in 14 days
223647935|NCT02964169|BEHAVIORAL|Family Planning Support|
223647936|NCT03494998|DIAGNOSTIC_TEST|PAT-POPS|Emergency Department-specific screening tool
223647937|NCT01117363|OTHER|dietary intervention (rye porridge or wheat bread)|A breakfast consisting of either active (rye porridge) or control (wheat bread) is given during 2 3-wk intervention periods in a randomized cross-over design. The two dietary intervention periods are separated by a 3-4 wks wash out.
223647938|NCT00986037|DRUG|ABT-308|Single IV doses
223647939|NCT00986037|DRUG|ABT-308|Multiple SC doses x 3
223647940|NCT00986037|DRUG|Placebo|Single IV dose
223647941|NCT00986037|DRUG|Placebo|Multiple SC doses x 3
223647942|NCT01497561|DRUG|insulin detemir|Each subject will be randomly allocated to two dose administrations out of four possible doses. Administrated subcutaneously (s.c., under the skin)
224233111|NCT03387098|DRUG|lovaza|Omega-3-acid ethyl esters
224233112|NCT03387098|DRUG|Oxaliplatin|cis-\[(1 R,2 R)-1,2-cyclohexanediamine-N,N'\] \[oxalato(2-)- O,O'\] platinum
224233113|NCT03387098|PROCEDURE|SBRT|Stereotactic Body Radiation Therapy
224233114|NCT03317236|DRUG|Quetiapine|A fixed 50 mg exteded release formulation.
224233115|NCT03345316|DRUG|FFI-1010|Intravenous single dosing
224320166|NCT03719651|BEHAVIORAL|EMDR|EMDR (Eye Movement and Desensitization Reprocessing), treatment method developed for treating patients with Post-Traumatic Stress Symptoms (PTSD).
224320167|NCT03719651|BEHAVIORAL|CT-PTSD|CT-PTSD (Cognitive Therapy for PTSD), treatment method developed for treating patients with Post-Traumatic Stress Symptoms (PTSD).
223647943|NCT01497561|DRUG|insulin NPH|Each subject will be randomly allocated to two dose administrations out of four possible doses. Administrated subcutaneously (s.c., under the skin)
223647944|NCT02967783|DEVICE|ID adaptor|ID adaptor fixed to the end of a standard ID needle and syringe to facilitate ID administration of the inactivated poliovirus vaccine
223647945|NCT02967783|DEVICE|ID Jet Injector (Tropis, Pharmajet)|ID disposable syringe (needle free) jet injector to facilitate ID administration of the inactivated poliovirus vaccine
223647946|NCT02967783|DEVICE|Needle and syringe|Standard ID needle and syringe for ID administration of the inactivated poliovirus vaccine
223647947|NCT04239014|DRUG|Olaparib|Olaparib 300 mg BD (2 × 150 mg tablets) continually in the olaparib monotherapy and ceralasertib+olaparib treatment arms.
223647948|NCT04239014|DRUG|Ceralasertib|Ceralasertib 160 mg QD (2 × 80 mg tablets) from Days 1 to 7 (inclusive) of every 28-day cycle.
223647949|NCT04239014|DRUG|Placebo to match olaparib|Per olaparib
223647950|NCT04230031|DRUG|Daratumumab|Experimental
223647951|NCT02302339|DRUG|glembatumumab vedotin|
223647952|NCT02302339|DRUG|glembatumumab vedotin and varlilumab|
223647953|NCT02302339|DRUG|glembatumumab vedotin and PD-1 targeted checkpoint inhibitor (nivolumab OR pembrolizumab)|
223647954|NCT02302339|DRUG|glembatumumab vedotin and CDX-301|
223647955|NCT02753452|BEHAVIORAL|Residential Immersive Life Skills programming|
223647956|NCT02753452|BEHAVIORAL|Non-residential life skills programming|
223647957|NCT02460237|PROCEDURE|Disease Screening|Complete HPV self-test
223647958|NCT02460237|OTHER|Educational Intervention|Receive culturally appropriate instructions for using and returning the HPV self-test device and a photo story information sheet about HPV and HPV self-testing
223647959|NCT02460237|OTHER|Informational Intervention|Receive standard instructions and information sheet
223647960|NCT02460237|OTHER|Laboratory Biomarker Analysis|Correlative studies
223647961|NCT02460237|OTHER|Survey Administration|Ancillary studies
223647962|NCT04270266|OTHER|Educational Intervention|Attend educational sessions
223647963|NCT04270266|OTHER|Meditation Therapy|Attend meditation sessions
223647964|NCT04270266|OTHER|Questionnaire Administration|Ancillary studies
223647965|NCT04264026|DRUG|3,4-methylenedioxymethamphetamine|Bottles are labeled with a unique container number, protocol number, IMP name, lot number, sponsor name and a statement that the IMP is restricted to clinical trial use only.
223647966|NCT05667493|DRUG|Eplontersen|Eplontersen will be administered by SC injection.
223647967|NCT05519982|BEHAVIORAL|Sleep Treatment Education Program (STEP-1)|Video conference instruction on behavioral changes to improve sleep.
223647968|NCT05519982|BEHAVIORAL|Enhanced Usual Care|Video conference instruction on relaxation techniques to improve sleep.
223647969|NCT06128759|OTHER|Focusing on Maryam's Flower|Effect of Focusing on Maryam's Flower During the First Phase of the labor
223647970|NCT02908672|DRUG|Atezolizumab|Will be administered as per the schedule described in individual arm.
223647971|NCT02908672|DRUG|Atezolizumab Placebo|Will be administered as per the schedule described in individual arm.
223647972|NCT02908672|DRUG|Cobimetinib|Will be administered as per the schedule described in individual arm.
223647973|NCT02908672|DRUG|Vemurafenib|Will be administered as per the schedule described in individual arm.
223647974|NCT02908672|DRUG|Vemurafenib Placebo|Will be administered as per the schedule described in individual arm.
223647975|NCT05127863|BEHAVIORAL|social communication intervention (pragmatic)|10 sessions of group intervention in order to improve pragmatic/social communication. one session of one hour per week. Activities will included role play, conversations, etc.
224233116|NCT00662129|BIOLOGICAL|bevacizumab|
224233117|NCT00662129|DRUG|gemcitabine hydrochloride|
224233118|NCT00662129|DRUG|paclitaxel albumin-stabilized nanoparticle formulation|
224233119|NCT03643419|PROCEDURE|Laminectomy|According to the standard procedure of laminectomy for acute spinal cord injury
224233120|NCT03643419|DEVICE|Spinal nerve laser therapeutic apparatus（Composed of 808-band fully automatic control laser device and implantable 360° scattering medical fiber）|According to the standard procedure of decompression of laminectomy for acute spinal cord injury, the patient in the Near Infrared Light Irradiation Group placed the implantable 360° scattering fiber laterally above the operation area at the end of the operation. Near infrared light irradiation is applied by spinal nerve laser therapeutic apparatus every day from the day after surgery, once a day for 60 minutes each time.
224233121|NCT02248077|DEVICE|AutoloGel|
224233122|NCT02248077|OTHER|Usual and Customary Care (UCC)|
223647976|NCT01342016|DRUG|tacrolimus capsule|oral
223647977|NCT01342016|DRUG|tacrolimus placebo|oral
223647978|NCT01342016|DRUG|leflunomide tablet|oral
223647979|NCT01342016|DRUG|leflunomide placebo|oral
223647980|NCT01342016|DRUG|prednisone|oral
224233123|NCT04534647|DIAGNOSTIC_TEST|different serum and urine biomarkers|urine exosomes and serum biomarkers
224233124|NCT06285721|DEVICE|transcranial alternating current stimulation (tACS)|tACS is a non-invasive brain stimulation technique which involves the application of a low intensity electric current between two or more surface electrodes. tACS uses stimulation with a current alternating at a specific frequency that can entrain endogenous neuronal oscillations by inducing neural synchronization. The administration of tACS is proposed to phase-lock large populations of neurons in the superficial layers of the cerebral cortex causing neural synchronization in the corresponding frequency, thereby altering connectivity. tACS will be delivered via a transcranial electrical stimulation (tES) device (Nurostym tES, Brainbox Ltd, United Kingdom). This device has been CE-marked for use as a medical device for the treatment of mental and neurological disorders.
224233125|NCT06285721|DEVICE|Sham transcranial alternating current stimulation (tACS)|Sham-tACS is a form of non-effective stimulation which can mimic the subjective sensation of active tACS treatment. During sham-tACS, the device will ramp up to 2.0 mA peak-to-peak intensity for 30 seconds, stimulate for 60 seconds and ramp down for 30 seconds, which mimics the sensation of actual tACS stimulation and improves blinding.The sham-tACS will be delivered via a transcranial electrical stimulation (tES) device (Nurostym tES, Brainbox Ltd, United Kingdom). This device has been CE-marked for use as a medical device for the treatment of mental and neurological disorders.
224233126|NCT00508560|BEHAVIORAL|Contingency Management|"Participants draw from a fishbowl to obtain tokens when they attend a smoking cessation treatment session. The number of draws will be based upon attendance at consecutive sessions. Tokens include messages of encouragement (Good job!) or VA canteen vouchers of varying monetary value."
224233127|NCT00508560|BEHAVIORAL|Reward|Participants receive set reward (VA canteen voucher) for each week of smoking cessation treatment they attend. The value of the reward will not change regardless of attendance at consecutive sessions.
224233128|NCT00858195|DRUG|Indomethacin 75mg Extended-Release Capsules, Sandoz|
224233129|NCT00858195|DRUG|Indocin 75mg SR Capsules|
224233130|NCT03325647|DRUG|Testosterone Cypionate 200 Milligram/Milliliter Injectable Solution|Subjects in one arm will be randomized to receive testosterone cypionate 200 mg/ml intramuscularly every 4 weeks for a total of three doses after visit 1, and receive placebo injectable saline for the same duration starting at visit 2. Subjects in the other arm will be randomized to receive placebo injectable saline every 4 weeks for a total of 3 doses after visit 1, and testosterone cypionate 200 mg/ml intramuscularly for the same duration starting at visit 2.
224233131|NCT03325647|DRUG|Placebo injectable saline|Subjects in one arm will be randomized to receive testosterone cypionate 200 mg/ml intramuscularly every 4 weeks for a total of three doses after visit 1, and receive placebo injectable saline for the same duration starting at visit 2. Subjects in the other arm will be randomized to receive placebo injectable saline every 4 weeks for a total of 3 doses after visit 1, and testosterone cypionate 200 mg/ml intramuscularly for the same duration starting at visit 2.
224233132|NCT00128557|DIETARY_SUPPLEMENT|vitamin A supplementation (15,000 ug retinol equivalents or 50,000 IU)|Single dose of 15,000 ug retinol equivalents at or near birth vs a placebo
224233133|NCT03348709|DIETARY_SUPPLEMENT|Isoosmolar|48 hours, 800 ml per 24 hours
224233134|NCT03348709|DIETARY_SUPPLEMENT|Hyperosmolar|48 hours, 800 ml per 24 hours
224233135|NCT01091025|OTHER|Glucose profile for 2 weeks|A study subject has an abnormal OGTT will be referred to a cystic fibrosis consultant who is not involved in the study.
224233136|NCT02848703|DEVICE|Magnetic Resonance Imaging (MRI)|
224233137|NCT02848703|DEVICE|phosphorus-31 Magnetic Resonance Spectroscopy|
223647981|NCT04740372|OTHER|No intervention. Method study. Psychometric testing|Patients will fill in the questionnaire followed by an interview (phase IIIA) or a debriefing questionnaire (Phase IIIB)
223647982|NCT05952882|DRUG|Liraglutide + Metformin|Metformin XR (extended-release) was initiated at 750 mg once daily and increased to 1500 mg once daily after 2 week. Concomitantly, Liraglutide was initiated at a subcutaneous dose of 0.6 mg once daily for 1 week, then titrated in increments of 0.6 mg once daily every 1 to 3 weeks to a maintenance dose of 3.0 mg once daily for up to 12 weeks
223647983|NCT05952882|DRUG|Metformin|Metformin XR (extended-release) was initiated at 750 mg once daily and increased to 1500 mg once daily after 2 week
223647984|NCT00005618|DRUG|arsenic trioxide|
223647985|NCT02606513|OTHER|MR Urography; CT Urography|
223647986|NCT01185080|DRUG|AZD8848|Nasal spray solution, intranasal, three times weekly for one month
223647987|NCT01185080|DRUG|Placebo|Nasal spray solution, intranasal, three times weekly for one month
223647988|NCT01185080|DRUG|AZD8848 and placebo|Nasal spray solution, intranasal, three times weekly for one month
223647989|NCT06255665|DRUG|JNJ-79032421|JNJ-79032421 will be administered.
223647990|NCT06255665|DRUG|JNJ-79032421|JNJ-79032421 will be administered at RP2D regimen.
223647991|NCT02876562|PROCEDURE|root coverage with collagen matrix|the material used is a porcine derived native collagen matrix which serves an alternative to connective tissue graft. the material is 1.5 mm in thickness with a specific tissue surface to allow for cell migration and a fibrous outer layer. it has a resorption time of 6 months.
223647992|NCT02808598|BEHAVIORAL|Breast Cancer Clinical Trials Education Program|The purpose of this study is to test a program designed to increase African American and Hispanic American women's scientific literacy, knowledge of clinical trials, and to facilitate breast cancer clinical trial participation.
223766317|NCT04229134|BEHAVIORAL|Project CONNECT|Home based pain self-management intervention using peer reinforcement to promote engagement and skill uptake
223766318|NCT05668923|BEHAVIORAL|Speech sound stimulation|Behavioral-, electrophysiological-, and magnetic resonance imaging-based speech sound testing
223766319|NCT06128265|BEHAVIORAL|Sleep Extension|Extending time in bed by 2 hours (going to bed earlier and/or waking up later)
223766320|NCT06128265|BEHAVIORAL|Sleep Regularity|Consistent bedtimes (within 30min)
224233138|NCT02848703|DEVICE|sodium-23 MRI|
224233139|NCT00653536|DEVICE|NeuroFlo|The device will be inflated for 45 minutes in acute ischemic stroke patients who have failed mechanical recanalization.
223647993|NCT06593548|DRUG|Ivosidenib (AK112)|Participants will receive Ivosidenib in combination with CapeOX chemotherapy and radiotherapy. Participants will first receive Ivosidenib in combination with CapeOX during the first cycle, followed by radiotherapy starting 2 weeks after medication. Depending on the dose limits of normal tissue radiation, Stereotactic Ablative Radiotherapy (SABR), large fraction radiotherapy, or high-dose combined with low-dose radiotherapy will be administered to primary and metastatic lesions. One week after completing radiotherapy, participants will continue to receive Ivosidenib in combination with CapeOX systemic treatment. If primary and metastatic lesions are too extensive for initial radiotherapy, participants will continue to receive Ivosidenib in combination with CapeOX systemic treatment until the lesions shrink, at which point radiotherapy may be considered.。
223647994|NCT01104311|PROCEDURE|Aggressive BP lowering|adjust the amount and number of antihypertensive drugs to lowering of systolic blood pressure to target level
223647995|NCT01104311|PROCEDURE|modest blood pressure lowering|adjust the amount and number of antihypertensive drugs
223647996|NCT06137495|DIAGNOSTIC_TEST|Sensitization to House dust mites|The SPT is performed at the time of diagnosis and after six-months follow-up period. Serum specific IgE is measured by immunoblotting, chemiluminescence, and ImmunoCAP assays
223647997|NCT06609577|DEVICE|Diaphragm Ultrasound-Guided External Diaphragm Pacing|This intervention, Diaphragm Ultrasound-Guided External Diaphragm Pacing (DU-EDP), is distinguished by its personalized approach, where diaphragm pacing is dynamically adjusted based on real-time diaphragm function measurements obtained through bedside diaphragm ultrasound (DU). Unlike standard external diaphragm pacing (EDP) interventions that use uniform pacing parameters, DU-EDP allows for the customization of pacing intensity, frequency, and duration for each patient. This intervention specifically integrates novel diaphragm function indices, such as diaphragm thickening fraction (DTF) and diaphragmatic rapid shallow breathing index (D-RSBI), to enhance precision in weaning from mechanical ventilation. The combination of these advanced metrics with real-time ultrasound guidance makes DU-EDP a highly individualized and innovative intervention for critically ill, mechanically ventilated patients.
223647998|NCT05788770|OTHER|FEops HEARTGuide|FEops HEARTGuide added to routine preoperative CT imaging. Results of the computer modelling will be discussed with TAVR implanting team prior to and during the procedure.
223647999|NCT03760718|DRUG|Preservative free 1% Chloroprocaine|40 ml of preservative-free 1% chloroprocaine is planned for administration into the peritoneal cavity after delivery of the baby.
223648000|NCT03760718|DRUG|Preservative free 2% Chloroprocaine|40 ml of preservative-free 2% chloroprocaine is planned for administration into the peritoneal cavity after delivery of the baby.
223648001|NCT03760718|DRUG|Preservative free 3% Chloroprocaine|40 ml of preservative-free 3% chloroprocaine is planned for administration into the peritoneal cavity after delivery of the baby.
223648002|NCT05758194|OTHER|Standardized RV Management|Standardized parameters for post-operative management (i.e., Rhythm Management, Ventilation Management, RV Ischemia Management, RV Preload, RV Afterload, RV Contractility, and RV Geometry)
223648003|NCT05758194|OTHER|Usual Care RV Management|No standardized parameters for post-operative management (i.e., Rhythm Management, Ventilation Management, RV Ischemia Management, RV Preload, RV Afterload, RV Contractility, and RV Geometry)
224233140|NCT03411005|DIETARY_SUPPLEMENT|Metabolic availability of lysine in sorghum|Four levels of lysine intakes will be provided by the reference protein drinks, 3 levels of lysine from sorghum and 1 level from sorghum with lentils.
224233141|NCT00738166|OTHER|Organic or conventional diet|12 days on fully controlled organic 1 diet, organic 2 diet and conventional diet
223648004|NCT07074574|OTHER|Present odors to participants while recording brain activity using fMRI|Present odors to participants while recording brain activity using fMRI
223648005|NCT05494164|OTHER|Nigella sativa nasal oil drops|in addition to the standard treatment, the study group will receive one nasal drop of the prepared N. sativa nasal oil drops in each nostril twice daily which are equivalent to a daily dose of 100 milligram of a pure N. sativa oil for four weeks. N. sativa oil was prepared from N. sativa seeds and it was mixed in Sesame oil with a ratio of 1 to 1. The prepared drops will then be placed in dark containers with a specific dropper. Each participant will be instructed regarding the dose, proper position and steps, assisted by a flyer which will be developed by the researcher.
223648006|NCT05494164|DRUG|standard treatment|intranasal corticosteroids in addition to nasal irrigation with sea water; for patients with allergy the standard treatment is oral antihistamines with or without oral corticosteroids.
223648007|NCT00022022|DRUG|docetaxel|
223648008|NCT00022022|PROCEDURE|quality-of-life assessment|
223648009|NCT05647161|DEVICE|BAX602|Consists of the spray agent, spray set, and spraying device (regulator). Dissolves a polyethylene glycol (PEG) derivative with an N-hydroxysuccinimide group at the end (COH102) and a PEG derivative with a thiol group (COH206) as an anti-adhesion agent, which is sprayed on the surgical surface to reduce the degree, frequency, and extent of organ adhesions after surgery.
223648010|NCT05647161|DEVICE|No Intervention|Control Group
224233142|NCT00738166|OTHER|Diet (organic or conventional)|organic or conventional diet
224320168|NCT03719651|BEHAVIORAL|TF-CBT|TF-CBT (Trauma-Focused Cognitive-Behavioral Treatment) treatment method developed for treating patients with Post-Traumatic Stress Symptoms (PTSD).
224320169|NCT00005553|PROCEDURE|Catheter Ablation|
224233143|NCT01055223|DRUG|TZD only (RSG or PIO or troglitazone)|Drug exposure will be inferred from prescription claims. Subjects who have been exposed to TZD for at least 6 months or at least 12 months will be considered for inclusion.
224233144|NCT01055223|DRUG|TZD + spironolactone|"Subjects who have been exposed to TZD for at least 6 months or at least 12 months will be considered for inclusion.~In order to be eligible for inclusion in this category, the prescription days supply for TZD and spirinolactone must overlap by at least 30 days."
224320170|NCT02129608|DEVICE|LLLT|The LLLT uses 6 diode laser heads - each emitting 17 mW output. Subject will receive 30 minutes of therapy in the frontal central area and 30 minutes of therapy in the back central area, once a week for 12 weeks.
224320171|NCT02129608|DRUG|Lorcaserin|10 mg pills twice daily for 12 weeks.
224320172|NCT01860274|DEVICE|External Mesh for vein grafts|
224320173|NCT03600389|BEHAVIORAL|Patient Priorities Care|
224233145|NCT01055223|DRUG|TZD + amiloride|"Subjects who have been exposed to TZD for at least 6 months or at least 12 months will be considered for inclusion.~In order to be eligible for inclusion in this category, the prescription days supply for TZD and Amiloride must overlap by at least 30 days."
224233146|NCT01017783|BEHAVIORAL|Dietary substitution A|Substitution of calorie-dense item with lower calorie choice A
224233147|NCT01017783|BEHAVIORAL|Dietary Substitution B|Substitution of calorie-dense item with lower calorie option B
224233148|NCT01017783|BEHAVIORAL|Healthy Choices|Multiple healthy choices presented with self-selection of choices used
224233149|NCT04812106|OTHER|No Intervention|No Intervention
224233150|NCT02381977|OTHER|No intervention|
224233151|NCT01093937|DRUG|varenicline|One to four 0.5 mg capsules (0.5-2.0 mg) orally per day for ten weeks.
224233152|NCT02799602|DRUG|BAY1841788 / darolutamide (ODM-201)|600mg (2 tablets of 300 mg) of darolutamide (ODM-201)/placebo twice daily with food, equivalent to a total a daily dose of 1200 mg in addition to standard ADT (luteinizing hormone releasing hormone (LHRH) agonist/antagonist or orchiectomy) and 6 cycles of docetaxel
224233153|NCT02799602|DRUG|Standard ADT (androgen deprivation therapy)|As prescribed by the treating physician.
224233154|NCT02799602|DRUG|Docetaxel|As prescribed by the treating physician.
224233155|NCT02799602|DRUG|Placebo|Placebo matching darolutamide (ODM-201) tablets in appearance, bid orally with food, in addition to standard ADT (luteinizing hormone releasing hormone \[LHRH\] agonist/antagonist or orchiectomy) and 6 cycles of docetaxel.
224233156|NCT04359641|DEVICE|CoMET Display|Display and presentation of predictive monitoring score CoMET
223648011|NCT03536117|BIOLOGICAL|MTBVAC|Live-attenuated Mycobacterium tuberculosis based on the deletion of phoP and fadD26 virulence genes
224233157|NCT03619031|OTHER|LONG LEAVENING|a long-leavened (60 h) pizza composed of sourdough and a flour mix.
224233158|NCT03619031|OTHER|SHORT LEAVENING|a short-leavened (5 h) pizza composed of sourdough and a flour mix.
224233159|NCT03619031|OTHER|TRADITIONAL|a short-leavened (5 h) pizza composed of brewer's yeast and 00 flour.
224233160|NCT04452578|PROCEDURE|Procedure: Heart Transplantation|A HCV negative or previously successfully treated recipient who recieves a HCV positive graft will be monitored. Patients who recieve an HCV graft will be treated for HCV according to accepted protocols.
224233161|NCT00744809|DRUG|TMC278; Moxifloxacin; Efavirenz|
224233162|NCT02771015|DEVICE|Mepilex Border®|randomization
223648012|NCT03536117|BIOLOGICAL|BCG|Live-attenuated Mycobacterium bovis obtained by subculture passaging in ox-bile and glycerated potatoes between 1908-1921 by Albert Calmette and Camille Guerin. BCG is the only licensed vaccine today against tuberculosis (TB) mainly used in TB-endemic countries.
223648013|NCT06048640|DIETARY_SUPPLEMENT|Dynamine (methylliberine)|Dynamine (methylliberine) is a purine alkaloid found in the kucha leaf, and available to consumers as a dietary supplement.
223766321|NCT06401486|DEVICE|Videolaryngoscope|For patients assigned to the videolaryngoscope Group, the operator will use a video laryngoscope on the first laryngoscopy attempt.
224233163|NCT02771015|DEVICE|Cosmopor steril®|randomization
224233164|NCT03455166|DIAGNOSTIC_TEST|Serum Markers|Serum Markers
223766322|NCT06401486|DEVICE|Macintosh laryngoscope|For patients assigned to the laryngoscope Group, the operator will use a Macintosh laryngoscope on the first laryngoscopy attempt.
223766323|NCT02143414|PROCEDURE|Biopsy Procedure|Undergo a biopsy
224233165|NCT04105881|DIETARY_SUPPLEMENT|Investigation|Cross sectional intervention
224233166|NCT02940743|BEHAVIORAL|Education (Edu)|This intervention will take place during weeks 1-4 at the dialysis center. Each week, study staff will present participants with a brief educational video on: phosphorus binder adherence (week 1), meeting dietary protein needs (week 2), restricting dietary sources of phosphorus (week 3), and eliminating phosphorus-based food additives (week 4). These videos will be loaded onto tablet (Personal Computers) PCs so that participants can easily view them during regular dialysis treatment.
224233167|NCT02940743|BEHAVIORAL|SM intervention|During the first 12 weeks of the intervention, a study dietitian will review the participants' records, and provide individualized feedback via a password-protected NYULMC email address. Feedback will be provided twice per week during weeks 1-4, once per week during weeks 5-8, and once every two weeks during weeks 9-12. The email messages will focus on both the importance of self-monitoring and the behavioral targets of the intervention. Feedback will use standardized language rather than specific dietary examples to avoid providing individualized counseling to participants (which is not the purpose of the SM intervention).
223766324|NCT02143414|PROCEDURE|Biospecimen Collection|Undergo a blood sample collection
224233168|NCT02940743|BEHAVIORAL|Social Cognitive Therapy (SCT)|This intervention will be delivered remotely online using the same tablet PCs provided for the SM intervention component of this treatment condition. The behavioral training program will focus on building a sense of self-efficacy with emphasis on mastery experiences that will include emphasizing past successes; setting incremental, easily achievable goals; self-monitoring to stay on track; identifying modifiable barriers to healthy behavior; positive feedback in goal achievement; and developing participant expertise in both the regimen and in problem solving around barriers to adherence.
224233169|NCT03918798|DRUG|Chloroprocaine 1% Injectable Solution|All the eligible patients will be administrated by Chloroprocaine 1 % according to the randomization criteria.
224233170|NCT03918798|DRUG|Chloroprocaine 2% Injectable Solution|All the eligible patients will be administrated by Chloroprocaine 1 % according to the randomization criteria.
223766325|NCT02143414|BIOLOGICAL|Blinatumomab|Given IV
223766326|NCT02143414|PROCEDURE|Bone Marrow Aspiration and Biopsy|Undergo a bone marrow aspiration and biopsy
223766327|NCT02143414|PROCEDURE|Computed Tomography|Undergo a CT scan
223766328|NCT02143414|DRUG|Dasatinib|Given PO
223766329|NCT02143414|PROCEDURE|Echocardiography Test|Undergo ECHO
223766330|NCT02143414|PROCEDURE|Lumbar Puncture|Undergo a lumbar puncture
223766331|NCT02143414|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223766332|NCT02143414|DRUG|Mercaptopurine|Given PO
223766333|NCT02143414|DRUG|Methotrexate|Given PO
223648014|NCT04198051|DRUG|adjuvant chemotherapy|"Form、dosage and frequency： Gastric cancer was given the SOX regimen (oxaliplatin + tegafur regimen,oxaliplatin 130mg/m2 intravenous infusion, the 1st day; tegafur 80mg/ m2/d orally Bid, the 1st to 14th day, every 21 days is one cycle) or XELOX regimen (oxaliplatin + capecitabine regimen，oxaliplatin 130mg/m2 intravenous infusion, the 1st day; capecitabine 1000mg/m2/d orally Bid, the 1st to 14th day, every 21 days is one cycle).~Colon cancer was given the XELOX regimen (the dosage、frequency and administration are the same as the gastric cancer) or FOLFOX regimen (oxaliplatin + calcium folinate + fluorouracil regimen，oxaliplatin 85mg/m2 intravenous infusion, the 1st day; calcium folinate 400 mg/m2 intravenous infusion, the 1st day; fluorouracil 400 mg/m2 intravenous infusion, the 1st day, then 1200 mg/m2/d × 2d continuous intravenous infusion，every 14 days is one cycle).~Duration：through chemotherapy completion，about six months."
223648015|NCT01888302|DRUG|Cisplatin|Given IV
223648016|NCT01888302|DRUG|Gemcitabine Hydrochloride|Given IV
223648017|NCT01888302|OTHER|Quality-of-Life Assessment|Ancillary studies
223648018|NCT01888302|DRUG|Sirolimus|Given PO
224233171|NCT05638425|RADIATION|Radiotherapy combined with PD-1 inhibitors|Radiotherapy should be carried out within 4 weeks after the first dose of PD-1 inhibitor; the radiotherapy method should be determined according to the patient's condition; PD-1 inhibitor and chemotherapy should refer to the actual product instructions
224233172|NCT01839084|DRUG|Xenon|general anaesthesia with xenon 60% in oxygen (FiO2=0.4)
224233173|NCT01839084|DRUG|Isoflurane|general anesthesia with isoflurane 1.2% in 40% oxygen/medical air
224233174|NCT04473079|DIETARY_SUPPLEMENT|Lacidofil|Investigational product intake daily for 6 weeks. Co-administration of H. pylori treatment with investigational product the first two weeks only.
224233175|NCT04473079|DIETARY_SUPPLEMENT|Placebo|Investigational product intake daily for 6 weeks. Co-administration of H. pylori treatment with investigational product the first two weeks only.
224233176|NCT00663910|DRUG|Aminolevulinic Acid|On Day 1, ALA will then be applied topically to the center of the tumor surface (at the location of its greatest diameter) in a standardized manner with great care not to include normal skin. The solution will be applied directly to the lesions by dabbing gently with a wet applicator tip. Enough solution will be applied to uniformly wet the exposed lesion surface. Once the initial application has dried, the ALA will be applied again in the same manner. The ALA will be left on for 2 hours under occlusion with Duoderm Extra Thin®.
224233177|NCT00663910|PROCEDURE|biopsy|Then local anesthesia, lidocaine 1% with epinephrine 1:100,000, will be administered and before the tumor is excised by one of the Cleveland Clinic MOHS surgeons, a 2mm punch biopsy will be taken from the area where the ALA was previously applied. The punch biopsy will be full thickness, extending to the subcutaneous fat.
224233178|NCT00663910|PROCEDURE|diagnostic imaging technique|Two hours after the amniolevlulenic acid was applied, the measurements of surface fluorescence will be repeated with the hand held dosimeter.
224320174|NCT04209283|BEHAVIORAL|Visuospatial interference|Behavioral: Brief cognitive intervention. A one-session intervention with a researcher including a simple cognitive task (a memory cue and 25 minutes of Tetris game play with mental rotation) with instructions to engage in the task self-guided in the subsequent weeks.
223648019|NCT00847509|DRUG|[F-18]FLT|The individual doses of \[F-18\]FLT contain a maximum of 10 mCi. The single IP dose is administered to the study subject approximately 30 to 60 minutes prior to the start of PET imaging.
223648020|NCT02223702|DRUG|Amoxicillin|500 mg, 3 times per day for 7 days
223766334|NCT02143414|DRUG|Methotrexate Sodium|Given PO
223766335|NCT02143414|DRUG|Prednisone|Given PO
223766336|NCT02143414|DRUG|Vincristine|Given IV
223766337|NCT02143414|DRUG|Vincristine Sulfate|Given IV
224233179|NCT00663910|PROCEDURE|therapeutic conventional surgery|The non-melanoma skin cancer will be excised using the MOHS procedure.
224233180|NCT04255459|OTHER|Moist Snuff|Moist Snuff product
224233181|NCT04255459|OTHER|Camel Snus|Camel Snus product
224320175|NCT02880670|DRUG|BMS-986142|
224233182|NCT04255459|OTHER|Cigarettes|Cigarette product
224233183|NCT04255459|OTHER|No tobacco usage|No tobacco usage
224233184|NCT03511352|BEHAVIORAL|Frequent sit-to-stands|Participants will visit the clinic for a 6-hour monitoring period. Following a 1-hour sitting run-in period, participants will sit for an additional 5-hour period including a 2-min stand every 15 min throughout the 5-hr protocol period. Baseline, mid-point, and end-of-visit bathroom breaks for urine sample collection will be conducted, with additional bathroom breaks allowed as needed.
224233185|NCT03511352|BEHAVIORAL|Stand More|Participants will visit the clinic for a 6-hour monitoring period. Following a 1-hour sitting run-in period, participants will sit for an additional 5-hour period including 5 8-minute standing interruptions, 1 per hour. Baseline, mid-point, and end-of-visit bathroom breaks for urine sample collection will be conducted, with additional bathroom breaks allowed as needed.
224320176|NCT03842319|OTHER|Microbiota analysis|From the feces and oral cavity samples, the DNA of the microbiota will be extracted using specific extraction kits and the microbiome will be analyzed through the study of 16S ribosomal RNA amplicons.
224320177|NCT03842319|OTHER|Immunological analysis|A study of immunological cell populations, inmunogenetics and cytokines will be carried out from fresh blood samples using antibody panels and flow cytometry
224320178|NCT03842319|OTHER|Proteome analysis|A study of host and microbiota proteome will be carried out from samples using mass spectrometry
224320179|NCT03842319|OTHER|Metabolome analysis|A study of host and microbiota metabolome will be carried out from samples using MS-based as well as NMR-based methods
224320180|NCT03842319|OTHER|Clinical evaluation|Clinical evaluation including hemostasis and biochemical studies
223648021|NCT02223702|DRUG|Metronidazole|500 mg, 3 times per day, for 7 days
223648022|NCT02223702|DRUG|Moxifloxacin|400 mg, once in a day for 7 days.
223766338|NCT02143414|PROCEDURE|X-Ray Imaging|Undergo an x-ray
223766339|NCT01356511|DRUG|Prednisone|Prednisone, po, 1 mg/kg/d, for 4 weeks.
223766340|NCT01356511|DRUG|Dexamethasone|Dexamethasone, po, 40 mg/d, for 4 days.
223766341|NCT06342713|DRUG|BGB-45035|Administered orally
223766342|NCT06342713|DRUG|Placebo|Administered orally
223766343|NCT02453113|OTHER|low power laser|Signaling in Human Skin Associated with Low-Power, Infrared Laser Treatment
223766344|NCT01316848|DRUG|tivozanib|tivozanib 1.5 mg capsule, 2 discrete single doses separated by 6-weeks
223648023|NCT01705509|DRUG|Ranolazine|The intervention will be ranolazine therapy after the initial CPET. The initial CPET will identify patients with underlying ischemia and serve as a baseline study. Patients whose CPET results meet the criteria for ischemia will be started on Ranexa 500mg BID and advanced within one week +/-4 days to 1000mg BID. A second CPET will be performed after 4 weeks +/- 4 days of maximum therapy. CPET results before and after therapy will undergo a statistical comparison. The initial off treatment CPET measurement will serve as the control to assess changes found during therapy.
223648024|NCT01227018|DRUG|STA-9090|Given IV
223648025|NCT01227018|RADIATION|Radiologic imaging|radiologic modalities used to evaluate response to treatment
223648026|NCT01227018|PROCEDURE|blood draw|Venous blood will be drawn from those patients who give consent. Serum will be used to look for biomarkers predictive of response
224233186|NCT00809809|DRUG|Zicam (Ionic zinc)|33mmol/l of ionic zinc
224233187|NCT00809809|DRUG|placebo|placebo swab
224233188|NCT04253548|BEHAVIORAL|iPeer2Peer Support Mentorship Program|iPeer2Peer is an online peer support mentorship program that has been established in multiple chronic disease populations as a self-management intervention, including chronic pain and juvenile idiopathic arthritis. The iPeer2Peer program provides modeling and reinforcement by pre-screened and trained young adult peer mentors to adolescent mentees.
224233189|NCT04351295|DRUG|Favipiravir|Favipiravir
224233190|NCT04351295|DRUG|Chloroquine|chloroquine oral tablets
224233191|NCT01854788|OTHER|Autogenic drainage|It was performed following J. Chevallier recommendations.In this trial it was considered a self-administrated technique because physiotherapist only gave oral advice in order to ensure a correct performance of the technique.
224233192|NCT01854788|OTHER|Slow expiration with glottis opened in lateral posture|It was performed following Postiaux´s recommendations. In this trial the technique was considered active-assisted because the physiotherapy played a role important in their execution.
224233193|NCT01854788|OTHER|Temporary-positive expiratory pressure|The diaphragmatic breathing was required for this technique whereas patients remain seated in front of the device with a nose clip. The inspiratory /expiratory ratio was 1:2.It was taken into account as a device-administrated technique for this trial.
224233194|NCT04712435|DRUG|N-acetylcysteine|Eligible patients will be randomised to receive N-acetylcysteine versus matching placebo
224233195|NCT04712435|DRUG|Placebo|Eligible patients will be randomised to receive N-acetylcysteine versus matching placebo
223648027|NCT05922800|DEVICE|Electro Press Needle|"Body acupoints will be stimulated by the press needles 0.25mm in diameter and 2mm in length and ear acupoints will be stimulated by the press needles 0.25mm in diameter and 0.9mm in length (all from ZhenXing Brand, Hangzhou Yuanli Medical Appliance Factory, China). After sterilization of the local skin, the needle will be pressed to the acupoints and the tape will be sticked to the skin. Then, the electric device (φ44×15.8mm Type ZXHPAMDZB-02C) together with the electrode patch will be sticked to the surface of skin (on top of the sticky tapes of the press needle) in the area of CV4 and bilateral EX-CA1, and bilateral SP6 respectively. The electric device will be switch to the mode of dense intermittent wave, and the current intensity will be increased gradually till the muscles around jumps slightly.All the needles on the body acupoints will be removed after each session, while those on the auricular acupoints can be kept for as long as 6 hours (removed before going to bed)."
223648028|NCT05922800|DRUG|Gamma-Oryzanol|The patients in this group were given orally gamma-oryzanol tablets 20mg each time, three times a day, for 6 months.
223648029|NCT00190151|DRUG|ciprofloxacin|
223648030|NCT05273671|DRUG|Nalbuphine|will receive 0.1 mg/kg NAL diluted in 10 ml I.V 10 minutes before the end of surgery
223648031|NCT05273671|DRUG|Dexmedetomidine|will receive dexmedetomedine 0.5 mic/kg diluted in 10 ml I.V 10 minutes before the end of surgery
224233196|NCT03503357|OTHER|IFT Testing1|Command List A
224233197|NCT03503357|OTHER|IFT Testing 2|Command List B
224233198|NCT03503357|OTHER|IFT Testing 3|Command List C
224233199|NCT03503357|OTHER|IFT Testing 4|Command List D
224233200|NCT01555619|DEVICE|CRT-D System|Implantation of a CRT-D System
224320181|NCT03842319|OTHER|Diet evaluation|Biochemical analysis and questionaries for diet adherence and exercise registration
223648032|NCT05273671|DRUG|normal Saline|will receive with a saline solution 10 min before the end of surgery
223648033|NCT03921645|DRUG|aerosol antibiotics|use of inhaled Antibacterial drug combined with intravenous antibiotics to treatment multiple drug resistance GNB ventilator associated pneumonia.
223648034|NCT00921167|DRUG|Bevacizumab/Irinotecan|Bevacizumab 10mg/kg D1 Irinotecan 125mg/m2 D1 (without enzyme-inducing antiepileptic drugs \[EIAEDs\] or 340mg/m2 for patients on EIAEDs) every 2 weeks
223648035|NCT02164409|PROCEDURE|Endoscopy tissue collection|The investigational part of this study is the requirement for an additional biopsy from a site that is already being biopsied at the time of a routine endoscopy. Any patients who develop bleeding following their routine clinical biopsies will not undergo any additional research biopsies.
223766345|NCT05893654|DRUG|Melphalan Injection|7.5mg of melphalan injected via intra-arterial catheterization of the ophthalmic artery.
224233201|NCT01533168|GENETIC|cytogenetic analysis|
224233202|NCT01533168|GENETIC|nucleic acid sequencing|
224233203|NCT01533168|OTHER|diagnostic laboratory biomarker analysis|
224233204|NCT01533168|OTHER|laboratory biomarker analysis|
224233205|NCT01533168|OTHER|medical chart review|
224233206|NCT05612386|BEHAVIORAL|COVID Booster text messages|Participants will receive text messages per descriptions listed in the arms.
224233207|NCT04317625|DIAGNOSTIC_TEST|mpMRI scanning|The patients whose PSA levels are between 2.5 and 4.0ng/ml will be recommended to mpMRI scanning at first but not biopsy or active surveillance.
224233208|NCT05998213|OTHER|Fecal microbiota transplant|Frozen FMT via duodenal tube (2 times) and enemas (4 times)
224233209|NCT00907842|DEVICE|Parietex Parastomal Mesh|mesh placed intraperitoneally around the stoma
224233210|NCT03112356|DRUG|99mTc-Leukoscan® scintigraphy|Gated single photon emission computed tomography with co-registered computer tomography (gated SPECT-CT) 6 hours and 24 hours after infusion of 99mTc-Leukoscan (1000 MBq)
224233211|NCT05731154|OTHER|taking periorbital selfie images using smartphones|taking periorbital selfie images using smartphones
224233212|NCT01371578|DRUG|GS-5885 tablet|30 mg active tablet
224233213|NCT01371578|DRUG|GS-9451 tablet|two active 100 mg tablets
224233214|NCT01371578|BIOLOGICAL|peginterferon alfa-2a|peginterferon alfa-2a (solution for injection) 180 µg/week
224233215|NCT01371578|DRUG|ribavirin tablet|ribavirin tablet (weight based: 1000 mg/day \<75 kg; 1200 mg/day ≥ 75 kg) divided twice daily (BID); tablet
224233216|NCT03805828|OTHER|Educational program on parenting stress and coping mechanism|The educational program will deliver as a one-day event in four sessions: (1)background of autism spectrum disorder(ASD) and coping mechanism,(2) targeting communication and social difficulties among ASD children using coping mechanism,(3) targeting behavior problems among ASD children using coping mechanism, and (4) stress management as coping mechanism. The contents of the educational program deliver through the use of PowerPoint slides, Whiteboard and marker, practical exercise, video clips followed by group discussion and provision a hard copy booklet containing all items which were supposed to discuss. As well as each session will approximately be taken one hour. Each group will consist of 10 participants.
224233217|NCT06412133|BEHAVIORAL|photography|This study examines the impact of phototherapy intervention on anxiety, stress, and body image among breast cancer patients. Participants engaged in a five-week, one-on-one session series, utilizing a pre-post-test design with parallel groups.
224233218|NCT00822198|DEVICE|plantar vibration|Subjects in the experimental component of the trial will be provided with a Juvent 1000-CS device in their home or workplace. The device will be placed in a convenient location where the device does not represent a trip hazard, and yet is readily accessible for use. The subjects will be instructed to use the device whenever it is convenient to do so, either by standing on the device, or by sitting with their feet on the device. Downloads of usage data will be obtained intermittently. Period interviews with the subjects will be conducted to ensure that the device is operating and that no problems are encountered with device usage.
224233219|NCT00050661|DRUG|Daclizumab|Humanized anti-CD25 antibodies (anti-TAC), or placebo (saline solution), will be given as intravenous infusions on the following schedule: 2 mg/kg initially (maximum dose 200 mg) infusion given over 60 minutes, followed by a 1 mg/kg (maximum of 100 mg) infusion given over 30 minutes every two weeks thereafter for a total of 8 doses.
224233220|NCT00050661|DEVICE|NB-UVB|total body NB-UVB at a dose that is 50% of the MED. Patients are treated 3-7 times per week, with increasing doses at every treatment if no burning occurs. This is continued until for a total of 20 ± 2 treatments total.
224233221|NCT00793845|DRUG|Cyclophosphamide|First HDCT
224233222|NCT00793845|DRUG|Etoposide|First HDCT
224233223|NCT00793845|DRUG|Carboplatin|First HDCT
224233224|NCT00793845|DRUG|Thiotepa|Second HDCT
224233225|NCT00793845|DRUG|Melphalan|Second HDCT
224233226|NCT00793845|RADIATION|Total body irradiation|Second HDCT
224233227|NCT04038970|BIOLOGICAL|KN019, 5mg/kg|Solution, intravenous, 5 mg/kg
223648036|NCT03613064|OTHER|Socially Enhanced Transitional Care Intervention|Components: 1) Standardized social vulnerabilities assessment tool, to be developed and incorporated into admission workflows. 2) Electronic community service referrals to existing community resources (i.e. food banks, shelters, community rehab), via the Dallas IEP or other information technology platform, for material (food, housing) and psychosocial needs (mental health/drug treatment). 3) Community-based cardiovascular self-management interventions, to be developed and piloted in conjunction with #3 - e.g., customized 'heart healthy' food baskets for CHF/IHD; risk factor monitoring (i.e., weight and blood pressure measurement at food banks, shelters, churches, modeled on the barber shop hypertension intervention); and 'heart buddy' support groups for CHF and IHD at community sites.
223648037|NCT03511196|DRUG|Adaptive Androgen Deprivation Therapy (ADT)|ADT with Leuprolide, Goserelin, or Triptorelin, as GnRH agonist, every 4 weeks as outlined in study arm description.
223648038|NCT03511196|DRUG|Abiraterone|Prednisone 5 mg once a day with food.
223648039|NCT03511196|DRUG|Prednisone|Abiraterone 1000 mg daily with empty stomach.
223648040|NCT06957600|PROCEDURE|Preoperative marking|Applying markings prior to uniport VATS wedge resections helps localize small, potentially early-stage lung tumors. After marking, the patients are positioned laterally and receive general anesthesia with single-lung ventilation. The investigators perform VATS wedge resection using uniportal techniques. The utility incision is made in the 5th intercostal space between the anterior and mid-axillary lines. Insufflation is not typically utilized. The lesion is localized, elevated, and confirmed by palpation. The investigators then staple around the lesion using the Endo GIA™ ultra universal stapler with an Articulating Reload featuring Tri-Staple™ Technology in 45 or 60 mm lengths, choosing purple or black loads based on parenchyma thickness. Finally, the investigators close the wound and place one chest drain in the thoracic cavity, set to active suction of 5-10 cm of water.
224233228|NCT04038970|BIOLOGICAL|KN019, 10 mg/kg|Solution, intravenous, 10 mg/kg
224233229|NCT04038970|BIOLOGICAL|Placebo|Solution, intravenous, Placebo
224233230|NCT04038970|COMBINATION_PRODUCT|Methotrexate|Tablets, oral, 7.5-25 mg weekly to be adjusted according to patient condition
224233231|NCT03231839|BEHAVIORAL|Caloric restriction|After the baseline measurements individuals underwent dietary counseling and had 6 sessions with a dietician (after, 1,4,8,12 16 and 20 weeks).
224233232|NCT03231839|BEHAVIORAL|no red meat|After the baseline measurements individuals underwent dietary counseling and had 6 sessions with a dietician (after, 1,4,8,12 16 and 20 weeks).
224233233|NCT03231839|BEHAVIORAL|Increased fiber intake|After the baseline measurements individuals underwent dietary counseling and had 6 sessions with a dietician (after, 1,4,8,12 16 and 20 weeks).
224233234|NCT00673491|OTHER|Clinical Pathways|Clinical pathways are a methodology for the mutual decision making and organization of care for a well-defined group of patients during a well-defined period. Defining characteristics of clinical pathways includes: an explicit statement of the goals and key elements of care based on evidence, best practice, and patient expectations; the facilitation of the communication, coordination of roles, and sequencing the activities of the multidisciplinary care team, patients and their relatives; the documentation, monitoring, and evaluation of variances and outcomes; and the identification of the appropriate resources.
224233235|NCT02564913|OTHER|clinical evaluation|
224233236|NCT01485913|OTHER|intensive education intervention using a network of involved diabetic patients (peer educators)|the purpose of this methodology is to set up coordinated training and education activities targeting populations with diabetes based on a pragmatic approach (the learning nests methodology) of appropriation and construction of knowledge that takes into account the individual, social, economic, cultural context. This work is being implemented on the basis of group modules specifically designed in their running: are studied the concrete elements of knowledge to mobilize, patients' actions, the role of health the educator, indicators of progress and monitoring during sessions and on the long term. Each patient is gotten to consider the elements involved in his/her disease, and the actions that can be achieved taking into account the feasibility in his/her own context. The education monitoring is envisaged through a data compendium present in the individual booklets that are given to patients at the end of each education session.
224233237|NCT04436692|BEHAVIORAL|Nudging|Use nudging approach by using smaller plates and glasses and increasing the availability of fruits and vegetables
224233238|NCT01781039|DEVICE|Hearing Aid fitting|Subjects with hfPTAs ranging from 0-55 dB HL will be recruitedwith 100 persons self-reporting difficulty HIN (\> 50% of the time), and 100 persons reporting little difficulty HIN (\< 50% of the time) will be randomly assigned to one of five groups (n = 200) based on enabled HA features using an online random assignment tool. Unaided HIQ and HIN assessments will be conducted in the sound field, and baseline DPOAE and CAP assessments will be measured. Subjects will be fit with binaural premium level receiver-in-the canal HAs (Phonak B90 or equivalent model at the start of the study) with 56 dB SPL gain receivers, using closed domes, and programmed to NAL-NL2 target gain, and randomly assigned to the groups.
224233239|NCT02275364|DEVICE|Test strip|Class I device for the application to the nose to facilitate better air flow through the nose
224233240|NCT02275364|DEVICE|Placebo strip|Placebo strip
224233241|NCT02275364|OTHER|Nasal spray|Nasal decongestant to be used on a single occasion (one spray per nostril), 20 minutes prior to commencing the third MRI scanning sessions.
224233242|NCT02579096|DRUG|allopurinol capsule, 100-800 mg by mouth once daily|Patients will be up-titrated up to the dose required to reach target uric acid levels.
224233243|NCT02579096|DRUG|febuxostat tablet 40-120 mg by mouth once daily|Patients will be up-titrated to the dose required to reach target uric acid levels.
224233244|NCT02579096|DRUG|Placebo, vehicle control (febuxostat-shaped)|Placebo tablets resembling febuxostat will be given with allopurinol.
224233245|NCT02579096|DRUG|Placebo, vehicle control (allopurinol-shaped)|Placebo capsules resembling allopurinol will be given with febuxostat.
224233246|NCT05151835|DEVICE|K2 Robotic Surgical System|The K2 Robotic Surgical System is a software-controlled, electro-mechanical system designed for surgeons to perform minimally invasive surgery in the thorax and abdomen. The K2 Robotic Surgical System consists of a Surgeon Console \[SGC\], a Patient Side Robot \[PSR\], and a Vision Cart \[VCT\], and is used with an endoscope, Surgical Instruments \[SGI\], and Accessories \[ACC\]. The surgeon views the three-dimensional endoscopic image on a High-Resolution Stereo Viewer (3D Viewer), which provides a view of the abdominal cavity and surgical instrumentation, along with icons and other user interface features.
224233247|NCT05854654|DIAGNOSTIC_TEST|Air Leaks|"The organs will be placed in an acrylic box and will be kept at a temperature of 37 Celsius degrees. The lungs will be mechanically ventilated connected by an endotracheal tube size 8 inserted in the bronchus with the balloon inflated and a silk suture providing an hermetic closure proximal to the balloon.~This setting will allow us to perform several different endoscopic and RAB procedures in emulated physiologic conditions to complete the study."
224233248|NCT03177603|DRUG|GSK2586881|GSK2586881 is a clear colorless liquid for IV infusion over 3- 5 minutes and will be administered a maximum dose of 0.8 mg/kg.
223648041|NCT06257433|BEHAVIORAL|Task Instructions|Participants will be given cued instructions as to whether they are in a high or low motivation condition
223648042|NCT03956654|DRUG|Ribociclib|combination of ribociclib and letrozole
223648043|NCT04068753|DRUG|Niraparib|Niraparib: 200 mg, oral, once daily, days 1-21
223648044|NCT04068753|DRUG|dostarlimab|dostarlimab: 500 mg IV, every three weeks for 4 cycles followed by 1000 mg every six weeks for up to two years
223648045|NCT03935958|DIETARY_SUPPLEMENT|Curcumin|Patients will receive curcumin 2000 mg a day, for 12 months
223648046|NCT03935958|OTHER|Placebo|Patients will receive placebo capsule identical in appearance and taste to the supplement, for 12 months
223648047|NCT03405532|DIAGNOSTIC_TEST|DM-ECC|Diabetes mellitus CPB
223648048|NCT03443570|DRUG|Rituximab|given with a fixed dose of 500 mg administered as an intravenous infusion every two weeks, for 2 times totally
223648049|NCT03443570|DRUG|Bortezomib|given subcutaneous injection at a fixed dose of 2.0 mg weekly, for 4 times totally
223648050|NCT02217358|DEVICE|NBI endoscopy|"see in detail description of the study part of the protocol"
223648051|NCT04858048|PROCEDURE|Anesthesia|2 types of anesthesia (general and WALANT) performed during the surgery
223648052|NCT01171482|DRUG|5-FU|15mg/kg/day continuous IV from day 1 to day 6 every 28 days.
223648053|NCT01171482|DRUG|Mitomycin|4mg/day IV push from day 1 to day 4 every 28 days
223648054|NCT01171482|DRUG|sorafenib|400 mg BID every 28 days
223648055|NCT03227640|PROCEDURE|stripping technique|The cyst is stripped from the healthy ovary by traction and countertraction; after the removal of the cyst, hemostasis is achieved by selective bipolar coagulation.
223648056|NCT03227640|DEVICE|CO2 laser (AcuPulse Duo, Lumenis)|The cyst content is drained and the internal wall is vaporized with CO2 laser beam (AcuPulse Duo, Lumenis, Israel)
223648057|NCT03007225|DRUG|Trans-arterial chemoembolization (TACE)|"TACE procedures were performed by experienced radiologists by fluoroscopy. The femoral artery was catheterized under local anesthesia, with a 4F catheter with Copra head configuration. Conventional angiography of the Coeliac and Hepatic arteries to delineate the feeding arteries of the tumors and to exclude portal venous shunting. Then vascular catheter was inserted super-selectively into the branch of the hepatic artery that is the main feeder of the tumor. Chemoembolization then was performed.~Ten milliliters of Lipiodol was mixed with 100 mg of Doxorubicin hydrochloride and 5ml of Urografin emulsified to create a milky solution. The emulsion slowly was infused into the tumour Gel foam embolization was performed by cutting gel foam sheets into small pledges mannully then mixed with a contrast material and an impirical antibiotic (gentamycin 80 mg). Injection of the mixture slowly under fluoroscopy guidance till complete stasis was achieved."
223766346|NCT05893654|RADIATION|Plaque brachytherapy|Brachytherapy will be performed using a 24-mm notched plaque with Ruthenium-106 seeds.
223766347|NCT01706510|DRUG|Ticagrelor|Ticagrelor 180 mg loading dose followed by 90 mg bid for 7 days ± 2 days
224233249|NCT06544434|DEVICE|Multiwave Locked System (MLS) laser (Mphi laser, ASA Srl, Vicenza, Italy)|MLS laser is a class IV NIR laser with two synchronized sources (905 nm with 75 W peak power, pulsed mode; 808 nm with power 1 W, continuous mode). Both laser beams were synchronized, the locked waves work with the range 1-2000 Hz.
224233250|NCT06544434|DRUG|Betahistine Mesylate tablet|Betahistine Mesylate tablet (Merislon, Eisai Co., Ltd., China) with the treatment of 6 mg, 3 times a day.
224233251|NCT01876186|DRUG|Solifenacin for 12 weeks|Solifenacin 5 mg one a day for 12 weeks
224233252|NCT01876186|DRUG|Solifenacin for 24 weeks|Solifenacin 5 mg once a day for 24 weeks
224233253|NCT05882474|DEVICE|PaCO2|Level of partial pressure of carbon dioxide
224233254|NCT05132413|DRUG|SHR-1701 + Pemetrexed Disodium + cisplatin/carboplatin + bevacizumab|SHR-1701 + Pemetrexed Disodium + cisplatin/carboplatin + bevacizumab
224233255|NCT05132413|DRUG|Placebo + SHR-1701 + Pemetrexed Disodium+ cisplatin/carboplatin|Placebo + SHR-1701 + Pemetrexed Disodium+ cisplatin/carboplatin
224233256|NCT05132413|DRUG|Placebo 1 + Placebo 2 +Pemetrexed Disodium + cisplatin/carboplatin|Placebo 1 + Placebo 2 +Pemetrexed Disodium + cisplatin/carboplatin
224233257|NCT05977257|DEVICE|VitaFlow® Transcatheter Aortic Valve Replacement System|This study is an observational study, for who have joined the VitaFlow® Catheter Aortic Valve System pre-market trial
223648058|NCT03007225|DRUG|TACE with Drug Eluting Beads procedure|"The same was done as cTACE till the super selective catheterization of the feeding artery.~Loading of the beads with Doxorubicin hydrochloride (100-150 mg) was done in vitro an hour before the beginning of catheterization. The loaded beads were then aspirated from the vial into a syringe filled with nonionic contrast medium. Once the feeding artery was identified and catheter was in placement, the loaded beads were infused slowly under fluoroscopic guidance. Two different sizes of DC beads were used, 100-300 μm and 300-500. Starting with the smaller sized beads to occlude the tumoral bed followed by the larger sized one to embolize the proximal vessels. The injection of the loaded beads was performed as selective as possible using either a4F diagnostic catheter (Cobra head catheter; Cordis, USA) or 2.7F microcatheter (Progreat; Terumo, Japan)."
223648059|NCT05475756|DEVICE|Intrauterine Biological Barrier|after Hysteroscopic adhesiolysis，use of Intrauterine Biological Barrier to repair uterine cavity
223648060|NCT05475756|DEVICE|Intrauterine Adhesion Barrier Gel|after Hysteroscopic adhesiolysis，use of Intrauterine Adhesion Barrier Gel to repair uterine cavity
223648061|NCT03952975|OTHER|Vaginal bleeding|Vaginal bleeding was classified into four categories according to the timing. Intraoperative bleeding (defined as bleeding that occur during the LEEP procedure), early postoperative bleeding (defined as bleeding that occur between end of the LEEP procedure and home discard), late postoperative bleeding (defined as bleeding that occur within two weeks after the home discard, and required hemostatic interventions such as electrocauterization, gauze packing, or cervical suturing, excluding menstrual bleeding), and persistent postoperative bleeding (defined as vaginal bleeding that occurs more than 2 weeks after the procedure with or without required hemostatic interventions, excluding menstrual bleeding).
223648062|NCT04245865|DRUG|Fluorouracil|2800 mg/m2 iv
223648063|NCT04245865|DRUG|Calcium folinate|400 mg/m2 iv
223648064|NCT04245865|DRUG|Oxaliplatin|85 mg/m2 iv
223648065|NCT04245865|DRUG|Bevacizumab|5 mg/kg OR 7.5 mg/kg iv
223648066|NCT04245865|DRUG|Capecitabine|2000 mg/m2 orally daily for two weeks
223648067|NCT04245865|DIETARY_SUPPLEMENT|Tocotrienol|300 mg orally x 3 daily
223648068|NCT04245865|OTHER|Placebo|Placebo orally x 3 daily
223766348|NCT01706510|DRUG|Clopidogrel|Clopidogrel 600 mg loading dose followed by 75 mg Daily for 7 days ± 2 days
223766349|NCT04605757|OTHER|Clinical, functional and radiological lung involvement evolution|Observational / Clinical, functional and radiological long term evolution of SARS-COV-2 lung involvement
223766350|NCT05679791|DEVICE|Dynamometer|to assses hand grip
223766351|NCT00110266|DRUG|Deferasirox|20 mg/kg/day over one year in patients with MDS
224233258|NCT02898649|DEVICE|Irreversible electroporation|IRE is operated to tumor under laparotomy or CT-guided percutaneous approach. Unipolar (19G) or bipolar (16G) electrode probe is inserted to around tumor. After insertion of probe, short duration (70-90㎲) of electric current (25\~45A) is generated by IRE device (NanoKnife IRE device, AngioDynamics, Queens bury, New York). It is possible to obtain a three-dimensional ablation zone using multiple electrode. IRE can cause apoptosis of tumor cells, without adjacent tissue damage.
224233259|NCT05070156|BIOLOGICAL|Biological/Vaccine: Low-dose group|1.0×105/kg positive CAR-T cells injection. 2-n doses will be evaluated by the investigator if participant is qualify for certain condition.
224233260|NCT05070156|BIOLOGICAL|Biological/Vaccine: Mid-dose group|2.0×105/kg positive CAR-T cells injection. 2-n doses will be evaluated by the investigator if participant is qualify for certain condition.
224233261|NCT05070156|BIOLOGICAL|Biological/Vaccine: High-dose group|3.0×105/kg positive CAR-T cells injection. 2-n doses will be evaluated by the investigator if participant is qualify for certain condition.
224233262|NCT06544876|BEHAVIORAL|sit-to-stand|test for balance during movement from sitting to standing
224233263|NCT06544876|BEHAVIORAL|stand to sit|test for balance during movement from standing to sitting
224233264|NCT06544876|BEHAVIORAL|standing perturbation|test for balance recovery following perturbation
224233265|NCT06544876|OTHER|MRI of sciatic nerve|measure of peripheral nerve diameter
223766352|NCT06098820|OTHER|Vitamin D status|Four different groups will be compared with each other in terms of vitamin D effect.
223766353|NCT02896400|BEHAVIORAL|Brief Negotiated Interview (BNI)|Brief motivational interview on smoking behavior
223766354|NCT02896400|DRUG|Nicotine replacement therapy (NRT)|6 weeks of nicotine replacement, patches and gum. First dose of each started in ED. Patches are 14mg or 21 mg. Gum is 2mg per piece.
223766355|NCT02896400|OTHER|CT Smokers Quitline (QL)|Faxed referral to the CT Smokers Quitline for the subject. QL will then call subject to offer phone based counseling.
223766356|NCT02896400|OTHER|SmokefreeText (Text)|Enrollment in a version of NCI's SmokefreeTxt, tailored for the study.
223648069|NCT02692638|PROCEDURE|Early laparoscopic enterolysis|The surgeon will make about 3-4 small incisions in the participant's abdomen. A port (nozzle) is inserted into one of the slits, and carbon dioxide gas inflates the abdomen. A laparoscope is inserted through another port. The laparoscope looks like a telescope with a light and camera on the end so the surgeon can see inside the abdomen. Surgical instruments are placed in the other small openings and used to cut the scar tissue in order to relieve the obstruction. After all this has been accomplished, the carbon dioxide is released out of the abdomen through the slits, and then these sites are closed with sutures or staples, or covered with glue-like bandage and steri-strips.
223648070|NCT02692638|PROCEDURE|nonoperative management|Sometimes a bowel obstruction can be treated by suctioning out the contents of the stomach, giving IV fluids, and not letting the patient eat for a few days.
223648071|NCT03482596|BEHAVIORAL|Reducing/breaking prolonged sitting|"The participants will be encouraged to reduce prolonged sitting by at least 60 minutes per day by introducing light upright movement breaks spread throughout their day. The frequency and duration of these breaks will be tailored to each participant to suit their individual circumstances.~The intervention will involve education regarding the health implications of prolonged sitting, personalised goal setting, behavioural feedback and self-monitoring of behaviour."
223648072|NCT00124436|DRUG|alitretinoin|
223766357|NCT02293785|DRUG|Oxycodone-Naloxone|
223766358|NCT00953797|DEVICE|Enhanced External Counterpulsation|A non-invasive method currently used for the treatment of ischemic coronary disease. During EECP therapy three compressive pneumatic cuffs are wrapped around the calves, lower thighs, and upper thighs. The cuffs inflate sequentially during diastole causing retrograde aortic flow, and increased venous return. At end diastole, the cuffs rapidly deflate resulting in unloading of the left ventricle and a decrease in systolic blood pressure.
224233266|NCT02097121|BIOLOGICAL|BOTOX®|Each vial of BOTOX (Botulinum Toxin Type A) purified neurotoxin complex, formulation No. 9060X contains 100 U of Clostridium botulinum toxin Type A, 0.5 mg albumin (human), and 0.9 mg sodium chloride in a sterile, vacuum-dried form without a preservative. The study medication was to be reconstituted with 0.9% sodium chloride (preservative-free). The 10 mL of study drug was to be administered as 20 injections each of 0.5 mL. Under direct cystoscopic visualization, injections were to be distributed evenly across the detrusor wall and spaced approximately 1 cm apart. To avoid injecting the trigone, the injections were to be at least 1 cm above the trigone. The injection needle was to be inserted approximately 2 mm into the detrusor for each injection.
224233267|NCT05265325|DRUG|AND017 capsules TIW|Orally, 3 times per week in Period 1 and dose adjustment in Period 2 at 2 mg/4 mg and 2-weeks interval according to Hb levels
224233268|NCT05265325|DRUG|AND017 capsules QW|Orally, once per week in Period 1 and dose adjustment in Period 2 at 4 mg/8 mg and 2-weeks interval according to Hb levels
224233269|NCT05265325|DRUG|epoetin alfa, darbepoetin alfa, Mircera®, or their biosimilars|Dose regimen and adjustment rules according to the USPI or SmPC or local practice
224233270|NCT03066999|PROCEDURE|Cystoscopy|Patients will assign to either Group Cystoscopy (catheter placement via cystoscopy)
223648073|NCT01413204|DRUG|TA-7284 Low|The patients will receive TA-7284-Low orally for 24 weeks.
223648074|NCT01413204|DRUG|TA-7284 High|The patients will receive TA-7284-High orally for 24 weeks.
223648075|NCT01413204|DRUG|Placebo|The patients will receive Placebo orally for 24 weeks.
223766359|NCT04852094|OTHER|Qualitative focus group|A qualitative focus group is performed with staff members and parents of hospitalised newborns in a NICU during Family-centered rounds management. The transcribed interviews are analyzed with qualitative content analysis in order to illuminate the experience, feelings and thoughts arisen among the staff members and the parents.
223766360|NCT02912286|DEVICE|conventional needle irrigation|conventional side-vented syringe used to deliver irrigant in root canal treatment
223766361|NCT02912286|DEVICE|passive ultrasonic irrigation|ultrasonic tip (IrriSafe) activate the irrigant after mechanical preparation in root canal treatment
223766362|NCT02912286|DEVICE|sonic irrigation|vibringe system is a sonic device that deliver and agitate the irrigant
223766363|NCT05295173|DRUG|Injection of recombinant human tissue plasminogen kinase derivatives|18mg/10ml/stick, provided by Angde Biotech
223766364|NCT05295173|DRUG|Recombinant human tissue plasminogen activator|20mg/stick, 50mg/stick, provided by Shanghai Boehringer Ingelheim Pharmaceutical Co. Ltd.
223766365|NCT06193538|DRUG|Recombinant NV-A01 adenovirus injection|Patients with advanced glioblastoma were intratumoral injected with NV-A01. Or the NV-A01 was injected after tumor resection.
224233271|NCT03066999|DEVICE|DirectVision|Patients will assign to either Group DirectVision (catheter placement via DirectVision)
224233272|NCT00661999|BIOLOGICAL|darbepoetin alfa|Given by injection
224233273|NCT00661999|DIETARY_SUPPLEMENT|ferrous sulfate|Given by mouth
223766366|NCT00123981|PROCEDURE|Off-Pump Coronary Artery Bypass Grafting|
223766367|NCT00864500|DRUG|Clobetasol Propionate 0.05% lotion, single exposure|A: Experimental Subjects received Alpharma USPD, Inc formulated products
223766368|NCT00864500|DRUG|Clobex TM 0.05% Lotion, single exposure|B:Active Comparator Subjects received Galderma Laboratories, L.P. formulated products
223766369|NCT05252026|BEHAVIORAL|PROCARE-I (UP-A for indicated purposes)|This intervention is meant to respond to the heterogeneity inherent in emotional difficulties presentation by extinguishing distress associated with the presentation of heightened negative emotion in general and reduction or elimination of resultant emotionally-driven behaviours, including avoidance, escape, aggression, and controlling behaviours (e.g., reassurance seeking) that reinforce emotional distress intensity over time.
223766370|NCT05252026|BEHAVIORAL|Active control condition|Psychoeducation about many different emotions, emphasis on discussing thoughts, feelings, and behavior as parts of emotion, and emphasis on providing support around generally distressing events.
224233274|NCT00661999|DRUG|sodium ferric gluconate complex in sucrose|Given by IV
224233275|NCT00661999|OTHER|placebo|Given by mouth
224233276|NCT06015048|DRUG|SHR-A1811 combined with Pyrotinib.|SHR-A1811 combined with Pyrotinib
224233277|NCT06015048|DRUG|SHR-A1811 combined with other antitumor therapies|SHR-A1811 combined with other antitumor therapies
224233278|NCT01157390|OTHER|Infant formula|Name: Infant formula with high proportion of palmitic acid in the sn-2 position Dosage \& frequency: Fed as need Duration: at least 3 months
223648076|NCT01318239|PROCEDURE|DCE MRI|"MRI and blood test(VEGFR2 signaling assay) will be undergoing at three time points in the patients with Avastin chemotherapy; at baseline (pretreatment), 3 days after Avastin alone treatment, 3 days after Avastin combined chemotherapy (about 10 days after initial Avastin alone treatment).~MRI and blood test(VEGFR2 signaling assay) will be undergoing at two time points in the patients who will get chemotherapy without antiangiogenic agent; at baseline (pretreatment), 3 days after chemotherapy."
223766371|NCT04928222|COMBINATION_PRODUCT|Doxorubicin-containing MNA|A 15 x 15 millimeter array containing 400 dissolvable microneedles delivering active agent
223766372|NCT04928222|DRUG|Placebo-containing MNA|A 15 15 x 15 millimeter array containing 400 dissolvable microneedles containing placebo
223766373|NCT06054672|DEVICE|Subthreshold Electrical stimulation|We will use a electrotherapy device to deliver subthreshold Electrical stimulation
223766374|NCT06043297|DRUG|Apixaban 5MG|Each film-coated tablet contains 5 mg apixaban
224233279|NCT01157390|OTHER|Breast feeding|Breast feeding
224233280|NCT00510510|DRUG|NVA237 100 µg|Dry powder inhalation once a day for up to 28 days
224233281|NCT00510510|DRUG|Placebo|Placebo to NVA237 dry powder inhalation once a day for up to 28 days
224233282|NCT00510510|DRUG|NVA237 200 µg|Dry powder inhalation once a day for up to 28 days
224320182|NCT03842319|OTHER|MedDiet|The high-intensity Mediterranean diet will include the promotion of the following: a) abundant use of olive oil (\>40 g/d) for cooking and dressing dishes; b) consumption of \>2 daily servings of vegetables; c) \>2-3 daily serving of fresh fruits; d) \>3 weekly servings of legumes; e) \>3 weekly servings of fish or seafood; f) \>1 weekly serving of nuts or seeds; g) select white meats instead of red meats or processed meats; and h) cook regularly with tomato, garlic and onion adding or no other aromatic herbs, and dress vegetables, pasta, rice and other dishes with tomato, garlic and onion adding or no other aromatic herbs. Two main meals per day should be eaten (seated at a table, lasting more than 20 minutes). A recommendation to drink a glass of wine per day during meals is given. Limited consumption is advised for cured ham, red meat, chocolate, cured or fatty cheeses
223648077|NCT03970317|DEVICE|Broad Band Light|Broad Band Light Device
223766375|NCT06043297|DRUG|Eliquis 5 mg|Each film-coated tablet contains 5 mg apixaban
223766376|NCT01728155|DRUG|chemotherapy|
224233283|NCT01938482|DRUG|0.3% GSK1940029 gel|Will be supplied as gel for topical application
224233284|NCT01938482|DRUG|1% GSK1940029 gel|Will be supplied as gel for topical application
224233285|NCT01938482|DRUG|0.3%/1% vehicle gel only|Will be supplied as gel for topical application
224233286|NCT03595657|BIOLOGICAL|CS1001|monoclonal antibody
224320183|NCT03573154|OTHER|administration of the liquid 1 and then the liquid 2|The patient will received the e-liquid 1 in the first visit and the e-liquid 2 in the second
224320184|NCT03573154|OTHER|administration of the liquid 2 and then the liquid 1|The patient will received the e-liquid 2 in the first visit and the e-liquid 1 in the second
224320185|NCT03054233|PROCEDURE|Crossed leg sitting position|Spinal anesthesia done in crossed leg sitting position
224320186|NCT05224128|DRUG|Imatinib 200mg|Imatinib have to be taken 200mg/day orally for 24 weeks in a seated position with a meal or a large (at least 250 mL) glass of water
223648078|NCT06318013|DIAGNOSTIC_TEST|vitality test|A vitality test will be performed using a vitalometer to check if the drowsiness is gone
223766377|NCT04140669|DEVICE|Automated Myocardial Performance Index (MPI)|Automated Myocardial Performance Index will be performed using Samsung HERA W10 prior too fetal surgical interventions, during surgery, and following surgery.
223766378|NCT04466514|DRUG|ASTX029|Form: tablet; Route of Administration: oral
223766379|NCT01014494|DEVICE|Adaprev|Class III Medical Device
223766380|NCT05108493|OTHER|Dry needling|Three sessions dry needling of lateral epicondyle region, once per week with disposable acupuncture needles (0.25x25mm).
223766381|NCT05108493|OTHER|Home exercise program|All participants will start the home exercise program during the study period consisting of range of motion exercises for wrist flexion, extension, ulnar and radial deviation, elbow flexion and extensor; forearm supinator, and pronator muscles; stretching exercises. Eccentric strengthening of the wrist flexor extensors, ulnar and radial deviation, forearm pronation, supination, and strengthening exercise training will be given to the elbow extensors and flexors. Progressive strengthening exercises will be added to the program. The exercise program will be terminated with stretching exercises. The exercises will be performed for 10 repetitions 2 times a day, stay in each position for 10 seconds, and rest for 30 seconds between periods. Both groups will be advised to continue the exercise program for 12 weeks.
223766382|NCT02320019|DRUG|Placebo|Placebo matching YH14618
223766383|NCT02320019|DRUG|YH14618|
223766384|NCT05206968|RADIATION|pelvic radiograph|Patients with hip involvement underwent a pelvic radiograph
224233287|NCT02294812|BEHAVIORAL|Cognitive training|"Participants will engage in eight weeks of training that focuses on improving various cognitive abilities. For example, short term memory.~Cognitive training will take place 30 minutes per day, five days per week, for eight weeks. Training will be done in the participant's own home using web-based software. Participants will be randomly assigned to either the active control group, the control cognitive training group, or the experimental cognitive training group following the second study visit.~After eight weeks, participants will no longer partake in training."
224233288|NCT00654264|PROCEDURE|Water immersion|Subjects will sit in tub for four hours.
224233289|NCT04790851|BIOLOGICAL|COVAX+IIV4; COVAX+PPV23|1st dose : combined vaccination of COVAX+IIV4; 2nd dose: combined vaccination of COVAX+PPV23
224233290|NCT04790851|BIOLOGICAL|COVAX only (1st and 2nd dose)|1st dose: COVAX only; 2nd dose: COVAX only
224233291|NCT04790851|BIOLOGICAL|IIV4 for the 1st dose and PPV23 for the 2nd dose|1st dose: IIV4 only; 2nd dose: PPV23 only
224233292|NCT00939445|PROCEDURE|Online HDF|Online HDF
224233293|NCT00939445|PROCEDURE|Short Daily Hemodialysis|Short Daily Hemodialysis
224233294|NCT06380946|BIOLOGICAL|iPRF|iPRF has been found to speed up OTM by stimulating the RANK/RANKL/OPG system to initiate osteoclast formation.
224233295|NCT01361126|BIOLOGICAL|Recombinant Coagulation Factor IX Albumin Fusion Protein|Study subjects will receive a single dose of 25IU/kg of rIX\_FP for pharmacokinetic analysis. Subjects will then be treated for approximately 5 months. The treatment dose will be based on the subject's PK profile and the subject's bleeding phenotype.
223648079|NCT04952948|OTHER|PILATES Training|During the PILATES sessions, the practitioner received orientations to to perform slow movements, aware, and combined with the respiratory cycle. The exercises program was performed on a soft ground covered with tatamis. During the program, a set of swiss balls of 45, 55, and 65 cm in size and elastic bands of very moderate resistance were used. Each exercise session was divided into 3 stages, namely (a) global initial static and dynamic stretching (10 minutes); (b) general conditioning (45 minutes) and; (c) relaxation (5 minutes). The amount of series and repetitions per set in exercises, in addition to the intensity required in each session in PILATES is presented in Table 2 of Melo et al. (2020) - Vide reference.
223648080|NCT00851058|BEHAVIORAL|Brief group counseling|Four group counseling sessions and six hours of direct observations of the emergency and trauma services in a busy urban hospital.
223648081|NCT00851058|BEHAVIORAL|Community Counseling|Four session of group counseling and six hours of guided observation of the emergency and trauma services at a busy urban hospital
223648082|NCT00851058|BEHAVIORAL|Prototypic community service|Two educational session on road safety and 16 hours of volunteering in a local not for profit community service.
223648083|NCT00851058|BEHAVIORAL|Prototypic community service|Four hours education about road safety and 16 hours volunteering at a local not for profit community service
223648084|NCT04445896|OTHER|Qualitative Interview|Qualitative Interview to explore thoughts and feelings related to previous discussions around care at end of life
223648085|NCT05542030|DIAGNOSTIC_TEST|EMR with CAD-Eye™|"Patients of group 1 undergoing Intervention 1 are subjected to an EMR with CAD-Eye™ to detect the remaining lesions immediately after the endoscopic procedure.~The suspected remaining lesions in the post-procedure defect detected with CAD-Eye™ are removed and sent to pathology to confirm the diagnosis."
223648086|NCT05542030|DIAGNOSTIC_TEST|EMR without CAD-Eye™|"Patients of group 2, undergoing intervention 2, subjected to an EMR alone. The immediate detection of remaining lesions is based on the visual impression of the expert.~The suspected remaining lesions in the post-procedure defect are removed and sent to pathology to confirm the diagnosis."
223648087|NCT05542030|DIAGNOSTIC_TEST|Follow-up colonoscopy with CAD-Eye™|"Patients undergoing Interventions 1 and 2, with a previous EMR, are assigned for a three-month follow-up using the CAD-Eye™ as a complementary procedure to detect remaining lesions.~For the detection of residual lesions, the colonoscope with the CAD-Eye™ assistance is used during the post-procedural scar evaluation. Suspicious lesions detected are removed and sent to pathology for final diagnosis."
223648088|NCT02749084|BIOLOGICAL|T reg DLI|"Purified Treg cells will be obtained from the original HSC donor (T reg DLI).~Tregs preparation will start with unstimulated donor leukapheresis from the original stem cell donor.~The apheresis product will be provided to the Cell Factory Calori,Milano, where T reg purification will take place.~T reg cells will be PURIFIED utilizing the CliniMACS Plus Systems for depletion of CD8 and CD19 positive cells and enrichment for CD25high cells.~Release Criteria of Treg cell preparation will be defined.~The product will be infused into the recipient through a venous catheter."
223648089|NCT00326430|BEHAVIORAL|Cognitive Therapy, Interpersonal Therapy|
223648090|NCT04922541|DRUG|PD-1 inhibitor|dosage form: intravenous injection; frequency: 2-3 weeks; duration: at least 3 months
223648091|NCT00000369|BEHAVIORAL|Individual psychotherapy|
223648092|NCT00000369|DRUG|Lithium carbonate|
223648093|NCT01039376|BIOLOGICAL|Ofatumumab|Ofatumumab for maintenance therapy as IV infusions every 8 weeks . The first dose was 300 mg followed 1 week later by 1000 mg and 1000 mg every 8 weeks thereafter for up to 2 years.
223648094|NCT01039376|OTHER|Observation|Observation/Safety Evaluation
223648095|NCT00753649|BIOLOGICAL|Infanrix™ hexa|Intramuscular, three doses
223766385|NCT03388073|OTHER|Berry extract I|Seabuckthorn berry proanthocyanidin extract 250 mg single dose
224233296|NCT00940368|DIETARY_SUPPLEMENT|Provision of capsules containing ginger powder or placebo|"The patients(children and adolescents) will be provided with Capsules containing either ginger powder or placebo on the three days when they receive chemotherapy.~For weight category 1(20-40kg),6 capsules are given in three divided doses and the amount of ginger powder administered per day is 1 gram.~For weight category 2(40-60kg), 5 capsules are given in three divided doses and the amount of ginger powder administered per day is 2 gram."
224233297|NCT02447900|DEVICE|BioXmark|
223648096|NCT03828071|PROCEDURE|Autologous hematopoietic stem cell transplantation|"Stem cell mobilization and collection: Peripheral blood stem cells were mobilized with cyclophosphamide (2.0 g/m2) for 2 days and granulocyte colony-stimulating factor (G-CSF) at 5-10 μg/kg per day was administered when the level of peripheral leucocytes was \< 1×109/L. Peripheral leukocyte counts were monitored, and harvesting was performed when the peripheral white blood cell level rebounded .~Conditioning and reinfusion of stem cells: The conditioning regimen consisted of intravenous cyclophosphamide (40 mg/kg/day × 4 days) 5 days before transplantation (a total dose 160 mg/kg) and rabbit antithymocyte globulin (ATG) (2.5mg/kg/day × 3 days) 4 days before transplantation. The dose of cyclophosphamide and ATG could be reduced according to the patients' condition."
223648097|NCT00120497|DRUG|somatropin (rDNA)|"Dosage form/strength: 13.8 mg powder in 2-chamber cartridge; reconstitutes to 10 mg/ml~Dosage regimen: 0.48 mg/kg/week~Route/rate of administration: subcutaneous injection, daily dose"
223766386|NCT03388073|OTHER|Berry Extract II|Seabuckthorn berry proanthocyanidin extract 500 mg single dose
223766387|NCT03388073|OTHER|Berry extract blend|Seabuckthorn berry blend with other berry-based antioxidants
223766388|NCT03388073|OTHER|Placebo|Placebo
223766389|NCT01557660|DRUG|inhaled treprostinil|0.6mg/mL inhalation solution, up to 12 breaths four times a day
223766390|NCT02885363|OTHER|Clinical examination|
223766391|NCT02885363|OTHER|Blood sample|
223766392|NCT02885363|PROCEDURE|Echocardiography|
223766393|NCT01260610|DRUG|Tenofovir|300 mg of Tenofovir daily
223766394|NCT01260610|DRUG|Telbivudine|600 mg of Telbivudine daily
224233298|NCT00624481|DRUG|Teriparatide|20ug subcutaneous injection daily for 24 weeks
224233299|NCT00624481|DRUG|Teriparatide Nasal Spray|teriparatide intranasally daily for 24 weeks
224233300|NCT00624481|DRUG|Teriparatide Nasal Spray|teriparatide intranasally daily for 24 weeks
224233301|NCT00624481|DRUG|Teriparatide Nasal Spray|teriparatide intranasally daily for 24 weeks
224233302|NCT00624481|DRUG|Teriparatide Nasal Spray|teriparatide intranasally daily for 24 weeks
224233303|NCT02593981|DIETARY_SUPPLEMENT|Fruit/Honey drink|2 canisters of powder containing fruit/honey mix to be mixed with water and ingested twice a day for 28 days
223766395|NCT01260610|DRUG|Tenofovir plus Telbivudine|Tenofovir (300 mg daily) plus Telbivudine (600 mg daily)
223766396|NCT05057676|BEHAVIORAL|Immediate Autoimmune Intervention Mastery Course (AIM)|Immediate access to an on line audio and video course with education about strategies to grow and improve resilience, diet quality, exercise, stress reduction and self-care
223766397|NCT05057676|BEHAVIORAL|Immediate Question and Answer sessions. (AIM Q and A sessions)|Immediate access to videos answering common questions about the course concepts. One video released each week, 7 videos total.
224233304|NCT02593981|DIETARY_SUPPLEMENT|Placebo|2 canisters of Placebo powder containing non-active ingredient to be mixed with water and ingested twice a day for 28 days
224233305|NCT03834675|DIAGNOSTIC_TEST|transpulmonary thermodilution|Thermodilution was attempted via PICC and via CICC
224233306|NCT06318858|DIETARY_SUPPLEMENT|Iron supplement|Group 1: 12.5 mg daily iron syrup supplementation from 6-9 months old
224233307|NCT05478993|DRUG|SPD：Selinexor Oral Tablet, Pomalidomide, Dexamethasone|"Patients diagnosed with multiple myeloma with CNS involvement to receive Selinexor (60 mg QW), pomalidomide (4 mg/day, on Days 1-21), and dexamethasone (40 mg/day, on Days 1, 8, 15, 22), with all agents dosed 28 days per cycle.~If patients reach maximum efficacy and have received SPD treatment for 8-12 cycles, maintenance treatment of Selinexor (20-60mg QW, optimal dose determined by the investigator) will be started and continued until disease progression or intolerable adverse events."
224233308|NCT00663871|DIETARY_SUPPLEMENT|Fish Oil|Participants will take 2 grams (1400 mg EPA and DHA) of fish oil supplements on a daily basis.
224233309|NCT00663871|DIETARY_SUPPLEMENT|Soybean Oil (Placebo)|Participants will take 2 grams of soybean oil supplements on a daily basis.
224233310|NCT03303638|BEHAVIORAL|Multi-sensory Environment|Multi-sensory environments (MSE), also known as Snoezelen® environments, are defined as behavioral environmental intervention to help people with cognitive and physical impairments reach sensory equilibrium. Typical elements within MSE include visual, auditory, tactile and olfactory stimuli, ergonomic vibro-acoustic furniture, bubble tubes, color-changing LED lighting solutions, music, fiber optics and aromatherapy.
224233311|NCT05655936|BEHAVIORAL|Heart Health Doula Intervention Program|The intervention group will be given a smart blood pressure cuff and a smart scale to monitor weight. The intervention group will receive support provided a postpartum doula until 8-12 weeks postpartum. The doula will provide individualized support during this time, and after 8-12 weeks, women will transition to a doula-moderated support group for the remainder of the study. The intervention group will continue to receive blood pressure and weight monitoring for the remainder of the study.
224233312|NCT05655936|BEHAVIORAL|Usual Care|Usual care includes enrollment into a clinical 6-week home-based blood pressure monitoring program with text messaging support which includes receiving a home blood pressure cuff. Women in the intervention group will be offered the same support as the usual care group, and in addition will receive the intervention and supplies.
224233313|NCT04094870|DRUG|Sertraline|daily SSRI (Sertraline 25mg)
224233314|NCT04094870|BEHAVIORAL|Interpersonal therapy|11 sessions over a 24-week period
224233315|NCT03384745|DRUG|M1095 (Sonelokimab)|M1095 (Sonelokimab) is a trivalent monomeric nanobody® that neutralizes interleukins IL-17A, IL-17F, and IL-17A/F.
224320187|NCT05224128|DRUG|Placebo|Capsules (similar appearance with imatinib) without active substance have to be taken orally for 24 weeks in a seated position with a meal or a large (at least 250 mL) glass of water
223648098|NCT06210217|DRUG|Dobutamine hydrochloride, Injectable|In the dobutamine group, 3\~6μg/kg/min dobutamine will be injected intravenously after anesthesia induction until hemostasis is completed. The dose of dobutamine will be increased if the operating field grade exceeds Grade II. Monitoring LVEDV and SV with TEE to ensure preload: after admission, the patient will be given 3-4 mL /kg/h equilibrium fluid as background infusion. LVEDV and SV will be monitored using TEE every 30 minutes after anesthesia induction. If LVEDV\<75mL or SV\<45mL, 200mL colloidal fluid will be given within 5min.
224233316|NCT03384745|DRUG|Placebo|Placebo contains no active drug.
224233317|NCT03384745|DRUG|Secukinumab|Secukinumab is a human immunoglobulin G1 (IgG1) monoclonal antibody that selectively binds IL-17A.
224233318|NCT03480828|DIAGNOSTIC_TEST|comparaison between DE and DTF in prediction of extubation success|diaphragm ultrasound and measurement of DE and DTF in patients meeting all extubation criteria during spontaneous breathing trial
224233319|NCT04263870|DRUG|sintilimab|oral capecitabine 1000mg per m2 bid d1-14, intravenous oxaliplatin 130mg d1 per m2, sintilimab 200mg (every 3 weeks)
224233320|NCT01798745|DRUG|JNJ-54452840|Once daily intravenous injection(s) (medication is injected into a vein) at doses ranging from 20 mg to 240 mg, given as a single injection (Cohorts A and B); injections given once daily over 3 to 5 days (Cohorts C, D, and F); or injections given once weekly up to Day 22 (Cohorts E and F).
224233321|NCT01798745|OTHER|Placebo|Once daily matching intravenous injection(s) (medication is injected into a vein) given as a single injection (Cohorts A and B); injections given once daily over 3 to 5 days (Cohorts C, D, and F); or injections given once weekly up to Day 22 (Cohorts E and F).
223648099|NCT06210217|DRUG|0.9% normal saline|In the control group, 3mL/h normal saline will be injected intravenously after anesthesia induction until hemostasis is completed. According to the currently commonly used principle of LCVP, the fluid will be limited to 3-4 ml /kg/h after anesthesia induction. If the operating field grade exceeds Grade II, nitroglycerin will be injected intravenously for remedial purposes at a rate of 0.3-0.8μg/kg/min.
223648100|NCT01678404|DRUG|131I-rituximab|
223648101|NCT04475302|BIOLOGICAL|BCG vaccine (Freeze-dried)|single dose of BCG vaccine (Freeze-dried) manufactured by Serum Institute of India, Pune. The composition of BCG vaccine is Live, attenuated BCG (Bacillus Calmette-Guerin Strain). (Each 1 ml contains between 2 x 106 and 8 x 106 Colony Forming Units (C.F.U.) with Diluent: Sodium Chloride Injection I.P.)
223648102|NCT06165315|BEHAVIORAL|Parenting program|Villages in the intervention group will receive the parenting program. The parenting program consists of 20 total sessions, whereby groups will meet twice a month for 10 months.
223648103|NCT05857475|DEVICE|CPAP therapy|Continous positive airway pressure therapy
223648104|NCT05857475|OTHER|Control|No CPAP
223766398|NCT05057676|BEHAVIORAL|Delayed Autoimmune Intervention Mastery Course (delayed AIM course)|Delayed access to an on line audio and video course with education about strategies to grow and improve resilience, diet quality, exercise, stress reduction and self-care
223766399|NCT05057676|BEHAVIORAL|Delayed AIM Question and Answer sessions|Delayed access to videos answering common questions about the course concepts. One video released each week, 7 videos total.
223766400|NCT04306224|BIOLOGICAL|IMC-002|IMC-002 blocks the interaction between CD47 and SIRPα.
224233322|NCT00669578|DRUG|CC-4047|CC-4047: taken orally each day in a 28 day cycle.
224233323|NCT01924390|DEVICE|Mineralized freeze-dried bone allograft alone|
224233324|NCT01924390|DEVICE|Combination of Mineralized and demineralized freeze-dried bone allograft alone|
224233325|NCT04695405|GENETIC|Saliva Genetic Samples|Patients will provide two saliva swabs containing genetic materials.
224233326|NCT01484821|DEVICE|ARFI|Muscle sonoelastography using ARFI(Acoustic Radiation Force Impulse) imaging
224233327|NCT02984683|DRUG|SAR566658 (ACT14884)|Pharmaceutical form:Solution Route of administration: Intravenous
224233328|NCT05960851|DRUG|LY3871801|Administered orally.
224233329|NCT05960851|DRUG|Placebo|Administered orally.
224233330|NCT02646345|PROCEDURE|Surgical checklist|Use of the World Health Organization Surgical checklist
224233331|NCT04050488|DRUG|Zinc Sulfate|At the age of 3 days or priming\> 20cc / kg body weight/day the research assistant will give a bottle of medicine containing zinc (according to the results of randomization) without knowing the contents either by the doctor or the room nurse.
224233332|NCT04050488|DRUG|Placebos|At the age of 3 days or priming\> 20cc / kg body weight/day the research assistant will give a bottle of medicine containing placebo (according to the results of randomization) without knowing the contents either by the doctor or the room nurse.
224233333|NCT01721525|DRUG|Afatinib, Ribavirin, and weekly carboplatin/paclitaxel|Patients will receive oral daily afatinib (days 1 - 21, per dose escalation scheme) plus daily oral ribavirin (days 1- 21) and paclitaxel (80 mg/m2 intravenously, days 1 and 8) + carboplatin (AUC 1.5 intravenously, days 1 and 8) of a 21-day cycle. Ribavirin will be administered according to standard weight-based dosing for this drug (1). Subjects ≤75 kg receive Ribavirin 400 mg PO qAM and 600 mg PO qPM (= 1000 mg/day). Subjects \> 75 kg receive Ribavirin 600 mg PO BID (=1200 mg/day). During the Dose Escalation portion of the study (Part 1), research bloodwork for pharmacokinetics is performed on days 1 and 8 of Cycle 1 only.
224233334|NCT02992405|BEHAVIORAL|FOCUS Resilience Enhancement Program|Each couple or family will have 10 weekly 75 minute sessions comprising the treatment protocol.Questionnaires will be administered at baseline-before the immediate treatment phase (T1) and after the 10-week treatment is completed (T2).
224233335|NCT02992405|BEHAVIORAL|Waitlist (No Study Treatment)|Participants assigned to the Waitlist (No Treatment) group will receive the study intervention only after the 10 weeks of the immediate treatment phase has been completed. Questionnaires will be administered at baseline-before the immediate treatment phase (T1) and after the immediate treatment phase is completed (T2).
224320188|NCT06632223|OTHER|Sensory motor training|Each session will be composed of 10 minutes of warm-up, followed by 50-60 minutes of sensory motor exercises, followed by 5-10 minutes of cool down.
224320189|NCT06632223|OTHER|Traditional physical therapy|traditional physical therapy program in form of stretching exercises, strengthening exercises, scar management, and gait training
223766401|NCT05390502|BEHAVIORAL|manual monitoring and general education on use|Patients will receive a standard blood pressure monitor and education on how to use it. Data will be reported as part of usual care.
223766402|NCT05390502|BEHAVIORAL|integrated monitoring and local wrap-around hypertension program|Patients will receive a standard blood pressure monitor and a local wrap-around hypertension program. Data will be sent directly to their participating health system.
223766403|NCT05757570|DRUG|povetacicept|Administered by subcutaneous injection every 4 weeks
223766404|NCT04261712|DRUG|Paltusotine|Paltusotine, once daily by mouth
224233336|NCT01394458|OTHER|30 % ethanol / 4% sodium citrate catheter locking solution|This solution is locked into the lumens of hemodialysis catheters between treatments to prevent infection and thrombosis. Before each dialysis session, the solution should be removed and discarded.
224233337|NCT01394458|DRUG|Heparin 1000 u / ml|In the control group, heparin 1000 u / ml will be locking into the hemodialysis catheters between treatments to prevent thrombosis. The heparin solution should be removed and discarded before each dialysis session.
224233338|NCT01877759|BIOLOGICAL|Mesenchymal stem cell|Intravenous dose of Mesenchymal stem cell derived from human Bone Marrow \& umbilical cord , IN 6 divided doses , at interval of 1 week .
224233339|NCT02742181|DRUG|Alvimopan|Subjects diagnosed with a post operative ileus after surgery will be given alvimopan
224233340|NCT02742181|OTHER|Control Group|Standard postoperative care
224233341|NCT01351142|OTHER|blood test and cognitive tests|Specific cognitive tests are performed at day 1, month 6, one year and 2 years Specific Blood samples tests are performed at inclusion, 1 years and 2 years
224233342|NCT00654485|DRUG|Rosuvastatin|
224233343|NCT00654485|DRUG|Atorvastatin|
224233344|NCT05764889|OTHER|wrapped with the Flexible Sleeve Penis Protection Device|"Patients in the experimental group were wrapped with the Flexible Sleeve Penis Protection Device post-operatively.~Patients in the control group were wrapped with traditional gauze post-operatively."
224320190|NCT04702243|DIAGNOSTIC_TEST|Genetic Testing for PCD or PID|Patients with high likelihood of a PID disorder or a high likelihood of PCD will initially undergo research genetic testing on a commercial approved panel for PID disorders or a panel of at least 37 PCD genes.
224320191|NCT04702243|OTHER|Unaffected Family Member Genetic Testing|Unaffected family members will undergo genetic testing if genetic findings are identified in their affected family member.
224320192|NCT01118065|DRUG|everolimus|
224320193|NCT03364946|OTHER|No intervention|No intervention, observational study
224320194|NCT02103504|DEVICE|DePuy Attune posterior stabilized fixed bearing total knee replacement|
223648105|NCT04490876|PROCEDURE|3D Pars Plana Vitrectomy associated with Extensive Brilliant Blue G-Assisted ILM Peeling Method|After the injection of Brilliant Blue-G (BBG) into the vitreous cavity, the epiretinal membrane (ERM) with cellular proliferation on the surface of the retina did not stain clearly, while the internal limiting membranes did stain clearly. We peeled off the internal limiting membrane (ILM) underlying the ERM using the ILM forceps for the macular area and the serrated forceps for the remaining ILM beyond the vascular arcades (Grieshaber, Alcon Laboratories, Inc., Fort Worth, Texas (Figure1) and enhanced membrane viewing with filters on the Ngenuity system. Restaining with BBG was needed and perfluorocarbon liquid PFCL was injected with a coaxial Dual Bore cannula (MedOne) to flatten the retina.
223648106|NCT03101332|BEHAVIORAL|Virtual Reality cognitive behavior therapy|"Cognitive interventions targeted to change catastrophic misinterpretations of the physiological symptoms that occur during a panic attack.~Exposure via Virtual Reality to filmed sequences of environments typically feared by agoraphobic patients such as underground station/train, a tunnel, a lift and a public square, as well as exposure to the feared symptoms that occur in a typical panic attack.~Interventions are delivered by a psychologist in face-to-face sessions."
223648107|NCT03108469|DRUG|IONIS-PKKRx (ISIS 546254)|Those randomized to IONIS-PKKRx (ISIS 546254) will receive subcutaneous injections containing 1.00 mL (200mg) of IONIS- PKKRx (ISIS 546254) weekly for weeks 1-16.
223648108|NCT03108469|OTHER|Placebo|Those randomized to placebo will receive subcutaneous injections 1.00 mL (200mg) weekly for weeks 1-16.
223648109|NCT00430404|OTHER|Collaborative care (Intervention)|Structured shared care with treatment protocol \& support
223648110|NCT01506804|OTHER|methylprednisolone|Steroid injection X 2 and 10 weeks exercise program of painful shoulder vs exercise program of contralateral shoulder
223648111|NCT00818701|DRUG|low dose Nesiritide|Nesiritide infusion 0.005ug/kg/min
223648112|NCT00818701|DRUG|nesiritide, Sildenafil|Nesiritide 0.005ug/kg/min Sildenafil 50 mg
223648113|NCT05793268|OTHER|Nuc Discontinuation|Eligible patients are randomly allocated with a 1:1 ratio to continue viral suppression or stop the treatment (entecavir or tenofovir). Patients will be followed up for 3 years. For patients who are assigned to the finite Nuc therapy, they should be monitored monthly for the initial 3 months and then every 3-6 months thereafter for relapse.
223648114|NCT05793268|DRUG|Entecavir or Tenofovir|Continuation of either entecavir or tenofovir treatment for 3 years
223648115|NCT03419923|DRUG|two stage regional citrate|4% trisodium citrate was infused at the arterial bubble trap at a rate according to the blood flow(3/4 x 1.2 x blood flow)ml/h,and at the venous bubble trap at a rate according to the blood flow(1/4 x 1.2 x blood flow)ml/h.
223648116|NCT03419923|DRUG|one stage regional citrate|4% trisodium citrate was infused at the arterial bubble trap at a rate according to the blood flow( 1.2 x blood flow)ml/h.
223648117|NCT00409552|BEHAVIORAL|Virtual Reality based distraction|Participants will undergo virtual reality based distraction using the head display while they go through the pain process.
223648118|NCT00409552|BEHAVIORAL|VR with flat projection display|VR with flat projection display
223648119|NCT00409552|BEHAVIORAL|non-interactive video with head display|non-interactive video with head display
223648120|NCT00409552|BEHAVIORAL|non-interactive video with with flat projection display|non-interactive video with with flat projection display
223648121|NCT01255436|OTHER|SMS text reminders|Patients in the intervention arm will receive 2 text messages per week delivered via SMS on randomly chosen days and times during the 12-week study period. The aims of the messages are to remind patients to take their blood pressure medications daily, what the target blood pressure is, and the benefits of daily intake of anti-hypertensive medications.
223648122|NCT01255436|OTHER|Usual Care|Patients in the usual care arm will receive the care usually provided by their physicians. This consists of consultations, medical advice, and prescriptions for maintenance medications. They will not be sent any SMS text reminders from the study.
223648123|NCT04816669|BIOLOGICAL|BNT162b2|Intramuscular injection
223648124|NCT01229267|BIOLOGICAL|V212|V212 viral antigen for HZ. Participants will receive consistency Lot 1, 2, or 3 or the High Antigen Lot.
223648125|NCT01229267|BIOLOGICAL|Matching placebo|Vaccine stabilizer for V212 with no virus antigen
223648126|NCT02901392|PROCEDURE|AMS-800|Artificial urianry sphincter
223648127|NCT02901392|PROCEDURE|ADVANCE/ADVANCEXP|Male sling
223648128|NCT02901392|PROCEDURE|VIRTUE|Male sling
224233345|NCT05764889|OTHER|wrapped with traditional gauze|"Patients in the experimental group were wrapped with the Flexible Sleeve Penis Protection Device post-operatively.~Patients in the control group were wrapped with traditional gauze post-operatively."
223648129|NCT02901392|PROCEDURE|INVANCE|Male sling
223648130|NCT01852409|DRUG|bevacizumab|
223648131|NCT03370900|OTHER|Testing|Participants either received 20 case testing with or without feedback
223648132|NCT02927561|OTHER|Diabetic Retinopathy screening|Diabetic Retinopathy screening
223648133|NCT04913935|DIAGNOSTIC_TEST|Muscle-Skeleton Ultrasonography|postero-anterior radiography
223648134|NCT03057483|BIOLOGICAL|Seasonal Influenza vaccine|Seasonal Influenza vaccine
223648135|NCT00919321|BIOLOGICAL|Pneumococcal polysaccharide vaccine (PPV)|One intramuscular injection
223648136|NCT00861562|DRUG|Imescard water smartweed composed pills|01 pill at every 8 hours for 5 days.
223648137|NCT00861562|DRUG|Placebo|01 pill at every 8 hours for 5 days, with the exact same appearance as the other intervention.
223648138|NCT00826462|DRUG|triamcinolone|Injection with triamcinolone 10 mg at start and at 3 weeks
223648139|NCT00826462|DRUG|Placebo|Injection with sodium chloride at start and at 3 weeks
223648140|NCT00826462|DRUG|Lidocaine|10 mg of lidocaine at start and at 3 weeks
223648141|NCT00826462|OTHER|Physiotherapy|12 treatments with deep friction massage, Mill's manipulation, soft tissue treatment and home exercises
223648142|NCT00826462|DRUG|Naproxen|Naproxen 500 mg bid for 14 days
223648143|NCT06521931|DRUG|PN20|Three dose cohorts: 0.2, 0.5 and 0.75 mg/kg, subcutaneous injections, on Day 1 of chemotherapy cycle before the administration of chemotherapy drugs
223648144|NCT06287099|DRUG|BRL-101|Subjects will receive a single infusion of BRL-101.
223648145|NCT03016494|DRUG|Co-administration of DWC20155 and DWC20156|
223648146|NCT03016494|DRUG|DWJ1386 Tab.|
224233346|NCT04240483|OTHER|Intracutaneous sterile water injections (ISWI) group|ISWI consists of 4 intracutaneous injections of 0.5 ml sterile water in the lumbosacral region while patient is in a seated position. One injection given at the posterior superior iliac spine (Point 1) on both sides and second injection at 1 cm medial, and 1-2 cm inferior to the first point on both the sides (Point 2) using an insulin needle. These points overlie the area called Michaelis' rhomboid.
224233347|NCT04240483|OTHER|Intracutaneous dry injections (IDI) group|Intracutaneous dry injections will be performed in the same manner described above, however, no sterile water or alternative solutions will be injected into the sites.
224233348|NCT05391399|DEVICE|Interlocking detachable coils system|Mainly used to block or slow blood flow in the peripheral vascular system during embolization procedures.
224233349|NCT05391399|DEVICE|Interlock Fibered IDC Occlusion System|Mainly used to block or slow blood flow in the peripheral vascular system during embolization procedures.
224233350|NCT04648059|DIAGNOSTIC_TEST|Blood sampling|Blood sampling will be performed to allow analyses of epigenetic markers
224233351|NCT06364800|BIOLOGICAL|γδ T cells|Cells will be extracted from a healthy donor by apheresis, followed by ex-vivo expansion and activation. The ex-vivo expanded γδ T cells from donors will be adoptively transfused.
224233352|NCT06364800|DRUG|PD-1 monoclonal antibody|Humanized programmed death receptor (PD-1) monoclonal antibody that binds to PD- and prevents binding of PD-1 with programed death ligands 1 (PD-L1) and PD-L2. It can function to activate cytotoxic T lymphocytes and inhibit tumor growth.
224233353|NCT06364800|DRUG|targeted drugs|Multi-target kinase inhibitors can act on VEGFR-1,VEGFR-2,VEGFR-3,FGFR1,PDGFR,cKit,Ret and other targets.
224233354|NCT05548933|PROCEDURE|non-surgical periodontal therapy|supragingival scaling,subgingival scaling
224233355|NCT02739984|BIOLOGICAL|Evolocumab|Administered by subcutaneous injection with an automated mini doser
224233356|NCT02739984|DRUG|Placebo to Evolocumab|Administered by subcutaneous injection with an automated mini doser
224233357|NCT05213078|OTHER|Educational Intervention|Receive teaching intervention
224233358|NCT05213078|OTHER|Quality-of-Life Assessment|Ancillary studies
223648147|NCT02955043|BEHAVIORAL|Behavioral techniques|"Improve nighttime sleep: Participants will receive a modified form of cognitive-behavioral therapy for insomnia with a primary focus on stimulus control, a set of techniques to strengthen the association between bed and sleep and weaken its association with stimulating behaviors.~Increase daytime activity: Participants will receive instruction in activity management strategies including prioritizing activities, planning activities during peak energy, activity pacing, and alternating between rest and activity. Participants will be provided with a basic step-count pedometer to enhance ability to self-monitor activity and increase motivation for activity.~The intervention will be adapted to individual needs based on assessments of sleep and activity patterns."
223648148|NCT00659737|DRUG|Aprepitant|40mg tablet
223648149|NCT00659737|DRUG|Scopolamine|1.5 mg patch delivering transdermally in vivo approx. 1.0mg over 3 days
223648150|NCT05876000|DEVICE|Corheart 6 Left Ventricular Assist System|Implantation of left ventricular assist device for mechanical circulatory support
223648151|NCT01081106|PROCEDURE|Low-Level Laser Therapy|"A LLLT device at 670 nm will be used for light application using lasers affixed in a rotating helmet apparatus. Treatment will be given twice weekly prior to commencing chemotherapy and will be administered once a week until one week after the last chemotherapy.~administration."
223648152|NCT01189409|DRUG|PEG then Senna|Stepped bowel protocol with PEG for 3 weeks followed by senna for 3 weeks. Both active treatments accompanied by placebo of alternate (lactose powder).
223648153|NCT01189409|DRUG|Senna then PEG|Stepped bowel protocol with senna for 3 weeks followed by PEG for 3 weeks. Both active treatments accompanied by placebo of alternate (lactose powder).
223648154|NCT00004366|PROCEDURE|Physical therapy|
223648155|NCT04579939|DIAGNOSTIC_TEST|Candy Glucose Tolerance Test|Participants will use a popular dextrose candy alternative to help assess glycemic response.
223648156|NCT04150848|BEHAVIORAL|Goal-Focused Emotion Regulation Therapy (GET)|Six sessions delivered individually over 8 weeks
223648157|NCT04150848|BEHAVIORAL|Individual Supportive Psychotherapy (ISP)|Six sessions delivered individually over 8 weeks
223648158|NCT02873494|DEVICE|PHYSIOFLOW - PF05 Lab1TM|
223648159|NCT03578952|DEVICE|TAVR with Evolut R valve|TAVR with Evolut R valve
223648160|NCT06441916|DRUG|Dabigatran Etexilate Capsules 150 mg|Dabigatran Etexilate
223648161|NCT04655352|DIETARY_SUPPLEMENT|Bacillus subtilis MB40|1-week placebo (maltodextrin and excipients) lead-in followed by 250 mg capsule (5 billion CFU/capsule) administered twice daily for 21 days
224233359|NCT05213078|OTHER|Questionnaire Administration|Ancillary studies
224233360|NCT06375928|PROCEDURE|Endoscopic biliary drainage|Decompression of the bile duct by endoscopic aproach.
224233361|NCT06375928|DEVICE|Self-expandable metallic stent (SEMS)|"Self-expandable metallic stent (SEMS) deployment:~* Covering: Uncovered or Partially Covered. Non covered if gallbladder is present.~* Size: 10x40mm or 10x60mm or 10x80mm."
223648162|NCT03498404|RADIATION|Photodynamic Therapy|After the sites are indicated for surgical therapy, they receive surgical access therapy associated with scaling and root planing and TfdA using the treatment protocol during periods of 0, 7, 14 and 30 postoperative days, or only surgical access therapy associated with scaling and root planing. As protocol, TfdA will be used laser light source 660nm wavelength in combination with phenothiazine, a photosensitizer with 10 seconds of exposure per site during surgery and 60 seconds in other applications.
224233362|NCT06375928|DEVICE|Lumen-apposing metal stent (LAMS) and double-pigtail plastic stent (DPPS)|"Lumen-apposing metal stent (LAMS) with coaxial double-pigtail plastic stent (DPPS) deployment:~* LAMS size: 6x8mm or 8x8mm. Consider 10x10mm if bile duct \> 18mm.~* DPPS size: 7Fr x 3-7cm."
224233363|NCT02233790|DRUG|Ticagrelor|a loading dose of 180mg pre-PCI, and then 90 mg twice daily for 1 Month within the study. Thereafter, the patients will take clopidogrel if Ticagrelor is not available on the market.
224233364|NCT02233790|DRUG|Clopidogrel|Clopidogrel 75 mg once daily after a loading dose of 300 mg pre-PCI.
223766405|NCT06399328|DIAGNOSTIC_TEST|Surface Enhanced Raman Spectroscopy|Spectral measurements of blood serum were performed on a silver nanoparticle substrate. Serum samples were collected and placed in sterile tubes with subsequent freezing at -18°C. Immediately before analysis, samples were thawed at room temperature. For spectral analysis, each 1.5 μL serum sample was applied to a substrate with a layer of silver nanoparticles and dried for 30 minutes. The spectral characteristics of serum were analyzed using an experimental bench consisting of a spectrometric system and a microscope (ADF U300, ADF, China). The spectra were excited in the near infrared range using a laser module with a center wavelength of 785 nm. Each of the obtained spectra represented a discrete set of 1700 parameters in the range of studied frequencies.
223766406|NCT03828305|OTHER|Training and creation of the Network-CPR|Training and creation of the Network-CPR that will cover the city. This network will be created with certain population groups that are routinely in contact with susceptible persons of OHCA (police, firemen, teaching staff, health personnel, merchants, pharmacists, university students, etc.), in addition, relatives of people with heart disease will be included. In the case of elderly people who are alone, they will include their neighbors or caregivers. In the city, there are 2,105 people with heart disease susceptible to OHCA. The research team and the health personnel of the participating primary care centers (PCC) will offer training courses on basic CPR maneuvers and use of the AED, following the protocol of the Center Català de Ressucitació (CCR). The training is aimed at training 430 people (20% of the relatives of people with heart disease) and will be made by trainers accredited by the CCR. There will be a total of 30 sessions with groups of approximately 15 people.
223648163|NCT03498404|OTHER|scaling and root planing|Scaling and root planing, also known as conventional periodontal therapy, or deep cleaning, is a procedure involving removal of dental plaque and calculus (scaling or debridement) and then smoothing, or planing, of the (exposed) surfaces of the roots, removing cementum or dentine that is impregnated with calculus, toxins, or microorganisms, the etiologic agents that cause inflammation. This helps to establish a periodontium that is in remission of periodontal disease. Periodontal scalers and periodontal curettes are some of the tools involved.
223648164|NCT00475956|DRUG|AZD2171|oral tablet multiple ascending doses 20, 30 or 45 mg
223648165|NCT00475956|DRUG|AZD0530|oral tablet multiple ascending doses 125 mg or 175 mg
223648166|NCT03181737|BEHAVIORAL|Covivio/Relaxio|Informations already included in arm/group descriptions.
223648167|NCT06001957|DIAGNOSTIC_TEST|Whole exome sequencing|"Bioinformatic analysis of raw WES data and variants prioritization were performed as previously described.~Reads were aligned to the hg38 reference genome sequence and visualized by Integrative Genomic Viewer."
223648168|NCT00859911|DIETARY_SUPPLEMENT|Multiple micronutrients|A tablet on three days a week containing: Vitamin A 1500 µg, Vitamin D 15 µg, Thiamine Mononitrate 1.22 mg, Riboflavin 1.7 mg, Ascorbic Acid 60 mg, Niacin amide 20 mg, Pyridoxine hydrochloride 2 mg, Folic Acid 400 µg, Calcium pantothenate 10.8 mg, Cyanocoblamin 6 µg, Vitamin E 18 IU, ferrous sulphate 19 mg, potassium iodide 145 µg, Potassium sulphate 11 mg, Manganese sulphate 0.38 mg, copper sulphate 0.509 mg, zinc sulphate 15 mg
223648169|NCT02291458|DRUG|L-arginine|9 gram L-arginine / day for 6 weeks
223648170|NCT02291458|DRUG|Placebo|9 gram placebo / day for 6 weeks
223648171|NCT05593068|PROCEDURE|MRI|Pancreatic MRI
223648172|NCT02238652|BEHAVIORAL|Communication|A preparation process before the patient become incapable of participating in life prolonging decisions
223648173|NCT02238652|BEHAVIORAL|Systematic Pain Assessment and Treatment|Assess pain with MOBID-2 Pain Scale and thereby improve pain management in dementia.
223648174|NCT02238652|BEHAVIORAL|Medication Review|An individual and systematic review of medication prescriptions to identify possible harmful drug effects and to reduce the use of psychotropic drugs.
223766407|NCT03828305|OTHER|Control Group|No intervention
223766408|NCT03721198|COMBINATION_PRODUCT|Acidulated phosphorous flouride|Acidulated phosphorous flouride is used to prevent white spot lesions
224320195|NCT02011477|OTHER|Neural Glide|This technique involves two movements, throughout several joints to glide the nerves. The subject sit on a couch with the right lower limb extended and the left lower limb flexed. The therapist will take the subject's head by putting his hands on the suboccipital and front region. In the initial movement, performe craniocervical flexion in the subject, while he helped with his right elbow to rectify the dorsal spine of the subject; at the same time, the subject performed dorsiflexion of the right ankle. In the final movement, the subject must increase thoracic kyphosis at the same time as performing plantarflexion in the right ankle; also, the therapist performed craniocervical extension in the subject
223648175|NCT02238652|BEHAVIORAL|Occupational therapy|Increase individual activities, based on function, personal interest and personality by educating the staff on these elements.
223648176|NCT02238652|BEHAVIORAL|Safety|Focusing on developing a culture where staff has an active and constant awareness of how to prevent adverse events and a commitment to safety.
223648177|NCT06109961|DRUG|Oxygen Gas for Inhalation|The active Hyperbaric Oxygen Therapy (HBOT) arm will receive 100% oxygen at 2.0-2.5 atmospheres (ATM).
223648178|NCT06109961|OTHER|Standard of care|The accepted standard of care for perianal Crohn's disease (PCD) involves conventional therapies such as immunosuppressive agents and biologics, which can be used to induce and maintain fistula remission.
223648179|NCT00737815|DIETARY_SUPPLEMENT|Magnesium Citrate: a total of 500 mg elemental magnesium|500 mg elemental magnesium
223648180|NCT00737815|OTHER|Placebo|Inactive placebo pill
223648181|NCT05305404|DRUG|Dexamethasone Oral|1.5mg oral dexamethasone to be administered once at 11:00PM
223648182|NCT05305404|DRUG|Placebo|oral placebo to be administered once at 11:00PM
223648183|NCT03408704|OTHER|ASP|"It consists of one educational session where doctors and staff at the center discuss current guidelines around management of patients attending for a sore throat. At the education the following is discussed:~1. The Swedish guidelines~2. Example of cases~3. Statistics from previous 6 month showing how well this clinic adheres to the Swedish guidelines."
223648184|NCT02506803|DRUG|NAC-GEMABR|NAC-GEMABR regimen includes gemcitabine 1000mg/m2 plus nab-paclitaxel 125mg/m2 3 times weekly 1week rest.
223648185|NCT05676021|BEHAVIORAL|motivational interview|motivational interview-based health education
223648186|NCT00163813|PROCEDURE|Early jejunal feeding (using frictional NJ tube)|
224233365|NCT04621942|OTHER|inertial rehabilitation|Inertial rehabilitation was performed twice a week (Monday and Thursday, between 5:00 and 8:00 PM) for 6 weeks using Cyklotren device (Inerion, Poland). Exercises were conducted by the same 2 researchers. Each training session included warm-up and 4 sets of shoulder ﬂexors, extensors, abductors, and adductors, with the right and left arms worked separately (16 sets for left and 16 sets for right arm). Each set lasted 15 seconds, a 2-minute break occurred between consecutive sets (without rest period between right and left arm). For all trained muscles 5 kg load was applied. During the training participants developed 70% of their maximal force achieved during the strength measurement. Participants observed developed during training force value displayed on-line on the screen. Cyklotren software allows to set the upper and lower limit of force; when developed strength was to low or to high a beep signal was emitted to correct participant force.
224233366|NCT04621942|OTHER|gymnastic rehabilitation|All women (from T and C group) participated in rehabilitation gymnastics twice a week during experiment (6 weeks). The gymnastics was conducted by a physiotherapist specializing in rehabilitation of women after mastectomy. The trehabilitation session lasted 45 minutes. During the sessions, the women mainly performed exercises involved shoulders, chest and the upper limbs muscles. Moreover, abdomen and back muscles were exercised.
224233367|NCT01760122|DRUG|Ypeginterferon alfa-2b|sc, qw, 48 weeks.
224233368|NCT01760122|DRUG|Pegasys|sc, qw, 48 weeks.
224320196|NCT02011477|OTHER|Neural stretching|In the start position, the subject was supine on a couch, with knees bent with the right leg above the left, and supported with the popliteal zone. Both hands were crossed over the chest. The therapist was on the subject´s side, with his knee below the subject's head, bringing stability. One hand was placed on the occipital, and the other hand was placed over the crossed hands of the subject
224320197|NCT01149408|DRUG|Decitabine (Dacogen)|Decitabine; 20 mg/m2; 1 hour intravenous infusion; 1 -3 days (will be given on a 28-day cycle for up to 18 months)
224320198|NCT00266539|DRUG|E-TRANS Fentanyl hydrochloride; Morphine|
224320199|NCT02686736|BEHAVIORAL|Internet-based educational intervention|The intervention will include four educational sessions about risky sexual behaviors and its prevention. The intervention will last one month (one session per week) followed by a three-month follow-up. Teens will be allowed to access to a weekly session at any time and as often as he/she likes.
224320200|NCT02140385|PROCEDURE|Abdominoplasty-Scarpa's fascia preservation|Thicker abdominal flaps will be preserved during the surgery.
224320201|NCT02140385|PROCEDURE|Abdominoplasty-Scarpa's fascia ablation|Thinner abdominal flaps will be preserved during surgery.
224320202|NCT02140385|DEVICE|Lymphoscintigraphy|Post-operative lymphatic imaging will be conducted using a common radiographic medium
223648187|NCT00163813|PROCEDURE|Standard feeding (using nasogastric [NG] tube)|
223648188|NCT04312659|DRUG|Infliximab|Participants will be observed who were treated with Infliximab.
223648189|NCT01305993|DRUG|SB injection|Infusion SBinjection of 21.87ml/m\^2, IV route, 24times for 4 months
223648190|NCT05326269|DRUG|Terbutaline|Subcutaneous injection
223648191|NCT05865119|DEVICE|OPTIMUS covered stent|The procedure involves placement of a long and large balloon-expandable covered stent in the superior vena cava that tunnels the abnormal pulmonary venous return to the left atrium.
224320203|NCT02140385|DEVICE|3D Imaging|Post-operative 3-dimensional photography will take place at a regularly scheduled clinic appointment.
224320204|NCT02140385|DEVICE|Abdominal ultrasound|Post-operative abdominal ultrasound will be used to determine the presence of fluid collections (seromas).
223648192|NCT05865119|PROCEDURE|Surgical correction of a SVD|Under cardiopulmonary bypass and open heart surgery, surgical correction of SVD either using single patch, double patch or Warden techniques
223648193|NCT05190497|DEVICE|Exercise group|Maximal respiratory pressure and reflecting muscles strength were measured by a mouth pressure meter
223648194|NCT01765972|DEVICE|etafilcon A with Lacreon|contact lens with Lacreon
223648195|NCT01765972|DEVICE|etafilcon A with Lacreon with print|contact lens with Lacreon and cosmetic print
223648196|NCT01765972|DEVICE|etafilcon A with print|contact lens with print
224320205|NCT06192056|BEHAVIORAL|RNT Focused Web- Based Self-Help Program|This 10 day long intervention contains psychoeducational contents, experimental exercises, monitoring behavior and committed action strategies. Each step of the intervention aims to develop a specific psychological flexibility skill like cognitive defusion etc.
224320206|NCT03581591|BIOLOGICAL|Burosumab|recombinant human IgG1 monoclonal antibody to fibroblast growth factor 23)
223648197|NCT01765972|DEVICE|Spectacles (habitual)|Spectacles
223648198|NCT03677453|OTHER|Interactive Perioperative Teaching Platform|An active video format will be used to provide instructions for navigating the hospital; describe induction of anesthesia and the surgical procedure; and provide post-surgery and post-discharge instructions for pain management.
223648199|NCT04326283|DRUG|Trametinib (0.5 mg)|0.5 mg/day
223648200|NCT04326283|DRUG|Trametinib (1 mg)|1 mg/day
223648201|NCT04326283|DRUG|Riluzole (100 mg)|100 mg/day (50 mg twice)
223648202|NCT01864603|OTHER|Universal ART in a streamlined care model|immediate ART start for all HIV+ in community with streamlined care
223648203|NCT01864603|OTHER|Annual Community Health Campaigns|HIV and multi-disease testing for all community members
223648204|NCT01864603|OTHER|Targeted PrEP and Targeted testing interventions|
223648205|NCT01864603|OTHER|Baseline community-based HIV and multi-disease testing|HIV and multi-disease testing for all community members at baseline only
223648206|NCT01956929|DRUG|Metformin|Metformin 1000mg daily for one week, then 2000 mg daily for the second week. 4 week washout period, then crossover to placebo.
223648207|NCT01956929|DRUG|Placebo|Placebo tablets for 2 weeks, then 4 weeks of washout period, then crossover to metformin.
223648208|NCT01107158|BIOLOGICAL|Whole blood sampling|Whole blood sampling for SNP polymorphism analysis
223648209|NCT01046838|DRUG|Sildenafil|40 mg three times daily for 9 weeks
223648210|NCT01046838|DRUG|Placebo|tablet 3 times daily for 9 weeks
223648211|NCT05113069|DRUG|SHR-A1912|SHR-A1912, dose escalation and expansion.
223648212|NCT01900717|DRUG|LV5FU2 simplified, FOLFOX 4 simplified, FOLFIRI modified|
223648213|NCT01900717|DRUG|LV5FU2 simplified,FOLFOX 4 simplified, FOLFIRI modified, Bevacizumab 5 mg/kg/ 2 weeks|
223648214|NCT02446899|BIOLOGICAL|Anifrolumab|Intravenous infusion (IV)
223648215|NCT02446899|DRUG|Placebo|Intravenous infusion (IV)
223648216|NCT03652285|DEVICE|Esophageal stent implantation|"An upper endoscopy will be performed with the use of fluoroscopy. Depending on the size of the stricture a dilation can be performed prior to the stent deployment. Otherwise, the stent will be deployed over a guidewire, under fluoroscopy.~After, the gastroscopy will go through the esophagus to check for the stent deployment, or any complications.~An injection of contrast agent will be done to be sure of the correct positioning and that no complications was happened.~The patient will be kept overnight, with liquid food for 3 days and under PPI until one month after the stent placement."
224233369|NCT05024071|DEVICE|Wushu athletes in the experimental group used a Swiss ball for 12 weeks of core strength training|"The experimental group was given 12 weeks of core strength training, divided into 6 types~1. Static action under steady state.~2. No load movement in steady state.~3. Static action under unstable state.~4. Movement to overcome its own resistance in an unstable state.~5. Free strength exercise in unstable state.~6. Core explosive power exercise under unstable conditions."
224233370|NCT05024071|DEVICE|Wushu athletes in the experimental group used a balance board for 12 weeks of core strength training|"The experimental group was given 12 weeks of core strength training, divided into 6 types~1. Static action under steady state.~2. No load movement in steady state.~3. Static action under unstable state.~4. Movement to overcome its own resistance in an unstable state.~5. Free strength exercise in unstable state.~6. Core explosive power exercise under unstable conditions."
224233371|NCT05781659|PROCEDURE|Ultrasound elastography guided pleural biopsy|The patients will undergo ultrasound elastography (Aixplorer V, SuperSonic Imagine, FRA) guided pleural biopsy.
224233372|NCT05781659|PROCEDURE|Traditional ultrasound guided pleural biopsy|The patients will undergo traditional ultrasound (Aixplorer V, SuperSonic Imagine, FRA) guided pleural biopsy.
224320207|NCT02842138|BIOLOGICAL|autologous anti-CD19 CAR T cells|Patients will receive a three-day regimen of chemotherapy consisting of fludarabine and cyclophosphamide aimed to deplete the lymphocytes. Four days after lymphodepletion, patients are intravenously infused autologous anti-CD19 CAR T cells. A prescribed CAR T cell dose will be intravenously infused to patient in a three-day split-dose regimen (day0,30%; day1, 30%; day2, 40%).
224320208|NCT05676814|DRUG|Pecto-intercostal Fascial Block (PIFB)|PIFB done with bupivacaine and epinephrine
223648217|NCT03652285|DEVICE|Stent removal|Six months after implantation, the removal of the stent will be performed. Patient will undergo a first endoscopy under general anesthesia for the placement of a FCSEMS. Then, depending on the importance of the hyperplasia, removal of both stents, under general anesthesia, will be done after 7 to 10 days.
223648218|NCT04259918|PROCEDURE|Alveolar recruitment maneuver|Applying 30 or 60 cmH2O of alveolar recruitment maneuver 5 times every 5 min at the end of bariatric surgery
223648219|NCT02192281|OTHER|Playworks|The Playworks program places full-time coaches in low-income schools to provide opportunities for organized play during recess and throughout the school day.
223648220|NCT04050202|BEHAVIORAL|Attachment and Biobehavioral Catch-up (ABC) Intervention|ABC is a 10 session, home-based, dyadic therapy that is delivered by a trained professional. The sessions focus on improving the parent-child relationship and children's biological and behavioral responses to stress.
223648221|NCT01615913|DRUG|3 mg terbinafine and 2 mg ketoconazole containing patch|A novel transdermal patch that is to be used to treat toenail onychomycosis with minimal body exposure to the antifungal drugs. The active substances in the patch are 3% terbinafine (contains 3-mg terbinafine/patch) and 2% ketoconazole (contains 2-mg ketoconazole/patch). The average daily released drug amount estimated from in-vitro skin permeation test were about 3.99 mcg for terbinafine and 1.70 mcg for ketoconazole, respectively.
223648222|NCT01615913|DRUG|6 mg terbinafine and 2 mg ketoconazole containing patch|A novel transdermal patch that is to be used to treat toenail onychomycosis with minimal body exposure to the antifungal drugs. The active substances in the patch are 6% terbinafine (contains 6-mg terbinafine/patch) and 2% ketoconazole (contains 2-mg ketoconazole/patch). The average daily released drug amount estimated from in-vitro skin permeation test were about 8.52 mcg for terbinafine and 2.03 mcg for ketoconazole, respectively.
223648223|NCT01615913|DRUG|8 mg terbinafine and 2 mg ketoconazole containing patch|A novel transdermal patch that is to be used to treat toenail onychomycosis with minimal body exposure to the antifungal drugs. The active substances in the patch are 8% terbinafine (contains 8-mg terbinafine/patch) and 2% ketoconazole (contains 2-mg ketoconazole/patch). The average daily released drug amount estimated from in-vitro skin permeation test were about 10.7 mcg for terbinafine and 2.17 mcg for ketoconazole, respectively.
223648224|NCT06522126|BEHAVIORAL|progressive relaxation exercise|One of the techniques employed to mitigate the prevalence of PMS complaints in women during this period is progressive relaxation exercises (PRE). It is one of the most preferred options due to its simplicity, cost-effectiveness, and reliability. Over the course of numerous years of research, progressive relaxation has been validated as an efficacious approach for regulating muscle tension. These exercises are performed to facilitate the distinction between tension and looseness in the body and to enable the individual to relax on her own in daily life. PRE involves the voluntary, systematic tension and relaxation of large muscle groups in the human body. PRE reduces anxiety levels by reducing muscle tension. It also provides the individual with a sense of profound rest, renewal, and rebirth.
223648225|NCT00908843|OTHER|Intravenous hydration with bicarbonate|Intravenous hydration with bicarbonate 1/6 M intravenous infusion (3ml/Kg/h) one hour before the administration of intravenous contrast
223648226|NCT00908843|OTHER|Oral hydration with Sodium solution|Oral hydration with Sodium solution (Casen solution of rehydration) in the 4 hours before of the intravenous contrast administration (75 ml/10 kg as equivalent to 0,25 g of sodium chloride /10 kg).
223648227|NCT05801341|DEVICE|Lollipop|An oral lollipop swab will be obtained by placing a flocked swab into the mouth and sucking on the swab for 20 seconds as one would suck on a lollipop
223648228|NCT00509483|RADIATION|Radioactive iodine|Radioactive iodine preceded by rhTSH
223766409|NCT03721198|OTHER|Resin modified glass ionomer varnish|Resin modified glass ionomer varnish is used to prevent white spot lesions
224320209|NCT05676814|DRUG|PIFB with adjuvants|PIFB with bupivacaine, epinephrine, clonidine, and dexamethasone
224320210|NCT02856438|DRUG|Elotuzumab|Specified dose on specified days
224320211|NCT02856438|DRUG|Lenalidomide|Specified dose on specified days
224320212|NCT02856438|DRUG|Dexamethasone|Specified dose on specified days
223648229|NCT04583774|OTHER|Prediction error tasks|The intervention involves two tasks, one that involves taste stimuli and another that involves monetary stimuli, and test their impact o brain response in electro encephalography (EEG) and functional magnetic resonance imaging (fMRI)
223648230|NCT04303676|OTHER|Virtual Practice Facilitation with e-Learning|"Virtual practice facilitation intervention using e-learning modules to guide the sessions includes:~a. Practice Facilitator (PF) conducts 7 monthly virtual visits with each practice QI team i. Optional: PFs and practices may choose to conduct virtual facilitation in groups of up to 5 practices simultaneously b. MAT training (combination of virtual academic detailing plus online training resource) plus ongoing support to deal with questions through email and/or office hours with our project staff, experts, with additional consultation if needed with an addiction medicine specialist.~c. Resources largely included as part of the e-learning module, but supplemented by online resource hub d. Centralized remote health information technology assistance, focused on implementation of registry functionality to track patients for population management and to report the measures required by AHRQ."
223766410|NCT04613297|OTHER|Baseline and during hospitalization blood samples|"Blood sample will be performed at the inclusion visit for all patient and for the hospitalized COVID-19 infected patients, extra-blood samples will be performed :~* at day 3~* day 5 and~* In case of aggravation~* At the discharge from hospital"
223766411|NCT04613297|OTHER|Baseline blood sample|Blood sample will be performed at the inclusion visit only
223648231|NCT04303676|OTHER|Virtual Practice Facilitation without e-Learning|"Virtual practice facilitation intervention without e-learning to guide the sessions includes:~a. Practice Facilitator (PF) conducts 7 monthly virtual visits with each practice QI team i. Optional: PFs and practices may choose to conduct virtual facilitation in groups of up to 5 practices simultaneously b. MAT training (virtual academic detailing) plus ongoing support to deal with questions through email and/or office hours with our project staff, experts, with additional consultation if needed with an addiction medicine specialist c. Online resource hub d. Centralized remote health information technology assistance, focused on implementation of registry functionality to track patients for population management and to report the measures required by AHRQ."
223648232|NCT04599413|OTHER|SURVEY|Pain survey on pianists
223648233|NCT01742117|DRUG|Clopidogrel|One 75 mg tablet per day by mouth for one year
223766412|NCT01978405|DRUG|Alpha lipoic acid|
223766413|NCT06518356|DEVICE|Transcutaneous Auricular Neurostimulation (tAN)|The intervention the investigators are studying is called transcutaneous auricular neurostimulation (tAN). tAN is simply electrical nerve stimulation administered at the ear which targets the auricular branch of the vagus nerve (ABVN) at the cymba conchae and mastoid process, and to a sham site (earlobe).
223766414|NCT04596878|BIOLOGICAL|GBS-NN/NN2|GBS-NN/NN2 bound to Alhydrogel as an adjuvant.
223766415|NCT04596878|BIOLOGICAL|Placebo|Normal Saline 0.9%
223648234|NCT01742117|DRUG|Ticagrelor|One 90 mg tablet twice per day by mouth for one year
223766416|NCT01010581|DRUG|SC12267 (4SC-101)|oral administration
223766417|NCT01010581|DRUG|Placebo|oral administration
223766418|NCT01010581|DRUG|Methotrexate|oral administration
223766419|NCT01010581|DRUG|Folic Acid|oral administration
223766420|NCT05109585|DIAGNOSTIC_TEST|assessment of the anti-SARS-CoV-2 IgG antibody titer in 3-dose schedule|evaluation of anti-SARS-CoV-2 IgG antibodies in patients after 2-dose vaccination schedule willing to receive a 3rd dose of vaccine
223766421|NCT05109585|DIAGNOSTIC_TEST|assessment of the anti-SARS-CoV-2 IgG antibody titer in 2-dose schedule|evaluation of anti-SARS-CoV-2 IgG antibodies in patients after 2-dose vaccination schedule unwilling to receive a 3rd dose of vaccine
224233373|NCT01499121|DRUG|Sunitinib|The starting dose will be 50 mg Sunitinib on the 28/14 schedule. In patients that develop ≥ grade-2 toxicity after 2 weeks, therapy will be held for 7 days or resolution before continuing therapy according to the 1st dose/schedule change. In patients that do not develop ≥ grade-2 toxicity, therapy will continue for 1-2 weeks or until ≥ grade-2 toxicity. In patients that develop \> grade-2 toxicity after less than 4 weeks, therapy will be held for 7 days or before continued according to the 1st dose/schedule change. Patients that do develop grade-2 toxicity (but no more) on the 50 mg 28/14 schedule, will remain on schedule but the time off therapy will be reduced to 7 days if toxicity has resolved after a 7-day break. Patients that develop ≤ grade-1 toxicity on the 50 mg 28/14 schedule, will be dose escalated according to protocol.
224233374|NCT05652621|DIETARY_SUPPLEMENT|probiotics|Resistant dextrin (water-soluble dietary fiber), Lactobacillus reuteri PLBK1, Luo Lactobacillus delbrueckii, Lactobacillus griffii PLBK3, Lactobacillus acidophilus PLBK4, Bifidobacterium lactis PLBK5）
223648235|NCT03925779|DRUG|Dexmedetomidine|dexmedetomidine sedation
223766422|NCT02694081|PROCEDURE|Uncut Roux-en-Y Reconstruction|All surgical procedures will be performed by the single surgery team ,which is leaded by professor Wang Quan. Uncut Roux-en-Y construction will be used in this group.
223766423|NCT02694081|PROCEDURE|Billroth II Reconstruction|All surgical procedures will be performed by the single surgery team ,which is leaded by professor Wang Quan. Uncut Roux-en-Y construction will be used in this group.
223766424|NCT05933434|BIOLOGICAL|Allogenic adipose derived mesenchymal stem cells (AD-MSC)|Laboratory isolated, cultivated and cryopreserved allogenic adipose derived mesenchymal stem cells (AD-MSC) from health donors undergoing cometic plastic surgery will be thawed on the injection day and formulated in 10 mL saline. The AD-MSCs will then be intraarticular injected using ultrasonic guidance.
223766425|NCT05933434|OTHER|Saline|10 mL saline will be intraarticular injected using ultrasonic guidance.
223766426|NCT01504334|DRUG|Pirfenidone|Pirfenidone（200mg）tablets will be taken 3 times a day during the whole study process. For the first week, 1 tablet will be taken each time. For the second week, 2 tablets will be taken each time. From the third week to the 48th week, 3 tablets will be taken each time. Base drug Acetyl Cysteine Tablets（600mg）will be taken once a day, 1 tablet each time from the first to the 48th week.
223766427|NCT01504334|DRUG|Placebo|Placebo（without active ingredient） tablets will be taken 3 times a day during the whole study process. For the first week, 1 tablet will be taken each time. For the second week, 2 tablets will be taken each time. From the third week to the 48th week, 3 tablets will be taken each time. Base drug Acetyl Cysteine Tablets（600mg）will be taken once a day, 1 tablet each time from the first to the 48th week for both groups.
223648236|NCT03925779|DRUG|Propofol|propofol sedation
223648237|NCT03925779|DRUG|Remifentanil|Remifentanil sedation
223648238|NCT04623853|DEVICE|Variable Stiffness AFO|The Dynamic AFO is able to adjust in stiffness depending on activity.
223766428|NCT00623883|PROCEDURE|Surgical removal of ACF|All ACF removed by either cold or hot colonoscopic biopsy forceps
224233375|NCT00564174|DRUG|Low molecular weight heparin and low dose aspirin|Fragmin 5000 IU/day by subcutaneous injection started at time of randomization and continued until 35 weeks gestation or delivery and low dose aspirin 81 mg/day started pre-conception and continued until 35 weeks gestation or delivery
224233376|NCT00564174|DRUG|Low dose aspirin|81 mg enteric coated started pre-pregnancy and discontinued at 35 weeks or delivery
224233377|NCT01015430|DRUG|Placebo (for RO4917523 ascending doses)|Placebo daily po
223648239|NCT00674713|OTHER|Acupuncture|
223648240|NCT00674713|DRUG|Ondansetron|
223648241|NCT00674713|DRUG|Physiological saline solution|
223648242|NCT00674713|OTHER|Sham acupuncture|
223648243|NCT00674713|DRUG|Ondansetron|
223648244|NCT00674713|OTHER|Acupuncture at P6 point|
223648245|NCT00674713|DRUG|Physiological saline solution|
223648246|NCT00674713|OTHER|Sham acupuncture|
223648247|NCT05733117|DRUG|Vitamin D|cholecalciferol
223648248|NCT00273494|PROCEDURE|Surgery|
223648249|NCT02730780|DIETARY_SUPPLEMENT|Low-Salt Diet|The low-salt diet (7 days) will consist of meals, snacks, and sodium free water provided by the study staff.
223648250|NCT02730780|DIETARY_SUPPLEMENT|High-Salt Diet|The high-salt diet (7 days) consists of each subject's usual diet, supplemented each day with 2 bouillon broth packets, which will be provided to the subject by the study staff.
223648251|NCT05540587|DRUG|Edoxaban|"Patients in the Edoxaban group take Edoxaban 60mg once daily. If any of the following conditions are present, take 30mg once daily.~* CrCl 15-50mL/min~* Body weight ≤ 60kg~* Concomitant use of P-glycoprotein inhibitor (Dronearone, Ciclosporine, Erythromycin or Ketoconazole)"
223648252|NCT05540587|DRUG|Warfarin|Patients in the Warfarin group take Warfarin 2-10mg once daily, dose adjusted with the target INR 2-3. In the elderly or frail patients, a lower dose administration is allowed at the discretion of the investigator.
223648253|NCT00673738|DRUG|Cetuximab|"* Cetuximab dose: based on patient's actual weight. Loading phase dose of cetuximab is 400 mg/m2 IV administered over 120 minutes, on day 1 followed by; Concurrent phase, weekly infusion dose at 250 mg/m2 IV over 60 minutes, on days 8, 15, 22, 29, 36, 43, 50.~* Radiation will be accompanied by weekly Cetuximab. Weekly Cetuximab will start on 1st day of radiation (Day 8). So, total number of cetuximab administrations will vary from 7 to 8. Patients will have every other week complete blood counts (CBCs), differentials, and blood urea nitrogen (BUN) plus creatinine and Mg. If patient's ANC drops below 1,000 and/or the platelet count below 75,000 during CTRT, the corresponding, weekly dose of cetuximab will be omitted."
223766429|NCT00623883|PROCEDURE|Colonoscopic evaluation only|Stain-enhanced magnification endoscopy performed, ACF quantified at entry and after one year
223766430|NCT03979365|DRUG|Envarsus XR|Twice daily tacrolimus vs. Envarsus XR
224233378|NCT01015430|DRUG|Placebo (for RO4917523 fixed dose)|Placebo daily po
224233379|NCT01015430|DRUG|RO4917523|RO4917523 ascending doses daily po
224233380|NCT01015430|DRUG|RO4917523|RO4917523 fixed dose daily po
224233381|NCT00003860|BIOLOGICAL|filgrastim|
224320213|NCT02437903|DEVICE|JUVÉDERM VOLUMA™ XC|Subjects will receive up to 4, 1mL syringes of JUVÉDERM VOLUMA™ XC for their initial injection and a maximum of 6, 1mL syringes of JUVÉDERM VOLUMA™ XC for the study. Subjects will undergo one touch-up injection approximately 2 weeks post initial treatment, and will continue to be evaluated at month 1, month 3, month 6, month 9, and month 12.
224233382|NCT00003860|DRUG|carboplatin|
224233383|NCT00003860|DRUG|etoposide|
224233384|NCT00003860|DRUG|ifosfamide|
224233385|NCT00003860|PROCEDURE|in vitro-treated peripheral blood stem cell transplantation|
224320214|NCT00002225|DRUG|Efavirenz|
223648254|NCT00673738|RADIATION|Conformal Thoracic Radiotherapy (CTRT)|"* Radiation will be accompanied by weekly Cetuximab. Weekly Cetuximab will start on 1st day of radiation (Day 8). So, total number of cetuximab administrations will vary from 7 to 8. Patients will have every other week CBCs, differentials, and BUN plus creatinine and Mg. If patient's ANC drops below 1,000 and/or the platelet count below 75,000 during CTRT, the corresponding, weekly dose of cetuximab will be omitted.~* Radiation therapy will begin on day 8 (with window of ± 3 days). Adequate hematologic profile (ANC \>1,000 and platelets \>75,000) required. Patient may be delayed for a max. of 2 weeks. If \> 2 week delay occurs, patient will come off study."
223648255|NCT02306902|DRUG|fenofibrate|130mg, Capsules
223648256|NCT02306902|DRUG|ANTARA® (fenofibrate)|130mg, Capsules
223648257|NCT02074410|DRUG|OMS643762|
223648258|NCT02074410|DRUG|Placebo|
223648259|NCT02705066|DIETARY_SUPPLEMENT|Citicoline supplement|
223648260|NCT02705066|DIETARY_SUPPLEMENT|Placebo supplement|Cellulose
223766431|NCT03979365|DRUG|Tacrolimus twice daily|Twice daily tacrolimus vs. Envarsus XR
223766432|NCT02473575|DIETARY_SUPPLEMENT|caffeine gum|Gum is consumed 30 minutes before commencement of run
223766433|NCT02473575|DIETARY_SUPPLEMENT|placebo gum|Gum is consumed 30 minutes before commencement of run
223766434|NCT03236844|DRUG|Gantenerumab|Gantenerumab HCLF manufactured by either G3 or G4 process will be administered on Day 1 (in the abdomen).
224233386|NCT05892757|DRUG|Atogepant|Oral Tablet
224233387|NCT05892757|DRUG|Ubrogepant|Oral Tablet
224233388|NCT04571723|BEHAVIORAL|Diabetes Prevention Program|This is the established Diabetes prevention program curriculum.
224233389|NCT04571723|BEHAVIORAL|Health Mindset modified diabetes prevention program|This is the established diabetes prevention program curriculum with the addition of curriculum focused on the role of mindset in health.
224233390|NCT00851045|DRUG|Irinotecan|Solution, IV, 180 mg/m2, Q14 days, Until PD
224233391|NCT00851045|DRUG|5-Fluorouracil (bolus)|Solution, IV, 400 mg/m2, Q14 days, Until PD
224233392|NCT00851045|DRUG|5-Fluorouracil (infusional)|Solution, IV, 2400 mg/m2, Q14 days, Until PD
224233393|NCT00851045|DRUG|Leucovorin calcium|Solution, IV, 400 mg/m2, Q14 days, Until PD
224233394|NCT00851045|DRUG|CT-322|Solution, IV, 2 mg/kg, Q7 days, Until PD
224233395|NCT00851045|DRUG|Bevacizumab|Solutions, IV, 5 mg/kg, Q14 days, Until PD
223648261|NCT05486624|OTHER|Reiki|Reiki, one of the complementary treatments, was applied by touching the chakra areas of the body by hand.
223648262|NCT01499277|DRUG|Ceftaroline fosamil|IV ceftaroline 600mg every 8 hours
223648263|NCT01499277|DRUG|Vancomycin|IV vancomycin 15mg/kg every 12 hours
223648264|NCT01499277|DRUG|Aztreonam|IV aztreonam 1 g every 8 hours
223648265|NCT02814552|OTHER|HTN PRA App|The HTN PRA App will be used to adjust standard of care medication dosages for high blood pressure drugs which may include: thiazide diuretic (water pill), usually called hydrochlorothiazide (HCTZ) or chlorthalidone, and an ACE inhibitor or an angiotensin receptor blocker.
223648266|NCT02814552|OTHER|Blood Sample|Blood sample for plasma renin activity activity will be obtained at least once (at baseline) and if BP is not controlled after 1-3 months, an additional blood sample may be obtained.
223648267|NCT03314129|BEHAVIORAL|UltimEyes|A computer program developed to improve contrast sensitivity and visual acuity.
223648268|NCT03314129|BEHAVIORAL|Contour Integration Training|A computerized program to improve contour integration (a form of perceptual organization).
223648269|NCT03314129|BEHAVIORAL|UltimEyes + Contour Integration Training|The combination of UltimEyes and Contour Integration Training
223648270|NCT03314129|BEHAVIORAL|MyBrainSolutions|A computer program consisting of exercises to improve cognition (attention, memory, planning) and to facilitate goal setting.
223766435|NCT05166122|DIAGNOSTIC_TEST|Artificial Intelligence|Introduction of digitized system with an AI tool to detect and intrepret the severity of diabetic retinopathy and presence of diabetic macular edema in screening for diabetes patients
223766436|NCT04377139|PROCEDURE|Prophylaxis|The intervention consists of analyzing the differences in the evolution of lung transplant recipients in relation to the intervention of prophylaxis or preemptive therapy against CMV in LTR
223766437|NCT04377139|PROCEDURE|Preemptive|The intervention consists of analyzing the differences in the evolution of lung transplant recipients in relation to the intervention of prophylaxis or preemptive therapy against CMV in LTR
223766438|NCT03457012|DRUG|Semaglutide|Patients will be treated with commercially available semaglutide in a prefilled pen injector (FlexTouch® variant) according to routine local clinical practice at the discretion of the treating physician. Other anti-hyperglycaemic treatments will be prescribed at the physician's discretion.
224233396|NCT00851045|DRUG|Bevacizumab Placebo (saline solution)|Solution, IV, 0 mg/kg, On day 8 of a 2-week cycle, Until PD
223766439|NCT00646204|DRUG|Memantine|10 mg bid
224233397|NCT00359229|DRUG|Zolpidem|Administration of Zolpidem 5mg
224233398|NCT00101972|BIOLOGICAL|monoclonal antibody RAV12|Escalating doses of RAV12 (weekly 0.3, 1.0, 1.5, 3.0, 4.0, 5.0, 6.0 mg/kg or 0.5 mg/kg BIW or TIW; 0.75 mg/kg BIW) for 4 weeks
224233399|NCT01880099|DRUG|placebo|placebo compared to 8mg of Galantamine
224233400|NCT01880099|DRUG|Galantamine 8mg|8mg of galantamine compared to placebo
224233401|NCT01880099|DRUG|Galantamine 16mg|16mg of galantamine compared to placebo
224233402|NCT00711503|DRUG|anakinra|The patients are instructed to administer anti-IL-1 therapy in the form of recombinant human non-glycosylated interleukin-1 receptor antagonist (IL-1Ra, anakinra, Kineret®, Amgen, CA, USA) \[13\] at a dose of 100 mg once daily by subcutaneous injection
223766440|NCT00646204|DRUG|placebo|2 tabs bid
223766441|NCT05892458|BEHAVIORAL|Abdominal massage|To perform abdominal massage, patients should keep their upper body in an upright or semi-decumbent position. Using their right four fingers or palm, they should apply pressure to the middle point of the lower margin of the right upper abdominal ribs, which corresponds to the opening of the gallbladder and common bile duct. The pressure should be firm, with a depth of approximately 3-4 cm and a length of 5-10 cm, and should be applied at least once a day for 10-15 minutes per session.
224233403|NCT00711503|DRUG|saline|The patients are instructed to administer placebo (saline) once daily by subcutaneous injection
224233404|NCT00955747|DRUG|Tagatose|powder; 15 grams three times daily; one year
224233405|NCT00955747|DRUG|Sugar Substitute Splenda|1.5 g powder tid
224233406|NCT05647083|OTHER|Massage therapy|Classical massage will be applied to the hands and feet, which is expected to take an average of 30 minutes.
223648271|NCT01423747|DRUG|VP16|patients with MSD receive as conditioning VP16 60mg/kg/d on day -3
223648272|NCT01423747|RADIATION|TBI|patients with a MSD receive TBI (12Gy in 6 fractions) as conditioning
224233407|NCT03623256|DRUG|Spinal fentanyl|25 mcg of fentanyl (0.5 mL) will be administered by intrathecal route.
224233408|NCT03623256|DRUG|Spinal bupivacaine|1.25 mg of preservative-free bupivacaine 0.25% (0.5 mL) will be administered by intrathecal route.
224233409|NCT03623256|DRUG|Spinal Fentanyl and Bupivacaine|1.25 mg of preservative-free bupivacaine 0.25% (0.5 mL), and 25 mcg of fentanyl (0.5 mL) will be administered by intrathecal route.
224233410|NCT03623256|DRUG|Epidural fentanyl /spinal bupivacaine|1.25 mg of preservative-free bupivacaine 0.25% (0.5 mL) will be administered by intrathecal route, and 100 mcg of fentanyl (2 mL) will be administered by epidural route.
224233411|NCT02610049|BEHAVIORAL|Cognitive Processing therapy|8 sessions of standard CPT from CPT manual developed by Dr. S Resick, Monson \& Chard (11/2010)
224233412|NCT02610049|BEHAVIORAL|Art + CPT|8 sessions of individual therapy of mixes techniques Art + CPT 8 sessions of standard CPT (same 8 as in control group) from manual developed by Dr.s Resick, Monson \& Chard (11/2010)
224233413|NCT02610049|BEHAVIORAL|CPT + Art Therapy|Subjects to complete 8 sessions of standard Cognitive Processing Therapy from manual developed by Dr. S. Resick, Monson \& Chard (1/2010) CPT + Art Therapy of mixed individual techniques
223648273|NCT01423747|DRUG|VP16, ATG|patients with a HLA matched unrelated Donor (9/10 oder 10/10) receive VP16 60mg/kg/d on day -3 and ATG fresenius 20mg/kg/d on day -3,-2,-1
223648274|NCT01423747|RADIATION|TBI|patients with a HLA matched unrelated Donor (9/10 oder 10/10) receive TBI (12Gy in 6 fractions)
223648275|NCT01423747|DRUG|Fludarabine, OKT3, Treosulfan, Thiotepa|patients with a MMD (haploidentical or cord blood) receive Fludarabine 30mg/m²/d on day -9 to -5, ATG 20mg/kd/d on day -3 to day -1, Treosulfan 14g/m²/d on day -7 to -5 and Thiotepa 2x5mg/kg/d on day -4
224233414|NCT01909583|OTHER|STAGES-Booklet|STAGES-booklet was designed by the investigators focussing on guiding parents through the pre-operative and operative admission period.
224233415|NCT03562403|DEVICE|Deep Brain Stimulation|stimulation of different basal ganglionic nuclei by a inserting a device
224320215|NCT00002225|DRUG|Stavudine|
223648276|NCT01423747|DRUG|VP16, ATG|patients with MMD-transplantation (8/10)receive VP16 60mg/kg/d on day -4, ATG from day -3 to day-1 20mg/kg/d
223648277|NCT01423747|RADIATION|TBI|patients with a MMD-transplantation (8/10) receive 12 Gy in 6 fractions
223648278|NCT01713101|DRUG|Early intravenous tranexamic acid administration|Initial history taking and physical examination --\> enrollment --\> 1g bolus over 10 minutes followed slow infusion over 8 hours.
223648279|NCT01713101|DRUG|placebo|
223648280|NCT01627730|OTHER|pretest and posttest scores|pretest and post-test scores are calculated for relative growth scores
223648281|NCT04195373|BIOLOGICAL|TMV-018 + 5-FC|"TMV-018: liquid frozen, life attenuated, oncolytic measles virus encoding the prodrug converting enzyme super cytosine deaminase; 1E+06 TCID50 to 1E+08 TCID50 per dose.~5-FC: 150 mg/kg/day for 2 days during each treatment."
224233416|NCT03349606|DRUG|d-amphetamine|oral d- amphetamine 0.5 mg/kg is used to stimulate dopamine release in the brain
224233417|NCT03349606|RADIATION|[C-11]FLB 457|PET radiotracer
224233418|NCT04288596|OTHER|Participants undergoing ACHD intervention|Participants will receive standard of care for their ACHD intervention.
224233419|NCT00539539|OTHER|Laerdal Q-CPR /technology|For the first three to six months, participating EMS agencies will have defibrillators with automated, real-time feedback inactivated. During this period, the baseline rate of ROSC (and secondary outcomes) will be collected. At the end of this baseline period, EMS agencies will be randomized to one of two interventions, with randomization stratified within site by agency, station, or device. All clusters will cross-over to the opposite feedback strategy at least once during the intervention phase.
224233420|NCT00634179|DRUG|Bortezomib|Bortezomib 1.6 mg/m² given on days 1 and 8
224233421|NCT00634179|BIOLOGICAL|Rituximab|Rituximab 375 mg/m²
224233422|NCT00634179|DRUG|Doxorubicin|Doxorubicin 50 mg/m²
224233423|NCT00634179|DRUG|Cyclophosphamide|Cyclophosphamide 750 mg/m²
224233424|NCT00634179|DRUG|Vincristine|Vincristine 1.4 mg/m² (capped at 1.5 mg maximum) given on day 1
224233425|NCT00634179|DRUG|Prednisone|Prednisone 100 mg/day given orally on days 1-5
224233426|NCT03427957|DIAGNOSTIC_TEST|Endometrial biopsy with the new hysteroscopic grasper with knurled terminal end and cutting jaws|Hysteroscopic endometrial biopsy performed through the new grasper with knurled terminal end and cutting jaws.
223648282|NCT04195373|BIOLOGICAL|TMV-018 + anti-PD-1|"TMV-018: liquid frozen, life attenuated, oncolytic measles virus encoding the prodrug converting enzyme super cytosine deaminase; 1E+06 TCID50 to 1E+08 TCID50 per dose.~Anti-PD-1 inhibitor dose according to its SMPC."
223648283|NCT04195373|BIOLOGICAL|TMV-018 + 5-FC + anti-PD-1|"TMV-018: liquid frozen, life attenuated, oncolytic measles virus encoding the prodrug converting enzyme super cytosine deaminase; 1E+06 TCID50 to 1E+08 TCID50 per dose.~5-FC: 150 mg/kg/day for 2 days during each treatment cycle.~Anti-PD-1 Inhibitor: dose according to its SMPC."
224233427|NCT03427957|DIAGNOSTIC_TEST|Endometrial biopsy with the hysteroscopic spoon grasper|Hysteroscopic endometrial biopsy performed through the spoon grasper.
224233428|NCT03427957|DIAGNOSTIC_TEST|Endometrial biopsy with the hysteroscopic alligator grasper|Hysteroscopic endometrial biopsy performed through the alligator grasper.
224233429|NCT05571709|OTHER|Exercise training|Resistance training of the lower limbs
224233430|NCT05571709|BEHAVIORAL|Questionnaire|Physical activity questionnaire
224233431|NCT05571709|PROCEDURE|Percutaneous muscle biopsy|Muscle biopsy of the vastus lateralis (m. quadriceps)
223648284|NCT06325592|PROCEDURE|surgical timing and operation path|surgical timing; laparoscopic hysterectomy or abdominal hysterectomy
223648285|NCT05118659|PROCEDURE|sustained natural apophyseal glides|It consists on a sustained apophyseal glides in a postero-anterior direction on C2 with a dose of three series of ten repetitions each
223648286|NCT05118659|PROCEDURE|SHAM SNAG|Subjects on SNAG group received a simulation of the contact used for the SNAGs, without any vertebral glide, and with an active cervical extension
223648287|NCT00605787|DRUG|Tetradecylthioacetic acid (TTA)|1000mg capsules once daily for 28 days
223648288|NCT03493217|DRUG|ICP-022|The drug product is a white, round, uncoated tablet.
223648289|NCT00779350|DRUG|sertraline 100 mg tablets|
223648290|NCT05593978|BEHAVIORAL|Culinary Medicine|The CM-group will receive weekly cooking demonstrations and education videos via electronic links for 16 weeks, and three nutrition education based on the content of the Nutrition Care Manual from the Academy of Nutrition and Dietetics to show age-appropriate recipes with correct preparation methods and different cooking methods for lean ground red meat to increase protein consumption.
223648291|NCT05593978|BEHAVIORAL|Control|The CN-group will receive weekly recipes via electronic links without the culinary medicine intervention.
223766442|NCT04527081|BIOLOGICAL|AG0302-COVID19|2.0 mg of AG0302-COVID19 twice at 2-week intervals
223766443|NCT04527081|BIOLOGICAL|AG0302-COVID19|2.0 mg of AG0302-COVID19 twice at 4-week intervals
223766444|NCT04527081|BIOLOGICAL|AG0302-COVID19|2.0 mg of AG0302-COVID19 three times at 2-week intervals
224233432|NCT05571709|PROCEDURE|Blood sample|Venous blood sample
224233433|NCT01858714|BEHAVIORAL|Behavior Therapy for Weight Loss|Standard behavioral treatment for weight loss and weight loss maintenance.
224233434|NCT01858714|BEHAVIORAL|Behavior Therapy + Environment|Standard behavioral therapy with an emphasis on environmental strategies.
224233435|NCT01858714|BEHAVIORAL|Acceptance-based Behavior Therapy + Environment|Behavioral therapy with acceptance-based and environmental strategies.
224233436|NCT01261481|DRUG|Tolvaptan|Tolvaptan 15 mg administered once orally as an intact tablet.
224233437|NCT01261481|DRUG|Tolvaptan|Tolvaptan 15 mg administered once via nasogastric tube.
224233438|NCT04784481|DRUG|Ivermectin|Experimental Group received Ivermectin orally 4 tablets of 6 mg = 24 mg every 7 days for 4 weeks.
224233439|NCT02231320|DRUG|Berodual® Respimat® - inhaler|
224233440|NCT03419195|OTHER|Cardiovascular exercise training|Following the completion of baseline testing, both subject groups will undergo supervised cardiovascular exercise training 3 times per week for 3 months (plus a 3 week ramp-up). Exercise training will take place on a treadmill, stationary bicycle, elliptical, rowing machine, or combination of machines. Each session will last 1 hour, which includes a 5 minute warm-up, 50 minutes of exercise, and a 5 minute cool down.
224320216|NCT00002225|DRUG|Didanosine|
223648292|NCT03585751|PROCEDURE|Pulpectomy for primary molars + triple antibiotic mix|complete extirpation of infected pulp from primary molars. Following instrumentation and copious irrigation ,the root canals are filled with one of .Following instrumentation and copious irrigation ,the root canals are filled with a triple antibiotic mix mixed with a Carrier ( MP) as an obturating material
223648293|NCT03585751|PROCEDURE|Pulpectomy for primary molars + 3mixstatin|complete extirpation of infected pulp from primary molars. Following instrumentation and copious irrigation ,the root canals are filled with one of .Following instrumentation and copious irrigation ,the root canals are filled with 3mixstatin (triple antibiotic mix + simvastatin) as an obturating material mixed with a Carrier ( MP) as an obturating material
223648294|NCT03585751|PROCEDURE|Pulpectomy for primary molars + simvastatin|complete extirpation of infected pulp from primary molars. Following instrumentation and copious irrigation ,the root canals are filled with simvastatin as mixed with a Carrier ( MP) as an obturating material
223648295|NCT05283941|DIETARY_SUPPLEMENT|Pistachio Group|Consumption of 2-ounce packs of pistachio nuts, daily, for 12 weeks.
223648296|NCT00811915|DRUG|Sirolimus|"Sirolimus introduction and tacrolimus withdrawal~Tacrolimus : 33 % decrease of daily dose with complete withdrawal at day 14. Sirolimus daily dose according to CYP3A5 genotype CYP3A5\*1/\*1 or \*1/\*3: 4 mg/d CYPY3A5\*3/\*3 : sirolimus 2 mg/j Adjusted to obtain a trough level between 6 and10 ng/ml"
223648297|NCT06514768|BIOLOGICAL|JY231|Infusion of JY231 Injection by dose of 1-10×10\^6 Transduction Units(TU)/ kg、1-5×10\^7 TU/kg、5-10 ×10\^7 TU/kg. Administration method: intravenous infusion、Splenic artery infusion、Lymph node infusion; Subjects will be treated with Fludarabine and Cyclophosphamide before cell infusion (PI evaluation is required)
224233441|NCT04654403|DRUG|Camrelizumab|Eligible patients receive Camrelizumab 200 mg by intravenous (iv.) infusion every 2 weeks (Q2W) for 4 cycles.Imaging will be performed 2-3 weeks after the 4th Camrelizumab administration.Patients who achieve PD and SD will be not included in the data statistics of this trial.The follow-up treatment according to investigator's and patients's choice(chemotherapy, Camrelizumab plus chemotherapy or Camrelizumab monotherapy).Other patients whose BOR is in remission (CR+PR) will be randomly assigned in a 1:1 ratio to receive Camrelizumab (200 mg every 2 weeks), or Camrelizumab plus chemotherapy(Camrelizumab 200 mg every 3 weeks,docetaxel 75mg/m2/d plus cisplatin 75 mg/m2/d on day 1 every 3 weeks),)Treatment will continue until confirmed radiographic progression,unacceptable toxicity, investigator or patient decision to withdraw, nonadherence to treatment or trial procedures or completion of 16 cycles of Camrelizumab (approximately 1 years).
224233442|NCT02627027|DRUG|Duvie Tab. 0.5mg, Glucodaun OR Tab. 750mg|oral administration
224233443|NCT02627027|DRUG|CKD-395 0.25/750mg|oral administration
224233444|NCT03441542|BEHAVIORAL|Data-assisted Case Navigation|"The researchers will develop a monthly task list for the patient navigator with patient by patient care cascade and treatment milestones that need to be accomplished per patient in the case group. The researchers will deliver the spreadsheet and the task list to the Grady Liver Clinic Director who will use it to direct and supervise the activities of the patient navigator.~Patient navigators will be responsible for reaching out to patients in only the intervention arm about their next step in the HCV care cascade."
223648298|NCT00604799|DEVICE|Talent Thoracic Stent Graft|TEVAR
223648299|NCT02532738|DRUG|Routine Treatment of CD|The Drug including 6MP, AZA, infliximab and thalidomide
223648300|NCT02532738|BIOLOGICAL|MSC treatment 01|Injection of 3×10E6/kg of MSC
223648301|NCT02532738|BIOLOGICAL|MSC treatment 02|Injection of 6×10E6/kg of MSC
223648302|NCT02532738|OTHER|NS|Injection of NS
223648303|NCT06016777|PROCEDURE|Ultrasound-guided paraspinal block and patient-controlled intravenous analgesia pump|Patients in this group will receive ultrasound-guided paraspinal block with 0.3% ropivacaine and 5mg dexamethasone in total of 20mL saline at T5 level on the operative side. Patients in all the groups will be treated with PCIA after surgery. PCIA with sufentanil will be applied to all participants, with background infusion at 1.8μg/hour, and total dosage \<5μg/hour.
223648304|NCT06016777|PROCEDURE|Ultrasound-guided erector spinal block and patient-controlled intravenous analgesia pump|Patients in this group will receive ultrasound-guided erector spinal block with 0.3% ropivacaine and 5mg dexamethasone in total of 20mL saline at T5 level on the operative side. Patients in all the groups will be treated with PCIA after surgery. PCIA with sufentanil will be applied to all participants, with background infusion at 1.8μg/hour, and total dosage \<5μg/hour.
223648305|NCT06016777|PROCEDURE|Patient-controlled intravenous analgesia pump|Patients in this group will not receive regional block. Patients in all the groups will be treated with PCIA after surgery. PCIA with sufentanil will be applied to all participants, with background infusion at 1.8μg/hour, and total dosage \<5μg/hour.
223648306|NCT03588585|PROCEDURE|Tension|Tension applied to catheter and taped firmly to leg.
223648307|NCT03588585|PROCEDURE|NO TENSION|Foley balloon will be taped loosely to the leg and not placed on tension. All other care will remain the same
223648308|NCT02980393|BEHAVIORAL|Lifestyle intervention|The structured lifestyle intervention involves alternating weekly phone calls with two health coaches: a registered dietitian and a fitness specialist. A total of 50 phone calls (25 nutrition-related and 25 physical activity-related) are delivered over the one-year study. After six months in the program, participants are introduced to supporting program-specific software that they can access online, as an additional way to interact with the program, set goals, and record their progress. Client and family-centred nutrition and physical activity counselling includes an initial and regular behavioural assessment, and subsequent conversations (i.e., phone calls) using motivational interviewing techniques intended to increase knowledge or skills, and improve behaviours.
223648309|NCT00946621|DRUG|Ramipril 10 mg Capsule (Sandoz)|
223648310|NCT00946621|DRUG|Altace (Ramipril) 10 mg Capsule (Aventis Pharmaceutical)|
223648311|NCT05008965|BIOLOGICAL|FB825|A humanized monoclonal immunoglobulin G1 (IgG1) targeting the CεmX domain on human B lymphocytic cells expressing membrane-bound IgE (mIgE).
223648312|NCT05008965|OTHER|Placebo|Formulation buffer
223648313|NCT02974543|DEVICE|Sham Treatment: unimodal auditory stimulation|All subjects will be told they will receive either Sham or Active Treatment, but will not know which treatment is assigned. Set up for the sham treatment is the same as the active treatment.
224233445|NCT03441542|BEHAVIORAL|Standard of Care|Patients will be recruited into the study by the patient navigator, be provided information about HCV infection, and will be informed that treatment is freely available should they seek it. Patients will also be provided contact and address information for the treatment clinic.
223648314|NCT02974543|DEVICE|Active Treatment: Bimodal auditory-somatosensory stimulation|"Somatosensory stimulation will be delivered by pads positioned on the cheek overlying the trigeminal ganglion, the juncture of the temporomandibular joint or on the neck at overlying cervical nerves, c1 or c2, determined by the manner in which the subject can modulate the tinnitus.~The auditory stimulus will be individualized based on subject baseline audiogram and tinnitus test results and is presented through a calibrated earphone."
223648315|NCT02804152|BEHAVIORAL|CBT for Chronic Pain in Pregnancy|"The content will be included in 8 weekly sessions, i.e., sessions 1-3 (Education on chronic pain, Theories of pain and diaphragmatic breathing and Progressive muscle relaxation and visual imagery), sessions 4 and 5 (Automatic thoughts and pain and Cognitive restructuring), sessions 7, 8 and 10 (Pleasant activity scheduling, Time-based pacing and Sleep hygiene), sessions 6 and 9 (Stress management and Anger management). Following this content, 1-2 sessions will be dedicated to review and reinforcement of key concepts or addressing any stuck points as well as cover content in session 11 (Relapse Prevention). The last session of therapy would include a review of achievements and commitment to continued application of CBT for chronic pain in participants daily lives."
223648316|NCT00742235|DRUG|ergocalciferol|Ergocalciferol 50,000 IU given every other day for 5 total doses
223648317|NCT03079843|OTHER|exposure to particulate matter with N 95 facemask|2 hours' / day exposure to particulate matter face mask worn during exposure.
223648318|NCT03079843|OTHER|exposure to particulate matter with no face mask|2 hours'/ day exposure to particulate matter with no face mask
223648319|NCT04509661|DRUG|LABA/LAMA or Placebo inhalation|Inhaled LABA/LAMA for one year.
223648320|NCT06437743|DEVICE|Nociception Level (NoL) Monitor|The NoL Monitor (PMD-200) is a multi-parameter sensor device placed on the patient's finger to estimate nociception levels during surgery. It provides continuous, real-time feedback to the anesthesiologist on the patient's nociception, assisting in the optimization of analgesic drug administration. The monitor integrates parameters such as heart rate variability, skin conductance, and other physiological signals to compute the NoL index, which ranges from 0 to 100, with target values between 10 and 25 for optimal nociception management.
223648321|NCT00133003|DRUG|Abciximab|0.25 mg/kg of body weight bolus, followed by a 0.125-microg/kg per minute \[maximum, 10 microg/min\] infusion for 12 hours, plus heparin, 70 U/kg of body weight
223648322|NCT00133003|DRUG|Placebo|Placebo consist of placebo bolus and infusion of 12 hours (NaCl 0.9%), plus heparin bolus, 140 U/kg of body weight
223648323|NCT05459844|DRUG|Lutetium[177Lu] Oxodotreotide Injection|Four administrations of 7.4 GBq (200 mCi) Lutetium\[177Lu\] Oxodotreotide Injection administered at 8 +/- 1-week intervals, which could be extended up to 16 weeks to accommodate resolving acute toxicity.
223648324|NCT05459844|DRUG|Octreotide LAR|60 mg Octreotide LAR treatment was given to the participants every 4 weeks (i.m. injections) until the end of the study, unless the participant progressed or died.
223648325|NCT01237899|DRUG|LY2623091|Administered orally.
223648326|NCT01237899|DRUG|Placebo|Administered orally.
223648327|NCT01237899|DRUG|Eplerenone|Administered orally.
223648328|NCT01051518|DEVICE|Medtronic CoreValve System|Transcatheter Aortic Valve
223648329|NCT06444620|DRUG|DTG/3TC|This is a fixed-dose combined DTG/3TC pill each containing 50mg of dolutegravir and 300mg of lamivudine
223648330|NCT04566926|DRUG|JNJ-64140284|Participant will receive JNJ-64140284 formulation 1 or 2 under fasting or fed condition.
223766445|NCT01634204|OTHER|KiloCoach|"Study participants in this arm will use the program to record nutrition and physical activity on at least 4 days per week within the first and ad libitum within the second 3 months of the intervention period.~Study visits will be conducted at baseline as well as after 1, 3 and 6 months. After 12 months a follow up visit will be conducted."
224233446|NCT03800069|DEVICE|Group K Diagnostic point of care device|Arm 1 will have a finger prick sample collected to test the ability of Group K Diagnostic point of care device and app to identify liver function values.
224233447|NCT00767325|DRUG|Abatacept|Abatacept, 10 mg/kg, solution given intravenously on Days 1, 15, 29,57, 85, 113, 141, and 169
224233448|NCT00767325|DRUG|Methotrexate|Methotrexate administered in a dose of 15 mg/week or higher for at least 3 months and at a stable dose for at least 28 days prior to baseline
223648331|NCT04566926|DRUG|Placebo|Participant will receive matching placebo.
223648332|NCT02141438|DRUG|Radium-223 dichloride (Xofigo, BAY88-8223)|This is a non-interventional study, the drug is used in its authorized indication from commercial supply. The decision to treat with Radium-223 will be agreed upon between the physician and the patient independently and prior to providing the patient study information. Treatment with Radium-223 should follow the approved local product information.
223648333|NCT05357950|DRUG|PrimeC|Ciprofloxacin and celecoxib combination extended release formulation
223648334|NCT05357950|DRUG|Placebo|Placebo matches active drug in size, color and taste
223766446|NCT01634204|OTHER|Control|"Study subjects try to reduce their body weight on their own. They are free to exercise and/or change nutritional habits. Not allowed is taking part in any structured weight loss program.~Study visits will be conducted at baseline as well as after 1,3 and 6 months. A follow up visit will be conducted after 12 months."
223766447|NCT01157481|DRUG|Conventional therapy plus nifedipine|Participants will receive 10 to 60 mg of sustained-release nifedipine once a day until December 2014
223766448|NCT01157481|DRUG|Conventional therapy|Conventional therapy
224233449|NCT04503798|BEHAVIORAL|Online Goal Management Training|Pre-recorded videos and games combine psycho-education, targeted skills training, and mindfulness practice to teach a system where participants can take control of their attention and cognitive faculties.
223648335|NCT04300621|DRUG|OTF 1|Participants will receive (S)-ketamine administered sublingually through OTF 1.
223648336|NCT04300621|DRUG|OTF 2|Participants will receive (S)-ketamine administered sublingually through OTF 2.
223648337|NCT04300621|DRUG|OTF 3|Participants will receive (S)-ketamine administered sublingually through OTF 3.
224233450|NCT04464044|DEVICE|verofilcon A toric contact lenses|Daily disposable toric soft contact lenses
224233451|NCT02002156|BIOLOGICAL|BCG, NeisVac-C®, Pediacel®, Infanrix™, Prevenar-13®, Menitorix®, Priorix®, Rotarix®|This group will receive BCG at birth and all routine vaccinations.
224233452|NCT02002156|BIOLOGICAL|BCG, NeisVac-C®, Pediacel®, Infanrix™, Prevenar-13®, Menitorix®, Priorix®, Rotarix®|This group will receive BCG at three months old and all routine vaccinations.
223766449|NCT03886064|OTHER|Multi-behavioral intervention|The interventional group will then meet regularly under the aegis of the trainer to work on modifying each person's risk factors. The one-hour sessions will be scheduled every two weeks for two months and then every month for two months and then every three months until the end of the study (13 sessions). These sessions will be behavior change sessions, focused on goal setting, action planning, and problem solving. Trainers will facilitate these sessions and use motivational interviewing techniques
223766450|NCT02582840|DRUG|Dapagliflozin 5mg|Dapagliflozin, a blood glucose lowering drug. Oral dose
223648338|NCT04300621|DRUG|OTF 4|Participants will receive (S)-ketamine administered sublingually through OTF 4.
223648339|NCT00792168|DRUG|venlafaxine (Effexor)|venlafaxine 37.5 mg. or placebo will be prepared by the UCLA Pharmacy for the initial phase of the study. For the open-label phase of the study, subjects will receive the medication and dosage that is clinically indicated by the subject's primary physician in the community. After a one-week placebo lead-in, subjects will be randomly assigned to receive one capsule of either venlafaxine or placebo, with the dosage increase every two days until subjects receive four capsules daily (subjects will achieve a dose 150 mg. of venlafaxine after 7 days). The first dose will be administered in the morning, with subsequent capsules added on a b.i.d. schedule
223648340|NCT00792168|OTHER|placebo|venlafaxine 37.5 mg. or placebo will be prepared by the UCLA Pharmacy for the initial phase of the study. For the open-label phase of the study, subjects will receive the medication and dosage that is clinically indicated by the subject's primary physician in the community. After a one-week placebo lead-in, subjects will be randomly assigned to receive one capsule of either venlafaxine or placebo, with the dosage increase every two days until subjects receive four capsules daily (subjects will achieve a dose 150 mg. of venlafaxine after 7 days). The first dose will be administered in the morning, with subsequent capsules added on a b.i.d. schedule
223648341|NCT02968108|DRUG|Ustekinumab|Subjects will receive a single IV administration of ustekinumab (3 mg/kg for subjects \<40 kg or 130 mg for subjects \>= 40 kg in Group 1 and 9 mg/kg for subjects \< 40 kg or 390 mg for subjects \>= 40 kg in group 2) at week 0 followed by SC administration of ustekinumab (2 mg/kg for subjects \< 40 kg or 90 mg for subjects \>= 40 kg at Week 8.
223648342|NCT05035420|DEVICE|Fitbit|Performance of the NIRS biosensor will be explored in comparison to this commercial wearable.
223648343|NCT05035420|DEVICE|Douglas Bag|The Douglas Bag will be used for inducing hypercapnia.
223648344|NCT05035420|DEVICE|Periflux 6000 EPOS|Tissue oxygen saturation measured by the Periflux 6000 will be compared with peripheral tissue saturation measured with the NIRS biosensor both at rest and during the induced hypercapnia, paced breathing and breath holding.
223648345|NCT05035420|DEVICE|BIOPAC|The BIOPAC system will be used to record the PPG signal, cardiovascular hemodynamics, and respiratory parameters in order to noninvasively monitor the heart rate, heart rate variability, respiratory rate, respiratory effort index, and arterial oxygen saturation.
223648346|NCT05035420|DEVICE|Flowmet|Flowmet will be used for a measurement of arterial blood flow within the finger or toe. Flowmet outputs a PPG waveform that will be compared with the NIRS biosensor.
223648347|NCT05035420|DEVICE|NIRS|a. Each subject will be monitored with the multimodal system for 10 minutes while sitting quiescent on a chair in resting position. All screening index parameters will be collected and recorded. b. Each subject will be studied for approximately 60-80 minutes while being exposed to a mild Hypercapnia (5% CO2), paced breathing and breath holding followed by a 10-minute recovery time after each task.
223648348|NCT05842174|DRUG|Hydroxychloroquine|Hydroxychloroquine to be administered intra-arterially at time of transarterial embolization as well as orally for 6 weeks following the procedure
223648349|NCT05842174|DRUG|Lipiodol|Lipiodol is an FDA-approved drug delivered agent and embolic which is administered as standard of care for transarterial embolization for hepatocellular carcinoma. Lipiodol will be administered intra-arterially in both arms at the time of procedure.
223648350|NCT05842174|DRUG|Placebo|Placebo will be administered orally for 6 weeks following the procedure to patients in arm 2
223648351|NCT06380270|DIETARY_SUPPLEMENT|Oral probiotic Streptococcus salivarius eK12|Bactoblis® EVOL (containing 10 billion CFU of S. salivarius eK12)
223648352|NCT06380270|OTHER|Placebo|Orally dissolving placebo tablets
223648353|NCT05010109|PROCEDURE|6 Minute Walk Functional Test|Participate in 6 MWT
223648354|NCT05010109|PROCEDURE|Biospecimen Collection|Undergo blood and urine sample collection
223648355|NCT05010109|PROCEDURE|Computed Tomography|Undergo SPECT/CT
223648356|NCT05010109|PROCEDURE|Echocardiography|Undergo echocardiogram
223648357|NCT05010109|PROCEDURE|Exercise Cardiac Stress Test|Undergo stress test
223648358|NCT05010109|OTHER|Questionnaire Administration|Complete questionnaires
223648359|NCT05010109|PROCEDURE|Single Photon Emission Computed Tomography|Undergo SPECT/CT
223648360|NCT04553757|OTHER|Survey Administration|Complete survey
223648361|NCT06628830|DEVICE|VamosJuntxs App|"Psychoeducational materials (videos, information and interactive exercises) about depression, anxiety and social support~Skills training through information and activities based on the principles of cognitive behavioral therapy (cognitive restructuring, behavioral activation, emotional regulation, problem solving and exposure)"
223648362|NCT06628830|OTHER|Web Conciencia Saludable|mental health psychoeducational campaign (https://concienciasaludable.uchile.cl/)
223648363|NCT06157892|DRUG|disitamab vedotin|Given into the vein (IV; intravenous)
223766451|NCT02582840|DRUG|Dapagliflozin 10mg|Dapagliflozin, a blood glucose lowering drug. Oral dose
223766452|NCT02582840|DRUG|Placebo tablet|Placebo tablet. Oral dose
223766453|NCT01934153|DRUG|[14C]Umeclidinium 18.5 mg|Umeclidinium will be supplied as clear, colorless solution, free from visible particulates, single dose, topical solution in clear glass jars. Dosage of 18.5 mg of Umeclidinium per gram is equivalent to 22 mg per gram of the bromide salt.
223648364|NCT06157892|DRUG|tucatinib|300mg given twice daily by mouth (orally)
223648365|NCT04620070|PROCEDURE|ECPR|Application of prehospital ECPR
223648366|NCT05575167|DRUG|Zoledronate or Alendronate|infusion (for zoledronate) or oral digestion (for alendronate)
223648367|NCT02363452|DRUG|Reverse transcriptase inhibitors: Zidovudine, Lamivudine, Abacavir|Oral Solution (syrup) or Tablets
224233453|NCT02002156|BIOLOGICAL|NeisVac-C®, Pediacel®, Infanrix™, Prevenar-13®, Menitorix®, Priorix®, Rotarix®|This group will receive no BCG but will receive all routine vaccinations.
224233454|NCT03982758|OTHER|isometric handgrip exercise|Isometric session with handgrip: 4 sets of 2 minutes of contractions sustained at 30% of CVM, for each arm. The time between sets and between arms will be 1 minute rest.
224233455|NCT03982758|OTHER|isometric of the lower limbs|Isometric session for lower limbs: 4 sets with 2 minutes of contractions sustained at 30% of 1RM. The rest interval will be 1 minute rest.
224233456|NCT03538756|DEVICE|Walkasins|Walkasins® consist of two parts for each leg: the Haptic Module (leg unit) and the Receptor Sole (foot pad). The Haptic Module wraps around the lower leg of the user and contains electronics for reading Receptor Sole pressure signals, a microprocessor, and four vibrating motors that provide gentle tactile sensory cues to the front, back, medial, and lateral surfaces of the user's leg. These cues reflect real-time foot pressure information at a location above the ankle where skin sensation is still present.
224233457|NCT01987804|DRUG|Oxytocin 100 i.u.|
224233458|NCT01987804|DRUG|Oxytocin 400 i.u.|
224233459|NCT01987804|DRUG|Placebo|
224233460|NCT00752856|DRUG|Kaletra + Isentress|kaletra 2 tabs twice a day + Raltegravir 1 tab twice a day
224233461|NCT00752856|DRUG|Atripla|Atripla 1 tab once a day
224233462|NCT03136692|BEHAVIORAL|Lose It! commercial weight loss app|Lose It! is a commercial weight loss smart phone app designed for easy caloric tracking. It provides a free mobile and web interface for users to construct an individualized weight loss plan by entering their goal weight and desired weekly weight loss. Using the user's height, current weight, gender and age, the app generates a daily caloric budget designed for the user to reach their goal. Users can then log their caloric intake, exercise, and weight to track progress toward their goal.
224233463|NCT03064633|DRUG|dexamethasone 8 mg|At the level of the umbilicus, the high-frequency ultrasound linear array probe (L 4 - 12) will be placed transversely on the anterolateral abdominal wall between the subcostal margin and the iliac crest. localization of the fascial plane between the internal oblique and the transversus abdominis muscles will be done. The local anesthetic solution mixture will be injected with short bevel needle. The TAP block will be performed on the both side using the same technique and the same local anesthetic solution mixture volume. For the patients randomized to dexamethasone group, the local anesthetic solution mixture will consist of a total volume of 40 ml containing bupivacaine 0.25 % and dexamethasone 8 mg.
224233464|NCT03064633|DRUG|dexmedetomidine 80 µg|At the level of the umbilicus, the high-frequency ultrasound linear array probe (L 4 - 12) will be placed transversely on the anterolateral abdominal wall between the subcostal margin and the iliac crest. localization of the fascial plane between the internal oblique and the transversus abdominis muscles will be done. The local anesthetic solution mixture will be injected with short bevel needle. The TAP block will be performed on the both sides using the same technique and the same local anesthetic solution mixture volume. For the patients randomized to dexmedetomidine group, the local anesthetic solution mixture will consist of a total volume of 40 ml containing bupivacaine 0.25 % and dexmedetomidine 80 µg.
224233465|NCT03064633|DRUG|Bupivacaine 0.25% Injectable Solution|38 ml of the solution will be prepared to be used in transversus abdominis plane block
224233466|NCT06175702|DRUG|Vincristine|dose 1.5 mg/m2 at days 1, 8, 15 and 22
224233467|NCT06175702|DRUG|Dexamethasone|40 mg on days 1-2, 8-9,15-16 and 22-23
224233468|NCT06175702|DRUG|Imatinib|600 mg per day from 1 to up to 5 years
224233469|NCT06175702|DRUG|Cytarabine|1000 mg/m2/ on days 1, 3 and 5 of consolidation with 2h infusion
224233470|NCT06175702|DRUG|Mercaptopurine|50 mg/m2 on days 1 to 28 of maintenance
224233471|NCT06175702|DRUG|Methotrexate|1000 mg/m2 on day 1 of consolidation with 24h infusion; and 20 mg/m2 on days 1, 8, 15 and 22 of maintenance
224233472|NCT06175702|DRUG|Ponatinib|15 mg per day from consolidation start up to 5 years
224233473|NCT06175702|PROCEDURE|allogeneic stem cell transplantation|Allogeneic stem cell transplantation from hematpoietic stem cells progenitors of familiar or not familiar origin. Cord blood transplantation can also be done.
224233474|NCT06175702|PROCEDURE|Total body irradiation|Fractionated dose with total dose of 12 Gy between days -4 and -1 of allogeneic stem cell transplantation (alloSCT)
224233475|NCT06175702|DRUG|Cyclophosphamide|60 mg/kg on days -6 and -5 before alloSCT
224233476|NCT06175702|DRUG|Fludarabine|30 mg/m2 intravenous on days -7, -6, -5 y -4 before alloSCT (alternative to cyclophosphamide)
224233477|NCT04973956|OTHER|Relaxation|This group will perform the APMR. This intervention consists of a standardized 20 min session in which subjects are asked to sequentially tense and relax various muscle groups. To do so, participants will listen to an audio with relaxation instructions while seated in a reclining seat and dimmed lighting.
224233478|NCT04973956|OTHER|Control|No intervention
223648368|NCT03879018|BEHAVIORAL|Reach training with visual feedback|Reach training will be accomplished using an Oculus Rift and Touch 3D headset. Active markers will be placed on the shoulder, elbow, wrist, and finger in order to capture limb movement in real time. During each training session, participants will first be familiarized with the task and then will reach from a home position to 4 virtual targets that are presented in the front of the participant and within the workspace where most natural arm movements are performed.Targets will be presented in a pseudorandom order and participants will reach a total of 400 times
223648369|NCT04329806|DRUG|Moxonidine 0.2 MG|Moxonidine 0.2 MG twice daily
223648370|NCT04329806|DRUG|Amlodipine 5 MG|Amlodipine 5 MG twice daily
223648371|NCT05017571|DRUG|Colchicine|Colchicine 1 capsule (0.6 mg) per day
223648372|NCT05017571|DRUG|Placebo|Placebo 1 capsule per day
223648373|NCT05814367|DRUG|Blink® Tears eye drops in a multidose bottle|Control
224233479|NCT03131999|DRUG|Imatinib Mesylate 400Mg Capsule|Sirolimus or everolimus will be withdrawn after 28 days if used at baseline
224233480|NCT03131999|DRUG|Placebo - Capsule|Sirolimus or everolimus will be withdrawn after 28 days if used at baseline
224233481|NCT02402868|DRUG|Ketamine and saline|Ketamine intravenous and intranasal
224233482|NCT02260492|DRUG|OT329 (combination of fluticasone propionate and salmeterol xinafoate)|Fluticasone propionate (100 mcg) and salmeterol xinafoate (50 mcg) administered by Solis dry powder inhaler
224233483|NCT02260492|DRUG|Advair Diskus (combination of fluticasone propionate and salmeterol xinafoate)|Fluticasone propionate (100 mcg) and salmeterol xinafoate (50 mcg) administered by Diskus dry powder inhaler
224233484|NCT02260492|DRUG|Placebo|Placebo (lactose) administered via the Solis dry powder inhaler
224233485|NCT01323998|DRUG|5ARI|Dutasteride or Finasteride
223766454|NCT06114576|OTHER|Orange juice enriched with vitamin D3 and encapsulated probiotics|25 high cardiometabolic risk volunteers will be asked to consume 250 ml orange juice enriched with 2000 IU vitamin D3 and 10\^8 cfu/ml encapsulated probiotics (Lactocaseibacillus casei shirota and Lactocaseibacillus rhamnosus GG) daily, for 8 weeks, without any other change in their dietary habits and physical activity.
223766455|NCT06114576|OTHER|Conventional orange juice|25 high cardiometabolic risk volunteers will be asked to consume 250 ml conventional orange juice daily, for 8 weeks, without any other change in their dietary habits and physical activity.
223766456|NCT02402010|BEHAVIORAL|Adjunctive Yoga|
223766457|NCT02402010|BEHAVIORAL|Enhanced Treatment as Usual|
224233486|NCT01323998|DRUG|AB|Doxazosin, Prazosin, Tamsulosin, Terazosin or Alfuzosin
224233487|NCT01898910|PROCEDURE|PVI+renal denervation|After AF ablation procedure, the angiogram of both renal arteries is performed via femoral access. After that the treatment catheter is introduced into each renal artery and is applied discrete, radiofrequency ablations lasting up to 2 min each and of 8 watts or less to obtain up to six ablations separated both longitudinally and rotationally within each renal artery. During ablation, the catheter system monitored tip temperature and impedance, altering radiofrequency energy delivery in response to a predetermined algorithm. After the procedure the control arterial angiogram should be done.
224233488|NCT01898910|PROCEDURE|PVI + GP ablation|To accomplish ganglionated plexi ablation, LA target sites were identified as the anatomic locations where vagal reflexes were evoked by transcatheter high-frequency stimulation (HFS). Rectangular electrical stimuli were delivered at a frequency of 20-50 Hz, output amplitude 15 V and pulse duration of 10 ms, for 5 sec (Stimulator B-53, Biotok Inc, Russia).
224233489|NCT01898910|DRUG|Optimal medial therapy (OMT)|Antiarrhythmic and antihypertensive therapy will be administered according to the guidelines
224233490|NCT00317954|DRUG|Spironolactone|
224233491|NCT04295395|DEVICE|NONIN SenSmart model X-100 near- infrared spectrometer|for to measure cerebral (cSO2) and renal (rSO2 ) regional tissue oxygen saturation on the day after echocardiography was done. The sensors were placed on the right/left forehead and the right/left lateral posterior flank
224233492|NCT04366479|BEHAVIORAL|Multistage Fitness Test|Participants only joined in one group will be given intervention for 5 weeks in the form of running 1600 meters duration of 20-30 minutes 3 times a week. It is important for the participants as well as for us to know which training methods are given. this information will be documented in our file, but we will not see these files until after the research is complete. this is the best way we have for testing without being influenced by what we think or expect might happen.
224233493|NCT06547593|BEHAVIORAL|multifaceted nutrition intervention|"In this group, a 3-month multifaceted nutrition intervention will be conducted. The specific content is as follows:~1. Anti-inflammatory dietary management: the elderly will receive an anti-inflammatory dietary menu designed based on the Chinese Dietary Guidelines for the Elderly (2022 Edition) provided by researchers.~2. Personalized nutritional intervention management: WeChat groups will be established to record the dietary status of the research subjects. The research subjects will be asked to keep a dietary diary and take photos of their diet daily. Trained researchers will record their daily diet and provide timely feedback to the research subjects.~3. Health education: Nutrition and health knowledge lecture will be held for elderly family caregivers and the elderly themselves every two weeks. The content will include basic knowledge of frailty, prevention and treatment guidance, health outcomes, medication management, and healthy behaviors."
224233494|NCT06547593|BEHAVIORAL|Nutritional and Exercise Combined Intervention|To investigate the combined effects of nutrition and exercise, this group added exercise intervention in addition to the corresponding intervention measures of the nutrition intervention group. The subjects were required to exercise 3 times a week, 1 hour each time. The project included 10 minutes of warm-up exercises (stretching), 10-20 minutes of aerobic exercise (balance ability, leg and core muscle strength, etc.), 10-20 minutes of muscle resistance strength training (legs, buttocks, feet, upper limbs, etc.) and 10 minutes of relaxation training. All exercise programs were uniformly trained by professional coaches, and compliance was ensured by uploading photos to punch the clock. The intervention period is 3 months, with a follow-up of 9 months.
224233495|NCT06547593|BEHAVIORAL|Control Group|The control group will undergo routine community health management, including regular chronic disease health education lectures, provision of health education materials, health counseling services, and comprehensive health examinations by qualified medical professionals.
223766458|NCT06166953|OTHER|digital technology-supported education|The education will include information about surgical process and care after surgery.
223766459|NCT00515333|DRUG|TRx0014|Hard capsule; 60 milligrams; t.i.d.
223766460|NCT00515333|DRUG|TRx0014|Hard capsule; 30 milligrams; t.i.d.
223766461|NCT00515333|DRUG|Placebo|Hard capsule; 0 milligrams; t.i.d.
223766462|NCT00515333|DRUG|TRx0014|Hard capsule, 100 milligrams, t.i.d.
223766463|NCT01929668|DRUG|polyethylene glycol|
223766464|NCT01929668|DRUG|Ascorbic Acid|
223766465|NCT05878938|DRUG|NNC0365-3769 (Mim8) PPX|Participants will receive Mim8 PPX once-weekly dosing (QW), once every two weeks dosing (Q2W), or once-monthly dosing s.c. injection using a prefilled fixed dose DV3407-C1 pen-injector for 26 weeks.
223766466|NCT04440293|OTHER|BBAT|The BBAT was applied by a trained and certified physiotherapist in this area for about an hour, two days a week, as a group therapy. The BBAT program includes movements related to daily activities such as lying, sitting, standing and walking. BBAT focuses on basic movement principles such as postural stability, energy adjustment in movements, comfortable breathing and coordination.
223766467|NCT04440293|OTHER|CT|The CT program was applied two days a week for about an hour. The CT program includes active range of motion (ROM) exercises, stretching, isometric and resistant strengthening, posture exercises and relaxation training.
223766468|NCT03427918|BEHAVIORAL|Mindfulness-Based Sex Therapy|Mindfulness-Based Sex Therapy in an integration of psychoeducation, sex therapy, and mindfulness-based skills.
223766469|NCT03107988|DRUG|Lorlatinib|Lorlatinib will be given orally once daily continuously in 28-day cycles. Lorlatinib will be provided as 5 mg or 25 mg tablets.
224233496|NCT05937113|BIOLOGICAL|RABIVAX-S|"1 ml dose vaccine containing ≥ 2.5 IU of purified rabies antigen (Pitman-Moore rabies virus strain 3218; acclimatized and cultured on vero cells, inactivated with β propiolactone).~Pre-exposure prophylaxis regimens for two groups~* Intramuscular 1ml on days D0, D7 and D21+7~* Intradermal injection 0.1 ml on days D0, D7 and D21+7 Blood samples were collected on days D0, D7 and D21 - 28"
224233497|NCT06544577|DRUG|ELacestrant|345 mg/day once daily oral dosing
224233498|NCT00197756|DIETARY_SUPPLEMENT|Vitamin A alone|30 mg beta-carotene plus 5000 IU preformed vitamin A) taken orally once per during pregnancy and lactation
224233499|NCT00197756|DIETARY_SUPPLEMENT|Multivitamins excluding vitamin A|30 mg thiamine, 20 mg riboflavin, 20 mg B-6, 100 mg niacin, 50 ug vitamin B-12, 500 mg vitamin C, 30 mg vitamin E, 0.8 mg folic acid taken orally once per day during pregnancy and lactation
223648374|NCT05814367|DRUG|Preservative-free investigational lubricating eye drops in a Novelia® eyedropper|Test
223648375|NCT05258656|BEHAVIORAL|Intervention|The intervention group will receive education about nutrition, resources, and specific instructions on promoting healthy development of their infant, including guidance regarding infant sleep, screen time, and building healthy relationships.
223648376|NCT05258656|BEHAVIORAL|Control|The control group will receive specific instructions on promoting healthy development of their infant, including guidance regarding infant sleep, screen time, and building healthy relationships.
223648377|NCT04604301|DEVICE|Celtra Quatro|Full ceramic crowns will be made from the high strength ceramic, Celtra Quatro
223648378|NCT02862431|DRUG|JNJ-64565111|Participants will receive JNJ-64565111 subcutaneously in the abdomen on Days 1, 8, 15 and 22.
224233500|NCT00197756|DIETARY_SUPPLEMENT|multivitamins including vitamin A|20 mg thiamine, 20 mg riboflavin, 25 mg vitamin B6, 100 mg niacin, 50 ug vitamin B12, 500 mg vitamin C, 30 mg vitamin E, and 0.8 mg folic acid taken once per day orally during pregnancy and lactation
223648379|NCT02862431|DRUG|Placebo|Participants will receive Placebo subcutaneously in the abdomen on Days 1, 8, 15 and 22.
223766470|NCT03107988|DRUG|Cyclophosphamide|Cyclophosphamide 250mg/m2/day will be administered as a 30 minute IV infusion on days 1-5 of each cycle
223766471|NCT03107988|DRUG|Topotecan|Topotecan 0.75mg/m2/day will be administered as a 30 minute IV infusion immediately following cyclophosphamide on days 1-5 of each cycle
223766472|NCT03107988|DRUG|Filgrastim/pegfilgrastim|"Filgrastim is to be given with each course beginning 24-48 hours following completion of cyclophosphamide and topotecan and continued through post-nadir count recovery with an ANC \> 2000/mm\^3 at 5mcg/kg/day. Filgrastim must be discontinued at least 24 hours prior to the start of the next course of therapy.~Pegfilgrastim (100mcg/kg; 6mg maximum dose) may be substituted and is given one time at 24-48 hours from completion of cyclophosphamide and topotecan."
223648383|NCT06843759|OTHER|mat pilates|Neck exercises Trunk stabilization exercises Shoulder exercises Posture exercises
223648384|NCT06843759|OTHER|reformer pilates|Foodwork Swan Short Spin Long Stretch Keen Stretch Hug Tree Bridge Pulling Straps Short Box Abdominal Hundred Twist Star
223648385|NCT02997228|DRUG|Atezolizumab|Given IV
224233501|NCT00197756|OTHER|Placebo|Placebo pill taken orally once per day during pregnancy and lactation
224233502|NCT02550756|DRUG|CTNX-4975|
224233503|NCT00102869|DRUG|levodopa|100mg levodopa per day over 10 days/ treatment phase
224233504|NCT00894907|OTHER|PiCCO-parameter-guided volume resuscitation|"Insertion of an arterial PiCCO catheter. Resuscitation using crystalloids and/or colloids with the following goals:~ITBI: 850-1000 ml/sqm, if ELWI \<=12\*ml/kg; ITBI 750-850 ml/sqm, if ELWI \>12\*ml/kg and/or PaO2:FiO2 \<200 (\*ELWI\<=12ml/kg, if MAP\>65mmHg without catecholamines; ELWI\<=14ml/kg, if catecholamines required for MAP\>65mmHg); SVV\<10% (only in controlled ventilation and sinus rhythm); MAP\>65mmHg (MAP: Mean Arterial Pressure); IAPP \>60mmHg (IAPP: Intra-abdominal Perfusion Pressure)"
224233505|NCT00894907|OTHER|Control-group|"Haemodynamic management without ITBI and ELWI using any other haemodynamic monitoring tool, with the exception of the PiCCO-system.~Main haemodynamic goals: CVP 8-12 mmHg; MAP \>65mmHg;IAPP \>60mmHg"
224233506|NCT02989142|BEHAVIORAL|INTER-ACT|"Pre-conception coaching sessions: We encourage less motivated women to participate to the trial by collaborating with Kind \& Gezin from the very beginning, as most timepoints of the counselling sessions coincide with the time points of the Kind\&Gezin vaccine scheme (postpartum week 6, week 8, week 12, 6 months). We will organize the coaching in a mother and baby friendly community-based setting or in the hospitals, as preferred by the mothers.~Pregnancy coaching sessions: take place in hospital, at the time of the three planned ultrasound scans.~By consequence, the applied methodology can be applied as such at the moment of global utilisation in Flanders."
223648386|NCT02997228|BIOLOGICAL|Bevacizumab|Given IV
223648387|NCT02997228|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
223648388|NCT02997228|PROCEDURE|Computed Tomography|Undergo CT or CT/PET
223648389|NCT02997228|DRUG|Fluorouracil|Given IV
223648390|NCT02997228|DRUG|Leucovorin|Given IV
223648391|NCT02997228|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223648392|NCT02997228|DRUG|Oxaliplatin|Given IV
223648393|NCT02997228|PROCEDURE|Positron Emission Tomography|Undergo CT/PET
223648394|NCT02997228|OTHER|Quality-of-Life Assessment|Ancillary studies
223648395|NCT02997228|OTHER|Questionnaire Administration|Ancillary studies
223648396|NCT04576104|PROCEDURE|Biopsy Procedure|Undergo biopsy
223648397|NCT04576104|DRUG|Extended Release Metformin Hydrochloride|Given PO
223648398|NCT04576104|DRUG|Megestrol Acetate|Given PO
223648399|NCT04576104|OTHER|Questionnaire Administration|Ancillary studies
223648400|NCT06232876|DEVICE|Blinded continuous vital sign monitoring|Continuous ward monitoring with vital signs recorded but not available to patients, clinicians, or investigators.
223648401|NCT06232876|DEVICE|Unblinded continuous vital sign monitoring|Continuous ward monitoring with vital signs available to clinicians and investigators.
223648402|NCT04077047|BEHAVIORAL|iEngage|The intervention is a network-based, social support intervention to improve Adolescents living with HIV (ALWH) retention in HIV care and antiretroviral therapy (ART) adherence
224233507|NCT01503723|OTHER|Determined by intended physician|We perform a prospective observational study. All the treatment for the patients are determined by intended physicians.
224233508|NCT00838877|DRUG|radioligand [18F]AZD4694|single dose of iv. admin. 1-2 times per subject
224233509|NCT00838877|DRUG|radioligand [11C]AZD2184|single dose of iv admin. 1 time per subject
224233510|NCT05653713|DRUG|CSL324|Single intravenous (IV) dose of CSL324
224233511|NCT05653713|DRUG|Placebo|IV dose of 0.9% saline
224233512|NCT06357026|DEVICE|Percutaneous Ventricular Assist System（Phigine Medical）|Percutaneous Ventricular Assist System or IABP provides intraoperative circulatory support during high-risk PCI.
224233513|NCT06357026|DEVICE|intra-aortic balloon pump (IABP)|IABP provides intraoperative circulatory support during high-risk PCI.
224233514|NCT03731481|BEHAVIORAL|Lifestyle Medicine|Lifestyle Medicine programs provide instruction in plant-based nutrition, food preparation, methods of stress reduction and incorporation of physical activity into daily routine.
224233515|NCT05809674|DEVICE|Polarization sensitive optical coherence tomography (PS-OCT)|The PS-OCT is a prototype, also known as an early version of a medical device, specially developed by the Ocular Imaging Research Group, Singapore Eye Research Institute, for prediction of myopia progression. It has not been approved for use in any other country. There is currently no method to identify who is at risk of myopia progression. The PS-OCT device will provide the capabilities of OCT scleral biomarkers, which may have the potential to identify individuals at high risk for myopia.
224233516|NCT04085081|OTHER|E-mail|Receive brief motivational text or email messages
224233517|NCT04085081|BEHAVIORAL|Exercise Intervention|Receive personalized walking program plus strength exercises
224233518|NCT04085081|OTHER|Quality-of-Life Assessment|Ancillary studies
224233519|NCT04085081|OTHER|Questionnaire Administration|Ancillary studies
224233520|NCT04085081|BEHAVIORAL|Telephone-Based Intervention|Receive intervention coaching sessions via telephone
224233521|NCT04085081|OTHER|Text Message|Receive brief motivational text or email messages
224233522|NCT00996736|DRUG|Natamycin|5% natamycin plus 0.02% preservative, one drop to the affected eye every one hour while awake for 1 week, then every 2 hours while awake until 3 weeks after enrollment.
224233523|NCT00996736|DRUG|Voriconazole|1% voriconazole plus 0.01% preservative, 1 drop applied to the affected eye every one hour while awake for 1 week, then every 2 hours while awake until three weeks after enrollment.
223766473|NCT04016324|DEVICE|InterStim Basic Evaluation lead and foramen needle|Commercial devices within their intended use as described in approved Instructions for Use.
223648404|NCT01897688|BIOLOGICAL|Islet Cell Transplant|
223648405|NCT02636595|DRUG|ABT-493/ABT-530|Tablet; ABT-493 coformulated with ABT-530
223648406|NCT03772158|DRUG|Cetirizine 10mg|Chewable tablet
223648407|NCT03772158|DRUG|Cetirizine 10 mg|Immediate Release Tablet
223648408|NCT03772158|DRUG|Cetirizine 10 mg|Immediate Release Tablet
223648409|NCT00099333|DRUG|exenatide|Exenatide 5 mcg subcutaneously injected twice daily for 4 weeks; then 10 mcg subcutaneously injected twice daily for 12 weeks.
223648410|NCT00099333|DRUG|Insulin|Insulin will be taken according to the subject's current regimen
223648411|NCT05393921|DRUG|Intravesical Botox injection|Intravesical botox injection given only in experimental group.100 units of Botox will be used and diluted in 10 mL of normal saline. 0.5 cc injections will be administered in 20 injection sites (trigone sparing).
223648412|NCT03147937|OTHER|Cognitive Testing|Computerized CogState Brief Battery (CBB), Cognigram, assesses changes in four cognitive domains including psychomotor function, attention, learning and memory, and working memory. The CBB is a computerized test based on card games that can be administered online
223648413|NCT04373720|PROCEDURE|Magnetic Resonance Elastography|Undergo MRE
223648414|NCT04373720|PROCEDURE|Magnetic Resonance Imaging|Undergo standard of care MRI
223648415|NCT04730271|DEVICE|Total Knee Replacement|Subjects will be implanted with an ATTUNE Primary total knee replacement.
223648416|NCT04006132|DEVICE|Fitting of Ponto 3 SuperPower|Bone-anchored hearing systems (BAHS) use the body's natural ability to transfer sound through bone conduction. The sound processor picks up sound and converts it into vibrations that are transferred through the skull bone to the inner ear (cochlea). Thus, for patients with conductive or mixed hearing losses, patients with lasting hearing loss following a middle ear disease or malformations (such as microtia), the vibrations are bypassing the conductive problem in the ear canal or middle ear. The intervention in this study is audiologically fitting two bone-anchored sound processors (Ponto 3 SuperPower) to patients that are already bilaterally implanted with abutments.
223648417|NCT00461370|DRUG|SRX251|
223648418|NCT06006884|PROCEDURE|Bronchoscopies and Bronchoalveolar Lavages (BALs)|Bronchoscopies use a thin, lighted tube, which enters through the mouth or nose and moves down the throat to the airways to look at the lungs. BALs are done during bronchoscopies to collect samples from the lungs for testing. During this procedure, a saline solution is put through the tube to wash the airways and collect a fluid sample.
223648419|NCT06006884|DIAGNOSTIC_TEST|Chest Tomography (CT)|X-ray to create images of the bones and internal organs of the body
223648420|NCT06006884|DIAGNOSTIC_TEST|Electrocardiogram (ECG)|Measures the electrical activity of the heart by using sticky pads that are placed on your chest and limbs.
223648421|NCT06006884|DIAGNOSTIC_TEST|Pulmonary function tests (PFTs)|Testing to measure how well lungs are working
223648422|NCT06006884|DIAGNOSTIC_TEST|6 minute walk test (6MWT)|Walking test to see how well the lungs function with exercise over 6 minutes
223648423|NCT01025726|BEHAVIORAL|Police Patrolled Walking plus Social Marketing|Identify walking route, hire walking leaders and police support, maintain route and monitor stray dogs PLUS grass-roots social marketing campaign to promote walking on the route
223648424|NCT01025726|BEHAVIORAL|Police Patrolled Walking Program Only|Identify walking route, hire walking leaders and police support, maintain route and monitor stray dogs
223648425|NCT01025726|BEHAVIORAL|General Health Education|Host community events for chronic disease education
224233524|NCT01412138|OTHER|genetic analysis|"1. To identify by flow cytometry through technique of Side Population the population of somatic stem cells present in both human endometrial eutopic and ectopic endometrium of women with ovarian endometriosis, peritoneal and recto-vaginal.~2. In vitro culture conditions for cell proliferation.~3. To characterize the somatic stem cell population using techniques of endometriotic cell and molecular biology.~4. Compare the results obtained from patients with endometriosis with control patients (without endometriosis) earlier work by our group."
224233525|NCT01729702|OTHER|blood sample collection|
224233526|NCT03577236|DEVICE|Zenflow Spring System|The Zenflow Spring System consists of the Spring Delivery System with Implant, Spring Scope, Camera Control Unit (CCU), Measurement Tool, and Spring Retrieval Tool.
224233527|NCT02688608|DRUG|Pembrolizumab|200 mg IV once every 3 weeks
224233528|NCT03863275|DEVICE|functional apparatus|The EMG activity will be recorded during different shots: T0. The activity of the muscles of the mastication in the position of clinical rest for a minute, in maximum intercuspidation. (It will be measured with a dynamometer to standardize the force), and with the use of the equipment. T1 The patient's citation is scheduled six months after the use of myofunctional device Sn1 and the test will be performed again measuring electrical activity of right and left masseter and right and left temporal muscle at clinical rest for one minute, in maximum intercuspation, and with the use of the equipment To avoid the effects of fatigue, a rest period of at least 5 minutes between each of the recordings will be allowed
223648426|NCT05483309|DIAGNOSTIC_TEST|CT scan|Patients receive a CT scan
223648427|NCT05483309|DIAGNOSTIC_TEST|FilmArray Pneumonia Panel|The FilmArray Pneumonia Panel is used to analysis the patient's sputum sample for the cause of the hospital acquired pneumonia
223648428|NCT03933085|BEHAVIORAL|Memory Support System (MSS)|A calendar/notetaking system focused on training a person with MCI to use a specific external memory compensatory strategy to complete relevant IADLs independently.
223648429|NCT01917162|DEVICE|Nelfilcon A contact lens|Soft contact lens CE-marked for daily disposable wear.
223648430|NCT01917162|DEVICE|UltraFilcon B contact lens|Silicone hydrogel soft contact lens CE-marked for daily disposable wear. Private-label versions may be used.
223648431|NCT05244135|PROCEDURE|Pulmonary rehabilitation|An in-patients 3-week high intensity rehabilitation program, five times a week, was used as the intervention treatment. A holistic pulmonary rehabilitation program for SARS-CoV-2 patients with combined treatment focused on increasing exercise capacity, restoring lung function, and supporting mental health, developed by a multidisciplinary team, was introduced. Rehabilitation program includes exercise capacity training on a cycle ergometer, breathing exercises, general fitness exercises, resistance training, and relaxation.
223648432|NCT00891670|DRUG|cilostazol|100mg twice daily for at least 1 month
223648433|NCT00891670|DRUG|clopidogrel|"75mg once daily (triple group arm)~150mg once daily (high maintenance dose group arm)"
223648434|NCT00891670|DRUG|aspirin|aspirin 100mg
223648435|NCT05492682|DRUG|PeptiCRAd-1|All patients will receive PeptiCRAd-1.
223648436|NCT05492682|DRUG|Cyclophosphamide|All patients will be pre-treated with one single dose of Cyclophosphamide.
223648437|NCT05492682|DRUG|Pembrolizumab|All patients will receive 6 doses of Pembrolizumab within the study.
223648438|NCT04336501|BIOLOGICAL|IM19 CAR-T|All patients will be treated with fludarabine and cyclophosphamide for 3 days,then,CAR-T cells expressing CD19 CAR will be infused 24-96 hours later
223648439|NCT00921518|DRUG|0.9% Sodium Chloride (Placebo)|0.9% Sodium Chloride (placebo) will infuse at 3 ml/kg/hr for one hour pre-operatively until the patient is started on cardiopulmonary bypass. Then the infusion will be reduced to 1 ml/kg/hr throughout cardiopulmonary bypass and for six hours following cardiopulmonary bypass.
223648440|NCT00921518|DRUG|Sodium Bicarbonate|Group two will receive sodium bicarbonate 150mEq in 850ml of a 5% dextrose solution at 3 ml/kg/hr for one hour pre-operatively until the patient is started on cardiopulmonary bypass. Then the infusion will be reduced to 1 ml/kg/hr throughout cardiopulmonary bypass and for six hours following cardiopulmonary bypass.
223648441|NCT06487494|PROCEDURE|Circumcision wound closure using 2-octyl cyanoacrylate glue with four interrupted sutures|2-octyl cyanoacrylate glue is a wound closure adhesive which will be used with four interrupted sutures following circumcision for wound closure.
223648442|NCT06487494|PROCEDURE|Circumcision wound closure using continuous sutuing|Continuous suturing is the standard following circumcision for wound closure.
223648443|NCT06531551|OTHER|The group to which Acupressure will be applied in each fraction|Acupressure application protocol will be started after patient information. This process is planned to take 30 minutes.Before the application, approximately 20 seconds of warming and rubbing without direct pressure on the acupressure points will be performed to reduce tissue sensitivity and prepare the points for acupressure. Subsequently, the researcher will apply pressure with the thumb on the predetermined acupressure points, considering the individual's pain threshold, with 10 seconds of pressure followed by two seconds of relaxation without lifting the finger, in consecutive presses following the rhythm of breathing. A digital clock (belonging to the researcher) will be used to determine the duration of the acupressure application.
223648444|NCT04806555|DIAGNOSTIC_TEST|Compression ultrasound examination|After successful revascularisation for acute ischemia and clinical suspicion of acute compartment syndrome, compression ultrasound (CU) will be performed in OR followed by standard intra-compartmental measurement. Two physicians will perform two subsequent measurements of the affected limb after revascularisation. The unaffected limb will be examined once to obtain baseline elasticity ratio values. All CU examinations will be documented in PACS (picture archiving and communication system) and evaluated after ICP measurement, and if necessary, fasciotomy is performed.
223648445|NCT06371001|OTHER|disease|Helicobacter Pylori Infection In Chonic Kidney Diseased Patien
223648446|NCT05377801|BEHAVIORAL|Multi-dimensional fall prevention intervention program for 12 weeks|The intervention group of this study is a multi-dimensional intervention conducted by nursing students over a 12-week period, consisting of four parts: individualized balance and strength training, vision screening, drug evaluation, home risk assessment and home repair and transformation. These components were carried out through a combination of personal home visits and telephone interviews.
224233529|NCT03863275|OTHER|Diagnosis and observation|Six months of observation in the control group: patients group the efforts are controlled. to obtain models and have an observation of the molar classification, and to verify if the terms of the inclusion in the study are taken into account, once it is confirmed that the activity is observed in the muscular activity of the chewing muscles, in two stages , at the beginning of the session and six months later. .
224233530|NCT01629875|DRUG|Generic equivalent of Clostridium Botulinum A Toxin|
224233531|NCT01629875|DRUG|Botox (Clostridium Botulinum A Toxin)|
224233532|NCT04065893|PROCEDURE|Catheter ablation of ventricular arrhythmia|PVC or VT ablation
224233533|NCT04065893|DRUG|Intensified medical therapy|Dosage increase / new onset of Betablocker / medical antiarrhythmic medication according to guideline and clinical practice
224233534|NCT04511390|DEVICE|Transparent, reusable respirator|A novel respirator with dual N95 filter cartridges
224233535|NCT05153122|DEVICE|SenseGuard|"SG is a wireless, wearable medical device, which includes nano-based sensors. It can seamlessly measure patient's tidal breathing during daily activities. SG extracts series of critical respiratory parameters, including; Respiration Rate (RR), Inhalation and Exhalation duration and ratio (I/E), as well as novel biomarkers. SG parameters are applicable to evaluate COPD patients' condition, or for monitoring patients with other respiratory conditions.~SG components are:~RSM (Respiratory Sensing Module): non-invasive module with sensors that can detect the exhaled humidity and condensation. The RSM is a non-sterile, disposable, single patient use.~ECU (Electronic Control Unit): a re-usable, wireless data acquisition and transmission unit. The ECU is connected to the RSM during the measurement and transmits the data via Bluetooth to the SG software.~SenseGuard™ Software: for data management, acquisition, processing, logging and presentation of the digital respiratory signals."
224233536|NCT00365352|DRUG|XP13512 600MG|XP13512 600MG ONCE DAILY
224233537|NCT00365352|DRUG|XP13512 1200MG|XP13512 1200MG ONCE DAILY
224233538|NCT00365352|DRUG|PLACEBO|PLACEBO ONCE DAILY
224233539|NCT02893748|DEVICE|HyGIeaCare Prep|Patients will receive the HyGIeaCare Prep, which is an open colon lavage system using warm water by gravity drip to evacuate the colon by stimulating peristalsis to cleanse the colon prior to colonoscopy.
224233540|NCT02893748|PROCEDURE|Colonoscopy|Screening colonoscopy as per standard of care.
224233541|NCT02893748|DRUG|polyethylene glycol (PEG)|PEG preparation to be delivered in two doses - 1/2 the night before and 1/2 the morning of the colonoscopy
224233542|NCT01575678|DRUG|Melatonin|blinded capsule 2-4 mg/day, oral use, for 4 weeks
224233543|NCT01575678|DRUG|Lactose|blinded capsule 1/day, oral use, for 4 weeks
224233544|NCT05443243|PROCEDURE|Total Hip Arthroplasty|Patient were operated, a Total hip arthroplasty was performed
224233545|NCT04659109|DRUG|glenzocimab|IV administration as a sterile product
224233546|NCT04659109|DRUG|Placebo|IV administration
224233547|NCT00097695|DRUG|Icatibant|30 mg (3mL) subcutaneous icatibant injection in the abdominal region
224233548|NCT00097695|DRUG|Placebo|Solution for injection, matched to study drug Single dose: 3 mL
224233549|NCT04258670|OTHER|No intervention|Patients in these cohorts will not be given anti-filariasis therapies because these drugs are not approved for use in patients with high worm burdens (\>20,000 Mf/mL)
224233550|NCT00235859|DRUG|adalimumab|
224233551|NCT00235859|DRUG|methotrexate|
224233552|NCT06211426|BEHAVIORAL|routine rehabilitation treatment|"All participants were given routine rehabilitation treatment by professional rehabilitation therapists, including exercise therapy, guided education, psychological therapy, acupuncture and massage therapy, to promote the development of motor and cognitive function, as well as to improve intellectual development\[. Besides, swallowing function training was also provided, including direct training, indirect training, and compensatory training, as follows The mendelson maneuver: performed 5 days per week, twice per day, 5-10 minutes each time.~Cold stimulation of the pharynx: performed every day, twice per day, 3-5 minutes each time.~Passive head extension: to stretch the submental muscle for 2-3 seconds, with upward resistance applied to the lower cheek for no less than 5 times a day and no less than 5 minutes each time.~Direct feeding training: with powdered milk, once a day, 5 days a week."
223648447|NCT06250725|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|The intervention protocol will include CBTi principles like stimulus control, sleep compression, relaxation, sleep hygiene, and cognitive restructuring. It will be done over 6 weeks with one session weekly via videoconference.
223648448|NCT06246448|PROCEDURE|Robotic-assisted radical cholecystectomy|Procedure will be performed robotic-assisted
223648449|NCT06246448|PROCEDURE|Open radical cholecystectomy|Procedure will be open
223648450|NCT03617198|BIOLOGICAL|CD4 CAR+CCR5 ZFN T-cells|A dual cohort, open-label, randomized study of the safety and tolerability of a single infusion of autologous T cells genetically modified to express a CD4 chimeric antigen receptor while also having zinc finger nuclease-mediated disruption of the CCR5 gene
223648451|NCT05350774|DRUG|IV normal saline|IV normal saline 250ml for 5 days
223648452|NCT05350774|DRUG|IV immunoglobulin|IVIg - IV immunoglobulin 0.4g/kg/day for 5 days
223648453|NCT05782179|BIOLOGICAL|GBS-NN/NN2|GBS-NN/NN2 bound to alhydrogel as an adjuvant
223648454|NCT05782179|BIOLOGICAL|Placebo|Normal Saline 0.9 %
223648455|NCT06053567|BEHAVIORAL|Aerobic Exercise|Participants will select a YMCA branch and will be assigned a personal fitness instructor who will oversee a 15-week exercise intervention. The weekly exercise prescription is 75 minutes of aerobic training.
223648456|NCT06053567|BEHAVIORAL|Counseling|Participants will receive the standard tobacco cessation package of up to 5 proactive interactions from the Texas Tobacco Quitline (TTQ). Interactions are typically phone calls, but can be chat or live text if the participant prefers. Interaction 1 is for assessment and quit date planning, Interaction 2 occurs prior to the quit date and can be a group session, Interaction 3 occurs shortly following the quit date, and Interactions 4 and 5 are for relapse prevention if the smoker has quit or problem solving if they have not quit. TTQ also offers a tobacco cessation text messaging program and access to a web portal with a variety of cessation resources.
223766474|NCT00309933|PROCEDURE|cognitive assessment|
223648457|NCT06053567|DRUG|Nicotine patch|On the target quit day (week 6), participants will be provided 8 weeks of nicotine replacement therapy (24-hour transdermal nicotine patches \[TNP\]).
223648458|NCT03564379|DRUG|JNJ-42165279|25 mg JNJ-42165279 tablet will be administered orally.
223648459|NCT03564379|DRUG|Placebo|Matching placebo tablet will be administered orally.
223648460|NCT06580951|PROCEDURE|Regenerative Peripheral Nerve Interface|The RPNI portion of the case will consist of blunt dissection of the cut sensory branches of the intercostal nerves at the T3 and/or T4 levels, with creation of a peripheral nerve interface using a small cuff of dissected pectoralis muscle and 3-0 Monocryl suture. The breast reconstruction will otherwise be performed as per standard protocol.
223648461|NCT06510686|OTHER|İnspiratory muscle training|exercises to strengthen inspiratory muscles
223648462|NCT06510686|OTHER|Core training|exercises to strengthen inspiratory and core muscles
223648463|NCT05821959|COMBINATION_PRODUCT|AAVAnc80-hOTOF via Akouos Delivery Device|AAVAnc80-hOTOF is a sterile suspension intended to be administered via a one-time unilateral intracochlear administration using the Akouos Delivery Device.
223648464|NCT05821959|COMBINATION_PRODUCT|AAVAnc80-hOTOF via Akouos Delivery Device|AAVAnc80-hOTOF is a sterile suspension intended to be administered via a one-time bilateral intracochlear administration using the Akouos Delivery Device.
223648465|NCT04033458|DRUG|JNJ-64140284|Participants will receive JNJ-64140284 orally.
223766475|NCT00309933|PROCEDURE|psychosocial assessment and care|
223766476|NCT00309933|PROCEDURE|quality-of-life assessment|
223766477|NCT02610192|DEVICE|nSTRIDE Autologous Protein Solution (APS) Kit|Intra-articular injection of APS
223766478|NCT00503841|DRUG|erlotinib hydrochloride|Patients receive erlotinib hydrochloride PO (orally) QD (every day) on days -14-0 immediately prior to scheduled surgery. Treatment continues in the absence of disease progression or unacceptable toxicity.
223766479|NCT00503841|OTHER|immunohistochemistry staining method|Assessed at the time of the initial biopsy and at the time of surgery.
223766480|NCT00503841|OTHER|laboratory biomarker analysis|Correlative studies
223766481|NCT00503841|PROCEDURE|biopsy|14 days prior to surgery
223766482|NCT00503841|PROCEDURE|conventional surgery|14 days after taking study drug erlotinib hydrochloride.
223766483|NCT00503841|PROCEDURE|neoadjuvant therapy|14 days after taking study drug erlotinib hydrochloride.
223766484|NCT01437514|RADIATION|preoperative short-course radiotherapy|preoperative RT received a total dose of 25 Gy in five fractions during five consecutive days. The clinical target volume included the primary tumor and the mesentery with vascular supply containing the perirectal, presacral, and internal iliac nodes(up to the S1/S2 junction).The recommended upper border was at the level of the promontory. Radiation treatment was delivered with a three-portal technique.
223766485|NCT06126757|DEVICE|PelviSense-assisted pelvic floor muscle training|The PelviSense consists of a high-precision, oval-shaped, wearable EMG sensor that displays the electrical activity of the PFMs on the user's mobile device. The re-usable sensor can be attached to the user's perineal region, and when positioned correctly, the width of the sensor is oriented along the medial-lateral axis, and the length is oriented along the anterior-posterior axis of the perineal region. The sensor detects PFM activity as the voltage between the two surface electrodes and transmits this activity to the data acquisition unit, which processes the signal and conveys it to a smartphone via a Wi-Fi connection. The mobile app provides real-time muscular feedback, displayed as EMG waveforms in microvolts.
223766486|NCT06126757|OTHER|Active Comparator|Pelvic Floor Muscle Training Exercise will be performed without the assistance of the PelviSense Device.
223766487|NCT04180215|DRUG|HB-201 intravenous administration.|Dose / Schedule determined by 3+3 dose escalation (3 to 6 patients per cohort).
223766488|NCT04180215|DRUG|HB-202 intravenous administration alternating with HB-201 intravenous administration.|Dose / Schedule determined by 3+3 dose escalation (3 to 6 patients per cohort).
223766489|NCT04180215|DRUG|HB-201 intravenous administration + standard of care regimen including pembrolizumab.|Dose Expansion
223766490|NCT04180215|DRUG|HB-202 / HB-201 alternating intravenous administration + pembrolizumab.|Dose Expansion
223766491|NCT04180215|DRUG|HB-202 / HB-201 alternating intravenous administration + standard of care regimen including pembrolizumab.|Dose Expansion
223766492|NCT04180215|DRUG|HB-201 or HB-201/HB-202 alternating treatment using CD8 PET Tracer (Zr-Df-IAB22M2C)|Dose escalation; 10 patients
223766493|NCT00326612|DRUG|Midazolam|Intranasal Midazolam 0.2 mg/kg given once for seizures longer than 5 minutes.
223766494|NCT00326612|DRUG|Diazepam|Rectal Diazepam (Diastat) given once for seizure greater than 5 minutes.
223648466|NCT01731561|DRUG|Rituximab (Arm B)|Rituximab infusion will be performed at D1 then ANCA status and CD19+ lymphocyte count will be monitored every 3 months, and patients will receive new 500 mg rituximab infusions either if CD19 are \> to 0/mm3, or if ANCA are positive again or if ANCA titer significantly raises. All patients received corticosteroids, starting from induction with prednisone (or equivalent) at a dose of 1 mg/kg/day with gradual tapering according to a regimen adjusted to body weight over a mean of 18 months since diagnosis.
223648467|NCT01731561|DRUG|Rituximab (Arm A)|Rituximab infusion will be performed at D1, D15, M6, M12 and M18(i.e. a total of 5 infusions), at the dose of 500 mg at a fixed dosage.All patients received corticosteroids, starting from induction with prednisone (or equivalent) at a dose of 1 mg/kg/day with gradual tapering according to a regimen adjusted to body weight over a mean of 18 months since diagnosis.
223648468|NCT01911884|BEHAVIORAL|evaluate quality of life of surgical and non surgical vaginal aplasia|protocol designed to evaluate quality of life of surgical and non surgical vaginal aplasia
223766495|NCT01332734|DRUG|Magnesium Sulfate|2 gram in 1 hour
223766496|NCT01446562|BIOLOGICAL|Y90 Ibritumomab Tiuxetan RIT|40 mCi/kg
223766497|NCT04261270|DRUG|ASC09F+Oseltamivir|ASC09F tablets:one tablet(400mg/tablet)twice a day for 14 days;Oseltamivir tablet:75mg,once a day
223766498|NCT04261270|DRUG|Ritonavir+Oseltamivir|Ritonavir tablet:three tablets(100mg/tablet)twice a day for 14 days;Oseltamivir tablet:75mg,once a day
223766499|NCT04261270|DRUG|Oseltamivir|75mg ,once a day
223766500|NCT04709965|DIAGNOSTIC_TEST|Face2Gene|This study investigates whether a new diagnostic intervention (Face2Gene facial recognition software) is better than using standard approach to diagnosis.
223766501|NCT02888028|PROCEDURE|ICD remote monitoring|ICD remote monitoring additionally to regular in-office visits
223766502|NCT02888028|OTHER|Control group|Regular in-office visits/FU 1,3,6 and 12 months post implantation of an ICD or post ICD replacement w/o remote FU
224233553|NCT06211426|PROCEDURE|Stellate ganglion block|The patients were provided with Stellate ganglion block , using 0.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate ganglion block . The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
224320217|NCT06582498|BEHAVIORAL|Active intervention|This group will receive a pamphlet with diet and lifestyle recommendations for cancer survivors at randomization (2nd visit). Furthermore, they will be offered 3 individual sessions with health professionals (oncological dietitian, sports therapist, and oncological psychologist) and 3 group sessions with the same professionals. The duration of the individual visits is expected to be 45-60 minutes approximately, and group sessions will be planned for 1.5h duration approximately.
224320218|NCT06582498|BEHAVIORAL|Low-intensity intervention|This group will receive a pamphlet with diet and lifestyle recommendations for cancer survivor at randomization (2nd visit). These recommendations are all based on information from the World Cancer Research Fund, the American Institute for Cancer Research, and the American Cancer Society.
224320219|NCT06139302|DRUG|BI 1015550|BI 1015550
224320220|NCT00360984|DRUG|insulin glargine|
224320221|NCT00360984|DEVICE|continuous subcutaneous insulin infusion|
224320222|NCT05935202|DRUG|Mitapivat sulfate|Subjects enrolled Maximum dose: will receive Mitapivat during 56 weeks Starting dose: 50 mg BD Maximum dose: 100 mg BD
224320223|NCT01857479|DRUG|Inhaled budesonide|The control group will receive only nebulized budesonide 1 mg b.i.d. thrice a week for four months. Patients will also receive a metered dose inhaler of formoterol/budesonide (6/200) at a dose of 2 puffs b.i.d. and as and when required \[max 10 puff/day\]. The first dose will be administered under direct supervision. If the first dose is tolerated, therapy would be continued for the total duration of the study (4 months). The patient will be advised to clean the nebulizer chamber with soap and water after each administration to avoid contamination.
224320224|NCT01857479|DRUG|Inhaled amphotericin|"Amphotericin B deoxycholate (50 mg) will be dissolved in 10 mL sterile water for injection (5 mg/mL). The solution remains stable for at least 7 days at 2°C to 8°C. Ten milligrams of the drug (2 mL) will be nebulized over 10-15 minutes twice in a day for three times a week (Effective dose: 10 mg b.i.d. thrice a week) using a jet nebulizer. Nebulized budesonide will be administered at a dose of 1 mg b.i.d. thrice a week after nebulization with amphotericin B. The total duration of therapy would last 4 months. Patients will also receive a metered dose inhaler of formoterol/budesonide (6/200) at a dose of 2 puffs b.i.d. and as and when required \[max 10 puff/day\].~The first dose will be administered under direct supervision."
224320225|NCT02214537|OTHER|MACS|
224320226|NCT05876637|OTHER|Left Nostril Breathing|The participants which will show cardiovascular hyper reactivity towards CPT will be divided into 2 groups having 30 participants in each group. Experimental group will receive Left Nostril Breathing(slow, deep breath taken through your left nostril while closing your right nostril with your right thumb. Then just as gently exhale long, slowly, and completely through the left nostril, just as gently. It will be done while sitting) for 10 minutes twice a day for the duration of 12 weeks. Follow up will be taken through administration Cold pressor test after every 4,8 and 12 weeks.
224320227|NCT05876637|OTHER|Conventional|30 participants will be recruited in conventional group which will receive simple deep breathing exercises of 3 sessions per week for the duration of 12 weeks.Follow up will be taken after every 4,8 and 12 weeks.
223766503|NCT01959646|DIETARY_SUPPLEMENT|Aged Garlic Extract Supplementation Group|Subjects will be asked to consume three (3) capsules of 600 mg aged garlic extract (AGE) with food twice a day, for a total of 3.6 grams per day.
223766504|NCT01959646|OTHER|Standard for Groups|To assess for eligible study participants, the research team will use the Cholestech LDX® System (Alere™ Inc, Waltham, MA) to analyze finger-prick blood samples. This is an efficient and economical point of care testing for c-Reactive Protein (CRP), cholesterol and related lipids, and blood glucose, as diagnostic tools which provide information for immediate risk assessment and therapeutic monitoring of heart disease, inflammatory disorders and diabetes. Each finger prick will be treated individually.
223766505|NCT01959646|DIETARY_SUPPLEMENT|Placebo|Participants will be asked to consume three (3) placebo capsules with food twice a day.
224320228|NCT05707793|OTHER|Evaluating sexual function, quality of life and pelvic floor muscle strength, as well as thickness and force (strength) of voluntary contractions of the core muscles|Evaluation through Vaginal Laxity Questionnaire, Female Sexual Function Index, Short-Form 36 Health Survey, modified Oxford grading scale and ultrasound imaging
224320229|NCT02614105|PROCEDURE|Pelvic floor muscle training|16 weeks of group-based exercise
224320230|NCT02614105|PROCEDURE|Cough-suppression therapy|Group and individual sessions of respiratory physiotherapy with focus on techniques to suppress cough
224320231|NCT02614105|OTHER|Control|Brief information only
224233554|NCT05895084|BEHAVIORAL|Group Yoga|Yoga is delivered as described in an earlier section in a group format. Classes are an hour in duration and occur once per week for 8 weeks, and they are led by an adaptive yoga specialist.
224233555|NCT00428415|DRUG|Tesofensine|
224233556|NCT00409578|DRUG|Placebo|Placebo tablets and capsules. In order to adequately blind the study, patients were required to take a total of 1 tablet and 2 capsules during the first 4 weeks of the study. During the remainder of the study, patients were required to take 2 tablets and 2 capsules. Each dose was taken by mouth with water at approximately 8:00 AM with or without food.
224233557|NCT00409578|DRUG|Aliskiren 300 mg|Following 1 week of treatment with 75 mg of aliskiren (tablets), patients in this arm were titrated up to 150 mg of aliskiren; 1 week later they were titrated up to 300 mg aliskiren for the remainder of the study. If a patient was not up-titrated or required down-titration, the patient continued on that dose for the remainder of the study. If 2 down-titrations were required, they stopped study drug. In order to adequately blind the study, patients were required to take 1 tablet and 2 capsules during the first 4 weeks of the study and 2 tablets and 2 capsules for the remainder of the study. Each dose was taken by mouth with water at approximately 8:00 AM.
223648469|NCT04894006|BEHAVIORAL|Community Health Worker (CHW) Home Visit Intervention|The on-site intervention will focus on stress reduction techniques and caregiving skills education for 4 weeks and two monthly caregiver-driven topics for the following two sessions. The education of dementia caregiving skills will include (1) understanding about Alzheimer's and dementias, (2) appropriate communication skills with PWD, (3) daily activities for or with PWD together (e.g., puzzles, writing, reading, singing, taking a walk, etc), and (4) care resources including support groups, adult day centers, or other dementia related social services (legal and financial matters). For stress reduction techniques to be effective, the investigators have installed an app on the smartwatch to remind them to practice mindful breathing exercises two times a day and when needed.
223766506|NCT03613207|OTHER|Dermal pharmacokinetic measurement|"* Each subject will have 9 test sites: 4 on the left thigh, 4 on the right thigh, 1 on the arm~* Each test site receives 2 dOFM probes~* Dosing:~  * 2 test sites: 15 mg/cm² lidocaine and prilocaine cream (2.5% lidocaine, 2.5% prilocaine, ACTAVIS LABORATORIES UT INC, US)~ * 2 test sites: 10 mg/cm² lidocaine and prilocaine cream (2.5% lidocaine, 2.5% prilocaine, ACTAVIS LABORATORIES UT INC, US)~ * 2 test sites: 5 mg/cm² lidocaine and prilocaine cream (2.5% lidocaine, 2.5% prilocaine, ACTAVIS LABORATORIES UT INC, US)~ * 1 test site: 10 mg/cm² Oraqix® gel (2.5% lidocaine, 2.5% prilocaine, Dentsply Pharmaceutical Inc., US/Dentsply DETRY GmbH, Germany)~ * 2 test sites: untreated test site~* ISF sampling: 24 hours post-dose~* Blood sampling: 7 samples post-dose"
223766507|NCT03613207|DRUG|Lidocaine and prilocaine cream|lidocaine and prilocaine cream (2.5% lidocaine, 2.5% prilocaine, ACTAVIS LABORATORIES UT INC, US) will be applied to 6 test sites per subject
223766508|NCT03613207|DRUG|Oraqix® gel|Oraqix® gel (2.5% lidocaine, 2.5% prilocaine, Dentsply Pharmaceutical Inc., US/Dentsply DETRY GmbH, Germany) will be applied to 1 test site per subject
223766509|NCT03613207|DEVICE|dOFM-System|Dermal open flow microperfusion system will be used to collect interstitial fluid in order to assess lidocaine/prilocaine concentrations over 24 hours
223766510|NCT03613207|PROCEDURE|Blood sampling|8 blood samples will be collected in order to assess systemic lidocaine/prilocaine concentrations pre-dose (1 sample) and 24 hours post dose (7 samples)
223766511|NCT04776395|DRUG|Dexamethasone|Given PO
224233558|NCT00409578|DRUG|Valsartan 320 mg|Following 1 week of treatment with 80 mg of valsartan (capsules), patients in this arm were titrated up to 160 mg of valsartan; 1 week later they were titrated up to 320 mg valsartan for the remainder of the study. If a patient was not up-titrated or required down-titration, the patient continued on that dose for the remainder of the study. If 2 down-titrations were required, they stopped study drug. In order to adequately blind the study, patients were required to take 1 tablet and 2 capsules during the first 4 weeks of the study and 2 tablets and 2 capsules for the remainder of the study. Each dose was taken by mouth with water at approximately 8:00 AM.
224233559|NCT00409578|DRUG|Aliskiren/valsartan 300/320 mg|Following 1 week of treatment with 80 mg of valsartan (capsules), patients in this arm were titrated up to 160 mg of valsartan; 1 week later they were titrated up to 320 mg valsartan for the remainder of the study. Beginning with Week 4, in addition to 320 mg valsartan, patients were treated with 75 mg of aliskiren (tablets); 1 week later patients were titrated up to 150 mg of aliskiren and 1 week later they were titrated up to 300 mg aliskiren for the remainder of the study. If a patient was not up-titrated or required down-titration, the patient continued on that dose for the remainder of the study. If 2 down-titrations were required, they stopped study drug. In order to adequately blind the study, patients were required to take 1 tablet and 2 capsules during the first 4 weeks of the study and 2 tablets and 2 capsules for the remainder of the study. Each dose was taken by mouth with water at approximately 8:00 AM.
223648470|NCT04894006|BEHAVIORAL|Attention Control Group with WIoT Technology|The caregivers randomly assigned to the AC group will be asked to wear the smartwatch during the day time and the smartring during the night for 3 months in order to monitor their physiological measures (heart rate variability, heart rate, activities, and sleep quality). CHW will give AC participants an overview of WIOT instruction at the baseline home visit. Caregivers will also receive resource information regarding Alzheimer's association and local social service information. CHWs will contact them monthly via phone for 6 months answering general questions from participants. CHW will visit participants' home at baseline, 3 months, and 6 months to administer survey assessments.
223648471|NCT04894006|BEHAVIORAL|Usual Care|The caregivers randomly assigned to UC group will receive resource information regarding Alzheimer's association and local social service information at the baseline home visit by CHW. CHWs will contact them monthly for 6 months by phone asking general questions from participants. CHWs will visit participants' home at baseline, 3 months, and 6 months to administer survey assessments.
223648472|NCT04624074|BEHAVIORAL|Teen Marijuana Check Up|Teen Marijuana Checkup will be adapted for youth and young adults with first episode psychosis. The Teen Marijuana Checkup includes two intervention sessions. In Session 1, the interventionist uses motivational interviewing skills to hear the adolescent's history and current concerns with marijuana. The personalized feedback report generated from the baseline assessment is reviewed. In Session 2, the interventionist elicits change talk and guides discussion on making changes to reduce or stop marijuana use.
223648473|NCT05963438|PROCEDURE|anterior retraction|After placement of mini-implants and extraction of maxillary first premolar, retraction of anterior either simultaneously or separately depending on the allocated group will be done
224233560|NCT03363581|BEHAVIORAL|Food Preference|Buffet meal to assess food preference
224233561|NCT04371978|DRUG|Linagliptin 5 MG|Linagliptin 5 mg PO once daily
224233562|NCT02109133|PROCEDURE|deep neuromuscular blockade|deep neuromuscular blockade using rocuronium and reverse with sugammadex
224233563|NCT02109133|PROCEDURE|moderate neuromuscular blockade|moderate neuromuscular blockade using atracurium and reverse with neostigmine
224233564|NCT02109133|DRUG|Rocuronium|
224233565|NCT02109133|DRUG|Sugammadex|
224233566|NCT02109133|DRUG|Atracurium|
224233567|NCT02109133|DRUG|Neostigmine|
224233568|NCT07036991|DRUG|Evolocumab (biweekly injections) + Rosuvastatin/Atorvastatin ± Ezetimibe|PCSK9 inhibitor (biweekly injections) + rosuvastatin/atorvastatin ± ezetimibe
224233569|NCT07036991|DRUG|Rosuvastatin/Atorvastatin ± Ezetimibe|Rosuvastatin/atorvastatin ± ezetimibe
224233570|NCT05241535|DRUG|MT-7117|oral
224233571|NCT05241535|DRUG|moxifloxacin|oral
224233572|NCT05241535|DRUG|Placebo|oral
224320232|NCT05998876|DEVICE|Remote Medication Monitor (RMM) - Prototype|Inserted Microneedle Electrode Array for assaying dermal interstitial fluid.
223766512|NCT04776395|DRUG|Iberdomide Hydrochloride|Given PO
223766513|NCT04776395|OTHER|Quality-of-Life Assessment|Ancillary studies
223766514|NCT04717128|OTHER|Breastfeeding Skills Workshop|Participants will complete the standardized patient-led breastfeeding skills workshop where they will learn breast massage techniques to alleviate plugged ducts and engorgement, hand expression of breast milk, effective breast pump use, and newborn positioning and attachment.
223766515|NCT05057416|BEHAVIORAL|Exercise Adherence|Our current study will compare three exercise groups which will all vary in intensity. Participants will be randomly assigned to one of the three groups. Two groups will be assigned to high intensity bouts of exercise with an active rest between, and one group will perform moderate intensity continuous training without resting. All groups will exercise for 20 minutes. Exercise adherence and it will be measured by a self-report online Google Document.
224233573|NCT06394102|OTHER|The automatic color temperature adjustment mode equipped on terminal display devices can reduce the discrepancy between the color temperature of the device and the ambient light.|A program mode on a terminal display device that reduces the difference between the color temperature of the ambient light and that of the display device.
224233574|NCT04054024|DRUG|Erenumab|140 mg Erenumab
224233575|NCT04054024|DRUG|Placebos|Saline
224233576|NCT01147120|BEHAVIORAL|Progressive Muscle Relaxation (PMR)|Progressive Muscle Relaxation (PMR) will be recorded on PDAs integrated with EMA software and offered to patients who will be instructed in the techniques and PDA use by study coordinators. They will be instructed to practice 25 minutes/day the first two weeks, 35 minutes/day weeks 3 and 4, and 45 minutes/day weeks 5 through 12. These time periods (25/35/45 minute) were selected to allow a more gradual acclimation to PMR.
224233577|NCT01147120|PROCEDURE|Clinical Massage Therapy (CMT)|PCPs will have the opportunity to refer patients with CLBP to local Licensed Massage Therapists (LMTs) to receive up to 10 clinical massage sessions over a 12-week period. CMT will be provided at no cost to the patients. At their first two sessions, the LMT will evaluate the patient and, with the patient, estimate the number of sessions and determine treatment goals. Based on previous literature, 10 sessions are anticipated over an average 12-week period. However, treatment will vary depending on assessment and progress. At the end of the treatment period, the patients will receive a list of all participating LMTs to facilitate patients' continued or future participation in massage therapy.
224233578|NCT03457909|DEVICE|DS-MCE|During the DS-MCE examination,the capsule is allowed to travel down into gastric cardia,from where the string is slowly pulled to allow the capsule to view the esophagus retrogradely.
224233579|NCT00161278|DRUG|Carboplatin|
224233580|NCT00161278|DRUG|Paclitaxel|
224233581|NCT00161278|PROCEDURE|Gene expression profiling (analysis) of tumor samples|
224233582|NCT04740385|DIAGNOSTIC_TEST|Lung auscultation|auscultation of air entry through chest wal
224233583|NCT04740385|DEVICE|Fiberoptic bronchoscopy|Checking correct double lumen position through direct vision using fiberoptic bronchoscopy
224233584|NCT04740385|DEVICE|Lung Ultrasound|real time visualization of air entry to the lungs using trans-thoracic lung ultrasound
224233585|NCT02218359|DRUG|Amikacin Fosfomycin Inhalation Solution|300 mg of amikacin and 120 mg of fosfomycin twice daily for 10 days to be administered by aerosol via the AFIS Inline System
224233586|NCT02218359|DRUG|Aerosolized placebo|Placebo twice daily for Days 1 -5 to be administered by aerosol using the eFlow Inline System.
224320233|NCT05998876|DRUG|Daily Methadone Dose|patient takes their prescribed daily dose of methadone
223766516|NCT02267629|DRUG|Rapastinel (formerly GLYX-13)|10 mg/kg IV Rapastinel (formerly GLYX-13)
223766517|NCT05836610|DRUG|Hydrocortisone|intravenous bolus hydrocortisone therapy during hypothermia treatment
223766518|NCT02281721|DEVICE|Surpass Flow Diverter(s)|Endovascular placement of a Surpass Flow Diverter(s) for the treatment of an intracranial aneurysm(s)
223766519|NCT04186910|BEHAVIORAL|Control group|The control group will carry the Fitbit for the entire period of the recovery but will receive no feedback and will not have the app downloaded onto the telephone.
224233587|NCT02218359|DRUG|Amikacin Fosfomycin Inhalation Solution|Open-label crossover for all patients Days 6-10
224233588|NCT00287027|DRUG|Risperdal Long Acting Injectable Antipsychotic Medication|
224233589|NCT04017013|PROCEDURE|Epidural Analgesia|"The epidural infusion will be as follows:~* Isobaric Bupivacaine 0.5% 40 cc~* Morphine 4 mg (1 ampoule up to 10 cc and 4 cc of the mixture will be applied)~* Saline solution 0.9% 156 cc.~* Total Volume: 200 cc.~This mixture will be prepared by a nurse outside the research group outside the operating room once indicated.~The infusion will be scheduled at 7 cc / hour per continuous infusion set and will be connected to the epidural catheter after its placement."
224320234|NCT05322122|DEVICE|Side-to-side anastomosis duodeno-ileostomy diversion procedure|Creation of Side-to-Side Compression Anastomosis Using the GT Metabolic Solutions Magnetic Anastomosis System (The MAGNET System) to Achieve Duodeno-Ileostomy Diversion.
224233590|NCT04017013|DRUG|Lidocaine Infusion|2% Lidocaine IV without epinephrine: 1 mg/kg/ hour for up to 24 hours, started immediately after anesthetic induction.
224233591|NCT00213811|BEHAVIORAL|clinical, biological, and radiological|
224233592|NCT01680185|DRUG|Insulin lispro, Humalog (Eli Lilly) in insulin pump|all covered above
224233593|NCT01680185|DRUG|Human insulin isophane, Humulin N (Eli Lilly)|all covered above
224320235|NCT04667286|PROCEDURE|Prone Position (PP)|Prone the patients on oxygen for at least 10 hrs a day
224320236|NCT06161779|OTHER|Surgical reconstruction|submental artery island flap (SMAIF) for the reconstruction of laryngeal and hypopharyngal defects after the surgical resection of hypopharyngeal cancer
224323514|NCT04424407|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|Participants will meet with a psychologist once a week for six weeks to complete a brief CBT-I intervention. Cognitive Behavioral Therapy for Insomnia consists of a cognitive therapy and a behavioral therapy. The cognitive therapy is designed to identify incorrect ideas about sleep, challenge their validity, and replace them with correct information. This therapy tries to reduce worry, anxiety, and fear that one won't sleep by providing accurate information about sleep. The behavioral therapy increases sleep quality by limiting excessive time spent in bed to increase homeostatic sleep drive and sleep consolidation.
224323515|NCT02362594|BIOLOGICAL|pembrolizumab|Pembrolizumab 200 mg administered intravenously (IV) on Day 1 of each 21-day cycle
224233594|NCT01680185|OTHER|Standard of care|all covered above
223648474|NCT06640023|BEHAVIORAL|Z-drug Default Quantity|For new orders of oral Z-drugs tablets (zolpidem, zolpidem CR, zaleplon, and eszopiclone), the EHR dispense quantity default will be changed to 10 pills with 0 refills for all dosage levels. Dispense quantities for Z-drug reorders and renewals will not be changed.
223648475|NCT06640023|BEHAVIORAL|Redirection + Accountable Justification|"For qualifying Z-drug orders, an EHR alert will suggest removing the Z-drug, adding a CBT-I referral, or both. If the alert recommendation is not followed, clinicians will be asked to provide a justification for their decision when the order is signed. The justification will display in the Encounter Report.~The alert suggestion depends on the recent history of Z-drug prescriptions for a given patient. When a Z-drug is being ordered for patients with 180 days supply of Z-drugs or fewer in the last 365 days, the alert will prompt removal of the Z-drug and addition of a CBT-I referral to the order. When a Z-drug is being ordered for patients with 181 days supply of Z-drugs or more in the last 365 days, the alert will only prompt addition of a CBT-I referral to the order.~If a CBT-I referral is already in the current order or has been ordered for a patient in the past 180 days, the alert to add a CBT-I referral to the order will not display."
223648476|NCT03187626|DRUG|botulinum toxin A|Ultrasound-guided injection of 50 Allergan Unities of botulinum toxin A (Botox®, Allergan) resuspended in 1 ml of saline in the trapeziometacarpal joint and custom-made thermoformed plastic splint to be worn for 48 hours after intra-articular injection then nightly
223648477|NCT03187626|DRUG|saline|Ultrasound-guided injection of 1 ml of saline in the trapeziometacarpal joint and custom-made thermoformed plastic splint to be worn for 48 hours after intra-articular injection then nightly
223648478|NCT05180383|BEHAVIORAL|Mobile Application to Prevent Suicide (MAPS)|Safety Planning Intervention, ecological momentary intervention smartphone app system, and bidirectional communication with study clinician.
223648479|NCT06440421|BEHAVIORAL|MTL Labels|The MTL label developed by the United Kingdom (UK) Food Standards Agency (FSA) includes per serving size information and grades each nutrient i.e., energy, sugar, fat, saturated fat, and sodium separately based on recommended thresholds. Green signifies a healthy amount of that nutrient; red signifies an unhealthy amount, and amber signifies that the nutrient levels fall between healthy and unhealthy amounts. Additionally, the label also shows how much of a person's daily allowance for a particular nutrient is met by consuming one serving of the product. Lastly, MTL includes the absolute values of each nutrient per serving of a product and the percentage of an adult's daily reference intake that is met by consuming a serving of this product. These will be displayed on all food and beverage products shown on this version of Bahrain e-Mart.
223648480|NCT04880239|PROCEDURE|Posterior colpoperineorrhaphy|Patients having a sacralcolpopexy will be randomized to ultra lightweight mesh (Coloplast Restorelle) with posterior colpoperineorrhaphy or the same procedure without the posterior colpoperineorrhaphy
223648481|NCT03603353|OTHER|ENDS (vaporizer/e-cig) and smoking cessation counseling|"Participants in the intervention group will receive an ENDS and nicotine-containing e-liquids, which they will be allowed to use ad libitum. Additionally, they will receive smoking cessation counseling.~Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 24-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6, 12 and 24 months, participants will be asked to come to a clinical visit."
223648482|NCT03603353|OTHER|Smoking cessation counseling|Participants in the control group will receive smoking cessation counseling only. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 24-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6, 12 and 24 months, participants will be asked to come to a clinical visit.
223648483|NCT04074356|OTHER|Clinical measure questionnaires|Collection of patient reported symptoms and perception of health
223648484|NCT04074356|DIAGNOSTIC_TEST|EESG|Use of silver-silver chloride cutaneous electrogastrogram (EGG) electrodes to get myoelectrical readings
223648485|NCT04074356|DIAGNOSTIC_TEST|MESG|MESG measures spatiotemporal properties of magnetic fields from the esophageal slow wave and allows characterization of the propagation of the slow wave in addition to evaluation of its frequency and power distribution
224233595|NCT01983956|BEHAVIORAL|SENS model|Palliative care with a structured approach (SENS model) based on the bio-psycho-social-spiritual model of care, the WHO definitions of palliative care as well as the National Comprehensive Cancer Networks (NCCN) Practice Guidelines for Palliative Care. The approach supports the assessment of areas and complexity of concerns from the patient perspective, determines the priority and structures the support needed. The intervention is performed by palliative care physicians and nurses collaboratively. It is utilized as baseline assessment and afterwards integrated in each routine oncology care out-patient and in-patient visit. Depending on the goals it may be applied between routine visits. In addition, patients will receive usual oncology care throughout the study period.
224233596|NCT06016855|PROCEDURE|Tumor Debulking|Undergo surgical debulking
223648486|NCT04074356|DIAGNOSTIC_TEST|High resolution manometry (HRM)|Dysphagia subjects will have undergone standard of care HRM to determine placement in the achalasia or hypercontractile/spastic disorder arms
224233597|NCT06016855|DRUG|Lutetium Lu 177 Dotatate|Given by IV
224233598|NCT06016855|PROCEDURE|Computed Tomography|Undergo Computed Tomography
224233599|NCT06016855|PROCEDURE|Magnetic Resonance Imaging|Undergo Magnetic Resonance Imaging
224233600|NCT06016855|DRUG|Copper Cu 64 Dotatate|Given by IV
224233601|NCT06016855|PROCEDURE|Positron Emission Tomography|Undergo Positron Emission Tomography
224233602|NCT02542306|DRUG|fibrinogen concentrate|Investigators administered fibrinogen concentrate when the plasma fibrinogen level was below 1.5 g/L at 5 minutes after protamine reversal and completion of surgical hemostasis in patients, who comprised the fibrinogen concentrate-treated group.
224233603|NCT02369809|DRUG|Neovasculgen®|Treatment according to routine clinical practice at the discretion of the treating physician. Patients receive two local intramuscular injections of Neovasculgen® at a course dose of 2.4 mg according to the summary of product characteristics (SmPC).
224233604|NCT04489407|DEVICE|Remote Photoplethysmography (rPPG) vital sign acquisition|Subject vital signs will be acquired using the rPPG app simultaneously with the conventional vital sign monitors and manual respiratory rate calculation.
224233605|NCT05140096|DRUG|Acalabrutinib|"Modify as Participants will receive a single oral dose of 100 mg (1 X 100 mg capsule) acalabrutinib either on Day 1 of Period 1 (Treatment A) and Day 1 of Period 2 (Treatment B) or Day 5 of Period 2 (Treatment C)."
223648487|NCT01512615|OTHER|Complex Cardiac rehabilitation|Complex Cardiac Rehabilitation consisting of exercise training (minimum 3 times a week for a total of twelve weeks) and psychoeducational care (5 sessions over 6 months)
223648488|NCT01512615|OTHER|Control group|Usual care, clinical control as provided by treating heart centre
223648489|NCT00860860|DRUG|TF2|TF2: 75-300 mg
223648490|NCT00860860|DRUG|IMP-288 labeled with In111 and Lu177|IMP-288: 100 microgram
223648491|NCT02465827|DRUG|nerve block with ropivacaine|Ultrasound guided nerve blocks of the saphenous and obturator nerve, posterior branch with ropivacaine 0.75% for both nerve branches
223648492|NCT02465827|DRUG|nerve block with ropivacaine and with saline|nerve blocks of the saphenous nerve with ropivacaine 0.75% and obturator nerve, posterior branch with saline
223648493|NCT02465827|DRUG|nerve block with saline|Ultrasound guided nerve blocks of the saphenous and obturator nerve, posterior branch with saline for both nerve branches
223648494|NCT05465122|PROCEDURE|Carotid Endarterectomy|This is the standard proven therapy for carotid stenosis that involves an arteriotomy followed by removal of plaque and reconstruction of the vessel.
223648495|NCT05465122|PROCEDURE|FDA-approved carotid stents|This is the standard proven therapy for carotid stenosis that involves an arteriotomy followed by removal of plaque and reconstruction of the vessel.
223648496|NCT05465122|OTHER|Intensive Medical Management|INTERVENT risk factor management program to help manage patient's risk factors. The INTERVENT program will provide individualized risk factor counseling sessions (via telephone or internet) at regular interval by healthcare workers who are specially trained to help patients follow the medical management plan.
223766520|NCT04186910|BEHAVIORAL|Feedback group|The feedback group will carry the Fitbit for the entire period of the recovery and will receive daily feedback on amount of physical activity carried out and percentage completed of target behavior at the end of the day from an app downloaded on their telephone. The feedback group will also participate in weekly one hour meetings focused on enhancing behavioral strategies to increase self-efficacy and motivation. They will also have their fitbit data analyzed and an agreed upon target of daily activity level increase.
224233606|NCT05140096|DRUG|Fluconazole|Participants will receive 400 mg fluconazole (2 × 200 mg tablets) on Day 1 Period 2 (Treatment B).
224233607|NCT05140096|DRUG|Isavuconazole|Participant will receive oral dose of 200 mg isavuconazole (2 × 186 mg of isavuconazonium sulfate capsules) three times daily on Day 1 and 200 mg isavuconazole (2 × 186 mg of isavuconazonium sulfate capsules) once daily on Days 2 to 5 in Period 2 (Treatment C).
224233608|NCT02933281|BIOLOGICAL|MTBVAC|Escalating dose levels (5 x 10\^3 CFU, 5 x 10\^4 CFU, 5 x 10\^5 CFU, and 5 x 10\^6 CFU
224233609|NCT02933281|BIOLOGICAL|BCG|BCG 5 x 10\^5 CFU
224233610|NCT03942523|BEHAVIORAL|Behavior Change Communication to promote hygiene behavior|"Behavior Change Communication sessions will be used to promote knowledge and practices among young children and to prevent communicable diseases.~This will include, capacity building of teachers and students, health awareness sessions at the school and improving school physical environment"
224233611|NCT04535908|RADIATION|Hypofractionated radiotherapy|Hypofractionated radiotherapy in prostate cancer patients
224233612|NCT02675543|DEVICE|Vitreous Tamponade with Silicone Oil|
224233613|NCT04601584|BIOLOGICAL|Cohort 1, GNR-084|0.01 ng/kg 6-hours intravenous infusion once a week; 4 doses per cycle, up to 5 cycles
224233614|NCT04601584|BIOLOGICAL|Cohort 2, GNR-084|0.1 ng/kg 6-hours intravenous infusion once a week; 4 doses per cycle, up to 5 cycles
224233615|NCT04601584|BIOLOGICAL|Cohort 3, GNR-084|1 ng/kg 6-hours intravenous infusion once a week; 4 doses per cycle, up to 5 cycles
224233616|NCT04601584|BIOLOGICAL|Cohort 4, GNR-084|4 ng/kg 6-hours intravenous infusion once a week; 4 doses per cycle, up to 5 cycles
224233617|NCT04601584|BIOLOGICAL|Cohort 5, GNR-084|10 ng/kg 6-hours intravenous infusion once a week; 4 doses per cycle, up to 5 cycles
224233618|NCT04601584|BIOLOGICAL|Cohort 6, GNR-084|20 ng/kg 6-hours intravenous infusion once a week; 4 doses per cycle, up to 5 cycles
224233619|NCT03211559|OTHER|Exercise|clinical pilates on mat
224233620|NCT04815642|RADIATION|radiotherapy|Hypofractionated radiotherapy concomitantly with weekly boost
224320237|NCT02798588|RADIATION|PET-MRI|18Fluoro-Desoxy-Glucose's infusion for PET (glucose neural metabolism assessment, with quantitative information permitted by radioactivity monitoring through arterial catheter ; dosage = 1,5 MBq/Kg + 18,5 MBq as loading dose 5 min= Outside the scanner, Installation and movement management: Curare+/- sedative injection with standardized routine care protocol 10 min= Outside the scanner, Starting PET continuous acquisitionT= 0, Morphological MRI sequences- 3DT1, 3DFlair, T2SE, T2 HR on brainstem, Susceptibility and simple Diffusion Weighted Imaging-Specifically dedicated MR sequences based upon clinical issues 25 min, MRI in Resting state N°1 (global short-term functional connectivity)13 min, MRI DTI acquisition, 64 directions, sensitive to white matter injury 8 min, IRM in 2D-Arterial Spin Labelling:Quantitative Cerebral blood flow information (no Gadolinium)-\>8 min, IRM in Resting state 2 (repeated occurrence to assess stationarity) 13 min, End of PET continuous acquisition
224233621|NCT02016300|DEVICE|Unloader Bracing|The bracing arm patients will be randomly selected and will wear an unloader brace post-operatively during the study period.
224320238|NCT02130115|DEVICE|LungPoint ATV System|The LungPoint ATV System is an image-guided navigation system used to access tissue samples in the lungs.
223648497|NCT00055913|BIOLOGICAL|bevacizumab|Given IV
223648498|NCT00055913|DRUG|erlotinib hydrochloride|Given orally
223648499|NCT00055913|OTHER|laboratory biomarker analysis|Correlative studies
223648500|NCT04423302|DIETARY_SUPPLEMENT|TOTUM-63 3 intakes per day|5-g dose of TOTUM-63 diet supplement, a mix of 5 plant extracts. Eight capsules per day to consume orally in three intakes (3 in the morning, 2 at lunch and 3 at dinner)
223648501|NCT04423302|DIETARY_SUPPLEMENT|Placebo 3 intakes per day|Placebo. Eight capsules per day to consume orally in three intakes (3 in the morning, 2 at lunch and 3 at dinner)
224233622|NCT02016300|DEVICE|Non-Bracing|Microfracture performed with no post-operative unloader bracing
224233623|NCT02309099|DEVICE|Cochlear Implant|Cochlear implantation used a treatment for single-sided deafness resultant of labyrinthectomy or a translabyrinthine surgical approach
224233624|NCT05495542|OTHER|ShotBlocker|ShotBlocker (Bionix, Toledo, OH) is one of the methods that can be used to reduce pain caused by IM injections. This small, flat, U-shaped plastic device used by holding it on the skin surface during injection did not have any side effects \[5\]. ShotBlocker has a surface of 2 mm thick with rounded nubs to stimulate the skin (Figure 1). The surface of the plastic device is placed on the skin just before the injection; there is a hole in the center where the injection is administered \[6\]. The rounded nubs on the surface of the plastic device do not damage the skin, these rounded nubs that create a slight pressure provide a warning for the Gate Control Theory \[7\]
224233625|NCT04396028|OTHER|data collection|retrospective data collection
223648502|NCT04423302|DIETARY_SUPPLEMENT|TOTUM-63 2 intakes per day|5-g dose of TOTUM-63 diet supplement, a mix of 5 plant extracts. Eight capsules per day to consume orally in two intakes (4 in the morning and 4 at dinner)
223648503|NCT01635296|DRUG|RO5045377|Multiple escalating oral doses, Days 1 to 10 of each 28-day cycle
224233626|NCT04289428|DIAGNOSTIC_TEST|Xpert® HBV DNA fingerstick point of care assay|Xpert® HBV DNA point of care assay from finger-stick whole blood
224233627|NCT04289428|DIAGNOSTIC_TEST|Point of Care ALT|Point of Care ALT from finger-stick whole blood
223648504|NCT01635296|DRUG|RO5045377|Multiple escalating oral doses, Days 1 to 5 of each 28-day cycle
223648505|NCT01635296|DRUG|cytarabine|20 mg/m2 sc, Days 1 to 10 of each 28-day cycle
224233628|NCT04289428|DIAGNOSTIC_TEST|Xpert® HBV DNA point of care assay from dried blood spot|Xpert® HBV DNA point of care assay from dried blood spot
224233629|NCT00665041|DRUG|Quinagolide|"• Quinagolide 200 μg/day (dose titration from 50 μg/day to 100 μg/day to 200 μg/day), oral. Quinagolida tablets, 50 mcg.~placebo, oral."
224233630|NCT06291688|BEHAVIORAL|Mobile healthcare education game|Game group will download an APP on a smart phone and play the mobile game which contains the educaitonal content regarding EGFR-related cutaneous adverse drug reactions.
224233631|NCT06291688|BEHAVIORAL|Mobile healthcare education application|Text group will download an APP on a smart phone and open the APP to see the text regarding EGFR-related cutaneous adverse drug reactions.
224233632|NCT06165744|DEVICE|UNITY Vitreoretinal Cataract System|UNITY Vitreoretinal Cataract System (VCS) with console, remote control, foot controller, UNITY TOTAL PLUS Combined Procedure Pak, and additional devices as needed to complete surgery
224233633|NCT06165744|PROCEDURE|Posterior segment surgery in the operating room with or without simultaneous cataract surgery|Posterior segment surgery involves removal of the vitreous (i.e., vitrectomy) followed by additional interventions as needed. Cataract surgery involves removal of the crystalline lens (which is often cloudy).
224233634|NCT06211491|OTHER|Urodynamic test|Urodynamic testing is performed using saline solution at the same temperature as body temperature (37 degrees) at two injection speeds of 10 mL/min and 100 mL/min, respectively.
224233635|NCT01096927|DRUG|Amoxicillin and Clavulanic Acid|7 days antibiotic therapy with Amoxicillin and Clavulanic Acid, 1 gr 3 times daily PO
224233636|NCT01056874|DRUG|Digoxin|Oral Digoxin 0.25 mg single dose
224233637|NCT01056874|DRUG|Digoxin|Oral Digoxin 0.25 mg single dose on Day 5
224233638|NCT01056874|DRUG|Maraviroc|Oral Maraviroc 300 mg twice daily for 6 days
224233639|NCT03244774|DRUG|Apatinib|"Apatinib 250mg p.o. qd in first cohort (3 subjects). 375mg p.o. qd in second cohort (3 subjects). 500mg p.o. qd in third cohort (3 subjects). 625mg p.o. qd in forth cohort (3 subjects); 750mg p.o. qd in fifth cohort (3 subjects).~Other Name:"
223766521|NCT00548808|DRUG|Insulin lispro low mixture|Dose depending on patient's need; subcutaneous injection before meal; start with once-daily injection before evening meal for 48 weeks, may add second injection before breakfast at any time during the treatment period if required, and may further add third injection before lunch at any time in the remainder of the treatment period if required.
224233640|NCT03244774|DRUG|POF|The POF regimen consisted of a 3-hour infusion of paclitaxel (135 mg/m2) followed by oxaliplatin (85 mg/m2) and Calcium Levofolinate (200 mg/m2).Subsequently, a 46-hour infusion of fluorouracil (2400 mg/m2) was administered using an ambulatory pump, repeating the cycle every 14 days.
224233641|NCT04997694|PROCEDURE|Pre Heating|Before anesthesia was given, the participants were warmed for 20 minutes with prewarming techniques. Presence of postoperative hypothermia, vital signs and temperature comfort level were evaluated.
223648506|NCT01635296|DRUG|cytarabine|1 gm/m2 iv, Days 1 to 6 of each 28-day cycle
224233642|NCT04788680|OTHER|Dietary intervention 1|Participants receive a beverage with a defined amount of non-nutritive sweetener.
224233643|NCT04788680|OTHER|Dietary Intervention 2|Participants receive a beverage with a defined amount of non-nutritive sweetener and maltodextrin.
224233644|NCT04788680|OTHER|Dietary Intervention 3|Participants receive a beverage with a defined amount of monosaccharide.
224233645|NCT04788680|OTHER|Dietary Intervention 4|Participants receive a beverage with a defined amount of disaccharide.
223648507|NCT05970289|BIOLOGICAL|PEG-IFNα|PEG-IFNα will be given via subcutaneous injection
223648508|NCT05970289|DRUG|BRII-835|BRII-835 will be given via subcutaneous injection
223648509|NCT02877589|OTHER|hepatitis B virus (HBV) and hepatitis C virus (HCV) serologies and a screening questionnaire to detect risk factors of hepatitis B virus (HBV) and hepatitis C virus (HCV)|
223648510|NCT03682770|DRUG|Dupilumab|Dupilumab will be administered subcutaneously (SC) in a single-use, pre-filled glass syringe every two weeks (Q2W)
223648511|NCT03682770|DRUG|Placebo matching dupilumab|Placebo matching dupilumab is prepared in the same formulation without the addition of protein
223648512|NCT03682770|DRUG|AR101|AR101 will be provided in dose-escalating capsules and then sachets during maintenance phase
223766522|NCT00548808|DRUG|Insulin glargine|Dose depending on patient's need; one daily subcutaneous injection before bedtime for 48 weeks
223766523|NCT00548808|DRUG|Insulin lispro|Dose depending on patient's need; subcutaneous injection before meal; may start once-daily injection before meal (e.g. lunch if the highest blood glucose value is measured before dinner) on top of insulin glargine at any time of the treatment period if required, and may further add second or even third injection in the remainder of the treatment period if required.
223766524|NCT02607488|DRUG|Placebo|"Participants will receive an intravenous bolus of 0.1 mL/kg of saline 0.9% solution followed by a continuous infusion 0.1 mL/kg/h of Saline 0.9% which will be continued for 24 hours after surgery.~All medications in the study protocol will be based on the dosing body weight \[ideal body weight (IBW) + 0.4 × (actual body weight-IBW)\]"
223648513|NCT02362282|BEHAVIORAL|Gait training|Treatment will include coordination exercises and over ground gait training for impaired muscle groups and related gait deficits. The therapy will be provided by a clinical physical therapist specializing in rehabilitation for stroke patients, according to established, conventional guidelines. The protocol was used in the investigators' prior studies, and is designed to restore voluntary control of ankle dorsiflexion during swing phase; hip flexion during swing phase, knee flexion at toe-off, knee flexion during swing phase; knee extension before heel strike; knee control during stance phase; pelvic control during stance phase; and whole body balance control during weight shifting. Newly-learned coordinated movements will be integrated into practice of coordinated gait components. Cognitive rehabilitation will begin with the least difficult aspects of attention control, and progress to the more difficult. Home practice and generalization exercises will be assigned.
223648514|NCT02362282|BEHAVIORAL|cognitive training|Cognitive training is designed to enhance attention, intention, executive function, decision making and reaction time. Commercially available computer software will be used, as well as custom cognitive training.
223648515|NCT02362282|BEHAVIORAL|Arm training|Treatment will include coordination exercises for reaching and grasping. Activities will include movement of shoulder, elbow, wrist and fingers.
223766525|NCT02607488|DRUG|Lidocaine 1%|"Participants will receive an intravenous bolus of 0.1 mL/kg of lidocaine 1.5% solution followed by a continuous infusion 0.1 mL/kg/h of lidocaine 1% solution which will be continued for 24 hours after surgery.~All medications in the study protocol will be based on the dosing body weight \[ideal body weight (IBW) + 0.4 × (actual body weight-IBW)\]"
223766526|NCT02607488|DRUG|Lidocaine 1.5%|"Participants will receive an intravenous bolus of 0.1 mL/kg of lidocaine 1.5% solution followed by a continuous infusion 0.1 mL/kg/h of lidocaine 1.5% solution which will be continued for 24 hours after surgery.~All medications in the study protocol will be based on the dosing body weight \[ideal body weight (IBW) + 0.4 × (actual body weight-IBW)\]"
223766527|NCT02607488|DRUG|Lidocaine 2%|"Participants will receive an intravenous bolus of 0.1 mL/kg of lidocaine 1.5% solution followed by a continuous infusion 0.1 mL/kg/h of lidocaine 2% solution which will be continued for 24 hours after surgery.~All medications in the study protocol will be based on the dosing body weight \[ideal body weight (IBW) + 0.4 × (actual body weight-IBW)\]"
223766528|NCT00625599|OTHER|Osteoporosis Prevention Information|Primary investigator designed osteoporosis prevention information.
223766529|NCT02177266|DRUG|Colchicine|Colchicine 0.6mg bid will be given to study participants randomized to the study drug arm beginning at 48-72 hours prior to the planned cardiac surgery and then continued for a total of 30 days.
223766530|NCT02177266|DRUG|Placebo|The placebo will match the study drug.
224233646|NCT04524065|OTHER|Early rehabilitation protocol for children hospitalized in the PICU|The early rehabilitation protocol was developed by a collaborative multidisciplinary team approach in Samsung Medical Center, and the central components include the involvement of physical therapy/occupational therapy (PT/OT).
224233647|NCT05456529|DRUG|Ruxolitinib Cream|Ruxolitinib cream 1.5% twice daily (BID) during the continuous and LTS treatment period.
224233648|NCT01496040|DRUG|rAAV2/4.hRPE65|"One injection in on eye~Cohorte 1 : 3 patients will receive one injection of up to 400 microliters of the IMP~Cohorte 2 : 3 patients will receive one injection of up to 800 microliters of the IMP.~Cohorte 3 : 3 patients under age of eighteen will receive one injection up to 400 or 800 microliters of the IMP."
224233649|NCT00797108|DRUG|sulopenem and PF-03709270|Sulopenem - 600 mg infused over 1 hour, single loading dose and switch to oral PF-03709270 - 1000 mg twice a day
224233650|NCT00797108|DRUG|Sulopenem and PF-03709270|Sulopenem - 600 mg infused over 1 hour twice daily for a minimum of 2 days and switch to oral PF-03709270 - 1000 mg twice a day
224233651|NCT00797108|DRUG|Ceftriaxone and amoxicillin/clavulanate|IV ceftriaxone (2g) infused over 30 minutes QD (once daily) for minimum of 2 days Step down oral amoxicillin/clavulanate potassium suspension (400 mg/5 ml) BID (every 12 hours)
224233652|NCT02518113|DRUG|LY3039478|Administered orally
224233653|NCT02518113|DRUG|Dexamethasone|Administered orally
224233654|NCT02518113|DRUG|Placebo|Administered orally
224233655|NCT03901014|OTHER|Standard American diet|Standard American diet with 50% energy from carbohydrate, 30% from fat, and 20% from protein.
224233656|NCT03901014|OTHER|Very low carbohydrate diet|Ketogenic diet with \<50g carbohydrate, 60-75% energy from fat, and 20% from protein
224233657|NCT01785836|DRUG|Dapsone Formulation A|Dapsone Formulation A applied once daily to the face and upper chest, upper back, and shoulders (as per protocol) for 12 weeks.
224233658|NCT01785836|DRUG|Dapsone Formulation B|Dapsone Formulation B applied once daily to the face and upper chest, upper back, and shoulders (as per protocol) for 12 weeks.
224233659|NCT01785836|DRUG|Dapsone Formulation C|Dapsone Formulation C applied once daily to the face and upper chest, upper back, and shoulders (as per protocol) for 12 weeks.
224233660|NCT01785836|DRUG|Dapsone 5% Gel|Dapsone 5% gel (ACZONE®) applied twice daily to the face and upper chest, upper back, and shoulders (as per protocol) for 12 weeks.
224233661|NCT02349165|PROCEDURE|Transepithelial versus epithelium-off CXL|A comparison of the CXL procedure with and without epithelium removal
224233662|NCT02349165|DRUG|Ricrolin TE|Ricrolin TE was instilled during 30 minutes before ultraviolet-A irradiation
224233663|NCT02349165|DRUG|Isotonic riboflavin|After epithelium removal, isotonic riboflavin was instilled during 30 minutes before ultraviolet-A irradiation
224233664|NCT03622866|DEVICE|Ultra-high pulse width stimulation|Algovita Spinal Cord Stimulation System with associated components
224233665|NCT03622866|DEVICE|Traditional pulse width stimulation|Algovita Spinal Cord Stimulation System with associated components
224233666|NCT02270736|DRUG|NT 201 Placebo|NT 201 placebo matching injection.
224233667|NCT02270736|DRUG|NT 201|NT 201 injection.
223648516|NCT05846854|OTHER|Assessment for bleeding disorder with tailored post-operative care|Intervention will be expanded lab work-up for hematologic conditions, consultation by Hematology and tailored intra-operative and post-operative plan with aim to mitigate bleeding and hemorrhage risk, balancing thrombotic risk with this intervention.
223648517|NCT01708785|BEHAVIORAL|Single food Cue Exposure Treatment|Subjects will be exposed to the same set of 4 foods in each cue exposure treatment session.
223648518|NCT01708785|BEHAVIORAL|Multiple food Cue Exposure Treatment|Subjects will be exposed to a different set of 4 foods in each cue exposure treatment session.
223766531|NCT01288534|RADIATION|Radiation Therapy|Patients will receive 5 fractions of radiation (you will not receive radiation therapy on two consecutive days). Each fraction size will be 7.4 Gy. The total dose will be 37 Gy. The 5 treatments will be scheduled to be delivered 2 fractions per business week (Monday through Friday). The total duration of treatment will be no shorter than 15 days and no longer than 19 days.
223766532|NCT01367808|DRUG|Placebo|The subjects will be given placebo twice a day for 5 days prior to the study
223766533|NCT01367808|DRUG|vorikonazole|The subject will be given vorikonazole twice a day for 5 days prior to the study. The dose will be 400 mg twice a day on day one ans 200 mg twice a day on days 2-5.
224233668|NCT04726202|OTHER|Standard procedure|Coding of cases follows the standard procedures established at the hospital
224233669|NCT04726202|OTHER|precoding|"Standard coding will be reviewed by dedicated physicians and corrected or extended if necessary.~Coding will compared to the written OP report for consistency. Dedicated physician visits patients daily (in addition to routine visits). Dedicated physicians review discharge report and will make changes and additions. DRG coding will be adapted to results from visits and discharge report."
224233670|NCT02474264|OTHER|Endothelial function assessment|reactive hyperemia index
224233671|NCT02474264|OTHER|Cardiovascular biomarkers|Cardiovascular biomarkers will be measure to test other aspects of endothelial and cardiac function: high-sensitivity troponin (hsTn) , C-reactive protein , D-dimer, N-terminal pro-brain natriuretic peptide (NT-proBNP)
224233672|NCT02474264|OTHER|Endothelial cells|Endothelial Progenitor Cells and Circulating Endothelial Cells profiles- will be characterized to evaluate endothelial injury.
224233673|NCT01631864|DRUG|LCZ696|LCZ696 was provided as 400 mg tablets.
224233674|NCT01631864|DRUG|amlodipine|amlodipine was provided as 5 mg tablets.
224233675|NCT01631864|DRUG|Placebo|Matching placebo to LCZ696 and amlodipine.
224233676|NCT05395000|BEHAVIORAL|Videos|A short video explaining briefly what type 1 diabetes is, the symptoms of hypoglycemia and the usefulness of glucagon as well as two short videos explaining how to administer glucagon, all less than 3 minutes long, will be viewed by the 2 groups for intranasal glucagon and injectable glucagon. Participants will have access to the videos for 2 weeks, approximately 3 months before the next stages of the project.
224233677|NCT05395000|BEHAVIORAL|Simulation|An intranasal and injectable glucagon administration test on a mannequin in a simulated stress environment will be done.
224233678|NCT05395000|BEHAVIORAL|Interview|At the end of the simulation, participants will participate in a semi-structured, recorded individual interview of approximately 20 minutes to share their experience related to preferences, barriers, emotional impact, and method of teaching the use of the two glucagon formulations.
224320239|NCT04573894|DIAGNOSTIC_TEST|Procalcitonin dosage|Plasma PCT levels measured by automated enzyme immunoassay (Kryptor).
223766534|NCT01367808|DRUG|posakonazole|The subjects will be given posaconazole 400 mg twice a day for 5 days prior to the study.
223766535|NCT00546715|DRUG|Daclatasvir|Oral Solution, Oral, Single Dose
223766536|NCT00546715|DRUG|Placebo|Oral Solution, Oral, Single Dose
224233679|NCT00265733|DRUG|capecitabine|
224233680|NCT00265733|DRUG|paclitaxel poliglumex|
224233681|NCT05625256|DEVICE|SentiCor-300|Continuous blood pressure measurement with the SentiCor-300.
224233682|NCT00861809|DRUG|GSK962040 25 mg|25 mg
224320240|NCT04660279|DIAGNOSTIC_TEST|Dynamic Whole-Body parametric PET/CT|Dynamic whole-body PET/CT imaging protocol
224320241|NCT00616421|BIOLOGICAL|MenACWY-CRM|1 injection of the Novartis MenACWY-CRM conjugate vaccine administered intramuscularly
224320242|NCT00616421|BIOLOGICAL|MenACWY-CRM|2 injections of the Novartis MenACWY-CRM conjugate vaccine administered intramuscularly to children 2 to 5 years of age
224320243|NCT00616421|BIOLOGICAL|Licensed meningococcal ACWY vaccine|1 injection of the licensed meningococcal ACWY was administered intramuscularly
224320244|NCT06200506|DEVICE|Transabdominal radiofrecuency application|"A transabdominal radiofrequency application will be performed, with a suprapubic active plate and a passive plate at the sacral level.~Patient position: Supine position. Sessions:9 Duration: 20 minutes Total intervention: 3 weeks.~Frequency: 3 times a week sessions will be held three times a week for three weeks"
224323516|NCT02362594|DRUG|placebo|Normal saline solution administered IV on Day 1 of each 21-day cycle
223766537|NCT02568488|DRUG|Metformin|850 mg orally twice daily for 6 months
223766538|NCT02206113|BEHAVIORAL|Standing workstation|
223766539|NCT02331446|BEHAVIORAL|Physical exercise intervention|
223766540|NCT05054296|BEHAVIORAL|Educational Intervention|Receive general education exercise packet
223766541|NCT05054296|BEHAVIORAL|Exercise Intervention|Participate in supervised and self-directed exercise sessions
223766542|NCT05054296|DEVICE|FitBit|Wear FitBit for activity tracking
223766543|NCT05054296|OTHER|Quality-of-Life Assessment|Ancillary studies
223766544|NCT05054296|OTHER|Questionnaire Administration|Ancillary studies
223766545|NCT03090399|DEVICE|FloTrac|For patients belonging to case group a Pulse Contour Analysis was adopted for optimize fluid administration
223766546|NCT01329081|OTHER|Postoperative rehabilitation after fast-track TKA|Six weeks of strength training combined with patient education
223766547|NCT01329081|OTHER|Postoperative rehabilitation after fast-track TKA|Six to eight weeks of supervised home training
223766548|NCT02628275|BEHAVIORAL|Moderate to vigorous physical activity|55-90% maximum heart rate for 150min/week (current recommendations)
224233683|NCT00861809|DRUG|Placebo|placebo comparator
224233684|NCT00861809|DRUG|GSK962040 50 mg|50 mg
224233685|NCT00861809|DRUG|GSK962040 1250 mg|125 mg
224233686|NCT02134756|DRUG|NutraStem Active|
224233687|NCT02134756|DRUG|NutraStem Placebo|
224233688|NCT00583700|DRUG|Pentoxifylline|Pentoxifylline 400 mg, 3 times daily for 7 months, beginning immediately after radiation therapy.
224233689|NCT00583700|DRUG|Vitamin E|Vitamin E (Over-the-counter) 400 I.U. once daily
224233690|NCT03443778|DRUG|Bupivacaine 0.5%|Marcaine 0.5% Injectable Solution
224233691|NCT03443778|DRUG|Bupivacaine 0.5% , Dexamethasone|Bupivacaine 0.5% , Dexamethasone
224233692|NCT03443778|DRUG|Nacl 0,9 %|Injectable Solution
224233693|NCT03338361|BEHAVIORAL|active approach avoidance training and sham visual probe training|patients receive active AAT training and sham VPT training
224323517|NCT05092581|DRUG|casirivimab+imdevimab|Single dose weight-based equivalent administered intravenously (IV)
223648519|NCT01708785|BEHAVIORAL|Partial Reinforcement - Enhanced Cue Exposure Treatment|Subjects will take random additional tastes of the food during cue exposure treatment.
223648520|NCT01708785|BEHAVIORAL|Partial Reinforcement -Consistent Cue Exposure Treatment|Subjects will consistently take the same tastes of the food during cue exposure treatment.
223648521|NCT01755182|DRUG|approved pharmacologic therapy|
223648522|NCT01755182|PROCEDURE|TAE|after randomization, and after 3 months
223648523|NCT01447459|BEHAVIORAL|Reinforced Asthma Education|"Before beginning the actual study, a board-certified Asthma Educator (AE) will prepare and administer an asthma education training session for the study personnel, including the PI, the co-investigators, and the study coordinator. The AE will also make herself available via pager for assistance with questions from the study personnel regarding asthma education.~At the end of the administration of the phone surveys (i.e. at 2 weeks, 1 month and 3 months following enrollment), the study coordinator will provide reinforced asthma education to the caregiver via telephone for the subjects enrolled in Group A (the intervention group). The reinforced asthma education will be consistent with the asthma education training session delivered by the AE before the beginning of the study."
223648524|NCT05974124|DEVICE|Povidone-Iodine 0.66%|Povidone-iodine 0.66% eye drops were instilled 4 times daily for 3 days before cataract surgery in the eye to be operated on. The contralateral eye was considered as control and received no treatment.
224233694|NCT03338361|BEHAVIORAL|sham approach avoidance training and active visual probe training|patients receive sham AAT training and active VPT training
224233695|NCT03338361|BEHAVIORAL|active approach avoidance training and active visual probe training|patients receive active AAT training and active VPT training
223648525|NCT05974124|DEVICE|Chlorhexidine 0.02%|Chlorhexidine 0.02% eye drops were instilled 4 times daily for 3 days before cataract surgery in the eye to be operated on. The contralateral eye was considered as control and received no treatment.
223648526|NCT06208280|DRUG|After preconditioning with Fludarabine and Cyclophosphamide, F01 will be evaluated.|"Drug: After preconditioning with Fludarabine and Cyclophosphamide, F01 will be evaluated.~Biological: 0.5-3×10\^9 CAR+NK Cells, Treatment follows a lymphodepletion Drug: Fludarabine: 25-30 mg/m\^2 (D-5\~D-3) Drug: Cyclophosphamide: 250-300 mg/ m\^2 (D-5\~D-3)"
223648527|NCT01278225|BEHAVIORAL|EEG biofeedback (BF) Group|Group 1 will take part in a minimum of 2 neurofeedback training sessions each week for up to 10 weeks, for a total of up to 20 training sessions.
223648528|NCT01278225|BEHAVIORAL|Wait-List Control (WLC) Group|Group 2 will be placed on a wait-list, will continue to receive standard care, will not take part in the neurofeedback training, but will take part in the follow-up visits.
223648529|NCT01278225|BEHAVIORAL|Follow UP Questionnaires|After Group 1 completes neurofeedback training, both Groups to complete 10 questionnaires that were completed at baseline.
223648530|NCT01470326|DRUG|Bazedoxifene|For adults, take 1 tablet (20 mg of the active ingredient) at a time, once a day.
223648531|NCT05357248|DEVICE|BT-NCBT-00X|the intervention group will consist of 20 patients to receive the BT-NCBT-00X treatment for 90 days. They will receive a baseline MRI-PDFF, Fibroscan and have the tests repeated at 90 days.
223648532|NCT05153096|DRUG|NBL-015|NBL-015 by intravenous infusion
223648533|NCT01166282|BIOLOGICAL|adalimumab|Adalimumab solution for subcutaneous injection.
223648534|NCT01166282|BIOLOGICAL|placebo for adalimumab|Placebo for adalimumab solution for subcutaneous injection.
223648535|NCT06081270|OTHER|Liquid biopsy|Blood withdrawal for each patient is performed (i) at the time of treatment initiation with tyrosine kinase inhibitors (TKI); (ii) at the time of the first planned instrumental re-evaluation according to clinical practice regardless of the type of response to the TKI employed (9-12 weeks); (iii) at the time of radiological progression according to RECIST 1 criteria. 1 at computerized tomography scan with contrast or metabolic progression at 18F-2-fluoro-2-deoxy-D-glucose fluorodeoxyglucose during TKI therapy; (iv) at the time of the change of therapeutic strategy decided by the investigator when used beyond progression and not coinciding with point iii. The ctDNA is extracted from plasma and analyzed with Illumina sequencing method.
224233696|NCT03338361|BEHAVIORAL|sham approach avoidance training and sham visual probe training|patients receive sham AAT training and sham VPT training
224233697|NCT00952783|DRUG|Lesion count|Lesion count in area treated by study drug in a prior study over a 12 month period No drug will be applied during this long-term follow up study. Drug was applied during the primary study.
223648536|NCT03588884|DRUG|Calcifediol Oral Capsule|Capsule, daily
224233698|NCT04066309|DEVICE|Neodent GM Helix Implant|4.0x10 mm Neodent GM Helix Implants will be placed 2mm subcrestally (in relation to the buccal bone plate) in the posterior region of the maxilla, under local anesthesia and with adequate bone bed preparation, as recommended by the manufacturer, using the guided surgery technique.
224233699|NCT04066309|DEVICE|GM Customizable Healing Abutment|Customizable healing abutments will be placed at the time of implant placement.
224233700|NCT04066309|DEVICE|GM Pro PEEK Abutment|Placement of temporary single prostheses (early loading), over temporary abutments.
224233701|NCT04066309|DEVICE|GM Exact Titanium Base|Insertion of the final abutment (Titanium Base and Zirconia Coping), following the digital workflow.
224233702|NCT00890877|DRUG|OC000459 or placebo|Pills, active and/or placebo given twice daily for 17 weeks
224320245|NCT06200506|DEVICE|Intracavitary radiofrequency application|"An intracavitary vaginal radiofrequency application will be performed, with an active intracavitary head and with a fixed plate at the sacral level.~Patient position: Supine position. Sessions:9 Duration: 20 minutes Total intervention: 3 weeks. Frequency: 3 times a week sessions will be held three times a week for three weeks."
224320246|NCT02490280|BEHAVIORAL|Trier Social Stress Test|The TSST is the gold standard social stress test and involves speaking in front of confederate judges and completing arithmetic tasks. The task takes 10-15 minutes.
223648537|NCT03588884|DRUG|Calcifediol Oral Product|Capsule, once a month
223648538|NCT03588884|DRUG|Cholecalciferol|Capsule, once a month
223648539|NCT03588884|DRUG|Paricalcitol Oral Capsule|Capsule, daily
223648540|NCT04666220|OTHER|VETC evaluation|We will evaluate VETC presence on tissue specimens
223648541|NCT06012552|DRUG|Tianeptine|Tianesal 12,5mg
223648542|NCT06012552|DRUG|Placebo|application as in the control group
223766549|NCT02628275|BEHAVIORAL|Light physical activity|40-55% maximum heart rate for 150min/week
224233703|NCT02792205|OTHER|Non interventional study|no intervention
223648543|NCT00132704|RADIATION|Ionizing radiation (IR) therapy|Tumors will be sliced into 0.5cm fragments, incubated in culture medium and then irradiated to evaluate the kinetics and dose-dependencies of the endothelial apoptotic response. We will irradiate tumor fragments ex vivo at 0, 7, 13, 15, 17, and 25 Gy.
223648544|NCT00132704|RADIATION|Ionizing radiation (IR)|Tissue fragments of a total quantity of at least a 4x4x4 cm3 will be required. For each tumor a paraffin block will also be made for routine staining and IHC. Endothelial cell populations (at least 500 cells) will then be exposed to radiation at 0, 7, 11, 13, 15, 17, and 25 Gy and harvested at 4, 5 and 8 hours post IR.
223766550|NCT05122949|DEVICE|3D Printed Ankle-Foot Orthosis|3D Printed (Fused Deposition Modelling) Ankle-Foot Orthosis with Polyamide Nylon-12 material
223766551|NCT05122949|DEVICE|Thermoformed Ankle-Foot Orthosis|Thermoformed Ankle-Foot Orthosis with homopolymer polypropylene
223766552|NCT02099721|DEVICE|ICD or CRT-D Device|Subjects who receive an ICD/CRT-D device implant will be implanted and follow protocol-specified programming. The programming is not investigational. Consistent programming is desirable in order to compare groups during statistical analysis.
223766553|NCT05925894|DRUG|Efficacy of a Standardized Intracameral Combination of Mydriatics and Anesthetic (Mydrane ®) for Cataract Surgery in Patients With Concomitant Primary Open Angle Glaucoma|60 patients with coexisting POAG and cataract who underwent elective cataract extraction. All patients underwent ophthalmic routine examinations including automatic visual field examination, anterior chamber configuration, specular microscopy and arterial blood pressure measurement prior to surgery, 24 hours and 30 days postoperatively. All cataract surgeries were videorecorded, and all measurements were performed using media player. 20 patients received topical mydriatic eye drops, 20 patients received Mydriasert ® whereas 20 patients received intracameral injection of Mydrane ® just after the first incision.
223766554|NCT04142541|DEVICE|Neuroguard® IEP 3-in-1 Carotid Stent and Post-Dilation Balloon System with Integrated Embolic Protection (Neuroguard IEP System)|The Neuroguard® IEP 3-in-1 Carotid Stent and Post-Dilation Balloon System with Integrated Embolic Protection is indicated for improving the carotid luminal diameter in patients with clinically significant carotid artery stenosis and for the simultaneous capture and removal of embolic material during angioplasty and stenting.
223648545|NCT00400972|DEVICE|GlideScope videolaryngoscope|
224233704|NCT03834805|OTHER|lung and liver elastography measurement of fetus|Other: lung and liver elastography measurement of fetus
224233705|NCT03602768|BEHAVIORAL|Goal Management Training|Pre-recorded videos and games combine psycho-education, targeted skills training, and mindfulness practice to teach a system where participants can take control of their attention and cognitive faculties.
224233706|NCT03602768|BEHAVIORAL|Memory & Aging Program|Pre-recorded videos and activities combine psycho-education, memory strategy training, and social support to educate about normal memory change in aging, normalize the experience of participants going through it, and equip them to handle age-related memory change.
224233707|NCT03602768|BEHAVIORAL|Cambridge Brain Sciences|Commercial brain training software available for subscription to the general public and for research studies.
224233708|NCT04217720|DRUG|SNS-301|SNS-301 (1x 1011 dose/1ml) ID injection every 3 weeks for 4 doses then every 6 weeks for 6 additional doses, and thereafter every 12 weeks up to 24 months.
224233709|NCT02841774|DRUG|Pravastatin|40mg daily (Weeks 2 - 14)
224233710|NCT02841774|DRUG|Rosuvastatin|20mg daily (Weeks 2 - 14); at Week 6, if AST, AST, and CK \<+1.5 x ULN, and LDL-c is \>60 and decreased by less than 25% compared with week 2, then dose will be increased to rosuvastatin 40mg daily
224233711|NCT05700591|DRUG|rhPro-UK|35 mg, administered intravenously with a bolus of 15 mg within 3 minutes and the remainder by continuous infusion within 30 minutes
223648546|NCT02902289|DRUG|Ibuprofen 200 mg/5 mL oral suspension|
223766555|NCT00830193|DRUG|N-acetylcysteine|Medication packages were prepared and dispensed by pharmacy and included three premixed and prepackaged minibags containing either 5 g of NAC or placebo in 100 cc D5W (pre-CT dose) or 2.5 g of NAC or placebo in 50 cc D5W (post-CT doses).
223766556|NCT00830193|DRUG|D5W Placebo|Medication packages were prepared and dispensed by pharmacy and included three premixed and prepackaged minibags containing either 5 g of NAC or placebo (D5W) in 100 cc D5W (pre-CT dose) or 2.5 g NAC or placebo in 50 cc D5W (post-CT doses).
223766557|NCT04285190|DRUG|T89|The subjects in the T89 treatment group will receive 30 pills of T89 orally, bid., for 10 days, except a standard background treatment (antiviral drug + antibacterial + oxygen therapy+ Traditional Chinese Medicine decoction). The subjects in the blank control group will only receive a standard background treatment.
223766558|NCT06382857|DIETARY_SUPPLEMENT|MDF|MDF will be provided to children on a weekly basis for children with SAM and bi-weekly basis for children with MAM at the health center until programmatic recovery but not thereafter.
223766559|NCT06382857|DIETARY_SUPPLEMENT|RUTF|RUTF will be provided to all children on a weekly basis at the health center until programmatic recovery but not thereafter
224233712|NCT05700591|DRUG|rt-PA|0.9 mg/kg (maximum 90 mg), with 10% administered intravenously as a bolus, followed by 90% infusion within 1 hour
224233713|NCT00073294|BEHAVIORAL|diet|
224233714|NCT01456481|DRUG|midodrine hydrochloride|Target dose is midodrine hydrochloride or placebo pills 10 mg three times a day for 12 months. The starting dose is 5mg q4h x3, and if tolerated a forced titration up to 10mg/dose. If there is an intolerance, then the dose can be reduced to 2.5mg/dose.
224233715|NCT01456481|DRUG|matching placebo|The target dose in this study is 10mg q4h x3 for 12 months. The starting dose is 5mg q4h x3, and if tolerated a forced titration up to 10mg/dose. If there is an intolerance, then the dose can be reduced to 2.5mg/dose.
224233716|NCT05390346|BEHAVIORAL|Nutrition education|The intervention programs consist of nutrition monitoring and diet intervention.
224233717|NCT05364957|DEVICE|Intragastric balloon device|Patients in the experimental arm will benefit from the placement of an Intra Gastric Balloon endoscopically
224233718|NCT05364957|PROCEDURE|Dietary|The patient will benefit from dietary intervention that follows a standard medical recommendation; In consultation with a dietician (at M1, M4, M7, M13, M19, M25), patients will be asked to follow an appropriate diet with a balanced intake of macronutrients (55% carbohydrates, 30% lipids and 15% proteins).
223648547|NCT02902289|DRUG|MOMENT 200 mg coated tablet|
224233719|NCT05364957|PROCEDURE|Exercise intervention|Patient will benefit from exercise intervention; Resistance and aerobic exercises will be performed twice a week for 3 months (between M4 and M7) under the supervision of a physiotherapist.
223648548|NCT05119361|OTHER|Early Dry protocol|"After meeting eligibility criteria, patients have a net ultrafiltration of 2mL/kg/h with systematic perfusion monitoring (lactate concentration, central venous saturation, mottling score and capillary refill time) and restrictive input.~If the patient presents hypoperfusion (at least to sign), net ultrafiltration is stopped and haemodynamic optimized.~If the patient presents pulmonary oedema or right ventricular failure, with venous congestion, ultrafiltration is set at 3mL/kg/h.~Ultrafiltration is set between 0.5 and 1mL/kg/h when the following criteria are fulfilled: weight inferior to the admission weight; central venous pressure inferior to 5mmHg; absence of clinical oedema.~The haemodynamic status is reevaluated all six hours."
223648549|NCT01302249|DRUG|Latanoprost 0.005%|q.d.
223648550|NCT01302249|DRUG|AR-12286 Ophthalmic Solution 0.5%|
224233720|NCT05948748|PROCEDURE|foot surgery|minimally invasive osteoarticular foot surgery
224233721|NCT04654104|OTHER|check immune check points|we will evaluate the expression of immune check points
224233722|NCT04908748|DRUG|Esflurbiprofen Hydrogel Patch|Esflurbiprofen is a cyclooxygenase (COX) inhibitor
224233723|NCT02433665|DRUG|Iopamidol|Iopamidol is the contrast material being used for this study. 100 subjects will receive a fixed dose and rate (150 mL of iopamidol with a concentration of 300 mg of iodine/mL at an injection rate of 3 mL/sec for a total dose of 45 grams of iodine) and 400 subjects will be administered a customized dose and rate (X mL of iopamidol with a concentration of 300 mg of iodine/mL at an injection rate of X mL/sec for a total dose of X grams of iodine).
224233724|NCT02433665|DEVICE|Mydose|400 subjects will receive a customized dose of contrast material (iopamidol) based on the experimental algorithm Mydose using a combination of subject parameters.
224233725|NCT03165448|DIAGNOSTIC_TEST|Pre-operative USOS scale testing|Patient has to self-report USOS questionnaire just before the procedure as main scale.
224233726|NCT03165448|DIAGNOSTIC_TEST|Pre-operative SDPQ, MDAS and VAS testing|Patient has to sel-report SDPQ, MDAS and VAS questions as control scales.
224233727|NCT03165448|DIAGNOSTIC_TEST|Post-operative doctor's reported USOS|Operating doctor has to fill the USOS doctor's part o questionnaire just after the procedure.
224233728|NCT03165448|DIAGNOSTIC_TEST|Re-testing 4-6 weeks later|All the participants has to refill USOS questionnaire 4-6 weeks later.
224233729|NCT00757601|DRUG|MK1006|"MK1006 capsules: 1 mg, 10 mg, and 20 mg.~Panel A: MK1006 capsules in five doses beginning at 15 mg and rising to 60 mg~Panel B: MK1006 capsules in five doses beginning at 60 mg and rising to 140 mg.~Panel C: MK1006 capsules in five doses beginning at 140 mg and rising to 260 mg.~There will a 7-day interval between each dose"
224320247|NCT03798925|OTHER|None Intervention|It is observational study
224320248|NCT02661217|DRUG|LCZ696|"LCZ696 film-coated tables were supplied to the investigators. Tablets were taken with a glass of water, and were administered with or without food.~The target dose of LCZ696 was 200 mg twice daily. Starting dose of LCZ696 was either 50 or 100 mg, twice daily. The dose of LCZ696 should be doubled every 2-4 weeks to achieve the target dose of 200 mg twice daily, as tolerated by the patient."
223648551|NCT01302249|DRUG|Timolol maleate ophthalmic solution 0.5%|
223766560|NCT06382857|DIETARY_SUPPLEMENT|RUSF|RUSF will be provided on a biweekly basis at the health center until programmatic recovery but not thereafter
224233730|NCT00757601|DRUG|Placebo|"Placebo capsule to match MK1006 1, 10, and 20 mg.~Panel A: Placebo to MK1006 capsules in five doses beginning at 15 mg and rising to 60 mg~Panel B: Placebo to MK1006 capsules in five doses beginning at 60 mg and rising to 140 mg.~Panel C: Placebo to MK1006 capsules in 5 doses beginning at 140 mg and rising to 260 mg.~There will a 7-day interval between each dose"
224233731|NCT04121390|BEHAVIORAL|Newborn Parenting Class|Newborn Parenting Class designed by Mount Sinai Parenting Center. The class is 1-hour long and taught be pediatric attending and residents to all families who deliver well babies at Mount Sinai.
224233732|NCT01552096|DRUG|peritonsillar infiltration|1.5 ml around each tonsil, 3 minutes before surgical incision as per group description
224233733|NCT04639596|BEHAVIORAL|Mindfulness-based Therapeutic Sailing (MBTS) versus a standard recreation therapy activity, bowling, (SRT).|This study will be a prospective randomized controlled trial (RCT) of Mindfulness-based Therapeutic Sailing (MBTS) versus a standard recreation therapy activity (bowling) among Veterans with psychiatric and/or substance use disorders.
224233734|NCT01868841|DRUG|AdreView|10 millicurie of AdreView (123I-mIBG)
224233735|NCT01868841|OTHER|Single Photon Emission Computed Tomography|
224233736|NCT00999869|DRUG|Botulinum toxin type A|Using concentration at 2 units per 0.1 of dilution with normal saline Injection in the first visit and follow up at 1 week, 1,2,3 and 4 months after injection
224233737|NCT00999869|DRUG|Triamcinolone acetonide|Using concentration at 10 mg/ml and equal amount of botulinum toxin A dilution
224233738|NCT03702621|DRUG|liposomal Bupivacaine|20 mL liposomal bupivacaine are injected into the liposomal bupivacaine group
224233739|NCT03702621|DRUG|Bupivacaine Hydrochloride|"40 mL of 0.125% bupivacaine hydrochloride are injected into the liposomal bupivacaine group.~60mL of 0.25% bupivacaine hydrochloride are injected into the standard bupivacaine group"
224233740|NCT00102908|DRUG|Zoledronate|Zoledronate infusion
224233741|NCT00102908|DRUG|Zoledronate placebo|Zoledronate placebo infusion
224233742|NCT00527423|DRUG|VEGF Trap Eye|Intravitreal injection
224233743|NCT04359238|BEHAVIORAL|Individualized excercise|The participants in the intervention group carry out regularly endurance and strength exercises.
224233744|NCT00650936|DEVICE|AMPLATZER Septal Occluder|AMPLATZER Septal Occluder
224233745|NCT03194464|OTHER|submaximal exercise (grip)|participants perform repeated gripping with visual feedback to task failure
224233746|NCT01764438|PROCEDURE|Primovist-enhanced MRI|Performance of Primovist-enhanced MRI in HCC patients with very early or early stage disease, but with no suspicious intrahepatic HCC lesions by liver dynamic CT.
224233747|NCT04322175|DRUG|Meloxicam|Meloxicam Eye Drops
224233748|NCT03103100|DRUG|1% Lidocaine|10 mL of 1% lidocaine
224233749|NCT03103100|DRUG|0.25% Bupivacaine|10 mL of 0.25% bupivacaine
224233750|NCT03103100|DRUG|Bupivacaine plus Lidocaine|5 mL of 1% lidocaine and 5 mL of 0.25% bupivacaine
224233751|NCT00842842|PROCEDURE|tack fixation of mesh|tack fixation of mesh
224233752|NCT00842842|PROCEDURE|glue fixation of mesh|glue fixation of mesh
223766561|NCT05040711|BEHAVIORAL|Mindfulness Coach|"This study will use Mindfulness Coach, an iOS- and Android-based app designed to deliver a mindfulness training course centered on Veteran's Affairs (VA) protocols. Developed by the VA's National Center for PTSD, the app provides an engaging introduction to MT, regardless of specific psychiatric illness or patient population. The app provides a training plan with 14 sequential levels, a practice now area with evidence-based mindfulness audio exercises, assessments using the Five-Factor Mindfulness Questionnaire Short Form (FFMQ-SF)90, and education about mindfulness. To progress to the next level, the user must interact with every element. The training plan levels include psychoeducation and exercises (guided meditations and seated practices), which increase in duration as users progress. Levels 1,7 and 14 also include an assessment with the FFMQ-SF. The practice now area has guided meditations to practice new skills."
223766562|NCT05040711|BEHAVIORAL|Active Comparator|A a widely available health and wellness app that provides users with daily content on general health, WebMD, will serve as the attention control. Similar health-based apps have been used as controls in other mHealth psychotherapy intervention trials.100,101 The control group will be instructed to access the app 4x/week (same as intervention group) and will receive an orientation and 2 booster sessions as well. I considered other control group options including treatment as usual, but attention control was selected due to the variability of treatment as usual.
224233753|NCT01079442|OTHER|Postoperative coffee|"schedule for coffee administration for the present trial was chosen as follows (starting 6 hours postoperatively):~* 08:00 100mL beverage~* 12:00 100mL beverage~* 16:00 100mL beverage"
224233754|NCT01079442|OTHER|water|"The control drink consists of 100 ml warm water which is administered according a same fixed schedule as Group A starting 6 hours postoperatively:~* 08:00 100mL beverage~* 12:00 100mL beverage~* 16:00 100mL beverage"
223648552|NCT06284135|OTHER|Michl-stitch|In the intervention group, a ventral fixation was performed by suturing the ventral bladder peritoneum to the plexus Santorini and from there to the right and left lateral endopelvic fascia (MICHL-stitch).
223648553|NCT05465577|OTHER|CC Links|The CC Links intervention is built on a platform of interdisciplinary team-based science, which ensured that the financial navigator worked closely with other members of the healthcare team including oncologists, nurses, transplant coordinators, social workers, and case managers, to help enhance financial hardship screening and connect survivors and caregivers with financial assistance services.
223648554|NCT01630876|PROCEDURE|Vitrectomy only group|The patients who will underwent 23- gauge transconjunctival sutureless vitrectomy only. The procedure will be done under retrobulbar anesthesia.
223648555|NCT01630876|PROCEDURE|Combined therapy group|The patients who will underwent 23- gauge transconjunctival sutureless vitrectomy with concomitant posterior subtenon Triamcinolone acetate injection. For the posterior subtenon Triamcinolone acetate injection injection, a 1 ml of a 40 mg/ml of triamcinolone acetonide was given in the inferotemporal quadrant using a 27-gauge needle on 3-ml syringe. The conjunctiva and the Tenon's capsule were penetrated with the bevel of the needle toward the globe. The needle was advanced toward the macular area, taking care to remain in contact with the globe until the hub was firmly pressed against the conjunctival fornix and then the corticosteroid was slowly injected.
223648556|NCT06008691|DRUG|"novel MAB (alone or in combination)"|"novel MAB (alone or in combination) based on presence of an EMA clinical indication since 2020 and prescribed according to the indications for use authorized for marketing in Italy"
223648557|NCT00586417|OTHER|punch biopsy|skin biopsies
223648558|NCT04945928|PROCEDURE|Surgery|Participants having been evaluated as operable after receiving first-line treatment (first-line chemotherapy, targeted therapy, immunotherapy, chemotherapy combined with immunotherapy, etc.) will receive surgery.
223648559|NCT06266832|DRUG|Adebrelimab|This product is administered by intravenously guttae. The recommended dose of subcutaneous injection is 20mg/kg, administered every 3 Weeks (Q3W).
223648560|NCT06266832|DRUG|Oxaliplatin|130mg/m2, ivgtt, d1, Q3W
223648561|NCT06266832|DRUG|Capecitabine|1000mg/m2, po, bid, d1-14, Q3W
223648562|NCT06266832|RADIATION|Short-course Radiation|Short-course radiotherapy, using three-dimensional conformal or intensity-modulated radiotherapy, the dose is divided into 5Gy/f, the total dose is 25Gy/5f, 1f/d, and the irradiation is completed within 7 days.
223648563|NCT06266832|PROCEDURE|Biopsy|local excision or TME surgery (total mesorectal excision) Biopsy can choose endoscopic or needle biopsy, colcal excision refers to excison of the local lession after total neoadjuvant therapy. The total mesorectal excision can choose open, laparoscopic or robotic according to the specific condition of the patient.
223766563|NCT02717533|OTHER|dry weight adjustment|dry weight change to match ideal blood volume obtained by blood volume measurement.
224233755|NCT00003399|DRUG|carmustine|
224233756|NCT00003399|DRUG|cisplatin|
224233757|NCT00003399|DRUG|cyclophosphamide|
224233758|NCT00003399|DRUG|dexamethasone|
223648564|NCT04693624|OTHER|Hormonal levels|"A total of ten (10) blood samples (2ml/each) will be collected during the study for subsequent analysis of progesterone, hCG, inhibin-A, and 17-OH-progesterone:~Day of triggering (before the injection of hCG, appx. 6 pm) Twelve (12 hours) after hCG injection (appx. at 6 am) Twenty-four (24) hours after hCG injection (appx. at 6 pm) Thirty-six (36) hours after hCG injection (appx. at 8 am, 2 hours after OPU) One (1) day after OPU (60h after hCG) (appx. at 6 am) Two (2) days after OPU (84h after hCG) (appx. at 6 am) Three (3) days after OPU 108h after hCG) (appx. at 6 am) Four (4) days after OPU (132h after hCG) (appx. at 6 am) Five (5) days after OPU (156h after hCG) (appx. at 6 am) Six (6) days after OPU (180h after hCG) (appx. at 6 am)"
224233759|NCT00003399|DRUG|etoposide|
224233760|NCT00003399|DRUG|melphalan|
224233761|NCT00003399|DRUG|paclitaxel|
224233762|NCT00003399|PROCEDURE|in vitro-treated peripheral blood stem cell transplantation|
224233763|NCT06330870|PROCEDURE|WGS/TME evaluation|WGS/TME evaluation with blood and brain metastasis tissue during brain metastasis curative surgery
224233764|NCT04502342|COMBINATION_PRODUCT|Hydroxycloroquine and Azythromycine|dual treatment with Hydroxycloroquine and Azythromycine
224233765|NCT04502342|COMBINATION_PRODUCT|Cospherunate/Azythromycine|dual treatment with Cospherunate and Azythromycine
224233766|NCT04502342|COMBINATION_PRODUCT|Cospherunate/Phytomedicine/Azythromycien|triple treatment with Cospherunate, Asen and Azythromycine
223648565|NCT00473096|BEHAVIORAL|Informed breast cancer surgical treatment|
224233767|NCT05219227|OTHER|laser acupuncture and abdominal exercises|"laser acupuncture on certain point on the abdomen The following abdominal acupuncture points were irradiated: Cv 8 (Shenque), St 25 (Tianshu, bilateral), and Sp 15 (Daheng~, bilateral). The laser irradiations were applied directly to the skin of the points with a perpendicular beam. 478 J/cm2~Abdominal exercises:~Types of abdominal exercises:~1. Static abdominal exercises:~2. Dynamic abdominal exercises:~   * Hip shrugging exercise from crook lying position:~  * Lateral flexion of the trunk from crook lying position:~  * Antero-posterior flexion of the trunk from crook lying position:"
223648566|NCT04301505|OTHER|Intervention 1|Checklist will be delivered at the beginning of the study. The educational intervention program will consist of a checklist that provides family physicians with COPD management for the elderly.
223648567|NCT04301505|OTHER|Intervention 2|The same checklist will be delivered at the beginning of the study and repeated after 6 months.
223648568|NCT00133068|BEHAVIORAL|Computer|Computer intervention only
223648569|NCT00133068|BEHAVIORAL|Reduction in financial barrier|Copay only
223648570|NCT00133068|BEHAVIORAL|Computer intervention & reduction of financial barrier|computer intervention \& copay
223648571|NCT00133068|BEHAVIORAL|Control|No intervention
223648572|NCT02194985|DRUG|migalastat HCl 150 mg|Migalastat HCl 150 mg (equivalent to 123 mg migalastat) was provided as capsules in blister packs. One capsule was taken orally every other day.
223648573|NCT00018083|DRUG|rifabutin|
223648574|NCT00018083|DRUG|isoniazid|
223648575|NCT00018083|DRUG|efavirenz|
223648576|NCT00225732|OTHER|Normal saline as placebo comparator|250 ml normal saline as a placebo comparator was administered every 6 hours for a total of eight doses over the first 48 hours. Those patients who received the initial eight doses could continue to receive additional doses as needed through the end of the treatment period (day 5)
223648577|NCT00225732|DRUG|Intravenous ibuprofen|"800 mg intravenous ibuprofen diluted in 250 milliliters of normal saline was administered every 6 hours for a total of eight doses over the first 48 hours.~Those patients who received the initial eight doses could continue to receive additional doses as needed through the end of the treatment period (day 5)"
223648578|NCT01131689|DRUG|sorafenib, TS-1|D1-14 S-1 dose of level 1/2/3/4 D1-21 Sorafenib 400mg twice daily Every 3 weeks-cycle
223648579|NCT04601649|BEHAVIORAL|PrEP Talk|The study is designed to provide education, support, and referrals for PrEP.
223648580|NCT00392769|DRUG|Cetuximab|Initial Dose = 400 mg/m\^2 IV Over 120 Minutes, Followed by Weekly Infusions at 250 mg/m\^2 IV Over 60 Minutes.
223648581|NCT01775618|BIOLOGICAL|BAY94-9027|Study drug dosing was adjusted to the clinical needs of each subject in the range of 25-60 IU/kg/administration, intravenous infusion, at least 50 EDs and a minimum of at least 6 months
223648582|NCT01775618|BIOLOGICAL|BAY94-9027|Twice per week prophylaxis: 25-60 IU/kg, intravenous infusion, for 12 weeks
223648583|NCT01775618|BIOLOGICAL|BAY94-9027|Study drug dosing was adjusted to the clinical needs of each subject in the range of 25-60 IU/kg/administration, intravenous infusion, at least 50 additional EDs to achieve at least 100 cumulative EDs, or until marketing authorization of the drug
223648584|NCT02561832|DRUG|Olaparib|tablets taken orally twice daily
223766564|NCT02634294|DRUG|Peg interferon alfa-2b|Eligible patients were treated with pegylated interferon alpha-2b (Peg Intron®; Schering-Plough (Brinny) Company, Innishannon, County Cork, Ireland) 1\~1.5ug/kg qw, until occurrence of grade II or higher grade of acute graft versus host disease, or no response to treatment after 8 doses of treatments.
223766565|NCT01740596|DEVICE|C-Pulse® System Counterpulsation|The Sunshine Heart C-Pulse System is an implantable, non-blood contacting, non-obligatory, heart assist device. The system provides cardiac assistance through an extra-aortic balloon Cuff and ECG sense lead connected by means of a Percutaneous Interface Lead (PIL) to an external pneumatic Driver. The PIL is held secure externally, at the exit site, with a simple adhesive clip (C-Patch or similar) for immobilization of the external part of the PIL. The Driver is adjusted using a dedicated notebook computer (Programmer) with specialized software.
223648585|NCT02561832|DRUG|Carboplatin|intravenous injections on day one of each cycle
223648586|NCT02561832|DRUG|Anthracycline|The choice of anthracycline and cyclophosphamide (AC) regimen in Part B will be up to local Investigator following international guidelines
223648587|NCT02561832|DRUG|Cyclophosphamide|The choice of anthracycline and cyclophosphamide (AC) regimen in Part B will be up to local Investigator following international guidelines
223648588|NCT05635253|OTHER|Hydrogen Peroxide 35%|Group that received only bleaching treatment. Soft tissue protection was performed with a Top Dam light-curing gingival barrier (FGM, Santa Catarina, SC, Brazil). Application of whitening gel (Whitness HP 35%/FGM) on the buccal surface from premolar to premolar in the upper and lower arches. Three 45-minute sessions were held with an interval of seven days between them.
223648589|NCT05635253|OTHER|Hydrogen Peroxide 35% + Polishing whitened teeth|Group that received only bleaching treatment followed by polishing. Soft tissue protection was performed with a Top Dam light-curing gingival barrier (FGM, Santa Catarina, SC, Brazil). Application of whitening gel (Whitness HP 35%/FGM) on the buccal surface from premolar to premolar in the upper and lower arches. Three 45-minute sessions were held with an interval of seven days between them. After bleaching, the vestibular surfaces were polished for 20s on each bleached tooth, with polishing paste and felt disc (Diamond Flex, FGM, Santa Catarina, SC, Brazil) in low rotation.
223648590|NCT00326859|DRUG|remifentanil|
223648591|NCT01641185|PROCEDURE|radiation|radiation with protons or carbon ions
223766566|NCT03670810|DRUG|Lasmiditan|Administered orally.
223766567|NCT03670810|DRUG|Placebo|Administered orally.
223766568|NCT00475007|DEVICE|IBV® Valve System|The IBV Valve is a small, umbrella shaped device designed to redirect airflow to healthier areas of the lungs. It is implanted without incisions using a bronchoscope.
223766569|NCT03040297|DEVICE|Tracheal gas insufflation 6 L/min|Endotracheal flow (6 L/min) of respiratory gases with standard FiO2
224233768|NCT00552331|DEVICE|Plates to treat fractures of the distal femur|use of dynamic condylar screws or locking condylar plates in the treatment of distal femur fractures
224233769|NCT00552331|DEVICE|LISS|treatment of distal femur fractures with less invasive stabilization systems
223766570|NCT03040297|DEVICE|Tracheal gas insufflation 11 L/min|Endotracheal flow (11 L/min) of respiratory gases with standard FiO2
223766571|NCT03040297|DEVICE|Tracheal gas insufflation catheter, without gas flow|Tracheal gas insufflation catheter, without gas flow
223648592|NCT00988728|DRUG|SCH 900435 (Org 25935)|"Oral tablets, containing 8 mg of active substance, two tablets (i.e. 16 mg) to be taken twice daily in the morning after breakfast and in the evening after dinner during 4 weeks.~Because of double-dummy design, subjects will be administered two tablets in the morning, and two tablets plus one capsule in the evening (in total 4 tablets with SCH 900435 plus 1 capsule with placebo per day)."
223648593|NCT00988728|DRUG|Placebo|"Oral capsules and tablets containing excipients only.~Because of the double-dummy design, subjects will be administered one capsule in the evening, plus two tablets in the morning after breakfast and two tablets after dinner."
223648594|NCT00988728|DRUG|Olanzapine|"Oral capsules containing 15 mg of active substance, one capsule to be taken once daily after dinner for four weeks.~Because of double-dummy design, subjects will be administered two tablets in the morning, and two tablets plus one capsule in the evening (in total 4 tablets with placebo plus 1 capsule with olanzapine per day)."
223648595|NCT06003894|OTHER|kegel exercises|Kegel exercises; It is done by squeezing your pelvic floor muscles for 3 to 5 seconds and relaxing them. Participants are expected to do this exercise in the form of hold-relax 10-15 times each set. Participants are expected to practice Kegel exercises, 2 sets a day, 3 days a week for 8 weeks.
223648596|NCT06003894|OTHER|360 degree expanded diaphragmatic breathing training|360-degree expanded diaphragm breathing is the delivery of air taken during inspiration to the postero-lateral wall of the abdomen. Breathing in this way ensures that the pressure in the abdomen is distributed equally in all directions. Practices for using this breathing pattern will be done 2 sets per day, each set for 10 minutes.
223648597|NCT03644472|DRUG|nitrate rich beetroot juice|This beverage contains 0.3 g of inorganic nitrate per 70 ml container, and is bottled and supplied by James White Drinks (UK).
223648598|NCT03644472|DRUG|nitrate depleted beetroot juice|This beverage is identical in look and taste to the Beet-It organic shot, but has the nitrate removed. It is also bottled and supplied by James White Drinks (UK).
223766572|NCT01172691|PROCEDURE|Inhaled Nitric Oxide (iNO)|iNO or placebo will be administered at 40 ppm during the procedure starting when the Warm Ischemia Time begins - liver from ice. Stop when patient transported to ICU
223766573|NCT05921994|OTHER|secukinumab|Prospective observational study. There is no treatment allocation. Patients administered secukinumab by prescription and administered according to the SmPC.
224233770|NCT02715869|DRUG|A pharmacologic cardiac preconditioning (Sevoflurane)|A Patients are anaesthetized by Sevoflurane more than 1 mac.
224233771|NCT02715869|PROCEDURE|B ischeamic preconditioning|B ischemic preconditioning will be done after induction and before cardiopulmonary bypass by inflation the cuff of blood pressure above 200mmhg in the lower limb every 5 min for 3cycles
224233772|NCT02907996|DRUG|Sofosbuvir|400 mg tablet administered orally once daily
224233773|NCT02192736|BIOLOGICAL|Trophic factors from umbilical cord mesenchymal stem cells|
224233774|NCT04774432|OTHER|GM-CSF group|GM-CSF added to CAPA and maturation medium
224233775|NCT04774432|OTHER|Control group|GM-CSF will not be added to CAPA and maturation medium
224233776|NCT05707000|OTHER|group A concentric muscle training|"One set of each of the following exercises will completed during each session:~* leg press,~* knee flexion,~* knee extension,~* Quad drills For each set, 12 repetitions will be performed at a resistance load of 60% of the one-repetition maximum (1RM) for that exercise. The exercises will be performed 2 times a week for 6 weeks."
224233777|NCT05707000|OTHER|Group B fascilitatory kinesiotaping|Kinesiotaping is applied on the anterior thigh (quadriceps) region starting at 1/5 of the distance between anterosuperior iliac spine (ASIS) and tibia tuberosity. The tape is applied with 20% tension of the tape. The tape was tensioned from proximal region of mid quadriceps down to tibia tuberosity and, once it reached the knee, the tape was divided in the middle allowing it to circle the joint
224233778|NCT02606500|DRUG|Elonva|"20 obese women will be the study group and 20 normal weighing women will be the control group. Both groups will receive 150 mcg of Elonva for controlled ovarian hyperstimulation (COH). Gonadotropin-releasing hormone (GnRH) antagonist will be used to prevent premature luteinizing hormone (LH) surge. Additional daily doses of 200 IU of recombinant follicle stimulating hormone (rFSH) will be used if necessary. Human chorionic gonadotropin (hCG) will be used for oocyte maturation. 2 mature follicles will be aspirated separately in each patient. Cumulus cell (CC) samples will be collected and stored on -80 oC for subsequent analysis. Clinical and molecular parameters of IVF success will be assessed and compared between the groups.~The exclusion criteria will be: polycystic ovary syndrome, severely abnormal sperm parameters, and age \> 38 years."
224233779|NCT05592509|DIETARY_SUPPLEMENT|Ozonized vegetable oil with vitamines|"description: A single capsule is composed by ozonized vegetable oil (75 mg), vitamin K2 (20 mcg), vitamin B9 (130 mcg). The posology is three capsules/day.~The time of administration is two months."
224233780|NCT02470507|OTHER|AKI|development of immune dysregulation and rise in inflammatory markers and activation of immune cells
224233781|NCT00436007|BIOLOGICAL|GSK 257049|GlaxoSmithKline (GSK) Biologicals' candidate Plasmodium falciparum malaria vaccine
224233782|NCT00436007|BIOLOGICAL|Tritanrix™ HepB/Hib|GSK Biologicals' re-constituted diphtheria, tetanus, pertussis, hepatitis B vaccine (Tritanrix™ HepB) and Haemophilus influenzae type B vaccine (Hiberix™)
224233783|NCT00436007|BIOLOGICAL|Rouvax™|Aventis Pasteur's attenuated measles vaccine.
224233784|NCT00436007|BIOLOGICAL|Stamaril™|Aventis Pasteur's attenuated yellow fever vaccine.
224233785|NCT00436007|BIOLOGICAL|Polio Sabin™|GSK Biologicals' oral polio virus vaccine
224233786|NCT04927533|OTHER|Ronnie Gardiner Method|"The Ronnie Gardiner Method (RGM), developed in 1993 by Swedish jazz drummer Ronnie Gardiner, is a promising multimodal, music-based intervention with potential to stimulate and improve several cognitive functions, motor skills, reading and speech skills and social interaction. RGM participants are required to follow (what is known as) choreoscores. This is a visual representation of the sequence of movements using four unique symbols. Each symbol represents a body half via color (red = left side, blue = right side) and the use of a body part via shape (the symbols resemble hands or feet). In addition, each movement has a specific name, based on drum sounds, which must be pronounced simultaneously. The exercises are guided by trained 'RGM-practitioners'. The course and difficulty of the session can be adapted in different ways by the RGM Practitioner, according to the capabilities of the participants."
224233787|NCT01957488|DEVICE|Coloplast Test Product 1|Coloplast Test product 1 is a newly developed 1-piece ostomy appliance
224233788|NCT01957488|DEVICE|Coloplast Test Product 2|Coloplast Test product 2 is a newly developed 1-piece ostomy appliance
223648599|NCT03244839|PROCEDURE|bariatric surgery|bariatric surgery
223648600|NCT02304367|BIOLOGICAL|Burosumab|Solution for subcutaneous injection
223648601|NCT04526769|DIAGNOSTIC_TEST|Tear Collection|"A microcapillary tube will be placed at the corner of the eyelid so tears can be absorbed to the tube without causing any trauma. The tube will be placed in a transfer tube. Standard virus sampling swabs will be used to collect samples from the same patient's nasopharynx. RT-PCR will be run to determine virus yield in each sample.~For the second part of the study, IHC staining will be done on the existing ocular tissue pathology slides to detect the expression of ACE2 and other cell surface and intracellular receptors. The investigators will use existing UMN ocular pathology lab and Lion's Eye Bank tissue samples. These are banked tissue samples that were collected and examined previously and then the remaining tissue samples were stored."
223766574|NCT02487589|OTHER|Telephone support, telemonitoring and tele-exercise|"The care model will provide 24/24 h assistance for six months and include:~Telephone Support: a nurse-tutor (NT) will follow-up the enrolled patients weekly mainly through scheduled appointments. NTs duties will be: 1 education (patients and family ' s health education on how to prevent falls, verification of the adherence to the pharmacological therapy, teaching on how to recognize problems that can conduct to falls) and 2. management. Occasional appointments will be required by patients on duty and managed by a nurse .~Telemonitoring: all patients will send proper biological traces and data will be registered on a personal health record.~Tele-exercise: Home exercises sessions will be provided by a DVD and monitored through a videoconference by a physiotherapist."
223766575|NCT06314958|OTHER|CENSURE|A panel of CpG sites, whose methylation level is tested in macro-dissected formalin-fixed and paraffin-embedded (FFPE) samples derived from the primary tumor.
224233789|NCT01957488|DEVICE|Coloplast SenSura|SenSura 1-piece is the commercial available CE-marked SenSura 1-piece from Coloplast A/S.
224233790|NCT03104322|OTHER|patientMpower platform|electronic health journal for patient to record compliance, spirometry, impact on daily life and symptoms
224233791|NCT03104322|OTHER|usual care|usual care
224233792|NCT03405207|DRUG|Vitamin D3 50000 UNT Oral Capsule|Holick's protocol of treating vitamin D deficiency lasting for 8 weeks
224233793|NCT03405207|DRUG|Placebo oral capsule|identical as active drug providing by pharmaceutical company unless it is placebo
224233794|NCT01439165|BIOLOGICAL|Tetanus Toxoid, Diphtheria Toxoid and Pertussis Vaccine|0.5 mL, Intramuscular
224233795|NCT01439165|BIOLOGICAL|Tetanus and Diphtheria Toxoids Adsorbed For Adult Use|0.5 mL, Intramuscular
224233796|NCT02101541|PROCEDURE|FIRM ablation|Radiofrequency catheter ablation of atrial fibrillation driving sources detected by sequential bi-atrial panoramic contact mapping.
224233797|NCT00810368|DRUG|Carnosine|500mg Carnosine x2 daily
224233798|NCT00810368|DRUG|Placebo|Microcrystalline cellulose placebo tablets x2 daily
224233799|NCT02274298|BEHAVIORAL|CKD feedback and tools|people in the intervention arm will receive feedback on ckd quality indicators and tools to help in the detection and management of ckd
224233800|NCT04021069|DIAGNOSTIC_TEST|Radiomic, pathomic, and clinical markers|This is a non-interventional study.
224233801|NCT05423808|OTHER|Health Professional Consortium|In the intervention group, the renewed, patient-centred care pathway will be coordinated by the Advanced Practice Nurse (APN) and will be supported by digital technology. The intervention aims to increase the involvement of the patient in the treatment decision process, to provide comprehensive care through the quarterly meeting of all professionals involved in the care of the patient during a Health Professional Consortium (HPC) and to support patient empowerment by supporting self-management by using digital tools.
223766576|NCT05620823|DRUG|Povorcitinib|Oral; Tablet
223766577|NCT05620823|DRUG|Placebo|Oral; Tablet
223766578|NCT05619705|BEHAVIORAL|Healthy for Two-Health Coaching (H42)|The H42-HV intervention includes health coaching calls, H42 web based app, mobile phone-based tracking.
223766579|NCT05619705|BEHAVIORAL|Maintain Healthy in Pregnancy and Postpartum(mHIPP)|A brief video on maternal warning signs that is available in English or Spanish.
224233802|NCT05423808|DEVICE|Holis Dashboard - Holis Patient App|In the intervention group, the renewed, patient-centred care pathway will be coordinated by the Advanced Practice Nurse (APN) and will be supported by digital technology. The intervention aims to increase the involvement of the patient in the treatment decision process, to provide comprehensive care through the quarterly meeting of all professionals involved in the care of the patient during a Health Professional Consortium (HPC) and to support patient empowerment by supporting self-management by using digital tools.
224233803|NCT03694990|OTHER|Follow-up schedule|Patients will be randomized into 1 of 3 follow-up schedules for post-operative clinic visits.
224233804|NCT00776503|DRUG|VORINOSTAT|vorinostat; 400mg once daily; increasing duration (7-10-14 days)
224233805|NCT03273244|DEVICE|NeuroSense monitoring and ANI monitoring|From the start of palliative sedation, monitoring of EEG with NeuroSense device (WAVcns: Wavelet Anesthetic Value of the Central Nervous System) and ANI-monitoring (Analgesia Nociception Index) will be initiated.
224233806|NCT04690270|DRUG|Sumatriptan 100 mg|Single dose Sumatriptan 100 mg
224233807|NCT01375881|DRUG|darunavir/ritonavir plus background regimen|darunavir/ritonavir, oral use, in naive and experienced patients at approved dosages
223648602|NCT00179192|PROCEDURE|angioplasty|angioplasty performed at the time of the angiogram; approach and technique to be determined by the interventional radiologist
223766580|NCT04163289|DRUG|Fecal Microbiota Transplantation|Fecal microbiota transplantation is the process of administering stool samples derived from healthy donors, which have been processed and prepared into capsules. Capsules will be taken 7 days or more prior to the first treatment with nivolumab and ipilimumab, and 1 to 3 days prior to the next 2 treatments with nivolumab and ipilimumab.
223766581|NCT04648046|DRUG|Cyclophosphamide|Non-ablative conditioning with cyclophosphamide.
223766582|NCT04648046|BIOLOGICAL|LVgp120duoCAR-T cells, low dose|A single dose of 3 x 10\^5 cells/kg LVgp120duoCAR-T cells will be infused.
223766583|NCT04648046|BIOLOGICAL|LVgp120duoCAR-T cells, high dose|A single dose of 1 x 10\^6 cells/kg LVgp120duoCAR-T cells will be infused.
223766584|NCT04648046|OTHER|Analytic Treatment Interruption|HIV antiretroviral therapy medications will be paused.
223766585|NCT06048913|DRUG|Nimotuzumab|Nimotuzumab 400mg plus normal saline 250ml intravenous infusion for not less than 60 minutes. Starting from week 1 of radiotherapy, 1 dose of the same dose each time for a total of 6 doses. The use of nimotuzumab is not interrupted due to interruption of radiotherapy during the administration until the end of radiotherapy.
224233808|NCT03165552|OTHER|Acute kidney injury education|A face to face, a constructivist learning approach to encourage users to explore and learn about the topic of AKI in a way that maximises educational value. The programme is supported by a web based resource that presents a series of realistic case studies highlighting common causes of AKI in primary care designed to be easy to access and navigate, whilst being visual and interactive to enhance user engagement. The educayion is delivered to healthcare staff not to patients.
224233809|NCT00343759|DRUG|Lapatinib|Patients will take 14 days of Lapatinib prior to definitive surgery.
224233810|NCT04277533|DIAGNOSTIC_TEST|Serum γ-Glutamyl transferase (GGT), Total serum bilirubin (TSB), Serum calcium concentration (Ca2+), Peripheral blood neutrophil to lymphocyte ratio (NLR)|GGT, Ca2+, NLR and TSB are serum markers which had been studied for early detection and prediction of severity of NEC.
224233811|NCT00766207|OTHER|Clinical decision support|multi-faceted decision support
224233812|NCT00766207|OTHER|stream-lined clinical alert|electronic notification that a medication is potentially teratogenic
224233813|NCT02047266|PROCEDURE|MICS CABG|Minimally invasive coronary artery bypass grafting - beating heart multi-vessel procedure in which the anastomoses are performed under direct vision through a lateral left mini-thoracotomy. The left internal thoracic artery is used to graft the left anterior descending artery or circumflex artery territories. Radial artery or saphenous vein are used (Y - grafts) to graft another myocardial territories. Right internal thoracic artery can be used as free Y-graft, as in-situ graft with radial artery (extension technique) or as in-situ graft without composite technique. Right gastroepiploic artery can be used to graft right coronary artery territory. Hybrid approach (MICS CABG + PCI), parallel transfemoral extracorporeal circulation without cardioplegia and CABG from the ascending aorta are acceptable for achievement of the complete revascularization.
224233814|NCT02047266|PROCEDURE|OPCABG|Off-pump coronary artery bypass grafting via sternotomy (aortocoronary bypass grafting or aortic no-touch technique composite grafting). Mechanical Devices are used for coronary artery stabilization and heart positioning. Pericardial traction sutures are used to position the heart where appropriate. Blowers and Intracoronary shunts are used routinely. Anticoagulation is obtained using sodium heparin at a dose of 2mg/kg with supplemental doses to maintain adequate heparinisation (Activated clotting time\>250seconds).
224233815|NCT02047266|PROCEDURE|ONCABG|On-pump coronary artery bypass grafting via sternotomy (aortocoronary bypass grafting or aortic no-touch technique composite grafting). Normothermic cardiopulmonary bypass and complex blood ante-retrograde cardioplegia are used. All patients are cannulated with an proximal aortic cannula and two-stage right atrial cannula. Extracorporeal circulation is provided by the Terumo System-1 heart-lung machine using cardiopulmonary bypass systems with physiological surfaces and opened venous reservoirs. The left internal thoracic artery is used to graft the left anterior descending artery, and radial artery or saphenous vein segments are used to graft another myocardial territories. Anticoagulation is obtained using sodium heparin at a dose of 3mg/kg (ACT, activated clotting time\>450seconds).
224233816|NCT02047266|DEVICE|Octopus® Nuvo, Starfish® Non-Sternotomy, thoracic retractor (ThoraTrak®)|Octopus® Nuvo - MICS CABG tissue stabilizer available for minimally invasive procedures. It minimizes the motion of a small area of the heart while the rest of the heart continues to beat normally and allows to perform anastomosis through a small incision. Starfish® Non-Sternotomy (NS) - MICS CABG heart positioner available for minimally invasive procedures. It allows for the positioning of the beating heart through a small incision, bringing coronary targets into the operative thoracotomy window. ThoraTrak® - a reusable, stainless steel MICS thoracic retractor system for minimally invasive heart surgery with multiple interchangeable blades, which allows to harvest left internal thoracic artery and to perform anastomosis through a small left thoracotomy(Medtronic, Inc., Minneapolis, MN).
223648603|NCT00179192|PROCEDURE|surgery|surgical revision of patient's PTFE in a timely fashion not to exceed 72-96 hours after the angiogram; method of revision to be determined by the surgeon performing the procedure
223648604|NCT01421615|DRUG|Vaginal capsules of lactobacilli|The patients in one-course group who were BV positive would receive the first course treatment of vaginal lactobacillus capsule and be repeatedly evaluated BV status after treatment. If their BV test result were still positive after one-course treatment, they would NOT receive any treatment but would be followed up to the 4th-7th days of postpartum.
223648605|NCT01421615|DRUG|Vaginal capsules of lactobacilli|The patients in two-course group who were BV positive would receive the first course treatment of vaginal lactobacillus capsule and be repeatedly evaluated BV status after treatment. If their BV test result were still positive after one-course treatment, they will receive the second course treatment of Lactobacilli preparation.
223648606|NCT04462614|DRUG|Decrease per-dialytic heparin therapy|Week 1: maintenance's dose stop Week 2: 50% drop in the loading dose Week 3: complete cessation of heparin therapy during the session.
223766586|NCT06048913|DRUG|S-1|Oral chemotherapy with the S-1 regimen is given on days 1 to 2 of radiotherapy, with the drug dose calculated based on body surface area, and the oral S-1 course from Monday to Friday is synchronized with radiation therapy.
223766587|NCT06048913|RADIATION|Concurrent radiation therapy|Outline the target area layer by layer on the enhanced CT image, PGTV, PTV. The endangered organs are delineated layer by layer on the cross-section, and extended 0.3cm to form a corresponding plan to endanger the organs. The reverse intensity modulated radiotherapy plan was designed on the Monaco treatment plan system, with a prescribing dose of 56Gy/30F for PTV and 60Gy/30F for pGTV, and the target dose distribution and organ exposure dose were evaluated layer by layer on a cross-sectional surface, and combined with dose-to-volume histogram (DVH) evaluation and optimal treatment plan, the maximum dose of radiation in the spinal cord \< 40 Gy and lung V20\<30%. After the treatment plan is confirmed, the dose is verified on the treatment machine, and the treatment plan is executed after it is accurate. govern
223766588|NCT05161065|DEVICE|Cardiologs|Apple Watch recordings interpreted by Cardiologs AI done simultaneously with each 12-lead ECG
223648607|NCT03544177|OTHER|BFR-Walking|Participants will perform 12 training sessions over 6 weeks, including a 10-minute warm up and cool down period. Patients will perform 5 six-minute bouts of over ground intermittent walking exercise (1-minute walk/rest) with their habitual walking device at a prescribed speed maintained by a metronome, starting from 60 steps/minute. A fixed resting period of 3 minutes will follow each walking bout. During walking, participants will wear BFR bands at both tights. Before every walking bout, the bands will be tightened at a low intensity (max 40% of blood systolic pressure) and untied at the end of every walking bout when patients will be asked to grade their RPE (Borg Scale). Walking speed will be weekly increased by 3 steps/minute, if the previous level was well-tolerated by the patient.
223648608|NCT03544177|OTHER|Conventional therapy|Participants will perform 12 training sessions over 6 weeks. Patients will perform assisted over-ground walking for a total of around 40 minutes, inserted between a 10-minute warm-up and cool-down period. The patient will be encouraged by the same experienced physiotherapist to walk back and forth on 50-meter indoor flat corridor with their habitual walking device. Patient will be asked to walk without stopping until reaching an effort corresponding to a value of 8 out of 10 of the rating of perceived exertion (Borg scale). When the exertion level is reached, the patients will be allowed to rest sitting on a chair if necessary; after a suitable rest period, when patients express sufficient desire to start again, the training will restart
223648609|NCT03916900|PROCEDURE|Pulpotomy|Pulpotomy is a procedure in which the coronal pulp is amputated, and the remaining radicular pulp tissue is treated with a medicament to preserve the pulp's health .This technique involves administration of local analgesia, Isolation of the tooth with rubber dam, Complete caries removal and then access to the pulp chamber using drills
223648610|NCT03916900|PROCEDURE|Root canal treatment|Root canal treatment is an often straightforward procedure to relieve dental pain and save teeth. Patients typically need a root canal when there is inflammation or infection in the roots of a tooth. During root canal treatment, an endodontist who specializes in such treatment carefully removes the pulp inside the tooth, cleans, disinfects and shapes the root canals, and places a filling to seal the space.
223648611|NCT03409016|OTHER|Blood Testing|Patients will undergo therapy per standard protocol. There are no study-related medications or interventions beyond blood testing.
223766589|NCT04734444|DEVICE|SonoClear ACF|The SonoClear ACF is intended to be used as an acoustic coupling fluid during ultrasound imaging in brain surgery of human beings
224233817|NCT02047266|DEVICE|Starfish®, Octopus®, Clearview® blower, ClearView® Shunt|Starfish® - heart positioner is designed to position and to hold the heart to give the surgeon easy access to the vessel requiring the bypass graft. Octopus® - tissue stabilizer minimizes / limits the motion of a small area of the heart while the rest of the heart continues to beat normally. This allows the surgeon to perform CABG surgery without stopping of the heart and without using the heart-lung machine. ClearView® Blower is designed to improve visualization of the surgical site. An irrigation mist gently clears blood from the site, improving visualization without drying or desiccating delicate tissue. The ClearView® shunt - Intracoronary shunt provides a clear anastomotic site during the procedure while providing blood flow to the distal myocardium (Medtronic, Inc., Minneapolis, MN)
224233818|NCT04779619|OTHER|Online self-report questionnaire completion|After reading the PIS and completing the consent page on Qualtrics participants will then be presented with the demographic, PHQ-9, GAD-7 and BSL-23 questionnaires which will be used to determine later allocation of their data to one of the three group. They will then be presented with the PERCI, FFMQ-15 and DERS.
224233819|NCT03951337|DRUG|64Cu-ATSM|64 Cu-ATSM PET/CT scan
224233820|NCT05435001|DEVICE|Holter ECG Monitoring|Holter electrocardiogram monitoring will be carried out for 24 h simultaneously with the PSG monitoring using a 2- lead ambulatory electrocardiograph (Fysiologic; kind courtesy: MedTech Company, Amsterdam, Holland). We will calculate the time-domain, frequency-domain and non-linear indices by HRV. Several parameters describing the differences between RR intervals will be calculated: the square root of the mean of the sum of the squares of differences between adjacent normal RR intervals (r-MSSD), SD of NN intervals (SDNN), SD of the averages of NN intervals in all 5-minute segments of the recording (SDANN), and mean of the SD of all NN intervals for all consecutive 5-minute segments of the recording (SDNN index). All variables will be calculated for the 24-hour, daytime (2:00 to 9:00 PM), and nighttime (midnight to 7 AM) periods, and the differences between daytime and nighttime values (D\[D/N\]) will be computed.
223648612|NCT04229537|BIOLOGICAL|SCT-I10A|200 mg intravenous (IV) on Day 1 of Q3W.
223648613|NCT04229537|BIOLOGICAL|SCT200|6mg/kg intravenous (IV) on Day 1 of QW, then 8mg/kg intravenous (IV) on Day 1 of Q2W
223648614|NCT04229537|OTHER|Chemotherapy|Capecitabine and Oxaliplatin.
223648615|NCT03387878|DEVICE|Intermittent Catheter|Intermittent urinary catheter for bladder drainage
223648616|NCT02442297|BIOLOGICAL|HER2-specific T cells|"Dosing Schedule 1:~Cycle 1 A: 1x10\^7 cells~Cycle 2 A: 1x10\^7 cells~Cycle 3 A: 1x10\^7 cells~Dosing Schedule 2:~Cycle 1 A: 1x10\^7 cells~Cycle 2 B: 3x10\^7 cells~Cycle 3 B: 3x10\^7 cells~Dosing Schedule 3:~Cycle 1 A: 1x10\^7 cells~Cycle 2 B: 3x10\^7 cells~Cycle 3 C: 1x10\^8 cells~Subsequent cycles\*~\*Additional cycles may be administered at ≤ the final cell dose reached in cycle 3, provided that the subject continues to meet eligibility criteria and does not have confirmed progressive disease."
223648617|NCT05021068|OTHER|Postural Assessment|Spinal mouse measurement
223766590|NCT04700696|BEHAVIORAL|Peer Recovery Support|Weekly visits with peer who has lived experience related to child welfare and addiction
223766591|NCT04700696|BEHAVIORAL|Family Treatment Drug Court with Medications for Opioid Use Disorders (MOUD)|Incentivized to participate in Family Treatment Drug Court with option for Medications for Opioid Use Disorders (MOUD)
223766592|NCT04700696|BEHAVIORAL|Relational Skill Building based on the Nurturing Parenting Program (NPP)|Home-based parenting support
223766593|NCT04152122|DIAGNOSTIC_TEST|The dynamic stereopsis test|The characteristics of preoperative dynamic stereopsis in 83 intermittent exotropia patients and its associations with clinical features were analysed, and the prognosis was followed up on the 1st day and 2nd, 6th and 12nd months postoperatively.
224233821|NCT02152878|DEVICE|Sham stimulation|For sham tDCS, the device will be turned off after 30 seconds of stimulation.
224233822|NCT02152878|DEVICE|Active stimulation|"For active tDCS, we will place the anode and the cathode over the left and right dorsolateral prefrontal cortex areas, respectively (corresponding to F3 and F4 according to the EEG 10-20 system). We will use 5x5 cm electrodes and a 2mA current for 30 minutes per day. This montage is known as bifrontal setup and has been previously used in major depression trials"
224233823|NCT02433678|DRUG|dapagliflozin|SGLT-2 inhibitor for the treatment of type 2 diabetes
223648618|NCT06254885|PROCEDURE|Equi-crestal Implant placement|A site will be prepared through consecutive drillings on an edentulous space of the osseous ridge after flap elevation. Then a titanium fixture will be screwed that will serve, after osseointegration, to carry a dental prosthesis. The implant will be screwed until the shoulder (upper marginal part of the implant) is exactly at the same level as the bone of the maxillary/mandibular edentulous crest.
223648619|NCT06254885|PROCEDURE|Sub-crestal Implant placement|A site will be prepared through consecutive drillings on an edentulous space of the osseous ridge after flap elevation. Then a titanium fixture will be screwed that will serve, after osseointegration, to carry a dental prosthesis. The implant will be screwed until the shoulder (upper marginal part of the implant) is 1mm below the level of the bone crest.
223648620|NCT00318643|DRUG|Mitomycin C|intravesical administration
223648621|NCT00318643|DRUG|Chemophase|intravesical administration
223648622|NCT02601846|OTHER|No intervention|This is an observational study, without any specific intervention.
223648623|NCT02778737|BEHAVIORAL|ACT-based intervention|"Treatment sessions will be conducted weekly by two co-therapists in groups of approximately 8-10 participants for 1 ½ hours. Although each session has specific objectives, therapists within the time frame, are encouraged to accommodate participants' discussion or other group dynamic issues that may arise.~Participants will receive their AP-ACT handbook including outlines of each session, activity plan assignments, and a CD with recorded mindfulness exercises.~Session highlights and AP-ACT activities relevant to each session will be given at each meeting, so that participants will follow along with the treatment protocol. Individuals missing more than two consecutive sessions will be considered as dropouts."
224233824|NCT02433678|DRUG|Placebo|
223648624|NCT02778737|BEHAVIORAL|CBT-based intervention|"Treatment sessions will be conducted weekly by two co-therapists in groups of approximately 8-10 participants for 1 ½ hours. Although each session has specific objectives, therapists within the time frame, are encouraged to accommodate participants' discussion or other group dynamic issues that may arise.~Participants will receive their AP-CBT handbook including outlines of each session, activity plan assignments, and a CD with recorded relaxation exercises.~Session highlights and AP-CBT activities relevant to each session will be given at each meeting, so that participants will follow along with the treatment protocol. Individuals missing more than two consecutive sessions will be considered as dropouts."
223648625|NCT02503761|DRUG|Meropenem.|Infants in both groups will receive a loading dose of 20 mg/kg/dose every 8 hours for sepsis and 40 mg/kg/dose every 8 hours in meningitis and pseudomonas infection
223648626|NCT01850654|GENETIC|LS tumor screening|All participants with CRC or EC will have LS tumor screening (MSI, IHC, methylation if applicable).
223648627|NCT01850654|GENETIC|Genetic testing|"Next-generation sequencing panel of several genes that increase the risk for hereditary cancers including the LS genes (MLH1, MSH2, MSH6, PMS2, EPCAM), polyposis genes (MUTYH, APC), and others.~The following study participants will have free genetic testing:~* CRC and EC study participants with unmethylated MSI-high (MSI-H) tumors~* CRC and EC study participants with microsatellite stable (MSS) or MSI-low (MSI-L) tumors who have abnormal IHC results and they do not have methylation of the MLH1 promoter~* CRC study participants diagnosed with CRC \<50 years, regardless of tumor studies or family history~* CRC study participants diagnosed with CRC ≥ 50 years with a FDR with CRC or EC OR synchronous or metachronous CRC or EC throughout their life, regardless of tumor studies.~At-risk relatives of the individuals found to have LS are eligible for free single site genetic testing."
223648628|NCT01850654|BEHAVIORAL|Genetic Counseling|"The participants found to have LS or another type of hereditary cancer will have free genetic counseling.~At-risk relatives of the individuals found to have LS are eligible for free genetic counseling."
223648629|NCT01850654|OTHER|Biorepository|The biorepository is an optional part of the OCCPI. CRC and EC participants will contribute leftover tumor and blood samples, as well as a saliva sample. FDR of the CRC participants will contribute a saliva sample. The at-risk relatives of those found to have LS will contribute blood and saliva samples.
223648630|NCT01850654|BEHAVIORAL|Questionnaire|
223648631|NCT02036814|BEHAVIORAL|Program Health Education|
223648632|NCT06561165|DEVICE|Standard HD-tDCS intervention|Participants will have three sessions along with behavioral assessments.
223648633|NCT06561165|DEVICE|Multifocal network targeted HD-tDCS intervention|Participants will have three sessions along with behavioral assessments.
223648634|NCT06561165|DEVICE|Functional Magnetic Resonance Imaging (fMRI)|Participants will have an MRI before or after having HD-tDCS intervention.
223648635|NCT05644158|PROCEDURE|Revascularization|Depending on the exact morphology of the lesion, patients with short superficial femoral artery lesions (\<25 cm) will be subdivided into group 2A with endovascular treatment (percutaneous transluminal angioplasty with or without stenting) and patients with long superficial femoral artery lesions (\>25 cm) will be subdivided into group 2B with open surgical treatment (femoropopliteal bypass) .
223648636|NCT05644158|OTHER|Exercise therapy|Home-based monitored exercise training (walking), 3 times a week, monitored with log book and activity sensors.
224233825|NCT00277745|DEVICE|miniaturized microfluidic system|Subjects will provide appropriate periodontal treatment as needed.
224233826|NCT02083315|DRUG|TRV130 1.5 mg|TRV130 1.5 mg IV x 1 dose
224233827|NCT02083315|DRUG|TRV130 3 mg|TRV130 3 mg IV x 1 dose
224233828|NCT02083315|DRUG|TRV130 4.5 mg|TRV130 4.5 mg IV x 1 dose
224233829|NCT02083315|DRUG|Morphine 10 mg|Morphine 10 mg IV x 1 dose
224233830|NCT02083315|DRUG|Placebo|Dextrose 5% in water IV x 1 dose
224233831|NCT00631033|DRUG|Placebo|
224233832|NCT00631033|DRUG|Diazoxide|
224233833|NCT00631033|DRUG|Metformin + Diazoxide|
224233834|NCT06189378|OTHER|Inclusion of patient-provided pictures into blood pressure diaries|Patient-provided pictures with positive meaning were included into blood pressure diaries
224233835|NCT06189378|OTHER|Conventional blood pressure diary|Conventional blood pressure diary
224233836|NCT01024738|DRUG|Fluoride|Brush half mouth twice daily for four days.
224233837|NCT01024738|DRUG|Triclosan, fluoride|Brush twice daily
224233838|NCT01024738|DRUG|Chlorhexidine Gluconate|Rinse mouth twice a day
224233839|NCT04076501|PROCEDURE|Oxygen application|Oxygen application Supplemental oxygen via mask
224233840|NCT04076501|PROCEDURE|Sham room air|Room air applied via mask
223648637|NCT03829644|DEVICE|Horizon 627 Lumbar Brace, Aspen Medical Company, Oak Canyon, Irvine, CA 92618|The brace is an FDA Class I device, one-size adjustable design to fit waists ranging from 24-70 inches. Participants will be instructed to wear the brace for six weeks. As this brace is semi-rigid, it does not prevent motion - only reduces motion in the lumbar areas. Our prior work and that of others have shown that this type of bracing does not reduce spinal function and is not associated with atrophy.
223648638|NCT02501577|DEVICE|SAD 1|Placement and fiberoptic control
223648639|NCT02501577|DEVICE|SAD 2|Placement and fiberoptic control
223648640|NCT05349799|DEVICE|TEOSYAL RHA® 1|"During the first phase of the study, ubjects will be treated with TEOSYAL RHA® 1 at baseline (V1) and may receive an optional treatment at 1 month (V2).~In the exploratory phase of the study, subjects will not receive any additional treatment."
223648641|NCT05349799|DEVICE|TEOSYAL RHA® 1 and TEOSYAL® PureSense Redensity 1 (needle)|"During the first phase of the study, ubjects will be treated with TEOSYAL RHA® 1 at baseline (V1) and may receive an optional treatment at 1 month (V2).~In the exploratory phase of the study, subjects will receive additional treatment with TEOSYAL® PureSense Redensity 1 using a needle. TEOSYAL® PureSense Redensity 1 will be administered over three sessions at 2, 3 and 4 months after baseline (respectively V3, V4 and V5)."
223648642|NCT05349799|DEVICE|TEOSYAL RHA® 1 and TEOSYAL® PureSense Redensity 1 (cannula)|"During the first phase of the study, ubjects will be treated with TEOSYAL RHA® 1 at baseline (V1) and may receive an optional treatment at 1 month (V2).~In the exploratory phase of the study, subjects will receive additional treatment with TEOSYAL® PureSense Redensity 1 using a cannula. TEOSYAL® PureSense Redensity 1 will be administered over three sessions at 2, 3 and 4 months after baseline (respectively V3, V4 and V5)."
223648643|NCT01917630|DRUG|ALV003|ALV003 is an orally administered mixture of two enzymes (cysteine endoprotease B-isoform 2 and prolyl endopeptidase)
223648644|NCT01917630|DRUG|placebo|
223648645|NCT06463457|DRUG|Darolutamide|Androgen receptor antagonist, tablet taken orally per protocol.
223648646|NCT06463457|DRUG|Relugolix|Gonadotropin-releasing hormone (GnRH) receptor antagonist, tablet taken orally per protocol.
223648647|NCT00523302|DEVICE|Active TMS|Active TMS uses the active TMS coil to stimulate the cortical area of interest. Active TMS involves 80 trains x 15 sec = 4000 pulses per session, 5 x per week= 20,000 pulses per week, x 2 weeks = 40,000 pulses.
223648648|NCT00523302|DEVICE|Sham TMS|Sham TMS uses the same stimulation frequency as the Active TMS but uses the Sham TMS coil instead to prevent actual stimulation from occurring (chosen as a priori stimulation based on studies showing antidepressant and anti-nociceptive effects): 10 Hertz - Pulse train duration (on time) 5 seconds, Power (intensity) level 120% of stored motor threshold, Inter-train interval (off time) 10 seconds (15 second cycle time). Additionally, stimulation-train duration and inter-stimulus intervals were determined such that they are in compliance with current published rTMS safety guidelines.
223648649|NCT03387618|DIAGNOSTIC_TEST|Digital PET/CT imaging|Next generation PET/CT imaging
223648650|NCT04411667|DRUG|Octagam|Standard of Care plus Octagam infusion for 3 days.
223648651|NCT01065727|OTHER|mitoxantrone - immunomodulator|mitoxantrone during 6 months and followed by immunomodulator during 2 years and half
223648652|NCT01065727|OTHER|natalizumab|monthly natalizumab during 3 years
223648653|NCT00067002|PROCEDURE|Expanded allogeneic cord blood (CB)|Transplantation of Two Unmanipulated Cord Blood Units.
223648654|NCT00067002|PROCEDURE|One Unmanipulated and One Expanded Cord Blood Unit|Transplantation of One Unmanipulated and One Expanded Cord Blood Unit.
223648655|NCT00067002|DRUG|Rituxan|375 mg/m2 by vein on Day - 9 for patients with CD20 + malignancies.
223648656|NCT00067002|DRUG|Melphalan|140 mg/m2 by vein on Day -8.
223648657|NCT00067002|DRUG|Thiotepa|5 mg/Kg by vein on Day -7.
223648658|NCT00067002|DRUG|Fludarabine|40 mg/m2 by vein on Days -6 to -3.
223648659|NCT00067002|DRUG|Cyclophosphamide|50 mg/kg by vein on Day -6.
223648660|NCT00067002|DRUG|Mesna|10 mg/kg by vein before the 1st dose of Cyclophosphamide, then 10 mg/kg every 4 hours for four more doses (total of 50 mg/Kg).
223648661|NCT00067002|RADIATION|Total body irradiation (TBI)|Total body irradiation (TBI) given on Day -1 at 2 Gy.
223648662|NCT04326803|BIOLOGICAL|Hepatitis B recombinant vaccine|Administration of 20 mcg of hepatitis B recombinant vaccine im at month 0, 1 and 2
223648663|NCT03483857|BEHAVIORAL|Peer Navigation|Utilizing Peer Navigators for HIV-Positive MSM for increase in uptake along the continuum.
223648664|NCT01017198|DRUG|BIIB021 and Food|Assessing the effect of food use on BIIB021
223648665|NCT01017198|DRUG|BIIB0121 and Antacid|Assessing the effect of antacid use on BIIB021
223648666|NCT00522808|DRUG|A-831|
223648667|NCT03315663|OTHER|Sweetch App & DBWS|Usual care for prediabetes management, Sweetch app, weight monitoring via digital body weight scale (DBWS).
223648668|NCT03315663|OTHER|Sweetch App Alone|Usual care for prediabetes management, Sweetch app alone.
223648669|NCT02733640|DRUG|Pantoprazole|pantoprazole 40 mg once-daily
223648670|NCT02733640|DRUG|Ranitidine|ranitidine 150 mg twice-daily
223766594|NCT04902859|DRUG|Clonidine Oral Liquid Product|Clonidine prepared from pharmacy with 20 mcg/ml concentration.
223766595|NCT04902859|DRUG|Sterile water|Sterile water used as placebo
224233841|NCT05641597|OTHER|Actimetric measurement|"Evaluation during 7 days in real life condition Carried out during the pre-operative evaluation (M0), the post-operative evaluation (M1) and the post-operative evaluation (M6)"
224233842|NCT05641597|OTHER|Evaluation of plantar flexion, dorsal flexion and ankle eversion forces|Performed at the preoperative (M0), postoperative (M1) and postoperative (M6) assessments
224233843|NCT05641597|OTHER|Assessment of static and dynamic balance and quality of life|Performed at the preoperative (M0), postoperative (M1) and postoperative (M6) assessments
224233844|NCT05641597|OTHER|Functional gait assessment (TM6)|Performed at the preoperative (M0), postoperative (M1) and postoperative (M6) assessments
224233845|NCT05108038|DRUG|CKD-382, D860, D027|QD, PO for 7days
224233846|NCT02551497|DRUG|CNV1014802|
224233847|NCT05717153|PROCEDURE|Biospecimen Collection|Undergo collection of blood
224233848|NCT05717153|PROCEDURE|Computed Tomography|Undergo CT
224233849|NCT05717153|DRUG|Eflornithine|Given PO
224233850|NCT05717153|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223648671|NCT02039141|OTHER|Every Little Step Counts Intervention|"Youth participants randomized to participate in the experimental group will attend weekly healthy lifestyles education session with their parent(s)/guardian(s) and will also attend exercise sessions 3 times a week for 12 weeks. The education sessions will cover topics such as healthy eating choices, roles and responsibilities of both parents and youth in the realm of the family unit as well as in youth's own health, and self esteem among other topics. The exercise sessions will incorporate both aerobic and resistance training as well as other free-play physical activities i.e. basketball, volleyball etc."
223648672|NCT02481219|DEVICE|PillCam® COLON 2 procedure-CONTROL|
223648673|NCT02481219|DRUG|Senna tablets|
223648674|NCT02481219|DRUG|PEG|
223648675|NCT02481219|DRUG|Metoclopramide|
223648676|NCT02481219|DRUG|Erythromycin|
223648677|NCT02481219|DRUG|SUPREP oral sulfate solution|
223648678|NCT02481219|DRUG|Bisacodyl|
223648679|NCT02481219|DRUG|SUPREP oral sulfate solution with Gastrografin|
223648680|NCT00843700|BEHAVIORAL|Interpersonal Psychotherapy-Trauma in Community Settings|Interpersonal Psychotherapy-Trauma in Community Settings (IPT-TCS) is Interpersonal Psychotherapy with modifications specifically designed for the treatment of depressed patients with trauma histories seen in community settings.
223648681|NCT00843700|BEHAVIORAL|Treatment as Usual|Individual psychotherapy following usual care practice in a community mental health center.
223766596|NCT02676544|DEVICE|Embosphere microspheres|This is a clinical trial assessing the feasibly and safety of prostate artery embolization (PAE) for benign prostatic hypertrophy (BPH) resulting in severe lower urinary tract symptoms (LUTS) in patients with gland size ≥90 grams who are TURP ineligible or non-operative candidates with Embosphere microspheres.
224233851|NCT05717153|DRUG|Polyamine Transport Inhibitor AMXT-1501 Dicaprate|Given PO
224233852|NCT05717153|PROCEDURE|Resection|Undergo surgical resection
224233853|NCT05717153|DEVICE|Microdialysis|Undergo Microdialysis
224233854|NCT05717153|PROCEDURE|Placement|Undergo placement of catheters
224233855|NCT03209882|DEVICE|TILS|Continuous-wave laser of a specific wavelength (1064 nm) was administered to the participants' right forehead for 8 minutes. The laser power was 3.4 Watts.
223766597|NCT02644967|DRUG|IMO-2125|Drug: IMO-2125 Intratumoral injection administered as 9 doses on Weeks 1, 2, 3, 5, 8, 11, 17, 23, and 29.
223648684|NCT01444040|DEVICE|iStent inject|Implantation of two iStent inject devices
223766598|NCT02644967|DRUG|Ipilimumab|4 doses administered intravenously at a dose of 3 mg/kg over 90 minutes on Weeks 2, 5, 8, and 11.
223766599|NCT05263427|DEVICE|TOCONAUTE|"This study will be carried out during delivery. The will be placed on the mother's abdomen to capture fetal and maternal heart rate as well as the uterine contractions in parallel of the cardiotocograph.~For each of the participants, the TOCONAUTE will remain on the mother's abdomen till childbirth. This procedure will not affect the usual care of the patient."
223648685|NCT01444040|DRUG|Travoprost|Travoprost drops
223648686|NCT02064023|DEVICE|insulin pump|subjects in the experimental arm will administer insulin using a pump
223648687|NCT02064023|OTHER|multiple daily insulin injection|Subjects will continue with usual insulin injections
223648688|NCT01354314|DRUG|Fluconazole|One 100 MG capsule taken twice daily, 12 hour dosing
223648689|NCT01354314|DRUG|Paroxetine|Two 10 MG capsules paroxetine once daily in the evening
223648690|NCT01354314|DRUG|Paroxetine and Fluconazole|One capsule 100 MG fluconazole every 12 hours orally per day; Two 10 MG capsules paroxetine orally once daily in the evening
223648691|NCT01354314|DRUG|Placebo|One capsule in the morning, three capsules in the evening
223648692|NCT02806102|PROCEDURE|Percutaneous coronary intervention|Percutaneous coronary intervention
223648693|NCT02806102|DRUG|Dual-antiplatelet therapy|Dual AntiPlatelet Therapy
223766600|NCT03844373|DIETARY_SUPPLEMENT|STOCKHOLM|STOCKHOLM is a Food for Special Medical Purposes (FSMP) and must, therefore, be used under medical supervision.
223766601|NCT01502644|DRUG|Oxycodone|Daily dosage up to 120 mg
223766602|NCT01502644|DRUG|Morphine|Daily dosage up to 90 mg immediate release or 180 mg extended release
223766603|NCT01502644|DRUG|Placebo|Placebo-matching oxycodone, placebo-matching morphine
224233856|NCT03209882|DEVICE|sham|The sham session consisted of administering the same laser to the participants' right forehead for totally 8 minutes. However, the laser power was turned to be 0 Watts.
224233857|NCT05252130|DEVICE|NoaScope|Smart digital stethoscope
224233858|NCT04855981|OTHER|whole body vibration|All participants in the WBV group will perform the WBV training on a vibrating device (Confidence Vibration Plate Power Plus, China), which produces a lateral peak-to-peak oscillation. They will stand on the WBV platform with a 150° knee angle during the exposure minute. They started the training with three sets of 1 min separated by a 1-min resting period and vibration amplitude of 1 mm. They will add one set every session until they performed 10 sets of WBV. The frequency started at 20 Hz, which will be increased gradually by 2 Hz every 2 weeks +magnesium (Mg) (250 g) and vitamin B6 supplementation
224233859|NCT04855981|OTHER|aerobic exercise|the subjects will receive aerobic exercises+ magnesium (Mg) (250 g) and vitamin B6 supplementation
223648694|NCT02806102|PROCEDURE|Percutaneous coronary intervention|Percutaneous coronary intervention
223648695|NCT02806102|DRUG|Dual-antiplatelet therapy|Dual AntiPlatelet Therapy
223648696|NCT02665390|PROCEDURE|Percutaneous cryoablation|Percutaneous cryoablation
223648697|NCT03406312|DIAGNOSTIC_TEST|Post Prandial Hypoglycemia test|three test assessing hypoglycemia will be used: liquid mixed meal tolerance test, solid mixed meal tolerances test, continuous glucose monitoring
223648698|NCT03807206|BEHAVIORAL|Questionnaire|Patient questionnaire
223648699|NCT04930471|DRUG|Metformin|Treatment with Metformin as prescribed by the treating physician.
223648700|NCT02797938|DEVICE|Taper guard tube|Taper guard tube was intubated
223648701|NCT02797938|DEVICE|Cylindrical tube|Cylindrical tube was intubated
223648702|NCT03553303|DRUG|Sacubitril / Valsartan Oral Tablet|Increasing doses of Sacubitril/Valsartan
223648703|NCT02978976|DRUG|Betamethasone|will receive two doses of 12mg betamethasone ( Dipropfos ® SCHERING-PLOUGH; Kenilworth, New Jersey, USA) intramuscularly (IM) 24 hours apart.
223648704|NCT02978976|DRUG|saline|saline placebo injection in the same regimen.
224233860|NCT04855981|OTHER|supplementation|the subjects will receive magnesium (Mg) (250 g) and vitamin B6 supplementation
224233861|NCT03393650|OTHER|Exercise + Placebo group|1/2 of the subject will follow a mixed power training: 4 power exercises + 6 functional exercises combined to a placebo
224233862|NCT03393650|OTHER|Exercise + Protein group|1/2 of the subject will receive 30 g/ d of protein (leucine+ vitD; divided in three equal doses: morning, afternoon and evening) + will follow a mixed power training: 4 power exercises + 6 functional exercises.
224233863|NCT02499666|PROCEDURE|Percutaneous Coronary Intervention|As clinically indicated, patients will have a percutaneous balloon angioplasty and stent deployment of a chronic total occlusion (i.e., an artery that has a 100% blockage for several months).
224233864|NCT02499666|DEVICE|Coronary stent|As clinically indicated, patients will have a coronary stent placement into their occluded coronary artery after successful balloon angioplasty
224233865|NCT02499666|DRUG|Clopidogrel|As clinically indicated, patients who are not already on dual antiplatelet therapy will be started on a second agent such as clopidogrel.
224233866|NCT03970564|DIAGNOSTIC_TEST|Neck ultrasound guide lymph node sampling|Neck ultrasound done first and lymph nodes larger than 5 mm that are technically feasible are sampled using fine needle aspiration and/or core needle biopsy
224233867|NCT03365375|BEHAVIORAL|MBSR Referral|Referral for mindfulness-based stress reduction (MBSR), a structured meditation training program consisting of 8 weekly group sessions.
224233868|NCT03365375|OTHER|Usual Care Referral|Referral to PCP or Psychiatry
224233869|NCT02317237|PROCEDURE|Local anesthesia|Conscious sedation
224233870|NCT05896956|OTHER|no interventions|no interventions
224233871|NCT05532085|OTHER|Evaluation of pain during voluntary termination of pregnancy with medication following consideration of predictive factors of pain without an established analgesic protocol|"Evaluation of the pain felt by women having an abortion by aspiration under local anes!thesia.~The intensity of the pain of patients during an abortion by aspiration under local anesthesia will be quantified by a Visual Analogue Scale (VAS) at the time of the abortion and in the following 4 days."
224233872|NCT05532085|OTHER|Evaluation of pain during a voluntary medical termination of pregnancy following consideration of predictive factors of pain with an established analgesic protocol|"Evaluation of the pain felt by women having a medical abortion following the application of an analgesic protocol indexed on the predictive factors of pain.~The intensity of the pain of patients during a medical abortion will be quantified by a Visual Analogue Scale (VAS) at the time of the abortion and in the following 4 days."
224233873|NCT05532085|OTHER|Assessment of pain during voluntary termination of pregnancy by aspiration under local anesthesia following consideration of predictive factors of pain without an established analgesic protocol|"Evaluation of the pain felt by women having an abortion by aspiration under local anesthesia.~The intensity of the pain of patients during an abortion by aspiration under local anesthesia will be quantified by a Visual Analogue Scale (VAS) at the time of the abortion and in the following 4 days.Evaluation of the pain felt by women having an abortion by aspiration under local anesthesia.~The intensity of the pain of patients during an abortion by aspiration under local anesthesia will be quantified by a Visual Analogue Scale (VAS) at the time of the abortion and in the following 4 days."
224233874|NCT05532085|OTHER|Assessment of pain during voluntary termination of pregnancy by aspiration under local anesthesia following consideration of predictive factors of pain with established analgesic protocol|"Evaluation of the pain felt by women having an abortion by aspiration under local anesthesia following the application of an analgesic protocol indexed on the predictive factors of pain.~The intensity of the pain of patients during an abortion by aspiration under local anesthesia will be quantified by a Visual Analogue Scale (VAS) at the time of the abortion and in the following 4 days."
224320249|NCT03417635|BEHAVIORAL|Guided focused attention|Participants will meet for 20 minute group sessions with 6-10 participants in each group. There will be three meetings a week for a four week period. The focused attention practice itself will last for 20 minutes with instructions being given during the 20 minute period. All sessions will occur in the retirement home in a community room to ensure the sessions are easily accessible to the participants.
224320250|NCT03417635|BEHAVIORAL|Acoustic music|Participants will meet for 20 minute group sessions with 6-10 participants in each group. There will be three meetings a week for a four week period. The acoustic music track itself will last for 20 minutes with instructions being given during the 20 minute period. All sessions will occur in the retirement home in a community room to ensure the sessions are easily accessible to the participants.
223648705|NCT00389038|BEHAVIORAL|Coping Skills Training|Behavioral Treatment 1 (coping skills training)--Behavioral Treatment session 1 and 2: Doses are one session a week for 8 weeks, followed by one session a month for 2 months, followed by 1 session every three months for 1 year.
223648706|NCT00389038|BEHAVIORAL|Headache Education|Behavioral Treatment 2 (headache education)
223648707|NCT00389038|DRUG|Amitriptyline|Amitriptyline: up to 1 mg/kg capsule taken once daily at bedtime. Taken up to Week 20. After Week 20 medications and doses may change with standard care.
223648708|NCT04588584|OTHER|Survey and Interviews|Survey and Interviews
223648709|NCT01094847|DRUG|DWJ1252|tablet(oral) administration following the schedule of each arm
223648710|NCT02143388|DRUG|IMRT combine with cisplatin concurrent chemotherapy|Patients in the control arm received radical radiotherapy with IMRT, and cisplatin (100mg/m2 on day 1) every three weeks for three cycles during RT.
223648711|NCT02143388|DRUG|IMRT combine with cisplatin concurrent chemotherapy plus capecitabine adjuvant chemotherapy|Patients in the experimental arm received radical radiotherapy with IMRT, and cisplatin (100mg/m2 on day 1) every three weeks for three cycles during RT,followed by adjuvant chemotherapy with oral capecitabine(1000mg/m2/ twice a day for 14 days)every three weeks for eight cycles.
223648712|NCT05365425|DRUG|Choline fenofibrate|choline fenofibrate 178.8mg (135mg as fenofibric acid)
223648713|NCT05365425|DRUG|Policosanol|policosanol 10mg
223648714|NCT06331143|DEVICE|Ultrasound-Guided Mid-Transverse Process to Pleura (MTP) Block|Patients will receive MTP block after induction of anesthesia.
223648715|NCT06331143|DRUG|Morphine|Patients will receive intrathecal morphine in a dose of 12 μg/kg (max 1000 μg) immediately after induction of anesthesia.
223648716|NCT01010646|DRUG|IFN alfa-2b XL 27 MUI + Ribavirin|IFN alfa-2b XL 27 MUI administered once a week for 12 weeks by subcutaneous injections, in combination with weight dosed ribavirin daily administered orally in two divided doses
223766604|NCT06425562|OTHER|Full lung function|This includes spirometry, body plethysmography and single breath gas transfer test. These are all non-invasive physiological measurements / lung function tests. Measures flow volumes, lung volumes and gas transfer respectively.
223766605|NCT06425562|OTHER|Multiple breath nitrogen washout|Non-invasive physiological measurement / lung function test. 100% oxygen is inhaled and the nitrogen concentration in the lungs is measured. This test gives information on the ventilation distribution in the lungs.
223766606|NCT06425562|OTHER|Impulse oscillometry|Non-invasive physiological measurement / lung function test. This technique superimposes sound waves on tidal breathing. The patient can breathe normally trough the device, no forced respiratory maneuvers are required. It gives information on the reactance and resistance of the lung.
223766607|NCT01552226|DEVICE|Continuous Preperitoneal Analgesia|Preperitoneal catheter placed at the completion of surgery in the standard fashion.
223766608|NCT01552226|DEVICE|Continuous Epidural Analgesia|Epidural catheter placed prior to the operation in the standard fashion.
223766609|NCT00637195|BIOLOGICAL|Subjects received 3 doses of GSK Biologicals' HPV vaccine (580299) (Cervarix™)|Intramuscular administration, 3 doses.
223648717|NCT01010646|DRUG|IFN alfa-2b XL 36 MUI + Ribavirin|IFN alfa-2b XL 36 MUI administered once a week for 12 weeks by subcutaneous injections in combination with weight dosed ribavirin daily administered orally in two divided doses
223648718|NCT01010646|DRUG|IFN peg alfa-2b 1.5 µg/kg + Ribavirin|IFN peg alfa-2b 1.5 µg/kg administered once a week for 12 weeks by subcutaneous injections in combination with weight dosed ribavirin daily administered orally in two divided doses
223648719|NCT03239106|DRUG|Apremilast|Apremilast 30 mg BID daily
223648720|NCT06217484|BEHAVIORAL|delayed feedback|participants learn through either immediate or delayed feedback during a computer task
223648721|NCT00402402|PROCEDURE|Tuberculin skin test|
223648722|NCT00402402|PROCEDURE|Quantiferon-TB Gold assay|
224233875|NCT05332015|OTHER|Hypotonic (distilled) water|orally given daily two liters of distilled water
224233876|NCT05332015|OTHER|Normal water|orally given daily two liters of normal water
224233877|NCT04566809|OTHER|FES+CBA|The experimental treatment was formerly composed by 20 sessions of FES for the hand in combination with a structured cognitive therapy
224233878|NCT04566809|OTHER|FES|The control treatment was formerly composed by 20 sessions of FES for the hand
224233879|NCT06301698|BEHAVIORAL|Comprehensive rehabilitation|"All the participants are provided with the comprehensive rehabilitation (routine rehabilitation and swallowing function training). The routine rehabilitation included intervention for risk factors (blood pressure, blood lipids, blood glucose, smoking and alcohol restriction, exercise, etc.).~Regrading swallowing function training, both groups are given swallowing function training, including 1) exercises of closure of the vocal folds, pharyngeal, and laryngeal muscles exercises, and respiratory muscle strength training, for 15 min each time and twice per day. 2) isotonic／isometric swallowing exercises, supraglottic swallowing exercises, for 20 min each time and twice per day. 3) effortful swallowing exercises, and cough reflex training, for 10 min each time and twice per day."
224233880|NCT06301698|PROCEDURE|Injection|the patients in the observation group were provided with Injection. The percutaneous approach via the paratracheal route was used for Stellate ganglion block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
223648723|NCT04883008|DEVICE|CorPath GRX with technIQ automated movements enabled (technIQ ON)|"The CorPath GRX System is intended for use in the remote delivery and manipulation of guidewires and rapid exchange catheters, and remote manipulation of guide catheters during percutaneous coronary and vascular procedures.~TechnIQ automated movements are software-based automation of common maneuvers that interventionalists perform when manipulating catheters, guidewires, and devices by hand. In this group, automated movements will be enabled and used at the discretion of the interventionalist."
223648724|NCT04883008|DEVICE|CorPath GRX with technIQ automated movements disabled (technIQ OFF).|"The CorPath GRX System is intended for use in the remote delivery and manipulation of guidewires and rapid exchange catheters, and remote manipulation of guide catheters during percutaneous coronary and vascular procedures.~TechnIQ automated movements are software-based automation of common maneuvers that interventionalists perform when manipulating catheters, guidewires, and devices by hand. In this group, automated movements will be disabled."
223648725|NCT00107913|DRUG|Doxil|
223648726|NCT02149043|DEVICE|Thermography|Thermographic imaging of the patient's abdomen surface
224320251|NCT02758639|BEHAVIORAL|Wonders & Worries Psychosocial Intervention|Session 1: Getting to Know Each Other The goal is to create a sense of safety within the group so that the children feel comfortable discussing difficult topics. Session 2: Cancer Education to provide developmentally appropriate education about the illness, treatment, and side effects. Session 3: Cancer Treatment Center Tour: This session consists of a treatment center tour and education about treatment plan involved in family's care in a safe environment. Session 4: Feelings: The focus of this session is expression and validation of all feelings the children may experience. Session 5: Stress and Coping: Goal is to emphasize the different ways individuals cope and differentiate positive vs. negative coping strategies. Session 6: Hopes for the Future/Closure: An emphasis is made on the idea that positive things may evolve from the most difficult circumstances.
223648727|NCT02149043|PROCEDURE|Colonoscopy|Endoscopic examination of the colon
223648728|NCT02904278|OTHER|Teen Pocket PATH® Mobile Application|Participants in the intervention group will receive the mobile application for improving adherence to their post-transplant medications. The intervention will prompt, remind, and warn participants when medications are due, inform parents when medication management is completed, and engage parents when no action is undertaken.
223648729|NCT02904278|OTHER|Control Group: Standard of Care|Adolescents and parents/guardians assigned to the Standard Care Condition will receive standard clinical care per standard site procedures.
223648730|NCT01804400|DRUG|QAW039|
223648731|NCT01804400|DRUG|Montelukast|
223648732|NCT01804400|DRUG|Placebo|
223766610|NCT00637195|BIOLOGICAL|Engerix™|Intramuscular administration, 4 doses.
223766611|NCT01092247|OTHER|Nutritional support with Standard diet|Nutritional support with Standard diet
223766612|NCT01092247|OTHER|Nutritional intervention with the Ketogenic diet|Nutritional intervention with ketogenic diet. The Diet plan will be based on each patient individually according to his nutritional needs. Age, weight, activity levels, culture and food preferences are taken in consideration
224233881|NCT06301698|DRUG|Lidocaine Hydrochloride|the patients in the observation group were provided with Stellate ganglion block, using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate ganglion block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
224233882|NCT06440564|PROCEDURE|Er:YAG Laser irradiation|The presented DALIR procedure differs in so far from a standard treatment that after exposure all accessible metal implant surfaces and the adjacent soft tissue is irradiated manually with the Er:YAG laser all over line-by-line with an intended overlap of approximately 10% at constant spot diameter.
224233883|NCT02747745|BEHAVIORAL|Four risk areas reflecting the great needs of FCGs of PWDs|The intervention involves home visits \& phone calls from the case manager to the dyads, and receiving telephone calls from FCGs. The case manager will target the prioritized risk from the 4 risk areas of FCG problems and healthy behaviors. The intervention mainly consists of needs assessment and nursing education on home environment modification and safety, behavioral management and communication skills; home-based cognitive stimulation on PWD with simple mathematical practice, patient preferred leisure activities and reminiscence by old time photos, stories and toys; brief consultation on 4 risk areas related to FCG stress; and case management to refer the dyads to the hospital-based dementia centers and community resources.
224233884|NCT00569062|DRUG|GW856553X|GW856553X 7.5mg BID for 6 weeks
223648733|NCT01872416|DEVICE|Liposomal Doxorubicin Combined With ifosfamide|Liposomal Doxorubicin Combined With ifosfamide Second-line Treatment in Small Cell Lung Cancer
223648734|NCT01740648|DRUG|trametinib|Trametinib will be given for 5-day lead-in period by mouth daily Monday-Friday starting at day -14 through -10 and concurrently for the duration of radiation therapy (approximately days 1-38).The dose of Trametinib will be escalated: 0.5 mg, 1.0 mg, 2mg. If the 2 mg dose level causes DLT (dose-limiting toxicity)in 2 out of 6 patients and the 1mg dose level was acceptable, then a 1.5 mg dose cohort will be used.
223648735|NCT01740648|DRUG|fluorouracil|Will be administered as a continuous infusion over 120 hours at a dose of 225 mg/m2/day on Monday to Friday of every week starting day 1-38.
223766613|NCT02388997|DRUG|omalizumab|This medication has been approved for clinical use to treat patients with moderate to severe asthma by the FDA in 2003 and for use in this study (BB-IND# 10510)
223766614|NCT02388997|BIOLOGICAL|Rhinovirus (strain 16)|This strain of pooled rhinovirus has been approved for use in experimental challenges (BB-IND# 15162) and for use in this study (BB-IND# 10510) by the FDA.
223766615|NCT02999958|BIOLOGICAL|Antioxidants|In the Treatment Arm, the G-Series culture media system will be used with antioxidants
224233885|NCT00569062|OTHER|Placebo|Placebo to match GW856553X
224233886|NCT06837311|DEVICE|Ecological Momentary Assessment (EMA)|Daily ecological momentary assessment (EMA), in addition to treatment as usual (TAU) using apTeleCare eHealth device. Daily surveys includes questions reflecting all Diagnostic and Statistical Manual of Mental Disorders (DSM) 5 symptom criteria for Depression, Generalized Anxiety Disorder, Post-Traumatic Symptom Disorder, evaluations of substance use (including dietary items at risk) as well as of two symptoms predictive of relapse (craving and loss of control), medication compliance and physical activity
224233887|NCT06837311|BIOLOGICAL|Biological assessment|Routine Biological assessment and of substance use
224233888|NCT06837311|BEHAVIORAL|Psychological examination and Substance Use symptomatology|Substance use symptomatology ; Neuropsychiatric symptomatology ; Functional outcomes ; Neurologic and Cardiovascular outcomes
224233889|NCT06837311|OTHER|Treatment as usual (TAU)|Treatment as usual (TAU)
224320252|NCT03593395|OTHER|Peer Mentoring [PM]|Virtual Peer Mentoring
223766616|NCT01739530|BIOLOGICAL|Repaircell|allogenic differentiated adipocyte
223766617|NCT03244228|DRUG|HTL0016878|Oral solution
223766618|NCT03244228|DRUG|Placebo - Concentrate|Matching placebo
223766619|NCT04631497|DIAGNOSTIC_TEST|test|"1. Beck's Test~2. Test STAI~3. Test PSS~4. the scale of the fascination with death~5. COPE"
223766620|NCT01110915|DEVICE|Medtronic Advisa MRI Implantable Pulse Generator (IPG)|Advisa MRI IPG is a dual chamber, multi-programmable IPG indicated to restore heart rates, improve cardiac output, prevent symptoms, or protect against arrhythmias related to cardiac impulse formation or conduction disorders. The IPG is indicated for use in patients who may benefit from rate-responsive pacing to support cardiac output during varying levels of activity and has been modified for use during an MRI exam.
223766621|NCT01110915|DEVICE|Medtronic CapSureFix MRI™ active fixation MRI lead|The Medtronic CapSureFix MRI™ active fixation MRI lead is a transvenous, bipolar, silicone, steroid eluting and active fixation pacing lead. It is based on the commercially available Medtronic Model 5076 lead and has been modified for use in the MRI environment. The MRI lead is used for both atrial and ventricular applications.
223766622|NCT01022034|PROCEDURE|sacral rectopexy with sutures or meshes|
223766623|NCT01022034|PROCEDURE|full rectal mobilization from the sacrum without sacral rectopexy|
223766624|NCT05158205|BEHAVIORAL|Yoga|12-week yoga intervention in which 60-minute classes are completed at Texas State University 3 times per week
223766625|NCT05158205|BEHAVIORAL|Slow, deep breathing|12-week home-based intervention in which 5 weekly 20-minute breathing sessions are completed
223766626|NCT05158205|BEHAVIORAL|Control breathing|12-week home-based intervention in which 5 weekly 20-minute breathing sessions are completed
223766627|NCT05532176|OTHER|Posture standards|Dynamic and static Postural measurements according to four types of tests
223766628|NCT06160076|DEVICE|Radiofrequency|Patient with atrial fibrillation ablated per catheter using radiofrequency energy
223766629|NCT06160076|DEVICE|Pulsed electric field|Patient with atrial fibrillation ablated per catheter using pulsed electric field
224233890|NCT06837311|DIAGNOSTIC_TEST|Expired carbon monoxide (CO)|Expired carbon monoxide (CO) measurement
224320253|NCT03593395|OTHER|Structured Education Based Transition Program STE|Education-based program
224320254|NCT01059578|DRUG|GSK206136|GSK206136 2mg, 10mg, 50mg, 100mg capsule
223648736|NCT01740648|RADIATION|radiation therapy|Radiation therapy will be delivered to the pelvis during (approximately) days 1-33 (five days a week, Mondays through Fridays for 25 fractions) using a 3-field or 4-field 3-D conformal plan to the primary tumor, surrounding soft tissues, and at risk lymph node stations (peri-rectal, presacral, internal iliac, with or without external iliac) to a total dose of 45 Gy in 1.8 Gy daily fractions. A boost radiation field will be delivered during (approximately) days 36-38. The boost will encompass the primary rectal tumor and involved lymph nodes with a 2-2.5 cm margin, which should include the presacral space. The boost dose will be 5.4 Gy in 1.8 Gy fractions for a total dose of 50.4 Gy.
223648737|NCT03537521|PROCEDURE|Urgent surgery which can not be postponed to the next 24 hrs|The urgent surgical intervention is not part of the registry protocol. The intervention is the acute event that leads to enrollment in the registry. It might be e.g. the surgical treatment of a trauma, fall, acute abdomen, appendicitis or anything else.
223648738|NCT03780166|DRUG|Parsaclisib|Parsaclisib administered orally once daily at the cohort-specified dose level.
223766630|NCT01545921|OTHER|Quality Of Life questionnaires completion|"Before randomization, all patients will have to complete questionnaires in this order : QLQ-C15-PAL, MVQOLI and QUAL-E.~MVQOLI and QUAL-E will be completed again 3 days after the first completion at baseline. After this second QoL assessment, the order will be modified according to patient's randomisation : arm A, B, C or D."
223766631|NCT00207142|DRUG|Atazanavir + 2 NRTIs|Capsules, tablets, Oral, 48 weeks (after a 26-to-30-week induction phase with ATV 300 mg + RTV 100 mg + 2 NRTIs)
223766632|NCT00207142|DRUG|Atazanavir + Ritonavir + 2 NRTIs|Capsules, tablets, Oral, 48 weeks (after a 26-to-30-week induction phase with ATV 300 mg + RTV 100 mg + 2 NRTIs)
223766633|NCT03566628|OTHER|Warmed Isotonic Saline|Isotonic saline warmed to 39ºC.
223766634|NCT03566628|OTHER|Room-Temperature Isotonic Saline|Isotonic saline at room temperature
223766635|NCT04552366|BIOLOGICAL|Ad5-nCoV|Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)
224233891|NCT05786573|DRUG|Obexelimab|Obexelimab is a monoclonal antibody that simultaneously binds CD19 and FcγRIIb, resulting in down regulation of B cell activity.
224233892|NCT05786573|DRUG|Obexelimab|Obexelimab is a monoclonal antibody that simultaneously binds CD19 and FcγRIIb, resulting in down regulation of B cell activity.
224233893|NCT05786573|OTHER|Placebo|Placebo
224233894|NCT05060627|DRUG|Belantamab mafodotin|"In phase 1:~* Dose level -1: Belantamab-Mafodotin 1.9 mg/kg day 1, Q8W~* Dose level 1,2,3: Belantamab-Mafodotin 2.5 mg/kg day 1, Q8W In phase 2: maximum tolerated dose (MTD) of the combination"
224233895|NCT05060627|DRUG|Carfilzomib|"In phase 1:~* Dose level -1, 1: Carfilzomib 20/45 mg/m2 days 1, 8, and 15, Q4W.~* Dose level 2: Carfilzomib 20/56 mg/m2 on days 1, 8, and 15, Q4W~* Dose level 3: Carfilzomib 20/70 mg/m2 on days 1, 8, and 15, Q4W.~In phase 2: maximum tolerated dose (MTD) of the combination"
224233896|NCT05060627|DRUG|Dexamethasone|Description: Dexamethasone 40 mg weekly (days 1, 8, 15 and 22) or 20 mg in patients \> 75 years old., Q4W
223648739|NCT04677088|BIOLOGICAL|TCR-T cells|Patients will receive 1 x 10\^4 cells/kg to 5 x 10\^6 cells/kg bodyweight of TCR redirected T cells by IV infusion.
223766636|NCT02500069|OTHER|placebo|infusion of tap water in all regions (duodenum, jejunum and ileum)
223766637|NCT02500069|OTHER|Casein (in duodenum)|infusion of protein in duodenum
223766638|NCT02500069|OTHER|Casein (in jejunum)|infusion of protein in jejunum
223766639|NCT02500069|OTHER|Casein (in ileum)|infusion of protein in ileum
223766640|NCT03306264|DRUG|ASTX727|ASTX727 oral tablet
224233897|NCT04955262|BIOLOGICAL|Bempegaldesleukin (NKTR-214)|Specified dose on specified days
224233898|NCT04955262|BIOLOGICAL|Nivolumab|Specified dose on specified days
224233899|NCT04955262|DRUG|⁸⁹Zr-Df-IAB22M2C|Specified dose on specified days
224233900|NCT06229925|DEVICE|Experimental Stimulation|Application of active direct current stimulation for 20 minutes, at an intensity of 2mA, with 30s of ramp up and ramp down, for 5 consecutive days. The anode will be positioned on M1 (C3) contralateral to the painful shoulder; The reference electrode (cathode) will be placed in the supraorbital region contralateral to the anode (Fp2). Direct current will be delivered through two 35cm2 surface sponge electrodes (7x5) soaked in saline solution, using a portable neuromodulator. During the entire stimulation, volunteers will remain seated in an air-conditioned and quiet place.
224233901|NCT06229925|DEVICE|Sham Stimulation|Application of active direct current stimulation for 20 minutes, at an intensity of 2mA, for 5 consecutive days, administered in the same way as the experimental intervention. However, the stimulator will be turned off after 30 seconds and the volunteers will not receive current for the rest of the session.
224233902|NCT03879239|DEVICE|Vibrating capsule|Vibrating Capsule administered 5 times per week
224233903|NCT01311804|PROCEDURE|parecoxib sodium|periarticular parecoxib sodium injection will be given during total knee arthroplasty
224233904|NCT01311804|PROCEDURE|parecoxib sodium|intravenous parecoxib sodium during total knee arthroplasty
223766641|NCT03306264|DRUG|Dacogen|Decitabine 20 mg/m\^2 one-hour IV infusion
224233905|NCT02780557|BEHAVIORAL|Contingent Reading Intervention|Caregivers will be provided with 6 picture books. They will be trained to use contingent talk when looking at picture books with their infants. They will be asked to spend 10 mintues each day engaging in contingent talk while looking at picture books. The intervention will run for 4 months. Parents will be asked to keep a daily reading diary.
224233906|NCT02780557|BEHAVIORAL|Book Provision Control|Caregivers will be provided with 6 picture books. They will not be trained to read with their child. They will receive information from other sources (e.g. health visitors and Book Start schemes) as normal.
224233907|NCT00002315|DRUG|Netivudine|
224233908|NCT00002315|DRUG|Acyclovir|
224233909|NCT01966042|PROCEDURE|Local sedation|All subjects enrolled in the study underwent local sedation for bone marrow aspiration.
223766642|NCT06569069|OTHER|US guided PE|"The multifidus muscle near the posterior dorsal root (at L4-L5 or L5-S1) was targeted using a transverse ultrasound view, inserting the needle at an 80º short axis or a 45º long axis, based on vessel presence. For the tibial nerve in the popliteal region, the needle was inserted at an 80º angle after a transverse cut of the nerve.~Physio invasiva® needles (0.30 x 40-60 mm) were used in the lumbar region, and 0.30 x 30 mm needles in the popliteal region. Both areas received galvanic current (1.5 mA for three seconds and three impacts). Treatment included three US-guided PE sessions over a 1:7:14 schedule, though two participants skipped the third due to pain resolution."
223648740|NCT01809340|DRUG|Minocycline|In the 12-day open-label treatment phase, patients will self administer oral minocycline 200 mg on Day 1, 100 mg twice daily on Days 2 to 11, and 100 mg on the morning of Day 12. In the 6-week blinded treatment phase, responders may self administer oral minocycline 100 mg twice daily from the evening of Day 12 for up to 6 weeks (Day 54), or until relapse, whichever comes first. In the 6-week open-label treatment phase, non-responders may self administer oral minocycline 100 mg twice daily from the evening of Day 12 for up to 6 weeks (Day 54).
223648741|NCT01809340|DRUG|Placebo|Patients in the 6-week blinded treatment phase, may self administer placebo twice daily from the evening of Day 12 for up to 6 weeks (Day 54), or until relapse, whichever comes first.
223648742|NCT01809340|DRUG|Ketamine|In the 12-day open-label treatment phase, all patients will receive 1 IV infusion of 0.5 mg/kg ketamine over 40 minutes on Days 1, 3, 5, 8, 10 and 12.
223648743|NCT02331888|DEVICE|Scalp electrode, fetal doppler and EUM|the parturient will be connected to the routine fetal Doppler and to the EUM. and When necessary to the scalp electrode will be connected. Tracings will be recorded simultaneously from all three devices until delivery. three separate outputs will be processed Output of the scalp electrode recording. Output of the fetal doppler. Output of the EUM. Three noncontinuous segments of 30 minutes each with two segments occurring during the first stage of labor and the third occurring during the second stage of labor, will be randomly picked from the scalp electrode recording with 3 matching segments in time from the EUM100pro and the fetal doppler.
223648744|NCT00714870|BEHAVIORAL|Behavioral nutrition and exercise program|The intervention consists of a behavioral nutrition and exercise program. Meetings occur monthly on a Saturday afternoon and last 4 hours. During this time we cover: 1)registration: monitoring of sedentary activities and liquid choices, motivational interviewing, exercise testing;2)exercise: includes strength training; 3) educational lectures; 4) didactic games and projects.
224233910|NCT01966042|PROCEDURE|Bone Marrow Aspiration|All subjects enrolled in the study underwent bone marrow aspiration after they had been anesthetized from the posterior iliac crest. The sample was aspirated into a series of sterile syringes and brought to the cell processing room/laboratory. The processing was in accordance to the Standard Operating Procedure developed observing Good Practice Guidelines.
224233911|NCT01966042|PROCEDURE|Minithoracotomy|The surgical procedure used as cardiac access route was the left anterolateral thoracotomy or left anterior minithoracotomy, depending on the segment of the left ventricle to be treated, allowing the good access to the viable myocardial areas.
224233912|NCT01966042|BIOLOGICAL|Autologous bone marrow mononuclear cells infusion|Once the subject had his or her chest opened and the coronary anatomy reviewed by examination of the pre-operatory nuclear scan to define the area of ischemia, the surgeon drew up the cells into a series of syringes and injected the entire contents of the cell preparation in a series of injections directly into the myocardium.
224233913|NCT01346423|BEHAVIORAL|Interdisciplinary intervention|Interdisciplinary collaboration deals with tasks often complex which require different skills to make a wide assessment.In this study the treatment team consists of a physician, a physiotherapist and a social service worker. The main goal for the team is to make a survey of the patient's situation, in which the biomedical tradition to make a diagnosis is replaced by a disability diagnosis, with systematically identification of barriers for return to work. The conclusion of the team will be followed by a targeted rehabilitation plan. Factors assessed to be the major cause of the reduced function at work will have priority in the following rehabilitation process. One of the team members will be responsible for the further process to follow the plan to help the patient back to work, in cooperation with the patient, the workplace, the general practitioner, and NAV.
224233914|NCT01346423|BEHAVIORAL|Control Group, Brief Intervention|The brief intervention is a standardized intervention and the essential features are interview and examination by a specialist in physical medicine and rehabilitation. Patients will be given time to express their concerns and problems in daily activities. The examination is thorough with detailed feedback on findings and normal functions, and clear and consistent explanations on pain and defense mechanisms. Somatic findings will be explained.Unless pathological findings, the patient will be encouraged to physical activity.
224233915|NCT04550195|DRUG|BMS-986337|Specified Dose on Specified Days
224233916|NCT04550195|OTHER|BMS-986337 Placebo|Specified Dose on Specified Days
224233917|NCT04550195|BIOLOGICAL|Famotidine|Specified Dose on Specified Days
224233918|NCT02259712|OTHER|Hypopressive exercises|45 minutes treatment by hipopressive exercises 2 times per week during 8 weeks. They will be doing in different positions: standing, kneeling, sitting and lying. The patient will be teach a total of 30 exercises. In the week number 8 the women with the physical therapist will choose 3 exercises that will be done daily at home during 20 minutes.
224233919|NCT02259712|BEHAVIORAL|Therapeutic education.|"The therapeutic education will be doing during the 8 weeks of treatment. In the first day the knowledge and the briefs of the pelvic floor dysfunction will be assessed. Dietary and behavioral habits will also be discussed. In the second day anatomical and physiological explanation of the pelvic girdle will be the priority. In the third day will be explained the signs and symptoms of the different pelvic floor dysfunctions. In the four day will be analyzed the risk factors that may cause or worsen pelvic floor dysfunctions.~In the fifth day will be begun to correct the bad habits. In the last day will be reviewed the knowledge and new habits acquired during the treatment. In all treatment days will be discussed the doubts of the participant."
224320255|NCT01059578|DRUG|PLACEBO|Placebo to match 206136 2mg, 10mg, 50mg, 100mg capsule
224320256|NCT01059578|RADIATION|PET|Each subject will undergo 3 PET Scans ; one at Baseline and the others following dosing with GSK206136 at approximately 2 hours post-dose and 24 hours post-dose
223648745|NCT01591525|BEHAVIORAL|Education on risk factors for Type II Diabetes|one-on-one education provided by a nurse practitioner or physician
223648746|NCT01591525|BEHAVIORAL|Education on Type II Diabetes|one-on-one education about having Type II Diabetes, the possible complications and treatment options provided by a physician.
223648747|NCT01591525|BEHAVIORAL|Education on regular visits to a Primary Care Provider|one-on-one education about the importance of visiting a primary care provider (PCP) on a regular basis. Patients are also provided a list of PCP's accepting new patients within a 3 mile radius.
223648748|NCT05474157|OTHER|Standard care treatment for COVID-19 in Intensive Care Unit|Standard care for ARDS patients consisted of respiratory support, intravenous fluid therapy, medical treatment including anticoagulation and sedation, nutrition, change of position every 4 hours and if needed, hemodynamic support.
223648749|NCT04563949|OTHER|Repeat Testing|Repeat Testing with the PLA will be conducted
224233920|NCT02259712|OTHER|Pelvic-perineal physiotherapy|45 minutes physical therapy treatment 2 times per week during 8 weeks. There will be done specific exercises of the pelvic floor muscles and coordination exercises of the pelvic floor muscles with other muscles in different positions. Electrostimulation, biofeedbak, cones and dinamometric devices can be employed to improve the muscle performance.
224233921|NCT02259712|OTHER|Physical Therapy assessment|Pre-treatment, post-treatment, 3, 6 and 12 months after physical therapy treatment. Will be done a specific evaluation of pelvic floor muscles using the Modified Oxford Scale, superficial electromyography, perineometry and dynamometer. For the evaluation of the impact, the signs and the symptoms questionnaires will be completed by the participants.
224233922|NCT04342923|OTHER|No intervention|Blood analysis
224233923|NCT05252481|DEVICE|Active tDCS|Eight sessions of transcranial current direct stimulation
224320257|NCT01524978|DRUG|cetuximab|Escalating doses administered on Day 1 and then once weekly by intravenous infusion.
224320258|NCT01524978|DRUG|vemurafenib|Escalating doses given orally twice a day starting on Day 2
223648750|NCT03895749|DIETARY_SUPPLEMENT|NEO40 Daily|Per Capsule: N5-carbamoylornithine 100 mg, crataegus laevigata 100 mg, L-ascorbic acid 50 mg, vitamin B-12 0.05 mg, vitamin C 50 mg.
223648751|NCT00493129|DRUG|Ontak (Denileukin Diftitox)|9 µg/kg by vein Days 1-5 of a 21 day cycle.
223648752|NCT03399552|DRUG|Avelumab|10mg/kg delivered by IV infusion
223648753|NCT03399552|RADIATION|Stereotactic Body Radiation Therapy|short course of SBRT after the first two doses of avelumab
223648754|NCT00544297|DRUG|PEP005 gel|Two day application, 0.05%
223648755|NCT01696539|BEHAVIORAL|Walking Intervention|Participants are provided with the current standard of prostate cancer care, and are additionally encouraged to walk 10,000 steps per day, as measured by pedometers provided at start of intervention. Once a week, participants will take part in a group walk with 7-8 other participants and a research nurse. Participants are also encouraged to keep a walking journal, in which they record the number of steps they walk each day. This journal is submitted to investigators at the end of the intervention period.
223648756|NCT01696539|OTHER|Standard of Care|Participants are provided with the current standard of prostate cancer care, but are not assigned to a physical activity intervention.
223648757|NCT04691076|DRUG|Propofol|Propofol is administered by target-controlled infusion
223648758|NCT04691076|DRUG|Esketamine|Esketamine is intravenously administrated
223648759|NCT04691076|DRUG|Fentanyl|Fentanyl is intravenously administrated
223648760|NCT00783107|DRUG|Cyclosporine|Cyclosporine Inhalation Solution, Once Daily
223648761|NCT00783107|DRUG|Placebo|
223648762|NCT03918564|DEVICE|Laparoscopic Gastric Vest (LGV)|"The Laparoscopic Gastric Vest (LGV), branded the ReShape Vest™, is a long-term, silastic, implantable system that is placed around the stomach to encompass the gastroesophageal junction to the Incisura Angularis.~The main materials used to make the LGV is Implant Grade Silicone (95%) and Barium Sulfate (5%).~The LGV is indicated for weight reduction for obese people with a Body Mass Index (BMI) between ≥35 kg/m2 and ≤55 kg/m2. It is indicated for use in adult patients (≥22 to ≤65 years) who have failed one or more conservative weight reduction alternative(s), such as supervised diet, exercise, and behavior modification program(s)."
223648763|NCT01573689|BEHAVIORAL|Group intervention based on mutual aid.|Development of a mutual aid group and his actualization on children between nine and twelve years old who had lost one of their parents.
223648764|NCT02357368|DRUG|Depot medroxyprogesterone acetate (DMPA)|DMPA will be administered every 12 weeks at the standard dose of 150 mg IM, beginning from week 3 of study enrollment and repeated at week 15.
223648765|NCT02357368|DEVICE|Etonogestrel implant (Eng-Implant)|A standard nexplanon rod implant will be placed at study week 3 by a trained clinician.
223648766|NCT02357368|DEVICE|Levonorgestrel intrauterine device (Lng-IUD)|A standard Mirena IUD will be placed at study week 3 by a trained clinician.
223648767|NCT02357368|DEVICE|ParaGard® T 380A Intrauterine Copper Contraceptive|A standard ParaGuard IUD will be placed at study week 3 by a trained clinician.
223648768|NCT00194428|BEHAVIORAL|Almond enriched diet|Subjects will consume 2 oz. of almond per day in addition to a low-fat diet
223648769|NCT00194428|BEHAVIORAL|Low fat caloric diet|Low fat caloric diet
223648770|NCT01162642|DIETARY_SUPPLEMENT|Green Tea|Green Tea 4 cups daily
223648771|NCT01162642|OTHER|Placebo|4 cups placebo tea for 6 weeks
223648772|NCT02894684|DRUG|Aztreonam|14 days of AZLI: 75mg TDS PLUS IV Colistin
223648773|NCT02894684|DRUG|Standard Care|14 days of IV Colistin plus one of Tazocin/Ceftazidime/Meropenem/Aztreonam/Fosfomycin
223648774|NCT04843462|DEVICE|edupression.com®|"Edupression.com® is an evidence-based self-help program that was developed for the treatment of mild to moderate unipolar depression. It is based on two core foundations, psychoeducation with elements of cognitive behavior therapy (CBT) and a mood chart. Both foundations are registered as a medical product. As such, detailed risk management documentation includes probability and severity of adverse events. Moreover, detailed strategies such as warnings were implemented in the software and documented accordingly.~It can be used on a PC as well as on mobile devices (browser, app) at any time."
223648775|NCT04843462|DRUG|Esketamine nasal spray|All patients included in this study are receiving esketamine nasal spray as treatment-as-usual
223648776|NCT04082793|COMBINATION_PRODUCT|Photobiomodulation therapy with mandibular exercises|Low-level laser therapy (BMI 1005 Laser 2200) Wavelength: 658 nm Power: 100 MW Energy density: 4J/cm2 Dose administered: 4J Mode: Pulsed Site of application: Over bilateral Temporomandibular joint Number of sessions: 3 sessions/week on alternating days for 12 minutes each, for 4 weeks Mandibular mobilization exercises Side to side movement of the jaw Forward jaw movement Tongue up Goldfish exercise (Partial opening) Goldfish exercise (Full opening) Exercise duration: 6 repetitions X 2 sets X 4 times a day Mandibular Stabilization exercises Exercise duration: 5 repetitions X 3 sec. Hold X 4 times a day
224320259|NCT01524978|DRUG|vemurafenib|960 mg vemurafenib orally twice a day until disease progression, unacceptable toxicity, or withdrawal of consent.
224320260|NCT03802071|DRUG|Durvalumab+doxorubicin cobination|Durvalumab 1500mg IV Doxorubicin 75mg/m2 IV D1 Q3weeks (up to 8cycles)
224320261|NCT05344131|OTHER|Bilişsel Egzersiz Terapi Yaklaşımı (BETY, Cognitive Exercise Therapy Approach)|Biopsychosocial approach
223648777|NCT04082793|COMBINATION_PRODUCT|Sonophoresis with mandibular exercises|"Ultrasound (BM1-1039) Ultrasonic massage with Diclofenac gel Frequency: 1.0 MHz Mode: Continuous Intensity: 0.8 to 1.5 W/cm2~Site of application: Over bilateral Temporomandibular joint Number of sessions: 3 sessions per week on alternating days for 8 minutes each, for 4 weeks Mandibular mobilization exercises Side to side movement Forward jaw movement Tongue up Goldfish exercise (Partial opening) Goldfish exercise (Full opening) Exercise duration: 6 repetition X 2 sets X 4 times a day Mandibular Stabilization exercises Exercise duration: 5 repetitions X 3 sec. Hold X 4 times a day"
223648778|NCT03831750|OTHER|Stress Reduction Intervention|The tri-component intervention is comprised of guided videos for breath-work (5-15 min), stretching (5-15 min), and meditation (10-30 min). The intervention will be delivered online via an access restricted website.
223648779|NCT02639221|DRUG|PXT002331|
223648780|NCT02377817|DEVICE|PrenaBelt|"The PrenaBelt is a belt-like, positional therapy (PT) device designed specifically for pregnant women. While the PrenaBelt does not prevent the user from lying on her back or right side during sleep, it is expected to significantly decrease the amount of time she spends in these two positions via the mechanism of PT. PT is a simple, non-invasive, inexpensive, long-established, safe, and effective intervention for preventing people with positional-dependent snoring or obstructive sleep apnea from sleeping on their back - a position that exacerbates their condition.~The PrenaBelt is worn at the level of the waist. By virtue of its design and position on the user's body, the PrenaBelt affects subtle pressure points on the back and right side of the user when she lies on her back or right side, respectively, activating her body's natural mechanism to spontaneously reposition itself to relieve discomfort, thereby reducing the amount of time she remains on her back or right side."
223648781|NCT02377817|DEVICE|Sham PrenaBelt|The Sham PrenaBelt and PrenaBelt are the same device except the plastic balls are removed from the Sham PrenaBelt so it cannot provide pressure points.
223648782|NCT02172885|BIOLOGICAL|Mesenchymal Stem Cells|Mesenchymal Stem Cell Infusions
223648783|NCT01734616|BEHAVIORAL|Old Exercise|
223648784|NCT01734616|DIETARY_SUPPLEMENT|Old Acute Cocoa|
223648785|NCT01734616|DIETARY_SUPPLEMENT|Old 7 Day Cocoa|
223648786|NCT05552989|OTHER|this is a non-interventional study|this is a non-interventional study
223648787|NCT05169008|BIOLOGICAL|Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)|Intramuscular injection
223648788|NCT05169008|BIOLOGICAL|Recombinant COVID-19 vaccine (adenovirus type 5 vector) for Inhalation (Ad5-nCoV-IH)|Nebulized inhalation through the mouth
223648789|NCT03895840|DRUG|Zilretta|Zilretta (triamcinolone acetonide extended-release injectable suspension) is indicated as an intra-articular injection for the management of pain due to knee osteoarthritis.
223648790|NCT05342714|DEVICE|Remote ischemic conditioning|The LRIC treatment consisted of 5 cycles of bilateral upper limb ischemia for 5 minutes followed by reperfusion for another 5 minutes performed twice a day for a total of 180 consecutive days.The procedure was performed by using an electric autocontrol device with cuffs that inflated to a pressure of 200 mmHg during the ischemic period and deflated during the reperfusion.(Patent No.CN200820123637.X, China).
223648791|NCT01931566|DRUG|Pioglitazone|Pioglitazone SR tablets
223648792|NCT01931566|DRUG|Pioglitazone placebo|Pioglitazone placebo-matching tablets
223766643|NCT06569069|OTHER|Sham Acupuncture|"Participants in the control group were also treated in a prone position. Sham acupuncture treatment was applied at the superficial level of the posterior face of the thigh on the affected side, using five Agupunt® needles of 0.16 x 25 mm, inserted superficially in the lateral aspect of the lumbar area (L3-L4), lateral gluteal region, greater trochanter, lateral part of the distal third of the thigh, head of the fibula and lateral aspect of the leg in its middle third. The needles were left superficially subcutaneously for 15 minutes, performing this approach in three different sessions, again following a periodicity of 1:7:14 days."
223766644|NCT05083481|DRUG|ASP1570|Oral tablet
223766645|NCT05083481|DRUG|pembrolizumab|Intravenous Infusion
223766646|NCT05083481|DRUG|Trifluridine + Tipiracil|Oral Administration
223766647|NCT05083481|DRUG|Bevacizumab|Intravenous Infusion
224233924|NCT05252481|DEVICE|Sham tDCS|Eight sessions of transcranial current direct stimulation (sham)
224233925|NCT02022813|DIETARY_SUPPLEMENT|Supplemental parenteral nutrition (SPN)|The amount of energy delivered by SPN will depend on the indirect calorimetry measurement and actual enteral feed delivery. SPN will be reduced with progressing EN
224233926|NCT02870712|PROCEDURE|Suture of perineum|suture of the tear to obtain hemostasis
223648793|NCT03382353|DIETARY_SUPPLEMENT|Nutritional supplementation|Daily consumption of Tramiprosate (100 mg) for 1 year
223648794|NCT03382353|BEHAVIORAL|Educational training|16 educational lessons (twice a week): basic principles of different cognitive domains (e.g. memory, attention, perception) and educational DVD viewing.
223648795|NCT03382353|BEHAVIORAL|Counselling on a brain-healthy diet|4 lessons on the principles of Mediterranean Diet lead by a nutritionist, aimed to teach how to include brain-healthy foods in daily diet (e.g. antioxidant, omega-3 fatty acids and vitamins). Each participant will receive the educational material presented.
223766648|NCT05083481|DRUG|Docetaxel|Intravenous Infusion
223766649|NCT04917276|DIAGNOSTIC_TEST|Circulating tumor cell|Detecting CTC in different time points of treatment (like PR, PD, pre and post-operation)
223766650|NCT03528434|DIETARY_SUPPLEMENT|Zinc|10mg dispersible zinc sulfate tablet
223766651|NCT03528434|OTHER|Placebo|Dispersible tablet with inert ingredients, identical to zinc in appearance
224233927|NCT02870712|PROCEDURE|hemostatis by digital compression|Digital compression of the tear to obtain hemostasis
224233928|NCT03997747|OTHER|cytology specimen|Biopsy and Genetic: DNA analysis;Genetic: RNA analysis;Genetic: microarray analysis; Genetic: mutation analysis; Genetic: polymorphism analysis
224233929|NCT01875575|DIETARY_SUPPLEMENT|Placebo|
224233930|NCT01875575|DIETARY_SUPPLEMENT|Glucose 25g|
224233931|NCT01875575|DIETARY_SUPPLEMENT|Glucose 10g|
224233932|NCT00404274|DRUG|Casopitant (GW679769) oral tablets|Casopitant will be available in the dose strength of 20,30 or 50 mg
224233933|NCT00404274|DRUG|Warfarin oral tablets|Warfarin will be available in the dose strength of 5 mg
224233934|NCT02586831|DRUG|Anti-Thymocyte Globulin (ATG)|2.5 mg/kg administered as two divided infusions of 0.5 mg/kg and 2 mg/kg on Days 1 and 2.
224233935|NCT02586831|DRUG|Interleukin 2|1 million IU per dose administered subcutaneously for 5 consecutive days on Days 10-14, and then every two weeks.
224233936|NCT02586831|DRUG|Exenatide|2 mg administered subcutaneously weekly for up to 52 weeks.
224233937|NCT02586831|DRUG|Adalimumab|50 mg administered subcutaneously once a month for 1 year.
224233938|NCT02586831|OTHER|ATG Placebo|ATG placebo mimicking Thymoglobulin administered intravenously.
224233939|NCT02586831|OTHER|IL-2 Placebo|IL-2 placebo mimicking Aldesleukin administered subcutaneously.
224233940|NCT02586831|OTHER|Adalimumab Placebo|Placebo mimicking Adalimumab administered subcutaneously.
224233941|NCT02586831|OTHER|Exenatide Placebo|Placebo mimicking Exenatide administered subcutaneously.
224233942|NCT03707873|OTHER|Education|Education + Medication adherence monitoring + Feedback when low adherence
224233943|NCT04879420|DRUG|Teriparatide|Teriparatide dispensing claim is used as the reference group.
223648796|NCT03382353|BEHAVIORAL|Physical exercise training|80 sessions of physical exercise supervised by a Fitness Training Expert with the aim of achieving 150 minutes of moderate-intensity physical activity per week
223648797|NCT03382353|BEHAVIORAL|Computerized cognitive training|16 cognitive training sessions (twice a week) supervised by a psychologist, aimed to improve Attention, Processing speed, Memory, Social skills and Intelligence using BrainHQ (www.brainhq.com).
223648798|NCT02622178|DIAGNOSTIC_TEST|Optical Coherence Tomography|Optical coherence tomography (OCT) is a noninvasive imaging modality that provides micrometer-scale resolution.It has been revolutionized in recent years by exploitation of Fourier domain (FD) techniques, which have a significant sensitivity advantage over traditional time domain (TD) OCT. In spectral-domain (SD-OCT) the reference mirror is stationary, and OCT signal is acquired using a spectrometer as detector or by varying the wavelength of the light source.
223648799|NCT02622178|DIAGNOSTIC_TEST|Visual evoked potential|Visual evoked potential is a means of objectively testing visual field by viewing a computer monitor at 1 meter with a square black/white checkerboard pattern reversal stimulus. Electrodes are placed on the head and face to monitor Electroencephalogram (EEG) activity during testing. Output parameters from VEP system include amplitude and latency measures for each stimuli.
223648800|NCT00760617|BIOLOGICAL|GSK Bio's influenza vaccine GSK2186877A|Intramuscular (IM) administration, 1 dose
223648801|NCT00760617|BIOLOGICAL|Fluarix|Intramuscular (IM) administration, 1 dose
223648802|NCT00002630|BIOLOGICAL|filgrastim|
223648803|NCT00002630|DRUG|cyclophosphamide|
223648804|NCT00002630|DRUG|melphalan|
223648805|NCT00002630|PROCEDURE|peripheral blood stem cell transplantation|
223648806|NCT00002630|RADIATION|low-LET cobalt-60 gamma ray therapy|
223648807|NCT00002630|RADIATION|low-LET photon therapy|
223648808|NCT06177626|BEHAVIORAL|Aerobic Training|Aerobic training on stationary bike 5x a week for 30 minutes a day
223648809|NCT06177626|BEHAVIORAL|Balance Training|Training 5x a week for 30 minutes. Standard of care.
223648810|NCT02421835|DIETARY_SUPPLEMENT|Olive leaf extract|132 mg of oleuropein per day suspended in olive leaf extract 700 mg
223648811|NCT02421835|DIETARY_SUPPLEMENT|Placebo|700 mg Maltodextrin per day
223648812|NCT01032252|OTHER|Exercise intervention|"16 week exercise once a week of 60 minutes intervention by trained fall prevention instructors and a home program.~Intervention includes strength/power training, balance/gait training, behavioral aspects and perceptual and functional training."
223648813|NCT04625101|DRUG|NBI-827104|Triple T-type calcium channel blocker.
223648814|NCT04625101|DRUG|Placebo|Non-active dosage form.
223648815|NCT00082797|DRUG|leucovorin calcium|
223648816|NCT00082797|DRUG|methotrexate|
223648817|NCT03829202|DEVICE|Own mechanical knee|Daily use of own mechanical knee
223648818|NCT03829202|DEVICE|RheoKnee microprocessor prosthetic knee|Daily use of RheoKnee microprocessor prosthetic knee
223648819|NCT03197896|OTHER|Educational Intervention|Review prostate cancer information
223648820|NCT01149018|DRUG|Tetrahydrocannabinol|Oral solution of THC in concentration of 5mg/0.2ml. Dose regimen: 5mg 2-4 times/day as tolerated.
223648821|NCT01149018|DRUG|Placebo|Orally administered olive oil. Dose: 0.2ml 2-4 times a day as tolerated
223648822|NCT00251732|DRUG|Standard dose (once daily) PPI plus low-dose antidepressant|20 mg. rabeprazole plus low dose tricyclic antidepressant(TCA)
223648823|NCT00251732|DRUG|Double dose PPI plus evening placebo|20 mg. twice daily with a placebo
223648824|NCT00251732|DRUG|Rabeprazole , placebo, placebo|20 mg rabeprazole(PPI) once daily -a.m. placebo -p.m. placebo -bedtime
224233944|NCT04879420|DRUG|Risedronate|Risedronate dispensing claim is used as the exposure group.
224233945|NCT01798069|BEHAVIORAL|reflective writing|Students allocated to the experimental arm will follow 5 sessions in Class-led instruction of reflexive writing workshops. They will be divided into 12 sub-groups of 8 students. They will write their stories about their own experiences or the experiences of their family / patient.
224233946|NCT01798069|BEHAVIORAL|reading medical publication workshops|
224233947|NCT04400526|BEHAVIORAL|A video competition|Each Individual/group will be required to produce a maximum of 2-minute video on one of the following themes: (1) the hazardous effects of drug especially less psychotropic drugs such as Cannabis, (2) encouraging messages to drug abusers, and (3) existing anti-drug services.
224233948|NCT04400526|BEHAVIORAL|A training workshop|The workshop will last for 6 hours, and will be delivered by an experienced counsellor from C.H.O.I.C.E. The content of the workshop will include (1) hazardous effects of drug abuse especially less psychotropic drugs such as Cannabis, (2) signs and symptoms of drug abuse particularly less psychotropic drugs like Cannabis, (3) alternatives to drug abuse, (4) community resources available, and (5) how to refer drug abusers. Besides, all children will be taught to use the AWARD model for referrals in the workshop.
224233949|NCT04400526|BEHAVIORAL|A mass promotional campaign|Children who complete the training workshop in phase 2 will be invited to join phase 3. They are encouraged to design their own promotional activities for community members in the targeted districts. The activities can be delivered by a group (a maximum of 5 ADAs per group) or by an individual. Types of activities can include but not limited to health talks, booths, outreaching activities, games, posters, leaflets and websites. Likewise, if the ADAs encounter any drug abuser in their social circles, the ADAs will be asked to deliver a brief advice based on the AWARD model.
224233950|NCT03718455|DEVICE|Axillary Magseed|The Magseed will replace the investigators' current clinical practice of using radioactive seeds in women receiving neoadjuvant chemotherapy.
224233951|NCT02617108|DEVICE|Foley balloon|a Foley balloon with 4 ml of normal saline solution will be placed into the uterine cavity at the end of the operation for five days.
223648825|NCT05147259|DRUG|HR011408 injection|Drug: HR011408 injection (formulation A), administered subcutaneously. Drug: HR011408 injection (formulation B), administered subcutaneously.
223648826|NCT04235621|OTHER|FSGS/TR-MCD|This is a non-interventional study
223648827|NCT04235621|OTHER|Diabetic Nephropathy (DN)|This is a non-interventional study
223648828|NCT02817464|DRUG|TV-46046 - 400 mg/mL|A single subcutaneous injection in the abdomen of undiluted TV-46046 - 400 mg/mL
223648829|NCT02817464|DRUG|TV-46046 - 200 mg/mL|A single subcutaneous injection in the abdomen of saline-diluted TV-46046 - 200 mg/mL
223648830|NCT00343096|DRUG|Lorazepam|All doses 0.1mg/kg once, repeat after 10 minutes x1
223648831|NCT03229980|DRUG|Cold blood cardioplegia (large volume)|Hearts will be arrested with cold blood cardioplegia, first dose (arrest dose) will be 30 ml/kg and the frequent doses every 20 min will be 15 ml/kg
223648832|NCT03229980|DRUG|Cold blood cardioplegia (small volume)|Hearts will be arrested with cold blood cardioplegia first dose (arrest dose) will be 10 ml/kg and the frequent doses every 20 min will be 5 ml/kg
223648833|NCT00559819|DRUG|placebo|Placebo (orange juice), same volume as alcohol
223648834|NCT00559819|DRUG|Alcohol|Dose with Alcohol (Vodka) to make blood alcohol concentration 0.08%
223648835|NCT01678495|OTHER|Sulfur hexafluoride + ultrasounds|
223648836|NCT01678495|DRUG|Recombinant tissue plasminogen activator|
223648837|NCT05504707|BIOLOGICAL|HER2 - primed Dendritic cells|"Dendritic cell will be administered at ultra-sound guided injections. Participants will receive 8 intratumoral injections. These injections will be administered twice per week per week (given 3 days apart). Participants will receive alternating injections (3 days apart) of HER2-primed followed by HER3-primed DCs.~Participants will be treated at the following dose levels:~Dose level 1: HER2 - primed Dendritic cells dose 10-20 million Dose level 2: HER2 - primed Dendritic cells dose 30-50 million Dose level 3: HER2 - primed Dendritic cells dose 80-100 million"
224233952|NCT00266409|DRUG|Niravam|
223648838|NCT05504707|BIOLOGICAL|HER3 - primed Dendritic cells|"Dendritic cell will be administered at ultra-sound guided injections. Participants will receive 8 intratumoral injections. These injections will be administered twice per week per week (given 3 days apart). Participants will receive alternating injections (3 days apart) of HER2-primed followed by HER3-primed DCs.~Participants will be treated at the following dose levels:~Dose level 1: HER3 - primed Dendritic cells dose 10-20 million Dose level 2: HER3 - primed Dendritic cells dose 30-50 million Dose level 3: HER3 - primed Dendritic cells dose 80-100 million"
223648839|NCT05557110|DRUG|Blinatumomab|Reduced-intensity chemotherapy followed by Blinatumomab
223648840|NCT06654375|PROCEDURE|Endovascular Thrombectomy|"Endovascular thrombectomy (EVT) in this clinical trial involves the mechanical removal of a thrombus from a blocked large cerebral artery using specialized devices like stent retrievers or aspiration catheters. Key distinguishing features of this EVT protocol include:~* Extended Time Window: Unlike standard EVT, which is typically performed within 24 hours after symptom onset, this intervention targets patients presenting beyond 24 hours.~* Collateral Circulation Assessment: Multi-phase CT angiography (CTA) is employed to evaluate collateral flow, prioritizing patients with favorable collateral grades. This selection process helps ensure the identification of patients most likely to benefit from EVT despite the late presentation."
223648841|NCT06654570|DRUG|Intravaginal estrogen during adjuvant letrozole|Postmenopausal patients undergoing adjuvant letrozole therapy and experiencing VVA symptoms were treated with vaginal estradiol for 12 weeks. Gynecologic examination and symptom screening were conducted at baseline and after 12 weeks. Serum E2 levels were analyzed at baseline, and at two, four, eight, and 12 weeks. E2 levels were measured using both a routine liquid chromatography-tandem mass spectrometry (LC-MS/MS) method and a highly sensitive (hsE2-MS) LC-MS/MS method.
223648842|NCT04462627|DIAGNOSTIC_TEST|Blood group determination|Determination of the blood group (ABO/LE)
223648843|NCT04462627|DIAGNOSTIC_TEST|Antibody titration|Natural anti-A and anti-B antibody levels will be determined by a gel agglutination technique on the Biorad IH-500 automaton.
223648844|NCT04462627|DIETARY_SUPPLEMENT|Probiotic|Administration of a probiotic to healthy volunteers to determine if it increases the level of circulating natural anti-A and anti-B antibodies (Probactiol Plus (Metagenics)).
224233953|NCT00266409|DRUG|SSRI/SNRI|Selective Serotonin Reuptake Inhibitor or Selective Norepinephrine Reuptake Inhibitor
224233954|NCT01933295|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|
223648845|NCT05903950|DEVICE|Air cleaners with HEPA filter|PM 2.5 exposure reduction using in home portable air cleaners fitted with HEPA filters
223648846|NCT05903950|DEVICE|Air cleaners without HEPA filter|Simulation of PM 2.5 exposure reduction using in home portable air cleaners without HEPA filters.
223648847|NCT07074080|OTHER|Performing chest compressions on a mannequin using the foot|Performing chest compressions on a mannequin using the foot
224233955|NCT01933295|BEHAVIORAL|Sleep Education|
223648848|NCT07074080|OTHER|Performance of standard chest compressions with the upper limbs.|Performance of standard chest compressions with the upper limbs.
223766652|NCT02577965|PROCEDURE|Percutaneous Coronary Intervention|Thrombus aspiration and histopathological analysis ,Optical Coherence Tomography assessment of culprit vessel during primary PCI, Primary PCI and Drug Eluting Stent (DES) - XIENCE PRIME Everolimus Eluting Coronary Stent implantation in culprit lesion, coronary angiography and OCT assessment at 9 months follow-up
223766653|NCT02577965|DEVICE|XIENCE PRIME Everolimus Eluting Coronary Stent System|Xience Prime Everolimus Eluting Coronary Stent System implantation to treat Acute Myocardial Infarction
224233956|NCT01933295|BEHAVIORAL|Sleep Restriction Therapy|
224233957|NCT00009711|PROCEDURE|management of therapy complications|
224233958|NCT06545383|OTHER|Dynamic Neuromuscular Stabilization Exercises|Exercises will last 45 minutes and will be 3 days a week for 6 weeks. Additionally DNS exercises will be performed in 40-minute sessions, 2 days a week for 6 weeks.
224233959|NCT06545383|OTHER|Exercise|Exercises will last 45 minutes and will be 3 days a week for 6 weeks. Additionally, the control group will be asked to walk at moderate intensity for 40 minutes, 2 days a week, for 6 weeks.
224233960|NCT02044783|BEHAVIORAL|Behavioral Counseling|
224233961|NCT05427097|DEVICE|Helical® patches|Active Helical® patches and non-active patches (placebo) are placed at cervical tension points
224233962|NCT05795491|DEVICE|Blue Light Emitting Diode Therapy|Light-emitting diode (LEDs) as a preferred light source for phototherapy is a semiconductor device that, through the process of electroluminescence, generates light emitted at different wavelengths, causing a differentiation in color and effects.
224233963|NCT05795491|DRUG|Azole Antifungal|Azole antifungals are a group of medicines that contain an azole ring and inhibit the growth of a wide range of fungi
224233964|NCT01876862|OTHER|Antiretroviral treatment interruption|pilot study in chronically HIV-infected patients with an ultralow HIV reservoir undergoing treatment-interruption.
224233965|NCT03576391|BEHAVIORAL|Control condition|45 minute rest while seated. Watching an animated movie, sleeping was not allowed.
223766654|NCT02102139|DRUG|DXM + Propofol|"After induction as mentioned at 'arm description', the effect-site propofol concentration was fixed at 5.0 μg mL-1 at the time of diluted epinephrine injection and was unchanged during the entire hydrodissection period in all patients.~The first patients received effect-site concentrations of remifentanil of 4 ng mL -1, respectively. The EC50 of remifentanil for stable hydrodissection was determined by a modification of Dixon's up-and-down method.If the response was success (SBP during the entire hydrodissection period being ±20% from baseline), the next target concentration of remifentanil was decreased by a step of 0.5 ng mL -1. If the response was fail(SBP \> ±20% from baseline), the target concentration was increased by 0.5 ng mL-1."
223766655|NCT02102139|DRUG|Saline + Propofol|All procedure would be same in DXM+Propofol group except saline loading rather than DXM loading before induction.
223766656|NCT00017758|DRUG|Pravastatin sodium|
224233966|NCT03576391|BEHAVIORAL|Rapid Arm Movements|2 blocks of 80 trials of RAM in either a forward (n = 40) or backward (n = 40) shoulder flexion direction and back to neutral as fast as possible, with maintaining extension in the elbow. Visual cues (arrows) indicated the movement direction.
224233967|NCT03576391|BEHAVIORAL|Physical fatigue condition|40 minutes rest while seated followed by static endurance tasks, i.e. modified Biering-Sörensen task and static abdominal curl task.
224233968|NCT03576391|BEHAVIORAL|Cognitive fatigue condition|45 minutes of a cognitively fatiguing condition consisting of a modified incongruent Stroop color-word task.
224233969|NCT00584766|PROCEDURE|High-dose chemotherapy|Cyclophosphamide 500 mg/m2 IV day 1; Doxorubicin 30 mg/m2 IV Day 1; Methotrexate 300 mg/m2 IV Day 8;5-FU 500 mg/m2 IV day 8; leucovorin 20 mg po q 6 h x 6 doses, day 9- cycles repeated q 21 days
224233970|NCT04842110|DEVICE|Experimental: eonTM FR 1064 nm device|The subject treatment area - abdomen, was treated with the 1064 nm wavelength laser.
223766657|NCT00017758|DRUG|Simvastatin|
223766658|NCT00017758|DRUG|Atorvastatin calcium|
224233971|NCT04549064|DIAGNOSTIC_TEST|diagnosis of pancreatic cancer|Diagnosis of pancreatic cancer based on the concentration of serum biomarkers
224233972|NCT04208659|PROCEDURE|Self-administration of auricular acupuncture without prosthesis|Participants will insert semi-permanent acupuncture needles in their ears without the guidance of a prosthesis
224233973|NCT04208659|PROCEDURE|Self-administration of auricular acupuncture with prosthesis|The same participants who previous self-administered a standardized auricular acupuncture will be given custom-molded prostheses midway through the study to assess how much the prostheses facilitate insertion.
224233974|NCT01938118|BEHAVIORAL|Obesity Prevention Group|
224233975|NCT01938118|BEHAVIORAL|Injury Prevention Group|
224233976|NCT04919421|DRUG|Dental injection and topical gel application|Topical anesthesia gel will be applied followed by dental injection with 1.8 ml Xylocaine 20mg/ml (DENSPLY Pharmaceutical); adrenaline: 1 : 100.000, delivered in cartridges using a 27 -gauge short needle (0.4 x 25 mm,C-K jet) and sterile non-aspirating syringe.
224233977|NCT04919421|DEVICE|Dental injection and virtual reality device|Dental injection will be made while the participants are wearing virtual reality device.
224233978|NCT01346332|DEVICE|Iontophoresis System with Headset|Iontophoresis of an anesthesia solution to the tympanic membrane using the Acclarent Iontophoresis System with Headset
223648849|NCT07075614|BEHAVIORAL|Parent Training Program|"Parent Training Programs are complementary interventions to special education, implemented by parents to support the social, cognitive, and behavioral development of children with autism and other developmental disorders.~Throughout the program, key developmental skills that children are expected to acquire-such as social skills (eye contact, joint attention, play, imitation), language, cognitive, motor, and self-care abilities-are explained using sample photos and simple instructions.~Additionally, the program provides guidance on how to foster secure attachment between parent and child and how to support social-communicative skills through warm, responsive interactions in daily life."
223648850|NCT07074470|DRUG|Induction therapy-2 cycles of VPX (Teniposide, PD-1 monoclonal antibody plus Selinixor)|2 cycles of VPX regimen (21days per cycle) Teniposide: intravenous drip, 50mg d1-3; PD-1 monoclonal antibody: intravenous drip, 200mg d1; Selinixor: take 40mg orally, W1，60mg，W2，40mg biw，W3，cycle 1； 40mg， biw，cycle 2
223648851|NCT07074470|PROCEDURE|Consolidation therapy with ASCT after TB (Thiotepa plus Busulfan) preconditioning|"TB preconditioning:~Thiotepa intravenous drip 300mg/m2 d-6-d-5; Busulfan: intravenous drip, 0.8mg/kg q6h d-4--d2; followed by autologous peripheral stem cells infusion at day 0"
223648852|NCT07074470|DRUG|Consolidation therapy-4 cycles of VPX (Teniposide, PD-1 monoclonal antibody plus Selinixor)|4 cycles of VPX regimen (21days per cycle) Teniposide: intravenous drip, 50mg d1-3; PD-1 monoclonal antibody: intravenous drip, 200mg d1; Selinixor: take 40mg orally biw, cycle 3-6；
223648853|NCT07074470|RADIATION|Consolidation therapy-whole brain radiation therapy|whole brain radiotherapy: CTV1: 20-30Gy/10fractions GTVp: 25-40Gy/10fractions
223648854|NCT07074470|DRUG|Maintenance treatment-PD-1 monoclonal antibody|PD-1 monoclonal antibody for up to 2 years intravenous infusion, 200mg d1 (21days per cycle)
223648855|NCT07075757|DRUG|Single in situ intra-arterial injection of bevacizumab|3 Escalating doses of an in situ intra-arterial injection of Bevacizumab (5 mg/kg, 7.5 mg/kg, 10 mg/kg)
223648856|NCT06927973|DIAGNOSTIC_TEST|Echocardiogram|Ultrasound
223766659|NCT00017758|DRUG|Nelfinavir mesylate|
223766660|NCT00017758|DRUG|Efavirenz|
223766661|NCT00019435|BIOLOGICAL|LMB-9 immunotoxin|
224233979|NCT04040010|DIETARY_SUPPLEMENT|Colostrum supplementation for bone loss|Participants in the interventions groups (i.e. colostrum supplementation) will take a colostrum mixture for 5 months (5 times per week; a total of 250ml per day in liquid form). Participants in the placebo groups (i.e. controls) will be taking a placebo mixture (a total of 250ml per day in liquid form per dose) for the same period of time.
224233980|NCT01801670|PROCEDURE|Biopsy|Two 6 mm skin punch biopsies (one from pruritic skin and from involved non pruritic skin).
224233981|NCT01801670|PROCEDURE|Blood|Peripheral blood (10 mls) to be drawn and used for cytokine analysis.
224233982|NCT05412498|BEHAVIORAL|BR-30|Battle rope training exercises will be performed for 30 seconds and the training volume will be consisted of 1 repetition.
224233983|NCT05412498|BEHAVIORAL|BR-45|Battle rope training exercises will be performed for 45 seconds and the training volume will be consisted of 1 repetition.
224233984|NCT00197951|DRUG|Treatment of psychiatric symptoms associated to alcoholism|
224233985|NCT00331890|DRUG|Citicoline|1g/12h iv during 3 days and then orally until complete 6 weeks of treatment
224233986|NCT00331890|DRUG|Placebo|As active drug
224233987|NCT00041509|DRUG|SB-424323|500 mg, oral, BID for 28 days or 125 mg, oral, BID for 28 days
224233988|NCT00041509|DRUG|Placebo|matching placebo, oral, BID for 28 days
224233989|NCT04491409|OTHER|Best Practice|Undergo standard of care
224233990|NCT04491409|OTHER|Medical Chart Review|Medical charts reviewed
224233991|NCT05704556|DRUG|VX-548|Tablets for oral administration.
224233992|NCT01781065|DEVICE|transcranial direct current stimulation|
224233993|NCT00783666|DRUG|Lactic Acid (Dermacyd PH_DETINBACK Tangerine Mix)|Lactic Acid
224233994|NCT02805803|OTHER|Quality of life questionary|Patients will be asked to fill out the questionaries before treatment initiation and at 3, 6 , 12 and 24 months after antibiotherapy initiation.
224233995|NCT04324008|DEVICE|Constic|Flowable resin composite
223648857|NCT07074366|BEHAVIORAL|Splint Therapy with Structured Communication|All participants received a stabilization splint for the management of TMDs, combined with a structured counseling protocol delivered by the assigned dentist.
223648858|NCT06932796|BEHAVIORAL|Health Care Provider Stigma Training and Clinic-Based Messaging Campaign|Providers in 10 HIV clinics participated in a 5 session anti-stigma health facility training focused on: 1) raising awareness about stigma and discrimination at the facility; and 2) changing attitudes and behaviors towards women who use drugs and/or trade sex; and 3) building a stigma-free clinic. Each of these clinics also received anti-stigma messaging materials (i.e., pamphlets, posters) to display in their clinics over a 6 month period. Providers received text-based message twice a month during this time to reinforce skills learned during trainings and to empower providers to be stigma change agents. Providers completed pre/post survey assessments.
223648859|NCT06482450|OTHER|LetsTalkShots (patient-facing CDS)|LetsTalkShots is a website which provides patients/parents with tailored videos addressing vaccine concerns.
224233996|NCT04324008|DEVICE|G-ænial Universal Flo|Flowable resin composite
224233997|NCT04324008|DEVICE|Tetric N-Flow (self-etch)|Tetric N-Flow (Tetric N-Bond Universal, self-etch mode)
224233998|NCT04324008|DEVICE|Tetric N-Flow (etch&rinse)|Tetric N-Flow (Tetric N-Bond Universal, etch\&rinse mode)
223648860|NCT06482450|OTHER|LetsTalkShots (provider-facing CDS)|The provider-facing CDS component will propagate patient concerns obtained from LetsTalkShots (and the appropriate talking points to address the talking points) into the electronic health record (EHR) for the provider at the point of care.
223648861|NCT06482450|OTHER|Appointment Reminder Message|"The regular text message and e-mail appointment reminder includes a vaccine primer (e.g. Vaccines are due and reserved for the participant's child), but no patient- or provider-facing CDS."
223648862|NCT05255289|PROCEDURE|Urodynamic investigations before and after a trans-obturator tape protocol.|Urodynamic investigations (The urodynamic study included free uroflowmetry, postvoid residual, filling and voiding cystometry, and a urethral pressure profile. The filling cystometry and urethral pressure profile were performed with 37 degrees C normal saline similar to body temperature at an infusion rate of 80 ml/min.)
224233999|NCT00635154|BIOLOGICAL|Anakinra (IL-1Ra)|100mg daily subcutaneously administered
224234000|NCT00635154|DRUG|Dexamethasone acetate|"Low dose - 20 mg/week~High dose - 40mg days 1-4, 9-12, 17-20 every 28 days ODD cycles OR 40 mg days 1-4 every 28 days EVEN cycles. (Starting dose was determined by treating physician)"
224234001|NCT02327000|DRUG|Pregabalin 150mg|GLA5PR GLARS-NF1 tablet 150mg/day(Pregabalin 150mg once a day)
224234002|NCT02327000|DRUG|Pregabalin 300mg|GLA5PR GLARS-NF1 tablet 300mg/day(Pregabalin 300mg once a day)
224234003|NCT02811809|DRUG|Apalutamide|Apalutamide 240 mg (4 60mg tablets) daily
224234004|NCT02811809|DRUG|IHT|Leuprolide 3-month depot 22.5 intramuscular dose
224234005|NCT01566071|OTHER|Assessment of drive abilities|
224234006|NCT02563756|PROCEDURE|Unicompartmental knee replacement|Participants with a medial gonarthritis are operated with a medial unicompartmental prosthesis
224234007|NCT02563756|PROCEDURE|Total knee replacement|Participants with a medial gonarthritis are operated with a total knee replacement
224234008|NCT04159909|DEVICE|Transcutaneous Nerve Stimulation|510(K) number: K110390 vagus nerve for 5 minutes twice a day for 4 consecutive days
224234009|NCT04159909|DEVICE|Sham Stimulation|sham stimulation (no electrical current) for 5 minutes twice a day for 4 consecutive days
224234010|NCT06403865|DRUG|Cabotegravir, Rilpivirine Drug Combination|Treatment switch to CAB+RPV LA
224234011|NCT04390828|BEHAVIORAL|Guided Imagery Meditation|the guided image meditation invention program of the intervention measures of this study include four important elements: 1) Meditation exercises: the exercises to adjust the body and mind through specific attention, so that people gradually feel the state of relaxation through practice; (2) Guided image: the simple visualization and use of mental images produced by imagination as a form of psychotherapy, images come from natural scenes (e.g., forests and mountains, streams and oceans), positive feelings and emotions are generated through psychological imagination to induce psychological and physiological relaxation state; (3) Music aids: reaching a relaxed state with comfortable and slow background music; (4) Breathing relaxation training: the patient is taught to take abdominal breathing to divert attention and stimulate the parasympathetic nervous system to achieve muscle relaxation. The entire intervention process takes about 15 to 20 minutes, 2 times a day.
224234012|NCT04122430|OTHER|Review of Health Information|
224234013|NCT01474226|DIETARY_SUPPLEMENT|Amino Acid Crystalline Lysine Amino Acid Mix|crystalline lysine from AA MIX (20, 40, and 60% of the mean lysine requirement of 35 mg/kg/d) Lysine will be given in the form of L-Lysine-HCl, Sigma-Aldrich Brand.
224234014|NCT01474226|DIETARY_SUPPLEMENT|Cooked Rice containing Lysine|Lysine (20,40 and 60 % of the mean lysine requirement) from Cooked Rice
223648863|NCT05255289|PROCEDURE|Urodynamic investigations before and after a tension-free vaginal tape-obturator (TVT-O)|Urodynamic investigations (stated above.)
223648864|NCT05255289|PROCEDURE|Urodynamic investigations before and after a mini Arc protocol.|Urodynamic investigations (stated above)
224234015|NCT04908826|PROCEDURE|Indocyanine Green (ICG) administration|Patients will undergo laparoscopic cholecystectomy after they are randomly divided into 3 (three) groups. A total of 240 patients will be randomized into three groups of 80. In the first group (A) standard cholangiography will be performed. In group (B) intravenous fluorescent cholangiography with indocyanine green will be performed during surgery. ICG at a dose of 0.3 mg / mL / Kg 6 (six) hours prior to surgery will be administered. In the third group (C), intraoperative cholangiography will be performed with direct administration of indocyanine green at a dose of 0.03 mg / ml / Kg to the gallbladder.
224234016|NCT01399736|PROCEDURE|FFR-guided revascularisation strategy|FFR-guided revascularisation strategy
224234017|NCT01399736|PROCEDURE|randomised to guidelines group|Staged revascularisation by proven ischemia or persistence of symptoms of angina
223648865|NCT05255289|PROCEDURE|Urodynamic investigations before and after an i-STOP mini adjustable sling protocol.|Urodynamic investigations (stated above)
223648866|NCT05255289|PROCEDURE|Urodynamic investigations before and after an Solyx sling protocol.|Urodynamic investigations (stated above.)
224234018|NCT01566318|BEHAVIORAL|Problem-Solving Therapy|6-8 sessions over 8 weeks, with booster
224234019|NCT05399264|BEHAVIORAL|Auditory-working memory training program|"The AT-WMT program is comprised of 1,200 daily used sentences either created or selected from newspapers, books, TV programs and magazines by the research assistants. The sentences are political-, cultural-, and religious-neutral sentences. Each of them contains 10 words. Noise was recorded from the upper and lower decks of a bus, in a café, a Chinese restaurant, an MTR (the Mass Transit Railway) carriage, and from a street.~During the training, the following two adaptive tasks will be administered simultaneously: repeating the sentences masked by noise (i.e., AT component) and recalling the first or the final two words of all sentences in a given sentence set (i.e., WMT component)."
224234020|NCT05399264|BEHAVIORAL|Auditory training program|During the training, an adaptive speech-in-noise perception task will be administered. Specifically, the sentences in a sentence set will be presented binaurally using a headphone at a level the listeners felt is comfortable. The trainees are expected to immediately repeat each noise-masked sentence after hearing it. If they cannot repeat the sentence, then the sound intensity of the noise will be automatically decreased (step size = 2 dB) until the sentence can be correctly repeated. If the sentence can be repeated at the first attempt, then the intensity of the noise will be automatically increased by 2 dB in the next sentence. To provide feedback, the targeted sentence will be replaced by an asterisk and only shown after clicking the sentence.
224234021|NCT05399264|BEHAVIORAL|Mindfulness training program|Participants in this group will participate in a mindfulness training program using newlife.330 (Psychiatric Rehabilitation Association, 2018) which is a Cantonese online platform for self-guided mindfulness training.
223648867|NCT04195841|PROCEDURE|Z shaped incision|"After local anaesthesia, a mucoperiosteal flap will be elevated at the edentulous ridge with two horizontal incisions placed with a no MB 69 blade, 1-2 mm away from the papilla of the teeth adjacent to the edentulous space following the mesial and distal contour of the teeth. The extend of the incisions should be up to the proximal line angles of the adjacent teeth. These two horizontal incisions are then connected by an oblique incision from the disto-buccal to mesio lingual point angles. A periosteal elevator is used to elevate a full thickness mucoperiosteal flap buccally and lingually to the level of the mucogingival junction, exposing the alveolar ridge of the implant surgical sites.~Endosseous implant placement is done followed by simple interrupted resorbable sutures"
223648868|NCT04195841|PROCEDURE|H shaped incision|"After local anaesthesia, a mucoperiosteal flap is elelevated by placing sulcular incisions placed in the proximal sides of the adjacent tooth facing the edentulous space in a bucco lingual direction extending between the proximal line angles using a MB 69 blade.~Mid crestal incision performed in the attached mucosa of the edentulous area connecting the sulcular incisions of the adjacent teeth from the distal to mesial tooth. A full thickness mucoperiosteal flap will be elevated buccally and lingually to the level of the mucogingival junction to expose the alveolar ridge of the implant surgical sites using a periosteal elevator.~Endosseous implant will be placed, followed by simple interrupted resorbable sutures."
223648869|NCT05358353|DEVICE|Bare Temporary Spur Stent System|Treatment of qualifying infrapopliteal arteries with the Bare Temporary Spur Stent System, in subjects with critical limb ischemia.
223648870|NCT01731431|OTHER|Insulin|
223648871|NCT01731431|DRUG|Glyburide|
224234022|NCT02779036|PROCEDURE|Task-oriented home exercise|Structured, walking related task-oriented home exercise program with three progressive steps, at moderate to high intensity, 60 minutes per session, three sessions per week for total 8 weeks.
224234023|NCT02779036|PROCEDURE|Usual Physiotherapy Care|Deficits-oriented free active and resisted lower extremity exercises with bicycling and overground walking , 60 minutes per session, three sessions per week for total 8 weeks.
224234024|NCT05701202|DIETARY_SUPPLEMENT|Super-Whey protein|2 different protein supplements (as above) will be given in a randomised crossover fashion to participants
224234025|NCT05701202|DIETARY_SUPPLEMENT|Isonitrogenous whey protein|2 different protein supplements (as above) will be given in a randomised crossover fashion to participants
223648872|NCT04894331|OTHER|Dietary intervention|"Each patient receives one of 5 dietary plans, different only for energy intake (1400-1600-1800-2000-2100 Kcal/day). The choice depends on the personalized energy needs. The energy requirement is calculated on basal metabolic rate (BMR) of the patient according to Harris \& Benedict's and Schofield's formulas.~All dietary plans include foods with low-Ni content. Finally, each patient completes 30-day personalized diet."
223648873|NCT04894331|OTHER|Video call|Each patient receives a follow-up remote visit through video call 15 and 30 days after the start of the dietary intervention.
223766662|NCT02166489|BIOLOGICAL|Intravenous injection autologous mesenchymal stem cells|Intravenous injection of mesenchymal stem cell in patients with PKD
223648875|NCT00384046|DRUG|Testosterone|patch, 300 mcg/day testosterone, patch changed every 3-4 days, 24 weeks
223648876|NCT00384046|DRUG|Placebo|patch, placebo, patch changed every 3-4 days, 24 weeks
223766663|NCT01822132|DRUG|Extended release naltrexone|
224234026|NCT03500484|DRUG|Liraglutide|Liraglutide will be supplied in the following package sizes containing disposable, pre-filled, multidose pens. Each individual pen delivers doses of 0.6 mg, 1.2 mg, 1.8 mg, 2.4 mg or 3 mg (6 mg/mL, 3 mL). Liraglutide will be self-administered daily for 12 weeks under the following regimen: 0.6mg for 1 week, 1.2mg for 1 week, 1.8mg for 1 week, 2.4mg for 1 week, 3.0mg until week 12.
224234027|NCT04509479|PROCEDURE|Valve replacement|Description of valve replacements
224234028|NCT03947138|BIOLOGICAL|GC3107|BCG Vaccine
224234029|NCT03947138|BIOLOGICAL|Intradermal BCG SSI inj.|BCG Vaccine
223648877|NCT03776006|PROCEDURE|Transperineal Laser Ablation|Transperineal Laser Ablation of the Prostate
224234030|NCT01046123|RADIATION|whole brain radiotherapy (WBRT) and a simultaneous integrated boost (SIB) using volumetric modulated arc therapy|Patients will be treated with WBRT/SIB using VMAT, delivering a total of 20 Gy in 5 fractions to the whole brain and 50Gy in 5 fractions to the brain metastases, delivered once daily on working days.
223648878|NCT02997306|PROCEDURE|Superior/Medial Running Sutures|Simple interrupted stitches and running (continuous) stitches are the two most frequently used suturing techniques. The erythema secondary to these suturing techniques will be compared by utilizing them side-by-side for closure of post-Moh's surgical defect repair in each patient. This intervention consists of running sutures being used for closure of the Superior/Medial half of the incision, and interrupted sutures being used on the Inferior/Lateral half of the incision.
223648879|NCT02997306|PROCEDURE|Inferior/Lateral Running Sutures|Simple interrupted stitches and running (continuous) stitches are the two most frequently used suturing techniques. The erythema secondary to these suturing techniques will be compared by utilizing them side-by-side for closure of post-Moh's surgical defect repair in each patient. This intervention consists of running sutures being used for closure of the Inferior/Lateral half of the incision, and interrupted sutures being used on the Superior/Medial half of the incision.
223648880|NCT03748004|BEHAVIORAL|IPS/SP|The 72 recruited clients receiving primary care services from one DTES clinical site who are employment ready will be randomly assigned to IPS and Peer Support (experimental group) or WorkBC control group
223648881|NCT03748004|BEHAVIORAL|WorkBC|36 out of the 72 participants who live in the DTES will be randomly assigned to the control group (WorkBC). Participants will be provided with WorkBC employment services.
223648882|NCT03688594|DIAGNOSTIC_TEST|NIPT Test|This test is based onto capture and high throw put sequencing adapted to cell free plasmatic DNA of pregnant women in order to detect point mutation present in her fetus. This approach has been previously described for others clinical applications such as liquid biopsy in cancers but not for NIPT analysis.
223648883|NCT03965390|BEHAVIORAL|Oral education|"Oral therapeutic education aims to improve dietary practices, daily hygiene and care, in an approach adapted to the characteristics and consequences of Parkinson's disease. An oral prevention package will be given to patients.~Initially, dentists expose various oral health problems commonly found in Parkinson's disease, in order to give patients the necessary information for the understanding Secondly, dentists dispenseront practical advice tailored to pathology, to maintain good oral health"
223648884|NCT03290599|OTHER|Mini Mental and Modified Mini Mental Test|Mini Mental Test was used for literate patients and Modified mini mental test was used for illiterated patients
223648885|NCT03207763|DEVICE|Microneedle Formulation 1|"Microneedle patches will be made of solid conical structures made of water-soluble excipients that from the Food and Drug Administration's Generally Recognized as Safe (GRAS) list and/or on the FDA list of inactive ingredients in approved products. The total mass of excipients delivered by placebo microneedle patch will be \<1.5 mg. The adhesive backing component is made from hypoallergenic material (commercial medical tapes designed to adhere to skin).~Microneedle patches will be administered topically by manual application to the skin. The sites of microneedle patch application will be cleaned with an alcohol swab and allowed to dry before the microneedle patch is applied. The microneedle patches will be packaged and provided as single patches."
223648886|NCT03207763|DEVICE|Microneedle Formulation 2|"Microneedle patches will be made of solid conical structures made of water-soluble excipients that from the Food and Drug Administration's Generally Recognized as Safe (GRAS) list and/or on the FDA list of inactive ingredients in approved products. The ratio of the excipients and excipients used will vary slightly from Formulation 1. The total mass of excipients delivered by placebo microneedle patch will be \<1.5 mg. The adhesive backing component is made from hypoallergenic material (commercial medical tapes designed to adhere to skin).~Microneedle patches will be administered topically by manual application to the skin. The sites of microneedle patch application will be cleaned with an alcohol swab and allowed to dry before the microneedle patch is applied. The microneedle patches will be packaged and provided as single patches."
223648887|NCT05582083|DRUG|Momelotinib|Momelitinib available as tablets.
223648888|NCT04856813|OTHER|Manual therapy active|massage or ischemic compression with active contraction, tha will be isometric or concentric.
223648889|NCT04856813|OTHER|Manual therapy|massage or isquemic compression without contraction
223648890|NCT04352036|OTHER|no interventional study|no interventional study
223648891|NCT02605122|DRUG|Solithromycin|
223648892|NCT02605122|DRUG|Standard of Care|Age- and weight-based dosing as appropriate per sites standard of care.
223648893|NCT06220942|DRUG|Phenylephrine|Pregnant female presented for C.S. after receiving spinal anesthesia, recording the vital data, phenylephrine will be given in a dose of 50 µg IV immediately if the heart rate increases ≥ 20 % of baseline
223766664|NCT01822132|DRUG|Placebo|
224234031|NCT02639949|BEHAVIORAL|Cognitive-behavioral adherence promotion program|A culturally sensitive group cognitive behavioral therapy combined with adherence promotion.
224234032|NCT02639949|BEHAVIORAL|Standard Care|
224234033|NCT04677062|DRUG|GV-328|Patients with GV-328 treatment
224234034|NCT02217865|BEHAVIORAL|Interviews - Colorectal Cancer Participants|Semi-structured interviews conducted exploring key issues relevant to colorectal cancer surveillance following curative resection. Interviews take between 30 minutes and 1 hour.
224234035|NCT02217865|BEHAVIORAL|Questionnaire|Questionnaire completion asking general health and demographic questions.
224234036|NCT02217865|BEHAVIORAL|Focus Groups|Focus groups conducted with participants and caregivers. Up to 4 focus groups conducted with up to 30 participants each. Focus groups expected to take 30 to 60 minutes.
224320262|NCT03146104|DRUG|Propofol|Intraoperative anesthesia will be maintained using propofol 100-150 mcg/kg/min, oxygen and air and FiO2 of 40% in propofol group (GROUP P)
224234037|NCT02217865|BEHAVIORAL|Interviews - Caregivers of Colorectal Cancer Participants|Semi-structured interviews conducted exploring key issues relevant to colorectal cancer surveillance following curative resection. Interviews take between 30 minutes and 1 hour.
224234038|NCT05946148|DRUG|Empagliflozin|Empagliflozin 10mg daily, as add-on to previous treatment regimen.
224234039|NCT05946148|DRUG|Dulaglutide|Dulaglutide 1.5mg weekly, as add-on to previous treatment regimen
224234040|NCT05946148|DRUG|Control Rx|Optimal anti-diabetic treatment excluding agents of the GLP1-ras or SGLT2-is families.
224234041|NCT02128048|DEVICE|Assessment of body composition and muscle function|Assessment of body composition by DEXA and BIA Measurement of muscle function by hand-grip dynamometer and physical tests Comparison between quitters and continued smokers
224234042|NCT02795104|BEHAVIORAL|Educational Intervention via brochure|"Educational Intervention via brochure:~In this arm of the educational intervention the participant receives brochures"
224234043|NCT02795104|BEHAVIORAL|Educational Intervention via DVD|Educational Intervention via DVD: In this arm of the educational intervention the participant receive a tailored interactive DVD to watch
224234044|NCT02795104|BEHAVIORAL|Educational Intervention-DVD & Telephone Based Navigation|Educational Intervention via Telephone-Based Navigation: In this arm of the educational intervention the participant receives a tailored interactive DVD to watch and telephone calls from a patient navigator
224234045|NCT04809246|OTHER|'One-stop-shop' hepatitis clinic|Establishment of a 'one-stop-shop' hepatitis clinic, integrating point-of-care HCV RNA testing, followed by clinical assessment, non-invasive liver fibrosis assessment by fibro-elastography (Fibroscan), and early DAA prescription (for those with chronic HCV) followed by linkage to ongoing hepatitis care, all in the same 60-minute visit.
224234046|NCT01255475|DRUG|Hydralazine/amlodipine|Patients will receive drug therapy aimed to reducing blood pressure - first line drug will be hydralazine up to 100mg/day; if systolic blood pressure reduces less than 20% from baseline and remains over 100mmHg patients will further receive amlodipine up to 10mg/day
224234047|NCT01255475|DRUG|Placebo|Patients will receive placebo
224234048|NCT02763722|OTHER|Emollient spray product|All patients will be instructed to use emollients spray on entire skin at least twice a day for four weeks.
224234049|NCT03763500|OTHER|Internet-based education|A six-step Internet-based patient education.
224234050|NCT00948675|DRUG|Pemetrexed|Induction therapy: 500 milligrams/square meter (mg/m²) given intravenously every 21 days for 4 cycles. Maintenance therapy: 500 mg/m² given intravenously every 21 days until disease progression or treatment discontinuation.
224234051|NCT00948675|DRUG|Carboplatin|Induction Therapy (every 21 days for 4 cycles): Area Under the Curve (AUC) 6 \[maximum possible dose of 900 milligrams (mg)\] intravenously infused over 30 minutes.
224234052|NCT00948675|DRUG|Paclitaxel|Induction Therapy (every 21 days for 4 cycles): 200 mg/m² intravenously infused over 3 hours
223648894|NCT00684060|BIOLOGICAL|Adult stem cells|One time infusion of approximately 150 million total nucleated cells (TNC) in 30 ml of 5% HSA/saline solution
223648895|NCT00684060|BIOLOGICAL|Placebo|One time infusion of 30 ml of HSA (5%)
223648896|NCT04643652|BEHAVIORAL|Noise Reduction Bundle|"Implementation of a bundle of noise reducing interventions. This concerns among other things:~reduction of alarms, phone calls/pagers/ beepers, introduction of a defined period in which there is a reduction of controllable sound (quiet time), etc"
223648897|NCT04917341|DIAGNOSTIC_TEST|re-evaluation of endometrial biopsy samples by a gynecopathologist working at a university hospital|The endometrial biopsy samples taken at the second stage state hospital were re-evaluated by the gynecopathologist working at the university hospital and / or the repeated endometrial biopsy sampling was examined and the evaluation process was carried out in two steps.
223648898|NCT06523101|DRUG|PJ009|Six participants in each dose level will be randomized to receive a single dose and/or multiple doses of PJ009 in a double-blind fashion.
223648899|NCT06523101|DRUG|Placebo|Two participants in each dose level will be randomized to receive placebo in a double-blind fashion.
223648900|NCT03708783|PROCEDURE|laparoscopic Spleen-Preserving No. 10 Lymph Node Dissection|For patients with locally advanced upper or middle third gastric cancer, laparoscopic total gastrectomy with D2 lymphadenectomy including spleen-preserving No. 10 lymph node dissection is performed.
223648901|NCT02641561|DRUG|Indomethacin|Indomethacin is a non-steroidal anti-inflammatory drug (NSAID) which is commonly used to reduce inflammation caused by gout, osteoarthritis and rheumatoid arthritis. It acts by blocking the cyclo-oxygenase 1 and 2 (COX) receptors. It has also been implicated to prevent post-ERCP pancreatitis
223648902|NCT02641561|DRUG|Lactated Ringer's Solution|Lactated ringer's solution (LR), is an intravenous fluid (IVF) used commonly during endoscopic procedures and operative procedures. It's composition is similar to that of humans including sodium, chloride, potassium, calcium and lactate. Studies have implicated the use of this fluid in pancreatitis treatment and prevention of post-ERCP pancreatitis
223648903|NCT02641561|DRUG|Normal Saline|standard IVF would include 0.9% normal saline (NS) solution used during all endoscopic procedures. 0.9% NS includes equal parts sodium and chloride.
223648904|NCT02641561|DRUG|Placebo|Placebo would be a suppository 50 mg x 2
223648905|NCT03340324|BIOLOGICAL|V-Endo|V-Endo is a tableted immunotherapeutic derived from hydrolyzed, heat-inactivated, pooled blood from women with endometriosis
223648906|NCT00702715|DRUG|sugammadex|"Each subject will receive an~intravenous (i.v.) single bolus dose of 0.6 mg.kg-1 rocuronium. After~this dose, maintenance doses of 0.1 - 0.2 mg.kg-1~rocuronium may be given. In case of maintenance dosing, the target depth of~neuromuscular blockade has to be maintained at 1-2 post-tetanic counts (PTC). After the last dose of rocuronium has been administered, the subject will receive a single bolus dose of 4.0 mg.kg-1 sugammadex at a target depth of blockade of 1-2 PTC."
223766665|NCT01018199|OTHER|CRP|C-reactive protein guided antibiotic therapy plasma CRP measurement to guide the duration of antibiotic therapy
223766666|NCT01018199|OTHER|PCT|Procalcitonin guided antibiotic therapy plasma PCT measurement to guide the duration of antibiotic therapy
224234053|NCT00948675|BIOLOGICAL|Bevacizumab|Induction therapy: 15 milligrams/kilogram (mg/kg) given intravenously every 21 days for 4 cycles. Maintenance therapy: 15 mg/kg given intravenously every 21 days until disease progression or treatment discontinuation.
224234054|NCT04465942|DRUG|(chemo)immunotherapy|Patients are receiving immunotherapy or chemoimmunotherapy as a standard of care
223648907|NCT04314297|DRUG|Anlotinib In Combination With Durvalumab|"At the end of chest radiotherapy (c2d1), the simultaneous administration of androtinib hydrochloride capsule and PD-1 / L1 inhibitor was started. L~Arotinib hydrochloride capsule, 12 mg, Po, QD, was taken orally for two weeks, one week, three weeks as a cycle, completed in the first 14 days until the disease progress;~Durvalumab injection, 1500mg, IV, once every three weeks, completed on the first day until the disease progresses.~Tetraprizumab injection, 240mg, IV, once every three weeks, completed on the first day until the disease progresses.~The choice of durvalumab / trepril mAb was at the discretion of the researchers."
224234055|NCT01072942|DRUG|Ciprofloxacin (Cipro InhaIe, BAYQ3939)|Ciprofloxacin Inhale 50 and 75 mg 2 times a day (BID) for 10 days
224234056|NCT01072942|DRUG|Placebo|Placebo TID for 10 days
224234057|NCT04634448|PROCEDURE|Interval appendectomy|interval appendectomy at 2 to 3 months after the initial non-operative treatment
224234058|NCT04634448|DIAGNOSTIC_TEST|Follow-up MRI at 1 year|follow-up MRI at 1 year for asymptomatic patients under 35 years of age not wanting to undergo surgery
224234059|NCT04751110|OTHER|ultrasound guided rhomboid intercostal block|A linear ultrasound probe was medially placed in the sagittal plane on the medial border of the scapula at the T5-T7 level. We inserted a 22-gauge needle into the fascial plane between the rhomboid major and intercostal muscles in a craniocaudal direction and injected 15 ml mixture of 0.25% bupivacaine with 8 mg of dexamethasone into the fascial plane.
224234060|NCT00160212|DRUG|Daglutril|
224234061|NCT00866242|BIOLOGICAL|CVD 1208S, Challenge strain of wild-type Shigella flexneri 2a|The challenge strain consists of freshly harvested Shigella flexneri 2a strain 2457T diluted in phosphate buffered saline to reach the desired inoculum Form: liquid Dose 10 to the 3rd power CFU in 1.0 ml Route: oral.
224234062|NCT01788956|DEVICE|Mespere Venous Oximeter|Mespere Venous oximeter provides non-invasive measurement of the oxygenation of the venous blood.
224234063|NCT01788956|DEVICE|Co-Oximeter|
224234064|NCT05531409|BEHAVIORAL|Responsible Behavior for Younger Children (RBYC)|RBYC is a school-based universal prevention program designed to provide adolescents and their parents (or other guardians) with the knowledge and tools to help adolescents interact appropriately with younger children and avoid engaging younger children in sexual behaviors.
224234065|NCT03372538|PROCEDURE|cesarean section or cesarean hysterectomy|upper segment cesarean section and or cesarean hysteroctomy
224234066|NCT01166542|BIOLOGICAL|REOLYSIN|3E10 TCID50, 1 hour intravenous infusion, administered on Days 1, 2, 3, 4 and 5 of a 21 day cycle
224234067|NCT01166542|DRUG|Carboplatin|5 AUC mg/mL min, 30 min intravenous infusion, given on Day 1 of a 21 day cycle
223648908|NCT01827423|DEVICE|Surgical removal of sinonasal papiloma|An endoscopic endonasal surgical device is used to remove the sinonasal papilomas in the study subjects.
223648909|NCT06831825|COMBINATION_PRODUCT|YAP101 (AAV9-Sav-shRNA)|YAP101 delivered using YAPCATH-101
223648910|NCT02945579|RADIATION|Undergo EBRT|Undergo EBRT
223648911|NCT02945579|OTHER|Laboratory Biomarker Analysis|Correlative studies
223648912|NCT02945579|OTHER|Quality-of-Life Assessment|Ancillary studies
223648913|NCT02945579|OTHER|Questionnaire Administration|Ancillary studies
223648914|NCT02945579|RADIATION|Partial Breast Irradiation|Undergo partial breast irradiation
223648915|NCT01560182|GENETIC|OTL-200 Gene Therapy|Autologous hematopoietic stem/progenitor cells collected from the bone marrow and transduced ex vivo with a Lentiviral vector encoding the human ARSA cDNA
223648916|NCT03751657|DRUG|Insulin icodec|Insulin 287 once weekly subcutaneous (s.c.) injections at the starting dose of 70 units. Dose adjustment was done for the individual patient based on the three pre-breakfast self-measured plasma glucose values measured on two days prior to titration and on the day of the contact. The insulin dose adjustment should aim to reach an SMPG of 3.9-6.0 mmol/L (70-108 mg/dL)
223648917|NCT03751657|DRUG|Placebo (insulin 287)|Participants will receive once weekly s.c. injections of placebo equivalent to insulin 287.
223648918|NCT03751657|DRUG|Metformin|Metformin is considered as non investigational medicinal product. Subject will continue metformin at stable pre-trial dose.
223648919|NCT03751657|DRUG|Dipeptidyl peptidase-4 inhibitors|Dipeptidyl peptidase-4 inhibitors are considered as non investigational medicinal products. Subject will continue dipeptidyl peptidase-4 inhibitor at stable pre-trial dose.
223648920|NCT03751657|DRUG|Insulin glargine|Insulin glargine (100 U/mL) once daily s.c. injections at the starting dose of 10 units. Dose adjustment will be done for the individual patient based on the three pre-breakfast self-measured plasma glucose values measured on two days prior to titration and on the day of the contact. The insulin dose adjustment should aim to reach an SMPG of 3.9-6.0 mmol/L (70-108 mg/dL).
223648921|NCT03751657|DRUG|Placebo (insulin glargine)|Participants will receive once daily s.c. injections of placebo equivalent to insulin glargine.
223648922|NCT03162913|DIETARY_SUPPLEMENT|Strawberry|12g freeze-dried strawberry (powder), twice daily with water, for 90 days
223648923|NCT03162913|OTHER|Placebo|12g red, strawberry-flavored powder, twice daily with water, for 90 days
223648924|NCT04466709|OTHER|none intervention type|This is an observational study, no intervention
224234068|NCT01166542|DRUG|Paclitaxel|175 mg/m2, 3 hour intravenous infusion, given on Day 1 of a 21 day cycle
224234069|NCT01166542|DRUG|Placebo|Placebo
224234070|NCT02636400|OTHER|controlled ovarian stimulation with gonadotropins + intrauterine insemination|
224234071|NCT04892979|OTHER|Cardiopulmonary exercise (centre-based)|Depending on the preference of participants, they can either choose to join three 60-minute centre-based sessions plus two sessions of 30-minute home exercise per week, or two 60-minute centre-based sessions plus four sessions of 30-minute home exercise per week. Each session will include warm-up and cool-down exercises, aerobic exercises, and progressive strengthening exercises prescribed based on individual ability (Table 1). Aerobic exercises will be performed at 60-75% (up to 85% for fit individuals) of the predicted maximum heart rate. The respective rate of perceived exertion during exercise will be maintained between 4 and 6 out of 10 on the Borg CR scale \[10\], indicating moderate to strenuous exercise levels. Additionally, physiotherapists will provide education related to COVID-19, energy conservation, and stress management during the program.
224320263|NCT03146104|DRUG|Isoflurane|in(GROUP I) maintenance will be done with 1 MAC of isoflurane, oxygen and air and FiO2 of 40%.
224320264|NCT05858112|DIAGNOSTIC_TEST|SuperTROPO novel assay to measure the long forms of cTnT|SuperTROPO novel assay to measure the long forms of cTnT
224234072|NCT04892979|OTHER|Cardiopulmonary exercise (online-based)|Participants in the OBR group will attend one face-to-face session to learn how to use a mobile application (app) followed by 6 weeks of home exercises. The online treatments will be delivered via the Caspar Health e-system, a German-designed Internet-based system, is available for desktop PCs and as a mobile app for both iOS and Android smartphones. This system will enable patients to follow their therapists' treatment plans in an asynchronous manner. The OBR programme will last for 6 weeks. Participants will be instructed to perform 40 minutes of structured exercises 6 times per week. In the first week, six 40-minute online exercise sessions will be delivered through push notifications on the mobile app.
224234073|NCT03843203|DEVICE|Transcranial Direct Current Stimulation - tDCS|\- Intervention: tDCS is a therapeutic method that modulates the membrane potential, where anodic stimuli induce cortical excitability and cathodic stimuli reduce it
224234074|NCT00001052|BIOLOGICAL|Aluminum hydroxide|
224234075|NCT00001052|BIOLOGICAL|QS-21|
224234076|NCT00001052|BIOLOGICAL|rgp120/HIV-1MN|
224234077|NCT02070185|BEHAVIORAL|2 exposures arm|"During this study, children were exposed to 2 flavored sweetened beverages: a high energy version (HE: 150kcal) and a no energy version (NE: 0kcal).~During a 4-wk conditioning period, children were exposed either 2 times to each beverage.~After a 3-wk stability period without exposure, children were exposed 3 times to both beverages in which the association between the flavor and the energy density had been switched (4-wk extinction period)."
224234078|NCT02070185|BEHAVIORAL|7 exposures arm|"During this study, children were exposed to 2 flavored sweetened beverages: a high energy version (HE: 150kcal) and a no energy version (NE: 0kcal).~During a 4-wk conditioning period, children were exposed either 7 times to each beverage.~After a 3-wk stability period without exposure, children were exposed 3 times to both beverages in which the association between the flavor and the energy density had been switched (4-wk extinction period)."
224234079|NCT04750187|OTHER|Hypo-pressive abdominal exercise intervention|An 8-week hypo-pressive abdominal exercise program
224234080|NCT05449977|DIAGNOSTIC_TEST|Diagnose|First, the participants will be asked to fill out a structured questionnaire containing their sociodemographic characteristics. Then, the 2-minute walk test, the International physical activity questionnaire, the SF-36 short form, and the World health organization quality of life questionnaire will be applied respectively.
224234081|NCT02502253|DRUG|grape seed polyphenolic extract, resveratrol|Bioactive Dietary Polyphenol Preparation (BDPP) is a combination of two nutraceutical preparations (grape seed polyphenolic extract \[GSE\], and resveratrol) that contain abundant concentrations of polyphenols.
224320265|NCT03349346|DRUG|Idelalisib|Tablet (s) or dispersible tablets for suspension administered orally twice daily
224320266|NCT03349346|DRUG|Rituximab|375 mg/m\^2 administered intravenously
223648925|NCT03283605|RADIATION|SBRT|SBRT to 2-5 oligometastases will be administered between Cycle 2 and 3 of durvalumab and tremelimumab. All SBRT will be completed within a 3-week period.
223648926|NCT03283605|DRUG|Durvalumab|Durvalumab (1500 mg IV q4weeks) for 4 cycles in combination with tremelimumab. Then, durvalumab alone until confirmed disease progression, death, unacceptable toxicity, withdrawal of consent, or other discontinuation criteria met.
224320267|NCT03349346|DRUG|Ifosfamide|3 mg/m\^2 administered intravenously
223648927|NCT03283605|DRUG|Tremelimumab|Tremelimumab (75mg IV q4weeks) for 4 cycles in combination with Durvalumab.
223648928|NCT02479308|DRUG|Moxifloxacin|Single administration
223648929|NCT02479308|DRUG|ALKS 5461|Daily administration for a total of 12 dosing days
223648930|NCT02479308|DRUG|Placebo|Placebo will be matched to Moxifloxacin or ALKS 5461
223766667|NCT04389125|DIETARY_SUPPLEMENT|Angelica Gigas Nakai and Allium Cepa L.Extract Mixtures|One packet once a day, after breakfast, for 12 week
223766668|NCT04389125|DIETARY_SUPPLEMENT|Placebo|Placebo for 12 week
223766669|NCT04601545|BEHAVIORAL|Pulmonary rehabilitation|"Three weeks of pulmonary rehabilitation conducted in an outpatient care facility:~* 5- time a week for 30 minutes a specific respiratory exercises- relaxation exercises for breathing muscles, exercises to increase breathing, prolonged exhalation exercise, chest percussion~* 5- time a week for 20-30 min training on a cycle ergometer - until the Heart Rate reaches 60% of the HRmax~* 5- time a week for 30 minutes a fitness and respiratory exercises - coordination and balance exercises, stretching exercises~* relaxation by Schultz Autogenic Training. The technique involves the daily practice of sessions that last around 15 minutes. During each session, the practitioner repeats a set of visualisations that induce a state of relaxation."
224234082|NCT04888910|OTHER|observational|observation of biomarkers in different asthma groups
224234083|NCT03729310|DEVICE|Propel 'implant'|The Propel 'implant' is composed of small, flexible tubes which dissolve while releasing Mometasone which is one type of steroid. This application has been approved for use by the FDA.
224234084|NCT03729310|DRUG|Triamcinolone|Triamcinolone has been approved for use topically elsewhere on the body, although the specific use of Triamcinolone in the sinuses has not been approved by the FDA.
224234085|NCT03729310|DEVICE|Nasopore|"This packing' is a sponge-like material which dissolves while releasing triamcinolone."
224234086|NCT00620009|BEHAVIORAL|Empathy Feedback|Discussion of empathy ratings between patients and therapists during psychotherapy sessions.
224234087|NCT00046267|DRUG|Niacin|
224234088|NCT01170286|BIOLOGICAL|Whole peanut extract|Four different doses of whole peanut extract expressed as micrograms (mcg) of peanut proteins (20, 100, 250, 500 mcg) and two different dosing regimen (epicutaneous application for 24 hours every 24 hours and epicutaneous application for 48 hours every 48 hours) will be tested for determination of the maximum tolerated dose during a 2-week treatment period.
224320268|NCT03349346|DRUG|Carboplatin|635 mg/m\^2 administered intravenously
224320269|NCT03349346|DRUG|Etoposide|100 mg/m\^2 administered intravenously
224234089|NCT01170286|BIOLOGICAL|Placebo formulation|Matching placebo at two different dosing regimen (epicutaneous application for 24 hours every 24 hours and epicutaneous application for 48 hours every 48 hours) will be tested in parallel to the peanut proteins doses for determination of the maximum tolerated dose during a 2-week treatment period.
224234090|NCT01048320|DRUG|Gemcitabine|"The starting dose of gemcitabine will be 400 mg/m2 on day 1 of a two-week cycle.~Gemcitabine is given on day 1 every two weeks according to the dose escalation schedule below:~Dose level -1 200mg/m2 Dose level 1 400mg/m2 Dose level 2 600mg/m2 Dose level 3 800mg/m2 Dose level 4 1000mg/m2 Dose level 5 1000mg/m2 It is administered as an intravenous infusion, the lyophilized powder being diluted in normal saline, at a fixed dose of 10 mg/m2/minute."
223648931|NCT01452932|OTHER|Physiotherapy|"The physiotherapeutic intervention was based on the Kabat (PNF) technique. Thirty-three sessions were planed. Each session lasted between thirty and fifty minutes.~The experimental group was guided by a physiotherapist or a physiotherapy student and each session took place in a hospital auditorium provided with oxygen cylinders, chairs and water.~Each session consisted of a warm up and stretch period, a period of resistance training of the upper limbs with their rest periods in which diaphragmatic breathing exercises and finally a cooling period.~The instructions and instruments given to each participant such as weights and elastic bands were the same for all of them."
223648932|NCT01452932|OTHER|Yoga|"The intervention for the other group was the Yoga technique. Thirty-six sessions were planed. Each session was based on breathing, relaxation, and stretching exercises. Each session lasted between thirthy and forty minutes.~The group was led by a Yoga Instructor and each sessions took place in a hospital auditorium provided by oxygen cylinders, chairs and water.~No instruments were needed for this intervention."
223648933|NCT03055130|OTHER|Thinprep Cytology Test (TCT) and HPV infection types were tested by gynecologist|
223648934|NCT02310204|BEHAVIORAL|multidisciplinary education program|both individual and group education sessions over a 6-month period in addition to standard psoriasis care
223648935|NCT02310204|OTHER|standard psoriasis care alone|
223648936|NCT04603027|DRUG|EDP1815|EDP1815 is an orally administered, pharmaceutical preparation of a single strain of bacteria
223648937|NCT04603027|DRUG|Placebo|Placebo oral capsule
223648938|NCT02831101|DRUG|Sufentanil|To evaluate, in the elderly, the impact of a concomitant administration of sufentanil during a step-wise propofol induction of anaesthesia on the depth of sedation measured using BIS and clinical sedation score.
223648939|NCT02831101|DRUG|Placebo|To evaluate presence or absence of strong opioid (sufentanil) on BIS values in the elderly during propofol induction until the loss of consciousness
223648940|NCT02248246|DEVICE|Harmonic ACE®+7 Shears|"Vessel sealing performance assessed for transection and sealing of the following named vessels:~* Inferior mesenteric artery (IMA)~* Inferior mesenteric vein (IMV) (if identified)"
223648941|NCT06067360|DEVICE|IFIS sleeve|IFIS sleeve will be inserted to prevent iris prolapse
223648942|NCT01619969|DRUG|celgosivir|100 mg capsules, 400 mg loading dose 200 mg bid
223648943|NCT01619969|DRUG|placebo|Capsules of identical appearance containing starch
223648944|NCT00598000|BEHAVIORAL|questionnaires|"QOL Measures- The following measures will be administered at Pre-Op, First Post-Op Visit 4, 8, 12 months Post-Op.~Brief Pain Inventory and daily analgesic log- enrollment, patients will fill out the BPI preoperatively, postoperative days 2 to 4, initial, 4-month, 8-month and 12-month postoperative visits."
223648945|NCT00598000|BEHAVIORAL|questionnaires|"QOL Measures- The following measures will be administered at Pre-Op, First Post-Op Visit 4, 8, 12 months Post-Op.~Brief Pain Inventory and daily analgesic log- enrollment, patients will fill out the BPI preoperatively, postoperative days 2 to 4, initial, 4-month, 8-month and 12-month postoperative visits."
223648946|NCT05259280|OTHER|Wellinks|Digital health and virtual care program for COPD management.
223648947|NCT05250388|PROCEDURE|Arthroscopic Bankart repair|Arthroscopic Bankart repair is a minimally invasive surgical procedure with the aim to reattach and tighten the detached labrum and ligaments within the shoulder joint.
223648948|NCT00807001|DRUG|IDX184|oral dose, active or placebo
223648949|NCT01628666|DRUG|Incremental|Single dose of Cefazolin and Vancomycin preoperatively, bacitracin wash and cefalexin post operative.
223648950|NCT01628666|DRUG|Conventional|Cefazolin preoperative
223648951|NCT03470844|BEHAVIORAL|Face-to-face neurocognitive tests|Assessment of attention, processing speed, working memory and executive function
223648952|NCT03470844|BEHAVIORAL|Psychological screening|Screening for the symptoms of depression, anxiety and post-traumatic stress disorder
223648953|NCT03470844|OTHER|fMRI|Brain volume, chemical markers, functional outcome
223648954|NCT03470844|BEHAVIORAL|Quality of Life Self-Assessment data|EQ-5D will be converted into a utility score using standard EQ-5D UK tariffs
223648955|NCT00590772|DRUG|montelukast|10 mg po each day (compared to placebo for 2 weeks)
223648956|NCT00590772|DRUG|placebo|placebo for 2 weeks
223648957|NCT03993067|PROCEDURE|Hemopatch|Hemopatch is a collagen based sealant is a hemostat agent. We want to investigate his role in the prevention of post operative biliary fistula
223648958|NCT03993067|PROCEDURE|Fribrin glue and Tabotamp|Fibrin glue and Tabotampis the standard treatment
223648959|NCT00170859|DRUG|Everolimus|
223648960|NCT03542786|DIETARY_SUPPLEMENT|Probiotic|"The probiotic i3.1 is a commercialized product. It will be supplied by the promoter and manufactured in ALIFARM S.A.~It contains:~* Lactobacillus plantarum CECT7484~* Lactobacillus plantarum CECT7485~* Pediococcus acidilactici CECT7483"
223648961|NCT03542786|DIETARY_SUPPLEMENT|Prebiotic|"ProSeed prebiotic is a non-commercialized product. It will be supplied by the promoter and manufactured in ALIFARM S.A.~It contains:~* Partially Hydrolyzed Guar Gum (PHGG)~* Inulin HPD~* Oat Beta-Glucans~* Pectin~* Inulin Low Protein Diet (LPD)~* Polydextrose~* Maltrodextrins"
223648962|NCT03542786|DIETARY_SUPPLEMENT|Placebo|It is a non-commercialized product. It is composed of the same excipients as the probiotic and the prebiotic. It will be supplied by the promoter and manufactured in ALIFARM S.A.
223648963|NCT00854113|DRUG|EGT0001474|Oral ascending doses given daily as capsules for up to 14 days
223648964|NCT00854113|DRUG|Placebo|Placebo to match EGT0001474
223648965|NCT02724618|DRUG|Curcumin|120mg/d oral nanocurcumin (3 capsules of SinaCurcumin®40 per day) 3 days before and during radiotherapy
223648966|NCT02724618|RADIATION|RT|EBRT is delivered as Intensity-Modulated Radiation Therapy (IMRT) or 3D-conformal RT
223773669|NCT06986694|OTHER|Group A will receive Voodoo Flossing Technique along with aerobic and strengthening exercises & conventional physiotherapy protocol for Knee OA.|"Patient will sit or lie down comfortably with affected knee exposed and in extension. Start by wrapping voodoo floss band at the shin bone just below the knee joint with 50% tension in the band and 50% overlapping on each wrap by working your way up towards the thigh. Keep the flossing band on for at least 1-2 minutes and perform gentle knee movements to promote mobility.~* Knee flexion and extension in full range of motion in standing position 20-30 sec.~* Knee squats with/without support 20-30 sec.~* Abduction and Adduction 20-30 sec. Perform each exercise with 10-15 seconds of rest between each set. After completing ROM exercises, allow the knee to rest in comfortable position and then carefully unwrap the voodoo band from the knee joint. Also monitor the knee for any changes."
223648967|NCT02724618|DRUG|Placebo|Placebo (3 placebo capsules of SinaCurcumin®40 per day), 3 days before and during radiotherapy
223648968|NCT04001530|DRUG|Half Normal Saline 0.45% Infusion Solution Bag|Randomization to half normal saline
223648969|NCT04001530|DRUG|Normal Saline 0.9% Infusion Solution Bag|Randomization to normal saline
223648970|NCT03206229|DRUG|PEG-rhG-CSF|PEG-rhG-CSF is going to be administered 2 mg/0.2 ml subcutaneously single dose in each study period as per the randomization schedule
223648971|NCT03206229|DRUG|Neulasta (PEG-rhG-CSF)|PEG-rhG-CSF is going to be administered 2 mg/0.2 ml subcutaneously single dose in each study period as per the randomization schedule
223648972|NCT02121119|DRUG|Lidocaine|Continuous block with lidocaine in both legs. Lidocaine infusion starts 0.5% to 5 ml hour Baxter Infusor elastomeric pump LV 5 ml / hr
223648973|NCT02121119|DRUG|Bupivacaine|Continuous block with lidocaine in both legs. Infusion starts bupivacaine 0.1% to 5 ml hour Baxter Infusor elastomeric pump LV 5 ml / hr
223648974|NCT03284307|DRUG|Dexmedetomidine|20 participants will be administered Dexmedetomidine.
223648975|NCT03284307|DRUG|Ketamine|20 participants will be administered Ketamine.
223648976|NCT03284307|DRUG|Propofol|20 participants will be administered Propofol.
223648977|NCT03284307|DRUG|Midazolam|20 participants will be administered Midazolam.
223648978|NCT03807856|DRUG|Dabigatran Etexilate Mesylate|Dabigatran 150mg BID for 3 days
223648979|NCT03807856|OTHER|Standard of Care|Daily vital signs, lab work and one outpatient clinic visit
223648980|NCT06444841|BEHAVIORAL|Digital - Google Calendar|"Digital calendar apps allow one to digitally off-load intentions either by typing them or by speaking them (speech-to-text voice-dictation capabilities). In addition, they deliver automated reminders to perform intended tasks, either at a single time (e.g., Monday at 9 am) or at recurring times (e.g., every night at 8 pm)."
223648981|NCT06444841|BEHAVIORAL|Paper-based - Memory Support System|The Memory Support System is an established paper-based solution for prospective memory functioning. There is considerable evidence in the literature for its utility in mild cognitive impairment (MCI) and it has face validity to patients as supporting memory.
223648982|NCT01680029|DEVICE|PBASE-system 2.0|
223648983|NCT04909918|DRUG|Dexamethasone|Baseline laboratory \& clinical data will be taken before and after the study drugs according to our protocol.Intravenous dexamethasone 8 mg/day given for 7 days
223648984|NCT04909918|DRUG|Methylprednisolone|Baseline laboratory \& clinical data will be taken before and after the study drugs according to our protocol. Intravenous methylprednisolone 1 mg/kg/day in 2 divided doses per day given for 7 days
223648985|NCT04683887|DEVICE|Tape application|Application of the tape with lymphatic technique to the fingers, both dorsally and volarly, of wrist fractured patients treated with a forearm cast
223648986|NCT02273596|DRUG|ALXN1840|Individualized oral doses of ALXN1840.
223648987|NCT02113137|DRUG|group 1: drug: chlorine dioxide|"First, each group practiced tooth brushing only for one week. After that each group was requested to do the following procedures.~group 1 - additional use of 12ml chlorine dioxide (ClO2) mouthwash two times per day, for three consecutive weeks besides tooth brushing.~At last, each group practiced all three methods of tooth brushing, tongue cleaning, mouth washing."
223648988|NCT02113137|DEVICE|group 2: device: small tooth brush for tongue cleaning|"First, each group practiced tooth brushing only for one week. After that each group was requested to do the following procedures.~group 2 - additional practice of tongue cleaning by a small tooth brush two times per day, for three consecutive weeks besides tooth brushing.~At last, each group practiced all three methods of tooth brushing, tongue cleaning, mouth washing."
223648989|NCT00468962|DRUG|FACOS (functional food)|
223648990|NCT04153396|DRUG|The Treatment group|The local infiltration solution in the treatment group will consist of betamethasone and ropivacaine. For local infiltration, a total of 30 ml solution will be prepared for each group, which will include 0.5ml of compound betamethasone injection(betamethasone propionate 5mg and betamethasone sodium phosphate 2mg per 1ml) added to 14.5ml of saline and 15ml of 1% ropivacaine. The surgeon will perform wound infiltration after induction of anesthesia and before surgery. A total of 10 ml of solution will be injected into each level. The study solution will be injected into the subcutaneous tissue, paravertebral muscles, along with the posterior area around the spinous process, lamina, transverse process and the facet joints, along both sides of the planned incision. The epidural space and intrathecal space will not be infiltrated.
223648991|NCT04153396|DRUG|The Control group|The local infiltration solution in the control group will consist of ropivacaine. For local infiltration, a total of 30 ml solution will be prepared for each group, which will include 15ml of ropivacaine added to 15 ml of saline for the Control group. The surgeon will perform wound infiltration after induction of anesthesia and before surgery. A total of 10 ml of solution will be injected into each level. The study solution will be injected into the subcutaneous tissue, paravertebral muscles, along with the posterior area around the spinous process, lamina, transverse process and the facet joints, along both sides of the planned incision. The epidural space and intrathecal space will not be infiltrated.
223648992|NCT02604160|DRUG|LY3113593|Administered by slow intravenous (IV) infusion.
224320270|NCT05383755|BEHAVIORAL|Digital intervention for pregnant adolescents living with HIV|The newly developed digital intervention will include SMS for reminder purposes and Web-based components such as virtual simulations, gamified elements, and didactic content to educate and build relevant skills (e.g., disclosure self-efficacy) to facilitate social support from caregiving family members. The intervention will (1) raise awareness about the intersecting stigmas of HIV and pregnancy; (2) highlight the effects of these stigmas on disclosure and social support; and (3) increase self-efficacy and communication skills for disclosure and enlistment of family members as social support allies. The goal of the intervention is to improve PMTCT engagement among pregnant unmarried ALHIV. Our theory-informed Web-based intervention will be use 3C Institute's Dynamic e-Learning Platform (DeLP), a customizable software platform that implements the evidence-based cognitive theory of multimedia learning (CTML) to effectively engage users.
223648993|NCT02604160|DRUG|Placebo|Administered by slow intravenous (IV) infusion.
223648994|NCT02427997|BEHAVIORAL|Treadmill training with Virtual Reality|"VR is defined in general as a high-end-computer interface that involves real time simulation and interactions through multiple sensorial channels. The VR system to be used requires subjects to negotiate virtual obstacles while walking on a treadmill, in a safe environment. This dual task activity has large cognitive components such as information processing, planning, and attention while allowing for training in a more stimulating and enriching environment that includes both cognitive and motor components."
223648995|NCT02427997|BEHAVIORAL|Treadmill training|The participants will walk on the treadmill, their gait speed over-ground will be measured at the beginning of each week of training. Progression will include increasing the duration of each of the walking bouts and increasing walking speed.
223648996|NCT00785642|DRUG|Dermacyd PH_DETINLYN Tangerine Mix (Lactic Acid)|
223648997|NCT01596062|DRUG|Simulect®|Simulect® was provided to the study center in its commercial package containing a powder vial with 20 mg of active product and sterile water for injection. The solution should be used immediately after reconstitution. The infusion was prepared by adding at least 50 mL of physiologic or 5% glucose solution to the reconstituted solution (at least 100 mL for 40 mg of Simulect®). Simulect® was transported and kept in a cold environment (2-8°C) as recommended in the summary of product characteristics (SPC).
223648998|NCT01596062|DRUG|Neoral®|Neoral® was provided to the study center in its commercial package as 10, 25, 50 or 100 mg soft capsules in thermoformed blister packs.
223648999|NCT01596062|DRUG|Certican®|Certican® was provided to the study center in its commercial package as 0.75, 0.5 and 0.25 mg tablets in thermoformed blister packs.
223649000|NCT01596062|DRUG|Myfortic®|Myfortic® was administered orally b.i.d. with a 12-hour interval. Tablets could be taken either with or outside meals but consistently throughout the study. To maintain the integrity of the enteric coating, tablets were not to be crushed. Myfortic® treatment was initiated either preoperatively or within 24 hours post transplantation according to local practice in each center. Starting dose was to be 2160 mg/day (1080 mg b.i.d.) for at least 2 weeks and for at most 4 weeks. Patients were then to receive 1440 mg/day (720 mg b.i.d.) until the end of the study. Myfortic® was administered as concomitant treatment to all patients, using the same regimen for all 3 study groups. It was provided to the study center in its commercial package as 180 and 360 mg gastro-resistant tablets.
223649001|NCT01596062|DRUG|Corticosteroids|Corticosteroid i.v. therapy could be administered peri or per operatively according to local practice in each center with the same scheme for each patient in the center. Oral corticotherapy was to be initiated rapidly, within one week following transplantation, with a minimal dose of 20 mg/day. Thereafter, the dose was to be decreased according to local practice but oral corticosteroids were to be continued throughout the study with a minimal dose of 5 mg/day.
223649002|NCT02611596|DRUG|Ranolazine|24 weeks of the assigned medication
223649003|NCT02611596|DRUG|Placebo|Placebo for 24 weeks
223649004|NCT04643717|OTHER|Electronic pupillometer analysis|Electronic pupillometer analysis
223649005|NCT02284698|OTHER|Health Education|Heath education will be given through awareness creation \& pamphlet distribution
223649006|NCT02139592|DRUG|Brentuximab vedotin (recombinant)|Brentuximab vedotin (recombinant) for IV infusion
223649007|NCT01864382|OTHER|Core stability|Core stability 5 days a week during 5 weeks
223649008|NCT01864382|OTHER|Standard Physiotherapy Exercises|Standard Physiotherapy Exercises is a conventional treatment program 5 days a week during 5 weeks
223649009|NCT01886599|DRUG|Asunaprevir|
223649010|NCT00171262|DRUG|Fluvastatin|
223649011|NCT04267913|DRUG|Dexamethasone|Given IV
223649012|NCT04267913|DRUG|Docetaxel|Given IV
223649013|NCT04267913|BIOLOGICAL|Ramucirumab|Given IV
223649014|NCT04267913|DRUG|Sapanisertib|Given PO
223649015|NCT04805099|DRUG|Checkpoint inhibitor|Treatment with checkpoint inhibitors in patients with preexisting autoimmune disease
223649016|NCT05960721|DRUG|Rivaroxaban 15mg|QD
223649017|NCT05960721|DRUG|Aspirin 100mg|QD
223649018|NCT05960721|DRUG|Clopidogrel 75mg|QD
223649019|NCT05960721|DRUG|Rivaroxaban 10mg|QD
223649020|NCT05960721|DRUG|Rivaroxaban 2.5mg|B.I.D
223649021|NCT01192802|DRUG|albendazole|1 tablet of 400 mg of albendazole per day for three consecutive days
223649022|NCT01192802|DRUG|albendazole|single 1 tablet of 400 mg of albendazole
223649023|NCT01192802|DRUG|albendazole|1 tablet of 400 mg of albendazole per day for two consecutive days
223649024|NCT05404672|OTHER|Aerobic Training|Progressive breathing retraining exercises for a period of 4 weeks, for 15 minutes twice daily. As patients progressed to the seated posture, the controlled pause technique (exercise) will be introduced. 4 times a day followed by a sustained period of breathing control. In addition to this Aerobic Training (cycling, treadmill) will also be practiced for 30 minutes constituting 5 days/ week. Initial training would avoid upright position. Mild-to-moderate-intensity endurance training, progressing from semi-recumbent to upright position plus strength training will be practiced.
223649025|NCT05404672|OTHER|Conventional Treatment|Progressive breathing retraining exercises for a period of 4 weeks, for 15 minutes twice daily. As patients progressed to the seated posture, the controlled pause technique (exercise) will be introduced. 4 times a day followed by a sustained period of breathing control.
223649026|NCT02185859|DRUG|Lidocaine|The lidocaine group (Group L)- 1% lidocaine 40 mL is prepared in a 50 mL syringe; A bolus dose of the studied drugs are administered for 15 minutes immediately after a subject is brought into the operating room, and the vital signs are checked (from the beginning of anesthesia induction). Subsequently, an intravenous injection of the maintenance dose is continuously performed and later stopped just before transferring the subject to a recovery room. (Group L subjects are administered lidocaine 2 mg/kg for 15 minutes immediately after the anesthesia induction, and then lidocaine 2 mg/kg/h is continuously injected. The dose of lidocaine and magnesium in this study has been shown in previous studies to be safe and to have an analgesic effect.)
223649027|NCT02185859|DRUG|Magnesium Sulfate|the magnesium group (Group M)- MgSO4 4g 40 mL is prepared in a 50 mL syringe.) A bolus dose of the studied drugs are administered for 15 minutes immediately after a subject is brought into the operating room, and the vital signs are checked (from the beginning of anesthesia induction). Subsequently, an intravenous injection of the maintenance dose is continuously performed and later stopped just before transferring the subject to a recovery room. The dose of magnesium in this study has been shown in previous studies to be safe and to have an analgesic effect.
223649028|NCT02185859|DRUG|Saline|the control group (Group C) - 0.9% normal saline 40 mL is prepared in a 50 cc syringe. A bolus dose of the studied drugs are administered for 15 minutes immediately after a subject is brought into the operating room, and the vital signs are checked (from the beginning of anesthesia induction). Subsequently, an intravenous injection of the maintenance dose is continuously performed and later stopped just before transferring the subject to a recovery room.Group C subjects are administered the same dose of normal saline.
223649029|NCT03278054|OTHER|Root Canal Treatment with hand instruments|Root canal treatment was performed with K files.
223649030|NCT03278054|OTHER|Root canal treatment with Protaper instruments|Root canals were enlarged with S1 S2 F1F2 F2 Protaper instruments
223649031|NCT03278054|OTHER|Root canal treatment with hybrid instrumentation|Root canal were enlarged with combination of a combination of ProTaper Universal instruments to shape the coronal and middle thirds and Hyflex CM to prepare the apical third
223649032|NCT03060980|DRUG|ITCA 650 20/60 mcg/day|ITCA 650 osmotic mini-pump delivering exenatide 20/60 mcg/day
223649033|NCT03060980|DRUG|Empagliflozin (oral)|10 mg/day and 25 mg/day
223649034|NCT03060980|DRUG|Glimepiride (oral)|1-6 mg/day
223649035|NCT02525770|DEVICE|radiostereometric analysis (RSA)|
223649036|NCT02687191|BIOLOGICAL|PF-05230907|PF-05230907 IV bolus injection
223649037|NCT05218291|OTHER|Yoga Practice|In this study, the yoga initiative to be made for the caregivers in the experimental group consists of breathing, meditation and yoga poses.
223649038|NCT05218291|OTHER|Ongoing caregivers|Caregivers included in the control group, who did not apply any yoga intervention, will be observed as caregivers.
224234091|NCT01048320|DRUG|Oxaliplatin|Oxaliplatin is given by intravenous infusion on day 2 every 2 weeks according to the dose escalation schedule below: Dose level -1 - 4 85mg/m2 Dose level 5 100mg/m2 Oxaliplatin should be diluted in 250 to 500 ml of 5% glucose solution to give a concentration not less than 0.2 mg/ml. It must be infused via a central venous line or peripheral vein over 2 hours. In the event of extravasation, administration must be discontinued immediately and the extravasation managed according to local procedures.
223649039|NCT03093571|DEVICE|Auricular stimulation|Auricular stimulation with indwelling fixed needles
223766670|NCT04601545|DEVICE|Virtual therapeutic support|"8 sessions of VR therapy (each of them 20 minutes long). As a virtual reality source, VR Tier One device (Stolgraf®) were used. Thanks to using head mounted display and the phenomenon of total immersion VR therapy provides an intense visual, auditory and kinesthetic stimulation. It can have a calming and mood-improving effect or help the patients recognize their psychological resources and motivate to the rehabilitation process. In the virtual therapeutic garden there are a rich set of symbols and metaphors based on Ericksonian Psychotherapy approach. The most important is the Garden of Revival which symbolizes the patient's health. It used to be full of life and energy, now it is neglected, requires work to be revived. In the therapeutic process day by day, the therapist tells the patient a symbolic story about his/her situation.~By performing tasks in the virtual garden, the patient becomes an active participant of the therapeutic process and sees the effects his/her work."
223766671|NCT05873465|DRUG|Sedation with Midazolam, Fentanyl, and Propofol|Patients will have teeth extracted under sedation with Midazolam, Fentanyl, and Propofol
223766672|NCT05873465|PROCEDURE|Extraction of teeth|The necessary teeth will be extracted
223766673|NCT04745897|OTHER|eTB Catalogue of Recommendations (eTB)|eTB Catalogue of Recommendations (eTB)
223766674|NCT04745897|OTHER|World Health Organization Tuberculosis Website (WHO TB)|World Health Organization Tuberculosis Website (WHO TB)
224234092|NCT01048320|DRUG|Imatinib|"Imatinib is given for 7 days every cycle starting 2 days before the gemcitabine is given, including administration on days 1 and 2 when gemcitabine and oxaliplatin are given, and for 3 days afterwards (i.e. days -2 to +5). It is thus given on a 7 days on and 7 days off intermittent dosing schedule. The dose will be fixed at 400 mg daily in tablet form and taken once daily with food.~Imatinib should commence either in the morning or lunchtime of day -2 and be taken at the same time daily for seven consecutive days in total."
223649040|NCT03093571|BEHAVIORAL|Relaxation|Progressive muscle relaxation
223649041|NCT02230514|DRUG|XCEL-MT-OSTEO-ALPHA|"ex-vivo expanded autologous mesenchymal stromal cells fixed in allogenic bone tissue in association with open surgery"
223649042|NCT02230514|OTHER|autologous iliac crest|Autologous iliac crest in association with surgery
223649043|NCT02230514|PROCEDURE|Surgery|Standard surgery for non-union fractures
223649044|NCT00865410|DRUG|Abrika Bupropion 150 mg Extended-Released Tablet|A: Experimental Subjects received Abrika formulated products under fasting conditions
223649045|NCT00865410|DRUG|Wellbutrin SR® 150 mg Extended-Release Tablet, single dose|B: Active comparator Subjects received GlaxoSmithKline formulated products under fasting conditions
223649046|NCT03180840|BIOLOGICAL|Pegunigalsidase alfa|Pegunigalsidase alfa 2 mg/kg every 4 weeks
224234093|NCT04330807|OTHER|Handgrip fatigability test|"Dynamometric and electromyographic assessment: patient is sitting on a chair, back upright, humerus vertically placed and forearm landing parallel to a support. Dominant arm is chosen for test and electrodes placement.~The assessment is divided in 4 phases for a total of 30 minutes duration: Warm-up, determination of reference force settings (fast sub-maximal contractions and maximal voluntary contractions), fatigability period and rest."
224234094|NCT04330807|OTHER|Questionnaires|Assessment of subjective fatigue with Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) and Multidimensional Fatigue Inventory (MFI-20) questionnaires
224234095|NCT03174756|DRUG|Hypochlorous Acid|Mouthwashes of antiplaque agents
224234096|NCT03174756|DRUG|Chlorhexidine|A disinfectant and topical anti-infective agent used also as mouthwash to prevent oral plaque.
224234097|NCT03174756|OTHER|Placebo|Sterile water as placebo
224234098|NCT02679001|DRUG|TNF inhibitor/TCZ|Participants with RA receiving TNF-inhibitor or TCZ according to standard of care and in line with the current SPC/local labeling will be observed.
224234099|NCT03463278|DIAGNOSTIC_TEST|Pregnancy Rate|The pregnancy and live birth rate according to number of blastocysts formed in our three groups
224234100|NCT04570904|BIOLOGICAL|Influenza vaccination at different time points|All HCWs will receive the seasonal influenza vaccine but at two different time points.
224234101|NCT00998023|DEVICE|Mynx Vascular Closure Device|Comparison of two different vascular closure devices.
224234102|NCT00998023|DEVICE|AngioSeal Vascular Closure Device|Comparison of two different vascular closure devices.
224320271|NCT00808314|DRUG|Rest/Dipyridamole Stress Rb-82 Myocardial Perfusion PET/CT|A CT scan will be acquired for attenuation correction of the rest image (9 mA, 120 kVp, 4.24 secs) during end-expiration breath-holding. This will be followed by infusion of approximately 60 mCi of Rb-82, 60 to 100 seconds after which resting images will be acquired with ECG-gating. Following rest imaging, 0.56 mg/kg of dipyridamole will be infused over 4 minutes. Three minutes after the completion of the infusion, approximately 60 mCi of Rb-82 will be infused. Peak stress images will be acquired with ECG-gating, starting 90 seconds after the the beginning of the infusion of Rb-82 and continuing for 5 minutes. A CT scan will be acquired for attenuation correction of the stress image (9 mA, 120 kVp, 4.24 secs) during end-expiration breath-holding.
224320272|NCT00808314|DRUG|Rest/Lexiscan(TM) Stress Rb-82 Myocardial Perfusion PET|A CT scan will be acquired for attenuation correction of the rest image (9 mA, 120 kVp, 4.24 secs) during end-expiration breath-holding. This will be followed by infusion of approximately 60 mCi of Rb-82, 60 to 100 seconds after which resting images will be acquired with ECG-gating. Following rest imaging, 400 umg of Lexiscan(TM) will be injected, and then approximately 60 mCi of Rb-82 waill be infused. Peak stress images will be acquired in list mode with ECG-gating, starting 90 seconds after the the beginning of the infusion of Rb-82 and continuing for 5 minutes. A CT scan willbe acquired for attenuation correction of the stress image (9 mA, 120 kVp, 4.24 secs) during end-expiration breath-holding.
223766675|NCT06362135|DEVICE|Virtual Home Visit|The virtual home visit will be made through the mobile application developed by the researchers. First, the patients who meet the sampling criteria will be included in the study after the caregivers of the patients apply to the Antalya Health Directorate Antalya Training and Research Hospital Home Health Unit. The virtual home visit is scheduled twice
224234103|NCT04887142|OTHER|Standard of health care|The patients in this observational study will be exposed to the standard health care interventions according to the hospital diagnostic and treatment protocols and procedures and clinical judgment of the treating physicians.
224234104|NCT01762085|PROCEDURE|nerve decompression|surgical decompression involves surgical division or incision of perineural fibrous or fibro-osseous tunnel tissues which pinch, choke, compress or sharply deviate nerve trunks.
224234105|NCT03265080|BIOLOGICAL|ADXS-NEO|Intravenous infusion
224234106|NCT03265080|BIOLOGICAL|Pembrolizumab|Intravenous infusion
224234107|NCT00594347|BIOLOGICAL|Pneumo 23|Vaccine (Pneumo 23)
224234108|NCT00594347|BIOLOGICAL|Prevnar|Vaccine (Prevnar)
224234109|NCT06250010|DIAGNOSTIC_TEST|tissue samples (healthy and tumor taken from the same patient) and tissue samples (decidualized endometrium and trophoblast taken from it patient)|Correlation between the immuno-score results of each patient with his prognosis, in terms disease-free survival, overall survival, relapse-free survival, disease-specific survival cancer, distant and/or local free survival, to validate their potential role independent in the progression of endometrial cancer; later, for a better characterization of the various ones risk classes, we will combine our immuno-score with the already known risk factors, included in the ESMO-ESGO-ESTRO classification and in the biomolecular classification of endometrial cancer, to investigate whether the Microenvironmental immunological factors in endometrial cancer could allow better stratification of patients in risk classes.
224234110|NCT04645615|DEVICE|Cardioblate surgical ablation system|This investigation is a prospective, non-randomized multicenter clinical trial evaluating the outcome of patients with AF requiring concomitant open heart surgery plus the Cardioblate Surgical Ablation System using the modified Maze III procedure. The trial population includes patients requiring valve replacements or repairs, atrial septal defect (ASD) repairs, patent foramen ovale (PFO) closure or coronary artery bypass grafts (CABG) procedures.
224234111|NCT04645615|PROCEDURE|Surgical RF Ablation|This investigation is a prospective, nonrandomized multicenter clinical trial evaluating the outcome of patients with AF requiring concomitant open heart surgery plus the Cardioblate Surgical Ablation System using the modified Maze III procedure. The trial population includes patients requiring valve replacements or repairs, atrial septal defect (ASD) repairs, patent foramen ovale (PFO) closure or coronary artery bypass grafts (CABG) procedures.
224320273|NCT01427530|DEVICE|Deep Brain Stimulation|Deep Brain Stimulation
223649047|NCT00790140|DIETARY_SUPPLEMENT|Prosure|This is an enteral tube feed with 125 kcals \& 6.65g protein per 100mls. It contains Fat, Carbohydrate, and vitamins and minerals and is enriched with 2.2g Eicosapentaenoic Acid per 500mls of feed. Patients on this trial who are randomized to Prosure will receive the product orally for 5 days prior to surgery and for 21 days post surgery vis a feeding jejunostomy tube
223649048|NCT00790140|DIETARY_SUPPLEMENT|Ensure Plus|This is a standard enteral tube feed with 150 kcals \& 6.3 g protein per 100mls as well as carbohydrate, fat and vitamins and minerals. It does not have any active immunonutrients. Patients randomized to this arm will receive the product for 5 days pre op and 21 days post surgery via a feeding jejunostomy tube
224234112|NCT00537225|BEHAVIORAL|exercise|tailored multifactor CVD risk reduction
224234113|NCT01096420|PROCEDURE|acupuncture|"Each patient had a fixed and classic acupuncture points Ex-HN-3,BL-2,GB-20,EX-HN-5 bilaterally in their 24 sessions.~Acupuncture consisted of 24 sessions of 30 min duration, administrated over 12 weeks (two sessions per week).~Sterile disposable and steel needle (3210) were used .~The needles were manipulated by rotation methods to produce a characteristic sensation know as De Qi."
224234114|NCT01096420|DRUG|topiramate|"The patients were submitted to the topiramate treatment also for 12 consecutive weeks.~The study phase consists of a 4-week titration and a 8-week maintenance period.~All dosages of topiramate will be initiated at 25 mg/d hs and increased by 25 mg/d weekly to a maximum of 100 mg/day (or to the maximal tolerated dose).~Study drug was administered daily in equally divided twice daily doses."
224234115|NCT04265365|DEVICE|rTMS+rPMS_iTBS_R|Repetitive peripheral magnetic stimulation (rPMS) intermittent theta-burst stimulation pattern (iTBS) will intermittently give a 2 s train of iTBS every 10s repeated 2 times for a total of 40 times at radial nerve on the affected hand(low pulse: 1200 pulses in total). Then following Repetitive transcranial magnetic stimulation (rTMS) will intermittently give a 2 s train of iTBS every 10s repeated 2 times for a total of 40 times on affected hemisphere(low pulse: 1200 pulses in total).
224234116|NCT04265365|DEVICE|rTMS+rPMS_cTBS_R|Repetitive peripheral magnetic stimulation (rPMS) continuous burst stimulation pattern (cTBS) will intermittently give a cTBS treatment consists of a continuous train of TBS for 40 seconds repeated for 2 times at radial nerve on the affected hand(low pulse: 1200 pulses in total). Then following Repetitive transcranial magnetic stimulation (rTMS) will intermittently give a 2 s train of iTBS every 10s repeated 2 times for a total of 40 times on affected hemisphere(low pulse: 1200 pulses in total).
223649049|NCT02648256|OTHER|Polymerase Chain Reaction on Oropharyngeal rinse|
223766676|NCT06362135|DEVICE|Control Group|"Face-to-face home visits will be carried out by the Antalya Education and Research Hospital home health team, as planned."
224234117|NCT04265365|DEVICE|rTMS +sham-rPMS|Repetitive peripheral magnetic stimulation (rPMS) sham burst stimulation pattern (sham TBS) will intermittently give a sham TBS treatment consists of a continuous train of TBS for 40 seconds at radial nerve on the affected hand(almost no pulse: 1200 pulses in total). Then following Repetitive transcranial magnetic stimulation (rTMS) will intermittently give a 2 s train of iTBS every 10s repeated 2 times for a total of 40 times on affected hemisphere(low pulse: 1200 pulses in total).
224234118|NCT04265365|DEVICE|rTMS+rPMS_iTBS_M/U|Repetitive peripheral magnetic stimulation (rPMS) intermittent theta-burst stimulation pattern (iTBS) will intermittently give a 2 s train of iTBS every 10s repeated 2 times for a total of 40 times at median nerve/nervus ulnaris on the affected hand(low pulse: 1200 pulses in total). Then following Repetitive transcranial magnetic stimulation (rTMS) will intermittently give a 2 s train of iTBS every 10s repeated 2 times for a total of 40 times on affected hemisphere(low pulse: 1200 pulses in total).
224234119|NCT04265365|DEVICE|rTMS+rPMS_cTBS_M/U|Repetitive peripheral magnetic stimulation (rPMS) continuous burst stimulation pattern (cTBS) will intermittently give a cTBS treatment consists of a continuous train of TBS for 40 seconds repeated for 2 times at median nerve/nervus ulnaris on the affected hand(low pulse: 1200 pulses in total). Then following Repetitive transcranial magnetic stimulation (rTMS) will intermittently give a 2 s train of iTBS every 10s repeated 2 times for a total of 40 times on affected hemisphere(low pulse: 1200 pulses in total).
224234120|NCT04265365|DEVICE|sham-rTMS+sham-rPMS|Repetitive peripheral magnetic stimulation (rPMS) sham burst stimulation pattern (sham TBS) will intermittently give a sham TBS treatment consists of a continuous train of TBS for 40 seconds at median nerve/nervus ulnaris on the affected hand(almost no pulse: 1200 pulses in total). Then following Repetitive transcranial magnetic stimulation (rTMS) will intermittently give a sham TBS treatment consists of a continuous train of TBS for 40 seconds on affected hemisphere(almost no pulse: 1200 pulses in total).
224234121|NCT04265365|DEVICE|rTMS + optimal-rPMS|The optimal Repetitive peripheral magnetic stimulation (rPMS) depend on previous results to give an iTBS or cTBS. Then following Repetitive transcranial magnetic stimulation (rTMS) will intermittently give a 2 s train of iTBS every 10s repeated 2 times for a total of 40 times on affected hemisphere(low pulse: 1200 pulses in total).
224234122|NCT04265365|DEVICE|sham-rTMS+optimal-rPMS|The optimal Repetitive peripheral magnetic stimulation (rPMS) depend on previous results to give an iTBS or cTBS. Then following Repetitive transcranial magnetic stimulation (rTMS) will intermittently give a sham TBS treatment consists of a continuous train of TBS for 40 seconds on affected hemisphere(almost no pulse: 1200 pulses in total).
224234123|NCT01709760|DRUG|Methotrexate|Methotrexate 15-25 mg/week
224234124|NCT01709760|DRUG|ENIA11|ENIA11 25 mg, sc twice weekly
224234125|NCT01709760|DRUG|Placebo|Placebo, sc twice weekly
224234126|NCT03397862|DRUG|Donepezil TDS|Donepezil patch
224234127|NCT03397862|DRUG|Vehicle TDS|Placebo patch
224234128|NCT00481780|DEVICE|plain balloon angioplasty|
223649050|NCT01278472|DEVICE|Single Port Cholecystectomy|Using transumbilical single port device: SILS Port
223649051|NCT01278472|DEVICE|4 Port Cholecystectomy|using 4 separate skin incisions and 2 5mm and 2 12 mm conventional ports
223649052|NCT02052076|BEHAVIORAL|Meal pattern|
223649053|NCT04254328|DEVICE|Nintendo Wii Fit|Nintendo Wii Fit group will perform including a series of yoga, balance, aerobics and muscle workout exercises by providing visual feedback on the TV screen with the Nintendo wii fit plus game console. Patients will perform these exercises in a room allocated to the thesis supervisor and together with the thesis supervisor physiotherapist. This process takes 40-50 minutes. Before starting test and after test, weight, blood pressure, pulse, respiratory rate, oxygen saturation value will be recorded. Patients will be rested if necessary during exercise.
223649054|NCT04254328|DEVICE|Threshold IMT|Patients in the breathing exercise group will perform deep breathing exercises at home by a small breathing apparatus called as Threshold IMT. It has no unexpected side effects.Patients will do this exercise twice in a day ; morning and evening during 15 minutes. After 4-5 deep breath, patients will take normal breath till feeling relaxed.
223649055|NCT05633316|DEVICE|Investigational device named ICSIA|Oocytes will undergo intracytoplasmic sperm injection using the ICSIA (the investigational) device.
224234129|NCT00481780|DEVICE|cutting balloon angioplasty|
224234130|NCT02193438|OTHER|Spices intake|Each subject had to ingest a single dose of each of the spices and placebo. Recording of outcomes was realized throughout the 90 minutes following ingestion.
224234131|NCT02193438|OTHER|Placebo|Tomato juice intake
223649056|NCT05633316|DEVICE|Manual ICSI|Oocytes will undergo intracytoplasmic sperm injection using the ICSI manual protocol
223649057|NCT02516540|BEHAVIORAL|Structured exercise training plus mediterranean diet|Structured exercise training plus mediterranean diet
223649058|NCT03940768|DIETARY_SUPPLEMENT|Lactobacillus plantarum 299v|Administration of Lactobacillus plantarum 299v in cancer patients who receive home enteral nutrition.
223649059|NCT03940768|DIETARY_SUPPLEMENT|Placebo|Administration of placebo in cancer patients who receive home enteral nutrition.
223649060|NCT00381290|BEHAVIORAL|Diet|The prescribed diet will include traditional healthy food and up to two meal replacement supplements. Initially, the diet will be set to result in an overall loss of 800 to 1000 calories per day.
223649061|NCT00381290|BEHAVIORAL|Exercise|The program will consist of 60-minute exercise sessions per week for the duration of the study. The exercise sessions will incorporate aerobic exercise and resistance training. Participants will also be encouraged to exercise at home.
223649062|NCT03089164|DIAGNOSTIC_TEST|Right heart catheterization|Each patient will have variables measured supine, sitting and standing positions
223649063|NCT06464237|BEHAVIORAL|Mio-App|The Mio-App aims to increase metacognitive knowledge, teaches mnemonic skills, trains the working memory capacity and motor skills to reduce cognitive and physical long-term sequelae after cancer during adolescence.
223649064|NCT00752440|OTHER|Inspiratory muscle training (IMT)|IMT (30 min 7 times per week, for 8 weeks)
223649065|NCT04860544|PROCEDURE|RED BLOOD CELLS TRANFUSION|
223649066|NCT01571544|DEVICE|Thermal suit|Thermal suit
223649067|NCT01571544|OTHER|Conventional clothing|Conventional clothing
223649068|NCT01343641|DRUG|MK-0677|The oral agent MK-677 is spiropiperidine, Merck L-163 191, GH secretagogue ghrelin mimetic which increases GH and IGF-I secretion, fat free mass and energy expenditure76-79. It is produced by Merck \& Co, Inc.
223649069|NCT01343641|DRUG|Placebo|Inactive Pill used as a comparator
223649070|NCT01305590|OTHER|Survey to Understand Medication Adherence among HIV Patients|"We want to better understand how this particular population would react to commitment devices designed to increase medication adherence. We will survey participants to see if they would prefer more commitment, in the form of a Take-Medication-Get-Paid plan; less commitment, in the form of an Attend-Clinic-Get-Paid plan; or if they would prefer to designate their own levels of commitment."
223649071|NCT02537158|DRUG|Sorafenib|sorafenib group patients will accept sorafenib therapy for one year（400 mg bid,orally).
223649072|NCT02537158|PROCEDURE|TACE|TACE group patients will accept TACE therapy once at a month after resection.
223649073|NCT01819818|DRUG|No intervention|This is an observational study. Korean schizophrenic participants receiving paliperidone palmitate as an intramuscular injections will be observed.
223766677|NCT02519712|DRUG|Induction Chemotherapy|Patients with newly diagnosed AML will receive standard induction chemotherapy with daunorubicin and cytarabine (7+3 scheme). Patients who achieve CR may undergo consolidation chemotherapy at the discretion of the treating leukemia physician.
223766678|NCT02519712|PROCEDURE|G-PBSC Infusion|G-CSF-mobilized peripheral blood cells will be collected from the donors in the Donor Room according to standard MSKCC BMT guidelines. Patients will be infused by infusion of unmanipulated G-PBSC from a haploidentical related donor.
224234132|NCT05540509|BEHAVIORAL|Community-based intervention|Mothers were given physical activity goals and coping resources to practice at home and were asked to record their experiences on an activity log. Course content was taught from a detailed training manual and was based on concepts and strategies from social cognitive theory that have been effective in increasing physical activity and fitness levels among mothers. In the first month, mothers attended group exercise sessions twice per week (total of eight group sessions) and exercised on their own once per week. In the second month, mothers attended group exercise sessions once per week (total of four group sessions) and exercised on their own twice per week. In the third month, mothers exercised on their own three times per week.
223766679|NCT03029689|DRUG|Raltegravir|Raltegravir 1200 mg (2 tablets x 600mg) once daily plus current ART during 48 weeks from randomization
223766680|NCT03029689|DRUG|Placebo|Placebo (2 tablets of placebo) once daily plus current ART during 48 weeks from randomization.
223766681|NCT03029689|DRUG|Current ART|3-drug antiretroviral treatment including PI/r/c or NNRTI
223649074|NCT01788358|DRUG|Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106)|Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106), tablet, 30/8 mg, orally once daily
223649075|NCT01788358|DRUG|Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106)|Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106), tablet, 30/16 mg, orally once daily
223649076|NCT01788358|DRUG|Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106)|Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106), tablet, 60/16 mg, orally once daily
223649077|NCT01788358|DRUG|Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106)|Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106), tablet, 60/32 mg, orally once daily
223649078|NCT06073145|DEVICE|conventional transcranial Doppler probe and wearable ultrasound patch.|Comparison of the measurements from conventional transcranial Doppler probe and wearable ultrasound patch.
223649079|NCT04461067|DIAGNOSTIC_TEST|ultrasonography|Ultrasonography of the stomach is performed to measure the diameter of the antrum
223766682|NCT05675553|DEVICE|robot-assisted rehabilitation intelligent treatment|Participants assigned to this condition were offered 10 individual sessions of robot-assisted rehabilitation treatment, delivered by the Robot-assisted rehabilitation intelligent system. The system contains 10 core cognitive-behavioral therapy (CBT) skill topics (such as functional analysis, coping skills training, reviewing practice exercises, and explaining CBT concepts). A robot therapist demonstrates the target CBT skills and assigns homework to participants. The treatment framework is semi-structured through human-computer interaction. The forms of interaction include inquiries, statements, recommendations summaries, and knowledge assessments.
223766683|NCT05675553|OTHER|treatment as usual|Both groups will receive treatment as usual, including medication, exercise, and psychological education.
223766684|NCT03057028|DRUG|Anakinra|
223766685|NCT01261858|DEVICE|Kryptonite|osteoconductive biologic bone cement to be applied upon sternal closure
223766686|NCT02995785|OTHER|simulation-based training|simulation-based training:The first aid skill simulation training with discussion and debriefing(75-min) and TMS online lecture(15-min).
223766687|NCT02995785|OTHER|traditional training|traditional training:Give TMS online lecture(15-min).
223649080|NCT01774656|DRUG|Pharmacological Treatment|The pharmacological treatment intended to enhance reverse remodeling includes 4 drugs initiated immediately after weaning of inotropic support once achieving adequate end-organ recovery and titrated (against symptoms, potassium, and renal function) to the following maximum doses: lisinopril 40 mg daily; carvedilol 25 mg 3 times daily; spironolactone 25 mg daily; digoxin 125g daily, and losartan 150 mg daily.
223649081|NCT04797624|PROCEDURE|Gastric cancer surgery|Appropriate gastric cancer surgery types for the convenient patients
224234133|NCT05540509|BEHAVIORAL|Home-based intervention|The HBI group received information on building social support and reducing physical activity barriers based on materials from the Diabetes Prevention Program. Participants were also given activity logs to record their physical activity each week, which was collected by research staff at each monthly assessment time point to assess how participants were progressing with their physical activity goals. Mothers exercised on their own for three months with the goal of meeting national physical activity guidelines
224234134|NCT00536575|DRUG|Bortezomib|"Dose Level 1: Bortezomib 1.3mg/m2 IV bolus on days 1, 8, 15, and 22 of each 5-week cycle.~Dose Level 2: Bortezomib 1.6 mg/m2 IV bolus on days 1, 8, 15, and 22 of each 5-week cycle.~Dose Level 3: Bortezomib 1.6mg/m2 IV bolus on days 1, 8, 15, and 22 of each 5-week cycle."
224234135|NCT00536575|DRUG|Sorafenib|"Dose Levels 1 and 2: 200 mg by mouth twice daily~Dose Level 3: 400 mg by mouth twice daily"
224234136|NCT02090608|DRUG|Paricalcitol|Paricalcitol was administered at the dose of 1 mcg/die
224234137|NCT00261196|DRUG|Collagenase|Anterior shoulder capsule injection
224234138|NCT02844153|OTHER|modalities of metformin prescription|Metformin prescription or not, in each CKD stage
224234139|NCT02026453|OTHER|Pharmacist obtains admission medication history|
224234140|NCT02026453|OTHER|Pharmacy technician obtains admission medication history|
224234141|NCT04971551|DRUG|Jaktinib Hydrochloride Tablets|Oral on an empty stomach
224234142|NCT00554151|DEVICE|Adjustable Annuloplasty Ring|The investigational device is intended for use in the treatment of mitral valve regurgitation.
224234143|NCT04112030|DIAGNOSTIC_TEST|Digital image analysis|
224234144|NCT04963192|DEVICE|Connected actimeter to measure physical activity in OSA patients|Connected actimeter worn for one week before initiation of treatment, at M3 and at M6, to measure average daily steps for OSA patients
224234145|NCT04963192|DEVICE|Connected BORA Band to measure physical activity in COPD patients only|Connected BORA Band worn for one week before initiation of treatment, at M3 and at M6, to measure average daily steps for COPD patients only
224234146|NCT04963192|OTHER|IPAQ to evaluated physical activity|Physical activity evaluated by IPAQ (International Physical Activity Questionnaire) at the inclusion, M3 and M6
224234147|NCT04963192|DEVICE|Connected scale to measure weight|Weight measured by a connected scale, before CPAP or NIV treatment, at M3 and M6
224234148|NCT04963192|DEVICE|Connected tensiometer to measure arterial pressure|Arterial pressure measured by a connected tensiometer, before CPAP or NIV treatment, at M3 and M6
224234149|NCT04963192|DEVICE|Connected BORA Band to measure oxygen saturation in COPD patients only|Daily oxygen saturation measured by the connected BORA Band for COPD patients only during 6 months
224234150|NCT04963192|DEVICE|Connected BORA Band to measure heart rate in COPD patients only|Daily heart rate measured by the connected BORA Band for COPD patients only during 6 months
224320274|NCT03046641|OTHER|Continuous training|Study group I (42 participants) received the continuous training.
223649082|NCT05189041|OTHER|Aneurysmal pulsation in functional MRI|Quantify the aneurysmal pulsation in functional MRI on the patient with Ruptured Cerebral Aneurysm
223649083|NCT06131476|DRUG|Blink® Tears eye drops|Control Drops
223649084|NCT06131476|DRUG|Investigational lipid eye drops|Test Drops
223649085|NCT05680532|DIETARY_SUPPLEMENT|Black raspberry|Experimental group subjects were requested to take 50 g of Black Raspberry powder for 4 weeks.
223649086|NCT05680532|OTHER|Placebo|Placebo group subjects were requested to take 50 g of dextrin for 4 weeks.
223649087|NCT01368224|DIETARY_SUPPLEMENT|Lactobacillus paracasei NCC 2461 and Bifidobacterium longum NCC3001|"1 treatment unit, in the form of a sachet of powder, to be reconstituted in a glass of water and taken once daily for 8 weeks (from D1 to D57), except if the last visit is bring forward or put back for no more than 3 days, in which case the subject will continue treatment until the final visit.~Oral route."
223766688|NCT02976896|DRUG|Apatinib Mesylate|Patients will receive Apatinib Mesylate at 500mg/times,oral one times daily for 28 days.
224234151|NCT04963192|DEVICE|Connected BORA Band to measure respiratory rate in COPD patients only|Daily respiratory rate measured by the connected BORA Band for COPD patients only during 6 months
224234152|NCT04963192|OTHER|EXASCORE to evaluated COPD severity|COPD severity evaluated by the EXASCORE questionnaire at inclusion, M3 and M6 for COPD patients only
224234153|NCT04963192|OTHER|Epworth scale to evaluate sleepiness|Sleepiness evaluated by the Epworth scale at baseline, M3 and M6
224234154|NCT04963192|OTHER|Pichot scale to evaluate fatigue|Fatigue evaluated by the Pichot scale at inclusion, M3 and M6
224234155|NCT04963192|OTHER|Usability questionnaire|Subjective assessment of each device by means of usability questionnaire at M6
224234156|NCT04963192|OTHER|SF36 questionnaire|Quality of life evaluated by the SF36 questionnaire at inclusion and M6
224234157|NCT01901666|DRUG|Growth Hormone|"All GH deficient patients with bone age \<14 years will be treated with GH therapy for one year.Serum IGF-1 will be measured 4weekly and GH dose will be titrated till S.IGF-1 is in mid-normal range and then after every 3 months.~Growth parameters will be assessed after every 3 months.Serum T4, TSH will be done after every 3 months. Patients will be monitored for any side effects of GH therapy"
224234158|NCT02800798|OTHER|Preeclampsia positive|
224234159|NCT05892978|OTHER|Vascular imaging|"Experimental group - Vascular imaging device with the infrared light group: Before PIVC, infrared light will be directed to the vein area and the procedure will be started after vein visibility is achieved.~Experimental group - Vascular access transillumination group: Before PIVC, a transilluminator will be inserted to the vein area and the procedure will be started after vein visibility is achieved"
224234160|NCT02252731|DRUG|Warfarin|Oral
224234161|NCT02252731|DRUG|FG-4592|Oral
224320275|NCT03046641|OTHER|The interval training|Study group II (40 participants) received the interval training.
224320276|NCT03697824|DRUG|GSK3377794|GSK3377794 is genetically engineered NY-ESO-1 Specific (c259) T cells.
223766689|NCT01398111|DRUG|Glycopyrrolate + Formoterol|glycopyrrolate pMDI + formoterol pMDI
223766690|NCT01398111|DRUG|Glycopyrrolate|glycopyrrolate pMDI
223649088|NCT02429180|OTHER|Rehabilitation|"ReTrain: an exercise-based functional training programme comprising two phases: (1) weekly supervised sessions; (2) monthly drop-in sessions, plus home-based exercise in each phase.~* Week 1: one-to-one consultations with trainer to introduce programme, assess individual's concerns and capabilities, introduce and negotiate initial goals~* Weeks 2-11: bi-weekly 90 minute group class with group-based activities and one-to-one coaching, based on ongoing goal negotiation review and progression.~* Week 12: one-to-one consultations with trainer to review goals and plan ongoing unsupervised exercise programme~* Weeks 13-24: monthly drop-in sessions for one-to-one consultation, support and progression."
223649089|NCT04992858|DRUG|CT053PTSA|CT053PTSA will be administered orally once a day
223649090|NCT04085900|BIOLOGICAL|Blood and saliva|Collect blood and saliva samples from participants
223649091|NCT04085900|DIAGNOSTIC_TEST|P85-Ab, EBNA1-IgA, VCA-IgA and EBV DNA|Detect P85-Ab, EBNA1-IgA, VCA-IgA for all participants, and detect EBV DNA for all male participants and P85-Ab positive female participants.
223649092|NCT04085900|DIAGNOSTIC_TEST|Fiberoptic endoscopy and biopsy|Screening participants will refer to fiberoptic endoscopy and biospy
223649093|NCT03209739|OTHER|WhatsApp reminder|An additional WhatsApp reminder with same content of the written instruction and a video of explanation of bowel preparation by a nurse 4 days prior colonoscopy
223649094|NCT04264481|PROCEDURE|Adductor Canal Block|Ultrasound guided perineural injection of 5cc bupivacaine, 5cc lidocaine and 10 cc Normal saline
223649095|NCT04264481|PROCEDURE|Intra-Articular Steroid and Lignocaine Injection|Intra-articular injection of 40mg triamcinolone and 1-2 cc of lidocaine
223649096|NCT02736890|DRUG|Botulinum Toxin A|Subjects will receive subcutaneous Botulinum Toxin A injections into the marked painful region. The syringes will be prepared by a third party prior to the injection and the administrator of the procedure will be blinded to syringe content. This physician will be performing the injections under sterile conditions. Local anesthesia, EMLA (lignocaine/prilocaine eutectic mixture) cream, up to 4 grams, will be applied topically for local anesthesia. After 50 minutes, the cream will be cleaned off. Overlying skin will be sterilized with either betadine or alcohol solution.
223649097|NCT02736890|DRUG|Placebo|Subjects will receive subcutaneous placebo injections into the marked painful region. The syringes will be prepared by a third party prior to the injection and the administrator of the procedure will be blinded to syringe content. This physician will be performing the injections under sterile conditions. Local anesthesia, EMLA (lignocaine/prilocaine eutectic mixture) cream, up to 4 grams, will be applied topically for local anesthesia. After 50 minutes, the cream will be cleaned off. Overlying skin will be sterilized with either betadine or alcohol solution.
223649098|NCT02465554|PROCEDURE|Myocardial contrast echocardiography|Myocardial contrast echocardiography will be performed to further stratify risk as described in the cohort section.
223649099|NCT03712423|DRUG|Cripec Docetaxel|89 Zirconium Cripec Docetaxel PET
223649100|NCT03089762|BIOLOGICAL|Intra-articular injection of SVF plus PRP|administering SVF and PRP intra-articularly into patients with osteoarthritis grade 1 and 2
223649101|NCT06000774|OTHER|Therapeutic Ketogenic Diet|therapeutic ketogenic diet
223766691|NCT01398111|DRUG|Formoterol|formoterol pMDI
223766692|NCT01398111|DRUG|Placebo|placebo pMDI
223766693|NCT01505192|DEVICE|continuous Hb monitor|Pre and post partum non invasive continuous Hb monitor
223766694|NCT01891851|DRUG|TMC435350 200 mg|Each patient will receive 200 mg (2 capsules) once daily orally from Day 1 to Day 7 in Session 1 and from Day 6 to Day 12 in Session 2
223766695|NCT01891851|DRUG|Ritonavir 100 mg|Each patient will receive 100 mg (1 capsule) of ritonavir twice daily orally from Day 1 until Day 15 of Session 2
224320277|NCT03697824|DRUG|Pembrolizumab|Pembrolizumab will be administered at a dose of 200 mg once every 3 weeks for adults and 2 mg/kg (up to 200 mg) once every 3 weeks for children.
224320278|NCT03697824|DRUG|Fludarabine|Fludarabine will be used as a lymphodepleting chemotherapy.
223649102|NCT04797559|PROCEDURE|SZMN Block|Suprazygomatic Maxillary Nerve (SZMN) Blocks bilaterally near the temples of the patient
223649103|NCT04031872|DRUG|LY3200882|Combination treatment with LY3200882 and capecitabine
223649104|NCT06004427|OTHER|Diet program|A diet program will be prepared with the help of a dietitian at the beginning of 12 weeks for all participants who agree to participate in the study, and this program will be controlled by a dietitian once a month and completed at the end of 12 weeks.
223649105|NCT06004427|OTHER|Exercise training protocols|calisthenic exercises exercises with lower and upper extremity theraband exercises with light dumbbells
223766696|NCT01247090|DRUG|Vasopressin - Very Low Dose|Intradialytic vasopressin (AVP) infusion. The dose is calculated based upon the individual's weight in kilograms. A kilogram is equal to 2.2 pounds. For example, a person who weighs 70 kg (or 154 pounds) would receive a dose equal to 0.15 mU \* 70 kg, or 10.5 mU of AVP per minute by infusion at their thrice-weekly dialysis treatments.
223766697|NCT01247090|DRUG|Vasopressin - Low Dose|Intradialytic vasopressin (AVP) infusion. The dose is calculated based upon the individual's weight in kilograms. A kilogram is equal to 2.2 pounds. For example, a person who weighs 70 kg (or 154 pounds) would receive a dose equal to 0.30 mU \* 70 kg, or 21 mU of AVP per minute by infusion at their thrice-weekly dialysis treatments.
223766698|NCT01247090|DRUG|Placebo Comparator|Participants in Group 3 will receive an equal volume of normal saline (placebo) infusion during their standard thrice-weekly dialysis treatments.
223766699|NCT05973747|DRUG|Calcium Gluconate|Infused intravenously over 10 minutes upon umbilical cord clamping. First 10 assigned patients received 2 grams per protocol. Subsequent 13 patients received 1.5 grams, dose recalibrated per protocol.
223766700|NCT05973747|DRUG|Calcium chloride|0.5 grams of calcium chloride, infused intravenously over 10 minutes upon umbilical cord clamping
223766701|NCT01226719|DRUG|Panitumumab|6 mg/kg, 60-90 minute IV infusion every 2 weeks
223766702|NCT01226719|DRUG|Oxaliplatin|85 mg/m2, 2-hour IV infusion every 2 weeks
223766703|NCT01226719|DRUG|Irinotecan|125 mg/m2, 1-hour IV infusion every 2 weeks
224320279|NCT03697824|DRUG|Cyclophosphamide|Cyclophosphamide will be used as a lymphodepleting chemotherapy.
224320280|NCT01666665|DRUG|Metformin|Metformin up to 1000mg/m2 body surface area by mouth of feeding tube up to 3 times each day for 12 months
223766704|NCT01226719|DRUG|Leucovorin|200 mg/m2, 2-hour IV infusion every 2 weeks
224234162|NCT03840057|DRUG|Azithromycin Injection|Azithromycin, a semi-synthetic macrolide antibiotic derived from erythromycin. The role of azithromycin as a prokinetic agent was first reported in a retrospective cohort study, which showed azithromycin to be equivalent to erythromycin in accelerating gastric emptying in patients with gastroparesis. The aim of this intervention arm is to evaluate the effectiveness of azithromycin as a prokinetic agent in the management of UGIB.
223649106|NCT04748198|PROCEDURE|Intracorneal ring segment implantation|Surgical procedure for keratoconus treatment. A tunnel is created in the corneal stroma with femtosecond laser and ring segments are implanted in the corneal stroma
223649107|NCT05492578|DRUG|Amlitelimab|Pharmaceutical form: Solution for injection Route of administration: Subcutaneous
223649108|NCT05492578|DRUG|Topical corticosteroids|Pharmaceutical form: Topical Route of administration: Topical
223649109|NCT05492578|DRUG|Topical calcineurin inhibitors|Pharmaceutical form: Topical Route of administration: Topical
223649110|NCT05492578|DRUG|Oral corticosteroids|Pharmaceutical form: Oral Route of administration: Oral
223649111|NCT03497195|DIAGNOSTIC_TEST|Screening at community level|comparison of chest x-ray and Xpert Ultra versus CRP and Xpert Ultra for active community based screening
223649112|NCT06833580|OTHER|The intervention group, who will receive the health belief model-based fall prevention education program|Each participant in this group will receive two in-person individual educational sessions based on the health belief model (HBM).
223649113|NCT02518594|DRUG|Vaginal progesterone|200mg micronized vaginal progesterone softgel capsule, daily from randomization to \< 35 wks
223649114|NCT02518594|DRUG|Placebo|placebo softgel capsule, daily from randomization to \< 35 wks
223649115|NCT02518594|DEVICE|Arabin Pessary|Placement management from randomization to \< 35 wks
223649116|NCT00337623|DRUG|Prednisolone|
223649117|NCT06160843|DRUG|Pembrolizumab IV infusion Q3W, with daily oral Olaparib.|Pembrolizumab IV infusion 200 mg Q3W, with daily oral Olaparib 300mg BID, over a 3-week cycle.
223649118|NCT05795608|DEVICE|respiratory exercise with incentive spirometry|Subjects in the intervention group were trained to perform 15 minutes of respiratory exercise with incentive spirometry four times a day for two days before surgery by trained medical personnel. First, subjects were instructed to make a good seal over the incentive spirometry mouthpiece with their lips. Afterward, they were asked to inhale deeply and slowly, and they were also directed to hold their breath at the end of inspiration
223649119|NCT02338271|OTHER|autologous adipose derived mesenchymal stem cell|autologous adipose derived mesenchymal stem cell (2 x 10\^7 cells/mL /vial or 4 x 10\^7 cells/mL /vial) and Tissuefill (hyaluronic acid derivatives) 1mL/syringe
223649120|NCT06025968|BEHAVIORAL|i-CBT|The content is based on manual by Perlis et al (2015) and has slightly reworked by the research team by shortening treatment from seven to six sessions and allowing for day-time naps that may be necessary for patient with MS (Siengsukon et al. 2020). Due to the high prevalence of fatigue in people with MS, naps during the day may be a necessity to cope with everyday tasks. In cases where patients could not refrain from naps, they were advised to limit them to maximum 20 minutes and to take them as early in the day as possible. Other components are sleep restriction, sleep hygiene, stimulus control and cognitive techniques..
223649121|NCT06025968|BEHAVIORAL|Applied relaxation|Treatment consits of 6 modules. The main components in the training program will be progressive muscle relaxation, short relaxation with release only and without tension, and finally the participants will be taught rapid relaxation.
223649122|NCT05742711|DEVICE|Primary Relief|Continuous neurostimulation with a set of pre-assigned stimulation parameters.
223649123|NCT05742711|DEVICE|Primary Relief - Sham Device|Standard treatment with the application of sham device shall be followed with additional analgesics available if necessary.
223649124|NCT02904954|DRUG|Durvalumab|Intravenously
223649125|NCT02904954|OTHER|Durvalumab plus SBRT|Intravenously plus radiotherapy
223649126|NCT05240391|DRUG|Midodrine Hydrochloride|Midodrine hydrochloride for PICD prevention
224234163|NCT03840057|DRUG|Metoclopramide Injectable Solution|Metoclopramide, a 5-HT4 agonist and a dopamine D2-receptor antagonist, is approved for short-term treatment of gastroparesis. The use of metoclopramide as a prokinetic agent in the setting of UGIB has been previously studied, but the number of subject involved was too low to adequately power the studies. The aim of this intervention arm is to further evaluate the effectiveness of metoclopramide as a prokinetic agent in the management of UGIB.
224234164|NCT03840057|DRUG|Sodium chloride 0.9%|Normal saline is used as a placebo control.
224234165|NCT00927810|DRUG|Canakinumab|
224234166|NCT04345978|BEHAVIORAL|Fasting hours|Normal Fasting hours before CRC surgery for 8 hours and feeding 8 hours after surgery; Prolong fasting hours before CRC surgery for 24 hours and feeding 24 hours after surgery.
224234167|NCT05276284|COMBINATION_PRODUCT|Atezolizumab, 6-mercaptopurine, 6-thioguanine|Combination therapy with Atezolizumab, 6-mercaptopurine and 6-thioguanine
224234168|NCT02334059|DRUG|Ketamine|Ketamine infusion plus placebo infusion of normal saline
224320281|NCT01666665|DRUG|Sugar pill|Sugar pill up to 3 times per day for 12 months
224320282|NCT02879344|OTHER|Blood draw|
224320283|NCT02538822|DEVICE|dynamic imaging|In vivo study of biomechanical behavior of ATA from preoperative dynamic imaging : dynamic CT-scan and 4D-magnetic resonance imaging (MRI)
223649127|NCT05240391|DRUG|Human Albumin 20%|Human ALbumin 20% for prevention of paracentesis induced circulatory disturbance
223649128|NCT05819827|OTHER|Blood and Tissue|"Patients will collect stool for microbiome analysis at baseline (i.e., 3 +2 days prior to chemotherapy) and again 5-7 days following initiation of chemotherapy.~Blood samples will be collected prior to their first chemotherapy treatment, and in the second week after chemotherapy."
223766705|NCT01226719|DRUG|5-Fluorouracil|3200 mg/m2 IV, 48-hour continuous infusion every two weeks
223766706|NCT00637039|DRUG|AZD8931|Tolerability and Pharmacokinetics of AZD8931 in Patients with Advanced Solid Malignancies.
223766707|NCT00006916|BIOLOGICAL|bleomycin|
224320284|NCT02538822|DEVICE|mechanical testing|In vitro study of with mechanical inflation testing of ATA tissue harvested during surgery.
224320285|NCT02982291|PROCEDURE|Williams flexion protocol|The Williams flexion protocol group will participate in 15 treatment sessions.
224320286|NCT02982291|PROCEDURE|Focused spinal stenosis rehabilitation|The focused spinal stenosis rehabilitation group will participate in 5 treatment sessions.
224234169|NCT02334059|DRUG|Ketamine plus magnesium|Ketamine plus magnesium infusion
224234170|NCT02334059|OTHER|Placebo|2 placebo infusions
224234171|NCT00314691|GENETIC|Blood samples|
224234172|NCT03784261|DRUG|"Drug: Salirumab"|To examine the effects of salirumab in RA patients
224234173|NCT03784261|DRUG|"Drug: Tocilizmab"|To examine the effects of tocilizmab in RA patients
224234174|NCT03784261|DRUG|"Drug: Abatacept"|To examine the effects of abatacept in RA patients
224234175|NCT00174642|DRUG|Insulin Glargine|One daily injection in the evening. 100 U/ml
224234176|NCT00174642|DRUG|Insulin Glulisine|Given immediately before each of the three main meals. 100 U/ml
224234177|NCT00174642|DRUG|Metformin|At same dosages as the previous treatment
224234178|NCT00174642|DRUG|insulin secretagogue|sulfonylurea or glinide
224234179|NCT04905342|DRUG|NVP-1805|orally, once daily on Period 1 and Period 3 (or Period 2 and Period 4) (NVP-1805 80/10/20.8mg)
224234180|NCT04905342|DRUG|NVP-1805-R1and NVP-1805-R2|orally, once daily on Period 1 or Period 3 (or Period 2 and Period 4) (NVP-1805-R1 80mg, NVP-1805-R2 10/20.8mg)
224234181|NCT00198029|DEVICE|Synvisc (hylan G-F20)|32 subjects in the pilot study have received 3 1ml injections of Synvisc intraarticular over the course of 3 weeks and then followed for 6 months post injection
224234182|NCT04820868|DEVICE|Multi-cancer early detection test|Blood collection and multi-cancer early detection test
224234183|NCT04128007|DRUG|Roflumilast foam 0.3%|experimental
224234184|NCT04128007|DRUG|Vehicle foam|experimental
224234185|NCT04774081|DEVICE|24h Continuous glucose monitoring and urinary C-peptide collection|Participants will be admitted to the research clinic for a 24-hour stay in a metabolic chamber. During the chamber stay, all urine excreted will be collected to assess C-peptide urinary excretion rate and interstitial glucose will be measured by a continuous glucose monitor (CGM). Participants will consume a eucaloric diet (50% carbohydrates, 30% fat and 20% protein).
224234186|NCT03651674|DEVICE|ECT treatment|Patients had bilateral temporal modified ECT four times a week for 3 consecutive weeks
224234187|NCT03651674|DRUG|Drug treatment|Patients only have antipsychotic drugs
224234188|NCT04337996|DIAGNOSTIC_TEST|COVID-19 diagnostic test|COVID-19 diagnostic tests performed at day 1 (antigen in blood serum, SARS-Cov2 PCR, antibodies in blood serum) COVID-19 diagnostic test performed at day 21 (antibodies in blood serum)
223766708|NCT00006916|DEVICE|Ommaya reservoir|
224234189|NCT00532337|DRUG|ONO-5334|Placebo - 24/mos.
224234190|NCT00532337|DRUG|ONO-5334|100mg QD /24 months
224234191|NCT00532337|DRUG|ONO-5334|50mg BID /24 mos.
224234192|NCT00532337|DRUG|ONO-5334|300mg QD /24 mos.
224234193|NCT00532337|DRUG|ONO-5334|Alendronate 70mg once weekly / 24 mos
224234194|NCT04117607|OTHER|Placebo|5% Dextrose Injection, USP, a sterile, nonpyrogenic solution of dextrose in water for injection. The solution has the osmolarity of 252 mOsmol/L, which is slightly hypotonic. This solution contains no bacteriostat, antimicrobial agent or added buffer.
224234195|NCT04117607|DRUG|Rezafungin|Rezafungin, 100 mg/mL, is a sterile liquid product supplied in single-dose vials containing 1.0 mL of extractable volume. The active pharmaceutical ingredient is rezafungin acetate, a water-soluble amorphous acetate salt. The inactive ingredient is mannitol.
224234196|NCT04117607|DRUG|Rezafungin|Rezafungin, 200 mg/vial, is a sterile product supplied as a white to pale yellow lyophilized powder in single-dose glass vials for reconstitution with Sterile Water for Injection, United States Pharmacopeia (USP). The reconstituted product is diluted in 0.9% Sodium Chloride Injection, USP for IV infusion. The active pharmaceutical ingredient is rezafungin acetate, a water-soluble amorphous acetate salt. The inactive ingredients include excipients of mannitol, polysorbate 80, and histidine.
224234197|NCT02250560|BIOLOGICAL|Replenine®-VF (High Purity Factor IX)|
224320287|NCT01606774|OTHER|Modernized prenatal care|Home monitoring/phone surveillance/28 week ultrasound in place of 4-5 routine prenatal visits between 18 and 36 weeks
223766709|NCT00006916|RADIATION|radiation therapy|60.0 Gy/30 fractions x 2.0 Gy. For the first 46 Gy/23 fractions the treatment volume should include the volume of contrast-enhancing lesion and surrounding edema on pre-operative CT/MRI scan plus a 2 centimeter margin. If no edema is present, the margin should be 2.5 cm. After 46.0 Gy, the tumor volume should include the contrast-enhancing lesion (without edema) on the pre-surgery MRI/CT scan plus a 2.5 centimeter margin.
224234198|NCT00537147|BIOLOGICAL|WN/DEN4delta30 vaccine|Live attenuated WN/DEN4delta30 vaccine (one of two doses)
224234199|NCT00537147|BIOLOGICAL|Placebo|Placebo for WN/DEN4delta30 vaccine
224320288|NCT02509169|DRUG|TAE plus P53 gene|Trans-catheter embolization combined with recombinant adenoviral human p53 gene therapy
224320289|NCT02509169|OTHER|TAE|Trans-catheter embolization
224320290|NCT06621446|OTHER|Comprehensive intervention model|A dry eye intervention strategy: including health education, the use of eye drops, and regular review.
224320291|NCT03394469|OTHER|collection|Blood, urinary and faecal samples
224234200|NCT01085344|BIOLOGICAL|Recombinant Factor VIII (Advate/Helixate FS/KoegenateFS)|escalating dose prophylaxis
224234201|NCT01085344|BIOLOGICAL|Recombinant Factor VIII (Advate/Helixate FS/KoegenateFS)|escalating dose
224234202|NCT04947956|DRUG|Camrelizumab|The camrelizumab-based treatment will be determined by the investigator.
224234203|NCT01589536|OTHER|interval-rehabilitation|The Patients in the intervention group receive a Stationary psychocardiological interval-rehabilitation.The Interval rehabilitation is divided into individual psychological therapy with focus of Behavior therapy and relaxation therapy.
224234204|NCT05083598|OTHER|6 Minute walking test|The patient is asked to repetitively walk along a 15 m track, at their best speed, in six minutes. Before and after the exercise, blood arterial pressure and dyspnea level (via Borg scale) are assessed. Cardiac frequency and peripheral Oxygen saturation are assessed before the test, and every minute and in the two minutes following the exercise.
224234205|NCT05083598|OTHER|Frailty questionaires|Clinical Frailty Score, Metabolic Equivalent of Task, DUKE Activity Status Index
224234206|NCT06547944|DRUG|Zanubrutinib|160mg bid/d, from C1 to CR and MRD-negative or C24
224234207|NCT06547944|DRUG|Lenalidomide|From C3 dose escalation, all 3 dose groups climbed from 5 mg/d to 10 mg/d, 15 mg/d, and 20 mg/d respectively, Taking 21 days of medication and 7 days of rest, 1 cycle every 28 days to CR and MRD-negative or C24
224234208|NCT06547944|DRUG|Obinutuzumab|1000 mg C1, d1/d8/15; 1000 mg C2-6, d1
223766710|NCT02895399|OTHER|Cervico-Vaginal Smears analysis|Cervico-Vaginal Smears analysis
224234209|NCT01839591|DEVICE|catheter ALAIR|Catheter ALAIR Radiofrequency 65°
224320292|NCT06124417|DRUG|Sertraline|The initial dose ranged from 25 to 50 mg, taken orally once daily, and the dosage was adjusted based on the patient's response to the medication.
224234210|NCT00074906|DRUG|Venticute|Patients With Pneumonia or Aspiration of Gastric Contents and Intubation/Ventilation/Oxygenation Impairment
224234211|NCT04944537|OTHER|No Intervention|No Intervention
224234212|NCT06114251|DIAGNOSTIC_TEST|Diagnosis of postoperative recurrence of liver cancer|HBV serological markers, such as hepatitis B surface antigen (HBsAg), hepatitis B e antigen (HBeAg) and HBV DNA were monitored regularly. The alpha-fetoprotein (AFP) level was determined every 1-2 months. The ultrasound or computed tomography or magnetic resonance imaging was performed every 3-6 months in HCC patients who underwent liver transplantation.
224234213|NCT06282705|BEHAVIORAL|Diagonal Drop Jumps 0cm|Participants will complete 4 unsupervised home drop jump sessions per week ( minimum 24 hours between each session) for the duration of the study (e.g., Mon, Wed, Fri, Sun) from a height of 0 cm (floor). They will perform 20 diagonal drop jumps on each side (20 x dropping left and 20 x dropping right) with 30 seconds between each jump. The routine will be demonstrated in full on the first laboratory session. The intervention will last 16 weeks.
224234214|NCT06282705|BEHAVIORAL|Diagonal Drop Jumps 40cm|Participants will complete 4 unsupervised home drop jump sessions per week ( minimum 24 hours between each session) for the duration of the study (e.g., Mon, Wed, Fri, Sun) from a height of 40 cm (plyo box). They will perform 20 diagonal drop jumps on each side (20 x dropping left and 20 x dropping right) with 30 seconds between each jump. The routine will be demonstrated in full on the first laboratory session. The intervention will last 16 weeks.
224234215|NCT06282705|BEHAVIORAL|Diagonal Drop Jumps 60cm|Participants will complete 4 unsupervised home drop jump sessions per week ( minimum 24 hours between each session) for the duration of the study (e.g., Mon, Wed, Fri, Sun) from a height of 60 cm (plyo box). They will perform 20 diagonal drop jumps on each side (20 x dropping left and 20 x dropping right) with 30 seconds between each jump. The routine will be demonstrated in full on the first laboratory session. The intervention will last 16 weeks.
224234216|NCT05283005|PROCEDURE|Grafting of the alveolar cleft|alveolar cleft grafting using either the conventional technique or the double cortex technique
224234217|NCT03648944|OTHER|Accelerated Rehabillitation|
224234218|NCT03648944|OTHER|Non-Accelerated Rehabillitation|
224234219|NCT00981357|DRUG|PF-04457845|PF-04457845 4 mg tablet once daily / matched placebo
224234220|NCT00981357|DRUG|PF-04457845|PF-04457845 4 mg tablet once daily / matched placebo
224234221|NCT00981357|DRUG|Naproxen|Naproxen 500 mg tablet twice daily / matched placebo
224234222|NCT00981357|DRUG|Naproxen|Naproxen 500 mg tablet twice daily / matched placebo
224234223|NCT00448578|DRUG|Quetiapine Fumarate|
224320293|NCT04742374|BIOLOGICAL|Blood sampling|Blood sampling before and after each type of cycle, Single Plasma Exchange or Double Filtration Plasmapheresis
224320294|NCT03806010|PROCEDURE|Quantitative sensory testing|Quantitative sensory testing
224320295|NCT05044195|BIOLOGICAL|aQIV|Participants receive a 0.5-mL intramuscular dose of aQIV on Day 1
223649129|NCT05246358|DEVICE|ChoniSense Polso|"A range of stable respiratory rates was elicited from each volunteer test subject. The rates were 5, 10, 15, 20, 25, 30, 35, 40 and 45 breaths per minute; with some natural variation from these exact numbers.~Each subject was instrumented with an open system mask that allows for measurement of the end tidal carbon dioxide (EtCO2) respiratory rate and tidal volume. The EtCO2 monitor was used as the Accuracy Reference Device (Reference) in this study."
223649130|NCT01857817|DRUG|VT-122|The following will be used in the study for VT-122: propranolol 22 mg immediate-release capsules and etodolac 340 mg capsules.
223649131|NCT01857817|DRUG|Placebo|The placebo capsules will be prepared to match the active drug.
223649132|NCT02427308|DRUG|Miltefosine|target dose = 2.5 mg/kg/day for 28 days
223649133|NCT06283667|DRUG|Semaglutide|Paricipants will be treated with commercially available Wegovy® according to routine clinical practice at the discretion of the treating physician, following approved label in Japan. The decision to initiate treatment with commercially available Wegovy® has been made by the patient and the treating physician before and independently from the decision to participate in this study.
223766711|NCT00816868|DRUG|erlotinib in combination with capecitabine|Erlotinib 150 mg Q.D. orally for 21 days plus Capecitabine 1000 mg/m2 twice daily for 2 weeks followed by 1 week break every 21 days Until PD, unacceptable toxicity or death.
223766712|NCT02967367|DEVICE|Jawbone sleep tracker|During one night of polysomnographic recording, investigators are going to place these 3 accelerometers on the wrist of the patient
223766713|NCT02967367|DEVICE|Withings sleep tracker|During one night of polysomnographic recording, investigators are going to place these 3 accelerometers on the wrist of the patient
224234224|NCT00448578|DRUG|Lithium|
224234225|NCT01415778|DRUG|ICI176,334-1|Subject will receive single dose of ICI176,334-1
224234226|NCT01415778|DRUG|Casodex 80 mg tablet|Subject will receive single dose of Casodex 80 mg tablet
224234227|NCT03734497|OTHER|"Group Carotis FTc 500 ml Ringer's lactate Lafleks®"|"will receive 500 ml Ringer's lactate Lafleks® if the patient is fluid responder"
224234228|NCT03734497|OTHER|"Group Preloading 10 ml/kg Ringer's lactate Lafleks®"|"will receive 10 ml/kg Ringer's lactate Lafleks® fluid preloading"
224234229|NCT03734497|OTHER|"Group Control 2 ml/kg Ringer's lactate Lafleks®"|"will receive 2 ml/kg Ringer's lactate Lafleks® during anesthesia"
224234230|NCT02253797|DRUG|14C-Tipranavir|
224234231|NCT02253797|DRUG|Tipranavir|
224234232|NCT02253797|DRUG|Ritonavir|
224234233|NCT01743157|DRUG|Biochemo + bevacizumab then ipilimumab|Bevacizumab 7.5mg/kg week 1,repeat weeks 4,7,10 (cycles 2, 3, \& 4)
224234234|NCT01184196|DRUG|Swab area with Betadine|A swab will be taken over the operative knee before surgical site preparation is started, after preparation has taken place, and 24 hours post-surgery.
224234235|NCT01184196|DRUG|Swab area with ChloraPrep|A swab will be taken over the operative knee before surgical site preparation is started, after preparation has taken place, and 24 hours post-surgery.
224234236|NCT00814463|BEHAVIORAL|MMSE|Neurocognitive function via MMSE done every 3 months for length of study.
224234237|NCT00814463|BEHAVIORAL|QOL via FACT-Br|Quality of Life via FACT-BR every 3 months for length of study.
223649134|NCT04149756|OTHER|observation of weight after 6months|"This study is an observational study for 96 people who have completed the previous weight loss program.~We will check the body composition and lipid profile of the participants who voluntarily visit after 6months after the end of the study. ."
223649135|NCT06003686|BEHAVIORAL|PVA Consumer Guide|"Subject's will receive education on the PVA consumer guide 3 times over the course of the study.~Each session will be approximately 10-15 minutes and will consist of a general review of the nutrition, exercise, and general healthy living guidelines content included."
223649136|NCT06003686|BEHAVIORAL|WebMD|Subject's will receive education on how to navigate the WebMD site and find information on health, exercise and nutrition 3 times over the course of the study. Each session will be approximately 10-15 minutes and will consist of a general review of the health and wellness content available on the website. At study completion, subjects in this group will be provided with the PVA guide and a brief orientation of the nutrition, exercise, and general healthy living guidelines content included in the guide.
223649137|NCT03520855|OTHER|Serious game|DIVE software will be accessible via internet, children and parents will have to their disposition a room at the hospital specifically to work on the software. The DIVE software is organized in chapters, each matches an item of the therapeutic education process and ends with a knowledge assessment. The child has to end every chapter and succeed every evaluation to pursue on the next chapter. Measures will be taken in order to avoid contamination bias between groups. Children will have to connect to DIVE 2 times per week for a time duration of at last 1 hour.
223649138|NCT03520855|BEHAVIORAL|ETP|"Initial therapeutic education only will be applied in this group, with the help of doctors and nurses, based on theoretical educational lessons, reported on the AJD book.~Health education sessions will also be taught by nurses."
223649139|NCT05393102|OTHER|No interventions|No interventions
223649140|NCT06047015|COMBINATION_PRODUCT|IRE plus checkpoint inhibitor|Nivolumab: Patients will receive 240 mg nivolumab (dissolved in 250 mL NaCl 0.9%) administered intravenously over 30 minutes. The first dose will take place one or two days before the IRE treatment. The second and third doses will be given 2 and 4 weeks post-IRE. Bloodwork will be done just prior to each treatment.
224234238|NCT00814463|PROCEDURE|MRI|MRI done every 3 months for the length of the study.
224234239|NCT00814463|RADIATION|Post-operative SRS|Single fraction SRS is currently a viable treatment option of intracranial metastatic lesions.
224234240|NCT02665143|DRUG|Nintedanib and AML induction|The AML induction regimen combines Idarubicin 12mg/m2/d day 1 to 3 and Cytarabine 0.667g/m2/d CIV day 1 to 3. In the phase I part, all patients will receive the combination with Nintedanib 200mg bid begun at day 8 and continued until end of cycle. If a significant incidence of dose limiting toxicities is demonstrated, Nintedanib will be given at a lower dose level (150mg bid).
224234241|NCT05754008|BEHAVIORAL|AURORA Care Strategy|Participants will be invited to partake in three telemedicine visits with the care navigator during the months following diagnosis. The visits center around proactive and tailored T2D self-management support.
224234242|NCT03973983|PROCEDURE|Ultrasound-guided transgluteal pudendal nerve injection (TG-PNI)|Ultrasound-guided transgluteal pudendal nerve local anesthetic injections
224234243|NCT03973983|PROCEDURE|Finger-guided transvaginal pudendal nerve injection (TV-PNI)|Finger-guided transvaginal pudendal nerve local anesthetic injections
224234244|NCT04945876|BEHAVIORAL|Digital follow-up|"Participants will receive:~One session of individual exercise and diet guidance focusing on goals and motivation.~An activity tracker and instructions on how to use it both for motivation, daily activity tracking, logging of specific exercise and using the wristbands heart rate monitor to control intensity level during exercise.~Monthly digital follow-up to provide support and address questions and goals regarding nutrition, daily energy expenditure and exercise.~Opportunity to send sms with questions regarding nutrition and exercise. Participants who are malnourished, or at risk of malnutrition will be offered a total of two hours of additional individualized, digital guidance on nutrition as needed."
224234245|NCT01041781|DRUG|carboplatin|Given IV
224234246|NCT01041781|DRUG|celecoxib|Given orally
224234247|NCT01041781|DRUG|gemcitabine hydrochloride|Given IV
223649141|NCT06047015|COMBINATION_PRODUCT|IRE plus Checkpoint Inhibitor plus CpG-ODN|"Patients will receive 240 mg nivolumab as above and also receive 8 mg of CpG-ODN dissolved in 1 mL normal saline administered peritumorally just before the IRE treatment. Three or four electrodes will be placed using a combination of ultrasound and CT guidance in preparation for treatment. Then using the electrodes as landmarks, injection of ¼ or 1/3 cc of the CpG solution will be performed near each of the 3 or 4 electrodes to achieve a peritumoral administration of the drug.~IRE is performed in the CT scanner. Patients will receive a general anesthetic and an ultrasound will be performed to locate the designated metastasis. Ultrasound-guided electrode placement (3 or 4 depending on cancer size, shape, and location) will be performed by interventional radiologist Dr. Chris Wall and the IRE device will be activated and used as per the technique of Martin et al."
223649142|NCT05097963|DEVICE|Endoscopic Ultrasound Shear Wave Elastography|Software to determine stiffness of liver for evaluating liver fibrosis.
223649143|NCT00214890|DRUG|Tenofovir|300 mg once daily
223649144|NCT00214890|DRUG|Abacavir|600 mg once daily
223649145|NCT01450332|DEVICE|Knee-T-Nol|The ACL prosthesis is intended for the treatment of ruptured ACL. It will be used as an implant to replace the native, torn ACL. Implantation will be done using arthroscopy
223649146|NCT02584010|OTHER|Silicon-based aerosol|Apply twice a day over the postoperative scar
223649147|NCT02584010|OTHER|Silicon-based gel|Apply twice a day over the postoperative scar
223649148|NCT03888417|DEVICE|Therapeutic plasma exchange (TPE)|All TPEs were performed by the centrifugation technique using the Fresenius Kabi COMTEC machine
223766714|NCT02967367|DEVICE|BodyMedia Sense Wear accelerometer|During one night of polysomnographic recording, investigators are going to place these 3 accelerometers on the wrist of the patient
223766715|NCT01607983|DRUG|inhaled nitric oxide|20 parts per million (ppm) of inhaled nitric oxide
224234248|NCT01041781|DRUG|pemetrexed disodium|Given IV
224234249|NCT01041781|OTHER|placebo|Given orally
224234250|NCT05237596|DRUG|Glucosamine Sulfate|Treatment for at least 6 months with prescription-grade crystalline Glucosamine Sulfate in addition to conventional treatment
224234251|NCT01265784|DRUG|TP-434|
224234252|NCT01265784|DRUG|Ertapenem|
224234253|NCT01265784|DRUG|Placebo|Administered IV to maintain the blind.
223649149|NCT04160754|BEHAVIORAL|Mindfulness Based Relapse Prevention|"Individuals assigned to the experimental group will receive interventions normally provided at the clinic and eight 1.5-hour group sessions of MBRP. Each sessions will occur once per week and will target a specific theme such as being aware of personal triggers, maintaining present focus, allowing or letting things be, responding to emotional and physical experiences in skillful ways, and recognizing intrusive thoughts. Each session will incorporate a mindfulness meditation technique (e.g.,SOBER breathing space and urge surfing). Participants will receive materials (e.g., recordings) with which to perform practices and meditation during the intervention phase."
224234254|NCT02532010|DRUG|Pacritinib|Pacritinib is a novel Janus kinase 2-fms-like receptor tyrosine kinase 3 (JAK2-FLT3) inhibitor that has shown promising antitumor activity. Pacritinib is a potent inhibitor of JAK2 and FLT3 kinase activities (50% inhibitory concentration (IC50) = 23 nanomolar (nM)and 22 nM, respectively). The drug also inhibits cellular proliferation in human leukemia and lymphoma cell lines selected for their dependence on either of the target kinases. Consistent with these activities, exposure to pacritinib resulted in the reduction of phos-JAK2, phos-STAT3 or phos-STAT5 in the relevant cell lines. Unlike some JAK2 inhibitors, pacritinib does not inhibit Janus kinase 1 (JAK1).
223649150|NCT04160754|BEHAVIORAL|Control (CTL)|Individuals assigned to the CTL group will receive interventions provided at the clinic and up to eight CTL sessions. The CTL group will receive information (reading) and videos once per week on health behaviors (e.g., exercise, eating) and the neurobiology of addiction. This approach will reduce the possibility that intervention effects are solely due to the experimental group's receiving extra attention. In contrast to the active intervention, sessions will be educational in nature, with no motivational, cognitive, or behavioral components
223649151|NCT02225002|DRUG|CP-870,893|
224234255|NCT02532010|DRUG|Decitabine|Commercial drug: For each cycle Decitabine 20mg/m2 intravenous daily for 10 days combined with ongoing pacritinib 200 mg twice daily.
224234256|NCT02532010|DRUG|Cytarabine|Commercial drug: For each cycle Cytarabine 20mg subcutaneous twice daily for 10 days combined with ongoing pacritinib 200mg twice daily.
224234257|NCT03644095|DRUG|Mucinex® SE|Single dose of Mucinex® SE extended-release 600 mg bi-layer tablet
224234258|NCT03644095|DRUG|Vicks Cough Syrup for Chesty Coughs|Vicks Cough Syrup for Chesty Coughs 15 mL (200 mg guaifenesin q4h) immediate release (IR) syrup
224234259|NCT00439764|BEHAVIORAL|General health talk|Routine clinical practice and talk on general health
224320296|NCT05044195|BIOLOGICAL|Comparator QIV|Participants receive a 0.5-mL intramuscular dose of Comparator QIV on Day 1
224320297|NCT04134195|DEVICE|Transcranial direct current stimulation|2mA stimulation for 20 minutes
223649152|NCT02873702|DRUG|Dexlansoprazole|Dexlansoprazole delayed-release capsules.
223649153|NCT02873702|DRUG|Lansoprazole|Lansoprazole capsules.
223649154|NCT02873702|DRUG|Placebo|Dexlansoprazole placebo-matching capsules.
223649155|NCT03164239|BEHAVIORAL|Intervention group - telephone and print exercise intervention|Intervention has previously been described.
223649156|NCT03269396|PROCEDURE|Larynx Allograft Transplantation|This study is a prospective clinical trial designed to assess the efficacy and safety of laryngeal transplantation. A total of 10 patients will be enrolled over a five-year timeframe. Study length is 5 years.
223649157|NCT01180582|DEVICE|Triathlon Periapatite (PA)-coated Tibial Component|Triathlon Periapatite (PA)-coated Total Knee Arthroplasty Tibial Component for uncemented fixation
223649158|NCT00583895|DRUG|10% ImCOOH cream|Twenty patients will receive a hydrophilic cream containing 10% ImCOOH and a placebo cream randomized over both limbs twice daily for 14 days with an additional morning application on Day 15.
223649159|NCT00583895|DRUG|Placebo|Five patients will receive placebo cream on both limbs twice daily for 14 days with an additional morning application on Day 15.
223649160|NCT04530383|DRUG|Metformin Hydrochloride|500-1000 mg twice daily
223649161|NCT00426413|DRUG|pioglitazone|Obese AA subjects with DKA or severe hyperglycemia that are able to discontinue insulin at 12 weeks or less will be randomized (blinded fashion) to receive either placebo or pioglitazone qd. The subjects will be followed while in the study arm and beta-cell function will be assessed using OGTT at set intervals.
223649162|NCT06385626|DIETARY_SUPPLEMENT|Raspberry leaf tea|10 g of raspberry leaf tea
223649163|NCT03638765|BIOLOGICAL|DCVax-Direct|activated, autologous dendritic cells
223649164|NCT04633005|DRUG|Polypill|Polypill formulation consisting of metoprolol succinate, empagliflozin, and spironolactone.
223649165|NCT04633005|DRUG|Control Rx|Typical prescriptions of guideline-directed therapies for heart failure with reduced ejection fraction.
223649166|NCT04110288|DRUG|Paclitaxel|Paclitaxel to treat peripheral arterial disease
223649167|NCT04110288|DEVICE|Non-drug coated Device Treatment|
223649168|NCT03249116|OTHER|animal-assisted intervention|Interaction with a therapy dog
223649169|NCT03249116|OTHER|active control|Interaction with a stuffed dog
223649170|NCT02948634|DEVICE|Sham Phoenix Laser Treatment|Sham treatment will be delivered via the same protocol in terms of time, application, and areas of treatment as stated above, except the laser unit will not discharge any photonic energy. Intervention will take place in the therapy room at the McDermott Center for Pain Management, which is appropriately equipped for laser administration. Application of therapeutic laser will be completed by licensed physical therapists who have completed safety training for therapeutic laser application including appropriate use of safety eyewear, room access, laser signage for laser use, and patient monitoring.
223649171|NCT02948634|DEVICE|Active Phoenix Laser Treatment|The 30 min treatments will include multiple 60 sec applications to all tender points on the spine or extremities and a 10 minute application along the bilateral sympathetic ganglion in the paraspinous region. The treatment will be applied via a non-contact method, with the laser applicator held 12-18 inches above the participant's skin.
223649172|NCT03762317|DRUG|Clonidine|clonidine will be given at 12 mcg/kg/d to the experimental arm in addition to oral morphine
223649173|NCT03762317|DRUG|Placebo|Placebo with volume similar to clonidine at 12 mcg/kg/d will be given to this arm in addition to oral morphine
223649174|NCT00766662|DRUG|Sulfadoxine pyrimethamine|
223649175|NCT00713167|DRUG|Grape Seed Extract (Vitagrape)|"Drug {Each Containing: Grape Seed Extract100 mg +...}~1 capsule twice daily for 2 months"
223766716|NCT05545670|DRUG|Placebo|not containing drugs
223766717|NCT05545670|DRUG|Allopurinol 300 MG|a competitive xanthine oxidase inhibitor, reduces oxidative stress and attenuates bacterial translocation
223766718|NCT00616850|PROCEDURE|Continuous femoral catheter block|A constant infusion of ropivacaine 0.2% without epinephrine will be given to each subject via continuous femoral catheter in Group A.
224234260|NCT00439764|BEHAVIORAL|Handout of The Back Book|Talk on health of the back and handout of The Back Book
224234261|NCT00439764|BEHAVIORAL|Back exercise|Routine clinical practice, talk on back health, handout of The Back Book and back exercise
224234262|NCT03846713|PROCEDURE|non-thermosoftening|By using airway exchange catheter, tube exchange is performed from single to double lumen tube that was put into normal saline at room temperature.
224234263|NCT03846713|PROCEDURE|thermosoftening|By using airway exchange catheter, tube exchange is performed from single to double lumen tube that was put into warm normal saline (40°C).
224234264|NCT03640156|DRUG|Oxytocin|A single dose (24IU) of nasal spray (3 puffs of 4IU per nostril) will be administered before the assessment of the neurophysiological measures.
224234265|NCT03640156|OTHER|Placebo|A single dose (24IU) of nasal spray (3 puffs of 4IU per nostril) will be administered before the assessment of the neurophysiological measures.
224234266|NCT02398877|OTHER|stress|
224234267|NCT05694091|OTHER|Collecting clinical data, blood gas data, Magnetic Resonance Spectroscopy (MRS) data and blood,urine, and feces sample|Collecting clinical data(before induction of anesthesia and first day after surgery), blood gas data(before induction of anesthesia and first day after surgery) ，MRS data (not more than 24h after surgery）and blood,urine, and feces sample （before induction of anesthesia and first day, third day and 7th day after surgery）
224234268|NCT01065103|PROCEDURE|FFR (Fractional Flow Reserve)|Single FFR measurement in non-culprit vessel
224234269|NCT00984295|BIOLOGICAL|Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live|A single 0.5 mL subcutaneous injection at Day 0
224234270|NCT00984295|BIOLOGICAL|Comparator: Tripedia|A single 0.5 mL intramuscular injection (at Day 0 or Day 42)
224234271|NCT00984295|BIOLOGICAL|Comparator: Comvax|A single 0.5 mL intramuscular injection (at Day 0 or Day 42)
224234272|NCT00984295|BIOLOGICAL|Comparator: Varivax|A single 0.5 mL subcutaneous injection at Day 0
224234273|NCT00984295|BIOLOGICAL|Comparator: M-M-R II|A single 0.5 mL subcutaneous injection at Day 0
224234274|NCT01147952|BEHAVIORAL|Structured exercise training|randomised to 12 weeks of exercise training up to three times weekly. Training will be interval training with active recovery, with 3 min intervals conducted 10bpm below angina threshold.
224234275|NCT04332302|OTHER|Power resistance training|Participants will take part in an intervention of 12 weeks duration in which they will train with musculation machines.
224234276|NCT06495814|DRUG|1/bag of Jinlida granules, 3 times/day, taken with hot water.|All observation and intervention groups received lifestyle interventions, with only the intervention group of high-risk obese impaired glucose tolerance receiving intervention with Jinlida granules.
224234277|NCT04799158|DRUG|Vonoprazan|Orally via capsules
223649176|NCT00713167|DRUG|Placebo of Grape Seed Extract|"Placebo {Each Containing: Gelatin 17mg + Cellulose Microcrystalline (Avicel) 67 mg + Dicalcium Phosphate 216mg}~1 capsule twice daily for 2 months"
223649177|NCT00221117|DEVICE|Neuroprosthesis-FES Therapy|The Compex Motion neuroprostesis, developed by Drs. R. Popovic and Thierry Keller,and company Compex SA, ia a flexible device designed to improve grasping function in both SCI and stroke patients.This multi-channel surface stimulation system for grasping provides both palmar and lateral grasp , and holds a number of advantages over the other existing neuroprostheses.
223649178|NCT00221117|OTHER|Conventional Ocupational Therapy (COT)|Conventional occupational therapy pertaining to hand function represents control activities against which the FES therapy was assessed. The conventional occupational therapy included: a) muscle facilitation exercises emphasizing the neurodevelopmental treatment approach; b) task-specific, repetitive functional training; c) strengthening and motor control training using resistance to available arm motion to increase strength; d) stretching exercises; e) electrical stimulation applied primarily for muscle strengthening (this is not FES but TENS application); f) activities of daily living including self-care where the upper limb was used as an assist if appropriate; and g) caregiver training.
223649179|NCT04299789|OTHER|Validating the Military Service Identification Tool|This study seeks to validate the Military Service Identification Tool in its ability to accurately determine military service status.
223649180|NCT02956200|DRUG|Fingolimod|Patients randomized to fingolimod will also receive oral fingolimod (Gilenya, Novartis) at a dosage of 0.5 mg once daily, for three consecutive days, with the first dose being given at the time in which patients are enrolled which is about one hour prior to mechanical thrombectomy.
223649181|NCT02787629|PROCEDURE|Simultaneous Intubation|Intubation with GlideScope and ETT inserted simultaneously
223649182|NCT02787629|PROCEDURE|Standard Intubation|Intubation with GlideScope inserted first and ETT insertion after the GlideScope view is obtained
223649183|NCT04520646|DRUG|Empagliflozin|empagliflozin of 10mg/day is added on the basis of primary care
223649184|NCT05069272|OTHER|Bakuchiol and Ethyl Linoleate|A synergistic combination of Bakuchiol and Ethyl Linoleate
223649185|NCT05069272|OTHER|Vehicle|No actives
223649186|NCT03830892|OTHER|E-cigarette Lab Session 15 watts, 10 mg nicotine|E-cigarette paired with low nicotine, low device power
223649187|NCT03830892|OTHER|E-cigarette Lab Session 15 watts, 30 mg nicotine|E-cigarette paired with low nicotine, low device power
223649188|NCT03830892|OTHER|E-cigarette Lab Session 30 watts, 10 mg nicotine|E-cigarette paired with low nicotine, low device power
223766719|NCT00616850|DRUG|Lidocaine|Lidocaine 1.33mg/kg/hr continuous IV infusion following induction of general anesthesia to 24 hours postoperatively.
224234278|NCT04799158|DRUG|Placebo|Orally via capsules
224234279|NCT06441071|PROCEDURE|position|Patients undergoing Video-assisted Thoracoscopic Surgery were selected for the study, and nerve block was performed before surgery, followed by holding different positions for 30 min, after which the effect of the block was measured.
224234280|NCT06207409|BEHAVIORAL|PARTS-SUD|The Program for Alleviating and Reducing Trauma, Stress and Substance Use (PARTS-SUD) is a 12-week, Internal Family Systems-based, group intervention with 6 individual clinical sessions on a biweekly basis.
224234281|NCT04137679|RADIATION|Definitive Radiochemotherapy|Radiotherapy,IMRT, 60Gy; Chemotherapy, Docetaxel （25mg/m2）+Cisplatin (25mg/m2) 1st/8th/15th/22nd day
223766720|NCT00616850|OTHER|Preservative free normal saline|Preservative free normal saline 1.33mg/kg/hr continuous IV infusion following induction of general anesthesia to 24 hours postoperatively.
223766721|NCT02456324|DEVICE|PICS-AF Device|This is a specialized closure system for anorectal fistulas that is sphincter sparing
223766722|NCT02456324|DEVICE|Historical Controls Treated with Commercially Available Fistula Plugs|These are patients previously treated with commercially available fistula plugs.
223766723|NCT05441735|COMBINATION_PRODUCT|APP|APP as an instructional tool for visiting health education
223766724|NCT04004728|PROCEDURE|1064 Nd:YAG laser|1064 laser - 135J 25ms spot 3mm GLicose - 75% - 3 ml
223766725|NCT01955070|OTHER|Multimedia Presentation for Ketamine sedation|PowerPoint presentation created with approval of section of emergency medicine for informed consent for ketamine sedation
223766726|NCT04203550|PROCEDURE|Intraoperative irrigation|Operation with irrigation
223766727|NCT04203550|PROCEDURE|No irrigation|Operation without irrigation
223766728|NCT04590495|DRUG|300 mg Cannabidiol (CBD) oil|Participant will either be given a 300mg dosage of CBD oil. After consumption of the study drug, the participant will wait for 120 minutes to allow for digestion and for CBD to begin taking effect. Next, individuals will undergo a driving simulation and all participants will drive the same course. The simulator presents the individual with real life driving scenarios and is equipped with screens, a steering wheel, signals, and pedals. The participant will be instructed to drive the course for 25-35 minutes. They will be instructed to follow normal driving rules. The simulation will include highway, suburban, rural, and urban driving scenarios which will incorporate turns, changes in speed, and avoidance of cars/pedestrians.
223766729|NCT04590495|DRUG|Placebo|Participant will either be given a placebo . After consumption of the study drug, the participant will wait for 120 minutes to allow for digestion and for CBD to begin taking effect. Next, individuals will undergo a driving simulation and all participants will drive the same course. The simulator presents the individual with real life driving scenarios and is equipped with screens, a steering wheel, signals, and pedals. The participant will be instructed to drive the course for 25-35 minutes. They will be instructed to follow normal driving rules. The simulation will include highway, suburban, rural, and urban driving scenarios which will incorporate turns, changes in speed, and avoidance of cars/pedestrians.
223766730|NCT04670991|RADIATION|EXATRAC imaging|Exatrac imaging performed before the standard CBCT imaging prior to each chemotherapy session
223766731|NCT04295603|OTHER|Toucher Massage (TM) on the feet|The intervention for the Experimental Group (EG) includes a massage time of about 15 minutes (according to current Geneva Hospital practice) on the foot area. At least four sessions will be delivered and spread over two weeks. The TM will be provided by the care team. The training time for the workers corresponds to 2 times 2 hours. In order to be as close as possible to a standardized session, practitioners will benefit from an intervention guide.
223766732|NCT04295603|OTHER|Homedics HM MP RELEX 90 device|"The Control Group (CG) will benefit from an intervention of identical duration. The treatment consists of a foot massage with a Homedics HM MP RELEX 90 device, a heat-free shiatsu program, which lasts about 15 minutes. The use of the Homedics device is no more a common treatment than the practice of Touch-Massage. TM involves a therapeutic relationship between caregiver and patient. It is for this reason that we need a comparator that should allow us to keep the aspect of the massage while decreasing the aspect of the therapeutic relationship and therefore offer us an adequate comparator."
223766733|NCT03431350|DRUG|Niraparib 200 mg|Participants will receive niraparib 200 mg orally.
223766734|NCT03431350|DRUG|Cetrelimab 240 mg|Participants will receive cetrelimab 240 mg IV every 2 weeks.
223766735|NCT03431350|DRUG|Cetrelimab 480 mg|Participants will receive cetrelimab 480 mg IV every 4 weeks.
223649189|NCT03830892|OTHER|E-cigarette Lab Session 30 watts, 30 mg nicotine|E-cigarette paired with low nicotine, low device power
223766736|NCT03431350|DRUG|Abiraterone acetate 1000 mg|Participants will receive AA 1000 mg orally.
223649190|NCT03830892|OTHER|Own Brand Session - E-cigarette|E-cigarette paired with own brand liquid and preferred power
223649191|NCT03830892|OTHER|Own Brand Session - E-cigarette/Cigarette|Own brand cigarette OR E-cigarette paired with own brand liquid and preferred power
223649192|NCT03752437|DIAGNOSTIC_TEST|ACT (Activated Clotting Time)|Measure of ACT in the two arms in order to determine if injection of heparin based on ideal weight is better or not than those one on real weight.
223649193|NCT03752437|DRUG|Heparin|300 IU of heparin
223649194|NCT02295670|DEVICE|Vividtrac|video-laryngoscopy
223649195|NCT02295670|DEVICE|MIL|direct-laryngoscopy
223649196|NCT01851759|DRUG|cinepazide|"2 branches of Methanesulfonic acid cinepazide injection were matched into 250 ml 0.9% sodium chloride injection, iv gtt, speed is 100ml/h, once per day.~1 branch of simulation agent of Methanesulfonic acid cinepazide injection was matched into 250 ml 0.9% sodium chloride injection, iv gtt, speed is 100ml/h, once per day."
223649197|NCT01851759|DRUG|placebo|"2 branches of simulation agent of Methanesulfonic acid cinepazide injection were matched into 250 ml 0.9% sodium chloride injection, iv gtt, speed is 100ml/h, once per day.~1 branch of simulation agent of Methanesulfonic acid cinepazide injection were matched into 250 ml 0.9% sodium chloride injection, iv gtt, speed is 100ml/h, once per day."
223649198|NCT04541459|DEVICE|new device against ambient electromagnetic radiation|New device provides protection against the radiations emitted by the smartphone and laptop devices. Device uses conductive fluids in a particular geometric arrangement intended to ameliorate the negative effects of EMW radiation.
223649199|NCT04541459|DEVICE|sham device against ambient electromagnetic radiation|Sham device as as a control for new device, which provides protection against the radiations emitted by the smartphone and laptop devices. Device uses conductive fluids in a particular geometric arrangement intended to ameliorate the negative effects of EMW radiation.
223649200|NCT04518189|DRUG|lidocaine patch|lidocaine patch applied 3 hours before the procedure
223649201|NCT04518189|DRUG|Sham patch|Sham patch applied 3 hours before the procedure
223649202|NCT04633044|DIETARY_SUPPLEMENT|Betaine|The intervention with supplement will start during the first 48h after birth and will last for 12 weeks
223649203|NCT04633044|DIETARY_SUPPLEMENT|Placebo|The intervention with supplement will start during the first 48h after birth and will last for 12 weeks
223649204|NCT04911543|DRUG|[18F]-JNJ-70099731|\[18F\]JNJ-70099731 injection will be administered intravenously.
223649205|NCT03255174|BIOLOGICAL|EVARREST® Fibrin Sealant Patch|EVARREST Fibrin Sealant Patch is a sterile, bio-absorbable combination product consisting of two constituent parts- a flexible matrix and a coating of biological components (human plasma-derived fibrinogen and thrombin) embedded in a flexible composite patch component.
223649206|NCT05267132|BEHAVIORAL|Other-Focused Acts of Kindness Intervention with Reflection|Participants engage in positive behaviors by completing acts of kindness for others three times per week. These acts should require effort and be outside of an individual's normal routine. Participants will then reflect on their kind acts after each week.
224234282|NCT04137679|PROCEDURE|Neoadjuvant Radiochemotherapy followed by surgery|Concurrent Radiochemotherapy: Radiotherapy,IMRT, 40Gy; Chemotherapy, Docetaxel （25mg/m2）+Cisplatin (25mg/m2) 1st/8th/15th/22nd day; Receive radical surgery 4 to 6 weeks later.
224234283|NCT06544993|DRUG|Meso-botox|Micro-Botox, is a highly diluted Botulinum toxin type A
224234284|NCT04928651|DRUG|Clonidine|"Clonidine will be administered to preterm infants in need of analgesia and sedation; either as the primary drug for comfort and light sedation or as an add-on drug to opioids according to an algorithm based on pain and sedative scoring results. Opioids are mostly given to postoperative patients. These drugs (morphine or fentanyl) will not be studied, but a baseline PK sample will be taken to correlate to the baseline aEEG."
224234285|NCT01698996|PROCEDURE|Packing vs No Packing|
224234286|NCT00809042|DRUG|hydroxyurea|Hydroxyurea (500 mg capsules) was administered in a single dose at a mean of 10/mg/kg/day (range8-12mg/kg/day).
223649207|NCT05267132|BEHAVIORAL|Other-Focused Acts of Kindness Intervention|Participants engage in positive behaviors by completing acts of kindness for others three times per week. These acts should require effort and be outside of an individual's normal routine.
223649208|NCT05267132|BEHAVIORAL|Daily Reports|Participants will report their daily activities three times per week. Aside from reporting at the end of the day, no changes should be made to the individual's normal routine.
223649209|NCT04954833|DEVICE|EMO-200|TEST Lens
223649210|NCT04954833|DEVICE|EMO-118|CONTROL Lens
223649211|NCT04023019|BIOLOGICAL|Nuwiq|Nuwiq is a recombinant FVIII concentrate from a human cell line. It is administered via intravenous injection at a dosage determined by the investigator's discretion, in consideration of the participants' clinical condition and prescribing information.
223649212|NCT04023019|BIOLOGICAL|Octanate|Octanate is a high-purity human Factor VIII / von Willebrand Factor (VWF) concentrate. It is administered via intravenous injection at a dosage determined by the investigator's discretion, in consideration of the participants' clinical condition and prescribing information.
223649213|NCT04023019|BIOLOGICAL|Wilate|Wilate is a high-purity human von Willebrand Factor (VWF)/Factor VIII concentrate. It is administered via intravenous injection at a dosage determined by the investigator's discretion, in consideration of the participants' clinical condition and prescribing information.
223649214|NCT04023019|BIOLOGICAL|Emicizumab|Emicizumab is a therapeutic antibody which brings activated factor IX and factor X together It is administered via subcutaneous injection at a dosage determined by the investigator's discretion, in consideration of the participants' clinical condition and prescribing information.
223649215|NCT04023019|BIOLOGICAL|Recombinant factor VIIa (rFVIIa)|Recombinant factor VIIa (rFVIIa) is a blood factor VII manufactured using recombinant technology. It is administered via intravenous injection at a dosage determined by the investigator's discretion, in consideration of the participants' clinical condition and prescribing information.
223649216|NCT04023019|BIOLOGICAL|Activated prothrombin complex concentrate (aPCC)|Activated prothrombin complex concentrate (aPCC) is an anti-inhibitor coagulant complex acting on multiple pathways to facilitate coagulation. It is administered via intravenous injection at a dosage determined by the investigator's discretion, in consideration of the participants' clinical condition and prescribing information.
223649217|NCT04339036|DRUG|Capecitabine Oral Product|Capecitabine 750 mg/m2 twice daily orally for 14 days
223649218|NCT04339036|DRUG|Temozolomide Oral Product|temozolomide 200 mg/m2 orally on Days 10-14, with 14 days between cycles
223649219|NCT04339036|COMBINATION_PRODUCT|transarterial radioembolization|Trans-arterial radioembolization (TARE) on Day 7 of cycle 2 and, if needed for the other lobe, Day 7 of either cycle 3 or 4.
223649220|NCT01854450|OTHER|Asymmetrical Lateral Decubitus|"After randomization, women are postured in pronounced lateral decubitus (side opposite to the back of the fetus), with the inferior leg in extension, and the superior leg in hyperflexion, during 1 hour (minimum 30 minutes).~Then, women are encouraged to take this posture during labor as frequently as possible if the fetus remains in occipitoposterior position"
223649221|NCT01854450|OTHER|control|usual obstetrical care
223766737|NCT03431350|DRUG|Prednisone 5 mg|Participants will receive prednisone 5 mg orally.
224234287|NCT00809042|DRUG|L-carnitine and hydroxyurea|Hydroxyurea (500 mg capsules) was administered in a single dose at a mean of 10/mg/kg/day (range8-12mg/kg/day). L-carnitine (Minoo, Iran, 250 mg tablets) was administered in divided doses (50mg/kg/day).
224234288|NCT00809042|DRUG|hydroxyurea and magnesium chloride|Hydroxyurea (500 mg capsules) was administered in a single dose at a mean of 10/mg/kg/day (range8-12mg/kg/day). Magnesium chloride powder ( tabib tajhiz nik, Iran) was formulated into suspension; each ml containing 1meq magnesium chloride. It was administered in divided doses at 0.6meq/kg/day.
224234289|NCT00809042|DRUG|hydroxyurea,L-carnitine and magnesium chloride|Hydroxyurea (500 mg capsules) was administered in a single dose at a mean of 10/mg/kg/day (range8-12mg/kg/day). L-carnitine (Minoo, Iran, 250 mg tablets) was administered in divided doses (50mg/kg/day). Magnesium chloride powder ( tabib tajhiz nik, Iran) was formulated into suspension; each ml containing 1meq magnesium chloride. It was administered in divided doses at 0.6meq/kg/day
224234290|NCT01058161|OTHER|high-field MRI (3 Teslas)|high-field MRI (3 Teslas)
224234291|NCT01058161|OTHER|high-field MRI (3 Teslas)|high-field MRI (3 Teslas)
224234292|NCT01058161|OTHER|high-field MRI (3 Teslas)|high-field MRI (3 Teslas)
224234293|NCT01058161|OTHER|high-field MRI (3 Teslas)|high-field MRI (3 Teslas)
224234294|NCT06484101|PROCEDURE|Exercise|3 x 30 seconds of supramaximal exercise
223649222|NCT06137365|DRUG|Cannabis|Cannabis gummy product will be prepared using cannabis flower extract.
223649223|NCT06137365|DRUG|Placebo|Placebo gummy product will be prepared using the same ingredients as the cannabis gummy but will not contain active cannabinoids.
223766738|NCT00414388|DRUG|Sorafenib|400mg twice daily
224234295|NCT03117673|OTHER|transesophageal echocardiography measurements|transesophageal echocardiography will be done routinely during the procedure. We will do additional measurements of the maximal TR velocity
224234296|NCT01441271|PROCEDURE|Ileal diversion and lavage|The surgical approach involves an attempted laparoscopic creation of a loop ileostomy after visually assessing the colon to assure viability. If the loop is unable to be safely performed laparoscopically an open loop ileostomy will be performed. Intraoperatively, 8 liters of warmed polyethylene glycol 3350/electrolyte solution \[GoLytely®; Braintree Laboratories\] will be infused into the colon via the ileostomy and collected via a rectal drainage tube. Post-operatively, the patients will receive antegrade vancomycin flushes \[500 mg in 500 ml of Lactated Ringers; q8 hours for duration of 10 days\] via a Malecot catheter \[24 French\] left in the efferent limb of the ileostomy (Figure 1). Additionally patients will be continued on intravenous metronidazole \[500mg q8 hours\] for 10 days.
224234297|NCT01441271|PROCEDURE|total abdominal colectomy|The surgical approach of the colon in a total abdominal colectomy involves a midline incision. The complete colon in the abdomen (from ileum to rectum) will be removed and an end ileostomy is performed.
224234298|NCT00896818|GENETIC|DNA analysis|
224234299|NCT00896818|GENETIC|genetic linkage analysis|
224234300|NCT00896818|GENETIC|loss of heterozygosity analysis|
224234301|NCT00896818|GENETIC|polymorphism analysis|
223649224|NCT05944081|DEVICE|ArcadiusXP L® Interbody Fusion System|The ArcadiusXP L® Interbody Fusion System is a stand-alone device intended to be used with four bone screws if no supplement fixation is used to stabilize the lumbar spine through an anterior approach. Levels of anterior lumbar interbody fusion for the indications listed in the instructions for use are from L2-S1.
223649225|NCT04239248|DIETARY_SUPPLEMENT|Tasty&Healthy intervention group|"patients will receive dietary advice to exclude pro-inflammatory dietary components based on the book Tasty\&Healthy."
223649226|NCT04239248|DIETARY_SUPPLEMENT|EEN intervention group|Oral exclusive feeding of formulated food (EEN), using Modulen formula only, for 8 weeks in amount based on the Daily Recommendations Intake. Those not tolerating oral EEN can receive EEN via a nasogastric tube.
223649227|NCT03208296|BIOLOGICAL|ASN-002|ASN-002 has been designed for clinical applications, especially for intratumoral administration in the treatment of various cancers. This rAd vector delivers the gene of interest, in the case of ASN-002 the human IFNγ gene, into target cells. The rAd vector in ASN-002 is replication deficient and although it infects cells, it is not able to replicate in the tumor or in normal human cells. The infected cells are able to transcribe and translate the IFNγ DNA leading to a sustained local concentration of IFNγ in the tumor mass that is designed to avoid high levels of systemic IFNγ that may be lead to unacceptable toxicity.
223766739|NCT02153775|BEHAVIORAL|Progressive Muscle Relaxation|Comparison of progressive muscle relaxation and no intervention (e.g., reading newspaper of the day) for the same amount of time.
224234302|NCT00896818|OTHER|laboratory biomarker analysis|
224234303|NCT00896818|OTHER|medical chart review|
224234304|NCT00896818|OTHER|questionnaire administration|
224234305|NCT01380028|DRUG|oral corticosteroids|Active treatment is prednisone establishment within 72 hours after the end of surgery at the dose of 1 mg / kg (rounded to the nearest 10 mg) once daily orally for one week . The daily dose then decreases in increments of 10 mg weekly, by the second week. Once the level of 10 mg / day reached the daily dose by one level lower than 5 mg weekly. Treatment is stopped after this week to 5 mg / day (average 2 months of treatment)
224234306|NCT01380028|DRUG|placebo|placebo
224234307|NCT00788957|DRUG|Panitumumab|Panitumumab for intravenous infusion
224234308|NCT00788957|DRUG|Ganitumab|Ganitumab for intravenous infusion
224234309|NCT00788957|DRUG|Rilotumumab|Rilotumumab for intravenous infusion
223649228|NCT05283109|BIOLOGICAL|Tumor Associated Antigen Peptide Vaccine P30-EPS Vaccine|Vaccine that includes 3 peptides (EphA2 linked to P30 peptide, pp65 linked to P30 peptide, and Survivin linked to P30 peptide)
223649229|NCT05283109|DRUG|Hiltonol|Hiltonol® is made up of synthetic (manmade) RNA (ribonucleic acid) and is used as an adjuvant to the vaccine, meaning it is used with the vaccine to stimulate or enhance the activation of your immune system.
223649230|NCT03810651|OTHER|Proton beam radiation using pencil beam scanning|Proton beam radiation using pencil beam scanning, characterized by Bragg peak dose deposition and high conformality of dose to target regions
223649231|NCT00735267|DRUG|PD 0332334|Dosage Form: 25 or 100 mg oral capsules Dosage and frequency: 350-600 mg twice a day Duration: 1 year
223649232|NCT02280343|OTHER|evaluated lung function|lung function tests
223766740|NCT01997268|DRUG|Placebo|Corn Oil
223649233|NCT03077841|OTHER|Laboratory Biomarker Analysis|Correlative studies
223766741|NCT01997268|DRUG|SC401B 2 capsules|
223766742|NCT01997268|DRUG|SC401B 4 capsules|
223766743|NCT01997268|DRUG|SC401B 6 capsules|
224234310|NCT00788957|DRUG|Placebo|Placebo intravenous infusion
224234311|NCT05555459|PROCEDURE|Operation|Bone fixation operation in foot or ankle area using bioabsorbable headless screw/s
224234312|NCT00001564|DRUG|EF-1 Peptide|
224234313|NCT00001564|DRUG|EF-2 Peptide|
224234314|NCT00001564|DRUG|PXFK Peptide|
224234315|NCT00001564|DRUG|E7 Peptide|
224234316|NCT00001564|DRUG|IL-2|
224234317|NCT00001564|DRUG|IL-4|
224234318|NCT00001564|DRUG|GM-CSF|
224234319|NCT00001564|DRUG|CD40 Ligand|
224234320|NCT06111456|OTHER|Questionnaire|Online self-administered questionnaire to quantitatively mesure parental knowledge and expectations on current and expanded newborn screeing and parental acceptability of expanded newborn screening using genetic.
224234321|NCT06111456|OTHER|Interview|Semi-structured interview to explore parental representations on the extension of newborn screening and - if concerned - to retrace the screening/diagnosis/care management pathway
224234322|NCT01938976|BEHAVIORAL|TAJ Plus (Adolescent Asthma Action in Jordan) Plus the added class smoke free pledge|Its is a school-based peer-led asthma and smoking prevention program that aims at improving asthma control and lowering nicotine dependence among smokers.
224234323|NCT03105609|DEVICE|Hyperspectral imaging|Hyperspectral retinal images will be taken at baseline (before treatment with Lucentis) and then at 3 and 9 months after treatment.
224234324|NCT02701075|DEVICE|MC5-A Scrambler Therapy|up to 10 sessions, each session lasting 30 minutes
224234325|NCT02701075|DEVICE|MC5-A Scrambler Therapy Sham Device|up to 10 sessions, each session lasting 30 minutes
223649234|NCT03077841|RADIATION|Partial Breast Irradiation|Undergo hypofractionated partial breast irradiation
224234326|NCT03246542|DIAGNOSTIC_TEST|shistocytes percentage|
224234327|NCT06301802|PROCEDURE|CIC|clean intermittent catheterization
224234328|NCT06301802|DRUG|Anticholinergic|antimuscarinic once daily
223649235|NCT03077841|OTHER|Questionnaire Administration|Ancillary studies
223649236|NCT06480084|DIAGNOSTIC_TEST|Continuous Laryngoscopy during Exercise Test (CLE test)|A flexible fiberoptic laryngoscope (Olympus, Tokyo, Japan) is introduced directly through the nose or via a slightly modified Hans Rudolph facemask, and into the pharyngeal space. A modified Bruce protocol with a 60-second incremental intensity step is used (Appendix A) and heart rate is monitored. During the CLE test participants perform incremental exercise on a treadmill until symptom-limiting distress or exhaustion. Forced expiratory flow-volume loops are measured before, during and after the CLE test.
223649237|NCT03842189|DRUG|M281|Participants will receive once weekly intravenous (IV) infusions of M281
223649238|NCT03061006|DRUG|Dabigatran Etexilate|150 mg BID (CrCL \> 30 mL/min) or 75 mg BID (CrCL \> 15 to 30 mL/min); Assessment of kidney function every 6 months.
223649239|NCT03061006|DRUG|Warfarin|Dose-adjusted (INR 2.0 - 3.0); Standard warfarin follow-up and education based upon system criteria.
223766744|NCT05098535|OTHER|Visual Aid|"The visual aid will include a graphic display of 100 individuals with number of individuals anticipated to suffer a myocardial injury highlighted by being filled in in red. There will also be a textual description stating the anticipated risk.~For example in a patient with an rCRI score = 2 the text will state 10 out of 100 patients will have a myocardial injury (MINS) and 90 out of 100 patients will have no myocardial injury and 10 of the patients will be shaded red on the visual aid. The patients in this intervention will also received the scripted discussion of perioperative risk of MINS."
224234329|NCT01820871|OTHER|Self-Management Using Smartphone Application for Type2 DM|
224234330|NCT01820871|OTHER|self-management using booklet for management type 2 DM|
224234331|NCT02629874|DRUG|EA-230|at t=0 30, 90 or 180 mg/kg EA-230 will be administered intravenously over 2 hours.
224234332|NCT02629874|DRUG|Endotoxin|at t=0 2ng/kg purified E.Coli endotoxin is administered intravenously
224234333|NCT02629874|DRUG|Placebo|
224234334|NCT02687009|DRUG|Niclosamide|Niclosamide will be taken orally in the morning of each day from day 1-7 prior to surgery for resection of primary tumor. Niclosamide tablets must be chewed well prior to swallowing.
224234335|NCT03795103|DEVICE|neuromuscular electrical stimulator|A 12-week program of neuromuscular electrical stimulation
224234336|NCT03795103|OTHER|Walking sessions|A 12-week program of walking sessions performed outdoors and independently
224234337|NCT03795103|OTHER|Advices|The usual practice associated with an information leaflet outlining tips for active living and walking.
224234338|NCT04736264|OTHER|Visual rehabilitation module: navigation and mobility|The visual rehabilitation regime consist of education and activity include dressing, feeding, personal hygiene and grooming activities, functional mobility, room orientation and memory, reading, eye hand coordination and also optokinetic training programme. A diary will be given to assess their compliance. Reassessment based on the number of fall, stumble etc when they go through a maze (developed in Phase 1)will be done every 2weeks for 8 weeks (4 times), every 4 weeks for next 8 weeks (2 times) and the final assessment 8 weeks later. A total study intervention will be 24 weeks
224234339|NCT04736264|OTHER|Visual rehabilitation module: exercise|An instruction course will be conducted and a CD (with step by step exercise demonstration) will be given to the patients in group A. They will be asked to come for another session in 2 weeks. Then they will be asked to conduct the exercise for at least three times a week for 24 weeks. Exercise diary and accelerometer will also be given to patients of both groups. They will be seen in the clinic every 8 weeks.
223649240|NCT02615639|BIOLOGICAL|HPDC-T cells & Entecavir|experimental groups will be given HPDC-T cells \& Entecavir. HPDC-T cells will be given for 24weeks on the basis of anti-HBV therapy ,and entecavir 0.5mg tablet every night by mouth
223649241|NCT02615639|DRUG|Entecavir|0.5mg tablet every night by mouth
223649242|NCT02615639|DRUG|HPDC-T cells & IFN-a-2a|experimental groups will be given HPDC-T cells \& IFN-a-2a. HPDC-T cells will be given for 24 weeks on the basis of anti-HBV therapy ,and IFN-a-2a 180ug subcutaneous injection every week
223649243|NCT02615639|DRUG|IFN-a-2a|IFN-a-2a 180ug subcutaneous injection every week
223649244|NCT02615639|DRUG|HPDC-T cells & Telbivudine|experimental groups will be given HPDC-T cells \& Telbivudine. HPDC-T cells will be given for 24weeks on the basis of anti-HBV therapy ,and Telbivudine 600mg tablet every day by mouth
223649245|NCT02615639|DRUG|Telbivudine|Telbivudine 600mg tablet every day by mouth
223649246|NCT01070485|DRUG|Radium-223 chloride (BAY88-8223)|The required volume of study drug to be administered to a patient was calculated using the patient's body weight (50 kBq/kg b.w.).
223649247|NCT03284580|OTHER|Ergonomic intervention|An ergonomic intervention program focused to caregivers, including recommendation about how they should help themself and the patients activities at home.
223649248|NCT03284580|OTHER|Postural plus kinesiotherapy intervention program|An ergonomic intervention program focused to caregivers, including recommendation about how they should help themself and the patients activities at home.
223649249|NCT03284580|OTHER|Control or conservative intervention|A control or conservative intervention, including general information about stroke disease for the caregivers of these patients
224234340|NCT04736264|OTHER|Visual rehabilitation module: reading|Patient in intervention group will be asked to complete a reading task (reading the given book) a day, number of pages completed in an hour per day and time taken to complete a page in given book. They are asked to complete the books within 24 weeks with follow up every 8 weeks.
224234341|NCT05618171|DIAGNOSTIC_TEST|Evaluation of the patient's pre- and post-treatment risk profile using the peri-implantitis risk diagram|"By using IDRA, a tool specially developed for patients who have had dental implants in our clinic, patients will be evaluated as low-moderate-high risk in terms of the risk of developing peri-implantitis, according to their initial status. Again, these patients will be re-evaluated 1 year after applying Phase I treatment using the IDRA tool. During this whole process, clinical and radiographic evaluations will be carried out simultaneously."
224234342|NCT02309749|OTHER|CAP|
223649250|NCT00768313|DEVICE|titanium rod|comparison of rods of varying yield strengths and their ability to hold correction of scoliosis.
223649251|NCT00768313|DEVICE|ultra strength stainless steel rod|interventions involving rods of various strength to treat scoliosis
223649252|NCT04738461|OTHER|Telerehabilitation|The Posterior Glenohumeral Capsule Stretching Exercise, Pectoral Stretching Exercise, Push-up Against Wall Exercise, Scapular Plan Exercise, 90 Degree Shoulder Flexion Exercise, Isometric External Rotation Exercise and Isometric Internal Rotation Exercise will be applied according to the severity of the disease and the size of the disability.
224234343|NCT05067049|DEVICE|Connected application arm|"patients have to respond different questionnaires about their quality of life on the mobile app.~And follow-up visits with the physicians as usual"
224234344|NCT05067049|DEVICE|Unconnected arm|Follow-up visits with the pysicians as usual
224234345|NCT03276975|DRUG|TISSEEL|TISSEEL is a fibrin sealant indicated for use as an adjunct to hemostasis in adult and pediatric patients (\>1 month of age) undergoing surgery when control of bleeding by conventional surgical techniques (such as suture, ligature, and cautery) is ineffective or impractical. TISSEEL is effective in heparinized patients
223649253|NCT04738461|OTHER|Standard Physiotherapy|Active-passive exercises accompanied by a physiotherapist and physical therapy methods (electrotherapy and thermotherapy) will be applied in accordance with the standard procedure according to the patient's needs.
223649254|NCT04738461|OTHER|Home Exercise Group|The same exercise program applied to telerehabilitation group.
223649255|NCT02991976|PROCEDURE|Oxygen concentration|Shunting, raising concentration of O2 because of improving regional cerebral oxygen saturation (rSO2), keeping blood pressure above 120-130 mmHg, positive end expiratory pressure (PEEP)
223649256|NCT01262989|DRUG|Test formulation|tamsulosin hydrochloride 0,4 mg (Synthon BV)
223649257|NCT01262989|DRUG|Reference formulation|tamsulosin 0,4 mg (Boehringer Ingelheim)
223649258|NCT01564576|DRUG|Profound neuromuscular blockade (Rocuronium, Rocuronium bromide, sugammadex, Bridion)|Rocuronium dose will be adjusted to maintain a depth of NMB of zero response to train of four and a post tetanic count of no more than 10 responses. At the end of surgery patients will receive a single bolus dose of 4 mg/kg sugammadex according to ideal body weight + 40%12. Extubation will be performed when train-of-four ratios ≥ 0.9.
223649259|NCT03599089|DRUG|CA-008|single-dose wound infiltration prior to surgical incision closure
223649260|NCT03599089|DRUG|Placebo|single-dose wound infiltration prior to surgical incision closure
223649261|NCT03599089|DRUG|Ketorolac|30mg IV administered intraoperatively
224234346|NCT01349556|DRUG|Tretinoin|tretinoin 0.025% cream
224234347|NCT00040378|DRUG|alphatocopherol|400 IU daily
224234348|NCT00040378|DRUG|Selenium|200mcg daily
224234349|NCT00040378|DRUG|Placebo replacement for vitamin E|1 placebo pill daily
224234350|NCT00040378|DRUG|Placebo replacement for Selenium|1 placebo pill daily
224234351|NCT01811043|BEHAVIORAL|Guided Meditation|
224234352|NCT01811043|BEHAVIORAL|Music|
224234353|NCT01811043|BEHAVIORAL|Supportive Dialogue|
224234354|NCT03845933|PROCEDURE|Colon polypectomy|Polyp search and resection will be performed during the withdrawal phase in both groups. Insertion polypectomy will not be performed. All proximal colon polyps will be removed irrespective of their size and appearance.
224234355|NCT05854758|OTHER|Core strengthening with conventional treatment|"A detailed musculoskeletal examination of lumbar spine will be performed before the start of treatment. Oswestry Low Back Pain Disability Questionnaire for pain will be noted. An expert physical therapist with more than 7 years clinical experience will assist the patients in performing core stabilization exercise with conventional physical therapy protocol and routine physical therapy exercise. The session with the physical therapist will usually last for up to 40 minutes.~This group will perform planks, side planks and superman exercises along with knee to chest, pelvic rotation, back extension, and bridge exercises after baseline treatment of therapeutic hot pack and transcutaneous electrical nerve stimulation. continuous mode for 10 minutes."
224320298|NCT06223802|BEHAVIORAL|biodex training|women group with a number of 29 women receiving 3-time biodex training per week, every time will be 10 minutes for 12 weeks
223649262|NCT03599089|DRUG|Acetaminophen|1000mg IV administered intraoperatively
223649263|NCT03599089|DRUG|Oxycodone|5mg PO prn post-surgery
223649264|NCT03599089|DRUG|Bupivacaine Hydrochloride|0.5% infiltration pre-surgery
223649265|NCT03214666|DRUG|GTB-3550 TriKE® Phase I|"The 1st two patients will be assigned Dose Level 1. The study statistician will assign each new cohort of 2 patients to the most appropriate dose level based on updated toxicity probabilities.~* Dose Level 1 - 5 μg/kg/day~* Dose Level 2 - 10 μg/kg/day~* Dose Level 3 - 25 μg/kg/day~* Dose Level 4 - 50 μg/kg/day~* Dose Level 5 - 100 μg/kg/day~* Dose Level 6 - 150 μg/kg/day~* Dose Level 7 - 200 μg/kg/day"
223649266|NCT03214666|DRUG|GTB-3550 TriKE® Phase II|Patients will receive the maximum tolerated dose (MTD) established during Phase I with monitoring guidelines to stop the study early for excessive toxicity.
223649267|NCT04108637|PROCEDURE|penicillin allergy assessment pathway|"Summary of penicillin allergy assessment pathway :~Stage-1 PAAP in Primary Care - Clinical History. Screening, questionnaire and antimicrobial history will be undertaken in primary care Stage-2 Skin Test(ST) in hospital clinic (this may not be needed for all participants) Stage 3 Oral Challenge Test (OCT) in hospital clinic Testing will involve half a day in clinic and then a three-day post clinic course of oral antimicrobial therapy, without a reaction"
223649268|NCT06835933|PROCEDURE|Laparoscopic sleeve gastrectomy|Laparoscopic sleeve gastrectomy (LSG) is most commonly performed bariatric/metabolic surgery. LSG is performed in patients with obesity and/or obesity-related comorbidities. During LSG, the stomach was resected from 5 cm proximal to the pylorus to the angle of His, guided by a 36-French bougie. In patients with hiatal hernia, concomitant HHR was also performed with LSG using non-absorbable sutures. Routine oral potassium-competitive acid blocker (PCAB) was prescribed for 3 months after surgery and the discontinuation of PCAB was determined based on GERD symptoms at the 3-month visit.
223649269|NCT06003270|DRUG|Quercetin 1000 mg|Active comparator
223649270|NCT06003270|DRUG|Quercetin 500 MG|Active comparator
223649271|NCT06003270|DRUG|Placebo|Placebo comparator
223649272|NCT00470275|DRUG|cytarabine|Given IV
223649273|NCT04551534|DRUG|DNL201|Oral dose(s)
224320299|NCT00185588|DRUG|Vatalanib|Vatalanib 250 mg PO Q12 hours x 7 days, 8th day forward 500 mg PO Q12 hours
223649274|NCT04551534|DRUG|Placebo|Oral dose(s)
223649275|NCT03048578|DRUG|Saxenda|Week 1: 0.6mg/day Week 2: 1.2mg/day Week 3: 1.8mg/day Week 4: 2.4mg/day Week 5 and Onward: 3.0mg/day
223649276|NCT03048578|DRUG|Placebo|Subcutaneous Saline Solution
223649277|NCT00499148|OTHER|herbal extract; root of woody shrub grown in India/Sri-Lanka|
223649278|NCT00526071|DRUG|migalastat HCl|
223649279|NCT01096459|PROCEDURE|Nerve Rerouting|All subjects will receive the unilateral nerve rerouting procedure.
223649280|NCT02961738|BEHAVIORAL|Cognitive Analytic Therapy (CAT)|Cognitive Analytic Therapy (CAT) is a relational, integrative and time-limited psychotherapy. This is a study with two active arms. Therefore in the full CAT arm the participants receive the full therapy, but in the CAT-NR arm participants get CAT with the narrative reformulation aspect removed.
223766745|NCT05098535|OTHER|Scripted Risk Discussion|The patients seen in PSS will have a standardized discussion of perioperative risk of myocardial injury read to them by the anesthesiologist in the PSS clinic.
223766746|NCT00180375|DEVICE|Prizm, Vitality, Renewal|Follow-up during 2 years
223766747|NCT04615559|DIAGNOSTIC_TEST|Contrast enhanced ultrasound|CEUS involves the use of microbubble contrast agents and specialized imaging techniques to enhance the signal from blood, thus showing flow in macroscopic vessels as well as tissue perfusion information
224234356|NCT05854758|OTHER|Conventional treatment|"A detailed musculoskeletal examination of lumbar spine will be performed before the start of treatment. Oswestry Low Back Pain Disability Questionnaire for pain will be noted. An expert physical therapist with more than 7 years clinical experience will assist the patients in performing core stabilization exercise with conventional physical therapy protocol and routine physical therapy exercise. The session with the physical therapist will usually last for up to 40 minutes.~This group will perform knee to chest, pelvic rotation, bridge and back extension exercises after baseline treatment of therapeutic hot pack and transcutaneous electrical nerve stimulation. continuous mode for 10 minutes. Each exercise will be repeated 10 times, with 10 second holds, followed by a five-minute rest interval"
223766748|NCT04719416|BEHAVIORAL|Guided Meditation|Approximately 10 minute recording of guided meditation focuses on muscle relaxation.
223766749|NCT00411619|DRUG|Everolimus|Initial everolimus dosage will be 3 mg/m2/d taken daily or every other day, with titration to achieve a trough serum level of 5-15 ng/ml. Patients unable to tolerate levels in this range will have doses held or reduced 25% to achieve trough serum levels of 5-10 ng/ml. If trough serum level of 5-15 ng/ml is not achieved at a dosage of 3 mg/m2/d, then dosage escalation by 25% will be undertaken as tolerated. Everolimus will be similarly adjusted during the extension phase. If a subject misses more than 10 consecutive everolimus doses, additional days of everolimus treatment will be added so total duration of treatment is 6 months. If this occurs, dates of subsequent study events will be adjusted according to number of missed doses. This process will also be followed in the extension phase.
224234357|NCT06348836|OTHER|Exercise|Description of exercises are noted in the arms/groups descriptions
224234358|NCT05197166|OTHER|Acute Clinical Settings|Acute clinical settings, like hospitals, where students are exposed to normal daily shift activities, involving prolonged walking and standing positions.
224234359|NCT04498923|DRUG|Bupivacaine, dexamethasone, epinephrine|Bupivacaine 75 mg, dexamethasone 4 mg, epinephrine 0,18 mg
224234360|NCT02029209|DRUG|Anlotinib|Anlotinib QD
224234361|NCT02029209|DRUG|Placebo Capsule|Placebo capsule QD
224234362|NCT01282996|OTHER|Abdominal surgery|to compare the influence of a lung protective ventilation with conventional ventilation on postoperative complications following major abdominal surgery
223649281|NCT00552435|DEVICE|Laser photocoagulation|Laser therapy is applied using a slit lamp and specific laser contact lens.
223649282|NCT01052701|DRUG|Ribavirin|"Daily Ribavirin alone 400 mg in the morning (AM) and 600 mg in the afternoon (PM) orally with 12 hours between the doses (Body Weight ≤75 kg)~OR~Daily RBV alone 600 mg orally every 12 hours (Body Weight \>75 kg)"
223649283|NCT01052701|DRUG|Ribavirin plus Abacavir (ABC)|"Daily Ribavirin 400 mg in AM and 600 mg in PM orally with 12 hours between the doses (Body Weight ≤75 kg)~OR~Daily RBV 600 mg orally every 12 hours (Body Weight \>75 kg)~Plus~Daily Abacavir 300 mg orally every 12 hours"
223649284|NCT05529797|OTHER|Veovita-VR|Veovita-VR is a VR intervention with positive emotional stimuli and positive behavioral activation designed to reduce depressive symptoms in people with at least moderate depressive symptoms. In the VR session, the participants stay in a beautiful environment (island, sandy beach, beautiful scenery). They can engage in activities that are perceived as positive (climbing, treasure hunting, listening to music, building sandcastles). The session has a length of approx. 30 minutes. Participants are free to continue to engage with any treatment they require during the duration of the study.
223766750|NCT00947492|BIOLOGICAL|Venous blood sample|Venous blood sample twice a year during 3 years
223766751|NCT04940845|DRUG|HS-20090-2|Subcutaneously injection of HS-20090-2 (60mg/1mL) once on the first day
223766752|NCT04940845|DRUG|Prolia|Subcutaneously injection of Prolia® (60mg/1mL) once on the first day
223766753|NCT00000102|DRUG|Nifedipine|
223766754|NCT03591575|DRUG|Deferiprone oral solution|Liquid formulation of deferiprone, with a concentration of 80 mg/mL
224234363|NCT00719290|PROCEDURE|Phacoemulsification (Acrylic Foldable Intraocular Lens (Acrysoft)), (Healon5)|Phacoemulsification of the lens with intraocular lens implant
224320300|NCT00185588|DRUG|Gemcitabine|850 mg/m2
223649285|NCT00287378|DRUG|omalizumab|omalizumab as per weight and IgE
223649286|NCT05290285|DIETARY_SUPPLEMENT|Amino-Ther Pro|Food supplements
223649287|NCT05290285|DIETARY_SUPPLEMENT|Placebo|Maltodextrin
223649288|NCT01723319|DEVICE|HBLPADD coil deep TMS|20 daily deep TMS treatment
223649289|NCT01723319|DEVICE|Sham|inactive treatment
223649290|NCT03346980|DIAGNOSTIC_TEST|Esophagogastroduodenoscopy|All patients will be evaluated with both standard HD gastroscope and side-viewing duodenoscope; the latter to ensure proper visualization of the major papilla.
224320301|NCT02604407|DRUG|SHP465 12.5mg capsules (one capsule daily)|one capsule daily
223766755|NCT03591575|DRUG|Placebo|Liquid solution that matches deferiprone oral solution in appearance and taste
223766756|NCT03464864|DRUG|Treprostinil Inhalation Powder|Single ascending dose
223766757|NCT04643106|PROCEDURE|Hemostatic agent (EVICEL®) application during laparoscopic ovarian cystectomy|During laparoscopic ovarian cystectomy, bleeding will be controlled by using a hemostatic agent (EVICEL®)
223649291|NCT06214091|PROCEDURE|Gastrointestinal decompression|Gastric tube is inserted within 24-hour severe ischemic stroke attack; gastrointestinal decompression is performed for 48 hours.
223766758|NCT04643106|PROCEDURE|suturing with barbed sutures during laparoscopic ovarian cystectomy|During laparoscopic ovarian cystectomy, suturing of ovarian inner surface will be conducted to stop bleeding
223766759|NCT00218543|DRUG|Atomoxetine|At the start of week 7, patients will be maintained at 80 mg/day or increased to the maximal dose of 100 mg/day if less than a 50% reduction of symptoms on the ADHD Rating Scale occurs, and if the patient is tolerating the medication well.
223766760|NCT06296303|OTHER|Pulsed electromagnetic therapy|Pulsed etromagnetic therapy (1000 gauss) on sciatic nerve in gluteal fold. ( 30 min )
223649292|NCT06214091|PROCEDURE|Control|Gastric tube is inserted within 24-hour severe ischemic stroke attack.
223649293|NCT03008200|DEVICE|ultrasound examination|intrauterine fetal pulmonary artery acceleration time to ejection time ratio measurement via ultrasound
223649294|NCT03698097|OTHER|patient satisfaction survey|Patient survey completed in a paper or survey monkey based internet version accessible via a QR code or link
223649295|NCT06232200|OTHER|ACUPUNCTURE|"Acupuncture application will be performed by bilateral needling of The Sanyinjiao (SP6), Yin Ling Quan (SP9), Zu San Li, Leg Three Mile (ST36) , Tai Chong (LIV3), Hegu (LI4), Taixi (KID3) , Zhongliao (BL33) and Guan Yuan (CV4) acupuncture points using sterile, disposable metal acupuncture needles. The needles will remain in place for approximately 20 minutes during the treatment, a total of 8 sessions are planned, 2 per week."
223649296|NCT03021343|DRUG|Colchicine|colchicine given as per trial protocol
223766761|NCT06296303|OTHER|Ultrasound phonophoresis|Phonophoresis using dexamethasone and topical diclofenac sodium gel on sciatic nerve in subgluteal fold and mid thigh
223766762|NCT06296303|OTHER|Conventional physical therapy|"Conventional physical therapy consisting of~1. IF current on lumbar spine. (15 min )~2. Hotpack on lumbar spine . (15 min )~3. Neurodynamic mobilization .~4. Mobilization and manipulation for lumbar spine.~5. Exercises"
224234364|NCT00719290|PROCEDURE|Phacoemulsification and goniosynechialysis (Acrylic Foldable Intraocular Lens (Acrysoft)), (Healon5)|Phacoemulsification of the lens with intraocular lens implant and goniosynechialysis
224234365|NCT00918567|DRUG|atomoxetine|open label treatment dosed up to 1.8mg/kg/day
224234366|NCT00918567|BEHAVIORAL|Behavior Modification Therapy|8 week behavioral modification course with school consultation, parenting groups using COPE and child social skills group
224234367|NCT06482463|BIOLOGICAL|CSF sample|an additional CSF sample of 1 ml is taken from the external ventriculostomy
224234368|NCT03978403|DRUG|"M207 3.8 mg Sled (two 1.9 mg patches made on a Sled coater, foil pouches)"|"M207 3.8 mg administered as two 1.9 mg upper arm patches 30 min wear time made on a Sled coater and packaged in foil pouches"
224234369|NCT03978403|DRUG|"M207 3.8 mg MACAP (two 1.9 mg patches made on a MACAP coater, foil cups)"|"M207 3.8 mg administered as two 1.9 mg upper arm patches 30 min wear time made on a MACAP coater and packaged in foil cups"
224234370|NCT03978403|DRUG|"M207 3.8 mg MiniMac (two 1.9 mg patches made on a MiniMac coater, foil cups"|"M207 3.8 mg administered as two 1.9 mg upper arm patches 30 min wear time made on a miniMac coater and packaged in foil pouches"
224234371|NCT03978403|DRUG|Zolmitriptan 2.5 mg/0.1 mL nasal spray [ZOMIG] single dose|Zolmitriptan 2.5 mg/0.1 mL nasal spray \[ZOMIG\] single dose
224234372|NCT06352320|BIOLOGICAL|Diagnosis of HCM|Hypertrophic cardiomyopathy (HCM) is defined as the presence of increased LV wall thickness (with or without RV hypertrophy) or mass that is not solely explained by abnormal loading conditions.
224234373|NCT06352320|BIOLOGICAL|Diagnosis of DCM|Dilated cardiomyopathy (DCM) is defined as the presence of LV dilatation and global or regional systolic dysfunction unexplained solely by abnormal loading conditions (e.g. hypertension, valve disease, CHD) or CAD.Very rarely, LV dilatation can occur with normal ejection fraction (EF) in the absence of athletic remodelling or other environmental factors; this is not in itself a cardiomyopathy, but may represent an early manifestation of DCM. The preferred term for this is isolated left ventricular dilatation. Right ventricular dilatation and dysfunction may be present but are not necessary for the diagnosis.
224234374|NCT06352320|BIOLOGICAL|Diagnosis of ARVC|Arrhythmogenic right ventricular cardiomyopathy (ARVC) is defined as the presence of predominantly RV dilatation and/or dysfunction in the presence of histological involvement and/or electrocardiographic abnormalities in accordance with published criteria.
224234375|NCT06352320|BIOLOGICAL|Diagnosis of NDLVC|The NDLVC phenotype is defined as the presence of non-ischaemic LV scarring or fatty replacement regardless of the presence of global or regional wall motion abnormalities (RWMAs), or isolated global LV hypokinesia without scarring.
223649297|NCT02893397|DEVICE|Activity Monitor|Wear a fitbit
223649298|NCT02893397|BEHAVIORAL|Exercise Intervention|Undergo supervised exercise sessions
223649299|NCT03259503|DRUG|Busulfan|Given IV
223649300|NCT03259503|DRUG|Gemcitabine|Given IV
223649301|NCT03259503|DRUG|Melphalan|Given IV
223649302|NCT03259503|DRUG|Olaparib|Given PO
223649303|NCT03259503|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo peripheral blood stem cell transplant
223649304|NCT03259503|OTHER|Pharmacokinetic Study|Correlative studies
223649305|NCT03259503|BIOLOGICAL|Rituximab|Given IV
223649306|NCT03259503|DRUG|Vorinostat|Given PO
223649307|NCT06453889|DEVICE|Multimode thermal therapy|The multimode thermal therapy procedure consists of a sequential rapid freezing, natural thawing, and radio-frequency (RF) heating of the target tumor tissue.
223649308|NCT03161444|OTHER|Biological sample collection|A blood sample collection for the study will be taken to each participant Each subject enrolled must have previously participated to the study CHIKVIH.
223649309|NCT02273804|DRUG|Topiramate|Topiramate for 9 months treatment, and then 27 months of follow-up Dose regimen will be determined according to theoretical weight (taken orally), escalated every 15 days. Patients who do not tolerate dose escalation will be reduced to the highest tolerated dose.
223649310|NCT02273804|DRUG|Placebo|Placebo will be taken orally following to the same dose regimen according to theoretical weight
223649311|NCT06841887|DIAGNOSTIC_TEST|US acquisitions|US acquisition from two anatomical regions i.e., the non-dominant arm and the neck.
223649312|NCT02689440|DRUG|Dasatinib|Given PO
223649313|NCT02689440|OTHER|Laboratory Biomarker Analysis|Correlative studies
223649314|NCT02689440|DRUG|Venetoclax|Given PO
223649315|NCT02922049|OTHER|Biopsies with histopathology|All samples taken by biopsies will be correlated with the images taken by CLE.
223649316|NCT03835949|DRUG|TJ004309|Antibody to CD73
223649317|NCT03835949|DRUG|Atezolizumab|Humanized monoclonal antibody to PD-L1
223649318|NCT04616456|DRUG|[F-18]PBR06|PET radiopharmaceutical
223649319|NCT04616456|DRUG|Verdiperstat|verdiperstat targets microglial inflammation in the brain
223649320|NCT05355246|OTHER|assisted sit-up exercises|Group A patients will be instructed to perform assisted sit-up exercises by lying on their back and lifting their torso. They will use their body weight to strengthen and tone the core stabilizing abdominal muscles. This exercise will perform a minimum of five and maximum of 10 repetitions, two times a day and two days a week. Isometrics, back stretching, and strengthening exercises will be given as a common intervention for both groups before starting treatment session.
224234376|NCT06352320|BIOLOGICAL|Diagnosis of RCM|Restrictive cardiomyopathy (RCM) is defined as restrictive left and/or RV pathophysiology in the presence of normal or reduced diastolic volumes (of one or both ventricles), normal or reduced systolic volumes, and normal ventricular wall thickness.Restrictive cardiomyopathy commonly presents as biatrial enlargement. Left ventricular systolic function can be preserved, but it is rare for contractility to be completely normal. Restrictive pathophysiology may not be present throughout the natural history, but only at an initial stage (with an evolution towards a hypokinetic-dilated phase). Restrictive physiology can also occur in patients with end-stage hypertrophic and dilated cardiomyopathy; the preferred terms are 'hypertrophic' or 'dilated cardiomyopathy with restrictive physiology'. Restrictive ventricular physiology can also be caused by endocardial pathology (fibrosis, fibroelastosis, and thrombosis) that impairs diastolic function
224234377|NCT06352320|BIOLOGICAL|Diagnosis of LVNC|The term 'left ventricular non-compaction' (LVNC) has been used to describe a ventricular phenotype characterized by prominent LV trabeculae and deep intertrabecular recesses. The myocardial wall is often thickened with a thin,compacted epicardial layer and a thickerendocardial layer. Left ventricular non-compaction is frequently a familial trait and is associated with variants in a range of genes, including those encoding proteins of the sarcomere, Z-disc, cytoskeleton, and nuclear envelope. Left ventricular non-compaction has also been used to describe an acquired and sometimes transient phenomenon of excessive LV trabeculation (e.g. in athletes, during pregnancy, or following vigorous activity)that must reflect increased prominence of an otherwise normal myocardial architecture, given that cardiomyocytes are terminally differentiated and the formation of new cardiac structures is impossible.The Task Force does not consider LVNC to be a cardiomyopathy in the general sense.
224234378|NCT02581800|OTHER|App group|
224234379|NCT00021658|PROCEDURE|Pesticide application procedures|
224320302|NCT02604407|OTHER|Placebo|Matching placebo capsule that appears identical in size, weight, shape, and color (one capsule daily)
223649321|NCT05355246|OTHER|swiss ball pikes exercises|Group B patients will be instructed to perform swiss ball pikes by getting into the pushup position, the rest of the tops of their feet on a swiss ball. Each patient should keep her legs as straight as possible, bend her hips and try to pull her feet towards their chest so that the ball rolls forward. Hold at the top for three to four seconds, then slowly roll back to the starting position. This exercise will perform a minimum of one or two and a maximum of 10 repetitions, two times a day and two days a week. Both exercises will be performed for 12 weeks in both groups. Isometrics, back stretching, and strengthening exercises will be given as a common intervention for both groups before starting the treatment session.
223649322|NCT03858309|BEHAVIORAL|Breathing Group 1|The 8-week breathwork intervention incorporates a set of breathing practices under the guidance of a certified yoga teacher.
223649323|NCT03858309|BEHAVIORAL|Breathing Group 2|The 8-week breathwork intervention incorporates a set of slow breathing practices under the guidance of a certified yoga teacher.
223649324|NCT02071394|DRUG|Xenon gas|Inhalation via endotracheal tube of 50% xenon for 18 hours, including during transport for outborn babies, starting within 5 hours after birth.
223649325|NCT02071394|OTHER|Whole body cooling|Cooling of baby to reduce rectal temperature to 33.5 degree Centigrade(standard treatment), including during transport for outborn babies, starting within 3 hours after birth.
223649326|NCT00663091|DRUG|Bacteriophage|"WPP-201 is a pH neutral, polyvalent phage preparation, which contains 8 bacteriophages (component bacteriophages or component phages) lytic for P. aeruginosa, S. aureus, and E. coli (Table 1). The cocktail contains a concentration of approximately 1 x 109 PFU/ml of each of the component monophages. The phage component of WPP-201 is roughly estimated to be £ 0.5 ppm by weight and the remainder is phosphate-buffered saline containing \< 1,000 ppm total organic carbon from the growth medium and biomass. All phages contained in the preparation have been originally isolated from the environment, and they have not been genetically manipulated in any way (i.e., the preparation is 100% natural). WPP-201 contains no preservatives and antioxidants."
223766763|NCT01864291|DEVICE|Nucleus 24 (discontinued) and ABI541 Auditory Brainstem Implants (ABI)|Nucleus ABI541 Auditory Brainstem Implant (ABI) surgery followed by device activation, testing, and clinical assessment for five years following surgery.
223766764|NCT03196752|PROCEDURE|laryngeal handshake|palpate for the cricothyroid membrane using the laryngeal handshake technique
223766765|NCT03196752|OTHER|simple palpation|conventional
224320303|NCT02604407|DRUG|SHP465 12.5mg, 25mg, or 37.5mg capsules (one capsule daily)|One capsule daily
224320304|NCT01914692|DRUG|Somatostatin|Somatostatin is a kind of traditional medicines ,which is for the treatment of intestinal fistula，upper gastrointestinal hemorrhage.
224320305|NCT03657186|DIETARY_SUPPLEMENT|ProbioSatys™|One capsule, twice a day, is to be orally taken with 100 mL of water during each breakfast and lunch (approx. 5 minutes after starting eating), total 2 capsules per day.
224320306|NCT03657186|OTHER|Placebo|One capsule, twice a day, is to be orally taken with 100 mL of water during each breakfast and lunch (approx. 5 minutes after starting eating), total 2 capsules per day.
223766766|NCT02170246|DRUG|Telmisartan|
223766767|NCT04482296|DRUG|SSRI with Zinc Sulfate|Zinc sulfate (30 mg) once daily for 8 weeks SSRI
223766768|NCT00085943|DRUG|LEXIVA (GW433908)|
223766769|NCT00085943|DRUG|Ritonavir|
223766770|NCT00085943|DRUG|KALETRA|
223766771|NCT00085943|DRUG|EPIVIR|
223766772|NCT00085943|DRUG|Ziagen|
223649327|NCT00663091|DRUG|WPP-201 Bacteriophage|"WPP-201 is a pH neutral, polyvalent phage preparation, which contains 8 bacteriophages (component bacteriophages or component phages) lytic for P. aeruginosa, S. aureus, and E. coli (Table 1). The cocktail contains a concentration of approximately 1 x 109 PFU/ml of each of the component monophages. The phage component of WPP-201 is roughly estimated to be £ 0.5 ppm by weight and the remainder is phosphate-buffered saline containing \< 1,000 ppm total organic carbon from the growth medium and biomass. All phages contained in the preparation have been originally isolated from the environment, and they have not been genetically manipulated in any way (i.e., the preparation is 100% natural). WPP-201 contains no preservatives and antioxidants."
223649328|NCT00663091|DRUG|Bacteriophages|"WPP-201 is a pH neutral, polyvalent phage preparation, which contains 8 bacteriophages (component bacteriophages or component phages) lytic for P. aeruginosa, S. aureus, and E. coli (Table 1). The cocktail contains a concentration of approximately 1 x 109 PFU/ml of each of the component monophages. The phage component of WPP-201 is roughly estimated to be £ 0.5 ppm by weight and the remainder is phosphate-buffered saline containing \< 1,000 ppm total organic carbon from the growth medium and biomass. All phages contained in the preparation have been originally isolated from the environment, and they have not been genetically manipulated in any way (i.e., the preparation is 100% natural). WPP-201 contains no preservatives and antioxidants."
223649329|NCT05594862|DEVICE|Lipogems|Micro-fragmented adipose tissue infiltration
223649330|NCT03915093|OTHER|Educational nursing protocol|It is a booklet given to study group ,which contains Knowledge and practice about thoracoscopy, pre - post operative care and home care instructions
223649331|NCT03915093|OTHER|Routine hospital care|The routine care given by physicians and nurses after thoracoscopic surgery
223649332|NCT01885598|DRUG|Apixaban|
223649333|NCT03327207|OTHER|Non Interventional|Non Interventional
223649334|NCT04268667|OTHER|Spinal manipulation|Application of upper cervical spine thrust joint manipulation or application of a full combination of cervical, cervico-thoracic and thoracic spine thrust joint manipulation.
223649335|NCT01446055|DEVICE|ResQ processed bone marrow sample|Autologous bone marrow is processed with ResQ at point of care, prior to the transplantation
223649336|NCT01446055|DEVICE|Ficoll conventional cell processing method|Comparison of different cell processing methods
223649337|NCT05120921|OTHER|Osteopathic Manual Treatment|includes touch, joint manipulations, stretching and massage
223649338|NCT05120921|OTHER|Self-management|Providing rehabilitative exercises to patients to do at home
223649339|NCT05120921|OTHER|Reassurance|Reassuring patients on their symptoms, diagnosis and prognosis.
223649340|NCT05120921|OTHER|Biopsychosocial management|Giving a central place to the patient in the decision-making to help them to get back to valued activities.
223649341|NCT06360120|DRUG|Atorvastatin 40 Mg Oral Tablet|The atorvastatin group consisted of 300 patients who received 40 mg daily atorvastatin for 3 months, and open-label clopidogrel at a loading dose of 300 mg and then 75 mg daily till the end of the 3 months.
223649342|NCT06360120|DRUG|Rosuvastatin 20mg|The rosuvastatin group consisted of 300 patients who received 40 mg daily rosuvastatin for 3 months, and open-label clopidogrel at a loading dose of 300 mg and then 75 mg daily till the end of the 3 months.
223649343|NCT06360120|DRUG|Clopidogrel 75 Mg Oral Tablet|open-label clopidogrel at a loading dose of 300 mg and then 75 mg daily till the end of the 3 months.
223649344|NCT06360120|DRUG|Clopidogrel 75 Mg Oral Tablet|open-label clopidogrel at a loading dose of 300 mg and then 75 mg daily till the end of the 3 months.
223649345|NCT02500797|BIOLOGICAL|Ipilimumab|Given IV
223649346|NCT02500797|OTHER|Laboratory Biomarker Analysis|Correlative studies
223649347|NCT02500797|BIOLOGICAL|Nivolumab|Given IV
223649348|NCT02500797|OTHER|Quality-of-Life Assessment|Ancillary studies
223649349|NCT00668889|DRUG|Lactic acid (Dermacid)|
223766773|NCT00085943|DRUG|Abacavir/Lamivudine|
223766774|NCT00085943|DRUG|Fosamprenavir|
223766775|NCT01387607|DRUG|pregabalin|Pregabalin capsule, 300-450mg/day, twice daily
223766776|NCT01387607|DRUG|placebo|Placebo, twice daily
223766777|NCT03080961|DEVICE|VIBLOK barrier cream|VIBLOK safety and performance has not been proven yet in humans with an HSV-2 infection.
223766778|NCT00869648|PROCEDURE|Extension|After anaesthesia induction the head is placed in extension
224234380|NCT02524990|BEHAVIORAL|Home-based follow-up with SQPT|Participants will be followed-up at home. They will receive an SQPT to perform at home two weeks after enrollment, and a scheduled follow-up phone call by study providers to determine the outcome of the procedure.
224234381|NCT02520115|DRUG|Dexamethasone|Given PO
224234382|NCT02520115|OTHER|Laboratory Biomarker Analysis|Analysis of serum and tissue samples
224234383|NCT02520115|DRUG|Valproic Acid|Given PO
224234384|NCT00880282|BIOLOGICAL|cixutumumab|Given IV
224234385|NCT00880282|DRUG|temsirolimus|Given IV
224234386|NCT00880282|OTHER|pharmacological study|Correlative studies
224234387|NCT00880282|OTHER|laboratory biomarker analysis|Correlative studies
224234388|NCT02494726|OTHER|Thromboelastography|TEG (Thrombelastography) measurements include: Split Point (SP) is the time elapsed for the clot to initially form fibrin when the blood is first placed in the TEG machine. Reaction Time (R) is the time elapsed from its initial fibrin formation until the clot reaches 2mm. K is the time measured from R until the level of clot firmness reaches 20mm, measuring the speed of clot strengthening. These are measured in minutes. Delta measures if the formation of the clot has been suppressed; measured as the difference between R and SP. Angle reflects the speed at which clots form by forming the slope of the TEG tracing at R from the horizontal line. Maximum Amplitude (MA) in mm is the measure of maximum strength of the clot, true platelet function. G is the measure of the clot firmness; measured by a formula (G=(5000\*MA)/(100-MA) in dynes/cm2). LY30 is a measure of clot lysis at 30 minutes after MA is reached.
224234389|NCT02153736|BEHAVIORAL|SPEEDI Intervention|Behavioral intervention provided through a collaboration between the mother of enrolled subjects and a physical therapist. Intervention starts in the Neonatal Intensive Care Unit and continues after discharge. SPEEDI includes both parent education and developmental activities.
224234390|NCT00767507|DRUG|cangrelor|
224234391|NCT00767507|OTHER|Placebo|Placebo IV infusion administered in the same fashion as the active study drug in order to maintain the blind in the study.
223649350|NCT01342159|PROCEDURE|Intravitreal injection|Intravitreal Injections were done under sterile conditions with topical anesthesia and insertion of a lid speculum. For the bevacizumab group, 1.25 mg (0.05 cc) bevacizumab (Avastin, made for F. Hoffmann-La Roche Ltd Basel, Switzerland by Genentech Inc., San Francisco, CA, USA) was injected intravitreally with a 30-gauge needle through the superotemporal quadrant. For the bevacizumab with triamcinolone group, in addition to intravitreal bevacizumab, 2 mg(0.05 cc) triamcinolone acetonide (Triamhexal, Hexal AG,Holzkirchen, Germany) was injected intravitreally through the inferotemporal quadrant. For triamcinolone group, 2 mg (0.05 cc) triamcinolone acetonide (Triamhexal, Hexal AG,Holzkirchen, Germany) was injected intravitreally.
224234392|NCT05566093|PROCEDURE|EUS-guided ethanol ablation|After puncturing with the needle, 95% ethanol under the guidance of EUS was injected into the tumor. The injection volume of ethanol was estimated according to the following principles: (1) The injection volume was not larger than the tumor spherical volume. (2) Injection volume was reduced when the tumor was adjacent to the pancreatic duct or vessel. (3) Injection volume for the lesions with repeated EUS-FNI was reduced.
224234393|NCT05566093|PROCEDURE|EUS-guided lauromacrogol ablation|After puncturing with the needle, lauromacrogol under the guidance of EUS was injected into the tumor. The injection volume of lauromacrogol was estimated according to the following principles: (1) The injection volume was not larger than the tumor spherical volume. (2) Injection volume was reduced when the tumor was adjacent to the pancreatic duct or vessel. (3) Injection volume for the lesions with repeated EUS-FNI was reduced.
224234394|NCT02697409|BEHAVIORAL|Education Against Tobacco intervention|
224234395|NCT05596708|DRUG|Telitacicept|Telitacicept will be subcutaneously injected at a dose of 240mg per week, lasting for 104 weeks.
224234396|NCT02294071|DRUG|Ibuprofen|oral liquid ibuprofen 10mg/kg (maximum 600 mg)
224234397|NCT02294071|DRUG|Acetaminophen|oral liquid acetaminophen 15mg/kg (max 975mg)
224234398|NCT02568384|DEVICE|Onyx BG Meter / App System|Subjects with diabetes used the Onyx BG Meter / App System at home and assessed software operations, ease of use of the system, and clarity and utility of user instructions.
224234399|NCT03475784|DRUG|Restrictive fluid therapy|This group will receive intraoperative crystalloids at rate of 10 mL/Kg/hour followed by postoperative crystalloids at rate of 2 mL/Kg/hour.
224234400|NCT03475784|DRUG|Liberal fluid therapy|This group will receive crystalloid preload of 5 mL/Kg, then will receive intraoperative crystalloids at rate of 10 mL/Kg/hour followed by postoperative crystalloids at rate of 6 mL/Kg/hour.
224234401|NCT01131858|DRUG|Vigantol|Vigantol 4000IU/day
224234402|NCT01131858|DRUG|Placebo|Placebo
224234403|NCT01485536|DRUG|AUY922|Starting Dose: 70 mg/m2 by vein on days 1, 8, 15, and 22 days of a 28 day cycle.
224234404|NCT00950157|OTHER|Presentation of information on approval based on a surrogate outcome and levels of caution|"Presentation of information that one drug is approved on a surrogate outcome only while another drug has clinical outcomes. Participants are randomized to 1 of 3 caution (e.g. open question) statements: no open question statement, non-directive open question statement or directive open question statement."
224234405|NCT00796510|DRUG|Sitaxsentan|Sitaxsentan = 100 mg tablet administered orally, once daily
224234406|NCT00796510|DRUG|Sitaxsentan and Sildenafil|Sitaxsentan = 100 mg tablet administered orally, once daily plus Sildenafil = 20 mg tablet administered orally, three times a day
224234407|NCT06266988|DRUG|Sacubitril and Valsartan Tablets 97mg/103mg|Each Tablet contains 97 mg of Sacubitril and 103 mg of Valsartan
224234408|NCT06266988|DRUG|Entresto (Sacubitril and Valsartan Tablets 97mg/103mg)|Each Tablet contains 97.2 mg sacubitril and 102.8 mg valsartan as sodium salt complex
224234409|NCT04111744|OTHER|Preoperative Exercise Training|Patients undergoing CABG and randomized to the Training Group complete six sessions of aerobic endurance training prior CABG surgery
224234410|NCT04111744|OTHER|Optimal medical therapy|Standard medication for stable CAD
224234411|NCT00859664|OTHER|Genotyping of Cytochrome P450|Genotyping of Cytochrome P450
224234412|NCT01291303|PROCEDURE|Optimized ventilation|Patients, ventilated in pressure support mode, were ventilated with initial setting PEEP and pressure support of 4 and as maximum tolerated cmH2O, inspiratory and expiratory trigger of 5 L/min and 50% of peak inspiratory flow, with changes driven by the analysis of flow and pressure curves; with a FiO2 to reach a SpO2 level between 88 and 92%.
224234413|NCT01291303|PROCEDURE|Standard ventilation|"Patients, ventilated in pressure support mode, were ventilated with standard setting of ventilation:~-same initial setting, same time at the bedside (15 minutes at the beginning of NIV, and 5 minutes at each patients' new evaluation) same physician that optimized ventilation mode, while the ventilator screen was obscured (numerical data were, however, always available)."
223649351|NCT00845117|PROCEDURE|Cultivated limbal stem cell graft transplantation|A limbal biopsy taken from the contralateral good eye in cases of unilateral disease or from a living related or cadaveric donor in cases of bilateral disease. The limbal stem cells from the biopsy are cultivated until a sheet of cells measuring approximately 12mm in diameter is obtained. This is then ready for transplantation onto the diseased eye.
224234414|NCT01000896|DRUG|AZD0530|film coated tablet, PO, daily
224234415|NCT01000896|DRUG|Carboplatin|intravenous, 3 weeks
224234416|NCT01000896|DRUG|paclitaxel|intravenous, 3 weeks
224234417|NCT02651441|DRUG|Gemcitabine|Gemcitabine 1000mg/m2 IV on day1 and day8, repeat every 3 weeks.
224234418|NCT02651441|DRUG|Cisplatin|Cisplatin 25mg/m2 IV on day 1,2 and 3, repeat every 3 weeks.
224234419|NCT02651441|BIOLOGICAL|D-CIK|8×10\^9 D-CIK cells for each infusion, IV (in the vein) for 3 cycles, each cycle received four infusions on day 14, 16, 30 and 32.
224234420|NCT01968252|OTHER|Concurrent TTE and TEE|All subjects will undergo both transthoracic echocardiography and transesophageal echocardiography to compare the results of measurements obtained from both imaging locations.
224234421|NCT01938950|OTHER|Aerobic Exercise|
224234422|NCT01938950|OTHER|Resistance Exercise|
224234423|NCT01938950|OTHER|Aerobic and Resistance Exercise|
224234424|NCT03532321|OTHER|NA : non interventional study|NA : non interventional study
224234425|NCT00899964|BEHAVIORAL|Physical activity|6-month physical activity intervention (endurance activities) delivered by internet with tailored training schedules
224234426|NCT02099461|DRUG|Denosumab|Single sucutaneous dose
224234427|NCT02099461|PROCEDURE|Percutaneous core needle breast biopsy|
223649352|NCT02780752|DRUG|hymecromone|Oral Hymecromone
223649353|NCT00925457|OTHER|No Intervention|Neither current domperidone nor current PPI
223649354|NCT00925457|DRUG|Current Domperidone|Current domperidone at any dose, regardless of proton pump inhibitor status
223649355|NCT00925457|DRUG|Current proton pump inhibitor (PPI)|Current PPI and not current dapoxetine
223649356|NCT01328132|DRUG|Saline|100 ml of saline will be given in addition to the standard of care every 8 hours for 24 hours.
223649357|NCT01328132|DRUG|25% albumin|100 ml of 25% albumin will be given in addition to the standard of care every 8 hours for 24 hours
223649358|NCT02382432|DRUG|Pethidine 0.4mg/kg|2ml intravenous bolus slowly injected in 2minutes.
223649359|NCT02382432|DRUG|Dexmedetomidine|2ml intravenous bolus slowly injected in 2minutes
223649360|NCT05777252|OTHER|Circuit Training|Warm-up and cool-down protocols will be applied before and after each CT, and each exercise will be performed as 15 repetitions and an average of 40 seconds of rest will be given between exercises. Also, the intensity of CT will be determined according to the Borg scale (between 11 and 14). CT will include 'mini squat', 'step up', 'sit ups', 'reverse sit ups', 'leg press', 'leg curl', 'leg extension', 'crunches', 'lunge', 'prone bridge', and 'side bridge' exercises.
223649361|NCT01956838|DIETARY_SUPPLEMENT|umami|intraduodenal infusion of umami tastant
223766779|NCT00869648|PROCEDURE|Neutral head position|After anaesthesia induction the head is placed in neutral position
223766780|NCT00869648|PROCEDURE|Anaesthesiologist's position|after anaesthesia induction the head is placed in a position deemed optimal by the anaesthesiologist
224234428|NCT02849925|DRUG|Sealants to arrest microcavitated caries.|Carious lesions will be treated by minimally invasive dentistry by the use of sealants instead of eliminating carious tissues and using conventional restorative materials.
224234429|NCT03730324|DIAGNOSTIC_TEST|mpMRI|Study subjects will undergo urine and plasma biomarker testing and mpMRI prior to biopsy
224234430|NCT03730324|DIAGNOSTIC_TEST|Urine and plasma biomarkes.|Study subjects will undergo urine and plasma biomarker testing prior to standard biopsy
224234431|NCT06166472|DRUG|AK132|IV infusion, specified dose on specified days.
224320307|NCT03885687|BEHAVIORAL|Exercise with Music|The Exercise with Music intervention is recorded exercise playlist, which provide exercise instructions tailored to patients' musical choices and exercise capacity.
224320308|NCT03885687|BEHAVIORAL|Exercise|The exercise group will receive exercise brochure and will be advised to exercise at least twice daily.
223766781|NCT00473915|DRUG|fluticasone furoate|corticosteroid nasal spray
223766782|NCT05091619|BIOLOGICAL|Diphtheria,Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed|Intramuscular injection
223766783|NCT05091619|BIOLOGICAL|Diphtheria,Tetanus and Acellular Pertussis Combined Vaccine, Adsorbed|Intramuscular injection
224320309|NCT02481869|BIOLOGICAL|Arthrocentesis/PRP|PRP (n=20): single intra-articular injection of 5 ml of a leukocyte-reduced platelet rich plasma (ACP, Arthrex, Naples, FL) at the time of closed reduction and initial stabilization using ankle-spanning external fixation
223649362|NCT01956838|DIETARY_SUPPLEMENT|bitter|intraduodenal infusion of bitter tastant
223649363|NCT01956838|DIETARY_SUPPLEMENT|sweet|intraduodenal infusion of sweet tastant
224234432|NCT01123486|DRUG|hydromorphone|hydromorphone 0.02 mg/kg
224234433|NCT05987046|BEHAVIORAL|Contrast training|Three sets of three repetitions of parallel squats at 90% of 1RM
224320310|NCT02481869|DRUG|Arthrocentesis/Saline|Control (n=20): single intra-articular injection of 5 ml of sterile 0.9% saline at the time of closed reduction and initial stabilization using ankle-spanning external fixation
223649364|NCT05744934|DEVICE|LUX-Dx™|Placement of LUX-Dx at the time of stage 1 palliation
223649365|NCT01673737|DRUG|SAR260301|Pharmaceutical form: film-coated tablets Route of administration: oral
223649366|NCT01673737|DRUG|Vemurafenib|Pharmaceutical form: film-coated tablets Route of administration: oral
223649367|NCT04670471|DRUG|Remimazolam|Remimazolam is an intravenous anaesthetic and sedative drug. Remimazolam exhibits its anaesthetic effects via the benzodiazepine binding site at the GABAA receptor.
223649368|NCT04670471|DRUG|Remifentanil|Remifentanil is a commonly used opioid in anaesthetic practice. It is a potent and fast-acting analgesic.
223766784|NCT05091619|BIOLOGICAL|Diphtheria,tetanus,pertussis(acellular,component),poliomyelitis(inactivated) vaccine(absorbed) and Haemophilus influenzae type b conjugate vaccine|Intramuscular injection
224320311|NCT02067962|BIOLOGICAL|Blood sample|Blood sample
224320312|NCT00560820|DRUG|Deferasirox|30 mg/kg/day
223649369|NCT01647347|DRUG|Supra- and subgingival rinsing with 10% PVP-iodine|rinsing prior to and during subgingival ultrasonic debridement
223649370|NCT01647347|OTHER|Water|
223649371|NCT01563809|DRUG|FSH+LH|75 IU of LH will be given from stimulation day 1
223649372|NCT01563809|DRUG|FSH+LH|75 IU of LH will be given from stimulation day 1
223649373|NCT02902861|DRUG|Methotrexate|methotrexate 50 mg/ml in syringes for sub-cutaneous injection; Once weekly (every 7 days) s.c. administration of 17.5 mg MTX; If PASI50 is not reached after 8 weeks, the dosing will be increased to 22.5 mg
223649374|NCT02902861|DRUG|Placebo ( for Methotrexate)|NaCl-Solution manufactured to mimic Methotrexate
223766785|NCT04816734|OTHER|Self-report questionnaires|"Evaluation system of initial therapeutic education program about pediatric home parenteral nutrition.~The assessment takes place after the parents have participated in the therapeutic education program and before their child returns home."
223766786|NCT06974565|DRUG|AZD2389|AZD2389 will be administered orally.
223766787|NCT06974565|DRUG|Quinidine|Quinidine will be administered orally.
223766788|NCT06505954|OTHER|Survey study|Survey study among medical students about lower urinary tract symptoms
224320313|NCT03863548|OTHER|complication|collection of post-operative bleeding complications
224320314|NCT03778138|DRUG|Anlotinib plus Pemetrexed|Anlotinib(12mg QD PO d1-14, 21 days per cycle) plus Pemetrexed (500mg/m2 IV d1)
224320315|NCT03180281|DRUG|DPP4|sitagliptin phosphate 100mg qd
224320316|NCT03180281|DRUG|Insulin|Insulin Glargine or detemir 0.2U/kg qd
224320317|NCT03180281|DRUG|SU|Glimepiride 1-2mg qd
224320318|NCT06452134|DRUG|Coenzyme Q10 100 MG Oral Tablet|Coenzyme Q10 oral Tablet with dosage of 100mg daily given for a period of 30 days after surgery.
224234434|NCT04906603|DEVICE|Theta Burst Stimulation|TBS will be administered three times per day and three days per week for four weeks (totaling 12 TBS intervention visits and 36 TBS intervention sessions). Each TBS intervention session will last approximately 10 minutes (stimulation parameters = 50 Hz, 3 pulses, 10 bursts, 10 second cycle time, 60 cycles, 1800 total pulses).
224234435|NCT02202018|OTHER|Active KT intervention|"1. Provider \& patient-directed infographics educating patients about home dialysis will be displayed in prominent clinic wall space~2. Educational white board presentations promoting home dialysis~3. Each clinic will receive reports outlining their current use of home dialysis in incident ESRD patients compared with provincial \& national averages~4. A Canadian version of the MATCH D tool will be provided to clinic staff, to help evaluate patient appropriateness for home dialysis.~5. Each clinic will receive an in-person visit from one of the study investigators/collaborators detailing the benefits of home dialysis, and the educational tools being offered to support care within their clinic."
224234436|NCT00720122|DRUG|Recombinant human insulin like growth factor-1 (rhIGF-1)|Twice daily
224234437|NCT01729936|BEHAVIORAL|Sitting time Change Intervention|Intervention to find alternatives to substitute sitting time by doing the regular activities standing or walking.
224234438|NCT01161641|DRUG|ODSH at 0.125 mg/kg/h|ODSH 1000 mg vials containing 20 cc of normal saline (50 mg/ml) to be prepared for 96-h IV infusion with normal saline based on subject's weight and dose assigned by Study Cohort 1 of 0.125 mg/kg/h.
224234439|NCT01161641|DRUG|ODSH at 0.375 mg/kg/h|ODSH 1000 mg vials containing 20 cc of normal saline (50 mg/ml) to be prepared for 96-h IV infusion with normal saline based on subject's weight and dose assigned by Study Cohort 3 of 0.375 mg/kg/h.
224234440|NCT01161641|DRUG|ODSH at 0.250 mg/kg/h|ODSH 1000 mg vials containing 20 cc of normal saline (50 mg/ml) to be prepared for 96-h IV infusion with normal saline based on subject's weight and dose assigned by Study Cohort 2 of 0.250 mg/kg/h.
224234441|NCT04976959|DRUG|High Fiber supplement|The supplement consists of a mixture of soluble fibers (from inulin and fibersol-2) and insoluble fibers (from oat bran, corn bran, wheat bran and sorghum bran) and it will be consumed as a drink.
224234442|NCT03862599|DEVICE|Extra-corporeal shockwave therapy (ESWT)|low-intensity extra-corporeal shockwave therapy
224320319|NCT06452134|DRUG|Placebo|Exactly same looking agent in the form of a tablet with same size and color to CoezymeQ10 with no active property given for a period of 30 days after surgery.
224320320|NCT01822717|BEHAVIORAL|Nonvisual foot inspection|Teaching use of nonvisual senses (tactile and olfactory) to empower people with diabetes and visual impairment to perform a systematic self-examination of their own feet
224320321|NCT01822717|BEHAVIORAL|Usual Care|Standard instructions for foot care for people with visual impairment include advice to have a sighted family member or friend check the person's feet regularly
224320322|NCT00734058|DEVICE|Laser MAZE by Ablation of Cardiac Tissue|The protocol calls for the creation of the pulmonary vein isolation lesion through the use of the SOLAR™. The additional lesions are to be created using the ATRILAZE™. At surgeon discretion, the ganglia may be ablated and left and right atrial appendages may be removed.
223649375|NCT02289157|DEVICE|Negative pressure wound therapy|Single use negative pressure wound therapy systems are composed of a pressure pump and dressing kit. The pump creates a negative pressure of 125 mmHg (+/- 20 mgHg) and the dressing directly covers surgical incision. The system is battery-powered and designed to be used for a minimum of two days and a maximum of seven days of continuous use. The investigators hypothesize that negative pressure wound therapy will decrease the wound complications in these patients. The investigators will be using Prevena Incision Management System as the negative pressure device in our study.
223649376|NCT00573300|PROCEDURE|Phlebotomy|Single blood draw
223649377|NCT03275649|OTHER|Help-seeking for non-motor symptoms|Brief, self-paced, online individually tailored intervention using LifeGuide software. Includes information, videos and exercises.
223649378|NCT00463515|DRUG|carboplatin/gemcitabine|
223649379|NCT00463515|PROCEDURE|cisplatin/radiation therapy|
223649380|NCT00561509|DRUG|SSRIs|Use within normal clinical practice
223649381|NCT00561509|DRUG|Dual antidepressants|Use within clinical practice
223649382|NCT04931706|OTHER|Magnetics Assisted by Singe port|Use of magnet for assistance through the surgery, and a novel approach as it is single port
223649383|NCT04016766|BEHAVIORAL|Mobile app prepartying intervention|The intervention is comprised of a theoretically-informed and empirically-supported, brief, accessible, and personalized intervention to address prepartying drinking. the prepartying intervention app will be tailored toward an individual's personal goals, beliefs (perceptions, expectancies, self-efficacy), and behavior (protective strategies), and focus on the core components of brief interventions that have been cited as constructs that mediate the effects of multiple component intervention programs (e.g., correcting perceived norms, use of protective behavioral strategies, increased self-efficacy, challenging expectancies, feedback on blood alcohol level).
224234443|NCT03862599|OTHER|Standard care|Cialis and vacuum pump
224234444|NCT06399770|DEVICE|Muscle ultrasound|Role of muscle ultrasound in LGMD
224234445|NCT04275687|RADIATION|thoracic irradiation|"For peripherally located recurrent tumors, stereotactic body radiation therapy is used at 5000-6000 cGy in 10 fractions.~For centrally located recurrent tumors, adaptive hypofractionated radiation is used: Patients are irradiated at 3000-4000cGy in 6-10 daily fractions in the first course. After a four-week interval, patients who have non-progressive disease and an adequate pulmonary function undergo adaptive re-planning, and are irradiated at 2400-3500cGy in 4\~7 daily fractions as a boost."
224234446|NCT04275687|DRUG|Concurrent chemotherapy|For centrally located recurrent tumors, concurrent chemotherapy consists of weekly docetaxel and nedaplatin.
224234447|NCT03776032|DRUG|Darbepoetin alfa|Administered by subcutaneous injection once a week
224234448|NCT03776032|DRUG|Placebo|Placebo matching to darbopoetin alfa administered by subcutaneous injection once a week.
224234449|NCT01604421|PROCEDURE|Thermoregulation-standard care|Standard care without plastic bag. One hour after birth, a blanket will be wrapped around the infant and he/she will receive a wool hat, according to standard practices. The infant's axillary temperature will be monitored for 24 hours or until discharge, whichever comes first.
223649384|NCT04033016|BEHAVIORAL|motivational interviewing|Motivational interviewing (MI) is a contemporary form of advisory support, which is often used for behavioral change. During the motivational interviewing educated health professional leads the counseling session by asking questions on lifestyle, attitude towards the behavioral change, and factors pro and against the change. During the MI the focus is on the patient/ client, his/her own perception of their health, understanding the reasons for current behavioral patterns, and encouragement to assess these patterns.
223649385|NCT04033016|BEHAVIORAL|online social media intervention|Facebook group was specially designed for purposes of intervention and was administered by the research team. It was used to motivate the participants to be more physically active. The intervention used hybrid approach, with health promotion campaign with motivational messages and pictures, journal articles, questions with the aim to spark a discussion on barriers or possibilities for physical activity and participatory approach (all members were allowed to post motivational messages or questions for their peers).
223649386|NCT01415882|DRUG|Cyclophosphamide|Given PO
223649387|NCT01415882|BIOLOGICAL|Daratumumab|Given IV
223766789|NCT05711927|DEVICE|SNOO Smart Sleeper|"Infants will be secured in the SNOO Sleep Sack. They will be placed in the center of the SNOO Smart Sleeper. The SNOO will be powered on and will start playing white noise and rocking from side-to-side. The SNOO's movement and sound settings will automatically ramp up and down as needed in response to the infant's sensed level of fussiness or crying per the manufacturer's programming. The preemie mode will be enabled, which caps motion at level 2 out of 5."
223766790|NCT05711927|DEVICE|Traditional bassinet|Infants will be swaddled using a standard hospital blanket. They will be placed in the center of the SNOO Smart Sleeper, but the SNOO will be left powered-off. No white noise will be played. No side-to-side rocking motions will occur.
223766791|NCT03878199|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic SCT
223766792|NCT03878199|DRUG|Liposome-encapsulated Daunorubicin-Cytarabine|Given IV
223766793|NCT03878199|DRUG|Ruxolitinib|Given PO
223766794|NCT06974877|DRUG|124I AT-01|124I-AT-01 is an amyloid-reactive synthetic 45-L amino acid polypeptide radiolabeled with iodine-124, with a theoretical molecular weight of 4763.6 Da (based on amino acid sequence). The polypeptide, AT-01, is not pharmacologically active. 124I-AT-01 binds many forms of human and murine amyloid and is intended to be a PET imaging agent for the detection of amyloid deposits.
223766795|NCT06635876|BEHAVIORAL|Coaching Sessions|"The coach will use motivational interviewing techniques to:~1. To assist and guide the caregiver to establish a standby caregiver relationship~2. To assist and guide the caregiver as to how to use the EPT"
223766796|NCT05526989|DRUG|Dostarlimab|300 mg Dostarlimb will be administered by IV, increasing to 1000 mg after cycle 4.
223766797|NCT05526989|DRUG|Niraparib|200 mg Niraparib will be taken once daily by mouth days 1-21 of all cycles.
224234450|NCT01604421|PROCEDURE|Thermoregulation with plastic bag|One hour after birth, the infant will be placed into a plastic bag up to his/her axillae, and the bag will be folded and taped to itself to prevent it from covering the infant's nose or mouth. A blanket will be wrapped around the infant, and he/she will receive a wool hat. The infant will remain in the bag, which will be changed when soiled, for 24 hours or until discharge, whichever occurs first.
224234451|NCT06544343|OTHER|Remote Monitoring|Follow-up at outpatient clinic at 3 and 6 months from drug prescription Two remote consultations at 15 and 45 days from drug prescription
224234452|NCT06544343|OTHER|On site monitoring|Follow-up at outpatient clinic at 3 and 6 months from drug prescription.
224234453|NCT02419638|DRUG|Rebif (IFN β-1a subcutaneous three times per week)|
224234454|NCT02419638|DRUG|Tecifdera (dimethyl fumarate)|
223649388|NCT01415882|DRUG|Dexamethasone|Given PO or IV
223649389|NCT01415882|DRUG|Ixazomib Citrate|Given PO
223649390|NCT01415882|OTHER|Laboratory Biomarker Analysis|Correlative studies
223649391|NCT01288261|DRUG|paclitaxel|Given IV
223649392|NCT01288261|BIOLOGICAL|bavituximab|Given IV
223649393|NCT01288261|OTHER|laboratory biomarker analysis|Correlative studies
223649394|NCT01288261|OTHER|pharmacological study|Correlative study
223649395|NCT00160901|DRUG|two complex naturopathic add-on therapies, leaflet 5-a-day|
223649396|NCT02390505|DRUG|Vitamin C|
223649397|NCT02390505|DRUG|Placebo|
223649398|NCT00163683|BEHAVIORAL|Dietary Therapy|
223766798|NCT02696551|OTHER|Medical education|
223766799|NCT03130322|OTHER|Imagery and Sleep questionnaires|Participants complete a motor imagery questionnaire to assess their ability to form vivid mental images, as well as sleep questionnaires to control the quality of their sleep
223766800|NCT03130322|OTHER|MEG recordings (pre-test)|"Participants of the Day group perform two motor tasks (a finger sequential motor task and an adaptation motor task using a trackball) in the MEG, during a pre-test (Day 1 - 9h).~Task 1: Participants perform an 8-digit motor sequential task where each finger (except the thumb) is used twice. Performance is assessed by using a 4-keys keyboard. Participants are required to keep their fingers on the keys to minimize amplitude are instructed to tap the sequence as few errors as possible Task 2: Participants perform a motor adaptation task requiring scrolling a trackball to superimpose a geometric shape on another one, strictly similar but presented from another angle, as fast as possible."
223766801|NCT03130322|OTHER|Practice session|Participants of the Day group perform a block of motor imagery practice of the two motor tasks.
223766802|NCT03130322|OTHER|MEG recordings (Post-test)|Participants perform the two motor tasks in the MEG (post-test, strictly similar to the pre-test)
223766803|NCT03130322|OTHER|MRI|The registration of the brain anatomy of each participant will be done by MRI 3D / T the week before the first experimental session.
223766804|NCT03069378|DRUG|Talimogene Laherparepvec (T-VEC)|Talimogene laherparepvec treatment will be given at Day 1 Week 1, and every 3 weeks thereafter .
223766805|NCT03069378|DRUG|Pembrolizumab|Pembrolizumab will be given at Day 1 week 1 and every 3 weeks thereafter.
224234455|NCT04147728|DRUG|Anlotinib|Anlotinib is a novel multi-target tyrosine Kinase inhibitor that inhibits VEGFR2/3, FGFR1-4, PDGFD α/β, c-Kit and Ret.
224234456|NCT04147728|RADIATION|Stereotactic Radiosurgery|Stereotactic Radiosurgery as the initial treatment of non small cell lung cancer patients with limited brain metastases
224234457|NCT04900233|OTHER|surgery|emergency surgery
224234458|NCT00414947|DRUG|Vildagliptin (LAF237)|
223649399|NCT00623142|DRUG|Hyperbaric Oxygen|100% Oxygen at 2.4 ATA for 30 minutes followed by 5 minutes break followed by 100% Oxygen at 2.4 ATA for another 30 minutes. This intervention was given about 4 to 5 hours prior to CABG
223649400|NCT05066932|OTHER|Additionnal blood samples|Additionnal blood samples
223766806|NCT06038838|DEVICE|Tioga TMVR System|A bioprosthetic mitral valve, as part of the Tioga TMVR System, is implanted percutaneously in a patient with MR via transfemoral-transseptal access.
223766807|NCT06977451|DRUG|nL-CHCHD-001|Personalized Antisense Oligonucleotide
223766808|NCT06979180|DIETARY_SUPPLEMENT|Papillex®|Participants will be instructed to take two capsules twice daily with food, with the first dose taken with the first meal of the day and the second dose taken with the last meal of the day.
223766809|NCT06979180|OTHER|Placebo|Participants will be instructed to take two capsules twice daily with food, with the first dose taken with the first meal of the day and the second dose taken with the last meal of the day.
223766810|NCT03665038|DRUG|Brexanolone|Administered as IV infusion.
223766811|NCT06842836|OTHER|Study intervention|From the date of study authorization, the principal investigator, together with his specially identified collaborators, will proceed to identify patients who meet the inclusion criteria. Then, during the first follow-up visit, the principal investigator, or one of his co-investigators, will deliver the informed consent to the parent(s) of the minor subject candidate for enrollment in the study, explaining all the characteristics and evaluations stipulated in the protocol and answering any questions. After the informed consent is signed, patients will be enrolled and the data required to conduct the study will be collected, and a fecal sample will be requested specifically for the conduct of the study. At the same time, completion of the KIDMED (Mediterranean Diet Quality Index in children and adolescents) questionnaire will be requested.
223766812|NCT06592274|BIOLOGICAL|HB0017|300mg Q12W
223766813|NCT06592274|BIOLOGICAL|HB0017|300mg Q8W
223766814|NCT06592274|BIOLOGICAL|HB0017|150mg Q4W
223766815|NCT06268873|DRUG|Baxdrostat/dapagliflozin|"baxdrostat tablet~dapagliflozin tablet"
223766816|NCT06268873|DRUG|Dapagliflozin in combination with placebo|"dapagliflozin tablet~placebo tablet"
223766817|NCT04331158|OTHER|Dry cupping therapy|Dry cupping therapy application on the patient's skin
223766818|NCT03841149|OTHER|Ultrasound Imaging|3D volume calculation using on-line and off-line softwares
224234459|NCT01847183|BEHAVIORAL|Click City®: Alcohol|A school based program, Click City®: Alcohol consists of 12 effective components delivered in 7th grade and a booster of 5 effective components delivered in 8th grade.
224234460|NCT01775215|RADIATION|Cardiac I123-MIBG Scintigraphy|
223766819|NCT06807411|OTHER|Conventional exercise|Participants in the conventional exercise group will receive a total of 24 sessions of conventional therapy over 8 weeks (3 days per week, 30-minute sessions).
223766820|NCT06807411|OTHER|Video game based exercise|The video-based game exercise group will undergo the same conventional therapy, with an additional video game-based exercise program using the Becure Extremity ROM device under physiotherapist supervision. The program will include KinectPong, KinectBalloon, ArmRotate, and Uball games. Balance, joint position sense, ROM, functionality, and quality of life parameters will be assessed before and after treatment.
224234461|NCT01775215|OTHER|Cardiac MRI|
224234462|NCT01775215|OTHER|Stress and rest Echocardiogram|
224234463|NCT01775215|OTHER|High Sensitivity Troponin I|
224234464|NCT01775215|OTHER|Brain Natriuretic Peptide|
224234465|NCT02113306|DEVICE|t-VNS|The device that will be used is approved for systematic use by those with epilepsy and depression in the European Union. It has been used in studies of acute stimulation with healthy participants with no significant changes in heart rate or breathing (Kraus et al., 2007; Busch et al., 2013).
224234466|NCT02113306|DEVICE|sham stimulation|electrodes will be put upside down
224234467|NCT05169164|OTHER|No intervention, observational|No intervention, observational
223649401|NCT00357006|DRUG|Estradiol|100 mcg adjunctive transdermal estradiol
223649402|NCT00357006|DRUG|Estradiol|200 mcg adjunctive transdermal estradiol
223649403|NCT00357006|OTHER|placebo|adjunctive transdermal placebo
223649404|NCT04178785|DRUG|Remifentanil|Patients electively admitted for laparoscopic hysterectomy will be approached for requirement. After obtaining a written informed consent, patients will be randomly assigned either to the study group (Remifentanil group) or to the control group (Fentanyl group) in a 1:1 ratio.
223649405|NCT00976560|DRUG|GW856553|Wet Granulated, film coated white, 9mm round, biconvex, plain faced tablets, containing 7.5 mg of GW856553
223649406|NCT00976560|OTHER|Placebo|Film coated white, 9mm round, biconvex, plain faced tablets obtained by direct compression.
223649407|NCT02131649|DEVICE|18F-FCH PET/MRI Scan|Patients will first undergo screening to ensure eligibility. If eligible, they will undergo a PET/MRI scan using 18F-FCH as the radiolabeled tracer. If prostate cancer is detected outside the prostate, patients may undergo a biopsy or follow-up 18F-FCH PET/MRI to confirm the results.
223649408|NCT02627261|BIOLOGICAL|blood samples and bone marrow aspirates will be collected|Serial analysis will be performed at different time point in order to evaluate the presence or absence of residual disease after different treatment steps (before treatment, after induction, after intensification, after consolidation)
224234468|NCT04094194|OTHER|Nordic diet|Healthy dietary pattern that is consumed in Nordic countries
224234469|NCT03008460|DRUG|Eziclen®/Izinova®|Oral solution taken the evening before the colonoscopy
224234470|NCT03008460|DRUG|Klean-Prep®|Oral solution taken the evening before the colonoscopy
224234471|NCT04479657|DRUG|QingFei Granule|QingFei Granule is made from 6 commonly herbal medicine granule, such as Jingjie,Huang Qin,Lianqiao,etc. The children were given one package of QingFei Granule every day, dividing into 3 times to be administrated. It's be given for 5 days.
224234472|NCT04479657|DRUG|Cefuroxime|30mg/kg/d,bid, used until to the normalization of blood routine。
224234473|NCT04555525|DRUG|sarecycline|sarecycline tablet
224234474|NCT04555525|DIETARY_SUPPLEMENT|Centrum Adult Multivitamin|Centrum Adult Mulltivitamin tablet
224234475|NCT06382181|BEHAVIORAL|Music therapy for community-dwelling individuals with unwanted loneliness|Music therapy workshops were implemented. The enjoyment and expression of feelings were encouraged by listening to songs, singing, dancing, guided relaxation with music, and group instrumental performance. There was one session per week. Total 12 sessions.
223649409|NCT03710161|DRUG|Vitamin D|Vitamin D taken in two different dosages daily for six months.
223649410|NCT05130515|DRUG|Niraparib|Niraparib 200mg po QD, day1\~21
223649411|NCT05130515|DRUG|Anlotinib|Anlotinib 10mg po QD, day1\~14, 3 weeks/cycle
223649412|NCT02132026|DRUG|Denosumab|
223649413|NCT02132026|DRUG|Alendronic Acid|
223649414|NCT02132026|DRUG|Denosumab Placebo|subcutaneous injection of 0.9%Saline at baseline, 6 months, 12 months and 18 months
224234476|NCT06382181|BEHAVIORAL|Health education for community-dwelling individuals with unwanted loneliness|Twelve health education workshops were carried out. They included group training talks on the following topics: sleep hygiene, diet, and cognitive stimulation, among others.
223649415|NCT02132026|DRUG|Alendronic Acid Placebo|Inert Capsule containing lactose monohydrate manufactured and labelled by Investigational Supplies Group (ISG) University of Edinburgh.
223649416|NCT06519851|OTHER|suprascapular nerve block with 10 ml bupivacaine 0.25% & shoulder anterior capsule block with 30 ml bupivacaine 0.25%|postoperative analgesic effect of combined shoulder anterior capsule (SHAC) block with suprascapular nerve block (SSNB) following shoulder surgery by ultrasound guided suprascapular nerve block (SSNB) with 10 ml bupivacaine 0.25% deep to the transverse scapular ligament and Shoulder anterior capsule (SHAC) block with 30 ml bupivacaine 0.25% (20 ml deep to the deltoid muscle between the deltoid and subscapularis tendon \&10mL in the pericapsular space)
223766821|NCT06984536|DRUG|Reduced ATG plus mini PTCy|The conditioning protocol comprises cytarabine (Ara-C) (4 g/m2/day, days -9), busulfan (Bu) (3.2 mg/kg/day, days -8 to -6), cyclophosphamide (Cy) (1.8 g/m2/kg, days -5 and -4), simustine (250 mg/m2, day -3) and r-ATG (total 7.5mg/kg ,from days -5 to -2). Mini PTCy 14.5mg/kg/day will be given on day +3 and +4.
223766822|NCT06658847|OTHER|Night Cream Usage|Participants will use the provided products only on their face and right upper inner arm. The auxiliary cleanser will be used twice per day (morning and evening). The auxiliary sunscreen will be used 15 minutes prior to sun exposure and reapplied after 80 minutes of sweating or swimming. The investigational night cream will be used daily in the evening/at night.
223766823|NCT06658847|OTHER|No Night Cream Usage|Participants will use the provided products only on their face and right upper inner arm. The auxiliary cleanser will be used twice per day (morning and evening). The auxiliary sunscreen will be used 15 minutes prior to sun exposure and reapplied after 80 minutes of sweating or swimming. No night cream will be used.
223766824|NCT06861439|DRUG|Tirzepatide|Tirzepatide will be initiated at a dose of 2.5 mg weekly and increased as tolerated to 5 mg weekly at four weeks for the remainder of the 9-month intervention period. Participants who are unable to tolerate the 5 mg dose will be decreased to the 2.5 mg dose.
224234477|NCT06382181|BEHAVIORAL|Physical exercise for community-dwelling individuals with unwanted loneliness|This intervention was implemented with 2 group sessions each week for 13 weeks. It included physical exercise adapted to the physical conditions of each participant.
224234478|NCT02398461|DRUG|rHIgM22|Administered via IV infusion
223649417|NCT06519851|OTHER|Interscalene block with 20 ml bupivacaine 0.25%|postoperative analgesic effect of Interscalene block (ISB) following shoulder surgery by ultrasound guided interscalene brachial plexus block (ISB) with 20 ml bupivacaine 0.25% around C5-C6-C7 nerve roots of the brachial plexus
223649418|NCT00171561|DRUG|valsartan/hydrochlorothiazide|
223649419|NCT03370978|BEHAVIORAL|Text Messaging|"To communicate with intervention patients after discharge from the ED, we will use a bidirectional text messaging service provided by another physician's research group within the University of Iowa. The nurse navigator will enter the patient's study identification number, first and last name and cell phone onto a secure study website established by this research group.~Patients will, as previously mentioned, have had their cell phone number tested in the text messaging system prior to leaving the Emergency Department (this includes the control group).~Patient's will receive a text message 3 days, and 1 day, prior to their scheduled follow-up appointment with Family Medicine (this appointment having been scheduled through the Emergency Department Nurse Navigators). Each text message will remind the patient of the date/time of their appointment, and provide them a link containing a map with the location of their appointment."
223766825|NCT05354375|BIOLOGICAL|CAR-T cell immunotherapy|This CAR-T cell immunotherapy with a novel specific Chimeric antigen receptor aiming at PSMA.
223766826|NCT06084013|OTHER|Non-Interventional Study|Non-interventional study
223766827|NCT06998407|DRUG|AVZO-021|AVZO-021 is an oral selective CDK2 inhibitor
223766828|NCT06998407|DRUG|Fulvestrant|Antineoplastic agent, estrogen receptor antagonist
223649420|NCT04413006|BEHAVIORAL|Self-Compassion for Chronic Pain Virtual Group Treatment Program|6-session group via video-conferencing for informational and experiential exercises to increase self-compassion in individuals with chronic pain
223649421|NCT01526304|OTHER|no intervention|No intervention, only observational study
223649422|NCT02921841|BEHAVIORAL|D*STAR|
223649423|NCT02921841|BEHAVIORAL|D*HEALTH|Digital general health promotion intervention. Time and attention matched intervention that targets health behaviors relevant to youth including exercise, nutrition, sleep, and smoking. Basic information about HIV and sexuality is also included.
223649424|NCT03210337|DRUG|A-101 Topical Solution|A-101 Topical Solution
223649425|NCT03210337|DRUG|A-101 Vehicle Solution|A-101 Vehicle Solution
224234479|NCT02398461|DRUG|Placebo|
223766829|NCT06998407|DRUG|Letrozole|Antineoplastic agent, aromatase inhibitor
223766830|NCT06998407|DRUG|AVZO-023|AVZO-023 is an oral selective CDK4 inhibitor
223766831|NCT07001644|DEVICE|microneedling|microneedling with topical application of PRP on one side of abdomen and microneedling only on the other side.
223766832|NCT07001644|DEVICE|Carboxytherapy|carboxytherapy with intradermal injection of PRP on one side of abdomen and carboxytherapy only on the other side.
223766833|NCT04579679|DRUG|Surufatinib|Surufatinib 300 mg oral once daily
224234480|NCT03735758|DRUG|pazopanib or guideline conform chemotherapy|Pazopanib (800mg/each day) or guideline conform chemotherapy
224234481|NCT05833386|PROCEDURE|Ureteral access sheath placement during flexible ureteroscope for renal stones|Ureteral access sheath placement during flexible ureteroscope
224234482|NCT00805558|DRUG|moxifloxacin|400 mg moxifloxacin once daily for 7 days
224234483|NCT00805558|DRUG|Ciprofloxacin plus metronidazole|Ciprofloxacin 1000 mg once daily for 7 days; Metronidazole 500 mg twice daily for 7 days
224234484|NCT01919190|DRUG|EXPAREL|TAP with EXPAREL
224234485|NCT01919190|DRUG|Placebo|Placebo
224234486|NCT03371290|OTHER|Mirror Therapy|The healthy UE will be positioned in front of the mirror and the paretic UE behind it, enabling the patient to observe the movements of the healthy limb through the mirror, interpreting that image as the affected limb. The MT protocol will be composed of active bimanual exercises of range of motion and functional exercises. Three sets of 15 repetitions will be performed for each exercise with a 20 seconds interval between each series, for 30 minutes. The exercises: 1) Elbow flexion/extension; 2) Wrist flexion/extension in neutral position; 3) Fingers flexion/extension in neutral position; 4) Forearm pronation/supination; 5) Roll the ball with hands; 6) Squeezing the sponge; 7) Drag a towel in anteroposterior direction; 8) Opponency of fingers; 9) Climb the mirror with the fingers (similar to walking the spider).
224234487|NCT03371290|OTHER|Control Intervention|"In the control intervention, patients will be performed the same bimanual activities proposed by the MT protocol, but without the reflector side of the mirror. The mirror will be placed in the same position as the MT intervention. However, the subject will have access to the non-reflective side of the mirror, directly visualizing the movement of his healthy arm.~Both interventions will be performed a single session of MT or control composed of 30 minutes of exercises. The participants who will be first assigned to the MT intervention, after 4-weeks washout period, will be performed the same procedures, but in the control intervention. Likewise, patients who will be first allocated to control intervention, after 4-weeks of washout, will be performed the same procedures, however in MT intervention."
224234488|NCT03830125|DRUG|BBT-877, Single dose|Single dose of BBT-877, 5 dose levels, oral capsule
224234489|NCT03830125|DRUG|Placebo group|Placebo matched to BBT-877, oral capsule
224234490|NCT03830125|DRUG|BBT-877, Multiple doses|Multiple doses of BBT-877, 14 days, 8 dose levels, oral capsule
224234491|NCT01544361|OTHER|Placebo|A single dose of placebo matched to MEDI7814 intravenous infusion over at least 60 minutes on Day 1.
224234492|NCT01544361|BIOLOGICAL|MEDI7814, 1 MG/KG|A single dose of MEDI7814, 1 mg/kg intravenous infusion over at least 60 minutes on Day 1.
224234493|NCT01544361|BIOLOGICAL|MEDI7814, 3 MG/KG|A single dose of MEDI7814, 3 mg/kg intravenous infusion over at least 60 minutes on Day 1.
224234494|NCT01544361|BIOLOGICAL|MEDI7814, 10 MG/KG|A single dose of MEDI7814, 10 mg/kg intravenous infusion over at least 60 minutes on Day 1.
224234495|NCT01544361|BIOLOGICAL|MEDI7814, 20 MG/KG|A single dose of MEDI7814, 20 mg/kg intravenous infusion over at least 60 minutes on Day 1.
224234496|NCT06008457|DEVICE|Labcorp COVID-19+Flu+RSV Test Home Collection Kit|The self-collected Labcorp COVID-19+Flu+RSV Test Home Collection Kit results as generated by the commercially available Labcorp Seasonal Respiratory Virus RT-PCR Test will be compared to the HCP-collected results as generated by Labcorp R\&D using the comparator assays.
224234497|NCT00026936|PROCEDURE|Radiotherapy|
224234498|NCT02322047|DRUG|Prazosin|Prazosin Dosing Days 1-2: 1 mg @ 9PM Days 3-4: 1 mg @ 9AM, 3PM, 9PM Days 5-7: 2 mg @ 9AM, 3PM, 9PM Days 8-10: 2mg @ 9 AM, 3 PM; 8mg @ 9 PM Days 11-14: 4mg @ 9 AM, 3 PM; 8mg @ 9 PM Days 15-42: 4mg @ 9 AM, 3 PM; 8mg @ 9 PM
224234499|NCT02322047|DRUG|Naltrexone|Naltrexone Dosing Days 1-42: 50mg @ 9PM
224234500|NCT02322047|DRUG|Placebo (Prazosin)|Placebo Dosing Days 1-2: 1 mg @ 9PM Days 3-4: 1 mg @ 9AM, 3PM, 9PM Days 5-7: 2 mg @ 9AM, 3PM, 9PM Days 8-10: 2mg @ 9 AM, 3 PM; 8mg @ 9 PM Days 11-14: 4mg @ 9 AM, 3 PM; 8mg @ 9 PM Days 15-42: 4mg @ 9 AM, 3 PM; 8mg @ 9 PM
224234501|NCT02322047|DRUG|Placebo (Naltrexone)|Placebo Dosing Days 1-42: 50mg @ 9PM
224234502|NCT02213796|DRUG|Meropenem|
224234503|NCT02058056|RADIATION|Irradiation: HA-PCI|25 Gy in 10 daily factions, five times a week
223649426|NCT02233361|BEHAVIORAL|Counseling|A randomized controlled design will determine whether hearing aid users who are informed in advance of a follow-up appointment have a different pattern of hearing aid use than a control group that is not preinformed in advance.
223766834|NCT06678438|PROCEDURE|Ultrasound-guided brachial plexus block|The block will be performed as either a lateral infraclavicular brachial plexus block or an axillary brachial plexus block
224234504|NCT03830645|BIOLOGICAL|Platelet Rich Plasma|Application of platelet rich plasma through the intercostal tube into the pleural space
224234505|NCT05699356|OTHER|Non Surgical treatment|Non Surgical
224234506|NCT05699356|PROCEDURE|laparoscopic drilling|Surgical intervension
224234507|NCT05699356|BEHAVIORAL|Treatment of Poly cystic ovary for infertility by Life style modification|Non Surgical
224234508|NCT05699356|PROCEDURE|Treatment of Poly cystic ovary for infertility by Assisted reproductive technique|Surgical intervention
224234509|NCT02207231|DRUG|Guselkumab 100 mg|100 mg by subcutaneous injection at Weeks 0, 4 and q8w thereafter through Week 252 (Group 1). 100 mg by subcutaneous injection at Weeks 16, 20 and q8w thereafter through Week 252 (Group II). 100 mg by subcutaneous injection at Week 52 and q8w thereafter through Week 252 (Group III).
224234510|NCT02207231|DRUG|Placebo for guselkumab|Subcutaneous injections to maintain the blind.
224234511|NCT02207231|DRUG|Adalimumab|80 mg by subcutaneous injection at Week 0, then 40 mg at Week 1 and every 2 weeks (q2w) thereafter through Week 47.
224234512|NCT02207231|DRUG|Placebo for adalimumab|Subcutaneous injections to maintain the blind.
224234513|NCT02954757|PROCEDURE|HIFU treatment|High intensity focused ultrasound
223649427|NCT05936697|DEVICE|fNIRS|For fNIRS to be recorded by the wearable OctaMon+ system (Artinis Medical Systems, The Netherlands), two sources, each surrounded by four detectors positioned approximately 3 cm apart, will be placed on the scalp such that the two channels near the fissure on each side of the head are surrounded F3 and F4. Data will be sampled at 50 Hz.
224234514|NCT04516525|DEVICE|cardiac resynchronisation therapy (CRT) implantation|In a group of 100 patients with chronic cardio-renal syndrome, the blood and urine biomarkers are tested before CRT implantation and after 48 hours, 3 months and 1 year of follow-up.
224234515|NCT01897974|OTHER|Survey|Families complete survey to measure medication compliance.
224234516|NCT04928261|DRUG|Trastuzumab|Patients with early-stage HER2-positive breast cancer who demonstrate a pathological complete response at time of surgery will be treated with HER2 targeted therapy for a total of 9 treatments every 3 weeks (or its equivalent if given weekly) including the treatment received preoperatively.
224234517|NCT03020121|PROCEDURE|Colposcopy/biopsy|Colposcopy/biopsy will be performed on all subjects
223649428|NCT05936697|DEVICE|EEG|For EEG to be recorded by the ANT eego rt8 amplifier (ANT Neuro, Hengelo, The Netherlands), electrodes will be placed at Fp1, F3, F4, Fz, Fpz, Cz, GND (ground), lower VEOG, and on the two earlobes (references). Data will be collected at 2,048 Hz.
223649429|NCT05936697|OTHER|Baseline Training|In the sham condition, participants will receive visual feedback based on pre-recordings and/or other participants' recordings. Participants will undergo a 3-min rest period before and after each training session to track changes in resting-state brain activity within and across sessions.
223649430|NCT04238897|DEVICE|soft contact lens|
223649431|NCT04730232|DRUG|Tislelizumab|Tislelizumab 200mg will be administered on Day 1 of each cycle for 4 treatment cycles.
223649432|NCT04730232|DRUG|Nab-paclitaxel|Nab-paclitaxel 200mg will be administered on Day 2 of each cycle for 4 treatment cycles.
224234518|NCT00326079|DEVICE|Stent|implantation of 1 Glaukos iStent versus 2 Glaukos iStents
223649433|NCT01782391|DEVICE|Stimulation|
224234519|NCT03990675|PROCEDURE|FNA, FNB|Endoscopic ultrasound guided fine needle aspiration, Endoscopic ultrasound guided fine needle biopsy
224234520|NCT02980887|OTHER|No Intervention|There is no intervention in this observational study
224234521|NCT05387902|DEVICE|Extracorporeal Membrane Oxygenation|Patients with high-risk PCI receive mechanical circulatory support with ECMO.
224234522|NCT03937063|OTHER|Collecting recorded videos of Colonoscopy screening tests|To evaluate, in objective way, the usability of the future alpha version of the APDS device by testing the sensitivity and specificity of its results achieved from running it on the collected recorded videos of Colonoscopy screening tests of the general population.
224234523|NCT02258256|DEVICE|Sphygmo|A team of engineers from Rice University has recently developed Sphygmo, an ambulatory, low-cost blood pressure monitor for use in the diagnosis and management of pre-eclampsia in low-resource hospitals
224234524|NCT04637997|DEVICE|compression stockings class I|Daily wearing of compression stockings class I for four weeks on the affected extremity.
224234525|NCT04637997|DEVICE|compression stockings class II|Daily wearing of compression stockings class II for four weeks on the affected extremity.
223649434|NCT01782391|DEVICE|SHAM|no stimulation
224234526|NCT00409994|DRUG|Rapamycin|dosis escalation: 2/4/6 mg rapamycin tablets, once daily during 13 days
223649435|NCT00555516|OTHER|EW02|"1. Name: EW02~2. Dosage form: capsule.~3. Dose(s): 350mg per capsule, 2 capsule tid.~4. Dosing schedule: 2 capsule tid; 15 days (D3 to D17) of EW02 or placebo in Cycles 2 and 3."
223649436|NCT05266170|DEVICE|aerobic and anaerobic exercises|"\[aerobic\]~1. Aerobic treadmill walking program without EX1~2. Aerobic treadmill walking program with EX1~3. High-intensity interval exercise (HIIT) program with EX1~\[anaerobic\]~1\. Fitness exercise program with EX1"
223649437|NCT01470118|DRUG|alcaftadine 0.25% ophthalmic solution|One drop of alcaftadine 0.25% ophthalmic solution instilled in each eye at Day 0 and Day 14.
224320323|NCT03908437|DRUG|buprenorphine/naloxone|"A mobile team will be led by a nurse practitioner (able to prescribe buprenorphine/naloxone in PA) and include a peer recovery specialist (PRS), and a case manager. The team will rapidly confirm opioid use disorder and risk of overdose, complete informed consent, and begin induction procedures for a transitional (one month) course of buprenorphine/naloxone treatment. During this time, the dedicated case manager and PRS will work with the participants to help them become engaged in existing medication assisted treatment programs"
224320324|NCT00226291|OTHER|Synthesized evidence report|Each consultation response included a documented bibliographic search strategy with corresponding references, a targeted list of full-text articles, and a written synthesis and critique of the relevant research materials.
223649438|NCT01470118|DRUG|olopatadine 0.2% ophthalmic solution|One drop of olopatadine 0.2% ophthalmic solution instilled in each eye at Day 0 and Day 14.
223649439|NCT01470118|DRUG|dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%|One drop of placebo instilled in each eye at Day 0 and Day 14.
223649440|NCT05475080|DRUG|Antiplatelet Drug|Any antiplatelet drug or combination
223649441|NCT05475080|DRUG|Anticoagulant|Any anticoagulante
223649442|NCT05475080|PROCEDURE|Endovascular|Angioplasty +- stent
223649443|NCT05475080|PROCEDURE|Surgery|Endarterectomy
223649444|NCT02458326|OTHER|Aerobic training|Treadmill training with proper heart rate for aerobic workout to 20 minutes duration and frequency of three times a week for three months.
224234527|NCT04957108|OTHER|Device identification using Xray.|PMIDa and CRMD-f applications were used to identify CIED
224234528|NCT01150487|PROCEDURE|bone marrow aspirations|A bone marrow aspiration from each hip bone of the patients.
223649445|NCT02458326|OTHER|Control Training|10 minutes of heating on the treadmill with a low speed that does not cause patient effort
223649446|NCT03339219|DRUG|Cabozantinib|Cabozantinib tablets
223649447|NCT01009216|DRUG|ABT-384|Doses will be administered daily for 5 days.
223649448|NCT04623632|DRUG|Transversus abdominus plane block|transversus abdominus plane block using 40 ml of bupivacaine 0.25%
223649449|NCT04623632|DRUG|Transversus abdominus plane placebo|injection of 40 ml of normal saline in the transversus abdominus plane
223649450|NCT04036396|BEHAVIORAL|Mobile Enhanced Prevention Support|Access to the newly developed GeoPassport App, incentives for accessing identified services, and a trained Peer Mentor.
223649451|NCT04036396|BEHAVIORAL|Usual Care plus Customized Referrals|Participants in the control arm will continue to receive services they would normally receive consistent with the setting in which they were recruited. This includes substance use treatment in jail, substance use treatment at a residential recovery facility, and/or supportive housing services. The study will provide referrals customized to their needs and preferences.
223649452|NCT02015962|DRUG|Intravenous potassium chloride|
223649453|NCT02015962|DRUG|Oral potassium chloride|
223649454|NCT02955849|DEVICE|SLT laser|Patients will be offered initial SLT laser by doctors
224234529|NCT01150487|PROCEDURE|lymph node collection|An Iliac lymph node collection.
224234530|NCT05326464|DRUG|Tofacitinib 10mg|10 mg given orally twice daily until evidence of progression, intolerance of treatment, withdrawal of consent, or death.
224234531|NCT05005949|DEVICE|Arctic Front™ Cardiac Cryoablation Catheter System|Pulmonary vein isolation will be performed with the Arctic Front™ Cardiac Cryoablation Catheter System
224234532|NCT05054868|DRUG|Oxycodone|Subjects randomized to the control group will receive oxycodone for postop pain management (standard of care).
224234533|NCT05054868|DRUG|Ketorolac|Subjects randomized to the treatment group will receive oxycodone and ketorolac for postop pain management.
224320325|NCT05531656|DRUG|CT1812|Study Drug
224320326|NCT05531656|DRUG|Placebo|Non-active study drug
223649455|NCT00235365|BEHAVIORAL|meta-cognitive therapy|Meta-cognitive therapy
224234534|NCT04808089|OTHER|Health Lung App. of mobile phone+ezOxygen mobile spirometry|"Subjects can get reminder to use inhaler on schedule, input ACT score to evaluate the asthma control, get education materials about asthma and operate spirometer to access lung function outside of hospital.~The physicians can get the information about control status, lung function, adherence of controller and usage of reliver of patients between each clinical visit, if patients following the instruction of Health Lung."
223649456|NCT00235365|OTHER|waiting list|waiting list control
224234535|NCT04808089|OTHER|Usual care|The research assistant assess/ teach inhaler technique, offering advice on adherence, delivering patient self-management asthma action plan and education the meaning of asthma control accessed by ACT.
224234536|NCT03462940|DIETARY_SUPPLEMENT|Tauroursodeoxycholic acid|Tauroursodeoxycholic acid is an ambiphilic bile acid. It is the taurine conjugate form of ursodeoxycholic acid.
224234537|NCT03467568|DIETARY_SUPPLEMENT|Sodium Chloride|300mg sodium chloride will be provided in a capsule
224234538|NCT03467568|OTHER|Placebo capsule|A capsule of identical appearance to that providing salt, but not containing electrolytes, will be consumed
223649457|NCT03212313|DRUG|Tozadenant|Two 60 mg tablets for a total single study dose of 120 mg
224320327|NCT00191191|DRUG|Pemetrexed 500 mg/m2|500 mg/m2, intravenous (IV), every 21 days, one year from registration date
224320328|NCT00191191|DRUG|Pemetrexed 1000 mg/m2|1000 mg/m2, intravenous (IV), every 21 days, one year from registration date
223649458|NCT03839797|BEHAVIORAL|Cadet Healthy Personal Skills|7.5 hour skills training group intervention
223649459|NCT03839797|BEHAVIORAL|Standard Health Education|Standard Health Education
223649460|NCT00643903|BEHAVIORAL|Cognitive behavioral coping effectiveness training|Coping effectiveness training will include five individual 90-minute counseling sessions. The sessions will focus on coping with stress, dealing with medication side effects, and staying on track with medications.
223649461|NCT00643903|BEHAVIORAL|Standard care|Participants will receive standard of care for HIV infections.
223649462|NCT00643903|BEHAVIORAL|Single group workshop on coping effectiveness training|Participants will attend one group workshop covering the same material as in the individual sessions. The workshop will be delivered after completion of the Month 18 final assessment.
223766835|NCT06678438|PROCEDURE|Haematoma Block|Participants will receive no peripheral nerve block and receive a haematoma block, with or without supplemental sedation and/or systemic analgesia for the closed reduction according to local guidelines and clinical practices
223766836|NCT06630832|OTHER|Simulated work in the heat with no cooling during rest breaks|Young and older adults will not undergo cooling during rest breaks applied during the implementation of work-rest allocations over the duration of a 180-min work period following a continuous work bout to 38.0°C (equivalent to a 1°C increase in body core temperature above resting levels).
223766837|NCT06630832|OTHER|Simulated work in the heat with partial cooling during rest breaks|Young and older adults will not undergo partial cooling during rest breaks applied during the implementation of work-rest allocations over the duration of a 180-min work period following a continuous work bout to 38.0°C (equivalent to a 1°C increase in body core temperature above resting levels).
224234539|NCT03467568|DIETARY_SUPPLEMENT|Water|Twice during the morning a drink of 150ml of water will be consumed
224234540|NCT03467568|BIOLOGICAL|No water consumed|No water will be consumed during the monring
224234541|NCT02276196|DRUG|Lixisenatide|GLP-1 receptor agonist
224234542|NCT02276196|DRUG|Insulin glulisine|Insulin analogue
224234543|NCT04879810|PROCEDURE|Sigmoidoscopy and biopsy, blood work|Flexible tube up lower colon, blood draws, quality of life questionnaires
224234544|NCT03803410|PROCEDURE|blood test, noninvasive test for liver fibrosis|blood test of HCV serology and virology.noninvasive test including M2BPGi and fibroscan for liver fibrosis
223649463|NCT05726708|BEHAVIORAL|E-Learning|On line modules of coaching for parents
224234545|NCT05497414|BEHAVIORAL|Sleep deprivation|Overnight sleep deprivation.
224234546|NCT00139321|DEVICE|Force platform and electromyography|
224234547|NCT03735602|BEHAVIORAL|perceptual training|orientation discrimination task
224234548|NCT05102175|OTHER|Focus Group|Eligible participants will be invited to a semi-structured focus group discussion. Each group will include 8 -12 participants.
224234549|NCT03913000|DRUG|ID-085|Hard capsules for oral administration formulated at a strength of 200 mg
223649464|NCT05083117|DRUG|XW001|It is anticipated that inhalation of 1 mg XW001 solution up to 14 days will result in a relatively lower systemic exposure in COVID-19 patients on oxygen therapy compared to that in healthy participants as COVID-19 patients tend to have impaired lung function of diffusive, restrictive, obstructive, or mixed origins.
223649465|NCT05083117|DRUG|Placebo|It is anticipated that inhalation of 1 mg Placebo solution up to 14 days will result in a relatively lower systemic exposure in COVID-19 patients on oxygen therapy compared to that in healthy participants as COVID-19 patients tend to have impaired lung function of diffusive, restrictive, obstructive, or mixed origins.
223649466|NCT02902237|BIOLOGICAL|tTF-NGR|tTF-NGR will be given as 1-hour infusion via central venous access once daily for 5 days with a subsequent rest period of 2 weeks and following cycles with dose escalation of 0.5 mg/m2 upon judgement of tolerability and therapeutic activity. Starting dose will be 1 mg/m2/day. Dose-escalation is stopped before the maximum number of 8 escalation steps if tumor response, tumor progression or a Dose-Limiting Toxicity (DLT) is observed.
224234550|NCT06237075|DEVICE|transcranial direct current stimulation|2-milliamp stimulation for 5\~15 min
224234551|NCT00502775|DRUG|fluticasone furoate, fexofenadine|
224320329|NCT04837144|DEVICE|Physical Rehabilitation with MAK exoskeleton|The participants will assist to 9 physical rehabilitation sessions with the MAK exoskeleton. During these sessions, different movements and therapies will be conducted using the studied device.
224320330|NCT05445492|DEVICE|CPM Device|The CPM device and reference device are used simultaneous to validate the CPM device.
224320331|NCT05933044|DRUG|Durvalumab|Chemoradiotherapy plus durvalumab
224320332|NCT04238650|DRUG|MB02 (Bevacizumab Biosimilar)|Solution for intravenous infusion, single dose of 3mg/kg, administered as 90- minute infusion
224320333|NCT04238650|DRUG|EU approved Avastin®|Solution for intravenous infusion, single dose of 3mg/kg, administered as 90- minute infusion
223649467|NCT02004678|DRUG|DS-1150b|
223649468|NCT02004678|OTHER|Placebo|
223649469|NCT03983811|DRUG|Icotinib|Patients receive 4 cycles of platinum-based doublet chemotherapy on day 1 with intercalated icotinib (D8-15) every 3 weeks, and continued icotinib for 2 years or until the occurrence of disease relapse, metastasis or unacceptable icotinib or chemotherapy toxicity
223649470|NCT03983811|DRUG|Placebo|Patients receive 4 cycles of platinum-based doublet chemotherapy on day 1 with intercalated placebo (D8-15) every 3 weeks, and continued placebo for 2 years or until the occurrence of disease relapse, metastasis or unacceptable toxicity
223649471|NCT03983811|OTHER|chemotherapy|Patients in each groups need to receive 4 cycles of platinum-based doublet chemotherapy
223649472|NCT04749056|BEHAVIORAL|EPAS (electronic psycho-oncological adapative screening program)|"Adaptive tests assess depression, anxiety and distress. Only items with highest information value are selected. Furthermore, patients fill in a checklist to report supportive care needs.~The results page contains (i) the extent of distress and additional information to interpret these levels, (ii) a summary of the reported supportive care needs and (iii) individualized recommendations for the use of psychosocial services at the institution based on the care needs.~The supportive care needs are transformed into concrete recommendations to use the adequate psychosocial service at the institution. Highly distressed patients are recommended to use psycho-oncological service irrespective of whether they have reported such a need in the check list. Physicians of highly distressed patients are recommended on their results page to talk with the patient about his/her psychosocial condition and further issues within such an appointment are suggested."
223649473|NCT04655807|DRUG|JNJ-64304500|JNJ-64304500 will be administered as SC injection.
223649474|NCT04655807|DRUG|Placebo|Matching placebo will be administered as SC injection.
223649475|NCT04655807|DRUG|Adalimumab|Adalimumab will be administered as SOC biological therapy.
223649476|NCT04655807|DRUG|Ustekinumab|Ustekinumab will be administered as SOC biological therapy.
223649477|NCT00533936|BIOLOGICAL|trastuzumab|
223649478|NCT00533936|DRUG|cyclophosphamide|
223649479|NCT00533936|DRUG|doxorubicin hydrochloride|
223649480|NCT00533936|DRUG|fluorouracil|
223649481|NCT00533936|DRUG|paclitaxel|
223766838|NCT06630832|OTHER|Simulated work in the heat with full cooling during rest breaks|Young and older adults will not undergo full cooling during rest breaks applied during the implementation of work-rest allocations over the duration of a 180-min work period following a continuous work bout to 38.0°C (equivalent to a 1°C increase in body core temperature above resting levels).
224234552|NCT01083875|DRUG|amlexanox|0.5% amlexanox oral rinse; use 5 ml every 2-3 hours during the awake hours of each day (a minimum of 6 times each day). The liquid was be swirled around the mouth then to be swallowed. Repeated daily until completion of radiation therapy: approximately 7-8 weeks.
224234553|NCT01083875|DRUG|Vehicle rinse|use 5 ml of the vehicle rinse every 2-3 hours during the awake hours of each day (a minimum of 6 times each day). The liquid is be swirled around the mouth then swallowed.
224234554|NCT03501875|RADIATION|CAC Score|Computed tomography angiography (CTA) with an injection of iodine-rich contrast material
224234555|NCT00998699|DRUG|Xoma 052|Sterile solution subcutaneously administered every 4 weeks for 12 weeks
224234556|NCT00998699|DRUG|Placebo|Sterile solution subcutaneously administered every 4 weeks for 12 weeks
224234557|NCT02127606|DEVICE|Vibration with tilt-table standing|
224234558|NCT00698906|BIOLOGICAL|HBV-MPL vaccine|5 different formulations, 2-dose intramuscular injection
224234559|NCT00698906|BIOLOGICAL|Engerix™-B|3-dose intramuscular injection
224234560|NCT02889185|DEVICE|RTX1 IMAGIN EYE retinal camera|In addition to the routine examination including OCT, an imaging using RTX1 IMAGIN EYE retinal camera will be performed.
224234561|NCT02375009|PROCEDURE|Selective laser trabeculoplasty|laser therapy to trabecular outflow pathway of the eye to lower intraocular pressure, delivered to 360 degrees of both eyes in a single session
224320334|NCT04289363|BEHAVIORAL|Clinical program implementation|Using mixed methods and triangulating multiple sources of data collected over the course of parent and ancillary studies to evaluate the feasibility, acceptability, sustainability, and impact of the ED-initiated BUP clinical program and implementation facilitation strategy and identify factors influencing diffusion and effectiveness. Converging provider and patient perspectives and field notes with process measures and intervention outcomes, including proportions screened, treated, and engaged in treatment, will provide explanation to contextualize and better understand feasibility, acceptability, and factors associated with the rate with which the ED-initiated BUP innovation is adopted and how well it is sustained.
224320335|NCT02704169|OTHER|Spatially registered endoscopy|
224320336|NCT00727012|DEVICE|mitral valve repair (SJM® Rigid Saddle Ring)|mitral valve repair due to mitral degenerative or functional disease
223649482|NCT00533936|PROCEDURE|adjuvant therapy|
223649483|NCT00533936|PROCEDURE|conventional surgery|
223649484|NCT00533936|PROCEDURE|neoadjuvant therapy|
223649485|NCT06056479|PROCEDURE|external oblique intercostal block|20 ml of bupivacaine 0.25% will be administered by US into external oblique intercostal plane at the level of sixth rib space .
223649486|NCT00629889|DRUG|levetiracetam|"After inclusion, patients receive Levetiracetam 2x250mg per day. The medication may be increased, in intervals of 500mg of Levetiracetam of at least 24h up to maximally: Levetiracetam 2x1500mg.~Patients might be treated up to one year within the study. If well tolerated, treatment might continue after end of study."
223649487|NCT00629889|DRUG|pregabalin|"After inclusion, patients receive Pregabalin 2x75mg per day. The medication may be increased, in intervals of 150mg of Pregabalin of at least 24h up to maximally: Pregabalin 2x300mg.~Patients might be treated up to one year within the study. If well tolerated, treatment might continue after end of study."
223649488|NCT03113461|DEVICE|CPAP|non-invasive positive airway pressure applied using an oronasal mask
223649489|NCT05791019|OTHER|Paleolithic diet effect on patients|Efficacy of paleolithic diet in control of blood level of glucose in type 2 DM patients
223649490|NCT05063773|DEVICE|Mixed reality heads up display|Physician will use a mixed reality headset for image guidance of the procedure
223649491|NCT01932437|BIOLOGICAL|ETI-204|monoclonal antibody
223649492|NCT01932437|OTHER|Placebo|Placebo for ETI-204
223649493|NCT01348516|DRUG|KM-023|-KM-023 is dosed orally via 75 mg tablets. Study doses are 75 mg, 150 mg, 300 mg, and 600 mg QD for 1 (SAD) or 7 (MAD) days.
224234562|NCT05231109|OTHER|vestibular rehabilitation|Vestibular rehabilitation consisted of a total of 12 sessions, rearranged every 15 days. These exercises were prepared gradually to increase the vestibulo-ocular reflex and vestibulospinal reflex. The following exercises were done with the patients: vestibular adaptation exercises, oculo-motor exercises, standing by changing the support area, the support surface and the arm positions, heel-toe walking, walking with head rotation, backward walking, counting on a soft surface with eyes open and closed, and dynamic balance exercises were taught to the patients. The therapist gave the patients a home exercise program. It was emphasized that the exercises should be applied as 10 repetitions. After the session, the exercises shown to the patients were explained in written form and given as home exercises. They were also asked to do home exercises 3 times a day, 10 repetitions, for 15 days. Patients were re-evaluated before the treatment, at the 3rd month and after the 6th month.
224234563|NCT00995137|BIOLOGICAL|NK Cell Infusion|Infusing genetically modified NK cells into research participants who have chemotherapy refractory or relapse B-lineage ALL.
224234564|NCT02586259|DRUG|budesonide MMX®|
224234565|NCT03492359|DEVICE|Thora-3Di|Device that uses a grid of structured light to measure chest and abdominal wall movement
224234566|NCT03492359|DEVICE|Body Plethysmography|A pulmonary function test (PFT) for measuring total lung volume.
223766839|NCT07024030|DRUG|0.02mg/kg|Slowly infuse intravenously 24 hours before the scheduled surgery. The investigator shall conduct near-infrared fluorescence imaging during the operation to assist with the surgery. Tissues detected with fluorescence need to be marked, and resection shall be guided by fluorescence until there is no fluorescent tissue within the surgical field.
224234567|NCT03492359|DEVICE|Spirometry|A pulmonary function tests (PFT) for measuring maximal forced expiratory flow and volume.
224234568|NCT01315145|PROCEDURE|Percutaneous Lumbar Decompression|The percutaneous procedure is performed under fluoroscopic guidance to effect a lumbar decompression with minimal surrounding tissue and bone disruption. The mild® Device Kit is utilized to access, capture and remove bone and tissue.
224234569|NCT01315145|DRUG|Epidural Steroid Injection|Injection of epidural steroids into the lumbar spine
224234570|NCT05224895|PROCEDURE|General Anesthesia in Trendelenburg position for robotic prostatectomy|in this arm, changes in preoperative and postoperative airway measurements and correlation with postoperative critical airway events will be monitored.
224234571|NCT04518774|BIOLOGICAL|Ex-vivo expanded allogeneic γδT cells|Cells will be extracted from a healthy donor by apheresis, followed by ex-vivo expansion and activation. The ex-vivo expanded γδT cells from donors will be adoptively transfused.
224320337|NCT02289872|DEVICE|Macintosh Laryngoscope|Direct-Laryngoscopy
224320338|NCT02289872|DEVICE|TruView PCD Video laryngoscope|Video-Laryngoscopy
224320339|NCT03347825|PROCEDURE|Robotic-assisted lobectomy using da Vinci Surgical System|Robotic-assisted lobectomy
224320340|NCT03347825|PROCEDURE|VATS (video assisted thoracic surgery)|VATS (video assisted thoracic surgery)
223766840|NCT07024030|DRUG|0.04mg/kg|Slowly infuse intravenously 24 hours before the scheduled surgery. The investigator shall conduct near-infrared fluorescence imaging during the operation to assist with the surgery. Tissues detected with fluorescence need to be marked, and resection shall be guided by fluorescence until there is no fluorescent tissue within the surgical field.
223766841|NCT07024927|PROCEDURE|AF ablation|Catheter ablation will be performed under general anesthesia or local anesthesia. Pulmonary vein isolation (PVI) was performed in all patients. Beyond this mandatory step, the specific ablation strategy/protocol and ablation parameters/settings will be determined at the discretion of the operating physicians at each participating center.
224234572|NCT06409962|OTHER|Technological combination|The intervention comprises workshops, individualized counseling, cooking classes, and physical activity promotion. It emphasizes nutritional education, hands-on cooking, and behavioral modification techniques. Participants receive personalized guidance and resources to make sustainable dietary and lifestyle changes. Social support networks foster motivation and accountability. By combining these components, the intervention aims to empower participants with the knowledge, skills, and support needed for long-term health improvements.
224234573|NCT06444074|BEHAVIORAL|Patient Activation through Conversations (PACT) Program|Participants in the intervention arm will undergo a 3-month long health coaching program where a care coach will review a participant's health parameters and current self-care behaviours, identify health motivators and set goals for improving their diabetes, as well as fortnightly support through text or phone call.
224234574|NCT06444074|BEHAVIORAL|Usual Care|Routine Chronic Disease care
224234575|NCT03392974|BIOLOGICAL|Valoctocogene Roxaparvovec|Adeno-Associated Virus Vector-Mediated Gene Transfer of Human Factor VIII in Hemophilia A
224320341|NCT03347825|PROCEDURE|Open lobectomy|Open lobectomy
224320342|NCT03277066|DRUG|Diclofenac Sodium Active Topical Patch 1|HP-5000 Active Topical Patch 1 were applied on subjects with Osteoarthritis of the knee(s)
224320343|NCT03277066|DRUG|Diclofenac Sodium Active Topical Patch 2|HP-5000 Active Topical Patch 2 were applied on subjects with Osteoarthritis of the knee(s)
224320344|NCT03277066|DRUG|Placebo patch|Topical placebo patches were applied on subjects with Osteoarthritis of the knee(s)
224320345|NCT03348163|DRUG|B/FTC/TAF|B/FTC/TAF is bictegravir + tenofovir alafenamide + emtricitabine in one pill (single tablet regimen)
224320346|NCT03348163|DRUG|Current ART|Current ART is emtricitabine plus tenofovir disoproxil fumarate or tenofovir alafenamide plus 3rd agent.
224320347|NCT00390208|DRUG|ranibizumab, dexamethasone and verteporfin|One 500 microgram dose (0.05cc) intravitreal dexamethasone (10 mg/ml vial) in combination with Visudyne Photodynamic Therapy and 0.5 mg intravitreal Ranibizumab injection on the same day.
224320348|NCT00390208|DRUG|Ranibizumab|One 0.5 mg intravitreal Ranibizumab injection
224320349|NCT03390855|OTHER|Broccoli sprouts|
224320350|NCT01749423|BIOLOGICAL|OnabotulinumtoxinA|Previous treatment with onabotulinumtoxinA for Chronic Migraine.
224320351|NCT00900419|OTHER|immunohistochemistry staining method|Laboratory test
224320352|NCT00900419|OTHER|laboratory biomarker analysis|Laboratory Test
224320353|NCT00900419|OTHER|sputum cytology|Laboratory Test
224320354|NCT00900419|PROCEDURE|biopsy|Laboratory Test
224234576|NCT01963039|DEVICE|percutaneous vertebroplasty|Using fluoroscopic guidance, the practitioner infiltrates the skin and subcutaneous tissues overlying the pedicle of the target vertebra or vertebrae with 1% lidocaine and infiltrates the periosteum of the pedicles with 0.25% bupivacaine (marcaine. For the vertebroplasty procedure, 11-gauge or 13-gauge needles are passed into the central aspect of the target vertebra or vertebrae. Bone cement is prepared on the bench and injected under constant fluoroscopy into the vertebral body. Injection is stopped when the PMMA reaches the posterior aspect of the vertebral body or leaks into an extraosseous space, such as the intervertebral disk or an epidural or paravertebral vein.
224320355|NCT05881434|OTHER|Emergency Department Visit Expectations Questionnaire|Patients presented with novel questionnaire designed to illicit patient's self-reported expectations across four domains (overall purpose of visit, medication intervention, imaging intervention and disposition) during check-in when arriving at the emergency department. Patients instructed to present the completed questionnaire to the treating provider.
224320356|NCT05894837|DRUG|Serplulimab+Regorafenib|Serplulimab: once every two weeks; Regorafenib: from the first day to the 21st day
224320357|NCT05894837|DRUG|Hepatic Artery Bicarbonate Infusion|hepatic artery bicarbonate infusion: once every four weeks
224320358|NCT01457937|DRUG|Pegylated Interferon, Ribavirin, Boceprevir|"PEG IFN alfa 2b 1,5 ug/kg once weekly; Ribavirin (800-1400 mg / day)~or~PEG IFN alfa 2b 1,5 ug/kg once weekly; Ribavirin (800-1400 mg / day); Boceprevir (1.5 mcg / kg QW)"
224320359|NCT02585778|DRUG|Alirocumab|Solution for injection, one subcutaneous injection in the abdomen, thigh, or outer area of upper arm with a disposable auto-injector.
224320360|NCT02585778|DRUG|Placebo|Solution for injection, one subcutaneous injection in the abdomen, thigh, or outer area of upper arm with a disposable auto-injector.
224320361|NCT02585778|DRUG|Lipid-Modifying Therapy (LMT)|Statins at stable, maximally tolerated dose with or without other LMT as clinically indicated.
224320362|NCT02585778|DRUG|Antihyperglycemic Drug|Insulin (injectable or inhaled) alone or with other antihyperglycemic drugs as clinically indicated.
224320363|NCT05731193|OTHER|Exposed group (EXP) - 35 students. EXP group will learn pathological and nonpathological sounds for 3 days.|After 3 days students will take 3 tests with different levels of white noise pollution added ( signal-to-noise ratio (SNR) 20, 40 and none added)
224320364|NCT00504751|DRUG|bortezomib, dexamethasone, ifosfamide|"VIPER chemotherapy will be administered every 28 days at the following doses:~* Dexamethasone 40 mg IV days 1-4~* Ifosfamide 1.0 gram/m2 CIVI over 24 hours days 1-4~* Mesna 1.0 gram/m2 CIVI over 24 hours days 1-4 (mix solution with ifosfamide)~* Cisplatin 25 mg IV days 1-4~* Etoposide 100 mg/m2 CIVI over 24 hours days 1-4~* Rituximab 500 mg/m2 IV day 1 prior to start of DICE (375 mg/m2 for subsequent cycles)~* VELCADE 1.5 mg/m2 on days 2 and 5"
224320365|NCT00504751|DRUG|mesna, cisplatin, etoposide, rituximab|"VIPER chemotherapy will be administered every 28 days at the following doses:~* Dexamethasone 40 mg IV days 1-4~* Ifosfamide 1.0 gram/m2 CIVI over 24 hours days 1-4~* Mesna 1.0 gram/m2 CIVI over 24 hours days 1-4 (mix solution with ifosfamide)~* Cisplatin 25 mg IV days 1-4~* Etoposide 100 mg/m2 CIVI over 24 hours days 1-4~* Rituximab 500 mg/m2 IV day 1 prior to start of DICE (375 mg/m2 for subsequent cycles)~* VELCADE 1.5 mg/m2 on days 2 and 5"
224320366|NCT03188744|OTHER|Assessment of the pelvic floor function|Vaginal palpation and perineometry.
224320367|NCT03188744|OTHER|Questionnaire application|Questionnaires: EORTC, WHOQoL-BREF, PFID-20; PSIQ-12 and PFIQ-7.
224320368|NCT03646994|DRUG|Crizotinib|Crizotinib Cap 250 mg po bid
224320369|NCT03438994|DIAGNOSTIC_TEST|Play.Care|iPad based game to assess movement as the player interacts with the screen
224320370|NCT01051362|DRUG|PLD and Carboplatin|Pegylated liposomal doxorubicin (PLD) 30 mg/m2, followed by Carboplatin AUC (area under the curve) 5, every 21 days for 4 cycles or until progression.
224320371|NCT01102101|DRUG|Remifentanil|Remifentanil (Ultiva; Glaxo-Smith-Kline; Vienna, Austria) will be applied intravenously during 60 minutes through a dedicated infusion pump (TCI Alaris PK Syringe Pump, Cardinal Health, Baesweiler, Germany), with a Target Controlled Infusion (following the integrated software algorithm by Minto), reaching the initial 18ng/ml plasma concentration in 180 seconds. This corresponds to approx. 0.7 µg kg-1 min-1.
224320372|NCT04495569|BIOLOGICAL|recombinant anti-rabies human monoclonal antibody injection (SYN023)|The finished product of SYN023 is a mixture of two anti-rabies human monoclonal antibodies, CTB011 and CTB012 by equal quantity, containing 3.0 mg/mL active ingredients in both.
224320373|NCT04495569|BIOLOGICAL|Rabies Vaccine|The Chinese licensed Vero Cell Freeze-dried Rabies Vaccine was injected to Cohort B as per the vaccination precedure on Days 1, 4, 8, 15, 28 respectively.
224320374|NCT01990586|DRUG|Rabeprazole sodium 20 mg Delayed Release tablet|
224234577|NCT01963039|PROCEDURE|Sham procedure|Using fluoroscopic guidance, the practitioner infiltrates the skin and subcutaneous tissues overlying the pedicle of the target vertebra or vertebrae with 1% lidocaine and infiltrates the periosteum of the pedicles with 0.25% bupivacaine (marcaine). During the sham intervention, verbal and physical cues, such as pressure on the patient's back, are given, and the methacrylate monomer (PMMA) is opened to simulate the odor associated with mixing of cement, but the needle is not placed and cement is not injected.
224320375|NCT02370238|DRUG|paclitaxel|paclitaxel 80 mg/m2 i.v. (Days 1, 8, and 15)
224320376|NCT02370238|DRUG|Reparixin|reparixin oral tablets 1200 mg t.i.d. continuing from D 1 to Day 21 of 28-day cycle
224320377|NCT02370238|DRUG|placebo|placebo oral tablets 1200 mg t.i.d. continuing from D 1 to Day 21 of 28-day cycle
224320378|NCT02819284|DRUG|KPI-121 0.25% Ophthalmic Suspension|
224320379|NCT02819284|DRUG|Vehicle of KPI-121 0.25% Ophthalmic Suspension|
224320380|NCT05639582|OTHER|fractal analysis|fractal analysis is a method that numerically expresses bone changes.
223649494|NCT01348516|DRUG|Placebo for KM-023|-Placebo for KM-023 is dosed orally via Placebo for KM-023 tablets. Study doses are 1, 2, 3, and 4 placebo tablets QD for 1 (SAD) or 7 (MAD) days.
223649495|NCT05013541|OTHER|No intervention|Observational study, standard record of need to void during cystometry
223649496|NCT00074490|DRUG|Rituximab|Rituximab: 375 mg/m(2)/day intravenous (IV), day 1 (for cluster of differentiation 20 (CD20+) patients).
223649497|NCT00074490|DRUG|Fludarabine|Fludarabine: 30 mg/m(2)/day intravenous (IV), days -6 to -3.
223649498|NCT00074490|DRUG|Etoposide|Etoposide: 50 mg/m(2)/day continuous intravenous (CIV), days 1-4.
223649499|NCT00074490|DRUG|Doxorubicin|Doxorubicin:10 mg/m(2)/day continuous intravenous (CIV), days 1-4.
223649500|NCT00074490|DRUG|Vincristine|Vincristine: 0.4 mg/m(2)/day continuous intravenous (CIV), days 1-4.
223649501|NCT00074490|DRUG|Cyclophosphamide|Cyclophosphamide, 300 mg/m(2)/day intravenous (IV), days -6 to -3.
224234578|NCT03006016|DRUG|Omega-3 Fatty Acid|The enrollment in the study is proposed by an investigator (surgeon) in each centre at the time of a preoperative visit (V0). Randomization takes place the week before the visit with the investigating surgeon in charge of the patient (V1) when the bariatric procedure is scheduled: omega-3 group (1650 mg of omega-3 / day for 4 weeks without caloric restriction) or placebo group.
224234579|NCT03006016|OTHER|Placebo|The enrollment in the study is proposed by an investigator (surgeon) in each centre at the time of a preoperative visit (V0). Randomization takes place the week before the visit with the investigating surgeon in charge of the patient (V1) when the bariatric procedure is scheduled: omega-3 group (1650 mg of omega-3 / day for 4 weeks without caloric restriction) or placebo group.
224234580|NCT00996190|DRUG|Phenylephrine|phenylephrine 120 micrograms/mL, administered either by continuous infusion or by intermittent bolus dose
224234581|NCT02879279|DEVICE|Amadeo, Pablo, Diego and Motore.|In the robotic rehabilitation group, patients will be treated with the following systems: Amadeo, Pablo and Diego (Tyromotion GmbH, Austria), and Motore (Humanware, Italy). A ratio of one therapist to every 3 or 4 patients will be used, depending on the patient's severity. The rehabilitation treatment will be performed daily for 45 minutes, for 5 days per week, for 6 weeks. A total of 30 sessions will be performed.
224234582|NCT02879279|OTHER|Conventional rehabilitation|In the conventional rehabilitation group, patients will undergo a conventional treatment with a ratio of one therapist to one patient. The rehabilitation treatment will be performed daily for 45 minutes, for 5 days per week, for 6 weeks. A total of 30 sessions will be performed.
224234583|NCT05232708|DRUG|Semaglutide B, 1.34 mg/mL|Subjects will receive single dose of 0.5 mg Semaglutide B, 1.34 mg/mL subcutaneously.
224234584|NCT05232708|DRUG|Semaglutide D, 1.0 mg/mL|Subjects will receive single dose of 0.5 mg Semaglutide D, 1.0 mg/mL subcutaneously.
224234585|NCT05232708|DRUG|Semaglutide D, 1.0 mg/mL|Subjects will receive single dose of 0.5 mg Semaglutide D, 1.0 mg/mL subcutaneously.
224234586|NCT05232708|DRUG|Semaglutide B, 1.34 mg/mL|Subjects will receive single dose of 0.5 mg Semaglutide B, 1.34 mg/mL subcutaneously.
224234587|NCT05014308|PROCEDURE|Piezoelectric Alveolar Decortication, fibrotomy|
224234588|NCT03643666|DRUG|dexamethasone|before closure of the laparoscopic entering sites the patients will receive instillation of 40 ml of normal saline containing 16mg dexamethasone
223649502|NCT00074490|PROCEDURE|Peripheral blood stem cell (PBSC) transplantation|PBSC transplantation, peripheral blood progenitor cell transplantation, transplantation, peripheral blood stem cell.
223649503|NCT00074490|GENETIC|T cell donor lymphocyte infusion (DLI) with unmanipulated donor T cells|The dose of the T cells will attempt to be held constant for each study recipient (target dose 2.5 x 10(7) T cells/kg; minimum dose will be 1 x 10(7) T cells/kg).
223649504|NCT00074490|DRUG|Prednisone|Prednisone: 60 mg/m(2)/day by mouth (PO), days 1-5.
224234589|NCT03643666|DRUG|magnesium sulphate|patients will receive instillation of 40 ml of normal saline containing 16mg dexamethasone plus magnesium sulphate 2 gm into the peritoneum at the end of the operation
224234590|NCT03643666|DRUG|Placebo (saline)|before closure of the laparoscopic entering sites the patients received instillation of 40 ml normal saline into the peritoneum
223649505|NCT00074490|PROCEDURE|Allogeneic hematopoietic stem cell transplant (HSCT)|Allogeneic Hematopoietic Stem Cell Transplant.
223649506|NCT00074490|DRUG|Filgrastim|Filgrastim: 5 mcg/kg/day subcutaneous (SC), day 6 (require absolute neutrophil count (ANC) \> 1000, two values; or ANC \> 5000 cells/ul on one occasion).
223649507|NCT00074490|GENETIC|T-Rapa cell Donor Lymphocyte Infusion (DLI)|The dose of T helper 2 (Th2) cells or unmanipulated donor T cells will attempt to be held constant for each study recipient (target dose 2.5 x 10(7) Th2/kg; minimum dose will be 1 x 10(7) Th2/kg).
223649508|NCT03810911|DRUG|Darbepoetin|Used to treat anemia. In the group labeled no intervention, the intervention is simply delayed 12 weeks after randomization as noted in the description.
223649509|NCT03973060|DEVICE|Concentric-eccentric muscular work|For muscular contraction, the physiotherapist carried out 12 repetitions with one minute rest between series and series, total working time of 12 minutes.
223649510|NCT03973060|GENETIC|Genetic polymorphism|Genetic polymorphism study by Polymerase Chain Reaction (PCR) to determine whether the genetic makeup of individuals for the improvement of muscular work in the results of the study.
223649511|NCT04794569|DRUG|tinzaparin|low molecular weight heparin
223649512|NCT04794569|DRUG|Rivaroxaban|direct oral anticoagulant
223649513|NCT02668536|DRUG|Standard Sunscreen|Areas will be treated with a standard preparation, consisting of padimate O (7%) and oxybenzone (3%) will be used as the control sunscreen.
223649514|NCT02668536|DEVICE|BNP|Additional areas will be treated with empty bioadhesive nanoparticles (BNPs).
223649515|NCT03111628|DRUG|Omalizumab|omalizumab 300 mg every 4 weeks by subcutaneous injection
223649516|NCT03937999|DRUG|Bezlotoxumab|Injection: 1,000 mg/40 mL (25 mg/mL) solution in a single-dose vial.
223649517|NCT05441813|DRUG|Virgin Coconut Oil|Standard of care with the addition of virgin coconut oil mouth rinse
224234591|NCT03365323|OTHER|Periprosthetic Joint Infection|Periprosthetic Joint Infection is diagnosed according to the diagnosing criteria from the Workgroup of the Musculoskeletal Infection Society.
224234592|NCT03365323|OTHER|Non-Periprosthetic Joint Infection|PJI can not be diagnosed for the lack of clinical evidence according to the diagnosing criteria from the Workgroup of the Musculoskeletal Infection Society.
224234593|NCT00655642|DRUG|Ondansetron|4 mg intravenous dose administered over 2 minutes through a peripheral intravenous catheter
223649518|NCT01182506|BEHAVIORAL|Cogmed Working Memory Training Program|"Women will be randomized to one of two 5-week rehabilitation software training programs that train working memory called Cogmed Working Memory Training Program.~The training software will be provided to each participant. For each group, training occurs for 30 minutes a day, 5 days a week for 5 weeks. As part of the set-up, training data is uploaded to the internet at a minimum of every 3 days. This function allows the coach (in this case, the PI and RSA) to review the training. A weekly coach phone call is made to review the training results, answer questions, troubleshoot, and motivate the participant. Participants can load the software onto multiple computers to provide flexibility for them to do training at home, after work, when they are away from home."
223649519|NCT05313945|PROCEDURE|Passive indwelling urinary catheter removal|"After washing the patient's perineal area with water and mild soap, the nurse deflates the indwelling urinary catheter balloon and instructs the patient to take a shower (standing).~During this time, the catheter will fall under gravity."
223649520|NCT05313945|PROCEDURE|Active indwelling catheter removal by a nurse|After washing the patient's perineal area with water and mild soap, the nurse deflates the balloon and removes the catheter from the urethra by manual traction.
223649521|NCT06276946|RADIATION|standard radiotherapy|radiotherapy planning goal is to restrict the mean parotid dose is equal to or less than 14Gy.
223766842|NCT07024927|PROCEDURE|VT ablation|For patients with hemodynamically stable VT, comprehensive chamber mapping (including activation mapping, substrate mapping, and entrainment mapping) is recommended. This aims to elucidate the VT activation sequence and identify the critical isthmus. Precise ablation targeting the isthmus should be performed to terminate the VT. For patients with hemodynamically unstable VT, substrate mapping during sinus rhythm can be performed first. This includes identification of low-voltage zones and abnormal electrograms (e.g., late potentials, local abnormal ventricular activities - LAVAs). Targeted substrate modification ablation should then be conducted based on the mapping findings. For all patients, complete substrate mapping is recommended after VT termination.
223766843|NCT07025473|DIAGNOSTIC_TEST|Smartphone-enabled otoscopy|Belle AI for ear image assessment
223766844|NCT07024277|BIOLOGICAL|ZG006|ZG006 will be administered as an intravenous (IV) infusion.
224234594|NCT00655642|DRUG|Metoclopramide|10 mg intravenous dose administered over 2 minutes through a peripheral intravenous catheter
224234595|NCT00655642|DRUG|Promethazine|12.5 mg intravenous dose administered over 2 minutes through a peripheral intravenous catheter
224234596|NCT00655642|DRUG|Normal Saline|Volume matched isotonic sodium chloride solution dose administered over 2 minutes through a peripheral intravenous catheter
223649522|NCT06276946|RADIATION|experimental radiotherapy|radiotherapy planning goal is to restrict the parotid duct dose is equal to or less than 14Gy
223766845|NCT07024498|OTHER|care coordination implementation strategies|The intervention will be a bundle of implementation strategies developed during a prior study and informed by the multi-team systems framework. Core implementation strategies are expected to include a standardized ED substance use navigator note (with education and billing support), a mechanism for sharing PHI information across ED-clinic pairs that use different electronic health record systems, an improved ability for patients to directly contact EDs and clinics, ensuring ED and outpatient teams mutually understand each other roles, implementing procedures to increase capacity for same-day outpatient buprenorphine refills, and interactive problem solving with an external facilitation team. Strategies will be adapted to local contexts at each site.
223766846|NCT07023549|PROCEDURE|ABC|Suction sampling should be conducted in the sequence of dry-suction, slow-pull and wet-suction.
223766847|NCT07023549|PROCEDURE|ACB|Suction sampling should be conducted in the sequence of dry-suction, wet-suction and slow-pull.
223766848|NCT07023549|PROCEDURE|BAC|Suction sampling should be conducted in the sequence of slow-pull, dry-suction and wet-suction.
223766849|NCT07023549|PROCEDURE|BCA|Suction sampling should be conducted in the sequence of slow-pull, wet-suction and dry-suction.
223766850|NCT07023549|PROCEDURE|CAB|Suction sampling should be conducted in the sequence of wet-suction, dry-suction and slow-pull.
224234597|NCT04483700|DRUG|Filgotinib|Tablets administered orally once daily
224234598|NCT04483700|DRUG|Placebo to Match Filgotinib|Tablets administered orally once daily
224234599|NCT05611034|DRUG|Oxaliplatin|Oxaliplatin infusion in single lung via IVLP technique
224234600|NCT03012477|DRUG|Cisplatin|chemotherapy
224234601|NCT03012477|DRUG|AZD1775|Wee1 tyrosine kinase inhibitor
224234602|NCT05450770|BIOLOGICAL|Yellow fever vaccination (STAMARIL)|Yellow fever vaccination (STAMARIL) for HIV positive and negative subjects
224234603|NCT01208480|DRUG|Avastin, docetaxel, carboplatin|Avastin, docetaxel, carboplatin
224234604|NCT06370663|RADIATION|Radiotherapy|Radiotherapy + Hepatic Arterial Infusion Chemotherapy (Gesitabine) + Chemotherapy (GEMOX)
224234605|NCT06370663|DRUG|HAIC (GEMOX)|Hepatic Arterial Infusion Chemotherapy (GEMOX)
224234606|NCT06370663|DRUG|Chemotherapy|Chemotherapy (Gesitabine)
224234607|NCT00287118|DRUG|Efalizumab|Subjects will receive a conditioning dose of 0.7 milligram per kilogram (mg/kg) efalizumab subcutaneously on study Day 0 followed by 1.0 mg/kg efalizumab subcutaneously once a week for 23 weeks.
224234608|NCT04713059|GENETIC|FGFR2|Mutation of FGFR2
224234609|NCT00262600|DRUG|warfarin|once a day
224234610|NCT00262600|DRUG|Dabigatran dose 1|twice daily
224234611|NCT00262600|DRUG|Dabigatran dose 2|twice a day
223649523|NCT06224933|DEVICE|Augmented Reality System|Subjects will undergo image guided needle aspiration, injection, or biopsy facilitated by the Augmented Reality system. The Augmented Reality guidance system will be operated by the interventional radiologist in the MRI suite.
223649524|NCT06444256|DRUG|SUVO|Participants will receive 20mg of SUVO for 7 days in the evening before bed on Day 5 through Day 11
224234612|NCT00988923|OTHER|group A: HYPERTHERMIA|All patients were treated for 8 sessions, twice a week, for a total of 4 weeks of treatment. All patients were evaluated at baseline (T0) and after 4 weeks (T1). The first two sessions were sham-treatment for both groups
224234613|NCT00988923|OTHER|No intervention|the intervention tool was switched in off, only bolus was activated
224234614|NCT00003123|DRUG|amifostine trihydrate|
224234615|NCT06440655|DEVICE|Platelet rich plasma|Subjects were treated by Platelet rich plasma in each side of head (Left or right)
224234616|NCT06440655|DEVICE|Platelet rich fibrin|Subjects were treated by Platelet rich fibrin in each side of head (Left or right)
224234617|NCT02422823|DRUG|Articaine|Injection of 1.8mL of 4% articaine with 1: 100,000 epinephrine in block the inferior alveolar nerve in patients with irreversible pulpitis of mandibular molar in 40 patients
224234618|NCT02422823|DRUG|Articaine|Injection of 3.6mL of 4% articaine with 1: 100,000 epinephrine in block the inferior alveolar nerve in patients with irreversible pulpitis of mandibular molar in 40 patients
224234619|NCT02422823|DRUG|Epinephrine|
224234620|NCT02464566|BEHAVIORAL|Intensive lifestyle intervention|
224234621|NCT02464566|OTHER|Health Education|
224234622|NCT01055964|DRUG|Tacrolimus|
224234623|NCT04112485|PROCEDURE|Microdiscectomy|
224320381|NCT04284072|DEVICE|Sensor Dot|Multimodal (EEG, ECG, EMG and motion) seizure monitoring with Sensor Dot to complement EMU-based video-EEG monitoring (EMU Phase), and optional home-based seizure diary logging (Home Phase).
223649525|NCT06444256|DRUG|TAU|Participants will receive supportive care and symptomatic medication per protocol at the inpatient facility.
223766851|NCT07023549|PROCEDURE|CBA|Suction sampling should be conducted in the sequence of wet-suction, slow-pull and dry-suction.
223766852|NCT06633302|OTHER|Simulated multi-day heatwave exposure|Older adults exposed to a multi-day simulated heat wave exposure
223766853|NCT07025499|BEHAVIORAL|Group ICT Intervention|Participants will be given access to a tablet. With this technology, participants will be invited to set personal goals related to using this technology to foster social connection and community participation. Participants will attend a group led by two occupational therapy students and an occupational therapist focused on digital literacy and how to use technology to meet their goals. In the group, participants will learn how to use their device and how to safely access various online resources and tools to support their recovery. Participants will keep their provided devices upon conclusion of the group sessions. Participants will complete quantitative outcome measures at the start and end of the group intervention. Participants will be invited to attend a semi-structured interview one month after the completion of the group about their experiences with the program.
224234624|NCT05209945|PROCEDURE|vibration|whole-body vibration, heel and soleus tendon vibrations were applied to the human body
224234625|NCT02397733|RADIATION|Prophylactic cranial irradiation (PCI)|Prophylactic cranial irradiation (PCI): 25 Gy in 10 daily fractions, five times a week
224234626|NCT02397733|RADIATION|Hippocampal avoidance PCI|Hippocampal avoidance prophylactic cranial irradiation 25 Gy in 10 daily fractions, five times a week
224234627|NCT02659722|DEVICE|InterFuse|TRansforaminal or Posterior placement of an InterFuse S and/or T device, in combination with approved posterior fixation
224234628|NCT00017784|DRUG|Valganciclovir|
224234629|NCT02906709|DRUG|Omarigliptin|Omarigliptin, 25 mg orally once weekly
224234630|NCT02906709|DRUG|Placebo|Placebo to omarigliptin orally once weekly
224234631|NCT02906709|BIOLOGICAL|Insulin|Insulin will be administered subcutaneously during the trial as monotherapy; dosage and administration following each package insert.
224234632|NCT06001632|DIETARY_SUPPLEMENT|krill oil (SuperbaBoostTM)|4 g/day of Krill oil supplements (LC n-3 PUFAs) (1g capsule containing 191mg EPA, 94mg DHA and 78mg choline).
224320382|NCT04456088|COMBINATION_PRODUCT|150 ppm Nitric Oxide delivered through LungFit Delivery System|Nitric Oxide delivered via LungFit system. Patients will receive inhalations of 150 ppm for 40 minutes 4 time per day plus standard supportive care.
224320383|NCT04456088|COMBINATION_PRODUCT|80 ppm Nitric Oxide delivered through LungFit Delivery System|Nitric Oxide delivered via LungFit system. Patients will receive inhalations of 80 ppm for 40 minutes 4 time per day plus standard supportive care.
223649526|NCT05025059|PROCEDURE|Discussion|Participate in coaching sessions
223649527|NCT05025059|OTHER|Exercise Intervention|Perform walking exercise
223649528|NCT05025059|OTHER|Exercise Intervention|Perform strength exercises
223649529|NCT05025059|OTHER|Informational Intervention|Receive WWE workbook and Growing Stronger Strength Training Program instruction manual
223649530|NCT05025059|OTHER|Informational Intervention|Maintain exercise log
223649531|NCT05025059|OTHER|Medical Device Usage and Evaluation|Wear fitness tracker
223649532|NCT05025059|OTHER|Quality-of-Life Assessment|Complete questionnaires
223649533|NCT05025059|OTHER|Questionnaire Administration|Complete questionnaires
223649534|NCT01617161|RADIATION|Proton Beam Therapy|5 days per week up to 9 weeks
223649535|NCT01617161|RADIATION|Intensity Modulated Radiation Therapy|5 times per week up to 9 weeks
223649536|NCT05539898|DEVICE|ICD implantation|All included in the study will undergo ICD implantation for primary prevention of SCD
223649537|NCT04713241|PROCEDURE|Electro-acupuncture|"20-30 minute acupuncture treatment in sessions from start of study (within 48 hours of diagnosis) to return of bowel functions~A practitioner stimulates certain points on the body by placing thin needles in the skin. Electrical stimulation is then added to some of the needles. This involves placing wires on the needles, which are connected to a machine that delivers a weak electrical current through the wires. The strength of the electrical current will be changed slowly until it is at a comfortable level."
223649538|NCT04713241|OTHER|Standard of Care Bowel rest|Bowel rest with NPO status and placement of nasogastric tube (NGT) if clinically indicated
223649539|NCT04184700|DIETARY_SUPPLEMENT|EHCF+LGG|Extensively hydrolyzed casein formula containing Lactobacillus rhamnosus GG
223649540|NCT04184700|DIETARY_SUPPLEMENT|RHF|Rice hydrolysed formula
223649541|NCT04184700|DIETARY_SUPPLEMENT|SF|Soy formula
223649542|NCT04184700|DIETARY_SUPPLEMENT|EHWF|extensively hydrolysed whey formula
223649543|NCT04184700|DIETARY_SUPPLEMENT|AAF|amino acid based formula
223649544|NCT00682123|DIETARY_SUPPLEMENT|19-norandrostendione|"Volunteers recieved 500mL of water containing 5g of creatine monohydrate and either 1.0μg, 2.5μg or 5.0μg of 19-norandrostendione in a single-blind crossover manner.~The amount of 19-norandrostendione administered was trivial, and far less than the amounts shown to be present in many popular dietary supplements. The recommended dosage according to the distributors is 100 mg 2-3 times daily, so the administered daily dose was not more than 0.05% of the recommended dose. This dose has no measurable physiological or pharmacological effects."
223649545|NCT01406782|BIOLOGICAL|rituximab|
223649546|NCT01406782|GENETIC|DNA analysis|
223649547|NCT01406782|GENETIC|gene expression analysis|
223649548|NCT01406782|GENETIC|polymerase chain reaction|
223649549|NCT01406782|OTHER|laboratory biomarker analysis|
224234633|NCT06001632|DIETARY_SUPPLEMENT|4g/day of mixed vegetable oil|vegetable oil capsules (mixture of olive oil (extra virgin, cold-pressed), maize oil (refined), palm kernel oil (refined) and medium-chain triglycerides, in the ratio 4:4:3:2).
224234634|NCT00623207|DRUG|Atropine|I.V Atropine 0.5mg up to 2 mg
224234635|NCT02886078|PROCEDURE|Dorsal approach CapFlex arthroplasty|Arthroplasty of the PIP joint with the CapFlex implant. Surgery will be done with the dorsal approach.
224320384|NCT04470648|DIAGNOSTIC_TEST|blood test for SARS-COV2 serology|each person who will accept to participate will have a bood test for a SARS-COV2 serology
223649550|NCT05445271|DIAGNOSTIC_TEST|Optic nerve sheath diameter measurement with linear ultrasound|In this study, we aimed to show whether endotracheal intubation or LMA applications with optic nerve sheath diameter measurement, which is a completely non-invasive method, have effects on intracranial pressure.
224234636|NCT02886078|PROCEDURE|Volar approach CapFlex arthroplasty|Arthroplasty of the PIP joint with the CapFlex implant. Surgery will be done with the volar approach.
224234637|NCT04552613|DRUG|EGFR-TKI|(A) Standard programme group, EGFR-TKI targeted therapy;
223649551|NCT00414336|DRUG|AMA1-C1/Alhydrogel + CPG 7909 Vaccine|
223649552|NCT03619382|RADIATION|Cone Beam Computed Tomography|Computer tomography (CT) of the foot/ankle for determination of motion and morphology
223649553|NCT03619382|RADIATION|Radiographs|Standard radiographs of the foot/ankle as part of the screening criteria
224234638|NCT04552613|DRUG|EGFR-TKI combined with chemotherapy (pemetrexed plus carboplatin)|(B) controlled programme group, EGFR-TKI targeted therapy combined chemotherapy(pemetrexed plus carboplatin for 4 cycles )
223649554|NCT04591808|DRUG|Atorvastatin/Perindopril|1 over-encapsulated S05167 capsule, fixed dose combination of Atorvastatin/Perindopril Arginine 40/10 mg, will be administered once daily each day before breakfast during 8 weeks.
223649555|NCT04591808|DRUG|Atorvastatin|1 over-encapsulated atorvastatin 40 mg tablet will be administered once daily each day before breakfast during 8 weeks.
223649556|NCT04591808|DRUG|Perindopril|1 over-encapsulated perindopril 10 mg tablet will be administered once daily each day before breakfast during 8 weeks.
223649557|NCT06405191|BEHAVIORAL|Web based education|The link to the web page was shared with the students in the experimental group (https://inonuhemsirelikesaslari.com, the expired page cannot be accessed at the moment). Theoretical training and application process steps video for IV catheterization and IM injection skills were taken to the students in the experimental group and uploaded to the web page. The students in the experimental group were given a username-password with which they could access the web page, and the access status of the students was followed by the researcher. The researcher was able to see the frequency of each student watching the videos and their scores in online tests. The student who did not watch the videos or did not take the test was interviewed and feedback was given about watching them. Students were able to access the web page as often as they wanted for two weeks.
223649558|NCT05481086|OTHER|No Interventions|There is no interventions in this study
223649559|NCT05847946|OTHER|Kinesio tape application and Core stabilization home program|Participants in the kinesiotape group will receive 2 sessions of kinesiotape per week, in addition to the core stabilization home program, 5 days a week for 4 weeks.
223649560|NCT05847946|OTHER|Core stabilization home program|Core stabilization exercises will be given to the participants as a home exercise program.
223766854|NCT07024485|DEVICE|AR animations and 5As model based on smoking cessation counseling Knowledge-Attitude-Practice (KAP)|The intervention group received a tutorial that incorporated Augmented Reality (AR) animations alongside conventional teaching materials. In addition to watching four real-life smoker scenario videos and reading corresponding case texts, students used their smartphones to interact with AR animations that visualized the physiological effects of smoking (e.g., lung cancer, vascular disease, aging). These animations were used during group discussions and role-play sessions, helping students to assess smokers' knowledge, illustrate health risks, and tailor counseling plans using the 5As model. The AR experience was designed to enhance learning engagement, emotional connection, and self-efficacy in delivering smoking cessation counseling.
223649561|NCT04379895|DEVICE|Radiofrequency ablation|Pulsed or heated RF ablation of the genicular nerves will be done as an Acceptable treatment for OA of the knee
223649562|NCT01463449|PROCEDURE|gastric bypass|Low grade inflammation in adipose tissue before and after gastric bypass
224234639|NCT03174119|DEVICE|Light therapy - active|Active light will be used for one week, as compared to placebo light.
224234640|NCT03174119|DEVICE|Placebo light|Placebo light will be used for one week, as compared to real light exposition.
224234641|NCT03923036|DRUG|Antineoplastic Agents|Exposure measurement to any anticancer drug in its therapeutic use for the metastatic colorectal cancer with its posology and duration (the list provided is non-limitative). Exposure to anticancer drugs for another indication than the colorectal cancer will also be collected.
224234642|NCT02972398|DRUG|N-acetylcysteine|Participants of interventional group receive 1000mg N-acetylcysteine twice daily for 12 weeks.
223649563|NCT03626909|OTHER|Primary visit and assessment|"At the initial visit on entry into the program CHW will collect information and the application will guide initial treatment and referral recommendations. At this visit:~Collection of demographic information and relevant past medical history Medication history, adherence and side effects Glycemic testing, vital signs, and other anthropometric data. Screening for possible complications of diabetes Recommendations for referrals Medication recommendations and counseling"
223649564|NCT03626909|OTHER|Follow up visits|CHWs will meet with patients once per month to follow up on adherence and tolerance to medications, assess glycemic control, assess for complications of diabetes, refill medications (with dosing adjustments as needed for side effects, non-adherence or poor glycemic control), and provide diabetic education. These monthly visits will be facilitated by the smartphone application monthly protocol
223649565|NCT03626909|OTHER|3 month visits|At every 3rd monthly visit, starting with the visit 3 months after enrollment, A1c will be assessed. When A1c is checked, the month 3 medication titration algorithm, is used rather than the monthly titration algorithm, which uses blood glucose. Other than checking A1c and using the A1c-based algorithm as indicated, the procedures performed at the month 3 visit are identical to those of the monthly visit.
224234643|NCT02972398|DRUG|placebo comparator of N-acetylcysteine|Participants of placebo group receive placebo comparator matching with N-acetylcysteine twice daily for 12 weeks.
224234644|NCT01073995|DRUG|Kenalog and Sensorcaine|Kenalog: 40 mg/ml Sensorcaine 0.25%: 1cc
224234645|NCT02402166|DRUG|SPD489|All subjects will begin with 5mg of SPD489 daily and will be titrated until optimal dose is reached (5, 10, 15, 20, and 30mg)
224234646|NCT06433453|DRUG|Indomethacin 50 MG|The medication is commenced when a preovulatory follicle is observed. It will be administered for a minimum of one day, up to a maximum of 7 days. It will be discontinued when anovulation is observed.
224234647|NCT06433453|PROCEDURE|Transvaginal ultrasound scans|Ultrasound scans done intermittently before and after an ovulatory or anovulatory event
223649566|NCT03626909|OTHER|Unscheduled visits|The CHWs live in the same communities as the patients they will be serving. As such, the investigators recognize that patients may come to them with concerns outside of the structure of monthly visits as described above. The investigators have designed an additional module for the smartphone application that guides the CHWs through an assessment for hypoglycemia or severe hyperglycemia and possible complications of diabetes. If a patient or CHW has a concern outside of the scope of these protocols, the CHW will contact a CHW coordinator and/or the medical director for guidance
223649567|NCT00002496|DRUG|chemotherapy|
223649568|NCT00002496|DRUG|cisplatin|
224234648|NCT06433453|DIAGNOSTIC_TEST|Finger prick blood test|Capillary blood extracted from a finger prick. Blood spots are collected on a specialized card, dried and frozen before reproductive hormones are assayed from them.
223649569|NCT00002496|DRUG|fluorouracil|
223649570|NCT00002496|PROCEDURE|conventional surgery|
224234649|NCT06433453|DIAGNOSTIC_TEST|Urine test|Early morning urine tests to assay reproductive hormones
224234650|NCT00789425|DIETARY_SUPPLEMENT|Standardized Extract of Olive Polyphenols|"Dietary supplement containing 250 mg of a standardized extract of olive polyphenols per day in 1 capsule.~A supplement with 1000 mg calcium per day will be supplied together with the active treatment."
224234651|NCT00789425|DIETARY_SUPPLEMENT|Placebo|Placebo (starch). A supplement with 1000 mg calcium per day will be supplied together with the active treatment.
224234652|NCT05233280|OTHER|Oral liquids and soft food 2 hours postoperative|Early versus delayed oral liquid feeding after ceasarean section
223649571|NCT00002496|RADIATION|low-LET cobalt-60 gamma ray therapy|
223649572|NCT00002496|RADIATION|low-LET electron therapy|
223649573|NCT00002496|RADIATION|low-LET photon therapy|
223649574|NCT02682043|DEVICE|Toy car|"The intervention is the provision of an electric toy car. This toy car will be modified to meet the postural and hand control preference of each child participant.~The child will have the toy car for an 8 week trial period. Parents and child will be instructed in the safe use of the toy car, given written guidelines, and encouraged to use frequently.~Parents will keep a log of what days they use the toy car, where and for how long."
224234653|NCT01223807|OTHER|Diaphragmatic breathing training|The training group will participate in a diaphragmatic breathing program which will consist of three 45-min sessions each week (12 sessions totally). The program training will be individualized and supervised by the same physiotherapist. In each session, the patients will be initially instructed to perform 3 series of 10 maximally inspirations, predominantly with abdominal motion, while reducing upper rib cage motion in a supine position.
223649575|NCT05370677|GENETIC|ARMS|amplification refractory mutation system
223649576|NCT05935670|DEVICE|Ischemic Conditioning|The cuff will be placed around the proximal, paretic thigh (or dominant thigh for controls) and inflated for 5 minutes in a supine or semi-reclined position, then released for a 5-minute recovery period. Five cycles of inflation and recovery will be performed (45 minutes total).These inflations will be done using a cuff similar to what is used for taking blood pressure.
223649577|NCT04569487|PROCEDURE|Biopsy|Muscle biopsy from vastus lateralis (100-200 mg from non-dominant leg)
223649578|NCT03306316|DIETARY_SUPPLEMENT|Prebiotic|Prebiotic experimental group
223649579|NCT03306316|DIETARY_SUPPLEMENT|Dextrose Control|Dextrose Control
223649580|NCT00659789|DRUG|Vacc-4x|Vacc-4x is a peptide-based HIV immunotherapy administered intradermally. Vacc-4x peptides are reconstituted in sterile water.
223649581|NCT00659789|DRUG|Sterile water|Sterile water is used in place of Vacc-4x and in place of Leukine
224234654|NCT04293666|DIETARY_SUPPLEMENT|Kefir|28 days supplementation kefir drink (prepared by inoculating pasteurized 9.2% reconstituted skim milk with powder kefir starter culture and fermented at 37 °C for 16 h. The fermented milk was then pasteurized at 100 °C for 30 min and freeze dried. The powder kefir starter culture used for inoculation was composed of defined lactic acid bacteria strains which contains Lactobacillus fermentum DSM 32784 (LF26), L. helveticus DSM 32787 (LH43), L. paracasei DSM 32785 (LPC12), L. rhamnosus DSM 32786 (LRH10), and Streptococcus thermophilus DSM 32788 (ST30)), 200ml/day
224234655|NCT04293666|DIETARY_SUPPLEMENT|placebo|Maltodextrin, same calorie as kefir, 200ml/day
224234656|NCT01690936|DIETARY_SUPPLEMENT|Almonds 43g/day|43 grams of almonds were supplemented to the 4 intervention arms but eaten at different times of day (with meals or alone as snacks) for 4 weeks. Control group was asked to avoid all nuts/seeds during the study period
224234657|NCT00060866|DRUG|Propranolol|
224234658|NCT00826774|BEHAVIORAL|Usual Care|Participants in this group will receive usual medical care, provided by their own primary care providers (PCPs). PCPs also will provide participants recommendations for weight management at quarterly-scheduled visits.
224234659|NCT00826774|BEHAVIORAL|Brief Lifestyle Counseling|These participants, like those in the Usual Care group, will receive the same PCP visits, plus monthly brief counseling sessions with an auxiliary health care provider (e.g., a medical assistant), on-site or by phone.
224234660|NCT00826774|BEHAVIORAL|Enhanced Brief Lifestyle Counseling|These participants will receive the same intervention as those in the Brief Lifestyle Counseling condition, including quarterly PCP visits and monthly sessions with a medical assistant who will instruct them in lifestyle modification. These individuals also will select, in consultation with their PCP, the use of either meal replacements or weight loss medication, to facilitate the induction and maintenance of weight loss
224234661|NCT00602329|BIOLOGICAL|bevacizumab|Given IV
223649582|NCT06416384|OTHER|Hand Massage Group|The patients in the hand massage application group were asked by the researcher; Hand massage with olive oil was applied 12 times in total, three times a week for four weeks. No application was made to the side with fistula.
223649583|NCT06416384|OTHER|Control Group|Patients in the control group received routine nursing care in the clinic for four weeks.
223649584|NCT01290770|OTHER|blood sample|blood sample at inclusion and 1 month after inclusion
223649585|NCT01764906|DEVICE|Novosis|
223649586|NCT01764906|PROCEDURE|Iliac crest bone graft|
223649587|NCT03348059|DRUG|Direct-acting antiviral therapy|HCV patients received direct-acting antiviral treatment for 12 or 24 weeks
223649588|NCT00662441|DRUG|Levitra (Vardenafil, BAY38-9456)|10mg taken 1 hours before sexual intercourse
223649589|NCT02360878|DEVICE|EndoBarrier Gastrointestinal Liner|Implantation with the EndoBarrier
224234662|NCT00602329|DRUG|fluorouracil|Given IV
224234663|NCT00602329|DRUG|leucovorin calcium|Given IV
223649590|NCT01879098|DIETARY_SUPPLEMENT|Probiotic: Bacillus subtilis|Bacillus subtilis will be taken as a capsule once daily for 6 weeks by subjects in the group receiving this supplement (group is unknown, double-blinded).
223649591|NCT01879098|DIETARY_SUPPLEMENT|Lactobacillus plantarum|Lactobacillus plantarum will be taken as a capsule once daily for 6 weeks by subjects in the group receiving this supplement (group is unknown, double-blinded).
223649592|NCT01879098|DIETARY_SUPPLEMENT|Bifidobacterium animalis|Bifidobacterium animalis will be taken as a capsule once daily for 6 weeks by subjects in the group receiving this supplement (group is unknown, double-blinded).
223649593|NCT01879098|DIETARY_SUPPLEMENT|Placebo|Placebo will be taken once daily for 6 weeks by every subject at some point in the study (crossover design).
223649594|NCT00434785|DRUG|AGG-523|
223649595|NCT00467753|DRUG|Oxcarbazepine|Oxcarbazepine is available in a 300mg/5ml solution. Dosage will start at 150 mg (2.5ml) at night for 3 days and will be increased to 150 mg in the am and pm. For children who are able to tolerate the 150 mg BID dose, the oxcarbazepine will be increased to 300 mg at night and 150 mg in the morning for 3 days and 300 mg BID for the next week. The children will remain on this dose until week 3, at which time if they are tolerating the medication and do not have a Clinical Global Improvement Scale (CGI) of 1 (very much improved) they will be increased to 600 mg twice a day in a method similar to the above increases. After week 4, the child will remain on the same stable dose.
223649596|NCT00467753|OTHER|Placebo/sugar pill|Dosage similar to active drug
223649597|NCT02175030|DRUG|Copper IUD|Randomization to copper/Paragard IUD for emergency contraception
223649598|NCT02175030|DRUG|Levonorgestrel IUD|Randomization to Levonorgestrel/Mirena IUD for emergency contraception
224234664|NCT00602329|DRUG|oxaliplatin|Given IV
224234665|NCT03236857|DRUG|chemotherapy|Dexamethasone and/or vincristine and/or pegasparaginase OR cytarabine and/or etoposide and/or pegasparaginase; tyrosine kinase inhibitor; cytarabine OR azacitidine OR decitabine; rituximab and/or dexamethasone and/or vincristine; cyclophosphamide and/or topotecan
224234666|NCT03236857|DRUG|venetoclax|Oral tablet for participants; Tablet for oral suspension (participants who cannot swallow a tablet)
224234667|NCT05586022|PROCEDURE|endovascular revascularization|percutaneous balloon dilatation, stent implantation, plaque resection, laser plasty, cutting balloon, drug balloon, cryoballoplasty, thrombolytic therapy with drugs or thrombectomy
224234668|NCT00919308|OTHER|Competency based simulation training|Completion of a hands-on ultrasound guided simulation training protocol on a partial task training simulator until competence is achieved as measured by the ability to cannulate a simulated vein under ultrasound guidance on first pass in five consecutive attempts and correct insertion of a central venous catheter on a partial task training simulator with no technical errors.
224234669|NCT01449266|DRUG|Dotarem® IV injection at 0.1 mmol/kg|Dotarem® was IV administered at a dose of 0.1 mmoL/kg (0.2 mL/kg).
224234670|NCT02428699|OTHER|Emulsified cod liver oil product|Participants are required to consume the dose (30 mL) within 1 min, followed by up to 300 mL of apple juice which needs to be consumed within 2 min
224234671|NCT02428699|OTHER|Non-emulsified cod liver oil product|Participants are required to consume the dose (5.8 mL) within 1 min, followed by up to 300 mL of apple juice which needs to be consumed within 2 min
224234672|NCT01690442|BEHAVIORAL|Couples Based HIV/STI Risk Reduction Intervention (CHSR)|The intervention includes a combination of empowerment and couple self-efficacy building strategies, which are employed to help couples overcome resistance to risk reduction.
224234673|NCT01690442|BEHAVIORAL|Renaissance Wellness Promotion (WP)|This intervention employs a psychoeducational approach to promote wellness, focusing on: maintaining a healthy diet on a low budget, exercising and fitness, stress reducing strategies and specific health related issues that affect IDUs, such as overdose.
224234674|NCT03231475|DRUG|SPH1188-11|qd.po
224234675|NCT03459937|BEHAVIORAL|Hatha Yoga Intervention|Hatha Yoga will focus on a restorative style of Hatha yoga. Total duration will begin at 100 minutes per week and will gradually progress in 4-week intervals until achieving the prescribed dose of 300 min/wk (5 days per week for 60 minutes per day). While attending the behavioral group sessions the participants will also engage in a supervised yoga session with a trained yoga instructor. To facilitate the additional 4 days of unsupervised yoga, we will provide yoga videos that mimic the asanas (poses) and flow patterns that are taught in the supervised yoga sessions. The intervention includes prescribed dietary recommendations based on the participants' baseline body weight, and self-monitoring diaries, meal plans, and sample recipes will be provided. Intervention lessons will also include information related to behavior strategies for achieving the recommended calorie and fat intake goals. Participants will also be provided weekly group intervention sessions across the study period.
224234676|NCT03459937|BEHAVIORAL|Vinyasa Yoga Intervention|Vinyasa Yoga will focus on a more vigorous form of yoga. Total duration will begin at 100 minutes per week and will gradually progress in 4-week intervals until achieving the prescribed dose of 300 min/wk (5 days per week for 60 minutes per day). While attending the behavioral group sessions the participants will also engage in a supervised yoga session with a trained yoga instructor. To facilitate the additional 4 days of unsupervised yoga, we will provide yoga videos that mimic the asanas (poses) and flow patterns that are taught in the supervised yoga sessions. The intervention includes prescribed dietary recommendations based on the participants' baseline body weight, and self-monitoring diaries, meal plans, and sample recipes will be provided. Intervention lessons will also include information related to behavior strategies for achieving the recommended calorie and fat intake goals. Participants will also be provided weekly group intervention sessions across the study period.
224234677|NCT00252356|DRUG|SR58611A|
223649599|NCT01637441|PROCEDURE|laparoscopic sacropexy|under laparoscopic vision, the vesico-vaginal space is dissected until the level of the bladder neck. a synthetic non absorbable mesh is placed between the bladder and the vagina. the mesh is sutured to the vagina and the apex (vaginal apex or uterus) and anchored to the prevertebral ligament in front of the promontorium.
223649600|NCT01637441|PROCEDURE|vaginal mesh|after anterior sagittal colpotomy, the bladder is dissected under the fascia layer, and the paravesical fossa are entered. a synthetic non absorbable mesh is placed with 4 arms suspension (trans obturator or not). treatment of the apex is mandatory.
223649601|NCT01521403|DRUG|Metronidazole|3x500 mg/day for 10 days
223649602|NCT01521403|DRUG|Placebo|3x1 tablet per day for 10 days
223649603|NCT03734913|DRUG|ZSP1602|ZSP1602 capsules for oral administration
223649604|NCT02440841|DRUG|fedovapagon|
223649605|NCT02440841|DRUG|Itraconazole|
223649606|NCT02440841|DRUG|rifampicin|
224234678|NCT02697903|DIETARY_SUPPLEMENT|Natural Pomegranate Juice|Supplements (1500ml) of pomegrenate juice (POMj) were taken three times daily in the 48h which proceed the first tested training sessions (i.e. 250ml × 6 times with 8-h intervals between it). Moreover, during this tested sessions, subject consumed an additional 500ml of POMj. Arm-specific: Experimental: 9 elite weightlifter
224234679|NCT02697903|DIETARY_SUPPLEMENT|Placebo Juice|Supplements (1500ml) of Placebo juice (PLA) were taken three times daily in the 48h which proceed the second tested training sessions (i.e. 250ml × 6 times with 8-h intervals between it). Moreover, during this tested sessions, subject consumed an additional 500ml of POMj. Arm-specific: Placebo Comparator: 9 elite weightlifter
224234680|NCT04611698|DEVICE|Baha sound processor BA400|Baha sound processor BA400 is a cochlear implant designed specifically for soft tissue preservation.
224320385|NCT06067165|BEHAVIORAL|POET feeling|"POET is adapted from online Emotion Regulation Individual Therapy for Adolescents developed by the research group (ClinicalTrials.gov Identifier: NCT03353961).~POET is also based on the Modal model of emotion and Process model of emotion regulation that provides a framework for understanding how emotions are generated, experienced and how they can be regulated. The youth component of POET will include psychoeducation, addressing maladaptive beliefs about emotions and emotion regulation, and teaching adaptive emotion regulation strategies, such as acceptance of emotions and flexible cognitive reappraisal. The parent component will include psychoeducation and teaching effective support and responding to their adolescent's and their own emotions."
224320386|NCT06067165|BEHAVIORAL|Supportive treatment|The treatment will include educative material on mental health and self-reflection on themes such as school, family and friends. The parent component will include educative material and self reflection in how to support their adolescent.
223649607|NCT05442476|OTHER|Kinesiotaping|For the KT application, participants will be asked to stand with keeping their feet at shoulder level in a comfortable manner. The patient will be in a standing position with lumbar spine flexion. A 5 cm wide long I-shaped piece of tape will be applied with 80% tension transverse to the patient's painful area and the bilateral SIJ region, with no tension applied to the ends of the tape. Another short piece of tape will be applied with 80% tension at an angle from the painful point to the hip, and no tension will be applied to the ends of the tape. An identical application will be performed on the other side of the sacroiliac region
223649608|NCT05442476|OTHER|Muscle Energy Technique|The subject will be asked for the sitting on the treatment table, back towards the therapist. Then the subject will be taken into flexion, rotation and side bending. When the subject will reach the tolerated limit of flexion, the therapist will ask him to perform extension, sidebending and rotation to the opposite side while holding the breath for 7-10 seconds and rest for 2-3 seconds, then the patient will be asked to release the breath. The therapist will wait for the participant's full exhalation and then will take her further in all the directions of restriction, towards the new barrier. MET will be performed for 10 repetitions.
223649609|NCT05442476|OTHER|conventional physiotherapy|conventional physiotherapy
223649610|NCT01072643|DRUG|Dexmedetomidine|This is a single center, dose escalation study of Dexmedetomidine in pediatric subjects with pulmonary hypertension (PVR\>4WU) undergoing hemodynamic cardiac catheterization and vasoreactivity drug testing. Cohorts of 8 evaluable subjects will receive dose level 1, dose level 2, or dose level 3 of Dexmedetomidine.
223649611|NCT01075542|DEVICE|AcrySof Toric intraocular lens, model SN60TT|The lens is made of foldable acrylic material and is implanted in the capsular bag
223649612|NCT01075542|DEVICE|AcrySof Monofocal IOL, model SN60AT|The lens is made of foldable acrylic material and is implanted in the capsular bag
223649613|NCT04919798|DEVICE|Non-invasive bladder emptying device|The NIBED is applied to the penis during urination to support bladder emptying in urinary retention patients. It is a battery-driven handheld device that is operated by the patient himself.
223649614|NCT00540085|DRUG|Rocuronium|0.6 mg/kg given intravenously before intubation
223649615|NCT00507143|DRUG|irinotecan|
224234681|NCT01151748|PROCEDURE|Intra-arterial infusion of chemotherapy|
224320387|NCT02054338|DRUG|Vinflunine+Gemcitabine|Vinflunine 320 mg/m² IV on day 1 and.Gemcitabine 1000 mg/m² on days 1 and 8 of each cycle repeated every 3 weeks
224320388|NCT02054338|DRUG|Paclitaxel+Gemcitabine|paclitaxel 175 mg/m² on day 1 plus gemcitabine 1250 mg/m² on days 1
224234682|NCT03637582|DRUG|lidocaine gel|Lidocaine (4%) gel from Quest Products, Inc.
224234683|NCT03637582|OTHER|Plain aqueous gel|KY jelly lubricant from Reckitt Benckiser
224320389|NCT00366743|PROCEDURE|Conventional LASIK|
223649616|NCT01867177|OTHER|HIV testing|"HIV testing. Enhanced testing protocol is used: RESPECT, an evidence-based HIV prevention counseling intervention helping people increase condom use, decrease risky behaviors (resulting in a decrease in STIs) compared to those who did not receive the intervention. RESPECT includes: one-on-one counseling using a structured protocol; teachable moments during counseling to motivate clients to change risk-taking behaviors; to explore the contexts in which risk behaviors occur to increase awareness of susceptibility; and negotiate achievable next steps with the client that support the larger risk reduction goal. Implemented using a structured protocol with monitoring to ensure the fidelity of the testing intervention."
223649617|NCT01867177|OTHER|standard of HIV care|Standard linkage and referral to HIV care includes HIV counseling, testing, and referrals. Both intervention and comparison groups will receive these.
224234684|NCT04647604|DRUG|Omegaven®|A highly refined fish oil in an emulsion for infusion with purified egg phosphatides and glycerol.
224234685|NCT04647604|DRUG|Sodium chloride|intravenously administered 2 mL/kg/day
224234686|NCT02922868|DEVICE|EndoSheath CST-5000 Scope|Cystoscopic procedures will be performed using the EndoSheath CST-5000 Scope.
224320390|NCT00366743|PROCEDURE|Wavefront-guided LASIK|
224320391|NCT01482312|DEVICE|lotrafilcon A contact lenses|Commercially marketed, silicone hydrogel, single-vision, soft contact lenses FDA-approved for daily and extended (overnight) wear for up to 30 nights of continuous wear.
224320392|NCT01482312|DEVICE|comfilcon A contact lenses|Commercially marketed, silicone hydrogel, single-vision, soft contact lenses FDA-approved for daily and extended (overnight) wear for up to 30 nights of continuous wear.
224320393|NCT01482312|OTHER|Glasses|Glasses per habitual prescription
223649618|NCT01867177|BEHAVIORAL|HIV care utilization|Sites will use a peer-based, client navigation model of an Integrated HIV/AIDS Early Intervention Services (ARTAS), Community Health Worker (CHW) Program, case management/support services linking people to continuous, coordinated care after HIV dx. Another site will do Motivational Enhancement Intervention (MEI) sessions with quality of ife workshops and support groups. Health Educators recruit clients, make appointments, escort to test sites, intake, review. Additional components can include food security support, social and group support, drop in centers, text messaging and social media, depending on sites. All sites focus on approaches to reach community members and facilitate their supportive linkage to care with behavioral and structural supports.
223649619|NCT05773001|DRUG|Ozone|Subjects will perform alternating 15 minutes rest with 15 minutes treadmill walk exercise periods for 135 minutes in while breathing Ozone (O3).
223649620|NCT01033799|OTHER|Fermented dairy product containing the probiotic Lactobacillus casei DN-114 001 (Actimel®)|
223649621|NCT01033799|OTHER|Non fermented dairy product (control)|
223649622|NCT02964091|DRUG|sofosbuvir/ledipasvir|
223649623|NCT01292629|DEVICE|iSert 251 intraocular lens|aphakic intraocular lens
223649624|NCT01579136|BEHAVIORAL|Home blood pressure monitor|The patients using home monitors checked their blood pressure on Monday, Wed, and Friday. They took 2 measurements 5 minutes apart after sitting 5 minutes in the left arm.
223649625|NCT03695367|DRUG|HTX-011|HTX-011 (bupivacaine/meloxicam), 300 mg/ 9 mg via instillation.
223649626|NCT03695367|DEVICE|Luer lock applicator|Applicator for instillation.
224234687|NCT02922868|DEVICE|Olympus Visera Elite OTV-S190 Scope|Cystoscopic procedures will be performed using the Olympus Visera Elite OTV-S190 Scope
224234688|NCT00995410|DRUG|PA32540|PA32540 tablets contain 325 mg enteric coated (EC) aspirin and 40 mg immediate-release omeprazole to be taken by mouth once daily
223649627|NCT03695367|DEVICE|Vial access device|Device for withdrawal of drug product.
223649628|NCT03695367|DRUG|Ibuprofen|Ibuprofen, 600 mg.
223649629|NCT03695367|DRUG|Acetaminophen|Acetaminophen, 1 g.
223649630|NCT03695367|DRUG|Ketorolac|Intraoperative IV ketorolac.
223649631|NCT02984605|DIETARY_SUPPLEMENT|nutritional meal replacement|1 times a day with bags of nutritional meal replacement + individualized exercise prescription
223649632|NCT03204864|DEVICE|RLD Group|patients CS placement will be guided by RLD measurement. Physician will place the CS lead in the site of longest RLD with a stable and acceptable pacing threshold.
223649633|NCT03204864|DEVICE|Conventional CS lead placement|Clinical Practice
223649634|NCT01707199|DRUG|Artesunate + Sulphadoxine-pyrimethamine|"AS+SP will be administered according to the patient's age, based on a dose of 4mg artesunate/kg body weight once daily for 3 days plus SP at a dose of 25mg sulphadoxine/kg body weight single dose on the first day.~One co-blister pack of Artecospe will be used per patient and obtained via WHO from Guilin Pharmaceutical Co. Ltd., Shanghai China, with appropriate expiry date."
224234689|NCT02415023|DRUG|fruquintinib+paclitaxel|28-day cycle of fruquintinib qd for 3 weeks followed by 1-week break combined with paclitaxel 80 mg/m2
224234690|NCT00146523|DRUG|Mifepristone|
224234691|NCT00146523|DRUG|placebo|
224234692|NCT06179238|OTHER|Education|Patients with urinary catheter insertion during the study periods will be identified and consent will be obtained for the study. In the first stage of the study, questionnaires will be applied face to face to the experimental group and the control group. Then, education and brochures will be given to the patients in the experimental group. Patients in the experimental group will be visited and evaluated every day until the urinary catheter is removed. After the urinary catheter is removed, the patients in the experimental group and urinary catheter self-care management scale will be applied to the control group.
223649635|NCT03990727|DIAGNOSTIC_TEST|Retina Analysis-mosaic|Fundus retina pattern study
223649636|NCT03990727|DIAGNOSTIC_TEST|Autofluorescence|Fundus reflectance-functionality
223649637|NCT03990727|DIAGNOSTIC_TEST|OCT- 1 micra|Fine tomography fundus retina
223649638|NCT03990727|PROCEDURE|Genotype analysis|Molecular target retina dystrophy analysis
223649639|NCT01600170|DRUG|Atorvastatin (generic Lipitor)|Atorvastatin is an FDA approved prescription drug which is frequently used to lower cholesterol levels.It is available in the form of tablets ranging in dose from 10-80mg.
223649640|NCT01600170|DRUG|placebo|A substance containing no medication and prescribed or given to reinforce a patient's expectation to get well.
223649641|NCT05242198|PROCEDURE|Robotic prostatectomy|patients who will undergo robotic prostatectomy
223649642|NCT03846492|DEVICE|Transcranial Direct Current Stimulation (tDCS)|tDCS is a non-invasive brain stimulation modality that does not require general anesthesia or surgical implantation of a device. tDCS utilizes low intensity electrical current either to increase cortical excitability with an anodal electrode or to suppress cortical excitability with a cathodal electrode. It uses 3 AAA batteries to deliver direct current via rubber electrodes enclosed in saline soaked sponges.
223649643|NCT06802198|PROCEDURE|total hysterectomy|Total hysterectomy (TH) involves the complete removal of the uterus including the cervix
223649644|NCT06802198|PROCEDURE|subtotal hysterectomy|subtotal hysterectomy (STH) preserves the cervix while removing the upper part of the uterus
223649645|NCT05775276|PROCEDURE|Proline mesh in hernioplasty|Hernioplasty using proline mesh then follow up for incidence of infection
223649646|NCT00569959|OTHER|fasting 12+ hours|fasting 12+ hours
223649647|NCT00569959|OTHER|Non-fasting|Non-fasting
223649648|NCT00069615|DEVICE|GlucoWatch® G2™ Biographer (GW2B)|
223649649|NCT00069615|DEVICE|Continuous Glucose Monitoring System™ (CGMS)|
223649650|NCT05006638|DRUG|Lipid Emulsion, Intravenous|Lipid emulsion is a mixture of soybean oil, egg phospholipids, glycerine, and is available in 10%, 20%, and 30% strengths. It has been used for decades as parenteral nutrition and for caloric supplementation and essential fatty acid deficiency. It has also been used as a carrier for lipid soluble medications
224234693|NCT06179238|OTHER|without patient education|without patient education
224234694|NCT04240938|PROCEDURE|Dacryocystorhinostomy|Anastomosis between lacrimal sac and nasal cavity
224234695|NCT01144936|DRUG|VX-985 or matching placebo|low dose
224234696|NCT01144936|DRUG|VX-985 or matching placebo|high dose
224234697|NCT01144936|DRUG|VX-985 or matching placebo|dose TBD
224234698|NCT00093990|DRUG|Tipifarnib;Zarnestra; R115777|
223766855|NCT07024485|DEVICE|5As model based on smoking cessation counseling Knowledge-Attitude-Practice (KAP)|The control group, received a conventional tutorial without the use of AR technology. They watched the same four smoker scenario videos and read the same case texts, then engaged in small group discussions and role-play activities to develop quit plans using the 5As counseling model. However, unlike the intervention group, their learning process relied solely on textual and video materials, without the immersive or interactive elements provided by AR. This approach represents standard smoking cessation training methods commonly used in nursing education.
223766856|NCT07024511|OTHER|Auricular acupuncture|Auricular acupuncture
223766857|NCT07024511|OTHER|Acupuncture|Acupuncture
223766858|NCT06878677|OTHER|Data-driven exercise|"The result from the Statistical Parametric Mapping 1D (SPM1D) analysis will be used to identify the magnitude of deviation from normal gait patterns in reference to healthy subjects for each lower limb joint. Thereby, the targeted action and joint position can be identified. Training will focus on the specific movement where the steepest gradients are observed.~The targeted exercises will be selected based on the five largest deviations observed during the swing or stance phase. Open-chain exercises will be applied to address deviations in the swing phase, while closed-chain exercises will be applied to address deviation in the stance phase. Each exercise will be performed for approximately 80-100 repetitions, with a total duration of 10 minutes per exercise, including rest periods."
223766859|NCT06878677|BEHAVIORAL|Standardized exercises|The participants will perform dose match standardised exericse program.
223766860|NCT06711965|PROCEDURE|Standard of care reconstruction|Participants will receive standard of care reconstruction
223766861|NCT06711965|PROCEDURE|Surgery, Breast Mold|Participants will undergo surgery. The surgeon may utilize the custom breast mold in shaping the autologous tissue flap for particiapnts.
223766862|NCT06719219|BIOLOGICAL|LTB-SA7|LTB-SA7 is a toxoid based vaccine consisting of five components including seven toxoids formulated with Alhydrogel.
223766863|NCT06719219|BIOLOGICAL|Placebo|Sodium Phosphate with Sodium Chloride
224234699|NCT04912349|PROCEDURE|TUSP|Patients received the transurethral split of the prostate(TUSP) treatment.
224234700|NCT04912349|PROCEDURE|TURP|Patients received the transurethral resection of the prostate(TURP) treatment.
224320394|NCT03225001|DEVICE|Edwards SAPIEN XT transcatheter valve, Model 9300TFX|Edwards SAPIEN XT THV system Model 9300TFX with the associated delivery systems.
224320395|NCT04080466|RADIATION|Low-dose CT Scan|"Low dose computed tomography, also known as qCT, is sensitive to the mineral content within bone tissue, and can assess bone mineral density, a strong predictor of bone strength and stiffness, which can influence the health of the cartilage. Participants will undergo a low dose CT scan of both hips.~Participants in the Cam Group will undergo this scan once as part of their standard of care. Participants in the Control Group will undergo this scan once as part of the study."
223649651|NCT05006638|DRUG|Atropine|a drug used as an antidote for some types of pesticides
223766864|NCT06728293|OTHER|Liver Link|Support Program
223766865|NCT07042672|DRUG|GLP-1|Subcutaneous GLP-1 receptor agonist prescribed for weight management according to routine clinical practice. Acceptable agents include liraglutide (up-titrated to ≤ 3.0 mg daily), semaglutide (≤ 2.4 mg weekly), or tirzepatide (≤ 15 mg weekly). Dose escalation and maintenance follow approved product labels and treating-physician judgment. Planned treatment duration: 12 months or longer.
223766866|NCT07042672|BEHAVIORAL|CBTe Group Therapy|Ten weekly 2-hour group sessions based on Cognitive Behavioral Therapy-Enhanced (CBT-E) plus individualized lifestyle consultations every 4 months over a 12-month period. Content targets eating patterns, weight-management behaviors, and emotion-regulation skills. Delivered by trained multidisciplinary staff at the Obesity Centre.
223766867|NCT06885931|DEVICE|Pudendal neuromodulation|In this feasibility study, all subjects will receive the Amber UI system.
223766868|NCT07086443|OTHER|Activate™ Matrix|Participants will receive weekly applications of Activate™ Matrix and Standard of Care until ulcer closure, or a maximum of 12 weeks, whichever occurs first.
223766869|NCT07086443|OTHER|AmnioDefend™ FT Matrix|Participants will receive weekly applications of AmnioDefend™ FT Matrix and Standard of Care until ulcer closure, or a maximum of 12 weeks, whichever occurs first.
223649652|NCT05006638|DRUG|Toxogonin|a drug used as an antidote for some types of pesticides
223649653|NCT05006638|DRUG|Sodium Bicarbonate Powder and ondansetron|standard of care for treatment of aluminuim phosphide is provided for patients poisoned with aluminuim phosphide
223649654|NCT02510508|BEHAVIORAL|Group CRAFT|CSOs will receive seven weekly 90 min sessions of CRAFT + Self-Directed CRAFT Delivery
223649655|NCT02510508|BEHAVIORAL|Self-Directed CRAFT Delivery|CRAFT self-help book (Self Directed CRAFT Delivery)
223649656|NCT02510508|OTHER|Non-intervention|Non-intervention
223649657|NCT01065883|BEHAVIORAL|community health worker|community health workers will provide education in the home
223649658|NCT01065883|BEHAVIORAL|mailed information|information will be mailed to the home on the same schedule as the experimental intervention
223649659|NCT00034268|DRUG|LY900003|
223649660|NCT05785442|DRUG|Anakinra Prefilled Syringe|Anakinra 100 mg administration subcutaneously once daily for 10 days (at least 4 days)
223649661|NCT05785442|DRUG|Placebo|0.67 ml N/S 0.9% w/v administration subcutaneously once daily for 10 days (at least 4 days)
223649662|NCT02846519|DRUG|Esketamine|100-mcL spray of 14% esketamine solution (14 mg) for a total dose of 56 mg.
223649663|NCT02846519|DRUG|Rifampin|2 capsules (300 mg each) of rifampin.
224234701|NCT02483975|DRUG|FF|FF will be provided as a dry powder inhaler with 30 doses per device, each containing 50 mcg of FF as a dry white powder per blister, to be inhaled orally via ELLIPTA.
224234702|NCT02483975|DRUG|Placebo|Placebo will be provided as dry powder inhaler with 30 doses per device, each containing placebo as a dry white powder per blister, to be inhaled orally via ELLIPTA.
224234703|NCT02483975|DRUG|Montelukast|Montelukast will be provided as 4 mg and 5 mg chewable tablets.
224234704|NCT02483975|DRUG|Albuterol/Salbutamol|Albuterol/Salbutamol will be provided as inhalation aerosol.
224234705|NCT04172870|DIAGNOSTIC_TEST|Molecular analysis|RT- PCR
223766870|NCT07086443|OTHER|Palisade™ DM Matrix|Participants will receive weekly applications of Palisade™ DM Matrix and Standard of Care until ulcer closure, or a maximum of 12 weeks, whichever occurs first.
223766871|NCT07086443|OTHER|Enclose™ TL Matrix|Participants will receive weekly applications of Enclose™ TL Matrix and Standard of Care until ulcer closure, or a maximum of 12 weeks, whichever occurs first.
224234706|NCT01578837|DIETARY_SUPPLEMENT|Ginseng|2.25g of encapsulated ginseng (1.5g American Ginseng and 0.75g Rg3-enriched Korean Red Ginseng)will be administered in 6 identical capsules, 2 capsules with each meal (total 6 capsules per day).
224234707|NCT01578837|DIETARY_SUPPLEMENT|Wheat Bran|2.25g of encapsulated 100% natural wheat bran will be administered in 6 identical capsules, 2 capsules with each meal (total 6 capsules per day).
224234708|NCT04138732|BEHAVIORAL|Improve health behaviors of medical personel|This arm will receive the intervention treatment aimed to help improve their health behaviors, as determined by employee-based steering committee. Interventions will target nutrition, physical activity and stress reduction
224234709|NCT00442806|DRUG|Injection of ADRC's|ADRC's are injected
224234710|NCT00442806|OTHER|Injection of Placebo|Placebo is injected
224234711|NCT06182020|DEVICE|Peripheral functional magnetic stimulation (ISKRA MEDICAL TESLA Former prestige Magneto therapy)|The peripheral functional magnetic stimulation will be conducted 30 minutes a session, 2 sessions per week, for consecutive 8 weeks. The stimulation will be placed over bilateral forearm flexor muscles and bilateral thighs over rectus femoris muscles.
224234712|NCT06182020|DIETARY_SUPPLEMENT|Nutritional supplementation (ENSURE HIGH CALCIUM)|"The nutritional supplementation includes 7 cans of ENSURE HIGH CALCIUM per week for 8 consecutive weeks."
224234713|NCT06182020|BEHAVIORAL|Education|The education includes a DVD and one session of oral instructions on general care and exercise suggestions for sarcopenia.
223649664|NCT05760339|BEHAVIORAL|Time-restricted feeding|Subjects in the will be instructed to follow a TRF regimen consisting of a daily 8h ad libitum eating period and 16h water fasting period during the last 2 weeks before surgery. Participants will be encouraged to begin their eating period at 08:00h and end it at 16:00h, since the metabolic benefits of TRF appear to be considerably more pronounced when the eating period starts early in the day.
223649665|NCT05760339|DIETARY_SUPPLEMENT|Carbohydrate loading|Subjects will continue their usual diet and will receive two quantities of a clear beverage containing 12.5 g/100 mL maltodextrin (50 kCal/100 mL, pH 5.0); 800 mL at 22.00h on the evening before surgery and 400 mL two hours before anaesthesia induction.
223649666|NCT02824614|DIETARY_SUPPLEMENT|E967-Xylitol|
223649667|NCT02824614|DIETARY_SUPPLEMENT|E968-Erythritol|
223649668|NCT02820493|DRUG|vedolizumab|
223649669|NCT04545580|DRUG|Placebo|Matching placebo for BAY1817080, will be taken twice daily orally as tablet(s)
223649670|NCT04545580|DRUG|BAY1817080|BAY1817080 will be taken twice daily orally as tablet(s)
223649671|NCT02469311|OTHER|chlorhexidine impregnated cloths|Pre-operative use of Chlorhexidine cloths night before and morning of surgery
223649672|NCT02469311|OTHER|Standard of care bathing with antibacterial soap and water|Patients had standard pre-operative bathing with antibacterial soap and water the night before surgery.
223649673|NCT06262516|PROCEDURE|Nephroureterectomy|Participants will undergo standard-of-care nephroureterectomy for UTUC.
223649674|NCT06262516|PROCEDURE|Lymph Node Dissection|Participants will receive lymph node dissection alongside nephroureterectomy for UTUC.
223649675|NCT05307965|DEVICE|Retriever Thrombectomy|The SolitaireTM X revascularisation device is a self-expanding stent designed for dynamic clot integration with radiopaque markers that enhance visualisation of the optimal working length. After a thrombotic occlusion has been identified and crossed with a guidewire, the stent-retriever thrombectomy proceeds. A microcatheter (e.g., PhenomTM, MarksmanTM) is advanced over the guidewire and once it has traversed the thrombotic occlusion, the SolitaireTM X device is advanced through the microcatheter until the usable length of the stent extends past each side of the thrombus in the vessel. As the microcatheter is retracted to the proximal radiopaque marker of the stent, the stent self-expands and entangles the thrombus. The microcatheter and SolitaireTM X Revascularisation Device are withdrawn as a unit into the guide catheter under continuous aspiration. PCI then proceeds driven by clinical decision making and department guidelines.
223649676|NCT05307965|PROCEDURE|Percutaneous Coronary Intervention|Standard of care
223649677|NCT05307965|PROCEDURE|Thrombus Aspiration|Standard of care treatment with manual thrombectomy catheter
223649678|NCT05411952|OTHER|Medical nutrition therapy and carbohydrate counting education|Children and their mothers have received family-based behavioral medical nutrition therapy and carbohydrate counting education for 6 months by trained dietitian
223649679|NCT05411952|OTHER|Medical nutrition therapy and carbohydrate counting education|Only children have received family-based behavioral medical nutrition therapy and carbohydrate counting education for 6 months by trained dietitian
223649680|NCT05411952|OTHER|No intervention|Control group didn't receive any intervention by trained dietitian. Furthermore they continued their routine health controls.
223649681|NCT05816421|BEHAVIORAL|KEEP|The KEEP model focuses on optimizing the role of foster/kin parents as the agents of positive change for children and youth. Parent KEEP groups for children (ages 4-12) and KEEP-Safe groups for teens (ages 13-19) are delivered by two co-group leaders for 16 weeks. Sessions are 90 minutes each week. The same group of 8-10 foster/kin parents attends each week. Each KEEP group follows a manualized curriculum that emphasizes tailoring the content to the unique needs of the parents and youth in the group. The key parenting principles of the model include: (a) reinforce normative and prosocial behavior, (b) incentivize the behavior that parents want to promote, (c) build cooperation, (d) teach new behaviors, (e) use non-harsh effective limit setting, and (f) manage emotions while parenting.
223649682|NCT05816421|BEHAVIORAL|Non-Affinity KEEP|Non-Affinity KEEP
223649683|NCT02847338|DRUG|Amlodipine|Amlodipine 5mg and Amlodipine 10mg will be one of the treatments in which patients will receive on the monotherapy arm and on the dual therapy arm.
223766872|NCT07086443|OTHER|Sentry™ SL Matrix|Participants will receive weekly applications of Sentry™ SL Matrix and Standard of Care until ulcer closure, or a maximum of 12 weeks, whichever occurs first.
223766873|NCT07086443|OTHER|Shelter™ DM Matrix + SOC|Participants will receive weekly applications of Shelter™ DM Matrix and Standard of Care until ulcer closure, or a maximum of 12 weeks, whichever occurs first.
224234714|NCT03942965|DEVICE|Double balloon accessory device|Double balloon accessory device is used during the endoscopic polypectomy procedure
223649684|NCT02847338|DRUG|Lisinopril|"Lisinopril 10mg and Lisinopril 20mg will be one of the treatments in which patients will receive on the monotherapy arm.~Lisinopril 20mg will be one of the treatments in which patients will receive on the dual therapy arm."
223649685|NCT02847338|DRUG|Amiloride|Amiloride 10mg will be one of the treatments in which patients will receive on the dual therapy arm.
223649686|NCT02847338|DRUG|Chlortalidone|Chlortalidone 25mg will be one of the treatments in which patients will receive on the dual therapy arm and monotherapy arm.
223649687|NCT06595875|OTHER|m-tapa block|Patients in Group M were placed in the supine position. After skin antisepsis with 5% povidone-iodine, a sterile drape was placed. The high-frequency (8-13 MHz) linear ultrasound (USG) probe was covered with a sterile sheath, and the transversus abdominis, internal oblique, and external oblique muscles were identified at the 10th costal margin in the sagittal plane at the costochondral angle. The probe was angled sagittally to visualize the costochondral angle at the edge of the 10th rib and to display the posterior surface of the rib cartilage in the midline. Using an in-plane technique, a 22-gauge, 100-millimeter (mm) Stimuplex A peripheral nerve block needle was advanced cranially, and the needle tip was directed towards the posterior surface of the 10th costal cartilage. After negative aspiration, 20 mL of 0.25% bupivacaine was injected under the lower surface of the costal cartilage. The same procedure was repeated on the opposite side.
223649688|NCT06594432|DRUG|R-CHOP+Z+MTX|"After receiving 1 cycle of pre-treatment with the R-CHOP regimen, patients with CSF-ctDNA (+) and MCD, BN2, and N1 subtypes will receive 5 cycles of R-CHOP combined with MTX + Zanubrutinib, followed by 1 cycle of R-MTX-Zanubrutinib.~After completing the above induction therapy, Patients with negative CSF-ctDNA results will continue with one more cycle of Rituximab. For patients with positive CSF-ctDNA results, the investigator will decide to continue treatment with Rituximab one more cycle combined with Temozolomide, Pomalidomide, or Lenalidomide, etc., until CSF-ctDNA turns negative.~Each combined regimen consists of a 21-day treatment cycle, and efficacy will be evaluated every three treatment cycles."
223649689|NCT06594432|DRUG|R-CHOP+MTX|"After receiving 1 cycle of pre-treatment with the R-CHOP regimen, patients with CSF-ctDNA (+) and EZB, A53, and other gene subtypes will receive 5 cycles of R-CHOP combined with MTX, followed by 1 cycle of R-MTX.~After completing the above induction therapy, Patients with negative CSF-ctDNA results will continue with one more cycle of Rituximab. For patients with positive CSF-ctDNA results, the investigator will decide to continue treatment with Rituximab one more cycle combined with Temozolomide, Pomalidomide, or Lenalidomide, etc., until CSF-ctDNA turns negative.~Each combined regimen consists of a 21-day treatment cycle, and efficacy will be evaluated every three treatment cycles."
223649690|NCT05968560|BEHAVIORAL|CBT Skills Group for CHR Youth|"CBT skills group is designed to boost peer support, reduce isolation, normalize psychotic-like experiences to lessen distress, reduce cognitive biases, facilitate positive beliefs, and enhance reasoning and decision-making. CBT skills group uses CBT to Prevent Paranoia manual to teach individuals to make adaptive appraisals of their experiences (e.g. voices and other cognitive intrusions) to prevent the perception of such events as threatening."
223649691|NCT05968560|BEHAVIORAL|Individual CBT sessions|CBT skills learned in group are personalized in individual sessions focused on: a) facilitating learning of CBT skills; b) tailoring CBT skills to personal goals; c) facilitating successful interaction with peers in the group; and d) providing academic and vocational support. Youth may opt to invite family members to join individual sessions as needed.
223649692|NCT05968560|BEHAVIORAL|CBT Skills Group for Families|"Family members are taught the same CBT skills that are taught to CHR youth to facilitate use of CBT skills at home. Family members also learn how to prompt CHR youth to use CBT skills through effective communication, such as empathic listening and encouraging alternative explanations. CBT skills group for family members uses a combination of didactic learning (skills are described in CBT Skills for Families manual and demonstrated via video examples) and practice (skills are role-played). Youth attend one group session and one individual session per week, and family members attend one group session per week."
223649693|NCT07074691|DRUG|Regional Dexamethasone|Patients were generally anesthetized, then a supraclavicular block is given (0.5% bupivacaine + dexamethasone 8 mg regionally), total volume = 20 mL (18 mL 0.5% bupivacaine + 2 mL dexamethasone).
223649694|NCT07074691|DRUG|Intravenous Dexamethasone|Patients were generally anesthetized, and then a supraclavicular block was administered (0.5% bupivacaine), with a total volume of 20 mL (18 mL of 0.5% bupivacaine and 2 mL of normal saline).
223649695|NCT07075653|OTHER|Survey using a questionnaire.|Participants fill out a brief survey in which they answer questions about vegetarian diets.
223649696|NCT07074223|PROCEDURE|Fascial wrapping the site of tendon repair|wrapping the tendon repair site by Pelnac or Fascial graft
223649697|NCT07074223|PROCEDURE|Modified Kestler tendon repair|Modified Kestler tendon repair
223649698|NCT07074223|PROCEDURE|ADM (Pelnac) wrapping of repaired tendon|Modifed kestler tendon repair wrapped by ADM ( Pelnac)
223649699|NCT04510961|OTHER|Paraffin baths therapy|Patients in treatment group will receive paraffin wax baths for five days per week for 12 weeks. Prepare the paraffin device and blocks of paraffin wax. Put the paraffin wax blocks inside the tank and set the thermostat 35 to 40◦C. Melting paraffin was taken from 90 to 120 minutes. Adjust the suitable temperature for each patient before immersion of patient's hand. Submerge patient's hand completely for three to four seconds then withdraw it
223649700|NCT00892346|PROCEDURE|Single ASCT with Thalidomide maintenance|"Single ASCT with Thalidomide maintenance:~1. Single Autologous Stem Cell Transplantation: conditioning with Melphalan 200mg/m2 (iv)~2. Thalidomide maintenance: starting from D60 after transplantation at 100-200mg daily (Oral)"
223649701|NCT06355180|DRUG|Esketamine|The experimental group will receive intravenous esketamine hydrochloride. Participants will be asked to fast for 8 hours prior to administration. On treatment days, esketamine will be administered at a dose of 0.2 mg/kg, diluted in 0.9% sodium chloride solution. The infusion rate will be controlled with an infusion pump or syringe pump to ensure a minimum administration duration of 40 minutes. Treatment will be administered three times per week (the recommended interval between sessions is 1 to 2 days, adjustable based on clinical judgment) for two consecutive weeks, totaling six sessions. For participants demonstrating intolerance to either the dose of 0.2 mg/kg or the six-session regimen, investigators could modify the treatment protocol based on efficacy and safety assessments.
223766874|NCT07085221|COMBINATION_PRODUCT|hospital external management|"(I) Symptom management: After enrollment, health managers regularly promoted health education to enhance patients' awareness of the disease and adherence to post-discharge management. Simultaneously, patients were managed via a digital platform, with each patient being provided with a chip-implanted sphygmomanometer to monitor their blood pressure and pulse in real time. If patients develop symptoms, they can report them in real-time and generate alerts to health managers. Through internal clinical decision-making algorithms, the telemedicine team would conduct clinical evaluations and seek decision guidance from clinical cardiologists if necessary.~(II) Clinical evaluation: the system stratified patients by risk levels and determined the frequency and intensity of management accordingly, with blood pressure and heart rate monitored daily. The digital management system automatically transmitted abnormal data to a doctor's assistant, with early detection of life-threatening complication"
223766875|NCT07085858|DIETARY_SUPPLEMENT|yeast β-glucan|Participants in the intervention group will take yeast β-glucan capsules daily. Each capsule contains 250 mg of yeast β-glucan, along with an appropriate amount of maltodextrin and silicon dioxide. All participants in the intervention group will take two capsules once daily, swallowed with warm water after meals.
223766876|NCT07085858|DIETARY_SUPPLEMENT|placebo|Participants in the placebo group will take two placebo capsules once daily in the same manner. The placebo capsules are identical to the intervention capsules in form, taste, appearance, and packaging, but contain only maltodextrin and a small amount of silicon dioxide.
224234715|NCT01505530|DRUG|LY2495655|Intravenous (IV) treatment every 14 days while on study. Number of Cycles: until treatment options are exhausted or unacceptable toxicity develops.
224234716|NCT01505530|DRUG|Placebo|Intravenous (IV) treatment every 14 days while on study. Number of Cycles: until treatment options are exhausted or unacceptable toxicity develops.
224234717|NCT01505530|DRUG|Standard of Care Chemotherapy|Standard of care, gemcitabine-based regimen (single-agent gemcitabine or gemcitabine plus erlotinib) or FOLFIRINOX (combination chemotherapy regimen including 5-fluorouracil, leucovorin, oxaliplatin, and irinotecan). The choice of gemcitabine-based regimen or FOLFIRINOX will be determined by the investigator (based on the standard of care used at the treating institution or as directed by local regulatory authorities).
224234718|NCT02492958|BIOLOGICAL|Staphylococcus aureus 4-antigen vaccine|a single 0.5 mL dose of investigational product into the deltoid muscle in the upper arm
224234719|NCT02492958|BIOLOGICAL|Placebo|a single 0.5 mL dose of investigational product into the deltoid muscle in the upper arm
224320396|NCT04080466|OTHER|Blood/Urine Collection|"Collection of blood and urine allows the researchers to look for a biomarker in the blood and urine that might help to predict the evolution of disease/hip osteoarthritis. Identifying a marker in the blood and urine that could be used for early detection of individuals with cam deformity that are at-risk of hip degeneration could greatly improve patient care.~Participants in the Cam Group will undergo the blood and urine collection twice; once before surgery and once 2-years post-operative. Participants in the Control Group will undergo a blood and urine collection once as part of the study."
223649702|NCT06355180|DEVICE|Electroconvulsive therapy|The control group will receive ECT. Prior to each session, participants will undergo safety evaluations and concomitant medication adjustments. Following an 8-hour fast and bladder evacuation, other preoperative preparations include intravenous administration of anticholinergic agents, short-acting anesthetics, and muscle relaxants. Electrodes will be placed unilaterally on the non-dominant hemisphere, with the seizure threshold determined via titration. The treatment will be administered three times per week (the recommended interval between sessions is 1 to 2 days, adjustable based on clinical judgment) for two consecutive weeks (six sessions in total). The protocol permitted regimen modifications for participants unable to tolerate the full course, based on efficacy and safety assessments.
223649703|NCT02201732|PROCEDURE|Hysteroscopy|Performed under general or local anesthesia, antibioprophylaxis in accordance to center practices may be administered. Cervical dilatation, will be made in order to introduce the hysteroscope. Operative hysteroscope used will include a handle. The distension of the uterine cavity will be performed with physiological saline or glycocoll, depending on the polarity of the high frequency generator necessary for resection system (monopolar or bipolar), with a pressure of maximum irrigation of 110 mm Hg.
223649704|NCT02201732|PROCEDURE|Curettage|Performed under general or local anesthesia, the used material may be rigid or flexible vacurette. In the same way, the prophylactic antibiotic, the diameter of the used vacurette, the importance of cervical dilation necessary and a possible peroperative ultrasound guidance will be left at the discretion of the operator and habits of the center. A check of the uterine vacuity by foam curette will be conducted at the end of curettage.
223649705|NCT01077050|DEVICE|SciBase III Electrical Impedance Spectrometer|SciBase III Electrical Impedance Spectrometer is based on Electrical Impedance Spectroscopy (EIS). EIS is a measure of the overall resistance within a skin tissue, at alternating currents of various frequencies. Enrolled subject will undergo skin measurements with SciBase III Electrical Impedance Spectrometer. The relevant skin lesion(s) will be excised and diagnosed as per routine treatment.
223649706|NCT04417127|OTHER|Integrated Community-Based (ICB) Care|The intervention will include the following components: (1) integrated care visits by clinical team occurring monthly during months 1-6 of the trial, and then quarterly for the remaining months (7-18), which include vital signs screening, consultation with a clinical officer, medication distribution (ART and other chronic and acute medications), and point- of-care (POC) laboratory testing (creatinine, blood glucose and hemoglobin A1C, and viral load as it becomes available); (2) peer support for promoting ART adherence during every monthly MF meeting; (3) referrals to facilities for emergency or acute care needs that are not feasible to address in the community. Integrated care refers to delivery of primary, HIV and NCD-related care, incorporating a focus on both chronic and acute needs.
223649707|NCT04417127|OTHER|Microfinance|"Group microfinance uses a client-driven model that involves community savings groups where members mobilize and manage their own savings, provide interest-bearing loans to group members, offer a limited form of financial insurance, and contribute to a social fund that is used for income-generating activities and in cases of emergency or welfare issues of group members.~For this study, group microfinance will refer to existing, active AMPATH Group Integrated Savings for Empowerment (GISE) microfinance groups with a majority of group members who are AMPATH HIV patients and have disclosed their HIV status. Groups will be considered active if the group was formed at least 6 months prior to study baseline, is consistently meeting as scheduled, and is actively engaging in saving and loaning."
224234720|NCT03168074|DRUG|lenvatinib|Eligible patients will be treated with approximately 2 weeks of single agent lenvatinib (range 10-28 days, depending on the date of breast cancer surgery; last dose of lenvatinib to be administered no later than 48 hours before surgery in patients who are planned to receive ≤14 days lenvatinib, and no later than 120 hours before surgery in patients who are planned to receive 15-28 days lenvatinib).Tissue sections from the pre-treatment and post-treatment tumor will be collected for biomarker analysis. Pre- and post-treatment ultrasound will be used to document the size of the target lesions.
223649708|NCT02759718|BIOLOGICAL|Chromogranin A|The plasma level of chromogranin A (CgA) was measured in enrolled patients who was diagnosed as PNET in preoperative condition.After surgical resection, the CgA level was only measured in the the patient with PNET. In the PNET group, the CgA level was regularly checked in a 3, 6, 12, and 24 months after surgical resection.
223766877|NCT07085208|PROCEDURE|Unsupervised Machine Learning for Clinical Phenotyping|This is a data-driven study that uses an unsupervised machine learning algorithm to perform clustering on patient multimodal features. These features include: preoperative demographics, comorbidities, and laboratory data; surgical information; and high-resolution intraoperative data, most notably continuous vital sign trajectories.
224234721|NCT04041765|DRUG|IgM-enriched IVIG|Contains human plasma protein 50mg/ml. With composition of Immunoglobulin M (IgM) 6mg, Immunoglobulin A (IgA) 6mg, Immunoglobulin G (IgG) 38mg (IgG subcl. approx. 63 % IgG1, 26 % IgG2, 4 % IgG3 and 7 % IgG4), Glucose monohydrate, sodium chloride, water for injections
223649709|NCT00880243|DRUG|GM-CSF|"Randomization 1: GM-CSF (5micogram/Kg/d) versus no GM-CSF during induction chemotherapy and all consolidation courses.~Randomiization 2: Consolidation high dose AraC versus consolidation EMA"
223649710|NCT03253861|OTHER|No intervention|No intervention
223649711|NCT03696459|DRUG|JNJ-53718678, 2000 mg|Participants will be administered JNJ-53718678, 2000 mg as oral suspension in Part 1 (Panel 1).
223649712|NCT03696459|DRUG|JNJ-53718678, 3000 mg|Participants will be administered JNJ- 53718678, 3000 mg as oral suspension in Part 1 (Panel 2).
223649713|NCT03696459|DRUG|JNJ-53718678, 4500 mg or Dose to be decided|Participants will be administered JNJ-53718678, 4500 mg as oral suspension in Part 1 (Panel 3). If this dose is considered safe and tolerable and if pharmacokinetic data require further dose escalation, then participants will receive JNJ-53718678 (Dose to be decided) in Part 1 (Panel 4). This dose (either from Panel 3 or Panel 4 ) will be used in Part 2 (Dose may be lower/higher based on review of safety, tolerability, and PK data obtained in Part 1).
223649714|NCT03696459|DRUG|JNJ-53718678 500 mg|Participants will be administered JNJ-53718678, 500 mg as oral suspension in Part 2.
223649715|NCT03696459|DRUG|JNJ-53718678 Placebo|Participants will be administered JNJ-53718678 matching placebo in Part 1 and 2.
223649716|NCT03696459|DRUG|Moxifloxacin 400 mg|Participants will be administered moxifloxacin 400 mg as capsule in Part 2.
223649717|NCT03696459|DRUG|Moxifloxacin Placebo|Participants will be administered moxifloxacin matching placebo in Part 2.
223649718|NCT01214096|DRUG|rhNRG-1|Subcutaneous Administration:0.6ug/kg/day for 10days
223649719|NCT01214096|DRUG|rhNRG-1|Subcutaneous Administration 1.2ug/kg/day for 10 days
223649720|NCT01214096|DRUG|rhNRG-1|Vein infusion:0.6ug/kg/day for 10 days
223649721|NCT01214096|DRUG|placebo|Subcutaneous Administration:0.6 or 1.2ug/kg/day for 10days
223649722|NCT00003182|DRUG|cisplatin|
223649723|NCT00003182|DRUG|gemcitabine hydrochloride|
223649724|NCT05426603|PROCEDURE|Pulmonary vein isolation|The 3D geometry of the LA will be created using CARTO 3 system (version 6) with UDM Module and VISITAG Optimum Device Performance (ODP) module. Continuous circumferential lesions will then be created encircling the right and left PV ostia using a 7.5F, 3.5-mm Thermocool SMARTTOUCH ablation catheter (Biosense Webster, Inc., Diamond Bar, CA, USA).Pentaray catheter will be used and facilitate the high density mapping of atrial substrate (PentarayTM, Biosense Webster Inc., Diamond Bar, CA, USA). The radiofrequency energy will be applied with contact force range 5-25 g continuously with a target Ablation Index target 380-400 on the posterior wall and 550 - 600 on the anterior wall and maximum power of 25-35W in a power control mode
223649725|NCT05426603|PROCEDURE|Substrate ablation(PRISM based)|Substrate modification will be guided by waveform periodicity analysis. The User Defined Map of waveform periodicity analysis will be also created by CARTO 3 system (version 6) with and VISITAG ODP module. Pentaray catheter will be used and facilitate the high density mapping of atrial substrate (PentarayTM, Biosense Webster Inc., Diamond Bar, CA, USA). Substrate modification based on waveform periodicity analysis will be performed by using a 7.5F, 3.5-mm Thermocool SMARTTOUCH ablation catheter (Biosense Webster, Inc., Diamond Bar, CA, USA). The radiofrequency energy will be applied with contact force range 5-25 g continuously with a target Ablation Index target 380-400 on the posterior wall and 550 - 600 on the anterior wall and maximum power of 25-35W in a power control mode.
223649726|NCT03198624|DRUG|HTL0018318|Part A single dose Part B five doses
223649727|NCT03198624|DRUG|Placebo oral capsule|Part B only
223649728|NCT06519721|DRUG|Lenvatinib Combined with VIC-1911|"Oral administration:~Lenvatinib:~Take the clinically normal dose: ≤60Kg body weight, 8mg/day; \>60Kg body weight, 12mg/day;~VIC-1911:~Phase 1: Accelerated titration phase Plan to enroll 3 patients. First, enroll 1 patient, give the initial dose of VIC-1911 25mg BID, observe for 1 week, if there is no dose-limiting toxicity (DLT), increase to 50mg BID. At the same time, enroll another 2 patients, give VIC-1911 25mg BID, observe for 1 week, if no DLT, increase to 50mg BID. Observe for 2 weeks at a dose of 50mg, if no DLT occurs, continue to increase to 75mg BID, observe for 4 weeks. If no DLT occurs, continue to increase by 25mg doses, with an observation period of 4 weeks, until one case of dose-limiting toxicity or two cases of moderate toxicity occur during the titration process, then reduce to the previous dose, and determine it as the final dosing regimen.~Phase 2: Expansion phase According to the final dosing regimen selected, enroll 12 patients and observe for 3 months."
223649729|NCT00006118|DRUG|cisplatin|
223649730|NCT00006118|DRUG|gemcitabine hydrochloride|
223649731|NCT00006118|DRUG|paclitaxel|
223649732|NCT05040113|DRUG|CBP-307|CBP-307 capsules oral administration
223649733|NCT03894813|DRUG|"Probiotics and Metronidazole"|Oral probiotics (Umeta-Miyue, Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14) (qd, 30 days)+Metronidazole Suppositories (qd, 7 days)
223649734|NCT03894813|DRUG|Metronidazole Vaginal|Metronidazole Suppositories,qd, 7 days
223649735|NCT00080444|DRUG|aprepitant|aprepitant capsules
223649736|NCT00080444|DRUG|ondansetron|ondansetron IV preparation
223649737|NCT00080444|DRUG|dexamethasone|dexamethasone tablets
224234722|NCT05050786|DEVICE|Negative Wound Pressure Therapy (Prevena(TM))|After skin closure, NPWT in the form of Prevena™ (KCI/Acelity, San Antonia, TX, USA) is applied using the following technique: The sterile foam dressing is removed from the package and placed on the incision in the entire length, on top of which the sterile dressing is placed, ensuring air tightness. An appropriate hole in the dressing is cut at the center of the dressing and the tube for the interface pad is connected and a negative pressure of 125mmHg is applied. The Prevena™ system is removed on the morning of postoperative day 3.
223649738|NCT00080444|DRUG|placebo to aprepitant|Matching placebo to aprepitant capsules
223649739|NCT00080444|DRUG|placebo to dexamethasone|Matching placebo to dexamethasone tablets
223649740|NCT00080444|DRUG|rescue medication|Participants are allowed to take rescue medication throughout for nausea or vomiting. At the discretion of the investigator, participants are provided with a prescription for rescue medications. Recommended rescue medications are: 5-HT3 antagonists, phenothiazines, butyrophenones, benzamides, corticosteroids, benzodiazepines, domperidone, H1-receptor antagonist, and piperazine derivatives.
223649741|NCT03975478|PROCEDURE|Gastric bypass|The GB technique consists of a 150-cm antecolic Roux limb with a 25-mm circular pouch-jejunostomy and exclusion of 50 cm of the proximal jejunum.
223649742|NCT03975478|PROCEDURE|Sleeve gastrectomy|The SG technique consists of a longitudinal resection of the stomach from the angle of His to approximately 5 cm proximal to the pylorus, using a 35 French bougie inserted along the lesser curvature.
223649743|NCT02932371|DEVICE|ECOM™.|
223649744|NCT02932371|DEVICE|Trans-esophageal echography|
223649745|NCT03016000|DRUG|Thalidomide|Thalidomide 50mg daily by mouth( increase 25mg after 2 weeks if tolerated Until 200mg/day) until disease progression or intolerance due to AEs.The dose could be reduced if patient experienced grade 2 or higher AEs. Does reductions for AEs were recommended (200 mg daily to 100 mg daily, 100 mg daily to 50 mg daily).In patients intolerant of 50mg/ day, thalidomide discontinuation was allowed.
223649746|NCT03016000|OTHER|Observation|Just observation
223649747|NCT00482066|DRUG|Abatacept (Orencia)|"500mg for patients under 60kg 750mg for patients 60-100kg~1g for patients\>100kg given as i.v. infusion over 30 minutes at day 0, 14, 28 and then monthly for a further 11 months 914 infusions in total) placebo groups receive saline only I.v."
223649748|NCT03773796|DRUG|Nabilone 0.25 mg|capsules, 0.25 mg up to 2 mg of nabilone taken orally on a daily basis
223649749|NCT04161703|PROCEDURE|focused ultrasound, diet and exercise|"Focused Ultra Sound using a device of Mabel6 DUO Ultra Cavitation Technology produced by DAEYANG MEDICAL CO., KOREA applied on the abdominal region which extending bilaterally from the line extending from mid-axilla to iliac crest, and above from center of diaphragm to the line extending between two iliac crests below.~an aerobic exercise 3 to5 times/week for 12 weeks in the form of walking on treadmill for 30 minutes with moderate intensity a weight maintenance diet, which ranged from 1700 kcal to 2200 kcal/day, which was calculated in an individual basis for each subject according to his BMR, throughout the study period (12 weeks) to ensure that the reduction in the circumference was due to the treatment intervention rather than due to their weight reduction"
223649750|NCT04161703|PROCEDURE|diet and exercise|weight maintenance diet, which ranged from 1700 kcal to 2200 kcal/day, which was calculated in an individual basis for each subject according to his BMR, throughout the study period (12 weeks) to ensure that the reduction in the circumference was due to the treatment intervention rather than due to their weight reduction. All subjects in both groups (A \& B) followed an aerobic exercise 3 to5 times/week for 12 weeks in the form of walking on treadmill for 30 minutes with moderate intensity (moderate intensity = 12-14 according to Borg Scale). The beginning period will be 15 mints and increased gradually until reaching 30 mints per time.
223649751|NCT03360318|DEVICE|elbow cast|elbow cast
223649752|NCT03360318|DEVICE|Removable elbow brace|Removable elbow brace
223649753|NCT03243292|OTHER|Bronchial Thermoplasty|patients had radio frequency ablation of the smooth muscle for asthma
223649754|NCT03805659|DEVICE|HD-tDCS|High-Dose transcranial Direct Current Stimulation
223766878|NCT07087236|BEHAVIORAL|Maximum Cognitive Load|Participants will perform a working memory task (through N-back 1-to-3) to evaluate the upper limit of cognitive demand.
224234723|NCT05050786|OTHER|Standard Wound Dressing|After skin closure, a standard operative dressing is applied in the entire length of the incision. This operative dressing is removed in the morning of postoperative day two. Only in the case of blood or serous fluid mandating changing of the dressing, will this be done prior to postoperative day 2.
223649755|NCT03805659|DEVICE|Sham|Sham sessions (no electric current)
223649756|NCT01350401|GENETIC|Autologous genetically modified T cells, NY-ESO-1ᶜ²⁵⁹T|Cytoreductive chemotherapy followed by infusion of NY-ESO-1ᶜ²⁵⁹T
223649757|NCT02228837|DIETARY_SUPPLEMENT|Pear|
223649758|NCT02228837|DIETARY_SUPPLEMENT|Placebo|
223649759|NCT03188497|DRUG|Lobaplatin|Lobaplatin for Injection
223649760|NCT03188497|DEVICE|linear accelerator|Medical linear accelerator
223649761|NCT04099264|OTHER|Personalized music|Patients in the intervention group will listen to personalized music from the Musicare application
223649762|NCT04099264|OTHER|Audio Books|Patients in the active comparator group will listen to audio books
223649763|NCT04800172|DRUG|Roflumilast|administration of roflumilast 500 mcg tablet once daily for 3 months.
223649764|NCT04800172|DRUG|placebo|administration of placebo tablet once daily for 3 months.
223649765|NCT02869737|DEVICE|Coagucheck, Roche, France|Capillary puncture for POC INR measurement
223649766|NCT01250145|DRUG|LY333334|Transdermal patch
223649767|NCT01250145|DRUG|Placebo|Transdermal patch
223766879|NCT07087236|BEHAVIORAL|Mental active/pasive activities|"Participants will engage in 7 activities, presented in a randomly assigned order across two separate days, to assess their impact on cognitive load:~1. playing a videogame (Tetris ®)~2. listening a podcast (including a final question)~3. watching a documentary (including a final question)~4. reading a document extract (including a final question)~5. watch a reality show extract (including a final question)~6. listening music, they like it~7. scrolling their Tik-Tok/Instagram"
223766880|NCT07087236|BEHAVIORAL|Baseline Cognitive Load|Participants will sit quietly for 5 minutes to establish baseline spontaneous neurophysiological parameters.
224234724|NCT05813587|BIOLOGICAL|Meplazumab for injection|Meplazumab is a humanized anti-CD147 immunoglobulin 2 (IgG2) monoclonal antibody which is expected to block the binding of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein to the human host-cell-expressed CD147, thereby blocking entry of SARS-CoV-2 into human tissue. This expectation is based on in vitro functional studies using Vero E6 cells infected with SARS-CoV-2 that demonstrated effective meplazumab mediated virus gene copy number inhibition upwards of 90% as evaluated by quantitative polymerase chain reaction. Meplazumab may also inhibit COVID-19 associated cytokine storm syndrome based on inhibition of the pro inflammatory factor Cyclophilin A host-cell CD147 interaction.
224234725|NCT05813587|OTHER|Normal saline|Normal saline
224234726|NCT03317197|DRUG|Control Group|Using Epinephrine(1 mg/cardiopulmonary resuscitation(CPR) cycle) only
224234727|NCT03317197|DRUG|Experimental Group 1|Using Epinephrine(1 mg/cardiopulmonary resuscitation(CPR) cycle) and Vasopressin(20 international unit(IU)/cardiopulmonary resuscitation(CPR) cycle)
224234728|NCT03317197|DRUG|Experimental Group 2|Using Epinephrine(1 mg/cardiopulmonary resuscitation(CPR) cycle) and Steroid(Methylprednisolone, 40 mg at first cycle)
224234729|NCT03317197|DRUG|Experimental Group 3|Using Epinephrine(1 mg/cardiopulmonary resuscitation(CPR) cycle), Vasopressin(20 international unit(IU)/cardiopulmonary resuscitation(CPR) cycle) and Steroid(Methylprednisolone, 40 mg at first cycle)
224234730|NCT04510701|OTHER|videoscope|a videoscope will be used to evaluate the integrity of the membrane while doing lateral maxillary sinus elevation surgery
224234731|NCT01901055|DEVICE|CPAP|CPAP is a device that has a mask worn over the nose that is attached to a device that provides positive airway pressure. CPAP is worn while sleeping, it splints open the airway and prevent apneas (cessation of breathing) and hypopneas (reduced airflow while breathing).
223649768|NCT05345340|OTHER|Telemedicine|"The 5-day rehabilitation program will consist of exercises to re-establish standard movement patterns within a multidisciplinary etiological framework, according to a validated rehabilitation protocol for FMDs. Treatment will be tailored to the needs of each patient, following general treatment principles in physiotherapy for FMDs.~Telemedicine sessions: the patient will perform specific exercises under the supervision of a qualified physiotherapist to provide feedback on the execution and adapt the treatment according to clinical changes/improvements.~Polar Vantage M devices will collect the objective measurement after the 5-day rehabilitation program (for five consecutive days), week 12 (for five consecutive days), and week 24 (for five consecutive days)."
223649769|NCT05345340|OTHER|Usual care|The 5-day rehabilitation program will be the same as the telemedicine group. A self-management paper log will be given to the patient at the end of the 5-day rehabilitation program. It will include goals, activity plans, and strategies to be used for retraining movements and redirecting attention. Videos stored on the patients' digital device (i.e., tablet, mobile) will include exercises demonstration and execution and strategies to retrain movements. Patients will be encouraged to perform the self-management plan at home on their own (or with their caregivers' help) which will be reported in a paper log and video recorded. The subjective assessment of the patient's motor activity will be collected by clinical diaries focusing on gait and activity level.
223649770|NCT02513927|DRUG|metoprolol|Metoprolol was given orally in a dose of 95 mg/day to treat patients in the metoprolol group for 12 weeks.
223649771|NCT02513927|DRUG|Nifedipine|Nifedipine was given orally in a dose of 30 mg/day to treat patients in the amlodipine group for 12 weeks.
223649772|NCT01404936|DRUG|Interferon-2A|4 (x106 IU/m\^2) subcutaneously on days 1-4.
223649773|NCT01404936|DRUG|Adriamycin|25 mg/m\^2 by vein on day 4.
223649774|NCT01404936|DRUG|Bleomycin|10 mg/m\^2 by vein on day 4.
223649775|NCT01404936|DRUG|Velban|6 mg/m\^2 by vein on day 4.
223649776|NCT01404936|DRUG|Dacarbazine|375 mg/m\^2 by vein on day 4.
223649777|NCT00156676|DEVICE|Body-weight supported treadmill|
223649778|NCT00156676|DEVICE|Lokomat|
223649779|NCT00156676|DEVICE|Body-weight supported treadmill|
223649780|NCT00156676|DEVICE|Lokomat|
223649781|NCT01398306|OTHER|Blood sampling by vena punction.|We obtain 10mL blood of the patients. The blood is obtained twice: once with angiogenesis inhibitors or mTOR inhibitors, and once without.
223649782|NCT01014351|DRUG|Paclitaxel|Paclitaxel, 175mg/m2 by IV infusion over 1-3 hours on day 1 of every 21 day cycle
223649783|NCT01014351|DRUG|Carboplatin|Carboplatin, AUC 6 given by IV infusion over 20-30 minutes on day 1 of every 21 day cycle
223649784|NCT01014351|DRUG|Everolimus|Everolimus, 5 mg by mouth (PO) once a day, continuous dosing every 21-day cycle
223649785|NCT01069900|DRUG|Moxifloxacin (Avelox, BAY12-8039)|For subjects 12 to less than (\<) 18 years of age and weighing at least 45 kilograms (kg), the dose of moxifloxacin will be 400 milligrams (mg), once daily (OD). Subjects 12 to \< 18 years of age and weighing less than 45 kg, the dose of moxifloxacin will be 4 mg/kg twice daily (BID), every 12 hours (q12h), not exceeding 400 mg/day. Subjects 6 to \< 12 years of age the dose of moxifloxacin will be 4mg/kg, q12h, not exceeding 400 mg/day. Subjects 2 to less than 6 years of age the dose of moxifloxacin will be 5mg/kg, q12h, not exceeding 400 mg/day. Subjects 3 months to less than 2 years of age the dose of moxifloxacin will be 6mg/kg q12h IV, not exceeding 400 mg/day. Subjects who were switched from IV to PO therapy, 400 mg or 50 mg moxifloxacin tablets were provided.
223649786|NCT01069900|DRUG|Ertapenem|For subjects 13 to \<18 years of age, the dosage of ertapenem was 1 gram (g) OD. For subjects 3 months to \< 13 years of age, the dosage was 15 mg/kg q12h not to exceed 1 g/day.
223649787|NCT01069900|DRUG|Amoxicillin/Clavulanate|Subjects 2 years to \< 18 years of age who were switched from IV to PO therapy receive amoxicillin/clavulanate suspension. The dosage of clavulanate was 3.2 mg/kg q12h. (maximum dose of clavulanate was 125 mg q12h). The dosage of amoxicillin was 22.5 mg q12h (a maximum dose of 875 mg amoxicillin q12h must not be exceeded).
223649788|NCT01069900|DRUG|Moxifloxacin placebo|Sterile 0.9% sodium chloride solution intended for IV use was used as the placebo for IV moxifloxacin. Tablets containing inactive ingredients were used as the placebo for PO moxifloxacin 400 mg and 50 mg tablets.
223649789|NCT01069900|DRUG|Ertapenem placebo|Sterile 0.9% sodium chloride solution intended for IV use was used as the placebo for IV ertapenem.
223649790|NCT01069900|DRUG|Amoxicillin/Clavulanate placebo|Suspension containing inactive ingredients was used as the placebo for PO amoxicillin/clavulanate suspension.
223649791|NCT03771170|DRUG|Rheosorbilact®|Administered intravenously (with speed 40-60 drip per minute) at a dose of 600 to 1,000 ml (10 to 15 ml/kg body weight per 24 hours) for 3 days.
224234732|NCT01901055|DEVICE|Sham-CPAP|Sham-CPAP is a device that has a mask worn over the nose that is attached to a device that looks and sounds like CPAP however it does not provide positive airway pressure. Sham-CPAP is worn while sleeping, it does not splint open the airway and prevent apneas (cessation of breathing) and hypopneas (reduced airflow while breathing).
224234733|NCT01901055|BEHAVIORAL|Diabetes Education|Diabetes Education will be delivered to participants in both the CPAP group and the Sham-CPAP group. The education will be based on ADA and AADE guidelines and consist of 2 in-person sessions (90 minutes and 60 minutes) and 3 follow-up phone calls 9about 15 minutes each)
224234734|NCT00731159|BIOLOGICAL|sperm capacitation|sperm capacitation measured at Bar Ilan University
224234735|NCT00731159|OTHER|biologic|sperm synthesis of G-actine to F-actine
224234736|NCT00731159|OTHER|sperm capacitation|sperm synthesis of G-actine to F-actine
224234737|NCT03864588|DRUG|Ropivacaine|For primary TKA, Ropivacaine is used in both arms, either performed intra-operatively by surgeon or post-operatively (ultrasound guided) by anesthesiologist.
224234738|NCT04620174|OTHER|Custom-made zirconia crowns|Ten decayed primary molars will be restored with custom-made zirconia crowns.
224234739|NCT04620174|OTHER|Prefabricated zirconia crowns|Ten decayed primary molars will be restored with prefabricated zirconia crowns.
224234740|NCT02983448|DEVICE|transcutaneous vagus nerve stimulation|All patients will receive both active and sham transcutaneous vagus nerve stimulation, with the order being randomized
224234741|NCT03202225|DEVICE|constrained polyethylene|constrained polyethylene insert
223649792|NCT03771170|DRUG|Ringer lactate|Administered intravenously (with speed 40-60 drip per minute) at a dose of 1,000 to 2,500 ml (15 to 40 ml/kg body weight per 24 hours) for 3 days.
223649793|NCT06421103|DRUG|Indocyanine Green (ICG)|Cohorts will receive 0.01 mg/kg, 0.02 mg/kg, 0.04mg/kg, 0.06 mg/kg, or 0.08 mg/kg intra-venous ICG at surgery. Patients will be consecutively allocated to different doses as per protocol.
223649794|NCT00248963|DRUG|Levonorgestrel 90 mg and Ethinyl Estradiol 20 mg|
223649795|NCT04044170|DRUG|Poziotinib|The poziotinib drug substance is a hydrochloride salt of poziotinib and is formulated as a tablet for oral administration.
223649796|NCT05768022|OTHER|Cura Kensio-tapping|Cura tapes, a cotton strip with an acrylic adhesive. allows for unidirectional elasticity up to 60% beyond its resting length.
223649797|NCT05768022|OTHER|placebo|placebo taping
223649798|NCT04330729|DRUG|Acetylsalicylic acid|Se arm description
223649799|NCT06220760|DIAGNOSTIC_TEST|Ultrasound|The use of US to calculate placenta accreta index
223649800|NCT03867370|DRUG|Toripalimab (JS001 )|Given IV
223649801|NCT03867370|DRUG|Toripalimab (JS001 ) Lenvatinib|Given IV 4 mg capsules
223649802|NCT03867370|DRUG|Toripalimab (JS001 ) Lenvatinib|Given IV 4 mg capsules
223649803|NCT00522236|BIOLOGICAL|Surface Antigen, Inactivated, Adjuvanted Influenza Vaccine, Formulation 2007-2008|"A single 0.5mL dose of Novartis adjuvanted subunit influenza vaccine, Fluad contained 45μg of viral hemagglutinin, composed of 15μg of the three influenza antigens:~* A(H1N1) strain: IVR-145 (Solomon Island/3/2006 - like strain)~* A(H3N2) strain: NYMC X-161B (A/Wisconsin/67/2005-like strain)~* B strain: (B/Malaysia/2506/2004-like strain) in accordance with the recommendations of the World Health Organization, the EU and the national Regulatory Agencies for the 2007/2008 season.~The vaccine is a milky liquid, and was packaged in ready to use, single dose syringes.~A single dose of FLUAD vaccine was administered intramuscularly, preferably in the deltoid muscle of the non dominant arm."
223649804|NCT00176956|PROCEDURE|Skin Biopsy|Skin biopsy.
223649805|NCT00422864|DRUG|oxaliplatin|"Week 1: Oxaliplatin 100 mg/m2 Day 1 (over 2 hours), leucovorin 200mg/m2 Day 1 concurrent with oxaliplatin over 2 hrs (then 5-FU).~Weeks 3 to 5: radiotherapy 25.2 Gy in 14 fractions over 3 weeks with 85 mg/m2 oxaliplatin on the first day Week 6: as per Week 1, Weeks 8-10: as per Weeks 3-5 Weeks 11: as per Week 1."
223649806|NCT00422864|DRUG|fluorouracil|"Week 1: (after Oxaliplatin and leucovorin)5-FU 400mg/m2 bolus Day 1, then 5-FU continuous infusion 2.4 g/m2 over 46 hours from Day 1.~Weeks 3 to 5: radiotherapy 25.2 Gy in 14 fractions over 3 weeks with 85 mg/m2 oxaliplatin on the first day and continuous infusion 5-FU 200 mg/m2/day on the days of radiotherapy, Week 6: as per Week 1, Weeks 8-10: as per Weeks 3-5 Weeks 11: as per Week 1."
223649807|NCT00422864|DRUG|leucovorin|Week 1: Oxaliplatin 100 mg/m2 Day 1 (over 2 hours), leucovorin 200mg/m2 Day 1 concurrent with oxaliplatin over 2 hrs (then 5-FU) Week 6: as per Week 1, Weeks 11: as per Week 1.
223649808|NCT00422864|PROCEDURE|External beam radiotherapy|Weeks 3 to 5: radiotherapy 25.2 Gy in 14 fractions over 3 weeks with 85 mg/m2 oxaliplatin on the first day and continuous infusion 5-FU 200 mg/m2/day on the days of radiotherapy, Weeks 8-10: as per Weeks 3-5
223649809|NCT00927914|DRUG|Ranirestat|Ranirestat 40 mg tablets
223649810|NCT00927914|DRUG|Placebo|Placebo tablets
223649811|NCT04196387|DIAGNOSTIC_TEST|urine culture|urine culture and antibiotic susceptibility test
223649812|NCT01456624|DRUG|Megace|800mg
223649813|NCT01456624|DRUG|DW-ES(B)|625mg
223649814|NCT01675544|PROCEDURE|Electrocardiogram|EKG voltage changes between admission and discharge
223649815|NCT01675544|PROCEDURE|Six minute walk test|
223649816|NCT05317091|OTHER|Laughter yoga practiced|"In this study, 8 sessions of laughter yoga were applied to the nurses in the experimental group as an intervention, twice a week for 4 weeks. Due to the Covid-19 pandemic; Laughter Yoga sessions were held on the web through the 'ZOOM' program.~For this reason, it is recommended that the laughter yoga sessions be done with a group and that the group should consist of at least five people in order to provide group dynamics. Sessions are planned according to the days and hours that nurses can attend. Sessions 1st group Monday-Thursday between 12:00-13:00; 2nd group Tuesday-Friday between 17:00-18:00; The third group was held on Wednesday-Saturday between 20:00-21:00. The nurses were constantly contacted (whatsapp, phone) to ensure that they attend the sessions regularly and that there is no interruption in the sessions. No experiment was performed on the control group during the study. However, after the research, a 4-week laughter yoga was given to the nurses who wanted it."
223649817|NCT04206280|BEHAVIORAL|Use of a pedometer following surgery|Subjects in the study group will receive a pedometer with graduated step count goals as discussed in arm description.
223649818|NCT04206280|BEHAVIORAL|Standard of care|Subjects in the control group will be counseled on the importance of ambulation during their pre-operative visit.
223649819|NCT00502411|DRUG|Doxorubicin|17.5 mg/m\^2 IV bolus infusion, followed by continuous IV infusion on days 1-4.
223649820|NCT00502411|RADIATION|Radiation Therapy|Radiation treatments 5 days a week for 6 - 6 1/2 weeks. 60 Gy in 6 weeks (negative resection margin) to 66 Gy in 6.5 weeks (positive resection margin).
224234742|NCT01493479|DRUG|90Y Ibritumomab tiuxetan|2 x iv infusions of 11.1 MBq/kg. 1st infusion at week 1, 2nd during weeks 9-13. 2nd infusion may be reduced to 7.4MBq/kg in the case of grade 3 haematological toxicity following the 1st infusion.
224234743|NCT01493479|DRUG|Rituximab|"All patients receive 2 x iv infusions of 250 mg/m2 Rituximab given 7-8 days apart prior to each zevalin infusion. The 2nd rituximab infusion is given immediately prior to Zevalin.~In addition patients with greater than 20% bone marrow involvement at screening receive rituximab pretreatment prior to entering the main treatment phase of the trial, consisting of 4 x weekly iv doses of rituximab(375 mg/m2). This is followed by a repeat bone marrow biopsy, bone marrow involvement must have fallen to \<= 20% to enter the main treatment phase of the trial."
224234744|NCT04330937|DIETARY_SUPPLEMENT|dietetics|90 days of consumption
224234745|NCT03922438|PROCEDURE|usage of cleft margin flap with anterior palatal closure during primary cleft lip repair.|Under general anesthesia, preparation of lip and palatal flaps will be done and then cleft margin flap which is designed to be inferiorly based will be used with anterior palatal closure in an attempt to decrease the incidence rate of naso-alveolar fistula (defect) that is usually occur and remain in those patients post-operatively.
224234746|NCT04547946|DRUG|dabrafenib + trametinib|There was no treatment allocation. Patients administered adjuvant treatment with combination therapy of Dabrafenib (Tafinlar®) and Trametinib (Mekinist®) by prescription that had started before inclusion of the patient into the study could be enrolled.
224234747|NCT02296775|BIOLOGICAL|DRL_RI|Two 1000 mg intravenous infusions, one each on Day 1 and Day 15
224234748|NCT02296775|BIOLOGICAL|Rituxan|Two 1000 mg intravenous infusions, one each on Day 1 and Day 15
224234749|NCT02296775|BIOLOGICAL|MabThera|Two 1000 mg intravenous infusions, one each on Day 1 and Day 15
224234750|NCT02090829|DRUG|Syntocinon (synthetic oxytocin)|Syntocinon is a nine residue cyclic peptide; the hormone is prepared synthetically to avoid possible contamination with vasopressin and other small polypeptides with biologic activity.
224234751|NCT02090829|OTHER|Placebo|"Placebo Comparator: Intranasal Placebo Intranasal placebo The placebo is identical to the oxytocin formulation with the exception of the active compound.~Route of administration: Intranasal Planned exposure: Each participant will receive one dose of intranasal placebo per day for 5 days.~One dose equals 6 spray puffs (3 puffs in each nostril)."
224234752|NCT03106584|DIETARY_SUPPLEMENT|Aquamin-Plus|"Aquamin (a calcium-rich marine multi-mineral) - 666.7mg magnesium hydroxide - 66.66mg pine bark - 30mg vitamin d3 - 2.5μg~Dosage:~4 Capsules is equal to effective dose"
224234753|NCT03106584|DIETARY_SUPPLEMENT|Glucosamine sulphate|"The Glucosamine sulphate supplement contains 500mg of the active ingredient Glucosamine sulphate per serving (one capsule).~Dosage:~4 Capsules is equal to effective dose"
224234754|NCT02554864|DRUG|lidocaine|Local anesthetic
224234755|NCT02554864|DRUG|ropivacaine|Local anesthetic
224234756|NCT05063409|OTHER|Treatment|Blood product transfusion at a ratio of 1:1 FFP to PRBC or 1:4 FFP to PRBC during the operative period (start of surgery to 12 hours post operatively)
224234757|NCT02625948|DRUG|Tranexamic Acid|
224234758|NCT04462263|DRUG|HTL0014242|Solid suspension capsule
224234759|NCT02497456|BEHAVIORAL|Follow-up counselling|
223649821|NCT00921895|DEVICE|RPS Adeno Detector IV|One time test with the RPS Adeno Detector IV
223649822|NCT00618345|DRUG|everolimus|
223649823|NCT00618345|GENETIC|DNA analysis|
223649824|NCT00618345|GENETIC|protein analysis|
223649825|NCT00618345|GENETIC|western blotting|
223649826|NCT00618345|OTHER|flow cytometry|
223649827|NCT00618345|OTHER|laboratory biomarker analysis|
223649828|NCT00618345|PROCEDURE|biopsy|
224234760|NCT03312257|COMBINATION_PRODUCT|Multifocal D +2.50 add & 0.01% atropine|Biofinity Multifocal D +2.50 add is a monthly disposable contact lens commercially available from CooperVision; 0.01% atropine is low-dose atropine compounded by local pharmacy.
224234761|NCT06111911|DIAGNOSTIC_TEST|HPV Diagnostic Kit (Bio Farma)|Urine samples (30 ml): collected from each subjects using urine pot. Cervical swab: collected from each subject using cyto brush and stored in special container which preservatives fluid.
224234762|NCT03392298|DRUG|Colla corii asini|15g Colla corii asini granule, once daily for 4 weeks
224234763|NCT02776709|PROCEDURE|ERCP with cholangioscopy|
224234764|NCT01431924|DRUG|Higher-dose inhaled corticosteroids|fluticasone propionate 110 or 220 mcg
224234765|NCT01431924|DRUG|Low-dose fixed dose fluticasone propionate/salmeterol xinafoate combination|Low dose inhaled corticosteroids/salmeterol xinafoate (100mcg/50mcg or 250 mcg/50mcg)
224234766|NCT02660242|DRUG|G-Pen Mini™ (glucagon injection)|Glucagon (150 µg) 5 minutes before the start of exercise (SQ-abdomen).
224234767|NCT02660242|OTHER|Glucose Tabs|Dextrose tabs orally (20 grams) 5 minutes before the start of exercise and at 30 minutes of exercise (total 40 grams).
224234768|NCT02660242|OTHER|Basal Insulin Reduction|Basal insulin reduction to 50% 5 minutes before the start of exercise.
224234769|NCT01282151|DRUG|Taxotere|Docetaxel 60 mg/m2 q3 weeks Cisplatin 70 mg/m2 q3 weeks
224234770|NCT01282151|DRUG|Pemetrexed|Pemetrexed 500 mg/m2 q3 weeks Cisplatin 70 mg/m2 q3 weeks
224234771|NCT01432795|DEVICE|Gliding aids for medical compression stockings|"Each subject tests devices:~* 3 gliding aids for stockings with closed tips~* 3 gliding aids for stockings with open tips~* 2 stocking butlers using~* 3 medical compression stockings with open tip, compression class 3 (36-46mmHg)~* 3 medical compression stockings w. closed tip, compression class 3 (36-46mmHg)~* 2 superimposed compression stockings class 1 (18 - 21 mmHg)"
224234772|NCT00770510|DRUG|Eszopiclone 1 mg|Eszopiclone 1 mg tablet, taken orally at bed time for 2 consecutive nights. Each participant was assigned to one of 10 prespecified treatment sequence patterns. Each interval (five total intervals) of 2 consecutive nights was separated by a washout of approximately 5 days. A follow-up period consisted of 6 days.
224234773|NCT00770510|DRUG|Eszopiclone 2 mg|Eszopiclone 2 mg tablet, taken orally at bed time for 2 consecutive nights. Each participant was assigned to one of 10 prespecified treatment sequence patterns. Each interval (five total intervals) of 2 consecutive nights was separated by a washout of approximately 5 days. A follow-up period consisted of 6 days.
224234774|NCT00770510|DRUG|Eszopiclone 3 mg|Eszopiclone 3 mg tablet, taken orally at bed time for 2 consecutive nights. Each participant was assigned to one of 10 prespecified treatment sequence patterns. Each interval (five total intervals) of 2 consecutive nights was separated by a washout of approximately 5 days. A follow-up period consisted of 6 days.
224234775|NCT00770510|DRUG|Placebo|Placebo tablet, taken orally at bed time for 2 consecutive nights. Each participant was assigned to one of 10 prespecified treatment sequence patterns. Each interval (five total intervals) of 2 consecutive nights was separated by a washout of approximately 5 days. A follow-up period consisted of 6 days.
224234776|NCT00770510|DRUG|Zolpidem Tartrate 10 mg|Zolpidem Tartrate 10 mg tablet, taken orally at bed time for 2 consecutive nights. Each participant was assigned to one of 10 prespecified treatment sequence patterns. Each interval (five total intervals) of 2 consecutive nights was separated by a washout of approximately 5 days. A follow-up period consisted of 6 days.
224320397|NCT04080466|OTHER|Patient Reported Questionnaires|"The purpose of the questionnaires is to assess how much trouble the participant is having with their hip and how it affects their quality of life.~Participants in the Cam Group will complete the questionnaires twice; once before surgery and once 2-years post-operative. Participants in the Control Group will complete the questionnaires once as part of the study."
224320398|NCT04080466|RADIATION|EOS Scan|"The EOS® uses a new imaging technique that allows precise measurement of the hip and pelvis geometry and structure. This innovative x-ray technique exposes participants to 2-10 times less radiation than a routine x-ray and can capture multiple images at once.~Participants in the Cam Group will undergo the EOS scan twice; once before surgery and once 2-years post-operative. Participants in the Control Group will undergo the scan once as part of the study."
224234777|NCT04188821|PROCEDURE|breast drain removal|"Investigators remove the drains when the suction drain flow was less than 30 ml/day for at least 2 days or at discharge, with no further signs of infection, fluid collection or impaired wound healing (complicated, see below). Ultimately, we removed drains 3 weeks postoperatively (21 days post op) even if the flow was higher than 30 ml/day. However, leakage or severe patient discomfort led to immediate drain removal at any time during postoperative care."
224320399|NCT04080466|RADIATION|PET-MRI|"Positron emission tomography combined with magnetic resonance imaging (PET-MRI) is a technology that allows physicians to examine bone and cartilage at the molecular level.~Participants in the Cam Group will undergo the scan twice; once before surgery and once 2-years post-operative. Participants in the Control Group will undergo the scan once as part of the study."
223649829|NCT01658644|OTHER|Provision of Clinical Care Handout|Patients assigned to groups B or C will be provided with a paper or electronic version displaying either a list of the names and roles of their clinical care staff (group B), or a list of names and roles accompanied by the respective photograph of each clinician (group C). This document will be presented to the patient at the earliest possible time after admission to the hospital.
224320400|NCT04080466|OTHER|Motion Analysis|"Motion analysis is the study of how joints move and which muscles fire during specific movements. In the lab, participants will be asked to perform movements that they might do during a typical day or when exercising.~Participants in the Cam Group will undergo the Motion Analysis session twice; once before surgery and once 2-years post-operative. Participants in the Control Group will undergo the Motion Analysis session once as part of the study."
224320401|NCT04080466|RADIATION|3T MRI|"Participants will undergo a 3-Tesla (3T) Magnetic Resonance Imaging (MRI) of both hips.~Participants in the Cam Group will undergo this scan once as part of their standard of care. Participants in the Control Group will undergo this scan once as part of the study."
223649830|NCT02296372|DEVICE|Continuous glucose monitoring|"Continuous glucose monitoring by subcutaneous or intravasal device for 72 hours.~In use MEDTRONIC SENTRINO® and Edwards GlucoClear® systems."
223649831|NCT02975232|BEHAVIORAL|F&V economic incentive|50% off eligible fresh, frozen and canned fruits and vegetables (up to $10/day)
223649832|NCT02975232|BEHAVIORAL|Cooking Matters Store Tour|Participants will be asked to attend one Coking Matters store tour during January or February 2017
224320402|NCT00790725|OTHER|Proportional Assist Ventilation|Proportional Assist Ventilation will be used to ventilate the patients.
224320403|NCT00790725|OTHER|Pressure Support Ventilation|Pressure Support ventilation will be used to ventilate the patients.
224320404|NCT01850134|OTHER|Experimental Study Product|
223649833|NCT02862353|BIOLOGICAL|blood sample|15 ml of blood
223649834|NCT04877951|BEHAVIORAL|LSVT BIG|LSVT BIG is a 4-week program that focuses on movement recalibration for people with a diagnosis of Parkinson's disease.
223649835|NCT05584319|DRUG|Empagliflozin 10 Mg|subjects in Empagliflozin group takes Empagliflozin 10mg per day
223649836|NCT00874926|BIOLOGICAL|Recombinant Factor VIII (Kogenate FS, BAY14-2222)|Haemophilia A patients
223649837|NCT06455046|DRUG|AK104|PD-1/CTLA-4 bispecific antibody
223649838|NCT06455046|DRUG|Recombinant Human Adenovirus 5 Injection|Recombinant Human Adenovirus 5 Injection
223649839|NCT02785796|OTHER|CV4|
223649840|NCT02785796|OTHER|SHAM TECHNIQUE|
223649841|NCT05165693|OTHER|Experimental Formula|Diabetes-specific study formula
223649842|NCT05165693|OTHER|Test Meal|Instant oatmeal
223649843|NCT00994344|DRUG|Darunavir/ritonavir|Darunavir/ritonavir 800/100 mg once daily
223649844|NCT00994344|DRUG|Lopinavir/ritonavir|Lopinavir/ritonavir 400/100 mg twice daily
223649845|NCT02146534|DRUG|extended release fampridine|pts will receive Fampyra 10 mg BID PO for the duration of the study
223649846|NCT02146534|DRUG|Placebo|placebo will be taken PO BID
223649847|NCT02225691|DEVICE|Paired testing of blood glucose Accu-Chek®|Patients in the paired testing arms will undergo training on paired testing with Accu-Chek® Active blood glucose meters. The paired testing training would include (1) how and when (testing regimen) to perform paired testing, and (2) how to respond to paired testing readings via lifestyle modifications, self-adjustment of insulin dose and additional testing, if applicable. Please refer to Annex A for further details of the training.
223649848|NCT05697185|DRUG|Evolocumab|Patients were randomly assigned of the ratio of 1:1 using a computer-generated random number and divided into two treatment groups: the statin alone therapy and the evolocumab plus statin therapy.
223649849|NCT01890603|OTHER|Data collection|Research involving materials (data, documents, records, or specimens) that have been collected, or will be collected, solely for non-research purposes (such as medical treatment or diagnosis).
224320405|NCT01850134|OTHER|Control Study Product|
224234778|NCT03150602|DRUG|Pralatrexate|This is a single arm study. Pralatrexate will be administered via IV over 3-5 minutes into a IV line containing normal saline (0.9% sodium chloride, NaCl) with the initial dose of 30 mg/m2/week on days 1, 8, 15, 22, 29, and 36 for 6 weeks in a 7-week cycle. The scheduled date can be done within a window time of plus or minus 1 day. The pralatrexate dose may be reduced to 20 mg/m2/week or omit if a patient experiences adverse events. Pralatrexate administration can be up to 5 cycles or until subject meets withdrawal criteria.
224234779|NCT00571428|DRUG|Arformoterol Tartrate Inhalation Solution|Nebulized arformoterol tartrate inhalation solution 15 microgram twice a day (BID)
224234780|NCT00571428|DRUG|Arformoterol Tartrate Inhalation Solution|Nebulized arformoterol tartrate inhalation solution 30 microgram once a day (QD)
224234781|NCT00571428|DRUG|Placebo|Placebo inhalation solution (citrate buffered 0.9% saline solution) once a day
224234782|NCT03996512|OTHER|Early Active Controlled Motion (EACM)|Early active controlled wrist motion rehab protocol using that will allow midcarpal row motion.
224234783|NCT02778919|DRUG|KLH-2109|
224234784|NCT02778919|DRUG|Placebo|
224234785|NCT02778919|DRUG|Leuprorelin acetate|
224234786|NCT05127577|OTHER|Abdominal massage|Abdominal massage will be applied to patients at least 30 minutes after morning and evening meals (8:30 in the morning, 20:30 in the evening) for 15 minutes each, similar to the literature \[33,34,38\]. Data of the patients will be collected again 15 minutes after the application of abdominal massage (09:00-09:15 in the morning, 21:00-21:15 in the evening). Abdominal massage will start in the evening of the day the patient is transferred to the clinic (20:30), and will be terminated when the patient defecates. In order to stimulate bowel movements, four basic movements will be used in the abdominal massage to be applied clockwise: superficial effusion, deep effusion, petrissage, and vibration.
224234787|NCT05830019|RADIATION|carbon ion radiotherapy|carbon ion radiotherapy
224234788|NCT00025896|DRUG|recombinant human acid alpha-glucosidase (rhGAA)|
224234789|NCT02192099|DRUG|Rapastinel (225 mg/450 mg IV administration)|Investigators began treatment in RAP-MD-05 based on the dose level to which the patient was assigned during participation in GLYX13-C-202; patients originally assigned to rapastinel 5 mg/kg received rapastinel 225 mg, and patients originally assigned to rapastinel 10 mg/kg received rapastinel 450 mg. Investigators had the option to decrease the dose level from 450 to 225 mg if a patient experienced an adverse event(s) that the investigator believed may be associated with rapastinel
224234790|NCT00628199|PROCEDURE|Improving the scientific process of human cell reprogramming|
224234791|NCT05261685|PROCEDURE|Single-step transepithelial PRK|Single-step transepithelial Photorefractive keratectomy (PRK) is a corneal refractive surgical procedure utilized to correct myopia, hyperopia and astigmatism where excimer laser is used in a single step to remove the corneal epithelium followed by stromal laser ablation to correct the patient's refractive error.
224234792|NCT05427656|RADIATION|[18F] TRACK|We propose to use the radiotracer \[18F\] TRACK to non-invasively image the concentration of TrkB/C in the living human brain with PET in the 3 cohorts. The different subgroups of healthy controls will be used to define the best quantification method for our TrkB/C ligands and to assess a possible age dependency of TrkB/C binding in the healthy population, and may be of particular importance for the future study of patients with Alzheimer's Disease or mild cognitive impairment. Each participantsubject will receive a single scan with 185 MBq \[18F\] TRACK injected into an antecubital vein. Dynamic PET data will be acquired in list mode for 90 minutes (\[18F\] TRACK) respectively on a CTI/Siemens HRRT PET scanner at the brain imaging center of the Montreal Neurological Institute following our published procedure for \[18F\] TRACK after a transmission scan.
224234793|NCT05427656|DEVICE|Measurement of Arterial Input Function|The non-invasive detector, hereinafter called NID, comprises of plastic scintillating fibers (BCF-12, St-Gobain, France) wrapped in a medical-grade acrylic heat-shrink tube (Vention Medical, USA). The scintillating fibers are coupled to 5 m long transmission fibers to bring the signal out of the PET detector. The fibers will be held in place using a 3D-printed structure composed poly-lactic acid. The NID is designed to measure both positrons and photons escaping the wrist. Post-processing software is used to calculate the arterial input function.
224234794|NCT05007288|OTHER|Restorative Eye Treatment (RET) cream|RET cream will be applied topically to either the left of right eyelid once daily for 4 consecutive weeks.
224234795|NCT05007288|OTHER|INhance with Trihex Technology|INhance will be applied topically to both eyelids once daily for 10 consecutive days after the SOC blepharoplasty surgery.
223649850|NCT01890603|OTHER|Data Collection|Research involving materials (data, documents, records, or specimens) that have been collected, or will be collected, solely for non-research purposes (such as medical treatment or diagnosis).
224234796|NCT05380271|DRUG|sequential DEB-BACE and Arotinib and Tirelizumab|DEB-BACE+Arotinib + Tirelizumab
223649851|NCT05202756|BEHAVIORAL|Mobile Application to Prevent Suicide (MAPS)|Safety Planning Intervention, ecological momentary intervention smartphone app system, and bidirectional communication with study clinician.
223649852|NCT05202756|BEHAVIORAL|EMA Monitoring Only|Safety Planning Intervention; ecological momentary assessment only
223649853|NCT05335915|OTHER|Nicotine|Nicotine pouches will be self-administered
223649854|NCT05335915|OTHER|Cigarette|Cigarette will be smoked
224234797|NCT05380271|DRUG|DEB-BACE alone|DEB-BACE alone
223649855|NCT06055439|BIOLOGICAL|CHM-2101 CAR-T cells|Cadherin 17 (CDH17) Chimeric Antigen Receptor (CAR)-positive T cells
223649856|NCT03675321|DEVICE|Active Auricular Neurostimulation|Active auricular neurostimulation for 4 weeks. Subjects in Active group who do not have significant improvement after 4 weeks may receive an additional 4 weeks of active neurostimulation therapy.
223649857|NCT03675321|DEVICE|Sham Auricular Neurostimulation|"Sham auricular neurostimulation for 4 weeks with identical device as the active but lacking the electrical charge.~Subjects in Sham group who do not have significant improvement after 4 weeks may receive an additional 4 weeks of active neurostimulation therapy."
223649858|NCT00936286|DEVICE|SpiroTiger|Respiratory muscle training with SpiroTiger device, 1 week training initiation and 4 weeks training period with 5 training days per week, training duration 30 min each. Respiratory bag volume set at 50% VC, respiratory frequency starting from 50% MVV. Weekly control trainings.
224234798|NCT00757809|DRUG|neratinib|HKI-272
224234799|NCT04671641|DEVICE|radiofrequency ablation|ultrasound-guided radiofrequency ablation is performed to treat varicose veins patients
224234800|NCT03553160|OTHER|Frequent Self-Weighing|Were given scales to weigh themselves daily. Change in weight was measured at the beginning and end of the two year observation period.
224234801|NCT04012697|BEHAVIORAL|Peer Support|Participants randomized to the intervention group will be seen by the peer support worker during their stay in the emergency department. The goal of the peer support worker's practice is to address the participant's wellness from a holistic point of view that includes their relationships, connections to the community, general well-being, and sense of empowerment, with an overall focus on quality-of-life goals (Sunderland et al., 2013). The peer support worker will provide a multi-faceted intervention, which aims to foster a peer-to-peer relationship encompassing elements of empathic communication, brief supportive counseling, advocacy for non-medical needs in hospital, liaising and collaborating with medical and nursing staff, motivational interviewing, and connection with programs in the community.
224234802|NCT06277193|DIAGNOSTIC_TEST|valuation of balance status, fear of falling and risk of falling in patients non-sarcopenia.|Daily living activities, frailty, physical performance, balance status, risk of falling, fear of falling, nutritional status, and mental status were evaluated with various scales.
224234803|NCT06277193|DIAGNOSTIC_TEST|Evaluation of balance status, fear of falling and risk of falling in patients with probable sarcopenia.|Daily living activities, frailty, physical performance, balance status, risk of falling, fear of falling, nutritional status, and mental status were evaluated with various scales.
224234804|NCT06277193|DIAGNOSTIC_TEST|Evaluation of balance status, fear of falling and risk of falling in patients with sarcopenia.|Daily living activities, frailty, physical performance, balance status, risk of falling, fear of falling, nutritional status, and mental status were evaluated with various scales.
224234805|NCT06277193|DIAGNOSTIC_TEST|Evaluation of balance status, fear of falling and risk of falling in patients with severe sarcopenia.|Daily living activities, frailty, physical performance, balance status, risk of falling, fear of falling, nutritional status, and mental status were evaluated with various scales.
224234806|NCT05316675|DRUG|Isotretinoin|isotretinoin 13-cis-retinoic acid), derived from vitamin A
224234807|NCT02652026|PROCEDURE|Nonsurgical periodontal treatment|Full mouth debridement, which consisted of scaling and root planing (SRP), was done in a single visit using an ultrasonic scaler (SATELEC P5 Newtron XS, Acteon, Merignac, France) and Gracey curretes (Hu- Friedy, Chicago, USA).
224234808|NCT02652026|PROCEDURE|Dental Prophylaxis|Removal superficial plaque using an ultrasonic scaler (SATELEC P5 Newtron XS, Acteon, Merignac, France)
224234809|NCT03629574|PROCEDURE|Ventilation during cardiopulmonary bypass|Mechanical ventilation during cardiopulmonary bypass
224234810|NCT02001558|DRUG|Microcyn|Microcyn is liberally sprayed on wound and permitted to remain on wound which will then be dressed with gauze that is moistened with Microcyn twice daily for the earlier of total wound closure or Week 24
224234811|NCT02001558|OTHER|Sterile saline|Sterile saline is liberally sprayed on wound and permitted to remain on wound which will then be dressed with gauze that is moistened with sterile saline twice daily for the earlier of total wound closure or Week 24
224234812|NCT00136201|DRUG|tigecycline|
224234813|NCT01961908|DRUG|Proellex|
224234814|NCT04716738|DIAGNOSTIC_TEST|Blood analyses and coprological|We will take a blood and stool sample
223649859|NCT05761886|OTHER|telehealth-based clinical pharmacy intervention|The pharmacist will perform an initial comprehensive review of the medication regimen, make any adjustments, document those in the patient's electronic health record (EHR) and communicate with the patient's T2D care team as needed. They will also call (using an EHR-based software) the patient using phone/video to educate them about T2D self-management and identify any medication-related unmet needs. Periodic reviews of the medication regimen and roughly biweekly follow-up patient calls will occur with frequency based on need (as judged by the pharmacist). Patient intervention calls will be personalized depending on HbA1c levels, comorbidities, and medication complexity
223649860|NCT00910416|DRUG|propofol, remifentanil, atracurium|propofol, remifentanil, atracurium dosages are adapted according to clinician's judgment
224234815|NCT03695926|DRUG|[18F]MNI-1054|Healthy volunteers recruited for the study will undergo a \[18F\]MNI-1054 PET scan.
224234816|NCT03605043|OTHER|Blood pressure management in the HIV program|Integrated care for hypertension and HIV in the HIV program
224234817|NCT02852564|DRUG|Ethacrynic Acid|One oral dose at 50 mg prior to bladder tumor removal surgery
224320406|NCT04811937|DIAGNOSTIC_TEST|Computer-aided polypectomy decision support by Artificial Intelligence|The AI system will capture the live video of the procedure and the AI feedbackwill be shown on a second screen installed next to the regular endoscopy screen. Screen A will show the regular endoscopy image and screen B will show the regular endoscopy image together with the areas that might harbor a polyp and the information to help the polypectomy.
223649861|NCT00910416|DRUG|propofol, remifentanil, atracurium, sevoflurane|dosages are adapted according to clinician's judgment
223649862|NCT00910416|DEVICE|EEG monitoring|simultaneous monitoring with Bis and Neurosense
223649863|NCT04422158|DIETARY_SUPPLEMENT|Nuun electrolyte tablet|Each table contains 2 grams of carbohydrate and a combination of electrolytes. calcium (13mg, 1%DV), sodium (300mg, 13%DV), potassium (150mg, 3%DV), magnesium (25mg, 6%DV), and chloride (40mg, 2%DV).
223649864|NCT04422158|OTHER|water|water
224234818|NCT03491436|DEVICE|iHealth Align|remote monitor glucometer
224234819|NCT05928780|DRUG|A1:SG with SHR3680|SG 10mg/kg d1, 8；SHR3680 240mg qd，3 weeks is a cycle
224234820|NCT05928780|DRUG|A2:SG|SG 10mg/kg d1, 8
224234821|NCT05928780|DRUG|B1:SG with SHR1210|SG 10mg/kg， d1, 8；SHR1210 200mg，d1，q3w；
224234822|NCT05928780|DRUG|B2:SG|SG 10mg/kg， d1, 8
224234823|NCT05928780|DRUG|C1:SG with SHR3162|SG 10mg/kg d1, 8；SHR3162，150mg，QD ，3 weeks is a cycle
224234824|NCT05928780|DRUG|C2:SG|SG 10mg/kg d1, 8
224234825|NCT05928780|DRUG|D1:SG with VEGFRI|SG 10mg/kg，d1, 8；BP102 15mg/kg，d1，3 weeks is a cycle
224234826|NCT05928780|DRUG|D2:SG|SG 10mg/kg d1, 8
224234827|NCT04031300|DEVICE|Prototype 0.5|Investigational Medical Device collecting spectral Raman data non-invasively from tissue
224234828|NCT00459888|DEVICE|PolarCath Peripheral Dilatation System (Boston Scientific)|
223649865|NCT01487343|BEHAVIORAL|questionnaire and interview|Interviews will be conducted with the first 10 participants who agree to be interviewed (or until data saturation is reached). Self-report questionnaires assessing adherence, beliefs about medications, side effect experience, self-efficacy, and satisfaction with patient education; the qualitative portion is an interview guided by two open-ended questions. Data will be collected approximately 2 weeks - 6 months (2 - 24 weeks) after being prescribed capecitabine.
223649866|NCT04284228|BIOLOGICAL|Infusion of NEXI-001 T Cells|"Procedure: A single IV infusion of NEXI-001 T Cells at Day 1 after Lymphodepletion(LD) Therapy.~At dose Level 1: 1.0 x 108 total viable T cells At dose Level 2: 2.0 x 108 total viable T cells~Procedure: Lymphodepletion: IV administration of fludarabine 30 mg/2 and cyclophosphamide 300 mg/m2 for 3 days.~lymphodepletion (LD) Therapy: Subjects will received bridging therapy agents during lymphodepletion for 3 consecutive days prior to receiving the NEXI-001 product~Drug: Fludarabine~Fludarabine infusion~Other Name: Fludarabine monophosphate~Drug: Cyclophosphamide~Cyclophosphamide infusion~Other Name: Cytoxan"
223649867|NCT04442802|PROCEDURE|Percutaneous transluminal angioplasty|Under local anesthesia the percutaneous arterial access will be created. Digital subtraction angiography of the whole limb will be performed. Occlusive-stenotic lesion of the superficial femoral and / or popliteal artery will be crossed with a guidewire. The plain old (non drug-eluting) will be positioned in the affected arterial segment and inflated up to nominal pressure. After balloon deflation and extraction the completion angiography will be performed. Presence (yes/no) and severity (grades A-B or C-F according to NHLBI classification) of dissection will be assessed independently by 3 study investigators basing on DSA images in 2 directions. Decision to classify the dissection as severe (grade C-F) and to perform the bailout stenting will be done by the agreement between at least 2 from 3 investigators.
223649868|NCT05095948|PROCEDURE|Discussion|Undergo audio recording of clinic conversations
223649869|NCT05095948|OTHER|Electronic Health Record Review|Review of medical records
223649870|NCT05095948|OTHER|Questionnaire Administration|Complete questionnaires
223649871|NCT00825487|DRUG|ARQ 621|Treatment will be initiated at a dose level of 10 mg/m\^2 IV infusion for an hour once weekly in 4-week (28 day) consecutive and continuous cycles. ARQ 621 should be infused IV over two hours at doses 200 mg/m\^2 and higher (cohort 8 and above).
223649872|NCT00343460|DRUG|APF530|Given subcutanously
223649873|NCT00343460|DRUG|dexamethasone|Given IV and orally
223649874|NCT00343460|DRUG|Palonosetron Hydrochloride|Given IV
223649875|NCT00343460|OTHER|placebo|Given subcutanously or IV
223649876|NCT05853991|OTHER|osteopathic manipulative treatment|The intervention will be based on the specific assessment and treatment of the preterm developed by the team and validated through different studies.
223649877|NCT05853991|OTHER|Active comparator|Application of affective touch
223649878|NCT05853991|OTHER|Placebo|Application of static touch
223649879|NCT05938400|DEVICE|Polyvinylsiloxane impression with different techniques|One step impression technique will be compared with the standard two step technique
223649880|NCT04751006|OTHER|Gaze Stabilization Exercises|Gaze group performed balance exercises with gaze stability exercise.Gaze stability exercises included two types of exercises vestibular adaptation and substitution exercises. In Adaptation exercises individual need to fixate on a visual target during horizontal and vertical head movement with a purpose of increasing gaze stability and a long term gain to vestibular system. Subsitution exercises are planned to use other eye movement stratigies to substitute vestibular function and sustained visual fixation. During Substitution exercises individual need to perfomed eye head movement between target with a purpose of clear sighting during these tasks. Balance exercises consist of both static and dynamic balance exercises with weekly progression making balance exercises more challenging.
223649881|NCT04751006|OTHER|Balance Training|Participants performed balance training with saccade eye exercises.balance exercises included both static and dynamic balance exercises with a purpose of increasing mobility and stability of a posture by weekly progression. These exercises included standing on firm and foam surface with eyes open or close, heel stand, toe stand, marching on firm surface, forward and backward walking with normal base of support with weekly progression. Each task was performed for 5 repetitions with weekly progression in each task.
223649882|NCT03230370|OTHER|UFT|The EUEP group receives additional daily 50 mins program focusing on training of the hemiplegic upper extremity,
223649883|NCT03230370|OTHER|LFT|The ELEP group receives additional daily 50 mins program focusing on training of the hemiplegic lower extremity.
223649884|NCT01318460|DRUG|Levosimendan infusion|Prophylactic 24h infusion of levosimendan at a dose of 0.1 mg/kg/min
223649885|NCT01318460|DRUG|Placebo infusion|Twenty-four hour administration of placebo
223649886|NCT05155514|PROCEDURE|Mobil-O-Graph PWA|After resting in a quiet room preoperatively, blood pressure was measured on the right arm using an oscillometric method.
223649887|NCT01491607|BIOLOGICAL|BioThrax|BioThrax, 0.5 mL administered subcutaneously on days 0, 14, and 28.
223649888|NCT01317277|BEHAVIORAL|individualized Texting for Adherence Building (iTAB)|"Behavioral: Psychoeducation~Participants will also receive daily text messages to evaluate mood and methamphetamine use, but these messages will not remind participants about medication adherence.~Behavioral: individualized Texting for Adherence Building (iTAB)~Intervention is designed to send automated text messages to HIV+ persons who are current methamphetamine (METH+) users. Text messages are personalized, automated, real-time text messages. The iTAB intervention is designed to improve adherence to ART medications among HIV+/METH+ persons above and beyond an active comparator group."
224234829|NCT03536338|OTHER|Spinal Stimulation|transcutaneous electrical stimulation of the lumbar spinal cord during rehabilitation.
224234830|NCT03536338|OTHER|Sit-to-stand Training|Rehabilitation of standing from a chair using the Keiser Rack
224234831|NCT01550211|DEVICE|Magnetoencephalograph (MEG)|Conducting a brain scan during a series of perceptual and linguistic tasks
224234832|NCT00007436|DRUG|Tenofovir disoproxil fumarate|
224234833|NCT00194103|BEHAVIORAL|Telephone Monitoring and Feedback|In addition to attending IOP, participants receive phone contact from our counselors but only to receive a monitoring assessment. There is no feedback or counseling from study staff in this condition.
224234834|NCT00194103|BEHAVIORAL|Telephone Monitoring and Counseling|In addition to attending IOP, participants have phone contact with study counselors, which includes monitoring, feedback, and counseling.
224234835|NCT02236507|DEVICE|3D high resolution anorectal manometry|Procedure will take about 15 min. During procedure resting, voluntary squeeze, bear down maneuver, cough reflex, ano-anal reflex and Rectoanal Inhibitory Reflex will be obtained, if possible.
224234836|NCT05169554|DRUG|Standard [RC8]: rifampicin plus clarithromycin (RC) therapy for 8 weeks.|Treatment will be rifampicin (600 mg, daily) and clarithromycin (500 mg, twice daily) for 8 weeks. On the posology, dosage for rifampicin and clarithromycin will be standardized according to patient body weight following WHO guidelines. In general, for a 60 kg adult dosage will be RIF, 10 mg/kg once daily and CLA, 7.5 mg/kg twice daily.
223649889|NCT01317277|BEHAVIORAL|Psychoeducation|"Behavioral: Psychoeducation~Participants will also receive daily text messages to evaluate mood and methamphetamine use, but these messages will not remind participants about medication adherence."
223649890|NCT00774566|PROCEDURE|PV-Isolation RF|Radiofrequency
224234837|NCT05169554|DRUG|Investigational [RCA4]: standard (RC) plus amoxicillin/clavulanate (A) for 4 weeks.|"On the posology, dosage for rifampicin and clarithromycin will be standardized according to patient body weight following WHO guidelines. In general, for a 60 kg adult dosage will be RIF, 10 mg/kg once daily and CLA, 7.5 mg/kg twice daily.~Dosages for amoxicillin/clavulanate are calculated according to manufacturer indications:~Dose of amoxicillin/clavulanate 1000/125 mg twice daily, which makes a total of 2000/250 mg/day, for patients over 40 kg, and 22.5/5.6 mg/kg twice daily, which makes a total of 45/11.25 mg/kg/day, for those equal and below 40 kg. For children, posology will be adapted to the age of the patient according to drug manufacturer indications. Frequency of AMX/CLV administration will match that of CLA, twice daily."
224234838|NCT05413603|PROCEDURE|ultrasonic focus Shock wave lithotripsy|successful Shock wave lithotripsy , accurate localization of the shock waves is performed by ultrasound (US) to fully focus the shock waves on the stone
224234839|NCT05413603|PROCEDURE|fluoroscopic focus Shock wave lithotripsy|successful Shock wave lithotripsy , accurate localization of the shock waves is performed by fluoroscope (FS) to fully focus the shock waves on the stone
224234840|NCT01033162|BEHAVIORAL|Enhanced ICCS with KPNW web resources and the Comprehensive Health Enhancement Support System (CHESS.)|"Half of the participating women will be randomly assigned to use an informative but static website (Basic ICCS), and half will be offered a fully interactive CHESS (Enhanced ICCS + the Basic ICCS). Study outcome data will be gathered from patients, clinicians, and the healthcare system (i.e., from the electronic medical record: EMR) for at least 8 months after study entry. We propose that the Enhanced ICCS relative to the Basic ICCS, will:~* Improve patients' sense of cancer information competence (perceived ability to obtain and use relevant information)~* Reduce patients' negative affect and increase their emotional well being~* Improve patients' sense of social support~* Improve patients' health self-efficacy~* Improve patients' ratings of experience with cancer specialty care services~* Improve patients' health related quality of life (HRQL)~* Improve clinicians' ratings of quality of patient contacts~* Reduce healthcare utilization and costs (obtained via the EMR)"
224234841|NCT02129348|DRUG|Lithium|
224234842|NCT02129348|DRUG|Placebo|
224234843|NCT06801093|BEHAVIORAL|Digital psychosocial tool|Wysa is a digital psychosocial tool that provides AI conversational chatbot support. The conversational agent acts as a companion, and understands, empathizes, and guides users through exercises grounded in cognitive behavioral therapy (CBT), mindfulness, and motivational intervention. Participants can progressively work through learning different skills and practice them in their daily life. The app also provides a repository of tools to manage problems and SOS resources for high distress.
223649891|NCT00774566|PROCEDURE|PV-Isolation Cryo|Cryo-Balloon
223649892|NCT06457750|BEHAVIORAL|Feeding, Lifestyle, Activity Goals (FLAGs) Digital Health Application|Feeding, lifestyle, activity goals (FLAGs) is a digital assessment and advisory tool developed by the investigators to facilitate early identification of lifestyle behaviour problems and abnormal feeding patterns in infants, with real-time feedback for caregivers. The FLAGs questionnaire examines the domains of energy regulation, timeliness and adequacy of weaning, dietary practices, and lifestyle habits. Tailored recommendations have been developed for each domain accordingly. The objective of FLAGs is shaping healthy lifestyle and feeding behaviours from birth, charting a trajectory to optimal metabolic health.
223649893|NCT02074683|PROCEDURE|Year A Pathway|Fat Grafting Operative Procedure followed by Standard of Care Follow-up.
223649894|NCT02074683|PROCEDURE|Year B Pathway|Standard of Care Followed by Fat Grafting Operative Procedure
223649895|NCT00852852|BEHAVIORAL|Electronic Self-Report Assessment - Cancer (ESRA-C)|The Electronic Self-Report Assessment-Cancer (ESRA-C) is a program allowing patients to report symptoms and quality of life issues and learn information about how to deal with these experiences.
223649896|NCT01397214|DRUG|Megace F|Megace F oral suspension
223649897|NCT01397214|DRUG|Megace OS|Megace oral suspension
223649898|NCT00006340|DRUG|arginine butyrate|
223649899|NCT00006340|DRUG|ganciclovir|
223649900|NCT06138496|DRUG|Cadonilimab Combined With Lenvatinib|"3.7.1 Lenvatinib Treatment Lenvatinib (8mg \[body weight \< 60 kg\] or 12 mg \[body weight ≥ 60 kg\]) orally once daily, with or without food.~3.7.2 Intravenous Infusion of Cardonilli (Injection) Infuse Cardonilli at a dose of 6mg/kg intravenously every two weeks, constituting one treatment cycle, a total of 6 cycles."
223649901|NCT04073108|DIAGNOSTIC_TEST|tuberculin test|tuberclin test used to diagnose tuberculosis as cause of fever of unknown origin
223649902|NCT02688777|BEHAVIORAL|Backward Walking Training|Backward Walking Training will occur both on a treadmill and overground. In brief, BWTraining will consist of 20-30 minutes of step training with a Body Weight Support and Treadmill system (BWST), rest periods provided as warranted, with manual assistance provided by trainers, followed by 15 minutes of overground gait training. A 20-30 min period of actual stepping is the goal for the intervention sessions on the treadmill with rest periods as needed. Each training session may last up to 1 hour and 30 minutes including time for warm-up, stretching, and cool down. Participants will be fitted with a harness around their hips and torso, which will be attached to an overhead support system directly above the treadmill. From a stationary position, the treadmill belt will gradually be increased in speed with intervention trainers assisting participant to step backward with their paretic leg, their non-paretic leg (if needed) and at the hips for weight-shift.
223649903|NCT02549365|DRUG|Live attenuated influenza vaccine|Administration of LAIV, with subsequent surveillance (nasal swabbing) during influenza season
223649904|NCT02549365|PROCEDURE|Surveillance (nasal swabbing) during influenza season|
223649905|NCT00912795|BEHAVIORAL|SMS Turkey|"6-week smoking cessation program delivered via daily text messages~SMS Turkey: 6-week smoking cessation program delivered via text messaging. SMS Turkey content is guided by the Cognitive Behavioral Therapy (CBT) theory.~Content was tailored based on participant's stage in quitting (i.e., pre-quit, quit day, early-quit, late-quit, relapse). Based on the typical relapse trajectory, content paths were created for participants based on whether or not they were smoking 2 days after quit day; and again at 7 days after quit day.~Depending on the participant's content path, the total number of messages received ranged from 91 (for those assigned to the encouragement arm) to 146 (for those who relapsed and then were assigned to the late quit messages)."
224234844|NCT02327195|DRUG|Methylphenidate HCl|Subjects will be randomly assigned to either the Methylphenidate or the Placebo arm, and be given a 20 mg dose (of Methylphenidate or Placebo) in liquid form (4 mL)
224234845|NCT02327195|DRUG|Placebo|20 mg of placebo (PO) will be given 2 hours prior to surgery
224234846|NCT01775319|DIETARY_SUPPLEMENT|Biofortified wheat|Extrinsic label 67Zn (ZnSO4) 0.2mg 70Zn added to the IV dose
224234847|NCT01775319|DIETARY_SUPPLEMENT|Fortified wheat|Extrinsic label 67Zn (ZnSO4) 0.2mg 70Zn added to the IV dose
224234848|NCT01775319|DIETARY_SUPPLEMENT|Placebo|
224234849|NCT04195997|DRUG|Bivalirudin|Patients would be given anticoagulant therapy with bivalirudin in left atrial appendage occusion.
224234850|NCT04195997|DRUG|Heparin|heparin during left atrial appendage occlusion.
224234851|NCT03509103|OTHER|Electronic Partograph|"The electronic version of the partograph was a state-of-the-art application that is accessed through smart phone or tablet pc or computer device. The application's user interface (UI) is segmented; users will have to concentrate only on a single portion at a time that would lessen the existing complexity of using paper-based partograph.~e-partograph application's user interface in Android programming language for smart tabs, and in ASP.net with C# language for personal computers. The application has options to save the data in local storage and in a remote central database storage concurrently. Local storage contains data for temporarility; the remote server contains the data permanently which makes the partograph information searchable at any time and place. This application allows partograph data to be monitored remotely."
224234852|NCT04339465|BEHAVIORAL|CARE-FAM|CARE-FAM is a family-based intervention for the diagnostic, early detection and early treatment of mental health issues of children affected by rare diseases, their siblings and their parents. CARE-FAM is a brief low-frequency intervention comprising six to eight sessions per family over a period of six months.
224234853|NCT04339465|BEHAVIORAL|WEP-CARE|WEP-CARE is an online-intervention that addresses parents of children and adolescents affected by rare diseases. The program is based on principles of cognitive-behavioral writing therapy. Supported by trained professionals, the participants perform 12 standardized writing tasks on a secured internet platform
224234854|NCT00540501|DRUG|Oseltamivir and Intravenous Zanamivir|"Oseltamivir will be administered PO q12h for 3 days (for a total of 5 doses ending the morning of day 3.~Both drugs will be administered simultaneously starting on Day 1 of Period 3. Zanamivir will be administered IV q12h for 3 days (for a total of 5 doses ending on the morning of day 3.~Zanamivir to be given four (4) hours after the oral dose of oseltamivir and infused over 30 minutes."
224234855|NCT01433666|DRUG|roflumilast (EU: Daxas, USA: Daliresp)|Acute intervention: 1 time each dose on different days. Capsulated
224234856|NCT01433666|DRUG|Placebo|Acute intervention: single administration, capsulated form.
224234857|NCT01433666|DRUG|roflumilast|Acute intervention: 1 time each dose (100ug, 300ug, 1000ug, placebo). Capsulated.
224234858|NCT02019940|DRUG|Riluzole|
224234859|NCT01598701|DRUG|Acetaminophen|Intravenous Acetaminophen, 1000 mg/100mL, Every 6 hours, Infused over 15 minutes.
224234860|NCT01598701|DRUG|Placebo|100 mL 0.9% Sodium Chloride
223649906|NCT02718144|DRUG|Estetrol|Estetrol formulated in tablets, in escalating doses, will be investigated in patients with estrogen receptor positive (ER+) locally advanced or metastatic breast cancer.
223649907|NCT04315740|OTHER|Particles from candles|Generating fine and ultrafine particles from lit candles
223649908|NCT04315740|OTHER|Particles from cooking|Generating fine and ultrafine particles from frying pork in an oven
223649909|NCT04315740|OTHER|Clean Air|Nothing but clean air
223649910|NCT00194506|BEHAVIORAL|Internet co-management module|
223649911|NCT02614599|DRUG|BP22042013|This group of patients receive 2.000 kilo-calories diet (60 g. carbohydrates, 144 gr of fat and 107 gr of proteins), including 2 protein shakes.
223649912|NCT02614599|DIETARY_SUPPLEMENT|Low carbohydrate diet|the second group of patients receive diet of 2.000 Kilo-calories without rapidly absorbed carbohydrates and without proteins supplements
223649913|NCT04366817|BEHAVIORAL|psychological assessment|psychological assessment at D10-12 and 6-8 weeks : Scheduled telephone interview using the assessment scales (EPDS, PPQ, MIBS, DAS-16) on D10-D12 and 6-8 weeks postpartum with a psychologist
223649914|NCT02865213|DEVICE|OBA|"The intrusion of posterior teeth using removable appliance OBA."
223649915|NCT02865213|DEVICE|Miniplates|"The intrusion of posterior teeth using temporary anchorage Miniplates."
224234861|NCT01409486|OTHER|Drawing blood spots from Newborns|Dry blood spots would be taken for determination of Alpha Glucosidase activity using LC-MS-MS
224234862|NCT02989688|DIETARY_SUPPLEMENT|Nepro HP (Abbott Nutrition)|oral nutritional supplement drink with modified carbohydrate composition
224234863|NCT02989688|DIETARY_SUPPLEMENT|Fortisip compact protein 125 ml + Calogen 20ml (Nutricia)|Fortisip compact protein 125 ml + Calogen 20ml (Nutricia) oral nutritional supplement drink macronutrient matched with standard carbohydrate composition
224234864|NCT02989688|DIETARY_SUPPLEMENT|Fortisip compact 125 ml (Nutricia)|Fortisip compact 125 ml (Nutricia) oral nutritional supplement drink - standard
224234865|NCT02223000|DRUG|BIBV 308 SE solution|
224234866|NCT02223000|DRUG|BIBV 308 SE capsule 1|
224234867|NCT02223000|DRUG|BIBV 308 SE capsule 2|
224234868|NCT02349893|DEVICE|RFA treatment|RFA treatment using CelonProSleep plus system
224234869|NCT01459328|RADIATION|Radiotherapy|"Short course radiotherapy: 25Gy in 5 daily fractions over 1 week Chemotherapy: - Bolus 5 Fluorouracil 450 mg/m2/day~* Injected Leucovorin 20 mg/m2/day for 5 days"
224320407|NCT05465837|PROCEDURE|Tracheostomy|Early and Late Tracheostomy (\</= 10 days: Early and \>10 days: Late)
223766881|NCT06929845|PROCEDURE|organoids models|Enrolled patients will undergo liver biopsy with sampling of tumor tissue and adjacent nontumor liver parenchyma. Alternatively, patients who are candidates for surgical resection of HCC will be enrolled. The tumor tissue obtained will be used partly for histological confirmation of HCC and then included in kerosene, partly used for organoid construction, and the nontumor tissue will be used solely for organoids. Genomic and transcriptomic changes resulting from the integration of PDO of HCC with the gut microbiota and host immune cells derived from the patient will be evaluated. In addition, PDOs from HCC will be tested for the efficacy of systemic therapies (ICI and TKI) and understand possible modifying co-factors.
223649916|NCT02865213|DEVICE|Miniscrews|"The intrusion of posterior teeth using temporary anchorage Miniscrews."
223649917|NCT01153334|DRUG|Early intensive rosuvastatin therapy (40 mg for 7days, starting in ER prior to primary PCI)|1\. Test group: Early intensive rosuvastatin therapy - rosuvastatin 40 mg for pre-PCI loading and 7 days post PCI and 10 mg daily thereafter 2. Control group: Conventional statin therapy - Placebo for pre-PCI loading in ER and rosuvastatin 10 mg daily after primary PCI
223766882|NCT07086001|BEHAVIORAL|stress management and coping|Online intervention focusing on stress and coping in university students. All resources were grouped in five main categories: Managing Stress, Enhancing Performance, Adulting, Socialising, and Well-being. The resource was hosted on a website and presented information in several multimedia formats (i.e., text, audio, video, interactive infographic) to account for diversity of preferences. All students in the intervention groups were provided with unlimited access to the intervention. Furthermore, all students were asked to complete screener questions on their stress and coping but only students in the directed group were directed to one of three unique pages on the website based on their responses on the screening questionnaire demonstrating low, moderate, or high need for support around stress and coping.
223649919|NCT06684704|OTHER|minimal and high flow anesthesia|Low-flow anesthesia technique is a technique based on the re-breathing of at least half of the gas exhaled in semi-closed systems by returning at least half of the exhaled gas to the patient in the next inspiration.
223649920|NCT02999672|DRUG|Trastuzumab Emtansine|Trastuzumab emtansine will be administered as Regimen A (2.4 mg/kg qw via IV infusion) or Regimen B (3.6 mg/kg q3w via IV infusion) until unacceptable toxicity, withdrawal of consent, disease progression, or death, whichever occurs first.
223766883|NCT07086495|OTHER|Aromatherapy|Participants inhaled lavender essential oil (3 drops in 100 ml water) via diffuser during a 15-minute post-exercise recovery period following the Bruce treadmill protocol.
223766884|NCT07086495|OTHER|Placebo Diffuser (No Essential Oil)|Participants were exposed to plain water vapor (100 ml of water without essential oil) via diffuser for 15 minutes during post-exercise recovery.
224320408|NCT03583307|DRUG|Sirolimus|Sirolimus was initiated at a dosage of 0.8 mg/m2 administered twice daily. Subsequently, the sirolimus dosage was adjusted monthly to achieve trough levels between 10 and 15 ng/mL.
223649921|NCT03565497|BEHAVIORAL|Wellness Education Control Condition|As per arm of the same name
223649922|NCT03565497|BEHAVIORAL|Mindfulness Training|As per arm of the same name
223649923|NCT03565497|BEHAVIORAL|Mindfulness Training Plus IE|As per arm of the same name
223649924|NCT04595981|DRUG|Cisplatin|Subjects will be admitted to the UAB Heart and Vascular Center, pre-medicated with 24 mg Ondansetron IV, 500 mg Prednisolone IV and 1.5 L NaCl with 20 meq KCl IV. The chemo-embolic agent is prepared in the HVC pharmacy by reconstituting 300 mg lyophilized Cisplatin in 60 mL 0.9% NaCl. Subjects are placed under anesthesia in the angiography suite. The access site is prepped and draped in sterile fashion then the femoral artery is catheterized using a 5-French catheter containing a coaxial microcatheter. After superselective visualization of the tumor-feeding vessel, a microcatheter is advanced into the target vessel and infused with 150 mg m2 cisplatin in 45-60 mL NaCl over 30-60 seconds. 10 seconds after the infusion starts, 9 gm sodium thiosulphate is administered IV to neutralize systemic Cisplatin. A post-infusion angiogram is then performed to assess the adequacy of embolization. The catheter is removed and the arteriotomy site closed with a subcutaneous suture.
223649925|NCT03731676|DEVICE|Fixed bearing total knee arthroplasty|Fixed bearing total knee arthroplasty
223649926|NCT03731676|DEVICE|Rotating platform total knee arthroplasty|Rotating platform total knee arthroplasty
223649927|NCT04765891|OTHER|Positional release therapy|Positional release therapy was administered in the upper trapezius muscle. The muscle was placed in a shortened position with light pressure and held for 90 seconds per treatment location.
223649928|NCT04765891|OTHER|Therapeutic Massage|Participants underwent a petrissage type massage for 5 minutes at the site of the trigger point in the upper trapezius.
223649929|NCT03103334|OTHER|Zeneo® - Methotrexate|0.625 mL of methotrexate solution 40 mg/ML for subcutaneous injection with a prefilled and needle-free delivery system
223649930|NCT03103334|DRUG|Methotrexate Biodim®|1 mL of methotrexate solution 25 mg/mL for subcutaneous injection with a conventional needle and syringe injection
223649931|NCT00232726|DRUG|CP-4055 (ELACYT)|
223649932|NCT01075685|BEHAVIORAL|interactive online programme to reduce alcohol consumption|"The programme includes several steps:~* personalized feedback on alcohol consumption and related risks~* reviewing motivations and fears regarding drinking reduction~* analyse of drinking habits~* reduction goal setting~* follow-up tools (alcohol diary, craving scales, well-being scales)~* a final screen allowing participants to monitor their progress through graphs and automatically adapted comments."
223649933|NCT01075685|BEHAVIORAL|Minimum information|"This intervention includes:~* information about hazardous drinking~* an alcohol diary"
223649934|NCT03516630|DRUG|Trazodone 20 mg|Oral drops
223649935|NCT03516630|DRUG|Trazodone 60 mg|Oral drops
223649936|NCT03516630|DRUG|Trazodone 140 mg|Oral drops
223649937|NCT03516630|DRUG|Placebo|Oral drops
223649938|NCT03516630|DRUG|Moxifloxacin 400mg|Tablet
223649939|NCT02037685|BEHAVIORAL|Motivational Interviewing (MINT)|"MINT has the following basic structure and goals:~* Establishing a connection and reinforcing autonomy: open ended questions regarding the health status or well being of the participant to establish an empathetic connection with the subject via reflective listening.~* Empathizing with ambivalence and rolling with resistance. The counselor will help the subject express the ambivalence they may have regarding taking their statins.~* Coach the subject towards expressions of commitment. Commitment is predictive of change. Speaking commitment out loud to an other enhances the likelihood that the commitment will be acted upon"
224234870|NCT01459328|RADIATION|Radiotherapy|"Conventional long course chemo-radiation:~* Radiation 50Gy in 25 daily fractions over 5 weeks~* Bolus 5 Fluorouracil 350mg/m2/d for 5 days~* Injected Leucovorin 20mg in both the first and last (5th) week of radiation~* Oral Capecitabine (CAPE) 825mg/m2 b.i.d. during the entire radiotherapy course over 5 weeks."
224234871|NCT01097408|DRUG|AZD7295|Up to 650mg AZD7295 capsules per dose. To be given 2 or 3 times daily for 5 days.
224234872|NCT01097408|DRUG|Placebo comparator|Placebo capsules
224234873|NCT01888081|DRUG|A-dmDT390-bisFv(UCHT1) (Resimmune®)|
224234874|NCT01888081|RADIATION|Ionizing Radiation|
223649940|NCT02037685|OTHER|Usual Care|We selected American Heart Association brochures on a variety of risk factors, including dyslipidemia and mailed them to subjects in the usual care.
223649941|NCT00531661|DEVICE|HF Pressure Measurement System|A pressure sensor is intended to be implanted into the pulmonary artery at the time of Swan-Ganz catheterization.
223649942|NCT03470298|PROCEDURE|Endometrial scratching|The patients in study undergo endometrial scratch technique after being randomly assigned in to one of two groups . First group undergo oocyte pickup just after finishing oocyte pick up and the other group undergo oocyte pickup one week before starting COH.ManualVaccum Aspiration (MVA) size 5 moved from below upwards with suction ,scrachning anterior uterine wall then posterior then left lateral uterine wall then right lateral uterine wall and lastly fundus. All patients were prescribed vibramycine 100 mg twice daily for 3 days starting one day before procedure
223649943|NCT01255683|DRUG|oral corticosteroid taper|This is an observational study in which patients self-select oral steroid treatment for symptoms of CRS. Drug treatments are NOT assigned in this investigation.
223649944|NCT01814267|OTHER|telemedicine|"Intervention group: care and follow-up through telemedicine (e-consultations)~* 1 hospital consultation at inclusion time, week 0~* then every 15 days, after the transmission of medical data and photos via internet by the nurse, telemedicine e-consultations until the wound has healed (week 2,week 4, week 6, week 8, week 10, week 12, week 14, week 16, week 18, week 20, week 22, week 24 : end point study), i.e. 12 e-consultations over a 6-month period.~* 1 hospital consultation to validate that the wound is well-healed"
223649945|NCT01814267|OTHER|conventional|"conventional group: iterative diabetes physicians consultations at hospital~* 1 consultation at inclusion time, week 0~* 1 consultation 2 weeks after inclusion, week 2~* 1 consultation per month until the wound has healed (week 4, week 8, week 12, week 16, week 20, week 24: end-point study), i.e. 6 consultations over a 6-month period~* 1 consultation to validate that the wound is well-healed"
223649946|NCT02812862|DRUG|Spiolto® Respimat® (Tiotropium / Olodaterol)|"LABA/ LAMA combination therapy:~A combination of two bronchodilators acting on two separate pharmacological targets - one ß-agonist and one anti-muscarinergic agent."
223649947|NCT02633709|DRUG|Itraconazole|Itraconazole will be administered as an oral 200 mg dose twice daily from Day 1 to Day 8 in Part 3.
223649948|NCT02633709|OTHER|Placebo|In Part 1 of the study matching oral placebo will be administered once on Day 1.
223649949|NCT02633709|DRUG|Risdiplam|Single ascending oral doses of Risdiplam will be administered on Day 1 of Part 1. In Part 2 a single dose of Risdiplam will be once administered under fasted and once under fed conditions. In Part 3 a single dose of Risdiplam will be once administered alone (Period 1) and once concomitantly to itraconazole (Period 2).
223649950|NCT04986761|PROCEDURE|Treatment of implant single crown|Digital or Conventional Workflows for treatment of implant single crown and materials used.
224234875|NCT02780687|DRUG|Afatinib|
224234876|NCT04170309|DRUG|Ceftobiprole medocaril|Participants in whom treatment with Ceftobiprole medocaril has been completed
224234877|NCT02165228|BEHAVIORAL|Mindfulness-based stress reduction|Stress reduction class and behavioral intervention
223649951|NCT05860309|OTHER|quadratous lumborum block|The patient will be placed in the lateral position, after sterilization.. QLB will be done using ultrasound, The probe will be positioned superior to the iliac crest, in the transverse orientation, at the posterior axillary line. The Shamrock sign will be identified at the L4 level, and the insulated nerve block needle will be advanced from posterior to anterior, through the QL muscle, until the needle tip is visualized in the interfascial plane between the QL muscle and psoas muscle. As the correct needle placement is confirmed with 2-3 mL of saline, 20 mL of 0.25% bupivacaine will be injected ensuring that the psoas muscle will be pushed deeply.
223649952|NCT01347619|OTHER|Toolkit only with Web Access to Online Version|NHs in this arm will receive a letter announcing the availability of an atypical antipsychotic toolkit within the facility and online at the Qualidigm website. The letter will be sent to the NH administrator, Director of Nursing, and Medical Director of each facility by Qualidigm. It will state that the toolkit is designed to provide NH staff, including prescribers, leadership, nursing staff, and patients' families with information about the use, risks and costs of atypical antipsychotics in the NH setting.
223766885|NCT07086040|BEHAVIORAL|RAS incorporated in upper-limb movement training|RAS will be metronome beat sound with different tempi and will be incorporated in upper-limb movement training, which will last for 40 minutes per session for a total of 21 sessions.
224234878|NCT02165228|BEHAVIORAL|Nutrition Enhancement|Nutrition education class and behavioral intervention
224234879|NCT04697511|DRUG|Midazolam|Participants will receive single oral dose of midazolam on Days 1, 3 and 13 under fed conditions.
224234880|NCT04697511|DRUG|M2951|Participants will receive multiple oral doses (twice daily) of M2951 on Day 3 to Day 13 under fed conditions.
224234881|NCT04832230|OTHER|Hearing test|"The hearing test is composed of several examinations:~* pure tone audiogram~* otoscopy~* tympanometry~Healthy individuals: The hearing test will be performed at enrollment (Day 0). Patients: The hearing test will be performed at Day 1, Day 3, Day 7 and Day 30."
224234882|NCT04832230|OTHER|Questionnaire about previous noise exposure|The participant will have to fill in a questionnaire about his/her previous noise exposure at enrollment (Day 0).
224234883|NCT04832230|OTHER|Otoacoustic emission measurement|"Healthy individuals: Otoacoustic emission will be measured at enrollment (Day 0).~Patients: Otoacoustic emission will be measured at enrollment (Day 0), at Day 1, Day 3, Day 7 and Day 30."
224234884|NCT04832230|OTHER|Electrocochleography|"Healthy individuals: Electrocochleography will be performed at enrollment (Day 0).~Patients: Electrocochleography will be performed at Day 30."
224234885|NCT04832230|OTHER|Speech audiometry in noise|"Healthy individuals: Speech audiometry in noise will performed at enrollment (Day 0).~Patients: Speech audiometry in noise will performed at enrollment (Day 0), at Day 1, Day 3, Day 7 and Day 30."
223649953|NCT01347619|OTHER|Toolkit, Periodic Audit/Feedback, Educational Messages|"Providing healthcare professionals with data about their performance (audit and feedback) may help improve their practice. It is more effective when clinicians previously agree to review their practice. We will use an adaptation of a Medicaid Utilization Report developed by AM Hamer. This report will show current atypical antipsychotic prescribing rates in the NH, with comparisons to state and national levels, and information regarding summary evidence for atypical antipsychotics from the AHRQ atypical antipsychotic CERSG. Reports will be sent to the NH administrator, Director of Nursing, and Medical Director of the facilities randomized to the moderate intensity arm on an every 4-month basis."
223649954|NCT01347619|OTHER|Items in Arm 2 plus Academic Detailing Program|This arm will receive the same information, toolkit, letters, and audit and feedback reports distributed to homes in the moderate-intensity arm. In addition, two visits to the NH will be scheduled by a pharmacist educator specially trained in the pharmacology of atypical antipsychotics, and communication techniques. Staff will be provided with up-to-date, unbiased information about antipsychotic use in NHs based on the AHRQ CER Review product adaptations. The educator will deliver targeted messages relevant to each stakeholder regarding roles in decision-making around the use atypical antipsychotic therapy in the NH setting. Each NH will receive up to two visits over the course of the 12-month intervention period.
223649955|NCT04570319|DIETARY_SUPPLEMENT|Probiotic Bths-08|A capsule containing the probiotic blend (dietary supplement), administered once daily for 12 weeks
223649956|NCT04570319|DIETARY_SUPPLEMENT|Placebo|A capsule containing the placebo (dietary supplement), administered one daily for 12 weeks
223649957|NCT05361148|OTHER|no interventions will be used|This is a cohort study with no interventions.
223649958|NCT02858362|DRUG|Ezutromid|Administered orally.
223649959|NCT04103749|DEVICE|Exalt Model D Single-Use Duodenoscope|Subjects will have a clinically indicated per standard of care ERCP or other duodenoscope-based procedure performed with the Exalt single use duodenoscope study device.
224234886|NCT04832230|OTHER|Multi-frequency impedance measurement|"Healthy individuals: Multi-frequency impedance will be measured at enrollment (Day 0).~Patients: Multi-frequency impedance will be measured at Day 30."
223649960|NCT01391052|DRUG|Norethindrone acetate pretreatment|5 mg tablets, three times a day for 21 days for 2 menstrual cycles.
223649961|NCT01391052|OTHER|No pretreatment|LVN IUS is placed withour Norethindrone acetate pretreatment.
223649962|NCT02557880|BEHAVIORAL|Sleep Application Diary|Tool used to document sleep hygiene.
223649963|NCT02557880|BEHAVIORAL|Treatment As Usual|Sleep hygiene counseling
223649964|NCT03358524|DRUG|Vitamin E 400 UNT|Vitamin-E capsule (alpha tocopherol) 400 IU (once per day)
223649965|NCT03358524|DRUG|Placebo oral capsule|sugar capsule manufactured to mimic vitamin E capsule once per day
223649966|NCT04243616|DRUG|Cemiplimab|350 mg, IV, Day 1 of Cycle 1-2 (3-week cycle)
223649967|NCT04243616|DRUG|Paclitaxel|80 mg/m\^2, IV, Day 1,8 and 15 of Cycles 1-4 (3-week cycle)
223649968|NCT04243616|DRUG|Carboplatin (not mandatory)|Area under curve (AUC)=6, IV, Day 1 of Cycles 1-4 of Paclitaxel cycles (3-week cycle)
223649969|NCT04243616|DRUG|Doxorubicin|60 g/m\^2, IV, Day 1 of Cycles 1-4 of ddAC (2-week cycle)
223649970|NCT04243616|DRUG|Cyclophosphamide|600 g/m\^2, IV, Day 1 of Cycles 1-4 of dose-dense Adriamycin (Doxorubicin) and Cyclophosphamide (ddAC) (2-week cycle)
223649971|NCT05274893|DRUG|SYHX2011 and Abraxane®|IV infusion, 260 mg/m\^2
223649972|NCT02459834|OTHER|Allulose|"A double-blind, randomized, multiple-crossover equivalence design. Each participant will act as their own control receiving the treatments in random order, each separated by a 1 week washout period. The treatment will be developed by Tate \& Lyle."
223649973|NCT02459834|OTHER|Fructose|"A double-blind, randomized, multiple-crossover equivalence design. Each participant will act as their own control receiving the treatments in random order, each separated by a 1 week washout period. The treatment will be developed by Tate \& Lyle."
223649974|NCT02459834|OTHER|Control|"A double-blind, randomized, multiple-crossover equivalence design. Each participant will act as their own control receiving the treatments in random order, each separated by a 1 week washout period. The treatment will be developed by Tate \& Lyle."
223649975|NCT05688722|PROCEDURE|Supine position|Patients preoxygenated in supine position before endotracheal intubation
223649976|NCT05688722|PROCEDURE|20 degree head elevation position|Patients preoxygenated in 20 degree head elevation position before endotracheal intubation
223649977|NCT05688722|PROCEDURE|30 degree head elevation position|Patients preoxygenated in 30 degree head elevation position before endotracheal intubation
223649978|NCT05688722|PROCEDURE|45 degree head elevation position|Patients preoxygenated in 45 degree head elevation position before endotracheal intubation
223649979|NCT02877992|PROCEDURE|Ovarian puncture|Donors and patients are subjected to ovarian puncture as part of their donation procedure or IVF treatment. Oocyte are retrieved in this procedure along with granulosa and cumulus cells. Donors and patients sign an informed consent in order to donate their granulosa and cumulus cells for the study.
223649980|NCT04904393|DEVICE|Implant of the device for Cardiac Contractility Modulation (CCM) Therapy|The intervention is an implant of CCM therapy devices and it is similar to conventional dual chamber cardiac devices with only difference of to insert n 2 leads fixed in right ventricular septum
223649981|NCT02813577|DEVICE|Lutonix® 035 Drug Coated Balloon PTA Catheter|Female subjects will receive the Lutonix® 035 Drug Coated Balloon PTA Catheter.
223649982|NCT06132815|DEVICE|Laser troughing|Laser troughing will be carried out by passing laser optic fiber in contact mode along the gingival sulcus. Laser energy will be delivered with a wavelength of 980nm and power of 0.8W, in continuous mode. Laser tip will be inserted 1mm into the gingival sulcus, to facilitate an accurate recording of finish line
223649983|NCT06132815|OTHER|Retraction cord and astringent|Partial isolation of the tooth with cotton rolls and saliva ejector will be performed. Appropriate size of retraction cord will be soaked in astringent for 5 mins. Then packing of the cord will be started from the mesial interproximal area by gently packing into the sulcus with the gingival cord packer instrument using the single cord technique. Retraction cord will be kept in place for 5 minutes. Cord will be removed immediately before the start of the intraoral scan
224234887|NCT04832230|OTHER|Assessment of tinnitus severity|Tinnitus severity will be assessed using a visual analogic scale at enrollment (Day 0), at Day 1, Day 3, Day 7 and Day 30.
223649984|NCT06132815|OTHER|Cordless retraction paste with astringent|The cordless paste with astringent will be injected gently into the sulcus, leaning on the tooth at the point of the cervical limit and not on the gingiva, the cannula will remain parallel to the axis of the tooth to exert optimal pressure. Then it will removed after 5 mins with copiously irrigated water until no traces of the materials left.
223649985|NCT06132815|OTHER|Cordless retraction paste without astringent|The cordless paste without astringent 10 will be injected into the sulcus of the gingiva. The suitable size of Comprecap will be held on the abutment to push the material deep into the sulcus of the gingiva, and the participants will be informed to bite over it for a period of 3 to 5 minutes. After 5 minutes, the comprecap with the set retraction material attached to it, will be removed from the patient mouth.
223649986|NCT00111852|DRUG|Desmoteplase|Desmoteplase 90 mcg/kg, intravenous administration.
224234888|NCT04832230|BIOLOGICAL|Blood sample collection|Healthy individuals: A blood sample will be collected at enrollment (Day 0). Patients: A blood sample will be collected at enrollment (Day 0), at Day 1, Day 3, Day 7 and Day 30.
223649987|NCT00111852|DRUG|Desmoteplase|Desmoteplase 125 mcg/kg, intravenous administration.
224234889|NCT01619826|BEHAVIORAL|Physical Activity|9-month afterschool program designed to increase physical activity and aerobic fitness.
224234890|NCT01619826|BEHAVIORAL|Physical Activity|Participants in this group partake in their regular afterschool activities, without intervention from the study staff.
224234891|NCT03777137|BEHAVIORAL|TMS (Rapid2, Magstim Corp)|Volunteers will take a telephone screening questionnaire and those meeting inclusion criteria will attend their first visit. Those signing the consent will have a T1 weighted MRI scan to localize sites in the brain to be stimulated with TMS. The subjects will then have four visits at intervals of two weeks; each visit will have a TMS intervention including SITE1, SITE2, SITE3, and SITE4. The sequence of the testing TMS four different visits (SITE1 to SITE4) will be randomly assigned among stimulation sites Medial Frontal (MF), Dorsal Lateral Frontal (DL), Primary motor cortex (M1) and Interparietal Sulcus (Sham) and counterbalanced across subjects (see Diagram below). During each of visits 2 to 5, each participant will undergo baseline Quantitative Sensory Testing (QST), followed by a TMS intervention, and then by repeat QST. QST will consist of pain thresholds for contact heat.
224234892|NCT05722509|PROCEDURE|"Distal Flap Reduction Group"|A surgical procedure consisting of a tissue reduction flap distal to the second molar prior to the extraction of the third molar will be performed.
224234893|NCT05722509|PROCEDURE|"Only Exodontia Group"|Third molar exodontia without associated surgery.
224234894|NCT01951846|DRUG|BIBF 1120|
224234895|NCT03825900|DEVICE|Sham OR active Transcranial direct current stimulation|Sham OR active transcranial direct current stimulation over the motor cortex
224234896|NCT01072110|PROCEDURE|Colonoscopy|Patients will undergo colonoscopy for evaluation of their symptoms.
224234897|NCT01072110|PROCEDURE|Confocal Laser Endomicroscopy|Patients will undergo CLE during their endoscopy. Findings will be compared to group 1.
224234898|NCT00368277|DRUG|Aliskiren|Aliskiren 150 mg and 300 mg tablets taken orally, once a day in the morning
224234899|NCT00368277|DRUG|Ramipril|Ramipril 5 mg and 10 mg capsules taken orally, once a day in the morning
224234900|NCT00368277|DRUG|Hydrochlorothiazide|Hydrochlorothiazide 12.5 or 25 mg capsules taken orally, once a day in the morning
224234901|NCT00368277|DRUG|Amlodipine|Amlodipine 5 mg or 10 mg tablets taken orally, once a day in the morning
224234902|NCT04137822|BIOLOGICAL|IMM-101|IMM-101 10mg/mL, a suspension of heat-killed whole cell M. obuense in borate-buffered saline. The treatment regimen with IMM-101 is one dose given every 2 weeks for three doses followed by 4 weeks rest, then one dose is given every 2 weeks for a further three doses. Subsequent doses are given every 4 weeks.
224234903|NCT01820377|BEHAVIORAL|Aboriginal Youth Mentorship Program|High school students volunteer as mentors, and develop an after-school program that they then deliver to children in grade 4. The mentors meet twice a week. The first day, they develop an activity plan and decide roles and responsibilities to ensure successful delivery of each activity. The second day, they deliver the program to the grade 4s, which incorporates a healthy snack, 45-minutes of physical activity, and educational games/activities. Grade 4s are our intervention group
224234904|NCT00519142|DRUG|placebo for mitiglinide|three times a day with meals
224234905|NCT00519142|DRUG|mitiglinide|three times a day with meals
224234906|NCT00519142|DRUG|mitiglinide|two times a day with meals
223649988|NCT00111852|DRUG|Placebo|Dose-Match Placebo, intravenous administration.
223649989|NCT00785382|DRUG|Placebo|Lactulose Placebo
224234907|NCT03318770|DRUG|Dasatinib and blinatumomab|Patients treated frontline with the sequential administration of dasatinib and the bispecific monoclonal antibody blinatumomab according to the protocol LAL2116
224234908|NCT00879242|DRUG|Deferasirox|Dispersible tables of 125, 250 and 500 mg at the dose of 30 mg/kg/day, oral administration.
224234909|NCT01584921|DRUG|Erythropoietin (Epoetin-beta, NeoRecormon®)|5000 IU/ml of NeoRecormon (Epoetin beta) is given subcutaneously as one ml before 10 O-clock a.m. on day 1,3,5,7,9,11 and 13. On day 1 and 3 5000 IU is given in one syringe and five ml of saline in total is given in five other syringes in order to maintain the double blinding. On day 2 six syringes of a total of 6 ml of saline is given in six syringes.
224234910|NCT01584921|DRUG|Erythropoietin (Epoetin-beta, NeoRecormon®)|"30.000 IU of NeoRecormon (Epoetin beta) is given subcutaneously as a total of six ml (5.000 IU/ml) given in six syringes before 10 O-clock a.m. on day 1,2 and 3.~On day 5,7,9,11 and 13 six ml of saline in total is given in six syringes in order to maintain the double blinding."
223649990|NCT00785382|DRUG|Pregabalin 150 mg|150 mg Q12H x 2 doses
223649991|NCT00285623|DRUG|Fibrinogen (human) + thrombin (human) (TachoSil)|treatment in surgery for improvement of haemostasis where standard techniques are insufficient
223766886|NCT07086040|BEHAVIORAL|Upper-limb movement training|Upper-limb movement training will last for 40 minutes per session for a total of 21 sessions.
223766887|NCT07086872|OTHER|Integrated Neuromuscular Inhibition Technique and mulligan therapy|patients will receive Integrated Neuromuscular Inhibition Technique in the form of intermittent ischemic compression, strain counter strain and muscle energy technique and mulligan therapy for limited cervical range of motion
223766888|NCT07086872|OTHER|Integrated Neuromuscular Inhibition Technique|patients will receive Integrated Neuromuscular Inhibition Technique in the form of intermittent ischemic compression, strain counter strain and muscle energy technique
224234911|NCT01584921|DRUG|Placebo|1 ml of saline (Sodium Chloride 9 mg/ml) is given subcutaneously before 10 O-clock a.m. on day 1,2,3,5,7,9,11 and 13. On day 1,2 and 3 six ml in total is given in six syringes in order to maintain the double blinding.
224320409|NCT03026491|OTHER|Chewing evaluation|Each child was required to bite and chew a standardized biscuit while chewing video recording. Chewing function was scored with the Karaduman Chewing Performance Scale (KCPS).
224320410|NCT02467140|DEVICE|Parietex ProGrib self-fixating mesh|Laparoscopic transabdominal preperitoneal inguinal hernioplasty using the Parietex ProGrib self-fixating mesh.
224320411|NCT02467140|DEVICE|Tack fixation|Laparoscopic transabdominal preperitoneal inguinal hernioplasty using the Parietex ProGrib self-fixating mesh using tack fixation.
224320412|NCT04562610|DRUG|Intravenous Infusion group|The intravenous infusion group will receive two medications via the intravenous infusion route. These medications are Ofirmev ( acetaminophen ) 1,000mg and tranexamic acid 2,000 mg , an antifibrinolytic drug. In addition to these drugs, study subjects will receive Celecoxib 200mg by mouth and Gabapentin 600 mg by mouth prior to operation.
224320413|NCT04562610|DRUG|All oral administration group|Subjects in the oral administration group will receive the following pre-emptive analgesic drugs, acetaminophen 1,000mg, Celecoxib 200mg and gabapentin 600mg via the oral route prior to operation. In addition they will receive the antifibrinolytic drug, tranexamic acid 2,000mg via an oral route as well prior to operation.
224320414|NCT02947360|OTHER|Focused vascular ultrasound of the carotid arteries|Emergency physicians and a trained research sonographer will perform a focused vascular ultrasound of the carotids (FOVUS) in patients presenting to the emergency department with chest pain. The diagnostic test characteristics (sensitivity, sensitivity, negative predictive value, positive predictive value and likelihood ratios) for FOVUS carotid plaque height will be determined in relation to our primary outcome (30-day major adverse cardiac events)
224320415|NCT00578474|DRUG|Moxidex otic solution|4 drops into the infected ear(s) twice daily (morning and evening) for 7 days
224320416|NCT00578474|DRUG|Ofloxacin otic solution|5 drops into the infected ear(s) twice daily (morning and evening) for 10 days
224320417|NCT00578474|DEVICE|Tympanostomy tubes|Tubes surgically inserted through the ear drum for the treatment of recurrent otitis media in children
224320418|NCT00714116|DRUG|SBI-087|Single IV or SC dose of SBI-087
224320419|NCT02905058|DRUG|Ketoprofen|oral non-steroidal antiinflammatory drug
224320420|NCT02905058|DRUG|placebo|
224320421|NCT04307888|DEVICE|Perclose Proglide (Abbott)|Common Femoral Artery percutaneous access closure by means of Perclose Proglide device
224320422|NCT03597295|DRUG|Retifanlimab|Retifanlimab 500 milligrams (mg) intravenously every 4 weeks (Q4W).
224320423|NCT01728129|DEVICE|DANA Rapid|The DANA Rapid is a neurocognitive test self-administered on a small handheld computer. The DANA Rapid subtests measure simple reaction time, procedural reaction time, and reaction time sensitivity.
223649992|NCT00606437|PROCEDURE|Total Body Irradiation with Fludarabine in UCB Transplants|Administration of the preparative regimen, infusion of the stem cell graft, inpatient care during the immediate post-transplant period and outpatient follow-up for the first 3 months after transplant and at 6, 12, 24 and 36 months. Patients will have human leukocyte antigen (HLA) serologic typing and DNA typing. Bags of UCB are thawed, and diluted by 1:1 volume using a 5% albumin/dextran solution. The thawed and diluted umbilical cord blood unit (UCBU) is next weighed and centrifuged. Specimens are obtained for cell count and viability, culture, clonogenic assays, and phenotype. The UCB is infused at a rate of 1-3 ml/min. Furosemide (0.5-1.0 mg/kg/dose) may be given if volume overload or decreased urine output occurs. Each UCB infusion shall be tested for sterility, CFU content, number of CD34+ cells, cell count and viability.
223649993|NCT00782847|BEHAVIORAL|DiaNe consultation and support program|the DiaNe consultation and support program for clients with diabetic nephropathy consists of 4 sessions at 90-120 minutes conducted every week in a period of 4 weeks
223649994|NCT03097809|OTHER|SEEG Recordings|To directly record brain activity from the frontal-limbic circuitry of subjects in the resting state and while they engage in behavioral tasks designed to assess emotional response to negative stimuli and different aspects of impulse control and emotional processing
223649995|NCT01516086|DRUG|Fluticasone Propionate (FP)|FP Inhalation BID
223649996|NCT01053780|OTHER|Intercessory Prayer|A committed group of six people selected by the chief investigator prayed nine consecutive days for the patients in the intervention group; they were blind to the identity , the patients' first name, were given to the intercessors.
223649997|NCT01053780|BEHAVIORAL|Intercessory Prayer|A committed group of six people selected by the chief investigator prayed nine consecutive days for the patients in the intervention group; they were blind to the identity , the patients' first name, were given to the intercessors.
223649998|NCT04885777|DRUG|Lidocaine|"Initially, a nasopharyngeal swab was performed on each group without any intervention. Investigators waited at least one hour for the second sample collection. If the participant was still in pain or felt discomfort due to the first sampling, the waiting time has been extended.~At the second stage, one ml of a solution containing 20 mg/ml of lidocaine, was applied to each nostril of the participants in the Lidocaine group. Thus, a total of 40 mg of lidocaine, 20 mg for each nostril, was given to the individuals of the Lidocaine group. The second samples were collected after waiting 5 minutes following the administration of the solution."
224234912|NCT04955379|DEVICE|EQ103|Ophthalmic Refractometer with a measurement and background channel
224234913|NCT05607914|PROCEDURE|percussion massage|percussion massage to the dominant leg hamstring muscle for 5 minutes
224234914|NCT05607914|PROCEDURE|static stretching|Static stretching to the dominant hamstring muscle for 5 minutes
224234915|NCT02762097|PROCEDURE|polypectomy|. During the second visit after she consents to removal of polyp revealed on prior saline sonography, a dilatation and curettage would be performed under ultrasound guidance and after successful removal of polyp (polypectomy) saline sonography would be repeated to ensure completeness of removal.
224320424|NCT01728129|OTHER|MACE|The MACE is currently the only standardized and Department of Defense-designated method for the initial evaluation of suspected concussion in military operational settings. The MACE documents the history of the injury-causing incident; assesses cognitive deficits in orientation, immediate memory, concentration, and delayed recalls; and involves a neurological screening by a clinician.
224320425|NCT00428116|DRUG|HAART|Combination first line antiretrovirals as previously described.
223649999|NCT04885777|OTHER|Placebo|"Initially, a nasopharyngeal swab was performed on placebo group without any intervention. Investigators waited at least one hour for the second sample collection. If the participant was still in pain or felt discomfort due to the first sampling, the waiting time has been extended.~At the second stage, the Placebo group received only a total of 2 ml of 0.9% NaCl (one ml for each nostril). The second samples were collected after waiting 5 minutes following the administration of the solution."
223650000|NCT03746119|OTHER|E-cigarette vapor containing nicotine|A fourth generation e-cigarette device will be used with pre-determined temperature, voltage and wattage settings, and pre-mixed e-solution containing nicotine.
223650001|NCT03746119|OTHER|E-cigarette vapor, nicotine free|A fourth generation e-cigarette device will be used with pre-determined temperature, voltage and wattage settings, and pre-mixed nicotine free e-solution.
223650002|NCT01301027|DRUG|Pioglitazone|15mg/day pioglitazone for 2 weeks, then 30mg/day pioglitazone for the remaining 24 weeks
224234916|NCT02762097|PROCEDURE|saline sonography|saline infusion sonography (SIS) on 8th to 11th day of menstrual cycle. On the day of admission SIS will be performed in an outpatient setting .Taking all aseptic measures a speculum will be inserted vaginally and up to 20 ml of sterile saline solution will be infused into the uterine cavity through a cervical foley's catheter of 5 french to distend the endometrial cavity. A transvaginal transducer will be used to scan the uterine cavity. In case the patient has polyps she would be offered removal under general anaesthesia on a subsequent visit as a day case procedure.
224234917|NCT02762097|DRUG|normal saline|Normal saline would be injected into uterine cavity to delineate defects
224234918|NCT00857636|BEHAVIORAL|Health literacy, health message|The intervention will consist of three main components: (1) 2-hour in-class health literacy-focused education; (2) tailored telephone counseling; and (3) healthcare system navigation assistance tailored to the woman's specific barriers.
224234919|NCT02746952|BIOLOGICAL|UCART19|
224234920|NCT00143819|DRUG|Neuroskin Forte|Subjects will apply study drug sprays 3 times a day (with optional 4th application) to the assigned, randomized sides of the body for 8 weeks
224234921|NCT00143819|DRUG|Placebo Application|Subjects will apply placebo sprays 3 times a day (with optional 4th application) to the assigned, randomized sides of the body for 8 weeks
224234922|NCT00000406|PROCEDURE|Progressive resistance exercise|
224234923|NCT02624570|DRUG|Midostaurin|Midostaurin, also known as PKC412 is a multi-kinase inhibitor of FLT3 (fms-like tyrosine kinase-3)
224234924|NCT03587207|BIOLOGICAL|MenABCWY vaccine|Two doses administered intramuscularly in the deltoid region of the non-dominant arm.
223650003|NCT01301027|DRUG|Placebo|1 pill a day for 26 weeks
223650004|NCT03088956|OTHER|Assessments|Cognitive, Behavioral and Functional as described in the Outcome Measures
223650005|NCT04919200|DIAGNOSTIC_TEST|the single-breath helium dilution method and Whole-body plethysmography|The patients with obstructive lung disease simultaneously subjected to the single-breath helium dilution method and Whole-body plethysmography tests.
223650006|NCT00277732|PROCEDURE|Pharmaceutical care at baseline and follow-up visits over 6 months|
223650007|NCT03705143|BEHAVIORAL|Treatment as usual|Treatment as Usual participants will receive the treatment typically provided to patients at the MMT clinic in Wuhan, China.
224234925|NCT03587207|BIOLOGICAL|rMenB+OMV NZ (Bexsero) vaccine|Two doses administered 2 months apart intramuscularly in the deltoid region of the non-dominant arm to subjects randomised to the rMenBOMV+ACWY\_S Group, rMenBOMV+ACWY\_D Group and rMenBOMV Group
224234926|NCT03587207|BIOLOGICAL|MenACWY (Menveo) vaccine|Two doses administered intramuscularly in the deltoid region of the dominant/non-dominant arm to subjects randomised to the rMenBOMV+ACWY\_S Group and rMenBOMV+ACWY\_D Group and one dose administered intramuscularly in the deltoid region of the dominant/non-dominant arm to subjects randomised to the MenACWY Group
224234927|NCT05240677|PROCEDURE|Upper GIT endoscopy|Upper gastrointestinal endoscpy for all participants and gastric biopsy for histopathological examination for suspicious lesions
224234928|NCT01473966|DIETARY_SUPPLEMENT|coffee|patients will receive a cup of coffee at room temperature orally twice daily
223650008|NCT03705143|BEHAVIORAL|Chinese translated LETS ACT|The Chinese translated Behavioral Activation (C-BA) will be provided in Mandarin. C-BA treatment includes psychoeducation regarding the link between mood and behavior, identification of values/goals/activities across life areas, planning and tracking of daily value driven activities.
223650009|NCT01279785|DRUG|123I-MIP-1072|Single IV dose
223650010|NCT02023697|DRUG|Radium-223 dichloride (Xofigo, BAY88-8223)|
223766889|NCT07086872|OTHER|mulligan therapy|patients will receive mulligan therapy for limited cervical range of motion
224234929|NCT01473966|DIETARY_SUPPLEMENT|coffee rectally|patients receive an enema of two cups of coffee at room temperature once daily
224234930|NCT03416595|DIETARY_SUPPLEMENT|N1115 Probiotic Supplement|Participators will receive a sachet each day during 8 weeks. The contents of the sachet should be added to warm water or milk, mixed until fully dissolved and served within 15 minutes.
224234931|NCT03416595|DIETARY_SUPPLEMENT|placebo|Participators will receive a sachet each day during 8 weeks. The contents of the sachet should be added to warm water or milk, mixed until fully dissolved and served within 15 minutes.
224234932|NCT00966953|DRUG|Fluoride|Brush twice daily
223766890|NCT07086872|OTHER|postural correction exercises|the patients will receive two strengthening exercises (deep cervical flexors and scapular retractors) and two stretching: cervical extensors (sub-occipital muscles) and pectoral muscles). The program was based on a program by Harman and Kendall
224234933|NCT00966953|DRUG|Triclosan/Fluoride toothpaste|Brush twice daily
224234934|NCT00966953|DRUG|Fluoride|Brush twice daily
224234935|NCT00966953|DRUG|Fluoride|Brush twice daily
224234936|NCT00966953|OTHER|antibacterial plant extract|Brush twice daily
224234937|NCT06496269|OTHER|No intervention|No intervention
224234938|NCT03283709|DEVICE|Full-contour monolithic zirconia abutment crowns|Subjects with RPD abutment teeth that require surveyed crowns will have them fabricated from monolithic multi-layered zirconia
224234939|NCT03283709|DEVICE|Conventional abutment crowns|Subjects with RPD abutment teeth that require surveyed crowns will have them fabricated from noble or high noble metals, veneered with feldspathic porcelain
224320426|NCT02125877|DRUG|Deferasirox dispersible tablet|Deferasirox DT was provided as 125 mg, 250 mg and 500 mg dispersible tablets for oral use.
223650011|NCT04293822|DRUG|Cetirizine|"The patients will be randomly divided into 2 groups; each group contains 30 patients. Patients in both groups will be given the treatment in identical non-labeled bottles with a code and neither the patient nor the doctor will know which treatment is given and what the code referred to. The patients will be instructed to use the treatment twice daily for 6 month duration.~This group will use Cetrizine 1% gel, which will be prepared at the department of Pharmaceutics, Faculty of Pharmacy, Assiut University in the form of Nano-transferosomes (NTF)."
224234940|NCT05345132|DRUG|Nifedipine 20 Mg|The initial dose of nifedipine will be 2 × 10 mg nifedipine capsules orally in the first hour, followed by 20 mg slow-release nifedipine every 6 hours for the next 47 hours. In the first hour after starting nifedipine, blood pressure and heart rate will be measured every 15 minutes. If blood pressure remains within the normal limits, treatment will be continued.
223650012|NCT04293822|DRUG|Minoxidil|"The patients will be randomly divided into 2 groups; each group contains 30 patients. Patients in both groups will be given the treatment in identical non-labeled bottles with a code and neither the patient nor the doctor will know which treatment is given and what the code referred to. The patients will be instructed to use the treatment twice daily for 6 month duration.~This group will use Minoxidil 5% gel"
224234941|NCT05345132|DRUG|Magnesium sulfate|Women will also receive MgSo4 as a loading dose of MgSo4 will be given immediately after enrollment as 4 gm diluted in 200 mL of saline solution administered intravenous over a period of 20 minutes. Afterwards, the maintenance dose of MgSo4 will be administered intravenous in a dose of 1 gm/hour given as 6 gm diluted in 500 mL saline solution titrated with a rate of 100 mL per hour, then this dose is repeated every 6 hours for 48 hours. Respiratory rate and knee jerk will be assessed hourly for women in the MgSo4 group. Serum magnesium level will be measured if clinically indicated.
224234942|NCT02359604|DRUG|PPI therapy|"PPI therapy (medication has FDA approval) for 8 weeks in children with proven GERD.~The medication used (esomeprazole) in this trial is approved by the FDA"
223650013|NCT04153552|DIETARY_SUPPLEMENT|HLNatural, Inc. Upset Stomach Relief|Supplement to take with mild to moderate indigestion. The degree of your indigestion pre and post will be recorded
223650014|NCT01271985|DRUG|PolyPill|A combination tablet containing Aspirin 81 mg, enalapril 5 mg (or valsartan 40 mg), atorvastatin 20 mg and hydrochlorothiazide 12.5 mg taken once daily
223650015|NCT01271985|OTHER|Minimal care|Health education pamphlet on reducing cardiovascular risk factors, direct education on reducing cardiovascular risk factors provided by the study physician and the Community Health Worker, biannual follow-up and BP measurement
224234943|NCT02359604|PROCEDURE|Stool sample|Stool sample will be obtained before initiation of PPI (before PPI therapy)
224234944|NCT02359604|PROCEDURE|Stool sample|Stool sample will be obtained 4 weeks after initiation of PPI (under PPI therapy)
224234945|NCT02359604|PROCEDURE|Stool sample|Stool sample will be obtained 8 weeks after termination of PPI therapy (after PPI therapy).
224234946|NCT05011500|RADIATION|Radiotherapy with Closed Mask|Radiotherapy for head and neck cancer, using a closed mask (full thermoplastic mask) to restrict patient movement.
223650016|NCT01420952|DRUG|[11C]LY2428703|
223650017|NCT02483962|OTHER|Gelatine capsule|Gelatine capsules containing no active ingredients.
223650018|NCT02483962|OTHER|Venavine Intensive®|Gelatine capsules containing 360 mg red vine leaf extract, 60 mg of horse chestnut extract, 35 mg of butchers broom extract and 3,2 mg of vitamin B6.
223650019|NCT03667456|PROCEDURE|Self-rehabilitation by digital support|Provision to patients selected by doctors or physiotherapists of an interactive digital tool (tablet + inertial sensor) to support self-rehabilitation home Parkinson's patients.
223650020|NCT03346694|DEVICE|Standard Island Dressing|participant randomized to control group before end of surgery to be applied on cardiovascular heart surgical sternal incision.
223650021|NCT03346694|DEVICE|Prevena Negative Pressure wound dressing|participant randomized to dressing before end of surgery to be applied on cardiovascular heart surgical sternal incision.
223650022|NCT03346694|DEVICE|Mepilex Border Post-Op Ag|Participant randomized to dressing before end of surgery to be applied on cardiovascular heart surgical sternal incision
223650023|NCT00915616|DRUG|Melatonin|
223650024|NCT00845897|DRUG|Botulinum Toxin|200 units of botulinum toxin, and 300 units of botulinum toxin. Injection are given at one session. 2 injections into the medial gastrocnemius, 2 injections into the lateral gastrocnemius, and 2 injections into the soleus
223650025|NCT00845897|DRUG|Saline|Placebo (saline) (3cc). Injection are given at one session. 2 injections into the medial gastrocnemius, 2 injections into the lateral gastrocnemius, and 2 injections into the soleus
223650026|NCT00636493|DEVICE|fluocinolone acetonide (Retisert Implant)|sustained release device consisting of 0.59 mg of fluocinolone acetonide
223650027|NCT04516070|OTHER|Questionnaire Administration|Ancillary studies
223650028|NCT04516070|RADIATION|Stereotactic Radiosurgery|Undergo SRS
223650029|NCT05838482|DEVICE|CT Photon-Counting|Enrolled subjects will complete an exam using the photon-counting CT, with or without IV contract as indicated. Images will then be compared with the previously acquired CT conducted as standard of care.
223650030|NCT04685889|PROCEDURE|Resin infiltration|"A sufficient amount of HCl was applied to the lesion using the icon etch syringe included in the set and was allowed to sit for 2 minutes. After washing with water for 30 seconds, the tooth was dried using an air spray. Once the enamel surface appeared chalky, Icon® dry application was initiated.~Ethanol was applied to the lesion using the Icon® dry syringe included in the set, and after 30 seconds it was dried using an air spray. Sufficient amount of resin infiltrant was applied to the lesion using the Icon® infiltrant syringe. The resin infiltrant was applied to the lesion surface by massaging with the tip of the syringe in circular movements for 3 minutes such that it penetrates the surface thoroughly. The resin infiltrant was polymerized for 40 seconds with a light device."
224234947|NCT05011500|RADIATION|Radiotherapy with Open Mask and Surface Scanning|Radiotherapy for head and neck cancer, using an open mask to restrict patient movement. Surface Scanning is used to monitor patient movement/positioning.
224234948|NCT05011500|RADIATION|Radiotherapy with No Mask|Radiotherapy for head and neck cancer, without using a mask to restrict patient movement. Surface Scanning is used to monitor patient movement/positioning.
224320427|NCT02125877|DRUG|Defearisox film-coated tablet|Deferasirox FCT was provided as 90 mg, 180 mg and 360 mg film-coated tablets for oral use.
223650031|NCT03557060|DRUG|Nucala|NUCALA injections will be administered to eligible subjects with diagnosis of EGPA. Dose unit, daily dose frequency, date of administration will be at the investigator discretion.
223650032|NCT02722499|BEHAVIORAL|High Frequency Financial Incentive|"1. Diabetes Education/Skills Component. Subjects will receive weekly telephone-delivered diabetes/skills training for 12 weeks with home telemonitoring.~2. High Frequency Financial Incentive: the high frequency incentive structure will receive a reward for uploading glucose measurements, attending educational sessions, and absolute percentage drops in HbA1c from baseline at 3-month follow-up, up to $300. Each week participants can receive up to $10 for uploading glucose measurements and having good glucose control throughout the week. If they upload measurements every day of the week and their average glucose measurements at the end of the week are 150 or below they will receive an additional $3. Participants can also earn $5 each week if they attend the educational session. After 3 months, if their HbA1c has dropped 2% from baseline, or absolute HbA1c is 7%, they will receive a reward of $130, for a 1% drop, or an absolute HbA1c between 7 and 8 they will receive a reward of $65."
224234949|NCT01734772|DRUG|dabigatran etexilate|multiple doses of dabigatran
224234950|NCT01734772|DRUG|dabigatran etexilate|medium dose dabigatran
224234951|NCT01734772|DRUG|ticagrelor|loading dose of ticagrelor
224234952|NCT01734772|DRUG|ticagrelor|multiple doses of ticagrelor
224234953|NCT01734772|DRUG|ticagrelor|loading dose of ticagrelor
224234954|NCT01734772|DRUG|dabigatran etexilate|single dose of dabigatran
224234955|NCT02535507|DRUG|Pyrotinib|Drug: Pyrotinib pyrotinib, single agent, 400mg p.o once daily until disease progressed
224234956|NCT02627911|DEVICE|Diabeloop System|Insulin delivery
224234957|NCT02627911|DEVICE|Continuous Glucose Monitoring|
224234958|NCT02627911|DEVICE|Accelerometer and heart rate monitor|Monitoring and measurement of physical activity
224234959|NCT02627911|DIETARY_SUPPLEMENT|Meals|Calibrated meals for all patients and outstanding dinners for patients being in outstanding meals situation (Centers : Grenoble, Toulouse, Montpellier)
224234960|NCT02556242|OTHER|Targeted indoor residual spraying|IRS is carried out in neighbourhoods of cases
224234961|NCT02556242|OTHER|Generalised Indoor residual spraying|IRS is carried out as normally practiced
224234962|NCT00914667|DRUG|warfarin|Single Dose Warfarin 25 mg on Day 1
224234963|NCT00914667|DRUG|Warfarin plus Fesoterodine|Fesoterodine 8 mg ER tablets QD for 9 Days and Single Dose Warfarin 25 mg on Day 3
224234964|NCT06309706|OTHER|No intervention|Just observation
224234965|NCT02281578|BEHAVIORAL|Community-based combination HIV prevention intervention|The combination package will include integrated biomedical, behavioral and structural components: (1) mobile HIV testing and risk reduction counseling; (2) service navigation to facilitate access to treatment and retention in care; (3) sensitivity training for HIV clinical care providers; (4) SMS text messages to promote adherence to care and ART; (5) venue-based peer education and condom distribution; and (6) a community drop-in-center to promote cohesion and collective action to reduce stigma and discrimination.
224234966|NCT02281578|BEHAVIORAL|Standard of care HIV services|Locally available standard of care HIV prevention, treatment and care services
224234967|NCT04984018|DRUG|chidamide + camrelizumab|Pts received 200 mg camrelizumab intravenously every 2 weeks and Chidamide 30mg orally twice (biw) per week for 4 consecutive weeks every 6 weeks until disease progression, unacceptable adverse events (AEs) or withdrawal of consent.
224234968|NCT02217722|OTHER|Ulcerative Colitis Diet|we have postulated that a diet that increases butyrate through fiber exposure, reduces intestinal sulfur exposure, and increases vitamin D levels could be beneficial for patients with Ulcerative Colitis. To date, no study has explored this possibility.
224234969|NCT02217722|DRUG|Antibiotic cocktail|We have postulating that antibiotic therapy can alter the microbiota clinically. Controlling the microbiota by antibiotics may allow for control of the disease without immune suppression
224234970|NCT03680170|BEHAVIORAL|Working memory updating training|Each training session includes four working memory updating tasks that is performed at the participants home on their computer via internet. Each training session takes about 20 minutes to perform.
224234971|NCT03680170|BEHAVIORAL|Placebo training|Each training session includes four short term memory tasks that is performed at the participants home on their computer via internet. Each training session takes about 20 minutes to perform.
224234972|NCT01809613|PROCEDURE|Functional Magnetic Resonance Imaging (fMRI)|During the deep brain stimulation (DBS) surgery of the subthalamic nucleus within the thalamocortical basal ganglion, an additional lead extendor will be connected to the DBS electrode to allow externalization of the lead. Following confirmation of electrode location with MRI, a series of fMRI scans will be run. Total scanning time will be limited to 35 minutes.
224234973|NCT01867242|OTHER|Cigarettes|Smoke their usual brand of cigarettes and follow their normal patterns of use.
224234974|NCT01867242|OTHER|Snus|Winterchill or Robust flavors
224234975|NCT05521763|BEHAVIORAL|ensuring the availability of influenza vaccine supply & developing influenza vaccine awareness|"The four interventions will be:~i) ensuring the availability of influenza vaccine supply; ii) developing influenza vaccine awareness; iii) both ensuring influenza vaccine supply and developing influenza vaccine awareness and iv) control arm with no intervention."
224234976|NCT01600495|OTHER|Experimental TENS|Use of Transcutaneous Nerve Electrical Stimulation in the lumbosacral region for 30 continuous minutes in the active phase of labor (4-5 cm).
224234977|NCT03139968|DEVICE|(sham) radiation absorbing drape (RADPAD®)|
224234978|NCT00569426|DEVICE|NovoFine® needle 6 mm|
224234979|NCT00569426|DEVICE|NovoFine® needle 8 mm|
224234980|NCT04297852|DIETARY_SUPPLEMENT|Vegan drink|Vegan based drink containing vegetables, fruits and plant oils. Dose: 500 mL a day
224234981|NCT04297852|DIETARY_SUPPLEMENT|Control|Placebo drink Dose: 500 mL a day
224234982|NCT03425864|PROCEDURE|connective tissue graft|patient will receive immediate implant and connective tissue graft
224234983|NCT03425864|DEVICE|immediate implant|patient will receive immediate implant with connective tissue graft.
224234984|NCT03339349|DRUG|Enoxaparin|Enrolled patients will receive real-time monitoring of peak and trough steady state anti-Xa levels. Out-of-range patients will receive real time dose adjustment of Enoxaparin using a clinical protocol developed with our inpatient pharmacists.
224234985|NCT01298856|PROCEDURE|hydrotherapy|hydrotherapy and ankle taping and land-based
224234986|NCT00218179|OTHER|Non-intervention|Measured total NNAL and PheT as biomarkers of exposure
224234987|NCT02324998|DRUG|Olaparib|PARP Inhibitor
224234988|NCT02324998|DRUG|Degarelix|Gonadotrophin releasing hormone blocker
224234989|NCT00034125|DRUG|LY353381|
224234990|NCT00034125|DRUG|tamoxifen|
224234991|NCT05525195|PROCEDURE|Congenital cardiac surgery|All children who underwent congenital cardiac surgery with cardiopulmonary bypass between 2008 and 2018
224234992|NCT03094910|DIAGNOSTIC_TEST|Examination of vibration perception threshold in fingertips|Vibration perception threshold is examined for 7 different frequences. All fingers are examined except for the thumbs.
224234993|NCT03094910|DIAGNOSTIC_TEST|Ewing's tests|A battery of tests invented to diagnose the cardiac autonomic neuropathy in diabetics. Heart rate and blood pressure are measured during Valsalva maneuver, deep breathing, active standing and prolonged handgrip.
224234994|NCT03094910|DIAGNOSTIC_TEST|Tilt table test|Blood pressure and heart rate are measured continuously while the participant is brought to a 60 degree position and held there for 15 minutes.
224234995|NCT03094910|DIAGNOSTIC_TEST|Thermography|An infrared thermographic camera is applied to record temperature of the fingers of the participant before and after cooling in 10 degree water for 1 min.
224234996|NCT03094910|DIAGNOSTIC_TEST|123I-MIBG|123I-MIBG is injected into a vein, and an early and a late scan is performed. Regions Of Interest are selected for the heart and mediastinum, and the ratio as well as well as the Washout Rate can be determined. MIBG is a noradrenaline analogue and the examination is performed to visualize a potential imbalance of the autonomic nervous system of the heart.
224234997|NCT03094910|DIAGNOSTIC_TEST|Blood samples|"The blood samples will be assayed for hemoglobin, long-term blood sugar, C-reactive protein, sodium, potassium, magnesium, albumin, TSH, vitamin B and D, and ionized calcium.~Patients with suspected Raynaud's disease will be tested for anti-nuclear antibodies (ANA) to screen for underlying rheumatic illness.~Blood samples will also be drawn during tilt table testing and assayed for plasma catecholamines."
223650033|NCT02722499|BEHAVIORAL|Moderate Frequency Financial Incentive|"1. Diabetes Education/Skills Component. Subjects will receive weekly telephone-delivered diabetes/skills training for 12 weeks with home telemonitoring.~2. Moderate Frequency Financial: the moderate frequency incentive structure will receive a reward for uploading glucose measurements, and absolute percentage drops in HbA1c from baseline at 3-month follow-up, up to $300. Each week participants can receive up to $10 for uploading glucose measurements and having good glucose control throughout the week. For each day they upload at least one glucose measurement, they will receive $1 (up to $7 at the end of the week). If they upload measurements every day of the week and their average glucose measurements at the end of the week are 150 or below they will receive an additional $3. After 3 months, if their HbA1c has dropped 2% from baseline, or absolute HbA1c is 7%, they will receive a reward of $170, for a 1% drop, or an absolute HbA1c between 7 and 8 they will receive a reward of $85"
223650034|NCT02722499|BEHAVIORAL|Low Frequency Financial Incentive|"1. Diabetes Education/Skills Component. Subjects will receive weekly telephone-delivered diabetes/skills training for 12 weeks with home telemonitoring.~2. Low Frequency Financial Incentive: the low frequency incentive structure will receive a reward for absolute percentage drops in HbA1c from baseline at 3-month follow-up, up to $300. After 3 months, if their HbA1c has dropped 2% from baseline, or absolute HbA1c is 7%, they will receive a reward of $300, for a 1% drop, or an absolute HbA1c between 7 and 8 they will receive a reward of $150."
223650035|NCT03841201|DRUG|Lenvatinib|oral
223650036|NCT03841201|DRUG|Nivolumab|iv infusion
223650037|NCT03935763|OTHER|observational disease study|observation of routine clinical practices in mCRC
223650038|NCT05567718|BEHAVIORAL|Paediatric Anaesthesia Emergence Delirium scale|measure emergence delirium in children
223650039|NCT00448643|RADIATION|Vaginal Brachytherapy|High-Dose Rate \[HDR\] or Low-Dose Rate \[LDR\], no earlier than during last cycle of Carboplatin/Taxol chemotherapy; or no later than 1 week before cisplation and WAR therapy
223650040|NCT00448643|DRUG|Cisplatin|Weekly at 40 mg/m2 (maximum of 70 mg) for 6 weeks, start no later than 6 weeks from last cycle of standard of care carboplatin and taxol chemotherapy
223650041|NCT00448643|RADIATION|Whole Abdominal Radiation [WAR] Therapy|Whole Abdominal Radiation Therapy, Dose Escalated \[2-Levels\]; 6 -8 hours after administration of Cisplatin chemotherapy
224234998|NCT04068142|OTHER|Peer Supporter Safety Planning|The rationale for testing a peer-delivered intervention in the ED relies on the following evidence: a) a peer is an individual with lived experience who is now supporting other mental health patients in crisis; b) the experience of a mental health patient in the ED often shapes the perception of the health system, and may influence willingness to seek future care; c) peers may provide more empathetic care than providers without lived experience, which may positively impact patients; d) peer-based programs for patients with serious mental illness that do not involve safety planning are at least as good as non-peer based programs at preventing hospitalizations and promoting engagement in care, with the most promising interventions involving self-management or peer-navigator roles; and e) existing evidence from high-quality studies is scarce, but in moderate-low quality studies has indicated that peers are no less effective than mental health workers
224234999|NCT00766688|DRUG|AVE5530|"* one tablet in the evening with dinner~* in addition to high doses of statin treatment"
224235000|NCT00766688|DRUG|Placebo|"* one tablet in the evening with dinner~* in addition to high doses of statin treatment"
224235001|NCT00186706|DRUG|Selenium|
224235002|NCT01790568|DRUG|Vorinostat|administered at a dose of 100 mg orally, twice daily starting on day -10 in order to achieve steady-state prior to beginning the conditioning chemotherapy, and continued after transplant (day 0) until day +100.
224235003|NCT01790568|DRUG|Tacrolimus|
224235004|NCT01790568|DRUG|Methotrexate|
224235005|NCT00219830|BEHAVIORAL|home-based walking program|Home-based walking program; included use of pedometer and daily walk diary
224320428|NCT05698225|OTHER|Streptococcus pneumoniae serotype 6B|A controlled concentration of streptococcus pneumoniae serotype 6B is placed in both nares of participants
224320429|NCT01685840|OTHER|Usual Care|Usual Care
224320430|NCT01685840|DEVICE|Biomarker-guided care NT-proBNP|Device: NT-proBNP
224320431|NCT01720888|OTHER|BM-MSCs|Intracoronary implantation of bone marrow-derived mesencymal stem cells
224320432|NCT03173287|PROCEDURE|Quantification of liver fibrosis|Procedure MRI and liver biopsy
223650042|NCT05428397|DIAGNOSTIC_TEST|Iopromide (Ultravist, BAY86-4877)|X-Ray/CT Diagnostic Imaging
224235006|NCT03301675|OTHER|Orange Juice (500 mL/d)|Nutritionists prescribed the same balanced diet for both groups keeping suffice energy to maintain the current weight, estimated from total energy expenditure (TEE) for each individual and based on individual weight. The dietary plan was composed of six meals/day: breakfast (fat-free milk and coffee; whole-grain bread with margarine, and an apple); snack 1 (250 mL OJ/ banana or other fruits and free-fat yogurt); lunch (brown rice, beans, grilled lean meat, salad, cooked vegetables); snack 2 (250 mL OJ / free-fat yogurt with oatmeal); dinner (brown rice, beans, grilled lean meat, cooked vegetables and salad); and snack 3 (salty crackers or oat cookies, tea without sugar). Body composition measurements were colected every two weeks; blood samples and dietary questionnaires, monthly.
224235007|NCT03958890|DRUG|HLX10 100 mg in 10 ml Injection|3mg/kg IV（HLX10+cis-platinum+5FU）
223650043|NCT04312724|DEVICE|Direct Socket TF|"The device is Class I, a low-risk product, and is a further development of a well-established technology. Össur Direct Socket (DS) technology has been on the market since 1996 (ICEX first generation) for the manufacture of leg prosthesis. This prosthetic socket for trans-femoral amputees (referred hereby to as DS-TF) has the same basic functional design as the Direct Socket (MSS) for trans-tibial amputees (referred hereby to as DS-TT) that is available on the market today in addition to the newly added silicon brim.~A prosthetic socket is a non-invasive, non-sterile, single user reusable device, which is used as part of prosthetic system. The aspect of the prosthesis that is in direct physical contact with the amputee is usually not the socket, to which a prosthesis is connected to, but the liner that serves as an interface between the amputee and the rest of the prosthesis. An amputee typically wears a prosthesis and thereby utilizes a socket, for up to 18 hours a day."
223650044|NCT04141436|BEHAVIORAL|Interventions Based on Hypnofertility|Affirmation Visualization Imagination Relaxation
223650045|NCT04141436|OTHER|Routine clinical procedure|Routine clinical procedure
224235008|NCT03958890|DRUG|Placebos|3mg/kg IV（placebo+cis-platinum+5FU）
224235009|NCT00210548|DRUG|paliperidone palmitate|
224320433|NCT04556786|BEHAVIORAL|Transitions of care|The intervention was a pharmacist-led transitions of care program that include medication reconciliation, daily schedule for medication taking and medical condition monitoring, and follow-up phone calls from a pharmacist at 60- and 90-day post-discharge in addition to the usual care.
224320434|NCT04928768|OTHER|Questionnaire|A validated questionnaire (five-point Likert scale) through 10 items developed by Lee et al 2018 is employed to measure the level of orthodontic treatment satisfaction in 10 items; overall satisfaction, tooth alignment, facial appearance, eating and chewing, confident smile and self-image, retention state, treatment duration, treatment costs, intention to recommend, and relief of previous concerns. Total satisfaction is calculated by averaging the Likert scores from the 10 items
224320435|NCT00898573|DRUG|lapatinib ditosylate|
224320436|NCT00898573|GENETIC|fluorescence in situ hybridization|
223650046|NCT02321176|DRUG|trans-resveratrol|"patients received 100mg Longevinex everyday,total of three days~1 capsule daily for one day containing 100 mg of trans resveratrol active ingredient"
223650047|NCT02472067|BEHAVIORAL|Psychologically - Based Physical Therapy|Psychologically - Based Physical Therapy targeting risk factors for disability.
223650048|NCT01009619|DRUG|Azithromycin|Azithromycin 250 mg daily during 5 days followed by 250 mg three times a week on Mon., Wed. and Fri. during study-period.
223650049|NCT01009619|DRUG|Placebo|Placebo once daily during 5 days, followed by one placebo three times a week on Mon., Wed. and Fri during rest of study-period.
223650050|NCT02506413|OTHER|MamaToto Package|"The MamaToto Package (later called Mama na Mtoto for the Tanzanian context) was an MNCH intervention built upon prior successes in Uganda and adapted to meet the needs in Misungwi District in Tanzania. The intervention included low-cost programming that built upon the existing district health system structure and resources in order to strengthen the MNH capacity and training of the district, health facilities, and community health workers."
223766891|NCT07085377|PROCEDURE|DIADEME strategy|"This strategy consists of implementing the standardized DIADEME protocol. It, in line with best practice recommendations, enables nurses to adjust methadone dosage on the basis of a clinical assessment scheme incorporating opioid withdrawal and overdosing and includes:~* initial medical consultation with the hospital practitioner for an addictology and psychiatry assessment, OUD assessment, and initial prescription of methadone for 3 months~* ECG prior to any methadone prescription, hepatitis B, C, HIV testing may be offered, and an emergency NALOXONE kit will be given to the patient or prescribed~* follow-up consultations with an nurse at least every 7 days, and more frequently if necessary.Dosages can be adjusted by the nurse on the basis of the standardized DIADEME protocol~* medical consultation are only in the event of major withdrawal symptoms or overdosing or in the event of any incident not covered by the protocol and warranting rapid medical advice or at the patient's request"
223766892|NCT07085377|PROCEDURE|Controle strategy|The control strategy corresponds to standard practice guidelines for patients suffering from drug addiction, with the care pathway provided by the hospital practitioner, assisted by the nursing team.
224235010|NCT00264810|PROCEDURE|RNS® System implantation|Using standard neurosurgical techniques the surgical team implants the RNS® System, which includes the RNS® Neurostimulator and intracranial NeuroPace® Leads. Up to 4 Leads (Cortical Strips and/or Depth Leads) are placed in or near the epileptogenic focus/foci. The Neurostimulator is placed in the skull and connected to up to 2 Leads. At first the Neurostimulator is programmed to record brain activity (electrographic patterns). The neurologist or neurosurgeon reviews the recorded electrographic patterns and identifies abnormal (epileptiform, or seizure-like) activity. The Neurostimulator is then programmed to detect the abnormal activity.
224235011|NCT00264810|DEVICE|RNS® System responsive stimulation|The RNS® System is programmed to provide responsive stimulation (stimulation is ON or enabled). Upon detecting electrographic patterns, previously identified by the neurologist or neurosurgeon as abnormal (epileptiform, or seizure-like) activity, the Neurostimulator provides brief pulses of electrical stimulation through the Leads to interrupt those patterns. The typical patient is treated with a cumulative total of 5 minutes of stimulation a day.
224235012|NCT06192251|BEHAVIORAL|Lifestyle Medicine|Education and support for lifestyle modification to improve health conditions
224235013|NCT05736081|DRUG|Intravitreal dexamethasone implant|Intravitreal implant of dexamethasone 0.7 mg with previous topic anesthesia and iodine drops
224320437|NCT00898573|GENETIC|gene expression analysis|
224320438|NCT00898573|GENETIC|mutation analysis|
223650051|NCT01620216|OTHER|Antitumor Drug Screening Assay|Undergo pre clinical kinase inhibitor activity screening
223650052|NCT01620216|DRUG|Dasatinib|Given PO
223650053|NCT01620216|DRUG|Idelalisib|Given PO
223650054|NCT01620216|OTHER|Laboratory Biomarker Analysis|Correlative studies
223650055|NCT01620216|DRUG|Pacritinib|Given PO
223650056|NCT01620216|OTHER|Pharmacological Study|Correlative studies
223650057|NCT01620216|DRUG|Ponatinib|Given PO
223650058|NCT01620216|DRUG|Ponatinib Hydrochloride|Given PO
223650059|NCT01620216|DRUG|Ruxolitinib|Given PO
224235014|NCT02994056|DRUG|SOF/VEL|400/100 mg FDC tablet administered orally once daily
224235015|NCT02994056|DRUG|RBV|Tablets administered orally at 600 mg, if well tolerated then up to a maximum total daily dose of 1000 to 1200 mg (based on weight) divided twice daily.
224235016|NCT01206842|OTHER|Training in Affect Recognition|A 12-session social cognitive training programming covering emotion perception and social perception administered in a group setting to up to four participants with schizophrenia at the time
224235017|NCT05991739|BEHAVIORAL|Familias Inmigrantes Empoderándose contra eStrés Tomando Acción (FIESTA)|FIESTA is a 10-session, group intervention led by community health workers that offers strategies related to individual stress management, family coping and communication, and community navigation.
223650060|NCT01620216|DRUG|Sorafenib|Given PO
224235018|NCT05717699|BIOLOGICAL|Ad-TD-nsIL12|After stereotactic biopsy, the Ommaya reservoir will be inserted through the biopsy channel and two injections of Ad-TD-nsIL12 will be delivered after surgery by Ommaya reservoir (with an interval of 3days). The interval between following injections in the subsequent treatment period will be 3 weeks ±4 days. The assigned dose for each patient will be 3x10\^9vp, 1x10\^10vp or 3x10\^10 vp suspended in 1 ml NS according to cohort design.
224235019|NCT05778409|BIOLOGICAL|Cordyceps cicadae extract|500mg/ day for one month
224235020|NCT01701284|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|
223650061|NCT01620216|DRUG|Sorafenib Tosylate|Given PO
223650062|NCT01620216|DRUG|Sunitinib|Given PO
224320439|NCT00898573|GENETIC|polymerase chain reaction|
223650063|NCT01620216|DRUG|Sunitinib Malate|Given PO
223650064|NCT01172717|DRUG|Panitumumab|Panitumumab will be given by intravenous infusion at a dose of 9 mg/kg on day 1 of study and then every 3 weeks until progression of disease
223650065|NCT03566485|DRUG|Atezolizumab|Given by IV
223650066|NCT03566485|DRUG|Cobimetinib|Given by mouth
223650067|NCT03566485|DRUG|Idasanutlin|Given by mouth
223650068|NCT01419652|OTHER|hold hypoglycemic meds|continue versus hold hypoglycemic medications
223650069|NCT06511401|OTHER|Pharmacogenomic (PGx) results.|These results are designed to provide specific dosing information based on the participant's unique genetics/genomics.
223650070|NCT04796090|OTHER|Clinical assessment|FSFI, ASEX and FSDS scores were compared between the adolescents with (Study group) or without (Control group) genital warts.
223650071|NCT06109662|DIAGNOSTIC_TEST|Cystatin C eGFR|Cystatin C eGFR is not used routinely currently in clinical practice in the UK. It involved a blood test to analyse Cystatin C.
223650072|NCT06109662|OTHER|Bioimpedance Analysis (Body composition analysis)|Participants will stand on a bioimpedance analysis machine which will measure different components of body composition
223650073|NCT04676399|DRUG|Hydrochlorothiazide 12.5mg|2 pills/day (1 pill every morning and 1 pill every evening) for 14 days.
223650074|NCT04676399|DRUG|Placebo|2 pills/day (1 pill every morning and 1 pill every evening) for 14 days
223650075|NCT04999852|DEVICE|Safe and Sound Protocol|SSP is a non-invasive acoustic vagus nerve stimulator consisting of 5 hours of filtered and processed music designed to promote efficient regulation of autonomic state, and available through an app. The SSP is delivered via a mobile app and may fall under the heading of medical devices under the category of software functions/mobile medical applications.
223650076|NCT04999852|BEHAVIORAL|Psychotherapy|All participants, regardless of study arm, will be recruited from the pool of Spencer Psychology clients who are actively recieving psychotherapy. Participants will continue to recieve psychotherapy during the course of the study.
223650077|NCT06218797|OTHER|a routine sedation protocol|In this study group, a routine sedation protocol in our clinic will be applied in the endoscopic unit. Premedication will not be given to the patients.
223650078|NCT06218797|DRUG|Nebulized with dexmedetomidine|Patients will be received nebulisation with dexmedetomidine 2mcg/kg 5 cc 20 minute prior to endoscopy. After that routine sedation protocol in our clinic will be applied.
223650079|NCT06959849|DEVICE|Use of robot surgical system|
223650080|NCT06095128|DRUG|Vedolizumab|Vedolizumab IV infusions
224235021|NCT04052867|DRUG|Lignocaine|Slow bolus of lignocaine is given over 15 min before the start of surgery, followed by infusion of lignocaine
224320440|NCT00898573|GENETIC|reverse transcriptase-polymerase chain reaction|
224320441|NCT00898573|OTHER|cell sorting|
224320442|NCT00898573|OTHER|immunohistochemistry staining method|
224320443|NCT00898573|OTHER|laboratory biomarker analysis|
223650081|NCT06095128|DRUG|Tofacitinib|Tofacitinib Tablets
223650082|NCT06102525|DRUG|RZ-001|Recombinant adenovirus harboring the modified ribozyme construct with HSV-tk as a therapeutic transgene
223650083|NCT06102525|COMBINATION_PRODUCT|VGCV|VGCV, used in a subject after RZ-001 administration, is a nucleoside analog that is metabolized by HSV-tk and other cellular kinases to form the cytotoxic nucleotide analog ganciclovir triphosphate. An approved oral VGCV will be used in the proposed clinical study of RZ-001.
223650084|NCT05901558|BEHAVIORAL|Strategies for Toddler ASD with Remote-therapy (STAR)|The intervention strategies in STAR model are designed under the Naturalistic Developmental Behavioral Intervention (NDBI) framework which are implemented in natural settings targeting at improving social and communicational capabilities
224235022|NCT04052867|DRUG|Normal saline|An equivalent volume of normal saline is given
224235023|NCT04107493|DEVICE|Portable Oxygen Cylinder|A POC is a medical device that is indicated for patients who require supplemental oxygen, including COPD patients
224235024|NCT04107493|DEVICE|Mobi|ResMed's variant of POC
224235025|NCT01197963|PROCEDURE|Sleeve Gastrectomy and Ileal transposition|Laparoscopic sleeve gastrectomy with ileal transposition
223650085|NCT05901558|BEHAVIORAL|Community intervention|Regular community intervention
223766893|NCT07085377|PROCEDURE|Individual semi directive interview|"Individual semi-directive interviews with a sample of patients from the DIADEME group (2 to 3 volunteer patients per CSAPA for a total of 20 to 30 interviews) will be conducted by a research psychologist and carried out at one month after the end of follow-up (3 months).~Themes covered will include: commitment to care, patient/professional relationship, understanding of follow-up and treatment, experience of care and services at the addictology center, satisfaction with services received, level of response to expectations).~Individual semi-directive interviews with a sample of healthcare professionals focus group will be also conducted by a research psychologist and carried out after the last patient has been included in the center. The aim will be to understand the effects of the intervention and identify its impact on professionals and the organization of the centers."
223766894|NCT07085130|BEHAVIORAL|Exercises and cold application|Hand and foot exercises combined with cold application interventions are non-pharmacological methods used to reduce pain, kinesiophobia, and fragility levels in patients with diabetic peripheral neuropathy.
223650088|NCT04991389|DRUG|129-Xe|Inhaled contrast for MRI
223650089|NCT06045754|DRUG|Vedolizumab|Vedolizumab intravenous infusion.
223650090|NCT06045754|DRUG|Adalimumab|Adalimumab subcutaneous injection.
223650091|NCT06045754|DRUG|Ustekinumab|Ustekinumab intravenous infusion.
223650092|NCT06045754|DRUG|Ustekinumab|Ustekinumab subcutaneous injection.
223650093|NCT02343237|PROCEDURE|Osteopathic treatment|osteopathic sessions of 20 minutes
223650094|NCT02343237|PROCEDURE|Factitious osteopathic treatment|6 factitious osteopathic sessions of 20 minutes
223650095|NCT06637852|BEHAVIORAL|SUFICS-PACT|SUFICS-PACT includes sexual and urinary dysfunction screening, collaborative treatment of sexual and urinary dysfunction, and care managers who are mental health professionals with training in psychosexual counseling. Mental health professionals will facilitate a comprehensive approach to sexual dysfunction, as emphasized by the biopsychosocial model of sexual health. SUFICS-PACT also emphasizes close follow up, which is important for sexual function recovery after prostate cancer treatment.
223650096|NCT05758389|DRUG|Tislelizumab, Paclitaxel (albumin-bound type), Cisplatin, 5-FU|evaluate the efficacy and safety of immunotherapy combined with chemotherapy
223650097|NCT05934305|BEHAVIORAL|Matter Intervention|This 5-session text-enhanced intervention is designed to mitigate the negative behavioral consequences of internalized stigma and shame among MSM and gender minority individuals with SUDs that perpetuate sub-optimal engagement in HIV self-care and consequently inconsistent viral suppression. The intervention involves five virtually delivered one-on-one therapy sessions focused on behavioral goal setting skill development and related self-efficacy, increasing meta-cognitive awareness(i.e.,non-judgmental awareness of emotions and cognitions), and teaching and reinforcing compassionate self-restructuring (i.e., self-compassion). Participants also receive daily text messages querying emotions during the one-on-one portion of the intervention. For eight weeks after the one-on-one portion, participants receive their compassionate self-statements via text in response to their indicated emotions. Participants will also receive phone-based resource navigation, as needed.
223650098|NCT05934305|BEHAVIORAL|Control Condition|The control condition will involve five sessions of prerecorded asynchronous content related to local resources (e.g., information related to substance use treatment and other ancillary services).
223650099|NCT06314477|DEVICE|CPAP treatment|Subjects allocated to this arm will receive continuous positive airway pressure (CPAP)
223650100|NCT06314477|OTHER|Hygienic and dietary advice|Subjects allocated to this arm will receive hygienic and dietary counselling
223650101|NCT05645016|BEHAVIORAL|COEST|Adapted version of our COEST training, targeting Black church members.
223650102|NCT05489523|DRUG|Tafamidis 61 MG|Tafamidis 61 mg by mouth daily for 12 months
223650103|NCT05222269|DRUG|68Ga-PTF|68Ga-PTF will be injected intravenously at three time points during the course of the standard treatment of the patient.
223650104|NCT06009393|DRUG|SHR-1918|Three administration
223650105|NCT06196164|PROCEDURE|EUS-BD|We observe the bile duct through endoscopic ultrasound, then puncture through the gastric or duodenum wall and place a guide wire, expanding along the guide wire, finally place a stent between the bile duct and the stomach or intestine for drainage.
223650106|NCT06196164|PROCEDURE|ERCP-BD|We use a Duodenoscopy to pass through mouth down to the small opening where the bile duct and pancreatic drain. A small narrow catheter is passed through the scope to gain access to the drainage duct , followed by advancement of a wire deep into the duct. A small cut is made at the bile duct opening to help facilitate a stent placed in the bile duct.
223650107|NCT01651585|DRUG|Valacyclovir arrow|dosage form:500mg, dosage:8g/day, frequency: 4 a day duration: 23 weeks maximum
224235026|NCT01197963|DIETARY_SUPPLEMENT|dietary and medical management|dietary and medical routine management patients are currently following with an endocrinologist.
224320444|NCT03981692|OTHER|Consecutive dual task|8 weeks and 2 days per week, one session 45 min. Consecutive dual task creates the idea that it may provide more workable work without creating stress while doing secondary task during dual task.
223650108|NCT04030455|DRUG|Carboplatin|Given IV
223650109|NCT04030455|DRUG|Cisplatin|Given IV
223650110|NCT04030455|DRUG|Docetaxel|Given IV
223650111|NCT04030455|BIOLOGICAL|Pembrolizumab|Given IV
223650112|NCT05889845|DRUG|Candin, Intradermal Solution|Injection at the base of the selected wart
223650113|NCT05889845|DRUG|Placebo|Injection at the base of the selected wart
223650114|NCT06215677|DRUG|Camrelizumab|Camrelizumab 200mg for 3 cycles. Patients will undergo surgery 2-3 weeks after the last cycle of immunotherapy, type and extent of the surgery will be selected by the surgeon.
223650115|NCT06364774|BIOLOGICAL|ALS20|novel lentiviral vector ALS20
223650116|NCT06228066|DRUG|Lurbinectedin|Lurbinectedin is administered IV over 1 hour at 3.2 mg/m2 on day 1 of each 21-day cycle
223650117|NCT06228066|DRUG|Avelumab|Avelumab is administered IV at 800 mg over 1 hour on day 1 of each 21-day cycle
223650118|NCT03664687|DRUG|Zoledronate|Administered intravenously (IV)
223650119|NCT04879329|DRUG|disitamab vedotin|Given into the vein (IV; intravenous) every 2 weeks.
223650120|NCT04879329|DRUG|pembrolizumab|Given by IV on Day 1 of each 6-week cycle.
223650121|NCT06580041|DRUG|Pramipexole|CAU plan modified to include a trial of pramipexole.
223650122|NCT06580041|DRUG|Methylphenidate|CAU plan modified to include a trial of methylphenidate (or, if contraindicated: guanfacine).
223650123|NCT06580041|DRUG|Phenelzine|CAU plan modified to include a trial of phenelzine (or, if contraindicated: brexpiprazole).
223650124|NCT06580041|BEHAVIORAL|Mindfulness-based Stress Sensitivity Therapy (MBSST)|CAU plan modified to include a trial of MBSST. MBSST is an individual psychotherapy delivered approximately weekly for 16 sessions.
223650125|NCT06580041|BEHAVIORAL|Complicated Grief Treatment (CGT)|CAU plan modified to include a trial of CGT.
223650126|NCT06580041|OTHER|Care as usual (CAU) plan|Unmodified CAU plan.
223650127|NCT06344403|DRUG|analgesic|Patients will receive daily 300 mg pregabalin in divided doses (150 mg/12 hours). Once the patient report mild pain (VAS ≤ 3), the trial for reducing the pregabalin dose will be done. Nonsteroidal anti-inflammatory drug celecoxib (200 mg on request, up to two times daily)27 and tramadol (100 mg on request, up to 400mg daily) will be available for as-needed analgesia.
223650128|NCT06344403|BEHAVIORAL|Tender point infiltration|Lidocaine mixed with diprospan injected into tender points.
223650129|NCT06233747|BEHAVIORAL|Improving Care, Accelerating Recovery & Education (ICARE)|I-CARE is a brief, digital intervention designed for adolescents who are boarding in a medical hospital awaiting transfer to a psychiatric inpatient unit. It consists of 7 tablet-based animated video modules and workbook exercises, facilitated by licensed nursing assistants or other non-specialist clinicians who provide one-on-one safety supervision during boarding. All modules are grounded in evidence-based practices, such as cognitive-behavioral therapy and dialectical behavior therapy. Given that one-on-one safety supervision is the current standard of care during boarding, I-CARE requires minimal additional resources beyond those already available in acute care hospitals and builds on well established research demonstrating the effectiveness of task-sharing, the redistribution of tasks within the workforce, to address the shortage of mental health professionals.
223766895|NCT07085130|OTHER|Exercises and virtual reality|Performing hand and foot exercises in a cold, snowy virtual environment using virtual reality goggles may be a non-pharmacological intervention to alleviate burning-type hand and foot pain in patients with diabetic neuropathy.
223650131|NCT05505955|DRUG|HRS-5965|Subjects took HRS5965 tablets in Part 1, Part 2 and Part 3.
223650132|NCT05505955|DRUG|Placebo|Subjects took Placebo in Part 1 and Part 2.
224320445|NCT03981692|OTHER|Integrated dual task|8 weeks and 2 days per week, one session 45 min. Integrated dual task is a proven mode of work that has positive effects on geriatrics
223650133|NCT04037527|DRUG|Gemcitabine|Gemcitabine will be administered on day 1 of each one-week cycle for 6 cycles concurrently with radiation to the extremity on a 3+3 escalating dose (100 mg/m² to 300 mg/m²)
223650134|NCT04037527|DRUG|Docetaxel|Docetaxel will be administered on day 1 of each one-week cycle for 6 cycles concurrently with radiation to the extremity (10 mg/m² to 25 mg/m²).
223650135|NCT04037527|RADIATION|Radiation|Radiation is to be done with standard preop dose of 50 Gy but at lower doses per fraction. Thus 50.4 Gy in 28 FX. Radiation will be given for 5 days (Monday - Friday) every week for approx. 6 weeks.
223650136|NCT04037527|PROCEDURE|Surgical Resection|Upon completing neoadjuvant chemotherapy plus radiation therapy, surgical resection will occur.
223650137|NCT04037527|OTHER|Blood draws|Before treatment, blood (about 2 tubes of 10 mls each) to better understand some aspects of participants' immune system before chemotherapy.
223650138|NCT05787002|DRUG|AZD0780|AZD0780 will be administered orally as a single dose after an overnight fast of at least 10 hours with approximately 240 mL of water.
223650139|NCT05787002|DRUG|Rosuvastatin|Rosuvastatin will be administered orally as a single dose after an overnight fast of at least 10 hours with approximately 240 mL of water.
223650140|NCT03587376|DRUG|Atabecestat|Blood samples will be collected from participants previously treated with atabecestat.
223650141|NCT03612934|PROCEDURE|Specialist Palliative Care|In the research, Specialist Palliative Care was provided according to the guidelines established by Mid-Western Health Board in a Report of the National Advisory Committee on Palliative Care as well as according to recommendations of Polish Society of Palliative Medicine and Polish National Healthcare Fund. In order to ensure interdisciplinary and integrated palliative care, a team of specialists was appointed. Team members were engaged in the process of treatment of each patient during the time of the study and applied their specialist skills according to the needs of the patients
223650142|NCT05252585|DRUG|Everolimus|"Everolimus tablets for oral use. The recommended everolimus starting dose will be 10 mg orally taken once daily for all patients, except for those with impaired liver function, for whom the everolimus dose will be:~* Child-Pugh grade A: 7.5 mg once daily (for patients with mild hepatic impairment)~* Child-Pugh grade B: 5.0 mg once daily (for patients with moderate hepatic impairment)"
223650143|NCT01648686|PROCEDURE|Dental extraction|3 dental radiographies realised immediately, then 30 days, then 90 days after dental extraction
223650144|NCT05942833|PROCEDURE|Sigmoid resection|Timing of sigmoid resection
223650145|NCT01434199|PROCEDURE|UPD guidance|A real time, three-dimensional image and position of the colonoscope would be provided to the endoscopist during the procedure.
223650146|NCT00612144|DRUG|Glimepiride/metformin fixed combination|"Amaryl M 1/250mg\~4/1000mg bid for 12\~26 weeks~* Maintenance dose for 10 weeks after 2\~14 weeks of dose titration~* Dose titration according to titration algorithm based on daily mean SMBG"
223650147|NCT00612144|DRUG|Metformin HCl|"Metformin HCl 500mg\~1250mg bid for 12\~26 weeks~* Maintenance dose for 10 weeks after 2\~14 weeks of dose titration~* Dose titration according to titration algorithm based on daily mean SMBG"
223650148|NCT02643446|BIOLOGICAL|IPV|IPV will be vaccinated at 2 months of age act as the first dose of poliovirus vaccine in the study group1 to group 4,group8 to group 11. IPV will be given at 3 month of age act as second vaccine in group 8,9,12
223650149|NCT02643446|BIOLOGICAL|OPV|"OPV will be vaccinated at 3 and 4 months of age, act as the second and third dose of poliovirus vaccine in the study group 1 to group 4,group 10 to group 11.~OPV will be vaccinated at 2, 3 and 4 months of age act as the full three primary immunization doses of polio virus vaccine in the study group 5 to group 7."
223650150|NCT00003469|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|Children with a Rhabdoid tumor will receive Antineoplaston therapy (Atengenal + Astugenal).
223650151|NCT04718155|DRUG|Atorvastatin|will receive 40 mg atrorvastatin 2 days
224320446|NCT03612349|BEHAVIORAL|Experimental Tobacco Marketplace Task|Participants will select tobacco products from an Experimental Online Tobacco Marketplace under both marketplace conditions.
223650152|NCT04718155|OTHER|placebo|will receive 40 mg placebo 2 days
223650153|NCT01138449|DRUG|Vitamin A|Retinol palmitate (50,000 IU) and minute amounts of vitamin E in soybean oil, orally as a single dose to neonates on the day of birth or in the next 2 days of birth keeping a minimum period of 2 hours between the birth and the dosing
223650154|NCT03610269|DEVICE|INVSENSOR00026 (Pulse CO-Oximeter and sensor)|Noninvasive Pulse CO-Oximeter and sensor that measures noninvasive hemoglobin (SpHb)
223650155|NCT01276210|DRUG|sorafenib tosylate|Given PO
224235027|NCT05793736|DEVICE|Biofeedback training|The intervention lasts 5 weeks, twice a week, each session lasts 45 minutes in which HRV (Heart Rate Variability) is detected, through plethysmographic sensors placed on the finger or earlobe during assigned tasks. During tasks that involve progressively more complex phases, they allow the person to receive immediate feedback on the video screen.
224235028|NCT05793736|DRUG|Treatment as usual|The sample will be treated only with standard therapies (treatment as usual) without the use of biofeedback training
223766896|NCT07085234|DRUG|Iparomlimab/Tuvorlimab(QL-1706) and modified TPF regimen|"Induction therapy: Albumin-bound paclitaxel 260 mg/m² + cisplatin 75 mg/m² (divided on days 1 - 3) + S1 calculated according to body surface area, taken twice daily (days 1 - 14) + Iparomlimab/Tuvorlimab(QL-1706) 5 mg/kg (day 1). One cycle lasts for 21 days, and the treatment continues for three consecutive cycles.~Concurrent chemotherapy: Cisplatin 80 mg/m², divided on days 1 - 3. One cycle lasts for 21 days, and the treatment continues for two consecutive cycles.~Radiotherapy regimen: Whole-course IMRT."
224235029|NCT02686840|DRUG|sublingual misoprostol|"All patients will receive three doses of sublingual misoprostol every four hours The first dose of misoprostol 800 mcg will be administrated at the hospital. Then the patient will be observed for 1 hour for any immediate adverse reaction Clear instructions about the method and timing of second dose will be given upon sending home.~* Two doses of misoprostol 800 mcg each (four tablets of 200 mcg per dose).~* Paracetamol, eight hourly, will be provided as analgesic or antipyretic.~* A specimen bottle to collect the POC if passed out.~* Two pairs of disposable gloves.~* Pre-filled histopathological examination form to be sent to the laboratory together with the products of conception"
224235030|NCT02686840|DRUG|vaginal misoprostol|"All patients will receive three doses of vaginal misoprostol every four hours The first dose of misoprostol 800 mcg will be administrated at the hospital. Then the patient will be observed for 1 hour for any immediate adverse reaction Clear instructions about the method and timing of second dose will be given upon sending home.~Paracetamol, eight hourly, will be provided as analgesic or antipyretic"
224235031|NCT01925313|DRUG|CJ-30044|20.51mg a day,PO,QD
224235032|NCT01925313|DRUG|TALION TAB. 10mg|10mg a day,PO,BID
224235033|NCT02199509|DRUG|Levetiracetam|Anticonvulsant
224235034|NCT04025034|PROCEDURE|Orbital decompression with ultrasonic bone removal|Deep lateral wall partial rim-sparing decompression for thyroid-related orbitopathy using SONOPET® appears to be safe and effective, reducing the complications associated and damage to neurovascular structures.
223650156|NCT01276210|RADIATION|stereotactic radiosurgery|Undergo stereotactic radiosurgery
223650157|NCT01276210|OTHER|laboratory biomarker analysis|Correlative studies
223650158|NCT05577299|DEVICE|PET/CT|18F-fluorodeoxyglucose positron emission tomography/computed tomography (18FFDG PET/CT) is a non-invasive imaging modality used for staging and surveillance of various types of malignancies through imaging of glucose metabolism in cancer cells.
223650159|NCT00135551|DRUG|Angiotensin receptor blockers|benidipine+angiotensin receptor blocker, titlation scheme
223650160|NCT00135551|DRUG|β-blockers|benidipine+β-blockers, titlation scheme
223650161|NCT00135551|DRUG|thiazide diuretics|benidipie+thiazide diuretics, titlation scheme
223650162|NCT00478023|DRUG|Morphine|20 mg IR; 4 - 6 hourly; Total 72 hours
223650163|NCT00478023|DRUG|CG5503 IR|50mg; 4 - 6 hourly; Total 72 hours
223650164|NCT00478023|DRUG|CG5503 IR|75mg; 4 -6 hourly; Total 72 hours
223650165|NCT00478023|DRUG|CG5503 IR|100mg, 4 - 6 hourly; Total 72 hours
223650166|NCT00478023|DRUG|Placebo|4 - 6 hourly; Total 72 hours
223650167|NCT00981110|DEVICE|AQUAGEL Ag Hydrofiber Wound Dressing|Hydrofibre dressing containing ionic silver: medication performed as for frequency and duration according standard procedure
223650168|NCT00981110|DEVICE|Mepore Self-adhesive absorbent dressing|Standard dressing: medication performed as for frequency and duration according standard procedure
223650169|NCT01004991|BIOLOGICAL|rituximab|375 mg/m2 on Day 8 of each of 6 cycles
223650170|NCT01004991|DRUG|cyclophosphamide|750 mg/m2 on Day 8 of each of 6 cycles
223650171|NCT01004991|DRUG|vincristine|1.4 mg/m2 on Day 8 of each of 6 cycles
223650172|NCT01004991|DRUG|doxorubicin|50 mg/m2 on Day 8 of each of 6 cycles
223650173|NCT01004991|DRUG|prednisone|100 mg PO days 8-12 of each of 6 cycles
223650174|NCT01004991|DRUG|azacytidine|Dose level 1: azacytidine 25 mg/m2 days 1-5 Dose level 2: azacytidine 50 mg/m2 days 1-5 Dose level 3: azacytidine 75 mg/m2 days 1-5
223650175|NCT00389259|DRUG|Placebo|IV placebo q4h
223650176|NCT06045156|DRUG|Tirofiban|Tirofiban is a selective glycoproteinⅡb/Ⅲa receptor inhibitor, which inhibits platelet aggregation and thrombi formation
224235035|NCT04018625|BEHAVIORAL|SMART Mom|SMART Pregnancy is an 8-session online stress management program offered in a group format. SMART Pregnancy is an adaptation of the Stress Management and Resiliency Training Program (Park et al., 2012).
224235036|NCT04018625|BEHAVIORAL|Mama Support|Participants will be enrolled in an 8-week time and attention matched, process-based support group.
224235037|NCT06173245|PROCEDURE|Intravitreal injection of ranibizumab|"These patients were received three intravitreal injection of ranibizumab with one month interval. 3D-OCT by enhanced depth spectral-domain imaging (EDI-OCT) was done preoperative and a month after every injection.~All patients recieved topical anesthesia as 0.5 mg/0.05 ml , ranibizumab is injected 4 mm (3.5 mm in Pseudophakia) from the limbus intravitreally (in the lower temporal quadrant) by a needle (27gauge)."
224235038|NCT01231061|RADIATION|SBRT|•24 Gy in 3 fractions to cover at least 90% of the defined target volume
224235039|NCT01231061|RADIATION|Radiosurgery|16 Gy in 1 fraction to cover at least 90% of the defined target volume
224235040|NCT03294356|OTHER|FT210771|An electronic cigarette
224235041|NCT03294356|OTHER|FT210751|An electronic cigarette
224235042|NCT03294356|OTHER|6T30134157764|An electronic cigarette
224235043|NCT03294356|OTHER|G41A7C071|An electronic cigarette
224235044|NCT03294356|OTHER|M011161212|An electronic cigarette
224235045|NCT03294356|OTHER|FT21002|A combustible cigarette
224235046|NCT04098536|BEHAVIORAL|Diesel exhaust|Exposure to diesel exhaust fumes
224235047|NCT06313047|DRUG|Doxorubicin|each recruited patient with HCC received a comprehensive review of their medical history, physical status, and laboratory results.
224235048|NCT03758833|DIAGNOSTIC_TEST|preimplantation genetic test of embryo by new generation sequencing (NGS)|This is a genetic test to evaluate 24 chromosomes by the new generation sequencing platform. For that is necessary a embryo biopsy in the blastocyst stage and evaluation of a greater number of cells extracted from the trophectoderm
224235049|NCT03758833|PROCEDURE|Single embryo transfer|Transfer of single embryo
224235050|NCT03758833|PROCEDURE|Double embryo tranfer|Transfer of two embryos
224235051|NCT00044226|DRUG|ML-04A|
224235052|NCT05875688|OTHER|Cementation Technique A|"* Use of adequate amount of cement.~* Prevention of wastage of cement.~* Retention of crowns for longer duration."
224235053|NCT05875688|OTHER|Cementation Technique B|"* Use of Sufficient Cement Quantity.~* Keeping cement from going to waste.~* Increased time that crowns remain in place."
224235054|NCT05875688|OTHER|Cementation Technique C|"* The utilisation of an appropriate quantity of cement.~* The mitigation of cement waste.~* Prolonged retention of dental crowns."
224235055|NCT02093689|DRUG|Part 1 OMS302|OMS302 drug product will be supplied as a sterile, clear colorless liquid, free from particulates of foreign matter. Each vial contains a nominal 4.5-mL solution containing 60.75 mM phenylephrine HCl (12.37 mg/mL) and 11.25 mM ketorolac trometamol (4.24 mg/mL) formulated in a 20 mM sodium citrate buffer (pH 6.3 ± 0.5). For administration to patients, 4.0 mL of the drug product is added to a 500-mL bottle of commercially available irrigation solution.
224235056|NCT02093689|DRUG|Part 2 OMS302|OMS302 drug product will be supplied as a sterile, clear colorless liquid, free from particulates of foreign matter. Each vial contains a nominal 4.5-mL solution containing 60.75 mM phenylephrine HCl (12.37 mg/mL) and 11.25 mM ketorolac trometamol (4.24 mg/mL) formulated in a 20 mM sodium citrate buffer (pH 6.3 ± 0.5). For administration to patients, 4.0 mL of the drug product is added to a 500-mL bottle of commercially available irrigation solution.
224235057|NCT02093689|DRUG|Part 2 Placebo|Placebo drug product is a sterile, clear colorless liquid, free from particulates of foreign matter. Each vial contains a nominal 4.5 mL of solution containing 20 mM sodium citrate buffer (pH 6.3 ± 0.5). For administration to patients, 4.0 mL of the drug product is added to a 500-mL bottle of commercially available irrigation solution.
224235058|NCT04950283|DIAGNOSTIC_TEST|magnetic resonance examination, anthropometric and metabolic characterization|Participants undergo a magnetic resonance examination, anthropometric characterization and metabolic characterization via oral glucose tolerance test.
223650177|NCT06045156|DRUG|Tirofiban simulant|Tirofiban simulant is placebo packed the same style as tirofiban
223650178|NCT00078546|BIOLOGICAL|EBV specific CTL Infusion|"One injection at one of the following dose levels~Dose level I: 2x107/m2 Dose level II: 5x107/m2 Dose level III: 1x108/m2"
223650179|NCT00078546|BIOLOGICAL|Anti CD45 monoclonal antibody|400ug/kg over 6 to 8 hr for 4 days
223650180|NCT04859933|PROCEDURE|AV-node isolation|Abaltion performed in the right atrium isolating the AV-node from the atrium
223650181|NCT04859933|PROCEDURE|AV-node ablation|Right sided ablation of the AV-node
223650182|NCT00721383|BEHAVIORAL|Enhancing Physical Activity Intervention|Physical activity and caregiver skill-building
223650183|NCT00721383|BEHAVIORAL|CSBI|Caregiver skill-building
223650184|NCT00140608|DEVICE|Seprapack Sinus Dressing|
223650185|NCT04198688|BEHAVIORAL|Intensive Smoking Cessation Intervention|The intervention comprises 5-6 meetings during six weeks, and can be held in group or as an individual intervention. It is based on counselling and a clearly structured manual-based patient education programme taught by specially trained staff, and contains individual counselling on nicotine replacement therapy or other medical support, according to the level of dependence measured by the Fagerström test score. The first two weeks cover teaching sessions on: ambivalence and motivation, pros and cons of continuous smoking versus cessation, and a quit date is set between the 2. and 3. week. The last 3 sessions cover: risk situations, withdrawal symptoms and medical support for withdrawal symptoms, relapse prevention and how to handle a completely smoke-free life.
223650186|NCT02888600|BEHAVIORAL|Mindfulness Training|Guided mindfulness meditation and stress management training
223650187|NCT02888600|BEHAVIORAL|Health Education|Guided health education and stress management training
223650188|NCT04117516|PROCEDURE|Open surgery|"Open carpal tunnel release will be performed, in the theatre, with tourniquet, under local anesthesia and sedation, through a short longitudinal volar classical approach of the hand, that allows to visualize the complete division of the ligament."
224235059|NCT03992287|DIETARY_SUPPLEMENT|Hydrolysed Red Ginseng Extract|10 ml/day, 2.4g/day for 12 weeks
224235060|NCT03992287|DIETARY_SUPPLEMENT|Placebo|Placebo for 12 weeks
224235061|NCT02739542|DRUG|Tecfidera|Blinded drug wallets will be dispensed during routine study appointments in 3 month supply, so that compliance can be reconciled at follow up visits and telephone consultations, and recorded in accountability logs.
224235062|NCT02739542|DRUG|Placebo|Blinded drug wallets will be dispensed during routine study appointments in 3 month supply, so that compliance can be reconciled at follow up visits and telephone consultations, and recorded in accountability logs.
224235063|NCT02042911|DRUG|SyB L-0501|SyB L-0501 is administered at 100 mg/m2/day by intravenous infusion on Day 1 and Day 2 followed by 26 days of monitoring. This is considered to be one cycle and may be repeated up to 6 cycles. Dose administration can be delayed or discontinued from the second cycle as necessary according to adverse events and the results of monitoring during the previous cycle, but dose reduction is permitted from the 3rd cycle.
224235064|NCT02153047|BEHAVIORAL|Spirometry|Will be given a brief but structured smoking cessation advice (according to the standards of the Tobacco Study Group of the Catalan Society of Family Medicine) together with a detailed and structured 20-minutes visit with details of the spirometry data (values of respiratory capacity and volumes referring on the theoretical)
224235065|NCT04986696|DEVICE|FLASH therapy|Dose escalation of high dose rate radiotherapy (FLASH therapy) as single dose treatment for skin melanoma metastases that progress locally despite systemic treatments.
224235066|NCT04947579|DRUG|CC-99677|Oral
224235067|NCT04947579|OTHER|Placebo|Oral
224320447|NCT03239847|OTHER|EndoPhys Sheath and Radial Arterial Line|
223650189|NCT04117516|PROCEDURE|Percutaneous surgery|Percutaneous carpal tunnel release will be performed, ambulatory, with a percutaneous scalpel, through a short transverse volar approach, 1-2cm proximal to the wrist, under Wide Awake Local Anesthesia with No Tourniquet.
224235068|NCT05720533|DRUG|Disitamab Vedotin Combined With Sintilimab|Disitamab Vedotin injection：2.5mg/kg，IV，Q3W Sintilimab injection：200mg，IV, Q3W
224235069|NCT04765033|DRUG|Nebulized 5% Hypertonic saline|nebulized 0.9% saline
223650190|NCT04283227|GENETIC|OTL-200|All subjects will receive OTL-200 gene therapy and will be followed up for 8 years following treatment with OTL-200.
223650191|NCT05623917|BEHAVIORAL|Tele-supervised diaphragmatic respiratory exercise|the group will contain 20 females. the females will receive tele-supervised Diaphragmatic Respiratory Exercise ( applied at the homes of the females two times per the day, at the morning and at the evening, twenty minutes for every time, the sessions will be applied daily for 3 months in all females).
223650192|NCT03899922|DRUG|Drugs inducing uveitis|Drugs susceptible to induce uveitis
223650193|NCT06411314|COMBINATION_PRODUCT|Natamycin + Lactulose 100 mg + 300 mg vaginal suppositories|1 suppository once daily at bedtime for 6 days
223650194|NCT06411314|DRUG|Lactulose 300 mg vaginal suppositories|1 suppository once daily at bedtime for 6 days
223650195|NCT06411314|DRUG|Pimafucin® (natamycin) 100 mg vaginal suppositories|1 suppository once daily at bedtime for 6 days
223650196|NCT02084407|OTHER|Clinical examination, skin biopsy, blood and urine sampling|
224235070|NCT02381509|DEVICE|IVC Filter|
224320448|NCT03239847|OTHER|EndoPhys Sheath|
223650197|NCT04040387|DEVICE|NightWare Therapeutic System|A wearable digital therapeutic system that will measure physiologic data when worn during sleep to deliver a mild vibration via the watch to elicit arousal thereby disrupting nightmares. This detection and stimulation sequence will be performed according to NightWare's proprietary algorithm.
223650198|NCT04040387|DEVICE|Sham NightWare|NightWare device not providing interventions
223650199|NCT05824104|OTHER|Intermittent Hypoxia|The intermittent hypoxia protocol refers to four cycles of 5 minutes hypoxia inhaling interval by 5 minutes normoxia, which is performed twice a day (at least 6 hours apart) in 7 days.
223650200|NCT03286517|BIOLOGICAL|Kisspeptin-10 (metastin 45-54, Calbiochem, Darmstadt, Germany)|A neurohormone
223650201|NCT02188888|DRUG|esmolol|Strict heart rate control: esmolol at any dose to maintain heart rate between 95 and 80 bpm
223650202|NCT05546632|DIAGNOSTIC_TEST|Blood sampling|Patients will have one blood sampling using one EDTA tube and one Cyto-Chex BCT tube, one after the other
223650203|NCT05019521|DRUG|Danicopan|Oral tablet.
223650204|NCT05019521|DRUG|Placebo|Oral tablet.
223650205|NCT00611026|DRUG|Tolterodine ER|The tolterodine treatment will be 4 mg once daily(QD) for 12 weeks.
223650206|NCT00611026|DRUG|Placebo|Placebo treatment will be once daily(QD) for 12 weeks.
224235071|NCT04223050|DRUG|Oxygen gas|Administering oxygen to achieve the desired peripheral oxygen saturation
223650207|NCT00611026|DRUG|Fesoterodine|The fesoterodine treatment will start with 4 mg once daily(QD) for 1 week followed by a forced dose-escalation to 8mg once daily(QD) for 11 weeks.
223650208|NCT01481818|DRUG|EGCG|Apply about 0.05ml/cm2 EGCG with different concentration topically for 3 times a day during radiotherapy
223650209|NCT02881606|DEVICE|Naso-alveolar molding (NAM)|
223650210|NCT02881606|DEVICE|Computer aided design NAM (CAD/NAM)|
223650211|NCT05477667|DIAGNOSTIC_TEST|real time pcr|Detection of expressin level of MiRNA-124 and let-7a using real time pcr
223650212|NCT01732289|GENETIC|genes|Draw blood for genetic screening
223650213|NCT01129596|DRUG|donepezil hydrochloride|This is a multicenter, open-labeled, practice-based, post-marketing surveillance study. Therefore, dosing is not specified.
223650214|NCT05895812|DRUG|Deuremidevir Hydrobromide Tablets|JT001 single dose, 0.3g
223650215|NCT02109497|DRUG|PBT2|PBT2 250 mg administered
223650216|NCT01147874|PROCEDURE|lab draws and imaging|1 set of lab draws, imaging consists of radiographic imaging or X-ray, ultrasound and MRI
223650217|NCT01436435|DEVICE|Jetstream Atherectomy System|Atherectomy
223650218|NCT04150861|DRUG|Follitropin Delta|Solution for Injection, subcutaneous administration
223650219|NCT01206725|OTHER|Exercise|"1. Moderate Intensity Exercise Group (ME). Exercise equivalent to the current exercise guidelines. In total 210 minutes per week of continuous moderate intensity (70% HRmax) exercise. Home based training.~2. Aerobic interval training (AIT). Exercise equivalent to the current guidelines achieved through high-intensity interval training.The exercise starts with warming-up for 10-min at 70% of HRmax before performing 4x4min intervals at 90-95% of HRmax, with 3-min active recovery at 70% of HRmax between each interval, and a 5-min cool-down period, giving a total of 40-min."
224235072|NCT05038813|DRUG|Anlotinib+TQB2450|"Anlotinib: 12mg, orally once a day (orally before breakfast, the daily medication time should be as the same as possible), continuous taking for 2 weeks, stopping for 1 week, 3 weeks (21 days) as a treatment cycle, until the disease progresses or Intolerable.~TQB2450: 1200mg, diluted to 250mL with normal saline, infusion time 60±10mins. The medication is taken on the first day of each cycle, and 3 weeks (21 days) is a treatment cycle. Until the emergence of disease progression or intolerable toxicity, the longest use time does not exceed 24 months."
224235073|NCT00046813|DRUG|Nicotine patch|
224235074|NCT04272021|DRUG|Methylphenidate|standard therapy for ADHD
224320449|NCT02195661|DIETARY_SUPPLEMENT|Melatonin|
224320450|NCT02195661|DRUG|Chloral Hydrate|
224320451|NCT06502366|DRUG|BDA MDI HFO 160/180 μg|Budesonide/albuterol pressurized inhalation suspension, HFO
224320452|NCT06502366|DRUG|BDA MDI HFA 160/180 μg|Budesonide/albuterol pressurized inhalation suspension, HFA
224320453|NCT06502366|DRUG|Placebo MDI HFA|Placebo pressurized inhalation suspension, HFA
224320454|NCT01464632|DEVICE|EPIK™ uni-compartmental knee|This device is intended for partial replacement of the articulating surfaces of the knee when only one side of the joint is affected due to compartmental primary degenerative or post-traumatic degenerative disease, previous tibial condyle or plateau fractures, deformity, or revision of previous arthroplasty.
224320455|NCT01128543|DRUG|lapatinib and Vinorelbine|Patients will receive 1250mg lapatinib once a day and vinorelbine 25mg/sqm IV Day 1and Day 8, every 3 week for 24 weeks.
224235075|NCT04656977|OTHER|VR|The proposed intervention will consist in three weekly sessions of 2h focused, respectively, on: (1) gathering information about the loss and psychoeducation about perinatal grief, and introduction to the virtual environment; (2) through the use of the virtual environment, women will be assisted in the elaboration and acceptation of loss; (3) recreate, using the features of the virtual environment (i.e., a series of different virtual landscapes and symbolic elements personalized to each participant as personal pictures, sounds or videos) a new and positive metaphor representing the woman's future life.
224235076|NCT04656977|OTHER|TAU|The TAU condition is a homogenous standard program proposed by the CERIF at UQO based on group counseling offered to women and men who experienced a perinatal loss.
224235077|NCT01547195|PROCEDURE|swim training|"Swimming training will be conducted with the implementation of the freestyle. The training will be held a week with 3 X 50 minutes for a period of 12 weeks.~Patients will be monitored by a frequency waterproof. When at the beginning of training are carried out five minutes of heating, followed by 40minutos swimming 5 minutes and cooling at the end of training."
224235078|NCT01547195|PROCEDURE|Training walk|"The control group will perform walking exercise outdoors, monitored by a frequency, with the heart rate at anaerobic threshold assessed by cardiopulmonary exercise test.~The training of walking will last 50 minutes, three times per week for 12 weeks.~At the beginning of training, there will be a heating time of 5 minutes, followed by LA walk in cooling for 40 minutes and 5 minutes."
224235079|NCT03714295|OTHER|Use of interdental brushes|No intervention they just use interdental brushes as it should be done routinely
224235080|NCT02202174|DEVICE|Supraglottic Airway Device|
224235081|NCT04322071|OTHER|Interview|Qualitative interviews only
224235082|NCT05796609|OTHER|Driving under the influence of alcohol|"Participants will drive in three different states (sober, drunk above and below the legal limit) on a designated circuit with a real car on a test track accompanied by a driving instructor. After the initial sober driving session, participants are administered pre-mixed alcoholic beverages (e.g., vodka orange). Participants are expected to achieve a target breath alcohol concentration of 0.35 mg/l (legal limit in Switzerland is 0.25 mg/l breath alcohol concentration) before the second driving session starts. Finally, the third driving session starts when the participants' breath alcohol concentration drops to 0.15 mg/l.~Participants will be blinded to their alcohol levels during the study.~Measurements: Heart rate, respiration rate, blood oxygen saturation, skin conductance, skin temperature, accelerometer, eye movement, radar, facial expression, audio recording, vehicle data, in-cabin gas concentration"
224235083|NCT05796609|OTHER|Driving under the influence of a placebo|"Participants will drive three times at the same intervals as the treatment group on a designated circuit with a real car on a test track accompanied by a driving instructor. After the initial driving session, participants receive placebo beverages (e.g., orange juice with vodka flavor).~Participants are fully blinded.~Measurements: Heart rate, respiration rate, blood oxygen saturation, skin conductance, skin temperature, accelerometer, eye movement, radar, facial expression, audio recording, vehicle data, in-cabin gas concentration"
224235084|NCT03769480|OTHER|Muscle strength evaluation and Respiratory function Tests|Muscle strength evaluation and Respiratory function Tests
224235085|NCT04915807|DRUG|Ramucirumab and paclitaxel|Ramucirumab/paclitaxel as a second-line chemotherapy after May 1, 2018, when health insurance coverage for the combination therapy started
224235086|NCT04915807|DRUG|Taxane, irinotecan, or fluoropyrimidine-based single or combined chemotherapy|Taxane, irinotecan , or fluoropyrimidine-based single or combined chemotherapy as a second-line therapy
224235087|NCT03501680|DRUG|Insulin|"Group A: intensive insulin (glycemic control 4.4-6.1mmol/L), Group B: standard insulin (glycemic control 7.8-10.0 mmol/L), and Group C: plasmapheresis.~Insulin was injected by insulin pump."
224235088|NCT03501680|DEVICE|plasmapheresis|Triglyceridemia should be less than 5.65 mmol/l.
223650220|NCT00575731|BEHAVIORAL|Weight management strategies|
224235089|NCT01575054|BIOLOGICAL|botulinum toxin Type A|Double-Blind Study Phase (12 weeks): On Day 1, botulinum toxin Type A 300 U will be given by intramuscular injections into specified muscles of the lower limb, and an optional dose of 100 U may be injected into additional lower limb muscles. Open Label Study Phase: Up to 3 treatments with botulinum toxin Type A up to 400 U will be given by intramuscular injections to the lower limb approximately every 12 weeks over a 42 week period.
224235090|NCT01575054|DRUG|Normal Saline|Double-Blind Study Phase (12 weeks): On Day 1, normal saline (placebo) will be given by intramuscular injections into specified muscles of the lower limb, and optional injections may be administered into additional lower limb muscles.
224235091|NCT03481309|DEVICE|anodal tDCS|The participant will receive anodal tDCS with 2 mA for 10 minutes on the left motor cortex.
223650221|NCT00000288|DRUG|Cotinine fumarate|
223766897|NCT07086534|DEVICE|GeminiOne Transcatheter Edge-to-Edge Repair (TEER) System|"The GeminiOne TEER System consists of a TEER clip implant, transcatheter delivery system and a guide sheath.~The clip is made of cobalt-chromium-nickel alloy with a nickel-titanium alloy gripper, covered with a braided mesh of polyethylene terephthalate (PET) materials."
223766898|NCT06864624|DRUG|Sunvozertinib|Neoadjuvant stage: 300mg for 12 weeks Adjuvant stage: 300mg for first 4 weeks, then 150mg for up to 2 years
223766899|NCT07086391|DEVICE|Polymyxin B Sulfate 25mg Jet Nebulization / Vibrating Mesh Nebulization|"* Group A: 25mg polymyxin B sulfate dissolved in 5ml sterile water, administered via jet nebulizer under mechanical ventilation.~* Group B: 25mg polymyxin B sulfate dissolved in 5ml sterile water, administered via vibrating mesh nebulizer under mechanical ventilation."
224235092|NCT03481309|DEVICE|cathodal tDCS|The participant will receive cathodal tDCS with -2 mA for 10 minutes on the left motor cortex.
223650222|NCT05577117|DRUG|Dexmedetomidine|drugs are injected with induction of general anesthesia
223650223|NCT03613519|BEHAVIORAL|SHUTi|A woman assigned to SHUTi receives access to an online program that includes 6 interactive sessions that are designed to be reviewed over a period of about 8 weeks. The online sessions include videos and written material that give information about factors that affect sleep, changes that might help sleep patterns, and how to make those changes. Each session takes about 45 to 60 minutes to complete. During and between sessions, the participant fills out sleep diaries to gather information about daily sleep patterns. At 3 different times, the woman is asked to fill out questionnaires about her sleep and health as well as sleep diaries. Time 1 is just before starting the first session of the SHUTi program. Time 2 is about 9 weeks later and Time 3 is about six months after that. The questionnaires will be used to assess the effect of the online program on the participant's sleep and health.
224235093|NCT03481309|DEVICE|sham tDCS|The participant will receive sham tDCS with 2 mA for 40 seconds on the left motor cortex which mimics the skin sensations as active tDCS interventions.
223650224|NCT03613519|BEHAVIORAL|modified SHUTi (i.e., SHUTi-BWHS)|A woman assigned to modified SHUTi (i.e., to SHUTi-BWHS) receives access to an online program that includes 6 interactive sessions that are designed to be reviewed over a period of about 8 weeks. The online sessions include videos and written material that give information about factors that affect sleep, changes that might help sleep patterns, and how to make those changes. Each session takes about 45 to 60 minutes to complete. During and between sessions, the participant fills out sleep diaries to gather information about daily sleep patterns. At 3 different times, the woman is asked to fill out questionnaires about her sleep and health as well as sleep diaries. Time 1 is just before starting the first session of the modified SHUTi program. Time 2 is about 9 weeks later and Time 3 is about six months after that. The questionnaires will be used to assess the effect of the online program on the participant's sleep and health.
223650225|NCT03613519|BEHAVIORAL|Patient education|A woman assigned to patient education receives access to a website that provides detailed information on habits and environments that may help or hinder sleep. The site can be visited as often as desired. At 3 different times, the woman is asked to fill out questionnaires about her sleep and health, as well as sleep diaries to gather information about her daily sleep pattern. Time 1 is just before first logging into the sleep information website. Time 2 is about 9 weeks later and Time 3 is six months after that. The questionnaires will be used to assess the effect of the sleep information program on the participant's sleep and health.
223650226|NCT02615899|OTHER|Matched: Targeted (specific) balance exercise interventions|
223650227|NCT02615899|OTHER|Mismatched: Untargeted (non-specific) balance exercise interventions|
223650228|NCT05173753|OTHER|Novel self-adhesive hybrid composite(Surefil one)|Surefil one, is a recent introduced esthetic dental restoration for treatment of carious teeth.
224235094|NCT03309956|DEVICE|Holter Monitor|A Holter monitor is a battery-operated portable device that measures and records your heart's electrical activity (ECG) continuously. Patients in this study will wear the monitor for 48 hours.
224235095|NCT03309956|DEVICE|Zio Patch|The Zio Patch is a small, adhesive, water-resistant single lead electrocardiographic monitoring device. Patients in this study will wear the patch for 48 hours.
224235096|NCT05013671|OTHER|repositioning maneuvers|The calcium crystals floating in the endolymphatic fluid will put back in place by putting the patient in several sitting and lying positions during specific repositioning maneuvers. During these maneuvers the calcium crystals will float from the semicircular canals back into the utriculus, after which the dizziness symptoms should disappear
224235097|NCT05013671|OTHER|balance|compare the balance of residents with BPPV with residents without BPPV
224235098|NCT01566409|DRUG|Polyethylene glycol 3350|Powder for solution. Each sachet contains 13.125 g of macrogol 3350. Disimpaction dosage consists of 1,5 g/kg, maintenance treatment are adjusted according til the Bristol stool chart. The drug can be taken at anytime of the day and can also be divided. Treatment duration up to ½ year.
224235099|NCT01566409|OTHER|Placebo|Placebo will be manufactured and packaged as a powder to make it identical to the bags with the PEG 3350. The powder will comprise of a non-active substance, like a mild rehydration solution, which is a composition consisting of salt and sugar.
224235100|NCT04516148|DRUG|Cefazolin|Dosing per hospital policy
223650229|NCT06400043|OTHER|Cognitive dual-task|Participants will be asked to walk at comfortable walking speed while playing an additional cognitive task, namely the Stroop Color and Word Test.
223650230|NCT06400043|OTHER|Motor dual-task|Participants will be asked to walk at comfortable walking speed while playing an additional motor task, namely a game that requires arm swing to hit the targets.
224235101|NCT04516148|DRUG|Clindamycin|Dosing per hospital policy
224235102|NCT03951948|OTHER|retrospective analysis of surgical performance, clinical and radiologic outcome|retrospective analysis of surgical performance, clinical and radiologic outcome
224320456|NCT04642404|DRUG|Epidiolex 100 mg/mL Oral Solution|Cannabidiol (CBD): is the primary non-psychoactive and non-addictive compound in cannabis, has already shown potential in treating pain such as arthritis, neuropathic, cancer and chronic pain
224320457|NCT04642404|DRUG|Placebo|Placebo drug will be a solution with the same taste, texture and color as the drug.
224320458|NCT00785148|DRUG|Dermacyd PH_DETINLYN Sweet Flower (Lactic Acid)|
223650231|NCT05918913|DRUG|Revumenib|Revumenib administered orally every 12 hours.
223650232|NCT05244252|DRUG|dexmeditomidine and bupivacaine|Transversus abdominis plane block will be given bilaterally
223650233|NCT05244252|DRUG|Bupivacaine|bupivacaine
223650234|NCT06105411|DIAGNOSTIC_TEST|68Ga-labelled TAFC PET/CT scan|68Ga-labelled TAFC PET/CT scan (whole body)
223650235|NCT03131609|OTHER|Container|Ambulatory patients in the Emergency Department who have a urine culture ordered by the physician receive one of four urine collection/hygiene options.
223650236|NCT03131609|OTHER|Silver Impregnated Wipe|Ambulatory patients in the Emergency Department who have a urine culture ordered by the physician receive one of four urine collection/hygiene options.
223650237|NCT03131609|OTHER|Funnel|Ambulatory patients in the Emergency Department who have a urine culture ordered by the physician receive one of four urine collection/hygiene options.
223650238|NCT03131609|OTHER|Castile-soap wipe|Ambulatory patients in the Emergency Department who have a urine culture ordered by the physician receive one of four urine collection/hygiene options.
223650239|NCT02185482|BEHAVIORAL|Physician Supported Care|
224320459|NCT06006429|OTHER|Numerical dental impression by intraoral scanner|Intervention consists in an 3D intra oral representation of the oral cavity
224320460|NCT00166647|PROCEDURE|Blood Sampling|
224320461|NCT05507736|OTHER|Acupuncture|13 Indwelling, sterile and disposable needles (SEIRIN NEW PYONEX® from 0.9 mm in length and 0.22 mm in diameter) on day 1 and 5 of the second cycle of irinotecan leaving them inserted for 4 days.
223650240|NCT02185482|OTHER|Usual care|
224320462|NCT04196647|OTHER|Home titration|Patients have their initial dosage titration of duodopa done in their own home, supported by one visit from nursing staff, and one video consultation a day
224320463|NCT05610423|OTHER|no intervention|No intervention. Observational study only
224320464|NCT04940637|DRUG|niraparib and dostarlimab|niraparib 300 mg/die and dostarlimab 500 mg day 1 Q3 weeks for the first 4 cycles followed by 1000 mg day 1 Q6 weeks
223650241|NCT04798404|OTHER|Multimodal exercise intervention|The intervention conducted was a progressive multicomponent training protocol. The training consisted on 2 collective sessions of 1h per week, during 10 weeks. Sessions involved functional exercises, muscular reinforcement performed at body-weight or with small materials (elastic bands or dumbbells), balance, and adapted sport and physical activities. Progression was based on an increase in workload (or in muscle strains). The workload was considered as the interaction of intensity and volume of exercise (set x repetitions). Intensity was based on effort tolerance, modulate by contraction regimen, velocity and load (elastic bands stiffness). Participants were encouraged to reproduce exercises at home when they were performed easily in supervised collective sessions.
223650242|NCT06370429|OTHER|Progressive Relaxation Exercises, randomized pretest-posttest|experimental and control ,a randomized pretest-posttest study to examine
223650243|NCT02394587|BEHAVIORAL|Mindfulness-based Stress Reduction|A non-pharmacological approach to pain management.
223650244|NCT05255315|BEHAVIORAL|Comparative analysis comparing the morbidity of the antebrachial free flap to that of the temporal flap flap during exenteration as well as the rate of fitting patients with epithesis.|"A retrospective analysis will be performed by comparing the computerized data of patients reconstructed with a free antebrachial flap to that of patients reconstructed with a temporal muscle flap.~Another analysis, this time prospective, will be carried out by comparing the answers to the reconstruction specific questionnaires as well as the POSAS scores of patients reconstructed with either a free antebrachial flap or a temporalis muscle flap."
223650245|NCT02533453|BIOLOGICAL|Bydureon|exenatide once weekly
223650246|NCT01579929|DRUG|LDE225, Etoposide and Cisplatin|In a standard, 3 + 3 dose escalation phase, two successive cohorts of ES-SCLC patients will receive LDE225 with etoposide and cisplatin with a dose of 200 mg to be reserved for de-escalation until the MTD is determined. Cohorts of at least 3 evaluable patients will be treated at each dose level of LDE225 (400 mg daily and 800 mg daily). One additional dose (200 mg daily) will be reserved for de-escalation. A minimum of 6 evaluable patients must be treated at the dose declared to be the MTD. Each cohort will consist of newly enrolled patients. An estimated total of 6 to 12 patients may be necessary to establish the MTD. Actual accrual will depend on the dose levels tested and the DLT observed. Upon completion of a minimum of four and a maximum of six cycles of LDE225 with etoposide and cisplatin, patients in each cohort with at least stable disease will receive maintenance LDE225 until disease progression or unacceptable toxicity.
223650247|NCT00885534|DRUG|Cisplatin, Vinblastine, Temozolomide|"Patients will receive CVT chemotherapy which consists of the following:~Cisplatin 25 mg/m2 given intravenously on days 2-5 Vinblastine 1.5 mg/m2 given as an intravenous push on days 2-5 Temozolomide 150 mg/m2 given orally on days 1-5. In patients who cannot receive temozolomide, dacarbazine can be used instead. Dacarbazine will be given at 800 mg/m2 IV on day 1."
223650248|NCT05866523|BEHAVIORAL|Team Based Inpatient ARTAS|Infectious Disease Team will provide inpatient consultation. Social Work Team will provide 1 session of case management inpatient and up to 5 case management sessions within 90 days post discharge or until the client is linked to medical care as evidenced by visit with HIV specialist within 90 days post discharge.
224320465|NCT01632657|DRUG|Sumatriptan|Single subcutaneous injection sumatriptan 6mg (in 0.5ml) in recovery
223650249|NCT05866523|BEHAVIORAL|Standard of Care|Subject admitted and seen by routine inpatient medical service.
223650250|NCT05940090|DEVICE|SkinIO|The device is simply an application that photographs skin lesions and identifies lesions that may require further examination
223650251|NCT00602017|DRUG|Amlodipine|
223650252|NCT03008369|OTHER|Laboratory Biomarker Analysis|Correlative studies
223650253|NCT03008369|DRUG|Lenvatinib|Given PO
223650254|NCT03008369|OTHER|Quality-of-Life Assessment|Ancillary studies
223650255|NCT04071288|PROCEDURE|total laparoscopic hysterectomy and simultaneous incontinence surgery with benign causes|total laparoscopic hysterectomy and simultaneous incontinence surgery with benign causes; Burch colposuspension and mid-urethral sling operations for stress urinary incontinence
223650256|NCT03873142|BEHAVIORAL|Mindful Parenting|The mindful parenting intervention is an adaption for parents of the Mindfulness-Based Cognitive Therapy (MBCT) for depression (Kabat-Zinn, 1990), and the Mindful-Based Stress Reduction program (MBSR; Kabat-Zinn, 1990). The mindful parenting intervention will follow the manual developed by Bögels and Restifo (2014). The intervention consists of 9x3hour sessions. Eight of these sessions are run on consecutive weeks and the final session is run eight weeks after the eighth session. These groups involve group discussions around parenting, meditation exercises, and yoga, amongst other things.
224320466|NCT01632657|OTHER|Placebo|Single injection saline 0.5ml subcutaneously in recovery
224320467|NCT03687840|DIAGNOSTIC_TEST|gait analysis|Computerized gait analysis system was used to 3 times to evaluate the spatio-temporal parameters of gait.
224320468|NCT06581367|DRUG|Tailoring the course duration to the patient's needs.|Patients will be advised to visit the center as soon as they feel better and are afebrile for a clinical assessment including vital signs (temperature, blood pressure, respiratory rate, pulse, and oxygen saturation) and C-reactive protein rapid testing after completing two full days of antibiotic.
224320469|NCT06581367|DRUG|Complete a 7-day course|The antibiotic course must be completed (7 days at least).
223766900|NCT07086313|DRUG|EB-1020 (Centanafadine) low dose|low dose, capsule, oral, once daily, for 6 weeks
223766901|NCT07086313|DRUG|EB-1020 (Centanafadine) high dose|high dose, capsule, oral, once daily, for 6 weeks
223766902|NCT07086313|DRUG|Placebo|Placebo, capsule, oral, once daily, for 6 weeks
224320470|NCT04566055|DEVICE|AlloSure|Patients will receive donor-derived cell-free DNA testing for surveillance and for-cause.
224320471|NCT05902338|OTHER|Music|"L400 Over Ear Music Headset Glowing Cat Ear Headphones 7 branded headphones will be used for musical measurements (70-80 bpm music)."
224320472|NCT01668914|PROCEDURE|IM-SLNB|IM-SLNB is performed according to the pre-operative lymphoscintigraphy
224320473|NCT01668914|RADIATION|99mTc-SC|Two syringes of 0.25\~0.5 mCi 99mTc-SC in 0.2\~1.0 mL volume were injected intraparenchymally into 2 quadrants of breast, at the 6 and 12 o'clock positions.
224320474|NCT01668914|DEVICE|Histologic Examination|All IMSLNs were analyzed by histologic examination for future therapy planning.
224320475|NCT01668914|DEVICE|LSG|lymphoscintigraphy was performed 0.5\~1.0 hour before surgery
224320476|NCT01668914|DRUG|Methylthioninium|Four milliliters of methylthioninium was injected intraparenchymally around the primary tumor 10 min before surgery
223650257|NCT01578876|DEVICE|cardiac shock wave therapy(CSWT)|CSWT was performed with the MODULITH SLC SW therapy device (Storz Medical, Switzerland).Shock waves were triggered by the R-wave of the ECG when the instrument was activated. The shock wave energy was increased from an initial low level up 0.09 mJ/mm2 if the patient experienced no discomfort such as chest pain. Point-to-point combination treatment for the ischemic areas with 200 pulses delivered to each point was given.
223650258|NCT00089869|DRUG|olanzapine|
223650259|NCT00089869|DRUG|atomoxetine|
223650260|NCT00089869|DRUG|placebo|
223650261|NCT00704236|DRUG|Coptis Chinensis, Astragalus mambranesceus, Lonicera Japonica (Traditional Chinese Treatment)|50 mg of Coptis Chinensis, 30 mg of Astragalus mambranesceus and 120 mg of Lonicera Japonica
223650262|NCT00704236|DRUG|Placebo|
224235103|NCT05777213|BIOLOGICAL|Secretome|The interventions given in this study were Conditioned Medium Wharton's Jelly-derived mesenchymal stem cells (CM-WJMSCs) as much as 0.1cc / 1cm intracutaneously with a flexpen device in the wound area every 2 weeks. The variables in this study were divided into two, namely the independent variable was the use of Conditioned Medium Wharton's Jelly-derived mesenchymal stem cells (CM-WJMSCs) were administered intracutaneously, and the dependent variables were wound healing and side effects caused by the interventions given. Wound healing or repair in this study was assessed from several variables, namely the presence of granulation tissue growth, reduced edema, reduced erythema and improvement in wound size both in terms of length, width, and area measured by using a standard ruler and digital photo.
224235104|NCT00721058|OTHER|CT-scan|A pre-operative CT-scan will be made
224320477|NCT05154838|PROCEDURE|Drainage and packing of pilonidal abscess|Patients will be treated as per standard care, their wound drained, cleaned and packed. Microbiology swab samples will be obtained.
223650263|NCT02064777|DRUG|Tacrolimus|
223650264|NCT04292899|DRUG|Remdesivir|Administered as an intravenous infusion
224320478|NCT00604682|DRUG|CC10004|2 X 10 mg caps taken once daily for a daily dose of 20 mg. Must be taken upon awakening and fasted
224320479|NCT05578599|DEVICE|Swiftsure CCS device|The Swiftsure CSS device will be used twice per patient in addition to standard oral health care procedures among intubated adult patients undergoing mechanical ventilation in the ICU.
223650265|NCT04292899|DRUG|Standard of Care|Standard of Care Treatment for COVID-19 Infection
223650266|NCT03016052|BEHAVIORAL|ABMT|Participants will be trained with a dot-probe task including angry-neutral faces. The task will be adapted for the oddball paradigm, such that in 80% of trials the probe will appear in place of the neutral face, and in 20% of trials in place of the angry face.
223650267|NCT01947140|DRUG|Pralatrexate|"Phase I - Schedule A: Intravenous drug given on days 1 and 8 of each 21 day cycle Schedule B: Intravenous drug given on days 1 and 15 of each 28 day cycle Dose escalation from 10 mg/m2 to 25 mg/m2~Phase II - 25 mg/m2 will be given intravenously once weekly on days 1 and 15 on a 28 day cycle."
223650268|NCT01947140|DRUG|Romidepsin|"Phase I - Schedule A: Intravenous drug given on days 1 and 8 of each 21 day cycle Schedule B: Intravenous drug given on days 1 and 15 of each 28 day cycle Dose escalation from 12 mg/m2 to 14 mg/m2.~Phase II - 12 mg/m2 will be given intravenously once weekly on days 1 and 15 on a 28 day cycle."
223650269|NCT05053802|COMBINATION_PRODUCT|Microwave ablation plus Camrelizumab|Tumor received treatment of microwave ablation and received no more than 16 cycles of Camrelizumab
223650270|NCT05053802|DEVICE|Microwave ablation|Tumor received treatment of microwave ablation
223650271|NCT00536419|DRUG|Methylphenidate|Methylphenidate SODAS 0.3 mg/kg/day (day 1); 0.7 mg/kg/day (day 2); 1.0 mg/kg/day (days 3 and 4)
223650272|NCT00536419|OTHER|Placebo|Placebo, daily dose, 4 days, oral administration
223650273|NCT05574413|OTHER|Moderate intensity continuous exercise|Participants will perform an acute bout of continuous cycling at 70% of the power output at lactate threshold until an energy expenditure of 350 kcal is achieved. Blood samples will be obtained immediately before and immediately, 30, and 90 minutes after exercise.
223650274|NCT05574413|OTHER|High intensity continuous exercise|Participants will perform an acute bout of continuous cycling at 10% of the difference between lactate threshold and VO2peak until an energy expenditure of 350 kcal is achieved. Blood samples will be obtained immediately before and immediately, 30, and 90 minutes after exercise.
224235105|NCT04935775|OTHER|Untrained Touch|Subject's feet, ankles, and lower legs are touched and rubbed during a bone marrow biopsy procedure.
224235106|NCT04666766|DEVICE|Microwave scanning of the head|A scan of the head will be performed with a microwave device to ascertain the likelihood of intracranial hemorrhage.
224235107|NCT02946099|PROCEDURE|Reciproc files in reciprocating motion|An endodontic file that works through a reciprocating motion
223650275|NCT05574413|OTHER|High intensity interval exercise|Participants will perform an acute bout of interval cycling at at 10% of the difference between lactate threshold and VO2peak until an energy expenditure of 350 kcal is achieved. Blood samples will be obtained immediately before and immediately, 30, and 90 minutes after exercise.
223650276|NCT05574413|OTHER|Resting (no exercise) control|Participants will remain in a rested state (i.e., no exercise) for the entire session. Blood samples will be obtained at the same time-points as the exercise sessions.
223650277|NCT02189733|BIOLOGICAL|Caplacizumab|Comparison of reconstituted lyophilised formulation versus liquid formulation of caplacizumab
223650278|NCT06140810|OTHER|Lung Recruitment|Lung Recruitment will be performed during general anesthesia to reduce areas of atelectasis
223650279|NCT04674761|DRUG|Odevixibat|Odevixibat is a small molecule and selective inhibitor of IBAT.
223650280|NCT04674761|DRUG|Placebo|Placebo identical in appearance to experimental drug (odevixibat).
223650281|NCT00136097|DEVICE|Placement of a silver impregnated central venous catheter|
223650282|NCT02469870|BEHAVIORAL|Autism Parent Trainer (APT)|Experimental condition
223650283|NCT02469870|BEHAVIORAL|Teaching Routines (Control)|Content comparison group.
223650284|NCT01974635|DEVICE|AMES Therapy|During the therapy session, the AMES device rotates the hand into flexion and extension, while the patient assists with this motion, as possible. At the same time, the AMES device provides sensory stimulation by vibrating the tendons of muscles stretched by the movement. The vibratory stimulus switches from one side of the limb to the other when the rotation reverses direction so that the sensory stimulation remains functionally related to the movement. The subject will receive visual bio-feedback of their contribution to the motor movement.
224235108|NCT02946099|PROCEDURE|ProTaper Next files in continuous rotary motion|An endodontic file that works through a continuous rotary motion
224235109|NCT04897698|DIETARY_SUPPLEMENT|LB001|Probiotics
224235110|NCT02768298|DRUG|LCZ696|LCZ696 100 mg bid for 2 weeks followed by LCZ696 200 mg bid for 10 weeks. Treatment was administered as oral tablets.
224235111|NCT02768298|DRUG|Enalapril|"Enalapril 5 mg bid for 2 weeks followed by enalapril 10 mg bid for 10 weeks. Treatment was administered as oral tablets.~Patients who prior Screening were at a stable daily dose of enalapril above 10 mg per day (or corresponding doses of other ACEI/ARB) started the study at a dose of enalapril 10 mg bid."
223650285|NCT04972617|DIAGNOSTIC_TEST|albumin function analysis (ABIC)|After centrifugation (10 minutes at 4000 rpm), the plasma is aliquoted and stored at minus 80° C until further analysis. The free as well as the total furosemide concentration is determined by HPLC. In addition to the characterisation of the albumin function by means of the ABiC, these samples can also be used for the determination of the albumin concentration (prerequisite for the determination of the ABiC) and free furosemide concentration as well as for the determination of further parameters relevant for the albumin function.
223650286|NCT01209325|BIOLOGICAL|quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine|
223650287|NCT01209325|OTHER|laboratory biomarker analysis|
223650288|NCT02454842|DRUG|TH-4000 (Tarloxotinib)|TH-4000 (Tarloxotinib) is a hypoxia-activated prodrug
223650289|NCT03401814|OTHER|Magnetic Resonance Elastography|rapidly developing technology for quantitatively assessing the mechanical properties of tissue, using externally applied mechanical waves
223650290|NCT04061330|DRUG|Ketamine|Initial bolus of ketamine 0.3 mg/kg IV (maximum 30 mg) followed by ketamine infusion of 0.25mg/kg/hr (maximum 25mg/kg/hr) for 6 hours or until patient leaves the emergency department (ED),whichever occurs first.
223650291|NCT04061330|DRUG|Morphine|Bolus doses of morphine 0.1 mg/kg (maximum 8 mg) intravenously every 2 hours for 6 hours or until patient leaves the ED, whichever occurs first.
223650292|NCT01523041|DRUG|biphasic insulin aspart 70|A single dose administrated subcutaneously (s.c., under the skin)
223650293|NCT01523041|DRUG|biphasic insulin aspart 70|A single dose administrated subcutaneously (s.c., under the skin)
223650294|NCT01523041|DRUG|biphasic insulin aspart 50|A single dose administrated subcutaneously (s.c., under the skin)
223650295|NCT04466670|DRUG|acetylsalicylic acid|acetylsalicylic acid (ASA) 100 mg daily PO up to 14 days OR arterial oxygen saturation greater than or equal to 92% on room air OR PaO2 to FiO2 ratio greater than 200 for 2 consecutive days, whichever is first.
223650296|NCT04466670|DRUG|Unfractionated heparin nebulized|unfractionated heparin - 25,000 U/ 5 ml nebulized inhalation every 6 hours up to 14 days OR arterial oxygen saturation greater than or equal to 92% on room air OR PaO2 to FiO2 ratio greater than 200 for 2 consecutive days, whichever is first.
223650297|NCT01638871|BEHAVIORAL|PainCOACH|The 8-week Internet-based pain coping skills intervention program includes 8 sessions. Each session takes 30-45 minutes to complete and includes text, illustrations, photos, animations, audio narration, interactivity, and delivery of personalized feedback. Users will be expected to complete 1 session per week.
223650298|NCT00396253|DRUG|Tenecteplase|2 mL (2 mg) of reconstituted lyophilized tenecteplase instilled into each lumen of the HD catheter.
223650299|NCT01280708|OTHER|Capture data|Capture and standardization of data of patients aged over 18 years received a kidney transplant or a simultaneous pancreas-kidney transplant from data sources will be performed by clinical research associates.The quality of data will be validated by cross annual audits. The statistical analysis will be made on a case by case according to clinical objectives.
223650300|NCT02282514|BIOLOGICAL|Autologous Hematopoietic Stem Cells|The stem cells will be collected from patient's blood during mobilization. Then the patient will be given high dose chemotherapy in accordance with approved recommendations for use in conditioning regimens for stem cell transplant in autoimmune diseases. Autologous Hematopoietic Stem Cell Transplantation is to re-infuse immature cells that can re-establish blood production and patient's immune system.
223650301|NCT02282514|DRUG|Cyclophosphamide|An alkylating agent which causes prevention of cell division by forming adducts with DNA
223650302|NCT02282514|DRUG|Mesna|Medication used to decrease the risk of hemorrhagic cystitis prophylaxis
223650303|NCT02282514|DRUG|rATG|A predominantly lymphocyte-specific immunosuppressive agent which contains antibodies specific to the antigens commonly found on the surface of T cells
223650304|NCT02282514|DRUG|Methylprednisolone|Steroid
224235112|NCT02768298|DRUG|Placebo matching enalapril|Patients randomized to LCZ696 arm also received placebo matching enalapril (enalapril 0 mg tablets) to ensure the blinding during the entire course of the study.
223650305|NCT02282514|DRUG|G-CSF|Granulocyte-colony stimulating factor; a glycoprotein that stimulates the bone marrow to produce granulocytes and stem cells and release them into the bloodstream
223650306|NCT02282514|DRUG|Rituxan|A chimeric monoclonal antibody used in the treatment of B cell non-Hodgkin's lymphoma, B cell leukemia, and some autoimmune disorders
223650307|NCT01093235|BIOLOGICAL|bevacizumab|
223650308|NCT01093235|DRUG|cyclophosphamide|
223650309|NCT01093235|DRUG|docetaxel|
223650310|NCT01093235|DRUG|epirubicin hydrochloride|
223650311|NCT01093235|DRUG|fluorouracil|
223650312|NCT01093235|PROCEDURE|assessment of therapy complications|
223650313|NCT01093235|PROCEDURE|neoadjuvant therapy|
223650314|NCT01093235|PROCEDURE|quality-of-life assessment|
223650315|NCT01093235|PROCEDURE|therapeutic conventional surgery|
223650316|NCT01594216|DRUG|Ruxolitinib|
223650317|NCT01594216|DRUG|Exemestane|
223650318|NCT05340478|BEHAVIORAL|Adjunctive Family - Cognitive Behavioral Therapy|AF-CBT provides family members psychoeducation on anxiety and teaches skills to facilitate the recovery of Veterans in the process of completing anxiety treatment.
223650319|NCT02149901|DRUG|Pseudoephedrine + 480 ml water|30 mg pseudoephedrine to be given with a pressor dose (480 ml) of drinking water
223650320|NCT02149901|DRUG|Pseudoephedrine + 50 ml water|Pseudoephedrine given with a non-pressor (50 ml) dose of drinking water
223650321|NCT02149901|OTHER|Placebo + 480 ml water (optional)|placebo PO with a pressor (480 ml) dose of drinking water
223650322|NCT02149901|OTHER|Placebo + 50 ml water (optional)|placebo PO with a non-pressor (50 ml) dose of drinking water
223650323|NCT02550405|BEHAVIORAL|Craving behavioral intervention|The CBI was given once a week for 6 weeks, conducted by four therapists. A pair of therapists was randomly assigned to a CBI+ group. Each session included 5 parts in 2.5-3 hours: warming-up exercise, discussion about the homework from the last session, main structured activity, brief summary, and the homework assignment. There were 6 sessions with each focused on a topic: recognize craving and its relationship with IGD; reduce craving through ameliorating the salience of cues and irrational beliefs, withdrawal symptoms and other negative affects; enhance self-monitoring and control for craving through time management training; relieve fulﬁllment of psychological needs through Internet use and attenuate the relation between craving and gaming behaviors through coping skill training
223650324|NCT02575586|DEVICE|Intervention-Dry Needling|"Deep Dry Needling into the site of the latent medial Myofascial Trigger Point of the soleus muscle.~1 session in soleus muscle moving the needle up and down ten times."
223650325|NCT02575586|DEVICE|Control-Dry Needling|"Deep Dry Needling distal to Myofascial Trigger Point but into the same taut band.~1 session in soleus muscle moving the needle up and down ten times."
223650326|NCT02506244|DEVICE|iRhythm ZIO XT Patch|Single-lead ECG monitoring via a wearable patch
223650327|NCT02506244|DEVICE|Wristband by Amiigo|Determines pulse rate using photoplethysmography.
223650328|NCT02441595|BEHAVIORAL|MBCP|Eight weekly sessions 2,5 h and homework 30 min/day. Practicing various mindfulness meditations coupled with practical skills and theory of birthing and parenting.
223650329|NCT02441595|BEHAVIORAL|Psychoprophylaxis|Three sessions 3h each, and practices to do at home. Practical skills of relaxation and breathing techniques for labor as well as knowledge of birthing and parenting.
223650330|NCT00314795|DRUG|Peginesatide|Peginesatide injection
223650331|NCT00492258|DRUG|sorafenib tosylate|
223766903|NCT07086690|DRUG|Group (1): Patients will receive nebulized ketamine (2 mg/kg)|"Drugs will be prepared in 3 mL of saline 0.9% before administration by a standard hospital jet nebulizer via a mouthpiece, with a continuous flow of oxygen at 6 L/min for 10 to 15 minutes. Treatment will be stopped when the nebulizer begin to sputter. All solutions will be prepared in identical syringes with matching random codes by an independent investigator not involved in the observation or the administration of the anesthesia.~\- All patients will be admitted on the day of the surgery and will be instructed to fast 6 hours before surgery for older patients, as for breast fed patients, they will be instructed for 4 hours for breast feeding and for formula fed patients they will be instructed to fast for 6 hours as recommended by the American society of anesthesiologists. Preoperative assessment will be done before surgery by one of the members of the team who will make sure that the inclusion and exclusion criteria of the patients are considered, and baseline vital signs willbe rec"
223766904|NCT07086690|DRUG|Group (2): Patients will receive nebulized combination of dexmedetomidine and ketamine (1 μg/kg + 1 mg/kg)|"Drugs will be prepared in 3 mL of saline 0.9% before administration by a standard hospital jet nebulizer via a mouthpiece, with a continuous flow of oxygen at 6 L/min for 10 to 15 minutes. Treatment will be stopped when the nebulizer begin to sputter. All solutions will be prepared in identical syringes with matching random codes by an independent investigator not involved in the observation or the administration of the anesthesia.~\- All patients will be admitted on the day of the surgery and will be instructed to fast 6 hours before surgery for older patients, as for breast fed patients, they will be instructed for 4 hours for breast feeding and for formula fed patients they will be instructed to fast for 6 hours as recommended by the American society of anesthesiologists. Preoperative assessment will be done before surgery by one of the members of the team who will make sure that the inclusion and exclusion criteria of the patients are considered, and baseline vital signs will be re"
224235113|NCT02768298|DRUG|Placebo matching LCZ696|Patients randomized to enalapril arm also received placebo matching LCZ696 (LCZ696 0 mg tablets) to ensure the blinding during the entire course of the study.
224235114|NCT04634409|DRUG|Bamlanivimab|Administered IV.
224235115|NCT04634409|DRUG|Etesevimab|Administered IV.
224235116|NCT04634409|DRUG|Placebo|Administered IV.
224235117|NCT04634409|DRUG|VIR-7831|Administered IV.
224235118|NCT04634409|DRUG|Bebtelovimab|Administered IV.
224235119|NCT00395707|DRUG|Lucentis|0.3mg/0.05 ml or 0.5mg/0.05 ml
223650332|NCT00492258|PROCEDURE|adjuvant therapy|
224235120|NCT00395707|DRUG|Ranibizumab|0.3mg/0.05 ml or 0.5mg/0.05 ml
224235121|NCT00395707|DRUG|Ranibizumab (Lucentis)|0.3mg/0.05 ml intravitreally
224235122|NCT00395707|DRUG|Ranibizumab (Lucentis)|0.5mg/0.05 ml
224235123|NCT00570271|OTHER|Placebo with BP dec (written form)|Placebo administration with a blood pressure decrease suggestion. Information provided to subjects in written form.
223650333|NCT01075490|DRUG|clonidine|addition of 1 µg/kg of clonidine to bupivacaine 1 mg/kg as spinal anesthesia
223650334|NCT01075490|DRUG|clonidine|equivalent volume of saline added to bupivacaine, 1 mg/kg as spinal anesthesia
223650335|NCT04883827|OTHER|Blood collection|20-40 mL of blood to extract cell free DNA
223650336|NCT04883827|OTHER|Urine collection|up to 15 mL of urine to extract cell free DNA
223650337|NCT01698398|DEVICE|Incremental pump speed of CF-LVAD.|Peak oxygen consumption with fixed versus incremental pump speed.
223650338|NCT04005131|DEVICE|Robot and tDCS on-line|Combined transcranial direct current stimulation(tDCS) on-line and upper extremity rehabilitation robot for 5 times a week for 10 weeks
223650339|NCT04005131|DEVICE|Robot and tDCS on-line after sham tDCS|Combined sham tDCS and upper extremity rehabilitation robot for 5 times a week for 5 weeks, followed by combined tDCS on-line and upper extremity rehabilitation robot for 5 times a week for 5 weeks
223650340|NCT05922917|DEVICE|pulsed-field ablation|application of pulsed-field energy for pulmonary vein isolation and linear ablations
223650341|NCT05285046|OTHER|No intervention|No intervention
223650342|NCT03523988|DRUG|Acetaminophen|Acetaminophen gel capsule
223650343|NCT03523988|DRUG|Ibuprofen|Ibuprofen gel capsule
223650344|NCT04961684|DEVICE|Solver Pen|One application per day for 3 months
224235124|NCT00570271|OTHER|Placebo with BP dec (doctor)|Placebo administration with a blood pressure decrease suggestion. Information provided to subjects by doctor.
224235125|NCT00570271|OTHER|Placebo with BP inc (written)|Placebo administration with a blood pressure increase suggestion. Information provided to subjects in written form.
224235126|NCT00570271|OTHER|Placebo with BP inc (doctor)|Placebo administration with a blood pressure increase suggestion. Information provided to subjects by doctor.
224235127|NCT00570271|OTHER|Placebo info given (written)|Subject informed about receiving placebo. Information provided to subjects in written form.
224235128|NCT00570271|OTHER|Placebo info given (doc)|Subject informed about receiving placebo. Information provided to subjects by doctor.
224235129|NCT01693783|BIOLOGICAL|Ipilimumab|Given IV
223650345|NCT04961684|DRUG|Loceryl 5%|One application per week for 3 months
223650346|NCT02951000|PROCEDURE|platysma suture|
223766905|NCT07086690|DRUG|Patients will receive intramuscular ketamine (4 mg/kg, intramuscularly) 15 mins before starting the procedure.|"Drugs will be prepared in 3 mL of saline 0.9% before administration by a standard hospital jet nebulizer via a mouthpiece, with a continuous flow of oxygen at 6 L/min for 10 to 15 minutes. Treatment will be stopped when the nebulizer begin to sputter. All solutions will be prepared in identical syringes with matching random codes by an independent investigator not involved in the observation or the administration of the anesthesia.~\- All patients will be admitted on the day of the surgery and will be instructed to fast 6 hours before surgery for older patients, as for breast fed patients, they will be instructed for 4 hours for breast feeding and for formula fed patients they will be instructed to fast for 6 hours as recommended by the American society of anesthesiologists. Preoperative assessment will be done before surgery by one of the members of the team who will make sure that the inclusion and exclusion criteria of the patients are considered, and baseline vital signs will be re"
223766906|NCT06907381|BEHAVIORAL|Blood flow-restricted resistance exercise|Participants will engage in baseline measurement of blood pressure, strength of target muscle contractions, and level of support needed for functional task performance. They will then begin BFRE treatment supplemented by electrical stimulation, if needed, two times weekly. Each exercise session will include performance of four sets of 20 repetitions of target muscle contraction on each side of the body followed by functional task performance.
224235130|NCT01693783|OTHER|Laboratory Biomarker Analysis|Correlative studies
223766907|NCT07093489|BIOLOGICAL|LC16m8|LC16m8 vaccine will be offered to all individuals aged \>1 year and meet the inclusion criteria within the catchment population. This will be done in line with the DRC government's LC16m8 vaccine roll out plan.
224235131|NCT04267666|DEVICE|incentive spirometer|Patient had to produce a high inspiratory pressure. The ball serves as visible feedback of the inspiratory flow and indicates the obtained flow on a calibrated scale on the transparent cylinder of the spirometer. If the patient flows greater than 300 milliliters per second, the float ball in first chamber will rise. As patient flow increases to 600 milliliters per second the second ball float will rise. If the patient flow exceeds 900 milliliters per second all three will be suspended. Patient should encourage holding the balls up for a few seconds
224235132|NCT04267666|OTHER|Inspiratory muscle trainer device|The threshold trainer is a small plastic handheld device supplied by respironics. It includes a mouthpiece and a calibrated spring loaded valve. The valve controls a constant inspiratory pressure training load and the patient must generate the inspiratory pressure in order for the inspiratory valve to be opened and allow inhalation of air.
224235133|NCT02958215|DRUG|Phenylephrine|it will be given as a prophylaxis for prevention of hypotension after spinal anesthesia in pregnant patients undergoing cesarean section
224235134|NCT02958215|OTHER|Placebo|5 ml normal saline will be given before spinal anesthesia
223650347|NCT02951000|PROCEDURE|no platysma suture|
223650348|NCT06044077|BIOLOGICAL|23-valent pneumococcal polysaccharide vaccine|23-valent pneumococcal polysaccharide vaccine from Aimei Vacin BioPharm (Zhejiang) Co., Ltd.
223650349|NCT06044077|BIOLOGICAL|control pneumococcal polysaccharide vaccine|23-valent pneumococcal polysaccharide vaccine from Merck Sharp \& Dohme Corp
224235135|NCT03400306|DRUG|Veliparib, capsule|capsule; 50 mg or 100 mg
224235136|NCT03400306|DRUG|Veliparib, tablet|tablet; 400 mg
224235137|NCT03400306|DRUG|Carboplatin|Intravenous
224235138|NCT03400306|DRUG|Paclitaxel|Intravenous
224235139|NCT04059211|DIAGNOSTIC_TEST|Urinary dipstick|Sensitivity and specificity of urinary dipstick for proteinuria in emergency departments
224235140|NCT04689074|OTHER|Biological sample collection|Collection of faeces, urine, saliva, PBMC and blood for biobanking, to evaluate the proteomic, metascriptomic, metabolomic, metagenomic, and metagenetic profile, and to perform routine screening
224235141|NCT04689074|OTHER|Questionnaire|Anamnestic questionnaire, 3-day food questionnaire, Food Frequency Questionnaire
224235142|NCT04689074|OTHER|Medical examination|Blood pressure measurement, abdominal and thoracic physical examination
224235143|NCT00260780|BEHAVIORAL|The MISTERS Intervention for Post Jail Release Men|
224235144|NCT01729130|PROCEDURE|Adipose tissue biopsy|Adipose tissue biopsy is done at time of transplant surgery. There is a second needle biopsy done between 3-12 months post transplant surgery.
224235145|NCT04758936|DRUG|Clonidine|The doses administered (clonidine 1500mg diluted in NaCl0.9% solution of 50 ml) ranged from 0.01μg/kg/min to 0.03μg/kg/min.
224235146|NCT04758936|DRUG|Dexmedetomidine|The doses administered (dexmedetomidine 200mg diluted in NaCl0.9% 50ml) ranged from 0.4μg/kg/h and can be titrated up to 1.4μg/kg/h.
223650350|NCT03141827|DRUG|Insulin|Insulin 40 IU, nasal spray, single dose
223650351|NCT03141827|DRUG|Placebo|Placebo, nasal spray, single dose
223650352|NCT02926885|DEVICE|CONVENTIONAL LIVER RETRACTOR DEVICE|LIVER RETRACTION FOR THE EXPOSURE OF THE ESOPHAGOGASTRIC JUNCTION USING CONVENTIONAL RETRACTOR DEVICE
223650353|NCT02926885|DEVICE|FLEXIBLE LIVER RETRACTOR DEVICE|LIVER RETRACTION FOR THE EXPOSURE OF THE ESOPHAGOGASTRIC JUNCTION USING FLEXIBLE LIVER RETRACTOR DEVICE
223650354|NCT02926885|PROCEDURE|LAPAROSCOPIC ROUX-EN-Y GASTRIC BYPASS SURGERY|LAPAROSCOPIC ROUX-EN-Y GASTRIC BYPASS SURGERY
223650355|NCT00928239|PROCEDURE|laparoscopic sacropexy with mid vaginal attachment|"* supracervical hysterectomy for uterine prolapse~* exposure of the anterior longitudinal ligament of sacrum and recto-vaginal septum posterior~* dissection up to ventrolateral part of the levator ani muscle~* Anterior dissection of vesico-vaginal fascia up to the lower third of the vagina below the trigonum of bladder~* Two separate meshes, Gynemesh® (Johnson\&Johnson) a polypropylene mesh, for anterior and posterior compartment~* suturing of posterior mesh caudally to levator ani muscle and proximally 4cm from the apex of the vagina or cervical stump~* placement of anterior mesh underneath bladder and attachment to caudal part of the vagina and the apex~* suturing together anterior and posterior mesh are sutured together at level of vaginal apex and attachment to longitudinal sacral ligament at level of S2"
223650356|NCT00928239|PROCEDURE|laparoscopic sacropexy with caudal vaginal attachment|"* supracervical hysterectomy for uterine prolapse~* exposure of the anterior longitudinal ligament of sacrum and recto-vaginal septum posterior~* dissection up to ventrolateral part of the levator ani muscle~* Anterior dissection of vesico-vaginal fascia up to the lower third of the vagina below the trigonum of bladder~* Two separate meshes, Gynemesh® (Johnson\&Johnson) a polypropylene mesh, for anterior and posterior compartment~* suturing of posterior mesh caudally to the levator ani muscle and proximally at caudal part of the vagina or cervical stump~* placement of anterior mesh underneath bladder and attachment to caudal part of the vagina and the apex~* suturing together anterior and posterior mesh are sutured together at level of vaginal apex and attachment to longitudinal sacral ligament at level of S2"
223766908|NCT06908655|OTHER|MRI|The procedure to be investigated will be to perform a diffusion tensor sequence during the MRI indicated as part of the treatment. The diffusion tensor sequence takes 10 minutes to acquire, for a total examination time of 30 minutes instead of 20 minutes, including set-up.
224235147|NCT02346201|DRUG|Methylphenidate|Two 5mg methylphenidate over-encapsulated drug taken twice a day for 6 months (total of 20 mg methylphenidate per day), and psychosocial intervention
223650357|NCT00654550|DRUG|Nexagon™ or Nexagon™ vehicle|Dose-escalation design in which cohorts of 6 subjects will be studied sequentially.
223650358|NCT04818372|DRUG|CM313-Dose escalation|Subjects will receive a single dose of CM313 followed by a 3-week period for DLT observation. After that subjects will have 6 infusions at weekly intervals.
223650359|NCT04818372|DRUG|CM313|Subjects will have 8 infusions at weekly intervals, and then 8 infusions at bi-weekly intervals. After that CM313 will be given every 4 weeks until disease progression or unacceptable toxicity.
223766909|NCT06909045|OTHER|Adaptive DBS|The Medtronic Percept device will be activated with the aDBS functionality. Participant will receive adaptive DBS.
223650360|NCT04818372|DRUG|Dexamethasone|dexamethasone 40 mg/day at day 1,8,15,22 at 28 days cycle
223766910|NCT06909045|OTHER|Continue DBS|The Medtronic Percept device will be equipped with aDBS functionality (to maintain the blinding of the allocation), but this functionality will remain inactive. Participant will receive continue DBS.
223766911|NCT06903754|DRUG|With ISGLT2|Patients for whom we will prescribe ISGLT2
223766912|NCT06912165|DRUG|WD-890 tablet|Participants will receive WD-890 Dose 1 QD and placebo from Week 0 through Week 16. Participants will receive placebo to maintain the blinding of dose regimens.
223766913|NCT06912165|DRUG|WD-890 tablet|Participants will receive WD-890 Dose 2 QD and placebo from Week 0 through Week 16. Participants will receive placebo to maintain the blinding of dose regimens.
223650361|NCT04818372|DRUG|Lenalidomide|25 mg/day lenalidomide 21 of 28 days cycle
223650362|NCT04163211|PROCEDURE|Abdominal drain|A latex-free drain (size 20F)
223766914|NCT06912165|DRUG|WD-890 tablet|Participants will receive WD-890 Dose 3 QD and placebo from Week 0 through Week 16. Participants will receive placebo to maintain the blinding of dose regimens.
223766915|NCT06912165|DRUG|Placebo|Participants will receive placebo QD from Week 0 through Week 16.
223766916|NCT06904547|OTHER|No intervention administered|No intervention administered
223766917|NCT06904547|OTHER|Non Interventional Study|Non Interventional Study
223766918|NCT06909890|BEHAVIORAL|Chios mastic beverage|Participants of this intervention arm will be provided with a sparkling beverage enriched with the natural mastic aqueous extract (0.2%), a by-product of Chios mastic processing, and will be asked to consume it daily (3 bottles of 200 mL each) for 3 months. Participants will also be instructed to maintain their usual lifestyle practices and medical treatment stable.
223766919|NCT06909890|BEHAVIORAL|Placebo beverage|Participants of this intervention arm will be provided with a placebo sparkling beverage (same organoleptic characteristics with experimental beverage but no active ingredients) and will be asked to consume it daily (3 bottles of 200 mL each) for 3 months. Participants will also be instructed to maintain their usual lifestyle practices and medical treatment stable.
223766920|NCT06909877|DRUG|HH2853 Tablets|25mg, 100mg and 200 mg BID oral administration
223766921|NCT06185842|BEHAVIORAL|breathing exercise, walking exercise and vaccination counseling|"Participants will perform diaphragmatic breathing exercises and pursed lip breathing exercises two days a week for eight weeks.~Participants will be asked to walk for 20-30 minutes every day for eight weeks. Monitoring will be done weekly.~Participants will be counseled about infectious diseases, modes of transmission and the importance of vaccination, and will be advised to receive influenza and pneumococcal vaccines recommended for this age group.~The 5A model guide will be used regarding behavioral change towards physical activity and vaccination."
224235148|NCT02346201|DRUG|Placebo|Two over-encapsulated placebo taken twice a day for 6 months and psychosocial intervention
224235149|NCT00698100|BIOLOGICAL|human tyrosinase|Patients will receive a total of 6 vaccinations. Each vaccination is given via the intramuscular route. Sites of injection should have intact lymphatic drainage. The vaccinations will be administered at three week intervals. Groups of six patients will be randomized at each dose level to receive either three immunizations with mouse tyrosinase followed by three immunizations with human tyrosinase or three immunizations with human tyrosinase followed by three immunizations with mouse tyrosinase
224320480|NCT06181149|BEHAVIORAL|Delaying speech initiation|This intervention will examine the effects of misalignment between prediction and auditory feedback in participants. We will use transcranial magnetic stimulation to induce a temporal misalignment between prediction and auditory feedback while participants produce speech.
223650363|NCT05825378|DRUG|Dexamethasone 8mg+0.375% ropivacaine|Ultrasound-guided intercostal nerve block was performed on the surgical side, and 3 to 5ml of a mixture of 0.375% ropivacaine and 8 mg dexamethasone was injected at each point
223650364|NCT05825378|DRUG|0.375% ropivacaine|Ultrasound-guided intercostal nerve block was performed on the surgical side, and 3 to 5ml 0.375% ropivacaine was injected at each point
223650365|NCT05079308|DEVICE|Peripheral sealing device for surgical mask or filtering face piece|The individuals used a Peripheral Sealing Device on a surgical mask or a filtering face piece mask and were submitted to a qualitative fit test, regulated by the Occupational Security and Health Administration (USA).
223650366|NCT05079308|DEVICE|IIR Surgical mask with Filtering face piece|The individuals used a IIR surgical mask with a filtering face piece mask and were submitted to a qualitative fit test, regulated by the Occupational Security and Health Administration (USA).
223766922|NCT07096232|DIAGNOSTIC_TEST|Multi-Agent AI Diagnostic Workflow (AEYE)|This intervention consists of an orchestrated diagnostic workflow utilizing multiple specialized artificial intelligence (AI) agents to analyze patient data and ophthalmic imaging for the diagnosis of refractive errors and keratoconus. The workflow, named Automated Evaluation for Your Eye (AEYE), integrates various AI modules designed for data extraction, image interpretation, and decision support. Each patient's clinical information, corneal topography, tomography, and other relevant imaging are processed sequentially through these AI agents, with results synthesized into a diagnostic recommendation. The system operates independently of clinician input, and outputs are blinded prior to comparison with consultant ophthalmologist assessments. The intervention is intended to assess diagnostic accuracy, efficiency, and concordance with expert clinical decision-making.
223766923|NCT06181786|DRUG|NAV-240|Intravenous administration of NAV-240
223766924|NCT06181786|DRUG|Placebo|Intravenous administration of matching placebo for NAV-240
223766925|NCT05909761|DRUG|UPLIZNA|Enrolled female participants with NMOSD who were exposed to UPLIZNA during pregnancy will be assessed. No study drug will be administered.
224235150|NCT00698100|BIOLOGICAL|mouse tyrosinase|Patients will receive a total of 6 vaccinations. Each vaccination is given via the intramuscular route. Sites of injection should have intact lymphatic drainage. The vaccinations will be administered at three week intervals. Groups of six patients will be randomized at each dose level to receive either three immunizations with mouse tyrosinase followed by three immunizations with human tyrosinase or three immunizations with human tyrosinase followed by three immunizations with mouse tyrosinase
224235151|NCT04951388|BIOLOGICAL|MVC-COV1901(S protein with adjuvant)|Approximately 330 participants will receive 2 doses of MVC-COV1901(S-2P protein with adjuvant) at Visit 2 (Day 1) and Visit 4 (Day 29) via intramuscular (IM) injection in the deltoid region
224235152|NCT04951388|BIOLOGICAL|MVC-COV1901(Saline)|Approximately 55 participants will receive 2 doses of MVC-COV1901(Saline) at Visit 2 (Day 1) and Visit 4 (Day 29) via IM injection in the deltoid region
223766926|NCT07095829|OTHER|No intervention|Evaluation of natural history of the disease
224235153|NCT04474938|DRUG|Daratumumab|16mg/kg, QW Cycles 1-2 (28 days/cycle), Q2W Cycles 3-6, and Q4W thereafter for up to 1 year
224235154|NCT04474938|DRUG|Bortezomib|1.3mg/m2 of subcutaneous bortezomib on days 1, 8, 15 and 22 of a 28-day cycle for 6 cycles
224235155|NCT04474938|DRUG|Dexamethasone|20mg of dexamethasone on days 1, 8, 15 and 22 of a 28-day cycle for 6 cycles
224320481|NCT06181149|BEHAVIORAL|Auditory errors and pre-speech auditory modulation|This intervention will examine the contributions of auditory errors to pre-speech auditory modulation. Participants will receive auditory perturbations while speaking, and we will collect their brain activities throughout the study.
224320482|NCT06181149|BEHAVIORAL|Contributions of the speech premotor cortex to pre-speech auditory modulation|This intervention will examine the effects of stimulation of the left ventral premotor cortex on pre-speech auditory modulation. Participants will receive electrical stimulation while speaking.
224320483|NCT06181149|BEHAVIORAL|Delaying auditory feedback|This intervention will examine the effects of misalignment between prediction and auditory feedback in participants. We will use delayed auditory feedback to induce a temporal misalignment between prediction and auditory feedback while participants produce speech.
223650367|NCT02772458|OTHER|Dodecanoate acid and saline|Test drink
223650368|NCT02116205|BIOLOGICAL|HTNV/PUUV DNA vaccine|HTNV/PUUV DNA vaccine mixture, composed of pWRG/HTN-M(co) and pWRG/PUU-M(s2)
223650369|NCT02116205|BIOLOGICAL|Placebo|0.9% sodium chloride
223650370|NCT02116205|DEVICE|TriGrid Delivery System (TDS)|The TDS-IM is an integrated, fully automated clinical EP system designed for delivering DNA-based vaccines and therapies to target tissues, through temporary disruption of cellular membranes via electrical pulses
223650371|NCT01234389|DEVICE|Electrochemical H. pylori detection method|Determination of H. pylori infection.
223650372|NCT01234389|DEVICE|IHC|Determination of H. pylori infection.
224235156|NCT00764309|DRUG|dasatinib|Tablets, Oral, 100 mg, once daily, 6 months
224235157|NCT03502642|DEVICE|wound infusion (Dosi-Pain® Kit, LEVENTON SAU, Spain)|After peritoneum closure a 16cm multiorifice perforated catheter (Dosi-Pain® Kit, LEVENTON SAU, Spain) was inserted by the surgeon below the fascia used for normal saline continuous infusion in the Placebo group and for continuous ropivacaine infusion (Ropivacaina Molteni®, MOLTENI FARMACEUTICI, Italy) in the ropivacaine group.
224320484|NCT01284452|DRUG|Placebo|Normal saline 50 ml intravenous every 6 hours for 7 days
223650373|NCT01234389|DEVICE|C13-urea breath test|Determination of H. pylori infection.
223650374|NCT01234389|DEVICE|HUT|Determination of H. pylori infection.
223650375|NCT00241436|DRUG|Anastrozole (ARIMIDEX™)|
223650376|NCT02219425|PROCEDURE|endometrial biopsy|
223650377|NCT02541604|DRUG|Atezolizumab|Atezolizumab was administered as IV infusion (maximum 1200 mg) on Day 1 of each 21-day cycle.
223650378|NCT02406534|BEHAVIORAL|HRQoL surveys|
223650379|NCT04245683|PROCEDURE|Bowel/rectal resection|surgical removal of the portion of the rectum where the tumor was originally identified
223650380|NCT04245683|OTHER|non-operative follow up|patients who choose the non-operative option will be required to adhere to a very intensive follow up protocol, including endoscopy and CT imaging
223650381|NCT02373683|DEVICE|Vapotherm-Heliox|Following separation from mechanical ventilation, patient is placed on heliox (70% oxygen-30% helium) delivered with Vapotherm, a proprietary heated, humidified, high-flow nasal cannula delivery system.
223650382|NCT03028337|RADIATION|Spine Radiosurgery|"Spine Radiosurgery - 1 Dose: For single fraction and multifraction arms, 0.01 cc of the cord allowed to receive 10 Gy and 14 Gy, respectively while 0.01 cc of the cauda equina allowed to receive 14 Gy and 18 Gy, respectively.~Spine Radiosurgery - 3 Doses (3 days): The dose for the multifraction arm is 27 Gy in 3 fractions (9 Gy per fraction)."
224320485|NCT01284452|DRUG|Hydrocortisone|Hydrocortisone 50 mg intravenous every 6 hours for 7 days
224320486|NCT00321178|DRUG|SR4 - switch to CR4|switch to oral treatment after 4 weeks SR 'standard' therapy
224320487|NCT02505737|BEHAVIORAL|TH-CBT|Telephone-Based Cognitive Behavioral Therapy (TH-CBT). A 10-session treatment protocol that incorporates behavioral activation, thought monitoring and restructuring, relaxation training, worry control, sleep hygiene, and caregiver psychoeducation and support
224320488|NCT02505737|OTHER|Enhanced Usual Care|Community-based treatment as usual and supplemental reading material
223766927|NCT06928467|BEHAVIORAL|Building Better Caregivers workshop|The BBC workshop is a 6-week, online, peer-led small group workshop designed for family caregivers of persons living with dementia or other form of cognitive impairment. It is an evidence-based workshop of the Self-Management Resource Center originally developed at Stanford University for the Veterans Administration and is now licensed for online delivery by Canary Health. Content focuses on increasing participant self-management behaviors, dementia caregiving skills, and peer social support. The workshop uses a peer-facilitated small group format with frequent online interactions between approximately 27 participants on threaded discussion boards. Activities are guided by two trained peer co-facilitators (caregivers themselves). Each week focuses on 2-3 new topics and tools for participants to learn and use. In threaded discussion board conversations participants interact, help each other, and provide peer social support.
224235158|NCT03502642|PROCEDURE|Spinal Anesthesia|Cesarean section was conducted under spinal anesthesia in both groups
224235159|NCT03502642|DRUG|intrathecal morphine|Intrathecal morphine was administered during spinal anesthesia in the placebo group but not in the ropivacaine group
223650383|NCT03028337|BEHAVIORAL|Questionnaires|"Participants complete 3 questionnaires about any pain they may be having, quality-of-life, and any other symptoms. It should take about 10 minutes to complete these questionnaires.~Questionnaires completed at Baseline and at Months 3,6,9,12,18, and 24 and then every 6 months after that during follow up."
223650384|NCT05932862|DRUG|XL309|XL309 will be administered orally per assigned schedule.
223650385|NCT05932862|DRUG|Olaparib|Olaparib will be administered orally per assigned schedule.
223650386|NCT05095376|DRUG|Lomustine|Given PO
223650387|NCT05095376|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223650388|NCT05095376|RADIATION|Photon Beam Radiation Therapy|Undergo radiation therapy
223650389|NCT05095376|OTHER|Questionnaire Administration|Ancillary studies
223650390|NCT05095376|DRUG|Temozolomide|Given PO
223650391|NCT05988632|DRUG|Regular Human Insulin then Placebo|Insulin: 80 IU (administered intranasally) THEN Placebo: 0.9% saline solution (administered intranasally)
223650392|NCT05988632|DRUG|Placebo then Regular Human Insulin|Placebo: 0.9% saline solution (administered intranasally) THEN Insulin: 80 IU (administered intranasally)
223650393|NCT02472028|OTHER|blood pressure lowering algorithm|"The treatments used in the enhanced strategy arm are those proposed by national (HAS2013, SFHTA2013) and international (ESH 2013) recommendations, according to their Marketing Authorization and Summary of Product Characteristics : Diuretics, beta-blockers, Angiotensin Converting Enzyme inhibitors, Angiotensin Receptor Blockers, Calcium Channel Blockers Throughout the study, choice of drugs in each therapeutic class is left on the investigator's initiative. All drugs of these classes may be used , no specific drug is tested in this study."
223650394|NCT02472028|OTHER|usual strategy|The implementation of antihypertensive therapy the current recommendations to reach the blood pressure target in usual care. Throughout the study, choice of drugs in each therapeutic class is left on the investigator's initiative. Combinations of different pharmacological classes can be tested in order to find the most effective and best tolerated combinations.
223650395|NCT04133792|DRUG|Simvastatin 40mg|40 mg orally daily for 5 years.
223650396|NCT04133792|DRUG|Placebo oral tablet|40 mg orally daily for 5 years.
223650397|NCT03604835|OTHER|No Intervention|Access to any treatment is through authorized commercial use or available expanded access programs only and not as a part of this DMP.
223650398|NCT06416306|BEHAVIORAL|Speech Intervention|The treatment will begin with imitation, whereby the child will produce target words following the study clinician's verbal model with 1:1 clinician feedback for the accuracy of the child's productions. This will include explicit articulatory instruction (i.e., verbal and visual cues) to elicit correct target forms. When a child achieves 75% accuracy following a verbal model across 2 consecutive sessions or completes the 9th session (whichever is first), treatment will shift to spontaneous production, in which the child will produce target words spontaneously or through elicitation without a verbal model. Treatment materials will be images of treatment target words, interactive games and stories, and a standard set of toys.
223650399|NCT03196453|DIETARY_SUPPLEMENT|Probiotic|probiotic and/or placebo intervention in toddlers
223650400|NCT05760573|BEHAVIORAL|Family Wellness Program (FWP)|The FWP will consist of the following general format: (1) 8 weekly 60-minute summer workshops; (2) 4 booster workshops throughout the year; and (3) 2-3 outreach text messages per week for 10 months.
223650401|NCT02272205|OTHER|Retrospective analysis of records|
223650402|NCT03150693|DRUG|Allopurinol|Given PO
223650403|NCT03150693|DRUG|Cytarabine|Given IT, IV, SC
223650404|NCT03150693|DRUG|Daunorubicin Hydrochloride|Given IV
223650405|NCT03150693|DRUG|Vincristine Sulfate|Given IV
223650406|NCT03150693|DRUG|Dexamethasone|Given PO or IV
223650407|NCT03150693|DRUG|Pegylated L-Asparaginase|Given IV
223650408|NCT03150693|DRUG|Methotrexate|Given IT, IV, PO
223650409|NCT03150693|PROCEDURE|Bone Marrow Aspiration and Biopsy|Undergo bone marrow aspiration and biopsy
223650410|NCT03150693|DRUG|Cyclophosphamide|Given IV
223650411|NCT03150693|DRUG|Mercaptopurine|Given PO
223650412|NCT03150693|BIOLOGICAL|Rituximab|Given IV
223650413|NCT03150693|DRUG|Doxorubicin|Given IV
223650414|NCT03150693|DRUG|Thioguanine|Given PO
223650415|NCT03150693|BIOLOGICAL|Inotuzumab Ozogamicin|Given IV
223650416|NCT03150693|OTHER|Laboratory Biomarker Analysis|Correlative studies
223650417|NCT01369888|DRUG|Cyclophosphamide|60 mg/m\^2, intravenous (IV) (in the vein) x 2 days
223650418|NCT01369888|DRUG|Fludarabine|25 mg/m\^2/day intravenous piggyback (IVPB) daily over 30 minutes for 5 days (days -5 to -1)
223650419|NCT01369888|BIOLOGICAL|Tumor Infiltrating Lymphocytes|IV over 30 minutes on day 0
223650420|NCT01369888|DRUG|IL-15|IV over 30 minutes, daily for 10 days, starting 3-4 hours after the TIL infusion. (day 0 to day 9). Doses will be increased every 3-6 patients.
223650421|NCT06005207|DRUG|progesterone vaginal sustained-release gel|90 mg progesterone vaginal sustained-release gel is added daily during endometrial transformation and luteal support
223650422|NCT02752165|OTHER|TEAM-ED|Facilitation of preventive asthma management through telemedicine assessment and follow-ups in addition to guideline-based provider prompting
223650423|NCT02752165|OTHER|Enhanced Usual Care|Report of symptoms to primary care physician
224235160|NCT03502642|DRUG|Ropivacaine (Ropivacaina Molteni®)|A10ml bolus of ropivacaine 7.5mg/ml were administered in the wound catheter after skin closure then an infusion of ropivacaine 2mg/ml at the rate of 5ml/h was administered as wound infusion via the Dosi-Pain® Kit for 48hours.
224235161|NCT03502642|DRUG|Normal saline|A10ml bolus of normal saline were administered in the wound catheter after skin closure then an infusion of normal saline at the rate of 5ml/h was administered as wound infusion via the Dosi-Pain® Kit for 48hours.
223650424|NCT04131647|OTHER|Weight Maintenance|Following a 12-week weight loss and exercise program, subjects will participate in a weight maintenance program of Heart Healthy nutrition, walking, and resistance band exercise
223766928|NCT06909448|DEVICE|abdominal belt|40 postpartum women will only wear abdominal belt for 14 weeks.
223650425|NCT04131647|OTHER|Weight Maintenance + Intermittent Fasting|Following a 12-week weight loss and exercise program, subjects will participate in a weight maintenance program of Heart Healthy nutrition, walking, resistance band exercise and intermittent fasting (2 small meals per day) one day per week for 24 weeks.
223650426|NCT04765683|OTHER|questionnaire|Survey of views on outpatient consultation format
223650427|NCT05530512|OTHER|electroacupuncture|acupuncture needling and stimulation are applied for 30 min
223766929|NCT06909448|DEVICE|TECAR therapy|will wear the same abdominal belt for 6 weeks then participating in TECAR therapy 3 sessions /week for 8 weeks.
223766930|NCT06909383|DRUG|Nanocrystalline megestrol acetate|Nanocrystalline megestrol acetate
223766931|NCT06909331|DIETARY_SUPPLEMENT|Exogenous ketone salt|Exogenous ketone salt supplement will be taken once to determine acute circulating levels of beta-hydroxybuyrate and acetoacetate compared to a control supplement.
223766932|NCT06909331|DIETARY_SUPPLEMENT|Placebo drink solution|Participants consumed a placebo drink that was flavor, color and calorie matched to the experimental drink.
223766933|NCT05947279|BEHAVIORAL|Comparing motor adaptation reaching performance|By comparing motor adaptation reaching performance between these three groups, the investigators can examine how stimulation to each specific area of the brain modulates different aspects of motor adaptation
223766934|NCT04708470|DRUG|Bintrafusp Alfa|"Subjects will receive bintrafusp alfa via IV infusion over 1 hour (-10 minutes / +20 minutes, that is, over 50 to 80 minutes) once every 2 weeks. Bintrafusp alfa will be administered as a flat dose of 300 mg independent of body weight. Bintrafusp alfa is administered as an intravenous infusion with a mandatory 0.2 micron in-line filter."
223766935|NCT04708470|DRUG|PDS01ADC|PDS01ADC will be administered at as dose of 4, 8, 12, or 16.8 micrograms/kg by SC injection every 2 or 4 weeks. The dose of PDS01ADC will be calculated based on the weight of the subject determined within 72 hours prior to the day of drug administration. The dose of PDS01ADC used for the previous administration can be repeated if the change in the subject's weight is 10% or less than the weight used for the last dose calculation.
223766936|NCT04708470|DRUG|Entinostat|The entinostat used in this study is a self-administered investigational agent and will be given orally at a designated dose once a week or as directed. Number of entinostat tablets will be calculated based on the dose for the participant.
223766937|NCT06361095|BEHAVIORAL|Traditional Attention Bias Modification|Each ABM trial begins with a central fixation cross for 1500ms, followed by a pair of POFA or IAPS stimuli (see Figure 3). POFA pairs will be presented for 3000ms, while IAPS pairs will be presented for 4500ms (due to the increased image complexity of IAPS images relative to POFA images). Longer stimulus duration times were selected based on evidence that attention biases for sad stimuli are prolonged in depression. Following offset of the images, either a single or double asterisk probe appears in the location of one of the images and will remain until a participant response or 10,000ms. In active ABM, the probe had an 80% probability of appearing in the location of the neutral stimulus. Investigators selected 80% rather than 100% to allow for computing attention bias during training and to facilitate task engagement. At the end of each ABM session, participants are provided feedback regarding their task performance relative to their last five sessions in a visual format.
223766938|NCT06361095|BEHAVIORAL|Gamified Attention Bias Modification|Each trial consists of the fixation stage, facial cue stage, and response stage. At the fixation stage, an image appears (a colorful medallion) for 500 ms. The fixation appears randomly within a fixed rectangular field on the user's smartphone screen, and is always at the midpoint between the two face cues that will appear in the next stage. Next, after the cue disappears, two animated faces appear on the screen, one happy and one sad, with a 1000ms duration. Immediately after they disappear, a target probe (a trail) appears in the location of the happy face cue. The path remains (up to 3 seconds) until participants respond by tracing it starting from the point at which the face cue disappeared. They are instructed to quickly but accurately trace the path with their finger and receive visual and haptic feedback during tracing to indicate they are tracing accurately, followed by the path disappearing.
223766939|NCT06361095|BEHAVIORAL|Sham Attention Bias Modification|Sham attention bias modification designed to match the active ABM condition in all respects except for the shifting attention away from negative stimuli in active attention bias modification.
223766940|NCT04638894|PROCEDURE|Surgical treatment of patients with adult spinal deformity|Including all surgical interventions for patients with adult spinal deformity.
223766941|NCT07107061|OTHER|Pilates exercises plus aerobic exercise|Pilates exercises are characterized as muscle strengthening and stretching, while aerobic exercises are characterized as a modality that works cardiorespiratory fitness.
223766942|NCT07107061|OTHER|Pilates exercises|Pilates exercises are characterized as muscle strengthening and stretching.
224235162|NCT02557607|DEVICE|MRI|An analysis of the three sessions MRI performed systematically within the first 14 days of the start of symptoms revealing the HSA will be
224235163|NCT03832465|DRUG|Levofloxacin film-coated tablet|"50 participants are randomly assigned to receive intraluminal eradication of H. pylori.~with medicaments containing levofloxacin powder or levofloxacin solution."
224320489|NCT00299130|DRUG|Folate|A stable dose, ≥ 5 mg/week given as either a single dose or as a divided weekly dose, orally.
223650428|NCT06483100|DRUG|Elrantamab|"\- Elranatamab will be dosed in 28-day cycles as follows:~* C1D1: 12 mg SC priming dose~* C1D4: 32 mg SC priming dose~* C1D8, C1D15, C1D22: 76 mg SC~* Cycle 2 and all subsequent cycles: 76 mg SC on D1 and D15"
223650429|NCT06483100|DEVICE|clonoSEQ|FDA approved MRD testing
223650430|NCT04618653|OTHER|assessment only|Three assessment will include computerized assessments, interviews, and subset will provide daily reports of prescribed AA behaviors and practices
224235164|NCT03832465|DRUG|Levofloxacin intravenous solution|"50 participants are randomly assigned to receive intraluminal eradication of H. pylori.~with medicaments containing levofloxacin powder or levofloxacin solution."
224235165|NCT03504111|PROCEDURE|Percutaneous Needle Tenotomy|A sham phlebotomy sample will be drawn on all study participants. Participants in this treatment group will be given local anesthesia with 1% lidocaine and then blinded to the intervention using a blind fold or shielding. Ultrasound guided needle tenontomy with be performed at the common extensor tendon at the area of tendinosis. There will be approximately 25 passes through the tendon with an 18 gauge needle. Investigators will keep track of the number of passes through the tendon. Investigators will keep track of the amount and type of anesthetic used to provide adequate and effective anesthesia
224235166|NCT03504111|PROCEDURE|PRP|A sham phlebotomy sample will be drawn on all study participants. Participants in this treatment group will be given local anesthesia with 1% lidocaine and then blinded to the intervention using a blind fold or shielding. Ultrasound guided injection of the PRP will be performed at the common extensor tendon at the area of tendinosis. Investigators will keep track of the amount and type of anesthetic used to provide adequate and effective anesthesia to the local skin
224235167|NCT01310296|DRUG|Lofexidine hydrochloride|Single Dose = Solution containing 400 μg lofexidine HCl and a tracer amount of 14C lofexidine
224235168|NCT01310296|DRUG|Lofexidine hydrochloride|Single Dose = 200 μg lofexidine in phosphate-buffered saline administered intravenously via infusion pump at a rate of 1 μg/min for 200 min
224235169|NCT01836419|PROCEDURE|classic LMA insertion|
224235170|NCT01975805|OTHER|Chlorhexidine Gluconate|
224235171|NCT01975805|OTHER|Povidone Iodine|
224320490|NCT00299130|DRUG|Methotrexate|A stable dose of between 10-25 mg/week, oral or parenteral, as prescribed by the treating physician.
223650431|NCT05220436|OTHER|DISCOVER workshop programme|See arm description. The manualised group workshop day is informed by Cognitive Behaviour Therapy and Acceptance \& Commitment Therapy principles.
223650432|NCT01704599|DRUG|Humira Then Humira plus 3 B vitamins|Humira alone for 16 weeks then Humira plus 100 mg daily pyridoxine, 5 mg daily folic acid and 1000 mcg daily cyanocobalamin
223766943|NCT07107061|OTHER|Aerobic exercise|Aerobic exercises are characterized as a modality that works cardiorespiratory fitness.
223766944|NCT06860230|DEVICE|Philips FAST SpO2 with Nellcor Pulse Oximetry Sensors|Noninvasive pulse oximeter
223766945|NCT05684510|DEVICE|clear aligners|clear aligners will be applied to the upper and lower arch, then a class II elastics 1\\4 and 6,5 oz will be use from the precision-cut Hook on the maxillary aligner to the button of mandibular first molar
223650433|NCT05788159|DRUG|Lacosamide Tablets|Reference preparation (R): Lacosamide Tablets Specification: 50mg/tablet Lot No.: 7883201 Content: 50mg/tablet Expiration date: September 2026 Storage condition: not more than 30C in airtight storage Manufacturer: Aesica Pharmaceuticals GmbH
223650434|NCT05788159|DRUG|Lacosamide extended release tablets|Test preparation (T): Lacosamide extended release tablets Specification: 100mg/tablet Lot number: 22121301 Content: 100mg/tablet Expiration date: December 12, 2024 Storage conditions: Store at 20℃\~25℃, short-term can be at 15C\~30℃ Manufacturer: Overseas Pharmaceutical,Ltd.
223650435|NCT02852395|DRUG|JNJ-48816274|Oral dose; dose range of 5 mg up to 250 mg
223650436|NCT02852395|DRUG|Placebo|Oral dose; appearance matched to JNJ-48816274
223650437|NCT02932852|PROCEDURE|Lipoaspiration|The patient will have a liposuction surgery from which the autologous ADAS cell to transplant in the cornea will be obtained.
223650438|NCT02932852|PROCEDURE|Transplantation|The ophthalmologist will carry out the transplantation of the ADAS cells with or without scaffold in the intrastromal cornea of the patient
223650439|NCT04812652|BEHAVIORAL|Digitally distributed yoga|Yoga distributed through internet.
223650440|NCT06212128|COMBINATION_PRODUCT|RAPIDO TNT|neoadjuvant therapy per RAPIDO protocol (Patients under RAPIDO group underwent 25Gy/5 sessions of short course radiotherapy followed by 6 cycles of neoadjuvant XELOX similar to that of the RAPIDO trial protocol)
223650441|NCT06212128|COMBINATION_PRODUCT|LCRT|LCRT group underwent conventional 50Gy/25-28 sessions of long course radiotherapy with concurrent oral capecitabine
223650442|NCT00996398|OTHER|Tepid water immersion|28°C ± 1°C for the cold water immersion for 30 minutes to the level of the umbilicus
224235172|NCT03708211|DRUG|TAK-931 PIC|TAK-931 PICs.
224235173|NCT03708211|DRUG|TAK-931 Tablet|TAK-931 Tablets.
224235174|NCT03708211|DRUG|Esomeprazole|Esomeprazole Tablets.
224235175|NCT01168505|DRUG|ferric hydroxide saccharate|single dose of 200 mg (2 ampoules), 24-48 hours after administration of chemotherapy for a total of four doses
224235176|NCT01179490|DRUG|SyB L-0501|SyB L-0501 (150 mg/m2/day) will be administered by intravenous drip infusion for 60 min for 2 consecutive days and the course will be observed for the next 26 days. This is taken as one cycle and administration is repeated for 2-9 cycles (when a plateau is not reached after nine cycles, administration of up to an additional three cycles for a maximum of 12 cycles is possible).
224235177|NCT01179490|DRUG|prednisolone|Prednisolone will be administered (60 mg/m2/day) orally for 4 consecutive days and the course will be observed for the next 24 days.
224235178|NCT00001683|DRUG|COL-3|
224235179|NCT04986228|OTHER|Digital aftercare|The intervention group will receive a digital aftercare service, consisting of video calls and an app, for a period of up to eight weeks after discharge. These enable an uncomplicated and yet intensive exchange with the clinic from the comfort of the participants' own homes. To enable to optimally plan the treatment and assess its success, all participants complete questionnaires on multiple time points about different topics.
224235180|NCT04986228|OTHER|TAU|The control group will receive the regular follow-up consultations in the clinic (treatment-as-usual, TAU). This includes at least one consultation with the case-leading therapist from the previous inpatient stay about 6 weeks after discharge. The assessment consisting of questionnaires at multiple time points about different topics is the same as in the intervention group.
224320491|NCT00299130|DRUG|Methylprednisolone|Intravenous infusion
224320492|NCT00299130|DRUG|Placebo|Placebo to rituximab intravenous infusion
224320493|NCT00299130|DRUG|Rituximab|Intravenous infusion
224320494|NCT02649569|DEVICE|Monitoring Device|Wear activity monitor
224320495|NCT02649569|OTHER|Quality-of-Life Assessment|Complete the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30
224320496|NCT03899246|DRUG|Eight Percent Topical Capsaicin|See arm description
224235181|NCT04876898|OTHER|prospective cohort in high body mass index patient with covid 19|A cohort study included 114 adult patients with confirmed COVID-19 were categorized by BMI levels
224235182|NCT01134523|DRUG|Epirubicin, CTX, Paclitaxel|Epirubicin 90mg/m2 and CTX 600mg/m2 on day1 of each 21-day cycle, 4 cycles; followed by Paclitaxel 175mg/m2 on day1 of each 21-day cycle, 4 cycles.
224235183|NCT01134523|DRUG|Epirubicin, Paclitaxel|Epirubicin 75mg/m2 on day1 and Paclitaxel 175mg/m2 on day2 of each 21-day cycle, 6 cycles.
224235184|NCT01508936|DRUG|Reslizumab|Reslizumab administered at a dosage of 3.0 mg/kg by intravenous (iv) infusion by qualified study personnel every 4 weeks for 16 weeks (for a total of 4 doses).
223650443|NCT02840461|DRUG|Ivermectin Cream, 1%|
223650444|NCT02840461|DRUG|Placebo/Vehicle cream|
223650445|NCT06648044|OTHER|Description: Research of therapeutic targets in the frame of nephronophthisis and renal associated ciliopathie|
223650446|NCT03983356|OTHER|Training program|An internet based training program will be offered to GPs. We will also offer face-to-face seminars with academic psychiatrists.
224235185|NCT01508936|DRUG|Placebo|Matching placebo administered by intravenous (iv) infusion by qualified study personnel every 4 weeks for 16 weeks (for a total of 4 doses).
224235186|NCT02676154|DRUG|Fesoterodine|4mg, oral, once daily for 12 weeks; dose adjustments may be permitted.
224235187|NCT02401126|DIETARY_SUPPLEMENT|Nitrate supplementation|Nitrate supplementation: concentrated nitrate-rich beetroot juice (2 x 70 ml/day; approximately 10 mmol nitrate/day; Beet It, James White Drinks, Ipswich, UK) for 8 consecutive days.
224235188|NCT02401126|DIETARY_SUPPLEMENT|Placebo|Placebo: nitrate-depleted beetroot juice (2 x 70 ml/day; approximately 0.01 mmol nitrate/day; Beet It, James White Drinks, Ipswich, UK) for 8 consecutive days. The placebo juice is similar to the concentrated beetroot juice in appearance, texture, smell and taste and is obtained by removing nitrate ions from the latter.
224235189|NCT03164148|DEVICE|T-REX TRI00A|Case management consists of confirmation of hospital visit date, checking the adverse effect
224235190|NCT00462982|DRUG|sunitinib malate|
224235191|NCT05707299|PROCEDURE|Intradermal acupuncture|"Procedure/Surgery: Bilateral Fengchi（GB20）and Qiuxu（GB40） will be stimulated. According to the position of the acupoints, the needle of φ0.20\*1.5mm will be chosen. After acupuncture point localization and routine disinfection, all subjects will receive the acupuncture in the same order, and follow the steps of resting- stimulating-preparing-stimulating-resting to complete the acupuncture operation alternately.Before acupuncture, rest for 60s as the baseline period, and then stimulate the bilateral Fengchi（GB20） for 2 mins. After stopping stimulation, wait for fNIRS to return to the resting level (i.e., the preparation period), then stimulate the bilateral Qiuxu（GB40） for another 2 mins, and stop the near-infrared scanning when the image of fNIRS returns to the resting level."
224235192|NCT00679367|DRUG|dexamethasone|40 mg once weekly
224235193|NCT00679367|DRUG|lenalidomide|10 mg/day D1-21
224235194|NCT00679367|DRUG|melphalan|5 mg/m2 D1-4
223650447|NCT04162678|PROCEDURE|Biospecimen Collection|Undergo collection of blood via HD-SCA fluid biopsy
224235195|NCT03958825|PROCEDURE|laparoscopic hepatic sectionectomy|patients undergoing a laparoscopic left hepatic sectionectomy within an enhanced recovery after surgery programme
224235196|NCT03958825|PROCEDURE|open left hepatic sectionectomy|patients undergoing open left hepatic sectionectomy within an enhanced recovery after surgery programme
224235197|NCT01180595|DEVICE|Trabecular Metal Modular Tibial Total Knee Component|The modular design of the Trabecular Metal Total Knee allows for increased options for physicians however, it is not clear how this modular feature will affect fixation since it may compromise some of the advantages of the original TM Monoblock tibial component.
224235198|NCT01180595|DEVICE|Trabecular Metal Monoblock Tibial Total Knee Component|
224235199|NCT01779622|OTHER|Mixed meal|Ingestion of mixed meal
224235200|NCT00905125|BIOLOGICAL|Fluzone®|Single 0.5 mL injection of the 2008-2009 seasonal inactivated trivalent influenza vaccine administered intramuscularly in the deltoid. Fluzone® does not contain thimerosal.
224235201|NCT00905125|BIOLOGICAL|Fluarix®|Single 0.5 mL injection of the 2008-2009 seasonal inactivated trivalent influenza vaccine administered intramuscularly in the deltoid. Fluarix® contains less than 1 microgram (trace or a very small amount) thimerosal per shot.
224235202|NCT01192646|BEHAVIORAL|HBLSS|Home Based life saving skills training will be done in the intervention cluster while in the control group no training
224235203|NCT02078063|DRUG|Mepivacaine|10 ml of Mepivacaine for injection (Carbocain®) 10 mg/ml instilled into the uterus through a hydrosonography catheter
224235204|NCT02078063|DRUG|Placebo|10 ml of NaCl 0.9 mg/ml instilled into the uterus through a hydrosonography catheter
223650448|NCT04162678|OTHER|Laboratory Biomarker Analysis|Correlative studies
223650449|NCT04162678|PROCEDURE|Liquid Biopsy|Undergo collection of blood via HD-SCA fluid biopsy
224235205|NCT02929693|DRUG|gefitinib|250 mg oral once a day until progression or unacceptable toxicity develops
224235206|NCT02929693|DRUG|Yiqi-yangyin-jiedu decoction|Yiqi-yangyin-jiedu decoction is a traditional chinese herbal medicine formula,and should be taken one package, twice a day, until progression or unacceptable toxicity develops.
223650450|NCT04162678|OTHER|Medical Chart Review|Review of medical chart
223650451|NCT05823467|DRUG|TMP-SMX DS|Oral Antibiotic - used to treat post operative wound infections.
223650452|NCT05823467|DEVICE|ciNPT dressing|Negative pressure wound VAC placed on incision post operatively.
223650453|NCT03657693|DIAGNOSTIC_TEST|NICU MRI|MRI device that is not FDA approved.
223650454|NCT03657693|DIAGNOSTIC_TEST|Polysomnography|Polysomnography to better determine obstruction index in the airway.
223766946|NCT05684510|DEVICE|traditional treatment Fixed appliances with class II elastics.|Agroup of patients in which participants will be undergo to the fixed multibracket treatment (with slot size 0.022 × 0.028 and MBT prescription , after completing leveling and alignment , Elastics will be applied from the hooks of canines brackets to the hooks of lower first molar when the 0.019× 0.025-inch stainless steel archwires placed.
223766947|NCT07111234|PROCEDURE|Carbon Monoxide Measurement|Ancillary studies
223766948|NCT07111234|DRUG|Nicotine Oral Pouch|Sample randomly-ordered ONPs
223650455|NCT06139887|BEHAVIORAL|BESST|The BESST intervention is a suicide prevention program designed to meet the unique needs of Veterans receiving care from community mental health treatment settings. BESST can be delivered by a trained mental health staff member, such as a mental health nurse, social worker, psychologist, or psychiatrist. The intervention consists of two synergistic components that work to support the patient after a mental health-related discharge in community settings: 1) Brief educational session, where the patient receives a one-hour, one-on-one, personalized educational session on suicide prevention; 2) Seven regular contacts after discharge, where the study interventionist who delivered the brief educational visit will contact the patient to monitor the patient's symptoms, assess treatment adherence, review their safety plan, and assist the patient with engaging in care, if needed.
223650456|NCT06139887|OTHER|Standard Mental Health Care|Patients randomized to the control arm will receive standard mental health care alone. Standard mental health care simply refers to the regular care provided to patients around the time of discharge from community care settings.
223650457|NCT05943067|BIOLOGICAL|CD45RA depleted donor lymphocyte infusion (DLI)|CD45RA depleted donor lymphocyte infusion (DLI) after TCRα/β depleted haploidentical HCT
223650458|NCT01737502|DRUG|Auranofin|Given PO
223650459|NCT01737502|DRUG|Sirolimus|Given PO
223650460|NCT01737502|OTHER|Laboratory Biomarker Analysis|Correlative studies
223650461|NCT01737502|OTHER|Pharmacological Study|Correlative studies
223650462|NCT04835857|DEVICE|ViTrack|ViTrack is a continuous non-invasive wearable blood pressure cuff.
223650463|NCT04835857|DEVICE|Oscillometric BP Device|Oscillometric blood pressure measurement is the standard of care for measuring blood pressure in outpatient / home settings.
223650464|NCT04835857|DEVICE|Auscultatory cuff|The auscultatory method is the gold standard for clinical blood pressure measurement. A brachial cuff is mounted and a trained healthcare provider uses a sphygmomanometer and listens for the Korotkoff sounds using a stethoscope to measure blood pressure.
223650465|NCT03741673|OTHER|Quality-of-Life Assessment|Ancillary studies
223650466|NCT03741673|OTHER|Questionnaire Administration|Ancillary studies
224235207|NCT02929693|DRUG|placebo|Oral granules, which the taste and smell are similar to YYJD, has no therapeutic effect, Oral granules, which the taste and smell are similar to experimental TCM granules, has no therapeutic effect, one package, twice a day, until progression or unacceptable toxicity develops.
224235208|NCT04843670|PROCEDURE|duodenopancreatectomy|resection of the head of the pancreas, the mower part of the biliary duct, and antrectomy
223650467|NCT03741673|RADIATION|Stereotactic Radiosurgery|Undergo SRS
223650468|NCT03819985|RADIATION|Hypofractionated Radiation Therapy|Undergo hypofractionated RT
224235209|NCT06871176|DRUG|[68Ga]Ga-PentixaFor|\[68Ga\]Ga-PentixaFor will be administered intravenously using the recommended activity for adults which is up to 150 MBq (4 mCi) fixed dose. There is no weight adaption recommended in the literature.
224235210|NCT04603937|DRUG|KSI-301|Intravitreal Injection
224235211|NCT04603937|DRUG|Aflibercept|Intravitreal Injection
224235212|NCT04603937|OTHER|Sham Procedure|The sham is a procedure that mimics an intravitreal injection. It involves pressing the blunt end of an empty syringe (without a needle) against the anesthetized eye. It will be administered to participants in both treatments arms at applicable visits to maintain masking.
224235213|NCT01932034|DEVICE|BestDose Computer Software|BestDose is made by the USC Laboratory of Applied Pharmacokinetics. It uses a multiple-model, Bayesian adaptive control algorithm to find the maximally precise dose that will achieve a user-specified target concentration or concentrations.
223650469|NCT03819985|OTHER|Quality-of-Life Assessment|Ancillary studies
223650470|NCT03819985|OTHER|Questionnaire Administration|Ancillary studies
223650471|NCT06482099|BIOLOGICAL|RSVpreF vaccine|Injection in the muscle, 1 dose 0.5mL
223650472|NCT05820191|DRUG|Amyvid, Intravenous Solution|Amyvid 370MBq (10mCi) absorbed dose 7mSv of will be introduced intravenously and 30-50 minutes after the PET images will be acquired.
223650473|NCT04672655|BEHAVIORAL|ONBOARD|Session 1: Overview; Wearing diabetes devices; Session 2: Managing CGM data; Session 3: CGM \& social situations; Session 4: Building trust with your CGM
223650474|NCT03224000|PROCEDURE|Modified Barium Swallow (MBS)|Modified barium swallow (MBS) performed at baseline and at 6 months, 2 years, and 5 years after finishing radiation therapy.
223650475|NCT03224000|BEHAVIORAL|Swallowing Questionnaire|Swallowing questionnaire completed at baseline, every week while receiving radiation therapy, and at 6 months, 2 years, and 5 years after finishing radiation therapy.
223650476|NCT03224000|BEHAVIORAL|Symptom Questionnaire|Symptom questionnaire completed at baseline, every week while receiving radiation therapy, and at 6 months, 2 years, and 5 years after finishing radiation therapy.
223650477|NCT03224000|PROCEDURE|Video-Strobe Procedure|Video-strobe procedure to check vocal cords performed at baseline, at week 3 during radiation therapy, and at 6 months, 2 years, and 5 years after finishing radiation therapy.
223650478|NCT03224000|PROCEDURE|MRI Guided Intensity Modulated Radiotherapy (IMRT) Planning|IMRT planned with MRI guidance.
223650479|NCT03224000|PROCEDURE|Standard-of-Care Intensity Modulated Radiotherapy (IMRT) Planning|IMRT planned by standard-of-care.
223650480|NCT03224000|RADIATION|Intensity Modulated Radiotherapy (IMRT)|Participants receive an individualized prescription of up to 70 Gy in 33 fractions with radiation therapy (RT) given once daily, 5 days a week, over 6 weeks and 3 days.
223650481|NCT04526418|DEVICE|24/7 EEG™ SubQ system|Electrographic seizure recording sensitivity of an ipsilaterally implanted 24/7 EEG™ SubQ system: proportion of identified ipsilateral seizures as compared to ipsilateral video-EEG during admission to the Epilepsy Monitoring Unit
223650482|NCT05237947|BIOLOGICAL|Diphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis Vaccine Adsorbed|Given IM
223650483|NCT05237947|OTHER|Questionnaire Administration|Ancillary studies
223650484|NCT05237947|BIOLOGICAL|Recombinant Human Papillomavirus Bivalent Vaccine|Given IM
223650485|NCT05237947|BIOLOGICAL|Recombinant Human Papillomavirus Nonavalent Vaccine|Given IM
223650486|NCT05741840|BEHAVIORAL|PBT-A|PBT-A provides all the elements of family based treatment for children with obesity, including nutrition and physical activity education, behavior therapy skills, and parenting skills.
223766949|NCT07111234|OTHER|Questionnaire Administration|Ancillary studies
223650487|NCT05741840|BEHAVIORAL|Health Education (HE)|The HE arm will provide information about nutrition, physical activity, sedentary behavior, sleep, emotions, and stress.
223650488|NCT04406818|DRUG|Carbon Dioxide|Participants inhale carbon dioxide while in magnetic resonance imaging scan to measure cerebrovascular reactivity
223650489|NCT00494676|DEVICE|High power (57 prism diopter) peripheral prism glasses|All patients will wear two pairs of prism glasses in a crossover design: the high power peripheral prism glasses and sham peripheral prism glasses. Each pair of prism glasses will be worn for four weeks
223650490|NCT00494676|DEVICE|Low power sham peripheral prism glasses|Low power (5 prism dioptre) prism glasses that provide only about 2 degrees of visual field expansion.
223650491|NCT06806709|DEVICE|PIVO-Pro needle-free blood collection device|The PIVO™ Pro Needle-free Blood Collection Device advances a flexible flow tube through the intravenous catheter to access optimal blood draw conditions, overcoming traditional hurdles to collect high-quality, reliable blood samples.
223650492|NCT06451406|DRUG|Selective serotonin re-uptake inhibitor|Patients received selective serotonin re-uptake inhibitor as medical treatment for treatment of premature ejaculate.
223650493|NCT06451406|DRUG|Hyaluronic acid|Patients received injection of glans penis with hyaluronic acid
223650494|NCT03384134|OTHER|Pain Buddy|Pain Buddy is a user interface (application) which contains a personalized avatar (Pain Buddy) to guide children and parents through daily diary entries using mobile devices. The Pain Buddy application has been designed to be used with children age 8-18, receiving outpatient chemotherapy, as well as their parents. Pain Buddy will capture real time pain data from patients and that will ultimately allow for remote monitoring of patient symptoms. Remote symptom monitoring in real time will provide an opportunity for implementation of appropriate interventions, thereby introducing the potential to decrease pain and symptoms and improve quality of life in children with cancer. The use of symptom monitoring and skills training will further increase patient engagement in healthcare.
223650495|NCT06065345|DEVICE|BRight DCB|The BRight Drug-Coated Percutaneous Transluminal Angioplasty (PTA) Balloon catheter (BRight DCB) is intended for dilatation of de novo lesions in native superficial femoral or popliteal arteries with a simultaneous release of drug to the vessel wall as a secondary action to reduce occurrence of a restenosis of the treated vessel segment.
224235214|NCT04823000|BIOLOGICAL|Mesenchymal Stem Cells (MSC)|Repeated intrathecal and intravenous injection of autologous mesenchymal stem cells (1 million cells per Kg of body weight) at 6 months intervals.
224235215|NCT00436878|BEHAVIORAL|Food portion size|Each of four experiments involves a 2 x 2 within-subjects factorial design, in which the first factor is the portion size of a food served to children: foods will be served in a reference amount (i.e. 250 g macaroni and cheese) or doubled in size(i.e. 500 g of macaroni and cheese). In the Experiment 1, the second factor of the 2 x 2 design is meal type: whether the food is consumed at a meal or a snack. In experiment #2, the second factor is food type: fruit vs. vegetable. In experiment #3, the second factor is entree energy density: a regular energy density or a 40% greater energy density. In experiment #4, the second factor is plate size: a 6 inch plate vs. a 10 inch plate.
224235216|NCT02518685|DEVICE|TransPyloric Shuttle|
224235217|NCT02518685|DEVICE|Sham procedure|
223650496|NCT06361303|DEVICE|SNOO Bassinet|This is a non-interventional, prospective observational and descriptive active surveillance study of a cohort of individuals who have purchased or rented a SNOO for use with their infant.
223650497|NCT02607709|PROCEDURE|Lymphadenectomy in conjugation with nephroureterectomy|"Lymphadenectomy (intervention group only):~Lymphadenectomy performs in four fractions on the right side and two fractions on the left side according to Dissection template (Appendix 1). Renal hilar nodes are included in fraction 1 and 3, respectively."
223650498|NCT02607709|PROCEDURE|Nephroureterectomy without lymphadenectomy|Removing the kidney, ureter and bladder cuff
223650499|NCT06603805|PROCEDURE|MAST group|
223650500|NCT06603805|PROCEDURE|breast-conserving surgery plus adjuvant radiotherapy|Patients with early-stage (stage I, stage II, T≤2), and having the willingness to receive BCS were treated with BCS. All patients with BCS received post-surgery radiotherapy. Radiotherapy was administrated with a prescribed dose of 40 Gy in 15 fractions with photons and a boost of 10-16 Gy in 5-8 fractions with electrons to the ipsilateral breast. If axillary lymph nodes were involved, a conventional fraction was delivered with a prescribed dose of 50 Gy in 25 fractions to the ipsilateral breast and draining lymph node regions.
223650501|NCT06589115|OTHER|Blood Flow Restriction Cuff|The standardized exercises will be performed while wearing a blood flow restriction cuff.
223650502|NCT06589115|OTHER|Physical Therapy|Standard physical therapy
223650503|NCT05287906|OTHER|Water|Each subject will receive one control and three treatments in the crossover design. The control contains water only.
223650504|NCT05287906|OTHER|Glucose|Each subject will receive one control and three treatments in the crossover design. The glucose contains water and glucose.
223650505|NCT05287906|OTHER|Steviol Glycosides|Each subject will receive one control and three treatments in the crossover design. The Steviol Glycoside beverage contains water and steviol glycosides.
223650506|NCT05287906|OTHER|Steviol Glycosides plus glucose|Each subject will receive one control and three treatments in the crossover design. The Steviol Glycoside plus glucose beverage contains water, glucose, and steviol glycosides.
223650507|NCT05287906|OTHER|Rebaudioside A|A leaf-based, extracted stevia product to compare to the Eversweet in the normal weight group only. The Rebaudioside A contains water and rebaudioside A.
223650508|NCT02279706|OTHER|questionnaire|Check the Korean version of rhinitis controlled assessment tests, the total non-symptom scores (total nasal symptoms score, TNSS), rhinitis-related quality of life (RQLQ), rhinitis controlled degree, severity, and after study enrollment and 4 weeks treatment.
223766950|NCT07111234|DRUG|Smoke usual brand cigarette|Participant will smoke their usual brand of cigarette during 1 study visit for 5 minutes.
223766951|NCT05835921|DEVICE|Virtual Reality|Both groups will receive a Virtual Reality Park experience, which is an empty park with no avatars. Only the experimental group will have a Virtual Reality Avatar experience, where they will see an avatar resembling themselves in a park setting.
224235218|NCT02518685|BEHAVIORAL|Lifestyle Counseling|The goal of lifestyle modification counseling is to promote adherence to a reduced calorie diet, increased physical activity and to recommend behavioral modification strategies.
223650509|NCT06841198|DEVICE|spinal cord transcutaneous stimulation|"Stimulation, using the Neostim-5 (Cosyma Ltd.), a 5-channel electrical stimulator, will be administered throughout the study period, beginning shortly after the injury and continuing at regular intervals until one year post-spinal cord injury. It will be performed in two settings:~1. During seated mapping to identify stimulation sites (potentially T7/8, T11/12, L1/2, and S1/2) and determine stimulation parameters (e.g., frequency, pulse wave, amplitude) that elevate systolic blood pressure (SBP) and maintain it within the target range of 110-120 mmHg.~2. During 70-degree tilt tests to elicit an orthostatic response (a drop in blood pressure accompanied by symptoms)."
223650510|NCT00487461|DRUG|Simvastatin 40 mg|Comparing two doses of Simvastatin to placebo
223650511|NCT00487461|DRUG|Placebo|Placebo tablet
223650512|NCT00487461|DRUG|Simvastatin 80 mg|Comparing two doses of Simvastatin to placebo
223650513|NCT06821178|BEHAVIORAL|Acute stress manipulation|Youth will be randomly assigned to the HS (high stress) or LS (low stress) TSST-M condition. The objective activities will be identical in the HS and LS conditions but the context will vary. The HS condition will be highly evaluative. The researcher will tell youth that they are being videotaped in order to code their behaviors later. The observers will maintain neutral expressions, provide instructions in a neutral tone, and avoid eye contact. In the LS condition, evaluative components are removed \[31, 53\]. Observers will be introduced as new, and the videotaping will be explained as a check to ensure that the observers follow instructions. The observers will appear disorganized while giving instructions, smile, and maintain an open body posture and eye contact.
223650514|NCT06609499|DEVICE|Flexible-tip Bougie|The device is used for intubation and then the manikin is ventilated
223650515|NCT06609499|DEVICE|Gum-elastic Bougie|The device is used for intubation and then the manikin is ventilated
223650516|NCT06855277|DRUG|AAA817|AAA817 is being studied for treating PSMA positive mCRPC. Inside the body, it attaches itself to PSMA on the cell surface of the prostate cancer cells and emits radiation to kill them. This treatment is also called a radioligand therapy.
223650517|NCT06855277|DRUG|ARPI|Androgen receptor pathway inhibitor (ARPI): An ARPI is approved for the treatment of prostate cancer. It works by blocking signals from male hormones, such as testosterone, that helps cancer cells grow. By blocking these signals, an ARPI slows down or stops the growth of prostate cancer cells. In this trial, participants will be given either enzalutamide or abiraterone.
223650518|NCT06855277|DRUG|Standard of Care|Standard treatment includes approved treatment for mCRPC. In this trial, the trial doctor will decide which available treatment participants will receive. The trial doctor will select either an ARPI of enzalutamide or abiraterone, or a taxane based chemotherapy of docetaxel or cabazitaxel.
223650519|NCT04250493|BIOLOGICAL|Homeostasis Model Assessment of insulin resistance (HOMA)|Fasting blood sample for : glucose, insulinemia, hemoglobin and lipid test to determine the Homeostasis Model Assessment of insulin resistance (HOMA) index
223650520|NCT04250493|BEHAVIORAL|MOntreal Cognitive Assessment (MoCA)|Cognitive evaluation with MOntreal Cognitive Assessment (MoCA)
223650521|NCT04250493|BEHAVIORAL|Clinical characteristics of AMS patients|Severity and progression of motor disorders assessed by the UMSARS scale, severity of dysautonomia assessed by the COMPASS31 scale ; quality of life questionnaire (AMS-Qol) for the level of difficulty experienced by the patient (on activities such as : move; walk; maintain balance; talk; feed)
223650522|NCT04250493|PROCEDURE|Brain Magnetic Resonance Imaging (MRI)|Brain Magnetic Resonance Imaging (MRI) : putamen imaging, bridge and cerebellum; white substance hypersignals volume
223650523|NCT04250493|BIOLOGICAL|Blood sampling|Optional blood sampling for the constitution of a biological collection
223650524|NCT06601790|BEHAVIORAL|Immediate application of the Smart Homespital system|The Smart Homespital system can be applied for the first 3 months (12 weeks), and then the primary and secondary variables will be evaluated at 3, 6, 9months. While applying the Smart Homespital system, exercise three times a week, measure sleep twice a week, and questionnaire assessments (mMRC, CRQ, EQ-5D, K-CESD) are conducted once every two weeks.
223766952|NCT07106814|DRUG|Metabolically Armed TIL cells|Each subject receive metabolically armed TIL cells by intravenous infusion.
223766953|NCT07117994|DIETARY_SUPPLEMENT|Radicle Revive Placebo Control Form 1|Participants will use their Placebo Control Form 1 as directed for a period of 6 weeks.
224235219|NCT00922779|DRUG|peginterferon alfa-2a [Pegasys]|180micrograms sc weekly for 12-48 weeks
224235220|NCT00922779|DRUG|ribavirin|800mg, or 1000-1200mg, po daily (dependent on HCV genotype and body weight)
224235221|NCT02249884|DRUG|Urea Dose A|Urea cream for topical use.
224235222|NCT02249884|DRUG|Urea Dose B|Urea cream for topical use.
224235223|NCT02249884|DRUG|Urea Dose C|Urea cream for topical use.
224235224|NCT02249884|DRUG|Chamomile Dose A|Chamomile gel for topical use.
224235225|NCT02249884|DRUG|Chamomile Dose B|Chamomile gel for topical use.
224235226|NCT02249884|DRUG|Chamomile Dose C|Chamomile gel for topical use.
224235227|NCT01922349|DRUG|BI 113608|Medium dose (Multiple dosing)
224235228|NCT01922349|DRUG|Placebo|Placebo (Multiple dosing)
223766954|NCT07117994|DIETARY_SUPPLEMENT|Radicle Revive Active Study Product 1|Participants will use their Radicle Revive Active Study Product 1 as directed for a period of 6 weeks.
223766955|NCT06923826|DRUG|Sacituzumab govitecan|Day 1 and Day 8: Sacituzumab Govitecan will be administered at the dose of 10 mg/kg via intravenous infusion.
224235229|NCT01922349|DRUG|BI 113608|Low dose (Multiple dosing)
224235230|NCT01922349|DRUG|Placebo|Placebo (Single dosing)
224235231|NCT01922349|DRUG|BI 113608|High dose (Single dosing)
224235232|NCT01922349|DRUG|BI 113608|Medium dose (Single dosing)
224235233|NCT01922349|DRUG|BI 113608|Low dose (Single dosing)
224235234|NCT01922349|DRUG|BI 113608|High dose (Multiple dosing)
224235235|NCT01611090|DRUG|Ibrutinib|Type=exact number, unit=mg, number=420 , form=capsule, route=oral use. Capsule is taken once daily continuously.
224235236|NCT01611090|DRUG|Bendamustine hydrochloride|Type=exact number, unit=mg, number=70 mg/m2, route=intravenous use. Administered intravenously on Cycle 1, Days 2-3 and Cycles 2-6, Days 1-2.
224235237|NCT01611090|DRUG|Rituximab|Type=exact number, unit=mg, number=375 mg/m2 and 500 mg/m2, route=intravenous use. Administered intravenously on Cycle 1, Day 1, and Cycles 2-6, Day 1, respectively.
224235238|NCT01611090|DRUG|Placebo|Form=capsule, route=oral use. Capsule is taken once daily continuously.
223650525|NCT06601790|BEHAVIORAL|Delayed application of the Smart Homespital system after 3 months|The waiting list-control group will receive general medical services for the first 3 months and will receive a Smart Homespital system for 3-6 months. Primary and secondary variables will be monitored between 3, 6, and 9 months. While applying the Smart Homespital system, exercise three times a week, measure sleep twice a week, and questionnaire assessments (mMRC, CRQ, EQ-5D, K-CESD) are conducted once every two weeks.
223650526|NCT05767749|DRUG|lidocaine + epinephrine 1:100,000|0.5 ml lidocaine + epinephrine 1:100,000, buffered 1/10 with sodium bicarb.
223650527|NCT05767749|DRUG|Ropivacaine 0.5% Injectable Solution|0.5 ml Ropivacaine 0.5% Injectable Solution
223650528|NCT05767749|DRUG|Bupivacaine 0.5% Injectable Solution|0.5ml bupivacaine 0.5%
223650529|NCT02968212|DRUG|Clofazimine|All participants in the experimental/treatment arm on this protocol will take a loading dose of 200 mg daily in soft capsule form of clofazimine for 16 weeks, dropping to 100 mg daily for the next 8 weeks.
223650530|NCT02968212|OTHER|sugar pill|All participants in the placebo arm on this protocol will take placebo in soft capsule form daily dropping to a smaller dose after 16 weeks to mirror the treatment arm dosing.
223650531|NCT00563472|DRUG|estetrol|10 mg orally per day for 28 days
223650532|NCT00563472|DRUG|estetrol|20 mg orally per day for 28 days
223650533|NCT00563472|DRUG|estetrol and desogestrel|20 mg estetrol and 150 microg desogestrel orally per day for 28 days
223650534|NCT00563472|DRUG|estetrol and progesterone|20 mg estetrol and 200 mg progesterone orally per day for 28 days
223650535|NCT02141828|DRUG|EPZ-5676|28-day continuous IV infusion of each 28-day cycle, given until disease progression or unacceptable toxicity develops.
223650536|NCT06611956|OTHER|No intervention (observational study)|No intervention (observational study)
223650537|NCT04756232|DRUG|Mecamylamine Challenge|Mecamylamine 20 mg oral pill administered once
223650538|NCT04756232|OTHER|Placebo Comparator Challenge|Matching placebo oral pill administered once
223650539|NCT06591338|DRUG|Ticagrelor 90 MG|The ticagrelor arm will receive (a 180mg loading dose of cilostazol during the first 24 hours of stroke onset, followed by 90mg once daily from the 2nd day to the 90th day) and an open-label loading 300 mg aspirin, followed by a maintenance dose of 75 mg aspirin
223650540|NCT06591338|DRUG|Clopidogrel|The clopidogrel arm will receive (a 300 mg loading dose of clopidogrel during the first 24 hours of stroke onset, followed by 75 mg once daily from the 2nd day to the 90th day) and open-label loading 300 mg aspirin, followed by a maintenance dose of 75 mg aspirin.
223766956|NCT07119307|PROCEDURE|Entire Papilla Preservation Technique|Entire Papilla Preservation Surgical Technique (EPPT) alone and combined with enamel matrix derivative (EMD) plus bone mineral derived xenograph (BMDX)
223766957|NCT07119307|PROCEDURE|Entire Papilla Preservation Surgical Technique (EPPT) alone|Entire Papilla Preservation Surgical Technique (EPPT) alone
223766958|NCT07119307|PROCEDURE|Entire Papilla Preservation Surgical Technique (EPPT) alone and combined with enamel matrix derivative (EMD)|Entire Papilla Preservation Surgical Technique (EPPT) alone and combined with enamel matrix derivative (EMD)
223766959|NCT07118124|DEVICE|Zio monitor|Evaluate analyzable time of the Zio monitor over the wear duration of up to 14 days in a pediatric population.
223650541|NCT06591338|DRUG|Aspirin 75 Mg Oral Tablet|open-label loading 300 mg aspirin, followed by a maintenance dose of 75 mg aspirin for three months.
223650542|NCT06591338|DRUG|Aspirin 75 Mg Oral Tablet|open-label loading 300 mg aspirin, followed by a maintenance dose of 75 mg aspirin for three months.
223650543|NCT07001943|OTHER|enteral nutrition|We'll use an enteral nutrition intervention with intact protein formulations. Initiate nasogastric tube feeding at 20ml/h and continue for 24 hours. Adjust feeding strategies based on patients' SMA blood flow reactivity.
223650544|NCT05799872|BEHAVIORAL|Positive Affect Treatment for Anorexia Nervosa (PAT-AN):|PAT-AN is an adaptation of the cognitive-behavioral outpatient individual therapy for anhedonia (17, 68). The overarching aim of PAT-AN is to enhance reward sensitivity (reward anticipation, experiencing, and learning) to non-eating disorder experiences and to decrease or replace reward sensitivity to weight-loss experiences (26). PAT-AN includes 6 sequential modules, each designated to target specific reward sensitivity disturbances (26, 68). Homework and experiential practice during sessions are essential components of PAT-AN, and participants are provided a workbook to assist with this practice. During each session, collaborative homework review is followed by skill development and homework assignments.
223650545|NCT05799872|BEHAVIORAL|Psychoeducational and Behavioral Therapy (PBT)|The comparison treatment is modeled off of educational and behavioral interventions used in prior clinical trials for AN and common elements of standard behavioral eating disorder treatments. The treatment is structured to parallel the modular format of PAT-AN.
223650546|NCT06678269|DRUG|Abemaciclib|The dose escalation portion of the study, a 3+3 design will be used. Once the MTD of Abemaciclib is reached, the phase Ib expansion portion will enroll up to 10 additional patients also requiring palliation to bone metastases
223650547|NCT06678269|RADIATION|Radiation Therapy|27Gy in 3 daily fractions or 30Gy in 5 daily fractions completed entirely within 28 days of simulation via stereotactic body radiotherapy (SBRT).
223650548|NCT04077879|DRUG|ASP1617|Oral
223650549|NCT04077879|DRUG|Placebo|Oral
223650550|NCT04708067|DRUG|Bintrafusp Alfa|Given IV
223650551|NCT04708067|PROCEDURE|Biopsy|Undergo biopsy
223766960|NCT07120100|DEVICE|rTMS|Repetitive Transcranial Magnetic Stimulation will be administered Monday-Friday for two weeks (10 sessions total)
223766961|NCT04348045|DRUG|Arm A - Olaparib|"300 mg orally twice daily, for a total daily dose of 600mg~Study treatment can be dose-reduced to :~First step : 250 mg twice daily , for a total daily dose of 500 mg Second step: 200 mg twice daily taken twice daily, for a total daily dose of 400 mg No further dose reduction is allowed, and study treatment should be discontinued."
223766962|NCT04348045|DRUG|ARM B - durvalumab plus selumetinib|"Durvalumab administered IV at a flat dose of 1500 mg on day 1 of every 28-day cycle, Selumetinib Starting Dose : 75 mg twice daily~Study treatment can be dose-reduced to :~Dose Level -1 : 75 mg once daily Dose Level -2 : 50 mg twice daily Dose Level -3 : 50 mg once daily"
223766963|NCT04348045|DRUG|ARM C FOLFIRI|FOLFIRI every two weeks Irinotecan 180 mg/m2 Intravenous (IV) on day 1 Folinic acid 400 mg/m2 IV on day 1, 5-FU 400 mg/m2 IV bolus on day 1 and 2, and 46h IV infusion of 5-FU 2400 mg/m2
223766964|NCT07148986|DIETARY_SUPPLEMENT|Clarity Active Product 1|Participants will use their Clarity Active Product 1 as directed for a period of 6 weeks.
224320497|NCT01198132|DIETARY_SUPPLEMENT|Cholecalciferol (Vitamin D3)|Subjects receive Cholecalciferol 100,000 IU one dose fortnightly (equivalent to a daily dose of approximately 7142 IU) for 96 weeks treatment period along with subcutaneous Rebif 44 mcg 3 times a week.
224320498|NCT01198132|DIETARY_SUPPLEMENT|Placebo|Subjects receive matching placebo to Cholecalciferol once every two weeks orally along with subcutaneous injection of Rebif 44 mcg 3 times weekly.
224320499|NCT01198132|DRUG|Rebif|Subjects receive subcutaneous injection of Rebif 44 mcg 3 times weekly.
223650552|NCT04708067|RADIATION|Hypofractionated Radiation Therapy|Undergo hypofractionated radiation therapy
223650553|NCT07007182|DRUG|SOX regimen|"The SOX regimen consists of oxaliplatin 130 mg/m² IV on day 1 plus oral S-1 (tegafur/gimeracil/oteracil) 40-60 mg twice daily, taken on days 1-14 followed by 7 days off, in a 21-day cycle.~Experimental arm: 3 cycles before surgery, 5 cycles after surgery. Control arm: up to 8 cycles as standard systemic therapy."
223650554|NCT07007182|DRUG|CAPEOX regimen|"The CAPEOX regimen consists of oxaliplatin 130 mg/m² IV on day 1 plus oral capecitabine 1000 mg/m² twice daily on days 1-14, repeated every 3 weeks (q3w), up to 8 cycles.~Used as a standard chemotherapy option in the control arm, with or without PD-1 inhibitor according to PD-L1 CPS score."
223650555|NCT07007182|DRUG|PD-1 inhibitor|"A PD-1 inhibitor is administered intravenously at a fixed dose of 200 mg every 3 weeks.~It is combined with SOX in the experimental arm (CPS ≥1 patients) during conversion and adjuvant phases, and with CAPEOX or SOX in the control arm (CPS ≥1 patients).~Maintenance PD-1 inhibitor continues for up to 1 year or until disease progression or unacceptable toxicity."
223650556|NCT07007182|RADIATION|Para-aortic lymph node radiotherapy (IMRT to station 16)|"Intensity-modulated radiotherapy (IMRT) is delivered postoperatively to the para-aortic (station 16) nodal basin.~Elective nodal basin: 45-50 Gy in 25 fractions Positive nodes: 56-60 Gy in 25 fractions Radiotherapy is given concurrently with oral capecitabine or S-1 as radiosensitizers."
223650557|NCT07007182|DRUG|Capecitabine / S-1 (radiosensitizer during IMRT)|"During para-aortic IMRT, patients receive concurrent oral capecitabine 825 mg/m² twice daily on radiation days, or oral S-1 dosed according to body surface area.~These agents are used as radiosensitizers during postoperative radiotherapy."
223650558|NCT02226731|DEVICE|Early Belfort-Dildy Balloon|Intrauterine tamponade with the Belfort-Dildy balloon, performed in the 15 minutes after randomization at the same time as the second line uterotonic treatment.
223650559|NCT02226731|DEVICE|Late Belfort-Dildy balloon|Intrauterine tamponade with the Belfort-Dildy balloon, performed if failure of second line uterotonic treatment, ie persisting bleeding 30 minutes after the beginning of this infusion.
223650560|NCT07018492|DRUG|BPN14770|Administered as specified in the treatment arm.
223650561|NCT07057908|PROCEDURE|Video Laryngoscope Intubation with Bougie|"Participants in this group will undergo tracheal intubation using a video laryngoscope under general anesthesia. After induction, a standard bougie will be advanced through the vocal cords under video guidance, and the endotracheal tube will be railroaded over the bougie into the trachea.~The primary outcome will be intubation time, measured from insertion of the device until confirmation of successful tracheal intubation. Additional parameters such as intubation success rate, ease of insertion, and complications (e.g., desaturation, airway trauma, failed attempts) will also be recorded. No extra procedures will be performed beyond routine airway management."
223650562|NCT07057908|PROCEDURE|Video Laryngeal Mask Airway (SaCoVLM) Intubation with Bougie|"Participants in this group will undergo tracheal intubation using a video laryngeal mask airway (SaCoVLM) under general anesthesia. After successful placement of the device, a standard bougie will be inserted through the SaCoVLM's dedicated lumen, and an endotracheal tube will be advanced over the bougie into the trachea under video guidance.~The primary outcome will be intubation time, defined as the duration from device insertion to confirmation of successful intubation. Secondary outcomes include intubation success rate, ease of insertion, and complications such as desaturation, trauma, or failed attempts. As both techniques are part of routine practice, no additional risks will be introduced."
223650563|NCT07075497|OTHER|Neuromuscular electrical stimulation (NMES)|NMES is applied during each 10-second isometric hamstring contraction using an Enraf Nonius TensMed S82 stimulator delivering biphasic, symmetric rectangular pulses at 50 Hz with a 250 µs pulse width. Two 5 × 5 cm self-adhesive electrodes are placed on the hamstrings-one approximately two finger-breadths below the gluteal fold and the other over the distal third of the muscle belly. Stimulation intensity is individually titrated to each participant's maximal motor threshold-eliciting a strong, yet painless, contraction-and the exact milliamperage is recorded for each leg. Elastic straps over the pelvis and distal thigh maintain pelvic anteversion and knee extension. During each session, one researcher secures limb positioning while a second adjusts and logs NMES intensity and cues the timing of the 10 s contraction and ensuing 30 s passive stretch.
223650564|NCT07075497|OTHER|Sham Neuromuscular electrical stimulation (NMES)|Sham NMES is delivered during each 10 s isometric hamstring contraction using an Enraf Nonius TensMed S82 stimulator with biphasic, symmetric rectangular pulses (50 Hz, 250 µs pulse width). Two 5 × 5 cm self-adhesive electrodes are placed on the hamstrings-one two finger-breadths below the gluteal fold and one over the distal third of the muscle belly. Intensity is individually set to the sensory threshold, defined as the minimal current producing a slight tingling without any visible muscle response; this milliamperage is recorded for each leg. Elastic straps over the pelvis and distal thigh maintain pelvic anteversion and full knee extension. During each session, one researcher secures limb positioning while a second adjusts and logs the NMES intensity and cues the 10 s contraction timing.
223766965|NCT07148986|DIETARY_SUPPLEMENT|Clarity Product Placebo Control|Participants will use their Clarity Product Placebo Control as directed for a period of 6 weeks.
224320500|NCT02271295|DRUG|Enoxaparine|Enoxaparine 4000UI/day during 24 months
224320501|NCT05416242|DEVICE|Traditional braces|MBT 0.022 perception traditional braces will be used without any acceleration method.
224320502|NCT05416242|DEVICE|Self-ligating braces|MBT 0.022 perception Self-ligating braces will be used without any acceleration method.
224320503|NCT05416242|PROCEDURE|Self-ligating braces + piezocision|Flapless corticotomy will be applied for the upper anterior teeth.
224320504|NCT02930759|DRUG|BAY987516|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation Code: Z46-096)
224320505|NCT03732430|DRUG|IBI308|A humanized anti-PD-1 monoclonal antibody
224320506|NCT04133987|BIOLOGICAL|Tetravalent live attenuated dengue vaccine admixture TV005|The admixtures of the candidate vaccines each contain 4 live attenuated dengue viruses, each of a different serotype.
223650565|NCT07075497|OTHER|Contract-Relax PNF (crPNF)|The crPNF Group engages in an isolated contract-relax proprioceptive neuromuscular facilitation (crPNF) stretching protocol. Participants are positioned in a long sitting posture with maximum knee extension until they feel a moderate-strong stretch sensation, without pain. Each stretch lasts for 30 seconds, followed by a 10-second maximal voluntary isometric contraction of the hamstrings. Participants complete three cycles of stretch and contraction. One researcher maintains the stretch position while a second researcher controls the timing of the stretching and contractions.
223650566|NCT07074938|DRUG|Jianmin Daopeng Angong Niuhuang Wan|An Gong Niu Huang Wan comes from JianMin Dapeng.
223650567|NCT07074938|DRUG|Tongrentang Angong Niuhuang Wan|Angong Niuhuang Wan comes from Tongrentang.
223650568|NCT06923488|DRUG|Leflunomide 10mg|Leflunomide 10mg tablet
223650569|NCT06923488|DRUG|Leflunomide 20mg|Leflunomide 20mg tablet
223650570|NCT06923488|DRUG|Decitabine|Decitabine dose of 20 mg/m2
223650571|NCT06938581|OTHER|ERAS Protocol|"The ERAS protocol consists of:~* Day before surgery: Oral carbohydrate drink (evening), Acetaminophen 1000mg (evening), Celecoxib 200mg (morning and evening)~* Morning of surgery: Oral carbohydrate drink (2-4 hours before surgery), Celecoxib 200mg, Acetaminophen 1000mg Additionally, optional perioperative medications (Acetaminophen, Scopolamine, Dexamethasone, Ondansetron) may be given as needed."
223650572|NCT06938581|OTHER|Standard Perioperative Care|Standard perioperative care without ERAS protocol components. Includes routine preoperative instructions and omission of oral carbohydrate drink, celecoxib, and preoperative acetaminophen. Optional perioperative medications (Acetaminophen, Scopolamine, Dexamethasone, Ondansetron) may be given as needed.
223650573|NCT05102253|PROCEDURE|Dense cranial electroacupuncture stimulation (DCEAS)|"DCEAS will be conducted for 2 sessions per week for 12 consecutive weeks. Electrical stimulation will be conducted on six pairs of forehead acupoints located on the frontal, parietal, and temporal scalp areas. The acupoints includes: Bai-Hui (GV20), Yin-Tang (EX-HN3), left and right Si-Shen-Cong (EX-HN1), Tou-Lin-Qi (GB15), Shuai-Gu (GB8), Tai-Yang (EX-HN5) and Tou-Wei (ST8).~Disposable acupuncture needles will be inserted at a depth of 10-30 mm perpendicularly or obliquely into acupoints. Manual manipulation will be carried out for all acupoints to evoke needling sensation, followed by electrical stimulation. The stimulation intensity will be adjusted to a level at which patients felt most comfortable. Each session of treatment will last 30 min."
223650574|NCT05102253|PROCEDURE|Transcutaneous electrical acupoint stimulation (TEAS)|"TEAS will be done for 3 times per week for 12 consecutive weeks by participants at home. A training workshop will be conducted to instruct participants how to use TEAS stimulator. Briefly, TEAS will be delivered on the bilateral Nei-Guan (PC6), which is located on the anterior forearm, between the tendons of the palmaris longus and ﬂexor carpi radialis, at the junction of the distal sixth and proximal ﬁve sixths of the line connecting the middle points of the wrist and elbow crease.~Constant current electrical impulses will be produced from a TEAS apparatus. Two electrode pads will be adhered onto the acupoint skin. The pulse amplitude will be adjusted to a level at which the perception of 'strong but comfortable' is achieved. Each session of treatment will last 30 min."
223650575|NCT05102253|OTHER|Wait-list control: Routine care|The routine care may include medications, advocacy intervention, and CBT. Post-trial treatment of TEAS+DCEAS will be offered to serve as a compensation for their participation.
223650576|NCT04508491|OTHER|Rhythm control|Rhythm control with medications or any procedure
223650577|NCT04508491|OTHER|Rate control|Rate control
223650578|NCT01934647|DRUG|MK-8892|Single oral capsule with 1 mg, 4 mg, or 8 mg of MK-8892
223650579|NCT06458478|OTHER|Hyper-oxygenated gel|Novox drop is a medical device (CE certified, class II b, non-invasive) based on oxygen-enriched olive oil (Excipients: Mint essential oil (2%), Stevia extract (1%)). Mechanism of action: facilitate the healing process by creating, thanks to the release of reactive oxygen species (ROS), a microenvironment favorable to the activation of the microcirculation and at the same time unfavorable to the proliferation of pathogens. Furthermore, it has a film-forming, protective, barrier and soothing action thanks to its oily nature.
223766966|NCT07124351|DRUG|CYTALUX™ (pafolacianine)|All subjects participating in the study are expected to receive CYTALUX™ (pafolacianine) injection and standard care surgery; 1 to 24 hours after CYTALUX™ (pafolacianine) injection infusion is completed, all tumors planned to be removed as part of standard care will undergo assessment with NIR light imaging both intraoperatively and on the back table following surgery.
223650580|NCT06458478|OTHER|glycerin based gel|The placebo consists of a viscous, colorless and transparent gel, based on glycerin (Conformity:FUI).
223650581|NCT00156468|BEHAVIORAL|Provider Prompt|
223650582|NCT00531791|DRUG|prednisone group|Patients in the prednisone group will receive prednisone 40 mg per day with concomitant placebo diskus 2 inhalations twice a day for 10 days. All patients will receive oral antibiotics for 10 days, which will include moxifloxacin (Avelox®) 400 mg die or amoxicillin/clavulanate (Clavulin®) 875mg bid and short-acting bronchodilators (Ventolin®, Bricanyl®, Atrovent®) as needed.
223650583|NCT00531791|DRUG|Advair group|Patients in the second group will receive Advair® 50/500 ug 2 inhalations twice daily with placebo pills once a day for 10 days (twice the regular dosage). All patients will receive oral antibiotics for 10 days, which will include moxifloxacin (Avelox®) 400 mg die or amoxicillin/clavulanate (Clavulin®) 875mg bid and short-acting bronchodilators (Ventolin®, Bricanyl®, Atrovent®) as needed.
223766967|NCT07138677|OTHER|transcranial magnetic stimulation|Neuronavigated Theta-Burst Transcranial Magnetic Stimulation
223766968|NCT07152184|DRUG|Use of antipsychotic treatment with marketing authorization at doses lower than those recommended: - Olanzapine - Zuclopenthixol - Risperidone - Pipotiazine palmitate / Pipotiazine - Quetiapine - Flup|"Biological A blood sample of up to 5 mL will be taken at visits V0, V5, and V14, for a maximum total volume of 15 mL for the study.~Behavioral Quality of life and disease assessment questionnaires will need to be completed by the patient and their caregiver."
223766969|NCT07153081|DEVICE|Actigraphy watch intervention|Participants in this group only will be given an Actigraphy watch to track their physical activity levels.
223766970|NCT07156721|DEVICE|Phototherapy with White Reflective Drape|Phototherapy device (24 blue LED, 1 red LED, Ertunç Özcan) at 35 cm distance; a double-layer white reflective drape (125 × 105 cm) was placed around three sides and overhead, with a white sheet under the infant.
223766971|NCT07156721|DEVICE|Standard Phototherapy|Phototherapy device (24 blue LED, 1 red LED, Ertunç Özcan) at 35 cm distance; no reflective drape or additional reflective material used.
223650584|NCT02067676|BIOLOGICAL|Capsule-Conjugate Campylobacter Vaccine (CJCV1)|The capsule of Campylobacter jejuni strain 81-176 (CPS81-176) conjugated to the mutated diphtheria toxin cross-reacting material 197 (CRM197) (lyophilized CPS-CRM197 conjugate) (CJCV1)
223650585|NCT02067676|DRUG|Alhydrogel®, aluminum hydroxide adjuvant (alum)|
223650586|NCT02164708|BEHAVIORAL|Mindfulness Meditation|"The program progressively trained students in mindfulness of breathing, a form of meditation frequently employed secularly. The tutorials were held on campus five times weekly, led by a faculty member and a graduate student who were trained, experienced MM practitioners. The tutorials were one hour in duration and typically involved 40-45 minutes of guided MM followed by a question-answer period that addressed recent research findings. Program participation required attendance at one tutorial per week, and participants were encouraged to maintain autonomous MM practice."
223650587|NCT00996333|DRUG|Gemcitabine, Docetaxel, Capecitabine|"1500mg/m2/day of Capecitabine for 14 days 750mg/m2 of Gemcitabine on Day 4 and 11 30mg/m2 of Docetaxel on Day 4 and 11~This 2-week regimen is followed by 1 week off for a total of a 21-day cycle. This is repeated for a total of 3 cycles."
224235239|NCT07036250|DRUG|U32 CAR-T|Lymphodepletion preconditioning is required prior to CAR-T cell therapy. Lymphodepletion will be performed using a regimen of cyclophosphamide (250-500 mg/m²) and fludarabine (25-30 mg/m²), each administered for 3 consecutive days.
224235240|NCT02448771|DRUG|Palbociclib|
224320507|NCT04133987|BIOLOGICAL|Placebo|PLASMA-LYTE A Injection pH 7.4 (Multiple Electrolytes Injection, Type 1, USP) is a sterile, nonpyrogenic isotonic solution in a single dose container for intravenous administration.
223650588|NCT01243580|DRUG|Ortho-Cyclen|Ortho-Cyclen is an oral contraceptive containing 35 µg of EE and 250 µg of norgestimate (NGM) in a 21 - 7 day regimen.
223650589|NCT01243580|DRUG|AG200-15|AG200-15 is a transdermal contraceptive delivery system delivering 100 - 120 mcg of LNG and 25 - 30 mcg EE
223650590|NCT03372681|PROCEDURE|Isoperistaltic Billroth II + Braun anastomosis|Laparoscopic distal gestrectomy will be applied with Isoperistaltic Billroth II + Braun reconstruction
223650591|NCT03372681|PROCEDURE|Antiperistaltic Billroth II + Braun anastomosis|Laparoscopic distal gestrectomy will be applied with antiperistaltic Billroth II + Braun reconstruction
223650592|NCT04660565|DRUG|Prednisone and Belimumab|Prednisone/prednisolone: started at 0.6-0. 8mg/kg.d for 2 to 4 weeks, tapered at 5mg per 1-2 weeks to equal to or less than 5mg per day in 3 months. Belimumab will start at the same time as the prednisone induction.
223650593|NCT04660565|DRUG|Prednisone|Prednisone/prednisolone: started at 0.6-0. 8mg/kg.d for 2 to 4 weeks, tapered at 5mg per 1-2 weeks to equal to or less than 5mg per day in 3 months.
223766972|NCT07160101|OTHER|Eggshell derived nano hydroxyapatite|Eggshell derived nano hydroxyapatite has high solubility and allows faster integration \& replaces with osseous tissue
223766973|NCT07160101|OTHER|Hydroxyapatite|Hydroxyapatite has similar chemical composition with crystalline structure of native bone
224235241|NCT02448771|DRUG|Bazedoxifene|
224235242|NCT00004584|DRUG|Atazanavir|
224235243|NCT00004584|DRUG|Ritonavir|
224235244|NCT00004584|DRUG|Saquinavir|
224235245|NCT03136783|OTHER|Development of the most specific physiologically relevant experimental patient models|Development of the most specific physiologically relevant experimental patient models: organotypic culture of biopsies, reconstituted skin (equivalents of dermis with melanoma, dermis equivalents and epidermis with melanoma), and in vitro evaluation The response of tumor cells to different combinations of targeted therapy molecules
224235246|NCT02328781|DEVICE|Drug-eluting stent|
224235247|NCT03604887|DIAGNOSTIC_TEST|ultrasonography|"Ultrasound evaluation will be done with transducer abdominal probe. The amount of amniotic fluid and umbilical cord sections will be determined by evaluating the images obtained from the sagittal plane in the ultrasound evaluations in the 4 abdominal quadrants.~When the anatomical structure of the umbilical cord is considered, it is folded in amniotic fluid. The folds appear as umbilical cord rings, side-by-side at the sagittal sections.~Scoring of umbilical cord length index~* 1 point will be given for each quadrant where the umbilical cord was observed.~* 0.5 point will be given for each umbilical cord ring in one quadrant. Every quadrant will be evaluated in this manner, and the total score will be calculated."
224235248|NCT03559764|BIOLOGICAL|Anti-BCMA CAR T cells|Transparent colorless or slightly yellow liquid
223650594|NCT02177071|DRUG|INFLIXIMAB|
223650595|NCT02177071|DRUG|AZATHIOPRINE|
224235249|NCT07056036|DEVICE|ActiveTreatment with BTL-699-2|Participants will receive six transcranial magnetic stimulation treatments with the BTL-699-2 device over the left dorsolateral prefrontal cortex. The intensity will be adjusted according to the subject's feedback, up to 70% of the individual's motor threshold. The treatments will be spaced 3 - 7 days apart.
224320508|NCT05794698|PROCEDURE|Surgical resection|Surgical resection of lung adenocarcinoma. Wedge resection, segmentectomy or lobectomy will be performed according to each patients' condition.
224320509|NCT02358512|OTHER|Enteral feeding|Bolus feeds or continuous feeds during a 10-day ICU stay
223650596|NCT02177071|DRUG|MERCAPTOPURINE|
223650597|NCT02177071|DRUG|Methotrexate|
223650598|NCT03655249|OTHER|Autogenic drainage|Autogenic drainage is an airway clearance technique that attempts to obtain the optimal airflow to evacuate the secretions. This technique uses modulation of inspiratory and expiratory airflow at different breathing level within the vital capacity.
223650599|NCT03655249|DRUG|Aerosoltherapy|Aerosolized drugs are individualized for each participants, in line with current standardized practice in our hospital. Those drugs will not be modified for the purpose of this study.
223650600|NCT03238495|DRUG|Taxotere, Carboplatin, Herceptin + Pertuzumab|TCH+P chemotherapy every 3 weeks for 6 cycles: Taxotere 75mg/m2, Carboplatin AUC 6, Herceptin 6mg/kg (first cycle loading dose of 8mg/kg), Pertuzumab 420mg (first cycle loading does of 840mg)
223650601|NCT03238495|DRUG|Metformin|TCH+P chemotherapy every 3 weeks for 6 cycles. Metformin 850 mg daily during the first cycle, then 850 mg twice daily for the remaining 5 cycles.
224320510|NCT04342195|PROCEDURE|Blood draw|Participants will have approximately 45 ml of whole blood drawn (3 Tablespoons) drawn at the study visit.
224320511|NCT03893643|OTHER|no intervention|no intervention in an observational study
224320512|NCT02252354|DRUG|[14C]-TAK-385 Oral Solution|TAK-385 oral radiolabelled solution
224320513|NCT02252354|DRUG|TAK-385 Tablets|TAK-385 tablets 2 X 40 mg
224320514|NCT02252354|DRUG|[14C]-TAK-385 Solution for Intravenous Infusion|TAK-385 intravenous (IV) radiolabelled solution
223650602|NCT04853017|DRUG|ELI-002 2P|Amph-CpG-7909 admixed with Amph modified KRAS peptides (Amph-G12D and Amph-G12R) administered via SC injection weekly for 4 consecutive weeks, followed by bi-weekly injections over 4 weeks, during the Immunization Period; additional SC injections weekly for 4 consecutive weeks during the Booster Period (the two periods are separated by 3 months of no dosing)
223650603|NCT03460262|DEVICE|Standard cutiplast®|Our standard dressing consists in a usual ready-to-use Smith and Nephew Cutiplast®. This dressing is open 48 hours after the operation (CDC recommendation) for the first time and then changed every day after wound disinfection.
223650604|NCT03460262|DEVICE|PICO®|PICO® is a negative pressure wound therapy consisting in a 4 layers ready-to-use dressing connected to a small console, responsible for the aspiration. The system is canister free. The fluid drained from the wound is lost by evaporation for 80% of it and only 20% remains in the dressing. This permits to the dressing to be kept in place for maximum 7 days. The wound is not checked during the hospital stay, allowing the patient to leave the hospital earlier after the operation.
223650605|NCT05985369|OTHER|Controlled diet and resistance exercise|Participants will adopt a 1-week completely controlled diet and perform 3 sessions of unilateral leg resistance exercise.
223650606|NCT00505349|BEHAVIORAL|Computer-based cognitive training|The experimental cognitive training program consists of interactive training exercises in which the participant responds to visual patterns and stimuli. The program is designed upon the principles of brain-plasticity, and, for the purposes of this study, is intended to be used for an 8-10 week period (40 total hours of training.)
223650607|NCT01802138|BIOLOGICAL|Activated T lymphocyte|intravenous dripping of 200 ml (10\^9\~2\*10\^10 lymphocytes) for 1 hour.
223650608|NCT03393988|DRUG|Fentanyl infusion|After induction of general anesthesia; Fentanyl infusion (0.5 µg/kg/hr) will be started (which will be afterwards adjusted intraoperatively according to the hemodynamics and Bispectral Index (BIS) reading).
223650609|NCT03393988|PROCEDURE|Ultrasound guided TAP block|After induction of general anesthesia; Patients will receive ultrasound guided subcostal oblique TAP block with 0.25 % bupivacaine 40 ml on each side resulting in a total volume of 80 ml, subcostal TAP block was given twice, at the beginning and at the end of the surgery.
223650610|NCT03393988|DRUG|Dexmedetomidine|Dexmedetomidine (200 µg in 2 ml diluted in 48 ml of saline) will be started in a dose of 1 μg/kg over 10 min then maintenance dose as continuous infusion between 0.2 and 0.8 μg/ kg/h through infusion pump (which will be adjusted according to the hemodynamics and BIS reading)
223650611|NCT04387084|DRUG|Atezolizumab|Given IV
223650612|NCT04387084|DRUG|Avelumab|Given IV
223650613|NCT04387084|BIOLOGICAL|Cemiplimab|Given IV
223650614|NCT04387084|BIOLOGICAL|Durvalumab|Given IV
223650615|NCT04387084|BIOLOGICAL|Nivolumab|Given IV
223650616|NCT04387084|BIOLOGICAL|Pembrolizumab|Given IV
223650617|NCT04387084|OTHER|Quality-of-Life Assessment|Ancillary studies
223650618|NCT04387084|OTHER|Short-Term Fasting|Undergo STF
223650619|NCT04387084|BIOLOGICAL|Dostarlimab|Given IV
223650620|NCT04387084|BIOLOGICAL|Retifanlimab|Given IV
223650621|NCT04387084|BIOLOGICAL|Toripalimab|Given IV
223650622|NCT04387084|BIOLOGICAL|Tislelizumab|Given IV
223650623|NCT03572595|DIAGNOSTIC_TEST|F-18 FDG-PET/CT|imaging using Positron Emission Tomography/ Computed Tomography with 18F-fluoro-2-deoxyglucose (18F- FDG PET/CT) in Patients with colorectal cancer either for staging or suspecting recurrence
224235250|NCT07056036|DEVICE|Sham Treatment with BTL-699-2|Participants will receive six transcranial magnetic stimulation treatments with the BTL-699-2 device over the left dorsolateral prefrontal cortex. The intensity will se to 5% of the individual's motor threshold. The treatments will be spaced 3 - 7 days apart.
223650624|NCT00887211|DEVICE|stent|ProStent rapamycin-eluting stent system manufactured by Tianjian Medical Technology (Suzhou) Co., Ltd.
223650625|NCT00887211|DEVICE|stent|Firebird drug-eluting stents from MicroPort Medical (Shanghai) Co., Ltd.
224235251|NCT01907009|DRUG|Melphalan|Patients will receive Melphalan in three cycles In the first cycle they recieve 60mg/m2 and then 40mg/m2 in the next two cycles.
224235252|NCT01907009|DRUG|Lenograstim|"Starting Lenograstim will be at 10mcg/kg/day and between cycles at 10mcg/kgs/day.~After the third cycle patient will receive 263mcg/day for 10 days."
223650626|NCT04112212|DRUG|Fluorescence molecular imaging procedure using vedolizumab-800CW|First vedolizumab-800CW was administered intravenously. 2-4 days later a fluorescence molecular imaging procedure was performed to enable the visualization and detection of fluorescence signals.
223650627|NCT04112212|OTHER|Fluorescence molecular imaging procedure without prior administration of vedolizumab-800CW|Fluorescence molecular imaging was performed to enable the visualization and detection of fluorescence signals.
223650628|NCT04112212|COMBINATION_PRODUCT|Fluorescence molecular imaging procedure using vedolizumab-800CW with prior administration of unlabeled vedolizumab|Patients on vedolizumab therapy received vedolizumab-800CW iv or patients first received an unlabeled dose of vedolizumab prior to the iv administration of vedolizumab-800CW. 2-4 days later a fluorescence molecular imaging procedure was performed to enable the visualization and detection of fluorescence signals.
223650629|NCT06103253|DIETARY_SUPPLEMENT|a Bla80 group|the BLa80 group received 2.9 g of maltodextrin + 0.1 g of BLa80 bacterial powder 10B daily.
223650630|NCT00003897|BIOLOGICAL|gp100 antigen|
223650631|NCT00003897|BIOLOGICAL|sargramostim|
223650632|NCT03300596|BEHAVIORAL|Brief intervention to prevent suicide attempt|A patient-centered, 3-session intervention that calls for videotaping the narrative story of a patient's suicide attempt, in his/her own words (session 1); reviewing segments of the tape to arrive at a shared understanding of the attempt and the sequence of events that led to it (session 2); and using this information, along with a homework task completed by the patient in-between sessions, in order to develop a collaborative, comprehensive written safety plan that addresses the patient's unique vulnerabilities (session 3).
223766974|NCT07164001|OTHER|Twin-Specific Growth Chart Interpretation|Participants in this arm will have their fetal growth assessed using twin-specific growth charts. These charts account for twin gestation norms and may influence clinical decision-making regarding growth restriction and perinatal management. The intervention does not involve any direct physical procedure or device but rather a change in the interpretation framework of routinely collected ultrasound data.
224235253|NCT01572766|OTHER|FRAX Assessment Tool|FRAX Assessment Tool is designed to assess risk for fracture based on country of origin, race, and other factors.
223650633|NCT03300596|BEHAVIORAL|Enhanced treatment as usual|Safety procedures' control intervention. For these procedures we will share summary results of the research assessments regarding suicidal thoughts, suicidal behaviors, alcohol and drug use and related problems, and depressive symptoms with appropriate hospital clinical staff. We will also arrange to send this information, with participants' permission, to their ongoing therapist or treatment program and, if none exists, to the therapist or program to which they are being referred. In this regard, the research assessment protocol serves a dual function of helping with additional monitoring of high-risk patients in addition to providing data for the study.
223650634|NCT01324037|OTHER|diagnostic algorithm|diagnostic algorithm consisting of a clinical decision rule, D-dimer and (serial) ultrasonography
223650635|NCT03641586|DRUG|BGB-283|
223650636|NCT03115788|OTHER|Heat induced pain|For the heat induced thermal pain, the research nurse will train the subject to estimate pain quantitatively using a 2 cm 2 Peltier controlled thermode (TSA®) applied to the skin of the arm. Typically, the subject is exposed to temperatures between 41° and 49° C using a random staircase method. After the volunteer learns to qualitatively estimate the thermal pain, pain will be established by heating the the leg with a 4 cm2 Peltier controlled thermode (TSA®) for 90 seconds with the probe clamped at a thermal intensity of 47°C.
223650637|NCT03115788|OTHER|Cold Induced Pain|Cold pain will be induced by placing a foot in a container of circulating water maintained at 10°C for 90 seconds (n=20). Half (n=20) of the subjects will have the foot placed in body temperature water of 38°C.
223650638|NCT03115788|OTHER|iPad|
223766975|NCT07164001|OTHER|Singleton-Based Growth Chart Interpretation|Participants in this arm will have their fetal growth assessed using singleton-based growth charts. These charts are commonly used in standard practice but may overestimate growth restriction in twin pregnancies. The intervention does not involve any direct physical procedure or device but alters the interpretation framework for standard prenatal ultrasound findings.
223650639|NCT06122415|DIAGNOSTIC_TEST|Plasma Amyloid Probability Score 2 (APS 2) score|APS 2 score (combination of ptau217/nptau217 and Ab42/Ab40). The cut off will be predefined. The samples will be analysed prospectively every two weeks.
223650640|NCT06122415|DIAGNOSTIC_TEST|Plasma ptau217/nptau217|The cut off will be predefined. The samples will be analysed prospectively every two weeks.
223650641|NCT06122415|DIAGNOSTIC_TEST|Plasma ptau217|The cut off will be predefined. The samples will be analysed prospectively every two weeks.
223650642|NCT06122415|DIAGNOSTIC_TEST|Plasma neurofilament light (NfL)|The cut off will be predefined. The samples will be analysed prospectively every two weeks.
223650643|NCT06122415|DIAGNOSTIC_TEST|Plasma Ab42/Ab40|The cut off will be predefined. The samples will be analysed prospectively every two weeks.
223650644|NCT04965597|DRUG|Treosulfan|Given IV
223766976|NCT07167810|PROCEDURE|bone cement|chest wall reconstruction using polymethyl methacrylate PMMA bone cement
223766977|NCT07167810|PROCEDURE|steel wires|chest wall reconstruction using no 05 stainless sternal steel wires
223766978|NCT07167199|PROCEDURE|Subcuticular monocryl suture|Under the skin suture placed by hand
223766979|NCT07167199|DEVICE|Subcuticular absorbable staple using Insorb device|Under the skin stapling device that delivers absorbable staples
223766980|NCT07170566|DEVICE|innovaMatrix AC|"nnovaMatrix® AC consists of ECM derived from porcine placental material. The device is supplied in a variety of sterile sheet configurations. It is packaged in double peel-open packages and is intended for single use only. The device is terminally sterilised using E-Beam sterilisation and is for licensed healthcare practitioner use only.~InnovaMatrix® AC is composed of collagen, elastin, laminin, fibronectin, hyaluronic acid and sulphated glycosaminoglycans. The wound dressing is provided in sheets that are approximately 40-100 microns thick in sizes ranging from 1 x 1cm to 5 x 5cm. They are provided as single-use, sterile wound coverings.~InnovaMatrix® AC received Food and Drug Administration (FDA) clearance under K193552 on October 21, 2020. InnovaMatrix® AC has an FDA classification of KGN, which designates it as a collagen wound dressing."
223766981|NCT07173413|OTHER|Telephone post-surgery physiotherapy follow-up|Post-operative physiotherapy follow-up delivered via a structured telephone consultation. The session focuses on recovery after lumbar spine surgery, addressing pain management, mobility, exercise recommendations, and guidance on daily activities. The physiotherapist evaluates the patient's status verbally, answers questions, and provides tailored advice to support safe rehabilitation without requiring the patient to attend the hospital physically.
223766982|NCT07173413|OTHER|In person post-operative physiotherapy follow-up|Post-operative physiotherapy follow-up delivered as an in-person consultation at the hospital. The session includes assessment of recovery after lumbar spine surgery, hands-on evaluation if needed, and tailored advice on pain management, mobility, exercise progression, and daily activity. This format allows the physiotherapist to physically observe and, if relevant, demonstrate exercises to ensure correct performance and safe rehabilitation.
224235254|NCT07076056|DRUG|DW1026C1|Sitagliptin 100mg+Empagliflozin 10mg
224235255|NCT07076056|DRUG|DW1026C2|Sitagliptin 100mg+Empagliflozin 25mg
223650645|NCT04965597|DRUG|Fludarabine Phosphate|Given IV
223650646|NCT04965597|DRUG|Tacrolimus|Given IV and PO
223650647|NCT04965597|DRUG|Methotrexate|Given IV
223650648|NCT04965597|BIOLOGICAL|Lapine T-Lymphocyte Immune Globulin|Given IV
223650649|NCT04965597|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo PBSC
223650650|NCT04965597|PROCEDURE|Allogeneic Bone Marrow Transplantation|Undergo bone marrow transplant
223650651|NCT04965597|OTHER|Quality-of-Life Assessment|Ancillary studies
223650652|NCT04965597|PROCEDURE|Echocardiography|Undergo ECHO
223650653|NCT04965597|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
223650654|NCT04965597|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy and aspiration
224235256|NCT07076056|DRUG|DW1026S|Sitagliptin 100mg
224235257|NCT07076147|OTHER|Non-Interventional Study|Non-interventional study
224235258|NCT07076108|DRUG|Normal regimen of treatment of anemia|Patients were on normal regimen of treatment of anemia.
224235259|NCT07076108|DRUG|Vitamin C|Patients were on 250 mg oral vitamin C daily for 3 months.
223650655|NCT04965597|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow biopsy and aspiration
223650656|NCT04965597|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223650657|NCT04965597|PROCEDURE|X-Ray Imaging|Undergo chest x-ray
223650658|NCT04965597|PROCEDURE|Computed Tomography|Undergo chest CT
223650659|NCT05566561|DRUG|Postoperative analgesia management|Intravenous 0.5 mg/kg tramadol and 400 mg ibuprofen will be administered to all patients 30 minutes before the end of the surgical procedure. In the postoperative period, patients will be administered ibuprofen iv 400 mg 3x1. Postoperative patient evaluation will be performed by another pain nurse who is unaware of the procedure. Patients in all groups will be attached to IV PCA containing 10 mcg/ml fentanyl, 10 mcg bolus without infusion dose, and 10 min lock time protocol. If the NRS score is ≥ 4, 0.5 mg kg-1 iv meperidine will be administered as a rescue analgesic.
223650660|NCT06375499|DEVICE|T2769|Daily dose regimen: 1 drop in each eye, from 3 to 6 times daily.
223650661|NCT06375499|DEVICE|Hylo-Forte®|Daily dose regimen: 1 drop in each eye, from 3 to 6 times daily.
223650662|NCT04729322|PROCEDURE|Biopsy|Undergo biopsy
223650663|NCT04729322|PROCEDURE|Fecal Microbiota Transplantation|Undergo colonoscopic FMT
223766983|NCT07173192|BEHAVIORAL|Individual empowerment program|"Data collection tools will be applied to individuals in the experimental and control groups as a pre-test.~Individual empowerment training sessions will be applied to individuals in the experimental group totaling (6 sessions) as part of the individual empowerment program. No intervention will be performed on individuals in the control group; they will receive standard discharge education. Data collection tools will be applied to individuals in both groups for post-tests immediately after the experimental group completes all individual empowerment program sessions."
224235260|NCT07076108|DRUG|Vitamin C|Patients were on 500 mg oral vitamin C daily for 3 months.
224235261|NCT07076095|DRUG|IBB0979|bifunctional antibody-cytokine fusion protein that targets B7-H3 and IL-10 receptor
224235262|NCT07076095|DRUG|topotecan hydrochloride for injection|Topotecan hydrochloride will be administered intravenously per prescribing information.
223650664|NCT04729322|DRUG|Fecal Microbiota Transplantation Capsule|Given PO
223650665|NCT04729322|DRUG|Metronidazole|Given PO
223650666|NCT04729322|DRUG|Neomycin|Given PO
223650667|NCT04729322|BIOLOGICAL|Nivolumab|Given IV
223650668|NCT04729322|BIOLOGICAL|Pembrolizumab|Given IV
223650669|NCT04729322|OTHER|Questionnaire Administration|Ancillary studies
223650670|NCT04729322|DRUG|Vancomycin|Given PO
223650671|NCT04223349|DRUG|JNJ-70033093|JNJ-70033093 capsules will be administered orally .
223650672|NCT04223349|DRUG|Placebo|Matching placebo in capsule will be administered orally.
223766984|NCT07174089|OTHER|RadEye SPRD-ER device: spectrometric radiation detector capable of detecting gamma radiation.|Acquisition of data during the infusion of PET radiotracers and the administration of α and β emitting radiopharmaceuticals for therapy.
224235263|NCT01640769|PROCEDURE|4D Model guided delivery of cardiac pacing leads|4D model-guided placement of LV and RV leads to optimal myocardial targets, as derived from pre-procedural Cardiac MRI
224235264|NCT01640769|PROCEDURE|Standard CRT lead delivery|Standard lead delivery
224235265|NCT05343130|DEVICE|Brain-Computer Interface|Hand movement will be elicited using functional electrical stimulation activated by the brain-computer interface based on hand movement intention.
224235266|NCT05343130|DEVICE|Sham Brain-Computer Interface|Hand movement will be elicited using functional electrical stimulation which activation will be independent of the brain-computer interface based on hand movement intention.
224235267|NCT03618979|BIOLOGICAL|PPP treatment|The day prior to or the morning of the procedure, patient will have their blood drawn by a phlebotomist and processed into 5 or 10 cc of PPP depending on if there is lumbar multifidus atrophy in one or two levels. Using sterile technique and ultrasound guidance, once touching the lamina the physician will inject 2.5 cc of PPP. The physician will then repeat the procedure on the opposite side.
224235268|NCT03618979|BIOLOGICAL|PRP treatment|The day prior to or the morning of the procedure, patient will have their blood drawn by a phlebotomist and processed into 5 or 10 cc of 5x PRP depending on if there is lumbar multifidus atrophy in one or two levels. Using sterile technique and ultrasound guidance, once touching the lamina the physician will inject 2.5 cc of PRP and remove the needle. The physician will then repeat the procedure on the opposite side and at the next level if indicated.
223650673|NCT04042337|BEHAVIORAL|Pivotal Response Treatment|PRT will target functional communication abilities
223650674|NCT03959878|DEVICE|Constant Pressure Skin Disk|The external disk is made of Dow Corning® Silastic Q7-4850 liquid silicone rubber. Placement of the disk will be done by the gastroenterologist or interventional radiologist during the gastrointestinal gastrostomy tube (GIG) or gastrointestinal jejunostomy tube (GIJ) placement procedure. The gastroenterologist or interventional radiologist will replace the manufacturer's external, adjustable skin disk with the external, adjustable Constant Pressure Skin Disk, by sliding the former off and the latter on to the feeding tube.
223650675|NCT02858505|DRUG|27 mg elemental iron|
224235269|NCT03618979|BIOLOGICAL|PRP and PL Combo treatment|The day prior to or the morning of the procedure patient will have their blood drawn by a phlebotomist and processed into 5 or 10 cc of 5x PRP and 5 or 10 cc of PL and 2 or 4 cc of 14x PRP depending on if there will be one or two levels injected. Using sterile technique, under ultrasound visualization into the lumbar multifidus and onto the lamina, the physician will inject the PRP and remove the needle. Under intermittent x-ray, epidural flow is confirmed with contrast, the physician will inject 2cc of the PL and 1cc of 0.5% ropivacaine into the epidural space. Once flow is confirmed for the epidural injection and facet with contrast, 1cc of the 14x PRP is injected into the facet joint. Procedure repeated on the opposite side and next level if indicated.
224320515|NCT01180426|DRUG|CHR-2797|120mg once daily oral for 48 weeks
223650676|NCT02858505|DRUG|54 mg elemental iron|
223650677|NCT06308718|BIOLOGICAL|FBX-101|A replication-deficient adeno-associated virus gene transfer vector expressing the human galactocerebrosidase (hGALC) cDNA will be delivered one-time through a venous catheter inserted into a peripheral limb vein.
223650678|NCT03099278|DRUG|Ezetimibe|Ezetimibe 20 mg oral daily
223650679|NCT06420297|DRUG|Carbetocin|Carbetocin nasal spray 3.2 mg three times daily (TID)
223650680|NCT05387759|DRUG|Aticaprant Supratherapeutic Dose|Aticaprant supratherapeutic dose capsule will be administered orally.
223650681|NCT05387759|DRUG|Aticaprant Therapeutic Dose|Aticaprant therapeutic dose capsule will be administered orally.
223650682|NCT05387759|DRUG|Placebo|Placebo will be administered orally.
223650683|NCT05387759|DRUG|Moxifloxacin|Moxifloxacin capsule will be administered orally.
223650684|NCT06398509|BEHAVIORAL|Control|The control intervention includes brief health education and coaching sessions just after well child visits in the first two years of life (total of 7 sessions), 2 text messages per week for the primary caregiver and up to two additional family members, and environmental prompts that support healthy behaviors. The control intervention focuses on home safety, home management of common childhood illnesses, and promotion of language development.
223650685|NCT06398509|BEHAVIORAL|Futuros Fuertes 2.0|The Futuros Fuertes 2.0 intervention includes brief health education and coaching sessions just after well child visits in the first two years of life (total of 7 sessions), 2 text messages per week for the primary caregiver and up to two additional family members, and environmental prompts that support healthy behaviors. The Futuros Fuertes 2.0 intervention focuses on optimal infant feeding, screen time, and sleep practices.
223650686|NCT06453265|DRUG|Cebranopadol- 600 ug|"Dose ascending cohorts~\- Cebranopadol 600 ug single dose"
223650687|NCT06453265|DRUG|Cebranopadol- 800ug|"Dose ascending cohorts~\- Cebraopadol 800 ug single dose"
223650688|NCT06453265|DRUG|Cebranopadol- 1000ug|"Dose ascending cohorts~\- Cebranopadol 1000 ug single dose"
223650689|NCT06453265|DRUG|Treatment A:|Cebranopadol, dose determined in Part A
223650690|NCT06453265|DRUG|Treatment B|Oxycodone HCl IR 40 mg
223650691|NCT06453265|DRUG|Treatment C|Placebo
223650692|NCT06453265|DRUG|Qualification|Oxycodone 40mg
223650693|NCT06453265|DRUG|Qualification|Matching Placebo
223650694|NCT04939415|DRUG|mQFPD|The dosage of mQFPD is 8 capsules three times a day for 14 consecutive days. It does not need to be consumed with food. It is best taken at least 30 minutes before OR at least 60 minutes after meals, in the morning, noon and evening. Accidentally missed doses will not need to be taken at a later time but will be recorded in a daily diary.
223650695|NCT04939415|DRUG|organic brown rice|The dosage of mQFPD is 8 capsules three times a day for 14 consecutive days. It does not need to be consumed with food. It is best taken at least 30 minutes before OR at least 60 minutes after meals, in the morning, noon and evening. Accidentally missed doses will not need to be taken at a later time but will be recorded in a daily diary.
223650696|NCT04216524|DRUG|Cyclophosphamide|Given IV
223650697|NCT04216524|DRUG|Cytarabine|Given IT or IV
223650698|NCT04216524|DRUG|Dexamethasone|Given PO or IV
223650699|NCT04216524|DRUG|Doxorubicin|Given IV
223650700|NCT04216524|DRUG|Mercaptopurine|Given PO
223650701|NCT04216524|DRUG|Methotrexate|Given IT, IV, or PO
223650702|NCT04216524|DRUG|Methylprednisolone|Given IV
223650703|NCT04216524|DRUG|Prednisone|Given PO
224235270|NCT06078488|OTHER|Individualized and Protocolized Nutritional Care Bundle|"Education on nutritional and wound care for patient/family based on the latest guidelines based on the The European Pressure Ulcer Advisory Panel, the National Pressure Injury Advisory Panel, and the Pan Pacific Pressure Injury Alliance Prevention and Treatment of Pressure Ulcers/Injuries: 2019 Clinical Practice Guideline. A dietetic consultation at baseline, week 4 and week 8 on optimizing nutritional intake to meet caloric/protein requirements, along with additional high protein high energy (HPHE) supplementation prescribed for those participants who do not meet nutritional requirements (25-35kcal/kg/d and 1.2-2.0g protein/kg/d). The dietetic consultation will be done via face-to-face home visits and/or telehealth. A specialised nutritional supplement containing 4.5 g Arginine, 156 mg Vitamin C, 40.9 mg alpha-tocopherol equivalents (Vitamin E), 30 kcal will be administered twice a day via oral ingestion or tube feeding (mixed in 100ml water) for 12 weeks."
224235271|NCT06078488|OTHER|Optimized Standard Care|Only receiving education and management from specialized nurses trained in nutritional management , with or without supplementation
224235272|NCT04476732|OTHER|Paraben-free skincare product|Paraben-free lotion will be applied twice a day for one week.
224235273|NCT04476732|OTHER|Paraben-containing skincare product|Paraben-containing lotion will be applied twice a day for one week.
224235274|NCT02358980|DEVICE|KIDNEY therapy|
224235275|NCT00002637|BIOLOGICAL|aldesleukin|
224320516|NCT02285088|DRUG|GBT440|GBT440 will be administered as oral capsules
224320517|NCT02285088|DRUG|Placebo|Matching placebo will be administered as oral capsules
223650704|NCT04216524|BIOLOGICAL|Rituximab|Given IV
223650705|NCT04216524|BIOLOGICAL|Tagraxofusp-erzs|Given IV
223650706|NCT04216524|DRUG|Venetoclax|Given PO
223650707|NCT04216524|DRUG|Vincristine|Given IV
223650708|NCT02629809|DRUG|Cyclophosphamide|Given IV
223650709|NCT02629809|DRUG|Fludarabine Phosphate|Given IV
223650710|NCT02629809|DRUG|Ibrutinib|Given PO
223650711|NCT02629809|BIOLOGICAL|Obinutuzumab|Given IV
223650712|NCT05130580|OTHER|Enhanced Consultation|Attend an enhanced consultation with decision aid
223650713|NCT05130580|OTHER|Standard of Care Consultation|Attend standard of care consultation
223650714|NCT05130580|PROCEDURE|Conventional Imaging|Undergo 2D and 3D torso imaging
223650715|NCT05130580|OTHER|Educational Intervention|Receive educational materials
223650716|NCT05130580|OTHER|Questionnaire Administration|Ancillary studies
223650717|NCT02425293|BEHAVIORAL|asthma patient education|
223650718|NCT05569239|BIOLOGICAL|OVX836 480µg|One single administration intramuscularly at Day 1.
223650719|NCT05569239|BIOLOGICAL|Saline Solution|One single administration intramuscularly at Day 1.
223650720|NCT02436629|DIETARY_SUPPLEMENT|Nitrate-rich concentrated beetroot juice|James White, Beet It Sport Shot, 70ml (Standard)
223650721|NCT02436629|DIETARY_SUPPLEMENT|Nitrate-depleted concentrated red beetroot juice|Beet It Sport Shot, 70ml (Placebo)
223650722|NCT03715348|DRUG|Prothrombin Complex Concentrate (PCC)|PCC is a blood product produced through pooling of thousands of human plasmas, which is then treated to inactivate enveloped viruses. From the pooled plasma, vitamin K dependent clotting factors (factors II, VII, IX and X, and protein C and protein S), are selected to produce the concentrated form called PCC.
223650723|NCT03715348|BIOLOGICAL|Fresh Frozen Plasma|Fresh Frozen Plasma a blood component manufactured from whole blood collection.
223650724|NCT02034864|OTHER|Osteopathic manipulative treatment|A standardized manipulative treatment according to the results of a physical examination including 7 anatomical areas will be given by trained osteopaths during 6 sessions (with an interval of 2 weeks between 2 sessions). Each session will last 45 minutes. Osteopaths will have 3 days of training in standardized manipulative treatment.
223766985|NCT07173231|DEVICE|Immersive Virtual Reality Distraction (IVR)|The first experimental group will receive the INSPIRE® IVR intervention in addition to usual care. Developed by Paperplane Therapeutics®, INSPIRE® is specifically designed to help manage pain and anxiety in clinical settings. This intervention integrates immersive virtual environments with sensor-guided deep breathing techniques to engage the parasympathetic nervous system and promote relaxation. Within a calming forest environment, participants are guided to synchronize their breathing with the movement of a feather, encouraging breath control and relaxation. The immersive experience is enhanced through personalized therapeutic content and calming visual and auditory stimuli, helping to reduce anxiety while minimizing the risk of cybersickness. This program has been endorsed by a multidisciplinary team of healthcare professionals.
224235276|NCT00002637|BIOLOGICAL|gene-modified tumor cell vaccine therapy|
224235277|NCT00002637|BIOLOGICAL|recombinant interferon gamma|
224235278|NCT04637438|OTHER|Fecal Microbiota Transplantation|FMT via colonoscopy
224235279|NCT04637438|OTHER|Placebo|Water infusion via colonoscopy
224235280|NCT02683187|DRUG|Active Comparator: Sitagliptin|Subjects will receive sitagliptin prior to the start of the experiment involving 1/2 of the subjects receiving Exendin-9 (a GLP-1 receptor blocker) first over 60 minutes ; followed by a bolus arginine (5g) infusion after 30 minutes into the Ex-9 infusion, with blood draws over the next 30 minutes. Followed by a 60 minute washout and the procedure is repeated , this time with saline instead of Ex-9 (these procedures are reversed - saline first then Ex-9 - half of the time).
224235281|NCT02683187|DRUG|Placebo Comparator - No Sitagliptin|Subjects will receive Placebo (instead of sitagliptin) prior to the start of the experiment involving 1/2 of the subjects receiving Exendin-9 (a GLP-1 receptor blocker) first over 60 minutes ; followed by a bolus arginine (5g) infusion after 30 minutes into the Ex-9 infusion, with blood draws over the next 30 minutes. Followed by a 60 minute washout and the procedure is repeated , this time with saline instead of Ex-9 (these procedures are reversed - saline first then Ex-9 - half of the time).
224235282|NCT00770315|BIOLOGICAL|Ambrosia artemisiifolia allergen extract (Amb a 1-U)|Rapidly dissolving tablet administered sublingually once daily, at a dose of 1.5, 6 or 12 units.
224235283|NCT00770315|BIOLOGICAL|Placebo|Placebo matching Ambrosia artemisiifolia allergen extract rapidly dissolving tablet, administered sublingually once daily
224235284|NCT02585258|DRUG|Prednisolone|1 capsule containing a tablet of 5 mg prednisolone/ day
224320518|NCT04158362|DRUG|Paclitaxel injection|Paclitaxel is administrated at the dose of 80 mg/m² as a 1-hour intravenous infusion every week (i.e., D1, D8 and D15) of a 3-week cycle
224320519|NCT04158362|DRUG|Capecitabine tablets|Capecitabine is given orally at a dose of 2000 to 2500 mg/m² daily for 14 days followed by a 7-day rest period every 3 weeks
224320520|NCT04158362|DRUG|Letrozole 2.5mg|Letrozole is administered orally at 2.5 mg/day continuous for patients nonsteroidal aromatase inhibitor naïve or relapsing \>1 year after the end of adjuvant endocrine therapy.
224235285|NCT02585258|DRUG|Placebo|1 capsule containing a placebo tablet / day
224235286|NCT00212095|DRUG|docetaxel and ketoconazole|"Docetaxel will be obtained locally from the manufacturer. Storage conditions for unopened vials, reconstitution, and storage conditions for the reconstituted solution will follow the manufacturer's recommendations. Docetaxel solutions should be prepared and stored in glass, polypropylene or polyolefin containers. Non-PVC containing and polyethylene-lined administration sets should be used.~Ketoconazole is available commercially in 200 mg tablet. Ketoconazole is to be administered at a dose of 200mg BID orally for six doses, starting two days before docetaxel administration. The fifth dose should be administered on the day of and before administering docetaxel, while the sixth dose should be administered in the evening of the day of docetaxel administration."
224235287|NCT01298570|DRUG|Regorafenib (BAY 73-4506)|Regorafenib, 160 mg, PO, Days 4-10 and Days 18-24 of 28 day cycle
224235288|NCT01298570|DRUG|FOLFIRI|FOLFIRI (Irinotecan,180 mg/m2 IV over 90 minutes; 5-Fluorouracil l400 mg/m2 IV bolus followed by 2400 mg/m2 IV over 46 hours; Leucovorin 200-400c mg/m2 IV over 2 hours) Day 1 and Day 15 of each 28 day cycle.
224235289|NCT01298570|DRUG|Placebo|Placebo, 160 mg, PO, Days 4-10 and Days 18-24 of 28 day cycle
224235290|NCT01298570|DRUG|FOLFIRI|FOLFIRI (Irinotecan,180 mg/m2 IV over 90 minutes; 5-Fluorouracil l400 mg/m2 IV bolus followed by 2400 mg/m2 IV over 46 hours; Leucovorin 200-400c mg/m2 IV over 2 hours) Day 1 and Day 15 of each 28 day cycle.
224235291|NCT06178081|OTHER|Periodontal Healthy|Non surgical periodontal therapy
224235292|NCT01210001|DRUG|Placebo|Placebo tablets matching BI 10773 low dose
224235293|NCT01210001|DRUG|BI 10773|BI 10773 tablets once daily
224235294|NCT01210001|DRUG|Placebo|Placebo tablets matching BI 10773 high dose
224235295|NCT01210001|DRUG|Placebo|Placebo tablets matching BI 10773 high dose
224235296|NCT01210001|DRUG|Placebo|Placebo tablets matching BI 10773 high dose
224235297|NCT01210001|DRUG|BI 10773|BI 10773 tablets once daily
224235298|NCT03111043|DIAGNOSTIC_TEST|Head to pelvis CT scan|Introduction of early head to pelvis CT scan within 6 hours of out of hospital arrest as an adjunct to standard of care (no randomization)
224235299|NCT04354532|PROCEDURE|Laparoscopic Banded Sleeve Gastrectomy|The investigators performed Laparoscopic Sleeve Gastrectomy adding a MiniMizer Ring (Bariatric Solutions), a radiopaque silicone ring with four closing positions. The ring has a blue colour and for this reason it can easily be found back in revision surgery. The pulling lid is left in place with all closing positions in order to be adjusted postoperatively without having to place a new ring. The ring is slightly elastic and the fixation loops provide an anchorpoint to fix the ring in place which prevents it from slipping
224320521|NCT04158362|DRUG|Anastrozole 1mg|Anastrozole is administered orally at 1 mg/day continous for patients nonsteroidal aromatase inhibitor (NSAI) naïve or relapsing \>1 year after the end of adjuvant endocrine therapy.
224320522|NCT04158362|DRUG|Fulvestrant Prefilled Syringe|Fulvestrant is administered at the dose of 500 mg intramuscular on D1-D15-D29 (as a loading dose), and then 500 mg every 28 days (as a maintenance dose) for patients relapsing on adjuvant or less than one year after completion of adjuvant NSAI.
224320523|NCT04158362|DRUG|Abemaciclib|Oral 150 mg BID continuous
224320524|NCT05662839|DEVICE|Cytological Brushing|All participants will undergo cytological brushing to collect cell samples for analysis
224320525|NCT03516513|BEHAVIORAL|Problem Solving Therapy as Usual|Treatment as usual to deliver 6 weekly sessions to teach patients how to use the seven step process to solve problems.
224235300|NCT02122796|OTHER|Acupuncture|Acupuncture involves inserting thin, sterile needles into the skin at certain points in the body.
224235301|NCT00590395|DRUG|18FDG (an FDA-approved radiopharmaceutical)|Route: Intravenous, Dosage: 5-10mCi, frequency: Single Administration
224235302|NCT01451762|DRUG|.9 normal saline|.9 normal saline administered before surgery.
224235303|NCT01451762|DRUG|25 mg diphenhydramine IV|25 mg diphenhydramine IV administered before surgery
224320526|NCT03516513|BEHAVIORAL|Assisted Problem Solving Therapy|Smart note assisted delivery of 6 weekly session to teach patients how to use the seven step process to solve problems
223650725|NCT02034864|OTHER|Placebo of osteopathic manipulative treatment|"A standardized placebo of manipulative treatment consisting in light touch and according to the results of a physical examination including 7 anatomical areas will be given by trained osteopaths during 6 sessions (with an interval of 2 weeks between 2 sessions). Each session will last 45 minutes. Osteopaths will have 3 days of training in standardized placebo of manipulative treatment."
223650726|NCT05677568|DEVICE|Carillon Mitral Contour System|"The Cardiac Dimensions Carillon Mitral Contour System (CMCS) is a medical device and consists of the following components:~1. A proprietary implant intended for permanent placement in the coronary sinus (CS)/great cardiac vein (GCV)~2. A catheter-based delivery system which consists of a curved CMCS delivery catheter (3.2mm outer diameter) and a handle assembly~3. A sizing catheter to enable the physician to estimate the overall CS/GCV dimensions so that an appropriately sized implant may be selected The implant is attached to the handle assembly and is delivered through the CMCS delivery catheter to the coronary vein along the posterolateral aspect of the mitral annulus. The implant is designed to re-shape the mitral annulus to reduce annular dilation and mitral regurgitation."
223650727|NCT06053658|DRUG|Tivozanib|Given by PO
223650728|NCT06053658|DRUG|Nivolumab|Given by IV (vein)
223650729|NCT02765750|BEHAVIORAL|Intraoperative positive messages|"The message You are in the operating room. Everything is going very well. When you wake up you will be very calm, you will not feel pain and you will not have nausea will be played in greek language by headphones to the patient when the Bispectral Index (BIS) is 40-60."
223650730|NCT02765750|BEHAVIORAL|Intraoperative positive messages|"The message You are in the operating room. Everything is going very well. When you wake up you will be very calm, you will not feel pain and you will not have nausea will be played in greek language by headphones to the patient when the Bispectral Index (BIS) is 20-40."
223650731|NCT02765750|BEHAVIORAL|No message|The headphones will be placed on patient's ears but no message will be played.
223650732|NCT03525795|DRUG|CPI-1205|Administered orally
223650733|NCT03525795|DRUG|ipilimumab|Administered intravenously
223766986|NCT07173231|DEVICE|Hypno-Virtual Reality Distraction (HVR)|The second experimental group will receive the HVR intervention in addition to usual care. This intervention, developed by HypnoVR, consists of a VR visual scenario combined with hypnotic verbal guidance specifically designed to reduce pain and anxiety during medical procedures. It is delivered through a validated and clinically approved HVR headset. The intervention includes reassuring and calming verbal suggestions aimed at helping participants regulate their emotions and manage anxiety throughout the procedure. Participants will be able to choose from 11 different visual scenarios, select their preferred language, and choose between a male or female voice for the hypnotic guidance. 6 different musical soundtracks will also be available to personalize the experience more.
223766987|NCT07173231|OTHER|Usual Care Group|The usual care group will only receive the standard preparation, which includes pre-treatment with Tylenol (1000mg) , Naproxen (500mg) and Ativan (1 mg) administered one hour prior to the procedure.
223766988|NCT07173348|OTHER|Hypnosis|Participants will undergo three 15-minute individual hypnosis intervention, conducted by a trained hypnotherapist, with a two-week interval between each session. A guide for the session has been developed by two experimented hypnotherapists specifically for this intervention and will be used for all sessions. A total of 3 hypnosis session will be realized.
223766989|NCT07174037|OTHER|Low spasticity group|low sapsticity (grade 1-2) unilateral ischemic stroke will be participate in this group
223766990|NCT07174037|OTHER|High spasticity group|high sapsticity (grade 3-4) unilateral ischemic stroke will be participate in this group
224235304|NCT01451762|DRUG|50 mg diphenhydramine IV|50 mg diphenhydramine administered IV before surgery
224235305|NCT03986177|BEHAVIORAL|Self-management Intervention Package|"Children will receive basic asthma education, based on the National Heart, Lung, and Blood Institute A Breath of Life asthma education program. Children/caregivers in the intervention arm will also be assigned a designated nurse case manager who will provide home visits and be available via text message and phone-based support throughout follow-up. Intervention components:~* Interactive education and support on use of an asthma action plan~* Locally adapted patient-provider communication tool~* Child-oriented educational materials in comic book format~* Modeling and hands-on practice of inhaler technique (written instructions, in person, video)~* Education regarding environmental trigger abatement~* Patient navigation, home visits, and goal setting support from nurse manager"
224235306|NCT05719870|BEHAVIORAL|Educational training|The intervention will include: first, educational training of patients/caregivers at hospital discharge by a multidisciplinary team; second, after hospital discharge, a phone recall on the prescribed therapies and a one-week phone consultant service managed by a geriatrician, supported by the multidisciplinary team, to address potential concerns on prescribed treatments.
223650734|NCT02239419|PROCEDURE|CO2-Enriched Tap Water (Carbothera)|Participants will undergo foot bathing with CO2-enriched tap water (CO2 concentration, 1000-1200 ppm) maintained at a temperature of 37˚C with an immersion time of 15 mins, 3 times per week for 4 consecutive months. Participants will be rested on a chair for 15 min before foot bathing. If participant is undergoing hemodialysis, foot bathing will occur prior to their routine hemodialysis procedure.
224235307|NCT03378700|BEHAVIORAL|Brief Hope Intervention|"The present Brief Hope Intervention (BHI) is a four-weeks individual intervention, consisting of four sessions: two face-to-face sessions (1-hour) and two telephone follow up sessions (30 minutes) in between.~The facilitator will guide participants to imagine how they navigate themselves to circumvent possible obstacles and accomplished their set goals and experience positive emotions.~A booklet will be given to the participants for reviewing their planned goals, recording achieved targets and successful experiences."
224235308|NCT03378700|OTHER|Pre-dialysis Education Group|Pre-dialysis educational class and standard care such as clinic follow up and normal hospital care will be provided. This session is led by clinicians with renal nursing training. The educational class aims at providing information on the treatment modalities for patients with ESRD, signs and symptoms of their illness and the basic advice on the importance of adherence to healthy lifestyle, nutrition and medications. Logistic call and social communication will be offered and initiated by trained nurses in the second week and the third week
224235309|NCT02495324|DRUG|Placebo|2 weeks of placebo PO daily
224235310|NCT02495324|DRUG|Fimasartan|60mg 1 tab PO daily for 2 weeks and 120mg 1 tab PO daily for 4 weeks
224235311|NCT02495324|DRUG|Valsartan|80mg 1 tab PO daily for 2 weeks and 160mg 1 tab PO daily for 4 weeks
224235312|NCT02495324|DRUG|Olmesartan medoxomil|10mg 1 tab PO daily for 2 weeks and 20mg 1 tab PO daily for 4 weeks
223650735|NCT02239419|PROCEDURE|Non-CO2-Enriched Tap Water|Participants will undergo foot bathing with non-CO2-enriched tap water maintained at a temperature of 37˚C with an immersion time of 15 mins, 3 times per week for 4 consecutive months. Participants will be rested on a chair for 15 min before foot bathing. If participant is undergoing hemodialysis, foot bathing will occur prior to their routine hemodialysis procedure.
223650736|NCT02057185|BEHAVIORAL|Study questionnaire|Questionnaire based on work situation of enrolled patients.
223650737|NCT02057185|BEHAVIORAL|SF-36 Questionnaire|Version 1.6
223650738|NCT00679900|DRUG|eplivanserin (SR46349)|5 mg/day
223650739|NCT00679900|DRUG|lormetazepam|1 mg/day
223650740|NCT06474026|DEVICE|ExAblate 4000 Type 2.1|"In Sham+Active arm, the subject will receive sham device application(Visit 2-1) and then active device application(Visit 2-2) after 7±2 days.~In Active arm, the subject will receive active device application(Visit 2)~Subjects will return to the site at Visit 3 (7±2 days post-active device application), Visit 4 (30±7 days post-active device application), Visit 5 (90±7 days post-active device application), and Visit 6 (180±7 days post-active device application) for safety and efficacy assessments."
224235313|NCT03268408|BEHAVIORAL|Baby Newsletter|eight newsletters sent home to newborns' parents with advices and recommendations on child care and development
224235314|NCT06799117|OTHER|EMBED CDS|"EMBED is a user user-centered, clinician clinician-facing clinical decision support system integrated into the electronic health record workflow to facilitate initiating buprenorphine in the emergency department by: diagnosing opioid use disorder with a checklist based on the diagnostic criteria of the DSM-5 (Diagnostic and Statistical Manual of Mental Disorders, fifth edition), assessing the severity of withdrawal with the Clinical Opioid Withdrawal Scale (COWS), motivating patients to accept treatment with a scripted brief negotiation interview, and automating the electronic health record workflow, including clinical and after visit documentation, order entry, prescribing, and referral for ongoing treatment in the community.~Intervention to be informed by CDS measurement and user feedback during the factorial trial phase (Optimization Phase, Stage 1)"
224235315|NCT06799117|OTHER|Nurse prompt to complete COWS|Nurse prompt to complete COWS
224235316|NCT06799117|OTHER|Provider Prompt|Provider Prompt to use EMBED: EMBED is a user user-centered, clinician clinician-facing clinical decision support system integrated into the electronic health record workflow to facilitate initiating buprenorphine in the emergency department by: diagnosing opioid use disorder with a checklist based on the diagnostic criteria of the DSM-5 (Diagnostic and Statistical Manual of Mental Disorders, fifth edition), assessing the severity of withdrawal with the Clinical Opioid Withdrawal Scale (COWS), motivating patients to accept treatment with a scripted brief negotiation interview, and automating the electronic health record workflow, including clinical and after visit documentation, order entry, prescribing, and referral for ongoing treatment in the community. Intervention to be informed by CDS measurement and user feedback during the factorial trial phase (Optimization Phase, Stage 1)
224235317|NCT06799117|OTHER|Patient facing materials|Provider prompt to give patient customized discharge instructions directing patient to resources matched to their needs.
223650741|NCT01314586|DIETARY_SUPPLEMENT|secoisolariciresinol diglucoside-containing extract of flaxseed|0, 150 or 300 mg/day as 2 pills taken at breakfast and dinner, dietary counseling to comply with NCEP Step I diet
223650742|NCT05717543|DEVICE|Retro-illuminator|The device Retro-illuminator will be used to photograph the eyes.
223650743|NCT00798993|OTHER|Structured Exercise program|30 minutes on an exercise bicycle during every dialysis
223650744|NCT00798993|DRUG|Cholecalciferol (25-Hydroxyvitamin D)|Cholecalciferol 2000U per day will be given for duration of study to all participants
223650745|NCT00798993|OTHER|Usual exercise|Participants randomised to this arm at 3 months will continue on their usual exercise routine for the remaining 3 months
223650746|NCT00690781|DIETARY_SUPPLEMENT|Pulse casein feeding during energy restriction|Obese subjects are subjected to a 35% energy restriction during 6 weeks and during this period, 25% of energy is given as protein, these proteins being casein. In addition, a pulse protein feeding pattern is used (8% protein in the morning, 80% for lunch, 4% at 1600 h and 8% in the evening).
223650747|NCT00690781|DIETARY_SUPPLEMENT|Spread casein feeding during energy restriction|Obese subjects are subjected to a 35% energy restriction during 6 weeks and during this period, 25% of energy is given as protein, these proteins being casein. In addition, a spread protein feeding pattern is used (25% of protein at each of the four meals of the day).
224235318|NCT06799117|OTHER|Optimized EMBED|CDS following Optimization Phase, Stage 2: Rapid serialized testing
223650748|NCT00690781|DIETARY_SUPPLEMENT|Pulse milk soluble protein feeding during energy restriction|Obese subjects are subjected to a 35% energy restriction during 6 weeks and during this period, 25% of energy is given as protein, these proteins being milk soluble proteins. In addition, a pulse protein feeding pattern is used (8% protein in the morning, 80% for lunch, 4% at 1600 h and 8% in the evening).
223650749|NCT00690781|DIETARY_SUPPLEMENT|Spread milk soluble protein feeding during energy restriction|Obese subjects are subjected to a 35% energy restriction during 6 weeks and during this period, 25% of energy is given as protein, these proteins being milk soluble proteins. In addition, a spread protein feeding pattern is used (25% of protein at each of the four meals of the day).
223650750|NCT00369265|DRUG|Lansoprazole|Lansoprazole 30mg twice daily
223650751|NCT00369265|DIETARY_SUPPLEMENT|Sugar pill|placebo twice daily
223650752|NCT04593537|OTHER|No intervention|This is an observational study, no intervention is involved
223650753|NCT06174415|DEVICE|Perceptual Learning|Perceptual training is carried out at home once a day, and the viewing distance of the patients from the display screen is uniformly 1.5m, 30 minutes each time, for three months, and they return to the hospital for re-examination of ophthalmology at the 3rd months after the training. When using the perceptual training program for the first time, the training program will adjust the size of the Gabor spot according to the size of the user's computer, and prompt the patient to adjust the brightness of the computer screen to unify the Gabor spot parameters of each user and ensure the consistency of the spot stimulation information received by each user.
223650754|NCT02736318|BIOLOGICAL|OD-PHOENIX|Decellularized, freeze-dried, irradiated osteochondral allograft
223650755|NCT01140126|DRUG|Antibody UB-421|Single intravenous infusion at day 0 of a liquid dose of 1, 5, 10 or 25 mg/kg body weight.
223650756|NCT04434456|DEVICE|CGuard stent implantation|CGuard stent implantation in the carotid artery with symptomatic, dissecting or enlarging aneurysm
223650757|NCT01543048|OTHER|Study Follow-Up|Colposcopy (+/- biopsies), cytology, and virology tests will be performed at the time of conization and during the follow-up period (6, 12, 24 months). HPV expression will be assessed by centralized validated marketed tests (Hybrid Capture 2, RLA genotyping, PreTect® HPV-Proofer) and by a real time PCR measuring E2, E6 and E7 viral load of HPV 1.
223650758|NCT01732237|DRUG|JNJ-42396302|A single dose of JNJ-42396302 100 micrograms (1 mL) will be administered orally with 240-mL non-carbonated water.
223650759|NCT01732237|DRUG|JNJ-42692507|A single dose of JNJ-42692507 100 micrograms (1 mL) will be administered orally with 240-mL non-carbonated water.
223650760|NCT01732237|DRUG|JNJ-53773187|A single dose of JNJ-53773187 100 micrograms (1 mL) will be administered orally with 240-mL non-carbonated water.
223650761|NCT05438212|PROCEDURE|Brain Surgery|Undergo surgery per standard of care
223650762|NCT05438212|OTHER|Quality-of-Life Assessment|Ancillary studies
223650763|NCT05438212|OTHER|Questionnaire Administration|Ancillary studies
223650764|NCT05438212|RADIATION|Stereotactic Radiosurgery|Undergo stereotactic radiosurgery
223650765|NCT03404180|PROCEDURE|Peripheral nerve block|All enrollees will have ultrasound-guided femoral and sciatic nerve blocks placed per current practice at research site. Single-injection obturator and lateral femoral cutaneous nerve blocks will also be performed.
224320527|NCT07134049|OTHER|sensory integration therapy|"Sensory Integration Therapy (SIT) is a client-centered rehabilitation approach aimed at improving adaptive and functional responses to sensory stimuli in changing environments. It is based on structured, individualized activities conducted in enriched sensory environments. These environments are designed to be engaging and motivating for children through the use of interactive and playful tasks that match their sensory processing profiles.~Sensory integration plays a key role in motor planning, postural control, attention, and emotional regulation. Deficits in sensory integration-particularly in vestibular, tactile, and proprioceptive systems-may result in poor muscle tone, difficulty with balance and coordination, and impaired motor planning. These issues can negatively impact the development of gross motor, fine motor, language, and academic skills. For this reason, sensory-based interventions that support neural organization and promote adaptive responses are commonly recommended i"
224320528|NCT07134205|DRUG|JMT101|JMT101, 6 mg/kg, administered by IV infusion once every two weeks (one treatment cycle is 4 weeks).
223650766|NCT03404180|DRUG|Intravenous Sedatives|Intravenous sedation using propofol or dexmedetomidine will be administered.
223650767|NCT03404180|PROCEDURE|Lateral femoral cutaneous nerve blocks|After administration of intravenous sedation, lateral femoral cutaneous and obturator nerve blocks (in addition to the femoral and sciatic catheters) will be performed under ultrasound guidance.
223650768|NCT03404180|PROCEDURE|Obturator nerve blocks|After administration of intravenous sedation, lateral femoral cutaneous and obturator nerve blocks (in addition to the femoral and sciatic catheters) will be performed under ultrasound guidance.
224320529|NCT07134205|DRUG|Irinotecan|Irinotecan, 180mg/m\^2, administered by IV infusion once every two weeks (one treatment cycle is 4 weeks).
223650769|NCT03635073|DRUG|Soticlestat|Soticlestat tablets or mini-tablets.
223650770|NCT00732537|DRUG|inhaled Nitric Oxide|"iNO started at 20 ppm for 1 hour, then weaned hourly over the next 4 hours (20 ppm to 10 to 5 to 2.5 to 1 to off). If \>5% drop in oxygen saturation was observed during weaning, study gas was increased to the previous concentration and weaning done 2 hourly. If \> 5% drop in oxygen saturation or \>5% Methemoglobin was observed during initial administration, the study gas would be weaned over 30 minutes and the infant would exit. The iNO was introduced into an oxygen hood (Oxydome ™ disposable hood from Maxtex ® Inc.) using an INOvent (Datex-Ohmeda). The INOvent ® was connected to the oxyhood by placing the injector module inline on the dry side of the humidifier chamber. Monitoring of O2, NO2, NO was done by placing the end of the sample line inside the oxyhood. A Masking Shield covered the Display/Control Panel and Cylinder Gauges, in order to maintain masking of the intervention. Only the respiratory therapist and research coordinator was aware of the allocation assignment."
223766991|NCT07173439|DEVICE|Model Name: EMT-SR01;red|The investigational device incorporated both a driving simulation and an N-Back cognitive training function. These features were designed to engage and improve key cognitive abilities such as attention, working memory, and executive function, which are often impaired in individuals with ADHD. The combined use of driving tasks and N-Back exercises aimed to provide a comprehensive and interactive therapeutic intervention to reduce core ADHD symptoms.
223650771|NCT00732537|DRUG|Oxygen (>90% by hood) - standard therapy|"Oxygen (\>90% by hood, standard therapy for PPHN prior to intubation) was introduced into an oxygen hood (Oxydome ™ disposable hood from Maxtex ® Inc.) using an INOvent (Datex-Ohmeda). The INOvent ® was connected to the oxyhood by placing the injector module inline on the dry side of the humidifier chamber. If the baby was randomized to the control group and did not receive NO, the INOmax® cylinder was opened and used only to pressurize the system, which prevented the Low NO Pressure alarm. A Masking Shield covered the Display/Control Panel and Cylinder Gauges, in order to maintain masking of the intervention. Only the respiratory therapist and research coordinator was aware of the allocation assignment."
223650772|NCT04752904|DEVICE|ClearSight System|Non-invasive, continuous blood pressure is monitored using ClearSight Sytem
223650773|NCT03519711|DRUG|PTC923|PTC923 will be administered per dose and schedule specified in arm description.
223650774|NCT00068419|DRUG|tamoxifen citrate|Given orally
223650775|NCT00068419|DRUG|sulindac|Given orally
223650776|NCT00068419|OTHER|laboratory biomarker analysis|Correlative studies
223766992|NCT07173439|DEVICE|Model Name: EMT-SR01;red (Placebo)|The placebo device incorporated only the driving simulation function and excluded the N-Back cognitive training component. The driving simulation was designed as a sham intervention to mimic the user experience without providing the active therapeutic elements targeting cognitive functions. This setup enabled a controlled comparison with the active digital therapeutic device.
223766993|NCT03865836|BIOLOGICAL|ATB200|
223766994|NCT03865836|DRUG|AT2221|
223766995|NCT07172828|BEHAVIORAL|Virtual Reality-Based Rehabilitation|Participants receive 20 minutes of motor control exercises combined with 20 minutes of Pilates-inspired virtual reality games (5 repetitions per set). Training will be delivered three times per week, 40 minutes per session, for 8 weeks (24 sessions in total).
223766996|NCT07172828|BEHAVIORAL|Conventional Motor Control Exercises|Participants perform 40 minutes of progressive spinal stabilization and motor control exercises (10 repetitions per set), three times per week for 8 weeks (24 sessions in total).
223766997|NCT05391633|BEHAVIORAL|Recorded Maternal Voice|60-minute looped recording of maternal voice, played once daily for 14 total days.
223766998|NCT05391633|BEHAVIORAL|Placebo Recording|60-minute blank recording played once daily for 14 total days.
224235319|NCT06799117|OTHER|Name of Intervention|Intervention to be informed by results during Evaluation Phase, Stage 1 and will involve refinement of user interface and workflows for the EMBED CDS: EMBED is a user user-centered, clinician clinician-facing clinical decision support system integrated into the electronic health record workflow to facilitate initiating buprenorphine in the emergency department by: diagnosing opioid use disorder with a checklist based on the diagnostic criteria of the DSM-5 (Diagnostic and Statistical Manual of Mental Disorders, fifth edition), assessing the severity of withdrawal with the Clinical Opioid Withdrawal Scale (COWS), motivating patients to accept treatment with a scripted brief negotiation interview, and automating the electronic health record workflow, including clinical and after visit documentation, order entry, prescribing, and referral for ongoing treatment in the community.
224320530|NCT07134205|DRUG|Regorafenib|Regorafenib, 160 mg, taken orally once daily for the first 21 days of each 28-day cycle.
223650777|NCT01475617|DIETARY_SUPPLEMENT|AquaVanta Chewable Tablet|AquaVanta Chewable Tablet (proprietary formulation of vitamin and minerals) 2 times a day for 6 months
223650778|NCT01475617|DIETARY_SUPPLEMENT|Flinstones Complete|Flinstones Complete Multivitamin 2 times a day for 6 months
223766999|NCT04895579|DRUG|Durvalumab|Durvalumab will be delivered at 10mg/kg via IV infusion at days 1 and 15 every 28 days or 1500 mg on D1, q4w.
223767000|NCT04895579|DRUG|Copanlisib|Copanlisib will be delivered at various doses (30-60mg/kg) via IV infusion at days 1 and 15 every 28 days.
223767001|NCT05133648|PROCEDURE|Hip Fracture Surgery|Hip fracture surgery
223650779|NCT01475617|DIETARY_SUPPLEMENT|Nature Made Calcium Softgels|Nature Made Calcium Softgels (Calcium Carbonate 600 mg and Vitamin D 200 mg) three times a day for 6 months
223767002|NCT05133648|OTHER|COVID-19 infection|COVID-19 infection
223767003|NCT00178958|DEVICE|Holter Monitor|
224235320|NCT03423888|DEVICE|high-flow nasal cannula oxygen therapy (HNFC)|"Set up of high-flow nasal oxygen for patient with dyspnea for a respiratory disease without possibility of curative care. Patients who require a treatment by oxygen are included.~After 7 days of treatment, acceptability is evaluated by the duration of use of HNFC."
223650780|NCT01475617|DIETARY_SUPPLEMENT|Nature Made Calcium Softgels|Nature Made Calcium Softgels (Calcium Carbonate 600 mg and Vitamin D 200 mg) three times a day for 6 months
223650781|NCT01475617|DIETARY_SUPPLEMENT|Twin Labs Iron Caps|Twin Labs Iron Caps (Ferrous Fumarate) 18 mg per day for menstruating women for 6 months
223650782|NCT01475617|DIETARY_SUPPLEMENT|Rexall Vitamin B12 Tablet|Rexall Vitamin B12 Tablet (Cyanocobalamin 500 mcg)per day for 6 months
223650783|NCT01366157|GENETIC|microarray analysis|
223767004|NCT03108339|OTHER|Guideline recommended physiotherapy care|The intervention will follow current care i.e. guideline informed intervention used by physiotherapists in the treatment of LBP in primary health care. The intervention will use a pragmatic approach and follow a framework of: 1) information of return to activity and to stay active 2) instruction on posture in loaded and unloaded positions 3) information on work and leisure based positions in activity and sitting 4) information on good sleeping position 4) instruction of an individualized exercise program based on findings from the examination enhancing core control 5) a choice of exercises as a home training program. Manual methods may if necessary be used. Choice of treatment, choice of exercises (loaded, unloaded) and also number of treatments is logged and noted.
223767005|NCT04916249|DRUG|Tibetree Pain Relieving Plaster|Participants who provide informed consent in the trial will receive either the Tibetree pain relieving plaster if randomized into the intervention arm, or an identical placebo plaster if randomized into the control arm. The treatment course for both arms are identical. Participants will be instructed to apply the plaster directly to the skin overlying the area of pain for 6 hours once daily for 14 consecutive days.
223767006|NCT04916249|OTHER|Placebo|Participants who provide informed consent in the trial will receive either the Tibetree pain relieving plaster if randomized into the intervention arm, or an identical placebo plaster if randomized into the control arm. The treatment course for both arms are identical. Participants will be instructed to apply the plaster directly to the skin overlying the area of pain for 6 hours once daily for 14 consecutive days.
223767007|NCT05101187|DRUG|Olorofim|Loading Dose: 5 tablets (150 mg) to be taken twice daily at a 12-hour (± 1 hour) interval on Day 1 Maintenance Dose: 3 tablets (90 mg) to be taken twice daily at 12-hour (± 1 hour) intervals from Day 2 until Day 84 (± 7 days)
223650784|NCT01366157|GENETIC|protein expression analysis|
223767008|NCT05101187|DRUG|AmBisome®|Initial course of at least 10 days of AmBisome® administered daily at a dose of 3 mg/kg by IV infusion over a 30- to 60-minute period or according to local guidelines Administration of SOC will follow international, national, or local guidelines and product labelling.
223767009|NCT05035745|DRUG|Talazoparib|Patients will be treated with Talazoparib daily on a 4 weekly cycle (28 days)
223767010|NCT05035745|DRUG|Selinexor|Patients will be treated with Selinexor once per week (3 out of 4 weeks), on a 4 weekly cycle (28 days)
223767011|NCT03587935|OTHER|3D-Colonoscopy Progression Score|The score is based on a movement analysis of the colonoscope from anus until max insertion(cecum). It is scaled from 0-1000. A score of zero equals an incomplete procedure and a score of 1 is a very poor score but the cecum was reached. Increasing score represents better technical performance with a maximum score of 1000.
224235321|NCT04471207|DEVICE|Therapist Guided Prolonged Exposure with BioWare Device|"Experimental: Intelligent Biometrics - Prolonged Exposure (therapist guided). In the therapist guided group, Study Therapists will use actionable data during in vivo exposures (IVEs) (galvanic skin response \[GSR\], heart rate \[HR\], and subjective units of distress \[SUDS\]) to modify the assignments in real-time.~All participants receive at least 10 sessions of prolonged exposure therapy for posttraumatic stress disorder."
224320531|NCT07133945|PROCEDURE|Silicone plaster or Steristrip or Vaseline|Prophylatic treatment of the skin before breakage of the skin in dupuytrens disease
223767012|NCT03587935|OTHER|3D-Colonoscopy Retraction Score|The score is based on a movement analysis of the colonoscope from cecum to the anus. It is scaled from 0-1000. A score of zero equals a very poor score, Increasing score represents better technical performance with a maximum score of 1000.
224235322|NCT04471207|DEVICE|Record Only Prolonged Exposure with BioWare Device|"In the record-only group, passive data collection will be utilized to collect and store biometric and behavioral data for future offline analyses to investigate predictors of outcome.~All participants receive at least 10 sessions of prolonged exposure therapy for posttraumatic stress disorder."
224235323|NCT01817556|DRUG|Stillen Tab.|
224320532|NCT07134309|OTHER|Exercise Training|Reformer, mat pilates, and general posture exercise training were performed twice a weekly for 12 weeks. Before starting pilates training, the key elements of pilates were taught to patients for one session. In evaluation, Visual Analog Scale (VAS) was used for pain intensity, Oswestry Low Back Pain Questionnaire for disability, Short Form - 36 Questionnaire (SF-36) for quality of life, Sit-lie test for flexibility, McGill extension test for trunk extension endurance. Demographic information of individuals was recorded.
223650785|NCT01366157|OTHER|immunohistochemistry staining method|
223650786|NCT01366157|OTHER|laboratory biomarker analysis|
223650787|NCT03951662|OTHER|Alcoholic Hepatitis Group|Alcoholic hepatitis is defined as having a total bilirubin level \>3mg/dL and AST level\>50U/L
223650788|NCT03951662|OTHER|Heavy Drinking Controls without Hepatitis|Normal levels of AST, ALT and total bilirubin and without evidence of cirrhosis or hepatosplenomegaly
223767013|NCT06297356|DEVICE|Stress ball|Stress balls are soft sponges with a diameter of 2-4 cm. The lightest starting level was preferred for the patients. Patients were allowed to take the stress ball in any hand they wanted. They were asked to squeeze and loosen the ball in their palm at 2-3 second intervals.
223767014|NCT04270825|BEHAVIORAL|Group CBT with IPT|Group treatment designed to target relationships with both possessions and people.
223767015|NCT05002946|DRUG|SP-104|single oral dose
223767016|NCT05002946|DRUG|Naltrexone Hydrochloride 50Mg Oral Tablet|single oral dose
223767017|NCT02610868|DRUG|MYOBLOC|After a screening period (up to 21 days), subjects who satisfy all eligibility criteria may receive single dose injections of 3,500 Units of MYOBLOC every 13 weeks (±2 weeks) for a total of 4 treatments via injections into the submandibular and parotid glands. Subjects will undergo safety and effectiveness assessments at Weeks 4, 8, 13, 17, 26, 30, 39, 43, and 52, and telephone follow up will occur at Weeks 21, 34, and 47
223767018|NCT00753207|DRUG|epirubicin hydrochloride|
223767019|NCT00753207|DRUG|lapatinib ditosylate|
223767020|NCT00753207|OTHER|biomarker analysis|
223767021|NCT00753207|OTHER|immunohistochemistry staining method|
224235324|NCT01817556|DRUG|Mucosta Tab.|
224235325|NCT05334771|DEVICE|Dual band pure tune audiometer|Orbiter 922 Tympanometry
223650789|NCT04788706|OTHER|Low level Laser Therapy and Russian electrical stimulation|LLLT over three weeks followed by an eight-week receiving Russian electrical stimulation
223767022|NCT00753207|OTHER|liquid chromatography|
223767023|NCT00753207|OTHER|mass spectrometry|
224235326|NCT06365645|BEHAVIORAL|M.Bapp|Please see experimental group description.
224235327|NCT06365645|BEHAVIORAL|App-based parenting education|Please see active comparator group description.
223650790|NCT04788706|OTHER|Placebo Laser and Russian electrical stimulation|Placebo laser over three weeks followed by an eight-week receiving Russian electrical stimulation
223650791|NCT04788706|OTHER|Low level Laser Therapy and Low level Laser Therapy plus Russian electrical stimulation|LLLT over three weeks followed by an eight-week receiving LLLT application combined with Russian electrical stimulation
223650792|NCT04788706|OTHER|Placebo Laser and Placebo Laser plus Russian electrical stimulation|Placebo laser over three weeks followed by an eight-week receiving Placebo laser application combined with Russian electrical stimulation
223767024|NCT06254417|PROCEDURE|Diaphragmatic ultrasound|Diaphragmatic ultrasound will be performed to all patients with respiratory disease to evaluate diaphragmatic thickening and estimate thickening fraction and to evaluate diaphragmatic excursion. Measurements will be obtained at bedside with a portable ultrasound machine equipped with a linear probe (Logic P6 Pro, GE Healthcare). Diaphragmatic thickness measures will be performed on right Intercostal approach through the zone of apposition. Diaphragmatic excursion will be performed using curved-array probe (Logic P6 Pro, GE Healthcare) is positioned below right costal arch at the mid-clavicular line. The ultrasound study will be done and /or supervised by ultrasound expert
223767025|NCT01700179|DRUG|ACH-0143102|
223767026|NCT01700179|DRUG|Ribavirin|
223767027|NCT00679341|DRUG|Trastuzumab emtansine [Kadcyla]|The total dose depended on the patient's weight on Day 1 of each cycle. Trastuzumab emtansine was administered every 3 weeks until investigator-assessed radiographic or clinical progressive disease (or until second disease progression for patients who crossed over), unacceptable toxicity, or study closure, whichever occurred first.
223650793|NCT03135496|OTHER|Study of endothelial function biological markers|Study of endothelial function biological markers
223650794|NCT05490888|DRUG|PHIN-214 Subcutaneous injection|subcutaneous injection(s) with PHIN-214 terlipressin derivative
223767028|NCT00679341|DRUG|Trastuzumab|The dose of trastuzumab was recalculated if body weight changed by more than ±10% from baseline. Trastuzumab was administered every 3 weeks until investigator-assessed radiographic or clinical progressive disease, or unmanageable toxicity. Patients in the trastuzumab + docetaxel arm who discontinued study treatment because of progressive disease were eligible to cross-over to trastuzumab emtansine treatment until a second progressive disease event, clinical deterioration, and/or intolerance.
223767029|NCT00679341|DRUG|Docetaxel|Docetaxel was given at a dose of 75 or 100 mg/m\^2 based on the investigator's decision. Patients in the trastuzumab + docetaxel arm who discontinued study treatment because of progressive disease were eligible to cross-over to trastuzumab emtansine treatment until a second progressive disease event, clinical deterioration, and/or intolerance.
223767030|NCT02560636|DRUG|Pembrolizumab|Pembrolizumab - Trial Treatment
223650795|NCT01567267|BEHAVIORAL|Experimental educational intervention|Educational intervention consisting of a 4-day-course in Evidence-based Medicine and Good Scientific Practice combined with the method of Problem-based Learning.
223650796|NCT01567267|BEHAVIORAL|Standard educational intervention|Educational intervention on the didactics of biology (4-day-course) not containing elements of Evidence-based Medicine, Good Scientific Practice or Problem-based learning.
223650797|NCT05289895|OTHER|No intervention|This study was an observational trial without any intervention
223650798|NCT01808105|OTHER|Control Formula|Feeding ad libitum
223650799|NCT01808105|OTHER|Experimental Formula 1|Feeding ad libitum
223650800|NCT01808105|OTHER|Experimental Formula 2|Feeding ad libitum
224235328|NCT03230851|DRUG|aspirin 100mg/d therapy|100mg aspirin for at least 5 days followed by aspirin 100mg/d
224235329|NCT03230851|DRUG|aspirin 100mg/2d therapy|100mg aspirin for at least 5 days followed by aspirin 100mg/2d
224235330|NCT03230851|DRUG|aspirin 100mg/3d therapy|100mg aspirin for at least 5 days followed by aspirin 100mg/3d
224235331|NCT03230851|DRUG|aspirin 50mg bid therapy|100mg aspirin for at least 5 days followed by aspirin 50mg bid
223767031|NCT02560636|RADIATION|Radiotherapy|Radiotherapy
223767032|NCT00184899|DRUG|Intravenous infusion of Intralipid/heparin|
224235332|NCT03230851|DRUG|aspirin 75mg/d therapy|100mg aspirin for at least 5 days followed by aspirin 75mg/d
223767033|NCT00184899|DRUG|Intravenous infusion of Glycerol/heparin|
223767034|NCT01004367|OTHER|Experimental|Environmental- and individual based components carried out in the school.
223767035|NCT00667342|BIOLOGICAL|Bevacizumab|Monoclonal Antibody against vascular endothelial growth factor (VEGF). Given intravenously (IV).
223767036|NCT00667342|DRUG|Cisplatin|Given IV.
223650801|NCT01808105|OTHER|Human Milk|Feeding ad libitum
223650802|NCT02354430|BEHAVIORAL|Water-exercise|"1. An instruction session at an indoor swimming pool, led by the research midwives and a specially trained coach. Participants is shown short movie clips of the six Aqua-Mama water-exercises and practical instructions by the coach while performing the exercises in water. The participants are encouraged to keep a training logbook during the project.~2. One training session consists of: eight laps (200 m) of swimming and AquaMama exercises. Each exercise is illustrated on a board and are performed twice~3. Unsupervised water-exercises (The six AquaMama exercises)~4. Motivating weekly emails during the 12 week training period.~5. Brush up sessions is held once every month for guidance in performing the exercises."
223650803|NCT05425940|DRUG|XL092|Supplied as tablets; administered orally daily
223650804|NCT05425940|DRUG|Atezolizumab|Supplied as 1200 mg/20 mL vials; administered as a 1200 mg IV infusion once in a 3-week cycle (q3w)
223650805|NCT05425940|DRUG|Regorafenib|Supplied as 40 mg tablets; administered orally daily at 160 mg for the first 21 days of each 28-day cycle
223650806|NCT06327880|DRUG|PF-07054894 or placebo|multiple oral doses of PF-07054894 for 14 days
223767037|NCT00667342|DRUG|Doxorubicin|Given IV.
223767038|NCT00667342|DRUG|Methotrexate|Given IV.
223767039|NCT00667342|DRUG|Ifosfamide|Given IV.
223767040|NCT00667342|DRUG|etoposide|Given IV.
223767041|NCT00667342|PROCEDURE|Surgery|Participants undergo definitive surgery and assessment of histologic response at week 10.
223767042|NCT00667342|RADIATION|Radiotherapy|Radiation therapy delivered for positive margins or intralesional resections.
224235333|NCT03230851|DRUG|aspirin 50mg/d therapy|100mg aspirin for at least 5 days followed by aspirin 50mg/d
224235334|NCT03230851|DRUG|indobufen 100mg bid therapy|100mg aspirin for at least 5 days followed by indobufen 100mg bid
224235335|NCT01667783|PROCEDURE|Gastric Banding|Laparoscopic Adjustable Gastric Banding using the LapBand
224235336|NCT01667783|BEHAVIORAL|Medical Weight Loss|Weight loss intervention using diet (meal replacments), physical activity and behavioral techniques administered with weekly one-on-one counselling by dieticians
224235337|NCT01667783|PROCEDURE|Gastric Bypass|Laparoscopic Roux-en-Y Gastric Bypass
224235338|NCT00232947|BIOLOGICAL|Influenza virus vaccine (Fluviral)|
224235339|NCT00232947|BIOLOGICAL|Influenza virus vaccine (Fluzone)|
223650807|NCT06406179|BIOLOGICAL|dd-cfDNA-guided|"In groups I and II, the blood sample for dd-cfDNA assay will be taken on D0, just prior to transplantation, for all patients.~in addition, for patients following a dd-cf DNA-guided strategy based on dd-cf DNA ; samples for dd-cf DNA assay will be taken at M3 and M12 visits and at visits for clinical indication (5 maximum) and the blood will be sent to the PARCC technical platform of INSERM UMR 970. By combining the dd-cfDNA level and relevant medical data, an integration report will be sent to the centers to stratify patients into high-risk or low-risk rejection profiles.~If the patient is classified in the low risk of rejection subgroup, he may decide not to perform the biopsy. If the patient is classified in the high risk of rejection subgroup, he may decide to perform the biopsy within 15 days of the sample being taken. the decision to perform the biopsy is left to the discretion of the physician."
223650808|NCT04460001|DRUG|Ranibizumab|Intravitreal
223650809|NCT04460001|DRUG|Ranibizumab|Intravitreal
223650810|NCT04460001|DRUG|triamcinolone acetate|intravitreal
223650811|NCT01809119|PROCEDURE|Partial nephrectomy|
223650812|NCT05846737|BIOLOGICAL|anti-BCMA CAR-T|Autologous BCMA-directed CAR-T cells, infusion intravenously at a target dose of 2-4 x 10\^6 anti-BCMA CAR+T cells/kg.
223650813|NCT00092443|BIOLOGICAL|RotaTeq™, rotavirus vaccine, live, oral, pentavalent|Three doses of RotaTeq™ administered 28 to 70 days apart.
224235340|NCT02320942|OTHER|Exercise Intervention|The semi-supervised intervention is a progressive program with a goal of three aerobic and two resistance exercise sessions per week. Aerobic exercise will consist of 20-40 minutes of bicycling using a stationary bike located on CP6 (supervised or un-supervised) or brisk walking at home. Resistance exercise will include exercise for the upper and lower extremities with stretch bands. Patients will complete at least one supervised aerobic and resistance session per week with the exercise trainer and complete a daily log of their exercise, including adherence, adverse events and symptoms.
224235341|NCT00561730|DRUG|Pantoprazole|Observational, non-interventional study (NIS). The physician decided about dosage according to individual needs (20 or 40 mg pantoprazole, once daily).
223650814|NCT00092443|BIOLOGICAL|Comparator: Placebo matching RotaTeq™|Placebo matching RotaTeq™ administered 28 to 70 days apart.
223650815|NCT01160822|BIOLOGICAL|Canakinumab|Intra-articular injection
223650816|NCT01160822|DRUG|Placebo to canakinumab|Intra-articular injection
223650817|NCT01160822|DRUG|Naproxen|Tablets for oral administration
223650818|NCT01160822|DRUG|Placebo to Naproxen|Tablets for oral administration
223650819|NCT01962350|DEVICE|Deep Brain Transcranial Magnetic Stimulation|H1-Coil deep brain rTMS at cortex prefrontal.
224235342|NCT06120127|RADIATION|SBRT|postoperative SBRT of liver lesions
224235343|NCT06120127|DRUG|Chemotherapy|XELOX/FOLFOX/FOLFIRI
224235344|NCT06120127|DRUG|PD-1 antibody|Sintilimab (200mg d1，q3w)
224235345|NCT05663281|DIAGNOSTIC_TEST|thrombus imaging appearance|Imaging appearance of intracranial and/or extracranial arterial thrombus
223650820|NCT03651024|DEVICE|ED surgery|The surgical implant for ED treatment
224235346|NCT03747822|PROCEDURE|fat filler,PEEK,sliding genioplasty|The procedure will be done under general anesthesia; the donor site lower abdomen, flank, lateral thigh, or inner thigh will be infused using a solution that consisted of 100 ml of normal saline with 50 mg (0.05%) of lidocaine and 0.1 ml of epinephrine. Liposuction will be performed using a 2-mm blunt cannula. A 20-cc syringe will be used to collect the fat. The fat will be injected into the chin in a supraperiosteal (subcutaneous) plane with a blunt 2-mm cannula using a fanning technique.
224235347|NCT03089112|DRUG|HGP1607|Take it once per period
223650821|NCT04772560|DEVICE|Precision1 for Astigmatism|Daily disposable soft toric contact lens
223650822|NCT04772560|DEVICE|Precision1 Sphere|Daily disposable soft spherical contact lens
223650823|NCT00707941|DRUG|Oseltamivir|"Children ≤12 years: Suspension by Weight (Kg) as follows: Dose X 5 days Volume (ml) \< 15kg = 30 mg PO BID (2.5 ml) 15kg - 22kg = 45 mg PO BID (3.75 ml) 23kg - 39kg = 60 mg PO BID (5 ml)~Patients≥12 years: 75 mg capsules as follows:~1 cap (75 mg) PO BID X 5 days~≥ 40 75 mg PO BID 6.25"
223650824|NCT00707941|DRUG|Placebo|"Children \< 12 years, suspension by weight (kg) as follows: Dose X 5 days Volume (ml) \< 15kg = 30 mg PO BID (2.5 ml) 15kg - 22kg = 45 mg PO BID (3.75 ml) 23kg - 39kg = 60 mg PO BID (5 ml)~Patients≥12 years: 75 mg capsules as follows 1 cap (75 mg) PO BID X 5 days~≥ 40 75 mg PO BID 6.25"
223650825|NCT03692104|DIAGNOSTIC_TEST|transrectal ultrasound|Use of US for post implant quality assessment
223650826|NCT01319552|PROCEDURE|Fresh transfusion|1 unit autologous transfusion of red blood cells stored for 3-7 days under standard conditions
223650827|NCT01319552|PROCEDURE|Old transfusion|1 unit autologous transfusion of red blood cells stored for 40-42 days under standard conditions
223650828|NCT03871218|BIOLOGICAL|Hyaluronic acid group|Applicaton of topical Hyaluronic acid
223650829|NCT01493167|OTHER|limb casting/splinting|ankle and arm cast
224235348|NCT03089112|DRUG|HGP1501|Take it once per period
224235349|NCT03089112|DRUG|HGP1607+HGP1501|Take it once per period
224235350|NCT03196024|BEHAVIORAL|Family-focused intervention arm|Family pairs including an individual family member at-risk for type 2 diabetes or CVD and a co-participating family member will be enrolled in the study. After completing baseline data they will be randomly selected to participate in one of the two study arms. For the family-focused arm, the family pair will attend 8 2-hour weekly educational sessions about type 2 diabetes and CVD risk reducing lifestyle behaviors. The sessions will be presented by community health workers (CHWs) in Spanish to groups of 5 to 6 family pairs. Following completion of the sessions, data will be collected from the family pairs. CHWs will call monthly to provide information and support through the end of the 12-month period at which time data will be collected from the family pairs.
223650830|NCT04717336|OTHER|Sodium Chloride|It is well established that increased dietary sodium can predispose to an increase in blood pressure; particularly in salt-sensitive individuals. Seeking to test the hypothesis that changes in dietary sodium intake are sufficient to influence the composition of the gut microbiome in association with sodium-induced changes in vascular function, epigenome, transcriptome and blood pressure in African Americans.
223650831|NCT04717336|OTHER|Placebo|placebo capsules
223650832|NCT03962062|DRUG|Moxidectin|2 mg tablets
223650833|NCT03200080|DRUG|Tozadenant|2, 4, 6 or 8 Tozadenant 60 mg tablets
223650834|NCT03200080|DRUG|Placebo oral tablet|2, 4, 6 or 8 Tozadenant matching placebo tablets
223650835|NCT03200080|DRUG|d-amphetamine|2 or 4 capsules, each containing 2 over-encapsulated d-amphetamine 5 mg tablets
223650836|NCT03200080|DRUG|Placebo oral capsule|2 or 4 capsules, each containing d-amphetamine matching over-encapsulated PLACEBO 200 mg lactose tablet
223650837|NCT04521725|DEVICE|Respiratory Function Monitor (RFM)|Use of respiratory function monitor to detect tidal volume and expired CO2 to guide mask ventilation during neonatal resuscitation.
223650838|NCT04521725|DEVICE|Cerebral Near-Infrared Spectroscopy (NIRS)|Use of cerebral NIRS to determine cerebral oxygenation to guide oxygen titration during neonatal resuscitation.
223650839|NCT02665832|DRUG|DWJ1351|
223767043|NCT00809289|DRUG|esreboxetine|Once daily administration of 4mg esreboxetine for 3 days, followed by 8mg esreboxetine for 3 days, followed by 10mg esreboxetine for 3 days. Drug will be administered double-blind.
223767044|NCT00809289|DRUG|placebo|Once daily administration of placebo for 9 days. Placebo will be administered double blind
224235351|NCT03196024|BEHAVIORAL|Individual-focused intervention arm|Family pairs including an individual family member at-risk for type 2 diabetes or CVD and co-participating family member will be enrolled in the study. After completing baseline data pairs will be randomly selected to participate in one of two interventions. For the individual-focused intervention, the at-risk individual will attend 8 weekly 2-hour education sessions on type 2 diabetes and CVD risk reducing lifestyle behaviors. Sessions will be presented by CHWs in Spanish to groups of 10 to 12 individuals. Following completion of sessions, data will be collected from the individuals. CHWs will call monthly to provide information and support through the end of the 12-month period at which time data will be collected from the at-risk individuals and their co-participating family members.
223650840|NCT02665832|DRUG|Co-administration of Sevikar (Olmesartan/Amlodipine) and Crestor (Rosuvastatin)|
223650841|NCT06079112|DRUG|9MW2821|1.0/1.25/1.5 mg/kg, intravenous (IV) infusion every cycle until disease progression or intolerable toxicity, etc.
223767045|NCT00809289|DRUG|moxifloxacin|Once daily administration of placebo for 8 days followed by open label single oral dose of 400mg moxifloxacin on day 9
223767046|NCT01973634|RADIATION|sequential boost (15 x 2.67 Gy WBI + 4 x 2.5 Gy boost)|Minimal surgical margin of 1 mm, conventional arm with sequential boost (15 x 2.67 Gy WBI + 4 x 2.5 Gy boost)
224235352|NCT01640496|DRUG|Vitamin D3|3000 IU Vitamin D3 tablets (Cholecalciferol) will be used. 28 pills per bottle. Subjects will be given 2 bottles to be taken for the duration of this study.
224235353|NCT01640496|OTHER|Placebo|Placebo will be given to subjects. 28 pills per bottle. Subjects will be given 2 bottles to be taken for the duration of this study.
223650842|NCT06079112|DRUG|Toripalimab|240mg intravenous (IV) infusion every cycle until disease progression or intolerable toxicity, etc.
223650843|NCT06273215|DRUG|The combinations of 10 µg midazolam, 375 µg dabigatran etexilate, 10 µg pitavastatin, 50 µg rosuvastatin, and 100 µg atorvastatin were administered to diabetic patients on an empty stomach.|Midazolam, dabigatran etexilate, pitavastatin, rosuvastatin and atorvastatin were provided by the Department of Pharmacy, Peking University Third Hospital, and were dissolved and mixed with normal saline respectively, and the mixing process needed to be fully stirred. Then, according to the concentration of the drug mixed solution, the corresponding volume of mixed solution was given to achieve the dosage of 10 μg midazolam, 375 μg dabigatran etexilate,10 μg pitavastatin, 50 μg rosuvastatin and 100 μg atorvastatin. In order to avoid the food effect, the test drugs were administered on an empty stomach on the administration day in this experiment.
223650844|NCT01951963|DRUG|Ketamine|
223767047|NCT01973634|RADIATION|SIB (15 x 2.67 Gy WBI and SIB 15 x 2.67-3.12 Gy)|Minimal surgical margin of 1 mm, experimental arm with SIB (15 x 2.67 Gy WBI and SIB 15 x 2.67-3.12 Gy)
223767048|NCT01973634|RADIATION|sequential boost (15 x 2.67 Gy WBI + 6 x 2.48 Gy boost)|Minimal surgical margin \< 1 mm, conventional arm with sequential boost (15 x 2.67 Gy WBI + 6 x 2.48 Gy boost)
223767049|NCT01973634|RADIATION|SIB (15 x 2.67 Gy WBI and SIB 15 x 2.67-3.33 Gy)|Minimal surgical margin \< 1 mm, experimental arm with SIB (15 x 2.67 Gy WBI and SIB 15 x 2.67-3.33 Gy)
223650845|NCT01951963|DRUG|Morphine|
223650846|NCT03632850|OTHER|web-based interactive tool|an online tool to assist users in decision-making in choice of treatment for advanced cancer
223650847|NCT04053803|DRUG|IMR-687|Oral administration of once daily IMR-687
223650848|NCT04497623|DEVICE|Invasive mechanical ventilation using the Unisabana-Herons Ventilator during 24 hours|Recruited patients will receive volume-controlled mechanical ventilation (assist-control mode) using the Unisabana-Herons ventilator for 24 hours. Information on clinical, hemodynamic, and respiratory variables will be recorded from 30 minutes before the start of mechanical ventilation with the Unisabana-Herons ventilator. Recordings will be made in the first 4 hours every 15 minutes in the CFR, except for arterial blood gases which will be taken every 30 minutes. In the following 20 hours, arterial blood gas controls will be taken at hour 12 from the start of the ventilator and at hour 24. Other hemodynamic and respiratory variables will be recorded every hour from hour 4 of ventilator start until hour 24.
223650849|NCT02550639|OTHER|BIOMARKER- elispot test|ELISPOT TEST
223650850|NCT00209612|DRUG|Taxol|Day1,15 X mg/m2, IV (in the vein)
223650851|NCT00209612|DRUG|Campt, Topotesin|Day1,15 Y mg/m2, IV (in the vein)
223767050|NCT03152812|PROCEDURE|plantar surface reconstruction by free flaps|use of free skin or free muscle flaps for reconstruction of plantar surface
223767051|NCT02692157|DRUG|Placebo|Placebo for Neurokinin 1,3 antagonist
223767052|NCT02692157|DRUG|NT-814 50 mg|Neurokinin 1,3 antagonist 50 mg
223767053|NCT02692157|DRUG|NT-814 100 mg|Neurokinin 1,3 antagonist 100 mg
223767054|NCT02692157|DRUG|NT-814 200 mg|Neurokinin 1,3 antagonist 200 mg
224235354|NCT00067236|DRUG|PG-116800 (given as PG-530742)|200 mg tablet of PG-116800 (given as PG-530742)twice a day for 90 days
223650852|NCT06804005|BEHAVIORAL|Music group|Music will be sung continuously in an area equipped with a sound system so that subjects can listen comfortably without headphones, and will be performed with the participation of students and peer support. Each intervention activity will last approximately 60 minutes.
223650853|NCT06804005|BEHAVIORAL|mandala group|In the mandala coloring activity, they will be asked to choose the picture they want from the mandala coloring booklets and color it however they want. This activity will take approximately 60 minutes.
223650854|NCT01500720|DRUG|Cabazitaxel|Cabazitaxel 25 milligram per square meter (mg/m\^2) intravenously (IV) on Day 1 every 3 weeks (21-day cycle) until unacceptable toxicity, disease progression or withdrawal consent.
223650855|NCT01500720|DRUG|Topotecan|Topotecan 1.5 mg/m\^2 IV on Day 1 to Day 5 every 3 weeks (21-Day cycle) until unacceptable toxicity, disease progression or withdrawal consent.
223650856|NCT02439437|BEHAVIORAL|Psychosocial Intervention|Telephone-based psychosocial intervention involving Eight telephone encounters. Each encounter will focus on strategies for dealing with pain and stress, and how to apply these strategies to patients own experiences.
223650857|NCT02527421|DRUG|DFD01 Spray|DFD-01 (betamethasone dipropionate) Spray, 0.05%
223650858|NCT05624970|BEHAVIORAL|aerobic training , tobacco cessation and nutritional advices|"1. Aerobic training program according to Taheri et al 2017:~   * Mode: recruits large groups of muscles and includes brisk walking on treadmill, cycling, swimming, and jogging~  * Intensity: submaximal aerobic exercise program (50-60% of maximal heart rate reserve) on treadmill~  * Frequency: 3 sessions a week for 2 months.~  * Duration: 60 min/session The training protocol was divided into three phases: the warm up period (10 minutes), the main program (aerobic exercise; 40 minutes), and a cool down period (10 minutes).~2. Tobacco Cessation Programs for 3 months~3. Nutritional advices according to American Diabetes Association (ADA) 2015: for 3 months"
223650859|NCT05624970|BEHAVIORAL|tobacco cessation and nutritional advices|Tobacco Cessation Programs for 3 months Nutritional advices according to American Diabetes Association (ADA) 2015: for 3 months
223650860|NCT00105781|BEHAVIORAL|Exercise counseling|
223650861|NCT02281513|OTHER|Smartphone Application|Is a self-monitoring tool to document fruit and vegetable consumption, sleep quantity and quality, and physical activity
223650862|NCT02281513|OTHER|Fitbit Activity Monitor|Is connected to this smartphone application so that participants who wear this monitor have data that automatically populates the smartphone application for physical activity.
223650863|NCT02281513|OTHER|Coaching Sessions|Using motivational interviewing (a counseling style used in helping persons change their behavior) at baseline after completion of all baseline assessments and at follow up after completion of all follow up assessments. Coaching session includes discussion of facilitators and barriers to increasing physical activity, fruit and vegetable consumption and sleep, as well as setting goals to work towards at next meeting. The coach will monitor the information that the participant enters into the smartphone application and will provide feedback on a weekly basis to the participant.
223650864|NCT02447523|PROCEDURE|Elective abdominal surgery|
223650865|NCT05557188|OTHER|Grounding|Each pregnant woman in the placebo group is going to be informed about the grounding stick and how to use it, with a 2-minute video showing. Participants walk on the ground for 30 minutes daily and go on for four weeks. During the program, the pregnant women will be called to their homes every week and necessary reminders will be made.
223650866|NCT05557188|OTHER|Sham grounding|Each pregnant woman in the placebo group is going to be informed about the Sham grounding stick and how to use it, with a 2-minute video showing. Participants walk on the ground for 30 minutes daily and go on for four weeks. During the program, the pregnant women will be called to their homes every week and necessary reminders will be made.
223650867|NCT05700019|BEHAVIORAL|Pinkwashed Advertisements|Real advertisements from alcoholic beverage companies' social media accounts that contain messaging or other features that associate the alcohol company with breast cancer awareness or research.
223650868|NCT05700019|BEHAVIORAL|Control - Standard Advertisements|Real advertisements from the same alcoholic beverage companies' social media accounts that do not contain messaging or other features associated with breast cancer awareness or research.
223650869|NCT04927169|DRUG|Interleukin-7|IM administration at 10μg/kg twice a week for three weeks and up to 7 administrations according to Hospital length of stay
224235355|NCT00067236|DRUG|Placebo tablet|placebo tablet, twice a day for 90 days
223767055|NCT00362804|DRUG|Tetrabenazine|The initial TBZ dose will be 12.5 mg and the dose will be increased to 25 mg at Week 2. Thereafter, the dose can be decreased to 12.5 mg or increased in 12.5 mg increments at weekly intervals, depending on clinical response and tolerability, to a maximum of 75 mg/day. For 37.5 and 50 mg daily, administration will be BID i.e., 25 mg QAM, 12.5 or 25 mg QHS. For 62.5 or 75 mg daily, a TID dosing will be employed i.e., 25 mg QAM, 12.5 or 25 mg QPM, 25 mg QHS
223767056|NCT05676671|PROCEDURE|Applications of self-etching adhesives and dental restorations|
223767057|NCT00949780|DRUG|Chloral Hydrate|
224235356|NCT04167566|COMBINATION_PRODUCT|Artemisinin Combination Therapy ACTs|All participants will be tested using RDTs and all confirmed cases will be treated with ACTs. The ACT regimen use at each time will be the one the National Malaria Control Programme will be using at that particular moment.
224235357|NCT00000775|BIOLOGICAL|rgp120/HIV-1MN Monovalent Octameric V3 Peptide Vaccine|
224235358|NCT02313103|DRUG|lofexidine HCl|400 micrograms
223767058|NCT04031885|DRUG|Abemaciclib|Administered orally
223767059|NCT04031885|DRUG|Fulvestrant|Administered IM
223767060|NCT04031885|DRUG|Standard Chemotherapy|Standard chemotherapy of physician's choice administered according to product label.
224235359|NCT03427970|BEHAVIORAL|observation|Control group will receive the standard of care according to the Scoliosis Research Society criteria: observation for patients with curves between 10°- 25°.
223767061|NCT01730495|DRUG|Etanercept|Weekly subcutaneous injections of Etanercept 50 mg, for up to 12 months.
223650870|NCT04927169|DRUG|PLACEBO|IM administration of a volume of saline identical to 10μg/kg CYT107, twice a week for three weeks and up to 7 administrations according to Hospital length of stay
223650871|NCT00806819|DRUG|Nintedanib (BIBF1120)|starting dose of 200 mg bid taken daily except on the day of pemetrexed infusion . The dose can be reduced to 150 bid and then to 100 mg bid.
223650872|NCT00806819|DRUG|Pemetrexed|500 mg/metre squared administered as an intravenous infusion over 10 minutes on Day 1 of each 21 day cycle.
223650873|NCT00806819|DRUG|pemetrexed|500 mg/metre squared administered as an intravenous infusion over 10 minutes on Day 1 of each 21 day cycle.
223650874|NCT00806819|DRUG|B12|1000 ug IM injection starting a week before first pemetrexed infusion and every 9 weeks thereafter until discontinuation of pemetrexed
223650875|NCT00806819|DRUG|dexamethasone (or corticosteroid equivalent)|4 mg PO bid the day before, the day of and the day after each pemetrexed infusion
223650876|NCT00806819|DRUG|placebo|starting dose of 200 mg bid taken daily except on the day of pemetrexed infusion . The dose can be reduced to 150 bid and then to 100 mg bid.
223650877|NCT00806819|DRUG|dexamethasone (or corticosteroid equivalent)|4 mg PO bid the day before, the day of and the day after each pemetrexed infusion
223650878|NCT00806819|DRUG|B12|1000 ug IM injection starting a week before first pemetrexed infusion and every 9 weeks thereafter until discontinuation of pemetrexed
223650879|NCT00806819|DRUG|Folic Acid|400 ug once daily starting 1-2 weeks prior to the first dose of pemetrexed and continuing for at least 3 weeks after stopping pemetrexed.
223650880|NCT00806819|DRUG|B12|1000 ug IM injection starting a week before first pemetrexed infusion and every 9 weeks thereafter until discontinuation of pemetrexed
223650881|NCT00806819|DRUG|dexamethasone (or corticosteroid equivalent)|4 mg PO bid the day before, the day of and the day after each pemetrexed infusion
223650882|NCT00806819|DRUG|Folic Acid|400 ug once daily starting 1-2 weeks prior to the first dose of pemetrexed and continuing for at least 3 weeks after stopping pemetrexed.
223650883|NCT00806819|DRUG|placebo|starting dose of 200 mg bid taken daily except on the day of pemetrexed infusion . The dose can be reduced to 150 bid and then to 100 mg bid.
223650884|NCT00806819|DRUG|Folic Acid|400 ug once daily starting 1-2 weeks prior to the first dose of pemetrexed and continuing for at least 3 weeks after stopping pemetrexed.
223767062|NCT01015846|OTHER|Exercise|Redcord (sling exercise) and traditional exercise
223767063|NCT01015846|OTHER|Core stability exercise|Traditional core stability exercise
223767064|NCT01081808|BIOLOGICAL|EGFRBi-armed autologous activated T cells|EGFRBi-armed autologous activated T cells infused twice a week for 4 weeks for a total of 8 infusions. The doses of the armed ATC will be escalated at the dose levels of 5, 10, 20, and 40 billion armed ATC per infusion. Subcutaneous aldesleukin (300,000IU/m2/day) and Sargramostim (250 ug/m2 twice per week) both starting 3 days before the 1st infusion and ending 7 days after the last dose of armed ATC.
223767065|NCT02366481|DIETARY_SUPPLEMENT|Placebo|Two placebo softgel capsules (containing no vitamin K2) every day for 8 weeks.
223767066|NCT02366481|DIETARY_SUPPLEMENT|Low-Dose Vitamin K2 Supplement (menaquinone-7; 90-mcg/d)|One 90-mcg vitamin K2 softgel capsules (containing no vitamin K2) and one placebo softgel capsule everyday for 8 weeks.
223767067|NCT02366481|DIETARY_SUPPLEMENT|High-Dose Vitamin K2 Supplement (menaquinone-7; 180-mcg/d)|Two 90-mcg vitamin K2 softgel capsules every day for 8 weeks.
223650885|NCT00806819|DRUG|Nintedanib (BIBF1120)|starting dose of 200 mg bid taken daily except on the day of pemetrexed infusion . The dose can be reduced to 150 bid and then to 100 mg bid.
223650886|NCT00806819|DRUG|Pemetrexed|500 mg/metre squared administered as an intravenous infusion over 10 minutes on Day 1 of each 21 day cycle.
223650887|NCT03564678|DIETARY_SUPPLEMENT|Levocarnitine|Given IV
223650888|NCT03564678|DRUG|Vitamin B Complex|Given PO
223650889|NCT03367702|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
223650890|NCT03367702|OTHER|Quality-of-Life Assessment|Ancillary studies
223650891|NCT03367702|OTHER|Questionnaire Administration|Ancillary studies
223650892|NCT03367702|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
223650893|NCT06487533|DEVICE|EmbracePlus Smartwatch|"The EmbracePlus is worn on the user's wrist and continuously collects raw data via specific sensors. These data can be wirelessly transmitted to a paired mobile device. The data received are analyzed by EmpaDSP, which computes the user physiological parameters. The Care App is responsible for transmitting raw data, device information, Care App-specific information, and computed physiological parameters to the Empatica Cloud. The device supports continuous data collection for monitoring of the following physiological parameters:~* Peripheral skin temperature~* Electrodermal activity~* Blood Oxygen Saturation under no motion conditions~* Activity associated with movement during sleep.~The EmbracePlus Watch has been used in previous human subject research studies for bio-physiological data collection in other medical conditions and have confirmed that there is minimal risk to participants. This device is therefore exempt from any IDE requirements."
223650894|NCT06487533|DEVICE|Corti Sensor|"The Corti Wearable is a sweat sensor that is worn continuously measure cortisol, melatonin, tumor necrosis alpha interleukin-6 (IL-6) in the protein analytes in the sweat of participants via electrochemical impedance spectroscopy. The Corti Wearable comprises a plastic reader and a replaceable polymer sweat-sensing strip with zinc oxide (ZnO) coated electrodes that is worn on the participant's forearm. It is manufactured through a screen-printing technique that allows for an affinity-based interaction between a capture probe antibody and the target molecule generating electrochemical activity.~The Cort Wearable has been used in previous human subject research studies for bio-physiological data collection in other medical conditions and have confirmed that there is minimal risk to participants. This device is therefore exempt from any IDE requirements."
223650895|NCT05449548|DRUG|Lenalidomide 10 mg|All subjects will be treated with lenalidomide 10mg/day with a regular follow-up of 12 weeks, followed by a 4-week observation after cessation of lenalidomide.
223650896|NCT04067830|OTHER|Best Practice|Receive usual care
223650897|NCT04067830|PROCEDURE|Laparoscopic Surgery|Undergo laparoscopic surgery
223650898|NCT04067830|OTHER|Quality-of-Life Assessment|Ancillary studies
223650899|NCT04067830|OTHER|Questionnaire Administration|Ancillary studies
223650900|NCT04067830|DEVICE|Respiratory Muscle Training Device|Use power lung device to complete RMT
223650901|NCT04067830|PROCEDURE|Video-Assisted Thoracic Surgery|Undergo video-assisted thoracic surgery
223650902|NCT06374602|DRUG|Pembrolizumab + Lenvatinib|Pembrolizumab is a programmed death receptor-1 (PD-1)-blocking antibody. Lenvatinib is Lenvatinib is a kinase inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4).
223650903|NCT05055050|DRUG|UGN-201|Intravesical 200 mg /50 ml x 1 dose
223650904|NCT05869708|DEVICE|Active RS-EFP|A minimum of 10 and up to 15 active NF Prism training sessions, aimed to train for upregulating the RS activity. Sessions will occur twice a week, on nonconsecutive days, over 5-8 consecutive weeks. Subjects will also receive two single booster sessions, one month and two months after their last training session.
223650905|NCT05869708|DEVICE|Sham RS-EFP|a minimum of 10 and up to 15 sham NF Prism training sessions, aimed to train for upregulating the RS activity. Sessions will occur twice a week, on nonconsecutive days, over 5-8 consecutive weeks. Subjects will also receive two single sham booster sessions, one month and two months after their last training session.
223650906|NCT02987712|OTHER|Thromboelastography based protocol|patients will be treated according to a new thromboelastography based protocol
223650907|NCT04016623|DEVICE|1-day toric test contact lens|somofilcon A 1-day toric test contact lens
223650908|NCT04016623|DEVICE|1-day toric control contact lens|somofilcon A 1-day toric control contact lens
223650909|NCT06084208|DEVICE|Biopsy with the Robotic- Ion Endoluminal System with Adjunct Real-time Imaging|Biopsy with the Robotic- Navigational Bronchoscopy System with Cone Beam Computed Tomography (CBCT)
223650910|NCT05555069|OTHER|Menthol-flavored electronic cigarette|Participants will receive 12 weeks of menthol -flavored electronic cigarettes to aid in switching from combustible cigarettes. Participants will be instructed on proper use of the electronic cigarettes, educated about electronic cigarettes and participate in motivation enhancement and substituting electronic cigarettes for cigarettes.
224235360|NCT03427970|BEHAVIORAL|three-dimensionally integrated exercise for scoliosis|Experimental group will receive a modified physiotherapeutic scoliosis specific exercises --the three-dimensionally integrated exercise for scoliosis program, which include auto-correction in 3D, postural correction, breathing training, resistance training, muscle fascia releasing, functional activities, balance training, core stability training, proprioceptive input exercises and patient education. Auto-correction exercise in 3D will combine with specific breathing mode, isometric training to correct abnormal spinal physiological curvatures in sagittal plane, and accompany with wedge pad to modify humpback, waist asymmetry, pelvic rotation in horizontal. While in coronal plane, longitudinal axial stretching, pelvic adjustments will be conducted to reduce the lateral curvature.
224235361|NCT02791100|BEHAVIORAL|Promotion of chicken eggs|Community is provided with chickens and young children are to receive 2 eggs a day plus egg shell
223650911|NCT05555069|OTHER|Tobacco-flavored electronic cigarette|Participants will receive 12 weeks of tobacco-flavored electronic cigarettes to aid in switching from combustible cigarettes. Participants will be instructed on proper use of the electronic cigarettes, educated about electronic cigarettes and participate in motivation enhancement and substituting electronic cigarettes for cigarettes.
223650912|NCT00823693|DRUG|Bimosiamose Cream|
223650913|NCT00823693|DRUG|Placebo Cream|
224235362|NCT04511559|DIAGNOSTIC_TEST|Circulating Tumor DNA Methylation Sequencing|Whole blood collection through venipuncture. DNA methylation levels by deep sequencing.
224235363|NCT04511559|DIAGNOSTIC_TEST|tissue DNA Methylation Sequencing|Isolate DNA from tissue samples from subjects. DNA methylation levels by deep sequencing.
224235364|NCT01574170|OTHER|Construction of a prognostic score (non-drug intervention types)|Record of clinical, histological and biological data and questionnaires data in patients starting a third line metastatic until progression
224235365|NCT00253032|DEVICE|PRIMA|
223650914|NCT02285946|PROCEDURE|major spine surgery|
223650915|NCT05231122|BIOLOGICAL|Anti-CD40 Agonist Monoclonal Antibody CDX-1140|Given IV
223650916|NCT05231122|BIOLOGICAL|Bevacizumab|Given IV
223650917|NCT05231122|BIOLOGICAL|Pembrolizumab|Given IV
223650918|NCT05231122|OTHER|Quality-of-Life Assessment|Ancillary studies
223650919|NCT05231122|OTHER|Questionnaire Administration|Ancillary studies
223650920|NCT00148083|DRUG|Risperdal Consta (drug)|
223650921|NCT00148083|BEHAVIORAL|Social Skills Training|
223650922|NCT02464696|DRUG|Methylprednisolone|IPS cohort only
223650923|NCT02464696|PROCEDURE|Oxygen Therapy|Receive high flow oxygen therapy
223650924|NCT02464696|DEVICE|Positive Air Pressure Device|Undergo NIPPV
223650925|NCT05842044|DRUG|Ketorolac|15-30mg Ketorolac administered via injection during intraoperative period every six (6) hours during post-surgery (inpatient) period.
223650926|NCT05842044|DRUG|Acetaminophen|1000mg Acetaminophen administered orally during preoperative period. Standardized regimen of Acetaminophen administered during post-surgery (inpatient) period, during postoperative follow-up period.
223650927|NCT05842044|DRUG|Oxycodone|"Standardized regimen of Oxycodone administered orally (PO) on demand for moderate pain during post-surgery (inpatient) period.~At discharge 5mg Oxycodone will be administered to participants on demand if pain score is greater than 7, or if participant required greater than 25mg Oxycodone during the hospitalization."
223650928|NCT05842044|DRUG|Hydromorphone|Standardized regimen of Hydromorphone administered intravenously (IV) on demand for severe pain during post-surgery (inpatient) period.
223650929|NCT05842044|DRUG|Ibuprofen|400mg Ibuprofen tablets administered orally (PO) every eight (8) hours for 5 days.
223650930|NCT05776823|BEHAVIORAL|Pharmacist Narcan Training|A 20-45-minute didactic presentation conducted with a skills training component designed to demonstrate appropriate administration of the Narcan nasal spray.
223650931|NCT05776823|BEHAVIORAL|BIRT|BIRT participants will receive a 30-45-minute session delivered by the pharmacist to introduce and encourage treatment options, MOUD information, OUD information, and treatment facility information (i.e., flyers (RDD study/CAST clinic/State Opioid Response III funded agencies) and educational materials), and a referral to treatment/linkage to service providers.
223650932|NCT05776823|BEHAVIORAL|SMC|SMS participants will receive a 5-10-minute counseling session delivered by the pharmacist providing MOUD information, OUD information, and treatment facility information (i.e., flyers (RDD study/CAST clinic/State Opioid Response III funded agencies) and educational materials).
223650933|NCT05776823|BEHAVIORAL|Substance Use Counselor Narcan Training|A 20-45-minute didactic presentation conducted with a skills training component designed to demonstrate appropriate administration of the Narcan nasal spray.
223650934|NCT05268003|DRUG|Ponatinib|Given by PO
223650935|NCT05268003|DRUG|Venetoclax|Given by PO
223650936|NCT05268003|DRUG|Mini-hyper CVD|Given by IV (vein)
223650937|NCT06518603|DRUG|Caffeine citrate 20mg/kg/day|Caffeine citrate 20mg/kg/day given orally once daily for 28 days
223650938|NCT06518603|DRUG|Placebo-Sterile water 1ml/kg/day|Placebo-sterile water 1mg/kg/day given orally once daily for 28 days
223650939|NCT05834569|DRUG|Acetaminophen and Ibuprofen|Patients in the Maxigesic group will be administered a total of 5 doses of the drug (20mg/kg, maximum dose per serving: 1g) every 6 h from immediately after anesthetic induction.
223650940|NCT05834569|DRUG|Normal saline|Patients in the control group will be administered equal amounts of normal saline at the same time points.
224235366|NCT00926406|DRUG|lead chelation therapy|Patients with lead poisoning (BLL\> 20μg/dl) are randomly assigned to a control or chelation group, on the 1:1 proportion. During the 3 months, 50 chelation group patients receive 2-hour weekly intravenous infusions of one vial (1 g) of calcium di-sodium EDTA mixed with 200 ml of normal saline until BLB is BLL \< 5 μg/dl. Fifty control patients receive weekly 2-hour infusions of one vial (20 ml) of 50% glucose mixed with 200 ml of normal saline over a period of 12 weeks9.
224235367|NCT04799600|OTHER|BRESCİA-COVİD Respiratory Severity Scale|KDIGO acute renal failure score BRESCİA-COVID Respiratory Severity Score
224235368|NCT02635100|OTHER|CPAP machine with MNT algorithm|"The multinight (MNT) algorithm will be evaluated on patients with Obstructive Sleep Apnea (OSA) over multiple nights while using CPAP in the home for a total of 45 days. In particular the main goal is to assess the behavior of the two main stages of the algorithm:~1. Fast Track (FT) stage. Assesses if the algorithm reliably and timely reaches approximate therapeutic pressure levels.~2. Slow Titration (ST) stage.Assesses if data samples are appropriately collected in a pressure range so that the therapeutic pressure can be inferred according to the algorithm proposed.~   1. Five days with standard auto titration.~  2. MNT algorithm : 7 days (maximum) with Fast Track mode, 27 days (maximum) in Slow Titration mode. After PMNT is found, the device remains at PMNT for 5 sessions. Total approximately 45 days."
224235369|NCT01385033|DRUG|[18F]MK-3328|IV dose of \~150 megabecquerel (MBq) \[18F\]MK-3328
224235370|NCT02301247|BEHAVIORAL|Memory retraining exercises|Memory retraining exercises will be administered on a laptop computer twice a week for 5 weeks (10 training sessions).
224235371|NCT02301247|BEHAVIORAL|Placebo control memory exercises|Placebo control memory exercises will be administered on a laptop computer twice a week for 5 weeks (10 training sessions).
224235372|NCT00802451|DRUG|Mesalamine|
223650941|NCT04671693|OTHER|PASCA intervention|"At each study visit (T1 = 1 month, T2 = 6 months, T3 = 24 months, T4 = 60 months), an exhaustive screening of complications as well as associated sub-clinical abnormalities and risk factors previously identified as such in the literature, will be conducted.~Management of complications consists of referring the patient to a healthcare professional belonging to the PASCA network based on the test results. Referral is defined by referring to pre-established decision trees. It is made to a specialist physician, a health professional from the paramedical field or the patient's general practitioner who confirms the diagnosis if necessary and initiates the patient's care and follow-up. These patients also receive their usual follow-up in the context of their tumor pathology in oncology and onco-hematology."
223650942|NCT02971748|BIOLOGICAL|Pembrolizumab|Given IV
223650943|NCT06193616|DRUG|Octreotide|All consenting patients treated with octreotide LAR according to Determina AIFA n. 1264 del 3 August 2018 and fulfilling the selection criteria will be collected at prespecified time-points according to the routine visits scheduled for these patients and the periodic follow-up visits till dialysis initiation as described in the AIFA indication on GU Serie Generale n.5 del 08-01-2020.
223767068|NCT02213276|OTHER|Oral Glucose Tolerance Test (OGTT)|At baseline participants are asked to drink a glucose solution consisting of 75 grams of glucose dissolved in 250 ml of water. Meanwhile and 15 minutes, 30 minutes, 1 hour, 2 hours and 3 hours later, blood is collected from an intravenous access, in order to asses primary and secondary outcomes.
223767069|NCT02213276|OTHER|Intravenous Glucose Tolerance Test (IVGTT)|In this intervention, the participant needs to have two intravenous accesses. In one we infuse an adjustable 20% glucose solution, and try to mimic the glucose profile found in the oral glucose tolerance test. In order to do this, blood glucose is measured every 5 minutes. At baseline and 15 minutes, 30 minutes, 1 hour, 2 hours and 3 hours later, blood is collected from another intravenous access, in order to asses primary and secondary outcomes.
223650944|NCT05819801|OTHER|Non-fasting|Instructing patients to eat before their local-only procedure
223650945|NCT05819801|OTHER|Fasting|Instructing patients to fast before their local-only procedure
223650946|NCT04755153|OTHER|Practice Facilitation|Tailored interventions provided by a trained Practice Facilitator
223650947|NCT04755153|OTHER|Non-Practice Facilitation|Implementation support without using Practice Facilitation
223650948|NCT05342883|DEVICE|Surgical tumor resection, GammaTile radiation therapy implantation, Stupp protocol (EBRT and Temozolamide)|At the initiation of the surgical phase maximal safe resection will be undertaken, and after 25 + 4 from surgery participants will start the concomitant phase and receive daily temozolomide (TMZ, 75mg/m2) and 20 fractions external beam radiation (EBRT). The EBRT treatment will be to the operative bed and any residual disease identified at the time of the imaging obtained for EBRT planning. The EBRT planning will utilize the GT implant dosimetry with the intent that the dose received from the GT will be accounted for during the EBRT treatment planning process. Twenty-eight days ±7 after the completion of concomitant TMZ and EBRT, participants will enter the adjuvant phase and will be treated with TMZ (150-200mg/m2) for 5 days at the start of every 28- day cycle, for 6 cycles.
223650949|NCT01189643|DRUG|irinotecan, temozolomide, and bevacizumab incorporated into an existing schedule of high dose alkylator|Two cycles of the investigational combination irinotecan, temozolomide and bevacizumab- will be given followed by conventional chemotherapy with a modified P6 approach and surgical local control. Completion of modified P6 chemotherapy will be followed by a second-look surgery.
223650950|NCT03137199|BIOLOGICAL|hMSCs|intravenous infusion of bone marrow-derived allogeneic stem cells
223650951|NCT02538354|DIETARY_SUPPLEMENT|Riboflavin supplementation|Supplementation of the normal diet with 1 capsule of 100 mg riboflavin (vitamin B2) during three weeks
223650952|NCT03422094|BIOLOGICAL|NeoVax|At each vaccination time point, patients will receive up to 20 synthetic long peptides co-administered with 1.5 mg of poly-ICLC divided into a maximum of four injections (pools). Each pool (of vaccine + poly IC:LC) will be administered to one of the four limbs (right axilla, left axilla, right inguina, left inguina) by subcutaneous injection.
223650953|NCT03422094|BIOLOGICAL|Nivolumab|Nivolumab is a programmed death receptor-1 (PD-1) blocking antibody
223650954|NCT03422094|BIOLOGICAL|Ipilimumab|Ipilimumab is a recombinant, human monoclonal antibody that binds to the cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4)
224235373|NCT02798484|DEVICE|Diffusion-weighted Nuclear Magnetic Resonance Imaging (MRI)|MRI examinations performed on two devices: Ingernia 3 Testla (Philips) on the Horta site of the CHU Brugmann hospital, and Area 1,5 Tesla (Siemens) on the Brien site of the CHU Brugmann hospital. Diffusion sequences last 6 minutes and are already performed in the standard of care. Compared to the standard of care, one additional MRI will be performed one month after the start of the neo-adjuvant treatment, with diffusion analysis.The post-processing of the examinations will be realized with the Syngo Onco Care application of Siemens.
224235374|NCT06411366|GENETIC|Follistatin plasmid|Follistatin-344 plasmid
224235375|NCT03735446|DRUG|Prexasertib|Checkpoint kinase 1 (CHK1) inhibitor
224235376|NCT03735446|DRUG|Mitoxantrone|Standard chemotherapy (topoisomerase inhibitor)
224235377|NCT03735446|DRUG|Etoposide|Standard chemotherapy (topoisomerase II inhibitor)
224235378|NCT03735446|DRUG|Cytarabine|Standard chemotherapy (anti-metabolite)
224235379|NCT05042856|PROCEDURE|PanOptix IOL implantation|All the patients will be bilaterally implanted with PanOptix IOL，one eye will be randomized selected for monocular analysis of each patient.
224235380|NCT02153398|DRUG|D961H sachet 10 mg|
224235381|NCT02153398|DRUG|D961H capsule 10mg|
224320533|NCT04521803|DRUG|high dose Rifampicin (RIF)|Simulations were performed to determine the dose of RIF required to achieve the most equitable drug exposures across the weight range, 30 to 100 kg. Demographic data of a reference cohort of TB patients (n = 1225), with or without HIV-1 coinfection, recruited in clinical trials conducted in West Africa and South Africa were used for the simulations35-38. An additional 12 250 virtual patients were generated using the weight and height distributions of the 1225 patients to increase the number of patients with a weight close to the boundaries of the weight range. Parameter estimates of the population PK model for RIF were used to simulate (100 replicates) RIF exposures22. Four dosing scenarios were evaluated using the weight-band based dosing with 4-drug FDC tablets and extra RIF tablets with each tablet containing 150 mg or 600 mg RIF. The FDC tablets were assumed to have 20% reduced bioavailability based on data from a clinical trial where the same formulation was used
223650955|NCT03422094|PROCEDURE|Research blood draw|-Baseline, cycle 2 day 1, cycle 4 day 1, and time of progression or discontinuation of treatment
223650956|NCT03422094|PROCEDURE|Leukapheresis for research|-Baseline, cycle 4 day 1, and time of progression or discontinuation of treatment
223650957|NCT04288284|PROCEDURE|Curative resection of colorectal cancer|
223650958|NCT05687500|DRUG|Glibenclamide|Amglidia®: glibenclamide oral suspension 6 mg/ml administered by gastric tube after dilution to 1/6th in human milk
223767070|NCT04447716|DRUG|Venetoclax|Given PO
223767071|NCT04447716|DRUG|Lenalidomide|Given PO
223767072|NCT04447716|BIOLOGICAL|Rituximab|Given IV
223767073|NCT04447716|BIOLOGICAL|Rituximab and Hyaluronidase Human|Given SC
223767074|NCT00315276|DRUG|Modafinil|
224235382|NCT02153398|DRUG|D961H capsule 20 mg|
224235383|NCT01234636|DIETARY_SUPPLEMENT|Placebo oil|Placebo oil of 4g/day
224235384|NCT04508998|DIAGNOSTIC_TEST|Blood tests including genotyping|Blood tests for alternative SNPs altering levels of ET-A receptor expression; blood will be further analysed for endothelin receptor mRNA and other plasma peptides important in the endothelin signalling pathway
224235385|NCT04508998|DIAGNOSTIC_TEST|Exercise Tolerance Test|Treadmill exercise test using the Bruce protocol
224320534|NCT06655857|OTHER|Usual Care|Participants are provided care as usual. Clinicians (CKD, HD, KTx) will educate participants on the kidney transplant process. Clinician will receive the education intervention to provide participants at study end.
223767075|NCT00972491|PROCEDURE|Insertion of Laryngeal Mask Airway|The LMA will be inserted at 0 sec, 60 sec. and 90 sec. after induction of general anesthesia
224235386|NCT04450745|BEHAVIORAL|Exercise in hypoxia|60 minutes training program of mixed exercise in normobaric hypoxic chamber
224235387|NCT04450745|BEHAVIORAL|Exercise in normoxia|60 minutes training program of mixed exercise in regular air conditions
224235388|NCT00721409|DRUG|PD 0332991|125 mg/d capsules orally for 3 out of 4 weeks in repeated cycles
224235389|NCT00721409|DRUG|letrozole|2.5 mg/d tablets orally on a continuous regimen
224235390|NCT00721409|DRUG|letrozole|2.5 mg/d tablets orally on a continuous regimen
224235391|NCT03528668|DEVICE|Virtual Reality Exposure|Exposure to Virtual Reality program for up to 30 minutes
223650959|NCT05687500|BIOLOGICAL|Pharmacokinetics study|"* For the first 10 patients during the test phase, four 0.2 ml samples will be taken at H3, H6, H10, and H24 (+/- 1 hour) after the first dose; an additional sample will be taken for patients whose blood sugar levels stabilize beyond 24 hours, after 6 hours of stable blood sugar levels (4-10 mmol/l);~* For subsequent patients included during phase II:~* 1 sample of 0.2 ml within the first 24 hours of treatment, during a care assessment.~* 1 sample of 0.2 ml within the first 24 hours of treatment, during a care assessment~* 1 sample of 0.2 ml per day at each daily check-up as part of care during the treatment period.~* In centers that are unable to perform the samples and the appropriate techniques for centralizing these PK points, these samples will not be taken.~PK parameters of glibenclamide will be determined using nonlinear analysis: area under the plasma concentration time curve (AUC), absorption constant, apparent clearance and volume of distribution."
223650960|NCT05687500|BIOLOGICAL|C-peptide proinsulin ratio|blood sampling at before first administration and after 24 hours for measurement of C-peptide proinsulin ratio if it is impossible to collect both volumes, the C-peptide collection will be prioritized
223650961|NCT05687500|BIOLOGICAL|Routine biological monitoring|"If there are not performed as part of standard care, biological monitoring of ALT, AST, complete blood count, hemostasis, urea, creatinine, blood ionogram, total bilirubin and conjugated bilirubin will be done before first administration at the following time frame : 48 hours after the first administration than each days during treatment period, and 48 hours after the end of treatment.~Transaminases and hemostasis will be done only in case of clinical indication before the first administration."
223650962|NCT02389309|DRUG|Cyclophosphamide|Given PO
223650963|NCT02389309|DRUG|Dasatinib|Given PO
223650964|NCT02389309|OTHER|Laboratory Biomarker Analysis|Correlative studies
223650965|NCT02389309|DRUG|Temsirolimus|Given IV
223650966|NCT01615029|DRUG|Part 1 (Dose Escalation): Daratumumab|Participants will receive intravenous (injection of a substance into a vein) infusion of daratumumab in an increased fashion from 2 milligram per kilogram (mg/kg) up to maximum dose of 16 mg/kg. Considering the safety and efficacy of dose in Part 1, recommended phase 2 dose (RP2D) for Part 2 of the study will be decided. A predose infusion of 10 percent (%) of the full dose of daratumumab will be administered a day before the first full infusion of the first cycle. Participants will receive 4 weekly infusions in the first 2 treatment cycles. From cycles 3 to 6 infusions will be administered every alternate week and monthly infusions will be administered from cycle 7 until disease progression.
223767076|NCT01690039|DRUG|Furosemide-Fludrocortisone-Test (test for urinary acidification)|The presence of a lack of urinary acidification will be assessed by an appropriate test in all patients.
223767077|NCT00124215|BIOLOGICAL|GI-5005|Heat-killed yeast cell transfected with NS3-Core fusion protien.
224235392|NCT05420051|BEHAVIORAL|Positive Psychology + Motivational Interviewing|The 8-week PP-MI intervention focuses on enhancing well-being (through PP) and increasing physical activity (through MI). Each week, participants will complete a PP activity and work towards a physical activity goal, then complete a phone session with a study trainer. The PP portion of the program will focus on the cultivation of well-being through the performance of easy-to complete activities (e.g., using a strength in a new way) and review of the positive feelings they generate. The MI portion of the program will focus on assisting participants to improve physical activity levels, resolve ambivalence to behavior change, set realistic physical activity goals, problem-solve barriers, and identify resources to complete behavior change. Finally, participants will receive twice weekly text messages (for 16 weeks) to encourage completion of PP activities and engagement in physical activity.
224235393|NCT05420051|BEHAVIORAL|Motivational Interviewing|The 8-week MI-alone intervention focuses on providing education and enhancing motivation to engage in health behaviors (through MI). Each week, participants will complete an activity related to a health behavior (e.g., consider the pros and cons of behavior change, set a health behavior goal), then complete a phone session with a study trainer. This program will focus on assisting participants to improve health behavior adherence (including physical activity), resolve ambivalence to behavior change, set realistic health behavior goals, problem-solve barriers, and identify resources to complete behavior change. Additional time in MI-alone phone sessions will be spent on review of core MI skills, problem-solving of barriers, and discussion of resources. Finally, participants will receive twice weekly text messages (for 16 weeks) to encourage engagement in health behaviors.
224235394|NCT01138683|PROCEDURE|ultrafiltration|Ultrafiltration through double lumen catheter, via central vein (Vena jugularis interna or Vena femoralis, 11 French, 15 cm for right jugular or 20 cm for femoralis and jugularis left-position). Based on severity of fluid overload the cardiologist determines the ultrafiltration rate. 'Multifiltrate Fresenius' (extracorporeal blood volume 72ml) in SCUF (slow continuous ultrafiltration) modus with pediatric lines (54 ml extracorporeal volume in the AV-set) and a pediatric filter (Ultraflux® AV paed, blood volume 18ml). Heparin to maintain an APTT between 65 en 85 seconds during ultrafiltration.
224235395|NCT01138683|DRUG|diuretics|Bumetanide continuous infusion to reach a prescribed negative fluid balance: dose adjustment according to the diuretic response.
224235396|NCT05190263|OTHER|non-interventional retrospective epidemiological observational study|non-interventional retrospective epidemiological observational study
224235397|NCT02136095|PROCEDURE|Intraoperative fluorescent cholangiography (IFC)|A standardized protocol with IFC including concomitant angiography was performed during laparoscopic cholecystectomy.
224320535|NCT06655857|OTHER|Community Health Worker Assistance|Community health worker will address unmet social needs and participant symptoms through evaluations and intake to clinical and community services
224320536|NCT06655857|OTHER|Intervention Providers|Intervention providers will receive education, which will include training on working with CHWs, reducing bias in clinical decision-making, and increasing affirming/reducing stigmatizing language in electronic health records (EHRs).
223767078|NCT04173338|DRUG|Cabozantinib|start at 20mg then increase by 20mg every cycle or until there's a dose-limiting toxicity.
224235398|NCT02635243|DRUG|SAR438544|"Pharmaceutical form:solution~Route of administration: subcutaneous"
223767079|NCT04173338|DRUG|Pemetrexed|Start with 400mg/m2, then increase and maintain 500mg/m2 unless dose-limiting toxicity.
223767080|NCT01440322|DEVICE|Lotrafilcon B contact lens with color|Silicone hydrogel contact lens with color
223767081|NCT01440322|DEVICE|Lotrafilcon B contact lens|Silicone hydrogel contact lens
223650967|NCT01615029|DRUG|Part 2 (Dose Expansion): Daratumumab|Participants will receive RP2D as determined in Part 1 of the study. Participants will receive 4 weekly infusions of RP2D in the first 2 treatment cycles. From cycles 3 to 6 infusions will be administered every alternate week and monthly infusions will be administered from cycle 7 until disease progression.
223650968|NCT01615029|DRUG|Lenalidomide|All participants (Part 1 and Part 2) will receive 25 mg lenalidomide orally (by mouth) from days 1 to 21 of each 28-day cycle until disease progression.
223650969|NCT01615029|DRUG|Dexamethasone|All participants (Part 1 and Part 2) will receive 40 mg (20 mg intravenously \[injection of a substance into a vein\]) dexamethasone once weekly. Participants older than 75 years or underweight (body mass index \[BMI\] less than \[\<\] 18.5), the dexamethasone dose will be administered at a dose of 20 mg once weekly until disease progression.
223650970|NCT06265012|BIOLOGICAL|PHV01|Marburg virus vaccine
223650971|NCT06265012|BIOLOGICAL|Placebo|Lactated Ringer's Solution
223650972|NCT01746836|OTHER|Laboratory Biomarker Analysis|Blood draws.
223650973|NCT01746836|DRUG|Ponatinib Hydrochloride|Starting dose: 30 mg by mouth once a day.
223650974|NCT01746836|OTHER|Quality-of-Life Assessment|Surveys completed.
223650975|NCT05030883|BEHAVIORAL|Source of news|The main intervention was the source of the news that was shown to participants
224235399|NCT02635243|DRUG|r-glucagon|"Pharmaceutical form:solution~Route of administration: subcutaneous"
224235400|NCT02635243|DRUG|insulin|"Pharmaceutical form:solution~Route of administration: intravenous"
224235401|NCT03931642|DRUG|RCHOP|"D1 : Rituximab 375 mg/m² IV + Cyclophosphamide 750 mg/m² IV + Doxorubicin 50 mg/m² IV + Vincristine 1.4 mg/m² IV.~From D1 to D5 : Prednisone 60 mg/m² PO."
224320537|NCT06981611|BEHAVIORAL|Vulvodynia Intervention: a multimodal treatment for provoked vulvodynia|The intervention is based around physiological and psychosocial components working with goal-directed behavioral change. Includes both educational and practical elements, examples of these are vulva care, lubrication exercises, pelvic floor relaxation, work with thoughts, feelings, and behaviors related to the pain, as well as thoughts, feelings and behaviors related to sex and desire, and educational and practical elements focusing on open communication and validation. The treatment sessions are approximately 60 minutes each. There is a possibility for the participants to involve partner during two of the treatment sessions.
224320538|NCT02881840|DRUG|14C-APD421|
224320539|NCT00967655|BIOLOGICAL|panitumumab|
223650976|NCT04901715|DRUG|Albuterol|Albuterol HFA Metered Dose Inhaler (90mcg/puff). Subjects to use 4 puffs one time.
223650977|NCT04901715|DIAGNOSTIC_TEST|Technetium99m - Sulfur Colloid (Tc99m-SC)|Aerosolized radiolabeled Tc99m-sulfur colloid will be delivered using a modified Pari-LC Star nebulizer. The activity of Tc99m-SC loaded in the nebulizer will be adjusted to provide an estimated 40 microcurie (µCi) deposited in the lung for the MCC/CC scan. Patients between the age 12-18 years old will receive three quarters of the adult dose to account for the smaller lung volume.
223650978|NCT04013542|BIOLOGICAL|Ipilimumab|Given IV
223650979|NCT04013542|BIOLOGICAL|Nivolumab|Given IV
223650980|NCT04013542|RADIATION|Radiation Therapy|Undergo radiation therapy
223650981|NCT04105166|BIOLOGICAL|RP-L301|Autologous genetically modified CD34+ hematopoietic stem cells containing the corrected PKD gene
223650982|NCT06567860|BIOLOGICAL|Influenza Fluzone vaccine|Fluzone vaccine administered in both May-June and in September-October for each participant.
223650983|NCT03404193|DRUG|Decitabine|Given IV
223650984|NCT03404193|OTHER|Laboratory Biomarker Analysis|Correlative studies
223650985|NCT03404193|DRUG|Venetoclax|Given PO
223650986|NCT06966804|DRUG|Terazosin|Subject will complete 14-day course of Terazosin
223650987|NCT06966804|DRUG|Tamsulosin|Subject will complete 14-day course of Tamsulosin
223650988|NCT06125028|DRUG|[68Ga]Ga-PentixaFor|\[68Ga\]Ga-PTF i.v. injection
223650989|NCT06125028|DRUG|[18F]Fluorodeoxyglucose|\[18F\]FDG i.v. injection.
223767082|NCT00239057|DRUG|Enteric-Coated Mycophenolate Sodium|
224235402|NCT03931642|DRUG|Blinatumomab|Blinatumomab by continuous vein infusion
224235403|NCT04014322|OTHER|E-cigarette|"All participants will be provided with 8 weeks of e-cigarettes at no cost based on self-report of regular cigarette use.~All participants will receive a total of 8-10 remote counseling sessions (via phone or video conference) and during which they will discuss ways to switch from smoking cigarettes to exclusively using e-cigarettes, barriers and strategies to overcome them. (All participants will receive sessions at baseline, 2 days, 7 days, 2 weeks, 3 weeks, and 4 weeks, 6 weeks , and 8 weeks after the baseline assessment. Two additional sessions at 5 weeks and 7 weeks (after the baseline assessment) will be provided to those who are still smoking combustible cigarettes at 4-week assessment.)"
224235404|NCT05984771|DIETARY_SUPPLEMENT|Epineuron|Superoxide Dismutase (SOD, 70 UI), Palmitoylethanolamide (PEA, 300 mg) Alpha Lipoic Acid (ALA, 300 mg), vitamins B6 (1.5 mg), B1 (1.1 mg), B12 (2.5 mcg), E (7.5 mg), Nicotinamide (9 mg) and minerals (Mg 30 mg, Zn 2,5 mg) in one tablet (Epineuron)
224235405|NCT05984771|OTHER|Placebo group|Usual care
224320540|NCT00967655|DRUG|capecitabine|
224320541|NCT00967655|DRUG|irinotecan hydrochloride|
224320542|NCT00967655|PROCEDURE|neoadjuvant therapy|
223767083|NCT06287060|OTHER|strawberry extract.|strawberry has a whitening effect due to its content of ellagic and maleic acids. the presence of acidic components namely ascorbic acid may increase the surface energy by removing the surface debris, thereby allowing the citric and maleic acids to penetrate into tooth surface to remove the surface stains.
224320543|NCT00967655|PROCEDURE|therapeutic conventional surgery|
224320544|NCT00967655|RADIATION|radiation therapy|
224320545|NCT03294720|PROCEDURE|Bio-ACL|ACL reconstruction with either hamstring or patellar autograft, wrapped in amion collagen wrap, and stem cells from bone marrow aspirate.
224320546|NCT03294720|DEVICE|amnion wrap and BMAC|amnion collagen wrap and bone-marrow aspirate in ACL reconstruction autograft
224320547|NCT06321679|PROCEDURE|Imaging evaluation|each patient will undergo imaging with CT, BS and WB-MRI at each study timepoint
224320548|NCT03071276|DRUG|Selinexor|Given orally on days 1,3,8,10,22 and 24 of each cycle
224320549|NCT03071276|DRUG|Fludarabine|Will be given intravenously (IV) over 30 minutes daily on days 16 through 20. Fludarabine may be given prior to day 16 if it is determined to be in the participant's best interest based on disease progression. Chemotherapy may be delayed by 1-3 days if clinically indicated.
223650990|NCT00580385|OTHER|Tissue Procurement|MTX polyglutamylation, MTX transport, XTT cytotoxicity assays, Quantitative RT-PCR, Southern blotting, Mutation detection, and Western blotting
223650991|NCT05359926|OTHER|Experimental|Early urethral foley removal after the surgery
223650992|NCT05359926|OTHER|Active comparator|Delayed urethral foley removal after the surgery
223650993|NCT04022499|BEHAVIORAL|Presessions|"The Pre-NDPP arm includes a pre-session with three components: 1) education about diabetes risks, 2) motivational interviewing (MI) to encourage participation in the NDPP and, 3) problem-solving of barriers to engagement."
223650994|NCT04022499|BEHAVIORAL|National Diabetes Prevention Program|The Diabetes Prevention Program was a successful clinical trial demonstrating that intensive lifestyle support for weight loss reduced diabetes incidence by 58%. The intervention was translated into the National Diabetes Prevention Program (NDPP) and disseminated by the Centers for Disease Control and Prevention as a yearlong group-based program since 2012.
223650995|NCT04988009|OTHER|Electronic Health Record Review|Review of medical chart
223650996|NCT04988009|OTHER|Survey Administration|Complete survey
223650997|NCT00735488|OTHER|Observational|Summary of data
223650998|NCT01745458|DRUG|SB-659032|
223650999|NCT01745458|DRUG|Placebo|Matched placebo
223651000|NCT02773316|DRUG|MR902|
223651001|NCT02773316|DRUG|IR morphine sulphate|
223651002|NCT00802945|DRUG|NKTR-102|NKTR-102 given on a q14 day schedule
223651003|NCT00802945|DRUG|NKTR-102|NKTR-102 given on a q21 day schedule
223651004|NCT06096467|BEHAVIORAL|Comprehension Exercise Training|Comprehension exercise: 45\~50 minutes exercise for each session(warm-up, resistive, functional activities and balance exercise, and cool-down)
223651005|NCT06096467|DIETARY_SUPPLEMENT|Placebo milk|Placebo milk: 8 g. protein for each serving and provided immediately after the CET session
223651006|NCT06096467|DIETARY_SUPPLEMENT|Protein Supplement|Protein Supplement: 40 g. whey protein for each serving and provided immediately after the CET session
223651007|NCT02844868|DEVICE|Active tDCS|During the first 20 min of training program, patient will have active tCDS : the patient received a 2 mA anodal tDCS over the lower limb ipsilesional motor area. The anodal electrode was positioned on the hotspot previously identified with TMS. The cathode was placed above the contralesional orbit.
223651008|NCT02844868|DEVICE|Sham tDCS|During the first 20 min of training program, patient will have sham tCDS : the patient received a 2 mA anodal tDCS (only during the first and the last 30 seconds of the stimulation) and then, patient will have sham tDCS. The anodal electrode was positioned on the hotspot previously identified with TMS. The cathode was placed above the contralesional orbit.
223651009|NCT04593862|OTHER|High-Intensity Interval Training|The intervention will be performed on a treadmill and will include a warm-up and cool-down at 50-60% and 40% of the VO2peak respectively, for up to five minutes. The HIIT protocol will be 4x4, which consists of four bouts of four minutes at a workload corresponding to vigorous intensity (75-95% of the baseline and 6-week VO2peak) alternating with three minutes of recovery intervals at 40% of the VO2peak. The exercise session will last 35 minutes and include 16 minutes of high intensity exercise.
223651010|NCT02324387|PROCEDURE|Molecular Breast Imaging (MBI)|Participants undergo 3 MBI scans with injections of injection of Tc99m sestamibi before each scan. First scan is 7 days before scheduled neoadjuvant chemotherapy (NAC) treatment, after 2 cycles of chemotherapy, and after completion of chemotherapy treatment.
223651011|NCT02324387|DRUG|Tc99m sestamibi|8 mCi of 99mTc sestamibi by vein before each molecular breast imaging (MBI).
223651012|NCT05575401|PROCEDURE|Lateral pharyngoplasty|Two figure-of-8 sutures using 3-0 vicryl are used to approximate the anterior and posterior tonsillar pillars and reconstruct the continuous mucosal covering of the lateral pharyngeal walls.
223651013|NCT05575401|PROCEDURE|Tonsillectomy|Extracapsular tonsillectomy
223651014|NCT04466007|DRUG|High dose allogeneic mesenchymal stromal cells|Allogeneic mesenchymal stromal cells derived from adipose tissue administered intramuscularly
223651015|NCT04466007|DRUG|Low dose allogeneic mesenchymal stromal cells|Allogeneic mesenchymal stromal cells derived from adipose tissue administered intramuscularly
223651016|NCT04466007|DRUG|Placebos|0,9% physiological saline
223651017|NCT06127303|DRUG|Toripalimab|Toripalimab treatment (240mg intravenously every 3 weeks) started on day 3 after cryoablation, until occurrence of termination event specified in the protocol.
223651018|NCT06127303|OTHER|Cryoablation|The ablation was performed on the first day of each cycle, and the target lesions were comprehensively screened for cryoablation based on the location and size of the lesions.
223651019|NCT05750732|BEHAVIORAL|Weight loss diet|Participants in the study group will be given training on the weight loss diet, which is a routine part of their treatment.
223651020|NCT04637867|OTHER|Collection of blood, salivary and nasopharyngeal samples.|"Each visit M6 and M12~* Blood: 1 PAXgene tube (2.5mL) 1 EDTA tube (4mL), 1 dry tube with gel (5mL), 3 EDTA tubes (10mL each)~* Salivary sample~* Nasopharyngeal sample"
224235406|NCT02984436|PROCEDURE|Blood Sample|Blood samples will be collected from study participants for hs-cTnT analysis. Results of hs-cTnT will be used for research purposes only. Providers and participants will be blinded to results and participants will be treated by their healthcare providers per the standard of care.
224235407|NCT02984436|BEHAVIORAL|HEART Score|The HEART Score is a prospectively studied scoring system to help emergency departments risk-stratify chest pain patients. Patients score on a scale of 0-10.
224235408|NCT03614195|DEVICE|MCDTT|The MCDTT group will undertake sitting to standing, standing balance, and treadmill walking training while concurrently perform motor and cognitive tasks.
224235409|NCT03614195|DEVICE|MDTT|The MDTT group will train the same set of sitting to standing, standing balance, and walking activities as the MCDTT group while simultaneously performing only motor task.
223651021|NCT03164460|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT/IMPT
223651022|NCT03164460|RADIATION|Proton Radiation|Undergo IMRT/IMPT
223651023|NCT03164460|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
223651024|NCT05985655|DRUG|GTAEXS617|Administered as specified in the treatment arm.
223651025|NCT05985655|DRUG|SoC|Participants will receive either fulvestrant (breast cancers) or paclitaxel + bevacizumab (HGSOC) as specified in the treatment arm.
223767084|NCT04835402|DRUG|Pembrolizumab|400mg every 6 weeks
223651026|NCT00433043|DRUG|Beta blocker (carvedilol or metoprolol succinate)|Both groups get CRT. Group 1 is uptitrated to target dose beta blocker after CRT. Group 2 maintains their b-blocker dose from study entry.
224235410|NCT03614195|DEVICE|CDTT|The CDTT group will train the same set of sitting to standing, standing balance, and walking activities as the MCDTT group while simultaneously performing only cognitive task.
223651027|NCT00433043|PROCEDURE|CRT (cardiac resynchronization therapy)|Both arms
223651028|NCT06947018|BEHAVIORAL|Adolescent Girls' and Boys' Empowerment Program|"The program was developed based on a social behavioural change (SBC) approach in order to change attitudes and behaviours of the participants, consisting of the following main activities on a 6 - 8 week cycle.~* Girls' Empowerment Training: Workshops comprise six sessions of approximately 80 minutes each, held separately with girls aged 12-15 and 16-18 years in groups of approximately 12-20 adolescents on a range of life skill themes.~* Boys' Awareness Raising Training: Similar to the girls' training, four workshops are organized for boys aged 12-15 and 16-18 years, in separate sessions, with similar length and group size.~* Awareness Raising Seminars to Caregivers: Caregivers (e.g., mothers, fathers) are invited to a one-time seminar focused on the negative outcomes of child marriage and role of caregivers in preventing child marriage, lasting approximately one hour and conducted separately for fathers and mothers to eventually influence social norms in the family and communities."
223651029|NCT06946836|DRUG|AK104|Eligible patients will be randomly assigned in a 1:1 ratio to either the PD-1 combined with chemotherapy group or the AK104 monotherapy group. Treatment will be administered every 3 weeks, with patients undergoing three preoperative treatment cycles before surgery.
224320550|NCT03071276|DRUG|Cytarabine|Will be given IV over 4 hours daily on days 16 through 20. Cytarabine may be given prior to day 16 if it is determined to be in the participant's best interest based on disease progression. Chemotherapy may be delayed by 1-3 days if clinically indicated.
223651030|NCT04598074|OTHER|Opioid Package Prototype (OPP)|The Opioid Package Prototype (OPP) is a child-resistant/senior-friendly, calendar-blister packaging of limited pill counts with flat readable billboard space for medication labeling.
223651031|NCT04598074|OTHER|Usual Care (standard amber vial)|The standard amber vial (orange bottle) is the container that medication is normally dispensed in outside of the study.
223651032|NCT03843541|DRUG|N-acetylcysteine (NAC) 600 mg|NAC will be administered twice a day, morning and evening, during treatment period.
223651033|NCT03843541|DRUG|Ambroxol hydrochloride 30 mg|Ambroxol hydrochloride will be administered twice a day, morning and evening, during treatment period.
223651034|NCT03843541|OTHER|placebo|Placebo will be administered twice a day, morning and evening, during treatment period.
223651035|NCT03896269|DRUG|Liposome-encapsulated Daunorubicin-Cytarabine|Given IV
223767085|NCT04835402|DEVICE|Irreversible electroporation|Percutaneous ablation of one liver metastasis
223651037|NCT05070416|DEVICE|Lithium disilicate crowns|The study population is separated in two groups. The teeth will be etched in total etch mode with 37% phosphoric acid (Total Etch, Ivoclar Vivadent AG). After the application of Adhese Universal-adhesive (Ivoclar Vivadent AG), MultiCore Flow (Ivoclar Vivadent AG) will be applied. The crowns will be polished, then etched with IPS Ceramic Etching Gel (Ivoclar Vivadent AG) and conditioned with Monobond Plus (Ivoclar Vivadent AG). The crowns will be luted as described for group 1 or 2. A final intraoral polishing step will be done with OptraGloss (Ivoclar Vivadent AG). All required light-curing steps are conducted with Bluephase G4 (Ivoclar Vivadent AG).
223651038|NCT05208450|OTHER|Practice support And Community Engagement (PACE)|A practical and sustainable implementation strategy, referred to as Practice Facilitation And social deTerminants of health support utilizing CHWs (PATCH), to support the implementation and evaluation of three multi-level evidence-based interventions: \[nurse case management (NCM) + remote blood pressure monitoring (RBPM) + social determinants of health (SDOH) support\] delivered as an integrated community-clinic linkage model \[Practice support And Community Engagement (PACE)\]
223651039|NCT06526884|OTHER|Next Day Clinic|A dedicated Next Day Clinic team consisting of a clinician and nurse case manager will provide care and specialist referrals to patients within 24 hours of an ED visit that would have resulted in hospitalization without this novel hospital avoidance initiative.
223651040|NCT04617925|DRUG|Belantamab mafodotin|Belantamab mafodotin will be administered as a monotherapy intravenously at a 2.5 mg/kg calculated dose
223651041|NCT06649630|DRUG|NNC0442-0344 A|"SAD: NNC0442-0344 A will be administered intravenously.~MAD: NNC0442-0344 A will be administered orally.~SSD: NNC0442-0344 A will be administered subcutaneously."
223651042|NCT06649630|DRUG|Placebo|"SAD: Placebo will be administered intravenously.~MAD: Placebo will be administered orally.~SSD: Placebo will be administered subcutaneously."
223651043|NCT06345794|DRUG|LY4100511 (DC-853)|Administered orally.
223651044|NCT06345794|DRUG|Itraconazole|Administered orally.
224235411|NCT05137678|DRUG|glibenclamide|Glibenclamide was given orally or by nasal feeding
223651045|NCT06345794|DRUG|Fluconazole|Administered orally.
224235412|NCT02445664|BEHAVIORAL|Educational video|Video: Information on osteoporosis and alendronate treatment.
224235413|NCT03767088|DEVICE|WB-EMS|whole body electromyostimulation
224235414|NCT03767088|OTHER|(synchronized) Training program without WB-EMS|20 min of pronounced eccentric movement patterns
223651046|NCT06345794|DRUG|Carbamazepine|Administered orally.
223767086|NCT05883982|PROCEDURE|I-PRF injection|Intra-articular I-PRF injection to temporomandibular joint cavity
223767087|NCT02246504|DEVICE|HIFU treatment|
224235415|NCT03331042|DRUG|SM-1|3-drug combination product containing 50-mg diphenhydramine, 5-mg delayed-release zolpidem and 0.5-mg delayed-release lorazepam.
224235416|NCT03331042|DRUG|D+Z|2-drug combination comparator product containing 50-mg diphenhydramine and 5-mg delayed-release zolpidem.
224235417|NCT03331042|DRUG|D+L|2-drug combination comparator product containing 50-mg diphenhydramine and 0.5-mg delayed-release lorazepam.
224235418|NCT03331042|DRUG|Placebo|Identical in appearance to SM-1, D+Z and D+L and has the same excipients, but no diphenhydramine, zolpidem, lorazepam or delayed-release coating materials.
224235419|NCT06291948|BIOLOGICAL|Humira® (adalimumab) AC Pen [Reference Product]|A single subcutaneous dose
223651047|NCT03400371|OTHER|Blood draw|Participation includes one visit for one blood draw per recruited patient. 10-20ml peripheral venous blood will be taken from the antecubital fossa. The DNA from the blood sample will then be extracted and resequenced for analysis.
223651048|NCT03400371|OTHER|Existing samples|Control DNA samples will be used that have been previously acquired in other studies.
223651049|NCT04858035|BEHAVIORAL|Perceptual training|"Perceptual training involves self-paced presentation of auditory stimuli via a computerized software program.~Stimuli are organized into three separate tasks:~Tasks 1 and 3 will train category goodness judgment: Participants will hear 75 naturally produced speech tokens containing /r/ from various speakers, with a balance of correct and incorrect productions. They will classify each /r/ as correct or incorrect and receive feedback on the accuracy of their classification. Tasks 1 and 3 differ in that task 1 will feature a subset of items designed to provide focused practice on a specific context (e.g., initial /r/ as in red; /r/ as syllable nucleus as in sir), with increasing difficulty over time, whereas task 3 will feature randomly selected items representing all contexts and difficulty levels.~Task 2: Participants will hear 75 items drawn from the synthetic rake-wake continuum used in the identification task administered at baseline."
223651050|NCT04858035|BEHAVIORAL|Production training|"Instruction: Discuss tongue shapes for /r/. Pre-practice: relatively unstructured, highly interactive elicitation; provide models and placement cue and KP on every trial.~Structured syllable practice: Practice will occur in blocks of 10 consecutive trials on the same syllable (e.g., 10 /ra/), after which a new syllable will be addressed (e.g., 10 /re/--but note that in the fully blocked condition, the same syllable should occur in two consecutive blocks of 10)."
223651051|NCT06274788|DRUG|Omegaven® (fish oil triglycerides) Injectable Emulsion|"Pediatric patients Pediatric patients with new-onset PNAC~Drug: Omegaven® (fish oil triglycerides) Injectable Emulsion Dose, frequency and duration is a decision of the Investigator"
223651052|NCT05307692|DRUG|Seltorexant|Seltorexant 20 mg will be administered orally as a tablet.
223651053|NCT05307692|DRUG|Placebo|Matching placebo will be administered orally as a tablet.
223651054|NCT06621017|DRUG|ROSE-010 99 mcg|Sub-cutaneous injection of ROSE-010 solution
223651055|NCT06621017|DRUG|Placebo|Sub-cutaneous injection of saline solution
223767088|NCT03307148|DRUG|ATRA|Administered orally on D1-15 of each 28 day cycle.
223767089|NCT03307148|DRUG|Gemcitabine|Intravenous Infusion on D1,8 and 15 of each 28 day cycle.
223767090|NCT03307148|DRUG|Nab-paclitaxel|Intravenous Infusion on D1,8 and 15 of each 28 day cycle.
223767091|NCT04186442|DRUG|Botulinum toxin type A injection|Experimental
223767092|NCT04186442|DRUG|Botulinum Toxin Type A Injection [Botox]|Active Comparator
223767093|NCT05351203|PROCEDURE|caudal block|". Sacral horns will be palpated and sacral hiatus and epidural area will be determined at S4-S5 level through the ultrasound,. Short axis (transverse) is used first to identify the two sacral cornua as two hyperechoic reverse U-shaped structure Frog sign and the sacrococcygeal ligament in between and epidural space beneath. An 18-gauge epidural needle (length 90 mm) is used for direct puncture of sacrococcygeal membrane out of plane then the probe is rotated to long axis (longitudinal) and the needle is seen in plane in the epidural space. Injection of 30 ml 0.125% bupivacaine will expand the epidural space."
223767094|NCT05351203|PROCEDURE|Erector spinae block|● The patient will be in the prone position, after skin sterilization, ESP block will be performed at the level of L3. a curvilinear high-frequency ultrasound transducer (Siemens acuson x300 3-5 MHz ultrasound) will be placed sagittal 3 cm lateral to L3 spinous process where a hyperechoic shadow of the transverse process (TP) and erector spinae will be defined. A 22-gauge spinal needle will be inserted in cranial to caudal direction toward TP in plane to the ultrasound transducer until the needle touches the TP crossing the whole muscles. The location of the needle tip will be confirmed by visible normal saline solution separating erector spinae muscle off the bony shadow of the TP on ultrasound imaging. After confirming the needle site, 30 mL of 0.25% bupivacaine will be injected. The procedure will be repeated following the same steps on the other side.
223767095|NCT01638338|BEHAVIORAL|Web assisted brief motivational interview on risky drinking|People allocated to this arm will be given a password to enter and follow a pre-decided set of questions and hints to reduce their drinking
223767096|NCT01638338|BEHAVIORAL|Face to Face|The counseling provided by the GPs will be done at month 0, 6, 12
223767097|NCT04659070|DRUG|Experimental : Ezetimibe / Rosuvastatin + Telmisartan|Ezetimibe 10mg / Rosuvastatin 20mg + Telmisartan 80mg PO, Once daily for 8 weeks
223767098|NCT04659070|DRUG|Active comparator1 : Ezetimibe / Rosuvastatin|Ezetimibe 10mg / Rosuvastatin 20mg PO, Once daily for 8 weeks
223767099|NCT04659070|DRUG|Active comparator2 : Telmisartan|Telmisartan 80mg PO, Once daily for 8 weeks
223767100|NCT04065724|OTHER|Physical training as resistance and aerobic training.|
223767101|NCT00348205|DEVICE|Technolas 217z Zyoptix Laser|Technolas 217z Zyoptix System with Treatment Planner Customized Treatment Calculation Software for the wavefront-guided LASIK treatment of hyperopia and hyperoptic astigmatism.
223767102|NCT03509129|BEHAVIORAL|TECH (Technology)|"Participants will receive a theory-based physical activity program. They will enroll in the study as part of a self-selected group of 3-8 individuals. They will be provided with a personal step goal and Fitbit Alta HR for self-monitoring physical activity. They will also have access to a study website that will be accessible across conventional and mobile platforms. They will be asked to visit the website each week to receive behavior change information and guidance.~Device: Fitbit Alta HR"
224235420|NCT06291948|BIOLOGICAL|Adalimumab Richmond [Test Product]|A single subcutaneous dose
223651056|NCT06621017|DRUG|ROSE-010 150 mcg|Sub-cutaneous injection of ROSE-010 solution
223651057|NCT05376566|DRUG|Hydrochloric Acid (2 M)|Hydrochloric acid (2 M) in a volume corresponding to dead space (0.3-1.8 ml) will be instilled and aspirated 10 min later; the instillation is completed 3 times.
223651058|NCT05376566|DRUG|Normal saline|Normal saline in a volume corresponding to dead space (0.3-1.8 ml) will be instilled and aspirated 10 min later; the instillation is completed 3 times.
223651059|NCT05413135|DRUG|ARO-APOC3|ARO-APOC3 Injection
223651060|NCT05209074|DRUG|Ivosidenib|Ivosidenibflat dose (250mgor 500mg) daily on day 1 of a 14 day cycle.
223651061|NCT05209074|DRUG|mFOLFIRINOX|mFOLFIRINOX on days 1-3 of a 14-day cycle. Surgical resection after up to ninety (90) days of treatment.
223651062|NCT04550442|DRUG|Azacitidine|Given IV or SC
223651063|NCT04550442|DRUG|Venetoclax|Given PO
223651064|NCT03151486|DRUG|JNJ-55308942 0.5 mg|Participants will receive JNJ-55308942 0.5 mg as an oral solution after an overnight fast on Day 1.
223651065|NCT03151486|DRUG|JNJ-55308942 1.5 mg|Participants will receive JNJ-55308942 1.5 mg as an oral solution after an overnight fast on Day 1.
223651066|NCT03151486|DRUG|JNJ-55308942 4 mg|Participants will receive JNJ-55308942 4 mg as an oral solution after an overnight fast on Day 1.
223651067|NCT03151486|DRUG|JNJ-55308942 12 mg|Participants will receive JNJ-55308942 12 mg as an oral solution after an overnight fast on Day 1.
223651068|NCT03151486|DRUG|JNJ-55308942 36 mg|Participants will receive JNJ-55308942 36 mg as an oral solution after an overnight fast on Day 1.
223651069|NCT03151486|DRUG|JNJ-55308942 100 mg|Participants will receive a single oral dose of JNJ-55308942 100 mg as an oral solution after an overnight fast on Day 1.
223651070|NCT03151486|DRUG|JNJ-55308942: Fed State|Participants will receive JNJ-55308942 as an oral solution in fed state on Day 1. The dose selected for this cohort will be based on the data obtained from the single ascending dose cohorts.
223651071|NCT03151486|DRUG|JNJ-55308942: MAD Part|Participants will receive JNJ-55308942 once daily as an oral solution for 10 consecutive days (Day 1 to 10). The doses for the MAD will be determined based on the data from the SAD part.
223651072|NCT03151486|DRUG|Placebo|Participants will receive matching placebo in all cohorts.
223651073|NCT06523387|BEHAVIORAL|Pivotal Response Treatment Online (PRT-O) Course|Pivotal Response Treatment - Parent Training
223651074|NCT05129020|DEVICE|Sparrow Fledging Therapy System|tAN sessions will be administered up to four times per day for up to 20 days total. Active tAN will be set to run for 30 minutes one hour prior to each planned morphine dose. When the 30-minute tAN session is complete, the system will be turned off and unplugged.
223651075|NCT05129020|DEVICE|Sham Sparrow Fledging Therapy System|Participants randomized to the sham group will have the device earpiece applied at the same timepoints and for the same duration as the active group, but stimulation will not be turned on. tAN sessions will be administered up to four times per day for up to 20 days total. Sham tAN will be set to run for 30 minutes one hour prior to each planned morphine dose. When the 30-minute tAN session is complete, the system will be turned off and unplugged.
223651076|NCT05660954|DRUG|Cabozantinib|"* All enrolled patients will receive cabozantinib at a fixed dose of 60 mg once a day (QD). Patients will continue study treatment until PD (either clinical or radiological), or until unacceptable toxicity, the need for another systemic anticancer treatment, or other reasons for treatment discontinuation.~* Patients will take the tablet(s) once daily at bed time except for Week 1 Day 1: the first dose of study treatment will be administered in the clinic so that each patient can be observed for initial tolerability. Subsequent doses will be self-administered at home. The tablets should be swallowed whole and not crushed and administered fasting for at least 2 hours before through 1 hour after. If a patient misses a dose, the missed dose should not be taken if it is less than 12 hours before the next dose."
223651077|NCT06852768|BIOLOGICAL|d-MAPPS|Based on randomization d-MAPPS, will be self-administered, 2 drops into each eye four times a day (QID) a day for ninety (90) days.
223651078|NCT06852768|BIOLOGICAL|Placebo|Based on randomization, Placebo, will be self-administered, 2 drops into each eye four times (QID) a day for ninety (90) days.
223651079|NCT06852768|OTHER|PI and Patient Masked|Both the PI and the participant are masked on the drug administered.
223651080|NCT04693468|DRUG|Axitinib|Given PO
223651081|NCT04693468|DRUG|Crizotinib|Given PO
223651082|NCT04693468|DRUG|Palbociclib Isethionate|Given PO
223767103|NCT03509129|BEHAVIORAL|TECH+COMP (Technology + Competition)|"Participants will receive the same intervention components as the TECH group, as well as a team competition. The competition will be based on the following two aspects: total daily steps accumulated relative to group size and total number of points retained for achieving weekly physical activity challenges.~Device: Fitbit Alta HR"
224235421|NCT02329756|DRUG|Tranexamic Acid (TXA)|1g Tranexamic Acid (TXA) will be given at the time of delivery. If in 30 minutes, heavy bleeding continues, a 2nd dose will be administered.
224235422|NCT02329756|DRUG|Sodium Chloride 0.9%|"Dose 1: 1 gram - to be administered by intravenous injection at an approximate rate of 1 mL/minute to all randomized women approximately 10 minutes prior to induction of anesthesia~Dose 2: 1 gram - If 30 minutes after beginning the cesarean section there is significant bleeding as defined by the need for the transfusion of 4 or more units of blood products, or if there is a rebleed within the 24 hours after the first dose, a second dose may be given. To be administered by intravenous injection at an approximate rate of 1 mL/minute.~The trial treatment injections should not be mixed with blood for transfusion, or infusion solutions containing penicillin or mannitol."
224235423|NCT04677907|DEVICE|Persona (Zimmer) posterior stabilised uncemented Trabecular Metal™ (Tibia and Femur) prosthesis|Persona (Zimmer) posterior stabilised uncemented Trabecular Metal™ (Tibia and Femur) prosthesis vs a Persona (Zimmer) posterior stabilised cemented prosthesis
223651083|NCT04693468|DRUG|Talazoparib Tosylate|Given PO
223651084|NCT05112289|DIAGNOSTIC_TEST|Brain Neuroimaging|Non-invasive magnetic resonance imaging sequences will investigate metabolic signatures unique to migraine WMH. Imaging data will be used for development of artificial intelligence (AI) algorithms to classify the cause of WMHs.
223651085|NCT02568267|DRUG|Entrectinib|TrkA/B/C, ROS1, and ALK inhibitor
223651086|NCT04903080|BIOLOGICAL|HER2 Specific CAR T Cell|HER2 CAR (Chimeric Antigen Receptor) T cells are T cells that have been genetically engineered to target the protein HER2 for the treatment of cancer.
223767104|NCT03587610|BIOLOGICAL|Remedial vaccination|"* if the patients vaccinations are up to date: no remedial vaccination is done and the patient is informed of the next remedial vaccination date~* if the patients vaccinations are not up to date: remedial vaccination is realised in the unit in the absence of contraindication, in case of a temporary contraindication the vaccination will be performed on an outpatient basis by the patients primary care provider and he will be given a prescription at hospital discharge for the remedial vaccination."
223767105|NCT05044234|DRUG|Cedirogant|Capsule, Oral
223767106|NCT05044234|DRUG|Placebo|Capsule, Oral
223767107|NCT04173130|DEVICE|Anuscope with needles|Injection of botulinum toxin into the anal sphincter with the investigational device (anuscope with needles).
223651087|NCT05056922|BEHAVIORAL|Tele-PCIT|"Families randomized to Tele-PCIT will receive a time-limited version of PCIT via telehealth. The first 5 sessions focus on the child directed interaction (CDI) phase. The first session includes a teaching session where the parent will learn PRIDE/Do skills and Don't skills. The next 4 CDI sessions include coaching where the therapist coaches the parent on the these skills within the context of play. The first PDI session includes a teaching session where parents will be given instructions for providing commands and timeout procedures. During the 4 PDI coaching sessions, the therapist coaches the parent through timeout procedures. Handouts are emailed to families throughout therapy. The treatment period is 12 weeks to complete the 10 sessions to account for scheduling challenges. Families will be provided a Bluetooth headset for sessions. Families who do not have access to a computer, tablet, or smartphone with internet access will be provided with a tablet for therapy use."
223651088|NCT05056922|BEHAVIORAL|Treatment as Usual|Families randomized to Treatment-as-Usual (TAU) will receive brief feedback and psychoeducation during the baseline visit and will be provided with community resources and referrals as needed. The TAU procedures will reflect the level of care families receive after an ASD assessment or professional consultation in our own clinic. For addressing behavioral concerns specifically, families will be provided handouts on behavior management tips, given access to a webinar workshop reviewing basic behavioral parenting principles, and instructed to engage with available services. The Vanderbilt Treatment \& Research Institute for ASD (TRIAD) Center offers a webinar series for managing challenging behaviors that parents will be directed to along with the Autism Speaks Challenging Behavior Toolkit handouts. The TAU period will be 12 weeks in length to match time specifications for the active treatment condition.
223651089|NCT01604330|DRUG|Baclofen|Baclofen will be administered orally for a maximum of 52 consecutive weeks. For the first 3 days, patients will receive baclofen in a dose of 5 milligrams three times a day; then the dose of baclofen will be increased to a maximum of 300 milligrams a day. In case of intolerance, dosage can be decreased.
223651090|NCT01604330|DRUG|Placebo|Sugar pill will be administered orally for a maximum of 52 consecutive weeks. For the first 3 days, patients will receive sugar pill in a dose of 5 milligrams three times a day; then the dose of sugar pill will be increased to a maximum of 300 milligrams a day. In case of intolerance, dosage can be decreased.
223651091|NCT05735951|DRUG|STIRIPENTOL oral administration|"Oral administration of:~* Days 1 and 2: 1000 mg of stiripentol (single dose at the end of breakfast),~* Day 3 to Day 14: 1000 mg of stiripentol bis in die (BID) (approximately 12 hours apart, at the end of breakfast and at the end of dinner),~* Day 15: 1000 mg of stiripentol (single dose at the end of breakfast)."
223767108|NCT03766503|OTHER|Daily|The main study intervention is the daily witnessing of participants while they self-administer their medications by trained pharmacy staff to ensure compliance. The staff in question will be provided by Leila pharmacy and will in addition provide support so that individuals can transition back into living independently through reminders to attend regularly scheduled medical appointments and counseling on correct use of prescribed medications.
223767109|NCT02896127|DRUG|Secukinumab|"Induction: 4x 150 mg Secukinumab s.c. weekly~Maintenance: 150 mg Secukinumab s.c. monthly~All Subjects received blinded treatment weekly starting at baseline, Weeks 1, 2, 3 and 4, followed by dosing every four weeks starting at Week 4 until Week 16. At Week 16, Group 1 patients continued using secukinumab 150 mg and Group 2 patients started receiving secukinumab 150 mg dosing every four weeks. Treatment was provided open-label from Week 16 onward, as all patients took 150 mg s.c. every 4 weeks; however, subjects, investigators, and site staff remained blinded to initial randomized group assignment."
223767110|NCT02896127|DRUG|Placebo|Induction: 4x placebo s.c. weekly Maintenance: placebo s.c. monthly
223767111|NCT00279708|DRUG|Atorvastatin|Placebo vs. Atorvastatin
224320551|NCT03071276|DRUG|methotrexate/hydrocortisone/cytarabine|Intrathecal (IT) triples will be given prior to cycle 1: IT cytarabine, IT methotrexate, and IT methotrexate/hydrocortisone/cytarabine (MHA) are acceptable. Patients without evidence of central nervous system (CNS) leukemia will receive no further IT therapy during cycle 1. Patients with CNS disease will receive weekly ITMHA until the cerebrospinal fluid becomes free of leukemia (minimum of 4 doses).
223651092|NCT04194437|DEVICE|OCS Liver System|The OCS Liver System will be used to preserve, optimize and assess livers from DCD donors.
223651093|NCT05382299|DRUG|Sacituzumab Govitecan-hziy|Administered intravenously
223767112|NCT00279708|OTHER|Placebo Oral Tablet|Placebo: Sham Therapy in an oral tablet formulation
223767113|NCT02251665|OTHER|No intervention|a single-center prospective observational study
224235424|NCT04677907|DEVICE|Persona (Zimmer) posterior stabilised cemented Trabecular Metal™ (Tibia and Femur) prosthesis|Persona (Zimmer) posterior stabilised uncemented Trabecular Metal™ (Tibia and Femur) prosthesis vs a Persona (Zimmer) posterior stabilised cemented prosthesis
224235425|NCT01608581|OTHER|multimedia burn awareness campaign|Television commercials x4 delivered 86 times over 10 days plus logo in print media daily in two papers in two cities
224235426|NCT00825227|DRUG|Armodafinil 150 mg/day|"* 150 mg/day armodafinil~* concurrent with one cycle of taxane chemotherapy alone or in combination with other agents~* patients may then continue receiving armodafinil treatment after the double-blind treatment period by entering a 24-week open-label extension period, with continuing taxane chemotherapy alone, or in combination with other agents"
224235427|NCT00825227|DRUG|Placebo,|"* placebo~* concurrent with one cycle of taxane chemotherapy alone or in combination with other agents~* patients may then continue receiving armodafinil treatment after the double-blind treatment period by entering a 24-week open-label extension period, with continuing taxane chemotherapy alone, or in combination with other agents"
224235428|NCT04518176|PROCEDURE|bilateral uterine artery ligation|The peritoneum over the vesico-uterine pouch already being incised horizontally, the peritoneum over the uterine isthmus and cervix was dissected downwards, and this dissection was then extended laterally
224235429|NCT04518176|DRUG|Oxytocin|20 units by slow intravenous drip injection
224235430|NCT04418726|OTHER|Intensified Monitoring|Apart from clinical assessment, use non-invasive devices to check for the haemodynamic consequences of stenosis by measuring Qa, using either indicator dilution techniques or duplex ultrasound every month.
223651094|NCT05382299|DRUG|Paclitaxel|Administered intravenously
223651095|NCT05382299|DRUG|nab-Paclitaxel|Administered intravenously
223651096|NCT05382299|DRUG|Gemcitabine|Administered intravenously
223651097|NCT05382299|DRUG|Carboplatin|Administered intravenously
223651098|NCT05065008|OTHER|Cranberry juice|The responders and non-responders will drink 20-30 oz of (590-885 mL) 27% cranberry juice daily for 3 weeks.
223651099|NCT05065008|OTHER|Apple juice|The participants will drink apple juice with matching sugar content and calories for 3 weeks
223651100|NCT04816513|DRUG|Ustekinumab|Ustekinumab will be administered as SC injection.
223651101|NCT05989204|BIOLOGICAL|TmCD19-IL18|autologous Chimeric Antigen Receptor (CAR) T cells directed against the human CD19 antigen that also express human Interleukin 18 (IL-18)
223767114|NCT05041088|DIETARY_SUPPLEMENT|ProdromeNeuro Plasmalogen|The product being investigated in this study is the ProdromeNeuro Omega 3 oil nutritional supplement. This product contains naturally occurring fatty acids in higher concentrations than similar products that are commercially available. The purpose of this research study is to better understand the effects of ProdromeNeuro Omega-3 nutritional supplementation among participants with age-related cognitive decline.
223651102|NCT04920578|DRUG|JNJ-69095897|JNJ-69095897 will be administered orally in Parts 1, 2 and 3.
223651103|NCT04920578|OTHER|Placebo|Matching placebo will be administered orally in Parts 1 and 3.
223651104|NCT06019611|DEVICE|Percutaneous epidural stimulation|"Abbott percutaneous trial lead for epidural neurostimulation (Model 3086)~Abbott clinician programmer for epidural and dorsal root ganglion neurostimulation (Model 3874)~Ripple Neuromed Nomad Neurostimulation System"
223651105|NCT06677905|BEHAVIORAL|web-based spinal cord injury self-management program|"Peer health coaches will be recruited from the United Spinal Connecticut Chapter and SCI BC. They will be at least 5 years post-SCI and will be certified in brief action planning and in Mental Health First Aid.~Online coaching sessions are expected to cover a health-related topic (eg. bladder, bowel, skin, pain, healthy eating, physical activity or stress, anxiety and depression etc) and a self-management skill topic (eg.action planning, goal setting, problem-solving, mood management, navigating the health care system, communicating with health care providers). To ensure we meet the unique needs of participants, the coach and participant will determine jointly how many sessions to spend on a topic. In addition, coaches will be able to link relevant information and resources contained in the resource library to each session."
223651106|NCT06677905|BEHAVIORAL|Peer support|Existing peer support program from the United Spinal Connecticut Chapter or SCI BC
223651107|NCT03374475|DRUG|JNJ-42847922 20mg|Participants will swallow 20 mg (2\*10 mg) JNJ-42847922 capsule orally for 5 weeks during treatment period.
223651108|NCT03374475|DRUG|JNJ-42847922 40mg|Participants will swallow 40 mg (2\*20 mg) JNJ-42847922 capsule orally for 5 weeks during treatment period.
223651109|NCT03374475|DRUG|Placebo|All participants will receive matching placebo capsule during lead in period, treatment period and withdrawal period.
223651110|NCT05991154|BEHAVIORAL|Usual Practice + JoyPop|Participants will be asked to use the app at least twice daily but will otherwise not be provided with requirements related to feature or total usage.
223651111|NCT05938322|OTHER|Ketogenic Diet|"In the group of intervention is prescribed a ketogenic diet plan characterized by the following composition: carbohydrates \< 30g/day, 1.2g-1.5g protein/kg/day and lipids \> 65%.~This diet will be followed during the period of treatment with chemo-radiotherapy (5 weeks)"
224235431|NCT00322491|DRUG|G-CSF Plus Plerixafor|Participants underwent mobilization with G-CSF 10 µg/kg/day for 4 days, administered by subcutaneous injection (SC) injection each morning. On the evening of Day 4, participants received a dose of plerixafor 240 µg/kg, administered by SC injection. On Day 5, participants returned to the clinic and received a morning dose of G-CSF 10 µg/kg and underwent apheresis approximately 10 to 11 hours after the dose of plerixafor (within 60 minutes after administration of G-CSF). Participants continued to receive an evening dose of plerixafor followed the next day by a morning dose of G-CSF and apheresis for up to a maximum of 5 aphereses or until ≥ 5\*10\^6 CD34+ cells/kg were collected.
224235432|NCT00376948|DIETARY_SUPPLEMENT|genistein|
224235433|NCT00376948|DRUG|erlotinib hydrochloride|
224235434|NCT00376948|DRUG|gemcitabine hydrochloride|
223651112|NCT05938322|OTHER|Standard Diet|The control group (SD) will follow the Mediterranean diet pattern based on ESPEN guidelines (carbohydrates 45-55%, protein 15-20% and lipids 30-35%).
223651113|NCT02978612|DRUG|Capecitabine|Capecitabine is a prodrug to 5-fluorouracil. It is used for adjuvant chemotherapy after surgery for colon cancer. The tablets are either 150 mg or 500 mg
223651114|NCT05344313|DIETARY_SUPPLEMENT|Ensure Plus Advance|as in the arm description of the intervention
223651115|NCT04817163|BEHAVIORAL|Web-based cognitive-behavioral therapy for insomnia (CBT-I)|Each week, the patients first have to read written information on the website (www.insomnet.ca), and then watch a video capsule (duration between 5 and 20 min each). Patients complete their daily sleep diary electronically on the website and the content is interactive. It includes the sending of automated emails to remind participants to complete the treatment tasks and encourage adherence, provision of tailored feedback (e.g., texts, charts) based on the information that they provide in their sleep diary, as well as quizzes with automated correction to reinforce patients' understanding of the content.
224235435|NCT05003648|DRUG|Pramipexole|Participants will be started on 0.125 mg pramipexole for the first week. If this dose is well tolerated but not effective, the dose can be increased to 0.25 mg for the following week. If this dose is well tolerated but not effective, the dose can be further increased to 0.5 mg for the remainder of the 2-month period.
224235436|NCT05003648|DRUG|Placebo|Matching placebo
224235437|NCT00846625|DRUG|triamcinolone|Intravitreal injection (4 mg/0.1 ml)
224235438|NCT00846625|DRUG|ranibizumab|Intravitreal injection, 0.5 mg
223651116|NCT04817163|BEHAVIORAL|Professionally-administered booster face-to-face CBT-I sessions|"Patients who obtain an ISI score of 8 and more after completing the web-based CBT-I are stepped up and offered to receive up to three 50-min booster sessions of CBT-I offered individually by a psychologist (if needed). Remitted patients (good sleepers; ISI score lower than 8) will receive no further treatment."
223651117|NCT02003924|DRUG|Enzalutamide|160 mg by mouth once daily
223651118|NCT02003924|DRUG|Placebo|Sugar pill to mimic enzalutamide
223651119|NCT05684172|DRUG|Tenecteplase|If patients are randomized and assigned to receive intra-arterial tenecteplase thrombolysis, tenecteplase will be injected according to protocol, proceeding to inject TNK through a distal access catheter or microcatheter located proximal to the residual thrombus (if still present) and distally to the origin of the pontine arteries.
223651120|NCT05684172|OTHER|endovascular thrombectomy alone|Patients will receive randomization if the eTICI score on cerebral angiography is 2b-3 and will stop the procedure if they have been assigned to the control group.
223651121|NCT02212535|DRUG|Plerixafor|0.24 mg / kg / day, by subcutaneous injection, 11h before the beginning of cytapheresis
223651122|NCT05764642|DRUG|Definity|Ultrasound contrast agent administered intravenously
223651123|NCT05764642|DIAGNOSTIC_TEST|Super-resolution ultrasound imaging|Imaging technology for microvessel imaging. This technology localizes and tracks individual microbubbles (FDA approved ultrasound contrast agents) to map microvessel morphology and flow speed at a spatial resolution about 10 times higher than conventional ultrasound imaging.
224235439|NCT05425667|OTHER|virtual reality walking training|The sensory integration training of this project will combine virtual reality technology and balance interference treadmill, and manipulate vision, vestibular sense and proprioceptive systems as the main training goals. It is expected to train twice a week for 1 hour, for a total of 6 weeks of training , in order to improve the balance and walking ability of patients with lumbar stenosis and neurological claudication, and to promote the ability of subjects to transfer the effect to daily life after training.
224235440|NCT00929539|DRUG|JTT-130|Tablets
224235441|NCT00929539|DRUG|JTT-130 Placebo|Tablets
224235442|NCT06364722|OTHER|Acupuncture treatment|We selected acupoints including Zhongwan (CV12) and bilateral Shangjuxu (ST37), Sanyinjiao (SP6), Gongsun (SP4), Taichong (LR3), Taixi (KI3), Hegu (LI4), and Quchi (LI11)17 according to the World Health Organization standard. Single-use 0.30×40 mm or 0.30×25 mm acupuncture needles (Hwato, Suzhou, China) 27,28 were vertically inserted into each acupoint to 20-30 mm depth to obtain a deqi sensation (a soreness, distention, numbness or heaviness sensation). Bilateral Zusanli (ST36) and Tianshu (ST25) were selected for moxibustion. Pure moxa sticks (diameter: 2.8 cm; Hanyi, Nanyang, China) were ignited and fixed on a moxibustion stand at a distance of 3-5 cm to the surface of acupoints. The temperature of skin surface at the acupoints was maintained at 43 ± 1°C and monitored with a miniature infrared thermometer (Fluke 62, Fluke Corporation, Everett, WA, USA). Acupuncture and moxibustion were concomitantly performed for 30 min.
224235443|NCT06364722|OTHER|Sham acupuncture|Sham acupuncture needles (0.35×40 mm) with flat tips (Hwato, Suzhou, China) were inserted towards the same acupoints to induce slight pain but without penetrating the skin. Sham moxibustion was made by igniting the same type of moxa sticks but fixing them at a distance of 8-10 cm from the skin of acupoints to maintain the temperature at 37 ± 1°C. Sham acupuncture and moxibustion were concomitantly performed for 30 min.
224235444|NCT04913896|DRUG|PD-1 inhibitor|SOX regimen for 3 cycles and/or PD-1 inhibitor before surgery
224235445|NCT03228095|DIAGNOSTIC_TEST|VOC detection in breath and in skin headspace|VOC will be detected in breath with off-line and on-line testing and in skin headspace with off-line testing
224235446|NCT03228095|DIAGNOSTIC_TEST|Breath sampling|Breath sampling for VOCs detections will be carried out using nano-sensor based devices (electronic nose)
224235447|NCT03228095|PROCEDURE|Upper endoscopy with biopsies|Upper endoscopy with proper biopsy work-up will be used for identification and stratification of gastric lesions as well as acquisition of biopsies for microbiota testing
224235448|NCT03228095|PROCEDURE|Colonoscopy with biopsies|Colonoscopy with proper biopsy or polypectomy material work-up will be used for identification and stratification of colorectal lesions as well as acquisition of biopsies for microbiota testing
224235449|NCT03228095|PROCEDURE|Whole blood/ Plasma / serum sampling|Whole blood/Plasma/serum sampling will be used to obtain information for group stratification
223651124|NCT01711554|BIOLOGICAL|Dinutuximab|Given IV
223651125|NCT01711554|DRUG|Isotretinoin|Given PO
224235450|NCT03228095|DIAGNOSTIC_TEST|Faecal sampling|Facal samples will be obtained for faecal occult blood testing as well as microbiota analysis
224235451|NCT03228095|PROCEDURE|Histological examination of surgical specimen|Routine histological exam for patients undergoing curative or palliative surgery. Indication for surgery are set based on underlying condition. Study does not interfere with decision making for surgical treatment
224235452|NCT03228095|DIAGNOSTIC_TEST|Headspace analysis for biological material|VOC analysis from headspace of surgical specimen, biopsy materials, blood/plasma, microbiota etc.
223651126|NCT01711554|OTHER|Laboratory Biomarker Analysis|Correlative studies
223651127|NCT01711554|DRUG|Lenalidomide|Given PO
223651128|NCT01711554|OTHER|Pharmacological Study|Correlative studies
223651129|NCT05227937|DRUG|Amikacin|patient will be treated with amikacin 15 mg/kg IV or IM, based on actual body weight; for patients \>120% of IBW, we will use AdjBW (IBW + 0.4(ABW-IBW)) rounded to nearest 50 mg. Patients who already have an IV will receive the medication IV, otherwise the dose will be given IM.
223651130|NCT04232228|OTHER|No intervention|No intervention was used in this study.
223651131|NCT06371755|DEVICE|Ultrasound examination with REMS technology|The proposed study is defined as interventional because it introduces an ultrasound examination in the standard clinical routine. The diagnostic approach does not vary during the study and the prescription of any therapeutic treatment is performed on the basis of the conventional DXA diagnosis. This ultrasound examination does not involve additional risks for the patient with the benefit of not using ionizing radiation; it lasts only few minutes and can be performed without moving the patient from the same bed on which he is already positioned for DXA examination.
223651132|NCT02405702|OTHER|restrospective study|
223651133|NCT05696717|DRUG|Ampreloxetine|Oral tablet, QD
224235453|NCT01052090|DRUG|PHN121|a size 0 hard gel capsule containing 323.6 mg active ingredient, a complex mixture prepared from 5 commonly practiced botanical traditional Chinese medicines
224235454|NCT05334849|DEVICE|Circulating exosomal lncRNA-GC1 detection|"Collect peripheral blood sample of 80 gastric cancer patients pre-treatment. Blood samples will be transferred to central lab to detect circulating exosomal lncRNA-GC1. Tumor response evaluation will be performed after two cycles of immunotherapy by CT/MRI based on RECIST.~Clinical data, including tumor stage, metastastic organ, regimen, objective response, progression free survival, overall survival, etc, will be collected according to study protocol."
224235455|NCT02276313|DEVICE|Passeo-18 Lux|Endovascular Therapy
224235456|NCT00605449|DRUG|GSK376501|
224235457|NCT00001849|DRUG|Pentetreotide|Binds primarily to the somatostatin receptors subtypes (sst) 2 and 5. A high dose (18mCi) was used if the conventional dose (6mCi) was negative and scheduling was available. High doses limited to 3 over the course of the study.
224235458|NCT00001849|DRUG|18F-DOPA|18F-DOPA is a radiolabeled amino acid used as a radiotracer in positron emission tomography (PET). Limited to 3 doses over the course of the study.
224235459|NCT00001849|DEVICE|CT scan|CT scan of chest, abdomen, neck and /or pelvis
224235460|NCT00001849|DEVICE|MRI|MRI scan of head/pituitary, chest, abdomen, neck and /or pelvis
224235461|NCT00001849|DRUG|18-FDG|FDG PET scan of body
224320554|NCT07133477|DIETARY_SUPPLEMENT|Omega 3-9-11|Fish oil capsules containing a fish oil concentrate from North Atlantic fish species containing EPA / DHA / cetoleic acid and gondoic in controlled amounts.
223651134|NCT05696717|DRUG|Placebo|Oral tablet, QD
223651135|NCT03870672|DEVICE|Contralaterally Controlled Functional Electrical Stimulation|Contralaterally Controlled Functional Electrical Stimulation (CCFES) uses electrical stimulation to open the weak hand. Sticky patches called electrodes are placed on the participant's affected arm to stimulate the hand muscles, and a special glove is worn on the participant's strong hand and controls the stimulator. When the participant opens the gloved hand, stimulation opens the weak hand; when they close the gloved hand, stimulation turns off and the weak hand relaxes. During the clinic visits, participants will use CCFES to assist hand opening during functional training. During participant home sessions, they will use CCFES to perform hand opening exercise.
223651136|NCT03870672|DEVICE|New rTMS approach|Participants in this arm will receive rTMS-based facilitation of the contralesional dorsal premotor cortex (cPMd) located in the non-stroke hemisphere before start of each session. High-frequency rTMS (5-Hz) will be delivered using 42 10-sec trains of 50 pulses each (total 2100 pulses) for a period of 24 minutes. Immediately after the completion of rTMS, participants will undergo upper limb training + CCFES for a total of one hour. Participants will receive these interventions 2 days a week for 12 weeks.
224235462|NCT02512666|DEVICE|AM4113-N5UT Dino-Lite|
224235463|NCT00005938|DRUG|exatecan mesylate|
224235464|NCT05524103|DRUG|ALMB-0166|A single dose of ALMB-0166 injection.
224320555|NCT07133477|DIETARY_SUPPLEMENT|Placebo|Corn oil capsules
224320556|NCT03591497|OTHER|Virtual Reality|As described in Experimental arm description.
224235465|NCT04494659|DRUG|Famitinib capsule|single dose and co-administrated with Rifampicin capsule
224235466|NCT04494659|DRUG|Rifampicin capsule|repeated doses of Rifampicin capsule
224235467|NCT00524459|DRUG|docetaxel|
224235468|NCT00524459|DRUG|pegylated liposomal doxorubicin hydrochloride|
224235469|NCT00524459|PROCEDURE|conventional surgery|
224235470|NCT00524459|PROCEDURE|neoadjuvant therapy|
224235471|NCT04371250|OTHER|Survey and Questionnaire|Resilience and Loneliness questionnaires
224235472|NCT04173013|BIOLOGICAL|Uromune|2 sprays of solution once daily for a total of 3 months.
224235473|NCT02295397|OTHER|food|food provocation, skin testing, blood sampling
224235474|NCT05898568|DEVICE|virtual reality|In addition to the routine hand rehabilitation programs for 4 weeks, 5 days, 40 minutes a day, 20 sessions (4 weeks, 5 days a week, 20 minutes) virtual reality based movement therapy program will be applied.
224235475|NCT05898568|BEHAVIORAL|routine treatment|20 sessions (4 weeks, 5 days a week, 60 minutes) routine hand rehabilitation program will be applied.
224235476|NCT00539877|DRUG|irinotecan|"Postoperative day 1, IP CPT-11 chemotherapy will be given by CAPD catheter. CPT-11 in 1L of normal saline, prewarmed to 37°C will be given intraperitoneally.~If there is no DLT and patients agree with the treatment, patients can receive 3 more times of IP chemotherapy with same dose of CPT-11 at 3 weeks interval. After total 4 cycles of IP chemotherapy, peritoneal disease will be reassessed with abdominal-pelvis CT. Pharmacokinetic study is not planned with this treatment."
224235477|NCT00530010|RADIATION|yttrium Y 90 glass microspheres|The target dose of TheraSphere® is 80-150 Gy (8,000-15,000 rad). Patients may receive a single dose to the whole liver, or lobar treatment delivered as a sequence of treatments approximately 30 -90 days apart.
224235478|NCT03689790|PROCEDURE|sleeve gastrectomy|sleeve gastrectomy
224235479|NCT03689790|PROCEDURE|gastric bypass|gastric bypass
224235480|NCT05019066|DIETARY_SUPPLEMENT|Herbal Supplementation|A proprietary blend of: Eclipta alba, Emblica officinalis, Centella asiatica and Hibiscus sabdariffa.
224235481|NCT03325530|BEHAVIORAL|Focus Group with Participants|Focus groups with leaders (18+) to investigate tolerance to healthy initiatives
224235482|NCT05318651|DEVICE|Kwit SAS - smoking cessation app|Kwit is a mobile app for smoking cessation. Different CBT techniques are used by the app already been proved as effective : Case analysis craving tool, Achievements badges,Diary, Goal (outcome) setting, A 9-steps preparation program, psychological education, Emotional monitoring, Access to groups on social networks, different strategies ( NRT/water/meditation), Motivational cards.
224235483|NCT05223582|DRUG|Abiraterone acetate|Patients would be treated with 1000mg abiraterone qd.
224320557|NCT06692686|DEVICE|Pre-fabricated (PF) ankle-foot orthosis (AFO)|These pre-manufactured orthoses are customized to fit each patient. These devices can help to distribute weight evenly along the foot, but do not offer much opportunity for adjustment to a patient's specific needs. These AFOs achieve ankle motion through material deflection and lack a single point of articulation.
224320558|NCT06692686|DEVICE|Carbon-strut (CS) ankle-foot orthosis (AFO)|These AFO designs are built from a custom mold of the patient's affected limb for a more individualized fit. It includes a solid ankle design and achieves ankle motion through material deflection and lacks a single point of articulation.
224320559|NCT06692686|DEVICE|Multifunctional articulating (MA) ankle-foot orthosis (AFO)|These AFO designs are also built from a custom mold of the patient's affected limb, but these orthoses have a true articulation at the ankle to provide controlled ankle movement in a range determined appropriate by the orthotist through gait analysis.
224320560|NCT05186675|PROCEDURE|superselective adrenal arterial embolization|Superselective adrenal arterial embolization is an operation to inject embolic agent into adrenal artery through catheter to embolize part of adrenal gland, so as to reduce the secretion of adrenal hormone and reduce blood pressure
224320561|NCT06689748|OTHER|Delphi procedure|The study involves generating consensus statements by experts on the training requirements for physicians involved with airway management in critically ill patients using a Delphi process.
224320562|NCT01770717|OTHER|Spatial Frequency Domain Imaging|Assessment of Pressure Ulcer Formation using Spatial Frequency Domain Imaging
224320563|NCT03677154|DRUG|Mosunetuzumab Intravenous (IV)|Participants in cohorts A and B will receive IV mosunetuzumab.
224320564|NCT03677154|DRUG|Mosunetuzumab Subcutaneous (SC)|Participants in Cohort C will receive SC mosunetuzumab.
224320565|NCT03677154|DRUG|Polatuzumab Vedotin|Participants in Cohort C will receive IV polatuzumab vedotin.
224320566|NCT03677154|DRUG|Tocilizumab|Participants will receive tocilizumab via IV as needed to manage severe cytokine release syndrome (CRS).
224320567|NCT07033598|DRUG|Pacritinib|100-mg capsules
224320568|NCT07033598|DRUG|Hydroxyurea|capsules or tablets
224320569|NCT03390426|DRUG|Mepivacaine|An ultrasound guided injection of mepivacaine superomedially to the femoral artery.
224320570|NCT03390426|PROCEDURE|Perifemoral Injection of Local Anesthetic|An ultrasound guided injection of mepivacaine superomedially to the formal artery in an effort to numb the nerves that contribute to tourniquet hypertension intraoperatively.
224320571|NCT03390426|DRUG|Saline|An ultrasound guided injection using a medication that does NOT numb any nerves called saline, or salt water.
224320572|NCT02593682|DRUG|suvorexant|
224320573|NCT02593682|DRUG|placebo|
224320574|NCT01568138|DEVICE|PliCath HF System|To evaluate the safety and feasibility of the BioVentrix PliCath HF Epicardial Catheter-based Ventricular Reduction (ECVR) System for left ventricular (LV) volume reduction in heart failure (HF). The System utilizes anchors that are implanted into the scarred portion of the heart, rendering the ventricle smaller.
224320575|NCT01682616|DRUG|ABT-199|ABT-199 is taken continuously once daily. This is a dose escalation study, therefore the dose of ABT-199 will change throughout the study.
224320576|NCT01682616|DRUG|Rituximab|Rituximab will be given by intravenous infusion on day 1 of Months 1, 2, 3, 4, 5, and 6. May be reinitiated for an additional 6 months.
224235484|NCT05223582|DRUG|Fluzoparib|Patients would be treated with 150mg fluzoparib bid.
224235485|NCT05223582|DRUG|Prednisone|Patients would be treated with 5mg prednisone bid.
224235486|NCT05223582|DRUG|Androgen deprivation therapy|Patients would get medical castration.
224235487|NCT05223582|PROCEDURE|Radical Prostatectomy|Patients would get radical prostatectomy after the neoadjuvant treatment.
224235488|NCT04663360|OTHER|Adverse Drug Reaction (ADRe) Profile|ADRe asks nurses to systematically check patients for the manifestation of itemised adverse side effects or undesirable effects of their primary care medicines, as listed in the BNF and manufacturers' Summaries of Product Characteristics (SmPCs), and seminal texts documenting known ADRs. Nurses are asked to share the identified problems with prescribers and pharmacists overseeing medicines charts.
224235489|NCT00004825|DRUG|recombinant human insulin-like growth factor I|
224235490|NCT05266248|OTHER|250 mg encapsulated caffeine|Zero calorie 500 ml (16.9 oz) flavored, carbonated energy beverage
224235491|NCT01574248|DRUG|icatibant|Subcutaneous at time 0 and 6 hours
224235492|NCT01574248|OTHER|Placebo|Subcutaneous at time 0 and 6 hours
224235493|NCT01424722|DEVICE|Fortify® ST, Fortify Assura® ST, Ellipse® ST family of devices|Algorithm for detecting ST changes that may be indicative of an acute coronary syndrome.
224320577|NCT05736627|OTHER|Online|Online research course delivered live digitally at a distance.
224235494|NCT00493272|DRUG|Fibrinogen|Fibrinogen behandling
224320578|NCT01325181|DRUG|Verteporfin|a 6mg/m2 infusion of verteporfin(Visudyne; Novartis)over 10 minutes followed by laser delivery
224320579|NCT01325181|DRUG|ranibizumab|Consecutive intravitreal injection of ranibizumab(Lucentis®, Novartis) 0.5mg/0.05ml for the first 3 months
224320580|NCT05808075|OTHER|NovaProTM Fill Universal Dental Composite|NovaProTM Fill Universal ,Nanova product
224320581|NCT02836938|OTHER|Collection of exhaled breath volatile organic compounds|
224320582|NCT03692390|DEVICE|Virtual Reality|Participants wear a Virtual Reality headset that consists of a ASUS phone and a VOX+ Z3 3D Virtual Reality Headset. The phone runs the VR Roller Coaster app to produce the virtual environment.
224320583|NCT02874209|OTHER|sodium MRI|
224320584|NCT00548093|DRUG|PF-00299804|PF-00299804 orally at 45 mg daily, on continuous schedule
224320585|NCT00548093|DRUG|PF-00299804|PF-00299804 orally at 45 mg daily, on continuous schedule
224320586|NCT03673527|DRUG|topical formulation of tacrolimus|Topical application of tacrolimus twice daily for 14 days (one dose on Day 14).
224320587|NCT02335736|DRUG|Gonadotropins releasing hormone antagonist|
224320588|NCT01781000|BEHAVIORAL|Brain Fitness & Brain Training- Posit Science|Computer aided cognitive program designed for intensive training of auditory perception, memory and attention
224320589|NCT01781000|BEHAVIORAL|Facial Affect Training- FAT|Computer-aided cognitive program designed for intensive training of facial affect discrimination, memory and attention
224320590|NCT01781000|BEHAVIORAL|Treatment as usual|standard treatment protocol of schizophrenia ward
224320591|NCT03540771|OTHER|Palliative Care|"The intervention will comprise an approach to render palliative care, as taught to hepatologists through an on-line learning platform, and as delivered by PC providers as routine care. The elements of the intervention, which will be guided by a checklist and implemented over the course of interactions with the patient and caregivers at the initial, 1, 2, and 3 month visits, to include:~1. Patient/caregiver understanding of diagnosis, illness and prognosis~2. Symptom assessment and management~3. Psychosocial assessment and management~4. Distress screening and management~5. Discussion of goals of care~6. Advanced directives"
223651137|NCT03870672|DEVICE|Conventional rTMS approach|Facilitation of M1 will be achieved using 5Hz rTMS. High-frequency rTMS (5-Hz) will be delivered using 42 10-sec trains of 50 pulses each (total 2100 pulses) for a period of 24 minutes. Immediately after the completion of rTMS, participants will undergo upper limb training + CCFES for a total of one hour. Participants will receive these interventions 2 days a week for 12 weeks.
224235495|NCT06200701|BEHAVIORAL|Job Crafting program|The training program designed for this study was implemented through twelve sessions, from which three theory and nine practical sessions were held in a room at the worksite. The sessions were conducted outside of working hours in the hospital These sessions lasted 21 hours; 3 theory hours (one hour for each theoretical session); and 9 practical sessions (two hours for each practical session). Having the whole number of nurses at the same time was difficult, so the nurses were classified into five groups each group consisting of about 16 nurses. All sessions were repeated to the five main groups until 80 nurses completed the entire 21-hours instruction period
224235496|NCT05885139|DEVICE|Exopulse Mollii Suit|Exopulse Mollii suits consists of a body Garments (Jacket and Pants) and a control unit. The body Garments (Jacket and Pants) is a suit with 58 embedded electrodes that can stimulate 40 groups of muscles, conductive wires and connectors to a detachable control unit, whose intended purpose is to transmit electric pulses from the control unit to key nerves and corresponding muscle groups throughout the body. The control unit is a battery powered electrical device which sends low intensity electric pulses through connectors to the Body Garments which in turn transmits the pulses from the connectors to key nerves and corresponding muscle groups throughout the body.
224235497|NCT05885139|DEVICE|Sham Exopulse Mollii Suit|In the sham condition, the control unit will be programmed to start stimulating for 1 minute then it will shut off.
224235498|NCT01781286|BEHAVIORAL|High Protein|250 kcal; 40% Protein; 40% Carbohydrate; 20% Fat
224235499|NCT01781286|BEHAVIORAL|Low Protein|5% Protein; 50% Carbohydrates; 45% Fat
224235500|NCT03594123|DRUG|Brexpiprazole|2 or 3 mg tablet
224235501|NCT03594123|DRUG|Brexpiprazole|0.5 to 3 mg tablet
224235502|NCT04123210|DIETARY_SUPPLEMENT|Vitamin A supplement|
224235503|NCT04123210|DIETARY_SUPPLEMENT|Placebo|
224320592|NCT01584453|DRUG|Sodium Nitrite|A bolus of sodium nitrite solution (1.8 micromol in 10 ml PRe-diluted in 0.9% sodium chloride in a syringe) will be delivered over 30-60 seconds via intracoronary injection initiated during the re-establishment of antegrade epicardial flow with PPCI.
224320593|NCT01584453|DRUG|Sodium Chloride Placebo|The control intervention is a bolus of 0.9% sodium chloride solution (prepared with an identical appearance to the sodium nitrite).
223651138|NCT03870672|DEVICE|Sham rTMS approach|In the sham rTMS group, ipsilesional motor hotspot will be targeted in half the patients and cHMC location will be targeted in the other half (based on random assignment). Immediately after the completion of rTMS, participants will undergo upper limb training + CCFES for a total of one hour. Participants will receive these interventions 2 days a week for 12 weeks.
223651139|NCT04595474|DEVICE|Transient Elastography|Transient elastography is a noninvasive imaging modality used to assess NAFLD and advanced fibrosis
223651140|NCT02498691|BIOLOGICAL|Biological collection|Blood and saliva samples, placenta and cord blood collection
224320594|NCT02516553|DRUG|BI 894999|film-coated tablets
224320595|NCT00313339|DRUG|Intra-coronary infusion|In our study there will be four dosing cohorts (5, 10, 20 and 30 x 106) of CD34+ cells.
224320596|NCT02516527|DRUG|Ipilimumab|
224320597|NCT02716727|DEVICE|Aquasil Ultra Cordless, Dentsply|Cordless gingival displacement procedure
223651141|NCT06015022|DRUG|Epigallocatechin gallate (EGCG)|EGCG is a green tea-derived catechin
224235504|NCT00864864|DRUG|Sunitinib|Taken orally on days 1-7 prior to surgery and then starting again on Day 22 for 4 weeks followed by a 2 week rest period
224235505|NCT05681208|BEHAVIORAL|Motivational interview|"Information will be given about the motivational interviews to be held and the objectives and content of the motivational interviews will be explained clearly. Care will be taken to ensure that the content of the brochures and materials provided is not too dense. It was prepared according to the Health Behavior Interaction Model of motivational interview steps. The first meeting of the motivational interview will start in the 4th month and the meetings will continue to be held every week for the first month and a half, and every two weeks for the next month and a half.~Negotiations will end in nine weeks. After the last interview, the scales will be applied to the mother again. Motivational interviews are planned to last 60-90 minutes (first session 45-50 minutes) every week."
224320598|NCT02716727|DEVICE|Ultrapak, Ultradent cord|Cordless gingival displacement procedure
224320599|NCT03986827|BEHAVIORAL|Cool Kids Anxiety Program - Social Enhanced|Specific G-CBT intervention for adolescents with social anxiety disorder
223651142|NCT06015022|OTHER|Placebo|Placebo in the same capsule with the experimental agent (EGCG).
223651143|NCT05186805|DRUG|Tapinarof cream, 1%|Tapinarof cream, 1% applied topically once daily
223651144|NCT04693767|DEVICE|Mechanical thrombectomy|"1. Clot specimen collection~2. Extracranial blood collection"
223651145|NCT04693767|OTHER|Minimally invasive surgery|"1. Clot specimen collection~2. Arterial blood collection"
223651146|NCT00065572|DRUG|ZD6126|
223651147|NCT00065572|DRUG|Placebo|
223651148|NCT03071419|BEHAVIORAL|Nutrition and Parenting Intervention|The proposed intervention will evaluate and explore the unique influences that low-income fathers have on their preschool age children's obesogenic behaviors and obesity risk.
223651149|NCT05023486|DRUG|NP-G2-044 Monotherapy|1600 mg QD, 2000mg QD, and 2100 mg QD
223651150|NCT05023486|DRUG|Anti-PD-1 Therapy|previously initiated per standard of care, at a dose and frequency in accordance with the package insert
223651151|NCT05023486|DRUG|NP-G2-044 Combination therapy|1600 mg QD or 2100 mg QD
223651152|NCT04033497|DEVICE|MRI|Magnetic Resonance Imaging will generate imaging of the brain to identify recurrence of tumor.
224235506|NCT01029938|PROCEDURE|Covered stent|Consecutive patients with CICA aneurysms were endovasculartreated with a Willis covered stent (group A) or coil embolization (group B)
224235507|NCT01029938|PROCEDURE|Coil|Consecutive patients with CICA aneurysms were endovasculartreated with a Willis covered stent (group A) or coil embolization (group B)
224320600|NCT03986827|BEHAVIORAL|Cool Kids Anxiety Program|Generic G-CBT intervention for adolescents with anxiety disorders
224320601|NCT03830827|DRUG|Vortioxetine|8-week 10-20mg/day vortioxetine; 2-hour MBRP intervention per week in 8 weeks
224320602|NCT02924727|DRUG|LCZ696 (sacubitril/valsartan)|LCZ696 (sacubitril/valsartan) tablet will be available in 24/26 mg, 49/51 mg and 97/103 mg, respectively
224320603|NCT02924727|DRUG|Ramipril|Ramipril 1.25 mg, 2.5 mg, and 5 mg oral capsules
224320604|NCT02924727|DRUG|Placebo of LCZ696|Matching placebo of LCZ696 tablets
224320605|NCT02924727|DRUG|Placebo of ramipril|Matching placebo of ramipril capsule
224320606|NCT02924727|DRUG|Valsartan|Valsartan (VAL489) 40 mg and 80 mg tablets, two doses for 1 day to patients who were previously treated with ACE inhibitors receiving the last dose of that agent during the last 36 hours prior to randomization
224320607|NCT02924727|DRUG|Placebo of valsartan|matching placebo of valsartan for one day to patients who will be randomized to received ramipril
223651153|NCT05754281|DEVICE|2nd Gen LabPatch Glucose Sensing System|"I. The 2nd Gen LabPatch chip which lies in the center of a clasp unit. The chip measures approximately 15.7 mm \[0.618\] x 15.7 mm \[0.618\]. The chip has a telescopic micropipette which draws interstitial fluid to be analyzed for glucose levels. The chip is also able to measure skin temperature to ensure appropriate skin contact~II. A LabPatch clasp device~III. A wire that connects the clasp unit to a Windows tablet which will communicate with the clasp via an application. Each data point will be viewed on the tablet and the application will also have some limited graphing capabilities to view trends of previous measurements"
223651154|NCT03023345|DEVICE|Microwave trans rectal focal treatment|Microwave trans-rectal ablation of the prostatic index tumor using MRI-transrectal ultrasound image registration
223651155|NCT07120295|DEVICE|Dragonfly™ Digital Pancreaticobiliary System|Dragonfly™ Digital Pancreaticobiliary System is indicated for use in the direct visualization of the biliary and pancreatic ducts for diagnostic and therapeutic interventions during endoscopic procedures. DPS is a single-use device that serves as an access and delivery catheter used with a proprietary DDC. The DDC is intended to control auto-illumination, and process images from the DPS for diagnostic and therapeutic applications during endoscopic procedures in the pancreaticobiliary system including the hepatic ducts.
224235508|NCT00508170|BEHAVIORAL|Questionnaire|The questionnaire contains 23 questions and is estimated to take approximately 10 minutes to complete.
224235509|NCT05554770|DIAGNOSTIC_TEST|Examinations in a TRV chair|Positional tests (Dix-Hallpike and SRT) traditionally used to diagnose BPPV uwith a TRV chair.
223651156|NCT05014256|BEHAVIORAL|STEPS Health System Outreach intervention|STEPS Transplant Social Worker Education and Outreach, STEPS Transplant Coordinator Outreach
224235510|NCT02716870|OTHER|Fructose-containing Sugars|An intervention in which calories from fructose-containing sugars are substituted, added, or subtracted in the diet
224235511|NCT02381171|DEVICE|Active rTMS|Repetitive Transcranial Magnetic Stimulation (rTMS) 10Hz (1600 pulses)
224235512|NCT02381171|DEVICE|Sham rTMS|Repetitive Transcranial Magnetic Stimulation (rTMS) with Placebo coil
224235513|NCT02381171|DEVICE|Active Neuroacupuncture|Neurofunctional electrical acupuncture 1Hz, continuous, 10mA current for 20 minutes.
224235514|NCT02381171|DEVICE|Sham Neuroacupuncture|Neurofunctional electrical acupuncture without needles
224235515|NCT02230007|DRUG|MEOPA|3 sessions of reeducation using MEOPA
224235516|NCT05641909|DRUG|Remifentanil|Remifentanil
224235517|NCT05641909|DRUG|Fentanyl|Dosage forms and strengths: 50 mcg/mL Fentanyl base/10 mL ampules. Manufacturer: Yichang Humanwell Pharmaceutical Co.,Ltd
224320608|NCT00682682|OTHER|Virtual Reality video distraction|"Virtual Reality involves wearing a helmet and playing a game called Snow world. This game has sound and is presented in 3D format. This game has immersive qualities that help user feel as if they are in the game."
224320609|NCT00682682|OTHER|Virtual Reality video game|"Virtual Reality video games involve wearing a helmet with vision and sound. this game is presented in 3D which gives the user the feeling of being in the game. The game used for this study is Snow World"
224320610|NCT06197373|PROCEDURE|Laparoscopic cholecystectomy|Doing laparoscopic cholecystectomy after ERCP at different intervals
224320611|NCT03720327|BEHAVIORAL|Get FIT|The Get FIT arm includes use of a free commercially available smartphone application to track daily food intake for 3 months; use of a Fitbit activity tracker for 3 months; and one 45 minute behavioral counseling session to set personal goals and provide education by a health coach.
224320612|NCT03720327|BEHAVIORAL|Get FIT+|The Get FIT+ arm includes use of a free commercially available smartphone application to track daily food intake for 3 months; use of a Fitbit activity tracker for 3 months; one 45 minute behavioral counseling session to set personal goals and provide education by a health coach; and personalized text messaging for 3 months by a health coach. The health coach will have access to these participants' daily food and activity data through the smartphone application, and will monitor progress and send push-only text messages to participants in this group based on the participant's goals and progress in the areas of physical activity, nutrition, and weight loss.
224320613|NCT06206382|PROCEDURE|Whipple operation|Whipple operation is the surgery used for pancreatic head cancer in the form of pancreaticoduodenectomy then reconstruction
224320614|NCT06262230|BEHAVIORAL|Online Inclusive Companionship Intervention|After prior intervention, professionals will conduct a lecture for ordinary children, which includes basic knowledge of ASD and communication skills with ASD children. These ordinary children will be paired with ASD children then. The entire intervention including 12 sessions will last for 3 months. Researchers will prepare a series of themes that the ASD children could choose, and the ordinary children need to ask their paired ASD children what activities they want to choose before each session. Then, they will carry out this entertainment online together through Tencent WeMeet. A researcher will supervise online at the same time and record the communication through instant video. The Researcher will turn off the video and sound throughout the process and will not intervene in the conversation between the ASD children and ordinary children except for special circumstances.
224320615|NCT01461564|PROCEDURE|Colonoscopy|Screening colonoscopy
223651157|NCT03181048|PROCEDURE|Periacetabular osteotomy|The Bernese periacetabular osteotomy has become the osteotomy of choice in North America for correction of the dysplastic hip. The ability to position the acetabular component in a specifically desired position for each individual patient improves joint biomechanics, restores joint balance and stability, and offloads the structures at risk for damage such as the labrum and the adjacent articular cartilage.
223651158|NCT03181048|PROCEDURE|Periacetabular osteotomy with hip arthroscopy|An intraarticular assessment with hip arthroscopy (HA) at the time of periacetabular osteotomy allows the surgeon to assess and treat the associated labral and chondral pathology and allows the surgeon to treat abnormalities of the femoral head junction.
223651159|NCT05579847|OTHER|mHealth Smart Phone Application|The mHealth interactive application consists of educational intervention geared towards eligible patients who are receiving Nivolumab/ Pembro with Axitinib/Cabozantinib/Lenvatinib. These patients commonly experience immune-related side effects, higher rate of fatigue, high blood pressure, and palmar-plantar erythrodysesthesia. The educational intervention will consist of multiple modules covering relevant information on treatment and adverse events and provided over a six-week period through an mHealth platform. This educational intervention includes a patient-friendly algorithm for early detection and management of the most common adverse events in patients with advanced renal cell carcinoma receiving combination immunotherapy.
223651160|NCT05579847|BEHAVIORAL|eHEALS digital literacy test|"The eHEALS digital literacy test is an 8-item measure of eHealth literacy developed to measure the participants combined knowledge, comfort and perceived skills at finding, evaluating and applying electronic health information to health problems. The test is measured with a 5-point Likert scale with response options ranging from strongly disagree to strongly agree. Total scores of the eHEALS are summed to range from 8 to 40, with higher scores representing higher self-perceived eHealth literacy."
223651161|NCT05579847|BEHAVIORAL|Weekly Quiz|Participants will take a weekly true/false quiz to assess knowledge of their diagnosis, expected outcome and treatment associated adverse effects at baseline and longitudinally. Each quiz will be administered at the beginning of the week before the weekly educational content is available, then the same quiz will be administered after the educational content is reviewed by the patient. Each quiz will be scored based on the number of correct answers.
223651162|NCT05579847|BEHAVIORAL|European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire|"The European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ C-30) comprises 30 single questions, 24 of which are aggregated into nine multi-item scales, that is, five functioning scales (physical, role, cognitive, emotional and social), three symptom scales (fatigue, pain and nausea/vomiting) and one global health status scale. The remaining six single-item (dyspnea, appetite loss, sleep disturbance, constipation, diarrhea and the financial impact) scales assess symptoms. No item occurs in more than one scale.~Scoring of the QLQ-C30 is performed according to QLQ-C30 Scoring manual. All of the scales and single-item measures range in score from 0 to 100. Higher score for the functioning scales and global health status denote a better level of functioning (i.e. a better state of the patient), while higher scores on the symptom and single-item scales indicate a higher level of symptoms (i.e. a worse state of the patient)."
223651163|NCT05579847|BEHAVIORAL|Patient Post Intervention Survey|The Patient Post Intervention Survey is a 7 question survey to help determine the effectiveness of the mHealth app. 3 questions are open fields for patient feedback, and 4 questions ask how often the app was used, how often the educational module was used and if the patient found it useful.
223651164|NCT01315652|BEHAVIORAL|Comorbidities treatment|" Comorbidities treatment:Number of actions initiated in order to treat or prevent Rheumatoid Arthritis comorbidities during the 6 months follow-up"
223651165|NCT01315652|BEHAVIORAL|Auto-DAS|"Auto-DASNumber of patients with a modification in their treatment between baseline and 6 months visits"
224235518|NCT00818883|DRUG|Azilsartan medoxomil and chlorthalidone|"Azilsartan medoxomil 40 mg and chlorthalidone 12.5 mg combination tablet, orally, once daily and hydrochlorothiazide placebo-matching tablets, orally, once daily for up to 10 weeks.~For participants who do not achieve target blood pressure by Week 6, the dose of chlorthalidone will be increased for the remaining 4 weeks of treatment."
223651166|NCT03000660|DRUG|Venetoclax|Venetoclax at one of four escalating doses
223651167|NCT03000660|DRUG|Dexamethasone|Dexamethasone 20mg by mouth on days 1, 8, 15, and 22 of each cycle.
223651168|NCT05091372|DRUG|Belantamab mafodotin|"Belantamab Mafodotin~Belantamab mafodotin dose levels:~Dose level -2 = 1.4 mg/kg IV every 12 weeks Dose level -1 = 1.9 mg/kg IV every 12 weeks Dose level 0 = 1.9 mg/kg IV every 8 weeks~Cycles 1 - 6:~All patients will start at dose level 0.~Cycles 7 and onwards\*:~Patients previously on dose level 0 (1.9 mg/kg IV every 8 weeks) will change to dose level -1 (1.9 mg/kg IV every 12 weeks) Patients previously on dose level -1 (1.9 mg/kg IV every 12 weeks) will continue at the same dose level.~Patients previously on dose level -2 (1.4 mg/kg IV every 12 weeks) will continue at the same dose level.~\*Reduction to a lower dose level is allowed in case of development of adverse effects or poor tolerance as determined by the treating physician."
224235519|NCT00818883|DRUG|Azilsartan medoxomil and hydrochlorothiazide|"Azilsartan medoxomil 40 mg, tablets, orally, once daily and hydrochlorothiazide 12.5 mg, tablets, orally, once daily for up to 10 weeks.~For participants who do not achieve target blood pressure by Week 6, the dose of hydrochlorothiazide will be increased for the remaining 4 weeks of treatment."
224235520|NCT01556009|DRUG|Vismodegib|150 mg per day for 7 continuous months then randomized for 3 month intervals to 28 months.
224235521|NCT01556009|DRUG|Aminolevulinic acid %20 topical solution|20% topical solution applied every three months from month 10, 13, 16, 19, 22. Applied and incubated for three hours.
224235522|NCT05283044|BIOLOGICAL|biopsy liquid|Patient performs a blood test at treatment baseline
224235523|NCT01485965|DRUG|SEN0014196|100 mg, immediate release tablets, once daily administration
224235524|NCT04569682|DEVICE|LifePort transrenal artery perfusion|transrenal artery perfusion group
224235525|NCT04569682|DEVICE|LifePort transrenal vein perfusion|transrenal vein perfusion group
224235526|NCT02758665|DRUG|ibrutinib|
224235527|NCT02758665|DRUG|obinutuzumab|
224235528|NCT02758665|DRUG|venetoclax|
224235529|NCT04475965|OTHER|Isometric exercise for shoulder external rotators|The intervention included the application of a series of isometric contraction for the external rotators shoulder muscles. The exercise protocol included two intensities; high-level isometric contraction (80% maximal voluntary isometric contraction) versus a low-level isometric contraction (20% maximal voluntary isometric contraction).
223651169|NCT05091372|DRUG|Lenalidomide|"Lenalidomide dose levels:~Dose level 0 (starting dose): Lenalidomide 10 mg/day PO continuously. Dose level -1: Lenalidomide 10 mg/day PO. One week off after every three weeks of treatment.~Dose level -2: Lenalidomide 5 mg/day PO. One week off after every three weeks of treatment."
223651170|NCT04253691|DEVICE|Virtual Reality Mediated Relaxation|Participants will use a brief Virtual Reality relaxation protocol to improve their insomnia. Their workbook will contain a handout that outlines the details. Participants will be encouraged to refer to it at home if they forget any part of the procedure.
224235530|NCT03795363|DRUG|Orkambi|Orkambi is a novel approved therapy for use in people homozygous for the F508del mutation in the CFTR gene. It is a combination of lumacaftor (VX-809) and ivacaftor( VX-770) that addresses both the processing and gating defects of the F508del mutation. The small-molecule corrector lumacaftor corrects the F508del processing defect and increases epithelial delivery of CFTR protein1. Ivacaftor is a CFTR potentiator that increases the channel open probability in F508del-mutant CFTRs that undergo epithelial delivery in vitro and has an additive effect with lumacaftor on chloride transport (2,3,4,5).
223651171|NCT06655779|DIAGNOSTIC_TEST|Acoustic Detection of Blood Flow|Subject will have the acoustic device scoring performed prior to a Coronary CTA. No treatment decisions will be based upon the acoustic device score.
223651172|NCT06655662|OTHER|β-globin restored autologous hematopoietic stem cells|Eight transfusion-dependent β-thalassaemia subjects aged 6-35 years will be reinfused with β-globin restored autologous hematopoietic stem cells modified with LentiHBBT87Q
223651173|NCT06654934|DRUG|Prednisolone|An initial dose of 40 mg/day will be administered for 1 week, followed by 30 mg/day for 1 week, 20 mg/day for 6 weeks, 15 mg/day for 4 weeks, 10 mg/day for 8 weeks, 5 mg/day for 4 weeks, 2.5 mg/day for 2 weeks after which the drug will be discontinued (cumulative prednisolone dose, 2485 mg).
223651174|NCT06654934|DRUG|Prednisolone|An initial dose of 40 mg/day will be administered for 1 week, followed by 30 mg/day for 1 week, 20 mg/day for 6 weeks, 15 mg/day for 4 weeks, 10 mg/day for 14 weeks, 5 mg/day for 24 weeks, 2.5 mg/day for 2 weeks after which the drug will be discontinued (cumulative prednisolone dose, 3605 mg).
223767115|NCT06236958|DEVICE|Transnasal jejunal tube|A naso-jejunal tube was placed in the operation, which is placed 15 cm below Traitz's ligament. A short-peptide enteral nutrient solution was heated by an enteral nutrient pump and infused into the patients within 24 hours after the operation. Before and at the end of the infusion, physiological saline was given to flush the tube, and at the end of the infusion, the catheter was closed to prevent liquid reflux and blockage of the tube. The catheter should be clamped shut at the end of the infusion. During the infusion period, the patient's gastrointestinal tolerance was dynamically evaluated. According to the results of a regular review of nutritional indicators, including hemoglobin, albumin, electrolytes, liver and kidney function, etc., increase the amount of enteral nutrients; remove the nasojejunal tube when the patient has no abdominal distension after exhaustion and feeding; and change to feeding through the mouth.
224235531|NCT05130892|DRUG|Colchicine|1 tablet (0.5mg) / time, once a day
223651177|NCT05902715|DEVICE|oral implant placement with socket shield technique|tooth is split in socket shield configuration, implant is immediately placed
223651178|NCT06590584|OTHER|Patients with obesity|Six-Minute Pegboard and Ring Test: It will be used to evaluate upper extremity exercise capacity. There are 20 rings on 4 iron bars on the board used and patients will be asked to attach the rings with both hands, first from top to bottom and then from bottom to top. At the end of the six minutes, the total number of rings attached will be recorded. Heart rate, blood pressure, respiratory rate, dyspnea and fatigue will be evaluated according to the Modified Borg Scale before and after the test.
224235532|NCT05130892|DRUG|Tranilast|1 capsule (0.1g) / time, 3 times a day
224235533|NCT05130892|DRUG|Oridonin|2 tablets (0.5g) / time, 3 times a day;
224235534|NCT00405314|DEVICE|Continuous positive airway pressure ventilation mask|
224235535|NCT05293990|RADIATION|Usefulness of Gadovist-enhanced FLAIR imaging in differentiation between a glioblastoma and solitary brain metastasis|Usefulness of Gadovist-enhanced FLAIR imaging in differentiation between a glioblastoma and solitary brain metastasis
224235536|NCT00973700|BIOLOGICAL|MF59-eH1N1_f|MF59 adjuvanted (adj) egg-derived A/H1N1 with traces of Thiomersal
223651179|NCT06597123|BEHAVIORAL|Basic AI (artificial intelligence)-Augmented Motivational Interviewing Training|Basic participants will participate in two motivational interviewing (MI) training sessions that involve role-play practice of MI. Artificial intelligence (AI) will be used to provide metrics on MI-skills (percentage of the time the clinician talks, use of open-ended questions, use of closed-ended questions, use of reflective statements, use of 0-10 scales) as measured by the ReadMI™ tool (Real-time Evaluation of Dialogue in Motivational Interviewing), and both the spirit of MI and presence of bias as measured by Dougall GPT.
223651180|NCT06597123|BEHAVIORAL|Plus AI (artificial intelligence)-Augmented Motivational Interviewing Training|Plus participants will participate in four motivational interviewing (MI) training sessions that involve role-play practice of MI. Artificial intelligence (AI) will be used to provide metrics on MI-skills (percentage of the time the clinician talks, use of open-ended questions, use of closed-ended questions, use of reflective statements, use of 0-10 scales) as measured by the ReadMI™ tool, and both the spirit of MI and presence of bias as measured by Dougall GPT.
223651181|NCT06590649|BEHAVIORAL|Household-level effects|At 3 months, participants randomized to the PILI 'Āina intervention will receive a 6-month intervention centered around the use of a raised-bed home garden as the means of engaging household members to 1) increase their access to and intake of vegetables, 2) learn culturally relevant ways of preparing/cooking fresh vegetables through hands-on cooking lessons with local experts, and 3) build family cohesion through family bonding activities. Participants will be given all the equipment and materials (e.g., soil, seeds, instructions, setup of equipment) needed to grow their vegetables using their raised-bed home garden box throughout the entire study. They will receive seeds for the vegetables that can grow in a relatively short period (i.e., within 6 weeks). The household participants will be analyzed side by side with the index participants.
223651182|NCT04626362|OTHER|Cranberry juice|Cranberry juice cocktail is a product of Ocean Spray Cranberries, Inc.
223651183|NCT05044468|DRUG|Lidocaine|Given via injection
223651184|NCT05044468|DRUG|Liposomal Bupivacaine|Given via injection
223651185|NCT05044468|OTHER|Questionnaire Administration|Ancillary studies
224235537|NCT00973700|BIOLOGICAL|eH1N1_f|Unadjuvanted egg-derived A/H1N1 with traces of Thiomersal
224235538|NCT01661452|OTHER|Referral to counseling services if desired|
223651186|NCT06812312|OTHER|PCR Trainning|A two-hour training intervention was conducted by a CPR-B instructor. The first 30 minutes were dedicated to explaining how to recognize a cardiopulmonary arrest, the correct technique for chest compressions, ventilations, and AED use. The remaining 90 minutes were for practical application of the intervention. This was conducted with five CPR-B training torsos (Little Anne QCPR training mannequin, Laerdal) and a simulated AED for CPR training (AED Practi-Trainer - Bilingual, WNL). Both theoretical and practical training were provided by a basic life support instructor from the Spanish Society of Intensive Care Medicine and Coronary Units (SEMICYUC), instructing participants under the 2021 European Resuscitation Council (ERC) recommendations.
223651187|NCT06654609|COMBINATION_PRODUCT|Insoles for Foot|Assess the condition of foot ulcers in patients, beginning with creating a cast of the affected foot. After the initial rectification, necessary modifications are made to prepare the rough insole. The size and fit of the insole are then carefully checked against the patient's foot. I use local silicone materials, secured with lady socks or stockinette to ensure the insole stays in place and provides durability.
223651188|NCT06655506|COMBINATION_PRODUCT|ERAS group|This group will include patients that achieved a compliance rate that exceeded 80% of the required predetermined criteria of ERAS protocols.
223651189|NCT06655506|COMBINATION_PRODUCT|Control group|This group will include patients that do not follow the predetermined criteria of ERAS protocols
223651190|NCT06654453|PROCEDURE|Thrombectomy|Manual thrombectomy followed by Percutaneous Coronary Intervention (PCI), a procedure involving mechanical removal of thrombus before stent placement in coronary arteries to restore blood flow in STEM
223651191|NCT06654453|PROCEDURE|Percutaneous Coronary Intervention|Percutaneous Coronary Intervention, involving balloon angioplasty and stent placement to open blocked coronary arteries in STEMI patients after thrombolysis.
223651192|NCT04301193|DEVICE|Quantra Analyzer|Subject's blood samples will be manipulated in the lab and will be tested with the Quantra Analyzer. After obtaining blood from each patient, the blood was diluted to varying dilutions to obtain different fibrinogen concentrations. This way, 89 samples were prepared from the blood from 13 patients. Each sample was analyzed for fibrinogen concentration in the lab using conventional technology. Additionally each sample was used to measure Quantra variables such as clot stiffness (CS), and fibrinogen contribution to clot stiffness (FCS).
224235539|NCT01232270|DRUG|propofol|1.1 mcg/ml for initial effect site concentration during spinal anesthesia (The effect site concentration will be changed at each subject by Dixon's up-and-down method.)
224235540|NCT06367452|DRUG|Sodium alginate + sodium bicarbonate + magaldrate + simeticone|Take an oral suspension of 10 mL 30 minutes after the ingestion of a standardized breakfast
224235541|NCT02412215|PROCEDURE|Phacoemulsification with toric Nanoflex IOL implantation|A self-sealing incision is made with a 2.2mm knife at 110°. Phacoemulsification is performed. The foldable nanoFlex toric IOL is injected in the capsular bag using the nanoPoint single-use injector system (STAAR) or 1620 sofTip Injector (ASICO). The IOL is rotated to align the cylinder axis with the steep corneal meridian using Z align function by Callisto Eye. Every movement of the IOL axis marks are noted.
223651193|NCT05723276|DRUG|Psilocybin|Psilocybin 25mg PO
224235542|NCT02412215|DEVICE|NanoFlex toric Intraocular Lens|
224235543|NCT02288832|OTHER|-self-collected vaginal samples|
224235544|NCT02288832|DRUG|zithromax|
224235545|NCT02288832|OTHER|usual practices|
224320616|NCT02636543|OTHER|Questionnaire after the reading of letter B.|Oral questionnaire after the reading of letter B.
223651194|NCT06646731|DEVICE|cryoneurolysis|Peripheral nerve cryoneurolysis of the foot
223651195|NCT06646731|DEVICE|sham cryoneurolysis|a sham probe will be placed percutaneously proximal to target nerves. No cryoneurolysis will be given.
224235546|NCT01051232|DRUG|Active|Six subjects will receive PF-00868554 (filibuvir) 100 mg under fasting condition.
223767116|NCT06236958|OTHER|Transvenous access|A uniform drip of nutritional solution was started 24 hours postoperatively. Configuration of nutritional solution: glucose and medium/long-chain fat emulsion as the main energy substances to provide calories, calculated at 30 \~ 35 kcal/(kg-d), glucose-fat ratio is 6:4, pancreatic glucose ratio for those without a history of diabetes mellitus is 1:6 \~ 8, and for diabetic patients depending on the level of glucose, pancreatic glucose ratio is 1:3 \~ 4, and then assisted with subcutaneous injections of insulin to control glucose, if necessary. Pay attention to the total amount of rehydration fluid, electrolytes, vitamins, and trace elements supplemented. Mix the nutrient solution evenly in the laminar flow clean table and infuse it through the route at 2500\~3000 ml/d; the infusion time is 8\~12 h/d. After exhaustion, start to eat through the mouth.
223767117|NCT02753712|DRUG|Fluticasone/Formoterol BAI|
223767118|NCT02753712|DRUG|Fluticasone/Vilanterol DPI (Relvar Ellipta DPI)|
224235547|NCT01051232|DRUG|Placebo|Two subjects will receive the placebo under fasting condition.
224235548|NCT01051232|DRUG|Active|Six subjects will receive PF-00868554 (filibuvir) 300 mg under fasting condition.
224235549|NCT01051232|DRUG|Placebo|Two subjects will receive the placebo under fasting condition.
224320617|NCT02636543|OTHER|Questionnaire after the reading of letters A and B|Oral questionnaire after the reading of letters A and B during individual interview.
224320618|NCT03791047|OTHER|Balance Analysis|Balance analysis is assessment method to estimate fall of risk and deterioration of postural control.
224235550|NCT01051232|DRUG|Active|Six subjects will receive PF-00868554 (filibuvir) 500 mg under fasting condition.
224235551|NCT01051232|DRUG|Placebo|Two subjects will receive the placebo under fasting condition.
224320619|NCT01404715|DRUG|Metformin|Subjects will be given an oral dose of 1000 mg of metformin followed by an oral dose of 850 mg for a grand total of 1850 mg in both study Arm 1 and study Arm 2.
224320620|NCT01404715|DRUG|Imatinib|A single oral dose of 600 mg of imatinib
224320621|NCT03778827|BEHAVIORAL|Intensive Center-Based Pivotal Response Treatment (PRT-C)|Intensive Center-Based Pivotal Response Treatment (PRT-C) will consist of a combination of weekly individual parent training sessions and center-based therapy for a total of 13 weekly treatment hours.
224320622|NCT05962580|PROCEDURE|Isolated anterior cruciate ligament reconstruction with lateral extra articular tenodesis|Anatomical single bundle ACLR with modified Lemiere technique
224320623|NCT05962580|PROCEDURE|Isolated anterior cruciate ligament reconstruction only|arthroscopic anatomical single bundle ACL Reconstruction
223651196|NCT06817239|DRUG|Esketamine|Esketamine (1mg/ml) will be administered at a loading dose of 0.2 mg/kg, namely at a infusion rate of 1.2ml/kg/h over 10 minutes after induction, then a maintenance infusion rate of 0.1 mg/kg/h until 40 minutes before the end of the surgery. For postoperative analgesia, patient-controlled intravenous analgesia (PCIA) is prepared with a formulation consisting of esketamine 50mg and sufentanil 200 μg, diluted to a total volume of 200 ml. The background dose is set at 2 ml/h, with a bolus dose of 2 ml and a lockout interval of 15 minutes.
223651197|NCT06817239|DRUG|Normal saline|Normal saline will be administered at a infusion rate of 1.2ml/kg/h over 10 minutes after induction, then a maintenance infusion rate of 0.1 mg/kg/h until 40 minutes before the end of the surgery. For postoperative analgesia, patient-controlled intravenous analgesia (PCIA) is prepared with sufentanil 200μg, diluted to a total volume of 200 ml. The background dose is set at 2 ml/h, with a bolus dose of 2 ml and a lockout interval of 15 minutes.
223651198|NCT04746183|DRUG|CST-2: EIDD-2801|"CST-2 Phase Ib: EIDD-2801 will be administered orally, twice daily (BID) for 10 doses (5 or 6 days). The starting dose will be established based on safety and pharmacokinetics from the EIDD-2801-1001-US/UK study, and dose escalations may occur as described in this CST.~Phase II: As per Phase Ib, with the dose determined by the recommended phase II dose."
223651199|NCT04746183|DRUG|CST-2: Placebo|CST-2 Phase II: Placebo will be administered orally, twice daily (BID) for 10 doses (5 or 6 days).
223651200|NCT04746183|DRUG|Nitazoxanide|"CST3A \& CST3B Phase I: Nitazoxanide will be administered orally, initially twice daily (BID) for 14 doses (7 days). The starting dose will be 1500mg BID based on existing dose information, but dose adaptations may occur.~Phase II: As per Phase Ib, with the dose determined by the recommended phase II dose."
223651201|NCT04746183|DRUG|VIR-7832|"CST-5: Phase I, Single doses of VIR-7832 will be administered by intravenous (IV) infusion over 1 hour. The starting dose will be 50 mg, and dose escalations of 150 and 500 mg are anticipated, with escalation guided by emerging safety data and decision by the SRC.~Phase II: As per Phase I, with the dose determined by the recommended phase II dose."
223651202|NCT04746183|DRUG|VIR-7831|CST-5 Phase II: A 500 mg dose of VIR-7831 will also be given by IV infusion over 1 hour.
223651203|NCT04746183|DRUG|CST-5: Placebo|CST-5 Phase 1, Phase II: Placebo given by intravenous infusion over 1 hour
223651204|NCT04746183|DRUG|Favipiravir|CST-6: Multiple doses of IV Favipiravir will be administered by intravenous (IV) infusion over 1 hour. Dosing regimen will be every 12 hours for 7 days duration. The starting dose will be 600mg (BID), and dose escalations to 1200mg (BID), 1800mg (BID) and 2400mg (BID) are anticipated as well as a de-escalation dose of 300mg (BID) if necessary, with de-escalation and escalation guided by emerging safety data and decision by the Safety Review Committee (SRC).
223651205|NCT04746183|DRUG|Molnupiravir|Molnupiravir 800mg Twice a day (BD) for 5 days as starting dose, with a de-escalation protocol reducing in increments of molnupiravir to 600mg BD, then 400mg BD if required.
224235552|NCT05518487|BIOLOGICAL|Sanofi-GSK monovalent (B.1.351) CoV2 preS dTM-AS03 COVID-19 vaccine|0.5 mL per dose of the Sanofi-GSK COVID-19 Vaccine will be administered intramuscularly in the deltoid muscle of the upper arm
224235553|NCT04352361|DRUG|TVB-2640|TVB-2640 tablets (25mg/50mg/75mg) one tablet at a time, once per day.
224235554|NCT04352361|DRUG|Placebo|Oral, matching number of placebo Tablets with active arm.
223651206|NCT04746183|DRUG|Paxlovid|Paxlovid® (300mg nirmatrelvir + ritonavir 100mg) twice a day (BD) for 5 days. The dose of Paxlovid® will be fixed for all cohorts.
223651207|NCT04746183|DRUG|ALG-097558|ALG-097558 600 mg Twice a day (BD) for 5 days
223651208|NCT04746183|DRUG|ALG-097558 and Remdesivir|ALG-097558 600 mg Twice a day (BD) for 5 days Remdesivir will be administered once daily by intravenous infusion over 30 to 120 minutes. 200 mg will be given on day 1 and 100 mg on day 2 and day 3.
223651209|NCT04746183|DRUG|NHS standard of care as per COVID-19 treatment guidelines|NHS standard of care as per COVID-19 treatment guidelines
223651210|NCT05301790|DEVICE|MRI|use of MRI modality of imaging in evaluation of pathologic response in patients with breast cancer
223651211|NCT00560352|DRUG|Dasatinib|Tablets; oral; approximately 2 years on study, depending on response; 50 mg once daily (QD), 100 mg QD, 140 mg QD
223651212|NCT00560352|DRUG|Bortezomib|Powder; intravenous; approximately 2 years on study, depending on response; 1.0 mg/m\^2 QD, 1.3 mg/m\^2 QD
224235555|NCT04270305|OTHER|Orientation|In the first group CP patients undergo a four week training with once daily sessions lasting 30 minutes. The treatment includes exercises to improve navigation competences and orientation. During walk in VR environment with labyrinths of increasing complexity. Exercises include abilities such as orienting in complex environments, perceiving distance and planning routes to distant locations. The presence of landmarks has been included in some exercises to facilitate allocentric orientation strategies.
224235556|NCT04270305|OTHER|walking|In the second group CP patients undergo a four week training with once daily sessions lasting 30 minutes. The treatment includes exercises to improve walking and balance abilities. Using engaging VR environments (e.g. transfer your load from the left to the right side to avoid obstacles while skiing; shoot balls at targets inside an area; walk in a forest as fast as possible; hit as many elves as possible by squatting, and so on). No exercises for orientation are included in this group.
224235557|NCT01931033|DRUG|Intranasal Oxytocin|
224235558|NCT00000941|DRUG|Pravastatin sodium|
223651213|NCT00560352|DRUG|Dexamethasone|Tablets; oral; approximately 2 years on study, depending on response; 20 mg QD
223651214|NCT02471937|BIOLOGICAL|Bacteriological analyses on clinical samples performed with Eswabs|"Clinical samples analysed :~mothervagina, breast milk, baby oral cavity, baby stool. Techniques: bacteriological cultures, Real time PCR"
223651215|NCT01916044|OTHER|Ultrasound|Measure of Uterine Segment by Ultrasound
224235559|NCT00000941|DRUG|Simvastatin|
224235560|NCT00000941|DRUG|Atorvastatin calcium|
224235561|NCT00000941|DRUG|Ritonavir|
224235562|NCT00000941|DRUG|Nelfinavir mesylate|
224235563|NCT00000941|DRUG|Saquinavir|
224235564|NCT05333432|PROCEDURE|Multiparameric MRI with injection|"Participants have a prostate multiparametric MRI with gadolinium injection (T2, diffusion and perfusion sequences) every year.~PIRADS-V2 is used as decisional endpoint, and subjective score LIKERT as secondary analysis.~To compute sensivity and specificity, we consider LIKERT as suspicious and/or malignant (PIRADS-V2 = 3, 4 or 5) as positive."
223651216|NCT06526793|DRUG|AZD0486|Investigational Product administered via intravenous infusion.
223651217|NCT05987007|DEVICE|Acoustic slow-wave activity enhancement|The acoustic enhancement of slow-wave activity will be conducted using the Dreem2 headband. This device utilizes five dry-EEG electrodes (O1, O2, FpZ, F7, and F8), a 3D accelerometer, and a pulse oximeter to detect slow-wave activity and generates acoustic stimulation of slow-waves to augment slow-wave sleep.
223651218|NCT05987007|BEHAVIORAL|Cognitive behavioral therapy for insomnia|Cognitive behavioral therapy for insomnia (CBTI) is a well-established first-line or complimentary treatment for insomnia which consists of cognitive and behavioral modifications, including addressing maladaptive sleep-related behaviors, controlling sleep environment, and limiting time spent in bed.
223651219|NCT06824727|OTHER|Baseline cell blood counts|Obtain one peripheral blood sample from participants who have severe thrombocytopenia defined as 30,000 platelets/mcl or less
223651220|NCT05458219|DRUG|IBI343|IBI343 will be administered intravenously (IV) on Day 1 of every 21-day cycle.
223651221|NCT04777175|DRUG|immunity therapy|The patient receives immunotherapy
224235565|NCT03873701|DIAGNOSTIC_TEST|bedside ultrasonography|Patients suspicious to urinary tract infection with kidney involvement are being examined by ultrasonography to detect hydroneprhosis. The treating clinicians fill out questionnaires to validate the impact of the bedside ultrasonography on the patient care and treatment.
224235566|NCT05014386|PROCEDURE|Ahmed Glaucoma Valve Implantation in secondary pediatric glaucomas.|A 7-0 silk traction suture was placed through the clear cornea.A conjunctival incision was made 4 mm posterior to the limbus in the supratemporal quadrant. After dissecting conjunctiva and Tenon's primed FP7 or FP8 AGV was inserted into the subconjunctival space and sutured to sclera using two interrupted 7-0 silk sutures 8-10 mm posterior to the limbus. A 23-gauge needle was used to enter the anterior chamber from the surgical limbus. The tube then was cut beveled up and inserted into the anterior chamber through the tunnel. Finally, conjunctiva and Tenon were approximated using a running 8-0 Vicryl suture.At the close of surgery, subtenon antibiotic and steroids were injected in all cases.
224235567|NCT05014386|PROCEDURE|Ahmed Glaucoma Valve Implantation with Ologen augmentation in secondary pediatric glaucomas|A 7-0 silk traction suture was placed through the clear cornea.A conjunctival incision was made 4 mm posterior to the limbus in the supratemporal quadrant. After dissecting conjunctiva and Tenon's primed FP7 or FP8 AGV was inserted into the subconjunctival space and sutured to sclera using two interrupted 7-0 silk sutures 8-10 mm posterior to the limbus. A 23-gauge needle was used to enter the anterior chamber from the surgical limbus. The tube then was cut beveled up and inserted into the anterior chamber through the tunnel. a round 12 × 1 mm circular Ologen disc will be placed over the FP7 or FP8 AGV-plate immediately before conjunctival closure. Finally, conjunctiva and Tenon were approximated using a running 8-0 Vicryl suture.At the close of surgery, subtenon antibiotic and steroids were injected in all cases.
224235568|NCT02052609|DRUG|KHK4827 140mg SC|Experimental1:KHK4827 140mg subcutaneous injection
224235569|NCT02052609|DRUG|KHK4827 210mg SC|Experimental2:KHK4827 210mg subcutaneous injection
224235570|NCT03130205|PROCEDURE|Core Needle Biopsy|Core Needle Biopsy is performed from liver metastasis.
224235571|NCT03130205|RADIATION|Computed Tomography|Computed Tomography
224235572|NCT03130205|RADIATION|18F-FDG-PET|18F Fluorodeoxyglucose Positron emission tomography
224235573|NCT03130205|PROCEDURE|Phlebotomy|3 EDTA tubes drawn from peripheral vein
224235574|NCT03130205|GENETIC|Molecular genetic analysis|Performed on biomaterial from peripheral vein and core needle biopsy
224235575|NCT03479736|DRUG|Oral Fluoroquinolones (FQ)|Participants will not receive any intervention as a part of this study. The FQ include all oral forms of FQ (24-hours extended release tablets, extended release tablets, oral solution, oral suspension, oral tablet, pack). The drugs included are ciprofloxacin, gatifloxacin, gemifloxacin, levofloxacin, moxifloxacin, norfloxacin, ofloxacin.
224235576|NCT03479736|DRUG|Other Antibiotics|Participants will not receive any intervention as a part of this study. Other antibiotics include amoxicillin, azithromycin, trimethoprim and trimethroprim/sulfamethoxazole.
224235577|NCT03479736|OTHER|Febrile Illness Not Treated with Antibiotics Will be Analyzed as an Exposure|Febrile illness not treated with antibiotics is defined as: concurrent diagnoses of viral disease with concurrent fever, and no concurrent prescription for any antibiotic during the 60-day period before and after the first date of viral disease diagnosis; or a diagnosis of influenza with no concurrent inpatient admission during the 60-day period pre- or post-influenza diagnosis, and no prescription for any antibiotics during the 60-day period pre- or post-influenza diagnosis.
224235578|NCT03420066|OTHER|Retrospective data collection|Retrospective collection of data recorded as standard of care for patients that were implanted with the Nexus device as part of Compassionate Use duly authorized according to country specific regulations.
224235579|NCT04043845|DRUG|Ibrutinib|Ibrutinib inhibits the function of Bruton's tyrosine kinase (BTK). Ibrutinib blocks signals that stimulate malignant B cells to grow and divide uncontrollably.
223767119|NCT02156427|DEVICE|VITICELL|graft of autologus cells (kaeratonicytes and melanocytes) obtained after trypsinization of thin skin biopsy resuspended into hyaluronic acid
223767120|NCT02156427|DEVICE|PLACEBO|hyaluronic acid alone
223767121|NCT01592188|BEHAVIORAL|Cognitively-Based Compassion Training (CBCT)|CBCT is a 12 week program that begins by teaching mindfulness and attention. It then goes on to use new mindfulness skills to consider topics of compassion, or unbiased acceptance and compassion for all other people, both friends, unfamiliar people, and enemies.
223767122|NCT01592188|BEHAVIORAL|Mindfulness training|Mindfulness training will consist of 6 weeks training in mindfulness meditation.
223651222|NCT06602232|DRUG|DR-01|DR-01 will be administered via IV infusion.
223651223|NCT06601595|DRUG|TNF inhibitors|tumour necrosis factor inhibitors approved as treatments for ulcerative colitis and/or Crohns disease
223651224|NCT06601595|DRUG|conventional ibd medical treatment|Conventional therapies for ulcerative colitis and Crohns disease (CD) include aminosalicylates, corticosteroids, thiopurines, methotrexate other than anti-tumor necrosis factor agents.
223651225|NCT06170411|DEVICE|Elexir (program1)|The Elexir is an external cranial neurostimulator designed for supraorbital neurostimulation, also known as Trigeminal Nerve Stimulation. The Elexir will deliver trigeminal nerve stimulation.
223651226|NCT06170411|DEVICE|sham device|The sham device will deliver sham trigeminal nerve stimulation.
223651227|NCT06609694|DEVICE|Portable oxygen concentrator Inogen G5 model|The concentrator weighs 4.7 lbs. and has a battery life of 13 hours. It has 6 settings with 1 providing the lowest pulse flow and 6 provides the highest flow. The setting will be increased every 30 minutes by 1 when oxygen nadir is lower than 94% and or obstructive index is ≥ 5 /hour.
223651228|NCT06860867|DEVICE|PerQdisc|PerQdisc Artificial Implant
223651229|NCT06862206|OTHER|benralizumab|non-interventional
223651230|NCT06858904|DIETARY_SUPPLEMENT|Placebo|Non- calorically sweetened Water
223651231|NCT06858904|DIETARY_SUPPLEMENT|ConcenTrace|1.25 milliliter of concentrace per liter
223651232|NCT06858904|DIETARY_SUPPLEMENT|ZeroLyte|Beverage with 1 pack of ZeroLyte per 500 milliliter of water
224235580|NCT04043845|DRUG|LY3214996|LY3214996 is an extracellular signal-regulated kinase (ERK) inhibitor. ERK inhibitors stop the signal that a cancer cell receives telling it to grow.
224235581|NCT04568681|DEVICE|Deep brain stimulation (DBS)|Deep brain stimulation is an FDA approved therapy that involves surgical implantation of electrodes in deep brain targets and an implantable pulse generator delivers electrical pulses.
224235582|NCT01910766|DRUG|Coenzyme Q10|no more details
224235583|NCT01910766|DRUG|clomiphene citrate|
224235584|NCT03887195|OTHER|Training mandatory module about the therapeutic relationship|"The training programme is composed by:~* 2 lectures (optional)~* 6 supervision sessions by Balint type groups (5 of which are mandatory);~* 5 role-plays (all required);~* 2 OSCE with patient actors (all required). This teaching is initiated by two lectures on the relationship, the awareness, the listening, the empathy, the therapeutic distance, and the personal impacts that affect the relationship.~It included six sessions of Therapeutic Relation Training Groups inspired by the Balint groups. Five role-play sessions are also organized from January to May, the students could play the doctor or the patient. The scenarios are about the following themes: announcement of bad news; accompaniment of chronic disease; management of aggressiveness and hostility; etc. After the role-play, a feedback done by the teacher and the group helps to elaborate what has happened. Finally, a formative assessment will be made during the Clinical Objective Structured Examination."
224235585|NCT02752776|DRUG|Secukinumab|Secukinumab was used as commercially available PFS of 150 mg. Patients received PFS at the site and were instructed to administer Secukinumab as needed (300 mg each application).
224235586|NCT00194740|DRUG|Docetaxel|60 mg/m2, IV, day 1 of each 21 day cycle
224235587|NCT00194740|DRUG|Vinorelbine|27.5 mg/m2, IV, days 8 \& 15 of each 21 day cycle
224235588|NCT00194740|DRUG|Filgrastim|5 µg/kg/day s.c., to be administered days 2-21 of each cycle.
224320624|NCT01879865|OTHER|Non-stimulation|The volunteers will be wearing noise-cancelling headphones (silent) and will be stimulated as little as possible. The volunteer will be instructed to keep his/her eyes closed.
224320625|NCT01879865|OTHER|Stimulation|The volunteers will be wearing noise-cancelling headphones, through which they will hear a continuous loop of recorded operating room noise (monitor beeps, talking), to simulate operating room conditions. The volunteer will be instructed to keep his/her eyes closed.
224320626|NCT00642681|DRUG|Technosphere Insulin|Technosphere® Insulin (TI) Inhalation Powder, prandial
224320627|NCT02767154|DEVICE|A colloid Dextran 40 solution for extracorporeal circulation|The oncotic pressure of the PrimECC solution is higher than that of a crystalloid Ringer-acetate/mannitol solution. It should maintain the plasma oncotic pressure during and after cardiopulmonary bypass (CPB). Subsequently, the leakage of fluids from the systemic circulation to the interstitial compartment during CPB can be reduced, and a higher plasma volume and a better fluid balance can be achieved.
223651233|NCT04434937|DRUG|parsaclisib|parsaclisib will be taken orally QD with water without regard to food except on mornings of PK clinic visits
223651234|NCT06246656|PROCEDURE|Maxillary Expansion|Palatal Expansion using a CAD/CAM appliance
223651235|NCT06993233|DRUG|CIT-013 high dose|subcutaneous injection
223651236|NCT06993233|DRUG|CIT-013 medium dose|subcutaneous injection
223651237|NCT06993233|DRUG|Placebo|subcutaneous injection
223651238|NCT06993831|BEHAVIORAL|Virtual Reality-based psychotherapy|"A manualized, modularized, Virtual Reality-based intervention comprising 10 sessions of 1 hour each. The VR therapy aims at enhancing anticipatory pleasure and positive emotions by amplifying exposure and reactivity towards social environments and rewarding activities using a highly elaborate VR software. The VR exposure comprises several different virtual social environments (e.g., a bus, a café, a park etc.) In a tailored treatment approach, therapists will guide participants to train focusing on positive stimuli, engage in activities, experience social rewards, and practice expressing emotions through body language.~The therapy focuses on increasing the awareness of positive outcomes that may influence motivation. The therapy deploys activity appraisal/re-appraisal intended to enhance the salience of future opportunities for reward and desire for such rewards, thus targeting reward anticipation processes and promoting enjoyable daily-life activities."
223651239|NCT05242900|PROCEDURE|Complete decongestive therapy|The investigators will identify participants undergoing clinically-indicated interventions that they are already receiving for their routine clinical management (complete decongestive physical therapy). They will make no evaluation of the efficacy of these procedures, but rather will test fundamental hypotheses regarding lymphatic clearance of tissue sodium.
223651240|NCT05242900|OTHER|Standard imaging protocol|The standard imaging protocol entails noninvasive magnetic resonance imaging techniques including sodium and lymphatic angiography.
223651241|NCT02544100|OTHER|Database Entry/Biospecimen Collection|blood, urine, CFS samples and medical data collected
223767123|NCT03287856|DEVICE|Transcatheter Aortic Valve Implantation (TAVI)|Implantation of the ALLEGRA Transcatheter Heart Valve in failing surgical bioprosthesis
224235589|NCT03086772|BEHAVIORAL|Tai Chi|Individuals in the Tai Chi intervention group will participate in a 12-week Tai Chi program (one hour per class, two classes per week, plus home practice for 12 weeks) led by an experienced Tai Chi Instructor, assisted by an undergraduate research assistant.
224320628|NCT02767154|DEVICE|Ringer-Acetate and Mannitol|Currently clinic standard for priming the CPB circuit.
224320629|NCT06122376|DEVICE|U-shaped Power Toothbrush|Twice daily brushing for 30 seconds with fluoride toothpaste
224320630|NCT06122376|DEVICE|Soft Manual Toothbrush|Twice daily brushing for two minutes with fluoride toothpaste
224235590|NCT03086772|BEHAVIORAL|Light Exercise|Individuals in the exercise control group will meet for a twice weekly class involving walking, weight training, stretching and health education (one hour per class, two classes per week for 12 weeks, taught by a trained graduate research assistant, assisted by an undergraduate research assistant.
224235591|NCT00386113|BIOLOGICAL|Fluarix and adjuvanted influenza vaccine|
223651242|NCT02587637|DEVICE|Dorsal root ganglion (DRG) stimulation|The role the DRG plays in the development and maintenance of chronic pain, we have developed a neurostimulator system for the management of chronic intractable pain by electrically stimulating the DRG
223651243|NCT06602947|OTHER|Low flow anaesthesia using ASA enviormental sustanibility commitee recomendation|"1. Induction: Set the Vaporizer to Deliver a Concentration Greater than Intended~2. Intubation: Turn Off the Fresh Gas Flow, Not the Vaporizer.~3. Maintanance: Minimize Fresh Gas Flow During Maintenance."
223651244|NCT06602726|DRUG|REGN1908|Administered per the protocol
223651245|NCT06602726|DRUG|REGN1909|Administered per the protocol
223651246|NCT06602726|DRUG|Placebo|Administered per the protocol
223767124|NCT03354429|DRUG|Ticagrelor|Ticagrelor arm: Day 1, loading dose of ticagrelor followed by daily maintenance dose until Day 30.
223767125|NCT03354429|DRUG|Placebo|Placebo arm: Day 1, loading dose of placebo followed by placebo daily maintenance dose until Day 30.
223651249|NCT06599281|OTHER|Physiotherapy|The physical therapy program was applied for 3 months, 6 days a week, 2 sessions per day, and an average session duration of 45 minutes. Each neurodevelopmental exercise and proprioceptive exercise was applied for 10 minutes, and stretching exercises were applied for 45 seconds and 3 repetitions. The exercises included functional rotation, sitting with or without arm support, crawling, kneeling, half kneeling, standing up by holding on, and sequencing exercises. Stretching exercises were mostly positional stretches aimed at lateral flexion of the spine.
223651250|NCT04528303|GENETIC|Whole genome sequencing|Genomic sequencing and molecular diagnostic results
223651251|NCT04528303|GENETIC|Whole exome sequencing|Genomic sequencing and molecular diagnostic results
223651252|NCT06614790|DRUG|Niraparib 200/300 MG|"We expect to enroll approximately 300 patients from about 10 sites. Treatment part of study.~Part I- looking retrospectively at the time period JAN 2021-MAR 2023. The retrospective data will include patients who are enrolled in niraparib treatment:~* under the EAP (started in JAN 2021, in continuation)~* under the B.50 drug program, which began in January 2022 Of note, the retrospective multi-center observational study will involve about 30 patients treated with niraparib in EAP (FIGO III R0 after PDS included) and patients who were treated with niraparib before starting RWE (about 120 pts) (JAN 2021- MAR 2023) by the drug program B.50 which has been started to adapt on 1st of Jan, 2022.~FIGO III PDS to R0 patients are included to this study. Part II- looking prospectively at the time period APR 2023 to DEC 2025. The prospective data will include patients who are enrolled in niraparib treatment under the B.50 drug program.~The prospective multi-center observational study will i"
223651253|NCT07134738|DRUG|Dimolegin|Dimolegin® is administered orally once daily,The recommended dose is 60 mg (six 10 mg tablets) once daily.
223651254|NCT06866691|DRUG|levetiracetam|levetiracetam 1000 mg intravenously or by mouth twice daily for a total of 7 days
224235592|NCT01193608|DRUG|AAB-003 (PF-05236812)|0.5 mg/kg AAB-003, IV
224235593|NCT01193608|DRUG|AAB-003 (PF-05236812)|1 mg/kg AAB-003, IV
224235594|NCT01193608|DRUG|AAB-003 (PF-05236812)|2 mg/kg AAB-003, IV
224235595|NCT01193608|DRUG|AAB-003 (PF-05236812)|4 mg/kg AAB-003, IV
224235596|NCT01193608|DRUG|AAB-003 (PF-05236812)|8 mg/kg AAB-003, IV
224235597|NCT01193608|OTHER|Placebo|Placebo, IV
224235598|NCT02419677|PROCEDURE|Radiofrequency ablation|Radiofrequency ablation is performed percutaneously under CT/US guidance.
224235599|NCT02419677|BIOLOGICAL|Cytokine-induced killer cells|The patients received autologous cytokine-induced killer cells transfusion one week after RFA treatment.
224235600|NCT04924309|OTHER|Exposure: donor sperm|One group use donor sperm through the process of assisted reproduction and the other uses husband's semen.
224235601|NCT05577585|DRUG|Ketamine 50 MG/ML Blinded|See also Arm description
223651255|NCT06866691|DRUG|lacosamide|lacosamide 200 mg intravenously or by mouth twice daily for a total of 7 days
223651256|NCT05002218|BEHAVIORAL|Aerobic Training|Aerobic training on stationary bike 5x a week for 30 minutes a day.
223651257|NCT05002218|BEHAVIORAL|Balance Training|Balance training 5x a week for 30 minutes as instructed by a therapist. Standard of care.
223767126|NCT02488629|DRUG|SCB01A|This study is a single arm, open-label, Phase II trial
223767127|NCT00471913|DEVICE|Femoral Nailing with Different Entry Points|See Detailed Description.
224235602|NCT05577585|DRUG|Midazolam|See also Arm description
224235603|NCT05577585|DRUG|Ketamine 50 MG/ML Open Label|Open Label Follow Up (up to 8 Infusions)
224235604|NCT05577585|OTHER|Treatment as Usual (TAU)|Treatment as Usual may include psychotherapy, pharmacotherapy, physiotherapy, ergotherapy, or a combination of these-at the discretion of the treating physician, independently of the study.
224235605|NCT05976971|OTHER|7T MRI|Subjects will have a 7T MRI and questionnaires on the only day of clinical study.
224235606|NCT04122105|DRUG|Sildenafil|The intervention group will receive standard care in all capacities with the exception of sildenafil administration. The first dose (50mg) will be given 1-hour prior to the surgery. Patients will be given Sildenafil twice daily up to 3 days post-transplant.
224235607|NCT06227065|DRUG|Epirubicin|"In PDOs from patients that show highest response to Epirubicin, this drug will be instilled intravesically once weekly for 6 times.~Epirubicin will be used as a concentrate for injection/instillation 2 mg/ml in total 50mg per vial. Prior to use, the concentrate for injection is diluted with 25ml of 0.9% saline solution to obtain the final Solution with 1mg/ml of Epirubicin."
224235608|NCT06227065|DRUG|Mitomycin|"In PDOs from patients that show highest response to Mitomycin, this drug will be instilled intravesically once weekly for 6 times.~Mitomycin C will be used as 20mg dry powder. Prior to use, the powder will be dissolved in 50ml of 0.9% saline solution according to the manufacturer instructions"
224320631|NCT02653430|PROCEDURE|Sleeve gastrectomy|"After complete exams such as EKG，UCG，spirometry and other basic exams,estimate the condition of patient whether he(she) can tolerate a surgical operation.Then we operate theSleeve gastrectomy laparoscopically by a group of experienced surgeons."
224320632|NCT03781284|DIAGNOSTIC_TEST|[18F]-FDG PET/MRI|
224320633|NCT03781284|DIAGNOSTIC_TEST|Colonoscopy|
224320634|NCT03122080|DEVICE|Electroacupuncture(EA)|"Participants in EA group will receive electroacupuncture treatment. Acupuncture will be applied at Baihui (GV20), Shenting (GV24), Yintang (GV29), bilateral Anmian (EX-HN22), Shenmen (HT7), SanYinjiao (SP6) and Neiguan (PC6). After needle insertion, rotating or lifting-thrusting manipulation will be applied for Deqi sensation. The EA apparatus (CMNS6-1, Jianjian Medical Device CO., LTD, China) will be connected to the needles at GV20 and GV29 for 30 minutes and deliver a continuous wave. The frequency will be set at about 30 Hz and the amplitude will be less than 20V. Participants can regularly take the antidepressants or sedative-hypnotics as before during the intervention. Besides, the investigators will strengthen health education about insomnia and depression for the patients."
223651258|NCT06592209|BEHAVIORAL|Sedentary Breaks|Participants recruited through a podcast series (Body Electric) produced by National Public Radio were asked to select one of three movement break conditions (5 minutes of movement for every 30-, 60-, or 120-minutes of sedentary time). Participants are asked to complete movement breaks during all waking hours on weekdays and weekends (i.e. 7 days a week). During movement breaks, participants are instructed to walk for 5 minutes in whichever way was most comfortable and safe (i.e. self-selected pace and location). Participants who use an assistive device such as a wheelchair or walker, were instructed to wheel, walk, or complete other convenient, comfortable, and safe types of movement such as upper body exercises with resistance bands, chair-based exercises, etc. No break reminders were provided, although participants were encouraged to set reminders in their phones or to utilize commercially available apps or wearable devices.
223651259|NCT06681402|DRUG|FLAMOD|FLAMOD (GMP-grade flagellin) inhalation
223651260|NCT06681402|DRUG|Placebo|Placebo inhalation
223651261|NCT06868537|BEHAVIORAL|Launching! to adulthood group therapy|Participants will be in a 12-week therapy program that includes weekly group sessions and individual coaching.
223651262|NCT06868537|BEHAVIORAL|standard of care|Participants will receive a list of resources
223651263|NCT06625034|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223651264|NCT06625034|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223651265|NCT06625034|RADIATION|Photon Beam Radiation Therapy|Undergo radiation therapy
223651266|NCT06625034|PROCEDURE|Positron Emission Tomography|Undergo PET
223651267|NCT06625034|OTHER|Questionnaire Administration|Ancillary studies
223651268|NCT06625034|RADIATION|Radiation Therapy Treatment Planning and Simulation|Receive human-driven treatment planning
223651269|NCT06625034|RADIATION|Radiation Therapy Treatment Planning and Simulation|Receive RapidPlan treatment planning
224235609|NCT06227065|DRUG|Gemcitabine|"In PDOs from patients that show highest response to Gemcitabine, this drug will be instilled intravesically once weekly for 6 times.~Gemcitabine will be used as 2000 mg/50ml. For intravesical application, 1000mg of gemcitabine (corresponding to 25ml) will be diluted in 25ml 0.9% saline solution, to obtain the gemcitabine concentration of 1000mg/50ml used for instillation."
224235610|NCT06227065|DRUG|Docetaxel|"In PDOs from patients that show highest response to Docetaxel, this drug will be instilled intravesically once weekly for 6 times.~Docetaxel will be used as 140mg/7ml solution. For intravesical application, 48.825ml of saline will be added to 1.875ml Docetaxel solution (according 37.5mg of Docetaxel). The concentration of this solution is 0.74mg/ml by a total volume of the instillation solution of 50,7."
224235611|NCT05128357|OTHER|the study is observational, no intervention foreseen|the study does not foresees any intervention, since it is a multi step observational study.
224235612|NCT00712010|OTHER|Whey protein native|Whey protein native against the 6 other arms
224235613|NCT00712010|OTHER|Whey protein microgels|Whey protein microgels versus the six other arms
224235614|NCT00712010|OTHER|Hydrolyzed whey protein|versus the six other arms
224235615|NCT00712010|OTHER|Casein native|versus the six other arms
224235616|NCT00712010|OTHER|Hydrolyzed casein|versus the six other arms
224235617|NCT00712010|OTHER|Total milk protein native|versus the six other arms
224235618|NCT00712010|OTHER|Hydrolyzed milk protein|versus the six other arms
224235619|NCT04282538|DEVICE|Active rTMS|4-week (5 days per week) active rTMS (90%rMT, M1, 10Hz for 10s, 50s interval, 20 trains)
224235620|NCT04282538|DEVICE|Sham rTMS|4-week (5 days per week) sham rTMS
224235621|NCT04282538|DEVICE|Active tDCS|4-week (5 days per week) active tDCS (2mA, DLPFC, 20 min)
224235622|NCT04282538|DEVICE|Sham tDCS|4-week (5 days per week) sham tDCS
224235623|NCT04282538|OTHER|Walking training|4-week (5 days per week) walking training
223651270|NCT05895292|DEVICE|CAD/CAM Milled Methacrylate Complete Removable Dentures based on bone-support concept.|The patients will receive complete removable dentures designed based on the bone-support concept and digitally manufactured using a milling machine.
223651271|NCT05895292|DEVICE|CAD/CAM Milled Methacrylate Complete Removable Dentures based on neutral zone concept.|The patients will receive complete removable dentures designed based on the neutral-zone concept and digitally manufactured using a milling machine
223651272|NCT06556810|DRUG|Atibuclimab (IC14)|Atibuclimab (IC14) is a monoclonal antibody against human cluster of differentiation (CD)14, a key signaling molecule of the innate immune system
223651273|NCT06398444|DRUG|Lutetium[177Lu] Oxodotreotide Injection|Participants will receive 7.4GBq (200mCi) Lutetium\[177Lu\] Oxodotreotide Injection every 8 weeks.
223651274|NCT06690905|DRUG|Piperacillin-tazobactam administered in a prolonged infusion|For patients with the prolonged infusion intervention, the piperacillin-tazobactam dose will be administered via 100 ml 0.9% NaCl mini-bags infused and a volumetric pump over 3 hours for piperacillin-tazobactam dosages every 6 hours or overs 4 hours for piperacillin-tazobactam dosages every 8 hours.
223651275|NCT06690905|DRUG|Piperacillin-tazobactam administered in a standard infusion|For patients with the standard infusion intervention, the piperacillin-tazobactam dose will be administered over 30 minutes for every piperacilline-tazobactam administered in the study (as instructed by the drug's monograph)
224235624|NCT04282538|OTHER|Cognition training|4-week (5 days per week) cognition training
224235625|NCT00409019|DRUG|Telbivudine|Study cancelled: Withdrawn before enrollment of any participants
224235626|NCT00409019|DRUG|Adefovir|
224235627|NCT00409019|DRUG|Tenofovir|
224235628|NCT01399164|OTHER|14C-B12 fortified bread|A single serving of 14C-B12 fortified bread
224235629|NCT03849599|BIOLOGICAL|PRV-300|Treatment
223651276|NCT07012005|DRUG|BPN14770|BPN14770 will be administered per schedule specified in the arm description.
223651277|NCT06619080|DRUG|Genicular nerve block with bupivacaine and corticosteroids|"\- GROUP 1:Genicular Nerve Block with Bupivacaine and Corticosteroids: 2.5 mL at three genicular nerve points.~All injections are ultrasound-guided and administered once. The primary outcome is pain reduction, measured using NRS, KOOS, WOMAC, and KUJALA scales at 4, 12, and 24 weeks post-injection. Follow-up includes phone and in-person consultations to monitor pain, functionality, and adverse effects."
224235630|NCT03849599|BIOLOGICAL|Placebo|Control
224235631|NCT03714100|BEHAVIORAL|Tai Ji Quan: Moving for Better Balance|Participants will attend one-hour Tai Ji Quan: Moving for Better Balance classes twice a week for 16-weeks. Groups of participants will gather at a local community site that has videoconferencing capabilities. The instructor will be teaching the class from a different location via a live video feed.
224235632|NCT05295771|PROCEDURE|Gingival Phenotype Modification|Autogenous Connective Tissue Graft is the current gold standard for soft tissue phenotype modification. This is being compared with a substitute material called Geistlich Fibro-Gide ® for soft tissue phenotype modification before orthodontic treatment. Geistlich Fibro-Gide ® is a porcine, porous, resorbable and volume-stable collagen matrix, designed for soft-tissue regeneration. Surgical flap design will be an envelope for both interventions.
224235633|NCT00314171|DRUG|Brinzolamide 10 mg/ml + Timolol 5 mg/ml eye drops, suspension|One drop in the study eye(s) twice daily for 12 months
224235634|NCT00314171|DRUG|Dorzolamide 20 mg/ml + Timolol 5 mg/ml eye drops, solution (COSOPT)|One drop in the study eye(s) twice daily for 12 months
224235635|NCT01946165|DRUG|Abiraterone Acetate|1,000 mg by mouth daily for each 28 day cycle.
224235636|NCT01946165|DRUG|Prednisone|5 mg by mouth once daily for each 28 day cycle.
223651278|NCT06619080|DRUG|Genicular nerve block with bupivacaine|"\- GROUP 2: Genicular Nerve Block with Bupivacaine: 2.5 mL at three genicular nerve points.~All injections are ultrasound-guided and administered once. The primary outcome is pain reduction, measured using NRS, KOOS, WOMAC, and KUJALA scales at 4, 12, and 24 weeks post-injection. Follow-up includes phone and in-person consultations to monitor pain, functionality, and adverse effects."
223651279|NCT06619080|DRUG|Genicular nerve block with saline|"\- GROUP 3: Genicular Nerve Block with Saline: 2.5 mL at three genicular nerve points.~All injections are ultrasound-guided and administered once. The primary outcome is pain reduction, measured using NRS, KOOS, WOMAC, and KUJALA scales at 4, 12, and 24 weeks post-injection. Follow-up includes phone and in-person consultations to monitor pain, functionality, and adverse effects."
223651280|NCT06874439|OTHER|WHO QualityRights program|"The WHO's QualityRights program involves an assessment, called observation, of mental health care services by an ephemeral multidisciplinary team, which provides feedback and recommendations for improving care practices. The observation team, trained in the QualityRights (QR) methodology, includes mental health professionals, researchers, legal experts, and management staff from mental health organizations. Each team always incorporates at least one expert by experience and one informal caregiver or family member. Participation in the program is voluntary and initiated at the request of healthcare facilities.~The observation is structured into three stages:~1. Site preparation~2. On-site observation~3. Restitution of observation report and follow-up"
223651281|NCT07031557|DEVICE|EchoStation Implementing REMS Technology|Ultrasound-based densitometry used for the prevention, diagnosis, and monitoring of bone health status and fracture risk at reference anatomical sites (femur and spine), including all patient categories.
223651282|NCT07031557|OTHER|Nutritional and Fracture Risk Assessment Questionnaires|Questionnaires regarding Calcium Intake, dietary habits assessment (Predimed), and Algorithm for Fracture Risk in Women of Childbearing Age (AFEF) developed by the Fragility Fracture Observatory (OFF)
223651283|NCT07037238|DRUG|Everolimus 10mg daily|An oral mTOR inhibitor
223651284|NCT06705686|DRUG|(R)-9bMS|(R)-9bMS will be given in clinic on day 1, two doses 12 hours (+/- 30 minutes) apart, and on day 2, 12 hours (+/- 30 minutes) after the second day 1 dose. Patients will be admitted overnight for these first 3 doses. Patient must be fasting 1 hour before and 1 hour after doses for these first 3 doses. (R)-9bMS should be taken with a glass of water. Patients will be dispensed home supply after C1D2 morning dose.
223651285|NCT07042100|BIOLOGICAL|Dose level (DL)1|Administered IV every 3 weeks
223651286|NCT07042100|BIOLOGICAL|DL2|Administered IV every 3 weeks
223651287|NCT07042100|BIOLOGICAL|DL3|Administered IV every 3 weeks
223651288|NCT07042100|BIOLOGICAL|DL4|Administered IV every 3 weeks
223651289|NCT07042100|BIOLOGICAL|DL5|Administered IV every 3 weeks
223651290|NCT06721507|DRUG|tirzepatide|Participants will be educated on dietary and lifestyle changes. Participants will self inject 2.5 mg tirzepatide subcutaneously once weekly and maintain a drug administration diary. Dose escalation will proceed per package directions if instructed by study team at follow up visits.
224235637|NCT01946165|DRUG|Enzalutamide|160 mg by mouth daily for each 28 day cycle.
224235638|NCT01946165|DRUG|LHRHa|Patients receive a LHRHa (monthly injection or three-month injection) for a maximum of 7 months before a prostatectomy is performed. Study doctor will decide what hormone therapy patient receives.
224235639|NCT03978884|DRUG|Losartan 50Mg Tab|Take 1 tab daily
224235640|NCT03978884|DRUG|Losartan/Hydrochlorothiazide 50 Mg-12.5 Mg ORAL TABLET|Take 1 tab daily
223651291|NCT06721507|BEHAVIORAL|Standard of Care|Participants will be educated on dietary and lifestyle changes
223651292|NCT07038356|DRUG|Empagliflozin 10 MG Oral Tablet [Jardiance]|Randomized treatment with 10 mg empagliflozin (Jardiance, one tablet) daily from day 1 until the day of hospital discharge, but no longer than 30 days, followed by 10 mg empagliflozin (Jardiance, one tablet) daily until day 90
223651293|NCT07038356|DRUG|Placebo|Randomized treatment with placebo (one tablet) daily from day 1 until the day of hospital discharge, but no longer than 30 days, followed by 10 mg empagliflozin (Jardiance, one tablet) daily until day 90
223651294|NCT06369233|DEVICE|MegaShield®-SP|MegaShield®-SP application Lumbar discectomy or laminectomy
224235641|NCT03978884|DRUG|Losartan/Hydrochlorothiazide 100 Mg-25 Mg ORAL TABLET|Take 1 tab daily
224235642|NCT03978884|DRUG|Amlodipine 5mg|Take 1 tablet daily
224235643|NCT05226910|DEVICE|tDCS and intensive therapies|This intervention will consist in the combination of tDCS with CIMT (30 hours) and then with BIT (3 hours and 45 minutes)
224235644|NCT05226910|DEVICE|Sham and intensive therapies|This intervention will consist in the combination of sham tDCS with CIMT (30 hours) and then with BIT (3 hours and 45 minutes)
223651295|NCT06369233|DEVICE|Guardix-SP Plus|Guardix-SP Plus application Lumbar discectomy or laminectomy
223651296|NCT04962412|OTHER|"Standard care bundle"|"The management for AKI patients were performed by implementing a standard care bundle suggested by the Kidney Disease Improving Global Outcome (KDIGO) guideline."
223651297|NCT06887634|OTHER|Rebozo and Maternal Procedures|"Combination of FLI and side-lying release SLR and Rebozo technique in a pre-specified order:~1\) FLI for 30 seconds repeated for 3 subconsequent contractions; 2) SLR for 30 seconds repeated for 3 consequent contractions; 3) Rest with free maternal postures for 15 minutes; 4) 15 minutes of Rebozo on maternal pelvis (women on hands and knees); 5) Rest with free maternal postures for 15 minutes; 6) 15 minutes of Rebozo on the side of the fetal spine (supine women).~Duration of the intervention ranges between 90 and 105 minutes. The intervention will start within thirty minutes after randomization; it can be interrupted at any time if needed. It will be considered performed when the proposed sequence is completed. After completion of the sequence, women will be allowed to move freely and adopt different postures. No FLI or SLR procedures or the Rebozo technique will be further allowed until sonographic assessment of the fetal head is performed at 3 hour and thirty after randomization"
223651298|NCT06887634|OTHER|Control|Standard of care, including upright, semi-recumbent, lateral recumbent, and hands-and-knees position. They will not receive forward-leaning inversion (FLI) and side-lying release (SLR) and Rebozo technique. the control group will continue to adopt maternal postures with no possibility of performing the FLI or SLR procedures or the Rebozo technique until sonographic assessment of fetal head position is completed at 3 hours and thirty after randomization.
223651299|NCT07048041|OTHER|Functional Assessment Battery|Participants completed a series of validated patient-reported outcome questionnaires (Oxford Hip Score, WOMAC, SF-12) and physical performance tests (Timed Up and Go, Four Square Step Test, 4-Meter Gait Speed Test) during a single outpatient assessment session. No therapeutic or invasive interventions were performed.
223651300|NCT06053684|DEVICE|Standard Non-Invasive Mechanical Servo Ventilation|The active comparator arm will utilize a standard non-invasive mode to provide ventilation support
223651301|NCT06053684|DEVICE|Neurally-Adjusted Ventilatory Assistance (NAVA) Non-Invasive Mechanical Servo Ventilation|The experimental arm will utilize a NAVA mode to provide non-invasive ventilation support
223651302|NCT06727500|BEHAVIORAL|HIIT plus plyometric training|"The HIIT plus plyometric training will perform two weeks of exercise adaptation involving 25 minutes of MICT at 65% of maximal heart rate (HRmax) and 5 minutes of jumps in place at 5 - 6 of the EPinfant scale of Perceived exertion. The HIIT plus plyometric training will perform 15 minutes of HIIT and 5 minutes of jumps each session. The HIIT phase will be performed in a work recovery intensity at 85 and 50% of the HRmax. The work phase of jumps will be performed all out, and the recovery phase will be performed at 5 - 6 of the EPinfant scale of perceived exertion. The work: recovery bouts will be progressed from 1:4 (15 seconds: 60 seconds) at weeks 3-6, to 1:3 (15 seconds: 45 seconds) at weeks 7-9, and to 1:3 (15 seconds: 30 seconds) at weeks 10-12. In all sessions, the rate of perceived exertion, heart rate, and exercise planning compliance will be measured."
223651303|NCT06727500|BEHAVIORAL|HIIT|The HIIT group will perform two weeks of exercise adaptation involving 30 minutes of moderate-intensity continuous training (MICT) at 65% of the maximal heart rate (HRmax) reached in the maximal oxygen consumption test. The HIIT group will perform 20 minutes of HIIT each session, with a work: recovery intensity at 85% and 50% of HRmax, respectively. The work: recovery bouts will be progressed from 1:4 (15 seconds:60 seconds) at weeks 3-6, to 1:3 (15 seconds:45 seconds) at weeks 7-9, and to 1:2 (15 seconds: 30 seconds) at weeks 10-12. In all sessions, the rate of perceived exertion, heart rate, and exercise planning compliance will be measured.
223651304|NCT03516617|DRUG|Acalabrutinib|Given PO
223651305|NCT03516617|OTHER|Laboratory Biomarker Analysis|Correlative studies
223651306|NCT03516617|BIOLOGICAL|Obinutuzumab|Given IV
223651307|NCT03516617|OTHER|Patient Observation|Undergo observation
223651308|NCT03516617|OTHER|Quality-of-Life Assessment|Ancillary studies
223651309|NCT05603312|GENETIC|AAV-GAD Low Dose|Bilateral infusion of AAV-GAD low dose
223651310|NCT05603312|GENETIC|AAV-GAD High Dose|Bilateral infusion of AAV-GAD high dose
223651311|NCT05603312|PROCEDURE|Sham Surgery|Sham infusion
223651312|NCT05289947|OTHER|Placebo|Caramel, chocolate brown, flavor (E\_1982648), dextrin
223651313|NCT05289947|DRUG|MLC1501|Powdered extract of Radix astragali, Rhizoma chuanxiong, Radix angelica sinensis, Radix polygala
223651314|NCT06739941|OTHER|Oat fiber (BG-OS)|Beta-glucan oligosaccharide (BG-OS) is beta-glucan predominant, dietary fiber obtained by extracting oat fiber from oat grain and applying a food-grade depolymerization process to shorten the polysaccharide chain length of the fiber. BG-OS retains the fiber structure of oat fiber but has a shorter chain length, which makes it water soluble and easily formulated into any food.
223651315|NCT06743243|DRUG|Tegoprazan|Tegoprazan OD tab. 50 mg PO + Saline 20ml IV, one hour before general anesthesia.
223651316|NCT06743243|DRUG|Famotidine|Famotidine 20mg/10ml+saline 10ml IV + Tegoprazan OD tab. 50 mg placebo PO, one hour before general anesthesia.
223651317|NCT06743243|DRUG|Placebo|Tegoprazan OD tab. 50 mg placebo PO + Saline 20ml IV, one hour before general anesthesia.
223651318|NCT07053826|DEVICE|Penile Traction Device|Patients will be randomized into one of two groups: penile traction therapy 30 min 3x/day x 3 months, or control (no treatment). Preoperative erectile function surveys will be recorded in the EMR per standard of care. Following randomization, patients allocated to the treatment arm will be instructed how to use the device properly. Patients in the treatment arm will record a daily journal of use of the device (Appendix 1). After a minimum of 3 months, patients in the treatment arm will return for their scheduled procedure. Control arm patients will be scheduled directly for an OR date.
223651319|NCT07053826|PROCEDURE|Inflatable Penile Prosthesis Implantation|Implantation of a three-component inflatable penile prosthesis.
223651320|NCT05372354|DRUG|CC-92480|Specified dose on specified days
223651321|NCT05372354|DRUG|Tazemetostat|Specified dose on specified days
223651322|NCT05372354|DRUG|BMS-986158|Specified dose on specified days
223651323|NCT05372354|DRUG|Trametinib|Specified dose on specified days
223651324|NCT05372354|DRUG|Dexamethasone|Specified dose on specified days
223651325|NCT07055438|PROCEDURE|Ultrasound guided Rectus sheath block|After receiving general anesthesia, bilateral ultrasound guided rectus sheath block with 20 ml of 0.25% bupivacaine on each side will be administered to 20 patients undergoing upper abdominal surgeries namely whipple operation and total gastrectomy
224235645|NCT02177084|DEVICE|PTNS|
224235646|NCT03138070|DRUG|BYL719|BYL719 400 mg daily by mouth continue for 14 days
224235647|NCT01400113|DRUG|Asenapine|Asenapine Sublingual Tablet 10mg, single-dose
223651326|NCT07055438|PROCEDURE|ultrasound guided external oblique intercostal plane block|After receiving general anesthesia, bilateral ultrasound guided external oblique intercostal plane block with 20 ml of 0.25% bupivacaine on each side will be administered to 20 patients undergoing upper abdominal surgeries namely whipple operation and total gastrectomy
223651327|NCT07057791|DRUG|Ivonescimab 10 mg/kg|Induction every 21 days x 4 cycles: Ivonescimab 10 mg/kg intravenous (IV) on Day 1 followed by carboplatin area under the curve (AUC) 5 IV on Day 1 and etoposide 100 milligrams per square meter (mg/m²) IV on Day 1, 2 and 3 followed by maintenance ivonescimab 10 mg/kg every 21 days until progression, unacceptable toxicity or participant withdrawal.
223651328|NCT07057791|DRUG|Ivonescimab 20 mg/kg|Induction every 21 days x 4 cycles: Ivonescimab 20 mg/kg IV on Day 1 followed by carboplatin AUC 5 IV on Day 1 and etoposide 100 mg/m² IV on Day 1, 2 and 3 followed by maintenance ivonescimab 20 mg/kg every 21 days until progression, unacceptable toxicity or participant withdrawal.
223651329|NCT07051733|BEHAVIORAL|Health Information Literacy Enhancement|"Participants will undertake a six-week programme to enhance their health information literacy. The specific details are as follows:~1. Capacity Building on Health Information Management via Health Education Based on the Health Empowerment Theory: ① Strengthening skills related to Health Information Literacy; ② Training on Medication Management Skills; ③ Practice of Self-Monitoring Skills; ④ Education on Diet and Exercise Management Knowledge.~2. Health Behavior Motivation Management Based on the Health Empowerment Theory: ① Personalized Goal Setting; ② Behavioral Incentives and Feedback; ③ Construction of Peer Support Networks; ④ Demonstration Effect of Role Models.~3. Health Management Support System Based on the Health Empowerment Theory: ① Online Dynamic Monitoring; ② Family-Community Collaborative Support; ③ Digital Monitoring Platform; ④ Continuous Supply of Resources."
223651330|NCT07053059|DRUG|Obecabtagene autoleucel|given by Infusion
223651331|NCT06883305|BIOLOGICAL|Tezepelumab|Tezepelumab subcutaneous injection
224235648|NCT01400113|DRUG|Placebo|Placebo Sublingual Tablet, single-dose
224235649|NCT01127542|DRUG|Lenalidomide|Daily oral lenalidomide. Starting dose of 2.5mg daily, escalating to target dose of 10mg daily.
224235650|NCT00140257|DRUG|Escitalopram|
224235651|NCT01179919|DRUG|Oseltamivir|Capsule, 75 mg by mouth for 9 doses
224235652|NCT01586741|PROCEDURE|Quill suture application for repair or polypropylene mesh|The first arm may be insertion of the-mesh The second arm may double row- suture The third arm may be conservative -training
224235653|NCT04787302|DRUG|CVL-231|Cohort 1: 30mg dose of CVL-231
224235654|NCT04787302|DRUG|CVL-231|Cohort 2: CVL-231 dose to be decided based on results of Cohort 1 or trial may be concluded
224235655|NCT04787302|DRUG|CVL-231|Cohort 3: CVL-231 dose to be decided based on results of Cohorts 1 and/or 2
223651332|NCT06883305|OTHER|Placebo|Placebo subcutaneous injection
223651333|NCT05904028|DRUG|Intravitreal injections of 6 mg faricimab on a Treat and Extend schedule|Intravitreal injections of 6 mg faricimab on a Treat and Extend schedule
223651334|NCT05904028|DEVICE|Intravitreal injections of 6 mg faricimab on a home optical coherence tomography-guided treatment schedule|Intravitreal injections of 6 mg faricimab on a Home OCT-guided treatment schedule
223651336|NCT02415621|DRUG|Abiraterone Acetate|1000 mg by mouth (PO) every day (QD)
223651337|NCT06654245|BEHAVIORAL|Telephone based interview|Receive SHAREDCare navigator calls
223651338|NCT06654245|OTHER|Survey using a questionnaire.|Ancillary studies
223651339|NCT06654245|OTHER|Electronic health record review|Ancillary studies
223651340|NCT06654245|OTHER|Referral|Receive standard of care automated referrals
223651341|NCT06843772|OTHER|ergonomic training|will receive ergonomic training.
223651342|NCT06843772|OTHER|exercise|People who will receive an exercise program. Participants will receive ergonomic training along with the exercise program.
223651343|NCT06775301|DIAGNOSTIC_TEST|Hyfe Cough Monitoring System|Smartwatch-based cough monitoring
223651344|NCT07074301|BEHAVIORAL|Caregiver Training Program|The intervention consists of a two-month structured education program including two face-to-face sessions and a mobile application. The training content covers PEG care, stoma and tube management, enteral nutrition, drug administration via tube, and troubleshooting complications.
223651345|NCT07076849|DIETARY_SUPPLEMENT|Lactiplantibacillus plantarum 299v|Probiotic
223651346|NCT07076849|OTHER|Placebo Capsule(s)|Placebo control
223651347|NCT05016505|BEHAVIORAL|Reduction (relocation and reduction of personal smoking) and cessation|Individual-level. Peer educator to provide reduction/cessation and/or relocation support.
223651348|NCT05016505|BEHAVIORAL|Resident Endorsement|Building-level. Peer educator to conduct building-level sessions.
223651349|NCT06101797|OTHER|Remote supervised exercise group|The exercise protocol for this group consists of individualized muscle-strengthening exercises for the lower extremities supervised by video call. The intervention will occur 2-3 times per week, each lasting approximately 40 minutes. The exercise protocol will consist of six muscle-strengthening exercises for the lower extremities, which will be guided, alternating muscle groups. In the first two weeks of treatment, exercise intensity will be monitored for participants to complete two sets of 8-12 repetitions in dynamic exercises. From the third week onward, participants will progress to one additional set. Adjustments to weight-bearing, the external load imposed by the elastic band, and exercise position throughout the protocol will be performed to maintain the participant's level of effort. After supervised exercise treatment, patients will be encouraged to maintain an exercise routine with the same exercise protocol, however, without physiotherapy supervision.
224235656|NCT00003096|GENETIC|DNA ploidy analysis|
224235657|NCT00003096|GENETIC|comparative genomic hybridization|
224235658|NCT00003096|GENETIC|cytogenetic analysis|
224235659|NCT00003096|GENETIC|fluorescence in situ hybridization|
224235660|NCT00806156|DRUG|NKTR-102 q14d|NKTR-102 given on a q14 day schedule
224235661|NCT00806156|DRUG|NKTR-102 q21d|NKTR-102 given on a q21 day schedule
224235662|NCT00417690|DRUG|4-Aminosalicylic acid|Oral granules administered as one 4 g packet three times daily for two weeks followed by one 4 g packet two times daily for two weeks
224235663|NCT00417690|DRUG|PASER placebo granules|Oral granules administered administered as one packet three times daily for two weeks followed by one packet two times daily for two weeks
224235664|NCT05292742|DRUG|Pyrotinib+Trastuzumab+Capecitabine|Patients in the experimental arm will receive trastuzumab + pyrotinib + capecitabine
224235665|NCT05292742|DRUG|Trastuzumab+Pertuzumab/Trastuzumab|Trastuzumab: Initial loading dose of 8 mg/kg followed by 6 mg/kg every 3 weeks. One year of trastuzumab treatment (including: neoadjuvant phase and adjuvant phase) Pertuzumab: 840 mg loading dose followed by 420 mg fixed dose
224235666|NCT03186066|DEVICE|Flamingo Device|Endoscopic Treatment of Buried Bumper Syndrome with the Flamingo Device
224235667|NCT03186066|PROCEDURE|Standard Therapy|Endoscopic Treatment of Buried Bumper Syndrome with an endoscopic submucosal dissection knife
224235668|NCT05483322|DRUG|LAM-002A|25mg capsules
224235669|NCT02106065|BEHAVIORAL|Education and Skill-Building Rehabilitation (ESBR)|ESBR intervention consists of four, 90-minute sessions over a 4-6 week period. These four sessions are supplemented with booster sessions at 3 and 9 months post-intervention. Each group session (10 or fewer participants) is attended either in-clinic or via video telehealth technology within the VAPAHCS.
224235670|NCT02106065|OTHER|Supplemental Education Materials|Participants randomized to the Usual Care (UC) group will receive supplemental educational materials related to aging and dementia.
224320635|NCT03122080|DEVICE|Placebo acupuncture|Participants in the control A group will receive placebo acupuncture treatment with streitberger needles at the same acupoints as the electroacupuncture group. When the tip of the blunt needles touches to the skin, the patient will get a pricking sensation but there is no real needle inserted into the skin. The electroacupuncture apparatus will be set beside the patients, with no connection to the needles. Inform the patients when removing the needles after 30 minutes. Use the dry cotton ball to press the acupoints so that patients can feel the withdrawal of the 'needles'. Same health education and regular administration of antidepressants or sedative-hypnotics will be given to the participants during the intervention.
224320636|NCT03122080|OTHER|Standard care|Participants in the control B group will keep their standard medical care for the first 8 weeks. Participants will take their regular antidepressants and the sedative-hypnotics during the whole intervention period. Same health education will be conducted as well for the participants. And after waiting for two months, these patients will be treated with the same electroacupuncture treatment as the EA group.
224320637|NCT01894594|DRUG|Sodium Bicarbonate|"Oral sodium bicarbonate tablets administered at a starting dose of 0.6 mEQ/Kg body weight and will be escalated once, at 4 weeks, to 0.9 mEQ/Kg body weight.~Weekly schedule:~0-4 weeks: Serial Measurement at baseline, without therapy 4-8 weeks: \*\~0.6 mEq/kg of ideal body weight of Sodium Bicarbonate tablets divided into TID dosing 8-12 weeks: \*\~0.9 mEq/kg of ideal body weight of Sodium Bicarbonate tablets divided into TID dosing~\* to the closest dose of 650 mg (7.74 mEq)~Ideal Body Weight is defined by the following formulas (Devine Calculation):~Ideal Body Weight (men) = 50 + 2.3 (Height (in) - 60) Ideal Body Weight (women) = 45.5 + 2.3 ( Height (in) - 60)"
224320638|NCT01925300|DRUG|Concor 5mg(Bisoprolol hemifumarate 5mg) 2Tab|
224320639|NCT01925300|DRUG|Crestor 20mg(Rosuvastatin calcium 20.80mg) 1Tab|
224320640|NCT01925300|DRUG|Concor 5mg 2T and Crestor 20 mg 1Tab|
224320641|NCT00201409|DRUG|Placebo|Placebo will be administered by slow intravenous infusion once daily for 14 days.
224320642|NCT00201409|DRUG|GM-CSF|Recombinant human GM-CSF (250 mcg/M2) will be administered by slow intravenous infusion once daily for 14 days.
224320643|NCT02094911|BEHAVIORAL|Combined lifestyle intervention|"10-month intervention period with:~* weekly group-based sports lessons supervised by a physiotherapist~* individual dietary advice by a dietician~* case management by practice nurse~* maintenance programme to guide subjects to maintain lifestyle behaviour change"
223767128|NCT02694341|PROCEDURE|Abdominal traction stitch|Abdominal traction stitch to prevent prolapse of the Bakri balloon. A suture is tied through the uterine end shaft hole of the Bakri balloon. The other end of the suture is placed through the uterine wall. The balloon is positioned in the lower segment.The abdominal traction stitch is held by forceps and fixed, with cephalad traction applied continuously to the balloon, preventing balloon prolapse.The abdominal traction stitch is fixed by an umbilical cord clamp on the abdominal wall, preventing the suture from receding into the abdominal cavity, and, thus, maintaining the correct position of the balloon and preventing prolapse. Removal of the balloon is easy, with no resistance; the suture does not hinder balloon removal. At the time of balloon removal, the suture that was placed through the abdominal wall will traverse the intra-abdominal and intrauterine cavities, and should be kept clean.
224235671|NCT00479622|DRUG|TRU-015|Arm 1 = 800 mg Arm 2 = 2000 mg
224320644|NCT02094911|OTHER|Usual care group|Written information on healthy lifestyle was provided at baseline, no individual advice or programme was provided. No additional appointments were scheduled, apart from the visits for follow-up measurements
224320645|NCT00509795|BIOLOGICAL|ranibizumab|Participants received a 0.5mg dose of ranibizumab via intravitreal (IVT) injection every 4 weeks for the first year. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.
224320646|NCT00509795|BIOLOGICAL|aflibercept injection (VEGF Trap-Eye, BAY86-5321)|Participants received a 2.0mg dose of aflibercept injection every 4 weeks for the first year. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.
224320647|NCT00509795|BIOLOGICAL|aflibercept injection (VEGF Trap-Eye, BAY86-5321)|Participants received a 0.5mg dose of aflibercept injection every 4 weeks for the first year. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.
224320648|NCT00509795|BIOLOGICAL|aflibercept injection (VEGF Trap-Eye, BAY86-5321)|Participants received a 2.0mg dose of aflibercept injection every 8 weeks (including one additional 2.0 mg dose at Week 4) for the first year and were to receive sham injections at interim monthly visits. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.
224320649|NCT02391480|DRUG|ABBV-075|ABBV-075 Oral tablets
224320650|NCT02391480|DRUG|Venetoclax|Venetoclax tablets, film-coated
223651350|NCT06101797|OTHER|In-person supervised exercise group|The exercise protocol for this group consists of individualized muscle-strengthening exercises for the lower extremities supervised at a physiotherapy clinic. The intervention will occur 2-3 times per week, each lasting approximately 40 minutes. The exercise protocol will consist of six muscle-strengthening exercises for the lower extremities, which will be guided, alternating muscle groups. In the first two weeks of treatment, exercise intensity will be monitored for participants to complete two sets of 8-12 repetitions in dynamic exercises. From the third week onward, participants will progress to one additional set. Adjustments to weight-bearing, the external load imposed by the elastic band, and exercise position throughout the protocol will be performed to maintain the participant's level of effort. After supervised exercise treatment, patients will be encouraged to maintain an exercise routine with the same exercise protocol, however, without physiotherapy supervision.
223651351|NCT06904664|OTHER|Individualized temperature health risk early warning and risk factor management|Receive individualized temperature health risk warning and prevention risk factor management information for stroke through the application
223651352|NCT06904664|OTHER|Temperature health risk early warning|Receive individualized temperature health risk warning through the application
223651353|NCT06904664|OTHER|Risk factor management|Receive individualized prevention risk factor management information for stroke through the application
223651354|NCT04274530|BEHAVIORAL|Cognitive Behavioural Therapy|Participants who are randomized to the CBT intervention will be encouraged to begin CBT immediately following randomization. The CBT intervention will focus on addressing maladaptive beliefs related to pain and recovery as well as teaching skills to enhance coping and management of pain symptoms. The specific focus of CBT sessions will be informed by each individual patient's responses to baseline questionnaires. All other aspects of post-operative care will be at the discretion of participant's surgeon.
223651355|NCT02153229|RADIATION|Photodynamic Therapy|
223651356|NCT02153229|PROCEDURE|Radical Pleurectomy|
223651357|NCT02153229|RADIATION|Chemotherapy|
223651358|NCT02153229|DRUG|Photofrin 2.0 mg/kg|If randomized to the RP with PDT arm, subject will receive Photofrin 2.0 mg/kg as an intravenous infusion 24 hours (range 18-30 hours) prior to intra-operative light delivery (PDT) during radical pleurectectomy
223651359|NCT04806464|DRUG|Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell))|Intratumoral injection only. The dosing date can be the Day 1 only or Days 1 through 5.
223651360|NCT05411523|OTHER|Quality-of-Life Assessment|Complete quality of life assessment
223651361|NCT05411523|OTHER|Questionnaire Administration|Complete questionnaires
223651362|NCT05411523|PROCEDURE|Spinal Cord Stimulation|Receive spinal cord stimulation therapy
223651363|NCT07090213|OTHER|Survey using a questionnaire|Eighty women, determined by the number of questions times the rule of 10, will be asked to fill out the Pelvi-Perineal Surgery Sexuality Questionnaire - PPSSQ and Female Sexual Function Index (FSFI) questionnaires and will be asked to fill out the PPSSQ again 7 days later for test-retest reliability.
223651364|NCT07098143|OTHER|Risk factor management|Receive individualized prevention risk factor management information for stroke through the application
223651365|NCT06927635|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|SBRT will be delivered as per institutional standard.
223767129|NCT02694341|DEVICE|Bakri Balloon|uterine compression balloon
224235672|NCT00525590|DRUG|GLIADEL|Resect the tumor as completely as possible. After repeated irrigation of the decompressed area demonstrates no bleeding, and care is taken not to have any foreign material enter the ventricle, up to 8 GLIADEL wafers should be placed to cover the entire surface area of the resection cavity (if possible). Slight overlapping of wafer edges is permitted. The number of wafers will be determined by the size of the tumor resection cavity. Each GLIADEL wafer contains 7.7 mg of carmustine, resulting in a dose of 61.6 mg when 8 wafers are implanted. The GLIADEL wafer is a round white to yellow disk with flat surfaces.
224235673|NCT04111770|DEVICE|IVUS guided Percutaneous Coronary Intervention|Pre-procedural IVUS will be used to determine lesion characteristics and post-procedural IVUS to confirm correct implantation of stent.
224235674|NCT04111770|DEVICE|QCA guided Percutaneous Coronary Intervention|QCA will be used to determine lesion characteristics
224235675|NCT01025037|DEVICE|Conexa Reconstructive Tissue Matrix|Conexa will be placed as a soft tissue reinforcement in primary open or mini-open rotator cuff repair procedures
223651366|NCT06927635|OTHER|Systemic therapy|Participants will receive Systemic Therapy. Participants in Arm 1 - SOC may change the Systemic Therapy throughout treatment. Participants in Arm 2 - Experimental will remain on the same Systemic Therapy throughout treatment.
223651367|NCT06904326|OTHER|Postoperative dynamic radiography|Participants will perform a dynamic radiography 3 months after lumbar decompression surgery under UBE to study vertebral instability
223651368|NCT03995134|COMBINATION_PRODUCT|Propofol and Remifentanil administered by TCI pump|Propofol, Remifentanil, Alaris PK (pharmacokinetic) infusion pump with TCI
223767130|NCT00225706|DRUG|Caldolor|
223767131|NCT02160366|OTHER|Biomarker Research|Research studies on new biomarkers conducted on previously banked blood and/or tumor tissue. Samples collected may include blood, fresh tumor tissue, urine, saliva, bone marrow, pleural fluid, ascites, skin or hair follicle.
223767132|NCT03194048|OTHER|Functional Chewing Training|"FuCT;~* Family training~* Providing optimal sitting posture for children to support oral sensorimotor functions~* Positioning the food to the molar area during every meal to stimulate lateral and rotational tongue movements~* Massage of the upper and lower gums through the front teeth to molar area~* Chewing training to stimulate lateral and rotational tongue movements~* Gradually increasing the food consistency, for 12 weeks in 5 sets (1 set = 20 min) each day"
223767133|NCT03194048|OTHER|Classical Oral Motor Exercises|"Classical Oral Motor Exercises;~* Family training~* passive and active lip and tongue exercises, for 12 weeks in 5 sets (1 set = 20 min) each day"
223767134|NCT01251133|BIOLOGICAL|LBVH0101 (Hib vaccine)|0.5mL
223651369|NCT07100522|DEVICE|Hearing aid in spectacle frame form factor|"eyewear frames embedded with groundbreaking technology which seamlessly integrate an air conduction hearing aid (over-the-counter OTC, in the United States) intended to amplify sound for adult users (18yrs and older) with a perceived mild to moderate hearing impairment. Nuance Audio Glasses may, if necessary, be used in association with prescription lenses for those adults who also require correction of visual defects. Nuance Audio Glasses can be worn all day and can be easily configured via the App to adapt to any situation, from business meetings to family time."
223651370|NCT07100522|DEVICE|hearing aid|Hearing aid in spectacle frame form factor
223767135|NCT01251133|BIOLOGICAL|Hiberix™ Vaccine|0.5mL
223651371|NCT07100587|BEHAVIORAL|Ketogenic diet|A structured, equicaloric ketogenic diet providing approximately 1200 kcal/day, consisting of high fat (70-80 g/day), moderate protein (80-90 g/day), and very low carbohydrate intake (20-30 g/day), primarily from non-starchy vegetables. The diet is administered for 3 consecutive weeks to induce nutritional ketosis. A sugar-free multivitamin supplement is provided throughout the intervention.
223651372|NCT07100587|BEHAVIORAL|Mediterranean diet|A structured Mediterranean diet administered for 3 weeks following a 2-week transition phase. The diet provides approximately 1200 kcal/day and emphasizes plant-based foods, extra virgin olive oil as the main fat source, moderate consumption of fish, dairy products, and whole grains, with limited red meat and processed foods.
223651373|NCT07103382|DIETARY_SUPPLEMENT|Attapulgite|Participants were administered daily attapulgite (2.5 g) for a duration of 12 weeks.
223651374|NCT07103382|DIETARY_SUPPLEMENT|Placebo|Participants were administered daily maltodextrin (2.5 g) for a duration of 12 weeks.
224235676|NCT05278806|OTHER|Equity Dashboard, Population Health Coordinator and Community Health Worker Support|"Providers will be given access to an equity dashboard that displays their practice's performance on ambulatory quality metrics stratified by race and language.~Population health coordinators (PHCs) will lead equity huddles with providers to review list of patients who are not at goal for their hypertension control and meet the inclusion criteria. Providers will formulate a follow up plan for each patient that the PHCs will help implement. For example, PHCs may contact patient via the online patient portal or phone to obtain recent home blood pressure readings, facilitate scheduling of follow up visits, etc.~In addition, patients may be referred to the community health worker (CHW) hypertension management program. Patients will work with the CHW for 3-6 months. During this time the CHW will focus their efforts on patient education/coaching, remote blood pressure monitoring, addressing psychosocial and socioeconomic barriers to care and care coordination."
223651375|NCT04695977|DRUG|CMP-001|Subjects will receive CMP-001 10 mg IT weekly for 7 doses after which CMP-001 will be administered every 3 weeks (Q3W).
223767136|NCT02443376|DEVICE|Complior Analyse System|Pulse Wave Velocity PWV and central Pressure analysis
224320651|NCT05151783|OTHER|conventional physiotherapy|"Control group receivewill routine physical therapy including modalities like ultrasound (3 MHz continuous type; duration 10 minutes), heat modalities (apply to the involved region of shoulder joint shoulder for 10 minutes), shoulder ROM exercises, capsular stretching, and joint mobilization 5 times per week for four weeks. Duration of session will be 40 minutes.~All Maitland mobilization will be given in supine position. After giving glenohumeral (GH) joint distraction, GH caudal glide, GH dorsal glide, and GH ventral glide were given at a rate of 2-3/second oscillations for 1-2 minutes to patients. Grade I or II rhythmic oscillations will be applied in pain free movement."
224320652|NCT05151783|OTHER|PNF technique|Group will receive scapular PNF techniques with routine physical therapy explained above For PNF techniques, patients will be lying on unaffected shoulder. In this group, 20 repetitions of diagonal scapular Pattern (Anterior Elevation and Posterior Depression and Posterior Elevation and Anterior Depression) with 20 sec rest period will be given to patients. Preparatory instructions for the desired movement will be given to patients at the start of procedure. PNF facilitation techniques of RI (Rhythmic initiation) \& repeated contractions will be used in all patterns
224320653|NCT00463697|DRUG|GW642444H (100mcg)|H salt
224320654|NCT00463697|DRUG|placebo|placebo
224320655|NCT00463697|DRUG|GW642444M (25, 100 & 400 mcg)|M salt
223767137|NCT02443376|DEVICE|BCM- Body Composition Monitor|"BCM - Body Composition Monitor gives information about:~Overhydration Urea distribution volume (V) Total body water, extracellular and intracellular water Lean Tissue Index (LTI) Fat Tissue Index (FTI) Body Cell Mass (BCM)"
224320656|NCT04842292|DRUG|Heparin|Nebulized heparin 25,000 units every 6 hours
224320657|NCT04842292|DRUG|Placebo|Sodium chloride 0.9% every 6 hours
223651376|NCT04695977|DRUG|Nivolumab|Nivolumab 360 mg IV is administered Q3W.
223651377|NCT05756855|BEHAVIORAL|adapted behavioral intervention|cognitive behavioral therapy based intervention that focuses on anger, violence, and psychosis
223651378|NCT06882317|OTHER|Long Term Follow-Up|No intervention is administered on this study. Subjects who have received CLBR001 autologous CAR-T cells in a primary Calibr treatment trial will be followed long term in line with FDA guidance.
223651379|NCT07145255|DRUG|ADC|MBRC-201 ADC
223767138|NCT05236309|DRUG|Jing-Guan-Fang(JGF) : Chinese herbal decoction|Use 100ml JGF decoction per day as a preventive measure for patients with COVID-19.
223767139|NCT02548013|OTHER|outpatient management|patients if stable will be discharged to continue treatment at home
223767140|NCT02548013|OTHER|Inpatient management|patients will continue there treatment in hospital till delivery
223767141|NCT06153108|DEVICE|PAMSys pendant PAMSys wrist sensors|The PAMSysTM sensor consists of a 3-axis accelerometer, battery, and built-in memory for recording long-term data. Accelerometer data is recorded at a sampling frequency of 50 Hz
223767142|NCT04206111|PROCEDURE|Preoxygenation|preoxygenation with high flow nasal cannula at 40l/min for 5min
223767143|NCT02940691|DRUG|Grazoprevir/elbasvir|Grazoprevir/elbasvir (100mg/50mg) once daily for 12 weeks.
223767144|NCT02142452|BEHAVIORAL|behavioral intervention|Behavioral intervention will include a group class for women in their 3rd trimester followed by a mobile texting program to support behavior change postpartum.
224320658|NCT00234962|DRUG|Lopinavir/Ritonavir|
223767145|NCT02142452|OTHER|Usual Prenatal Care|
223767146|NCT06014255|DRUG|Enoblituzumab|Enoblituzumab 15mg/kg IV (in the vein) every 2 weeks for 12 weeks prior to radical prostatectomy on day 84.
223767147|NCT06014255|OTHER|Standard of Care|Radical prostatectomy within 4-8 weeks of randomization.
224235677|NCT05278806|OTHER|Equity Dashboard and Population Health Coordinator Support|"Providers will be given access to an equity dashboard that displays their practice's performance on ambulatory quality metrics stratified by race and language.~In addition, population health coordinators (PHCs) will lead disparities focused huddles with providers. During the huddle, they will review list of patients who are not at goal for their hypertension control and meet the inclusion criteria. Providers will then formulate a follow up plan for each patient that the Population Health Coordinators will help implement. For example, PHCs may contact patient via the online patient portal or phone to obtain recent home blood pressure readings, facilitate scheduling of follow up visits, etc."
224235678|NCT00622609|DRUG|GSK249320A|GSK249320A intravenous infusion will be formulated as 100 milligrams/milliliters in 2 milliliters vials (filled to 1 milliliter), in phosphate buffer and delivered by a syringe and programmable pump.
224235679|NCT00622609|DRUG|Placebo|Sodium chloride intravenous infusion will be given as matching placebo.
223651380|NCT07145034|DRUG|Prosman|Prosman, the study drug is prepared from the gummy extract (pygeum) from the Indian plum tree Prunus domestica and is available in various dosage forms. Originally, pygeum, was obtained from the African prune tree bark (Prunus africanum) and was used for the treatment of various urinary problems.
223651381|NCT07145034|OTHER|Placebo|Placebo matched to the Prosman
223651382|NCT07145502|BIOLOGICAL|Allogeneic MSC infusions (IV)|Optional T-reg therapy (experimental/compassionate-use basis)
223767148|NCT06086184|BEHAVIORAL|ACT group therapy|"Participation in four sessions of the inpatient Compass Group and eight sessions of the inpatient Here-and-Now Group. This should be completed within four weeks and may be completed within six weeks in exceptional cases. The groups are designed as a semi-open group with one therapist and one cotherapist each and are integrated into the existing therapy plan."
224235680|NCT00414297|DEVICE|ECP Therapy|application of ECP Therapy to CAD Patients
223767149|NCT02866877|OTHER|Pharmacokinetic modeling|Timed blood draws and urine collections to model drug clearance
224235681|NCT05105698|DRUG|gemigliptin and dapagliflozin 50/10 mg film-coated tablet (Fasting)|Subjects will check-in a night before investigational product administration, supervised for at least 8 hours overnight fasting prior to dosing and in-house stay until 24 hours post-dose.(fasting)
224235682|NCT05105698|DRUG|gemigliptin and dapagliflozin 50/10 mg film-coated tablet (fed)|Subjects will check-in a night before investigational product administration, supervised for at least 8 hours overnight fasting prior to dosing and in-house stay until 24 hours post-dose.(fed)
224235683|NCT00337571|DRUG|Aripiprazole|Tablets, Oral, once daily, 8 weeks
224235684|NCT00337571|DRUG|Placebo|Tablets, Oral, once daily, 8 weeks
224235685|NCT03934073|OTHER|DEXTRAIN|12 sessions of 1 hour of rehabilitation (3 sessions / 4 weeks) for the DexTrain group will consist of 20 minutes of conventional training followed by 40 minutes of exercises using the DexTrain targeting the dexterity components.
224235686|NCT03934073|OTHER|CONVENTIONNELLE|12 sessions of 1 hour of rehabilitation (3 sessions / 4 weeks) Conventional will be constituted of conventional training consisting of stretching of the spastic muscles as well as exercises used classically in the protocols of rehabilitation post-stroke
224235687|NCT03934073|OTHER|CONTROLE|Only one assessment will be provided for the control group which will include, Box \& Blocks Test (BBT), FFM Dexterity Assessment, Moberg Pick-Up Test (MPUT), Maximal Finger Tapping Rate, Proprioception, SMT, fMRI, Spontaneous hand activity (accelerometry / portable electromyography)
224235688|NCT04078451|PROCEDURE|preserve the main cystic artery|The experimental group preserve the main cystic artery, and the control group cut off the main cystic artery
224235689|NCT03856970|DRUG|Microgestin®|30 μg/1500 μg tablets for oral administration
224235690|NCT03856970|DRUG|Levothyroxine|600 μg tablets for oral administration
224235691|NCT03856970|DRUG|Glyburide|5 mg tablets for oral administration
224235692|NCT03856970|DRUG|Digoxin|0.25 mg tablets for oral administration
224235693|NCT03856970|DRUG|IW-3718|500-mg film-coated tablets for oral administration
224235694|NCT02895529|DRUG|Itraconazole|Participants will receive 200 milligram (mg) of itraconazole intravenously (IV) twice daily on Day 1 and Day 2, followed by 200 mg once daily through Day 14. From Day 15 to Day 28, participants will receive 200 mg (20 milliliters \[mL\]) of itraconazole oral solution orally twice daily. Participants, who are not suitable for oral administration of itraconazole based on the investigator's judgment, will receive 200 mg of itaconazole IV once daily from Day 15 to Day 28.
224235695|NCT02895529|DRUG|Caspofungin|Participants will receive 70 mg of caspofungin IV once daily on Day 1 followed by 50 mg IV infusion once daily thereafter through Day 28.
224235696|NCT04191564|PROCEDURE|low perfusion state|reduce SAP below 100 mmHg
224235697|NCT04191564|PROCEDURE|normal perfusion state|maintain SAP above 100 mmHg
224235698|NCT05815069|DIAGNOSTIC_TEST|[18F]AlF-NOTA-pentixather PET/CT|The radiotracer 18F-AlF-NOTA-pentixather PET/CT (dose 4.81 MBq/Kg body weight) was injected intravenously according to the patient's body weight. The whole-body PET/CT examination from the top of the skull to the root of the thigh was performed using a PET/CT examination instrument (Siemens Biograph mCT Flow) 50-60 minutes after the injection of radiopharmaceuticals. Flow Motion flow scanning technology with a matrix of 128x128 and a layer thickness of 3 mm was used. all PET images were iteratively reconstructed. Patients who have undergone surgery routinely undergo pathological examination.
223651383|NCT07139795|BEHAVIORAL|Mindful eating and movement|Group mindful eating sessions will be conducted once per week, one hour per session, for eight weeks. Participants will be encouraged to attend at least two, 45-minute yoga sessions per week.
223651384|NCT07144033|DIETARY_SUPPLEMENT|Butyrate and Taurine|This dose of butyrate is chosen to maximize any treatment effect in postoperative pain. Butyrate was reported to be safe at this dose for a prolonged period of 8 weeks. The dose of taurine is considered safe according to the European Food Safety Authority and was used in previous human perioperative trials. A human pharmacokinetic study showed that after taking 4g taurine (32 mmol) orally, plasma taurine levels reached a peak level of 86 mg/L (or 0.7 mmol/L) at 1.5 hours, exceeding the physiological plasma taurine level (0.01-0.1 mmol/L), which is needed to exert its pharmacological benefits.
223651385|NCT07144033|OTHER|Placebo|indistinguishable placebo capsules will be administered orally after enrolment on the day before surgery, followed by daily administration for three months after surgery.
223651386|NCT07142668|BEHAVIORAL|Harm Reduction Tax - Normal Nicotine Cigarettes Available|In the Harm Reduction Tax Condition, tobacco products in the Experimental Tobacco Marketplace are placed into three tax tiers: high-, medium-, and no-tax. All combustible products with high abuse liability are placed in the high-tax tier. All non-combustible products or combustible products with low abuse liability are placed in the medium-tax tier. Nicotine Replacement Therapy products are placed in the no-tax tier. The participant's preferred normal-nicotine content cigarettes are available in the marketplace. Participants complete two trials with all products offered at market price, and five trials with prices for each product increasing proportionally to tax tier.
223651387|NCT07142668|BEHAVIORAL|Harm Reduction Tax - Normal Nicotine Cigarettes Not Available|In the Harm Reduction Tax Condition, tobacco products in the Experimental Tobacco Marketplace are placed into three tax tiers: high-, medium-, and no-tax. All combustible products with high abuse liability are placed in the high-tax tier. All non-combustible products or combustible products with low abuse liability are placed in the medium-tax tier. Nicotine Replacement Therapy products are placed in the no-tax tier. The participant's preferred normal-nicotine content cigarettes are NOT available in the marketplace. Participants complete two trials with all products offered at market price, and five trials with prices for each product increasing proportionally to tax tier.
223651388|NCT07142668|BEHAVIORAL|Modified Risk Tobacco Product Tax - Normal Nicotine Cigarettes Available|In the Modified Risk Tobacco Products tax condition, tobacco products in the Experimental Tobacco Marketplace are placed into three tax tiers: high-, medium-, and no-tax. In this condition, all non-MRTP tobacco products are placed in the high-tax tier, MRTPs are placed in the medium-tax tier, and Nicotine Replacement Therapy products are placed in the no-tax tier. The participant's preferred normal-nicotine content cigarettes are available in the marketplace. Participants complete two trials with all products offered at market price, and five trials with prices for each product increasing proportionally to tax tier.
223651389|NCT07142668|BEHAVIORAL|Modified Risk Tobacco Product Tax - Normal Nicotine Cigarettes Not Available|In the Modified Risk Tobacco Products tax condition, tobacco products in the Experimental Tobacco Marketplace are placed into three tax tiers: high-, medium-, and no-tax. In this condition, all non-MRTP tobacco products are placed in the high-tax tier, MRTPs are placed in the medium-tax tier, and Nicotine Replacement Therapy products are placed in the no-tax tier. The participant's preferred normal-nicotine content cigarettes are NOT available in the marketplace. Participants complete two trials with all products offered at market price, and five trials with prices for each product increasing proportionally to tax tier.
223651390|NCT07142668|BEHAVIORAL|Nicotine Content Tax - Normal Nicotine Cigarettes Available|In the Nicotine-Content Tax Condition, products in the Experimental Tobacco Marketplace are placed into three tax tiers: high-, medium-, and no-tax. In this condition, products with greater than 3 mg nicotine per single unit are placed in the high-tax tier, products with 0.6-3.0 mg/unit in the medium-tax tier, and those with 0.5 mg/unit or less in the no-tax tier. The participant's preferred normal-nicotine content cigarettes are available in the marketplace. Participants complete two trials with all products offered at market price, and five trials with prices for each product increasing proportionally to tax tier.
223651391|NCT07142668|BEHAVIORAL|Nicotine Content Tax - Normal Nicotine Cigarettes Not Available|In the Nicotine-Content Tax Condition, products in the Experimental Tobacco Marketplace are placed into three tax tiers: high-, medium-, and no-tax. In this condition, products with greater than 3 mg nicotine per single unit are placed in the high-tax tier, products with 0.6-3.0 mg/unit in the medium-tax tier, and those with 0.5 mg/unit or less in the no-tax tier. The participant's preferred normal-nicotine content cigarettes are NOT available in the marketplace. Participants complete two trials with all products offered at market price, and five trials with prices for each product increasing proportionally to tax tier.
223651392|NCT07142668|BEHAVIORAL|Tobacco Parity Tax - Normal Nicotine Cigarettes Available|In the Tobacco Parity Tax condition, tobacco products in the Experimental Tobacco Marketplace are placed into three tax tiers: high-, medium-, and no-tax. In this condition, all tobacco products are placed in the high-tax tier while products that do not contain tobacco (e.g., herbal cigarettes and nicotine-free ENDS) are placed in the medium-tax tier. Nicotine Replacement Therapy products are placed in the no-tax tier. The participant's preferred normal-nicotine content cigarettes are available in the marketplace. Participants complete two trials with all products offered at market price, and five trials with prices for each product increasing proportionally to tax tier.
224235699|NCT02806921|DEVICE|ZenLens|The ZenLens™ semi-scleral lenses are manufactured by Alden Optic Laboratories Inc., Lancaster, NY. They will be made in Boston XO material.
224235700|NCT05528016|PROCEDURE|Upper Eyelid Blepharoplasty|Blepharoplasty is a procedure that the skin, orbicularis oculi muscle, and fat pads are excised to treat visual field loss caused by dermatochalasis.
224235701|NCT00861445|DRUG|SPM927/Lacosamide|SPM927 (film-coated tablets, 25/50/100mg per tablet), dosage 400mg/day, intake in the morning and in the evening, intake for 10 weeks
224235702|NCT00861445|OTHER|Placebo|Placebo tablets two times a day for 10 weeks
224235703|NCT05043233|DRUG|Methimazole(MMI)|Methimazole is a widely used antithyroid drug and is often used in the treatment of Graves' disease hyperthyroidism
224235704|NCT02386033|DRUG|Atorvastatin (ATV)|After SRP, ATV gel was delivered subgingivally into the pocket
224235705|NCT02386033|DRUG|Placebo Gel|After SRP, placebo gel was delivered subgingivally into the pocket
224235706|NCT00927147|RADIATION|BNCT|Boronophenylalanine infusion followed by neutron irradiation
224235707|NCT00927147|DRUG|cetuximab|cetuximab infusion 250 to 400 mg/kg intravenously, 1 to 3 infusions
224235708|NCT00756288|PROCEDURE|Topical retinoid and blue-light therapy with photosensitizing agent|Topical Retinoid - Apply to AKs for 4 weeks Photo-therapy with photosensitizing agent- Apply to AKs at week 4
224235709|NCT00756288|PROCEDURE|Photodynamic Therapy (PDT)|Photo-therapy with sensitizing agent - apply to AKs at week 4
224235710|NCT03361371|DEVICE|Battery operated nasal aspirator|Suctioning prior to every feed with battery operated nasal aspirator for three days in addition to the routine standard of care.
224235711|NCT03361371|DEVICE|Suction bulb|Suctioning prior to every feed with bulb nasal aspirator for three days in addition to the routine standard of care.
224320659|NCT03859765|BEHAVIORAL|HCT Symptoms and Steps|HCT Symptoms and Steps will provide patients with cognitive behavioral coping skills training and activity coaching sessions to enhance their ability to manage symptoms that interfere with activity.
224320660|NCT05212389|DRUG|Femicept|150 μg levonorgestrel +30 μg ethinylestradiol
223651393|NCT07142668|BEHAVIORAL|Tobacco Parity Tax - Normal Nicotine Cigarettes Not Available|In the Tobacco Parity Tax condition, tobacco products in the Experimental Tobacco Marketplace are placed into three tax tiers: high-, medium-, and no-tax. In this condition, all tobacco products are placed in the high-tax tier while products that do not contain tobacco (e.g., herbal cigarettes and nicotine-free ENDS) are placed in the medium-tax tier. Nicotine Replacement Therapy products are placed in the no-tax tier. The participant's preferred normal-nicotine content cigarettes are NOT available in the marketplace. Participants complete two trials with all products offered at market price, and five trials with prices for each product increasing proportionally to tax tier.
223767150|NCT02718638|OTHER|physical exercises|Physical exercises were performed during HD sessions, at second hour of HD, three times per week for 3 months. The first exercise was knee extension from 90° to 0°. The patient remained in the 0° position for 5 seconds (an isometric contraction) and then returned to the starting position (90º). 2) The second exercise consisted of a triple flexion followed by extension of the lower limbs. The patient flexed the thigh, knee and ankle (elastic band placed at the level of the metacarpals) followed by a double extension of the thigh and knee. 3) In a co-isometric contraction, the patient performed a leg extension against the ankle-cuff resistance (located under the distal third of the leg at the level of the malleolus) for 10 seconds. 4) The patient performed a unilateral hip joint flexion of the lower limb with the knee extended by rising to their functional limit.
223767151|NCT00001996|DRUG|Atovaquone|
223767152|NCT00001996|DRUG|Pentamidine isethionate|
223767153|NCT01045226|PROCEDURE|Proton Beam Radiation Therapy|Proton Beam Radiation Therapy
223767154|NCT01045226|OTHER|Quality-of-Life assessment|Quality of Life Assessment
223767155|NCT01045226|OTHER|Questionnaire Administration|Questionnaire Administration
223767156|NCT06131515|DEVICE|extra corporeal shock wave therapy device|"Patients were seated in a relaxed position with their forearm and finger placed on the table. The median nerve was identified at the pisiform level of the proximal carpal tunnel, with the palm facing upwards. rESWT was delivered with the Physio Shock Wave Therapy system .The rESWT probe was located and oriented perpendicularly on the median nerve, and treatment comprised graduated shots at a bar pressure of 4 and a pulse repetition frequency of 5Hz for each patient ( The treated area was parallel to the median nerve from the pisiform level to 2 cm proximal to the inlet of the carpal tunnel with equal diffusion of 800, 900, 1000, 1100 shots from first to fourth session respectively. The procedure was painless, and there was no need for additional anesthesia or analgesia.~In the control group, sham rESWT just made the same sound without energy emission"
223767157|NCT01440309|BIOLOGICAL|Biological: mesenchymal stem cell|Mesenchymal stem cells,5-50 million/kg, Intravenous infusion, One dosage，whether to give another dosage depending on patients' condition
223767158|NCT01440309|DRUG|ursodeoxycholic acid|13-15 mg/kg/day, to the end of the study
223767159|NCT03712475|DRUG|Pregabalin|pharmacokinetic study under fasting conditions
223767160|NCT02210585|OTHER|Rehabilitation|"12 weeks : 5 sessions per week (1 supervised session at home every month)~92 weeks : spontaneous training (supervised by phone every month)"
223767161|NCT00164450|DRUG|Rifapentine + isoniazid once weekly for 3 months|
223651394|NCT07144215|DRUG|Dexmedetomidine 3 mcg|Patient received spinal injection of dexmedetomidine 3 mcg.
223767162|NCT03082794|DIETARY_SUPPLEMENT|NCD|Negative Calorie Diet
223767163|NCT03082794|DIETARY_SUPPLEMENT|LCD|Low Calorie Diet
223767164|NCT01464320|DRUG|ABT-614|Active
223767165|NCT01464320|DRUG|Placebo Comparator|Placebo
223767166|NCT03912233|DRUG|VX-121|Tablets for oral administration.
223767167|NCT03912233|DRUG|TEZ|TEZ tablet for oral administration.
223767168|NCT03912233|DRUG|VX-561|Tablets for oral administration.
223767169|NCT03912233|DRUG|TEZ/IVA|Fixed-dose combination tablets for oral administration.
223767170|NCT03912233|DRUG|IVA|Tablets for oral administration.
223767171|NCT03912233|DRUG|Placebo|Placebos matched to VX-121, TEZ, and VX-561 for oral administration.
223767172|NCT04135638|PROCEDURE|Cover Group|"Cover when the ILM flap is everted over the MH gap in a single layer"
223767173|NCT04135638|PROCEDURE|Fill Group|"Fill when the ILM is folded into multiple layers within the MH"
223767174|NCT03996200|DEVICE|MINIject CS627 implant|"MINI SO627 is an integrated system comprising a minimally-invasive Glaucoma Drainage Implant (CS627) and a single operator delivery tool.~The delivery tool is a single-use tool, designed for inserting the CS627 implant into the suprachoroidal space in the eye."
223767175|NCT00370526|PROCEDURE|Acute hemodynamic assessment using PV Loops (CD Leycom, The Netherlands) during LV lead placement|
223651395|NCT07144215|DRUG|Dexmedetomidine 4 mcg|Patient received spinal injection of dexmedetomidine 4 mcg.
223651396|NCT07144215|DRUG|Dexmedetomidine 5 mcg|Patient received spinal injection of dexmedetomidine 5 mcg.
223651397|NCT07144215|DRUG|Dexmedetomidine 6 mcg|Patient received spinal injection of dexmedetomidine 6 mcg.
223651398|NCT07144215|DRUG|Bupivacain hyperbaric 0.5% 12.5 mg|Patient received spinal injection of Bupivacain hyperbaric 0.5% 12.5 mg
223767176|NCT01646697|OTHER|cytology specimen collection procedure|Undergo cytopathologic sample collection
223767177|NCT06211816|OTHER|communication strategy|an intensive communication strategy on end-of-life practice was implemented, based on a framework developed by the International Delphi Conference.
223767178|NCT00654628|DRUG|ezetimibe (+) simvastatin|Vytorin 10/20 (ezetimibe 10 mg /simvastatin20 mg) tablet once daily consecutively for 6 weeks.
223767179|NCT03392636|PROCEDURE|Herniotomy|In Mitchell Banks Herniotomy, one of investigators will do herniotomy without opening inguinal canal and in Ferguson Gross Herniotomy , one of investigators will do herniotmy by opening inguinal canal.
223767180|NCT06390475|DIAGNOSTIC_TEST|MR Direct Thrombus Imaging (MRDTI)|Both groups will get the same MRDTI, the study is a proof-of-concept study to investigate if MRDTI can reliable distinguish between acute and chronic splanchnic thrombosis.
223767181|NCT01873989|DRUG|Testosterone replacement|
223767182|NCT01873989|OTHER|Waitlist control|
223767183|NCT00494494|DRUG|Standard Care|topical antibiotic for 10 days plus topical corticosteroids for 1 month
224320661|NCT05212389|DRUG|Placebo|Placebo
224320662|NCT05289973|DEVICE|TruNatomy Files|Newly introduced endodontic file with high flexibility.
224320663|NCT05289973|DEVICE|HyFlex EDM Files|Endodontic files
224235712|NCT02114697|DRUG|Statin therapy|Statin therapy includes rosuvastatin 20 mg administered orally, once a day, for the duration of the trial, which is 3 years. Participants may also receive a different type of statin as prescribed by their cardiologist based on clinical judgement.
224320664|NCT00409448|BEHAVIORAL|Counselor-assisted problem solving (CAPS)|In CAPS, a trained counselor will guide families through a 6-month structured online problem-solving and skill-building program via one-on-one videoconference sessions.
224320665|NCT00409448|BEHAVIORAL|Internet-resource comparison (IRC)|Families in the IRC group will receive computers, high speed internet access, and links to brain injury information and resources, but not the CAPS website content.
224320666|NCT03889080|DIAGNOSTIC_TEST|functional MRI|functional MRI scan of the brain
224320667|NCT01467986|DRUG|Dasatinib|Pharmacotherapeutic Group: protein kinase inhibitor ATC-Code: L01XE06 Excipients: Tablet core: Lactose monohydrate, Cellulose, microcrystalline, Croscarmellose sodium, Hydroxypropyl cellulose, Magnesium stearate. Film-coating: Hypromellose, Titanium dioxide, Macrogol 400 Formulation: film coated tablet Route of Administration: orally. Patients should be instructed to swallow the tablets as a whole and not to split, chew, or crush them.
224320668|NCT01467986|DRUG|Rapamycin|Pharmacotherapeutic Group: Immunosuppressive agents - mTOR Inhibitors ATC-Code: L04A A10 Excipients: Polysorbat 80, Phosal 50 PG ((3-sn-Phosphatidyl)cholin from Soy beans, Propylenglycol, lipid acid mono- and -diglyzeride from Soy oil, Ethanol (1,5% bis 2,5%), Soy liid acid and Palmitoyl ascorbic acid) Formulation: Oral solution Route of Administration:orally
224320669|NCT01467986|DRUG|Irinotecan|Pharmacotherapeutic Group: cytostatic topoisomerase-I-inhibitor ATC-Code: L01XX19 Excipients: Sorbitol (E420), lactic acid, sodium hydroxid (to adjust the pH to 3.5), water for injection Formulation: concentrate for solution for infusion Route of Administration: intravenously
223651399|NCT07144748|OTHER|68Ga-NYM096 PET/CT|Participants will be administered a single, intravenous bolus of 68Ga-NYM096 The recommended administered activity of 68Ga-NYM096 is 1.8-2.2 MBq per kilogram bodyweight, subject to variation that may be required owing to variable elution efficiencies obtained during the lifetime of the 68Ga / 68Ga generator. The CT and PET imaging session will begin approximately 45 to 75 minutes after 68Ga-NYM096 administration.
223651400|NCT07146958|OTHER|Chia seeds|Chia seeds will be added to soup and bread recipes.
224235713|NCT02114697|BEHAVIORAL|Lifestyle modification|Lifestyle modification includes a recommended exercise regimen, a healthy diet and decreasing alcohol intake for 3 years.
224235714|NCT05329805|BEHAVIORAL|job crafting intervention|the participated nurses will receive session about job crafting followed by activity related to job crafting
223651401|NCT07146958|OTHER|Hemp seeds|Hemp seeds will be added to soup and bread recipes.
223651402|NCT07146958|OTHER|Placebo|The placebo will be food items that are not enriched with the intervention products.
223651403|NCT07148934|DIAGNOSTIC_TEST|Smartphone seismographic recording and Bed Based Ballistocardiographic recordings|A short recording of heart rhythm using a smartphone and bed-based ballistocardiogram.
224235715|NCT02632877|DRUG|Pirfenidone with MODD|Patients with diabetic foot ulcer will be treated three times a day with a smooth layer (standar finger tip unit 0.5g for an area of 100 to 120 square centimeters) of KitosCell Q (Pirfenidone with MODD) in form of gel and the wound will be covered with a bandage.
223651404|NCT06947785|OTHER|Combined Neural Mobilization with Manual myofascial Release|Combined neural mobilization with manual myofascial release will be provided to each subject.
223651405|NCT06947785|OTHER|Neural Mobilization|neural mobilization will be provided to each subject.
224235716|NCT02632877|DRUG|Ketanserin|Patients will be administered ketanserin twice a day usign the standar finger tip unit (0.5g for an area of 100 to 120 square centimeters) and the wound will be covered with a bandage. This arm is a control for evolution of diabetic foot ulcer.
224320670|NCT01467986|DRUG|Temozolomide|"Pharmacotherapeutic Group: Antineoplastic agents - Other alkylating agents, ATC-Code: L01A X03 Excipients: Capsule content: Anhydrous lactose, Sodium starch glycolate Type A, Colloida anhydrous silica, Tartaric acid, Stearic acid. Capsule shell: Gelatine, Titanium dioxide (E171).~Printing ink: Shellac Propylene glycol, Titanium dioxide (E171), Sunset yellow FCF Aluminium Lake (E110) Formulation: capsule, hard Route of Administration: orally; Temomedac hard capsules should be administered in the fasting state. The capsules must be swallowed whole with a glass of water and must not be opened or chewed"
224320671|NCT01467986|DRUG|Irinotecan|Pharmacotherapeutic Group: cytostatic topoisomerase-I-inhibitor ATC-Code: L01XX19 Excipients: Sorbitol (E420), lactic acid, sodium hydroxid (to adjust the pH to 3.5), water for injection Formulation: concentrate for solution for infusion Route of Administration: intravenously
223651406|NCT06947785|OTHER|Manual Myofascial Release|Manual myofascial release will be provided to each subject.
223651407|NCT07142044|DRUG|EC5026 oral tablet|Oral soluble epoxide hydrolase inhibitor
223651408|NCT07142044|DRUG|Placebo|Matching oral placebo
223651409|NCT07145710|DIETARY_SUPPLEMENT|Whole wheat muffin|Participants received Whole wheat muffin once a day
223651410|NCT07145710|DIETARY_SUPPLEMENT|Whole wheat muffin enriched with raw banana flour (RBF) (contains 17.5g RBF)|Participants received Whole wheat muffin enriched with raw banana flour (RBF) (contains 17.5g RBF)
223651411|NCT07145710|DIETARY_SUPPLEMENT|Whole wheat muffin enriched with raw banana flour (RBF) (contains 20g RBF)|Participants received Whole wheat muffin enriched with raw banana flour (RBF) (contains 20g RBF)
223651412|NCT07147296|PROCEDURE|ARC-IM System Implantation|Implantation of the ARC-IM Thoracic Lead in the epidural space and ARC-IM Neurostimulator
223651413|NCT07147296|DEVICE|ARC-IM Therapy (active)|The ARC-IM System is programmed since day 0 to deliver active electrical spinal cord stimulation at the low thoracic level for the management of symptomatic blood pressure instability in people with chronic spinal cord injury
223651414|NCT07147296|DEVICE|ARC-IM Therapy (sham)|The ARC-IM System is programmed at month 3 to deliver active electrical spinal cord stimulation (after 3 months of sham stimulation) at the low thoracic level for the management of symptomatic blood pressure instability in people with chronic spinal cord injury
223651415|NCT00387985|DRUG|MOA-728|
224235717|NCT05362448|DEVICE|Frequency|First, we will calculate for each patient and each frequency the amplitude therapeutic window (difference between therapeutic and side effect threshold). We will determine an optimal amplitude for each frequency that we will apply in the second part of the study.
224235718|NCT00991848|DRUG|Lidocaine|received 240 mg lidocaine diluted in 125 mL 0.9% saline.
224235719|NCT01286038|DRUG|Eltrombopag|In Stage 1 the best dose of eltrombopag will be found to take into Stage 2, which will treat 15 participants at this dose.
224235720|NCT00890019|BIOLOGICAL|AdCh63 ME-TRAP|"1. A:Intradermal injection 1x10\^8 vp at day 0~2. A:Intradermal injection 1x10\^9 vp at day 0~3. A:Intradermal injection 1x10\^10 vp at day 0~4. A:Intradermal injection 5x10\^10 vp at day 0~5:Intramuscular injection 1x10\^10 vp at day 0~6A:Intramuscular injection 5x10\^10 vp at day 0~7A: Intramuscular injection 2x10\^11 vp at day 0"
224235721|NCT00890019|BIOLOGICAL|AdCh63 ME-TRAP; MVA ME-TRAP|"1. B: AdCh63 ME-TRAP intradermally at dose of 1x10\^8 vp at day 0; MVA ME-TRAP intradermally at dose of 2x10\^8 pfu at day 56 (+/- 7 days)~2. B: AdCh63 ME-TRAP intradermally at dose of 1x10\^9 vp at day 0; MVA ME-TRAP intradermally at dose of 2x10\^8 pfu at day 56 (+/- 7 days)~3. B: AdCh63 ME-TRAP intradermally at dose of 1x10\^10 vp at day 0; MVA ME-TRAP intradermally at dose of 2x10\^8 pfu at day 56 (+/- 7 days)~4. B: AdCh63 ME-TRAP intradermally at dose of 5x10\^10 vp at day 0; MVA ME-TRAP intradermally at dose of 2x10\^8 pfu at day 56 (+/- 7 days)~6B: AdCh63 ME-TRAP intramuscularly at dose of 5x10\^10 vp at day 0; MVA ME-TRAP intradermally at dose of 2x10\^8 pfu at day 56 (+/- 7 days)~7B and 7C: AdCh63 ME-TRAP intramuscularly at dose of 2x10\^11 vp at day 0; MVA ME-TRAP intradermally at dose of 2x10\^8 pfu at day 56 (+/- 7 days)"
224235722|NCT04344418|DEVICE|Nurse-performed Focused cardiac ultrasound (FoCUS)|A FoCUS-trained nurse will perform a FoCUS examination within 30 minutes of triage by the triage clinician. The Philips Lumify® handheld ultrasound device (HUD) with a phased array probe will be used and studies limited to a maximum of 10 minutes each. A presumptive diagnosis will then be selected by the nurse from a FoCUS checklist based on pre-defined thresholds for each FoCUS target condition and the time the diagnosis is made recorded. Additional imaging and lab tests may be requested at the discretion of the clinical team but the FoCUS nurses will be blinded to the results of these.
224235723|NCT04344418|OTHER|Usual care|The control arm will consist of usual care ie a combination of physical examination, lab tests and imaging. The need for a formal echocardiographic evaluation by a cardiologist or cardiac sonographer in patients assigned to the control arm will be at the discretion of the clinical teams, as is usual care at KNH and AKUHN
224235724|NCT01952249|DRUG|Demcizumab|administered intravenously
224235725|NCT01952249|DRUG|Taxol|administered intravenously
224235726|NCT04897802|DRUG|Experimental: GLP1-RA (exenatide) administration|a single dose of 10 mcg of GLP-RA (exenatide) will be administered subcutaneously and samples to assess OT secretory patterns will be collected over 2 hours
224235727|NCT04897802|DRUG|Control: Placebo administration|Sodium Chloride 0.9% will be administered subcutaneously at equivalent volume than 10 mcg of exenatide
224235728|NCT00006864|BIOLOGICAL|aldesleukin|
224235729|NCT05842538|DEVICE|Triathlon|Total knee arthroplasty
224235730|NCT04662892|DRUG|Pegfilgrastim-Cbqv|Date, Dose, and cycle for subjects who received Udenyca will be recorded. Other FN prophylaxis such as Neulasta, or other pegfilgrastim biosimilars will be collected.
224235731|NCT05981625|OTHER|Giomer varnish containing surface pre-reacted glass fillers|"Giomer varnish (PRG barrier coat) will used as the intervention agent in this study. , Giomer is considered as a hybrid material between the resins modified glass ionomers and the composite resins. It is composed of 45% Sio2, 24.5% Na2O, 24.5% Ca O and 6% P2O5~. The presence of sodium is very important due to its bioactivity while the phosphate is responsible for the degree of degradation and formation of apatite. Based on this composition, giomer has several clinical applications in implant, periodontics, bone generation, pulp capping, Root canal treatment, as restorative materials, in air abrasion, enamel remineralization and finally dentin hypersensitivity"
223651416|NCT07146763|BEHAVIORAL|Prescribing Feedback|Automated prescribing feedback messages are delivered to clinician prescribers in participating emergency departments. Messages are based on Geriatric Emergency Medication Safety Recommendations (GEMS-Rx) recommendations and include aspirational norms and benchmark comparisons. Depending on study arm, feedback is sent either from a credible peer messenger or through an anonymous messenger system.
223651417|NCT07150455|OTHER|Echocardiographic Assessment (2D Speckle Tracking)|All participants will undergo standardized 2D echocardiographic examination including Global Longitudinal Strain (GLS) measurement. No drug or device intervention is applied.
223651418|NCT07154875|PROCEDURE|Assisted Hatching|Laser-assisted zona drilling performed either on Day-3 or Day-5 of culture, depending on randomization arm.
223651419|NCT07158333|DEVICE|Mobile Cardiac Telemetry (MCT System)|MCT System without data transmission
223651420|NCT07157072|OTHER|Corrective rigid taping|Rigid taping used to correct pelvic torsion in patients with CAI
223651421|NCT07157059|BEHAVIORAL|Doula Care|Participants assigned to the Doula care group received care from the doula pre, during, and post delivery.
224235732|NCT05478148|DEVICE|Gingival thickness|After the classification the phenotype, gingival thickness was measured with Endodontic File and Modified Florida Probe from the 3 different points. First point was the probing depth level, second one was 1mm apical to this level and third one from the 2mm apical to probing depth.
224235733|NCT00414401|BEHAVIORAL|Clinical Reminder|
224235734|NCT00717457|DRUG|exenatide|5mg twice daily for 4 weeks followed by 10mg twice daily
224235735|NCT00717457|DRUG|taspoglutide|10mg once weekly
224235736|NCT00717457|DRUG|taspoglutide|10mg once weekly for 4 weeks followed by 20mg once weekly
224235737|NCT00469625|DRUG|paricalcitol (initial dose 1 mcg orally per day)|
224235738|NCT05438797|DRUG|Adoptive TIL-TCM transfer therapy|Abraxane:100-200 mg/m2，QD×1D;Cyclophosphamide:15-35 mg/kg/d，QD×2D. Biological: Adoptive TIL-TCM transfer therapy
224235739|NCT01825109|BIOLOGICAL|Rotavirus Vaccine & Breastfeeding|Administration of Rotarix at 6 and 10 weeks co-administered with oral polio virus vaccine with no intervention in normal breastfeeding practices before and after receiving vaccine.
224235740|NCT01825109|BIOLOGICAL|Rotavirus Vaccine & Breastfeeding|Administration of Rotarix at 6 and 10 weeks co-administered with oral polio virus. Breastfeeding will not be permitted 45 minutes prior to vaccine administration and 45 minutes after each vaccine administration.
223651422|NCT07157891|BIOLOGICAL|MSC-Derived Secretome|The secretome will be collected from cultured MSCs under sterile, GMP-compliant conditions and concentrated to retain bioactive molecules. It will be injected into the affected knee under ultrasound guidance.
223767184|NCT00494494|DRUG|nepafenac|liquid drops, administered three times per day for 1 month in addition to standard care use of topical antibiotic and topical corticosteroid
223767185|NCT06382623|PROCEDURE|The percutaneous A1 pulley release|Ultrasound-guided percutaneous pulley release is a procedure aimed at loosening the pulley using various cutting instruments or hypodermic needles under ultrasound guidance.
223767186|NCT06382623|OTHER|The peritendinous Betamethasone group|USG-guided injection of corticosteroid between the A1 pulley and the flexor tendon sheath.
223767187|NCT00226603|BEHAVIORAL|Specific training programme (behavior)|
223767188|NCT03595371|DRUG|dapansutrile|500 mg dapansutrile administered twice daily (with a potential to increase the dosage to 2 g dapansutrile daily) for a duration of up to 14 consecutive days.
223767189|NCT01997086|PROCEDURE|Percutaneous transforaminal endoscopic discectomy (PTED)|Percutaneous transforaminal endoscopic discectomy
223767190|NCT01997086|PROCEDURE|Microendoscopic discectomy (MED)|Microendoscopic discectomy
224235741|NCT01825109|BIOLOGICAL|Rotavirus Vaccine & Breastfeeding|Administration of Rotarix at 14 and 18 weeks co-administered with oral polio virus, with no intervention in normal breastfeeding practices before and after receiving vaccine.
224235742|NCT01825109|BIOLOGICAL|Rotavirus Vaccine & Breastfeeding|Administration of Rotarix at 14 and 18 weeks co-administered with oral polio virus. Breastfeeding will not be permitted 45 minutes prior to vaccine administration and 45 minutes after each vaccine administration.
224235743|NCT02471469|DRUG|Enzalutamide, 160mg, 40 mg soft capsules, once daily|Exclusively determine pharmacokinetics and pharmacodynamics of enzalutamide for the indication according to the drug label
224235744|NCT02060006|DRUG|Meloxicam 7.5mg daily for 8 weeks|Meloxicam 7.5mg daily for 8 weeks
224235745|NCT05561400|DEVICE|tDCS|5x5 saline-soaked sponge electrodes will be used with the cathode placed over the right cerebellar hemisphere; 1cm under and 4cm lateral of the inion targeting lobule VII and the anode will be placed on the right shoulder. The electrode placement will be the same across both conditions.
224235746|NCT05561400|OTHER|Placebo|sham tDCS to the right cerebellum
224235747|NCT04085770|DRUG|Alfacalcidol 1 MCG Oral Capsule|2 mcg of oral Bone Care© soft gelatin capsules once daily with food starting from the day of admission till the end of hospital stay
224235748|NCT00079170|DIETARY_SUPPLEMENT|garlic|
224235749|NCT00079170|DRUG|docetaxel|
224235750|NCT04670432|DRUG|Hydroxyethylrutoside|500 mg film-coated tablet
224235751|NCT03732170|DEVICE|TotalFill® Bioceramic sealer|The participant will be treated with TotalFill® Bioceramic sealer.
224235752|NCT03732170|DEVICE|AH plus® sealer|The participant will be treated with AH plus® sealer.
224235753|NCT02714309|DIETARY_SUPPLEMENT|Whey protein|20 g whey protein isolate (Arla Foods Ingredients Group) added to 200ml water and served as a beverage
223767191|NCT00211471|DRUG|anecortave acetate|
224235754|NCT02714309|OTHER|Mixed macronutrient breakfast meal|A standardised mixed-macronutrient breakfast served to all participants. The macronutrient distribution of the breakfast is 13% protein, 70% carbohydrate, 17% fat (1958 kilojoules (kJ); 468 kcal total)
224235755|NCT02714309|OTHER|Ad libitum lunch meal|A mixed-macronutrient lunch served to all participants ad libitum. The macronutrient distribution of the lunch is 14% protein, 51% carbohydrate, 35% fat
224235756|NCT02714309|OTHER|Low/moderate intensity exercise|A 30 minute bout of treadmill walking is performed on a motorised treadmill at a low/moderate intensity (55% estimated VO2max)
224235757|NCT02521207|DRUG|Ibuprofen|
224235758|NCT05458609|DRUG|Lemborexant 10 mg|10 mg of Lemborexant
224235759|NCT05458609|DRUG|Naltrexone|50 mg of Naltrexone
224235760|NCT00593281|DRUG|Hylenex|Add Hylenex to SC injection of Morphine
223767192|NCT00953329|DRUG|alefacept|Alefacept 15 mg IM once a week were to be administered for 12 weeks, which is the FDA approved dosage, duration, and frequency. This study allowed an additional 8 doses if subject did not achieve a 'clear' response with the original 12 weeks of treatment. Each enrolled subject must have failed a response to anti-TNF therapy prior to entering this study.
223767193|NCT05649163|DRUG|Disitamab Vedotin|Cohort 1: received a regimen containing Disitamab Vedotin. Cohort 2: received an investigator-selected regimen in addition to Disitamab Vedotin; Treatment options selected by the investigator: no treatment containing Disitamab Vedotin was given, and other systemic antitumor agents (including chemotherapy, such as paclitaxel, docetaxel, irinotecan, and fluorouracil) were selected by the investigator in line with clinical practice. Targeted therapy: such as apatinib, ramucirumab; Combination therapy: ramucirumab + paclitaxel; Immune checkpoint inhibitors such as PD1/PD-L1); Cohort 3: receiving a regimen containing Disitamab Vedotin.
223767194|NCT00184340|DEVICE|eTherapy|secured e-mail system between patient and therapist
223767195|NCT02652533|DEVICE|Ultrasound Shear Wave Elastography|The investigators have recently published a very small study in neonates/infants with suspected BA showing that US liver shear wave speed (i.e. - liver stiffness) can differentiate BA from other causes of cholestasis, potentially with a very high degree of accuracy. Additional research is needed to confirm these very preliminary results and determine if liver shear wave speed measurements either before or after (including longitudinally) Kasai can predict key outcomes.
224235761|NCT04108325|DRUG|YY-20394|Each treatment cycle is comprised of 28-day consecutive of YY-20394, 80mg QD (days 1 to 28). Upon completion of each cycle, patients may continue to receive oral YY-20394 tablets if there are benefit from the treatment and the toxicity is tolerable.
224235762|NCT00345410|DRUG|AVE1625 B|
224235763|NCT05028842|OTHER|No intervention|None.This is an observational study
224235764|NCT01634906|DRUG|Temporary discontinuation of statin therapy|All statins, e.g. atorvastatin, simvastatin, fluvastatin, rosuvastatin, pravastatin
224235765|NCT01632709|DRUG|Bupivacaine|one injection of 10ml of .25%
224235766|NCT01632709|DRUG|Placebo|Dry needling
224235767|NCT04884893|DRUG|Nitrous Oxide|50% nitrous oxide
224235768|NCT04555928|OTHER|No intervention|This is a prospective cohort (survey) study. It has no intervention.
224235769|NCT06149936|DEVICE|excimer light|Excimer laser using high-dose monochromatic UV radiation
224235770|NCT03783208|DRUG|G-CSF|Slow infusion of G-CSF into the endometrial cavity using a soft embryo transfer catheter.
224235771|NCT03783208|OTHER|Saline|Slow infusion of saline into the endometrial cavity using a soft embryo transfer catheter.
224235772|NCT01969357|DRUG|Placebo|Tablets(n=4),once daily for 84 days
224235773|NCT01969357|DRUG|50 mg SP2086|Tablets(n=1),50mg strength+tablets(n=3) 0 mg once daily for 84 days
224235774|NCT01969357|DRUG|100 mg SP2086|Tablets(n=1),100 mg strength+tablets(n=3) once 0 mg daily for 84 days
224235775|NCT01969357|DRUG|200 mg SP2086|Tablets(n=2),100 mg strength+tablets(n=2) 0mg once daily for 84 days
223651423|NCT07157891|BIOLOGICAL|MSC-Derived Secretome + Autologous PRGF|MSC-derived secretome will be collected from mesenchymal stem cell cultures under sterile, GMP-compliant conditions. Autologous PRP will be prepared from the participant's own peripheral blood using a standardized single-spin centrifugation method and combined with 10% calcium chloride to activate growth factors. Both components will be mixed and administered into the affected joint under ultrasound guidance.
224320672|NCT01467986|DRUG|Temozolomide|"Pharmacotherapeutic Group: Antineoplastic agents - Other alkylating agents, ATC-Code: L01A X03 Excipients: Capsule content: Anhydrous lactose, Sodium starch glycolate Type A, Colloida anhydrous silica, Tartaric acid, Stearic acid. Capsule shell: Gelatine, Titanium dioxide (E171).~Printing ink: Shellac Propylene glycol, Titanium dioxide (E171), Sunset yellow FCF Aluminium Lake (E110) Formulation: capsule, hard Route of Administration: orally; Temomedac hard capsules should be administered in the fasting state. The capsules must be swallowed whole with a glass of water and must not be opened or chewed"
223651424|NCT07156487|DEVICE|Digital Anesthesia with SleeperOne 5|For both maxillary and mandibular teeth, 1.7 mL of Ultracaine D-S Fort carpule (4% articaine with 1:200,000 epinephrine) was administered in two stages (gingival and intraosseous injection) using a computer-controlled intraosseous anesthesia system with a 30-gauge, 9 mm Effitec needle.
223651425|NCT07156487|DEVICE|Infiltration Anesthesia with a Metal Cartridge Syringe|For maxillary teeth, buccal infiltration is performed using a metal carpule syringe and a 30G, 16 mm Effitec needle (Dental Hi Tec, France); after aspiration, Ultracaine D-S Fort is slowly injected over 1 minute.
223651426|NCT07156487|DEVICE|Mandibular Block Anesthesia with a Metal Cartridge Syringe|For mandibular teeth, the injection site is dried, and a 27G, 35 mm Effitec needle (Dental Hi Tec, France) is inserted between the pterygomandibular raphe and internal oblique ridge, aligned with contralateral molars. After aspiration, Ultracaine D-S Fort is slowly injected over 1 minute using a traditional metal carpule syringe, following the standard mandibular block technique.
223651427|NCT07157124|OTHER|Dynamic Visual Noise (DVN)|DVN is a brief visual array of patterns of flickering black and white dots. In alignment with prior literature, the DVN array will consist of an 80 x 80 grid of 4 x 4 black and white pixel squares that will change at a rate of 640 frames per second. The DVN will be 30 seconds in duration, though participants will be able to keep watching for as long as desired by restarting the video of the array.
223651428|NCT07157124|OTHER|Static Visual Noise (SVN)|SVN is similar to DVN, but refers to a static (or still) image of an array of black and white squares. The SVN will consist of an 80 x 80 grid of 4 x 4 black and white pixel squares. SVN has been used in previous working memory-loading studies as a control for DVN. Similar to the DVN, participants in the control group will view the SVN for at least 30 seconds (but they will be able to keep viewing it for as long as desired).
223651429|NCT07156162|OTHER|Videos: Taste vs Health|Participants in this intervention will watch taste and health focused messaging videos to determine which version is better suited to improve herb and spice usage to improve diet quality in American adults.
223651430|NCT07156162|OTHER|Health vs. Taste|Participants in this intervention will watch health and taste focused messaging videos to determine which version is better suited to improve herb and spice usage to improve diet quality in American adults.
223651431|NCT07157826|DEVICE|Guided Imagery Application|"Guided Imagery Intervention:~Scenario-based guided imagery, one of the guided imagery techniques, will be utilized. The scenario will be developed with input from experts to promote functional recovery. Expert opinions will be obtained from a psychologist and a psychiatric nurse. The scenario will begin with breathing exercises and continue with the safe place technique. Patients will be instructed to listen to the audio recording using headphones in an environment free from disturbances, to set their phones to airplane mode, and to inform their relatives not to interrupt them before starting the session. Headphones will be provided by the researcher for each patient. After the content of the audio recordings is created during the initial session, it will be recorded via phone and transferred as a file to the patients' phones, with instructions on how to use it. The audio recording will last approximately 15 to 20 minutes and will include relaxing, soft background music."
223651432|NCT07157436|OTHER|Non-interventional study|observational study. non-interventional
223651433|NCT07157657|BIOLOGICAL|Surgical implantation with standard (DRM) or photosynthetic dermal regeneration matrices (PDRM) in same patient.|Under sterile conditions and appropriate anesthesia, standard dermal regeneration matrices (DRMs) and photosynthetic dermal regeneration matrices (PDRMs), containing live photosynthetic microalgae, are implanted in separate wound areas or in anatomically distinct wounds on the same patient. Each site is then covered with a transparent adhesive dressing. In the experimental (PDRM) area, a light-emitting dressing is applied to stimulate photosynthesis and promote localized oxygen production.
223651434|NCT07157657|PROCEDURE|Autologous split-thickness skin grafting over implanted matrices|Approximately 21 days after the initial intervention, and once the wound bed meets predefined grafting criteria based on clinical evaluation, an autologous dermo-epidermal skin graft is performed.
223651435|NCT07156214|OTHER|Assessment of markers of oxidative stress in peripheral blood samples|Participants will perform serial blood samples at interval of 12 months to compare levels of markers of oxidative stress
223767196|NCT05666401|PROCEDURE|follicle diameter and duration of procedure|to investigate if smaller follicles thrive embryos as the bigger follicles
223767197|NCT04453384|DRUG|XAV-19|Phase 2a: Administration on Day 1 and day 5 for Group1 and 2, Administration on Day 1 for Group 3 Phase 2b: Administration on Day 1
224235776|NCT01969357|DRUG|100 mg Sitagliptin|Tablets(n=1),100 mg strength+tablets(n=3),0 mg strength once daily for 84 days
224235777|NCT02045121|DEVICE|Indwelling Pleural Catheter|
224235778|NCT02045121|PROCEDURE|Talc Pleurodesis|
224235779|NCT01767064|OTHER|Posted commitment letter|
224320673|NCT04275986|PROCEDURE|Intensity modulated radiotherapy (IMRT)|Intensity-modulated radiation therapy (IMRT) with a total dose of 45Gy in 25 fractions
224320674|NCT04275986|DRUG|Chemotherapy|Nedaplatin 25 mg/m2 and Paclitaxel liposome 45mg/m2, day 1, every week, 5 weeks
224320675|NCT02458859|DEVICE|PICO (single use portable negative pressure wound therapy)|Single use portable negative pressure wound therapy
224320676|NCT00685776|DRUG|anacetrapib|Participants will receive one tablet of anacetrapib 100 mg once daily for 76 weeks.
223651436|NCT07156968|DRUG|Bupivacaine-fentanyl|A peripheral intravenous (IV) catheter will be inserted, and a 7 mL kg-1 crystalloid infusion will be initiated. The patients will be premedicated with 0.03 mg kg-1 midazolam IV. Heart rate and peripheral oxygen saturation (SpO2) will be monitored continuously; systolic, diastolic, and mean arterial pressure (MAP) will be measured noninvasively at 5 min intervals during the procedure and at 15 min intervals during the post anesthesia care unit (PACU) stay. The baseline values will be recorded. Nasal oxygen 2 L min-1 will be administered during the whole procedure
223651437|NCT07156747|OTHER|Visual Analog Scale|The Visual Analog Scale (VAS) is a linear instrument employed to measure perceived pain intensity, spanning from 0 (indicating no pain) to 10 (representing the most severe pain), where patients indicate the level that most accurately represents their experience.
223651438|NCT07156747|OTHER|State-Trait Anxiety Inventory|The STAI is a self-administered questionnaire with two parts: STAI-1 measures state anxiety, representing a transient emotional state triggered by a particular circumstance, while STAI-2 examines trait anxiety, denoting a consistent predisposition to experience anxiety across diverse situations.
223651439|NCT07156747|OTHER|Video|watching video on Digital Platfrom (for example, Youtube)
223651440|NCT07156747|OTHER|Image|Prostate biopsy information with images
223651441|NCT07156877|PROCEDURE|Pulsed Field Ablation (PFA) with VOLT Catheter|Participants in this arm will undergo pulmonary vein isolation (PVI) using the VOLT catheter, a novel single-shot ablation device that delivers pulsed field energy (a non-thermal ablation method). The catheter features a balloon-in-basket design and enables electro-anatomical mapping. The procedure is performed under conscious sedation or general anesthesia and follows standard PVI protocols adapted for the PFA technology.
223651442|NCT07156877|PROCEDURE|Thermal Ablation (Radiofrequency or Cryoablation)|"Participants in this arm will receive PVI using established thermal ablation techniques, either:~* Radiofrequency ablation, a point-by-point technique using heat delivered through a catheter tip guided by mapping systems, or~* Cryoballoon ablation, which uses freezing energy delivered via a balloon catheter.~The choice between RF and cryoablation is at the discretion of the treating physician, in line with standard care."
223651443|NCT07157371|OTHER|Supervised structured aerobic exercise training|Supervised structured aerobic exercise plan will be conducted in gym by the physiotherapist
223651444|NCT07157371|OTHER|Walk|Females with PCOS will be instructed to do a walk at home with medications
223651445|NCT07156617|PROCEDURE|Interventional therapy|Interventional therapy
223651446|NCT07156617|DRUG|Systemic therapy|Targeted Therapy drugs include but are not limited to Lenvatinib, Apatinib, etc. Immunotherapy drugs include but are not limited to Camrelizumab, Tislelizumab
223651447|NCT07157345|DRUG|PDR001|This drug was packaged into AAV9 capsids and delivered via bilateral stereotaxic injection into the subthalamic nucleus
223651448|NCT07156656|PROCEDURE|Conventional treatment|Beside the using of Sivelestat Sodium or placebo, all postoperative care will adhere to each center's standard protocols for type A aortic dissection.
224235780|NCT05941221|PROCEDURE|pericapsular nerve group (PENG) block|patients will receive PENG block through ultrasound. The regional block was performed with the patient in the supine position. A curvilinear low-frequency ultrasound probe (2-5MHz) was initially placed in a transverse plane over the AIIS and then aligned with the pubic ramus by rotating the probe counterclockwise approximately 45 degrees. In this view, the IPE, the iliopsoas muscle and tendon, the femoral artery, and pectineus muscle were observed . A 22-gauge, 80-mm needle was inserted from lateral to medial in an in-plane approach to place the tip in the musculofascial plane between the psoas tendon anteriorly and the pubic ramus posteriorly. Following negative aspiration, the local anesthetic solution was injected in 5-mL increments while observing for adequate fluid spread in this plane for a total volume of 20 mL bupivacaine 0.25%.
224235781|NCT01856088|DEVICE|Inspiron Stent|stent implantation
224235782|NCT01856088|DEVICE|Biomatrix Flex Stent|stent implantation
224320677|NCT00685776|DRUG|Comparator: placebo|Participants will receive one placebo tablet once daily for 76 weeks.
224320678|NCT00482586|OTHER|medical chart review|Review the medical charts of patients with hepatic neoplasms who undergo Image-guided Therapy.
224320679|NCT00482586|OTHER|questionnaire administration|Patients with hepatic neoplasms who undergo Image-guided Therapy
223651449|NCT07156656|DRUG|Sivelestat sodium|The daily dose (4.8 mg/kg) is diluted in 48 mL of 0.9 % saline and administered as a continuous intravenous infusion over 24 hours at 2 mL/h (equivalent to 0.2 mg/kg/h) for 72 consecutive hours.
223651450|NCT07156656|DRUG|Placebo|An equal volume of placebo-containing only the excipients of sivelestat sodium and diluted to 48 mL with 0.9 % saline-will be infused at 2 mL/h for 72 consecutive hours.
223651451|NCT07157462|DIETARY_SUPPLEMENT|Multi-species probiotic powder for oral solution. Dietary supplement containing six bacterial strains (Lactobacillus and Bifidobacterium species)|The probiotic powder is provided in sachets. The Participants dissolve the powder in water and ingest twice daily for 12 weeks.
224320680|NCT00482586|PROCEDURE|quality-of-life assessment|Patients with hepatic neoplasms who undergo Image-guided Therapy
223651452|NCT07157462|DIETARY_SUPPLEMENT|Placebo Powder for Oral Solution|The placebo powder is provided in sachets. The Participants dissolve the powder in water and ingest twice daily for 12 weeks.
223651453|NCT07157033|DRUG|XER-001|XER-001 (Amifostine for nasoduodenal delivery)
223651454|NCT07156682|DRUG|QL1706|neoadjuvant administered at a dose of 5 mg/kg, intravenous infusion, every three weeks (Q3W), on day 1 of each cycle, 4 cycles
223651455|NCT07156682|DRUG|XELOX|Oxaliplatin 130 mg/m² by intravenous infusion on Day 1; Capecitabine 850-1000 mg/m² orally twice daily (morning and evening) from Day 1 to Day 14; 4 Cycles in total.
223651456|NCT07158138|OTHER|Digital yoga intervention|Digital yoga intervention
223651457|NCT07156604|DRUG|Vebreltinib Enteric Capsules|treated with Vebreltinib (200 mg bid po) for 8 weeks before surgery.
223651458|NCT07156227|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
223651459|NCT07156227|DRUG|Camonsertib|Given PO
223651460|NCT07156227|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
223651461|NCT07156227|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
223651462|NCT07156227|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
223651463|NCT07158177|DEVICE|Acrysof™ PanOptix™ toric or not, trifocal IOL CE marked, Alcon company.|both of the patient's eyes will be implanted: 1 CPO and the other APO
223651464|NCT07158177|DEVICE|Clareon Panoptix|both of the patient's eyes will be implanted: 1 CPO and the other APO
223767198|NCT04453384|DRUG|Placebo|Phase 2a: Administration on Day 1 and day 5 for Group1 and 2, Administration on Day 1 for Group 3 Phase 2b: Administration on Day 1
223767199|NCT02880566|PROCEDURE|Scalp block|Full scalp block
223767200|NCT01639170|RADIATION|chest radiograph|"All enrolled patients underwent erect chest x-rays assessment. In all cases the diagnosis of pneumoperitoneum was based upon the plain film identification of subdiaphragmatic air on the upright posteroanterior chest radiograph.~All patients were transported from their hospital rooms to the radiology department in wheelchairs and remained in an upright position for more than 10 min before the chest radiographs were obtained. In all cases upright posteroanterior was obtained with the patient standing, using 183-cm distance, 125 kVp, phototimed exposure, and radiographic film with a wide exposure latitude.~The disappearance of intraabdominal free gas will be evaluated every 48h and will be defined as the loss of the"
223767201|NCT00622427|DRUG|Ramelteon|8 mg tablets every night for 2 weeks
223767202|NCT00622427|DRUG|Placebo|placebo tablets for every night for 2 weeks
223767203|NCT01403207|OTHER|musculoskeletal|Many musculoskeletal conditions are impacted by the chromosomal sex of the patient. While osteoarthritis (OA) is predominant in men younger than 50 years of age, after age 50 the condition is more prevalent in women, particularly post-menopause. This has implications for diagnosis and treatment of OA, as well as for joint replacement.
223767204|NCT02967952|DEVICE|supraglottic airway (SGA) V.S. endotracheal intubation (ETI)|already being described above
223767205|NCT02477020|DRUG|TAK-063 20 mg|TAK-063 tablet.
224235783|NCT03044548|OTHER|Supportive supervision|" Supportive supervision. The specific characteristics of the supportive supervision as intended in this project are outlined below.~Frequency: Biweekly in the first 3-5 months, than monthly. Duration: approximately 2 hours in each HC at each visit. Provider: local staff (nutritionist, DHO) trained in integrated management acute malnutrition (IMAM) guidelines and in methods of  supportive supervision.~Receivers: nurses working at HC level with children with malnutrition.~Reference guidelines:~• Current National IMAM guidelines~Attitude and philosophy:~• Participatory peer-to-peer model based on the Plan - Do- Study- Act quality improvement (QI) Cycle ."
223767206|NCT02477020|DRUG|Placebo|TAK-063 matching-placebo tablet.
223767207|NCT01045291|DEVICE|Cardiac Resynchronization Therapy-Defibrillator (CRT-D)|Market approved InSync Sentry™ model 7298, dual chamber Implantable Cardioverter Defibrillator (ICD) with Cardiac Resynchronization Therapy (CRT) including sequential biventricular pacing and OptiVol® fluid monitoring or market approved InSync Maximo™ model 7304 dual chamber ICD with CRT including sequential biventricular pacing.
223767208|NCT01927250|BEHAVIORAL|Okada Health and Wellness program|Each participant were encouraged to practice the diet program and art therapy established by the MOA International Corporation, and to receive Okada Purifying Therapy, a domain of biofield therapy, for 3 consecutive months.
223767209|NCT00895219|OTHER|Breathing re-training|Breathing re-training
223767210|NCT00895219|OTHER|Breathing re-training and musculoskeletal techniques|Breathing re-training and musculoskeletal physiotherapy techniques including mobilisation techniques to normalise muscle and joint restrictions, doming of the diaphragm to enhance contraction and relaxation, and rib raising to free restriction in rib cage motion.
223767211|NCT06316466|OTHER|Lp(a)|The cut-off value for Lp (a) was determined based on one-year survival rates after diagnosis. Patients were then categorized into the high and low Lp (a) groups.
223767212|NCT00075868|DRUG|octreotide acetate|
223767213|NCT00075868|OTHER|Placebo|
224235784|NCT01932840|BEHAVIORAL|Mock package questionnaire|Within a online questionnaire we exposed participants randomly to 4 mock margarine packages differing only by the claim it carried and asked participants to answer several questions on attitudes and understanding after each mock package.
223767214|NCT00004144|DRUG|bryostatin 1|
223767215|NCT00004144|DRUG|gemcitabine hydrochloride|
223767216|NCT04341480|DRUG|Chemotherapy|Routine chemotherapy for individual tumor type.
223767217|NCT06352944|DIAGNOSTIC_TEST|procalcitonin|level of procalcitonin in bronchoalveolar lavage
223767218|NCT03515460|OTHER|sugar oral load|The individuals will receive a sugar oral load (high sugar meal)
223767219|NCT03515460|OTHER|fat oral load|The individuals will a receive fat oral load (high fat meal)
223767220|NCT03515460|OTHER|sugar and fat oral load|The individuals will a receive sugar and fat oral load (high sugar and high fat meal)
223767221|NCT01465802|DRUG|Dacomitinib|Dacomitinib 45 mg orally daily on a continuous schedule until disease progression, toxicity, death or withdrawal of consent
224235785|NCT00321542|OTHER|Imaging study, No intervention|Imaging with coronary computed tomographic angiography
223651465|NCT07158385|OTHER|Standard test meal (SM)|Participants were given a standard breakfast meal with a fat and protein content similar to their daily intake. Insulin was administered according to their individual carbohydrate-to-insulin ratio. On the test day, venous blood samples were collected from the catheter inserted for GLP-1, glucagon, and free fatty acid analysis immediately before the meal (t=0 minute) and at 30, 60, 90, 120, 240, and 360 minutes after the meal.
223651466|NCT07158385|OTHER|High fat high protein meal-carbohydrate counting (HFHP)|On the high-fat, high-protein meal-carbohydrate counting test day (HFHP), participants were given a high-fat and high-protein breakfast. Insulin was administered according to the individual carbohydrate-to-insulin ratio. On the test day, venous blood samples were collected from the catheter inserted for GLP-1, glucagon, and free fatty acid analysis immediately before the meal (t=0 minute) and at 30, 60, 90, 120, 240, and 360 minutes after the meal.
223767222|NCT01465802|DRUG|Dacomitinib|Dacomitinib 45 mg orally daily on a continuous schedule for the first 10 days in Cycle 1, followed by 4 days off treatment, followed by continuous daily dosing until disease progression, toxicity, death or withdrawal of consent
223767223|NCT01465802|DRUG|Doxycycline|Doxycycline or Doxycycline placebo BID for 4 weeks
223767224|NCT01465802|DRUG|Probiotic|VSL#3 probiotic 4 capsules orally daily or 1 sachet orally daily for up to 5 weeks (starting between Day minus 7 to Day minus 4 and continuing through Day 28)
223767225|NCT01465802|DRUG|Alclometasone cream|Topical alclometasone diproprionate cream 0.05% applied to face, hands, feet, neck, back and chest at bedtime for 4 weeks
224235786|NCT03825809|DRUG|Celecoxib|Post-Operative Non Opioid Pain Protocol
223651467|NCT07158385|OTHER|High fat high protein meal-fat counting (HFHP-a)|On the high-fat, high-protein meal-fat-counting test day (HFHP-a), participants were given a high-fat and protein breakfast. In addition to their individual carbohydrate/insulin ratio, insulin was administered based on fat counting (1 unit for every 15 g of fat after the first 15 g of fat in the meal). In this method, the insulin dose calculated based on their individual carbohydrate/insulin ratio was delivered via insulin pump as a standard bolus, while the insulin dose calculated based on their fat count was delivered as a 4 hour extended bolus.
223651468|NCT07158385|OTHER|High fat high protein meal-fat and protein counting (HFHP-b)|On the high-fat, high-protein meal-fat and protein counting test day (HFHP-b), participants were given a high-fat and protein breakfast. In addition to the individual carbohydrate/insulin ratio, insulin was administered according to the adapted Pankowska Algorithm (1 FPU for every 100 kcal after the first 200 kcal of the meal). In this method, the insulin dose calculated based on the individual carbohydrate/insulin ratio was delivered as a standard bolus by an insulin pump, while the insulin dose calculated based on the fat and protein count was delivered as a spread over 4 hours.
223651469|NCT07156383|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|Cognitive Behavioral Therapy for Insomnia (CBT-I) is the first line treatment for Insomnia. Participants will receive weekly CBT-I during which they will receive the tools to improve their sleep.
223651470|NCT07157410|OTHER|Machinable lithium-disilicate ceramic onlay (IPS e.max CAD)|Single indirect onlay restoration milled from an IPS e.max CAD block and crystallized according to the manufacturer's Instructions for Use, then adhesively luted on a randomized molar under.
224235787|NCT03825809|DRUG|Hydrocodone-Acetaminophen|Traditionally used narcotic pain protocol
224235788|NCT03825809|DRUG|Ketorolac|Post-Operative Non Opioid Pain Protocol
224235789|NCT03825809|DRUG|Gabapentin|Post-Operative Non Opioid Pain Protocol
224235790|NCT03825809|DRUG|Acetaminophen|Post-Operative Non Opioid Pain Protocol
224235791|NCT03825809|DRUG|Diazepam|Post-Operative Non Opioid Pain Protocol
224235792|NCT05310370|GENETIC|Testing of homologous recombination deficiency|A multiple panel testing of germline and somatic genes, including BRCA1/2, and HRD score are provided for all participants.
224235793|NCT00394056|DRUG|Vestipitant|NK1 receptor antagonist
224235794|NCT00394056|DRUG|Vestipitant + Paroxetine|NK1 receptor antagonist and SSRI
224235795|NCT00394056|OTHER|Placebo|Placebo
224235796|NCT03552757|DRUG|Semaglutide 1.0 mg|Subcutaneous (s.c.) injections of semaglutide once weekly at an escalating doses (0.25 mg/week, 0.5 mg/week, 1.0 mg mg/week). The dose will be escalated to next level every 4 weeks.
224235797|NCT03552757|DRUG|Semaglutide 2.4 mg|Subcutaneous injections of semaglutide once weekly at an escalating doses (0.25 mg/week, 0.5 mg/week, 1.0 mg mg/week, 1.7 mg/week and 2.4 mg/week). The dose will be escalated to next level every 4 weeks.
224235798|NCT03552757|DRUG|Placebo I (Semaglutide)|S.c. injections of placebo once weekly at a similar dose escalation manner as semaglutide 2.4 mg (placebo matched to semaglutide 0.25 mg/week, 0.5 mg/week, 1.0 mg mg/week, 1.7 mg/week and 2.4 mg/week). The dose will be escalated to next level every 4 weeks.
224235799|NCT03552757|DRUG|Placebo II (Semaglutide)|S.c. injections of placebo once weekly at a similar dose escalation manner as semaglutide 1.0 mg (placebo matched to semaglutide 0.25 mg/week, 0.5 mg/week, 1.0 mg mg/week). The dose will be escalated to next level every 4 weeks.
224235800|NCT02351726|DEVICE|Mitroflow DL|Treatment with Mitroflow Pericardial Aortic Heart Valve with Phospholipid Reduction Therapy (Model DL)
224235801|NCT00449150|DRUG|Cetrorelix 78 mg + 78 mg|
224235802|NCT00449150|DRUG|Cetrorelix 78 mg + 52 mg|
224235803|NCT00449150|DRUG|Placebo|
224235804|NCT01673958|OTHER|Exercise|Comparison between stair descending and stair ascending training
224235805|NCT02674334|DEVICE|NIRS|Near infrared spectroscopy (NIRS) monitor allows anesthesiologist to treat cerebral desaturations according to NIRS results while maintaining Mean Arterial Pressure (MAP) at least 60mmHG or at least 80% of baseline
224235806|NCT02674334|DEVICE|NIRS monitored not treated|Near infrared spectroscopy (NIRS) monitored but anesthesiologist blinded to NIRS information and treatment is standard of care.
223651471|NCT07157410|OTHER|Pressed lithium-disilicate ceramic onlay (IPS e.max Press)|Single indirect onlay restoration heat-pressed from an IPS e.max Press ingot and then adhesively luted on a randomized molar under rubber-dam isolation.
223651472|NCT07157410|OTHER|Machinable composite onlay (BRILLIANT Crios)|Single indirect onlay restoration milled from a BRILLIANT Crios block and then adhesively luted on a randomized molar under rubber-dam isolation.
223767226|NCT01340976|DRUG|LY2787106|Administered IV.
223767227|NCT01340976|DIETARY_SUPPLEMENT|Iron Supplementation|Administered orally.
223767228|NCT03684447|DRUG|Propofol|Series of 6 treatments with propofol.
224235807|NCT04182971|OTHER|Fruit|Phase 1 is 227g of orange fruit, Phase 2 is 230g of apple fruit
224235808|NCT04182971|OTHER|Fruit juice|Phase 1 is 250g of orange juice, Phase 2 is 235g of apple juice
224235809|NCT04182971|OTHER|Fruit juice plus fiber|Phase 1 is 157g of orange juice + 100g of orange pomace fiber (39% pomace by weight), Phase 2 is 129g of apple juice + 106g of apple pomace fiber (45% pomace by weight)
224235810|NCT00109109|DRUG|MK0683, vorinostat, Suberoylanilide Hydroxamic Acid (SAHA) / Duration of Treatment - Up to 8 Cycles or 6 months|
224235811|NCT01562496|BEHAVIORAL|Exercise|six-months long exercise intervention on a stationary virtual reality bike, 3-5 times a week, each session lasting 30-45 minutes at a target heart rate (60-85% heart rate reserve).
224235812|NCT00600925|DRUG|gentamicin-collagen sponge dipped in saline|2 gentamicin-collagen sponges inserted before closure of the laparotomy
224235813|NCT05621265|BEHAVIORAL|Automated Text messaging|daily text message
224235814|NCT03333226|PROCEDURE|Axillary Reverse Mapping (ARM)|ARM lymph node preservation versus removal
224235815|NCT03765632|GENETIC|Infusion of autologous cryopreserved EFS-ADA LV CD34+ cells (OTL-101)|Autologous cryopreserved EFS-ADA LV CD34+ cells (OTL-101) are infused intravenously
224235816|NCT03765632|DRUG|Busulfan|Busulfan is used for non-myeloablative conditioning
224235817|NCT03765632|DRUG|Peg-Ada|Peg-Ada Enzyme Replacement Therapy (ERT) is discontinued at Day +30 (-3/+15 days) after successful engraftment
224320681|NCT01824043|DRUG|intravitreal ranibizumab injections|Patients will be treated monthly: intravitreal ranibizumab (0.5 mg) will be administered in an open-label fashion, using 3 monthly injections (at day 0, day 30 and day 60) followed by an additional post treatment visit, a month after the last injection, for posterior reports
223651473|NCT07156734|DEVICE|Neuromuscular Electrical Stimulation|Studies in healthy individuals have demonstrated that NMES applied to the quadriceps of one limb induces short-term increases in strength and neural drive in the contralateral homologous muscle. Since these effects have only been observed in healthy individuals, it is essential to investigate whether similar responses occur in ACL patients.
224320682|NCT04875936|BEHAVIORAL|Motor Imagery and Real-Time fMRI Neurofeedback|Survivors of left-hemisphere stroke (\<10 weeks post-stroke) or healthy volunteers will use right-hand motor imagery coupled with fMRI neurofeedback to help them re-engage the left hemisphere by shifting brain activation leftward relative to the initial left-right asymmetry. Following group assignment, participants will perform a motor imagery task and complete 3 sessions of motor imagery and reading tasks in the MRI scanner over 3 weeks. During the MRI sessions they will receive real time neurofeedback about how well they are engaging the left side of their brain compared to the right side. They will also practice the same task for 30 min a day as homework using the most effective motor imagery strategy that worked for them in the MRI scanner.
224320683|NCT04875936|BEHAVIORAL|Motor Imagery and Sham fMRI Neurofeedback|Survivors of left-hemisphere stroke (\<10 weeks post-stroke) or healthy volunteers will practice right-hand motor imagery coupled with sham fMRI neurofeedback. As the experimental group, participants will perform a motor imagery task and complete 3 sessions of motor imagery and reading tasks in the MRI scanner over 3 weeks. However, during the MRI sessions they will receive sham neurofeedback on the basis of another participant's brain activity. Like the experimental group, they will also practice the same task for 30 min a day as homework.
224235818|NCT04905433|BEHAVIORAL|Cardiac rehabilitation with breathing retraining|A cardiac rehabilitation program for 3 days/week (day after day) for 12 weeks(including aerobic, and resisted exercise, with educational sessions, and counseling), with a breathing retraining (using breathing calisthenics, and inspiratory muscle training)
224235819|NCT04905433|BEHAVIORAL|Cardiac rehabilitation|A cardiac rehabilitation program for 3 days/week (day after day) for 12 weeks(including aerobic, and resisted exercise, with educational sessions, and counseling) only
223651474|NCT07156266|PROCEDURE|Kegal Exercise|"Dead Bugs:Participants will begin by lying on their backs with their arms extended overhead and legs bent at a 90-degree angle. While engaging their core muscles, they will gradually lower their arms and legs toward the floor, then return to the starting position.~Bridging Exercise: Lying on their backs with knees bent and feet flat on the ground, participants will gently raise their hips upward while activating the pelvic floor muscles, then slowly lower them back to the starting position."
223651475|NCT07156266|PROCEDURE|Squats Exercise|"Sumo Squats: Participants will stand with their feet placed wider than shoulder-width apart and toes pointing outward. They will then squat down, keeping their backs straight and their weight on their heels, pause briefly at the bottom, and return to a standing position.~Narrow Squats: With their feet set shoulder-width apart and toes pointing forward or slightly outward, participants will lower their bodies into a squat position while keeping their backs straight and their weight centered in the heels. After a brief pause, they will return to a standing position."
223651476|NCT07157293|BEHAVIORAL|Online Motivation Enhancing Intervention|This is a online intervention that will ask participants to review and complete 30 minutes of material each week.
223651477|NCT07158372|DIAGNOSTIC_TEST|AI-assisted Intraoperative Anatomy Analysis|This is a prospective study on patients aged 18 years or more diagnosed with laparoscopic cholecystectomy. We will collect information such as laparoscopic cholecystectomy videos and procedure type, excluding patients who did not undergo surgery at the original hospital or whose videos were blurry.
223651478|NCT07157423|DRUG|Eptacog alfa (NovoSeven)|Participants will receive single dose of intravenous bolus injection of eptacog alfa (NovoSeven)
223651479|NCT07157098|DEVICE|asymmetrical high-flow nasal cannula|high-flow nasal oxygen therapy via asymmetrical nasal prongs
223651480|NCT07157098|DEVICE|non-invasive ventilation with standard mask|non-invasive ventilation with standard oronasal mask, clinically used in the participting site
223651481|NCT07157098|DEVICE|non-invasive ventilation with a new mask|non-invasive ventilation with a new mask design, with under-nose, bridge-free design
223651482|NCT07157358|BEHAVIORAL|standardized audio hypnosis recordings for healthy children at primary school|8 different audio hypnosis recordings hat chidlren will listen too at a daily basis (one recording per day)
223651483|NCT07157007|DRUG|Ratutrelvir (83-0060) non-randomised|83-0060, a covalent inhibitor of the SARS-CoV-2 main protease (Mpro; 3CL)
224235820|NCT00005842|BIOLOGICAL|trastuzumab|
224235821|NCT00005842|DRUG|tipifarnib|
224235822|NCT04466085|BIOLOGICAL|Recombinant new coronavirus vaccine (CHO cell) low-dose group|Intramuscular injection of deltoid muscle of upper armof 25μg/0.5ml/person doseRecombinant new coronavirus vaccine (CHO cells).
224235823|NCT04466085|BIOLOGICAL|Recombinant new coronavirus vaccine (CHO cells) high-dose group|Intramuscular injection of deltoid muscle of upper armof 50μg/0.5ml/person doseRecombinant new coronavirus vaccine (CHO cells).
224235824|NCT04466085|BIOLOGICAL|Recombinant new coronavirus vaccine (CHO cells) placebo group|Intramuscular injection of deltoid muscle of upper armof 0.5ml/person doseRecombinant new coronavirus vaccine (CHO cells).
223651484|NCT07157007|DRUG|Paxlovid|Paxlovid (Nirmatrelvir+ Ritonavir , boosted 3CL-protease inhibitor)
224235825|NCT00543478|DRUG|Saccharomyces boulardii|250mg, twice a day in sachets, for 8 weeks
224235826|NCT00543478|DRUG|Methyl cellulose powder (low viscosity)|twice a day sachets for 10 weeks
224235827|NCT04655599|DRUG|Olorinab|Olorinab tablet by mouth, 3 times a day for 4 days with a final dose on Day 5.
224235828|NCT04655599|DRUG|Placebo|Olorinab matching placebo tablet by mouth, 3 times a day for 4 days with a final dose on Day 5.
224235829|NCT04362397|BEHAVIORAL|FoCo|This is an attention, care and self-care training.
224235830|NCT04362397|BEHAVIORAL|No intervention|This is a waiting list
224235831|NCT01307098|DRUG|Sebelipase alfa 0.35 mg/kg|Sebelipase alfa is a recombinant human lysosomal acid lipase.
223651485|NCT07157007|DRUG|Ratutrelvir (83-0060)|83-0060, a covalent inhibitor of the SARS-CoV-2 main protease (Mpro; 3CL)
224235832|NCT01307098|DRUG|Sebelipase alfa 1 mg/kg|Sebelipase alfa is a recombinant human lysosomal acid lipase.
224235833|NCT01307098|DRUG|Sebelipase alfa 3 mg/kg|Sebelipase alfa is a recombinant human lysosomal acid lipase.
224235834|NCT00982553|DRUG|Ribavirin|800mg once daily
224235835|NCT00982553|DRUG|Raltegravir|400mg twice daily
224235836|NCT01124851|DRUG|ABT-652|See arm description for details
224235837|NCT01124851|DRUG|Placebo|See arm description for details
224235838|NCT03977051|BEHAVIORAL|Focus group|Kidneys transplant patients will discuss their attitudes and beliefs towards immunosuppressant medication adherence
224235839|NCT03194581|DEVICE|Cerebral oxygenation|Evaluate cerebral oxygenation using normoxic challenges
224235840|NCT01722981|PROCEDURE|Percutaneous tracheostomy|Three methods of percutaneous tracheostomy
224235841|NCT01137695|DRUG|Pramlintide|120 mcg SQ three times daily for 6 months.
224235842|NCT01137695|DRUG|Pramlintide|360 mcg SQ three times daily for 6 months
224235843|NCT01137695|DRUG|Pramlintide|120 mcg SQ three times daily for 6 months
223651486|NCT07158398|DRUG|Vimseltinib|Administered orally
223651487|NCT07158398|DRUG|Rosuvastatin|Administered orally
223651488|NCT07158294|OTHER|Peripheral blood withdrawal for BCR::ABL1 mutations testing|Peripheral blood samples taken from patients treated according to clinical practice with resistance to imatinib or 2GTKI therapy according to the ELN recommendations will be shipped to one of the reference laboratories and analyzed by ddPCR using Bio-Rad ADS assays and reagents. Samples will be analyzed in batches of suitable size. ddPCR results will be compared with NGS results. In patients positive for mutations below 20% by ddPCR (low level mutations) peripheral blood sample(s) will be collected every 3 months at subsequent follow-up visits to monitor the kinetics of mutations in relation to therapy continuation or change.
223651489|NCT07158008|PROCEDURE|Nissen-Sleeve Gastrectomy (N-SG)|Laparoscopic Nissen-Sleeve Gastrectomy is a modification of standard sleeve gastrectomy that incorporates an anti-reflux procedure. The greater curvature of the stomach is mobilized and short gastric vessels are divided. A segment of the gastric fundus is preserved and passed behind the distal esophagus to create a 360-degree wrap (Nissen fundoplication) around the lower esophageal sphincter. The crura of the diaphragm are approximated if necessary. Following fundoplication, the remainder of the stomach is resected longitudinally over a 40 French bougie using a linear stapling device, creating a tubular gastric conduit. This approach aims to achieve weight loss while providing a functional anti-reflux barrier and maintaining gastrointestinal continuity.
223767229|NCT03684447|DRUG|Propofol|Series of 6 treatments with propofol. May be able to cross over and receive 6 additional treatments with the high dose of propofol.
223767230|NCT02472665|DRUG|plasma-derived FVIII/VWF concentrate|1 single dose of 80 IU/kg VWF:RCo of Fanhdi will be administered
223767231|NCT04453124|BIOLOGICAL|Topical antiseptic treatment|Prevent the development of bacterial cutaneous ulcers by applying antiseptic sap from Ficus septica tree on small wounds.
224235844|NCT01137695|DRUG|Pramlintide|360 mcg SQ three times daily for 6 months
224235845|NCT03056781|BEHAVIORAL|social interaction|Participants will engage in a social interaction with another person
224235846|NCT03056781|BEHAVIORAL|food consumption|Participants will be offered food stuffs to eat/drink
224235847|NCT02064595|PROCEDURE|External fixator|Treatment with external fixation
224235848|NCT02064595|PROCEDURE|Intramedullary nail|Fracture treated with intramedullary nail
224235849|NCT01345019|DRUG|Denosumab|Administered by subcutaneous injection once every 4 weeks.
224235850|NCT01345019|DRUG|Zoledronic acid|Administered by intravenous infusion over 15 minutes once every 4 weeks
223767232|NCT00054613|DRUG|Methoxsalen|
223767233|NCT00054613|PROCEDURE|Extracorporeal Photopheresis|
224235851|NCT01345019|DRUG|Placebo to Denosumab|Administered by subcutaneous injection once every 4 weeks.
224235852|NCT01345019|DRUG|Placebo to zoledronic acid|Administered by intravenous infusion over 15 minutes once every 4 weeks
224235853|NCT01345019|DRUG|Denosumab (for the open-label treatment phase)|Administered by subcutaneous injection once every 4 weeks.
224235854|NCT05718778|DRUG|Piamprimab (AK105)|Piamprilizumab (AK105) combined with radiotherapy for neoadjuvant treatment of soft tissue sarcoma
224235855|NCT01706471|DRUG|Everolimus + Low dose CsA +PD|Group A : Initiation of 5mg/kg bid Neoral dose and 720mg bid Myfortic and then adjusting Neoral targeting 150-200ng. After 1 month reduce Neoral dose as following table and Certican starting 0.75mg bid then adjust Certican 3-8ng/ml. Myfortic continue until Certican trough level goes up \>3 ng/mL. Steroid dose follows local protocol.
224235856|NCT01706471|DRUG|Myfortic+ Standard CsA + PD|Group B : Initiation of 5mg/kg bid Neoral dose and 720mg bid Myfortic and then adjusting Neoral targeting 150-200ng/ml. After 1 month reduce Neoral dose targeting 100-200ng with no change of Myfortic dose. Steroid dose follows local protocol.
224235857|NCT00971893|DRUG|Oral Methylprednisolone Tablets|Oral Methylprednisolone tablets given as per locally approved prescribing information
224235858|NCT02992171|BEHAVIORAL|care management by oncology nurses|The intervention employs a care management approach to facilitate provision of primary palliative care within existing oncology clinic structures. The intervention is deployed through a series of nurse-led encounters occurring before or after regularly-scheduled oncology clinic visits.
224235859|NCT00235456|PROCEDURE|Perioperative supplemental oxygen|Patients were assigned to 80% fraction of inspired oxygen (FIO2) intraoperatively and for 6 hours after surgery. Anesthetic treatment and antibiotic administration were standardized.
224235860|NCT00235456|PROCEDURE|Standard oxygen|Patients were assigned to 30% fraction of inspired oxygen (FIO2) intraoperatively and for 6 hours after surgery. Anesthetic treatment and antibiotic administration were standardized.
224235861|NCT01818856|DRUG|Ritonavir withdrawal, atazanavir 200 mg/12h|
224235862|NCT01818856|DRUG|Telaprevir interactions|
224235863|NCT04558307|DIAGNOSTIC_TEST|Pilot a rapid SARS-CoV-2 testing strategy|Rapid testing strategy at an FQHC using Mayo Clinic Laboratory (MCL) diagnostic processing with a real-time polymerase chain reaction assay for SARS-CoV-2 and a Mayo Clinic drive-through collection protocol.
223767234|NCT01175694|RADIATION|Interstitial multicatheter brachytherapy|Interstitial PDR- and HDR-brachytherapy up to 50 Gy-eq
224235864|NCT04558307|OTHER|Community-driven messages to promote COVID-19 testing|A one-time communication about the availability of COVID-19 testing at the FQHC to patients randomized to the intervention group using any available means of communication (text and/or mailed letter).
224235865|NCT03816371|OTHER|Head-of-bed elevation|Respiratory pattern including respiratory rate, peripheral oxygen saturation and dyspnea, and drainage including amount of drainage and hematoma formation of all patients were evaluated at 1st, 2nd, 3rd, and 4th hours after positions.
224235866|NCT00114426|DEVICE|non-invasive mechanical ventilation|
224235867|NCT00925626|PROCEDURE|Sub-Vastus arthrotomy|Sub-vastus arthrotomy
224235868|NCT00925626|PROCEDURE|Mid - Vastus arthrotomy|Mid-vastus arthrotomy
224235869|NCT05960526|DRUG|extract Binahong|Extract Binahong 2.5% as nasal irrigation solution
224235870|NCT05960526|DRUG|Isotonic saline nasal irrigation|NaCl 0.9% as nasal irrigation solution
224235871|NCT00526968|DRUG|EVT 101|8 mg capsule, single oral dose
224235872|NCT00526968|DRUG|EVT 101|15 mg capsule, single oral dose
224235873|NCT00526968|DRUG|placebo|Placebo capsule, single oral dose
223651490|NCT07158008|PROCEDURE|Roux-en-Y Gastric Bypass (RYGB)|Laparoscopic Roux-en-Y Gastric Bypass is a standard bariatric procedure that combines gastric restriction with intestinal bypass. A small proximal gastric pouch is created using linear staplers, completely separating it from the gastric remnant. A 100 cm alimentary (Roux) limb of jejunum is measured from the ligament of Treitz and anastomosed to the gastric pouch (gastrojejunostomy) using a linear stapler. A jejunojejunostomy is then performed 150 cm distal to the gastrojejunostomy to connect the biliopancreatic limb to the alimentary limb, restoring intestinal continuity. The mesenteric defects are closed to reduce the risk of internal hernia. This procedure promotes weight loss and has established effectiveness in reducing gastroesophageal reflux symptoms.
223651491|NCT07158008|PROCEDURE|Sleeve Gastrectomy (SG)|Laparoscopic Sleeve Gastrectomy is a restrictive bariatric procedure involving longitudinal resection of the stomach to create a tubular gastric conduit. The greater curvature is mobilized and short gastric vessels are divided. Using a bougie as a guide, the stomach is divided with a linear stapling device from the antrum to the angle of His, removing approximately 75-80% of gastric volume, including most of the fundus. This reduces stomach capacity and ghrelin production, promoting weight loss while maintaining gastrointestinal continuity.
224235874|NCT02192346|DRUG|2.4 mg/kg α-TEA|Patients receive oral α-TEA 2.4 mg/kg daily for the first 14 days of a 28 day cycle.
224235875|NCT02192346|DRUG|4.8 mg/kg α-TEA|Patients will receive oral α-TEA 4.8 mg/kg daily for the first 14 days of a 28 day cycle.
224235876|NCT02192346|DRUG|8.0 mg/kg α-TEA|Patients will receive oral α-TEA 8.0 mg/kg daily for the first 14 days of a 28 day cycle.
224235877|NCT02192346|DRUG|9.6 mg/kg α-TEA|Patients will receive oral α-TEA 9.6 mg/kg daily for the first 14 days of a 28 day cycle.
224235878|NCT02192346|DRUG|12 mg/kg α-TEA|Patients will receive oral α-TEA 12 mg/kg daily for the first 14 days of a 28 day cycle.
224235879|NCT02192346|DRUG|16.8 mg/kg α-TEA|Patients will receive oral α-TEA 16.8 mg/kg daily for the first 14 days of a 28 day cycle.
224235880|NCT02192346|DRUG|19.2 mg/kg α-TEA|Patients will receive oral α-TEA 19.2 mg/kg daily for the first 14 days of a 28 day cycle.
224235881|NCT02192346|DRUG|22.3 mg/kg α-TEA|Patients will receive oral α-TEA 22.3 mg/kg daily for the first 14 days of a 28 day cycle.
224235882|NCT02192346|DRUG|26.8 mg/kg α-TEA|Patients will receive oral α-TEA 26.8 mg/kg daily for the first 14 days of a 28 day cycle.
224235883|NCT04087395|DEVICE|RHA®4 with new anesthetic agent|A sterile, biodegradable, biocompatible, viscoelastic, clear, colorless, homogenized gel implant. It consists of cross-linked hyaluronic acid produced by fermentation of Streptococcus zooepidemicus, formulated to a concentration of 23 mg/g and 0.3% w/w of new anesthetic agent in a physiologic buffer.
223651492|NCT07156344|DIAGNOSTIC_TEST|Progression and Outcome of Intracranial Atherosclerosis|"Progression and Outcome of Intracranial Atherosclerosis is the primary endpoint; all others are secondary endpoints. Stroke defined as any stroke and new ipsilateral stroke (including ischemic and hemorrhagic stroke) associated with vascular stenosis."
223651493|NCT07157306|DRUG|Gecacitinib Combined With Donafenib and PD-1 Inhibitor|Subjects were enrolled and started receiving treatment with Gecacitinib (100mg, Bid, po) for 7 consecutive days; thereafter, they were treated with PD-1 antibody (Q3W, iv) and Donafenib (200mg, Bid, po), counting the day of infusion of PD-1 monoclonal antibodies as C1D1, with each cycle lasting 3 weeks. Subsequent treatments involved administering Gecacitinib for 1 week before each infusion of PD-1.
223651494|NCT07156695|PROCEDURE|Deep Marginal Elevation (DME)|Deep Marginal Elevation (DME) is performed by elevating the deep margin of Class II cavities using resin-modified glass ionomer cement (RMGIC), followed by adhesive bonding and placement of a nanofilled composite resin restoration. This procedure improves accessibility of the restorative margin, enhances marginal sealing, and facilitates plaque control.
223651495|NCT07158021|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223651496|NCT07158021|OTHER|Electronic Health Record Review|Ancillary studies
223651497|NCT07158021|DRUG|Goserelin|Given SC
223651498|NCT07158021|DRUG|Leuprolide|Given IM
223767235|NCT04688840|PROCEDURE|hip arthropalsty|follow up of patients with primary hip arthroplasty with at least one year follow up electronically and by routine method
223767236|NCT02077517|PROCEDURE|Roux en Y Gastric Bypass|
224235884|NCT04087395|DEVICE|RHA®4-Lidocaine|A sterile, biodegradable, biocompatible, viscoelastic, clear, colorless, homogenized gel implant. It consists of cross-linked hyaluronic acid produced by fermentation of Streptococcus zooepidemicus, formulated to a concentration of 23 mg/g and 0.3% w/w lidocaine in a physiologic buffer.
224235885|NCT05530681|DIAGNOSTIC_TEST|Questionnaire|The survey consists in standardized and validated questionnaires on urinary function (ICIQ-SF, 4 items), bowel function (SMIS, 7 items and PAC-SYM, 12 items), symptoms of prolapse (POPDI, 6 items) and sexual function (Female Sexual Function Index FSFI, 19 items and Female Sexual Distress Scale - Revised FSDS-R, 13 items). questionnaire will be used at recruitment, at the postpartum visit, at the first annual follow-up visit.
224320684|NCT00758966|DRUG|Fluoxetine 60 mg|Two week titration followed by daily dosing of fluoxetine 60 mg for 8 weeks. Response is assessed at after 8 weeks. Responders will continue on fluoxetine 60 mg for an additional 6 weeks. Non-responders will have naltrexone SR 32 mg added to their therapy.
223651499|NCT07158021|OTHER|Questionnaire Administration|Ancillary studies
223767237|NCT00125827|DRUG|clofarabine (oral formulation)|Cohorts of 3 patients each were to receive oral clofarabine administered daily for 5 days followed by 23 days of rest (1 cycle) and repeated every 28 days depending on toxicity and response. The starting dose of clofarabine was to be 1 mg/m2/day with subsequent dose escalation to occur in increments of 50% for the first 5 dose levels (1.5, 2.25, 3.5, and 5.0 mg/m2/day) and in increments of 25% thereafter until the MTD/RP2D was determined.
223767238|NCT01963624|DEVICE|Ultrasonography|Comparison of B-mode US alone and combined use of elasto-doppler US along with B-mode US.
223767239|NCT04560803|DEVICE|CelluTomeTM Epidermal Harvesting System|Autologous epidermal grafts that will be placed at the treatment site
223767240|NCT05612516|PROCEDURE|Assessment of hydrogen peroxide levels in saliva using trays with reservoir.|During bleaching using trays with reservoir.
223767241|NCT05612516|PROCEDURE|Assessment of hydrogen peroxide levels in saliva using trays without reservoir.|During bleaching using trays without reservoir.
224235886|NCT05530681|DIAGNOSTIC_TEST|Pelvic floor ultrasound|Pelvic floor ultrasound is the preferred imaging modality for documenting pelvic floor anatomy during pregnancy or after delivery. This examination is routinely performed in the outpatient clinic during patient visits (including the one year check-up after delivery). The technique used to assess the pelvic floor is described in detail in the 2019 practice parameters issued by IUGA.
223651500|NCT07156578|DRUG|Bivamelagon|daily dose of oral bivamelagon
223651501|NCT07158164|DRUG|Fluorouracil injection|Experimental arm Fluorouracil injection with possible escalation to 75 or 100 percent if tolerated.
223651502|NCT07158164|DRUG|Xeloda|Experimental arm Fluorouracil injection with possible escalation to 75 or 100 percent if tolerated.
223651503|NCT07157722|DRUG|Iron chelating intervention|JADENU is indicated for the treatment of chronic iron overload due to blood transfusions.
223651504|NCT07157722|DRUG|N Acetyl cysteine 600mg|N-acetyl cysteine (NAC) 600 mg will be administered orally once daily for 12 weeks.
223651505|NCT07157722|DRUG|Alpha Lipoic Acid 600 MG Oral Tablets|Alpha lipoic acid (ALA) 600 mg will be administered orally once daily for 12 weeks.
223651506|NCT07157020|PROCEDURE|ommaya capsule implantation technique|Intervention criteria: Low-threshold intervention group and high--threshold intervention group
223767242|NCT06020404|PROCEDURE|supine position|At the end of the PEEP trial (i.e. at PEEP 5 cmH2O), patients will lay in the supine position for 15 minutes arterial blood gases will be performed and then a one-breath derecruitment maneuver (5-second exhalation, respiratory rate \< 8 bpm) from PEEP 5 cmH2O to 0 cmH2O will be conducted to assess baseline functional residual capacity (FRC), defined as the EELI measured at 0 PEEP.
223767243|NCT06020404|PROCEDURE|prone position|"After the supine step, each enrolled patient will be placed in the prone position for 1 hour.~For safety reasons, enteral feeding will be interrupted 30 minutes before prone positioning and re-established after the study ending.~During pronation FiO2 will be increased up to 80% and then gradually decreased to the baseline value within the first 30 minutes of prone positioning. After 30 minutes of PEEP 12 cmH2O (provided that plateau and driving pressures did not exceed 30 cmH2O and 15 cmH2O, respectively) to stabilize lung volumes, the same measurements applied for the supine step will be performed. Any further modifications in the MV settings will be discouraged over the entire course of the study; nonetheless, if needed to achieve the SpO2 target, an increase in FiO2 will be allowed and recorded.~In case of sudden worsening of the oxygenation impairment or haemodynamic, 100% FiO2 will be set, and the patient will be promptly positioned in the supine semi-recumbent position."
223767244|NCT05834140|OTHER|Traditional Physical Therapy|"TENS (transcutaneous electrical nerve stimulation) on continuous mode at 80-120 Hz for 15-20 min and Heating pads for 10-15 min~Total 4 sessions will be given in 2 days"
223767245|NCT05834140|OTHER|Muscle Energy Technique|"Muscle energy technique (Post Isometric relaxation) along with TENS and Heating pads.~* MET of the scaleni~* MET of Sternocleidomastoid~* MET of Levator Scapulae~* MET of Upper fibers of Trapezius~Total 4 sessions will be given in 2 days"
223767246|NCT02247310|DRUG|Interferon beta-1b (Betaferon®, BAY 86-5046)|Patients will be treated with Betaferon
223767247|NCT02247310|DEVICE|BETACONNECT|Auto-injector device to support the injection of Betaferon
223767248|NCT00117091|DRUG|Anakinra (Kineret®)|
223767249|NCT06572826|OTHER|Cardiac Rehabilitation intervention|The cardiac rehabilitation program for post-CS patients includes respiratory physiotherapy, muscle strengthening and endurance training such as walking, treadmill exercises, and cycling, all tailored to the patient's capabilities. Cardiovascular training involves interval and continuous aerobic exercises to improve heart function. The program emphasizes secondary prevention strategies, including lifestyle changes and medication management. Neuromotor rehabilitation addresses sarcopenia and polyneuropathies through targeted exercises like balance training, gait retraining, and the use of advanced technologies like functional electrical stimulation (FES), robotic devices, and virtual/augmented reality. Cognitive-behavioral therapy (CBT) helps manage the psychological effects of severe cardiovascular events. The program also includes speech and occupational therapy, planning for home reintegration, and telerehabilitation to ensure long-term recovery.
223767250|NCT04878705|DRUG|TWP-201|a single subcutaneous injection
224235887|NCT02864758|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Tablets, 20mg once daily
224235888|NCT02864758|DRUG|Vitamin K antagonists|Tablets, dose is based on International Normalized Ratio
224235889|NCT02864758|DRUG|dabigatran (Pradaxa)|Tablets, 150 mg twice daily
224235890|NCT03151018|DEVICE|Resolute Onyx|
223651507|NCT07158489|DRUG|Gemcitabine + Ivonescimab|"The trial combines two Investigational Medicinal Products (IMPs):~* Gemcitabine, either alone or in combination regimens, is the standard of care (SoC) for several solid tumors, such as advanced or metastatic non-small cell lung cancer (mNSCLC).~* Ivonescimab is developed for cancer immunotherapy. Ivonescimab binds to human vascular endothelial growth factor (VEGF) which is involved in tumor angiogenesis, and to human programmed cell death 1 (PD-1) that is a cell surface receptor expressed primarily on activated T cells and acts to inhibit their activation."
223651508|NCT07158437|BIOLOGICAL|SL-325|DR3 blocking antibody
223651509|NCT07158437|OTHER|Placebo (Normal Saline)|Normal saline
223651510|NCT07158424|PROCEDURE|Serious games|Participants in the experimental groups engage in daily sessions of serious games from the Vana Vital Platform (Super Surfer, Hungry Woo, Paddle Waddle, Woo's Wonderful World Adventure). Each child will for 30 minutes per day over 10 training days.
224235891|NCT03057249|OTHER|Dynamic infrared thermography (DIRT)|Evaluating abdominal skin perfusion with DIRT
224320685|NCT00758966|DRUG|Naltrexone 32 mg and fluoxetine 60 mg|Two week titration followed by daily dosing of naltrexone SR 32 mg and fluoxetine 60 mg for 8 weeks. Response is assessed at after 8 weeks. Responders will continue on a daily dose of naltrexone SR 32 mg and fluoxetine 60 mg for an additional 6 weeks. Non-responders will have their daily dose adjusted to naltrexone SR 48 mg and fluoxetine 80 mg.
224320686|NCT00758966|DRUG|Naltrexone SR 32 mg|Two week titration followed by daily dosing of naltrexone SR 32 mg for 8 weeks. Response is assessed at after 8 weeks. Responders will continue on naltrexone SR 32 mg for an additional 6 weeks. Non-responders will have fluoxetine 60 mg added to their therapy.
224320687|NCT03387566|DRUG|HB002.1M|HB002.1M is a Vascular Endothelial Growth Factor Receptor Decoy.
224320688|NCT00481403|BEHAVIORAL|Microarray analysis|Microarray analysis
224320689|NCT00481403|BEHAVIORAL|Microarray|Microarray
224320690|NCT03166137|DEVICE|Carbon dioxide laser|Radiation by carbon dioxide laser
224320691|NCT03166137|DEVICE|Cryotherapy|Device using cooling effect
223651511|NCT07158424|PROCEDURE|Intensive rehabilitation|"Participants receive their intensive rehabilitation program, which includes:~30 minutes of physical therapy (PT) 20 minutes of occupational therapy 5 minutes of spinal manipulative therapy 60 minutes of full-body massage with reflexotherapy 15 minutes of joint mobilization 15 minutes of treadmill gait training (with or without suspension) 15 minutes of strength training 30 minutes of group rhythmic gymnastics"
223651512|NCT07158424|PROCEDURE|Physical therapy|Participants receive an additional 30 minutes of physical therapy (PT)
223651513|NCT07156812|DEVICE|Custome made 3D PEEK plate|Custome made 3D PEEK plate
223651514|NCT07156812|DEVICE|3D Titanium plate|Pre-bent 3D Titanium plate
223651515|NCT07157592|OTHER|Ventrogluteal IM Injection tecnique|"Ventrogluteal IM injection technique:~During IM injection into the ventrogluteal region:~* The entrance angle of the needle is 90º.~* The 25-gauge (1-inch) syringe is held with the active hand as if holding a pen, and no hand change is made during the injection.~* The needle is rapidly inserted into the skin and withdrawn at the same angle 5 seconds after the injection.~* The drug is injected for 5 seconds/mL without blood aspiration during injection.~* Light pressure is applied to the area after injection, with no massage performed.~To evaluate the appropriateness of the application ventrogluteal IM injection technique, the opinions were obtained of five experts in nursing principles and child health and disease nursing."
223651516|NCT07156175|DRUG|SAR444336|Pharmaceutical form:Solution for injection -Route of administration:Subcutaneous
223651517|NCT07156175|DRUG|Placebo|Pharmaceutical form:Solution for injection -Route of administration:Subcutaneous
223651518|NCT07156981|BEHAVIORAL|Physiotherapy|The treatment program will include patient education, lifestyle recommendations, breathing exercises, pelvic floor muscle training, and stabilization exercises. The treatment program will last for a total of 8 weeks.
223651519|NCT03847428|DRUG|Durvalumab|Durvalumab IV (intravenous)
223651520|NCT03847428|DRUG|Bevacizumab|Bevacizumab IV (intravenous)
223651521|NCT03847428|OTHER|Placebo|Saline solution for Durvalumab and/or Bevacizumab masking (IV intravenous) or Dextrose for Durvalumab masking
223651522|NCT04951947|DRUG|JS201 combine with Lenvatinib|JS201 300mg i.v Q2wLenvatinib 8mg po. Qd
223651523|NCT01671917|OTHER|Educational and exercise program|"* 4 (twice a week) group education sessions lasting 30 minutes plus an education booklet about knee replacement~* 4 (twice a week) sessions of an exercise programme lasting 1 hour"
223651524|NCT01671917|OTHER|Usual care|Information and counseling usually provided in orthopedics department and an information booklet about knee replacement.
223651525|NCT05523778|PROCEDURE|placement of pancreatic duct stents before enucleation surgery|Advance placement of pancreatic stents endoscopically
223651526|NCT05523778|PROCEDURE|Direct enucleation surgery|Patients will receive direct enucleation surgery
223651527|NCT04002492|BEHAVIORAL|Bodyweight training|Video guided and physical therapist guided bodyweight training sessions will be performed twice a week for 6 (to 8) weeks. These sessions include the following five workouts at 3 sets of 10 repetitions: step ups, calf raises, wall push ups, chair squats, and chair dips.
223651528|NCT01213199|DRUG|Adapalene|Adapalene Gel 0.3%
223767251|NCT04878705|DRUG|placebo|a single subcutaneous injection
223767252|NCT01358981|DRUG|LY2881835|Administered orally
223767253|NCT01358981|DRUG|Placebo|Administered orally
223767254|NCT04745143|DRUG|NMDAE|Use of an NMDA enhancer for the treatment of schizophrenia
223767255|NCT04745143|DRUG|Placebo Cap|Use of placebo as a comparator
223767256|NCT00403091|BEHAVIORAL|Internet Intervention|Internet-based intervention aims to improve guideline adherence by rural physicians caring for adult patients with type 2 diabetes.
224235892|NCT01651702|DEVICE|Carto|Group of patients where Carto Express system will be used for electroanatomical mapping.
224235893|NCT01651702|DEVICE|Ensite|Group of patients where Ensite Velocity system will be used for electroanatomical mapping.
224235894|NCT03830164|DRUG|Atorvastatin|Given PO
224235895|NCT03830164|DRUG|Pentoxifylline|Given PO
224235896|NCT03830164|DIETARY_SUPPLEMENT|Vitamin E Compound|Given PO
224235897|NCT05655832|DEVICE|Vivalink wearable device|a CE marked device modified to add a temperature measurement algorithm in addition to ECG and respiratory rate measurements
224320692|NCT03645707|BEHAVIORAL|CAR Training and Psychoeducational Sessions|"Participation in the CAR Training Program, a 1-day training program developed by the J\&J Human Performance Institute (HPI). The CAR Training Program uses a holistic approach that focuses on moving between stress and strategic recovery to help build resilience and enable higher performance.~Participants will attend eight weekly follow-up psychoeducational group sessions facilitated by a licensed mental health counselor that will meet for 90 minutes. The themes of these sessions will be RISE - Resilience, Insight, Self-Compassion, and Empowerment. Due to limited time and flexibility in sessions, participants will practice skills through optional homework activities to facilitate learning between sessions."
224320693|NCT03513133|BEHAVIORAL|working memory training|Hierarchical cognitive training of the different components of working memory according to Baddeley model; 15 tasks are used addressing: the phonological loop (8 tasks), the visuospatial sketchpad (4 tasks) and the central executive 3 tasks). Task are given in a hierarchical order, according to each individual patient's deficits and improvement.
224235898|NCT02348385|DRUG|Amphetamine|Subjects will have 2 PET scans on the same day. Up to 3 hours before the second PET Scan, amphetamine (0.4mg/kg, orally) will be administered.
224320694|NCT01410656|BEHAVIORAL|Telephone Implementation Intention|Telephone implementation intention counseling
224320695|NCT01410656|BEHAVIORAL|Self-completed implementation intention|Self-administered implementation intention intervention
224235899|NCT00379756|DRUG|LEVITRA (vardenafil)|active comparator
224235900|NCT00379756|DRUG|placebo|placebo comparator
224235901|NCT06486116|BEHAVIORAL|Task Specific Physical Therapy Home Program|Home exercise program based on specific findings from physical therapy evaluations.
223651529|NCT03083873|BIOLOGICAL|LN-145|A tumor sample is resected from each patient and cultured ex vivo to expand the population of tumor infiltrating lymphocytes. After NMA lymphodepletion, patients are infused with their autologous TIL (LN-145) followed by IL-2 administration.
223651530|NCT03083873|BIOLOGICAL|LN-145-S1|A tumor sample is resected from each patient and cultured ex vivo to expand the population of tumor infiltrating lymphocytes. After NMA lymphodepletion, patients are infused with autologous TIL (LN-145-S1) followed by IL-2 administration.
223651531|NCT06125080|DRUG|Utidelone|Utidelone (30 mg/m2, days 1-5, every 3 weeks)
223651532|NCT06125080|DRUG|Tirelizumab|Tirelizumab（200mg, day1, every 3 weeks）
223651533|NCT06125080|DRUG|Bevacizumab|Bevacizumab(7.5mg/kg, day1, every 3 weeks)
223651534|NCT01677377|DRUG|Risperidone|Oral risperidone was supplied as 2, 3, or 4 mg tablets in blister packs or bottles and taken daily only during the oral dosing periods of the study, days -14 through -8 (if applicable), days -7 through -1, and days 85 through 87.
223651535|NCT01677377|DRUG|RBP-7000|RBP-7000 60 mg, 90 mg, and 120 mg were a mixture of the ATRIGEL® Delivery System and 60 mg, 90 mg, or 120 mg risperidone, respectively. Treatment was delivered as subcutaneous injections on study days 1, 29 and 57.
223651536|NCT00296699|DRUG|Duloxetine|"Day 1-7: 20 mg/d; day 8-24: 30 mg/d; day 15-28: 60 mg/d; day 29-56: 120 mg/d.~\* dose raises will occur only if pt. is tolerating the previous dose and not remitting.; dose may be lowered or increased in 30 mg increments if pt. has difficulty tolerating."
223651537|NCT01284335|DRUG|Gemcitabine|1000 mg/m2 administered intravenously on Days 1 and 15 of a 28 day cycle until disease progression, unacceptable toxicity or other discontinuation criteria are met.
223651538|NCT01284335|DRUG|Docetaxel|60 mg/m2 administered intravenously over 60 minutes on Day 1 of the 28-day cycle until disease progression, unacceptable toxicity or other discontinuation criteria are met.
223651539|NCT01284335|DRUG|Temozolomide|200 mg/m2 administered orally on days 1-5 of a 28 day cycle until disease progression, unacceptable toxicity or other discontinuation criteria are met.
223651540|NCT01284335|DRUG|Cisplatin|75 mg/m2 administered intravenously on Day 1 of the 28-day cycle until disease progression, unacceptable toxicity or other discontinuation criteria are met.
223651541|NCT01284335|DRUG|Erlotinib|150 mg administered orally days 1-28 of a 28 day cycle until disease progression, unacceptable toxicity or other discontinuation criteria are met.
223767257|NCT00403091|BEHAVIORAL|Control|The comparison group will receive a text-based, non-interactive Internet posting of publicly available resources.
223767258|NCT04777344|BEHAVIORAL|Tobacco Treatment Specialist (TTS) intervention|A trained Tobacco Treatment specialist (TTS) embedded in the multi-disciplinary CF care team will provide tobacco use counseling to smoking caregivers of children with CF.
224235902|NCT01718639|DEVICE|IQP-LH-101 tablet|Oral medical device in the form of a chewable tablet
224235903|NCT01718639|DEVICE|IQP-LH-101 liquid|Oral medical device in the form of a liquid
224235904|NCT01718639|OTHER|Placebo|
224235905|NCT02840409|DRUG|Vinblastine|
224235906|NCT02840409|DRUG|Bevacizumab|
224235907|NCT01432977|DRUG|paracetamol /droperidol|
224235908|NCT01432977|DRUG|paracetamol / ondansetron|
224235909|NCT02796664|DIETARY_SUPPLEMENT|Ginseng|Korean Red Ginseng extract tablet (0.5 grams/tablet, 2 tablets twice a day) daily for 12 months.
224235910|NCT02796664|DIETARY_SUPPLEMENT|Placebo|Placebo (0.5 grams/tablet, 2 tablets twice a day) daily for 12 months.
224320696|NCT02862561|DRUG|Chemotherapy|Cisplatin：60mg/m2，5-FU：500mg/m2,Physiological saline 100ml:IV (in the vein) once a week with a total of six times.
224320697|NCT02862561|BIOLOGICAL|Precision Cells|DC cell suspension (1×10\*7 DC+physiological saline + 0.25% human bloodalbumin)1ml for each infusion, subcutaneous injection for each infusion, 3 cycles, each cycle received two infusions on day 19, 20; 40, 41; 61, 62. Precision cells suspension (1-6×109 Precision cells + physiological saline + 0.25% human bloodalbumin) 300ml for each infusion, IV (in the vein) for each infusion, 3 cycles, each cycle received one infusions on day 21, 42, 63.
223651542|NCT01284335|DRUG|LY573636|Individualized dose is dependent on participant's height, weight, gender and is adjusted to target a specific exposure range corrected for a participant's laboratory parameters. Intravenous dosing is done on Day 1 of a 28 day cycle. Participants may continue on study drug until disease progression, unacceptable toxicity, or other withdrawal criteria are met.
223651543|NCT02656693|BEHAVIORAL|Online weight management program|Patients who are enrolled in one of the two arms using the online weight management program (BMIQ) will complete structured educational sessions, follow specific calorie goals and meal plans, participate in self-monitoring activities (i.e., regular tracking of weight, diet, and physical activity), and interact with other features of the program.
223651544|NCT02656693|BEHAVIORAL|Population health management support|Patients will receive weight-related population health management support from their primary care practice; their online weight management program data will be monitored by the population health manager, who will conduct outreach with patients at designated points according to the protocol.
223651545|NCT00994968|DRUG|cyclophosphamide|
223651546|NCT00994968|DRUG|docetaxel|
223651547|NCT00994968|DRUG|doxorubicin hydrochloride|
224235911|NCT03388307|PROCEDURE|unilateral laminotomy|minimally invasive technique
224235912|NCT03388307|PROCEDURE|decompressive laminectomy|classic surgery
224235913|NCT03382756|DIETARY_SUPPLEMENT|High fat diet|A diet consisting of more than 900kcal and 35% of fat
224235914|NCT03382756|DRUG|CKD-337|Test Drug
224235915|NCT00674999|BIOLOGICAL|Amnion|Application of Amnion with processing procedures involving the use of trypsin-EDTA
224235916|NCT00674999|BIOLOGICAL|Amnion|Application of Amnion with processing procedures involving the use of Dispase II
223651548|NCT00994968|DRUG|tegafur-gimeracil-oteracil potassium|
223651549|NCT00994968|PROCEDURE|neoadjuvant therapy|
223651550|NCT00994968|PROCEDURE|therapeutic conventional surgery|
223651551|NCT01403597|DEVICE|Refirme ST Applicator and Matrix RF Applicator|5 treatments with combination of devices every 4 weeks to the facial (or sub facial regions).
223651552|NCT00842751|DRUG|First Intervention (7 days)|Acyline 300mcg/kg subcutaneous (days 1, 15 \& 29) + testosterone undecanoate 200 mg, twice daily orally + finasteride placebo
223651553|NCT00842751|OTHER|First Washout (7 days)|Washout of 7 days between each of the 3 treatment arms
223651554|NCT00842751|DRUG|Second Intervention (7 days)|Acyline 300mcg/kg subcutaneous + testosterone undecanoate 200 mg, twice daily orally + finasteride 0.5mg twice daily, orally
223651555|NCT00842751|DRUG|Third Intervention (7 days)|Acyline 300mcg/kg subcutaneous + testosterone undecanoate 200 mg, twice daily orally + finasteride 1mg twice daily, orally
223651556|NCT00842751|OTHER|Second wash-out period|Washout of 7 days between each of the 3 treatment arms
223651557|NCT00693901|BEHAVIORAL|Community-based participatory research (CBPR)|CBPR will involve park advisory boards and community members in the research process, including the park assessments and data analysis. The assessment research will be used to inform use of discretionary funds for park programming and facilities in the hopes of increasing community physical activity. Park directors will be provided with analysis of descriptive information and community feedback to help improve outreach, park programming, and features to attract more park users and increase physical activity.
223651558|NCT00693901|BEHAVIORAL|Director-only|Park directors will be provided with descriptive information on park use and community feedback. They will also receive assistance on how to improve outreach, programming, and park features that will increase park use and physical activity. These parks will not take part in any assessments.
223651559|NCT03319758|PROCEDURE|buccal bone augmentation|Subjects in need of one implant replacing tooth to be removed in the maxilla within region 13-23 are included. At least 15 patients are recruited.
223651560|NCT04535778|BEHAVIORAL|COMPASS|An 11 module, therapist-supported online CBT program.
223651561|NCT04535778|BEHAVIORAL|Standard charity resources|Resources provided by the charities involved, including supportive listening, online support groups, information resources and local community support groups.
223651562|NCT02269267|DRUG|Imatinib (Stopping their TKI)|Patients with CML on treatment with imatinib and are in confirmed deep molecular response will stop their TKI. Confirmed deep (\> 4 log reduction) molecular response (\>MR4) defined as p210 (bcr-abl) fusion protein (BCR-ABL) \< 0.01%, for at least two years. Concurrently, the study will assess a wide range of PROs before stopping TKIs and after discontinuation in conjunction with PCR testing, though at fewer time points, utilizing online and/or phone questionnaires.
223651563|NCT02269267|DRUG|Dasatinib (Stopping their TKI)|Patients with CML on treatment with dasatinib and are in confirmed deep molecular response will stop their TKI. Confirmed deep (\> 4 log reduction) molecular response (\>MR4) defined as p210 (bcr-abl) fusion protein (BCR-ABL) \< 0.01%, for at least two years. Concurrently, the study will assess a wide range of PROs before stopping TKIs and after discontinuation in conjunction with PCR testing, though at fewer time points, utilizing online and/or phone questionnaires.
223651564|NCT02269267|DRUG|Nilotinib (Stopping their TKI)|Patients with CML on treatment with nilotinib and are in confirmed deep molecular response will stop their TKI. Confirmed deep (\> 4 log reduction) molecular response (\>MR4) defined as p210 (bcr-abl) fusion protein (BCR-ABL) \< 0.01%, for at least two years. Concurrently, the study will assess a wide range of PROs before stopping TKIs and after discontinuation in conjunction with PCR testing, though at fewer time points, utilizing online and/or phone questionnaires.
223651565|NCT02269267|DRUG|Bosutinib (Stopping their TKI)|Patients with CML on treatment with bosutinib and are in confirmed deep molecular response will stop their TKI. Confirmed deep (\> 4 log reduction) molecular response (\>MR4) defined as p210 (bcr-abl) fusion protein (BCR-ABL) \< 0.01%, for at least two years. Concurrently, the study will assess a wide range of PROs before stopping TKIs and after discontinuation in conjunction with PCR testing, though at fewer time points, utilizing online and/or phone questionnaires.
223651566|NCT03620877|BEHAVIORAL|Personalized intervention|Personalized intervention by a preventive nurse, relying on validated prevention models, in improving participation in the colonoscopic screening of siblings
224320698|NCT05753878|DRUG|HH-120 nasal spray, PartA cohort 1|A single dose of HH-120 nasal spray premixed with 1mg/ml methylene blue injection.
223651567|NCT03053167|DRUG|Irinotecan|Irinotecan: 180mg/㎡+NS250ml, ivgtt, 90min, d1 Every 3 weeks
223651568|NCT03053167|DRUG|Raltitrexed|Raltitrexed: 3mg/㎡+NS100ml，ivgtt，15min, d1 Every 3 weeks
223651569|NCT01158599|BIOLOGICAL|IXIARO®|IXIARO®, 0.5 ml (6 µg), intramuscular (i.m.) injection, two vaccinations, Days 0 and 28
223651570|NCT05906290|OTHER|Multigenerational eHealth Intervention for Grandparents and Grandchildren|Participants in this group will use an online program for 30-45 minutes per week over the course of 2 weeks delivered via smartphone, focusing on increasing physical activity.
223651571|NCT02543424|BEHAVIORAL|Motor, cognitive and neuropsychological assessment|Cognitive and motor testing and/or experimental cognitive or motor changes and/or cognitive or motor rehabilitation depending on part of the study investigated.
223651572|NCT06182956|DEVICE|Noninvasive mechanical ventilation|Noninvasive mechanical ventilation is a respiratory technique which allows the administration of positive inspiratory and expiratory airway pressures in order to ventilate the lungs.
223651573|NCT06182956|DEVICE|Nasal high-flow oxygen therapy|Nasal high-flow is a respiratory technique which allows the administration of warmed and humidified air, associated with oxygen.
223651574|NCT06182956|DEVICE|Continuous positive airway pressure|Continuous positive airway pressure is a respiratory technique which allows to maintain a constant positive airway pressure during inspiration and expiration.
224320699|NCT05753878|DRUG|HH-120 nasal spray, Part A cohort 2-7|A single dose of HH-120 nasal spray.
224320700|NCT05753878|DRUG|HH-120 nasal spray, Part A cohort 8-9|Two doses of HH-120 nasal spray.
224320701|NCT05753878|DRUG|HH-120 nasal spray, Part B|HH-120 nasal spray, 10 times daily for 7 consecutive days.
224320702|NCT05753878|OTHER|Placebo nasal spray, Part B|Placebo nasal spray, 10 times daily for 7 consecutive days.
224320703|NCT00683345|DRUG|Anakinra|Anakinra 0.67 ml (100 mg) daily subcutaneously for 4 weeks.
224320704|NCT00683345|DRUG|Placebo|Saline 0.67 ml daily subcutaneously as placebo drug.
224320705|NCT00015873|DRUG|asparaginase|
223767259|NCT01785745|OTHER|Neurocognitive therapeutic exercise|Ten exercises involving specific instruments (e.g., table inclined with a board with five concentric circles, sponges of various texture). One-hour session for three times a week for five weeks.
223767260|NCT01785745|OTHER|Traditional therapeutic exercise|Different exercises as strengthening exercises, stretching exercises, Codman's pendulum exercises and exercises against elastic band resistance. One-hour session for three times a week for five weeks
223767261|NCT06459518|OTHER|Bowen Therapy along with conventional therapy|"Bowen Technique Group Assignment: Participants will be assigned to undergo targeted Bowen Technique therapy sessions.~Session Details: The therapy sessions will include:~* Gentle, rolling-type maneuvers~* Specific placements of fingers and thumbs~* Focus on muscles, tendons, and ligaments associated with neck pain Therapeutic Pauses: There will be intentional pauses between sets of moves to allow the body time to respond to the therapeutic stimulation.~Conventional Therapy: Hot pack, TENS, Passive Stretching 2 times a week for 4 weeks"
223767262|NCT06459518|OTHER|Muscle Energy Technique with Conventional Therapy|"MET Session Structure: Participants will engage in Muscle Energy Technique (MET) sessions that focus on:~* Isometric muscle contractions, where muscles are contracted without changing length.~* Therapist-guided, controlled contractions against specific resistance.~* Relaxation Periods: Each contraction session will be followed by a period of relaxation to allow muscles to recover and respond to the therapy.~conventional therapy: Hot pack, TENS, Passive Stretching 2times a week for 4 weeks."
223767263|NCT04408820|DRUG|Roxadustat|Oral
223767264|NCT04088786|DRUG|nanoliposomal irinotecan|The starting dose of nal-IRI will be 70 mg/m2 (cohort level 1) applied for 30 min using a closed HIPEC technique following completion of cytoreductive surgery. If there is dose limiting toxicity (DLT) in cohort level 1, then the dose will be reduced the dosage of the next cohort to 50 mg/m2 (cohort level 0). If there is no DLT, the dose of nal-IRI will be increased to 140 mg/m2, 210 mg/m2 and 280 mg/m2 . If one of the patients experiences DLT, then the cohort will expand to 6 patients and accrual to the current dose level and dose escalation will stop if 2 or more patients experience a DLT at a given dose level.
223767265|NCT03866759|BEHAVIORAL|Determine the Incidence and Point Prevalence|Determine the Incidence and Point Prevalence of human immunodeficiency virus (HIV) Infection and the Most Common Sexually Transmitted Infections in Individuals With Sexual Risk Behavior.
224320706|NCT00015873|DRUG|cytarabine|
223651575|NCT01173289|RADIATION|External Beam Radiotherapy|"Definition of target volume:~* Gross tumor volume (GTV) = gross tumor defined with intravenous bolus contrast administration given CT scan~* Clinical target volume (CTV) = GTV + included volumes of clinical and suspected subclinical involvement (draining lymph nodes)~* Planning target volume (PTV) = CTV + 5-10 mm of lateral, craniocaudal, and anteroposterior margins.~Radiation dose and planning~* Total dose 65 Gy for gross tumor, 62.4 Gy for microscopic involved area, 58.5 Gy for high risk lymph node area and 52 Gy for elective lymph node area in 26 fractions during 6 weeks~* Dose prescription: 90% isodose volume of prescribed dose encompassed PTV~* The dose-volume histogram (DVH) of targets, such as GTV, CTV, and PTV, and the normal tissues, such as the esophagus, lung, contralateral normal thyroid, arytenoids, vocal cord and spinal cord, etc., was calculated."
223651576|NCT01833156|DEVICE|MoistureMeterD|measuring erythema size and the dielectric constant values
223651577|NCT02082119|RADIATION|Hypofractionated IMRT|Hypofractionated IMRT
223651578|NCT03263663|DRUG|targeted substance according to the avatar model|individualized second line treatment
223651579|NCT01773759|BEHAVIORAL|Intervention child care programs|Interventions will be designed based on findings from Aims 1 and 2, will include outreach and education, and may include on-site demonstration and USIIS training or peer tutoring.
223651580|NCT03768648|OTHER|Clinical assessment|EDSS (Kurtzke JF; 1983) and the modified MS functional composite (MSFC) score. MS history and MS treatment will be recorded
223651581|NCT03768648|OTHER|Ecological evaluation|Virtual reality task : Urban DailyCog© and Actual reality
223651582|NCT03768648|OTHER|Neuropsychological evaluation|cognitive tests exploring information processing speed, attention/concentration, working and episodic memories and executive function
223651583|NCT03768648|OTHER|Psychological evaluation|questionnaires for depression, anxiety and fatigue
223651584|NCT03768648|DEVICE|MRI Evaluation|morphological MRI and resting state functional MRI (fMRI)
223767266|NCT04155320|BEHAVIORAL|IMPART|Subjects receive counseling about partner notification and are assisted in identifying all their partners and choosing a notification method for each partner. Subjects have the option to: 1) disclose their HIV status to their partner(s) by themselves (self-tell), 2) disclose their HIV status to their partner(s) with a healthcare provider present (tell together), or 3) have their partner(s) notified confidentially by a disease notifier (anonymous provider referral), who will locate partners, notify them of potential HIV exposure, and offer them HIV testing. Partners with an initial reactive HIV screening test will be referred to care and treatment services.
224235917|NCT00674999|DRUG|Polysporin/Bacitracin/Mycostatin|Application of Prepared antibiotic ointment: Polysporin, Bacitracin and Mycostatin combined
224235918|NCT01305070|DEVICE|Admiral Xtreme|For balloon angioplasty of in-stent restenosis in the superficial femoral artery
224320707|NCT00015873|DRUG|mercaptopurine|
223651585|NCT00796419|DRUG|5% human albumin|Intravenous administration of 250 milliliters (mL) 5% human albumin every 8 hours for 5 days
223651586|NCT00796419|DRUG|6% hetastarch|Intravenous administration of 250mL 6% hetastarch every 8 hours for 5 days
223651587|NCT01047605|DRUG|Neurapas balance|6 tablets single dose
224235919|NCT01305070|DEVICE|In.Pact Admiral|For balloon angioplasty of in-stent restenosis in the superficial femoral artery
224320708|NCT00015873|DRUG|methotrexate|
224320709|NCT00015873|DRUG|prednisolone|
223651588|NCT01047605|DRUG|Pascoflair 425 mg|3 tablets , single dose
223651589|NCT01047605|DRUG|P-Tabletten weiß|3 tablets, single dose
223651590|NCT04491513|DIAGNOSTIC_TEST|Computed tomography angiography|Computed tomography angiography for the detection of proximal coronary lesions in patients in the work-up for TAVI
224320710|NCT00015873|DRUG|vincristine sulfate|
223651591|NCT00082862|BIOLOGICAL|recombinant interferon alfa|
223651592|NCT00082862|DRUG|cisplatin|
223651593|NCT00082862|DRUG|gemcitabine hydrochloride|
223651594|NCT00082862|PROCEDURE|hyperthermia treatment|
223651595|NCT04455464|DRUG|Midodrine Oral Tablet|Midodrine will be given 10 mg for one time only.
224320711|NCT03848390|BEHAVIORAL|Conventional diet|The conventional diet arm will be asked to consume a hypocaloric diet, and they will be allowed to eat at any time of the day with no time restriction.
223767267|NCT04155320|BEHAVIORAL|Standard Care|Subjects receive counseling about partner notification and are assisted in identifying all their partners and choosing a notification method for each partner. Subjects are responsible for contacting and notifying their partner(s) on their own. Subjects have the option to: 1) disclose their HIV status to their partner(s) by themselves (self-tell) or 2) disclose their HIV status to their partner(s) with a healthcare provider present (tell together). Subjects may decide which partners to notify and may choose the same or a different method for each partner.
223767268|NCT05098353|DRUG|Quetiapine|25-75 mg per day for 6 weeks
223767269|NCT03523117|DRUG|Ferric carboxymaltose|Intravenous iron
223767270|NCT03523117|DRUG|Ferrous Sulfate|oral iron therapy
223767271|NCT02092090|BEHAVIORAL|Dietary sodium reduction|Ongoing dietary advice and a supply of a reduced-sodium added-potassium salt substitute
223767272|NCT02306967|PROCEDURE|resection of oral cancer|Oral cancer will be resected.
223651603|NCT01368328|DIETARY_SUPPLEMENT|Chromium nicotinate|The intervention is offered during three months. There is a placebo group, chromium nicotinate 50 mcg group and chromium nicotinate 200 mcg group. Each patient is oriented to consume one capsule one hour after lunch and one capsule one hour after dinner.
223651604|NCT06278441|OTHER|Kangaroo care and White noise|CG newborns underwent routine heel lancing, and no intervention was performed.
223651605|NCT01460043|DRUG|Homeopathy|Each homeopathic medication was given as 1 g dose of homeopathic preparation in 30c potency. The dose is prepared as lactose globules on which the homeopathic preparation.
223651606|NCT01460043|DRUG|placebo|corresponding placebo was identical in appearance of homeopathic globule prepared in alcohol.
223651607|NCT01137201|PROCEDURE|Suturing of mesenteric defects|
223651608|NCT06343480|DRUG|Labour Induction|the use of misoprostol sublingual for labour induction compared with oxytocin titration in parturients with prelabour membrane rupture at term.
223651609|NCT02642315|DRUG|Horizant|"Phase1: During phase 1 therapy, Horizant will be added on as an adjunct to all subjects taking part in the study along with stable dose of their current dopaminergic (DA) agent and both medication will be continued for a total period of 90 days from day 0 to day 90. Subjects will be evaluated for three visits (days 0, 30 and 90) during Phase I.~Phase 2: At the 90th day follow-up visit, with initiation of phase 2 therapy, all subjects will be tapered off (by 50% reduction in dose each week) of their current dopaminergic agents while maintaining the same dose of Horizant and will be on Horizant monotherapy. All subjects will be evaluated for additional three clinic visits (days 120, 180, 360)."
223651610|NCT01760785|DRUG|divalproex sodium|Doses will be given in 250mg increments and titrated over the first four days of study until a starting dose of 750 mg is reached. The Study Oversight Team, who is not involved in any clinical visits, will be un-blinded to study drug assignment and will have plasma concentration results and adverse event reports available to them. If a subject has no adverse events and is not at therapeutic level as indicated by the blood levels, the Study Oversight Team may inform the research pharmacy to increase the dose by 1 tablet of 250 mg to 1000 mg per day. The Study Oversight Team may also inform the research pharmacy to reduce the daily dosage back down to 750 mg per day if plasma concentrations or adverse events become intolerable. The maximum dose for the purpose of this study will be 1250 mg daily and the minimum dose will be 750 mg daily. Subjects who cannot tolerate the minimum dose will be excluded from any further study participation.
223651611|NCT01760785|DRUG|Placebo|Doses will be titrated over the first four days of study in the same manner as the active study drug. After titration, the research pharmacy may increase the dose by 1 tablet per day, in the same fashion that the active drug may be adjusted, so that the participant and clinical team remain blinded to the drug assignment. The research pharmacy may also reduce the daily dosage back down by one tablet per day for the same reason.
224320712|NCT03848390|BEHAVIORAL|Modified Time-restricted Feeding|The modified time-restricted feeding arm will be asked to consume any food but will be asked to consume this food for only a 9 hour daytime period.
223651612|NCT04475042|DRUG|Dapagliflozin|10mg od
223651613|NCT04475042|DRUG|Placebo|Placebo
223651614|NCT03310489|BEHAVIORAL|Digitalized cognitive-behavioral intervention for anxiety|An internet-based CBT, including telephone coaching
223651615|NCT03310489|BEHAVIORAL|Psychoeducation about anxiety|Psychoeducative material about anxiety in internet
223651616|NCT03353337|BEHAVIORAL|aerobic exercise|Cycling at the intensity of 50%-70% of maximum heart rate (220-age) for 30 mins per day, 4 days per week, last for 1 months.
223651617|NCT03353337|BEHAVIORAL|Placebo controlled group|General intensity activities of recreation therapy, including Handicraft manufacture, reading activity, singing entertainment, walking.
223651618|NCT01193257|DRUG|Orteronel|Orteronel tablets
223651619|NCT01193257|DRUG|Prednisone|Prednisone tablets
223651620|NCT01193257|DRUG|Orteronel Placebo|Orteronel placebo-matching tablets
223651621|NCT03543787|COMBINATION_PRODUCT|Health IT and Peer Support Intervention|"Health IT will support referral system by establishing 1) communication between healthcare providers and peer navigators 2) decision support for clinician to facilitate appropriate referrals 3) tracking of referred patients real-time 4) dashboards to monitor key evaluation metrics.~Peer Support intervention: peer navigators at each level of the referral network will ensure 1) referral adherence by link clinicians and patients 2) health system navigation 3) psychosocial support: leverage their shared disease experience to help patients overcome barriers to health seeking behaviour."
223767273|NCT02306967|PROCEDURE|resection of oral cancer|Oral cancer will be resected
223767274|NCT02851537|OTHER|an advanced technique as magnetic resonance spectroscopy (MRS)|subjects who had an advanced technique as magnetic resonance spectroscopy (MRS) It is based on the detection of cerebral metabolites, and the variations of their concentration to characterize different pathologies.
223767275|NCT02611492|DRUG|Nilotinib|400 mg/12h per os D1 to D28 cycles 1-4 300 mg/12h per os D1-D14 interphase
223767276|NCT02611492|DRUG|Methotrexate|1 g/m2 continuous Intravenous Infusion (CIV) D1 cycles 2 and 4 25 mg/m2 per os D1, D8 interphase
224320713|NCT03848390|BEHAVIORAL|Physical activity|At least 30 minutes of physical activity per day 5 times per week.
224320714|NCT03848390|BEHAVIORAL|Restricted consumption of sweetened beverages|Restricted consumption of juice, soda, and other sweetened beverages.
224235920|NCT05823207|OTHER|sage essential oil|It will be applied 2 times a day, at the same times, at a distance of 30 cm from the nose for 5 minutes with normal breathing and 3 drops of essential oil by placing a tampon. The PMS scale and the quality of life scale are administered to the participants at the end of the 1st, 2nd and 3rd cycles of the menstrual cycle.
224235921|NCT05867576|BEHAVIORAL|Acceptance and Commitment Therapy (ACT)|"Acceptance and commitment therapy (ACT) is an evidence-based psychological therapy that has been successfully used to improve physical and mental health among children and adults with chronic conditions. It is a third wave cognitive behavioural therapy that encourages openness to and awareness of the present moment in order to help participants maintain behaviours consistent with their life goals. ACT fosters engagement with, rather than avoidance of, painful experiences to move towards acceptance of unchangeable difficulties alongside building a rich and meaningful life despite the presence of ongoing difficulties. This gives ACT strong face validity for application to TCS patients where there can be permanent cognitive impairment and unavoidable ongoing physical symptoms and functional limitations."
224235922|NCT02246478|DRUG|TAS-205|"* Single-dose phase: 3 steps (low dose, middle dose or high dose group), 5 patients/step, single oral administration after meals~* Multiple-dose phase: 3 steps (low dose, middle dose or high dose group), 5 patients/step (the same patients between single- and multiple-dose phases), repeated oral administration for 7 days, BID after meals"
224235923|NCT02246478|DRUG|Placebo|"* Single-dose phase: 3steps (low dose, middle dose or high dose group), 2 patients/step, single oral administration after meals~* Multiple-dose phase: 3 steps (low dose, middle dose or high dose group), 2 patients/step (the same patients between single- and multiple-dose phases), repeated oral administration for 7 days, BID after meals"
224235924|NCT00711464|DRUG|modafinil (M1, M2, M4)|modafinil 100, 200, and 400 mg oral dose
224235925|NCT02309827|DRUG|PF-06651600 or Placebo|PF-06651600 or placebo will be administered as an extemporaneously prepared solution in each cohort.
224235926|NCT00010647|PROCEDURE|Acupuncture|
224235927|NCT05493176|OTHER|Dry immersion|Subjects are immersed up to the neck for 5 days in a specially designed bath filled with tap water.
223767277|NCT02611492|DRUG|Aracytine (Ara C)|Age\<45 years: 3 mg/m2/12h D2, D3 cycles 2 and 4 Age\>=45 years: 1.5 mg/m2/12h D2, D3 cycles 2 and 4
223767278|NCT02611492|DRUG|Granulocyte Colony-Stimulating Factor (G-CSF)|5µg/kg/d (SC) D6 until neutrophils \> 1 G/L D15 cycles 1 and 3; D6 cycles 2 and 4
224235928|NCT01375322|DRUG|Amlodipine+Benazepril|Amlodipine besylate 5 mg + Benazepril hydrochloride 10 mg, daily use and forced titrate till 16-week end
224235929|NCT01375322|DRUG|Valsartan+Hydrochlorothiazide|Valsartan 80 mg + Hydrochlorothiazide 12.5 mg, daily use and forced titrate till 16-week end
224235930|NCT03453125|BEHAVIORAL|Spanish modified Story Memory Technique (mSMT)|
224235931|NCT05207280|COMBINATION_PRODUCT|Noradrenaline plus Terlipressin|Comparison Norepinephrine plus placebo versus Terlipressin plus Norepinephrine for the Treatment of Septic Shock
224235932|NCT05475353|BEHAVIORAL|Asyncronized Exercise|This group will be informed about ergonomics and protective exercises for the musculoskeletal system with an online seminar.
224235933|NCT05475353|PROCEDURE|Syncronized Exercise|This group will be informed about ergonomics and protective exercises for the musculoskeletal system with an online seminar. Then, participants will complete the 6 weeks of exercise training at an online video conference program two times a week under the physiotherapist's supervise.
224235934|NCT02805322|DEVICE|ARC InstaTemp MD|Measurement of Body Temperature using an Infrared Non-Touch Thermometer - Experimental arm.
224235935|NCT02805322|DEVICE|Covidien Genius 2 Tympanic Thermometer|Measurement of Tympanic Temperature using a standard approved method - Control arm.
224235936|NCT02805322|DEVICE|Welch Allen SureTemp Plus Sublingual Thermometer|Measurement of Sublingual Temperature using a standard approved method - Control arm.
223651622|NCT03118661|OTHER|For Step 2: Structured treatment interruption|-Accepted tool in the evaluation of immunological interventions, gene therapy, or therapeutic vaccines for the treatment of HIV infection
223651623|NCT03118661|PROCEDURE|Peripheral blood draw|-Screening, entry for Step 1, Step 1 visit 2, entry for Step 2, weekly, week 16, monthly through week 52, week 52, quarterly through year 5, year 5, and viral relapse
223651624|NCT04882345|DRUG|Almonertinib|"Almonertinib is a class 1 new drug,the third-generation small molecule EGFR TKI, which can irreversibly and highly selectively inhibit EGFR sensitive mutations (such as exon 19 deletion and L858R mutation) and T790M resistance mutations.~Patients meeting the criteria for inclusion and exclusion were included in the Almonertinib treatment group and received 110 mg of Almonertinib orally once a day."
223651625|NCT00108875|BIOLOGICAL|Survivin peptide vaccine|
223651626|NCT03393247|DRUG|infliximab and azathioprine combination at week 0|All enrolled CD patients will schedule on IF X (week 0, 2, 6 and then every 8 weeks at 5mg/kg).Experimental group will receive azathioprine at week 0.
223651627|NCT03393247|DRUG|infliximab and azathioprine combination at week 14|All enrolled CD patients will schedule on IF X (week 0, 2, 6 and then every 8 weeks at 5mg/kg).Control group will receive azathioprine at week 14.
223651628|NCT05780424|BIOLOGICAL|BRII-196|BRII-196 is a fully human immunoglobulin G (IgG)-1 monoclonal antibody (mAb) derived from antibody P2C-1F11 that was isolated directly from human B cells of a convalescent COVID-19 patient.
223651629|NCT05780424|BIOLOGICAL|BRII-198|BRII-198 is a fully human IgG-1 mAb derived from antibody P2B-1G5 that was isolated directly from human B cells of a convalescent COVID-19 patient.
223651630|NCT05780424|BIOLOGICAL|Placebo|Commercially available 0.9% sodium chloride solution
223651631|NCT05780424|BIOLOGICAL|Remdesivir|Antiviral agent
223651632|NCT00264758|DEVICE|Conventional hemodialysis|Three times per week in-center hemodialysis
224235937|NCT02115646|DEVICE|fractionated carbon dioxide laser|patients will have serial laser treatments
224235938|NCT01531205|DRUG|Androgen Ablation|All patients will receive luteinizing hormone-releasing hormone (LHRH) agonist therapy (leuprolide or goserelin acetate) concurrent with Cabazitaxel, before surgery. A course of bicalutamide 50 mg daily orally for 14-21 days is recommended for patients starting LHRH agonist therapy and suspected to be at risk for tumor flare, e.g., significant obstructive urinary symptoms and will be optional in other patients.
224320715|NCT04570787|PROCEDURE|Urinary bladder catheterisation|Installation of Foley catheter into the urinary bladder
223651633|NCT00264758|DEVICE|Frequent hemodialysis|Six times per week in-center hemodialysis
223651634|NCT04385693|PROCEDURE|Pulpotomy|Pulpotomy using bioactive bioceramic cement of 1.5 mm layer of a newly FDA approved calcium-based silicate cement (Nusmile NeoPutty) will be placed on the pulp chamber floor and canals' orifices for pulp and root therapy. Pulpotomy is a procedure in which the coronal pulp is amputated, and the remaining radicular pulp tissue is treated with a medicament to preserve the pulp's health.This technique involves administration of local analgesia, Isolation of the tooth with rubber dam, complete caries removal and then access to the pulp chamber using drills.
223767279|NCT02611492|DRUG|Depomedrol|40 mg + methotrexate 15 mg + Aracytine (AraC) 40mg IT cycle 1: D1, D8, D15 IT cycles 2 and 4: D9 IT cycle 3: D1
224235939|NCT01531205|DRUG|Cabazitaxel|Intravenous treatment with Cabazitaxel 25 mg/m\^2 is given on day 1 every 21 days. A cycle of chemotherapy will be defined as 21 days. A total of four cycles of combination therapy are planned for a total duration of 12 weeks (before surgery), starting within 3 weeks of protocol entry, to be given concurrent with hormone therapy.
223767280|NCT02611492|DRUG|Dexamethasone|40 mg per os, D1-D2, D8-D9, D15-D16, D22-D23, cycles 1 and 3
224235940|NCT01531205|DRUG|Salvage Therapy|Patients will undergo 4 cycles of chemotherapy in conjunction with LHRH agonist therapy (before surgery) subsequent to which they will have their serum Prostate-specific antigen (PSA), bone scan, abdominal pelvic computed tomography (CT) or magnetic resonance imaging (MRI) repeated. Patients with a detectable metastatic diseases will be removed from the study. Salvage surgery will be performed within 8 weeks after the completion of Cabazitaxel chemotherapy. For patients who achieved undetectable PSA following surgery, androgen deprivation therapy will be discontinued.
224235941|NCT01531205|DRUG|Neoadjuvant Treatment - Hormonal Therapy|All treatment will be given on an outpatient basis. Treatment should start within 3 weeks of protocol entry. All patients will receive androgen ablation with LHRH agonist therapy in conjunction with the 4 cycles of Cabazitaxel for neoadjuvant chemohormonal therapy. Androgen ablative therapy will be discontinued before surgery. A course of bicalutamide 50 mg daily orally for 14-21 days is recommended for patients starting LHRH agonist therapy and suspected to be at risk for tumor flare, e.g., significant obstructive urinary symptoms and will be optional in other patients.
224235942|NCT01531205|DRUG|Neoadjuvant Treatment - Cabazitaxel|"All treatment will be given on an outpatient basis and should start within 3 weeks of protocol entry. Intravenous treatment with Cabazitaxel is given on Day 1 every 3 weeks. A cycle of combination therapy will be defined as 3 weeks. A total of 4 cycles of combination therapy are planned before surgery for a total duration of 12 weeks.~Cabazitaxel will be administered before surgery by one-hourly infusions via central or peripheral intravenous access at a dose of 25 mg/m\^2 as a one hour intravenous infusion in combination with oral prednisone 10 mg administered daily throughout Cabazitaxel treatment. It is advised that all patients receiving Cabazitaxel have a reliable form of venous access, e.g., central venous catheter to ensure their ability to receive therapy without undue delay."
224235943|NCT00995553|BEHAVIORAL|Cognitive Remediation|This is an adaptive, computer-based cognitive training intervention. Participants will complete 3 1-hour cognitive training sessions focused on attention and working memory processes weekly for 4 months.
224320716|NCT05258383|OTHER|3D maps of physical doses|3D maps of physical doses delivered to organs by positioning imaging will be calculated based on the patient's CT image used by the treatment planning system (dosimetric calculation performed by Monte Carlo method).
224320717|NCT00589927|DRUG|cilostazol|cilostazol 200mg loading dose within 1 hours after successful stenting, followed by 100mg bid for 8 months
223651635|NCT04385693|PROCEDURE|Extraction and placement of space maintainer|If during the pulpotomy procedure, hemostasis is not obtainable, or signs of advanced pulp degeneration such as dark and limited or no bleeding from canals, the pulp will be diagnosed as chronically inflamed or necrotic, and tooth will be extracted. As part of the standard of care after extractions of primary molars, space maintenance will be assessed, and a space maintainer fabricated if indicated. Extracted teeth will serve as controls, and information regarding the need or not of space maintenance.
223651636|NCT05710445|OTHER|Augmented Reality|Mixed reality smart glasses will be used to view a virtual monitor which mirrors the ultrasound screen in real-time.
223651637|NCT03546868|DRUG|[18F]FSPG|Patients will receive 200 MBq of \[18F\]FSPG and undergo PET/CT for assessing disease activity in inflammatory bowel disease
223651638|NCT01292824|DRUG|ITX 5061|ITX 5061 (150mg) pre-transplant, immediately post-transplant and daily thereafter for 1 week.
223651639|NCT04740138|BEHAVIORAL|Dialectical Behavioral Therapy Skills + Parent Training|"The DBT/Parent training group intervention is a novel integration of three evidence-based treatments (i.e. DBT Skills, Parent Management Training (PMT), and Emotion Coaching (EC)). The DBT Skills portion of each session follows the DBT Skills Training Manual Second Edition and DBT Skills Training Handouts and Worksheets Second Edition. DBT Skills portions cover the four modules of traditional DBT Skills: mindfulness, distress tolerance, emotion regulation and interpersonal effectiveness.~PMT portions of the intervention cover: praise, positive interactions and parental attention, reward systems, effective commands, use of consequences, and problem solving. EC portions of the intervention cover: psychoeducation on children's emotional development, teaching children to identify and label emotions, validation of children's emotions, handling children's negative emotions, fostering children's positive emotions and parental modeling of emotion regulation and expression."
223767281|NCT02611492|DRUG|Vincristine|2 mg total dose IV, D1 D8 D15 D22 cycles 1 and 3
223767282|NCT02611492|DRUG|Imatinib|300 mg/12h per os in post-SCT maintenance therapy for during at least 2 years
223767283|NCT02611492|DRUG|6 Mercaptopurine (6MP)|60 mg/m2 per os, D1 to D14, interphase
223767284|NCT00450710|PROCEDURE|ileal interposition with a sleeve gastrectomy|
223767285|NCT04996992|PROCEDURE|MR-guided focused ultrasound|MR-guided focused ultrasound pallidothalamic tractotomy is a minimally invasive and effective procedure for thetreatment of Parkinson's disease(PD) patients.
224320718|NCT00589927|DRUG|placebo|placebo 200mg loading dose within 1 hours after successful stenting, followed by 100mg bid for 8 months
223651640|NCT04473742|BIOLOGICAL|Blood collection|4 EDTA tubes for 24 mL blood collection
223651641|NCT04473742|BIOLOGICAL|Blood sample|2 drying tubes for 12 mL blood collection
223651642|NCT04473742|BIOLOGICAL|Blood sample|1 drying tube for 6 mL blood collection
223651643|NCT05055492|DIAGNOSTIC_TEST|Take home saliva kits|Saliva kits will be made available at schools for pick up to support symptomatic testing using PCR for students, staff and family members.
223651644|NCT01097031|OTHER|Infusion Intermittent|
223651645|NCT01027273|BEHAVIORAL|Prevent Return of Stroke|Prevent Return of Stroke is a community-based, peer-led stroke recurrence prevention program. This is a bilingual (English/Spanish) education program written at a 4th grade reading level, and contains simple, actionable, messages, easily taught by lay leaders, and focuses on enhancing self-efficacy to make lifestyle changes, to help reduce stroke recurrence risk factors. It consists of 6 sessions (1½ hours each) held over 6-weeks. Topics include learning the risk factors for stroke, controlling hypertension, LDL cholesterol, preventing blood clots, medication adherence, and stress management.The intervention arm will participate in the intervention shortly after enrolling in the trial.
223651646|NCT01027273|BEHAVIORAL|Prevent Return of Stroke|The intervention arm will participate in the intervention shortly after enrolling in the trial. The usual care arm will be offered the intervention after 12 months from enrolling in the trial.
223651647|NCT02490020|BIOLOGICAL|mesenchymal stem cell|
223651648|NCT04768608|DRUG|PD1-PSMA-CART cells|PD1-PSMA-CART cells will be given IV at split doses
223651649|NCT04657094|DRUG|Acalabrutinib|Given PO
223651650|NCT02383212|DRUG|Cemiplimab|
223651651|NCT02383212|RADIATION|Hypofractionated radiotherapy|
223651652|NCT02383212|DRUG|Cyclophosphamide|
223651653|NCT02383212|DRUG|Docetaxel|
223651654|NCT02383212|DRUG|Carboplatin|
223651655|NCT02383212|DRUG|GM-CSF|
223651656|NCT02383212|DRUG|Paclitaxel|
223651657|NCT02383212|DRUG|Pemetrexed|
223651658|NCT02817009|BEHAVIORAL|Social Support|The social worker for the parent support group addresses culturally specific questions and adopts culturally acceptable strategies for setting limits and promoting healthy behaviors, engaging the group as a whole and building peer support.
223651659|NCT02817009|BEHAVIORAL|Nutrition Session|Nutrition sessions will focus on how to make traditional Latin American foods healthier, including the sharing of recipes and learning what foods to buy in local supermarkets. Home visits by the nutritionist assists with family-centric strategies for healthier eating in their urban Latino households, including those with large extended families.
223651660|NCT02817009|BEHAVIORAL|Physical Activity Session|45 minutes physical activity session to promote healthy behaviors
223651661|NCT05773170|DRUG|Refralon|1 mg/ml concentrate for solution for intravenous injection. (Prior to the administration, 2 mL of Refralon® must be diluted to 20 mL in 0.9 % sodium chloride).
223651662|NCT05282602|OTHER|baseline physical therapy treatment along with Wii Fit based exercises|Group A performed Wii Fit based exercises for 6 weeks. Group A will be treated with Wii Fit based exercises (40 mins session, 3 days/week, Penguin slide, soccer heading, tilt table, tightrope walking)
223651663|NCT05282602|OTHER|Proprioceptive exercises|Group B will be treated with Proprioceptive training (40 min session, 3 days/week, toe walking, heel walking, cross-body leg swings right and left sides, partial squat, ). In both groups pre and post-test measurements of Balance and Fall of risk will be assessed through Berg Balance scale, STAR excursion, Modified Fall Efficacy scale, and Timed Up and Go (TUG). Evaluation will be done before session start and at the end of 6th Week.
223651664|NCT00337675|DRUG|montelukast sodium|Montelukast 4 mg (or 5 mg, depending on age of patient) qd + episode driven supplemental Pbo qd for 12 days for a 52-wk treatment period.
223651665|NCT00337675|DRUG|Comparator: Placebo (unspecified)|Placebo (Pbo) qd + episode driven supplemental Pbo for 12 days for a 52-wk treatment period.
223651666|NCT00337675|DRUG|montelukast sodium|Pbo qd + episode driven supplemental Montelukast 4 mg (or 5 mg, depending on age of patient) qd for 12 days for a 52-wk treatment period.
223651667|NCT06845501|DIETARY_SUPPLEMENT|purine-rich diet|diet to achieve a purine intake of 160mg/d
223651668|NCT05140720|BIOLOGICAL|PNEUMOSIL®|"Study subjects will be vaccinated PNEUMOSIL® with the primary doses as described below:~Group 1: 3 doses, 4 to 8 week interval Group 2: 2 doses, dose interval \> 1 month Group 3: 2 doses, dose interval \> 2 months"
223651669|NCT05611502|DEVICE|TMS|TMS will be administered in a pattern that is either excitatory or inhibitory.
223651670|NCT06131983|DRUG|ARO-DUX4 for Injection|single or multiple doses of ARO-DUX4 by intravenous (IV) infusion
223651671|NCT06131983|DRUG|Placebo|calculated volume to match active treatment by IV infusion
223651672|NCT05562258|BEHAVIORAL|Parent Coaching and Patient Education|This group includes 12 weeks of eating disorder therapy provided to the patient. Outside of therapy, parents will have access to a coach and patients will have access to weekly educational material.
223651673|NCT05562258|BEHAVIORAL|Parent Education and Patient Coaching|This group includes 12 weeks of eating disorder therapy provided to the patient. Outside of therapy, parents will have access to weekly educational material and patients will have access to a coach.
223651674|NCT06021132|DEVICE|cochlear implant|Insertion of a electrode into the cochlear with the aim of providing deaf and severe hearing handicapped with the ability to hear speech.
223651675|NCT04095065|BEHAVIORAL|itMatters|Increase knowledge related to STIs, STI risk, alcohol impairment, condom use, alcohol use behavior tracking skill, testing \& treatment knowledge. Correct misperceptions regarding approval (injunctive norms) and prevalence (descriptive norms) of alcohol misuse \& sexual risk taking.
223651676|NCT04095065|BEHAVIORAL|itMatters and itMatters Sexual Violence Prevention|Increase knowledge related to STIs, STI risk, alcohol impairment, condom use, alcohol use behavior tracking skill, testing \& treatment knowledge. Correct misperceptions regarding approval (injunctive norms) and prevalence (descriptive norms) of alcohol misuse \& sexual risk taking. Additionally, increased knowledge related to sexual violence (prevalence, key definitions, individual rights and responsibilities, laws) and increased knowledge, efficacy, and intentions to use bystander behaviors during moments of sexual violence.
223767286|NCT00461539|OTHER|Treatment as usual|Those participants receiving standard care will be referred to special programs as needed to reduce their involvement in risky health behaviors.
223651677|NCT04095065|BEHAVIORAL|itMatters Well-being and itMatters Sexual Violence Prevention|Increase knowledge related to sleep, including biological effects of sleep and sleep hygiene. Increase knowledge related to time management, including important definitions, sleep management strategies, and effective time management routines. Additionally, increased knowledge related to sexual violence (prevalence, key definitions, individual rights and responsibilities, laws) and increase knowledge, efficacy, and intentions to use bystander behaviors during moments of sexual violence.
223651678|NCT04095065|BEHAVIORAL|itMatters Well-being|Increase knowledge related to sleep, including biological effects of sleep and sleep hygiene. Increase knowledge related to time management, including important definitions, sleep management strategies, and effective time management routines.
223651679|NCT06170242|DRUG|EDP-323 Dose Regimen 1|EDP-323 capsule
223651680|NCT06170242|DRUG|EDP-323 Dose Regimen 2|EDP-323 capsule
223651681|NCT06170242|DRUG|Placebo|Placebo capsule
223651682|NCT04141839|BEHAVIORAL|Safer Bars|Safer Bars, a primary perpetration prevention program based on a bystander intervention model and the theory of planned behavior. Bar staff are trained to recognize and respond to sexual aggression and its precursors among patrons.
223651683|NCT02329652|DEVICE|Networked Neuroprosthetic System for Grasp and Trunk|Receive implanted networked neuroprosthesis
223651684|NCT01742299|DRUG|imatinib mesylate|Imatinib will be provided as 100 mg and 400 mg tablets taken orally once daily unless other wise instructed by investigator
223651685|NCT03217058|BEHAVIORAL|Clinic-based screening and behavioral interventions|As part of routine HIV primary care visits, patients will complete self-administered computerized substance use, anxiety and depression screening measures. Results will be integrated into the electronic health record. A behavioral health specialist on the clinic staff will contact patients who screen positive for high-risk substance use, anxiety or depression, and offer behavioral interventions including motivational interviewing and cognitive behavioral therapy.
223651686|NCT01900132|DEVICE|EIM testing|EIM device is placed on the muscle and a high frequency current is delivered to the skin.
223651687|NCT01900132|DEVICE|Nerve &amp; muscle ultrasonography|Ultrasound waves to examine the muscles and nerves
223651688|NCT01900132|DEVICE|Nerve conduction studies|Small metal disk electrodes attached to wires onto skin to measure how fast nerves conduct electrical impulses and the strength of the connection between nerves and muscles.
223651689|NCT01900132|DEVICE|Electromyography (EMG)|Thin needle placed into muscles to record electrical activity-adults only
223651690|NCT04487470|OTHER|Flavored filtered cigars|Flavored and unflavored Cheyenne filtered cigars that are currently available in the marketplace for purchase
223651691|NCT04487470|OTHER|Unflavored filtered cigars|Flavored and unflavored Cheyenne filtered cigars that are currently available in the marketplace for purchase
223651692|NCT06039878|BEHAVIORAL|Bonding-Evoked Oxytocin|Mother participates in bonding activity with infant at ages 1, 3, and 6 months
223651693|NCT06039878|BEHAVIORAL|Distress Relieving Effects of Sucrose|Researcher elicits distress in the infant (sequence of unswaddling, pacifier removal, and arm restraint), followed by delivery of oral sucrose in one condition and water in other condition
223651694|NCT06039878|BEHAVIORAL|Hedonic Response to Sucrose|Researcher gives infant opportunity to suck from two bottles, one containing sucrose and one plain water at infant ages 1, 3, and 6 months
223651695|NCT06039878|BEHAVIORAL|Typical versus Challenging Feeding-Social|Mother feeds infant on four counterbalanced days at infant ages 1, 3, and 6 months crossing two conditions: (1) regular size nipple versus smaller aperture nipple ('challenging') and (2) providing social interaction while feeding versus not.
223651696|NCT06039878|BEHAVIORAL|Caloric Compensation-Social|Mother feeds infant on four counterbalanced days at infant ages 1, 3, and 6 months crossing two conditions: (1) offering a bottle feeding ad lib for 3 hours versus offering a bottle feeding every hour for 3 hours; (2) providing social interaction while feeding versus not.
223651697|NCT06039878|BEHAVIORAL|Ability to Delay Gratification for Food in Infants-Social Task (ATDG-FIT-Social)|When mother indicates infant is hungry, she presents the infant the bottle but withholds feeding for 5 minutes, feeds for one minute, withholds feeding for 30 seconds, and then resumes feeding. She does so under two conditions (providing social interaction during feeding versus not) on two counterbalanced days at infant ages 1, 3, and 6 months.
223651698|NCT01022515|OTHER|plasma EM66 & CgA levels assessment|After inclusion checking to eliminate the presence of pheochromocytoma / paraganglioma, a blood sample will be drawn to assess plasma EM66 and CgA levels.
223651699|NCT01022515|OTHER|usual follow up with regular EM66 & Cga levels assessment|"Patients with pheochromocytoma / paraganglioma will be followed-up as the international standards recommend.~Regularly, blood samples will be drawn for the usual assessment of CgA levels and also EM66 (research purpose) levels."
223651700|NCT02586207|DRUG|pembrolizumab (MK-3475)|200mg IV on days -7(loading dose), 15, 36, 57, 78, 99, 120, 141.
223651701|NCT02586207|DRUG|Cisplatin|Cisplatin 40 mg/m2 IV on days 1, 8, 15, 22, 29, 36
223651702|NCT02586207|RADIATION|Radiation|70 Gy fractionated over 35 days
223651703|NCT06449313|DRUG|Cemiplimab-Rwlc|350 mg every 3 weeks, intravenously, on day 1 of a 21 day cycle for 4 cycles, then every 3 weeks after surgery for 1 year.
223651704|NCT02606149|BEHAVIORAL|Truthful information on chemotherapy risks|One of two trained oncologist will meet the patient and inform him following an interview-guideline
223651705|NCT02606149|BEHAVIORAL|Standard of information|
223651706|NCT00441064|DRUG|Aliskiren|
223651707|NCT03962504|BEHAVIORAL|trauma-focused treatment|cognitive behavioral treatment for posttraumatic stress disorder that consists of exposure to the trauma memory.
223651708|NCT02689362|DRUG|Evogliptin|1 tablet per day
223651709|NCT02689362|DRUG|Sitagliptin|1 tablet per day
223767287|NCT00461539|BEHAVIORAL|Behavioral health intervention|Participants assigned to the health education intervention will attend 10 weekly education sessions that will be led by trained health educators. Parents or guardians may be asked to attend sessions depending on their interest in the intervention and the age of the youth participant. Topics covered will include teenage smoking, alcohol and drug abuse, risky sexual behaviors, and obesity. Cognitive-behavioral strategies, role playing, and media clips will be used to stimulate discussion and involvement in the intervention.
223767288|NCT01410149|OTHER|PAV|Proportional Assist Ventilation will be used to ventilate the patient for a 24 hour period
223767289|NCT01410149|OTHER|PSV|Pressure Support Ventilation will be used to ventilate the patient for a 24 hour period
224235944|NCT00995553|BEHAVIORAL|Computer Skills|This is a computer-based course in which participants will be taught how to use Microsoft Office applications and typing skills. Participants will attend a 1-hour course three times a week four 4-months.
224235945|NCT02079753|DEVICE|Inogen|single pulse dose concentrator (Inogen One G2 portable. Inogen) device for 24 hours
224235946|NCT02079753|DEVICE|Combination system of a portable and a stationary device.|"Combination system of a portable and a stationary device (reservoir of liquid oxygen Liberator 30, Caire and a liquid Stroller oxygen pack Caire for patients using previously liquid oxygen, or a VisionAire5 Airsep stationary concentrator and an Inogen One G2 portable Inogen concentrator for patients using previously concentrators)"
224235947|NCT01089647|DRUG|budesonide and montelukast|budesonide aqua nasal spray 1 spray each nostril bid for 12 weeks Montelukast pill 10 mg po daily for 12 weeks
224235948|NCT01089647|DRUG|Placebo|sugar pill po daily for 12 weeks salt water nasal spray 1 spray each nostril bid for 12 weeks
224235949|NCT02632136|DRUG|TAP Block Group|Transversus Abdominus Plane (TAP) block: Bupivacaine (30 ml of 0.25%)is injected between internal oblique and transveralis facia. The location of needle and the bleb that is formed after the injection is inspected under diect laparoscopic vision.
224235950|NCT02632136|DRUG|Peri-Portal Block Group|15 ml of 0.5% Bupivacaine is injected in the skin and subcutaneous tissue before inserting the ports. 7 ml out of it is injected at sub-umblical port and 4 ml each a the site of other two ports.
224235951|NCT04230083|DRUG|Dienogest 2.0 mg Test Drug|Bioequivalence
224235952|NCT04230083|DRUG|Dienogest 2.0 mg Reference Product|Bioequivalence
224235953|NCT05277727|DIETARY_SUPPLEMENT|Fucoidan 500mg|1 capsule to be taken twice daily with food (morning and evening).
224235954|NCT05277727|DIETARY_SUPPLEMENT|Placebo|1 capsule to be taken twice daily with food (morning and evening).
224320719|NCT04841005|OTHER|The Square-Step Exercise Training|The Square-Step Exercise is instructed to walk according to the step pattern shown on a 100 \* 250 cm mat, divided into 40 squares of 25 cm each. It includes forward, backward, lateral and diagonal steps, and step patterns are progressively made more complex. Each pattern consists of two to 16 steps; Individuals are asked to repeat the step pattern until they reach the end of the mat. Each step pattern is repeated 4-10 times to ensure that individuals can complete the pattern. The individuals included in the study will exercise in easy-difficulty patterns for the first 2 weeks, medium-difficulty patterns in the 3rd and 4th weeks, medium and advanced patterns in the 5th and 6th weeks, and advanced patterns in the 7th and 8th weeks. The square-step exercise group will perform 15 minutes of warm-up exercise, 30 minutes of progressive square-step exercise, and 10 minutes of cool-down exercise accompanied by a physiotherapist, 3 days a week.
224320720|NCT04841005|OTHER|Strengthening Exercise Training|Thera-Band brand elastic bands will be used to apply resistance in strengthening training. To determine the intensity of the exercise, the perceived difficulty level after 15 repetitions with the elastic band will be evaluated with the Borg scale. If the perceived difficulty level is at the level of 12-14 (slightly difficult), it will be considered as the starting difficulty level.In the strengthening exercise group will perform, shoulder abduction, shoulder press after elbow flexion, horizontal abduction, punching with an elastic band, triceps strengthening, external rotation of the shoulder, hip abduction with external rotation and sit-to-stand exercises for 8 weeks, 3 days / week , 3 sets / sessions, 8-12 repetitions. For each exercise, it will be applied as 8 repetitions in the initial workload. In the next exercise sessions, the number of repetitions will be increased until the patient can comfortably perform 12 repetitions with the same load.
223651710|NCT02689362|DRUG|Placebo Evogliptin|1 tablet per day
223767290|NCT01410149|OTHER|ACV|Assist Control Ventilation will be used to ventilate the patient for a 24 hour period
224235955|NCT02081521|BEHAVIORAL|Community behaviour change campaign|Community campaign targeting exclusive breastfeeding, handwashing with soap, and use of ORS and zinc to manage child diarrhoea. Includes a range of activities within the community (large events and small group sessions); clinic activities (ORS preparation), radio adverts.
224320721|NCT03608527|BEHAVIORAL|Voluntary-based upper limb motor rehabilitation|Exercises for neuromuscular control to improve proprioceptive sensibility, muscle strength, stability and coordination of the upper limbs, mainly including task-oriented movements with the goal to improve activities of daily living. Both proximal and distal muscles are involved, in actions such as grasping wooden cubes of different sizes, pinching, reaching targets displayed in front of the patient, and doing patchwork or paper mandala.
224320722|NCT03608527|BEHAVIORAL|Passive upper limb mobilization|Passive mobilization delivered by a physical therapist of shoulder, elbow, wrist and fingers without detectable muscle activity.
223651711|NCT02689362|DRUG|Placebo Sitagliptin|1 tablet per day
223651712|NCT00000400|DRUG|Human parathyroid hormone [hPTH-(1-34)]|37 mcg once daily by self-administered sc injection
223651713|NCT00000400|DRUG|alendronate|70 mg/week by oral route
223651714|NCT03159039|OTHER|Conventional Physiotherapy|
224235956|NCT05742581|OTHER|Computed Tomography|In our study, computerized tomography of 24 rotator cuff tears (rotator cuff tear group) and 20 Bankart lesions, and no rotator cuff tears (control group) were examined. CSA and AI were measured on three-dimensional glenohumeral joint models obtained by three-dimensional reconstructions of computed tomography examinations.
224235957|NCT05042336|DRUG|camrelizumab/lenvatinib combined with TACE|"Lenvatinib 4mg qd body weight≤60,8mg；body weight\>60,12mg~Camrelizumab 200mg q2w/q3w"
223651715|NCT03159039|OTHER|Prolonged slow exhalation technique|Postural drainage associated with manual vibration and a mild pressure in the end of expiratory phase
223651716|NCT02039024|DRUG|18F- DTBZ|"During this study, subjects will receive a single i.v. administration of approximately 370MBq (10 mCi) 18F- DTBZ immediately prior to imaging. The dosage of DTBZ is 10 nmole. The effective dose in human body is about 5.6 mSV.~During this study, subjects will receive a single i.v. administration of approximately 370MBq (10 mCi) florbetapir F-18 immediately prior to imaging. The dosage of DTBZ is 10 nmole. The effective dose in human body is about 5.6 mSV.~The proposed dose for this study is based on our phase I study. At the proposed human dose of 10 mCi, the whole body effective dose (ED) will be approximately 680 mrem. The estimated human ED is expected to be comparable to or below the range of other approved brain imaging agents, such as 18F-FDG (Lin 2010)."
223767291|NCT03770468|PROCEDURE|Blood drawl|
223767292|NCT01584947|DRUG|Bupivacaine|Bupivacaine lozenge taken 3 times a day for two weeks
223767293|NCT01584947|DRUG|Placebo|Placebo lozenge taken three times a day for two weeks
224320723|NCT04479644|DRUG|BRII-198|BRII-198 given intravenously
224320724|NCT04479644|DRUG|Placebo|Placebo given intravenously
223651717|NCT02730013|BEHAVIORAL|Square Stepping Exercise|"Square Stepping Exercise involves mimicking a stepping pattern demonstrated by an instructor. The stepping patterns become progressively difficult and involve forward, backward, lateral and diagonal movements on a 250cm long mat with 25cm square grids.~In a group setting, an instructor will demonstrate walking patterns on a gridded mat to the participants and the participants must memorize and repeat the patterns on their own. This program has over 200 patterns that increase in difficulty from beginner to advanced. Eighty percent of the group must successfully complete the patterns to move onto the next pattern. Social engagement is encouraged."
223651718|NCT01048034|DRUG|Azacitidine|100 mg / m(2) subcutaneously day 1-5 every 4 weeks for 6 cycles. Another three cycles will be given together with epo for those not responding to the first 6 cycles of Azacitidine
223651719|NCT01048034|DRUG|Erythropoetin|For those patients not responding to Azacitidine alone, the combination of Azacitidine and erythropoetin 60 000 U / week for 16 weeks will be given.
224320725|NCT04005612|DIETARY_SUPPLEMENT|vitamin D3|50,000 IU VD3 / week for 8 weeks
224320726|NCT04005612|DIETARY_SUPPLEMENT|omega-3 fatty acid|300 mg of omega 3-FA once daily for 8 weeks
224320727|NCT04005612|DIETARY_SUPPLEMENT|vitamin D3 and omega-3 fatty acid|50,000 IU VD3 / week for 8 weeks and 300 mg of omega-3FA once daily for 8 weeks
224320728|NCT04005612|OTHER|control|no intervention
223651720|NCT05569070|OTHER|Guided Young United Parents! Website Intervention|Participants assigned to Guided YUP! will receive two months of structured use of the YUP! website intervention, which involves weekly review of written and video content, meetings with near-peer mentors, use of the goal tool, interaction with the online community, and receipt of tips and affirmations.
223651721|NCT05569070|OTHER|Nutrition Website|Participants assigned to the Nutrition Website will be provided with the link to the MyPlate website, which is maintained by the U.S. Department of Agriculture. At the enrollment session, participants will be given brief instruction during the enrollment session about features available on the website that may be interesting to them and encouraged to engage in any of the website or app features at whatever level they are comfortable with. No further direction will be provided to them after the enrollment session.
223651722|NCT03293368|BIOLOGICAL|Platelet rich plasma|Platelet rich plasma will be prepared from the patients own blood in the same visit using a double spin technique, then 0.5 ml of PRP will be injected per 1 cm2 of eroded oral mucosa.
223651723|NCT03293368|DRUG|Triamcinolone Acetonide|0.5 ml of triamcinolone acetonide 40mg will be injected per 1 cm2 of eroded oral mucosa
224320729|NCT02759692|DEVICE|TEST Contact Lens|
223651724|NCT02009280|DRUG|Administration of anesthesia: Propofol|Maintenance of anesthesia with the propofol
223651725|NCT02009280|DRUG|Administration of anesthesia: Sevoflurane|Maintenance of anesthesia with the sevoflurane
223651726|NCT05509842|DEVICE|rTMS|A MagPro X100 magnetic stimulator with a 90mm figure-8 coil (MC-B70, MagVenture Inc.) will be used to apply rTMS to targeted locations marked on the structural MRI using a frameless infrared stereotactic neuronavigation system (Brainsight, Rogue Research).
223651727|NCT05756426|OTHER|Prospective|Single arm, healthy adult volunteers for blood donation.
223651728|NCT05035212|BIOLOGICAL|RSVpreF|RSV vaccine (RSVpreF)
223651729|NCT05035212|BIOLOGICAL|Placebo|Placebo
223651730|NCT00018044|DRUG|Clofazimine|
223767294|NCT00274599|DRUG|Telmisartan|
223767295|NCT00274599|DRUG|Ramipril|
223767296|NCT03932942|DIAGNOSTIC_TEST|QIAstat at pediatric emergency room|Pediatric acute care nurses will obtain respiratory samples for testing from all patients with fever or any respiratory symptom.
224320730|NCT02759692|DEVICE|CONTROL Contact Lens|
224320731|NCT06570187|DRUG|Dexmedetomidine|Dexmedetomidine will be administered with an initial dose of 0.2 μg/kg/hour, infusion rate is to be titrated based on response for at least 24 hours.
224320732|NCT06570187|DRUG|Propofol|Propofol will be administered as the comparator sedative with the standard treatment of sepsis and septic shock.
224320733|NCT04169945|OTHER|Ultrasonic instrumentation|Full mouth root surface debridement
224320734|NCT04169945|OTHER|Air polishing with erythritol powder|Air flow PLUS
224320735|NCT06093230|DRUG|Deuremidevir Hydrobromide Tablets|JT001 single dose, 0.3g
224320736|NCT05871034|PROCEDURE|phacoemulsification|cataract extraction
224320737|NCT00679133|DRUG|MGCD265|Oral daily administration; 7 days on / 7 days off
224320738|NCT00732485|DRUG|fenofibrate|Fenofibrate, PO, 5 mg/kg/day from admission to 6 months post burn
224320739|NCT00732485|DRUG|placebo|Placebo, sugar pill, from admission to 6 months post burn
224320740|NCT00451178|DRUG|enzastaurin|1125 milligrams (mg) then 500 mg, oral, daily, six 21-day cycles or up to 3 years
224320741|NCT00451178|DRUG|rituximab|375 milligrams per square meter (mg/m\^2), intravenous (IV), Day 1 every 21 days, six 21-day cycles
224320742|NCT00451178|DRUG|cyclophosphamide|750 mg/m\^2, IV, Day 1 every 21 days, six 21-day cycles
224320743|NCT00451178|DRUG|doxorubicin|50 mg/m\^2, IV, Day 1 every 21 days, six 21-day cycles
224320744|NCT00451178|DRUG|vincristine|1.4 mg/m\^2, IV, Day 1 every 21 days, six 21-day cycles
224320745|NCT00451178|DRUG|prednisone|100 mg, oral, Days 1-5, six 21-day cycles
224320746|NCT05792579|PROCEDURE|stoma closure|early closure of stoma in trauma patients
224320747|NCT02653833|DRUG|Tadalafil 20 MG|Blood flow to the forearm is visualized via an ultrasound technique at rest and with graded exercise. The experiment is then repeated shortly after the subject takes the study agent, beetroot juice extract.
224320748|NCT02653833|OTHER|beetroot juice extract|Blood flow to the forearm is visualized via an ultrasound technique at rest and with graded exercise. The experiment is then repeated shortly after the subject takes the study agent, beetroot juice extract.
224320749|NCT03764618|DRUG|Fostamatinib disodium|"Fostamatinib (100mg PO bid or 150 mg PO bid)~The dose may be reduced at any time to a dose as low as fostamatinib 100 mg PO qd or matching placebo if dose limiting adverse events are observed."
224320750|NCT03764618|DRUG|Placebo|Placebo
224320751|NCT07069517|BEHAVIORAL|Cognitive-Behavioral Therapy for Insomnia (CBTi)|CBTi focuses on stimulus control, eliminating maladaptive coping habits, reducing arousal, and challenging maladaptive thoughts about sleep in an effort to reduce time to fall asleep and time awake during the night.
223651731|NCT06402526|OTHER|Mobile Epilepsy Education Package|"MEEP education section contains a range of topics. After completing the relevant section at the end of each week, participants complete the end-of-section test and switch to the next week's topic. Completion of the first part will take approximately 90-120 minutes per week for a total of 4 weeks of use.~Parental Monitoring Section, parents can actively record information on the mobile application related to their child's diagnosis (anonymous); treatments; timing and frequency of the seizures; and appointments; and schedule treatment and examination reminders to optimize compliance. Completion of this second part will take approximately 1-2 minutes and depends on the parental choice to use and how much information they would like to share. The second part, together with the first part, will be evaluated for a total of 1 month."
223651732|NCT06402526|OTHER|Standard care consisting of epilepsy education|This standard care includes the information and education provided by nurses and physicians during visits and hospitalisations. Standard information and education include topics such as: counseling by the neurologist regarding seizure safety precautions, prognosis, and sudden unexpected death in epilepsy (SUDEP); provision of paper or electronic resources regarding epilepsy; and telephone support provided by neurology clinic nurse regarding any issues or concerns). Information and education is usually provided orally and through printed brochures.
223651733|NCT05941520|DRUG|Acolbifene Hydrochloride|Given PO
223651734|NCT05941520|PROCEDURE|Biospecimen Collection|Undergo collection of blood
223651735|NCT05941520|PROCEDURE|Mammography|Undergo 3D mammography
223651736|NCT05941520|OTHER|Questionnaire Administration|Ancillary studies
223651737|NCT05941520|PROCEDURE|Random Periareolar Fine-Needle Aspiration|Undergo RPFNA
223651738|NCT05941520|DRUG|Tamoxifen|Given PO
223651739|NCT03776812|DRUG|Relacorilant|Relacorilant is supplied as capsules for oral dosing.
223651740|NCT03776812|DRUG|Nab-paclitaxel|Nab-paclitaxel is administered as IV infusion over 30-40 minutes.
223651741|NCT06045247|DRUG|Prednisone|Given by IV (vein)
223651742|NCT06045247|DRUG|Rituximab|Given by IV (vein)
223651743|NCT06045247|DRUG|Cyclophosphamide|Given by IV (vein)
223651744|NCT06045247|DRUG|Vincristine|Given by IV (vein)
223651745|NCT06045247|DRUG|Epcoritamab|Given under the skin
223651746|NCT06054113|DRUG|Blinatumomab|Administered via CIVI
224235958|NCT03629158|BEHAVIORAL|CLIMB intervention|"The intervention group will receive the Cardiac Lifestyle Intervention for Maintaining healthy Behaviors (CLIMB) intervention. Participants will participate in a 3-session, one-on-one intervention that takes place over the course of two weeks. Sessions range from 1-2 hours in length, including questionnaire completion. Participants will be given information and taught relevant skills to increase engagement in lifestyle behaviors relevant to cardiac health."
224235959|NCT04705142|DRUG|MgSo4|Before and during administration of MgSO4, B.P, Capillary refill time, Heart rate and respiratory rate will be assessed closely i-e on 10 minutes interval, infusion of MgSO4 will be give over 30 minutes and baby will be monitored every 15 minutes interval after completion of infusion as well for 1 hour.
224320752|NCT07069517|BEHAVIORAL|Cognitive Behavioral Therapy for Nightmares (CBTn)|CBTn involves writing about a distressing or frequent nightmare, rewriting the narrative of the nightmare to target trauma-related themes, and reading the rescripted nightmare narrative.
224320753|NCT07069517|BEHAVIORAL|Written Exposure Therapy (WET)|WET is a trauma-focused intervention in which individuals write about their worst traumatic experience following scripted instruction from the therapist.
224320754|NCT07069517|BEHAVIORAL|Sleep Hygiene|Involves reviewing sleep diary data, sleep education, and reviewing and discussing sleep hygiene practices.
224320755|NCT06898593|BEHAVIORAL|Collaborative care model with clinical decision support system|A new patient-level clinical decision support system (CDSS) will include enhancing the existing pre-visit questionnaire to capture patient-reported goals and concerns, and displaying pre-visit questionnaire responses and clinical information within a patient-level dashboard in the electronic health record (EHR) for use by clinicians and patients.
223651747|NCT06641050|DIAGNOSTIC_TEST|Triage+ Score|The TriAGE+ score is used to evaluate the risk of cerebrovascular disease in patients presenting with dizziness. The score assists in determining the necessity of advanced diagnostic evaluation for stroke, potentially improving diagnostic accuracy and patient outcomes.
223651755|NCT02917798|BEHAVIORAL|Assessments|
223651756|NCT06036875|OTHER|Non-Interventional Study|Non-interventional study
223651757|NCT04107077|DRUG|Cisplatin|Laparoscopic HIPEC will be performed at a maximum of two (2) times spaced approximately 6 weeks apart. The dosing of the drugs will be the same during each administration but adjusted if needed based on lab work. The typical dosages are 200mg of Cisplatin
223651758|NCT04107077|DRUG|Mitomycin|Laparoscopic HIPEC will be performed at a maximum of two (2) times spaced approximately 6 weeks apart. The dosing of the drugs will be the same during each administration but adjusted if needed based on lab work. The typical dosages are 30mg of Mitomycin C.
224235960|NCT00013546|DRUG|TMTDS|
224235961|NCT03920657|DRUG|Deferasirox|Fixed dose of 3.5 mg/kg/day of DFX FCT
224235962|NCT00669630|BEHAVIORAL|Lay Health Promoter (LHP) with maintenance|Lay Health Promoters (LHPs) and their congregations will join an existing social and organizational support network, comprised of LHPs and congregations who are part of an active community health improvement collaborative.
224235963|NCT00006156|OTHER|Control|No injection of FSH
224235964|NCT00006156|DRUG|Drug: FSH|FSH Stimulation Test
223767297|NCT02442817|DRUG|Linagliptin|12 weeks of treatment and week for assessment. Linagliptin, 5 mg by mouth once per day for 12 weeks, in combination with continued antipsychotic treatment.
224235965|NCT03463356|BEHAVIORAL|Shame Intervention|In the Shame Intervention, participants will meet with a therapist and learn to: 1) Recognize the experience of shame, 2) Understand the connection between shame and social anxiety, 3) Identify shame triggers and vulnerabilities, 4) Identify the thoughts and behaviors that keep participants stuck in shame, and 5) Learn how to use new, healthier thoughts and behaviors that will help participants move through and decrease shame.
224235966|NCT00339768|DRUG|Amoxicillin/omeprazole|To treat Helicobacter pylori infections. 2 week course of amoxicillin 1gm bid, omeprazole 20mg bid. This factorial trial also investigated a supplement of vitamin C, vitamin E and selenium and a garlic supplement.
224235967|NCT02483637|DEVICE|RejuvenAir|Device: RejuvenAir
224235968|NCT00531375|DEVICE|Silicone hydrogel contact lens|
224235969|NCT02371525|BEHAVIORAL|Prepmate|A novel multi-modal, technology-based intervention for pre-exposure prophylaxis (PrEP) adherence support .
224235970|NCT01106963|PROCEDURE|Tibial intramedullary nailing|Patients' operations were performed using the peritendinous approach. A medial longitudinal incision was made, with care being taken not to damage the patellar tendon or its sheath. Standard proximal and distal locking screws were used. All patients were given postoperative instructions for thigh muscle rehabilitation and the same physiotherapy was performed after IM nailing during hospitalization. Nails were removed from some of the patients with the presence of knee pain or pain at the insertion points of the locking screws, however, no nails were removed earlier than one year postoperatively. Proof of the healed bone fracture was confirmed by radiologic examination.
224235971|NCT05152719|BEHAVIORAL|Cognitive Performance|Cognitive function will be measured biweekly 20 minutes after exercise, or at a matched time for the Time Restricted Eating Protocol arm. The Stroop test will be completed on Mondays and the Corsi block test will be completed on Wednesdays. Body composition will be measured on Fridays using a BodPod at baseline, week 3, and week 6.
224235972|NCT00322907|DRUG|Cotrifazid vs mefloquine or quinine+SP|
224235973|NCT02493244|OTHER|Cliradex|Cliradex is simply water and 4-Terpineol, a natural organic compound found Melaleuca alternifolia. The other ingredients in Cliradex are in less than 1% of the formulation and are Glycerin, Polysorbate 20, Polysorbate 80, Carbomer, Triethanolamine.
224320756|NCT06898593|BEHAVIORAL|Collaborative care model|Collaborative care model of integrated behavioral health and primary care.
223651766|NCT05130866|DRUG|REC-2282|Participants will receive REC-2282 3 times per week orally for 3 weeks followed by 1 week off for a 4-week cycle.
223651767|NCT05130866|DRUG|Placebo|Participants will receive placebo orally 3 times per week for 3 weeks followed by 1 week off for a 4-week cycle.
223651768|NCT05033288|OTHER|Electronic Health Record Review|Medical records are reviewed
223651769|NCT05033288|OTHER|Quality-of-Life Assessment|Complete quality of life questionnaires
223651770|NCT06560697|RADIATION|SABR VS Intracavitary 3D Brachytherapy|Arm 1 will be the experimental arm and will consist of patients with CC clinical stages IB3-IIIC1 who will be treated with CT/RT with a minimum dose of 45Gy and boost in the case of macroscopic nodes (1.8Gy per fraction from Monday to Friday) with cisplatin and cervical boost with SBRT of 28Gy in 4 fractions administered at least every 40 hours to achieve an EQD210(Gy) at PTV D90% of 83.9Gy. Arm 2 will be the control arm that will consist of patients with CC clinical stages IB3-IIIC1 and will be treated with CT/RT with a minimum dose of 45Gy and boost in the case of macroscopic nodes (1.8Gy per fraction from Monday to Friday) with cisplatin and cervical boost with high-dose-rate 3D brachytherapy with a dose of 28Gy in 4 fractions administered at least every 40 hours to achieve an EQD210(Gy) at point A of 83.9Gy.
223651771|NCT01842386|DRUG|Rituximab|Subjects will receive intravenous (IV) infusions of rituximab 1 gram on days 1 and 15, and subsequently if indicated up to once a month for 5 months (+/-5 days for each visit) starting approximately on day 42. Subjects whose infections respond positively to the treatment but then relapse may be offered additional treatment.
223651772|NCT06316830|DRUG|Buprenorphine|Buprenorphine in a highly effective treatment for opioid use disorder (OUD). Buprenorphine dose guidelines for OUD treatment were determined by clinical trials conducted in populations with a history of heroin use. However, fentanyl is changing the calculation of treatment, and optimal buprenorphine dosing for people who use fentanyl is unknown.
223651773|NCT05796141|BEHAVIORAL|Core Behavioral Weight Loss (BWL) intervention|Behavioral weight loss core (lessons, self weighing, self-monitoring, individual action planning, feedback and progress check ins)
223651774|NCT05796141|BEHAVIORAL|Dyadic Action Planning|Participants will develop dyadic action plans together.
223651775|NCT05796141|BEHAVIORAL|Joint Feedback|Participants will see data on their partner's progress, in addition to their own weight and behavioral data.
223651776|NCT05796141|BEHAVIORAL|Autonomy Support Training|Participants will receive training in how to create an autonomy supportive environment within their marriage/partnership.
223651777|NCT05796141|BEHAVIORAL|Home Environment Modifications|Participants will be trained in how to structure their home environment to support health behavior.
223651778|NCT05615844|DRUG|Antibiotic Cement Bead Pouch|The antibiotic bead pouch provides an antibiotic delivery mechanism. It is made by combining polymethyl methacrylate (PMMA) cement with generic forms of vancomycin and tobramycin powder.
223651779|NCT05615844|DEVICE|Negative Pressure Wound Therapy|Standard application of negative pressure wound therapy
223651780|NCT04793022|DRUG|TIVA with Propofol|Total intravenous anesthesia with propofol
223651781|NCT04793022|DRUG|Inhaled Anesthesia|General anesthesia given with inhaled anesthetics
223651782|NCT00001247|DRUG|Sirolimus|Drug not used in study.
223651783|NCT06577363|DRUG|Maribavir|Maribavir tablets
223767298|NCT02867605|DIETARY_SUPPLEMENT|Hyaluronan|
223767299|NCT03534856|BEHAVIORAL|Mindfulness meditation|Short guided mindfulness meditations were provided on an MP3 player.
223767300|NCT04690127|OTHER|Plyometric Exercise|Plyometric training consisting of ten different exercises \[vertical unilateral and bilateral counter movement jump, horizontal unilateral and bilateral counter movement jump, drop jump (30 cm), squat jump, step-hop (20 cm), 180 degree rotation in transverse plane, frontal plane hurdle jump (20 cm) and sagittal plane hurdle jump (20 cm)\] for 8 weeks, 3 sessions per week. Individuals will not participate in a real plyometric training. Volunteers will watch videos to be prepared (action observation) and imagine them performing those exercises (motor imagery)
223651789|NCT05518617|OTHER|Positron Emission Tomography (PET) scan using DASB tracer|"DASB is a highly selective PET radioligand for serotonin transporter and is a reliable tool to investigate serotonin terminals and neurons.~The included Magnetic Resonance Imaging (MRI) sequences serve to provide additional information plus complement PET data.~To quantify dopaminergic pathology with \[123I\]FP-CIT SPECT,"
223651790|NCT05204719|PROCEDURE|Prophylactic Delivery Room Continuous Positive Airway Pressure|Prophylactic Delivery Room Continuous Positive Airway Pressure (DR-CPAP) of 5-6 cm H20 will be provided for 20 minutes through the face mask or the appropriate size of nasal prong after the initial steps as per the participating institution's neonatal resuscitation protocol.
223651791|NCT06807437|PROCEDURE|Biospecimen Collection|Undergo blood sample and pancreas fluid collection
223651792|NCT06807437|PROCEDURE|Distal Pancreatectomy|Undergo distal pancreatectomy
223651793|NCT06807437|DRUG|Lanreotide|Given SC
223651794|NCT06807437|OTHER|Questionnaire Administration|Ancillary studies
223651795|NCT06807437|OTHER|Saline|Given SC
223651796|NCT06495996|DEVICE|Percutaneous mechanical thrombectomy (PMT)|Percutaneous mechanical thrombectomy (PMT) is the endovascular removal of thrombus by catheter-based mechanical or aspiration methods. The term PMT generally describes interventional procedures performed without the use of lytic agents and frequently involves instrumentation in extensive amounts of fresh thrombus.
223651797|NCT06803056|DIAGNOSTIC_TEST|Clinical exam|An experienced physical therapist with expertise in dry needling will confirm study eligibility and complete a standard clinical exam for myofascial pain. Gold standard for diagnosing myofascial pain as defined by Travell and Simons will be used. The criteria for muscle trigger point (TrP) include: 1) a taut band of skeletal muscle that is tender to palpation, 2) sustained compression of the taut band reproduces or exacerbates the participant's symptoms. Healthy tissue is defined as no palpable taut band.
224235974|NCT03538236|DEVICE|Intragastric balloon|Intragastric balloon insertion will be performed by an endoscopist under monitored anesthesia care. The Intragastric BalIoon (GB) comes as a deflated balloon pre-loaded on a catheter, which is inserted transorally into the proximal gastric body. An endoscope is then inserted alongside the device allowing for direct visualization of the balloon. Once in place, the intragastric balloon will be filled with saline through an external port. The balloon is inserted for 6 months then retrieved endoscopically
224235975|NCT03538236|BEHAVIORAL|Lifestyle intervention|All patients included in the study will undergo an evaluation by a nutritionist. All participants will receive recommendations for a diet. Participants will be instructed to keep a daily food diary and will meet with the nutritionist to reinforce the behavior every 12 weeks for 12 months.
224235976|NCT02200900|OTHER|Pharyngeal pressure|Babies will have pharyngeal pressures measured during the CPAP and HFNC respiratory support.
224235977|NCT02200900|OTHER|Transcutaneous carbon dioxide|Babies will have transcutaneous carbon dioxide measured during CPAP and HFNC respiratory support.
224235978|NCT02200900|OTHER|Pharyngeal gas concentrations|Measurement of pharyngeal oxygen and carbon dioxide concentration will be done during CPAP and HFNC respiratory support.
224235979|NCT02200900|OTHER|Tidal volume|Tidal breathing indices including tidal volume and FRC base line changes will be recorded during CPAP and HFNC respiratory support.
224235980|NCT04252469|OTHER|Oral care|oral care using 20mL of 0.12% CHX and gargling with 30 seconds.
224235981|NCT00257153|DEVICE|Coronary thrombus aspiration catheter|
224235982|NCT02594462|DRUG|etonogestrel-releasing implant contraceptive|The etonogestrel implant will be inserted until the fifth day of the menstrual cycle . Anthropometric measurements will be performed , blood pressure measurement , application of pain questionnaire for the last three months, and collection of fasting blood in our clinic . After these measures , the ENG implant will be applied per researcher trained for such a procedure , following the recommendations outlined by the manufacturer. Women are instructed to return after 3, 6, 9, 12 months, fasting 8h , when they will be measured anthropometric measurements , blood collection, and delivery of pain questionnaires and standard of menstrual bleeding.
224235983|NCT04506242|DRUG|SHR-1210|PD-1
224235984|NCT04506242|DRUG|Apatinib|VEGFR2
224235985|NCT02024087|DRUG|Dalantercept plus sorafenib|Subcutaneous (SC) injection of dalantercept once every 3 weeks and oral sorafenib daily.
224235986|NCT01807637|DEVICE|transcranial direct current stim (tDCS)|During anodal tDCS, participants will receive 20 min at 2mA over motor cortex (with 30 seconds of ramp-up and ramp-down). During sham stimulation the stimulator is turned off.
224235987|NCT01637038|OTHER|RIPC|Those undergoing remote ischemic postconditioning. Remote ischemic postconditioning consists of three 5-min cycles of upper limb ischemia, which was induced by an automated cuff-inflator placed on the unilateral upper limb and inflated to 250 mm Hg, with an intervening 5 min of reperfusion during which the cuff was deflated.
224235988|NCT01861366|OTHER|A one year multifaceted implementation strategy|
224235989|NCT01861366|OTHER|A three hour lecture about the guidelines|
224235990|NCT03083171|DRUG|Endotoxin|At T=0 1 ng/kg E. Coli type O113 lipopolysaccharide is administrated intravenously as a bolus, followed by 1 ng/kg/hour for 3 hours.
224235991|NCT03083171|DRUG|Placebo|At T=1 hour, placebo will be administered intravenously over a 1 hour period. Placebo is indistinguishable from Adrecizumab.
224235992|NCT03083171|DRUG|Adrecizumab|At T=1 hour, Adrecizumab will be administered intravenously over a 1 hour period.
224235993|NCT05203393|DEVICE|Harmony Headset|"The Harmony headset is a non-invasive nonsignificant risk observational device to collect intracranial waveform data. The headset will be placed on normal study participants to collect data for a period of 3 minutes and transferred to investigators for analysis."
224235994|NCT03195985|OTHER|Mindfulness-based intervention|A shortened, 4 week mindfulness intervention course based on the original 8 week mindfulness-based stress reduction course by Jon Kabat-Zinn
224235995|NCT03195985|OTHER|Age Well psycho-education|4-week active control condition aimed at psycho-education regarding healthy ageing
224235996|NCT00950807|DRUG|Tiotropium|long-acting muscarinic receptor antagonist; 18mcg once-daily
223651798|NCT06803056|DIAGNOSTIC_TEST|Ultrasound imaging|Shear wave elastography and b-mode ultrasound imaging techniques will capture the biomechanical and structural profile of foot and ankle muscle on the involved side.
223651799|NCT06803056|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|T1rho and IDEAL sequences will be used to capture the biochemical and structural profile of foot and ankle muscles on the involved side
223651800|NCT01812694|BEHAVIORAL|Enhanced standard care|Standard prenatal care plus education
223651801|NCT01812694|BEHAVIORAL|Intensive lifestyle intervention|Intervention to limit excess gestational weight gain
223651802|NCT06213311|DRUG|Glofitamab|Given by IV
223651803|NCT06213311|DRUG|Obinutuzumab|Given by IV
223651804|NCT06213311|DRUG|Axi-cel|Given by IV
223651805|NCT05887271|DRUG|Low calorie meal replacement plan|Meal replacement diet containing \~850 kcal/day (40% protein, 50% carbohydrate, 10% fat) supplied by Counterweight® (www.counterweight.org).The meal replacement plan will comprise of 3-4 meal packs/day (to equate to 850 kcal) with sweet and savoury options, and an allowance of 100ml semi-skimmed milk or a non-dairy alternative.
223651806|NCT05887271|DIAGNOSTIC_TEST|Cardiovascular magnetic resonance (CMR) imaging and magnetic resonance spectroscopy|CMR scanning performed on a 3T MRI scanner. Standardised protocol incorporating cine functional assessment to determine LV mass, systolic function and left atrial volumes; global systolic strain and diastolic strain rates will be assessed by tagging and with tissue tracking analysis from cine images, adenosine rest and stress myocardial perfusion to assess reserve index and qualitative perfusion defects as previously described, aortic distensibility and pulse wave velocity to measure aortic stiffness, delayed contrast enhancement for assessment of LV fibrosis and evidence of previous myocardial infarction. Myocardial and liver triglyceride content will be assessed using the modified Hepafat® sequence or 1H MR spectroscopy at the inter ventricular septum. DIXON technique for the quantification of visceral adiposity and subcutaneous adipose tissue. Cardiac 31P magnetic resonance spectroscopy imaging to assess cardiac muscle energetics according to a standardised operating procedure
223651807|NCT05887271|DIAGNOSTIC_TEST|Transthoracic echocardiography|Comprehensive transthoracic echocardiography, including: tissue Doppler indices of diastolic filling and speckle tracking for systolic and diastolic strain/strain rate, exclusion of valvular abnormalities, assessment of LV size and function
223651808|NCT05887271|DIAGNOSTIC_TEST|Blood test|Collection of blood samples from each participant to characterise the participant's health status and fibroinflammatory markers.
224235997|NCT00950807|DRUG|Placebo|Inactive/ excipients only
224235998|NCT00950807|DRUG|GSK573179|GSK573179 investigational drug
223651809|NCT05887271|DIAGNOSTIC_TEST|Electrocardiogram|An ECG will be obtained to assess for baseline rhythm.
224235999|NCT01238237|DRUG|Superselective Intraarterial Cerebral Infusion of Cetuximab|Intraarterial Mannitol 25% 3-10 ml to open the blood brain barrier followed by Intraarterial Cetuximab single dose (starting at 100mg/m2 and escalating up to 500mg/m2)
224236000|NCT01587222|DRUG|Albumin|Albumin (20%) 1g/kg iv on day 1 and 80 g every 2 weeks during a period of 12 weeks.
224236001|NCT01587222|DRUG|Midodrine|"Oral midodrine 5 mg / 8 hours for 12 weeks. The dose may be increased on day 7 10mg/8h.~If creatinine does not decrease ≥ 25% and systolic blood pressure is bellow 150 mmHg and diastolic 90 mmHg doses will be changed."
224236002|NCT01587222|DRUG|Octreotide|"Octreotide by subcutaneous injection 0.1 mg every 8 hours for 12 weeks. The dose may be increased to 0.2 mg / 8 h on day 7.~If creatinine does not decrease ≥ 25% and systolic blood pressure is bellow 150 mmHg and diastolic 90 mmHg doses will be changed."
224236003|NCT05960864|DRUG|Celecoxib|If we find any behavior that affects the safety of patients in the experiment, we will stop
224236004|NCT05003011|DEVICE|Cardiospire|Non-invasive hemodynamic monitoring
224236005|NCT05432011|PROCEDURE|PENG Block|At the end of surgery, in Post Anesthesia Recovery Room (PACU), PENG block with 20 mL of 0.5 % Ropivacaine will be executed as described by Giron-Arango et al. using a low frequency curvilinear probe. A 22G 80 mm needle (Stimuplex Ultra 360, B.Braun) will be used.
223651810|NCT05887271|DIAGNOSTIC_TEST|Accelerometery|Accelerometer (GeneActiv) measured daily activity levels continuously for 7 consecutive days.
223651811|NCT05887271|DIAGNOSTIC_TEST|6 minute walk test (6MWT)|Supervised 6MWT will be performed with symptom assessment using dyspnoea scale (Borg's).
223651812|NCT05887271|DIAGNOSTIC_TEST|Skeletal muscle strength using handgrip strength and quadriceps (Cybex dynamometer)|Skeletal muscle strength will be measured using a cybex dynamometer.
223651813|NCT05887271|OTHER|Assessment of quality of life and heart failure symptoms|Quality of life and HF symptoms will be assessed using the Minnesota Living with Heart Failure (MLWHF) questionnaire, which is used as a standardised measure of self-reported health status, and HF symptoms and is considered to have a good discriminatory power and validity
223651814|NCT05887271|OTHER|Assessment of sarcopenia|Participants will be assessed for presence of sarcopenia using the Strength, Assistance with walking, Rise from a chair, Climb stairs and Falls (SARC-F) questionnaire. It is a robust tool for diagnosis of sarcopenia and prediction poor physical function, with excellent specificity in multimorbid individuals.
223651815|NCT05887271|OTHER|Assessment of frailty|Frailty will be assessed using the Edmonton Frail Scale (EFS). The EFS is a multidimensional frailty assessment which assesses multiple domains of frailty including functional independence, social support, cognition, medication use, and mood.
223767301|NCT04404959|OTHER|fascia iliaca compartment block with ropivacaine|the fascia iliaca compartment block catheter will be placed with the use of ultrasound till the day of surgery. Bolus doses will be given every 12 hours (40 ml of ropivacaine 0.25%)
223767302|NCT04404959|OTHER|fascia iliaca compartment block with placebo|the fascia iliaca compartment block catheter will be placed with the use of ultrasound till the day of surgery. Bolus doses will be given every 12 hours (40 ml of normal saline)
224236006|NCT05432011|PROCEDURE|Lateral Femoral Cutaneous Nerve Block|At the end of surgery, in Post Anesthesia Recovery Room (PACU), ultrasound guided Lateral Femoral Cutaneous Nerve Block will be performed with 10 mL of 0.5 % Ropivacaine using a high frequency linear probe. A 22G 50 mm needle (Stimuplex Ultra 360, B.Braun) will be used.
224236007|NCT05432011|PROCEDURE|Wound Infiltration|At the end of operation, the surgeon will perform wound infiltration with 20 mL of 0.5 % Ropivacaine.
224236008|NCT04933825|BIOLOGICAL|ET-02|A conditioning therapy with cyclophosphamide and fludarabine will be conducted before ET-02 injection.
224236009|NCT03652077|DRUG|INCAGN02390|Part 1: INCAGN02390 at the protocol-defined starting dose administered every 2 weeks (Q2W), with dose escalation in 7 total cohorts to determine the maximum tolerated dose or PAD.
224236010|NCT00337077|DRUG|eribulin mesylate|Given IV
224236011|NCT01460797|OTHER|Glycemic Index Diets and Metformin hydrochloride|1g of Metformin hydrochloride a day in High Glycemic Index Diet
224236012|NCT03395106|BEHAVIORAL|Parent source|Having a parent feature prominently in a news story
224236013|NCT03395106|BEHAVIORAL|Doctor source|Having a doctor feature prominently in a news story
224236014|NCT03395106|BEHAVIORAL|Deliberative content|News story content includes process of weighing the risks/benefits of vaccinating, the importance of vaccines for community protection, and concludes with a recommendation to vaccinate.
224236015|NCT03395106|BEHAVIORAL|Intuitive content|News story content focuses on the consequences of not vaccinating (including vaccine preventable diseases) and the decisional regret.
224320757|NCT06817278|BEHAVIORAL|Adaptable IERITA|IERITA is a 12-week acceptance-based behavioral therapy. The goal is to reduce self-injury through learning and using other ways to regulate emotions. IERITA includes modules where the participants can read text, watch videos, listen to audio, and message their allocated therapists. The adolescent treatment is 11 modules, and the parent course is six. Both adolescents and parents receive separate asynchronous online therapist support. The adapted IERITA intervention is tailored to the participant and can thus entail different adaptions for different participants. Adaptions can entail changes in therapist contact, what material to focus on, and how to work with the treatment. The adapted IERITA intervention is offered between week four and 12.
223651816|NCT05887271|OTHER|Qualitative interview|Participants in the MRP and control groups will be invited to attend a focused semi-structured, 1-2-1 interview aimed to elicit barriers and enablers to the MRP and describe their perspective on the relationship between healthy eating and health interview during the 12-week visit. Participants who complete or drop out will be eligible. Inclusion of participants in the control arm will allow us to compare the experiences of MRP versus health coaching and detect any specific issues people face when trying to introduce lifestyle changes themselves.
223651817|NCT01147445|BIOLOGICAL|Recombinant Double Mutant Heat-Labile Toxin LT(R192G/L211A) (dmLT) Oral enterotoxigenic Escherichia coli (ETEC) Vaccine|LT(R192G/L211A), or dmLT is a derivative of wild-type enterotoxigenic Escherichia coli heat labile enterotoxin. LT(R192G/L211A) is formulated as a freeze-dried (lyophilized), white to off-white cake, containing 700 micrograms of vaccine protein in a 3 mL, multi-dose, Wheaton Serum Vial. Vaccine dosage levels: 5, 25, 50, 100 micrograms as a single, oral dose.
223651818|NCT06686615|DRUG|Bempedoic acid|No drug was administered in this observational study.
223651819|NCT06686615|DRUG|Ezetimibe|No drug was administered in this observational study.
223651820|NCT06686615|DRUG|Rosuvastatin|No drug was administered in this observational study.
223651821|NCT06686615|DRUG|Atorvastatin|No drug was administered in this observational study.
223651822|NCT06075953|DRUG|Tamoxifen|"For premenopausal women: 20 mg tamoxifen orally daily (standard dose) or 10 mg every other day (low dose).~For postmenopausal women who are not tolerating an AI, investigators can change them to the low dose (10 mg every other day) or standard dose (20 mg) of tamoxifen."
223651823|NCT06075953|DRUG|Exemestane|For postmenopausal women: standard oral doses of AI of choice: exemestane 25 mg daily, or reduced exemestane dosing: 25 mg 3 times per week orally
223651824|NCT06075953|DRUG|Letrozole|For postmenopausal women: standard oral doses of AI of choice: letrozole 2.5 mg daily.
223651825|NCT06075953|DRUG|Anastrazole|For postmenopausal women: standard oral doses of AI of choice: anastrozole 1 mg daily.
223651826|NCT06075953|DRUG|Testosterone + Anastrazole|Investigational drug. Both pre- and post- menopausal subjects. 100mg testosterone in combination with 4mg anastrazole administered subcutaneously every 3 months for up to 3 years.
223651827|NCT06075953|DRUG|Elacestrant|Investigational drug. Both pre- and post- menopausal subjects. Elacestrant 400mg PO with food once daily up to 36 months.
223651828|NCT06075953|DRUG|Z-endoxifen|Investigational drug. Both pre- and post- menopausal subjects. (z)-endoxifen 10mg delayed release capsule 1 hour before a meal or 2 hours after a meal once daily for up to 36 months.
223767303|NCT01830140|DRUG|Bimatoprost 0.01%|Bimatoprost 0.01% (LUMIGAN® 0.01%) administered each evening in both eyes for 6 weeks.
224236016|NCT00154180|DRUG|Conjugated equine estrogens 0.45 mg/day|Pill, 1 pill taken daily each month for the study duration
224320758|NCT06817278|BEHAVIORAL|Standard IERITA|IERITA is a 12-week acceptance-based behavioral therapy. The goal is to reduce self-injury through learning and using other ways to regulate emotions. IERITA includes modules where the participants can read text, watch videos, listen to audio, and message their allocated therapists. The adolescent treatment is 11 modules, and the parent course is six. Both adolescents and parents receive separate asynchronous online therapist support.
224320759|NCT06817278|OTHER|Treatment as usual|Participants are free to any receive regular care (i.e., psychosocial treatment, medications, or a combination of both) as needed during the trial.
224320760|NCT07134985|OTHER|No intervention|No intervention
224236017|NCT00154180|DRUG|Transdermal estradiol, 50 mcg/day|Patch; 1 patch is applied to the skin weekly. Patch site is rotated on a weekly basis.
224236018|NCT00154180|DRUG|Micronized progesterone, 200 mg/day x 12 d/month|capsule, 1 capsule taken daily for the first 12 days of each month for the study duration
224236019|NCT00154180|DRUG|CEE , progesterone, estradiol patch or placebo for each|CEE 0.45mg 1 PO QD Progesterone 200 mg 1 PO HS first 12 days of the month estradiol patch use 1 per week
224236020|NCT00154180|DRUG|CEE, progesterone, transdermal patch or the placebo|CEE 0.45 mg 1 PO QD or placebo equivalent Prometrium 200 mg 1 PO qHS for first 12 dasy of each month or placebo equivalent transdermal patch 0.05 mg use 1 patch per week or placebo equivalent
224236021|NCT03773848|PROCEDURE|Open Reduction Internal Fixation (ORIF)|Open Reduction Internal Fixation (ORIF) of fracture lateral third clavicle by hook plate \& tightrope
224236022|NCT04026126|BEHAVIORAL|Heat Therapy Treatment|Subjects will undergo 10 hot water immersions of 40.5 degrees Celsius for approximately 45 minutes per session over 14 days. Subjects will be immersed up to the shoulder until rectal temperature reacher 38.5 degrees Celsius (approximately 15-20 minutes). Subjects will then remain in the water bath submerged at waist level to maintain between 38.5 to 39.0 degrees Celsius for another 30 minutes. Following hot water immersion, subjects will be monitored for 10 minutes, or until temperature falls below 38.5 degrees Celsius.
224236023|NCT01264224|DRUG|PAC-14028|tablets, oral administration, single/multiple dosing, dose escalation
224236024|NCT04351204|RADIATION|radiotherapy|multiple new techniques and software for MR-guided adaptive radiation therapy.
224236025|NCT04312906|OTHER|no intervention|No intervention
223767304|NCT01830140|DRUG|Bimatoprost 0.03%|Bimatoprost 0.03% (LUMIGAN® 0.03%) administered each evening in both eyes for 6 weeks.
223767305|NCT00215826|DRUG|Alferon LDO|
224236026|NCT03043924|DRUG|Cyproterone Acetate + estradiol|"PCOS will receive:~50mg cyproterone acetate (Androcur®) in combination with p.o. 2mg estradiol daily"
224320761|NCT05565079|BIOLOGICAL|Regenerative tissue matrix and enamel matrix derivative|Subjects in this group will receive a coronally positioned tunnel with a regenerative tissue matrix (AlloDerm, RTM) and a porcine-derived enamel matrix derivative (Emdogain).
224320762|NCT05565079|BIOLOGICAL|Regenerative tissue matrix|Subjects in both groups will receive a coronally positioned tunnel with a regenerative tissue matrix (AlloDerm, RTM).
224320763|NCT06828237|DEVICE|KOS® S|Delivery of medical device as injection
224320764|NCT06827951|BEHAVIORAL|Parent-Child Interaction Therapy (PCIT)|"Participants will undergo the standard PCIT program, which consists of two phases: Child-Directed Interaction (CDI) and Parent-Directed Interaction (PDI).~* CDI Phase: Parents will learn and practice techniques that focus on strengthening the parent-child relationship through play and positive reinforcement.~* PDI Phase: Parents will be coached in effective discipline strategies to manage their child's behavioral problems."
224320765|NCT00633347|DRUG|Antagonist GnRH Cetrotide|Cetrotide 0.25 mg. daily/ 7 days
224236027|NCT03043924|DRUG|Levonorgestrel, Ethinyl Estradiol 0.1-0.02Mg Oral Tablet|Healthy volunteers receive combined oral contraceptive (COC) consisting 0.02 mg ethinylestradiol and 0.1mg of progestins (Leeloo Gé®)
224320766|NCT00633347|DRUG|Agonist GnRH Acetate Triptoreline|Acetate Triptorelina (Agonist GnRH), 3.75 mg. single dose
224320767|NCT06196814|DRUG|PD-1/VEGR bispecific antibodies (AK112) plus Platinum-based Chemotherapy|PD-1/VEGR bispecific antibodies (AK112) plus Platinum-based Chemotherapy.
224320768|NCT07113236|BEHAVIORAL|Instructions, advices|A first moment: informed conversation and exploration of myths and realities with the aim of exploring the perceptions and attitudes of participating children and adolescents towards the vaccine against HPV-associated cancers through an open and reflective dialogue; a second moment with the presentation of a testimonial video and reflection with the aim of learning from the experiences of others, finding inspiration and motivation in their stories, and feeling connected with other people; and a third moment of 360° feedback with the aim of receiving final information about HPV, HPV-associated cancers, and the importance of vaccination.
223651829|NCT01847027|DRUG|NutraStem|"Determine whether NutraStem® in combination with an exercise stimulus will cause increased human peripheral blood sample levels of CD34+ and CD133+ adult stem cells and whether these stem cells display more protection against oxidative stress.~Determine whether NutraStem® in combination with an exercise stimulus will cause increased human peripheral blood sample levels of CD34+ and CD133+ adult stem cells and whether these stem cells display more protection against oxidative stress."
224236028|NCT00790959|BEHAVIORAL|SASA!|"A community mobilization approach to try to change community and individual attitudes and behaviours that support both the perpetration of violence against women and HIV risk behaviours~The intervention team engages with four major groups of actors: community volunteers selected from the general public; community leaders (e.g. religious, cultural and local council leaders); resource persons (health care providers, police, etc); and institutional leaders. The community volunteers are a key component of the intensive intervention."
224236029|NCT00790959|OTHER|Control|"Control communities will receive the full SASA! intervention after completion of the SASA! Study.~For the duration of the study, they will receive a less intensive intervention comprising the Division-level elements of SASA! (involving community leaders, resource persons and institutional leaders) without the community volunteers."
224236030|NCT04842045|DRUG|Psilocybin and Midazolam|"The psilocybin used in this study is synthetically manufactured in a laboratory and meets quality specifications suitable for human research use. The active drug is encapsulated using a hydroxypropyl methylcellulose (HPMC) capsule and contains 25 mg of psilocybin.~The midazolam in this study will be administered intravenously. The total dose administered to a given subject is dependent on the individual's level of amnesia, sedation scale score, age, and weight."
224236031|NCT05554822|DRUG|Aspirin 100mg|Single antiplatelet therapy with aspirin 100 mg OD for 6 months after the procedure
224236032|NCT05554822|DRUG|Aspirin 100 mg OD plus clopidogrel 75 mg OD|Double antiplatelet therapy with Aspirin 100 mg OD plus clopidogrel 75 mg OD for 3 months, followed by 3 months of single antiplatelet therapy with aspirin 100 mg OD.
224236033|NCT05657496|DRUG|Triamcinolone Acetonide 40 mg/ml Inj, Susp|Prepared in clinic by physician or medical staff
224236034|NCT05657496|BIOLOGICAL|Platelet-rich plasma Inj|Produced from participant's whole blood venous draw of approximately 15 mL. Prepared by centrifuge in clinical office
224236035|NCT00665730|DEVICE|Sepraspray|
224236036|NCT01127022|DIETARY_SUPPLEMENT|choline chloride|Women will consume a diet providing 380 mg/d total choline plus 100 mg/d supplemental choline \[from choline chloride\] for a total choline intake of 480 mg/d. The choline chloride will be administered in cran-grape juice.
224236037|NCT01127022|DIETARY_SUPPLEMENT|Choline Chloride|Women will consume a diet providing 380 mg/d total choline plus 550 mg/d supplemental choline \[from choline chloride\] for a total choline intake of 930 mg/d. The choline chloride will be administered in cran-grape juice.
224236038|NCT01434121|DRUG|Ascorbic Acid|The infusion of either a high dose of ascorbic acid, low dose ascorbic acid, or placebo
224236039|NCT01434121|DRUG|Placebo|
224236040|NCT04548453|DEVICE|uterine electromyography|Multichannel uterine electromyography will record uterine biosignals during labor.
224236041|NCT04929626|DRUG|Magnesium Sulfate 500 mg/ml+ ventolin|3 doses of magnesium sulphate i.e; 250mg(0.5ml), 500mg(1ml), 750mg(1.5ml) will be used in nebulized form
223651830|NCT01847027|DRUG|Placebo|Determine whether NutraStem® in combination with an exercise stimulus will cause increased human peripheral blood sample levels of CD34+ and CD133+ adult stem cells and whether these stem cells display more protection against oxidative stress.
223651831|NCT01320917|DEVICE|Levonorgestrel releasing device|LNG-IUD device releases levonorgestrel in circulation
223651832|NCT01320917|DEVICE|Cu-IUD insertion|The action of a Cu-IUD does not release any hormonal compound
223651833|NCT00986765|DRUG|Lovenox® (enoxaparin)|Injectable solution 4000 UI
223651834|NCT00986765|DRUG|Aspegic ® (Aspirin)|100 mg/day
224236042|NCT04929626|DRUG|Ventolin|it will be given to control group in nebulized form after every 20 min in 1st hour
223767306|NCT00226616|DRUG|Zinc|
223767307|NCT04403022|DEVICE|Robotic Assisted Surgery|da Vinci SP Surgical System, instruments, and accessories in complex colorectal procedures such as low anterior resection procedure or right colectomy with or without total mesorectal excision
223767308|NCT04879303|BEHAVIORAL|Robot-assisted social skill intervention|Social robotics will be used by the instructor to teach social skills to the children with ASD for 12 weekly sessions.
223651835|NCT05022576|DIAGNOSTIC_TEST|Robotic arm assisted PSMA PET/CT guided prostate biopsy|The patients were positioned prone on PET/CT table. The regional PET/CT image of the lower pelvic region were acquired for the procedure. The images were transferred to the ROBIO™ EX workstation. The ARA workstation determined the needle trajectory, depth of the lesion and angulations. The planned trajectory was appraised for its relationship with the vital organs. Strict surgical aseptic approach was followed for the procedure under local anesthesia. An 18G x 20cm coaxial system was manually introduced through the bush and pushed with the help of robotic arm through the gluteal skin entry site to the predetermined depth in the prostate. The real-time placement of the needle was confirmed with low dose CT and the biopsy specimens were retrieved. After the procedure, patient vitals and any difficulty in micturition were observed for two hours in the recovery area. The specimens were sent for histopathological examination.
223767309|NCT04879303|BEHAVIORAL|Human-only instruction programme on social skill training|The children will receive only the human-delivered training throughout the 12 sessions, with the content and sequence of activities the same as the robotic intervention group.
223767310|NCT03526523|BEHAVIORAL|Mindfulness-based stress reduction|8 weekly 2.5-hour group sessions of mindfulness based stress reduction, led by a certified MBSR instructor
223651836|NCT02181088|BIOLOGICAL|ChAd63 RH5 low dose|ChAd63 RH5 at 5 x 10\^9 vp
223651837|NCT02181088|BIOLOGICAL|ChAd63 RH5 full dose|ChAd63 RH5 at 5 x 10\^10 vp
223651838|NCT02181088|BIOLOGICAL|MVA RH5 low dose|MVA RH5 at 1 x 10\^8 pfu
223651839|NCT02181088|BIOLOGICAL|MVA RH5 full dose|MVA RH5 at 2 x 10\^8 pfu
223651840|NCT04667221|DEVICE|Active transcranial direct current stimulation|A high-definition tDCS set-up will be used with a battery-driven stimulator (Starstim 8, Neuroelectrics). Active stimulation will be conducted with 1.5 milliampere (mA) with two electrodes using three reference electrodes for each active one for 20 minutes.
223651841|NCT04667221|DEVICE|Sham transcranial direct current stimulation|A high-definition tDCS set-up will be used with a battery-driven stimulator (Starstim 8, Neuroelectrics). Sham stimulation will have a 40 seconds ramp-up and down. No stimulation will be applied after this 40 seconds.
223651842|NCT03278171|BEHAVIORAL|Impact Event Scale Revisited|Evaluating the ability of the Impact Event Scale -Revisited within 8 days following the intensive care unit exit to predict a post-traumatic stress disorder at 3 months (Impact Event Scale -Revisited score strictly greater than 34)
223651843|NCT00048074|DRUG|ibandronate [Bonviva/Boniva]|2mg iv every 2 months
223651844|NCT00048074|DRUG|ibandronate [Bonviva/Boniva]|2.5mg po daily
223651845|NCT00048074|DRUG|ibandronate [Bonviva/Boniva]|3mg iv every 3 months
223651846|NCT03054532|DRUG|Durvalumab|Durvalumab intravenous 1500 mg
223651847|NCT03054532|DRUG|Lenali|Lenalidomide oral 20 mg/day
223651848|NCT06351007|OTHER|Nutritional education and psychological intervention|"In the two intervention groups, after the delivery of the meal plan, the educational and psychological intervention will begin, with a duration of 5 months. The main objective of the educational program in pre-dialysis patients is to delay the progression of renal damage and in dialysis patients is control of complications. The content of monthly educational sessions will be:~Month 1: proteins (predialysis group), potassium (dialysis group) Month 2: Sodium and fluids (predialysis group), phosphorus (dialysis group) Month 3: Phosphorus (predialysis group), sodium and fluids (dialysis group) Month 4: Potassium (predialysis group), proteins (dialysis group) Month 5: Myths and facts about food (both groups) Simultaneously, group psychological sessions will be carried out, aimed at modifying patient behaviors to increase adherence to diet plan through understanding the patient´s situation, promoting the development of healthy behaviors, barrier identification and goal setting"
223651849|NCT06351007|OTHER|Standard care|"The control group (predialysis and dialysis patients) will receive standard nutritional care consisting of dietary prescription with follow-up for questions and adjustment of the meal plan every 2 months.~Based on the nutritional status, biochemical parameters and stage of renal disease, the meal plan will be calculated.~The characteristics of the diet will be as follows:~Calories - 30 kcal/Kg ideal body weight/day Protein - 0.8 g/kg ideal body weight/day (predialysis group) 1.2 kg ideal body weight/day (dialysis group) Carbohydrates - 50-60% of total calorie content Lipids - 30% of total calorie content Sodium \&lt; 2300 mg/day Potassium \&lt; 2000 mg/day Phosphorus \&lt; 1000 mg/day Fluids - Urine output + 500 ml"
223767311|NCT04293159|DIETARY_SUPPLEMENT|Lactobacillus casei DG (Enterolactis duo®)|Lactobacillus casei DG (Enterolactis duo®)
223767312|NCT01177501|DRUG|Topotecan|Six sequential doses established in the absence of limiting toxicity, as follows : 7.5 - 8.0 - 8.5 - 9.0 - 10.0 mg/m²
224236043|NCT02502110|DRUG|rosuvastatin|All recruited patients with paroxysmal atrial fibrillation will be randomly allocated to receive oral rosuvastatin 20mg/day or blank control from 7 days before ablation and last for 3 months.
224236044|NCT06257745|OTHER|Compliance with ERACS guideline as described in the current ERACS guidelines from Engelman et al. 2019|Compliance with the interventions as proposed in the ERACS guidelines and described in our previous publication (https://doi.org/10.1016/j.jtcvs.2022.07.010
224236045|NCT05873023|OTHER|Chewing gum|chewing gum everyday for 12 weeks. Alternate chewing for 10 minutes on the right and 10 minutes on the left.
224236046|NCT05629884|OTHER|COPERIA-REHAB|"After the randomization of the patient there will be some preliminary sessions where the means of self-monitoring training and the Borg 1/10 effort scale will be explained and training videos will be shown. Doubts will also be answered.~Afterwards, training will start through the COPERIA-REHAB platform, which will last 8 weeks (6 days per week)."
224236047|NCT03038737|OTHER|bre.flex|"In the recent time thermoplastic materials become quite popular in clinical practice such as nylon and acetal resins. since the 1950, polyamide resin (nylons) provide improved esthetics and reduction of rotational forces on the abutment teeth due to their low elastic modulus(3).~The major disadvantage of a nylon RDP is the inability for a reline procedure and the lack of occlusal rests as well as rigid frameworks, that could lead to occlusal instability and sinking, especially in Kennedy class I and II cases. On the other hand, acetal resins present adequate mechanical strength to form a frame-work more rigid than nylon with retentive clasps, connectors, and supportive elements; however, the acetal resin material lacks natural translucency and vitality."
224320769|NCT07113236|OTHER|No instructions|No instructions for vaccination
223651850|NCT06116370|PROCEDURE|Rezum procedure|In Rezūm procedure, the Rezūm System (NxThera Inc., Maple Grove, MN, USA) consists of a radiofrequency (RF) power supply generator and single-use transurethral delivery device. Starting 1 cm distal to the bladder neck, injection was done at 3 and 9 o'clock sites. The needle was inserted for 9 s duration, retracted, and then delivered to another treatment site in 1 cm distance distal to the previous one.
223651851|NCT06116370|PROCEDURE|B-TURP procedure|In B-TURP, Olympus SurgMaster™ UES-40 bipolar generator (Olympus Europe, Hamburg, Germany) was used. Current's settings used were cut/coag 200/120. Using continuous flow 26Fr resectoscope first resection of the median lobe from the level of the bladder neck to the apex of the prostate was done followed by resection of the lateral lobes. Using Ellic evacuator, Prostatic chips were extracted from the field. A 22 fr three-way silicon Foley catheter was placed with traction applied and the balloon inflated by normal saline of 30-80 cc according to the size of the prostate.
223651852|NCT02873377|DRUG|Nicorette Gum|GlaxoSmithKline Nicorette Gum (nicotine replacement therapy)
223651853|NCT02873377|DRUG|Nicoderm CQ|GlaxoSmithKline Nicoderm CQ (nicotine replacement therapy)
223651854|NCT02873377|OTHER|Smoking Quitline Referral|Fax referral to the State smoking Quitline
223651855|NCT02873377|BEHAVIORAL|Behavioral Smoking Cessation Counseling|One time face-to-face smoking cessation counseling and follow-up phone call
223651856|NCT01773213|PROCEDURE|Ice-water-test|
223651857|NCT01586572|DRUG|mOPV1|Monovalent type 1 oral poliovirus vaccine (mOPV1) containing at least106 TCID50 of Sabin- strain poliovirus type 1.
223651858|NCT01586572|DRUG|bOPV 1,3|The bivalent vaccine containing at least 106 CCID50 of Sabin poliovirus type 1 and 105•8 CCID50 of Sabin poliovirus type 3.
223651859|NCT04951609|DRUG|Seltorexant|Participants will receive a single oral dose of seltorexant.
224236048|NCT03038737|OTHER|PEEK|PEEK has been successfully used over the last years in the medical ﬁeld, and orthopedics, speciﬁcally. which presents high biocompatibility, good mechanical properties, high temperature resistance, and chemical stability due to a 4 GPa modulus of elasticity, it is as elastic as bone and can reduce stresses transferred to the abutment teeth.Additional advantages of this polymer material are elimination of allergic reactions and metallic taste, high polishing qualities, low plaque afﬁnity, and good wear resistance, it has only recently been used in dentistry.
224236049|NCT02175706|DEVICE|Resolute Integrity®|Biolinx-zotarolimus coating on a chobalt-cromium alloy stent platform that has a novel sinusoidal design.
224236050|NCT02175706|DEVICE|Promus Element®|fluoropolymer-everolimus coating on a novel stent platform made from a platinum-chromium alloy
224236051|NCT02134080|DRUG|PF-04457845|PF-04457845 will be administered orally at 4mg daily for four weeks.
224236052|NCT02134080|DRUG|Placebo|Placebo will be administered orally at 4mg daily for four weeks.
224236053|NCT01021150|DRUG|ombrabulin (AVE8062)|"Pharmaceutical form:injection solution~Route of administration: intravenous infusion"
224236054|NCT01021150|DRUG|cisplatin|"Pharmaceutical form: injection solution~Route of administration: intravenous infusion"
224236055|NCT05964634|DIAGNOSTIC_TEST|OCT imaging|Image J or Spectralis OCT built-in software package was used to manually locate and measure the area and width of the temporal parapapillary atrophy.
224236056|NCT02508961|BEHAVIORAL|Exercise|web-based physio exercise programme
224236057|NCT03670238|DEVICE|Orogastric intubation|Patient was placed in Fowler position (45º) and intraoral infiltrative anesthesia was carried out with Lidocaine 2% (without vasoconstrictor) at gingival papilla in the vestibular-palatine direction. A polyurethane enteral tube (Medicone®, Cachoeirinha - Brazil) was inserted through the mouth and passed into de stomach, followed by fixation of the tube tip to a superior molar or premolar, in its palatine surface. For dental amarry it waas used a suture wire in stainless steel size 1.0
224236058|NCT03670238|DEVICE|Nasogastric intubation|After nostril anesthesia with xylocaine gel, a polyurethane enteral tube was inserted through the nose and its tip was positioned in the gastric lumen, according to the nose-ear-xiphoid method. The tube was attached to the face using antiallergic adhesive tape.
224236059|NCT02933866|DRUG|DSXS topical|topical treatment
223651860|NCT04951609|DRUG|Placebo|Participants will receive matching placebo orally.
223651861|NCT04573582|DRUG|Enasidenib|100 mg enasidenib (CC-90007)
223651862|NCT02925299|DEVICE|FlorenceM (US) and FlorenceX (UK)|"The automated closed loop system (FlorenceM in US) will consist of:~Next generation sensor augmented Medtronic insulin pump 640G (Medtronic Minimed, CA, USA) incorporating the Medtronic Guardian3 CGM and glucose suspend feature.~The automated closed loop system (FlorenceX in UK) will consist of:~The DANA Diabecare R insulin pump (Sooil Development, Korea) incorporating the Dexcom G6 CGM.~An Android smartphone containing the Cambridge model predictive algorithm and communicating wirelessly with the insulin pump using a proprietary translator device."
223651863|NCT02925299|DEVICE|Insulin pump therapy|Subjects will continue using their own insulin pump for 6 months.
223651864|NCT03313167|OTHER|Non-interventional|Non-interventional
223651865|NCT06343545|BEHAVIORAL|Standard of Care|Standard of Care provided by enrolling hospitals
223651866|NCT06343545|BEHAVIORAL|Rehabilitation|An implementation bundle of measures to improve outcomes in intensive care unit, hospital, and after hospital discharge, including rehabilitation at home performed through telemedicine.
223651867|NCT02376153|DEVICE|ABS deployed and active|ABS is deployed onto surgical field and is turned on.
223651868|NCT02376153|DEVICE|ABS deployed and NOT active|ABS is deployed onto surgical field and is NOT turned on.
223651869|NCT04496583|OTHER|Fluid depletion strategy|The fluid depletion strategy will be individualized depending on the response to the standardized furosemide test (one-time dose of 1.0 or 1.5 mg/kg depending on prior furosemide-exposure) with a urinary output (UO) cutoff of 200 ml at 2 hours. The desired depletion endpoint will be targeted by using diuretics (40 mg q6h iv initially, adjusting dose by UO) or ultrafiltration (UF) if UO \<200 ml/2h
223651870|NCT06347120|PROCEDURE|nasogastric tube|nasogastric tube (NGT), intravenous administration of fluids, and clinical and biochemical monitoring for 72h.
223651871|NCT06347120|OTHER|NOM without NGT insertion|intravenous administration of fluids, nill per os, analgesic, antiemetic treatment, and clinical and biochemical monitoring for 72h
223651872|NCT02129127|DEVICE|Paclitaxel Coated Chocolate Balloon Angioplasty|Balloon Angioplasty with the Chocolate Balloon resulting in vessel dilatation and localized delivery of Paclitaxel
223651873|NCT01817270|BIOLOGICAL|Live Attenuated Varicella Vaccine|
224236060|NCT02933866|DRUG|Vehicle topical|topical treatment
224236061|NCT02583503|RADIATION|Hindfoot alignment view x ray|Diagnostic x rays used to measure leg alignment.
224236062|NCT05342857|DRUG|Aflibercept Injection [Eylea]|Aflibercept 2.0 mg with the T\&E criteria in Taiwan local consensus
224236063|NCT04127409|OTHER|Control Chicken-meat|
223651874|NCT04044001|DRUG|BTZ-043|BTZ-043 (250mg per tablet)
223651875|NCT04044001|DRUG|Rifafour e-275®|Rifafour e-275® (150mg rifampicin, 75mg isoniazid, 400mg pyrazinamide, 275 mg ethambutol per tablet)
223651876|NCT04044001|DRUG|Probe Drug Cocktail|"A probe drug cocktail will be given to randomly selected patients after inclusion on Day 1 and on Day 14 once orally. The probe drug cocktail consists of~* Caffeine: 1 tablet à 150mg~* Tolbutamide: 1/4 tablet à 500mg~* Dextromethorphan: 10 ml syrup à 15mg/5ml~* Midazolam:2 ml solution à 5mg/5ml~* Digoxin: 2 tablets à 0.25mg"
223651877|NCT04044001|DRUG|Dolutegravir 50mg Tab|1 tablet à 50mg Dolutegravir will be given to randomly selected patients after inclusion on Day 1 and on Day 14 once orally.
223651878|NCT06091683|PROCEDURE|Pressurized intraperitoneal aerosol chemotherapy (PIPAC)|"Laparoscopic exploration of the abdominal cavity with dissection of adhesions and biopsies of suspect findings (if needed).~PIPAC will be administered with oxaliplatin (92 mg/m2 body surface area in 150 ml dextrose solution) for 30 minutes under the following spraying conditions: cytostatic application at a rate of 30 ml/min, pressure of 1380 kilo-pascal over 30 minutes, and temperature of 22°C. One hour before the beginning of PIPAC, intravenous infusion of 5-fluorouracil (400 mg/m2) and folinic acid (20mg/m2) will be initiated. Standard protectionist procedures will be adopted to avoid contamination of operators and the environment with nebulized chemotherapy."
223651879|NCT03929497|DRUG|Lu AF11167|Lu AF11167 - 2 or 4 mg/day; tablets, orally
223651880|NCT05115149|DEVICE|VIBRAINT RehUp robotic orthosis|VIBRAINT RehUp robotic orthosis is a robotic arm that supports movement of a paralyzed arm. The robotic device is connected to a BCI. VIBRAINT RehUp software decodes imagery of a movement of the paralyzed arm and/or selective attention to the target of movement.
223651881|NCT05115149|PROCEDURE|tSCS during the exercise|"During the exercise transcutaneous stimulation of the spinal cord and, in some cases, peripheral nerves is also performed.~tSCS is performed with the localization of electrodes between the spinous processes of the vertebrae C2-C3 and C5-C6, anodes - above the clavicles or above the crests of the iliac bones, bipolar or monopolar pulses with a frequency of 30 Hz, modulated with a frequency of 5 Hz."
223651882|NCT05115149|PROCEDURE|tSCS prior to the exercise|"Prior to the exercise transcutaneous stimulation of the spinal cord and, in some cases, peripheral nerves is also performed.~tSCS is performed with the localization of electrodes between the spinous processes of the vertebrae C2-C3 and C5-C6, anodes - above the clavicles or above the crests of the iliac bones, bipolar or monopolar pulses with a frequency of 30 Hz, modulated with a frequency of 5 Hz."
223651883|NCT05115149|DEVICE|Neostim-5|Neostim-5 is intended for the transcutaneous spinal cord noninvasive stimulation from 0 up to 250 2 mA (step 1mA). Neostim allows to stimulate up to five different segments of spinal cord. The device can be synchronised with other devices.
223651884|NCT05115149|PROCEDURE|Exercise|The partcipant recieves a mental task - to imagine a movement or to concentrate on the goal. Upon successful completion of the given mental task, the VIBRAINT RehUp robotic exerciser moves the paralyzed limb. In the presence of muscular activity in a limb, an additional condition for the start of movement can be EMG activity in an agonist muscle assisting the robot movement.
223651885|NCT05000255|BEHAVIORAL|Intervention 1: According to DGP|The first intervention is designed according to a current recommendation of the Deutsche Pneumologen Gesellschaft e.V. Its approach is resource-oriented, psychoeducational and is expected to have a positive effect on the symptomatology of depression and anxiety in the short and medium term. An additional focus was added to the intervention: planning more physical activity in daily life after discharge. The DPG intervention focuses more on the current state and aims to activate patients' resources in the short and long term. To ensure randomization of study participants, interventions will alternate weekly.
223651886|NCT05000255|BEHAVIORAL|"Intervention 2: According to Cacioppo E.A.S.E."|"The second intervention, E. A. S. E. according to Cacioppo and Patrick (2008), addresses the social action radius of patients (here assuming that loneliness is a predictor of depression). This intervention is about planning social activities against loneliness. Cacioppo's intervention aims to encourage more social activity in the long term."
224236064|NCT04127409|OTHER|Control Eggs|
224236065|NCT04127409|OTHER|Omega-3-PUFA Enriched Chicken-meat|
224236066|NCT04127409|OTHER|Omega-3PUFA Enriched Eggs|
224236067|NCT01701726|OTHER|acupuncture|In each session, acupuncture are applied bilaterally. Except the acupoints around the neck(ST9.GB20.non-acupoints 4) ,6 auxiliary needles will be punctured at 2mm lateral to each acupoints or non-acupoints.as to auxiliary needle we will not do any manipulation. We use transcutaneous electric acupoints stimulation to stimulate the acupoints and non-acupoints.
224236068|NCT01701726|OTHER|Sham acupuncture|In contrast to acupuncture, sham acupuncture is given at 4 sham points with skin penetration. Electroacupuncture is also applied.
224236069|NCT00005910|PROCEDURE|Intraoperative ultrasound|
224236070|NCT04182009|DEVICE|Omron NE-U17 Ultrasonic nebuliser|The Omron Ultrasonic nebuliser dispenses sterile saline from a medication cup as an aerosol, which is inhaled.
224236071|NCT04182009|DEVICE|Akita Jet Inhalation System|The Akita Jet Inhalation System is a breath actuated nebuliser, which works with a positive pressure.
224236072|NCT00290056|DRUG|Eicosapentanoic acid (EPA) and Docosahexanoic acid (DHA).|3.6 gram oral supplementation for 6 months.
224236073|NCT02698800|DEVICE|Blue blocking (BB) lenses|Participants will wear blue blocking lenses each night for 1 week for 2 hours preceding bedtime.
224236074|NCT02698800|DEVICE|Clear lenses|Participants will wear clear lenses each night for 1 week for 2 hours preceding bedtime.
224236075|NCT04646109|DRUG|Ivermectin|"Ivermectin 5mg/5ml solution was manufactured by NEUTEC™ Pharmaceutical Company-Turkey, under Good Manufacturing Practices (GMP) certification conditions."
224320770|NCT06919952|BEHAVIORAL|Resilience|The Resilience program focuses on drawing on resilience assets and resources, both internal and external. Participants will have access to materials (e.g., lessons, videos, webinars, coaching calls) supporting the adoption of strategies for improving well-being. Behavior change strategies used are meant to increase intervention adherence and improve well-being and resilience.
223651887|NCT00218842|BEHAVIORAL|Individualized exercise|individualized exercise, physical activity and training in daily life situations given by trained physical therapists and occupational therapists
223651888|NCT01448980|PROCEDURE|Thai Traditional Massage (TTM)|Thai Traditional Massage will receive massage 2 time per week for 6 weeks
223651889|NCT01448980|PROCEDURE|Physical therapy program|Physical therapy program 2 times per week for 6 weeks.
223651890|NCT04336878|BEHAVIORAL|Healthy Habits in Pregnancy and Beyond|Habit-based intervention to support the development of 10 healthy dietary and activity behaviours for pregnant women with overweight or obesity.
223651891|NCT06403332|BEHAVIORAL|brief intervention|The intervention for cohort A (intervention arm) based on brief intervention on alcohol consumption performed by a psycologist, medical visit peformed by an hepatologist including assessment of underlying liver disease with non invasive test (i.e Fibroscan and lab work).
223651892|NCT03643068|DRUG|KSP-QRH-E3-IRDye800 (Peptide 919288G), 0.6 mg|The investigational agent to be used in this study is KSP/QRH dimer: a fluorescently-labeled peptide dimer composed of a 14-amino acid sequence \[Lys-Ser-Pro-Asn-Pro-Arg-Phe\] and \[Gln-Arg-His-Lys-Pro-Arg-Glu\] attached via a PEG3, Lys and Cys linker \[PEG3\]2-Lys-Cys to a near-infrared fluorophore, IRDye800CW (0.6 mg dose).
223651893|NCT03643068|DRUG|KSP-QRH-E3-IRDye800 (Peptide 919288G), 1.8 mg|The investigational agent to be used in this study is KSP/QRH dimer: a fluorescently-labeled peptide dimer composed of a 14-amino acid sequence \[Lys-Ser-Pro-Asn-Pro-Arg-Phe\] and \[Gln-Arg-His-Lys-Pro-Arg-Glu\] attached via a PEG3, Lys and Cys linker \[PEG3\]2-Lys-Cys to a near-infrared fluorophore, IRDye800CW (1.8 mg dose).
223651894|NCT00553371|OTHER|biomarker analysis|
223651895|NCT00553371|PROCEDURE|computed tomography|
224236076|NCT01679821|OTHER|A questionnaire and a clinical examination|Seventy dental students of State University of West of Paraná - UNIOESTE, seventy patients treated at the UNIOESTE Dental Clinic that wore removable partial denture (partially edentulous) and seventy patients with double complete dentures treated in Center for Dental Specialties of Cascavel, Paraná, Brazil. Students in orthodontic treatment or with less than one year after the end of orthodontic treatment were excluded from the research. Patients wearing a complete denture in one maxillary and a removable partial denture in another maxillary, and patients wearing just one complete denture were not included in the research.
224236077|NCT05718609|DRUG|Rabeprazole|proton-pump inhibitor (PPI)
224236078|NCT05718609|DRUG|Colloidal Bismuth Pectin Granules|Gastric mucosal protective drug with anti-H. pylori effect
224236079|NCT05718609|DRUG|Amoxicillin|Antibiotic for H. pylori eradication
223651896|NCT06139367|DRUG|TQB3454 tablets|TQB3454 is a Isocitrate dehydrogenase 1 (IDH1) mutation inhibitor.
223651897|NCT02864056|OTHER|Tai Chi|Ancient Chinese form of mind/body gentle exercise; this will be done while standing to improve postural balance.
223651898|NCT00793013|DEVICE|Volume-Cycled Assist-Control (AC) mode|"1. Patients ventilated with volume-cycled assist-control mode with PEEP and goal FIO2 \< 40%~2. Rate of mandatory time-cycled, pressure controlled breaths,initially at 12 per breaths/min~3. Initial tidal volume set at 8mL/kg using predicted body weight (PBW) with a goal of 6mL/kg \& setting positive end-expiratory pressure (PEEP) based on level of initial FiO2~4. Inspiratory to Expiratory ratio set at 1:1 to 1:3~5. If frequency of triggered breaths increased greater than 10 per min sedation will be increased. If needed,rate of mandatory breaths increased~6. Mgmt of PEEP will be conducted as per the ARDSnet Protocol~7. Oxygenation goal PaO2: PaO2-55-80 mm Hg O2 Sat: 88-95%~8. Tidal volume and respiratory rate adjusted to the desired pH and plateau pressures per ARDSnet protocol"
223651899|NCT00793013|DEVICE|Airway Pressure Release Ventilation (APRV) mode|"1. Ventilation uses Drager Model X1~2. Spontaneous breathing allowed throughout ventilatory cycle at 2 airway pressure levels~3. Time periods for the high \& low pressure levels can be set independently~4. Duration of the lower pressure level will be adjusted to allow expiratory flow to decay to 75% of total volume~5. Duration of higher pressure levels will be adjusted to produce 12 pressure shifts per min~6. Spontaneous frequency will be targeted for 6 to 18 breaths/per min~7. If spontaneous breathing is achieved,level of sedation will be decreased~8. If spontaneous respirations are \>20 breaths/min, sedation will be increased~9. If spontaneous breathing frequency increased greater than 20/per min, sedation was increased and if needed the mechanical frequency increased"
223651900|NCT01850758|PROCEDURE|Regenexx SD|stem cell treatment
223651901|NCT01850758|OTHER|Exercise Therapy|exercise therapy control
223651902|NCT04083768|DEVICE|15° and 30° wedge sponges|After the spinal anesthesia is completed, the wedge sponge is placed between the patient's pelvis and ribs and the wedge is removed before the skin is cut.
223651903|NCT03950297|DRUG|609A|609A is a recombinant anti-PD-1 humanized IgG4 kappa antibody that targets the human PD-1
223651904|NCT02210494|DRUG|Secretrol|
223651905|NCT01286051|DRUG|Follistim administration|adminstation of FSH for ovulation induction
224236080|NCT05718609|DRUG|Furazolidone|Antibiotic for H. pylori eradication
224236081|NCT05718609|DRUG|Clarithromycin|Antibiotic for H. pylori eradication
224236082|NCT06286969|PROCEDURE|acupuncture|The needles are inserted into the subject in a certain way to stimulate specific parts of the body to treat the disease.
224236083|NCT04066166|DIAGNOSTIC_TEST|Palpation|All healthy subjects palpated
224236084|NCT05504603|DRUG|zanubrutinib and rituximab|zanubrutinib 160mg PO BID d1-28; rituximab 375mg/m2 IVGTT d1,8,15,22. Other name: Part A
224236085|NCT05504603|DRUG|zanubrutinib and rituximab|zanubrutinib 160mg PO BID d1-28; rituximab 375mg/m2 IVGTT d1. Other name: Part B
224320771|NCT06919952|BEHAVIORAL|Physical Activity|The Physical Activity program focuses on supporting physical activity health habits. Participants will have access to materials (e.g., lessons, videos, webinars, coaching calls) supporting the adoption of strategies of evidence-based strategies for physical activity goals. Behavior change strategies used are meant to help establish, improve or maintain healthy physical activity habits.
223651906|NCT01286051|DRUG|Follistim plus Ganirelix|Follistim plus single injection of ganirelix
223651907|NCT02233868|OTHER|connectivity|Magnetic resonance imaging (MRI) scans will be done to assess brain structure, functional reactivity and functional connectivity.
224320772|NCT07115394|OTHER|EEG recording|EEG will be recorded at high sampling rate
224320773|NCT07117669|DRUG|ENP-501|"* Part 1: Participants will receive buccal administrations of ENP-501 daily for 6-14 weeks~* Part 2: Participants will receive buccal administrations of ENP-501 daily for 52 weeks following achieving the 2000 µg target dose"
224236086|NCT05504603|DRUG|BEAM pretreatment|semustine 250mg/m2 PO d1; etoposide 200mg/m2 IV d2-5; cytarabine 400mg/m2 IV d2-5; melphalan 140mg/m2 IV d6.
224236087|NCT05504603|DRUG|zanubrutinib maintenance|zanubrutinib 160mg PO BID.
223651908|NCT02233868|DRUG|neuroinflammation|The use of \[11C\]PBR28 will allow us to assess for the first time in vivo if there is neuroinflammation in the brain of alcoholics. It will also allow us to assess if it recovers with alcohol detoxification.
224236088|NCT01607645|DRUG|decitabine|Given IV
223651909|NCT02233868|OTHER|neurofunction|To assess regional brain glucose metabolism.
223651910|NCT03820895|DIAGNOSTIC_TEST|Blood test|Serum 25-hydroxyvitamin D 25(OH) D levels were measured for Vitamin D status, by electrochemiluminescence immunoassay (Roche, USA). Cobb's angle measurement was done by measuring the major spinal curve and was taken from the upper end vertebra to the lower end vertebra through an x-ray for all the patients included in the study.
224320774|NCT07117669|DRUG|Placebo|"* Part 1: Participants will receive buccal administrations of placebo daily for 6-14 weeks~* Part 2: Participants will receive buccal administrations of placebo daily for 52 weeks following achieving the 2000 µg target dose"
224320775|NCT07121946|BIOLOGICAL|LTZ-301|LTZ-301 will be dosed IV, in initial 28 day cycles. First cycle dosing is every week. Second through fifth cycles are dosed every 2 weeks. Sixth cycle and beyond are 21 day cycles, and are dosed once every 3 weeks.
224320776|NCT07121946|BIOLOGICAL|LTZ-301|LTZ-301will be dosed IV, as above
224320777|NCT07121946|BIOLOGICAL|LTZ-301|LTZ-301will be dosed IV, as above
224236089|NCT01607645|DRUG|idarubicin|Given IV
224236090|NCT01607645|DRUG|cytarabine|Given IV
224236091|NCT01610258|OTHER|Blood and placenta samples|"The placenta sample is realised, specially for the study, in surgical unit after the delivery.~The blood samples are taken, specially for the study, the day of admission and at time of delivery or seven days after the admission."
224236092|NCT05894863|DEVICE|Smart flex stent|Smart flex stent will be used for femoropopliteal occlusive lesions.
224236093|NCT04641481|BIOLOGICAL|BBV152|BBV152 (6µg-Algel - Imidazoquinoline)
224236094|NCT04641481|BIOLOGICAL|Placebo|Placebo (PBS+Alum, without antigen)
224236095|NCT01683617|BEHAVIORAL|Coping skills and relaxation training with new technologies|
224236096|NCT01683617|BEHAVIORAL|Traditional coping skills and relaxation training|
224236097|NCT06776003|PROCEDURE|Vertebroplasty|Polymethyl-methacrylate (PMMA) cement is injected slowly into the vertebral body under constant bi-plane fluoroscopy
224236098|NCT06776003|PROCEDURE|Sham Vertebroplasty|A short needle is passed through the skin, but not as far as the periosteum. PMMA is mixed to mimic the PVP procedure but not injected into the vertebral body.
224236099|NCT05293223|BIOLOGICAL|Ad5-nCov|Participants enrolled in Group A with only the 1st dose of Sputnik V will receive Ad5-nCoV vaccine at least 21 days but no more than 180 days after the first dose. They will be followed to evaluate the immunogenicity and safety of Ad5-nCoV vaccine during 6 months
224236100|NCT05826925|OTHER|Decision aid|A decision aid will be developed based on qualitative data from Aim 1 and iterative refinement with input from stakeholders from Aim 2. Anticipated content includes: 1) information about cardiovascular risk following hypertensive disorders of pregnancy; 2) goal-setting exercises for blood pressure, weight management, glucose control, physical activity, and smoking cessation; 3) self-care steps to achieve management targets; 4) values clarification exercises to identify values related to cardiovascular risk management and identify priority areas for focus and improvement; and 5) discussion of how to communicate questions and goals of treatment to their provider.
224236101|NCT06779981|OTHER|Nasopharyngeal swabs|Completion of an electronic Diary (eDiary) and collection of nasopharyngeal swabs in case the subject experiences ILI symptoms
224320778|NCT05371041|DEVICE|Medtronic Percept Neurostimulator|This is a deep brain stimulator that can also record brain signals and deliver stimulation through a control algorithm based on brain activity.
224320779|NCT07128056|BEHAVIORAL|Mobile phone video game distraction|Children in the intervention group will play age-appropriate, non-violent mobile phone video games for approximately 20 minutes before induction of anesthesia. This is intended as a distraction technique to reduce preoperative anxiety and improve postoperative pain outcomes. Participants will also receive standard perioperative care.
224320780|NCT07128056|OTHER|Standard peri operative care|Standard preoperative and postoperative care according to institutional protocol, without mobile phone video game distraction.
223651911|NCT02967224|DRUG|insulin glargine (U300)|"Pharmaceutical form: solution~Route of administration: subcutaneous"
224236102|NCT05820737|DIETARY_SUPPLEMENT|EF2001|One capsule to be consumed once a day
224236103|NCT05820737|DIETARY_SUPPLEMENT|beLP1|One capsule to be consumed once a day
224236104|NCT05820737|DIETARY_SUPPLEMENT|Placebo|One capsule to be consumed once a day
224236105|NCT01639508|DRUG|Cabozantinib|Patients will receive cabozantinib at an initial dose of 60 mg orally daily. The drug is taken continuously over a period of 28 days (4 weeks), which constitutes one treatment cycle. Dose modifications for drug toxicity are permitted as per a prescribed algorithm. During the Treatment Period subjects will receive cabozantinib until either disease progression, the occurrence of unacceptable drug-related toxicity or for other reason(s) for subject withdrawal.
224236106|NCT06186037|DRUG|Combination drug group of Ezetimibe 10 mg/Rosuvastatin 5 mg|Oral administration once a day, taking it for 3 years
224236107|NCT06186037|DRUG|Mono drug group of Rosuvastatin 20 mg|Oral administration once a day, taking it for 3 years
224236108|NCT06784648|BIOLOGICAL|pembrolizumab (KEYTRUDA®)|fixed dose 200mg
224236109|NCT06784648|BIOLOGICAL|BI-1607|Each cohorts will receive either 350mg or 700mg per cycle for 4 cycles
224236110|NCT06784648|BIOLOGICAL|Ipilimumab (YervoyTM, 50 mg/10 mL solution)|Each cohort will receive either 1mg/kg or 3mg/kg for 4 cycles
224236111|NCT03317847|DRUG|Bromfenac 0.09 % Ophthalmic Solution|Patients will self-administer 1 drop of Bromfenac twice daily to the affected eye beginning 1 day after cataract surgery and then continuing through the first 14 days of the postoperative period.
224236112|NCT03317847|DRUG|Dexamethasone 0.1% ophthalmic suspension|Patients will self-administer 1 drop of Dexamethasone to the study eye beginning 1 day after cataract surgery 4 times daily during the first postoperative week and 2 times daily in the second postoperative week.
224236113|NCT03815942|BIOLOGICAL|ChAdOx1-MVA 5T4 vaccine|ChAdOx1.5T4 will be administered intramuscularly in an extremity (e.g. thigh) at a dose of 2.5 x10\^10 virus particles followed by MVA.5T4 administered via the same route at the dose of 2x10\^8 plaque forming units
224236114|NCT03815942|DRUG|Nivolumab Infusion [Opdivo]|Nivolumab is to be administered as a flat dose of 480 mg over approximately 60-minutes via IV infusion
224320781|NCT07128238|BEHAVIORAL|lifestyle intervention|This study implemented lifestyle interventions including dietary and exercise interventions. Based on the assessment of the physical condition of the volunteers, a personalized training plan is formulated and a standardized diet is provided. The entire intervention process lasts for 8 weeks.
224320782|NCT07133711|DEVICE|Noninvasive ventilation|Weaning from noninvasive ventilation for patients with acute exacerbation of COPD
224320783|NCT06937788|DRUG|Upadacitinib|30 mg tablet daily
223651912|NCT02967224|DRUG|insulin glargine (U100)|"Pharmaceutical form: solution~Route of administration: subcutaneous"
224236115|NCT05094180|OTHER|Face-to-face appointment|Participants will be scheduled with face-to-face appointments as usual (control arm). All phone calls (except reminders for scheduled visits) performed by the physician during the study will be recorded. Per protocol, participants allocated in the control arm can receive up to 25% of physician-doctor interactions by phone (that is, one phone call allowed for three face-to-face appointments).
224236116|NCT05094180|OTHER|Remote consultation (telephone or video consultation mode)|"Patients will be seen through one of the two remote consultation modalities: video consultation or telephone. Patients will receive a reminder by text or call before the appointment.~In the case of telephone consultation, patients will be informed of the date and time slot in which they must wait for the doctor's call. At the time of the appointment, the doctor will call the contact phone number of the patients and/or their family members, starting with the first contact number that appears in the patient's medical history, and using the rest of the contacts available if there is no response. .~In the case of video consultation, at the time of the appointment, patients will receive a link to the application that manages the teleconsultation. Once in the application, they will remain in the virtual waiting room until the doctor switches to the videoconference."
224236117|NCT04249154|DRUG|Eligard|Eligard dose of 22.5mg given, 50Gy in 20 treatments of radiation therapy to start 12 weeks after first injection concurrent with second injection of Eligard
224236118|NCT02602184|DRUG|AR/101|
224236119|NCT02602184|DRUG|Placebo|
224236120|NCT00295178|DRUG|Daptomycin|
224236121|NCT00295178|DRUG|Vancomycin|
224236122|NCT00442845|DRUG|Atorvastatin (Lipitor)|
224236123|NCT00311961|DRUG|Intravenous prednisolone|
224236124|NCT00311961|DRUG|Oral prednisolone|
224236125|NCT05147077|PROCEDURE|Acupuncture|"Acupuncture:~Scalp acupuncture includes middle line of forehead (MS1), a front line by the forehead (MS2), and middle line of vertex (MS5), these acupoints are needled for 1 inch with the direction with scalp tilted 15-30 degrees.~Body acupuncture includes Yintang (DU29), Taichong (LR3), Shenmen (HT7), Neiguan (PC6), Danzhong (RN17), Tongli (HT5), Xingjian (LR2).~Traditional Chinese medicine Danzhixiaoyao Power: Danpi 10g, fried Zhizi 10g, Danggui 12g, Baishao 12g, fried Chaihu 6g, Fuling 10g, fried Baishu 10, roasted Gancao 3g.~Repetitive transcranial magnetic stimulation The CCY-I magnetic field stimulator from Wuhan Irid Medical Equipment New Technology Co is used, with a frequency of 1Hz.~Standard care The same as the standard care group."
224236126|NCT02785913|OTHER|Laboratory Biomarker Analysis|Correlative studies
224320784|NCT06937788|BIOLOGICAL|Dupilumab|300 mg injection every other week
224320785|NCT00550030|RADIATION|UVB-311nm radiation|UVB-311nm radiation randomized to one body half given 3 times a week for 6 weeks; the other body half remains UV-non-irradiated.
223651913|NCT02967224|DRUG|NPH insulin|"Pharmaceutical form: solution~Route of administration: subcutaneous"
223651914|NCT02967224|DRUG|insulin detemir|"Pharmaceutical form: solution~Route of administration: subcutaneous"
223651915|NCT02967224|DRUG|insulin degludec|"Pharmaceutical form: solution~Route of administration: subcutaneous"
223651916|NCT02062619|BEHAVIORAL|Computer-based behavioural word reading therapy|"Each patient participates in two blocks of reading training (one with real tDCS, one with sham tDCS). Different words will be trained in each training block.~Each training block comprises 10 hours of reading therapy per week for four weeks (three 1-hour sessions/week at research site; 1-hour of training/day at home)"
223651917|NCT02062619|OTHER|Real tDCS|Real tDCS 20 minutes per session, three times per week
223651918|NCT02062619|OTHER|Sham tDCS|Sham tDCS, 20 minutes per session, 3 sessions per week
224236127|NCT02785913|DRUG|Taselisib|Given PO
224236128|NCT03745859|DEVICE|Fraxinus VBN system|Open source planning tool for bronchoscopy
224236129|NCT03717064|DRUG|RO7049389|RO7049389 will be taken orally, in tablet form, BID on Days 1-6 of Period 2.
224236130|NCT03717064|DRUG|Pitavastatin|Pitavastatin will be taken orally, in tablet form, once on Day 1 of Period 1, and once on Day 4 of Period 2.
224236131|NCT03852706|OTHER|LORETA|Twenty sessions of neurofeedback training using LORETA in combination with z-scores.
224236132|NCT03852706|OTHER|Treatment as usual|Treatment-as-usual
224236133|NCT03787459|DRUG|Arbidol|Oseltamivir plus Arbidol will be administrated from Days 1-7.
224236134|NCT03787459|DRUG|Placebos|Oseltamivir plus placebos will be administrated from Days 1-7.
224236135|NCT02841709|DRUG|ACT-541468|Capsules for oral administration containing ACT-541468 at a strength of 5 mg, 10 mg or 25 mg
224236136|NCT02841709|DRUG|Placebo|Capsules for oral administration matching the ACT-541468 capsules
224236137|NCT01929109|DRUG|LY2409021|Administered orally
224236138|NCT01292161|DRUG|Silymarin|Tab 210 mg, 630 mg, daily, six months.
224320786|NCT00550030|OTHER|No treatment|no UV exposure
224320787|NCT01123967|OTHER|proactive outreach (PRO)|a mailed invitation letter followed by telephone outreach
224320788|NCT01123967|OTHER|telephone counseling (TC)|free telephone counseling
224320789|NCT01123967|OTHER|Nicotine replacement therapy (NRT)|free nicotine replacement therapy (NRT)
224320790|NCT01123967|OTHER|Usual care (UC)|nicotine replacement products (patch, gum, lozenge, inhaler, and nasal spray)
223767313|NCT06384729|DEVICE|EXOPULSE Mollii Ⓡ|The EXOPULSE Mollii method (EXONEURAL NETWORK AB, Danderyd, Sweden) is an innovative approach to non-invasive and self-administered electrical stimulation with multiple electrodes incorporated into a full-body suit. It consists of comfortable, breathable, and washable synthetic material pants and a jacket. It has been primarily designed to reduce disabling spasticity and improve motor function. The method refers to the concept of reciprocal inhibition induced by stimulating the antagonist of a spastic muscle, at low frequencies and intensities, which is considered to reduce spasticity.
223767314|NCT04925297|OTHER|No intervention|No intervention will be given
224236139|NCT03508713|DRUG|disease modified antirheumatic drugs or biological agents|Enrolled patients will be treated according to the 2015 American College of Rheumatology Guideline for the Treatment of RA
224236140|NCT02354742|OTHER|Echo guided fluid resuscitation|Patients will have their fluid resuscitation care guided by measurements obtained during an echo.
224236141|NCT02354742|OTHER|EGDT fluid resuscitation|Patients will have their fluid resuscitation care guided by an EGDT protocol, which is currently used as standard of care.
224236142|NCT02391064|BEHAVIORAL|Cognitive evaluation|"* Questionnaires for assessment of confounding factors~* Cognitive evaluation~* Walking tests and 9 Hole Peg Test"
224236143|NCT02391064|BEHAVIORAL|Expanded Disability Status Scale (EDSS) score|\- EDSS score
223651919|NCT01497223|DRUG|MGCD290|1 Oral Dose Administration
223651920|NCT01939769|OTHER|Exercise - Low-intensity exercise|
223651921|NCT01939769|OTHER|Exercise - High-intensity exercise|
223651922|NCT01420211|DRUG|Primovist® 0,25 mmol/ml solution for injection|intravenous bolus injection of 25 µmol/kg (=0,1 ml/kg) body weight Primovist® and blood sampling before (serum blank) and 6, 11, 21, 31, 45, 65, 95, 125 min and 3, 4, 6, 8, 12, 24 and 48 h after drug administration
223767315|NCT01404468|DEVICE|pulsed ultrasound device with lidocaine|Lidocaine (approximately 2 cc) was administered transdermally using a transducer (pulsed ultrasound)
223767316|NCT01404468|OTHER|off device|off device with Lidocaine (approximately 2 cc) was administered transdermally
223767317|NCT01404468|DEVICE|continuous ultrasound device with lidocaine|Lidocaine (approximately 2 cc) was administered transdermally using a transducer (continuous ultrasound )
224236144|NCT00076102|DRUG|Pirfenidone|Pirfenidone orally as capsules three times a day approximately every 8 hours for cycles of 28 days with no rest period between cycles (28 day treatment cycles); 500 mg/m\^2 every 8 hours (1500 mg/m2/day).
224236145|NCT02702960|PROCEDURE|living related donor partial liver transplantation|HLA matched or haploidentical related living donor partial liver transplant followed by tacrolimus, prednisone, and MMF immunosuppression for \>3 wks
224236146|NCT02702960|RADIATION|Total body irradiation|200 cGy total body irradiation (TBI) on Day -1.
224236147|NCT02702960|PROCEDURE|Bone marrow transplant from same donor|BMT using cells from the same Human Leukocyte Antigen (HLA)-matched or -haploidentical living related donor will be performed on Day 0
224236148|NCT02702960|DRUG|Cyclophosphamide|Pre-transplantation low dose cyclophosphamide given day -6 and -5 Post-transplantation high dose cyclophosphamide (PTCy; 50 mg/kg/day) will be administered on Days 3 and 4 with hydration
224236149|NCT02702960|DRUG|Mesna|administered on Days 3 and 4 with PTCy
224236150|NCT02702960|DRUG|Filgrastim|administered daily starting on Day 5 until absolute neutrophil count (ANC) recovery
224236151|NCT02702960|DRUG|Tacrolimus|Given after liver transplant for through day -7, stopped on day -6 and restarted on day 5 post BMT
224236152|NCT02702960|DRUG|mycophenolate mofetil|Given after liver transplant for through day -7, stopped on day -6 and restarted on day 5 post BMT
224236153|NCT02702960|DRUG|Prednisone|Given after liver transplant for through day -7, stopped on day -6 and restarted on day 5 post BMT
224236154|NCT02702960|DRUG|Antithymocyte globulin|Given from Day -16 to Day -14 prior to bone marrow transplantation on day 0
224236155|NCT02702960|DRUG|fludarabine|fludarabine given from Days -6 to Day -2 before BMT
224236156|NCT06369805|OTHER|there is no intervention|there is no intervention
224236157|NCT03920007|DRUG|ATSN-101|Pharmaceutical form:Solution for intraocular administration Route of administration: Subretinal injection
224236158|NCT03920007|DRUG|ATSN-101 Diluent Solution|Pharmaceutical form:Solution for parenteral use Route of administration: Subretinal injection
223651923|NCT01420211|DEVICE|MRI|lmaging of 20 slices (thickness: 3 mm; max. time of imaging 10 s) before and 0.25, 1, 2, 3, 4, 5, 7, 8, 9, 10, 20, 30, 40, 50, 60, 90 and 120 min after intravenous bolus injection of 25 µmol/kg (=0,1 ml/kg) body weight Primovist®
223651924|NCT04473469|DEVICE|Medtronic Interstim II Model 3058 Neurostimulator|Patients will undergo stimulation of the pudendal nerve. All stimulation parameters used will be within the normal hard-coded limits of the implantable pulse generator (IPG).
223651925|NCT01809743|DRUG|Regadenoson central -central|To test the accuracy of Regadenoson to induce maximal and steady state hyperemia as compared to central venous infusion of adenosine for assessing fractional flow reserve. (adenosine is considered to be the golden standard).
223651926|NCT01809743|DRUG|Regadenoson peripheral - peripheral|To test the accuracy of Regadenoson to induce maximal and steady state hyperemia as compared to central venous infusion of adenosine for assessing fractional flow reserve. (adenosine is considered to be the golden standard).
223767318|NCT05235529|PROCEDURE|Aortic valve replacement|Surgery replacement od the aortic valve
223767319|NCT05235529|DEVICE|TAVI|Transcatheter aortic valve implantation
223767320|NCT04630405|DEVICE|Wright jet nebulizer|Roxon Medi-Tech, Montreal, QC, Canada
223767321|NCT04630405|DEVICE|Aerogen Solo|Aerogen Ltd., Galway, Ireland
223767322|NCT03867513|OTHER|Multimodal imaging|All participants will attend the Sir Peter Mansfield Imaging Centre for a scanning session using three imaging systems (SQUID MEG, OPM MEG and 7T MRI), cognitive testing and symptom questionnaires. Remote symptom monitoring and cognitive testing at three and six months.
223767323|NCT04670016|OTHER|This study does not include an intervention.|This study does not include an intervention.
223767324|NCT04463381|PROCEDURE|choledochotomy techniques during LCBDE|
223767325|NCT06351605|DEVICE|Valeda Light Delivery System|The Valeda Light Delivery System will deliver two alternating and sequential treatments of 590 nm and 850 nm for 35 seconds, or a total of 70 seconds; and 660 nm for 90 seconds, or a total of 180 seconds.
224236159|NCT03920007|DRUG|Prednisone|Pharmaceutical form:Tablet Route of administration: Oral
223651927|NCT01809743|DRUG|Regadenoson central - peripheral|To test the accuracy of Regadenoson to induce maximal and steady state hyperemia as compared to central venous infusion of adenosine for assessing fractional flow reserve. (adenosine is considered to be the golden standard).
224236160|NCT03920007|DRUG|Triamcinalone Acetonide|Pharmaceutical form:Suspension Route of administration: Peri-ocular injection
224236161|NCT03920007|DRUG|1% Prednisolone|Pharmaceutical form:Suspension Route of administration: Drops
224236162|NCT03920007|DRUG|Trimethoprim/polymyxin B|Pharmaceutical form:Solution Route of administration: Topical
223651928|NCT01809743|DRUG|Regadenoson peripheral - central|To test the accuracy of Regadenoson to induce maximal and steady state hyperemia as compared to central venous infusion of adenosine for assessing fractional flow reserve. (adenosine is considered to be the golden standard).
223651929|NCT01809743|DRUG|Adenosine|Fractional flow reserve is measured by inducing hyperaemia using central adenosine infusion.
223651930|NCT00004101|BIOLOGICAL|apolizumab|
223651931|NCT04485351|OTHER|no intervention|no intervention
223651932|NCT00973232|DRUG|DDS-06C (650 mg acetaminophen and 75 mg tramadol HCl)|DDS-06C (650 mg acetaminophen and 75 mg tramadol HCl: two tablets, single dose, total administered of 1300 mg acetaminophen/150 mg tramadol HCl under fasting conditions
223651933|NCT00973232|DRUG|DDS-06C (650 mg acetaminophen and 75 mg tramadol)|DDS-06C (650 mg acetaminophen and 75 mg tramadol HCl: two tablets, single dose, total administered of 1300 mg acetaminophen/150 mg tramadol HCl under fed conditions
223651934|NCT00973232|DRUG|Zaldiar®|Zaldiar® (325 mg acetaminophen and 37.5 mg tramadol HCl): two tablets; dose of 650 mg acetaminophen/75 mg tramadol HCl administered at Time = 0 hr (fasting)and second dose at Time = 6 hr (fed) Ultracet® (325 mg acetaminophen and 37.5 mg tramadol HCl)
223651935|NCT00973232|DRUG|Ultracet®|Ultracet® (325 mg acetaminophen and 37.5 mg tramadol HCl)two tablets; dose of 650 mg acetaminophen/75 mg tramadol HCl administered at Time = 0 hr (fasting)and second dose at Time = 6 hr (fed) Ultracet® (325 mg acetaminophen and 37.5 mg tramadol HCl)
223651936|NCT00973232|DRUG|Two tablets of DDS-06C (650 mg acetaminophen and 75 mg tramadol HCl), multiple doses, under both fed and fasting conditions|Two tablets of DDS-06C, twice daily at 12-hour intervals under fed conditions for the first 4 days, then under fasting conditions for the 5th day. The total daily dose administered was 2600 mg Acetaminophen/300 mg tramadol HCl
223651937|NCT00973232|DRUG|Zaldiar®, multiple doses,(fed & fasting):|Two tablets of Zaldiar®, 4 times daily at 6-hour intervals under fed conditions for the first 4 days, then under fasting conditions for the 5th day. The total daily dose administered was 2600 mg Acetaminophen/300 mg tramadol HCl
223651938|NCT00973232|DRUG|Ultracet®, multiple doses, (fed & fasting)|Two tablets of Ultracet®, 4 times daily at 6-hour intervals under fed conditions for the first 4 days, then under fasting conditions for the 5th day. The total daily dose administered was 2600 mg Acetaminophen/300 mg tramadol HCl
223651939|NCT02565667|DEVICE|KOL|KOL staple was used for rectal anastomosis
224236163|NCT05510648|OTHER|high-intensity laser therapy|A total of 15 sessions of hotpack, TENS and exercise program will be applied to the patients for three weeks, 5 days a week, 1 session a day. The patients in the HILT group will be treated with a BTL 6000 brand device (Figure 5) for 3 sessions of high-intensity laser with a power of 10.0 w in the first week, energy density of 12 j/cm², every 25 cm² for 2 minutes in analgesic mode, and 5 sessions in the following 2 weeks. While 6 sessions of .0 w power, energy density of 120 j/cm², each 25 cm² for 10 minutes, will be applied in biostimulant mode for 6 sessions for three weeks, is applied in analgesic mode for 3 sessions every other day in the first week, and 6 sessions every other day in the biostimulant mode for the next two weeks, for a total of 9 sessions for three weeks.
224236164|NCT05510648|OTHER|sham high-intensity laser therapy|Hotpack, TENS and exercise program applications will be applied to the patients in the same way as in the HILT group, 5 days a week, 1 session a day, a total of 15 sessions for three weeks. HILT is administered as a placebo for three weeks, 3 sessions a week, every other day, for a total of 9 sessions.
224236165|NCT02528760|DRUG|Metaclopramide|23\. Metoclopromide to be given 10mg iv 8 hourly
224236166|NCT02528760|DRUG|Erythromycin|Erythromycin to be given 70mg iv 12 hourly.
224236167|NCT02528760|OTHER|Placebo|
224236168|NCT01621022|DRUG|bupropion + nicotine gum|150 mg bupropion twice daily plus 4 mg nicotine gum as needed (up to 12 pcs/day)
223651940|NCT02565667|DEVICE|traditional staple|traditional staple was used for rectal anastomosis
223651941|NCT01030926|DRUG|insulin degludec|0.4 U/kg body weight injected subcutaneously (under the skin), single dose
223767326|NCT00322062|DRUG|macrogol3350 NA sulphate NACL KCL ascorbic acid NA ascorbate|2L gut lavage solution
223651942|NCT01030926|DRUG|insulin glargine|0.4 U/kg body weight injected subcutaneously (under the skin), single dose
223651943|NCT05283772|BEHAVIORAL|Development of eye tracker for simulation training in nursing|"Purpose: To develop a cost-effective and effective eye tracker for simulation training in nursing in Turkey.~The wearable eye tracker consists of a front camera that will detect the pupil and determine the gaze region of the eye, and glasses or an alternative headband to which these cameras will be connected. A portable mini-computer will be used to process the obtained images. While recording and monitoring the eye movement with the pupil detection camera, real-world images in the user's field of view will be recorded by the front camera and the focal points will be determined. By establishing a linear connection between these found points, temperature (heat) maps will be created at the points where the eye looks."
223651944|NCT02985528|OTHER|further diagnostic|further diagnostic procedures - mainly CHEST CT -
223767327|NCT00322062|DRUG|Sodium Phosphate Solution|1 x 45ml solution, BID
223767328|NCT00627679|DRUG|Budesonide Inhalation Suspension|Treatment A = a single dose of Pulmicort Respules® (budesonide inhalation suspension) delivered by nebulization at Visit 2, 3, 4, or 5 as per protocol.
224236169|NCT01621022|DRUG|Active bupropion-Placebo gum|150mg bupropion twice daily plus placebo nicotine gum as needed (up to 12 pcs/day)
224236170|NCT01621022|DRUG|Placebo bupropion-Placebo gum|Placebo bupropion twice daily + placebo nicotine gum as needed (up to 12 pcs/day)
224236171|NCT02515422|DRUG|Ketamine|Subcutaneous infiltration of ketamine
224236172|NCT02515422|DRUG|Bupivacaine|Subcutaneous infiltration of bupivacaine
224236173|NCT02515422|DRUG|Placebo (0.9% saline solution)|
224236174|NCT01056796|DEVICE|CAR™ 27|Creation of a low colorectal (side or pouch low rectal) compression anastomosis in previously radiated patients
224236175|NCT01076972|DRUG|Lopinavir/ritonavir (Kaletra)|Lopinavir/ritonavir evaluated separately in patients who were naive to previous antiretroviral treatment and those who were not.
224236176|NCT06202716|DRUG|Cadonilimab plus CapeOX chemotherapy|Cadonilimab plus oxaliplatin/capecitabine (CapeOX) chemotherapy as first-line treatment in patients with advanced gastric cancer or gastro-esophageal junction adenocarcinoma: Cadonilimab 10mg/kg, iv, q3w + oxaliplatin 130mg/m2, vd, d1 + capecitabine 1000mg/m2, po, bid, d1-d4, q3w (3 weeks as a cycle, a maximum of 8 cycles of treatment). Then the maintenance treatment phase with tislelizumab + lenvatinib is entered, and the specific dosage is the same as the treatment period.
224236177|NCT05567614|RADIATION|Liver Fibroscan|Patients with CHB virus will do liver fibroscan and correlat between platelets count and degree of liver fibrosis
224236178|NCT00424203|DRUG|AC regimen|
224236179|NCT00424203|DRUG|cyclophosphamide|
224236180|NCT00424203|DRUG|doxorubicin hydrochloride|
224236181|NCT00424203|PROCEDURE|adjuvant therapy|
224236182|NCT00424203|PROCEDURE|cognitive assessment|
224236183|NCT00424203|PROCEDURE|management of therapy complications|
224236184|NCT00424203|PROCEDURE|psychosocial assessment and care|
223651945|NCT01627288|RADIATION|Boost radiation|Many studies have utilized a sequential boost to deliver a total dose of 55 - 60 Gy to the pelvic sidewall (covering the lower pelvic lymph nodes), including 8-10 Gy that is usually delivered with brachytherapy (1-3). This study treatment plan will escalate the dose to pelvic and para-aortic nodal disease from 60 Gy in 2.4 Gy per fraction to 70Gy in 2.8 Gy per fraction in 3 dose cohorts, using an integrated boost technique utilizing the same number of fractions for all cohorts (25 fractions) while the elective volumes are held constant at 45Gy
223651946|NCT02773576|DRUG|Risperidone implant|
223651947|NCT01804127|DRUG|R-CHOP|rituximab 375mg/m2 day 0, cyclophosphamide 750mg/m2 IV day 1, doxorubicin 50mg/m2 IV day 1, vincristine 1.4mg/m2 IV day1 (maximum: 2mg), prednisone 50mg PO days 1-5 twice per day
223767329|NCT00627679|DRUG|MAP0010 low dose|Treatment B = a single dose of MAP0010 (unit dose budesonide) low dose delivered by nebulization at Visit 2, 3, 4, or 5 as per protocol.
223767330|NCT00627679|DRUG|MAP0010 intermediate dose|Treatment C = a single dose of MAP0010 (unit dose budesonide) intermediate dose delivered by nebulization at Visit 2, 3, 4, or 5 as per protocol.
223767331|NCT00627679|DRUG|MAP0010 high dose|Treatment D = a single dose of MAP0010 (unit dose budesonide) high dose delivered by nebulization at Visit 2, 3, 4, or 5 as per protocol.
224236185|NCT00424203|PROCEDURE|quality-of-life assessment|
224236186|NCT02154308|BIOLOGICAL|IL-YANG FLU Vaccine Prefilled Syringe INJ 0.5mL|IL-YANG FLU Vaccine Prefilled Syringe INJ 0.5mL by intramuscular injection
224236187|NCT00664781|DRUG|rucaparib (CO-338; formally AG-014699 or PF-01367338)|
224236188|NCT00664781|GENETIC|protein expression analysis|
224236189|NCT00664781|GENETIC|western blotting|
224236190|NCT00664781|OTHER|immunohistochemistry staining method|
224236191|NCT00664781|OTHER|liquid chromatography|
224236192|NCT00664781|OTHER|mass spectrometry|
224236193|NCT00664781|OTHER|pharmacological study|
224236194|NCT01402908|DRUG|PI-88|Lyophilized powder reconstituted to provide 160 mg of PI-88
223651948|NCT01237197|DRUG|Exenatide|Exenatide 5 micrograms (mcg) twice per day (BID) for one month; up-titrated to 10 mcg twice per day for remainder of study.
223651949|NCT01237197|DRUG|Placebo|Participants were randomized to a placebo injection for the first three months, then given open-label Exenatide for the remaining three months (Initiated at 5 mcg, twice per day, delivered by subcutaneous injection. After 1 month, exenatide was uptitrated to 10 mcg, twice per day for the remaining 2 months of the drug treatment phase).
223651950|NCT01032889|DRUG|Deoxycholic acid injection|
223651951|NCT01032889|DRUG|Placebo|Phosphate buffered saline placebo for injection
223651952|NCT02374749|BEHAVIORAL|self-assessment/self-management|Nurse led-program of self-assessment/ self-management of spondyloarthritis
223767332|NCT03025828|DRUG|ACTHar|for 6 months
223651953|NCT02374749|BEHAVIORAL|Comorbidities (detection/prevention)|Standardized assessment of comorbidities by nurses
223767333|NCT01650363|OTHER|Acupuncture, homeopathy, osteopathy- and reflexology|a combination of the above mentioned treatments
223767334|NCT01650363|DRUG|Homeopathic placebo medication|2-3 mm small spheric suger pils
224236195|NCT01402908|OTHER|Placebo|Lactose lyophilized powder
224236196|NCT04002700|DRUG|Haloperidol|Stroke rates among participants from 01 January, 2002 through 31 December 2017 will be estimated among new users of haloperidol. No drug will be administered as part of this study.
224236197|NCT04002700|DRUG|Typical Antipsychotics|Stroke rates among participants from 01 January, 2002 through 31 December 2017 will be estimated among new users of typical antipsychotics which includes Haloperidol, Loxapine, Thioridazine, Molindone, Thiothixene, Fluphenazine, Trifluoperazine, Perphenazine, Chlorpromazine. No drug will be administered as part of this study.
224236198|NCT04002700|DRUG|Atypical Antipsychotics|Stroke rates among participants from 01 January, 2002 through 31 December 2017 will be estimated among new users of atypical antipsychotics which includes Aripriprazole, Asenapine, Brexpiprazole, Cariprazine, Clozapine, Iloperidone, Lurasidone, Paliperidone, Ziprasidone, Risperidone, Quetiapine, Olanzapine. No drug will be administered as part of this study.
224236199|NCT00872079|DEVICE|Genomics|Model predictive control is a computer based algorithm that can be applied to drug dosing. This computer tool uses a model of how a patient will respond to a drug dose based on demographic and historical dosing information to predict a new drug response. A drug dose controller applies all possible doses to the response model and selects the one dose that best meets the stated goals of the drug therapy. In the case of warfarin, we will calculate an international normalized ratio (INR) value within a specific target range.
224236200|NCT03633890|DRUG|DaZhu Rhodiola Rosea Capsule|Oral administration, 4 capsules, 3 times a day, for 8 weeks
224236201|NCT03633890|DRUG|DaZhu Rhodiola Rosea Simulation Capsule|Oral administration, 4 capsules, 3 times a day, for 8 weeks
224236202|NCT04251390|DEVICE|trexo Home|12 week intervention, with weekly contact/assessments of the affects of using the trexo Home.
224236203|NCT06240390|DEVICE|Ultrasound-guided percutaneous neuromodulation (NMP)|Epte Bipolar System is a medical device for health professionals that combines several techniques that extend the therapeutic variety of electrostimulation, for the treatment of different pathologies of the musculoskeletal system and peripheral and central nervous system. It is a nationally manufactured device that meets all quality standards, being the perfect tool for the application of techniques such as transcranial direct current stimulation. It is a versatile, compact, portable and easy to use equipment that has the ability to adapt the parameters to achieve any protocol established by scientific evidence to treat the various pathologies. The Epte® Bipolar System device has an CE Health Certificate
224236204|NCT06240390|DRUG|pharmacological treatment by Opioids|Opioid analgesics are the main option for pain treatment in cancer patients, but their side effects and inadequate treatment lead to cheaper, quicker options with lower risk of addiction and/or side effects.
224236205|NCT02328690|OTHER|Binaural Beat Technology|A phenomenon when two nearly similar frequencies (between 30-1000 hertz \[Hz\]) are presented to each ear and the brain detects the difference between the two sounds. These two sounds are processed in the superior olivary nucleus of each hemisphere of the brain. This integration of brain hemispheres produces a frequency that in turn affects the reticular activating system which alters the electrical potentials of the thalamus and cerebral cortex changing brainwave frequency.
224236206|NCT01739790|DRUG|N-Acetylcysteine|1800 mg twice daily for 8 weeks
224236207|NCT01739790|DRUG|Placebo|Identical placebo manufactured to mimic appearance of intervention drug with identical frequency and duration.
224236208|NCT06111703|BEHAVIORAL|Knowledge assessment|Knowledge, Attitude and Practice Survey
224236209|NCT04790448|DRUG|Cetuximab|Route of administration: Intravenous
224236210|NCT04790448|DRUG|Irinotecan|Route of administration: Intravenous
223651954|NCT02410564|BEHAVIORAL|cognitive behavioral therapy for insomnia (CBTI)|SHUTi program is made up of six, weekly treatment Cores modeled after weekly facetoface(CBTI). Each Core begins by providing a rationale for learning the material, explains main content, homework page with suggestions for improving sleep, and a summarized review of main points. The main content each Core addresses myths about sleep, indepth information about topics, vignettes, and quizzes to evaluate users learning in an interactive. As well as being interactive, SHUTi allows for personalization.Modifications are made to sleep recommendations based in sleep diary data and individually set treatment goals. The cores include Overview, Sleep Behavior Core, Sleep Behavior Core 2, Sleep Education Core, Sleep Thoughts Core, and Problem Prevention Core. Each Core takes approximately 45 to 60 minutes to complete. Cores are presented one at a time; next Core becomes available to users a week after they complete one Core.
223651955|NCT02410564|BEHAVIORAL|Waitlist control condition|Phone calls with control participants, no advice regarding sleep will be given and if participants ask, they will be informed that such advice can be provided in a few weeks if they choose to crossover to the treatment condition at the end of the study.
223651956|NCT01439828|DRUG|N-acetylcystein|Visit 1: Consent signed. Blood and urine analysis. Questionnaires assessing cannabis and tobacco's craving.N-acetylcystein and placebo doses will be increased if craving decreases \<25% compared to previous visit.The doses start at 200 mg x 4/24h to 800 mg x 4/24h.Visit 2 to 5: Medication safety and cannabis craving and withdrawal assessment during 4 weeks.
223651957|NCT00000596|DRUG|prednisone|
223651958|NCT00000596|DRUG|cyclophosphamide|
223651959|NCT00000596|DRUG|dapsone|
223651960|NCT04910841|DEVICE|CGM GUARDIAN 2|continuous blood glucose monitoring system
223651961|NCT02039843|OTHER|Emotional Support Dogs|Emotional Support Dogs were required to pass the American Kennel Club Canine Good Citizen and the American Kennel Club Community Canine tests and be well-behaved and well-socialized.
223651962|NCT02039843|OTHER|Service Dogs|Service Dogs were required to pass the American Kennel Club Canine Good Citizen and the Assistance Dogs International Public Access tests and trained to complete five PTSD-specific tasks (lights, sweep, bring, block, \& behind).
223651963|NCT04130503|DEVICE|PAP|Positive airway pressure (PAP) treatment of obstructive sleep apnea (OSA).
223651964|NCT04130503|BEHAVIORAL|HLE|All patients (randomized and non-randomized) will receive a healthy lifestyle education (HLE) intervention focused on secondary stroke prevention.
223651965|NCT00909298|DRUG|TTP889|300 mg
223651966|NCT00909298|DRUG|Placebo|Placebo
223651967|NCT02015910|DRUG|Sitagliptin|Comparison of Sitagliptin a dipeptidyl-peptidase four (DPP-4) inhibitor 100mg pill with placebo comparator
224236211|NCT04790448|DRUG|Vemurafenib|Route of administration: Oral
224236212|NCT04578158|DRUG|Standard COVID-19 care|Patients will receive standard covid-19 care as per the hospital/physician guidelines
224236213|NCT04578158|DIETARY_SUPPLEMENT|Quercetin Phytosome|Patients will receive a daily dose of 400 mg of oral Quercetin Phytosome
224236214|NCT04000217|BEHAVIORAL|Written Exposure Therapy|In this study, written exposure therapy is delivered in an online format with coaching from trained peer support specialists. Participants will complete 4-8 sessions, depending on their level of symptom reduction (i.e., allow for early termination when low symptom levels are achieved).
223651968|NCT02015910|DRUG|Placebo|Sugar pill manufactured to mimick Sitagliptin 100mg pill.
223767335|NCT05096611|BEHAVIORAL|Attachment and Biobehavioral Catch up|ABC is delivered by a trained parent coach. The parent coach provides information about parenting and child development. The focus is on providing support for parents of young children and improving the parent-child relationship.
224236215|NCT04000217|BEHAVIORAL|Imaginal Exposure Therapy|Delivery of imaginal exposure in this study will mirror the procedures used in WET. It will be delivered in an online format with coaching from trained peer support specialists. Participants will complete 4-8 sessions, depending on their level of symptom reduction (i.e., allow for early termination when low symptom levels are achieved).
224236216|NCT02315690|DRUG|dihydroartemisinin-piperaquine (DHAp)|In the fMDA arm, all individuals in the target area will receive dihydroartemisinin-piperaquine (DHAp) once daily for 3 days with the first dose taken no later than 5 weeks from the index case presentation (goal within one week).
224236217|NCT02315690|PROCEDURE|reactive case detection|Individuals in RACD target areas will be tested by RDT and if positive will be taken to the nearest health facility for treatment as per program operating procedures.
224236218|NCT02592161|DRUG|Experimental|"Test drug : Granules, Chung A Won 3g (Eucommiaceae, Psoralea corylifolia, Walnut, Ginger) Three times a day, oral administration for 24weeks~Reference drug : Granules, Placebo 3g (Lactose hydrate, Corn starch, Caramel pigment)~Three times a day, oral administration for 24weeks"
223651969|NCT00792220|PROCEDURE|MSU|"In the Mobile Stroke Unit procedure: Conventional Emergency Medical Service together with the MSU will meet at the side, where the patient is found. The MSU is an ambulance, equipped with a neurologist and neuroradiologist and includes CT scanner and point of care laboratory unit. The patient's medical history and the physical examination will be directly performed by the neurologist. CT scan analysis will be performed by the neuroradiologist, while the neurologist will analyze the blood samples with the point of care laboratory unit. If the inclusion and exclusion criteria are fulfilled, the thrombolytic therapy will directly be started by the neurologist. A possible thrombolytic therapy will be performed under the current inclusion and exclusion criteria that are associated with the rt-PA drug approval in Europe. After performance of the acute therapy, the patient will be transported to the University Hospital of the Saarland."
224236219|NCT00316745|DRUG|Campto, Topotesin|100 mg/m2, IV (in the vein) on day 1,15 of each cycle.
224236220|NCT00316745|DRUG|TS-1|S-1 Day1\~14, everyday P.O.(Day 15\~28 rest)
224236221|NCT00316745|DRUG|L-Plat|Oxaliplatin (85mg/m2) Day 1, 15
224236222|NCT00316745|DRUG|Isovorin|l-leucovorin (200mg/m2) Day 1, 15
223651970|NCT00792220|PROCEDURE|OCCM|In the optimized conventional clinical management: After patient's medical history, physical examination and emergency treatment by the emergency physician, the patient will be transported to the University Hospital of the Saarland. The delivery of the patient will directly take place at the CT scanner. The neurologist will perform a second medical history, physical examination, while the blood will be drawn by the assisting nurse. CT scan will be performed, while the blood will be analyzed by point of care technique, placed close to the CT scanner. Additionally the blood will be sent in parallel to the hospital central laboratory for conventional laboratory analysis. Depending on the results, a thrombolytic therapy will be initiated directly at the CT. Thereafter, the patient will be transported to the hospital Stroke Unit.
223651971|NCT04615377|BEHAVIORAL|Kaia hip and knee pain application|The Kaia Knee and Hip pain app software, when loaded onto a smartphone, recommends to the participant specific exercises for the lower extremity. Using the camera on a smartphone, the software then tracks the participant's movements as the participant performs the exercises, analyzes those movements using machine learning, and provides audio-visual feedback to the participant. The exercise therapy is augmented by educational content and cognitive behavioral therapy to provide a multidisciplinary approach to self-management of osteoarthritis. Behavioral Health Coaches ensure participant motivation throughout the program based on a predefined curriculum.
223651972|NCT04615377|OTHER|Treatment as usual|Participants allocated to the control arm will be advised to continue receiving treatment as usual ( standard care) without restrictions, except participation in other investigational trials, and will likewise be followed up for 90 days. Apart from that, they are encouraged to seek care, as they would do normally.
223651973|NCT05211843|OTHER|Drinking water|The intervention will compare the effects of a usual serving of drinking water with the effects of a usual serving of apple juice. Both beverages will also be assessed relative to the effects of not drinking anything at all.
223651974|NCT05211843|OTHER|Apple juice|apple juice
224236223|NCT00316745|DRUG|5-FU|400 mg/m2, IV (in the vein) on day 1,15 of each 28 day cycle. 2400 mg/m2, CIV (in the vein) on day 1\~3 (48 hours) of each 28 day cycle.
224236224|NCT02581345|BIOLOGICAL|M923|Recombinant human immunoglobulin G subclass 1 (IgG1) monoclonal antibody specific for human tumor necrosis factor-alpha (TNF-α)
224236225|NCT02581345|BIOLOGICAL|Humira|Recombinant human immunoglobulin G subclass 1 (IgG1) monoclonal antibody specific for human tumor necrosis factor-alpha (TNF-α)
224236226|NCT02101346|DIETARY_SUPPLEMENT|Mixed High Fat Diet|Healthy, Round 1
224236227|NCT02101346|DIETARY_SUPPLEMENT|Saturated fat diet|Healthy, Round 1 Healthy, Round 2
224236228|NCT02101346|DIETARY_SUPPLEMENT|Monounsaturated fat diet|Healthy, Round 1
224236229|NCT02101346|DIETARY_SUPPLEMENT|Polyunsaturated fat diet|Healthy, Round 1
224236230|NCT02101346|DIETARY_SUPPLEMENT|Triolein 13C|Healthy, Round 2
224236231|NCT02101346|DIETARY_SUPPLEMENT|Low fat|Healthy, Round 1
224236232|NCT01393678|DRUG|NISSEL|Biphenyl Dimethyl Dicarboxylate 25mg ............. 1 cap
224236233|NCT01393678|DRUG|PENNEL|Biphenyl Dimethyl Dicarboxylate 25mg \& garlic oil 50mg ............. 1cap
224236234|NCT04511273|DRUG|Follow up of female sexual function|Mirabegron 50mg once daily for treatment of overactive bladder symptoms
224236235|NCT02279797|BEHAVIORAL|survey|Survey about Knowledge, Attitude and Practice About bone marrow donation
224236236|NCT02346097|DEVICE|Cardiac Resynchronization Therapy (St. Jude Qaudripolar LV lead)|"Optimal electrical resynchronization vs. routine CRT strategy, imaging guided. For more details refer to Arm descriptions"
224236237|NCT01921920|DRUG|Omeprazole|Omeprazole 20 mg (AstraZeneca - test) Omeprazole 40 mg (AstraZeneca - test) Omeprazole 20 (Merck - reference) Omeprazole 40mg (Merck - reference)
224236238|NCT00907998|DRUG|APL180|
224236239|NCT00907998|DRUG|APL180|
224236240|NCT00907998|DRUG|Placebo|
224236241|NCT05473052|BEHAVIORAL|Preoperative home-based exercise training|"1\) Home-based aerobic and resistance exercise training (preoperative period)~Dose of aerobic exercise:~1. Type: Walking~2. Frequency: 3 sessions per week~3. Duration: 30 minutes~4. Intensity: Rate of perceived exertion on Borg Category Ratio-10 (3-5)~5. Progression: Increase the walking duration in 10 minutes (after week 2)~Dose of resistance exercise:~1. Type: Six exercises for upper and lower limbs using bodyweight and free-wights of 1-2kg~2. Frequency: 2 sessions per week~3. Duration: 2 sets x 15 repetitions~4. Rest in-between sets: 45 seconds~5. Intensity:Rate of perceived exertion on Borg Category Ratio-10 (3-5)~6. Progression: Increase the number of sets (3 sets of 15 repetitions after week~2\) Weekly telephone supervision: A physical therapist carried out weekly telephone calls with all participants to monitor adverse events, give positive reinforcement and recommend strategies to overcome barriers that arise during the exercise program."
224236242|NCT00098488|DRUG|tanespimycin|Given IV
224236243|NCT00098488|BIOLOGICAL|rituximab|Given IV
224236244|NCT03958032|OTHER|No intervention|No intervention is planned for the participants for the treatment of gastric cancer. Treatment decision will be in line with clinical practice guidelines. Surgical team will be blind to the participant's sarcopenia status.
223651975|NCT06376331|DRUG|washed microbiota transplantation|The prepared microbiota suspension was infused into the participates' lower gut.
223651976|NCT00954226|DRUG|Erlotinib Hydrochloride|Given PO
223651977|NCT00954226|OTHER|Laboratory Biomarker Analysis|Correlative studies
223651978|NCT00857688|DRUG|Bismu-Jet|Bismuth sodium tartrate, neomycin sulfate, procain hydrocloride
223651979|NCT00857688|OTHER|Placebo|Placebo: Menthol, saccharin sodium, propylene glycol, sodium hydroxide, glycerol, ethyl alcohol, water
223651980|NCT05925868|BEHAVIORAL|mindfulness app|Parents will use the mindfulness app, Headspace, for at least 10 minutes on 4 days/week.
223651981|NCT00983658|DRUG|huMAb OX40L|Intravenous repeating dose
223651982|NCT00983658|DRUG|placebo|Intravenous repeating dose
223651983|NCT05408546|DRUG|TS23|Monoclonal antibody to a2-antiplasmin
223651984|NCT05408546|DRUG|Placebo|Placebo
223651985|NCT02624986|DRUG|Idasanutlin|Participants received idasanutlin film-coated tablets orally at a starting dose of 100 mg daily on Days 1 to 5 of each 28-day cycle. Escalation was to occur in at least 50-mg increments, and daily doses greater than or equal to (≥) 400 mg will be split into twice daily dosing.
223651986|NCT02624986|DRUG|Obinutuzumab|Participants received a fixed dose of obinutuzumab 1000 mg intravenous (IV) infusion to be given on Days 1, 8 and 15 of Cycle 1 and on Day 1 of Cycles 2 to 6 (1 cycle = 28 days). For eligible participants with FL, post-induction treatment was to be given at a dose of 1000 mg via IV infusion on Day 1 once every 2 months for a maximum of up to 24 months.
224236245|NCT06327815|DRUG|Xigduo (Dapagliflozin and Metformin hydrochloride extended-release) tablets|10 mg Dapagliflozin/1000 mg Metformin HCl extended-release
223651987|NCT02624986|DRUG|Rituximab|Participants received a fixed dose of rituximab, 375 mg/m\^2 IV infusion on Day 1 of Cycles 1-6. Post-induction treatment for eligible participants was to be given at a dose of 375 mg/m\^2 IV infusion on Day 1 of every other month for up to 6 months, until disease progression or unacceptable toxicity.
223651988|NCT03830307|DEVICE|NSS-2-Bridge|NSS-2-Bridge auricular therapy will be given in addition to standard of care
223651989|NCT03056196|DIAGNOSTIC_TEST|point of care ultrasound|want to assess the ability of d-dimer test and point of care ultrasound to role out lower leg DVT
223651990|NCT04254185|PROCEDURE|Simple decompression|Surgical technique
223651991|NCT04254185|PROCEDURE|Subcutaneous anterior transposition|Surgical technique
223651992|NCT02181244|OTHER|Egg, one a day, for breakfast|One egg per day as breakfast for 5 weeks followed by a 3 week washout period and 5 additional weeks on oatmeal. This is a randomized crossover design. Half of subjects started with the eggs and the other half with oatmeal. Blood lipids, glucose and inflammatory measurements will be finished 24. weeks after completion of the study. Data will be reported 1 year after the completion of the study.
223651993|NCT02181244|OTHER|Oatmeal, one cup a day|Subjects will be fed oatmeal for a period of 5 weeks. After 3 weeks they will be switched to the alternate diet. This is a randomized control trail in which plasma glucose, plasma lipids and inflammatory markers will be measured. All these measurements will be finished 24 weeks after completion of the study. Data will be reported after 1 year of the completion of the study.
223651994|NCT05809297|DEVICE|Diode laser combined with photodynamic-red laser therapy by RapidoPodia Laser Diodo®|According to the manufacturer's recommendations, the treatment will be carried out in consultation in 8 sessions by a specialised podiatrist.
223651995|NCT05809297|DRUG|Ciclopirox Hydroxypropyl Chitosan (HPCH) Nail Lacquer|The application of Ciclopirox Hydroxypropyl Chitosan (HPCH) Nail Lacquer will be performed at home by the patient once a day.
223651996|NCT00740857|DRUG|placebo|2 placebo gels capsules delivered as a single dose.
223651997|NCT00740857|DRUG|ibuprofen Formulation 1|2 marketed ibuprofen gels
223651998|NCT00740857|DRUG|ibuprofen Formulation 2|2 marketed ibuprofen gels
223651999|NCT03227419|DRUG|Tocilizumab Prefilled Syringe|"Treatment arm: tocilizumab (RoActemra®):~162 mg weekly a schema for therapeutic adaptation with injection intervals determined according to transaminase levels or blood cell counts (neutropenia, thrombopenia) as recommended by Roche-Chugaï (see table below)."
223652000|NCT03227419|DRUG|Abatacept Prefilled Syringe|"Treatment arm: abatacept (Orencia®)~125 mg weekly after an initial dose of 500 mg (body weight \<60kg), 750 mg (body weight between 60 and 100 kg), or 1000 mg (body weight \>100 mg) 24 hours before the first subcutaneous injection."
223652001|NCT03433040|DRUG|17-Hydroxyprogesterone Capronate|17-Hydroxyprogesterone Capronate 250mg versus 500mg
223652002|NCT03532451|DRUG|Nivolumab|Nivolumab 480 mg intravenously (IV) over approximately 30 minutes every 4 weeks for 2 neo-adjuvant doses (week 0 and 4) followed by RC with bilateral (standard or extended) PLND as soon as possible but within 6 weeks after the last neoadjuvant infusion.
223652003|NCT03532451|DRUG|Nivolumab/Lirilumab|Nivolumab 480 mg IV over approximately 60 minutes every 4 weeks for 2 neo-adjuvant doses (week 0 and 4) with at least a 30 minute rest between infusions followed by lirilumab 240 mg IV over approximately 60 minutes every 4 weeks for 2 neo-adjuvant doses (week 0 and 4) followed by RC with bilateral (standard or extended) PLND as soon as possible but within 6 weeks after the last neoadjuvant infusion.
223652004|NCT05173064|DEVICE|The AI-powered Technological Surrogate Physiotherapist|"The AI-powered Technological Surrogate Physiotherapist will have three key features:~1. Evidence-based exercise videos instructed by physical therapists~2. Real-time movement feedback and performance score~3. Exercise records."
223652005|NCT05173064|BEHAVIORAL|Face-to-face physiotherapist-supervised exercise program|Physiotherapists will give usual face-to-face therapy. The assessment of participants' exercise movements will only be achieved in the traditional manner during face-to-face exercise sessions - by physiotherapists' visual inspection of and professional judgement on postural alignment and effectiveness, with verbal instructions for posture correction. The features of real-time movement feedback and tracking of exercise progress will not be provided.
223652006|NCT05173064|COMBINATION_PRODUCT|The AI-powered Technological Surrogate Physiotherapist Plus Face-to-face physiotherapist-supervised exercise program|This group will attend in-person group therapy sessions, while additionally completing weekly home exercise sessions using the TSP system.
224236246|NCT06327815|DRUG|Dapagliflozin tablets and Metformin HCl extended-release tablets|Dapagliflozin tablets: 10 mg Metformin HCl extended-release tablets: 1000 mg
224236247|NCT02222428|DRUG|BI 1744 CL/BI 54903 XX FDC|
224236248|NCT02222428|DRUG|BI 54903 XX|
224236249|NCT02222428|DRUG|BI 1744 CL|
224236250|NCT02538445|OTHER|Memorization of the verbs by miming the action|The participant reads aloud the verbs that appear on the screen, by performing the corresponding action verb.
224236251|NCT02538445|OTHER|Memorization of the verbs by imagining the action|The participant reads aloud the verbs that appear on the screen, by imagining the corresponding action verb.
224236252|NCT02538445|OTHER|Memorization of the action verbs by means of another word|The participant reads aloud the verbs that appear on the screen. Then, he reads, without memorizing it, a word associated with the action verb to be learnt to favor the memorization of that one. The word is written near the action verb.
224236253|NCT02538445|OTHER|Simple memorization of the verbs|The participant reads aloud the verbs that appear on the screen, without additional instructions (control condition).
224236254|NCT02188797|BEHAVIORAL|Group MI risk reduction program|
224236255|NCT05588856|OTHER|In depth Interview|In depth Interviews
224236256|NCT00769106|BIOLOGICAL|cytokine-induced killer cell (CIK) treatment|cytokine-induced killer cell treatment every two weeks, for 4 cycles
224236257|NCT02280629|DRUG|LT-02|LT-02 1.6g twice daily AND mesalamine PLACEBO three-times daily
224236258|NCT02280629|DRUG|Placebo|LT-02 PLACEBO twice daily AND mesalamine PLACEBO three-times daily
224236259|NCT02280629|DRUG|Mesalamine|LT-02 PLACEBO twice daily AND mesalamine 500mg three-times daily
223652007|NCT00466596|DRUG|Gamma Tocopherol|14 days of daily high dose (1200mg) Gamma Tocopherol. Subjects will receive a 14 day supply (28 softgel capsules, approximately 600 grams of gT each) dispensed by the University of North Carolina Hospitals Investigational Drug Service and provided by YASOO Medical.
223652008|NCT02615184|DRUG|Dexlansoprazole|Dexlansoprazole capsules
224236260|NCT01210729|DEVICE|Solitaire FR, ev3|Placement of the stent in the occluded vessel segment, withdrawal in its unfolded state.
224236261|NCT03233620|OTHER|Knee arthroplasty|Effectiveness of knee arthroplasty surgery.
224236262|NCT00376220|DRUG|Riluzole|Initially dispensed 50 mg capsules to take twice a day (BID). At two weeks, increase dose to 50 mg/100 mg. At four weeks increase to 100 mg BID (two capsules in the morning (qAM), two capsules in the evening (qHS). If significant side effects occur (at any time), titration can be slowed and doses can be reduced to a minimum daily dose of 50 mg/day, after which titration may resume by no more than 50 mg a week. Subjects who are unable to tolerate the minimal daily dose permitted in the study will be discontinued from further participation. In addition, if clinical remission is observed at a lower dose of study medication (defined as Montgomery Asberg Depression Rating Scale (MADRS) \< 12) the dose will not be increased further unless clinical symptoms recur.
223652009|NCT06154252|BIOLOGICAL|CABA-201 following preconditioning with fludarabine and cyclophosphamide|Single intravenous infusion of CABA-201 at a single dose level following preconditioning with fludarabine and cyclophosphamide
223652010|NCT05393466|DRUG|BPI-361175|BPI-361175 is an oral fourth-generation EGFR inhibitor. The activation of EGFR signaling pathways is associated with various biological events such as proliferation, migration, differentiation, and apoptosis.
223652011|NCT04145622|DRUG|Ifinatamab deruxtecan (I-DXd)|A total anti-B7H3 antibody and MAAA-1181a
223652012|NCT02543983|DEVICE|Magnetic Resonance Imaging scanner, 3T|Non-significant risk device used for brain imaging.
223652013|NCT02543983|DEVICE|NeurOptics PLRTM-3000 Pupillometer|The NeurOptics PLRTM-3000 Pupillometer will use quantitative infrared technology to objectively and accurately measure pupil size and dynamics.
223652014|NCT02543983|DEVICE|Experimental Anxiety Devices|Acoustic startle and shock devices are used to evaluate anxious responses to stimuli. Both are considered non-significant risk under this study.
223767336|NCT05096611|BEHAVIORAL|Attachment and Biobehavioral Catch up Plus Depression Treatment|ABC+D offers the same 10-sessions of parenting support that is provided by ABC and additionally provides weekly short videos that help mothers develop skills for coping with stress and regulating mood.
224236263|NCT00376220|OTHER|Placebo|Initially dispensed 50mg capsules to take BID. At two weeks increase dose to 50 mg/100 mg. At four weeks increase to 100 mg BID (two capsules qAM, two capsules qHS). If significant side effects occur (at any time), titration can be slowed and doses can be reduced to a minimum daily dose of 50 mg/day, after which titration may resume by no more than 50 mg a week. Subjects who are unable to tolerate the minimal daily dose permitted in the study will be discontinued from further participation. In addition, if clinical remission is observed at a lower dose of study medication (defined as MADRS \< 12) the dose will not be increased further unless clinical symptoms recur.
224236264|NCT05733572|DRUG|CHF6467|drug eyedrops
224236265|NCT05733572|DRUG|Placebo|placebo eyedrops
224236266|NCT04347291|BEHAVIORAL|FAMS 2.0|FAMS components include monthly phone coaching following a semi-structured protocol plus daily automated text message support to the patient participant and less frequent automated text messages to their support person, if enrolled.
224236267|NCT04347291|BEHAVIORAL|Print Materials|Quality print materials about diabetes management provided upon enrollment and in quarterly study newsletters.
224236268|NCT00678366|PROCEDURE|addition of 4% oxygen|addition of 4% oxygen to the carbon dioxide pneumoperitoneum
224236269|NCT00678366|PROCEDURE|carbon dioxde|classic pneumoperitoneum with 100 % carbon dioxide
224236270|NCT03238066|RADIATION|Brachytherapy|HDR/PDR brachytherapy
224236271|NCT03238066|OTHER|Hyperthermia|Interstitial hyperthermia
224236272|NCT00269048|DRUG|SB-480848|SB-480848
224236273|NCT00269048|DRUG|placebo|placebo
224236274|NCT01672190|OTHER|Yoga Therapy Program|
223652015|NCT02543983|DEVICE|Magnetic Resonance Imaging scanner, 7T|Non-significant risk device used for brain imaging.
223652016|NCT02543983|DRUG|Ketamine Hydrochloride|A non-competitive N-methyl-D-aspartate receptor antagonist. This drug is exempt from FDA IND review under the study.
223767337|NCT01020019|DRUG|Dronabinol|Dronabinol: 20 mg/TID
223767338|NCT01020019|DRUG|Placebo|Placebo control
224236275|NCT00919464|DEVICE|Pressure monitoring device|monitoring device inserted to measure thigh compartment pressures
224236276|NCT00919464|DEVICE|Compartmental fracture pressure monitoring|
224236277|NCT00919464|DEVICE|This small project is designed to be a non-randomized, investigational prospective trial of compartment pressures in the thigh following femoral fracture|
224236278|NCT05251103|OTHER|time-restricted feeding trial|The 5-day time-restricted feeding trial and the control trial. The meals of the time-restricted feeding trial were provided at 12:00, 16:00, and 20:00.
223652017|NCT03366116|DRUG|aza-TdC|Methylation-mediated silencing of genes is an epigenetic mechanism implicated in carcinogenesis; agents that inhibit this mechanism are of clinical interest because of their potential to re-activate silenced tumor suppressor genes. The nucleoside analog 5-aza-4'-thio-2'- deoxycytidine (Aza-TdC) is incorporated into DNA, where it engages the active site of DNA methyltransferase I (DNMT1), a maintenance methyltransferase that contributes to hypermethylation and silencing of tumor suppressor genes. Aza-TdC offers an improvement over traditional DNMT inhibitors via higher incorporation into DNA and lower cytotoxicity; Aza-TdC has greater antitumor activity than another recently developed DNMT1 inhibitor, TdCyd, in some solid tumor xenograft models. Treatment with Aza-TdC is anticipated to yield inhibition of tumor growth due to DNMT1 depletion at oral doses that are well tolerated in extended dosing schedules.
223652018|NCT05949021|DRUG|Combination of liposomal doxorubicin|Combination of liposomal doxorubicin 30 milligrams per square meter and carboplatin (area under the curve 5), administered every 4 weeks for 4 cycles.
223652019|NCT02838394|PROCEDURE|Dry needling|Acupuncture filiform needles are inserted into myofascial trigger points
223652020|NCT02838394|OTHER|Sham dry needling|Blunted needles will be pressed against the skin, but no actual penetration will occur
223652021|NCT06849258|DEVICE|FloStent|Flexible cystoscopy to deploy medical device used to treat BPH
223652022|NCT06849258|DEVICE|Sham (Control)|Flexible Cystoscopy without deployment of medical device used to treat BPH
223652023|NCT03532828|OTHER|polysomnography|Patients will have a polygraphy, a postural evaluation including Vicon system, EOS imaging, ang a force platform
223652024|NCT06451757|DRUG|Sonlicromanol|Oral administration of 100 mg sonlicromanol (KH176) twice daily during 52 weeks
223652025|NCT06451757|DRUG|Placebo|Oral administration of 100 mg placebo twice daily during 52 weeks
224236279|NCT05560464|DRUG|VX-548|Tablets for oral administration.
224236280|NCT00682084|PROCEDURE|Surgery|Surgical removal of either a pituitary or ectopic ACTH producing tumor or an adrenal tumor
224236281|NCT01098721|DRUG|WBI-1001|Comparison of two doses (0% and 1.0%) of the the WBI-1001 cream applied topically, twice daily for 12 weeks.
224236282|NCT05865600|OTHER|Optimization of guideline-directed medical therapy|Consultation every second week with optimization of guideline-directed medical therapy according to 2019 ESC guidelines on chronic coronary syndrome. Focus will be on risk-factor modification and anti-anginal medication with the treatment aim to achieve freedom from angina and dyspnea with a heart rate at rest ≤ 60 beats/min and systolic blood pressure \> 100 mmHg.
224236283|NCT05865600|DIAGNOSTIC_TEST|Immediate referral for invasive coronary angiography|Immediate referral for invasive coronary angiography
224236284|NCT05865600|DIAGNOSTIC_TEST|3-months delayed referral for invasive coronary angiography|3-months delayed referral for invasive coronary angiography
224236285|NCT05865600|OTHER|Standard of care|Standard of care
223652026|NCT02476058|DRUG|JNJ-42847922|JNJ-428479, 20 milligram (mg) capsule, orally, once daily, at bedtime for 10 days in women of childbearing potential (WOCBP) or for 4 weeks in all other participants.
223652027|NCT02476058|DRUG|Diphenhydramine|Diphenhydramine 25 mg capsule, orally, once daily, at bedtime for 10 days in women of childbearing potential (WOCBP) or for 4 weeks in all other participants.
223652028|NCT02476058|DRUG|Placebo|Matching placebo (capsules containing neutral pellets), orally, once daily, at bedtime for 10 days in women of childbearing potential (WOCBP) or for 4 weeks in all other participants.
223652029|NCT05041166|DRUG|Hyperpolarized [13C] Pyruvate|Will be injected at a dosage of 0.43 ± 0.05 mL/kg body weight
223652030|NCT01422343|PROCEDURE|percutaneous transluminal angioplasty femoro-popliteal|percutaneous transluminal angioplasty femoro-popliteal
223652031|NCT01006993|DEVICE|NeuroFlo catheter|NeuroFlo™ catheter 45 minute treatment
224236286|NCT03304600|DEVICE|Active stimulation|Patients will receive a tDCS stimulation during 30 mn with an intensity of 2 milliampere (mA).
224236287|NCT03304600|DEVICE|Sham stimulation|Patients will receive a Sham stimulation during 30 mn
224236288|NCT06172842|DIAGNOSTIC_TEST|Echocardiography|Multi-modality echocardiography
223652032|NCT02178137|DRUG|Diacerien|
223652033|NCT02178137|DRUG|Glucosamine/Chondroitin|
223652034|NCT02178137|DRUG|Placebo|
223652035|NCT00912197|DIETARY_SUPPLEMENT|Oligofructose|Participants will be asked to consume 30g of oligofructose daily for six weeks after a 2-week run-in.
223652036|NCT00912197|DIETARY_SUPPLEMENT|Placebo|Participants will be asked to consume 3 doses (a total of 30g dietary fibres) of the placebo product daily for six weeks after a 2-week run-in
223652037|NCT02267837|DEVICE|OrthoPulse™|Patients carry out daily OrthoPulse™ treatments at home.
223652038|NCT06073561|OTHER|learning curve of Underwater mucosectomy|Patients will be submitted to underwater mucosectomy (U-EMR)
223652039|NCT03461588|RADIATION|free-breathing|patients are irradiated to whole breast +- regional nodal areas with free-breathing technique after breast conserving surgery
223652040|NCT03461588|RADIATION|deep inspiratory breath-holding|patients are irradiated to whole breast +- regional nodal areas with deep inspiratory breast-holding technique after breast conserving surgery
223652041|NCT01209533|DRUG|Iloprost|Inhaled iloprost 2.5 or 5 micrograms four times daily for 14 days
223652042|NCT04373252|BIOLOGICAL|FMT Lower Delivery (FMP 30)|Participants will receive two fecal microbiota transplants via antegrade enema, one week apart.
223652043|NCT06268977|DRUG|SGLT2 inhibitor|a class of prescription medicines that are FDA-approved for use with diet and exercise to lower blood sugar in adults with type 2 diabetes.
223652044|NCT03693391|DRUG|JNJ-64140284|Single dose of JNJ-64140284 up to 3 mg oral solution will be administered under fasted conditions.
223652045|NCT03693391|DRUG|Fluorine-18 Labeled [18F]-JNJ-64511070|An intravenous (IV) bolus injection of 185 MegaBecquerel (MBq) \[18F\]JNJ-64511070 will be administered.
223767339|NCT01020019|DRUG|Lofexidine|Lofex: .6 mg/ TID
223767340|NCT03748940|DRUG|LY3074828|Administered SC
223767341|NCT03748940|DRUG|Placebo|Administered SC
223767342|NCT03748940|DRUG|LY900021|Administered SC
224236289|NCT00531206|DRUG|Tipranavir|
224236290|NCT00531206|DRUG|Ritonavir|low dose
224236291|NCT05976399|OTHER|Connective Tissue Massage|"In participants in the CTM group, the treatment was started with the sacral region called the basic region and the whole back was treated. Pulls in the interscapular region were more intense than in other regions. After the interscapular region, the cervical, clavicular, and facial regions were also included in the treatment. Both short and long pulls were used according to the region during CTM. The applications first started with the basic region and then progressed to the lower thoracic, scapular, and interscapular regions. Then, the cervical and clavicular regions were treated. In each region, the applications were performed three times on each of the right and left sides. While positioning the patients, we paid attention to their privacy and the temperature of the room where the treatment was carried out. A total of 12 sessions, which were conducted 2 days a week and took 6 weeks, were performed."
223652046|NCT03801044|DIAGNOSTIC_TEST|NT-BNP, VEGF|VEGF-C levels were measured in the serum samples. R\&D Systems kit (Minneapolis, MN) (Catalog Number DVEC00) was used for the assays according to the user instructions. NT-proBNP was measured on the Elecsys 2010 analyzer (Elecsys proBNP Immunoassay; Roche Diagnostics).
224236292|NCT05976399|OTHER|Manual Lymph Drainage|The patients, who had filled out their pain diary before and submitted a consent form, were first evaluated before the treatment and then they lay on their back with their neck area open, paying attention to the protection of their privacy. Hand strokes, one of the basic techniques applied for treatment, were planned in accordance with the anatomy and physiology of the lymphatic system. MLD was applied to the lateral neck and face region in 5-7 repetitions so that the lymph collectors could give an adequate reaction to the application. The treatment was performed 2 days a week for 6 weeks, with a total of 12 sessions. Each session lasted 45 minutes.
224236293|NCT01878370|OTHER|High risk|"Aggregate-level feedback reports focusing on the proportion of patients with hypertension and/or diabetes and/or ischemic heart disease meeting criteria for high-risk sent via courier every six months and available on a password protected website. Family physicians in this arm will also have access through this website to a list of chart numbers identifying those patients at highest risk.~Family physicians in Arm 2 are asked to complete a worksheet that also includes goal setting and action planning, but focuses on reducing the number of patients with high-risk criteria and offers some suggested practice-based approaches."
224236294|NCT01878370|OTHER|Best Practice|"Standard, aggregate-level feedback reports focusing on the proportion of patients with hypertension and/or diabetes and/or ischemic heart disease meeting targets sent via courier every six months and available on a password protected website. Family physicians in this arm will also have access through this website to patient-level data to identify patients not achieving optimal quality of care targets.~Family physicians in Arm 1 are asked to complete a worksheet that follows continuous quality improvement principles, including setting an aim statement, engagement with team members in the clinic, testing change concepts at first on a small scale, and then scaling up in a effort to spread best practices."
224236295|NCT05975970|DEVICE|MyoTrain AR|MyoTrain AR is a virtual prosthesis functional training system. From a hardware perspective it consists of an augmented reality head-mounted display (HMD), four SteamVR kinematic trackers, eight surface EMG electrodes based on the Element electrode platform, and a desktop computer to facilitate wireless communication between the various hardware components. From a software perspective, MyoTrain AR was developed in the cross-platform Unity 4.0 game development engine.
224236296|NCT05975970|BEHAVIORAL|Motor Imagery|Motor imagery describes the process by which a prosthesis user mentally simulates the execution of a desired limb movement and activates the musculature of the residual limb that would generate the desired movement.
224236297|NCT05420506|DEVICE|NROT1|Dental anchored intestinal placement of obesity treatment device with endoscopic intervention
224236298|NCT05422547|DIAGNOSTIC_TEST|Immunoscore Colon Test|Immunoscore® is a tissue-based immune test that measures the host's immune response at the site of the tumor. It is performed on formalin-fixed paraffin-embedded (FFPE) tumor tissue samples from resections of localized colon cancer. The test uses whole slide imaging and artificial intelligence algorithms for assessment of the type, density, and location of T cells in FFPE tumor sections to determine an individual Immunoscore® for each patient.
224236299|NCT04765709|COMBINATION_PRODUCT|durvalumab plus platinum-based chemotherapy (cisplatin or carboplatin plus vinorelbine or pemetrexed)|Induction therapy: durvalumab plus histology-based chemotherapy regimen (cisplatin or carboplatin plus vinorelbine for squamous histology and pemetrexed for non-squamous histology).
224236300|NCT04765709|COMBINATION_PRODUCT|Durvalumab plus radiotherapy|Concomitant durvalumab and radiotherapy
224236301|NCT04765709|BIOLOGICAL|durvalumab|Consolidation treatment with durvalumab
224236302|NCT06066502|OTHER|Precision ventilation|The intervention arm prioritizes mitigation of ventilator-induced-lung-injury by individualizing support to patient-specific mechanics in an integrated approach to limit overdistension and atelectrauma. This is accomplished in this arm by titration of tidal volume to limitation of driving pressure at 12 centimeters of water (cmH2O) or less and using esophageal manometry to titrate PEEP to a transpulmonary pressure of 0 cmH2O with adjustments in respiratory rate to allow for permissive hypercapnia and FiO2 adjustments to assure adequate oxygenation.
224236303|NCT06066502|OTHER|Guided usual care ventilation|The comparison arm allows clinician discretion when titrating PEEP and tidal volume, while setting general targets for allowable PEEP/FiO2 combinations, target range for SpO2, and target range for tidal volume. This arm applies routine best-practice guidelines. This includes maintenance of tidal volumes of 6-8 cc/kg of ideal body weight, limiting plateau pressures to 30 cmH2O or less and application of PEEP-FiO2 combinations which include a wide range of typical usual care with esophageal manometry only for data collection and not clinical adjustment.
224236304|NCT05649176|OTHER|Diet without soy|The diet is designed to moderate the blood glucose response with a similar macronutrient composition as the experimental diet but does not contain soy.
224236305|NCT05649176|OTHER|Diet with soy|The diet is designed to moderate the blood glucose response with a similar macronutrient composition as the comparator diet but contains soy.
224236306|NCT00726960|DRUG|aprepitant|Oral, 125 mg once daily for one week
223652047|NCT03801044|DIAGNOSTIC_TEST|Echocardiography|Transthoracic echocardiography was performed by the same cardiologist blinded to all other parameters. It was done while abdomen was empty. LV end diastolic diameter (mm), interventricular septum thickness (mm), posterior wall thickness (mm), ejection fraction (%), left ventricle end diastolic volume (ml), left atrial volume (ml), left ventricle mass index (LVMI) (g/m2), left ventricle filling velocity(cm/sec), E/E' ratio, pulmonary artery systolic pressure (mm Hg) were the parameters taken by echocardiography
224236307|NCT00726960|DRUG|Pseudo-placebo - buprenorphine|Randomized to receive either 8 mg sublingual tablets or 0.4 mg sublingual tablets
224236308|NCT00000880|DRUG|Cyclosporine|
224236309|NCT05897580|BEHAVIORAL|Heart Rate Variability - Biofeedback (HRV-BF)|"The HRV-BF was delivered over 30 minutes once weekly for 8 weeks by our nurse-led Community Health Worker (RN/CHW) team trained to deliver scripted material created by a trained biofeedback practitioner on our study team. The weekly sessions included the use of a tablet device to share a 10-minute video which teaches the basic techniques and breathing practices of HRV-BF and guiding the participant through a 20-minute practice, using the techniques while watching their heart rate data in real time using an HRV-BF device, the EmWave Pro (HeartMath).~Participants were also asked to complete daily practices on their own, without the HRV-BF device, for 10 minutes, twice a day, to reinforce topics and skills taught in videos. Practices logged by the participant were collected weekly by the CHW and referral to resources were provided."
224236310|NCT05897580|BEHAVIORAL|Health Promotion (HP)|The HP active control group was delivered over 30 minutes, once weekly for 8 weeks by our nurse-led Community Health Worker team, trained to deliver scripted materialized content created. In the HP program, PEH were educated on common physical chronic diseases PEH experience, including hypertension, diabetes, heart disease and arthritis, along with referrals provided based on needs expressed by PEH.
224236311|NCT05057715|BIOLOGICAL|VCN-01|Intravenous administration of VCN-01
224236312|NCT05057715|BIOLOGICAL|huCART-meso Cells|Intravenous administration of huCART-meso cells
224236313|NCT05478226|OTHER|drugs or BPA|PAH target drugs，for example， Tadanafiland, Maxitensin, Prostacyclins, riociguat and etc. CTEPH treat with balloon pulmonary angioplasty or riociguat
224236314|NCT05227820|DRUG|NE3107|Participants will take 20mg twice daily (BID) approximately 12 hours apart. The dose will be stable the duration of the study intervention (3 months)
224236315|NCT06173336|PROCEDURE|gastric per-oral endoscopic myotomy (G-POEM)|Comparing single versus double pyloromyotomy in G-POEM for refractory and severe gastroparesis.
223652048|NCT03801044|RADIATION|Chest Radiography|All radiographies were taken when the patient was standing erect position during deep inhalation. They were reported by an expert radiologist blinded to clinical data. Films taken at supine position or during exhalation were excluded. Chest radiographies were classified into 3 stages to reflect degree of hypervolemia. Stage 1 was redistribution defined as increased artery-to-bronchus ratio in the upper and middle lobes. Stage 2 was interstitial edema evident by Kerley B lines and peribronchial cuffing. Stage 3 was alveolar edema phase perihilar consolidation and air bronchograms, pleural fluid, increased width of the vascular pedicle, enlarged cardiac silhouette.
223652049|NCT03801044|DIAGNOSTIC_TEST|Lung Ultrasound|It was performed by 28 area method which contains ultrasound examination from second to fifth intercostals spaces at parasternal region, midclavicular line, anterior and mid axillary lines. Lung ultrasound had been done by same radiologist who was an expertise in ultrasonography blinded to all other parameters. It was performed by 1,6 megaHertz convex probe when patient lying at the supine position.
223767343|NCT04958109|DIAGNOSTIC_TEST|Oral Glucose Tolerance Test|Administration of a 75 gm oral glucose tolerance test
223767344|NCT04958109|DRUG|Kisspeptin|Intravenous administration of kisspeptin 112-121 x 16 hours
223767345|NCT04958109|DRUG|Placebo|Intravenous administration of Placebo 16 hours
224236316|NCT04662372|OTHER|Description|description of the cognitive and behavioral profile of stroke mimics patients, without evidence of neurological disease.
224236317|NCT03714165|DIAGNOSTIC_TEST|Alpha defensin and 16SrRNA gene|Alpha defensin 16S rRNA gene CBC: Complete blood count CRP: C reactive protein ESR: Erythrocyte sedimentation rate Culture and antibiotic sensitivity of synovial fluid
224236318|NCT06254248|DRUG|Systemic therapy|"Atezolizumab-Bevacizumab every 3 weeks until progression or side effects in combination with Standardized immunosuppressive treatment:~Tacrolimus (objective 5-7 ng/ml) Mycophenolate Mofetil 1000 mg per day Corticosteroids at least 5 mg per day Everolimus will be continued if already started before the inclusion (objective 5-7 ng/ml). If everolimus has not been started prior to inclusion, do not start it, but adopt the following protocol: corticoids + Tacrolimus + Cellcept."
224236319|NCT04860492|DIETARY_SUPPLEMENT|Renalof 325mg|RENALOF® is a preparation that contains active Agropyron repens extract. It is designed with specific antioxidant compounds triggered by a bio-catalyst process that enables improved control of the production mechanism of anti-stress molecules. RENALOF® contains extracts of couch grass (triticin, potassium salts, agropyron, silicic salt, inositol, vanillin, saponin, mucilage, iron, and others trace elements), mannitol, corn starch and magnesium silicate. The magnesium in RENALOF® inhibits stone formation by inhibition of growth of crystals and aggregation.
224236320|NCT03818048|DRUG|Propofol|after inicial bolus of propofol, remained sedated with propofol infusion (1-2 mg/kg/min)
224236321|NCT03818048|DRUG|Sevoflurane|after inicial bolus of propofol, remained sedated by inhalation with sevoflurane at a concentration of 2 vol% through a nasal cannula with an oxygen flow.
224236322|NCT00763022|DRUG|TAK-559|TAK-559 16 mg, tablets, orally, once daily for up to 26 weeks.
224236323|NCT00763022|DRUG|TAK-559|TAK-559 32 mg, tablets, orally, once daily for up to 26 weeks.
224236324|NCT00763022|DRUG|Placebo|TAK-559 placebo-matching tablets, orally, once daily for up to 26 weeks.
224236325|NCT00012857|DRUG|acetaminophen 650 mg qid and placebo qid PRN. The other arm was placebo qid and acetaminophen 650 mg qid PRN|
224236326|NCT03273322|DRUG|Rivaroxaban 10 mg qd|10mg qd
224236327|NCT03273322|DRUG|Rivaroxaban 15 mg qd|15mg qd
224236328|NCT03273322|DRUG|DAPT|Aspirin 75 mg qd + Clopidogrel 75 mg qd
224236329|NCT00048646|DRUG|IV Progesterone|
224236330|NCT00920140|DRUG|GSK1120212|Starting dose based on GSK protocol MEK111054 and then dose escalation based on Dose Limiting Toxicities per protocol.
224236331|NCT00920140|DRUG|GSK1120212|Dose will be maximum tolerated dose based on Phase I results.
224236332|NCT04428567|BEHAVIORAL|Dual-Task Treadmill exercise + Cognitive Training|The dual-task regimen will include treadmill exercise of 5-10 min warm-up and cool-down, 30 minutes of running towards target heart rate, combined with respond demands with the addition of cognitive tasks. The level of duration and intensity of treadmill exercise will progressively increase over the duration of 6 weeks.
224236333|NCT03215108|DEVICE|Endoscopic Retrograde CholangioPancreatography(ERCP)|This study is prospective randomized multicenter study by using Endoscopic Retrograde CholangioPancreatography(ERCP). Comparison between Novel flower-type covered stent and Conventional covered stent in malignant extrahepatic biliary obstruction will be conducted after stent insertion by using Endoscopic Retrograde CholangioPancreatography(ERCP).
224236334|NCT00825708|DEVICE|rTMS|42 2 sec trains of 20HZ rTMS in 100% MT
224236335|NCT00825708|DEVICE|shamTMS|sham TMS session
224236336|NCT05368623|DIAGNOSTIC_TEST|Color fundus photograph|Subjects will undergo color fundus photography before and after pharmacological dilation of pupils.
224236337|NCT05368623|DIAGNOSTIC_TEST|Optical Coherence Tomography (OCT) of the retina|Subjects will undergo OCT of the retina after pharmacological dilation of pupils.
224236338|NCT05368623|DRUG|Mydriatic Agent|Pharmacological dilation of pupils will be done by instilling mydriatic agent in eyes of Subjects
224236339|NCT03876613|BEHAVIORAL|Different music types|the type of music that reduces anxiety best and most effectively.
224236340|NCT06256536|DRUG|GZR18|0.6 mg-30 mg
224236341|NCT06256536|OTHER|Placebo|administered the same volume as GZR18
224236342|NCT06484218|PROCEDURE|conventional endodontic treatment|The conventional access cavity was prepared under the microscope through the incisal edge as this approach facilitates straight-line access. A high-speed contra-angle handpiece, associated with a long surgical bur 010 (Meisinger, CO, USA), was used until the dentin was exposed, which is in general 3 to 4 millimeters from the incisal edge. Then, the ultrasonic tip ED5 (woodpecker-DTE, Guilin, China) was marked with a stopper according to the calcification level viewed on the preoperative CBCT and then used gently at the stopper level until the canal was found.
224236343|NCT06484218|PROCEDURE|Guided endodontic treatment|In all cases, digital and clinical protocols were followed according to the method reported by Zehnder et al. and Connert et al. The guide was replaced, and the access cavity precisely drilled using the EG6 drill, mounted on a low-speed contra-angle handpiece. With every 3 mm of progression, the cavity was rinsed, and the head of the bur was cleaned until reaching the canal. The irrigation was done to avoid overheating the dentine and the accumulation of dentine debris
224236344|NCT01124149|DRUG|MMX mesalamine/ mesalazine|4.8g/day given QD (four 1.2g tablets) for 8 weeks, 2.4g/day given QD (two 1.2g tablets) for 12 months
224236345|NCT00977106|DRUG|tocilizumab [RoActemra/Actemra]|single iv infusion 8 mg/kg
224236346|NCT00977106|DRUG|placebo|single iv infusion
224236347|NCT00977106|DRUG|tocilizumab [RoActemra/Actemra]|iv infusion 8mg/kg every 4 weeks for 11 months
224236348|NCT01278849|DRUG|ASA404|
224236349|NCT03913806|DRUG|Bevacizumab-IRDye800CW|dose finding:10mg; 25mg; 50mg
224236350|NCT04669236|BEHAVIORAL|Intervention to promote healthy sleep behavior|An action group (6 - 8 pupils) was conducted at each school. Brainstorm sessions about effective strategies to change sleeping behavior in this population were held. Strategies, perceived as effective by the target population, will be summarized in an overview. Also feedback of adolescent, who are not part of the action group, will be asked. After feedback, the intervention will be developed by the intervention schools. Thereby, three different intervention strategies will be implemented and tested (one intervention at each school) to meet the individuals needs of each school. The action groups will develop the intervention materials during sessions this year. Afterwards, they will implement the intervention themselves in collaboration with teachers of the school and the researchers.
224236351|NCT04375254|OTHER|NbB psychopharmacology training|a two part course in psychopharmacology based on Neuroscience based Nomenclature
224236352|NCT03875157|BIOLOGICAL|IBI318|0.3 mg intravenous infusion, C1D1 and afterwards Q2W
224236353|NCT03875157|BIOLOGICAL|IBI318|1 mg intravenous infusion, C1D1 and afterwards Q2W
224236354|NCT03875157|BIOLOGICAL|IBI318|3 mg intravenous infusion, C1D1 and afterwards Q2W
224236355|NCT03875157|BIOLOGICAL|IBI318|10 mg intravenous infusion, C1D1 and afterwards Q2W
224236356|NCT03875157|BIOLOGICAL|IBI318|30 mg intravenous infusion, C1D1 and afterwards Q2W
224236357|NCT03875157|BIOLOGICAL|IBI318|100 mg intravenous infusion, C1D1 and afterwards Q2W
224236358|NCT03875157|BIOLOGICAL|IBI318|300 mg intravenous infusion, C1D1 and afterwards Q2W
224236359|NCT03875157|BIOLOGICAL|IBI318|600 mg intravenous infusion, C1D1 and afterwards Q2W
223652050|NCT03801044|DIAGNOSTIC_TEST|Bioelectrical Impedence Analysis|The Body Composition Monitor (BCM) (type 0BJA1394, Fresenius Medical Care AG \& Co. KGaA, D-61343 Bad Homburg) was used for assessment of hydration status in patients. Peritoneal cavities were free of intraperitoneal fluid during measurement. Patients were accepted as normovolemic if their result were between -1.1lt and 1.1 lt.
224236360|NCT03875157|BIOLOGICAL|IBI318|Intravenous infusion, C1D1 and afterwards Q3W
224236361|NCT03875157|BIOLOGICAL|IBI318|Intravenous infusion, C1D1 and afterwards Q3W
224236362|NCT03875157|BIOLOGICAL|IBI318|Intravenous infusion Q3W
224236363|NCT05680233|DRUG|OA-235i (4 mg)|3 participants will receive 4 mg as a single subcutaneous dose
224236364|NCT05680233|DRUG|OA-235i (8 mg)|3 participants will receive 8 mg as a single subcutaneous dose
224236365|NCT05680233|DRUG|OA-235i (16 mg)|3 participants will receive 16 mg as a single subcutaneous dose
224236366|NCT05680233|DRUG|OA-235i (30 mg)|3 participants will receive 30 mg as a single subcutaneous dose
224236367|NCT05680233|DRUG|OA-235i (40 mg)|3 participants will receive 40 mg as a single subcutaneous dose
224236368|NCT05680233|DRUG|OA-235i or placebo|9 participants will receive a daily subcutaneous dose of OA-235i or placebo for 7 consecutive days
224236369|NCT00796900|DRUG|Dantrolene|Patients who satisfy the inclusion/exclusion criteria of the study and who are enrolled in this study will be randomized with computer-generated grouping to either one of two groups. One group of subjects will be given dantrolene for the first episode of fever. The other group will be given placebo. Dantrolene is supplied in 70-ml vials containing 20 mg dantrolene. Dantrolene will be given in the following dose: 5 mg/kg BW given intravenously over 30 minutes. As placebo NaCl 0,9% will be used.
223652051|NCT03194230|OTHER|With cervical dilatator|Induction of labour by cervical placement of hygroscopic dilators (Dilapan-S Hygroscopic cervical dilator )
223652052|NCT05285605|DRUG|Ulipristal Acetate|Ulipristal acetate 30mg x 1 dose as needed for unprotected intercourse
224236370|NCT00796900|DRUG|Placebo|Patients who satisfy the inclusion/exclusion criteria of the study and who are enrolled in this study will be randomized with computer-generated grouping to either one of two groups. One group of subjects will be given dantrolene for the first episode of fever. The other group will be given placebo. Dantrolene is supplied in 70-ml vials containing 20 mg dantrolene. Dantrolene will be given in the following dose: 5 mg/kg BW given intravenously over 30 minutes. As placebo NaCl 0,9% will be used.
224236371|NCT00059852|DRUG|erlotinib hydrochloride|
224236372|NCT00059852|DRUG|gemcitabine hydrochloride|
224236373|NCT01644500|DRUG|Dulaglutide|Administered SC
224236374|NCT01644500|DRUG|Glimepiride|Administered orally
224236375|NCT01644500|DRUG|Placebo as Capsules|Placebo for glimepiride is administered orally as one to three capsules daily.
224236376|NCT01644500|DRUG|Placebo as SC Injection|Placebo for dulaglutide is administered as one SC injection.
224236377|NCT04911959|DRUG|Lenvatinib|Lenvatinib is taken orally.
224236378|NCT04911959|PROCEDURE|TACE|TACE treatment once.
224236379|NCT00891475|PROCEDURE|Radiofrequency ablation; Interferon-alpha|Patients undergo ablation by radiofrequency energy under CT-guidance. RFA continues until the entire tumor is treated. Treatment ceases when the entire lesion has undergone necrosis or the zone of necrosis or significant heat deposition approaches vital neurovascular structures. 38 patients will receive following immunotherapy with Interferon-alpha 9 MIU subcutaneously three times per week, 3 weeks on, 3 weeks off till progression. 38 patients will receive sunitinib maleate 50 mg orally once day, 28 days on, 14 days off till progression. Evaluation for response will be after second cycle.
224236380|NCT00891475|PROCEDURE|Radiofrequency ablation; Sunitinib maleate|Patients undergo ablation by radiofrequency energy under CT-guidance. RFA continues until the entire tumor is treated. Treatment ceases when the entire lesion has undergone necrosis or the zone of necrosis or significant heat deposition approaches vital neurovascular structures. 38 patients will receive sunitinib maleate 50 mg orally once day, 28 days on, 14 days off, till progression. Evaluation for response will be after second cycle.
224236381|NCT00891475|DRUG|Sunitinib maleate|38 patients with unresected primary tumor will receive sunitinib maleate 50 mg orally once day, 28 days on, 14 days off, till progression. Evaluation for response will be after second cycle.
224236382|NCT02773836|OTHER|Questionnaire|Questionnaire: To evaluate the impact of the implementation of the EU Tobacco Products Directive (TPD) and Framework Convention on Tobacco Control (FCTC)
223652053|NCT01326104|BIOLOGICAL|TTRNA-xALT|TTRNA-xALT 3 x 10\^7/kg by intravenous injection once.
224236383|NCT01573065|BEHAVIORAL|Counseling intervention with rapid HIV testing|Counseling intervention (modeled after Brief Negotiation Interview and Project RESPECT-2) coupled with rapid HIV testing. Telephone booster at 2 weeks.
224236384|NCT06206356|DEVICE|PNS Injectrode F1|The PNS Injectrode F1 is a flexible conductor that conforms to the shape of a peripheral nerve and patient anatomy. The device is approximately 1 mm in overall diameter and is provided in lengths of 9 or 10 cm. The device is placed in a minimally invasive procedure via a standard 18g needle. The stimulating end of the device is placed in close proximity to the lumbar medial branch nerve with a collector end left subcutaneously. Electrical stimulation is provided via an externally placed patch electrode connected to the provided external pulse generator over the collector end of the device. Transcutaneous electrical stimulation will occur prior to device placement, on Day 0 after device placement, and on Day 25 prior to device removal. Minimally invasive removal is completed by a small incision and forceps using standard medical procedures and equipment.
224236385|NCT06139237|OTHER|High-protein supplement|High protein supplement 200 mL
224236386|NCT06139237|OTHER|Balanced supplement|Balanced supplement 200 mL
223652054|NCT01326104|BIOLOGICAL|TTRNA-DCs|TTRNA-DCs 1 x 10\^7 by intradermal injection every 2 weeks for 3 total doses.
223767346|NCT00323128|PROCEDURE|Calculation of inuline clearance|Calculation of inuline clearance.
223652056|NCT04815278|BEHAVIORAL|Immediate Chronic Disease Prevention Program (CDPP)|The CDPP is an adaptation of the Diabetes Prevention Program (DPP). It will take place over a 24 week period and involve online instruction and individualized lifestyle coaching sessions. The online classroom curriculum includes 8 modules: Goal setting, self-monitoring and problem solving (M1), Managing stress and negative thoughts (M2), Healthy eating (M3), Taking more steps (M4), Keeping alcohol in check (M5), Lifestyle change (M6), Taking charge of what (and who) is around you (M7), and Staying motivated (M8). The lifestyle coaches will meet in person and over the phone intermittently over the 24 week period (Weeks 2, 4, 6, 10, 12, 16, 24).
223652057|NCT04815278|BEHAVIORAL|Workplace Equity, Job and Health Supports Employer Intervention|The employer intervention combines implicit bias awareness training for supervisors of hired DSS-E clients, and regular, structured, interactions between supervisors and DSS-E hires.
223652058|NCT04815278|BEHAVIORAL|Delayed, attenuated Chronic Disease Prevention Program (CDPP)|Participants will have access to a delayed, attenuated online-only version of the CDPP at the time they complete the 12 month data collection. This version will provide all modules, self-monitoring options (including through use of a Fitbit contingent on the completion of the 12 month data collection) but will not include face-to-face or phone lifestyle coach sessions.
223652059|NCT01287741|DRUG|Rituximab|Rituximab at a dose of 375 mg/m\^2, administered by intravenous (IV) infusion on Day 1 of each 21-day cycle for 8 cycles.
223652060|NCT01287741|DRUG|Obinutuzumab|Obinutuzumab 1000 mg IV infusion, administered on Day 1 of each 21-day cycle for 8 cycles. During Cycle 1, obinutuzumab was also infused on Days 8 and 15.
223652061|NCT01287741|DRUG|Cyclophosphamide|Cyclophosphamide 750 milligrams per square metre (mg/m\^2), administered intravenously (IV) on Day 1 of each 21-day cycle.
223652062|NCT01287741|DRUG|Doxorubicin|Doxorubicin 50 mg/m\^2 IV, administered on Day 1 of each 21-day cycle.
223652063|NCT01287741|DRUG|Vincristine|Vincristine 1.4 mg/m\^2 (maximum 2 mg) IV, administered on Day 1 of each 21-day cycle.
223652064|NCT01287741|DRUG|Prednisone|Prednisone 100 mg (or equivalent prednisolone or methylprednisolone), administered orally on Days 1-5 of each 21-day cycle.
223767347|NCT00323128|PROCEDURE|Measuring serum creatinine|Measuring serum creatinine.
223767348|NCT00021268|DRUG|tocladesine|
224320791|NCT03207867|DRUG|NIR178|"NIR178, a new, non-xanthine based compound, is a potent oral adenosine A2a receptor against antagonist being developed by Novartis.~NIR178 was administered orally twice daily (BID) as a capsule (Part 1, Part 2 and Japanese safety run-in) and as a film-coated table (Part 3). There were up to 3 dose levels assessed: 80, 160 and 240 mg. Three alternative dosing schedules were evaluated: continuous (Part 1, Part 2, Part 3, Japanese safety run-in), 2 weeks on/2 weeks off (Part 2) and 1 week on/1 week off (Part 2).~Each cycle consisted of 28 days."
223767349|NCT01690767|DRUG|2% lidocaine gel|Children \< 7 kg and \> 7 kg will receive 1 cc and 1.5 cc of 2% lidocaine gel, respectively
224236387|NCT02334371|RADIATION|MR-PET|The MR-PET will be performed with the Biograph mMR system (Siemens Healthcare, Erlangen, Germany). This system integrates a 3Tesla MRI and PET scan which makes simultaneous acquisition of whole-body MRI and PET images possible. The Biograph mMR holds the CE mark and was FDA approved in June 2011. The Biograph mMR is intended to be used in the Academical hospita! Maastricht for standard patient care. The radiotracer that will be used is 18F-Iabeled fluorodeoxyglucose (18F-FDG), according to standard PET -protocol.
224236388|NCT03505853|DRUG|Givosiran|single dose of givosiran by subcutaneous (sc) injection
224236389|NCT03505853|DRUG|5-probe cocktail|includes midazolam, caffeine, losartan, omeprazole, and dextromethorphan
224236390|NCT03770923|DRUG|Rupatadine|Rupatadine 10 mg daily
224236391|NCT03770923|DRUG|Montelukast|Montelukast 10 mg daily
224236392|NCT03828045|DRUG|Apremilast|Apremilast
224236393|NCT00216398|DRUG|Lanreotide (Autogel formulation)|
224236394|NCT04844840|DRUG|STP705|STP705 is composed of two siRNA oligonucleotides, targeting TGF-β1 and COX-2 mRNA, respectively
224236395|NCT04844840|OTHER|Placebo|Saline
224236396|NCT00006106|DRUG|cisplatin|
224236397|NCT00006106|DRUG|fluorouracil|
224236398|NCT00006106|DRUG|ONYX-015|
224236399|NCT01536626|DRUG|biphasic insulin aspart 30|Prescription at the discretion of the treating physician
224236400|NCT03510559|DRUG|Forearm Nerve Block|Blockade of the arm below the elbow using local anesthetic (0.5% bupivacaine and 2% lidocaine) deposited under ultrasound guidance to facilitate performance of the surgical procedure.
224236401|NCT03510559|DRUG|Brachial Plexus Block|Blockade of the entire arm using local anesthetic (0.5% bupivacaine and 2% lidocaine) deposited under ultrasound guidance to facilitate performance of the surgical procedure.
224236402|NCT01989728|PROCEDURE|psychiatric examination and feedback|
224236403|NCT05137756|OTHER|no intervention|no intervention
224236404|NCT00002899|PROCEDURE|adjuvant therapy|
224236405|NCT00002899|RADIATION|radiation therapy|
224236406|NCT00002899|RADIATION|stereotactic radiosurgery|
224236407|NCT00487227|DRUG|caffeine|
224236408|NCT00487227|DRUG|Placebo|
224236409|NCT05333523|RADIATION|Sentinel lymph node biopsy guided selective elective neck irradiation|"Patients will undergo sentinel lymph node biopsy. Based on the histopathologic status of the sentinel lymph node(s), selective elective neck irradiation is performed with standard radiation treatment of the primary tumor.~There are 3 possible treatment scenarios.~1. Bilateral elective neck irradiation is indicated when sentinel lymph nodes at both sides of the neck contain metastases or when sentinel lymph node detection fails.~2. Unilateral elective neck irradiation is indicated when sentinel lymph node(s) at one side of the neck contain metastases.~3. Full omission of elective neck irradiation is indicated when all sentinel lymph nodes are free of metastases."
224236410|NCT05333523|RADIATION|Standard elective neck irradiation|Patients randomized to the control arm will receive the standard of care, according to (inter)national clinical practice guidelines. This will consist of (chemo)radiotherapy to the primary tumor with standard elective neck irradiation in all patients. No sentinel lymph node biopsy will be performed.
224236411|NCT00418470|PROCEDURE|regular dilution of antibiotic in NS|IV administration of ceftazidime tid diluted in regular NS volume
224236412|NCT00418470|PROCEDURE|higher dilution of antibiotic in NS|IV administration of ceftazidime tid diluted in larger NS volume
224236413|NCT02068482|DRUG|Rifaximin|Rifaximin 200 mg 6 tbs per day per 15 days/ month for 2 months
224320792|NCT03207867|DRUG|PDR001|PDR001 is a human monoclonal antibody (MAb) administered on Day 1 of each cycle. PDR001 400 mg was administered via intravenous (i.v.) infusion over 30 minutes every 4 weeks (Q4W).
224320793|NCT05327192|OTHER|No intervention, only sampling|No intervention
224320794|NCT02447744|BEHAVIORAL|Mindfulness based intervention|The intervention is an 8-week structured mindfulness based behavioral intervention program that teaches mindfulness meditation, mindful yoga and psychological knowledge about stress.
224236414|NCT05140447|OTHER|preheating of resin composite|evaluate the effect of preheating BIS-GMA free resin composite at different temperatures on temperature change of the pulpal floor and restorations and compare it with BIS-GMA containing resin composite.
224236415|NCT01239251|OTHER|GlowCap device|Participants will be provided with a device called the GlowCap for a period of 30 days. The device has visual and auditory cues to help patients remember to take their medication at the same time each day. The GlowCap will be programmed to glow when it is time for each patient to take her medication. The GlowCap will initially glow bright orange for the first hour from the time the patient is scheduled to take the medication. During the second hour, the GlowCap system will play music in addition to continuing to glow. If after 2 hours the patient still has not opened the medication bottle, she will receive a phone call reminding her to take her medication.
224236416|NCT04915092|DEVICE|CoSIE app|"The app is a mobile phone application compatible with both iOS and Android operating system. Parents are able to register their children and to keep track of their weight status and activities. The app include five themes: child development, physical activity, healthy food, critical situations, BMI.~Push notification on healthy behaviours, on important event taking place in the province of Reggio Emilia, on food advices based on seasonality and on party tips are constantly delivered by the app."
224320795|NCT00912912|DRUG|Sunitinib Malate|50 mg capsules once a day (by mouth) for 4 weeks in a row in a 6 week cycle.
224320796|NCT00306995|BIOLOGICAL|SB218352_15|Non-adjuvanted pandemic influenza A formulation 1 vaccine
224320797|NCT00306995|BIOLOGICAL|SB218352_8|Non-adjuvanted pandemic influenza A formulation 2 vaccine
224320798|NCT00306995|BIOLOGICAL|SB218352_4|Non-adjuvanted pandemic influenza A formulation 3 vaccine
224320799|NCT00306995|BIOLOGICAL|SB218352_2|Non-adjuvanted pandemic influenza A formulation 4 vaccine
224236417|NCT05608512|OTHER|interview|The first phase included a qualitative study. We conducted a qualitative phenomenological method to better explicate and understand palliative care nurses' emotional labor experiences, as well as the dilemmas and solutions they encounter when physical, mental, and emotional labor intertwine at work. In the early stage, we compiled an interview outline by a written qualitative meta-analysis about the emotional labor, and added the contents in the interview outline according to the actual situation in the later interview process.
223652065|NCT02861885|OTHER|Chromoendoscopy|Colonoscopy will run in accordance with standard procedure, including air insufflation throughout the endoscope rise. The endoscope will be a Olympus NBI videoscope (180 series and latest). First, progression will run until caecum without systematic terminal ileum intubation. Polyps will be searched out during descent phase. The patient will be eligible as soon as the operator suspects an ascendant colon SSL with white light. The operator will have to initiate the WLI colonoscopy. If a SSL is suspected in the colon, the operator will run at the same time, a NBI colon examination, then an indigo carmine chromoendoscopy colon examination. Each lesion will be pictured before and after mucus clean-up. Lesions biopsy or resection will be ran in accordance with standard procedure.
224320800|NCT00306995|BIOLOGICAL|SB218352_8AL|Pandemic influenza A formulation 2 aluminium-adjuvanted vaccine
223652066|NCT04421027|DRUG|Baricitinib|Given orally
223652067|NCT04421027|DRUG|Placebo|Given orally
223652068|NCT03756324|DRUG|CHPM (Chinese Herbal Patent Medicine )|Pugongying (Herba Taraxaci) granules is named as Pugongying Granules in China and produced by Kunming pharmaceutical factory co. LTD. The form is granules, and the participants will take the medicine after dissolved as 15g/tid for 3 days, and the investigators will follow them up for 7 days when the participants are stopped administrating.
223652069|NCT03756324|DRUG|Antibiotics Cefdinir Capsules|Cefdinir Capsules is also named as Cefdinir and produced by Astellas Pharma Inc. The form is capsule, and participants will take orally the capsules with water as 0.1g/tid for 3 days, and the investigators will follow them up for 7 days when the participants are stopped administrating.
223767350|NCT01690767|DRUG|Health Care Lubricating Jelly|Non-medicinal lubrication gel
224236418|NCT01879839|DIETARY_SUPPLEMENT|Diet|Patients receive special diet 4 days prior to contrast-agent administration.
224236419|NCT06167538|OTHER|Decannulation|From the 1st of September 2021, the investigators started to perform decannulation earlier after admission to the Department of Brain Injury. Before attempting to decannulate a patient, several factors were considered and assessed by the patient's treating team: patient's level of consciousness, hemodynamical stability, need for and frequency of salivary aspiration, cough strength and respiration frequency. Patients could not be under treatment for pneumonia and simultaneously have respiratory instability at the time of decannulation.
224236420|NCT03270007|DRUG|Vinorelbine|different from primary chemotherapy(containing anthracycline or paclitaxel)
224236421|NCT02550223|PROCEDURE|radial artery Catheterization|Insertion of radial artery catheter for sampling and blood pressure measurement
224236422|NCT01567930|DRUG|Temsirolimus|Intervention: Temsirolimus IV Eligible patients will receive temsirolimus IV on days 1,8,15 every 21 days. Treatment will continue till disease progression or untolerable side effects
224236423|NCT01879280|PROCEDURE|Traditional pterional craniotomy|In the standard pterional craniotomy group, the attachment of the temporalis will be cut and the temporalis will be mobilized prior to exposure of the underlying bony calvarium. This maneuver is currently accepted for use by the majority of neurosurgeons nationwide.
224320801|NCT00306995|BIOLOGICAL|SB218352_4AL|Pandemic influenza A formulation 3 aluminium-adjuvanted vaccine
224320802|NCT00306995|BIOLOGICAL|SB218352_2AL|Pandemic influenza A formulation 4 aluminium-adjuvanted vaccine
224320803|NCT06379724|DRUG|Tranexamic acid|100mg/mL 10mL vials x2 of injectable tranexamic acid will be filled into a 20 milliliter syringe with a spray tip.
224320804|NCT06379724|DRUG|Thrombin JMI|The wound base is then sprayed with a film of Thrombin-JMI
223652070|NCT03756324|BEHAVIORAL|Education|Doctors will give suggestions and the medical orders to all participants, including dietary, emotional regulation and the knowledge of breast-feeding.
223652071|NCT03756324|DRUG|Antibiotics Cefdinir Capsules|Cefdinir Capsules is also named as Cefdinir and produced by Astellas Pharma Inc. The form is capsule, and participants will take orally the capsules with water as 0.1g/tid for 2 days, and the investigators will follow them up for 7 days when the participants are stopped administrating.
223652072|NCT05374603|DRUG|Savolitinib|Savolitinib combine with Durvalumab
223652073|NCT05374603|DRUG|Durvalumab|savolitinib plus durvalumab
223652074|NCT05036733|DRUG|Dupilumab|"Participants will receive 8 doses of Dupilumab. The initial loading dose (visit 1) of 600 milligrams (two 300 milligram injections) will be given subcutaneously (SQ). Then the participants will receive 300 milligrams SQ every other week (q 2 weeks) either at a study visit or self-administered at home between visits.~Additionally, participants will complete questionnaires, have specimens collected, as well as perform breathing procedures at various timepoints."
223652075|NCT06946810|BEHAVIORAL|Combined visits-based transition|In this arm, patients experience a gradual transition involving joint consultations where both pediatric and adult gastroenterologists are present. This includes at least one combined visit at the pediatric clinic and one at the adult clinic, allowing for collaborative care and direct communication between all parties during the transition process.
223652076|NCT06946810|BEHAVIORAL|Letter-based transition|In this arm, patients are transitioned from pediatric to adult gastroenterology care through a referral system where the pediatrician prepares a comprehensive clinical report that accompanies the patient to their first adult gastroenterology appointment. The transition occurs without joint visits between pediatric and adult specialists.
223652077|NCT06343987|BEHAVIORAL|Physical Activity|12-week physical activity program with training 3 times a week. The training consists of high-intensity training such as weight-lifting and cardiovascular training, and low-intensity training such as relaxation and stretching.
223652078|NCT06164795|DRUG|Zoledronate|intravenous infusion
224320805|NCT06379724|PROCEDURE|skin graft|Skin is taken from uninjured part of the participant's body and used to surgically cover a wound or injured area with skin that contains the epidermis and a portion of the dermis.
223652079|NCT06164795|DRUG|Denosumab|subcutaneous injection
223652080|NCT06164795|DRUG|Teriparatide|subcutaneous injection
223652081|NCT06164795|DRUG|Romosozumab|subcutaneous injection
223652082|NCT06164795|DRUG|Abaloparatide Injection (80 mcg)|daily subcutaneous injection
224236424|NCT01879280|PROCEDURE|Osteoplastic craniotomy|"In the osteoplastic group, the temporalis will be left attached to the bony calvarium prior to exposure of the tumor. There are ways to turn a bone flap with the temporalis still attached (i.e., an osteoplastic craniotomy). However, this method is thought to be slightly more time-consuming and is used less often in many centers. Aside from the extra time involved, we do not feel that leaving the temporalis attached to the bony calvarium disadvantages the patient in any fashion and may--in fact--result in less post-operative morbidity."
223652084|NCT05978713|DRUG|Tirzepatide|Administered SC
223652085|NCT04123938|OTHER|Pea Protein|Soluble pea protein
223652086|NCT04123938|OTHER|Whey Protein|Whey protein concentrate
223652087|NCT04123938|OTHER|Maltodextrin|Non-protein isocaloric comparator
223652088|NCT05972889|DEVICE|NexWave|Device subjects receive designated treatment mode twice daily for up to 8 weeks.
223652089|NCT05972889|DEVICE|Sham|Sham subjects provided with Sham Device and treatment instructions identical to that of NexWave Device Arm for their designated Sham Arm. Sham subjects participate for 4 weeks with the option to crossover to the NexWave Device Arm for an additional 4 weeks (up to 8 weeks total).
223652090|NCT04223193|DRUG|Tavapadon|Participants will be randomized to receive tavapadon 5 mg QD to 15 mg QD tablet once daily orally for 27 weeks.
223652091|NCT04223193|DRUG|Placebo|Participants will receive placebo matching to tavapadon QD orally for 27 weeks.
224236425|NCT00902876|DEVICE|Mucograft|Collagen Matrix for soft tissue regeneration
224236426|NCT00902876|PROCEDURE|Coronally advanced flap (CAF)|
224236427|NCT05473169|DEVICE|Videofluoroscopy|Swallowing assessment
223652092|NCT05555108|BEHAVIORAL|ACTCOM-I Intervention|ACTCOM-I s an individual treatment protocol based on Acceptance and Commitment Therapy (ACT) with targeted behavioral components for insomnia treatment and a specific focus on selfcompassion as a protector for sleep disturbance.
223652093|NCT05555108|BEHAVIORAL|Standard CBT-I Intervention|Standard CBT-I treatment for chronic insomnia. Treatment protocol adapted from Morin's protocol (1993)
223652094|NCT05407064|DRUG|MM-120 (LSD D-Tartrate)|A psychoactive substance that mediates effects mainly through an agonist activity in the serotonin 2A receptor (5-HT2A).
223652095|NCT05407064|OTHER|Placebo|A substance that is designed to have no therapeutic value.
224236428|NCT03204526|DEVICE|deep brain stimulation|
224236429|NCT04848948|BEHAVIORAL|Calory Restriction (F.X. Mayr & VLCD)|"VLCD restricts calory intake to 630 - 700 kcal per day (20% fat, 34% protein, 46% carbohydrates).~F.X. Mayr diet similarly applies calorie restriction to 700 - 800 kcal per day and includes daily ingestion of isotonic magnesium sulfate solution."
224236430|NCT04848948|BEHAVIORAL|Biofeedback|Three sessions of biofeedback (50 minutes) over a time frame of 14 days, aimed at improving biological functions and especially heart-rate-variability under stress condition.
224236431|NCT01362725|DEVICE|Spinal cord stimulation system|An implantable pulse generator (IPG) will deliver low-intensity electrical pulses which travel from the IPG through the leads to the electrodes positioned at the selected nerve fibers to provide the therapeutic stimulation.
224236432|NCT03239522|DRUG|[14C]-GSK1278863 solution for IV infusion|It is a clear, colorless solution free from visible particulate matter. Participants will receive 10 mL of 5 µg/mL of \[14C\]-GSK1278863 IV solution (total dose: 50 µg) by IV infusion over 1 hour.
224236433|NCT03239522|DRUG|[14C]-GSK1278863 oral solution|It is a clear, colorless solution. Participants will receive 125 mL of 200 µg/mL of \[14C\]-GSK1278863 oral solution (total dose: 25 mg).
224236434|NCT03239522|DRUG|Daprodustat 6 mg oral tablet|It is a 9.0 millimeter (mm) round, white film coated tablet.
224236435|NCT01400425|DRUG|florbetapir F 18|IV injection, 370 megabecquerel (MBq) (10 millicurie \[mCi\]), single dose
224236436|NCT04503330|PROCEDURE|buccal mucosal graft to repair iatrogenic PUJO|Augmented buccal mucosal graft anastomosis to repair iatrogenic PUJO or long segment ureteric stricture disease
224236437|NCT03652701|OTHER|Hair Up|Herbal topical
223652102|NCT03217071|DRUG|Pembrolizumab|All study participants will receive pembrolizumab every 3 weeks, for 2 cycles.
223652103|NCT03217071|RADIATION|stereotactic radiation therapy (SRT)|Patients in Cohort 2 of the Safety run-in and patients in the expansion cohort who are randomized to the 'pembrolizumab +radiation arm' will receive one dose of SRT within 1 week (+/- 3 days) following the second administration of pembrolizumab.
224236438|NCT03652701|OTHER|Placebo|Placebo
223652104|NCT03217071|PROCEDURE|Surgery (Non-interventional, standard of care)|Standard of care surgery to remove cancer
223652105|NCT02022124|DRUG|Microcrystalline cellulose (open-label inert substance)|The intervention will be an inert substance, microcrystalline cellulose in a capsule. Participants will take two capsules daily.
223652106|NCT03012399|BEHAVIORAL|Hypnosedation|Undergo hypnosedation
223652107|NCT03012399|OTHER|Questionnaire Administration|Ancillary studies
223652108|NCT03012399|BEHAVIORAL|Verbal Support|Speak with min-body specialist
223652109|NCT06555601|DRUG|UCB3101|Study participants will receive UCB3101 as prespecified in each cohort.
223652110|NCT06555601|DRUG|Placebo|Study participants will receive placebo as prespecified in each cohort to maintain the blinding.
223652111|NCT06653179|PROCEDURE|Sacral Erector Spinae Plane Block|The patient is placed in the prone positionon a procedure table. The sacral region is exposed, and the area is prepped with antiseptic solution under sterile conditions. The ultrasound high-frequency linear transducer is placed transversely over the sacrum. The sacral cornua are typically seen as bony structures adjacent to the sacral hiatus, appearing as two hyperechoic structures. Rotate the ultrasound probe to a sagittal position over the sacrum to align with the fourth and fifth sacral vertebrae. Under continuous ultrasound guidance, block needle is inserted in-plane with the ultrasound probe. Direct the needle through the soft tissue towards the plane between the erector spinae muscle and the sacrum. After confirming needle placement, the injectate mixture of 8 mg dexamethasone and 10 mg bupivacaine (0.5% concentration) is administered. A total volume of 10 mL is injected, and real-time ultrasound is used to observe the spread of the injectate within the target tissue plane.
223652112|NCT06653179|PROCEDURE|Caudal Epidural Injection|The patient is positioned in the prone position on the procedure table, and the sacral region is exposed and prepped with antiseptic solution under sterile conditions. The fluoroscope is positioned laterally to visualize the sacral hiatus. Under fluoroscopic guidance, the block needle is inserted through the skin and advanced toward the sacral hiatus. Continuous fluoroscopy is used to ensure correct needle placement, typically visualized at the level of the sacral canal. After confirming the appropriate position with contrast media, the injectate consisting of 8 mg dexamethasone and 10 mg bupivacaine (0.5% concentration) is slowly administered, with a total volume of 10 mL. During injection, careful monitoring of the needle position is performed to avoid intravascular injection. After the procedure, patients are monitored for potential complications such as hypotension and allergic reactions.
223652113|NCT03018860|PROCEDURE|"Moderate management"|"After randomization, women allocated to the intervention group, i.e. moderate pushing, are encouraged to push only 2 times per contractions, to respect contractions without pushing and there is no limit of pushing duration."
223652114|NCT03018860|PROCEDURE|"Intensive management"|This group corresponds to usual obstetrical management of active second stage in France. In France, national guidelines recommend to limit maternal expulsive efforts to 30 minutes (grade C). Thus, physicians (midwives and obstetricians) encourage usually women to push 3 times per contractions and to push on every contraction in order to deliver into a 30 minutes timing.
224236439|NCT05385068|DRUG|Niraparib|"Niraparib 200 or 300mg\* QD PO continually;~\*The starting dose of niraparib was individualized based on patients' bodyweight and baseline platelet count; 200 mg QD for Patients with baseline body weight \<77 kg or platelets count \<150,000/μL;300 mg QD for Patients with baseline body weight ≥77 kg and platelets count ≥150,000/μL.~For patients who had experienced grade 4 adverse events from previous use of PARPi, niraparib staring dose was 200 mg QD.~Anlotinib 10mg QD PO from Day 1 to 14 of every 21-day cycle"
223652115|NCT06655844|DEVICE|Sana Pain Reliever|The Sana Pain Reliever (Sana PR) by Sana Health Inc is a device comprised of one (1) main component (Mask with Earbuds) and two (2) ancillary components (Charger and Headband). The device is worn over the eyes (with earbuds in ears).
223652116|NCT06655844|DEVICE|Sham SPR|Participants will receive the SPR device and a tablet with instructions of how to use the device and how to answer the questionnaires on the tablet mobile application. Each session with the device will last 15 minutes and run under the device's sham settings. The session consists of periods of light and sounds (beeps). Participants will be instructed to use the device each day at the end of the day prior to going to sleep and whenever they experience heightened pain during the day.
223652117|NCT06982716|DEVICE|Lexie Lumen Hearing Aids|The Lexie Lumens (Lexie Hearing) are self-fitting wireless air conduction hearing aids consisting of 16 channels, wide-dynamic-range compression technology, feedback reduction, Bluetooth connectivity and programming, digital noise reduction, and a directional microphone array. These hearing aids will be sourced at a cost of $240 USD per pair as this study will be conducted in low-income settings. The hearing aids allow for Bluetooth in-situ hearing aid fitting using the Lexie proprietary fitting algorithm that is based on the NAL/NL2 algorithm from a smartphone application (Lexie Hearing) based on the four hearing thresholds tested. These digital hearing aids were designed for use by adults over the age of 18 years with known or self-perceived mild-to-moderate hearing loss. The Lexie Lumens are behind-the-ear (BTE) hearing aids powered by replaceable batteries. Individuals can conduct an in-situ hearing test via the hearing aids for customized amplification or select a minimal gain.
224236440|NCT05258864|BEHAVIORAL|Check Your Drinking (CYD)|The CYD is a brief online intervention designed to provide personalized normative feedback aimed at motivating reductions in drinking
223652118|NCT06982716|DEVICE|Go Ultra Hearing Aids|Go Ultras (GoHearing) are rechargeable, BTE pre-set hearing aids with advanced audio features, digital sound processing and Bluetooth-streaming capabilities. Designed for adults with mild-to-moderate hearing loss, these hearing aids have four unique programs that the user can manually change to ensure optimal listening comfort. These devices have both program and volume memory functions, as well as noise and wind noise reduction. Go Ultras will be sourced at a cost of less than $130 USD per pair, as this study will be conducted in low-income settings.
224236441|NCT00688064|DRUG|Adapalene BPO Gel associated with Doxycyline Hyclate|Adapalene BPO Gel: Topical to the face, once daily in the evening Doxycycline Hyclate: Oral, 1 tablet once daily in the morning. Both during 12 weeks.
224236442|NCT00688064|DRUG|Vehicle Gel associated with Doxycycline Hyclate|Vehicle Gel: Topical to the face, once daily in the evening; Doxycycline Hyclate: Oral, 1 tablet once daily in the morning. Both during 12 weeks.
223652121|NCT02987387|DEVICE|SAPIEN XT THV|SAPIEN XT THV will be implanted in the pulmonic position.
224236443|NCT00720096|DRUG|Liposomal Doxorubicin|Liposomal Doxorubicin 40 mg/m2 q 28 days
224236444|NCT00720096|DRUG|Topotecan|"1. Topotecan (daily x 5 days of a 21 day cycle)~2. Per amendment #15: Topotecan (days 1, 8, 15 of a 28 day cycle)"
224236445|NCT06486324|DEVICE|A locked modified acrylic bonded rapid maxillary expansion appliance (ARME)|asymmetric maxillary expansion
224236446|NCT06486324|DEVICE|A locked modified acrylic bonded rapid maxillary expansion appliance (ARME)|asymmetric maxillary expansion
224236447|NCT04940455|OTHER|Educational digital platforms|The digital educational platforms will be implemented through games of questions and answers, simulated cases sent via google forms about the nurse's performance in a critical care unit facing the patient with signs and symptoms of sepsis. The questions in the games will aim to develop clinical judgment and quick decision-making in nursing students in order not to compromise the health care of the patient in sepsis.
224236448|NCT02524223|OTHER|Systematic HPV DNA assay in semen and cervicovaginal scrape|Screening of HPV status at the genital level of males enrolled in MAP program.
224236449|NCT02524223|OTHER|Systematic HPV DNA cervicovaginal scrape|Screening of HPV status at the genital level of females enrolled in MAP program.
224236450|NCT02524223|OTHER|systematic HPV Status in newborns in case of pregnancy|
223652122|NCT06600087|BEHAVIORAL|Questionnaire|Standardized self-administered questionnaire specifically designed for this study.
223652123|NCT06589024|OTHER|Computerized Plasticity-Based Adaptive Cognitive Training|Training on computerized exercises that targets processing speed, attention and executive function for about 36 minutes per session, 5 sessions per week for a total of 36 sessions.
224236451|NCT01297049|BEHAVIORAL|Cognitive behavior therapy (CBT)|All patients will receive standard care (reassurance, education, physiotherapy, and necessary medication). Complementary to this standard care, the participants will be required to closely monitor their blood glucose levels, weight, eating behavior and daily activities, and to relay this information to the nurse specialist trained in treating somatic patients with CBT. The nurse will then suggest appropriate treatment decisions, the patients will receive situational feedback based on the electronic diary during 3 months (daily during 4 weeks intensive treatment and weekly during 2 months as a complement).
223652124|NCT06589024|OTHER|Sleep Hygiene Education|Access to sleep hygiene education materials
223652125|NCT02930018|DRUG|Nerinetide (NA-1), 2.6 mg/kg|Single intravenous infusion of nerinetide over 10 ± 1 minutes
223652126|NCT02930018|DRUG|Placebo|Placebo Comparator: Placebo
224236452|NCT00442936|DRUG|Telcagepant potassium 150 mg|Telcagepant 150 mg liquid-filled soft gel capsules
223652127|NCT06813963|DRUG|Topical Minoxidil（5%） to the scalp.|The patient will apply 5% Minoxidil topical solution to the scalp twice daily, with 7 sprays (approximately 1 mL) per application, for a duration of 12 months.
223652128|NCT06813963|DRUG|Placebo|The patient will apply placebo to the scalp twice daily, with 7 sprays (approximately 1 mL) per application, for a duration of 12 months.
223652129|NCT06289907|DIETARY_SUPPLEMENT|Bonafide-HF3.0|Take 2 capsules once daily in the mornings with food
223652130|NCT06289907|DIETARY_SUPPLEMENT|Placebo|Take 2 capsules once daily in the mornings with food
224236453|NCT00442936|DRUG|Telcagepant potassium 300 mg|Telcagepant 300 mg liquid-filled soft gel capsules
224236454|NCT00442936|DRUG|Zolmitriptan 5 mg|Zolmitriptan 5 mg tablets
224236455|NCT00442936|DRUG|Placebo to telcagepant 150 mg|Placebo to match telcagepant 150 mg liquid-filled soft gel capsules
224236456|NCT00442936|DRUG|Placebo to tecagepant 300 mg|Placebo to match tecagepant 300 mg liquid-filled soft gel capsules
224236457|NCT00442936|DRUG|Placebo to zolmitriptan 5 mg|Placebo to match zolmitriptan 5 mg tablets
224236458|NCT00442936|DRUG|Rescue medication|If moderate or severe migraine headache pain continues or recurs 2 hours after dose of study drug, participants are allowed to take an optional second dose of study drug or their own non-study rescue migraine medication, which may include analgesics (e.g., nonsteroidal anti-inflammatory drugs \[NSAIDs\] or opiates), anti-emetics, or zolmitriptan. Triptans other than zolmitriptan and ergot derivatives are prohibited for 24 hours following the last dose of study drug.
224236459|NCT03400384|OTHER|Direct-to-consumer educational brochure|The intervention arm will be mailed an evidence-based, theory-driven direct-to-consumer educational brochure, highlighting the potential benefits and harms of opioids when used to treat chronic non-cancer pain.
224236460|NCT00521170|DRUG|Levocetirizine|
224236461|NCT06850688|DEVICE|Remote monitoring platform|"EPOCA Intelligence Information System is a remote monitoring plateform. The medical device is used as a SaaS platform with restricted access for healthcare professionals. Patients and their families interact with the medical device via notifications and secure links, upon request. The medical device integrates the use of other medical devices such as oximeters, blood pressure monitors, glucometers, bracelets, etc., which are connected and whose use is also governed by their user manuals and training.~Patient is monitoring via the remote monitoring platform for 30 days after hospital discharge"
224236462|NCT01292109|DRUG|sodium picosulphate|Sodium picosulphate (PICOPREP®) taken by participant prior to X-ray examination, endoscopy or surgery.
224236463|NCT04039542|OTHER|Compassion focused therapy (CFT)|Compassion focused therapy (CFT) sessions (developed from cognitive behavioural therapies) to target underlying shame and self-criticism - 10 x 90 minute sessions
224236464|NCT00925314|BIOLOGICAL|CB-10-01 (Transgenic Lymphocyte Immunization)|1 Primary Infusion and 2 Booster Infusions
223652131|NCT06123741|BEHAVIORAL|Parental Guidance|Parents get guidance for children's positive behaviour support by using parts of Self-Help Program on the MentalHub.fi (in Finnish: Mielenterveystalo.fi) website regarding children's challenging behaviour (in Finnish: Lasten haastavan käytöksen omahoito-ohjelma) .
223652132|NCT06123741|BEHAVIORAL|Virtual Reality Game|Virtual reality game for rehabilitation of attention, activity control and executive functions by using the virtual environment that corresponds to the typical everyday situations at home.
223652133|NCT06981923|DEVICE|CMAC D-Blade|Intubation will be performed using the CMAC D-Blade
223652134|NCT06981923|DEVICE|CMAC Video Stylet|Intubation will be performed using the CMAC Video stylet
223652135|NCT06593743|DRUG|Perianal NRL001 Gel 3 strengths|A single application of 0.3%, 1.0%, 3.0% NRL001 gel in stepwise dose ascending fashion.
223652136|NCT06593743|DRUG|Intraanal NRL001 Gel 2 strengths|A single application of 3.0% or 1.0% Gel
223652137|NCT06593743|DRUG|Intrarectal NRL001 Gel|A single application of 1.0% Gel
223652138|NCT06593743|DRUG|NRL001: 10mg suppository|NRL001 10mg suppository applied to rectum.
224236465|NCT06101836|OTHER|Training intervention|Trainees underwent a one-day training course (intervention) by consciously competent endoscopists who were physically remote consisting of interactive theoretical sessions and live sessions, where trainees performed colonoscopy in their local endoscopy unit receiving real-time instructions via a tele-conference monitor. Trainers and trainees not doing the colonoscopy, followed the procedure in real-time. KPIs were assessed on trainee-performed colonoscopies for 3 weeks prior and 4 weeks after the intervention.
224236466|NCT06278142|OTHER|Internet Based Intervention - GUIDED|In the expert-supported application, each participant will be sent a folder to be shared by the user and the guide via Google Drive, and the user is expected to perform the application in the folder. A module is added to the folder every Monday and the participant is asked to complete the relevant module until Friday of the same week. In the following two days, a feedback message is provided by the expert, taking into account the user's responses.
223652139|NCT00001465|DEVICE|Toshibia Aquilion One CT|The Toshiba Aquilion ONE CT system is currently being used for studies in both general CT radiology and CT cardiac imaging. One of the unique aspects of the Aquilion ONE CT system is its ability to acquire whole organ volume images in a single rotation by utilizing an x-ray detector that is configured as 320 detector rows with a 0.5 mm width, providing a z-axis coverage of 16 cm of anatomy. In line with the evolutionary changes to CT systems, the Aquilion ONE will be upgraded with new technology that will expand its capabilities. The changes being made to the Aquilion ONE will provide enhancements to image acquisition capabilities, reduce ionizing radiation dose, and improve subject access to the system. All of these features assist in enhancing the safety of the currently installed Aquilion ONE CT system.
223652140|NCT01857492|DEVICE|tDCS|
223652141|NCT01857492|BEHAVIORAL|Meditation|Both Active and SHAM groups will receive Meditation.
223652142|NCT06360094|DRUG|BI 1839100|BI 1839100
223652143|NCT06360094|DRUG|Placebo|Placebo
223652144|NCT06610461|DEVICE|HFNO-Treatment|The investigated intervention is the application of HFNO throughout a high-risk upper GI-endoscopy. Concentration of oxygen is 100%. Prior to induction, flow rate is set to 20 l/min and increased to 30 l/min if tolerated by the patient. After induction of anesthesia, flow rate is increased to 60 l/min and maintained throughout the anesthesia.
224236467|NCT06278142|OTHER|Internet Based Intervention - WİTHOUT GUİDANCE|The developed implementation plan is communicated to the participants without expert support and their participation is ensured. A common folder will be created with the participants accepted to the study and in the group without expert support, and the process is managed by transmitting the module to the user via the folder every Monday.
224236468|NCT02295956|BEHAVIORAL|Questionnaires|Series of physical and quality of life assessments administered to participants, taking about 20 minutes to complete.
224320806|NCT05422625|DEVICE|PTNS Treatment|Patients will be placed in a comfortable position, sitting or supine. The treatment leg will be propped up comfortably on a footrest but draped and out of view from the patient. A 34-gauge needle electrode will be inserted at a 60-degree angle 5 cm cephalad to the medial malleolus and slightly posterior to the tibia. A PTNS surface electrode will be placed on the ipsilateral calcaneus as well as 2 inactive sham surface electrodes, 1 under the little toe and 1 on the top of the foot. When the PTNS lead set is connected to the Urgent PC stimulator, a current level of 0.5 to 9 mA at 20 Hz is selected based on each patient's foot and plantar motor and sensory responses. Treatment lasts 30 minutes and given once weekly for 12 consecutive weeks.
224236469|NCT02295956|OTHER|Exercise|Participants instructed to perform resistance/strengthening exercises for 30 minutes two times each week. Participants to walk 20-30 minutes at least 3 times a week. Participants issued a set of 3 resistance exercise bands with which the exercises can be performed.
224236470|NCT02295956|OTHER|Nutrition Counseling|Within 7 days after being enrolled on study, participant meets with a dietitian to discuss nutrition.
224320807|NCT05422625|DEVICE|Sham PTNS Treatment|"Patients will be positioned similarly as PTNS patients. A Streitberger needle will be used at the tibial nerve insertion site as described above to simulate needle placement. Three electrodes will be placed on the patient's foot, two active TENS electrodes and one inactive TENS electrode. The TENS grounding pad will be a gel electrode pad from a TENS unit device that is placed on the bottom of the foot just below the smallest toe. Another gel electrode will be placed on the top of the foot just above the small toe for conduction. These two electrodes will be connected to the TENS unit lead wires for sham stimulation. A third, inactive, gel electrode, will be placed near the medial aspect of the calcaneus to mimic the PTNS treatment. The TENS electrode will be connected by lead wires to the TENS unit set at 20 HZ. The TENS unit will be turned on and stimulation slowly increased to the patient's first sensory level and then turned off."
224320808|NCT03205527|OTHER|Overground slip perturbation training|Slips will be induced by a low-friction platform (65×30×0.6 cm, μ\<0.05) embedded side-by-side in the walking path, set nearly flush with the floor surround. The moveable platform, mounted on top of a pair of force platforms (AMTI, Newton, MA) for measuring ground reaction forces is firmly locked in a stationary position. An unannounced release occurs at heel strike of the perturbed, without the knowledge of subject, after which the platform is free to slide up to 150 cm. The mechanical release is controlled by the loading on the force platforms and the computer.
223652145|NCT06858306|DEVICE|Sphere-9™ Catheter and Affera™ Ablation System|De novo pulmonary vein isolation procedure using commercially available Sphere-9™ Catheter and Affera™ Ablation System
223652146|NCT06990269|DRUG|ADX-038|siRNA duplex oligonucleotide
223652147|NCT06990269|DRUG|Placebo|Saline
223652148|NCT06011551|DEVICE|The ReGelTec HYDRAFIL™ System|The ReGelTec HYDRAFIL System is designed to deliver an injectable hydrogel implant (the HYDRAFIL implant) for the treatment of a degenerative lumbar disc.
224236471|NCT02295956|BEHAVIORAL|Phone Calls|Participants receive phone calls from study staff every 2 weeks for 6 weeks to check for adherence, and if they are having any side effects from the exercise.
223652149|NCT06011551|OTHER|Conservative Care Management|Conservative care management (including physical therapy and/or pain medication)
223652150|NCT05909904|DRUG|Tislelizumab|Administered intravenously
223652151|NCT05909904|DRUG|BGB-A425|Administered intravenously
223652152|NCT05909904|DRUG|LBL-007|Administered intravenously
223652153|NCT05446272|DEVICE|NIV-NAVA|Infants in the intervention arm will be managed with non-invasive neurally adjusted ventilatory assist (NIV-NAVA) using FDA-approved servos with associated FDA-approved Edi catheter.
223652154|NCT05446272|DEVICE|NS-NIPPV|Infants in the active comparator arm will be treated with non-synchronized non-invasive positive pressure ventilation (NIPPV) through FDA-approved ventilators currently in use at each site.
223652155|NCT03892967|OTHER|Interview|Participate in interview
223652156|NCT03892967|OTHER|Quality-of-Life Assessment|Ancillary studies
224236472|NCT02295956|OTHER|Booklet|Exercise instructional booklet given to all participants describing all exercises.
224236473|NCT03672110|DRUG|Advagraf|intervention: different advagraf dosing in the study compared to the control arm, see above
224236474|NCT06434285|OTHER|Questionnaire development|Cognitive interviewing group will be run to inform questionnaire development.
224236475|NCT05754047|DIAGNOSTIC_TEST|immunohistochemistry (IHC) and in situ hybridization (ISH) Test|These tests are usually applied for breast cancer patients to assist the surgeon to better understand the clinicopathological characteristics and survival features of tumors
223652157|NCT03892967|OTHER|Questionnaire Administration|Ancillary studies
223767351|NCT00649337|PROCEDURE|Comparison of Automated Whole Breast Ultrasound Screening with Blinded Screening Mammography|"AWBU is a computer-based system for performing and recording ultrasound scans of the whole breast. The transducer of any suitable high-resolution compound ultrasound equipment is attached to a mechanical arm guided by computer, and images are acquired in longitudinal rows, overlapping to assure complete coverage. The mechanical arm controls transducer speed and position, with a technician maintaining appropriate contact pressure and orientation vertical to the skin. Approximately 150-300 images per row are immediately displayed on the AWBU monitor, then permanently stored.~The AWBU software creates a continuous ciné loop of the images, creating the appearance of real-time scanning. With spatial registration, any point on an image can be identified as a distance from the nipple in a specific radius. Image review is optimized by playback on a high-resolution monitor to allow compressed image size, 3-D reconstruction, and adjustment of contrast, brightness and review speed."
224236476|NCT03203915|DIETARY_SUPPLEMENT|Chardonnay grape marc marc high polyphenol dose (120mg)|3 prepackaged capsules taken once in the morning with meal for 3 weeks. The total dose will be 120mg of total polyphenols
224236477|NCT03203915|DIETARY_SUPPLEMENT|Chardonnay grape marc powder low polyphenol dose (75mg)|3 prepackaged capsules taken once in the morning with meal for 3 weeks. The total dose will be 75mg of total polyphenols
224236478|NCT03203915|DIETARY_SUPPLEMENT|Placebo (0mg)|3 prepackaged capsules taken once in the morning with meal for 3 weeks. The total dose will be 0mg of polyphenols
224236479|NCT03388320|DEVICE|A-CHESS|Use of smartphone application: Addiction Comprehensive Health Enhancement Support System (A-CHESS)
224320809|NCT06010628|DRUG|Tenecteplase|intravenous tenecteplase (0.25 mg/kg, a single bolus over 5 to 10 seconds, a maximum of 25 mg).
224236480|NCT05901948|OTHER|Classification|Novel Asherman Scoring Classification
224320810|NCT05083416|BEHAVIORAL|Prolonged Nightly Fasting|Limiting daily period of food intake to 10 hours and nightly fasting period to 14 hours.
224320811|NCT05083416|BEHAVIORAL|Regular Eating pattern|Food intake not limited to a specific time during day/night.
224320812|NCT04188678|OTHER|Bone Marrow Transplant (BMT)|Bone marrow transplantation will be conducted according to the investigators' institution's standard of care, or else according to research protocol (if applicable).Study visits that include the performance of assessments will occur prior to the start of conditioning chemotherapy and at 1 month and 6 months post-BMT. All dates are +/- 7 days. The initial study visit will take place during standard of care pre-transplant evaluations, which typically span 3-4 days. The post-BMT visits will take place before or after regularly-scheduled BMT follow up.
223652158|NCT04917757|DIAGNOSTIC_TEST|1mg Dexamethasone test|For each patient a 1mg dexamethasone test has been performed.
223652159|NCT06595680|DRUG|Medialipide 20% perfusion|Each patient will receive during a 4 hours hemodialysis session a perfusion of Medialipide 20% at a rate of 0,11 g/kg/h. Medialipide will be perfused using the venous line connected to the hemodialysis machine.
223652160|NCT06595680|DRUG|NaCl 0,9%|Each patient will receive during a 4 hours hemodialysis session a perfusion of NACL 0,9% with a volume corresponding to the one of Medialipide 20%. NaCl 0,9% will be perfused using the venous line connected to the hemodialysis machine.
223652161|NCT06595680|BIOLOGICAL|Blood sample|Serial biological sampling for the measurement of different blood concentrations : electrolytes, serum protein , albumin, renal function (urea, creatinine), hemoglobin, hematocrit, liver test, lipid test, ketone bodies, 6 uremic toxins (including IS and p-CS), sodium octanoate and decanoate.
223652162|NCT06861049|DIETARY_SUPPLEMENT|Psychobiotic Supplement|Lactobacillus helveticus R0052 Bifidobacterium bifidum R0071 Bifidobacterium longum R0175
223652163|NCT06861049|DIETARY_SUPPLEMENT|Placebo Supplement|Maltodextrin
223652164|NCT03708003|DRUG|Ibrutinib|"Patients receive 6 cycles (cycle = 28 days) of ibrutinib monotherapy at the daily dose of 420 mg (3x 140 mg).~Venetoclax is added on ibrutinib treatment starting from cycle 7 as weekly dose ramp-up (20 mg, C7 day 1-7; 50 mg, C7 day 8-14; 100 mg, C7 day 15-21; 200 mg, C7 day 22-28; 400 mg, C8-31 day 1-28).~Venetoclax (400 mg d1-28) and ibrutinib (420 mg d1-28) continue until cycle 31. Depending on MRD-neg CR/CRi patients will continue the combination treatment (maintenance) or stop treatment (observation) up to 5 years after cycle 31."
223652165|NCT03708003|DRUG|Venetoclax|"Venetoclax is added on ibrutinib treatment starting from cycle 7 as weekly dose ramp-up (20 mg, C7 day 1-7; 50 mg, C7 day 8-14; 100 mg, C7 day 15-21; 200 mg, C7 day 22-28; 400 mg, C8-31 day 1-28).~Venetoclax (400 mg d1-28) and ibrutinib (420 mg d1-28) continue until cycle 31. Depending on MRD-neg CR/CRi patients will continue the combination treatment (maintenance) or stop treatment (observation) up to 5 years after cycle 31."
223652166|NCT06863220|OTHER|Intravesical Ozone Therapy|Patients received 50 mL ozonated saline (20-40 µg/mL) intravesically twice weekly for 3 weeks.
223652167|NCT06863220|OTHER|Placebo (Normal Saline)|Patients received 50 mL normal saline intravesically twice weekly for 3 weeks.
223652168|NCT06863220|OTHER|Control|Patients continued standard care (e.g., oral pentosan polysulfate) without intravesical intervention.
223652169|NCT00114517|DRUG|17B-estradiol|Oral 17B-estradiol 1 mg daily
223652170|NCT00114517|OTHER|Placebo|Matching oral 17B-estradiol placebo daily
223652171|NCT03669341|OTHER|Deep Inspiration Breath Hold (DIBH)|human-based DIBH method with short-term breath-hold training
223652172|NCT03669341|OTHER|High Frequency Percussive Ventilation (HFPV)|device-based HFPV technique
223652173|NCT06599918|DRUG|Nicotinamide|Administration of NAM on a variable dose depending on the participant's body weight. Administration is done orally, daily.
223652174|NCT06599918|DRUG|Placebo|Administration of placebo on a variable dose depending on the participant's body weight. Administration is done orally, daily.
223652175|NCT06530394|DIETARY_SUPPLEMENT|Greek yogurt|Whole food dairy products, such as Greek yogurt (GY), offer a high quality, nutrient-dense snack, high in bone-supporting ingredients, including protein, calcium, and phosphorus. These nutrients are crucial to the structural integrity and strength of bone, i.e., the collagen and hydroxyapatite matrices.
223652176|NCT05748600|DRUG|Dexpramipexole Dihydrochloride|administration of dexpramipexole tablet
223652177|NCT05748600|DRUG|Placebo|administration of placebo tablet
223652178|NCT00024622|DRUG|18F-Fluoro-L-dopa|
223652179|NCT00024622|DRUG|O-15 Water|
223652180|NCT07134660|PROCEDURE|Liposomal Bupivacaine intercostal nerve block|Ultrasound-guided intercostal nerve block with liposomal bupivacaine 266 mg (20 mL total; 4 mL per intercostal space at the incision and adjacent spaces), performed at the end of surgery before emergence from anesthesia. All patients receive standard postoperative analgesia with intravenous patient-controlled opioid analgesia.
223652181|NCT07134660|PROCEDURE|Bupivacaine Hydrochloride intercostal nerve block|Ultrasound-guided intercostal nerve block with 0.25% bupivacaine hydrochloride (20 mL total; 4 mL per intercostal space at the incision and adjacent spaces), performed at the end of surgery before emergence from anesthesia. All patients receive standard postoperative analgesia with intravenous patient-controlled opioid analgesia.
223652182|NCT07134660|OTHER|Standard Postoperative Analgesia|No intercostal nerve block. Patients receive standard postoperative analgesia consisting of an intravenous patient-controlled opioid pump per institutional protocol.
223652183|NCT07127432|DEVICE|The Storytelling Caterpillar|The Storytelling Caterpillar is a plastic toy measuring 19.5 × 5.5 × 25.5 cm and is recommended for use in children aged 1-6 years. It is designed in the form of a storybook and includes interactive f
223652184|NCT06675643|OTHER|Non-Interventional Study|Non-Interventional study
223652185|NCT07008469|DRUG|Del-desiran (AOC 1001)|Del-desiran will be administered by intravenous (IV) infusion.
223652186|NCT07129811|PROCEDURE|Stellate Ganglion Block|The stellate ganglion is located in front of the anterior tubercle of the C6 vertebra. An ultrasound-guided intervention will be performed from the affected side and 2 cc of 1% lidocaine will be injected.
223652187|NCT06347926|PROCEDURE|Questionnaires given before and after photobiomodulation|Questionnaires given at 1 month, 6 months and 12 months
223767352|NCT02214121|DRUG|Ticagrelor Dose 1a + Dose 2a|Ticagrelor Dose 1a and ticagrelor Dose 2a single doses + 1 week ticagrelor repeated dosing followed by 4 weeks repeated dosing ticagrelor or placebo.
223767353|NCT02214121|DRUG|Ticagrelor Dose 1b + Dose 2b|Ticagrelor Dose 1b and ticagrelor Dose 2b single doses + 1 week ticagrelor repeted dosing followed by 4 weeks repeated dosing ticagrelor or placebo.
223767354|NCT02615951|OTHER|blood sampling|Blood sample retrieval for biological and genetic analysis and comparison
223767355|NCT02459314|DIETARY_SUPPLEMENT|plant sterol and soluble fiber-enriched soymilk|Sterols compete with LDL-C for absorption in GI tract. A meta-analysis of 41 trials indicated that an intake of 2 g sterols/stanols reduces the LDL-C level by 10%. Additive effects occur when sterols are combined with statins; the combination being more efficacious than a 2 times up-dosing of statins alone. Soluble dietary fibers also have significant cholesterol lowering effects. In a meta-analysis, Brown et al estimate that a daily soluble fiber intake ranging from 9-30 g/d, were associated with 10.6% reduction in LDL-C levels.
223767356|NCT02459314|DIETARY_SUPPLEMENT|soymilk|Soy protein is another LDL-C and total cholesterol lowering food. A meta-analysis by Reynolds K et al. discovered that volunteers receiving 20 to more than 61 g of soy protein had reductions in total cholesterol by 5.26 mg/dL (95% CI -7.14 to -3.38), and LDL-C by 4.25 mg/dL (95% CI -6.00 to -2.50), with an increase of HDL-C by 0.77 mg/dL (95% CI 0.20 to 1.34). Reductions in LDL cholesterol were larger in hypercholesterolemic than in normocholesterolemic subjects.
223767357|NCT00715793|DRUG|Decitabine|"In Part I patients will be treated on a standard 3+3 phase I dose-escalation design starting at 0.075 mg/kg until a decitabine dose level of 0.15 mg/kg is reached, or, in case unacceptable toxicities are observed, at the maximum tolerated dose (Phase II recommended dose). Decitabine will be administered at the specified dose level, intravenously, daily 5 days a week for the first 2 weeks of a 6-week cycle."
223767358|NCT00715793|DRUG|Temozolomide|Temozolomide is available in 25 mg and 100 mg tablets that will be administered orally; doses will be rounded to the nearest 25 mg. Temozolomide will be administered orally at 75 mg/m2 daily for 4 weeks starting on week 2 of a 6-week cycle.
223767359|NCT00715793|PROCEDURE|biopsy|Fine needle aspirates (FNA) and/or core biopsies of tumor samples will be obtained from consenting patients with accessible, evaluable disease, on days 1, 8, 15, and 29 of the first cycle and when patients go off study. Biopsies are optional in Phase I and required for all consenting subjects in Phase II.
223767360|NCT00000327|DRUG|Heroin Dependence|
223767361|NCT02903667|DEVICE|Bone grafting|
223767362|NCT02423941|PROCEDURE|Retrogade reperfusion|Retrogade caval reperfusion of the donor liver during the transplant procedure with consequent arterial reperfusion.
223767363|NCT02423941|PROCEDURE|Antegrade reperfusion|Antegrade conventional portal reperfusion of the donor liver during the transplant procedure with consequent arterial reperfusion.
223767364|NCT00835497|DRUG|5 mg/500 mg Glipizide Metformin Hydrochloride Tablets|1 x 5 mg/500 mg, single-dose fasting
223767365|NCT00835497|DRUG|5 mg/500 mg METAGLIP™ Tablets|1 x 5 mg/500 mg, single-dose fasting
223767366|NCT03033797|DEVICE|MoviLetrando|Half of the participants will play two different levels of the Game MoviLetrando, two minutes each.
223767367|NCT03033797|DEVICE|MoveHero|Half of the participants will play 2 minutes of the game MoveHero.
223767368|NCT03244306|BIOLOGICAL|Patient-derived CD22-specific CAR T-cells also expressing an EGFRt|Patient-derived CD22-specific chimeric antigen receptor T-cells expressing an EGFRt
223767369|NCT04988685|DEVICE|Sirolimus Eluting Balloon|PTCA with either a Sirolimus eluting balloon or Paclitaxel eluting balloon
223767370|NCT03894059|OTHER|Educational Intervention|Additional training provided to ambulance telecommunicators in participating sites to help increase recognition of agonal breathing in the presence of out-of-hospital cardiac arrest.
223767371|NCT06538688|PROCEDURE|Orthodontic extrusion of the impacted mandibular third molar by using the maxillary miniscrew and cross arch elastic power chain as a temporary anchorage device before extraction|Orthodontic extrusion of the impacted mandibular third molar of high-risk for nerve injury using maxillary TAD.
223767372|NCT02961699|DEVICE|Transpose ® RT System|adipose-derived stem cell therapy
223767373|NCT02961699|OTHER|debridement/dressing of wound|standard of care debridement and wound dressing
223767374|NCT05700552|BEHAVIORAL|skin to skin contact|For skin-to-skin contact (TTT), the newborn is placed naked on the mother's bare chest in the prone (prone) position, the newborn's abdomen and chest are in contact with the mother's skin, and the newborn's head is turned to the side so that the airway remains open.
223767375|NCT01889017|OTHER|patient questionnaire (tablet pc based)|
223652188|NCT05038098|PROCEDURE|Gastrectomy|Undergo surgery
223652189|NCT05038098|DRUG|Indocyanine Green|Given peritumorally
223652190|NCT05038098|OTHER|Iron Conjugated Polymers in Saline Suspension|Given peritumorally
223652191|NCT03578783|DRUG|Placebo|"For each sexual encounter during the 4-week treatment period the study spray will be applied 5 minutes before intercourse and any excess will be wiped off prior to penetration.~Study subjects should leave at least 24 hours between each dosing."
223652192|NCT03578783|DRUG|PSD502|"For each sexual encounter during the 4-week treatment period the study spray will be applied 5 minutes before intercourse and any excess will be wiped off prior to penetration.~Study subjects should leave at least 24 hours between each dosing."
223652193|NCT03644511|DRUG|Regorafenib (Stivarga, BAY73-4506)|Prescribed by physician.
223652194|NCT03644511|DRUG|Sorafenib (Nexavar, BAY43-9006)|Prescribed by physician.
223652195|NCT04549298|OTHER|No interventions|No interventions - observational study
223652196|NCT03543917|COMBINATION_PRODUCT|Perfusion with New Combination Medication|Intravenous administration of Actovegin, vitamins B1, B6, B12, C, oxytocin/dexamethasone, calcium gluconate, etc in 250 ml normal saline administered during approximately 2 hours
223652197|NCT07013747|BIOLOGICAL|Acne mRNA vaccine|Pharmaceutical form: suspension for injection Route of administration: intramuscular
223767376|NCT03833284|BEHAVIORAL|Participant Barriers to TVU Screening|Workshops tailored toward patients to increase knowledge about TVU screening guidelines and benefits.
223767377|NCT03833284|BEHAVIORAL|Provider Barriers to TVU Screening|Workshops tailored toward providers to increase knowledge about TVU screening guidelines and benefits.
223767378|NCT01849588|DRUG|Sorafenib|
223767379|NCT00237588|DRUG|Amlodipine 10 mg or Losartan 100 mg + Amlodipine 5 mg|
223767380|NCT03718611|DRUG|BR9001|BR9001 is a test drug as generic
223767381|NCT03718611|DRUG|BR900A|BR900A is a reference drug
223652198|NCT07013747|OTHER|Placebo|Pharmaceutical form: liquid solution for injection Route of administration: intramuscular
223767382|NCT03906318|DRUG|Iticitinib|
223652199|NCT06623292|OTHER|Motivational interviewing-based breastfeeding education|This program includes breastfeeding motivational interviewing consisting of a total of 4 sessions and breastfeeding education consisting of one session.
223652200|NCT06691035|DRUG|Elacestrant|"345 mg (or 86 mg tablets) orally daily during vaccination and continued after until progression.~Cycle Length 28 days (4 weeks)"
223652201|NCT06691035|BIOLOGICAL|DC1 native/mutated ESR1|"2.0-5.0 x 10 (20-50 million) cells (Injections in groin nodes (or accessible breast tumor if available) weekly with DC1 for eight consecutive weeks, alternating between native ESR1 DC1s and mutated ESR1 DC1s.~Mutated ESR1 DC1s on week 1 followed by native ESR1 DC1s on week 2, alternating during the initial vaccination series and the subsequent booster phase.~Pulsed DC1 will be administered after initial induction every four weeks x 3 doses."
223767383|NCT05012605|OTHER|Observation|Observe physical function and sleep disorder symptoms following stroke
223767384|NCT05216367|DRUG|Fruquintinib|Fruquintinib will be administered as a single oral dose on the morning of day 1 under fasting conditions
223767385|NCT00554749|BEHAVIORAL|Interventions at home, in the kindergarten/school|Weekly interventions including behavior techniques (stimulus fading)
224236481|NCT05428722|BEHAVIORAL|deep breathing exercises with a incentive spirometer|Deep breathing exercise will be explained to the patients with an incentive spirometer (IS), it will be demonstrated in practice and it will be applied from the first day of hospitalization in addition to routine treatment and care. The patient will be informed about whether they are doing it right and their questions will be answered. It will be ensured that the patients start after breakfast in the morning and make 5-10 inspirations, hold her/his breath for 3 seconds and 5-10 expirations per hour with IS until they fall asleep. The research nurse will warn the patients that they should do the exercise every hour, and the alarms of the patients' mobile phones will be set to ring every hour to be a warning. The start and end time of the exercise will be decided together with the patient, and usually the time of waking and going to bed will be taken into account.
224236482|NCT00082563|DRUG|Azithromycin/Chloroquine|
223767386|NCT03417141|DRUG|Mechlorethamine 0.016% Top Gel|Valchlor, a 0.016% gel formulation of mechlorethamine. Once daily application of Valchlor in decreasing disease activity in patients with Lichen Planopilaris.
223767387|NCT00401336|DEVICE|Magnetic resonance imaging multiecho gradient-echo sequence|Breath-hold gradient echo sequences with a single echo and a new multiple-echo gradient-echo sequence
223767388|NCT05755828|BIOLOGICAL|ASCT+CAR-T Cell Infusion|CD19 CAR-T cells were prepared from peripheral lymphocytes of NHL patients with PR after 3 to 4 courses of chemotherapy, and autologous stem cells were collected and frozen after mobilization of patient stem cells by granulocyte stimulating factor (10μg/kg/d\*5d). BEAM pretreatment was performed. Autologous stem cells were injected 24 h after pretreatment, and the number of CD34+ cells was \> 2\*106/kg. On the 6th day after transplantation, autologous Anti-CD19 CAR T cells were transfused, and the dose was determined by the investigator according to the subjects' own disease conditions and in vitro preparation. The patients were given constant intravenous drip/push infusion for 30 minutes.
224236483|NCT00082563|DRUG|Chloroquine|
224236484|NCT03597490|COMBINATION_PRODUCT|Multimodal physical therapy with exercise|Multimodal physical therapy will compose of thermotherapy (hot pack or cold pack) and electrotherapy (transcutaneous electrical nerve stimulation or interferential current) and therapeutic ultrasound (at least two of them). Therapeutic exercise will compose of combination of range of motion, stretching, strengthening,neuromuscular and task specific exercises according to the clinical condition of patient under the supervision of a physiotherapist. Additionally, all patients will be allowed to carry on home exercise program.
223652202|NCT06203132|DRUG|Doravirine + tenofovir DF + lamivudine|Oral administration
223652203|NCT06203132|DRUG|Dolutegravir + tenofovir DF + lamivudine or emtricitabine|Oral administration
223652204|NCT07022743|DRUG|Imatinib|Imatinib is a first-line tyrosine kinase inhibitor which is used in the management of chronic myeloid leukaemia. It will be used by all the patients in the 3 arms of the study (Groups A, B and C)
223652205|NCT07022743|DRUG|Artesunate|Artesunate has been established to reverse resistance to some chemotherapeutic agents. patients in 2 arms of the study (Groups B and C) will be given artesunate at 4mg/kg (not exceeding 200mg daily) in combination with imatinib
223652206|NCT07022275|DIETARY_SUPPLEMENT|Hemp protein powder|Agoge Universal Hemp Protein Powder - A certified cannabinoid-free hemp protein powder.
223652207|NCT06325813|DEVICE|Active repetitive TMS|In this study, ADHD children will receive two trains of intermittent theta burst stimulation. Intermittent theta burst stimulation is a form of repetitive TMS. Both iTBS trains will be active stimulation using the active TMS coil.
223652208|NCT06325813|DEVICE|Sham repetitive TMS|In this study, ADHD children will receive two trains of intermittent theta burst stimulation. Intermittent theta burst stimulation is a form of repetitive TMS. The first iTBS train will be sham stimulation using the sham TMS coil. The second iTBS train will be active stimulation using the active TMS coil.
223652209|NCT06223373|DEVICE|Blood Flow Restriction|In the BFR group, the tourniquet will be pressurized to 50% limb occlusion pressure (LOP), which is the pressure necessary for occluding 50% of arterial limb flow in the upper extremity.
223652210|NCT06223373|DEVICE|"sham Blood Flow Restriction"|In the sham BFR group, the tourniquet will be pressurized to 0% occlusion pressure, while maintaining enough pressure to keep the tourniquet in place.
223652211|NCT03632473|DIAGNOSTIC_TEST|multimodal evoked potentials (mmEP)|combination of visual evoked potentials (VEP) and motor evoked potentials (MEP) or the combination of VEP, MEP and somato-sensory evoked potentials (SSEP)
224236485|NCT05993156|DEVICE|modified Fixed twinblock|modified fixed twin block functional appliance, with cemented bands on the first molars
223652212|NCT06872775|OTHER|Blood draws to assess RNA expression levels|None. Standard of Care (SOC) only.
223652213|NCT06874205|DRUG|11C-JMJ-129|Injected IV followed by PET scanning
223652214|NCT06217640|DIAGNOSTIC_TEST|Dual X Ray Absorptiometry|"* Dual X Ray Absorptiometry in the combination with functional tests~* Near-infrared spectroscopy in combination with hand grip strength"
224236486|NCT05993156|DEVICE|removable twin block|Conventional Removable Clark twin block myofunctional appliance
224236487|NCT03943056|DRUG|BIIB091|Administered as specified in the treatment arm.
224236488|NCT03943056|DRUG|Placebo|Administered as specified in the treatment arm.
224320813|NCT05338528|BEHAVIORAL|BE-FIT exercise program|BE-FIT is an evidence-based exercise program that focuses on early mobilization and recovery by minimizing bed rest, promoting functional tasks, and encouraging self-management. The intervention ist based on the Mobilization of Vulnerable Elders (MOVE) program and consists of a bedside exercise plan, done independently by the patient without the need for additional rehabilitation or healthcare staff.
224320814|NCT05792020|DEVICE|Focused Ultrasound Stimulation|This aim will test whether motor tFUS parameters thought to be excitatory (50% duty cycle) vs. inhibitory (5% duty cycle) elicit their predicted effects on MEPs before and after each of three stimulation blocks, using 50 MEPs at each time point.
223767389|NCT06167395|DIETARY_SUPPLEMENT|Beta Alanine high dose|Subjects should consume 4 intakes of 5 g of beta alanine every 3 hours each day.
223767390|NCT06167395|DIETARY_SUPPLEMENT|Beta Alanine low dose|Subjects should consume 4 intakes of 2,5 g of beta alanine every 3 hours each day.
223767391|NCT06167395|DIETARY_SUPPLEMENT|Control product|Subjects should consume 4 intakes of 2,5 g of wheat semolina every 3 hours each day.
223767392|NCT04249804|DRUG|Magnesium Sulfate 1000 MG|intrathecal versus IV infusion of Magnesium sulfate for prevention of postspinal shivering
224236489|NCT03313609|BEHAVIORAL|Investigating Burnout in Intensive Care in Middle Incoming Turkey|single-group studies
224236490|NCT04023409|OTHER|NA: no intervention|NA: no intervention
224236491|NCT03437083|DRUG|Eribulin mesylate|intravenous infusion
224236492|NCT03992196|DRUG|Rotigotine 1 mg/24 h|Pharmaceutical Form: transdermal patch Route of administration: transdermal use Concentration: Application of rotigotine transdermal patch with 1 mg/24 h (5 cm\^2 patch size).
224236493|NCT03992196|DRUG|Rotigotine 2 mg/24 h|Pharmaceutical Form: transdermal patch Route of administration: transdermal use Concentration: Application of rotigotine transdermal patch with 2 mg/24 h (10 cm\^2 patch size).
224236494|NCT03992196|DRUG|Rotigotine 3 mg/24 h|Pharmaceutical Form: transdermal patch Route of administration: transdermal use Concentration: Application of rotigotine transdermal patch with 3 mg/24 h (15 cm\^2 patch size).
224236495|NCT00048048|DRUG|methoxy polyethylene glycol-epoetin beta [Mircera]|Differing doses and frequencies of sc administration
224236496|NCT05919966|OTHER|Chlorhexidine bathing|The procedure involved pouring an entire bottle (200ml) of 2% CHG solution (PBF Biotech, Taipei, Taiwan) onto a pre-packed set of eight single-use cotton wipes before each bathing session. A minimum of six wipes were required to thoroughly cover the entire body, including the bilateral upper and lower extremities, front and back of the trunk, perineum, and buttocks.
224236497|NCT02684578|DRUG|Metformin|
224236498|NCT06056869|DRUG|hyoscine butylbromide|will be given during first stage of labor intravenously
224236499|NCT06056869|OTHER|normal saline|placebo
224236500|NCT00733330|DEVICE|Either P.F.C. Sigma or L.C.S. Complete knee replacement using the conventional surgical approach and manual surgical technique|Orthopaedic implants for total knee replacement implanted with a standard approach using standard instrumentation
224236501|NCT00733330|DEVICE|Either P.F.C. Sigma or L.C.S. Complete knee replacement using minimally invasive surgical approach and computer navigation|Orthopaedic implants for total knee replacement implanted with a minimally invasive approach and computer navigation
224236502|NCT00309972|DRUG|Control arm (SEQ):|Four cycles of cisplatinum/vinorelbine given in a 21 day cycle followed by radical radiotherapy, 55 Gy in 20 once daily fractions in four weeks (2.75 Gy/day).
224320815|NCT02721459|DRUG|XL888|"Level 1: XL888 30 mg by mouth (PO) twice weekly (BIW). Level 2: XL888 45 mg PO BIW.~Level 3: XL888 60 mg PO BIW. Level 4: XL888 90 mg PO BIW."
224320816|NCT02721459|DRUG|Vemurafenib|Vemurafenib 720 mg by mouth twice a day (BID)
223652215|NCT04087109|OTHER|Electronic decision support for deprescribing (MedSafer tool)|During the intervention phase, MedSafer will provide users with individualized and prioritized deprescribing opportunities: a) identifying the medication, b) explaining why that medication is potentially inappropriate and c) providing instructions on how to safely stop/taper the medication. The user will review these opportunities and appropriate candidate medications for deprescribing can then be tapered or stopped directly in the EMR. Patients or proxy will also receive educational medications brochures (EMPOWER) from the research assistant or staff at the nursing home, as applicable to the medications they are taking (PPI, sedative-hypnotic, antipsychotic, antihistamine, sulfonylurea, NSAID, opioid/narcotic).
223767393|NCT04099667|DRUG|Phase 2; Low Dose MYOBLOC|Intramuscular injections on Day 1
223767394|NCT04099667|DRUG|Phase 2; High Dose MYOBLOC|Intramuscular injections on Day 1
223652216|NCT07031765|BIOLOGICAL|exHSC|Ex vivo expanded CD34+ hematopoietic stem cells (exHSCs) at a targeted dose of 2.5 x 106 cells/kg (or maximal achievable dose, with a minimum deliverable dose of 1/10 target dose; max dose 1.0 x 108 total cells for patients ≥40kg).
224236503|NCT00309972|DRUG|Experimental arm (CON):|concurrent chemo-radiotherapy \[55 Gy in 20 daily fractions in 4 weeks (2.75 Gy/day) with cisplatinum given concurrently with fractions 1-4 and 16-19, and vinorelbine prior to fractions 1, 6, 15 and 20\] followed by two cycles of cisplatinum/vinorelbine.
224236504|NCT02388763|DEVICE|Stenfilcon A contact lenses|Contact lenses worn during Period 1 or 2, as randomized
224236505|NCT02388763|DEVICE|Narafilcon A contact lenses|Contact lenses worn during Period 1 or 2, as randomized
224236506|NCT01434108|DRUG|Ornithine-phenylacetate|"Phase A: Open-label scalating dose of OP. Treatment will be initiated at 1/3 of the final dose and will be scalated every 12 hours up to the full dose, except if there are problems of tolerance. Duration of the infusion 5 days.~Phase B: Comparative study of experimental drug vs placebo for 5 days OP (OCR-002) at a dose of 10 g diluted in 150 ml of water for injection administered as a continuous i.v. infusion for 24 hours (8.3 ml/h)during 5 days."
224236507|NCT04630938|DRUG|Morphine Sulfate|intrathecal morphine will be added to anaesthetics
224236508|NCT04630938|DRUG|morphine+lidocaine|local anesthetic will be infused intravenously
224236509|NCT04630938|DRUG|Saline|intravenous saline infusion
224236510|NCT04051970|DRUG|Antiretroviral|"Antiretroviral treatments (ART) will be allocated through central randomization (1:1:) according to the following two strategies:~Tritherapy-Bitherapy (TRI-BI) strategy:~TRI between D0 and W16: 3-drug combination (3-DR) including 2 NRTI (either TDF or TAF+XTC) and a once daily integrase inhibitor (Stribild® or Genvoya® or Biktarvy®) or TDF/XTC Gé + Tivicay® or TDF/XTC Gé + Isentress® QD 1200 mg when available) during 16 weeks BI between W16 and W96: if pVL viral load \<500 cp/mL at W4 and \<50 cp/mL at W12, participants will start the 2-DR regimen TDF or TAF / XTC (TDF/XTC Gé or Descovy®) at W16, until W96.~(Descovy® : provided that it is available in France), (XTC = FTC or 3TC)~Immediate Bitherapy (BI) strategy Dolutegravir (DTG, Tivicay® 50 mg QD) plus lamivudine (3TC, 300 mg QD) between D0 and W96.~Antiretroviral drugs will be prescribed in the context of standard of care."
224236511|NCT03916952|DIAGNOSTIC_TEST|Six Minute Walk Test|The patients walked as far as possible for 6 minutes--over two separate trials. In one trial, an examiner walked with the participant. In the second trial, the participant walked independently. A paired T test was performed to see if there was a significant difference in the distance walked or gait speed between the trials.
224236512|NCT03561142|RADIATION|Radiotherapy|Radiotherapy: 28 x 1.8 Gy (total: 50.4 Gy), 5 fractions per week on day 1- 38
224236513|NCT03561142|DRUG|Chemotherapy|chemoradiotherapy is started according to the following schedule: 5-FU: 250 mg/sqm per day, iv, on day 1-14, day 22-35; Oxaliplatin: 50 mg/sqm, day 1, 8, 22, and 29. After a break of two and a half weeks, patients receive three chemotherapy cycles, starting on day 57, 71 and 85, consisting of: Folinic acid: 400 mg/sqm, 2h-iv; Oxaliplatin: 100 mg/sqm, 2h-iv; 5-FU: 2400 mg/sqm, 46h-iv
224236514|NCT03561142|OTHER|Deep regional hyperthermia|"Deep regional hyperthermia to the pelvis, total time 90 min, target temperature 41-42°C. Twice weekly, up to a total of 10 sessions within d1 and d38.~Deep regional hyperthermia is offered at the centers in Tübingen and Erlangen."
223652217|NCT07031765|DRUG|Nivolumab|Nivolumab 3mg/kg once every 2 weeks, max dose 240mg. Nivolumab will be administered on day 1 and day 15 of each cycle for a total of 10 cycles. Nivolumab may continue for a total two years of therapy, at the discretion of the treating team.
223652218|NCT07031765|PROCEDURE|Resection or biopsy|Patients must be candidates for standard of care surgical resection or biopsy.
223652219|NCT06715670|DRUG|Zibotentan|Participant will receive 4 different single doses of zibotentan on Day 1 of each treatment period orally.
223652220|NCT07039136|OTHER|Virtual Reality Mirror Therapy|"Participants will be seated on a chair with back support, their feet in contact with the ground, and both arms placed on a table. Data from participants' right forearms will be collected using Leap Motion tracking. In the virtual reality environment, both the original and mirrored forearms will be displayed within the participants' field of view.~The mirror therapy session will consist of two 15-minute segments with a 10-minute rest period in between. Activities to be practiced during the session will include wrist flexion and extension, forearm pronation and supination, finger flexion and extension, finger opposition movements, squeezing a cloth, grasping a round object, wiping a table, and object manipulation. The therapy program will follow a progression from simple to complex and functional movements throughout the session. Each session will begin with basic exercises such as flexion and extension movements of the fingers, wrist, and elbow, with 10 repetitions for each movement."
223767395|NCT04099667|DRUG|Phase 2; Placebo|Intramuscular injections on Day 1
223767396|NCT04099667|DRUG|Phase 3; MYOBLOC|Intramuscular injections on Day 1
223767397|NCT04099667|DRUG|Phase 3; Placebo|Intramuscular injections on Day 1
224236515|NCT05339100|DRUG|Anifrolumab|Participants will receive SC doses anifrolumab via AI or APFS.
223767398|NCT05403554|DRUG|Biological NI-1801|Treatment will be administered in 28-day cycles for up to 12 months until disease progression, unacceptable toxicity, or Investigator/patient decision to withdraw study consent. Each subject will receive the assigned dose of NI-1801 on Cycle 1, Day 1. Subsequent doses will be given Q2W, which may be adjusted to every three weeks if recommended from the ongoing PK/PD model analysis.
223767399|NCT05403554|DRUG|NI-1801 in combination with anti-PD1 (Pembrolizumab)|In the combination with pembrolizumab cohort, the starting NI-1801 dose will be 300 mg. Pembrolizumab will be administered at the dosage of 400 mg every 6 weeks, in 4 cycles. Pembrolizumab will be administered as first drug; later, NI-1801 will be infused after 30 minutes.
224236516|NCT05339100|DEVICE|Autoinjector|Autoinjector will be use to administer single SC dose of anifrolumab.
224236517|NCT05339100|DEVICE|Accessorized Pre-Filled Syringe|Accessorized Pre-filled syringe will be use to administer single SC dose of anifrolumab.
224320817|NCT02721459|DRUG|Cobimetinib|Cobimetinib 40 mg by mouth once daily (QD). Administered 3 weeks on, 1 week off.
224320818|NCT02679144|DRUG|Difluoromethylornithine (DFMO)|Subjects will receive 730 Days of oral difluoromethylornithine (DFMO) at a dose of 750 mg/m2 ± 250 mg/m2 BID (strata 1, 2, 3, and 4) OR 2500 mg/m2 BID (stratum 1B) on each day of study.
224320819|NCT05541887|OTHER|Muscadine Wine Polyphenol|dealcoholized muscadine wine with alcohol content \<0.5% with addition of 50ppm of sodium metabisulfite for preservation
223652221|NCT07039136|OTHER|Conventional Mirror Therapy|Participants will be seated on a chair with back support, their feet in contact with the ground, and both arms placed on a table. The mirror therapy session will consist of two 15-minute segments with a 10-minute rest period in between. Activities to be practiced during the session will include wrist flexion and extension, forearm pronation and supination, finger flexion and extension, finger opposition movements, squeezing a cloth, grasping a round object, wiping a table, and object manipulation. The therapy program will follow a progression from simple to complex and functional movements throughout the session. Each session will begin with basic exercises such as flexion and extension movements of the fingers, wrist, and elbow, with 10 repetitions for each movement.
223652222|NCT07039136|OTHER|Sham Virtual Reality|Participants will experience pre-recorded virtual environments while seated and wearing a virtual reality headset, without interacting with the environment. The virtual reality application will be used for 10 minutes at the end of each session of conventional mirror therapy.
223652223|NCT07039591|DEVICE|Pro-type IVR|Women will test three non-medicated IVRs on two one-day clinic visits (two on the first day, one on the second day) by manipulating them, vaginally inserting each ring and then performing a controlled set of tasks simulating routine daily activities with the ring in the vagina.
223652224|NCT06722118|DRUG|Dexamethasone IV|IV-DXM 4mg/ml, injectable solution. Dosage of 0.25 mg/kg (maximum 5 mg per dose), prepared in a syringe of 5 to 10 ml and administered intravenously to the patient over 10 minutes every 6 hours. The treatment duration ranges from 6 hours (minimum of two doses: H0, H6) to 18 hours (maximum of four doses: H0, H6, H12, H18).
224236518|NCT05375175|OTHER|Hybrid Snack|"The intervention will consist of the administration of 20 g of the snack (produced by Fertinagro Company) that will be eaten at fasting in the morning. Participants will be fasting for 12 hours for solid or liquid food and more than 1 hour after ingestion of water. Blood samples will be obtained after venepuncture at 7:45 a.m. before eating snacks and 15, 30, 60, 90 and 120 minutes after it.~Hybrid snack: combination of legumes in the highest proportion and lean meat.~It will have the following composition:~Ingredients (%):~Chickpea flour 45.40% Natural emulsifier 0.40% Meat 15.50% Olive oil 1.00% Sunflower oil 4.00% Water 22.50% Onion powder 0.30% Garlic powder 0.20% Thyme 0.60% Tomato powder 10.00%"
223652225|NCT06722118|OTHER|Placebo|Placebo: 0.9% NaCl solution, prepared in a syringe of 5 to 10 ml and administered intravenously to the patient over 10 minutes every 6 hours. The treatment duration ranges from 6 hours (minimum of two doses: H0, H6) to 18 hours (maximum of four doses: H0, H6, H12, H18).
223652226|NCT06712797|BEHAVIORAL|Physical Activity (PA)|"Participants will receive a Fitbit (Inspire 3, Google LLC, Mountain View, CA, USA) to encourage and self-monitor Physical Activity (PA) using active minutes, which approximate moderate-to-vigorous PA.~Fitbits will be synced to a HIPAA-compliant platform created by Moffitt's Biostatistics and Bioinformatics Shared Resource (BBSR).~Study personnel will view active minutes to provide individualized feedback and encourage progression. Weekly feedback will encourage participants to increase active minutes by 10% until achieving ≥ 150 minutes to meet cancer prevention recommendations.~Participants who reach ≥ 150 active minutes will be encouraged to maintain or exceed recommendations."
223652227|NCT06712797|BEHAVIORAL|Nutrition (N)|"Participants will undergo counseling at baseline (T0) to address nutritional symptoms and provide targets for daily calories and protein following a Mediterranean diet. This diet includes a high intake of vegetables, legumes, fruits, and unsaturated fatty acids, low intake of saturated fatty acids, and a moderately high intake of fish.~Total caloric intake will be calculated. A standard breakdown of 40% carbohydrates, 30% fats and 30% protein will be used. Individuals will review this calculation during their office encounters and follow these values using the FitBit, application, which will adjust to their daily energy expenditure.~Additional counseling (in-person or via Zoom) will occur at baseline (T0) + 12 weeks to gauge progress toward calorie and protein targets, monitor weight change, and guide dietary changes.~Participants will log daily food intake and self-monitor progress toward calorie and protein goals."
223767400|NCT05403554|DRUG|NI-1801 in combination with paclitaxel|The experimental arm will receive the investigational drug NI-1801 at the P2RD every two weeks in combination with weekly administration of paclitaxel (80 mg/m\^2) over 4-week cycles. The control arm will be treated with weekly paclitaxel at the same regimen.
223767401|NCT05403554|DRUG|Paclitaxel|The control arm will be treated with weekly administration of paclitaxel (80 mg/m\^2) over 4-week cycles.
223767402|NCT00972803|DRUG|pistacia Mutica extract|The subjects were asked to use a mouthwash containing pistacia Mutica extract twice a day for 4 days.
223767403|NCT00972803|DRUG|Placebo|The subjects were asked to use a placebo mouthwash twice a day for 4 days.
223767404|NCT00972803|DRUG|Chlorhexidine|The subjects were asked to use a mouthwash containing Chlorhexidine twice a day for 4 days.
223767405|NCT04278534|OTHER|Educational Intervention|Complete radiation therapist-led education module using virtual reality
224236519|NCT05375175|OTHER|Meat snack|"The intervention will consist of the administration of 20 g of the snack (produced by Fertinagro Company) that will be eaten at fasting in the morning. Participants will be fasting for 12 hours for solid or liquid food and more than 1 hour after ingestion of water. Blood samples will be obtained after venepuncture at 7:45 a.m. before eating snacks and 15, 30, 60, 90 and 120 minutes after it.~Snack sausage:~Composed solely of meat from loin tape~It will have the following composition:~Ingredients (%):~Shoulder meat 4 mm 94.13% Low sodium salt 3.30% Maltodextrin 1.65% Spices 0.28% Natural dye 0.64%"
223767406|NCT04278534|OTHER|Educational Intervention|Receive the usual verbal and written education materials
223767407|NCT04278534|OTHER|Educational Intervention|Complete radiation therapist-led face-to-face education module
223767408|NCT04278534|OTHER|Survey Administration|Ancillary studies
223767409|NCT03214003|RADIATION|SIB|patients will recieve twice-daily radiotherapy by simultaneous integrated boosting technique concurrent with chemotherapy
223767410|NCT03214003|RADIATION|Standard|patients will recieve standard twice-daily radiotherapy concurrent with chemotherapy
223767411|NCT00153491|DRUG|artemether-lumefantrine|
223767412|NCT03697811|DRUG|DE-117 Ophthalmic Solution|Interventional treatment will be made with DE-117 Ophthalmic Solution 0.002% once daily in the evening for the duration of the 3 month treatment period.
223767413|NCT01313572|DRUG|Apadenoson SPECT-MPI|Apadenoson single bolus IV injection 100 or 150 ug
223767414|NCT01313572|DRUG|Adenosine SPECT-MPI|Single IV infusion for 6 minutes at a rate of 140 µg/kg body weight per minute
223652228|NCT06466421|DRUG|Fexofenadine|Fexofenadine 60 mg orally once daily for 3 months
223652229|NCT06466421|DRUG|Gabapentin|100 mg after each dialysis session (thrice weekly). Dose may be titrated after 2 weeks, according to response and tolerability, to 100 mg orally once daily for 3 months.
223652230|NCT06883344|DEVICE|Automated insulin delivery (AID) system|An AID system incorporates data from a continuous glucose monitor (CGM) to automatically adjust the amount of insulin delivered by an insulin pump via an algorithm that incorporates multiple factors, including predicted glucose level in the next 30-60 minutes, target glucose level, and recent insulin delivery.
223652231|NCT06883344|OTHER|Intravenous (IV) insulin|Variable rate IV insulin infusions are used in most labor/delivery units as the standard of care for glycemic management for pregnant people with T1D. A continuous rate of IV insulin is infused, with manual rate adjustments made based on current glucose level and hospital-specific protocols.
223652232|NCT05122455|DRUG|ASA|During the intervention phases, eligible patients will sequentially receive ASA 100 mg 1x/day + edoxaban 60 mg 1x/day for a period of 10 ± 2 days. Subsequently, ASA and edoxaban will be suspended and clopidogrel 75 mg once a day will be administered for 10 ± 2 days (washout period of the ASA). Subsequently, it will be associated with edoxaban 60 mg once a day to clopidogrel 75 mg once a day for 10 ± 2 days and, finally, only edoxaban 60 mg once a day for 10 ± 2 days will be administered. After the end of the interventions, the ASA 100 mg once a day will be restarted.
223652233|NCT05122455|DRUG|Clopidogrel|During the intervention phases, eligible patients will sequentially receive ASA 100 mg 1x/day + edoxaban 60 mg 1x/day for a period of 10 ± 2 days. Subsequently, ASA and edoxaban will be suspended and clopidogrel 75 mg once a day will be administered for 10 ± 2 days (washout period of the ASA). Subsequently, it will be associated with edoxaban 60 mg once a day to clopidogrel 75 mg once a day for 10 ± 2 days and, finally, only edoxaban 60 mg once a day for 10 ± 2 days will be administered. After the end of the interventions, the ASA 100 mg once a day will be restarted.
223652234|NCT05122455|DRUG|Edoxaban|During the intervention phases, eligible patients will sequentially receive ASA 100 mg 1x/day + edoxaban 60 mg 1x/day for a period of 10 ± 2 days. Subsequently, ASA and edoxaban will be suspended and clopidogrel 75 mg once a day will be administered for 10 ± 2 days (washout period of the ASA). Subsequently, it will be associated with edoxaban 60 mg once a day to clopidogrel 75 mg once a day for 10 ± 2 days and, finally, only edoxaban 60 mg once a day for 10 ± 2 days will be administered. After the end of the interventions, the ASA 100 mg once a day will be restarted.
223652235|NCT06890312|PROCEDURE|Administration of heparin after sheath insertion|Administration of heparin after sheath insertion
223767415|NCT06317805|DRUG|Generic treprostinil sodium + Standard of Care (Double Oral)|Treprostinil (prostacyclin analogue) solution for continuous subcutaneous (SC) or intravenous (IV) infusion (1 mg/ml; 2.5 mg/ml; 5 mg/ml; 10 mg/ml in 10 mL glass vial) will be administered by an infusion pump system and up-titrated to ≥40 ng/kg/min or to the maximum tolerated dose within 24 weeks. Further up-titration shall be performed until trial completion according to the discretion of the investigator.
223767416|NCT06317805|DRUG|Standard of Care - Double Oral|All patients will receive standard of care double oral background treatment consisting of one Phosphodiesterase type 5 inhibitor (i.e., tadalafil or sildenafil) and one Endothelin Receptor Antagonist (i.e. ambrisentan, bosentan or macitentan)
223767417|NCT03706690|DRUG|Durvalumab|Durvalumab 1500 mg every 4 weeks \[q4w\] intravenously \[iv\] until clinical progression/ deterioration or confirmed radiological progression.
223767418|NCT03706690|OTHER|Placebo|Matching placebo for infusion every 4 weeks iv until clinical progression/deterioration or confirmed radiological progression
223767419|NCT04450966|BEHAVIORAL|Computer-facilitated Screening and Brief Intervention|cSBI includes: 1) computer self-administered screening that adolescents complete prior to seeing their clinician, immediately followed by 2) computer-delivered brief psychoeducation on the health risks of substance use to prime patients for the clinician encounter, and 3) a Clinician Report Form with screen results and prompts that clinicians use to provide motivational interviewing-based individualized counseling during the visit.
223767420|NCT02098109|DRUG|XM02 Filgrastim|
223767421|NCT02098109|DRUG|Filgrastim|
223767422|NCT02098109|PROCEDURE|Apheresis|
223767423|NCT02098109|DRUG|Plerixafor|
223767424|NCT02098109|PROCEDURE|Stem Cell Transplant|
223767425|NCT04021264|DRUG|Ropivacaine-Sufentanil|Local anesthetic injection
223767426|NCT04021264|DRUG|Dextrose 5|Sham injection
223767427|NCT06232382|OTHER|Hypnosis audio|"* After informed consent was obtained and baseline assessment, patients will be randomly assigned to one of the three conditions in 20 minutes:~  1. Audio hypnosis (HYP)~ 2. Audio mindfulness (MM)~ 3. A control condition (a voice reading neutral text) These audios will be produced together with hypnotherapist in Thailand, psychiatrist and researchers.~* The randomization process will be performed using a computerized random sequence generator.~* The patient listens to Hypnosis audio recording through headphones in a private room.~* Participants will be blind to the study hypotheses.~* To keep the experimenter blind, the participants will not reveal what they hear in the audios.~* Pain intensity will be assessed both at pre- and post-session (5 minutes).~* Secondary outcomes will be assessed at pre- and post-session by the questionnaires (5 minutes).~* Post-session quality of sleep will be assessed by telephone interview 1 day after session."
223767428|NCT06232382|OTHER|Mindfulness meditation audio|"* After informed consent was obtained and baseline assessment, patients will be randomly assigned to one of the three conditions in 20 minutes:~  1. Audio hypnosis (HYP)~ 2. Audio mindfulness (MM)~ 3. A control condition (a voice reading neutral text) These audios will be produced together with hypnotherapist in Thailand, psychiatrist and researchers.~* The randomization process will be performed using a computerized random sequence generator.~* The patient listens to Mindfulness Meditation audio recording through headphones in a private room.~* Participants will be blind to the study hypotheses.~* To keep the experimenter blind, the participants will not reveal what they hear in the audios.~* Pain intensity will be assessed both at pre- and post-session. (5 minutes)~* Secondary outcomes will be assessed at pre- and post-session by the questionnaires. (5 minutes)~* Post-session quality of sleep will be assessed by telephone interview 1 day after session."
224236520|NCT04035642|RADIATION|IGRT 24 Gy Single dose|Previously untreated patients with prostate cancer will be treated with 24Gy in in one session.
224320820|NCT05541887|OTHER|Placebo|this placebo beverage is formulated with matching sugar and organic acid content to the muscadine wine polyphenol. Food coloring is added to match the color of the intervention. 50ppm of sodium metabisulfite for preservation
223652236|NCT06890312|PROCEDURE|Administration of heparin prior to sheath insertion|Administration of heparin prior to sheath insertion
223652237|NCT07054333|BEHAVIORAL|Internet-delivered exposure-based cognitive behavior therapy|The primary treatment component is exposure to stimuli (situations and activities) that give rise to pain, distress, and unwanted emotional responses. The treatment proceeds in accordance with functional analysis. Exercises are tailored for the patient so that, for example, individuals whose main coping strategy is to be overly active (i.e., persistence behavior) are encouraged to sit down and observe pain and other aversive bodily sensations as they arise. The protocol also includes regular exercises where the participant is encouraged to observe and name physical sensations without acting on them.
223652238|NCT07074769|DEVICE|Evaluation of speech-in-noise intelligibility and listening effort|The speech in noise testing will be performed in lab settings; the listening effort evaluated trough a standardized questionnaire
223652239|NCT06823180|DRUG|Hydromorphone hydrochloride low dose|15min before the end of the operation, 0.1mg hydromorphone hydrochloride was injected into the epidural space in the low-dose group for preemptive analgesia.
223652240|NCT06823180|DRUG|Hydromorphone hydrochloride high dose|15min before the end of the operation, 0.3mg hydromorphone hydrochloride was injected into the epidural space in the high-dose group for preemptive analgesia.
223652241|NCT06823180|DRUG|0.9% sodium chloride|15min before the end of the operation, 0.9% sodium chloride injection was given in the control group.
223652242|NCT06762444|BEHAVIORAL|Speech-language pathologist (SLP) protocol|The SLP intervention protocol consists of six components, all of which will be implemented by the treating speech-language pathologist
223767429|NCT06232382|OTHER|Natural text audio (control audio)|"* After informed consent was obtained and baseline assessment, patients will be randomly assigned to one of the three conditions in 20 minutes:~  1. Audio hypnosis (HYP)~ 2. Audio mindfulness (MM)~ 3. A control condition (a voice reading neutral text) These audios will be produced together with hypnotherapist in Thailand, psychiatrist and researchers.~* The randomization process will be performed using a computerized random sequence generator.~* The patient listens to Control audio recording through headphones in a private room.~* Participants will be blind to the study hypotheses.~* To keep the experimenter blind, the participants will not reveal what they hear in the audios.~* Pain intensity will be assessed both at pre- and post-session. (5 minutes)~* Secondary outcomes will be assessed at pre- and post-session by the questionnaires. (5 minutes)~* Post-session quality of sleep will be assessed by telephone interview 1 day after session."
224236521|NCT04035642|PROCEDURE|Image-guided, volumetric intensity-modulated arc radiotherapy (IGRT-VMAT)|Patients enrolled in the study will undergo IGRT-VMAT with state-of-the-art treatment-planning and quality assurance procedures with emphasis on normal tissue sparing and delivery accuracy via the use of devices that ensure stability and beam location reproducibility.
224236522|NCT04035642|DEVICE|Rectal balloon with air filling|A rectal balloon with air filling will be used for prostate target immobilization and anatomical reproducibility.
224236523|NCT04035642|DEVICE|Urethral catheter loaded with beacon transponders|A urethral catheter loaded with beacon transponders will be used to ensure set-up reproducibility and online target tracking.
224236524|NCT02268032|DRUG|DHEA|DHEA 2.2 g in vaginal ring
224236525|NCT02268032|DRUG|Another Androgenic Agent (VRaA)|Testosterone 35 mg in vaginal ring
224236526|NCT02268032|DRUG|Fixed combination of 2 androgenic agents (VR2A)|DHEA 1.5 g/testosterone 25 mg fixed combination in vaginal ring
224236527|NCT05749133|BIOLOGICAL|Anti-GPRC5D CAR-T Cells Injection|"This is a3+3dose escalation study, in which three dose groups are set three different dose levels of CAR-T cells: Initial dose group: 3.0×10\^6/kg±20%; Low dose group: 3.0×10\^6/kg±20%; High dose group: 6.0×10\^6/kg±20%. Dose was weight-based."
224236528|NCT06253676|BEHAVIORAL|Problem Management Plus (PM+)|Validated across multiple low- and middle-income country settings, PM+ is World Health Organization-developed, five-session task-sharing intervention for mild to moderate distress. Per the (manualized) intervention, trained non-specialist providers coach eligible clients to address practical problems and/or distress in their daily lives via the use of fundamental cognitive behavioral strategies (e.g., deep breathing and stress management, behavioral activation, strengthening of social support, etc.).
224320821|NCT05904132|DEVICE|tACS device|you will receive one of four treatment conditions that include active and sham tACS. The four conditions are the following: (1) closed-loop-tACS (peak-locked), (2) closed-loop-tACS (trough-locked), (3) open-loop tACS, and (4) sham tACS. Although each subject will undergo all four treatments in four separate study visits, the order of the treatments will be randomized
224320822|NCT05291676|BIOLOGICAL|Fluzone|Fluzone High-Dose 0.7 ml intramuscular injection, standard as recommended by manufacturer
224320823|NCT05291676|BIOLOGICAL|Fluad|Fluad Quadrivalent, MF59 adjuvanted 0.5 ml intramuscular injection, standard as recommended by manufacturer
223652251|NCT07082816|DRUG|Netarsudil 0.01%/latanoprost 0.005% ophthalmic solution|Investigational ophthalmic solution
223652252|NCT07082816|DRUG|Netarsudil 0.02%/latanoprost 0.005% ophthalmic solution|Commercially available ophthalmic solution
223652253|NCT07087314|DRUG|SG301 Subcutaneous injection|Subcutaneous injection every weeks (QW\*6),subsequently, administer it once every two weeks for a total of three times (Q2W\*3). The total number of doses is nine.
223652254|NCT03487432|DEVICE|Super High-Pressure NC PTCA Balloon (OPN NC)|Strategy of Super High-Pressure NC PTCA Balloon (OPN NC) after unsuccessful lesion preparation with conventional NC balloon angioplasty.
223652255|NCT03487432|DEVICE|Scoring PTCA Balloon (NSE Alpha)|Strategy of Scoring PTCA Balloon (NSE Alpha) after unsuccessful lesion preparation with conventional NC balloon angioplasty.
223652256|NCT06901700|OTHER|Experimental Group|Total 40\~60 minutes, 3 sessions per week in alternate day for 8 weeks, total 24 sessions 5 min warm up and 5 min cool down Power training (using body weight as resistance): hip flexor, hip extensor, hip adductor, hip abductor, knee flexor, ankle plantarflexor, hip external rotator, hip internal rotator, knee extensor, ankle dorsiflexor, ankle invertor, ankle evertor
223652257|NCT06901700|OTHER|control group|Health education
223652258|NCT06905197|DRUG|DZD6008|Daily dose of DZD6008
223652259|NCT05693649|BEHAVIORAL|No Direct Patient Outreach|Patient will not receive direct outreach prompting them to schedule and/or complete colorectal cancer screening.
223652260|NCT05693649|BEHAVIORAL|Direct Patient Outreach: Colonoscopy Only|Patient will receive direct outreach including an order to schedule and complete colonoscopy.
223767430|NCT00847275|OTHER|Exclusive nephrology follow-up|"250 patients will be included and randomized in the exclusive nephrology follow-up arm will continue their usual nephrology follow-up with consultations every 6 months during 3 years for dialysis patients or with consultations every 6 months before dialysis, 3 months after starting dialysis and every 6 months for a total duration of 3 years for non-dialysis patients. In addition to their nephrology consultations, patients will benefit from a geriatric evaluation with MMS, GDS and ADL scoring."
223767431|NCT00847275|OTHER|Geriatric follow-up|"250 patients will be included and randomized in geriatric follow-up arm will continue their usual nephrology follow-up with consultations every 6 months during 3 years for dialysis patients or with consultations every 6 months before dialysis, 3 months after starting dialysis and every 6 months for a total duration of 3 years for non-dialysis patients. Patients randomized in the geriatric follow-up arm will also have more complete tests to evaluate cognitive functions (memory, language and movements), psychological functions (depression and anxiety) and dependency in activities of daily living. Other tests will allow evaluate vision, audition, mobility and nutritional status."
223767432|NCT04510935|PROCEDURE|general anesthesia|the patient will receive general anesthesia during surgery in this group.
223767433|NCT04510935|PROCEDURE|local anesthesia|the patient will receive local anesthesia during surgery in this group.
224236529|NCT06374615|DIAGNOSTIC_TEST|IgG and IgM search for specific Tick-Borne Patogens|"Ticks will be classified based on morphological characteristics by microscopy observation.~For TBP detection by molecular test, Nucleic acid extraction will be performed on ticks lysate or blood using kits MagMAX TM Viral/Pathogen Nucleic Acid Isolation Kit (Thermo Fisher Scientific) on MagEX STARlet platform from Hamilton. Species identification by molecular method will be performed by Sanger sequencing for Rickettsiae and Babesia, and Multi-Locus Sequence Typing will be used to characterize Borrelia.~Serum samples collected throughout the study will be tested to assess any seroconversions during the follow-up period.~Samples will be tested for the presence of specific IgG and IgM for the following TBPs: TBEV, R. typhi. R. conorii, Borrelia spp, Anaplasma, Ehrlichia and Babesia."
224236530|NCT04519437|DRUG|REGN10933+REGN10987|Administered subcutaneous (SC) every 4 weeks (Q4W)
224236531|NCT04519437|DRUG|Placebo|Administered subcutaneous (SC) every 4 weeks (Q4W)
224236532|NCT02802371|BEHAVIORAL|Psychosocial intervention|Caregivers included in this group will benefit from a multi-component intervention with three collective sessions and individual interview in face-to-face or by phone according to the follow-up time.
224236533|NCT02802371|OTHER|Pharmaceutical care and psychosocial support|"Caregivers included in this group will benefit from the same multi-component intervention that group psychosocial intervention with the integration of pharmaceutical care by a clinical pharmacist. The clinical pharmacist will intervene in: 1) the pharmaceutical need assessment of the caregivers considering their medication management and the medication management of their relatives at the inclusion; 2) a collective session on medication management; and 3) personalized interviews to consider needs, medication problems and difficulties in the therapeutic optimization process."
223652261|NCT05693649|BEHAVIORAL|Direct Patient Outreach: Sequential Choice|Patient will receive direct outreach including an order to schedule and complete colonoscopy then an at-home fecal immunochemical test (FIT) if colonoscopy is not completed.
223652262|NCT05693649|BEHAVIORAL|Visit-Based Nudge/Text|Patient's clinician will receive an alert prompting them to discuss colorectal cancer screening with their patient upon visit. Patient will also receive a text message 3 days after visit reminding them to complete colorectal cancer screening.
223652263|NCT05693649|BEHAVIORAL|No Nudge/Text|Patient's clinician will not receive an alert prompting them to discuss colorectal cancer screening with their patient upon visit. Patient will not receive a text message 3 days after visit reminding them to complete colorectal cancer screening.
223652264|NCT01805076|PROCEDURE|Breast surgery|
223767434|NCT05218759|DRUG|Anlotinib|anlotinib administration at a dose of 10 mg daily
223767435|NCT00443183|BEHAVIORAL|Brief Negotiation Interview (BNI)|The Brief Negotiation Interview is a manual guided intervention using techniques based on motivational interviewing, brief advice, and behavioral contracting and is designed to be delivered in less than 10 minutes.
223767436|NCT00443183|BEHAVIORAL|Discharge Instructions|Used as a placebo comparator, scripted discharge instructions are to be read by emergency practitioner and designed to be less than 1 minute in length.
223767437|NCT00259558|DRUG|retarded release phosphatidylcholine|
223767438|NCT02847793|BEHAVIORAL|Gaze training|Participants are required to maintain their gaze in a given picture (e.g., a happy face), for a given time (i.e., 750ms vs 1500 ms) to advance to the next trial. (A total of 576 trials will be distributed in a 2-day intervention).
224236534|NCT01449071|BIOLOGICAL|Placebo|Placebo infusions at study weeks 0, 1, 2, and 3.
224236535|NCT01449071|BIOLOGICAL|Epratuzumab 400 mg|Epratuzumab 400 mg infusions at study weeks 0, and 2, and placebo infusion at study weeks 1 and 3.
224236536|NCT01449071|BIOLOGICAL|Epratuzumab 1200 mg|Epratuzumab 1200 mg infusions at study weeks 0, and 2, and placebo infusion at study weeks 1 and 3.
224236537|NCT01449071|BIOLOGICAL|Epratuzumab 100 mg|Epratuzumab 100 mg infusions at study weeks 0, and 2, and placebo infusion at study weeks 1 and 3.
223652265|NCT01805076|PROCEDURE|Magnetic resonance imaging|
223652266|NCT01805076|PROCEDURE|Mammography|
223652267|NCT05943106|BIOLOGICAL|Durvalumab|Participants will receive Durvalumab via intravenous infusion from Week 1 for 13 cycles every 4 weeks (q4w) for maximum 12 months.
223652268|NCT05943106|BIOLOGICAL|BCG|Participants will receive BCG via intravesical as induction weekly for 6 weeks starting at Week 1, Day 1 and subsequently for maintenance for 3 weekly doses up to 3, 6, 12, 18, and 24 months, at the physician's discretion as Standard of care.
223652269|NCT06901466|DRUG|Experimental: Rivaroxaban monotherapy|Rivaroxaban monotherapy
223652270|NCT06901466|DRUG|Active Comparator: Rivaroxaban+Aspirin|Rivaroxaban+Aspirin
223652271|NCT07097428|OTHER|Temperature health risk early warning|Receive individualized temperature health risk warning through the application
223652272|NCT07092670|DRUG|Dabrafenib + Trametinib|There is no different use in the clinical application of the drugs reported above, the study on fertility will be implemented in the women with completely resected melanoma enrolled in the study
223652273|NCT07092670|DRUG|Pembrolizumab|There is no different use in the clinical application of the drugs reported above, the study on fertility will be implemented in the women with completely resected melanoma enrolled in the study
224236538|NCT01449071|BIOLOGICAL|Epratuzumab 600 mg|Epratuzumab 600 mg infusions at study weeks 0, 1, 2, and 3.
224236539|NCT03831451|BEHAVIORAL|Stroke preparedness intervention|Face-to-face interaction with research staff lasting between 5-10 minutes
224236540|NCT03831451|BEHAVIORAL|Healthy lifestyle stroke risk reduction intervention|Face-to-face interaction with research staff lasting between 5-10 minutes
224236541|NCT05126056|OTHER|Plant stanol ester|Product with active ingredient vs product without active ingredient
224236542|NCT05126056|OTHER|Placebo|Placebo
224236543|NCT02603783|OTHER|Capsaicin|capsaicin 1,5 mg
224236544|NCT02603783|OTHER|Placebo|0,9% saline 75 ml
224236545|NCT05884853|BEHAVIORAL|PEERS|The Program for the Education and Enrichment of Relational Skills (PEERS®) studies is an evidence-based 16-week group-based social skill training program developed for adolescents and young adults with ASD.
224236546|NCT02003053|DEVICE|Inspiratory Muscle Trainer|
224236547|NCT04084483|DRUG|K-161|K-161 alternate dosage
223652274|NCT07092670|DRUG|Nivolumab|There is no different use in the clinical application of the drugs reported above, the study on fertility will be implemented in the women with completely resected melanoma enrolled in the study
223652275|NCT07092670|OTHER|Observation|Patients who will not initiate adjuvant therapy, but will undergo observation (due to refusal, comorbidities, other reasons).
224236548|NCT04084483|OTHER|Placebo (Vehicle)|Placebo solution
223652276|NCT04985565|OTHER|Dietary Intervention|Participate in Mediterranean diet
223652277|NCT04985565|PROCEDURE|Radical Prostatectomy|Undergo standard of care radical prostatectomy
223652278|NCT06753305|PROCEDURE|Gingivectomy and gingivoplasty surgery and periodontal paste +ozone therapy application|After taking systemic and dental anamnesis from all patients, Phase 1 periodontal treatment will be performed and oral hygiene education will be given. Patients will be called 4 weeks after treatment for re-evaluation and surgical treatment will be planned. After local anesthesia, the incision line will be determined with a marking press or periodontal probe according to the amount of gingival enlargement. An external bevel incision will be made along the determined incision line with a number 15 scalpel. After the incision is completed, the remaining tissues will be removed using microsurgical scissors. Then gingivoplasty will be performed. After gingivectomy and gingivoplasty, the surgical site will be left for secondary healing. Periodontal paste (Coe-pak) will be applied to the area left for secondary healing after ozone therapy (activated oxygen (Cure 09 Active Oxygen))
224236549|NCT00305045|DEVICE|Repetitive Transcranial Magnetic Stimulation|Magnetic pulses to specified brain structures.
224236550|NCT01362998|DRUG|Preservative free morphine|3mg given epidurally during the Cesarean section.
224236551|NCT01362998|DRUG|Fentanyl|An infusion of epidural fentanyl started during the Cesarean section. It will be given on a patient controlled analgesia basis, with a basal rate of 60 micrograms, a demand dose of 16 micrograms, and a lockout of 15 mins.
224236552|NCT01458405|BIOLOGICAL|CAP-1002 Allogeneic Cardiosphere-Derived Cells|Single dose, blinded, intracoronary infusion of 25 Million cardiosphere-derived cells
224236553|NCT01458405|DRUG|Placebo|Single, blinded, intracoronary infusion of a placebo solution
224236554|NCT05402852|DRUG|EuBone ® capsule|Subjects are given EuBone® capsules, 4 capsules ×500mg/capsule per day for 360 days.
224236555|NCT05402852|DRUG|placebo|Subjects are given placebo capsules, 4 capsules ×500mg/capsule per day for 360 days.
224236556|NCT02029105|BIOLOGICAL|Mesothelin, hyaluronan, osteopontin, syndecan-1|We compere the serum levels of the tumor markers in patients with pleural diseases according to the groups for the diagnosis and differential diagnosis of the diseases.
224236557|NCT02194998|DRUG|Paritaprevir/ritonavir/ombitasvir (PTV/r/OBT)|PTV/r/OBT: 150/100/25 mg (two 75/50/12.5 mg fixed-dose combination tablets) orally once a day
223652279|NCT06753305|PROCEDURE|Gingivectomy and gingivoplasty surgery and periodontal paste application|After taking systemic and dental anamnesis from all patients, Phase 1 periodontal treatment will be performed and oral hygiene education will be given. Patients will be called 4 weeks after treatment for re-evaluation and surgical treatment will be planned. After local anesthesia, the incision line will be determined with a marking press or periodontal probe according to the amount of gingival enlargement. An external bevel incision will be made along the determined incision line with a number 15 scalpel. After the incision is completed, the remaining tissues will be removed using microsurgical scissors. Then gingivoplasty will be performed. After gingivectomy and gingivoplasty, the surgical site will be left for secondary healing. Only periodontal paste will be applied after the surgery.
223652280|NCT04347629|BEHAVIORAL|Advance Care Planning Video Decision Aid|The video decision aid explores ACP options for medical care for end-stage renal disease (ESRD) and reviews hemodialysis, peritoneal dialysis, as well as medical management without dialysis; it also reviews cardiopulmonary resuscitation (CPR). Patients will also audio- or video-record their preferences using a tablet.
224236558|NCT02194998|DRUG|Dasabuvir (DSV)|DSV: 250 mg orally twice a day
224236559|NCT02194998|DRUG|Ribavirin (RBV)|RBV: 1,000 or 1,200 mg (weight-based) dosed in two divided doses orally twice a day (all participants (version 1); only participants with HCV genotype 1a (version2))
224236560|NCT05887297|BEHAVIORAL|Cognitive behavioural therapy for insomnia|CBT-I is a multi-component, evidence-based intervention which incorporates both cognitive and behavioural techniques to address symptoms of insomnia, aiming to improve satisfaction with the duration and quality of sleep by reducing trouble falling and/or staying asleep. CBT-I will be delivered over 4 weekly 1-hour sessions, via videoconferencing. Session 1 will include psychoeducation about sleep (the relationship between sleep and mental health, the '3P' model of insomnia), and begin to explain components of CBT-I (sleep restriction and relaxation). Session 2 will reinforce previous learning about these components and introduce stimulus control. Session 3 will introduce sleep hygiene and its importance in preventing poor sleep. Session will 4 discuss cognitive therapy techniques and relapse prevention.
224236561|NCT01190748|DRUG|Galantamine 4 mg Tablet, single dose|A: Experimental Subjects received Purepac Pharmaceutical, Company, U.S.A. formulated products under fasting conditions
224236562|NCT01190748|DRUG|Reminyl 4 mg Tablet, single dose|B: Active comparator Subjects received Janssen Pharmaceutica Products,U.S.A., formulated products under fasting conditions
224236563|NCT01454466|PROCEDURE|Partial posterior hyaloidectomy (a modified procedure of vitrectomy)|The core vitrectomy entails more extensive removal of vitreous gel, in contrast to the conventional core vitrectomy. IPVD was conducted by engaging the attached posterior cortical vitreous with a 23-gauge needle with angulated tip in the area adjacent to the optic disc followed by gently moving the tip to approximately 3 disc diameters away from the margin of the optic disc. After then, slightly elevating the tip in a posteroanterior direction with slowly proceeding it to the extent that we planned. With IPVD, the surgeon was able to visualize a floating Weiss ring in all of the cases. Active suction to initiate IPVD was not used in any of the cases. In the temporal direction, the extension of a PVD was restricted to approximately 2 disc diameters distance beyond the margin of temporal major vascular arcade
224236564|NCT05956197|OTHER|No intervention|No intervention. This is a cohort study
224236565|NCT03259581|COMBINATION_PRODUCT|Transarterial chemoembolization|Delivery of lipiodol, chemotherapy (Deoxyrubicin), and particles (embosphere particles) to the arteries feeding hepatocellular carcinoma. While both chemotherapy and particles are delivered this is a single procedure in which the chemotherapy is delivered followed immediately by particles.
224236566|NCT02497781|DRUG|Ceftazidime -avibactam|Patients randomised (3:1) to the CAZ-AVI or cefepime treatment
224236567|NCT02497781|DRUG|Cefepime|Patients randomised (3:1) to the CAZ-AVI or cefepime treatment
224236568|NCT06038357|BEHAVIORAL|CBITS|The CBITS program is a skills-based group and individual intervention, which uses evidence-based cognitive-behavioral techniques (e.g. psychoeducation, relaxation, social problem solving, cognitive restructuring, and exposure) and is designed for delivery by mental health professionals. The program consists of 10 45-minute group sessions (about 6-8 students/participants per group), 1-3 individual sessions, 2 parent/caregiver psychoeducational sessions, and 1 teacher/ child welfare staff educational session. For this study, we will specifically train and supervise study therapists to deliver the intervention within child welfare programs.
224236569|NCT06038357|OTHER|TAU+|In the control condition (TAU+), child welfare programs will follow their usual procedures (i.e. routine care of child welfare, referral to medical practitioners and psychotherapists, handling of prescribed medication, referral to inpatient treatments in case of risk to self and others) which reflects treatment as usual in child welfare programs and the mental health care system in Germany. Additionally, participants in the control condition will receive the same baseline assessment and reporting of screening results as participants in the treatment condition after each assessment.
224236570|NCT04524039|DEVICE|intermittent theta burst stimulation using a MagPro X100|Patients randomized to receive iTBS in left dorsolateral prefrontal cortex, each treatment will consist of 600 stimuli (triplet 50 Hz bursts, repeated at 5 Hz; 2 s on and 8 s off; total duration of 3 min 12 s). Simulated iTBS will be administered using Magventure static cooling MCF-B65 coil.
224236571|NCT04524039|DEVICE|sham intermittent theta burst stimulation using a MagPro X100|Patients randomized to receive sham iTBS will undergo the same procedure to patients receiving real iTBS. Sham iTBS will be administered using Magventure static cooling MCF-P-B65 coil that shares the same mechanical outline and produces identical sound level to MCF-B65 coil without stimulating the cerebral cortex.
224236572|NCT02709356|DIETARY_SUPPLEMENT|1-month of 60-40 MCT oil|1-month supplementation of 30 g MCT oil (60% C10 + 40% C8)/day
224236573|NCT02709356|DIETARY_SUPPLEMENT|1-month of C8 MCT oil|1-month supplementation of 30 g MCT oil (100% C8)/day (1-month of C8 MCT oïl)
224236574|NCT02637193|DRUG|Venlafaxine|Multiple doses of Venlafaxine for 14 days plus 3 days of down titration
223652281|NCT07103967|BEHAVIORAL|Calorie information manipulation|The intervention will be administered by changing the information presenting to participants at point-of-choice when ordering alcoholic drinks and bar snacks. When alcohol calorie information is present, participants will see the calorie content of alcohol products on menus and at other point-of-choice locations. When it is not present, this information will be absent.
223652282|NCT07103967|BEHAVIORAL|Serving size manipulation|The intervention will be administered by changing the availability of alcoholic drinks. When serving sizes are reduced, participants will only be able to order 2/3 pint of 1/2 servings of beer, and 125 ml servings of wine. When serving sizes are not reduced, participants will be able to order 1 pint servings or 1/2 servings of beer, and 175 ml or 125 ml servings of wine.
223652283|NCT07110116|OTHER|Alternate nostril breathing with Incentive Spirometery|Participants in experimental group were instructed to close their left nostril by left index finger and inhale through their right nostril for six seconds, then closing the right nostril and holding breath for six seconds. Afterward, they exhaled through the left nostril slowly for six seconds. Next, they inhaled through left nostril, keeping the right nostril closed for six seconds then hold the breath by closing both nostrils for six seconds subsequently, and then exhaled through the right nostril, keeping the left closed for six seconds repeating these steps several times for 10 minutes
223652284|NCT07110116|OTHER|Incentive spirometery|The control group participants were asked to do breathing exercise with incentive spirometry. The subject is asked to create a tight seal around the mouthpiece and asked to inhale deeply and slowly and the subject would observe the flow meter for visual feedback of his/her effort. At the end of the inspiration the subject is asked to sustain the inhalation 2-3 seconds to facilitate the Inspiratory hold. Subject relaxes the seal around the mouthpiece and exhales. Normal breathing is taken, then the exhalation phase in the incentive spirometry is done and the whole cycle is repeated 5 - 10 times thrice a day over a period 6 weeks
224236575|NCT02637193|DRUG|Moxifloxacin|400 mg single dose moxifloxacin
224236576|NCT02637193|DRUG|Drug - placebo|Placebo administered for 16 days
224236577|NCT04209972|DEVICE|Precision Ultra-High-Resolution CT scanner|Patients will be divided on one of the two CT scanners. This group will be scanned on the Precision CT scanner.
224236578|NCT04209972|DEVICE|Genesis high-end CT scanner|Patients will be divided on one of the two CT scanners. This group will be scanned on the Aquilion one Genesis.
224236579|NCT00981786|DRUG|Brimonidine/timolol fixed combination drops added to travoprost|twice daily administration
224236580|NCT00981786|DRUG|Brinzolamide/timolol fixed combination drops added to travoprost|twice daily dosing
224236581|NCT02236130|PROCEDURE|Regional block|Single shot peripheral nerve block
224236582|NCT02236130|PROCEDURE|General Anesthesia|General Anesthesia with O2/N2O/Sevoflurane
224236583|NCT02236130|DRUG|Local Anesthetic Ropivacaine|0.5% Ropivacaine
224236584|NCT02236130|DRUG|Opioids Morphine|Morphine
224236585|NCT02236130|DRUG|Oral pain medication Acetaminophen with Hydrocodone|Acetaminophen with Hydrocodone
224236586|NCT03162666|DEVICE|ALTERA|degenerative disc disease (DDD) at one or two contiguous levels from L2 to S1. with up to grade 1 spondylolisthesis
224236587|NCT05127993|DEVICE|Passive Talaris Demonstrator|"The amputee will walk with the passive Talaris Demonstrator, a novel prosthetic foot, designed and built by Axiles Bionics."
224236588|NCT01697020|DRUG|Mercaptopurine 20mg/ml oral suspension|50mg
224236589|NCT01697020|DRUG|Mercaptopurine 50mg tablet|50mg
224236590|NCT00780520|DIETARY_SUPPLEMENT|alanine-glutamine infusion|
224236591|NCT03082274|DIAGNOSTIC_TEST|ConfirmMDx|ConfirmMDx is a molecular diagnostic assay which utilizes DNA isolated from biopsy tissues to determine if aberrant DNA methylation is occurring in three genes: GSTP1, RASSF1 and APC. ConfirmMDx is currently available to clinicians for use in cancer-negative extended-core biopsies to determine if occult cancer is present in the prostate.
224236592|NCT03082274|DIAGNOSTIC_TEST|SelectMDx|SelectMDx for Prostate Cancer is a reverse-transcription PCR (RT-PCR) assay performed on post-DRE, first-void urine specimens from patients with clinical risk factors for prostate cancer, who are being considered for biopsy. The test measures the mRNA levels of the DLX1 and HOXC6 biomarkers, using KLK3 as internal reference gene, to aid in patient selection for prostate biopsy.
224236593|NCT02238223|DRUG|Alesion®|
224236594|NCT04956419|DRUG|SHR8008 capsule|once daily for 2 days(Day 1 and Day 2),oral
224236595|NCT04956419|DRUG|Fluconazole capsule|once daily for 2 days(Every 72 hours) ,oral
223652285|NCT04044872|DIAGNOSTIC_TEST|[1-13C]pyruvate along with MRI imaging|\[1-13C\]pyruvate: 0.1 mmol/kg dose will be injected at 5 mL/s followed by a 25 mL saline flush at 5 mL/s at the time of imaging performed at baseline (prior to radiation therapy), and 1 month after completion of radiation therapy.
223652286|NCT07113990|PROCEDURE|Active EA|Participants will receive electroacupuncture once daily for 2 consecutive weeks (total 10 sessions). Disposable sterile needles will be inserted at standardized acupoints to achieve de qi, then connected to an electroacupuncture device for 30 minutes per session.
223652287|NCT07113990|PROCEDURE|Sham EA|Participants will receive sham electroacupuncture once daily for 2 consecutive weeks (total 10 sessions). Disposable blunt needles will be placed at the same acupoints without skin penetration or electrical stimulation, with the electroacupuncture device turned on but delivering no current, for 30 minutes per session.
223652288|NCT07113990|DEVICE|Active rTMS|Participants will receive high-frequency rTMS to the ipsilesional M1 area once daily for 2 consecutive weeks (total 10 sessions). Stimulation will be delivered with a MagPro R30 stimulator at 10 Hz, 1600 pulses per session, 4-second trains with 41-second inter-train intervals.
223652289|NCT06557798|DEVICE|Any commercially available transcatheter aortic valve|Redo TAVI will be performed using any commercially available transcatheter aortic valve according to the preferences of the local team in keeping with standard clinical care.
223652290|NCT06557798|PROCEDURE|Surgical explantation and aortic valve replacement|Surgical explantation and aortic valve replacement will be performed according to the preferences of the local team in keeping with standard clinical care. Any commercially available approved surgical aortic valve may be used. Additional surgery, such as aortic root replacement, root enlargement, CABG, mitral valve repair/replacement, etc. will be performed at the discretion of the local team.
223652291|NCT06557798|OTHER|Conservative management|Conservative treatment, including optimal medical therapy +/- balloon aortic valvuloplasty
223652292|NCT06922591|DRUG|TNG462|MTA cooperative PRMT5 inhibitor
223652293|NCT06922591|DRUG|RMC-9805|RAS(ON) G12D selective covalent inhibitor
223652294|NCT06922591|DRUG|RMC-6236|RAS(ON) multi-selective inhibitor
223652295|NCT06931158|DRUG|Open-label Placebo|Open-label placebo pill for 21 days at 2 per day
223652296|NCT06931158|BEHAVIORAL|Standard Rationale|Scientific rationale about the placebo effect
223652297|NCT06931158|BEHAVIORAL|Mindfulness|Mindfulness based rationale
223652298|NCT06931158|BEHAVIORAL|Control Rationale|Basic epidemiological information about chronic pain to achieve structural equivalence for the control groups
223652299|NCT07132281|BEHAVIORAL|Language activities active inference|Participants will join reading or writing activities and come up with their own inference about wording or plots.
223652300|NCT07132281|BEHAVIORAL|Language activities passive|Participants will join reading or writing activities and will be given step-by-step explanations about the wording and plots.
223652301|NCT07132281|BEHAVIORAL|Board Games|Participants will play board games with each other.
223652302|NCT05020184|DRUG|Cimetidine|Oral Cimetidine 800mg twice daily.
223652303|NCT05020184|DRUG|Placebo|Placebo twice daily
223652304|NCT06935422|DEVICE|Ultrasound|Measuring cerebroplacental ratio discordance in monochorionic twins at 16-20 Weeks of gestation
224236596|NCT03967249|DRUG|IONIS GHR-LRx|Participants will receive IONIS GHR-LRx by subcutaneous injection.
224236597|NCT03967249|DRUG|Somatostatin Receptor Ligand (SRL)|Participants will receive Somatostatin Receptor Ligand (lanreotide, octreotide) once monthly.
224236598|NCT03724006|BEHAVIORAL|Psychoeducational intervention|"The intervention, prepared by a multidisciplinary team, will consist of two 90 minutes collective sessions (max. 8 families). Sessions will consist of lectures, group discussion and relaxation. The program includes content on the effects of a diagnosis of a congenital anomaly on a child in the parents and in the family, stages of mourning, adaptation process, coping strategies, legislative framework and social protection. This is a non-specific intervention for CHD, where the main focus is the diagnosis of a congenital anomaly.~In second session, written support material will be distributed. Participants will be asked to practice relaxation in the next 4 weeks."
224236599|NCT05234437|DRUG|tigilanol tiglate|"Single or multiple Intratumoural treatments of tigilanol tiglate up to a fixed dose level of 3.6mg/m2.~Tigilanol tiglate is a novel, short-chain diterpene ester in early clinical development for local treatment of a wide range of solid tumours."
224236600|NCT05664256|OTHER|Build capacity of canteen|"The investigators will conduct 1 day orientation training to the school nurse, principal and canteen managers of the facilities.~Different sessions on basic nutrition concept, healthy eating, healthy cooking practices including purchasing and serving will be conducted.~The investigators will develop training manuals: training curriculum, facilitators guide, and participants guide, aligning with policy contents."
224236601|NCT05664256|OTHER|Information, Education and Communication materials|Posters showing healthy plate model will be displayed on the canteen walls. The fact sheet on healthy eating will be distributed to all the public facilities and make it available at the entrance/ gate of the canteen.
223652305|NCT02844309|DRUG|Thalidomide|thalidomide 50-150 mg per night
224236602|NCT05664256|OTHER|Monitoring visit|A monitoring team from each municipality will be formed. The monitoring plan will be prepared with the team. At least one monitoring visit from the municipality government with onsite feedback will be done.
224236603|NCT04113343|DRUG|Remimazolam|Remimazolam via oral administration
224236604|NCT04113343|OTHER|Alcohol|Alcohol
224236605|NCT03812081|DEVICE|Group A : Baska Mask Airway|Size selection is based on the manufacturer's recommendation of weight-based estimate plus clinical judgment. The Baska Mask is available in four sizes: size three (30 to 50 kg), size four (50 to 70 kg), size five (70 to 100 kg),The membranous cuff of the Baska Mask appears bulkier than the equivalent inflatable cuff on cuffed laryngeal masks. The mask can easily be decreased in size during insertion by compressing the proximal, firmer part of the mask below the airway tube, between the thumb and two fingers
224236606|NCT03812081|DEVICE|Group B: Proseal Laryngeal Mask Airway|Proseal LMA (size 3,4,5) was used for ventilation according of patient body weight.Size selection is based on the manufacturer's recommendation of weight-based estimate plus clinical judgment.
223652306|NCT07143903|OTHER|artificial application|The conceptual framework for this study proposes that an AI-powered labor monitoring application, designed to track contractions, analyze symptoms, provide educational resources, and utilize predictive analytics, will enhance maternal experience by increasing perceived control, reducing anxiety, and boosting confidence during the first stage of labor. These improvements in maternal experience are expected to mediate positive outcomes, including higher maternal satisfaction, lower stress levels, and timely interventions when necessary, ultimately leading to better fetal outcomes, such as higher Apgar scores and reduced NICU admissions. The framework hypothesizes that expectant mothers using the AI application will have a more empowered labor experience compared to those receiving traditional monitoring, with measurable benefits for both mothers and their newborns.
224320824|NCT05921643|DEVICE|verre bioactif 45S5 GlassBONE|All patients will benefit from surgical management for a first stage cholesteatoma in the operating room under general anesthesia. The surgical technique (closed technique) is the reference technique for the management of cholesteatoma in adults. It involves a cartilaginous removal to reconstruct the attical region. Then a filling material is used to fill the mastoid (GlassBONE™ or Bonalive™), and above all to stabilize the cartilaginous fragment to prevent a recurrence. The mastoid filler used is left to the discretion and habits of the surgeon.
223652307|NCT07141225|PROCEDURE|Off-Clamp Sutureless Technique|During the procedure, the renal artery and its branches are not clamped. The tumor is completely resected with a gross margin of 0.5-1 cm from its edge. Monopolar or bipolar electrocautery is used for hemostasis during resection. Following tumor removal, the renal resection bed is subjected to meticulous hemostasis, followed by the application of hemostatic agents without suture closure.
223652308|NCT06284330|OTHER|Enhanced cascade testing|Direct mailed at-home genetic testing kit to probands' relatives.
224236607|NCT00454636|DRUG|Cisplatin|80 mg/m2/day, intravenous (IV), every 3 weeks
224236608|NCT00454636|DRUG|Capecitabine|1,000 mg/m2, oral, twice daily for 2 weeks, followed by 1 week of rest in each cycle
224236609|NCT00454636|DRUG|Epirubicin|50 mg/m2/day, IV, every 3 weeks
224236610|NCT00454636|DRUG|Cisplatin|60 mg/m2/day, IV, every 3 weeks
224236611|NCT00454636|DRUG|Capecitabine|625 mg/m2, oral, twice daily per 3-week cycle
224236612|NCT00454636|DRUG|Oxaliplatin|130 mg/m2/day, IV, every 3 weeks
224236613|NCT00454636|DRUG|Docetaxel|60 mg/m2/day, IV, every 3 weeks
223652309|NCT01650597|DRUG|JNJ-42165279 2.5 - 500 mg oral|Type=exact number, unit=mg, numbers=2.5, 10, 30, 100, 250 and 500, form=suspension, route=oral use. One single dose administered orally.
223652310|NCT01650597|DRUG|Placebo|Type=exact number, unit=mg, form=solution, route=oral use. One single dose administered orally.
223652311|NCT01650597|DRUG|JNJ-42165279 100 mg oral|Type=exact number, unit=mg, form=solution, route=oral use. One single dose administered orally.
223652312|NCT00108199|BEHAVIORAL|Problem-Solving Training|
224236614|NCT00454636|DRUG|Capecitabine|825 mg/m2, oral, twice daily for 2 weeks
223652313|NCT00108199|BEHAVIORAL|Work-Related Social Skills Training|
224236615|NCT03879200|OTHER|Group antenatal care|Care will be provided in group sessions in dialogue sensitive to language and cultural issues. Group numbers will be around 8; the woman with partner or other companion welcome. The content of the sessions will be designed in collaboration with midwives and Somali born women, following the present parental education and findings from the focus groups. The sessions will be held at the antenatal clinic led by one or two midwife, assisted by the trained female Somali interpreter.
224236616|NCT02824900|DEVICE|Vibration stimuli to neck muscles|
224236617|NCT02824900|DEVICE|Vibration stimuli to hand|
224236618|NCT02824900|BEHAVIORAL|conventional physiotherapy|
224236619|NCT02141100|DRUG|6-thioguanine|"All eligible patients will be supplemented with 6-thioguanine in addition to the standard therapy with 6-mercaptopurine and methotrexate.~In case of significant myelo-/hepatotoxicity all therapy will be paused. If patients develop VOD they will be excluded from further 6TG therapy."
224236620|NCT00816959|DRUG|R-mabHDI and ABVD|"The subjects will receive R-mabHDI intravenously, separately for about 7 hours on days 1,8,15 and 22 (once a week) of every cycle. Each cycle is 4 weeks. R-mabHDI will be given for 2 cycles.~Also the subjects will receive the ABVD combination intravenously for about 1 hour on day 1 and 15 of every cycle (every 2 weeks). Each cycle is 4 weeks. ABVD will be given for 6 cycles."
224236621|NCT00816959|DRUG|ABVD|The subjects will receive the ABVD combination intravenously for about 1 hour on day 1 and 15 of every cycle (every 2 weeks). Each cycle is 4 weeks. ABVD will be given for 6 cycles.
224236622|NCT01437865|DRUG|Gadofosveset contrast agent enhanced MRI Axilla|A MRI of the Axilla will be performed before and after administration of a single IV bolus injection of gadofosveset of an equivalent of 0.03 mmol Gd/kg body weight at an injection speed of 1.5 mL/sec., followed by a saline flush of 25 mL at an injection speed of 1.5 mL/sec.
224236623|NCT05909267|DRUG|L-dopa/Carbidopa|Patients and healthy controls will receive one time administration of L-dopa/Carbidopa (100/25 mg).
224236624|NCT05909267|DRUG|Placebo|Patients and healthy controls will receive one time administration of Placebo.
224236625|NCT03554096|DIETARY_SUPPLEMENT|2-HOBA|2-HOBA is a compound found in buckwheat and is given as 2-HOBA acetate
224236626|NCT04059796|DEVICE|Omega Gemini III Rev 2 Device|Eyes randomized to receive the Gemini III Rev 2 device will receive the study device in conjunction with an approved monofocal or toric IOL post cataract extraction
224320825|NCT05921643|DEVICE|verre bioactif S53P4 Bonalive|All patients will benefit from surgical management for a first stage cholesteatoma in the operating room under general anesthesia. The surgical technique (closed technique) is the reference technique for the management of cholesteatoma in adults. It involves a cartilaginous removal to reconstruct the attical region. Then a filling material is used to fill the mastoid (GlassBONE™ or Bonalive™), and above all to stabilize the cartilaginous fragment to prevent a recurrence. The mastoid filler used is left to the discretion and habits of the surgeon.
224320826|NCT06489899|BEHAVIORAL|PEGISUS|PEGISUS is an 8-session intervention for substance use and gender equitable beliefs.
223652314|NCT06947252|DIAGNOSTIC_TEST|Oral food challenge test|Oral food challenge test at home or in the hospital
223652315|NCT06947161|DRUG|Gengigel|Throat pack will be soaked with gengigel, and post operatively, will see if there is any presence of sore throat, severity of sore throat. 10 mlm of gengigel, in liquid form will be used to soak the throat pack. 30 patients will receive gengigel spray soaked throat pack, and control group will receive normal saline soaked throat pack
223652316|NCT06945965|PROCEDURE|Injectable platelet-rich fibrin (i-PRF) scaffold|The separated plasma and platelets form a light-yellow-colored layer, which is situated at the top of the tube. This is then aspirated using a syringe with a needle (partially active injectable form).
223652317|NCT06945965|PROCEDURE|platelet-rich fibrin (PRF)scaffold|The fibrin clot was removed from the test tube with sterile tweezers, then cut into fragments, then placed incrementally in the canal space below the CEJ using hand pluggers (without prior induction of apical bleeding).
223652318|NCT06945965|PROCEDURE|blood clot (BC) scaffold|A sterile saline-soaked cotton pellet was placed into the canal 2 mm below the orifice for 15 minutes to form a blood clot.
223652319|NCT06955468|BEHAVIORAL|Priming Survey|13-item priming survey assessing patients' goals, treatment preferences, and disease understanding.
223652320|NCT07144839|OTHER|Data Collection Throughout Pregnancy and Delivery|Participants will receive monitoring by ultrasound and blood tests at three time points during pregnancy, and delivery and neonatal data will be collected.
223652321|NCT07147114|DRUG|Combination therapy|Macitentan 10mg, Dapagliflozin 10mg or 5mg po tablet q.d. in 24 weeks
223652322|NCT07147114|DRUG|Monotherapy|Macitentan placebo, Dapagliflozin 10mg or 5mg po tablet q.d. in 24 weeks
223652323|NCT07150585|DEVICE|Ultrasonic Activation Group|In this group, during single-visit nonsurgical root canal retreatment, irrigant activation in the final irrigation protocol was performed using the Ultra X device (Eighteeth) with ultrasonic tips.
223652324|NCT07150585|DEVICE|Sonic Activation Group|In this group, during single-visit nonsurgical root canal retreatment, irrigant activation in the final irrigation protocol was performed using an EDDY sonic activation tip (VDW, Munich, Germany)
223652325|NCT07150585|DEVICE|Laser Activation Group|In this group, during single-visit nonsurgical root canal retreatment, irrigant activation in the final irrigation protocol was performed using the LightWalker (Fotona, Ljubljana, Slovenia) Er:YAG laser device in SWEEPS mood
224236627|NCT04059796|DEVICE|Control Eye|Control eyes will receive an approved monofocal or toric IOL post cataract extraction
224236628|NCT04175496|OTHER|Blueberry Cake|Blueberry cake containing 25 g available CHO will be served to the participants after 10-hours fasting and asked to consume it within 15 minutes, along with 250 ml of water. Taking the first bite from test food will be considered as 0 min. Blood samples will be collected at time points 0,15, 30, 45, 60, 90 and 120 min.
224236629|NCT04175496|OTHER|Snacks with Cheese|Snacks with cheese containing 25 g available CHO will be served to the participants after 10-hours fasting and asked to consume it within 15 minutes, along with 250 ml of water. Taking the first bite from test food will be considered as 0 min. Blood samples will be collected at time points 0,15, 30, 45, 60, 90 and 120 min.
224236630|NCT04175496|OTHER|Spicy Crackers|Spicy crackers containing 25 g available CHO will be served to the participants after 10-hours fasting and asked to consume it within 15 minutes, along with 250 ml of water. Taking the first bite from test food will be considered as 0 min. Blood samples will be collected at time points 0,15, 30, 45, 60, 90 and 120 min.
224236631|NCT04175496|OTHER|Glucose Solution First Repeat|The glucose solution will be prepared by dissolving 25 g of glucose in 250 ml of water. Participants consume the glucose solution within 15 minutes after 10-hours fasting. Blood samples will be collect at time points 0,15, 30, 45, 60, 90 and 120 min.
224236632|NCT04175496|OTHER|Glucose Solution Second Repeat|The glucose solution will be prepared by dissolving 25 g of glucose in 250 ml of water. Participants consume the glucose solution within 15 minutes after 10-hours fasting. Blood samples will be collect at time points 0,15, 30, 45, 60, 90 and 120 min.
224236633|NCT00209118|DRUG|paroxetine|
223652326|NCT07152912|DRUG|Isoflurane|Patients will receive general anesthesia and maintenance by isoflurane.
223652327|NCT07152912|DRUG|Sevoflurane|Patients will receive general anesthesia and maintenance by sevoflurane.
223767439|NCT02847793|BEHAVIORAL|Placebo intervention|Participants are exposed to the same amount of time to the experimental stimuli used in the experimental group but there is no contingency between participants' gaze patterns and the end of each of the 576 trials.
224236634|NCT04076358|BEHAVIORAL|Tab-CBI|Participants receive a tablet preloaded with Tab-CBI application and an accelerometer.
224236635|NCT04487210|BIOLOGICAL|MVC-COV1901|MVC-COV1901 is formulated in the different dosages of Spike (S) protein with CpG 1018 and aluminum content as adjuvant.
224236636|NCT01095510|BIOLOGICAL|CINRYZE|
224236637|NCT05376046|BIOLOGICAL|Erythrocytic parameters and thrombin generation assay measurement|Erythrocytic parameters and thrombin generation assay measurement
224236638|NCT00599209|OTHER|clinical decision support|CDS is provided to prescribers on intervention units upon ordering medication which offers advice on prescribing and monitoring practices
224320827|NCT04324073|DRUG|Sarilumab|(an IV dose of 400 mg of sarilumab in a 1 hour-infusion at D1
224320828|NCT06797362|DRUG|NVL-520|Oral tablet
223767440|NCT02143843|DRUG|Bimatoprost|Bimatoprost Ocular Insert used continuously for 7 months, then replaced with a new Bimatoprost Ocular Insert and used continuously for another 6 months.
223767441|NCT05117944|OTHER|"drama-supported patient role experience"|The students participated in 3 hours of drama activities and played the role of a patient whose basic needs such as nutrition, dressing and oral care were met by the nurse, lying down for 4 hours in the skills laboratory.
224320829|NCT06795945|DIETARY_SUPPLEMENT|TPG1|"* Thymus Nuclear Extract Dose 1 (860 mg \[2 tablets, 2x/day; total 4 tablets per day\])~* Placebo (6 tablets, 2x/day; total 12 tablets per day)"
223767442|NCT03560713|DEVICE|Functional Electrical Stimulation (FES)|Participants will perform 12 weeks of FES (Neurodyn High Volt, IBRAMED, São Paulo/SP, Brasil), three times a week, frequency 25Hz, pulse rate of 200μs, ON:OFF 5:5, individual maximum tolerated intensity; minimum at strong but comfortable visible muscle contraction (without causing undue pain or discomfort to the participant). during 30 minutes nd receive aerobic exercise training and resistance exercises for upper limbs and lower limbs.
223767443|NCT03560713|OTHER|Functional Electrical Stimulation (FES) sham|Participants will perform 12 weeks of Functional Electrical Stimulation (FES) sham (Neurodyn High Volt, IBRAMED, São Paulo/SP, Brasil), three times a week, frequency 5Hz, pulse rate of 200μs, ON:OFF 5:5, without muscle contraction during 30 minutes nd receive aerobic exercise training and resistance exercises for upper limbs and lower limbs.
224320830|NCT06795945|DIETARY_SUPPLEMENT|TPG2|"* Thymus Nuclear Extract Dose 2 (2150 mg \[5 tablets, 2x/day; total 10 tablets per day\])~* Placebo (3 tablets, 2x/day; total 6 tablets per day)"
224320831|NCT06795945|DIETARY_SUPPLEMENT|TPG3|Thymus Nuclear Extract Dose 3 (3440 mg \[8 tablets, 2x/day; total 16 tablets per day\])
223652328|NCT07156513|PROCEDURE|Epidural Pulsed Radiofrequency|Pulsed radiofrequency applied via a guidable epidural catheter electrode (Cosman RCE-E401519-P), advanced through the sacral hiatus to the target lumbar or sacral root (L5 and/or S1) under fluoroscopic guidance. Parameters: 45 V, 2 Hz, 20 ms pulses, applied at a single location with continuous temperature monitoring (≤42°C). Procedure performed with Cosman C4 generator.
223652329|NCT07156513|DRUG|Betamethasone (Epidural Corticosteroid Injection)|Epidural injection of 12 mg betamethasone diluted in 8 ml sterile saline, administered via the sacral hiatus under fluoroscopic guidance.
223652330|NCT07158268|DRUG|HSK47388|HSK47388 tablets will be administered orally, once a day
223652331|NCT07157501|BEHAVIORAL|Accupressure|Acupressure will be applied by pressing in circular movements on the acupoint with the thumb finger first in clock wise and then anti-clock wise direction. The finger must remain at the same point on the skin and be moved in small circles
223652332|NCT07157501|OTHER|Aromatherapy inhaler|The lavender inhalation application will be explained to the children and their mothers. Two drops of 100% pure organic lavender oil will poured on a cotton. The cotton will have fixed by the child at 5 cm distance from his or her nose and will asked to breathe slowly for 10-15 minutes
223652333|NCT07156500|DRUG|HS-20094 Injection|HS-20094 injected subcutaneously once weekly
223652334|NCT07156500|DRUG|HS-20094 Placebo Injection|HS-20094 Placebo injected subcutaneously once weekly
223767444|NCT06462690|OTHER|pre-mid-post test|(PIF) (DLQI) (GCS) Data Collection Forms Humidity measurement with DMM device
223767445|NCT02353247|DRUG|Norethindrone acetate|
223767446|NCT00665184|BEHAVIORAL|Resistance Exercise via Negative Eccentric Work|High intensity resistance training delivered 2-3 times per week for 12 weeks
223767447|NCT00665184|BEHAVIORAL|Standard care exercise training|Evidence based exercise training (resistance training, aerobic training, flexibility training) 2-3 times per week for 12 weeks.
223767448|NCT03440671|BIOLOGICAL|Hutox Inj|Hutox Inj(Clostridium botulinum type A)
223767449|NCT03440671|BIOLOGICAL|Botox Inj|Botox Inj(Clostridium botulinum type A)
223767450|NCT03144882|DRUG|Curcumin Pill|Turmeric rhizome at first was washed and dried out in a warm and dry place for a week , then powdered rhizomes were encapsulated by Clinical Pharmacy Research Center of Shahid Beheshti University of Medical Sciences, using hard gelatin capsules. Also placebo capsules were made by the same center using Sorbitol. Curcumin level of turmeric was measured by HPTLC analysis for quantification of variability in content of curcumin
224236639|NCT04371809|OTHER|DNA methylome|Epigenomics tools combined with bioinformatic analysis to find and correlate putative useful clinical biomarkers with clinical features
224236640|NCT02356471|DEVICE|Management of Therapy Complications Fitbit Zip (portable pedometer device)|Use pedometer to monitor physical activity
224236641|NCT02356471|OTHER|Questionnaire Administration|Ancillary studies
224236642|NCT02356471|OTHER|Quality-of-Life Assessment|Ancillary studies
223652335|NCT07156500|DRUG|HS-20094 Injection|HS-20094 injected subcutaneously once weekly
223652336|NCT07156500|DRUG|HS-20094 Placebo Injection|HS-20094 Placebo injected subcutaneously once weekly
223652337|NCT07158411|DRUG|Vimseltinib|Administered orally
223652338|NCT07158411|DRUG|Metformin|Administered orally
223652339|NCT07157969|DRUG|Lenvatinib|≥60 kg: 12 mg once daily, or \<60 kg: 8 mg once daily
223652340|NCT07157969|DRUG|Pembrolizumab|200 mg intravenously every three weeks
223652341|NCT07157969|DRUG|Atezolizumab|1200 mg intravenously every three weeks
223652342|NCT07157969|DRUG|Bevacizumab|15mg/kg intravenously every three weeks
223652343|NCT07157969|DRUG|Camrelizumab|200 mg intravenously every three weeks
223767451|NCT03144882|DRUG|Placebo|placebo
223767452|NCT05281614|DRUG|Etanercept|Etanercept is a fully humanized monoclonal antibody that targets TNFα.
223767453|NCT05281614|DRUG|Vedolizumab|Vedolizumab is a humanized monoclonal antibody that targets α4ß7 integrin.
223767454|NCT03196466|BIOLOGICAL|Valproic acid|titration
224236643|NCT03363074|DEVICE|Orthotic Insole|A computer numerical control machine was used to product insoles according to pedobarographic pressure data;35 Shore A hardness ethyl vinyl acetate was used for the main insole,and 3mm,15 Shore A hardness ethyl vinyl acetate was used for covering.Orthotic insoles have been emplemented in a pair of sports shoes.
224236644|NCT03363074|DEVICE|Low-Level Laser|A low density laser with a power density of 0.05-0.10 (w / cm2), a therapeutic dose of 0.7-7 (j / cm 2) of gallium-arsenic 904 nm will be applied. It will be 3 administered times a week for 5 weeks. Laser treatment will be applied along the tibialis posterior tendon. 3 different point (proximal tibial tendon, distally tibial tendon and posterior medial malleol) applications will be done.
223652344|NCT07157969|DRUG|Apatinib|250mg once daily
223652345|NCT07157969|PROCEDURE|TACE|The specific number and interval of interventional therapy sessions will be determined according to the patient's individual condition.
223652346|NCT07157969|PROCEDURE|HAIC|The specific number and interval of interventional therapy sessions will be determined according to the patient's individual condition.
223652347|NCT07157969|PROCEDURE|DEB-TACE|The specific number and interval of interventional therapy sessions will be determined according to the patient's individual condition.
223652348|NCT07158190|BIOLOGICAL|Vaccine|Vaccine TAK003 administration
223652349|NCT07157384|DIETARY_SUPPLEMENT|Low calorie meal replacement plan|intervention provided to both arms in 2 out of the 3 study phases: Phase 1 (total dietary replacement) and Phase 2 (food re-introduction)
223652350|NCT07157384|BEHAVIORAL|Diabetes self management education|intervention provided to both arms throughout study conducted as in-person session and telephone sessions
223652351|NCT07157384|DEVICE|Intermittently scanned continuous glucose monitoring|intervention provided to the intervention arm only: isCGM + LCMR + DSME
223652352|NCT07157384|DEVICE|capillary blood glucose monitoring|intervention provided to the control arm only: CBG + LCMR + DSME
223652353|NCT07156279|BEHAVIORAL|EFT(Emotional Freedom Technique)|EFT is a behavioral intervention in which participants tap with their fingertips on specific acupressure points while focusing on a target issue. The technique is non-invasive, painless, and simple to apply. Sessions also include the use of positive affirmations during tapping.
223652354|NCT07157488|BEHAVIORAL|Conventional Physical Therapy With Dual Task Training|"Participants undergo a 50-minute session, 3 times/week for 12 weeks.~Warm-up (10 min): Trunk and lower extremity ROM exercises (Lee et al., 2021).~Conventional PT (20 min): Wide leg squatting, hip flexion/extension, hip abduction/adduction, knee extension/flexion with ankle weights (Uysal et al., 2024).~Dual Task Training (20 min): Balance activities (semi-tandem stance, tiptoe, heel stance, one-leg stance, line walking) with cognitive activities (verbal fluency, simple math, memory recall, daily routine recall)."
223652355|NCT07157488|BEHAVIORAL|Dual Task Training With Vestibular Stimulation|"Participants undergo a 50-minute session, 3 times/week for 12 weeks.~Warm-up (10 min): Trunk and lower extremity ROM exercises (Lee et al., 2021).~Dual Task Training (20 min): Same as Intervention 1 (balance + cognitive tasks).~Vestibular Stimulation (20 min): Sliding activity on physio roll (10 repetitions) and vertical bouncing on physio roll for 10 minutes (Parashar et al., 2017)."
223652356|NCT07156903|OTHER|Interview|Patients and their care-givers will be asked to participate in interviews
223652357|NCT07158203|DEVICE|CADx simultaneously|The investigators showed the CADx suggestion during the 15-second playback of the video
223767455|NCT03196466|BIOLOGICAL|carbamazepine|titration
223767456|NCT03196466|BIOLOGICAL|phenobarbital|titration
223767457|NCT03196466|BIOLOGICAL|phenytoin|titration
223767458|NCT03196466|BIOLOGICAL|levetiracetam|titration
223767459|NCT03196466|BIOLOGICAL|lamotrigine|titration
224236645|NCT01890915|OTHER|Heat Exposure|Heat exposure of 95 degrees F for up to 2 hours.
224236646|NCT05431868|OTHER|AT LISA tri 839MP (Carl Zeiss Meditec AG)|This prospective cohort study collected data of patients who underwent bilateral or unilateral cataract surgery with the AT LISA tri 839MP implantation.
224236647|NCT01609764|BEHAVIORAL|One year fitness training|Regular training schedule of moderate intensity, at 50% of heart rate reserve, as available for the specific age group in fitness centres
224236648|NCT02663596|DRUG|Vancomycin|Patient requiring CRRT and vancomycin that provide consent will be given vancomycin as a continuous infusion by mixing the vancomycin into the CRRT solution(s)
224236649|NCT05903365|OTHER|Blood sampling|Additional blood samples at J100, M6, M12, M24
224236650|NCT04238156|OTHER|Hypopressive abdominal exercises|Three sessions per week during four consecutive weeks (Total: 12 sessions). Each session time: 30 minutes.
223652358|NCT07158203|BEHAVIORAL|CADx delayed|During the 15-seconds polyp video the CADx suggestion appear only in the last 3 seconds of the video
223767460|NCT03196466|BIOLOGICAL|topiramate|titration
224236651|NCT00424489|BIOLOGICAL|Hematopoietic Stem Cell Transplantation|Autologous Hematopoietic Stem Cell Transplantation
224236652|NCT00424489|DRUG|Cyclophosphamide|
224236653|NCT00424489|DRUG|ATG (rabbit)|
224236654|NCT00424489|DRUG|Mesna|
224236655|NCT00424489|DRUG|Methylprednisolone|
224236656|NCT00424489|DRUG|G-CSF|
224236657|NCT03614520|OTHER|Administration of olive oil|25 mL of extra virgin olive oil
223652359|NCT07151508|DEVICE|Secukinumab was administered in a weight-adapted dosing regimen ? Dupilumab was administered at a dose dependent on the patient's weight and age|"Secukinumab was administered in a weight-adapted dosing regimen equivalent to that used in clinical trials for psoriasis: 75 mg for less than 25 kg,150 mg for 25 to 50 kg, and 300 mg for greater than 50 kg at baseline and weeks1,2,3, and 4 and monthly there after.~Dupilumab was administered at a dose dependent on the patient's weight and age in accordance with the instructions."
223652360|NCT07156773|DRUG|XJN010 Nasal Spray|"In the XJN010 Nasal Spray group, subjects will receive XJN010 Nasal Spray，Based on the frequency of the off periods experienced by Parkinson's patients."
223652361|NCT07156773|DRUG|Placebo|"In the XJN010 Nasal Spray blank preparation group, subjects will receive XJN010 Nasal Spray blank preparation, Based on the frequency of the off periods experienced by Parkinson's patients ."
223652362|NCT07157943|OTHER|Abridge AI Scribe|"Users will have access to the Abridge AI scribe software, either integrated into Epic Haiku (Abridge Inside) or via standalone app that send information back to Epic (Abridge Integrated)."
223767461|NCT03196466|BIOLOGICAL|oxcarbazepine|titration
223767462|NCT03196466|BIOLOGICAL|stiripentol|titration
223767463|NCT03196466|BIOLOGICAL|clobazam|titration
223767464|NCT03196466|BIOLOGICAL|brivaracétam|titration
223767465|NCT03196466|BIOLOGICAL|felbamate|titration
223767466|NCT03196466|BIOLOGICAL|lacosamide|titration
223767467|NCT03196466|BIOLOGICAL|rufinamide|titration
223767468|NCT03196466|BIOLOGICAL|gabapentine|titration
223767469|NCT03196466|BIOLOGICAL|pregabaline|titration
223767470|NCT03196466|BIOLOGICAL|sultiame|titration
223767471|NCT03196466|BIOLOGICAL|tiagabine|titration
223767472|NCT03196466|BIOLOGICAL|vigabatrine|titration
223767473|NCT03196466|BIOLOGICAL|mesuximide|titration
223652363|NCT07157943|OTHER|DAX Copilot|Users will have access to DAX Copilot integrated into Epic Haiku or via standalone app.
223652364|NCT07156643|DRUG|Anlotinib and bempegaldesleukin|"Subjects will receive concurrent anlotinib, bempegaldesleukin, and radiotherapy, followed by maintenance therapy with anlotinib, bempegaldesleukin, and chemotherapy.~Concurrent Radiotherapy Phase:~Anlotinib: 10 mg orally once daily on days 1-14, every 3 weeks (q3w), for 2 cycles during radiotherapy.~Bempegaldesleukin: 1200 mg IV on day 1, q3w, for 2 cycles during radiotherapy. Radiotherapy: Delivered once daily, with a total biological effective dose (BED) of 36-100 Gy. Techniques may include conventional fractionation or stereotactic body radiotherapy (SBRT), as determined by the investigator.~Maintenance Phase:~Chemotherapy: Doxorubicin 40 mg/m² IV day 1 + ifosfamide 1.2-2.4 g/m² IV days 1-5 per 21-day cycle for 4-6 cycles.~Anlotinib: 10 mg orally once daily on days 1-14, q3w. Bempegaldesleukin: 1200 mg IV on day 1, q3w."
223652365|NCT07158359|BEHAVIORAL|chewing gum mastication|chewing gum mastication
223652366|NCT07157761|BEHAVIORAL|Buit in de klas|The program is taught by a trusted teacher of the students (for example, their mentor). The program consists of a lesson of about one hour. It includes a short film and an interactive chat box that allows students to chat with the main character of the film. In addition, there is a guideline for discussing the topic in the classroom and information on where to find help.
223767474|NCT03196466|BIOLOGICAL|primidone|titration
223767475|NCT03196466|BIOLOGICAL|perampanel|titration
223767476|NCT03196466|BIOLOGICAL|ethosuximide|titration
223767477|NCT03196466|BIOLOGICAL|zonisamide|titration
223652367|NCT07156422|PROCEDURE|A scalp biopsy using a 4 mm punch in the retroauricular hair zone|a scalp biopsy using a 4 mm punch in the retroauricular hair zone under local anesthesia
223767478|NCT03196466|BIOLOGICAL|cannabidiol|titration
223767479|NCT03196466|OTHER|genetic polymorphisms|genetic polymorphisms
223767480|NCT00719004|PROCEDURE|Ultrasound of the foot|These volunteers will have one ultrasound scan of each foot
223767481|NCT00005669|DRUG|Metformin HCL|Medication studied for ability to alter body weight and body composition.
223767482|NCT00005669|DRUG|Placebo|Control capsules for metformin
223767483|NCT05206474|DEVICE|IRADYN|"One course of IRADYN® at baseline, consisting of a mono-dose intra-articular administration (2 ml).~From week 1 to week 6, injection will be performed, if necessary, during the visit, following the dosage reported in the instruction for use / summary of product characteristic."
223767484|NCT02915614|PROCEDURE|Pulmonary rehabilitation|3-weeks of inpatient pulmonary Rehabilitation including exercise Training (daily endurance and strength Training)
223767485|NCT06317311|BIOLOGICAL|Dostarlimab|Dostarlimab is administered via intravenous (IV) infusion at a dose of 500 milligram (mg) for first 6 cycles (each cycle is of 21 days) followed by 1,000 mg from cycle 7 (each cycle is of 42 days)
223767486|NCT06317311|DRUG|Carboplatin|Carboplatin is administered IV at a dose of Area under the concentration time curve (AUC) 5 milligram\*millilitre/ minute (mg•mL/min) for cycles 1 to 6 (each cycle is of 21 days)
223767487|NCT06317311|DRUG|Paclitaxel|Paclitaxel is administered IV at a dose of 175 milligram per meter square (mg/m2) for cycles 1 to 6 (each cycle is of 21 days)
223767488|NCT01148004|DRUG|Fenofibrate|
223767489|NCT01148004|DRUG|Ritonavir|
223767490|NCT01148004|DRUG|Lopinavir/Ritonavir|
223767491|NCT01922024|DEVICE|LRT55 Testing|Testing on the Unyvero LRT55
223767492|NCT06478004|OTHER|Direct composite restoration of carious primary anterior teeth using custom 3D printed templates|A patient dental model is acquired by digital scan then digital waxing-up is performed using the Exocad software to 3D print clear templates for direct composite resin restoration.
223767493|NCT06478004|OTHER|Direct composite restoration of carious primary anterior teeth using conventional strip crowns|Direct composite resin restoration using celluloid crown forms
223767494|NCT02611622|BEHAVIORAL|LUMA ENT™|
223767495|NCT02611622|OTHER|Survey|Demographic and Patient Satisfaction Survey
223767496|NCT00196781|BEHAVIORAL|CD-ROM-based prostate cancer treatment education|The goal was to explore men's use of a CD-ROM-based decision aid for early-stage PCa treatment decisions.
223767497|NCT00196781|BEHAVIORAL|CD-ROM-based prostate ca treatment education+decision tools|The goal of the present study was to explore men's use of a CD-ROM-based decision aid for early-stage PCa treatment decisions.
223767498|NCT02367599|DRUG|Vitamin D Supplement|Subjects enrolled into this sub-study will be provided Vitamin D 4000IU/day for 24 Weeks.
223767499|NCT01302821|BIOLOGICAL|Adenovirus-p53 transduced dendritic cell vaccine|The Ad.p53 DC vaccine will be injected intradermally (through the skin) into four separate sites. The patient's vaccine will be the same dose throughout the study.
223767500|NCT01302821|DRUG|1-methyl-D-tryptophan|Each treatment cycle is comprised of 21 days. The treatment is continuous with no breaks in between cycles. Patients would not be allowed to take any tryptophan containing supplements while participating on this study.
223767501|NCT01302821|RADIATION|Carbon C 11 alpha-methyltryptophan|The experimental examination for this research is the administration by a needle in a vein of Tryptophan labeled with a radioactive tracer (a substance is believed to enhance imaging for easier detection and measurement), Carbon 11, when when the patient has not eaten for five hours. A standard PET/CT scanner is then used to create images of the tracer a few minutes later.
223767502|NCT03385239|DRUG|ISIS 678354|ISIS 678354 solution for SC injection.
223767503|NCT03385239|DRUG|Placebo|Sterile Normal Saline (0.9% NaCl).
223767504|NCT04952220|DEVICE|ultrasound|Describe the sonographic abnormalities observed at Day 0, Day 10, 6 weeks, 3 months, 6 months, during native septic arthritis of the knee
223767505|NCT01357993|DRUG|JNS001|18 mg, 27 mg and 36 mg tablets (18-72 mg/day) once daily for 48 weeks
223767506|NCT04732637|DIAGNOSTIC_TEST|"Test At Home's Proprietary Lollipop Buccal Cavity Swab"|"Self-collected Test At Home's proprietary Lollipop Buccal Cavity Swab with VTM."
223767507|NCT01574703|DRUG|placebo|All dosing to have taken place per study A3051123
223767508|NCT01574703|DRUG|varenicline tartrate|All dosing to have taken place per study A3051123
223767509|NCT01574703|DRUG|bupropion hydrochloride|All dosing to have taken place per study A3051123
223767510|NCT01574703|DRUG|Nicotine Replacement Therapy Patch|All dosing to have taken place per study A3051123
224236658|NCT03614520|OTHER|Administration of red wine|150 mL or Red Wine
224320832|NCT06795945|DIETARY_SUPPLEMENT|Placebo|Placebo (8 tablets, 2x/day; total 16 tablets per day)
224236659|NCT03614520|OTHER|Combination of red wine and olive oil|150 mL of Red wine + 25 mL of Extra Virgin Olive oil will be administred at the same time
224236660|NCT03614520|OTHER|Water|Mineral water will be given as placebo
224236661|NCT03614520|OTHER|Dark beer|250 mL of IPA beer (alcohol 8.5% vol)
223652368|NCT07156422|OTHER|a general health questionnaire|a general health questionnaire : demographics, history, treatment, smoking, alcohol consumption, phototype.
223652369|NCT07156422|OTHER|Questionnaires concerning their sensitive scalp|"* The characteristics of a sensitive scalp (location, chronicity, triggering and soothing factors, use of cosmetics, etc.)~* Sensitive Scalp Score (3S)~* Impact on quality of life: BoSS questionnaire~* Impact of pruritus on quality of life (ItchyQol)"
223652370|NCT07157956|DRUG|CVL006 combined with pemetrexed and carboplatin|CVL006 combined with pemetrexed and carboplatin
223652371|NCT07157956|DRUG|CVL006 in combination with SKB264|CVL006 in combination with SKB264
224236662|NCT03614520|OTHER|Light Beer|250 mL of blonde ale beer (alcohol 4,5% vol)
224236663|NCT03614520|OTHER|Alcohol free Beer|250 mL of alcohol free beer (alcohol 0.0% vol)
223652372|NCT07157956|DRUG|CVL006 in combination with DS-8201|CVL006 in combination with DS-8201
223652373|NCT07157956|DRUG|CVL006 in combination with Enfortumab Vedotin|CVL006 in combination with Enfortumab Vedotin
223652374|NCT07156799|DRUG|Kaempferol Gel|Local topical application of Kaempferol gel into the implant site during one-stage delayed implant placement to enhance peri-implant bone healing and osseointegration.
223652375|NCT07156942|BEHAVIORAL|Story-Based Digital Game|Participants in this arm played a story-based digital game during their regular hemodialysis sessions. The game was administered once per week, with each session lasting approximately 10 to 15 minutes, over a 4-week period. The game was accessed via an online platform and designed to educate patients on dietary choices, fluid management, and dialysis self-care through interactive storytelling and decision-making tasks.
223652376|NCT07156565|DRUG|[Ac 225]RTX-2358|\[Ac225\]RTX-2358 will be given as an intravenous injection once every 8 weeks for up to 6 doses. Each group (3 total) will receive a set administered activity level (dose) of \[Ac 225\]RTX 2358 given once every 8 weeks. The first group will received the lower dose, the second group will received the mid level dose, and the third group the highest dose. A Safety Review Committee will determine when/if it is appropriate to allow the next group to proceed.
223767511|NCT04906642|DEVICE|Next Science|Solution is a clear, colorless, aqueous solution that is used to remove debris, including microorganisms, from wounds via hydrodynamic shear across the wound. This aids in the removal of foreign material such as, microorganisms, dirt, and debris.
223767512|NCT04906642|OTHER|Standard of Care|Normal Saline will be used in place of Next Science for irrigation
224236664|NCT05921890|DRUG|GS3-007 oral liquid|The dosage was calculated according to body weight, once a day or twice a day.
224236665|NCT04558554|OTHER|pharmacy-based PrEP delivery|The intervention is a new model of PrEP delivery that has never been tried before in an African setting: pharmacy-based PrEP delivery.
223652377|NCT07156565|DIAGNOSTIC_TEST|[Cu64]LNTH-1363S|\[Cu64\]LNTH-1363S is a investigational radioactive diagnostic imaging agent to demonstrate that the tumor expresses Fibroblast Activation Protein. An imaging test is performed after a single injection with \[Cu64\]LNTH-1363S 13-35 days before the first administration of study drug \[AC225\]RTX-2358 to confirm that the sarcoma has FAP expression.
223652378|NCT07157748|DRUG|Fufang E'jiao Jiang|Oral solution; 20 mL TID for 90 days;
223652379|NCT07157748|DRUG|Matching Placebo|Oral solution; 20 mL TID for 90 days;
224236666|NCT02921477|DRUG|bosutinib|
224236667|NCT01856153|DIETARY_SUPPLEMENT|Before meal|
224236668|NCT01856153|DIETARY_SUPPLEMENT|With Meal|
224236669|NCT01856153|DIETARY_SUPPLEMENT|After meal|
224236670|NCT03236181|OTHER|SFA|High saturated fatty acid/SFA oil source
224236671|NCT03236181|OTHER|MUFA|High monounsaturated fatty acid/MUFA oil source
224236672|NCT03236181|OTHER|PUFA|High polyunsaturated fatty acid (linoleic)/PUFA oil source
224236673|NCT03236181|OTHER|LCn3|High polyunsaturated fatty acid (omega-3)/LCn3 oil source
224236674|NCT02834611|DRUG|Ceramide NanoLiposome|Intravenous administration of Ceramide NanoLiposome
224236675|NCT05556109|DIAGNOSTIC_TEST|Inflammatory serum biomarkers|Measuring inflammatory serum biomarkers by ELISA
224236676|NCT01252069|DRUG|PGL4001, placebo, drug free period|PGL4001 10mg once daily (oral tablets) for 3 months followed by a period of 10 days of placebo (oral tablets) during 3 periods each ending with a drug free period until return of menses.
224236677|NCT01252069|DRUG|PGL4001, progestin, drug free period|PGL4001 10mg once daily (oral tablets) for 3 months followed by a period of 10 days of progestin Norethisterone acetate 10mg once daily (oral tablets) during 3 periods each ending with a drug free period until return of menses.
223652380|NCT07156253|DRUG|SYN818 and Olaparib will be administered|Patients will orally receive SYN818 and Olaparib
223652381|NCT07156305|BEHAVIORAL|Protective Behavioral Strategies|Participants receive psychoeducation about protective behavioral strategies and are asked to choose three strategies that they do not already engage in regularly but would be willing to start using more.
223652382|NCT07156305|BEHAVIORAL|Goal-Setting|Participants receive psychoeducation about protective behavioral strategies and goal-setting. They are asked to choose three strategies that they do not already engage in regularly and identify two goals related to each strategy.
223767513|NCT05339607|OTHER|Thermal ablation of resection margins by STSC and biliary orifice by cystotome.|Patients who are eligible will undergo thermal ablation of the resection margins.
224236678|NCT00072124|DRUG|cisplatin|
224236679|NCT00072124|DRUG|dacarbazine|
224236680|NCT00072124|PROCEDURE|conventional surgery|
224236681|NCT04999553|DEVICE|Repetitive Transcranial Magnetic Stimulation|rTMS will employ the MagPro X100/R30 stimulator equipped with the cool-B70 as we used a cool-B70 in our past non-inferiority trial. The dose will be a 120% rMT in accordance to our latest trial using iTBS. The target area to stimulate will be the right dorsolateral prefrontal cortex (DLPFC) for LFR and the left DLPFC for iTBS as established in prior clinical trials. The localization of both targets will follow the well-established procedures for either R-DLPFC or L-DLPFC using a heuristic method.
224236682|NCT04999553|DEVICE|Intermittent Theta Burst Stimulation (iTBS)|Intermittent Theta Burst Stimulation (iTBS)
224236683|NCT04999553|DEVICE|Low Frequency Right (LFR)|Low Frequency Right (LFR)
224236684|NCT05834283|OTHER|aerobic exercises|"This group will be received aerobic exercises 3 sessions per week for 8 weeks. Warm up phase: in which each participant will walk at 80 m/min at 0.0% grade for 5 mint.~Active phase: treadmill speed will be increased to 147 m/min and grade will be increased gradually untill reached 25% grade for 20 mint.~Cool down phase: in which the treadmil speed and grade will be decreased to 2.0miles/h and 0.0% grade during a cool down period consisted of 5 mint."
224236685|NCT05834283|OTHER|core stability exercises|"This group will be received core stability exercises 3 sessions per week for 8 weeks.~All participants in both groups will be evaluated before and after the treatment programs.~Lie on your back and place your feet on a wall so that your knees and hips are bent at 90 degrees angles. Tighten your abdominal muscles.~Raise your head and shoulders off the floor. Return to the start position and repeat."
223652383|NCT07157813|BEHAVIORAL|Structured Health Dialogue|"Health Screening (Approx. 15-20 minutes):~Measurement of height, weight, BMI, and waist-to-hip ratio Blood pressure recording Collection of fasting blood samples to assess glucose, cholesterol, and triglyceride levels~Health and Lifestyle Questionnaire:~Self-reported assessment of physical activity, dietary habits, alcohol and tobacco use, psychosocial stress, and family history of cardiovascular disease~Creation of an Individualized Health Curve:~Visual summary of the patient's current cardiovascular risk factors, showing how these factors interact and where improvement is needed~Structured Health Dialogue (60-90 minutes):~A one-on-one conversation between the participant and a trained nurse using principles of motivational interviewing Focused on identifying personal health goals, enhancing motivation for lifestyle change, and discussing possible support strategies Tailored Health"
224236686|NCT00921193|DEVICE|Radiation Therapy Positioning System (RTPS)|
224236687|NCT03716141|OTHER|Autologous Platelets Rich Plasma Treatment|For PRP preparation 10 mL of the patient blood was collected. The blood was centrifuged at 2000 rpm for 5 min to obtain plasma. Then, this plasma was centrifuged at 3000 rpm for another 5 min to collect platelets. Platelets were diluted in 5 mL plasma to form PRP.
224236688|NCT03716141|OTHER|Conventional Saline dressing|saline dressing of diabetic wounds will be done
224236689|NCT04462458|DEVICE|Medacta Anatomic Ribbon Surgery (M-ARS ACL)|M-ARS ACL allows to reconstruct the anterior cruciate ligament using the Anatomic Ribbon Technique
224236690|NCT00000462|PROCEDURE|angioplasty, transluminal, percutaneous coronary|
224236691|NCT00000462|PROCEDURE|coronary artery bypass|
224236692|NCT03931876|DRUG|Placebos|Single ascending dose administration
224236693|NCT03931876|DRUG|AV-006|Single ascending dose administration
224236694|NCT00386009|DRUG|Tadalafil|20 mg tadalafil tablet taken by mouth once a day for 12 weeks.
224236695|NCT00386009|DRUG|Placebo|Placebo tablet taken by mouth once a day for 12 weeks.
224236696|NCT00005006|DRUG|Parathyroid Hormone|Alendronate 70mg/week; Teriparatide 20mcg/ day
224236697|NCT00005006|DRUG|Alendronate|Alendronate 70mg/week
224236698|NCT00005006|DRUG|Teriparatide|Teriparatide 20mcg/day
224236699|NCT01013025|PROCEDURE|Ultrasound or CT or MRI to locate implant|Scanning methods (eg, ultrasound, CT, or MRI) were used to locate the implant.
224236700|NCT01141465|DRUG|Fluticasone / formoterol metered dose inhaler|Prescribed at the same BDP-equivalent dose as baseline ICS
224320833|NCT06795529|OTHER|"Palliative Care Intervention, TARGET-PC"|Palliative care intervention focused on eliciting patients' goals and values to facilitate discussion and documentation of health care preferences.
224320834|NCT06795529|OTHER|Enhanced Usual Care|Oncology clinicians will receive an electronic message to encourage them to discuss and document their patients' health care preferences.
223652384|NCT07158320|BEHAVIORAL|Relaxation training|In Jacobson's progressive muscle relaxation method, the first step is to make various muscle groups contract, to realize what it feels like to contract in this body area; The second step is to release these contracted muscle groups and notice how a relaxed muscle feels as the contraction subsides. During the exercise, the contraction is continued for 5 seconds. After the contraction, the muscles are relaxed for 10-15 seconds and in the meantime, rest is provided. Before starting the training, the person is taught the correct breathing technique and is asked to use the correct breathing technique throughout the practice. The practice should be done calmly without haste. During the practice, people should choose clothes that they can feel comfortable in. The practice should be applied in a quiet, dim environment where people can feel comfortable. It can also be performed with the eyes closed.
223652385|NCT07156240|BEHAVIORAL|Experimental I (SDT)|SDT-based course aiming to inmprove professionals operational interpersonal qualities
223652386|NCT07156240|BEHAVIORAL|Experimental II (Hedonic)|Hedonic-based course aiming to inmprove professionals operational interpersonal qualities
223652387|NCT07156240|OTHER|Control group|FITT-VP bases course aiming to improve exercise prescription
223652388|NCT07156994|OTHER|No Intervention: Observational Cohort|Participants will be followed digitally using the LCC app. They will complete questionnaires about their health status and do voice recordings on their own rhythm during the entire study duration.
223767514|NCT05558293|PROCEDURE|Scaling and root planing|Full mouth or quadrant SRP
224236701|NCT01141465|DRUG|Fluticasone / salmeterol dry powder inhaler|Prescribed at the same BDP-equivalent dose as baseline ICS
224236702|NCT01141465|DRUG|Budesonide / formoterol dry powder inhaler|Prescribed at the same BDP-equivalent dose as baseline ICS
224236703|NCT01141465|DRUG|Fluticasone / salmeterol dry powder inhaler|Prescribed at ≥twice BDP-equivalent dose as baseline ICS
224236704|NCT01141465|DRUG|Fluticasone / salmeterol metred dose inhaler|Prescribed at ≥twice BDP-equivalent dose as baseline ICS
224236705|NCT01141465|DRUG|BUD/FOR dry powder inhaler|Prescribed at ≥twice BDP-equivalent dose as baseline ICS
224236706|NCT04320173|DRUG|Lidocaine patch 1.8%|Three patches are applied to the subject's back for 12 hours.
224236707|NCT04320173|DRUG|Lidocaine patch 5%|Three patches are applied to the subject's back for 12 hours.
224236708|NCT04320173|DRUG|Lidocaine medicated plaster 5%|Three plasters are applied to the subject's back for 12 hours.
224236709|NCT01282359|OTHER|Clinical practice group|Clinical practice group will not receive any specific education
224236710|NCT01282359|OTHER|"Gold Standard educational group"|"Gold Standard educational group will receive a formal program of structured and individualized education"
223652389|NCT07157683|OTHER|Biospecimen collection|"If a blood sample is drawn as part of standard care, up to six additional EDTA tubes (42 mL max) will be collected for research.~In addition, the following optional samples may be collected, depending on investigator assessment and/or patient preference:~* Saliva sample (if no blood draw is performed)~* Urine sample~* Stool sample"
224236711|NCT01282359|OTHER|Intervention group|Intervention group will take the limited educational asthma program which have three parts: basic information, establishment and revision of a small Action Plan (MiniPlan) and training and review of the inhalation skill of the prescribed device. Educators involved will attend a short workshop (6 h), where they will be trained in the program.
224236712|NCT04854148|OTHER|Smartphone Movement Health Assessment|Participants will perform the assessment using an App installed on a smartphone device. Following the smartphone assessment, gold standard clinical assessments will be performed and scored for comparison
224236713|NCT02465567|DRUG|BGF MDI 320/14.4/9.6 μg|Budensonide, Glycopyrronium, and Formoterol Fumarate
224236714|NCT02465567|DRUG|GFF MDI 14.4/9.6 μg|Glycopyrronium, and Formoterol Fumarate
224236715|NCT02465567|DRUG|BGF MDI 160/14.4/9.6 μg|Budensonide, Glycopyrronium, and Formoterol Fumarate
224236716|NCT02465567|DRUG|BFF MDI 320/9.6 μg|Budensonide, and Formoterol Fumarate
224236717|NCT06356675|DRUG|Tislelizumab|200mg iv D1 Q3W
224236718|NCT06356675|DRUG|Anlotinib|Anlotinib 12mg D1-12 Q3W
224236719|NCT02651636|DRUG|myo-inositol,alpha-lipoic acid and folic acid|
224236720|NCT04553575|BIOLOGICAL|serology|biological blood samples withdrawn at 6, 12 and 24 months
224236721|NCT05101174|BEHAVIORAL|Integrated Intervention Group (IIG)|"The IIG attends 150 min exercise per week, which consists of one 90-min trainer-supervised session and multiple online sessions for 6 months. Each session consists of (1) warm-up, (2) resistance exercise and flexibility exercise, (3) resistance exercise and coordinative exercise from the Eastern exercise perspective, (4) social interaction exercise, and (5) cool-down and meditation."
224236722|NCT05101174|BEHAVIORAL|Control Group|The Control Group is informed to maintain their lifestyles and invited to attend one 60-min online educational course per week. The participants are required to provide their physical activity behavior once every month for 6 months (6 times).
224236723|NCT02234466|DRUG|Oral dexamethasone|Patients will received their study drug ( or placebo) 2 hours pre-induction. Allowing for the shifting schedules of the OR with the possibility of the previous case finishing early or late, the allowable range is 90-200 minutes pre-induction.
224236724|NCT02234466|DRUG|Ondansetron|Patients in both groups will receive 6mg IV ondansetron at time of skin closure as their standardized prophylaxis for postoperative nausea and vomiting.
224236725|NCT02234466|OTHER|Gelatin capsule|Gelatin capsule enclosing either dexamethasone tabs or second gelatin capsule
223652390|NCT07157150|BEHAVIORAL|Free Play SSG|Other current and former name(s) or alias(es), if any, different from the Intervention Name(s), that the sponsor has used publicly to identify the intervention(s), including, but not limited to, past or present names such as brand name(s), or serial numbers
223652391|NCT07157150|BEHAVIORAL|Controlled Pass|Participants train in 3v3 and 4v4 football games under Controlled Pass rules for 8 weeks.
223652392|NCT07157709|OTHER|non-pharmacological interventions|Care staff collaborate with residents to select the most suitable non-pharmacological intervention from the designated toolkit to reduce pain. It is imperative to pay attention to the resident's preferences and to ascertain which intervention they would like to attempt.
223652393|NCT07156292|OTHER|Observational study, not interventional|Observational study, not interventional
223767515|NCT04401891|BEHAVIORAL|Formal pre-operative education|One group of patients will receive formal pre-operative education prior to surgery from an occupational or physical therapists while the other group of patients will only receive routine education in the MD office.
224236726|NCT05020548|OTHER|peak inspiratory pressure 10 cmH2O|pressure controlled mask ventilation with peak inspiratory pressure of 10 cmH2O
224236727|NCT05020548|OTHER|peak inspiratory pressure 15 cmH2O|pressure controlled mask ventilation with peak inspiratory pressure of 15 cmH2O
224236728|NCT05020548|OTHER|peak inspiratory pressure 20 cmH2O|pressure controlled mask ventilation with peak inspiratory pressure of 20 cmH2O
224236729|NCT04527809|DEVICE|tDCS-active|One session of active Trasncranial Direct Current Stimulation combine to a Virtual Reality task.
224236730|NCT04527809|DEVICE|tDCS-sham|One session of sham Trasncranial Direct Current Stimulation combine to a Virtual Reality task.
224236731|NCT05037149|DRUG|STP707|STP707 Powder for Injection
224236732|NCT03141203|DRUG|Romidepsin|10mg vial for Injection
224236733|NCT03141203|DRUG|Carfilzomib|60mg vial for injection
224236734|NCT03712722|OTHER|Faecal microbiota transplantation (FMT)|FMT delivered by colonoscopy, nasojejunal tube, glycerol-based capsules, or freeze-dried encapsulated donor faeces
224236735|NCT00497796|DRUG|maribavir|100mg twice a day for 14 weeks.
224236736|NCT00497796|DRUG|ganciclovir|1000mg three times per day for 14 weeks.
224236737|NCT02771548|PROCEDURE|Anterior Cruciate Ligament Reconstruction|
224236738|NCT04418388|DRUG|PBK-1801|Administered orally
224236739|NCT04418388|DRUG|PBK-1801|Administered orally
224236740|NCT04418388|DRUG|PBK-1801|Administered orally
223652394|NCT03474965|DRUG|Crizanlizumab|Crizanlizumab (SEG101) is a concentrate for solution for infusion, i.v. use. Supplied in single use 10 mL vials at a concentration of 10 mg/mL. One vial contains 100 mg of crizanlizumab.
223652395|NCT03229941|PROCEDURE|Blood Transfusion|Blood Transfusion
223652396|NCT03478514|DRUG|Palbociclib|Taken at 100 mg once daily for 21 days, followed by 7 days off
223652397|NCT03478514|DRUG|Ibrutinib|560 mg taken orally all patients throughout the study
223652398|NCT06676033|DRUG|epcoritamab|Samples from subjects receiving epcoritamab on another clinical trial GCT3013-03 will be collected.
223652399|NCT06308081|OTHER|Tailored|Messages will be in the form of high-quality English-language anti-vaping messages comprising static text and imagery designed to resemble social media posts (e.g., image and a caption). We will create 24 messages based on the top-ranked tailoring features and belief themes tested in Aim 2 to comprise SGM-tailored messages. For the non-tailored message condition, we will create 24 anti-vaping social media messages that mirror the SGM-tailored messages but do not contain SGM identity cues. We will match the belief themes used in the tailored and non-tailored messages such that they represent a range of belief targets (e.g., addiction, physical health effects, mental health effects) as indicated in Aims 1 and 2. We do not utilize a social media platform for the delivery of the message to avoid potential contamination across randomized conditions.
223652400|NCT03808610|DRUG|Cyclophosphamide|Given IV
223652401|NCT03808610|DRUG|Cytarabine|Given IV
223652402|NCT03808610|DRUG|Dexamethasone|Given IV or PO
223652403|NCT03808610|DRUG|Methotrexate|Given IV
223652404|NCT03808610|DRUG|Nelarabine|Given IV
223652405|NCT03808610|DRUG|Pegaspargase|Given IV
223652406|NCT03808610|DRUG|Prednisone|Given PO
223767516|NCT04216082|DRUG|Anlotinib|Anlotinib is a oral small molecule receptor tyrosine kinases inhibitor with the potency of inhibiting tumor angiogenesis as well as cell proliferation simultaneously and have been approved to treat advanced non-small cell lung cancer (NSCLC) in China. Anlotinib capsules given orally in fasting conditions , once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21).
223767517|NCT03365284|DEVICE|Smart Kneebrace with a smart phone app|Smart Kneebrace will be used during the rehabilitation. Patients wearing the Smart KneeBrace are able to know their daily activity summary and exercise performance during rehabilitation training through a smart phone app.
223767518|NCT03365284|OTHER|regular rehabilitation procedure|regular rehabilitation procedure, especially muscle strengthening exercises
224236741|NCT05575271|PROCEDURE|Vagus Nerve Stimulation Modulation of the Coeruleus-Norepinephrine Network|The implant surgery is performed under general anesthesia. The generator is implanted subcutaneously in the left upper chest or left axillary border. The electrode lead wire is attached to the left mid-cervical vagus nerve through a second incision in the left neck area. The lead wire is passed through a subcutaneous tunnel and attached to the pulse generator.
224236742|NCT02292745|RADIATION|stereotactic radiotherapy|
224236743|NCT05488197|OTHER|uterine artery doppler at 18-23 weeks of pregnancy|uterine artery doppler at 18-23 weeks of pregnancy
224236744|NCT00004579|BIOLOGICAL|gp160 MN/LAI-2|
224236745|NCT00004579|BIOLOGICAL|ALVAC-HIV MN120TMG (vCP205)|
224236746|NCT06487676|PROCEDURE|Toe transfer|Toe-to-hand transfer
223652407|NCT03808610|BIOLOGICAL|Rituximab|Given IV
223652408|NCT03808610|DRUG|Venetoclax|Given PO
224236747|NCT06487676|PROCEDURE|Replantation|Finger or thumb replantation after amputation
224236748|NCT04860219|DIETARY_SUPPLEMENT|Lactoferrin|7 successive days treatment of Lactoferrin started within day 0 of COVID-19 diagnosis by RT-PCR
224236749|NCT00973193|DRUG|panitumumab|intravenous infusion of panitumumab, 6 mg per kg body weight, once every 14 days for a total of 42 days
224236750|NCT00219323|DRUG|Omalizumab|
224236751|NCT01184560|DRUG|Sibutramine|"○ Dosing standard Run-in period: All subjects would administer Sibutramine placebo 1 capsule (once daily) and Orlistat placebo 1 capsule (three times daily). The total dosing period is 2 weeks.~Treatment period: The total dosing period is 12 weeks.~* Sibutramine monotherapy group: Sibutramine 1 capsule once daily + Orlistat placebo 1 capsule three times daily~* Orlistat and Sibutramine combination group: Sibutramine 1 capsule once daily + Orlistat 1 capsule three times daily"
223652409|NCT03808610|DRUG|Vincristine|Given IV
223652410|NCT02502786|BIOLOGICAL|humanized anti-GD2 antibody|
223652411|NCT02502786|DRUG|GM-CSF|
223652412|NCT06399263|DRUG|Psilocybin|The psilocybin will include two dose administration sessions, first a 20mg administration, and second an administration of up to 30mg.
223652413|NCT06399263|BEHAVIORAL|Preparation and Integration Sessions|The psilocybin therapy will include three preparatory sessions, two dose A integration sessions, and four final integration sessions.
223652414|NCT05617677|DRUG|Deucravacitinib|Specified dose on specified days
223652415|NCT05617677|OTHER|Placebo|Specified dose on specified days
223652416|NCT02255435|DRUG|Omaveloxolone Capsules, 2.5 mg|
223652417|NCT02255435|DRUG|Omaveloxolone Capsules, 5 mg|
223652418|NCT02255435|DRUG|Omaveloxolone Capsules, 10 mg|
223652419|NCT02255435|DRUG|Placebo|
223652420|NCT02255435|DRUG|Omaveloxolone Capsules, 20 mg|
223652421|NCT02255435|DRUG|Omaveloxolone Capsules, 40 mg|
223652422|NCT02255435|DRUG|Omaveloxolone Capsules, 80 mg|
223767519|NCT00122720|DRUG|Darbepoetin Alfa|
224236752|NCT01184560|DRUG|Orlistat|"○ Dosing standard Run-in period: All subjects would administer Sibutramine placebo 1 capsule (once daily) and Orlistat placebo 1 capsule (three times daily). The total dosing period is 2 weeks.~Treatment period: The total dosing period is 12 weeks.~* Sibutramine monotherapy group: Sibutramine 1 capsule once daily + Orlistat placebo 1 capsule three times daily~* Orlistat and Sibutramine combination group: Sibutramine 1 capsule once daily + Orlistat 1 capsule three times daily"
224236753|NCT02301676|BEHAVIORAL|Korean version of telephone interview for cognitive status|The telephone interview for cognitive status (TICS), developed by Brandt et al. (1988), is one of the most popular telephone interview-based screening instruments. Especially, the Korean version of TICS is translated more suitable for Korean culture with the permission of the authors of the original version. The Korean version of TICS consists of 11 items, total score is 41.
223652423|NCT02255435|DRUG|Omaveloxolone Capsules, 160 mg|
223652424|NCT02255435|DRUG|Omaveloxolone Capsules, 300 mg|
223652425|NCT02255435|DRUG|Omaveloxolone Capsules, 150 mg|
223652426|NCT05645718|DRUG|Cyclophosphamide|Given by (IV) vein
223652427|NCT05645718|DRUG|Vincristine|Given by (IV) vein
223652428|NCT05645718|DRUG|Blinatumomab|Given by (IV) vein
223652429|NCT05645718|DRUG|Methotrexate|Given by (IV) vein
223767520|NCT04007172|PROCEDURE|neural therapy|Intracutaneous quaddle injections were performed using 1% lidocaine preparation as a local anesthetic for local application to painful points with palpation on the back and shoulders and for the segmental application, 2 cm lateral to the midline of the C1-T5 vertebrae and on spinous processes.
223652430|NCT05645718|DRUG|Cytarabine|Given by (IV) vein
223652431|NCT05645718|DRUG|Mercaptopurine|Given by (IV) vein
223652432|NCT05645718|DRUG|Prednisone|Given by PO
223652433|NCT05645718|DRUG|Pegfilgrastim|Given by (IV) vein
223652434|NCT05645718|DRUG|Inotuzumab ozogamicin|Given by (IV) vein
223652435|NCT05645718|DRUG|Rituximab|Given by (IV) vein
223652436|NCT05645718|DRUG|Dexamethasone|Given by (IV) vein
224236754|NCT02301676|DRUG|Sevoflurane|Sevoflurane is one of the most commonly used volatile anesthetic agents, particularly for outpatient anesthesia, and including in anesthesia of children and infants, and in veterinary medicine.
224236755|NCT02301676|DRUG|propofol|Propofol is highly protein-bound in vivo and is metabolized by conjugation in the liver. The half-life of elimination of propofol has been estimated to be between 2 and 24 hours.
224236756|NCT02301676|DEVICE|dexmedetomidine|Dexmedetomidine is a sedative medication used by intensive care units and anesthesiologists. It is relatively unusual in its ability to provide sedation without causing respiratory depression.
223652437|NCT03943511|OTHER|Oral Antibiotics-Close Monitoring|To receive oral antibiotics and close monitoring, defined as twice weekly telephone calls by a member of the care team, of their chest tube and valve.
223652438|NCT03943511|OTHER|Standard of Care|No calls from the care team but waiting for the subject to contact the care team when the air leak has stopped.
223652439|NCT06297629|DRUG|ASTX727|Given by PO
224236757|NCT04761731|DRUG|ADVAGRAF®|"Administration method The total daily dose of tacrolimus will be converted to 1:1 (mg:mg) and the total daily dose of ADVAGRAF® will be administered only once daily in the morning, starting from Day 1 (at least one hour before breakfast or 2 to 3 hours after breakfast).~* Dose adjustment after conversion On Day 1, the total dose will be converted to 1:1. It is recommended to check the blood concentration of tacrolimus at each visit and adjust the dose to achieve the blood concentration maintaining at 5\~8ng/ml for 0 to 3 months and then at 5ng/ml or below for 3 to 6 months of study treatment.~* Duration of treatment The investigational product will be administered for 24 weeks."
223652440|NCT06297629|DRUG|Donor Lymphocyte Infusion|Given by Infusion
223652441|NCT06643481|BIOLOGICAL|VHB937|VHB937 solution for infusion
223652442|NCT06643481|OTHER|Placebo|Solution for infusion
223652443|NCT03603899|DRUG|Hp 129Xenon|129 Xenon is a noble gas with no taste or smell. It will be made slightly magnetic (also called hyperpolarizing) and then inhaled into the lungs to provide better pictures of the lungs during MRI.
223652444|NCT06788990|DRUG|Ficerafusp alfa|Investigational
223652445|NCT06788990|DRUG|Pembrolizumab (KEYTRUDA®)|Immunotherapy agent used in combination with investigational agent
223652446|NCT06788990|DRUG|Placebo|Placebo Control
223652447|NCT04553185|OTHER|Study procedure|All participants will undergo a collection of demographic data, personal and family history for PD, a neurological examination and administration of clinical scales. All participants will undergo a collection of venous blood sample. At the end of the visit they will receive a wristwatch to monitor their sleep at home (Actigraph) and a sleep diary, together with a prepaid envelope to post the watch and the diary back to the investigators. They will also receive a link for a series of online tests for non-motor symptoms related to Parkinson's disease that they can complete remotely at home.
224236758|NCT02116712|DRUG|Saracatinib|Saracatinib is escalated as follows: Three dose levels will be administered for 1 month each: 50 mg, 125 mg and 175 mg. Three subjects will be treated at the lowest daily dose of 50 mg. If no subject experiences DLT (dose limiting toxicity), the dose level is escalated to 125 mg/day for the next cohort of 3 different subjects and so on to next dose.
224236759|NCT00604500|DRUG|SCH No. 418131 (Mometasone Furoate/Formoterol Furoate abbreviated MF/F )|MF/F MDI 100/10 mcg BID with an integrated dose counter (administered as two inhalations of MF/F MDI 50/5 mcg, twice a day) over a 4-week Treatment Period.
223652450|NCT06789757|DRUG|Memantine Hydrochloride|Memantine (5mg) is an N-methyl-D-aspartate (NMDA) receptor antagonist given in 21-day cycles over six months in combination with Bevacizumab and Atezolizumab. Each week memantine will be escalated by 5mg as tolerated
224236760|NCT01492400|DRUG|dexamethasone Intravitreal Implant|Injection of 700 ug dexamethasone intravitreal implant into the study eye on Day 1, Month 5, and Month 10.
223652451|NCT06789757|DRUG|Bevacizumab|Bevacizumab (15mg/kg) is a vascular endothelial growth factor inhibitor given in 21-day cycles over six months in combination with Memantine and Atezolizumab.
223652452|NCT06789757|DRUG|Atezolizumab|Atezolizumab (1200mg) is a programmed death-ligand 1 (PD-L1) blocking antibody given in 21-day cycles over six months in combination with Memantine and Bevacizumab
223652453|NCT02531880|DRUG|Mangafodipir|Patients will be imaged interictally with a gadolinium enhanced MRI session. The administration of mangafodipir will be done as an inpatient during long-term video EEG recording, to ensure administration in the peri-ictal period.
223652454|NCT01581580|DEVICE|Medtronic Activa Tremor Control System|Medtronic DBS Therapy delivers electrical stimulation to an area in the brain to help treat Parkinson's Disease, dystonia, and essential tremor.
223652455|NCT01581580|PROCEDURE|Deep Brain Stimulation|standard of care DBS surgery for patients with Parkinson's Disease, dystonia, and essential tremor
223652456|NCT06257875|DRUG|Lutikizumab|Subcutaneous (SC) Injection
223652457|NCT06257875|DRUG|Lutikizumab|Intravenous (IV) Infusion
223652458|NCT06257875|DRUG|Adalimumab|SC Injection
223652459|NCT01961557|DEVICE|EA-KAFO|This study tests a single device that contains multiple potential configurations as outlined in Table 1 of the protocol. Each participant be evaluated in multiple configurations, minimally including the baseline configuration and the motor assist condition at the knee.
223652460|NCT06754501|DRUG|Atezolizumab|Given by vein
223652461|NCT06754501|DRUG|Tiragolumab|Given by vein
223652462|NCT06664801|BIOLOGICAL|Sotatercept|SC administered every 3 weeks.
223652463|NCT06664801|BIOLOGICAL|Background PAH Therapy|Background PAH therapy may consist of the following drug classes: single, double, or triple combination of therapy with endothelin-receptor antagonists, phosphodiesterase inhibitors, soluble guanylate cyclase stimulators, and/or prostacyclin analogs or receptor antagonists
223652464|NCT01861821|DEVICE|Multiport flexible catheter|Multiport flexible catheter has three ports for the delivery of epidural medication
223652465|NCT01861821|DEVICE|Uniport flexible catheter|Uniport flexible catheter has one port for the delivery of epidural medication
223652466|NCT06236724|DRUG|Asciminib|Given by PO
223652467|NCT01399385|DEVICE|MR Imaging Techniques - 1|Group 1 will consist of subjects with a 10-year total CHD risk \<10% (low)They will undergo a series of multiple small discovery studies in order to look at the multiple different MR methods of visualizing the coronary arteries
223652468|NCT01399385|DEVICE|MR Imaging Techniques - 2|Group 2 will consist of subjects with a 10-year total CHD risk 10-20% (intermediate)They will undergo a series of multiple small discovery studies in order to look at the multiple different MR methods of visualizing the coronary arteries
223652469|NCT01399385|DEVICE|MR Imaging Techniques - 3|Group 3 will consist of subjects with a 10-year total CHD risk \>20% (high)They will undergo a series of multiple small discovery studies in order to look at the multiple different MR methods of visualizing the coronary arteries
223652470|NCT01399385|DEVICE|MR Imaging Techniques - 4|Group 4 no known risk factors (control subjects)They will undergo a series of multiple small discovery studies in order to look at the multiple different MR methods of visualizing the coronary arteries
224236761|NCT01492400|DRUG|ranibizumab|Injection of ranibizumab 0.5 mg into the study eye on Day 1. Patients may receive additional injections on a monthly basis, as needed, for disease progression.
224236762|NCT02648607|DEVICE|Customised Dynamic Elastomeric Fabric Orthosis (DEFO)|Eligible participants will be measured and fitted with a customised Dynamic Elastomeric Fabric Orthosis (DEFO). Participants will also be issued with standardised advice on PGP management via an information leaflet from Association of Chartered Physiotherapists in Women's health website.
224236763|NCT00628888|BEHAVIORAL|Unified Protocol for Adolescents (UP-A)|All participants will be offered the UP-A intervention, inclusive of 8 and 21 weekly sessions of an emotion-focused treatment with cognitive-behavioral elements, either immediately following randomization or after an 8-week delayed treatment waitlist. The UP-A sessions are delivered in a flexible manner. Several of the UP-A's treatment elements are fixed and received by all participants (psychoeducation about emotions and emotional behavior, awareness and mindfulness skills, antecedent cognitive reappraisal/problem-solving skills, emotion exposure strategies, and relapse prevention skills), although applied for varying numbers of sessions depending on clinical need. Other strategies (motivational enhancement, parenting strategies and crisis management strategies) are applied on an as-needed basis based on client needs.
224236764|NCT04211493|BEHAVIORAL|whole-body-workout|20 minutes whole-body-workout
224236765|NCT04211493|DEVICE|EMS|Electromyostimulation-intensity 5 (muscle stimulation)
224236766|NCT04211493|DEVICE|EMS-Placebo|Electromyostimulation-intensity 1 (no muscle stimulation)
224236767|NCT00821028|DRUG|Paclitaxel|Paclitaxel will be administered intra-arterially through an irrigating catheter to treat a diseased segment of superficial femoral artery. Dosing will be based on ther lesion surface area, and will be calculated using the following formula: dose= 22/7 X diameter (mm) X length (mm) X 3 micrograms/mm\^3
224236768|NCT00804661|DEVICE|SENTEC device|Nocturnal recording SAO2 and PtcCO2 and wrist movements by means of actigraphy
224236769|NCT00878397|DEVICE|School-based delivery of long lasting insecticide nets|Free distribution of long lasting insecticide nets to school children and their younger siblings
224236770|NCT00201305|DRUG|Gemcitabine+5FU+Leucovorin|
224236771|NCT05899478|DEVICE|Tyknot® Suture-Mediated Closure System|Arterial closure to ensure hemostasis at femoral artery puncture points
224236772|NCT05899478|DEVICE|Perclose® ProGlide Suture-Mediated Closure System|Arterial closure to ensure hemostasis at femoral artery puncture points
224236773|NCT00113347|DRUG|Erlotinib|Beginning on Day 2 of treatment, 100, 125, or 150 mg by mouth once a day every day while on treatment, except on days docetaxel is received.
224236774|NCT00113347|DRUG|Docetaxel|15 mg/m\^2 or 20 mg/m\^2 by vein over 15 to 30 minutes on Days 1, 8, 15, and 22 of treatment.
223652471|NCT00001309|OTHER|Vitamin C|Outpatient subjects will be encouraged to consume vitamin C in foods. As inpatients, vitamin C deficiency will be induced by placing subjects on a tightly restricted scorbutic diet. Plasma vitamin C will be monitored several times per week. When subjects have achieved a plasma ascorbate concentration of 5-10 micromolar, blood sampling and urine collection over 24 hours will be performed. After platelets and leukocytes are collected, ascorbate repletion will begin. Escalating doses of ascorbate will be administered orally and intravenously for the remainder of their inpatient admission. Total daily doses of 30mg, 60mg, 100mg, 200mg, 400mg, 1000mg and 2500mg will be given in two divided doses. Bioavailability of ascorbate will be determined at each dosage increment. When plasma ascorbate concentration reaches steady state for each dose, subjects will undergo 36 hr plasma sampling and a timed 48 hr urine collection.
223652472|NCT05642026|DRUG|Ropivacaine|Patients in this group will receive CINB (continuous local intercostal infusion of 0.2% Ropivacaine). A single catheter will be placed for short segment involvement and two catheters will be placed in series for longer segments of involvement. If necessary and as part of standard of care, CINB treatment will continue after patient discharge. The administration of CINB therapy will continue in the same manner as inpatient therapy.
223652473|NCT05642026|DRUG|Non steroidal anti-inflammatory drug and opioids|Patients in this group receive nonsteroidal and opioid pain medications (intravenous/oral inpatient and oral outpatient) per standard of care.
223652474|NCT06963827|DRUG|Mezagitamab|Mezagitamab injections administered SC.
223652475|NCT06963827|DRUG|Placebo|Mezagitamab-matching placebo injections administered SC.
224236775|NCT00113347|RADIATION|Radiation Therapy|Radiation therapy to head/neck beginning on day 1 of treatment once daily 5 times per week (Monday through Friday), delivered in 40 fractions.
224236776|NCT02597998|DRUG|14C-BI 409306|
224236777|NCT01622998|DRUG|NicoDerm Patch|"Dosage: 21mg patch; 14mg patch; 7 mg patch Frequency: NRT patch application once per day Duration: 10 week treatment period~\*Titration for experimental group (NRT+) based on smoking history, and option to increase dose if withdrawal symptoms are unmanageable."
224236778|NCT01622998|DRUG|Nicorette Inhaler|Nicorette Inhaler: Box, 42 cartridges (4mg/cartridge) Dosage: Ad libitum Maximum dosage: 6-12 cartridges/day
224236779|NCT03748082|DRUG|Nitric Oxide|Inhaled nitric oxide (iNO) will be administered via the CPB machine and after CPB via the inspiratory limb of the anesthetic or ventilator circuit, and thereafter via the mechanical ventilator in the ICU. Test gas administration will commence at the onset of CPB and last for 24 hours. At the end of 24 hours, iNO will be weaned and discontinued.
223767521|NCT04007172|DEVICE|Physical Therapy|Physical therapy program was consist of transcutaneous electrical nerve stimulation- TENS (30-40 Hz, 20 minutes), hotpack (20 minutes) and continuous ultrasound (1mHz, 1.5w / cm2, 10 minutes) on painful points with palpation on the back and shoulders.
223767522|NCT04712604|BEHAVIORAL|My Sleep Our Sleep (MSOS) Program|MSOS Program is a weekly one-hour Zoom session that focuses on psychoeducation on sleep health for both patients and their sleep partners.
223652478|NCT05672316|BIOLOGICAL|Balstilimab|Given IV
223652479|NCT05672316|PROCEDURE|Biospecimen Collection|Undergo collection of blood
223652480|NCT05672316|BIOLOGICAL|Botensilimab|Given IV
223652481|NCT05672316|PROCEDURE|Computed Tomography|Undergo CT
223652482|NCT05672316|DRUG|Regorafenib|Given PO
224236780|NCT03748082|DIAGNOSTIC_TEST|Reactive Hyperemia Index|Vascular responsiveness will be assessed with peripheral arterial tonometry which measures the transient increase in forearm blood flow (Reactive Hyperemia Index, RHI) in response to a five-minute occlusion of the brachial artery with a pressure cuff.
224236781|NCT03748082|PROCEDURE|Endothelial Cells Collection|Endothelial cells are collected before and after surgery from a peripheral vessel using a soft J-shaped wire inserted through an intravascular catheter.
224236782|NCT00320112|BEHAVIORAL|Reciprocal Diabetes Peer Support Program|participants are paired with another age-matched participation. Paired peer partners were encouraged to talk weekly using a telephone platform that recorded call frequency and duration and provided automated reminders promoting peer contact.
224236783|NCT00320112|BEHAVIORAL|Nurse Case management|patients are not paired in the NCM arm attended a 1.5 hour session to receive education on care manager services and diabetes educational materials and be assigned to a nurse care manager with whom they were encouraged to follow-up regularly.
223652485|NCT03656562|DRUG|VAY736|150 mg powder in vial for solution for injection; after reconstitution to 150 mg/mL per vial, a dose of 300 mg
224236784|NCT00320112|BEHAVIORAL|group outpatient counseling visits|Participants in the peer group were also offered three optional 1.5 hour patient-driven group sessions at month 1, 3, and 6
223652486|NCT03656562|DRUG|VAY736 Placebo|solution for injection; 0 mg/mL administered as 2 mL s.c. injection
223652487|NCT03656562|DRUG|CFZ533|150 mg/mL as concentrate in vial for infusion, administered at a dose of 10 mg/kg as i.v. infusion
223652488|NCT03656562|DRUG|CFZ533 Placebo|Placebo as concentrate in vial for infusion, administered at a dose of 10 mg/kg as i.v. infusion
223652489|NCT04550481|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
224236785|NCT05767385|PROCEDURE|Single Arm|"* Phase 1- Baseline: A fetal echocardiogram will be performed as part of routine standard clinical care.~* Phase 2- MH: The participant will be placed on 8 litres of 100% FiO2 (inspired oxygen fraction) via a non-rebreather face mask for 10 minutes. After 10 minutes, additional images will be obtained. MH will be discontinued after additional imaging is complete.~* Phase 3- Recovery: After at least 5 minutes of discontinuation of MH, additional images will be obtained to ensure any changes have returned back to baseline."
224236786|NCT05767385|PROCEDURE|Neonatal Neurobehavioral Scale|Neonatal Intensive Care Unit Network Neurobehavioral Scale (NNNS) evaluation: All neonates with CHD expected to undergo neonatal cardiac intervention or surgery have pre-operative NNNS assessment as PCH as standard of care. The NNNS takes approximately 30 minutes to complete. It is administered by a licensed physical, speech, or occupational therapist who has completed training and additional certification. The NNNS therapist will be blinded to the results of the fetal echocardiogram and MCA-PI.
224236787|NCT02045927|OTHER|sedation monitoring with RASS score|
223652490|NCT04550481|DRUG|Lisinopril|Given PO
224236788|NCT02045927|OTHER|sedation monitoring with BIS-Guided monitoring|
223652491|NCT04550481|PROCEDURE|Liver Ultrasonographic Elastography|Undergo transient elastography
223652492|NCT04550481|PROCEDURE|Magnetic Resonance Elastography|Undergo PDFF MRE
223652493|NCT04550481|PROCEDURE|Magnetic Resonance Imaging|Undergo PDFF MRI
223652494|NCT04550481|PROCEDURE|Proton Density Fat Fraction|Undergo PDFF MRI/MRE
223652495|NCT04550481|OTHER|Questionnaire Administration|Ancillary studies
223652496|NCT06239974|DRUG|Vericiguat|Patients will be prescribed vericiguat once a day for 6 months, starting at 2.5mg and titrated up to the full dose of 10mg per day (doubling of dose every 2 weeks) in addition to optimised medical therapy and standard follow-up like the control group
223652497|NCT06239974|DIAGNOSTIC_TEST|Stress Cardiac Magnetic Resonance|All patients will have stress CMR examinations at recruitment and at the end of trial.
223652498|NCT05621538|BEHAVIORAL|Realtime fMRI Neurofeedback - Active|fMRI aided reinforcement of craving regulation
223652499|NCT05621538|DEVICE|TMS - Active|rTMS to right dorsolateral prefrontal cortex to reduce craving
223652500|NCT05621538|BEHAVIORAL|Realtime fMRI Neurofeedback - Yoked Sham|Display of feedback from other participant's sessions to serve as a sham for fMRI aided reinforcement of craving regulation
223652501|NCT05621538|DEVICE|TMS - Sham|rTMS using placebo coil (no brain stimulation, emulates other features of active TMS), placed over right dorsolateral prefrontal cortex
223652502|NCT00097474|DRUG|Hydrocortisone|Hydrocortisone will be given alone or in combination with Melatonin to see if symptoms of jet lag are alleviated
223652503|NCT00097474|DRUG|Melatonin|Melatonin will be given alone or in combination with Hydrocortisone to see if symptoms of jet lag are alleviated
223652504|NCT00097474|DRUG|Placebo|Placebo
223652505|NCT06797973|DRUG|Intrathecal Morphine|80 μg preservative-free morphine (0.2 ml) added to a single-shot spinal anaesthesia consisting of 11.5 mg hyperbaric bupivacaine and 10 μg fentanyl
223652506|NCT06797973|DRUG|Placebo (Sodium Chloride Injection, 0.9%)|0.2 ml of isotonic sodium chloride added to a single-shot spinal anaesthesia consisting of 11.5 mg hyperbaric bupivacaine and 10 μg fentanyl.
223652507|NCT05548556|DRUG|Placebo|Participants will receive subcutaneous (SC) placebo every 4 weeks (Q4W)
223652508|NCT05548556|DRUG|RO7204239|Participants will receive SC RO7204239 Q4W
223652509|NCT02400190|OTHER|endocrine therapy alone without radiotherapy|Patients will not receive radiotherapy, which is the current standard for treatment for their type of breast cancer.
223652510|NCT06161532|DRUG|Sacituzumab govitecan|Sacituzumab govitecan is administered IV at 10 mg/kg on days 1 and 8 of each 21-day cycle.
223652511|NCT06161532|DRUG|Atezolizumab|Atezolizumab is administered IV at 1200 mg on day 1 each 21-day cycle.
223652512|NCT06790121|DRUG|Lunsekimig|Pharmaceutical form: Solution for injection in vial Route of administration: Subcutaneous injection
223652513|NCT06790121|DRUG|Placebo|Pharmaceutical form: Solution for injection in vial Route of administration: Subcutaneous injection
223652514|NCT03216187|DRUG|Pregabalin|pregabalin 150 mg capsules
223652515|NCT03216187|DRUG|Placebos|capsules identical to pregabalin but without active drug
223652516|NCT06118840|DEVICE|True-AI-integrated intracranial aneurysms diagnosis strategy|The True-AI deep-learning based model for intracranial aneurysms detection had a patient-wise sensitivity, lesion-wise sensitivity and specificity of 0.96, 0.87, and 0.80 in the internal validation dataset.
224236789|NCT01674582|OTHER|MRI, neuropsychological evaluation, blood sampling|"MRI at timepoints given above, neuropsychological testing after surgery, but before radiotherapy or chemotherapy.~Neuropsychological testing month 3 during treatment. Neuropsychological testing after 1 year. Neuropsychological testing after 2 years."
224236790|NCT02844803|DRUG|Combination of Metformin + S. Baicalensis|the combination therapy for 8 weeks
224236791|NCT02844803|DRUG|Combination of Metformin + Placebo|the metformin single therapy for 8 weeks
224236792|NCT02899338|DRUG|BI695501 Prefilled syringe|
224236793|NCT02899338|DRUG|BI695501Autoinjector|
224236794|NCT06370221|BEHAVIORAL|The effect of psoriatic Arthritis|to assess the frequency rates of sexual problems and associated factors in a cohort of married females with Psoriatic arthritis, and to investigate the correlation between sex hormones profile ( estrogen and progesterone level) and female sexual function in Psoriatic arthritis patients.
224236795|NCT04296149|DRUG|Y90-DOTA-Tyr3-Octreotide|Patients enrolled for surgery will receive a small amount of Y-90-DOTATOC, in order to check beta- radioactivity by the probe
223652517|NCT06118840|DEVICE|Sham-AI-integrated intracranial aneurysms diagnosis strategy|The Sham-AI deep-learning based model for intracranial aneurysms detection is designed to have a sensitivity close to 0% and a similar specificity to the True-AI. In the internal validation dataset, the Sham-AI had a patient-wise sensitivity, lesion-wise sensitivity, specificity of 0.02, 0.01, and 0.80, respectively.
223652518|NCT06798298|GENETIC|Non-interventional|No study drug administered. Long-term follow-up only.
223652519|NCT06335264|DEVICE|Watch HOP|A multisensorial wearable smartwatch that measures actigraphy (motion), skin temperature, heart rate variability (PPG), electrodermal activity, and voice (via App)
223652520|NCT04269265|BIOLOGICAL|Yellow Fever Vaccine|YF-VAX®, Yellow Fever Vaccine, for subcutaneous use
223652521|NCT05104723|DRUG|XELJANZ (tofacitinib)|The XELJANZ 5-mg tablets or 11-mg XR tablets will taken orally twice daily or once daily, respectively, in this study.
223652522|NCT05757102|DRUG|FF/UMEC/VI|FF/UMEC/VI will be administered.
223652523|NCT05757102|DEVICE|ELLIPTA|FF/UMEC/VI and FF/VI will be administered via ELLIPTA inhaler
223652524|NCT05757102|DRUG|FF/VI|FF/VI will be administered.
223652525|NCT04305431|BEHAVIORAL|Cooking Intervention|90-minute culinary education sessions.
223652526|NCT06578104|DEVICE|PulseSelect™ PFA system|Ablation using the PulseSelect™ PFA system
223767523|NCT03325907|DEVICE|navigational template|The navigational template was created based on computed tomography data using three-dimensional technology.
223767524|NCT03545607|BIOLOGICAL|MultiStem|single intravenous infusion 18-36 hours after stroke
223767525|NCT03545607|BIOLOGICAL|Placebo|single intravenous infusion 18-36 hours after stroke
223767526|NCT01865825|RADIATION|Esophageal Barium Xray|"•Fast for 4 hours prior to the Esophagram (upper GI x-ray). You will drink a liquid that has barium or another contrast agent in it. The radiologist will use the X-ray machine to look at your upper GI tract while you drink the contrast liquid. The x-ray exam should take between 10-15 minutes.~We will have patients complete the Mayo Dysphasia Questionnaire-30 day."
223767527|NCT03759756|OTHER|AI presentation|AI presentation means the automatic diagnosis information of AI and AI presentation means it is visible in the group.
223767528|NCT03759756|OTHER|no AI presentation|AI presentation means the automatic diagnosis information of AI and no AI presentation means it is invisible in the group.
223767529|NCT01301222|DRUG|Inj. Octreotide|100 mcg subcutaneously for 5 days
223767530|NCT03703635|DEVICE|intracranial balloon angioplasty|A balloon (recommending the Neuro RX and Neuro LPS Intracranial Balloon Dilation Catheter \[Sinomed Inc., Tianjin, China\]) is navigated by the microwire to the lesion of the target artery.
224236796|NCT06495905|PROCEDURE|transbronchoscopic interventional debridement|"1. combination drug therapy：liposomal amphotericin B + posaconazole or Isavuconazole：3-5mg/kg/day+ Posaconazole 300 mg once daily; target blood trough concentration is \>1ug/mL; if posaconazole is unavailable, Isavuconazole 200 mg once daily may be an alternative.~2. transbronchoscopic local precision infusion of amphotericin B: Maximum dose not more than 30mg per session~3. transoral nebulized inhalation of amphotericin B：amphotericin B 10mg + 5ml of sterilized water for injection, inhalation 2/day.~4)transbronchoscopic interventional debridement"
224236797|NCT03006445|DRUG|FYU-981|
224236798|NCT03328780|DEVICE|Hemocue and Rad-67 measurement|Measurement of the hemoglobin level
224236799|NCT04980001|BEHAVIORAL|Families OverComing Under Stress Trauma Informed Care in Childhood Obesity among Minorities (FOCUS TIC-COM)|FOCUS TIC-COM is a program that helps doctors coach families to recognize how emotions or feelings about various life stressors may affect a child's dietary choices and physical activity. FOCUS TIC-COM is for families of children who have been identified by their doctor as overweight or obese. The goal of the program is to help children and their families understand how their mental health may impact their physical health and develop strategies to address their mental health needs.
224236800|NCT00811668|DEVICE|CPAP before SOMNOVentCR|4 weeks CPAP treatment, 1 week wash out period, 4 weeks SOMNOventCR treatment
224236801|NCT00811668|DEVICE|SOMNOventCR before CPAP|4 weeks SOMNOventCR treatment, 1 week wash out period, 4 weeks CPAP treatment
224236802|NCT05233163|DRUG|Empagliflozin|Empagliflozin 10 mg oral daily for 12 weeks
224236803|NCT03131310|OTHER|clinical audit|is to assess the quality of care and management of children with cardiorespiratory arrest admitted to assuit university children hospital according to the American Heart Association (AHA) Guidelines for Cardiopulmonary Resuscitation
224236804|NCT02305823|DRUG|Aripiprazole|
224236805|NCT02305823|DRUG|Quetiapine|
224236806|NCT02305823|DRUG|Ziprasidone|
224236807|NCT00138060|DRUG|irinotecan|180 mg/m² or 260 mg/m² in 90 minutes every 15 days
224236808|NCT00138060|DRUG|5 fluorouracil|400 mg/m² in bolus in day 1 and 2400 mg/m² in 46 hours perfusion
224236809|NCT04439396|DRUG|Ketorolac Tromethamine|nonsteroidal anti-inflammatory drug
224236810|NCT04439396|OTHER|Saline|saline fluid injection
224236811|NCT02107690|PROCEDURE|Low temperature lidocaine injection|4 °C
224236812|NCT02107690|PROCEDURE|Room temperature lidocaine injection|20 °C
224236813|NCT02107690|PROCEDURE|Body temperature lidocaine injection|37 °C
224236814|NCT04055337|PROCEDURE|Flap sliding|"All subjects underwent the flap sliding technique, which was performed at the Alforsan Eye Centre in Assiut, Egypt. Prior to surgery, all subjects underwent corneal imaging with anterior segment optical coherence tomography to confirm the presence of striae. All surgical procedures were performed by the same surgeon 1 or 2 days following LASIK.~Subjects were administered a topical anesthetic. Striae location and orientation were then determined after drying the corneal surface with a cellulose sponge. The sponge was used to push the LASIK flap over the stromal bed in a direction that was perpendicular to the striae. The flap was pushed from the proximal side of the striae toward the flap edge. The ultimate goal was to move striae and put the flap into its proper place. Following surgery, OCT imaging was repeated."
224236815|NCT00137397|DRUG|Tolterodine ER|
224236816|NCT00137397|DRUG|Placebo|
224236817|NCT05723822|DEVICE|Walkasins|"Walkasins is a non-invasive, wearable, lower limb sensory prosthesis, prescribed by a healthcare professional for long-term daily use as a prosthesis. It directly replaces the part of the function of the sensory end organs that persons with peripheral neuropathy have lost, the sensation in the soles of their feet. The system is comprised of two primary operating components:~* A Receptor Sole, properly placed in the shoe, detects and transmits plantar pressure information normally performed by the mechanoreceptors and distal axons in the soles of the feet.~* A Haptic Module, worn around the lower leg, generates directional specific mechanical tactile stimuli that produce action potentials that signal relevant balance information to the nervous system."
224236818|NCT05182489|DEVICE|Medtronic Adaptix™ titanium implants|Patients who will be having a spinal fusion procedure as part of their standard of care treatment will be randomized to receive either the Medtronic titanium or the PEEK cage supplemented with a pedicle screw system and milled local autograft bone supplemented with GRAFTON DBM DBF. In order to assess fusion, patients will undergo a research-only CT Scan at 6 months post-surgery.
223652527|NCT06548828|BEHAVIORAL|NNS Restriction Intervention|"Discuss current scientific literature surrounding NNS consumption, obesity, and chronic disease and the emerging evidence that consumption in pregnancy/lactation may have unfavorable effects on infants' adiposity and health.~Provide detailed handouts, which will include a list of specific foods and beverages containing NNS to avoid during the study and summarize current scientific evidence on the metabolic and health effects of NNS.~Emphasize that sugar is not the best alternative to NNS, and that the participant should drink still water, sparkling water, flavored waters with no added sweeteners, or unsweetened tea instead.~Bi-weekly shipments of unsweetened beverages of participant's choice to replace usual consumption of NNS containing beverages.~Automated text messages will also be sent to mothers once per week with reminders that they should avoid NNS"
223652528|NCT06548828|BEHAVIORAL|Control Intervention|"Counsel about best practices for home safety and babyproofing.~Provide a detailed booklet to take home, which will provide information about home safety and baby proofing.~Educate about common causes of accidental infant and young child injuries or death.~Automated text messages will also be sent to mothers once per week with reminders about home safety, infant safety, and baby proofing."
224236819|NCT05182489|DEVICE|Medtronic CAPSTONE® PEEK cage|Medtronic CAPSTONE® PEEK cage
224236820|NCT02729376|DRUG|galeterone|
224236821|NCT02770963|PROCEDURE|Acupuncture|"Shenshu (BL23) on bilateral sides and Dachangshu (BL25), Weizhong (BL40), and Chengshan (BL57) on the affected side will be applied.~A Huatuo Brand needle (0.3\*75 mm) for BL25 will be inserted at a depth of 40-70 mm vertically until the patient feels soreness and a distension sensation that radiates to the leg. The needle will be lifted 1-2 mm without rotating or lifting. Huatuo Brand needles (0.3\*40 mm) at the other acupoints (BL23, BL40 and BL57) will be inserted 30 mm and manipulated by lifting, thrusting, twirling evenly until the Deqi sensation is achieved. The needles in these acupoints will be manipulated by small evenly applied lifting, thrusting, and twirling movements 3 times every 10 minutes."
224236822|NCT02770963|PROCEDURE|Sham acupuncture|"Specially designed sham needles (0.3\*25 mm) will be used. The sham needle consists of a needle handle, needle body, blunt tip and a sterile polyethylene cylindrical foam pad (identical to the pads in the acupuncture group).~The acupoints will be the same as the acupuncture group. The needle will be inserted vertically until pressed against the skin without penetration. The manipulation will be consistent with the acupuncture group and blind to the patients."
224236823|NCT04551638|OTHER|Psychological assessment with the Repertory Grid Technique|The RGT is a constructivist psychological tool to explore the structure and content of personal identity.
224236824|NCT04180345|OTHER|Psychometric validation of the questionnaire|"Delph Process : expert panel will include HCPs and patients. They will evaluate the relevance of items on a Likert scale (HCPs N = 25 ; Patients N = 25 ) Think aloud interviews (N = 10 patients) Psychometric validation ( N = 200 patients)"
224236825|NCT00896285|OTHER|Large bore chest drain + NSAID based analgesic regimen|Chest tube greater than 14 French size and ibuprofen.
224236826|NCT00896285|OTHER|Small bore chest drain + NSAID based analgesic regimen|Chest tube less than or equal to 14 French size and ibuprofen.
224236827|NCT00896285|OTHER|Large bore chest drain + opiate based analgesic regimen|Chest tube greater than 14 French size and morphine.
224236828|NCT00896285|OTHER|Small bore chest drain + opiate based analgesic regimen|Chest tube less than or equal to 14 French size and morphine.
224236829|NCT03806777|DRUG|Dexmedetomidine|Highly selective alpha-2 adrenergic agonist with sedative properties.
224236830|NCT02353169|DRUG|Dexmedetomidine|
224236831|NCT02353169|DRUG|Saline|
223652529|NCT06522373|DRUG|MT-0169|Given by Vein (IV)
223652530|NCT05953480|BIOLOGICAL|Redasemtide|Lyophilized white powder reconstituted in 0.9% saline for injection
223652531|NCT05953480|DRUG|Placebo|Lyophilized white powder reconstituted in 0.9% saline for injection
223652532|NCT06233461|DRUG|TAK-279|TAK-279 capsules.
223652533|NCT06233461|DRUG|Placebo|TAK-279 placebo-matching capsules.
223652534|NCT06269055|OTHER|Interview|Telephone interview and questionnaires about the results and side effects experienced
223652535|NCT06092034|GENETIC|RP-A501|RP-A501 is a gene therapy product consisting of a rAAV9 capsid containing the human LAMP2B transgene which will be administered as a single IV infusion.
223652536|NCT05785962|OTHER|Vojta Therapy|The therapy consists of the application of a stimulating pressure in the pectoral area in the pattern of the locomotion complex of reflex rolling in its first phase. For this, the subject will be placed in a supine position aligned with respect to the axial axis, with the arms along the body, the lower extremities in extension, and the head extended with a rotation of approximately 30º towards one side of the stimulation. The manual stimulation pressure will be exerted in the space between the 6th-7th or the 7th-8th rib under the mammillary line, with a force of about 2 kg.
223767531|NCT03703635|DRUG|aggressive medical management|Aspirin 100mg once/day during the follow-up period, Clopidogrel 75mg once/day for at least 90 days, Atorvastatin 20-80mg once/day as the situation requires and risk factors management including blood pressure to maintain 130-140/80-90 mmHg and LDL lower than 70 mg/dl or 1.8mmol/L.
223767532|NCT00772551|DRUG|Raltegravir and ezetimibe|Group 1: raltegravir 400 mg orally twice daily for 10 days followed by 10 days of raltegravir 400 mg twice daily and ezetimibe 10 mg orally once daily for 10 days followed by a 10 days wash out period and ezetimibe 10 mg once daily for 10 days
223652539|NCT06840873|DEVICE|wearable device|Participants wore a knee brace with a sensor module on one side of the leg, the sensor could connect with the KNEESUP care APP which were installed in participant's mobile phone. The APP was designed with an individualized exercise program and the knee brace sensor could detect the action moment of the participants during exercise. This equipment could help the participants to achieve professional-level home rehabilitation, including 3 aerobic and 2 strengthening exercise sessions per week at a moderate intensity, 30 min/session.
223652540|NCT06840873|BEHAVIORAL|Healthy consulation|Participants received routine outpatient health education.
223652541|NCT06274671|OTHER|Magnetic Resonance Imaging|A Magnetic Resonance Imaging (duration: about 60 minutes) with research sequences for the visualization of alterations of the glymphatic system.
223652542|NCT01266577|OTHER|NSR MAGNETOM 7T|The 7 Tesla scanner is a magnet system used to acquire magnetic resonance imaging and spectroscopy
223652543|NCT01266577|OTHER|1Tx x 32Rx Head Coil|Used to perform proton imaging and spectroscopy in the human heads.
223652544|NCT04666649|DRUG|Venetoclax and pegcrisantaspase|Therapeutic
223652545|NCT05609968|BIOLOGICAL|Sacituzumab Govitecan|IV infusion
223652546|NCT05609968|BIOLOGICAL|Pembrolizumab|IV infusion
223652547|NCT05612035|DRUG|Frespaciguat|Frespaciguat 380 µg administered as dry powder inhalation once daily.
223652548|NCT05612035|DRUG|Placebo|Placebo administered as dry powder inhalation once daily.
223767533|NCT00772551|DRUG|Ezetimibe and raltegravir|Group2: ezetimibe 10 mg orally once daily for 10 days followed by ezetimibe 10 mg and raltegravir 400 mg orally twice daily for 10 days followed by a 10 days wash out period and raltegravir 400 mg twice daily for 10 days
223767534|NCT02485028|DRUG|Dapoxetine 30mg tablet|
223767535|NCT02485028|DRUG|Mirodenafil 50mg tablet|
223767536|NCT02322554|BIOLOGICAL|Cellular and tissue based products|Procedure: Application of device or biological to wounds
223767537|NCT01524770|BIOLOGICAL|Dulaglutide|Administered by subcutaneous (SC) injection
223767538|NCT03023566|DRUG|Dotarem|Dotarem at dose of 0.1 mmol/kg of body weight (routine/standard of care)
224236832|NCT01790204|DIETARY_SUPPLEMENT|Watercress Juice|The juice is prepared, by a trained member of the Chung laboratory staff, in the following manner; each serving of watercress juice will be prepared with 55gm watercress (from a local grocery store) with 220 ml purified water, for a proportion of 1:4 (w/w). The watercress and water will be placed in a 1.5 L mechanical blender and blended at low speed for approximately 15 seconds, followed by blending at a high speed for one additional minute. The resulting suspension will be filtered through two layers of cheese cloth. Remaining liquids will be manually extracted from the cheese cloth into the same container. Each serving will be measured to 200 ml. The remaining 20 ml will be used for analysis of ITC content. Each serving will be prepared and kept at 40 C until needed, no more than one hour prior to participant consumption by the subject.
223652556|NCT06264167|DIAGNOSTIC_TEST|High-resolution bilateral groin ultrasound surveillance|Participants in the Interventional Treatment (serial ultrasounds) group will undergo surgical excision of the primary tumor, either via radical wide local excision or radical vulvectomy. Post-vulvar surgery, follow-up appointments occur bi-monthly for 12 months, involving a clinical examination and groin ultrasound. Senior imaging specialists review bilateral ultrasound scans for positive lymph nodes or suspicious findings, promptly sending reports to the primary care physician and trial manager if detected within 3 business days. Subsequently, participants consult their primary care physician for options. Depending on clinical judgment, they may be referred for LND or continue with bi-monthly ultrasounds based on preference and clinician guidance.
223652557|NCT06628362|DRUG|Placebo|Placebo will be volume-matched and administered subcutaneously (SC) once weekly.
223652558|NCT06628362|DRUG|CT-388|CT-388 will be administered subcutaneously (SC) once weekly at the randomized dosing regimen.
223652559|NCT02210078|BIOLOGICAL|Allogeneic Cytomegalovirus-Specific Cytotoxic T lymphocytes|Given IV
223652560|NCT05416515|DRUG|Fisetin|100 mg capsules orally for 2 consecutive days and, after 1 month, another 2 consecutive days
223652561|NCT03213652|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223652562|NCT03213652|PROCEDURE|Bone Marrow Aspiration and Biopsy|Undergo a bone marrow aspiration and/or biopsy
223652563|NCT03213652|PROCEDURE|Bone Scan|Undergo a bone scan
223652564|NCT03213652|PROCEDURE|Computed Tomography|Undergo a CT scan
224236833|NCT00442390|DRUG|hydrocortisone substitution therapy versus withdrawal|
224236834|NCT00679965|DRUG|AN2690, 2.5%|Once daily application for 90 days and 3 x weekly for 90 days
224236835|NCT00679965|DRUG|AN2690, 5%|Once daily application for 90 days and 3 x weekly for 90 days
223652565|NCT03213652|DRUG|Ensartinib|Given PO
223652566|NCT03213652|OTHER|Laboratory Biomarker Analysis|Correlative studies
223652567|NCT03213652|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223652568|NCT03213652|OTHER|Pharmacological Study|Correlative studies
223652569|NCT03213652|PROCEDURE|Positron Emission Tomography|Undergo a PET scan
223652570|NCT03213652|PROCEDURE|Radionuclide Imaging|Undergo radionuclide imaging
223652571|NCT03213652|PROCEDURE|X-Ray Imaging|Undergo an x-ray
223652572|NCT06843408|DRUG|INCA034176|IV infusion
223652573|NCT04838626|DRUG|[18F]CTT1057|PET/CT imaging with \[18F\]CTT1057
223652574|NCT06844214|BIOLOGICAL|SAR446268|Pharmaceutical form: Solution for infusion; Route of administration: IV infusion
223652575|NCT05121012|OTHER|Study procedures|"All participants will undergo a collection of demographic data, a neurological examination and administration of clinical scales relevant for MSA-P. All participants will undergo a collection of venous blood sample for routine analyses.~Participants will undergo one PET scan with the tracer \[11C\]UCB-J, and one PET scan with the tracer \[18F\]FDG. All participants will also undergo one MRI scan.~Participants will also undergo one lumbar puncture (optional).~All procedures will be performed at baseline and after one-year follow-up."
223652576|NCT04716452|DRUG|Ceramide NanoLiposome (Ceraxa)|Ceramide NanoLiposome will be given by IV twice a week. The dose, which is based on body size, will be increased for the next group of patients if the first group of patients tolerates that dose and it will decrease for the next group if they do not tolerate the dose.
224236836|NCT00679965|DRUG|AN2690, 7.5%|Once daily application for 90 days and 3 x weekly for 90 days
224236837|NCT00679965|DRUG|AN2690 Solution Vehicle|Once daily application for 90 days and 3x weekly for 90 days
223767539|NCT06087965|DRUG|Fingolimod|0.5mg/day oral fingolimod over a course of 3 consecutive days
223767540|NCT02467725|OTHER|Dynamic culture platform|Patients will have their cohort of embryos split in half. Half will be cultured in the dynamic platform and the other half cultured in static.
223767541|NCT04334499|OTHER|Sample collection from tissue discard|Collection of vitreous humor tissue and venous blood from subjects undergoing ocular surgery that may provide vitreous humor discarded tissue.
223652577|NCT06579222|OTHER|Primary Care Rheumatology Family Physician Consultation|The participant will be booked with a primary care rheumatology family physician for rheumatoid arthritis comorbidity screening. They will complete weight, height, blood pressure measurement, assess for risk factors for dyslipidemia, type 2 diabetes, hypertension, bone mineral density loss and vaccine preventable infectious diseases.
223652578|NCT03242642|DEVICE|Medtronic Intrepid Transcatheter Mitral Valve Replacement System (TMVR)|mitral valve replacement
223652579|NCT03242642|DEVICE|Medtronic Intrepid Transcatheter Mitral Valve Replacement System (TMVR)|Medtronic Intrepid Transcatheter Mitral Valve Replacement System (TMVR) mitral valve replacement
223767542|NCT05404269|DEVICE|AGC mode|Automated Gas Control mode at Maquet FLOW-i anesthesia machine
224236838|NCT02274129|DEVICE|Healing cap II|Healing cap II is used instead of the traditional healing cap as part of the surgical dressing after bone anchored hearing aid implant surgery
224236839|NCT04978766|BEHAVIORAL|Interactive Book Reading|"The intervention is a package including five children's books and information on how to practice interactive book reading. Information includes 36 audiovisual products delivered via text messaging over a 12-week period. Products include:~1. An introductory video about interactive book reading, along with a written list of recommendations on how to practice interactive book reading.~2. Two videos of child development experts explaining the benefits of interactive reading.~3. Thirty written text messages strengthening content provided in the videos.~4. Three audio messages guiding the progress of the intervention.~Based on Abraham and Michie's (2008) taxonomy of behavior change techniques, one audiovisual product prompts specific goal settings, 13 provide instruction, one provides information on consequences, 10 prompt practice, three use follow-up prompts, one prompts self-monitoring of behavior, one models or demonstrates the behavior and six prompt barrier identification."
224236840|NCT03635359|DIAGNOSTIC_TEST|blood test|analysis of cell-free DNA in maternal plasma
224236841|NCT00242021|BEHAVIORAL|Fatty acid composition of a margarine (spread)|
224236842|NCT04659421|DRUG|combined therapy with rh-ES and CV|"All the patients receive combined therapy with recombinant human endostatin and traditional weekly CV regimen.~Carboplatin is administered at a dose of 220 mg/m2. Vincristine is administered at a dose of 1.5 mg/m2 (maximum dose 2 mg). Recombinant human endostatin (rh-ES) is administrated at a dose of 15mg daily, for 14 consecutive days every 3 weeks."
224236843|NCT04057144|BEHAVIORAL|ACT|Acceptance and commitment therapy (ACT) sessions, lead by 2 qualified therapists, using a manual based on Steven Hayes et al 1999 that was adapted to group therapy and includes all the dynamic processes of ACT.
223652580|NCT00098072|PROCEDURE|Heart Catheterization|Heart Catheterization and collection of samples
223652581|NCT06231238|BEHAVIORAL|Balance Acceptance and Commitment Therapy|Balance-ACT is an ACT-based psychological intervention specifically designed for people with PCS/LC. Balance-ACT will use ACT techniques and mindfulness and will focus on establishing a balance psychologically and physiologically and regulating homeostasis. More specifically, Balance ACT will aim to regulate behaviours such as sleep, stress and activity, which can subsequently have an impact on homeostasis and physiology. Balance-ACT will also encourage people to live a values-based life and set goals according to their values.
223652582|NCT05989451|BEHAVIORAL|Dialectical behavior therapy (DBT)|The modified DBT protocol, developed by the principal investigator and co-investigators, will be offered in an individual therapy format. It consists of 12 weekly individual sessions, each lasting 50-60 minutes. It is made based on the manual, retaining the essence of DBT and remaining dialectically focused. Each session focuses on specific skills within the context of modules.
223652583|NCT06308588|DRUG|Blinatumomab|Given by Infusion
223652584|NCT06308588|DRUG|Asciminib|Given by PO
223652585|NCT06405633|DRUG|WVE-006|RNA editing oligonucleotide
224236844|NCT04057144|BEHAVIORAL|mindfulness exercises and audio recordings|mindfulness exercises introduced in the ACT sessions. In addition daily home meditation exercises based on the program developed by Kabat-Zinn 2005 and with help of audio recordings.
224236845|NCT04057144|BEHAVIORAL|Education program|"Self-management education program. Information given by a qualified health professional on pain and symptom management, stress, sleep, eating habits, mental health problems. Group discussions about thoughts and experiences.~communication skills and physical activity"
223652586|NCT02867384|DRUG|Obinutuzumab|B cell depletion
223652587|NCT02867384|DRUG|Placebo|Placebo
224236846|NCT04483102|DEVICE|Declined liver in Normothermic Machine Perfusion (NMP)|The discarded livers rejected by all other centers and meeting pre-NMP eligibility criteria will receive NMP using the OrganOx® metra device. The NMP-treated liver that meets the viability criteria will be transplanted to patients who are eligible and consented to the study.
223652588|NCT05423262|BIOLOGICAL|TRK-950|5 or 10 mg/kg administered intravenously over 60 minutes (weekly)
223652589|NCT05423262|BIOLOGICAL|TRK-950|10 mg/kg administered intravenously over 60 minutes (weekly)
223652590|NCT05423262|BIOLOGICAL|TRK-950|20 mg/kg administered intravenously over 60 minutes (bi-weekly)
223652591|NCT05423262|DRUG|Nivolumab|240 mg administered intravenously over 30 minutes (bi-weekly)
223652592|NCT05423262|BIOLOGICAL|TRK-950|10 mg/kg administered Intravenously over 60 minutes (weekly)
223652593|NCT01445509|DRUG|Bevacizumab|Once the MTD of dasatinib with bevacizumab 5 mg/kg IV every two weeks is determined, one final dose level will be accrued with that MTD dose of dasatinib with bevacizumab at 10 mg/kg IV every two weeks in order to determine if we can safely escalate bevacizumab to full dose with dasatinib concurrently.
223652594|NCT01445509|DRUG|Dasatinib|We will start dasatinib at 50 mg PO QD which is less than half the recommended Phase 2 dose as well as bevacizumab at 5 mg/kg IV every two weeks, which is half the single agent dose. If this is well-tolerated, study drugs will be escalated per schema to maximize the dose of dasatinib when given concurrently.
223652595|NCT06526702|DEVICE|High-flux hemodialysis|FX CorDiax 100 dialyzer
223652596|NCT06526702|DEVICE|Post-dilution hemodiafiltration|FX CorDiax 1000 dialyzer
223652597|NCT05616650|DRUG|18F-DCFPyL|Each participant will receive a single IV dose of 18F-DCFPyL by bolus injection. The target administered activity will be 6.5 mCi with a lower limit of 6 mCi; dose variations will be in accordance with the Nuclear Regulatory Commission (NRC) standard dose variation (i.e., 20%) permitted for diagnostic clinical studies.
223652598|NCT05616650|RADIATION|Stereotactic Body Radiation Therapy|Intensity modulated radiotherapy will be delivered to a dose of 26Gy in two fractions with the second fraction performed within 8 days of the first session.
223652599|NCT05722769|BEHAVIORAL|CSTOP Now!|Child sex trafficking stops with you. Implement and evaluate the effectiveness of a multi-level bystander-informed program (CSTOP Now!) aimed at Kentucky public middle school staff. Participants will be trained to use the See It To Stop It Indicator Tool (SITSII) by using tiers of concern (clear concern, possible concern, and monitor of emerging concern). The SITSII tool directs the bystander actions to Decide, Directly Intervene, Disrupt, Delegate, and Document.
223652600|NCT05722769|BEHAVIORAL|Prevent Child Abuse Kentucky Online Training|The Kentucky State Police, in association with Prevent Child Abuse Kentucky, have developed videos we invite active comparator schools to review which also include how to identify and report child sex trafficking.
223652601|NCT05552664|GENETIC|GIFT|GIFT features a web-based intervention that offers access to an online family communication program containing key facts about genetics, cancer risk, and the role of genetic testing and helps patients share health information with their first-and second-degree relatives, whom they can invite to join the study to receive education/support and access to low-cost genetic testing.
223652602|NCT06270719|GENETIC|Delandistrogene Moxeparvovec|No study medication will be provided by the sponsor during this study.
223652603|NCT06270719|DRUG|Standard of Care|No study medication will be provided by the sponsor during this study.
223652604|NCT05807594|BEHAVIORAL|HMZ 2.0 Intervention|The intervention may be adapted such that a woman receives more support with each adaptation (only women who need added support to regulate GWG will receive adaptation). The model-based predictive control system in the HMZ 2.0 digital platform will continually and automatically evaluate GWG, identify when a woman may exceed GWG guidelines, and recommend an adaptation. The registered dietitian will review the data and behavior strategies that are suggested (guided PA workouts, EI cooking demonstrations, customized grocery planning, portion size control, food scales, and meal replacements). Practical, easy-to-adopt examples will be provided (walking in 5-10 min increments throughout the day to increase PA kcal, reduce sitting by 5 min/hour; replace 8 oz of whole milk with skim milk to reduce EI kcal) to facilitate behavior change while adhering to safety standards. Each woman's unique preferences and past successes with strategies are also considered when personalizing the dosage.
223652605|NCT05807594|BEHAVIORAL|Attention Control Intervention|Consistent with guidelines for comparator groups, all women will receive prenatal care offered by recruitment sites with routine provider visits, counseling about prenatal behaviors (e.g., no smoking), and clinical oversight of health. Women randomized to the attention control group will complete the same measurement procedures as the intervention group.
223652606|NCT03033303|BIOLOGICAL|Hu3F8|Day 1: hu3F8 infused iv over \~30 to 90 minutes. Day 3: hu3F8 infused iv over \~30 to 90 minutes. Day 5: hu3F8 infused iv over \~30 to 90 minutes.
223652607|NCT03033303|DRUG|GM-CSF|Days -4 to 0: GM-CSF 250 mcg/m2/day, subcutaneously. Days 1 to 5: GM-CSF 500 mcg/m2/day, subcutaneously.
223652608|NCT03033303|DRUG|Isotretinoin|Isotretinoin is administered at 160 mg/m2/d, divided into two doses, x14 days.
223652609|NCT04456920|OTHER|phone consultation|At D1, D2 and D3, patients in the experimental group 1 will receive a call from a neuro-psychologist during which pain, anxiety and esthetical biopsy impact will be assessed using numeric or visual analog scales during a semi-direct interview. During this call, any adverse events related to the breast biopsy will also be noted, as well as the amount, nature and dose of analgesics, anxiolytics, anti-depressants, anti-inflammatory and hypnotics taken linked to the biopsy. If detected, pain or significative distress would be specifically managed.
223652610|NCT04456920|OTHER|e-PRO self-completed via connected objects (tablet/phone)|Patients in the experimental group 2 will be asked by SMS or notification to connect to the application in order to complete online the numeric and visual anog scales of pain, anxiety and esthetical impact. Any adverse events related to the breast biopsy will also be noted online, as well as the amount, nature and dose of analgesics, anxiolytics, anti-depressants, anti-inflammatory and hypnotics taken for the biopsy. If detected, pain or significative distress would be specifically managed
223652611|NCT04456920|OTHER|phone consultation|At D4 post biopsy, all patients (of the 3 groups) will receive a phone call from a neuro-psychologist to assess pain, anxiety and esthetical impact, using numeric scales, and to collect adverse events. If detected, pain or significative distress would be specifically managed.
223652612|NCT04456920|OTHER|visit|And at D10 (+/- 2 days), all patients will physically come to the Cancer center in the consultation of biopsy results announcement. At the beginning of this consultation, pain, anxiety and esthetical impact will be assessed using numeric scales. . The adverse events related to the breast biopsy will be collected as well as the amount, nature and dose of analgesics, anxiolytics, anti-depressants, anti-inflammatory and hypnotics taken for the biopsy and its findings. Insomnia will be evaluated by the Insomnia Severity Index. If detected, pain or significative distress would be managed as usually in the center.
223652613|NCT02178410|DIETARY_SUPPLEMENT|Vitamin D3|Vitamin D3 (cholecalciferol), 2000 IU per day.
223652614|NCT02178410|DRUG|Omega-3 fatty acids (fish oil)|Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid \[EPA\] and 375 mg of docosahexaenoic acid \[DHA\]).
223767543|NCT03467425|DRUG|FF/UMEC/VI|FF is a dry white powder containing 100 mcg GW685698 blended with lactose in one blister in the first strip of the DPI. UMEC/VI is a dry white powder containing 62.5 mcg of UMEC and 25 mcg of VI per blister, both blended together with lactose and magnesium stearate in the second strip of the DPI.
223767544|NCT03467425|DRUG|Inhaled Corticosteroid|Inhaled Corticosteroid (ICS) as prescribed by the physician.
223767545|NCT03467425|DRUG|LAMA|LAMA as prescribed by the physician.
223767546|NCT03467425|DRUG|LABA|LABA as prescribed by the physician.
224236847|NCT04483102|PROCEDURE|Standard cold preservation of liver|"The study will have three comparison groups - one local comparison group and two comparison groups from the national UNOS data.~Comparison group 1 will be patients who received a standard liver transplantation and follow-up care at the Washington University/ Barnes Jewish Hospital (n=50). Patients will be matched by a 5-year age category, sex, MELD score, donor liver graft type (e.g., DCD, DBD), donor age (5-year category), and donor sex. Washington University/ Barnes Jewish Hospital maintains a liver transplantation database that prospectively collects pre- and post-transplantation patient data.~Comparison group 2 will be patients who received DBD liver transplantation in the OPTN/UNOS database (n=100). Patients will be matched by age, sex, MELD score, donor age, and donor sex.~Comparison group 3 will be patients who received DCD liver transplantation in the OPTN/UNOS database (n=100). Patients will be matched by age, sex, MELD score, donor age, and donor sex."
224236848|NCT00741871|DRUG|SB1518|SB1518 taken orally daily for 28 consecutive days in a 28 day cycle
224236849|NCT06325579|DEVICE|Immersive Virtual Reality for Dysphagia Treatment|Patients wore a VR headset while undergoing their rehabilitation session
224236850|NCT02767193|BIOLOGICAL|DCV3|"Autologous differentiated adult dendritic cells from monocytes of peripheral blood non expanded pulsed with autologous inactivated HIV virus.~Patients will receive three immunizations of dendritic cells during weeks 0, 2 and 4"
224236851|NCT02767193|BIOLOGICAL|DCV3 with PEG-INF|Autologous differentiated adult dendritic cells from monocytes of peripheral blood non expanded pulsed with autologous inactivated HIV virus with PEG\_INF Patients will receive three immunizations of dendritic cells during weeks 0, 2 and 4 and INF during weeks 4,5 and 6
224236852|NCT02767193|BIOLOGICAL|Placebo|Autologous differentiated adult dendritic cells from monocytes of peripheral blood non expanded Patients will receive three immunizations saline + 1% albumin during weeks 0, 2 and 4
223652615|NCT02178410|DIETARY_SUPPLEMENT|Fish oil placebo|Fish oil placebo
223767547|NCT03467425|DRUG|COPD rescue medications|Rescue medications for COPD will be prescribed and obtained according to usual practice.
223767548|NCT02318693|DRUG|Sitagliptin|Sitagliptin 50 mg orally once a day before breakfast for 14 days
223767549|NCT02318693|DRUG|Glibenclamide|Glibenclamide 1.25 mg orally twice a day (2.5 mg/day) before breakfast and dinner for 14 days
223767550|NCT01282216|BIOLOGICAL|Havrix|1440 ELISA units, or 1 mL, IM
223652616|NCT02178410|DIETARY_SUPPLEMENT|Vitamin D3 placebo|Vitamin D3 placebo
223652617|NCT06284837|OTHER|Access site|The SAFER-TAVI trial is randomized study comparing secondary access via a transradial versus transfemoral approach among patients undergoing transfemoral TAVI for aortic valve disease. Secondary access is gained along with primary access at the commencement of the TAVI procedure and is used for aortography before and after valve deployment and for assessment of the primary femoral access site after closure to confirm haemostasis. For patients assigned to radial access, the radial sheath will be removed using a radial band at the end of the procedure. For patients assigned to femoral access, the puncture site will be obtained under ultrasound guidance and fluoroscopic landmark identification. Unless contraindicated, the use of vascular closure devices will be recommended for all femoral cases. The choice of closure device is at the discretion of the operator. Catheters used in the access groups will be 5 or 6 French size at the discretion of the operator.
223652618|NCT05205291|DRUG|Lipopolysaccharide|All participants will receive one dose of Lipopolysaccharide (1ng/Kg) after the first PET/MR scan with \[11C\]PBR28 and four hours before the second PET/MR scan with \[11C\]PBR28.
223767551|NCT01282216|BIOLOGICAL|PCV13|0.5 mL IM
223767552|NCT00186004|DEVICE|Continuous Glucose Monitor|Subjects are fitted with a CGM system and perform self blood glucose measures three or more times per day for 3 days.
223767553|NCT04625738|BIOLOGICAL|Ex vivo expanded Wharton's Jelly Mesenchymal Stem Cells|"Ex vivo expanded Wharton's Jelly derived mesenchymal stem cells will be infused at day 0, day 3 and day 5 (+/- 1 day), in patients with moderate to severe ARDS with a mechanical ventilation.~day 0: 1.10\^6 MSC/kg day 3: 0.5. 10\^6 MSC/kg day 5: 0.5 . 10\^6 MSC/kg"
223767554|NCT04625738|BIOLOGICAL|Placebo|Only the vehicle solution, without MSCs, containing albumin 4% , NaCl 0,9% and ACD will be injected to patients at day 0, 3 and 5 (+/-1 day).
223767555|NCT03633435|PROCEDURE|assisted home hemodialysis patients|Arteriovenous fistula cannulation at the patient's home provided by a trained private nurse at each dialysis session with the rope-ladder technique, and connection to the Nxstage System One
223767556|NCT02648191|DEVICE|NeuroCoach II Stim|"A noninvasive vagus nerve stimulator consists of two components. An electrode is placed in the left ear concha and will be used by the patient for 4-5 hours per day in segments of 1 hour minimum.~For this intervention, the stimulations are active."
223767557|NCT02648191|DEVICE|NeuroCoach II Stim|"A noninvasive vagus nerve stimulator consists of two components. An electrode is placed in the left ear concha and will be used by the patient for 4-5 hours per day in segments of 1 hour minimum.~For this intervention, the stimulations are inactive."
224236853|NCT02767193|BIOLOGICAL|Placebo with PEG-INF|Autologous differentiated adult dendritic cells from monocytes of peripheral blood non expanded with PEG\_INF Patients will receive three immunizations saline + 1% albumin during weeks 0, 2 and 4 and INF during weeks 4,5 and 6.
224236854|NCT05283681|DRUG|Risankizumab|Subcutaneous Injection via Prefilled Syringe (PFS)
224236855|NCT05283681|DRUG|Risankizumab|Subcutaneous Injection via Auto-Injector (AI)
223652619|NCT05205291|RADIATION|PET/MR with [11C]PBR28|A PET/MR scan using the tracer \[11C\]PBR28 will be performed to all participants before and four hours after the administration of LPS
223652620|NCT06201676|DRUG|Ketorolac Injection|Ketorolac tromethamine is a nonsteroidal anti-inflammatory drug (NSAID) that exhibits analgesic activity in animal models. The mechanism of action of ketorolac, like that of other NSAIDs, is not completely understood but may be related to prostaglandin Reference ID: 3281582 3 synthetase inhibition. The biological activity of ketorolac tromethamine is associated with the S-form. Ketorolac tromethamine possesses no sedative or anxiolytic properties.
224236856|NCT02560350|OTHER|no intervention|no intervention
224236857|NCT04574193|DEVICE|digital therapeutic for substance use disorders|The Continuing Care application (app) is a HIPAA-compliant, mobile-friendly, software program designed to meet the recovery and personal support needs of probationers and parolees with SUDs who are at elevated risk of relapse, re-arrest, and incarceration.
224236858|NCT04574193|OTHER|Treatment As Usual|12-weeks of weekly group cognitive behavioral therapy
223652621|NCT06201676|OTHER|Normal Saline|0.9% Sodium Chloride Injection, USP is sterile and nonpyrogenic. It is a parenteral solution containing sodium chloride in water for injection intended for intravenous administration. Each 100 mL of 0.9% Sodium Chloride Injection, USP contains 900 mg sodium chloride in water for injection. Electrolytes per 1000 mL: sodium (Na+) 154 mEq; chloride (Cl-) 154 mEq. The osmolarity is 308 mOsmol/L (calc.).
223652622|NCT03901469|DRUG|ZEN003694|PO QD
223652623|NCT03901469|DRUG|Talazoparib|PO QD
223652624|NCT05482958|DEVICE|HOP watch|A multisensor smartwatch that includes neurophysiological sensors such as heart rate sensor to monitor the vitals of the participant.
223652625|NCT04485013|DRUG|TTX-080|Variable dose (Q3W)
223652626|NCT04485013|DRUG|TTX-080|Specified dose (Q3W)
223652627|NCT04485013|DRUG|pembrolizumab|Specified dose (Q3W)
223652628|NCT04485013|DRUG|cetuximab|Specified dose on specified days
223652629|NCT04485013|DRUG|FOLFIRI|Specified dose (Q2W)
224236859|NCT05881096|OTHER|START - Startle Adjuvant Rehabilitation Therapy|Application of startling acoustic stimuli during practice of movement task
224236860|NCT05881096|OTHER|Sham Control|Practice of movement task without START
224236861|NCT04996238|PROCEDURE|Blood and nasal fluid sampling before and after COVID-19 vaccination|Blood and nasal fluid sampling take place just before the first COVID-19 vaccination and at 14-30 days after the second dose with the same vaccine. Sampling will be repeated at 6 months after the second vaccination, at 14-30 days after the third vaccination and at 6 months after the third vaccination. At all moments, a questionnaire is filled in.
224236862|NCT02602379|OTHER|Tetanic stimulation|Standard Tetanic stimulation will be used as the stimulus to evaluate responses of the intraoperative pain indexes (ANI and NoL) at different concentration of i.v. remifentanil during anesthesia.
224236863|NCT00980603|DRUG|docetaxel|docetaxel 75 mg/m2, IV on day 1 of each 3 week cycle until progression or unacceptable toxicity develops
224236864|NCT00980603|DRUG|docetaxel, cisplatin|docetaxel 60 mg/m2 and cisplatin 60 mg/m2, IV on day 1 of each 3 week cycle until progression or unacceptable toxicity develops
224236865|NCT00980603|DRUG|docetaxel, S-1|docetaxel 60 mg/m2 IV on day 1 and S-1 30 mg/m2 bid PO on days 1-14 of each 3 week cycle until progression or unacceptable toxicity develops
224236866|NCT06452160|DRUG|BGC515|Capsules for oral administration
224236867|NCT05564832|DRUG|Pilocarpine 1.25% Eye drop|One millimeter of pilocarpine eye drop (Bakhtarbiochemistry Company, Iran) contains pilocarpine hydrochloride 1.25% (12.5 mg) as an active ingredient, equivalent to 1.06% (10.6 mg) pilocarpine free-base. The medication preservative is 0.0075% benzalkonium chloride. Inactive ingredients in the ophthalmic are boric acid, sodium citrate dihydrate, sodium chloride, purified water. Another pilocarpine eye drop was Vuity® (1.25% pilocarpine; Allergan company) contains the active intergradients of pilocarpine hydrochloride 1.25% (12.5 mg/mL), equivalent to 1.06% (10.6 mg/mL) pilocarpine free-base and the preservative agents was 0.0075% benzalkonium chloride.
224236868|NCT01887626|DRUG|Ticagrelor 90 mg whole tablet|Ticagrelor 90 mg whole tablet administered as a single oral dose
224236869|NCT01887626|DRUG|Ticagrelor 90 mg tablet crushed|Ticagrelor 90 mg crushed and suspended in water
224236870|NCT01887626|DRUG|Dispersed ticagrelor 90 mg tablet suspended in water - nasogastric tube|Dispersed 90 mg ticagrelor 90 mg tablet suspended in water and administered through a nasogastric tube into the stomach
224236871|NCT00429806|DRUG|DHEA|DHEA
224236872|NCT00429806|DRUG|Placebo|Placebo
224236873|NCT02512913|BEHAVIORAL|Adapted/enhanced MAPS|The plan is for recruitment at the first prenatal care visit followed by a proposed eight-session phone counseling sequence for the women, consistent with the session frequency in the original MAPS intervention: 1st call at 14 weeks gestation (75% of Romanian women begin prenatal care in 1st trimester), three monthly calls through the 2nd trimester (18-22-26 weeks gestation), a 5th and 6th calls in the 3rd trimester (32 and 36 weeks), and two postnatal calls (2 and 6 weeks postpartum). Four calls are planned for the partners: at 14-, 22-, and 32-weeks, and at 2-weeks postpartum.
223652630|NCT04485013|DRUG|cetuximab|Specified dose (Q2W)
223652631|NCT04485013|DRUG|TTX-080|Specified dose (Q2W)
223652632|NCT06453187|DEVICE|Urinary Bladder Matrix (UBM) sheet device for Venous Leg Ulcers|Application of Urinary Bladder Matrix (UBM) sheet device, a porcine-derived extracellular matrix scaffold, and participants will receive weekly treatment with standard of care (cleaning, debridement, ulcer moisture balance, and offloading) until ulcer closure, or a maximum of 12 weeks, whichever occurs first.
223652633|NCT06453187|DEVICE|Urinary Bladder Matrix (UBM) sheet device for Diabetic Foot Ulcers|Application of Urinary Bladder Matrix (UBM) sheet device, a porcine-derived extracellular matrix scaffold, and participants will receive weekly treatment with standard of care (cleaning, debridement, ulcer moisture balance, and offloading) until ulcer closure, or a maximum of 12 weeks, whichever occurs first.
223767558|NCT06290856|DIAGNOSTIC_TEST|Multiplex PCR-test for circulating tumor DNA|All recruited patients will be tested for
224236874|NCT01870661|DEVICE|Long axis IV placement with ultrasound|Peripheral IV placement with the ultrasound probe viewing the vessel in the long axis.
223652634|NCT06453187|DEVICE|AmnioExcel Plus for Venous Leg Ulcers|Application of AmnioExcel Plus, a tri-layer (amnion-chorion-amnion) dehydrated human placental membrane allograft, and participants will receive weekly treatment with standard of care (cleaning, debridement, ulcer moisture balance, and offloading) until ulcer closure, or a maximum of 12 weeks, whichever occurs first.
223652635|NCT06453187|DEVICE|AmnioExcel Plus for Diabetic Foot Ulcers|Application of AmnioExcel Plus, a tri-layer (amnion-chorion-amnion) dehydrated human placental membrane allograft, and participants will receive weekly treatment with standard of care (cleaning, debridement, ulcer moisture balance, and offloading) until ulcer closure, or a maximum of 12 weeks, whichever occurs first.
223652636|NCT06453187|PROCEDURE|Standard of Care|Participants will receive weekly treatment with standard of care (cleaning, debridement, ulcer moisture balance, and offloading) until ulcer closure, or a maximum of 12 weeks, whichever occurs first.
223652637|NCT06794983|OTHER|In-person visit with study team member|Participants meet with a study team member before they are released from prison.
223652638|NCT06794983|OTHER|In-person visit with NCM|Participants meet with a NCM before they are released from prison.
223652639|NCT06794983|OTHER|Phone calls and texts|Study team member calls and texts participants after they are released from prison.
223652640|NCT06794983|OTHER|Phone calls and texts - NCM|Nurse case manager calls and texts participants after they are released from prison.
223652641|NCT04902924|BEHAVIORAL|repeated cold water therapy|This information can be found the description of the experimental arm.
223652642|NCT04902924|BEHAVIORAL|repeated warm water therapy|This information can be found the description of the experimental arm.
223652643|NCT04902924|OTHER|control|This information can be found the description of the experimental arm.
223652644|NCT05916625|OTHER|neuropsychological assessment|a consultation to assess cognitive and psycho-behavioral functions with questionnaires
223652645|NCT05916625|OTHER|biological sample|10 mL intravenous whole blood collection in EDTA tube
223652646|NCT05916625|PROCEDURE|medical imagery|Pet scan with the specific radioligand \[11C\]SB207145 and MRI
223767559|NCT04042883|PROCEDURE|Acute normovolemic hemodilution|500 ml of blood will be taken from the patient with simultaneous replacement with hydroxyethyl starch (HES 130/0.4) in another IV line
223767560|NCT00569686|DRUG|lovaza|lovaza 4 gm po daily
223767561|NCT00569686|DRUG|placebo|placebo
223652650|NCT03738228|DRUG|Atezolizumab|Given IV
223652651|NCT03738228|RADIATION|Brachytherapy|Undergo standard of care image guided brachytherapy
223652652|NCT03738228|DRUG|Cisplatin|Given IV
223652653|NCT03738228|RADIATION|Radiation Therapy|Undergo standard of care radiation therapy
223652654|NCT04837586|OTHER|Standard Care|Individuals will receive standard care for their obesity through the Pediatric Weight Management Clinic.
223652655|NCT04837586|DEVICE|Simple Scale|Individuals will be encouraged to perform daily weighing at home on a simple scale.
223652656|NCT04837586|DEVICE|EHR-Connected Scale|Individuals will be encouraged to perform daily weighing at home on a Smart scale that connects to the EHR. Clinic staff will review weight entries in the EHR and provide feedback.
223652657|NCT06706076|DRUG|BH-30643|BH-30643 will be provided as either 10 mg or 40 mg capsules. Subjects will take BH-30643 orally depending on their dose level assignment.
223652658|NCT06706076|DRUG|BH-30643|BH-30643 will be provided as either 10 mg or 40 mg capsules. Subjects will take BH-30643 orally depending on their dose level assignment.
223652659|NCT04896073|DRUG|Minnelide|Administered orally (2 mg) once daily for 21 days of 28-day cycles for 12 cycles.
224236875|NCT01870661|DEVICE|Short axis IV placement with ultrasound|Peripheral IV placement with the ultrasound probe viewing the vessel in the short axis.
224236876|NCT00158119|BEHAVIORAL|InVEST (Increased Velocity Exercise Specific to Task)|
224236877|NCT00117949|DRUG|Degarelix|One dose (2 x 2 mL) of degarelix 40 mg (10 mg/mL), subcutaneous injection.
224236878|NCT00117949|DRUG|Degarelix|One dose (2 x 2 mL) of degarelix 80 mg (20 mg/mL), subcutaneous injection.
224236879|NCT00117949|DRUG|Degarelix|One dose (2 x 2 mL) of degarelix 120 mg (30 mg/mL), subcutaneous injection.
223652660|NCT04896073|DIAGNOSTIC_TEST|ECG|Screening and end of treatment visit.
223652661|NCT04896073|DIAGNOSTIC_TEST|CT/MRI|Screening. Subsequent cycles Day 1 (≤3days) and Day 15 (±2 days) (every other cycle). End of treatment visit.
223652662|NCT04896073|PROCEDURE|Tumor Biopsy|Optional. Baseline Cycle 1, Day 1 and Cycle 1, Day 15. End of treatment visit or progressive disease.
223652663|NCT06960291|BEHAVIORAL|Group Exercise Classes|Participants will take part in a combination of aerobic, resistance, balance, and flexibility exercises delivered in a circuit-type class setting, twice weekly for a 8-12-week period (duration of intervention depends on scheduling logistics for the coordinating hubs and their spokes sites). The exercise sessions will be conducted in groups with a ratio of up to 15 participants per instructor. The program follows exercise progression principles (i.e., frequency, intensity, time, type, overload and progression) over the 8-12-weeks, with tailoring of any exercise to meet individual participant needs as required, in order to promote fitness and wellness benefits.
224236880|NCT00117949|DRUG|Degarelix|One dose (2 x 2 mL) of degarelix 160 mg (40 mg/mL), subcutaneous injection.
224236881|NCT03475927|OTHER|Concerning and knowledge about radiation hazard questionnaire|Concerning and knowledge about radiation hazard questionnaire to determine the concerning and knowledge of radiation hazard among surgeon and anesthesiologist
224236882|NCT03777033|DRUG|Prophylactic protocol with Ca and Vit D|"3g calcium /day for 5 days and then 2g/day for 10 days 2 Micrograms Alfacalcidol/day and then 1 microgram /day for 10 days~the Prophylactic protocol with Ca and Vit D will be given in the form of Alfacalcidol 0.5 Micrograms Capsule and CALCIUM CARBONATE + CALCIUM GALACTOGLUCONATE 1000mg tablet"
223652667|NCT03600701|DRUG|Atezolizumab|Given IV
223652668|NCT03600701|PROCEDURE|Biopsy Procedure|Undergo biopsy
223652669|NCT03600701|PROCEDURE|Biospecimen Collection|Undergo collection of blood
223652670|NCT03600701|DRUG|Cobimetinib|Given PO
223652671|NCT03600701|PROCEDURE|Computed Tomography|Undergo CT scan
223652672|NCT03600701|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223652673|NCT05041140|DEVICE|29-XeMRI imaging|129-XeMRI scan
223652674|NCT01385176|DEVICE|Implant of investigational device system|Vagus nerve stimulation lead was wrapped around the right cervical vagus nerve and then connected to a stimulator permanently implanted in the right pectoral region.
223652675|NCT01385176|PROCEDURE|Titration during the randomization phase|Amplitude of the chronically delivered vagus nerve stimulation in the experimental arm was adjusted to the highest tolerable by patient value. No chronically delivered vagus nerve stimulation in the control arm during the randomization phase.
223652676|NCT01385176|PROCEDURE|Titration after the randomization phase|Amplitude of the chronically delivered vagus nerve stimulation was adjusted to the highest tolerable by patient value in all patients in both arms of the study.
223652677|NCT01385176|DIAGNOSTIC_TEST|Blood Draw|Blood draw before implant and 6 months after implant at the end of the randomization phase.
223652678|NCT05807399|DRUG|BTZ-043|BTZ-043 1000mg once daily in arms 4 and 6.
223652679|NCT05807399|DRUG|Rifampicin|Rifampicin will be dosed in a fixed high-dose (2100 mg for arms 1 and 2) or a weight-banded regular dose (10 mg/kg) in arm 3, 5 and 7.
223652680|NCT05807399|DRUG|Isoniazid|Isoniazid will be dosed at fixed dose of 300mg in arms 1 and 2, and regular dose of 5 mg/kg in arm 3 and 7.
223652681|NCT05807399|DRUG|Pyrazinamide|Pyrazinamide will be dosed in a fixed regular dose in arm 1 (1600 mg), a weight banded high dose in arm 2 (2000/2400 mg) or a weight-banded regular dose (25 mg/kg) in arm 3, 5 and 7.
223652682|NCT05807399|DRUG|Moxifloxacin|Moxifloxacin will be dosed at 600 mg orally once daily in arms 1-2.
223652683|NCT05807399|DRUG|Alpibectir (GSK3729098)|Alpibectir 45 mg OD plus Ethionamide 500 mg OD combined with rifampicin pyrazinamide and ethambutol at standard weight-banded doses in arm 5.
224236883|NCT00615784|DRUG|Bexarotene|Bexarotene given orally at a dose of 300mg/m2 until disease progression or unacceptable toxicities experienced by patient
224236884|NCT01107002|PROCEDURE|Day 5 embryo transfer group|Embryo will transfer at blastocyst stage (day 5 after ovum pick up)
224236885|NCT06132646|OTHER|Proprioceptive exercises|Specific proprioceptive exercises for the wrist that the patient has to do currently with standard rehabilitation.
224236886|NCT00159965|DRUG|sertraline|flexible dose sertraline
224236887|NCT00159965|DRUG|placebo|flexible dose placebo
224236888|NCT01434836|OTHER|active tDCS and working memory training|This group will receive 2.0 mA anodal DC stimulation over the left DLPFC and cathodal stimulation over the right DLPFC. During the stimulation, this group will be trained on working memory processes. Sessions will be scheduled daily for two consecutive weeks.
224236889|NCT01434836|OTHER|sham tDCS and working memory training|This group will receive sham stimulation (e.g., identical stimulation set-up but no electric current is sent through the electrodes). Patients however receive the real working memory training, daily, for two weeks.
224236890|NCT01661270|DRUG|Aflibercept|Pharmaceutical form: Concentrate for Solution for infusion; Route of administration: Intravenous
223652684|NCT05807399|DRUG|Ganfeborole (GSK3036656)|Ganfeborole 20 mg OD in arm 6
224236891|NCT01661270|DRUG|Placebo|Pharmaceutical form: Concentrate for Solution for infusion; Route of administration: Intravenous
223652685|NCT05807399|DRUG|Delpazolid (LCB01-0371)|Delpazolid 1200mg OD in arm 6
223652686|NCT05807399|DRUG|Pretomanid (Pa)|Pretomanid 20mg OD in arm 6.
223652687|NCT05807399|DRUG|Ethambutol (E)|Ethambutol 20mg/Kg OD in arm 3, 5 and 7
223652688|NCT05807399|DRUG|Ethionamide|Ethionamide 500mg OD in arm 5.
223652689|NCT06445959|DRUG|Olutasidenib|Given by PO
223652690|NCT06445959|DRUG|Venetoclax|Given by PO
223652691|NCT06445959|DRUG|Decitabine|Given by IV
223652692|NCT06445959|DRUG|Decitabine/cedazuridine|Given by PO
223652693|NCT06484088|OTHER|Frustration task|The experimental manipulation for this study is the frustration task. The frustration task is designed to elicit the emotional state of frustrative non-reward (FNR). During the task, participants are asked to use button press (left or right) to alternately press one of the two doors displayed on the monitor. The task has two non-frustration blocks (Block 1 and 2) and one frustration block (Block 3). During the non-frustration blocks, participants earn money for correct press on a fixed schedule. During the frustrative block, participants will not always receive reward for correct press.
223652694|NCT04266093|DRUG|GeneTherapy|Observation/ Gene Therapy Long-term Follow-up. Subjects who have enrolled on an applicable NCI CIO gene therapy treatment protocol.
223652695|NCT06833125|DRUG|Garlic powder standardized to allicin|The intervention is the administration of garlic tablets (Tomex plus 300 mg) two tablets twice daily (which contains 5.4 mg allicin the active ingredient with anibacterial effect) for 6 days just after ICU admission
223652696|NCT05006716|DRUG|BGB-16673|Orally administered
223652697|NCT02306161|DRUG|Cyclophosphamide|Given IV
223652698|NCT02306161|DRUG|Doxorubicin|Given IV
223652699|NCT02306161|DRUG|Doxorubicin Hydrochloride|Given IV
223652700|NCT02306161|DRUG|Etoposide|Given IV
223652701|NCT02306161|DRUG|Etoposide Phosphate|Given IV
223652702|NCT02306161|RADIATION|External Beam Radiation Therapy|Undergo EBRT
223652703|NCT02306161|BIOLOGICAL|Ganitumab|Given IV
223652704|NCT02306161|DRUG|Ifosfamide|Given IV
223652705|NCT02306161|RADIATION|Stereotactic Radiosurgery|Undergo SBRT
223652706|NCT02306161|PROCEDURE|Therapeutic Surgical Procedure|Undergo surgery
223652707|NCT02306161|DRUG|Vincristine|Given IV
223652708|NCT02306161|DRUG|Vincristine Sulfate|Given IV
224236892|NCT04811768|PROCEDURE|Maxillary sinus augmentation|The surgery was performed under local anaesthesia in both groups, lateral window preparation and window coverage was carried out based on randomization.
224236893|NCT03184441|DEVICE|Premie Pouch|The Premie Pouch is an experimental device meant to manage the development of Deformational Plagiocephaly (DP) starting immediately following birth. The Premie Pouch has a concave-shaped foam insert that will provide a resting surface for the infant's head and body that will eliminate uneven pressure on the infant's occiput while maintaining correct body alignment. Also, the posterior neck area of the infant will be supported by a fixed bridge section of the foam insert. The Premie Pouch is designed specifically for the very low birth weight (VLBW) infant.
224236894|NCT01333527|PROCEDURE|No Sling|Early range of motion
224236895|NCT01333527|PROCEDURE|Sling|Patients will use the sling for 6 weeks, as per usual care
224236896|NCT06081647|DEVICE|the COMBO Endoscopy Oropharyngeal Airway|Using the COMBO Endoscopy Oropharyngeal Airway for oxygenation.
223652709|NCT05763537|BEHAVIORAL|Standard Doula Care Plus PMAD Intervention|Doulas trained in the DONA training, and the PMAD-focused training will provide care to perinatal people.
223652710|NCT05763537|BEHAVIORAL|Standard Doula Care|Doulas trained in the DONA training will provide care to perinatal people.
223652711|NCT06441578|DRUG|Recombinant ADAMTS13|Recombinant ADAMTS13, Intravenous injection
224236897|NCT06081647|DEVICE|Regular Nasal Cannula|Using regular nasal cannula for oxygenation.
224236898|NCT01868009|DEVICE|ELLIPTA|Novel dry powder inhaler (placebo) with 30 doses (2 strips with 30 blisters per strip)
224236899|NCT01868009|DEVICE|DISKUS|Multidose dry powder inhaler (placebo) containing a foil strip worth 60 blisters (1 strip with 60 blisters per strip)
224236900|NCT04652570|DRUG|VB119|Humanized, immunoglobin (Ig) G1 monoclonal antibody (mAb) to be administered as intravenous infusion at multiple timepoints during the study.
224236901|NCT05496075|DRUG|Orlistat|Orlistat was administered orally on the basis of lifestyle guidance . Orlistat: Take 0.12g (1 capsule) with or within one hour after meals, 3 times a day. Medication time course: continuous administration for a total of 12 weeks.
224236902|NCT05496075|DRUG|Orlistat placebo|Lifestyle guidance: low-purine diet; orlistat placebo: take 1 capsule with or within one hour after a meal, 3 times a day. Medication time course: continuous administration for a total of 12 weeks.
224236903|NCT01276782|DRUG|Levothyroxine|It is FDA approved drug for thyroid disease
224236904|NCT00001805|DRUG|Rituximab|
224236905|NCT00968370|OTHER|Day-care clinic|Inj. Ceftriaxone and other micronutrients will be given to children at the day-care clinic from 8:00 a.m. to 5:00 p.m. daily.
224236906|NCT00968370|OTHER|Hospital Management|Inj. Ceftriaxone and other micronutrients will be given to children at the hospital from admission till discharge.
224236907|NCT00165399|DRUG|Docetaxel|Given intravenously on day 2 of four three-week cycles
224236908|NCT00165399|DRUG|Estramustine|Taken orally three times a day for 5 days starting on day one of each three-week cycles (4 cycles)
224236909|NCT00165399|DRUG|Casodex|Started 3 weeks after last chemotherapy treatment; taken orally once a day for 15 months
224236910|NCT00165399|DRUG|Zoladex|Started one week after the start of casodex; zolades is given as an injection (in the stomach once every 3 months for a total of 5 injections.
224236911|NCT01482156|DRUG|RAD001 + BEZ235|RAD001 is formulated as tablets of 2.5 mg and 5 mg strength, blistered in units of 10 tablets (for oral use) each. Blisters should be opened only at the time of dministration as the drug is both hygroscopic and light-sensitive. RAD001 should be administered immediately after a meal with a large glass of water. BEZ235 is supplied as 50-mg, 200-mg, 300-mg and 400-mg sachets (for oral use). BEZ235 is packaged in aluminum foil bags. Bags are packaged in a box. Patients will receive RAD001 in combination with BEZ235.
224236912|NCT03493100|DIETARY_SUPPLEMENT|oral nutritional supplementation|The intervention group will receive optimized nutritional support, by ONS. While hospitalized each patient receives 2 portions of oral supplementation per day. For remaining days supplementation is calculated individually according to a sarcopenia/energy balance schema resulting in none or maximum 2 portions per day.
224236913|NCT03493100|OTHER|Usual care|The control group will receive treatment according to usual care.
224236914|NCT06004609|DEVICE|Low-level laser therapy (LLLT)|Low-level laser therapy (LLLT), three time each week, 10 minutes each time, during the first 8 weeks of the treatment trial.
224236915|NCT06004609|OTHER|Conventional physical therapy|Conventional physical therapy will be applied three time each week, for 12 weeks
224236916|NCT02986009|BEHAVIORAL|Parenting|"The parenting intervention consists of four weekly sessions, each lasting two hours. The intervention was designed according to the parenting characteristics of Chinese parents in Hong Kong. The four sessions cover: 1) response modification (stop and rest), 2) relaxation/enhancing positive moods (relax and play), 3) cognitive reframing (think), and 4) using social support (talk and share). Discussion, practice, and questions are involved in each session."
224236917|NCT02986009|BEHAVIORAL|Information|The information intervention consists of four weekly sessions, each lasting for two hours. The contents cover information and resources about education, medical care, housing, employment, and community facilities available in Hong Kong and Mainland China.
224236918|NCT04895111|DIAGNOSTIC_TEST|Endobronchial ultrasound strain elastography|Measurement of tissue elasticity of hilar and mediastinal lymph nodes through strain elastography measured during an endonbronchial ultrasound examination
224236919|NCT00205049|DRUG|pentoxifylline|daily dosing
224236920|NCT04770961|PROCEDURE|Erector spinae plane catheter with 0.5% Ropivacaine|Ultrasound guided, right sided, ESP catheter inserted at the level of T5. 20 cc injection of 0.5% Ropivacaine is injected at the time of catheter placement. Postoperatively, a programmed intermittent bolus infusion of 0.2% Ropivacaine will be delivered via the ESP catheter.
224236921|NCT04770961|PROCEDURE|Erector spinae plane catheter with saline|Ultrasound guided, right sided, ESP catheter inserted at the level of T5. 20 cc injection of saline is injected at the time of catheter placement. Postoperatively, a programmed intermittent bolus infusion of saline will be delivered via the ESP catheter.
223652712|NCT06486441|DRUG|Sacituzumab govitecan-hziy|Administered intravenously
223652713|NCT06486441|DRUG|Doxorubicin|Administered intravenously
223652714|NCT06486441|DRUG|Paclitaxel|Administered intravenously
223652715|NCT06196853|DRUG|Aminophylline|Give aminophylline for 5 days to keep serum theophylline level 5-15 mg/dl
223652716|NCT03290950|DRUG|daratumumab|Cycle 1 ONLY: Daratumumab 16 mg/kg days 1, 8, 15, and 22, Cycle 2: Daratumumab 16mg/kg days 1, 8, 15, and 22; Cycles 3-6: Daratumumab 16mg/kg days 1 and 15, Cycles 7-8: Daratumumab 16mg/kg day 1; Daratumumab rate of infusion is per MSKCC guidelines.
223652717|NCT03290950|DRUG|carfilzomib|Cycle 1 ONLY: Carfilzomib 20 mg/m2 per dose, days 2 and 3; Carfilzomib 36 mg/m2 per dose, days 8, 9, 15, and 16; Cycles 2-8: Carfilzomib 36 mg/m2 per dose, days 1, 2, 8, 9, 15, and 16
223652718|NCT03290950|DRUG|lenalidomide|Cycle 1 ONLY: Lenalidomide 25 mg/day, days 2-21 every 28 days; Cycles 2-8: Lenalidomide 25 mg/day, days 1-21 every 28 days
223652719|NCT03290950|DRUG|dexamethasone|Cycle 1 ONLY: Dexamethasone 20 mg/dose, days 2, 3, 8, 9, 15, 16, Cycles 2: Dexamethasone 20mg/dose, days 1, 2, 8, 9, 15, 16 and 22; Cycles 3-4: Dexamethasone 20mg/dose, days 1,2,8,9,15 and 16, Cycles 5- 8: Dexamethasone 10mg/dose, days 1, 2, 8, 9, 15, and 16
223652720|NCT03290950|DRUG|dexamethasone|Cycle 1 ONLY: Dexamethasone 20 mg/dose, days 1, 2, 22; 40 mg/dose days 8 and 15, Cycles 2: Dexamethasone 40mg/dose, days 1, 8, 15; 20 mg/dose day 22, Cycles 3-4: Dexamethasone 40mg/dose, Days 1, 8 15, Cycles 5-8: Dexamethasone 20mg/dose, Days 1, 8, 15
223652721|NCT04995419|DRUG|Enfortumab vedotin|Intravenous Infusion
223767562|NCT05980780|BEHAVIORAL|video game group|"Pretest: Participants will be informed about FMF, treatment of FMF, side effects of treatment, factors that trigger attacks, symptoms that occur during the attack, symptom management/disease self-management, and coping with stress through a video game. At the beginning of the application, questions for the collection of demographic data and scales applied to the control group will be applied. The game will be played at home once a week for 1 month. For this, reminder messages will be sent once a week by obtaining the contact information of the mothers.~Post-test 1: The scales will be re-administered 1 month after the pre-test. Post-test 2: The scales will be administered again 3 months after the pre-test."
223767563|NCT05980780|BEHAVIORAL|Education booklet group|"Pretest: Participants will be informed about FMF, treatment of FMF, side effects of treatment, factors that trigger attacks, symptoms that occur during the attack, symptom management/disease self-management, and coping with stress through a training booklet. At the beginning of the application, questions for the collection of demographic data and scales applied to the control group will be applied. The booklet will be read at home once a week for 1 month. For this, reminder messages will be sent once a week by obtaining the contact information of the mothers.~Post-test 1: The scales will be re-administered 1 month after the pre-test. Post-test 2: The scales will be administered again 3 months after the pre-test."
223767564|NCT05951244|DEVICE|Transcranial Direct Current Stimulation-TessaNova (Teknofil-Turkiye)|Sponge electrodes 5 x 7 cm in size will be used for tDCS application. The sponge electrodes will be wetted with saline and the cathode electrode will be placed on the seizure focus determined by EEG recording and seizure clinic, while the anode electrode will be placed on the contralateral shoulder-deltoid muscle.
223767565|NCT02256046|DEVICE|Esophagogastroduodenoscope|Endoscopic therapies for varices aim to reduce variceal wall tension by obliteration of the varix. The two principal methods available for esophageal varices are endoscopic sclerotherapy (EST) and band ligation (EBL). Endoscopic therapy is a local treatment that has no effect on the pathophysiological mechanisms that lead to portal hypertension and variceal rupture. However, a spontaneous decrease in HVPG occurs in around 30% of patients treated with either EST or EBL to prevent variceal rebleeding.
223767566|NCT06466850|BIOLOGICAL|Exosome|intra-articular injection is suggested for two times: day 1and day 90
223767567|NCT02026115|BEHAVIORAL|PAINReportIt|PAINReportIt is a software program developed with an electronic McGill Pain Questionnaire (MPQ) and now includes questions about analgesics used by patients and a shortened version of the pain Barriers Questionnaire (BQ). It is designed as an interactive, touch screen way to assess pain. It can be self-administered and requires little or no patient computer experience and little or no provider time. The patient can read instructions on-screen and practice all types of selection responses found the program. Directions from the paper tools were modified to address the touch screen method of recording responses. The copyright is owned by Dr. Ronald Melzack for the MPQ and Dr. Sandra Ward for the BQ. Both individuals authorized the modifications, format, and computerized use of the tools.
224236922|NCT05847699|OTHER|MRI sequences and biopsies|Addition of a contrast injection and optimized SWI sequences during the pre-DH MRI examination performed as part of the care Addition of two 1x1 cm biopsy samples of cortex in two different non-functional ischemic areas, one of which is within the SWI hyposignal remodeling, during the DH. This will be a cold pial dissection without the use of coagulation.
224236923|NCT03319498|OTHER|Peppermint Oil Vapor|"2ml of the oil will be placed in the urine collection hat that fits into the bowl of the toilet. Participants will then sit on the toilet in normal fashion, exposing their perineum to the vapor of the oil. The perineum will NOT come into contact with the oil directly - only the vapor from the oil will contact the perineum."
224236924|NCT03319498|OTHER|Mineral Oil Vapor|"2ml of the mineral oil will be placed in the urine collection hat that fits into the bowl of the toilet. Participants will then sit on the toilet in normal fashion, exposing their perineum to the vapor of the oil. The perineum will NOT come into contact with the oil directly - only the vapor from the oil will contact the perineum."
224236925|NCT04803357|DEVICE|Continuous glucose monitor|We are offering you an opportunity to wear a medical device that monitors your blood sugars (glucose). This device is called a continuous glucose monitor (CGM). The CGM measures glucose levels through a tiny plastic filament that is inserted under the skin in your abdomen by a skin prick. Typically, you cannot feel this device once it is inserted.
224320838|NCT06847152|DIAGNOSTIC_TEST|spatial memory test|"The assessment of spatial memory corresponds in our study to a navigation task, i.e. learning a route through the hospital. The route encoding phase is first carried out. The participant follows the experimenter, with the instruction to pay close attention to the route in order to be able to do it again alone. For directions, it is said this way or that way and not left or right. The route includes 18 intersections.~The participant immediately does the route again alone. The number of correct answers (BR), i.e. correct directions taken at each intersection, is counted as well as the time to complete the route (TR). Direction errors are corrected. This is recall 1.~The participant is then asked to do the route a second time. The correct answers and the times to complete the route are recorded. Errors are corrected (feedback). This is recall 2.~If the participant makes a mistake on recall 1 or 2, a third attempt is made. This is recall 3.~After an interval of 1 hour, the partic"
223652722|NCT03306173|OTHER|Commercially available cigarette|Commercially available cigarette with either \~0% or \~25% filter ventilation. Menthol flavor will be available in both types.
223652723|NCT05600777|DRUG|BLU-5937|Oral administration of BLU-5937 Tablets
224320839|NCT06847399|DRUG|Tirzepatide|Tirzepatide
223652724|NCT05600777|DRUG|Placebo|Oral administration of matching placebo for BLU-5937 Tablets
223652728|NCT06072326|DRUG|Dapagliflozin (Forxiga®)|5 mg/day as a tablet
223652729|NCT06072326|DRUG|SC0062 strength 10mg|20 mg/day, twice daily, capsule
223652730|NCT06072326|DRUG|SC0062 and dapagliflozin|20 mg/day SC0062 10 mg twice daily as a capsule in combination with 5 mg/day dapagliflozin 5 mg as a tablet
224236926|NCT05083403|DEVICE|AcumenTM HPI Software Feature|The AcumenTM HPI Feature Software provides the clinician with physiological insight into a patient's likelihood of trending toward a hypotensive event. The AcumenTM HPI Feature Software suite is enabled by the minimally invasive Acumen IQ sensor.
223652731|NCT06848361|DEVICE|MPowerHub|The MPowerHub app allows participants to visualize combined trends from a continuous glucose monitor (CGM) and activity monitor as well as daily self-reports in a display that the participant can customize to overlay the behavioral data they would like to compare to intraday and daily glucose data. Summary data will be displayed over time to allow users to identify potential associations between activity, sleep, stress, diet, and medication adherence and time-in-range and blood glucose variability. Participants receive daily prompts to complete five brief questions about daily health behaviors and two weekly goals/action plans and reflections based on motivational interviewing principles.
223652732|NCT06848361|DEVICE|Continuous Glucose Monitor (CGM)|A CGM is a wearable device that collects frequent data on glucose levels. It includes an integrated sensor that is inserted under the skin and is connected to a small transmitter that automatically sends information to a smart device, allowing the user to track changes in glucose levels.
223652733|NCT06848361|DEVICE|Activity Monitor|A wearable activity monitor will be used to track activity (e.g., steps) and sleep levels. Data can be viewed on the activity monitor or a smart device.
223652734|NCT02969746|DRUG|Activated Charcoal|"Patients will take oral activated charcoal after randomization in the intervention arm.~A blood sample(TO) will be collected after patient enrollment and before charcoal administration and 4 blood samples will be collected on a 8h length period (T1 to T4)"
223652735|NCT00007150|PROCEDURE|Phlebotomy|Therapeutic phlebotomy, the periodic, frequent removal of the iron contained in the hemoglobin of red blood cells.
223652736|NCT06072664|BEHAVIORAL|Caloric Compensation Index (COMPX)|Researcher gives child opportunity to consume high- and low-calorie preloads and then free access to a palatable snack
223652737|NCT05508867|BIOLOGICAL|favezelimab/pembrolizumab|Coformulated favezelimab/pembrolizumab (800 mg/200 mg), IV infusion
223652738|NCT05508867|DRUG|bendamustine|IV infusion
223652739|NCT05508867|DRUG|gemcitabine|IV infusion
224236927|NCT05083403|OTHER|Non-protocolized Standard of Care|Non-protocolized standard of care to treat subjects
224236928|NCT05209841|DRUG|Low dose heparin|Catheters will be sealed with 3 mL of Fibrillin Ⓡ (heparin 20UI/mL)
224236929|NCT05209841|DRUG|Normal saline|Catheters will be sealed with 3mL of 0.9% sodium chloride
224236930|NCT05202704|PROCEDURE|Procedure/Surgery: Experimental: Hidden conditioning + Positive Expectation|Patients will be submitted to quantitative sensory testing to determine different thresholds of noxious heat pain stimulus (intense, moderate or weak). Afterward, participants will receive instructions with the aim to induce positive expectations about the treatment by means of a workshop. Immediately after the first session of manipulative therapy, participants will be submitted again to the QST but now the heat pain threshold of the hidden conditioning group will be surreptitiously downgraded (the intense noxious stimulus will be downgraded to the moderate stimulus - individually obtained during the QST) as a mean to conditioning patients to believe that spinal manipulative therapy promoted pain relief. Patients will be invited to report the pain intensity perceived just after the QST (second test - conditioning procedure). The objective of questioning the pain intensity after the conditioning test is a procedure check to ensure that the conditioning procedure worked.
224236931|NCT05202704|PROCEDURE|Procedure/Surgery: Active Comparator: Positive Expectation|Patients in this group will be submitted to a quantitative sensory testing to determine different thresholds of noxious heat pain stimulus (intense, moderate or weak). Afterward, participants will receive instructions with the aim to induce positive expectation about the treatment by means of a workshop. Immediately after the first session of spinal manipulative therapy, participants will be submitted again to the QST (without downgrading of the intense noxious heat stimulus). Patients will be invited to report the pain intensity perceived during the QST after the intervention. The objective of questioning the pain intensity in this group is a procedure check - to investigate whether the positive instructions will show any effect.
224236932|NCT05202704|PROCEDURE|Procedure/Surgery: Active Comparator: Neutral Expectation|Patients in this group will be submitted to a quantitative sensory testing to determine different thresholds of noxious heat pain stimulus (intense, moderate or weak). Afterward, participants will receive instructions with the aim to induce neutral expectation about the treatment by means of a workshop. Immediately after the first session of spinal manipulative therapy, participants will be submitted again to the QST (without downgrading of the intense noxious heat stimulus). Patients will be invited to report the pain intensity perceived during the QST after the intervention. The objective of questioning the pain intensity in this group is a procedure check - to investigate/confirm the effect of neutral instructions.
224236933|NCT05202704|PROCEDURE|Spinal Manipulative Therapy|All the groups recruited in the study will receive five sessions of Spinal Manipulative Therapy. The intervention will be performed with the patient in the supine position. The clinician-researcher will passively lean over the patient to the side to be manipulated and ask the patient to place their hands behind their head. The researcher will then passively rotate the patient on the side to be manipulated and perform a posterior and inferior thrust on the opposite anterosuperior spine. The patients will receive 4 maneuvers (twice towards right side and twice towards left side).
224236934|NCT00863525|DRUG|odanacatib|A single oral dose of 100 mg odanacatib administered with a light meal in one treatment period and without a meal in the other treatment period. There will be 10 days between treatment periods.
224236935|NCT00863525|DRUG|Comparator: Placebo|A single oral dose of Placebo to odanacatib administered with a light meal in one treatment period and without a meal in the other treatment period. There will be 10 days between treatment periods.
224236936|NCT00783757|DEVICE|Optical Imaging|TOBI scan performed before the participant starts cancer treatment and at the start of each treatment cycle
224236937|NCT01512381|DEVICE|Implantation of CRT device|RV lead of CRT system is implanted into the middle part of interventricular septum
224236938|NCT01512381|DEVICE|Implantation of conventional VVI(R) pacemaker|RV lead is implanted into the middle part of interventricular septum
223652740|NCT06205056|BIOLOGICAL|Ad26.Mos4.HIV in CH505 TF chTrimer + ALFQ [Arm 1a]|Participants in Arm 1a will receive dose consistent injections (5x10\^10 vp/0.5 mL) of Ad26.Mos4.HIV in a 0.5 mL injection volume and dose consistent injections of CH505 TF chTrimer (300 µg)+ALFQ (200 µg MPLA/100 µg QS-21) in a 1.1 mL injection volume on Study Days 1 and 57
223652741|NCT06205056|BIOLOGICAL|CH505 TF chTrimer + ALFQ [Arm 1a]|Participants in Arm 1a will receive a dose-consistent injection of CH505 TF chTrimer (300 µg)+ALFQ (200 µg MPLA/100 µg QS 21) in a 1.1 mL injection volume on Study Day 169.
223652742|NCT06205056|BIOLOGICAL|Placebo [Arm 1a]|Participants in Arm 1a will receive dose-consistent 0.5 mL injection and a 1.1 mL injection of Placebo on Study Days 1 and 57, followed by a 1.1 mL injection of Placebo on Study Day 169.
223652743|NCT06205056|BIOLOGICAL|Ad26.Mos4.HIV in CH505 TF chTrimer +ALFQ [Arm 2a]|"Participants in Arm 2a will receive a lower dose of Ad26.Mos4.HIV (2.5x10\^10 vp/0.25 mL) in a 0.25 mL injection volume and a lower dose of CH505 TF chTrimer (30 µg)+ALFQ (50 µg MPLA/25 µg QS-21) in a 0.5 mL injection volume on Study Day 1.~Participants in Arm 2a will receive an injection Ad26.Mos4.HIV (5x10\^10 vp/0.5 mL) in a 0.5 mL injection volume and CH505 TF chTrimer (300 µg)+ALFQ (200 µg MPLA/100 µg QS 21) in a 1.1 mL injection volume on Study Day 57."
223652744|NCT06205056|BIOLOGICAL|CH505 TF chTrimer +ALFQ [Arm 2a]|"Participants in Arm 2a will receive a rapid, dose escalating injections of CH505 TF chTrimer (100 µg, 150 µg, and 300 µg)+ALFQ (50 µg MPLA/ 25 µg QS-21) on Study Days 4 (0.5 mL injection volume), 8 (0.5 mL injection volume), and 15 (0.9 mL injection volume).~Participants in Arm 2a will receive a injection of CH505 TF chTrimer (300 µg)+ALFQ (200 µg MPLA/100 µg QS 21) in a 1.1 mL injection volume on Study Day 169."
223652745|NCT06205056|BIOLOGICAL|Placebo [Arm 2a]|Participants in Arm 2a will receive a 0.25 mL injection and a 0.5 mL injection of Placebo on Study Day 1; followed by 0.5 mL, 0.5 mL, and 0.9 mL injections of Placebo on Study Days 4, 8, and 15, respectively; followed by a 0.5 mL injection and a 1.1 mL injection of Placebo on Study Day 57; followed by a 1.1 mL injection of Placebo on Study Day 169.
223652746|NCT06205056|BIOLOGICAL|CH505 TF chTrimer + ALFQ [Arm 1b]|Participants in Arm 1b will receive dose consistent injections of CH505 TF chTrimer (300 µg)+ALFQ (200 µg MPLA/100 µg QS-21) in a 1.1 mL injection volume on Study Days 1, 57, and 169.
223652747|NCT06205056|BIOLOGICAL|Placebo [Arm 1b]|Participants in Arm 1b will receive a 1.1 mL injection of Placebo on Study Days 1, 57, and 169.
223652748|NCT06205056|BIOLOGICAL|CH505 TF chTrimer + ALFQ [Arm 2b]|"Participants in Arm 2b will receive a lower dose of CH505 TF chTrimer (30 µg)+ALFQ (50 µg MPLA/25 µg QS 21) in a 0.5 mL injection volume on Study Day 1.~Participants in Arm 2b will receive a rapid, dose escalating injections of CH505 TF chTrimer (100 µg, 150 µg, and 300 µg)+ALFQ (50 µg MPLA/ 25 µg QS-21) on Study Days 4 (0.5 mL injection volume), 8 (0.5 mL injection volume), and 15 (0.9 mL injection volume).~Participants in Arm 2b will receive a injections of CH505 TF chTrimer (300 µg)+ALFQ (200 µg MPLA/100 µg QS 21) in a 1.1 mL injection volume on Study Days 57 and 169."
223652749|NCT06205056|BIOLOGICAL|Placebo [Arm 2b]|Participants in Arm 2b will receive a 0.5 mL injection of Placebo on Study Days 1, 4, and 8; followed by a 0.9 mL injection of Placebo on Study Day 15; followed by a 1.1 mL injection of Placebo on Study Days 57 and 169.
223652750|NCT04130854|DRUG|APX005M, mFOLFOX, and Radiation Therapy 5Gy x 5 days|"1. APX005M 0.3mg/kg intravenously on day 3 of radiation and on day 3 of cycles 1-5 of mFOLFOX~2. Short course radiation therapy 5 Gy x 5 days~3. Oxaliplatin 85mg/m2 intravenous day 1 of each cycle~4. Leucovorin 400mg/m2 IV Day 1 of each cycle~5. 5-FU 2400 mg/m2 continuous infusion over 46 hours of each cycle"
223652751|NCT04130854|DRUG|mFOLFOX and Radiation Therapy 5Gy x 5 days|"1. Short course radiation therapy 5 Gy x 5 days~2. Oxaliplatin 85mg/m2 intravenous day 1 of each cycle~3. Leucovorin 400mg/m2 IV Day 1 of each cycle~4. 5-FU 2400 mg/m2 continuous infusion over 46 hours of each cycle"
223652752|NCT06529523|DRUG|Tislelizumab|Patients will receive standard dose of tislelizumab 200mg IV flat dose q3weeks until disease progression, unacceptable toxicity, patient/physician decides to withdraw patient, death, or completion of 104 weeks treatment (35 administrations).
223652753|NCT04961567|DRUG|Litifilimab|Administered as specified in the treatment arm.
223652754|NCT04961567|DRUG|Placebo|Administered as specified in the treatment arm.
223652755|NCT02970617|OTHER|Memory Intervention|Ring bell after final radiation treatment
223767568|NCT02026115|BEHAVIORAL|PAINConsultN|PAINConsultN for hospice nurses. Our previous studies support the feasibility and clinical effect of PAINConsultN. This narrative and graphic tool provides decision support for the nurse's clinical decisions regarding management of the patient's pain. Based on the PAINReportIt output and published cancer pain guidelines, PAINConsultN generates an algorithm-based consultation report with a list of recommendations that could be useful to provide improved pain relief. If the patient's PAINReportIt output indicates the pain level is consistent with the patient's goals for pain management and represents no pain or a mild pain level, the consultation report acknowledges the therapy plan and reinforces its consistency with pain guidelines.
224236939|NCT02608853|OTHER|No treatment given|No treatment is actively administered. Patients are treated according to routine clinical practice at the discretion of their treating physicians.
224236940|NCT05197907|PROCEDURE|Fascial release of diaphragm muscle.|The intervention consists of deep tissue massage techniques and manual mobilization of the fascia performed within the diaphragm attachments in the area of the costal arches.
224236941|NCT05197907|PROCEDURE|Classic massage of the abdomen.|The intervention consists of selected classic massage techniques - mainly stroking (effleurage) - performed on the superficial layers of the abdominal region
223652756|NCT02970617|OTHER|Questionnaire Administration|Ancillary studies
223652757|NCT04886804|DRUG|zongertinib|zongertinib
223652758|NCT04057209|RADIATION|Single Vocal Cord Irradiation (SVCI)|The following planning aim will be pursued: full coverage of the PTV with at least 95% of the prescribed dose and a maximum (0.03 cc) PTV dose of \<107%: 16 x 3.63 = 58.08 Gy in 5 fractions per week using 5 to 9 static IMRT or VMAT.
223652759|NCT04057209|PROCEDURE|Arm A: Transoral CO2-Laser Microsurgical Cordectomy (TLM)|"The TLM has to be performed using a CO2 laser, coupled to an operative microscope, at 4-8W in ultrapulse mode. The type of cordectomy performed must be mentioned using the following classification according the classification of the European Laryngological Society.~The type of resection chosen should provide complete removal of the primary lesion with negative margins.~Surgery will generally be performed within 3 weeks after randomization and not more than 6 weeks after panendoscopy.~The extent of the cordectomy must include a complete anterior, posterior, inferior and supero-lateral mucosal and deep soft tissue margin."
223652760|NCT04613596|DRUG|Adagrasib|Adagrasib 400 mg twice daily (BID) in combination with pembrolizumab (Cohort 1a)
224236942|NCT00182091|DRUG|Recombinant human growth hormone|Starting dose based on age, sex, and estrogen status and ranged from 3-6 mcg/kg/day. GH doses were adjusted based on IGF-1 levels to target the mid-normal range for age.
223652761|NCT04613596|DRUG|Adagrasib|Adagrasib 600 mg BID monotherapy (Cohort 1b)
223652762|NCT04613596|DRUG|Adagrasib|adagrasib 400 mg BID in combination with pembrolizumab
223652763|NCT04613596|DRUG|Adagrasib|Adagrasib 400 mg BID + pembrolizumab 200 mg every Q3W
223652764|NCT04613596|DRUG|Pembrolizumab|Pembrolizumab 200 mg IV Q3W
223652765|NCT05948943|DRUG|Alpelisib|"In Stage 1: adult participants (≥18 years of age) will receive dose 1 or dose 2 of alpelisib; pediatric participants (6-17 years of age) will receive dose 2 or dose 3 of alpelisib.~In Stage 2: Adult participants will receive alpelisib at the dose selected for confirmatory phase in adult participants; pediatric participants (6-17 years of age) will will receive alpelisib at the dose selected for confirmatory phase in pediatric participants; and pediatric participants of 0-5 years of age will receive dose 3 of alpelisib"
223652766|NCT05948943|DRUG|Placebo|In Stage 2, participants will receive matching placebo for 24 weeks of the study
223652767|NCT05357040|DRUG|Nitrous oxide gas for inhalation|"60-minute sessions of inhaled 50% nitrous oxide in oxygen (FiO2 0.5) or 25% nitrous oxide in oxygen (FiO2 0.75), administered weekly for 4-weeks.~Administration will be under the direct supervision of a licensed practitioner who is experienced in the use and administration of the study drug, and is familiar with the indications, effects, dosages, methods, and frequency and duration of administration, and with the hazards, contraindications, and side effects and the precautions to be taken (MD, or CRNA); with study patient monitoring of pulse oximetry, heart rate, respiratory, non-invasive blood pressure, and end-tidal carbon dioxide."
223652768|NCT05357040|DRUG|Placebo|"60-minute sessions of inhaled oxygen-air mixture (FiO2 ≈0.3) to be administered weekly for 4-weeks.~Administration will be under the direct supervision of a licensed practitioner who is experienced in the use and administration of the study drug, and is familiar with the indications, effects, dosages, methods, and frequency and duration of administration, and with the hazards, contraindications, and side effects and the precautions to be taken (MD, or CRNA); with study patient monitoring of pulse oximetry, heart rate, respiratory, non-invasive blood pressure, and end-tidal carbon dioxide."
223652769|NCT04176718|DRUG|Daratumumab|predetermined dose, intravenously, at predetermined times per cycle
223652770|NCT04176718|DRUG|Carfilzomib|predetermined dose, intravenously, give 3 times per cycle
223652771|NCT04176718|DRUG|Pomalidomide|predetermined dose, orally, daily per cycle
223652772|NCT04176718|DRUG|Dexamethasone|predetermined dose, orally, given 8 times per cycle
223652773|NCT04544111|DRUG|Trametinib|"2mg by mouth daily~\*If patient loses the ability to swallow while on study, trametinib may be provided as a powder in bottle for reconsititution. Trametinib, as a powder in bottle, will be mixed with sterile/purified water into an oral solution and administered PO or through enteral feeding tube"
223652774|NCT04544111|DRUG|Dabrafenib|150 mg twice daily (OR at dose the patient previously tolerated)
223652775|NCT04544111|DRUG|PDR001|400mg IV every 4 weeks
223652776|NCT02015013|BIOLOGICAL|Filgrastim|10 microgram/kg daily for 5 days, Subcutaneous injection.
223652777|NCT02015013|DRUG|Plerixafor|IV injection 0.24 mg/kg as a single dose, 11 hours prior to apheresis
223652778|NCT04628026|DRUG|Venetoclax|Venetoclax will be administered in Induction cycle 1, Induction cycle 2 and in the chemo consolidation therapy in addition to the standard chemotherapy
223652779|NCT04628026|DRUG|Placebo|Placebo will be administered in Induction cycle 1, Induction cycle 2 and in the chemo consolidation therapy in addition to the standard chemotherapy
223652780|NCT04628026|COMBINATION_PRODUCT|Standard chemotherapy|"Induction cycle 1: Patients will receive cytarabine 200 mg/m2 continuous IV (days 1-7) and daunorubicin 60 mg/m2 IV (days 1-3). Induction cycle 2: Patients ≤ 60 yrs will receive cytarabine 1000 mg/m2 BID (3h IV), days 1-4, and daunorubicin 60 mg/m2 IV (days 1-3). Patients \>60 yrs will receive cytarabine 1000 mg/m2 BID (3h IV), days 1-4 without daunorubicin.~Consolidation chemotherapy with intermediate doses of cytarabine. Patients ≤60 yrs will receive up to 3 cycles of IDAC (single dose 1500 mg/m2 every 12 hours, days 1-3). Patients who are \>60 yrs will receive up to 3 cycles of IDAC with single doses of 1000 mg/m2, every 12 hours, days 1-3. In patients \>60 yrs less than 3 cycles of IDAC or dose-reduced IDAC (500 mg/m2 per single dose) may be given based on an individual risk assessment."
223652781|NCT04628026|OTHER|Allogeneic stem cell transplantation|Generally, patients will proceed to allogeneic HCT upon completion of remission induction chemotherapy. It is however allowed, as per investigator's discretion, for a patient to receive 'bridging' consolidation chemotherapy in exceptional cases of delay towards transplantation. At baseline, HLA-compatible donor search must be initiated as soon as possible, first among siblings and second in the world donor bank for unrelated donors or cord blood. In order to avoid inappropriate delay in cases where no suitable sibling is present, high-resolution HLA typing should be performed immediately after registration, enabling a more rapid matched-unrelated donor search. In case no sibling or unrelated donor can be identified, haploidentical allogeneic HCT is allowed. Conditioning and GVHD prophylaxis will take place according to institutional guidelines. Patients who undergo allogeneic HCT will not receive venetoclax during conditioning, engraftment or after hematologic recovery.
223652782|NCT03841617|DRUG|Thyrogen|intramuscular injection administered once/day for 2 consecutive days at Week 3; then once annually for subjects who meet criteria.
223652783|NCT03841617|RADIATION|I-131|therapeutic dose administered orally to treat thyroid cancer at Week 8. 5-7 days later, the post-treatment I-131 Whole Body scan w/ SPECT is performed; then administered once annually, if the patient needs to be re-treated
223652784|NCT03841617|RADIATION|I-124|one capsule ingested orally once at Week 3, and Week 8; then administered once annually to subjects who meet criteria.
223652785|NCT03841617|OTHER|Thyroid hormone withdrawal|withdrawal of thyroid hormone during weeks 4 through 8
223652786|NCT05055297|DEVICE|SELUTION SLR™ DEB 014|a non-surgical procedure that uses a catheter to inflate a drug-eluting balloon to open up peripheral below-the-knee arteries that have been narrowed by chronic limb-threatening ischemia
224236943|NCT00182091|DRUG|Saline|To maintain study-subject blinding, doses were sham adjusted.
224236944|NCT04872322|DRUG|Ropivacaine 0.5% Injectable Solution|Participants will receive the nerve block preoperatively using 0.5% ropivacaine
224236945|NCT04872322|DRUG|Ropivacaine 0.25% Injectable Solution|Participants will receive the nerve block preoperatively using 0.25% ropivacaine
224236946|NCT04872322|DRUG|Percocet Pill|After surgery participants will be given a prescription for Percocet to be taken as needed for pain
224236947|NCT04872322|DRUG|Norco Pill|After surgery participants will be given a prescription for Norco to be taken as needed for pain
223652787|NCT05055297|DEVICE|Plain (Uncoated) Balloon Angioplasty (PTA)|a non-surgical procedure that uses a catheter to inflate a commercially available, non-drug-eluting balloon to open up peripheral below-the-knee arteries that have been narrowed by chronic limb-threatening ischemia
223652788|NCT04496362|DRUG|subcutaneous heparin anticoagulation|The primary objective of this study is to evaluate the safety and efficacy of subcutaneous heparin anticoagulation compared to the standard of care systemic intravenous anticoagulation during veno-venous extracorporeal membrane oxygenation for respiratory failure. Subjects will be prospectively randomized in 1:1 ratio to subcutaneous heparin anticoagulation or systemic intravenous anticoagulation and followed until 1 week after discontinuation from ECMO support.
224236948|NCT04872322|PROCEDURE|Foot/Ankle Surgery|Participant will undergo foot or ankle surgery and receive a popliteal nerve block
224236949|NCT03246295|OTHER|lifestyle intervention or insulin treatment|Firstly，the gestational diabetes mellitus（GDM） women were treated with lifestyle intervention.Those women were treated with insulin if their blood glucose was not well Controled.
224236950|NCT03526965|OTHER|Yoga Chikitsa|Intervention consisted of combination of static movements, yoga style exercise, yoga postures, breathing practices, relaxation and yoga counselling.
224236951|NCT03526965|DRUG|Usual care|Intervention included pain medications and exercise movements for neck.
223652793|NCT06798909|DRUG|Valganciclovir (Pre-emptive CMV Therapy)|Valganciclovir, 900 mg given orally twice daily to Preemptive Therapy group subjects as a PET only after a positive CMV PCR test and stopped after PCR is negative for 2 consecutive weeks.
223652794|NCT06798909|DRUG|Valganciclovir CMV Prophylaxis|Valganciclovir, 900 mg given orally once daily to all Prophylaxis group subjects for 200 days post transplantation as prophylaxis.
223652795|NCT06026345|DEVICE|Affera Platform|A cardiac ablation will be performed using the Affera Platform
223652796|NCT04573023|DRUG|JR-141|IV infusion, 2.0 mg/kg/week
223652797|NCT04573023|DRUG|Idursulfase|IV infusion
223652798|NCT04573023|DRUG|JR-141 or Idursulfase|"The subjects who have achieved the pre-specified criteria\* are able to change the drug.~\*If a subject in Idursulfase group shows decline in their neurocognitive outcome, idursulfase can be switched to JR-141.~If a subject in JR-141 group shows decline in their peripheral outcome, JR-141 will be switched to idursulfase."
223652799|NCT05974722|DEVICE|OviTex Mesh|Patient will receive Ovitex Mesh (TELA Bio)
223652800|NCT05974722|OTHER|Pledgeted sutures|Patient will receive pledgeted sutures
223652801|NCT03555578|DRUG|Leuprorelin Acetate|Leuprorelin Acetate Injection Kit
223652802|NCT06066515|DRUG|survodutide|once weekly subcutaneous injection
223652803|NCT06066515|DRUG|Placebo|once weekly subcutaneous injection
224236952|NCT00315549|DRUG|Telithromycin|
224236953|NCT00315549|DRUG|Penicillin|
224236954|NCT04930081|BEHAVIORAL|Positive Parenting Program, Mindful Parenting|"The Positive Parenting Program (Triple P) consists of 5 weekly group sessions (each lasting for 2 hours) plus three weekly individual telephone interview sessions (each lasting for around 20 minutes). Program materials is available in Chinese.~The Mindful Parenting program consists of 8 weekly group sessions, each lasting for 2 hours. Programme materials have already been translated into Chinese by local partners of the programme developer."
224236955|NCT00003422|DRUG|fluorouracil|
224236956|NCT00003422|DRUG|leucovorin calcium|
224236957|NCT00003422|PROCEDURE|adjuvant therapy|
224236958|NCT00003422|PROCEDURE|conventional surgery|
224236959|NCT00003422|PROCEDURE|neoadjuvant therapy|
224236960|NCT00003422|RADIATION|radiation therapy|
223652804|NCT04758637|BEHAVIORAL|Overdose Notification|We will identify overdoses from state vital records and insurance claims data linked to emergency departments. We will use electronic health record data to identify prescriptions of scheduled drug to patients who experienced a non-fatal or fatal overdose within the health system. If randomized to the overdose notification group, physicians who prescribed the controlled substances to the deceased or surviving patient in the year prior to their overdose will be informed of the overdose via letter. The letters will alert prescribers to the patient's opioid-related overdose, recommend the use of the state-level PDMP, and list evidence-based interventions to lower opioid-related overdoses. The letters will increase the salience and availability of opioid-related harms, which may cause clinicians to be more wary of a future overdose when prescribing opioids, benzodiazepines, muscle relaxants, or sedative-hypnotics.
223652805|NCT05359562|BEHAVIORAL|Exposure & Response Prevention (EX/RP)|Exposure and Response Prevention (EX/RP) is a type of Cognitive Behavioral Treatment for treating OCD. This is a brief protocol consisting of 8 sessions of exposure and Response Prevention (EX/RP). This protocol includes two psychoeducation/planning sessions, followed by six exposure sessions.
223652806|NCT06043323|DRUG|Axicabtagene Ciloleucel|Given by IV (vein)
223652807|NCT06043323|DRUG|Cyclophosphamide|Given by IV (vein)
223652808|NCT06043323|DRUG|Fludarabine phosphate|Given by IV (vein)
223652809|NCT06043323|DRUG|Prednisone|Given by IV (vein)
223652810|NCT06043323|DRUG|Diphenhydramine|Given by IV (vein)
223652811|NCT06043323|DRUG|Acetaminophen|Given by IV (vein)
223652812|NCT03737370|DRUG|Docetaxel|Docetaxel will be administered every 2 weeks (on Day 1 and Day 15 of a 28 day cycle). Fractionated dosing dependent on cohort.
223652813|NCT03737370|RADIATION|Radium 223|Radium 223 will be delivered every 28 days (on day 1) for 6 cycles.
224236961|NCT00041808|DRUG|MTC-DOX for Injection|
224236962|NCT00041808|PROCEDURE|Chemotherapy|
224236963|NCT00969800|DEVICE|Cleverin Gel|Chlorine dioxide gas concentration at a range of 0.005 to 0.03 ppm.
224236964|NCT00969800|DEVICE|Inactive Cleverin Gel|Seemingly same chlorine dioxide gas-generating device, but no gas is generated.
224236965|NCT05285085|DRUG|Statin|Statin use
224236966|NCT02445456|DRUG|Sienna+ injection|Endoscopic injection of magnetic tracer
224236967|NCT02445456|OTHER|MRI scan|MRI scan of pelvis to detect spread of magnetic tracer
224236968|NCT02445456|PROCEDURE|Surgery to excise rectal cancer|Surgery as scheduled according to size and stage of rectal cancer. This will be either radical surgery or transanal endoscopic microsurgery (TEM)
224236969|NCT02445456|DEVICE|Sentimag probe|Probe to detect the previously injected magnetic tracer (Sienna+)
224236970|NCT06144671|DRUG|GT201|Autologous tumor infiltrating lymphocyte injection
224320840|NCT06847399|DRUG|Lisdexamfetamine Dimesylate|Lisdexamfetamine dimesylate
223652814|NCT04354012|COMBINATION_PRODUCT|methylene blue, gentian violet, and ovine forestomach wound dressings|"Hydrofera Blue is an antibacterial foam dressing that contains methylene blue and gentian violet to manage wounds. This is a safe, non-cytotoxic product that can be worn for 7 days while not inhibiting growth factors. This products wicks bacteria into the foam and away from the wound surface using natural negative pressure through capillary flow.~Endoform (ovine forestomach) is a natural dermal template used in all phases of wound healing. This product helps to stabilize, build, and organize tissue in acute and chronic wounds.~Hypafix tape aids in stabilization of wound dressings. This productIt is easy to apply, skin friendly, and comfortable to use."
223652815|NCT05631301|OTHER|Exercise Circuits|Weekly exercise circuits with a focus on strength, balance, cardiovascular fitness, and coordination
223652816|NCT05631301|BEHAVIORAL|Goal Setting|Goal setting focused on the management of persistent post concussion symptoms, exercise, and engagement in daily activities
223652817|NCT05631301|BEHAVIORAL|Psychoeducation-Youth|Targeted educational sessions with a focus on the physical, cognitive, and psychological implications of persistent post-concussion symptoms.
223652818|NCT05631301|BEHAVIORAL|Psychoeducation-Caregiver|Psychoeducational sessions focused on social support, in addition to addressing the implications of caring for youth experiencing persistent post concussion symptoms
223652819|NCT05631301|OTHER|Waitlist Control Surveys|Surveys completed in week 1, and 8 for a subset of participants who are not involved in the study intervention to mirror study timeline and serve as control data for outcome measures assessed during experimental intervention
223652820|NCT04931017|PROCEDURE|Biopsy|Undergo biopsy
223652821|NCT04931017|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223652822|NCT04931017|PROCEDURE|Bronchoscopy|Undergo bronchoscopy
223652823|NCT04931017|DRUG|Extended Release Metformin Hydrochloride|Given PO
223652824|NCT04931017|OTHER|Questionnaire Administration|Ancillary studies
223652825|NCT04847063|DRUG|Mitomycin C|Arm 2, intraperitoneal (IP) Mitomycin C monotherapy: dosing divided into two 60-mL syringes, 30 mg per syringe. 30 mg will be given at time = 0, and the remaining 10 mg of the dose will be given at time = 60 minutes. Part of Arm 4: Mitomycin C co-therapy 15 mg/m2 for 60 minutes, given at time = 0 with cisplatin
223652826|NCT04847063|DRUG|Cisplatin|Part of Arms 3 and 4, intraperitoneal (IP)cisplatin co-therapy: 75 mg/m2 for 60 minutes, mixed in 1 L of 0.9% sodium chloride. For cisplatin-based HIPEC, intravenous sodium thiosulfate given as a loading dose of 7.5 g/m2 in 150 mL 0.9% sodium chloride at the time of introducing cisplatin into the perfusion circuit, followed by a 12-hour pump-based infusion of 25.56 g/m2 in 1 L 0.9% sodium chloride
223652827|NCT04847063|PROCEDURE|Heated Intraperitonial Chemotherapy|Heated Intraperitonial Chemotherapy (HIPEC) with with standardized doses of chemotherapeutic agents as indicated by the subject's Arm assignment
223652828|NCT04847063|DRUG|Doxorubicin|Part of Arm 3: intraperitoneal (IP) Doxorubicin co-therapy 15 mg/m2 for 60 minutes, given at time = 0 with cisplatin
223652829|NCT04847063|DRUG|Oxaliplatin|Arm 1, intraperitoneal (IP) Oxaliplatin: 200 mg/m2 for 90 minutes, mixed in 250 mL of 5% dextrose solution. For oxaliplatin-based HIPEC, intravenous 5-fluorouracil given at a dose of 400 mg/m2 in 250 mL 0.9% sodium chloride over 10 minutes, co-administered with intravenous leucovorin at 20 mg/m2 in a separate bag of 250 mL 0.9% sodium chloride
223652830|NCT04847063|DRUG|5-Fluorouracil|Part of Arm 1, for oxaliplatin-based HIPEC: intravenous 5-fluorouracil given at a dose of 400 mg/m2 in 250 mL 0.9% sodium chloride over 10 minutes, co-administered with intravenous leucovorin at 20 mg/m2 in a separate bag of 250 mL 0.9% sodium chloride
223652831|NCT04847063|DRUG|Sodium Thiosulfate|Part of Arms 3 and 4, for cisplatin-based HIPEC: intravenous sodium thiosulfate given as a loading dose of 7.5 g/m2 in 150 mL 0.9% sodium chloride at the time of introducing cisplatin into the perfusion circuit, followed by a 12-hour pump-based infusion of 25.56 g/m2 in 1 L 0.9% sodium chloride
223652832|NCT02879812|OTHER|Performance Feedback Reports|Medical directors will be provided performance feedback reports that are a summary of clinical performance of transplant and racial disparity performance over a period of time aimed at providing information to allow them to assess and adjust their transplant performance. The report will emphasize tailored facility-specific information on the mean time on dialysis for patients in that facility and transplant access performance measures, such as wait listing and transplantation, including the magnitude of racial disparity, detailing when a facility is performing below the national or regional average.
223652833|NCT02879812|OTHER|Educational Video for Staff|Dialysis facility staff will watch a \~10 minute educational video that describes the role of dialysis staff in improving transplant access, the new kidney allocation policy, and how the new policy impacts minority patients and those on dialysis for a substantial period of time.
223652834|NCT02879812|OTHER|Educational Video for Patients|Dialysis facilities will receive a \~10 minute educational video targeted to dialysis patients to explain the transplant process and allocation policy.
223652835|NCT02879812|OTHER|Educational Webinar|Education for medical directors and facility staff about the kidney allocation policy will be discussed in a webinar and information will be hosted on a website for participants to access. The seminar will be roughly 45 minutes, and continuing medical education (CME) credits will be offered.
223652836|NCT02879812|OTHER|Standard Care|Dialysis facilities will conduct standard or usual care and education regarding transplantation.
223652837|NCT02879812|OTHER|United Network for Organ Sharing (UNOS) Pamphlet|Dialysis facility staff will be provided an educational pamphlet detailing the changes in the new kidney allocation policy .
223652838|NCT03600883|DRUG|sotorasib|Characterize the pharmacokinetics (PK) of sotorasib following administration as an oral Tablet formulation
223767569|NCT02026115|BEHAVIORAL|PAINUCope|We tested the PAINUCope piece of the intervention in 3 completed studies. PAINUCope is a multimedia, computer generated tool that gives tailored information to overcome patients' misconceptions about pain and help them engage in activities that help reduce their pain. PAINUCope focuses on 2 crucial aspects of pain management: 1) reporting cancer pain and 2) safe and effective use of pain medicines. The educational materials are written at a 6th grade reading level and presented as 21st Century best-practices, evidence-based facts or scripts for the person with cancer or sickle cell disease (in one study). The facts or scripts are customized to the patient's need for this type of health information. The patient's responses on PAINReportIt guide the specific information shared via PAINUCope.
224320841|NCT06847399|BEHAVIORAL|Guided self-help cognitive behavioral therapy|Guided self-help cognitive behavioral therapy
224236971|NCT01408199|DRUG|Lenalidomide|5 mg daily will be administered until the achievement of complete response, and then tapered progressively according to clinical response
224236972|NCT03025594|DRUG|Gonyautoxins|Periarticular infiltration of 40mcg of Gonyautoxin diluted in 30cc of Sodium Chloride 0.9%, with pH 6.2 and isosmotic. This solution will be administer targeting posterior capsule, both retinaculum, collateral ligaments, quadriceps and patelar tendon and subcutaneous tissue just before wound closure of total knee arhroplasty
224236973|NCT03025594|DRUG|Chirocaine ketorolac epinephrine|Periarticular infiltration of 150ml of Chirocaine 2%, 60mg of ketorolac and 0.75mg of epinephrine. This solution will be administer targeting posterior capsule, both retinaculum, collateral ligaments, quadriceps and patelar tendon and subcutaneous tissue jbefore wound closure of total knee arhroplasty.
224236974|NCT04768179|DRUG|3-dayIVM 200 mcg/kg/day/14-day 75mgASA/day + standard of care (intervention 1)|Low dose aspirin for 14 days plus ivermectin at 200 mcg/kg/day or 600 mcg/kg/day for 3 days
224236975|NCT00881556|DRUG|Palifermin|60 mcg/kg/day for 6 days
224236976|NCT00881556|DRUG|Fludarabine|30 mg/m2 IV x 1 for 6 days
224236977|NCT00881556|DRUG|Busulfan|4 mg/kg/day IV divided BID for 4 days
224236978|NCT00881556|DRUG|Lorazepam|0.02-0.05 mg/kg for 5 days
224236979|NCT00881556|DRUG|Alemtuzumab|20 mg/m2 IV for 5 days
224236980|NCT00881556|DRUG|Tacrolimus|0.03mg/kg/24 hours as continuous infusion for 4 days
224236981|NCT00077948|DRUG|Enoximone|Enoximone administered orally
224236982|NCT00077948|DRUG|Metoprolol succinate|Metoprolol succinate administered orally
224236983|NCT00077948|DRUG|Placebo to match enoximone|Placebo to match match enoximone administered orally
224236984|NCT00077948|DRUG|Placebo to match metoprolol succinate|Placebo to match metoprolol succinate administered orally
224236985|NCT02885077|DEVICE|High-intensity IMT + combined exercise|
223652839|NCT03600883|DRUG|Anti PD-1/L1|Administered as an intravenous (IV) infusion
223652840|NCT03600883|DRUG|Midazolam|Administered as an oral hydrochloride (HCI) syrup
223652841|NCT05110872|BEHAVIORAL|Cigarette flavor restricted and e-cigarette flavor restricted|"1. Tobacco cigarettes will be available in the Experimental Tobacco Marketplace~2. Tobacco-flavored e-cigarettes will be available in the Experimental Tobacco Marketplace"
223652842|NCT05110872|BEHAVIORAL|Cigarette flavor restricted and e-cigarette flavor unrestricted|"1. Tobacco cigarettes will be available in the Experimental Tobacco Marketplace~2. Tobacco-flavored and a range of flavored e-cigarettes will be available in the Experimental Tobacco Marketplace"
223652843|NCT05110872|BEHAVIORAL|Cigarette flavor unrestricted and e-cigarette flavor restricted|"1. Tobacco and menthol cigarettes will be available in the Experimental Tobacco Marketplace~2. Tobacco-flavored e-cigarettes will be available in the Experimental Tobacco Marketplace"
223652844|NCT05110872|BEHAVIORAL|Cigarette flavor unrestricted and e-cigarette flavor unrestricted|"1. Tobacco and menthol cigarettes will be available in the Experimental Tobacco Marketplace~2. Tobacco-flavored and a range of flavored e-cigarettes will be available in the Experimental Tobacco Marketplace"
223652845|NCT05090566|DRUG|Elranatamab + Nirogacestat|BCMA-CD3 bispecific antibody + gamma secretase inhibitor
224236986|NCT04761965|DIAGNOSTIC_TEST|Bone marrow cellularity by mDixon-quant|if trepanobiopsy was performed during the diagnosis, then comparison with MRI Bone marrow cellularity by mDixon-quant
224236987|NCT01244126|DRUG|Intranasal fentanyl|2mcg/kg fentanyl IN
224236988|NCT01244126|DRUG|morphine IM|0.1 mg/kg morphine IM for postop pain
224236989|NCT01244126|DRUG|IV morphine|0.1 mg/kg morphine IV
224236990|NCT03354026|DRUG|AICH-PXZY|8herbals (with 2 herbals of Activating blood stagnation and expelling blood stasis herbs) one dose, bid, for 10 days
224236991|NCT03354026|DRUG|AICH-without PXZY|AICH-2(herbal medicine without Hirudo, Tabanus) (6herbals, without 2 herbals of promoting blood stasis) one dose, bid, for 10 days
224236992|NCT03354026|DRUG|AICH-placebo|The placebo is made up of Starch, bitter taste and cyclodextrin
224236993|NCT02853279|BEHAVIORAL|Interval exercise training|"Interval exercise sessions (INT) involving work:recovery ratios of 40 s at 70% delta work-rate followed by 80 s active recovery at 20 W. 70% delta (∆) is 70% of the difference between work rate peak (WRpeak) and work rate at the lactate threshold (WRLT) calculated as:~70%∆ =0.7(〖WR〗\_peak- 〖WR〗\_LT )+ 〖WR〗\_LT~Where WR is work rate, LT is lactate threshold)~Each session was for 30 min and this was undertaken twice per week for 12 weeks. One home based exercise session was incorporated per week."
224236994|NCT02853279|BEHAVIORAL|Continuous exercise training (CON)|Exercise sessions involved cycling at 20%∆ work-rate peak for the duration of the session. This work-rate was chosen so that all participants in the group would be exercising in the heavy-intensity domain. To enable participants in the CON exercise group to complete the same amount of work (kJ) as the participants in the INT exercise group, the amount of work that would be completed if the CON participants completed an INT exercise session was calculated. Participants exercised for 26 min (varying to match interval group) twice per week for 12 weeks.
224236995|NCT02445300|OTHER|AQUACEL® Ag Surgical dressing (study group)|The AQUACEL® Ag Surgical dressing was applied to the wound in the operating theater by the surgeon. Clinical indications for removal of the AQUACEL® Ag Surgical dressing were leakage from the dressing beyond the hydrocolloid exterior layer and more than a 50% saturation of the Hydrofiber® inner layer10. If there were no indications to change the dressing, it was changed at the day of discharge usually the 4th or 5th postoperative day (POD) and remained cover of the wound for 7 days except for exudate across the dressing.
224236996|NCT02445300|OTHER|Sofra-Tulle® dressing (control group)|The Sofra-Tulle® dressing was applied to the wound in the operating theater by the surgeon. The Sofra-Tulle® dressing was routinely changed at a daily basis. If there were strikethrough on the gauze, the nursing staff would proceed the dressing change automatically between the daily routine. After discharge from the hospital, the family who had been taught well to do this job during the patient's stay in the hospital conducted the daily dressing change.
224236997|NCT06799260|DIETARY_SUPPLEMENT|Ketone Monoester (KME)|500 mg/kg body weight of the KME supplement
224236998|NCT06799260|DIETARY_SUPPLEMENT|Placebo|Taste-matched placebo drink
224236999|NCT06799260|DEVICE|iTBS|iTBS stimulation will be applied using a butterfly figure-of-eight Cool-B70 coil connected to a MagPro R30 stimulator with add-on Theta Burst option (MagVenture A/S, Farum, Denmark).
224320842|NCT06847399|DRUG|Placebo (oral)|Placebo (oral)
224320843|NCT06847399|DRUG|Placebo (injection)|Placebo (injection)
223652846|NCT05090566|DRUG|Elranatamab + lenalidomide + dexamethasone|BCMA-CD3 bispecific antibody + immunomodulatory
223652847|NCT05726032|DRUG|Empagliflozin 10 MG|Participants will be randomized to Empagliflozin 10 mg or placebo for 14 days. A 14 day washout period follows and then participants is crossed over to the alternate treatment for 14 days.
223652848|NCT05726032|DRUG|Matching Placebo|Participants will be randomized to Empagliflozin 10 mg or placebo for 14 days. A 14 day washout period follows and then participants is crossed over to the alternate treatment for 14 days.
223652853|NCT04362748|DRUG|AMG 256|AMG 256 administered as an intravenous (IV) infusion.
223652854|NCT05316974|OTHER|Prevalence of lymphoedema|Measures of lymphoedema
223652855|NCT04203316|PROCEDURE|Biospecimen Collection|Undergo collection of blood
223652856|NCT04203316|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
223652857|NCT04203316|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
223652858|NCT04203316|DRUG|Enasidenib|Given PO
223652859|NCT04203316|DRUG|Enasidenib Mesylate|Given PO
223652860|NCT06230718|OTHER|Motor Imagery (MI)|mental process where an individual visualizes or imagines themselves performing a movement without actually executing it physically. This cognitive process involves the mental rehearsal of motor actions, engaging similar neural pathways that are used when physically performing the action.
223652861|NCT06230718|OTHER|Action Observation (AO)|rehabilitation technique based on the principle of observing actions to improve motor function and learning. This approach is rooted in the concept of the mirror neuron system, a group of neurons that are activated both when a person performs an action and when they observe the same action performed by others.
223652862|NCT06230718|OTHER|Control condition- placebo|Recording with images of landscapes without the presence of any person or animal that could evoke MI or OA.
223652863|NCT04365374|DEVICE|Gamma Tile-Surgically Targeted Radiation Therapy (STaRT)|GammaTiles are a permanently implanted radiation device consisting of Cs-131 seeds positioned within a collagen tile
223652864|NCT04365374|RADIATION|Stereotactic Radiation Therapy|External Beam Radiation Therapy
223652865|NCT05384769|PROCEDURE|Liquid Biopsy|Undergo liquid biopsy
223652866|NCT05384769|PROCEDURE|Low Dose Computed Tomography of the Chest|Undergo low dose CT
223652867|NCT05384769|OTHER|Survey Administration|Ancillary studies
223652868|NCT04405167|DRUG|Tasquinimod|Tasquinimod will be supplied as oral capsules.
223652869|NCT04405167|DRUG|IRd chemotherapy|IRd chemotherapy with ixazomib, lenalidomide, and dexamethasone
223767570|NCT02219815|BEHAVIORAL|Prehab Intervention|Pre-operative, structured exercise intervention.
223767571|NCT03492177|DRUG|selexipag (Uptravi)|Film-coated tablets for oral administration
223652870|NCT00804154|DRUG|Intrathecal Resiniferatoxin|phase I, single-site, non-randomized, open-label, dose-escalation study to determine the safety and efficacy of IT RTX in subjects with severe refractory pain due to advanced malignancy
223652871|NCT06080789|DRUG|RABI-767|125 mg single-dose given by endoscopic-ultrasound (EUS) guided peripancreatic injection.
223652872|NCT06445907|DRUG|Azacitidine|Given by IV
223652873|NCT06445907|DRUG|Venetoclax|Given by PO
223652874|NCT06445907|DRUG|Q702|Given by PO
223652875|NCT05182164|DRUG|Association of pembrolizumab + cabozantinib|"A treatment cycle consists of 3 weeks. Pembrolizumab will be administered intraveinously on day 1 every 3 weeks (200 mg).~Cabozantinib will be administered per os, once daily (40 mg), and given on a continuous basis."
223652876|NCT00862433|DRUG|Alpha tocopherol|intravenous deuterated vitamin E at doses of 2mg, 5mg, 7.5mg, 10mg and 30mg.
223652877|NCT00862433|OTHER|Vitamin E|Deuterated vitamin E, oral and intravenous, at doses of 2mg, 5mg, 7.5mg, 10mg and 30mg.
223652878|NCT00862433|OTHER|Vitamin C|Oral vitamin C, one gram daily.
223652879|NCT04964934|DRUG|AZD9833|Dosage formulation: AZD9833 tablets will be administered orally
223652880|NCT04964934|DRUG|AZD9833 Placebo|Dosage formulation: AZD9833 placebo tablets will be administrated orally.
223652881|NCT04964934|DRUG|Anastrozole|Dosage formulation: anastrozole tablets will be administered orally.
223652882|NCT04964934|DRUG|Anastrozole placebo|Dosage formulation: anastrozole placebo tablets will be administrated orally.
223652883|NCT04964934|DRUG|Letrozole|Dosage formulation: letrozole tablets will be administered orally.
223652884|NCT04964934|DRUG|Letrozole placebo|Dosage formulation: letrozole placebo tablets will be administered orally.
223652885|NCT04964934|DRUG|Palbociclib|Dosage formulation: palbociclib tablets/capsules will be administered orally
223652886|NCT04964934|DRUG|Abemaciclib|Dosage formulation: abemaciclib tablets will be administered orally
223652887|NCT04964934|DRUG|Luteinizing hormone-releasing hormone (LHRH) agonist|Men (when medically applicable) and pre- or peri-menopausal women are required to receive a monthly LHRH agonist.
223652888|NCT04964934|DRUG|Ribociclib|Dosage formulation: ribociclib tablets will be administered orally
223767572|NCT05660265|DRUG|GSK4172239D|Different strength of GSK4172239D will be administered in different cohorts.
223767573|NCT05660265|OTHER|Placebo|Matching placebo will be administered.
223767574|NCT05355870|BEHAVIORAL|Cognitive Training Intervention|Participants in the intervention group will complete a series of cognitive training exercises adapted from the BrainHQ. Results from the intervention development activities will be used to finalize the dose, frequency, and duration of the training. Each session will include 2 training exercises that target different cognitive domains. As participants progress, the difficulty level will be automatically adapted based on participants' performance.
223767575|NCT04107636|PROCEDURE|Vacuum assisted biopsy|First, the tumor will be removed under local anesthesia using the VAB system with US guidance, through a small skin incision (\<0.5 cm). A localization marker will be placed in the biopsy cavity, to help determine the cavity location.
224237000|NCT06799260|DEVICE|cTBS|cTBS stimulation will be applied using a butterfly figure-of-eight Cool-B70 coil connected to a MagPro R30 stimulator with add-on Theta Burst option (MagVenture A/S, Farum, Denmark).
224237001|NCT01273337|BIOLOGICAL|ALD-401|3 mL ALDHbr cells isolated from autologous bone marrow given as a one-time infusion via intracarotid infusion.
224237002|NCT01273337|PROCEDURE|Sham Procedure|Sham bone marrow harvest and sham product infusion procedures.
224237003|NCT02139553|PROCEDURE|Rhythmic rehabilitation|Stroke patients have 12 rehabilitation sessions on a planar rehabilitation robot, Reaplan, focussed on rhythmic arm movements.
224237004|NCT00245609|DRUG|Pregabalin|
224237005|NCT00245609|DRUG|Alprazolam|
223652889|NCT05516719|OTHER|Positron Emission Tomography (PET) scan using BU99008 tracer|A positron emission tomography (PET) scan produce detailed 3-dimensional images of the inside of the body by showing radiation from tracers used to highlight specific areas of the brain.
223652890|NCT05516719|OTHER|FP-CIT Single-photon Emission Computed Tomography (SPECT) scan|A single-photon emission computerized tomography (SPECT) scan allows analysis of brain function by creating 3D Pictures using compounds called tracers.
223652891|NCT05516719|OTHER|Magnetic Resonance Imaging (MRI) Scan|MRI (magnetic resonance imaging) uses magnets alongside radio waves to create pictures of the brain.
223652892|NCT05516719|OTHER|Lumbar puncture|A lumbar puncture is where a thin needle is inserted between the bones in your lower spine using local anaesthetic. This allows the collection of Cerebrospinal fluid ( CSF)
223652893|NCT03245541|DRUG|Durvalumab|Durvalumab will be given 750 mg, intravenously (IV) over 60 minutes (+/- 5 minutes), Q14 days beginning D1. Four doses of durvalumab will be administered on the Q14 day schedule. Subsequently Durvalumab will continue as maintenance 1500mg, intravenously (IV) over 60 minutes (+/- 5 minutes), Q28 days up to 1 year or until progression (11 doses), unacceptable toxicity or other reason. If a patient undergoes resection, they will resume durvalumab once appropriately healed from surgery (approximately 4-8 weeks) at discretion of treating medical oncologist.
223652894|NCT03245541|RADIATION|Stereotactic Ablative Body Radiotherapy (SABR)|SABR delivered as 6.6 Gy/fraction x 5 fractions given within two weeks will be administered weekdays and will begin D8.
223652895|NCT04863443|DEVICE|Ultrasound|ultrasound scanner to collect sonographic imaging data from the breast
223652896|NCT04997642|BEHAVIORAL|neuropsychiatric and cognitive testing questionnaires|"Demographic data such as race, sex, age Family History Risk Factor Questionnaire Hoehn and Yahr Stage UPDRS Parkinson's symptom checklist Medication list Neuropsychological Test Battery Behavioral Exams~* Geriatric Depression Scale Quality of Life Questionnaire~* PDQ-39, SF-12"
223767576|NCT04107636|PROCEDURE|conventional lumpectomy|After 3 weeks, the breast conserving surgery is performed, excising the VAB excision cavity and a ≥1 cm of surrounding tissue, as deemed appropriate by the attending breast surgeon. A sentinel node biopsy will be performed in the same procedure.
223767577|NCT07019246|DRUG|EP mixture|Patients will receive etomidate - propofol mixture during induction and maintenance. Sufentanil 0.2-0.7 μg/kg，Cisatracurium 0.15 mg/kg，EP mixture（E：P=1:2） 0.1-0.25 ml/kg for induction, EP mixture 0.4\~ 1.2 ml/kg/h and remifentanil 0.05μg/kg/min \~0.3 μg/kg/min for maintenance.
223767578|NCT07019246|DRUG|Propofol|Patients will receive propofol during induction and maintenance.Sufentanil 0.2-0.7 μg/kg，Cisatracurium 0.15 mg/kg，propofol 0.1-0.25 ml/kg for induction, propofol 0.4\~ 1.2 ml/kg/h and remifentanil 0.05μg/kg/min \~0.3 μg/kg/min for maintenance.
223767579|NCT06462131|BEHAVIORAL|Cultural Adapted Group cognitive Behaviroal therapy (CaGCBT)|In first session, introduction of the therapist/facilitator and group members will be made. Group rules will be discussed with members. Group members' introduction primarily focuses on participant/clients' expectations, addictive behaviors and its status, and goals. Moreover, it also emphasize on identification of any other significant issue that is contributing in burden of disease.
223767580|NCT07023653|PROCEDURE|All-Inside Techniques|All-inside ACL reconstruction technique avoids creating full-length bone tunnels. Instead, it uses retrograde drilling to form bone sockets, and the graft is secured with adjustable-loop suspensory fixation on both the femur and tibia.
223767581|NCT07023653|PROCEDURE|Complete Tibial Tunnel techniques|Complete Tibial Tunnel Technique is a conventional technique for ACL reconstruction which involves the creation of full-length bone tunnels in the tibia for graft passage via an anterograde approach. Graft fixation is typically achieved using a bio-interference screw on the tibial side and a fixed-loop suspensory device on the femoral side
224237006|NCT00245609|DRUG|Placebo|
224237007|NCT04978649|DRUG|Allisartan Isoproxil|Allisartan Isoproxil 240mg daily will be used to lower BP to below 120 mm Hg systolic.
224237008|NCT04978649|DRUG|Amlodipine|Amlodipine 5mg daily will be added to Allisartan Isoproxil and afterwards increased to 10mg daily, if necessary to reach the blood pressure goal (below 120 mm Hg systolic).
224237009|NCT01771965|BEHAVIORAL|CB Intervention|The Cognitive Behavioral (CB) intervention is a brief, manualized, tailored one-on-one single session lasting 45-60 minutes and administered by phone. An individual format was chosen to reduce the potential discomfort of stigma of individual concerns in the presence of others. The intervention targets a change in the beliefs that influence whether or not someone enters mental health or substance use treatment. During the session, participants will be given a brief introduction to CBT and informed that CBT is based on the theory that cognitions (i.e., thoughts/beliefs), feelings and behaviors all interact with each other;101, 102 therefore, thoughts about certain situations or things influence behavior. Since thoughts are modifiable, changing thoughts about situations may change behavior.
224237010|NCT03146247|DRUG|Apremilast;Apremilast;Apremilast 10 MG; 20 MG; 30 MG Oral Tablet|All patients are scheduled to receive Apremilast with a titration phase of one week, followed by 23 weeks of regular treatment.
224237011|NCT04697498|PROCEDURE|Bilateral bi-level Erector spine plane block|After intubation of the trachea and rotation on the abdomen before the skin incision will be performed bilateral bi-level Erector spine plane block. Before surgery, the level of screw placement will be discussed with the surgeon, and the blockade will be performed at two levels of the spine bilaterally as close as possible to the screw placement site. For blockade a solution for prolonged blockade of peripheral nerve plexuses with bupivacaine 0.375%, dexamethasone 0.02% and epinephrine 0.00018% will be used.
223652908|NCT05645380|DRUG|Carboplatin|AUC=6, IV
223652909|NCT05645380|DRUG|Docetaxel|75 mg/m2, IV
223652910|NCT05645380|DRUG|Doxorubicin|60 mg/m2, IV
224237012|NCT04697498|PROCEDURE|General anaesthesia|The control group - will include patients who will undergo surgery under general anaesthesia
224237013|NCT00863746|DRUG|Sorafenib (Nexavar, BAY43-9006)|Sorafenib 400 mg twice daily (BID)
224237014|NCT00863746|DRUG|Placebo|Placebo - 2 tablets twice daily (BID)
224237015|NCT04461808|DIAGNOSTIC_TEST|tomosynthesis + synthetic 2D|"Women will be screened for one round with tomosynthesis + synthetic 2D, two projections, double reading with consensus or arbitration, according to local protocols, for discordant readings.~After two years (one years for women 45-49 yo) women will be re-screened with digital mammography."
224237016|NCT04461808|DIAGNOSTIC_TEST|digital mammography|"Women will be screened for one round digital mammography, two projections, double reading with consensus or arbitration, according to local protocols, for discordant readings.~After two years (one years for women 45-49 yo) women will be re-screened with digital mammography."
223652911|NCT05645380|DRUG|Cyclophosphamide|600 mg/m2, IV
223652912|NCT05645380|DRUG|Pembrolizumab|200 mg, IV
223652913|NCT04735185|OTHER|Autologous stem cells|In this intervention participants will receive a 2 mL intradiscal injection into each affected disc of autologous bone marrow-derived mesenchymal stem cells from bone marrow aspirate of the posterior ilium.
223652914|NCT04735185|DRUG|Corticosteroid|In this intervention participants will receive a 1 mL intradiscal injection of the steroid methylprednisolone (40 mg/mL) into each affected disc.
223652915|NCT04735185|DRUG|Local anesthetic|In this intervention participants will receive a 1 mL intradiscal injection of the local anesthetic bupivacaine 0.5% into each affected disc.
223652916|NCT04631601|DRUG|Acapatamab|Acapatamab will be administered as an intravenous (IV) infusion.
223652917|NCT04631601|DRUG|Enzalutamide|Enzalutamide will be administered orally.
223652918|NCT04631601|DRUG|Abiraterone|Abiraterone will be administered orally.
223652919|NCT04631601|DRUG|AMG 404|AMG 404 will be administered as an intravenous (IV) infusion.
224237017|NCT05589896|OTHER|Ossium HPC Marrow, Bone Marrow Transplant|Hematopoetic Cell Transplantation
224237018|NCT05589896|OTHER|Pre-transplant conditioning - Myeloablative (MAC)|Regimen A or Regimen B
224237019|NCT05589896|OTHER|Pre-transplant conditioning - Reduced Intensity (RIC)|Regimen C or Regimen D
224237020|NCT05589896|OTHER|Post-transplant treatment|Post-transplant treatment
224237021|NCT06309901|OTHER|Exercise|"Home exercises were applied in 3 progressive phases.~1st phase: postoperative 0-4. week, 2nd phase: 5-12. week, 3rd phase 12-15. week.~In the 1st phase, ice application, strengthening for the hip, knee and ankle, and walking exercises were applied. 90 degrees knee flexion range of movement (ROM) was targeted.~In the 2nd phase, the resistance of the strengthening exercises was increased and closed kinetic chain exercises were added. Weight bearing, step climbing and balance exercises were performed. Full ROM targeted in the knee.~In the 3rd phase, pain-free full ROM was targeted, and progressive strengthening, balance and agility exercises for sports and recreational activities were applied."
224237022|NCT06309901|OTHER|Fascial Distortion Model|"At the beginning of the 2nd phase of the treatment, starting from the 5th week, twice a week for 4 weeks, a total of 8 sessions of FDM technique were applied.~In this study, trigger band technique was chosen to apply around the knee. Interventions were made directly to the skin in the form of medial, lateral, anterior, posterior techniques of the knee and posterior and lateral techniques of the thigh. The techniques was made after the exercises."
224320844|NCT06166186|OTHER|music|A music with a standard volume will be delivered to the patients via headphones from the beginning of anesthesia induction to extubation.
224320845|NCT06166186|OTHER|no music|Headphones will be applied to the patients but no music will be played from the beginning of anesthesia induction to extubation.
223652924|NCT06305767|BIOLOGICAL|Pembrolizumab|Administered via intravenous (IV) infusion at a dose of 400 mg on Day 1 of every 6-week cycle for up to 9 adjuvant cycles for Adjuvant Cohort participants, or at a dose of 200 mg on Day 1 of every cycle for up to four 3-week neoadjuvant cycles and up to thirteen 3-week adjuvant cycles for Perioperative Cohort participants.
223652925|NCT06305767|BIOLOGICAL|Intismeran autogene|Administered via intramuscular (IM) injection at a dose of 1 mg every 3 weeks for a total of up to 9 adjuvant doses for Adjuvant Cohort participants, or at a dose of 1 mg every 3 weeks for a total of up to 9 doses in the neoadjuvant and adjuvant periods for Perioperative Cohort participants.
223652926|NCT06305767|OTHER|Placebo|Intismeran autogene diluent only (saline and/or dextrose) administered via IM injection Q3W for up to 9 doses.
223652927|NCT06305767|BIOLOGICAL|Enfortumab Vedotin|Administered via IV infusion at a dose of 1.25 mg/kg on Day 1 and Day 8 of every cycle for up to four 3-week neoadjuvant cycles and up to five 3-week adjuvant cycles for Perioperative Cohort participants.
223652928|NCT06305767|PROCEDURE|Surgery (RC plus PLND)|Curative intent surgery (RC plus PLND) will be administered to all participants in the Perioperative Cohort and will be done in accordance with the American Urological Association/American Society for Radiation Oncology/American Society of Clinical Oncology/Society of Urologic Oncology guidelines. RC plus PLND will be performed within 6 weeks of the last dose of neoadjuvant intismeran autogene plus pembrolizumab plus EV treatment. Adjuvant intismeran autogene plus pembrolizumab plus EV treatment will begin within 8 weeks of completing RC plus PLND.
223652933|NCT05064358|DRUG|Belantamab mafodotin|Belantamab mafodotin will be administered.
223652934|NCT06443190|OTHER|Indigenous Patient Navigator Support|See Arm Description
223652935|NCT06969573|DRUG|Placebo|Participants will breathe placebo (room air) from the Tyvaso Inhalation System Ultrasonic nebulizer
223652936|NCT06969573|COMBINATION_PRODUCT|Treprostinil Inhalation Solution 36 mcg|Participants will breathe either 36 mcg of Treprostinil from the Tyvaso Inhalation System Ultrasonic nebulizer
223652937|NCT06969573|COMBINATION_PRODUCT|Treprostinil Inhalation Solution 78 mcg|Participants will breathe either 78 mcg of Treprostinil from the Tyvaso Inhalation System Ultrasonic nebulizer
223652938|NCT06582784|BEHAVIORAL|Behavioral Activation Therapy App|Moodivate focuses on tracking daily activities, recording daily mood, and identifying new activities to complete that may help improve mood. Participants will be asked to complete questionnaire measures weekly for 8 weeks, with a final follow-up questionnaire at 12 weeks following study enrollment.
223652939|NCT06582784|BEHAVIORAL|Treatment as Usual|Participants will be provided educational material about mood management available via the EHR with the suggestion to discuss questions with their oncology provider. Participants will be asked to complete questionnaire measures weekly for 8 weeks with a final follow up at week 12.
223652940|NCT06151574|DRUG|zongertinib|zongertinib
223652941|NCT06151574|DRUG|pembrolizumab|pembrolizumab
223652942|NCT06151574|DRUG|cisplatin|platinum-pemetrexed chemotherapy
223652943|NCT06151574|DRUG|carboplatin|platinum-pemetrexed chemotherapy
223652944|NCT06151574|DRUG|pemetrexed|platinum-pemetrexed chemotherapy
223767582|NCT07025733|DEVICE|Semiconductor Embedded Sock|Semiconductor Embedded sock will be given to this intervention arm
224237023|NCT06309901|OTHER|Instrument Assisted Soft Tissue Mobilisation|"At the beginning of the 2nd phase of the treatment, starting from the 5th week, twice a week for 4 weeks, a total of 8 sessions of IASTM technique were applied.~In this study, the Graston technique was chosen to apply IASTM around the knee. Technique was applied with using stainless steel and ultrasound gel to around the knee, m. quadriceps, m. hamstring, iliotibial band and medial thigh. The technique was performed for at least 2 minutes in each region."
224237024|NCT05004194|PROCEDURE|Vestibular Caloric Stimulation|Irrigation of the right external ear canal
224237025|NCT05165381|DEVICE|Video PPG|Contactless vital signs and stress measurement using video PPG technology. An iPad will be used to record a video of the participant's, which can then be converted to vital signs using a specialized algorithm.
224237026|NCT05281822|OTHER|The stress management training|The women in the experimental group were provided with stress management training to help cope with stress conditions how to use positive coping in conditions in case of stress and tension.
224237027|NCT03065582|OTHER|Topical Product A|topical application sunscreen containing topical antioxidants and sunscreen filters
224237028|NCT03065582|OTHER|Topical Product B|topical application of product A without topical antioxidants
224237029|NCT03065582|OTHER|Topical Product C|Topical application of antioxidants only
224237030|NCT03065582|OTHER|Control|No product applied
224237031|NCT03718234|DRUG|Subcutaneous hydrocortisone|Pulsatile subcutaneous hydrocortisone administered in 8 doses per day via SQ infusion pump for 6 weeks
224237032|NCT00218530|DRUG|Lofexidine|
223652945|NCT03223610|DRUG|Venetoclax|Administered orally, days 2-14, at varying doses of 200-800 mg (based upon assigned dose level); every 21 days for up to 6 cycles, or until disease progression or unacceptable toxicity
223652946|NCT03223610|DRUG|Ibrutinib|Administered orally, days 1-14, at a dose of 560 mg; every 21 days for up to 6 cycles, or until disease progression or unacceptable toxicity
223652947|NCT03223610|DRUG|Prednisone|Administered orally, days 1-7, at a dose of 100 mg; every 21 days for up to 6 cycles, or until disease progression or unacceptable toxicity
223652948|NCT03223610|BIOLOGICAL|Obinutuzumab|Administered intravenously, days 1 and 2, at a dose of 1000 mg; every 21 days for up to 6 cycles, or until disease progression or unacceptable toxicity
223652949|NCT03223610|DRUG|Revlimid (lenalidomide)|Administered orally, days 1-15, at a dose of 15 mg; every 21 days for up to 6 cycles, or until disease progression or unacceptable toxicity
223652950|NCT02600949|DRUG|Imiquimod|Applied topically
223652951|NCT02600949|BIOLOGICAL|Pembrolizumab|Given IV
224237033|NCT00384852|DRUG|rhBMP-2/CPM|
224237034|NCT02357732|DRUG|Nivolumab|
224237035|NCT02357732|DRUG|Trametinib|
224237036|NCT02357732|DRUG|Dabrafenib|
224237037|NCT06162793|BEHAVIORAL|RehaPlus+|24-week eHealth intervention
223652952|NCT02600949|BIOLOGICAL|Sotigalimab|Given IV
223652953|NCT02600949|BIOLOGICAL|Synthetic Tumor-Associated Peptide Vaccine Therapy|Given SC
223652954|NCT02600949|PROCEDURE|Computed Tomography|Undergo CT
223652955|NCT02600949|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223652956|NCT06089109|BEHAVIORAL|The Big 3|Our research team has developed an online, interactive learning management system (LMS) training. This training seeks to provide helping professionals with information and resources to identify, intervene, and prevent maternal injuries from interpersonal violence, substance use/disorder (IPV and SU/D). This training will provide healthcare professionals with the knowledge, skills, and efficacy to intervene and build capacity for prevention of maternal injuries and death due to violence.
223767583|NCT07025733|DEVICE|Control Compression Sock|Control sock that is just compression sock
223767584|NCT07025772|BEHAVIORAL|ST+ABR|ST+ABR participants will complete seven weekly sessions of 15 minutes of computerized training (ABR), followed by a 45-minute session of standard smoking cessation treatment (CBT+NRT). Participants will be instructed to pull or push a joystick depending on the tilt, which will be positive-related or smoking-related images.
224237038|NCT04079088|DRUG|Placebo|Administered as specified in the treatment arm.
224237039|NCT04079088|DRUG|BIIB061|Administered as specified in the treatment arm.
224237040|NCT04079088|BIOLOGICAL|Interferon-beta1|Stable dose as prescribed by the physician.
224237041|NCT04079088|DRUG|Glatiramer acetate|Stable dose as prescribed by the physician.
224237042|NCT03149861|PROCEDURE|PET/MR-ultrasound guided Fusion biopsy|All focal lesion with PI-RADS \>=3 on MR or with DCFPyL uptake on PET will undergo a focal fusion biopsy
224237043|NCT03149861|PROCEDURE|Systemic TRUS guided biopsy|Transrectal ultrasound guided systemic prostate biopsy
224237044|NCT05561413|BEHAVIORAL|Mindfulness and exercise|The mindfulness and exercise group aims to gradually increase participants exercise levels so that they begin to achieve the recommended levels along with the strengthening exercises for all major muscle groups. Along side this mindfulness will be introduced and built on to help consolidate exercise uptake and help manage symptoms experienced by the participants.
224237045|NCT05561413|BEHAVIORAL|Mindfulness|The delivery of this practice will be through the app downloaded by participants. The practice based on mindfulness based stress reduction (MBSR). Will build on practice over the 8 weeks.
224237046|NCT03852199|OTHER|Test protocol for proprioceptive force sense in case group|"* The FS in the knee region was measured by the pressure, biofeedback device (Stabilizer ™, Chattanooga Group Inc., Chattanooga, TN).~* Surface EMG device (Noraxon USA, Inc., Scottsdale, AZ) was used to measure activation levels of M. Vastus Medialis Obliquus (VMO), M. Vastus Lateralis (VL) and M. Rectus Femoris (RF) muscles. Due to the characteristics of the Bipolar Ag/AgCl surface electrodes, the distance between the electrodes was set to 1 cm and the electrode width to 2 cm. The electrode placement was determined according to the SENIAM (Surface ElectroMyoGraphy for the Non-Invasive Assessment of Muscles) criteria."
224237047|NCT02237183|DRUG|Iloprost|Given via inhalation
224237048|NCT02237183|OTHER|Placebo Administration|Given via inhalation
224237049|NCT02237183|OTHER|Quality-of-Life Assessment|Ancillary studies
223652957|NCT06089109|BEHAVIORAL|Implementation and Effectiveness of VIP Corps Training|Implement and evaluate the effectiveness of VIP Corps training aimed at students enrolled in helping professions in their last program year. intervention efficacy to change in students' knowledge, attitudes, and practices of intimate partner violence (IPV) screening, detection, and referrals; participant practices will be the primary, longer-term outcome; while changes in knowledge and attitudes will be short-term outcomes. Secondary outcomes will include changes in detecting symptoms of a) SU/D and b) depression and/or anxiety and providing appropriate resources.
223652958|NCT06362824|BEHAVIORAL|De Pie Intervention|Participants are guided by a health coach trained in motivational interviewing through 6 biweekly phone sessions. Each session involves reviewing goals and problem-solving barriers from the prior 2 weeks experience; covering a topic related to Step 1 goals (or Step 2 goals if they pass the safety assessment) such as how to enjoy movement, social support, and using your surroundings; and setting goals and an action plan for the following two weeks.
223652959|NCT06362824|OTHER|Active Comparison Group: Healthy Actions And Lifestyles To Avoid Dementia (HALT-AD)|Those in the active comparison program will receive no additional health coaching sessions. They will work through the HALT-AD content at their own pace, setting goals in the online platform as they go.
223652960|NCT05899608|BIOLOGICAL|Ivonescimab Injection|Subject will receive ivonescimab and chemotherapy as an IV injection
223652961|NCT05899608|BIOLOGICAL|Pembrolizumab Injection|Subject will receive pembrolizumab and chemotherapy as an IV injection
223652962|NCT06054893|DRUG|Omaveloxolone|Administered as specified in the treatment arm
223652963|NCT02911103|PROCEDURE|DBS surgery|Unilateral thalamic DBS therapy
223652964|NCT02911103|DEVICE|Medtronic Activa Rechargeable System|Used for diagnostic purposes.
223767585|NCT07025772|BEHAVIORAL|ST+Sham|ST+Sham participants will complete seven weekly sessions of 15 minute computerized control sessions (AAT), followed by a 45-minute session of standard smoking cessation treatment (CBT+NRT). Participants will be instructed to pull or push a joystick depending on the tilt, which will be positive-related or smoking-related images.
223652966|NCT04633252|DRUG|ADT|For mCSPC patients: Androgen Deprivation Therapy (ADT) may include GnRH agonist or monthly degarelix converted to GnRH agonist after 3 months. For mCRPC patients: ADT will be continued as per standard of care.
223652967|NCT04633252|DRUG|Prednisone|For mCSPC patients, prednisone is optional and if given, should be taken orally, at 5 mg once a day. For mCRPC patients, prednisone should be taken orally either, at 5mg twice a day for each dose or 10 mg once a day as is the patient s preference.
223652968|NCT04633252|DRUG|M7824|M7824 (2400 mg) will be administered as a 1 hour intravenous (IV) infusion once every three weeks.
224237050|NCT02237183|OTHER|Questionnaire Administration|Ancillary studies
223652969|NCT04633252|DRUG|Docetaxel|Docetaxel 75mg/m\^2 will be administered intravenously every 21 days (i.e., a 3-week cycle) for up to 6 cycles in mCSPC and until progression or unacceptable toxicity in mCRPC.
223652970|NCT04633252|DRUG|M9241|M9241 at escalating doses and then at RP2D will be administered as a subcutaneous injection every three weeks.
223652971|NCT04174105|GENETIC|zocaglusagene nuzaparvovec|AT845 is an AAV8 vector delivering a functional copy of the human GAA gene, under the control of a muscle-specific promoter
223652972|NCT06969287|DRUG|Fluvoxamine|"100mg Fluvoxamine Capsule~1. Day of surgery - Study drug to be taken morning of surgery and evening of surgery~2. Post-operative day 1 - Study drug to be taken morning and evening"
223652973|NCT06969287|DRUG|Placebo|"Placebo Capsule~1. Day of surgery - Study drug to be taken morning of surgery and evening of surgery~2. Post-operative day 1 - Study drug to be taken morning and evening"
223652974|NCT04679012|DRUG|Polatuzumab Vedotin|Polatuzumab vedotin will be administered as an IV infusion at 1.8mg/kg on Day 1 of each cycle, every 21 days.
223652975|NCT04679012|DRUG|Rituximab|Rituximab will be obtained from commercial supply, and will be given for a total of 6 cycles for all patients. The drug will be given by IV route.
223652976|NCT04679012|DRUG|Etoposide|Etoposide will be obtained from commercial supply, and will be given for a total of 6 cycles for all patients. The drug will be given by IV route.
223652977|NCT04679012|DRUG|Prednisone|Prednisone will be obtained from commercial supply, and will be given for a total of 6 cycles for all patients. Prednisone will be given orally.
223652978|NCT04679012|DRUG|Cyclophosphamide|Cyclophosphamide will be obtained from commercial supply, and will be given for a total of 6 cycles for all patients. The drug will be given by IV route.
223652979|NCT04679012|DRUG|Hydroxydaunomycin|Hydroxydaunomycin will be obtained from commercial supply, and will be given for a total of 6 cycles for all patients. The drug will be given by IV route.
223767586|NCT07025772|BEHAVIORAL|ST Only|ST Only will consist of 7 weekly 45-minute sessions of standard treatment (CBT+NRT) for smoking cessation.
223767587|NCT07024862|BIOLOGICAL|nivolumab + ipilimumab|First-line (1L) nivolumab + ipilimumab + 2 cycles of chemotherapy (NIC)
224237051|NCT00090038|DRUG|rituximab|Dose, schedule,and duration specified in protocol
224237052|NCT04933513|BEHAVIORAL|pre DBS patients responding to the DBS-PS scale|we propose to parkinson's disease patients selected for subthalamic deep brain stimulation to complete the DBS-PS scale preoperatively
224237053|NCT04236765|OTHER|TB infection-screening benefiting group|The children who participate in the study will be recruited during a programmed visit to a traveler health clinic or a primary care center. During the first visit the parents or legal guardian will be interviewed, a questionnaire will be completed with sociodemographic, epidemiologic and clinical data and a tuberculin skin test (TST) will be performed and read at 48-72 hours. At 8-12 weeks after returning from the travel abroad the child will have a new visit. A new interview will be carried out with the parents or legal guardian and a questionnaire will be completed with epidemiological and clinical data. The child will undergo a new TST and QFT-Plus test.
223652980|NCT05801939|DRUG|Cevostamab|Cevostamab will be given as an IV infusion once every 3 weeks, starting roughly 10 weeks (day 70 +/- 4 days) post-CAR T cell infusion, with subjects planned to receive 8 cycles initially. Subjects receive a single step-up dose of 3.6 mg of cevostamab on cycle 1, day 1 (C1D1), followed by the recommended target dose (160 mg, 132mg, or 90 mg based on results of safety run-in data and safety review) on C1D8. Myeloma responses are assessed every cycle, and a repeat bone marrow aspirate and biopsy (BMbx) is performed at the start of cycle 8. If participants are not in an MRD-negative CR at this timepoint (or if the BM bx is inevaluable/indeterminate for CR or MRD testing), they continue with another 8 cycles (C9-16) of cevostamab. If they are in MRD-negative CR at start of C8, they stop therapy after receiving this cycle and are observed.
223652981|NCT06469281|OTHER|27T51|Intravenous (IV) infusion
223652982|NCT06469281|DRUG|Cemiplimab|IV infusion
223652983|NCT06469281|DRUG|Bevacizumab|IV Infusion
223652984|NCT06616051|OTHER|Multicomponent SMS reminder|"SMS reminder will be delivered every Sunday, Tuesday and Thursday for a duration of eight weeks, or until the child attends the hospital. Research team has already developed an automated text message reminder system for this study, taking into account the local context. The messages was designed with input from a panel of public health consultants and research supervisors, drawing on resources from the WHO Health Promotion and Disease Prevention Messages Library \[21\].~It will comprise two main components: a) web-based application for children registration and automated reminder scheduling, and b) an SMS application for text messaging that is sent automatically. Messages will be sent in Urdu, the native language, and will not require a reply. Each message will include four elements: Health promotion message, visual depiction of a child's vision, a customized action plan detailing how to get to the hospital including the location, how much money is needed and what to carry with them."
223652985|NCT05835310|BIOLOGICAL|Anifrolumab|Participants will receive a single dose of Anifrolumab via IV infusion.
223652986|NCT05835310|DRUG|Placebo|Participants will receive matching placebo via IV infusion
223652987|NCT05853458|DRUG|Hydroxyurea|Hydroxyurea is commercially available in Germany and will be prescribed based on clinical judgment
223652988|NCT05268562|DRUG|Ketamine|1-2 mg/kg induction with additional medication administered as needed to achieve intubating conditions
223652989|NCT05268562|DRUG|Propofol|0.5-1 mg/kg induction with additional medication administered as needed to achieve intubating conditions
223652990|NCT04976192|COMBINATION_PRODUCT|TEV-45779|TEV-45779 (Omalizumab) solution for injection 150 mg/mL prefilled syringe
223652991|NCT04976192|COMBINATION_PRODUCT|XOLAIR® Injection|XOLAIR (omalizumab) injection is supplied as a single dose PFS. Each PFS of XOLAIR contains 150 mg of omalizumab in 1 mL of solution.
223652992|NCT04692675|DIAGNOSTIC_TEST|mpMRI|3T endorectal coil MR imaging of the prostate gland
223652993|NCT02621151|BIOLOGICAL|Pembrolizumab|
223652994|NCT02621151|PROCEDURE|Transurethral Resection of Bladder Tumor|
223652995|NCT02621151|DRUG|Gemcitabine|
223767588|NCT07023562|PROCEDURE|ABC suction sequence|Suction sampling should be conducted in the sequence of dry-suction, slow-pull and wet-suction.
224237054|NCT01545076|BIOLOGICAL|IgPro20 (low dose)|"20% liquid formulation (200 mg/mL) of human normal immunoglobulin for subcutaneous use administered weekly during the SC treatment period of the study according to the randomization:~0.2 g/kg body weight (low dose arm)"
224237055|NCT01545076|BIOLOGICAL|Placebo|2% human albumin administered by weekly SC infusions during the SC treatment period of the study.
224237056|NCT01545076|BIOLOGICAL|IgPro10|10% Immunoglobulin G (IgG) liquid formulation of human normal immunoglobulin (Privigen®) administered intravenously during Restabilization Period of the study and/or as Rescue Therapy during SC Treatment Period for subjects with a CIDP relapse.
224237057|NCT01545076|BIOLOGICAL|IgPro20 (high dose)|"20% liquid formulation (200 mg/mL) of human normal immunoglobulin for subcutaneous use administered weekly during the SC treatment period of the study according to the randomization:~0.4 g/kg body weight (high dose arm)"
224237058|NCT05241184|DIAGNOSTIC_TEST|Multiparametric stress CMR protocol|Multiparametric stress CMR protocol
224237059|NCT01398384|DRUG|Nitric Oxide|MI size at 48-72 hours
224237060|NCT01398384|DRUG|MI size at 48-72 hours|Placebo gas
224237061|NCT01195714|DRUG|Ofatumumab|solution for perfusion, 1000mg per cycle, 1 cycle every 3 weeks, total 6 cycles
223652996|NCT02621151|RADIATION|External Beam Radiation Therapy|
223767589|NCT07023562|PROCEDURE|ACB suction sequence|Suction sampling should be conducted in the sequence of dry-suction, wet-suction and slow-pull.
223767590|NCT07023562|PROCEDURE|BAC suction sequence|Suction sampling should be conducted in the sequence of slow-pull, dry-suction and wet-suction.
223767591|NCT07023562|PROCEDURE|BCA suction sequence|Suction sampling should be conducted in the sequence of slow-pull, wet-suction and dry-suction.
223767592|NCT07023562|PROCEDURE|CAB suction sequence|Suction sampling should be conducted in the sequence of wet-suction, dry-suction and slow-pull.
223767593|NCT07023562|PROCEDURE|CBA suction sequence|Suction sampling should be conducted in the sequence of wet-suction, slow-pull and dry-suction.
224237062|NCT02019810|DRUG|Norepinephrine|
224237063|NCT02019810|DRUG|Dobutamine and norepinephrine|
224237064|NCT03444038|DRUG|Valbenazine|vesicular monoamine transporter 2 (VMAT2) inhibitor
224237065|NCT00689013|OTHER|Personalized letter|On Day 1 of the 2nd month, a personalized letter (addressing specific patient) was mailed to current pharmacy patients with indications for the Zostavax vaccine. Current patients were defined as those receiving at least one prescription medication from the pharmacy within 6 months. The personalized letter provided detailed information about herpes zoster infection, the vaccine for herpes zoster prevention, indications for vaccine receipt and contraindications for vaccine receipt.
223652997|NCT04073225|DEVICE|MindPod Dolphin|"The immersive video game being tested in this study is called Bandit the Dolphin, developed by neurologist Dr. John Krakauer, and engineers in the Brain, Learning, Animation, and Movement Lab at Johns Hopkins. Bandit the Dolphin provides an oceanic environment in which the individual's arm movements control a simulated dolphin. The neuromotor effects of this game have been designed to be used in the clinical setting to rehabilitate arm and hand function following stroke. The game has further been modified to a Microsoft Kinect-based system and piloted for play in non-laboratory settings among community-dwelling adults. The game offers a unique combination of skilled arm movements plus varying levels of cognitive challenge. In this way, the individual's arms are challenged the same way the legs would be when walking in a complex, outdoor environment. Importantly, the participant plays while standing, thus engaging the whole body in this novel multi-sensorial experience."
223652998|NCT04073225|BEHAVIORAL|10 Keys to Healthy Aging|"The 10 Keys™ to Healthy Aging Program in an evidence-based program that originated from the University of Pittsburgh Center for Aging and Population Health. This educates and empowers older adults to reach personal goals and help others to so in the community as well. It is designed to teach older adults how to reduce the risk of disease over the aging process by promoting healthy lifestyle changes with the most recent established scientific guidelines. The 10 Keys program also aims to empower individuals to be health ambassadors in the individual's own families and communities, teaching individuals to 'Share the Wealth on Health'. Participants will work towards personal health goal(s) adapted to the participant's lifestyle and abilities."
223652999|NCT02285439|DRUG|MEK162|• MEK162 is currently supplied as film-coated tablets in dose strength of 15 mg. The film-coated tablets consist of MEK162 drug substance, lactose monohydrate, microcrystalline cellulose, colloidal silicon dioxide, croscarmellose sodium, magnesium stearate, and a commercial film coating. The original tablets are yellow to dark yellow capsule-shaped
223653000|NCT06436742|BIOLOGICAL|ARGX-119|Intravenous infusion of ARGX-119
223653001|NCT06436742|OTHER|Placebo|Intravenous infusion of placebo
223653002|NCT05287854|DEVICE|Virtual reality headset|Once the patient is on the operating table, the nurse proposes the different possible VR scenarios and installs the RV headset and an audio headset.
223767594|NCT07024368|DEVICE|Reliability of the Sensory Organization Test on the SMART Balance Master across multiple administrations|"The Sensory Organization Test (SOT) on the SMART Balance Master® will be administered a total of five times. On the first day, participants will complete three SOT sessions, each separated by a 20-minute break. An additional SOT will be conducted on day 45, followed by a final SOT on day 50.~SOT test scores will be analyzed using Equilibrium Scores (ESs), which provide information on the integration of multiple sensory systems involved in balance through a linear measurement method. Additionally, scores will be evaluated using Multiscale Entropy (MSE), a non-linear model for assessing complexity in postural stability."
223767595|NCT07023913|OTHER|kinetic Control exercises|Kinetic Control exercises consist of 45-minute sessions, with 3 sessions per week for 8 weeks. The framework for testing and rehabilitation includes initial assessment, rehabilitation before failure, and retesting the same position. Biofeedback measures scapular retraction, and biofeedback pressure training assesses and improves scapular stabilizer control by monitoring pressure changes during specific movements.
224237066|NCT00689013|OTHER|Flyer advertisement|Beginning on Day 1 of the 2nd month, flyer advertisements were distributed with all pharmacy sales. Flyer advertisements provided detailed information about herpes zoster infection, the vaccine for herpes zoster prevention, indications for vaccine receipt and contraindications for vaccine receipt.
223653006|NCT04222413|DRUG|Metarrestin|Phase IA: Loading dose on Day 1 of Cycle 1 for Dose Levels 1-7. Loading dose on Days 1 and 3 of Cycle 1 for Dose Levels 8-11. After the loading dose on Day 1 or Days 1 and 3 of Cycle 1, continue on Mondays-Wednesdays-Fridays of every following cycle. Phase IB: PO according to the dose and schedule estimated during Phase IA
223653007|NCT06285890|DRUG|HC-7366|Given by PO
223653008|NCT00004847|DRUG|([18F]-DOPA)|is L 3, 4 dihydroxyphenylalanine (L-DOPA) labeled with the radioactive isotope 18F. In general, PPGLs belong to the group of neuroendocrine tumors. This heterogeneous group of tumors takes up amino acids, transforms them into biogenic amines (dopamine and serotonin) by decarboxylation and stores the amines in vesicles. L DOPA is a precursor of catecholamines (dopamine, norepinephrine and epinephrine). Epinephrine conversion to dopamine is catalyzed by the aromatic amino acid decarboxylase. According to previous and current studies, \[18F\]-DOPA PET is highly sensitive and specific for detection of PHEO/PGL67-69. However, there are only a few reports in the literature using \[18F\]-DOPA as a PET agent and particularly for patients with metastatic PPGLs. PET imaging will be done together with either a CT, an MRI or both modalities.
223653009|NCT00004847|DRUG|([18F]-6F-DA)|is an imaging agent developed at the NIH, that may improve specificity and sensitivity in the localization of PPGLs. \[18F\]-6F-DA enters cells via the membrane norepinephrine transporter. Once inside cells, \[18F\]-6F-DA is translocated via the vesicular monoamine transporter into storage vesicles, where the radioactivity is concentrated. After injection of \[18F\]-6F-DA, the much faster disappearance of \[18F\]-6F-DA-derived radioactivity from the bloodstream and non-neuronal cells than from chromaffin cells should enable rapid visualization of PPGLs by PET scanning.
223653010|NCT04723836|DIETARY_SUPPLEMENT|Riboflavin (5mg)|From 16th week gestation until end of pregnancy
223653011|NCT04723836|DIETARY_SUPPLEMENT|5-methyltetrahydrofolate (400µg)|From 16th week gestation until end of pregnancy
223653012|NCT04723836|DIETARY_SUPPLEMENT|Placebo|From 16th week gestation until end of pregnancy
223653013|NCT03019471|GENETIC|Isolation of tumor DNA|
223653014|NCT06424288|DRUG|vicadrostat|vicadrostat
223653015|NCT06424288|DRUG|empagliflozin|empagliflozin
223653016|NCT06424288|DRUG|Placebo|Placebo matching vicadrostat
223653017|NCT06072638|BEHAVIORAL|Eating in Absence of Hunger|Researcher gives child free access to palatable foods following a satiating meal.
223653018|NCT02133196|DRUG|Aldesleukin|Aldesleukin 720,000 (Arm 1) or 72,000 (Arm 2) IU/kg IV (based on total body weight) over 15 minutes every 8 hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to a maximum of 9 doses in Arm 1 and 12 doses in Arm 2.
223653019|NCT02133196|DRUG|Fludarabine|Days -7 to -3: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days.
223653020|NCT02133196|DRUG|Cyclophosphamide|Days -7 and -6: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with Mesna 15 mg/kg/day X 2 days over 1 hour.
223653021|NCT02133196|BIOLOGICAL|Young TIL|Day 0: Cells will be infused intravenously (IV) on the Patient Care Unit over 20-30 minutes.
223653022|NCT02592317|DRUG|JNJ 56021927|JNJ 56021927 will be administered once daily orally in a dose of 240 mg from Study Day 15 up to disease progression, unacceptable toxicity, withdrawal of consent, lost to follow-up, the participant is no longer receiving clinical benefit in the opinion of the Investigator, the start of subsequent anticancer therapy, or the Sponsor ends the study.
223653023|NCT02592317|DRUG|Drug Cocktail|Drug cocktail comprise of midazolam (2 mg), warfarin (10 mg), vitamin K (10 mg), omeprazole (40 mg), and fexofenadine (30 mg) will be administered on Study Day 1 and 43.
223653024|NCT02592317|DRUG|Pioglitazone|Pioglitazone 15 mg will be administered orally on Study Day 8 and 50.
223653025|NCT02592317|DRUG|Rosuvastatin|Rosuvastatin 15 mg will be administered orally on Study Day 9 and 51.
224237067|NCT00689013|OTHER|Newspaper press release|During the first week of the 2nd month, local newspapers published press releases. The press release provided detailed information about herpes zoster infection, the vaccine for herpes zoster prevention, indications for vaccine receipt and contraindications for vaccine receipt.
224237068|NCT06123520|PROCEDURE|Ho-YAG Laser Visual internal urethrotomy|"the operations will be performed by an expert surgeon and operative time will be considered. The procedure will be performed under spinal or general anaesthesia in lithotomy position. Antibiotic will be given just before and 12 h after procedure and continued for next 5 days.~Normal saline will be used for irrigation during the procedure. A Holmium laser at an energy of 1,200 to 2.000 mJ with a frequency of 10 to 15 Hz will be used By use of a 22 F cystoscope and Ho:YAG laser, the stricture site will be completely incised while sparing healthy mucosa. a fiber will be positioned about 1 mm away from the tissue and the laser will be fired.~An 18 F silicone Foley catheter will be left in the urethra at the end of the procedure. urethral catheter removal and voiding trial will be given at postoperative Day 7."
223767596|NCT07023913|OTHER|traditional treatment|traditional therapy inform of stretching and strengthening exercise as shoulder roll, arm circle, wall climb, back climb and hand behind neck. Patients will receive 3 sessions per week for 8 weeks, the time of session is 45 - 60 min according to patient ability
223767597|NCT07023861|DRUG|18F-FDG|18F-FDG is administered through a superficial dorsal vein, and the patient is given a dose of about 0.1-0.15 mCi/kg.
223767598|NCT07023861|DRUG|89Zr-LNCab190|89Zr-LNCab190 is administered through a superficial dorsal vein, and the patient is given a dose of about 1-3 mCi
224237069|NCT06123520|PROCEDURE|Ho-YAG Laser Visual internal urethrotomy combined with intralesional submucosal injection of Paclitaxel|"The investigators will follow the same interversion protocol in the first group then paclitaxel is going to be injected via Williams cystoscopic injection needle (5 F size and 23 G needle size) through the cystoscope after laser ablation of the stricture in the submucosa with an assumed dose of 3.5µg/mm2 (reaching a urethral diameter of 30 Fr and a total length of 2 cm a total dose of 2.2 mg divided along 3 injection is to be injected). the dose is divided at 12,4 and 8 o'clock respectively along the length of the stricture.~An 18 F silicone Foley catheter will be left in the urethra at the end of the procedure. urethral catheter removal and voiding trial will be given at postoperative Day 7."
224237070|NCT01626664|BIOLOGICAL|KW-0761|1.0 mg/kg weekly x 4 in cycle 1 then every other week until progression
224237071|NCT01626664|DRUG|Pralatrexate|30 mg/m2 weekly for 3 weeks followed by 1 week of no therapy until progression
223653032|NCT03930251|BEHAVIORAL|Clinic-Based Cognitive Remediation|Computer-based exercises targeting impairments in cognitive domains (sensory processing, processing speed, attention, working memory, executive functions) are paired with verbal discussions and group-based activities to strengthen metacognition and bridge newly learned cognitive skills to everyday life. Sessions are led twice weekly by a clinician in small groups.
223653033|NCT03930251|BEHAVIORAL|Partial-Remote Cognitive Remediation|Computer-based exercises targeting impairments in cognitive domains (sensory processing, processing speed, attention, working memory, executive functions) are paired with verbal discussions and group-based activities to strengthen metacognition and bridge newly learned cognitive skills to everyday life. Sessions are led once weekly by a clinician in small groups and clients gain additional practice by accessing clinician-assigned computer-based exercises independently.
223653034|NCT02253316|BIOLOGICAL|Ixazomib|
223653035|NCT02253316|DRUG|Lenalidomide|
223653036|NCT02253316|DRUG|Dexamethasone|
224237072|NCT01626664|DRUG|gemcitabine plus oxaliplatin|gemcitabine 1000 mg/m2, followed by oxaliplatin 100 mg/m2 every 2 weeks until progression
224237073|NCT01626664|DRUG|DHAP|dexamethasone 40 mg on Day 1-4, cisplatin 100 mg/m2 on Day 1 followed by 2 doses of cytarabine 2000 mg/m2 every 4 weeks until progression
224237074|NCT02310165|PROCEDURE|Z-tract Insertion Technique|
224237075|NCT02310165|PROCEDURE|Coaxial Insertion Technique|
224237076|NCT01675557|DIETARY_SUPPLEMENT|Vitamin D3|a single oral dose of vitamin D3
224237077|NCT01675557|DIETARY_SUPPLEMENT|Vitamin D2|a single oral dose of vitamin D2
224237078|NCT01675557|DIETARY_SUPPLEMENT|Placebo|a single oral dose of placebo
224237079|NCT04709848|OTHER|None - standard of care|Observational study only. Pre-screening group were not screened for Strongyloides, as per the standard of care at the time. Screened group were screened for Strongyloides, because the standard of care at our centre changed.
224237080|NCT04223440|OTHER|MRI|MRI on both shoulder
224237081|NCT04223440|OTHER|ultrasonographic explorations|ultrasound and elastography explorations on both shoulder
224237082|NCT00001221|DRUG|Growth Hormone (Humatrope)|
224237083|NCT06389409|OTHER|Observation of testicular cancer patients|Collection of clinical data of all patients suffering from neoplastic testicular pathology undergoing surgery
223653037|NCT00001595|PROCEDURE|MRI|
223653038|NCT00001595|PROCEDURE|Tissue specimen collection|
223653039|NCT06034925|DRUG|Maribavir|maribavir 400mg twice daily
223653040|NCT06034925|DRUG|Valganciclovir|valganciclovir 900mg once daily
223653041|NCT00006421|DRUG|2-Fluorodeoxyglucose|
223653042|NCT07113743|DRUG|Busulfan|Conditioning drug
223653043|NCT07113743|DRUG|Tocilizumab|Monoclonal Antibody
223653044|NCT07113743|DRUG|Eltrombopag|Thrombopoietin Receptor Agonist
223653045|NCT07113743|DRUG|Sirolimus|Post transplant immunosuppressant drug
223653046|NCT07113743|OTHER|pCCLChimGp91lentiviral vector containing the human gp91 phox (CYBB) gene|Intervention Infusion on Day 0
223653047|NCT02219659|DRUG|Sedation Protocol with Daily Interruption|Continuous infusion of fentanyl and midazolam is started and titrated to target pain and RASS score: Fentanyl started at 25 mcg/hr titrated by 25 mcg/hr every 30 minutes to goal pain score; Midazolam started at 1 mg/hr titrated by 1 mg/hr every hour to goal RASS score for the study design duration (28 days) or for the duration of mechanical ventilation. Every morning both infusions are stopped and when the patient is awake and met the SBT safety screen, 120-min CPAP trial is performed. If the patient meets the CPAP passing criteria, arterial blood gas (ABG) is done and the patient is placed back to the previous ventilator setting. ABG result is notified to the physician for determination for extubation. If the patient does not pass the CPAP trial it is repeated next morning.
223653048|NCT02219659|DRUG|Sedation Protocol Without Daily Interruption|Continuous infusion of fentanyl and midazolam is started and titrated to target pain and RASS score: Fentanyl started at 25 mcg/hr titrated by 25 mcg/hr every 30 minutes to goal pain score; Midazolam started at 1 mg/hr titrated by 1 mg/hr every hour to goal RASS score for the study design duration (28 days) or for the duration of mechanical ventilation. Every morning when the patient's RASS score is 0 to -2 and the patient passes the SBT safety screen, 120-min CPAP trial is performed. If the patient meets the CPAP passing criteria, arterial blood gas (ABG) is done and the patient is placed back to the previous ventilator setting. ABG result is notified to the physician for determination for extubation. If the patient does not pass the CPAP trial it is repeated next morning.
223653049|NCT02219659|DRUG|Fentanyl Push First|Fentanyl 25 mcg intravenous push (IVP) every 5 min up to 4 doses hourly as needed to target pain score for the study design duration (28 days) or for the duration of mechanical ventilation. Every morning when patient's RASS is 0 to -2 and passes the SBT safety screen, 120-min CPAP trial is performed. If patient meets CPAP passing criteria, the physician will be notified for determination of extubation. If patient does not pass, it is repeated next morning. If target RASS is not achieved with fentanyl IV push alone, study team is notified and fentanyl infusion at 50 mcg/hr titrated by 25 mcg/hr every 30 min to target pain score (max 6 hrs). If target RASS score is not achieved with the fentanyl IV, propofol infusion is started at 5 mcg/kg/hr titrated by 5 mcg/kg/hr every 15 min to target RASS score (max 6 hrs).
223653050|NCT06977880|DRUG|LY4292009|Administered orally
223653051|NCT06977880|DRUG|Placebo|Administered orally.
223653052|NCT06979336|DRUG|RO7837195|RO7837195 will be administered as per the schedule specified in the protocol.
223653053|NCT06979336|DRUG|RO7837195 Matched Placebo|RO7837195 matched placebo will be administered as per the schedule specified in the protocol.
223653054|NCT00124306|DRUG|Amitriptyline|Amitriptyline will be titrated over a 6-week period as tolerated, to a maximum dose of 75mg. During the 6-week titration period, the patient who cannot tolerate a scheduled increased dose may adjust the medication dose for tolerance by tapering down one 25mg tablet.
224237084|NCT00264797|DRUG|Methylphenidate (OROS-MPH)|Participants will be scheduled for weekly medication (OROS-MPH) and research assessment visits (approximately 45 minutes to 1 hour in length). A forced titration dosing strategy will be used starting with 18 mg/day OROS-MPH for 3 days, increasing to 36mg/day for the next three days; increasing to 54 mg/day in week two, and to 72 mg/day in week three through the remainder of the study (as tolerated). Participants will also attend weekly CBT sessions (approximately 1 hour in length) targeting their drug use.
223653055|NCT00124306|OTHER|Placebo|Placebo will be dosed exactly as active arm.
223653056|NCT00068003|DRUG|Anti-CD19 CAR PBL|
223653057|NCT01049230|RADIATION|Proton Beam radiation|Once a day, 5 days a week (Monday-Friday), for 4-8 weeks
223767599|NCT07023861|DRUG|89Zr-LNCab002|89Zr-LNCab002 is administered through a superficial dorsal vein, and the patient is given a dose of about 1-3 mCi
223653061|NCT06902714|DRUG|oral tranexamic acid|one group of subjects will receive oral tranexamic acid and the other will receive oral placebo
223653062|NCT06902714|DRUG|Placebo|one group of randomized subjects will receive placebo and the other will receive oral tranexamic acid
223653063|NCT05554172|DEVICE|taVNS|Participants will receive vagal nerve stimulation approximately 3 days a week for 30 minutes over the course of 4 weeks while they are attending treatment for Anorexia Nervosa in the Eating and Weight Disorder Intensive Program.
223653064|NCT05554172|DEVICE|Sham|Participants will receive sham stimulation approximately 3 days a week for 30 minutes over the course of 4 weeks while they are attending treatment for Anorexia Nervosa in the Eating and Weight Disorder Intensive Program.
223767600|NCT07023861|DRUG|89Zr-LNCab072|89Zr-LNCab072 is administered through a superficial dorsal vein, and the patient is given a dose of about 1-3 mCi
223767601|NCT04745689|DRUG|Durvalumab|"IV infusions through induction phase.~IV infusions through maintenance phase until PD or other discontinuation criteria."
223767602|NCT04745689|DRUG|AZD2811|IV infusions through maintenance phase until PD or other discontinuation criteria.
223767603|NCT04745689|DRUG|Carboplatin|IV infusions through induction phase if chosen by Investigator.
223767604|NCT04745689|DRUG|Cisplatin|IV infusions through induction phase if chosen by Investigator.
223767605|NCT04745689|DRUG|Etoposide|IV infusions through induction phase.
223767606|NCT07025759|DEVICE|Peripheral magnetic stimulation (90% of RMT + 1 Hz)|Low-frequency stimulation (1 Hz) at 90% of resting motor threshold intensity, delivering a total of 2400 pulses.
223767607|NCT07025759|DEVICE|Peripheral magnetic stimulation (90% of RMT + 10 Hz)|High-frequency stimulation (10 Hz) at 90% of resting motor threshold intensity, totaling 2400 pulses.
223653074|NCT03076554|DRUG|Avelumab|Avelumab will be administered at a dose of 10 mg/kg intravenously once every two weeks until disease progression or development of intolerable adverse events.
223653075|NCT06812988|DRUG|SAR442970|Pharmaceutical form: Solution Route of administration: Subcutaneous injection
223653076|NCT06812988|DRUG|Placebo|Pharmaceutical form: Solution Route of administration: Subcutaneous injection
223767608|NCT07025759|DEVICE|Peripheral magnetic stimulation (90% of RMT + 25 Hz)|High-frequency stimulation (25 Hz) at 90% of resting muscle threshold intensity, with 2400 pulses.
223767609|NCT07025759|DEVICE|Peripheral magnetic stimulation (100% of RMT + 1 Hz)|Low-frequency (1 Hz), at resting motor threshold intensity (100%) protocol delivering 2400 pulses.
223767610|NCT07025759|DEVICE|Peripheral magnetic stimulation (100% of RMT + 10 Hz)|High-frequency (10 Hz), at resting motor threshold intensity (100%) protocol delivering 2400 pulses.
224237085|NCT00264797|DRUG|Methylphenidate (OROS-MPH) - Placebo|Participants will be scheduled for weekly medication and research assessment visits (approximately 45 minutes to 1 hour in length). A forced titration dosing strategy will be used starting with 18 mg/day OROS-MPH placebo for 3 days, increasing to 36mg/day for the next three days; increasing to 54 mg/day in week two, and to 72 mg/day in week three through the remainder of the study (as tolerated). Participants will also attend weekly CBT sessions (approximately 1 hour in length) targeting their drug use.
224237086|NCT06196060|BEHAVIORAL|Visual perspective taking training|Participants will be instructed to utilize small building blocks for the construction of diverse three-dimensional models, with a particular emphasis on employing various perspectives. The visual perspective taking training sessions will be conducted three times weekly over a period of 4 weeks.
223653084|NCT06586710|OTHER|Assessment activation of interferon pathway|"* Peripheral blood collection (as part of routine blood draws) on which interferon signature will be performed at the time of enrollment and in case of remission and/or any renal flare.~* Renal biopsies (routinely performed for diagnostic purposes and during clinical follow-up) on which Myxovirus resistance protein 1 (MXA) expression and histopathologic characterization will be assessed.~* Collection of clinical and laboratory data from routine visits performed at baseline and 3, 6, 12, and 24 months (or last available visit) after the renal biopsy was performed."
223653085|NCT04477603|DEVICE|Impella ECP|Subjects will receive the Impella ECP prior to high-risk percutaneous intervention. Device escalation or early termination of the study will be allowed for subjects as deemed necessary by the treating physician. Subjects will be followed until 30-days post-intervention.
223653086|NCT04062266|DRUG|Azacitidine|Given SC or IV
223653087|NCT04062266|DRUG|Venetoclax|Given PO
223653088|NCT05458908|DIAGNOSTIC_TEST|Non-contrast cranial MDCT head scan|Non-contrast cranial MDCT imaging for visualization of the brain parenchyma (the choice of the device is up to the investigator)
223653089|NCT05458908|DIAGNOSTIC_TEST|Non-contrast syngo DynaCT Sine Spin head scan and application software|Non-contrast syngo DynaCT Sine Spin imaging for visualization of the brain parenchyma with ARTIS icono biplane angiography system and syngo application software with syngo DynaCT Sine Spin 3-D head imaging protocol.
223653090|NCT02669251|DRUG|MPH966|"Phase 1b Cycle= 14 days: Each dose level will increase by 60mg PO BID, up to a maximum of 240mg PO BID~Phase 2 Cycle=28 days: MTD PO BID"
223653091|NCT05629871|PROCEDURE|Polysomnography|Polysomnography will be performed for 24 hours at inclusion and 24 months
223653092|NCT05629871|BEHAVIORAL|Neuropsychological assessment|A full neuropsychological assessment will be performed at inclusion, 12 and 24 months
223653093|NCT05629871|BEHAVIORAL|Questionnaires on sleep and behavioural problems|Questionnaires on sleep and behavioural problems
223653094|NCT05629871|PROCEDURE|Actimetry|Measurement of actimetrics for 14 days at inclusion and at 24 months
224237087|NCT06196060|BEHAVIORAL|Block building training|Participants will be instructed to utilize unit building blocks to construct diverse three-dimensional models. The block building training sessions will be conducted three times weekly over a period of 4 weeks.
224237088|NCT06196060|BEHAVIORAL|Thought-bubble training|Participants will be instructed in the comprehension of mental states through the utilization of cartoon thought-bubbles as a representational tool. The thought-bubble training sessions will be conducted three times weekly over a period of 4 weeks.
224237089|NCT06196060|BEHAVIORAL|Treatment as usual|Participants will continue to receive treatment as usual during the trial.
224237090|NCT03533465|BEHAVIORAL|Complicated Grief Therapy (CGT)|CGT is an evidence based 16 session targeted grief therapy delivered in individual one hour weekly sessions. Treatment will end at 16 sessions (offered over the course of 20 weeks)
224237091|NCT02931474|DRUG|Tesamorelin|Growth Hormone-Releasing
224237092|NCT02931474|OTHER|Placebo|
224237093|NCT02268669|OTHER|Reperfusion strategies|Two different reperfusion strategies in STEMI will be compared: primary angioplasty vs. post-thrombolysis angioplasty
224237094|NCT04271722|OTHER|Cervical ripening|Subjects will undergo cervical ripening in the outpatient setting. The patients will then be scheduled to return the next morning for induction of labor.
224237095|NCT05323864|BIOLOGICAL|Hypoxia|Participants will be randomly assigned to start with the normobaric hypoxia condition or the sham hypoxia condition. They will swap to the other condition during the second visit, which will be executed at least 14 days after the first visit. Each sojourn will last for six hours and participants will reside in the chamber individually. During the six-hour stay, participants will be allowed to move freely within the chamber.
224237096|NCT02305966|PROCEDURE|surgery|All patients will receive a Delta XTEND reverse shoulder implant
223653095|NCT05629871|DIAGNOSTIC_TEST|Fractional diuresis|Split diuresis from 7pm-7am, 7am-12am and 12pm-19pm during polysomnography at inclusion inclusion and 24 months to measure melatonin concentration
223653096|NCT05629871|PROCEDURE|Internal temperature measurement|eCelsius capsule to measure internal temperature at inclusion and 24 months
223653097|NCT05629871|OTHER|Biomarker assay|Determination of the biomarkers Aβ42, Aβ40, Tau and P-Tau in blood and in the cerebrospinal fluid
223653098|NCT02112916|DRUG|Bortezomib|Given IV
223653099|NCT02112916|DRUG|Cyclophosphamide|Given IV
223653100|NCT02112916|DRUG|Cytarabine|Given IT, IV, or SC
223653101|NCT02112916|DRUG|Daunorubicin|Given IV
223653102|NCT02112916|DRUG|Daunorubicin Hydrochloride|Given IV
223653103|NCT02112916|DRUG|Dexamethasone|Given PO or IV
223653104|NCT02112916|DRUG|Doxorubicin|Given IV
223653105|NCT02112916|DRUG|Doxorubicin Hydrochloride|Given IV
223653106|NCT02112916|DRUG|Etoposide|Given IV
223653107|NCT02112916|DRUG|Hydrocortisone Sodium Succinate|Given IT
224237097|NCT02305966|DEVICE|0.8 mm diameter Tantalum marker beads|At the time of surgery, 0.8 mm diameter Tantalum marker beads will be injected into the bone surrounding the implant,
223653108|NCT02112916|DRUG|Ifosfamide|Given IV
223653109|NCT02112916|DRUG|Leucovorin Calcium|Given PO or IV
223653110|NCT02112916|DRUG|Mercaptopurine|Give PO
223653111|NCT02112916|DRUG|Methotrexate|Given IT, IV, or PO
223653112|NCT02112916|DRUG|Pegaspargase|Given IV
223653113|NCT02112916|RADIATION|Radiation Therapy|Undergo radiation therapy
223653114|NCT02112916|DRUG|Thioguanine|Given PO
223653115|NCT02112916|DRUG|Vincristine|Given IV
223653116|NCT02112916|DRUG|Vincristine Sulfate|Given IV
223653117|NCT06817161|DEVICE|transcutaneous auricular vagus nerve stimulation|"The intervention begins on the first day of chemotherapy and continues daily until 21 days after the end of chemotherapy (6 cycles).~The dispositive is used every day at home, twice daily (during 30 minutes)"
223653118|NCT06817161|DEVICE|Placebo device|"The intervention begins on the first day of chemotherapy and continues daily until 21 days after the end of chemotherapy (6 cycles).~The dispositive is used every day at home, twice daily (during 30 minutes)"
223767611|NCT07025759|DEVICE|Peripheral magnetic stimulation (100% of RMT + 25 Hz)|High-frequency (25 Hz), at resting motor threshold intensity (100%) protocol delivering 2400 pulses.
223767612|NCT07025759|DEVICE|Peripheral magnetic stimulation (110% of RMT + 1Hz)|Low-frequency (1 Hz), above resting motor threshold intensity (110%) protocol delivering 2400 pulses.
223767613|NCT07025759|DEVICE|Peripheral magnetic stimulation (110% of RMT + 10Hz)|High-frequency (10 Hz), above resting motor threshold intensity (110%) protocol delivering 2400 pulses.
223653122|NCT06661564|OTHER|Basal tear collection for the analysis of metabo-lipidomic profiles and concentrations of protein biomarkers (Tau, phosphorylated Tau, Aβ 1-40, and Aβ 1-42)|Collection of a tear volume of (i) 2 x 5µL using glass microcapillary tubes and (ii) 12µL using Schirmer strips after the instillation of anesthetic eye drops for metabo-lipidomic analysis and multiplexing of protein markers
223653123|NCT06661564|OTHER|Collection of a blood sample (5 mL) for blood biomarkers analysis|Collection of a blood sample (5 mL) for blood biomarkers analysis.
223653124|NCT06663826|DIAGNOSTIC_TEST|oculomotor and pupillary function assessment|This is an exploratory open-label single-centre research project intended to collect data of PD patients in order to develop machine learning models for helping in the diagnosis and monitoring of PD. Each patient will have an initial visit and then a second visit after two weeks. The estimated duration of the study visit 1 is 3 hours, not taking into account the time for patient information and informed consent. The estimated duration of the study visit 2 is 2 hours. During these two visits, patients will undergo an MDS-UPDRS assessment, a neos examination, a standard manual ocular motor and pupil function examination, and gait assessment simultaneously with GaitQ senti and an IMU sensor placed on their back. In the two weeks separating the two visits, patient's gait will be monitored daily at home with GaitQ senti, where they will perform a daily TUG test comprising of 15 m walk, 5 sit to stand, and 5-minute walk. Healthy individuals data will be included from a previous study.
223653125|NCT04238819|DRUG|Abemaciclib|Administered orally
223653126|NCT04238819|DRUG|Irinotecan|Administered IV
224237098|NCT01153984|DRUG|Erlotinib|Erlotinib 150 mg oral doses will be administered daily.
223653127|NCT04238819|DRUG|Temozolomide|Administered orally
223653128|NCT04238819|DRUG|Dinutuximab|Administered IV
223653129|NCT04238819|DRUG|GM-CSF|Administered SC
223653130|NCT06824467|BIOLOGICAL|Sacituzumab tirumotecan|IV Infusion
223653131|NCT06824467|BIOLOGICAL|Bevacizumab|IV Infusion
223653132|NCT06824467|DRUG|H1 receptor antagonist|Rescue medication taken per approved product label before sacituzumab tirumotecan
223653133|NCT06824467|DRUG|H2 receptor antagonist|Rescue medication taken per approved product label before sacituzumab tirumotecan
223653134|NCT06824467|DRUG|Acetaminophen (or equivalent)|Rescue medication taken per approved product label before sacituzumab tirumotecan
223653135|NCT06824467|DRUG|Dexamethasone (or equivalent)|Rescue medication taken per approved product label before sacituzumab tirumotecan
223653136|NCT06824467|DRUG|Steroid mouthwash (dexamethasone or equivalent)|Rescue medication taken orally 4 times daily
223653137|NCT06665594|PROCEDURE|Hyaluronic Acid (HA)|Injectable gel
223653138|NCT06665594|DRUG|Tranexamic Acid (TXA)|Injection of TXA
223653139|NCT06665594|DRUG|Saline (placebo)|Injection of saline
223653140|NCT06117501|DEVICE|Axoguard HA+ Nerve Protector™|Axoguard HA+ Nerve Protector™ is a surgical implant that provides non-constricting protection for non-transected peripheral nerve injuries where there is no gap. Axoguard HA+ Nerve Protector™ is designed to be an interface between the nerve and the surrounding tissue.
223653141|NCT04880707|DRUG|Twin block local anesthetic nerve block using standard dental anesthetic|2% lidocaine with 1:100,000 epinephrine is the standard dental local anesthetic in universal use. This drug will be administered as the Twin block local anesthetic nerve block targeting the branches of the mandibular nerve supplying the temporalis and masseter muscles.
223653142|NCT04880707|OTHER|Twin block with placebo|Instead of the standard dental anesthetic, sterile normal saline will be delivered using the Twin block injection
223653143|NCT06979700|DIAGNOSTIC_TEST|Automated Pupillometry|Measurements will be performed on comatose participants at 0-6 hours, 20-28, 44-52 and 66-72 hours after enrolment for both pupils and include: Neurological pupil index, pupillary size, pupillary minimum diameter, pupillary constriction amplitude, pupillary constriction velocity, pupillary maximum constriction velocity, pupillary latency and pupillary dilation velocity.
223653144|NCT06979700|DIAGNOSTIC_TEST|Transcranial Doppler Ultrasound|Measurements will be performed on comatose participants at 0-6 hours, 20-28, 44-52 and 66-72 hours after enrolment on both middle cerebral arteries and include the following: Peak systolic velocity, end diastolic velocity, mean velocity, pulsatility index and resistance index.
224237099|NCT02460159|DRUG|EZ 10 mg/Atorva 20 mg FDC|
224237100|NCT02460159|DRUG|EZ 10 mg/Atorva 10 mg FDC|
224237101|NCT01689480|OTHER|FSHD training|The training will consist in 3 sessions of 35 min of training per week at home on an ergocycle. The training will be divided in (i) 2 sessions of 30 min aerobic exercises at a constant but moderate (60% of maximal aerobic power, MAP) intensity followed with 5 sets of 10 revolutions at near-maximal intensity and (ii) an interval-training session. This latter session will consist in 5 min warm-up at 40% MAP followed by 5 times 1 min at 80% MAP (recovery = 4 min at 40% MAP) followed by 5 min of active recovery. A systematic supervision of the sessions by the coach will be performed by phone, by using the heart rate recordings and values of Analogic Visual Scale for pain and fatigue.
223653145|NCT06979700|DIAGNOSTIC_TEST|Optic Nerve Sheath Diameter|Measurements will be performed on comatose participants at 0-6 hours, 20-28, 44-52 and 66-72 hours after enrolment on both eyes using ultrasound and include the following: optic nerve sheath diameter of right and left side and mean optic nerve sheath diameter.
223653146|NCT06979700|DIAGNOSTIC_TEST|Continuous EEG and EEG Reactivity|"Continuous 4-channel EEG will be established on participants as soon as possible within 0-6 hours. EEG will be stopped at successful extubation or when 72 hours has passed since study inclusion.~EEG Reactivity will be performed on comatose participants at the following times: 0-6, 20-28, 44-52 and 66-72 hours after study inclusion. Reactivity includes 7 standardized stimuli, including 1 visual, 3 auditive and 3 pain stimuli.~EEG data will be reviewed in Stratus EEG Analysis (Kvikna Mediacal ehf. version 5.1). Timestamps for EEG-reactivity will be manually inserted in the file. EEG Reactivity will be analysed quantitatively by power spectrum analyses performed in LabVIEW 2016 (National Instruments) according to the principles of a previous method (PMID: 36041343). Background activity within 5 minutes following reactivity stimuli, prioritizing time periods without artifacts, will be analysed by power spectrum analyses, Mindray quantitative analysis and manually analyzed by experts."
223653147|NCT06479434|DRUG|Metformin|Females diagnosed with polycystic syndrome will be given metformin tablets for 8 weeks and followed up. Blood samples will be collected along with anthropometric data (weight (kg), height (m) etc)
223653148|NCT06290128|DRUG|Riliprubart|Pharmaceutical form: Solution Route of administration: IV Infusion
223653149|NCT06290128|DRUG|Placebo|Pharmaceutical form: Solution Route of administration: IV Infusion
223653150|NCT06290128|DRUG|Riliprubart|Pharmaceutical form: Solution Route of administration: SC Injection
223653151|NCT06290128|DRUG|Placebo|Pharmaceutical form: Solution Route of administration: SC Injection
223653152|NCT06669208|BIOLOGICAL|HydroVax-005 CHIKV|HydroVax-005 CHIKV vaccine
224237102|NCT01624519|PROCEDURE|Blood Lactate Analysis|When an arterial lactate is deemed to be necessary as part of ICU management, a central venous and peripheral venous sample will also obtained within 5 minutes. All of the samples will be analyzed using the same analyzer as quickly as possible.
224237103|NCT01474564|OTHER|Blood draw|Patients with pancreatic adenocarcinoma will be enrolled. Venous blood is collected in a standard 10 ml heparin blood collection tube. We may ask for blood samples at different times during the course of the study, specifically, before you start treatment and when your treatment changes. During the one year of the study, the physician anticipates blood samples will be collected a minimum of one and a maximum of four times. The amount of blood collected at any of these times will be 10 mL, about 1 tablespoon.
224237104|NCT01520051|DRUG|Mepolizumab|3 monthly intravenous infusions of 750 mg
224237105|NCT01520051|DRUG|Placebo|3 monthly intravenous infusions with saline
223653153|NCT06669208|OTHER|Placebo|NaCl 0.9%, Normal Saline
223767614|NCT07025759|DEVICE|Peripheral magnetic stimulation (110% of RMT + 25Hz)|High-frequency (25 Hz), above resting motor threshold intensity (110%) protocol delivering 2400 pulses.
224237106|NCT00003666|DRUG|6-hydroxymethylacylfulvene|11mg/sq m IV infusion over 5 min q day for 5 days each 28 day cycle
224237107|NCT00000866|BIOLOGICAL|MN rgp120/HIV-1|
224237108|NCT00000866|BIOLOGICAL|TBC-3B Vaccine|
224237109|NCT00762086|DEVICE|AngioPress Intermittent pneumatic compression (IPC) Device|Treatment with Intermittent pneumatic compression (IPC) for PAD
224237110|NCT00762086|OTHER|Medications and Standard walking exercises|Aspirin/Clopidegrol and Standard walking exercises
224237111|NCT04315857|OTHER|interstitial glycaemia|Continuous measurement of interstitial blood glucose during the first 15 days of the first two chemotherapy courses.
224237112|NCT03145714|DRUG|Maintainance of anesthesia with Intravenous Propofol infusion|The dosage of Intravenous Propofol will be titrated to maintain BIS Values between 40 -60.
224237113|NCT03145714|DRUG|Maintainance of anesthesia with Intravenous Dexmedetomidine|The dosage of Intravenous Dexmedetomidine will be titrated to maintain BIS Values between 40 -60.
224237114|NCT02596334|DRUG|dolutegravir 50mg +abacavir 600mg +lamivudine 300mg|
224237115|NCT02596334|DRUG|dolutegravir|
224237116|NCT06193395|OTHER|Questionnaire|No intervention, only clinical testing of questionnaire
223653154|NCT06608823|DEVICE|Transcatheter Aortic Valve Replacement (TAVR) using Trilogy THV System|Transcatheter Aortic Valve Replacement (TAVR) with Trilogy Device
223767615|NCT07023770|BEHAVIORAL|specific lateropulsion rehabilitation program (exoskeleton + specific physiotherapy orientation rehabilitation)|"5 times a week during 30 minutes sessions = 15 Physiotherapy sessions, focused on the active vertical body orientation in the frontal plane and comprising exoskeleton-assisted balance and gait exercises.~\+ 5 times a week during 30 minutes sessions = 15 conventional physiotherapy without exercises dedicated to lateropulsion or verticality representation alleviation The intervention description is more extensive in the study description section"
223767616|NCT07023770|BEHAVIORAL|Conventional physiotherapy without without exercises dedicated to lateropulsion or verticality representation alleviation|10 times a week, during 30-minutes
224237117|NCT03902171|DEVICE|Soberlink|Soberlink delivers real-time blood alcohol results to people who support individuals in recovery from alcohol use disorder. In-Home Addiction Treatment program Care Team monitors and responds to results as part of care to improve treatment outcomes.
224237118|NCT04308577|OTHER|Ketogenic diet with added MCT|The intervention is a ketogenic diet consisting of KetoCal 2,5:1 LQ MCT Multi Fibre (Nutricia), Liquigen (MCT)(Nutricia) and ketogenic meals provided by the hospital kitchen. The macronutrient composition of the ketogenic diet given approx.: Protein 11 E%, Carbohydrate 3 E%, Fat 86 E%.
224237119|NCT00000619|PROCEDURE|catheterization, Swan-Ganz|
224237120|NCT01215890|DRUG|risedronate|
224237121|NCT01215890|DRUG|placebo|
223653155|NCT06608823|DEVICE|SAVR|SAVR using commercially available surgical prosthetic valves.
223653156|NCT06862375|BEHAVIORAL|Mayo Clinic Diet|"Subjects will utilize their choice of the following resources for 12 weeks:~* Mayo Clinic Diet book, 3rd Edition~* Digital Wellness app subscription~* Both the Mayo Clinic Diet book and Digital Wellness app"
223653157|NCT06862375|BEHAVIORAL|Usual Care|Subjects will be given the 'Eat Well Use the Plate' informational hand-out, as well as a list of food, physical activity and weight tracking apps to be utilized as resources for self-monitoring .
223653158|NCT06231940|OTHER|Complex Decongestive Therapy (CDT) in venous insufficiency,|Complex Decongestive Therapy (CDT) is a comprehensive treatment approach primarily used for lymphedema and related conditions, but it's also beneficial for chronic venous insufficiency and other edematous conditions. CDT aims to reduce swelling and maintain the reduction, improve skin condition, and alleviate symptoms. It typically involves two phases: an intensive phase to reduce swelling as much as possible and a maintenance phase to sustain the achieved results. The main components of CDT include: Manual Lymph Drainage (MLD),Compression Therapy, Exercise, Skin Care, Education and Self-Care:
223653159|NCT06997081|DRUG|Lenalidomide|Participants will receive 25mg of Lenalidomide orally on Days 2-21 of Cycle 1, then 25 mg by mouth on Days 1-21 of the remaining cycles.
224237122|NCT02232100|BEHAVIORAL|Attentional bias modification training (AMG)|Attentional bias modification, administered via an internet-delivered visual-probe task that trains attention away from pain-related information
224237123|NCT02232100|BEHAVIORAL|Attentional bias placebo (ACG)|Attentional bias placebo, administered via an internet-delivered visual-probe task that does not train attention either away or towards pain-related information
224237124|NCT00526786|DEVICE|CryoSpray Ablation System (510(k) NO: K070893)|no drug interventions specified
224237125|NCT00845156|DIETARY_SUPPLEMENT|Alpha Lipoic Acid|Two 400 mg tablets of Alpha Lipic Acid are taken 3 times daily
224237126|NCT00710229|DRUG|Ranibizumab|intravitreal injection
224237127|NCT00710229|DRUG|Bevacizumab|intravitreal injection
224237128|NCT00388180|DRUG|GW501516|
224237129|NCT00388180|DRUG|GW590735|
224237130|NCT00394108|PROCEDURE|Determination of neuropsychological status|
224237131|NCT01189123|BIOLOGICAL|High dose influenza vaccine Sanofi-Pasteur|High dose influenza vaccine Sanofi-Pasteur at standard dosing intramuscular injection
224237132|NCT01189123|BIOLOGICAL|fluzone by sanofi pasteur|standard dose fluzone
224237133|NCT05801263|DIAGNOSTIC_TEST|CDO1 and HOXA9 methylation assay|CDO1 and HOXA9 methylation assay in plasma circulating tumor cells
223767617|NCT07023900|OTHER|Manual traction|The pacemaker or ICD lead extraction with manually.
224237134|NCT01076452|DEVICE|Bilateral Deep Brain Stimulation|The DBS site (STN or GPi) was assigned on a random basis at the time the patient enters the surgical phase of the trial.
224237135|NCT00860405|DRUG|HES 130/0.4 (6%) in sodium chloride (Voluven®, solution for infusion), Human serum albumin (HSA 50g/L)|Study medication will be given as part of the priming of the ECC and for plasma volume replacement after start of ECC up to the maximum dosage of 50 mL/kg body weight/day.
224237136|NCT00860405|DRUG|Human serum albumin (HSA 50g/L)|Human serum albumin (HSA 50g/L)
224237137|NCT04556214|PROCEDURE|Liver Transplant|Liver Transplant
224237138|NCT01900509|DRUG|Bendamustine|Route of administration: intravenously (IV) over approximately 60 minutes, days 1-5.
224237139|NCT01900509|DRUG|Clofarabine|Route of administration: IV days 1-5.
224237140|NCT01900509|DRUG|Etoposide|Route of administration: IV days 1-5.
224237141|NCT01900509|DRUG|Etoposide phosphate|Route of administration: Used in substitution for etoposide in participants who experience allergic reaction, Etopophos® will be administered IV.
224237142|NCT01900509|DRUG|Dexamethasone|Route of administration: three times daily orally (by mouth), days 1-5.
224237143|NCT03531021|BEHAVIORAL|Heart healthy intervention|Intervention consists of educational modules, goal setting and brainstorming around strategies and barriers, and a series of heart healthy challenges such as walking a certain number of steps or eating healthy foods a certain number of times in a week.
224237144|NCT05177627|OTHER|Theoretical and classroom learning interventions|"aim of intervention: introduce students to the conceptual framework of fundamental of care, focus on three dimensions necessary for the delivery of high-quality fundamental care (the nurse-patient relationship; addressing different fundamental needs; and a context that supports these goals)~components and activities:~* educational interventions to understand how the communication and the relationship of trust between nurse and patient are the prerequisites for high quality nursing care;~* drawing attention to five essential relational elements for establishing the nurse-patient relationship (Trust; Focus; Anticipate; Know; Evaluate)~mode of delivery:~* classroom lessons on philosophies and theories on communication and trust~* small-group learning on realistic cases focused on fundamental needs to develop reflexivity, analytical skills, investigation~duration of the intervention: 12 hours of theoretical and classroom learning"
224320846|NCT06087159|BEHAVIORAL|mHealth Toolkit for Wellness & Empowering Lives of School Community (mWEL)|mWEL-App is a preventive intervention tool for teachers and parents as a self-help support. It integrates three key mental health presentive service functions: i) comprehensive screen to assess mental health (anxiety, depression), stress, and related contextual risks; ii) a tailored strength and weakness profile/report with recommendations to promote self-awareness and mental health knowledge; and iii) tailored evidence-based strategies and additional support and clinical resources to improve skills in stress management, emotion regulation, and maintain mental wellness. mWEL will be designed as a self-administered tool. Participating parents and teachers can access to mWEL app after they sign up for an account. Intervention participants will have access to the App anytime within a 3-5 month study period.
224320847|NCT05456191|DRUG|Asciminib|Asciminib 80 mg QD administered under fasting conditions.
223653160|NCT06997081|DRUG|Dexamethasone|Participants will receive 20mg of Dexamethasone orally on Days 1, 3, 8, and 15 of Cycle 1, then 4mg orally on Days 1 and 15 of Cycles 4-6.
223653161|NCT06997081|DRUG|Elranatamab|Participants will receive 12mg Elranatamab subcutaneous (SC) on Cycle 1; 32mg subcutaneous (SC) on Cycle 1 Day 3; 76mg subcutaneous (SC) on Cycle 1 Day 8 and Day 15. Then, participants will receive 76mg subcutaneous (SC) on Days 1 and 15 of Cycles 2-6. Lastly, participants will receive Elranatamab subcutaneous (SC) on Day 1 of the remaining cycles.
223767618|NCT07024680|OTHER|Observational, None intervention|Observational, None intervention
223653162|NCT07000149|DRUG|Volrustomig|Volrustomig will be administered as an intravenous (IV) infusion.
223653163|NCT07000149|DRUG|Casdatifan|Casdatifan will be administered orally.
223653164|NCT07000149|DRUG|Nivolumab|Nivolumab will be administered as an IV infusion.
223653165|NCT07000149|DRUG|Ipilimumab|Ipilimumab will be administered as an IV infusion.
223653166|NCT07001423|PROCEDURE|Laparoscopic cholecystectomy|Laparoscopic cholecystectomy within 2 weeks after endoscopic removal of common bile duct stone
223653167|NCT06617858|DRUG|AMB-05X|Given by IV
223653168|NCT06149481|DRUG|Retifanlimab|500 mg infused via IV over 30 minutes every 28 days
223653169|NCT06149481|BIOLOGICAL|Therapeutic CEA, Brachyury and MUC1 TriAdeno Vaccine Platform|5x10\^11 virus particles per 1 mL administered via subcutaneous injection in the upper arm and anterolateral upper thigh on Day 1 of Cycles 1, 2, 3 and every 3 cycles after that
223653170|NCT06149481|DRUG|N-803|15 ug/kg administered via subcutaneous injection to the abdomen every 28 days
223653171|NCT06149481|DRUG|SX-682|100 mg administered orally twice per day on days 6-26 of every cycle
223653172|NCT06664879|DRUG|MBG-453 + Azacitidine|Given intravenously (by vein)
223767619|NCT07025057|BEHAVIORAL|Provider training|The study will address patient-provider interactions through actionable, experiential provider trainings focused on communication provider, cultural relevance, and awareness of and referrals to community care services including Community Health Workers (CHW) and home visiting, for both clinical and community settings. Trainings are rooted in both history and in current research about how to address maternal mortality disparities, and will include self-learning, didactics, reflection, discussion, and identifying ways to tailor trainees settings to better hear, respect, and meet the needs of perinatal Black and Hispanic women.
223767620|NCT07025655|BEHAVIORAL|Multifaceted Mindfulness Program|Ten-week mindfulness classes
223767621|NCT07025655|BEHAVIORAL|Placebo|Regular daily activity
224237145|NCT05177627|OTHER|Simulation interventions|"aim of intervention:~To develop active listening and use of non-verbal and verbal communication skills to establish a therapeutic relationship based on compassion, trust and respect; to apply the FoC conceptual framework, reflexivity and analytical skills to meet patient fundamental needs.~Students will express these goals during simulation activities with behaviours outlined by the FoC framework.~components and activities: - Implementation of communication simulation activities to develop interaction skills with patients; Implementation of simulation activities to apply the FoC conceptual framework and reflection to meet patient fundamental needs in realistic scenarios.~mode of delivery:~\- simulation activities on communication and trust Use ad hoc validated scenarios to apply the FoC conceptual framework to develop reflection and meet patient fundamental needs.~duration of the intervention: 25 hours"
224237146|NCT05177627|OTHER|Internship interventions|"Aim of intervention: to apply active listening and non-verbal communication skills; to use the FoC conceptual framework, reflexivity, and analytical skills to meet patient fundamental needs.~Students will express these goals during simulation activities with behaviours outlined by the FoC framework.~components and activities:~\- to establish effective and trusting communication with patients to demonstrate compassion and respect and to enable patients to remain calm, involved and dignified; to apply the FoC conceptual framework to meet patient fundamental needs.~mode of delivery:~* attendance of clinical internship~* analysis and reflections guided by the clinical preceptor on real cases using elements of FoC conceptual framework.~duration of the intervention: 150 hours of internship."
224237147|NCT02184130|OTHER|transcranial magnetic stimulation and motion stimuli|
224237148|NCT04284488|DRUG|APG-1387 for Injection|APG-1387 IV on Days 1 and 8 of each 21-Day Cycle. The following doses of APG-1387 to be studied: 20, 30, and 45mg. In the phase II, the assigned recommended phase two dose will be administered in all cohorts.
224237149|NCT04284488|DRUG|Toripalimab|240 mg toripalimab IV on Day 1 of each 21-Day Cycle
224237150|NCT06145815|PROCEDURE|Arthroscopic rotator cuff repair|Patients underwent an arthroscopic repair for rotator cuff lesions
224237151|NCT04338126|DRUG|Tranexamic acid|previously described
224237152|NCT04338126|DRUG|Placebo oral tablet|previously described
224237153|NCT02361047|BEHAVIORAL|Phone Coaching Program|Participants in this group will receive a 10-session nutrition and physical activity program delivered via phone by a health behavior coach to promote healthy lifestyle changes. Participants will also receive standard-of-care physician counseling regarding lifestyle recommendations to achieve/maintain a healthy weight trajectory after cancer treatment.
224237154|NCT04133376|OTHER|Electronic hookah vaping with nicotine|Participants will be invited to vape a 30-minute session of e-hookah containing nicotine
224237155|NCT04133376|OTHER|Electronic hookah vaping without nicotine|Participants will be invited to vape a 30-minute session of e-hookah without containing nicotine
224237156|NCT02707848|OTHER|No intervention|
224320848|NCT05456191|DRUG|Nilotinib|Nilotinib 300 mg BID administered under fasting conditions.
223653173|NCT07005154|DRUG|ASP5541|Intramuscular Injection
223653174|NCT07005154|DRUG|Prednisone|Oral
223653175|NCT07005154|DRUG|Prednisolone|Oral
223653176|NCT07005154|DRUG|abiraterone acetate|Oral
223653177|NCT05563051|DEVICE|i-ED COIL|The i-ED COIL System (i-ED COIL and detachment box) are intended for the endovascular embolization of intracranial aneurysms and other neurovascular abnormalities such as arteriovenous malformations and arteriovenous fistulae.
223653178|NCT06623422|BIOLOGICAL|Pembrolizumab|IV Infusion
223653179|NCT06623422|DRUG|Cisplatin|IV infusion
223767622|NCT07024238|DIETARY_SUPPLEMENT|SCFA|Participants randomized to this group will receive 1000 mg of sodium butyrate daily for 12 weeks. The intervention aims to evaluate the effect of high-dose SCFA supplementation on the gut microbiome and systemic/urinary metabolome in kidney transplant recipients.
223653180|NCT06623422|DRUG|Carboplatin|IV infusion
223653181|NCT06623422|DRUG|Pemetrexed|IV infusion
223653182|NCT06623422|DRUG|Gemcitabine|IV infusion
223653183|NCT06623422|DRUG|Paclitaxel|IV infusion
223653184|NCT06623422|BIOLOGICAL|Intismeran autogene|IM injection
223653185|NCT06623422|OTHER|Placebo|IM injection
223653186|NCT06628206|DRUG|LPX-TI641|Oral solution administered QD for 28 consecutive days
223653187|NCT06628206|DRUG|Placebo|Drug is LPX-TI641 oral solution. Placebo an identical oral solution without the LPX-TI641.
223653188|NCT06693674|DRUG|Entresto Pill|Patients will take a 24/26 mg dose orally, twice daily, for weeks 1 and 2, 49/51 mg orally, twice daily, for weeks 3 and 4, and 97/103 mg orally twice daily, for the remaining 48 weeks (total duration: 52 weeks).
224237157|NCT00946803|BEHAVIORAL|Patient-Controlled Cognitive-Behavioral Intervention|Selection of 12 recorded imagery- and non imagery-based cognitive-behavioral coping strategies provided on an MP3 player to be used at least once per day or more frequently, as needed for pain, fatigue, and sleep disturbance.
224237158|NCT03178500|DRUG|Clomiphene Citrate 50mg|stair-step clomiphene adminstration
224237159|NCT01743378|PROCEDURE|TAP Block Ropivacaine 0,75 %|
224237160|NCT01743378|PROCEDURE|TAP Block Saline 0,9 %|
224237161|NCT06497153|PROCEDURE|lung ultrasound|lung ultrasound repeated according to protocol during the stay in the paediatric intensive care unit
224237162|NCT01922648|PROCEDURE|Blood sample|An extra volume of blood is obtained, with prior consent, when phlebotomy is required for another unrelated clinical reason.
224237163|NCT01826123|DEVICE|Conventional laboratory testing (Central laboratory)|aPTT, INR, fibrinogen concentration, platelet count
224237164|NCT01826123|DEVICE|POC testing|ROTEM: Clotting time (CT) in the EXTEM- and INTEM-test, Maximal clot firmness in the FIBTEM-test, Clot Lysis Index (CLI) multiplate: Area under the aggregation curve following stimulation with arachidonic acid (ASA) and Adenosine diphosphate (ADP)
224237165|NCT01351688|DRUG|AZD3514|Patients will be given AZD3514 tablets or capsules administered orally as a single dose, and then multiple once-daily dosing following a 7 day washout.
224237166|NCT01509300|BIOLOGICAL|anti-thymocyte globulin|On days -10 to -9
224237167|NCT01509300|BIOLOGICAL|filgrastim|Beginning on day 4 and continuing until blood counts recover
224237168|NCT01509300|RADIATION|Total body irradiation|2Gy D-6 to D-4
224237169|NCT01509300|DRUG|Fludarabine|30mg/M2 once daily IV on days -8 to -4
224237170|NCT01509300|DRUG|cyclophosphamide|60 mg/kg IV on day-3 and -2
224237171|NCT01509300|DRUG|Tacrolimus|begin on 0
224237172|NCT01509300|DRUG|Mycophenolate mofetil|begin on 0
224237173|NCT01509300|DRUG|Rituximab|375mg/m2 on day +21
224237174|NCT02936856|DEVICE|Hepatic Arteriography|
223653189|NCT06693674|OTHER|Placebo|Patients taking placebo tablets will take 1 tablet orally, twice daily
223653190|NCT06629584|DRUG|Asciminib|Patients will receive asciminib 80 mg PO once daily continuously for 28-day cycles for 2 years.
224237175|NCT02293083|DRUG|trigger point injection|
224237176|NCT05711771|BEHAVIORAL|medication therapy management|Patients receive medication therapy management within the primary care office
224237177|NCT06295653|PROCEDURE|implant placement and soft tissue augmentation with Autogenous Subepithelial Connective Tissue Graft or Amniotic Chorion Membrane|assess the efficacy of the peri-implant mucosal thickness enhancement following either subepithelial connective tissue grafts or Amniotic Chorion Membrane placed simultaneously with dental implant placement.
224237178|NCT02550574|PROCEDURE|Wound Closure with 2-octylcyanoacrylate|
223653191|NCT06872892|DRUG|BI 1291583|BI 1291583
223653192|NCT06872892|DRUG|Placebo matching BI 1291583|Placebo matching BI 1291583
223653193|NCT05920109|PROCEDURE|ESP block|Patients in the experimental group will have a continuous Erector Spinae Plane Block within the first 6 hours post-admission, with a continuous 1ml/h infusion of Ropivacaine (2mg/ml) associated with a 25 ml bolus every 6h. The catheter will be used from the trauma bay to the ICU as long as possible with a dedicated infusion pump (with a bolus mode). In case of accidental catheter removal, a second introduction of ESP block catheter is allowed within the first 24 hours. In case of continuous ESP block failure (incidence \< 5% of the total experimental group), patients will be switched to the control group.
224237179|NCT02550574|PROCEDURE|Wound Closure with 5-0 Vicryl Sutures|
224237180|NCT00822874|PROCEDURE|prematuration culture|"The aneuploidy rate and the developmental potential of embryos obtained from PDE3 inhibitor-treated oocytes (a prolonged IVM (PMC)) in comparison to conventional IVM will be analysed. It is intended to assess the nuclear and cytogenetic constitution of the obtained embryos."
224237181|NCT01543880|DRUG|somatropin|Prescribed at the discretion of the treating physician according to product labelling
224237182|NCT02347501|DRUG|Sitagliptin (Januvia)|Sitagliptin 100mg tablet once daily (or 50mg once daily for participants with moderate kidney disease) for twenty four weeks in patients due to undergo NBUVB light therapy.
224237183|NCT01541280|DRUG|Azacitidine|Azacitidine (AZA) is to be administered every 28 days beginning day +56 to 100 posttransplant for one year provided the patients has a platelet count of \>15 x 109/L without transfusion for at least 2 successive days, and an absolute neutrophil count of \>1 x 109/L without growth factor for at least 2 successive days, and no acute GVHD greater than grade I and no clinical evidence of life-threatening infection. AZA is given 32 mg /m²/day subcutaneously for 5 days every 28 days (
224237184|NCT01541280|OTHER|DLI|"Donor lymphocyte infusion (DLI) is to be given from day +126 (week 18) in patients without immunosuppressive therapy for at least one month and following 3 cycles of AZA, and without clinical signs of GVHD, and without uncontrolled infection and without a recent history of \>grade 2 acute GVHD. DLI are schedules every 8 weeks. There are 3 DLI scheduled.~If first cycle of AZA is postponed beyond day 56 (maximum to Day 100), all subsequent cycles and DLI will be post poned too."
224237185|NCT02157220|DEVICE|Fixed bearing prosthesis|
224237186|NCT02157220|DEVICE|Mobile bearing prosthesis|
224237187|NCT00765648|DRUG|nicardipine intravenous|nicardipine intravenous 5 mg/hour titrated every 5 minutes by 2.5 mg/hour until target systolic blood pressure range (TSBPR) is reached or maximum dose of 15 mg/hour is achieved.Following achievement of target systolic blood pressure range the infusion rate should be decreased to 3 mg/hour
224237188|NCT00765648|DRUG|Labetalol|Labetalol: bolus therapy to start at 20 mg intravenous injection over 2 minutes, may repeat 20mg, 40mg or 80mg injections every 10 minutes until target systolic blood pressure range(TSBPR)is reached or a maximum of 300 mg is injected.
224237189|NCT03165968|DEVICE|Neuro Kinetics, Inc, i-PAS|This is a test of i-PAS device reliability only.
224320849|NCT06572228|DRUG|dupilumab|Administered by subcutaneous (SC) injection
224320850|NCT06572228|DRUG|Matching Placebo|Administered by SC injection
224320851|NCT06572228|DRUG|ICS/LABA|Administered at a blinded dose
224320852|NCT06145633|PROCEDURE|Biopsy Procedure|Undergo biopsy
224320853|NCT06145633|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
224237190|NCT02401386|BEHAVIORAL|The Eight Brocades|Patients received closely supervised, group-format EB program and practiced EB revised by Chinese Medicine Master Zhi-zheng Lu for one hour, twice weekly for 12 weeksmovements, a review of principles, and breathing techniques in EB. Participants will be asked to practice EB at home for at least 16 minutes each day which is how long it takes to complete an EB exercise, using an instructional Digital Video Disc. The program will be taught by experienced EB masters.
224237191|NCT04364568|RADIATION|Magnetic Resonance Imaging|IRM Sequences T1, T2, FLAIR, T2\*, Cerebral Blood Flow (CBF) et mean diffusivity (MD)
224237192|NCT03597334|BEHAVIORAL|aerosol therapy|Aerosol inhalation therapy refers to a local administration method in which a drug is made into aerosol particles having a very small diameter and is inhaled by a patient and the drug directly acts on the airway
224237193|NCT06192134|DEVICE|CPM device|CPM brace
224237194|NCT02931318|BEHAVIORAL|Nevsehir|The data of the study were collected with the questionnaire
224237195|NCT01370408|DRUG|Palonosetron|Prior to IV chemotherapy - ondansetron 8mg IV \& Dexamethasone 10 mg IV On the last day of chemotherapy - Palonosetron .25 mg IV, dexamethasone 10mg IV Day 1-2 after IV chemotherapy - Dexamethasone 8 mg PO
224237196|NCT01370408|DRUG|ondansetron|Prior to IV chemotherapy - ondansetron 8mg IV \& Dexamethasone 10 mg IV On the last day of chemotherapy - Palonosetron .25 mg IV, dexamethasone 10mg IV
224237197|NCT01370408|DRUG|Dexamethasone|Prior to IV chemotherapy - ondansetron 8mg IV \& Dexamethasone 10 mg IV On the last day of chemotherapy - Palonosetron .25 mg IV, dexamethasone 10mg IV
223653194|NCT07028125|DRUG|cabozantinib and nivolumab|"cabozantinib and nivolumab according to the labelling indication, namely:~* CABOZANTINIB 40 mg per oral route once daily~* NIVOLUMAB 240 mg per intravenous route every 2 weeks~During this combined treatment, the digital monitoring system is used to collect weekly data on treatment tolerance by patient self-report."
223653195|NCT07028749|DRUG|MAR001|Subcutaneous Injection
223653196|NCT07028749|DRUG|Placebo|Subcutaneous injection
223653197|NCT07029282|DIETARY_SUPPLEMENT|MMS|Pregnant women in this arm will receive 6gms of MMS (UNIMAPP MMS) in a ready to use sachet form which includes 15 nutrients.
223653198|NCT07029282|DRUG|MMS Plus|Pregnant women in this arm will receive 6gms of MMS Plus in a ready to use sachet form which includes 18 nutrients.
223653199|NCT07029282|DIETARY_SUPPLEMENT|IFA|Pregnant women in this arm will receive 6gms of IFA (Iron/Folic Acid) in a ready to use sachet form which includes 2 nutrients.
223653200|NCT07031817|DIAGNOSTIC_TEST|Venous blood sample for measuring blood biomarkers related to bipolar disorder|Participants will undergo a venous blood draw for analysis by an investigational composite medical device designed to aid in the diagnosis of bipolar disorder. The device analyzes specific circulating biomarkers hypothesized to differ between patients with bipolar disorder and those with unipolar depression.
223653201|NCT07031817|OTHER|Standardized psychiatric assessment tools|Participants will complete validated psychiatric screening tools used as reference standards to evaluate bipolar disorder, including the Mood Disorder Questionnaire (MDQ). These tools will be used to compare their diagnostic output with that of the investigational blood test.
223653202|NCT07035132|DIETARY_SUPPLEMENT|Oral supplementation with nutritional oligomeric formula|Patients will be supplemented with the specific oligomeric formula (1 or 2 bottles/day, as per investigator's decision) during, at least, the 12 weeks of the study follow-up.
223653203|NCT06704269|GENETIC|YTB323|CAR-T cell suspension for intravenous infusion
223653204|NCT06707688|DEVICE|Amulet™ 2 Left Atrial Appendage (LAA) Occluder|Patient will undergo the implantation of the Amulet™ 2 Left Atrial Appendage (LAA) Occluder
223653205|NCT07034924|DEVICE|Abdominal Aortic and Junctional Tourniquet - Stabilized (AAJT-S)|The AAJT-S is a non-invasive, externally applied medical device designed to achieve temporary occlusion of the abdominal aorta and inferior vena cava by inflating a pneumatic bladder to 250 mmHg. In this study, the device will be used as a temporizing measure for patients with severe postpartum hemorrhage unresponsive to standard uterotonics and balloon tamponade. The device will be applied horizontally over the upper abdomen and inflated using a built-in pressure gauge. The intended effect is to reduce pelvic blood flow and allow time for mobilization of surgical resources and blood transfusion. Maximum application time will not exceed 60 minutes, in accordance with established safety guidelines.
223653206|NCT07037459|DRUG|Maridebart cafraglutide|Maridebart cafraglutide will be administered SC.
223653207|NCT07037459|DRUG|Placebo|Placebo will be administered SC.
223653208|NCT07040566|DRUG|Varenicline 1mg BID|12 weeks following the standard titration of 1 mg, twice daily
223653209|NCT07040566|DRUG|Placebo|Matching placebo twice daily
223653210|NCT07042217|DEVICE|transcranial direct current stimulation (tDCS) and mindfulness instruction|tDCS together with audio providing mindfulness instruction and music
224237198|NCT01282606|DRUG|SI-6603|SI-6603 is administrated into the nucleus pulposus of an intervertebral disc.
223653211|NCT07042217|DEVICE|Sham tDCS and Mindfulness|Placebo electrical sitmulation and audio-guided mindfulness instruction
223653212|NCT03520660|DRUG|Epclusa|sofosbuvir/velapatasvir combination (Epclusa)
223653213|NCT06728553|DRUG|MTX101|One 2 mg sublingual tablet of MTX101
223653214|NCT06728553|DRUG|Placebo|One sublingual tablet of placebo
223653215|NCT07042347|BEHAVIORAL|Behavioral economics strategies|Behavioral economics features designed to increase motivation to collect data and ease of data collection on the electronic platform.
223653216|NCT07042347|DEVICE|Electronic platform|Electronic platform to collect data
223767623|NCT07024238|DIETARY_SUPPLEMENT|Placebo|Participants in this group will receive placebo capsules (sacharosis) identical in appearance to the active SCFA capsules, administered twice daily for 12 weeks. This arm serves as a control to evaluate the specific effects of SCFA supplementation.
224237199|NCT06021821|OTHER|SoundMind App|he SoundMind application uses binaural beats to encourage relaxation, focus, and alertness.
224237200|NCT06021821|OTHER|Spotify Playlist|"Participants will listen to a calm vibes playlist by Spotify."
224237201|NCT00605709|DRUG|API 31510 Topical Cream|Topical treatments to lesion twice daily of randomized treatments.
224237202|NCT02958709|DRUG|High-dose: RIF, INH, PZA, EMB|high-dose rifampicin plus standard dose H,Z,E, given for 8 weeks in treatment Arms 1 and 2
224320854|NCT06145633|PROCEDURE|Bone Scan|Undergo bone scan
223653221|NCT06733922|DEVICE|ETNATM-ProgMS|To that end, the study will use the patented investigational ETNATM-ProgMS SaMD (v1.0.11 or later), which has not yet received Health Canada approval, to reliably and accurately track eye movements with precision. Of note, investigational versions of this SaMD are used for the purpose of clinical research only and will not be commercialized.
223653222|NCT06778382|COMBINATION_PRODUCT|Oligometastasis Treatment|"Oligometastatic Radiotherapy Group: Patients will receive radiotherapy to lung lesions, with the lung metastases outlined as the Gross Tumor Volume (GTV). The prescribed dose will be based on a BED (Biologically Effective Dose) of 72-100 Gy, using either conventional split, macrodissected, or SBRT (Stereotactic Body Radiation Therapy) at the investigator's discretion. No systemic therapy will be administered.~Oligometastatic Radiofrequency Ablation Group: For lesions suitable for radiofrequency ablation, this will be performed in consultation with the Department of Interventional Medicine, considering patient and family preferences. Systemic therapy will not be given.~Oligometastatic Surgery Group: For lesions suitable for surgical resection, patients will undergo surgery after consultation with the Department of Surgery. No systemic therapy will be performed."
223653223|NCT03568461|BIOLOGICAL|tisagenlecleucel|Tisagenlecleucel is single infusion.
223653224|NCT06760546|DRUG|Setmelanotide|Solution for daily subcutaneous injection
223653225|NCT06760546|DRUG|Placebo|Placebo matched to setmelanotide for daily subcutaneous injection
223653226|NCT06738420|DIETARY_SUPPLEMENT|ABB S3|Postbiotic ABB S3 for suspension into Nutritional supplementation with Medical Nutrition Formula for the management of gastrointestinal symptoms secondary to enteral nutrition
223653227|NCT06738420|DIETARY_SUPPLEMENT|ABB C22|Oral Rehydration Solution containing postbiotics ABB C22 for the management of diarrhoea signs of dehydration
223653228|NCT06738420|DIETARY_SUPPLEMENT|Placebo|Placebo for suspension into Nutritional supplementation with Medical Nutrition Formula for the management of gastrointestinal symptoms secondary to enteral nutrition
223653229|NCT06738420|DIETARY_SUPPLEMENT|Placebo|Oral Rehydration Solution containing placebo for the management of diarrhoea signs of dehydration
223653230|NCT06736795|OTHER|Exercise|All participants will be instructed in a progressive Achilles tendon loading exercise program.
223653231|NCT06736795|OTHER|Education|All participants will receive education on Achilles tendinopathy terminology, common symptoms, diagnosis, expected recovery timeline, importance of physical activity, self-management strategies, multiple factors influencing pain, alternative and adjunct treatment options.
223653232|NCT06743373|BEHAVIORAL|Cannabis Discontinuation|Cannabis-using participants will participate in an orientation session with a clinician and asked to abstain from cannabis use for four weeks, using established procedures for abstinence monitoring and reinforcement.
223653233|NCT06894043|OTHER|Adapted Physical Activity (APA)|The APA intervention will consist of a 2-week running-in period, followed by a period of adapted physical activity (APA) for 8 weeks.
223653234|NCT06894043|BEHAVIORAL|Compensatory Nutrition (NC)|The Compensatory Nutrition (NC) intervention will consist of a 2-week running-in period, followed by a period of compensated nutrition (NC) for 8 weeks.
223653235|NCT07051304|OTHER|numerical rating scale|"The Numerical Rating Scale (NRS) is a standardized, self-reported pain assessment tool in which patients are asked to rate their pain intensity on a scale from 0 to 10.~0 represents no pain~10 represents the worst pain imaginable"
223653236|NCT07051304|OTHER|Video-Based Pain Expression Scenarios|"This novel pain assessment method involves showing postoperative patients a set of pre-recorded video scenarios that visually represent different levels of pain intensity. The videos are 8 seconds long and were created using AI-generated scripts and VEO-3 software. Each scenario corresponds to a specific Numerical Rating Scale (NRS) range (1-2, 3-4, 5-6, 7-8, 9-10) and is portrayed by actors matched to the patient's age group and gender (18-44, 45-65, \>65 years; male and female versions available).~Participants are asked to watch the full video set and select the one that best represents their current postoperative pain experience. This intervention is designed to offer a visual and contextual method of pain expression, particularly beneficial for patients who have difficulty understanding or using abstract numerical scales."
223653237|NCT07052630|OTHER|Internet-Based Intervention|Interact with PACT website
223653238|NCT07052630|BEHAVIORAL|Patient Navigation|Receive a patient navigation session
223653239|NCT07052630|OTHER|Best Practice|Receive standard/usual care
223653240|NCT07052630|OTHER|Survey Administration|Ancillary studies
224237203|NCT02958709|DRUG|High dose: RIF, INH, PZA, LEVO|high-dose rifampicin plus standard dose H,Z, with levofloxacin substituted for ethambutol for 8 weeks in treatment Arm 2
223653243|NCT06797635|BIOLOGICAL|Patritumab deruxtecan|Administered via IV infusion as neoadjuvant treatment
223653244|NCT06797635|BIOLOGICAL|Pembrolizumab|Administered via IV infusion as neoadjuvant treatment in Part 1 and via IV infusion as neoadjuvant and adjuvant treatment in Part 2
223653245|NCT06797635|DRUG|Paclitaxel|Administered via IV infusion as neoadjuvant treatment
223653246|NCT06797635|DRUG|Carboplatin|Administered via IV infusion as neoadjuvant treatment
223653247|NCT06797635|DRUG|Doxorubicin hydrochloride|Administered via IV infusion as neoadjuvant treatment in Arm C and an option for adjuvant treatment for participants with residual disease in Arms A and B in Part 2
223653248|NCT06797635|DRUG|Epirubicin hydrochloride|Administered via IV infusion as neoadjuvant treatment in Arm C and an option for adjuvant treatment for participants with residual disease in Arms A and B in Part 2
223767624|NCT07024446|OTHER|The time interval between PCI and NCS|Using 6 weeks post-PCI as the demarcation point, patients within 6 weeks were assigned to the observation group, while those beyond 6 weeks formed the control group.
224237204|NCT02958709|DRUG|Standard of care: RIF, INH, PZA, EMB|standard doses of R,H,Z,E given for 8 weeks in treatment Arm 3, control arm.
224237205|NCT02285738|DRUG|Aspirin|81mg/day for 4 weeks
224237206|NCT02285738|DRUG|Simvastatin|Daily dose of Simvastatin for 4 weeks
224237207|NCT02285738|OTHER|Observation|participants will be observed for thrombotic evens for 4 weeks
224320855|NCT06145633|PROCEDURE|Computed Tomography|Undergo CT, PET/CT, SPECT/CT
224320856|NCT06145633|OTHER|Fludeoxyglucose F-18|Undergo FDG PET/CT
223653249|NCT06797635|DRUG|Cyclophosphamide|Administered via IV infusion as neoadjuvant treatment in Arm C and an option for adjuvant treatment for participants with residual disease in Arms A and B in Part 2
223653250|NCT06797635|DRUG|Capecitabine|Administered via oral tablets as an option for adjuvant treatment for participants with residual disease in Part 2
223653251|NCT06797635|DRUG|Olaparib|Administered via oral tablets as an option for adjuvant treatment for participants with germline BRCA mutations and residual disease in Part 2
223653252|NCT06566742|DRUG|Olutasidenib|Given by PO
223653253|NCT05155332|DRUG|BI 1831169|BI 1831169
223653254|NCT05155332|DRUG|anti-PD-1 antibody|anti-PD-1 antibody
223653255|NCT04111627|BEHAVIORAL|Aerobic exercise|Participants with symptomatic knee osteoarthritis and depressive symptoms will be enrolled in a progressive walking program designed to reduce pain and disability and improve psychosocial health.
223653256|NCT04111627|DRUG|Duloxetine|Duloxetine is an FDA-approved selective serotonin and norepinephrine reuptake inhibitor antidepressant approved for the treatment of neuropathic pain in symptomatic knee osteoarthritis as well as depression in adults. Participants with symptomatic knee osteoarthritis and depressive symptoms will receive duloxetine to decrease pain and depression severity to enhance their ability to engage in aerobic exercise.
223653257|NCT06868316|OTHER|Walking|"Weeks 1-2, Sessions 1-4: The first condition will be walking with the speed self-selected based on a comfortable pace to walk for exercise as determined during the Baseline testing session. This speed will be held constant for the 10-minute walking portion prior to each condition but will be progressed for the remaining walking condition sessions (Sessions 2-4). The minimum speed will be limited to 1 mph."
223653258|NCT06868316|OTHER|Rucking|"Weeks 3-4, Session 5-8: The second condition will require participants to wear a standard rucksack equal to 20% of their body weight (minimum ruck weight: 15 pounds, maximum ruck weight: 45 pounds). The initial speed used during this condition will be self-selected based on a comfortable pace to walk for exercise carrying this weight as determined during the Baseline testing session."
223653259|NCT06868316|OTHER|Running|"Weeks 5-6, Sessions 9-12: The final condition is running. The self-selected running pace will be chosen as a pace that the participant can sustain for a leisure run for 20 minutes, as determined at the Baseline testing session. Participants will only run for the 15-minute condition period."
224237208|NCT01909076|BEHAVIORAL|Electronic decision support tools|"Electronic decision support tools available to both control and intervention PCPs include patient pain assessments, (Brief Pain Inventory, Pain/Enjoyment/General Function PEG), substance abuse (DAST, AUDIT) depression (PHQ9), PTSD (PTSD ChecklistCivilian), and risk of prescription drug misuse (SOAPP and COMM). The tools calculate scores with recommendation for specific action for each tool, when appropriate."
223653260|NCT06700356|DEVICE|Phase 1-Validation of thalamus seizure detection with concurrent video EEG monitoring|Epilepsy monitoring unit evaluation will follow standard of care practices for seizure characterization, and antiseizure medications may be reduced to facilitate the recording of seizures. Patient clinical management, and video-EEG interpretation will be completed by the clinical epilepsy monitoring unit team which consists of physicians, nurse practitioners, registered nurses, and in-house 24-hour 7-days-per-week EEG technicians. Continuous full-bandwidth thalamus recordings (250 Hz) will be acquired by the research study team using a standard clinician programmer and telemetry module. Hospital monitoring will last up to 4 days.
223653261|NCT06700356|DEVICE|Phase 2-DBS Stimulation with Medtronic Percept DBS device-Out Patient|Patients will then transition to the ambulatory phase. In the outpatient setting, patients will have constrained ambulatory thalamus recordings using recording parameters determined by Phase 1. DBS treatment stimulation will be programmed in the clinical epilepsy neuromodulation lab using typical high frequency (\>50 Hz) stimulation. High frequency stimulation is the conventional approach to DBS for epilepsy, as was used in the pivotal study leading to premarket approval (SANTE study)2 of anterior nucleus of the thalamus (ANT) DBS for focal epilepsy, which is typical for epilepsy DBS practice3, and several studies of DBS for generalized epilepsy4-6, in a sensing friendly electrode configuration. Patients will keep a detailed seizure diary. Ambulatory thalamus recordings by the DBS system and patient reported seizure diaries will be collected during routine clinical DBS programming visits (q3-9 months).
223653262|NCT05592938|RADIATION|rPBI|External beam partial breast reirradiation (rPBI) using 26Gy in 5 fractions delivered daily over 1-week
223653263|NCT06492291|DRUG|Enlicitide Decanoate|Oral tablet
224237209|NCT01909076|BEHAVIORAL|Enhanced patient education materials|Patient education materials will be developed and made available to both control and intervention patients. The investigators will design the materials for patients with low literacy, using pictures and simple graphics to augment written language. The research staff will make PDFs of the materials available on the study website during and after the project.
224237210|NCT01909076|BEHAVIORAL|Nurse care management|The nurse/care management intervention will be modeled on BMC's successful collaborative care office-based opioid treatment (OBOT) program. One fulltime nurse care manager will work with PCPs assigned to the intervention condition. The care manager will be based centrally, in the Section of General Internal Medicine, and will divide his/her time between the 3 health centers. The main focus of the nurse care manager is to assure that patients are receiving guideline-adherent care, which involves appropriate clinical assessments, opioid treatment agreements, refill management, administering monitoring tools according to risk level (urine toxicology screen, pill counts, PMP data extraction) and timely physician visits to assess pain (minimum every 6 months).
224237211|NCT01909076|BEHAVIORAL|Electronic Patient Registry|The registry will be a freestanding centralized disease management application and built using standard database technology. This system will communicate with the electronic medical record (EMR) at each community health center and with the Massachusetts State Prescription Monitoring Program (PMP) system. Data that will feed into the registry include clinical data recorded from the EMR (documentation from other clinicians and labs), data from clinical users entered into the registry via pain and opioid management forms, and the PMP. The nurse care manager will use a custom registry interface to monitor key practice activities across the entire practice at each site. The nurse care manager will use population management tools to provide aggregate measures for quality monitoring and workforce management. All quality metrics can be downloaded in aggregate form for further analysis.
224320857|NCT06145633|OTHER|Gallium Ga 68 Gozetotide|Given IV
224320858|NCT06145633|DRUG|Lutetium Lu 177 Vipivotide Tetraxetan|Given 177Lu-PSMA-617
224320859|NCT06145633|PROCEDURE|Positron Emission Tomography|Undergo 68Ga-PSMA-11 PET
224237212|NCT01909076|BEHAVIORAL|Academic detailing|All PCPs in the intervention group will receive one 30 minute individual visit 23 months after project implementation at the PCP's practice site. The visits will be conducted with at least one of the study experts in pain medication management. Visit content will combine elements of audit and feedback (e.g. review registry of individual PCP compared with that of peers and goals) as well as traditional educational outreach. Specifically, experts will review each aspect of guideline concordant care (assessment of risk and appropriateness for opioid medication, medication dosing, monitoring for harm/adherence, and pain outcomes) to solicit barriers to implementation or lack of knowledge on the underlying evidence for each aspect of care. The experts will work with the individual PCPs to address barriers identified using motivational interviewing as needed to facilitate behavioral change in applying guideline concordant care.
224237213|NCT04963491|DEVICE|Personalized TKA prosthesis|TKA prosthesis that is designed and manufactured according to the patient's knee joint anatomy
224237214|NCT04963491|DEVICE|Zimmer NexGen prostheses|Commercial products used on a large scale
224237215|NCT05546359|DRUG|Amisulpride Injection|Dose finding treatment for continuation to phase 3
224237216|NCT05546359|DRUG|Dexamethasone|Standard of care treatment
224237217|NCT04448223|DRUG|CKD-351|Latanoprost (25ug/ml), Dorzolamide (20mg/ml), twice a day
223767625|NCT07024069|OTHER|Tongue ultrasound via submental approach|"Descriptive and anthropometric data will be recorded for each participant, including age, sex, weight (kg), height (m), neck circumferences (cm). Body mass index (expressed in kg/m2) will be calculated.~Submental ultrasound (US) images of the tongue will be performed on a patient lying supine, using a 5-15 MHz convex transducer. The parameters will be identical for all subjects and set at a depth of 9 cm, a focus of 4 cm and a gain of 45%. Each measurement will be taken thrice by a trained operator; the mean and standard deviation being used for analysis."
223767626|NCT07023926|DEVICE|electroacupuncture|The supine position, the local skin of the acupoints was routinely sterilized, and the selected acupoints were pasted with Acupuncture auxiliary device. The main acupuncture points are DU20, bilateral EX-HN5, ST8, GB20, GB20, LI4, LR3, ST40. Select compatible acupoints based on the patient's accompanying symptoms: 1.Discomfort in the neck: EX-B2 of Cervical 3-4; 2.Emotional anxiety, depression or sleep disorders: GV29, HT7; 3.Stomach or abdominal discomfort: CV12, ST25 and CV6. The disposable acupuncture needles and the electronic acupuncture treatment instrument SDZ-V nerve and muscle intimulator both manufactured by Suzhou Medical Appliance Factory Co., Ltd., China.The specifications of acupuncture needles are Φ0.30×25mm, Φ0.30×40mm. The needles will be inserted into the skin of acupuncture points and manipulated manually by using the techniques such as lifting, thrusting, and twirling, until the internal compound sensation known as deqi.
224237218|NCT04448223|DRUG|Latanoprost+Dorzolmamide|Latanoprost(50ug/ml) , once a day Dorzolmamide(20mg/ml), threetimes a day
224237219|NCT04283084|DEVICE|Virtual Reality Based Balance and Coordination Exercises|With the developed virtual reality based balance and coordination training system, balance and coordination exercises will be applied twice a week (12 sessions in total) for 6 weeks.
223653270|NCT05109234|DRUG|Brivaracetam Film-coated tablet|"* Pharmaceutical form: Film-coated tablet~* Route of administration: Oral use~Brivaracetam film-coated tablet \[10, 25 or 50 mg\] will be administered twice per day in equal doses."
223653271|NCT05109234|DRUG|Brivaracetam oral solution|"* Pharmaceutical form: Oral solution~* Route of administration: Oral use~Brivaracetam oral solution \[10 mg/mL\]) will be administered twice per day in equal doses."
224237220|NCT05586009|DRUG|cisplatin with hydration magnesium|Optimal doses of magnesium in prevention cisplatin induced nephrotoxicity
224237221|NCT01062256|DRUG|Placebo|One placebo tablet administered orally as a single dose
223653272|NCT06841055|DRUG|Pumitamig|Intravenous infusion
224237222|NCT01062256|DRUG|Guaifenesin|One 400 mg immediate release tablet administered orally as a single dose
224237223|NCT01062256|OTHER|Buckwheat Honey|10 mL administered orally as a single dose
224237224|NCT03246100|BEHAVIORAL|Reminders|Reminders are sent either through autodial or postcards reminding patients to get flu vaccine.
224237225|NCT03049488|BIOLOGICAL|VRC-RSVRGP084-00-VP|VRC-RSVRGP084-00-VP is an investigational respiratory syncytial virus (RSV) vaccine.
224237226|NCT03049488|OTHER|Aluminum Hydroxide Suspension|Aluminum Hydroxide Suspension, alum, is an adjuvant.
224237227|NCT03157856|OTHER|Fluorescence assessment|All subjects of the study are going to have a radical prostatectomy. The FEMTO-ST medical device is used on 3 fresh biopsies (2 healthy and 1 malignant) which will be prelevated from the resected prostate in order to determine the prostatic or non-prostatic nature of tissue.
224237228|NCT04004312|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|Shorter radiation therapy means that a higher dose will be offered. To limit side effects of exposure to a high dose, a medical device protecting the rectum will be used. The medical device to be used is called SpaceOAR hydrogel (device). The SpaceOAR hydrogel creates space between the rectum and the prostate, making it much less likely that the rectum is exposed to radiation. It is injected into place prior to the start of radiation treatment using a needle. Patients may be awake or asleep under local anesthesia for the procedure. SpaceOAR hydrogel is not painful, it remains stable during radiation therapy and then is gradually absorbed by the body over the course of approximately six months, once radiation therapy has been completed.
223653273|NCT06841055|DRUG|Docetaxel|Intravenous infusion
223653274|NCT06814145|BIOLOGICAL|Sotatercept|subcutaneous injection
223653275|NCT06872645|DRUG|5% Dextrose/Water|Patients will be randomized to undergo up to two-hour dwell with 5% dextrose in sterile water for 5 days
223653276|NCT06872645|DRUG|1.5% standard PD fluid|Patients will be randomized to undergo up to two-hour dwell with 1.5% standard PD fluid for 5 days
223653277|NCT04548752|PROCEDURE|Biopsy Procedure|Undergo tumor biopsy
223653278|NCT04548752|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223653279|NCT04548752|PROCEDURE|Computed Tomography|Undergo CT scan
223653280|NCT04548752|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223653281|NCT04548752|DRUG|Olaparib|Given PO
223653282|NCT04548752|BIOLOGICAL|Pembrolizumab|Given IV
223653283|NCT00001230|DRUG|Diethylcarbamazine|Diethylcarbamazine is a drug administered under an IND held by the CDC. Standard dosing is used.
223653284|NCT04826341|DRUG|Berzosertib|Berzosertib will be supplied as 20 mg/mL M6620 to be diluted with 5% dextrose in water solution before intravenous infusion.
223653285|NCT04826341|DRUG|Sacituzumab Govitecan|Sacituzumab Govitecan will be administered as an intravenous infusion once weekly on Days 1 and 8 of 21-day treatment cycles.
223653286|NCT01306019|BIOLOGICAL|Ex vivo culture and transduction of the patient's autologous CD34+ HSC with lentivirus vector VSV-G pseudotyped CL20- 4i-EF1alpha-hgammac-OPT vector|Transduced cell product administered intravenously over approximately 30 minutes by authorized licensed personnel consistent with NIH Clinical Center Department of Transfusion Medicine's standard operating procedures for cellular products.
223653287|NCT01306019|DRUG|Busulfan|3mg/kg per day with drug levels obtained on Day -3. Busulfan dose on day -2 will be adjusted (if busulfan AUC result is available) to achieve targeted busulfan AUC 4500 min\*umol/L/day. If the result is not available in time to adjust, then proceed to give the standard 3mg/kg on the second day
223653288|NCT01306019|DRUG|Palifermin|Mucositis prophylaxis commenced- Infusion of keratinocyte growth factor (palifermin) at 60 mcg/kg/day before (Days -6 to Day -4) administration of busulfan and (Days +1 to +3) post-busulfan administration
223653289|NCT07069361|BEHAVIORAL|Mindfulness-Based Cognitive Therapy - Life Course Adaptation (MBCT-L)|MBCT-L (Mindfulness-Based Cognitive Therapy for Life) Is a structered, group-based intervention developed for use with healthy adults. The programs runs for 8 consecutive weeks, with sessions lasting 2 hours and 15 minutes. It includes formal and informal mindfulness practices, exercises to develop cognitive and emotion awareness, with elements adapted from cognitive therapy. The course was designed to support participants in cultivating habits that increase emotion regulation and psychological well-being. Home practice is assigned daily using audio-guided meditations. The intervention is standardized and delivered by a instructor trained under Oxford Mindfulness Centre (OMC) protocols. MBCT-L is distinct from the clinical MBCT model used for relapse prevention. And it is also disting from other Mindfulness-Based interventions as it uses different exercises than, for example, Mindfulness-Based Stress Reduction which emphasis stress theories in the intervention.
223653290|NCT06855524|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223653291|NCT06855524|DIETARY_SUPPLEMENT|Oligo-fucoidan|Given PO
223653292|NCT06855524|DRUG|Placebo Administration|Given PO
223653293|NCT06855524|OTHER|Questionnaire Administration|Ancillary studies
224237229|NCT03027830|DEVICE|iFR pressure-wire|The instantaneous wave-free ratio (iFR) as an adenosine-independent index of coronary stenosis severity, calculated as the ratio between the distal trans-stenotic pressure and the proximal coronary pressure during a specific diastolic wave-free period
223653294|NCT05723380|PROCEDURE|Erector spinae plane block|T2 ESPB group where ESPB is performed at T2 with local anesthetics 20ml
223653295|NCT07066254|DEVICE|Mepilex Ag Dressing|A silver-impregnated antimicrobial foam dressing (Mepilex Ag) will be placed over the cesarean incision immediately following skin closure in the operating room. Participants assigned to this intervention will be instructed to leave the dressing in place for 7 days, in accordance with manufacturer guidelines, unless earlier removal is necessary due to dressing saturation, displacement, or clinical concern. Mepilex Ag is FDA-cleared for use as a wound dressing and is designed to maintain a moist wound environment while providing sustained antimicrobial protection to help reduce the risk of surgical site infection.
223767627|NCT07023926|DEVICE|Sham electroacupuncture|"The SEA group will use Hua Tuo brand disposable blunt-tip sham needles (Φ0.3mm×25mm) and the electronic acupuncture treatment instrument SDZ-V nerve and muscle intimulator both manufactured by Suzhou Medical Appliance Factory Co., Ltd., China. Sham points 1-2, 3-4, 5-6, and 7-8 are bilaterally located at the midpoints between the following pairs of acupoints: SP19 and EX-UE12, SP6 and LR5, EX-UE1 and HT1, and HT7 and SI8. sham LI4: Bilateral of midpoint between acupoint LI4 and LU9; sham LR3: Bilateral of midpoint between acupoint LR3 and ST44; sham ST40: Bilateral of midpoint between acupoint ST40 and GB35. Compatible acupoints: EX-B2 of Cervical 3-4 horizontal side by 0.5 cun; sham GV29: midpoint between acupoint GV29 and BL2. sham CV12: midpoint between acupoint CV12 and ST21; sham ST25: Bilateral of midpoint between acupoint ST25 and SP15; sham CV6: 3 cun lateral to the level of the CV6; The width of the interphalangeal joint of the patient's thumb was 1 cun."
223767628|NCT07024537|DRUG|FOLFOXIRI-HAIP+Fuquinitinib|All patients received oral fruquintinib at an initial dose of 4 mg once daily from day 1 to day 21 of each 28-day cycle, and FOLFOXIRI-HAIP chemotherapy with Oxaliplatin 85 mg/m² and Leucovorin 400 mg/m² infused via arterial pump over 2 hours on day 1, Irinotecan 150 mg/m² infused via arterial pump over 90 minutes on day 1,and 5-Fluorouracil 2400 mg/m² infused via arterial pump over 46 hours, repeated biweekly until disease progression, patient's refusal, unacceptable toxic effects, or withdrawal of consent.
224237230|NCT03027830|DEVICE|Conventional|Other diagnostic devices (including FFR and angiography)
224237231|NCT03967730|COMBINATION_PRODUCT|Sonodynamic therapy(SDT)|Sonodynamic Therapy (SDT) Sinoporphyrin Sodium (DVDMS) as sonosensitizer, is dissolved in 0.9% sodium solution for following skin test and intravenous injection. 0.01mg/ml DVDMS solution (0.1ml) is prepared for skin test followed by 0.04 mg/ml DVDMS solution intravenous injection(0.2mg/kg).The target atherosclerotic lesions are marked on the corresponding skin with ultrasound guidance and underwent ultrasound exposure after 4 hours incubation. The therapeutic ultrasonic transducer is fixed to the marked skin site for 15 min of each lesion. Ultrasound parameters included intensity of 2.1W/cm2 for each lesion, resonance frequency: 1.0 MHz and duty factor: 30%.
224237232|NCT01028469|DEVICE|Artelon MTP Spacer|Metatarsophalangeal hemi-implant
224237233|NCT02067364|DEVICE|Fit & Function test|
224237234|NCT01666470|OTHER|Questionnaires|DrHy-Q (Thai version) and WHOQOL-BREF-THAI will be asked
224237235|NCT00891293|DRUG|Antara (fenofibrate) + Lovaza (omega-3-acid ethyl esters)|Open-label Antara (fenofibrate) + open-label Lovaza (omega-3-acid ethyl esters) \[formerly known as Omacor\]
224237236|NCT01271530|OTHER|Upper Limb Ergometry|Cardiovascular training will be performed using upper limb ergometers at home for 8 weeks. Each subject will receive an individually prescribed programme and will begin exercising for at least ten minutes per day three days per week. If an individual has difficulty exercising for 10 minutes continuously, the 10 minute session may be broken into 2-3 minute bursts of exercise, with one minute rests. Subjects will aim to increase exercise durations to 20 minutes per day five days per week and will exercise at moderate to high intensities.
224237237|NCT00500474|PROCEDURE|endolymphatic sac drainage with steroids|
224237238|NCT01815073|BIOLOGICAL|Live Attenuated Varicella Vaccine + Live Attenuated JE Vaccine|
224237239|NCT01815073|BIOLOGICAL|Live Attenuated Varicella Vaccine|
224237240|NCT01815073|BIOLOGICAL|live attenuated JE vaccine|
223653296|NCT07066254|DEVICE|Standard Surgical Dressing (Telfa non-adhesive dressing, gauze, and Primapore adhesive bandage)|A standard postoperative dressing consisting of a sterile Telfa non-adhesive pad placed over the cesarean incision, covered with gauze, and secured with a Primapore adhesive bandage. The dressing is applied immediately following skin closure in the operating room as part of routine institutional care. It is typically removed within 24 to 48 hours postoperatively, depending on wound condition and provider discretion.
223653297|NCT07073547|BIOLOGICAL|AZD0120|AZD0120 is a BCMA/CD19 dual CAR T cell product under investigation for early-line treatment in subjects with multiple myeloma
223653298|NCT06899594|DRUG|Psilocybin 25 mg|25 mg administered orally (capsules)
223653299|NCT06782373|DRUG|Pacritinib|Supplied in hard capsules.
223653300|NCT06782373|DRUG|Placebo|Supplied in hard capsules.
223653301|NCT06780137|BIOLOGICAL|Gocatamig|IV infusion
223653302|NCT06780137|BIOLOGICAL|Ifinatamab Deruxtecan (I-DXd)|IV infusion
223653303|NCT06780137|BIOLOGICAL|Durvalumab|IV infusion
223653304|NCT00001168|BEHAVIORAL|Balanced diet|Dietary studies for the diagnosis of post-prandial hyperlipidemia will include a 3 week period while subjects are on a baseline, isoweight, 15% fat, 42% carbohydrate, normal polyunsaturated fat ratio (0.1-0.3) 250-300 mg cholesterol diet.
223653305|NCT06828939|DEVICE|pulsed field ablation|Pulsed field ablation using a ultra-compliant endoscopic PFA balloon.
223653306|NCT00001452|DRUG|oCRH|
223653307|NCT06217666|DRUG|PCX-12|treatment combining radiation therapy with PCX12
223653308|NCT06656936|BEHAVIORAL|PharmFIT|The PharmFIT intervention involves the following components: referral notice to patient, FIT ready notification, FIT ready reminders, FIT distribution, FIT completion reminders, negative and positive results notification, patient navigation support.
223653309|NCT06129916|DRUG|long-acting depot buprenorphine (LADB)|The intervention will measure patient-centered outcomes in people initiating LADB among a cohort of opioid-dependent PWID across sites in the seven project LMIC. Study participants will be enrolled from selected clinics that deliver routine opioid agonist maintenance treatment to PWID. The intervention will 1) Compare characteristics at baseline of those service clients who do and do not initiate LADB in relation to demographic characteristics, history of drug use, and outcomes; 2) Measure side effects and adverse events among those initiating LADB; and 3) Where appropriate, assess changes in outcomes between time of LADB initiation and 48 week follow-up, including HCV and HIV testing and treatment, quality of life, employment opportunities, and service preferences.
223767629|NCT03238911|DRUG|Iron isomaltoside/ferric derisomaltose|"Iron isomaltoside/ferric derisomaltose (Monofer®/Monoferric®; 100 mg/mL) was the test product in this trial.~The dose of iron isomaltoside/ferric derisomaltose for the individual subject was a single IV infusion of 1000 mg (10 mL containing 1000 mg iron isomaltoside/ferric derisomaltose diluted in 100 mL 0.9 % sodium chloride), given over approximately 20 minutes (50 mg iron/min) at baseline (cumulative dose: 1000 mg)."
223767630|NCT03238911|DRUG|Ferric carboxymaltose|"Ferric carboxymaltose (Injectafer®; 50 mg/mL) was the comparator in this trial.~Ferric carboxymaltose was administered as 750 mg, infused over at least 15 minutes at baseline and on day 7 (cumulative dose: 1500 mg)."
223653312|NCT00646022|DRUG|[18F]-DOPA|18F-DOPA PET/CT Scan.
223653313|NCT06801041|DRUG|Psilocybin|Participants will recive treatment by mouth on an outpatient basis.
223653314|NCT06827860|DRUG|Talquetamab|SC monotherapy starting with three step-up doses followed by the standard 800 μg/kg dose every other week. Cycles will be 28 days long.
223653315|NCT06827860|DRUG|Daratumumab|SC at the standard dose (weekly for 2 cycles, every other week for 4 cycles, monthly thereafter)
223653316|NCT01747213|DRUG|BNC|
223653317|NCT01747213|OTHER|Placebo|Microcrystalline cellulose fiber
223767631|NCT07023874|PROCEDURE|Bupivacaine group|Participants will receive bilateral ultrasound-guided pecto-intercostal fascial plane block
223653318|NCT06121297|BIOLOGICAL|CABA-201|Single intravenous infusion of CABA-201 at a single dose level following preconditioning with fludarabine and cyclophosphamide
223653319|NCT04086485|DRUG|Lu-177-DOTATATE|Lu-177-DOTATATE will be given by IV every 8 (+/-2) weeks for a total of 4 administrations
223653320|NCT04086485|DRUG|Olaparib|Olaparib is given as a pill taken orally and is to be taken twice a day, starting from 2 days before the first administration of Lu-177-DOTATATE until 4 weeks after the last administration
223653321|NCT04086485|DIAGNOSTIC_TEST|Ga dotatate scanning|Ga68-DOTATATE PET/CT scan will be done at baseline, at week 32, then every 24 weeks in followup period.
223653322|NCT04086485|DIAGNOSTIC_TEST|FDG-PET scanning|F18-FDG PET/CT scan will be done at baseline, at week 32, then every 24 weeks in followup period.
223653323|NCT04086485|DRUG|Amino Acid infusion|Concomitant administration of an IV infusion of an amino acid (AA) solution will also be done for renal protection. The AA infusion will begin at least 30-60 minutes prior to injection of Lu-177-DOTATATE and will continue during and after the Lutathera infusion until the entire prescribed amount is infused.
223653324|NCT03383094|DRUG|Pembrolizumab|Pembrolizumab 200 mg IV infusion every 3 weeks x 20 cycles
223653325|NCT03383094|RADIATION|Radiation therapy|70 Gy in 33-35 fractions
223653326|NCT03383094|DRUG|Cisplatin|100 mg/m2 Weeks 1, 4, and 7.
223653327|NCT07079995|BEHAVIORAL|Mentoring program|Schools in this group will participate in meetings and receive newsletters to help with program implementation.
223653328|NCT07079995|BEHAVIORAL|Waitlist|Schools in this group will wait 1 year to receive HSRC. Schools will not add or remove any current physical activity and/or healthy eating programs.
223653329|NCT07081568|DEVICE|transcutaneous auriculai vagus nerve stimulation|During bi-ear synchronous vagus nerve stimulation, the patient was positioned in a supine position. Two stimulating electrodes were placed bilaterally in the concha cymba and concha cavum of the ears. The patient received treatment for 30 minutes per session, once daily, 5 days per week, for a total of 4 weeks. Following each treatment session, the device was disinfected with 75% alcohol.
223653330|NCT05851443|DRUG|povorcitinib|povorcitinib
223653331|NCT05851443|OTHER|placebo|placebo
223653332|NCT05851443|DRUG|ICS-LABA|Background Therapy
223653333|NCT06297226|BIOLOGICAL|Arlocabtagene Autoleucel|Specified dose on specified days
223653334|NCT06282159|DRUG|DNTH103|Day 1: IV loading dose Week 1 to Week 11: DNTH103 administered SC every 2 weeks
223653335|NCT06282159|DRUG|Placebo|Day 1: IV infusion of placebo Week 1 to Week 11: placebo administered SC every 2 weeks
224237241|NCT03194412|DIETARY_SUPPLEMENT|Diet /nutritional|"• Duration:~* the first stage - 3 months: 12 weeks~* second stage - 3 months: 12 weeks~Each patient collect a detailed menu of the last two days before making the description. Then the menu is analyzed by a nutrition consultant. The role of nutrition consultant is:~* make a diet modification to include the products recommended in frailty~* modifying eating habits~The diet modification is mainly focused on adequate supply:~* vitamin D (according to Central Europe guidelines -2013 for seniors)~* protein (according to European Society for Clinical Nutrition and Metabolism (ESPEN recommendations)"
223767632|NCT07023874|PROCEDURE|bupivacaine + dexmedetomidine group|Participants will receive bilateral ultrasound-guided pecto intercostal fascial plane block using 30 mL of 0.25% bupivacaine with one µg/kg dexmedetomidine in each side
223653337|NCT06846723|OTHER|Stress ball|In addition to the routine treatment and care practices of the outpatient clinic, the patients included in the study group will be applied stress ball during ESWL. The researcher (CK) will explain and show the patients how to apply the stress ball 10 minutes before the procedure. The stress ball will be applied during the ESWL session and a round, medium-hard, high-quality silicone ball with an average diameter of 6 cm will be used. Patients will be asked to take the ball in the palm of their hand and squeeze and release the ball once after counting to three. Patients will be instructed to continue this practice until the end of the ESWL procedure and to pay attention to the stress ball during the procedure. The ball will be washed and cleaned after each use and wiped with disposable asepsis wipes before being given to the patient.
223653338|NCT04645160|DRUG|Tivozanib|Oral tivozanib taken daily for Days 1-21 continuously (of each 28-day cycle) followed with 7 days off medication (except for patients in DL-1, with dosing every other day of the 28-day cycle). Phase I: The starting dose (DL1) is 0.89 mg taken once a day continuously for Days 1-21 with 1 week off medication (except for those patients assigned to DL-1, where tivozanib should be taken every other day, around 48 hours apart in 28-day cycle). Patients may escalate to 1.34 mg taken once a day (DL2) continuously for Days 1-21 with 1 week off medication for their second cycle if there are no dose-limiting toxicities. Phase II: Tivozanib dose level will be at the recommended Phase II dose (RP2D) established in Phase I.
224237242|NCT03194412|BEHAVIORAL|Physical activity|"* Duration:~  * the first stage - 3 months: 12 weeks~ * second stage - 3 months: 12 weeks~* Frequency: twice a week~* Duration of each session: 60 minutes~Worksheets for the elderly with frailty syndrome have been developed:~* resistance exercises and strength training, which aim to improve muscle strength in the limbs~* exercises aimed at improving motor coordination, flexibility and speed~* stretching exercises."
224237243|NCT03194412|COMBINATION_PRODUCT|Comprehensive therapy|"Combination of special diet for elderly (as in Group 1) and regular physical activity into everyday life of the elderly (as in Group 2)~Duration:~* the first stage - 3 months- 12 weeks~* the second stage - 3 months- 12 weeks Frequency of physical activity: twice a week Duration of each session: 60 minutes"
224237244|NCT03194412|BEHAVIORAL|Caregivers of elderly|"Group: formal and informal caregivers of elderly with frailty syndrome Materials and Tools: multimedia presentation about frailty prevention and treatment (nutrition, physical activity, dietary supplement diet).~Duration:~* the first stage - 3 months: 12 weeks~* the second stage - 3 months: 12 weeks~Frequency: 1 (at the beginning of stage 0, 1 and 2) Duration: 60 minutes"
224237245|NCT06360627|RADIATION|Computed Tomography|Computed Tomography CHEST
224237246|NCT01221376|DRUG|Imatinib Mesylate|Patient will receive Imatinib Mesylate, continuous-use, 260 mg/m2/day dose, maximum allowed 400 mg, for 24 months.
224237247|NCT06115889|BEHAVIORAL|Smart Taiko Drumming|Participants will play drumming with the developed Smart Taiko Drumming System for 30-45 minutes three times per week for 16 weeks, in addition to usual care.
224237248|NCT05732766|BIOLOGICAL|Hillchol vaccine|Hillchol® (BBV131) (The whole cell inactivated Stable Hikojima expressing both Inaba and Ogawa LPS) inactivated bacteria of a stable recombinant Vibrio cholerae O1 El Tor Hikojima serotype strain expressing approximately 50% each of Ogawa and Inaba O1 LPS antigens.
224237249|NCT05512026|DEVICE|Feasibility Assessment|To validate the performance of the Poseidon System™ for fluid management during water-aided endoscopic procedures in the colon.
224237250|NCT05890157|OTHER|PRF|Split mouth randomized clinical trial will be the design of the study. 12 periodontitis patients with 24 opposite shallow periodontal pockets (4-6 mm in depth) will be selected. Randomization in this study will be achieved using toss of coin method in which periodontal pockets were designated either control site or test site. PRF will be used as an adjunct to scaling and root planing to treat the test sites. While control sites will be treated by scaling and root planing only. Clinal periodontal parameters will be recorded and GCF level of PDGF-BB will be measured at baseline and1- and 3- month follow-up visits to evaluate the healing response to the treatment.
223653339|NCT02355184|DRUG|PRO 140 350mg weekly subcutaneous (SC) injection.|CCR5 Antagonist
223767633|NCT07024407|DRUG|Andecaliximab|Participants will receive weekly subcutaneous injections of andecaliximab during inpatient hospitalization, clinic visit, or self-administration if discharged from the hospital
223767634|NCT06708897|DRUG|ZE 50-0134|oral capsules QD
224237251|NCT01448057|DRUG|Paracetamol (500 mg)/dimethindene maleate (1 mg)/ phenylephrine hydrochloride (10 mg) tablets|Paracetamol (500 mg)/dimethindene maleate (1 mg)/ phenylephrine hydrochloride (10 mg) tablets
224237252|NCT01448057|DRUG|Paracetamol (500 mg) tablets|Paracetamol (500 mg) tablets
223653340|NCT06668584|DRUG|Olutasidenib|Given by mouth
223653341|NCT07082543|DRUG|AZ-3102|Nizubaglustat
223653342|NCT07082543|DRUG|Placebo|Placebo
223653343|NCT07200778|PROCEDURE|umbilico-uterine trunk occlusion|participants will undergo umbilico-uterine trunk occlusion during laparoscopic myomectomy
223653344|NCT07200778|PROCEDURE|local epinephrine infiltration|participants will undergo local injections of epinephrine into the serosal and/or myometrium, covering the myoma before the uterine incision during laparoscopic myomectomy
223653345|NCT07195955|OTHER|Cold Spray Application|A cold spray is applied to the skin at the planned injection site immediately before LMWH administration to reduce pain and ecchymosis.
223767635|NCT02239536|PROCEDURE|hot snare polypectomy|hot snare polypectomy using electrosurgical snare with application of electrocautery for eligible polyps
223767636|NCT02239536|PROCEDURE|hot snare polypectomy after saline injection|hot snare polypectomy after saline injection using electrosurgical snare with application of electrocautery for eligible polyps
223767637|NCT06885034|BIOLOGICAL|GSK5764227|GSK5764227 will be administered
223653346|NCT07200752|BEHAVIORAL|Telerehabilitation-Based Neck Exercise Training|Participants received a 6-week Telerehabilitation exercise program delivered via video calls and digital platforms, three sessions per week. The program included stretching, active range of motion, isometric strengthening, and postural correction exercises with progressive intensity.
223653347|NCT07200752|BEHAVIORAL|Supervised physiotherapy exercise training|Participants received the same 6-week exercise program as the Telerehabilitation group, but delivered face-to-face in a supervised clinical setting by a physiotherapist, three sessions per week.
223653348|NCT07210710|BEHAVIORAL|CKD Awareness, Referrals, Education, and Support (CARES)|We will target diabetic patients eligible for an early-stage CKD diagnosis with a nurse-delivered, pre-PCP-visit 1:1 virtual session including 1) tailored, evidence-based CKD education 2) motivational interviewing with self-management goal setting, and 3) social determinants of health screening with referrals to services as needed.
223653349|NCT07210710|BEHAVIORAL|Attention control|The control group will receive an attention control session of general education about diabetes-related health behaviors (e.g., diet and physical activity) that does not refer to CKD, based on American Diabetes Association materials.
223653353|NCT07210346|OTHER|fairy tales|The children's stories will be selected by child psychologists. The stories will be read by a story therapist and recorded on a voice recorder. The story playback will begin five minutes before the request begins and continue throughout the request process. The stories will be played for five days. Afterward, there will be a one-week detoxification period before moving on to the next intervention.
223653354|NCT07210346|OTHER|mother's voice|Children's stories will be selected by child psychologists. The stories will be read by the children's mothers and recorded on a voice recorder. Story repetition will begin five minutes before the request begins and continue throughout the request period. The stories will be listened to for five days. Following this, there will be a one-week detoxification period before moving on to the next intervention.
224237253|NCT03124966|DEVICE|Pulse Oximeter sensor|
224237254|NCT03354221|DEVICE|Cytosponge|Patients undergoing the six food elimination diet will be monitored during the initial elimination period at 2, 4 and 6 weeks with swallowing the cytosponge. This is a ten minute procedure in the office. The cytosponge will be sent to the lab for histology reading of the eosinophilic count.
224237255|NCT03354221|OTHER|Diet|During the initial 6 week elimination period, participants will eliminate the 6 most common food allergens from their diet (fish, nuts, eggs, soy, wheat, dairy). Participants will return for the cytosponge during this time at 2, 4 and 6 weeks of elimination.
224237256|NCT03354221|OTHER|EEsAI Pro|This is a short questionnaire to assess the participants swallowing. This will be completed at baseline and during each cytosponge visit during the initial elimination period (2, 4, 6 weeks).
224237257|NCT03354221|OTHER|Likert Scoring Scale|"This is a short questionnaire for patients to compare their experiences swallowing the cytosponge versus completing an upper endoscopy. The scale is rated from worst experience to best experience."
224237258|NCT03472365|BIOLOGICAL|SHR-1210|SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody
224237259|NCT03472365|DRUG|Capecitabine|1000 mg/m\^2 administered as continuous oral twice daily (BID) of each 3-week cycle.
224237260|NCT03472365|DRUG|Oxaliplatin|130 mg/m\^2 administered IV Q3W on Day 1 of each 3-week cycle.
224237261|NCT03472365|DRUG|Apatinib|375 mg administered as continuous oral once daily (QD) of each 3-week cycle.
224237262|NCT03593980|DIETARY_SUPPLEMENT|Cranberry juice|400ml cranberry juice
224237263|NCT04550065|BEHAVIORAL|Digital game|A digital family game with theme-based mini games (epidemic prevention, exercise, diet, communication and parenting)
224237264|NCT01728922|DIETARY_SUPPLEMENT|5000IU vitamin D|Vigantol Oil
224237265|NCT01728922|DIETARY_SUPPLEMENT|10000IU vitamin D|Vigantol Oil
223653355|NCT07210346|OTHER|Cartoons|The cartoons children will watch will be selected by child psychologists. Children will be shown cartoons on tablets. Watching will begin five minutes before the request period and continue throughout the request period. Children will be shown cartoons for five days.
223653356|NCT07209722|BEHAVIORAL|PrEP acronym (pre-exposure prophylaxis)|Tracked PrEP prescriptions over 8 months among patients who completed the survey
223653357|NCT02042872|DRUG|Zoledronic acid|At baseline, study subjects in the treatment group will receive 5 mg of zoledronic acid (Reclast: 5 mg; Novartis Pharmaceuticals Inc., East Hanover, NJ) by intravenous infusion over 30 minutes.
223653358|NCT00229385|DRUG|Ziprasidone|40-80 mg BID
223653359|NCT03795246|PROCEDURE|Consultation|Consultation in oncology: collection of oncological data and ongoing cancer treatments, clinical exam Consultation in gynecology: collection of gynecological data, contraception and reproductive medicine
223653360|NCT03795246|BIOLOGICAL|Biological Test|"Blood test:~* FSH, LH, E2 and AMH~* 4 tubes of 7 mL"
223653361|NCT03795246|PROCEDURE|Pelvic Ultrasound|Antral Follicles Count
223653362|NCT03007641|BEHAVIORAL|Didactic session|This session will include an overview of the approach to and management of older MBC patients through a case-based presentation.
223653363|NCT03007641|BEHAVIORAL|Comprehensive Geriatric Assessment|The Comprehensive Geriatric Assessment (CGA) is a composite of assessment scales evaluating physical, psychological, and social well-being, and is the recommended tool for evaluating an older cancer patient and determining appropriateness of therapy.
223653364|NCT04384133|DIAGNOSTIC_TEST|Impulse oscillometry|Impulse oscillometry is a pulmonary function test. During the test, the participant is told to breathe normally.
223653365|NCT04384133|DIAGNOSTIC_TEST|Spirometric pulmonary function test|In the spirometric pulmonary function test, the participant is asked to perform respiratory maneuvers such as breathing deeply.
223653366|NCT04384133|DIAGNOSTIC_TEST|Fractional exhaled nitric oxide (FENO) test|In the FENO test, the participant is asked to perform respiratory maneuvers such as breathing deeply.
223653367|NCT04384133|DIAGNOSTIC_TEST|Thorax Computed Tomography|Computed tomography is a radiological examination.
223653368|NCT04384133|DIAGNOSTIC_TEST|Chest X Ray|Chest X ray is a radiological examination.
223653369|NCT04384133|DIAGNOSTIC_TEST|Blood eosinophil level|A tube of blood will be drawn from the participant.
223653370|NCT04384133|OTHER|CAT|It consists of 8 questions.
223653371|NCT04384133|OTHER|mMRC|It is the scale used to measure the severity of shortness of breath.
223653372|NCT00094484|DRUG|Cinacalcet HCl|
223653373|NCT01027806|DRUG|Montelukast|1 pill per day for 4 months
223653374|NCT01186172|DRUG|Ethanol-lock therapy|Daily ethanol-lock with 70% ethanol instilled in device dead-space, leaved in place for the longest possible interval, and then discarded. For dialysis devices, it is acceptable to leave the lock in place between dialysis sessions. Lock therapy will be continued for 7 days.
223653375|NCT01186172|DRUG|Antibiotic-lock|Daily antibiotic-lock according to 2009 IDSA Guidelines,instilled in device dead-space, leaved in place for the longest possible interval, and then discarded. For dialysis devices, it is acceptable to leave the lock in place between dialysis sessions. Lock therapy will be continued for 7 days.
223653376|NCT00409669|DEVICE|Barraquer tonometer|barraquer tonometer
223653377|NCT01264705|DRUG|bavituximab (0.3 mg/kg) and sorafenib|Bavituximab:0.3 mg/kg weekly Sorafenib: 400mg PO twice daily
223653378|NCT01264705|DRUG|bavituximab (1.0 mg/kg ) and sorafenib|Bavituximab: 1.0 mg/kg weekly Sorafenib: 400mg PO twice daily
223653379|NCT01264705|DRUG|bavituximab (3.0 mg/kg) and sorafenib|Bavituximab: 3.0 mg/kg weekly Sorafenib: 400mg PO twice daily
223653380|NCT04096599|OTHER|Xylitol toothpaste|At-home preventive measures + xylitol-containing (25%) toothpaste
224237266|NCT01728922|OTHER|Placebo|Placebo Oil
224237267|NCT06341322|BEHAVIORAL|Standard letter|A reminder letter to encourage recipients to order the colorectal cancer home testing kit, based on the current invite letter.
224237268|NCT06341322|BEHAVIORAL|Behaviorally informed letter|A reminder letter to encourage recipients to order the colorectal cancer home testing kit, with incorporates severally behaviorally informed components, including an active choice prompt, social norm, call to action, chunking and simplification.
223653381|NCT04096599|OTHER|Fluoride toothpaste|At-home preventive measures + fluoride (1000 ppm F) toothpaste
223653382|NCT03823313|BEHAVIORAL|SCAI (Spiritual Care Assessment and Intervention)|4 sessions completed with an IU Health chaplain using a framework of questions called the Spiritual Care Assessment And Intervention tool. The weekly sessions will focus on one of the 4 areas of spiritual experience (meaning and purpose, relationships, transcendence and peace, self-worth and identity)
223653383|NCT06434142|PROCEDURE|implant overdenture|Following the two-stage surgical protocol, two dental implant fixtures with a length of 10 mm and a diameter of 3.7 mm were inserted at the canine area of the mandibular alveolar ridge.
223653384|NCT00539864|BIOLOGICAL|FluBlok Influenza Vaccination|0.5mL dose for intramuscular injection
223653385|NCT00539864|BIOLOGICAL|TIV (Fluzone) Influenza Vaccination|0.5mL dose for intramuscular injection
223653386|NCT05593263|PROCEDURE|surgical correction of astigmatism with cataract|The Steep meridian will be identified and marked, relaxing limbal / corneal incisions will be designed according to it.
223653387|NCT03160235|RADIATION|Magnetic resonance imaging|
223653388|NCT03160235|DEVICE|EEG|
223653389|NCT03160235|DEVICE|NIRS|
223653390|NCT03439384|DEVICE|Home Telemonitoring|Patients will monitor their weight, blood pressure, oxygen saturation and symptoms with sensors and a tablet computer provided to them. Patients are asked to do this everyday for 60-days. A monitoring nurse will be receiving the data electronically and reviewing on a daily basis.
223653391|NCT01326338|DRUG|Nitazoxanide|Nitazoxanide Oral Suspension 100 mg/5 ml for patients aged 1-3 years twice daily for 3 days or Nitazoxanide Oral Suspension 200 mg/10 ml for patients aged 4-11 years twice daily for 3 days
223653392|NCT06146283|COMBINATION_PRODUCT|Jamar Hydraulic Hand Dynamometer|"This device measures hand grip strength. The individual should be in an upright sitting position. There should be no arm support on the sitting surface. ...~The knee angle should be 90 degrees. Elbow angle should be 90 degrees. The wrist should be held without deviation. The measurement should be performed 3 times with an interval of 10 seconds."
224237269|NCT06341322|BEHAVIORAL|Home testing colorectal cancer kit|The home testing kit is included with the reminder letter, instead of the usual process of responding to the letter to order the kit
224237270|NCT06427057|DRUG|Cadonilimab plus chemotherapy|AK104 (10mg/kg ,Q3W，intravenously) plus chemotherapy（e.g. gemcitabine or albumin paclitaxel，dosage based on guidelines or instructions）
224237271|NCT06427057|DRUG|Cadonilimab plus TKI|Patients will receive AK104 (10mg/kg ,Q3W，intravenously) plus TKI（e.g. sunitinib, pezopanib，dosage based on guidelines or instructions)
224237272|NCT03769844|DRUG|GM-CSF|Subjects demonstrating immunoparalysis (defined by a whole blood ex vivo LP-induced TNF-alpha production capacity \< 200 pg/ml) will receive 7 days of GM-CSF treatment by either the IV or SQ route at a dose of either 125 or 250 mcg/m2/day for 7 days.
223653393|NCT05083858|OTHER|Classical Physiotherapy Program + Cervical Stabilization Exercises|First of all, patients will be taught correct craniocervical flexion movement without activation of superficial muscles in different positions (supine, prone, crawling, sitting, standing). The program will be continued by asking to maintain the cranio-cervical flexion position during all movements. In order to gain dynamic stabilization, unilateral, bilateral, contralateral, ipsilateral and reciprocal extremity movements will be added to the program together with craniocervical flexion movement. Resistance will be added to the exercises as control of the movement is achieved. The exercises will progress from static to dynamic, from stationary floors to moving floors, from simple movements to complex movements.
223653394|NCT05083858|OTHER|Classical Physiotherapy Program + Oculomotor Exercises|Oculomotor Exercises is a program consisting of exercises that support proprioception in the cervical region. It consists of 4 main contents; Sacadic Eye movements, Gaze stability, Head/eye coordination, Head repositioning exercise.
223767638|NCT07042997|PROCEDURE|Evaluation of Anatomical Accuracy in Targeting Forearm Extensor Muscles with Blind Dry Needling in Patients with Lateral Epicondylitis Using Ultrasound Guidance|"Using a high-resolution linear probe (5-12 MHz) , the muscle in which the needle tip is located is monitored in real time in the transverse and longitudinal planes. Whether the needle is in the targeted muscle is recorded as correct or incorrect."
223653395|NCT05083858|OTHER|Classical Physiotherapy Program|"Conventional TENS will be applied to apply analgesic current. TENS application will be made to the cervical paravertebral region, using four 5 x 5 cm adhesive surface electrodes, at 80 Hz frequency for 20 minutes, 100 msec.~All participants will be asked to lie in a prone position. The neck will be in a neutral position. The hot pack will be applied to the cervical region for 20 minutes.~Classical massage will be applied for 20 minutes using the Swedish technique. The technique will be performed on the upper and neck region of the back with 3 strokes, 3 kneading and 3 strokes. The patient will be massaged while lying in the prone position.~Stretching/Posture Exercises Exercises will be applied as a 5-10 minute warm-up-cool-down program at the beginning and end of the study. Cervical flexor, lateral flexor, rotator muscles, pectorals, inferior shoulder joint capsule will be stretched. In addition to this, posture exercises will also be done."
223653396|NCT04611399|BEHAVIORAL|VR for psychoeducation and relaxation|"Use of specifically developed VR contents to deliver psychoeducational content on stress and anxiety (i.e., MIND-VR) and to train on relaxation techniques (i.e., The Secret Garden)."
223653397|NCT04611399|OTHER|Control (CR)|The CR Group will undergo pre- and post-protocol tests without undergoing any treatment.
223653398|NCT00536445|DEVICE|NAVA|Neurally Adjusted Ventilatory Assist (mechanical ventilation controlled by the diaphragm electrical activity)
223653399|NCT01745822|DRUG|tenofovir disoproxil fumarate|administration: tablet 300 mg, once a day, from enrollment at 28 weeks' gestation until 2 months postpartum
223653400|NCT01745822|DRUG|placebo|administration: one tablet, once a day, from enrollment at 28 weeks' gestation until 2 months postpartum
223653401|NCT00407056|DRUG|Difluprednate Ophthalmic Emulsion|
223653402|NCT03550352|DRUG|TN-TC11M2 oral capsules (THC 2.5 mg/CBD 2.5 mg)|Participants will start by taking 1 capsule twice daily for 1 week (5 mg THC/5 mg CBD) and increase the number of capsules as tolerated to a maximum of 6 capsules taken throughout the day by weeks 5-12 (15 mg THC/15 mg CBD total per day).
223653403|NCT03550352|DRUG|TN-C200M2 oral capsules (CBD 200 mg)|Participants will start by taking 1 capsule once daily for 1 week (200 mg CBD) and increase the number of capsules as tolerated to a maximum of 4 capsules taken throughout the day by weeks 5-12 (800 mg CBD total).
223653404|NCT00544700|BIOLOGICAL|bevacizumab|7.5 mg/kg i.v. bevacizumab every 21 days until progression or unacceptable toxicity
223653405|NCT00544700|OTHER|no maintenance|No treatment until progression
223653406|NCT00030459|DRUG|cisplatin|
223653407|NCT00030459|DRUG|mitomycin C|
224237273|NCT01944267|PROCEDURE|Apically positioned flap|"Standard TUSDM Periodontology Clinic procedures will be followed. Local anesthesia will be achieved. Center of implant fixtures will be located. Crestal incision thru the center of implant fixture will be made. Implant fixture will be uncovered and healing abutment/s will be inserted. Horizontal incision at approximately 0.5mm coronal to buccalmucogingival junction will be made 1 tooth mesial to 1 tooth distal to the treating area.~No vertical incision will be made Gingiva coronal to horizontal incision will remain intact Partial thickness flap will be prepared and displaced apically approximately 7mm from the horizontal incision and secured with sutures.~Prepared surgical area will be measured apico-coronally and mesio-distally."
224237274|NCT01944267|PROCEDURE|Free Gingival Graft|"Standard Clinic procedures followed. Local anesthesia achieved. Center of implant fixtures located. Crestal incision thru center of fixture will be made.~Implant fixture uncovered and healing abutment/s inserted. Horizontal incision at approx 0.5mm coronal to buccalmucogingival junction will be made 1 tooth mesial to 1 tooth distal to the treating area.~No vertical incision made. Gingiva coronal to horizontal incision remains intact.~Partial thickness flap prepared and displaced apically approximately 7mm from horizontal incision; secured with sutures. Prepared recipient bed measured apico-coronally and mesio-distally. Masticatory mucosa from palate of treating side (Right or Left) harvested according to size measured from recipient bed with width of approximately 5mm at line of measurement. Harvested graft material will be transplanted on recipient bed, lined with initial horizontal incision line with sutures"
224237275|NCT01944267|PROCEDURE|apically positioned flap with Mucograft|"Standard TUSDM Periodontology Clinic procedures followed. Local anesthesia achieved.~Center of implant fixtures will be located. Crestal incision thru the center of implant fixture will be made. Implant fixture will be uncovered and healing abutment/s will be inserted. Horizontal incision at approximately 0.5mm coronal to buccalmucogingival junction will be made 1 tooth mesial to 1 tooth distal to the treating area.~No vertical incision will be made. Gingiva coronal to horizontal incision will remain intact. Partial thickness flap will be prepared and displaced apically approximately 7mm from the horizontal incision and secured with sutures.~Prepared recipient bed will be measured apico-coronally and mesio-distally. Mucograft material will be prepared according to the manufacturer's instruction and trimmed as the size measured from the recipient and be placed and secured on the recipient bed with sutures."
224237276|NCT03006419|DRUG|Basiliximab|Standard induction therapy
224237277|NCT03006419|DRUG|Thymoglobulin|Induction therapy
224237278|NCT03883906|BIOLOGICAL|Viral Specific T-cells (VSTs)|VSTs will be infused into stem cell transplant recipients
224237279|NCT03063814|BEHAVIORAL|APP|See arm description
223653408|NCT00030459|DRUG|vinblastine sulfate|
223653409|NCT00030459|DRUG|vinorelbine tartrate|
223653410|NCT00943072|BIOLOGICAL|VEGF Trap-Eye 2.0mg|Monthly intravitreal injection out to the Week 24 Primary endpoint
223653411|NCT00943072|DRUG|Sham|Monthly sham intravitreal injection out to Week 24 Primary Endpoint
223653412|NCT04870489|COMBINATION_PRODUCT|Isotretinoin and CO2 laser|Patients must complete at least 2 months of Isotretinoin prior to starting the study and then continue it for the duration of the 3 months of treatment with the CO2 laser.
223653413|NCT04870489|DEVICE|Co2 laser|After 6-12 months of no treatment for acne the patient comes to do second side of face only laser treatment
223653414|NCT00662675|DRUG|Pancrease MT 10.5, or MT 21|Pancrease MT capsules for maximum dose of 10,000 lipase units / Kg / day
223653415|NCT00662675|DRUG|Placebo for Pancrease MT 10.5 or MT 21|Capsules with Pancrease MT excipients without the active enzymes
224237280|NCT03063814|BEHAVIORAL|PHY|see arm description
224237281|NCT00486837|DRUG|Alpha1-Proteinase Inhibitor (Human)|25 mg of Alpha1-Proteinase Inhibitor (Human) in the lungs, one inhalation per day over 4 weeks.
224320860|NCT06145633|PROCEDURE|Single Photon Emission Computed Tomography|Undergo SPECT/CT
224320861|NCT06145633|DRUG|Vorinostat|Given IV
223653416|NCT05971576|BIOLOGICAL|LM103|Fresh tumor samples will be resected from enrolled patients. Autologous TILs will be extracted and reinfused to corresponding patients after ex vivo stimulation, activation and extensive expansion.
223653417|NCT03774056|DRUG|HC-1119|oral
223653418|NCT04534816|DIAGNOSTIC_TEST|Indocyanine Green|Perfusion assessments
223653419|NCT03887702|OTHER|Best Practice|Receive best practice
223653420|NCT03887702|DRUG|Entecavir|Given PO
223653421|NCT03887702|DRUG|Tenofovir Alafenamide|Given PO
223653422|NCT03887702|DRUG|Tenofovir Disoproxil Fumarate|Given PO
223653423|NCT04432727|DEVICE|Flexitouch Plus with Cellular Connectivity (FT-CC)|Daily use of FT-CC
223653424|NCT00107640|BEHAVIORAL|Patient-provider education|Experimental patients received an intervention consisting of the following components: written reports and educational materials, a telephone health educator intervention (at baseline, 3 and 6 months), and a brief provider intervention.
223653425|NCT01643421|OTHER|Deep inspiration and positive expiratory airway pressure|It was used a device the combines deep inspiration and positive expiratory airway pressure in asthmatic subjects, for 5 weeks, twice a day.
223653426|NCT01089517|DRUG|E10030 plus Lucentis|once a month intravitreal injection
223653427|NCT01089517|DRUG|Lucentis|10 mg/mL intravitreal injection monthly
223653428|NCT04966663|DRUG|Nivolumab|Antineoplastic agent
223653429|NCT04966663|DRUG|Pemetrexed|Antineoplastic agent
223653430|NCT04966663|DRUG|Gemcitabine|Antineoplastic agent
223653431|NCT04966663|DRUG|Cisplatin|Antineoplastic agent
223653432|NCT04966663|DRUG|Carboplatin|Antineoplastic agent
223653433|NCT04966663|PROCEDURE|ctDNA blood test|Blood will be collected for ctDNA testing
223653434|NCT01595022|DRUG|Placebo: Flexi ring FR01|Intrauterine device, inserted once for 3 months
223653435|NCT01595022|DRUG|Placebo: Flexi ring FR20|Intrauterine device, inserted once for 3 months
223653436|NCT01595022|DRUG|Placebo: Ultra low dose levonorgestrel contraceptive system (LCS)|Intrauterine device, inserted once for 3 months
223653437|NCT01204008|PROCEDURE|conservative discectomy|a smaller incision with removal of the disc fragment with little invasion of the disc
223653438|NCT01204008|PROCEDURE|aggressive discectomy|a large open incision with aggressive removal of the disc fragments and curettage of the disc space
223653439|NCT03032302|DIETARY_SUPPLEMENT|Swisse Womens 50+ Ultivite Multivitamin|Single tablet taken once daily
223653440|NCT03032302|DIETARY_SUPPLEMENT|Holland and Barrett Triple Strength Omega-3 Fish Oil|Single capsule taken once daily
223653441|NCT03137264|DRUG|Other|Patients who are T790M positive via cobas plasma and/or cobas tissue testing during Part 1 will be treated per standard of care during Part 2, which may include osimertinib.
223653442|NCT01615536|PROCEDURE|Canine fossa trephine technique|Patients undergoing standard ESS and a canine fossa trephine technique, which is a 6 mm puncture in the anterior wall of the maxillary sinus, to allow standard sinus debrider blades and instruments to pass into the sinus to clear polyps in the maxillary sinus.
223653443|NCT01615536|PROCEDURE|Standard Endoscopic Sinus Surgery|Patients undergoing standard ESS without canine fossa trephination with clearance of the maxillary sinus polyps via a wide maxillary antrostomy (WMA) with use of curved debrider surgical blades and instruments.
223767639|NCT06888895|OTHER|Passive-active stretching (PAS)|Passive-active stretching (PAS) combines conventional passive stretching with active exercises designed to activate muscles that promote hamstring elongation. On the other hand, passive stretching (PS) is a commonly administered intervention to improve hamstring flexibility.
223767640|NCT06888895|OTHER|Passive hamstring stretching|Participants will receive one minute of passive hamstring stretching applied three times for each lower limb, with a 30-second rest time between stretches.
223767641|NCT07056140|PROCEDURE|Epidural Simulation Training|The group will have access to a epidural simulator and would have possibility to freely experiment and improve their skill on the phantom before their residency period in the obstetric unit
224237282|NCT02724800|BEHAVIORAL|CBTI|28 Veterans with chronic insomnia will be randomized to CBTI. The intervention will be delivered in 5 face-to-face session within an 8 week time period. The intervention will be delivered at the VA Pittsburgh Healthcare System. Treatment visits will last approximately 45 minutes.
223653444|NCT01088048|DRUG|Idelalisib|Idelalisib tablet administered orally
223653445|NCT01088048|DRUG|Rituximab|Rituximab administered intravenously
223653446|NCT01088048|DRUG|Bendamustine|Bendamustine administered intravenously
223653447|NCT01088048|DRUG|Ofatumumab|Ofatumumab administered intravenously
223653448|NCT01088048|DRUG|Fludarabine|Fludarabine administered orally
223653449|NCT01088048|DRUG|Everolimus|Everolimus administered orally twice daily until disease progression
223653450|NCT01088048|DRUG|Bortezomib|Bortezomib administered as a subcutaneous injection
223653451|NCT01088048|DRUG|Chlorambucil|Chlorambucil administered on Days 1-7 every 28 days to allow appropriate therapy for participants with CLL and to coordinate into a cycle period equivalent to other study treatment regimens.
223653452|NCT01088048|DRUG|Lenalidomide|Lenalidomide administered orally
223653453|NCT05762068|OTHER|Delphi procedure|The study involves generating consensus statements by experts on airway management in critically ill patients on the definition and management of a physiologically difficult airway (PDA) using a Delphi process.
223653454|NCT04857320|COMBINATION_PRODUCT|Human insulin|Human Insulin from recombinant source delivered in a solution capable of enabling transdermal delivery formulated at 100 IU/mL of delivery vehicle.
223653455|NCT00452816|BEHAVIORAL|Workplace Solutions Consulting approach|"Consulting process includes:~1. baseline measure of best practices~2. gap analysis and recommendations reporting~3. delivery of solution set toolkits for each practice chosen for implementation"
223653456|NCT00452816|BEHAVIORAL|Delayed intervention|Abbreviated version of the Workplace Solutions Consulting process applied in the intervention group
223653457|NCT03260751|DIETARY_SUPPLEMENT|Zingiber officinale Roscoe extract 200 mg|2 cap/day, 800 mg/cap for 12 weeks
223653458|NCT03260751|DIETARY_SUPPLEMENT|Placebo|Placebo for 12 weeks
223653459|NCT04073979|DEVICE|Mistral implantation|Mistral implant is implanted in the Tricuspid valve
223653460|NCT01111799|PROCEDURE|endometrial biopsy|two endometrial biopsies will be taken with a PIPELLE catheter on days 12 and 21 of the spontaneous menstrual cycle that precedes the fertility treatment.
223653461|NCT01111799|PROCEDURE|endometrial biopsy|two endometrial biopsies will be taken with a PIPELLE catheter on days 12 and 21 of the spontaneous menstrual cycle that precedes the fertility treatment.
223653462|NCT01111799|PROCEDURE|natural cycle + IUI + endometrial biopsy|two endometrial biopsies will be taken with a PIPELLE catheter on days 12 and 21 of the spontaneous menstrual cycle that precedes the fertility treatment.
223653463|NCT04320589|DRUG|Dexmedetomidine|which in addition to the orally prescribed drugs; on admission to the ICU, the Pheo-patient has serum-Mg level measurement \& a bolus of 40 mg/kg MgSo₄ is given I.V. \& may be repeated until the therapeutic level of MgSo₄ 2-4 mmol/Liter is reached (7\&10). Dexmedetomidine sedation is started the evening prior to surgery by loading dose of 1µg/Kg followed by 0.2-0.7 µg/Kg/hour according to each patient
223653464|NCT04320589|DRUG|General anesthetic|1\) Traditional group in which the patients̕ hemodynamic adjustment will be conducted using orally or IV α₁ \& β-adrenergic blockers \[Prazocin (minipress): 0.5-20 mg/day, Propranolol (Inderal) :10-360 mg/day, Bisoprolol (Concor): 2.5-20 mg/day, Atenolol (Tenormin): 25-100 mg/day \&/or Labetalol (Trandate)200-600 mg/day, ACI \& ACRB e.g. Tritace 2.5-10 mg/day \& Atacand 4-16 mg/day\]
223653465|NCT00967421|DRUG|ethanol|BAC level 0.5 g/dL (drink + placebo pill). Drink with 2,4 grams per kilo body weight, administered orally during 60 min, administration ending 30 min prior to start of testing. Placebo pill.
223653466|NCT00967421|DRUG|Ethanol|BAC level 1.0 g/dL (drink + placebo pill). Drink with 3,6 grams per kilo body weight, administered orally during 60 min, administration ending 30 min prior to start of testing. Placebo pill.
223653467|NCT00967421|OTHER|Placebo drink|Placebo drink containing no alcohol + placebo pill
223653468|NCT02563067|DRUG|QAW039|QAW039 150 mg once daily
223653469|NCT02563067|DRUG|QAW039|QAW039 450 mg once daily
223653470|NCT02563067|DRUG|Placebo|Placebo once daily
223653471|NCT02495519|DRUG|Imatinib|Imatinib 400 mg/day until disease progression
223653472|NCT03873818|BIOLOGICAL|Ipilimumab|Given IV
223653473|NCT03873818|BIOLOGICAL|Pembrolizumab|Given IV
223653474|NCT00839319|DRUG|Acyline|300 ug/kg subcutaneous injections on Day 1.
223653475|NCT00839319|OTHER|placebo hCG (no active ingredient)|placebo hCG
223653476|NCT00839319|DRUG|hCG (human chorionic gonadotropin)|15 IU subcutaneous injection every other day for 10 days (5 doses)
223653477|NCT00839319|DRUG|hCG (human chorionic gonadotropin)|60 IU subcutaneous injection
223653478|NCT00839319|DRUG|hCG (human chorionic gonadotropin)|125 IU subcutaneous injection
223767642|NCT07056140|PROCEDURE|Standard Clinical Training|Participants will receive a standard clinical training based on frontal lessons regarding indications , controindications to epidural analgesia and the technique will be explained also with the use of video material
223767643|NCT06743204|OTHER|Self-Reported Risk Screening for PrEP and Diagnostic STI testing|The intervention arm will include: 1) Standard-of-care STI symptom screening: The investigators will ask participants if any STI symptoms 2) PrEP screening (if HIV- only): PrEP eligibility screening will be done using the standard-care Ministry Health self-reported risk screening (SRST) tool for PrEP 3) STI laboratory diagnostic testing: Regardless of HIV serostatus, vaginal swabs will be collected to test for chlamydia, gonorrhea, trichomonas, and human papilloma virus. Syphilis testing will be performed using blood samples participants provided in the Rakai Community Cohort Study. Participants who test positive for a curable sexually transmitted infection (chlamydia, gonorrhea, trichomonas, or syphilis) OR who screen eligible for PrEP using the Ministry of Health SRST AND are HIV- will be referred for same-day PrEP initiation. Participants who have symptoms indicative of STIs or who test positive for an STI will be provided with free treatment, as will the partner(s).
223653479|NCT00839319|DRUG|Testosterone gel|75 mg testosterone gel applied transdermally for 10 days
224237283|NCT02724800|BEHAVIORAL|BBTI|28 Veterans with chronic insomnia will be randomized to BBTI. The intervention will be delivered over 4 consecutive weeks, which include individual face-to-face visits on Weeks 1 and 3 (option for telephone), and telephone appointments on Weeks 2 and 4. Interventions will be delivered at the VA Pittsburgh Healthcare System. The duration of the first treatment visit is approximately 45-minutes, and the follow-up visit on Week 3 will last no more than 30 minutes. Brief (\<20 minutes) telephone sessions will be conducted on Weeks 2 and 4.
223653480|NCT02444767|DRUG|13mg Bimatoprost Ocular Insert|13mg Bimatoprost Ocular Insert in each eye.
223653481|NCT04014868|DEVICE|Nasal high-flow|See arm description.
223653482|NCT04014868|OTHER|Sham nasal high-flow|See arm description.
223653483|NCT00774267|DRUG|BZA 20 mg/CE 0.45 mg|There was no drug taken during study 3115A1-4000. During the 3115A1-303 study the test article was supplied as baxedoxifene/CE tablets in capsules. Subjects took one capsule orally, once daily at approximately the same time each day on a continuous regimen for 2 years or until early termination from the study.
223653484|NCT00774267|DRUG|BZA 20 mg/CE 0.625 mg|There was no drug taken during study 3115A1-4000. During the 3115A1-303 study the test article was supplied as baxedoxifene/CE tablets in capsules. Subjects took one capsule orally, once daily at approximately the same time each day on a continuous regimen for 2 years or until early termination from the study.
223653485|NCT00774267|DRUG|Raloxifene 60 mg|There was no drug taken during study 3115A1-4000. During the 3115A1-303 study the test article was supplied as raloxifene tablets in capsules. Subjects took one capsule orally, once daily at approximately the same time each day on a continuous regimen for 2 years or until early termination from the study.
223653486|NCT00774267|DRUG|Placebo|There was no drug taken during study 3115A1-4000. During the 3115A1-303 study the test article was supplied as placebo capsules. Subjects took one capsule orally, once daily at approximately the same time each day on a continuous regimen for 2 years or until early termination from the study.
223653487|NCT03544333|DEVICE|transcranial magnetic stimulation|We will assess safety and efficacy of the following protocol: 1Hz of rTMS over the Sylvian parietal temporal area (area Spt) four times on 1 day (1 pulse/second and a total of 1'000 pulses: 16 minutes' protocol at 100 % of motor threshold modified based on Hoffman et al., 1999). Area Spt will be localized via baseline structural imaging and our Localite TMS navigation system.
223653488|NCT02335788|DEVICE|The EMBA Peripheral Embolization Device|arterial and venous embolization in the peripheral vasculature
223653489|NCT05631613|PROCEDURE|cTACE(conventional transarterial chemoembolization)|transarterial chemoembolization with lipiodol-idarubicin emulsion
224237284|NCT01037283|BEHAVIORAL|Interpersonal and Social Rhythm Therapy|Interpersonal and Social Rhythm Therapy delivered in two individual therapy sessions and six group therapy sessions.
223653490|NCT03363490|BEHAVIORAL|Self-management program|Self-management diary will record the frequency of pain, fatigue and injury of knee joint due to knee OA, if patients maintain proper activities, it will be also recorded by an smart phone APP. Patients diet and intake calorie will also be recorded in the diary，which help clinicians to adjust their diet, control their body weight.
223653491|NCT03363490|BEHAVIORAL|Neuromuscular exercise therapy|The exercise therapy is basically combined with neuromuscular training and anti resistance training. The aim is to improve the stability of the joints, enhance sensory motor control of lower extremities, reconstruct neutral position line. The exercise mode, frequency, intensity and duration will be adjusted individually through monitoring patient's pain.
223653492|NCT03363490|BEHAVIORAL|Health education|All four groups of patient will receive two times of health education in the first week.
223653493|NCT04021641|DIAGNOSTIC_TEST|Speech recognition in noise|Measurement of speech recognition performance in noise
223653494|NCT02110043|DEVICE|tDCS|transcranial direct current stimulation (tDCS)
224237285|NCT01197339|BEHAVIORAL|resonant voice|A 4-hr resonant voice exercise will be prescribed to subjects following vocal loading.
224237286|NCT01197339|BEHAVIORAL|voice rest|A 4-hr voice rest will be prescribed to subjects following vocal loading.
224237287|NCT01197339|BEHAVIORAL|Breathy voice|A 4-hr breathy voice exercise will be prescribed to subjects following vocal loading.
223653495|NCT02110043|BEHAVIORAL|training|intensive training of visual-spatial abilities (in LOCATO task)
223653496|NCT05844007|BEHAVIORAL|Trauma-Informed Yoga|Trauma-informed yoga intervention, delivered either in-person or remotely for 6 weeks, twice weekly for 45 minutes sessions
223653497|NCT01039519|DRUG|Ganetespib|Ganetespib 200 mg/m\^2 during an approximately 1-hour infusion once weekly for three consecutive weeks followed by a treatment-free week. Participants who demonstrate acceptable tolerability and objective clinical benefit (defined by at least stable disease or objective response per RECIST) can continue to receive ganetespib until disease progression or appearance of unacceptable toxicity.
224237288|NCT01197339|BEHAVIORAL|Relaxation exercise|A 4-hr relaxation exercise will be prescribed to subjects following vocal loading.
224237289|NCT01197339|BEHAVIORAL|Resonant voice and relaxation exercise|A 4-hr resonant voice and relaxation exercise will be prescribed to subjects following vocal loading.
224237290|NCT00350246|PROCEDURE|Laser Refractive Surgery|
224237291|NCT00743548|DEVICE|IB = Interdental brush, the intervention|IB is a small multi-tufted brush on a wire attached to a long angled handle that is inserted in a horizontal plane between the teeth. The IB is inserted once and removed.
224237292|NCT00743548|DEVICE|DF = Dental floss, the positive control|DF is waxed dental floss; nylon covered with a water soluble unflavoured wax to facilitate easier access the contact points of teeth. DF is rubbed against the interproximal surfaces of the teeth 2-4 times on each surface.
224237293|NCT00262964|DRUG|Niacin|Subjects randomized to Niacin therapy will be treated with Niacin at night for 16 wks to reduce plasma free fatty acid concentrations. The dose of medication will be gradually increased: 500 mg/day during week 1, 1000 mg/day during week 2, 1500 mg/day during week 3, and 2000mg/day during weeks 4-16.
224237294|NCT00262964|DRUG|fenofibrate|Subjects randomized to fenofibrate will be treated with 200 mgs per day for eight weeks.
224237295|NCT00262964|DRUG|placebo|Subjects randomized to placebo will be treated with one placebo pill per day for eight weeks.
224237296|NCT01155986|DRUG|Lidocaine 5% medicated plaster|Topical hydrogel plaster (700mg lidocaine)
223653498|NCT04323657|DRUG|TC-110 T Cells|TC-110 T Cells
223653499|NCT04323657|DRUG|Fludarabine|Flu/Cy Lymphodepletion
223653500|NCT04323657|DRUG|Cyclophosphamide|Flu/Cy Lymphodepletion
223653501|NCT03419559|BIOLOGICAL|LN-145|adoptive cell therapy (ACT) with autologous TIL therapy
223653502|NCT03419559|DRUG|Durvalumab|PD-L1 antagonist monoclonal antibody
223653503|NCT01994096|DRUG|Caspofungin|
223653504|NCT03062540|DRUG|TNX-102 SL|Patients will take 2 tablets of randomly assigned study drug sublingually each day at bedtime starting on Day 0 for 12 weeks
223653505|NCT03062540|DRUG|Placebo SL Tablet|Patients will take 2 tablets of randomly assigned study drug sublingually each day at bedtime starting on Day 0 for 12 weeks
223653506|NCT05231512|OTHER|Respiratory Music Therapy Protocol|Participants will engage in eight (8) 45-minute virtual music therapy groups containing up to 6 participants over the course of 8 weeks. Within these groups, participants will be invited to use instruments provided including a Yamaha recorder and a Grover Trophy slide whistle. 45 minute virtual music therapy sessions facilitated by board-certified music therapy will consist of music-assisted relaxation through music visualization, followed by gentle pulmonary exercise via wind instrumental playing, and concluding with group singing.
224237297|NCT01155986|DRUG|Placebo topical plaster|Topical hydrogel plaster
224237298|NCT02307734|BEHAVIORAL|Quit Smoking for a Healthy Family|The experimental/intervention study arm focuses on providing smoking cessation education and support through 2 LHW outreach small group educational sessions (4-5 weeks apart) and 2 individual follow-up telephone calls to smoker and family participants separately at 2-3 weeks after each group session for a total of 4 intervention contacts over 2 months. The LHW and dyads will choose the site of sessions, such as the LHW's or a participant's home, or LHW Agency's office. Each small group session will last 90 minutes, be interactive, and involve sharing personal stories, learning using a flip chart, and setting individual goals. Each telephone call will be 15- 20 minutes to reinforce progress and provide support.
224237299|NCT02307734|BEHAVIORAL|Healthy Living|"In this comparison arm, participants will receive the same number of contacts on the same schedule and in the same format (2 small group sessions and 2 telephone calls). The comparison LHWs will receive training about Healthy Living focusing on nutrition and physical activity education. Participants will also receive the Smoking Cessation Resource Handout."
224237300|NCT00920764|DRUG|Placebo for Atrasentan 0.2 mg/mL solution|10 mL oral solution, daily, 8 weeks
224237301|NCT00920764|DRUG|0.25 mg Atrasentan QD|10 mL oral solution, daily, 8 weeks
224237302|NCT00920764|DRUG|0.75 mg Atrasentan QD|10 mL oral solution, daily, 8 weeks
224237303|NCT00920764|DRUG|1.75 mg Atrasentan QD|10 mL oral solution, daily, 8 weeks
223653507|NCT05428657|OTHER|EC Brain After-school Program|"* Computerized Eye-tracking Attention and Impulse Control Training~* Computerized Temporal Processing Training~* Education on Relaxation, Stress Management and Healthy Balanced Diet"
223653508|NCT05428657|OTHER|conventional intervention|Conventional cognitive training on their language and learning capacities (e.g., learning adjectives, logical reasoning, composition, reading words and story) and attention ability
223653509|NCT00385437|BEHAVIORAL|Driving Simulator Testing|
223653510|NCT00385437|DRUG|Mirtazapine Treatment|
223653511|NCT03261427|DRUG|Lyrica 150Mg Capsule|150 mg oral administered (BID)
223653512|NCT03261427|DRUG|YNP-1807 330Mg Tablet|330 mg oral administered (QD)
223653513|NCT01330108|DRUG|ambrisentan|ambrisentan 2.5mg, 5mg, \& 10mg. Daily dosage.
223653514|NCT02437708|PROCEDURE|REP with L-PRF|
223653515|NCT02437708|PROCEDURE|REP|
223653516|NCT02437708|BIOLOGICAL|stem and progenitor cells|
223653517|NCT01897818|DEVICE|communication system P300 Speller|
223653518|NCT05145218|DRUG|Anlotinib Hydrochloride Capsules|Anlotinib Hydrochloride is a multi-target tyrosine kinase inhibitor.
223653519|NCT05145218|DRUG|Paclitaxel injection|Paclitaxel is a novel anti-microtubule agent.
223653520|NCT05145218|DRUG|TQB2450 injection|TQB2450 is a programmed cell death protein 1 (PD-1) humanized monoclonal antibody.
223653521|NCT00485134|BIOLOGICAL|240 µg Shigella flexneri 2a Invaplex 50 vaccine|Vaccines were administered intranasally on Days 0, 14, and 28. The investigational vaccine was supplied as 1 mL of a sterile, clear liquid in a 3 ml glass vial. Each vial contained 3.5 mg of protein and 567 μg of LPS. The pH was 8.9 and the buffer was 250 mM NaCl in 20 mM Tris.
223653522|NCT00485134|BIOLOGICAL|480 µg Shigella flexneri 2a Invaplex 50 vaccine|Vaccines were administered intranasally on Days 0, 14, and 28. The investigational vaccine was supplied as 1 mL of a sterile, clear liquid in a 3 ml glass vial. Each vial contained 3.5 mg of protein and 567 μg of LPS. The pH was 8.9 and the buffer was 250 mM NaCl in 20 mM Tris.
223653523|NCT00485134|BIOLOGICAL|690 Shigella flexneri 2a Invaplex 50 vaccine|Vaccines were administered intranasally on Days 0, 14, and 28. The investigational vaccine was supplied as 1 mL of a sterile, clear liquid in a 3 ml glass vial. Each vial contained 3.5 mg of protein and 567 μg of LPS. The pH was 8.9 and the buffer was 250 mM NaCl in 20 mM Tris.
223653524|NCT00485134|OTHER|Shigella challenge strain|300 colony forming units (CFU) of Shigella challenge strain, Shigella flexneri 2a strain 2457T
223653525|NCT00002213|DRUG|Abacavir sulfate|
223653526|NCT00002213|DRUG|Amprenavir|
223653527|NCT00002213|DRUG|Efavirenz|
223653528|NCT03620864|OTHER|Motor Control Exercises|Patients will receive 8 sessions of motor control exercise program of 30 min duration for 4 weeks, twice per week. Exercises will be demonstrated to the participants by an experienced physical therapist. On each session, the therapist will correct each subject personally. Participants will be asked for practicing the exercises at home once daily for 20 minutes over the 8-week intervention period. The motor control exercise program will consist of a progression from isolated contraction of the transversus abdominis and/or isolated contraction of the multifidi to combined contraction of both transversus abdominis in different positions from supine or prone to bridging or four-point kneeling.
223653529|NCT03620864|OTHER|Motor Control Exercise Plus Neurodynamic Intervention|Patients will receive 8 sessions of motor control exercise program of 30 min duration for 4 weeks, twice per week. Exercises will be demonstrated to the participants by an experienced physical therapist. On each session, the therapist will correct each subject personally. Participants will be asked for practicing the exercises at home once daily for 20 minutes over the 8-week intervention period. The motor control exercise program will consist of a progression from isolated contraction of the transversus abdominis and/or isolated contraction of the multifidi to combined contraction of both transversus abdominis in different positions from supine or prone to bridging or four-point kneeling. In addition, participants allocated to the neurodynamic group will also receive a nerve neurodynamic slider intervention targeting the main trunk of the sciatic nerve of the affected side during al treatment sessions (n=8).
223653530|NCT00473304|DEVICE|Johnson&Johnson Acuevue daily disposable lenses|
223653531|NCT01780064|BEHAVIORAL|interviews with a psychologist|interviews with a psychologist
223653532|NCT01780064|BEHAVIORAL|Questionnaires|Questionnaires
223653533|NCT01146327|DRUG|PF-04620110|Multiple oral doses of 5 mg of PF-04620110 will be given once daily for 2 weeks.
223653534|NCT01146327|DRUG|PF-04620110|Multiple oral doses of 1.5 mg of PF-04620110 will be given twice daily for 2 weeks.
223653535|NCT01146327|DRUG|PF-04620110|Multiple oral doses of 3 mg of PF-04620110 will be given once daily for 2 weeks.
223653536|NCT01146327|DRUG|PF-04620110|Multiple oral doses of 2.5 mg of PF-04620110 will be given twice daily for 2 weeks.
223653537|NCT01146327|DRUG|Placebo|Multiple oral doses of placebo will be given once daily for 2 weeks.
223653538|NCT03257319|DRUG|inhaled titration of morphine chlorhydrate|Patient in arm A will receive 1 to 3 titration
223653539|NCT03257319|DRUG|IV placebo|Patient in arm A will receive 1 to 6 injection
223653540|NCT03257319|DEVICE|Inhaled placebo|Patient in arm B will receive 1 to 3 titration
223653541|NCT03257319|DRUG|IV titration of morphine chlorhydrate|Patient in arm BA will receive 1 to 6 injection
223653542|NCT05631483|DEVICE|DAISe|Use of the DAISe Thrombectomy Device
223653543|NCT04294680|DEVICE|Cryotherapy|see opiate sparing description
223653544|NCT01453985|PROCEDURE|Full-Thickness-Gastroplication|
223653545|NCT02812251|DRUG|JNJ-61393215|JNJ-61393215 (projected dose levels as described above for Part 1) will be administered as an oral suspension.
223653546|NCT02812251|DRUG|Placebo|Matching placebo will be administered.
223653547|NCT01464060|DRUG|PPI, amoxicillin, metronidazole and clarithromycin|Dual therapy for 7 days: 40 mg omeprazole and 1g amoxicillin every 12h. After dual therapy continue with a quadruple therapy for 7 days: 40 mg omeprazole, 1g amoxicillin, 500 mg metronidazole and 500 mg clarithromycin every 12h.
223653548|NCT01464060|DRUG|PPI, amoxicillin, metronidazole and clarithromycin|Quadruple therapy for 14 days: 40 mg omeprazole, 1g amoxicillin, 500 mg metronidazole and 500 mg clarithromycin every 12h
223653549|NCT03383341|DIETARY_SUPPLEMENT|Cricket Protein Powder|Cricket powder was supplied by Entomo farms and consists of roasted and milled whole crickets.
223653550|NCT03383341|OTHER|Placebo control|Placebo controls consisted of intervention foods (muffin and smoothie powder packet) that were visually and organoleptically similar to cricket-containing foods but contained no cricket powder.
223653551|NCT06230237|BEHAVIORAL|Smiling is fun + professional support|"Participants will receive an intervention called Smiling is Fun; a cognitve-conductual online program with the most effective psychological procedures for depression and other techniques to promote coping ability, emotional regulation and resilience along 8 modules.~While they do the online program, they will receive periodically professional support. The professional support will be contacts of 20 minutes long, will take place every two weeks and will last 3 months."
223653552|NCT06230237|BEHAVIORAL|Smiling is fun|Participants will receive an intervention called Smiling is Fun; a cognitve-conductual online program with the most effective psychological procedures for depression and other techniques to promote coping ability, emotional regulation and resilience along 8 modules.
223653553|NCT04027608|OTHER|Reinforcing value of HED and LED foods in response to snack food monotony|Each child will be asked to eat two different snack foods over the course of two weeks each. The RRV of that food (vs alternative reinforcer) will be tested and baseline and post exposure. Increases in RRv for food after monotony will be considered sensitization to that food. All children will be followed to observe weight change over time for 2 years each.
223653554|NCT02950467|DRUG|Psilocybin|One individual oral psilocybin treatment session
223653555|NCT02950467|BEHAVIORAL|Modified brief Supportive Expressive Group Therapy|Ten sessions of twice-weekly manualized group therapy
223653556|NCT03176537|DRUG|Testosterone gel|Androgel (50mg testosterone), gel, daily
223653557|NCT03176537|DRUG|Placebos|Placebo, gel, daily
223653558|NCT02921178|OTHER|Omalizumab|comparision of using Omalizumab and non-Omalizumab treatment
223653559|NCT04651842|DEVICE|PCI|Acute Insulin Resistance on Myocardial Blush in Non- Diabetic Patients Undergoing Primary Percutaneous Coronary Intervention
223653560|NCT03565328|DIETARY_SUPPLEMENT|Nicotinamide Riboside|Nicotinamide Riboside (NR) will be started at 500 mg daily (250 mg BID) be increased at two weekly intervals by 250 mg/dose (BID) (500 mg/day) to a final dose of 1000mg PO BID (2000 mg/day).
223653561|NCT05494424|BEHAVIORAL|Goal Management Training (GMT)|Goal Management Training is a cognitive rehabilitation intervention that relies on metacognitive strategies to reengage top-down attention processes, in addition to teaching problem-solving techniques, attempting to address executive dysfunctions.
223653562|NCT05255809|OTHER|Alexander Technique + Routine Physical Therapy|Verbal Instructions in Trunk stabilizing exercises. The time duration will be 15 minutes. Verbal instructions in Stance Phase Time duration 15 minutes.Ankle Strategy. 40 minutes with rest of 5 minutes after 10 minutes. Lessons would be two days a week for 16 weeks.
223653563|NCT05255809|OTHER|Routine Physical Therapy|Trunk stabilising exercises time duration will be 15 minutes. Stance Phase time duration will be 15 minutes. Ankle Strategy. 40 minutes with rest of 5 minutes after 10 minutes. Two days a week for 16 weeks.
223653564|NCT03897517|DIETARY_SUPPLEMENT|Proprietary Botanical Blend|Oral administration of capsules containing proprietary botanical blend 30 minutes prior to carbohydrate ingestion.
224237304|NCT02590159|DEVICE|BONGO NASAL EPAP|The BONGO NASAL EPAP device consists of two nasal inserts (a connected pair), each containing an actuated valve, with a patient attachment mechanism. The device works by providing an inhalation port that offers minimal inhale resistance during inhalation, but is closed by the actuated valve so that exhalation occurs against a fixed orifice. This mechanism provides increased EPAP upon exhalation.
224237305|NCT04154579|BEHAVIORAL|HeRe We Arts|Art Therapy interventions to promote health, resilience \& well-being will discussed; \& experiences such as key chain making, collaging on journal covers, creating sculpture garden will be utilized. Music therapy interventions such as lyric discussion, singing, instrument playing, \& music-assisted relaxation techniques will be utilized; \& discussion of use of music to elicit positive physical \& emotional responses will be held. Drums Alive (drumming \& movement) will be used to promote physical activity. Art appreciation will include discussion of public art forms. Journaling will include different techniques for journaling, writing poetry, etc. Theater games such as Password, Press Conference, Props Only, \& Draw What You Hear will be utilized. Chair yoga will be introduced as a form of exercise. Education will be provided on the various topics.
223653565|NCT03897517|DIETARY_SUPPLEMENT|Placebo|Oral administration of capsules containing rice flour (placebo) 30 minutes prior to carbohydrate ingestion.
223653566|NCT00025480|DRUG|carboplatin|
223653567|NCT00025480|DRUG|paclitaxel|
223653568|NCT00025480|DRUG|tipifarnib|
223653569|NCT00025480|RADIATION|radiation therapy|
223653570|NCT05466617|BEHAVIORAL|Mobile Health for Physical Activity Behavior Change|All participants received visualized step-by-step instructions (eg, search and download on Google Play or App Store, user registration, goal setting, and PA behavior tracking) on the assigned PA app (PuzzleWalk or Google Fit) and used it from the beginning of the intervention start (fourth week) until the end of the intervention (eighth week). Both the PuzzleWalk and Google Fit groups received reminders regarding the use of the PA app during the first week of the intervention period and autonomously continued to use the app until the intervention ended.
223653571|NCT00060619|BEHAVIORAL|thermal biofeedback|
223653572|NCT00060619|BEHAVIORAL|relaxation training|
223653573|NCT00060619|BEHAVIORAL|cognitive coping skills|
223653574|NCT00060619|BEHAVIORAL|parent education|
223653575|NCT01214733|DRUG|tocilizumab [RoActemra/Actemra]|8 mg/kg intravenously every 4 weeks in combination with allowed DMARDs
223653576|NCT05045495|DIAGNOSTIC_TEST|Sucrose Hydrogen Methane Breath Test|Subjects will collect 2 buccal swabs for the sucrase genetic test and then subjects will simultaneously conduct the sucrose challenge test, sucrose hydrogen methane breath test, and the 13C-sucrose following ingestion of 50-grams of sucrose (table sugar) mixed with 8 ounce of water.
223653577|NCT05744843|BEHAVIORAL|exercise|cardiovascular and lower limb strengthening exercise programme
223653578|NCT05744843|PROCEDURE|Deep venous stenting|Planned surgical intervention
223653579|NCT01879358|DEVICE|Drug-eluting stent|
223653580|NCT03846908|OTHER|MCT|patients will receive fat load with MCT
223653581|NCT03846908|OTHER|SFA|patients will receive fat load with SFA
223653582|NCT03846908|OTHER|MUFA|patients will receive fat load with MUFA
223767644|NCT06743204|OTHER|Self-reported risk screening for PrEP and syndromic management for STIs|This active comparator (control) arm will receive the following: 1) Standard-of-care STI symptom screening: Regardless of HIV serostatus, participants will be asked if any STI symptoms 2) Syphilis testing for pregnant participants: Regardless of HIV serostatus, syphilis testing will be performed using blood samples provided in the Rakai Community Cohort Study. 3) PrEP screening (if HIV- only): Participants will be screened for PrEP eligibility using the standard-care Ministry Health self-reported risk screening (SRST) tool for PrEP. Participants who screen eligible for PrEP using the Ministry of Health SRST OR pregnant participant's who test positive for syphilis AND are HIV- will be referred for same-day PrEP initiation. Participants who have symptoms indicative of STIs or who test positive for syphilis will be provided with free treatment, as will the partner(s).
223767645|NCT07061275|BEHAVIORAL|Telehealth-Supervised Resistance Training|"The exercise protocol will incorporate a variety of exercise modalities adapted for home use in limited space environments. Elastic resistance bands will be used for lower-limb strength exercises such as leg presses, hip abduction, and ankle dorsiflexion, while sandbag-style leg weights will be employed for activities including knee extensions, seated marches, and standing squats. To target balance, low-cost tools such as foam pads, balance cushions, or step platforms will be used for tasks including static standing, single-leg stance, and step-up exercises designed to challenge postural control in a safe, progressive manner.~Sessions will be delivered through a secure live-streaming platform accessible on smartphones. The streaming platform supports background audio, allowing exercise sessions to be accompanied by music, which may help increase motivation and enjoyment for participating children. Each session will be led by trained instructors from the Hunan Normal University."
223767646|NCT05026554|GENETIC|Tape stripping|Optional genetic analysis for chronic hand eczema
223767647|NCT06747156|DRUG|ABO2203 Injection|Name of Active Ingredient: mRNA encoding CD19/CD3 T cell engager
223767648|NCT07064785|BEHAVIORAL|Video-based ART adherence counseling|"* Clinical visit which includes ART provision at 0, 12 and 24 weeks~* Two one-hour video-based sessions with associated activities at 0 and 12 weeks~* Enhanced/Intensive adherence counselling with video component between 24-35 weeks for those with high viral load"
224237306|NCT04154579|BEHAVIORAL|HeRe We Ed|Educational components and some experiential components will be utilized to educate the participants on health, resilience, well-being, nutrition, healthy eating, weight management, eating disorders, obesity, exercise, physical activity, sleep hygiene and the importance of sleep, mental health, stress management, the importance of improving life satisfaction, holistic approaches, wellness, integrative medicine, complementary and alternative medicine, chronic illness, chronic pain, methods for dealing with chronic versus acute illnesses, changing behaviors and/or maintaining healthy behaviors in order to promote health and stay out of the hospital, and navigating the healthcare system. Specific experiential components will include Chair Yoga and Stress Management Techniques.
223653583|NCT02932241|BEHAVIORAL|Computerized Dialectical Behavior Therapy Skills Training|8, 50 minute skill training sessions made available to participants each week
223653584|NCT02978599|DRUG|AVL-3288|daily for 5 days
223653585|NCT02978599|DRUG|Placebo|daily for 5 days
223653586|NCT00533676|DRUG|MK0524A, /Duration of Treatment : 8 Weeks|
223653587|NCT00533676|DRUG|Comparator : placebo (unspecified) /Duration of Treatment : 8 Weeks|
223653588|NCT03384862|DIETARY_SUPPLEMENT|Vitamin B12|5 μg/d vitamin B12 to be given orally. This is a standard nutritional supplement commonly used in the US.
223653589|NCT03384862|DIETARY_SUPPLEMENT|Placebo|Placebo pills, with same appearance as intervention pills.
223767649|NCT07064785|BEHAVIORAL|Standard of Care (SOC)|"* Clinical visit which includes ART provision at 0, 12 and 24 weeks~* Basic adherence counselling between 24-35 weeks for those with high viral load"
223767650|NCT07064109|DRUG|Colchicine 0.5 MG Oral Tablet Once Daily|Colchicine 0.5 MG Oral Tablet Once Daily
223767651|NCT07068919|BEHAVIORAL|Seizure diary|collection of a seizure diary during 3 months
223767652|NCT07068919|BEHAVIORAL|Questionnaries|Daily self-assessment via the Epiday application during 3 months
223767653|NCT06767345|DRUG|statins, ezetimibe|Rosuvastatin 20mg once daily
223767654|NCT06767345|DRUG|Combination therapy|Rosuvastatin 10mg + Ezetimibe 10mg
223767655|NCT06894212|DRUG|SEP-363856|tablet
223767656|NCT06894212|OTHER|Placebo|tablet
223767657|NCT07067632|DRUG|Antihypertensive treatment|"Any intervention (pharmacological, device-based, lifestyle) intentionally directed at lowering BP~Control groups receiving placebo, standard of care, or no intervention"
223767658|NCT06466837|BEHAVIORAL|Just-in-time intervention|The intervention group participants will receive just-in-time intervention from a developed app for healthy behavior reminder
223653590|NCT03384862|DIETARY_SUPPLEMENT|Folic Acid|400 μg/d folic acid to be given orally. This is a standard nutritional supplement commonly used in the US.
223653591|NCT01147913|BEHAVIORAL|Computerized Information-Processing Bias Retraining|The intervention consists of the presentation of three-line ambiguous scenarios via a computer program, one line at a time. A disambiguating word fragment completes the scenario (in either a positive or neutral valence, depending on the scenario), after which participants will type the first letter of the word on the keyboard to ensure they are encoding the interpretation valence. The computer will indicate if they have correctly identified the word. This is followed by a Y/N comprehension question. Each session presents 100 training scenarios.
223653592|NCT01147913|BEHAVIORAL|Attention Control Training|"Four sessions of interpretation training for filler or neutral scenarios, unrelated to themes associated with depression."
223653593|NCT03800940|PROCEDURE|Fistulography and trans-drain occlusion|"1. Fistulography: an 18G needle is inserted into the tube and diluted contrast medium is slowly injected into the tube.~2. Trans-drain occlusion: a 0.035-inch guidewire is inserted via the puncture needle. The drain tube is removed, cut at 4 cm proximal to the skin fixation site, and preserved for reinsertion. After inserting a 40cm 5Fr KMP catheter over the guidewire, the guidewire is removed. Afte rinsing the KMP catheter with 3ml 5% glucose water, withdraw the catheter and simultaneously inject glue (33%, 1:2, 0.5ml of NBCA + 1ml Lipiodol) into the catheter until the proximal 5cm of the catheter remains inside the tract. The guidewire is re-inserted through the catheter, and then the original drain tube is re-inserted over the guidewire. The guidewire is removed and the drain is fixed."
223767659|NCT06466837|BEHAVIORAL|Active control|The control group participants will receive six nursing consultations during the 3-month program period.
223767660|NCT06832787|DEVICE|Negative Pressure Wound Therapy|NPWT applied over wound without any adjuncts
223767661|NCT06832787|DEVICE|Kerecis|Kerecis Omega3 Wound Dressing is derived from fish skin and is used as a dermal substitute.
223653594|NCT03800940|PROCEDURE|Fistulography|Fistulography: an 18G needle is inserted into the tube and diluted contrast medium is slowly injected into the tube.
223653595|NCT00993148|DRUG|maraviroc|150 mg tab by mouth once daily for 96 weeks
223767662|NCT06832787|DEVICE|Delayed primary closure with local flap|Delayed primary closure with local flap to close wound
223767663|NCT06901037|OTHER|A chatbot-based intervention|A smartphone-delivered AI-based chatbot program designed to provide personalized physical activity and dietary recommendations
223767664|NCT07064876|DRUG|Serplulimab|PD-1 inhibitor, 300 mg intravenous infusion, once every 3 weeks (Q3W) for up to 6 cycles, starting after cryoablation recovery and in the absence of major procedural complications.
223767665|NCT07064876|PROCEDURE|CT-guided Cryoablation|Percutaneous cryoablation performed under CT guidance to achieve local tumor ablation. Procedure done once (per-protocol) prior to systemic therapy.
223767666|NCT04078828|PROCEDURE|Pelvic floor Reconstruction|Pelvic floor Reconstruction after laparoscopic anterior resection and double-stapling technique anastomosis were finished.
223767667|NCT06849544|DRUG|0.03mg/kg ZOPOCIANINE given day of surgery|A single dose of 0.03mg/kg ZOPOCIANINE used with NIR fluorescent imaging during prostatectomy and lymph node dissection
223767668|NCT06849544|DRUG|0.06mg/kg ZOPOCIANINE given day of surgery|A single dose of 0.06mg/kg ZOPOCIANINE used with NIR fluorescent imaging during prostatectomy and lymph node dissection
223767669|NCT06849544|DRUG|0.03mg/kg ZOPOCIANINE given day prior to surgery|A single dose of 0.03mg/kg ZOPOCIANINE used with NIR fluorescent imaging during prostatectomy and lymph node dissection
223767670|NCT06849544|DRUG|0.06mg/kg ZOPOCIANINE given days prior to surgery|A single dose of 0.06mg/kg ZOPOCIANINE used with NIR fluorescent imaging during prostatectomy and lymph node dissection
223767671|NCT06841341|DIAGNOSTIC_TEST|electromyography|electromyography of a set of muscles usually examined during diagnosis of ALS (typically tongue, bilateral deltoid, first dorsal interosseur, abductor pollicis brevis, paraspinals, vastus lateralis, anterior tibialis and additionally bilateral sternocleidomastoideus and rectus abdominis). In each muscle recording in relaxation and in maximal voluntary effort will be done. The presence of signs of acute (fibrillations, sharp waves) and chronic (fasciculations, reduction of the recording of the effort) denervation as well as presence of activity coupled with the rhythm of respiration will be assessed.
223767672|NCT06841341|DIAGNOSTIC_TEST|ultrasonography|Ultrasonographic measurements include cross-sectional area (CSA) and diameter of bilateral phrenicus, vagus and accessory nerves as well as diameter of diaphragm. The diameter of diaphragm will be measured during normal, quiet respiration as well as at the peak inspiration and expiration.
223653596|NCT00993148|DRUG|darunavir|800 mg tab by mouth once daily for 96 weeks
223653597|NCT00993148|DRUG|ritonavir|100 mg capsule by mouth once daily for 96 weeks
223653598|NCT00452972|DRUG|Spinal Anesthesia|
223653599|NCT06471348|DRUG|Bupivacaine liposome injectable suspension|EXPAREL is a milky white too off-white aqueous suspension available as single-dose vials. Each mL contains 13.3 mg of bupivacaine, which is contained in multivesicular liposomes.
223767673|NCT06841341|DIAGNOSTIC_TEST|Arterial blood gas analysis|Assessment of partial oxygen (PaO2) and partial carbondioxide pressure (PaCO2) in arterial blood.
223767674|NCT06841341|DIAGNOSTIC_TEST|slow vital capacity|Slow vital capacity (SVC) will be measured as the full exhalation done after inspiration which will follow a period of quiet breathing. The test will be performed thrice and the final value will be the average value.
223767675|NCT01038778|BIOLOGICAL|Aldesleukin|Given IV
223767676|NCT01038778|PROCEDURE|Computed Tomography|Undergo FDG-PET/CT
223653600|NCT06471348|DRUG|Bupivacaine Hydrochloride and Epinephrine Injection|Sensorcaine-MPF with Epinephrine 1:200,000 is a clear, colorless to slightly yellow solution available as single-dose vials. Each mL contains bupivacaine hydrochloride, 0.005 mg epinephrine, and 0.5 mg sodium metabisulfite (antioxidant), and 0.2 mg anhydrous citric acid (stabilizer).
223653601|NCT02905890|DRUG|Norethisterone enantate|Noristerat® 200mg, solution for intramuscular injection given every 8 weeks
223653602|NCT02905890|DEVICE|Condoms|Latex male condoms
223653603|NCT06489626|DRUG|Methylprednisolone 4 milligram Tab|6-day 4 milligram methylprednisolone oral taper
223653604|NCT06489626|DRUG|Dexamethasone injection|4 milligram intravenous dexamethasone will be administered intraoperatively
223653605|NCT03990610|PROCEDURE|Mammoplasty|Undergo standard of care breast reconstructive surgery
223653606|NCT03990610|PROCEDURE|Vascularized Lymph Node Transfer|Undergo vascularized lymph node transfer
223653607|NCT05952518|DEVICE|Sprint PNS system|Temporary electrical stimulation of the medial nerve with implanted wires and wearable stimulator
223653608|NCT05952518|PROCEDURE|Radiofrequency Ablation|Thermal ablation of the medial nerve
223653609|NCT05947058|PROCEDURE|Arthroplasty|The type of hip prothesis (hemi or total; cemented or uncemented) will be at the discretion of the treating surgeon.
223653610|NCT05947058|PROCEDURE|Internal Fixation|Both fixed angle devices and multiple screws will be permitted for the internal fixation group.
223653611|NCT05239624|DRUG|Enfortumab vedotin|Enfortumab vedotin will be administered at 1.25 mg/kg on day 1 and day 8 of each 21-day cycle, for up to 6 cycles.
223767677|NCT01038778|DRUG|Entinostat|Given PO
223767678|NCT01038778|RADIATION|Fludeoxyglucose F-18|Undergo FDG-PET/CT
223767679|NCT01038778|OTHER|Laboratory Biomarker Analysis|Correlative studies
223767680|NCT01038778|OTHER|Pharmacological Study|Correlative studies
223767681|NCT01038778|PROCEDURE|Positron Emission Tomography|Undergo FDG-PET/CT
223767682|NCT06830200|PROCEDURE|Non-surgical periodontal treatment with chitosan brush|Non-surgical treatment of pre-implantitis with chitosan brush
223767683|NCT06830200|DEVICE|Non-surgical treatment of pre-implantitis with titanium curette|Description: Non-surgical treatment of pre-implantitis with titanium curette
223767684|NCT06896435|BEHAVIORAL|Safety Behavior Fading for Appearance Concerns|Participants are asked to reduce or eliminate safety behaviors via text message reminders and checklists to monitor progress.
223767685|NCT06896435|BEHAVIORAL|Relaxing Video|Participants are asked to view weekly videos lasting 15 minutes each to engage in relaxation exercises.
223767686|NCT07074353|DRUG|NALIRI|Irinotecan liposomes
223767687|NCT07074353|RADIATION|LCRT|Long-course concurrent chemoradiotherapy
223767688|NCT07074353|DRUG|FOLFOX|Fluorouracil/Leucovorin, Oxaliplatin (5-FU/LV, OX)
223653612|NCT05239624|DRUG|Pembrolizumab|Pembrolizumab will be administered on day 1 of each cycle, every 21 days, for 6 cycles.
223653613|NCT06667726|PROCEDURE|Computed Tomography|Undergo PET/CT
223653614|NCT06667726|DRUG|Fluorodopa F 18|Given IV
223653615|NCT06667726|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
223653616|NCT05857995|BEHAVIORAL|Kentucky LEADS Collaborative Lung Cancer Survivorship Care Program|KLCLCSC is a survivor or survivor plus caregiver-focused psychosocial and behavioral intervention designed to engage lung cancer survivors and improve lung cancer outcomes.
223653617|NCT05857995|BEHAVIORAL|Enhanced Usual Care|EUC involves a combination of the standard of care plus a bibliotherapy intervention and assessment.
223653618|NCT06620003|BIOLOGICAL|cAd3-Marburg Vaccine|The recombinant chimpanzee adenovirus Type 3-vectored Marburg vaccine, (cAd3-Marburg Vaccine) is composed of a cAd3 vector that expresses Marburg wild type glycoprotein (WT GP) from the Angola strain.
223653619|NCT06620003|BIOLOGICAL|Placebo|0.9% NaCl solution for injection.
223653620|NCT01934660|DRUG|13N-amonia|PET/Scan
223653621|NCT01934660|DRUG|Fludeoxyglucose F18|PET/Scan
223653622|NCT06448806|OTHER|mobile health lifestyle intervention|You will be asked to record all dietary and physical activity log for 12 months on an application. Mobile sms reminders will be sent to you on regular basis. At day 0, at 6th and 12 months you will be asked to provide 3 ml of blood for the methylation and advance glycation level testing and your weight and body fat percentage will be measured. During this period you will have to follow the lifestyle and diet chart provided to you by the researchers.
223653623|NCT06243952|DEVICE|ARC-BSI Lumbar system|Implantation of a 64 channel - ECoG array over the sensory motor cortex of the lower limbs, combined with an implantation of 16 channel spinal cord stimulation system over the lumbar region. The decoded motor intentions are driving the implanted spinal cord stimulation system. Brain-controlled spinal cord stimulation is used for training and rehabilitation to recover voluntary movements.
223653624|NCT05958316|BEHAVIORAL|Computerized Symptom Capture Tool (C-SCAT) Intervention|"The C-SCAT includes the 32 symptoms from the Memorial Symptom Assessment Scale (MSAS). Users select symptoms they have experienced over the past week, rate each symptom's severity and distress, and name a perceived cause. They then identify temporal and causal relationships between symptoms using lines and arrows, designate groups, i.e., clusters of symptoms, and give a name to each cluster. They are asked the reason for a symptom's designation as a priority symptom and what they do to alleviate that symptom. Next, they are asked to designate a priority cluster and finally, to confirm whether the image accurately reflects their symptom experience. Then, at the clinic visit, the AYA shares the visual image with the HCP, and more importantly, their priority symptoms, which can facilitate the symptom discussion. The C-SCAT intervention group will complete the C-SCAT prior to each of three encounters with their health care providers (HCPs)."
223653625|NCT05958316|BEHAVIORAL|Usual Care Control|Usual care is defined as the usual approach to assessing symptoms during the HCP encounter. To provide attentional control to the usual care control group and prevent disproportionate attrition from that group, study staff will contact participants three times during the intervention period (approximately 3 months) when they are in for a scheduled clinic visit and communicate the following: 1) express appreciation for ongoing study participation; 2) ask how everything is going with their treatment; 3) ask if anything has changed with their treatment plan since the last study visit; and 4) confirm continued participation in the study.
223653626|NCT04656535|DRUG|Zimberelimab|Zimberelimab (AB122) is a fully human immunoglobulin G4 (hIgG4) monoclonal antibody (mAb) that targets PD-1.
223653627|NCT04656535|DRUG|Domvanalimab|Domvanalimab (AB 154) is a humanized immunoglobulin G1 (IgG1) monoclonal antibody that targets TIGIT.
223653628|NCT04656535|DRUG|Placebo|Saline placebo comparator for pre-surgery treatment in cohort B4
223653629|NCT01143558|DEVICE|Lyme Disease Xenodiagnosis|Clean laboratory-bred ticks are the FDA registered IDE. These ticks are placed on patients to search for evidence of Borrelia burgdorferi.
223653630|NCT05564052|DRUG|Ibrutinib|Ibrutinib capsules will be administered orally.
223653631|NCT05564052|DRUG|Lenalidomide|Lenalidomide capsules will be administered orally.
223653632|NCT05564052|DRUG|Rituximab|Rituximab will be administered IV.
223653633|NCT05564052|DRUG|Bortezomib|Bortezomib will be administered either intravenously or subcutaneously.
223653637|NCT05516732|OTHER|Positron Emission Tomography (PET) scan using CIMBI-36 tracer|This scan creates images of regional serotonin release in by using a tracer compound called CIMBI to highlight the brains capacity to release serotonin.
223653638|NCT05516732|OTHER|Magnetic Resonance Imaging (MRI) Scan|MRI (magnetic resonance imaging) uses magnets alongside radio waves to create pictures of the brain
223653639|NCT05516732|OTHER|Positron Emission Tomography (PET) scan using DASB tracer|To create images of the brain using a tracer called DASB, which is a highly selective for serotonin transporters, this highlights serotonin terminals and neurons in the brain.
223653640|NCT05516732|OTHER|FP-CIT Single-photon Emission Computed Tomography (SPECT) scan|A single-photon emission computerized tomography (SPECT) scan allows analysis of brain function by creating 3D Pictures using compounds called tracers.
223767689|NCT07085780|OTHER|LEP|"1. Apply a thin, even layer of the Lep directly onto the clean and dry affected area.~2. Cover the application with a layer of clean cotton.~3. Allow the Lep to remain on the area for at least 2 days,~4. Avoiding exposure to direct heat or open flame during this period.~5. In this study, on Day 04, gently remove the Lep using warm water and soft cotton cloth and thoroughly cleanse the area with mild soap and water."
223767690|NCT07084987|OTHER|neonatal massage|Standardized neonatal massage before phototherapy
223767691|NCT07084987|OTHER|Tub Bathing|Tub bath before phototherapy
223767692|NCT07084987|OTHER|sponge bath|Sponge (wipe) bath before phototherapy
224237307|NCT01139437|BIOLOGICAL|Standard Dose HPIV2 Vaccine|10\^6 tissue culture infectious dose 50% (TCID50) administered intranasally in a single dose
223767693|NCT07086209|DIETARY_SUPPLEMENT|Branched-Chain Amino Acid Supplement|Oral BCAA blend (leucine, isoleucine, valine), 10 g/day divided into two doses, pre- and post-training, for 6 weeks.
223653641|NCT05516732|OTHER|Lumbar puncture|A lumbar puncture invovles a thin needle is inserted between the bones in your lower spine using local anaesthetic. This allows the collection of Cerebrospinal fluid ( CSF)
223653644|NCT04877197|BEHAVIORAL|BA-HT|Behavioral Activation for depression delivered via home-based telehealth (BA-HT) will be implemented over 12, weekly 50-minute sessions via VA approved telehealth software.
223653645|NCT04877197|OTHER|Standard Care|Best practices standard care delivery for post-CVD hospitalization as regularly implemented at the RHJ VAMC. Standard care may include all or some of the following: post-operative follow up, referral to VA primary care clinic at 1 month post-procedure, primary care visit with VA mandated assessments of pain and depression with referral for these conditions, referral to facility-based or home-based cardiac rehabilitation program as appropriate. All participants in this condition will be referred to mental health care. In addition, these participants will receive a weekly telephone call from project staff during which time supportive questioning about patient progress and general mood and recovery.
223653646|NCT00702533|DEVICE|Pentagastrin Injection BP|
223767694|NCT07086209|BEHAVIORAL|Therapeutic Exercise Program|6-week structured program including isometric, eccentric, plyometric, and sprint-specific exercises.
223767696|NCT06896825|BEHAVIORAL|Self-monitoring|All participants will receive a Garmin and use the associated app to monitor their weekly physical activity (in Intensity Minutes, the term used by Garmin for moderate to vigorous physical activity). Enrolled participants are insufficiently active (engaging in 60 minutes or less of moderate to vigorous physical activity per week) and will receive weekly text messages to incrementally increase physical activity over the course of the study. Goals will be 20% greater than the number of Intensity Minutes from the previous week, with the ultimate goal of reaching 150 Intensity Minutes or more per week, aligning with national activity guidelines.
223767697|NCT07085689|DEVICE|Sodium Fluoride Varnish (5%)|After isolating and drying the teeth to be treated using cotton rolls, 5% sodium fluoride (NaF) varnish (Proshield Varnish, President Dental, Munich, Germany) was applied to the tooth surfaces in two thin layers with the help of a disposable microbrush. The cotton rolls were then removed to allow the varnish to come into contact with saliva and harden. After the procedure, participants were advised to avoid consuming hard foods and brushing their teeth for 4 to 6 hours.
223767698|NCT07085689|DEVICE|Silver diamine fluoride- potassium iodide|After isolating and drying the teeth to be treated using cotton rolls, a gingival barrier (Top Dam, FGM Dental Group, Brazil) was applied around the cervical area of the crown to cover the surrounding gingiva and was light-cured. After applying petroleum jelly to the lips for isolation, the first step, 38% silver diamine fluoride (Riva Star, SDI, Bayswater, Australia), was applied to the entire tooth surface using a disposable microbrush. Immediately afterward, the second step, potassium iodide, was applied generously to the entire tooth surface using another disposable microbrush. The agent was applied until the creamy white appearance on the tooth disappeared. Excess material on the tooth surface was gently dabbed dry with a cotton pellet.
223767699|NCT07085689|DEVICE|Aqueous Silver Fluoride|After isolating and drying the teeth to be treated using cotton rolls, a gingival barrier (Top Dam, FGM Dental Group, Brazil) was applied around the cervical area of the crown to cover the surrounding gingiva and was light-cured. After applying petroleum jelly to the lips for isolation, the first step, 38% aqueous silver fluoride (Riva Star Aqua, SDI, Bayswater, Australia), was applied to the entire tooth surface using a disposable microbrush. Immediately afterward, the second step, potassium iodide, was applied generously to the entire tooth surface using another disposable microbrush. The agent was applied until the creamy white appearance on the tooth disappeared. Excess material on the tooth surface was gently dabbed dry with a cotton pellet.
224237308|NCT01139437|BIOLOGICAL|Low dose HPIV2 vaccine|10\^5 TCID50 administered in a single dose
224237309|NCT01139437|OTHER|Placebo|Matched placebo
224237310|NCT06195618|BIOLOGICAL|Peptide (neoantigen) pulsed autologous Dendritic cell|Intradermal vaccination with peptide-pulsed autologous dendritic cells in 200 µL of patient's serum in six doses, one weekly after surgery.
224237311|NCT02303808|DEVICE|INHALATION WITH PEP DEVICE (Acapella Duet)|Intervention will be performed during 5 consecutive days. The performance order of both arms will be randomized.
223653647|NCT00702533|DRUG|Pentagastrin|
223653648|NCT00353158|DRUG|Doxycycline|100mg twice daily for 3 days. Two hours after the last dose of doxycycline is taken in the clinic, on-medication phototesting with ssUVR, UVA, and visible light will be performed.
223653649|NCT00353158|DRUG|Voriconazole|After taking voriconazole for (Bullet)7 days to achieve a steady state of voriconazole for subjects, on-medication phototesting with ssUVR, UVA, and visible light will be performed.
223653650|NCT04191811|BEHAVIORAL|Internet-delivered cognitive behavioral therapy for major depressive disorder|Cognitive behavioral therapy delivered over a period of 12 weeks, guided by a psychologist who provides written feedback on home assignments and questions.
223653651|NCT04191811|BEHAVIORAL|Internet-delivered cognitive behavioral therapy for insomnia|Cognitive behavioral therapy delivered over a period of 12 weeks, guided by a psychologist who provides written feedback on home assignments and questions.
223653652|NCT04191811|BEHAVIORAL|Internet-delivered cognitive behavioral therapy for social anxiety disorder|Cognitive behavioral therapy delivered over a period of 12 weeks, guided by a psychologist who provides written feedback on home assignments and questions.
223653653|NCT04954599|DRUG|CP-506|CP-506 is a hypoxia-activated DNA alkylating agent specifically designed to have a bystander effect, aqueous solubility, oral bioavailability, and no off-mechanism activation by the human aerobic reductase AKR1C3
223653654|NCT04954599|DRUG|Carboplatin|Antineoplastic agent, ATC Code: LO1X A02
223653655|NCT04954599|DRUG|Immune checkpoint inhibitor|Drug that blocks immune checkpoint proteins: PD-1, PD-L1, CTLA-4
223653656|NCT06975371|OTHER|No drug|No study drug was administered in this non-interventional study.
223653657|NCT06972407|BIOLOGICAL|Exendin 9-39|A competitive antagonist of the GLP-1 receptor
223653658|NCT06972407|OTHER|Saline|Saline infusion will serve as an inactive comparator
223653659|NCT06730009|BIOLOGICAL|SLOG + Allogeneic NK cell|"Drug: SLOG chemotherapy S-1, leucovorin, oxaliplatin, and gemcitabine (SLOG)~Biological:~Allogeneic Magicell-NK contains NK cells suspended in 100 mL of normal saline Ph I dose starts at 10 × 10\^8 cells (Cohort 1) and escalates to 20 × 10\^8 cells (Cohort 2).~Ph II dose will be determined lower than or equal to Ph I MTD/MFD."
223653660|NCT06730009|DRUG|SLOG chemotherapy|Drug: SLOG chemotherapy S-1, leucovorin, oxaliplatin, and gemcitabine (SLOG)
224237312|NCT04559854|BEHAVIORAL|Mindful After Cancer|The intervention includes eight weekly sessions (1.5-2 hours each), plus participant educational materials and audio recorded meditations, and is delivered to women in their homes via group videoconference led by a trained facilitator. Participants are asked to complete activities and mindfulness practice between sessions.
224237313|NCT04551885|DRUG|FT516|Experimental Interventional Therapy
224237314|NCT04551885|DRUG|Avelumab|Monoclonal antibody
224237315|NCT04551885|DRUG|Cyclophosphamide|Lympho-conditioning agent
224237316|NCT04551885|DRUG|Fludarabine|Lympho-conditioning agent
224237317|NCT04551885|DRUG|IL-2|Biologic response modifier
224237318|NCT00843609|DEVICE|Navigator continuous glucose monitor (Freestyle Navigator®)|Continuous use of the Free Style Navigator for monitoring of glycemia in patients with type 1 diabetes with HbA1c below 7.5 %
224237319|NCT06075654|OTHER|no intervention it is considered (Epidemiological Study)|It was a survey used Visual Analog Scale and WaLIDD scale to measure the severity of primary dysmenorrhea between both groups
224237320|NCT02370407|DEVICE|a laparoscopic simulator (Fundamentals of Laparoscopic Surgery (FLS), VT Medical Inc, Waltham, MA)|10 repetitions of practice on laparoscopic simulator.
224237321|NCT02370407|DEVICE|Mimic da Vinci robotic simulator|10 repetitions of practice on Mimic da Vinci robotic simulator.
224237322|NCT00718679|DRUG|IVN201|Intralymphativ injection of the study drug
224237323|NCT00718679|DRUG|Placebo|
224237324|NCT02899390|BEHAVIORAL|Lifestyle Intervention|"Before implementation of the National Diabetes Prevention Program, adaptations will be made in order to be culturally acceptable in the community taking in consideration the type of food they eat and their activities in the population.~The lifestyle intervention will be implemented by group and individual sessions and is aimed at achieving a 7% loss weight from baseline and 150 minutes per week of physical activity. Sessions will be held weekly in a period of 6 months. Individual sessions consist in nutritional counseling according to energy needs and food preferences of each participant."
224237325|NCT04260503|OTHER|Monitoring of the gut-microbiome and ultrasound elasticity.|The investigator will investigate the alteration of gut-microbiome and liver stiffness by restoration of bile flow by operation.
224237326|NCT04260503|OTHER|Monitoring of the gut-microbiome|The investigator will investigate the alteration of gut-microbiome before and after operation.
224237327|NCT04260503|OTHER|Monitoring of the gut-microbiome|The investigator will investigate the alteration of gut-microbiome along with the disease progress.
223653661|NCT00018057|BEHAVIORAL|Attention Bias Modification Training|The intervention is computer-based. The active and control treatments have two components. In one component of the active intervention, subjects are asked to indicate the identity of a letter that appears behind a neutral face, opposite from an angry face. In another component of the active intervention, subjects are asked to identify numbers that are hidden within a puzzle, in locations distal from angry faces. In both components of the active intervention, subjects implicitly learn to shift their attention away from angry faces. This is because the faces are systematically arranged to be far removed from letters and numbers that need to be identified. The control arm of the intervention involves similar components. However, unlike in the intervention arm, angry faces appear in various locations near letters and numbers. Therefore, attention is not shaped in the control arm. This intervention requires five minutes per session and is administered before weekly psychotherapy sessions.
223653662|NCT00018057|DRUG|Fluoxetine|Randomized assignment.
224237328|NCT04260503|OTHER|Monitoring of the gut-microbiome.|The investigator will investigate the alteration of gut-microbiome according to the normal development.
224237329|NCT00212069|DRUG|gemcitabine, carboplatin|
224237330|NCT05951569|DEVICE|Community-Derived Open-Source Automated Insulin Delivery Loop System|The Loop System consists of an insulin pump and a Dexcom CGM. The system includes an iPhone with the Loop app and a RileyLink to communicate between the pump and iPhone. An Apple Watch may optionally be used with the system.
224237331|NCT02623088|OTHER|PAP Therapies (CPAP)|Patients with sleep apnea syndrome treated by PAP Therapies (CPAP) after diagnosis and followed 5-7 years.
224237332|NCT03186911|BEHAVIORAL|E-liquid sampling and preference assessment|Participants will sample two different e-liquids that vary in nicotine content, complete questionnaires about each one, and then choose between the two e-liquids in a preference assessment task.
224237333|NCT05274711|OTHER|Whole body vibration training|The participants will be instructed to stand on the vibration platform bare footed and distribute their weight evenly on both feet (fig 3). Next, they will be asked to do a head and neck retraction while looking forward with their knees at 30 degrees of flexion. In order to prevent fatigue in the subject's cervical area due to holding their head and neck in retraction, they will be asked to hold this position for 15 seconds then rest for 5 seconds. Since each set will last 60 second this allowed the subjects to do 3 retractions in each set. In total each subject will perform 15 retractions during the training. The subjects will experience a vertical vibration at a frequency and amplitude of 30 Hz and 4 mm during the sets (Salami et al., 2018).
224320862|NCT02723734|OTHER|Decipher® Testing|Decipher® Prostate Cancer Classifier (Post-Op and Biopsy), a Genomic Classifier (GC) test. Biopsy and prostatectomy specimens will be collected for GC testing.
223653663|NCT06572852|OTHER|No intervention|No intervention
223653664|NCT05931276|DRUG|Metoprolol Succinate|a dialyzable, beta-1 selective beta blocker
223653665|NCT05931276|DRUG|Carvedilol|a non-dialyzable, non-selective beta blocker with alpha-1 antagonist properties
223653666|NCT05629585|DRUG|Dato-DXd|Experimental drug. Provided in 100mg vials. IV infusion
223653667|NCT05629585|DRUG|Durvalumab|Experimental drug. Provided in 50mg vials. IV infusion
223653668|NCT05629585|DRUG|Capecitabine|Active Comparator. Tablet. Oral route of administration
223767700|NCT07085689|DEVICE|Hydroxyethyl Methacrylate and Glutaraldehyde|After isolating and drying the teeth to be treated using cotton rolls, a gingival barrier (Top Dam, FGM Dental Group, Brazil) was applied around the cervical area of the crown to cover the surrounding gingiva and was light-cured. One to two drops of a desensitizing agent containing hydroxyethyl methacrylate and glutaraldehyde (Gluma, Heraeus Kulzer GmbH, Hanau, Germany) were applied to the tooth surface using a disposable microbrush in a rubbing motion. After waiting for 30-60 seconds, the tooth surface was completely dried until the liquid disappeared and the surface lost its shine, and then rinsed with water.
223767701|NCT07084831|DRUG|Xanomeline/trospium|Participants will receive xanomeline/trospium during the trial
223767702|NCT07084857|OTHER|correlational analysis between BMD and isokinetic lower extremity strength|correlational analysis between BMD and isokinetic lower extremity strength
223767703|NCT07086859|PROCEDURE|TEST 1|Autogenous whole tooth graft with metformin
223767704|NCT07086859|PROCEDURE|Control|Autogenous whole tooth graft
224237334|NCT05274711|OTHER|Conventional physical treatment|Posturalcorrectionexercisesintheformofstretchingandstrengthening exercise. Manual stretching exercises as passive stretch to (upper trapezius, levator scapulae, sub occipitalis, scalene, sternocleidomastoid, and pectoralis major muscles), 30 seconds of 3-5 repetitions for each muscle, followed by 30 seconds of rest, as well as isotonic exercises (to strength deep neck flexors and scapular retractor muscles) 3 sets of 12 repetitions each with a 6 second hold in between, with a 1-2-minute rest between sets (Kisner. and Colby 2012).
224237335|NCT00140517|DRUG|sulphadoxine-pyrimethamine|
224237336|NCT00140517|DRUG|chloroquine|
224237337|NCT06343948|DRUG|BL-B01D1|Administration by intravenous infusion for a cycle of 3 weeks.
224237338|NCT06343948|DRUG|Eribulin|Administration by intravenous bolus for a cycle of 3 weeks.
224237339|NCT06343948|DRUG|Vinorelbine|Administration by intravenous infusion for a cycle of 3 weeks.
224237340|NCT06343948|DRUG|Gemcitabine|Administration by intravenous infusion for a cycle of 3 weeks.
224237341|NCT06343948|DRUG|Capecitabine|Oral administration for a cycle of 3 weeks.
224237342|NCT00796822|DRUG|Pentoxifylline|400 mg three times a day for 8 weeks
224237343|NCT00796822|DRUG|Placebo|One pill three times a day for 8 weeks
224237344|NCT00906347|DRUG|Misoprostol|75 micrograms orally every 4 hours for up to 2 doses.
224237345|NCT00906347|DRUG|Oxytocin|Intravenous oxytocin will be administered per the established Labor and Delivery protocol at Parkland Memorial Hospital
224237346|NCT04442906|DRUG|Dexmedetomidine|Group BD received Intra-articular injection of 20 ml bupivacaine 0.25%+ 1 ml dexmedetomidine (100 ug).
224237347|NCT04442906|DRUG|Fentanyl|Group BF received Intra-articular injection of 20 ml bupivacaine 0.25%+ 1 fentanyl (50 ug)
224237348|NCT04442906|DRUG|Bupivacain|Group B received Intra-articular injection of 20 ml bupivacaine 0.25%+ 1 ml saline.
224237349|NCT02437149|BEHAVIORAL|Video|Real stories video presentation about distracted driving. Produced by the National Highway Traffic Safety Administration.
223653669|NCT05629585|DRUG|Pembrolizumab|Active Comparator. Provided in 100mg vials. IV infusion
223653670|NCT06532747|BEHAVIORAL|Integrated Lifestyle Intervention (ILI)|ILI participants will receive training in empirically supported strategies to improve psychological function (e.g., restructuring negative thoughts, distress tolerance), with a focus on changing discrete behaviors linked to inflammation (e.g., sleep, processed foods, physical activity), all intertwined with BWL content adapted to meet the needs of EAs.
223767705|NCT06597487|PROCEDURE|Full pulpotomy|"The patients will receive full pulpotomy as follows:~-Under rubber dam isolation, the operator will perform caries removal, complete the access cavity preparation, achieve hemostasis from all canals, and apply the bioceramic material. The operator will seal the cavity with glass ionomer restoration."
224237350|NCT02437149|BEHAVIORAL|Power Point|Brief power point presentation with information about distracted driving. Produced by the National Highway Traffic Safety Administration.
224237351|NCT02437149|BEHAVIORAL|Brochure|Brochure with the National Highway Traffic Safety Administration information about distracting driving.
224237352|NCT01241942|DEVICE|Steen Solution™|This solution is a buffered dextran and albumin-containing extracellular perfusate with an optimal colloid osmotic pressure developed specifically for extra-corporeal perfusion of lungs. After EVLP, lungs will be cooled in the circuit to room temperature, then flushed with cold Perfadex™ and taken to UNC Hospitals (UNCH) where they will have an ex-vivo CT scan. Lungs determined suitable will be offered to consented patients at UNCH based on Lung Allocation Score. Lungs not considered for transplantation may be subjected to different experiments but are not to be a part of this research study. In summary, lungs with good and stable function during EVLP with Steen Solution™ will be transplanted into recipients as per current clinical practice.
224237353|NCT01241942|OTHER|Conventional Lung Transplant|No experimental procedures will be carried out. Lungs from conventional brain-dead organ donors will be used for transplant.
224237354|NCT03743480|OTHER|early palliative care|experimental arm. Patients in this arm will meet with the palliative care team soon after the decision on their last active treatment
224320863|NCT06141018|DEVICE|Cross-linked intra-articular hyaluronic acid|Patients in the treatment arm will receive 3 ml, 90 mg hyaluronic acid injection intra-articularly, while the ones in the placebo arm will receive 3 ml saline injection intra-articularly. The groups will be crossed-over at 3rd month.
223653671|NCT06532747|BEHAVIORAL|Monitoring with digital tools|All participants will receive digital tools to facilitate self-monitoring-the initial 4-month program will consist of group sessions via Zoom (8 weekly, 4 bi-weekly) with weekly tailored e-coaching, followed by monthly boosters through 12 months.
223653672|NCT06517758|DRUG|Iptacopan|Hard gelatin capsule
223653673|NCT06517758|OTHER|Matching Placebo|Hard gelatin capsule
223653674|NCT06284811|BEHAVIORAL|HIIT Exercise program focusing on quadriceps|Participants will be asked to perform the exercise program that focusing on quadriceps muscle.the participants started to 20-minute HIIT for the lower extremity. The HIIT protocol included static lunch, squats, squat walk, sumo squat, lateral squat walk, front and back lunge, kneel to squat, squat pulses and side lunge exercises. Exercises were performed as 40 seconds exercise and 10 seconds rest. During training, heart rate (HR) was monitored using an activity monitor. All participants completed HIIT Training, after received either percussion therapy or massage therapy according to their randomizations.
223653675|NCT05382312|DRUG|GSK3036656|GSK3036656 will be administered.
223653676|NCT05382312|DRUG|Bedaquiline|Bedaquiline will be administered.
223653677|NCT05382312|DRUG|Delamanid|Delamanid will be administered.
223653678|NCT05382312|DRUG|RIFAFOUR e-275|RIFAFOUR e-275 will be administered.
223653679|NCT05382312|DRUG|BTZ-043|BTZ-043 will be administered.
223653680|NCT04058756|DRUG|PDR001|PDR001
223653681|NCT02689466|DRUG|[18F]FP-TZTP|radioligand
223653682|NCT05189366|BEHAVIORAL|Sophrology|"Sophrology is a relaxation method that's sometimes referred to as hypnosis, psychotherapy, or a complementary therapy.~Sophrology uses techniques such as: hypnosis, visualization, meditation, mindfulness, breathing exercises, gentle movements, body awareness...~Sophrology techniques may be useful during medical procedures that cause stress and discomfort.~Sophrology techniques may be useful during medical procedures that cause stress and discomfort.~Patients will receive 6 sessions of sophrology"
223653683|NCT05189366|BEHAVIORAL|Speech therapy|Speech therapy is a treatment that can help improve communication skills. patients will benefit from two speech therapy sessions per week for 6 months, lasting from 30 minutes to 1 hour depending on the patient's general condition.
224237355|NCT05946993|OTHER|Physiotherapy|participant will have 2 x 1h exercise classes per week with a physiotherapist, who will develop individualized plans based on medical history and scan reviews. Participants will be progressively guided through the programme, incrementally increasing in intensity or with modifications based on symptomatic presentation. This will be based on their baseline strength and cardiovascular fitness testing and grounded on evidence-based protocols previously demonstrating an effect in this patient population. Individualised tailored exercise programme which includes strength and conditioning.
224237356|NCT05946993|OTHER|Dietitian Support|The main goal of the nutritional intervention is to improve the diet quality of each patient using a standardized nutrition assessment, offering evidence-based diet group education and developing personalized nutrition goals. Participants will be progressively guided through the nutrition education programme; with modifications to the individual's usual diet, thereby recognizing personal eating patterns and preferences, which form the basis for individualized dietary counselling. The dietary counselling identifies the type, amount, and frequency of feeding and specifies the caloric/protein level to attain, together with any restrictions and limited or increased individual dietary components.
223653684|NCT04910568|DRUG|Cevostamab|Cevostamab will be administered intravenously on a 28-day cycle, up to a total of 13 cycles (Arm A), in 28-day cycles Q2W followed by Q4W (Arm B) and in 21 day cycles from C1-C8 Q3W and 28-day cycles from C9 onwards Q4W (Arm C). For Arm A, participants have the option to enter re-treatment after Cycle 13. For Arms B and C, participants can be treated until disease progression or unacceptable toxicity.
223653685|NCT04910568|DRUG|Tocilizumab|Tocilizumab will be administered for the treatment of cytokine release syndrome (CRS) when necessary.
223653686|NCT04910568|DRUG|Pomalidomide|Pomalidomide will be administered orally (PO) on a 28-day cycle.
223653687|NCT04910568|DRUG|Daratumumab|Daratumumab will be administered subcutaneously (SC) on 21 day (C1-8) and 28-day cycles (C9 onwards).
223653688|NCT04910568|DRUG|Dexamethasone|"Arm A: Dexamethasone will be administered as a premedication.~Arms B and C: Dexamethasone will be administered via IV or orally at 20 mg as study investigational medicinal product."
223653689|NCT00427765|DRUG|Busulfan|Test Dose = 32 mg/m\^2 IV for 1 Day; 130 mg/m\^2 IV for 4 Days
223653690|NCT00427765|DRUG|Melphalan|70 mg/m\^2 IV for 2 Days
223653691|NCT03564691|DRUG|MK-4830|MK-4830 will be administered intravenously (IV) Q3W. In Part C, MK-4830 will be administered after completion of pembrolizumab infusion. Dose escalation will proceed based on emerging safety and tolerability data of MK-4830 as monotherapy (Part A and B) and as combination therapy with pembrolizumab (Part C). For each dose level, an assessment will be made of the safety and tolerability data in order to define the next dose level to be tested.
223653692|NCT03564691|DRUG|Pembrolizumab|Pembrolizumab will be administered at 200 mg IV Q3W.
223653693|NCT03564691|DRUG|Carboplatin|Carboplatin will be administered IV Q3W.
223767706|NCT06597487|PROCEDURE|Conventional root canal treatment|The patients will receive conventional root canal treatment, which is the gold standard treatment protocol in cases with irreversible pulpitis.
224237357|NCT05946993|OTHER|Nursing and Psychosocial|Nursing, Psycho-oncology, pastoral care and social work-led sessions to inform participants on items including diagnosis shock, acceptance, coping with relationship changes with their partner and their roles, fear of uncertainty and the future, medication management, masculinity (male values being strong, capable, independent), practical management of bills, and household tasks. There will be an inclusion of practical information sessions including health systems information and managing side effects such as urinary symptoms, hot flushes, penile shortening, and loss of body hair.
224237358|NCT02099500|PROCEDURE|Liposuction|Liposuction using aspiration syringe and tumescent local anesthesia
224237359|NCT02099500|OTHER|Stem Cell Injection|Stem cell implantation will be performed using intramuscular injection into the affected ischemic site of interest
224237360|NCT04552704|BIOLOGICAL|CD24 Extracellular Domain-IgG1 Fc Domain Recombinant Fusion Protein CD24Fc|Given IV
224237361|NCT04552704|DRUG|Placebo Administration|Given IV
224237362|NCT00680121|DRUG|Benfotiamine|Benfotiamine 600 mg
224237363|NCT00680121|DRUG|Placebo|Placebo
223653694|NCT03564691|DRUG|Pemetrexed|Pemetrexed will be administered IV Q3W.
223653695|NCT03564691|DRUG|Lenvatinib|Lenvatinib will be administered orally once daily.
223653696|NCT03564691|DRUG|Paclitaxel|Paclitaxel will be administered IV QW on Days 1, 8, and 15 of each 21-day cycle until disease progression or prohibitive toxicity (Arm J) and on Days 1, 8, and 15 Q4W until disease progression or prohibitive toxicity (Arm K).
223653697|NCT03564691|DRUG|Cisplatin|Cisplatin will be administered IV Q3W.
223653698|NCT03564691|BIOLOGICAL|MK-4830A|MK-4830A, a coformulation of MK-4830 800 mg + pembrolizumab 200 mg, will be administered IV Q3W.
224237364|NCT03441581|DRUG|Eluxadoline|Eluxadoline 100 mg oral tablets BID with food.
224237365|NCT03401710|DRUG|Erythropoietin|Erythropoietin 4000 UI will be administered every other day subcutaneously
224237366|NCT02534948|BEHAVIORAL|Mindfulness and acceptance group therapy|The manual group intervention will be provided as per the second edition of Mindfulness and Acceptance-Based Group Therapy for Social Anxiety Disorder: A Treatment Manual developed by Fleming, and Kocovski (2014). The intervention will consist of 10 group therapy sessions. Each session will be conducted in 120 minutes. It includes therapist manual, client handouts, and is written to be used in conjunction with The Mindfulness and Acceptance Workbook for Social Anxiety and Shyness. The treatment manual can be easily adapted for individual therapy clients.
224237367|NCT00446732|DEVICE|UroSshield|Attachment of the UroShield device to the external part of the urinary catheter
224237368|NCT02603952|DRUG|Oseltamivir|75 mg capsules orally BID from Day 1 to Day 5.
224237369|NCT02603952|DRUG|MEDI8852|MEDI8852 is a human IgG1 kappa monoclonal antibody (mAb) administered as a single IV infusion of 750 mg or 3000 mg on Day 1.
224237370|NCT02603952|DRUG|Placebo|Placebo is salt-water solution containing no active ingredients and administered as a single IV infusion on Day 1.
224237371|NCT01402037|DRUG|Glucose|Glucose 20% intravenous
224237372|NCT01402037|DEVICE|Continuous glucose monitoring|Blood glucose profiles: during 5 days glucose profiles will be determined by seven-point self-monitoring of blood glucose (SMBG) (pre-breakfast: assumed time 7 am, post-breakfast: 8.30 am, pre-lunch: 12 am, post-lunch: 1.30 pm, pre-supper: 6 am, post-supper: 7.30 pm, bedtime: 10 pm) and by continuous glucose monitoring (CGM). Participants will be blinded for the CGM results.
224237373|NCT03472729|OTHER|AGE-ON Workshop|Series of workshops to reduce social isolation through technology use.
224237374|NCT02572310|DEVICE|Simplex High Viscosity Bone Cement|high viscosity bone cement for total knee replacement
224237375|NCT05480722|OTHER|Dietary Intervention|Subjects will consume a low salt diet for 1 week and a high salt diet for 1 week to determine sodium sensitivity
224237376|NCT05480722|OTHER|Hypertonic Saline|Subjects will undergo MRI with a hypertonic saline infusion with and without NKCC2 antagonism (furosemide)
224237377|NCT00006166|PROCEDURE|Transjugular intrahepatic portasystemic shunts (TIPS)|
224237378|NCT00006166|PROCEDURE|Total paracentecis (TP)|
224237379|NCT04504513|DRUG|Trilaciclib|"Trilaciclib is a highly potent, selective, and reversible cyclin-dependent kinase 4/6 inhibitor administered intravenously prior to chemotherapy for chemotherapy-induced myelosuppression (CIM).~In patients being treated for SCLC, trilaciclib transiently maintains G1 cell cycle arrest of hematopoietic stem and progenitor cells (HSPCs) in the bone marrow, thus protecting the cells from damage by cytotoxic chemotherapy (myelopreservation). This can reduce chemotherapy-related toxicity, making chemotherapy safer and more tolerable, and also reduce the need for rescue interventions that address the effects of myelosuppression, such as growth factors or blood and platelet transfusions."
224237380|NCT04028453|OTHER|Survey|There will be a first part with a retrospective study in order to collect pregnancy data to answer to the primary endpoint. Then, there will be a prospective part where mothers and their children will have to answer an evaluation survey.
223653699|NCT06996639|BEHAVIORAL|Non-Fasting|No pre-procedural fasting required; participants may eat and drink as usual.
224237381|NCT03558308|BEHAVIORAL|Computer based cognitive rehabilitation|Computer based cognitive rehabilitation is a supplementary computerized tool for cognitive rehabilitation design to train various cognitive functions. Many programmes are available. The current study investigates the effects on two such programmes on rehabilitation of executive functions in the chronic phase after acquired brain injury.
224237382|NCT03558308|OTHER|Sham computerized gaming|Sham training with generally stimulating computer-games
224237383|NCT04304963|OTHER|NO intervention - observational study|NO intervention - observational study
224237384|NCT06970613|BEHAVIORAL|Watching cartoons|While watching the cartoons, local anesthesia will be applied and restorative treatments will be completed.
223653700|NCT06996639|BEHAVIORAL|Fasting|"Standard pre-procedural fasting (≥6 hours for solids, ≥2 hours for clear liquids) or NPO at Midnight."
223767707|NCT07085312|PROCEDURE|Exosome-Enriched IVF Culture|IVF culture media supplemented with 10 µg per well of GMP-certified exosomes (Exosmart or equivalent). Retrieved MI oocytes are cultured in this media for up to 4 hours to assess progression to MII.
224237385|NCT06970613|BEHAVIORAL|Robot cat|Local anesthesia will be applied with the robot cat in their lap during the treatment and their restorative treatments will be completed.
224237386|NCT02206659|DRUG|Telmisartan|
224237387|NCT02206659|DRUG|Placebo|
224237388|NCT04871737|BIOLOGICAL|Recombinant NDV Vectored Vaccine for SARS-CoV-2|Recombinant Newcastle Disease Virus Vectored Vaccine for SARS-CoV-2
224237389|NCT05559268|DRUG|Denosumab 60 MG/ML Injectable Solution [Prolia]|1 ml (60 mg) subcutaneous injection Denosumab give in the posterior part of the upper arm after TKA
224237390|NCT05559268|DRUG|Placebo|1 ml (60 mg) subcutaneous injection Saline give in the posterior part of the upper arm after TKA
224237391|NCT05524688|DIETARY_SUPPLEMENT|Beta-glucan|2, 250 mg capsules of beta-glucan per day
224237392|NCT05524688|DIETARY_SUPPLEMENT|Placebo|2, 250 mg capsules of cellulose
224237393|NCT00002595|DRUG|toremifene|
224237394|NCT00002595|PROCEDURE|conventional surgery|
224237395|NCT02028936|OTHER|Grape juice R@isol|
224237396|NCT02028936|OTHER|Commercially-available grape juice|
224237397|NCT02070237|DRUG|Enoxaparin|Enoxaparin will be given in either once daily or twice daily doses. One arm will receive 40 mg enoxaparin subcutaneous injection daily. The other arm will receive 0.5 mg/kg dosed subcutaneously twice daily. This medication will be started 8-12 hours after cesarean section and will be continued while the patient is admitted. It will be stopped at the time of discharge.
224237398|NCT02923947|DRUG|Osimertinib; AZD9291|80mg tablet dose to be taken orally - single dose in part A, daily dosing in Part B and continued access until progression or no longer receiving benefit
224237399|NCT02183064|DRUG|Meloxicam|
224237400|NCT02183064|DRUG|NSAID|
224237401|NCT00597194|PROCEDURE|Hernia repair|Hernia repair laparoscopically (LH) or by open operation (OH)
224237402|NCT01911975|DRUG|Lacosamide|comparison between lacosamide 200mg twice daily and microcrystalline cellulose (placebo) 200mg twice daily.
223653701|NCT06865027|OTHER|Ventilation strategy|"The selected PaCO2 targets are:~Normocapnia: PaCO2: 5.0-5.5 kPa Hypercapnia: PaCO2: 6.4-7.0 kPa~The adjustments on the ventilator needed to achieve these targets will be administered by the anesthetic nurse and attending anesthesiologist and held within the following limitations:~Tidal volume: 4 - 8ml ml/kg IBW Inspiratory pressure 5-30 cm H2O Respiration rate 10-18 per minute PEEP 5-10 mmHg~\*IBW: 50 + 0.91 (height in centimeters - 152.4) Peep, I:E ratio, and FiO2 will be administered at the anesthetic nurse's and the anesthesiologist's discretion."
224237403|NCT01911975|DRUG|Placebo|comparison between microcrystalline cellulose (placebo) 200mg twice daily and lacosamide 200mg twice daily.
223653702|NCT05913908|DEVICE|DUO Transcatheter Tricuspid Coaptation Valve System|Reduction of tricuspid regurgitation through a transcatheter approach
223767708|NCT07086157|DIETARY_SUPPLEMENT|Probiotic|"A probiotic supplement in capsule form containing 4 strains of microorganisms, with a total of 10 × 10⁹ CFU (colony-forming units) per capsule. The strain composition per capsule was:~Lactobacillus acidophilus L1 - 2.9 × 10⁹ CFU, Bifidobacterium longum LBL-01 - 2.9 × 10⁹ CFU, Lactobacillus rhamnosus - 2.9 × 10⁹ CFU, Saccharomyces boulardii - 1.3 × 10⁹ CFU. Each participant in this arm took one capsule per day in the morning on a full stomach, for a duration of 4 weeks. No other dietary interventions were applied to this group. This probiotic supplement was chosen because the strains in its content are among the most frequently researched and known strains in terms of intestinal health. Additionally, it does not contain FOS or inulin due to FODMAP restriction.~."
224237404|NCT01171495|DIETARY_SUPPLEMENT|Theragran-M; Ensure Plus|Theragran-M: One tablet daily for 6-months. Ensure Plus: One 8 fl.oz. bottle daily for 6-months. Nutritional counselling: at baseline, and at monthly follow-up visits.
224237405|NCT01171495|DIETARY_SUPPLEMENT|Theragran-M|Theragran-M: One tablet daily for 6-months. Nutritional counselling: at baseline and at monthly follow-up visits.
224237406|NCT00978900|DIETARY_SUPPLEMENT|Artificial sweeteners; Carbohydrate Sugars|sweetening agent dissolved in tap water, administered via intragastric tube
224237407|NCT00978900|DIETARY_SUPPLEMENT|Water|
224237408|NCT01570465|OTHER|Observation|Assess the impact of each type of severe infections (SI) over the 24-month overall survival of young patients with newly diagnosed acute myeloid leukemia along a predefined antileukemic treatment strategy.
224237409|NCT05898451|DRUG|Tumor necrosis factor-thymosin alfa 1 recombinant (TNF-T)|has a direct antitumor effect in vitro and in vivo on various tumor cell lines
224237410|NCT05898451|DRUG|Tumor necrosis factor-thymosin alfa 1 recombinant (TNF-T) and chemotherapy|Refnot has a direct antitumor effect in vitro and in vivo on various tumor cell lines, chemotherapy has a cytostatic and cytotoxic effect.
224237411|NCT00577460|DRUG|Pramipexole|Pramipexole ER 0.375 -4.5 mg
224237412|NCT00577460|DRUG|Placebo|Placebo tablets identical to Pramipexole ER tablets
224237413|NCT04141033|DIAGNOSTIC_TEST|assessment of neopterin levels|neopterin is a macrophage biomarker used for diagnosis of active periodontitis and the response to treatment
224237414|NCT01206257|DRUG|Iopromide (Ultravist, BAY86-4877)|Intravenous/intraarterial digital subtraction angiography (DSA); Generally doses of up to 1.5 g iodine per kg body weight are well tolerated.
224237415|NCT01318499|DRUG|Nepafenac Ophthalmic Suspension, 0.3%|Nepafenac Ophthalmic Suspension, 0.3%, one drop in affected eye once daily, for 16 days. An additional drop was administered between 30-120 minutes prior to surgery.
224237416|NCT01318499|DRUG|Nepafenac Ophthalmic Suspension, 0.1%|Nepafenac Ophthalmic Suspension, 0.1%, one drop in affected eye once daily, for 16 days. An additional drop was administered between 30-120 minutes prior to surgery.
224237417|NCT01318499|OTHER|Nepafenac Vehicle 0.3%|Nepafenac Vehicle 0.3%, one drop in affected eye once daily, for 16 days. An additional drop was administered between 30-120 minutes prior to surgery.
224237418|NCT00352261|DRUG|Esomeprazole|
224237419|NCT00352261|DRUG|Lansoprazole|
224237420|NCT00849459|BIOLOGICAL|adenovirus-mediated human interleukin-12|"The purified ADV-hIL12 is suspended in formulation buffer (10mM Tris, pH 7.5/~1mM MgCl2/ 150mM NaCl/ 10% glycerol) and aliquoted into 1ml cryovials. The filled vials are stored at or below -60 degC."
223767709|NCT07086157|OTHER|Low-FODMAP Diet|A structured low-FODMAP diet intervention designed to restrict intake of fermentable oligosaccharides, disaccharides, monosaccharides, and polyols. The diet was individualized and monitored by a registered dietitian over a 4-week period to ensure adherence and nutritional adequacy.
224237421|NCT01988922|DRUG|ketamine|0.4 mg/kg oral racemic ketamine
224237422|NCT05161611|DRUG|Zinc sulfate|10 mg of oral zinc sulfate will be given to neonates per day
224237423|NCT05161611|OTHER|Placebo|10 mg of normal saline will be given to neonates per day
224237424|NCT05161611|OTHER|Phototherapy|Neonates will be put under phototherapy
224237425|NCT05328141|OTHER|Bread and butter|A bread with butter meal without insect biomass with FeSO4 (isotopic iron 54)
223653708|NCT06807593|DRUG|Ustekinumab|Given by infusion
223653709|NCT06676319|DRUG|Lunsekimig|Pharmaceutical form:Solution for injection in vial-Route of administration:Subcutaneous injection
223653710|NCT06676319|DRUG|Short-Acting Beta Agonists (SABA)|Pharmaceutical form:Varies and depends on pharmaceutical presentation-Route of administration:Oral Inhalation
223653711|NCT06676319|DRUG|Placebo|Pharmaceutical form:Solution for injection in vial-Route of administration:Subcutaneous injection
224237426|NCT05328141|OTHER|X.gideon|Intrinsically labelled (57Fe) or non labelled X.gideon flour mixed with butter and sugar meal with FeSO4 (extrinsic label, isotopic iron 58)
224237427|NCT05328141|OTHER|X.gideon with ascorbic acid|Intrinsically labelled (57Fe) or non labelled X.gideon flour mixed with butter and sugar meal with FeSO4 (extrinsic label, isotopic iron 58) and ascorbic acid
223653712|NCT06676319|DRUG|Fluticasone/salmeterol|Pharmaceutical form:Varies and depends on pharmaceutical presentation-Route of administration:Oral Inhalation
223653713|NCT06676319|DRUG|Budesonide/formoterol|Pharmaceutical form:Varies and depends on pharmaceutical presentation-Route of administration:Oral Inhalation
223653714|NCT06999837|RADIATION|[68Ga]Ga-PSMA-11|Dynamic whole-body \[68Ga\]Ga-PSMA acquisition to HCC patients
224237428|NCT01780415|OTHER|blastocoele aspiration|
224237429|NCT00715442|DRUG|Sunitinib|50 mg by mouth daily for 28 consecutive days
224237430|NCT00715442|PROCEDURE|Nephrectomy|Nephrectomy will occur approximately 24 hours after the last dose of sunitinib.
224237431|NCT06115265|BEHAVIORAL|Ketogenic diet|KDDP and NDPP will deliver identical comprehensive lifestyle counseling and follow up to participants, but dietary interventions in each group will differ, with KDDP participants receiving a ketogenic diet and NDPP participants receiving a low fat diet.
224237432|NCT06115265|BEHAVIORAL|Low Fat diet|KDDP and NDPP will deliver identical comprehensive lifestyle counseling and follow up to participants, but dietary interventions in each group will differ, with KDDP participants receiving a ketogenic diet and NDPP participants receiving a low fat diet.
223653715|NCT04073706|PROCEDURE|TH BSO with SNB Note: If participants (≤45yo), Grade 1 endometrial adenocarcinoma with myometrial invasion <50%, wish to retain their ovaries a BSO may be omitted|"Removal of uterus, tubes and ovaries with a sentinel node biopsy. A tracer dye (ICG) +/- Methylene Blue Dye is injected into the surroundings of the primary tumour, it is transported via local lymphatic channels towards the draining lymphatic basin, and the first node that the tracer reaches is called the sentinel node. These one or two nodes are thought to be first involved with cancer spread."
223653716|NCT04073706|PROCEDURE|TH BSO without retroperitoneal node dissection Note: If participants (≤45yo), Grade 1 endometrial adenocarcinoma with myometrial invasion <50%, wish to retain their ovaries a BSO may be omitted|Removal of uterus, tubes and ovaries without retroperitoneal node dissection
223653717|NCT07005674|BEHAVIORAL|Cycle Nation|Participants will be asked to attend nine weekly 90-minute face-to-face sessions, delivered by trained facilitators at community cycling organisations. Sessions include off road cycling skills and on-road group rides, behaviour change techniques (e.g. goal setting), and bicycle maintenance training. Two extra group rides will be offered during the programme for additional practice, along with two catch-up sessions at the end for those who missed any content. Participants will be added to a WhatsApp group to encourage peer communication. Bicycles, helmets, and locks will be loaned to participants for 10-12 weeks to support participation.
224237433|NCT05057494|DRUG|Acalabrutinib|Dose formulation: Capsule or Tablet
224237434|NCT05057494|DRUG|Venetoclax|Dose formulation: Tablet
224237435|NCT05057494|DRUG|Obinutuzumab|Dose formulation: Injection
224237436|NCT05065879|BIOLOGICAL|COVAX|2 doses of Covid-19 vaccine
224237437|NCT03752541|BIOLOGICAL|BCMA-UCART|A conditioning therapy with cyclophosphamide and fludarabine will be conducted for subjects before CART therapy.
224237438|NCT01347710|DRUG|Flurpiridaz F18|Injection of Flurpiridaz F18 for the purposes of PET myocardial profusion imaging (MPI) analysis
224237439|NCT01347710|DRUG|99mTechnicium (sestamibi or tetrofosmin)|Injection of 99mTc sestamibi or tetrofosmin for the purposes of SPECT MPI analysis
224237440|NCT05557565|DRUG|QL1706|The dosage of QL1706 is 5.0 mg/kg, and QL1706 is administered every 3 weeks (Q3W) by intravenous infusion
224237441|NCT03262974|DIAGNOSTIC_TEST|PCR|PCR
224237442|NCT03262974|DIAGNOSTIC_TEST|HPLC-UV|HPLC-UV
224237443|NCT05287984|DRUG|Zanubrutinib, Fludarabine, cyclophosphamide and rituximab|Patients aged 65 years or younger who can tolerate FCR.
224237444|NCT05287984|DRUG|Zanubrutinib, bendamustine, rituximab|For patients older than 65 years or who cannot tolerate FCR regimens.
224237445|NCT03089203|BIOLOGICAL|CART-PSMA-TGFβRDN cells|autologous CAR T cells
224237446|NCT03089203|DRUG|Cyclophosphamide|300 mg/m2/day given over 3 days
224237447|NCT03089203|DRUG|Fludarabine|30 mg/m2/day given over 3 days
224237448|NCT01302314|BEHAVIORAL|Goal management training (GMT)|Fourteen hours of GMT during a time period of three months.
224237449|NCT06543524|OTHER|Care of premature infants|No intervention was performed
224237450|NCT00284102|PROCEDURE|Mechanical ventilation|measurement of gas exchange, dead space, respiratory mechanics 5, 15, 30, 60 minutes from PEEP change (5 and 15 cmH2O)
224237451|NCT02133339|DRUG|TRN-157|
224237452|NCT02133339|DRUG|Placebo|
224237453|NCT02215174|DRUG|Rosuvastatin|Rosuvastatin 20mg po x1
224237454|NCT04016636|OTHER|Standard of Care|Participants in this observational study with confirmed diagnosis of CLL receiving ibrutinib in routine clinical practice settings will be observed approximately for 12 months.
224237455|NCT04812587|BEHAVIORAL|exercise intervention program|The experimental group will receive a 12-week combined exercise intervention program with extra emphasis on balance, muscle strength, and walking ability which involved two 2-hour sessions once per week.
224237456|NCT04591626|DRUG|Dulaglutide|Administered SC
224237457|NCT04591626|DRUG|Placebo|Administered SC
224237458|NCT04591626|DRUG|Insulin Glargine|Administered SC
224237459|NCT03051685|DRUG|DFN-15 Dose 1|
224237460|NCT03051685|DRUG|DFN-15 Dose 2|
224237461|NCT03051685|DRUG|DFN-15 Dose 3|
224237462|NCT03051685|DRUG|Active Comparator|
224237463|NCT02494713|DRUG|Degarelix|Subcutaneous injection, once/month for 4 months
224237464|NCT02494713|DRUG|Doxorubicin|20 mg/m2 as a 24-hour intravenous infusion on day 1 each week, weeks 1, 3, and 5
224237465|NCT02494713|DRUG|Ketoconazole|400 mg orally 3 times daily for 7 days, in weeks 1, 3, and 5
224237466|NCT02494713|DRUG|Docetaxel|35 mg/m2 intravenously on day 1 of each week, weeks 2, 4, and 6
224237467|NCT02494713|DRUG|Estramustine|280 mg orally 3 times daily for 7 days, in weeks 2, 4, and 6
224237468|NCT00551005|DRUG|celecoxib|
224237469|NCT00551005|DRUG|etoposide|
224237470|NCT00551005|OTHER|immunoenzyme technique|
224237471|NCT00551005|OTHER|laboratory biomarker analysis|
224237472|NCT00023283|DRUG|Buprenorphine|"1. Experimental Standard Medical Management with once-weekly medication dispensing~2. Experimental Standard Medical Management with thrice-weekly medication dispensing~3. Experimental Enhanced Medical Management with thrice-weekly medication dispensing"
224237473|NCT02672553|DEVICE|EDWARDS INTUITY Valve System, Model 8300A|To evaluate cardiac performance characteristics and adverse events rates associated with the EDWARDS INTUITY Valve in patients undergoing MIS-AVR.
224237474|NCT02672553|DEVICE|Stented Aortic Bioprostheses|In comparison to control valves available on the market undergoing FS-AVR
224237475|NCT03203148|DIAGNOSTIC_TEST|Point-of-Care ACT|Comparison between two point-of-care devices for measurement of the activated clotting time
224237476|NCT03137563|OTHER|questionnaire|The questionnaire will be distributed and collected by the same investigator in one of the eight centers involved in the study. The investigator will verify the inclusion criteria and the absence of exclusion criteria.
224237477|NCT03979248|DRUG|BMS-986165|Specified dose on specified days.
223653718|NCT07005674|BEHAVIORAL|Cycling Scotland standard cycling session|Participants will be asked to participate in Cycling Scotland's 'Introduction to On-Road Cycling' a single 2-2.5-hour session that is offered as standard. The session covers key cycling skills such as hazard awareness, road positioning, and communicating with other road users. Activities are tailored to participants' needs and may include navigating junctions, using shared infrastructure, and performing U-turns. Bicycles and helmets will be provided for the session.
223653719|NCT06868264|DRUG|Bemnifosbuvir-Ruzasvir (BEM/RZR)|BEM/RZR Fixed-dose Combination (FDC) tablets administered orally once daily for a total of 8 weeks (in those without cirrhosis) or 12 weeks (in those with compensated cirrhosis)
223653720|NCT06868264|DRUG|Sofosbuvir-Velpatasvir (SOF/VEL)|SOF/VEL Fixed-dose Combination (FDC) tablets administered orally once daily for a total of 12 weeks
223653721|NCT04070183|BEHAVIORAL|POST Facilitation|Advanced steps is initiated as a component of quality end-of-life care for frail elders and those whose death in the next 12 months would not be unexpected. The AS planning conversation is focused on goals of care to make timely, proactive, and specific end-of-life decisions. Ideally, these decisions are converted into medical orders that can be followed throughout the continuum of care. The Physician Orders for Life-Sustaining Treatment (POLST) program is the nationally recognized model for this stage of planning.
223653722|NCT04070183|BEHAVIORAL|Home Safety Evaluation|Nurse evaluation and education on how to improve safety at home for community dwelling older adults (examples of education and evaluation includes fall risks, fire and carbon monoxide (CO) detectors, transferring safety (e.g. in and out of the tub, bed, etc.) and others.
223653723|NCT06869954|DEVICE|Internal HAART 200 annuloplasty device|For the INTERNAL group, the HAART 200 internal annuloplasty ring (CorCym, London, UK), specifically designed for BAV morphology, will be used for all patients. Intraoperative sizing for the internal ring is based on the geometric orientation and size of the non-fused cusp. A standard ball sizer is used for the measurement of the non-fused cusp to assess commissural orientation and surface area of the non-fused cusp. Sizing typically results in values of 23mm or 25mm, with other sizes being very rare. Both commissural posts of the internal annuloplasty ring are fixed using two subcommissural sutures \[10\]. A modified technique for placement of transannular looping sutures will be used to secure the internal ring in the subannular position, as recently published \[21\]. Cusp maneuvers (i.e., shaving, thinning of the raphe, central plication sutures) will be performed to achieve an effective height of 8-10 mm. When indicated (i.e., for ascending aortic diameter \> 45mm or aiming to achieve th
223653724|NCT06869954|DEVICE|double external ring annuloplasty|For the EXTERNAL group, all study patients will undergo double external Dacron ring annuloplasty by simultaneous stabilization of the basal virtual ring and the STJ \[22\]. The surgical technique of double external annuloplasty, detailed by the Lansac group \[22\], involves aortic annulus sizing with a Hegar dilator to select the sizes of the external subannular annuloplasty ring and STJ ring (same size). After deep dissection of the aortic root, 6-7 2-0 pledgeted U sutures are placed circumferentially at the level of the virtual basal ring for external subannular ring implantation. Cusp maneuvers are performed similar to those in the INTERNAL group. STJ stabilization is achieved using an external STJ ring or ascending aortic replacement with a vascular tube graft (e.g., in cases with a high offspring of the right coronary artery). Treatment of the tubular ascending aorta is identical to the INTERNAL group.
223653725|NCT07003308|PROCEDURE|Anterior White Line Advancement Surgery|This technique involves a skin incision at the eyelid crease, dissection through the orbicularis muscle to expose the tarsus, and proximal dissection in the pre-Müller-conjunctival plane to visualize the white line. A double-armed 5-0 absorbable suture is used to advance the white line to the anterior tarsal surface. Eyelid height and contour are assessed before final fixation. Skin closure is completed with a non-absorbable suture.
223653726|NCT07003308|PROCEDURE|Posterior White Line Advancement Surgery|This conjunctival technique uses a traction suture and eyelid eversion to access the posterior surface of the eyelid. A conjunctival incision is made above the superior tarsal border, followed by dissection to expose the white line. A double-armed 5-0 absorbable suture is passed through the anterior tarsus and the white line, and tied after confirming adequate eyelid position. The conjunctiva is not sutured.
223767710|NCT07086417|PROCEDURE|Robot-Assisted Arthroscopic ACL Reconstruction|This intervention involves the use of a customized robotic surgical system to assist in arthroscopic anterior cruciate ligament (ACL) reconstruction. The system integrates preoperative planning with CT/MRI fusion imaging, intraoperative surgical guidance for femoral and tibial tunnel creation, and real-time biomechanical evaluation. The robot provides enhanced precision in tunnel positioning and graft placement compared to conventional techniques.
224237478|NCT03979248|DRUG|Rabeprazole|Specified dose on specified days.
224237479|NCT04232150|DRUG|single-dose midazolam for sedation under spinal anesthesia.|Induction of neuraxial anesthesia was done using 2.8cc of 0.5 % Heavy Bupivacaine and 20mcg fentanyl injected intrathecally for all patients. Supplemental oxygen was given via facemask with capnography monitoring. Group O received 0.025mg/kg midazolam at skin incision.
224237480|NCT04232150|DRUG|Double-dose midazolam for sedation under spinal anesthesia.|Induction of neuraxial anesthesia was done using 2.8cc of 0.5 % Heavy Bupivacaine and 20mcg fentanyl injected intrathecally for all patients. Supplemental oxygen was given via facemask with capnography monitoring. Group M received 0.025mg/kg midazolam at skin incision and repeated 5 minutes before maximum stimulation.
224237481|NCT04232150|PROCEDURE|spinal anesthesia with no sedation.|Induction of neuraxial anesthesia was done using 2.8cc of 0.5 % Heavy Bupivacaine and 20mcg fentanyl injected intrathecally for all patients. Supplemental oxygen was given via facemask with capnography monitoring.
223653732|NCT07014722|DEVICE|MERITMEDICAL Careflow™ Two-Lumen Central Venous Catheter|7 Fr, 150 mm, radio-opaque polyurethane catheter (OD 2.4 mm)
223653733|NCT07014722|DEVICE|ARROW Two-Lumen Central Venous Catheter|7 Fr, 160 mm, radio-opaque polyurethane catheter (OD 2.5 mm)
224237482|NCT00870922|PROCEDURE|Active release techniques|Participants will receive ART and have Therabite (mouth opening) and pain (VAS) measured before and after ART
223653734|NCT07014722|DEVICE|ARROWg+ard Blue Plus® Two-Lumen Central Venous Catheter|8 Fr, 160 mm, radio-opaque polyurethane catheter with antimicrobial coating
223653735|NCT07014722|DEVICE|Multicath 2 Expert UP Two-Lumen Central Venous Catheter|7.5 Fr, 160 mm, central venous catheter (OD 2.5 mm). Polyurethane shaft embedded with silver ions.
224237483|NCT01946347|OTHER|mixed meal|"Baguette Cheese Gourmet (Crocodile:~180g, energy 452.8 Kcal, composition: carbohydrates 49,2 g (44,55%), proteins 18,5 g (16,74%), lipids 18,8 g (38,7%), of which saturated 6,8 g, monounsaturated 6,0 g, polyunsaturated 5,0 g."
224237484|NCT01946347|OTHER|Acute in vivo induced hyperinsulinemia|Hyperinsulinemic (1mU/kg/min) euglycemic clamp 3 hours long
224237485|NCT01606306|DRUG|daily fluticasone propionate|Flovent® HFA, 44 mcg per inhalation, 2 inhalations twice daily
224237486|NCT01606306|DRUG|Montelukast|Singulair®, 4 mg granules or chewable tablets by mouth once daily in the evening
224237487|NCT01606306|DRUG|as-needed fluticasone propionate|Flovent® HFA, 44 mcg per inhalation, 2 inhalations, as needed for asthma symptoms
224237488|NCT02761096|DEVICE|acupuncture|"Acupuncture, electroacupuncture, and intradermal acupuncture will be performed at every session.~Sterile disposable stainless steel acupuncture needles (0.25 mm × 30 mm) will be used. Acupuncture needles will be inserted bilaterally at the following acupuncture points: LI4, LI11, PC6, ST36, GB39 and LR3, and GV20. If GV20 is close to the surgical site, this acupoint may be excluded.~An electric stimulator will be connected to the handle of each needle at LI4, LI11, ST36, and LR3 and a current of 5 Hz will be applied.~After the needles are removed, intradermal acupuncture needles with tape (DB130A; 0.25 mm × 1.5mm) will be inserted at the same acupoints (LI4, LI11, PC6, ST36, GB39, and LR3 bilaterally, and GV20) and left in place until the next session."
224237489|NCT02761096|OTHER|conventional treatment|The subjects in the control group will only receive conventional treatment. This involves general management after craniotomy in the department of neurosurgery and includes stabilizing vital signs, pain control, prevention and treatment of infections, and other IV fluid or drug therapy required based on the condition of the patient.
224237490|NCT04554654|DIAGNOSTIC_TEST|transvaginal ultrasound,|transvaginal ultrasound performed on day of the start of progesterone supplementation and on the day of frozen embryo transfer; serum progesterone level measurement on day of frozen embryo transfer
223653741|NCT06874491|BEHAVIORAL|Moving and 3D Book|After the data collector is taken to the environment where the child will receive inhalation treatment, the child and the parent will be introduced and the purpose of the study will be explained and the scales will be filled out. During the inhaler treatment, the child will spend time with a moving and 3D book that will be specially designed for inhalation treatment. After the treatment is completed, the child's reactions will be evaluated and the scales will be filled out again. Filling out the forms will take an average of 5-10 minutes.
223653742|NCT06874491|BEHAVIORAL|Hand Puppet|After the data collector is taken to the environment where the child will receive inhalation treatment, the child and the parent will be introduced and the purpose of the study will be explained and the scales will be filled out. During the inhaler treatment, the child will spend time with a hand puppet that will be specially designed for inhalation treatment by the researcher. After the treatment is completed.
223653743|NCT06626438|OTHER|Treatable traits model of care|Embedded multidisciplinary clinic with treatable traits model of care.
223653744|NCT03704389|BEHAVIORAL|Clinical decision support|Clinical decision support nudges within the electronic health record
223653745|NCT07020741|PROCEDURE|Indispensable Amino Acid Oxidation|Participants will ingest six hourly meals designed to provide 50% of the daily intake of 1.1 g·kgLBM. Additional energy (1.5x daily resting metabolic rate), carbohydrate (55%), and fat (35%) will be provided in beverages and protein-free cookies (for palatability). The first drink will contain priming doses of NaH13CO2 (0.176 mg·kg-1), \[13C\]phenylalanine (1.86 mg·kg-1), \[2H5\]phenylalanine (0.34 mg·kg-1) with all subsequent drinks containing 1.2 mg·kg-1 \[13C\]phenylalanine and 0.51 mg·kg-1 \[2H5\]phenylalanine.
224237491|NCT06364670|PROCEDURE|acupuncture|Acupuncture will be performed at acupoints including TE17 (Yifeng), SI19 (Tinggong), GB2 (Tinghui), TE5 (Waiguan), TE3 (Zhongzhu), ST36 (Zusanli ), KI3 (Taixi), and etc.
223653746|NCT07020741|PROCEDURE|Stable Isotope Oral Glucose Tolerance Test|Participants will consume a 75g glucose drink dissolved in 250 ml of water enriched with \[6,6\_2H2\]glucose and \[13C6\]glucose.
223653747|NCT07015242|DRUG|Rituximab|Specified dose on specified days
223653748|NCT07015242|DRUG|Methotrexate|Specified dose on specified days
223653749|NCT07015242|DRUG|Procarbazine|Specified dose on specified days
223653750|NCT07015242|DRUG|Temozolomide|Specified dose on specified days
223653751|NCT07015242|BIOLOGICAL|Liso-cel|Specified dose on specified days
223653752|NCT07015242|DRUG|Fludarabine|Specified dose on specified days
223653753|NCT07015242|DRUG|Cyclophosphamide|Specified dose on specified days
223653754|NCT07015242|DRUG|Calcium folinate|Specified dose on specified days
223653755|NCT05338944|BEHAVIORAL|Dialectical behavioral therapy|Working with psychologists through DBT skills training.
223653756|NCT05338944|BEHAVIORAL|Lifestyle|Working with kinesiologist and registered dietician to improve lifestyle habits.
223653757|NCT00924027|RADIATION|High Dose Radiation (HDR) Brachytherapy|Brachytherapy, the placement of a radioactive source close to a tumor, is a well-established part of the treatment of many malignancies, both for palliative and definitive applications. High dose brachytherapy is useful in many malignancies in order to deliver a high dose of radiation therapy to tumor in a conformal fashion with a rapid dose fall-off with the objective of sparing normal surrounding tissue.
223653758|NCT00924027|DIAGNOSTIC_TEST|MRI|When deemed necessary.
224237492|NCT01353300|GENETIC|DNA analysis|
224237493|NCT01353300|GENETIC|cytogenetic analysis|
224237494|NCT01353300|GENETIC|gene expression analysis|
224237495|NCT01353300|GENETIC|gene rearrangement analysis|
224237496|NCT01353300|GENETIC|mutation analysis|
224237497|NCT01353300|GENETIC|polymerase chain reaction|
223653759|NCT00924027|DIAGNOSTIC_TEST|CT|Obtained based on the sites of target, as clinical situation dictates and at each follow-up to determine local control.
224237498|NCT01353300|GENETIC|polymorphism analysis|
224237499|NCT01353300|OTHER|laboratory biomarker analysis|
224237500|NCT01353300|OTHER|medical chart review|
224320864|NCT06141018|OTHER|Placebo|Patients in the treatment arm will receive 3 ml, 90 mg hyaluronic acid injection intra-articularly, while the ones in the placebo arm will receive 3 ml saline injection intra-articularly. The groups will be crossed-over at 3rd month.
223653760|NCT00924027|DIAGNOSTIC_TEST|PET Scan|When deemed necessary.
223653761|NCT06626633|DRUG|CRD3874|CRD3874-SI is a STING agonist. CRD3874 is a synthetic drug that activates STING, and STING stimulates the immune system to kill cancer cells. In experiments on blood from humans, CRD3874 makes blood cells produce molecules responsible for anti-cancer activity. CRD3874 was tested in mice with cancers including leukemia, head and neck cancer, lung cancer, pancreatic cancer and sarcoma. In these mice, CRD3874 made tumors shrink or disappear, and some mice developed long-lasting immunity against cancer.
223653762|NCT05120349|DRUG|Osimertinib|The initial dose of Osimertinib 80mg once daily can be reduced to 40mg once daily. Treatment can continue until disease recurrence, unacceptable toxicity or other discontinuation criteria are met.
223653763|NCT05120349|DRUG|Placebo|Matching placebo. Initial dose of 80mg once daily can be reduced to 40mg once daily.
224237501|NCT01434342|DRUG|Nicotine Replacement Patch|Study participants will receive a baseline assessment after they consent to participate and before randomization. The intervention period will last 12 weeks (approximately 1 week for the in-office intervention and 12 weeks for all components of the Quitline intervention- telephone counseling and habitrol patches). Follow-up assessments will be administered at 3, 6, 12, \& 24 weeks after the date of the in-person intervention (for Quitline Intervention group) or the provision of the physician letter (for the Usual Care Plus group).
224237502|NCT02740608|DEVICE|OrganOx metra|Normothermic Machine Liver Perfusion
223653764|NCT05185661|BEHAVIORAL|eHealth education|"eHealth education intervention regarding the dietary plan, healthy-lifestyle, and hygiene:~1. Group-wise eHealth education through online PowerPoint presentation session among study participants with their guardian: Two times (Before starting the intervention and mid-line; end of 4th-month intervention)~2. eHealth education through phone calls \& SMS~   * 1st to 4th month: 4 times in a month~  * 5th to 6th month: 3 times in a month~  * 6th to 8th month: 2 times in a month~3. Control group will not get care and education"
223653765|NCT07068295|DRUG|NNC0471-0119 H|NNC0471-0119 H will be administered subcutaneously.
223653766|NCT07068295|DRUG|Insulin Aspart|Insulin aspart will be administered subcutaneously.
223653767|NCT07077005|OTHER|Exercise training|Supervised, combined endurance and resistance training
223653768|NCT06561360|DRUG|Vemurafenib|Vemurafenib orally twice daily (b.i.d.) continuously in cycles of 4 weeks (28 days) for a total of 4 cycles.
224237503|NCT04500522|DRUG|INH|3 vaginal tablet of isonicotinic acid hydrazide 900 mg inserted by the patient 12 hours before the scheduled office hysteroscopy.
224237504|NCT04500522|DRUG|Placebo|3 vaginal tablet of Placebo inserted by the patient 12 hours before the scheduled office hysteroscopy.
223653769|NCT06561360|DRUG|Obinutuzumab|Obinutuzumab will be administered concomitantly with vemurafenib starting at cycle 2 of treatment in cycles of 4 weeks.
223653770|NCT06561360|DRUG|Cladribine|Cladribine IV on days 1-5 concurrently with rituximab.
223653771|NCT06561360|DRUG|Rituximab|Rituximab on days 1-5 concurrently with rituximab.
223653772|NCT06904261|DRUG|Migalastat HCl 20 mg|Migalastat will be supplied as 20-mg dispersible tablets. Migalastat 20-mg dispersible tablets contain 16 mg migalastat free base.
223653773|NCT06878859|BEHAVIORAL|Amplification of Positivity - Cannabis Use (AMP-C)|AMP-C is a smartphone-based digital intervention that includes activities that focus on positivity (e.g., noticing and capitalizing on positive events) to increase positive emotions, thoughts, and behaviors. The role and impact of CU on the maintenance of depression and reward dysfunction (and vice versa), is intertwined throughout the intervention.
224237505|NCT00408902|DRUG|tandutinib|Given orally, 500 mg bid daily
223653774|NCT06735534|DEVICE|FARAPULSE™ Pulsed Field Ablation System|"The FARAPULSE™ Pulsed Field Ablation System is indicated for the treatment of symptomatic atrial fibrillation.~The FARAWAVE Catheter is indicated for the isolation of pulmonary veins and posterior wall in the treatment of drug-refractory, recurrent, symptomatic paroxysmal and persistent atrial fibrillation. The FARAWAVE Catheter is also indicated for the for the isolation of pulmonary veins and posterior wall in the treatment of persistent atrial fibrillation as an alternative to anti-arrhythmic drug (AAD) therapy as an initial rhythm control strategy.~The FARAPOINT™ PFA Catheter is indicated for use as an adjunctive device for 1) the creation of an ablation line between the inferior vena cava and the tricuspid valve and/or 2) Mitral Isthmus, when the FARAWAVE Catheter is used in the endocardial treatment of persistent atrial fibrillation (episode duration no greater than 12 months)."
223653775|NCT00001529|DRUG|G-CSF|After medical clearance, volunteers will undergo outpatient mobilization with daily subcutaneous injections of filgrastim (G-CSF). The first dose will be administered at the NIH Clinical Center, with one-hour monitoring for immediate reactions. Volunteers may either return to NIH for daily injections or self-administer at home after training.
223653776|NCT06817226|BEHAVIORAL|Assess decision making context.|Semistructured interviews will be conducted to understand the situations and settings in which breast reconstruction decisions occur for this population, including the role of digital tools and social media.
223653777|NCT06817226|BEHAVIORAL|Solicit input from the target population|Solicit input from the target population about the tool such as translation, website programming, and community feedback.
224237506|NCT00408902|OTHER|laboratory biomarker analysis|Correlative studies
223653778|NCT06817226|BEHAVIORAL|Integration and refinemen of the decision aid|A final round of cognitive interviews with breast cancer survivors while they use the revised tool and a final round of website programming.
224237507|NCT00970281|DRUG|Rapid-Acting Intramuscular Olanzapine|Administered by means of intramuscular injection (IM) with the possibility of second 10 milligram (mg) injection 2 to 4 hours after first injection, for a maximum of 2 injections
224237508|NCT00970281|DRUG|Placebo|Administered by means of IM with the possibility of second injection 2 to 4 hours after first injection, for a maximum of 2 injections
224237509|NCT03696381|OTHER|Real tRNS|The treatment consists of a set of 1-h sessions, three sessions per week for 8 weeks. A series of cognitive exercises of attention, memory, and executive functions will be conducted in each session. During the first 20 minutes of each cognitive training session, patients will receive bi-frontal and bi-parietal tRNS. It has a start and end ramp of two seconds in each case to avoid the slight unpleasant sensation that occurs in the first moments of the introduction of direct current DC.
223653779|NCT02311374|OTHER|Brain connectivity and physiology|Two MRI scanning session will be obtained for each participant both at the same time of day (9AM 12 PM). In one occasion they will be scanned after a night of rested sleep while awake and on another day they will be scanned after one night of sleep deprivation while sleeping in the scanner. In addition to the most sensitive technique selected in the development phase (either DWI or MT), each imaging MRI session will include (1) a resting-state functional connectivity (RSFC; 10 minutes) scan using single-shot T2\*-weighted EPI; and (2) quantitative T1 relaxometry (T1) in a CSF voxel (1mL; cubic) using an inversion recovery experiment with increased interpulse intervals (TI = 200, 300, 400, 500, 700, 1000, 1500, 2000, 3000, 5000, 10000 ms) and a long TR (10000 ms; scan time 2 min) to assess the level of solutes in CSF.
223767711|NCT07086417|PROCEDURE|Conventional Arthroscopic ACL Reconstruction|This intervention uses standard arthroscopic techniques for ACL reconstruction without robotic assistance. Tunnel positions are determined manually using surgical landmarks and guides. Graft placement, tensioning, and isometry assessment are performed by the surgeon using conventional methods.
223653780|NCT02311374|OTHER|Brain Wave|ECG will be used to monitor heart rate variability (HRV), which differ significantly between the waking state and the different sleep stages
223653781|NCT07091630|BIOLOGICAL|Empasiprubart IV|Intravenous infusion of empasiprubart
223653782|NCT07091630|OTHER|Placebo IV|Intravenous infusion of placebo
223653783|NCT07082725|DRUG|Nizubaglustat|AZ-3102
223653784|NCT07082725|DRUG|Placebo|Matching placebo
223653785|NCT06792695|DRUG|Volrustomig|Volrustomig will be administered as intravenous (IV) infusion.
223653786|NCT06792695|DRUG|FOLFIRI (Fluorouracil (5-FU), leucovorin, irinotecan)|FOLFIRI will be administered as IV infusion.
223653787|NCT06792695|DRUG|Bevacizumab|Bevacizumab will be administered as IV infusion.
223653788|NCT07094269|OTHER|Occupational Therapy Intervention|"Participants in the intervention group will take part in the structured, manualized Packer Managing Fatigue Group Program (Packer et al.), delivered in groups of 8-10 by a licensed occupational therapist. The intervention will consist of six weekly sessions, each lasting 120 minutes, held in a dedicated outpatient room equipped with a whiteboard, group seating, and educational materials.~Each session will address a specific theme: (1) The importance of Rest, (2) Communication and Body Mechanics, (3) Tools, Technology, and ergonomics, (4) Priorities and Standard (5) Putting it all Together, (6) Some Closing Thoughts. Materials will include a participant workbook2, printed handouts, pens, markers, and name tags. All materials will be provided in Italian."
223653789|NCT07094269|BEHAVIORAL|Fact-sheets|Participants in the control group will receive six weekly fact sheets containing general information about Parkinson's disease. These fact sheets serve as a placebo intervention to control for attention and information exposure, without providing any structured fatigue management strategies. This approach helps isolate the specific effects of the active intervention compared to usual care.
223653790|NCT07091968|BEHAVIORAL|Technology-Enabled Tailored Referral|Participants in the intervention arm will receive a technology-enabled, text-based referral platform designed to improve depression referral uptake. The platform includes an initial text with a brief video explaining common barriers, tailored text messages based on participant-identified barriers, and an automated referral link. Messages are mapped to stages of readiness using the Transtheoretical Model and sent every two days over a two-week period to non-responders or decliners. This approach aims to engage survivors with depression through personalized, accessible, and stage-matched communication.
223653791|NCT06901531|DRUG|zolbetuximab|Participants will receive an IV infusion of zolbetuximab on Cycle 1 Day 1 (C1D1) followed by subsequent IV infusion every 2 weeks or every 3 weeks.
223653792|NCT06901531|DRUG|Pembrolizumab|Participants will receive an IV infusion of pembrolizumab every 3 weeks or every 6 weeks.
223653793|NCT06901531|DRUG|Capecitabine|Participants receiving CAPOX regimen of chemotherapy will receive capecitabine Tablet twice daily orally on days 1 through 14 and days 22 through 35 of each cycle.
223653794|NCT06901531|DRUG|Oxaliplatin|Participants receiving CAPOX or mFOLFOX6 regimen of chemotherapy will receive an IV infusion of oxaliplatin once every 2 or 3 weeks.
223653795|NCT06901531|DRUG|Folinic acid (leucovorin or local equivalent)|Participants receiving mFOLFOX6 regimen of chemotherapy will receive an IV infusion of Folinic acid (leucovorin or local equivalent) once every 2 weeks.
223653796|NCT06901531|DRUG|5-fluorouracil (5-FU)|Participants receiving mFOLFOX6 regimen of chemotherapy will receive an IV infusion, or IV bolus of 5-FU once every 2 weeks.
223653797|NCT06901531|DRUG|Placebo|Participants will receive an IV infusion of placebo (0.9% of sodium chloride) on C1D1 followed by subsequent IV infusion every 2 weeks or every 3 weeks.
223767712|NCT07085741|DEVICE|MAGNET System, DI Biofragmentable|Anastomoses achieved by magnetic compression.
223767713|NCT05527184|DRUG|IMGN151|IMGN151 is an antibody-drug conjugate (ADC).
223653800|NCT07092501|BEHAVIORAL|Mentholated cigarette sampling|Participants will participate in five sampling trials (menthol cigarette, non-menthol cigarette, non-menthol cigarette mentholated with accessory 1, with accessory 2, and with accessory 3). They will be exposed to these trials in a randomized order. In each trial, participants will take four guided puffs from one cigarette. They will have a 20-minute washout period between trials. They will first complete subjective ratings for the product they just sampled. Then, during the washout period, participants will be instructed to rinse their mouth thoroughly with room-temperature water three times. Each rinse will last approximately 10 seconds, and participants will be guided to swish the water around all areas of the mouth before expectorating. A one-minute rest will follow each rinse to allow residual taste to dissipate. No food or drink will be allowed during this period.
223767714|NCT06238921|RADIATION|Stereotactic Radiation|Stereotactic Radiation to intact brain metastases or post-operative cavity.
223767715|NCT06238921|DRUG|Zimberelimab|One week +/- 4 days following receipt of SRS, zimberelimab 360 mg IV will be administered. This will be followed by zimberelimab 360 mg IV every 3 weeks.
223767716|NCT06238921|DRUG|Sacituzumab govitecan|SG will be administered on days 1 and 8 (10 mg/kg) of 21 day treatment cycles. This will be one week +/- 4 days following receipt of SRS for the first dose.
223767717|NCT06912100|DIETARY_SUPPLEMENT|Placebo|Participants consume capsules containing only an inactive placebo (maltodextrin and magnesium stearate).
223653801|NCT07092501|BEHAVIORAL|Hypothetical Policy Scenarios|Participants will complete the real Experimental Tobacco Marketplace consisting of one control trial and two menthol flavor restrictions (menthol cigarettes unavailable and both menthol cigarettes and menthol-flavored accessories unavailable). Participants will complete a total of 3 purchasing trials each for 7 days worth of products. In each trial, participants will buy tobacco products to use throughout the next 7 days. At the end of the session, the participant will randomly draw an individual purchasing trial and will receive all the products purchased at that trial to use over the next week. During the following 7 days, the participant is asked to use only the tobacco/nicotine products received during the study.
223653802|NCT07092501|BEHAVIORAL|Subjective value assessment|Participants will complete a hypothetical purchase task where the price of a variety of products will increase progressively during the task.
223653803|NCT01562405|DRUG|ACE-011|Injection every 28 days, dose escalation levels from 15-45 mg
224237510|NCT03696381|OTHER|Sham tRNS|The treatment consists of a set of 1-h sessions, three sessions per week for 8 weeks. A series of cognitive exercises of attention, memory, and executive functions will be conducted in each session. We will apply a sham tRNS for the first 20 minutes of each cognitive training session. The subjects will receive sham tRNS and will perform the same type of cognitive training as the rest of patients and will receive the same type of adverse reaction questionnaire. Subjects receiving simulated stimulation will receive the same type of ramps at the beginning and end of the session to ensure triple-blind maintenance .
224237511|NCT05290181|OTHER|A support program with pilates exercise and whatsapp text message|Female students in the intervention group will be given online pilates exercises 2 days a week for 8 weeks. Pre Pilates exercises, Pilates Mat Program: Beginner Level, Pilates Mat Program: Intermediate Level, Pilates Mat Program: Advanced level exercises will be provided. The exercises will be performed in the company of a research physiotherapist who has The Australian Physiotherapy \& Pilates InstituteMatwork Level 1 (APPI) certificate. 3 days a week, individual short messages will be sent to the smartphones of female students via the Whatsapp application. General information about PMS will be sent in the first week, and motivational messages about lifestyle will be sent in the following weeks. Short message contents will be prepared by researchers in line with the literature and expert opinion will be taken. When the support program ends, PMSS will be applied to female students in the intervention group.
224237512|NCT04641936|OTHER|No intervention required|No intervention required
224237513|NCT01512043|BEHAVIORAL|Breathing control|Practice of device guided breathing control twice a day for four weeks.
224237514|NCT05151406|OTHER|educational program|The needed knowledge about hematopoietic stem cell transplantation in a trial to correct their myths and misconceptions about this type of treatment. The educational pamphlet included three theoretical parts: bone marrow transplantation, bone marrow donation, and stem cells banking
224237515|NCT01310049|DRUG|LEO 32731|"* Part 1 and 2: Oral single dose of oral solution or capsule~* Part 3: Twice daily dose of oral solution or capsule for 7 days"
224237516|NCT03314025|DRUG|Tamsulosin Hydrochloride 0.4 MG|Peri-operative therapy of Tamsulosin Hydrochloride 0.4 milligrams daily for a total of 7 days.
224237517|NCT03314025|DRUG|Placebo oral capsule|Peri-operative therapy of a Placebo oral capsule daily for a total of 7 days.
224237518|NCT03314025|DEVICE|Foley catheter|Every patient with a post-operative urinary retention will have a foley catheter, as standard of care.
224237519|NCT03676803|OTHER|mixed spices|All spices in the spice mixture capsules contains 1g or 20% cinnamon, 1.5g or 30% oregano, 1.5g or 30% ginger, 0.85g or 17% black pepper, 0.15g or or 3% cayenne pepper for a total of 5.0g spice mixture. They are identical to herbs and spices sold in grocery stores for human consumption.
223653804|NCT01562405|DRUG|Lenalidomide|15 to 25 mg days 1-21, given orally
223653805|NCT01562405|DRUG|Dexamethasone|40 mg days 1,8,15,22; given orally
223653806|NCT01562405|DRUG|Pomalidomide|Pomalidomide 4 mg daily on days 1-21
223653807|NCT06830720|DRUG|ribociclib + AI ± LHRH|ribociclib in combination with an aromatase inhibitor ± LHRH as described in the current effective summary of product characteristics. This is an observational study. There is no treatment allocation. The decision to initiate treatment will be based solely on clinical judgement.
223653808|NCT06830720|DRUG|abemaciclib + ET ± LHRH|abemaciclib in combination with an endocrine therapy ± LHRH as described in the current effective summary of product characteristics. This is an observational study. There is no treatment allocation. The decision to initiate treatment will be based solely on clinical judgement.
223653809|NCT06830720|DRUG|ET mono ± LHRH|endocrine monotherapy ± LHRH. This is an observational study. There is no treatment allocation. The decision to initiate treatment will be based solely on clinical judgement.
223653810|NCT06892548|BIOLOGICAL|BNT324|Intravenous infusion
223653811|NCT06892548|BIOLOGICAL|BNT327|Intravenous infusion
223653812|NCT07072234|DRUG|Lymphodepleting chemotherapy|Given by IV
224237520|NCT03676803|OTHER|placebo capsule containing 5 g of maltodextrin|placebo capsule containing 5 g of maltodextrin
224237521|NCT01406678|PROCEDURE|RIPC|3 cycles of 5 min left upper arm ischemia by inflation of a blood pressure cuff to 200 mmHg and 5 min reperfusion
223653813|NCT07072234|DRUG|Dexamethasone|Given PO
223653814|NCT07072234|DRUG|Fludarabine|Given by IV
223653815|NCT07072234|DRUG|Cyclophosphamate|Given by IV
223653816|NCT07072234|DRUG|TGFBR-2 KO CD70 CAR NK|Given by IV
224237522|NCT01406678|PROCEDURE|Control|Coronary artery bypass surgery without remote ischemic preconditioning protocol
224237523|NCT01406678|DRUG|isoflurane+sufentanil anesthesia|Anaesthesia is maintained by inhaled isoflurane in concentrations 0.7-0.8 % end-tidal with additional sufentanil injected during surgery, as required. During extracorporal circulation patients receive isoflurane via a vaporizer incorporated in the extracorporeal gas supply in the same concentrations.
223653817|NCT06179160|DRUG|INCB161734|INCB161734 will be administered at protocol defined dose.
223653818|NCT06179160|DRUG|Cetuximab|Cetuximab will be administered at protocol defined dose.
223653819|NCT06179160|DRUG|Retifanlimab|Retifanlimab will be administered at protocol defined dose.
223653820|NCT06179160|DRUG|GEMNabP|GEMNabP will be administered at protocol defined dose.
223653821|NCT06179160|DRUG|mFOLFIRINOX|mFOLFIRINOX will be administered at protocol defined dose.
223653822|NCT00065676|OTHER|Quercetin|1 or 2 grams of quercetin or placebo will be given while patients undergo 6-hour OGTT
223653823|NCT00065676|OTHER|Placebo|
223767718|NCT06912100|DIETARY_SUPPLEMENT|Probiotic|Participants consume capsules containing L. acidophilus (TW01) at 4×10\^10 CFU/capsule (three capsules daily, totaling 1.2×10\^11 CFU/day) plus a commercial fiber source (Fibersol-2).
223767719|NCT07111065|DIETARY_SUPPLEMENT|FISH OIL 500MG OMEGA-3 SOFT GEL MINIS|Translucent, light yellow, oblong soft gelatin capsule containing a straw to amber light liquid.
223653826|NCT02979873|DRUG|Sirolimus|Sirolimus will be started on day 1 for subjects in the Sirolimus arm. A baseline CBC will be obtained within one week of randomization, or on Day 0. Thereafter, CBC will be monitored on a weekly basis for subjects in both arms. In the event of relapse (see definition of outcomes Section 6.7), the patient shall return to the NIH CRC for evaluation to include bone marrow biopsy and aspirate to exclude clonal evolution to MDS. Assessment will include (i) flow cytometry phenotyping of peripheral blood mononuclear cells for regulatory T-cells (Tregs, e.g. CD4+ CD25high FOXP3+) and regulatory dendritic cells (DCregs) and (ii) proteomics assay (research labs).
223653827|NCT07104630|BEHAVIORAL|Pulmonary Rehabilitation (PR)|"Participants will complete an 8-week course of PR, administered by certified respiratory therapists. For each week of the course, participants will attend two PR sessions. Each session will review topics such as physical function, nutrition, and psychosocial health. Participants will also be given an exercise prescription to complete throughout the 8-week course. The exercise prescription will include individualized cardiopulmonary activities."
223653828|NCT07104630|OTHER|No intervention: Usual care|Participants will receive standard-of-care, publicly available education on Nutrition and Cancer Survivors and Physical Activity and Cancer Survivors published by the American Institute for Cancer Research.
223767720|NCT07111065|OTHER|Dietary Guidelines for Americans diet|The Dietary Guidelines provides science-based advice on what to eat and drink to promote health, help reduce risk of chronic disease, and meet nutrient needs.
224237524|NCT06298656|OTHER|No intervention|It is an observational study.
223653831|NCT00001721|DRUG|Cholesterol Suspension|
224237525|NCT00055783|BIOLOGICAL|apolizumab|
224237526|NCT06497387|BIOLOGICAL|PRG-1801|PRG-1801 (BCMA-targeting CAR-T Cells)
224237527|NCT01849042|DRUG|Ebixa|add-on of Ebixa oral pump already receiving donepezil with stable dosage
224237528|NCT01849042|DRUG|donepezil|
224237529|NCT02537756|BEHAVIORAL|Project Voice|A tablet-based intervention that directs participants through different activities related to adolescent HPV vaccination based on their assigned condition
223653832|NCT00001721|DRUG|CRH|
223653833|NCT00001721|DRUG|Cholesterol|
223653834|NCT02535702|OTHER|In vivo MRS|1H MR spectroscopy to assess brain metabolites.
223653835|NCT02535702|OTHER|fMRI|Three fMRI sessions to assess test-retest reliability of functional connectivity (FC) measures at rest and during task performance.
223653836|NCT02535702|OTHER|EEG/EOG|Electroencephalography or electrooculography (EEG/ EOG) sessions to record electrical activity of the brain or measure corneo-retinal standing potentials.
223653837|NCT02535702|OTHER|Stimulation tasks|To be used in the context of fMRI to study blood-oxygenation-level- dependent responses in the brain to sensory stimulation.
223653838|NCT02535702|OTHER|NSPRD|To be used in conjunction with pupillometry in the context of fMRI to study blood-oxygenation-level-dependent responses to selective neurostimulation of pain fibers.
224237530|NCT00878995|DRUG|Placebo Testosterone|Placebo (Saline) Testosterone given IM once per week.
224237531|NCT00878995|DRUG|Testosterone Enanthate 100 MG/ML|Testosterone Enanthate 100mg/ml given once per week IM.
224237532|NCT02968485|DRUG|SHR7390|SHR7390 is provided as white, film-coated,immediate release tablets containing SHR7390 at dosage strengths of 0.125 mg and 0.5 mg. Multiple tablets of SHR7390 will be administered daily to achieve targeted doses of SHR7390: 0.25 mg-4 mg. Tablets will be orally administered with 240 ml water, once daily, 2 hours after a meal.
224237533|NCT04586621|DEVICE|Atoldys/ Lexilens - SHAM|Atoldys/ Lexilens: glasses with specific light frequency SHAM: glasses with no frequency
224237534|NCT04586621|DEVICE|SHAM- Atoldys/ Lexilens|SHAM: glasses with no frequency Atoldys/ Lexilens: glasses with specific light frequency
223653839|NCT02535702|OTHER|Structural MRI|High spatial MRI and diffusion tensor imaging (DTI) to assess brain morphology and structural connectivity.
223653840|NCT01799538|DRUG|albuterol inhaler|2 puffs of Metered Dose inhaler for Bronchodilation
223653841|NCT01799538|DRUG|albuterol nebulizer|Albuterol administered by nebulization will produce a greater increase in FEV1
223653842|NCT01799538|PROCEDURE|PFT|Breathing Test
224237535|NCT02253979|DEVICE|Standard double lumen tube|Endotracheal left side double lumen tube
223653844|NCT06520787|COMBINATION_PRODUCT|ACDP® and pharmacological treatment for obesity|40 Families of children with obesity that are already undergoing treatment and are willing to join a combined intervention. After the recruitment, the family will join Adhera Caring Digital Program® for 10 months. The combined intervention (digital and pharmacological intervention) will last one year, and there will be a 2-month follow-up. During the whole study (12 months, from recruiting to the end of follow-up) participants will wear a smartwatch (Fitbit or similar).
223653845|NCT02522611|DRUG|Resiniferatoxin|Resiniferatoxin (RTX) is an ultrapotent agonist analog of capsaicin that targets a receptor expressed on specific dorsal root sensory ganglia (DRG) neurons and is expected to reduce pain within the targeted zone.
224237536|NCT02253979|DEVICE|VivaSight double lumen tube|VivaSight double lumen endotracheal intubation
224237537|NCT02291900|PROCEDURE|core decompression|retrograd drilling of the avascular talar necrosis, followed by osseous autograft
223653848|NCT07102381|DRUG|Zanidatamab|Administered intravenously (IV)
224237538|NCT00841100|DRUG|Kuvan|20mg/kg by mouth once daily
224237539|NCT00841100|OTHER|Diet|Phenylalanine-restricted diet (4-10 mg/kg/day phenylalanine) using the prescribed phenylalanine-free medical formula and low protein foods tested with the patients for taste and acceptance to lower blood phenylalanine levels below 600 umol/l.
224237540|NCT03338972|BIOLOGICAL|Autologous Anti-BCMA-CAR-expressing CD4+/CD8+ T-lymphocytes FCARH143|Given IV
224237541|NCT03338972|DRUG|Cyclophosphamide|Given IV
224237542|NCT03338972|DRUG|Fludarabine|Given IV
224237543|NCT03338972|PROCEDURE|Leukapheresis|Undergo leukapheresis
224237544|NCT01355081|DRUG|Vortioxetine|Vortioxetine tablets
224237545|NCT01355081|DRUG|Placebo|Vortioxetine placebo
224237546|NCT02480764|DRUG|Azilsartan medoxomil|Azilsartan medoxomil tablets
223653849|NCT07102381|DRUG|Paclitaxel|Administered intravenously (IV)
223653850|NCT07102381|DRUG|Docetaxel|Administered intravenously (IV)
223653851|NCT07102381|DRUG|Carboplatin|Administered intravenously (IV)
223653852|NCT07102381|DRUG|Trastuzumab|Administered intravenously (IV)
223653853|NCT07102381|DRUG|Pertuzumab|Administered intravenously (IV)
223653854|NCT07112053|BIOLOGICAL|CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine|Given ID
223653855|NCT07112053|DRUG|Capecitabine|Given SOC capecitabine
223653856|NCT07112053|PROCEDURE|Computed Tomography|Undergo CT or ultrasound-guided biopsies
224237547|NCT02480764|DRUG|Valsartan|Valsartan 80 mg capsules
224237548|NCT02480764|DRUG|Azilsartan medoxomil Placebo|Azilsartan medoxomil placebo-matching tablets
224237549|NCT02480764|DRUG|Valsartan Placebo|Valsartan placebo-matching capsules
224320865|NCT03128060|OTHER|Home-based palliative care|The HBPC model consists of home visits by an interdisciplinary primary palliative care team (a physician, nurse, social worker, and chaplain). This team provides pain and symptom management, psychosocial support, advance care planning, spiritual counseling, grief counseling, and other services to meet patient and caregiver needs. Within the first week of a patient's enrollment, team members separately visit the patient at home to assess his/her needs as well as the needs of his/her caregiver. Following the patient's initial assessment, subsequent home visits are based on the patient's and caregiver's needs. At a minimum, a core team member visits the patient at home once per week. Additionally, a 24/7 helpline provides access to nurse counseling and after-hours home visits as needed. As a patient's health declines and he/she becomes eligible for hospice care, HBPC clinicians will refer the patient to hospice.
223653857|NCT07112053|DRUG|Cyclin-Dependent Kinase 4 Inhibitor|Given SOC CDK4/6i
223653858|NCT07112053|DRUG|Cyclin-Dependent Kinase 6 Inhibitor|Given SOC CDK4/6i
223653859|NCT07112053|DRUG|F-18 16 Alpha-Fluoroestradiol|Undergo FES PET
223653860|NCT07112053|DRUG|Hormone Therapy|Given SOC ET
223653861|NCT07112053|PROCEDURE|Positron Emission Tomography|Undergo FES PET
223653862|NCT07112053|PROCEDURE|Ultrasound Imaging|Undergo CT or ultrasound-guided biopsies
223653863|NCT07112053|PROCEDURE|Biopsy Procedure|Undergo CT or ultrasound-guided biopsies
223653864|NCT07112053|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
223653865|NCT06918106|BEHAVIORAL|Simple advice, Brief-counseling and brochure|"Participants assigned to the intervention group will receive simple advice plus brief counseling and health broacher and then they will be screened for alcohol consumption at 6 months and 12 months of follow-ups."
223653866|NCT06136650|DRUG|Opevesostat|Administered orally
223653867|NCT06136650|DRUG|Dexamethasone|Administered orally
223653868|NCT06136650|DRUG|Fludrocortisone acetate|Administered orally
223653869|NCT06136650|DRUG|Hydrocortisone|Administered orally or IM as a rescue drug
223653870|NCT06136650|DRUG|Abiraterone acetate|Administered orally
223653871|NCT06136650|DRUG|Prednisone acetate|Administered orally
223653872|NCT06136650|DRUG|Enzalutamide|Administered orally
223653873|NCT03646214|DEVICE|Midline traction oral appliance|Device positions the mandible forward to open airway; device can be titrated to gradually advance the mandible.
223653874|NCT07115745|GENETIC|BMS-986515|Specified dose on specified days
223653875|NCT07115745|DRUG|Fludarabine|Specified dose on specified days
223653876|NCT07115745|DRUG|Cyclophosphamide|Specified dose on specified days
223653877|NCT07115745|DRUG|Tocilizumab|Specified dose on specified days
223653878|NCT06776406|DEVICE|Freedom Pursuit Robotic Platform|The Freedom Pursuit Robotic Platform is a robotic head holder device that uses data from the AlignRT system (3D surface imager) to make small movements of a patient's head to stabilize it during radiation therapy.
223653879|NCT06305715|DEVICE|Radiation Therapy|Enrolled subjects will be given radiation doses, at the discretion of the treating physicians, that range from 24-60 Gy in 1-15 fractions with a minimum biologically effective dose (BED\^10) of 58 Gy.
223653880|NCT06305715|DRUG|Targeted TKI therapy|Immediately following radiation therapy, subjects with an actionable driver mutation will receive a standard-of-care TKI. The choice of TKI will be at the discretion of the treating oncologist.
223653881|NCT07116967|DRUG|Deucravacitinib|Specified dose on specified days
223653882|NCT07116967|DRUG|Ustekinumab|Specified dose on specified days
223653883|NCT06932458|PROCEDURE|Retroperitoneal Lymph Node Dissection|Open bilateral nerve-sparing RPLND.
223653884|NCT06918847|OTHER|Myofacial release|Myofascial release (MFR) for the calf muscle will be administered with the patient in a prone position, holding for 120 seconds. The MFR technique involves allowing the lateral aspect of the therapist's thumb to sink into the central portion of the muscle belly. MFR will be performed for 15 minutes.
223653885|NCT06918847|OTHER|Dynamic cupping therapy|In dynamic cupping therapy, patients will be comfortably positioned in a prone position, ensuring that the lower limb is exposed and accessible for treatment. Appropriately sized cups will be selected and applied to the calf and hamstrings region. Prior to application, a small amount of lubricant or oil will be applied to facilitate the smooth movement of the cups over the skin surface during the therapy. The technique of dynamic cupping will involve compressing the cups and gently situating them onto the area being treated, applying the necessary force to generate negative pressure. The duration of dynamic cupping therapy will be 10 minutes.
223653886|NCT04209660|DRUG|Lenvatinib|Lenvatinib 20mg daily (two 10mg lenvatinib capsules) taken orally will be administered with water orally once a day (with or without food) in 21-day cycles at approximately the same time each day.
224320866|NCT03128060|OTHER|Enhanced usual care|"Usual primary care consists of: 1) appointment-based access to primary care providers (PCPs) as requested by the patient; 2) case management services; and 3) provider support through palliative care consultation. These PCPs provide family/internal medicine services as well as access to specialist care. They also offer disease case management and pain and symptom management.~These usual care services are enhanced through training in palliative care provided to PCPs. The training addresses core elements of palliative care, specifically these 6 topics: a palliative care overview; strategies for improving patient-provider communications; instruction in ACP; instruction in managing patients' pain and symptoms; care coordination; and preventing medical crises."
224320867|NCT06267846|DRUG|NBI-1070770|Suspension for oral administration
224320868|NCT06267846|DRUG|Placebo|Suspension for oral administration
223653887|NCT04209660|DRUG|Pembrolizumab|Pembrolizumab (200mg) will be administered as a 30-minute IV infusion, Q3W +/-3 days (infusions lasting between 25-40 minutes are acceptable on C1D1.
223653888|NCT06764316|DRUG|BAY 3547926|antibody conjugate with actinium-225 label
224237550|NCT03365726|DIAGNOSTIC_TEST|Dobutamine stress test with trans-esophageal echocardiography|"Dobutamine stress echocardiography will be performed: before skin incision and at the end of surgery.~After a TEE evaluation at rest to assess myocardial structure, function and potential regional wall motion abnormalities, dobutamine infusion will be started~* If no regional wall motion abnormalities will be detected, a dobutamine stress echocardiography will be started at the range infusion of 50 γ/kg/min (ADST: Accelerated Dobutamine Stress Test). The Test will be continued up to the 85% of maximum heart rate adjusted for the patient age and echo images will be stored.~* If regional wall motion abnormalities are present, a gradual dobutamine stress test will be started at the initial dose of 10 mcg/kg/min (GDST: Gradual Dobutamine Stress Test) and it will be increased every 3 minutes until the 85% of maximum heart rate, adjusted for patient's age (maximal dose: 40 mcg/kg/min) and echo images will be stored."
224237551|NCT05084001|DRUG|silver diamine fluoride|topical application of the agent on tooth surface
224237552|NCT05084001|DRUG|sodium fluoride varnish|topical application of the agent on tooth surface
224237553|NCT05084001|OTHER|tonic water|topical application of tonic water on tooth surface
224237554|NCT05128981|BEHAVIORAL|MI-CBT|Education of MI and common reactions, Interoceptive exposure, Exposure in-vivo, Behavioral activation, Relapse prevention
224237555|NCT04807270|OTHER|Intra-articular T-LAB / PRP KIT injection|Intra-articular 3 ml T-LAB / PRP KIT injection in 3 sessions will be applied. As a home exercise program, hamstring and quadriceps stretching, quadriceps isometric strengthening, short arc terminal extension exercises will be given at least three days a week with 3 sets of 10 repetitions.
224237556|NCT04807270|OTHER|Intra-articular T-LAB / PRP INJECTION SYRINGE injection|Intra-articular 3 ml T-LAB / PRP INJECTION SYRINGE injection in 3 sessions will be applied. As a home exercise program, hamstring and quadriceps stretching, quadriceps isometric strengthening, short arc terminal extension exercises will be given at least three days a week with 3 sets of 10 repetitions.
224237557|NCT04807270|OTHER|Intra-articular SALINE injection|Intra-articular 3 ml SALINE injection in 3 sessions will be applied. As a home exercise program, hamstring and quadriceps stretching, quadriceps isometric strengthening, short arc terminal extension exercises will be given at least three days a week with 3 sets of 10 repetitions.
224237558|NCT05483153|BEHAVIORAL|Infant-Directed Singing Coaching|At-risk mothers will receive four, 30-minute, in-person infant-directed singing coaching intervention sessions that take place over two weeks. Mothers will learn how to better read infant cues and respond with sensitive singing. Infants will gain experience in self-regulation of arousal states.
224237559|NCT06139224|DIETARY_SUPPLEMENT|10 day prebiotic consumption|20 HIV-infected ART-suppressed individuals will be provided a with commercially available prebiotic (FOS) for 10 days. Participants will be instructed to consume the prebiotic daily during the first three days and then twice daily for an additional seven days. Participants will be instructed to consume the powder in the morning on the first three days, then in the morning and afternoon for the following week. Each participant will have a baseline visit and a follow up visit after 10 days of the FOS intervention. Blood and stool will be collected at both visits.
224237560|NCT03963206|DRUG|Cabozantinib group|The patient starts at 60 mg / day at a distance from meals In the event of intolerance to this dose of 60 mg; specific adapted measures will be taken according to the recommendations of the good practices of use of Cabozantinib within the framework of its MA. If the symptomatic treatments are not enough, each investigator can adapt the dose of Cabozantinib reducing it to 40 or even 20 mg / day Cabozantinib will be continued for as long as radiological and / or clinical benefit is observed for the patient (no progression of the disease) or until the occurrence of unacceptable toxicity.
224237561|NCT05326659|DRUG|Benvitimod Cream|Benvitimod cream, 1%, applied twice daily for 12 weeks after enrolment.
224237562|NCT05326659|DRUG|Placebo|Placebo, applied twice daily for 12 weeks after enrolment.
224237563|NCT03477500|DRUG|Cyclophosphamide and ATG|Hematopoetic stem cell transplantation
224237564|NCT03477500|DRUG|Alemtuzumab|Alemtuzumab (Lemtrada)
224237565|NCT03477500|DRUG|Cladribine Pill|Cladribine (Mavenclad)
224237566|NCT03477500|DRUG|Ocrelizumab|Ocrelizumab (Ocrevus)
224237567|NCT02968888|OTHER|Strength training|
223653889|NCT06764316|DRUG|BAY 3547922|antibody conjugate without actinium-225 label as preinjection
223653890|NCT07139457|DEVICE|Wearable seizure prediction and alert glasses|A glasses-based wearable EEG system using the international 10-20 electrode placement standard with 4 dry spiked electrodes at F7, F8, T3 and T4. The device integrates neuromorphic computing for real-time seizure prediction, an artifact removal algorithm, and multi-modal alerts (vibration, light, sound). Data is logged for model improvement. The system is intended for continuous use in both hospital-monitored and daily-life settings.
223653891|NCT07140484|DRUG|Sotatercept|0.7mg/kg
223653892|NCT03105713|OTHER|Patient Safety Checklist|The intervention is developed, validated and to be implemented in seven surgical clusters in two hospitals, in a stepped wedge cluster randomized controlled trial of the PASC for patients to use.
223653893|NCT06072651|BEHAVIORAL|Relative Reinforcing Value of Food|Researcher gives child opportunity to press a button to earn three types of rewards: a high-reward food, a low-reward food, and a non-food reward.
223653894|NCT06935370|DRUG|vicadrostat|vicadrostat
223653895|NCT06935370|DRUG|empagliflozin|empagliflozin
223653896|NCT06935370|DRUG|Placebo|Placebo matching vicadrostat
223653897|NCT06938347|DRUG|Agitated Saline SoC|The recommended initial dose of agitated saline SoC is approximately 10 mL of saline containing approximately 1 mL of air, per institutional policy, rapidly mixed (approximately 10-20 presses) to manufacture microbubbles. No additives are allowed to the saline, including blood, dextrose, or bacteriostatic saline.
223653898|NCT06938347|DRUG|ASI-02|Each injection shall utilize one (1) ASI-02 product connected to one (1) pre-filled 10 mL 0.9% sodium chloride (saline) syringe. The ASI-02 investigational product will be connected to a standard luer lock connector and administered in its entirety. The intravenous bolus injected dose of ASI-02 is 9 mL of saline and 1 mL of air.
223653899|NCT05932914|PROCEDURE|Liver Biopsy|Standard transjugular liver biopsy under moderate sedation
223653901|NCT07072832|DEVICE|3D-Shelf|Treatment of hip dysplasia using novel 3D printed 3D-Shelf device.
223653902|NCT06942923|DRUG|AZD4144|AZD4144 will be administered orally as per arms they have been assigned.
223653903|NCT06942923|DRUG|Placebo|Placebo will be administered orally as per arms they have been assigned.
223653904|NCT07141121|DEVICE|Histolog Scan|Upon prostate removal, the prostate is taken to the Histolog scanner, dipped in proprietary fluorescent dye, rinsed with saline, and then scanned on five different sides. This involves simply placing the prostate on the surface of the scanner and acquiring images on each side, giving a high-resolution (cellular level) microscopic imaging of the prostate's surfaces. Once images are collected, the prostate is returned to the pathology lab to undergo the NeuroSafe procedure, which is standard of care (SOC).
223653905|NCT05472987|PROCEDURE|Ventral Hernia Repair|Patients will undergo retromuscular ventral hernia repair
223653906|NCT05616585|OTHER|Pharmacokinetic (PK)- Controlled Feeding Diet|Pharmacokinetic- single-day isocaloric meals of beef, potatoes, chicken, whole wheat bread, corn, cheese, yogurt, and oats with blood and urine samples taken at Time Zero and every hour (blood) or two hours (urine) after eating, over 10 hours; and at 24 hr.
223653907|NCT05616585|OTHER|Dose Response (DR)- Controlled Feeding Diet|Dose Response-3 level, six days controlled feeding study with assignment to either beef/whole wheat bread, chicken/potato, salmon/corn, cheese/soybeans, or yogurt/oats within a standard diet at zero, medium, and high doses for 6 days.
223653908|NCT07136168|BEHAVIORAL|Health dialogue|"1. Pre-visit 20 minutes including timed-up and go (TUG) walking test, length, weight, blood pressure, and blood tests ( HbA1C, PEth)~2. Structured health dialogue by a dedicated nurse practitioner for about 60 minutes covering living conditions, activity, everyday function, lifestyle habits and formation of a plan for improved health and referral to physician, physiotherapist or other primary care worker when appropriate~3. Follow-up call at 3 months with the nurse practitioner for evaluation and adjustment of the plan"
223653909|NCT04193189|BIOLOGICAL|HEPLISAV-B|Administered by IM injection
223653910|NCT04193189|BIOLOGICAL|ENGERIX-B|Administered by IM injection
223653911|NCT06947538|BEHAVIORAL|webSTAIR|WebSTAIR consists of 10 online modules that provide psychoeducation on trauma and emotions and teach skills to improve coping with emotions and strengthen interpersonal relationships. Modules are completed at the participants' own pace and utilize interactive exercises, and audio and video components to aid in delivery.
223653912|NCT06947538|BEHAVIORAL|WebSTAIR plus coaching|WebSTAIR with up to five 30-min coaching sessions with a CHW will focus on guiding participants through the program, discussing exercises that are valuable or problematic, and reviewing module content.
223653913|NCT06947538|BEHAVIORAL|Clinician administered Brief STAIR|Brief STAIR is a brief, low intensity, therapy that utilizes psychoeducation, coping skills training, and does not include recounting of the trauma memory, making it highly tolerable. It will be delivered by mental health clinicians in five to six 30-minute individual sessions.
223653914|NCT06947538|BEHAVIORAL|Clinician administered WET|WET is a brief, high intensity, exposure-based treatment delivered by mental health clinicians consisting of six 30-minute individual sessions that cover treatment rationale, psychoeducation about PTSD, and directing participants to write in session about their traumatic experience using scripted instructions.
223767721|NCT06077097|GENETIC|Biological samples|This project also includes an auxiliary exploratory biological study of subcellular mechanisms, using high-throughput sequencing (Next Generation Sequencing, NGS) to identify gene expression variations in order to determine the resilience/vulnerability of the variables studied with respect to the DC experience (cytogenetics and transcriptome).
223767722|NCT06936748|COMBINATION_PRODUCT|Spatially Fractionated Radiation Therapy Followed by Sequential Hypofractionated or Conventional Fractionated Radiotherapy Combined with Iparomlimab and Tuvonralimab|"Radiotherapy Phase: Spatially fractionated radiotherapy (SFRT, 10-20 Gy/1F) to the tumor, followed by hypofractionated/conventional fractionated radiotherapy (dose investigator-determined).~Immunotherapy Phase: Iparomlimab and Tuvonralimab (5 mg/kg) initiated within 1 week post-radiotherapy, infused IV over 20-60 minutes (Day 1, every 3 weeks) in 100 mL saline/5% glucose. Treatment continues until disease progression, intolerable toxicity, new antitumor therapy, consent withdrawal, or investigator decision, with a maximum duration of 1 year. Progression may allow continued therapy after patient-investigator discussion; re-progression mandates permanent discontinuation."
224237568|NCT02968888|DIETARY_SUPPLEMENT|Milk 1%|
224237569|NCT02968888|DIETARY_SUPPLEMENT|Whey protein concentrate 80|
223653915|NCT06947915|OTHER|Co-design workshop|Co-design workshops to develop the implementation model
223653916|NCT06947915|OTHER|Survey|Survey of care staff knowledge and confidence
223653917|NCT06947915|OTHER|Interview|Interview to explore care staff experience of the falls management support
223767723|NCT06940817|BEHAVIORAL|CHEF-ED + Food Delivery|CHEF-ED is a 7-week, digital, video-based parental intervention that teaches healthy cooking practices and an optimal way to involve children in home cooking. Each week features a video, infographics, and recipe content. The content is designed to be integrated into the home food environment without major changes to shopping habits. However, some basic culinary ingredients that are featured may not already be part of participating family pantry stocks. To support participants in effectively learning the healthy cooking strategies, participating families are provided a one-time home food delivery of non-perishable basic culinary ingredients and kitchen utensils, such as cooking oil, spices, whole wheat pasta, low sodium soy sauce, bowls.
223767724|NCT06940817|BEHAVIORAL|Food Delivery Only|The Food Delivery Only intervention involves participants receiving a one-time home food delivery of non-perishable basic culinary ingredients and kitchen utensils, such as cooking oil, spices, whole wheat pasta, low sodium soy sauce, bowls.
223767725|NCT06941844|OTHER|Placebo|A substance that is designed to have no therapeutic value
223767726|NCT06941844|DRUG|MM120 (LSD D-Tartrate)|A psychoactive substance that mediates effects mainly through an agonist activity in the serotonin 2A receptor (5-HT2A)
223767727|NCT06942455|BEHAVIORAL|SIESTA|Active condition
223653923|NCT06953466|DRUG|QRX003, 4% Lotion|QRX003 Topical Lotion containing 4% active drug (serine protease inhibitor)
224237570|NCT02968888|DIETARY_SUPPLEMENT|Native whey|
224237571|NCT06033482|PROCEDURE|The reasonable range of No.12a lymph node dissection|The lymph node overlying the proper hepatic artery is defined as No.12aa. The lymph node overlying the left side of the portal vein is defined as No.12av. Observation of lymph node metastasis rates in two groups.
224237572|NCT05607238|PROCEDURE|Ultrasound Guided Vascular Access - Midline catheter|Ultrasound guided vascular access with a midline IV catheter
223653924|NCT07145801|DIAGNOSTIC_TEST|Lumason|Following baseline ultrasound imaging, CEUS will be performed using dual B-mode and CEUS mode. For the first injection using Lumason the approximate tumor mid-line will be imaged during breath hold until complete tumor enhancement is achieved followed by imaging sweeps through the tumor. Intermittent imaging will be performed after that. Following a 10 minute Lumason wash-out period, participants will then receive a bolus injection of Sonazoid with identical imaging protocol to Lumason for the first 60 seconds to evaluate arterial phase enhancement. Imaging sweeps of the tumor will then be obtained at 1 and 2 minutes to evaluate enhancement within the late vascular phase to detect early washout. After visualization in the late phase, imaging will resume to evaluate the Kupffer phase of contrast enhancement. Following completion of the exam, patients will be monitored for at least 30 minutes before being discharged and all data will be exported for later off-line analysis
223653925|NCT07145801|DIAGNOSTIC_TEST|Sonazoid|Participants will receive a bolus injection up to (0.12 µl of MB/kg) of Sonazoid, followed by 5-10 ml of normal saline. Imaging of Sonazoid will be identical to the protocol described above for the first 60 seconds to evaluate arterial phase enhancement. Imaging sweeps (5-10 seconds) of the tumor will then be obtained in at 1 and 2 minutes to evaluate enhancement within the late vascular phase and detect early washout. After that imaging will resume to evaluate the Kupffer phase of contrast enhancement. Kupffer phase imaging (also called the postvascular phase) starts approximately 8-10 mins after injection when the free circulating microbubbles have been eliminated from the vasculature with Kupfer-cell enhancement persisting for up to 2 hours. Sonazoid CEUS will be performed in all patients after Lumason clearance from the circulation, usually within 15 min after injection.
223653926|NCT05169047|OTHER|Best Medical Treatment|For each patient who is randomized to BMT, an optimal individual treatment plan will be developed by the treating physician.
223653927|NCT05169047|OTHER|Subthreshold Spinal Cord Stimulation|SCS will be programmed at subthreshold stimulation.
223653928|NCT05963971|BEHAVIORAL|PEDALL|Twenty-six hour nutrition education intervention delivered virtually over a six month period
223653929|NCT05963971|OTHER|Standard of care|Nutrition education per institutional standard of care
224237573|NCT05607238|PROCEDURE|Ultrasound Guided Vascular Access - peripheral IV|Ultrasound guided vascular access with a peripheral IV catheter
224237574|NCT01674556|DRUG|Gemzar|Gemcitabine in combination with ultrasound (US) contrast agent under sonication
224237575|NCT01150747|DRUG|ceftriaxone|250mg IM once
224237576|NCT01150747|DRUG|Azithromycin|1 gm once
224237577|NCT05158777|BIOLOGICAL|Live attenuated varicella vaccines manufactured by Shanghai Institute of Biological Products Co.,Ltd.|live varicella-zoster virus in 0.5 mL of sucrose, sodium chloride, potassium chloride, sodium glutamate, phosphate and injection water per injection
224237578|NCT05158777|BIOLOGICAL|Live attenuated varicella vaccines manufactured by Changchun BCHT Biotechnology Co.,Ltd|live varicella-zoster virus in 0.5 mL of mannitol, dextrose tincture, sucrose, trehalose, human serum albumin and injection water per injection
224237579|NCT00234429|DRUG|Gefitinib, raltitrexed|
224237580|NCT01475474|DEVICE|Renew Insert|The Renew Insert is indicated for the management of accidental bowel leakage due to bowel incontinence. The Renew Insert is designed for self-insertion to seal and help prevent the involuntary leakage of stool from the rectum.
224237581|NCT04782609|DRUG|Icapamespib|to test the safety, tolerability and pharmacokinetics of single agent oral icapamespib in patients with recurrent brain lesions.
224237582|NCT04323670|DEVICE|"Selectra 3D guiding catheter"|His lead measurements
223653930|NCT07156448|BEHAVIORAL|Multicomponent Exercise Program|Participants in the intervention group received a structured, multicomponent exercise program consisting of resistance training, stretching, and walking. The program began on the second day of hospitalization and continued until discharge, with a frequency of five sessions per week. Each session lasted approximately 30 minutes, including about 20 minutes of resistance and stretching exercises targeting major muscle groups through functional movements (e.g., sit-to-stand, leg flexion-extension) and flexibility exercises for the upper arms, back, and posterior legs, performed in 2 to 3 sets of 8 to 12 repetitions. Each session also incorporated approximately 10 minutes of walking, with intensity adjusted according to individual tolerance.
223653931|NCT06460961|BIOLOGICAL|MK-6837|IV Infusion
223653932|NCT06460961|BIOLOGICAL|Pembrolizumab|IV Infusion
223653933|NCT06460961|DRUG|Rescue Medications|Antihistamine, H2 receptor antagonist, acetaminophen (or equivalent), dexamethasone (or equivalent) administered per product label prior to MK-6837.
223653934|NCT07151014|OTHER|blood sample collection|blood sample collection in old patients in order to study the trombophilic risk
223653935|NCT07158099|DRUG|Methylconalamin Injection(WP205)|25 mg intramuscular injection in the upper-arm deltoid
224237583|NCT01046253|DRUG|Lansoprazole|30 mg Delayed-Release Capsules
224237584|NCT01046253|DRUG|Prevacid®|30 mg Delayed-Release Capsule
224237585|NCT03349671|PROCEDURE|ultrasound|A 3D volume of the uterus will be acquired by transabdominal sonography. The sweep angle was set at 85º and the probe will be kept perpendicular to the placental plate. The placenta will be examined and the size of the volume box will be adapted in such a way that the placenta fitted into it completely. The volume will then stored for later offline analysis.
224237586|NCT03301909|DEVICE|PillCam™ Endoscopy System|Subject may be assigned to any procedure involving modification of any of the PillCam™ Endoscopy System component as listed in the arm description.
224237587|NCT03301909|DRUG|Bowel prep combination|Subject may be assigned to any bowel preparation combination.
224237588|NCT04353908|PROCEDURE|Rehabilitation|The Kabat procedure consists of facilitating the voluntary response of an impaired muscle through a global pattern of an entire muscular section which undergoes resistance. This method considers that harmony, coordination and optimal strength of body movements mainly depend upon the fact that they are performed following diagonal lines with respect to the sagittal axis of the body, thus implying a 'rotational' effect. It will performed twice a week for 8 weeks
224237589|NCT04353908|PROCEDURE|Collagen Injection|With an insulin-type syringe and 30-gauge needle, a bolus of about 0.4 cc per point of the collagen solution will be injected in the orbicularis oculi muscle 1 cm outside the orbital rim and 0.5 cm superior and inferior to the first injection point, respectively, and in the orbicularis oris muscle, where the 2 injection points are on the border between the pars peripheralis and pars marginalis, located about 5 mm above the superior and inferior vermilion, respectively
223653936|NCT07158099|DRUG|Methylconalamin for Injection|25 mg intramuscular injection in the upper-arm deltoid
223653937|NCT02211768|PROCEDURE|MRI, FDG-PET/CT scans|Standard of care to be obtained as part of the study
224237590|NCT03438448|OTHER|High sensitive Troponin T monitoring|Three determinations of Roche high-sensitive troponin T (99th percentile (14 ng/L) for each patient: preoperative (during the preoperative visit or just before surgery), 48h, and 72h after surgery. If a rise and/or fall of hs-cTnT with at least one value above the 99th percentile upper reference is detected, a clinical evaluation and a 12-lead ECG will be performed. If no ECG changes, ischemic symptoms, or pulmonary edema to fulfill the diagnostic for PMI the patients will undergo an echocardiographic study.
224237591|NCT00372788|DRUG|AZD6244|oral vial
223653938|NCT02211768|DRUG|[18F]-FLT-PET/CT scans|FLT PET to be performed as a research imaging study as it is not considered standard imaging in NF1
223653939|NCT07159971|DEVICE|School B|Nutritional therapy supported by a mobile application.
223653940|NCT07159971|OTHER|Control|Conventional nutritional treatment.
224237592|NCT00372788|DRUG|Pemetrexed|oral
224237593|NCT02914795|OTHER|diagnostic analysis of platelet function|analysis of platelet aggregation using optical measurements as well as the commercial VerifyNow technique
224237594|NCT05131126|PROCEDURE|Latarjet method|This operation consists of fixing a bone graft
224237595|NCT05131126|OTHER|Different arms exercices|"Perform 5 elevation movements in each of the elevation planes (sagittal, scapular and coronal) with the right and left arms~* Perform 5 circumduction movements with the right and left arms~* Maintain a weight of 1kg twice for 5 seconds with the arms at 90 ° of elevation."
224237596|NCT01271439|DRUG|Cetuximab|400mg/m2 intravenous infusion the week before radiotherapy, 250mg/m2 intravenous infusion weekly for 6 weeks during radiotherapy
224237597|NCT04081480|DRUG|Valacyclovir|PK curve collection to determine acyclovir exposure after administration of valacyclovir oral solution
224237598|NCT06101121|DEVICE|Lubri-Cream|Lubri-cream is indicated as a surface lubricant for bladder catheterization and cystoscopy. It will be slowly applied on the device, exerting gentle and constant pressure on the tube. Its contents will be evenly distrubuted from the tip to a suitable distance according to the technique to be performed. An individualized dose will be applied according to the technique to be performed and at the discretion of the healthcare professional
224237599|NCT03703063|DRUG|Gemcitabine|Administered by intravenous infusion over 30 minutes.
224237600|NCT03703063|DRUG|nab paclitaxel|Administered by intravenous infusion over 30-40 minutes.
224320869|NCT05832177|BEHAVIORAL|Cancer CientoUno (101) program|The Spanish version of Cancer 101 consists of several modules that address cancer control and prevention, risk factors, early detection and screening guidelines, cancer diagnosis and stages, cancer treatment, cancer and genetics, cancer and chronic disease, patient and caregiver support, HPV, biobanking, and clinical trials. All modules contain a written summary with learning objectives, a PowerPoint presentation, pre- and post-module evaluations with an answer sheet, a glossary, references, and supplemental resources. This program will occur on an ongoing basis.
223653941|NCT07156630|DEVICE|iCare ST500|Measurement of IOP
223653942|NCT07156630|DEVICE|iCare IC200|Measurement of IOP
223653943|NCT07156630|DEVICE|GAT|Measurement of IOP
223653944|NCT07156630|DEVICE|Tonovera|Measurement of IOP
223653945|NCT07177040|PROCEDURE|Maitland|Maitland technique therapy, which consists of passive mobilizations applied to the lumbar facet joints in an anterocranial direction while the patient is in a prone lying position
223653946|NCT07177040|PROCEDURE|SNAG|The technique involves applying a sustained glide to the lumbar facet joints while the patient is in a sitting position, and the pelvic girdle will be stabilized by a belt. Then the therapist will ask the patient for active forward flexion of the spine while the pressure on the facet joint is maintained during the movement till its end
223653947|NCT05335941|DRUG|Pemetrexed|Given by vein (IV)
224237601|NCT03703063|DRUG|Onivyde|Administered by intravenous infusion over 90 minutes.
224237602|NCT03703063|DRUG|Leucovorin|Administered by intravenous infusion over 30 minutes.
224237603|NCT03703063|DRUG|5-fu|Administered by intravenous infusion over 46 hours.
224237604|NCT02339909|BEHAVIORAL|Fixed financial incentive|"Participants receiving the fixed financial incentive intervention will be sent a screening appointment letter offering them a fixed amount of £10 if they attend their screening appointment."
224237605|NCT02339909|BEHAVIORAL|Probabilistic financial incentive|"Participants receiving the probabilistic financial incentive intervention will be sent a screening appointment letter offering them an entry into a lottery with at least a 1 in 100 chance of winning £1000 if they attend their screening appointment."
224237606|NCT02339909|BEHAVIORAL|Control|"Participants receiving the active comparator, (i.e. control) intervention, will be sent the standard diabetic retinopathy screening appointment letter."
224237607|NCT02703610|DRUG|Oxycodone/acetaminophen|Patients will be discharged home with a 3 day supply of oxycodone/acetaminophen
224237608|NCT02703610|DRUG|Ibuprofen/acetaminophen|Patients will be discharged home with a 3 day supply of ibuprofen/acetaminophen
224237609|NCT00855283|DRUG|IN NEO|20 mg Neostigmine via intranasal and sublingual administration
224237610|NCT00855283|DRUG|IN NEO|40 mg Neostigmine via intranasal administration
223653948|NCT05335941|DRUG|Zimberelimab|Given by vein (IV)
223653949|NCT05335941|DRUG|Etrumadenant|Given by PO
223653950|NCT07177976|PROCEDURE|Pilates Breathing Technique along with standard pharmacological management|"Patients in this group will receive pilates breathing technique along with pharmacological management.~A total 3 weeks protocol will be followed in which 2 seesions per week will be supervised by physiotherapist and 5 days at home.~Pilates breathing will be performed in sitting or supine position. The patient will place a hand over the Lower Posterior rib Cage and inhale through the nose.~While breathing they will actively contract the Transverse Abdominis (TrA) as if preparing for punch or holding in urine and engaging the pelvic floor muscles."
223767728|NCT06942455|BEHAVIORAL|Sleep education and health education control|Attention Control
224237611|NCT00855283|DRUG|IN NEO|60 mg Neostigmine via intranasal administration
223653951|NCT07177976|PROCEDURE|Pursed-lip breathing along with pharmacological management|"Patient in this group will receive pursed-lip breathing along with pharmacological management. A total 3 weeks protocol will be followed in which 2 sessions per week will be supervised by physiotherapist and 5 days at home.~The patient will sit comfortably with straight back and relaxed shoulders. They will inhale slowly through the nose, with a deep relaxed breath, and then exhale slowly through the pursed lips, as if blowing out a candle. The exhalation should take 2-3 times longer than inhalation. This breathing cycle will be repeated with a focus on slow and relaxed breathing.~Pharmacological management: Patient will receive medications as per prescribed by pulmonologist"
223653952|NCT07173803|BIOLOGICAL|AADvac1|Active immunotherapy
223653953|NCT07173803|DRUG|Treatment B|Tau-directed, neuroprotective or other therapy
223653954|NCT07179458|BEHAVIORAL|Criterion-learning practice|The experiments will be presented on a computer. On each criterion-learning trial, a picture is presented and the participant is asked to try to produce the name for the object with or without a cue. Correct-answer feedback is provided. Criterion learning involves presenting a block of items in fixed order, and on each trial, the experimenter or a voice-recognition component will code the response during the trial as correct/incorrect. When the item reaches its assigned criterion level, it is dropped from further training in a session.
223653955|NCT07182838|BIOLOGICAL|HIV Therapeutic Biologic Mix - HIV GP160 plus BCG Vaccine Mix for percutaneous use|"* By the percutaneous route with the multiple puncture device~* HIV GP160 0.1 mg x 1 mL plus BCG Organism 50 MG Mix"
223653956|NCT07160075|BEHAVIORAL|Simultaneous administration of OAT and oral PrEP at existing pharmacy-based programs|Simultaneous administration of OAT and oral PrEP (direct observed therapy or home supply) at existing pharmacy-based programs
223653959|NCT07192458|BIOLOGICAL|Fluzone High Dose Inactivated Influenza Vaccine|Fluzone High-Dose (Influenza Vaccine) for intramuscular use is an inactivated influenza vaccine, prepared from influenza viruses propagated in embryonated chicken eggs. The virus- containing allantoic fluid is harvested and inactivated with formaldehyde. Influenza virus is concentrated and purified in a linear sucrose density gradient solution using a continuous flow centrifuge. The virus is then chemically disrupted using a non-ionic surfactant, octylphenol ethoxylate (Triton® X-100), producing a split virus. The split virus containing hemagglutinin (HA) antigen is further purified and then suspended in sodium phosphate-buffered isotonic sodium chloride solution. The Fluzone High-Dose process uses an additional concentration factor after the ultrafiltration step to obtain a higher HA antigen concentration. The purified split virus from the three strains included in the vaccine are produced separately and then combined to make the trivalent formulation.
223653960|NCT07192458|BIOLOGICAL|Fluzone Standard Dose Inactivated Influenza Vaccine|Fluzone Standard Dose is a vaccine indicated for active immunization for the prevention of disease caused by influenza A subtype viruses and type B virus contained in the vaccine.
223653961|NCT07193082|DEVICE|Experimental Inspiratory Muscle Training (IMT Group)|Experimental (IMT Group): Inspiratory Muscle Training (POWERbreathe® device, twice daily, 30 breaths per session, 5 days/week, 4 weeks, resistance starting at 40% of MIP and increased weekly).
223767729|NCT05559320|DEVICE|Ride-on-toy navigation training|The training program will involve a set of activities where children will be encouraged to drive a joystick-operated ride-on-toy to navigate through their physical environment. The training will involve will involve progressively challenging multi-directional navigational games such as shape mazes, treasure hunts, relay races, and obstacle courses that will require children to use their affected arm skillfully to navigate through the courses.
223767730|NCT05559320|BEHAVIORAL|Upper extremity functional training|In addition to the navigation practice, along the multi-directional courses, children will complete tasks at multiple stations that will involve both gross and fine motor activities. The goal of the training will be to use their arm for functional goal-directed tasks and games that will involve elements of reaching, grasping, in-hand manipulation, and release. We will use props such as balls, bean bags, cups, cones, and small toys to practice skills such as catching, throwing, picking up, pushing, pulling, opening, closing, etc.
223767731|NCT06933056|DRUG|Sotagliflozin (SOTA) followed by 3 drugs in a random order|400 mg/day SOTA Each drug will be given daily for 2 weeks.
223767732|NCT06933056|DRUG|Aspirin followed by 3 drugs in a random order|81 mg/day Aspirin Each drug will be given daily for 2 weeks.
223767733|NCT06933056|DRUG|Clopidogrel followed by 3 drugs in a random order|75 mg/day clopidogrel Each drug will be given daily for 2 weeks.
223767734|NCT06933056|DRUG|Eliquis followed by 3 drugs in a random order|5 mg orally twice daily Eliquis Each drug will be given daily for 2 weeks.
223767735|NCT06944964|PROCEDURE|Single Implant Fixation (SIF)|This intervention involves using one implant for fracture fixation. The implant can be either a lateral locked plate or a retrograde intramedullary nail, based on the surgeon's preference.
224237612|NCT00855283|DRUG|IN NEO + IN Glycopyrrolate|Intranasal or sublingual Neostigmine (at effective dose: 20, 40, or 60 mg) + 4-12 mg intranasal or sublingual Glycopyyrolate
224237613|NCT00855283|DRUG|IV Visit|2mg NEO and .4mg GLY given intravenously to see if the subject responds to the intervention. If they respond, then they will proceed to the IN portion of the study.
224237614|NCT03086356|DRUG|Dabigatran etexilate|Days 1-4 and Day 8-11
224237615|NCT03086356|DRUG|Idarucizumab|Day 11
224237616|NCT00981305|DRUG|Lactate-containing vaginal lubricant|vaginal applying at least 3cc of lactate-containing lubricant at the time of sexual intercourse or before sleeping for 8 weeks (at least 3 times/week)
224237617|NCT00981305|DRUG|Placebo vaginal lubricant|vaginal applying at least 3cc of placebo lubricant at the time of sexual intercourse or before sleeping for 8 weeks (at least 3 times/week)
223653962|NCT07193082|DEVICE|Control Group: No inspiratory muscle training.|Control Group: No inspiratory muscle training.
224237618|NCT03536624|BEHAVIORAL|6 days spa residential program|6 days spa residential program combining psychological intervention, physical activity, thermal spa treatment, health education and corrections of eating disorders.
224237619|NCT02289768|DRUG|5-fluorouracil/salicylic acid|
224237620|NCT02289768|DRUG|Vehicle|
224237621|NCT05112328|DRUG|Exocrine Pancreatic Enzyme|Pancreatic enzyme supplementation for critically ill patients on enteral nutrition
224237622|NCT05112328|DRUG|Placebo|Placebo of Pancreatic enzyme for critically ill patients on enteral nutrition
224237623|NCT06597149|DEVICE|Transcutaneous Auricular Vagus Nerve Stimulation|Healthy adult participants will be assigned to either the stimulation group or the sham group. The stimulation group will receive mild stimulation from the TeNS device and the sham group will receive no stimulation but will believe that they are receiving stimulus.
224237624|NCT00169936|DEVICE|Magnetocardiograph|
224237625|NCT03194035|BIOLOGICAL|blood sample|Study per and post-exertional changes in proinflammatory biological (IL1, IL6, TNF alpha, HMG beta1 and CRP) and anti inflammatory parameters (IL4, IL10 and IL13, TGF beta, LPS, lipoproteins, lipids) during an ultra endurance race.
223653963|NCT07190287|DEVICE|NEUSleeP system (FUS-EEG wearable device)|"The NEUSleeP system is a wearable FUS-EEG device integrating hydrogel-based EEG and focused ultrasound neuromodulation. The intervention includes:~1. Device testing in 4 healthy volunteers to assess EEG signal and impedance over 4 weeks vs. wet electrodes;~2. STN targeting validation in up to 20 participants using MRI-guided tFUS with NEUSleeP and BrainSonix Pulsar 1002, with fMRI analysis of BOLD activation in stress-related areas (amygdala, insula);~3. REM sleep modulation in 16 healthy participants across two nights, evaluating REM sleep architecture and stress-related fMRI changes following STN stimulation during REM;~4. A similar protocol in 12 individuals with self-reported poor sleep and moderate stress, assessing subjective stress (PSS), sleep dynamics, and connectivity changes post-tFUS."
223653964|NCT07190287|DEVICE|BrainSonix Pulsar 1002|The BrainSonix Pulsar 1002 is a research-grade focused ultrasound device used to evaluate STN targeting in up to 20 healthy participants. COMSOL 2D acoustic simulations and structural MRI are used to localize the STN. The BrainSonix system is tuned and installed for STN stimulation during fMRI scanning. Pre- and post-stimulation fMRI is conducted to verify BOLD signal changes in the STN and related regions. These responses are compared with those from NEUSleeP stimulation, using identical imaging protocols. Ultrasound parameters are iteratively adjusted to optimize targeting while adhering to FDA diagnostic ultrasound safety limits. A linear mixed model is used to assess stimulation-induced changes.
223653965|NCT07199504|DRUG|Dipyridamole 50mg tid|Participants will take dipyridamole daily (50mg each time, three times a day) for 6 months
224237626|NCT03202758|DRUG|Durvalumab, Tremelimumab and ,FOLFOX|"Study will be performed in 2 step:~STEP 1 (phase Ib) will assess the safety of the combination of Durvalumab 750mg q2w + tremelimumab 75mg q4w + FOLFOX during the 2 first cycles of treatment (1 month)~STEP 2 (phase II) will assess the efficacy of the combination of Durvalumab 750mg q2w + tremelimumab 75mg q4w + FOLFOX"
224237627|NCT01264952|PROCEDURE|Electrochemotherapy|"Treatment procedure: anesthesia, positioning of electrodes, intravenous in bolus administration of bleomycin (15 mg/m2), within 5-30 min after administration of bleomycin application of electric pulses (8 pulses, duration 100 microseconds, frequency 4 Hz with amplitude adequate to cover the whole treated lesion with electric field necessary for reversible plasma membrane permeabilization), removal of electrodes.~The maximum duration of procedure is 90 minutes."
224237628|NCT01365962|GENETIC|gene expression analysis|
223653966|NCT07198282|PROCEDURE|Conventional Suturing|Wound edges are approximated using 3/0 braided, non-absorbable silk sutures (Doğsan®, Turkey). Standard oral surgery closure technique.
223653967|NCT07198282|PROCEDURE|Sutureless Technique|The wound is left to heal by secondary intention without using any suturing material.
223653968|NCT07198282|PROCEDURE|Surgical Drain|A biocompatible sterile plastic drain is placed in the surgical site to facilitate drainage of blood and fluids, helping to reduce edema and hematoma formation.
223653969|NCT07198282|PROCEDURE|Cyanoacrylate Tissue Adhesive|Cyanoacrylate-based medical tissue adhesive (PeriAcryl®90 High Viscosity) is applied to the wound edges, providing rapid polymerization and effective closure.
223653970|NCT07198100|DEVICE|Transcutaneous non-invasive vagus nerve stimulation (tVNS)|To stimulate vagal afferents, the electrode will be placed at the cymba conchae of the right ear using a previously established conventional stimulation protocol (30 s ON, 30s OFF, 25 Hz frequency, 250 µs pulse widths; tVNS R device, tVNS Technologies GmbH, Erlangen, Germany). Stimulation intensity will be pre-set for each participant for the following stimulation period to correspond to a mild pricking sensation determined with a staircase procedure in the lab session.
224237629|NCT01365962|OTHER|immunohistochemistry staining method|
224237630|NCT01365962|OTHER|laboratory biomarker analysis|
224237631|NCT01365962|OTHER|mass spectrometry|
224237632|NCT01994525|BIOLOGICAL|PfRAS|Radiation-attenuated Plasmodium falciparum sporozoites (PfRAS) administered by the bite of infected Anopheles stephensi mosquitoes
224237633|NCT01994525|BIOLOGICAL|Placebo|Administered by the bite of noninfected Anopheles stephensi mosquitoes
224237634|NCT01994525|OTHER|Challenge|5 infectious Anopheles stephensi mosquito bites carrying infectious Plasmodium falciparum sporozoites within a controlled clinical environment.
224237635|NCT00060905|DRUG|Divalproex Sodium (Depakote ER)|
224237636|NCT04183231|DRUG|Anti-caries varnish|topical tooth varnish
224237637|NCT05324735|DRUG|Pentoxifylline|All participants will receive pentoxifylline 400 mg (orally ingested) twice a day for 12 weeks.
224237638|NCT05324735|DRUG|Placebo|All participants will receive placebo (orally ingested) twice a day for 12 weeks.
224237639|NCT04131361|OTHER|Ultrasound-guided Inferior vena cava diameter dependent colloid challenge versus routine crystalloid strategy Fluid replacement|The inferior vena cava largest and smallest diameters will be measured proximal to the opening of the hepatic veins in the longitudinal axis with the M-mode using a 8-2 MHz curved array ultrasound probe placed longitudinally in the subcostal region.
223653971|NCT07198100|DEVICE|Sham stimulation|The control intervention consists of a sham stimulation. The electrode will be placed at the earlobe, which is not innervated by vagal afferent fibers. To improve blinding, the same stimulation protocol as for the tVNS will be applied (30 s ON, 30s OFF, 25 Hz frequency, 250 µs pulse widths; tVNS R device, tVNS Technologies GmbH, Erlangen, Germany) and stimulation intensities will be adjusted to correspond to a mild pricking sensation.
223653972|NCT07198100|DIAGNOSTIC_TEST|Oral glucose tolerance test (oGTT)|"The oGTT will be conducted as a standardized metabolic challenge to assess glucose metabolism and insulin sensitivity. After an overnight fast, participants ingest a 75 g glucose solution. Venous blood samples are collected at five time points (0, 30, 60, 90, and 120 minutes) to measure plasma glucose and insulin concentrations. The primary variable of interest will be the peripheral insulin sensitivity index (ISI) according to Matsuda and DeFronzo as 10,000/(G0 × I0 × Gmean × Imean)1/2 with G = glucose and I = insulin.~Additionally we will investigate the correspondence of ISI with other measures of insulin sensitivity (HOMA-IR), and Insulin secretion indices (Insulinogenic index (IGI), Corrected insulin response (CIR), Areas under the curve (AUC)), and HbA1c."
223653973|NCT07202091|DRUG|Trimethoprim Sulfamethoxazole|Once daily trimethoprim-sulfamethoxazole (co-trimoxazole) 160mg/800mg. NB: Doxycycline 100mg daily as an alternative for patients with hypersensitivity to co-trimoxazole.
223653974|NCT07202091|DRUG|Amoxycillin/clavulanic acid|Patients will be provided with amoxycillin/clavulanic acid 1750-2000mg/250mg and ciprofloxacin 750 mg to keep at home for initial use if symptoms of infection develop, with immediate review by their treating clinical team, or nearest emergency department or medical practitioner with phone contact to treating team if most practical.
223653975|NCT07202091|BIOLOGICAL|Immune Globulin Intravenous|Participants will continue treatment with their current Ig replacement schedule. Participants will receive monthly (every 4 weeks ± 1 week) intravenous immunoglobulin at a dose of 0.4g/kg, modified to achieve an IgG trough level of at least lower limit of age-specific serum IgG reference range. For patients who have already had their Ig dose titrated to IgG trough level, they may continue on their current monthly dose of Ig replacement. SCIg, weekly, may be used in patients who meet local criteria for home-based self-administration in centres with established SCIg programs. Dosing is usually given at 100mg/kg/week, modified to achieve an IgG steady state level of at least the lower limit of the serum reference range.
223653976|NCT07202052|BIOLOGICAL|Intravenous immunoglobulin|(IVIg) intravenous immunoglobulin every 4 weeks ± 1 week at a dose of 0.4g/kg, modified to achieve an (IgG) immunoglobulin G trough level of at least lower limit of age-specific serum IgG reference range; or SCIg, weekly, may be used in patients who meet local criteria for home-based self-administration in centres with established SCIg programs. Dosing is usually given at 100mg/kg/week, modified to achieve an IgG steady state level of at least the lower limit of the serum reference range. A loading IVIg dose may be given in the first month if required.
223653977|NCT07202052|DRUG|Trimethoprim / Sulfamethoxazole|Once daily trimethoprim-sulfamethoxazole (co-trimoxazole) 160mg/800mg. Doxycycline 100mg daily as an alternative for patients with hypersensitivity to co-trimoxazole.
223653978|NCT07202052|DRUG|Amoxicillin clavulanic acid|Patients will be provided with amoxycillin/clavulanic acid 1750-2000mg/250mg and ciprofloxacin 750 mg to keep at home for initial use if symptoms of infection develop, with immediate review by their treating clinical team, or nearest emergency department or medical practitioner with phone contact to treating team if most practical. Clindamycin 600 mg is permitted as an alternative to amoxycillin/clavulanic acid for patients with hypersensitivity to penicillin. Ciprofloxacin is omitted for participants with hypersensitivity.
223653979|NCT07202052|BIOLOGICAL|Intravenous immunoglobulin (IVIG)|"Arm A: Low dose (IgRT) immunoglobulin replacement therapy: Participants will be treated with intravenous immunoglobulin monthly (every 4 weeks ± 1 week) at a dose of 0.25g/kg. No dose adjustment for trough serum IgG levels is required.~Arm B: Usual dose: Participants will be treated with intravenous immunoglobulin monthly (every 4 weeks ± 1 week) at a dose of 0.4g/kg, modified to achieve an IgG trough level of at least lower limit of age-specific serum IgG reference range."
223653980|NCT07199218|DRUG|Terpenes-Enriched CBD-Predominant Oil|Oral cannabidiol (CBD; 7.2 mg/kg/day), tetrahydrocannabinol (THC; 0.257 mg/kg/day, equivalent to 1:28 of the CBD dose), and terpenes (0.5 mg/kg/day), administered in two daily doses. The formulation is an olive oil-based solution (CBD/THC: 280/10 mg per g) produced by Bazelet Group, Israel.
223653981|NCT07199218|DRUG|Placebo|Oral olive oil with added flavors to mimic the appearance, texture, and taste of the study drug, administered in two daily doses.
223653982|NCT07199218|DRUG|Terpenes-Enriched CBD Oil (THC-Free)|Oral cannabidiol (CBD; 7.2 mg/kg/day) and terpenes (0.5 mg/kg/day), administered in two daily doses. The formulation is an olive oil-based solution (CBD- 280 mg per g) produced by Bazelet Group, Israel.
223653983|NCT07199335|DRUG|APRETUDE (cabotegravir)|All participants will be prescribed APRETUDE based on APRETUDE's FDA approved indication, which is sexual risk of HIV transmission.
223767736|NCT06944964|PROCEDURE|Dual Implant Fixation (DIF)|This intervention involves using two implants for fracture fixation. The combination can be either dual plate fixation (DPF) or combination nail plate fixation (NPF) .
224237640|NCT03726190|PROCEDURE|Oblique Lateral Lumbar Fusion|Oblique lateral lumbar interbody fusion (OLLIF) is a lumbar spinal fusion. OLLIF is performed with the patient in the prone position and employs an oblique lateral approach that enables the instrumentation to pass through Kambin's triangle which is defined as the space between the exiting nerve, the superior border of the caudal vertebra, and the superior articulating process of the inferior facet. This approach may be performed without direct visualization, guided by electrophysiological monitoring and biplanar fluoroscopy. During the approach, a blunt probe is used to make contact with the disc, followed by a series of gentle dilations. Discectomy is performed through a 10-mm access portal. The cage is inserted under continued electrophysiological monitoring and fluoroscopy.
224237641|NCT00860028|DRUG|Extended Varenicline Pretreatment|4 weeks varenicline (Chantix) titrated to 1 mg oral tablet twice per day before the smoking quit date followed by 4 weeks varenicline (Chantix) 1 mg oral tablet twice per day treatment.
224237642|NCT00860028|DRUG|Short-term Varenicline Pretreatment|3 weeks placebo + 1 week varenicline (Chantix)pretreatment + 4 weeks varenicline 1 mg oral tablet twice per day treatment following the smoking quit date.
223767737|NCT06171789|DRUG|GEN1107|IV infusion of GEN1107
224237643|NCT06347757|PROCEDURE|Anti-Reflux Alimentary Reconstruction After Laparoscopic Proximal Gastrectomy|laparoscopic proximal gastrectomy with single-tract jejunal interposition (LPG-STJI) versus double-tract reconstruction (LPG-DTR) versus tube-like stomach reconstruction (LPG-TLR).
223653984|NCT07201116|DEVICE|Health-GIS Rehabilitation Coordination Platform|Participants receive access to a specialized mobile application with integrated Geographic Information System (GIS) components for rehabilitation service coordination. While hospitalized, patients submit rehabilitation requests through the platform, indicating their location, desired time, and specific rehabilitation needs. Registered rehabilitation centers within the platform receive these requests and can submit counter-proposals with available slots, services offered, and estimated costs. The platform provides real-time visualization of available rehabilitation facilities on an interactive map, displays facility ratings, services offered, current capacity, and waiting times. Patients receive automated notifications about new proposals and can compare options based on location proximity, service quality ratings, and availability. Technical support is available through in-app messaging and a dedicated helpline during business hours.
223653985|NCT07201116|OTHER|Standard Rehabilitation Referral|Upon discharge, patients receive written recommendations stating that rehabilitation is advised as part of their post-operative care plan. No specific rehabilitation facilities are recommended or contacts provided by the surgical team. Patients are instructed to contact their assigned primary care physician (general practitioner) at their local polyclinic for further referral coordination. The primary care physician is responsible for identifying available rehabilitation facilities, making referrals, and coordinating the rehabilitation timeline based on their knowledge of local resources and current availability. This intervention represents routine clinical practice typically provided to patients after total hip arthroplasty.
223653986|NCT07201506|DEVICE|PVC and VT ablation with ICE|Premature ventricular contraction (PVC) and ventricular tachycardia (VT) ablation with intracardiac echocardiography (ICE)
223653987|NCT07201506|DEVICE|PVC and VT ablation without ICE|Premature ventricular contraction (PVC) and ventricular tachycardia (VT) ablation without intracardiac echocardiography (ICE)
223653988|NCT07195734|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223653989|NCT07195734|DRUG|Carboplatin|Given IV
223653990|NCT07195734|BIOLOGICAL|Cemiplimab|Given IV
223653991|NCT07195734|DRUG|Cisplatin|Given IV
223653992|NCT07195734|PROCEDURE|Computed Tomography|Undergo CT scan
223653993|NCT07195734|DRUG|Paclitaxel|Given IV
223653994|NCT07195734|PROCEDURE|Positron Emission Tomography|Undergo PET scan
223653995|NCT07195734|RADIATION|Radiation Therapy|Undergo radiation therapy
224237644|NCT05803915|DRUG|Toripalimab|The participants will receive Toripalimab 240mg intravenous infusion every 3 week, and Nimotuzumab 150mg/㎡ every 2 week for 2 cycles
223653996|NCT07195734|PROCEDURE|Salvage Surgery|Undergo standard of care salvage surgery
223653997|NCT04865887|DRUG|Pembrolizumab|200mg, every 3 weeks, IV infusion
223653998|NCT04865887|DRUG|Lenvatinib|20 mg (2 capsules x10mg), daily, orally
223653999|NCT07205107|DRUG|clindamycin phosphate, adapalene and benzoyl peroxide|Topical treatment
223654000|NCT07195695|DRUG|Zongertinib|Zongertinib
223654001|NCT07195695|DRUG|Pembrolizumab|Pembrolizumab
223654002|NCT07195695|DRUG|Atezolizumab|Atezolizumab
223654003|NCT07195695|DRUG|Durvalumab|Durvalumab
223654004|NCT07195695|DRUG|Nivolumab|Nivolumab
223654005|NCT07203677|DRUG|Initiation of tirzepatide|New use of tirzepatide dispensing claim is used as the exposure.
223654006|NCT07203677|DRUG|Initiation of sitagliptin|New use of sitagliptin dispensing claim is used as the reference.
223654007|NCT07197905|DRUG|Intravenous iron|The Intravenous iron infusion will be administered according to standard clinical care. The provider will choose the dosage and formulation of IV iron.
223654008|NCT07199465|DRUG|Letermovir|Administered orally (as tablets/pellets) or via gastrostomy or nasogastric tube (as pellets) for 7 consecutive days.
223654009|NCT07205796|BIOLOGICAL|HZ Vaccine (IN001)|Formulation for injection
223654010|NCT07205796|BIOLOGICAL|Shingrix|Sterile suspension for injection
223654011|NCT07200687|OTHER|Music therapy|this research hopes to offer new insights into the benefits of combining music therapy with occupational therapy.
223654012|NCT07200687|OTHER|occupational therapy|standard treatment
223654013|NCT07200739|DIAGNOSTIC_TEST|Mini-mental State Examination|Participants will be recorded during the test in order til allow the AI to learn and analyze speech patterns.
223654014|NCT07200739|DIAGNOSTIC_TEST|Addenbrooke's Cognitive Examination|Participants will be recorded during the test in order til allow the AI to learn and analyze speech patterns.
223654015|NCT07200739|OTHER|Speech task - Picture Description|Participants will be asked to describe the Cookie Theft Picture from the Boston Diagnostic Aphasia Examination. The task will take 2 minutes. Participants will be recorded during the speech task in order to allow the AI to learn and analyze the speech patterns.
223654016|NCT07200739|OTHER|Speech task - Story Retellling|"Participants will be asked to retell the fairy-tale Cinderella, based on pictures that summarize the fairy-tale. In case Cinderella is not known, participants are asked to tell a story with a start, a middle and an end based on the provided pictures. The task will take 4 minutes. Participants will be recorded during the speech task in order to allow the AI to learn and analyze the speech patterns."
223654017|NCT07200739|OTHER|Fluency tasks|"Two fluency tasks from the Addenbrooke's Cognitive Examination. First, the participant is asked to name as many animals as possible within 1 minutes. Next the participant is asked to name as many words starting with S as possible within 1 minute.~Participants will be recorded during the tasks in order to allow the AI to learn and analyze speech patterns."
224237645|NCT02687256|DEVICE|Extended Wear infusion set|For two of the 4 weeks the Extended Wear insulin infusion set will be used.
223654018|NCT07200739|DIAGNOSTIC_TEST|MRI|"For healthy controls an MRI will be conducted to provide comparable imaging and as part of screening to ensure they do not meet exclusion criteria (neuroradiological findings that could affect cognitive functions).~For participants in the follow-up or new referral cohorts, imaging will be performed as part of the standard diagnostic battery and results will be obtained from the electronic journal."
223767738|NCT05568550|BIOLOGICAL|Pembrolizumab|Pembrolizumab will be delivered via IV at 200mg on day 1 of each 3-week cycle for approximately 12 months. Cycle 1 begins 21 days prior to radiation therapy and cycles 2-17 are administered during and after radiation therapy.
224237646|NCT02687256|DEVICE|Standard Infusion set|For two of the 4 weeks the Standard infusion set will be used
224237647|NCT02687256|DRUG|Heparin|
223654019|NCT07200739|DIAGNOSTIC_TEST|blood sampling|"Healthy control participants will undergo a standard blood test panel commonly used in dementia diagnostics. The panel includes complete blood counts, inflammatory markers, kidney- and liver function markers, thyroid-stimulating hormone (TSH), vitamine B12 and folate. These tests are performed to exclude underlying medical conditions that could mimic cognitive impairment.~For participants in the follow-up or new referral cohorts, blood sampling will be performed as part of the standard diagnostic battery and results will be obtained from the electronic journal."
223654020|NCT07200739|DIAGNOSTIC_TEST|Depression screening|"Performed on healthy controls to rule out depression using either the geriatric depression scale (GDS) for patients \> 65 year of age or the Major Depression Index (MDI) for patiens \<65 year of age.~For participants in the follow-up or new referral cohorts, depression screening will be performed as part of the standard diagnostic battery and results will be obtained from the electronic journal."
223654021|NCT07200739|OTHER|Somatic- and neurological examination|"Healthy controls will undergo a standard somatic and neurological examination to exclude conditions that may affect cognition. This includes basic neurological assessment and clinical evaluation of general health status.~For participants in the follow-up or new referral cohorts, a somatic and neurological examination will be performed as part of the standard diagnostic battery and results will be obtained from the electronic journal"
223654022|NCT07202078|DRUG|Trimethoprim / Sulfamethoxazole|Once daily trimethoprim-sulfamethoxazole (co-trimoxazole) 160mg/800mg. NB: Doxycycline 100mg daily as an alternative for patients with hypersensitivity to co-trimoxazole.
223654023|NCT07202078|BIOLOGICAL|Immune Globulin Intravenous|IVIg every 4 weeks ± 1 week at a dose of 0.4g/kg, modified to achieve an IgG trough level of at least lower limit of age-specific serum IgG reference range; or SCIg, weekly, may be used in patients who meet local criteria for home-based self-administration in centres with established SCIg programs. Dosing is usually given at 100mg/kg/week, modified to achieve an IgG steady state level of at least the lower limit of the serum reference range. A loading IVIg dose may be given in the first month if required.
223654024|NCT07201168|OTHER|Structured Multimodal Educational Program for Critical Limb Ischemia|A comprehensive 12-month educational program combining face-to-face and digital learning modalities. Components include: weekly interactive group sessions (4 weeks) led by vascular specialists covering disease pathophysiology, risk factor modification, and treatment options; digital platform access with multimedia educational materials, printed educational materials for home reference; peer support group participation; medical hotline access for patient-initiated consultations and urgent questions; smoking cessation counseling; supervised exercise program recommendations; wound care training. The program emphasizes patient self-management skills, early recognition of complications, and adherence to medical therapy alongside standard clinical care.
223654025|NCT07201168|OTHER|Standard medical care|Routine clinical management for critical limb ischemia according to current standard of care guidelines. Includes vascular surgery consultation, standard medical therapy (antiplatelet agents, statins, antihypertensive medications as indicated), routine wound care instructions, general lifestyle counseling typically provided during clinical encounters, and scheduled follow-up appointments as clinically indicated. No structured educational materials, formal patient education sessions, or additional follow-up contacts beyond routine clinical care are provided. Patients receive standard verbal and written discharge instructions and have access to the same medical and surgical treatments as the intervention group when clinically warranted.
223654026|NCT07202065|BIOLOGICAL|Immune Globulin Intravenous|Participants will be treated with intravenous immunoglobulin monthly (every 4 weeks ± 1 week).
223654027|NCT07210749|RADIATION|External Beam Radiation Therapy|12 Gy in 6 fractions of external beam radiation therapy
224237648|NCT00677911|BEHAVIORAL|In-vivo pain catastrophizing induction|All participants underwent a 10-minute in-vivo pain castastrophizing induction.
224237649|NCT03029520|OTHER|Root canal obturation with iRoot SP sealer|Postoperative pain after root canal obturation with iRoot SP sealer with patients who has (mandibular premolar/molar) vital and devital pulps.
223654028|NCT07209956|PROCEDURE|Echocardiographic assessment of TAPSE|"Non interventional study (study of a prognostic factor). The study procedure is the echocardiographic assessment of TAPSE at every admission in PICU for acute bronchiolitis.~Transthoracic echocardiography is a non invasive, non radiative examination, that is usually performed at every admission in PICU, however not mandatory. Inclusion in the study will lead to a systematic echocardiographic assessment at admission, potentially adding this examination to the patient's course.~As transthoracic echocardiography is systematically monitored in intubated children, no additional examination will be necessary for those requiring invasive mechanical ventilation."
223654029|NCT07211113|DIETARY_SUPPLEMENT|Fonte Essenziale® mineral water|400 ml/day of Fonte Essenziale® mineral water, taken every morning on an empty stomach for 12 consecutive months, in addition to a specialist-prescribed controlled nutritional regimen
223654030|NCT07209384|PROCEDURE|Transarterial chemoembolization|Transarterial chemoembolization with FOLFOX plus/minus intravenous cetuximab/bevacizumab
223654031|NCT07210866|OTHER|no physical or medical interventions|Data from patients after successive rescucitaion will be evaluated by machine learning programs.
223654032|NCT07211334|PROCEDURE|Exercise Training|Adapted High Intensity Interval Training (HIIT), Moderate-Intensity Continuous training (MICT), therapeutic education workshops to help people become independent regarding their program
224237650|NCT03029520|OTHER|Root canal obturation with AH Plus Sealer|Postoperative pain after root canal obturation with AH Plus sealer with patients who has (mandibular premolar/molar) vital and devital pulps.
224237651|NCT00483496|DRUG|Titanium dioxide (Ti02) microfine 12.15% alone (formula RV3131A-MV1209)|
224237652|NCT00483496|DRUG|Ti02 pigmentary 3% alone (formula RV3131A-MV1211)|
224237653|NCT00483496|DRUG|bisoctrizole 10% alone (formula RV3131A-MV1237)|
224237654|NCT00483496|DRUG|Ti02 microfine 12.15% + Ti02 pigmentary 3% (formula RV3131A-MV1213)|
224237655|NCT00483496|DRUG|Ti02 microfine 12.15% + bisoctrizole 10% (formula RV3131A-MV1329)|
224237656|NCT00483496|DRUG|Ti02 pigmentary 3% + bisoctrizole 10% (formula RV3131A-MV1212)|
224237657|NCT00483496|DRUG|Ti02 microfine 12.15% + Ti02 pigmentary 3% + bisoctrizole 10% [V0096 CR (formula RV3131A-MV1166)]|
224237658|NCT00483496|DRUG|V0096 CR vehicle (formula RV3131A-MV1197)|
223654033|NCT07210580|BEHAVIORAL|MBC-IBD Intervention|Measurement Based Care for Inflammatory Bowel Disease - Intervention group. Veteran participants who are randomized to 12-months of MBC-IBD will be enrolled for 12 months. They will each complete surveys at baseline, 6-months, and 12-months post-randomization. After baseline completion, participants will be asked to complete weekly surveys. These assessments require completion of self-report questionnaires (PROs) which will be completed by phone or electronically using VA REDCap. MBC in IBD will not replace but rather provide care continuity between clinic visits. Patients allocated to MBC in IBD will receive automated reminders to complete weekly questionnaires. Further, patients will receive quarterly reports of their PRO data trends.
223767739|NCT05568550|DRUG|Olaparib|200mg Olaparib will be given twice daily for a total of 3 cycles. Cycle 1 begins 21-days prior to radiation therapy.
223767740|NCT05568550|DRUG|Androgen Deprivation Therapy|Androgen Deprivation Therapy (either LHRH agonist or LHRH antagonist) as per treating physician choice will be allowed within 3 months prior to randomization. Duration is per institutional standards.
223654034|NCT07210580|OTHER|Enhanced Treatment as Usual (E-TAU)|E-TAU will receive standard of care, including monitoring and treatment as directed at the discretion of their gastroenterologist. Participants will also receive educational videos and fact sheets on various IBD-specific topics.
223654035|NCT07209371|DRUG|Rifaximin|Given PO
223767741|NCT05568550|RADIATION|Radiation Therapy|Definitive radiation (total dose and fractions) will be dosed per institutional standards. Definitive radiation may include external beam radiation therapy with or without brachytherapy, based on NCCN risk score and as per treating physicians.
223767742|NCT04397328|DRUG|Hydroxychloroquine|Hydroxychloroquine vs placebo (1:1 design) double blind intervention
223767743|NCT04397328|DRUG|Placebo|Hydroxychloroquine vs placebo (1:1 design) double blind intervention
223767744|NCT07145515|DEVICE|OCS Heart|Preservation of donor hearts with OCS Heart System and novel OCS Solution and OCS Functional Enhancer.
223654036|NCT07209371|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223654037|NCT07211061|DRUG|Stannous Fluoride Dentifrice|brush 2x a day in using a power brush (2 minutes of brushing)
223654038|NCT07211061|DRUG|Sodium Fluoride Dentifrice|brush in their customary manner
223767745|NCT07145515|OTHER|Static Cold Storage (SCS)|Preservation of donor hearts with static cold storage.
223767746|NCT06949735|DIETARY_SUPPLEMENT|Digestive Enzyme Blend|Oral
223767747|NCT06949735|DIETARY_SUPPLEMENT|Placebo|Oral
223767748|NCT06947967|DRUG|CHOP (cyclophosphamide, hydroxydaunorubicin [doxorubicin], Oncovin [vincristine], prednisone)|Cyclophosphamide 750 mg/m2 , intravenous infusion on day 1 of each 21-day cycle. Doxorubicin 70mg/m2 , intravenous infusion on day 1 of each 21-day cycle, total 6 cycles. Vincristine 1.4mg/m2(Max dose 2mg), intravenous injection on day 1 of each 21-day cycle , total 6 cycles. Prednisone 100 mg, oral, day 1-5 of each 21-day cycle,total 6 cycles.
223767749|NCT06947967|DRUG|Tucidinostat|oral, taking as prescribed by the protocol
224237659|NCT03389386|DIAGNOSTIC_TEST|Blood withdrawal for laboratory analysis|"Participants in this study will have their peripheral blood sampled from the cubital vein and the total volume withdrawn for the purposes of this study will be no more than 22 mL per person.~Parameters of interest in the laboratory analysis will include serum catestatin levels, NT-proBNP levels, hs-cTnI, parameters of inflammation and renal function as well as standard biochemistry and complete blood count (CBC) panels."
224237660|NCT03389386|OTHER|Standard-of-care treatment|Patients diagnosed with chronic heart failure will receive optimal standards of care in terms of pharmacologic management, according to their current clinical condition.
224237661|NCT03389386|DIAGNOSTIC_TEST|Transthoracic echocardiography (TTE)|Participants from both groups will undergo transthoracic echocardiography examination that will measure established hemodynamic parameters of systolic and diastolic cardiac function as well as parameters of LV and RV strain in the selected subset of patients.
224237662|NCT02559583|OTHER|Chronic Lymphocytic Leukemia (CLL)|This is observational study. Participants with Chronic Lymphocytic Leukemia (CLL) will be observed for 1 year.
224237663|NCT02559583|OTHER|Multiple Myeloma (MM)|This is observational study. Participants with Multiple Myeloma (MM) will be observed for 1 year.
224237664|NCT02559583|OTHER|Non-Hodgkin's lymphoma (NHL)|This is observational study. Participants with non-Hodgkin's lymphoma (NHL) will be observed for 1 year.
224237665|NCT06056388|DEVICE|Straumann BLX implant|Implant system with a deep fixture thread depth.
223654039|NCT07211061|DEVICE|electric toothbrush|brush using a electric brush (2 minutes of brushing)
223654040|NCT07211061|DRUG|Cetylpyridinium Chloride (CPC)|use 20 ml of mouth rinse for 30 seconds
223654041|NCT07211061|DEVICE|manual toothbrush|brush in their customary manner
223767750|NCT06947967|DRUG|Placebo|oral, taking as prescribed by the protocol
223767751|NCT06409494|BIOLOGICAL|EuHZV|Drug(injection)
223767752|NCT06409494|BIOLOGICAL|Shingrix|Drug(injection)
223767753|NCT07172971|DRUG|SGLT-2 inhibitor|SGLT-2 inhibitor will be given once daily by mouth
223767754|NCT07172971|DRUG|SGLT2 inhibitor|SGLT-2 inhibitor will be given once daily by mouth
224237666|NCT06056388|DEVICE|Straumann BLT implant|Implant system with a regular fixture thread depth.
224237667|NCT02159105|DEVICE|FAST scan and non-invasive hemoglobin measurement|"A FAST scan, or abdominal ultrasound will be performed within one hour of cesarean delivery to establish normal levels of postoperative intraabdominal fluid.~Women will also have their hemoglobin measured via a non-invasive method, the Masimo Pronto 7, at 3 time points: immediately prior to surgery (within 2 hours), immediately after surgery (within 1 hour), and the morning following surgery (within 24 hours)."
224237668|NCT01658943|DRUG|Akt Inhibitor MK2206|Given PO
224237669|NCT01658943|DRUG|Fluorouracil|Given IV
224237670|NCT01658943|DRUG|Oxaliplatin|Given IV
224237671|NCT01658943|DRUG|Selumetinib|Given PO
224237672|NCT06455020|PROCEDURE|Catheter ablation|Emergency catheter ablation is defined as ablation performed within 48 hours of hospital admission
224237673|NCT06455020|PROCEDURE|Stepped-care strategies|Patients randomized to the stepped-care strategy arm will receive treatment through a systematic, stepwise protocol beginning with anti-arrhythmic drugs, followed by sedation and anesthesia, and progressing to haemodynamic mechanical support devices if earlier treatments prove ineffective. Catheter ablation will be reserved as the final rescue intervention.
224237674|NCT01002690|DRUG|Etoricoxib|90 mg/day orally for 10-13 days
223654042|NCT07206056|DRUG|Tulmimetostat DL1 QD|"Part 1a (dose escalation):~Doses of tulmimetostat beyond DL1 once a day (QD) will be opened depending on outcome of Dose Escalation Meetings (DEM(s))"
223654043|NCT07206056|DRUG|Tulmimetostat DL2 QD|"Part 1a (dose escalation):~Doses of tulmimetostat beyond DL1 once a day (QD) will be opened depending on outcome of Dose Escalation Meetings (DEM(s))"
224237675|NCT06824701|DRUG|Tazemetostat|Tazemetostat will be self-administered BID as an oral treatment on a 28-day cycle.
224237676|NCT06824701|DRUG|Zanubrutinib|Zanubrutinib will be self-administered BID as an oral treatment on a 28-day cycle.
224237677|NCT06824701|DRUG|Rituximab|Rituximab or a biosimilar will be administered intravenously per standard of care.
224237678|NCT06824701|DRUG|Obinutuzumab|Obinutuzumab will be administered intravenously on days 1, 8, 15 of cycle 1 and then day 1 of cycles 2 to 12.
224237679|NCT01487733|GENETIC|gene expression analysis|
224237680|NCT01487733|GENETIC|in situ hybridization|
224237681|NCT01487733|OTHER|immunohistochemistry staining method|
224320870|NCT05832177|BEHAVIORAL|Latinos y el cáncer/Hablemos de cáncer (Translation in English: Latinos and Cancer/Let's Talk About Cancer)|This is a biennial cancer symposium focused on cancer topics important to Hispanic/Latinos. This day-long event includes a plenary session and concurrent sessions where healthcare professionals present educational information about cancer, cancer prevention, early detection methods, and other related topics.
223654044|NCT07206056|DRUG|Tulmimetostat DL3 QD|"Part 1a (dose escalation):~Doses of tulmimetostat beyond DL1 once a day (QD) will be opened depending on outcome of Dose Escalation Meetings (DEM(s))"
223654045|NCT07206056|DRUG|Tulmimetostat Doses 1 or 2 QD|"Part 1b (dose expansion and optimization):~tulmimetostat doses 1 or 2 QD"
223654046|NCT07206056|DRUG|Tulmimetostat RP2D QD|"Part 2:~tulmimetostat Recommended Phase 2 Dose (RP2D) QD"
223654047|NCT07206056|DRUG|JSB462 Dose 1 QD|JSB462 Dose 1 QD
223654048|NCT07206056|DRUG|JSB462 Dose 2 QD|JSB462 Dose 2 QD
223654049|NCT07206056|DRUG|JSB462 QD|The dose of JSB462 QD will be determined based on the totality of data from Part 1a
223654050|NCT07206056|DRUG|Standard of Care (SoC)|Androgen Receptor Pathway Inhibitors (ARPI), chemotherapy or Pluvicto (AAA617) at the discretion of the investigator
223654051|NCT07211256|DEVICE|tDCS of the motor cortex|Home-delivered tDCS device
223654052|NCT07209592|OTHER|AI gamification|The treatment program for AI gamification group will be in the form of cognitive tasks accompanied by cognitive driven motor tasks ( integrating cognitive strategies into motor tasks) exercises of the upper limb (shoulder, elbow, hand) in the form of AI gamification model. For each patient in study group, session will be for 6 minutes , three times per week for 4 weeks. The patients Will receive AI gamification via X-box with 3 D kinetic motion analysis giving the patient real time feedback, visual and auditory feedback about the range and task .Using this technology we will gain the benefits of both AI and Gamification, the patients will be engaged in the exercise intensively and for a longer time with out getting bored and the tasks will be enjoyable to capture their attention , in addition to traditional training plus conventional therapy
223654053|NCT07209592|OTHER|conventional therapy|"the patiens will receive conventional therapy exercises in the form of flexibility exercises, strengthening exercises, Aerobic training exercise~* flexibility exercises , it will be in the form of functional stretching for shoulder adductors and flexors, elbow flexors ,wrist and finger flexors~* strengthening exercises , it will be mainly strengthening exercises for upper limb (shoulder extensors, elbow , wrist and finger extensors) in addition to trunk control exercises targeting proximal stability for distal mobility.~Aerobic training exercise, as a form of cognitive training exercises"
224237682|NCT01487733|OTHER|laboratory biomarker analysis|
224237683|NCT02625545|DEVICE|UroLift System procedure|Minimally invasive procedure for treatment of lower urinary tract symptoms (LUTS) due to BPH
224237684|NCT00145938|DRUG|sildenafil|
224237685|NCT00543686|DRUG|Montelukast|Intake of Montelukast
224237686|NCT00543686|DRUG|Fluticasone|Intake of Fluticasone
224237687|NCT01079676|DRUG|Filgrastim (Eurofarma)|Filgrastim will be given at the daily dose of 5 µg/kg body weight, subcutaneously. The weight considered will be the actual weight, for patients weighing up to 120 kg.
224237688|NCT01079676|DRUG|Filgrastim (Granulokine, Amgen)|Granulokine will be given at the daily dose of 5 µg/kg body weight, subcutaneously. The weight considered will be the actual weight, for patients weighing up to 120 kg.
224237689|NCT01966081|OTHER|Blood sample|
224237690|NCT01966081|OTHER|tissue samples from abdominal subcutaneous adipose|
224237691|NCT00475020|DRUG|Busulfan|Test dose = 32 mg/m\^2 by vein x 1 day; 100 mg/m\^2 by vein daily over 3 hours x 4 days
224237692|NCT00475020|DRUG|Fludarabine|40 mg/m\^2 by vein daily over 1 hour x 4 days
224237693|NCT00475020|DRUG|Thymoglobulin (ATG)|2.5 mg/kg by vein over 6 hours x 3 days if there is an unrelated or a mismatched donor
224237694|NCT03218592|DRUG|Maraviroc Pill|Subjects will take a single dose in Phase 1, Daily Doses in Phase 2 for 28 days, and then be randomized in Phase 3 to zero doses, one dose a week or three doses weekly
224237695|NCT03218592|DRUG|Dolutegravir Pill|Subjects will take a single dose in Phase 1, Daily Doses in Phase 2 for 28 days, and then be randomized in Phase 3 to zero doses, one dose a week or three doses weekly
224237696|NCT03218592|DRUG|Truvada Pill|Subjects will take a single dose in Phase 1, Daily Doses in Phase 2 for 28 days, and then be randomized in Phase 3 to zero doses, one dose a week or three doses weeklySubjects will take a single dose in Phase 1, Daily Doses in Phase 2 for 28 days, and then be randomized in Phase 3 to zero doses, one dose a week or three doses weekly
224237697|NCT02514174|DRUG|Afatinib|afatinib starting at 30 mg daily dose
224237698|NCT01255371|DRUG|Lopinavir|Evaluation of second line antiretroviral regimen including boosted lopinavir
224237699|NCT01255371|DRUG|Atazanavir|Evaluation of second line antiretroviral regimen including boosted atazanavir
224237700|NCT01669109|BEHAVIORAL|Hatha yoga|
224320871|NCT05832177|BEHAVIORAL|¡Salud! Serie de Charlas (Translation in English: Health! Talk Series)|This is an educational and community outreach effort comprised of local charlas (talks) led by Hispanic/Latino healthcare professionals (e.g., the partnership Community Health Educator \[CHE\], topic experts) who provide education and answer questions about specific cancer topics. The charlas may be conducted in multiple modalities (in person, virtual, hybrid) and may be conducted in English and/or Spanish. At least three events will be held each year in the partnership locations.
223654054|NCT07210970|DIAGNOSTIC_TEST|Tuberculin Skin Test (TST)|Intradermal injection of 5 unit (0.1 mm) of purified protein derivative (PPD) with measurement of induration after 48-72 hours.
223654055|NCT07210203|PROCEDURE|Neural mobilization with Balance training with conventional physical Therapy|"( HOT pack 10 mins + TENS 10 mins)~Neural Moblization Includes the following protocol:~Hot Pack 10 mins TENS 10 mins Upper limb and lower limb sliding techniques . (10 reps) Upper limb lower limb tentioning technique (10 reps) Tibial Nerve sliding,Siatic Nerve Sliding,Median nerve Sliding, (10 reps) Combine sliding plue Tensioning,(10 reps) Balance Training Sitting to standing (10 reps × 2 sets) Standing unsupported (Hold 30s × 3) Standing to sitting (10 reps × 2 sets) Transfers ( 10 reps) Standing with eyes closed( Hold 10-20s ×3) Standing with feet together (Hold 10-20s × 5) Reaching forward with outstretched arm (10 reps) Retrieving object from floor (8-10 reps) Turning to look behind (10 reps each side) Turning 360 degrees (3 reps each) Placing alternate foot on stool(10 reps each) Standing with one foot in front (Hold 15-30s × 3) Standing on one foot( Hold 15-30s × 3) Repetitions will increase gradually week wise"
223767755|NCT07172451|DRUG|Balanced Gelatin Solution|Balanced gelatin solution (4% succinylated gelatin in a balanced crystalloid carrier). Administered as resuscitation fluid in patients with sepsis undergoing emergency abdominal surgery. Infusion follows a stroke volume-guided, goal-directed fluid therapy protocol. The total dose is limited to 30 mL/kg (ideal body weight) during the intraoperative period and the first 24 postoperative hours. If the maximum dose is reached, additional resuscitation is provided with balanced crystalloid solution.
223767756|NCT07172451|DRUG|Acetate Ringer's Solution|Acetate Ringer's solution, a balanced crystalloid, administered as the sole resuscitation fluid in patients with sepsis undergoing emergency abdominal surgery. Fluid therapy follows the same stroke volume-guided, goal-directed protocol as the experimental arm. There is no upper limit for the total volume of crystalloid infusion during the intraoperative and first 24 postoperative hours.
223767757|NCT07173140|DIAGNOSTIC_TEST|MRI|Participants undergo an additional MRI scan using novel MRI sequences
224237701|NCT01649622|DRUG|Bendamustine|75 mg/m2 by vein twice daily for four days (Days 1-4). Cycles may be repeated every 3 to 10 weeks based on leukemia response for up to 12 courses.
224237702|NCT02525328|OTHER|blood or saliva specimen|blood or saliva specimen is sampled for DNA extraction in CT family's members
224237703|NCT06073249|OTHER|Auricular vagus stimulation|Non-invasive transcutaneous devices stimulate the vagus nerve via the auricular or carotid artery. It is also used to treat various disorders such as epilepsy, pain and headache. This device stimulates the auricular branch of the vagus nerve non-invasively without any procedure. As a result, it has been found that the pain threshold increases and mechanical pain sensitivity decreases.
224237704|NCT06073249|OTHER|Tibial Nerve Stimulation|The sacral plexus provides innervation of the perineal muscle. Its branches (lumbar 4-5 and sacral 1-3) merge to form the nervus ischiadicus, which then divides into two branches. The thick branch of the nervus ischiadicus is the nervus tibialis (lumbar 4-5 and sacral 1-3) and the thin branch is the nervus peroneus communis (lumbar 4-5 and sacral 1-2).
224237705|NCT04455659|DEVICE|Trans-cutaneous Electrical Nerve Stimulation|TENS that was applied once daily, three times per week for 8 weeks. Each treatment session was conducted for 20 minutes, two electrodes were positioned over the perineal area between anus and scrotum on the Centrum tendineum, while the other two electrodes were applied under the buttocks medially at the level of the ischial spines (medial to the ischial spines bilaterally) with the patient in comfortable supine hook-lying position with abducted hips. to prevent burn beneath the electrodes, the surface area of the electrode should be equal to or greater than 4 cm2 to minimize the heat production. In addition, to decrease the current density between electrodes, the inter-electrode distance was less than the cross sectional area of the electrode
224237706|NCT04455659|PROCEDURE|Conventional physical therapy exercise|physical therapy program for 30 minutes, and 3 times per week for 8 weeks in the form of strengthening exercise, clam - shell exercise, and stretching exercise focusing on obturator internus muscle, range of motion exercise for the hip and pelvis musculature for 30 minute three times a week for consecutive 8 weeks , each type of exercise was performed for a duration of 6 seconds and repeated 10 times
224237707|NCT02130466|BIOLOGICAL|Pembrolizumab|IV infusion
224237708|NCT02130466|DRUG|Dabrafenib|oral capsule
224237709|NCT02130466|DRUG|Trametinib|oral tablet
224237710|NCT02130466|DRUG|Placebo|IV infusion
224237711|NCT00801190|OTHER|HES (130/0.4)|33 ml/kg i.v. during surgery
224237712|NCT00801190|OTHER|Ringer's Lactate|33 ml/kg i.v.
224237713|NCT05654909|PROCEDURE|Prehospital assessment unit|The prehospital assessment unit was developed to provide a paramedic responding by car to 1-1-2 calls in the area of Region Zealand. Further details are mentioned in the description.
224237714|NCT02924480|PROCEDURE|Cystectomy|
224237715|NCT02924480|DRUG|Lidocaine|Patients will receive lidocaine infusion during surgery
224237716|NCT02924480|DRUG|Saline|Patients will receive saline infusion during surgery
224237717|NCT01963364|DIETARY_SUPPLEMENT|Inulin challenge|On two study days one week apart, fasted participants will consume 500ml of water, flavoured with lime juice, containing 40g inulin.
224237718|NCT01963364|DIETARY_SUPPLEMENT|oligofructose supplement|Starting at the end of study day 1, consumption of 5 grams oligofructose coloured with carmine red food dye(\<5%), dissolved in a hot drink, twice daily for 6 1/2 days/ 13 doses. The 14th dose of the week is the inulin challenge consumed as part of study day 1.
224237719|NCT05612438|DEVICE|RADIX 2 Stent|RADIX 2 stent implantation for the treatment of occlusive lesions of the native renal arteries; or in the case of inadequate results (residual stenosis \> 30%) or dissection of the vessel wall following PTRA procedure with or without stenting.
224237720|NCT00458900|DRUG|IV and enteral administration of moxifloxacin|IV and enteral administration of moxifloxacin
224237721|NCT05155800|DEVICE|SDx3|The SENSE Device (SDx3) is a non-invasive device that detects differences in the absorption of transmitted RF energy across the skull and brain and is intended to be used to evaluate intracranial hemorrhage.
224237722|NCT05337709|OTHER|Education intervention and medication review|Education on osteoarthritis and pain management will be provided to the patients by face-to-face communication at the first meeting, aided with a leaflet, then patients will get the follow-up calls and a video will be shown to enforce the intervention. Medication review includes the assessment of patients' knowledge on the indication, identification of any drug-related problem, and counseling on the proper use of medication.
224237723|NCT03287700|OTHER|No intervention|No intervention will be administered to any group in this observational study.
224237724|NCT03307239|OTHER|cold application|"We manufactured two ice packs (17 × 12 cm) with a combined weight of 600 g. The ice packs were inserted into adjustable wraps made in our hospital so that they can be fixed next to the skin on each side of the chest tube in patients awaiting CTR. The combined contact area of the ice packs was approximately 25 cm in diameter around the chest tube.~For patients of the experimental group, they were received 15-minutes cold application."
224237725|NCT03307239|OTHER|tap water packs application|"We manufactured two tap water packs (17 × 12 cm) with a combined weight of 600 g. The tap water packs were inserted into adjustable wraps made in our hospital so that they can be fixed next to the skin on each side of the chest tube in patients awaiting CTR. The combined contact area of the tap water packs was approximately 25 cm in diameter around the chest tube.~For patients of the sham group, they were received 15-minutes tap water application."
224237726|NCT05320263|PROCEDURE|Contact aspiration Thrombectomy|"The contact aspiration approach is performed, as in standard care, using a long sheath positioned in the distal cervical vasculature using an exchange technique.~A large bore balloon guide catheter as to be placed into the cervical ICA. The microcatheter is then advanced close to the thrombus and the large-bore aspiration catheter is advanced as close to the proximal aspect of the thrombus as possible. A control superselective angiogram may be used to document the extent of occlusion and thrombus. After a 3 min waiting period, the large-bore aspiration catheter is connected to a continuous aspiration from the dedicated aspiration pump while simultaneously advancing the aspiration catheter up to the face of the thrombus. through the long sheath positioned in the cervical vasculature."
224237727|NCT05320263|PROCEDURE|Stent retriever thrombectomy|The technique used should be in accordance with the device IFU. A large bore access guide catheter possible is recommended. A suitable delivery microcatheter is navigated over a microwire across the occlusion. A control superselective angiogram may be used to document the extent of occlusion and thrombus. The stent is left in place according to the internal practice of each participating center before the withdrawal. Any CE-marked stent retriever device is then deployed across the occlusion. A minimum of 3 attempts with SR should be performed. A revascularization score will be recorded after each device attempt.
224237728|NCT02419352|DRUG|Sugammadex|
224237729|NCT02419352|DRUG|Neostigmine/atropine|
224237730|NCT04529109|DEVICE|etafilcon A investigational cosmetic lens 1|TEST
224237731|NCT04529109|DEVICE|etafilcon A investigational cosmetic lens 2|CONTROL
223654056|NCT07210203|PROCEDURE|Balance Training only with conventional physical therapy|"balance training program combines conventional physical therapy with hot pack (10 min) and TENS (10 min), delivered over 4-6 weeks, 3-4 sessions per week, 30-40 minutes each. Training begins with easier Berg Balance Scale (BBS) tasks and progresses as the patient improves.~In Weeks 1-2, basic static and supported tasks are practiced, including sit-to-stand, standing unsupported (wide to narrow base), supervised transfers, reaching forward, and standing with eyes closed. Weeks 3-4 focus on dynamic stability with picking objects from the floor, head/torso turns, 360° turns, step-ups, and heel-to-toe stance. Weeks 5-6 progress to advanced functional tasks such as alternating foot placement on a stool, tandem stance, one-leg standing, gentle perturbations, and walking 5-10 m with head turns."
223654057|NCT07210697|DRUG|Xylitol Gum|1 gram of xylitol per piece of gum with one serving being 2 pieces of gum
223654058|NCT07209345|DRUG|FA+Ropivacaine|0.5 mL FA (50 mg; by Beijing Taide Pharmaceutical Co., Ltd) and 15 mL of 1% ropivacaine (Nai Le Pin 10mg/mL; by AstraZeneca AB, Sweden) diluted to a total volume of 30 mL in normal saline
223654059|NCT07209345|DRUG|Normal (0.9%) saline|Control group:
223654060|NCT07209345|DRUG|Ropivacaine|15 mL of 1% ropivacaine diluted to a total volume of 30 mL in normal saline
223654061|NCT07211048|DRUG|Anti-CD19 gene injection|Intravenous infusion of Anti-CD19 gene injection （three dosage groups）
223654062|NCT07210918|PROCEDURE|Blood Product|Collecting 5 ml of blood sample from individuals in the study group and obtaining serum from it.
224237732|NCT04523649|DEVICE|Remote atrial fibrillation screening with handheld single lead ECG recorder|Patients in this group will be given a handheld single lead ECG recorder (Comfit Healthcare Devices Limited, Hong Kong SAR, China) and a patient-facing smartphone application specially designed for the study, and they will be requested to record daily ECG and certain vital measurement.
224237733|NCT01834053|BIOLOGICAL|autologous Stem Cell|Intrathecal transplantation of autologous 100 millions Stem cells{MNCs } per dose'
224237734|NCT00605748|PROCEDURE|Segmental PV-Isolation of the arrhythmogenic vein(s)|isolation of pulmonary veins for curing atrial fibrillation
224237735|NCT00605748|PROCEDURE|Segmental PV-Isolation of all veins|isolation of pulmonary veins for curing atrial fibrillation
224237736|NCT01567956|DRUG|Propionyl-L-Carnitine|500 mg modified release tablets, 500 mg bid; treatment duration 8 weeks
224237737|NCT01567956|DRUG|Placebo|500 mg inert substances modified release tablets, 500 mg bid; treatment duration 8 weeks
224237738|NCT04302948|OTHER|HCV RNA screening|The Cepheid Xpert testing requires a fingerstick to obtain blood spots which are then tested for HCV RNA. Results available within one to two hours, facilitating counseling for patients to link to care.
224237739|NCT00001765|DEVICE|Nexell Isolex with T-cell Depletion|
224237740|NCT00001765|DEVICE|Baxter isolex 300i|
224237741|NCT03059862|DIETARY_SUPPLEMENT|L-tryptophan|3 g/day of L-tryptophan added to the standardized low-tryptophan diet. Duration: 3 weeks.
224237742|NCT03059862|DIETARY_SUPPLEMENT|Placebo|A placebo will be added to the standardized low-tryptophan diet. Duration: 3 weeks.
224237743|NCT02725307|DEVICE|Noninvasive pulse wave analysis sensor, ECG-sensor|Noninvasive pulse wave sensors and ECG-sensors are attached
224237744|NCT06345248|PROCEDURE|US-TAP|regional block team under ultrasound guidance
224237745|NCT06345248|PROCEDURE|LAPTAP|performed TAP block under direct visualization with the laparoscope
224237746|NCT06344338|DEVICE|tDCS stimulation|In the real-stimulation group, Treatment was for 20 min, repeated twice in a day, then again over the next few days. The maximum number of stimuli required to terminate the status epilepticus should not exceed 10. In the sham-stimulation group, The duration and frequency of tDCS are the same as those in the treatment group, but the tDCS device is not active during the 20 minutes of sham-stimulation
224237747|NCT06344338|DEVICE|TDCS sham-stimulation|TDCS sham-stimulation
223654063|NCT07210645|OTHER|Gerofit Power Training|Gerofit Power Training will include a power training exercise prescription which will focus on having participants perform concentric portions of each resistance exercise as fast and as safely as possible with the eccentric component performed in a slow and controlled manner. The target dose of the power training intervention is 40-60% of the participant's 1-repetition maximum for 4-6 repetitions across 3-6 sets for each exercise. Exercises will focus on the major groups of the upper and lower body. All other Gerofit program components (balance, aerobic, and flexibility) will be consistent with the standard of care group. Sessions will be the same duration as the standard of care Gerofit group (60-75 minutes). The power training and standard of care groups will only differ in the form of resistance training performed.
223654064|NCT07210645|OTHER|Gerofit Standard of Care|Gerofit standard of care is a 60-75 minute multimodal exercise program which includes 20-30 minutes of aerobic training, traditional strength training of the major upper and lower body muscle groups (1-3 sets of 8-12 repetitions at moderate load), flexibility training and balance training.
223654065|NCT07209735|DEVICE|Ultrasound|Participants in this arm will receive the structured MINUTES bundle during the first 30 minutes of shock management in the emergency department. The bundle includes: continuous monitoring, intravenous access and fluid resuscitation, early initiation of norepinephrine when indicated, point-of-care ultrasound assessment (cardiac, IVC, and lung ultrasound) to guide diagnosis and resuscitation, essential laboratory tests, early antibiotics if infection is suspected, and source control or stabilization measures.
223654066|NCT07209657|BEHAVIORAL|Live Music Therapy|The recorded music interventions will consist of the presentation of commercially available recordings of participant preferred music. The songs utilised in the recorded music interventions will be the same as those presented during the live music therapy interventions, and only the presentation format will be different. The same music therapist who facilitates the live music therapy interventions will be present in the participant's room during the presentation of the recorded music intervention and will present the recorded music via iPad and small portable speaker.
224237748|NCT04426799|OTHER|lemon essential oil|A randomized, pre-test-post-test design was carried out to examine the effectiveness of lemon essential oil in reducing test anxiety in first-year students of the Faculty of Medical Sciences of a private university in Istanbul
224237749|NCT06312371|DEVICE|Intermittent Oro-esophageal Tube Feeding|Before each feeding, inside and outside of the tube was cleaned with water. During feeding, the patient should maintain a semi-reclining or sitting position with mouth opened, and the tube was inserted slowly and smoothly into the upper part of the esophagus by medical staffs while the appropriate depth of intubation was checked with the calibration markings on the tube wall. The distance from the incisors to the head part of the tube should be between 22-25 cm.
224237750|NCT06312371|DEVICE|Nasogastric Tube Feeding|Within 4 hours after admission, the placement of the feeding tube was conducted by professional medical staffs and after intubation, the tube was secured to the patient's cheek with medical tape. The feeding was conducted once every 3-4 hours, with 200-300ml each time.
224237751|NCT05481307|DRUG|RLD2202|Take it once a day per period
224237752|NCT05481307|DRUG|RLD2203|Take it once a day per period
224237753|NCT01217086|DRUG|Infliximab|Infliximab 3mg/kg is going to be administered for both arm as a 2-hour infusion per dose.
224237754|NCT06683508|DRUG|LY3549492|Administered orally
224237755|NCT06683508|DRUG|Placebo|Administered orally
223654067|NCT07209657|BEHAVIORAL|Recorded Music|The recorded music interventions will consist of the presentation of commercially available recordings of participant preferred music. The songs utilised in the recorded music interventions will be the same as those presented during the live music therapy interventions, and only the presentation format will be different. The same music therapist who facilitates the live music therapy interventions will be present in the participant's room during the presentation of the recorded music intervention and will present the recorded music via iPad and small portable speaker.
224237756|NCT00231296|DEVICE|Cardiac CryoCor Cryoablation System|Treatment with CryoCor Cardiac Cryoablation system
223654068|NCT07209449|DRUG|Abemaciclib|orally only in the evening
223654069|NCT07209449|DRUG|Elacestrant|orally once daily in the morning
224237757|NCT00231296|DRUG|Medical management|Medical management- treatment with standard medical therapy, which includes anti-arrhythmic medications
224237758|NCT04029675|DIETARY_SUPPLEMENT|Vitamin C|Vitamin C is a strong antioxidant and has been shown to regenerate other antioxidants such as vitamin E, vitamin C also play an important role in immune function
224237759|NCT07027657|DEVICE|Treatment with BTL-699-2|Six transcranial magnetic stimulation treatments with the BTL-699-2 device will be delivered over the left dorsolateral prefrontal cortex, spaced 3 to 7 days apart. The intensity will be adjusted according to the subject's feedback, up to 70% of the individual's motor threshold.
224237760|NCT07027657|DEVICE|Treatment with BTL-699-2 (sham)|Six transcranial magnetic stimulation treatments with the BTL-699-2 device will be delivered over the left dorsolateral prefrontal cortex, spaced 3 to 7 days apart. The intensity will be adjusted according to the subject's feedback, up to 5% of the individual's motor threshold.
224237761|NCT01261884|BEHAVIORAL|Exercise support|Group B (exercise support) will be given the ACOG pamphlet on exercise in pregnancy, a daily activity log, and a pedometer. This group will be asked to wear the pedometer for 7 consecutive days between Visits 1 and 2, and record daily activities.
224237762|NCT01261884|BEHAVIORAL|Exercise intervention|Group C (exercise intervention) will be given the ACOG pamphlet on exercise in pregnancy, a daily activity log, a pedometer, a resistance band, and a handout on specific exercises (type and frequency) to be performed. The study coordinator will demonstrate each exercise and then observe the participant perform each exercise to assure full understanding. In addition to wearing the pedometer for 7 days and completing the activity log, this group will also record compliance with the exercise regimen.
224237763|NCT05263232|OTHER|Natural or artificial office light exposure|Over 4.5 days, participants will stay at our research facilities under different light conditions. Over these days different measurements will take place, including 24h continuous glucose monitoring, 24h blood and saliva sampling, 24h blood pressure and heart rate assessments, 24h core and skin temperature assessments, 24h energy expenditure and whole-body substrate metabolism, and a skeletal muscle biopsy and a mixed meal tolerance test with indirect calorimetry will be performed on the respectively last test day.
224237764|NCT06130358|OTHER|Experimental: Well-being intervention followed by classic intervention|2 x 6 weeks of weekly museum visits
223654070|NCT07209631|OTHER|Serum Lipoprotein-a level|A venous blood sample was taken from each patient a month or so after discharge to check their Lp (a) levels. The samples were centrifuged for 10 minutes at 2-8 °C, after which the serum was divided into aliquots and stored at -20 ° C.
223654071|NCT07209943|DEVICE|Cognixion + Apple Vision Pro|An Apple Vision Pro device, integrated with Cognixion's brain sensing band and Assisted Reality software. The integrated device enables users to construct AI assisted communication and computer control commands using a combination of attention, eye gaze and head pose.
223654072|NCT07211308|DEVICE|Spinal Cord Stimulation|Differential target multiplexed stimulation
223654073|NCT07209397|DEVICE|Detrusor nerve radiofrequency ablation|A single, vaginal radiofrequency (RF) treatment. The procedure is performed with a bipolar RF applicator and requires no anesthesia. Delivered in a single session in an outpatient setting.
223654074|NCT07209397|DEVICE|Simulated (sham) detrusor nerve radiofrequency ablation|A simulated (sham) radiofrequency (RF) treatment, but with no energy delivered. The procedure mimics the appearance, duration, and positioning of the active device, without therapeutic effect.
224237765|NCT06130358|OTHER|Experimental: Classic intervention followed by well-being intervention|2 x 6 weeks of weekly museum visits
224237766|NCT03176550|DEVICE|Transcutaneous electrical nerve stimulation|TENS is performed using a commercially available device (ProStim, Alimed Inc, Dedham, Massachusetts, USA). One pair of 2 x 3.5 inches rectangular electrodes (Vermed ChroniCare TENS Electrodes, Vermed, Buffalo, NY, USA) are placed to simultaneously stimulate both median and ulnar nerves at the wrist, while a second pair of round 2 inch diameter electrodes are used to stimulate the radial nerve on the forearm. Bursts of electrical stimulation at 10 Hz (100 microsecond pulse width duration) are delivered to all nerves simultaneously for 2 hours.
224237767|NCT07064746|DIAGNOSTIC_TEST|¹²³I-MIBG SPECT/CT|Patients take Lugol's iodine 2 days and on the day of injection for thyroid blockade. ¹²³I-MIBG (3-5 MBq/kg; max 370 MBq) is given IV. Whole-body planar imaging is performed 24 h post-injection, then focused SPECT/CT of any suspicious areas with low-dose CT; children are sedated only if motion control is required.
224237768|NCT07064746|DIAGNOSTIC_TEST|SSTR PET|Patients receive an intravenous bolus of 68Ga-DOTA-TATE (1.8-2.2 MBq/kg, max 200 MBq). After a 45-60 min uptake phase, a low-dose whole-body PET/CT or PET/MRI (skull base-mid-thigh) is acquired for \~20 min; MRI or CT provides attenuation correction. Sedation used when required.
224237769|NCT04125654|DEVICE|mNGS for pathogen detection|This assay is a metagenomic test undertaken by BGI Genomics Co., Ltd. for comprehensive detection of viruses, bacteria, fungi, and parasites in clinical samples.
224237770|NCT00993616|DRUG|belinostat|Given IV
224237771|NCT00993616|DRUG|carboplatin|Given IV
224237772|NCT06899646|DEVICE|Treatment with BTL-699-2|Four transcranial magnetic stimulation treatments with the BTL-699-2 device will be delivered over the left dorsolateral prefrontal cortex, spaced 5 to 10 days apart. The intensity will be adjusted according to the subject's feedback, up to 100% of the individual's motor threshold.
224237773|NCT05600374|DEVICE|Bossdevice|The bossdevice is a real-time digital signal processor consisting of hardware and software algorithms. It is designed to read-in a real-time raw data stream from a bio-signal amplifier (electroencephalography, EEG), to continuously analyze this data and to detect patterns based on oscillations in different frequencies. When such a specific bio-signal pattern is detected, the device indicates this through a standard output port. This enables a connected device to know with millisecond accuracy when a specific biosignal pattern occurs.
224237774|NCT04611035|DEVICE|QPOP|QPOP will then be applied to establish the most efficacious drug combination for the specific organoid. Additional drugs other than those listed above may be screened depending on availability of cancer organoids. When patients progress after first-line treatment, QPOP generated second-line options will be informed to treating physicians and the physician will exercise his/her discretion to select the most suitable drug based on patient's comorbidities and organ function after a formal molecular/phenotype tumour board.
224237775|NCT06481800|OTHER|Progressive muscle relaxation (PMR)|patients receive progressive muscle relaxation (PMR) for 20 minutes after each dialysis session during the first 2 hours the dialysis treatment with routine medical care for dialysis patients
224237776|NCT06481800|OTHER|cnotrol group|Routine medical care for RLS and sleep quality in hemodialysis Anemia management, electrolyte balance,Avoiding caffeine and alcohol, establishing a regular sleep schedule leg care,Medicines that increase dopamine in the brain, affecting calcium channels, Opioids , Gabapentin and Pregabali , Benzodiazepines,Regular monitoring of kidney function, blood tests
224237777|NCT06481800|OTHER|Manual lymphatic drainage (MLD)|Manual lymphatic drainage (MLD) for 20 minutes within after each dialysis session during the first 2 hours the dialysis treatment with routine medical care for dialysis patients
224237778|NCT06504472|DIETARY_SUPPLEMENT|ProstaThrive™ Supplement|Participants in this arm will take three ProstaThrive™ capsules daily after the final meal of the day for 90 days.
224237779|NCT06504472|DIETARY_SUPPLEMENT|Placebo|Participants in this arm will take three placebo capsules daily after the final meal of the day for 90 days. The placebo capsules will contain an inert substance that mimics the appearance of the ProstaThrive™ supplement.
224237780|NCT03533946|DRUG|Rucaparib|Treatment with rucaparib will begin on Cycle 1 Day 1 and continue at 600 mg twice daily. Therapy continues until Prostate Specific Antigen (PSA) progression or intolerable toxicities.
224237781|NCT01536522|DIETARY_SUPPLEMENT|Nutritional approach for asthma|participants will be provided a medium chain triglyceride supplement or placebo
224237782|NCT01536522|DIETARY_SUPPLEMENT|Low Caloric Shake|participants will be provided a low caloric dietary shake
223654075|NCT07209917|BEHAVIORAL|ASHA-Health HPV Intervention|The ASHA-Health HPV program will include three components: 1) Individual 1:1 weekly ASHA support; 2) 8 group sessions for the 42 W-Co-V in the ASHAHealth cohort, covering content in Modules 1-4; and 3) referral to life skills classes. The assigned ASHA will provide services to support the W-Co- V in accessing and/or adhering to HPV and ART appointments (arrange transportation, provide counseling, promote healthy lifestyle choices, and link with community resources). ASHA will also promote positive coping, social support, and aid in dealing with stigma. The 8 group sessions will be held over the six months, based on the needs identified by the women. Overall, the intervention content targets the provision of emotional support, skill building, HPV/ HIV and nutrition education, and protein-enriched food supplements, and ways to deal with stress, stigma, and the importance of engagement and retention in care. Food selections will be guided by our nutrition experts.
223654076|NCT07209917|BEHAVIORAL|Enhanced Standard of Care (SOC+)|"Selecting our base at the Belgaum ART Centers will provide the most up to date services for the SOC~\+ group. Yet, there is no typical standard of care in India as it relates to HPV screening for W-Co-V and stigma associated with both diseases is high. Further, in India, screening services are lacking at most ART centers. Since it would be unethical to withhold potentially lifesaving information about HPV, we will offer an enhanced standard of care to include usual care + 3 (1.5 hour) group sessions on wellness, basic nutrition, coping with mental health issues, and HIV/ HPV information. Thus, women will meet as a group three times over the six-month period. In addition, the women have access to our SOC+ nurse and ASHA to respond to questions."
223654077|NCT07209709|DEVICE|Conventional exercises with dual task training (cognitive task)|"Individuals in this group will undergo exercise sessions under the supervision of a physiotherapist, with cognitive tasks added to conventional exercises, 3 days a week for a total of 8 weeks.~EXERCISES~1. Sit-Reach in Bed (15 seconds each)~2. Hip Flexor Stretch Exercise (15 seconds each)~3. Cat-Camel Exercise~4. Bridge Exercise~5. Biceps Curl/Triceps Extension/Upper Limb Abduction While Sitting in a Chair~6. Sit-to-Stand in a Chair~7. One-Legged Stand~8. Mini Squat 9. Tandem Walk Cognitive Tasks to be Used in the Dual-Task Training Group Weeks 1 and 2 Simple single-digit addition Generate random numbers between 1 and 100 Count the days of the week Count the months of the year Repeat two spoken words Count from 0 to 100, incrementing by 10 Generate words starting with the specified letter Count from 1 to 100 The remaining cognitive task examples are in the study description. The exercises and cognitive tasks will be conducted sequentially and simultaneous"
223767758|NCT07165704|OTHER|Visual arts|The arts intervention will consist of two parts: (a) implementation of one-hour session of Visual Arts (e.g., painting, drawing, printing techniques exercises). The activities will be guided through a theme (Emotions), by a professional artist, to obtain a final individual artistic product. Peer contact, shared learning, and a feeling of community are all made possible by the group-based approach. This facilitator will offer assistance, motivation, and technical training as they lead participants through the creative process. Using narrative-building and dialogue-based methods, the artist will encourage children to share their stories, experiences, and perspectives, through art. (b) Children's final artistic products will be displayed in Community Galleries in their neighbourhood in an opening ceremony.
223767759|NCT07172399|PROCEDURE|blood sampling|blood samples will be taken to discover if there is hyperlipedemia,hyperthrodism or acute kidney injury
224237783|NCT01536522|BIOLOGICAL|whole lung allergen challenge|inhalation of allergens by allergic patients with or without asthma, will be used to define mechanisms underlying the development of airway inflammation
224237784|NCT05026866|DRUG|Donanemab|Administered intravenously
224237785|NCT05026866|DRUG|Placebo|Administered intravenously
224237786|NCT03630718|BEHAVIORAL|Psychoeducational Intervention|"The psychoeducational intervention will be a structured education programme and will consist of informing patients about fatigue dimensions, aetiology and treatments, by helping them to develop strategies to cope with fatigue better and by teaching them to manage the balance between activities and rest.~The construction of the contents of the sessions of this intervention will aim to reduce fatigue via the programme developed by Reif et al. in cancer patients and is composed of 6 sessions of 90 minutes, one session per week. It is a group intervention for 8 patients. For this project, the investigators have reorganised the sessions and their content to fit with an individual format adapted to PBC. This format is more appropriate to take into account the specificity of the manifestation of fatigue for each patient."
224237787|NCT03630718|BEHAVIORAL|Hypnosis intervention|"The hypnosis intervention will consist of decreasing fatigue and the related distress, and increasing feelings of energy and well-being.~Therefore, each hypnosis exercise will be audiotaped and given to the patient at the end of the session. Patients will be asked to use these recordings as much as they want to help them to manage fatigue. The techniques used are inspired by those used in chronic pain management and fatigue."
224237788|NCT03737214|DRUG|Lucerastat|Administered in hard gelatin capsules containing 250 mg of lucerastat.
224237789|NCT06497101|BEHAVIORAL|Temperament Based Therapy with Support (TBT-S)|Participants included in the intervention arm will receive TBT-S (5-day treatment) in addition to treatment as usual (TAU)
224237790|NCT06784973|DRUG|Obeldesivir|Administered orally
224237791|NCT06784973|DRUG|Obeldesivir Placebo|Administered orally
224237792|NCT06132113|DRUG|BI 764532|BI 764532
224237793|NCT06132113|DRUG|Carboplatin|Standard of care
224237794|NCT06132113|DRUG|Etoposide|Standard of care
224237795|NCT06132113|DRUG|Cisplatin|Standard of care
223767760|NCT07172399|OTHER|• BP will be measured using a calibrated, automated oscillometric device suitable for pediatric use.|All the study participants will be examined for assessment of the height and weight using calibrated equipment, Body Mass Index ,blood pressure will be measured.
224237796|NCT06830785|BEHAVIORAL|rhythmic auditory stimulation incorporated in upper-limb movement training|Rhythmic auditory stimulation will be metronome beat sound with different tempi and will be incorporated in upper-limb movement training, which will last for 40 minutes per session, three sessions per week, and a total of 24 sessions.
224237797|NCT06830785|BEHAVIORAL|Upper-limb movement training|Upper-limb movement training will last for 40 minutes per session, three sessions per week, and a total of 24 sessions.
224237798|NCT02704351|PROCEDURE|Surgery|Sugammadex to reverse neuromuscular blockade
224237799|NCT06955715|OTHER|Pasteurized Donor Human Milk|This is a single arm study in which all participants will receive pasteurized donor human milk sourced from the Norther Star Mother's Milk Bank (Calgary, AB, Canada)
224237800|NCT04894513|OTHER|Kabat motor control re-education therapy|Kabat motor control re-education therapy that includes specific movements with predefined patterns of facial muscles exercises, which is spiral and diagonal movements involve the facial muscles, which are brought to train in global patterns. The program of treatment for three times per week for six weeks.
224237801|NCT04894513|OTHER|conventional selected program|the conventional selected program in the form of electrical stimulation (Faradic current) of affected muscles, facial muscle exercise program in front of the mirror, and home advices.
224237802|NCT00482521|DRUG|CC-4047|Oral CC-4047 once daily on days 1-21 followed by a 7-day recovery period. Cohorts of 3-6 patients receive escalating doses of CC-4047 until the maximum tolerated dose (MTD) is determined.
223654078|NCT07209709|DEVICE|Conventional Exercise With Action Observation Therapy|Individuals in this group will watch exercises on a computer screen in three sessions (in bed, sitting, and standing), three days a week for a total of eight weeks. Each exercise in each session will be monitored for two minutes, and each session will be performed under the supervision of a physical therapist for one minute. A one-minute break will be provided between sessions. Each session will last approximately 40-50 minutes. EXERCISES 1. Sit-Reach in Bed (15 seconds each) 2. Hip Flexor Stretch Exercise (15 seconds each) 3. Cat-Camel Exercise 4. Bridge Exercise 5. Biceps Curl/Triceps Extension/Upper Limb Abduction While Sitting in a Chair 6. Sit-to-Stand in a Chair 7. One-Legged Stand 8. Mini Squat 9. Tandem Walk For Example: After watching the video of the exercise period in which you sit and stand on a chair on the computer, do the same exercise by imitating it. (1 set, 10 repetitions) Device: Handheld dynanometer, chair, stopwatch, computer
223654079|NCT07209709|DEVICE|Conventional Exercise (Control Group)|"Individuals in this group will perform conventional exercise sessions under the supervision of a physical therapist three days a week for a total of eight weeks. Each session will last approximately 40-50 minutes. No cognitive tasks or action monitoring therapy will be used during the exercises. EXERCISES 1. Sit-Reach in Bed (15 seconds each) 2. Hip Flexor Stretch Exercise (15 seconds each) 3. Cat-Camel Exercise 4. Bridge Exercise 5. Biceps Curl/Triceps Extension/Upper Limb Abduction While Sitting in a Chair 6. Sit-to-Stand in a Chair 7. One-Legged Stand 8. Mini Squat 9. Tandem Walk.~Device: Handheld dynanometer, chair, stopwatch"
223654080|NCT07209969|BEHAVIORAL|CBT-I group|Refer to the arm description
223654081|NCT07210515|DRUG|Neridronate|neridronate 100 mg, given as a 2-hour infusion on Days 1, 4, 7, and 10.
223654082|NCT07210515|DRUG|Placebo|placebo comparator
223654083|NCT07210294|DEVICE|The press needle and medication|"Press needles using the needle sizes 0.17mm x 0.9mm on auricular acupuncture points (MA-IC6 (Stomach) bilaterally) and the needle sizes 0.20 mm x 1.5mm on body acupuncture points (ST36 bilaterally). After that, apply an adhesive patches on top of the press needle. The press needle is attached for 14 days (on the 7th day the press needle is replaced).~Medication using proton pump inhibitor drugs"
223654084|NCT07210294|DEVICE|The sham press needle and medication|"Sham press needle uses adhesive patches without needles on auricular acupuncture points (MA-IC6 (Stomach) bilateral) and body acupuncture points (ST36 bilateral). The sham press needle is attached for 14 days (on the 7th day the sham press needle is replaced).~Medication using proton pump inhibitor drugs"
223654085|NCT07210905|BEHAVIORAL|3-step Assess-Advice-Refer|Four implementation strategies will be conducted individually for each of the study unit at the timepoint when the study unit is being randomly allocated to the implementation condition. For each study unit, all site facilitators will first receive a half-day training. Each study unit under the implementation condition will receive weekly audit and feedback reports to summarize the proportion of eligible patients, proportion of eligible patients being screened, proportion of patients appropriately referred to JCICC. The senior research assistant with a nursing background will receive training and mentoring from the PI and will be the guided facilitator. The guided facilitator will conduct weekly site visits to address operational issues arise during the implementation. Lastly, while the FitARise protocol is standardized and cannot be modified, the routine workflow for each study unit can be adjusted according to its context and resources.
223654086|NCT07211347|PROCEDURE|Stellate Ganglion Block|There is no randomized clinical study in the literature that evaluated the efficacy and safety of the stellate ganglion infiltration procedure in patients with electrical storm.
223654087|NCT07211022|PROCEDURE|Digital impression using intraoral scanner|Digital impression of complete- arch edentulous patients using intraoral scanner
223767761|NCT07172360|DRUG|VC005 tablets|VC005 groups repeat administration for 48 weeks
223767762|NCT07172360|DRUG|VC005 Tablets Placebo|VC005 placebo groups repeat administration for 48 weeks
223767763|NCT07172490|OTHER|APA-FIT interdisciplinary program|"Intervention: APA-FIT~The APA-FIT program is an interdisciplinary intervention targeting three core domains in adults with chronic conditions at moderate or high risk for physical activity (PA): physical exercise, nutritional habits, and positive mental health. Over nine months, participants receive:~* Individualized PA Prescription~  * Bimonthly follow-up visits with a certified PA prescriber (physician, nurse, or physiotherapist)~ * Weekly supervised exercise sessions led by a coach~ * Automated PA logging and goal tracking via the APA-FIT app~* Nutritional Counseling~  * Initial and final dietary assessments with a registered nutritionist~ * Bimonthly follow-up and three hands-on Mediterranean-diet workshops~* Psychosocial Support for Positive Mental Health~  * Four bimonthly group sessions facilitated by the primary-care emotional-well-being lead~ * In-app materials, peer support features, and one-on-one check-ins"
223767764|NCT07172282|DRUG|Nelitolimod|Nelitolimod drug product is a clear to slightly opalescent, colorless to pale yellow solution free of visible particles and is supplied by TriSalus to the study sites in single-use vials. One vial is to be used per patient, and each vial should be discarded immediately after use.
224237803|NCT03893539|DEVICE|Ion Endoluminal System™|The Ion™ Endoluminal System, Model IF1000, is a software-controlled, electro-mechanical system designed to assist qualified physicians to navigate a catheter and endoscopic tools in the pulmonary tract using endoscopic visualization of the tracheobronchial tree for diagnostic and therapeutic procedures.
223654088|NCT07211022|PROCEDURE|Digital impression using intraoral photogrammetry|Digital impression of complete-arch edentulous patients using intraoral photogrammetry
223654089|NCT07210177|OTHER|Bio-C Temp Intracanal Medication|Bio-C Temp (Angelus, Paraná, Brazil) is a ready-to-use calcium silicate-based material designed for use between appointments. Bio-C Temp is indicated for use as a substitute for calcium hydroxide, as a medicament for necrotic teeth or root canal resurfacing treatments, and for the treatment of internal and external root resorption and immature teeth.
223767765|NCT07173179|DRUG|Papillary epinephrine injection combined with rectal indomethacin|All patients in this group receive preprocedural 100mg indomethacin spp and post-procedure 4 ml of undiluted epinephrine injected around the duodenal papilla on four quadrants, over a period of 60 seconds using a sclerotherapy needle
224237804|NCT01674530|DRUG|Lubiprostone|24 mcg Capsules to be given in the experimental arm with Placebo Of AMITIZA
224237805|NCT01674530|DRUG|Lubiprostone|24 mcg Capsules with placebo of Lubiprostone ( Manufactured by Dr Reddy's Laboratories Ltd)
224237806|NCT01674530|DRUG|Placebo|24 mcg capsules of both experimental Lubiprostone and AMITIZA
224237807|NCT00788125|DRUG|carboplatin|
224237808|NCT00788125|DRUG|dasatinib|
224237809|NCT00788125|DRUG|etoposide phosphate|
223654090|NCT07210177|OTHER|Metapaste Intracanal Medication|Metapaste (Meta Bıomed Co.,Ltd., Chungcheongbuk-do,Korea) is a ready-to-use calcium hydroxide-based material designed for use between appointments.Metapaste is indicated for use as a medicament for necrotic teeth or root canal resurfacing treatments, and for the treatment of internal and external root resorption and immature teeth.
223654091|NCT07211269|OTHER|Real-time fMRI neurofeedback training|Real-time neurofeedback information is computed using the Turbo Brain voyager (TBV) 4.0 software (Brain Innovation, Maastricht, The Netherlands). Functional images are collected and processed in real time based on contrasts of regulation vs. rest conditions. The BOLD signal of the target region is then transformed into visual bars and displayed to participants via the projector screen while participants keep using regulation strategy (heartbeat interoception in our study) to upregulate the target region.
224237810|NCT00788125|DRUG|ifosfamide|
224237811|NCT00788125|GENETIC|microarray analysis|
224237812|NCT00788125|GENETIC|western blotting|
223767766|NCT07173179|DRUG|Rectal indomethacin alone|All patients in this group receive preprocedural 100mg indomethacin spp
223767767|NCT07172217|DRUG|RC48|Disitamab Vedotin (RC48) : 2.5 mg/kg, administered once every 3 weeks (Q3w), via intravenous infusion on Day 1 of each treatment cycle
223767768|NCT07172217|DRUG|QL1706|Drug: QL1706 Iparomlimab and Tuvonralimab (QL1706) : 5 mg/kg in total, administered once every 3 weeks (Q3w), via intravenous infusion on Day 1 of each treatment cycle
223767769|NCT07173465|DEVICE|Virtual Reality (VR)|Participants will engage in the VR gaming intervention three times a week for 12 weeks. Each session will last approximately 45 minutes, providing ample gameplay, instruction, and debriefing time.
223767770|NCT07173465|OTHER|Physical Activity (PA group)|The intervention includes a 5-minute warm-up, 10 minutes of strengthening exercises (lunges and squats), 20 minutes of balance and cardiovascular endurance activities (HIIT exercises), 20 minutes of aerobic exercises (stationary bike and dancing), and a 5-minute cool-down with breathing control. Participants also continue with personalized occupational therapy to enhance their functional abilities.
223767771|NCT07173465|OTHER|occupational therapy|the group will undergo their normal occupational therapy activities that include drawing, coloring, mathematical problems as well as solving mazes
223767772|NCT07172919|DRUG|Sotorasib|Sotorasib will be administered orally as a tablet.
223767773|NCT07172919|DRUG|Panitumumab|Panitumumab will be administered as an IV infusion.
223767774|NCT07172815|DRUG|tadalafil|Once daily dose of Tadalafil will be commenced at 10 mg for 2 weeks, followed by an increase to 20 mg for another 2 weeks and finally increased to 40 mg.
223767775|NCT07172815|DRUG|Placebo|Matched Placebo will be taken once daily.
223767776|NCT07172685|COMBINATION_PRODUCT|Darolutamide , Docetaxel , ADT and Transrectal HIFU Focal Therapy|"Darolutamide , Docetaxel , ADT and Transrectal HIFU Focal Therapy Group:~Darolutamide (600 mg, orally, twice daily) GnRHa (Goserelin 10.8 mg sustained-release implant, subcutaneous injection, every 3 months) Docetaxel (75 mg/m², intravenous infusion, every 3 weeks, for 6 cycles) Dexamethasone (8 mg, orally, 12/3/1 hour before docetaxel infusion)\* Prednisone/Prednisolone (at the investigator's discretion)\* Transrectal High-Intensity Focused Ultrasound (HIFU) for prostate focal therapy (ablation extent determined based on MRI and biopsy findings; number of treatments ≤ 2)~\*Note: Dexamethasone and prednisone/prednisolone are adjunct medications and are not assigned as separate intervention arms; urinary catheter placement is a procedural detail and not listed as an intervention."
224237813|NCT00788125|OTHER|immunohistochemistry staining method|
224237814|NCT00788125|OTHER|laboratory biomarker analysis|
224237815|NCT00788125|PROCEDURE|therapeutic conventional surgery|
224237816|NCT00788125|RADIATION|radiation therapy|
223654092|NCT07211165|DRUG|[14C]Clifutinib|The subjects are required to take the test drug on an empty stomach for at least 10 hours and without drinking water for 1 hour. After taking the drug, they should fast for 4 hours and refrain from drinking water for 1 hour.
224237817|NCT01669538|DRUG|Galantamine|
223767777|NCT07173972|RADIATION|Definitive radiotherapy|The prescribed dose is 56 Gray (Gy) in 16 fractions over 4 weeks (14 Gy per week) with a maximum dose-escalation to the tumor core of 80 Gy (5 Gy per fraction).
223767778|NCT07173244|DRUG|Adebrelimab|adebrelimab-based regimen
223767779|NCT07172620|PROCEDURE|Non-extracorporeal multiple coronary artery bypass graft (CABG) performed under direct visualization through a small incision in the left side of the chest.|Exposure group (MICS-Notouch group): Direct visualization non-extracorporeal coronary artery bypass grafting with a small left chest incision, including the use of LIMA (left internal mammary artery) + SVG (saphenous vein) multibranch bypass grafting.
224237818|NCT01669538|DRUG|Placebo|
224237819|NCT00148681|DRUG|Herceptin|Intravenously every week for 12 weeks (weeks 1-12) Intravenously every three weeks for 40 weeks (weeks 32-72)
224237820|NCT00148681|DRUG|Navelbine|Intravenously every week for 12 weeks
224237821|NCT00148681|DRUG|Doxorubicin|Every 3 weeks for 12 weeks
224237822|NCT00148681|DRUG|Cyclophosphamide|Intravenously every 3 weeks for 12 weeks
224237823|NCT00148681|DRUG|Paclitaxel|Weekly for 12 weeks (or a similar schedule)
223767780|NCT07172620|PROCEDURE|Multi-branch coronary artery bypass grafting with conventional median open heart and off-pump circulation|Control Group (OPCAB Group): Conventional median open multiple coronary artery bypass grafting with extracorporeal circulation.
223767781|NCT07173829|OTHER|samples|A 50 ml blood sample will be taken from the patient before the operation, and two 0.3 cm3 tumor samples will be taken during the operation from the resected tumor.
223767782|NCT07173621|OTHER|Amnioeffect|Amnioeffect is a placental-based allograft made of lyophilized human amnion/intermediate/chorion membrane (LHACM)
224320872|NCT05832177|BEHAVIORAL|Community/Researcher Forum: El Puente (Translation in English: The Bridge).|The main goal of the El Puente annual event is to generate dialogue between community members and researchers about cancer treatment and cancer-focused research topics. During El Puente's presentations, researchers present their projects and data results to community members, allowing community members to react to the research, make suggestions, and express concerns.
224237824|NCT03272048|BEHAVIORAL|Lethal Means Counseling|Lethal means counseling is broadly defined as clinician-initiated discussions that encourage an individual at risk for suicide to safely store his or her firearms. Examples in this domain include applying a gun lock, separating the gun from its ammunition, dismantling the firearm and keeping its components locked and/or separated, or safely transferring the firearm to a trusted loved one, friend, or police station until risk abates (Bryan, Stone, \& Rudd, 2011; Jin, Khazem, \& Anestis, 2016). Further, given that recent purchasers of firearms are at markedly increased risk of death by suicide (Wintemute, Parham, Beaumont, Wright, \& Drake, 1999), anticipatory counseling on firearm safety should also be considered for at-risk individuals who do not report currently owning or having access to a firearm, but who report prior firearm ownership/access or intentions of obtaining a firearm in the future (Harvard T.H. Chan School of Public Health, 2017).
223654093|NCT07209475|BIOLOGICAL|Amnio-Maxx® Dual Layer Amnion Patch|Application of Amnio-Maxx® Dual Layer Amnion Patch
224237825|NCT01491009|DRUG|Remifentanil|IV infusion
224237826|NCT01491009|DRUG|Midazolam|IV infusion
224237827|NCT03228693|PROCEDURE|Biopsy and/or triamcinolone injection|Subjects will have their blood drawn during the first study visit. Subsequently, a punch biopsy and/or triamcinolone injection will be given based on group timeline.
224237828|NCT03228693|PROCEDURE|Excisional Biopsy|Complete excision of an earlobe keloid will be taken.
223654094|NCT07209475|OTHER|Standard of Care (Investigator Choice)|Cleansing, debridement, wound documentation, off-loading
223654095|NCT07210385|PROCEDURE|anterior horizontal maxillary bone augmentation using autogenous and bovine sticky bone|Participants in this group will undergo maxillary horizontal ridge augmentation using a mixture of autogenous bone chips and S1 Bovine Bone Graft in a 70:30 ratio. The graft will be prepared as Sticky Bone and applied to the defect site for augmentation.
223654096|NCT07210385|PROCEDURE|anterior horizontal maxillary bone augmentation using autogenous and bovine bone shell technique (khoury)|Participants in this group will undergo maxillary horizontal ridge augmentation using the Khoury Bone Shell Technique, combining autogenous bone blocks and Bovine Bone Graft to reconstruct the alveolar ridge. The graft will be fixed and stabilized to provide a rigid shell for bone regeneration.
223654097|NCT07210359|PROCEDURE|human treated dentin matrix hydrogel|material used for regenerative dentistry
223654098|NCT07210359|PROCEDURE|Theracal LC - Demineralized dentin matrix combination|material used for regenerative dentistry
224237829|NCT01465477|BIOLOGICAL|Inactivated split virion Influenza vaccine|WHO recommended 2011 Influenza vaccine
223654099|NCT07210359|PROCEDURE|Retro Mta|material used for regenerative dentistry
223654100|NCT07210151|DEVICE|VERAFEYE Anatomic Guidance System|The VERAFEYE Anatomical Guidance System will be used during standard of care, catheter-based treatments for atrial flutter and/or atrial fibrillation.
223654101|NCT07210320|DRUG|Epinephrine Auto-Injector 0.3 mg/0.3 mL|Epinephrine injection
223654102|NCT07210320|DRUG|Epinephrine 0.3 mg intramuscular manual injection via a syringe and needle|Epinephrine injection
223654103|NCT07210320|DRUG|IN-001 9.06 mg Sublingual Spray|Sublingual Spray
223654104|NCT07210320|DRUG|IN-001 13.59 mg Sublingual Spray|Sublingual Spray
223654105|NCT07209488|BEHAVIORAL|Phono-Motor Therapy|Orthographic stimuli (letters) are introduced from the beginning as each phoneme is being trained. This maintains the focus on phonology, while emphasizing its relevance to reading. PMT consists of an initial phase focused on training of individual phonemes and phoneme sequences in spoken language, followed by written language tasks. English phonemes are first trained in isolation, followed by phoneme sequences in words and pseudowords. They are trained multi-modally through emphasis on auditory, motor, tactile-kinesthetic, visual, and orthographic representations for each consonant and vowel. When sequences are introduced, focus on phonology is maintained by training on pseudowords first before real words are introduced. Participants work on identifying, repeating, parsing, blending, and manipulating phonemes that make up the pseudoword and word stimuli. To maintain focus on phonology, pictures and definitions of the stimuli are never shown or discussed.
223680933|NCT05946980|OTHER|Multi-component hand hygiene intervention in primary health care facilities|"Intervention facilities will receive (1), two novel Gravit'eau (https://www.graviteau.ch/) handwashing systems which are locally produced. These systems recycle water for handwashing with gravity through a membrane filter without electricity up to a month. Facilities also receive (2), a behavior change intervention lead by RANAS (https://www.ranasmosler.com/ranas), expert psychologist for behavior change in WASH. They will also receive (3), support to implement WASH FIT (https://washfit.org/#/) in their facilities, a tool developed by WHO to sustainably maintain and improve WASH infrastructure in health care facilities. Additionally, we are recruiting a circuit rider responsible for the regular inspection and maintenance of WASH infrastructure. (4), the facilities will receive support for regular water chlorination."
224237830|NCT01465477|BIOLOGICAL|WHO recommended 2011 Influenza vacccine|WHO recommended 2011 Influenza vacccine
224237831|NCT02696070|DEVICE|Provant Therapy System|
224237832|NCT03769285|DRUG|Nicotinamide|Oral nicotinamide (500 mg) twice daily for at least 52 weeks
224237833|NCT03769285|DRUG|Placebo oral capsule|Matching placebo taken twice daily for at least 52 weeks
224237834|NCT00951925|OTHER|Bone Marrow Aspirate Draw|5cc of Bone Marrow Aspirate will be drawn
224237835|NCT02435225|BEHAVIORAL|Mindfulness Based Stress Reduction for Teens Group|A 12-Week weekly group intervention to train adolescents in mindfulness practice
224237836|NCT01653626|OTHER|package of 3 interventions|Emergency Obstetric Care training, social marketing approach and link TBS with public sector services
224237837|NCT02048111|BIOLOGICAL|IB1001|"Prophylaxis (during Treatment and Continuation phases): 40 - 75 IU/kg twice weekly.~The starting dose for prophylaxis may be based on previous recombinant factor IX product use. The recommended starting prophylaxis dose is 40 - 60 IU/kg twice weekly, however, the investigator may prescribe up to 75 IU/kg twice weekly at their discretion (after clinically assessing the subject) and discretion of the subject.~The dose or the frequency of IB1001 prophylaxis may be adjusted at the discretion of the investigator."
224237838|NCT00323349|PROCEDURE|Oral Glucose Tolerance Testing|
224237839|NCT00323349|BEHAVIORAL|Education tailored to learning style preferences|
224237840|NCT06213844|DRUG|IBI3002|Single dose of IBI3002 (Dosage 1, Dosage 2, Dosage 3, Dosage 4, Dosage 5, Dosage 6), administered subcutaneously on Day 1
224237841|NCT06213844|DRUG|Placebo|Single dose of Placebo, administered subcutaneously on Day 1
223654106|NCT07209488|BEHAVIORAL|Semantic Feature Analysis|"SFA activates semantic features of the target word to help retrieve the spoken form of the word. To target reading, a modified SFA is used with written words rather than pictures as the primary materials. Pictures are instead included for each word as a semantic feature. Stimuli will consist of 80 highly imageable nouns with a range of word frequencies. During treatment the therapist will present a written noun and ask the participant a series of questions about the features of that noun. For example, if the presented noun is juice, the therapist would have the participant select the corresponding picture from an array of pictures. The therapist then would ask, what do you do with it? (eliciting a feature from the function category) and where do you store it in your home? (eliciting a feature from the context category). This is done for a total of 6 categories of semantic features. The process is repeated until the participant reads the noun correctly three times in a row."
223654107|NCT07209865|DRUG|68Ga-P16-093|Intravenous injection of Ga-P16-093 with a dosage of 111-148 MBq (3-4 mCi), followed by PET/CT or PET/MRI acquisition according to standard methods.
223654108|NCT07211100|BEHAVIORAL|Mobile Health Application|A mobile health application developed by the research team to support hemodialysis patients. The application includes modules on treatment adherence (medication, diet, fluid restriction, dialysis attendance), symptom management (fatigue, pain, itching), nutrition guidance, exercise recommendations, reminder notifications, expert Q\&A, and personal tracking. The aim is to improve adherence to treatment, reduce symptom burden, and support patient self-care.
223654109|NCT07210099|DIETARY_SUPPLEMENT|Concentrated olive fruit water|Supplementation of OliPhenolia twice daily for eight days. Dose equivalent to ≤1.0mg∙kg-1 of hydroxytyrosol.
223654110|NCT07210099|DIETARY_SUPPLEMENT|Placebo|Placebo matched for taste and appearance consumed twice daily for eight days in the equivalent volume to the experimental product.
223654111|NCT07210099|DIETARY_SUPPLEMENT|Anhydrous caffeine|A single bolus of flavoured water (150mL) containing 6mg/kg anhydrous caffeine taken as a pre-exercise beverage
223654112|NCT07210099|DIETARY_SUPPLEMENT|Placebo beverage|A single bolus of flavoured water (150mL) containing 6mg/kg microcrystalline cellulose
223654113|NCT07210840|PROCEDURE|Virtual Reality treatment|Exercises delivered via a VR system simulating balance tasks and environments
223654114|NCT07210840|PROCEDURE|Traditional Vestibular Rehabilitation Therapy|Customized vestibular exercises (gaze stabilization, balance, habituation, gait training).
223654115|NCT07210567|BEHAVIORAL|Mindfulness|Participants will complete 4 counseling sessions (30 minutes), download and use a smartphone app for 4 weeks, complete 4 online surveys (baseline, quit date, end of treatment, and 3-month follow-up), and a brief phone call at the end of treatment to provide feedback. Participants will use the app every day to complete daily diaries and ecological momentary assessments (EMAs), receive brief mindful skills, and practice formal mindfulness meditations (5-30 minutes). Participants will also be provided with nicotine patches.
223654116|NCT07210567|BEHAVIORAL|Quitline|Participants will be referred to Quitline to receive standard care smoking cessation treatment, including counseling and nicotine patches. Participants will complete 4 online surveys (baseline, quit date, end of treatment, and 3-month follow-up) and a brief phone call at the end of treatment to provide feedback. Participants will use the app every day to complete daily diaries.
223654117|NCT07211321|OTHER|No Intervention: Observational Cohort|No Intervention
223654118|NCT07210489|PROCEDURE|Reconstructive surgery after anterior cruciate ligament rupture|surgical technique for repairing the cruciate ligament
223654119|NCT07210489|OTHER|sessions from a physical therapist|sessions from a physical therapist in accordance with standard practice
223680934|NCT04895189|OTHER|No intervention|There is no intervention for this observational study. The investigators are observing the changes in participants before and after the participants receive the COVID-19 vaccine, which participants will receive outside of the study.
224237842|NCT06387186|DRUG|Leucine-Enriched Essential Amino Acid powder|Leucine-Enriched Essential Amino Acid Powder will be orally/enterally administered by mixing in water or ketogenic formula.
224237843|NCT01475448|OTHER|Long distance training|Long distance training during four months, 3 times per week
224237844|NCT01475448|OTHER|Walking training|Walking training during four months, three times per week
224237845|NCT05594472|DRUG|Ozonated olive oil|Topical treatment will be applied for 5 consecutive days on the erosions.
224320873|NCT05832177|BEHAVIORAL|Lunch and Learn Updated Recommendations Series.|This is a virtual podcast that will discuss cancer-related recommendations and guidelines from the United States Preventive Services Task Force (USPSTF). The podcasts are pre-recorded, 30 minute long, and will be in English and/or Spanish. This podcast will be hosted by the Outreach Core (OC) CHE, and feature experts who will explain the updated recommendations and active steps that community members and providers can take to facilitate adherence. This activity will begin according to the project timeline
223680935|NCT05480696|DIETARY_SUPPLEMENT|Fructo-oligosaccharide enriched inulin supplement|Experiment
223680936|NCT05480696|OTHER|Maltodextrin|Placebo.
223680937|NCT06638879|DRUG|Tacrolimus|Participants will receive a tacrolimus treatment via toothpaste application twice daily for three months.
224237846|NCT05594472|DRUG|Topical garamycin cream|Conventional topical treatment will be applied for 5 consecutive days on a comparable erosion
224237847|NCT06245265|OTHER|ELISA (Enzyme-Linked ImmunoSorbent Assay)|In this study, 15 periodontitis patients with RA, 15 healthy individuals with RA, 15 systemic healthy periodontitis patients and 15 systemic periodontally healthy individuals will be included. ANGPTL-4 biomarker and other biomarkers (MMP-13, TNF-α, IL-6) that have not been previously analysed in the serum and saliva of both RA and periodontitis patients will be evaluated before and 3 months after COPT. Clinical parameters (Plaque index, probing depth, gingival recession, clinical attachment level, bleeding on probing), biochemical evaluations of serum, saliva and gingival samples will be performed and correlated with clinical parameters at baseline and 3 months after COPT in all individuals with periodontitis included in the study.
224320874|NCT05832177|BEHAVIORAL|Community Engagement (CE) Training Program for U54 Partnership Investigators|This is a series of 2 1/2-day CE workshops designed and delivered up to 20 partnership researchers (including faculty and junior investigators) delivered across four sessions per year (6 to 10 researchers per year). Each session includes two hours of lectures (didactic material) and one hour of practice activities (practical application of the theoretical content). Session topics will include CE: concepts and principles, theoretical roots, levels, and ethics. The OC team will provide educational materials and additional references in each session.
223654120|NCT07209501|OTHER|Aromatherapy inhaler|Participants in the intervention group will receive inhalation therapy via an aromatherapy inhaler stick\*, on top of standard care. They will be instructed to use the inhaler stick every four hours when they are awake, and whenever they feel nauseous, by holding the inhaler stick a finger's length away from their nostrils and inhaling through one nostril at a time. Each administration should not last more than 5 minutes. Participants will commence using the inhaler stick on the day of chemotherapy, until five days after the completion of chemotherapy (total of six days). Given the subjective nature of scents, participants in the intervention group will be given a choice between two therapeutic aroma blends - N1 and N2 - before commencing the study. This approach aims to minimize the risk of negative associations with a particular scent and enhance participant adherence to the intervention.
223654121|NCT07209501|OTHER|Aromatherapy inhaler (placebo)|Participants in the control group will receive the placebo intervention in addition to standard care. They will be provided with an identical aromatherapy inhaler stick infused solely with jojoba oil. Jojoba oil, primarily used as a carrier oil for dilution, has littleto- no scent and no known therapeutic or anxiolytic effects when inhaled.
223654122|NCT07210398|BEHAVIORAL|Quiet Focus|Mindfulness-based cognitive therapy adapted for older adults at-risk for chronic pain and depression
223654123|NCT07209995|OTHER|retroclavicular infraclavicular brachial plexus block for|The patient will be placed supine, head facing the contralateral side. A high- frequency 13-6 MHz linear array transducer probe will be placed medial to the coracoid process below and perpendicular to the clavicle to obtain a short-axis view of the cords of the brachial plexus and the axillary vessels. The needle will be inserted in the supraclavicular fossa, approximately one cm posteriorly to the clavicle, and advanced in plane parallel to the probe. After passing the initial blind zone of about 2 cm caused by the clavicle's acoustic shadow, the needle tip will be continuously seen, until it appears posterior to the axillary artery. A single injection of the local an esthetic will be performed without needle repositioning unless paresthesia is elicited
223654124|NCT07209995|OTHER|axillary block|The axillary nerve block is performed from behind the patient with the patient seated. The axillary nerve will be identified within the quadrilateral space by placing high frequency linear probe parallel to the long axis of the humeral shaft. The nerve was identified next to the circumflex artery
223654125|NCT07209761|DRUG|BPaQM|Bedaquiline 400 mg once daily for 2 weeks then 100 mg once daily for 15 weeks + Pretomanid 200 mg QD for 17 weeks + Quabodepistat 30 mg once daily for 17 weeks + Moxifloxacin 400 mg once daily for 17 weeks
223654126|NCT07209761|DRUG|BPaLM|Bedaquiline 400 mg once daily for 2 weeks then 200 mg thrice a week for 24 weeks + Pretomanid 200 mg QD for 26 weeks + Linezolid 600 mg once daily for 26 weeks + Moxifloxacin 400 mg once daily for 26 weeks
223654127|NCT07209761|DRUG|BPaQ|Bedaquiline 400 mg once daily for 2 weeks then 100 mg once daily for 24 weeks + Pretomanid 200 mg QD for 26 weeks + Quabodepistat 30 mg once daily for 26 weeks
224237848|NCT00890981|PROCEDURE|high-resolution peripheral quantitative computed tomography (HR-pQCT)|Bone densitometry and microarchitecture assessments of the distal radius and the distal tibia by HR-pQCT on Day 1.
223654128|NCT07209761|DRUG|BPaL|Bedaquiline 400 mg once daily for 2 weeks then 200 mg thrice a week for 24 weeks + Pretomanid 200 mg QD for 26 weeks + Linezolid 600 mg once daily for 26 weeks
223654130|NCT07210138|DRUG|PeriGuard regimen|0.45% Stannous Fluoride Toothpaste, CPC-Zinc Fluoride Mouthwash, Gummy Toothbrush
223654131|NCT07210138|DRUG|Colgate Dental Cream regimen|Colgate Cavity Protection Toothpaste, Fluoride Mouthwash,Colgate Extra Clean Soft-Bristled Toothbrush
223654132|NCT07211152|BIOLOGICAL|Participants will receive one dose of vaccine (0.5 mL) of Sinovac QIV|Participants will receive one dose of vaccine (0.5 mL) of Sinovac QIV
223654133|NCT07211152|BIOLOGICAL|Vaxigrip QIV|Participants will receive one dose of vaccine (0.5 mL) of Vaxigrip QIV
223654134|NCT07210762|OTHER|Early space closure|Space closure will be started 1 week after extraction
224237849|NCT00890981|PROCEDURE|Dual energy X-ray absorptiometry (DXA)|Bone densitometry assessments of the forearm by DXA on day 1.
224237850|NCT00890981|BIOLOGICAL|Denosumab|Denosumab 60 mg subcutaneously every 6 months in the previous study
224237851|NCT00890981|DRUG|Placebo|Placebo to denosumab subcutaneously every 6 months in the previous study
224237852|NCT05035355|PROCEDURE|a weaning protocol|a weaning protocol that is combined spontaneous breathing trial (SBT) with the high-flow nasal cannula (HFNC)
224237853|NCT02400047|DRUG|Dexamethasone 0.2 mg/kg|Single injection of DXM (Mylan Dexamethasone® 20 mg/5 ml or 4 mg/1 ml injection ampoule solution) at 0.2 mg / kg after general anesthesia induction and before surgery incision.
224237854|NCT02400047|DRUG|Dexamethasone 0.4 mg/kg|Single injection of DXM (Mylan Dexamethasone® 20 mg/5 ml or 4 mg/1 ml injection ampoule solution) at 0.4 mg / kg after general anesthesia induction and before surgery incision.
224237855|NCT02400047|DRUG|Ketoprofen 1 mg/kg|Single injection of ketoprofen (Medac ketoprofen ® 100 mg/4 ml injection ampoule solution) at 1 mg /kg after general anesthesia induction and before surgery incision.
224237856|NCT02975141|DRUG|Afatinib 30Mg Tab|Study Drug
224237857|NCT02975141|DRUG|Afatinib 40Mg Tab|Study Drug
224237858|NCT02975141|DRUG|Gemzar|Chemotherapy Backbone
224237859|NCT02975141|DRUG|Abraxane|Chemotherapy Backbone
224237860|NCT00453362|OTHER|2-deoxy-2-[18F]fluoro-D-glucose (FDG)|FDG prepared in sterile buffered solution for intravenous injection. Dosage was based on the participant's weight not to exceed 15 mCi (millicurie).
224237861|NCT00453362|OTHER|3'-deoxy-3'-[18F]fluorothymidine (FLT)|FLT 7 mCi dose prepared in sterile buffered solution for intravenous injection.
224237862|NCT00453362|DRUG|erlotinib HCl|Tablets taken orally 150 mg/day.
223654135|NCT07210762|OTHER|Delayed space closure|Space closure will be started 8 weeks after extraction
223654136|NCT07209904|BEHAVIORAL|mindline.sg|mindline.sg is a polydigital mental health platform with resources, wayfinding, and peer support via a forum. The website was built by the MOH Office for Healthcare Transformation together with Ministry of Social and Family Development, National Council of Social Service and Institute of Mental health. The content was cureated by the mindline.sg team and vetted by a clinical review panel which included clinicians from IMH and Fei Yue Community Services.
223654137|NCT07209800|OTHER|Sensory integration therapy|Sensory integration therapy (SIT) was delivered individually in a play-based format, three times per week for four weeks, totaling 12 sessions. Each session lasted 60 minutes, and parents were instructed to reinforce the activities at home as homework. All interventions were administered one-on-one by an experienced therapist in a therapy room. The therapist who administered the intervention did not take part in the evaluation process; therefore, the study was conducted in a single-blind manner. Before the intervention, a trust-based relationship was established with the children, and sensory activities were performed within a play context. The interventions were not limited to oral activities but aimed to support overall sensory development \[8\]. Based on this program, sensory integration procedures were applied at regular intervals.
223654138|NCT07209618|PROCEDURE|utogenous mandibular ramus block grafting with simultaneous dental implant placement|Horizontal alveolar ridge augmentation performed using autogenous block grafts harvested from the mandibular ramus. The graft was fixed to reconstruct the buccal wall, followed by immediate placement of dental implants in the same surgical session. Prosthetic loading was initiated 4 months postoperatively.
223654139|NCT07209618|PROCEDURE|Autogenous mandibular ramus block graft with simultaneous implant placement|Horizontal alveolar ridge augmentation performed using autogenous block grafts harvested from the mandibular ramus. The graft was fixed to reconstruct the buccal wall, followed by immediate placement of dental implants in the same surgical session. Prosthetic loading was initiated 4 months postoperatively.
223654140|NCT07209982|BEHAVIORAL|Dual-Task Training (DTT)|This intervention combines gait and balance practice with a simultaneous secondary task to mimic real-world multitasking demands. Participants complete 60-minute sessions, three times per week for six weeks. Secondary tasks include simple cognitive activities (such as serial subtraction, word recall, or visual scanning) or light motor tasks (such as carrying an object or tossing a ball). Task complexity is increased gradually according to participant tolerance. All sessions are supervised by a trained physiotherapist, with rest breaks and safety precautions provided.
223654141|NCT07209982|BEHAVIORAL|Single-Task Training (STT)|This intervention provides gait and balance training without any added secondary tasks. Participants complete 60-minute sessions, three times per week for six weeks. Exercises include level walking, directional changes, obstacle negotiation, static and dynamic balance activities, and surface progressions (such as standing on foam). Progression is achieved by altering the physical task difficulty only. Sessions are supervised by a physiotherapist with safety measures in place and rest breaks as needed.
223654142|NCT07209670|PROCEDURE|peripherally inserted central catheter insertion|Neonates who received peripherally inserted central catheters within the first 28 days of life.
223654143|NCT07209670|PROCEDURE|umbilical venous catheters insertion|Neonates who received umbilical venous catheters within the first 28 days of life
223654144|NCT07210996|DRUG|pimicotinib capsules|pimicotinib capsules
223654145|NCT07210801|DEVICE|CIEDimplantation|Compare current procedural CIED practice at AUHH to recent ESC guidelines.
223654146|NCT07210086|DRUG|ADT|Androgen Deprivation Therapy
224237863|NCT05172622|DRUG|JP-2266|"* Single Ascending Dose: Single administration on Day 1~* Food effect cohort: Single administration on Day 1 of each period~* Multiple Ascending Dose: Repeated administrations from D1 to D15"
224237864|NCT05172622|DRUG|JP-2266 Placebo|"* Single Ascending Dose: Single administration on Day 1~* Food effect cohort: Single administration on Day 1 of each period~* Multiple Ascending Dose: Repeated administrations from D1 to D15"
224237865|NCT03359434|DEVICE|Clearsight device (Edwards) around the finger|Continuous measurement of blood pressure with the Clearsight device (Edwards) around the finger, within 24 hours after reperfusion:
224237866|NCT03359434|DEVICE|Intermittent blood pressure measurements with cuff.|Standard method: 35 blood pressure measurements with cuff within 24 hours after reperfusion
224237867|NCT00153803|DRUG|Erlotinib (tarceva)|Erlotinib 150mg orally each day. Patients will be treated on a continuous, once daily oral dosing schedule until disease progression, withdrawal of consent, unacceptable adverse events, death or completion of 3 years of therapy.
223654147|NCT07210086|DRUG|ARSI|Androgen Receptor Signaling Inhibitor
224237868|NCT00153803|DRUG|Placebo|Matched placebo orally each day. Patients will be treated on a continuous, once daily oral dosing schedule until disease progression, withdrawal of consent, unacceptable adverse events death or completion of 3 years of therapy.
224237869|NCT05369247|OTHER|High intensity Interval Training|HIIT protocol consisted of 10 one-minute intervals of high-intensity work (i.e., \> 90% HRmax) interspersed with nine one-minute intervals of self-paced active recovery (19-minutes total).
224237870|NCT05369247|OTHER|Moderate Intensity Continuous Training|The MICT protocol consisted of 30-minutes of moderate intensity cycling (i.e., 64 - 76% HRmax).
224237871|NCT04885296|DEVICE|TRP-200|JJVC Investigational Contact Lens
224237872|NCT04885296|DEVICE|JJVC Marketed Contact Lens|ACUVUE Oasys 1-Day
224237873|NCT01421030|PROCEDURE|Percutaneous pulmonary valve implantation or open heart surgery|Outcomes before percutaneous pulmonary valve implantation or open heart surgery before, 1, 3, 6 and 12 months after the treatment
224237874|NCT00862979|DRUG|Everolimus (EVR)|Everolimus 0.25mg, 0.75mg or 1.0mg based on blood levels (5-10 ng/mL)
224237875|NCT00862979|DRUG|cyclosporine A (CyA)|10 mg, 25 mg, 50 mg or 100 mg capsule according to blood levels for CNI-regimen group. For CNI-free-regimen dispense on month 6 to 9 only
224237876|NCT00862979|DRUG|tacrolimus (TAC)|0.5 mg, 1 mg, or 5 mg capsule given according to blood levels for CNI-regimen. For CNI-free-regimen give on month 6 to 9 only
224237877|NCT00862979|DRUG|Enteric coated mycophenolate sodium (EC-MPS)|180 mg or 360 mg tablet dosed 1440-2280 mg per day
224237878|NCT00862979|DRUG|mycophenolate mofetil (MMF)|250 mg or 500 mg tablets with a dose of 1500-3000 mg per day
224237879|NCT00862979|DRUG|Corticosteroids|according to local standard: 0.05-0.3 mg/kg of prednisolone or equivalent
224237880|NCT05941403|BEHAVIORAL|Enhanced Produce Prescription Implementation|Practices make modifications to their usual produce prescription program based on an implementation blueprint. While the exact implementation strategies to be added will be defined based on qualitative data (data collection in progress), possible implementation strategies may include training or technical assistance.
223767783|NCT07173283|OTHER|MenTOras: Peer Mentorship Program for Newly Graduated Occupational Therapists|The MenTOras intervention is a structured peer mentorship program designed for newly graduated occupational therapists in Aragón, Spain. The program pairs early-career occupational therapists (mentees, graduated within the past two years) with experienced colleagues (mentors, with at least five years of practice). Over approximately three months, each mentor-mentee pair participates in at least six structured sessions (online or in person). Sessions follow three phases-initiation, development, and closure-focusing on professional identity, reflective practice, emotional support, and skill integration. Mentors receive orientation and guidance to ensure program consistency. COPTOA also offers topic-specific training to address emerging professional needs. The intervention aims to foster professional integration, enhance self-confidence, and promote well-being among new occupational therapists, while strengthening professional cohesion and retention.
223767784|NCT07171905|DRUG|investigating the role of CAIX as target in VHL disease and in VHL-/- tumors.|Participants VHL disease and in VHL-/- tumors, will receive a single dose of the diagnostic radiopharmaceutical \[89Zr\]Zr-DFO-Girentuximab and subsequently undergo imaging with a hybrid PET/CT scanner.
223767785|NCT07174102|DIAGNOSTIC_TEST|High resolution computed tomography|High resolution computed tomography perfomed in patients with rheumatoid arthritis and connective tissue diseases with or without interstitial lung disease, and idiopathic pulmonary fibrosis
223767786|NCT07172022|DRUG|Crovalimab|Crovalimab will be administered at a dose of 680 mg (for participants with BW ≥ 40 kilograms \[kg\] to \< 100 kg) or 1020 mg (for participants with BW ≥ 100 kg), as a SC injection, at Weeks 1, 2, and 3 and Q4W from Week 5 onwards.
224237881|NCT04916652|RADIATION|MRI|MRI is a safe, non-invasive, cutting edge imaging technology widely used to study the human brain both internationally (NIH connectome project) and in China (China Brain Project). The Baby Connectome Project (BCP) led by NIH scientists has begun data collection on the structural and functional brain development among American infants (Howell, Styner et al. 2019).
223654148|NCT07210086|OTHER|No ADT/ARSI -decline|Recurrent prostate cancer with oligometastatic disease who decline ADT/ARSI and are treated with ablative intent RT alone and who have \<=5 extrapelvic lesions detected on a baseline PSMA-PET and have rising PSA.
223654149|NCT07210229|DIETARY_SUPPLEMENT|ashwagandha root|This substance is extracted from the root of the plant.
223654150|NCT07210229|DIETARY_SUPPLEMENT|ashwagandha root and leaf|This substance is extracted from both the root and leaves of the plant.
223654151|NCT07210229|OTHER|Placebo|The inert placebo does not contain any of the plant matter.
223767787|NCT07172022|DRUG|Placebo|Placebo matching crovalimab will be administered as per the schedule specified in the respective arm.
224237882|NCT05467683|BEHAVIORAL|Exposure-Based Therapy|"Treatment will consist of 12 one-hour sessions, delivered over the course of 12 weeks. EBT will be delivered by trained and experienced license-eligible clinicians. The study clinician will develop a personalized assessment and treatment plan for each patient. Consistent with contemporary models of EBT, exposure practice aims to help patients reestablish a sense of safety around feared cues. Hence, exposure exercises are planned to ensure violation of threat expectancies. That is, exposure practice is deemed appropriate and effective if it allows the patient to learn that what they feared would happen does not happen. Practice will occur across relevant contexts both within and outside the session (i.e., homework) and clinicians will guide patients in processing practice to facilitate the consolidation of safety learning. To achieve these ends, study clinicians will use the manual Personalized Exposure Therapy: A Person-Centered Transdiagnostic Approach."
224237883|NCT05193279|BIOLOGICAL|Candidate vaccine, SCB-2019|a recombinant SARS-CoV-2 trimeric S-protein subunit vaccine for COVID-19
224237884|NCT03100903|DRUG|BI 655130|single dose
224237885|NCT00283699|DRUG|albendazole|Active drug or placebo dosed bid p o for 8days
224320875|NCT05832177|BEHAVIORAL|Community Advisory Panels (CAP)|These CAPs work closely with the (CHE) to oversee the identification, development, and coordination of the outreach activities; provide advice on the development and implementation of community needs and assessments; provide guidance for recruitment and retention of research participants; and assist in the recruitment for educational events and research and vetting community educational materials and the content of protocols for research projects.
223654152|NCT07210944|DEVICE|Repetitive transcranial magnetic stimulation|Transcranial magnetic stimulation applied a figure-8 coil to the premotor area at 80%-100% of the healthy-side MEP threshold. Treatment lasted 20 min in two phases: weeks 1-2 on the ipsilateral M1 (1Hz, 10s on/5s off), and weeks 3-4 on the contralateral M1 (10Hz, 3s on/12s off). Treat once a day, 5 days a week, for a total of 4 weeks.
223654153|NCT07210944|PROCEDURE|Scalp acupuncture|Scalp acupuncture selected bilateral upper-limb cortical MEP points (2 points total). The healthy-side hot spot was identified first; if the affected side had no MEP, its mirror point was used. Needles were inserted from point A (affected) to B (healthy) and beyond along the AB line. After insertion, needles were rotated for 2-3 min, manipulated every 10 min, and retained for 30 min. Treat once a day, 5 days a week, for a total of 4 weeks.
223654154|NCT07210944|COMBINATION_PRODUCT|Conventional rehabilitation treatment|Conventional drug therapy included secondary stroke prevention, neurotrophy, and improved cerebral circulation. Routine rehabilitation involved exercise, occupational, and physical therapies, with a total daily treatment time of 90 minutes.
223654155|NCT07209852|DEVICE|Pacemaker lead|The pacemaker lead under investigation is a bipolar, steroid-releasing pacemaker electrode with active fixation (IS-1 connection) designed for chronic stimulation and sensing in the right atrium, right ventricle or left bundle branch area (LBBA). In this study, the lead is implanted in the LBBA and connected to a single- or dual-chamber pacemaker. Implantation is performed using a compatible, CE-marked catheter for pacemaker implantation.
223767788|NCT07172022|DRUG|VKA|Dose administration of VKA will be in accordance with the local prescribing information for the respective product. The VKA regimen will be titrated to a therapeutic target INR based on investigator discretion and local standard of care (SOC).
224237886|NCT00283699|OTHER|placebo|an inactive substance
224237887|NCT06834230|DRUG|Dotinurad|Start at 0.5 mg once daily, and then referring to the attached document, gradually increase the dose to the maintenance dose (2 mg once daily).
224237888|NCT06834230|DRUG|Febuxostat|Start at 10 mg once daily, and then referring to the attached document, gradually increase the dose to the maintenance dose (40 mg once daily).
223654156|NCT07209813|BIOLOGICAL|GKL-006|GKL-006（3.0±0.9）×108 iNKT cells/m2 IV single infusion on Day 1 of each 14-day cycle for up to 11 cycles (≈6 month) in the absence of disease progression or unacceptable toxicity.
223654157|NCT07211282|DEVICE|Activity score|4 month follow-up and feedback from a heart rate and personal characteristics based activity score.
223654158|NCT07210333|DEVICE|non-invasive intracranial pressure monitoring|non-invasive intracranial pressure monitoring that provides continuous bedside monitoring.
223654159|NCT07211178|OTHER|There are no interventions in this observational study.|There are no interventions in this observational study.
223654160|NCT07211204|PROCEDURE|Physical examination|Physical examination and interview for obtaining a medical record
223654161|NCT07211204|OTHER|Liquid-based cytology|Screening test for cervical precursor lesions and/or cancer. LBC is a procedure in which a cervical smear is examined under the microscope.
223654162|NCT07211204|OTHER|Molecular screening|The molecular screening detects three human biomarkers associated with cervical precursor lesions and/or cervical cancer. Biomarker detection is done by Western blot and ELISA in human sera.
223654163|NCT07211204|OTHER|HPV DNA test|HPV DNA detection is performed using a cervical swab.
223654164|NCT07211204|DIAGNOSTIC_TEST|Colposcopy|A diagnostic procedure to visually examine the cervix, vagina, and vulva with a colposcope.
223654165|NCT07211204|DIAGNOSTIC_TEST|Histopathology|Is the definitive diagnosis of cervical precursor lesions and cervical cancer. It is the microscopic study of diseased cells and tissues stained with hematoxylin and eosin.
223654166|NCT07209683|DEVICE|transcranial photobiomodulation|"The Vielight Neuro Gamma TPBM devices (©Vielight Inc.) will be used to transmit pulsed near-infrared (NIR) energy through the cranium. Device emits NIR photons at 810 m wavelength generating \~100 mW/cm2 pulsed NIR power modulated at 40 Hz frequency. The six NIR light sources are positioned along the midline over the frontal, pariatel and occipital cortices, bilaterally over the temporal cortex, and intranasally. Due to its portable design, Vielight Neuro TBPM instruments can be used in the laboratory, bedside, or at the participant's home.~Active / sham photobiomodulation sessions last for 20 minutes and will be administered at a laboratory-, home-, or office-based setting depending on the preference of the participant. TPBM will be performed three or four times a week for four weeks, maximum once every other day. Participants will complete a questionnaire of adverse events after each photobiomodulation session."
223654167|NCT07210047|BIOLOGICAL|HuL001-10 mg/kg|Anti-ENO1 monoclonal antibody
223654168|NCT07210047|BIOLOGICAL|HuL001-15 mg/kg|Anti-ENO1 monoclonal antibody
224237889|NCT05395533|DRUG|Recombinant CD20 monoclonal antibody-MMAE conjugte for injection|The dose of the enrolled subjects was increased according to the following 6 dose groups: 0.1mg/kg, 0.5mg/kg, 1.0mg/kg, 1.5mg/kg, 1.8mg/kg, and 2.1mg/kg.
224237890|NCT01188707|DRUG|Belinostat and Erlotinib|"The design of the first phase is a 3 +3 phase I trial. The Belinostat dose will start at 500 mg and will be increased with 250 mg until a maximum dose of 1500 mg, administered daily in 2/3 weeks. Each patient will at the same time receive 150 mg of Erlotinib daily continously.~When the patient is enrolled at one dose level, there will be no further dose escalation for that individual patient.~3 patients will be treated at each dose level."
224237891|NCT04788836|OTHER|Questionnaire (Survey and Food Frequency Questionnaire (FFQ))|Each participant will be asked to fill a web-based questionnaire that captures sociodemographic, lifestyle, physical and mental health information (Survey) and dietary intake patterns (FFQ). This will be done pre-treatment (only for those included pre-treatment), 6 months after the start of obesity treatment, 1 year after the start of the treatment and then yearly until 5 year after the start of the treatment.
224237892|NCT04788836|OTHER|Collection of digital receipts from grocery shopping|"Participants will create their BitsaboutMe-account (GDPR-compliant data sharing platform from Bern, Switzerland) with the help of study team members. Data from digital receipts will be obtained from Migros Cumulus and Coop Supercard via their BitsaboutMe-account. The data collection allow retrospective digital receipts collection for up to 2 years and automatically continuous collection during study duration.~GDPR: General Data Protection Regulation"
223767789|NCT07173673|OTHER|Usual Care (General Practice)|Participants receive routine care based on current clinical guidelines. Symptom-driven evaluation is performed by physicians, including at least one diagnostic test within 6 months such as a standard 12-lead ECG, Holter monitoring, or patch ECG. The choice and frequency of monitoring are determined by physician discretion, reflecting real-world practice patterns.
224237893|NCT06630676|BEHAVIORAL|Control|Brief 4-slide presentation without a separate session for questions and answers
224237894|NCT06630676|BEHAVIORAL|Education|Patients will review 27 slides that discuss the different etiologies (causes) of back pain, how common they are, what causes them (e.g., wear and tear, trauma), factors that exacerbate and alleviate the pain, how they are diagnosed and treated, and have an opportunity to ask questions.
224237895|NCT04888221|DRUG|Tocilizumab|"Tocilizumab will be administered subcutaneously at a dose of 162mg/0.9mL weekly (each week, on the same day) from week 0 to week 24.~At the first injection (Baseline D0), a therapeutic education is provided for patients/caregivers who can carry out the injections themselves as part of their usual care."
223654169|NCT07210047|DRUG|Lenalidomide and Dexamethasone|Lenalidomide in combination with dexamethasone is indicated for the treatment of adult patients with multiple myeloma (MM)
223654170|NCT07209748|DIAGNOSTIC_TEST|sCD163 level|The significance of soluble CD163 level in the early detection and severity assessment of HELLP Syndrome
223654171|NCT07210190|DEVICE|Microneedeling with topical application of VAMP™ ADVANCED Topical Multivitamin Serum|VAMP™ ADVANCED Topical Multivitamin Serum is not indicated for use in pregnancy, lactation, or in individuals under the age of 18. Female participants of childbearing potential will be required to undergo urine pregnancy testing at baseline and prior to each treatment session. They will also be instructed to use an acceptable form of effective contraception for the duration of the study.
223654172|NCT07210541|PROCEDURE|aortic valve/root replacement|Aortic valve or aortic root replacement with stented biological prosthesis or aortic allograft
223654173|NCT07210060|OTHER|hip + knee joint exercise group|Hip: squat, glute bridge and gluteus medius exercise Knee: knee flexor and extensor, isometric squat hold
224237896|NCT04888221|DRUG|Placebo|Placebo administered subcutaneously (SC) weekly during 24 weeks
223654174|NCT07210060|OTHER|ankle + knee joint exercise group|Knee: knee flexor and extensor, isometric squat hold Ankle: plantar flexor, dorsi flexor and lunge
223654175|NCT07210060|OTHER|Stretching group|Education Handout on Lower Limb Stretching
223654176|NCT07210684|DIETARY_SUPPLEMENT|Placebo 400 mg|Participants will receive 4 placebo capsules daily for 6 weeks. Each capsule contains 100 mg of microcrystalline cellulose, which serves as a inactive control substance.
223654177|NCT07210684|DIETARY_SUPPLEMENT|Dihydroberberine（DHB）400 mg|Participants will receive 4 capsules of DHB (Dihydroberberine) 100 mg each, orally, once daily for 6 weeks. The total daily dose is 400 mg of DHB.
223654178|NCT07209826|OTHER|Trios 5|Each patient's edentulous ridges are planned to be scanned three times with Trios 5.To ensure optimum accuracy, scans were performed in a standard dark environment in accordance with the manufacturer's scanning protocols.
223654179|NCT07209826|OTHER|iTero Lumina|Each patient's edentulous ridges are planned to be scanned three times with iTero Lumina.To ensure optimum accuracy, scans were performed in a standard dark environment in accordance with the manufacturer's scanning protocols.
223654180|NCT07209826|OTHER|Medit i700|Each patient's edentulous ridges are planned to be scanned three times with Medit i700.To ensure optimum accuracy, scans were performed in a standard dark environment in accordance with the manufacturer's scanning protocols.
223654181|NCT07209826|OTHER|E4 Lab Scanner|Conventional measurements will be taken from each patient, and the resulting master model (reference scan) will be scanned using an industrial scanner with high scanning accuracy (E4 lab scanner, 3shape, Denmark) to obtain digital data.
223654182|NCT07210281|DRUG|received an ossein-hydroxyapatite complex|Patients in the study group with fractures received an ossein-hydroxyapatite complex (830 mg of ossein-and-hydroxyapatite complex, with 444 mg of hydroxyapatite, equivalent to 178 mg of calcium and 82 mg of phosphorus) throughout the entire period following fracture healing. The tablets were taken orally, one tablet twice daily.
223654183|NCT07211217|OTHER|Time Restricted Eating|See arms description
223654184|NCT07210957|OTHER|Manual Therapy|"Myofascial Release:~Myofascial techniques will be implemented to masseter, temporalis, suboccipital, scalene, levator scapula and trapezius muscles. These techniques will be lasted for 90 seconds and using with a sliding motion between the origin and insertion of the muscles.~Trigger Point Therapy:~The ischemic compression approach will be implemented for 45-60 seconds to stretch the soft tissue over the trigger points of muscles. The emphasis will be on masseter, temporalis and scalene muscles~. The emphasis will be on the fascial chains of cranio-cervical and cranio-mandibular transition areas."
223654185|NCT07210957|OTHER|Sham manual therapy|The duration of each session will be lasted around 40-45 minutes (same as the therapy in the intervention group). The sham techniques will be implemented such as light contact by the therapist's hands, the impression of tissue manipulation, the touches with the effect of gravity and the performing non-therapeutic pressure to muscles. These sham techniques will not be implemented to the actual treatment points; however, they will be on the neck and jaw regions.
223654186|NCT07209410|DRUG|Brimonidine Tartrate Ophthalmic 0.025%|Lumify is an approved eye drop to minimize ocular hyperemia.
223654187|NCT07210983|DEVICE|Low-Intensity Pulsed Ultrasound|The LIPUS therapy protocol was administered by a trained nurse following standardized procedures. Starting on the third day post-enucleation, patients in the ultrasound group underwent LIPUS therapy using the OSTEOTRON IV device (Japan), set at a frequency of 1.5 MHz and an intensity of 30 mW/cm², with 20-minute sessions for 10 consecutive days (Fig. 1). Treatments were conducted in a temperature-controlled environment, with patients positioned supine. Prior to each session, the skin over the cyst site was cleansed and coated with ultrasound transmission gel (Hinuo, Qingdao, China).
223654188|NCT07211087|BEHAVIORAL|COMBEX|The intervention (COMBEX) is a combined approach to routine psychotherapy (including CBT and medication management) with additional ERIC strategies incorporated.
223654189|NCT07211087|BEHAVIORAL|COMB|COMB is a combined approach to routine psychotherapy (including CBT and medication management).
223654190|NCT07210450|DRUG|L-glutamine|Oral L-glutamine powder, administered at a dose of 0.1 g/kg/day for 60 days in adult patients with non-transfusion-dependent thalassemia (NTDT). The supplement is given in addition to each participant's standard care regimen (e.g., hydroxyurea or iron chelation therapy, as clinically indicated).
224237897|NCT00517647|DRUG|ATMX|Medication phase: After screening assessments are completed, the child will enter the medication phase of the study. The child will be started on atomoxetine at 0.5 mg/kg/day, with the dosage increased to a maximum dose of 1.8 mg/kg/day. The dose will be determined by how well the child responds to and tolerates the drug. The dose will be given twice a day to minimize side effects. After the optimum dose is determined, the child will be kept at this stable dose for 4 weeks.
224237898|NCT00433147|DRUG|Afegostat tartrate|
224237899|NCT01882647|DRUG|000-0551 Lotion|
224237900|NCT01882647|DRUG|Vehicle Lotion|
223654191|NCT07211243|DEVICE|PHMB-impregnated biocellulose wound dressing with additional polyethylene film on top, compression therapy, systemic antomicrobial therapy (optional)|Application of a wound dressing with additional polyethylene film on top and compression therapy. Optional usage of the systemic antimicrobial therapy.
223654192|NCT07211243|DEVICE|PHMB-impregnated biocellulose wound dressing without additional polyethylene film on top, compression therapy, systemic antomicrobial therapy (optional)|Application of a wound dressing without additional polyethylene film on top and compression therapy. Optional usage of the systemic antimicrobial therapy.
223654193|NCT07210892|OTHER|Measurement of needle insertion angles|Individualization of needle insertion angle depending on the skin to dural sac distance
223654194|NCT07210073|BEHAVIORAL|Video Education|Videos were created using deepfake technology, utilizing AI to replicate the voice of the patients' primary physician.
223654195|NCT07210073|OTHER|Control|Standard treatment
223680938|NCT05851326|DEVICE|Active Sonodyn|Sonodyn emits ultrasound, electrical and magnetic stimulation signals with a pre-defined, fixed set of parameters for each of the independently operated power sources.
223680939|NCT05851326|DEVICE|Sham|Non-functional Sonodyn device that cannot convey any energy signals to the device output, however, looks and behaves fully identical as the active Sonodyn device.
224237901|NCT01887262|DEVICE|BCM-guided fluid management|
223654196|NCT07209527|DEVICE|Truway Portable Ultrasound Device|Participants in the intervention group will use the Truway Portable Ultrasound Device, a FDA-regulated diagnostic tool, to perform non-invasive imaging for early detection of chronic conditions such as cardiovascular disease. The device will be used under supervised primary care protocols over a 6-month period, with training provided to care providers. Calibration and maintenance will be managed by Truway Health, Inc.
224237902|NCT01887262|PROCEDURE|Fluid management based on the clinical information alone|
223654197|NCT07209527|DEVICE|Truway Blood Glucose Monitor|Participants in the intervention group will utilize the Truway Blood Glucose Monitor, an FDA-regulated device, to measure blood glucose levels for early detection and management of diabetes. The device will be employed under supervised primary care protocols over 6 months, with follow-ups at 3 and 6 months to assess accuracy and clinical outcomes. Training and support will be provided by Truway Health, Inc.
223654198|NCT07209527|DRUG|Standard Oral Hypoglycemic Agent|Participants in the intervention group with diagnosed prediabetes or Type 2 Diabetes Mellitus may receive a standard oral hypoglycemic agent (e.g., metformin) as prescribed by their primary care provider, in conjunction with the Truway diagnostic devices. The drug will be administered according to FDA-approved guidelines over the 6-month study period, with dosages adjusted based on blood glucose monitoring results obtained from the Truway Blood Glucose Monitor. Follow-ups at 3 and 6 months will assess glycemic control and safety.
223654199|NCT07209553|DEVICE|Mobi|Mobi is a conversational AI coach that serves as an occupational health coach for employees. Through coaching conversations, Mobi gets to know each employee and help them set micro-goals to work towards their overall health goal/objective. Mobi suggests small, personalized activities for the micro-breaks that align with these goals. To ensure ease of use it is integrated into Slack and MS Teams.
223654200|NCT07210112|DRUG|Psilocybin 25 mg per os|Caps of psilocybin administered orally once (V3) under medical and psychologist supervision in group 1, 2, and 3 and in an open-label setting for group 4
223654201|NCT07210112|DRUG|Trazodone 5mg|Oral preparation of trazodone administered orally once (V3) with psilocybin in Group 2
223654202|NCT07210112|DRUG|Trazodone 30 mg|Oral preparation of trazodone administered orally once (V3) with psilocybin in Groups 3 \& 4
224237903|NCT05550519|OTHER|Entecavir (ETV)|ETV will continue throughout screening and will be stopped at baseline.
224237904|NCT05550519|OTHER|Tenofovir Disoproxil Fumarate (TDF)|TDF will continue throughout screening and will be stopped at baseline.
224237905|NCT05550519|OTHER|Tenofovir Alafenamide (TAF)|TAF will continue throughout screening and will be stopped at baseline.
224237906|NCT01609322|BEHAVIORAL|Activity, Balance, Learning, and Exposure|An in-home intervention that integrates exposure therapy with cognitive restructuring, exercise, and a home safety evaluation.
224237907|NCT01609322|BEHAVIORAL|Fall prevention education|In-home, individual sessions with a health educator regarding fall prevention
224237908|NCT02203448|DEVICE|Facet Wedge spinal system|
224237909|NCT06203522|PROCEDURE|Data collection of successful completion of MRI|age, sex, autistic disorders, epilepsy, polyhandicap, non-autistic neurodevelopmental disorders, success of MRI procedure
223654203|NCT07210112|DRUG|Placebo of psilocybin|Caps of psilocybin placebo will be administered at V3 in group 4
224237910|NCT02405325|BEHAVIORAL|Physical Activity|intervention activities will remain at the daily level, including using pedometers, having daily goals, attendance at Peer lead group walks and recognition of efforts through monthly celebrations and bi-weekly goal tracking with peer Health Coaches.
224237911|NCT05119439|DRUG|Mifepristone + 2 doses of misoprostol 800 mcg|Will use a mifepristone-misoprostol regimen of: 200 mg mifepristone followed in 24-48 hours by a first dose of 800 µg misoprostol buccally and then in another 4 hours by a second dose of 800 µg misoprostol buccally. For buccal administration of misoprostol, participants will place 2 misoprostol tablets in each cheek and hold them for 20-30 minutes, after which they will swallow any remnants.
224237912|NCT01027143|DIETARY_SUPPLEMENT|omega-3 polyunsaturated fatty acids|ProEPA Xtra 1000mg softgels: 3 softgels twice daily
224237913|NCT01027143|DRUG|Omega-3 Fatty Acid|Soybean oil: 3(age 12-25) matched softgel caps twice daily
223654204|NCT07210112|DRUG|Placebo of trazodone|A placebo of trazodone will be administered orally at V3 in group 1
223654205|NCT07209891|DEVICE|Kinesio Tape|Cotton elastic tape applied along the full length/width of the target hypertrophic scar with \~25-50% stretch while the scar is on gentle lengthening. Continuous wear; replaced every 2-3 days.
223654206|NCT07209891|DEVICE|Low-Level Laser Therapy (LLLT), 905-nm pulsed Ga-As|Fluence 16.2 J/cm² at skin; pulse frequency 3000 Hz; session duration \~15 min at standardized distance (\~10 cm) using an orange medical filter; protective eyewear for patient and staff.
223680940|NCT01676597|DRUG|pentoxifylline and rifaximin|Tab Rifaximin 400 mg thrice daily + Pentoxifylline 400 mg thrice daily for 12 weeks
223680941|NCT01676597|DRUG|Pentoxifylline and placebo|Tab Pentoxifylline 400 mg thrice daily + Placebo thrice daily for 12 weeks
224237914|NCT03730597|DEVICE|reverse shoulder arthroplasty|prosthesis implantation
224237915|NCT02493270|BEHAVIORAL|Smoking cessation therapy|Multidisciplinary smoking cessation therapy, performed by a team comprising physicians, nurses, a psychologist and dentists. It consisted of four 1-h counselling lectures, psychologist-assisted cognitive behavioural therapy, nicotine replacement therapy and medication (bupropion or varenicline). Smoking cessation motivation was reinforced by dentists at the maintenance sessions, by means of motivational interviewing techniques
224237916|NCT02493270|PROCEDURE|Non-surgical periodontal therapy|full-mouth supra and subgingival scaling and root planing (with curettes and ultrasonic scaler); oral hygiene instruction and motivation and removal of intra-oral plaque retentive factors
224237917|NCT06451445|DEVICE|Irreversible Electroporation (NanoKnife)|Irreversible Electroporation (IRE) using NanoKnife technology uses high voltage current pulses via probes placed around the prostate tumour via the perineum. The electricity damages the cell membranes rendering the cells dead. Hypothesized benefits of IRE over other focal therapy options include the ability to treat large or small lesions. Also, because the technology spares vessels, it can be used to treat prostate areas adjacent to sensitive structures (ie prostate apex near the sphincter and lateral peripheral zone near the neurovascular bundle). Finally, treatments take approximately 1-1.5 hours, thus the technology could be used to treat several patients per day.
224237918|NCT00038675|DRUG|Imatinib Mesylate (Gleevec)|Imatinib mesylate 400 mg orally daily, and in HES patients start with imatinib mesylate 100 mg orally daily
223654207|NCT07209891|OTHER|Standardized Scar Care (concomitant for all arms)|Uniform background care applied across all groups; recorded in CRFs; prohibited co-interventions (e.g., intralesional steroids, microneedling, ablative lasers, new pressure garments during the study).
223654208|NCT07210125|DRUG|Lenacapavir long-acting|Until recently, only oral formulations of PrEP were available. With the availability of long-acting PrEP injectables, new strategies will need to be developed to deliver this new treatment option. The availability of L4P offers an opportunity to expand PrEP access outside traditional healthcare settings. However, data on the feasibility and acceptability of L4P in community pharmacies is lacking. Community pharmacies are ideal for L4P due to their accessibility and the ability to utilize both pharmacy and medical billing for reimbursement of medication and clinical services, unlike traditional healthcare settings. Pharmacists are one of the most highly accessible healthcare professionals in the community. There are over 60,000 community pharmacies across the U.S. The study will evaluate implementation outcomes (feasibility, acceptability), real-world effectiveness, and whether L4P can be used for same day starts or treatment switches.
223654209|NCT07210125|OTHER|Standard of Care (SOC)|In aim 2, subjects enrolled in the L4P cohort will have the option of conducting STI testing every 6 months versus every 3 months. A retrospective matched cohort study will be conducted to assess the differences in retention and STI positivity rates between groups. All participants will be able to get tested in between monitoring visits.
223654215|NCT07210554|BIOLOGICAL|Stapokibart injection|subcutaneous injection
223654216|NCT07210554|DRUG|Placebo|subcutaneous injection
223654217|NCT07210658|DIETARY_SUPPLEMENT|Oral nutritional supplementation|As directed by the HCP
223654218|NCT07210502|RADIATION|4D Low Dose Rate Prostate Brachytherapy|Permanent implantation of radioactive seeds in the prostate gland which slowly deposit half their dose approximately every 60 days. Prescription dose 145 Gy.
223654219|NCT07210502|RADIATION|Ultra-hypofractionated Radiotherapy|The prescription dose is 36.25 Gy given in 5 fractions over 1-2 weeks (i.e. daily or alternate daily at department discretion) delivered on linear accelerator
223654220|NCT07209930|OTHER|Exercise|"After a 12h overnight fast, baseline measurements are collected. Participants are then provided with a standardized breakfast meal (60g carbohydrate). After consumption of the breakfast, participants remain seated seated for 30 minutes, before cycling on a cycle ergometer for 30 minutes at an intensity equivalent to 10% above the first ventilatory threshold (VT1). Sixty minutes of rest sitting on a chair will follow the 30-minute cycle.~During the total 120 minute test, various measurements are collected at regular intervals, including: blood glucose measurements via finger prick, CGM measurements, RPE, HR, measures of heart rate variability (HRV) (RMSSD (Root Mean Square of Successive Differences) and SDNN (Standard Deviation of NN intervals)), and intensity of any hypoglycaemia-related symptoms using a Visual Analogue Scale (VAS)."
223654221|NCT07209930|OTHER|Rest|The procedure for the resting condition visits is identical to that of the exercise condition, with the only difference being that the 30-minute cycling session will be replaced by an additional 30 minutes of seated rest. This will ensure that the total duration of the session and the timing of all measurements will remain consistent across conditions.
223654222|NCT07210164|DIETARY_SUPPLEMENT|Ocoxin|"Food Supplement based on Amino Acids, Plants, Vitamins and Minerals. Composition: Maltodextrin, L-Arginine, L-Cysteine, Microcrystalline cellulose, Talcum, Vitamin C (L-ascorbic acid), Zinc sulfate, Green Tea Extract (Camellia sinensis (L.) Kuntze), Manganese sulphate, Extracto de Canela (Cinnamomum verum J. Presl.), Vitamin B6 (pyridoxine hydrochloride).~Ocoxin utilizes Catalysis' Molecular Activation Technology (MAT) to enhance the biological activity of its natural antioxidant ingredients, such as green tea polyphenols (EGCG), to increase their antitumoral and immunomodulatory effects. This patented technology is applied to boost the efficacy of compounds within Ocoxin, such as EGCG, enabling them to exert more potent effects on cancer cells by inducing apoptosis, inhibiting tumor growth and metastasis, and supporting the body's immune response."
223654223|NCT07210164|PROCEDURE|Structured self-guided exercise|"The patient exercises in a structured manner with the help of a relevant interactive form/guide and simple aids (e.g. chair, step, water bottle, broomstick) by performing six categories of exercises: 1. Breathing exercises, 2. Pelvic floor exercises-pelvic mobility, 3. Upper trunk exercises, 4. Lower trunk exercises, 5. Aerobic exercises, 6. Stretching exercises, at a predetermined pace (number of repetitions) of each exercise and a limit of not exceeding the value 5-6 on the ten-point modified Borg fatigue scale. The intern records her activity on a form-exercise log. The recommendation is the maximum implementation of the exercise program but in any case not less than 3 times a week."
224237919|NCT03292653|DRUG|Sotagliflozin|Pharmaceutical form: Tablet; Route of administration: Oral
224237920|NCT03292653|DRUG|Placebo|Pharmaceutical form: Tablet; Route of administration: Oral
224237921|NCT04344847|PROCEDURE|Laparoscopic sleeve gastrectomy|Excision of Gastric GIST along fundus or body of stomach in the same specimen of LSG with safety margin 1-2cm
224237922|NCT06327022|OTHER|Social media-based electronic bibliotherapy|Eight weekly sessions of bibliotherapy are delivered via their daily social media.
224237923|NCT06327022|OTHER|Usual care|The routine services provided by community centers
224237924|NCT06157710|BEHAVIORAL|Digital intervention through modules|"* Introduction~* Goal Setting Techniques~* Motivation~* Barriers to Action~* Managing Maladaptive Thoughts and Beliefs~* Value Clarification~* Moving Forward"
223654224|NCT07210008|DRUG|Prednisolone|"Active Comparator: prednisolone. Oral prednisolone will be administered and tapered over 6 months, according to the following schedule\*:~0.5 mg/kg/day (not exceeding 40mg/day) x 4 weeks, 0.25 mg/kg/day (not exceeding 20mg/day) x 4 weeks, 15 mg/day x 4 weeks, 10 mg/days x 4 weeks, 5 mg/day x 10 weeks"
223654225|NCT07210008|DRUG|Placebo|Dispersible placebo administered and tapered over 6 months according to the schedule detailed in the protocol
223654226|NCT07210593|BEHAVIORAL|FAMS|"PWD participants will receive FAMS components (monthly phone coaching and text message support for goals and medication adherence) for 3 months. PWD participants will receive high-quality print materials upon enrollment.~Co-enrolled SP participants will receive high-quality print materials upon enrollment and receive text message support tailored to the goal set by the linked PWD."
223654227|NCT07210593|BEHAVIORAL|PEER|PWD participants will receive PEER components (monthly phone coaching and text message support for goals and medication adherence) for 3 months. PWD participants will receive high-quality print materials upon enrollment PWD participants assigned to PEER will be matched with another PWD participant assigned to peer to provide peer support to each other.
223654228|NCT07211126|DEVICE|t:slim X2 insulin pump with Control-IQ technology (Control-IQ System)|Participants enrolled in the study will start use of the t:slim X2 insulin pump with Control-IQ technology (Control-IQ System) with Dexcom G6 or Dexcom G7, and be followed for 12 months.
223767790|NCT07173673|DEVICE|AI-ECG Guided Care (SmartECG-AFrisk)|Participants undergo SmartECG-AFrisk analysis of baseline 12-lead ECGs recorded in sinus rhythm. The algorithm calculates an atrial fibrillation risk score, classifying participants as high-risk (score ≥50) or low-risk (\<50). Monitoring strategies are adapted accordingly: high-risk participants undergo targeted and potentially repeated ECG monitoring using 12-lead ECG, Holter, or patch ECG, while low-risk participants follow standard guideline-based care.
223767791|NCT07173478|DRUG|OPA-15406|1% foam, topical, twice daily, for 4 weeks
223767792|NCT07173478|DRUG|Vehicle|vehicle, topical, twice daily, for 4 weeks
224237925|NCT05989438|OTHER|Orientations for families|"Guidance for parents will follow the guide/manual prepared by the researchers, in addition to verbal and video guidance. Once a week a reminder will be sent, and once a month researchers will contact you by phone for guidance.~There will be 3 evaluations with an interval of 4 months. (4 months; 8 months; 12 months) and more one avaliation with an interval of 12 months at 24 months."
224237926|NCT05989438|OTHER|Professional stimulation more orientations for families.|"Each session will last approximately 50 minutes, where the stimuli will be performed in: supine position; Ventral Decubitus; Seated; Four supports, kneeling/semi-kneeling and standing.~If the child no longer uses the posture or it is not an acquisition for the age group in which the baby is, the time will be distributed in order to contemplate the expected acquisitions for the age group in which the baby is. The stimuli will be performed based on the neuropsychomotor development, in order of progression and according to the corrected age of the baby.~The frequency of consultations may vary due to the different degrees of prematurity, and the stipulated initial frequency will vary between 1-8 times a month.~The orientations will also be provided to family members during consultations, and families will also perform stimuli at home according to written, verbal and video guidance.~There will be 3 evaluations with an interval of 4 months. (4 months; 8 months; 12 months)."
224237927|NCT02146261|DRUG|E6011|Subcutaneous administration of E6011 (at doses of 50, 100, 200 and 400 mg)
224237928|NCT02146261|DRUG|Placebo|Subcutaneous administration of placebo
223654229|NCT07210528|DRUG|Emtricitabine (FTC)|"Capsule, 200mg FTC. White Opaque Body / Light Blue Opaque Cap with GILEAD and Gilead logo on body. 200 mg on cap printed in black."
223654230|NCT07210528|DRUG|Descovy® (TAF/FTC)|Emtricitabine (FTC) 200 mg / Tenofovir Alafenamide (TAF) 25 mg. Tablets, Rectangular-Shaped, Debossed, Film-coated blue.
224237929|NCT04507711|DRUG|0 ul of palonosetron|Venous blood is taken from 11 healthy volunteers and divided into four specimen bottles, which were added with different doses (0 ul) using palonosetron
223654231|NCT07210528|DRUG|Placebo to Match Emtricitabine 200mg/Tenofovir Alafenamide 25 mg.|Placebo to Match Emtricitabine 200mg/Tenofovir Alafenamide 25mg. Tablets, Rectangular-Shaped, Debossed, Film-Coated Blue.
223654232|NCT07210528|DRUG|Placebo Capsules to Match Emtricitabine Capsules, 200mg.|"White Opaque Body/Light Blue Opaque Cap with GILEAD and Gilead logo on body, 200 mg on cap printed in black."
223654233|NCT07210021|DEVICE|AK+ Guard™ ECG Application|An investigational Software as a Medical Device (SaMD) that analyzes Lead I electrocardiogram (ECG) data using artificial intelligence to detect moderate to severe hyperkalemia (serum potassium ≥ 6.5 mmol/L). ECG inputs may be obtained from standard 12-lead ECGs, clinical-grade ECG devices with Lead I capability, or consumer wearable devices (e.g., Apple Watch, HeartBeam).
223767793|NCT07172295|PROCEDURE|Accelerated NaviFUS-ctbFUS stimulation|"Three consecutive sessions of NaviFUS-ctbTUS stimulation were performed, with a 5-minute interval between each session.~The acoustic pressure was set such that the estimated intracranial pressure at 30% skull transmission was approximately 0.5 MPa.~The stimulation target was the center of the Vop, with a total of 7 stimulation points."
223767794|NCT07173296|OTHER|Opalescence XTra Boost 40% HP|In-office tooth bleaching material
223767795|NCT07173296|OTHER|Pola Office Plus 37.5% HP|In-office tooth bleaching material
223767796|NCT07171944|BEHAVIORAL|Structured orientation program|Artificial intelligence technology will be incorporated into the orientation training program developed for patients in the intensive care unit who are assigned to the intervention group. The program will be administered twice daily over a three-day period. In this group, delirium-free days will be tracked, changes in anxiety and depression levels will be evaluated, and the length of intensive care unit stay among patients who remain free of delirium through this intervention will be examined.
223767797|NCT07171944|BEHAVIORAL|Human Nurse|Researchers will administer a structured orientation training program lasting approximately 10 minutes face-to-face to participants in the control group. This training program will be administered twice daily for 3 days. Following the training program, delirium-free days, anxiety and depression scores, and length of stay in the intensive care unit will be evaluated.
223767798|NCT07172477|DEVICE|Pivot Extend|"The investigational Pivot Extend device will be inserted through a small incision in the femoral vein and guided to the heart using a catheter. The Pivot Extend device is designed to sit in the space where the valve isn't closing, helping the flaps of the valve to close tightly and reducing the amount of blood leaking back through the valve."
224237930|NCT04507711|DRUG|1 ul of palonosetron|Venous blood is taken from 11 healthy volunteers and divided into four specimen bottles, which were added with different doses (1 ul) using palonosetron
223654234|NCT07211009|OTHER|Patient-Reported Outcome (PRO)-Based Symptom Management|Postoperative esophageal cancer patients will receive a PRO (patient-reported outcome) symptom self-report system via a WeChat mini-program/electronic form. The system covers 12 target symptoms-pain, fever, cough with sputum, dyspnea, palpitations, fatigue and activity limitation, nausea/vomiting, acid reflux/heartburn, abdominal bloating, diarrhea, swallowing obstruction (dysphagia), and hoarseness with coughing when drinking-and uses a five-level severity scale: 0 (none), 1 (mild), 2 (moderate), 3 (severe), and 4 (very severe). If any of the 12 symptom scores entered in the mini-program reaches the predefined intervention threshold (≥2, indicating moderate to very severe), the system sends a real-time alert to the surgeon, who is required to respond within a specified time window. After discharge, interventions are delivered via WeChat, text message, or telephone. Interventions mainly include counseling, patient education, prescription medication.
223654235|NCT07211009|OTHER|Conventional Management|Patients in the control arm receive conventional postoperative symptom management. The electronic questionnaires use the same content and time points as the intervention arm, but reported symptoms do not trigger alerts, and surgeons cannot view the symptom scores. During the postoperative inpatient stay, surgeons typically assess symptom severity based on patient reports during morning and afternoon rounds and manage symptoms according to the same guidelines and consensus as the intervention arm. After discharge, patients do not receive proactive symptom management from their primary surgeon unless they actively seek medical care.
223654236|NCT07210814|PROCEDURE|saliva and plaque sample collection for analysis|"For collection of plaque two different gingival sites are selected for sampling in each participant. Prior to sampling, supragingival plaque is removed with a sterile instrument. Subgingival plaque is then collected from the same site using a sterile Gracey curette.~Saliva samples are collected using a commercially available saliva collection kit (Sallivete®, SARSTEDT AG, Germany). Participants should open the Sallivete® tube, remove the synthetic swab, and place it in their mouth for 1-2 minutes, ensuring it moves around to facilitate optimal saliva collection while avoiding chewing."
223654237|NCT07210814|OTHER|using commercial mouthwash|Participants use the commercial mouthwash octenident (cosmetic) twice daily after their normal dental routine for 30 seconds for consecutive seven days
223767799|NCT07173816|BEHAVIORAL|EMPOWER|EMPOWER, a group-based 6 sessions telehealth behavioral intervention, will comprise sexual health goals and values elicitation, sexual health plan development, and motivational enhancement skills will be used to promote effective HIV prevention decision-making within the relationship context, incorporating the sexual values of each participant. This will allow each participant to develop a personalized, tailored sexual health plan that includes PrEP deliberation to enhance PrEP decision-making, uptake and persistence within a culturally congruent and empowering program that aims to reduce stigma around HIV and barriers to access.
224237931|NCT04507711|DRUG|10 ul of palonosetron|Venous blood is taken from 11 healthy volunteers and divided into four specimen bottles, which were added with different doses (10 ul) using palonosetron
223767800|NCT07172724|BIOLOGICAL|Vivaxin vaccine manufactured by CT Vacinas/Cristália Laboratory|lyophilized antigen for reconstitution with the adjuvant CTVad (a squalene-based nanoemulsion), at the time of use.
224237932|NCT04507711|DRUG|100 ul of palonosetron|Venous blood is taken from 11 healthy volunteers and divided into four specimen bottles, which were added with different doses (100 ul) using palonosetron
224237933|NCT06485869|OTHER|Measure the improvement in quality of life|Improvment of quality of life is measured by the QLQ-C30 quality of life questionnaire
224237934|NCT06485869|OTHER|Measure the level of satisfaction of patients and nursing staff|Patient satisfaction is measured using a five-point scale ranging from 1 = strongly disagree to 5 = strongly agree. Higher scores indicate higher levels of satisfaction.
224237935|NCT06485869|OTHER|Measurement of anxiety and pain|Anxiety and pain is measured by Visual Analogue Scale (VAS). This measurement is complemented by physiological responses to anxiety, measured by heart rate and mean arterial blood pressure (HR and BP)
224320876|NCT05832177|BEHAVIORAL|Research Corner|The goal is to provide bidirectional communication between the community and researchers to increase CE strategies into cancer disparities research through periodic meetings between community members and researchers to discuss CE strategies, research recruitment strategies, dissemination strategies, among others.
224237936|NCT06485869|OTHER|Measurement of depressive state|Depressive State is measured by HAD score
224237937|NCT06485869|OTHER|measuring fatigue levels|Fatigue levels is measured by Visual Analogue Scale (VAS).
224237938|NCT06485869|OTHER|measurement of acute nausea and vomiting|acute nausea and vomiting is measured by MASCC Antiemesis Tool (MAT)
224237939|NCT00679640|DRUG|Candesartan|Oral tablets
224237940|NCT05942612|DRUG|SHR-2001|Subcutaneous injection, single dose or multiple doses.
224237941|NCT05942612|DRUG|Placebo|Subcutaneous injection, single dose or multiple doses.
224237942|NCT04272632|DRUG|4 ml/kg group|4 ml/kg compound sodium chloride (0.85% NaCl, 0.03% KCl, and 0.033% CaCl2) was given immediately after spinal anesthesia.
224237943|NCT04272632|DRUG|8 ml/kg group|8 ml/kg compound sodium chloride (0.85% NaCl, 0.03% KCl, and 0.033% CaCl2) was given immediately after spinal anesthesia.
224237944|NCT04272632|DRUG|12 ml/kg group|12 ml/kg compound sodium chloride (0.85% NaCl, 0.03% KCl, and 0.033% CaCl2) was given immediately after spinal anesthesia.
224237945|NCT05317052|BEHAVIORAL|Massage group|Massage and music therapy
224237946|NCT05673642|OTHER|Myofascial Release Techniques|Myofascial Release Technique (MFR), which we will apply to the muscles we choose related to the facial system connection
224237947|NCT01382433|PROCEDURE|Magnetoencephalograph (MEG)|Brain imaging device that records the magnetic fields in the brain.
224237948|NCT01382433|BEHAVIORAL|Cambridge Neuropsychological Test Automated Battery (CANTAB).|the CANTAB is sensitive to cognitive changes caused by a wide range of Central Nervous System disorders and medication side-effects . The CANTAB uses a computer with a touch screen, and affords a rapid and non-invasive assessment of cognitive functions.
223767801|NCT07172724|OTHER|Placebo|adjuvant CTVad (a squalene-based nanoemulsion)
224237949|NCT01382433|BEHAVIORAL|Experimental: Scale for the Assessment of Negative Symptoms (SANS) and the Positive and Negative Syndrome Scale (PANSS)|The SANS and PANSS scales asses the presence and severity of Positive and Negative of Schizophrenia
224237950|NCT05863949|DIETARY_SUPPLEMENT|vitamin D +/- calcium|vitamin D 1000iU daily +/- calcium 500mg BID daily
224237951|NCT05863949|OTHER|Placebo|placebo pill x3 daily
224237952|NCT03129919|DEVICE|Carriere SLX® (Passive self-ligating braces)|Changes in the inclination of the incisors, expansion of the arches at the end of the alignment and leveling phase of the orthodontic treatment
224237953|NCT03129919|DEVICE|Empower® (Interactive self-ligating braces)|Changes in the inclination of the incisors, expansion of the arches at the end of the alignment and leveling phase of the orthodontic treatment
224237954|NCT00248638|DRUG|Glutamine dipeptide with 15% Clinisol|Subjects randomized to AG-PN will receive PN containing 0.5 g/kg/day of L alanyl L GLN (AG) dipeptide (Dipeptiven 20%; Fresenius-Kabi) and 1.0 g/kg/day of 15% Clinisol (Baxter Inc., Deerfield, IL) AA solution (total = 1.5 g/kg/day, with AG replacing 1/3 of Clinisol AA). The amount of GLN dipeptide administered each day will be determined by daily PN volume intake data.
224237955|NCT00248638|DRUG|15% Clinisol|Subjects randomized to STD-PN will receive 1.5 g/kg/day of 15% Clinisol. The amount of Clinisol administered each day will be determined by daily PN volume intake data.
224237956|NCT05037123|DRUG|Continuous ketamine infusion|Continuous ketamine infusion (0.35 mg/kg after induction, followed by 0.25 mg/kg/hr until 2 hours after surgery) plus saline IV dose in post-anesthesia care unit
223654238|NCT07209566|DIAGNOSTIC_TEST|Visceral Pain Stimulus|Participants will receive a visceral pain stimulus while being monitored for heart rate variability (HRV), and will have hip mobility and dorsiflexor strength assessed before and after.
223654239|NCT07209696|BEHAVIORAL|Tell-Show-Do|The conventional behavior guidance technique in pediatric dentistry, where the dentist explains and demonstrates dental procedures before performing them.
224237957|NCT05037123|DRUG|Ketamine + Saline|Saline dose and infusion intraoperatively, then single-dose IV ketamine (0.60 mg/kg) in post-anesthesia care unit plus 2 hours of saline administration after surgery
224237958|NCT05037123|OTHER|Placebo|Placebo, Saline dose and infusion intraoperatively, then saline IV dose in post-anesthesia care unit plus 2 hours of saline administration after surgery
224237959|NCT00663559|DRUG|Sunitinib|Sunitinib 50mg oral in the morning during 4 weeks with 2 weeks of break.
224237960|NCT05084742|DEVICE|Biodentine™|"Biodentine™ is a bioactive dentin substitute from the  Active Biosilicate Technology®  innovation.~Study participants were treated from 1 year to 5,5 years ago through an endodontic microsurgery using Biodentine™ used in its endodontic indications, i.e., root end-filling, external or internal root resorption repair, root and furcation perforation repair, apexification, and revitalization procedure by means of revascularization."
224237961|NCT03928782|RADIATION|5 Gy or 10 Gy units of whole-body radiation|8 subjects will be received 5 Gy units of whole-body radiation or 10 Gy units of whole-body radiation.
224237962|NCT05118906|DRUG|BP1.4979 active drug|2 tablets 15 mg of BP1.4979 per day
224237963|NCT05118906|DRUG|Placebo|2 tablets of placebo per day
224237964|NCT05426720|OTHER|no intervention|no intervention; This study is a observational study. All patients received routine anti-tuberculosis regimen. Researchers will observe the clinical manifestation, pulmonary function and pulmonary CT manifestation within a few years after the cure of tuberculosis.
224237965|NCT01578174|DRUG|Dexmedetomidine|Dexmedetomidine(Dexmedetomidine 2 mL and normal saline 98 mL mixed -\> 2㎍/mL) : the infusion of 0.2㎍/kg/hr is started at 30 minutes before the procedure and the infusion dose is raised to 0.4㎍/kg/hr after completion of procedure
224237966|NCT01578174|DRUG|Normal saline 0.9%|Normal saline 100mL(guess as 2㎍/mL):the infusion of 0.2㎍/kg/hr is started at 30 minutes before the procedure and the infusion dose is raised to 0.4㎍/kg/hr after completion of procedure
224237967|NCT04055363|OTHER|HMO-supplemented infant formula|Starter Infant Formula supplemented with 1.5g/L of Human Milk Oligosaccharides
224237968|NCT01367275|DRUG|Brivanib|800 mg (4 x 200 mg tablets) self-administered orally at approximate same time each day on a continuous daily schedule Days 1-14 of 14 day cycle.
223654240|NCT07209696|BEHAVIORAL|Storybook Preparation|Home-based preparation using a child-friendly storybook that introduces the dental visit, instruments, and procedures in simple language and illustrations.
223654241|NCT07209696|BEHAVIORAL|Animation Video Preparation|The conventional behavior guidance method where the dentist explains and demonstrates dental procedures before performing them, to reduce anxiety and improve cooperation.
223680942|NCT05373940|DEVICE|ICD implantation|"This group will undergo an ICD implantation (type and manufacturer at the discretion of the local investigator) in addition to heart failure medical therapy optimization.~Patients of the HFOT+ICD group will be scheduled for ICD implantation."
223680943|NCT05373940|DEVICE|No ICD implantation|"Patients of the HFOT alone group will not undergo ICD implantation (except if they develop sustained ventricular arrhythmias and fulfil for secondary prevention ICD implantation), and continue with medical therapy optimization only."
223680944|NCT04111939|OTHER|Communities That HEAL|The Communities That HEAL (CTH) intervention is a community-engaged intervention designed to increase the adoption of an integrated set of evidence-based practices delivered across healthcare, behavioral health, justice, and other community-based settings. It includes 3 components: community engagement to assist key stakeholders in applying evidence-based practices to addressing their opioid crisis, a menu of evidence-based practices for communities to select and implement, and a communications campaign to build demand for evidence-based practices to address overdose and opioid use disorder.
223680945|NCT04111939|OTHER|Wait-list control|Communities in the wait-list control condition will continue usual care during the first 30 months of the trial. At month 31, Wave 2 communities will begin receiving the CTH intervention.
223680946|NCT04656275|DRUG|BI 1323495|BI 1323495
223680947|NCT04656275|DRUG|Placebo|Placebo
223680948|NCT00811889|OTHER|Placebo|Placebo
223680949|NCT00811889|DRUG|Bardoxolone Methyl (RTA 402)|Oral, Once Daily
223680950|NCT00528554|PROCEDURE|laser acupuncture|laser acupuncture according to traditional chinese medicine criteria, energy dosage 1J/point, average of 8 points to be treated, once daily during chemotherapy course
224237969|NCT01367275|DRUG|Irinotecan|180 mg/m\^2 by vein on Day 1 of a 14 day cycle.
224237970|NCT00750659|DRUG|Nilotinib|Nilotinib 400 mg po/BID until transplant. Nilotinib 200-400 mg po/BID post transplant in escalated doses.
224237971|NCT06376032|DEVICE|EndeavorOTC®|EndeavorOTC is an over the counter digital therapeutic designed to improve attention function as measured by computer-based testing in patients 18 and older with primarily inattentive or combined type ADHD, who have a demonstrated attention issue. EndeavorOTC utilizes the same proprietary technology underlying EndeavorRx®, an FDA-authorized prescription digital therapeutic indicated to improve attention function in children ages 8-17. EndeavorOTC is deployed on mobile devices and incorporates adaptive, simultaneous cognitive tasks in a consumer-grade action videogame-based platform with high-quality graphics and reward mechanisms.
224237972|NCT04438356|COMBINATION_PRODUCT|M-Health|The study was randomized (wait-list-control), and it was estimated that 80 subjects were randomly assigned to the immediate treatment group and the wait-list-control group. The two groups were tested for baseline before intervention in the mHealth. After the first questionnaire evaluation, the experimental group was involved in the mHealth for three months, and after three months, the experimental group and the waiting intervention control group were post-tested. To assess the effectiveness of the two groups before and after the mHealth . Control group that waits for intervention in the fourth month from the beginning of the fourth month to the end of the sixth month.
224237973|NCT00449878|DRUG|Liprotamase|Administered orally
224237974|NCT00449878|DRUG|Placebo|Administered orally
224237975|NCT01751347|DRUG|Bupivacaine|Local anesthetics
224237976|NCT01751347|DRUG|Lidocaine|Local anesthetics
224237977|NCT03631524|DEVICE|Telerehabilitation|The treatment arm will be given up to 1 hour of physiotherapist-prescribed resistive training exercises administered via a telerehabilitation device per day in addition to standard therapy for a total of 10 sessions over a 2 week period.
224237978|NCT05346055|BEHAVIORAL|Engage Prism (2.0)|Brief Behavioral Treatment for Depression (Engage) combined with tablet-based social support system (Prism 2.0)
224237979|NCT05262621|OTHER|progressive muscle relaxation|Practice muscle relaxation for 20 minutes once/a day
224237980|NCT05262621|OTHER|Listening to relaxing music once/day|Right after practising progressive muscle relaxation, the participants will listen to relaxing music for 20 minutes
224237981|NCT03403764|OTHER|Wellness Intention|
224237982|NCT01059500|DEVICE|Webtool|Webtool provides the numeric PTP estimate for ACS and PE, and one of three testing recommendations. For ACS, PTP \<2.5% with low clinical suspicion and available follow-up, no further testing; PTP 2.5 to 5.5%: obtain a troponin I measurement at presentation and 120 minutes later, and if both are normal, no further testing; PTP \>5.5%: proceed to provocative testing. For PE, PTP\<2.5% with low clinical suspicion and available follow-up, no further testing; PTP 2.5-10%, obtain a quantitative D-dimer and if normal, no further testing. PTP 10-20%, proceed directly to pulmonary vascular imaging, and if PTP\>20% consider empiric anticoagulation with heparin if no contraindications.
224237983|NCT05671484|OTHER|Transversalis Fascial Plane Block|Patients will receive ultrasound-guided transversalis fascial plane block with 0,3 ml/kg of bupivacaine 0.25% just after general anesthesia induction
224237984|NCT05671484|OTHER|Quadratus Lumborum Plane Block|Patients will receive ultrasound-guided quadratus lumborum plane block with 0,3 ml/kg of bupivacaine 0.25% just after general anesthesia induction
223654244|NCT07209332|DRUG|WVE-N531|WVE-N531 is an antisense oligonucleotide (ASO)
223654245|NCT07209423|OTHER|Strength and Range of Motion|Shoulder external rotation and internal rotation strength will be measured with a dynamometer at the end range, as well as at retroverted shoulder neutral and zero degrees for three times. Grip strength will also be measured three times using the dynamometer after the shoulder strength assessments.
223654246|NCT07209605|PROCEDURE|Group A Pull-out Suture Technique|A Brunner volar incision will be made, and the volar plate avulsion fragment will be identified. A 2-0 nonabsorbable braided suture will be passed through the volar plate using Kessler pattern, and Keith needles will be used to exit the sutures dorsally . .
223654247|NCT07209605|PROCEDURE|Group B- Mini-anchor Technique|Using the same volar approach, the volar plate will be reattached with two Mitek Micro QuickAnchors (1.3 x 3.7 mm), placed at the distal phalanx. Anchors will be inserted under fluoroscopic guidance to avoid dorsal cortex penetration. A hemimodified Kessler stitch pattern will be used with 3-0 polyester sutures.
223654248|NCT07210723|DRUG|danicamtiv|Danicamtiv will be administrated twice daily for up to 26 weeks
223654249|NCT07210723|DRUG|Placebo|Placebo will be administrated twice daily for up to 26 weeks
223654250|NCT07210424|PROCEDURE|Mesh Fixation|Mesh fixation during Lichtenstein inguinal hernia repair.
223654251|NCT07209787|DEVICE|SIS-reinforced anastomosis|This intervention uses a porcine small intestinal submucosa (SIS) reinforcement patch during rectal anastomosis. The sterile, biologic, acellular mesh is mounted onto the stapler anvil and cartridge. When fired, it encircles and externally reinforces the staple line. This provides immediate mechanical support and promotes healing by serving as a scaffold for tissue integration. It is a single-use, resorbable material intended to reduce anastomotic leakage by improving seal integrity, distinguishing it from standard unreinforced stapling or other synthetic/biologic grafts.
223654252|NCT07210775|DRUG|Imiquimod (topical use)|Participants will be prescribed imiquimod 5% cream, with instructions to apply the cream with soft tray or gauze daily for one hour, five days a week (Monday to Friday). 6 week as one course and additional course may be added based on participant's conditions and consent. 2 follow up biopsies are scheduled 6 months and 12 months after the start of the treatment course.
224237985|NCT05848986|OTHER|Flow cytometry|Analysis of blood samples from a health sample's allergic patients and analysis with flow cytometry
224237986|NCT02745977|OTHER|Dairy Free Diet|Dairy Free Diet x 3 stool guaiacs. If positive, dairy is reintroduced to diet.
224237987|NCT03820921|DIAGNOSTIC_TEST|EUS-FNB|"EUS WITH EUS-FNB will be performed for confirmation of diagnosis and analysis of MMR status and PD-L1 expression~Protocol of EUS with EUS-FNB should include linear EUS instruments with complete examinations of the pancreas. Tumor characteristics (echogenicity, echostructure, size) will be described as well as presence/absence of power Doppler signals.~EUS-FNB will be performed in all pancreatic masses with at least three passes in the absence of an onsite cytopathologist using a fanning technique with a 22-gauge needle (SharkCore FNB needle Medtronic Corp. or Acquire FNB needle Boston, MA)."
224237988|NCT03820921|OTHER|Immunohistochemistry|IHC will be performed on treatment-naïve formalin-fixed paraffin-embedded EUS-FNB pancreatic specimens. Briefly, 4-μm-thick tissue sections will be stained using the Ventana BenchMark XT automated slide-staining system using the following antibodies: Anti-PD-L1 (clone SP263, VENTANA, Tucson, AZ), MLH1 (clone G168-728, Cell Marque, Rocklin, California, United States), MSH2 (clone FE11, Biocare Medical, Concord, Massachusetts, United States), MSH6 (clone BC/44, Biocare Medical, Concord, Massachusetts, United States), and PMS2 (clone A16-4, Biocare Medical, Concord, M Massachusetts, United States). Antigen-antibody reactions will be visualized using UltraView detection with diaminobenzidine as the chromogen. The specimen will be considered to have PD-L1 expression if PD-L1 is expressed in ≥ 1 % of tumor cells and a high level of expression if ≥ 50 %. Tumors will be classified as dMMR if they exhibit absent nuclear staining of DNA mismatch repair proteins (MLH1, MSH2, MSH6, or PMS2).
224237989|NCT03882320|PROCEDURE|Patient Controlled Analgesia (PCA)|Patient Controlled Analgesia (PCA)
224237990|NCT03399526|DRUG|Mapracorat (ZK 245186, BAY 86-5319)|0.1% (1 mg/g) of the active ingredient mapracorat plus excipients as ointment
224237991|NCT03399526|DRUG|Prednicarbate 0.25% ointment|0.25% (2.5 mg/g) of the active ingredient prednicarbate as ointment
224237992|NCT03399526|DRUG|Clobetasol 0.05% ointment|0.05% (0.5 mg/g) of the active ingredient clobetasol as ointment
224237993|NCT03399526|DRUG|Calcipotriene 0.005% ointment|0.005% (0.05 mg/g) of the active ingredient calcipotriene as ointment
224237994|NCT03399526|DRUG|Calcipotriene 0.005%/Betamethasone dipropionate 0.05% ointment|0.005% (0.05 mg/g) of the active ingredient calcipotriene/0.05% (0.5 mg/g) of the active ingredient betamethasone dipropionate as ointment
223654253|NCT07209878|DRUG|68Ga-PSMA-11|Intravenous injection of 68Ga-PSMA-11 with a dosage of 111-148 MBq (3-4 mCi), followed by PET/CT or PET/MRI acquisition according to standard methods.
224237995|NCT03413631|BEHAVIORAL|Prenatal mentalization intervention|
224237996|NCT03413631|OTHER|Prenatal obstetric treatment as usual|
224237997|NCT04760067|OTHER|Sports Injury Anxiety Scale|Sports Injury Anxiety Scale
224237998|NCT02564263|BIOLOGICAL|pembrolizumab|200 mg administered as IV infusion on Day 1 of every 21-day cycle
224237999|NCT02564263|DRUG|paclitaxel|80-100 mg/m\^2 administered as IV infusion on Days 1, 8, and 15 of each 28-day cycle
224238000|NCT02564263|DRUG|docetaxel|75 mg/m\^2 administered as IV infusion on Day 1 of every 21-day cycle
224238001|NCT02564263|DRUG|irinotecan|180 mg/m\^2 administered as IV infusion on Day 1 of every 14-day cycle
224238002|NCT03311646|OTHER|Normal nicotine content cigarettes (NNC, Baseline)|Participants will exclusively smoke research cigarettes that have a normal nicotine content for five days/four nights while staying in a hotel.
224238003|NCT03311646|OTHER|Very low nicotine content (VLNC)|Participants will exclusively smoke research cigarettes that have a very low nicotine content for five days/four nights while staying in a hotel.
223654254|NCT07210931|BEHAVIORAL|Self-managed exercise in a fitness center|The participants are offered a 6-month membership of a local fitness club at no cost (paid by the trial). They will receive an introduction to the fitness centre and receive instructions from a personal trainer in the centre to create a personalized exercise programme
223654255|NCT07210931|BEHAVIORAL|Supervised Exercise|The particiopants are offered participation in the usual care exercise delivered at municipal rehabilitation centers or private physiotherapy clinics, aat the discretion of the referring doctor.
223654256|NCT00460512|DRUG|Paliperidone ER|Paliperidone ER tablet in dose range of 3 to12 milligram (mg) per day was given orally for 6 months as per Investigator's discretion to participants who transitioned to Paliperidone ER from other oral antipsychotics due to lack of efficacy, lack of tolerability, lack of compliance or other reasons.
223654257|NCT02685267|DRUG|Docetaxel|
224238004|NCT00000949|DRUG|Aldesleukin|
224238005|NCT04638166|OTHER|Mineral water|Drinking mineral water for 12 weeks
224238006|NCT04638166|OTHER|Plain water|Drinking plain water for 12 weeks
224238007|NCT00676871|DRUG|MEDI-538|Dose one of MEDI 538 as a continuous IV infusion - dose level is 5 mg/m2/24h (Phase 1)
224238008|NCT00676871|DRUG|MEDI-538|Dose two of MEDI 538 as a continuous IV infusion - dose level is 10 mg/m2/24h (Phase 1)
224238009|NCT00676871|DRUG|MEDI-538|Dose three of MEDI 538 as a continuous IV infusion-dose level is 15mg/m2/24h (Phase 1)
223654258|NCT02685267|DRUG|Enzalutamide|
224238010|NCT00676871|DRUG|MEDI-538|Dose four of MEDI 538 as a continuous IV infusion - dose level is 30 mg/m2/24h(Phase 1)
224238011|NCT00676871|DRUG|MEDI-538|Dose five of MEDI 538 as a continuous IV infusion - dose level is 45 mg/m2/24h (Phase 1)
224238012|NCT00676871|DRUG|MEDI-538|Dose six of MEDI 538 as a continuous IV infusion - dose level is 60 mg/m2/24h (Phase 1)
224238013|NCT00676871|DRUG|MEDI-538|Phase 2 part of the study, 20 to 60 patients will be treated with MEDI 538 as a continuous IV infusion through a central line catheter. The dose of MEDI-538 will be determined in the Phase 1 part of the study.
224320877|NCT05832177|BEHAVIORAL|Community-based Training Program (CBTP) for Community Leaders and Stakeholders.|The CBTP provides the opportunity to acquire knowledge to impart cancer prevention education (Cancer 101) and skills necessary to disseminate educational information (hands-on experiences through OC educational activities). This training will be provided in-person and remotely to increase participation. This activity will begin according to the project timeline.
223654259|NCT02685267|DRUG|Prednisone|
223680951|NCT00528554|PROCEDURE|placebo laser acupuncture|laser acupuncture according to traditional chinese medicine criteria, average of 8 points to be treated, once daily during chemotherapy course
223654260|NCT05203900|DIETARY_SUPPLEMENT|Infant formula with Human Milk Oligosaccharide|Although breastfeeding is encouraged, the shortage is supplemented with the investigational formula. After obtaining the informed consent, the investigational formula is administered to infants under the doctor's direction until a medical check-up at one-month-old.
223654261|NCT05203900|DIETARY_SUPPLEMENT|Infant formula without Human Milk Oligosaccharide|Although breastfeeding is encouraged, the shortage is supplemented with the control formula. After obtaining the informed consent, the control formula is administered to infants under the doctor's direction until a medical check-up at one-month-old.
223654262|NCT03270579|DRUG|[18F]JNJ-64511070|An IV injection of 185 MBq \[18F\]JNJ-64511070 will be administered.
223654263|NCT02832362|DRUG|Carbomer 980|Test product containing 0.5% carbomer 980 gel
223654264|NCT02832362|OTHER|Placebo|Reference product containing vehicle without 0.5% carbomer 980 gel
223654265|NCT06155396|DRUG|Disitamab Vedotin|2.0 mg/kg IV every 2 weeks
223654266|NCT06155396|DRUG|Zimberelimab|240mg IV every 2 weeks
223654267|NCT00696917|BIOLOGICAL|HBV-MPL vaccine 208129|2-dose intramuscular injection 3 different vaccine lots
223654268|NCT00696917|BIOLOGICAL|Engerix™-B|3-dose intramuscular injection
223654269|NCT04800770|DIAGNOSTIC_TEST|4C mortality score|4C mortality score and phosphate levels
223654270|NCT04730661|DIAGNOSTIC_TEST|Sit to stand test|"The sit to stand test (or STST) is a test consisting of performing as many sit-to-stand tests as possible in one minute, from a chair without armrests.~We note before and during this test, the SpO2 (pulsed oxygen saturation) (rest value and minimum value during exercise), heart rate (HR), dyspnea on the modified Borg scale as well as the number of chair lifts performed. completely and minimum SpO2 during the recovery phase.~The possible results from this one-minute test are as follows:~* If SpO2 \<90% or appearance of signs of respiratory distress: Immediate stop of the test and hospitalization~* SpO2 \<90% or decrease in SpO2 ≥ 4% during the test or during the recovery period: Hospitalization~* SpO2 ≥90% and no decrease in SpO2 ≥ 4% during the test or during the recovery period which will be 3 minutes maximum: discharge."
223654271|NCT00667108|DRUG|Gabapentin|Gabapentin 250 mg oral capsule 30 minutes prior to bedtime
223654272|NCT00667108|DRUG|Gabapentin|Gabapentin 500 mg oral capsule 30 minutes prior to bedtime
223654273|NCT00667108|DRUG|Placebo|Matched placebo 30 minutes prior to bedtime
223654274|NCT04136015|DRUG|Dasatinib 100 MG|The CML-CP patients with early(3m to 6m) molecular response failure on imatinib,Conversion dasatinib group or Imatinib group
223654275|NCT04900532|DIETARY_SUPPLEMENT|Tocotrienol rich fraction|Supplementation with a Vitamin E compound.
223654276|NCT04900532|DIETARY_SUPPLEMENT|Placebo|Administration of placebo containing 0,96mg of tocotrienol and 1,76mg of tocopherol twice a day for three months.
224238014|NCT03460197|PROCEDURE|Endoscopic Ultrasound-Guided Fine-Needle Aspiration|Patients will be submitted to both techniques of tissue acquisition in the same procedure of endoscopic ultrasound. Capillarity technique, requires not remove the stiletto from the needle until the punctures are done for the biopsy sampling. Wet suction technique, requires saline solution to replace the air column. Samplings will be placed in two different jars, where Jar 1 corresponds to Capillarity Technique sampling and Jar 2 to Wet Technique. Once the sampling preparation is concluded will be send to the Pathology Department to be subsequently blindly analyzed by two independent pathologists, that means they would not be aware of the tissue acquisition method used in each of the microscopic slides to analyze.
224238015|NCT00093925|DRUG|clevidipine|
224238016|NCT00093925|DRUG|nicardipine|
223654277|NCT06231771|DRUG|Allogeneic mesenchymal stem cells (MSCs)|Dosage · Dosing of IMP is based on ulcer size. The recommended dose is 1 million cells/cm2 of ulcer. Administration · Injections will be done through peri-ulcer route. · Injection will be done 0.75 cm from the edge of the ulcer. · Injection will be done using 24G. The volume of injection will 4.0 - 6.0 ml per patient (maximum 0.1 to 0.2 ml per injection; 30 injections maximum per patients)
223654278|NCT06231771|DRUG|Normal Saline|Dosage · Dosing of placebo is based on ulcer size. the volume will be samed as the experimental groups which is 2 ml per 1cm2 Administration · Injections will be done through peri-ulcer route. · Injection will be done 0.75 cm from the edge of the ulcer. · Injection will be done using 24G. The volume of injection will 4.0 - 6.0 ml per patient (maximum 0.1 to 0.2 ml per injection; 30 injections maximum per patients)
223654279|NCT00295386|BEHAVIORAL|Cognitive behavior therapy (CBT)|
223654280|NCT00295386|DRUG|Zopiclone|
224238017|NCT01860248|DRUG|Vapocoolant spray|The Vapocoolant spray containing alkane is applied for 20 seconds.
224238018|NCT01860248|DRUG|Water spray|This spray is covered so the patient and the investigator can not find the spray type out.
224238019|NCT05912322|DIETARY_SUPPLEMENT|Black chokeberry juice|100ml black chokeberry juice/day
224238020|NCT00125424|DRUG|AQUAVAN® (fospropofol disodium) Injection|
223654281|NCT00367614|DRUG|pantoprazole|
223654282|NCT00068861|DRUG|metformin XR|
223654283|NCT00068861|DRUG|clomiphene citrate|
223654284|NCT00942097|DRUG|Sulph, Puls, Lyc, Lack t, Con, Sep, Nux v, Calc c, Phos|CH 12 preparation, 6 drops, twice a day, 4 days per week, until the end of pregnancy. One medication per appointment.
223654285|NCT00942097|DRUG|Homeopathy and Nutritional oriented diet|Homeopathy 6 drops twice a day 4 days per week, active and placebo and Balanced nutritional oriented diet for both groups.
223680952|NCT02819232|OTHER|Blood sampling|Detection of bacteria will be performed on a blood sample
223680953|NCT03526588|BIOLOGICAL|Autologous umbilical cord blood|6×10\^6 mononuclear cells isolated from the patient's own umbilical cord blood per dose. 4 total doses administered intravenously over 7 days.
223680954|NCT00000496|DRUG|aspirin|
224238021|NCT00125424|DRUG|Midazolam HCl|
223680955|NCT00000496|DRUG|dipyridamole|
223680956|NCT01797406|OTHER|Air insufflation|Air is inflated into the bowel to help searching the cavity while advancing the colonoscope until reaching the cecum
223680957|NCT01797406|OTHER|Water injection|Water was injected through the working channel instead of air to follow the intestinal cavity until reaching the caecum .
223680958|NCT01860729|DRUG|Anacetrapib|
223680959|NCT01860729|DRUG|Placebo|
223680960|NCT05418309|DRUG|Tislelizumab Nab paclitaxel|Tislelizumab 200mg will be administered on Day 1 of each cycle for 4 treatment cycles;Nab-paclitaxel 200mg will be administered on Day 2 of each cycle for 4 treatment cycles.
223654286|NCT04037696|BEHAVIORAL|General Health Promotion Approach|"The trained Research assistants will ask the subjects about the priority of engaging in any desirable health-related lifestyle practice as identified in the completed baseline questionnaires and to state a targeted goal that they perceive as the easiest to achieve. Each subject will then receive an individual face-to-face brief MI (about 5 mins) with generic health advice on selected health-related lifestyle practice. They will then be informed to receive an individual brief MI intervention to assist behavioural changes or achieve goals as desired or chosen by them via WeChat or WhatsApp in smart phones throughout the study period.~The RA will then deliver brief MI to each subject individually via WeChat or WhatsApp in smart phones throughout the study period.~Readiness of quitting smoking will be assessed at 3-month follow-up. Upon request by subjects, we shall provide them with more comprehensive information on quitting."
223654287|NCT04037696|BEHAVIORAL|Control|The subjects will be given general brief advice and a self-help smoking cessation booklet with Hotline (Tel.: 1833183). However, subjects in the control group will not receive brief MI and follow-up booster intervention.
223654288|NCT02682862|DRUG|olodaterol hydrochloride 2.5mcg, tiotropium bromide 2.5mcg|Inhaler: 2.5 microgram tiotropium (as bromide monohydrate) and 2.5 microgram olodaterol (as hydrochloride) per puff. 2 puffs once daily
223654289|NCT02682862|DRUG|olodaterol 2.5 mcg|Inhaler: 2.5 microgram Olodaterol (as hydrochloride) per puff. 2 puffs once daily
223654290|NCT02981615|DRUG|Levofloxacin|one tablet (500mg) a day, from day 10 to day 28 in every cycle of the 4 first cycles
223654291|NCT02981615|DRUG|Placebo Oral Tablet|one tablet a day, from day 10 to day 28 in every cycle of the 4 first cycles
223654292|NCT02840799|DRUG|Potassium Nitrate (KNO3)|The effect of potassium nitrate (KNO3) supplementation on exercise capacity and peak oxygen consumption in HFpEF will be assessed.
223654293|NCT02840799|DRUG|Potassium Chloride (KCl)|Potassium Chloride (KCl) is the matching placebo control drug in this trial.
223654294|NCT02267876|DEVICE|BD HPV Assay on Viper LT|The BD HPV specimen will be tested with the BD HPV Assay on the Viper LT instrument.
223654295|NCT02267876|PROCEDURE|Colposcopy|The colposcopy will be performed on subjects that have abnormal cytology. At the third year visit all subjects will have an exit colposcopy.
223654296|NCT02565784|DEVICE|Restylane|Facial tissue augmentation
223654297|NCT02565784|DEVICE|Perlane|Facial tissue augmentation
224238022|NCT01034319|BEHAVIORAL|Diabetes Genetic Counseling|Subjects will be genotyped based on a 37-allele aggregate score and counseled regarding the implications of the results prior to enrollment in a 12-week diabetes prevention program
224238023|NCT01034319|BEHAVIORAL|No genetic counseling|These subjects will not be genotyped or counseled prior to enrollment in a 12-week diabetes prevention program
224238024|NCT03577509|DRUG|ABCD|Intravenous infusion of dexamethasone 5mg before ABCD intravenous administration; Single infusion.
223654298|NCT02586558|OTHER|Experimental Infant formula|Ready-to-feed infant formula to be fed ad libitum
223654299|NCT02586558|OTHER|Reference group|Ready-to-feed infant formula to be fed ad libitum
223654300|NCT00578734|DRUG|Lucinactant|Slow intra-tracheal instillation
223654301|NCT00578734|OTHER|Sham Comparator|Slow intra-tracheal instillation
223654302|NCT04990804|DRUG|Opioid Analgesic|Patients will be provided a prescription for low dose opioids for 5 days postoperatively (Hydrocodone/Acetaminophen 5/325mg or Oxycodone/Acetaminophen 5/325mg) to be taken every 6 hours as needed for pain. Refills may be provided (Hydrocodone/Acetaminophen 5/325mg or Oxycodone/Acetaminophen 5/325mg) if requested by the patient at the providers discretion. In addition, patients will also be prescribed Gabapentin 300mg q8 hours or Pregabalin 75mg twice daily and a muscle relaxer (Methocarbamol 750mg BID or Flexeril 5-10 mg TID) as needed for spasms. Alternative muscle relaxers (Metaxalone 800 mg TID or Tizanidine 2-6 mg TID) may be utilized if contraindications to methocarbamol and cyclobenzaprine exist.
223654303|NCT04990804|DRUG|Opioid-Free Postoperative Pain Regimen|Patients will receive no opioids. Pain will be managed with Acetaminophen 1000mg q8 hours, Ketorolac 10mg every 6 hours (for 5 days), Gabapentin 300mg q8 hours or Pregabalin 75mg twice daily, and a muscle relaxer (Methocarbamol 750mg BID or Cyclobenzaprine 5-10 mg TID) all to be taken as scheduled for the first 2 weeks (except Ketorolac - 5 days) postoperatively as side effects permit. Other NSAIDS (Naprosyn 500 mg BID or Ibuprofen 800 mg TID) may be utilized if contraindications to Ketorolac exist. Famotidine (20mg BID) or Omeprazole (20mg daily) will be prescribed along with NSAIDS for GI prophylaxis. Alternative muscle relaxers (Metaxalone 800 mg TID or Tizanidine 2-6 mg TID) may be utilized if contraindications to methocarbamol and cyclobenzaprine exist.
223654304|NCT02417506|OTHER|E-OA-07 (Lanconone)|
223654305|NCT02417506|DRUG|Ibuprofen|
223654306|NCT00580528|BEHAVIORAL|Tailored Internet Newsletters|Tailored newsletters delivered via the Internet with content for improving eating and activity to reduce blood pressure
223654307|NCT00580528|BEHAVIORAL|Tailored print newsletters delivered via mail|Tailored Newsletters with content to improve eating and activity to reduce blood pressure
223654308|NCT04202419|DEVICE|FRAX 1940 nm laser|A fractional 1940 nm solid-state diode laser will deliver linear arrays of microbeams to create nonablative microscopic treatment zones (MTZs) in the skin, in order to treat pigmented skin lesions.
223654309|NCT00251043|BEHAVIORAL|Interpersonal psychotherapy for depression in pregnancy|IPT-P will include 45-minute weekly sessions for 12 weeks. During sessions, participants will learn ways to address emotional stressors associated with childbirth.
223767802|NCT07173153|BIOLOGICAL|AAV9.SLC6A1 Gene Therapy|This is an open-label, single injection study of an AAV9 vector carrying the SLCA1 coding sequence delivered one time through an intrathecal injection.
224238025|NCT03190577|GENETIC|blood sample|two 5 ML EDTA tubes of blood will be collected once by patient
224238026|NCT02973893|BIOLOGICAL|Placebo|Placebo
224238027|NCT02973893|BIOLOGICAL|VF001-DP LD|VF001-DP contains parts of normal vitronectin and Insulin-like growth factor 1 (IGF-I) combined in a single protein.
224238028|NCT02973893|BIOLOGICAL|VF001-DP HD|VF001-DP contains parts of normal vitronectin and Insulin-like growth factor 1 (IGF-I) combined in a single protein.
224238029|NCT01347788|DRUG|cabozantinib|Cabozantinib PO QD
224320878|NCT05832177|BEHAVIORAL|Integrate Cancer 101 into the Stakeholders Programs|This program will offer stakeholders a no-cost workshop of three credit hours to increase cancer prevention education among Hispanic/Latinos. CMEs will be provided virtually to increase participation. This activity will begin according to the project timeline.
224238030|NCT05759975|DEVICE|Photobiomodulation therapy (intraoral)|Intraoral photobiomodulation therapy (660nm, 100mW, 10 J/cm 2 , 3 s/point) for the management of oral side effects related during hematopoietic stem cell transplantation (HSCT). Mainly in the decrease of oral OM rates and OM severity, healing of OM ulcers and pain relief. Second, evaluate quality of life,hyposalivation/xerostomia, functional evaluation and dysfagia, in the arm. All results obtained in the group will be compared with the other arm.
223654310|NCT00251043|BEHAVIORAL|Parenting education program (PEP)|PEP will include 45-minute weekly sessions for 12 weeks. During sessions, participants will learn about the stages of pregnancy, childbirth, and early infant development.
223654311|NCT02325869|DEVICE|Bell Balloon Catheter|An angioplasty procedure to open the blockage in blood vessels will be performed. Standard angioplasty procedure includes local analgesia of the groin area and a small cut through which the procedure will be performed. An introducer sheath (thin tube) will be inserted. The Bell Balloon dilatation will then be inserted. The Bell Balloon works in fashion similar to standard balloon with the same physical and behavioral characteristics. Upon deflation, debris from the blockage is withdrawn into the cavity formed between the deflated balloon and its outer capsule. Then balloon is retracted and retrieved through the guiding catheter, together with the captured debris and trap it between the outer surface of the balloon and the inner surface of the membrane.
223654312|NCT05339867|BEHAVIORAL|Prevent Maternal Mortality using Mobile technology (PM3)|"PM3: The app will include:~1. integrated self-management and tailored health messaging feature~2. support center based on social support gaps which will also provide a centralized place for identifying healthcare providers and facilities~3. multimedia resource kit comprised of videos, current events, news feeds, podcasts, and support groups related to women's postpartum health and community resources~4. a feature that will update women on maternal and reproductive health policies that impact women."
223654313|NCT04930341|OTHER|Self-Acupressure|Acupressure is a therapy method performed with an instrument or hand, fingertip, palm, elbow, knee, thumb relaxation and wrist bands on various points representing the waist organs in order to ensure the continuation and balance of the energy in our body.
223654314|NCT05815875|COMBINATION_PRODUCT|STEADI Program|The investigators will conduct STEADI Algorithm for Falls Prevention educational sessions for healthcare providers in the neurosurgery unit, including doctors, nurses, physical therapists, and pharmacists. All healthcare providers in the neurosurgery unit will be invited to attend the educational sessions. Their participation will be voluntary and no obligations will be made, though. Healthcare providers will be invited to attend one 2-hour educational session. In each session, The investigators will have between 8-10 healthcare providers. The educational sessions will be delivered in the classroom available in the neurosurgery unit to facilitate the healthcare providers' access. PowerPoint presentations, videos, quizzes, case studies, and in-class discussions will be used to deliver learning content during the educational sessions. Healthcare providers will then be asked to apply the STEADI interventions on a group of patients.
223654315|NCT05815875|OTHER|Routine care|The control group participants will receive routine care. Routine care involves only assessing for falls using Morse Falls Scale (MFS). MFS assesses a patient's fall risk upon admission, following a change in status, and at discharge or transfer to a new setting.
223654316|NCT04986436|DRUG|HS-10360|Single or multiple dose(s) of HS-10360
223654317|NCT04986436|DRUG|Placebo|Single or multiple dose(s) of Placebo
223654318|NCT04976907|DEVICE|Contactless vital sign information collection|Collection of facial blood flow and temperature information via conventional and infrared/thermal video of the face for the purpose of estimating vital signs using machine learning-based computational models.
223654319|NCT00552188|DRUG|VIA-2291|100 mg, oral dosing, 1 time daily for 24 weeks
223654320|NCT00552188|DRUG|Placebo|oral dosing, 1 time daily for 24 weeks
223654321|NCT03717870|PROCEDURE|Laparoscopic enucleation of ovarian endometrioma.|Laparoscopic enucleation of ovarian endometrioma (stripping of the peripheral capsule and coagulation using the lowest energy source available).
223654322|NCT03717870|PROCEDURE|Prolonged pituitary downregulation|Treatment with GnRH-a (triptorelin, goserelin, and leuprolide), with add-back therapy (combined oral contraceptive) for 3-6 months.
223654323|NCT03717870|PROCEDURE|Assisted Reproductive Technology (ART)|Fresh ART cycle: ovarian stimulation, oocyte retrieval, in vitro fertilization and embryo transfer.
223654324|NCT05008900|RADIATION|Salvage radiotherapy|Standard of care salvage radiotherapy to the prostate bed which may include the lymph nodes.
223654325|NCT05143372|DEVICE|Vibrolung|Vibroacoustic respiratory therapy
223767803|NCT07172425|DIETARY_SUPPLEMENT|Inorganic potassium nitrate-fortified biscuits supplementation|Four millimoles of inorganic potassium nitrate, within the acceptable daily intake (ADI), were added to commonly consumed oat-based products (biscuits). During the trial, participants will receive nitrate-fortified biscuits as a single-day acute supplementation.
223767804|NCT07172425|DIETARY_SUPPLEMENT|Inorganic potassium nitrate-fortified cereal bar supplementation|Four millimoles of inorganic potassium nitrate, within the acceptable daily intake (ADI), were added to commonly consumed oat-based products (cereal bar). During the trial, participants will receive nitrate-fortified cereal bar as a single-day acute supplementation.
223654326|NCT01617226|DRUG|Azacitidine|Azacitidine both arms; 75mg/m\^2 by subcutaneous injection for 7 days of a 28-day cycle for up to 6 cycles.
223654327|NCT01617226|DRUG|Vorinostat|Vorinostat (with azacitidine) combined therapy arm; 300mg twice daily for 7 days starting on day 3 of each cycle in 28-day cycles for up to 6 cycles.
223654328|NCT02447224|DRUG|1 gm IV ertapenem at enrollment|
223654329|NCT02447224|DRUG|1 gm IV ertapenem at Day 2 and oral metronidazole and cefdinir to complete 10 days|
223654330|NCT02447224|PROCEDURE|Appendectomy|
223654331|NCT03708354|DRUG|placebo softgel|One 430 mg olive oil softgel daily for 24 weeks. Each placebo softgel of 430 mg olive oil will contain no tocotrienol or tocopherols at detectable levels.
223654332|NCT03708354|DRUG|DeltaGold® Tocotrienol 70%|Each TT softgel (DeltaGold® Tocotrienol 70%) contains 430 mg TT (90% δ-TT+10% γ-TT) with a 70% purity, representing 300 mg TT.
223654333|NCT03059355|BIOLOGICAL|UCMSCs|Allogeneic Umbilical Cord Tissue derived MSCs (UCMSCs)
223654334|NCT03059355|BIOLOGICAL|BMMSCs|Bone Marrow derived Mesenchymal Stem Cells (BMMSCs)
223654335|NCT03059355|OTHER|Placebo|a single administration of placebo delivered via peripheral intravenous infusion.
223654336|NCT00732407|DRUG|aliskiren|Aliskiren will be given in a preliminary dosage of 150 mg per day, after a follow up of two weeks dosage will be increased to 300 mg per day.
223654337|NCT00732407|DRUG|losartan|Losartan will be given in a preliminary dosage of 50 mg per day and after a two weeks follow up dosage will be increased to 100 mg per day
223654338|NCT00272896|DRUG|Vasoactive intestinal peptide|
223654339|NCT00458224|BEHAVIORAL|parental counseling|Group-based family oriented program involving pediatricians, physiotherapists, dieticians, psychologists and nurses with special training
223654340|NCT03347292|DRUG|Regorafenib(Stivarga, BAY73-4506)|Regorafenib 80mg/120mg/160mg q.d., 3 weeks on / 1 week off + pembrolizumab 200mg i.v. every 3 weeks
223654341|NCT03347292|DRUG|Pembrolizumab|200 mg i.v.(Intravenous(ly)) every 3 weeks (Q3W). This dose will not be escalated or deescalated and the dosing schedule will not be changed
223654342|NCT05002244|DRUG|CTL0801 (Azilsartan)|CTL0801 (Azilsartan), single dose, daily, repeated oral administration
223654343|NCT05002244|DRUG|CTL0802 (Rosuvastatin)|CTL0802 (Rosuvastatin), single dose, daily, repeated oral administration
223654344|NCT05002244|DRUG|CTL0801 (Azilsartan) + CTL0802 (Rosuvastatin)|CTL0801 (Azilsartan) + CTL0802 (Rosuvastatin), single dose, daily, repeated oral administration
223654345|NCT02789267|OTHER|Regular dietary support|Systematic and regular dietary support after radiotherapy
223654346|NCT04188444|BIOLOGICAL|Blood test|20 ml of blood, three times
223654347|NCT02817932|DRUG|Ranolazine|
223654348|NCT00550641|OTHER|physical therapy|physical therapy in warm pool performing stretching
223654349|NCT00550641|OTHER|physical therapy|physical therapy in warm pool performing Ai Chi
223654350|NCT05178368|PROCEDURE|Surgical/ Transcatheter aortic valve replacement|The choice of intervention will be made by the local clinical team. The timing of intervention will be determined by randomisation as part of the main EASY/EVOLVED trials
223654351|NCT04561726|OTHER|Connective Tissue Manipulation|Connective tissue manipulation is a soft tissue manipulative technique and also a reflex therapy which is characterized by localised and specific strokes performed in where the fascia is superficial or palpable. A shear force is created between the skin-underlying fascia or dermis-hypodermis and angulatory force is applied to the collagen fibers to produce reflex and mechanical effects.
223654352|NCT04561726|OTHER|Exercise|The purpose of the given home exercises is to increase motor ability in activities such as standing, walking and posture, to increase muscle strength and also to elongate muscles. Exercises progressed day by day according to the adaptation of the motor system and muscle strength to the exercises.
223654353|NCT00215176|DRUG|modafinil|
223654354|NCT04502940|DIAGNOSTIC_TEST|Flow Cytometric analysis|Blood samples will be taken from the patients with biliary pancreatitis and healthy volunteers to perform flow-cytometric analysis and to determine lymphocyte subgroups
223654355|NCT03332680|BIOLOGICAL|EmbryoGlue® (laboratory culture medium)|Embryos placed in this medium prior to transfer
223654356|NCT03332680|BIOLOGICAL|Standard control medium|Embryos placed in this medium prior to transfer
223654357|NCT00947440|DRUG|ABT-072|See arm description for more information
223654358|NCT05272345|PROCEDURE|sexual therapy|In sexual therapy; A total of 4 sessions of therapy were initiated with the patients, one session per week for 1 month.
224238031|NCT05759975|DEVICE|Photobiomodulation therapy (extraoral)|Extraoral photobiomodulation therapy (810 + 980 nm, 1 W, 6.11 J/cm2 , 30 s/point) for the management of oral side effects related during hematopoietic stem cell transplantation (HSCT). Mainly in the decrease of oral OM rates and OM severity, healing of OM ulcers and pain relief. Second, evaluate quality of life,hyposalivation/xerostomia, functional evaluation and dysfagia, in the arm. All results obtained in the group will be compared with the other arm.
223654359|NCT00581880|BEHAVIORAL|questionnaires|A battery of questionnaires concerning your thoughts, opinions, and attitudes about your illness and outlook on life. In addition, we will ask to provide some background information about you and your illness. The questions will take approximately 30 to 45 minutes to complete. You fill out the questionnaire once only.
223654360|NCT05224167|DRUG|Melatonin 5 MG Sublingual Tablet|Melatonin 5 mg 12 hours and 2 hours prior to surgery
223654361|NCT05224167|DRUG|Hydroxyzine|Hydroxyzine 1mg/kg 12 hours and 2 hours prior to surgery
224238032|NCT04022148|BIOLOGICAL|Gardasil|Experimental arm: Vaccine group VS Control arm: Non-Vaccine group
224238033|NCT02523105|DEVICE|EEG monitoring|"EEG evaluation will be done using two off the shelf EEG devices for research and consumer use. The first one is a device called MindWave by NeuroSky ltd (http://neurosky.com) the second called EPOC by Emotiv ltd (https://emotiv.com/epoc.php).~EEG evaluation will be conducted for a total duration of 20 minutes with and without auditory stimulation. The auditory stimulation will be performed using standard headphone or earphones to reduce external noises."
224238034|NCT00861965|BIOLOGICAL|AlloStim-8|intravenous infusion of mis-matched AlloStim-8
224238035|NCT00861965|BIOLOGICAL|AlloStim-8|intravenous infusion of AlloStim-8 on day 7
224238036|NCT00861965|BIOLOGICAL|AlloStim-8|intravenous infusion of AlloStim-8 on day 14
224238037|NCT00861965|BIOLOGICAL|AlloStim-8|intravenous infusion of AlloStim-8 on day 21
223654362|NCT00899496|OTHER|immunological diagnostic method|
223654363|NCT00899496|OTHER|physiologic testing|
223654364|NCT00484848|DEVICE|Vortex port and Celsite port|
223654365|NCT05917678|OTHER|Repositioning Therapy|Caregivers will be instructed how to increase tummy time activities and reshape their infant's heads using at-home methods to direct their attention to the non-preferred side.
223654366|NCT05917678|DEVICE|Cranial Remolding Orthosis|A custom cranial remolding orthosis (FDA Class II device) will be made to fit affected infants. this should be worn 23 hours per day and the Orthotist needs to be seen regularly for adjustments until the head shape is resolved.
223654367|NCT00689260|DEVICE|easypod|Subjects is aware that the device records injection information that can be viewed by user
223654368|NCT00689260|DEVICE|easypod|Subjects is not aware that the device records injection information that can be viewed by user
223680961|NCT00946140|PROCEDURE|DCE-MRI scans|Initially you will be given safety information about MRI scans and a questionnaire to determine your compatibility with the MRI scanner. For each patient, DCE-MRI data sets will be acquired three times - at baseline just prior to the start of the drug therapy, within 24-48 hours of the start of the therapy, and within 6-8 weeks of the start of the therapy.
223654369|NCT06466018|DIAGNOSTIC_TEST|Schirmer test paper|"This paper is centrifuged and your tears are collected then frozen before analysis. We collect the fat from your tears by scraping the edge of your lower eyelid with small sterile tweezers. All surgical waste will be collected during eye surgeries only if you must have them.~During each ocular surgical procedure, the vitreous, subretinal fluids and/or aqueous humor will eventually be recovered when required by the procedure. The rest of the blood samples, not used during diagnostic analyses, will be kept for later analyses.~Tears will be collected using a non-invasive and painless method that takes around ten minutes. The tissues (connectiva, cornea, retina, epi-retinal membrane) which must have been removed when required by the surgical procedure will also be preserved."
224238038|NCT01752257|DRUG|EF5 Hypoxia|EF5 is a dye used to measure hypoxia
223654370|NCT01870934|DEVICE|Camera|No real intervention, but a comparison of different methods including the new medical device 3D camera.
223654371|NCT03227783|DEVICE|transcranial direct current stimulation (tDCS)|tDCS is one of non-invasive brain stimulation. Constant, low current is delivered to the specific brain areas to change brain plasticity.
223654372|NCT04381546|OTHER|Functional Electrical Stimulation FES|Functional electrical stimulation (FES) is delivered to the quadriceps and hamstrings of the paretic limb in patients with hemiplegia. It is based on the real-time estimation of the knee angle and support phase during gait.
223654373|NCT00476008|DRUG|Memantine|One tablet memantine (Namenda)10mg morning and evening (BID) for 12 months
223654374|NCT00476008|DRUG|Placebo|One tablet placebo morning and evening (BID) for 12 months
223654375|NCT03970044|DRUG|Exenatide 2 MG|Glucagon-like peptide-1 receptor
223654376|NCT03970044|DRUG|Dapagliflozin 10 MG|sodium-glucose co-transporter 2 (SGLT2) inhibitor
223654377|NCT04988360|DEVICE|HMD: Immersive VR|"Participants with dementia will view 360-degree films using a commercially-available Virtual Reality head mounted display (HMD) that has built-in speakers. While wearing the HMD, participants with dementia will be able to visually explore the virtual environments by turning their head to face different directions. Caregivers-participants will take part in the VR experience concurrently by viewing a tablet that is connected to the HMD through the screen mirroring function."
223767805|NCT07172425|DIETARY_SUPPLEMENT|Inorganic potassium nitrate-fortified porridge supplementation|Four millimoles of inorganic potassium nitrate, within the acceptable daily intake (ADI), were added to commonly consumed oat-based products (instant porridge). During the trial, participants will receive nitrate-fortified porridge as a single-day acute supplementation.
223767806|NCT07172334|OTHER|Questionnaires|Patients will complete questionnaires on professional exposures with the help of a trained professional (estimated time: 30 minutes), followed by self-questionnaires on indoor and outdoor pollution, medications, drugs and socio-economic variables (estimated time: 30 minutes).
224238039|NCT05456074|OTHER|Data collection|Retrospective data collection
223654378|NCT04988360|DEVICE|Tablet: Non-immersive VR|Participants with dementia will view 360-degree films on a commercially-available tablet that has built-in speakers. Participants with dementia will be able to visually explore the virtual environment using the touch screen (dragging the view around with one's finger). Caregiver-participants will take part in the VR experience concurrently by viewing the tablet while sitting or standing beside the participant with dementia.
223654379|NCT06359444|OTHER|Combined aerobic + strength training|"Participants will follow a combination of endurance and strength training for 14 weeks.~There will be three sessions every week: two at Ghent university department of rehabilitation and one at home. Each session will last approximately one hour."
223654380|NCT06359444|OTHER|Combined strength + HIIT training|"6 weeks of endurance training and strength training, 8 weeks of strength training and HIIT.~Participants will follow the same combination of endurance and strength training for the first six weeks, to build up to a baseline level of physical fitness. They will then switch to eight weeks of a combination of strength training and High Intensity Interval Training (HIIT).~There will be three sessions every week: two at Ghent university department of rehabilitation and one at home. Each session will last approximately one hour."
223654381|NCT01170247|DRUG|Ketamine|Intranasal Ketamine (100 mg/mL)
223654382|NCT01170247|DRUG|Ketamine|Intramuscular Ketamine
223767807|NCT07172334|OTHER|Samples|Two strands of hair (or beard or axillary hair) will be taken, along with a urine and blood sample.
223767808|NCT07173556|DRUG|QLC1401|CDK4/6 inhibitors: Palbociclib, Abemaciclib, Ribociclib
223767809|NCT07173556|DRUG|QLC1401|mTOR inhibitors: Everolimus
223767810|NCT06132360|DRUG|RN0191|This is a randomized, placebo-controlled, single ascending-dose (SAD) study of RN0191 administered SC to adult subjects with elevated LDL-C. Subjects who have signed an Ethics Committee (EC)-approved informed consent form (ICF) and have met all the protocol eligibility criteria during screening may be enrolled into the study.
223767811|NCT05346406|DEVICE|Midline Catheter|Bard Powerglide 8 cm midline catheter
224238040|NCT00683020|BEHAVIORAL|ATSM Intervention|"The ATSM system is designed to promote the efficiency of a care manager by having her focus outreach phone calls to patients who, by virtue of their responses to the ATSM system, report a need for further support. The purpose of these call-backs is to have the care manager directly engage patients in setting goals and developing an action plan to improve their overall health. The care manager is trained to perform motivational interviewing, assess and overcome barriers to health communication.~For some patients, the ATSM system as described above is augmented by additional phone communications from care manager to patient, triggered by health IT derived from 2 additional data sources: SFHP pharmacy claims data and CHNSF diabetes registry. The latter combines clinical data (labs and blood pressure). Based on clinical criteria, the ATSM system will alert care manager to make additional calls to patients."
224238041|NCT01220830|DEVICE|Cytotron|Exposure to RFQMR with Cytotron for 28 consecutive days for one hour daily.
223767812|NCT05346406|DEVICE|Peripherally Inserted Central Catheter|Bard 3fr, 4fr or 6fr; Cook 4fr; or Medcomp 1.9fr and 2.6fr
224238042|NCT03064022|OTHER|Growth|Some preterm infants grow at higher rates than others
224238043|NCT02716025|PROCEDURE|Upper gastrointestinal endoscopy|Thorough examination of the esophagus, stomach and duodenum to the second part was done to all patients using Olympus CV-150 or Pentax EPM-3500.
224238044|NCT05904808|DRUG|IV Furosemide|Given over 4-hour drip using IV pump, 40mg of the 250mg will be given as a bolus
224238045|NCT05904808|DRUG|IV Furosemide and PO Metolazone|Given over 4-hour drip using IV pump, 40mg of the 250mg will be given as a bolus +5mg PO Metolazone
223654383|NCT01901796|BEHAVIORAL|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy- an effective, non-pharmacological treatment for depression and anxiety.
223654384|NCT01075308|DRUG|HDAC inhibitor SB939|SB939 given orally every other day 3 times a week (i.e. Monday /Wednesday /Friday, or Tuesday /Thursday / Saturday) for 3 consecutive weeks followed by one week off-dosing. A treatment cycle is 4 weeks (28 days).
224238046|NCT05904808|DRUG|IV Furosemide and IV Acetazolamide|"Furosemide would be given over 4-hour drip using IV pump, 40mg of the 250mg will be given as a bolus.~500mg IV Acetazolamide would be given in 100cc of saline over half an hour"
224238047|NCT03814343|DRUG|amphotericin B in 30% DMSO|amphotericin B in 30% DMSO was given to patients in active comparators group for continuous 12 weeks.
223654385|NCT04321135|BEHAVIORAL|Guided Lifestyle Program Intervention|The Guided Lifestyle Program will receive sessions that meet twice weekly and 2-3 text messages weekly.They will also receive a participant informational binder (wellness guide) with health and exercise information and tools as directed by ACS nutrition and physical activity guidelines.
223654386|NCT04321135|BEHAVIORAL|Self-Guided Lifestyle Program (Control Arm)|In the self-guided weight loss program, participants will be given the sane informational binder with health and exercise information and tools as directed by ACS nutrition and physical activity guidelines but they will not receive in-person classes or text messaging
223654387|NCT04049409|DRUG|CMAB809|CMAB809 will be administered by IV infusion at a single dose of 6mg/kg.
223654388|NCT04049409|DRUG|Trastuzumab|Trastuzumab will be administered by IV infusion at a single dose of 6mg/kg.
223654389|NCT00662298|DRUG|prednisolone|40mg of prednisolone once a day for 14 days
224238048|NCT03814343|DRUG|30% DMSO|30% DMSO was given to patients in placebo comparators group for continuous 12 weeks.
224238049|NCT05353764|OTHER|scalp nerve block combined with intercostal nerve block using 0.5% ropivacaine|Participants randomized to the SNB group will receive general anesthesia combined with scalp nerve block and intercostal nerve block with 0.5% ropivacaine, which was performed exclusively by an attending anesthesiologist.An attending anesthesiologist will select the site of SNB based on the surgical incision site. Scalp nerve was blocked including greater occipital nerve (2-3ml), superficial temporal nerve (2-3ml), trochlear nerve (2-3ml) and supraorbital nerve (2-3ml). The total volume in scalp nerve block will not exceed 10 ml.Ultrasound-guided unilateral ICNB will be performed at the level of T4-T5 next to the sternum.10-15ml of 0.5% ropivacaine will be injected into the intercostal spaces where incision locates after negative aspiration.
224238050|NCT03156764|OTHER|Qp/Qs ratio monitoring|Op/Qs -monitor will be calculated using SpO2 and cerebral oximetry Op/Qs -blood will be calculated using ABGA and VBGA
224238051|NCT02015000|PROCEDURE|P.E.R.F.A.M.T|Surgical Result of Primary and Recurrent Pterygium by Using Pterygium Extended Removal followed by Fibrin Glue Assisted Amniotic Membrane Transplantation (P.E.R.F.A.M.T)
224238052|NCT02171052|DRUG|Dabigatran etexilate|
224238053|NCT02171052|DRUG|Digoxin|
224238054|NCT04809675|DEVICE|Hard occlusal splint|Use of a hard occlusal splint at times they considered helpful.
224238055|NCT04809675|DEVICE|Flexible customized mouthguard|Use of a flexible customized mouthguard at times they considered helpful.
223654390|NCT05576545|DEVICE|The Breast Cancer Self-Care App|The Breast Cancer Self-Care App includes several parts- introduction to breast cancer, types of treatment, side effects care, nutrition, relaxation videos, insurance, medical news and recording side effects, etc. The researcher assisted in installing the App on the patient's mobile phone, entered the personal account, and asked the patient to fill in questionnaires. Patients were given individual health education task in the Breast Cancer Self-Care App every week according to the type of chemotherapy drugs. After four weeks, they filled in questionnaires again.
223654391|NCT05061043|OTHER|Routine physical therapy treatment|Control group will receive the routine physical therapy treatment that will include EMS, Infrared and Intermittent stretching of facial muscles for 36 sessions on alternate days, each session comprise 30 minutes for 5 days a week
223654392|NCT05061043|OTHER|Routine physical therapy along with orofacial therapy|Experimental group will receive routine physical therapy along with orofacial therapy (36 sessions on alternate days, each session comprise 45 minutes)
223654393|NCT02044107|BEHAVIORAL|Co-packaging and counseling messages|The intervention involves co-packaging in 2 distinct packages: 1) for diarrhea treatment to package zinc \& ORS for the treatment of diarrhea using a plastic bag with printed messages that were pre-tested in formative research; and 2) for pneumonia treatment to co-package zinc \& antibiotics in a plastic bag with printed messages that were pre-tested in a formative research phase. Pre-tested zinc treatment messages will be on posters displayed in the intervention health centers. Orientation will be provided to health facility staff in control and intervention areas.
223654394|NCT01528202|DIETARY_SUPPLEMENT|Cherry juice|30 mLs preceding morning meal and 30 mLs preceding evening meal each day for 7 days.
223654395|NCT01528202|DIETARY_SUPPLEMENT|Fruit juice cordial|fruit flavoured juice concentrate
223654396|NCT02746224|PROCEDURE|Initially dissection of inferior mesenteric vein|Laparoscopic left hemicolectomy for left colon cancer or laparoscopic low anterior resection for rectal cancer. In the group 1A the surgical technique initially dissects the inferior mesenteric vein (IMV)
223654397|NCT02746224|PROCEDURE|Initially dissection of inferior mesenteric artery|Laparoscopic left hemicolectomy for left colon cancer or laparoscopic low anterior resection for rectal cancer. In the group 1B the surgical technique initially dissects the inferior mesenteric artery.
223654398|NCT02746224|PROCEDURE|Latero-terminal colorectal anastomosis|The patients who will undergo a colorectal anastomosis will be included in the study 2 and will be randomized to group 2A and group 2B: in group 2A the patients will have a latero-terminal colorectal anastomosis and in group 2B a termino-terminal colorectal anastomosis.
223767813|NCT01659749|BEHAVIORAL|Metabolic camp|To use an recreational camp setting to instruct PKU females of reproductive age how to make responsible dietary and reproductive decisions.
224238056|NCT00004099|DRUG|cisplatin|
224238057|NCT00004099|DRUG|fluorouracil|
224238058|NCT00004099|DRUG|leucovorin calcium|
224238059|NCT00004099|PROCEDURE|neoadjuvant therapy|
224238060|NCT00728949|BIOLOGICAL|IMC-A12 (cixutumumab)|10 mg/kg I.V.
224238061|NCT00728949|DRUG|tamoxifen|Daily 20 mg, oral
224238062|NCT00728949|DRUG|Anastrozole|Daily 1 mg, oral
224238063|NCT00728949|DRUG|Letrozole|Daily 2.5 mg, oral
224238064|NCT00728949|DRUG|Exemestane|Daily 25 mg, oral
223654399|NCT02746224|PROCEDURE|Termino-terminal colorectal anastomosis|The patients who will undergo a colorectal anastomosis will be included in the study 2 and will be randomized to group 2A and group 2B: in group 2A the patients will have a latero-terminal colorectal anastomosis and in group 2B a termino-terminal colorectal anastomosis.
223654400|NCT02058745|BEHAVIORAL|CAU+ (Enhanced Care as Usual)|"CAU+ is defined as the care received from the care recipient's oncologist supplemented by unlimited access to three components of the study website: caregiver guides, links to web-based resources, and a basic friends and family page. These resources are routinely available on the Internet. We provide these as a one-stop shopping resource in order to standardize care as usual for caregivers. All caregivers will be sent personalized e-mails from the project director every week during the intervention period."
223654401|NCT02058745|BEHAVIORAL|Beating the Blues|"Beating the Blues is an established, self-directed, web-based cognitive behavioral therapy program for managing depressive symptoms. Caregivers are asked to complete 8 weekly sessions, each lasting approximately 50 minutes. Participants are also given simple homework after each lesson."
224238065|NCT00728949|DRUG|Fulvestrant|Monthly 250 mg, intramuscularly
224238066|NCT05527756|OTHER|Scar Cosmesis Assessment and Rating (SCAR) scale|The SCAR scale consists of two simple questions about symptoms (itch and pain) with yes/no response options that are responded to by the patient and six clinician-related items that are rated by observers through photos of the incisions. This scale includes both objective measurements and patient-reported symptoms
224320879|NCT05832177|BEHAVIORAL|Community Engagement (CE) Training Program for Lay Community Members|A series of two-day CE workshops designed and delivered to 30 lay community members over a four-year period (6 to 10 participants per year). The proposed CE workshops includes: 1) CE principles, 2) cancer prevention education principles, and 3) community-based promotion strategies for cancer prevention. This activity will begin according to the project timeline.
224238067|NCT05527756|OTHER|Numerical rating scale (NRS)|The NRS scale, in which the patients score the cosmetic appearance of the scar from 0 to 10, is questioned.
224238068|NCT00989352|DRUG|Methotrexate|3g/m² i.v. max. 9 times
224238069|NCT00989352|DRUG|Lomustine|110 mg/m² p.o., max. 3 times
224238070|NCT00989352|DRUG|Procarbazine|60 mg/m² p.o. for 10 days, max. 3 times 100 mg p.o. for 5 days, max. 6 times
224238071|NCT00989352|DRUG|Rituximab|375 mg/m² i.v., max. 10 times
224238072|NCT01550588|DEVICE|Device closure|PFO Amplatzer device closure
223654402|NCT02058745|BEHAVIORAL|SmartCare|SmartCare is a web-based, nurse guided intervention for caregivers based on the Representational Approach of symptom management. The RA builds on traditional cognitive-behavioral interventions by promoting in depth reflection of previous and current experiences, beliefs, and knowledge (referred to as representations) prior to providing new information or engaging in problem-solving.
224238073|NCT01550588|DRUG|Standard medical treatment|Standard Medical management using anti-coagulant therapy
223654403|NCT04854447|DEVICE|Single-Vision Spectacles|Spectacle correction for myopia treatment
223654404|NCT01916291|DRUG|Propess insertion group|
223680962|NCT01871480|DRUG|Group A:cytokine-induced killer cell +gefitinib|CIK cells: intravenous infusions; D14-16; one cycle every month,at least 6 cycles;Gefitinib treated with 250mg for daily oral administration in the absence of disease progression or unacceptable toxicity.
224238074|NCT02885337|OTHER|Multi-Modal Frailty Intervention|"Exercise: A physiotherapist will develop an individualized exercise program and schedule appointments with the patient at a physiotherapist clinic. Participants will be offered free YMCA membership.~Cognitive-behavioural Change Strategy(CBCS) and education: Throughout the intervention, CBCS and education about exercise, hip or knee arthroplasty and osteoarthritis will be administered.~Protein Supplement: Participants will be provided with 1-2 daily supplements (containing 20-40 gram protein, 1.5 g β-Hydroxy β-Methylbutyrate /serving) to be taken with a meal or on activity days within 3-hours of exercise.~Vitamin D: All participants in the intervention arm will be provided with a supply of Vitamin D3 (1000 IU/day tablets) for the duration of the intervention period.~Medication Review: A geriatrician will review the medications for patients in the intervention arm."
223680963|NCT01871480|DRUG|Group B:Gefitinib|Gefitinib treated with 250mg for daily oral administration in the absence of disease progression or unacceptable toxicity
223680964|NCT01012648|DRUG|Fluid resuscitation|Volume resuscitation
224238075|NCT02885337|OTHER|Usual Care|"Patients in the control arm will receive usual care which may include the recommendation to attend fitness classes before surgery, however these patients will not receive the more intensive assessment/intervention of the physiotherapist and other intervention components. Control participants will be asked pre-operatively and post-operatively to indicate whether or not they exercise, take protein or vitamin supplements.~For participants in intervention and control groups will, 1) we will monitor the YMCA attendance and 2) participants will be instructed on the completion a dietary intake log (including days of the week and weekend days) that indicate the type of food and amount over a four-day period in order to calculate energy and micronutrient consumption."
224238076|NCT03658837|PROCEDURE|Ivor Lewis Oesophagectomy|Patients who underwent Ivor-Lewis Oesophagectomy for cancer of oesophagus
224238077|NCT01346085|DRUG|CNI free immunosuppression|Immunosuppression consisted of: (i) pre-Tx rapamycin treatment (0.1 mg/kg/day) for at least 30 days; (ii) induction therapy with ATG (1.5 mg/kg/day for 4 days starting at day -1) and a steroid bolus (methyl-prednisolone 500 mg, day -1) plus low dose steroids (prednisone, 10 mg/day) and interleukin-1 (IL-1) receptor antagonist (100 mg/day) for 2 weeks (with ATG and steroid bolus administered only prior to the 1st islet infusion; (iii) maintenance with rapamycin (0.1 mg/kg/day) plus mycophenolate mofetil (2 g/day).
224238078|NCT03127137|DRUG|Experimental Group 1 triamcinolone and lidocaine|Experimental Group 1 will receive Interlaminar cervical ESI at the C7-T1 level with triamcinolone 80 mg + 2 mL 1% lidocaine (total volume 4 cc)
224238079|NCT03127137|DRUG|Experimental Group 2 triamcinolone and saline|Interlaminar cervical ESI at the C7-T1 level with triamcinolone 80 mg + 2 mL preservative saline (total volume 4 cc)
224238080|NCT02304588|BIOLOGICAL|Mesenchymal stem cells|10-20 x 10\^6 cells/20mL
224320880|NCT03418844|OTHER|Self-questionnaires of living conditions and quality of life|Patients will complete self-questionnaires of living conditions and quality of life (MFI-20, FACT-G/FACT-O, FACT/COG-NTX, FACT-Cog, HADS, Insomnia Severity Index , International Physical Activity Questionnaire)
223680965|NCT01012648|DRUG|HES 130/0.4 (6%), Voluven balanced vs. Lactated Ringer's solution|Volume Resuscitation
223654405|NCT01862692|BEHAVIORAL|Baby-Net|Parents randomized to the intervention condition will receive a computerized adaptation of the empirically supported PALS parenting program as well as a laptop and wireless Internet connection. In this study, we adapted original 10-session PALS program for computer administration and included a session on reading (Read to Me, Inc.; http://www.readtomeprogram.org/index.html), developed to be incorporated within the PALS program. Each session includes the following: (a) a presentation of concepts, behaviors, and examples, (b) check-in questions recorded to the data base for review by both parent and coach, (c) the creation of a 5 minute computer-collected video of mother-infant interactions for later review by coach and parent, (d) a summary of topics, (e) daily activities (homework), (f) feedback about the program recorded to the database and (g) a weekly telephone coach call to review mother-infant computer-administered video and session topics and skills.
223654406|NCT01862692|BEHAVIORAL|Developmental Awareness Skills|Mothers in this condition will receive weekly phone contact with a coach as well as a laptop and wireless Internet connection. The laptop will contain a computer-based infant intervention program that is structurally similar to the Infant Program in terms of components (e.g., information pages, mother-infant video recording pages; coach contact pages), however weekly information will focus on their infants' development, with no direct maternal skills instruction. Mothers in this condition will receive the same number of contacts with the computer and coach as mothers in the InfantNet condition and will participate in weekly phone calls with a coach. During phone calls, parents will co-view weekly mother-infant video with their coach, with mothers having been instructed to play with their infant (with no prescribed tasks to perform) and the discussion will focus on general infant development.
223654407|NCT01168219|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic hematopoietic stem cell transplantation
223654408|NCT01168219|BIOLOGICAL|Anti-Thymocyte Globulin|Given IV
223654409|NCT01168219|DRUG|Azacitidine|Given SC or IV
223654410|NCT01168219|DRUG|Busulfan|Given IV
223654411|NCT01168219|DRUG|Fludarabine Phosphate|Given IV
223654412|NCT01168219|OTHER|Laboratory Biomarker Analysis|Correlative studies
223654413|NCT01168219|DRUG|Methotrexate|Given IV
223654414|NCT01168219|OTHER|Pharmacological Study|Correlative studies
223654415|NCT01168219|DRUG|Tacrolimus|Given PO or IV
223767814|NCT01792999|DEVICE|Contrast-enhanced KBCT|Contrast-enhanced KBCT includes pre-contrast KBCT scan and post-contrast KBCT scan. After the pre contrast scan is completed, a bolus injection of a low osmolar, nonionic, iodinated 300mg of iodine per mL contrast agent, will be injected at a rate of approximately 2.0 mL/s, for a total injection time of approximately 30-60 seconds. 30-60 seconds after the contrast injection, the post-contrast scan will be acquired.
223767815|NCT02306980|OTHER|Colostrum|Mother's own colostrum (0.2 ml) will be administered into the mouth of the infant every 2 hours for 48 hours.
223767816|NCT06794047|DIETARY_SUPPLEMENT|Vitamin C|Vitamin C tablets, please instruct the patient to swallow with water, 500mg twice daily, morning and evening.
223654416|NCT04596436|OTHER|no intervention|no intervention
223654417|NCT06531889|OTHER|classical physiotherapy program|Classical physiotherapy program=Classical physiotherapy program included transcutaneous electrical nerve stimulation, infrared radiation for 15 min, continuous ultrasound for 5 min and home exercise program. For active assistive shoulder range of motion (ROM), home exercises included the Codman exercise, flexion exercise at the ladder, and the Wand exercise, as well as some strengthening and stretching exercises performed at the pain limit with 10 repetitions twice a day (six weeks)
223654418|NCT06531889|OTHER|Core Stabilization Exercises|The interventions of the core exercise were applied when the patient lay on his/her back with his/her knees at flexion. The number of repeats for each exercise was five, and these exercises were done 3 times a week for 6 weeks with the same physiotherapist. The further steps in the exercises were extended according to the activation duration of the core muscles, and this extension was elongated 5 s
223654419|NCT03758300|OTHER|Radiofrequency|See previous page
223654420|NCT03820700|BEHAVIORAL|Hypnosis (Hypn)|The hypnosis session will consist of a 20-minute hypnosis recording created by Marie-Elisabeth Faymonville and recorded by Anne-Sophie Nyssen, both professionals in hypnosis from University of Liège. The recording includes suggestions about relaxation, corporal sensations, respiratory techniques and visual imaginative stimuli about a beautiful landscape. With this tool, the hypnosis session is standardized for all patients and there is no need of a psychotherapist to deliver hypnosis.
223654421|NCT03820700|BEHAVIORAL|Virtual reality (VR)|VR sessions. This session will consist in using a head-mounted 3D graphical display with goggles. With this tool, participants will be able to visualize a 3D immersive landscape for 20 minutes consisting of a shed near a lake at sunrise followed by a relaxing moment in the clouds. The session ends on the lake's edge.
223654422|NCT03820700|BEHAVIORAL|Virtual reality hypnosis (VRH)|The combined tool sessions. Participants will be simultaneously subjected to the same hypnosis recording and 3D visual stimuli used in the Hypn and VR conditions.
223654423|NCT02847676|PROCEDURE|Tissue sample donation|Patients undergo planned gynaecological surgery. Tissue samples, which are routinely taken, are donated.
223654424|NCT02816827|DIETARY_SUPPLEMENT|AG-01|Product to increase mental alertness
223767817|NCT06794047|OTHER|Placebo|Tablets with the same material, flavor, and appearance as the intervention group.
223654425|NCT02816827|DIETARY_SUPPLEMENT|AG-05|Product to increase mental alertness
223654426|NCT02816827|DIETARY_SUPPLEMENT|AG-06|Product to increase mental alertness
223654427|NCT02816827|DIETARY_SUPPLEMENT|AG-07|Product to increase mental alertness
223654428|NCT00514748|PROCEDURE|DIEP|flap survival, operation time, flap complications, donor site morbidity.
223654429|NCT00514748|PROCEDURE|Interconnected DIEP|flap survival, operation time, flap complications, donor site morbidity.
223767818|NCT02866617|DEVICE|Vacuum Formed Thermoplastic Retainers Constructed On 3D Reconstructed Orthodontic Study Model|
223767819|NCT01395472|BEHAVIORAL|Acute Physical Exercise|Patients and healthy volunteers will be submitted to a protocol of progressive maximal exercise until voluntary exhaustion and one weak later to 30 minutes of physical exercise in ventilatory threshold I, both in the same cycloergometer.
223767820|NCT01395472|BEHAVIORAL|Stretching protocol|TBI patients will be submitted to 30 minutes of stretching exercises composed of 15 exercises that prioritize back, legs and hip.
223767821|NCT00178438|DEVICE|Capsule Endoscopy|
223654430|NCT04193072|BEHAVIORAL|Assessment of imagery ability|Movement imagery, kinesthetic imagery, and visual imagery ability assessed.
223654431|NCT02727439|OTHER|Acute Exhausting Exercise (AE)|A single progressive rowing training to maximal exhaustion (AE).
223654432|NCT00506636|BEHAVIORAL|Tissue engineering for hair follicle regeneration|
223654433|NCT01385397|OTHER|Preceptorship and virtual community|
223654434|NCT02799251|OTHER|Collection of plasma cell rate|Lymphocytes counts are obtained from patients undergoing pulmonary or digestive cancer surgery. The rates are assessed before surgery (day 0) and at days 1, 3, 5 and 8 after surgery. Anesthetic and surgical procedures are collected as well as risk factors for postoperative infections recognized in the literature. Clinical and biological signs of infection are collected.
223654435|NCT00620932|BEHAVIORAL|Exercise|Patients will be randomly assigned to groups and will either be given an exercise program individually tailored to them for them to participate in for 6 months or else be wait-listed for 6 months and remain on whatever exercise regimen they were already on.
223654436|NCT06138860|OTHER|strain counter strain technique|It will be done in accordance with the technique principles in which the therapist will locate trigger point, and then find a position of comfort or mobile point (at least a 70% decrease in tenderness),monitored the tender point, holding the position o f comfort for 90 seconds, It will be conducted three times per session, for twelve sessions three times per week every other day over the course of a month.
223654437|NCT06138860|OTHER|physical therapy exercises|"Physical therapy exercises for twelve sessions, three times a week, over the course of a month.~Exercises will include:~stretching exercises for the hamstring, calf muscles, and back muscles.~strengthening exercises for back muscles and abdominal muscles."
223654438|NCT05300438|DRUG|TSN084|Oral tablets
223654439|NCT00792571|DRUG|Beraprost Sodium Modified Release|
223654440|NCT01949467|DRUG|iron fumarate|All patients will receive a tablet of 66mg of iron, in the form of iron fumarate (Fumafer®) with 50 ml water.
223654441|NCT00593476|OTHER|PCD|pre-packaged, portion-controlled (PCD) meal plan for 24 weeks
223654442|NCT00593476|OTHER|DSE|12 weeks of diabetes support and education (DSE) (weeks 0-12) and then crosses over to 12 weeks of PCD from weeks 13-24
223654443|NCT02836639|DRUG|Busulfan|Busulfan 0.8 mg/kg four times per day from day -7 to day -5
223767822|NCT03830294|OTHER|different temperature-controlled breast prostheses|Two types of temperature-controlled breast prostheses were applied to patients in each group
223767823|NCT01663272|DRUG|CABOZANTINIB|Daily oral cabozantinib administered days -7 until disease progression, intolerable adverse event(s) or patient choice.
223767824|NCT01663272|DRUG|gemcitabine|Gemcitabine administered intravenously on days 1, 8, and 15 every 28 days.
223767825|NCT04371276|OTHER|No intervention|Blood samples will be collected from recruited subjects from invited households for testing for hepatitis B (HBsAg, anti-HBs and anti-HBc) and hepatitis A (anti-HAV)
223654444|NCT02836639|DRUG|Etoposide|Etoposide 400 mg/m2 from day -5 to day -4
223654445|NCT02836639|DRUG|Bendamustine|Bendamustine 200 mg/m2 starting dose on day -3 and -2
223654446|NCT02600819|DRUG|E/C/F/TAF|150/150/200/10 mg FDC tablets administered orally once daily
223654447|NCT02600819|DRUG|B/F/TAF|50/200/25 mg FDC tablets administered orally once daily
223767826|NCT02665481|BEHAVIORAL|MBSR|
223767827|NCT02665481|BEHAVIORAL|Exercise|
224238081|NCT02747615|OTHER|transfused pre-operatively donated autologous blood.|Pre-operative autologous donation for minimising perioperative allogeneic blood transfusion
224238082|NCT02747615|DRUG|intravenous tranexamic acid (TXA) infusion|Intravenous tranexamic acid is a safe pharmacological treatment to reduce blood loss and transfusion requirements in patients undergoing major orthopedic surgery.
224238083|NCT02747615|OTHER|transfused only allogeneic blood.|
224238084|NCT01949194|DRUG|Regorafenib|"The dose of regorafenib given will be 160 mg once a day (od) oral (po), using a 21 days on / 7 days off treatment schedule. This equates to four (4) tablets once a day for three (3) weeks. The patient should take the dose at the same time each day, with a full glass of water, and following a light meal. A light mealconsists of less than 30% fat and around 300-550 calories."
224238085|NCT02252562|DEVICE|Sage Personal Hand Hygiene System|Utilization of a health care provider worn personal hand hygiene system during routine practice in the intra-operative setting with provider specific individual feedback.
223654448|NCT04153708|BEHAVIORAL|Retrieval patients lost to follow-up with positive HCV antibodies without RNA request or positive RNA by phone call.|Patients assigned to strategy 1 will be called to schedule an appointment with the hepatologist over a period of 14 days.
223654449|NCT04153708|BEHAVIORAL|Retrieval patients lost to follow-up with positive HCV antibodies without RNA request or positive RNA by mail letter|Patients assigned to strategy 2 will receive an invitation letter with an appointment with the hepatologist over a period of 14 days.
223654450|NCT00347373|DRUG|Tonalin Conjugated linoleic acid (dietary supplement)|
223654451|NCT06476639|DIAGNOSTIC_TEST|High-resolution bilateral groin ultrasound monitoring|Participants in the Interventional Group will undergo surgical excision of the primary tumor, either via radical wide local excision or radical vulvectomy. Post-vulvar surgery, participants will receive a groin node ultrasound every 2 months and a clinical examination every 3 months, for a follow up period of 12 months. Senior imaging specialists review bilateral ultrasound scans for positive lymph nodes or suspicious findings, promptly sending reports to the primary care physician and trial manager if detected within 3 business days. Subsequently, participants consult their primary care physician for options. Depending on clinical judgment, they may be referred for LND or continue with bi-monthly ultrasounds based on preference and clinician guidance.
223654452|NCT03104660|DEVICE|CE certified mitral valve repair systems|Patients receive a transcatheter mitral valve repair with CE certified transcatheter mitral repair systems.
223654453|NCT05767879|DRUG|Encorafenib + Binimetinib|"In the open label phase II study, the combination of BRAF/MEK inhibition with encorafenib/binimetinib in the neo-adjuvant setting will be investigated.~Furthermore, efficacy of adjuvant BRAF/MEK inhibition with encorafenib/binimetinib, for 44 weeks will be evaluated."
223654454|NCT04619160|DRUG|Propofol|TCI 4 µg/mL start until BIS-value of 50
223654455|NCT04619160|DRUG|Sevoflurane|start 1 MAC, until BIS-value of 50
223767828|NCT02665481|BEHAVIORAL|Health Education|
223767829|NCT04163549|BEHAVIORAL|Safe at Home|Discussion-based intervention
223654456|NCT02490969|PROCEDURE|Routine management observation|Early rule out of myocardial infarction with combined copetine and troponin testing at admission
223654457|NCT01638442|DRUG|CHR-2797|Two 60 mg capsules (120 mg dose) of CHR-2797 administered orally with 240 mL room temperature tap water after an approximately 10 hour fast.
223654458|NCT01638442|DRUG|CHR-2797|"Two 60 mg capsules (120 mg dose) of CHR-2792 administered orally with 240 mL room temperature tap water within 30 minutes of receiving a high-fat meal.~\--------------------------------------------------------------------------------"
223654459|NCT06260722|DRUG|Retatrutide|Administered SC.
223654460|NCT06260722|DRUG|Semaglutide|Administered SC.
223654461|NCT05585944|DIAGNOSTIC_TEST|Genotyping of rs1883832C/T related single-nucleotide polymorphism|Genotyping of rs1883832C/T related single-nucleotide polymorphism by real time pcr
223654462|NCT02975362|OTHER|Acupuncture Treatment|Acupuncture Treatment Acupoint selection base on disease stage combined adjunct acupuncture acupoint base on syndrome differentiation.①Base on disease stage: Flaccid paralysis period: DU24, DU20, Motor Area , LI15, LI14, LI11, SJ5, LI4, GB31, EX-LE2, GB34, ST36, ST40.Spastic period: DU24, DU20, Motor Area , SJ10, SJ13, LI10, SJ8, SJ5, SJ4, SJ4, BL37, BL40, BL39, BL55, BL57, ST41, GB40, BL60.②Base on syndrome differentiation:Excess syndrome of yang-type: LR3, ST37; Deficiency syndrome of Yang-type: KI3, BL23; Excess syndrome of yin-type: SP9, GB20;Deficiency syndrome of Yin-type: CV6, BL23.③Electroacupuncture acupoint: Flaccid paralysis period: LI15, LI4, GB31, ST40; Spastic period: SJ13, SJ5, BL40, BL57.30minutes each time,twenty times / treatment course，two treatment courses in total.
223654463|NCT02975362|OTHER|Rehabilitation Treatment|Rehabilitation treatment The rehabilitation program was designed according to the Chinese stroke rehabilitation treatment guidelines, which included physical therapy (PT) and occupational therapy (OT). The rehabilitation programs will be carried out five times a week (that is, Monday to Friday) for 8 weeks, and every time the rehabilitation treatment( PT and OT) will last approximately for 1 hour. All rehabilitation treatment will be carried out by qualified therapists
223654464|NCT05139329|DIAGNOSTIC_TEST|Imaging|To better understand the prevalance of further imaging for evaluation of myocarditis, all patients with negative workup will be included and see what number of patients undergo further CMRI, FGD-PET, or speckle tracking echocardiography. Patients will then be categorized as those with myocarditis with positive diagnosis, negative diagnosis or unknown.
223654465|NCT05296395|OTHER|Lactobacillus Plantarum 299v in fermented oat drink|The intervention is a probiotic lactobacillus that is contained in food products in the US
223654466|NCT05296395|OTHER|Heat-Killed Placebo control fermented drink|The intervention is the GoodBelly StraightShort that has been treated to heat kill all Lp299v
223654467|NCT02631590|DRUG|Cisplatin|Cisplatin administered once as intravenous (IV) infusion over 60 minutes. Treatment is on Days 1 and 8 every 21 days.
223654468|NCT02631590|DRUG|Gemcitabine|Gemcitabine administered as 30-min IV infusion. Treatment is on Days 1 and 8 every 21 days.
223654469|NCT02631590|DRUG|Copanlisib|Experimental Drug: Copanlisib administered as an IV over 60-minutes beginning 1 hour after completing gemcitabine infusion. Treatment is on Days 1 and 8 every 21 days.
223654470|NCT03437590|DRUG|JNJ-55308942|JNJ-55308942 will be administered as oral solution.
223654471|NCT03437590|DRUG|[18F]-JNJ-64413739|\[18F\]-JNJ-64413739 fluid for injection administered intravenously.
223654472|NCT06395337|DRUG|[111In]In-DOTA-ANTI-CEA antibody injection|tracer injection
224238086|NCT06261229|BEHAVIORAL|Intermittent fasting|The participant will consume food about/ within 8-hour per day
224238087|NCT06261229|BEHAVIORAL|Intermittent fasting + Behavioral economic|The participant will consume food about/ within 8-hour per day. They will be received a reward as money when achieve weight loss goal or/and success doing intermittent fasting 5 days/week
223767830|NCT03652298|OTHER|Memory structuring intervention + Vagal breathing|"The MSI component will teach participants to chronologically organize the segments of their memory of the incurable diagnosis, to verbally label feelings or somatic sensations they had at that moment, and to provide causal links between the event's segments and causality to their feelings and sensations, following the protocol of Gidron et al. (2001).~In the MSI part, the patient will talk, and the therapist will note the different event parts and their real timing. Each time the patient says a feeling or sensation, the therapist will ask to verbally elaborate and provide the cause of these feelings and sensations. Then, the therapist will retell the story in a chronological manner, with verbal titles and causes for feelings and sensations. Finally, the patient will be asked to retell the story in this structured manner, after being explained how to do so.~vagal breathing (i.e., deep, paced breathing) is a way to increase HRV, and thus parasympathetic activation"
223767831|NCT03652298|OTHER|support and attention (usual care)|support and attention (usual care)
223767832|NCT03285646|DRUG|Fasinumab|Subcutaneous (SC) every 4 weeks (Q4W)
224238088|NCT06261229|BEHAVIORAL|Intensive Lifestyle Modification|Advice about nutrition knowledge, healthy eating diet, diet prescription, and exercise
224238089|NCT05803746|DRUG|18F-FDG|All study participants will undergo one 18F-FDG PET/ CT scan.
224238090|NCT02319148|DRUG|itraconazole|itraconazole dosed at 200 mg
224238091|NCT02319148|DRUG|diltiazem|diltiazem dosed at 240 mg
224238092|NCT02319148|DRUG|SR verapamil|SR verapamil dosed at 240 mg
224238093|NCT02319148|DRUG|PF-00489791|PF-00489791 20 mg single dose administration
223654473|NCT06395337|RADIATION|SPECT/CT scan|abdominal and thoracic SPECT/CT scan
223654474|NCT06395337|PROCEDURE|Resection surgery|oncological resection surgery will be performed extended with the use of dual-modality imaging.
223767833|NCT03285646|DRUG|Placebo|Subcutaneous (SC) every 4 weeks (Q4W)
223767834|NCT02294201|DEVICE|Spatial Repellent product with active ingredient|Spatial Repellent product
223767835|NCT02294201|DEVICE|Active ingredient|Transfluthrin (Active ingredient)
224320881|NCT03418844|DIAGNOSTIC_TEST|Cardiac, pulmonary, auditory and biological assessment|"Patients will perform :~* Cardiac assesments (ECG, Carotid and humeral Doppler ultrasound, Trans-thoracic echocardiography 2D and 3D)~* Pulmonary and auditory assesment ( Respiratory Functional Exploration, Tonal audiogram)~* Blood tests"
223654475|NCT05709093|DRUG|Lemzoparlimab+Azacitidine (AZA)|"1. Lemzoparlimab is administered by intravenous (IV) infusion once a week at a dose of 30 mg/kg in 28-day treatment cycles~2. Azacitidine (AZA): AZA is administered by subcutaneous injection once a day at a dose of 75 mg/m2 on D1 to D7 of each treatment cycle in 28-day treatment cycles."
223654476|NCT05709093|DRUG|Azacitidine (AZA)|AZA is administered by subcutaneous injection once a day at a dose of 75 mg/m2 on D1 to D7 of each treatment cycle in 28-day treatment cycles.
223654477|NCT05400382|BEHAVIORAL|Mindfulness|Meditation training to help reduce stress and reactivity to pain and other stressors.
223654478|NCT05033704|DRUG|5% human plasma protein fraction (PPF)|"Infusion of 5% human plasma protein fraction PPF. PPF 5% Octapharma 5 % is a colloid solution containing (47.6-52.5% proteins, of which 45.6-52.5 gm/L albumin and 142.5-157.5 mmol/L sodium)."
223654479|NCT00578149|DRUG|Bevacizumab|
223654480|NCT00578149|DRUG|Carboplatin|
223767836|NCT02294201|DEVICE|Spatial Repellent product without active ingredient (SHIELD)|Spatial Repellent Product - Passive Emanator. The name of the product is SHIELD from SCJohnson
223767837|NCT05397379|DRUG|HEC96719|Oral tablets
223767838|NCT05397379|DRUG|Placebo|Comparator
223767839|NCT04955938|DRUG|Ivosidenib|A drug used to treat acute myeloid leukemia that has a mutated (changed) form of a gene called isocitrate dehydrogenase-1 (IDH1).
224238094|NCT06369948|PROCEDURE|Pericapsular Nerve Group (PENG) Block|The PENG block will be performed with the patient in the supine position. A linear high-frequency ultrasound probe (GE LOGIQ/P7 ultrasound, korea/ L6-12RS probe) is initially placed in a transverse plane over the anterior inferior iliac spine (AIIS); the probe is turned slightly medial until the hyperechoic continuous shadow of the iliopubic eminence (IPE). The target will be the plane between the psoas tendon and pubic ramus. The skin puncture site will be anesthetized using lidocaine 2% after skin disinfection and draping. A 22-gauge, 100 mm echogenic needle (Spinocan, B. Braun Melsungen AG, Germany) will be inserted in an in-plane approach to place the tip in the musculofascial plane between the psoas tendon anteriorly and the pubic ramus posteriorly. Following negative aspiration, 25 mL of the local anesthetic solution (bupivacaine 0.5%) was injected in 5 mL increments while observing for adequate fluid spread in this plane.
224238095|NCT06369948|PROCEDURE|elective hip hemiarthroplasty without receiving a PENG block.|elective hip hemiarthroplasty without receiving a PENG block.
224238096|NCT06369948|DRUG|bupivacaine 0.5% injection|bupivacaine 0.5% injection
223654481|NCT00578149|DRUG|Paclitaxel|
223654482|NCT01621802|BIOLOGICAL|Priorix|One dose administered subcutaneously in the triceps region of the right arm.
223654483|NCT01621802|BIOLOGICAL|M-M-R II|One dose administered subcutaneously in the triceps region of the right arm.
223654484|NCT01621802|BIOLOGICAL|Kinrix|One dose administered by deep intramuscular injection in the upper left deltoid.
223767840|NCT04955938|DRUG|Enasidenib|A drug used to treat acute myeloid leukemia (AML) that has recurred (come back) or has not gotten better after treatment with other anticancer therapy.
223767841|NCT04955938|DRUG|Fedratinib|This medication is used to treat a certain type of cancer (myelofibrosis). Fedratinib belongs to a class of drugs known as JAK (janus kinase) inhibitors. It works by slowing or stopping the growth of cancer cells.
224238097|NCT04797130|DEVICE|Hospital Fit 2.0|HF consists of a smartphone app combined to an accelerometer. HF provides patients and physiotherapists direct feedback on patients' physical activity behavior.. Individual goals regarding the number of minutes per day spent walking can be set by the therapist. HF also shows patients insight into their own recovery progress. During every treatment, the physiotherapist will evaluate the extent of functional recovery. In addition, Hospital Fit will give physiotherapists the option of creating a patient-specific exercise program supported by videos. During every treatment session, the patient and physiotherapist will evaluate (and if necessary adapt) the amount of activity performed since the previous treatment, the extent of functional recovery and the exercise program.
224238098|NCT05106166|BEHAVIORAL|Occupational Therapy|occupational therapy sessions are based on the joint attention
224238099|NCT06399822|DIAGNOSTIC_TEST|Nail capillaroscopy|"The intervention studied as part of the project is capillaroscopy. This examination consists of visualizing the capillaries located at the base of the nail using a device called a capillaroscope. This device magnifies the image of the capillaries to clearly visualize them. Capillaries are the smallest blood vessels, which allow the passage of only one red blood cell at a time. At the nail bed, they form a network of loops and are aligned next to each other. This alignment allows them to be viewed over their entire length. Researchers have described abnormalities in capillaries that are associated with certain diseases involving microvascular damage.~The results of capillaroscopy will be reported qualitatively, for all eight long fingers examined."
224238100|NCT02735174|DEVICE|Sensor cap system for inhalers|All subjects will be given a commercially available inhaler cap with monitoring sensor on clinically prescribed asthma inhalers.
224238101|NCT02735174|OTHER|App for SmartPhone|All subjects will be given smart phone with mobile software management platform to motivate and record medication adherence.
224238102|NCT02735174|BEHAVIORAL|Motivational interviews|All subjects will have motivational telehealth visits to assess adherence and promote problem-solving skills
224238103|NCT02735174|OTHER|Telehealth clinic visits|All subjects will have asthma medical visits via telehealth technology to assess asthma control.
224238104|NCT02048865|DRUG|Apixaban|Apixaban 2.5 mg tablets BID for 6 months
224238105|NCT02048865|DRUG|Placebo drug|placebo drug 2.5mg BID for 6 months
224238106|NCT00751465|BEHAVIORAL|Task Concentration Training|Task Concentration Training TCT following Bögels et al. (1997).
223767842|NCT03623828|DRUG|Apomorphine Hydrochloride 50Mg/10mL Prefilled Syringe|Product administered using an external continuous subcutaneous infusion pump.
223767843|NCT05717998|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223767844|NCT05717998|PROCEDURE|Computed Tomography|Undergo cardiac PET/CT
223767845|NCT05717998|PROCEDURE|Magnetic Resonance Imaging of the Heart|Undergo CMR
223654485|NCT01621802|BIOLOGICAL|ProQuad|One dose administered subcutaneously in the triceps region of the left arm.
223654486|NCT03236376|OTHER|additional sensorimotor therapy for the upper limb|The intervention will consist of additional physiotherapy for the upper limb after stroke consisting of sensory discrimination training and sensorimotor training.
223767846|NCT05717998|PROCEDURE|Positron Emission Tomography|Undergo cardiac PET/CT
223654487|NCT03236376|OTHER|additional motor therapy for the upper limb after stroke|The intervention will consist of additional physiotherapy for the upper limb after stroke consisting of cognitive-attention based training and motor training
223654488|NCT02850913|DRUG|Doxycycline|"* 115 participants will be randomized to either oral Doxycycline 100 mg daily for six weeks.~* Treatment will be initiated in hospital but will be continued at home.~* Scheduled study clinic visits will be made by the participants at 6, 12 and 24 months.~* Each participant will be visited at home at 2, 4 and 6 weeks for adherence monitoring and assessment of safety"
223654489|NCT02850913|OTHER|Placebo|\- Placebo (matching capsules containing no active ingredients)
223654490|NCT05909657|OTHER|questionnaires (surveys)|Mixed-methods study. Both the qualitative interview guides and the questionnaire surveys are adapted from the Sickle Cell Disease Implementation Consortium (SCDIC) project which is a multicentre study occurring in the United States.
224238107|NCT00751465|BEHAVIORAL|Standard CBT|Standard CBT following the Clark-and-Wells (1995) model of social anxiety disorder, relying on the German manual for SAD (stangier et al., 2006). Includes the model, role-plays with and without safetey behavior, video-feedback.
224238108|NCT02583204|DEVICE|Onicolife nail drops|The prescription free, CE (Conformité Européenne) marked product is for local application, and has a novel mode of action involving the modulation of mast cell action with the fatty acid amide, Adelmidrol ®. Mast cells are known to have a key role in the ability of the body to promote healing /repair and control tissue damage caused by chemo and radiotherapy. This includes damage to the nail and/ or nail matrix. OnicoLife ® thus helps to control inflammation and pain whilst antimicrobial action also provides antibacterial and antifungal support.
224238109|NCT02583204|OTHER|Nail polish|One dark colour of nail polish (deep burgundy/red) will be used in this study since this colour is considered more acceptable to many more women than a pure black coloured nail polish and hence, more likely to ensure compliance. No nail polish containing hardeners will be used since there is some evidence to suggest they can induce nail changes. As dark nail polish can stain the nail plate (and therefore mask any changes in nail pigmentation induced by chemotherapy), one clear base coat, two coats of coloured, and one clear top coat of polish will be required for each application. This standard of application is proposed as a gold standard for the prevention of nail staining and hypersensitivity reactions by an eminent podiatrist (Spalding, 2008).
224238110|NCT03026270|OTHER|Paraffin|The application of paraffin wax will be performed with the patient in the supine position at rest for at least 10 min, then with an appropriate brush (5 cm wide), will spend several layers with the brush into two distinct groups, seven or ten layers depending on the outcome of randomisation, in the region of interest of the upper limb, being scarred, surrounded by a plastic film film remaining in the area for 15 minutes, and then discarded
224238111|NCT01087970|DRUG|Pemetrexed|Administered intravenously, for maximum of 6 cycles.
224238112|NCT01087970|DRUG|Cetuximab|"Administered intravenously in combination therapy, for a maximum of 6 cycles.~After the completion of 6 cycles, participants who have not experienced disease progression will continue on cetuximab monotherapy until disease progression."
224238113|NCT01087970|DRUG|Carboplatin|Administered intravenously, for a maximum of 6 cycles
223654491|NCT03713346|OTHER|Lactose free milk|Single dose of lactose free milk
223654492|NCT03713346|OTHER|Jersey milk|Single dose of jersey milk
223654493|NCT03713346|OTHER|High A1 β-casein milk|Single dose of high A1 β-casein milk (commercial milk)
223654494|NCT03713346|OTHER|High A2 β-casein milk|Single dose of A2 β-casein milk
223654495|NCT02405377|PROCEDURE|hydration|Before the coronary procedures, investigators used the same 0.9% sodium chloride for hydration in all patients. Investigator monitored the central venous pressure (CVP) by placing an 5-French catheter in the jugular vein in the intervention group, and administration fluid rate was adjusted according to the CVP as follows: 3 ml/kg/h for CVP lower than 6 mmHg, 1.5 ml/kg/h for pressure of 6-12 mmHg, and 1ml/kg/h for pressure higher than 12 mmHg. The control group was hydrated with 0.9% sodium chloride at 1 ml/kg/h, continued for the duration of 12 h post-procedure in both groups. Thus, both study groups received intravenous fluids for the same duration but at different rates. All study participants received intra-arterial Visipaque(320 mg I/ml; GE Healthcare) iso-osmolar contrast medium.
223767847|NCT06366490|BIOLOGICAL|Innocell Autologous Cellular Immunotherapy|Innocell Autologous Cellular Immunotherapy
224238114|NCT01087970|DRUG|Cisplatin|Administered intravenously, for a maximum of 6 cycles
224238115|NCT06234670|OTHER|No intervertion|This study is a retrospective observational study without intervention.
223767848|NCT05524324|DEVICE|CRT ON (biventricular pacing) / CRT OFF (inactive or univentricular pacing)|Patients randomized to the CRT ON / CRT OFF arm will undergo a first intervention to activate their device and then a second intervention for 3 months to inactivate their device.
223767849|NCT05524324|DEVICE|CRT OFF (inactive or univentricular pacing) / CRT ON (biventricular pacing)|Patients randomized to the CRT OFF / CRT ON arm will undergo a first intervention to inactivate their device and then a second intervention for 3 months to activate their device.
223767850|NCT02653196|PROCEDURE|Allogeneic hematopoietic stem cell transplant following thiotepa-based marrow ablative chemotherapy|Allogeneic hematopoietic stem cell transplant (HSCT) following thiotepa-based marrow ablative chemotherapy (MAC) for children with high-grade and/or recurrent neuro-epithelial and other solid tumors.
223767851|NCT02653196|DRUG|Keratinocyte Growth Factor|KGF 60 mcg/kg IV: 6 doses
223767852|NCT02653196|DRUG|Alemtuzumab|Alemtuzumab 12 mg/m2 IV: 2 doses (not given if matched related donor is 10/10 HLA matched sibling donor)
223654496|NCT02405377|DRUG|Visipaque|All study participants received intra-arterial (320 mg I/ml; GE Healthcare)
223654497|NCT02405377|DRUG|0.9% sodium chloride ﬂuid administration|
223654498|NCT02405377|DEVICE|5-French catheter|
223767853|NCT02653196|DRUG|Thiotepa|Thiotepa 300 mg/m2 IV: 3 doses
223767854|NCT02653196|DRUG|Etoposide|Etoposide 100 mg/m2 IV: 3 doses
223767855|NCT02653196|DRUG|Fludarabine|Fludarabine 30 mg/m2 IV: 3 doses
223767856|NCT02653196|DRUG|Melphalan|Melphalan 70 mg/m2 IV: Day 2 doses
223654499|NCT03169725|BIOLOGICAL|Inactivated Poliomyelitis Vaccine (Sabin strain)|Investigational IPV based on Sabin strain (LBVC). Should be injected by intramuscular three injections in the anterolateral aspect of thigh at 6, 10 and 14 weeks of age.
223654500|NCT03169725|BIOLOGICAL|Inactivated Poliomyelitis Vaccine (Salk strain)|Commercialized IPV based on Salk strain (Imovax Polio). Should be injected by intramuscular three injections in the anterolateral aspect of thigh at 6, 10 and 14 weeks of age.
223654501|NCT03790696|DEVICE|Cognitive Training Program|"The cognitive training program has been designed by Dr. Sylvester. It is a simple computer game looking at some shapes and faces on a computer screen and pressing a button when a target shape appears.~This is the first study to use this exact computer training regimen for testing in its ability to reduce symptoms of anxiety in children with anxiety disorders. Each session of the computer game takes approximately 45-60 minutes and subjects complete 8 total sessions over one month. The computer game involves paying attention to parts of the screen while distracting square boxes appear at other locations. A target X appears at the location that participants are paying attention to and the subjects press a button when it appears."
223654502|NCT04743986|BIOLOGICAL|Platelet Rich Plasma (PRP)|RegenLab, Lausanne, Switzerland
223654503|NCT04743986|DRUG|Corticosteroid (CS)|40mg/ml triamcinolone in 2 ml 0.5% bupivicaine
223654504|NCT03353506|BIOLOGICAL|LFMT|Lyophilized fecal microbiota transplant
223654505|NCT03353506|BIOLOGICAL|LSFF|Lyophilized sterile fecal filtrate
223654506|NCT01149148|DEVICE|INVOS Somanetics Cerebral Oximeter|"Sequence of Interventions To Increase Cerebral Oxygen Saturation~1. Check head and cannula position~2. Increase mean arterial pressure~3. Increase pump flow~4. Increase systemic oxygenation~5. Increase PaCO2 \> 45~6. Increase anesthetic depth by increasing volatile anesthetic or by administering propofol boluses~7. Consider PRBC transfusion for Hct \< 21%"
223654507|NCT01149148|DEVICE|INVOS Somanetics Cerebral Oximeter|INVOS Cerebral Oximetry blinded monitoring with no deviation in surgical procedures or standard of care in anesthesia.
223654508|NCT03599219|BIOLOGICAL|sample|confirmation of platelet dysfunction
223654509|NCT02595489|DIETARY_SUPPLEMENT|vitamin D3|Daily oral supplement provided by study investigators
223654510|NCT03436082|DEVICE|A mobile health platform|Patients pilot testing the smartphone based, mobile health platform called HUGO. Patients will also be given syncable devices to use that will provide additional insights into their health and health outcomes.Patients will be queried about specific symptoms related to their procedure at enrollment, one week post-procedure, at 4 weeks and again at 8 weeks.
223654511|NCT02449148|OTHER|Calorie Restriction|diet intervention to reduce the risk for obesity associated diseases
223654512|NCT04867304|OTHER|Patient education about chronic pancreatitis.|"Patients in the second cohort were educated about their disease phenotype in a structured and personalised manner that included their disease course, symptoms, imaging, treatment option and possible long-term outcomes and prognosis. This was followed by answering all the queries of the patient and their caregivers.~The patients were advised to visit the Pancreas clinic after 3-months for re-evaluation of the clinical, psychological and metabolic parameters."
223654513|NCT01079299|DEVICE|Intermittent, gradient, pneumatic compression device|lymphedema pump provides external compression in a segmental,gradient fashion
223654514|NCT04043858|DRUG|Midodrine 2.5 mg tab|Patients receive an oral daily dose of 2.5 mg midodrine if age 7-12 years and receive 2.5 mg twice daily of more than 12 years
223654515|NCT06168916|DIAGNOSTIC_TEST|PET/CT with contrast medium in a single session.|Patients will undergo low dose PET/CT with FDG. Following the PET exam, a Standard CT with contrast medium will be acquired, using the CT tomography inserted inside the PET.
224238116|NCT03500861|OTHER|Dry Needling|"The trigger point DN procedure was performed by a certified physiotherapist. While the patient was sitting, the therapist firstly cleaned the area with alcohol. Then, DN was applied into the active TrPs on the basis of the technique described by Hong (19). The needle remained in the trigger points for 20 minutes. Upon removal of the needle, the area was compressed firmly with a cotton swab for 60 secs. The DN procedure used sterile stainless-steel acupuncture needles of 0.25x40 mm and 0.25x 25 mm dimensions (Hua Long ®). DN was applied three times a week for 2 weeks, in previously diagnosed active trigger points located in the musculature of the head and the neck.~the Sham Dry Needling procedure was applied into the adipose tissue located at any area where an active TrPs was absent."
224238117|NCT03618953|BIOLOGICAL|Ad-E6E7|Adenovirus vaccine expressing mutant HPV E6 and E7
224238118|NCT03618953|BIOLOGICAL|MG1-E6E7|MG1 Maraba oncolytic virus expressing mutant HPV E6 and E7
224238119|NCT03618953|BIOLOGICAL|Atezolizumab|monoclonal antibody; checkpoint inhibitor
224238120|NCT05692999|DRUG|Pembrolizumab 200 mg Q6W|Pembrolizumab 200mg Q6W
224238121|NCT05692999|DRUG|Pemetrexed 500 mg/m^2 Q3W|Pemetrexed 500 mg/m\^2 Q3W
224238122|NCT05692999|DRUG|Pembrolizumab 200 mg Q3W or 400 mg Q6W|Pembrolizumab 200 mg Q3W or 400 mg Q6W
223654516|NCT03145870|OTHER|Echoing of the lower limbs and measuring the systolic pressure index|Echoing of the lower limbs and measuring the systolic pressure index
223654517|NCT01851603|DEVICE|AVL-3288|Drug
223654518|NCT01851603|DRUG|Placebo|Identical diluent to that used for AVL-3288
223654519|NCT01818011|DRUG|GSK1322322 Initial fit for purpose tablets|Beige, capsule shaped, film-coated tablet with unit dose strength of 500 mg/tablet and dose level of 1500 mg (3 x 500 mg) for single dose oral administration in Part A
223654520|NCT01818011|DRUG|GSK1322322 over granulated tablets|Light beige, oval shaped, film-coated tablet with unit dose strength of 500 mg/tablet and dose level of 1500 mg (3 x 500 mg) for single dose oral administration in Part A
223654521|NCT01818011|DRUG|GSK1322322 intended commercial tablets|Light beige, oval shaped, film-coated tablet with unit dose strength of 500 mg/tablet and dose level of 1000 mg (2 x 500),1500 mg (3 x 500 mg) and 2000 mg (4 x 500mg) for single dose oral administration in Part A and B and repeat dose administration twice daily in Part C
223654522|NCT01818011|DRUG|Placebo tablets|Light beige, oval-shaped, film-coated tablet for repeat dose oral administration (BID for 6 days) in Part C
223654523|NCT01818011|DRUG|13C-GSK1322322 stable isotope powder|White to slightly colored non-sterile crystalline powder for oral suspension with dose level of 50 mg as a single dose with GSK1322322 tablets in Part A
223654524|NCT01818011|DRUG|GSK1322322 for injection|White to slightly colored lyophilized powder cake in clear glass vials with unit dose strength of 400 mg/vial and dose levels of 600 mg (1.5 x 400 mg/vial), 900 mg (2.25x400mg/vial), 1200 mg (3x400mg/vial and 1200 mg (3 x 400 mg) for IV administration either as single dose in Part B or as a repeat dose (BID for 4 days) in Part C
223654525|NCT01818011|DRUG|Placebo injection|A clear and colorless 0.9% Sodium Chloride solution for intravenous administration twice daily for 4 days in Part C
224320882|NCT04524000|DRUG|Alpelisib|"\[Part 1\] Alpelisib administered at 200 mg (DL 1), 250 mg (DL 2) or 300mg (DL 3) orally once daily on a continuous dosing schedule starting on Cycle 1 Day 1 in a 28 day cycle.~If DL 1 is tolerated, the alpelisib doses of 250 mg will be investigated. If DL 2 is tolerated, the alpelisib doses of 300 mg will be investigated.~\[Part 2\] In the Part 2, participants will be enrolled into Cohort 2 (CDK4/6 inhibitor naive) and Cohort 3 (CDK4/6 inhibitor pre-treated) in parallel and alpelisib will be administered at the recommended dose identified in Part 1."
223654526|NCT03473509|OTHER|CKD Registry|Health Service intervention
223654527|NCT03791957|OTHER|Blood Haemoglobin|Routine haemotological investigation of blood haemoglobin levels in gm/dL will be recorded from withdrawn venous blood
223654528|NCT02049593|DRUG|PARP inhibitor BMN-673|Given PO
223654529|NCT02049593|DRUG|temozolomide|Given PO
223654530|NCT02049593|DRUG|irinotecan hydrochloride|Given IV
223654531|NCT02049593|OTHER|pharmacological study|Correlative studies
223654532|NCT02049593|OTHER|laboratory biomarker analysis|Correlative studies
223654533|NCT03498937|DEVICE|Active tDCS|10 active tDCS sessions (2 sessions/day for 5 days, 30 min each, 2 mA) applied to the dlPFC
223654534|NCT03498937|DEVICE|Sham tDCS|10 sham tDCS sessions (2 sessions/day for 5 days, 30 min each, 0 mA) applied to the dlPFC
224320883|NCT04524000|DRUG|Fulvestrant|Fulvestrant is administered at a dose of 500 mg intramuscular on Cycle 1 Day 1, Day 15, and Day 1 of every cycle thereafter (where a cycle is 28 days).
223654535|NCT01931319|DRUG|Intravenous baclofen|
223654536|NCT02637492|OTHER|Collection of clinical signs and symptoms|Collection of clinical signs and symptoms used for developing a Clinical prediction rule of critical lower limb ischaemia (diagnosed by haemodynamic methods: ankle pressure, toe pressure-laser Doppler or photo-plethysmography, transcutaneous oxygen pressure) in patients with peripheral occlusive arterial disease
223654537|NCT00950859|DRUG|GSK1349572 (Cohort I)|50 mg once daily
223654538|NCT00950859|DRUG|GSK1349572 (Cohort II)|50 mg twice daily
223654539|NCT04896086|DRUG|VRC-GENADJ0110-AP-NV (Adjuplex)|Adjuplex is a sterile, pyrogen-free adjuvant solution produced by the VRC Pilot Plant. Adjuplex comprises highly purified de-oiled soy lecithin and benzene-free carbomer homopolymer formulated in phosphate buffered saline. Adjuplex adjuvant was mixed with FluMos-v1 at 20% by volume in the pharmacy during product preparation for the vaccinations of Groups 5A-5B.
223654540|NCT04896086|BIOLOGICAL|Flucelvax|Flucelvax is an inactivated influenza vaccine licensed for the 2020-2021 season.
223654541|NCT04896086|DRUG|VRC-FLUMOS0111-00-VP (FluMos-v1)|FluMos-v1 investigational vaccine is composed of engineered pentameric promoters based on C. albicans lumazine synthase assembled with 20 trimeric promoters displaying HA ectodomains. It contains hemagglutinin (HA) proteins from the following 4 influenza strains: A/Idaho/07/2018, A/Perth/1008/2019, B/Colorado/06/2017 and B/Phuket/3073/2013.
223654542|NCT02917642|DEVICE|Ultrasonic Irrigation|Passive Ultrasonic Irrigation is based on the transmission of acoustic energy through the irrigant by a stainless steel wire or endodontic file
223654543|NCT02917642|DEVICE|Non-Ultrasonic Irrigation|Syringe and needle irrigation with no-ultrasonic activation
223654544|NCT02765581|DEVICE|Verum acupuncture|"The main acupuncture points are bilateral Hegu (L14) and Taichong (LR3), unilateral Taiyang(EX-HN5), Fengchi (GB20) and Shuaigu (GB8). Additional points can be chosen according to individual syndrome differentiation of meridians: (1) Yangming headache: Touwei (ST8); (2) Taiyang headache: Tianzhu (BL10); (3) Jueying: Baihui (GV20). The NO.16 special type of acupuncture (0.30 x 30 mm) produced by German asia-med company will be applied.The needles will be inserted into the skin of acupuncture points and manipulated manually by using the techniques such as lifting, thrusting, and twirling, until the internal compound sensation known as deqi."
223654545|NCT02765581|DEVICE|Sham acupuncture|"We use a non-insertive sham control produced by Asia-med Company in Germany-the streitberger placebo-needle. Sham points are described as follows: 1) Bilateral of midpoint between acupoint Jianjin(GB21) and Jugu(LI16); 2) 5 cun lateral to the seventh thoracic spine; 3) 5 cun lateral to the eighth thoracic spine; 4) 5 cun lateral to the ninth thoracic spine. Cun is a distance measure unit used in locating acupoints in traditional Chinese medicine (TCM) acupuncture, and the width of patient's thumb interphalangeal joint is regarded as one cun."
223654546|NCT02765581|BEHAVIORAL|Usual care|Health education is provided in three aspects: lifestyle changes, behavioral therapies and migraine self-management.
223767857|NCT02653196|DRUG|Tacrolimus|Tacrolimus 0.05 mg/kg/day IV (Cyclosporine may be substituted for Tacrolimus): Start Day -2, begin taper on Day +100, discontinue on Day +180
224238123|NCT02359331|PROCEDURE|H. pylori culture and antimicrobial susceptibility testing|"This intervention will be performed in 7 days tailored therapy group.~All the patients who enrolled in this arm, they will be received endoscopy guided biopsy procedure. Minimum inhibitory concentrations (MICs) were determined by the agar dilution method. Amoxicillin, clarithromycin, metronidazo, tetracycline and moxifloxacin for the H. pylori isolates were examined by use of the serial two fold agar dilution method"
224238124|NCT02359331|DRUG|14 days empirical bismuth quadruple therapy (Proton pump inhibitor)|"Giving the 14 days PBMT regimen as 2nd rescue therapy~Proton pump inhibitor (PPI) regular dose b.i.d., tripotassium dicitrate bismuthate 300 mg q.i.d. (three tablets at 30 min before meals and one tablet at 2 hours after dinner), metronidazole 500 mg t.i.d., and tetracycline 500 mg q.i.d."
224238125|NCT02359331|DRUG|Metronidazole|
224238126|NCT02359331|DRUG|Tetracycline|
224238127|NCT02359331|DRUG|tripotassium dicitrate bismuthate|
224238128|NCT02359331|DRUG|7 days tailored therapy Proton Pump Inhibitor|
224238129|NCT02359331|DRUG|Moxifloxacin|
224238130|NCT02359331|DRUG|Amoxicillin|
224238131|NCT00263965|DRUG|Tesaglitazar|
224238132|NCT00263965|DRUG|Metformin|
224320884|NCT06400238|PROCEDURE|Biopsy Procedure|Undergo biopsy
224320885|NCT06400238|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
224320886|NCT06400238|PROCEDURE|Computed Tomography|Undergo CT scan
223654547|NCT04437134|OTHER|On-line exercise and education|"Exercise:~Exercise is performed twice weekly for 6 weeks. Each exercise session lasts approximately 60 min. and consists of three parts; warm-up (10 min.), neuromuscular exercises (40 min.), and cool-down/stretching (10 min.). The neuromuscular exercises include exercises for core stability, postural orientation, function and leg muscle strength. Exercises are performed in 2-3 sets with 10-15 repetitions with three levels of difficulty described. The exercises follow the standardized GLA:D exercise protocol. Patients are instructed in how to use alternative equipment at home for each exercise if necessary prior to the first on-line exercise session.~Education:~Patients attend two to three on-line educational sessions at the start of each GLA:D program. The educational sessions focus on disease-management and self-help strategies, including OA disease features and symptoms, treatment options, and exercise and physical activity as treatment."
223654548|NCT04437134|OTHER|On-site exercise and education|"Exercise:~Exercise is performed twice weekly for 6 weeks. Each exercise session lasts approximately 60 min. and consists of three parts; warm-up (10 min.), neuromuscular exercises (40 min.), and cool-down/stretching (10 min.). The neuromuscular exercises include exercises for core stability, postural orientation, function and leg muscle strength. Exercises are performed in 2-3 sets with 10-15 repetitions with three levels of difficulty described. The exercises follow the standardized GLA:D exercise protocol. The exercise sessions are delivered at physiotherapy clinics in Denmark.~Education:~Patients attend two to three on-site educational sessions at the start of each GLA:D program. The educational sessions focus on disease-management and self-help strategies, The educational sessions focus on disease-management and self-help strategies, including OA disease features and symptoms, treatment options, and exercise and physical activity as treatment."
223654549|NCT00475696|DRUG|Duloxetine|
223654550|NCT00458978|DRUG|Cediranib Maleate|Given orally
223654551|NCT00458978|OTHER|Laboratory Biomarker Analysis|Correlative studies
223654552|NCT05576636|BEHAVIORAL|Simulation training|"Expectations regarding the scenario were explained to the participants before the implementation. They were given information about the standard patient. Roles were distributed, and the implementation time of the scenario was announced. Written permission was obtained from students involved in the scenario. The intervention group was given scenario-based education appropriate for the approach to a standard patient with COVID-19. During the implementation of the scenario, the instructor did not interfere with students, and after the feedback, the show-do method was used to improve the incorrect skill steps. Two instructors evaluated students' performance on the standard patient simulation as achieved-failed and the application was recorded as a pre-test."
223654553|NCT05576636|OTHER|Control Group|The control group didn't apply any interference during the study. Participants in the control group continued their routine follow-up.
223654554|NCT03398083|DRUG|THC|THC capsule
223654555|NCT03398083|DRUG|Alprazolam|Alpraxolam capsule
223654556|NCT03398083|DRUG|Placebo oral capsule|Sugar pill capsule
223654557|NCT03398083|DRUG|CBD|CBD capsule
223654558|NCT04396561|DRUG|Paravertebral group (group P):|"In both groups, one reading of mean arterial pressure and heart rate were taken before induction of general anaesthesia and were defined as baseline readings and then were recorded intra-operatively at 15 min intervals.~Additional bolus doses of fentanyl 0.5µg/kg were given when the mean arterial blood pressure or heart rate raised above 20% of baseline levels."
223654559|NCT02249832|DEVICE|seated robot-assisted ankle therapy|The MIT anklebot provides over one thousand total dorsi/plantar flexion and inversion/eversion robot-assisted movements of the ankle while in a seated position.
223654560|NCT03357588|OTHER|Intensified monitoring|Intensified virological monitoring during first-line ART with viral load monitoring at month 6 of ART and 3-monthly thereafter, followed-up consecutively by point-of-care qualitative drug level testing and drug resistance testing in case of a viral load \>1000 copies/mL, during first-line antiretroviral treatment (ART) for HIV-1 infection as prescribed by South African national guidelines.
223654561|NCT03357588|OTHER|Standard of care monitoring|Standard-of-care virological monitoring during first-line ART as described by WHO and South African National Department of Health ART guidelines, consisting of viral load monitoring at month 6 and 12 of ART and annually thereafter, followed-up by a repeat measurement within 3 months after a viral load \>1000 copies/mL, during first-line antiretroviral treatment (ART) for HIV-1 infection as prescribed by South African national guidelines.
223654562|NCT01635426|DRUG|Aspirin|Aspirin 75 mg daily for 2 months after meals
224320887|NCT06400238|DRUG|Copanlisib|Given IV
223654563|NCT01635426|DRUG|Clopidogrel|Clopidogrel 75 mg daily for 2 months after meals
223654564|NCT05212818|DRUG|TF0023|Techfields Inc. is developing TF0023, a new investigational prodrug, indicated for relief of the signs and symptoms of ARDS and pneumonia caused by COVID-19 and other viruses.
223654565|NCT02664571|DEVICE|Pet scan with FBB|"Patients will have a pet scan with Florbetaben (NEURACEQ : FBB). All other care corresponds to routine care.~Florbetaben is used during pet scans to visualize beta amyloid plaques and cannot be a separate intervention in and of itself."
223654566|NCT02664571|DEVICE|MRI scan|Subjects will have an MRI scan at inclusion.
223654567|NCT02664571|BIOLOGICAL|APO E genotyping|Subjects will have APO (apolipoprotein) E genotyping if not already known.
223654568|NCT03765034|BEHAVIORAL|Constrain-induced Movement Therapy|8-week therapy program utilizing constraint of the unaffected arm
223654569|NCT03765034|BEHAVIORAL|Usual Occupational Therapy|8-week therapy program without constraint of the unaffected arm
223654570|NCT05799248|DRUG|rhPSMA-7.3 (18F)|Patients will receive a dose with an administered activity of 8 mCi (296 MBq) ± 20% of rhPSMA-7.3, delivered as an IV bolus injection with a 10 mL fast 0.9% sodium chloride flush, followed by PET imaging.
223654571|NCT06529926|OTHER|Observational|Only classical physiotherapy application for 4 weeks.
223654572|NCT06529926|OTHER|IASTM Technique Application|IASTM application for 2 sessions per week with classical physiotherapy for 4 weeks.
224320888|NCT06400238|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
224320889|NCT05861986|DRUG|Risdiplam|Participants will receive risdiplam orally at the currently approved dose. The dose should be adapted for weight and age.
224320890|NCT06106295|DRUG|Metyrapone|250 to 1000 milligram (mg) orally in one or two doses in the evening (administered 4 and 2 hours prior to bed)
223654573|NCT04000854|DRUG|Calcium hydroxide (Calacept)|Long-term follow up of pulp regenerative treatment using two different root canal dressings: calcium hydroxide and chlorhexidin digluconate in immature necrotic traumatized incisiors
223654574|NCT03398499|DEVICE|VIOFOR (Med & Life)|Device: VIOFOR (Med \& Life) Magnetic-light applicators, generating a slow-changing electromagnetic field and light ener-gy (830 nm and 640 nm), emitted from LEDs during a physiotherapeutic treatment application parameters: frequency of basic field pulses: 180-195 Hz frequency of packet the field pulses: 12.5 Hz-29 Hz magnetic induction: 15 μT wavelength of light: 830 nm and 640 nm Duration: 10 min number of treatments: 10
223654575|NCT00229567|DRUG|Lidocaine infusion plus ketamine injection|
223654576|NCT01804738|OTHER|Jasmine rice|Standardised rice:cooking liquid ratio for 50g available carbohydrate portion
223654577|NCT01804738|OTHER|Parboiled basmati rice|Standardised rice:cooking liquid for 50g available carbohydrate portion
223654578|NCT00717704|DRUG|ixabepilone|by vein once every 3 weeks
223654579|NCT00717704|DRUG|Dasatinib|by mouth once daily
223654580|NCT02516969|RADIATION|Stereotactic Body Radiotherapy|Radiation
223654581|NCT01588418|DRUG|Exenatide|Exenatide (5mcg) was administered in random order 30 min before OGTT-PET study, crossover study
223654582|NCT01588418|DRUG|Placebo|Placebo was administered in random order 30 min before OGTT-PET study in the same subject
223654583|NCT04216264|BEHAVIORAL|Standard response|Parents pick from a menu of behavior changes
223654584|NCT04216264|BEHAVIORAL|Targeted response|Stepped up phone interaction with parents based on menu of behavior changes
223654585|NCT00701883|DRUG|Placebo|2 capsules, once a day for 8 weeks
223654586|NCT00701883|DRUG|MBX-8025|2 capsules, once daily for 8 weeks
223654587|NCT00701883|DRUG|MBX-8025|2 capsule, once daily for 8 weeks
223654588|NCT00701883|DRUG|Atorvastatin|2 capsules, once daily for 8 weeks
223654589|NCT00701883|DRUG|MBX-8025|2 capsules, once daily for 8 weeks
223654590|NCT00701883|DRUG|MBX-8025|2 capsules, once daily for 8 weeks
223654591|NCT04212962|BEHAVIORAL|Transitional care model (TCM)|Patient education about post-discharge self-care and medications, arrangement of needed social services, coordination of information from medical providers interacting with patient
223654592|NCT04212962|BEHAVIORAL|Usual care|usual hospital discharge and post-discharge care
223654593|NCT00970996|DRUG|Temozolomide|250 mg/m\^2 by mouth on days 1, 2, and 3 of each 21-day cycle.
223654594|NCT00970996|DRUG|Abraxane|100 mg/m\^2 given in a short intravenous infusion 1 hour after completion of Temozolomide and a 2nd dose of 70 mg/m\^2 given on day 5 of each 21-day cycle.
223654595|NCT00970996|DRUG|Cisplatin|20 mg/m\^2 intravenously on days 1, 2, 3, and 4 delivered immediately after Abraxane of each 21-day cycle.
223654596|NCT00970996|BIOLOGICAL|Interleukin-2|9 MIU/m\^2 in a continuous intravenous infusion over 24 hours on days 1, 2, 3, and 4 (total of 96 hours) beginning after completion of Cisplatin of each 21-day cycle.
223654597|NCT00970996|BIOLOGICAL|Interferon alpha 2b|5 MIU/m\^2 in subcutaneous injection on days 1, 2, 3, 4, and 5 of each 21-day cycle.
223654598|NCT01571518|DRUG|late leukostim|injection of G-CSF (leukostim)5㎍/kg from day 5 of TAC chemotherapy
223654599|NCT01571518|DRUG|early leukostim|injection of G-CSF (leukostim)5㎍/kg from day 2 of TAC chemotherapy
223654600|NCT03847506|DRUG|Ezetimibe/Rosuvastatin|Ezetimibe/Rosuvastatin 10 mg/10 mg + Candesartan cilexetil/Amlodipine besylate 8 mg/5 mg + Candesartan cilexetil 8 mg placebo
223654601|NCT03847506|DRUG|Candesartan cilexetil/Amlodipine besylate|Candesartan cilexetil/Amlodipine besylate 8 mg/5 mg + Ezetimibe/Rosuvastatin 10 mg/10 mg placebo + Candesartan cilexetil 8 mg placebo
223654602|NCT03847506|DRUG|Candesartan cilexetil|Ezetimibe/Rosuvastatin 10 mg/10 mg + Candesartan cilexetil 8 mg + Candesartan cilexetil/Amlodipine besylate 8 mg/5 mg placebo
223654603|NCT02644603|PROCEDURE|Enhanced Recovery After Surgery|"Before operation:~Preoperative optimization of organ function, No preoperative bowel preparation, Prohibit eating 6h, drinking water 2h before operation, Oral rehydration before operation.~In operation:~Optimized combined anesthesia, Minimal invasive operations, Normothermia, Minimal use of tubes and drains.~After operation:~Postoperative analgesia and antiemetic, Early mobilization, Oral nutrition, Early and scheduled mobilization."
223654604|NCT00594243|BEHAVIORAL|Mindfulness based stress reduction program|8-week mindfulness based stress reduction program
223654605|NCT00594243|OTHER|Wait-list control|No treatment given.
223654606|NCT00429728|DRUG|GW876008|
223654607|NCT03072108|DIETARY_SUPPLEMENT|Bonolive|2 caps per day of Bonolive
223654608|NCT03072108|DIETARY_SUPPLEMENT|Placebo|2 caps per day of Placebo
223654609|NCT00243269|BEHAVIORAL|Acupressure expectancy enhancement|"This study hypothesizes that patients receiving efficacy enhancing information about the acupressure bands will expect less treatment-related nausea, which will subsequently result in less treatment-related nausea compared to patients who do not receive such information.~This study extends prior research by utilizing a randomized controlled trial in a clinical environment to examine the efficacy of an intervention that is specifically designed to reduce patients' response expectancies concerning nausea development from cancer treatments, and, thereby, reduce nausea."
223654610|NCT00004802|DRUG|dichlorphenamide|
223654611|NCT04909073|DRUG|Afatinib|Continuous treatment of afatinib 30mg tablet once daily in the absence of disease progression or unacceptable treatment-related toxicity, Investigator decision or patient decision to discontinue study treatment.
223654612|NCT03291964|DIAGNOSTIC_TEST|Rapid Brain MRI|Children undergoing head CT for evaluation of acute head injury will also undergo rapid brain MRI with GRE sequence that is specific for blood. Their clinical care will not change at all based on the MRI.
223654613|NCT05776095|PROCEDURE|Cataract surgery|Subjects will undergo surgery to remove cataract (the cloudy lenses) via phacoemulsification, and implant the Eyedeal® Model PX65AS1 IOL in the eye capsule.
223654614|NCT05776095|DEVICE|Eyedeal® Model PX65AS1 IOL|Subjects will undergo surgery to remove cataract (the cloudy lenses) via phacoemulsification, and implant the Eyedeal® Model PX65AS1 IOL in the eye capsule.
223654615|NCT00970684|BIOLOGICAL|bevacizumab|15 mg/kg on day 1 of a 21-day cycle
223654616|NCT00970684|DRUG|docetaxel|75 mg/m2 on day 1
223654617|NCT00970684|DRUG|gemcitabine hydrochloride|900 mg/m2 on days 1, and 8,
223654618|NCT05432089|DRUG|Intranasal Oxytocin|24IU (12IU\*2) of OT, Sorbitol, Benzyl, alcohol glycerol, distilled water.
224238133|NCT00263965|BEHAVIORAL|Dietary and lifestyle modification counseling|
223654619|NCT01123551|DRUG|nebulized morphine|After randomization, patients will receive 10 mg of morphine (1ml) diluted in 4 ml normal saline and nebulized with 6 l/mn during 10 min. Nebulization will be repeated systematically 3 times every twenty minutes unless the patient pain was resolved (VAPS 30%). In addition, patients receive a bolus of IV placebo(5 ml normal saline . IV placebo (2 ml) will be repeated every 10 minutes if the objective of analgesia was not reached .
223654620|NCT01123551|DRUG|Intravenous morphine|After randomization, patients will receive a bolus of 5 mg of IV morphine (5 ml. Then, 2mg of IV morphine (2ml) will be added every 10 minutes if the objective of analgesia was not reached (VAPS \>30%). In addition, normal saline (5ml)is nebulized with 6 l/mn during 10 min and will be repeated systematically every 20 minutes unless the patient's pain was not resolved (VAPS \>30%).
223654621|NCT03030976|DRUG|cyclophosphamide|Patients receive cyclophosphamide (Cy) on day -2 and day -1 to reduce B cells. The dose is 0.5g/m2/d.
223654622|NCT03030976|DRUG|anti-CD19-CAR-T cells|A 2nd CAR, CD19 as target protein, 4-1BB as co-stimulator, and optimized the spatial conformation by a suitable hinge \& transmembrane domain sequences. Patients infused with anti-CD19-CAR-T cells transduced with lentivirus on day 0 in the absence of disease progression or unacceptable toxicity to treatment of SLE. The dose is 1E6\~1E7 CD19-CAR positive T cells. The cells infusion process may last for 30 min.
223654623|NCT00481091|DRUG|ABT-263|Tablet; Oral
223654624|NCT00006119|DRUG|hydroxyurea|
223654625|NCT05198440|DEVICE|non-invasive neuromodulation|"The modulations of the vection phenomenon will then be studied over two sessions of 1h30, separated by a minimum of 3 to a maximum of 15 days (the first session will be performed following the MRI). Each session will include: the installation of an EEG headset and the parameterization of the stimulation (30 min), then a phase of recording of the vection with neuromodulation (1h) according to 2 experimental conditions:~* Experiment 1: recording of vection at rest (20 min), then during and after neurostimulation by tES (20 min). Active and sham (placebo) stimulation will be tested separately during the two sessions (counterbalanced order).~* Experiment 2: recording of vection during neuromodulation by rTMS triggered in real time (1h). Triggering will be based on behavioral response (experiment 2a) or oscillatory activity detection (experiment 2b). Active and sham (placebo) stimulation will be tested in both sessions (randomized order)."
223654626|NCT05198440|DEVICE|electroencephalography|"The modulations of the vection phenomenon will then be studied over two sessions of 1h30, separated by a minimum of 3 to a maximum of 15 days (the first session will be performed following the MRI). Each session will include: the installation of an EEG headset and the parameterization of the stimulation (30 min), then a phase of recording of the vection with neuromodulation (1h) according to 2 experimental conditions:~* Experiment 1: recording of vection at rest (20 min), then during and after neurostimulation by tES (20 min). Active and sham (placebo) stimulation will be tested separately during the two sessions (counterbalanced order).~* Experiment 2: recording of vection during neuromodulation by rTMS triggered in real time (1h). Triggering will be based on behavioral response (experiment 2a) or oscillatory activity detection (experiment 2b). Active and sham (placebo) stimulation will be tested in both sessions (randomized order)."
223680966|NCT05293392|BEHAVIORAL|Culturally-Tailored COVID-19 Vaccine Uptake Intervention|This is a multi-component intervention to increase COVID-19 vaccine uptake among youth that was co-created with community partners and refined with qualitative feedback from Black and Latino youth and parents. The intervention consists of culturally-tailored educational materials to increase awareness about the COVID-19 vaccine, culturally-sensitive communication strategies employed by pediatric primary care providers and community health workers, and strategies to facilitate and standardize access to the COVID-19 vaccine in the primary care clinic.
224238134|NCT02314338|OTHER|Pulmonary rehabilitation|In-patient pulmonary rehabilitation including individualized exercise prescription, group based exercise training, education, individual sessions with a multi professional health care team
224238135|NCT02402348|DRUG|Metformin|
224238136|NCT04219501|OTHER|VIVO|Non-invasive mapping system software product that combines patient-specific images (MRI or CT) of the torso and cardiac structures and a 3D image of the torso that identifies precise ECG lead placement to generate a 3D model of the patient's heart.
224238137|NCT04260204|PROCEDURE|Pediatric cardiac surgery|
224238138|NCT03727568|PROCEDURE|Cryobiopsy|"In this study the investigators want to evaluate the diagnostic yield comparing 2 different techniques of performing cryobiopsy. A shorter freezing time and more number of biopsies vs a longer freezing time and less number of biopsies would be compared. Patients are randomised to the groups 1 or 2 immediate before the bronchoscopy.~Group 1: a total of 3 samples with a freezing time of 7 seconds at least for the first biopsy and freezing time for 5 seconds or more for the followings biopsies Group 2: a total of 8 samples with a freezing time of 3 seconds at least for the first biopsy and freezing time for less than 5 seconds for the followings biopsies"
224320891|NCT04936854|DRUG|Sirolimus 1 mg Oral Tablet|2 mg Sirolimus (two 1 mg tablets) on the first day, followed by 0,5 mg Sirolimus (half 1 mg tablet) per day for 12 weeks.
224238139|NCT02084004|DRUG|Bifidobacterium viable pharmaceutics|
224238140|NCT02084004|DRUG|Berberine Hydrochloride|
224238141|NCT05360316|DEVICE|ESWT|extracorporeal shock wave therapy
224238142|NCT04277910|DRUG|MT2004|MT2004 oral capsules
224320892|NCT04936854|DRUG|Methylprednisolone|500 mg Methylprednisolone intravenously once a week for 6 weeks, followed by 250 mg once a week for 6 weeks. Total period of treatment 12 weeks.
224320893|NCT01184495|DRUG|Epoetin Alfa-BioManguinhos|Subcutaneous administration of EPO-BioManguinhos
224320894|NCT01184495|DRUG|Epoetin Alfa-BioSimilar|Subcutaneous administration of EPO-BioSimilar
224320895|NCT00080145|DRUG|Risperidone|
224320896|NCT00080145|BEHAVIORAL|Behavior Therapy|
224238143|NCT04277910|DRUG|Placebo|Placebo oral capsules
224238144|NCT05505812|BIOLOGICAL|HS-IT101|Adoptive transfer of 1x10\^9-6x10\^10 autologous TIL to patients i.v. in 30-60 minutes.
224238145|NCT06357338|OTHER|no intervention|No intervention
224238146|NCT05522270|PROCEDURE|revitalization by concentrated growth factor|modified platelet concentrate
224320897|NCT01432067|OTHER|Adapted physical activity|Physical activity advices according to a program adapted to physical status of the patient.
224320898|NCT01432067|OTHER|Classic physical activities|Daily physical activities based on a standard guide
223767858|NCT02653196|DRUG|Cyclosporine A|Cyclosporine A dosed as follows: Age ≤ 6 years: 6 mg/kg/day IV in divided doses (e.g. 2 mg/kg every 8 hours) OR Age \> 6 years: 3 mg/kg/day IV in divided doses (1.5 mg/kg every 12 hours): Start Day -2, begin taper on Day +100, discontinue on Day +180
223767859|NCT02653196|DRUG|Mycophenolate mofetil|Mycophenolate mofetil 15 mg/kg every 8 hours oral or IV: Start Day 0 (4-6 hours post stem cell infusion) to Day +40, then taper weekly until discontinuation on Day +90
223767860|NCT01299233|DEVICE|Spectralis® SD-OCT, Heidelberg Engineering GmbH, H|Measurement of the peripapillar nerve fiber layer with different settings of ART
223767861|NCT05448924|DIAGNOSTIC_TEST|Hormone panel tests|Patient was subjected to a battery of hormone tests, including FSH, LH, estrogen, progesterone and growth hormone
223767862|NCT03275727|BEHAVIORAL|iACT-BC|A Guided INternet-delivered Individually-tailored ACT-influenced Cognitive Behavioural INtervention to ImprOVe Psychosocial Outcomes in Breast Cancer Survivors
223767863|NCT01922310|BEHAVIORAL|Communication intervention|"The intervention is a modification of current standard practice procedures for requesting consent for donation.~The intervention period commences when the possibility of organ donation is first raised with the family, and includes the time for families to make a decision. This time may last up to 72 hours."
223767864|NCT06532201|OTHER|Su jok seed therapy|Su Jok will be applied to the reflection points on the hand based on the painful area of the individual. The painful areas will be determined with the applicator and black pepper seeds will be placed on these areas. Circular massage will be applied to the areas where the seeds are located for 30 minutes.
223767865|NCT01344057|BIOLOGICAL|Seasonal Influenza Vaccine|This phase II is performed as a multicenter study in elderly subjects. Enrolled subjects received one single IM dose of trivalent subunit inactivated adjuvanted flu vaccine during the vaccination visit, according to the study protocol (follow-up period: until day 22) .
223767866|NCT05951816|DRUG|99mTc-p5+14 is an amyloid reactive peptide labeled with technetium-99m.|Peptide p5+14 is a pan-amyloid reactive, synthetic 45 L-amino acid polypeptide with a net +12 positive charge that can bind two major components of all extracellular amyloid deposits: (i) hypersulfated heparan sulfate glycosaminoglycans (proteoglycans) and (ii) amyloid fibrils. The polypeptide, labeled with iodine-124, has been shown (study AMY1001) to bind amyloid in all organs including the heart. This study will evaluate a Tc-99m-labeled version of the peptide for gamma imaging.
223767867|NCT05951816|DRUG|99mTc-Pyrophosphate and 99mtc-p5+14 - an Amyloid Reactive Peptide Labeled With Technetium-99m.|99mTc-PYP is an FDA-approved, commercially available bone-seeking radiotracer used routinely in nuclear medicine. 99mTC-PYP imaging is used clinically for the diagnosis of cardiac ATTR amyloidosis.
223767868|NCT00306592|BIOLOGICAL|BG00002 (natalizumab)|
223680967|NCT05293392|BEHAVIORAL|Standard Care|Standard care includes routine offer of the COVID-19 vaccine and counseling about the COVID-19 vaccine by pediatric primary care providers.
223680968|NCT03284918|DIETARY_SUPPLEMENT|Plant stanol ester|
223767869|NCT01401491|DRUG|clozapine plus fluvoxamine|clozapine 100 mg/day plus fluvoxamine 50 mg/day
223767870|NCT01401491|DRUG|clozapine plus placebo|clozapine 300 mg/day plus placebo
223767871|NCT03245567|OTHER|PLM|Participants will take the PLM on the visual estimation of LVEF. They will also take a pretest, a post-test and a delayed test at 6 months.
223767872|NCT03245567|OTHER|Pre, post, delayed test|Participants will perform a pretest, a posttest and a delayed test at 6 months.
223767873|NCT05439226|OTHER|CMNT diet|Hypocaloric CMNT diet plan: A diet plan with intermittent use of enriched traditional-Chinese-medicinal-foods CMNT diet
223767874|NCT05958992|OTHER|E-cigarette|Participants will self-administer experimenter-provided e-cigarettes
224238147|NCT03489759|DEVICE|ViE15-A|The type of dialytic treatment that will be used during the study will be continuous venous hemofiltration (CVVH-Continuous veno-venous hemofiltration). The filter will be ViE15-A.
224238148|NCT03489759|DEVICE|REXEED-15A|The type of dialytic treatment that will be used during the study will be continuous venous hemofiltration (CVVH-Continuous veno-venous hemofiltration). The filter will be REXEED-15A.
224238149|NCT00650000|DRUG|Modafinil Tablets 200 mg|200mg, single dose fasting
224238150|NCT00650000|DRUG|Provigil® Tablets 200 mg|200mg, single dose fasting
224238151|NCT00543309|DRUG|nesiritide|Nesiritide bolus 2 mcg/kg on CPB, then infusion of 0.015 mcg/kg/min. infusion dose may be adjusted
224238152|NCT00543309|DRUG|milrinone|Milrinone 50 mcg/kg bolus on CPB, the infusion of 0.5 mcg/kg/min. Infusion rate may be adjusted
224320899|NCT03102606|DRUG|Plinabulin|Plinabulin (BPI-2358) is a synthetic, low molecular weight, new chemical entity that belongs to the diketopiperazine class of compounds. Plinabulin is intended for intravenous (IV) infusion and is diluted in D5W and administered for 30 minutes (± 5 minutes).
223680969|NCT03284918|DIETARY_SUPPLEMENT|Placebo|
223680970|NCT04933643|OTHER||
223680971|NCT00735189|OTHER|anticoagulation clinic care|Patient receives care from the outpatient anticoagulation management service
223680972|NCT00735189|OTHER|usual care|patient receives usual anticoagulation care from their regular primary care physician
223680973|NCT01868919|BEHAVIORAL|Positive Parenting Program|Level 3 or 4 of Triple P
223767875|NCT05580913|BEHAVIORAL|Resistance training|12 weeks of resistance-training performed two times per week
223767876|NCT02348164|OTHER|Pink grapefruit first followed by tangerines two weeks later|A 504 gram serving of pink grapefruit was fed as a single meal followed by 234 grams tangerines two weeks later
223767877|NCT02348164|OTHER|Tangerines first followed by pink grapefruit two weeks later|A 234 gram serving of tangerines was fed as a single meal followed by 504 grams pink grapefruit two weeks later
223767878|NCT05669092|DRUG|Toripalimab|3mg/Kg iv d1q2w
224238153|NCT00543309|DRUG|placebo|Placebo bolus on CPB, then placebo infusion
224238154|NCT01249664|BIOLOGICAL|VEGF Trap-Eye (BAY86-5321)|1 intravitreal injection of the experimental drug, followed by monthly re-injections if needed
224238155|NCT01249664|PROCEDURE|No Drug|Sham procedure NOT involving injection of any substance; patient´s eye is anesthetized and a syringe without needle gently pressed on the cornea
224238156|NCT04541719|DRUG|Patient-controlled remifentanil analgesia|Patient controlled remifentanil analgesia with a regimen to provide a bolus of 40 μg remifentanil with a lockout interval of 2 min
223767879|NCT05669092|RADIATION|CRT|IMRT 50Gy/25fx 625mg/m2 bid d1-5 qw Irinotecan:1、Full wild (GG+6/6): 80mg/m2/week for 5 times 2、Single site mutation (GG+6/7 or GA+6/6): 65mg/m2/week for 5 times 3、Double locus mutation (GG+7/7 or AA+6/6 or GA+6/7): 50mg/m2/week for the 1st, 2nd, 4th and 5th week for 4 times
223767880|NCT05669092|RADIATION|SCRT|25Gy/5fx
223767881|NCT05669092|DRUG|XELIRI|Capecitabine: 1000mg/m2 bid d1-14 Irinotecan: 200mg/m2 ivgtt d1 q3w
223767882|NCT05669092|DRUG|FOLFRINOX|Irinotecan: 150mg/m2 ivgtt d1 (double locus mutation downregulated to 120mg/m2) Oxaliplatin: 85mg/m2 ivgtt d1 5-FU: 2400mg/m2 ivgtt 46h q2w
224238157|NCT04541719|DRUG|Epidural analgesia|Patients will receive continuous epidural analgesia using bupivacaine 0.125% in conjunction with fentanyl 2 ug/ml at a rate of 8-15 ml/hr
224238158|NCT05701683|DRUG|Lactobacillus Reuteri Probiotic|Experimental group receiving Lactobacillus Reuteri Probiotic with sequential therapy
223654627|NCT05198440|DEVICE|anatomical MRI|"The modulations of the vection phenomenon will then be studied over two sessions of 1h30, separated by a minimum of 3 to a maximum of 15 days (the first session will be performed following the MRI). Each session will include: the installation of an EEG headset and the parameterization of the stimulation (30 min), then a phase of recording of the vection with neuromodulation (1h) according to 2 experimental conditions:~* Experiment 1: recording of vection at rest (20 min), then during and after neurostimulation by tES (20 min). Active and sham (placebo) stimulation will be tested separately during the two sessions (counterbalanced order).~* Experiment 2: recording of vection during neuromodulation by rTMS triggered in real time (1h). Triggering will be based on behavioral response (experiment 2a) or oscillatory activity detection (experiment 2b). Active and sham (placebo) stimulation will be tested in both sessions (randomized order)."
223654628|NCT03975244|BEHAVIORAL|Exercise program|Twelve-week of semi-supervised exercise program. The exercise program will combine resistance and endurance training. Both the volume and intensity of training will start at moderate intensity, and progressively be increased at higher volumes and intensities.
223654629|NCT01296672|DRUG|Finasteride|Finasteride 5mg every day by mouth for 3 months
223654630|NCT01296672|DRUG|Placebo|Placebo every day by mouth for 3 months
223767883|NCT04147013|DRUG|Celecoxib|Patients will receive celecoxib 200 mg PO BID for 7 days post endoscopic sinus surgery, starting on the evening of the day of surgery.
223767884|NCT04147013|DRUG|Placebo|Patients will receive placebo PO BID for 7 days post endoscopic sinus surgery, starting on the evening of the day of surgery.
223767885|NCT04387253|DIAGNOSTIC_TEST|Identification by PCR of the SARS-COV-2 virus in samples taken from the fetus|Identification by PCR of the SARS-COV-2 virus in samples taken from the fetus Presence of SARS-COV-2 virus in samples taken from mother and father. Circulating anti-SARS-COV-2 antibodies in the mother.
223767886|NCT04889560|OTHER|Experimental group|Home-based version of a computerized cognitive training (CoRe)
224238159|NCT05485909|OTHER|Radiofrequency ablation|For multiple intrahepatic lesions, select 1 to 2 lesions for radiofrequency ablation
224238160|NCT05485909|DRUG|Regorafenib and Toripalimab Combination|Toripalimab 200 mg, iv drip, d1, d15, q4w, Regorafenib 80mg, po, d1-d21, Q4w.
224238161|NCT02000856|DIETARY_SUPPLEMENT|Beetroot juice|
224238162|NCT03027661|DRUG|Bupivacaine|Inject 10 mL of 0.5% bupivacaine into cervical stroma
224238163|NCT03027661|DRUG|0.9% Sodium Chloride|Inject 10 mL of 0.9% NaCl into cervical stroma
224238164|NCT03756857|PROCEDURE|Afterload Transfer|"Embryo transfer is done by using afterload transfer method"
224238165|NCT03756857|PROCEDURE|Trial followed by transfer|"Embryo transfer is done by using afterload transfer method"
224238166|NCT03582332|DRUG|Indomethacin SR, 75 Mg Oral Capsule, Extended Release|Indomethacin SR, 75 Mg Oral Capsule, Extended Release orally twice daily
224238167|NCT03582332|DRUG|Indomethacin 25 Mg Oral Capsule|Indomethacin 25 Mg Oral Capsule, 2 capsule orally twice daily
224238168|NCT03582332|DRUG|Etoricoxib 90 mg|Etoricoxib 90 mg once daily orally
224320900|NCT03102606|DRUG|Pegfilgrastim|PEGFILGRASTIM is a long-acting granulocyte colony-stimulating factor that stimulates the growth of neutrophils, to reduce the incidence of fever and infection in patients with certain types of cancer who are receiving chemotherapy that affects the bone marrow.
224320901|NCT03102606|OTHER|Saline Placebo|Placebo Syringe 0.6 ml Saline to match the 0.6 ml pegfilgrastim administration
224320902|NCT03102606|OTHER|D5W Placebo|Placebo 250 ml D5W to match the administration of plinabulin diluted in 250 ml D5W
223767887|NCT04889560|OTHER|Control group|Computerized cognitive training (CoRe)
223767888|NCT06271551|DRUG|Transdermal estrogen|Participants (n=155) receiving transdermal estradiol for 12 months.
223767889|NCT06271551|DRUG|Active Comparator: Androgen deprivation therapy|Participants (n=155) receiving solely androgen deprivation therapy for 12 months.
223767890|NCT06271551|BEHAVIORAL|Resistance training|Participants (n=30 in each arm) performing supervised resistance training for six months.
223767891|NCT02182544|DRUG|WAL801CL dry syrup|
223767892|NCT02182544|DRUG|Ketotifen fumarate dry syrup|
223767893|NCT02182544|DRUG|Ketotifen fumarate dry syrup placebo|
223767894|NCT02182544|DRUG|WAL 801 CL dry syrup placebo|
223767895|NCT05682547|DRUG|3% Diquafosol tetrasodium|3% Diquafosol tetrasodium eye drops will be used to assess its usefulness in diabetic dry eye symptoms
223767896|NCT05682547|DRUG|0.1% hyaluronate|0.1% hyaluronate eye drops will be used to assess its usefulness in diabetic dry eye symptoms and compared to 3% Diquafosol tetrasodium eye drops.
223767897|NCT00824863|DRUG|ketoconazole 2% foam|topical antifungal foam to be applied to the folliculitis BID for 2-4 weeks.
224238169|NCT03582332|DRUG|Etoricoxib 60 mg|Etoricoxib 60 mg once daily orally
224238170|NCT05640453|DRUG|Pregabalin|Patients will receive pregabalin capsules (75 mg) every 12 h for 24 hours by nasogastric tube.
224238171|NCT05640453|DRUG|Dexmedetomidine|Patients will receive a bolus dose of 0.4 μg/kg dexmedetomidine (over a period of 10 to 20 min)
224238172|NCT02636907|DRUG|BI 695501 Autoinjector|
224238173|NCT02636907|DRUG|BI 695501 Prefilled syringe|
223654631|NCT02285608|OTHER|PIMM/SAM|The PIMM program will include education to improve patients' knowledge regarding their medication's purpose, dosage, benefits, and side effects. The program will also include tools like a checklist or alarm clock to remind patients of when and how to take their medication. Furthermore, the program will contain an interactive listening period where healthcare professionals involved in medication dispensing will listen to patients' concerns, questions and thoughts regarding their medications.
223654632|NCT04661579|BIOLOGICAL|Malaria Vaccine RTS,S/AS01E|RTS,S/AS01E vaccine 0.5 mL, containing 25 μg protein comprising circumsporozoite protein (CS) and hepatitis B surface antigen (RTS,S), 25 μg monophosphoryl lipid (AMPL), 25 μg Quillaja saponaria 21 (QS21) in a liposomal formulation) for the first two immunizations. One-fifth dose RTS,S/AS01E vaccine was used for the third immunization.
223654633|NCT04661579|BIOLOGICAL|Abhayrab rabies vaccine|Abhayrab rabies vaccine, 0.5 mL, contains 2.5 IU rabies antigen.
223654634|NCT04661579|DRUG|Dihydroartemisinin-piperaquine (DHA/Pip)|"Dihydroartemisinin (120 mg or 160 mg based on weight) and piperaquine tetraphosphate (960 mg or 1280 mg based on weight) mg) administered once a day for 3 days.~DHA/Pip is a long acting anti-malarial used to clear asexual stage and young gametocyte parasites."
223654635|NCT04661579|DRUG|Artemether / Lumefantrine|"Artemether (80 mg) and lumefantrine (480 mg) administered twice a day for 3 days.~Coartem is a short-acting artemisinin combination therapy used to provide clearance of blood stage parasites in order to establish a clean baseline for determination of vaccine efficacy."
223654636|NCT04661579|DRUG|Primaquine|One dose of 15 mg primaquine. Low dose primaquine (LD PQ) is used to clear mature gametocytes of P. falciparum.
223654637|NCT01490905|OTHER|Theramine (A medical food)|Theramine two capsules twice daily for 28 days.
223654638|NCT01490905|DRUG|Theraprofen|Theramine two capsules twice daily and ibuprofen 400mg once daily for 28 days.
223654639|NCT01490905|DRUG|Ibuprofen|Ibuprofen 400mg once daily for 28 days.
223654640|NCT01338454|DRUG|transamin|TA was administered intravenously over a 5 min period at delivery of the anterior shoulder
223654641|NCT02560077|OTHER|placebo|Subject receive the Placebo product (placebo group had same color and smell of treatment groups)
223654642|NCT02560077|OTHER|cashew apple juice|Subject received the cashew apple juice at dose of 120 mg/day after meal
223654643|NCT02560077|OTHER|cashew apple juice|Subject received the cashew apple juice at dose of 240 mg/day after meal
223654644|NCT05156021|DRUG|anti-VEGF|To explore whether adding post-vitrectomy anti-VEGF agent injection can reach a better prognosis in PDR patients with NVG who underwent PPV combined with PRP and pressure-reducing valve implantation
223654645|NCT04207541|BEHAVIORAL|Brief motivational interview|Client (who has suboptimal diabetic control with oral anti-diabetic agent) will be advised for insulin initiation with brief motivational interviewing in one session of individual education.
223654646|NCT03966339|DRUG|Growth hormone|GH has been considered as a cogonadotropin, which plays an important role in the synthesis of ovarian steroid hormone and follicular development as a paracrine hormone.GH can regulate the growth hormone receptor and strengthen the function of mitochondria to improve the quality of the female oocyte.
223654647|NCT01743859|DRUG|Azacitidine|Enrolled patients will receive 75 mg/m2 of azacitidine subcutaneously (SC) or intravenously (IV) on days 1-7 alone.
223654648|NCT01743859|DRUG|Lenalidomide|Beginning on day 8, patients will receive 50 mg of lenalidomide PO, and will take this daily from day 8 through 28.
223654649|NCT01743859|OTHER|Off Therapy|2 weeks off therapy, then begin sequence again for 12 weeks.
223654650|NCT03868813|BEHAVIORAL|Semi-structured Interview|One-on-one semi-structured interviews
223654651|NCT02817529|DEVICE|Pulmonica|The Pulmonica is a specially constructed and tuned Pulmonary Harmonica that produces deep, resonant, meditative sounds that can be felt vibrating in the lungs and sinuses. Participants who will be instructed to inhale and exhale through Pulmonica at least ten times daily for up to six months.
223654652|NCT02817529|DEVICE|RC-Cornet|RC-Cornet is an oscillatory positive expiratory pressure device, which is designed to aid in the loosening and removal of mucus build-up in the lungs. Participants who will be instructed to inhale and exhale through RC-Cornet at least ten times daily for up to six months.
223654653|NCT00613275|OTHER|patient Navigation|Assigning a patient navigator to patients with abnormal breast and cervical cancer screening results at one of 6 affiliated community health centers
223654654|NCT00201513|BEHAVIORAL|Isolated Transversus abdominis (TrA) exercise|Eight weeks Isolated Transversus abdominis (TrA) exercise(low load) program; Isolated TrA control through biofeedback
223654655|NCT00201513|BEHAVIORAL|sling exercise|Eight weeks sling(high load) exercise program; Isolated TrA control through biofeedback
223767898|NCT06843668|DRUG|EMA colistin dosing strategy|The EMA colistin group will receive I.V colistin based on creatinine clearance (mL/min) level , with fixed loading dose 9 MIU equivalent to 300 mg of colistin-based activity (CBA). The maintenance dose will be administered after 12 h following the loading dose over 1 h every 12h (twice daily).
224238174|NCT05369871|DEVICE|Closed-loop system|Closed-loop system consisting of a terminal including the Diabeloop algorithm that is associated with the Dexcom G6 CGM and the Accu-Chek Insight insulin pump.
223767899|NCT06843668|DRUG|US FDA colistin dosing strategy|The weight-based colistin group will receive I.V. colistin based on the lower (ideal body weight or actual body weight) with a loading dose of (4) X (patient weight in kg). Loading dose might exceed 300 mg.
223654656|NCT00201513|BEHAVIORAL|group exercise|Eight weeks non-specific group exercise program; Isolated TrA control through biofeedback
223654657|NCT00504946|DRUG|prednisone, lactose|"Allergen immunotherapy (build-up phase)premedication with orally administrated in the day of immunotherapy:~20mg prednisone+ 0.3mg lactose"
223767900|NCT06455774|DEVICE|Wearable Postural Feedback Device|The postural feedback wearable device we will use in the study is programmed to vibrate when hunched postures are detected (based on changes in the curvature and curvature of the spine), alerting users to changes in their body position.
224238175|NCT05369871|DEVICE|Open-loop system|Open-loop system consisting of a terminal without the Diabeloop algorithm that is associated with the Dexcom G6 CGM and the usual insulin pump.
224238176|NCT03048162|DRUG|sodium chloride|500 ml of 0.9% isotonic sodium chloride
224238177|NCT03048162|DRUG|Hydroxyethylstarch|500 ml of 6% Hydroxyethylstarch
224238178|NCT03048162|DRUG|Ringer-Lactate Infusion Solution Bag|500 ml of Ringer-Lactate Infusion Solution Bag
224238179|NCT05909124|DEVICE|MCE|underwent MCE examination
223654658|NCT00504946|DRUG|prednisone, colecalciferol, lactose|"Allergen immunotherapy (build-up phase)premedication with orally administrated in the day of immunotherapy:~20mg prednisone + 1000j colecalciferol + 0.3mg lactose"
223654659|NCT00504946|DRUG|lactose|"Allergen immunotherapy (build-up phase)premedication with orally administrated in the day of immunotherapy:~0.3mg lactose"
223654660|NCT00504946|DRUG|montelukast sodium|Allergen immunotherapy (build-up phase)premedication with montelukast sodium. Children 6-14 years received 5 mg of montelukast and children \> 14 years old received 10mg oral tablet once daily at bedtime
223654661|NCT00504946|DRUG|lactose|Allergen immunotherapy (build-up phase)premedication with 0,3mg lactose once daily at bedtime
223654662|NCT00986011|OTHER|questionnaire administration|
223654663|NCT00986011|OTHER|study of socioeconomic and demographic variables|
223654664|NCT00986011|OTHER|survey administration|
223654665|NCT00986011|PROCEDURE|study of high risk factors|
223654666|NCT00796978|BIOLOGICAL|trastuzumab|Trastuzumab (Herceptin®) IV over 30-90 minutes on day 1. Treatment repeats every 3 weeks for up to 52 weeks in the absence of disease progression or unacceptable toxicity.
223654667|NCT00796978|OTHER|laboratory biomarker analysis|Blood is collected every 6 weeks during treatment. Samples are assessed for plasma cardiac markers (N-terminal brain natriuretic protein and troponin-I) and pro-inflammatory cytokines (interleukin-6 and tumor necrosis factor-α).
223654668|NCT00796978|PROCEDURE|adjuvant therapy|Patients receive trastuzumab (Herceptin®) IV over 30-90 minutes on day 1. Treatment repeats every 3 weeks for up to 52 weeks in the absence of disease progression or unacceptable toxicity.
223654669|NCT00796978|PROCEDURE|quality-of-life assessment|Patients complete Quality of Life and Quality of Health and Comprehensive Geriatric assessments of functional, cognitive, and mental status changes at baseline, weeks 26, and 52.
223654670|NCT03253341|BEHAVIORAL|Smart Aging Program|Comprehensive lifestyle and fitness program designed to improve the health of older adults. The Smart Aging Program represents a package consisting of a dedicated health coach, mobile monitoring, specialized curriculum, and exercise opportunities.
223654671|NCT03253341|BEHAVIORAL|Educational Materials|Current standard of care. Includes education materials covering benefits of a healthy lifestyle.
223654672|NCT04330313|PROCEDURE|Traction|Intermittent traction will be applied to the cervical region in a supine position with the neck at 25-30 ° flexion. The target weight is determined as 10% of the patient's weight. Traction pulling force applied to the target weight will be achieved gradually increasing from low. Traction therapy will be applied intermittent traction for 15 minutes in each session as 60 seconds retention and 60 seconds rest. The therapy will be held for 18 sessions, 3 days / week.
223654673|NCT04330313|PROCEDURE|Laser therapy|Laser therapy will be applied to the participants with a GaAs laser with 904 nm wavelength, 6 points transforaminally, 120 seconds to each point, at 2 J / cm² density, total dose of 12 J laser therapy by keeping the probe in constant contact with the skin.
223654674|NCT04330313|PROCEDURE|Hot pack|The hot pack, which is the superficial heat agent, will be held in the neck area of the participants for 20 minutes in each session.The therapy will be held for 18 sessions, 3 days / week.
223654675|NCT04330313|PROCEDURE|Stretching|Stretching exercises will be repeated 3 times a day in total, 2 times a day self-stretching at home and 1 time under the supervision of a physiotherapist. Exercises for upper trapezius muscle, sternokleudomasteudeus (SCM) muscle and the scalene muscle to be applied in a 3 repeat by waiting 30 seconds, stretching under tension.The therapy will be held for 18 sessions, 3 days / week.
223654676|NCT04282746|DRUG|JNJ-54135419|Single dose of JNJ-54135419 oral solution will be administered sublingually.
223654677|NCT05324761|DRUG|Pregabalin 75mg|Each patient complaining of pain associated with spine surgery who is randomly enrolled this arm of the study and start the specific medication of the arm with the recommended dose and duration for a period of one month, patient will be followed regularly regarding compliance to doses and to register any side effect.
223654678|NCT05324761|DRUG|Gabapentin 300mg|Each patient complaining of pain associated with spine surgery who is randomly enrolled this arm of the study and start the specific medication of the arm with the recommended dose and duration for a period of one month, patient will be followed regularly regarding compliance to doses and to register any side effect.
223654679|NCT00859456|DRUG|Sunitinib|"Taken daily PO for a 42 day cycle. This cycle is repeated at least twice.~A small molecule, multi-targeted receptor tyrosine kinase inhibitor that selectively targets and intracellularly blocks the signaling pathways of receptor tyrosine kinase (RTKs)."
223654680|NCT01049542|DRUG|Astressin 2B|After an initial saline washout, increasing doses of Astressin 2B (at 0.032, 0.32, 3.2, 32, 320 and 3200 pmol/min) will be infused, for 10 minutes at each dose,intra arterially using forearm venous occlusion plethysmography. Forearm blood flow will be measured with each incremental dose of Astressin 2B.
223654681|NCT05521399|DIAGNOSTIC_TEST|MRI Sequencing|MRI test-retest (select healthy volunteers) for development of MRI sequence.
223654682|NCT05521399|DIAGNOSTIC_TEST|MRI Testing (pediatric)|Comprehensive cardiac MRI measures will be evaluated for the identification of complications after heart transplantation (ACR, CAV) in children.
223654683|NCT05521399|DIAGNOSTIC_TEST|MRI Testing|Cardiac MRI to improve HTx monitoring for ACR and CAV as well as outcome prediction
223654684|NCT05461508|BIOLOGICAL|Amoxicillin combined with vonoprazan and fucoidan|Fucoidan was used in combination with amoxicillin and vonoprazan. The purpose of this study was to explore the effect of fucoidan on the eradication rate of Helicobacter pylori and the intestinal flora of subjects.
223654685|NCT05461508|OTHER|Amoxicillin combined with vonoprazan|Amoxicillin and vonoprazan were used as the study control group
223654686|NCT00578292|DRUG|Busulfan|"4.0 mg/kg/day divided into four doses daily for four days; total dose = 16 mg/kg~Days -9 through -6"
223654687|NCT00578292|DRUG|Fludarabine|30mg/m2 Day -5 through Day -2
223654688|NCT00578292|DRUG|Campath 1H|Per institutional guidelines Days -5 through -2
223654689|NCT00578292|DRUG|Cyclophosphamide|50 mg/kg Days -5 through -2
223654690|NCT00578292|DRUG|MESNA|10 mg/kg x 5 Days -5 through -2
223654691|NCT02977962|BEHAVIORAL|Cognitive-Behavior Therapy|This therapy has been designed for adolescents with high functioning ASD and involves 16 weekly session where the participant learns coping skills related to addressing anxiety (e.g., exposure therapy, cognitive therapy, social skills training).
224238180|NCT05154721|DEVICE|experimental Group - Mila-Learn|Eight tasks are used in Mila-Learn.
223654692|NCT02977962|OTHER|Treatment as Usual|Those who choose to participate will be enrolled in the 16 week study. They will required to attend 3 assessments - pre-treatment (week 0), mid-treatment (week 8), and post-treatment (week 16). Those in this group will not receive the Cognitive-Behavior Therapy, and instead will undergo therapy for their anxiety as they usually would, whether by using medication or working with a therapist.
223654693|NCT04849559|DRUG|Tradipitant|Tradipitant Capsule
223654694|NCT04849559|DRUG|Placebo|Placebo Capsule
223654695|NCT06395467|BEHAVIORAL|InTEGRA|"Session topics are as follows: Parent Info Session - Informational and Q\&A format; Motivation Building- Addressing AA/NA Expectancies and Experiences; AA/NA Expectancies and Treatment Goal Setting Session; Alcohol and Drug Refusal Skills; Coping with Urges and Other Thoughts about Drinking; Problem Solving; Anger Management (AA/NA and Hungry, Angry, Lonely, Tired HALT; Effective Communication (Sharing at AA/NA meetings; getting a sponsor); Depression Management; Using AA/NA for enhancing Social Support and Increasing Pleasant Activities; Planning for Emergencies and Coping with Relapse"
223654696|NCT06395467|BEHAVIORAL|MET/CBT|Session topics are as follows: Motivation Building Session; Goal Setting Session; Alcohol and Drug Refusal Skills; Coping with Urges and Other Thoughts about Drinking; Problem Solving; Anger Management; Effective Communication; Depression Management; Enhancing the Social Support Network and Increasing Pleasant Activities; Planning for Emergencies and Coping with Relapse
223654697|NCT02910986|BEHAVIORAL|Written educational brochure|Written educational brochure about breast density
223654698|NCT02910986|BEHAVIORAL|Promotora interaction|Promotora education about breast density
223654699|NCT05667454|DRUG|Atropine Ophthalmic 0.05%|Atropine 0.05% sulphate ophthalmic solution
223654700|NCT05667454|DRUG|Atropine Ophthalmic 0.5%|Atropine 0.5% sulphate ophthalmic solution
223654701|NCT05500404|DIAGNOSTIC_TEST|Ultrasound measurment of placental thickness|The maximum placental thickness in the lower uterine segment will obtained using trans-abdominal ultrasound scan. For the image to be deemed suitable, a midline sagittal section of the lower uterine segment (with the implanted placenta) and the cervical canal, with the intervening urinary bladder will be required (Bhide et al., 2019). The measurement will be performed by a researcher who will be blinded to the final diagnosis.
223654702|NCT02906176|DRUG|Vfend (voriconazole) intravenous infusion|Vfend (voriconazole) 200 mg intravenous infusion during 1.5 h
223654703|NCT02906176|DRUG|Vfend (voriconazole) tablet|Vfend (voriconazole) 200 mg tablet once
223654704|NCT00679796|PROCEDURE|Varicella (chickenpox) lesion sampling|
223654705|NCT06014658|DRUG|Antibody-Drug Conjugate|MBRC-101: AN ANTI-EPHA5 MONOMETHYL AURISTATIN E (MMAE) ANTIBODY DRUG CONJUGATE
223654706|NCT02522663|OTHER|24/7-telephone support|ICU nurses answer the calls from treated AVR patients during the first month after discharge, and use an evidence-based information manual to answer questions from the patients.
224238181|NCT05154721|DEVICE|control Group - Mila-Placebo|Eight tasks similar to Mila-Learn are used in the placebo group
223654707|NCT02541396|DRUG|Wafermine|35 or 70 mg ketamine in a sublingual wafer
223654708|NCT02541396|DRUG|Oxycodone|5 mg oxycodone capsule
223654709|NCT02541396|DRUG|Placebo|Placebo capsule or placebo wafer
223654710|NCT00006205|DRUG|ondansetron + cognitive behavioral therapy|ondansetron (4 mcg/kg b.i.d)
223654711|NCT00006205|DRUG|topiramate + cognitive behavioral therapy|topiramate (up to 300 mg/day)
223654712|NCT00006205|DRUG|Placebo + cognitive behavioral therapy|placebo
223654713|NCT00006205|DRUG|ondansetron + topiramate + cognitive behavioral therapy|ondansetron (4 mcg/kg b.i.d) + topiramate (up to 300 mg/day)
223654714|NCT02966444|OTHER|MUFA-rich HF Meal|
224320903|NCT03707405|BEHAVIORAL|Ride-On Cars Training with Different Postures|All programs will include 120 minutes/per session, 2 sessions/per week. All participants will continue their regular therapy during the whole study. The treatment strategy of ROC training with different postures will be based on the exploratory learning which focuses on providing opportunities to the participants to explore environmental properties with various motor patterns during the intervention.
223654715|NCT02966444|OTHER|PUFA-rich HF Meal|
223654716|NCT02966444|OTHER|SFA-rich HF Meal|
224238182|NCT03375593|DRUG|Hydrocodone 5Mg/Acetaminophen 500Mg Tab|tablet
223654717|NCT05910190|DRUG|Use of buprenorphine with FAO > 30 OME|Patients will receive buprenorphine with concurrent FAO \>30 OME and be assessed for withdrawal, pain, and other symptoms.
223654718|NCT05910190|BEHAVIORAL|CPM Rx application use|The CPM Rx application is used on smart phones to allow patients to input time-stamped data about medication type, dosage, and pain score. This will allow analysis of trends in self-reported pain and optimal dosing patterns. Usage over three months will be assessed.
223654719|NCT02566369|DRUG|CD5789 (trifarotene) 50μg/g cream|CD5789 (trifarotene) 50µg/g cream applied once daily for 12 weeks.
223654720|NCT02566369|DRUG|Placebo cream|Placebo cream applied once daily for 12 weeks
223654721|NCT00558649|BIOLOGICAL|Flu Vaccine (FLUARIX®)|Influenza Virus Vaccine, FLUARIX®, 2006-2007 Formula
223654722|NCT02415478|OTHER|endoscopic lung volume reduction by valves|"Independent of the study, subject will get a bronchoscopy with chartis measurement in general anaesthesia. chartis measurement is a Balloon angioplasty. Balloon will be well-positioned in lung and filled by air for occlusion of lobe of the lung. System recognizes collateral ventilation of lobe of the lung via calculation of airflow resistance.~Negative result allows the endoscopic placement of selfexpandig endobronchial valves in the subject lung. Inhale airflow will be inhibit an enclosed air and liquids can exhaust."
224238183|NCT03375593|DRUG|Acetaminophen 500Mg Tab|tablet
223654723|NCT06193668|BEHAVIORAL|High-fat overnutrition|Overnutrition: 40% higher lipid consumption per day than required
223654724|NCT06193668|BEHAVIORAL|Normocaloric macronutrient-balanced nutrition|"Normocaloric, macronutrient-balanced nutrition:~Calories requirement for weight maintenance \[(kcal/d) 55% carbohydrates, 15% proteins, 30% fat\]"
223654725|NCT03527732|DRUG|Albendazole|Monotherapy of albendazole (400 mg)
223654726|NCT03527732|DRUG|Albendazole and Ivermectin|Combination therapy of albendazole (400 mg) and ivermectin (200 µg/kg)
223654727|NCT02050893|DRUG|sedatives(Midazolam and Propofol)|
224238184|NCT03375593|DRUG|Ibuprofen 600 mg tab|tablet
224320904|NCT01277601|DRUG|TDF|TDF 300 mg tablets administered orally once daily
224320905|NCT01277601|DRUG|Peg-IFN|Peg-IFN 180 µg administered via subcutaneous injection once weekly
223654728|NCT04609462|PROCEDURE|Conventional oxygen therapy|Oxygen therapy by conventional nasal cannula / prongs, venturi mask, or mask with reservoir
223654729|NCT04609462|PROCEDURE|High flow nasal cannula|Breathing support with High-flow nasal cannula
223654730|NCT00748904|DRUG|Rifaximin|400 mg orally
223654731|NCT00748904|DRUG|Lactulose|20 grams titrate to 2-3 bowel movements in one day
223654732|NCT00509613|DRUG|Sorafenib|
223654733|NCT00509613|DRUG|Sirolimus|
223654734|NCT05241548|PROCEDURE|BMAC on PCL Scaffold|Horizontal ridge augmentation in aesthetic zone by using bone marrow aspirate concentrate on PCL scaffold
223654735|NCT06134024|PROCEDURE|Introduction of double pigtail plastic stents through the LAMS during endoscopic transmural drainage of post-inflammatory pancreatic and peripancreatic fluid collections|During endoscopic procedure of endoscopic transmural drainage of post-inflammatory pancreatic and peripancreatic fluid collections the operator introduces double pigtail plastic stents through the LAMS.
223654736|NCT06134024|PROCEDURE|Endoscopic transmural drainage of post-inflammatory pancreatic and peripancreatic fluid collections with use of LAMS only|During endoscopic procedure of transmural drainage of post-inflammatory pancreatic and peripancreatic fluid collections the operator introduces transmurally the LAMS only, without the double pigtail plastic stents.
223654737|NCT02280408|OTHER|Placebo|Normal saline placebo.
223654738|NCT02280408|BIOLOGICAL|V920|Vesicular Stomatitis Virus (VSV)-based vaccine 1-mL injection containing 3x10\^6, 2x10\^7, or 1x10\^8 pfu.
223654739|NCT01287312|PROCEDURE|Endoscopic repair of recurrent TEF by trichloroacetic acid aplications|
223654740|NCT03680326|DEVICE|OCT|only OCT
223654741|NCT04079309|BEHAVIORAL|Lavender/Orange|A diffuser containing 120 ml water and 0.3 ml lavender oil / 0.3 ml orange oil will be set into the parents' perioperative waiting rooms to mist at least 1 hour before the parent arrive.
223654742|NCT04980092|OTHER|one-year follow-up|patients will be followed during the year after ICU discharge, in order to assess kidney function, and muscle and bone health
223654743|NCT04482452|PROCEDURE|Colonoscopy|Diagnostic colonoscopy will be performed
223654744|NCT02474069|DRUG|Secukinumab|
223654745|NCT04173494|DRUG|Momelotinib|Momelotinib tablets will be self-administered orally once daily
223654746|NCT04173494|DRUG|Placebo to match danazol|Danazol placebo capsules will be self-administered orally twice daily
223654747|NCT04173494|DRUG|Danazol|Danazol capsules will be self-administered orally twice daily
223654748|NCT04173494|DRUG|Placebo to match momelotinib|Momelotinib placebo tablets will be self-administered orally once daily
223654749|NCT04518579|PROCEDURE|thoracic epidural|undergo insertion of an epidural catheter, between T9 and T11 in patients undergoing left-sided resections and between T8 and T10 in patients undergoing right-sided resections
223654750|NCT04078256|OTHER|Proprioceptive exercise program|Group A will carry out two sessions of proprioceptive training per week, in a total of 8 weeks, during the pre-season period (September-October). Each session will last approximately 30 minutes and will include 6 exercises. The execution of the exercises will be supervised by a physiotherapist and a national trainer of athletics.
223654751|NCT04078256|OTHER|Usual training routine|The subjects of the control group (group B) will be informed so that they do not include any change in their usual training routine.
223654752|NCT03656380|DRUG|Mepolizumab 300 mg|Mepolizumab 300 mg subcutaneous injection
223654753|NCT03656380|DRUG|Mepolizumab 100 mg|Mepolizumab 100 mg subcutaneous injection
223654754|NCT03656380|OTHER|Placebo|Saline subcutaneous injection
223654755|NCT01623050|DEVICE|SinuSys Dilation System|Sinuplasty
223654756|NCT02133690|BIOLOGICAL|Live Attenuated Pentavalent (G1-G2-G3-G4-G9) Human X Bovine Reassortant Rotavirus Vaccine (BRV-PV)|Live Attenuated Pentavalent (G1-G2-G3-G4-G9) Human X Bovine Reassortant Rotavirus Vaccine (BRV-PV), at a dosage of ≥ Log10\^5.6 fluorescent focus units (FFU)/Serotype/Dose in 2.5 ml of buffered diluent
223654757|NCT02133690|OTHER|Placebo|Lyophilized minimal essential medium (MEM) + excipients reconstituted in 2.5 ml of buffered diluents
223654758|NCT05263778|DRUG|Bempedoic Acid / Ezetimibe Oral Tablet|Bempedoic acid 180 mg/ezetimibe 10 mg by mouth once daily for 12 weeks
223654759|NCT05263778|DRUG|Placebo|Matching placebo by mouth once daily for 12 weeks
223654760|NCT04578236|COMBINATION_PRODUCT|Aerosolized 13 cis retinoic acid plus Inhalation administration by nebulization captopril 25mg|Infected patients will receive aerosolized 13 cis retinoic acid in gradual one dose per day increases from 0.2 mg/kg/day to 4 mg/kg/day as inhaled 13 cis retinoic acid therapy for 14 days plus Inhalation administration by nebulization captopril 25mg for 14 days
223654761|NCT04578236|DRUG|Drug: Standard treatment Standard treatment|Drug: Standard treatment Standard treatment is according to the protocol of treatment of 2019-nCoV infection
223654762|NCT01191762|DRUG|sevelamer carbonate|2400 mg with each meal for 4 weeks
223654763|NCT01191762|DRUG|placebo|3 tablets with each meal
223654764|NCT03336112|BEHAVIORAL|Internet-delivered cognitive behavioral therapy (I-CBT)|The intervention (I-CBT) will consist of 5 weeks of Internet-delivered cognitive behavioral therapy using three main parts. The first is psychoeducation that aims to educate the patients about chest pain and other causes than the cardiac ones. The other part concerns avoidance and exposure. This includes exposing the patients to physical activities that patients perceive as a threat to the heart. The third part contains awareness (mindfulness) training to teach the patients to have contact with the present moment despite chest pain and not trying to avoid it.
223654765|NCT03336112|OTHER|Information program|Information program delivered by the Internet during 5 weeks.
223654766|NCT00459186|DRUG|RAD001|Daily for two weeks
223654767|NCT00459186|DRUG|Docetaxel|Infusion once per cycle
223654768|NCT00459186|DRUG|Prednisone|Prednisone 5 mg by mouth twice daily
223654769|NCT03715049|PROCEDURE|Fraxel Laser Treatment|The device to be used in this study is a FDA approved device \[510(k) approval\] used for aesthetic dermatological procedures. The Fraxel Repair laser system utilizes a sealed off, all metal carbon dioxide gas tube that is radio frequency (RF) excited and air cooled, emitting light at a wavelength of 10.6 μm with programmable pulse duration and frequency. The Fraxel Repair laser has a continuous motion (rolling) optical tracking system. The Fraxel system consists of a treatment component and an internal control component. The treatment component consists of the laser delivery handpiece. A computer with a touch screen keyboard to enter subjects' information also provides controls for the fractionated delivery of the 10.6 μm beam.
223767901|NCT06455774|OTHER|Exercise|Trapezius, Sternocleidomastoid (SCM), Scalene, pectoral muscles will be targeted for stretching exercises and deep neck flexors, Trapezius, Levator Scapula, Rhomboids will be targeted for strengthening exercises. The intensity of the exercises will be increased according to the weeks. Stretching exercises will be performed as a single set at the pain limit, maintaining the position of the muscle groups in the longest tolerable position for 30 seconds. In strengthening exercises, participants will hold the position for 5-10 seconds at the end of the movement. Moderate resistance elastic bands and free weights will be used for resistance exercises. In the following weeks, progression will be made in all exercises according to the patient's condition.
223767902|NCT06289257|DIAGNOSTIC_TEST|Vitamin D level|Vitamin D level in blood
223767903|NCT06289257|OTHER|Vitamin D receptor|Vitamin D receptor in endometriosis tissue
223767904|NCT00486122|DRUG|Atomoxetine Hydrochloride|
223767905|NCT00486122|DRUG|Placebo|
223767906|NCT01594593|BEHAVIORAL|Acceptance and Commitment Therapy|group-based behavioral workshop to address cancer-related distress
223654770|NCT02516852|OTHER|Egg production|Establishment and support of a community-owned and -operated egg production facility located at a central location in the community
223654771|NCT04681976|BEHAVIORAL|Telematic dance program|"Telematic dance program~The dance program will consist of 24 sessions distributed twice a week for a total period of 3 months. Each session will include:~A) Warm up: It will consist of analytical and global movements of increasing intensity and stretching exercises. It will also involve body awareness and motor control exercises.~B) Choreography part: the participants must follow and learn the choreographies. Intensity ranges shall vary between low and moderate. (3-4 in Borg's Modified Scale (0-10)).~C) Cool down: It will consist of global movements of decreasing intensity, stretching, breathing, and relaxing exercises."
223654772|NCT03072004|DEVICE|LLLT|The LLLT will be applied using a diode laser device (Recover Laser MMOptics, São Carlos/SP- Brazil) with parameters: 808nm, continuous output, 100mW, 8J. Laser probe will be applied directly and perpendicularly in skin contact (5 points), the time of irradiation will be 80 seconds per point, and treatments will be applied for three times a week for 12 sessions.
223654773|NCT03072004|DEVICE|Sham LLLT|"That group receive application sham LLLT. The laser will be turned off, but the procedure will be the same as with the LLLT group"
223654774|NCT03710083|DEVICE|Guardian™ Sensor (3)|Use two Guardian™ Sensor (3)s each connected to a Guardian™ Connect transmitter for approximately 7 days.
223654775|NCT05862168|DRUG|Tislelizumab|The participants will receive 3 cycles of Tislelizumab, with 21 days each. 200mg of Tislelizumab will be used intravenously on the first day of each cycle.
223654776|NCT05862168|DRUG|Albumin paclitaxel|The participants will receive 3 cycles of Albumin paclitaxel, with 21 days each. 200mg/m\^2 of Albumin paclitaxel will be used intravenously on the first day of each cycle.
223654777|NCT05862168|DRUG|Cisplatin|The participants will receive 3 cycles of Cisplatin, with 21 days each. 20mg/m\^2 of Cisplatin will be used intravenously on days 1 through 3 of each cycle.
223654778|NCT05862168|DRUG|5-Fluorouracil|The participants will receive 3 cycles of 5-Fluorouracil, with 21 days each. 600mg/m\^2/d of 5-Fluorouracil will be used as a 120-hour continuous intravenous infusion on days 1 through 5.
223654779|NCT05068882|DIETARY_SUPPLEMENT|Immunonutrition|Oral immunonutrition containing arginine, omega-PUFAs and antioxidants
223654780|NCT05068882|DIETARY_SUPPLEMENT|High-protein nutrition|Oral nutrition with high-protein content
223654781|NCT05068882|DIETARY_SUPPLEMENT|Standard nutrition|Oral nutrition with standard ingredients
223654782|NCT01903980|OTHER|No intervention. It is a retrospective study|No intervention. It is a retrospective study
223654783|NCT00192634|DRUG|Emtricitabine 200mg - Tenofovir 300mg|1 tablet once daily for 96 weeks
223654784|NCT00192634|DRUG|Abacavir 600mg - Lamivudine 300mg|1 tablet once daily for 96 weeks
223654785|NCT01632618|BEHAVIORAL|Trunk Muscle Training+NMES|Progressive exercise program for the stabilizing muscles of the trunk, as well as neuromuscular electrical stimulation to the lumbar paraspinals
223767907|NCT05114304|OTHER|Evaluation of co-morbid psychiatric disorders|"Added scales :~* Mini Internationnal Neuropsychiatric Interview~* Fagerström test~* DSM-5 Scale~Additional dosage : - a urine sample will be taken to evaluate the presence of tobacco and nicotine breakdown products and the presence of various toxics~Expired carbon monoxide for patients using nicotine substitutes"
223767908|NCT05023590|PROCEDURE|ablation of left atrium during mitral valve open chest intervention|open chest mitral valve surgery (reconstruction or replacement) with additional ablation of left atrium by cryo or radio frequency method
223767909|NCT03148548|GENETIC|thrombophilia screening|genetic Evaluation of Factor-V-Leiden, Factor-II\_G20210A Mutation;
223767910|NCT05764213|BEHAVIORAL|Listening to Women & Pregnant and Postpartum People|Participants are enrolled in text message-based screenings with immediate automated feedback, paired with remote care coordination and, if appropriate, home-based telemedicine mental health and substance use disorder treatment services.
223767911|NCT00560261|OTHER|NO-CO inhalation and expiration|NO-CO inhalation and expiration
223767912|NCT00560261|OTHER|NO-CO inhalation and expiration|NO-CO inhalation and expiration
223767913|NCT03777189|BEHAVIORAL|Cognitive-Behavioral Therapy|Cognitive-behavioral therapy will be delivered in line with recommendations (e.g., NICE 2017). Format will be guided self help with added content related to physical activity.
223767914|NCT01860417|BIOLOGICAL|Allogenic Mesenchymal Stromal Cells|
223767915|NCT01860417|DRUG|Mepivacaine|
223767916|NCT02771639|PROCEDURE|Hip arthroplasty|Treatment with a hip arthroplasty (semi- or total hip arthroplasty) for a displaced femoral neck fracture
223767917|NCT00349596|DRUG|Decitabine|Administered intravenously (IV) over 1 hour at 10 mg/m2 daily x 5 days every other week.
224320906|NCT00151931|DRUG|Lanthanum carbonate|
224320907|NCT03120182|DRUG|Acetylsalicylic acid|Patients will receive acetylsalicylic acid 100mg daily for 12 days after randomization
223654786|NCT01632618|BEHAVIORAL|Passive control intervention|Passive physical therapy approach to low back pain
223654787|NCT06519695|BEHAVIORAL|Multicomponent exercises|Performed exercise three times a week, one time at a community health service station and two times at home
223654788|NCT04265105|DRUG|fluticasone-vilanterol|LABA-ICS combination Inhaled Long acting Beta agonist and inhaled corticosteroid
223654789|NCT04265105|DRUG|Standard Preparation|inhaled SABA or Inhaled corticosteroid
223767918|NCT01989533|BIOLOGICAL|Ad4-mgag|Ad4 live virus vaccine with an HIV insert
223767919|NCT01989533|BIOLOGICAL|Ad4-EnvC150|Ad4 live virus vaccine with an HIV insert
223767920|NCT01989533|BIOLOGICAL|gp 120 Protein Boost|HIV protein boost
224238185|NCT06447883|BEHAVIORAL|Lifestyle modification program|The LMP included 12 treatment modules which was administered by the occupational therapist with a national occupational therapist license and a certification from the USC Lifestyle Redesign® course in 2001. The experimental group engaged in 24 weekly group sessions, each lasting approximately 2 hours. Each session started with stretching, followed by knowledge sharing, group discussion, and activities participation which aligned with the session's themes and discussion topics. The four strategies, including didactic presentation, peer exchange, direct experience, and personal exploration, were employed to deliver the treatment module content. Following these strategies, the primary researcher emphasized the connection between participants' personal meanings, individual contexts, and occupations. Afterward, participants were encouraged to formulate a personalized action plan and integrate what they had learnt into their daily routine.
223654790|NCT00885222|DEVICE|DBS parameters setting|DBS parameters will be set to increase the DBS affected volume to include both the cognitive and limbic territories in addition to the dorso-lateral motor territories of the STN. This novel approach to parameter selection is directed to achieve improvement in cognitive and limbic as well as motor domains of PD. The patients will therefore be assessed for cognitive, limbic and motor state at multiple time points; there will be a baseline assessment prior to starting treatment (prior to DBS surgery and/or prior to parameters changes); thereafter assessments will follow the stimulation parameter changes; thereafter follow-up assessments at 6 - 12 months. Stimulation parameters will be changed every 2 weeks or earlier if an urgent clinical state emerges. Patients with depression will be monitored for antidepressant effects of stimulation changes. Patients without depression will be monitored for evidence of treatment emergent depression.
223654791|NCT05213767|DRUG|TQB2916 injection|TQB2916 injection is a kind of Tumor necrosis factor receptor superfamily member 5 (CD40) agonist, which is a humanized immunoglobulinG2 (IgG2) monoclonal antibody targeting CD40. This product can bind to CD40 on target cells to activate downstream signaling pathways and generate anti-tumor immune responses. At the same time, it can promote the apoptosis of B-cell lymphoma Ramos cells.
223654792|NCT05433844|DRUG|Reference Drug or Test Drug|"Test Drug: single administration of JW0301 Reference Drug: single administration of C2105~Tablet, Oral, QD for 1 Days, Washout period is more than 14 days after administration"
223654793|NCT00842322|BEHAVIORAL|high fluid intake|fluid intake of 4 litres per day
223654794|NCT00842322|BEHAVIORAL|normal fluid intake|Fluid intake of 2 litres per day
224238186|NCT00866593|DRUG|Generic Escitalopram|10mg/d or 20mg/d
224238187|NCT00866593|DRUG|Innovator Escitalopram|10mg/d or 20mg/d
224238188|NCT04791553|DRUG|Cenobamate|Cenobamate (YKP3089) is a small molecule approved in the United States (US) for the treatment of partial onset seizures (POS) in adult patients.
224320908|NCT03120182|DRUG|Placebo Oral Tablet|Patients will receive placebo medication 100mg daily for 12 days after randomization
223654795|NCT01636518|PROCEDURE|Standard of Care|Standard of care procedure as determined by treating physician for Atrial Fibrillation
223654796|NCT00838513|DRUG|eculizumab|All patients received open-label eculizumab administered intravenously on the following dose schedule: Induction dose - 900 mg per week for four weeks and a dose of 1200 mg one week later; Maintenance dose - 1200 mg every two weeks. Patients who received plasma exchange or infusion during the eculizumab treatment period received a supplemental dose of 600 mg within one hour before plasma infusion or within one hour after the completion of each plasma exchange.
223654797|NCT05261698|OTHER|Home-based Exercise Manual|in the experimental group we will provide moist heating pads along with TENS on the neck for 10 minutes and then neck isometrics and strengthening exercises shall be performed. Patients in the experimental group will also receive a home-based exercise manual.
223654798|NCT05261698|OTHER|Conventional PT|In this group patients will receive routine physical therapy including hot pack for 10 minutes, stretching, strengthening exercise and TENS at the end of each session.
223654799|NCT05988606|BEHAVIORAL|15 minutes of high-intensity interval training|Participants completed an 8 min warm-up and 1 round of high-intensity interval training
223654800|NCT05988606|BEHAVIORAL|43 minutes of high-intensity interval training|Participants completed an 8 min warm-up and 5 rounds of high-intensity interval training
223654801|NCT05988606|OTHER|Hot environment|Participants exercised in a hot environment, \~ 35 °C, \~40% relative humidity.
223767921|NCT01697436|DRUG|ribavirin [Copegus]|tablet under fed condition
223767922|NCT01697436|DRUG|ribavirin [Copegus]|tablet under fasted condition
223767923|NCT01697436|DRUG|ribavirin [Copegus]|oral solution under fed condition
223767924|NCT01697436|DRUG|ribavirin [Copegus]|oral solution under fasted condition
223767925|NCT03794284|DIAGNOSTIC_TEST|VereMTB|At least 2 mL of patient's expectorated or induced sputum would be collected for VereMTB assay and their clinical data would be retrieved for analysis use.
223767926|NCT00832208|DRUG|Liposomal amphotericin B (Ambisome)|21.0 mg/kg total dose. Given iv as 3mg/kg/day on days 1,2,3,4,5, and 14 and 21
223767927|NCT00832208|DRUG|Liposomal amphotericin B (Ambisome)|liposomal amphotericin b given intravenously as single dose at 7.5 mg/kg increasing to 10, 12.5 and 15.0mg/kg depending on results of interim analyses.
223767928|NCT03050905|DRUG|VEKIRAX|"Patients will be treated according to label recommendation as for GT1b (with and without cirrhosis) for 12 weeks. All subjects will receive Ombitasvir+Paritaprevir+Ritonavir (Viekirax).~Study Regimen: ombitasvir+paritaprevir+ritonavir (25+150+100mg once daily)"
223767929|NCT03050905|DRUG|EXVIERA|"Patients will be treated according to label recommendation as for GT1b (with and without cirrhosis) for 12 weeks. All subjects will receive Dasabuvir (Exviera).~Study Regimen: dasabuvir (250 mg twice daily)"
224238189|NCT00043381|DRUG|decitabine (5-aza-2'deoxycytidine)|
224238190|NCT04931667|DRUG|Lorecivivint|Healthcare professional-administered intra-articular (IA) injection into one or both knees as clinically indicated. Bilateral injections of 0.07 mg of LOR are allowed. IA injection performed on Day 1. Additional IA injections of LOR to same knee (with at least a 6 month separation) between Day 1 and Month 33.
224238191|NCT06441435|DIETARY_SUPPLEMENT|Low protein diet with AC-134|Low protein diet combined with AC-134 Dosage: 2 capsules,three times/day
224238192|NCT06441435|OTHER|Standard treatment|Low protein diet
223654802|NCT05988606|OTHER|Temperate environment|Participants exercised in a temperate environment, \~ 22 °C, \~40% relative humidity.
224238193|NCT04856345|OTHER|Walking with music with synchronisation|Walking with music than one can synch to
223654803|NCT01594528|OTHER|pain tests|pain induction with pressure application or ischemia on the arm
224238194|NCT04856345|OTHER|Walking with music without synchronisation|Walking with music than one cannot synch to
223654804|NCT04004871|DRUG|Nab-paclitaxel, Cisplatin and Fluorouracil|Patients receive Nab-paclitaxel (200mg/m2 on day 1), cisplatin (60mg/m2 on day 1) and fluorouracil (600mg/m2 on Days 1 to 5) every three weeks for three cycles before concurrent chemoradiotherapy.
223654805|NCT04004871|RADIATION|concurrent chemoradiotherapy|Patients receive radical radiotherapy and cisplatin (100mg/m2) every three weeks for three cycles during radiotherapy.
223654806|NCT04625517|PROCEDURE|Digital Mammography|Digital Mammography enhanced with an iodinated contrast agent
223654807|NCT04625517|DRUG|Low Osmolar Contrast Material, 300-399 Mg/Ml Iodine Concentration, Per Ml|Injection of low osmolar contrast material during the digital mammography exam
223654808|NCT01828151|DEVICE|Noninvasive ventilation mask|
223654809|NCT01842217|PROCEDURE|FES-PET|
223654810|NCT02943434|OTHER|Processed food|This is examining the effects of processed foods on diet-induced thermogenesis.
224238195|NCT04856345|OTHER|walking without music|Walking without music
224238196|NCT03107468|OTHER|Mokhuri intensive treatment|Patients in this arm will be treated with acupuncture, Chuna and patient consultation during 5 weeks. For acupuncture therapy, disposable sterile needles will be placed on LI4, ST36, LV3, B22, B23, B24 and B25 of both sides of a patient for 15 minutes. For Chuna therapy, the patient lies on the Ergo Style™ FX-5820 Table in the prone position and back muscles will be relaxed by manual manipulation during flexion and extension movement of the table for 5 to 6 minutes. Patient consultation regarding the precautions for everyday life, the precautions for activity in bed, the precautions for walking, the precautions for particular movements and the exercises will be offered for 5 minutes.
224238197|NCT03107468|OTHER|Non-surgical conventional standard treatment|Patients in this arm will be treated with 10 sessions of non-surgical conventional standard treatment including conventional drug treatment and injection treatment under the consultation of neurosurgeons or doctors of anesthesiology or rehabilitation medicine during 5 weeks. For drug therapy, muscle relaxants, NSAIDs, gabapentin, pregabalin or tricyclic antidepressants will be prescribe. For epidural steroid injection, 3cc of epidurals will be injected at the affected lesion once or twice. For physical therapy, participants shall participate in conventional physical therapy with the aid of physical therapists, including heating pad, deep tissue heating device and transcutaneous electrical nerve stimulation (TENS) twice a week during the five weeks of participation.
224238198|NCT02116049|BEHAVIORAL|Disclosure Intervention|The experimental condition is a 4-session + 3 month booster intervention. Session 1 includes an introduction to the project, goal setting, assessment of disclosure strategies or tactics utilized, and disclosure triggers. Session 2 focuses on the costs and benefits of disclosing to casual sexual partners and previous best and worst disclosure experiences. Session 3 begins with the delivery of the encouraging messages and review of the disclosure strategies already employed. Session 4 is a continuation of session 3 activities with an additional focus on expanding the participant's repertoire of strategies; discussion of methods of sexual negotiation, and rehearsal. The booster session includes a discussion of what strategies have been used in the preceding months, which strategies worked and how can these be enhanced, which strategies did not work with opportunities for troubleshooting, and an examination of rewards experienced or costs encountered.
224320909|NCT04034927|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223654811|NCT04468152|BEHAVIORAL|Dietary habits and intake|Optical coherence tomography (OCT) withdrawals and central foveal thickness (CFT) evaluations of those included in the study were made by the doctor and directed to the dietician (researcher). The dietary intake of participants was assessed using a validated quantitative food frequency questionnaire (QFFQ) (21). The total food intake was then converted to total nutrient intake based on the food's nutrient profile. Standardized food recipes for Turkey and the Nutrition Information System (BEBIS) program, which is a food composition database for nutrient estimation, were used to determine the average daily energy and nutrient intake for each participant.
223654812|NCT01646229|OTHER|Polymyxin-B hemoperfusion|
223654813|NCT01646229|OTHER|Control|
223654814|NCT00210912|DRUG|topiramate|
223654815|NCT02902562|PROCEDURE|Contrast Enhanced Ultrasound (CEUS)|An intravenous line (IV) line will be inserted into a vein in your arm. You will be asked to lie on a table for the ultrasound imaging. First, a regular ultrasound (without contrast) will be performed and the images will be recorded. For the contrast enhanced ultrasound, the contrast agent will be injected into your IV line. We will perform another ultrasound and the images will be recorded
223654816|NCT02902562|PROCEDURE|Magnetic Resonance Imaging (MRI)|For the contrast MRI, the contrast agent will be injected into your IV line The MRI scanner is a small, tunnel-like machine in which a patient will be required to lie still for a long period of time. There is little space inside the scanner, which causes anxiety and discomfort for patients who fear enclosed spaces. A technician will be present at all times during the examination to communicate with you about how you are feeling.
223654817|NCT01388335|DRUG|warfarin|Administered orally
223654818|NCT01388335|DRUG|enzastaurin|Administered orally
223654819|NCT04292418|DRUG|Tacrolimus capsule , mycophenolic acid|measuring tacrolimus level by elisa test then correlated with hematocrit level measuring mycophenolic acid by elisa test for study group 1 and study group 2
223654820|NCT02087696|DRUG|Tocilizumab|Tocilizumab dose 8mg/kg administered every 4 weeks during 24 weeks.
223654821|NCT04638361|OTHER|Questionnaires|To explore the quality of life, two questionnaires will be submitted to the parents and the child. The first one is the pediatric version of the VHI (Voice Handicap Index), which explore, using 23 items, the functional, physical and emotional aspects of the dysphonia. The second one is the PEDI-EAT-10 (Pediatric Voice Handicap Index - Eating Assessment Tool), which explore, through 10 items (ranging from 0 to 4), the risk of aspiration and assess the impact of possible dysphagia on quality of life.
224320910|NCT04034927|PROCEDURE|Computed Tomography|Undergo CT
224320911|NCT04034927|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
224320912|NCT04034927|DRUG|Olaparib|Given PO
224320913|NCT04034927|BIOLOGICAL|Tremelimumab|Given IV
223654822|NCT01681719|DEVICE|WBV and Resistance|"use of WBV and resistance device during 03 months in elderly health people. The WBV used progressive increases of time and amplitude and the resistance training improves the weight.~For Resistance: performed in upper and lower limbs in weight machine Mega II Movement®, used guidelines from American College of Sports Medicine for elderly, with two series of 08 repetitions (75% weight of one RM), considered for RM calculation the maximum voluntary isometric contraction.~For WBV: used MY3 platform (Power Plate®, MY3, UK) frequency 35 hertz, tri-axial, amplitude 02 mm in adaptation and initial phases, increasing to 04 mm in phases intermediate and final. The time initial was 10 minutes, progressed to 15 min in second month, concluding with 20 min. Rest time between series remained 01 min."
224238199|NCT02116049|BEHAVIORAL|Attention Control Case Management|Comprehensive Risk Counseling and Services (CRCS) will be used to guide the case management activities. CRCS combines traditional case management and HIV risk-reduction in an individualized, client-centered program which focuses on the reduction of risk behavior and addresses a client's psychosocial and medical needs. CRCS focuses on seven core elements: recruitment and engagement; screening, enrolling, and assessing; prevention planning; risk reduction counseling; referrals and service coordination; monitoring; and discharge and maintenance.
224320914|NCT05660408|BIOLOGICAL|pp65 RNA LP (DP1)|This is an off the shelf RNA-LP vaccine used to prime for the immune response while we produce the patient specific pp65/tumor mRNA RNA-LP (DP2)
223654823|NCT01681719|DEVICE|resistance & sham WBV|"used only resistance~For Resistance: performed in upper and lower limbs in weight machine Mega II Movement®, used guidelines from American College of Sports Medicine for elderly, with two series of 08 repetitions (75% weight of one RM), considered for RM calculation the maximum voluntary isometric contraction.~For WBV: used MY3 platform (Power Plate®, MY3, UK)off."
223654824|NCT01681719|DEVICE|WBV & resistance sham|"used really the WBV, but sham for resistance training~For Resistance: performed similar movments in upper and lower limbs in weight machine Mega II Movement®, without using weights.~For WBV: used MY3 platform (Power Plate®, MY3, UK) frequency 35 hertz, tri-axial, amplitude 02 mm in adaptation and initial phases, increasing to 04 mm in phases intermediate and final. The time initial was 10 minutes, progressed to 15 min in second month, concluding with 20 min. Rest time between series remained 01 min."
223654825|NCT06170099|RADIATION|low level laser therapy|irradiation with LLLT by the following regimen 0, 3, 7 and 14 from the activation of the bony supported Distal Jet and then every 15 days till completion of distalization
223654826|NCT06170099|DEVICE|bonny supported distal jet|distal jet distalizing appliance is supported on two paramedian screw
223654827|NCT06433492|DEVICE|Intra-articular injection|Three doses of intra-articular injection administered in weekely intervals.
223654828|NCT00889720|DRUG|Varenicline|Varenicline film coated tablets - escalating dose with maximum dose of 1mg bd
223654829|NCT00670306|DRUG|Cetrorelix Pamoate|Cetrorelix Pamoate IM, 52 mg week 0, 26 mg week 2,
223654830|NCT05711563|OTHER|Observational study|Observational study
223654831|NCT03808259|DRUG|(S)-ketamine Oral Thin Film|(S)-ketamine OTF sublingual formulation at a dose of 7 mg, 14 mg, and 28 mg will be administered in sequential cohorts.
223654832|NCT03808259|DRUG|(S)-ketamine IV Infusion|(S)-ketamine IV solution will be infused at a dose of less than or equal to 14mg.
223654833|NCT03808259|DRUG|Placebo|Participants will receive matching placebo.
223654834|NCT04893304|DEVICE|co2 laser|types of laser
223654835|NCT02931773|DEVICE|Task Force® Monitor|A head up tilt test carried out with a Task Force monitoring system
223654836|NCT00295373|DRUG|Rosuvastatin|
223654837|NCT00295373|BEHAVIORAL|Exercise Training|
223654838|NCT03446404|DIAGNOSTIC_TEST|Standing Computed Tomography|Provides weight bearing 3D view of knees.
223654839|NCT04038021|BEHAVIORAL|Phosphatidylethanol-based Contingency Management|In CM, tangible reinforcers are provided after individuals demonstrate biochemically verified abstinence of various substances. CM is associated with increased abstinence from illicit drugs, nicotine, and alcohol and is the most powerful psychosocial treatment for initiating abstinence of these substances. When participants submit a negative result for alcohol (via blood phosphatidylethanol biomarkers), the subject will receive rewards (gift cards). In contrast, they will not receive rewards when their samples test positive for alcohol.
223654840|NCT04038021|BEHAVIORAL|Non-Contingent Control|In the non-contingent control intervention, participants will receive rewards (gift cards) regardless of the alcohol biomarker results in their samples. Once the samples have been received, the subjects will receive reinforcers that is consistent with the average from the CM group's earnings.
223654841|NCT00775593|DRUG|clofarabine|"Patients will receive one course of low-dose Clofarabine in combination with Temsirolimus (CloTor regimen) for remission induction.~Induction therapy~\- Clofarabine 20 mg/m2/day, administered by iv infusion over 1 hour on days 1 through 5"
223654842|NCT00775593|DRUG|temsirolimus|"Those who achieve morphologic CR and morphologic CRi will receive maintenance treatment with Temsirolimus monthly for 12 months, or until relapse.~Those who achieve a PR will receive one additional course of CloTor and, if a CR/CRi is obtained, maintenance treatment with Temsirolimus as above.~Induction therapy:~\- Temsirolimus 25 mg (flat dose) administered iv over 30 minutes on days 1, 8 and 15.~Maintenance therapy:~\- Temsirolimus 25 mg (flat dose) administered iv over 30 minutes on days 1 and 8 of each month for 12 months, or until relapse."
223654843|NCT04440865|OTHER|Genius® System-assisted Colonoscopy|Genius® Intelligence System is used to assist Colonoscopy
223654844|NCT04440865|OTHER|Standard Colonoscopy|Standard Colonoscopy without Genius® Intelligence System is performed
223654845|NCT04712630|PROCEDURE|Non-incised papila surgical approach without grafting biomaterial|Periodontal reconstructive surgery
224320915|NCT05660408|BIOLOGICAL|pp65/tumor mRNA RNA-LP (DP2)|This is a patient specific RNA-LP vaccine generated from the patient's tumor RNA.
224320916|NCT05660408|PROCEDURE|Surgical Biopsy/Resection|Eligible participants will be enrolled and undergo sterile collection of tumor material .
224320917|NCT05698563|DIAGNOSTIC_TEST|Magnetic resonance imaging|MRI scan with contrast of the foot or feet
224320918|NCT05698563|DIAGNOSTIC_TEST|Ultrasound|Ultrasound scan of the feet
224320919|NCT05698563|DRUG|Corticosteroid injection|Administered ultrasound guided to patients with intermetatarsal bursitis
224320920|NCT05698563|OTHER|Clinical foot evaluation|An examination of the feet
224320921|NCT05698563|OTHER|Picture of the feet|To evaluate the presence of V-sign/spreading toes
223654846|NCT04712630|PROCEDURE|Non-incised papila surgical approach with grafting biomaterial|Periodontal reconstructive surgery
223654848|NCT03283514|OTHER|Complete denture|questionnaire
223654849|NCT04411732|DEVICE|MyotonPro|Measurement of relaxation time, stiffness and elasticity of the following muscles, using the MyotonPro® device: on both sides thenar and hypothenar, m. biceps brachii, m. triceps brachii, m. deltoideus, m. quadriceps femoris, m. tibialis anterior and gastrocnemius muscles.
224238200|NCT00708019|BEHAVIORAL|PRO-SELF PLUS Pain Management Program|The psychoeducational intervention will be conducted by specially trained oncology nurses and will include the components of knowledge, skills training, and coaching to improve cancer pain management. Patients in both groups will be seen in their homes over the course of 10 weeks with phone calls conducted in between the home visits. Patients in the HIGH-DOSE group will receive 6 visits and 10 phone calls \[total time 12.3 hours\]. Patients in the LOW-DOSE group will receive 4 visits and 6 phone calls \[8.0 hours\]. Follow-up visits to assess the sustainability of the intervention will be done at 2 weeks, 1 month and 3 months after the intervention. Both quantitative and qualitative analyses will be conducted to evaluate patient outcomes.
224238201|NCT01135641|DRUG|Rituximab|Patients will receive in addition to ciclosporine A and corticosteroids (prednisone) 1 mg/kg/day, Rituximab at 375 mg/m²/infusion once a week for 4 consecutive weeks.
223654850|NCT04411732|DIAGNOSTIC_TEST|Six-minute walk test|The six-minute walk test (6MWT) measures the distance an individual is able to walk over a total of six minutes on a hard, flat surface. The goal is for the individual to walk as far as possible in six minutes. The individual is allowed to self-pace and rest as needed as they traverse back and forth along a marked walkway. The 6MWT has been used with a variety of other conditions than the chronic obstructive pulmonary disease (COPD) such as heart failure and stroke and is widely used in neuromuscular diseases. The six-minute-walk-test will be conducted as recommended by the American Thoracic Society. In this study, the six-minute-walk test will be performed once on visit 1 to detect the impact of muscle weakness, muscle stiffness and myotonia on muscular endurance.
223680974|NCT01843647|DRUG|Icotinib|Patients receive 8-week icotinib induction treatment before surgery and 1-year icotinib adjuvant therapy after surgery.Icotinib is administered orally with a dose 125 mg 3 times daily.
224238202|NCT01135641|DRUG|Ciclosporine|
224238203|NCT01135641|DRUG|Corticosteroids|
224238204|NCT00719316|DRUG|Aliskiren|Aliskiren 300mg per day for 6 weeks
224238205|NCT02272764|DRUG|Itraconazole|Administered orally in a crossover design
224238206|NCT02272764|DRUG|ALKS 5461|Administered sublingually in a crossover design
224238207|NCT00369590|BIOLOGICAL|ziv-aflibercept|Given IV
224238208|NCT00369590|OTHER|pharmacological study|correlative studies
224238209|NCT00369590|OTHER|laboratory biomarker analysis|correlative studies
224238210|NCT00639990|OTHER|PEEP|Application of positive end expiratory pressure
224238211|NCT00639990|OTHER|PEEP|Application of positive end-expiratory pressure
224238212|NCT00639990|OTHER|PEEP|Application of positive end-expiratory pressure
224238213|NCT00639990|OTHER|PEEP|Application of positive end-expiratory pressure
224238214|NCT02220868|DRUG|Sofosbuvir, Ribavirin, and Stribild|
224238215|NCT03598439|BIOLOGICAL|Standard IIV4|Standard inactivated influenza vaccine
224238216|NCT03598439|BIOLOGICAL|Recombinant|Influenza vaccine that uses a hemagglutinin protein manufactured in insect cells with a baculovirus vector
224238217|NCT03598439|BIOLOGICAL|Cell-culture|inactivated influenza vaccine manufactured using mammalian cell lines; current vaccine uses a cell-propagated H3N2 strain.
224238218|NCT01215409|DRUG|Vardenafil (Levitra, BAY38-9456)|5 mg or 10 mg or 20 mg of Vardenafil, orally when necessary for 2 months
224238219|NCT03974256|OTHER|Training in the use of the automaton|2 days training on automaton use
224238220|NCT04500509|DRUG|diclofenac potassium + dinoprostone|patients will have of oral diclofenac potassium 60 minutes before the procedure plus one tablets of vaginal dinoprostone (6 mg) 6 hours prior to the procedure by the patient
223680975|NCT01843647|DRUG|Chemotherapy|"After surgery patients receive 4-cycle adjuvant chemotherapy with vinorelbine~/cisplatin regimen, until untolerable toxicity or disease progression."
224238221|NCT04500509|DRUG|diclofenac potassium + placebo|patients will have of oral diclofenac potassium 60 minutes before the procedure plus one tablets of vaginal placebo 6 hours prior to the procedure by the patient
224238222|NCT05457101|OTHER|AI-based biliopancreatic EUS navigation system|The endoscopists in the experimental group will be assisted by EndoAngel, which can in real-time prompt standard stations and anatomical structures during EUS. The system is an non-invasive AI system .
224238223|NCT02946762|OTHER|Test and treat|All incarcerated individuals found to have HIV infection will be offered universal voluntary HIV counseling and testing (HCV) through routine care provided at the correctional facility followed by referral to the study for immediate (routine, non-study prescribed) ART, regardless of CD4 cell count. The ART regimen prescribed will be the standard first-line, fixed-dose combination efavirenz plus lamivudine/emtricitabine and tenofovir per Zambian national guidelines.
224238224|NCT04493723|PROCEDURE|Surgery|To collect tumour tissue
224238225|NCT04493723|PROCEDURE|Venepuncture|To collect blood samples
223680976|NCT05806489|OTHER|Intermittent Fasting|Participants received a 3-day individualized diet plan consisting of 3 meals per day. Meals needed to be consumed during 6 hours (while fasting for the remaining 18 hours). Diet plans were matched for energy and macronutrients.
223680977|NCT05806489|OTHER|Control Diet|Participants received a 3-day individualized diet plan consisting of 3 meals per day. Meals needed to be consumed during 12 hours (while fasting for the remaining 12 hours). Diet plans were matched for energy and macronutrients.
223680978|NCT05195138|BEHAVIORAL|Mindfulness-Based Diabetes Education|Mindfulness-Based Diabetes Education described in study arm.
223680979|NCT05195138|BEHAVIORAL|Standard Diabetes Self-Management Education (DSME)|Standard DSME described in study arm.
223680980|NCT04896450|PROCEDURE|Guided tissue regeneration (GTR)|GTR is handled with the utilization of a coronally advanced flap, followed by a thorough debridement of the denudated root surface and the intrabony component. Regenerative materials are resorbable collagen membrane (BioGide, Geistlich Phara AG, Wolhusen, Switzerland) and deproteinized bovine bone mineral (BioOss, Geistlich Phara AG), finally surgery is finished with multilayer suturing technique.
223767930|NCT06503835|PROCEDURE|Fluoroscopy Guided Transforaminal Epidural Ozone Injection|All procedures were performed under light sedation in a sterile operating room. Ozone was created by an ozone generator (Dr. J. Hänsler Ozonosan, Iffezheim, Germany). Appropriate diffusion of the non-ionic contrast agent into the periradicular and epidural area was verified through anteroposterior and lateral fluoroscopic images and the injections were then safely performed. Patients who underwent transforaminal epidural steroid plus ozone injection received additionally 5ml of ozone at a concentration of 28 g/ml for each transforaminal epidural injection level.
223767931|NCT06503835|PROCEDURE|Fluoroscopy Guided Transforaminal Epidural Steroid Injection|All procedures were performed under light sedation in a sterile operating room.Appropriate diffusion of the non-ionic contrast agent into the periradicular and epidural area was verified through anteroposterior and lateral fluoroscopic images and the injections were then safely performed. Patients who underwent transforaminal epidural steroid injection received two mL of dexamethasone (8 mg) and 3 mL of saline for each transforaminal epidural injection level
223767932|NCT03592641|DRUG|Savolitinib|Given PO
223767933|NCT00149708|DRUG|growth hormone administration for 6 months|depot GH (Nutropin depot) 13.4 mg every 14 days
224238226|NCT06316921|PROCEDURE|Epidural patient-controlled analgesia|Epidural patient-controlled analgesia for postoperative pain after lumber spine surgery
224238227|NCT06316921|PROCEDURE|Standard postoperative pain management|Standard of care for postoperative pain after lumber spine surgery
224238228|NCT00795015|DRUG|insulin regular IV infusion|IV insulin was administered by continuous infusion and the rate changed every hour according to the blood glucose level as determined by each of the protocols being compared
224238229|NCT00795015|DRUG|IV insulin infusion|IV insulin was administered by continuous infusion and the rate changed every hour according to the blood glucose level as determined by each of the protocols being compared
224238230|NCT05844722|BEHAVIORAL|Mindfulness-based intervention therapy|Mindfulness-based cognitive therapy consists of meditation techniques to stay in the present moment with acceptance (breathing exercises, body scan, gentle yoga, awareness of thoughts and feelings) and some aspects of cognitive therapy, and psycho-education.
224238231|NCT05844722|OTHER|usual care|Usual care means received standard multidisciplinary stroke care
223654851|NCT04411732|DIAGNOSTIC_TEST|Semiquantitative muscle ultrasound|Muscle ultrasound is an ideal imaging modality that allows for atraumatic, noninvasive, radiation-free point-of-care neuromuscular imaging. Muscular dystrophies are typically associated with an increase in the echogenicity from the muscle substance, distal attenuation of muscle echo and a corresponding loss of bone echo. Spinal muscular atrophies and neuropathies also showed an increase in muscle echo along with atrophy of the muscle and increase in depth of subcutaneous tissue, but a persisting bone echo. In several other myopathies, similar changes are seen. In semi-quantitative muscle ultrasound, muscle intensity will be documented using the 4-point Heckmatt score. In addition to that, cutis, subcutaneus fat and muscle will be measured in mm.
223654852|NCT04411732|DIAGNOSTIC_TEST|Hand-held Dynamometry of muscle strength|Muscle strength will be assessed by handheld dynamometry using the MicroFET2 myometer, produced by Hoggan Health Industries. This test is widely used in patients with neuromuscular diseases. To perform a test, the examiner holds the dynamometer stationary while the patient exerts a maximal force against the dynamometer. The patient makes a gradual increase in force and then completes an isometric hold for 4-5 seconds. The following muscle groups will be tested: Arm abduction, elbow flexion, elbow extension, knee extension, knee flexion, foot extension, foot flexion.
223654853|NCT06338969|OTHER|Carbohydrate Restriction after a Gastric Bypass|"All patients will undergo laparoscopic one anastomotic gastric bypass. In the postoperative period, all patients will receive normal daily amounts of protein and fat. Depending on the amount of carbohydrates that will be received after surgery, patients will randomly (no mask) be divided into three groups:~The first group: 51-75% deficit in carbohydrates Second group: 26-50% deficit in carbohydrates The third group: has a 1-25% deficit in carbohydrates."
223654854|NCT00019201|OTHER|cytology specimen collection procedure|
223654855|NCT00019201|OTHER|immunohistochemistry staining method|
223654856|NCT00019201|OTHER|sputum cytology|
223654857|NCT00019201|PROCEDURE|bronchoscopic and lung imaging studies|
223654858|NCT00019201|PROCEDURE|bronchoscopy|
223654859|NCT00019201|PROCEDURE|comparison of screening methods|
223654860|NCT00019201|PROCEDURE|endoscopic biopsy|
223654861|NCT06160648|OTHER|Management according to Mechanical Diagnosis and Therapy|MDT management is based on the patient response to repeated end range movements.
223654862|NCT06160648|OTHER|Management according to the Cervical Spine Clinical Practice Guidelines|CPG management is based on clinical research regarding management of people with neck pain.
223654863|NCT04510441|OTHER|Nil intervention|Nil intervention; retrospective cohort study
223654864|NCT03904693|DRUG|FDC macitentan/tadalafil|Film-coated tablet with 10 mg macitentan and 40 mg tadalafil, to be administered orally once daily.
223654865|NCT03904693|DRUG|Macitentan 10 mg|Film-coated tablet with 10 mg macitentan, to be administered orally once daily.
223654866|NCT03904693|DRUG|Tadalafil 40 mg|Film-coated tablet with 40 mg tadalafil (2 x 20 mg tablets), to be administered orally once daily.
223654867|NCT03904693|DRUG|Placebo FDC|Matching placebo not containing any active substance but otherwise identical in appearance to the respective active drug tablet, to be administered orally once daily.
223654868|NCT03904693|DRUG|Placebo macitentan|Matching placebo not containing any active substance but otherwise identical in appearance to the respective active drug tablet, to be administered orally once daily.
223654869|NCT03904693|DRUG|Placebo tadalafil|Matching placebo not containing any active substance but otherwise identical in appearance to the respective active drug tablet, to be administered orally once daily.
223654870|NCT02100696|DRUG|Etrozulimab|Participants will receive 105 mg etrolizumab administered by SC injection Q4W.
223654871|NCT02100696|DRUG|Placebo|Participants will receive placebo (matched with etrolizumab) administered by SC injection Q4W.
224238232|NCT01652001|DRUG|Malic Acid|Oral spray for application into the oral cavity
224238233|NCT01652001|OTHER|Placebo|Oral spray for application into the oral cavity
224238234|NCT01682083|DRUG|Dabrafenib|Each capsule contained 50 mg or 75 mg of free base (present as the mesylate salt)
224238235|NCT01682083|DRUG|Trametinib|Each tablet contained 0.5 mg or 2.0 mg of trametinib parent (present as the DMSO solvate)
223767934|NCT03370328|OTHER|Peppermint oil|The study product is a commercial essential oil product and nasal inhaler. It is to be prepared by a trained, independent individual who will add 4 drops of one of the three oils/oil combinations. The subject will be instructed to twist off the cap and position inhaler in such a way as to allow the subject to inhale the vapors; it can be reused for multiple administrations. Essential oils have been the subject of other studies in treating nausea. If nausea is unrelieved, treatment will progress to the ordered antiemetic.
224238236|NCT01682083|DRUG|Placebos|The placebo capsules and tablets contained the same inactive ingredients and film coatings as the dabrafenib and trametinib study treatment
224238237|NCT03928197|BEHAVIORAL|Tilt Test|Volunteers need to lay down for 15 minutes and afterwards stand up for 15 minutes
224238238|NCT03928197|DEVICE|Inbody S10|Bio-electrical impedance measurement every 5 minutes
224238239|NCT03928197|DEVICE|Tape measurements|Every 5 minutes, circumference of every leg is measured using a tape measure
224238240|NCT03928197|DEVICE|SOMNOtouchTMNIBP, Vivisol, Belgium|Continous measurement of blood pressure, heart rate and saturation
224238241|NCT06054152|DRUG|PD-1 inhibitor based immunotherapy|Patients received at least 4 cycles of PD-1 inhibitor-based immune monotherapy or chemoimmunotherapy. PD-1 drug selection should be limited in 4 types of PD-1 inhibitor approved by China FDA and launched in China and Opdivo or Keytruda.
224238242|NCT03701256|PROCEDURE|Bilateral ultrasound guided TAP bloc|In the TAP group: Bilateral ultrasound guided TAP bloc for laparoscopic gynecologic surgery
224238243|NCT03701256|DRUG|Neuromuscular blockade agent: Atracurium 01mg/kg per bolus|In the TRAC group: Neuromuscular blockade agent: Atracurium 01mg/kg per bolus for maintaining muscular relaxation and immobilization during laparoscopic gynecologic surgery
224238244|NCT05537051|DRUG|PM1021, PM8001|Participants will be administered with PM1021 on Part A Day 1. Participants will be administered with PM1021 and PM8001 on Part B Day 1. PM1021 and PM8001 combination therapy administrated every 3 weeks from Part C Day 1 until disease progression, intolerable toxicity, until the patient withdraws/is withdrawn, or study completion.
224238245|NCT06179056|DIAGNOSTIC_TEST|assess the possible role of Salicylic acid, Isotretinoin, and N-acetylcysteine in improving the susceptibility of C. acne for Azithromycin and Doxycycline.|"Microbiological samples were collected from all patients for:~1. Isolation of C. acnes~2. Antibiotic susceptibility testing for C. acnes isolates against the most commonly used antibiotics in the treatment of acne(Azithromycin and Doxycycline) in the presence and absence of Salicylic acid, Isotretinoin, and N-acetylcysteine~3. Testing biofilm forming ability of C. acnes isolates in the presence and absence of Salicylic acid, Isotretinoin, and N-acetylcysteine"
224238246|NCT04331665|DRUG|Ruxolitinib|Ruxolitinib is an inhibitor of JAK1 and JAK2 (proteins important in cell signalling) approved for the treatment of myelofibrosis, polycythemia vera, and graft-versus-host disease.
224238247|NCT04813705|RADIATION|Reduced dose|The patients with CMR and more than 70% PMR at 25th fraction will receive reduced-dose radiotherapy for 30 fractions.
223654872|NCT00078897|DRUG|Selenium|Participants will be randomized either to selenium or placebo, taking the randomized intervention for 3 to 5 years, depending on when their recommended follow up colonoscopy is scheduled.
223654873|NCT05867498|BEHAVIORAL|Concurrent exercise|Strength component (circuit-based exercise) and aerobic component (based on musicalized and outdoor activities).
223654874|NCT05867498|BEHAVIORAL|Aerobic exercise|Low-to-moderate-intensity continuous training and interval training based on musicalized and outdoor activities.
223654875|NCT03865381|DEVICE|Onduo App|The Onduo App is a software application which tracks data relevant to diabetes care, such as, but not limited to, medication, meal logs and glucose readings, and activity data. The Onduo App connects wirelessly to a Care Team Console through the Internet. The Onduo App may also connect wirelessly to commercially available FDA-regulated (i.e., cleared and approved) medical devices and non-medical devices through the subject's Smartphone.
223654876|NCT05343728|DIAGNOSTIC_TEST|Thromboelastography|Thromboelastography was done by using TEG 5000 Hemostasis Analyzer (Haemonetics Corp., USA)
223654877|NCT05343728|DIAGNOSTIC_TEST|Standard coagulation profile laboratory examination|Standard coagulation profile laboratory examination (platelets, PT/APTT, fibrinogen, and D-dimer) was performed by using Sysmex® CS-2500 and 5100 (Sysmex Corp., Japan)
223654878|NCT05626322|DRUG|Maplirpacept|Intravenous infusion
223654879|NCT05626322|DRUG|Tafasitamab|Intravenous infusion
223654880|NCT05626322|DRUG|Lenalidomide|Oral (by mouth)
223654881|NCT04713007|BEHAVIORAL|Quality of Life Ted Talks|There will be 9 training modules released weekly on the tablet. A survey will be required at baseline, each of the 9 weeks and at 3 months.
223654882|NCT04713007|BEHAVIORAL|Quality of Life Supportive Resources|The tablet will be preloaded with cancer information and supportive care resources from the National Cancer Institute. A survey will be required at baseline, each of the 9 weeks and at 3 months.
223654883|NCT03824145|BEHAVIORAL|Lifestyle Intervention|The lifestyle intervention is a 16-week cognitive-behavioral intervention that addresses key changes in diet and PA behaviors to promote positive body composition changes.
223654884|NCT03824145|BEHAVIORAL|Attention Control|"The attention control participants will receive a home/work organization intervention:~Following completion of the attention control home/work organization program and 16-week assessment, women will receive the lifestyle program."
223654885|NCT02606084|DRUG|Esketamine|Participants will self-administer esketamine solution intranasally 28 milligram (mg) on Day 1.
223654886|NCT05268497|DRUG|Esketamine|Esketamine will be self-administered as nasal spray.
223654887|NCT05268497|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|Clinician-directed CBT supplemented by the Mindset app will be administered.
223654888|NCT05268497|DRUG|Antidepressant|Antidepressant will be administered orally.
224238248|NCT04813705|RADIATION|Conventional dose|The patients who do not achieve CMR or 70% PMR at 25th fraction will receive conventional dose radiotherapy for 33 fractions.
224320922|NCT06730217|DEVICE|Intervention : mechanical insufflator|Participants randomized to the intervention group will benefit from a mechanical insufflator during airway clearance sessions (EOVE-70®, Air Liquide Medical Systems France).
223654891|NCT04565119|OTHER|No intervention. This is an observational study.|There are no interventions being tested in the Bio-BOOST study.
223654892|NCT00030914|DRUG|medroxyprogesterone|
223654893|NCT00030914|DRUG|venlafaxine|
223654894|NCT03854279|DEVICE|tonsillar dissection|The tonsils will be removed by bizact device
224238249|NCT04813705|DRUG|Chemotherapy|The patients with stage II will receive concurrent cisplatin during Intensity modulated radiotherapy (IMRT), and stage III-IVA patients will receive platinum based induction chemotherapy every 21 days for at least two cycles followed by concurrent cisplatin during IMRT.
224238250|NCT04283513|DRUG|Virazole|Virazole (Ribavirin), USP Injection 0.1 g/mL in a phosphate buffer solution. Each vial contains 1.2 g of Ribavirin in 12 mL
224238251|NCT04777396|DRUG|Semagludtide|Oral semaglutide once-daily, dose gradually increased to 14 mg. The study will last for up to 173 weeks
224238252|NCT04777396|DRUG|Placebo (semaglutide)|Oral placebo (semaglutide) once-daily, The study will last for up to 173 weeks
224238253|NCT01476085|RADIATION|ML10|\[18F\]ML10 radioligand apoptosis biomarker
223654895|NCT03937622|OTHER|17 items questionaire|This is a prospective multicenter observational trial. Included patients and attending physician complete a standardised questionnaire.
223654896|NCT05463484|DRUG|Test composition Saliactive® (olive product, betaine and xylitol)|Fluoridated toothpaste with Saliactive®.
223654897|NCT05463484|DRUG|Placebo|Fluoridated toothpaste without Saliactive®.
223654898|NCT05463484|DRUG|Control|Commercial Fluoridated toothpaste for gingivitis with zinc citrate.
223654899|NCT04338802|DRUG|Nintedanib 150 MG|Nintedanib cloth sulfonate 150 mg, twice a day, about 12 hours apart. Continuous medication for 8 weeks.
223654900|NCT04338802|OTHER|Placebo|Empty capsules with the same appearance and ingredients as Nidanib soft capsules: one capsule at a time, twice a day, with an interval of about 12 hours each time. Continuous medication for 8 weeks.
223654901|NCT03980704|DRUG|IMPACT|Administration of oral immunostimulating oral supplement
224238254|NCT03968796|OTHER|Transcutaneous Electrical Nerve Stimulation (TENS)|
224238255|NCT03968796|OTHER|Sham Transcutaneous Electrical Nerve Stimulation (TENS)|
224238256|NCT03968796|OTHER|Kinesio Taping|
224238257|NCT03968796|OTHER|Sham Kinesio Taping|
224238258|NCT00431600|OTHER|100% Oxygen|100% Oxygen- breathing over 30 minutes
224238259|NCT03653260|DRUG|Lidocaine (Zingo)|0.5 mg lidocaine, 20 bar pressure
224238260|NCT03653260|DRUG|Placebo|Placebo injector, 20 Bar pressure, empty injector
224238261|NCT01019603|DRUG|Tazarotene|Topical Tazarotene foam applied daily for 22 days.
224238262|NCT01019603|DRUG|Tazaroc Gel|Topical tazarotene gel applied daily for 22 days.
224238263|NCT06562413|DRUG|MAbs|Monthly or quarterly mAbs administration
224238264|NCT05053165|DRUG|LB-P6|Healthy subjects will be randomized to receive LB-P6 once daily orally
224238265|NCT05053165|DRUG|LB-P8|Healthy subjects will be randomized to receive LB-P8 once daily orally
224238266|NCT05053165|DRUG|Placebo|Healthy subjects will be randomized to receive placebo once daily orally
224238267|NCT04684901|OTHER|AlloWrap® Amniotic Membrane|AlloWrap is a human amniotic membrane designed to provide a biologic barrier following surgical repair.
224238268|NCT03433430|DEVICE|truSculpt|Subjects will receive utreatments and will be followed at 12 weeks post final treatment.
223654902|NCT03980704|DRUG|resource protein|Administration of oral high-protein oral supplement
223654903|NCT02610114|OTHER|Z-Score and computer algorithm|In addition to the routine Z-score for zygote selection, if needed, the photographs of the zygotes already taken for quality and safety reasons are analysed using the new computer algorithm. Within a few minutes it generates a score, determining the quality of the cells. The two best cells upon Z-score result and new computer algorithm result are selected for first transfer.
224238269|NCT00056134|BIOLOGICAL|Dendritic cell vaccine plus denileukin difitox|
224238270|NCT06495983|DEVICE|dynamic microdialysis sampling|Included patients will perform 24-hour dynamic microdialysis sampling from subcutaneous tissue fluid of the lower abdomen, applying the U-Rhythm sampler. Simutaneous measurements of blood pressure, glucose, and registration of activity level, meals and sleep pattern during microdialysis sampling may be performed. Microdialysis sampling will be performed during various conditions: during daily life activities, during saline infusion suppression testing and during dexamethasone suppression testing. Repeated sampling may be performed post treatment.
224238271|NCT00661596|DRUG|Levitra (Vardenafil, BAY38-9456)|5 mg, 10 mg and 20 mg one hour prior to sexual intercourse
224238272|NCT00661596|DRUG|Placebo|Matching placebo
224238273|NCT00242346|DRUG|candesartan cilexetil|
224238274|NCT03080090|BEHAVIORAL|Aerobic exercise|Individuals will work with a YMCA personal trainer to engage in aerobic exercise 3 times a week (25 mins each) for 15 weeks.
224238275|NCT03080090|BEHAVIORAL|Smoking Cessation Intervention|Individuals will work with a national quitline to help them with their smoking cessation goals and make a quit attempt at week 5 of the program.
224238276|NCT03249064|DIAGNOSTIC_TEST|CD 91 levels|
224238277|NCT03249064|DIAGNOSTIC_TEST|Tregs|
224238278|NCT03316729|DRUG|DS-9231|DS-9231 in saline solution for intravenous infusion
224238279|NCT03316729|DRUG|Placebo|Placebo is matching saline solution for intravenous infusion
224238280|NCT01625026|DRUG|Obeticholic acid|Obeticholic acid 25 mg/day in three weeks
224238281|NCT01625026|DRUG|Placebo|Placebo to obeticholic acid
224238282|NCT03629925|DRUG|Sintilimab|200mg, Q3W, day1, I.V.; consecutive cycles
224238283|NCT03629925|DRUG|Gemcitabine|1000mg/m\^2, Q3W, day 1and 8, I.V.; first 4 or 6 consecutive cycles.
224238284|NCT03629925|DRUG|Cisplatin|75 mg/m\^2, Q3W, day1, I.V.; first 4 or 6 consecutive cycles.
224238285|NCT03629925|DRUG|Placebo|NA, Q3W, day1, I.V.; consecutive cycles
224238286|NCT03629925|DRUG|Carboplatin|AUC 5mg/ml/min, Q3W, day1, I.V.; first 4 or 6 consecutive cycles.
224238287|NCT04251611|OTHER|Maintenance of physical exercise|Objectives will be established with the patient to increase the practice of physical exercise and reinforce the control of cardiovascular risk factors (CVRF) and the maintenance of a long-term cardio-healthy lifestyle.
224238288|NCT03378466|DRUG|Unfractionated heparin|UFH initiated at 18 IU/kg/hr, dosed according to total body weight and pragmatically adjusted according to local institutional policy to achieve an activated partial thromboplastin (aPTT) of 1.5 to 2.5 times that of the reference aPTT value or anti-Xa values targeted to local practice levels. Duration of study intervention will be a maximum of 5 days (120 hours) or until vasopressors have been discontinued for 24 continuous hours. All participants will then receive venous thromboprophylaxis according to local practice.
224238289|NCT03378466|OTHER|Venous thromboprophylaxis (VTE)|May include subcutaneous heparin or dalteparin, sequential compression device or graduated compression stockings
224238290|NCT04346706|DEVICE|Extraction and Implant insertion (test)|"The surgical procedure was conducted under local anesthesia. Intrasulcular incisions were performed around the mesial and distal tooth to the implant recipient site. Buccal and palatal mucoperiosteal flaps were elevated. Tooth extractions were carried out atraumatically using periotomes. Implant site preparation was completed in compliance with the general surgical principles and protocols defined by the manufacturer and screw-shaped implants (UFII, DIO™) were inserted at no less than 35 Ncm. Final insertion torque (IT) was measured and recorded using a manual hand wrench (DIO™). Resonance frequency analysis (RFA) was performed using an Osstell device (Sävedalen, Sweden). For each implant, three Implant Stability Quotient (ISQ) readings were recorded by the same operator to calculate the mean ISQ, at implant placement (T0) and 3 months after implant insertion (T3) prior to final abutment torque and crown cementation.~Absorbable interrupted 4.0 sutures were used for flap closure."
224238291|NCT04346706|DEVICE|Implant insertion (control)|"The surgical procedure was conducted under local anesthesia. Intrasulcular incisions were performed around the mesial and distal tooth to the implant recipient site. Buccal and palatal mucoperiosteal flaps were elevated, the implant site preparation was completed in compliance with the general surgical principles and protocols defined by the manufacturer and screw-shaped implants (UFII, DIO™) were inserted at no less than 35 Ncm. Final insertion torque (IT) was measured and recorded using a manual hand wrench (DIO™). Resonance frequency analysis (RFA) was performed using an Osstell device (Sävedalen, Sweden). For each implant, three Implant Stability Quotient (ISQ) readings were recorded by the same operator to calculate the mean ISQ. This was done at implant placement (T0) and 3 months after implant insertion (T3) prior to final abutment torque and crown cementation.~Absorbable interrupted 4.0 sutures were used for flap closure."
224238292|NCT04815902|DRUG|Fisetin|Oral Fisetin 20 mg/kg taken for 10 days total.
224238293|NCT04815902|DRUG|Losartan|12.5 mg oral Losartan taken for 30 days total.
224238294|NCT04815902|DRUG|Placebo - Losartan|Losartan appearance-matched microcrystalline cellulose placebo. 12.5 taken for 30 days total.
224238295|NCT04815902|DRUG|Placebo Fisetin|Fisetin appearance-matched microcrystalline cellulose placebo. 20 mg/kg taken for 10 days total.
224238296|NCT01074554|DRUG|Antibiotic Regimen|Levaquin 750 mg loading on day 1, then 500 mg po QD Ethambutol 15-25 mg/kg for a maximum of 1200mg QD Azithromycin 500mg on day 1, then 250 mg po QD Rifampin 5-10 mg/kg for a maximum of 300mg po QD All four drugs are given concomitanly
224238297|NCT01074554|DRUG|Placebo Regimen|lactose control tablets; one for each antibiotic with equivalent pills
224238298|NCT01715038|DIETARY_SUPPLEMENT|LNS-PLW|"Dietary supplement: Lipid-based nutrient supplement~Lipid-based nutrient supplement for pregnant and lactating women (LNS-PLW)~Daily dose of LNS-PLW will be 20 g, packaged in one sachet"
224238299|NCT01715038|DIETARY_SUPPLEMENT|LNS-Child|"Dietary supplement: Lipid-based nutrient supplement~Lipid-based nutrient supplement for infants and young children (LNS-Child)~Daily dose of LNS-Child will be 20 g, packaged in two 10 g sachets"
224238300|NCT01715038|DIETARY_SUPPLEMENT|MNP|"Dietary supplement: Micronutrient powder~Micronutrient powder for infants and young children (MNP)~The MNP for children will be packaged in 1 g sachets, so that each day, the child will consume one sachet."
224238301|NCT01715038|DIETARY_SUPPLEMENT|IFA|"Dietary supplement: Iron and folic acid nutrient supplement~Iron-folic acid tablets for pregnant and lactating women~Daily dose of iron-folic acid supplement will be one tablet containing 60 mg iron and 400 mcg folic acid"
224238302|NCT03056248|DRUG|Placebo oral capsule|On day 0, the day of the cardiac surgery placebo will be given once On day 1, one day after cardiac surgery placebo will be given once On day 2, two days after cardiac surgery placebo will be given once
224238303|NCT03056248|DRUG|Lithium Carbonate|On day 0, the day of the cardiac surgery oral lithium will be given at dose 900mg once On day 1, one day after cardiac surgery oral lithium will be given at dose 900mg once On day 2, two days after cardiac surgery oral lithium will be given 900mg once
223654904|NCT02610114|OTHER|Z-Score|After fertilisation pronuclei and nucleoli can be seen inside the cells by microscope. Routinely, the alignment of nucleoli can be used generating a score, the Z-score 1-4, established by Scott. Two zygotes getting the best Z-score are selected for cell culture and the cells that develop to embryo stage are used for first transfer.
223654905|NCT02196662|DRUG|IBD98-M:|single adiministration
224238304|NCT01997203|DRUG|Vitamin D|vitamin D was given to 50 patients (HCV under treatment)
224238305|NCT01976130|PROCEDURE|Bronchoscopy|
224238306|NCT01239121|OTHER|HIE-Enhanced Medication Reconciliation|Medication reconciliation enhanced by regional health information exchange, implemented by a pharmacist
224238307|NCT01239121|OTHER|Optimal Medication Reconciliation without HIE|Medication reconciliation implemented by a pharmacist without regional health information exchange
224238308|NCT02590861|PROCEDURE|Dental implant|All participants will receive the same intervention, this is a single group study.
224238309|NCT00430079|DRUG|etanidazole|Given IV
224238310|NCT00430079|PROCEDURE|conventional surgery|Undergo surgery
224238311|NCT00430079|OTHER|pharmacological study|Correlative studies
224238312|NCT00430079|OTHER|laboratory biomarker analysis|Correlative studies
224238313|NCT02283775|DRUG|Isatuximab SAR650984|Pharmaceutical form:solution for infusion Route of administration: intravenous
223654906|NCT02196662|DRUG|IBD98-M without HA|single adiministration
223654907|NCT02196662|DRUG|Delzicol|single adiministration
223654908|NCT05955781|PROCEDURE|Spinal Mobilization With Leg Movement|spinal mobilization with leg movement is the intervention given to experimental group. This technique involves applying pressure to the relevant spinous process while the patient moves their limb through the previously restricted range of motion. It is assumed that the restriction of movement is due to a spinal issue but it does not always indicate nerve damage as spinal movement is necessary for limb movement beyond a certain point. The goal is to address any spinal mechanical limitations and there may also be potential effects on the nerves.
224238314|NCT02283775|DRUG|Pomalidomide|Pharmaceutical form:capsules Route of administration: oral
223654909|NCT05955781|PROCEDURE|Spinal Mobilization|The patients will be given Spinal mobilization transverse glide(kaltenborn glide) on the effected spinous process. The total time duration will be 25-30 minutes.
223654910|NCT05955781|PROCEDURE|Conventional treatment|Participants will be given Hot pack for 15 minutes, TENS for 10 minutes
223654911|NCT02407600|DRUG|FOSAPREPITANT (Emend)|Uee of fosprepitant in EITHER first OR 2nd cycle of carboplatin containing combination chemotherapy in patients with advanced NSCLC
223767935|NCT03370328|OTHER|Ginger oil|The study product is a commercial essential oil product and nasal inhaler. It is to be prepared by a trained, independent individual who will add 4 drops of one of the three oils/oil combinations. The subject will be instructed to twist off the cap and position inhaler in such a way as to allow the subject to inhale the vapors; it can be reused for multiple administrations. Essential oils have been the subject of other studies in treating nausea. If nausea is unrelieved, treatment will progress to the ordered antiemetic.
224238315|NCT02283775|DRUG|Dexamethasone|Pharmaceutical form:tablets or solution for infusion Route of administration: oral or intravenous
224238316|NCT02396875|PROCEDURE|Blood sampling and exercise protocol pre and post CRT implant|
224238317|NCT02396875|PROCEDURE|Peripheral blood sampling|
224320923|NCT06730217|OTHER|Control : standard care|Participants randomized to the control group will receive standard care
224320924|NCT03573648|DRUG|Avelumab|Avelumab (10 mg/kg) will be given intravenously on cycles 2 - 4, every 2 weeks.
224320925|NCT03573648|DRUG|Endocrine therapy|"The endocrine therapy given will depend on menopausal status.~Premenopausal women will receive tamoxifen AND either Goserelin or Leuprolide:~* Tamoxifen (20mg) will be given orally daily x 4 cycles. (Other Names: Nolvadex)~* Goserelin (3.6mg) will be given subcutaneously (under the skin) on Day 1 of each cycle x 4 cycles. (Other Names: Zoladex)~* Leuprolide (3.75mg) will be given intramuscularly (in the buttock, thigh, or upper arm) on Day 1 of each cycle x 4 cycles. (Other Names: Leuprorelin, Lupron, Eligard)~Postmenopausal women will receive letrozole:~\- Letrozole (2.5mg) will be given orally daily each cycle x 4 cycles. (Other Names: Femara)"
224238318|NCT02396875|PROCEDURE|Central blood sampling pre and post CRT implant|
224238319|NCT02396875|PROCEDURE|Central blood sampling on one occasion and exercise protocol and 6 month peripheral sampling|
224238320|NCT06090149|DEVICE|PHASE 1 Lowenstein medical BiLevel Prisma 25ST device: withount oxygen support.|"The patient will be invited to enter the study's first phase using the Lowenstein medical BiLevel Prisma 25ST device without additional oxygen support. The study will be conducted within 1-3 days. If patients fail to achieve proper blood oxygen saturation without oxygen supplementation, patient will be selected to proceed to the next step - oxygen-enriched positive airway pressure intervention~During monitoring TA, RR, HR, SpO2, as well as CO2 in both exhales/inhales and transcutaneous positions will be measured by Lowenstein Medical Sonata and Sentec device."
224238321|NCT06090149|DEVICE|PHASE 2. Continous/Bilevel positive airway presure with additional oxygen support by Devilbiss 525 KS oxygen concentrator|"The patient will be invited to enter the third phase of the study with rapid oxygen titration. Titration occurs in an inpatient department where the patient is connected to the Lowenstein medical BiLevel Prisma 25ST device with oxygen support during the daytime. As part of the study, the patient will be supplied with oxygen by Devilbiss 525 KS oxygen concentrator at a dosing interval of 1-10 L/min. Every 2 hours oxygen support will be increased by 2L/min.~During monitoring TA, RR, HR, SpO2, and CO2 in both exhales/inhales and transcutaneous positions will be measured by Lowenstein Medical Sonata and Sentec device."
224238322|NCT01282047|DRUG|Lenalidomide|oral course, 25 mg, day 1 to 21, per month, 7 days of wash-out each month. Duration according to initial response: 24 weeks and 12 weeks more if complete remission, 24 weeks more if partial remission or stable disease and stop in case of progression.
224238323|NCT04614961|OTHER|Lifestyle therapy - individual|Individual therapy
224238324|NCT04614961|OTHER|Lifestyle therapy - group|Group therapy
224238325|NCT04614961|OTHER|Medical therapy|Medical therapy
224238326|NCT04614961|PROCEDURE|Bariatric surgery|Surgical and endoscopic therapy
224238327|NCT02645526|OTHER|Woolen cap|
224238328|NCT04276883|DRUG|Sublingual film containing Dexmedetomidine (BXCL501)|Sublingual film containing Dexmedetomidine (BXCL501)
224238329|NCT04276883|DRUG|Placebo Film|Placebo Film for BXCL501
224238330|NCT02918994|BEHAVIORAL|LearningRx cognitive training|A clinician will deliver three 90-minute cognitive training sessions per week for 14 weeks. There are 16 different categories of leveled training procedures sequenced in intensity and difficulty for a total of 530 training tasks.
224238331|NCT04038060|BEHAVIORAL|WhatsApp Group|Participants will receive peer adherence support through WhatsApp groups
224238332|NCT04038060|BEHAVIORAL|2-way SMS|Participants will receive healthcare worker adherence support through 2-way SMS
224238333|NCT04038060|BEHAVIORAL|Drug level feedback|Participants will receive adherence counseling based on tenofovir drug levels
224238334|NCT04038060|BEHAVIORAL|Monthly counseling sessions|Participants will receive monthly counseling on a variety of issues that may be impacting their PrEP adherence
224238335|NCT02366780|PROCEDURE|Pump|Breast milk expression using manually or using an electric pump
224238336|NCT02556944|DEVICE|Phacoemulsification with multifocal intraocular lens|Phacoemulsification and implantation of a multifocal intraocular lens (IOL) with two different add power (+2.75 diopters (D) or +3.25 D, respectively) in each eye of a patient, contralaterally. They're called mix and matched patients.
224320926|NCT03573648|DRUG|Palbociclib|Palbociclib (125 mg) will be given orally on days 1-21 of each cycle x 4 cycles.
223654912|NCT02407600|DRUG|Placebo|
223654913|NCT05821881|OTHER|Discontinuation of levothyroxine treatment|Step-wise reduction of levothyroxine treatment guided by thyroid function and symptoms
223654914|NCT04041167|DRUG|alpha lipoic acid|alpha lipoic acid treatment
223654915|NCT04041167|DRUG|Saline|No alpha lipoic acid treatment
223654916|NCT02037230|DRUG|MK-1775|MK-1775 will be given as an oral capsule on days 1 and 2, and on days 8 and 9 of every 3-week cycle .
223654917|NCT02037230|DRUG|Gemcitabine|Gemcitabine 1000mg/m2 will be infused over 30 minutes on days 1 and 8 of a 3 -week treatment cycle.
224320927|NCT06531434|COMBINATION_PRODUCT|"Docetaxel, Cisplatin, fluorouracil, Radiation"|Induction chemotherapy with Docetaxel, Cisplatin, and fluorouracil for 4 to 8 cycles, followed by concurrent chemoradiotherapy with Cisplatin and Radiation 30.6-40 Gy.
224320928|NCT03374267|OTHER|Routine care as per site standard.|Physician's choice according to patient's needs.
224320929|NCT06432036|PROCEDURE|Angiogram|Undergo angiogram
224320930|NCT06432036|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
224238337|NCT05251025|OTHER|Passive sustained stretching|"The Group A received Passive Stretching Technique. Along with the Passive Stretching Technique, this group also received certain conventional treatments which included resistive exercises, gait training exercises, bridging and exercises in other functional positions were also undertaken by the included individuals.~All the exercises mentioned above were performed for 30 minutes and there was not any specific division of time for all these mentioned activities. The patients used to perform these conventional treatments and exercises on their motor control basis. The exercises were performed for 30 minutes and been done for 5 days in a week for consecutive 6 weeks."
224238338|NCT05251025|OTHER|Myofascial Release|The Group B received Myofascial Release Technique and along with conventional treatments. The Myofascial Release Technique for hamstrings was given to the patient in prone position. The technique was applied either by the crossed hands or thumbs. This total treatment was given for 30 minutes consecutively. After the technique the Myofascial structures were stretched and then were hold for straight 120 seconds so that the tissues get softened. The technique was given to patients with 6 repetitions and with a hold for 120 seconds. The treatment was continued for 5 days a week for straight 6 weeks.
224238339|NCT05999669|OTHER|GLASS staging|use the Global Limb Anatomic Staging System (GLASS) to evaluate its correlation with clinical outcomes after revascularization
224238340|NCT06176287|PROCEDURE|Dental Implantation with high torque|Fifteen patients with bilateral single-tooth loss in the posterior mandible will be included in the study. One implant was randomly placed with high insertion torque in each patient. A total of 15 implants will be placed, and insertion torque values will be recorded.
224238341|NCT06176287|PROCEDURE|Dental Implantation with low torque|Fifteen patients with bilateral single-tooth loss in the posterior mandible will be included in the study. One implant was randomly placed with low insertion torque in each patient. A total of 15 implants will be placed, and insertion torque values will be recorded.
224238342|NCT01876706|DEVICE|UroLift® System|The NeoTract UroLift System is a medical device approved for sale in the European Union, Australia, and Canada. The UroLift® System is indicated for the treatment of symptoms due to urinary outflow obstruction secondary to benign prostatic hyperplasia (BPH) in men 50 years of age or older. During the procedure, an implant is delivered into the prostatic lobe obstructing the urethra and restricting urine flow. The distal end of the device is used to compress the lobe then the implant is delivered to retain the lobe in position, thereby increasing the urethral opening and reducing the fluid obstruction through the prostatic urethra.
224238343|NCT05498805|RADIATION|Radiation|According to the lesion sites, SBRT or hyperfractionated radiotherapy was used.
224238344|NCT01345045|DRUG|ABT-639|ABT-639 Twice Daily for six weeks.
224238345|NCT01345045|DRUG|pregabalin|pregabalin starting dose twice daily for 1 week then titrated to maintenance dose twice daily for the remainder of the study.
224238346|NCT01345045|DRUG|Placebo|Placebo twice daily for 6 weeks.
224238347|NCT00620048|BIOLOGICAL|Intramyocardial injection of autologous CD34-positive cells (stem cells)|Comparison between a low dose and high dose of autologous (one's own) CD34-positive cells (stem cells) delivered via injections into the heart muscle.
224238348|NCT04353791|DRUG|OST-122|Active dose
224238349|NCT04353791|DRUG|Placebo|Placebo
224320931|NCT06432036|PROCEDURE|Computed Tomography|Undergo CT scan
224320932|NCT06432036|RADIATION|Radioembolization|Undergo radioembolization
223654918|NCT02037230|RADIATION|Radiation Therapy|52.5Gy in 25 fractions (2.1Gy/fraction), using intensity modulated radiation therapy (IMRT). Radiation therapy will be administered after chemotherapy.
223654919|NCT04995952|BEHAVIORAL|Gross motor training|Gross motor training activity (1 hour session, 3 times a week for 3 months). Pre ad post assessments will be taken. The Gross motor training activity will include: sit to stand, step-ups and walking. The sit to stand will be performed for 20 minutes involving 20 repetitions. We will progress from high seat sit to stand to low seat sit to stand. The step up will progress initially from a bench having low height to high height and then to stepping of stairs for 20 minutes involving 30 repetitions. The walking will occur from 3m walk and then increasing the distance
223680981|NCT04896450|DEVICE|Orthodontic tooth movement (OTM)|An early initialization of the tooth movement with the help of a multibond fixed orthodontic device utilizing low level of continuous orthodontic forces.
223680982|NCT02475824|DRUG|Midazolam®|midazolam (0.05 mg/kg, 30% reduction for patients if age ≥70 or ASA class III-IV; Bukwang Pharm Co., Seoul, Republic of Korea)
223680983|NCT02475824|DRUG|"Meperidine (pethidine®)"|Meperidine (50mg. 25mg for patients aged ≥70 years; pethidine HCL, Hana Pharm Co., Seoul, Republic of Korea).
223680984|NCT02475824|DRUG|Propofol®|Repeated doses of 10-20 mg propofol are titrated to achieve the target level of sedation.
223680985|NCT02475824|DRUG|Dexmedetomidine (Precedex®)|Dexmedetomidine (1μg/kg/h, Precedex; Hospira, Seoul, Republic of Korea) or the same volume of normal saline were administered in the MMD and midazolam-meperidine group
223680986|NCT00934648|DRUG|rituximab [MabThera/Rituxan]|1000mg iv on days 1 and 15
223680987|NCT00934648|DRUG|methotrexate|10-25mg weekly
223680988|NCT02689102|DEVICE|Probe based optical techniques|During the diagnostic bronchoscopy, optical biopsy of the mucosa and alveolar compartment will be conducted by two different probe based optical techniques (Confocal Laser Endomicroscopy (Mauna Kea technologies) and Optical Coherence Tomography (St Jude Medical)). After the study measurements a biopsy will be obtained in the same area.
223680989|NCT01482390|DRUG|Ribavirin|Participants will receive a total daily dose of 1000 milligrams (mg) (for participants weighing less than \[\<\] 75 kg) or 1200 mg (for participants weighing greater than or equal to \[\>=\] 75 kg) orally for 24 or 48 weeks.
223680990|NCT01482390|DRUG|Mericitabine|Participants will receive mericitabine 1000 mg orally twice daily.
223680991|NCT01482390|DRUG|Peginterferon Alfa-2a|Participants will receive 180 micrograms (mcg) subcutaneous injection once weekly.
223680992|NCT01482390|DRUG|Placebo|Participants will receive placebo matching to mericitabine orally twice daily.
223680993|NCT01482390|DRUG|Telaprevir|Participants will receive telaprevir 750 mg orally three times daily.
223680994|NCT03131401|DIAGNOSTIC_TEST|Diagnosis of lymphatic filariasis|Field validation of the diagnostic performance of diagnostic tests for infection with W. bancrofti.
223680995|NCT03131401|DIAGNOSTIC_TEST|Diagnosis of lymphatic Filariasis and onchocerciasis|Field validation of the diagnostic performance of diagnostic tests for infection with both W. bancrofti and O. volvulus.
223654920|NCT04995952|BEHAVIORAL|Trunk targeted training|"Trunk targeted training (1hour session, 3 times a week for 3 months). Pre and Post assessment will be evaluated. The trunk targeted training will include: weight supported treadmill walk, specific trunk exercises with vibration therapy and reaching forward to the limits of stability.~Specific trunk exercises will involve stride sitting to standing, sitting on a roll and moving the roll in diagonal and forward backward directions along with giving vibrational therapy on wobble board, side sitting. This activity will be performed for 30 minutes with 30 repetitions. Reaching forward to the limits of stability exercises will be performed. Asking the children to hold objects from right hand while reaching for an object on left side and vice versa. This will be performed for 20 minutes having 20 repetitions."
223654921|NCT00545636|OTHER|education|The intervention is an education of the medical teams that instruct children to fast before the administration of general anesthesia
223654922|NCT03771313|DRUG|Ceftaroline|Patients will have intravenous ceftaroline dosed according to current recommendations based upon its approved usage in pediatric patients for community acquired pneumonia. Blood samples will be collected for PK/PD analysis.
223767936|NCT00436280|DRUG|enzastaurin|1125 mg loading dose then 500 mg, oral, daily, until disease progression or 3 years
223767937|NCT00436280|DRUG|gemcitabine|1000 mg/m², IV, once, every two weeks, four to eight 2 week cycles
223767938|NCT00436280|DRUG|rituximab|375 mg/m², IV, once every 2 weeks, four to eight 2 week cycles
223767939|NCT00436280|DRUG|oxaliplatin|100 mg/m², IV, once every two weeks, four to eight 2 week cycles
223767940|NCT04412941|BEHAVIORAL|Myofunctional exercises|"Myofunctional exercises: Respiratory rehabilitation exercises with diaphragmatic breathing, thoracic mobilization exercises and manual pompage techniques, followed by manual trigger point therapy techniques, that were identified by palpation following the guidelines provided by Travell and Simons trigger point manual, the accessory inspiratory muscles like pectoralis minor muscle, scapula elevator muscle, Sternocleidomastoid muscle.~Home oropharyngeal exercises: at every patient will be taught oropharyngeal exercises to perform at home twice a day (the duration of 15 minutes each session) involving in particular exercises for soft palate, tongue, facial and genio-glosso muscle.~The rules of sleep hygiene: a list of behaviours that physiologically promote a good night's sleep."
223767941|NCT04412941|BEHAVIORAL|The rules of sleep hygiene|The rules of sleep hygiene: a list of behaviours that physiologically promote a good night's sleep.
223767942|NCT04904510|DIAGNOSTIC_TEST|INDICAID™ COVID-19 Rapid Antigen Test|The diagnostic assay will be compared to a EUA SARS-CoV-2 assay
223767943|NCT03752723|DRUG|GX-I7|i.m.
223767944|NCT03752723|DRUG|Pembrolizumab(KEYTRUDA®)|i.v.
223767945|NCT03752723|DRUG|Cyclophosphamide|i.v.
223767946|NCT04875104|DEVICE|Orthodontic treatment with Invisalign system|Patients are going to receive an orthodontic treatment with Invisalign aligners.
223767947|NCT04875104|DEVICE|Orthodontic treatment with Spark system|Patients are going to receive an orthodontic treatment with Spark aligners.
223767948|NCT04875104|DEVICE|Orthodontic treatment with Quicksmile system|Patients are going to receive an orthodontic treatment with Quicksmile aligners.
223767949|NCT04875104|DEVICE|Orthodontic treatment with ClearCorrect system|Patients are going to receive an orthodontic treatment with ClearCorrect aligners.
223767950|NCT02175069|PROCEDURE|Interscalene Nerve Block|ultrasound guided interscalene plexus block (UISB) immediately before magnetic resonance imaging of the neck.
223767951|NCT02175069|DRUG|Ropivacaine 0.75%, 20ml|20 ml of ropivacaine 0.75%
223767952|NCT02175069|DRUG|Gadopentetate-Dimeglumine 0.0125 mmol|0.0125 mmol of gadopentetate-dimeglumine
223767953|NCT02175069|DRUG|Gadopentetate-Dimeglumine 0.05 mmol|0.05 mmol of gadopentetate-dimeglumine
223767954|NCT02175069|DRUG|Ropivacaine 0.75%, 5ml|5 ml of ropivacaine 0.75%
223767955|NCT02175069|PROCEDURE|Shoulder Surgery|As per individual requirement (patient-dependent)
223767956|NCT03815162|DIETARY_SUPPLEMENT|High Flavanol Cocoa extract|Experimental group
223767957|NCT03815162|DIETARY_SUPPLEMENT|Alkalised cocoa|Control group
223767958|NCT01403090|DEVICE|Angel Catheter|The Angel Catheter will be inserted in the femoral vein following standard central line placement techniques. Once the catheter is on the Inferior Vena Cava, the filter will be deployed following the manufacturer instructions and secured to the skin.
223767959|NCT01663259|DRUG|Cetuximab|Before Radiotherapy patients you will receive a single loading dose of cetuximab. Patients will also have two additional biopsies before and after cetuximab to determine how the tumor is affected. A Cetuximab infusion will also be delivered once a week during radiotherapy.Radiation will be started (70 Gy in 35 fractions over 7 weeks to the gross tumor, 50-60 Gy to subclinical target volumes) five days a week until the total dose of radiation prescribed by the doctor is reached. Radiation will be delivered concurrent with weekly cetuximab 250 mg/m2, delivered on Monday or Tuesday each week. In order to evaluate swallowing problems from radiotherapy, patients will undergo an evaluation of swallowing by videofluoroscopy (VF). Quality of Life questionnaires will be given before therapy and periodically up to 36 months after therapy. In order to assess if the tumor was completely eradicated, CT-PET scan will be performed 3 months after the completion of therapy.
223767960|NCT01663259|RADIATION|Radiotherapy|Radiation will be started (70 Gy in 35 fractions over 7 weeks to the gross tumor, 50-60 Gy to subclinical target volumes) five days a week until the total dose of radiation prescribed by the doctor is reached. Radiation will be delivered concurrent with weekly cetuximab 250 mg/m2, delivered on Monday or Tuesday each week.
223767961|NCT01049919|DEVICE|Bone marrow concentration device|Concentration of autologous bone marrow aspirate for intramuscular delivery to affected limb
223767962|NCT01049919|PROCEDURE|Placebo procedure (sham)|Sham bone marrow aspiration, sham delivery to affected limb
223654923|NCT04650529|DEVICE|stent, ballooning|DES, BMS, BRS, DEB, and POBA can be used for PCI
223654924|NCT01339572|DRUG|Plerixafor|"240 mcg/kg/day based on ideal body weight will be given for the following conditions:~1. Pre-apheresis peripheral blood CD34+ count \<20 cells/μL on day 5.~2. Estimated CD34+ cell collection is \< 25% of target cell dose after 1 day of apheresis.~3. Estimated CD34+ cell collection is \< 50% of target cell dose after 2 days of apheresis."
223654925|NCT01339572|DRUG|Filgrastim|"All patients will receive filgrastim starting 4 days prior to apheresis (D1-4 mobilization). The dose and schedule of filgrastim will based upon the risk category of the patient:~* Standard risk: 5 μg/kg SQ BID.~* High risk: 10 μg/kg SQ BID."
224320933|NCT06432036|PROCEDURE|Single Photon Emission Computed Tomography|Undergo SPECT
223654926|NCT01210404|DRUG|filibuvir|Filibuvir, 600mg bid administered along with methadone on days 2-11
223654927|NCT00946283|DIETARY_SUPPLEMENT|Lactobacillus rhamnosus GG|Culturelle DS (Lactobacillus GG) will be administered one capsule (10 billion live lactobacillus GG) daily with water
223654928|NCT05079243|BIOLOGICAL|Scaffold and adipose-derived stromal cell enriched fat grafts|eight different solutions of fat, ASCs, scaffold and CO2 laser in dermis three different solutions of fat, ASCs and scaffold in the subcutaneous layer
223654929|NCT00063843|BIOLOGICAL|Recombinant Protective Antigen, Anthrax Vaccine Adsorbed|
224238350|NCT04370665|DEVICE|Exablate BBBD with Cerezyme|"Blood Brain Barrier Disruption via Exablate to deliver Cerezyme.~Other Names:~Exablate Neuro"
224238351|NCT01864330|DEVICE|Thealoz Duo®|Eye Drops
223654930|NCT02877771|DEVICE|t:slim insulin pump with predictive low glucose suspend|To assess the functionality of a predictive low glucose suspend (PLGS) system that uses Continuous Glucose Monitoring (CGM) values to suspend basal insulin delivery when hypoglycemia is predicted as well as resume basal insulin delivery once Continuous Glucose Monitoring (CGM) values begin to increase.
223654931|NCT04588467|OTHER|Medical treatment|Pregnant women complaining thrombosed haemorrhoids will receive dietary modification (intake of at lest 3 liers of water), stool-softeners (a 25 ml solution containing: Macrogol 3350: 13.125 g Sodium chloride: 0.3508 g Sodium hydrogen carbonate: 0.1786 g Potassium chloride: 0.0502 g) and local anesthetics application
224238352|NCT01864330|DEVICE|Hyabak®|Eye Drops
223654932|NCT04588467|PROCEDURE|Surgical treatment|Pregnant women complaining thrombosed haemorrhoids will receive local excision or thrombectomy under local anesthesia
223654933|NCT04422483|OTHER|Realist evaluation|In-depth exploration of individual service models will be carried out to determine the interrelationship of context, intervention, mechanisms and outcomes as they occur in their natural setting. Data will be gathered within case studies using mixed methods at two levels: (i) service model and (ii) individual child/ family. Methods will include semi structured realist Interviews, focus groups, and document reviews to assemble a comprehensive description of the service and model. Interviewees will include commissioners, service managers, clinicians, referrers, parents and young people. Interviews will be recorded and transcribed, proceeding to qualitative analysis based on components of the programme theory. Regular team meetings will discuss coding, address inconsistencies, and refine collective understanding of coding framework. Coded data will be collated using NVivo software.
223654934|NCT05109195|OTHER|Standard of Care (SOC)|Participants will not receive any intervention as a part of this study. Participants will receive SOC treatment.
223654935|NCT04628325|DRUG|Furosemide|Intravenous Furosemide Plus Small Hypertonic Saline Solutions (HSS)
223680996|NCT03131401|DIAGNOSTIC_TEST|DEC Patch|Field validation of the diagnostic performance of diagnostic tests for infection with O. volvulus.
223680997|NCT00000481|BEHAVIORAL|diet, fat-restricted|
223680998|NCT05265780|PROCEDURE|kinesiotape|an elastic adhesive tape
223680999|NCT05265780|PROCEDURE|sham taping|a sham taping without the tension
223681000|NCT00479583|DRUG|BMS-690514 / FOLFIRI|Tablets / IV, Oral / IV, up to 200 mg / irinotecan 180mg/m2, leucovorin 400 mg/m2, 5FU 400mg/m2 bolus, 2400 mg/m2 inf, once daily / q 2 weeks, up to 24 mos
224238353|NCT01864330|DEVICE|Hydrabak®|Eye Drops
224238354|NCT06311942|DRUG|HAIC plus PD-1 inhibitors plus lenvatinib|Patients in the triple adjuvant therapy group received one cycle of HAIC about a month after liver resection, HAIC was adopted the FOFOLX6 program (Folinic acid+5-fluorouracil+Oxaliplatin). The first cycle of PD-1 monoclonal antibody was administrated 2-4 weeks postoperatively, 200 mg IV, every 21 days for a total of 9 cycles. Lenvatinib was initiated orally 2-4 weeks postoperatively for 6 months.
224238355|NCT06311942|DRUG|PD-1 inhibitors plus lenvatinib|The first cycle of PD-1 monoclonal antibody was administrated 2-4 weeks postoperatively, 200 mg IV, every 21 days for a total of 9 cycles. Lenvatinib was initiated orally 2-4 weeks postoperatively for 6 months.
224238356|NCT02884232|PROCEDURE|Nasofibroscopy|
224238357|NCT01825993|DRUG|L-BUPIVACAINE ; MORPHINE|
224238358|NCT01825993|DRUG|MORPHINE|
224238359|NCT04590378|OTHER|intensive care unit admission ratio|intensive care unit admission ratio
224238360|NCT05527678|OTHER|Questionnaires|Written or by phone
224238361|NCT05395247|OTHER|Geriatric assessment|Geriatric assessment by a trained nurse and a geriatrician for older kidney transplantation candidates in Caen University Hospital. The geriatric assessment includes a evaluation of cognitive functions, depressive symptoms, risk of fall, nutrition, frailty, and functional status.
224238362|NCT04326998|PROCEDURE|solvent|using solvent (GuttaClear) in procedure
224238363|NCT04326998|PROCEDURE|non-solvent|non-solvent
224238364|NCT02962297|DRUG|Vitamin E softgel|All participants receive standardized recommendations for life-style modification (Diet modification, weight loss, exercise).
224238365|NCT02962297|DRUG|Placebo|"All participants receive standardized recommendations for life-style modification (Diet modification, weight loss, exercise).~Height and weight, waist-to-hip ratio Review of diet and exercise"
224238366|NCT02339233|DEVICE|Standing and Stepping with spinal cord Epidural Stimulation|Standing and Stepping with support from trainers as needed, overground or in a harness with body weight support on a treadmill. Epidural stimulation with specific configurations will be administered to generate standing and stepping.
224238367|NCT06354504|PROCEDURE|Non-surgical periodontal treatment|Scaling and root planing in two sessions over the course of a 48-hour period comprised the standard treatment procedure
224238368|NCT00006734|BIOLOGICAL|filgrastim|Given IV
224238369|NCT00006734|DRUG|cyclophosphamide|Given IV
224238370|NCT00006734|DRUG|doxorubicin hydrochloride|Given IV
224238371|NCT00006734|DRUG|etoposide|Given IV
224238372|NCT00006734|DRUG|ifosfamide|Given IV
224238373|NCT00006734|DRUG|vincristine sulfate|Given IV
224238374|NCT00006734|PROCEDURE|adjuvant therapy|
224238375|NCT00006734|PROCEDURE|conventional surgery|
224238376|NCT00006734|PROCEDURE|neoadjuvant therapy|
224238377|NCT00006734|RADIATION|brachytherapy|
224238378|NCT00006734|RADIATION|radiation therapy|
224320934|NCT06432036|OTHER|Survey Administration|Ancillary study
224320935|NCT06432036|RADIATION|Yttrium Y 90 Glass Microspheres|Given intra-arterially
223654936|NCT06380413|OTHER|Tai Chi Chuan Plus Walking|Participants perform a 12-week program with two weekly sessions on non-consecutive days. The sessions last 75 min (5 min of warm-up, 45 min of Tai Chi Chuan (TCC), 20 min of walking, and 5 min of cool-down). The intervention occurs at the School of Physical Education, Federal University of Pelotas. The TCC section occurs in a mirrored dance studio, while walking occurs on an indoor sports court. The TCC sections are based on the simplified Yang 16-movement form. Over the 12 weeks, participants learn the fundamentals and basic principles of TCC and practice the 16 movements. In the walking sections, the intensity of the effort and recovery periods are controlled through the Rate of Perceived Exertion (RPE) using the Borg scale 6-20. Effort and recovery periods are on 13 and 11 RPE, respectively. The effort and recovery lengths vary over the weeks. The training sessions are collective, with 5 to 20 participants, supervised by two experienced instructors, a TCC and a fitness instructor.
223654937|NCT06380413|OTHER|Walking|Participants perform a 12-week training program with two weekly exercise sessions on non-consecutive days. The sessions last 30 minutes (5 minutes of warm-up, 20 minutes of walking, and 5 minutes of cool-down) throughout the intervention period. The intervention occurs in an indoor sports court at the School of Physical Education, Federal University of Pelotas. In the walking sections, the intensity of the effort and recovery periods are controlled through the Rate of Perceived Exertion (RPE) using the Borg scale 6-20. Effort and recovery periods are on 13 and 11 RPE, respectively. The effort and recovery lengths vary over the weeks. The training sessions are collective, with 5 to 20 participants, supervised by two experienced instructors, a TCC and a fitness instructor.
223654938|NCT00666016|DRUG|TRO19622|TRO19622 500 mg once a day before noon meal during 6 weeks
223654939|NCT03174730|BEHAVIORAL|Growth Mindset|The intervention is aimed at creating more flexible thinking about addiction to tobacco. Participants will be sent tips by email to help foster the belief that people can overcome addiction to smoking.
223654940|NCT03174730|BEHAVIORAL|SmartQuit|This is an Acceptance and Commitment Therapy based intervention designed a smoking cessation smartphone application.
223767963|NCT00754247|DRUG|0.5% hydrocortisone, silicone, vitamin E lotion|0.5% hydrocortisone, silicone, vitamin E lotion will be applied topically to cover the selected scar twice daily for 16 weeks. The lesion will be cleansed with soap and water and dried thoroughly. The medication will be applied with a brush and allow it to dry for one minute before contact with clothing.
223767964|NCT00754247|DRUG|Onion extract gel|Onion extract gel is applied and massaged into the selected scar 3 to 4 times daily according to product instructions for 16 weeks.
223767965|NCT00754247|DRUG|Cetearyl alcohol lotion|Placebo is cetearyl alcohol lotion with no steroids, silicone, vitamin E, or onion extract and will be applied 2 times a day to the lesion.
223767966|NCT04425499|OTHER|Learning running subcuticular sutures on the Gamified Educational Network|Each arm will have 15 participants who will learn how to perform running subcuticular sutures through videos on GEN.
223767967|NCT00718172|PROCEDURE|Liver Biopsy|
223767968|NCT00718172|DRUG|Peginterferon &amp; Ribavirin for Hepatitis C|
223767969|NCT00718172|DRUG|Pre-treatment Ribavirin|
223767970|NCT01751464|BEHAVIORAL|WrapAround Case Management|Youth Injured by Violence will be paired with a support worker who has extensive experience working with youth affected by violence.It is important to note that the wraparound concept involves individualized care planning and management. As such, the specific care plan will be different for each participant. Through early intensive meetings, they will develop a mentoring relationship. They will work with the youth to develop a support team, which may include family, teachers, child welfare workers and truly anyone the youth has decided can help them in their path to making positive choices.
223767971|NCT01540227|DRUG|Regular Treatment for Syphilis|"Drug: Benzathine Penicillin G (Bicillin)~Dose: 2.4 million units~Mode of Administration: intramuscular injection~Duration of Treatment: one dose~Health Canada approved indication: Yes"
224238379|NCT04745546|DEVICE|WeFlow-JAAA Stent Graft System|The abdominal aorta stent graft system consists of the abdominal aorta embedded stent system, the abdominal aorta bifurcation stent system and the extended stent system. The abdominal aorta embedded stent has two embedded branch stents and two fenestrations. It can be combined with a peripheral small stent system of appropriate specifications to reconstruct the superior mesenteric artery, bilateral renal arteries and keep the abdominal trunk unobstructed. At the same time, the combination of the abdominal aorta embedded stent, the abdominal aorta bifurcation stent and the extended stent can solve the proximal renal and transrenal abdominal aortic aneurysm lesions with the upper edge of the abdominal aortic aneurysm body and the lower edge of the superior mesenteric artery opening ≥ 5 mm.
224238380|NCT02601495|BEHAVIORAL|Women in a court diversion program|Women in Recovery (WIR) is an intensive outpatient alternative for eligible women facing long prison sentences for non-violent, drug-related offenses in Oklahoma.
224238381|NCT00239421|DRUG|Test: Tiotropium 18 µg per day (one inhalation capsule) plus 12 µg formoterol twice daily (two times one inhalation capsule)|
224238382|NCT00239421|DRUG|Reference: Salmeterol MDI 50 µg (2 puffs of 25 µg each) b.i.d., plus fluticasone propionate MDI 500 µg (2 puffs of 250 µg each) b.i.d.|
224238383|NCT00803803|DRUG|Pilocarpine Concentration|Varying concentration 0.5 to 8%
224238384|NCT00803803|DRUG|Pilocarpine Frequency|1 to 4 times daily
224238385|NCT06006364|OTHER|Survey|"The scales and forms used are respectively:~1. Demographic Information Form~2. Nomophobia Scale~3. Cornell Musculoskeletal Disorder Questionnaire~4. Smart phone Addiction Scale~5. Pittsburgh Sleep Quality Index~6. International Physical Activity Survey~7. McGill Melzack Pain Questionnaire"
224238386|NCT02120443|DEVICE|ivWatch Model 400|The ivWatch Model 400 monitored tissue at common IV sites over a 24 hour period.
224238387|NCT00188864|DRUG|dexamethasone|
224238388|NCT03202576|DEVICE|Nasal Bridle|Nasal bridle placement and securement of the tube. Instead of taping the tube to the patient's face, nose or upper lip the bridle is a device whereby a magnetic retrieval system is attached to 1/8 inch umbilical tape which is inserted via the nares, looping around the nasal septum and vomer bone and ending with both ends of the bridle (umbilical tape) secured together and to the feeding tube just outside the nose.
224238389|NCT00005576|BIOLOGICAL|monoclonal antibody Ch14.18|Given IV
224238390|NCT00005576|DRUG|isotretinoin|Given orally
224238391|NCT00005576|BIOLOGICAL|aldesleukin|Given IV
224238392|NCT00005576|BIOLOGICAL|sargramostim|Given IV
224238393|NCT00119886|DRUG|Botulinum toxin|
224238394|NCT05915403|DIAGNOSTIC_TEST|Fibromyalgia Impact Questionnaire|diagnostic tests
224320936|NCT05522660|RADIATION|Stereotactic radiosurgery|"Depending on the investigator's preference, the following standard of care fractionation schedules are recommended: 1x 18-22 Gy, 3x 9 Gy or 5x 6 Gy. Fractionated stereotactic radiotherapy is favoured in principle, but not mandated, for postoperative radiotherapy and for metastases with a diameter of \>20 mm or for \>4 brain metastases.~For patients randomised to Arm A, radiotherapy should be initiated within 14 days after randomisation."
223654941|NCT00249899|DRUG|Lapaquistat acetate and stable statin therapy|Lapaquistat acetate 100 mg, tablets, orally, once daily and stable statin therapy for up to 24 weeks.
223654942|NCT00249899|DRUG|Stable statin therapy|Lapaquistat acetate placebo-matching, tablets, orally, once daily and stable statin therapy for up to 24 weeks.
223654943|NCT02785523|DRUG|Ganoderma Spore Lipids|
223654944|NCT02785523|DRUG|Placebo|
223654945|NCT02785523|DRUG|Chemotherapy|
223654946|NCT01900210|BEHAVIORAL|WaySafe|
223654947|NCT00135499|DRUG|Rituximab|375 mg/m², D1, 4 cycles
223654948|NCT00135499|DRUG|Doxorubicin|75 mg/m², D1, 4 cycles
223654949|NCT00135499|DRUG|Cyclophosphamide|1200 mg/m², D1, 4 cycles
223654950|NCT00135499|DRUG|Vindesine|2 mg/m², D1, D5, 4 cycles
223654951|NCT00135499|DRUG|Bleomycin|10 mg, D1, D5, 4 cycles
223654952|NCT00135499|DRUG|Prednisone|60 mg, D1-D5, 4 cycles
223767972|NCT02558608|PROCEDURE|DIPL|dissection of the inferior pulmonary ligament
223767973|NCT02558608|PROCEDURE|WR|wedge resection of the lung bleb
224238395|NCT00979732|DIETARY_SUPPLEMENT|grape seed extract|grape seed extract 150 mg twice a day (BID) in beverage or capsule form
224238396|NCT00979732|DIETARY_SUPPLEMENT|grape seed extract placebo|grape seed extract 150 mg twice a day (BID) in beverage or capsule form
224238397|NCT04829227|DEVICE|Sofwave|The Sofwave System, comprised of an applicator and a console, generates high intensity, non-focused ultrasonic energy which can be delivered percutaneously to tissues.
224238398|NCT06544018|GENETIC|Genetic analysis of NLRP3|Blood test for genetic analysis of NLRP3
224238399|NCT06544018|DEVICE|Circadian rhythm measurement|Wear a Withings Pulse HR (heart rate) actigraphic watch 24 hours a day for 1 month to define circadian rhythm
224238400|NCT06544018|BIOLOGICAL|Saliva sampling|Saliva sampling for salivary melatonin determination
224238401|NCT06544018|OTHER|Questionnaire|Questionnaire to determine chronotype
224238402|NCT06544018|OTHER|AIDAI score|Disease activity score using AIDAI score (only for patients in the CAPS group) AIDAI : AUTO-INFLAMMATORY DISEASE ACTIVITY INDEX
224238403|NCT06544018|BIOLOGICAL|Blood sampling|"1. Inflammatory cytokines measurement : IL1-beta (Interleukin-1) and IL-18.~2. Molecular characterization of circadian clock signaling pathways"
224238404|NCT00208026|DRUG|Pimecrolimus 1% Cream|Open label single arm
224238405|NCT02221765|DRUG|PP1420|Single dose of PP 1420, administered subcutaneously. Dose levels: 8, 16, 32, 64 mg.
224238406|NCT02221765|DRUG|Placebo|0.9% (w/v) saline single-dose, administered subcutaneously
224238407|NCT00487500|DEVICE|Electroconvulsive Therapy (ECT)|Electroconvulsive therapy involves applying a small electrical charge to the scalp while the patient is anesthetized and provoking a short-lasting generalized seizure
224238408|NCT05013112|DRUG|SGLT2 inhibitor|Empagliflozin 20mg once daily from discharge
224238409|NCT05013112|DRUG|Metformin|Metformin 500mg twice daily from discharge
224238410|NCT05013112|OTHER|Placebo|Placebo group
224238411|NCT05335408|DEVICE|Acunex Vario intraocular lens|This is an extended depth of focus IOL, made by Teleon Surgical B.V.
224238412|NCT05335408|DEVICE|Alcon AcrySof IQ Vivity intraocular lens|This is an extended depth of focus IOL, made by Alcon.
223654953|NCT00135499|DRUG|Prednisone|40 mg, D1-D5, 4 cycles
223654954|NCT00135499|DRUG|Doxorubicin|50 mg/m², D1, 4 cycles
223654955|NCT00135499|DRUG|Cyclophosphamide|750 mg/m², D1, 4 cycles
223654956|NCT00135499|DRUG|Vincristine|1.4 mg/m², D1, 4 cycles
223654957|NCT00618228|DRUG|Balsalazide|
223654958|NCT02094157|DRUG|Tapered warfarin regimen|This intervention is assigned to the experimental arm - Tapered warfarin regimen
223654959|NCT02094157|DRUG|Bridged regimen Low-molecular-weight heparin|This intervention is assigned to the active control arm - Bridged regimen
223654960|NCT01055431|OTHER|Control bread|Control bread
223654961|NCT01055431|OTHER|Teff Bread|Teff bread
223767974|NCT02558608|PROCEDURE|thoracoscopic surgery|surgery performed by video assisted thoracoscopy
223767975|NCT05521893|OTHER|Telemedicine care|"In the telemedicine group, the appointments are performed online via scheduled videoconferences, on a monthly basis.~All women in the telemedicine group receive a smartphone with the installed application that enable transfer of the measured capillary glucose concentration."
224238413|NCT05210738|DEVICE|Single incision sling|Single incision sling is used to treat occult SUI
224238414|NCT05210738|DRUG|Bulkamid bulking agent|Urethral bulking by Bulkamid is used to treat occult SUI
223767976|NCT05521893|OTHER|Standard care|In the standard care group, visits are scheduled at the diabetes clinic on a monthly basis.
223767977|NCT01412840|OTHER|Diclofenac and sterile water injections|The patients in the intervention group will be given standard treatment, i.e. intramuscular injection of 50 mg diclofenac. Patients in this group will also be given four subcutaneous injections of 0.5 ml sterile water at the same segmental level, i. e. the area in which the patient reports the pain.
224238415|NCT01522664|DRUG|DEDN6526A|Multiple ascending doses
224238416|NCT01822600|DRUG|Human albumin|Each patient in the intervention group received Human Albumin 20%® (ZLB Behring, Marburg, Germany), immediately. The dosage of albumin infusion was 10 g q8h for 1 day in patients with albumin levels ranging from 25 g/L to 29 g/L or 2 days in those with albumin levels \< 25 g/L.
224238417|NCT01822600|DRUG|Omeprazole|"After endoscopic hemostasis, each enrolled patient received an 80 mg loading dose of intravenous omeprazole (Losec®, AstraZeneca, Sweden) immediately. Patients then received a 3-day continuous omeprazole infusion in dosage of 80 mg per day.~After omeprazole infusion, oral esomeprazole (Nexium®, AstraZeneca, Sweden) 40 mg per day was given in the normal albumin group and the intervention group until the end of follow-up.~After omeprazole infusion, oral omeprazole (Losec®) 20 mg per day was given in the cohort control group until the end of follow-up."
223654962|NCT01175499|DEVICE|Direct Rigid Endoscopy|Laryngoscopy is performed under general anesthesia with a rigid laryngoscope. Mucosal surfaces of the oropharynx, hypopharynx, and glottis (base of tongue, vallecula, epiglottis, aryepiglottic folds, arytenoids, piriform sinuses, true and false vocal cords, and esophageal inlet) are systematically visualized. Areas of irregularity are biopsied with 2mm and/or 4mm cupped forceps. Esophagoscopy and bronchoscopy will be performed per the standard of care.
223654963|NCT01175499|DEVICE|Transnasal Flexible Endoscopy with Narrowband Imaging|Transnasal flexible endoscopy with and without narrowband imaging- additional diagnostic test. This examination is performed after topical intranasal anesthesia with 2% Pontocaine spray. A fiberoptic laryngoscope is passed into the nasal cavity to the pharynx where mucosal surfaces of the UADT can be visualized. The optics of a standard fiberoptic scope are generally considered to be inferior to direct visualization. The addition of narrowband imaging does not change the procedure, but enhances visualization of the mucosal vasculature. Biopsies are performed through a second channel in the endoscope with 1.8mm cupped forceps and will require an additional dose of topical anesthesia.
223654964|NCT01519167|DRUG|Dexmedetomidine|0.1 - 1.0 mcg/kg/hr IV
223654965|NCT01519167|DRUG|Midazolam|0.025 - 2 mg/kg IV
223654966|NCT01519167|DRUG|Fentanyl|0.5 - 3 mcg/kg IV
223654967|NCT05744674|DRUG|HR18034|HR18034 228mg/342mg/456mg
223654968|NCT05744674|DRUG|Ropivacaine Hydrochloride Injection|Ropivacaine Hydrochloride Injection 60mg/90mg/120mg
223654969|NCT00557713|DRUG|bevacizumab|"1. -Induction treatment. 4 cycles (every 3 weeks) of bevacizumab (7,5mg/kg day 1) + oxaliplatin (130mg/m2 day 1) + capecitabine (1000mg/m2/12h days 1-14)~2. -Concomitant (CT+RT) treatment (3 weeks later): bevacizumab (5mg/kg day 1 of 1st, 3th and 5th weeks) + capecitabine (825mg/m2/12h daily during radiotherapy treatment) + radiotherapy (45Gy (25fractions of 1,8Gy/day over 5weeks) followed by boost 5.4Gy (1,8Gy/day over 3days))~3. -Surgery (6-8 weeks after last bevacizumab dose)~4. -Adjuvant treatment: It will be individual decision of each investigator, but it's recommended 4 cycles of XELOX (equal dose at induction treatment)"
223654970|NCT02602210|DRUG|Hydrocortisone|IV bolus of 100 mg hydrocortisone in 50ml NaCl 0.9% (sodium chloride); followed by continuous IV infusion of 200 mg hydrocortisone in 50 ml NaCl 0.9% at a rate of 2 ml/h until the start of day 4.Reduction of infusion rate with 0.5 ml/h/day.
223654971|NCT02602210|DRUG|NaCL 0.9%|IV bolus of 50 ml NaCL 0.9%; followed by continuous IV infusion of NaCL 0.9%
223654972|NCT00556504|DRUG|TCM-700C|An add-on drug to conventional treatment of Hepatitis C
223654973|NCT00556504|DRUG|Peginterferon alfa-2a|conventional treatment of Hepatitis C
223654974|NCT00556504|DRUG|Ribavirin|conventional treatment of Hepatitis C
223654975|NCT00556504|DRUG|Placebo|Placebo, without acting ingredient.
223654976|NCT00565188|DRUG|Adenosine 5'-triphosphate|Weekly ATP infusions (in total 8 infusions) during 8 - 12 hours in a maximum dose of 50 mcg/kg.min
224238418|NCT03223233|OTHER|procalcitonin level|serum procalcitonin level will be measured in both groups.
223654977|NCT05808543|OTHER|Both EARS training package (BEARS)|The BEARS training package comprises of three games addressing different hearing functions: speech-in-noise perception, music listening and sound-source localisation. Each game is based on an audio-visual task performed through a virtual-reality interface. Players are guided through on-screen visual prompts to support the gameplay with feedback given on their performance and progress through levels of increasing difficulty. The BEARS training package design allows for the training to be self-administered, played anywhere and at any time. There is no upper limit to the frequency of use of the BEARS training package, it is advised to play the games for a minimum of 1 hour a week over a minimum of 2x 30-minute sessions, all three games will need to be played.
223654978|NCT05808543|OTHER|Usual Care|This is an annual review appointment with the patient and their clinician. This could be face-to-face, virtual video consultation, questionnaire, or be cochlear remote care checks. As a minimum this review will check the following: Microphone covers changed, Reported or recorded device use, all external and internal equipment working (known through no reported or recorded degradation in hearing ability). During the appointment, the clinician would establish if there were any concerns regarding the cochlear implant functioning and the patient's rehabilitation programme. They will then make any repairs or adjustments to the device and manage additional support and contact as required. Between the annual review appointments patients can attend the implant centre for repair appointments or have spare equipment posted. There is no limit to the level of contact between the patient and the implant centre.
223654979|NCT00158496|DRUG|pegylated interferon alpha2a|
223654980|NCT00158496|DRUG|ribavirin|
223654981|NCT02546518|DEVICE|Moniri Otovent|Please see Arm Description.
223767978|NCT01412840|OTHER|Diclofenac and isotonic saline|The patients in this group will be given standard treatment, i.e. intramuscular injection of 50 mg diclofenac They will also be given four subcutaneous injections of isotonic saline at the same segmental level, i. e. the area in which the patient reports the pain.
223767979|NCT01849705|OTHER|No intervention|
223767980|NCT02566759|DRUG|TAK-831 Oral Suspension|TAK-831 oral suspension.
223767981|NCT02566759|DRUG|TAK-831 Placebo|TAK-831 placebo-matching oral suspension.
223767982|NCT02566759|DRUG|TAK-831 Tablet|TAK-831 tablet.
224238419|NCT00002132|DRUG|Itraconazole|
224238420|NCT00002132|DRUG|Fluconazole|
224238421|NCT00183807|DRUG|irinotecan, cisplatin, celecoxib|
224238422|NCT02921737|DRUG|TAS-102|TAS-102 (35 mg/m2/dose) orally 2 times daily beginning the morning of Day 1 of each cycle and ending the evening of Day 5 of each cycle, as well as beginning the morning of Day 8 and ending the evening of Day 12 of each cycle. No TAS-102 will be given on Days 6-7 or Days 13-28 of each cycle.
224238423|NCT04836000|OTHER|In addition to the conservative treatment, Low-level laser therapy|"For Experimental Group A Gallium-aluminum-arsenide (Ga-Al-As) diode laser instrument (Roland Serie, Elettronica Pagani, Paderno, Italy, Mod IR 27/1) will be used (wavelength 904 nm, 5500 Hz frequency, 27 W maximum power output per pulse, 13.2 mW average power, 0.8-cm2 spot size, 1.6 J of total energy will be delivered per point at each session at a power density of 16.5 mW/cm2, and the cumulative energy per point for all sessions was 16 J).~Ga-Al-As laser therapy will be applied to experimental group patients two times per week for 6 weeks in 10-min sessions. LLLT will be applied over the tuberculum majus and minus, the anterior and posterior faces of the capsule, and the subacromial regions. Each point will be treated for 120 sec. The head of the instrument will be held perpendicular to the body surface and in skin contact without pressure."
223654982|NCT02546518|DEVICE|Tympanostomy tube in the ear drum|Insertion of tympanostomy tube/Grommet in the ear drums.
223654983|NCT02401789|DEVICE|Implants (OsseospeedTM,EV Astra Tech System, DentsplyTM, Mölndal)|
223654984|NCT04711226|DRUG|AT-1501|AT-1501 IV infusion
223654985|NCT04297527|PROCEDURE|Conventional Physiotherapy|Conventional Physiotherapy consist of Hotpacks, TENS and US.The participants were positioned in prone and supported with a pillow under the abdomen, 20 min hot pack was applied. Therapatic Ultrason were applied with the frequency of 1 MHz, intensity of 1,5 watt/cm² and duration of 5 minute. TENS was applied to the lumbar region with 2-channel, 4 surface electrodes at 60-120 Hz, and 50-100 pulse duration for 20 minutes.
223654986|NCT04297527|PROCEDURE|Mulligan Mobilization|Extension SNAGS in prone, SNAGS in lion position and Lumbar flexion SNAGS in sitting, techniques were used. The techniques were applied in 3 sets with 10 repetitions and 60 seconds rest between sets.
223654987|NCT05486377|DRUG|Remimazolam besylate|Remimazolam besylate TIVA
223654988|NCT02561338|DRUG|HMS5552|75mgQD
223654989|NCT02561338|DRUG|HMS5552|100mgQD
223654990|NCT02561338|DRUG|HMS5552|50mgBID
224238424|NCT04836000|OTHER|In addition to the conservative treatment, Low-level laser therapy (turned off)|For Placebo Group In the placebo group, laser instrument will be applied in the same way but the device will be turned off during treatment sessions. Patients and physiotherapist will be asked to use protective eyeglasses during therapy for safety.
224238425|NCT04836000|OTHER|Conservative treatment solely|For Control Group All patients using an immobilization bandage up to post-operative 6th week will receive the standardized 6-week supervised rehabilitation program advocated by the same physiotherapist (CK), 7 years of experience in the clinical treatment of rotator cuff tear, after the baseline assessment. Composed of 30 treatment sessions (five days/week) of 45 to 60 minutes, the rehabilitation program will be provided individually to all participants. Physiotherapy sessions will be devoted to strength, mobilizations, stretching, perturbation, and sensorimotor training using motor control exercises, hence, to restore adequate shoulder neuromuscular control. The treatment program will also be included patient education.
224238426|NCT05723809|DEVICE|Percussive Therapy Device|Same as group description
224238427|NCT05723809|BEHAVIORAL|Physical Therapy|Same as group description
224238428|NCT01826383|BEHAVIORAL|Active-Video|This group will watch an active-video with pain management strategies for parents
224238429|NCT01826383|BEHAVIORAL|Placebo Video|This group will watch a placebo-video describing immunization generally.
224238430|NCT04164745|DRUG|Anlotinib, oral capsule|Participants receive Anlotinib 12 mg p.o, qd on Days 1-14 of each 3-week cycle until progressive disease or unacceptable toxicity plus pembrolizumab 200 mg via intravenous (IV) infusion on Day 1 of each 3-week cycle for up to 35 administrations (up to approximately 2 years).
224238431|NCT04164745|BIOLOGICAL|Pembrolizumab|Participants receive Anlotinib 12 mg p.o, qd on Days 1-14 of each 3-week cycle until progressive disease or unacceptable toxicity plus pembrolizumab 200 mg via intravenous (IV) infusion on Day 1 of each 3-week cycle for up to 35 administrations (up to approximately 2 years).
224238432|NCT00422747|DRUG|beclomethasondipropionate|2 x 100 ug dd for two months, via aerochamber
223654991|NCT02561338|DRUG|HMS5552|75mgBID
223654992|NCT02561338|OTHER|Placebo|QD/BID
223654993|NCT01039883|DRUG|Albaconazole tablet 400mg|Albaconazole tablet 400mg single dose, then four albaconazole capsule 100mg single dose
223654994|NCT01039883|DRUG|Albaconazole 100mg capsules, then albaconazole 400mg tablet|Four albaconazole capsule 100mg single dose, then albaconazole tablet 400mg single dose
223654995|NCT00882817|OTHER|Pulmonary Rehabilitation|The intervention group will perform a 6 month pulmonary rehabilitation program which consists of training, patient education, nutrition counseling and psychosocial support. They will be evaluated with some tests for the study.
223654996|NCT02411097|PROCEDURE|femoral nerve block|use the nerve stimulator,the femoral nerve block will be administered before or after the surgery
224238433|NCT06079645|PROCEDURE|Infiltration of triamcinolone acetonide (2mg/ml) through syringes and needles|Infiltration of triamcinolone acetonide (2mg/ml) through syringes and needles
224238434|NCT06079645|PROCEDURE|Infiltration of triamcinolone acetonide (40 mg/ml) with needles|Infiltration of triamcinolone acetonide (40 mg/ml) through needles of tattoo machine
224238435|NCT03729297|DRUG|Cabozantinib|cabozantinib tablets (Cabometyx®) once daily until progressive disease, intolerable toxicity, or investigator and/or patient decision to withdraw for a maximum duration of 2 years.
224238436|NCT00986297|RADIATION|hypofractionated radiation therapy|hypofractionated radiation therapy
223654997|NCT04236609|DEVICE|Abluminus DES+ Sirolimus Eluting Stent System (SES)|The Sirolimus-eluting stent manufactured by Envision and distributed by Concept Medical
223654998|NCT04236609|DEVICE|XIENCE Everolimus Eluting Coronary Stent System (XIENCE family)|The Everolimus-eluting stent manufactured and distributed by Abbott Vascular Santa Clara, CA
223654999|NCT01849731|OTHER|Face-to-face|is carried out by the GPs during the clinic visit and consists of seven visits, one every three months. Each session consists of completing a diabetes care record sheet (DCRS) together with the patient. The DCRS consists of two parts: Five questions on self-care activities in the last three months and a graph with previously measured HbA1c levels. This information is completed at each session, resulting in a graph showing the evolution of glycaemic control related to self-care activities. The DCRS is explained patients, emphasising the relationship between self-care and glycemic control. At the end of the session, patients are given a copy of the DCRS and suggested to show it and discuss it with their relatives.
223681001|NCT00479583|DRUG|BMS-690514 / FOLFOX|Tablets / IV, Oral / IV, up to 200 mg / oxaliplatin 85 mg/m2, leucovorin 400 mg/m2, 5FU 400mg/m2 bolus, 2400 mg/m2 inf, once daily / q 2 weeks, up to 24 mos
223681002|NCT01197001|DRUG|Amlodipine plus Losartan|Amlodipine/Losartan low dose
223681003|NCT01197001|DRUG|Amlodipine, Losartan|Amlodipine, Losartan
223681004|NCT02755792|BEHAVIORAL|Calligraphy Training|
223681005|NCT02755792|BEHAVIORAL|iPad Training|
223681006|NCT04515862|OTHER|Breastfeeding education|The importance of breastfeeding Benefits of breastfeeding for mother and baby Structure of the breast and milk production Breastfeeding techniques and positions Breastfeeding problems and breast care
223681007|NCT03372889|BEHAVIORAL|Patient educaiton materials - Print based|Print (paper) based materials
224238437|NCT05332925|DRUG|Standard of care immune checkpoint inhbitors|This is NOT an interventional study.
224238438|NCT00714740|DRUG|acetazolamide|acetazolamide 2 times 250mg per day
224238439|NCT01787058|OTHER|Dubai Cares beneficiary|Installation or rehabilitation of school water points, latrines and hygiene kits; promotion of good WASH practices and behavior change at school and within the community; establishment of management systems to ensure sustained WASH financing, monitoring and maintenance.
224238440|NCT04934917|DEVICE|Magnetic Resonance Imaging|Magnetic Resonance Imaging. Pain testing: Temporal summation, Pain thresholds. Assessment of symptoms: Questionnaires. All interventions are made at baseline only (1 time/subject).
224238441|NCT03356821|BIOLOGICAL|Mesenchymal Stem Cells|One dose of 50x10\^6 bone marrow-derived allogeneic MSCs via the nasal route as soon as possible after confirmation of the stroke (in the middle cerebral artery), but within the first week of onset of presenting clinical symptoms. Within 30 minutes after cleaning the nose with saline, using standard procedures operative at the Neonatal Intensive Care Unit, the MSC will be delivered.
224238442|NCT02367638|BIOLOGICAL|MG1111|Low, Medium, High Plaque-Forming Unit (PFU) of MG1111 in 0.5 mL dose is administered by subcutaneous injection
224238443|NCT02367638|BIOLOGICAL|VARIVAX|VARIVAX is administered by subcutaneous injection
224238444|NCT03237364|DIAGNOSTIC_TEST|Perfluorinated Gas/Oxygen Mixture|19-Fluorine (19F) MRI of the lungs with 21%/79% Oxygen/Perfluorinated Gas, ≤ 25 liters, gas, single visit, \< 1 hour
224238445|NCT03982485|DRUG|Apatinib|Apatinib 250mg, Oral, day 2,3,4,5,6,7, every week
224238446|NCT03982485|DRUG|Paclitaxel|Paclitaxel 80mg/m2, Intravenous, day 1, 8, 15, 22, every 28 days for a cycle
224238447|NCT03982485|DRUG|Cisplatin|Cisplatin 25mg/m2, Intravenous, day 1, 8, 15, every 28 days for a cycle
224238448|NCT03982485|PROCEDURE|Surgery|Surgery
224238449|NCT03239509|PROCEDURE|bioprosthesis implantation between 2000-2015|Implantation of a bioprosthesis in aortic position with cardiopulmonary bypass
224238450|NCT03239509|PROCEDURE|mechanical prosthesis implantation between 2000-2015|Implantation of a mechanical prosthesis in aortic position with cardiopulmonary bypass
224238451|NCT02468778|DEVICE|HeartMate PHP|The HeartMate PHP System is a temporary (\<6 hours) ventricular assist device indicated for use during high-risk percutaneous coronary interventions (PCI) performed electively or urgently in hemodynamically stable patients with severe coronary artery disease, when a heart team, including a cardiac surgeon, has determined high-risk PCI is an acceptable therapeutic option. Use of the HeartMate PHP Systems in these patients may prevent hemodynamic instability, which can result from repeat episodes of reversible myocardial ischemia that occur during planned temporary coronary occlusions and may reduce peri-and post-procedural adverse events.
224238452|NCT02468778|DEVICE|Any Abiomed Impella® device approved for use in high-risk PCI|Any Abiomed Impella® device approved for use in high-risk PCI.
223655000|NCT01849731|OTHER|Face-to-face intervention plus telephone reinforcement|In this group patients receive the above described intervention A plus a telephone reinforcement It consists on five telephone calls lasting about 10 minutes each, to provide advice on carrying out physical exercise and eating a balanced diet and to encourage the use of health services related to diabetes control. Any problems or doubts that patients have stemming from any aspect of diabetes care are also discussed. Telephone reinforcement is carried out by a professional who has previously been trained in promoting T2DM self-management and in motivational interviewing techniques.
224238453|NCT00660647|DRUG|Adalimumab|Adalimumab injection 0.8 ml (40 mg) s.c. every second week in up to 2 years
224238454|NCT00660647|DRUG|Placebo|Saline injection 0.9%, 0.8 ml s.c. every second week up to 2 years
224238455|NCT05240222|BEHAVIORAL|Pre-implementation enhancement strategies (SC-PIES)|The SC-PIES was delivered to teachers as a one-hour professional development session immediately before receiving specific training about evidence-based student behavioral management practices and follow-up consultation. SC-PIES content was grounded in three social-cognitive principles: (a) growth mindset, (b) saying-is-believing, and (c) commitment and consistency.
224238456|NCT05240222|OTHER|Sham comparator|Participants in the active control condition will meet with school administrators to talk about their work irrelevant to SC-PIES or student behaviors. The meeting lasted for the same duration as the SC-PIES at the same time as those in the treatment condition.
224238457|NCT00858923|DEVICE|Energex HemoModulator|To use ultraviolet light to reduce HIV virus in the patient's blood
224238458|NCT05070260|DRUG|Intravenous glenzocimab (ACT017) 1000 mg|Add-on therapy to the standard of Care in the treatment of the acute ischemic stroke symptoms
224238459|NCT05070260|DRUG|Intravenous Placebo|Add-on therapy to the standard of Care in the treatment of the acute ischemic stroke symptoms
223655001|NCT04200352|DRUG|TEV-50717|Oral tablets are 6, 9, and 12 mg.
224238460|NCT00147030|PROCEDURE|Whole body mild induced hypothermia|Target rectal temperature 33-34°C for 72 hours, commencing by 6 hours of age; followed by re-warming at 0.5°C to normothermia
224238461|NCT02552342|DRUG|methylprednisolone|
224238462|NCT02552342|DRUG|Normal saline|
224238463|NCT01064570|DRUG|all-trans retinoic acid (ATRA)|
224238464|NCT03916497|DIAGNOSTIC_TEST|Quantiferon CMV|Evaluate and compare interferon gamma (IFNy) production by T CD8 cells exposed to CMV antigens in CMV seropositive kidney transplant recipients, hemodialysis and control patients
224238465|NCT05857098|OTHER|Local Field potential recording|Continuous recording of Local Field potentials in patients implanted with Deep brain stimulation
224238466|NCT04739020|DIAGNOSTIC_TEST|Resp-Aer-Meter|Measurement of respiratory aerosols (particle size and concentration) through breathing into the Resp-Aer-Meter for 3-6 Minutes and comparison between groups.
224238467|NCT04739020|DIAGNOSTIC_TEST|Spirometry|Comparison of peak expiratory flow (PEF) and forced expiratory volume in one second (FEV1) between groups.
224238468|NCT04739020|DIAGNOSTIC_TEST|Qualitative and quantitative virus PCR of respiratory secretions in patients with high aerosol concentrations|Comparison between result of aerosol measurement and quantitative and qualitative virus PCR of respiratory secretions that are caught in a filter in which the patient breathes for 10 minutes. Test will be conducted on patients with high aerosol concentrations (\>5000/L).
224238469|NCT03736382|OTHER|Mild intermittent hypoxia|Participants will be exposed to twelve two minute episodes of mild intermittent hypoxia 5 days a week for 3 weeks.
223655002|NCT00474591|DRUG|Fondaparinux|
223681008|NCT03372889|BEHAVIORAL|Patient educaiton materials - Media based|Media (electronic) based materials
223681009|NCT03224780|DIAGNOSTIC_TEST|maternal serum creatine kinase|Biochemical marker
224238470|NCT03736382|OTHER|Sham protocol|Participants will be exposed to twelve two minute episodes of sham mild intermittent hypoxia (i.e. room air) 5 days a week for 3 weeks.
223655003|NCT02135926|DEVICE|Thrombectomy|Stent retriever are intended to restore blood flow in patients with acute ischemic stroke secondary to intracranial occlusive vessel disease by providing temporary bypass across the occlusion and/or by the non-surgical removal of emboli and thrombi. They may be used with aspiration and with the injection or infusion of contrast media and/or other fluids. For subjects enrolled in this protocol who are randomly assigned to undergo the thrombectomy procedure, the device will be used according to the Instructions-for-Use (IFU) that is packaged with the device.
223655004|NCT02135926|OTHER|Best medical care|Best medical treatment will be performed as detailed in established Standard Operating Procedures, following regional guidelines (American Heart Association (AHA), European Stroke Organisation (ESO), Deutsche Schlaganfall-Gesellschaft (DSG), local country, etc.).
223655005|NCT04371393|BIOLOGICAL|Remestemcel-L|administered twice during the first week, with the second infusion at 4 days following the first injection (± 1 day)
223655006|NCT04371393|DRUG|Placebo|administered twice during the first week, with second infusion at 4 days following the first injection (± 1 day)
223655007|NCT04690452|BEHAVIORAL|Compassion Cultivation Training|The Compassion Cultivation Training (CCT©) is an 8-week standardized meditation program conducted in groups of 15-20 participants and consisting of weekly 2 hour on-line sessions with 20-30 minutes of daily formal meditation practices and informal compassion practices. The CCT© program will be guided by a certified instructor form the Center for Compassion and Altruism Research and Education at Stanford University. The CCT© program comprises six sequential steps: 1) Settling the mind; 2) Loving-kindness and compassion for a loved one; 3) Self-directed loving-kindness and compassion; 4) Common humanity; 5) Cultivating compassion for others; and 6) Active compassion (Tonglen).
223655008|NCT05689580|DIETARY_SUPPLEMENT|Ketogenic diet|The course of the trial to medium-chain triglyceride lipid intervening 50-70% of dietary intake
223655009|NCT05689580|DIETARY_SUPPLEMENT|Balanced diet|Balanced diet
223655010|NCT01318980|DRUG|GSK2190915 100mg milled tablet|Taken orally
223655011|NCT01318980|DRUG|[14C] radiolabelled GSK2190915 solution|Microtracer solution
223655012|NCT01318980|DRUG|GSK2190915 100mg milled tablet administered to the proximal small bowel.|Ground half of a 200mg tablet. Administered via Enterion capsule.
223655013|NCT01318980|DRUG|GSK2190915 100mg milled tablet administered to the distal small bowel.|Ground half of a 200mg tablet. Administered via Enterion capsule.
223655014|NCT01318980|DRUG|GSK2190915 100mg enteric-coated tablet.|Taken orally
224238471|NCT03736382|OTHER|Continuous positive airway pressure (CPAP)|All participants will be treated with CPAP each night for a duration of 3 weeks.
224238472|NCT01112280|DEVICE|cap-assisted chromoendoscopy|A cap (irrigation cap) is a simple plastic device that can be attached to the tip of a colonoscope before performing the colonoscopy. For chromoendoscopy, 0.09% indigocarmine was administered via irrigation cap .
224238473|NCT06302374|BIOLOGICAL|GR2001|intramuscular injection
224238474|NCT06302374|BIOLOGICAL|Placebo|intramuscular injection
223655015|NCT01989494|DEVICE|Pedometer|All groups will receive a pedometer to measure their daily steps
223655016|NCT04558840|PROCEDURE|Macromastia|Patients with macromastia seeing the principle investigator (PI) (JMK) at his office at the Outpatient Building, which includes the Outpatient Surgery Center (OSC), in the Department of Plastic Surgery clinic at UT-Southwestern for their initial operative consultation for reduction mammaplasty will be offered enrollment in the trial if they are deemed appropriate surgical candidates, based on the PI's clinical judgement and expertise.
223655017|NCT05226637|DEVICE|ESWT (extra-corporeal shock wave therapy)|The ESWT device (Storz Medical Duolith SD1),
223655018|NCT05226637|DEVICE|Sham : The ESWT device (Storz Medical Duolith SD1),|In doing so, the sham head still actuates and makes the same sounds but produces no shockwave. Because the patients receiving this intervention are naïve to ESWT, they will not be biased by the sensation it produces. Communication during treatment will be limited to avoid inadvertent bias.
223655019|NCT06307197|DEVICE|HAAL platform|"The HAAL platform is composed by 6 devices (lifestyle monitoring system, a smart mattress, a GPS tracking system, a social robot, an interactive game for cognitive training, and an alarm system), 1 tablet and 1 dashboard. Each user benefits of a combination of such devices, according to its own needs. The dashboard, that is used by the Formal Caregiver, receives, analyses, and show data acquired by those devices.~The platform uses Artificial Intelligence (AI) algorithms - in particular machine learning (ML) is used - to analyse the collected data. The main reason for using AI in HAAL is that the platform collects data from different sensors."
223655020|NCT00233064|BIOLOGICAL|Lyophilized Palivizumab|Patients will receive 15 mg/kg of lyophilized palivizumab administered intramuscularly every 30 days for a total of 5 injections.
223681010|NCT03224780|DIAGNOSTIC_TEST|3D Doppler ultrasound|Doppler for placental vessels
223681011|NCT03313232|OTHER|ROAT with oxidized R-limonene at 1%, 0.3% and 0.1%|A twice daily repeated open application test (ROAT) study for up to three weeks of exposure to oxidized R-limonene at 1%, 0.3% and 0.1% concentrations
223681012|NCT03313232|OTHER|ROAT with oxidized R-limonene at 1%|A twice daily repeated open application test (ROAT) study for up to three weeks of exposure to oxidized R-limonene at a 1% concentration
223681013|NCT03828370|BEHAVIORAL|B-SMART Intervention Group|The B-SMART mobile web app will contain four modules: 1) Supporting Abstinence, 2) Shared Positive Activities, 3) Common Challenges for Family Members with IID, and 4) Effective Communication. Within each module there will be a series of learning activities, including presentation text, interactive engagement, and videos. All app content will be available in both English and Spanish, based on user language preference.
223681014|NCT03828370|BEHAVIORAL|Usual and Customary Information Group|Participants randomized to the usual and customary care (UC) group will receive a website with a pamphlet on the IID installed in their vehicle and the manufacturer information provided about the IID in PDF format, in both English and Spanish. This constitutes a UC group, as such pamphlets are widely available to DWI offenders who have IIDs installed in their vehicles. Thus, providing this pamphlet represents a standard information provision for first-time DWI offenders and their CFMs.
224238475|NCT06302374|BIOLOGICAL|HTIG|intramuscular injection
224238476|NCT06302374|BIOLOGICAL|Tetanus Toxoid|intramuscular injection
223655021|NCT00233064|BIOLOGICAL|Liquid Palivizumab|Patients will receive 15 mg/kg of liquid palivizumab administered intramuscularly every 30 days for a total of 5 injections.
223655022|NCT06328413|DEVICE|photobiomodulation|Photobiomodulation application at different extraoral and intraoral points for 60 seconds with a wavelength of 940 nm in repeated sessions after the extraction of third molar
223655023|NCT06328413|OTHER|Leukocyte and Platelet Rich Fibrin|Leukocyte and platelet rich fibrin ( blood product centrifuged for 12 minutes at 2700rpm) application after third molar extraction, single session.
223655024|NCT03508908|DIAGNOSTIC_TEST|HIV-1 RNA testing|During the intervention period, a blood sample will be obtained and tested for AHI using point-of-care Xpert® HIV Qual assay (Cepheid, Sunnyvale, California, USA). Individuals who test positive will undergo rapid tests to differentiate acute from prevalent HIV infection. Newly diagnosed individuals will be offered immediate ART and assisted partner notification with the HIV-1 RNA testing intervention delivered to partners following the same approach.
223655025|NCT04251403|DIAGNOSTIC_TEST|Mucosal Irrigation|Following routine endoscopic evaluation, investigators will utilize the ERBEJET 2 device (ERBE USA Inc), which is commercially available for the treatment of mucosal lesions, to sample cells from the mucosal surface of the stomach. The aspirate will be collected for cytologic/pathologic assessment.
223655026|NCT06120361|DIAGNOSTIC_TEST|Plasma APS 2 score|APS 2 score (combination of ptau217/nptau217 and Ab42/Ab40). The cut off will be predefined. The samples will be analysed prospectively every two weeks.
223655027|NCT06120361|DIAGNOSTIC_TEST|Plasma p-tau217/np-tau217|The cut off will be predefined. The samples will be analysed prospectively every two weeks.
223655028|NCT06120361|DIAGNOSTIC_TEST|Plasma p-tau217|The cut off will be predefined. The samples will be analysed prospectively every two weeks.
223655029|NCT06120361|DIAGNOSTIC_TEST|Plasma neurofilament light (NfL)|The cut off will be predefined. The samples will be analysed prospectively every two weeks.
223655030|NCT06120361|DIAGNOSTIC_TEST|Plasma Ab42/Ab40|The cut off will be predefined. The samples will be analysed prospectively every two weeks.
223655031|NCT06120361|DIAGNOSTIC_TEST|MRI and CT of the brain|Structural brain imaging
223655032|NCT06120361|DIAGNOSTIC_TEST|Different cognitive tests|Both standard paper-and-pen tests as well as digital cognitive tests will be evaluated.
223655033|NCT05922865|DEVICE|KNEESUP smart knee assistive device + KNEESUP care APP|In KNEESUP smart knee assistive device + KNEESUP care APP group, participants used the KNEESUP intelligent knee assistive device. Participants wore a knee brace with a sensor module on one side of the leg, the sensor could connect with the KNEESUP care APP which were installed in participant's mobile phone. The APP was designed with an individualized exercise program and the knee brace sensor could detect the action moment of the participants during exercise. This equipment could help the participants to achieve professional-level home rehabilitation.
223655034|NCT05922865|BEHAVIORAL|Healthy consulation|In Healthy consulation group, participants received routine outpatient health education.
223655035|NCT03263559|PROCEDURE|Haploidentical Bone Marrow Transplantation|Eligible patients with a first degree Human Leukocyte Antigen (HLA)- haploidentical donor will undergo Haploidentical bone marrow transplantation at Day 0 with non T-cell depleted bone marrow. For Graft-vs-Host Disease (GVHD) prophylaxis, patients will be given sirolimus and mycophenolate mofetil beginning on Day +5.
223655036|NCT03263559|DRUG|Hydroxyurea|HU will be given daily at 30mg/kg from Day -70 through Day -10.
223655037|NCT03263559|DRUG|Rabbit-ATG|Rabbit-ATG (rATG) will be given at 0.5mg/kg on Day -9, and at 2.0mg/kg on Day -8 and Day -7.
223655038|NCT03263559|DRUG|Thiotepa|Thiotepa will be given at 10mg/kg on Day -7
223655039|NCT03263559|DRUG|Fludarabine|Fludarabine will be given at 30mg/m2 from Day -6 to Day -2
223767983|NCT04510116|BEHAVIORAL|Adults in the Making program|The AIM prevention program, modeled after an existing family-based skills-training intervention in a group format for rural African American preadolescents, consists of six consecutive weekly group meetings held at community facilities, with separate parent and youth skill-building curricula and a family curriculum. Each of the six meetings includes separate, concurrent training sessions for parents and youth, followed by a joint parent-youth session during which the families practice the skills they learned in their separate sessions. Concurrent and family sessions each last 1 hour. Thus, both parents and youth receive 12 hours of prevention training.
223655040|NCT03263559|DRUG|Cyclophosphamide|Cyclophosphamide will be given at 14.5mg/kg on Day -6 and Day -5, and at 50 mg/kg on Days +3 and +4.
223655041|NCT03263559|RADIATION|Total Body Irradiation|Total Body Irradiation will be given at 200cGy on Day -1
223655042|NCT03263559|DRUG|Mesna|Mesna will be given at 40mg/kg on Days +3 and +4
223655043|NCT06019000|COMBINATION_PRODUCT|CYR-064|CYR-064 is a nasal solution.
223655044|NCT01881828|DRUG|Metformin (glucophage)|The strength of each tablet will be 500 mg. Participants will build up to a daily dose over four weeks by taking one tablet per day for 7 days, one tablet twice daily for 7 days, one tablet in morning and 2 tablets at night for 7 days, and then 2 tablets in the morning and 2 tablets at night, daily throughout the remainder of the study treatment period.
223655045|NCT01881828|OTHER|oral placebo|
223655046|NCT03836950|DEVICE|MagVenture MagProX100 stimulator (MagVenture, Falun, Denmark)|The coil will be held tangentially to the skull at approximately 45º from the midline. One rTMS session will consist of 40 trains of 5sec each at 110% of resting motor threshold and 15Hz will be provided at the left DLPFC.
223655047|NCT03836950|DEVICE|MagVenture MagProX100 stimulator (MagVenture, Falun, Denmark)|The coil will be held tangentially to the skull at approximately 45º from the midline. The sham coil will not release any stimulation, but it will look, feel and sound like the real rTMS
223655048|NCT04638543|DRUG|ABP-671|ABP-671 Tablet
223655049|NCT04638543|DRUG|Placebo|Placebo
223655050|NCT03388710|RADIATION|XRay|Xray to confirm the location of the endotracheal tube
223655051|NCT04915612|DRUG|Gemtuzumab Ozogamicin|Given IV
223655052|NCT04915612|DRUG|Liposome-encapsulated Daunorubicin-Cytarabine|Given IV
223655053|NCT01120964|DRUG|Intravenous L-Citrulline|
223655054|NCT01120964|DRUG|Placebo of Intravenous L-Citrulline|Placebo of intravenous L-Citrulline given at the same prescribed times as L-Citrullne Drug
223655055|NCT01003769|DRUG|Lenalidomide|Given PO
223655056|NCT01003769|DRUG|R-(-)-Gossypol Acetic Acid|Given PO
224238477|NCT01258725|PROCEDURE|amnioinfusion procedure|Single/serial amnioinfusions aimed at restoring amniotic fluid volume until a normal amount (AFI≥8cm).(Every pregnant women presenting with severe (AFI\<5) idiopathic (with unknown origin) oligohydramnios is treated with amnioinfusion at our Dept.)
224238478|NCT00414765|DRUG|Aldesleukin|
223655057|NCT01003769|OTHER|Laboratory Biomarker Analysis|Correlative studies
223655058|NCT03747861|DEVICE|SenceBand|Wristband for registration of ECG RR intervals for one hand, SenceBand will collect data from 5-minutes intervals each 30 minute within 24 hours
223655059|NCT00826202|DRUG|D-serine|60 mg/kg/day
223655060|NCT00826202|OTHER|Placebo|Inert Placebo
224238479|NCT05561127|COMBINATION_PRODUCT|GIE Medical ProTractX3 TTS DCB|"The ProTractX3 Drug-coated balloon is a 0.035 guidewire compatible over-the-wire catheter."
224238480|NCT05561127|OTHER|Control|Standard of Care Endoscopic Dilation
223655061|NCT02545088|DEVICE|Hybrid Assistive Limb (HAL)|Intensive gait training with Hybrid Assistive Limb (HAL) is performed 1 session/day, 3 days/week for 6 weeks and each session will not exceed 60 min of effective walking time with HAL. In addition, each session will include conventional gait training that will not exceed 30 min effective training time.
223655062|NCT02545088|OTHER|1st control group|Conventional gait training performed 1 session/day, 3 days/week for 6 weeks that will not exceed 1h 30 min effective training time.
223655063|NCT02545088|OTHER|2nd control group|The 2nd control group will not receive an intervention.
223655064|NCT02831972|DRUG|AG120|
223655065|NCT02831972|DRUG|Itraconazole|
223655066|NCT04237116|BIOLOGICAL|Investigational Arm - secukinumab|secukinumab 300mg s.c. weekly in first 4 weeks, followed by q4w up to Week 20; and placebo 300mg s.c. at weeks 13, 14 and 15 to maintain the blind
224238481|NCT04617327|RADIATION|Hypofractionation|"Shorter radiation therapy means that a higher dose will be given on a daily basis. The goal is to target microscopic disease and decrease the chances of local recurrence.~Organs at risk (OAR) will receive doses following the constraints from the Timmerman tables used for reference when using 5 or more fractions of EBRT.~Treatment will be delivered every 2nd day, for a maximum of 3 fractions per week. Daily pretreatment Image Guided Radiotherapy Images (IGRT) (Cone-Beam CT - CBCT) will be co-registered with the CT simulation dataset to adjust patient position before each treatment by matching the bone adjacent to the planned tumour volume (PTV). Treatment will be administered if there is \<3 mm in any dimension, or rotation is \<3 degrees. If the isocentre set-up exceeds 3 mm at any given treatment session, the treatment couch will be translated to restore its planned position."
223655067|NCT04237116|BIOLOGICAL|Control Arm - placebo|placebo 300 mg s.c. weekly in first 4 weeks, followed by q4w up to Week 8; and secukinumab 300 mg s.c. weekly for 4 weeks starting at Week 12, followed by q4w up to Week 20
223655068|NCT00619710|DRUG|Meropenem|Intravenous
224320937|NCT05522660|DRUG|Immune checkpoint inhibitor|"Systemic therapy follows the current standard of care, according to the type of the primary tumour.~* For patients with melanoma, with or without BRAF-mutation, systemic therapy consists of~  * an approved immune-checkpoint inhibition combination therapy (cohort 1a) or~ * an approved immune-checkpoint inhibition monotherapy (cohort 1b).~* For patients with NSCLC and a targetable oncogenic driver alteration (cohort 2a), systemic therapy consists of an approved targeted therapy (for example: EGFR-, ALK- or ROS1-targeted treatment).~* For patients with NSCLC without a targetable oncogenic driver alteration (cohort 2b), systemic therapy consists of an approved immune-checkpoint inhibition therapy (with or without chemotherapy)."
223655069|NCT00619710|DRUG|Imipenem-cilastatin|Intravenous
223655070|NCT04690023|PROCEDURE|Pericapsular nerves group (PENG) block|Patients scheduled for total hip arthroplasty with spinal anesthesia receive before intra-thecal injection, ultrasound-guided PENG block with injection 20 ml of ropivacaine 0,75%, between the anterior hip articular capsule, the ilii-psoas muscle, the ileo-pubic eminence and the antero-inferior iliac spine.
223655071|NCT04690023|PROCEDURE|Supra-inguinal fascia-iliaca compartment block|Patients scheduled for total hip arthroplasty with spinal anesthesia receive before intra-thecal injection, ultrasound-guided supra-inguinal fascia iliaca compartment block with injection over de inguinal ligament of 40 ml of ropivacaine 0,375%, between de ilio-psoas muscle and internal oblique muscle.
223655072|NCT04690023|DRUG|Ropivacaine 0,75% in PENG block|20 ml injection of ropivacaine 0,75%
223655073|NCT04690023|DRUG|Ropivacaine 0,375% in SFICB block|40 ml injection of ropivacaine 0,375%
223655074|NCT06428968|DRUG|160 units nasal insulin spray|Initially, a series of MRI scans, including high-resolution T1-weighted anatomical images, diffusion tensor imaging, resting-state functional MRI, and arterial spin labeling, will be conducted. Subsequently, 160 units of nasal insulin spray will be administered, followed by a second round of MRI scans after a 30-minute interval, encompassing high-resolution T1-weighted anatomical images, resting-state functional MRI, and arterial spin labeling.
224238482|NCT03130699|BEHAVIORAL|Dulce Digital|One-size-fits-all educational text messages, with patient monitoring and transmission of blood glucose values.
223655075|NCT00829504|DRUG|Ropinirole HCl 0.25 mg Tablets|1 x 0.25 mg
223655076|NCT00829504|DRUG|Requip® 0.25 mg Tablets|1 x 0.25 mg
223655077|NCT03212144|OTHER|High Intensity Interval Training|Subjects will exercise according the the high intensity aerobic interval training regiment four times a week for four weeks
223655078|NCT03212144|OTHER|Peanut Consumption|Subjects will consume peanuts twice a day to replace 20% of their daily caloric intake for four weeks.
223655079|NCT06052319|DEVICE|Care4Today® Connect CAD-PAD Mobile Application|Participants will not receive any drug intervention in this study. Participants will use Care 4Today® Connect CAD-PAD mobile application for 3 months. The study will assess participant engagement and usefulness.
224238483|NCT03130699|BEHAVIORAL|Dulce Digital-Me (Automated Delivery)|Educational text messages, with patient monitoring and transmission of blood glucose values, plus personalized goal-setting and tailored feedback delivered via automated algorithm-driven messaging, incorporated into existing primary care team processes.
223655080|NCT05462379|PROCEDURE|Ovarian graft|Before the beginning of pelvic radiotherapy, one of the ovaries will be removed by laparoscopy. Ovary slices of 1-2 mm will be prepared in sterile environment and engrafted in the fatty tissue of inner tight. One representative fragment will undergo histologic evaluation. These procedures will be done in the same surgical time.
223655081|NCT03882255|DRUG|Ponesimod dose range (2 - 20 mg)|Participants will receive ponesimod oral tablet at a dose of 2 mg in Treatment period 1 and as an up-titrating regimen (dose range: 2mg-20mg) in Treatments period 2.
223655082|NCT03882255|DRUG|Placebo Propranolol|Participants will be administered placebo propranolol oral capsule from Day 1 to Day 19 in Treatment A of Treatment period 2.
223655083|NCT03882255|DRUG|Propranolol 80 mg|Participants will receive propranolol 80 mg long acting oral capsule from Day 1 to Day 19 in Treatment B of Treatment period 2.
223655084|NCT03214510|DRUG|Bupivacaine|Given via thoracic epidural catheter or TAP block
223655085|NCT03214510|DRUG|Fentanyl|Given via thoracic epidural catheter
223655086|NCT03214510|DRUG|Hydromorphone Hydrochloride|Given via thoracic epidural catheter
223655087|NCT03214510|DEVICE|Implanted Medical Device|Undergo placement of thoracic epidural catheter
223655088|NCT03214510|DEVICE|Implanted Medical Device|Undergo placement of ultrasound-guided, four-quadrant transversus abdominus plane block
223655089|NCT03214510|DRUG|Liposomal Bupivacaine|Given via TAP block
223655090|NCT03214510|BEHAVIORAL|Questionnaire|Ancillary studies
223655091|NCT05994261|DEVICE|Cereset Research|The upgraded platform for medical research using the HIRREM technology has been rebranded as Cereset Research® (CR). This system uses the same core technology and algorithms to echo brainwaves in real-time using audible tones, as with HIRREM. The CR system also includes 64-bit processing architecture for faster feedback, the use of 4 sensors, and the use of standard protocols (with flexibility regarding the length and sequencing of the standard protocols), all done with eyes closed. Four sensors are applied to the scalp at a time. However, only two sensors are actively echoing feedback. The software automatically switches from one sensor pair to the other when needed. This reduces the number of sensor placement changes needed, resulting in shorter session time and fewer interruptions.
223655092|NCT06209580|DRUG|AMT-253 for injection|Administered intravenously
223655093|NCT00930033|PROCEDURE|Nephrectomy|Current surgery
223655094|NCT00930033|OTHER|Sunitinib alone|Sunitinib alone without nephrectomy
223655095|NCT06044727|PROCEDURE|Minimally invasive non surgical periodontal therapy|using Magnifying loupes
224238484|NCT03130699|BEHAVIORAL|Dulce Digital-Me (Medical Assistant)|Educational text messages, with patient monitoring and transmission of blood glucose values, plus personalized goal-setting and tailored feedback delivered by Medical Assistants, incorporated into existing primary care team processes.
224238485|NCT05461547|DIAGNOSTIC_TEST|Lung Ultrasound|LUS will be performed and interpreted in real-time to guide acute management.
224238486|NCT05461547|OTHER|Usual Care|Usual care to decide diagnosis and treatment
224238487|NCT02468024|PROCEDURE|Lung Surgery|Sublobar Lung Resection
224238488|NCT02468024|RADIATION|Radiation therapy|Stereotactic Ablative Radiotherapy, 54 Gy in 3 fractions
224238489|NCT01199861|DRUG|Fingolimod|Fingolimod 0.5 mg capsules for oral administration.
224320938|NCT06163235|OTHER|Obemar platform|Online platform for education and follow-up
223655096|NCT06044727|PROCEDURE|Conventional subgingival instrumentation|Conventional subgingival instrumentation
223655097|NCT07115121|DRUG|Intravenous Ferric Carboxymaltose|Patients were given ferric carboxymaltose as a maximum single dose of 1000 mg diluted in 250 mL of sterile 0.9% normal saline as a slow infusion over 45 minutes.
223655098|NCT07115121|DRUG|Intravenous Iron Sucrose|Patients received intravenous injections of iron sucrose complex, which contained 200 mg of elemental iron (equivalent to 2 ampoules of 5 ml), mixed in 100 ml of 0.9% normal saline and infused over a period of 30 minutes every other day for up to 5 doses.
223655099|NCT06654180|DEVICE|Orthokeratology|Orthokeratology is to a rigid contact lens with reverse design to flat the central cornea to correct the myopia, which is to use at night during sleep; DIMS and SVS are both spectacles to wear at daytime; DIMS has many tiny lenses at peripheral of the big lenses to make the peripheral retina myopic defocus during the daytime; SVS has only one focus while DIMS has many focuses made by the tiny segments lenses around the peripheral vision fields; DISK is a soft contact lens with peripheral myopic power design to make the myopic eyes defocus at peripheral during the daytime.
224238490|NCT01199861|DRUG|Placebo|Matching placebo capsules for oral administration.
224238491|NCT01199861|BIOLOGICAL|Seasonal influenza vaccine|Commercially available injectable influenza vaccine for the 2010/11 influenza season.
224238492|NCT01199861|BIOLOGICAL|Tetanus toxoid vaccine|Commercially available tetanus toxoid vaccine booster injection.
224320939|NCT05732103|DRUG|CTX-712|CTX-712 will be provided as a 20 mg tablet for oral administration. Patients will take CTX-712 once or twice weekly, depending on their dose level assignment, during each 28-day cycle.
223655100|NCT06654180|DEVICE|defocus-incorporated multiple segment lenses (DIMS) spectacles|It is the special lenses with peripheral lots of tiny segments of plus lenses around the center
223655101|NCT06654180|DEVICE|DISK|SVS
223655102|NCT06654180|DEVICE|Single-focus spectacles|Myopic Glasses with mono-focus in each eye
223655103|NCT02102204|DRUG|Etelcalcetide|Etelcalcetide was supplied as a sterile, preservative-free, ready-to-administer aqueous solution.
223655104|NCT05957471|DRUG|Drug: BC3195 for Injection|BC3195 via intravenous(IV).
223655105|NCT01426841|RADIATION|Adaptive Radiation|Thoracic Radiotherapy which is adapted or adjusted during its course to account for tumor volume shrinkage which occurs during treatment
223655106|NCT04230135|DEVICE|Hap-pas-Hapi|Hap-pas-Hapi is a Smartphone-based intervention for the treatment of psychological distress. It includes five sessions and uses a narrative approach. Behavioural activation is the main active therapeutic agent in the intervention, along with stress management, positive self-talk, mood tracking, social support, and relapse prevention.
223655107|NCT00609531|DRUG|Citalopram|Pill, 5-20mg once a day for twelve weeks
223655108|NCT00609531|DRUG|Placebo|Placebo pill once a day for twelve weeks
223655109|NCT01111578|DEVICE|Enteral feeding tube|The esophageal and gastric pressure, measured with this new device, will be recorded and compared with those ones measured with a standard esophageal catheter
223767984|NCT06563323|DRUG|Guselkumab|Subjects with PG will be treated with 100 mg in a pre-filled syringe to be injected subcutaneously every 4 weeks for 28 weeks.
223767985|NCT01126541|DRUG|rituximab|Arm A: 1000 mg IV (one infusion) every 2 months \\nArm B: 2 x 1000 mg IV (2 infusions) every 2 months
223767986|NCT03533400|DEVICE|Jamboxx Respiratory Therapy Device|Jamboxx Respiratory Therapy Device is a novel device that uses interactive gaming to encourage patient compliance with their prescribed respiratory therapy routines. The device consists of a computer game controller with mouthpiece containing a breath flow sensor that connects to a tablet. With the Jamboxx respiratory therapy device, users can choose from a suite of breath controlled respiratory therapy games to guide them through their routines while receiving real-time feedback, and long-term progress tracking.
223767987|NCT03533400|DEVICE|Jamboxx Musical Device|Jamboxx musical device is a hands free, breath controlled music device designed for people with quadriplegia. It resembles a common harmonica in that the user slides a mouthpiece along its horizontal axis to change the pitch of the instrument. The device connects to a personal computer via a mini USB to USB cable to interface with software that provides visual feedback for playing notes and sends the information to the computer speakers. The mouthpiece acts as a transducer, changing air pressure created by the user's lungs to a joystick signal to the computer via a differential pressure sensor. The Jamboxx musical device can produce musical sounds of many instruments (trumpet, drums, etc.) in many different scales and in any key
223767988|NCT01532687|DRUG|Gemcitabine|Given IV
223767989|NCT01532687|DRUG|Gemcitabine Hydrochloride|Given IV
223767990|NCT01532687|OTHER|Laboratory Biomarker Analysis|Correlative studies
223655110|NCT04199130|BEHAVIORAL|BrainHQ|"BrainHQ is a web-based brain-training program. The investigators will assign participants to attention specific modules that they will complete at home with the goal of restoring attentional functions lost through injury via repetitive tasks of graded difficulty."
223655111|NCT04199130|BEHAVIORAL|Goal Management Training|"This is a manualized, interactive, metacognitive-strategy training designed to promote a mindful approach to complex real-life tasks and reduce lapses in attention via implementation of compensatory mechanisms for monitoring tasks."
223655112|NCT02460796|OTHER|Hippotherapy|The sessions began with a 5 minutes warm up that involved stretching and body awareness exercises. Then, the training was conducted for 20 minutes with arms and torso exercises, changes of direction called serpentine movements; up and down hip movements with feet on stirrups, and forced expiration. In the final 5 minutes, exercises for relaxation were conducted with the horse which involved moving the hand on the horse's neck, laying forward on the head and stroking the horse. The horses walking speed was between 5.8 and 6.4 Km/h.
223655113|NCT04319692|DIETARY_SUPPLEMENT|Fermented Prunus Mume Vinegar group|This group takes Fermented Prunus Mume Vinegar for 8 weeks
223655114|NCT04319692|DIETARY_SUPPLEMENT|Placebo group|This group takes placebo for 8 weeks.
223655115|NCT02260180|DRUG|A-101|Topical Solution
223655116|NCT01043289|OTHER|Light therapy|During the 5-week treatment period, subjects sit in front of a light box for 60 minutes daily after awakening, at a specified distance that provides the required light intensity.
223767991|NCT01532687|DRUG|Pazopanib|Given PO
224238493|NCT05055921|DEVICE|Multi Pulse Therapy as delivered from the Cardialen External Stimulation System|"The Cardialen External Stimulation System (CESS) is the research delivery system for the proprietary Cardialen MultiPulse Therapy (MPT). The CESS is a custom designed and built research device. It is comprised of off-the-shelf commercial components (power supplies, waveform generators, laptop computer, monitor, rack, ECG system, leads, etc.) combined with a custom electrical circuit board and custom software.~Other Names:~* Unpinning Termination Therapy~* Multi-stage therapy~* Multi-stage electrotherapy~* MultiPulse Therapy"
224238494|NCT00917033|DEVICE|GlideScope|Orotracheal intubation
223655117|NCT00611403|DRUG|Cyclosporine Ophthalmic Emulsion 0.05% (RESTASIS®)|Cyclosporine Ophthalmic Emulsion 0.05% administered twice daily in each eye for 6 months following LASIK surgery
223655118|NCT00611403|DRUG|Artificial Tears REFRESH ENDURA®|REFRESH ENDURA® administered twice daily in each eye for 6 months following LASIK surgery
223655119|NCT03945604|DRUG|SHR-1210 + Apatinib +Fluzoparib|SHR-1210 will be administered as an intravenous infusion Apatinib tablets will be given orally Fluzoparib capsule will be given orally 28 days per cycle, until disease progression or unacceptable toxicity.
223767992|NCT01532687|DRUG|Pazopanib Hydrochloride|Given PO
223767993|NCT01532687|OTHER|Placebo Administration|Given PO
223767994|NCT05972434|OTHER|Sunscreen A|Participants will apply sunscreen A topically.
224238495|NCT00917033|DEVICE|Macintosh direct laryngoscope|Orotracheal intubation
224238496|NCT04534283|DRUG|Abemaciclib|Subjects will receive Abemaciclib 150 mg orally twice daily until disease progression, unacceptable toxicity, or patient preference to withdraw from study.
223767995|NCT05972434|OTHER|Sunscreen B|Participants will apply sunscreen B topically.
223767996|NCT03844191|DRUG|RUC-4 Compound|single subcutaneous administration of RUC-4
223767997|NCT04502771|DRUG|Antifungal treatment|Treatment by fluconazole, voriconazole,posaconazole or caspofungin during the patient stay in Intensive Care Unit
223767998|NCT03861468|OTHER|Care pathway|Screening for OSA using a combination of bicarbonate assay and STOP-BANG questionnaire and further management by a pneumologist as necessary
223767999|NCT01423513|OTHER|Fibular Taping|Tape with be applied with tension.
224238497|NCT04534283|DRUG|LY3214996|Subjects will recieve LY3214996 200 mg orally daily until disease progression, unacceptable toxicity, or patient preference to withdraw from study.
223768000|NCT01423513|OTHER|Sham Taping|Tape will be applied without tension
223768001|NCT05494125|OTHER|Ropivacaine|Patients will receive a continuous infusion of ropivacaine through bilateral ESP catheters
223768002|NCT05494125|OTHER|Placebo|Patients will receive a continuous infusion of saline solution through bilateral ESP catheters
224238498|NCT00661505|DRUG|methoxy polyethylene glycol-epoetin beta|120, 200 or 360 micrograms iv every 4 weeks (starting dose)
223655120|NCT05127746|DRUG|Aricept 5mg Tablet|1 tablet once daily
223655121|NCT05127746|DRUG|Aricept 10mg Tablet|1 tablet once daily
223655122|NCT05127746|DRUG|DA-5207 A|1 patch once weekly
223655123|NCT05127746|DRUG|DA-5207 B|1 patch once weekly
223655124|NCT04952155|DRUG|IL-2|The administration period was divided into 6 courses. 6 cycles of IL-2 were administered subcutaneously at a dose of 1 million IU every other day for 2 weeks, followed by a 2-week break in treatment. The adminstration course was 24 weeks.. The 24-week follow-up period was followed after the treatment.
223655125|NCT01710540|OTHER|Metformin GSK 850mg|EVALUATE BIOEQUIVALENCE BETWEEN METFORMIN 850 MG TABLETS MANUFACTURED BY SAVIPHARM J.S.C, VIETNAM AND GLUCOPHAGE® 850 MG TABLETS MANUFACTURED BY MERCK SANTE S.A.S.2, RUE DU PRESSOIR VERT-45400 SEMOY-FRANCE AND BE REGISTERED IN VIETNAM IN HEALTHY, ADULT, HUMAN MALE SUBJECTS UNDER FASTING CONDITION
223655126|NCT01710540|OTHER|Gluocophage 850mg|EVALUATE BIOEQUIVALENCE BETWEEN METFORMIN 850 MG TABLETS MANUFACTURED BY SAVIPHARM J.S.C, VIETNAM AND GLUCOPHAGE® 850 MG TABLETS MANUFACTURED BY MERCK SANTE S.A.S.2, RUE DU PRESSOIR VERT-45400 SEMOY-FRANCE AND BE REGISTERED IN VIETNAM IN HEALTHY, ADULT, HUMAN MALE SUBJECTS UNDER FASTING CONDITION
223655127|NCT00129844|DRUG|Motexafin Gadolinium|
224238499|NCT04544371|DEVICE|gastric ultrasound|Focused gastric ultrasound was performed in semi-sitting position then right lateral position mindray curved transducer for examination of abdomen with low frequency (2-5 MHz) by a trained physician. The antrum of the stomach was located in the epigastrium after a sweep of the probe from left to right subcostal margins. This could be done using left lobe of liver as an anterior landmark and descending abdominal aorta as a posterior landmark
223655128|NCT03817047|BEHAVIORAL|Physical education|"Physical education (60 minutes): In addition to the ordinary PE-lessons. The pedagogical activities taught in this lesson should be in line with the curriculum of 9th grade and led by the PE-teacher. In the Don't worry - be happy intervention this class was also organized by the students. The students practiced their Be Happy-activities, or they introduced their class peers to their Be Happy-activity. A PE-teacher was present to support the students if necessary."
223655129|NCT03817047|BEHAVIORAL|Physical active learning|The curriculum of the subjects (i.e. maths, English, Norwegian) were taught in a physically active manner. The lesson should last 30 minutes and be led by the teacher of the current subject.
223655130|NCT03817047|BEHAVIORAL|Physical activity|"Without a connection to any specific subject Physical activity should be performed as 30 minutes a week. There are no specific aims to be taught in this lesson, but physical activities that stimulates mastery, joy and well-being should be in focus."
223655131|NCT03817047|BEHAVIORAL|Be happy|The Be Happy classes were self-organized activity groups of at least three students, developed according to activity preferences across regular classes. The Be Happy groups practiced traditional sports and physical activities, lifestyle sports, dancing, out-door recreation, drama etc. - inside or outside school.
223655132|NCT00632788|OTHER|acute myocardial infarction checklist|For every patient fulfilling the criteria of enrollment, an acute myocardial infarction checklist was incorporated into the patient's medical records at emergency department immediately after a diagnosis of acute ST-elevation myocardial infarction was made. All the time sequences concerning different managements at different locations were recorded by nurses and/or physicians as instructions on the checklist.
223655133|NCT06348290|DRUG|JMKX001899|Oral
223655134|NCT06348290|DRUG|Itraconazole|Oral
223655135|NCT06348290|DRUG|Midazolam|Oral
223655136|NCT06348290|DRUG|Rifampin|Oral
223655137|NCT06348290|DRUG|dextromethorphan|Oral
223655138|NCT06348290|DRUG|Rosuvastatin|Oral
223655139|NCT06348290|DRUG|digoxin|Oral
223655140|NCT02375061|BEHAVIORAL|e-BPS|
223655141|NCT02375061|BEHAVIORAL|Daily Activities|
223655142|NCT03860818|OTHER|Health services delivery|Technology-enabled pharmacist intervention
223655143|NCT03126344|DEVICE|King Vision video laryngoscope|nasal intubation using King Vision video laryngoscope Device after general anesthesia induction
223655144|NCT03126344|DEVICE|McGrath MAC video laryngoscope|nasal intubation using McGrath MAC video laryngoscope Device after general anesthesia induction
223655145|NCT03126344|DEVICE|Macintosh laryngoscope|nasal intubation using Macintosh laryngoscope Device after general anesthesia induction
223655146|NCT05344404|DIETARY_SUPPLEMENT|Nicotinamide Riboside|3000mg total daily. Administered in capsule form in doses of 1500mg twice daily for the duration of the trial (4 weeks).
223655147|NCT05344404|DIETARY_SUPPLEMENT|Placebo|Placebo drug. Administered in tablet form twice daily for the duration of the trial (4 weeks).
223655148|NCT03664596|DIETARY_SUPPLEMENT|Sublimated mare's milk|Supplement obtained through sublimation of mare milk, packed into one-dosage sachet (20g), and dissolved in a warm water (36 degrees of Celcius).
223655149|NCT03664596|DRUG|Ursodeoxycholic Acid|Ursodeoxycholic acid in the form of 250 mg capsule.
223655150|NCT01936441|BEHAVIORAL|Cognitive Behavioral Therapy-Insomnia (CBT-I)|See Experimental Arm Description
223655151|NCT01936441|BEHAVIORAL|Menopause Education Control (MEC)|See Experimental Arm Description
223655152|NCT03052400|DRUG|Mifepristone 600 mg daily|Glucocorticoid receptor antagonist
223655153|NCT03052400|DRUG|Placebo|Matching placebo
223655154|NCT00555061|DRUG|Retapamulin Ointment, 1%|1% Ointment
223655155|NCT02309905|DEVICE|Telemedicine|Inmates of prisons having telemedicine after implementation of telemedicine
223655156|NCT00951613|DRUG|NK012|30 minute IV infusion once every 28 days. NK012 dose is 28 mg/m\^2 (or 18 mg/m\^2 depending on UGT1A1 polymorphism, with potential to dose escalate). Dose escalation cannot exceed 28 mg/m\^2. Dosing will proceed until progression or unacceptable toxicity develops, or decision by patient or investigator to stop.
223655157|NCT00047164|BIOLOGICAL|ipilimumab|
223655158|NCT04466579|OTHER|BIS monitor|BIS monitor is used to control and monitor the depth of general anesthesia.
223655159|NCT04466579|OTHER|Standard care|Standard anesthesiology care according to the protocol of the study
223655160|NCT02527603|PROCEDURE|Boss-Holzach-Matter method|The patient holds both his hands around his knees in a supine position until the dislocated shoulder is reduced
223655161|NCT02527603|PROCEDURE|Spaso method|The physician holds the dislocated arm of the patient in a supine position and proceeds with gentle, soft movements of adduction, flexion and external rotation of the limb in this order until reduction is accomplished.
224238500|NCT04544371|PROCEDURE|nasogastric tube insertion|Nasogastric tube (18-french) was inserted after induction of anaesthesia and endotracheal intubation. Aspiration of gastric contents was performed through gentle suction using 50 ml syringe with synchronous epigastric massage and gentle movement of nasogastric tube in and out for 10 minutes after confirmation of nasogastric tube position.
224238501|NCT06307028|BEHAVIORAL|SISTA-P Intervention|This intervention is a small group discussion designed specifically for Black women. The sessions cover topics including: self pride and self-care; HIV \& PrEP education; assertiveness skills training; coping skills; skills practice; and barriers and facilitators to HIV prevention and PrEP.
223655162|NCT02527603|DRUG|Anti-Inflammatory Agents, Non-Steroidal|"All patients will be administered a dose of NSAI intra-muscular or orally (Dexketoprofen, Enantyum®) it is part of the normal treatment of these patients to cope with pain."
223655163|NCT03893461|RADIATION|x|Stereotactic body radiation therapy for localized NSCLC
223655164|NCT01668862|BIOLOGICAL|Autologous Human Platelet Lysate|Subjects will receive one injection of Autologous Human Platelet Lysate in the lateral epicondyle space
223655165|NCT01668862|DRUG|Corticosteroid|Subjects will receive one injection of Corticosteroid in the lateral epicondyle space
223655166|NCT04119830|BIOLOGICAL|Pembrolizumab|Given IV
224238502|NCT00669864|DRUG|biphasic insulin aspart 30|Subcutaneous (under the skin) injection, twice daily
224238503|NCT00669864|DRUG|metformin|Tablets, 1000 - 2000 mg daily
224320940|NCT06075745|DRUG|CMV-MVA Triplex|The dosage used will be 5.0 x 10\^8 pfu, administered under sterile conditions intramuscularly. The CMV-MVA Triplex vaccine lots range in titre from 5.0 to 9.0 x 10\^8 pfu/mL in a supplied volume of 1.0 mL
224320941|NCT06075745|DRUG|Placebo for CMV-MVA Triplex|Arm 2 participants receive two doses of matching placebo CMV-MVA Triplex
223655167|NCT04119830|OTHER|Questionnaire Administration|Ancillary studies
223655168|NCT04119830|DRUG|Rintatolimod|Given IV
223655169|NCT02682225|DRUG|Intravenous placebo|Participants will receive placebo, 40-minute, intravenous infusion on Day 1 of Sequence 1, on Day 2 of Sequence 2, on Day 1 of Period 1 in Sequence 3, 5 and 6, on Day 1 of Period 2 in Sequence 3, 4 and 6, on Day 1 of Period 3 in Sequence 4, 5 and 6, and on Day 1 of Period 4 in Sequence 3, 4 and 5.
223655170|NCT02682225|DRUG|Intranasal placebo|Participants will receive placebo, intranasally, on Day 1 or Day 2 in Sequence 1 and 2, on Day 1 of Period 1 in Sequence 3 and 4, on Day 1 of Period 2 in Sequence 4 and 5, on Day 1 of Period 3 in Sequence 3 and 6 and on Day 1 of Period 4 in Sequence 5 and 6.
223655171|NCT02682225|DRUG|Intravenous racemic ketamine|Participants will receive 0.5 mg/kg racemic ketamine, intranasally, on Day 2 in sequence 1, on Day 1 in sequence 2, on Day 1 of Period 1 in Sequence 4, on Day 1 of Period 2 in Sequence 5, on Day 1 of Period 3 in Sequence 3, and on Day 1 of Period 4 in Sequence 6.
223655172|NCT02682225|DRUG|Esketamine 112 mg|Participants will receive 112 mg of Esketamine, intranasally, on Day 1 of Period 1 in Sequence 6, on Day 1 of Period 2 in Sequence 3, on Day 1 of Period 3 in Sequence 5, and on Day 1 of Period 4 in Sequence 4.
223655173|NCT02682225|DRUG|Esketamine 84 mg|Participants will receive 84 mg of Esketamine, intranasally, on Day 1 of Period 1 in Sequence 5, on Day 1 of Period 2 in Sequence 6, on Day 1 of Period 3 in Sequence 4, and on Day 1 of Period 4 in Sequence 3.
223655174|NCT01396447|DRUG|Placebo|Placebo was supplied in capsules.
223655175|NCT01396447|DRUG|Cariprazine|Cariprazine was supplied in capsules.
223655176|NCT04463992|BEHAVIORAL|Program participants|The intervention is a 12-month telephonic program in which a lay health worker (LHW), supervised on-site by a registered nurse practitioner (RNP), assessed patient symptoms after diagnosis using the validated Edmonton Symptom The intervention is a 12-month telephonic program in which a lay health worker (LHW), supervised on-site by a registered nurse practitioner (RNP), assessed patient symptoms after diagnosis using the validated Edmonton Symptom Assessment Scale (ESAS) (cite) with the frequency of symptom assessment varying based on patient risk.
223655177|NCT04463992|OTHER|Usual Care|Usual care as provided by local oncologists
223655178|NCT03080896|DEVICE|King Vision video-laryngoscope with #3 disposable blade and endotracheal tube stylet|intubation using King Vision video-laryngoscope with #3 disposable blade with stylet convert to intubation with video-laryngoscope and fiber-optic bronchoscope bronchoscope (aScope III) for failure to intubate after three attempts
223655179|NCT03080896|DEVICE|fiberoptic bronchoscope aScope III|Intubation using the videolaryngoscope/fiberoptic bronchoscope (aScope III)
223655180|NCT00476853|DRUG|HAART containing nevirapine|Initially NVP 200 mg BID (400 mg per day) was compared to 400 mg BID and 200 mg OD NVP (600 mg per day). 400 mg/day versus 600 mg/day.
223655181|NCT02649751|DRUG|Roscovitine|Roscovitine is an experimental drug candidate in the family of pharmacological cyclin-dependent kinase (CDK) inhibitors that preferentially inhibit multiple enzyme targets including CDK2, CDK7 and CDK9. Seliciclib is a 2,6,9-substituted purine analog.
223655182|NCT02649751|DRUG|Placebo|The placebo treatment is lactose capsule.
223655183|NCT04881942|OTHER|e-Vapor Product A|e-Vapor product XL25F
223655184|NCT04881942|OTHER|e-Vapor Product B|e-Vapor product XL40CB
223655185|NCT04881942|OTHER|e-Vapor Product C|e-Vapor product XL35WM
223655186|NCT04881942|OTHER|e-Vapor Product D|e-Vapor product XL40MB
223655187|NCT04214691|DRUG|Acetaminophen|Acetaminophen tablet will be administered orally in treatment sequence 1 and 2.
223655188|NCT00097656|OTHER|multi-center, randomized, controled periodontal therapy|periodontal therapy
223655189|NCT05106153|DRUG|Suvorexant|Suvorexant will be administered orally as per assigned treatment sequence.
223655190|NCT05106153|DRUG|Zolpidem|Zolpidem will be administered orally as per assigned treatment sequence.
223655191|NCT05106153|DRUG|Seltorexant|Seltorexant will be administered orally as per assigned treatment sequence.
224238504|NCT00450307|BIOLOGICAL|monoclonal antibody 3F8|
224238505|NCT00450307|BIOLOGICAL|sargramostim|
224320942|NCT03823742|OTHER|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy (CBT): Study treatments for the child will be conducted by a psychologist or master's level therapist. Therapists will be provided with a standardized protocol for each session . CBT treatment will be given over 1 hour, once a week, for three weeks .
224320943|NCT03823742|OTHER|Low FODMAP Diet|Low FODMAP Diet Condition: Subjects will receive detailed education by a dietitian about following a low FODMAP diet including a definition of FODMAPs, how to select low FODMAP foods, and how to read food labels to identify FODMAPS. The dietitian will contact the family for 1 hour, once a week, for three weeks.
224320944|NCT03996447|DRUG|gadopiclenol|single intravenous (IV) bolus injection at a rate of 2ml/second
224320945|NCT03996447|DRUG|Gadobutrol 1Mmol/mL Solution for Injection Vial|single intravenous (IV) bolus injection at a rate of 2ml/second
223655192|NCT05106153|DRUG|Placebo|Placebo will be administered orally as per assigned treatment sequence.
224238506|NCT01326403|DRUG|Tranexamic acid|"GROUP A - receive IV Tranexamic acid 1 gram upon diagnosis and consent in the emergency room. A second 1 gram in a slow drip during the next 8 hours.~GROUP B - IV Tranexamic acid 1 gram five minutes before skin incision and a second 1 gram in a slow drip during the next 8 hours.~Group C - A control group will only receive placebo in the emergency room and in the OR."
223655193|NCT06311617|DIAGNOSTIC_TEST|Optical coherence tomography|Non-mydriatic fundus photography and optical coherence tomography will be performed at 3 timepoints
223655194|NCT05227170|OTHER|Lactobacillus Plantarum 299v Freeze Dried Capsule|The intervention is a probiotic lactobacillus that is contained in food products in the US
223655195|NCT05227170|OTHER|Freeze Dried Potato Starch Capsule|The intervention is potato starch that is freeze dried designed to mimic the lp299v capsule.
224238507|NCT04259229|OTHER|Mediterranean Diet -- Mushrooms|During the 2-week baseline period all participants will consume their usual, unrestricted self-chosen diets. During intervention weeks 1-8, all participants will consume the same Mediterranean-style diet, rich in fruits and seafoods and lower in dairy, designed to meet their estimated energy needs. The mushroom group will consume 0.5 cups/day of cooked mushrooms (white button mushrooms and yellow oyster mushrooms on 4 and 3 days/week, respectively). All foods will be provided to subjects during the intervention to achieve the desired eating pattern.
224238508|NCT04259229|OTHER|Mediterranean Diet -- Control|During the 2-week baseline period all participants will consume their usual, unrestricted self-chosen diets. During intervention weeks 1-8, all participants will consume the same Mediterranean-style diet, rich in fruits and seafoods and lower in dairy, designed to meet their estimated energy needs. The control group will not consume mushrooms at any point. All foods will be provided to subjects during the intervention to achieve the desired eating pattern.
224238509|NCT05742529|PROCEDURE|TIP|TIP An 8F straight sound is passed into the hypospadiac meatus to assess skin coverage over the urethra., a circumscribing incision is made 2 mm proximal to the meatus, a U-shaped incision is extended proximally to healthy skin The key step in the operation is a midline relaxing incision made from within the meatus to the distal extent of the plate. This incision extends through the epithelial surface of the plate deeply into underlying connective tissues down to the corpora cavernosaNext, a 6F stent is passed into the bladder for postoperative urinary diversion. Then the urethral plate is tubularized. , stitches are ever taken further distally to ensure the neomeatus has a generous oval openingticular closures. .
224320946|NCT06148623|DEVICE|Philips FAST SpO2 with Masimo Pulse Oximetry Sensors|Noninvasive pulse oximeter
224320947|NCT04269551|DRUG|BIVV020|Pharmaceutical form:solution for injection Route of administration: intravenous
223655196|NCT05741164|PROCEDURE|Biopsy|Undergo tumor biopsy
223655197|NCT05741164|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223655198|NCT05741164|PROCEDURE|Computed Tomography|Undergo CT scan
223655199|NCT05741164|BIOLOGICAL|Pembrolizumab|Given IV
223655200|NCT05741164|DRUG|Propranolol|Given PO
223655201|NCT05741164|OTHER|Questionnaire Administration|Ancillary studies
223655202|NCT02905851|OTHER|Feedback group|Monitoring ability to use teledermatology to modify antibiotic burden
223655203|NCT02905851|OTHER|Non Feedback group|To use as control to see if antibiotic burden has been reduced in the active feedback group
223655204|NCT02333617|OTHER|Dry Needling|Dry Needling will be performed on the patient's ipsilateral gluteus medius muscle with the patient in sidelying. The treating therapist will use the appropriate needle based upon patient's size and location of trigger point \[No. 5 (0.25 x 40mm), No. 8 (0.30 x 50mm), or No. 11 (0.30 x 75mm)\]. They will target trigger points identified in the ipsilateral gluteus medius. Once the needling is inserted into the trigger point the needle will be moved in multiple directions until the first local twitch response is noted. Once the first local twitch response is obtained, the needling will be performed in an up-and-down fashion, performing 2- to 3-mm vertical motions with no rotations (fast-in and fast-out technique), at approximately 1 Hz for 25 to 30 seconds, with the aim of eliciting local twitch responses. The treating therapist can dry needle each trigger point identified in the gluteus medius with a maximum treatment time of 5 minutes.
223655205|NCT02333617|OTHER|Soft Tissue Mobilization|Soft tissue mobilization will be performed on the patient's ipsilateral gluteus medius muscle with the patient in sidelying. The treating therapist will apply firm pressure with the palm and side of their hand. The treating therapist will mobilize the gluteus medius muscle in 4 separate directions (Proximal-Distal, Distal-Proximal, Medial-Lateral, and Lateral-Medial). The treating therapist will apply the pressure to reach the upper limit of the patient's tolerable discomfort. At any point in time the patient can request for the therapist to decrease the pressure applied. The treating therapist will perform soft tissue mobilization for 20 mobilizing strokes in each of the 4 directions.
223655206|NCT02333617|OTHER|Placebo Control|Treating therapist will place hands on the patient's gluteus medius muscle and gently rub, but not apply enough pressure to treat the muscles trigger point. This placebo control is designed to account for hands on time from therapist in the 2 other treatment groups, as well as blinding patient to treatment group.
223655207|NCT02333617|OTHER|Hip and core strengthening exercises|Patient will perform standardized hip and core exercises using body weight, and elastic bands for resistance. Exercises will take approximately 40 minutes to complete.
224320948|NCT03814252|DEVICE|MRI-TULSA|"The technology is developed to ablate targeted prostate tissue through transurethrally inserted probe that transmit ultrasound energy under MRI guidance and control. The therapeutic endpoint of this method is thermal coagulation of prostate tissue.~TULSA-PRO (Profound Medical Inc, Toronto, Canada): PAD-105, integrated into a 3 Tesla MR-system (Ingenia 3.0 Tesla, Philips Healthcare, Best, Netherlands)"
224320949|NCT04846517|DEVICE|Transcranial Magnetic Treatment|"iTBS treatment: Trains of 50 Hz pulses every 200 ms lasting 2 s, with an 8 s intertrain interval (ITI), repeated 60 times 1800 total pulses each day Treatment Duration: 9 minutes Location: Left DLPFC~LF-rTMS treatment: Delivered immediately after iTBS treatment as described above.~SMA will involve a continuous train of 1 Hz stimulation for a total of 1200 pulses lasting 20 minutes Treatment Duration: 20 minutes Location: SMA"
224320950|NCT05292326|DEVICE|PacePress|an electronically-controlled compression site which, thanks to a well-selected compression force, may contribute significantly to preventing hemorrhagic complications following electrotherapy procedures, including to increasing safety of CIED implantation procedures and accelerate wound healing significantly
223655208|NCT04745572|BEHAVIORAL|High Carbohydrate Diet|Participants randomized to this group will participate in a group-based weight behavioral management program and consume a high carbohydrate (HC) diet. Because this protocol uses a sequential, multiple assignment, randomized trial (SMART) design, response will be assessed at week 4. Responders will continue with their 1st stage assignment for the remainder of the study. Non-responders will be randomized to 2nd stage intervention of either combine HC diet with time-restricted eating (TRE) or HC diet with additional exercise counseling and support.
223655209|NCT04745572|BEHAVIORAL|Reduced Carbohydrate Diet|Participants randomized to this group will participate in a group-based behavioral weight management program and consume a reduced carbohydrate (RC) diet. Because this is a sequential, multiple assignment, randomized trial (SMART) design, response will be assessed at week 4. Responders will continue with their 1st stage assignment for the remainder of the study. Non-responders will be randomized to 2nd stage intervention of either combine RC diet with time-restricted eating (TRE) or RC diet with additional exercise counseling and support.
223655210|NCT06373354|DEVICE|Digital Breast Tomosynthesis (DBT)|Undergo tomosynthesis imaging
223655211|NCT01349959|DRUG|Azacitidine|Given SC
223655212|NCT01349959|DRUG|Entinostat|Given PO
223655213|NCT01349959|OTHER|Laboratory Biomarker Analysis|Correlative studies
223655214|NCT01349959|OTHER|Pharmacological Study|Correlative studies
223655215|NCT02675634|DEVICE|Coloplast Test A|Test A is a new 1-piece ostomy appliance developed by Coloplast A/S
224320951|NCT05292326|DEVICE|standard compression band|standard used compression band/sand bag
224320952|NCT05620238|DRUG|Carfilzomib|Investigate the home administration of Carfilzomib IV reported by both patients and health care staff compared to the hospital setting.
224320953|NCT04648449|OTHER|Artificial intelligence on emergency calls|AI listens to all calls to Bergen EMCC, detecting calls regarding possible stroke.
223655216|NCT02675634|DEVICE|Coloplast Test B|Test B is a new 1-piece ostomy appliance developed by Coloplast A/S
223655217|NCT02675634|DEVICE|Subjects own product|The comparator product is the ostomy appliance product that the subject normally uses. This could include products like SenSura , SenSura Mio, Confidence Natural, Moderma Flex and many more. data from the subject own product will be pooled so they appear as one comparator group.
223655218|NCT01652534|DRUG|Amantadine|Amantadine 100mg daily, for a week, if it is tolerated Amantadine will increase to 1 tab twice a day. Amantadine will then be administered orally twice daily in the morning with breakfast and at noon with lunch (AM and NN).
223655219|NCT01652534|DRUG|Placebo|Sugar Pill
223768003|NCT03865121|DRUG|Nicotine Nasal Spray 10 MG/ML (0.5 MG/SPRAY)|Patients will receive incremental doses of Nicotine Nasal Spray 10 MG/ML (0.5 MG/SPRAY) starting with 3 bilateral puffs per day (3 mg total) for 3 days, followed by 5 bilateral puffs per day (5 mg) for 3 days, followed by 8 bilateral puffs per day (8 mg) for 4 days, followed by 10 bilateral puffs per day (10 mg) for 10 days.
224320954|NCT05656781|OTHER|Brief Intervention and Contact (BIC) based on Word Health Organization (WHO)|Intervention based on: Clinical WHO - SUICIDE PREVENTION DOCUMENT MULTISITE INTERVENTION STUDY ON SUICIDAL BEHAVIOURS - SUPRE-MISS: PROTOCOL OF SUPRE-MISS. Brief Intervention and Contact with participants using follow up questions about mood or any suicide attempts.
223655223|NCT00261820|DRUG|tacrolimus|
223655224|NCT00261820|DRUG|mycophenolate mofetil|
223655225|NCT00261820|DRUG|methylprednisolone|
223655226|NCT00261820|DRUG|prednisolone|
223655227|NCT00261820|DRUG|sirolimus|
223655228|NCT01085994|OTHER|Literature search|Literature search followed by systematic review and meta-analysis
223655229|NCT00731302|DRUG|aspirin and meloxicam|aspirin 81 mg daily then aspirin 81 mg plus meloxicam 7.5 mg daily
223655230|NCT02663401|BEHAVIORAL|Front-of-pack labelling 5-CNL|Introduction of the 5-CNL Front-of-pack nutrition label on shelf display tags for every food and beverage sold in the cafeteria
223655231|NCT05997303|OTHER|Continuous norepinephrine infusion via an infusion pump|Patients will be randomized 1:1 to continuous norepinephrine infusion via an infusion pump or to manual bolus norepinephrine administration. The norepinephrine dose will be at the discretion of the treating anesthesiologists.
223655232|NCT05997303|OTHER|Manual bolus norepinephrine administration|Patients will be randomized 1:1 to continuous norepinephrine infusion via an infusion pump or to manual bolus norepinephrine administration. The norepinephrine dose will be at the discretion of the treating anesthesiologists.
223655233|NCT03082625|DRUG|Transdermal Magnesium|Magnesium
223655234|NCT03082625|DRUG|Placebo|
223655235|NCT06338137|DEVICE|Holmium Yag laser|Use two laser energy low and high to reach the optimal setting for stone dusting
223655236|NCT00122551|PROCEDURE|Intermittent antiretroviral therapy|
223655237|NCT04140513|RADIATION|Fludeoxyglucose F-18|Given via injection
223655238|NCT04140513|PROCEDURE|Positron Emission Tomography|Undergo dPET
223655239|NCT03067714|OTHER|Infant formula with added synbiotics|Intervention group: Infant Formula / Follow-On formula with partially hydrolysed cow's milk protein supplemented with prebiotics and probiotics.
223655240|NCT03067714|OTHER|Standard infant formula|Control group: Standard Infant Formula / Follow-On formula with intact cow's milk protein (only standard ingredients, without addition of pre- and probiotics).
223655241|NCT00905801|OTHER|CT Perfusion|Subjects will be examined with a CTP Imaging protocol which comprises repeated CT-scans of the tumor over a period of 50 seconds following the injection of a 30cc bolus of an FDA-approved low osmolar, iodinated CT contrast agent using a 64 row-multidetector row CT unit (LightSpeed VCT, GE Healthcare, Milwaukee, WI). One scan will be acquired every 3 seconds over a 50s period at 100 kV, and 100mA tube current. With this method, a 4cm long segment of the tumor can be analyzed, and 32 images of a slice thickness of 1.25 mm reconstructed simultaneously. Images will be evaluated using standard CT blood flow software (Perfusion 2, AW, GE Health Care, Milwaukee, WI).
223655242|NCT00201188|BEHAVIORAL|Status Reports|Interpreted Analysis of Peak-Flow Monitoring Trends
223655243|NCT05163626|BEHAVIORAL|Combined aerobic exercise and cognitive training program|Participants will take part in a combined aerobic exercise and cognitive training program. The program will include moderate cycling exercise and cognitive game resolving at the same time. The tasks will be instructed and supervised by a fitness expert and a trained clinical neuropsychologist.
223655244|NCT02757716|OTHER|Questionnaire|Every patient who undergo surgery will fill out a questionnaire containing validated scales concerning food, alcohol, nicotine, internet and exercise and drug addiction prior, 6 months and 24 months after surgery.
223655245|NCT02328638|BEHAVIORAL|Parent Education Program|The PEP intervention consists of didactic sessions regarding basic information about Autism Spectrum Disorders.
223655246|NCT02328638|BEHAVIORAL|Manual-based Behavioral Treatment|The Manual-based Interdisciplinary Behavioral Treatment consists of nutritional and behavioral interventions to improve dietary intake (increase water, decrease sweetened beverages and snack foods, improve balanced diet), increase exercise, and teach behavioral strategies to address barriers to these goals.
224238510|NCT05742529|PROCEDURE|STITCH BY STITCH|SBS in brief Operative technique :starts with penile degloving, preparation of the flap (Site of hypospadic meatus is determined after degloving). Creation of a narrow strip of the urethral plate with wide glanular wings is done using bilateral incisions which are extended to the tip of the glans. The width of the urethral plate is about 3 mm then we suture the flap to the narrow urethral plate in two layers in continuous manner using vicryl 6/0 over a suitable plastic catheter. Triangular (Vshape) area of the distal part of the flap is excised a the midline. After this we anastomose the flap to thetip of the glans. The glans appears opened in the midline as inverted V shape. Closure of the glans is finished in the midline using three mattress interrupted sutures with another three simple stitches are used in between
223655247|NCT01765257|DRUG|AZILECT®|
223655248|NCT01765257|DRUG|Placebo|
223655249|NCT02105961|DRUG|Mepolizumab|Humanised IgG antibody (IgG1, kappa) with human heavy and light chain frameworks, provided as a lyophilised cake in sterile vial. Vial to be reconstituted with Sterile Water for Injection, just prior to use.
224238511|NCT00462852|DRUG|dalteparin|
224238512|NCT00462852|DRUG|gemcitabine hydrochloride|
224238513|NCT00462852|OTHER|diagnostic laboratory biomarker analysis|
224238514|NCT06063135|OTHER|Physical Exercise Intervention|Two strength training session per week and one endurance training session per week
223655250|NCT02105961|DRUG|Placebo|Sterile 0.9percent sodium chloride solution
223655251|NCT03860259|DEVICE|Auriculotherapy cryopuncture device without nitrogen gas|Auriculotherapy cryopuncture device without nitrogen gas will be administered. In addition, an interscalene block will be performed as well as standard of care treatment for surgery, post-operative pain management and physical therapy
223655252|NCT03860259|DEVICE|Auriculotherapy cryopuncture device with nitrogen gas|Auriculotherapy cryopuncture device with nitrogen gas will be administered. In addition, an interscalene block will be performed as well as standard of care treatment for surgery, post-operative pain management and physical therapy
223655253|NCT05482100|DIAGNOSTIC_TEST|Patients monitored with OmniGraf testing|This is an observational study there are no protocol mandated interventions. OmniGraf results will be utilized in conjunction with standard of care assessments to determine patient management.
223655254|NCT04607317|BEHAVIORAL|Exercise program|a telehealth-delivered exercise program with the goal of progressing to 150 min/week (5 days per week, 30 minutes of steady state walking per day)
223655255|NCT04607317|BEHAVIORAL|Health Coach|The coach will work directly with each participant during their once-weekly virtual 1:1 meeting to progress intensity and duration. Participants will meet with the coach to review a brief social cognitive theory-based module, which will provide education on core behavior change concepts and the benefits of physical activity for those with epilepsy. The coach will review the previous week's exercise during meetings, and will then work with the participant to revise and reset goals for the coming week.
223655256|NCT04607317|BEHAVIORAL|Health Information|Participants will be contacted by a study coordinator via telephone every 2 weeks for health education. During this time, they will review resources and healthy lifestyle guidelines for people with epilepsy, including healthy diet, medication compliance, seizure precautions, stress management, and sleep hygiene.
223655257|NCT05613465|DRUG|Codonopsis|Codonopsis pilosula Nnannf is oral liquid, which has been approved for listing
223655258|NCT05613465|DRUG|Placebo|Placebo is packaged in the same package as the drug
223655259|NCT05512156|OTHER|Supervised Toothbrushing|"* Recruitment, consent, and Questionnaires (Behaviors, Quality of Live, Cost Analysis) distribution.~* Inclusion \& Exclusion Criteria Applied~* Baseline Dental examination~* Toothbrushes \& Toothpastes Home and school use packs delivery-Colgate (six pack per child a year- child soft toothbrush with a1450ppm fluoridated toothpaste))~* Supervised teachers training~* Three months intervals monitoring visits~* 12months Follow up and Questionnaires (Behaviours) distribution~* Endpoint dental Examination and Questionnaires (Behaviours, Quality of Live, Cost Analysis) distribution"
223655260|NCT00158418|PROCEDURE|Cemented Humeral Stem|
223655261|NCT00158418|PROCEDURE|Uncemented Humeral Stem|
223655262|NCT00811018|DRUG|Sitaxsentan|Sitaxsentan 100 mg tablets once daily
223655263|NCT03792906|DRUG|Norepinephrine 6 mcg|An intravenous bolus of norepinephrine 6 mcg will be administered for management of maternal hypotension.
223655264|NCT03792906|DRUG|Norepinephrine 10 mcg|An intravenous bolus of norepinephrine 10 mcg will be administered for management of maternal hypotension.
223655265|NCT03792906|DRUG|Norepinephrine infusion|Prophylactic norepinephrine infusion will be started after subarachnoid block.
223655266|NCT03792906|DRUG|Bupivacaine hydrochloride|Subarachnoid block will be performed using Bupivacaine hydrochloride (2.2 mL) in addition to fentanyl 25 mcg.
223655267|NCT01558648|BEHAVIORAL|Quality of Life instruments, FACT-E, Symptom Assessment Scale, Brief Pain Inventory and Daily Analgesic Log|Initial pre-operative assessment post-operative assessment in-hospital assessment at first post-operative visit (clinic visits, or by telephone or mail) assessments at 4, 8, 12, 18, and 24 months post-operatively (+/- 2 month window). For patients who have their surgery delayed, they may be asked to complete another, more updated set of pre-surgery surveys. For the dysphagia score and CT Scan vs EUS subset will be a dysphagia questionnaire, administered at the time of the initial clinic visit.
223655268|NCT01558648|BEHAVIORAL|Quality of Life instruments, FACT-E, Symptom Assessment Scale, Brief Pain Inventory and Daily Analgesic Log|Initial pre-operative assessment post-operative assessment in-hospital assessment at first post-operative visit (clinic visits, or by telephone or mail) assessments at 4, 8, 12, 18, and 24 months post-operatively (+/- 2 month window). For patients who have their surgery delayed, they may be asked to complete another, more updated set of pre-surgery surveys. For the dysphagia score and CT Scan vs EUS subset will be a dysphagia questionnaire, administered at the time of the initial clinic visit.
224238515|NCT00535106|DEVICE|Automated external defibrillator (Philips FR2+ AED)|Patients in this arm will be provided with immediate defibrillatory shock coupled with otherwise standard resuscitative efforts.
224238516|NCT00535106|DEVICE|SmartCPR|Patient in this arm will be treated with standard resuscitation efforts except that the first AED analysis will utilize an waveform-based algorithm to recommend either immediate defibrillation or delayed defibrillation for each patient.
224238517|NCT00535106|OTHER|Delayed defibrillation|In New York City only, all patients not initially treated by study personnel will receive other regional standard for resuscitation - delayed defibrillation.
223655269|NCT00162019|DRUG|Human Plasma-Derived Coagulation Factor VIII Concentrate (Virus Inactivated by Polysorbate 80 Treatment and Vapor Heat Treatment)|
223655270|NCT04420104|PROCEDURE|erector spinae plane block|ESP Block: Bilateral ESP block and with ultrasound guidance will be applied A total 40 ml, 20 ml bupivacaine 0.5%, 20 ml saline.
223655271|NCT04420104|DRUG|iv analgesia|iv contromal
223655272|NCT04978298|OTHER|Placebo|Placebo
223655273|NCT04978298|DRUG|Rasigiline|Rasigiline
223655274|NCT04978298|DRUG|Phenelzine|Phenelzine
223655275|NCT04978298|DRUG|Ozanimod|Ozanimod
223655276|NCT04495920|DRUG|CGB-S-100|Alcohol and choline geranate
223655277|NCT00272532|DRUG|Thiocolchicoside|
223768004|NCT03160703|OTHER|Stannous fluoride (SnF2, 0.454%), Sodium tripolyphosphate (STP, 5%), 2.0% abrasive silica|Participants will apply a full brush head of their dentifrice containing 0.454% SnF2 / 5% STP; 2.0% abrasive silica (RDA\~58) and will brush twice daily (morning and evening) for one timed minute (in their usual manner) and expectorate.
223768005|NCT03160703|OTHER|Stannous fluoride (SnF2, 0.454%), Sodium tripolyphosphate (STP, 5%), abrasive silica (3.5%)|Participants will apply a full brush head of their dentifrice containing 0.454% SnF2 / 5% STP; 3.5% abrasive silica (RDA\~77) and will brush twice daily (morning and evening) for one timed minute (in their usual manner) and expectorate.
223768006|NCT03160703|OTHER|Sodium Monofluorophosphate (1000 ppm fluoride ), RDA~80|Participants will apply a full brush head of their dentifrice containing 1000 ppm fluoride as SMFP with moderate abrasivity (RDA\~80) and will brush twice daily (morning and evening) for one timed minute (in their usual manner) and expectorate.
223768007|NCT03160703|OTHER|Stannous fluoride (SnF2, 0.454%), RDA~120|Participants will apply a full brush head of their dentifrice containing 0.454% SnF2 with higher abrasivity (RDA\~120) and will brush twice daily (morning and evening) for one timed minute (in their usual manner) and expectorate.
224238518|NCT02385097|DRUG|Chloroprocaine HCl 2%|Single Administration (20mL) by Axillary Nerve Route
224238519|NCT02385097|DRUG|Ropivacaine 0.75%|Single Administration (20mL) by Axillary Nerve Route
224238520|NCT01303978|DRUG|APD421|Single dose
224238521|NCT03473314|DRUG|Nitric Oxide gas at 160ppm|Nitric oxide gas at 160 ppm inhaled three times daily for 50-80 min delivered with air as the carrier via inhalation for a maximum total of 90 days (extended 365 days twice). Total dose of 480 ppm hours per day.
224238522|NCT01822548|DRUG|Vildagliptin|100 mg daily
224238523|NCT01822548|DRUG|Glibenclamide|2.5 mg (total daily), progressively increased up to a maximum dose of 5 mg x 2/ day.
224238524|NCT01822548|DRUG|Metformin|concomitant therapy with metformin is present in each arm (MAX dose: 2500 mg/die)
224238525|NCT03229655|PROCEDURE|Protocol for increasing number of stents across the anastomosis|Sequential placement of straight plastic biliary stents across the duct-to-duct anastomosis without dilation or stent exchange. Multiple ERCPs will be performed with addition of a single stent at each ERCP until the final ERCP when all stents will be removed.
224238526|NCT02809183|DRUG|Placebo|oral suspension
224238527|NCT02809183|DRUG|TRC101|oral suspension
223655278|NCT01356251|BEHAVIORAL|Questionnaires & online virtual support group|Part 1 surveys mesothelioma patients' psychological and physical symptom burden and quality of life by administering a set of questionnaires that covers topics including coping, interpersonal support, mood, anxiety, and overall quality of life. All mesothelioma patients who complete the questionnaires in part 1 will be offered an opportunity to participate in a trial of a therapeutic Internet-based discussion group. The groups will consist of either approximately 3-5 surgical patients or approximately 3-5 non-surgical patients. The groups will run for approximately 60 minutes once a week for six consecutive weeks.
223655279|NCT01356251|BEHAVIORAL|Questionnaires & online virtual support group|Part 1 surveys mesothelioma patients' psychological and physical symptom burden and quality of life by administering a set of questionnaires that covers topics including coping, interpersonal support, mood, anxiety, and overall quality of life. All mesothelioma patients who complete the questionnaires in part 1 will be offered an opportunity to participate in a trial of a therapeutic Internet-based discussion group. The groups will consist of either 3-5 surgical patients or 3-5 non-surgical patients. The groups will run for approximately 60 minutes once a week for six consecutive weeks.
223655280|NCT01662609|PROCEDURE|Endoscopic Ultrasound (EUS)|Ultrasound scope will be passed through the participant's mouth into their stomach and their pancreas will be evaluated completely by the ultrasound scope. If an abnormality is found in their pancreas, a biopsy may be performed to obtain a diagnosis.
223655281|NCT00271453|DRUG|Durogesic® (fentanyl transdermal drug delivery system)|
223655282|NCT01976091|GENETIC|SRP-9004|Isolated Limb Infusion (ILI)
223655283|NCT03042819|DRUG|Selinexor|Selinexor is a Selective Inhibitor of Nuclear Export (SINE) compound that binds and inactivates Exportin 1 (XPO1), thereby forcing the nuclear retention of key tumor suppressor proteins (TSPs).
224238528|NCT02860481|PROCEDURE|blood sample for FSHR analysis|
223655284|NCT03042819|DRUG|Doxorubicin|Doxorubicin is currently approved for various cancers. Doxorubicin inhibits DNA synthesis and repair by inhibiting topoisomerase II and also by intercalation between base pairs on the DNA helix. These actions result in the blockade of DNA and RNA synthesis and fragmentation of DNA.
223655285|NCT01802996|DRUG|Magnesium Isoglycyrrhizinate Injection|200mg IV on day 1-5
223655286|NCT02252796|RADIATION|Hypofractionated Stereotactic Boost|An ablative dose of radiation is delivered to the primary tumor target over a week through Stereotactic Ablative Radiotherapy.
223655287|NCT02252796|DRUG|Carboplatin|Given during chemo-radiation phase and optional consolidative phase.
224238529|NCT02860481|PROCEDURE|blood sample for FSHR analysis|
224238530|NCT02545998|OTHER|Telehealthcare|Telephone consultation plus e-mail with attached PAAP and video link
224238531|NCT05187026|OTHER|electronic PROMs questionnaire|Patients are asked to complete EPIC-26 questionnaire in paper and electronically
223655288|NCT02252796|DRUG|Paclitaxel|Given during chemo-radiation phase and optional consolidative phase.
223655289|NCT02252796|RADIATION|Image-guided IMRT|Given during chemo-radiation phase
223655290|NCT04565639|DEVICE|Powered Hand Orthosis|A prototype powered hand orthosis system designed to improve grip strength and improve ability to perform tasks of daily living.
223655291|NCT00934362|DRUG|Lucinactant first|lucinactant 120 mg (20 mg/ml) x 5 doses over 24 hours, then washout period x 14 days, then vehicle x 5 doses over 24 hrs
223655292|NCT00934362|DRUG|Placebo first|6 mL normal saline x 5 doses over 24 hours, then washout period x 14 days, then lucinactant x 5 doses over 24 hours
223655293|NCT00540852|DEVICE|Diffuse Optical Spectroscopy Imaging|Diffuse Optical Spectroscopy Imaging
223655294|NCT03472261|DRUG|Botulinum toxin type A|Dysport
223655295|NCT03472261|OTHER|Upper extremity orthoses|Twister
223655296|NCT03472261|OTHER|Home exercise program|Specific exercises for pronation deformity
223655297|NCT06268756|OTHER|Data collection|Data collection
223655298|NCT02170103|PROCEDURE|percutaneous intervention (PCI)|Successful PCI with the patent vessel and at least Thrombolysis in Myocardial Infarction (TIMI) 2 flow in the left anterior descending artery (LAD) post-PCI.
223655299|NCT02170103|DRUG|Microbubbles|The agents will be divided into two separate doses (two vials per study), and mixed with approximately 29 milliliters of saline (approximately a 2.0-4.0% infusion). The first dilution will be administered pre PCI therapy, and the second dilution infused immediately post PCI. Since Optison is less stable in saline, an alternative approach will be to give the Optison as intermittent 0.1 milliliter boluses followed by 3-5 saline flushes over 10 seconds. The entire duration of each treatment before PCI will be up to 30 minutes depending on time constraints in getting to the catheterization laboratory, while the duration of treatment immediately after PCI will be 30 minutes.
223655300|NCT02170103|PROCEDURE|Ultrasound|Intermittent high Mechanical Index (MI) impulses (0.8-1.4 MI; Frequency 1.0-1.7 MegaHertz (MHz); pulse duration 4-44 microseconds) will be administered over the microvasculature where there are wall motion abnormalities and a perfusion defect using an imaging plane that best aligns itself with the risk area
223655301|NCT00631943|DRUG|Pregabalin (Lyrica)|Oral pregabalin (Lyrica) capsules, initial dose of 75 mg twice daily, which could be increased to 300 mg twice daily at the discretion of the investigator. Patients were treated for up to 21 days.
224238532|NCT03091946|OTHER|Overnight oats with additional dried fruits, nuts and seeds|Oatmeal
224238533|NCT03091946|OTHER|Cooked cream of rice with additional dried fruits, nuts and seeds|Cooked cream of rice
224238534|NCT02942966|DEVICE|Tack Endovascular System|Repair of post-PTA dissections using the Intact Vascular Tack Endovascular System.
223655302|NCT04223219|DRUG|Fentanyl|"* Induction of anesthesia : Midazolam 2 mg, Fentanyl 3 µg/kg, propofol 50-100 mg and Atracurium 0.5 mg/kg.~* Maintenance of anesthesia (intraoperative until tracheal extubation):~Maintenance will be achieved by isoflurane with concentration 0.5-1.5 % with 40% oxygen. During cardiopulmonary bypass by continuous infusion of Propofol at a rate of 2 mg/kg/hr. and Atracurium at a rate of 10 g/kg/min.~* The patients will receive fentanyl infusion at a rate of 1 µg/kg/h and fentanyl bolus 20-40 µg according to patient hemodynamics. (tachycardia: increase of heart rate \>20% of baseline or hypertension: increase of blood pressure \>20% of baseline).~* After tracheal extubation:~all the patients will receive standard analgesia (i.v. paracetamol 1 gm every 12 hours and i.v. ketorolac 30 mg every 12 hours) and morphine patient controlled analgesia with bolus dose = 2 mg, lockout interval = 10 minutes, 4-hour dose limit = 10 mg, with no background infusion."
223681015|NCT01125787|DRUG|ofatumumab + bendamustine|Loading dose of ofatumumab at 300mg IV with subsequent doses at 100mg IV on D1 of all cycles (maximum of 6 cycles) in combination with bendamustine 90mg/m2 on day 2 of all cycles. Neulasta 6mg SQ will also be given on day 8 of cycle 1 only.
223681016|NCT01663077|DRUG|Clozapine|A fixed dose of Clozapine 300 mg/day (150 mg x 2)for 3 month
223681017|NCT02359175|DRUG|Bupivacaine in epidural catheter|Bupivacain to be given in epidural catheter
224320955|NCT03336736|DIAGNOSTIC_TEST|Exercise|"The study design will be a prospective cross-sectional observational project, with no intervention.~Data on a participant's physical activity levels, physical fitness and quality of life will be collected using physical testing and questionnaires."
224320956|NCT00305474|DRUG|Risperidone|Risperidone will be given in low dosage to a random sample of family members of Schizophrenic patients
224320957|NCT02580110|OTHER|Sucrose|
223681018|NCT02359175|DRUG|Fentanyl in epidural catheter|Fentanyl to be given in epidural catheter
223681019|NCT02359175|DRUG|Placebo (for Bupivacain and Fentanyl i epidural catheter)|Saline to be given in epidural catheter
223681020|NCT02359175|DRUG|Oral Paracetamol|Paracetamol to be given orally
223681021|NCT02359175|DRUG|Oral NSAID|NSAID to be given orally
223681022|NCT02359175|DRUG|Oral opioids|Opioids to be given orally
223681023|NCT02359175|DRUG|Placebo (for oral opioids)|Placebo tablets to be given instead of oral opioids
223681024|NCT01076894|PROCEDURE|epidural anesthesia|In the epidural group prior to the induction of general anesthesia, a thoracic epidural catheter will be was placed at the level of the TH6-TH8. 8 ml ropivacaine 1% were administered through the epidural catheter. EDA is aimed at a sensory block level from TH2 to TH10.
223681025|NCT01076894|PROCEDURE|intercostal anesthesia|In the intercostal group, before chest closure, each 4 ml ropivacaine 0.75 % will be injected by the surgeon under direct vision into the proximal intercostal space at the level of the thoracotomy and two spaces above and below as well as 5 ml ropivacaine 0,75 % at the thoracic drainage tube exits
223681026|NCT00976118|DRUG|masitinib (AB1010)|oral masitinib 3 or 6 mg/kg/day
223681027|NCT00976118|DRUG|placebo|matching placebo to masitinib
223655303|NCT04223219|DRUG|Fentanyl, Propofol|"* Induction of anesthesia : Midazolam 2 mg, Fentanyl 3 µg/kg, propofol 50-100 mg and Atracurium 0.5 mg/kg.~* Maintenance of anesthesia (intraoperative until tracheal extubation):~Maintenance of anesthesia will be achieved by isoflurane with concentration 0.5-1.5 % with 40% oxugen. During cardiopulmonary bypass by continuous infusion of Propofol at a rate of 2 mg/kg/hr. and Atracurium at a rate of 10 g/kg/min.~* The patients will receive fentanyl bolus 20 µg/hr and propofol 20 mg at the time of surgical stimulation and according to patient hemodynamics (repeated as required).~* After tracheal extubation:~all the patients will receive standard analgesia (i.v. paracetamol 1 gm every 12 hours and i.v. ketorolac 30 mg every 12 hours) and morphine patient controlled analgesia with bolus dose = 2 mg, lockout interval = 10 minutes, 4-hour dose limit = 10 mg, with no background infusion."
223655304|NCT04223219|DRUG|Dexmedetomidine, Ketamine, Magnesium sulfate|"* Induction of anesthesia : Midazolam 2 mg, Fentanyl 3 µg/kg, propofol 50-100 mg and Atracurium 0.5 mg/kg.~* Maintenance of anesthesia (intraoperative until tracheal extubation):~Maintenance of anesthesia will be achieved by isoflurane with concentration 0.5-1.5 % with 40% oxygen. During cardiopulmonary bypass by continuous infusion of Propofol at a rate of 2 mg/kg/hr. and Atracurium at a rate of 10 g/kg/min.~* The patients will receive infusions of dexmedetomidine 0.2 µg/kg/h, ketamine 2 µg/kg/min, and magnesium sulfate 5 mg/kg/h.~* After tracheal extubation:~all the patients will receive standard analgesia (i.v. paracetamol 1 gm every 12 hours and i.v. ketorolac 30 mg every 12 hours) and morphine patient controlled analgesia with bolus dose = 2 mg, lockout interval = 10 minutes, 4-hour dose limit = 10 mg, with no background infusion."
224238539|NCT05802966|BEHAVIORAL|Mindfulness-Based Cognitive Therapy|MBCT will be offered according to the MBCT manual developed for relapse prevention in MDD (Zindel V. Segal, Williams, \& Teasdale, 2002). Thus, MBCT will consist of 8-weekly sessions of 2,5 hours, a 6-hour silent day, and daily home practice (± 45min). MBCT will be taught by a certified MBCT teacher meeting the advanced criteria of the Association of Mindfulness Based Teachers in the Netherlands and Flanders (Belgium) which are in concordance with the Good Practice guidelines of the UK Network of Mindfulness-Based Teacher Trainers (Crane et al., 2012).
224238540|NCT00858910|OTHER|Motor imagery (MI) training|MI training encloses the internal rehearsal of a known motor skill without any overt motor output.
223655305|NCT00629369|DEVICE|Extra 3 mouth guard, Shock doctor mouth guard v3.0|Dental mouthguard, molded for each individual patient when in labor. The device is put in the water then in microwave for one minute to soften the device. The device is then applied to the patient's mouth for over 10 seconds to mold it.
223655306|NCT04551872|BEHAVIORAL|Digital weight loss intervention|Participants with obesity enter into a proven 6 month weight loss program that utilizes health coaching and goal-setting. It is a remote intervention that is delivered entirely over their phones. Participants will also receive a FitBit and electronic scale.
224238541|NCT00858910|OTHER|Control intervention|"The control intervention encloses relaxation and breathing exercises, and information about:~* the disease (stroke),~* therapy options,~* self-help groups and their offers for support,~* helping aids for independent living at home."
223655307|NCT02290678|BEHAVIORAL|Adventure-based Programming|
223655308|NCT01092117|DEVICE|Ovation™ Abdominal Stent Graft System|Implant of Ovation™ Abdominal Stent Graft System
223655309|NCT01526759|DIETARY_SUPPLEMENT|LM pectin (10%)|15 days 1 daily consumption of a drink with 10g pectin added
223655310|NCT01526759|DIETARY_SUPPLEMENT|gelatin|15 days 1 daily consumption of a drink with 10g gelatin added
223655311|NCT04133688|DEVICE|ASC|mobile app
224238542|NCT05295758|BEHAVIORAL|PAL2|"Community health worked based intervention to mitigate psychosocial and life circumstance barriers to optimize health promotion coupled with high blood pressure and lifestyle disease state education~Other Names:~Pragmatic personalized, adaptable approach to lifestyle and life circumstance"
224238543|NCT03955770|COMBINATION_PRODUCT|High-flow oxygen therapy (HFOT)|HFOT will be applied by a dedicated large bore nasal cannula (Optiflow+, Fisher\&Paykel, New Zealand) at a flow rate 60 L/min, FiO2 45%, temperature 32 °C, using a HFOT device (myAIRVO2, Fisher\&Paykel, New Zealand).
224238544|NCT03955770|COMBINATION_PRODUCT|Low-flow oxygen therapy (LFOT)|LFOT will be provided by a standard nasal cannula at a flow rate of 3 L/min using an oxygen concentrator (EverFlow, Philips Respironics).
224238545|NCT05090657|COMBINATION_PRODUCT|methylene blue 0.01%/chlorhexidine gluconate 0.25% + light activation|After topical application photosensitive solution bilateral nasal light diffusers will be inserted into each nostril and two 2-minute non-thermal light applications of 670 nm light will be used to activate the photosensitizer to achieve an oxidative burst to destroy pathogens.
224238546|NCT04366609|DRUG|Methylphenidate|Treatment with methylphenidate through dose escalation
224238547|NCT00854321|DRUG|rituximab|rituximab two 1000 mg intravenous infusions separated by two weeks
224238548|NCT00854321|DRUG|rituximab, observational study amon patients with active RA|two 1000 mg intravenous infusions separated by 2 weeks
224238549|NCT03319056|OTHER|Air purifier|active- or sham-mode air purifier used in 6 classrooms in a school with a crossover design
224238550|NCT05282888|OTHER|blood sample|in order to develop a diagnostic assay using an innovative technology by imaging flow cytometry to identify red blood cell morphological anomalies in the diagnosis flowchart of anemia.
223655312|NCT05911685|DEVICE|SeaLA™ left atrial appendage occluder|"1. Guided by esophageal ultrasound (TEE) and angiography, the diameter of the left atrial appendage anchoring zone and the longest depth of the left atrial appendage were measured to determine the appropriate size of the left atrial appendage occluder.~2. Maintain Activated Clotting Time (ACT) greater than 250 seconds after atrial septal puncture to the completion of the entire procedure.~3. Before the plugging device is released, confirm whether there is a residual peri-device leak, and if there is a residual peri-device leak, consider retracting the occluder to reposition the release or retract the occluder to choose a larger size occluder to re-occlusion. If ultrasound confirms residual peri-device leak greater than 5 mm, do not release and implant the left atrial appendage occluder.~4. Before and after release, confirm the position and stability of the occluder under ultrasound (TEE), and confirm that the occluder completely occludes the left atrial appendage."
223655313|NCT03367078|DEVICE|Anodal tDCS|Anodal tDCS, on L-DLPFC area, is started 2 weeks after admission to the sABI Operative Unit with: one session per day (in the morning), possibly for 5 consecutive days per week (from Monday to Friday), for 2 consecutive weeks. Each tDCS session lasts 20 minutes. Current intensity is 1 mA during the first week, 2 mA in the second week
223655314|NCT03367078|OTHER|Usual care|Usual care of DOC patients
223768008|NCT01570075|PROCEDURE|HR|SR was carried out under general anesthesia using a right subcostal incision with a midline extension. Intra-operative ultrasonography was performed routinely to evaluate the tumor burden, liver remnant, and the possibility of a negative resection margin. Anatomic resection, in the form of segmentectomy and/or subsegmentectomy as described by Makuuchi et al. (16) was the preferred surgical method of liver resection. Pringle's maneuver was routinely used with a clamp and unclamp time of 10 min and 5 min, respectively; this technique was used repeatedly throughout the entire procedure.
223768009|NCT01570075|PROCEDURE|RFA|For PRFA, we used a commercially available system with a 375-KHz computer-assisted radiofrequency generator (Elektrotom HiTT 106, Berchtold, Medizinelektronik, Germany) and an open-perfused electrode (Berchtold, Tuttlingen, Germany) of 15 cm (or 20 cm), 14 Ga, and a 15 mm (or 20 mm) active electrode tip with microbores.
223768010|NCT06562036|DRUG|Sildenafil|Patients were given oral sildenafil as 2 mg per kg per day, 6-hourly with an increment of 0.5 mg per kg per dose and a target maintenance dose of 2 mg per kg per dose every 6 hour by nasogastric tube.
224238551|NCT02463149|BEHAVIORAL|Youth Chef Academy|Nutrition and culinary curriculum delivered in the classroom
224238552|NCT01430741|BEHAVIORAL|Maintaining Independence and Sobriety Through Systems Integration, Outreach, and Networking (Veterans Edition)|MISSION-Vet has been developed to target mental health, substance abuse and related issues facing homeless Veterans through assertive outreach, psychoeducation, and linkages to community-based resources
224238553|NCT01430741|OTHER|Getting To Outcomes|"GTO strengthens the knowledge, attitudes, and skills practitioners need to carry out evidence based programs. GTO consists of a series of steps practitioners should follow in order to obtain positive results and then provides them with the guidance necessary to complete those steps with quality. According to GTO, carrying out an evidence based program includes a series of steps corresponding to three general areas: (1) planning - e.g., developing goals and performance targets, ensuring staff are trained in the evidence based program; (2) implementation - e.g., monitoring program activities, maintaining adherence to an evidence based program model, supervision; and (3) self-evaluation - e.g., tracking patient outcomes, using data to improve program operations."
224238554|NCT01430741|BEHAVIORAL|Maintaining Independence and Sobriety Through Systems Integration, Outreach, and Networking (Veterans Edition)|MISSION-Vet has been developed to target mental health, substance abuse and related issues facing homeless Veterans through assertive outreach, psychoeducation, and linkages to community-based resources
224238555|NCT01430741|OTHER|Getting To Outcomes|"GTO strengthens the knowledge, attitudes, and skills practitioners need to carry out evidence based programs. GTO consists of a series of steps practitioners should follow in order to obtain positive results and then provides them with the guidance necessary to complete those steps with quality. According to GTO, carrying out an evidence based program includes a series of steps corresponding to three general areas: (1) planning - e.g., developing goals and performance targets, ensuring staff are trained in the evidence based program; (2) implementation - e.g., monitoring program activities, maintaining adherence to an evidence based program model, supervision; and (3) self-evaluation - e.g., tracking patient outcomes, using data to improve program operations."
224238556|NCT01430741|BEHAVIORAL|Maintaining Independence and Sobriety Through Systems Integration, Outreach, and Networking (Veterans Edition)|MISSION-Vet has been developed to target mental health, substance abuse and related issues facing homeless Veterans through assertive outreach, psychoeducation, and linkages to community-based resources
224238557|NCT01623622|DRUG|HC-58|once or more / week
224238558|NCT01623622|DRUG|Placebo|once or more / week
224238559|NCT06004102|OTHER|reminder text message|The study aimed to assess the impact of text message reminders on medication adherence among kidney transplant recipients.
223655315|NCT04335019|OTHER|Pulmonary ultrasound|Pulmonary ultrasound results: quotation in 8 fields (right antero-superior, left antero-superior, right antero-inferior, left antero-inferior, right postero-superior, left postero-superior, right postero-inferior and postero-upper left).
223655316|NCT02138448|BEHAVIORAL|Interactive Preventive Health Record|The interactive preventive healthcare record (IPHR) is a patient-centered application that links patients to their clinician's record, explains information in lay language, displays tailored recommendations and educational resources, and makes preventive care actionable.
223768011|NCT06562036|DRUG|Milrinone|In this group, Milrinone was initiated at 0.5 ug per kg per minute using intravenous infusion through a syringe pump, and sildenafil was given in the same protocol mentioned for the Sildenafil Group.
223768012|NCT06198192|OTHER|Pilates Exercises|Ten repetitions of Pilates exercises will be performed with a 2-minute rest period between repetitions. Pilate group will receive the intervention program three times/week for total 10 weeks
224238560|NCT06272409|DRUG|DEP114|DEP114 oral solution
223655317|NCT06259370|BEHAVIORAL|Vigorous intermittent lifestyle physical activity|The specific exercise regimen involves performing rope jumping activities three times a day, with each session aimed at surpassing the exercise threshold (not conducted in a continuous manner), where the heart rate should exceed 160 beats per minute. This routine will be undertaken five times a week, continuously for a span of 8 weeks.
223655318|NCT04380519|DRUG|RPH-104 80 mg|solution for subcutaneous administration 40 mg/mL, 2 mL in the 4-mL glass vial
223655319|NCT04380519|DRUG|Olokizumab 64 mg|solution for subcutaneous administration 160 mg/mL, in the 2-mL glass vial (target volume 0,4 ml)
224238561|NCT06272409|DRUG|Desloratadine 0.5 MG/ML|Desloratadine oral solution
224238562|NCT00265304|DRUG|Ketoprofen|
224238563|NCT05047406|DIETARY_SUPPLEMENT|Bacillus clausii Probiotic liquid|mini bottles for oral administration containing 2 million spores of Bacillus clausii
224238564|NCT04826809|DEVICE|N95 mask|Standard 1870 N95 one time use mask
224238565|NCT04826809|DEVICE|Nordell single E-100 layer mask|Nordell mask design using one layer of E-100 fabric plus cotton fabric overlay
224238566|NCT04826809|DEVICE|Nordell double E-100 layer mask|Nordell mask design using two layers of E-100 fabric
224320958|NCT02580110|OTHER|Stevia glycosides|
224320959|NCT02580110|OTHER|saccharin|
223655320|NCT04380519|DRUG|Placebo|Normal Saline (0.9% Sodium Chloride solution for Injection), in the market package
224320960|NCT04643977|DEVICE|mARG-01-17 (mesohyal AGRIBENONE)|Dermal Filler
224320961|NCT01478412|OTHER|Polymer based fiducial placement|Fiducial marker placement with rectal ultrasound imaging.
224320962|NCT02291510|DRUG|Met DR|metformin delayed-release tablets
223655321|NCT03005899|DRUG|SyB P-1501|"After extubation and adequate titration by Fentanyl intravenous injection, the investigational product is applied to outer upper arm or chest on patient who confirmed treatment eligibility. Fentanyl 40 μg per dose is delivered over a 10-minute period by pressing the dosing button by the subject as needed. The 10-minute dosing period is a system lock-out time, allowing for a maximum of 6 doses per hour. One system is operable for 24 hours or until 80 doses are delivered, whichever occurs first.~Duration of application of the investigational product is 24 hours. Duration of application may be extended for up to 72 hours or until the third system is used, whichever occurs first, if the patient requests it and the specified tests can be performed"
223655322|NCT03005899|DRUG|SyB P-1501 placebo|Identical to SyB P-1501 containing hydrogel that contains the active ingredient fentanyl HCI in its structure and appearance but production of an electric current and subsequent drug administration by iontophoresis are prevented because of its modified circuit.
223655323|NCT04300166|DEVICE|Telemedicine & Humidification|Wireless control of CPAP usage, adherence, leakage and humidifier usage
223768013|NCT06198192|OTHER|Conventional Therapy and Balance Exercises|this group receive conventional therapy along with balance exercises. Standing with feet together while the therapist sitting behind and manually locking the child knees, and then slowly tilt him to each side, forward and backward. Step standing with therapist behind the child guiding him to shift his weight forward then backward alternately. High step standing and try to keep balanced. Standing with manual locking of the knees then tries actively to stoop and recover. Equilibrium, righting and protective reactions training. Open environment gait training will be conducted with the different obstacles. Session includes three times/week for total 10 weeks
224238567|NCT04835922|PROCEDURE|Intercostal Nerve Block|: Following PCNL Intercostal nerve block will be given at 11th and 12th Intercostal space on the side of surgery with 20cc of 0.25% bupivacaine under fluoroscopy guidance in prone position lateral to mid scapular line by Urologists. The 23 G spinal needle tip will be used and located above the innermost intercostal muscle. The needle tip will be located above the innermost intercostal muscle. In the next step, following negative aspiration for blood, 20 ml of 0.25% bupivacaine will be injected into the intercostal space between innermost intercostal muscle and pleura below 11th, and 12th ribs (10 ml each)
224238568|NCT04835922|PROCEDURE|Peritract Infiltration|At the end of PCNL a single dose of Peritract infiltration of 20cc of 0.25% bupivacaine will be given by Urologists. A 23 gauge spinal needle will be inserted up to the renal capsule along the nephrostomy tract at 6 and 12 o'clock (10ml at each position) under fluoroscopic guidance, 0.25 % bupivacaine will be infiltrated into the nephrostomy tract from renal capsule to the skin area (10 ml for each position).
223655324|NCT00158964|DEVICE|EASYTRAK 4 STEERABLE LV lead|
223655325|NCT00244543|DRUG|R89674 (generic name not yet established)|
223655326|NCT04316091|DRUG|neoadjuvant chemotherapy+SPIONs/SMF|Intratumoral injection of SPIONs, followed by SMF, combined with conventional neoadjuvant chemotherapy
223655327|NCT04316091|DRUG|neoadjuvant chemotherapy|Conventional neoadjuvant chemotherapy only
224238569|NCT04195165|BEHAVIORAL|SIT|For the SIT and SIT+EX conditions, the subject will be asked to take \<3,000 steps. This is meant to achieve \~12-13 hours of sitting per day, are the investigators are measuring the effect of inactivity and exercise on insulin sensitivity.
224238570|NCT04195165|BEHAVIORAL|ACTIVE|For the ACTIVE+EX condition, the subject will be asked to take \>10,000 steps for the two intervention days. This is meant to simulate an active lifestyle.
223655328|NCT02861001|DEVICE|conventional bronchoscopy|optical guidance of percutaneous tracheotomy is done by conventional bronchoscopy
223655329|NCT02861001|DEVICE|VivaSight-SL tube|optical guidance of percutaneous tracheotomy is done by the VivaSight-SL tube
223655330|NCT03733886|DEVICE|Burst SCS (Abbott Proclaim IPG and single lead Abbott Octrode at level Th9/10)|Burst SCS implies high frequency SCS treatment in intermittent packets with stimulation below detection level. Abbott BurstDR at default setting: Pulse width 1000 microseconds, frequency 500 Hz/40 Hz, continuous stimulation (no cycling). Pulse amplitude at maximum 60% of sensory threshold
223655331|NCT02283827|DRUG|BIA 2-093|
223655332|NCT02283827|DRUG|Phenytoin|
224238571|NCT04195165|BEHAVIORAL|EX|The SIT+EX and ACTIVE+EX conditions will include an exercise bout on the evening of the second intervention day, and have the oral glucose tolerance test the next morning.
223655333|NCT02411890|PROCEDURE|Adductor canal block (active)|adductor canal block: single injection, 0.5% levobupivacaine 15 ml with adrenaline 5 µg/ml, ultrasound guidance with nerve stimulator
223768014|NCT06573827|DIAGNOSTIC_TEST|Blood and urine sample evaluation|Blood and urine sample evaluation will be performed in healthy female volunteers.
223768015|NCT03548870|OTHER|CWRT with low frequency transcutaneous electrical nerve stimulation|"4 self adhesive surface electrodes will be positioned by pair on quadriceps. Patients will have a low frequency TENS for 20 min at rest. During this period, intensity will be increased every 5 minutes to the maximum tolerated by the patient (below pain threshold, sensation strong but comfortable). Thereafter, intensity is not increased anymore during the test.~Current characteristics : Rehab 400, CefarCompex 5Hz 200 µs frequency bidirectional"
224238572|NCT04154033|DRUG|Naltrexone|Topical naltrexone cream (1%)
223655334|NCT02411890|PROCEDURE|Femoral nerve block (active)|femoral nerve block: single injection, 0.25% levobupivacaine 30 ml with adrenaline 5 µg/ml, ultrasound guidance with nerve stimulator
223655335|NCT02411890|PROCEDURE|Femoral nerve block (sham block)|30 mL of normal saline injected into absorbing cloth through stump needle at the inguinal area but not penetrating skin, ultrasound guidance and nerve stimulator with percutaneous electronic guidance to create quadriceps contraction before injection
224238573|NCT04154033|OTHER|Placebo Cream|Topical placebo cream
224238574|NCT05238493|DRUG|VEL-101|Intervention administered via subcutaneous injection or 1-hour intravenous infusion on Day 1
224238575|NCT05238493|DRUG|Placebo|Intervention administered via subcutaneous injection or 1-hour intravenous infusion on Day 1
224238576|NCT01493908|DRUG|High price|Acetaminophen label as high price
224238577|NCT01493908|DRUG|Low price|Acetaminophen label as low price
224238578|NCT01493908|DRUG|Low price participants aware paying part|Acetaminophen label as low price; participants aware they are paying part of the full price
224238579|NCT01493908|DRUG|No price|acetaminophen. No price - price issue not introduced to participants.
224238580|NCT01493908|DRUG|Free of charge|Acetaminophen. participants aware the product is free of charge
224238581|NCT01820026|DRUG|Imipenem|second line therapy
224238582|NCT01820026|DRUG|Vancomycin|Second line therapy
224238583|NCT01820026|DRUG|azithromycin|Second line therapy
224238584|NCT01820026|DRUG|Cefotaxime|Standard antibiotic therapy
224238585|NCT01820026|DRUG|Amoxicillin|Standard therapy
224238586|NCT04528420|OTHER|optimised management|"At the inclusion , the patient will benefit from an early consultation with a nutritionist, a pain doctor and a social worker.~During the preparation phase for radiotherapy the patient will benefit from weekly consultations with a pain nurse and a dietician.~During the radiotherapy the patient will be weighed daily and have an assessment of their nutritional needs and a weekly consultation with a pain nurse and dietician and then twice a month until three months post-radiotherapy."
224238587|NCT04407819|RADIATION|WHOLE BODY DXA|Muscle mass was estimated by using the whole body DXA (Hologic Horizon W)
224238588|NCT04173754|PROCEDURE|Motion Style Acupuncture Treatment(MSAT)|Motion Style Acupuncture Treatment(MSAT) is a therapeutic technique using acupuncture needle created in Jaseng Hospital. This treatment involves patients with musculoskeletal pain to move the part of their body actively during acupuncture treatment under physicians' observation
224238589|NCT01211548|OTHER|contrast CTA of the CAP|CT coronary angiography results will be reported for all patients by adjudicators blinded to their inclusion in the study.
224238590|NCT00003313|BIOLOGICAL|filgrastim|
224238591|NCT00003313|DRUG|amifostine trihydrate|
224238592|NCT00003313|DRUG|carboplatin|
224238593|NCT00003313|DRUG|paclitaxel|
224238594|NCT00003313|RADIATION|radiation therapy|
224238595|NCT04480411|BEHAVIORAL|Doctorgram Patient Kit|Participants will use the Doctorgram Patient Kit for remote monitoring and remote use stethoscope.
224238596|NCT02789033|DRUG|Chitosan|Chitosan chemically is a high-molecular-weight linear polycationic heteropolysaccharide comprising copolymers of 1,4-linked D-glucosamine and N-acetyl-D-glucosamine
224238597|NCT02789033|DRUG|Isosorbide dinitrate|Isosorbide dinitrate (ISDN), is an organic nitrate, is a vasodilator with effects on both arteries and veins. The chemical name of ISDN is 1,4:3,6-dianhydro-D-glucitol 2,5-dinitrate
224238598|NCT02789033|DRUG|Placebo|placebo
224238599|NCT03437356|OTHER|Pulmonary vein isolation using CLOSE protocol|'CLOSE' protocol: Ablation index \> 400 at the posterior wall (reduce to 300 if esophagus temperature rise), ablation index \> 550 at the anterior wall, and inter-lesion distance \< 6.0mm
224238600|NCT03437356|DRUG|Antiarrhythmic drug therapy (ADT)|"During the first 3 months after PVI, patients continue oral anticoagulants and antiarrhythmic drug therapy (ADT). ADT is a continuation (or restart) of previously ineffective Class IC and III ADT. At the time of discharge, dosage is optimized according to the 2016 ESC guidelines on AF management.~Preferred dosages:~Flecainide: Tambocor or Flecainide EG 100mg b.i.d., Apocard R 100 to 200mg overdose (OD) Propafenone: Rytmonorm or Propafenone EG 300 mg b.i.d., except 225 mg b.i.d. if ≥70 years or \<70 kg Sotalol: Sotalex or Sotalol EG 80mg b.i.d., Except 80mg t.i.d. if men \< 70 years, Cr \<1.5mg/dl, \>70kg, except 80 mg OD if female \>70 years or Cr \>1.2mg/dl~In case of amiodarone intake before PVI, amiodarone is switched to sotalol or class IC ADT."
224238601|NCT05328713|DIAGNOSTIC_TEST|Cardiac MRI|This study will use Cardiac MRI to identify subclinical cardiac dysfunction.
223655336|NCT02411890|PROCEDURE|Adductor canal block (sham block)|30 mL of normal saline injected into absorbing cloth through stump needle at the midfemoral area but not penetrating skin, ultrasound guidance and nerve stimulator with percutaneous electronic guidance without muscle contraction
223655337|NCT05724095|OTHER|high frequency acupoint stimulation|electrodes are attached to area of acupoints and electrical stimulation at 10/50 Hz is given
223655338|NCT05724095|OTHER|low frequency acupoint stimulation|electrodes are attached to area of acupoints and electrical stimulation at 2/10 Hz is given
223655339|NCT05724095|OTHER|electrodes attached|electrodes are attached to area of acupoints
223655340|NCT02193503|OTHER|Treatment|Treatment is the implantation of loaded capsules + injection of irradiated autologous tumor cells
223655341|NCT04799093|DIAGNOSTIC_TEST|EyeBOX|Eye-Tracking based diagnostic
223655342|NCT04287270|OTHER|Assesment|Evaluations which explained in the arms section will be made as described.
223655343|NCT01599988|DIETARY_SUPPLEMENT|Caseinate|The test meal is a vanilla flavoured enteral drink, containing 1.5kcal/ml, 21% CHO, 6% protein and 5% fat. The 6% protein in this test meal is Caseinate
224238602|NCT04820608|DEVICE|Cross-linking|Oxygen-boosted, epithelium-on, customized cross-linking. Highest UV-A application is focused on the apex of the cone. The cone area receives a moderate amount of UV-A, while healthy cornea is spared.
224238603|NCT00301756|DRUG|Belinostat|Given IV
224238604|NCT00301756|OTHER|Laboratory Biomarker Analysis|Correlative studies
224238605|NCT06158269|DRUG|DVRd|The patients will receive 4 cycles of DVRd induction therapy. After achieving PR or better response, they will receive stem cell mobilization, collection and the following ASCT. Then, the patients will accept 4 cycles of DVRd consolidation and DVR maintenance therapy. Once they sustain MRD negative condition for at least 12 months, the patients will enter the maintenance stage of lenalidomide monotherapy. Otherwise, the triple drug maintenance therapy will be continued for a total of 24 cycles or until disease progression, death, intolerance, withdrawal due to other reasons, or termination/end of the study.
224238606|NCT03199157|DRUG|Fentanyl transdermal patch|Patients received fentanyl 12 mcg transdermal patch group 8 hours preoperatively and until 24 hours after the surgery
224238607|NCT00249275|DEVICE|spectacles|
224238608|NCT00431548|DRUG|100% O2|
224238609|NCT01539109|BEHAVIORAL|Rehabilitation|Patients will receive training upon tasks of daily living. Patients will perform these exercises in our laboratory under the supervision of qualified personnel.
224238610|NCT01539109|PROCEDURE|Noninvasive brain stimulation: tDCS|TDCS is a method of noninvasive stimulation of the brain. Using electrodes placed in saline-soaked sponges, low level of direct current (2mA) is delivered over the scalp. This intervention is considered safe and noninvasive because it does not involve implantation or injection or any skin penetration. In the present study, tDCS will be delivered to patients in the experimental group for 2 hr each day for 5 days a week for 2 weeks in conjunction with therapy for the affected hand.
224320963|NCT02291510|DRUG|Met XR|metformin extended-release tablets
224320964|NCT02291510|DRUG|Met IR|metformin immediate-release tablets
223655344|NCT01599988|DIETARY_SUPPLEMENT|Milk Protein Isolate|The test meal is a vanilla flavoured enteral drink, containing 1.5kcal/ml, 21% CHO, 6% protein and 5% fat. The 6% protein in this test meal is Milk Protein Isolate.
223655345|NCT02147561|BIOLOGICAL|botulinum toxin Type A|Botulinum toxin Type A injected across specific head and neck muscles on Day 0.
223655346|NCT02829567|BEHAVIORAL|Motivational interviewing|
223655347|NCT06222788|DEVICE|Convertible Plasma Jet|NTP will be applied to the patients using the Convertible Plasma Jet (CPJ, NexPlasmaGen Inc.)
223655348|NCT05727852|DIAGNOSTIC_TEST|Breath test using the Compact PTR-TOF-MS|Breath samples will be analyzed with a proton-transfer reaction mass spectrometer (Compact PTR-MS, Ionicon, Austria) to obtain eVOCs profiles listed as ions at various mass-to-charge ratios (m/z).
223655349|NCT05727852|DIAGNOSTIC_TEST|"Portable cardiac monitor CardioQvark"|"Record an electrocardiogram (ECG) in one lead with an assessment of the pulse wave using a portable cardiac monitor CardioQvark (Russia, LLC L Card , RU No. RZN 2019/8124 dated February 15, 2019) once. Devices automatically transfer data to the A\&D Connect app paired with it (link). When transferring data, they are completely protected. The data obtained using the application must be sent to the specialists of the research group in a depersonalized form."
223655350|NCT05727852|DIAGNOSTIC_TEST|Assessment of arterial stiffness using the VaSera VS-1500N|Assessment of arterial stiffness using the VaSera VS-1500N Fukuda Denshi device by non-invasive measurement of blood pressure in four limbs with simultaneous recording of ECG, PCG and pulse waves on the carotid, femoral arteries, as well as on the arteries of four limbs.
223655351|NCT05818969|BEHAVIORAL|Hypnosis Therapy|Pre-recorded hypnosis therapy audio recording with accompanying visual of a calming ocean scene to be played at least once daily for 7 days preoperatively.
223655352|NCT02952443|BEHAVIORAL|Exercise|Participants will be randomized, using a table of random numbers, to either an Exercise (EX) or a Control (CON) group. The EX group will participate in a 16-week multi-component training intervention (3x per week, 45 to 60 minutes/session, at moderate to vigorous intensity) that will include primarily resistance exercises, an aerobic warm-up and cool down, and include both flexibility and balance exercises throughout the session (Bray et al., 2016).
223655353|NCT02952443|BEHAVIORAL|Control|The CON group will be asked to maintain their normal daily living habits for the same duration (16 weeks). At the conclusion of the 16-weeks the exercise program will be made available to the CON group.
223655354|NCT00262626|DRUG|Intraocular pressure reduction|
223655355|NCT00262626|PROCEDURE|Argon laser trabeculoplasty|
223655356|NCT00262626|PROCEDURE|Trabeculectomy|
223655357|NCT03691194|DIETARY_SUPPLEMENT|fresh orange juice|The fresh oranges will be bought from Sysco. They will be squeezed at the kitchen of School of Allied Health Professional with a juicer. They will either be squeezed the night before or on the same day. The juice will not be treated with additional preservatives or sugar. The brand of the juicer is Kitchen Aid. Eight ounces of fresh orange juice needs approximately two and half oranges. They will be put into 32 oz water bottles that were bought from Sysco, and then store them in the refrigerator. They will be given to the subjects every three or four days.
223681028|NCT04335201|DRUG|Defibrotide Injection|Patients will be treated according to the standard institutional procedures and will receive the best available treatment as per institutional guidelines in association with the experimental drug: Defibrotide 25 mg/kg body weight total dose in 2 hours duration infusion each, every 6 hours (Defibrotide 6.25 mg/kg body weight each dose) Treatment duration = 7 days
223681029|NCT04127812|BEHAVIORAL|Savor the Flavor|A series of five interactive classroom lessons focused on mindfulness in eating.
223681030|NCT03518476|BEHAVIORAL|intensive multi-disciplinary education program on tobacco treatment for pharmacists|Participants in the intervention group will participate in an intensive education program delivered by a multi-disciplinary group of educators, researchers, and clinicians with expertise in tobacco control and tobacco dependence treatment. The program will be delivered over 4 days (run over 2 weekends) with an average of eight contact hours per day (a total of 32 contact hours) at Qatar University.
223681031|NCT03518476|OTHER|Control arm|Participants in control arm will receive a non-tobacco related training or educational session
223681032|NCT00041587|DRUG|IL13-PE38QQR|
223681033|NCT00041587|PROCEDURE|targeted fusion protein therapy|
223681034|NCT00041587|PROCEDURE|surgery|
223681035|NCT03032770|DEVICE|two-dimensional ultrasound and color Doppler|the eligible participants will be searched for signs suggestive of placenta accreta; low implantation of the gestational sac (\<4cm from the external os), presence of placental lakes, Disruption of placental-myometrial interface and trophoblast overlapping a uterine scar by 2 dimensional transvaginal ultrasound and Intraplacental dilated vessels, turbulent blood flows and greatly increased periplacental vascularity by Doppler ultrasound by level II sonographer and co-investigator under his supervision using ultrasound device.
223681036|NCT02844686|OTHER|Cardiac SPECT|3-D dynamic acquisition of cardiac SPECT at rest and after pharmacological stress
223681037|NCT03110939|OTHER|hyperthermic perfusion|hyperthermic perfusion 1800-2000ml, normal saline, 45-48℃, 1 hour, speed 300-600ml/min (after surgery of advanced lung cancer/esophageal cancer)
223681038|NCT03253471|DRUG|AL-611|AL-611 tablets
223681039|NCT03253471|DRUG|Placebo|Placebo to Match AL-611
223681040|NCT02323360|RADIATION|SBRT|Patients with single nodule no more 5 cm or 1- 3 nodules no more 3 cm in diameter after incomplete TAE or TACE, are randomized to stereotactic radiotherapy in 3 or 6 daily fractions
223681041|NCT02323360|PROCEDURE|TACE|Patients with single nodule no more 5 cm or 1- 3 nodules no more 3 cm in diameter after incomplete TAE or TACE, are randomized to a new cycle of TAE or TACE
223681042|NCT02712814|DRUG|Topical hormonal cream (estrogen)|Patients will be instructed to stop hormonal contraception and to apply 0.1 ml topical cream containing 0.1% of estriol to the vestibule, once daily for 3 months
223681043|NCT02712814|PROCEDURE|Pelvic floor physical therapy|PF physical therapy once weekly for 3 months
223681044|NCT02712814|PROCEDURE|Low Level Laser therapy|non-thermal laser irradiation (low levels of red and near infrared light) is applied directly to the vestibule
223681045|NCT05543434|DRUG|Hyaluronic acid|anti-inflammatory, anti-edematous, osseoinductive.
223681046|NCT03255070|DRUG|ARX788|An antibody drug conjugate
223655358|NCT03691194|DIETARY_SUPPLEMENT|concentrated orange juice|The concentrated orange juice will be bought from Sysco then reconstituted. One part of concentrated orange juice needs four parts of water to reconstitute. Then, it will be measured and the reconstituted orange juice will be put into 32 oz water bottles that we bought from Sysco. They will be stored in the refrigerator. The subjects will need to get the reconstituted orange juice every three or four days.
223655359|NCT00528593|DRUG|epoetin alfa|Group 1 will receive Procrit once every three weeks, and group 2 will receive Procrit every week.
223655360|NCT04635540|BEHAVIORAL|Educational Brochure|Educational brochure on decreased empathy and emotion recognition in patients with neurodegenerative disease
224238611|NCT01539109|PROCEDURE|Sham tDCS: placebo noninvasive brain stimulation|Placebo set-up for noninvasive brain stimulation will be similar to that for the active tDCS; sponge electrodes would be placed on the scalp and connected to a batter-operated device. Patients will not receive the effective level of direct current as would delivered in active tDCS intervention. But patients will not be able to decipher whether they are receiving active or placebo tDCS.
224238612|NCT03879356|DRUG|N-acetyl cysteine|effect of N-acetyl cysteine in Aluminum phosphide poisoning patients
223655361|NCT02874976|DEVICE|Active and Active Phototherapy|Participants performed a aerobic training. Ninety-six subjects practice a regular aerobic exercise program on a treadmill was applied 3 times a week for 12 weeks,each session lasting 30 minutes, ranging between 70-80 % of maximum heart rate intensity and the evaluations are done monthly through a maximum progressive exercise protocol. Phototherapy, active or placebo, were applied in 9 different points of quadriceps,6 points in the posterior thigh and two points in the gastrocnemius muscle, depending the group randomized, before and after each training session.
224238613|NCT01840371|DRUG|Conventional sedation|"Propofol Meperidine : 25 mg IV just before procedure~* IV bolus of 1 mg/kg for sedation induction,~* Infusion of 60 mcg/min/kg for maintenance of sedation~* Additional bolus dose of 10mg as needed for adequate sedation"
224238614|NCT01840371|DRUG|Experimental sedation|"Fentanyl~* IV bolus of 1 µg/kg for sedation induction~* Additional bolus dose of 0.5 µg/kg as needed for adequate pain control Propofol~* IV bolus of 0.4 mg/kg for sedation induction~* Infusion of 30 µg/min/kg for maintenance of sedation~* Additional bolus dose of 10mg as needed for adequate depth of sedation"
224238615|NCT06134778|OTHER|Inspiratory Muscle Training|Inspiratory muscle training was performed for six weeks. Athletes performed two daily sessions of 30 forced inspirations followed by long but not maximal expirations, with load adjusted between 50% and 60% of maximum inspiratory pressure, five times a week. A specific device was used for this purpose (Classic, Powerbreathe, United Kingdom), with light or medium resistance adjustment, depending on the subject's maximum inspiratory pressure.
224238616|NCT05687058|DRUG|Empagliflozin 25 mg thrice-weekly post-hemodialysis dosing|Participants in Group I will be asked to take empagliflozin 25 mg after each hemodialysis session at home.
224238617|NCT05687058|DRUG|Empagliflozin 10 mg daily dosing|Participants assigned to Group II will be asked to take empagliflozin 10 mg each morning between 8:30 and 9:30 a.m. at home.
224238618|NCT05370183|PROCEDURE|Hyperambulatory tenotomy|Using mini-optics a minimally invasive device, hypermabulatory tenotomy is performed in consultation, with a local anethesia
224238619|NCT05370183|PROCEDURE|Operating room tenotomy|Operating room tenotomy is performed according standard practice, with general anesthesia.
224238620|NCT03577964|DIAGNOSTIC_TEST|Glucose Measurements,|Measurement of glucose Levels in bronchio alveolar secretions
223655362|NCT02874976|DEVICE|Active and Placebo Phototherapy|Participants performed a aerobic training. Ninety-six subjects practice a regular aerobic exercise program on a treadmill was applied 3 times a week for 12 weeks,each session lasting 30 minutes, ranging between 70-80 % of maximum heart rate intensity and the evaluations are done monthly through a maximum progressive exercise protocol. Phototherapy, active or placebo, were applied in 9 different points of quadriceps,6 points in the posterior thigh and two points in the gastrocnemius muscle, depending the group randomized, before and after each training session.
223655363|NCT02874976|DEVICE|Placebo and active Phototherapy|Participants performed a aerobic training. Ninety-six subjects practice a regular aerobic exercise program on a treadmill was applied 3 times a week for 12 weeks,each session lasting 30 minutes, ranging between 70-80 % of maximum heart rate intensity and the evaluations are done monthly through a maximum progressive exercise protocol. Phototherapy, active or placebo, were applied in 9 different points of quadriceps,6 points in the posterior thigh and two points in the gastrocnemius muscle, depending the group randomized, before and after each training session.
223655364|NCT02874976|DEVICE|Placebo and Placebo Phototherapy|Participants performed a aerobic training. Ninety-six subjects practice a regular aerobic exercise program on a treadmill was applied 3 times a week for 12 weeks,each session lasting 30 minutes, ranging between 70-80 % of maximum heart rate intensity and the evaluations are done monthly through a maximum progressive exercise protocol. Phototherapy, active or placebo, were applied in 9 different points of quadriceps,6 points in the posterior thigh and two points in the gastrocnemius muscle, depending the group randomized, before and after each training session.
223655365|NCT00005035|DRUG|oxaliplatin|
223655366|NCT03554564|BEHAVIORAL|VOICE/Fitbit|During the VOICE (intervention) phase, participants will use the digital health platform plus Fitbit walking activity tracking for a total of five weeks (one week run-in phase plus four week study phase)
224238621|NCT04696419|OTHER|Different intensities of contact to dogs|Each subject is exposed to four test situations of 10 minutes. Three situations with increasing intensity of dog contact, and one control test situation with no contact to a dog. The order of the test situations is random and with 30 minute washout in-between
224238622|NCT04480788|BIOLOGICAL|T cell injection targeting CD7 chimeric antigen receptor|Drug name: T cell injection targeting CD7 autologous chimeric antigen receptor. Package specification: 10-50ml bag, 1-4 bags / person, which is determined according to the body weight of the subject and the effective content of cell preparation
224238623|NCT04667078|DRUG|Cangrelor|administration of cangrolor by iv befor thrombectomy
224238624|NCT04667078|OTHER|best medical management|used yhe best medical management
224238625|NCT03093506|DRUG|Low-dose rhEpo|60IU/kg/week
224238626|NCT03093506|DRUG|Micro-dose rhEpo|20IU/kg/week
224238627|NCT03093506|OTHER|Placebo Control|Saline
224320965|NCT05664594|DEVICE|Computerized Cognitive Training|Participants will complete computerized cognitive training developed by Posit Science Corporation. For a description of the training paradigms please review arm descriptions.
223655367|NCT03554564|OTHER|Daily self-reported exercise adherence|During usual care, patients will self-report on a daily basis if they met the walking exercise goal consistent with instructions from their clinician. Self-report will be recorded as a daily categorical (yes/no) variable.
223655368|NCT02679118|DEVICE|Sentire|The device, at predetermined time points, will draw a small amount of gas from the abdomen. Upon obtaining the samples, the machine will analyze the sample for evidence of bowel gas. After each sample, the device will be purged prior to the acquisition of the next gas sample. The results of the analysis of the gas samples will be recorded for future analysis.
223655369|NCT00984997|PROCEDURE|Surgery|Segmentectomy or lobectomy with en bloc resection of the involved chest.
223655370|NCT00984997|RADIATION|Chest Irradiation|Radiation therapy consists of 60 Gy in 50 fractions for negative margins, or 64.8 Gy in 54 fractions for positive margins, at 1.2 Gy per fraction, 2 fractions per day, 5 days per week.
223655371|NCT00984997|DRUG|Cisplatin|50 mg/M\^2 given intravenously on days 1 and 8; the cycle will be repeated beginning on day 29.
224238628|NCT03724149|DRUG|Zepatier|Zepatier (grazoprevir 100mg and elbasvir 50 mg once daily) is taken by mouth for 12 weeks unless a genetic variation is detected. In this case treatment with Zepatier will be extended to 16 weeks. Study subjects with treatment failure will be provided open-label Zepatier + sofosbuvir (sovaldi) 400mg + Ribavirin (generic), renally dosed based on creatinine clearance per the manufacturer guidelines.
223655372|NCT00984997|DRUG|Etoposide|given by mouth 30-60 minutes prior to each administration of radiotherapy, on days 1-5 and days 8-12; the cycle will be repeated beginning day 29.
223655373|NCT00984997|RADIATION|Prophylactic Cranial Irradiation|25 Gy in 10 fractions of 2.5 Gy, 1 fraction per day, will be given at the completion of chest irradiation, and is optional.
223655374|NCT02003599|DEVICE|Laser therapy|The low level laser therapy used in this trial will be Photon Lase III (DMC, approved by ANVISA for medicinal purposes). This InGaAIP laser emits a pulsed 660 nanometer beam with an average output of 80 milliwatts and the average energy density delivered to the breast will be 3 J/cm2.
223655375|NCT02003599|DEVICE|Placebo|In the control group, 26 patients will be submitted to a laser, but the laser will be disabled without affecting its apparent function , five days a week before radiotherapy .
223655376|NCT06227793|BEHAVIORAL|pharmaceutical intervention|Individuals randomized to the intervention group will undergo monthly pharmaceutical consultations for health education, initiated after randomization. There will be three in-person consultations, starting in month 1 with monthly spacing, scheduled by the pharmacist in the office, except for the first consultation, which will be scheduled by the pharmacist over the phone after randomization. These consultations will be part of the intervention study's educational process and will take place between the initial and final assessments. The educational process scripts for each consultation include a pharmaceutical follow-up form and an inhalation technique assessment form. Once the consultation is completed, the patient will also receive, via WhatsApp and/or email according to their preference, an educational video demonstrating the step-by-step inhalation technique based on their prescribed treatment.
223655377|NCT00505401|BIOLOGICAL|recombinant HIV-1 Tat protein|
223655378|NCT06384118|BEHAVIORAL|Impact of an IMB theory-based health education intervention on hypoglycemic coping in patients with type 2 diabetes: a pilot study|Based on IMB health education theory Questionnaire collection, face-to-face interview, and manual interpretation on the first day of admission; questionnaire collection, face-to-face interview, and manual interpretation on the first day of admission; hypoglycemia knowledge promotion on the second day; Peer experience sharing on the third day; access to WeChat group and knowledge pushing on the fourth day; hypoglycemia-related lectures and practical teaching on the fifth day, face-to-face teaching and development of blood glucose management plan. Hypoglycemia knowledge contest on the day before discharge; One week, two weeks and three weeks after discharge for WeChat push or phone call; WeChat push, phone call and questionnaire.
223655379|NCT00746057|BIOLOGICAL|DNA chip|One biopsy is realized before graft, another biopsy is realized one year after graft and a blood sample is collected 3 months after graft to realize DNA chip. Blood samples are also collected at day 0, day 1, month 3, month 6 and month 12 to analyze biochemistry, proteinuria, haematology, creatinine clearance and immunology at day 0, month 3 and month 12.
223655380|NCT04518267|BEHAVIORAL|Structured clinical interview|A structured clinical interview will be performed at enrollment.
223655381|NCT04518267|BEHAVIORAL|Psychological questionnaires|Several psychological questionnaires will be performed at enrollment.
223655382|NCT03898557|BEHAVIORAL|Provision of HIV self-test with Commitment and planning prompts|The interventions will use behavioral interventions such as commitment and planning prompts to increase the update of HIV self-testing
223655383|NCT03898557|BEHAVIORAL|Provision of HIV self-test|This arm will receive a HIV self-test
223681047|NCT00461331|DRUG|Insulin Aspart|Either one of these insulins were given to the patient as the second insulin (depending on which was given as the first one, the other insulin was insulin 2). Patients used this insulin in the same dose as they did prior to entering the study.
223681048|NCT00461331|DRUG|Insulin Lispro|Patients were given either insulin Aspart or Lispro in test period 1. Then they were switched to the other insulin in test period 2.
223681049|NCT04678206|DRUG|BLU-5937|Oral administration of BLU-5937 Tablets
223681050|NCT04678206|DRUG|Placebo|Oral administration of matching placebo for BLU-5937 Tablets
223681051|NCT02582762|DRUG|Nail gel|apply nail gel on affected nails twice daily for 2 months
223681052|NCT02273609|DRUG|Vitamin K antagonists (acenocoumarol or warfarin)|"INR values of patients treated with acenocoumarol or warfarin in the last 12 months will be recorded according to clinical practice of each center.~No specific recommendation about treatment will be provided by sponsor."
223681053|NCT00003184|BIOLOGICAL|BCG vaccine|
223681054|NCT00003184|BIOLOGICAL|CD80 breast cancer vaccine|
223681055|NCT00003184|BIOLOGICAL|sargramostim|
223681056|NCT00375947|OTHER|Hand Exercise|
223681057|NCT00375947|OTHER|sham hand cream|placebo intervention
223681058|NCT02258984|DEVICE|Mespere Venus 1000 Non-Invasive CVP System|The Venus 1000 CVP System is a non-invasive central venous pressure measurement system that utilizes the proven science of NIRS. Approved by FDA, received Health Canada Medical Device Licence and CE Marked, the Venus 1000 has been proven to be clinically equivalent to measurements made via right heart catheterization.
223655384|NCT06193226|OTHER|Cryotherapy|"Cryotherapy can be done in two ways:~1. Open technique: Using cotton swabs or a cryogun spray, the cryogen is delivered directly to the lesion in this technique.~2. Closed technique: Cryo-probes are used to apply the cryogen to the lesion in this procedure.~The spray's nozzle of the Cryogun spray -50 ◦C was situated 1 cm away from the skin's surface and applied on the oral lesion for 30 seconds. Each freezing cycle lasted 10 to 30 seconds, with the subsequent 60-second thaw interval lasting twice as long as the freezing time. The ice ball that formed during freezing was totally melted before the subsequent freezing process could begin.~The application process should went from the core out to the edges. The management of lesions that are too big to be frozen by a single spray requires many overlapping treatments of liquid nitrogen. Mucoceles and erosive lichen planus took 30 to 50 seconds to freeze, whereas fibromas and leukoplakia took 60 to 70 seconds."
223655385|NCT06245980|DRUG|SGLT2 inhibitor|According to whether SGLT2i was used
223655386|NCT04456855|PROCEDURE|Locoregional surgery|Patients had pathologically confirmed operable stage IV breast infiltrating carcinoma at initial presentation, and had locoregional surgery for the breast cancer.
223655387|NCT02519985|DEVICE|ArcScan Insight 100 very high-frequency digital ultrasound|"The ArcScan Insight 100 VHF digital ultrasound scanner that can measure individual layers within the cornea with very high precision, as well as being able to image the interior of the eye including the chamber between the iris and the cornea, the lens and other structures behind the iris.~The ArcScan Insight 100 device is a digital ultrasound scanner, meaning that it uses ultrasound waves to measure parameters of the eye. The Insight examination involves the patient sitting in front of the ultrasound unit and looking through a disposable goggle-like eyepiece at a light source. Warm sterile balanced saline solution (like natural tears) are used to fill the space between the light source and the eye, to allow ultrasound transmission. There is no contact between the instrument and the eye other than being immersed in this water bath."
223655388|NCT02279264|DEVICE|RightSpot Infant pH Indicator|pH indicator
223655389|NCT03238430|DRUG|intrathecal morphine|A single intrathecal injection of 300 micrograms of Morphine preoperatively, just before induction.
223655390|NCT03238430|DRUG|Morphine PCA|a postoperative Morphine PCA
223655391|NCT03238430|DRUG|Ropivacaine infiltration|Ropivacaine 2mg / ml at the rate of 8ml per hour via a multiperforated catheter with connector after bolus of 20 ml
223655392|NCT01829152|DEVICE|CHM|
223655393|NCT03331640|DRUG|OFF|"OFF:~5-FU 2000 mg/m2 as 24 hour infusion + Na folinic acid 200 mg/m2 on D1, 8, 15, 22 Oxaliplatin 85 mg/m2 on D8, 22 3 weeks rest after D22; Cycle q42d"
223655394|NCT03331640|DRUG|FOLFIRI Protocol|Irinotecan 180 mg /m2 5-FU 400 mg/m2 (bolus) + 2400 mg/m2 as 46 hour infusion Na folinic acid 200 mg/m2 Cycle q2w
223655395|NCT02507700|PROCEDURE|Popliteal block|In group P, popliteal block will be performed with ultrasound guidence.
223655396|NCT02507700|DRUG|Sevoflurane|Sevoflurane will be used to all patient's for anesthesia induction and maintenance
223655397|NCT02507700|DEVICE|Ultrasound|For recognize the nerve (sciatic nerve), ultrasound will be used in group P.
223655398|NCT02507700|OTHER|Plaster cover|Plaster cover will be used to control group for sham procedure
223655399|NCT02507700|DRUG|bupivacaine|Bupivacaine 0.25% will be performed for popliteal block to group P.
223655400|NCT02507700|OTHER|Laryngeal mask airway|After anesthesia induction, laryngeal mask airway will be inserted to all patients
224238629|NCT03724149|DRUG|Epclusa|Epclusa (sofosbuvir 400mg and velpatasvir 100mg once daily) is taken by mouth for 12 weeks. Study subjects with treatment failure will be provided an alternative DAA + sofosbuvir (sovaldi) 400mg + Ribavirin (generic), renally dosed based on creatinine clearance per the manufacturer guidelines.
224238630|NCT01677078|DEVICE|Neuronavigation system|Neuronavigation
224238631|NCT01677078|DEVICE|Standard localisation method|Manual localisation of the DLPFC using the standard localisation method (i.e. the '5-cm method')
223655401|NCT02364635|DRUG|icosabutate|Single dose at each dose levet
223655402|NCT02743104|DRUG|Ketamine|
223655403|NCT02743104|DRUG|Propofol|
223655404|NCT02743104|DRUG|midazolam and atropine|
223655405|NCT02743104|DRUG|Lidocaine|
223655406|NCT05252091|DRUG|herombopag olamine tablets|The first day of chemotherapy was d1, and the drug was started from d-5, 5 days before chemotherapy, with oral herombopag 5 mg/day for a maximum of 14 days. After chemotherapy, when the thrombocytopenia rises to ≥200×109/L, drug discontinuation can be considered
223655407|NCT02349217|BEHAVIORAL|Mindfulness-Based Relationship Enhancement (MBRE)|Participant and partner take part in an 8-week Mindfulness-Based Relationship Enhancement (MBRE) intervention course. MBRE course consists of meditation and yoga techniques and handouts.
223655408|NCT02349217|BEHAVIORAL|Self-Help Materials|Participants and partner receive self-help materials.
223655409|NCT02349217|BEHAVIORAL|Pain Assessment|Pain assessment administered at baseline and at follow up visit. Pain assessment involves submerging hand in cold water.
223768016|NCT03548870|OTHER|CWRT with sham-low frequency transcutaneous electrical nerve stimulation|4 self adhesive surface electrodes are positioned by pair on quadriceps. Patients will have a sham-low frequency TENS for 20 min at rest. During this period, intensity will be increased for 1 minute to the maximum tolerated by the patient. After this procedure, intensity will be progressively setted back to 1mA. Current characteristics : Rehab 400, CefarCompex 5Hz 200 µs frequency bidirectional
223768017|NCT05647824|DEVICE|Capillary Testing|Testing Contour Fit BGMS with capillary blood
223768018|NCT05647824|DEVICE|Alternative Site Testing (AST)|Testing Contour Fit BGMS using blood from alternative site
223768019|NCT05647824|DEVICE|Venous Testing|Testing Contour Fit BGMS with venous blood
224238632|NCT00163449|DRUG|Ciclesonide|Efficacy and Safety of Ciclesonide
224238633|NCT00163449|DRUG|Placebo|Placebo
224238634|NCT03581448|BEHAVIORAL|Sensory Restoration During Prosthesis Control|Human subjects who use a robotic arm/hand interface will experience variable sensations of touch over time.
224238635|NCT03157622|BEHAVIORAL|Exposure in vivo|10 sessions based on an individualized fear hierarchy
224238636|NCT03157622|BEHAVIORAL|Cognitive Behavioural Psychotherapy|graded activity, relaxation techniques and cognitive interventions
224238637|NCT01279525|DEVICE|multifactorial|individual advice, information leaflet, physical exercise workshop and home visits
224238638|NCT01284439|DRUG|hydroxypropylmethylcellulose|TearA: QID to every 2 hous , 1-2 drops per each time , duration 1 month
223768020|NCT04844229|PROCEDURE|Bilateral transnasal sphenopalatine ganglion block.|SPG block will be performed with the patient in supine position using cotton-tipped plastic hollow applicator inserted in the nose with the swab soaked in 1.5 ml 10%lignocaine. The applicator will be inserted parallel to the floor of the nose until resistance encountered. The swab will be rested in the pterygopalatine fossa superior to the middle turbinate and removed after 10 min. This procedure will be repeated in the other nostril too.
223655410|NCT02349217|BEHAVIORAL|Questionnaires|Questionnaires completed at baseline and at follow up visit. Questionnaires ask about fatigue, mood, stress, social support, marital satisfaction, depression, and general demographics (age, race and so on). It should take about 1½ hours total to complete the questionnaires.
223768021|NCT04844229|PROCEDURE|Bilateral ultrasound guided greater occipital nerve block.|GONB will be performed with the patients lying in prone position using high frequency (6-13 MHz) probe of Siemens Acuson X300 machine placed in transverse orientation lateral to external occipital protuberance parallel to the superior nuchal line to detect occipital artery where the nerve is located medial to it 1.5inch; then 20 gauge needle will be inserted out of plane to avoid vascular injury. 4 ml of treatment solution containing 2.5 mg/ml bupivacaine and 1 mg/ml dexamethasone (prepared by adding 2 ml bupivacaine 0.5% + 1 ml dexamethasone + 1 ml saline) will be injected on each side.
224238639|NCT01284439|DRUG|sodium hyaluronate|QID to every 2 hous, 1-2 drops per each time, duration 1 month
223655411|NCT02349217|BEHAVIORAL|Neurocognitive Tests|Neurocognitive tests administered at baseline and at follow up visit. Tests to check memory and thinking abilities.
223655412|NCT02349217|PROCEDURE|Cortisol Tests|Cortisol testing performed after baseline visit and at follow up visit. Participants asked to collect saliva samples for cortisol assays immediately, 30, 45, and 60 minutes after awakening (representing the cortisol awakening response) and at noon, 4 P.M. and 8 P.M.
223655413|NCT02349217|BEHAVIORAL|Interviews|Interviews conducted after follow up visit. These interviews are audio-taped and transcribed.
223655414|NCT00299169|BEHAVIORAL|N of 1 Trials|N of 1 Trials of statin therapy
223655415|NCT04306861|DIAGNOSTIC_TEST|MRI|Baseline contrast-enhanced MRI and 2 follow-up contrast-enhanced MRIs (mid-treatment and treatment completion)
223655416|NCT02970903|DEVICE|VitalPAD|VitalPAD prototype device
223655417|NCT02970903|DEVICE|Traditional tools|Paper based records, screenshots of monitors and therapy devices
223655418|NCT05676840|PROCEDURE|orthodontic treatment with fixed appliances|comprehensive orthodontic treatment with fixed orthodontic appliances for the correction of misaligned teeth.
223655419|NCT01790997|DRUG|DLBS1033|1 tablet of DLBS1033 490 mg thrice daily, after meal
223655420|NCT01790997|DRUG|Aspirin|1 tablet of aspirin 80 mg once daily, after meal
223655421|NCT01790997|DRUG|Clopidogrel|1 tablet of clopidogrel 75 mg once daily, after meal
223655422|NCT00075257|DRUG|DVS-233 SR|
223655423|NCT01492335|BEHAVIORAL|Cognitive Report|Physicians in the Cognitive Report group receive the results of their patients cognitive assessment which includes a clinical diagnosis (Normal, Mild Cognitive Impairment, Dementia) and treatment recommendations
223655424|NCT01492335|BEHAVIORAL|Treatment As Usual|Physicians in the Treatment As Usual group do not receive the results of their patients cognitive assessments, they are not given treatment recommendations nor are they told of the patients clinical diagnosis (Normal, Mild Cognitive Impairment, Dementia).
223655425|NCT02096640|PROCEDURE|Type of surgical teqnique for tracheostomy|
224238640|NCT05787639|DRUG|Evorpacept|After stereotactic radiation to primary tumor and neck on week 1 of study, Evorpacept 45 mg/kg is administered by IV infusion every three weeks starting on Week 2, Day 1 of study for a total two 21-day cycles (6 weeks)
224238641|NCT04807621|BIOLOGICAL|Platelet transfusion|Platelets (10 ml/kg body weight) is transfused.
224238642|NCT04807621|BIOLOGICAL|Fibrinogen concentrate|Fibrinogen concentrate (300 mg/kg body weight) is administered.
224238643|NCT01718938|DRUG|velusetrag dose 1|
224238644|NCT01718938|DRUG|velusetrag dose 2|
223655426|NCT02428725|OTHER|blood sample|Biological samples will be done to determine platelet reactivity testing by VASP-index, will be obtained between 6 and 12 hours after receiving ticagrelor
223655427|NCT00000903|DRUG|Indinavir sulfate|
223655428|NCT00000903|DRUG|Lamivudine/Zidovudine|
223655429|NCT00000903|DRUG|Nelfinavir mesylate|
223655430|NCT00000903|DRUG|Efavirenz|
223655431|NCT04988243|OTHER|All aortic valve products on the market|"1. Subjects with severe aortic valve stenosis~2. Subjects who plan (or have) to use the transcatheter aortic valve replacement system for percutaneous aortic valve replacement~3. The patients agreed to join the study, voluntarily signed the informed consent and completed the follow-up;~4. Be able to contact the subjects or their legal guardians / relatives;~5. The medical record records the subjects who have died and can't get any contact information of the subjects（ (for dead cases only)~Sign the informed consent form, then check the inclusion and exclusion criteria, register after meeting the criteria, obtain the registration number, perform aortic valve replacement surgery, follow-up 24 hours, discharge, 30 days, 1 year, 2 years, 3 years, 4 years and 5 years after operation according to the test requirements, and carry out relevant follow-up according to the scheme requirements to collect data"
223655432|NCT01995188|DRUG|Bevacizumab|Bevacizumab 15 milligrams per kilogram (mg/kg) administered via IV infusion on Day 1 of each 21-day cycle until disease progression or death, whichever occurs first.
223655433|NCT01995188|DRUG|Carboplatin|Carboplatin fixed dose of AUC=6 mg/mL\*min administered by IV infusion on Day 1 of each 21-day dose escalation and expansion cycles. Carboplatin will be administered for a maximum of 6 cycles or until disease progression or unacceptable toxicity, whichever is first.
224238645|NCT01718938|DRUG|velusetrag dose 3|
224238646|NCT01718938|DRUG|placebo|
224238647|NCT02300090|DEVICE|Test Group|Patients receive a mobile phone with the Me \& My COPD app installed. Patients also receive a bluetooth inhaler device that is fitted to their usual reliever inhaler.
224238648|NCT02300090|OTHER|Control Group|Patients in the control group receive only standard care; there are no interventions within this group of patients
224238649|NCT03611894|OTHER|radiological comparison|comparison between clinical and radiological characteristics
224238650|NCT01490944|DRUG|Iron, Folic acid and Cyanocobalamin|"Total duration= 6 months Iron=100 mg, Folic acid= 500 mcg, Cyanocobalamin 500 mcg weekly supplementation in the form of capsule for 6 weeks~Iron=100 mg, Folic acid= 500 mcg, Cyanocobalamin 15 mcg weekly supplementation in the form of capsule for next 20 weeks"
223655434|NCT01995188|DRUG|DNIB0600A|DNIB0600A at an initial dose of 1.2 mg/kg will be administered via IV infusion further following a dose-escalation until DLT under consultation of the investigator on Day 1 of 21 day dose-escalation cycle. RP2D will be administered further in dose-expansion for until disease progression or death, whichever occurs first.
223655435|NCT02471599|PROCEDURE|tonsillectomy|The tonsillectomy will be performed by the otolaryngologist. In addition, all subjects will receive the conventional drug treatments, defined as treatment of participants using the angiotensin-converting enzyme inhibitor (ACEi)/angiotensin II receptor blocker (ARB), anticoagulants, antihypertensives, corticosteroids so on, according to individual status.
224238651|NCT01490944|DRUG|Iron and Folic Acid|Iron= 100 mg, Folic acid= 500 mcg weekly supplementation in the form of capsule for 6 months
223655436|NCT02471599|OTHER|non-tonsillectomy|The non-tonsillectomy group received conventional drug treatments defined as treatment of participants using the ACEi/ARB,Anticoagulants, Antihypertensives, corticosteroids and so on, according to individual status.
223655437|NCT01572285|PROCEDURE|transforaminal dexamethasone injection|Subjects received transforaminal infiltration of lidocaine 1% 0.5mL and 1.5mL of Dexamethasone 10mg/ml
223655438|NCT01572285|PROCEDURE|Sham|Sham procedure using a non-penetrating needle
223655439|NCT00947687|DRUG|PUR003|Twice-daily (BID) doses of PUR003 will be delivered via inhalation using a commercially available nebulizer for a total of 7 days
223655440|NCT00947687|DRUG|Placebo|
223655441|NCT03173183|DRUG|genuine regional Rhizoma Atractylodis (Maozhu granule)|"Maozhu granule, 9g per bag, manufactured by Guangdong Yifang Pharmaceutical Co., Ltd.~Luozhu granule, 9g per bag, manufactured by Guangdong Yifang Pharmaceutical Co., Ltd.~Simulants (granule), 9g per bag, manufactured by Guangdong Yifang Pharmaceutical Group Co., Ltd."
223768022|NCT00226941|DRUG|Cetuximab|Cetuximab is a chimeric anti-epidermal growth factor receptor (anti-EGFR) monoclonal antibody, administered via a intravenous (IV) infusion at 400 mg/m² (initial loading dose) or 250 mg/m² (weekly dose). Dosage is based on m² of body surface area (BSA)
224238652|NCT03102580|OTHER|OA Care Plan|Patient and surgeon will receive the OA Care Plan (currently under development). This Care Plan will inform Shared Decision for treatment of moderate to sever OA, including surgical and non-surgical options.
223655442|NCT02052388|DRUG|Daptomycin|Active Comparator
223655443|NCT02052388|DRUG|Brilacidin|Experimental Drug
223655444|NCT01072604|DRUG|Acetylsalicylic acid (Aspirin, BAY1019036)|One oral dose of new formula Aspirin Prototype 1 under fasting conditions
223655445|NCT01072604|DRUG|Acetylsalicylic acid (Aspirin, BAY1019036)|One oral dose of new formula Aspirin Prototype 2 under fasting conditions
223655446|NCT01072604|DRUG|Acetylsalicylic acid (Aspirin, BAYE4465)|One oral dose of Aspirin Plain Tablet under fasting conditions
224238653|NCT02673580|OTHER|Open Access telePRO|"In open access, contacts to the outpatient clinic are initiated solely by the patient. Contacts may be in the form of a PRO assessment like in standard telePRO, but at a time decided by the patient via the Danish National Health website Sundhed.dk."
224238654|NCT02673580|OTHER|Standard telePRO|Standard care: fixed interval telePRO follow-up. Patients receive a questionnaire with individually pre-specified intervals.
223655447|NCT01072604|DRUG|Acetylsalicylic acid (Aspirin, BAYE4465)|One oral dose of Aspirin Dry Granules under fasting conditions
223655448|NCT02453204|BEHAVIORAL|Sitting|
223655449|NCT02453204|BEHAVIORAL|Standing|
223655450|NCT02453204|BEHAVIORAL|Walking|
223655451|NCT05080699|DIETARY_SUPPLEMENT|Peptamen Intense VHP, Nestlé Health Science, Switzerland|An enteral formula containing hydrolyzed whey protein, maltodextrin, long-chain triglycerides, medium chain triglycerides (MCT), vitamins and minerals. Compared to standard enteral formula, Peptamen Intense is higher in protein (37 kcal%) and lower in carbohydrates (29 kcal%). The energy content is 1.0 kcal/mL.
223655452|NCT04098484|OTHER|Control Trial|Participants will abstain from exercise throughout a 3-month period
223655453|NCT04098484|OTHER|Exercise Trial|Participants will execute a 3-month exercise training program
223768023|NCT00226941|DRUG|Oxaliplatin|Oxaliplatin is a cancer medication used to treat colorectal cancer, and is administered on Days 2 and 23.
223768024|NCT00226941|DRUG|Capecitabine|Capecitabine is a cancer medication, and is administered based on m² of body surface area (BSA) delivered in equivalent morning and evening doses
224238655|NCT00411866|DRUG|SB773812|SB-773812 20 mg will be available as white round film coated tablets.
224238656|NCT00411866|DRUG|Ketoconazole|Ketoconazole will be available as 200mg tablets.
224238657|NCT01936922|DEVICE|GaitAid®|Provides visual and auditory cues for walking.
224238658|NCT05829148|DRUG|Dexmedetomidine|Comparison the effect of Dexmedetomidine, Melatonin and Pregabalin on hemodynamics, recovery profile and postoperative pain in patients undergoing Functional endoscopic sinus
223655454|NCT00038818|BIOLOGICAL|CD8 Depleted Donor Lymphocyte|
223655455|NCT02827929|BEHAVIORAL|Education|3 times systemic education program will be provided to patients were diagnosed as asthma or COPD by their physicians.
223655456|NCT00710541|DEVICE|ventilators designed for non invasive ventilation|Patients are advised to use the ventilator for non invasive ventilation as long term treatment for at least 6 hours per day over one year.
223655457|NCT01328067|DEVICE|Exablate 2100|MRgFUS
223655458|NCT01328067|PROCEDURE|Myomectomy|Non-Hysteroscopic Myomectomy
223655459|NCT00393861|DRUG|Bevacizumab and Oxaliplatin|Oxaliplatin 85 mg/M2 IV over 2 hours plus Bevacizumab 10 mg/kg IV over 90 minutes
223655460|NCT04571567|DRUG|Secukinumab|Each 300mg dose is given as two subcutaneous injections of secukinumab 150mg, 1mg liquid formulation in a pre-filled syringe.
223655461|NCT04968769|OTHER|ischemic compression|manual therapy
223655462|NCT04968769|OTHER|kinesio taping|elastic therapeutic taping
223655463|NCT04968769|OTHER|exercise|posture exercises
223655464|NCT02796261|DRUG|Eflornithine|Eflornithine 2.8 g/m2 administered orally every 8 hours on a 2 week on, 1 week off schedule
223655465|NCT02796261|DRUG|Lomustine|Lomustine 90 mg/m2 administered orally once every 6 weeks
223768025|NCT00226941|RADIATION|Radiotherapy|"Radiotherapy is administered on weekdays in 180 centigray fractions (doses), for 28 total fractions delivering a total dose of 5040 centigray (cGy)"
223768026|NCT00226941|DRUG|Diphenhydramine hydrochloride (HCl)|Diphenhydramine HCl 50 mg (or equivalent) is administered as a per-medication for cetuximab
223655466|NCT02796261|DRUG|Lomustine|Lomustine 110 mg/m2 administered orally once every 6 weeks
224238659|NCT05829148|DRUG|Melatonin|Melatonin
224238660|NCT05829148|DRUG|Pregabalin|Pregabalin
224238661|NCT05829148|DRUG|Placebo|Placebo
224238662|NCT04947748|OTHER|Oral versus intravenous administration of antibacterial treatment|Mode of administration of antibacterial treatment
224238663|NCT00005939|RADIATION|brachytherapy|
223655467|NCT01081964|DRUG|Zabofloxacin|Zabofloxacin 400mg capsule once daily for 3 days
224238664|NCT00005939|RADIATION|phosphorus P32|
224238665|NCT03413046|DIAGNOSTIC_TEST|Peripheral and bone marrow sampling|We obtained blood from peripheral and bone marrow sampling. Then we analyze Treg population and Treg related cytokines with flow cytometry and ELISA methods.
224238666|NCT05395858|OTHER|No intervention|Retrospective analysis using database without any intervention assigned in the study.
224238667|NCT03900624|DRUG|Dexamethasone|Non-randomized, open-label, prospective use of intravenous dexamethasone for children admitted to the PICU with status asthmaticus
224238668|NCT03165058|DIAGNOSTIC_TEST|mucosal impedance (MI) testing|During routine colonoscopy, consented study participants will have a MI catheter sensor positioned along the mucosal wall to measure resistance across the mucosa. The physician will take measurements in each segment of the colon, including segments that appear inflamed and normal adjacent areas (up to 10 locations). To obtain a stable reading, the sensor must remain in contact with the mucosa for five seconds. The study procedure will add approximately 1-2 minutes of anesthesia time for each participant. Basic demographic information, prior IBD treatments, and prior colonoscopic data will be collected from the medical record following the procedure for those patients who consent to research.
224238669|NCT05240196|OTHER|music|playing binaural or non-binaural music
224238670|NCT03252964|DEVICE|Continuous Glucose Monitor (CGM)|Subjects will use a CGM to develop an understanding of how their behaviors influence their glucose levels.
224238671|NCT03252964|DEVICE|Activity Tracker|Subjects will use the activity tracker, in combination with a continuous glucose monitor (CGM), to develop an understanding of how their activity levels affect their glucose levels.
224238672|NCT03252964|BEHAVIORAL|Coaching|Coaches will help subjects understand the readings from the CGMs and how they are affected by diet choices, use of diabetes medications, etc. Coaches and subjects will have weekly conversations about CGM data and behaviors that affect CGM readings. Coaching will occur via telephone, text messaging, and automated text messaging.
224238673|NCT01130623|DRUG|Pazopanib (GW786034)|
223655468|NCT01081964|DRUG|Levofloxacin 500mg|Levofloxacin 500mg orally for 7 days
224238674|NCT05261464|DRUG|Metoprolol tartrate|Prescribe oral metoprolol tartrate according to doses and time duration until patient reach targeted HR of less than 60 bpm or maximize dose according to each drug protocols prior to CCTA.
224238675|NCT05261464|DRUG|Ivabradine|Prescribe oral ivabradine according to doses and time duration until patient reach targeted HR of less than 60 bpm or maximize dose according to each drug protocols prior to CCTA.
224238676|NCT05261464|DRUG|Diltiazem|Prescribe oral diltiazem immediate-release according to doses and time duration until patient reach targeted HR of less than 60 bpm or maximize dose according to each drug protocols prior to CCTA.
224238677|NCT01075581|DRUG|Epinephrin (Intranasal injection)|A total of 8 mL of epinephrine 1:100,000 will be injected in the lateral nasal wall, followed by placement of cotton pledgets (soaked in 1 mL epinephrine 1:1,000) in the nasal cavity when required.
223655469|NCT01081964|DRUG|Zabofloxacin 400mg|Zabofloxacin 400mg orally for 5 days
223655470|NCT04202172|PROCEDURE|Stent implantation in the infart-related artery in patients with ST elevation myocardial infarction|"The 6-month scheduled coronary angiography will perform 3 interventions:~1. Endothelial function assessment with intracoronary acetyl-choline infusion.~2. Microcirculatory function assessment with a pressure wire during endovenous adenosine infusion.~3. Stent healing assessment using optical coherence tomography"
223655471|NCT00617968|DRUG|DOCETAXEL|
223681059|NCT06179368|DIAGNOSTIC_TEST|hypothroidism|throid fuction will be evaluated on admission of hepatic failure patients, and the hypothyroid patients will be enroled in this group.
223681060|NCT06179368|DIAGNOSTIC_TEST|euothyroid|throid fuction will be evaluated on admission of hepatic failure patients, and the euothyroid patients will be enroled in this group.
223681061|NCT02554279|DRUG|menotropin|
223681062|NCT02554279|DRUG|recombinant FSH|
223681063|NCT00812487|DRUG|Intravenous insulin|Patients will receive continuous insulin infusion through the vein.
223681064|NCT00812487|DRUG|Subcutaneous insulin|4 injections of insulin/day
223681065|NCT01680133|OTHER|Hyperinsulinemic euglycemic clamp|
223681066|NCT04695587|DIAGNOSTIC_TEST|123 MIBG scintigraphy testing|123 MIBG scintigraphy testing in subacute phase and 12 months after the acute episode in a subgroup of patients according to individualized needs.
223681067|NCT04695587|DIAGNOSTIC_TEST|MSNA|MSNA in subacute phase and 12 months after the acute episode
223681068|NCT04695587|DIAGNOSTIC_TEST|ABPM|ABPM in subacute phase and 12 months after the acute episode
223681069|NCT04695587|DIAGNOSTIC_TEST|ECHO|ECHO in subacute phase and 12 months after the acute episode
223681070|NCT04695587|DIAGNOSTIC_TEST|24hour ECG|24hour ECG in subacute phase and 12 months after the acute episode
223681071|NCT04695587|DIAGNOSTIC_TEST|CMR|CMR in 12 months after the acute episode
223681072|NCT00882401|DRUG|Ergocalciferol (Vitamin D)|ergocalciferol: 50,000 IU per week for 1 month followed by 50,000 IU per month for 5 months.
223681073|NCT00882401|DRUG|Placebo|Matching placebo at same dose schedule as ergocalciferol
223681074|NCT02146144|PROCEDURE|ILM Peeling|"common surgical procedure:~For phakic eyes with cataract • phacoemulsification and implantation of a posterior chamber intraocular lens~For all patients:~* Central and peripheral 25 Gauge vitrectomy~* dissection of the epimacular membrane~* injection of Membraneblue-Dual® according to protocol, wait of 1 minute with the infusion line closed, and then suction of surplus and washing of the vitreous cavity~* Intraoperative picture to see the possible spontaneous ILM peeling~* If no spontaneous ILM peeling, the patient will be randomized at the operating block~Specific surgical procedure:~• • Randomization into two groups:~* Arm 1: no peeling, where the ILM peeling will not be made~* Arm 2: active peeling, where the ILM peeling will be made"
223768027|NCT01513291|DRUG|MK-6096|MK-6096, two 5 mg tablets (total 10 mg dose), orally, once daily
223768028|NCT01513291|DRUG|Placebo|Placebo, 2 tablets, orally, once daily
223768029|NCT04612491|BEHAVIORAL|Pre-operative Consultation|Pre-operative consultation will be given before Mohs surgery
223768030|NCT05691140|OTHER|Cognitive Behavioural Therapy|Cognitive Behavioural Therapy targeting Intolerance of Uncertainty
223768031|NCT03424915|BEHAVIORAL|Harvard Health Professionals survey|Participants will be asked a series of questions (using a validated questionnaire) to assess self-reported exercise exposure over the past 12 months.
223768032|NCT03424915|OTHER|Blood draw|Participant will provide a blood sample
223768033|NCT03424915|OTHER|CPET Procedures|CPET with 12-lead ECG
223768034|NCT03424915|OTHER|stool sample|Research stool sample (within ±1 week of surgery), if possible
223655472|NCT06061757|DEVICE|Imaging guidance with TEE and ICE for Left atrial appendage closure|The occluder size for both LAAC devices will be selected based on the maximal diameter of the LAA orifice following the manufacturer guidelines and using the maximal length of the LAA measured on Echocardiogram. Intraprocedural measurements of the LAA width and depth were acquired on both ICE and TEE per protocol. Both ICE and TEE will be used to assess for any procedural complications prior to insertion of the device delivery sheath.
223655473|NCT04155580|DRUG|ASTX660|Capsule for oral administration
223768035|NCT03424915|PROCEDURE|Research Tissue sampling|Sample of the tumor and normal breast tissue may be taken from the tissue removed during breast cancer surgery if there is enough tissue left over for research testing.
223768036|NCT03732638|DRUG|Rimegepant|Rimegepant 75 mg tablet EOD
223768037|NCT03732638|DRUG|Placebo|Placebo tablet to match rimegepant tablet EOD
223768038|NCT01061060|DRUG|Prostaglandin I2|oral
223768039|NCT01061060|DRUG|Placebo|oral
223655474|NCT04155580|DRUG|ASTX727|Tablet for oral administration
223768040|NCT01114841|DRUG|Tazarotene Foam|"Patches containing Tazarotene Foam 0.1% will be applied to randomized sites on the subject's back and will be assessed 3 times per week for 3 weeks. Patches will be removed and evaluated every 48 to 72 hours.~There will be a 10-14 day rest period followed by a single 48-hour patch application (challenge).~These patches will then be evaluated at 24, 48, and 72 hours.~There may be a second rest period and a second 48-hour patch application and evaluation, if required."
224238678|NCT01075581|DRUG|Epinephrin (Topical administration)|An intranasal injection of saline solution, followed by placement of cotton pledgets (soaked in 1 mL epinephrine 1:1,000) in the nasal cavity when required.
224320966|NCT05533671|PROCEDURE|medial patellofemoral reconstruction|Surgery to correct dislocated (knocked out of place) knee cap. This surgery anchors the kneecap back into the correct position and supports the kneecap.
224320967|NCT05533671|PROCEDURE|Non-operative group|Physical therapy by following a specific regimen.
224320968|NCT06045221|DRUG|Orforglipron|Administered orally
223768041|NCT01114841|DRUG|Vehicle Foam|"Patches containing Vehicle Foam will be applied to randomized sites on the subject's back and will be assessed 3 times per week for 3 weeks. Patches will be removed and evaluated every 48 to 72 hours.~There will be a 10-14 day rest period followed by a single 48-hour patch application (challenge).~These patches will then be evaluated at 24, 48, and 72 hours.~There may be a second rest period and a second 48-hour patch application and evaluation, if required."
223768042|NCT01068327|DRUG|gemcitabine hydrochloride|Given IV
223768043|NCT01068327|DRUG|leucovorin calcium|Given IV
223768044|NCT01068327|DRUG|fluorouracil|Given IV
223768045|NCT01068327|DRUG|nelfinavir mesylate|Given PO
223768046|NCT01068327|RADIATION|stereotactic body radiation therapy|Undergo radiotherapy
223768047|NCT01068327|RADIATION|hypofractionated radiation therapy|Undergo radiotherapy
223768048|NCT01068327|PROCEDURE|therapeutic conventional surgery|Undergo surgery
223768049|NCT03728582|DEVICE|Active tDCS plus Speech-Language Therapy|1-2 milliamps (mA) of Anodal tDCS stimulation is induced between 5cm X5 cm saline soaked sponges where one sponge is placed on the left inferior frontal gyrus (IFG). The stimulation will be delivered at an intensity of 1-2 mA in a ramp-like fashion for a maximum of 20 minutes. Speech-language therapy will be verb naming therapy in a sentence context.
223768050|NCT03728582|DEVICE|Sham tDCS plus Speech-Language Therapy|Sham tDCS stimulation is provided to the left inferior frontal gyrus (IFG) using a tDCS device. Speech-language therapy will be verb naming therapy in a sentence context.
223768051|NCT01083381|DRUG|MS14|MS14 will be administered at an oral dose of 25-50 mg/kg/day in two divided doses for three months
223768052|NCT01083381|DRUG|Risperidone|The treatment group receives Risperidone 2 mg per day in the beginning which is increased by 1 mg every day until reaching 4 mg/day; this regimen will be continued for three months.
223655475|NCT05300763|DEVICE|senofilcon A prototype|Test
223655476|NCT05300763|DEVICE|Dailies Total 1|Control
223655477|NCT04059315|OTHER|surgical treatment of facial bone fracture|oral and maxillofacial injury patients admitted in our hospital. patients are getting treatment of soft and bone frature as follow soft tissue repaire, IMF, ORIF, consrvative.
223655478|NCT03386916|PROCEDURE|CT scan guide percutaneous biopsy of lytic bone metastases of lung cancer|
223768053|NCT00967408|DRUG|Escitalopram|Rehabilitative treatment + Oral Escitalopram 5 mg/day for the first week, 10 mg/day from second to fourth week and 20 mg/day until 6th month.
223768054|NCT00967408|DRUG|Placebo|Rehabilitative treatment + oral inactive placebo for 6 months
223768055|NCT00967408|OTHER|Rehabilitative treatment|Rehabilitative treatment
223768056|NCT01431768|DEVICE|Respirio Flu Test|The Respirio Flu Test (RFT) is a rapid test for identifying whether a patient is infected with the Influenza A or B virus. The test separates the Influenza virus from the patient's nose blow sample and utilizes the same underlying technology as a pregnancy test (lateral flow/immuno-chromatography) to deliver a positive or negative result in less than 10 minutes. The RFT is easy to use, designed with a 3 step process similar to that of the home pregnancy test. Results are presented to the patient as a combination of different coloured lines, depending on whether the patient has Influenza A or B.
224320969|NCT06045221|DRUG|Semaglutide|Administered orally
224320970|NCT06585488|DRUG|BGB-53038|Administered orally
224320971|NCT06585488|DRUG|Tislelizumab|administered by intravenous infusion
224320972|NCT06585488|DRUG|Cetuximab|administered by intravenous infusion
223655479|NCT01632124|OTHER|Lung function measurement|Spirometry and measurement of diffusing capacity for carbon monoxide
223655480|NCT03993106|DRUG|sEphB4-HSA|sEphB-HSA may prevent tumor cells from multiplying and blocks several compounds that promote the growth of blood vessels that bring nutrients to the tumor.
223655481|NCT02928016|OTHER|Mixed meal 1|20 adults with type 1 diabetes (T1DM) on intensive insulin treatment consumed a dish made with thick pasta, minced meat and béchamel sauce and 20 g kalamata olives. The meal provided 794 kcal and contained approximately 500 kcal from protein and fat. Insulin requirements for the test meal were calculated based on the carbohydrate content of the dish according to the personalised carbohydrate to insulin ratio.
223655482|NCT02928016|OTHER|Mixed meal 2|20 adults with type 1 diabetes (T1DM) on intensive insulin treatment consumed grilled chicken with vegetables.The meal provided 399 kcal and contained approximately 300 kcal from protein and fat. Insulin requirements for the test meal were calculated based on the carbohydrate content of the dish according to the personalised carbohydrate to insulin ratio.
223655483|NCT02928016|OTHER|Mixed meal 3|20 adults with type 1 diabetes (T1DM) on intensive insulin treatment consumed baked giant beans and 20g kalamata olives. The meal provided 502 kcal and contained approximately 300 kcal from protein and fat. Insulin requirements for the test meal were calculated based on the carbohydrate content of the dish according to the personalised carbohydrate to insulin ratio.
223768057|NCT03830502|PROCEDURE|Surgical sterilization|Surgical sterilization either standard salpingectomy or tubal ligation with Pomeroy technique
224238679|NCT01843608|OTHER|Physical Intervention|The exercise program will be designed and conducted by qualified in Physical Activity and Sport Sciences. The exercise program will consist in a combined two days per week of supervised training program and one day per week of briskly walking by themselves, following a document, designed by the specialist trainer, which will be given at the beginning of the program. The intervention will have a duration of 12 consecutive weeks. The intensity will be increasing progressively from 65% to 85% of heart rate. The intensity will be controlled by heart rate monitor trademark POLAR FT7 in aerobic exercise and with the number of repetitions (from 8 to 15) and sets (from 2 to 3) in strength exercises. Prescription intensity will be done using Karvonen equation, recommended method to work with risk population.
224238680|NCT03171155|DEVICE|XPro System|Implantation of the XPro System
223655484|NCT02928016|OTHER|Mixed meal 4|20 adults with type 1 diabetes (T1DM) on intensive insulin treatment consumed a dish made with thick pasta, minced meat and béchamel sauce and 20 g kalamata olives and 11 ml extra virgin olive oil. The meal provided 893 kcal and contained approximately 600 kcal from protein and fat. Insulin requirements for the test meal were calculated based on the carbohydrate content of the dish according to the personalised carbohydrate to insulin ratio.
223655485|NCT02928016|OTHER|Mixed meal 5|20 adults with type 1 diabetes (T1DM) on intensive insulin treatment consumed grilled chicken with vegetables and 11 ml extra virgin olive oil. The meal provided 497 kcal and contained approximately 300 kcal from protein and fat. Insulin requirements for the test meal were calculated based on the carbohydrate content of the dish according to the personalised carbohydrate to insulin ratio.
223681075|NCT01364675|DRUG|Metformin+Enalapril+Simvastatin|Poly-pill - composed of Metformin (500 mg), Enalapril (10 mg) and Simvastatin (10 mg) in single tablet given once daily after dinner for 4 years
223681076|NCT01364675|DRUG|Placebo tablet|Identical Placebo Tablet
224238681|NCT00583258|DRUG|Alfuzosin (Xatral)|10 mg PO once a day
224238682|NCT00583258|DRUG|Placebo Alfuzosin|10 mg PO once a day
224238683|NCT05039502|OTHER|Protaper Universal Retreatment|D1-D2-D3 Retreatment files were used in 500 rpm and 3 Ncm with X-Smart endomotor
224238684|NCT05039502|OTHER|Reciproc|R25 retratment files were used with X-Smart endomotor in reciprocal motion
224238685|NCT05039502|OTHER|XP-Endo finisher R|XP-Endo finisher r file were used in 1000 rpm 1 Ncm with X-Smart endomotor
224238686|NCT00444145|DRUG|Prevacid|30 mg bid for 3 months
224238687|NCT00444145|PROCEDURE|Esophageal and Laryngeal Biopsies|repeat egd with biopsy after Prevacid 30 mg bid for 3 months
224238688|NCT01195298|DRUG|Capecitabine and Bevacizumab|"Drugs will be administered in 3-week cycles as follows:~* Bevacizumab 15mg/kg via i.v. infusion on day 1~* Capecitabine 1000 mg/m2 tablets twice-daily, on days 1 through 14."
224238689|NCT04814745|DRUG|intrathecal infusion|morphine 150 mcg will be used by intrathecal administration
224238690|NCT04814745|DRUG|Intravenous Infusion|tramadol administration
224238691|NCT04814745|DRUG|Ropivacaine injection|bilateral transversus abdominis plane block by using ropivacaine 80 mg
224238692|NCT05046548|BIOLOGICAL|Vaccine for intramuscular injection|Volunteers (10 at the Stage 1; 140 at the Stage 2; 150 at the Stage 3) will receive the vaccine twice spaced 14 days apart, intramuscularly, at a dose of 0.5 ml
224238693|NCT05046548|OTHER|Placebo comparator (without active ingredient) for intramuscular injection|Volunteers (5 at the Stage 1; 45 at the Stage 2; 50 at the Stage 3) will receive the vaccine twice spaced 14 days apart, intramuscularly, at a dose of 0.5 ml
224238695|NCT03968549|DIETARY_SUPPLEMENT|Probiotic|Those patients in group Probiotic will receive the capsules containing Lactobacillus acidophilus and will need to take one of it everyday during the study.
224238696|NCT03968549|OTHER|Placebo|Those patients in group Placebo will receive the capsules containing vegetable oil and corn starch and will need to take one of it everyday during the study.
224238697|NCT05390437|DIETARY_SUPPLEMENT|Nutritional intervention with Ready to use theraputic food (RUTF) and prebiotic GOS (galacto oligosaccharides) in combination|4gm of prebiotic GOS ( Galactooligosaccharides) and Ready to use theraputic food (RUTF) as per WHO standard on daily basis for 60 Days
224238698|NCT05390437|DIETARY_SUPPLEMENT|Ready to use theraputic food (RUTF) and Starch (placebo)|Ready to use therapeutic food (RUTF) as per WHO standard and (Starch Placebo) soluble in water and mix in food on daily basis for 60 Days
224238699|NCT05289713|PROCEDURE|appendectomy|Laparoscopic appendectomy is performed within 18 hours after randomization in the surgery group. Patients in the symptomatic treatment group are carefully monitored and the same intervention (laparoscopic appendectomy) is performed in case of treatment failure.
224238700|NCT03467165|DEVICE|MRgFUS treatment|MRgFUS treatment of pain caused by trapeziometacarpal OA (and/or scaphotrapezial OA)
224238701|NCT03467165|DEVICE|MRgFUS treatment|MRgFUS treatment of pain caused by hip OA
224238702|NCT03022773|OTHER|Carotenoid measurements|"Carotenoid measurements of the eye (macula) are obtained through non-invasive ophthalmic photographs using the Heidelberg Spectralis imaging system.~Carotenoid measurements of the skin are measured by a laboratory instrument that uses a painless blue laser light for exposure of the skin and a photodetector for scattered light.~Carotenoid measurements in the blood are obtained through routine venipuncture."
224238703|NCT02700464|DEVICE|Bladder EpiCheck Urine Test|The Bladder EpiCheck test is an in vitro diagnostic device for the detection of DNA methylation patterns in urine that are associated with bladder cancer. It is intended for use as a noninvasive method for monitoring for tumor recurrence in conjunction with cystoscopy inpatients previously diagnosed with bladder cancer
224238704|NCT02700464|PROCEDURE|Cystoscopy and pathology|Routine cystoscopy for bladder cancer recurrence and pathology confirmation for patients with positive cystoscopy
224238705|NCT00448097|DRUG|cetuximab|No verifiable data available, PI relocated
224238706|NCT00448097|DRUG|docetaxel|No verifiable data available, PI relocated
224238707|NCT02793453|OTHER|periodontal smears|
224238708|NCT02195245|DEVICE|memsorb|
224238709|NCT05017298|BIOLOGICAL|Allogeneic adipose-derived stem cells|Culture expanded mesenchymal stem cells isolated from a patient's own abdominal fat tissue
223655486|NCT02928016|OTHER|Mixed meal 6|20 adults with type 1 diabetes (T1DM) on intensive insulin treatment consumed baked giant beans and 20 g kalamata olives and 11 ml extra virgin olive oil. The meal provided 601 kcal and contained approximately 400 kcal from protein and fat. Insulin requirements for the test meal were calculated based on the carbohydrate content of the dish according to the personalised carbohydrate to insulin ratio.
223655487|NCT04316988|DIAGNOSTIC_TEST|Ultrasonography|A real time 2D ultrasound evaluation was done over the trachea of the patient.
223655488|NCT02170415|DRUG|Protective analgesia|"Participants in the intervention arm of the study (if no contraindications exist) will be administered one pre-procedure dose of 150mg of oral pregabalin.~For a total of five days post-procedure the participants in the intervention limb of the study will take oral pregablin twice daily at a dose of 75mg twice a day."
223768058|NCT02174094|DRUG|Clobazam|
224238710|NCT02244034|PROCEDURE|hypothermia|
224238711|NCT02456779|OTHER|in vitro diagnostic test (Peptest)|saliva samples obtained and tested in laboratory conditions for the presence of pepsin using Peptest
224238712|NCT02456779|OTHER|Questionnaire|all recruited subjects to complete the RDQ as a determinant of inclusion criteria
224238713|NCT02456779|OTHER|Questionnaire|control subjects to complete RSI as a determinant of inclusion criteria
224238714|NCT00724256|DRUG|ceftibuten|ceftibuten 9mg/kg once a day for 7 days.
224238715|NCT00724256|DRUG|ceftibuten|ceftibuten 9mg/kg once a day for 10 days.
224238716|NCT03189888|DEVICE|apheresis|
224238717|NCT00630305|DEVICE|alphafilcon A toric|Subjects that were randomized to receive alphafilcon A toric during one of the four sessions (Sessions A, B, C and D).
224238718|NCT00630305|DEVICE|lotrafilcon B toric|Subjects that were randomized to receive lotrafilcon B toric during one of the four sessions (Sessions A, B, C and D).
224238719|NCT00630305|DEVICE|senofilcon A toric|Subjects that were randomized to receive senofilcon A toric during one of the four sessions (Sessions A, B, C and D).
224238720|NCT06223347|DIAGNOSTIC_TEST|Chromoendoscopy|"Chromoendoscopy: is a dye based staining of colonic mucosa. NBI: is an optical image enhancing technology that allows a detailed inspection of vascular and mucosal patterns, providing the ability to predict histology during real-time endoscopy.~TXI: is a digital technique that enhance texture and color of the tissues to be more visible."
224238721|NCT05901857|DIAGNOSTIC_TEST|convolutional neural network|A deep learning model for dental age classification from panoramic images
224238722|NCT04949620|BEHAVIORAL|REThink therapeutic game|REThink is a online therapeutic game developed by David and collaborators (2018), proved to be an efficient intervention for the reduction of emotional symptoms in children and adolescents.
224238723|NCT04949620|BEHAVIORAL|Online parenting program|The online parenting intervention consists of a newly developed parenting program, including rational emotive behavioral therapy and schema therapy principles
224238724|NCT00467220|BEHAVIORAL|calorie restriction|"Subjects in the calorie restriction arm and the alternate day fasting arm will be asked to follow a menu plan, for three months, that includes some level of calorie restriction."
224238725|NCT03339856|DEVICE|Selective retina therapy|"The selective retina therapy (SRT) is a laser treatment to the retina using the R:GEN device (Lutronic, Goyang-si, South Korea).~Laser energy began at 80 µJ and was increased in 5-10 µJ intervals until the optimal energy delivery was confirmed by the RFD system. Following confirmation, the optimal laser energy was applied to fluorescein leakages. If the energy was indeed optimal at leakage points, laser shots were administered around the leakages. If the energy was not optimal at the leakage points, laser energy was again increased in 5-10 µJ increments until optimal energy delivery."
224238726|NCT04639765|OTHER|CBT without Personalization|Intervention involves a video describing CBT without a message about personalization.
224238727|NCT04639765|OTHER|CBT with Personalization|Intervention involves a video describing CBT with a message about personalization.
224238728|NCT04639765|OTHER|ADM without Personalization|Intervention involves a video describing antidepressant medication without a message about personalization.
224238729|NCT04639765|OTHER|ADM with Personalization|Intervention involves a video describing antidepressant medication with a message about personalization.
224238730|NCT04639765|OTHER|Combined Treatment without Personalization|Intervention involves a video describing the combination of cognitive behavior therapy and antidepressant medication without a message about personalization.
224238731|NCT04639765|OTHER|Combined Treatment with Personalization|Intervention involves a video describing the combination of cognitive behavior therapy and antidepressant medication with a message about personalization.
224238732|NCT00186290|PROCEDURE|ablative allogeneic hematopoietic cell transplantation|
224238733|NCT00714103|DRUG|8-Chloro-Adenosine|45 mg/m\^2 intravenous over 1 hour daily for 5 days every 4 weeks (± 3 days).
224238734|NCT01494506|DRUG|MM-398|"Arm A: MM-398 120 mg/m2 IV Q3W~Arm C: MM-398 80mg/m2 IV Q2W"
224238735|NCT01494506|DRUG|5 Fluorouracil|"Arm B: 5 Fluorouracil 2000 mg/m2 IV for 4 weeks followed by 2 weeks of rest every 6 weeks~Arm C: 5 Fluorouracil 2400 mg/m2 IV every 2 weeks"
223768059|NCT02174094|DRUG|Placebo|
224238736|NCT01494506|DRUG|Leucovorin|"Arm B: Leucovorin 200 mg/m2 IV for 4 weeks followed by 2 weeks of rest every 6 weeks~Arm C: Leucovorin 400 mg/m2 IV every 2 weeks"
224238737|NCT02753842|DEVICE|5 Fitted Condoms, 5 Thin Condoms, 5 Standard Condoms|"Fitted condoms are available in 56 sizes based on combinations of length (approximately 10mm increments) and circumference (approximately 2 mm increments). Fitted condom thickness is 70 microns ± 10 microns. Appropriate condom size is user-determined with a paper template fitting tool graduated with non-sequential numbering and lettering for maximum privacy. Participants also received ten plain foil packets of 10ml commercially available condom-compatible water-based lubricant.~Thin condoms have dimensions of 185mm ± 10mm length, 53mm ± 2mm width, and 50 microns ± 5 microns thick. Participants also received ten plain foil packets of 10ml commercially available condom-compatible water-based lubricant.~Standard condoms have dimensions of 185mm ± 10mm length, 53mm ± 2mm width, and 70 microns ± 10 microns thick. Participants also received ten plain foil packets of 10ml commercially available condom-compatible water-based lubricant."
224238738|NCT05701670|BEHAVIORAL|Purrble+SSI|"Purrble intervention as described above.~Single Session Intervention (SSI) (\~30mins) combining the theories of ER with the experiences from students involved in previous studies, and follows a traditional SSI structure (Schleider et al 2020). Specific content has been co-produced with students and experts."
224238739|NCT01979341|PROCEDURE|final oocyte maturation trigger|when ≥3 follicles reach 17mm patients will be randomized to receive one of two types of trigger for final oocyte maturation; dual trigger: GnRH agonist plus hCG (both full doses) hCG only: full dose of hCG only
224238740|NCT00236457|DRUG|risperidone|
224238741|NCT04500470|DRUG|Ketoprofen + INH|patients will have of oral Ketoprofen 60 minutes before the procedure plus 3 table 900 mg vaginal isonicotinic acid hydrazide by the patient 12 hours before the procedure
223655489|NCT02170415|OTHER|Pain education|Participant will receive a pain education leaflet
223655490|NCT02170415|BEHAVIORAL|Psychological support|Participants demonstrating psychological morbidity will be offered psychological support prior to surgery
223655491|NCT02170415|PROCEDURE|Paravertebral block/local anaesthetic infiltration|Patients on the intervention limb will be encouraged to have a paravertebral block if not contraindicated
223655492|NCT02170415|OTHER|Daily visits from pain team whilst in hospital|
223655493|NCT05657808|DIETARY_SUPPLEMENT|Rest Study Active Product 1.1 Usage|Participants will use Radicle Rest Active Product 1.1 as directed for a period of 6 weeks.
223655494|NCT05657808|DIETARY_SUPPLEMENT|Rest Study Active Product 1.2 Usage|Participants will use Radicle Rest Active Product 1.2 as directed for a period of 6 weeks.
224238742|NCT04500470|DRUG|Ketoprofen + placebo|patients will have of oral Ketoprofen 60 minutes before the procedure plus 3 table placebo by the patient 12 hours before the procedure
224238743|NCT00075543|DRUG|docetaxel|
224238744|NCT00075543|DRUG|oxaliplatin|
224238745|NCT03596190|DIAGNOSTIC_TEST|ultrasonographic diaphragmatic assessment|"Diaphragmatic dysfunction will be determined by intercostal diaphragm thickening. The available image will be saved.~Diaphragmatic motion assessments will be conducted on the side to be blocked both at baseline, and then every 5 minutes until patient leaves for operating room or 30 minutes (whatever is earlier)."
224238746|NCT02627209|OTHER|spectrophotometric assay|measurement of enzyme activity in the serum
224238747|NCT02627209|OTHER|radial immunodiffusion|measurement of the precipitated ring diameters showing enzyme activity in the serum
224238748|NCT03659656|BEHAVIORAL|Lifestyle coaching|Goal setting and behavior change barriers will be discussed through lifestyle behavioral change coaching. Personalized weekly physical activity achievement report will also be sending to participants in experimental group. The participants will also have a Fitbit to use for 3 months.
224238749|NCT03659656|DEVICE|Fitbit usage|The participants will have a Fitbit to use for 3 months.
224238750|NCT02303548|DRUG|Sodium bicarbonate|Administer Sodium bicarbonate 50 mEq IV over 2 minutes
224238751|NCT02303548|DRUG|Normal saline|Placebo
224238752|NCT02019056|DRUG|Placebo /bid P.O|
224238753|NCT02019056|DRUG|MG-1|
224238754|NCT02019056|DRUG|MG-2 : MG1000mg, Placebo /bid P.O|
224238755|NCT02019056|DRUG|metadoxine|
224238756|NCT05216081|BEHAVIORAL|Virtual cOaching in making Informed Choices on Elder Mistreatment Self-Disclosure (VOICES)|Virtual cOaching in making Informed Choices on Elder Mistreatment Self-Disclosure (VOICES) screening tool.
224238757|NCT01311908|PROCEDURE|Methods of gastrojejunostomy reconstruction|Roux-en-Y reconstruction in pancreaticoduodenectomy
224238758|NCT05526950|DEVICE|Device: CytoSorb|Medical device used hemoperfusion and cytokine adsorption in conjunction with lung transplantation.
224238759|NCT02359981|BEHAVIORAL|MyBehavior|The intervention automatically provides personalized suggestions based on users behavior and user context. Suggestions relates to users life and how often they have done them in the past. Since the suggestions relate to users' lives, they are easy to follow.
223655495|NCT05657808|DIETARY_SUPPLEMENT|Rest Study Active Product 2.1 Usage|Participants will use Radicle Rest Active Product 2.1 as directed for a period of 6 weeks.
223655496|NCT05657808|DIETARY_SUPPLEMENT|Rest Study Active Product 2.2 Usage|Participants will use Radicle Rest Active Product 2.2 as directed for a period of 6 weeks.
223655497|NCT05657808|DIETARY_SUPPLEMENT|Placebo Control Form 1|Participants will use Placebo Control Form 1 as directed for a period of 6 weeks.
223655498|NCT05657808|DIETARY_SUPPLEMENT|Placebo Control Form 2|Participants will use Placebo Control Form 2 as directed for a period of 6 weeks.
223655499|NCT05657808|DIETARY_SUPPLEMENT|Placebo Control Form 3|Participants will use Placebo Control Form 3 as directed for a period of 6 weeks.
223655500|NCT05657808|DIETARY_SUPPLEMENT|Rest Study Active Product 3.1 Usage|Participants will use Radicle Rest Active Product 3.1 as directed for a period of 6 weeks.
223655501|NCT05657808|DIETARY_SUPPLEMENT|Placebo Control Form 4|Participants will use Placebo Control Form 4 as directed for a period of 6 weeks.
223655502|NCT05657808|DIETARY_SUPPLEMENT|Rest Study Active Product 4.1 Usage|Participants will use Radicle Rest Active Product 4.1 as directed for a period of 6 weeks.
224238760|NCT02359981|BEHAVIORAL|Generic suggestions|A nutritionist and an exercise trainer jointly created 45 food and exercise suggestions based on guidelines posted by the NIH. These suggestions ask users to walk for 30 minutes or eat healthier foods. These suggestions however doesn't personalize to users daily behavior into account.
223655503|NCT05657808|DIETARY_SUPPLEMENT|Rest Study Active Product 4.2 Usage|Participants will use Radicle Rest Active Product 4.2 as directed for a period of 6 weeks.
223655504|NCT05657808|DIETARY_SUPPLEMENT|Rest Study Active Product 4.3 Usage|Participants will use Radicle Rest Active Product 4.3 as directed for a period of 6 weeks.
223655505|NCT03812276|DEVICE|Dental Implants|Dental Implants will be used according to standard routine in daily practice, according to all indications as specified by the manufacturer in the IFU (informations for use).
223655506|NCT05008406|OTHER|Satisfaction|Students Satisfaction
223655507|NCT01727024|DRUG|Tiotropium|Tiotropium via Respimat® device once a day
223768060|NCT04384536|PROCEDURE|Neural therapy application|Local injections, C5-T8 segmental injections, trigger point injections of the forearm muscles and stellate ganglion injections are applied in each session, using a 27-gauge, 4-6 cm needle. The local injection is applied first in the first extensor compartment at the point of maximal tenderness and is directed proximally toward the radial styloid.trigger point is detected, approximately 5 mL lidocaine was injected to that point. C5-T8 segmental injections are applied intradermally to each spinous process and to 0.5-2 cm lateral of each process on the affected side. Finally, the stellate ganglion injection is applied using Fischer's modified technique.
223768061|NCT01034397|DRUG|tocilizumab [RoActemra/Actemra]|8mg/kg (minimal dose 480mg, maximum dose 800mg) iv infusion every 4 weeks for 24 weeks
223768062|NCT01034397|DRUG|placebo|iv every 4 weeks for 24 weeks
223768063|NCT01034397|DRUG|non-biological DMARDs|stable dose at investigator's prescription
223768064|NCT01396616|DEVICE|Experimental - Toric Intraocular lenses|Toric Intraocular Lenses will be implenated with cataract patients having astigmatism
224238761|NCT02359981|DEVICE|Smartphone|An Android Smartphone with operating system version higher than 2.2
224238762|NCT02576353|DRUG|Fentanyl|Fentanyl Sublingual Spray (FSS)
224238763|NCT02576353|DRUG|Fentanyl Citrate|Fentanyl Citrate IV (FCIV)
224238764|NCT04172454|BIOLOGICAL|AK104|AK104, 6mg/kg, Q2W
224238765|NCT00715065|PROCEDURE|fMRI Scan|Subjects will undergo a functional MRI scan of the head lasting \~45 minutes. They will be repeatedly shown video clips of blood, other disgusting things, or are neutral.
224238766|NCT02393482|DRUG|Estroprogestinic therapy (Etinil-estradiol/levonorgestre)|Etinil-estradiol/levonorgestrel (100 mcg/20 mcg)/die
224238767|NCT02393482|DRUG|Gonadotropin-releasing hormone agonist (Leuprorelin acetate)|Leuprorelin acetate (3,75 mg/2 ml)/month
224238768|NCT02393482|DRUG|Add back therapy 1 (tibolone)|tibolone 5 mg/die
224238769|NCT02393482|DRUG|Add back therapy 2 (calcium carbonate/colecalciferol)|calcium carbonate/colecalciferol (500mg/400UI)/die
223768065|NCT03055234|DRUG|Oral Treprostinil|Extended-release oral tablet for TID administration
223768066|NCT03055234|DRUG|Placebo|Matching placebo for TID administration
223768067|NCT01018264|DRUG|solifenacin succinate (VESIcare)|up to 10mg every day orally
223768068|NCT01018264|DRUG|placebo|placebo matching solifenacin succinate (VESIcare) up to 10mg orally every day
223768069|NCT00963664|DRUG|lovastatin|lovastatin tablets, oral administration, daily dose 1.5 mg/kg, divided into three or four essentially equal doses with meals
223768070|NCT00963664|DRUG|interferon alfa-2b|interferon alfa-2b for subcutaneous injection, each injection 100,000 international units per kg body mass, three injections weekly
223768071|NCT01785524|DRUG|Beetroot Juice (Beet-It Stamina Shot) and Exercise Training|The beverage is high in inorganic nitrate and bottled and supplied by James White Drinks. This supplement will be used in conjunction with supervised exercise training.
223768072|NCT01785524|OTHER|Placebo Comparator Beverage (Beet-It Stamina Shot) & Exercise Training|The beverage is identical in look and taste to Beet-It Stamina Shot but with active ingredient removed. It is also bottled and supplied by James White Drinks. This placebo supplement will be used in conjunction with supervised exercise training.
223768073|NCT00014144|DRUG|gefitinib|
223768074|NCT01162629|DEVICE|Osteon bone graft|Osteon bone substitute placed to a height of 2 mm above the top of the dental implant
223768075|NCT06314698|DRUG|Narlumosbart|Administered by subcutaneous injection once every 4 weeks.
223768076|NCT06314698|DRUG|Denosumab|Administered by subcutaneous injection once every 4 weeks.
223768077|NCT00402389|DRUG|Omega-3 Fatty Acids (EPA plus DHA)|Four capsules will be taken daily for 8 weeks.
223768078|NCT00402389|BEHAVIORAL|Supportive psychotherapy|Supportive psychotherapy will provide education to increase understanding of the condition, guidance on how to cope with depression, and methods on how to improve self-esteem.
223768079|NCT00402389|DRUG|Placebo|Four capsules will be taken daily for 8 weeks.
224238770|NCT05525026|DEVICE|BTL-785-7|Treatment with the BTL-785-7 applicator to the BTL-785F system.
224238771|NCT05034653|OTHER|Intermittent Fasting|During fasting day, no food or drink allowed from dawn to dusk
224238772|NCT05034653|OTHER|Healthy Plate|Quarter-quarter-half meal concept
224238773|NCT01149629|DRUG|Droxidopa|One capsule containing 300 mg droxidopa, given once
224238774|NCT01149629|DRUG|Droxidopa|3 capsules each containing 100 mg droxidopa, give 3 times at 4 hour intervals
224238775|NCT01149629|DRUG|Droxidopa|3 capsules each containing 100 mg droxidopa, given once
224238776|NCT00202982|DRUG|glatiramer acetate 20 mg|glatiramer acetate 20 mg
224238777|NCT00202982|DRUG|glatiramer acetate 40 mg|glatiramer acetate 40 mg
224238778|NCT01845363|DRUG|Cefazolin used in antimicrobial prophylaxis|"Cefazolin administered a first dose of 2g in anesthetic induction, followed by continuous dosage of 1g diluted in 250mL of saline solution for two hours.~Two samples of subcutaneous tissue were collected for analysis: the first soon after the incision, and a second before skin synthesis.~The samples were processed by HPLC."
223655508|NCT01727024|DRUG|Indacaterol|Indacaterol via Breezhaler® device once a day
223655509|NCT00002751|BIOLOGICAL|monoclonal antibody Me1-14 F(ab')2|
223655510|NCT01614691|DRUG|SPARC1203|Active
223655511|NCT01614691|DRUG|Placebo|Placebo
223655512|NCT05284526|OTHER|electroencephalogram (EEG) of control and parkinsonian subjects during the preparation and execution of movements|electroencephalogram (EEG) of control and parkinsonian subjects during the preparation and execution of movements
223655513|NCT06131060|OTHER|Progressive eccentric exercises|This include progressive eccentric exercises thrice a week for 6 weeks.
223655514|NCT06131060|OTHER|Bodyweight exercises|This include bodyweight exercises thrice a week for 6 weeks
223768080|NCT01936961|DRUG|CTLA-4 Antibody|administered intravenously over 90 minutes every 3 weeks for a total of four doses
224238779|NCT06242275|DIAGNOSTIC_TEST|Salivary Alpha-amylase|"Saliva samples will be obtained using a saliva collection system and salivary Alpha-amylase (SAA) level will be measured preoperatively, immediately postoperative, at the end of the 1st, 2nd, and 3rd postoperative days. For sampling, the swab will be placed into the patient's mouth for 2-5min by a specially trained nurse.~A minimum of 0.2mL of saliva will be needed as per the manufacturer's recommendations to saturate the swab."
224238780|NCT05257746|PROCEDURE|Rectal resection|Open or minimally invasive rectal resection with total mesorectal excision
223655515|NCT01485172|DRUG|ropinirole monotherapy|ropinirole as monotherapy in Parkinson's disease
223655516|NCT01485172|DRUG|placebo monotherapy|placebo as monotherapy in Parkinson's disease
223655517|NCT00974480|OTHER|Redermic|Cosmetic cream formulation 609637 43.
223655518|NCT00974480|DRUG|Tretinoin (Rejuva-A)|Tretinoin 0.025% cream.
223655519|NCT02283762|DRUG|Riociguat (Adempas, BAY63-2521)|Starting dose 0.5 mg TID, increase by 0.5 mg every 2 weeks until highest possible dose of 2.5 mg TID
223655520|NCT02283762|DRUG|Placebo|Sham-titration
223655521|NCT02549924|DRUG|Resveratrol|Resveratrol capsules, 500 mg 3 times daily with the first bite of each meal
223655522|NCT02549924|DRUG|Placebo|Placebo capsules, 500 mg 3 times daily with the first bite of each meal
223655523|NCT05037799|DRUG|Rb-82 Radioisotope|Quadratic dosing: Rubidium-82 activity prescribed as a squared function of body-weight instead of linear function of body-weight or fixed activity independent of body-weight
223655524|NCT04372940|DRUG|Tranexamic Acid Irrigation|Tranexamic acid (TXA) is a synthetic lysine analogue that inhibits the activation of plasminogen to plasmin, temporarily inhibiting the degradation of fibrin clots.
223655525|NCT04372940|OTHER|Saline Irrigation|Saline will serve as the control.
223655526|NCT00050362|DRUG|Rofecoxib and Bupivacaine|
223655527|NCT02501395|OTHER|No intervention, observational|
223655528|NCT02302014|OTHER|Palliative Care Intervention|Baseline interview with trial cardiologist and trial nurse lasting for up to 1 hour Creation of a Future Care Plan (FCP) document following this baseline interview Sharing of FCP document with primary care and unscheduled care organisations 6 week interview with trial nurse lasting for up to 1 hour to review FCP 12 week interview with trial nurse lasting for up to 1 hour to review FCP Continuous access to trial nurse by mobile telephone 9am - 5pm Monday-Friday for 12 weeks Trial nurse will - ensure FCP is appropriately shared with primary and secondary care, patient is registered on primary care palliative care register and will liaise with specialist PC services and the general practitioner as needed.
223655529|NCT00540332|DRUG|Placebo|Single IV dose of placebo, 3 days before the start of RT, then once weekly placebo doses at the same dose during a planned 6 week RT course.
223655530|NCT00540332|DRUG|palifermin|120μg/kg, single IV, 3 days before the start of Radiotherapy (RT), then once weekly at the same dose during a planned 6-week RT course
224238781|NCT04910126|DRUG|Camrelizumab|Camrelizumab 200mg q3w up to 2 years
223655531|NCT05998057|OTHER|exercise|"Exercises:~Lunge to Hamstrings Stretch 3 sets of 30 seconds~* Standing Hip Out 3 sets of 30sec~* 90-90 Hip Stretch 3 sets of 30 seconds~* World's Greatest Stretch 3 sets of 30 seconds~* Star Excursion 3 sets of 5 reps~* Side Jumps+ Balance 3 sets of 10 reps~* Forward Hops + Balance 3 sets of 10 reps~* Squat 3 sets of 10 reps~* Squat Jump 3 sets of 10 reps~* Jumping Spider Push-up 3 sets of 10 reps~* Double Leg Vertical Jump 3 sets of 10 reps~* Broad Jumps 3 sets of 10 reps~* Lateral Box Shuffles 3 sets of 10 reps~* Plank 3 sets of 30 seconds~* Side Plank 3 sets of 30 seconds~* Bird Dog 3 sets of 10 reps~* Glute Bridge 3 sets of 10 reps~* Single Leg Glute Bridge 3 sets of 10 reps~* Single Toe Raises 3 sets of 30sec~* Nordic Hamstrings 3 sets of 10 reps~* Monster Walk 3 sets of 10 reps"
223655532|NCT05998057|OTHER|control|The control group was asked to continue the standard (routine) classical training training (5 days/12 weeks).
223655533|NCT05237089|OTHER|Electroacupuncture|Regular acupuncture will be applied at the main and the additional acupoints with 0.25mm\*40mm or 0.30mm\*75mm needles. The main acupoints include Shangwan (CV13), Zhongwan (CV12), Jianli (CV11), Xiawan (CV10), bilateral Quchi (LI11), Hegu (LI4), Liangmen (ST21), Tianshu (ST25), Daheng (SP15), Fujie (SP14), Shuidao (ST28), Zusanli (ST36), Fenglong (ST40), Wailing (ST26), Guilai (ST29). Additional acupoints include bilateral Shangjuxu (ST37) and Neiting (ST44), bilateral Yinlingquan (SP9) and Shuifen (CV9), Qihai (CV6) and Guanyuan (CV4). Acupuncturists will use all main acupoints and choose the combined acupoints based on the patients' patterns during each treatment session. The EA apparatus will be connected to the needles at the bilateral ST21, ST25, SP15, using continuous wave type, frequency at 3 Hz, and intensity of 4-5 mA based on the endurance of each patient. Needles will be retained for 30 minutes before removal.
223768081|NCT01936961|RADIATION|Hypofractionated Radiotherapy|
223768082|NCT01339533|DEVICE|Mechanical Ventilation|Patients who experience problems breathing and require assistance in breathing are placed on a machine that delivers air to the lungs through a tube through the vocal cords. This study is testing 3 protocols for that machine.
223768083|NCT05578560|PROCEDURE|Prehabituation|chemical labyrinthectomy with intratympanically installed gentamicin
223768084|NCT05578560|PROCEDURE|3D optokinetic stimulation in virtual reality space|3D optokinetic stimulation via virtual reality goggles with the software designed by Pro-Zeta comp.
223768085|NCT05578560|PROCEDURE|Vestibular training|vestibular training program adopted for patients with acute vestibular loss under the supervision of a physical therapist. The program includes gaze stability exercises, smooth pursuit, and saccadic eye movements, and postural exercises to improve balance control and gait stability. Each session lasts around 30 minutes and happened daily for the 7 postoperative days.
224238782|NCT04910126|DRUG|Adriamycin|adriamycin 20mg/m2 d1-3 q3w maximum 6 cycles
224238783|NCT05019469|DEVICE|Rhythmic vibration cueing (lower leg)|A non-invasive wearable device worn against both gastrocnemius muscles provides rhythmic vibrations when triggered.
224238784|NCT02321384|DRUG|Placebo|Placebo matched to RO6889678 will be administered orally as a single dose on Day 1 in SAD cohorts and multiple doses BID from Day 1 to Day 14 (no second BID dose on Day 14) in MAD cohorts.
223768086|NCT01421810|DRUG|Dexamethasone|1 mg PO
223768087|NCT01421810|DRUG|rhCG|25 mcg IV
223768088|NCT05664646|DEVICE|DS8R|transcutaneous stimulation of the spinal cord.
223768089|NCT05664646|OTHER|Arm Ergometry|Study 1 will use the arm ergometry as a form of exercise.
223768090|NCT05664646|OTHER|Cool Environment|Study 2 will be completed in a cool environment setting.
223768091|NCT06142279|BIOLOGICAL|Sampling|At baseline, nasal, salivary and blood sampling will be taken for the participants.
223768092|NCT06142279|BIOLOGICAL|PCR (polymerase chain reaction) SARS-CoV-2|At baseline, this PCR SARS-CoV-2 will be taken for the participants.
223768093|NCT04603430|OTHER|Participation in a community wellness program|Participation in the STEPS program, a physical therapy student-run community wellness program for local seniors.
223768094|NCT01264861|DRUG|Safinamide|"Safinamide 100 mg/day = two 50 mg tablets administered orally, once a day, in the morning, with or without food.~Safinamide 200 mg/day = four 50 mg tablets administered orally, once a day, in the morning, with or without food; this will be preceded by a three day titration of 150 mg = three 50 mg tablets administered orally, once a day, in the morning, with or without food.~Safinamide 300 mg/day = six 50 mg tablets administered orally, once a day, in the morning, with or without food; this will be preceded by a three day titration of 250 mg = five 50 mg tablets administered orally, once a day, in the morning, with or without food."
223768095|NCT00626977|DRUG|ropivacaine|15 ml of ropivacaine 0.125% peridural once
223768096|NCT00626977|DRUG|ropivacaine and clonidine|15 ml of ropivacaine 0.0625% plus 75 mcg clonidine
223768097|NCT02533843|PROCEDURE|radiofrequency catheter ablation|Radiofrequency catheter ablation of atrial fibrillation with or without being guided by FIRMap (using RhythmView™ Workstation from TOPERA)
223768098|NCT00226434|PROCEDURE|Early antiretroviral treatment|The ARV treatment is started 2 weeks after the diagnosis and the start of the anti-tuberculosis treatment
223768099|NCT00226434|PROCEDURE|Late antiretroviral treatment|The ARV treatment is started 8 weeks after the diagnosis and the start of the anti-tuberculosis treatment
223768100|NCT05242614|BEHAVIORAL|The Hybrid Mindfulness-based Dementia caregiving program (MBDCP)|The hybrid MBDCP includes 6 weekly 90-minute group-based sessions delivered through a face-to-face (1st, 2nd, and 6th sessions) and online approach (3rd, 4th, and 5th sessions). The online session is designed for self-directed learning. The MBDCP includes different mindfulness practices (e.g., mindful eating, body scanning, and mindful walking), psychoeducation on caregiving, and group sharing, aimed at helping caregivers to develop mindfulness skills through the formal and informal practice of mindfulness, and to integrate these skills into their everyday life. The duration of each session is 90 minutes. Th MBDCP will be delivered by a qualified mindfulness therapist. In the MBDCP's online sessions, the caregivers will watch a teaching video (e.g., a video demonstrating mindfulness practices) through a website.
223655534|NCT05237089|OTHER|Sham acupuncture|Patients will receive superficial acupuncture treatment at the same main acupoints as EA group with 0.22\*0.25mm needles. The electroacupuncture apparatus will connected to the needles at the bilateral Liangmen (ST21), Tianshu (ST25), Daheng (SP15) without current output. Needles will be retained for 30 minutes before removal. The treatment will be given 3 times a week in week 1-12, 2 times a week in week 13-20, and once a week in week 21-24, totaling 56 sessions of real or sham acupuncture.
223655535|NCT05237089|OTHER|Health education|The health management brochure will be distributed to all patients in the trial after enrollment, and health education will be arranged online or offline at week 4, 8, 12, 16, 20 and 24 for about 60 minutes, including lifestyle, diet and physical activity. According to the specific situation of each patient, healthier individual lifestyle and behavior will be recommended to all patients, but there will be no strict restrictions on the diet or physical activity.
223655536|NCT05525481|DRUG|Tamoxifen|Hormone therapy
223655537|NCT01901913|DEVICE|MD-bolus calculator for pre-meal bolus|
223655538|NCT01901913|DEVICE|No MD-bolus calculator for pre-meal bolus|
223655539|NCT00709865|DRUG|tonapofylline|IV
223655540|NCT00709865|DRUG|Placebo|IV
223655541|NCT00495014|DRUG|GSK376501|
223655542|NCT00495014|DRUG|Placebo|
223655543|NCT03311698|BEHAVIORAL|Nutrition-sensitive intervention|Nutrition-sensitive intervention using behavior change communication on home gardening, diet, nutrition, WASH, and women's empowerment.
223655544|NCT03233984|BEHAVIORAL|"sensibilisation program Ma maison, mon environnement santé"|The aim of this program is to spread the awarness about endocrine disruptors through workshops and presentation.
223655545|NCT00299390|DRUG|Sagopilone (BAY86-5302, ZK 219477)|Sagopilone; 16 mg/m2 (maximum 32 mg) as 3 hour i.v. infusion
223768101|NCT05242614|BEHAVIORAL|Psychoeducation educational program|This program serves as a control for the social effects of the MBDCP. The brief education program consists of 6 weekly 90-minutes group sessions in which the sessions (1st, 2nd, and 6th) and (3rd 4th 5th) will be delivered through the face-to-face and online approach respectively, with the similar group size of the MBDCP. The education contents include caregiving skills, education on mood, and group sharing. The program will be led by a nurse.
224238785|NCT02321384|DRUG|RO6889678|RO6889678 will be administered orally as a single dose on Day 1 in SAD cohorts and multiple doses BID from Day 1 to Day 14 (no second BID dose on Day 14) in MAD cohorts.
223655546|NCT04659213|DEVICE|esolution catheter|esolution is a catheter-based therapy designed to displace the esophagus away from the source of ablation energy during ablation of AF and to eliminate the risk of esophageal injury
223655547|NCT00202878|DRUG|ezetimibe/simvastatin|Ezetimibe/simvastatin 10/40 mg per day from randomization through the end of participation. As per the original protocol, if LDL-C response was inadequate, the dose of simvastatin in the VYTORIN arm or simvastatin arm, could be increased to 80 mg (Note: per June 2011 protocol amendment, criteria for continued use of 80 mg simvastatin were modified and new increases of simvastatin dose to 80 mg were stopped).
223655548|NCT00202878|DRUG|simvastatin|Simvastatin 40 mg per day from randomization through the end of participation. As per the original protocol, if LDL-C response was inadequate, the dose of simvastatin in the VYTORIN arm or simvastatin arm, could be increased to 80 mg (Note: per June 2011 protocol amendment, criteria for continued use of 80 mg simvastatin were modified and new increases of simvastatin dose to 80 mg were stopped).
223655549|NCT00202878|DRUG|Placebo for simvastatin 40 mg|one or two tablets orally daily
224238786|NCT02321384|DRUG|Midazolam|Single dose of 100 mcg midazolam solution will be administered orally, before (Day -1) and after (Day 14) the treatment with RO6889678 or matching placebo.
224320973|NCT02196181|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
224320974|NCT02196181|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
223655550|NCT00202878|DRUG|Placebo for ezetimibe 10 mg/simvastatin 40 mg combination|one tablet orally daily.
223768102|NCT01503489|DRUG|Selective Serotonin Reuptake Inhibitors (SSRI), Serotonin-Norepinephrine Reuptake Inhibitor( SNRI), and Tricyclics.|Risk for antidepressant-associated switch from depression to hypomania, mania, or mixed episode during the 8 weeks after the introduction of an antidepressant or after increasing the dosage of baseline antidepressant.
223768103|NCT00672438|DRUG|Alfentanil|Target controlled intravenous infusion of alfentanil at a plasma concentration of 100ng/ml
223768104|NCT00672438|OTHER|Saline placebo infusion|Intravenous infusion of normal saline
223768105|NCT03915548|BEHAVIORAL|The Behavioral Activation/ Problem Solving Intervention|The interventionist presents the rationale for BA/PS, promotes a positive problem orientation, and educates about the framework for problem-solving and action planning. The interventionist then administers the Canadian Occupational Performance Measure to elicit participant priorities, motivation, and long-term goals. The interventionist then guides the participant in using the BA/PS framework to set a goal, brainstorm solutions to challenges, and create a detailed action plan for the coming week.
223768106|NCT03915548|BEHAVIORAL|Attention Control Condition|The interventionist provides education regarding nine cancer survivorship topics (i.e., healthy diets, physical activity, lymphedema management, smoking cessation, stress management, communication with providers, body image and sexuality, communication with social supports, work accommodations) during the control telephone contacts.
224238787|NCT02321384|DRUG|Ritonavir|RTV will be administered orally as a single dose on Day 1 in RTV-boosted SAD cohorts and multiple doses BID from Day 1 to Day 14 (no second BID dose on Day 14) in RTV-boosted MAD cohorts.
224238788|NCT00448695|PROCEDURE|MRI Targeted Focal Thermal Therapy of Prostate Cancer|The Interstitial Laser Thermal Therapy (LTT) procedure is similar to brachytherapy, with fibers and probes inserted trans-perineal using transrectal ultrasound guidance. Patients will be under general anesthetic, and the procedure is expected to last 3 hours. Patients will be able to return home the day of the procedure.
224238789|NCT04462926|DIAGNOSTIC_TEST|[68Ga]Ga-PSMA-11 PET/CT|1.8-2.2 MBq (0.049-0.060 mCi) per kilogram bodyweight will be injected intravenously prior to perform the PET/CT
224238790|NCT00234078|DRUG|0.5% OPC-12759|
224238791|NCT00234078|DRUG|1% OPC-12759|
223655551|NCT06316024|DIETARY_SUPPLEMENT|water|The participants drink 240 mL of water approximately 6-8 hours after surgery
223655552|NCT06316024|DIETARY_SUPPLEMENT|juice/sport drink group|The participants drink 240 mL of juice/sport drink approximately 6-8 hours after surgery
223655553|NCT06316024|DIETARY_SUPPLEMENT|Chewing gum group|The participants eat chewing gum approximately 6-8 hours after surgery
223655554|NCT03565419|DEVICE|Smart glasses|Participants confirm the real-time ultrasound image displayed on the viewer of smart glasses.
223655555|NCT02920242|DRUG|Rifaximin (Sandoz GmbH) tablet|200 mg tablet administered orally.
223655556|NCT02920242|DRUG|Rifaximin (Xifaxan)|200 mg tablet administered orally
223655557|NCT02920242|DRUG|Placebo|Matching Placebo tablet administered orally
223655558|NCT03338738|DIAGNOSTIC_TEST|Stool culture ans swab|"Patients with ESBL enterobacteria, antibiotic pressure are patients with ESBL positive result diagnosed by stool culture and a rectal swab.~The intervention correspond to addition of 4 stool samples (or 4 rectal swabs in the absence of stool emission) and a blood sample."
223655559|NCT04815148|DRUG|MH004 Ia(0.1%)|Spread approx. 1 g of MH004 topical cream to the upper thigh skin.
224238792|NCT00234078|DRUG|2% OPC-12759|
224238793|NCT00234078|DRUG|placebo|
224238794|NCT03571893|BEHAVIORAL|Weight Watchers Freestyle (Flex)|Participants will be referred to their local Weight Watchers meeting and provided with a promotional code to allow them to participate in the Weight Watchers program free of charge for 12 months. At the randomization visit, study staff will help participants identify a convenient Weight Watchers meeting location and download the program app onto their smartphone.
224238795|NCT03571893|BEHAVIORAL|DIY Personal Plan|Participants will be provided with a written resource with descriptions of a variety of approaches that have been shown to promote healthy weight loss through behavioral modification. Participants will be encouraged to assess their preferences for dietary change and physical activity and adopt an approach that will lead to negative energy balance and moderate (1-2 lbs. per week) weight loss.
223655560|NCT04815148|DRUG|MH004 Ia(0.3%)|Spread approx. 1 g of MH004 topical cream to the upper thigh skin.
223655561|NCT04815148|DRUG|MH004 Ia(1%)|Spread approx. 1 g of MH004 topical cream to the upper thigh skin.
223655562|NCT04815148|DRUG|MH004 Ia(3%)|Spread approx. 1 g of MH004 topical cream to the upper thigh skin.
223655563|NCT04815148|DRUG|MH004 Ib-1(0.1%)|Spread approx. 0.5 g of MH004 topical cream to the area of Target AD Lesions.
223655564|NCT04815148|DRUG|MH004 Ib-1(0.3%)|Spread approx. 0.5 g of MH004 topical cream to the area of Target AD Lesions.
223655565|NCT04815148|DRUG|MH004 Ib-1(1%)|Spread approx. 0.5 g of MH004 topical cream to the area of Target AD Lesions.
223655566|NCT04815148|DRUG|MH004 Ib-2(0.3%)|Spread approx. 0.5 g of MH004 topical cream to the Target Joint.
224238796|NCT03471078|DRUG|Avatrombopag|Oral avatrombopag tablet
223655567|NCT04815148|DRUG|MH004 Ib-2(1%)|Spread approx. 0.5 g of MH004 topical cream to the Target Joint.
223655568|NCT04815148|DRUG|MH004 Ib-2(3%)|Spread approx. 0.5 g of MH004 topical cream to the Target Joint.
223655569|NCT03146299|PROCEDURE|TLH vs LAVH|"TLH: The subjects undergoing laparoscopic hysterectomy with a giant uterus of 500 g or more~LAVH: The subjects undergoing Laparoscopic Assisted Vaginal Hysterectomy with a giant uterus of 500 g or more"
224238797|NCT03471078|DRUG|Placebo Oral Tablet|Placebo comparator tablet
224238798|NCT01504698|PROCEDURE|Advice and exercise-based treatment plus joint manipulation|The treatment can consist of advice, activation and exercise and/or manual soft-tissue treatment plus joint manipulation.The areas and frequency of manipulative treatment will be determined by the chiropractor and will consist of high-velocity, low-amplitude manipulation and/or mobilization to the spine and/or the extremities.
224238799|NCT01504698|PROCEDURE|Advice and exercise-based treatment|The treatment can consist of advice, activation and exercise and/or manual soft-tissue treatment. However, assisted stretching is not allowed as this will approach mobilization.
224238800|NCT05525871|DIETARY_SUPPLEMENT|Nitrates and Citrulline Malate|"Female soccer players should consume the experimental product for 30 days to evaluate the efficacy of a sports supplement high in nitrates combined with citrulline malate in the improvement of performance in high-intensity intermittent exercise.~high intensity"
223768107|NCT05871125|BEHAVIORAL|Reimbursement|Patients will be dosed in cohorts of 5, with a maximum available sample size of 30. The first cohort of 5 patients will be enrolled at the first reimbursement dose level of $1000 per month for 4 months ($4000 per patient in total). At the end of the 4-month period, reimbursement dose suitability will be determined as suitable by a cumulative negative financial toxicity screen and reimbursement dose deemed acceptable and appropriate in at least 4 patients. If the reimbursement dose is found suitable, we will de-escalate the reimbursement dose for the next cohort of 5 patients. If the reimbursement dose is found unsuitable, the next cohort of 5 patients will be enrolled at the same reimbursement amount ($1000 per month for 4 months).
223655570|NCT03284281|DEVICE|Tragus stimulator|Tragus nerve stimulation for at least 8 hours per day for 1 week post discharge.
223655571|NCT03284281|DEVICE|Sham Tragus stimulator|No stimulation will be performed
223655572|NCT00685568|DRUG|celecoxib|Orally, twice daily for 3 months; 50 mg tablets. Celecoxib escalating doses starting at 4 mg/kg/day.
223655573|NCT00685568|OTHER|placebo|Orally, twice daily for 3 months
223655574|NCT04724824|DEVICE|Brain-Computer Interface|Passive hand movement will be provided to patients' paralyzed hand by means of a robotic hand orthosis that will be activated by the brain-computer interface based on hand movement intention.
223655575|NCT04724824|DEVICE|Sham Brain-Computer Interface|Passive hand movement will be provided to patients' paralyzed hand by means of a robotic hand orthosis which activation will be independent of the output of the brain-computer interface based on hand movement intention.
223655576|NCT02083913|BEHAVIORAL|Telehealth supervised exercise training|Endurance and strength training (3x/week during 12 weeks)
223768108|NCT01183793|RADIATION|Barium follow-through and MR-enterography|Assessment of the lack of difference between surgical and MR enterography small bowel length measurement with a comparison sample test
223768109|NCT03217136|DRUG|Ceftolozane/Tazobactam|Ceftolozane 20 mg/kg (maximum 1 g) and tazobactam 10 mg/kg (maximum 0.5 g/dose) administered IV every 8 hours for between 5 to 14 days.
223768110|NCT03217136|DRUG|Metronidazole|Metronidazole 10 mg/kg (maximum 1.5 g/day) administered IV every 8 hours for between 5 to 14 days. Participants ≤ 28 days old, start with a loading dose of 15 mg/kg; then if ≤ 2 kg are dosed 7.5 mg/kg/ every 12 hours; or if \> 2 kg are dosed 10 mg/kg every 8 hours.
224238801|NCT05525871|DIETARY_SUPPLEMENT|Control product|Fruit puree
224320975|NCT02196181|DRUG|Dabrafenib Mesylate|Given PO
224238802|NCT01638988|DRUG|Metformin|"1. cycle 2000 mg of Metformin : Day 1 to day 30; beginning with 1/2 tablet by day with an increasing until 4 pills by day~2. to 6 cycle 2000 mg of Metformin : Day 1 ot day 30; 4 pills of Metformin by day Positive pregnancy test : 4 pills of Metformin by day until 12 weeks of pregnancy"
223655577|NCT04462588|DRUG|Cipro 400 MG in 200 ML Injection|medical tratment group
223655578|NCT04462588|DRUG|Flagyl I.V. RTU|medical tratment group
223655579|NCT04462588|PROCEDURE|appendectomy (open or laparascopic)|appendectomy (open or laparascopic)
223655580|NCT05755243|DEVICE|glucose sensor|skin biopsy (punch)
223655581|NCT04812262|DRUG|DD01|The active of DD01 is a synthetic peptide, administered in a 1mL volume for injection.
223655582|NCT04812262|DRUG|Placebo|Placebo drug of DD01, administered in a 1mL volume for injection
223655583|NCT02030236|DEVICE|Cooling|Temperature reached Duration of exposure to cold.
223768111|NCT03217136|DRUG|Meropenem|Meropenem 20 mg/kg (maximum 1 g/dose) administered IV every 8 hours for between 5 to 14 days.
223768112|NCT03217136|DRUG|Placebo for Metronidazole|Placebo for metronidazole administered IV every 8 hours for between 5 to 14 days.
223768113|NCT01905982|PROCEDURE|reflectory breathing therapy|duration:2x60 minutes
224238803|NCT01638988|DRUG|Clomiphene citrate|Cycle 1: Day 3 to day 7; 50 mg; 1 tablet of Clomiphene Citrate by day Cycle 2: Day 3 to day 7; 100 mg; 1 tablet of Clomiphene Citrate two times a day Cycle 3 to 6 : Day 3 to day 7; 150 mg; 1 tablet of Clomiphene Citrate 3 times a day
224238804|NCT01058278|PROCEDURE|Selective Laser trabeculoplasty|The Selective Laser Trabeculoplasty is done with the Latina lens after applying a drop of iopidine in the treated eye and alcaïne in both eye. Fifty spots are done over 180°. The maximal and total energy is written in the chart. After the treatment, prednisolone acetate 1% (a corticosteroid), diclofenac 0.1% (an NSAID) or a placebo is used. The three treatments were administered 4 times a day (at breakfast, lunch, dinner and at bedtime) for five days.
224238805|NCT02248597|DRUG|fludarabine phosphate|Given IV
224238806|NCT02248597|DRUG|busulfan|Given IV
224238807|NCT02248597|DRUG|cyclophosphamide|Given IV
224320976|NCT02196181|PROCEDURE|Echocardiography Test|Undergo ECHO
224320977|NCT02196181|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
223768114|NCT01905982|PROCEDURE|conventional breathing therapy|duration:4x30 minutes
224238808|NCT02248597|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Undergo myeloablative or reduced intensity allogeneic stem cell transplant
224320978|NCT02196181|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
223655584|NCT03347955|PROCEDURE|Neural implantation group|Cultured mesencephalic tissue from four embryos was implanted into the putamen bilaterally for those receiving the implant
223655585|NCT03347955|PROCEDURE|Sham surgery|Steel frame affixed to head and four burr holes drilled into forehead of sham surgery patients
223655586|NCT06492863|GENETIC|FT-003|Administered via intraocular injection.
223655587|NCT01251341|BEHAVIORAL|Cognitive-Based Compassion Training|Eight-week training in compassion meditation, using a protocol developed by Geshe Lobsang Negi, Ph.D. of Emory University
223655588|NCT01251341|BEHAVIORAL|Mindful Attention Training|Eight week training in mindful attention, using a protocol developed by B. Alan Wallace, Ph.D.
224238809|NCT02248597|DRUG|tacrolimus|
224238810|NCT02248597|DRUG|mycophenolate mofetil|
224238811|NCT04697745|DRUG|Intrathecal dexamethasone|intrathecal adjuvants to bupivacaine
224238812|NCT04697745|DRUG|Intrathecal dexmedetomidine|intrathecal adjuvants to bupivacaine
224320979|NCT02196181|DRUG|Trametinib Dimethyl Sulfoxide|Given PO
224320980|NCT03933631|DRUG|Pilocarpine|pilocarpine hydrochloride ophthalmic solution 2% (20 mg/mL)
224320981|NCT03933631|DRUG|Prednisolone|Prednisolone acetate ophthalmic suspension 1%
224320982|NCT03933631|DRUG|Ofloxacin|Ofloxacin Drops
223768115|NCT00451620|DRUG|glyburide|Subjects will undergo 2 Standard Meal Tests with Ensure 325 ml separated by 15 - 30 days. Group 1 will receive GlucoNorm 1 mg during the 1st Standard Meal Test and Glyburide 2.5 mg during the 2nd Standard Meal Test. Group 2 will receive Glyburide 2.5 mg during the 1st Standard Meal Test and GlucoNorm 1mg during the 2nd Standard Meal Test.
223768116|NCT00451620|DRUG|GlucoNorm|Subjects will undergo 2 Standard Meal Tests with Ensure 325 ml separated by 15 - 30 days. Group 1 will receive GlucoNorm 1 mg during the 1st Standard Meal Test and Glyburide 2.5 mg during the 2nd Standard Meal Test. Group 2 will receive Glyburide 2.5 mg during the 1st Standard Meal Test and GlucoNorm 1mg during the 2nd Standard Meal Test.
223768117|NCT03839667|BEHAVIORAL|intensive diet intervention|the participants will be instructed to restrict the total daily calorie intake to 800 kcal by receiving the very-low-calorie meal replacement formula for 2 consecutive days per week. They will be allowed to maintain their normal diet in the remaining 5 days, but need to restrict total intake to 2000 kcal per day.
223768118|NCT03839667|BEHAVIORAL|Enhanced physical activity intervention|the participants will take high-intensity exercise in accordance with High Intensity Interval Training (HIIT) prescriptions, with maximum heart rate and relative maximal oxygen uptake monitored. They will take both aerobic and resistance training exercise consecutively, and total training time will be expected to reach at least 150 minutes per week.
223655589|NCT01251341|BEHAVIORAL|Adult Health Education Curriculum|Eight week training in health and wellness, using a curriculum developed specifically for this study.
223655590|NCT02876536|DEVICE|TENS|The effect of TENS device will be compared in case and control groups.
223655591|NCT02028208|DIAGNOSTIC_TEST|Ammoniated mercury|Metal allergen panel containing ascending doses of ammoniated mercury and a negative control.
223655592|NCT02028208|DIAGNOSTIC_TEST|Aluminum chloride and aluminum lactate|Metal allergen panel containing ascending doses of alumium chloride, aluminum lactate and a negative control.
223655593|NCT02028208|DIAGNOSTIC_TEST|Sodium tetrachloropalladate|Metal allergen panel containing ascending doses of sodium tetrachloropalladate and a negative control.
223655594|NCT03405961|DEVICE|Carestream 3600 intra oral scan|"Carestream 3600 is CE marked intra oral scanner manufactured by Carestream Dental. It is already licensed for use in dentistry to produce digital study models. The scanner is 220 x 38 x 58 mm large and operates using video capture technology. It emits no radiation.~Carestream 3600 is connected to a computer via a USB port and a computer software (CS Model +) converts the scan into digital study models using trigonometric calculations. The software is then used to take measurements on the digital models and calculate PAR scores"
223655595|NCT00602758|BEHAVIORAL|Motivational interviewing with cognitive behavioral therapy|Counseling sessions are completed face-to-face or by telephone at baseline and Weeks 1, 2, 4, 6, 9, 11, 15, 19, and 23. Counselors are trained in motivational interview technique and focus on ART medication adherence.
223655596|NCT00602758|BEHAVIORAL|Modified directly observed therapy|From baseline to Week 16, Monday through Friday, study staff meet the participants daily to observe one dose of their ART and to leave with the participants all other doses needed until the next observed dose. The frequency of observed doses begins to taper at Week 17 through to Week 24.
223655597|NCT02837107|DIETARY_SUPPLEMENT|Mind Master|80ml Mind Master / day for 8 weeks
223655598|NCT02837107|DIETARY_SUPPLEMENT|Placebo|80ml a look-alike Placebo / day for 8 weeks
223655599|NCT03034070|DIAGNOSTIC_TEST|Diagnostic performance 3D T1|"Although non-invasive, the prospective addition of a new MRI sequence to a routine MRI protocol is considered by our ethical committee as an interventional study."
223768119|NCT03839667|BEHAVIORAL|Standard education|the participants will receive no extra intervention but diabetes health education, which will be carried out in large classrooms, in groups, and over the telephone. The education is mainly consisted of instructions on healthy diet and exercise plans, prevention for acute and chronic complications and self-glycemic monitoring.
224238813|NCT01269801|DRUG|onabotulinumtoxinA|"* Group 1 will initially receive BOTOX® Cosmetic or VISTABEL® injections to the affected facial regions;~* Group 2 will initially receive JUVÉDERM® Ultra XC or JUVÉDERM® Ultra 2 (for moderate facial lines or folds) or JUVÉDERM® Ultra Plus XC or JUVÉDERM® Ultra 3 (for severe facial lines or folds) injections to the affected facial regions.~At 4 weeks,Group 1 patients who initially received BOTOX® Cosmetic or VISTABEL® treatment will be crossed over and receive JUVÉDERM® treatment, and Group 2 patients who initially received JUVÉDERM® treatment will be crossed over to receive BOTOX® Cosmetic or VISTABEL® treatment."
224320983|NCT04969978|BEHAVIORAL|Enhanced Academic Detailing|"* Group training of clinic staff prior to activation of the eReferral system and 12 months post-activation~* Follow-up booster sessions~* Monthly performance audit and feedback"
224320984|NCT04969978|OTHER|Informational Intervention|Receive overview of Quitline services and use of Quitline eReferral via online materials
224320985|NCT06390839|PROCEDURE|Biopsy Procedure|Undergo biopsy
224320986|NCT06390839|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
224320987|NCT06390839|PROCEDURE|Computed Tomography|Undergo CT scan
224320988|NCT06390839|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223655600|NCT02820948|DRUG|Vitamin E ointment application|Before the skin stapling and after the subcutaneous irrigation with normal saline, sterile Vitamin E acetate ointment was applied in the subcutaneous tissue; 2 ml were applied in the suprapubic incision and 0.5 ml in the rest of port sites.
223655601|NCT04344561|OTHER|Postural Positioning|Investigators will adjust the positioning of hospital beds to assess improvements in oxygenation and respiratory status.
223655602|NCT01914341|OTHER|Music|Live music played on the pentatonically tuned children's harp
223655603|NCT01600534|BEHAVIORAL|lifestyle counseling|Participants receive lifestyle counseling on healthy eating and physical activity through an internet-based program or self-directed educational program.
223655604|NCT02803983|PROCEDURE|Pediatric hip plate|Children were treated with pediatric hip plate.
223655605|NCT02803983|PROCEDURE|Cannulated screw|Children were treated with cannulated screw.
223655606|NCT03563183|OTHER|Encoding of data collected in Zoster 006 and Zoster 022 studies|Not applicable (disease epidemiology study)
223655607|NCT06204835|DRUG|RD-Cy7 fluorophore|Fluorophore targeting ITGA6 that is overexpressed in HCC cells
223655608|NCT02236936|DIETARY_SUPPLEMENT|Standard care of parenteral nutrition|Standard treatment according to the discretion of the center, any required nutritional support (enteral tube feeding by nasogastric tube or percutaneous endoscopic gastrostomy) when considered necessary is allowed
223655609|NCT02236936|DIETARY_SUPPLEMENT|Parenteral over night nutrition|Patients in interventional Arm B will receive parenteral overnight nutrition with ZentroOLIMEL® 5.7% with electrolytes, vitamins (Cernevit®) and micronutrients (Addel Trace® or Nutryelt®) starting with 15 ml/kg body weight/day. In case of weight loss of more than 5%, dose of ZentroOLIMEL® has to be increased up to 25 ml/kg/body weight/day.
223768120|NCT03169140|DEVICE|TheraBand Kinesiology Tape|A 20 cm strip of tape will be applied to each side of the low back directly over the erector spinae muscles at the site of pain. This tape will remain there, and be reapplied when necessary, for one week.
223768121|NCT03169140|DEVICE|Biofreeze|The topical analgesic will be sprayed directly on top of the erector spinae and site of pain low back directly, from inferior to superior to inferior 4 times a day for one week.
223768122|NCT03169140|BEHAVIORAL|Advice|An at-home pain management care sheet, outlining standard care advice will be followed for at home pain management for one week.
223768123|NCT00228592|DRUG|HepeX-B|
224238814|NCT01269801|DRUG|JUVÉDERM|"Group 1 will initially receive BOTOX® Cosmetic or VISTABEL® injections to the affected facial regions;~• Group 2 will initially receive JUVÉDERM® Ultra XC or JUVÉDERM® Ultra 2 (for moderate facial lines or folds) or JUVÉDERM® Ultra Plus XC or JUVÉDERM® Ultra 3 (for severe facial lines or folds) injections to the affected facial regions.~At 4 weeks,Group 1 patients who initially received BOTOX® Cosmetic or VISTABEL® treatment will be crossed over and receive JUVÉDERM® treatment, and Group 2 patients who initially received JUVÉDERM® treatment will be crossed over to receive BOTOX® Cosmetic or VISTABEL® treatment."
224238815|NCT01124929|DRUG|RNTCP Category I treatment for 6 months|2H3R3Z3 E3 + 4H3R3
224238816|NCT01124929|DRUG|RNTCP Category I treatment for 9months|2H3R3Z3 E3 + 7H3R3
224238817|NCT05498480|BIOLOGICAL|Relatlimab|Specified dose on specified days
224238818|NCT05498480|BIOLOGICAL|Nivolumab|Specified dose on specified days
224238819|NCT03127904|PROCEDURE|Vein Fitness|Vein fitness is a combination of whole-limb exercises, manual lymphatic drainage, and usual care (wound care and compressive therapy).
224238820|NCT03127904|PROCEDURE|Compressive therapy and wound care|"Compressive therapy consists in the application of pressure to the inferior limb. Investigators describe the specifics in the arm section.~As previously described, a trained nurse will be in charge of keeping the wound healthy, verifying the surface is clean, debriding it, and removing biofilm from it."
224238821|NCT02473640|DRUG|SYN-004|
224238822|NCT02473640|DRUG|Esomeprazole|
224238823|NCT02473640|DRUG|Ceftriaxone|
224238824|NCT05620225|DEVICE|Axon Therapy and CMM|transcutaneous magnetic stimulation (TMS)
224238825|NCT05620225|DEVICE|Sham and CMM|Sham and CMM
224238826|NCT06000280|PROCEDURE|Trabeculectomy surgery|The Trabeculectomy aims to create a permanent drainage outflow channel for the aqueous humor, connecting the anterior chamber to the sub-Tenon's space, using mitomycin C consisted of opening the conjunctival base of the fornix and applying mitomycin C 0.4 mg/ml for 2 minutes. The trabeculectomy techniques require controlled outflow of aqueous humor through a sclerostomy and a partial-thickness scleral flap to form a subconjunctival bleb. The protected strength of the flap, with or without sutures, and the strength of the episcleral tissue determine the final IOP.
224238827|NCT05859386|BEHAVIORAL|Mindfulness maintenance program|"1. Four-week course to strengthen and extend skills learned in 8-week MBCT course. This will consist of four 2-hour sessions, occurring weekly for four weeks.~2. Monthly 1.5 hour meeting sessions. These will be led by an experienced MBCT teacher and will consist of a group meditation practice, a check-in time, and discussion of a topic relevant to the MBSR course.~3. Monthly check-in survey. This will be a brief (5 - 10 minute) survey (using Qualtrics) with questions about mood (PROMIS Depression and Positive Affect scales) and recent meditation practice."
224238828|NCT02472522|DRUG|Ropivacaine + Dexmedetomidine|Patients satisfying inclusion criteria will receive Subarachnoid Block with Bupivacaine Heavy 0.5% (11 mg/2.2 ml) with 25 micrograms of fentanyl. At the end of the procedure, bilateral TAP block will be performed using Landmark Technique with 2.5 mg/kg of ropivacaine and 1 micrograms/kg dexmedetomidine (combination drug) diluted with 0.9% saline to a total volume of 40 ml (20 ml each side) for the TAP block
224238829|NCT02472522|OTHER|Ropivacaine|Patients satisfying inclusion criteria will receive Subarachnoid Block with Bupivacaine Heavy 0.5% (11 mg/2.2 ml) with 25 micrograms of fentanyl. At the end of the procedure, bilateral TAP block will be performed using Landmark Technique with 2.5 mg/kg of ropivacaine diluted with 0.9% saline to a total volume of 40 ml (20 ml each side)
224238830|NCT02609139|DRUG|PF-06650833|Up to 400mg modified release tablets administered under fasted conditions
223655610|NCT02236936|BIOLOGICAL|Cetuximab|"Weekly during radiotherapy; not given if cisplatin is given during radiotherapy~Cetuximab 400 mg/m2 (saturation) Cetuximab 250mg/m2 (during radiotherapy; in total 7x)"
223655611|NCT02236936|DRUG|Cisplatin|Cisplatin total dose of \>200 mg administered weekly (40 mg/m2/week) or every three weeks (100 mg/m2 every three weeks) according to local standard; not given in combination with cetuximab
223768124|NCT00228592|DRUG|Hepatitis B Immune Globulin (HBIg)|
223768125|NCT03131063|OTHER|Antibiotic plasma dosage|Measurement of the concentration of antibiotics administered as part of the routine care of intensive care patients
223768126|NCT02559388|DRUG|Montelukast|
224238831|NCT02609139|DRUG|PF-06650833|100mg modified release tablet administered under fasted conditions
224238832|NCT02609139|DRUG|PF-06650833|20mg modified release tablet administered under fasted conditions
224238833|NCT02609139|DRUG|PF-06650833|Up to 400mg modified release tablets administered with high fat meal food intake
224238834|NCT02609139|DRUG|PF-06650833|100mg modified released tablet administered with high fat meal food intake
224238835|NCT02609139|DRUG|PF-06650833|20 mg modified release tablet administered with high fat meal food intake
223655612|NCT02236936|RADIATION|Radiotherapy|70 Gy / 5 fractions per week, over 7 weeks
223655613|NCT02296983|BIOLOGICAL|VSV-ZEBOV|VSV-ZEBOV
223768127|NCT02559388|DRUG|placebo|Placebo (For Montelukast) Placebo pills manufactured for mimic 10 milligram montelukast pills
223768128|NCT00395239|DRUG|inhaled corticosteroid|Fluticasone; Budesonide; Ciclesonide Dosage and frequency is patient dependant.
223768129|NCT03584672|OTHER|Static Balance Test|Balance control is assessed by the Static Balance Test.
223768130|NCT03584672|OTHER|Berg Balance Scale|Functional balance is assessed by the Berg Balance Scale.
223768131|NCT03584672|OTHER|Timed Up an Go Test|Functional mobility is assessed by the Timed Up and Go test.
223768132|NCT03584672|OTHER|Four Square Step Test|Dynamic balance is assessed by the Four Square Step Test.
223768133|NCT03584672|OTHER|Functional Reach Test|Limits of stability is assessed by the Functional Reach Test.
223655614|NCT00271284|DRUG|insulin glulisine / insulin glargine|insulin glargine administered subcutaneously by the patient once a day, in the evening, between 18.30 and 24.00
223655615|NCT00271284|DRUG|insulin glulisin / insulin detemir|insulin detemir administered subcutaneously by the patient once a day, in the evening, between 18.30 and 24.00
224238836|NCT02648620|DEVICE|SurVeil Drug Coated Balloon|Angioplasty procedure with the SurModics SurVeil Paclitaxel-Coated, Percutaneous Transluminal Angioplasty (PTA) Balloon Catheter (Paclitaxel-coated PTA Catheter)
223768134|NCT03584672|OTHER|One-leg Stance Test|Postural steadiness is assessed by the One-leg Stance Test.
223768135|NCT04139928|DIETARY_SUPPLEMENT|Picometer-ionic form of magnesium chloride|Single-dose (300 mg) of the picometer-ionic form of magnesium chloride
223768136|NCT04139928|DIETARY_SUPPLEMENT|Magnesium citrate or magnesium oxide|Single-dose (300 mg) of magnesium citrate or magnesium oxide
224238837|NCT02648620|PROCEDURE|Angioplasty|Angioplasty procedure with the SurModics SurVeil Paclitaxel-Coated, Percutaneous Transluminal Angioplasty (PTA) Balloon Catheter (Paclitaxel-coated PTA Catheter)
224238838|NCT05760872|OTHER|Placing esophageal probe|Placing an esophageal probe through the mouth
224238839|NCT02395822|BIOLOGICAL|IL-15|"Preparative Regimen:~Fludarabine 25 mg/m2 x 5 days start day -6 Cyclophosphamide 60 mg/kg x 2 days on day -5 and -4 (if \< 4 months from prior transplant, omit day -4 dose)~IL-15 Activated Donor NK Cells:~The apheresis product (collected day -1) will be enriched for NK cells with the large-scale CliniMacs® device (Miltenyi) by depletion of CD3+ cells to remove T-lymphocytes and depletion of CD19+ cells to remove B-lymphocytes. The NK cell enriched product will be activated by overnight incubation with10 ng/ml IL-15 under GMP conditions and infused on day 0.~IL-15 to Facilitate NK Cell Survival and Expansion:~IL-15 at 2 mcg/kg subcutaneously (SC) beginning day +1, once a day for 5 days followed by a 2 day rest, and then once a day for 5 days for 10 doses total"
224238840|NCT02715622|PROCEDURE|Hernia repair|Patient undergoing Hernia repair using different surgical modalities as per the surgeon's standard of care practice
224320989|NCT06390839|DRUG|Palbociclib|Given PO
223655616|NCT02556528|BEHAVIORAL|Health Coaching|
223655617|NCT03801031|DRUG|Lidocaine Topical|Many women treated for gynecologic cancer complain of sexual dysfunction and discomfort. It is thought that topical lidocaine application prior to sexual encounters may have reduced discomfort and improved overall quality of life during and following cancer treatment. The use of the lidocaine solution/placebo is the intervention.
223655618|NCT03801031|DRUG|Placebo|Placebo solution intervention used to validate the effects of the lidocaine solution usage.
223655619|NCT06159218|DEVICE|CEST - coiled oesophageal string test|All patients will swallow a small string (CEST) which will be removed and then analysed for biomarkers and microbiome.
223655620|NCT05865041|DRUG|Farudodstat|Farudodstat tablets administered orally
223655621|NCT05865041|DRUG|Placebo|Placebo tablets administered orally
223655622|NCT01419288|OTHER|Treadmill Training|The program requires volunteer participants to attend 15 sessions over 10 to 12 weeks with a total time commitment of 13.5 hours. There is an initial testing session that includes an assessment of the participant's legs, balance, and walking abilities. The entire program includes 12 treadmill training visits that take place three times per week for four weeks, a post-training testing session one week after completion of the training, and a follow-up testing session four weeks after completion of the training.
223768137|NCT04139928|DIETARY_SUPPLEMENT|Placebo|Placebo
223768138|NCT02760134|PROCEDURE|Super-Mini Percutaneous Nephrolithotomy|Patients undergo Super-Mini Percutaneous Nephrolithotomy
223768139|NCT03192150|DRUG|ISV-305|Dexamethasone in DuraSite® 2 twice daily for 16 days
223768140|NCT03192150|OTHER|Vehicle|Vehicle twice daily for 16 days
223768141|NCT01187082|BEHAVIORAL|bladdertraining in groups|Cognitive training in groups of 4 patients at hospital by a continence nurse in 3 sessions (1 hour)over a period of 1 month. Follow up after 1 month. During all 2 month the patient has selfinitiatied daily training with a pocket bladder schedule.
223768142|NCT01187082|BEHAVIORAL|bladdertraining individually|Cognitive training individually at hospital by a continence nurse in 3 sessions (1 hour)over a period of 1 month. Follow up after 1 month. During all 2 month the patient has selfinitiatied daily training with a pocket bladder schedule.
223768143|NCT00133081|DRUG|All registered antiepileptic drugs|
223768144|NCT02579616|DRUG|Lenvatinib|Lenvatinib will be administered orally once daily in 28-day cycles. Participants will be treated until disease progression, unacceptable toxicity, withdrawal of consent, participant's choice, etc.
223768145|NCT02275897|PROCEDURE|Slow Speed of spinal injection|Speed of injection over 60 seconds
223768146|NCT02275897|PROCEDURE|Fast Speed of spinal injection|Speed of injection over 15 seconds
224238841|NCT02777528|DEVICE|GORE® TAG® Thoracic Branch Endoprosthesis|Endovascular repair with the TBE Device
223768147|NCT05460065|DRUG|single E4 28.3 mg|Administration of a single intravenous (i.v.) infusion of estetrol (E4) 28.3 mg (n=6)
223768148|NCT05460065|DRUG|single E4 94.4 mg|Administration of a single i.v. infusion of E4 94.4 mg (n=6)
223768149|NCT05460065|DRUG|multiple E4 94.4 mg|Administration of an i.v. infusion of E4 94.4 mg (or lower dose, depending on single dose results) once a day for 5 consecutive days (n=8)
223768150|NCT05460065|DRUG|Placebo|"Cohort A: Single dose of placebo (n=2);~Cohort B: Single dose of placebo (n=2);~Cohort C: multiple dose of placebo (n=4)"
223768151|NCT03758040|OTHER|Slips on Turns|A slip will be administered to participants at 3 different times in the gait cycle for each of 3 different patch curvatures and 2 different legs for a total of 18 slip episodes. Slips will be delivered while walking along a straight path (infinite radius), or curved paths with radii 2, or 1 meters.
224238842|NCT02777528|PROCEDURE|Revascularization Procedure|Revascularization procedure of the great vessel
224320990|NCT04458922|DRUG|Atezolizumab|Given IV
224320991|NCT04458922|PROCEDURE|Biopsy Procedure|Correlative studies
224320992|NCT04458922|PROCEDURE|Biospecimen Collection|Correlative studies
224320993|NCT04458922|PROCEDURE|Computed Tomography|Undergo CT scan
223655623|NCT03679520|OTHER|New programme|"Time for topics related to the time after birth and in reversed chronological order to give an early and joint focus on parenthood for both parents. Involving new parents to share their experiences of early parenthood with expectant parents. Introducing and using evidence-based websites in the sessions A breastfeeding preparation that gives tools to meet common challenges in the initial phase of breastfeeding. Based on principles for adult learning.~Sessions~1. Introduction, life-change of becoming a parent and co-parenting~2. Early parenthood~3. Breastfeeding, caring for the baby and early parenthood~4. and 5 Labour, birth and postnatal care"
224238843|NCT04437862|DEVICE|Q Revascularization System|Q Revascularization System for mechanical thrombectomy
224238844|NCT00936169|PROCEDURE|IVUS optimised DES implantation|Ivus optimised stent implantation
224238845|NCT00936169|PROCEDURE|angiographically guided DES implantation|angiographically guided DES implantation
224238846|NCT01785368|OTHER|Implementation of guidelines|The participating ER doctors are required to request imaging exams for their patients according to a guide mutually constructed by the emergency and imaging departments of the Nîmes university hospital.
224238847|NCT01785368|OTHER|Baseline observation|During this period of the study, baseline data will be collected.
224238848|NCT04206644|OTHER|biological analysis|biological analysis of the Concentration of CCL18
224238849|NCT06218680|DRUG|Propofol|recieve propofol 0.5 mg/kg intravenously at end of sevoflurane anesthesia
224238850|NCT06218680|DRUG|Normal saline|recieve propofol 0.5 mg/kg intravenously at end of sevoflurane anesthesia
224238851|NCT02012244|DRUG|fentanyl-based analgesia|fentanyl based patient-controlled analgesia + additional pethidine for postoperative 48 hour
224238852|NCT02012244|DRUG|local anesthetic wound infiltration-based anlagesia|continuous wound inflitration with ropivacaine + tramadol patient-controlled analgesia + additional ketorolac or propacetamol for postoperative 48 hour
224238853|NCT02127281|DEVICE|Prevena|Device will be applied at end of procedure over closed incision.
224238854|NCT02821247|DRUG|Aflibercept (Eylea, BAY86-5321)|Intravitreal injection; should comply with the recommendations written in the local Summary of Product Characteristics (SPC) of the product
224238855|NCT02937701|BIOLOGICAL|ABP 710|Administered by intravenous infusion
223768152|NCT03758040|OTHER|Slips on Slopes|Slips will be administered to participants at 3 different times in the gait cycle over sloped ground surface of no slope, ±5.0 and ±10.0 degrees slopes in the direction of walking, and 5.0 and 10.0 degrees perpendicular to the direction of walking. On slopes perpendicular to the direction of walking, slips will be administered to the uphill or downhill foot. A total of 27 slip episodes will be administered. Sloped walking surfaces will be generated with the Computer Assisted Rehabilitation Environment (CAREN) system treadmill.
224238856|NCT02937701|BIOLOGICAL|Infliximab|Administered by intravenous infusion
224238857|NCT00002166|DRUG|Nevirapine|
224238858|NCT00076947|BIOLOGICAL|EnvPro|
224320994|NCT04119739|OTHER|Median nerve neural mobilization|Manual therapy maneuver performed in the upper limb.
223768153|NCT05446909|BEHAVIORAL|IBMT mindfulness|IBMT is an effortless mindfulness technique; health education is a class including health-related topics - exercise, sleep, nutrition, lifestyle, stress management
224238859|NCT05880056|DRUG|Nerkardou (5 mg) & (10 mg)|Bisoprolol oral dissolved film ODF(5 mg): equivalent to 5 mg of bisoprolol fumarate Bisoprolol oral dissolved film ODF (10 mg): equivalent to 10 mg of bisoprolol fumarate.
224238860|NCT04088422|PROCEDURE|peripheral blood collection|peripheral blood collection at treatment start, interm PET/CT, end of treatment PET/CT, one-year and two-year follow-up and or progression or relapse
224238861|NCT04786080|BEHAVIORAL|Parent Positive|"Parent Positive is a smartphone app delivering information and parenting support aiming to improve wellbeing within the family and reduce pressures on services given the ongoing pandemic-related challenges. It will consist of three zones, providing:~1. structured advice, support and tips for parents~2. facilitated parent-to-parent communication platform where parents can post questions of one another and parenting experts~3. access to carefully selected high-quality, evidence-based online parenting resources."
224238862|NCT03048526|DEVICE|NovaTears®|Topical eye drops for lubrication of the ocular surface
224238863|NCT03048526|DEVICE|Hydrabak®|Eye drops
224238864|NCT04681703|BEHAVIORAL|Nurse-led program on accuracy of blood pressure self-measurement|The training program was performed in accordance with current guidelines and consisted of a 1-h educational session led by one family nurse (FN) tasked with instruction of the patients. During the training program the FN emphasized that since morning and evening blood pressure (BP) values can widely differ, especially in patients taking medications, BP should be measured twice a day, in the morning and at evening, at specific fixed times (between 6:00 am and 9:00 am and between 6:00 pm and 9:00 pm) at least during the first week of monitoring. Thereafter, measurements can be taken before antihypertensive drugs are taken.
224238865|NCT05218798|DIAGNOSTIC_TEST|Cardio Respiratory Fitness testing|"In a randomized cross over designed study, we will measure Vo2max by using different tests:~1. Continous Treadmill Running Test~2. Continous 2-mile run test~3. 30-15 Intermittent Fitness Test - first trial and second trial"
224238866|NCT00587470|DRUG|Candesartan|Maximum vasodilation.
224238867|NCT00587470|DRUG|atacand|maximum vasodilation
224238868|NCT00587470|DRUG|Placebo|Placebo
224320995|NCT04119739|DRUG|Ibuprofen Arginine|Oral tablets
224238869|NCT04720664|DRUG|SM-88|"* SM-88, Two 230 mg capsules taken orally twice daily (920 mg daily).~* Methoxsalen, One 10 mg capsule taken orally once daily.~* Phenytoin, One 50 mg tablet taken orally once daily.~* Sirolimus, One 0.5 mg tablet taken orally once daily."
224238870|NCT02223741|OTHER|Korean medical treatment|acupuncture and herbal drugs
224238871|NCT06027879|BIOLOGICAL|Specific T- Lymphocytes|Peripheral blood mononuclear cells will be collected from the donor and loaded onto Miltenyi Biotec CliniMACS Prodigy® or CliniMACS® Plus where they will be stimulated in vitro with Adenovirus viral-specific antigen(s). The cells are then immunomagnetically labeled with interferon gamma via the cytokine capture system, captured and infused.
224238872|NCT03323125|OTHER|Self-Assessment Questionnaire|Self-assessment questionnaire with sun exposition, sun protection, vitiligo severity and vitiligo outbreaks, will be suggested to patient during medical consultation.
223655624|NCT03679520|OTHER|Regular programme|"Antenatal parental preparation as usual. As no guidelines exist the number of sessions may vary between 2 and 3 sessions and smaller variations in content may also occur.~Sessions~1. (or 1 and 2) Labour, birth and postnatal care~2. or 3 Breastfeeding, caring for the baby and early parenthood"
223655625|NCT02880436|OTHER|air pollution|impact of various pollution agents above threshold and their correlation with acute myocardial infarctions are analyzed
223655626|NCT01942733|DRUG|Brexpiprazole|2-3 mg/day, once daily, tablets, for oral use. The patients received 1mg/day brexpiprazole during Week 1 and 2mg/day during Week 2 (up-titration) and from Weeks 3 to 6 they received 3mg/day; depending on tolerability the dose could be reduced to 2mg/day based on the investigator's judgment.
223655627|NCT00922012|DEVICE|Electromagnetic Stimulation Therapy|Electromagnetic Stimulation Therapy for 24 weeks
223768154|NCT05446909|BEHAVIORAL|health education|Health education includes health-related topics - exercise, sleep, stress management, nutrition, lifestyle
223768155|NCT05620836|DRUG|Povorcitinib|Oral, Tablet
223768156|NCT05620836|DRUG|Placebo|Oral, Tablet
224238873|NCT04048148|DEVICE|Novel designed myopia control spectacle lenses|A novel designed myopia control spectacle lenses (test lenses) will be given to both arms to wear for 12 months.
224238874|NCT01110265|BEHAVIORAL|attention training|
224238875|NCT01110265|BEHAVIORAL|placebo training|
223655628|NCT01409811|DRUG|zoledronic acid|Given IV
224238876|NCT01513083|DRUG|trastuzumab emtansine|Multiple intravenous doses
224238877|NCT02037997|DRUG|docetaxel|docetaxel 75mg/m2 ivgtt D1
224238878|NCT02037997|DRUG|pemetrexed|pemetrexed 500mg/m2 ivgtt D1
223655629|NCT01409811|OTHER|laboratory biomarker analysis|Correlative studies
223655630|NCT01409811|PROCEDURE|therapeutic conventional surgery|Undergo definitive lumpectomy or mastectomy
223655631|NCT00634101|DEVICE|nelfilcon A|contact lens
223655632|NCT00634101|DEVICE|narafilcon A|contact lens
224238879|NCT02037997|DRUG|Erlotinib|Erlotinib 150mg qd
224320996|NCT05849454|DEVICE|Messy Memories Intervention|"Messy Memories is a mobile application that allows users to self-administer exposure therapy techniques outside of the traditional psychotherapy context. Participants are asked to audio record a difficult (messy) memory, including what they did, felt, thought, smelled, saw, etc. They are then asked questions about what it was like to re-experience the memory, such as what emotions were elicited (e.g., sadness, anger, fear). Next, participants are asked to process what the memory means to them. They are then instructed to listen to their recording as often as they like, until the memory becomes easier to re-experience. They respond to processing questions each time they listen to their prior difficult memory."
223655633|NCT04506099|DEVICE|TINS Active protocol|Electrical stimulation will be applied to the T6-T11 levels of intercostal nerves, as close to the level directly below the level of injury as possible. Electrodes 2 inch by 4 inch will be placed according to anatomic landmarks with the negative electrode applied to the lateral ribcage and the positive electrode applied to the ventral aspect, verified with contraction of the rectus abdominis. The intensity level will be set to the amperage immediately under the threshold for motor contraction. If there is no contraction seen, patients will be excluded. In addition, if the patient perceives pain, the intensity will be lowered until comfortable. Stimulation frequency of 20 Hz and pulse width of 200ms in continuous mode will be used.
223768157|NCT06373614|OTHER|foot massage|Interventions are to be performed in the evening before bedtime for 4 consecutive days.
223768158|NCT06373614|OTHER|bed bath|Interventions are to be performed in the evening before bedtime for 4 consecutive days.
223768159|NCT03738826|BEHAVIORAL|Behavioral Intervention|Lupus clinic providers will be prompted to assess adherence level using Surescripts refill information and address any adherence barriers that arise during the clinical encounter.
224238880|NCT00758849|DRUG|Placebo|One placebo tablet administered tid for 12 days in each of the three crossover treatment blocks, each block separated by 2-days placebo washout
224238881|NCT00758849|DRUG|Fipamezole|One 30-mg tablet of Fipamezole tid from day 1 to 3; one 60-mg tablet of Fipamezole tid from Day 4 to 6; and one 90-mg tablet of Fipamezole tid from Day 7 to 12 in each of the three crossover treatment blocks, each block separated by 2-days placebo washout
224238882|NCT06004726|OTHER|School-based Substance abuse Prevention Programme (SSPP)|"Module 1 :Introduction~* Orientation about Training Programme using PowerPoint slides~* Psychoeducation and Video Assisted Teaching to enhance awareness of substance abuse.~* Distribution of informational booklet on basics about substance abuse~Module 2:~* Role play to develop a positive attitude towards the prevention of substance abuse.~* Case-based scenario to increase resistance to peer pressure.~* Demonstration of drug refusal techniques.~Module3:• Storytelling on Life skills Training Components (Problem solving, Emotion Management)~Module 4:• Demonstration of Life skills training components (Communication skills, Decision making skills, Creative thinking skills, Stress Management strategies )"
224238883|NCT02392364|DRUG|Intravitreal Aflibercept Injection|
224238884|NCT02475915|DRUG|Vorinostat|Vorinostat (suberoylanilide hydroxamic acid) inhibits histone deacetylases class I and II. Vorinostat is supplied as 100mg capsules and will be administered at 400mg/ day in 2 week cycles beginning at week 0 for 10 weeks - 42 doses.
224238885|NCT02475915|DRUG|Hydroxychloroquine|Hydroxychloroquine is supplied as 200mg tablets and will be administered at week 0 for 10 weeks
224238886|NCT02475915|DRUG|Maraviroc|Maraviroc will be administered at 150 to 600mg/ml twice daily depending on the subject's ART regimen at week 0 for 10 weeks
224238887|NCT02475915|DRUG|Tenofovir|NRTI. Tenofovir will be administered at 300mg 1 X day at week 0 for 10 weeks
224238888|NCT02475915|DRUG|Emtricitabine|NRTI. Emtricitabine will be administered at 200mg 1 X day at week 0 for 10 weeks
224238889|NCT02475915|DRUG|Efavirenz|NNRTI. Efavirenz will be administered at 600 mg 1 X day at week 0 for 10 weeks
224238890|NCT02475915|DRUG|Darunavir|Protease Inhibitor. Darunavir will be administered at a dose of 900mg 1 X day for subjects on NNRTI based ART beginning at week 8 until week 10
224238891|NCT04533607|BEHAVIORAL|MAAPS|Modular intervention system integrating evidence-based strategies to address core and associated features of ASD and ongoing coaching.
224238892|NCT00079807|DRUG|Alpha-Lipoic Acid|
224238893|NCT02287545|PROCEDURE|trabeculectomy|Standard trabeculectomy with the use of antimetabolites (mitomycin C) for glaucoma patients with insufficient intraocular pressure (IOP) control taking maximally tolerated IOP-reducing medication, visual field progression despite maximally tolerated IOP-reducing medication, adverse events because of maximally tolerated IOP-reducing medication or nono.compliance.
224238894|NCT04480398|DRUG|Guduchi Ghan Vati|Guduchi Ghan Vati is an Ayuvedic classical preparation which is prepared from aqueous of extract of Tinospora cordifolia.
224238895|NCT05806710|DIETARY_SUPPLEMENT|GourMed© meal|patients receive GourMed© meal as lunch for 7 consecutive days
223655634|NCT04506099|DEVICE|Sham protocol|Electrical stimulation will be applied to the T6-T11 levels of intercostal nerves, as close to the level directly below the level of injury as possible until contraction is seen in the rectus abdominis. Stimulation frequency of 20 Hz and pulse width of 200ms in continuous mode will be used. Electrodes 2 inch by 4 inch will be placed according to anatomic landmarks with the negative electrode applied to the lateral ribcage and the positive electrode applied to the ventral aspect. The intensity level will be set to 1mA . If there is no contraction seen, patients will be excluded. In addition, if the patient perceives pain, the intensity will be lowered until comfortable.
223655635|NCT00822549|DRUG|intravenous morphine titration|intravenous morphine titration
223655636|NCT03373396|DIAGNOSTIC_TEST|Blood samples|Collected data will contain epidemiological and biological data, blood samples with chlordecone dosage.
223655637|NCT05861167|BIOLOGICAL|selective intensive induction therapy based on ustekinumab clinical decision-making tools|At week 0 and week 8, UST was induced intravenously twice (stratified according to body weight, see instructions for dosage), and at the third time, intravenous or standard subcutaneous injection regimen was used according to CRP standard
223655638|NCT01098513|DRUG|GSK1349572 formulation AP|GSK1349572 50 mg single dose fasted.
223655639|NCT01098513|DRUG|GSK1349572 formulation AW|GSK1349572 formulation AW 50 mg single dose in Part A and 75 to 200 mg fasted or with moderate or high fat meal in Part B.
223655640|NCT01098513|DRUG|GSK1349572 formulation AX|GSK1349572 formulation AX 50 mg in Part A and 75-200 mg fasted or with a moderate or high fat meal in Part B
223655641|NCT01543633|DRUG|Propofol|Propofol will be infused using a computer controlled delivery system running the program STANPUMP. Loss of consciousness will be defined as loss of response to auditory stimulus (button press).
223655642|NCT05952609|OTHER|Surefil One|Ion-releasing restoration
223655643|NCT05952609|OTHER|Cention N|Ion-releasing restoration
223655644|NCT05952609|OTHER|Bulkfil resin composite|resin composite (No ion-release)
223655645|NCT02416622|BIOLOGICAL|rAAV2tYF-CB-hRS1|adeno-associated virus vector expressing retinoschisin
223655646|NCT00139477|DRUG|Metformin|Metformin, 250mg by mouth twice a day with meals will be started and if tolerated increased to 500mg twice a day in 3 days in those less than 12 years old and titrated further to 1000mg twice a day if tolerated.
224238896|NCT04200482|BEHAVIORAL|One Diet and Physical Activity Session|Attend 1 remote diet and physical activity session
223655647|NCT00139477|BEHAVIORAL|Dietary modification with caloric restriction|The life style intervention changes will include a hypocaloric diet representing at least a 500 kcal/day reduction based on their dietary histories and Resting Energy Expenditure (REE) determined by the initial calorimetry.
223655648|NCT00139477|BEHAVIORAL|Establishment of exercise protocol|Participants will attend the Fitness Center 3 times per week and supervised by an exercise technician or exercise specialist. Exercise will be individually prescribed for each participant based on their functional abilities. Exercise will consist of 5-10 minutes for warm up and stretching, followed by 15-30 minutes of cardiovascular exercise (i.e. treadmill, bicycle ergometer, rower, nustep, etc), 10-20 minutes of strength training (supervised using weight stack equipment), and 5-10 minutes of cool down and stretching. As children typically do not need an exercise prescription based on heart rate, we will familiarize them with perceived exertion scales and monitor that they are exercising in the moderate to hard range of perception of effort. Participants will be started at 15 minutes of cardiovascular exercise and 10 minutes of strength training exercise, progressing by 2-3 minutes every week until 30 and 20 minutes is achieved for each respectively.
223655649|NCT03934099|DRUG|LC350189 formulated capsule|Xanthine Oxidase Inhibitor
224238897|NCT04200482|OTHER|Electronic (e) Health (eHealth) Communication Intervention|Receive eHealth communication intervention
224238898|NCT04200482|BEHAVIORAL|Twelve Diet and Physical Activity Group Sessions|Attend 12 remote diet and physical activity sessions in 6 months
224238899|NCT04200482|OTHER|Questionnaire Administration|Ancillary studies
224238900|NCT04200482|OTHER|Quality-of-Life Assessment|Ancillary studies
224238901|NCT06526962|DEVICE|5Fr hysteroscopic bipolar electrode or conical optical 5Fr fibers for dual wave-length diode laser|Outpatient hysteroscopic polypectomy
224238902|NCT01880073|DEVICE|FemVue device|The device will be used in conjunction with what is now considered the standard of care to determine if it's as effective.
223655650|NCT03934099|DRUG|Placebo|Matching placebo
224238903|NCT06437431|DRUG|glenzocimab|Two vials (2x500 mg) of glenzocimab should be administered concomitantly for eligible patients for a total dose of 1g of glenzocimab as an IV infusion over 6 hours, with 1/4 of the dose administered by a 15-minutes bolus and 3/4 of the dose administered by 5h45minutes continuous infusion.
224238904|NCT06437431|DRUG|placebo|Placebo of glenzocimab is 0.9% NaCl for IV administration. It is supplied for clinical trial use in vials of 50 mL. Two vials of placebo should be administered concomitantly for eligible patients. The administration scheme will be the same as in the experimental arm.
224238905|NCT00349947|BEHAVIORAL|Exercise Program|Participants who live within 15 miles of the Palo Alto VA Hospital will take part in a supervised aerobic exercise program 3 days a week. Participants who live farther than 15 miles from the hospital will receive a detailed exercise plan and will exercise on their own while wearing a heart rate and activity tracking device. They will also attend monthly study visits for review of their progress. All participants assigned to the exercise program will be encouraged to increase their daily exercise. Each day they will wear a pedometer; twice a month they will wear a global positioning system (GPS) and heart rate monitor.
224238906|NCT03281109|DIAGNOSTIC_TEST|diagnosis|diagnosis with ELISA
224238907|NCT04107870|BEHAVIORAL|Virtual Reality Exposure Therapy sessions|Female adolescents aged 13 to 18 are proposed virtual reality exposure therapy sessions, accompanied by a cognitive and behavioral therapy (CBT) therapist, to work on their body representations
223655651|NCT02380469|BEHAVIORAL|Identification and provision of lacking information|The intervention consists of an interview about the caregiver's responses (baseline measurement) to a list about 'lack of information' within 13 areas. For each area, the patient's nurse will enquire about what information is requested by the caregiver and the patient. Subsequently, the nurse provides the requested information. She may involve the doctor and arrange follow-up visits or phone calls until the need is covered
223655652|NCT04088058|DRUG|GXHPC1|autologous ADSCs
223655653|NCT00528450|DRUG|arsenic trioxide|
223655654|NCT00528450|DRUG|idarubicin|
223655655|NCT00528450|DRUG|tretinoin|
223655656|NCT02909543|OTHER|Observation and Interviwe|The research data will be conducted by using a semi structured interview of the participants in the study.
223655657|NCT04588454|OTHER|18F-PSMA-1007 PET tracer|18F-PSMA-1007 PET/CT
223655658|NCT00045318|DRUG|exatecan mesylate|
223655659|NCT04796194|COMBINATION_PRODUCT|LTX-315 in combination with pembrolizumab|"Phase A Pembrolizumab will be given as 200 mg IV infusion over 30 minutes on Days 1 and 22.~Phase B Pembrolizumab will be given as 400 mg IV infusion over 30 minutes every 6 weeks starting at Day 43 (3 weeks after the last dose of pembrolizumab in Phase A) until discontinuation from the study or for a maximum of 24 months' total therapy, whichever comes first."
223655660|NCT04154527|OTHER|Pelvic Floor and Abdominal Exercises|two repetitions of each exercise, during exhalation phase
223655661|NCT00573144|DRUG|Nesiritide|Infusion of 72 hours of IV nesiritide at 0.006 mcg/kg/min.
223655662|NCT00573144|DRUG|Placebo|Infusion of 72 hours of saline solution (packaged to match active comparator)
223655663|NCT04574635|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
223655664|NCT02699606|DRUG|Erdafitinib|Participants will receive 8 mg of erdafitinib, once daily with option to up-titrate to 9 mg.
224238908|NCT04107870|BEHAVIORAL|Psychomotor therapy sessions|Psychomotor therapy sessions are proposed to female adolescents aged 13 to 18 years, ac-companied by a psychomotor therapist, to work on their body representations.
224238909|NCT01737671|PROCEDURE|Ommaya Reservoir|Surgical catheter placement into the fourth ventricle of the brain.
223655665|NCT02114073|DRUG|Cyclosporine|In study arm, ophthalmic emulsion of cyclosporine A 2% will be prescribed in postoperative phase.
223655666|NCT02114073|DRUG|Betamethasone|In control arm, betamethasone eye drop will be prescribed in postoperative period.
223655667|NCT01695759|DRUG|Epoetin alpha|Participants assigned to this arm will receive two subcutaneous administrations per week of 50 UI/kg of Epoetin alpha (Eritromax), totaling 100 UI/kg/week. After the first four weeks of treatment, once a month throughout the study the medication dose can be adjusted by the study Investigator according to the laboratory results.
224238910|NCT01737671|DRUG|Methotrexate|2 mg into fourth ventricle of the brain via the Ommaya Reservoir for 4 days. Each patient will undergo three cycles with at least two weeks between each cycle.
224238911|NCT01737671|DRUG|Leucovorin|5 mg/square meter per dose administered every 6 hours by vein or mouth.
224238912|NCT00637390|DRUG|Alemtuzumab|will be given Alemtuzumab therapy three times in your first week on the study and then once a week for six additional weeks
224238913|NCT01828996|DEVICE|Shock wave therapy|A total of 3000 pulses will be applied, moving the shock head every 500 pulses to cover the entire prostate and pelvic floor region.
223655668|NCT01695759|DRUG|Eprex|Participants assigned to this arm will receive two subcutaneous administrations per week of 50 UI/kg of Epoetin alpha (Eprex), totaling 100 UI/kg/week. After the first four weeks of treatment, once a month throughout the study the medication dose can be adjusted by the study Investigator according to the laboratory results.
223655669|NCT02090842|DIETARY_SUPPLEMENT|Ca-caseinate|
223655670|NCT02090842|DIETARY_SUPPLEMENT|Maltodextrin|
223655671|NCT02090842|DIETARY_SUPPLEMENT|Whey protein isolate|
223655672|NCT02625909|DRUG|SOF/VEL for 6 weeks|Open-label SOF/VEL 400mg/100mg once daily to be given to participants randomised to Arm A (6 weeks short treatment duration).
223655673|NCT02625909|DRUG|SOF/VEL for 12 weeks|Open-label SOF/VEL 400mg/100mg once daily to be given to participants randomised to Arm B (12 weeks standard treatment duration).
223655674|NCT00953056|BIOLOGICAL|Rotavirus Vaccine, Live, Oral, Pentavalent|"Single 2.0 mL dose V260 (RotaTeq™) administered orally at enrollment.~The 2-mL vaccine consists of an oral solution of 5 live human-bovine reassortant rotaviruses."
223655675|NCT00953056|BIOLOGICAL|Comparator: Placebo|Single 2.0 mL dose of matching placebo to RotaTeq™ administered orally at enrollment.
223655676|NCT00953056|BIOLOGICAL|Rotavirus Vaccine, Live, Oral, Pentavalent|"Three 2.0 mL doses of RotaTeq™ administered orally at 3 separate visits scheduled 28 to 70 days apart. The third dose was administered by 32 weeks of age.~The 2-mL vaccine consists of an oral solution of 5 live human-bovine reassortant rotaviruses."
223655677|NCT00953056|BIOLOGICAL|Comparator: Placebo|Three 2.0 mL doses of matching placebo to RotaTeq™ administered orally at 3 separate visits scheduled 28 to 70 days apart. The third dose was administered by 32 weeks of age.
223655678|NCT00903188|DRUG|cyclosporine|"Cyclosporine (Group 1):~basiliximab dose: 1x20 mg IV on Day 0 and 1x20 mg IV on Day 4~Cyclosporine: 8 mg/kg PO given before surgery, followed by 2x4 mg/kg/d. C-0h levels: month 1: 150-250 ng/ml; month 2: 100-200 ng/ml; month 3: withdrawal steroids: 100-150 ng/ml.~C-2h levels: month 1: 900-1100 ng/ml; month 2: 800-1000 ng/ml; month 3: withdrawal steroids: maintain level of 750 ng/ml~Enteric-coated mycophenolate(MPA):720mg PO pre-operatively followed by 1.44 g/day.~Steroids: pre-operatively: 250mg methylprednisolone IV; day 1:125mg IV.~Methylprednisolone:day 2-30:PO 12mg/d; day 31-60:tapered to 8mg/d ,day 61-90 :4mg/d; Month 3:stop"
223655679|NCT00903188|DRUG|Everolimus|"Everolimus (Group 2):~Basiliximab dose: idem as in group 1~Cyclosporine: first three months idem group 1; month 3: decreased dose by 50%, simultaneously initiate everolimus at a starting dose of 0.75 mg bid.~Once the everolimus blood levels range 6 - 12 ng/ml, cyclosporine will be stopped.~Enteric-coated mycophenolate (MPA) dosing idem as group 1.~Everolimus starting dose: 0.75 mg bid, trough levels: 6-12 ng/ml.~Steroid dosing: idem group 1, but maintained at 4 mg methylprednisolone after day 60."
223655680|NCT02575157|OTHER|No intervention|No intervention
223655681|NCT04310189|PROCEDURE|Biopsy|All patients will have a blood sample and 2 skin biopsies (2 mm diameter) in lesional and non lesional area
223655682|NCT03846206|DIETARY_SUPPLEMENT|mediterranean diet|a Mediterranean diet supplemented with 50 g / day of olive oil and 15g / day of nuts for three months
223655683|NCT00329355|DRUG|sumatriptan succinate/naproxen sodium|
223655684|NCT00483977|DRUG|Oxycodone|Oxycodone: oral controlled release, 20 mg, twice a day for 2 weeks
223655685|NCT00483977|DRUG|Placebo|Placebo: oral for 2 weeks.
223655686|NCT00483977|DRUG|PF-000592379|PF-00592379: oral, 30 mg, once a day for 2 weeks
223655687|NCT02367833|DRUG|Combined Oral Contraceptive|The proposed study is a preclinical, multi-site trial comparing the short-term effects of oral and non-oral ethinyl estradiol on the GH/IGF-1 axis and bone metabolism. Using a prospective repeated measures design, we will test the effects of 2 cycles of combined oral contraceptive (Apri or Reclipsen) on the GH/IGF-1 axis.
223655688|NCT02367833|DRUG|Transdermal Contraceptive|The proposed study is a preclinical, multi-site trial comparing the short-term effects of oral and non-oral ethinyl estradiol on the GH/IGF-1 axis and bone metabolism. Using a prospective repeated measures design, we will test the effects of 2 cycles of a transdermal contraceptive (Xulane) on the GH/IGF-1 axis.
223655689|NCT02367833|DRUG|Contraceptive Vaginal Ring|The proposed study is a preclinical, multi-site trial comparing the short-term effects of oral and non-oral ethinyl estradiol on the GH/IGF-1 axis and bone metabolism. Using a prospective repeated measures design, we will test the effects of 2 cycles of vaginal ring contraceptive (Nuva Ring) on the GH/IGF-1 axis.
223655690|NCT04276948|DIETARY_SUPPLEMENT|NAD3|NAD3 is an over-the-counter dietary supplement available online to consumers.
223655691|NCT01077076|DRUG|Zegerid|Zegerid taken once daily for 11 days.
224238914|NCT01828996|DEVICE|Placebo|A total of 3000 pulses will be applied, moving the shock head every 500 pulses to cover the entire prostate and pelvic floor region
224238915|NCT05198050|DRUG|Letrozole tablets|Letrozole is a third-generation non-steroidal aromatase inhibitor
224238916|NCT05198050|DRUG|Misoprostol Tabets|a synthetic prostaglandin medication
224238917|NCT05198050|DRUG|Placebo tablets|Placebo tables with a similar appearance to letrozole
224238918|NCT00023309|DRUG|Lamivudine and adefovir|Lamivudine (100 mg/day) and adefovir (10 mg/day)
224238919|NCT00023309|DRUG|Adefovir alone|Adefovir (10 mg/day)
224238920|NCT04132856|OTHER|Psychosocial Navigator|Services of psychosocial navigator
224238921|NCT04132856|OTHER|Communication of Summary Profile|Both patient/caregiver dyad and HCPs will receive a summary of the PAT results and levels of depression and anxiety.
224238922|NCT04744909|DEVICE|SafeTrach for tracheotomy|The navigation system is a forceps-like instrument with an outer and an inner shank. The inner shank serves as a ventilation lumen and stabilizes the orotracheal tube in the midline of trachea. The outer shank acts as a three-dimensional guide for the puncturing needle to the midline of trachea
224238923|NCT06348693|OTHER|cell isolation from tumor biopsies and biomarker investigation|cellular and molecular analysis on cancer stem cells and endothelial cells from tumor biopsies and investigation of tissue and systemic biomarkers
224238924|NCT04509180|PROCEDURE|Catheter ablation|Endovascular approach
223655692|NCT01077076|DRUG|Prilosec OTC™ Tablets|Prilosec OTC™ Tablets taken once daily for 11 days.
223655693|NCT01077076|OTHER|Placebo|Placebo taken once daily for 11 days.
223655694|NCT06134804|BIOLOGICAL|ExPEC9V|ExPEC9V will be administered as an IM injection.
223655695|NCT06134804|BIOLOGICAL|Placebo|Placebo will be administered as an IM injection.
223655696|NCT06134804|BIOLOGICAL|HD quadrivalent influenza vaccine|HD quadrivalent influenza vaccine will be administered as IM injection.
223655697|NCT02156934|BIOLOGICAL|paraurethral injection|Paraurethral injection of muscle derived stem cell in patients with stress urine incontinency.
223655698|NCT00433134|BEHAVIORAL|Adherence|
223655699|NCT00946387|DRUG|Ondansetron HCl 24 mg Tablets (Sandoz, Inc.)|
223655700|NCT00946387|DRUG|Zofran (Ondansetron HCl) 24 mg Tablets (GlaxoSmithKline)|
223655701|NCT00035932|DRUG|Atazanavir + ritonavir + tenofovir + nucleoside|Active Comparator, Capsules, tablets, Oral
223655702|NCT00035932|DRUG|Atazanavir + saquinavir + tenofovir + nucleoside|Active Comparator, Capsules, tablets, Oral
223655703|NCT00035932|DRUG|Lopinavir/ritonavir + tenofovir + nucleoside|Active Comparator, Capsules, tablets, Oral
223655704|NCT02268175|DRUG|Enzalutamide|160 mg (four 40 mg capsules), oral, once daily, 28 days (4 weeks) 6 cycles maximum. Can be taken with or without food.
223655705|NCT02268175|DRUG|Abiraterone Acetate|1000 mg (four 250 mg tablets), oral, once daily, 28 days (4 weeks) 6 cycles maximum. No food should be consumed for at least two hours before the dose and for at least one hour after the dose.
223655706|NCT02268175|DRUG|Prednisone|5 mg, oral, once daily, 28 days (4 weeks) 6 cycles maximum.Take with food, preferred to be taken in the morning .
223655707|NCT02268175|DRUG|Leuprolide Acetate|Either 7.5 mg monthly or 22.5 mg every three months, Intramuscular, monthly or every three months.
224238925|NCT04509180|PROCEDURE|Convergent procedure|Surgical and endovascular approach
224238926|NCT05425888|OTHER|Hemophilia group|Evaluation of the study variables: dorsal flexion; dorsiflexion strength; tibialis anterior muscle activation; biomechanical analysis of gait and balance; and functionality.
224238927|NCT01866319|BIOLOGICAL|Pembrolizumab|10 mg/kg IV, administered Q2W or Q3W based upon randomization.
224238928|NCT01866319|BIOLOGICAL|Ipilimumab|3 mg/kg IV Q3W.
224238929|NCT01661114|DRUG|Gemcitabine|
224238930|NCT01661114|DRUG|5-FU|
224238931|NCT01661114|DRUG|Cisplatin|
224238932|NCT03980483|BIOLOGICAL|GSK3196165 (Otilimab)|GSK3196165 solution in vial/pre-filled syringe (PFS) to be administered SC.
224238933|NCT03980483|DRUG|Tofacitinib 5 mg|Tofacitinib cap (over encapsulated 5mg tablet) to be administered orally.
224238934|NCT03980483|DRUG|Placebo|Placebo sterile 0.9 percentage (%) weight by volume (w/v) sodium chloride solution in vial/pre-filled syringe (PFS) to be administered SC.
224238935|NCT03980483|DRUG|Placebo|Placebo cap (containing lactose) to be administered orally.
224238936|NCT01164813|DRUG|Nabumetone|Nabumetone 750 mg Tablets of Dr. Reddy's Laboratories Limited
224238937|NCT01164813|DRUG|Relafen|Relafen® 750 mg Tablets of Glaxosmithkline Research Triangle Park, NC.
224238938|NCT02612636|OTHER|ear plug|The patients will receive the intervention (ear plug) in the third night (N3) from 9 pm to 6 am.
224238939|NCT02612636|OTHER|eye mask|The patients will receive the intervention (eye mask) in the second night (N2) from 9 pm to 6 am.
224238940|NCT06222749|DRUG|Intranasal oxytocin administration|24 international units (IU) of Syntocinon, nasal spray solution; 1 ml nasal spray contains 40 I.U. oxytocin (equivalent to 67 mcg). One spray hub (0.1 ml) contains 4 I.U. oxytocin (equivalent to 6.7 mcg).
224238941|NCT06222749|DRUG|Intranasal placebo administration|Nasal spray solution; Placebo will be administered as the placebo controlled condition.
224238942|NCT04495049|DEVICE|Alcon Vivity or Vivity Toric IOL|Patients who previously underwent cataract surgery with the Alcon Vivity or Vivity Toric IOL in both eyes.
224238943|NCT00784849|DRUG|Methylene blue|1 mC1
224238944|NCT01009398|OTHER|Fluoroscopic examination|Localisation of the paravertebral catheter tip and documentation of the spread of contrast dye injected through the catheters by fluoroscopic examination
224238945|NCT00001025|DRUG|Zidovudine|
224238946|NCT00001025|DRUG|Didanosine|
224238947|NCT01225146|DRUG|ranibizumab|Ranibizumab is formulated as a sterile solution aseptically filled in a sterile 3-mL stoppered glass vial. Each vial contains 0.5 mL of 40 mg/mL (2.0-mg dose level) ranibizumab aqueous solution.
224238948|NCT04360993|RADIATION|Radiotherapy|Patients have received radiotherapy as a treatment modality for Head and neck cancer
223655708|NCT03501108|OTHER|STOPPFrail deprescribing criteria|STOPPFrail is a recently validated set of explicit deprescribing criteria devised specifically for use in older patients with advanced physical and /or mental morbidity such that the 1-year survival prognosis is likely to be poor. STOPPFrail-defined medications that appear on the patient's medication list are highlighted to the attending physician for his/her consideration for deprescribing i.e. removal from the medication list immediately or gradually as appropriate.
223655709|NCT04413617|DRUG|PF-06650833|400 mg
223655710|NCT04413617|DRUG|PF-06651600|100 mg
224238949|NCT01014728|DRUG|propofol|100-200mcg/kg/min by infusion
224238950|NCT01014728|DRUG|sevoflurane|1-3% of sevoflurane (expired)
224238951|NCT00623779|DRUG|AZD0837|ER formulation
224238952|NCT00623779|DRUG|Aspirin|Oral form
223655711|NCT04413617|DRUG|Tofacitinib|11 mg
223655712|NCT01327482|DRUG|Raltegravir|Dosage: 400mg/PO (by mouth) Frequency: Twice daily Duration: During course of menstrual cycle (28 days)
223655713|NCT00476229|DRUG|Thymoglobulin|1.5 mg/kg by vein on Days -11 to -7.
223655714|NCT00476229|RADIATION|Total Lymphoid Irradiation|80 cGy daily on days -11 to -7 and -4 to 0.
223655715|NCT00476229|PROCEDURE|Peripheral Blood Stem Cell Infusion|PBSC infusion administered on day 0.
223655716|NCT00476229|DRUG|Rituximab|375 mg/m\^2 by vein on days -13, -6, 1, \& 8. Only those patients whose tumors express CD20 will receive Rituximab.
223655717|NCT05699694|DIETARY_SUPPLEMENT|StemRegen product|"Products will be consumed orally in capsules with a glass of water. Six capsules per day will be consumed daily for 6 month. Two main administration schedules are possible:~Two in the morning, 2 at noon, and 2 in the evening at each meal depending on individual habits of the volunteers to reduce non-compliance."
223655718|NCT04680182|PROCEDURE|Suction drain|Suction drain either kept for three weeks or gradually pulled out.
223655719|NCT01776216|OTHER|Dairy diet|During the DAIRY diet, subjects will be asked to incorporate 3 servings of dairy: 375 ml of reduced fat milk (1% fat), 175 g of low fat yogurt (1.5% fat) and 30g of regular cheese (34% fat) into their every day diet.
223655720|NCT01776216|OTHER|Control diet|During the CONTROL diet of the study, participants will be asked to consume energy equivalent replacement products (290 ml of fruit juice, 156 ml of vegetable juice, 1 homemade cookie, 20g of cashew).
223655721|NCT03126513|PROCEDURE|G-POEM|After confirmation of refractory gastroparesis, participants will undergo to gastric POEM. Participants will be admitted to hospital 24hrs before procedure and IV antibiotics will be given and then the procedure will be done. Technique consist of 4 steps: First: a submucosa injection of saline solution with methylene blue at 3-4cms from pylorus. Second: a submucosa incision and tunnel creation up to pyloric area. Third: Myotomy of the circular and longitudinal muscular layers of the pylorus and the antrum. Fourth: closure of the mucosal incision with hemoclips. After procedure they will be kept on surveillance and will be followed-up with clinical, endoscopic and scintigraphic studies up to 1 year after procedure.
224238953|NCT01050647|DRUG|17-Hydroxyprogesterone Caproate|Weekly injections of 17-hydroxyprogesterone caproate.
224238954|NCT01050647|OTHER|Caster Oil injections|Weekly injection of Caster Oil (Placebo) until patient reached 34 weeks gestation.
224238955|NCT00220337|DRUG|Lacosamide|Lacosamide film-coated tablets; two times per day; up to 400 mg/day for 2.75 years
223655722|NCT02164461|BIOLOGICAL|Axalimogene filolisbac|
223655723|NCT01814241|DRUG|Open label peanut OIT|Subject will take increasing amounts of peanut protein up to a maximum maintenace dose of 1450mg.
224238956|NCT00944697|DRUG|Oxycodone Naloxone|Oxycodone Naloxone tablets
224238957|NCT00944697|DRUG|Placebo tablets|Placebo Oxycodone Naloxone tablets
224238958|NCT05163951|PROCEDURE|Trabeculectomy|trabeculectomy
224238959|NCT05163951|PROCEDURE|SPI+GSL+GT|Peripheral iridectomy (SPI) combined with goniosynechialysis (GSL) and goniotomy (GT)
224238960|NCT01056770|DRUG|smallpox vaccine CJ-50300|Conventional CJ-50300 2.5 x 100000 pfu/dose vaccination
224238961|NCT02799797|PROCEDURE|ultrasound guided long axis placement of adductor canal catheter|The long axis of the ultrasound probe is placed parallel to the long axis of the adductor canal while scanning, and the catheter is placed along the long axis of the canal using an in-plane approach
224238962|NCT02799797|PROCEDURE|ultrasound guided short axis placement of adductor canal catheter|The long axis of the ultrasound probe is placed vertical to the long axis of the adductor canal while scanning, and the catheter is placed along the short axis of the canal using an in-plane approach
224238963|NCT02799797|DEVICE|Philip CX 50 Ultrasound Scanner|The linear (C5-12) probe of Philip CX 50 Ultrasound Scanner is used for scanning
224238964|NCT02799797|DEVICE|PAJUNK Contiplex S Catheter|
223655724|NCT05680688|OTHER|Manual Therapy|"* Postero-anterior mobilizations: the physiotherapist will place his thumbs on the posterior surface of the spinous process of the vertebra previously assessed as the most painful to mobilise. The oscillations will be performed at the frequency of 1 oscillation per second and will be performed 3 series of 3 minutes, with a 1 minute rest interval.~* Pressure: The point of greatest pain shall be treated by maintained pressure in each of the following areas: right upper trapezius, left upper trapezius, right paravertebral musculature and left paravertebral musculature. Pressure shall be applied to each of the points for 1 minute.~* Massage: Pressure is applied to the muscles by sliding along the muscle belly. This will be done slowly to control the pain that is being provoked. 3 minutes will be carried out on each upper trapezius, sliding from the acromion to the occipital and another 3 minutes on the paravertebral musculature on each side, sliding from T1 to the occipital."
223655725|NCT02069860|DEVICE|Bone Anchored Port System (BAP)|The port body will be implanted onto the petrous bone and a sealing cap, a twofold valve system and a catheter are connected to the port body. The catheter is tunneled under the skin, enters the internal jugular vein and ends in the right atrium of the heart. The novelty of the access lies in its location (retro auricular on petrous bone) and its bone fixation.
223655726|NCT03375697|DRUG|JNJ-63733657|Subjects will receive single (Part 1) or multiple (Part 2) ascending dose levels of JNJ-63733657 intravenously.
223655727|NCT03375697|DRUG|Placebo|Subjects will receive matching placebo intravenously.
223655728|NCT04451187|DRUG|Seltorexant Dose 1|Participants will receive Dose 1 of seltorexant OD from Day 1 to Day 8 as part of Treatment A as per assigned treatment sequence.
223655729|NCT04451187|DRUG|Seltorexant Dose 2|Participants will receive Dose 2 of seltorexant OD from Day 1 to Day 8 as part of Treatment D as per assigned treatment sequence.
223655730|NCT04451187|DRUG|Placebo|Participants will receive placebo of seltorexant OD from Day 1 to Day 8 as a part of Treatment A and C and from Day 2 and Day 7 as a part of Treatment B as per assigned treatment sequence.
223655731|NCT04451187|DRUG|Zopiclone|Participants will receive Dose 3 of zopiclone OD from Day 1 to Day 8 as a part of Treatment B as per assigned treatment sequence.
223655732|NCT03879161|DEVICE|Vu-Path™|Femoral arterial access in eligible participants will be performed using the Vu-Path™.
223655733|NCT00722306|DRUG|PD 0200390|Extemporaneous solution of C14 Labelled PD 0200390 60 mg single dose
223655734|NCT02457143|BEHAVIORAL|Letter|
223768160|NCT05560932|BEHAVIORAL|IMB-motivational interviewing (MI) techniques (IMB-MI)|The clinical pharmacist will employ MI in informational, participant-centered discussions in which the clinical pharmacist and participant collaboratively discuss the harms of drinking and polypharmacy (specifically alcohol interactive medications), symptoms associated with alcohol and specific medications, and how to mitigate these harms. Motivational elements include messages highlighting the participant's personal risk of bothersome symptoms from their use of alcohol and level of polypharmacy, attitude change elements to improve attitudes toward the intended behavior change, social normative support for the intended behavior change including identification of people who can support the participant in this process, and a menu of options for referrals for skill building (e.g. Social Work, meeting with the clinical pharmacist at their clinic, follow-up with the HIV clinician, alcohol-reduction programs, based on what is locally available as part of VA-based care).
223768161|NCT06323304|OTHER|Auricular acupressure|Auricular acupressure therapy will be performed once a week for 4 weeks using Vaccaria seeds, which is an herb in traditional medicine. The acupoints on the ear that will be treated with auricular acupressure therapy are Shenmen (TF4), Internal nose (TG4), Lung (CO14), Wind stream (SF1,2i), Adrenal gland (TG2p). These acupoints are believed to be effective in the treatment of allergic rhinitis. The patches will be kept on the auricle for one week.
223768162|NCT06323304|OTHER|Sham acupressure|Sham acupressure therapy will be performed once a week for 4 weeks using Vaccaria seeds. The acupoints that will be treated with auricular acupressure therapy are Helix 2 (HX10), Shoulder (SF4), Clavicle (SF6), Anus (HX5) and Tooth (LO1). These acupoints are not used to treat allergic immune-related problems or respiratory diseases. The patches will be kept on the auricle for one week.
223768163|NCT06323304|OTHER|Standard treatment|Standard treatment, continuously administered over the 4-week intervention period, involves standard doses of fluticasone propionate nasal spray as needed, and lifestyle modifications.
223768164|NCT04747236|DRUG|Azacytidine|Azacytidine, 300 mg po daily on Days 1-14
223768165|NCT04747236|DRUG|Romidepsin|Romidepsin, 14 mg/m2 as an intravenous infusion over 4 hours on Days 8, 15, and 22 of a 35-day cycle
223768166|NCT04747236|DRUG|Belinostat|Belinostat, 1000 mg/m2 as an intravenous infusion over 30 minutes on Days 1-5 every 21 days.
223768167|NCT04747236|DRUG|Pralatrexate|Pralatrexate, 30 mg/m2 as an intravenous infusion over a 3-5 minute push once weekly for 6 weeks of a 7 week treatment cycle.
224238965|NCT02799797|DRUG|Ropivocaine|0.2% ropivacaine 10ml is given as loading dose. Following that, 0.2% ropivacaine 5ml/h is given as maintenance dose.
223655735|NCT02457143|BEHAVIORAL|Phone call|
223655736|NCT04298671|BEHAVIORAL|Yoga-Pilates|As above
223655737|NCT03414931|DRUG|NMDA|Use of an NMDA enhancer for the treatment of MDD in late life
224238966|NCT02799797|DRUG|rescue sulfentanil given postoperatively as PICA|bolus: 2mg, lock time: 10min, 1h limitation: 8mg
224238967|NCT00003797|BIOLOGICAL|trastuzumab|
224238968|NCT00003797|DRUG|gemcitabine hydrochloride|
224238969|NCT02238145|DRUG|Atrovent® Inhaletten|
224238970|NCT03358849|BIOLOGICAL|Natural killer cell|Patients who received natural killer cell injection
224238971|NCT02803242|OTHER|Patient Reported Outcomes|
224238972|NCT00186108|DRUG|Oral Triamcinalone|
224320997|NCT03852147|PROCEDURE|: hemodynamic management|"Control group: hemodynamic management of patients is done according to usual practices by maintenance of blood pressure by norepinephrine as well as optimization of SV by vascular filling and use of dobutamine if necessary.~Experimental group: perioperative hemodynamic management is based on an algorithm that includes RQ measurement and includes volume expansion, norepinephrine, FiO2 enhancement, RBC transfusion and dobutamine."
223655738|NCT03414931|DRUG|Sertraline|Use of SSRI as an active comparator
223655739|NCT03414931|DRUG|Placebo - Cap|Use of placebo as a comparator
223655740|NCT02502617|DIETARY_SUPPLEMENT|medical nutrition|The participants are expected to improve their body weight with 10-30% during a closely monitored inpatient-treatment comprising nutritional rehabilitation.
223655741|NCT01957046|DRUG|Laxative|
223655742|NCT01192191|DRUG|Fluticasone Furoate/GW642444 Inhalation Powder 100/25mcg|Fluticasone furoate/GW642444 inhalation powder inhaled orally once daily for 52 weeks
223655743|NCT01192191|DRUG|Fluticasone Furoate/GW642444 Inhalation Powder 200/25mcg|Fluticasone furoate/GW642444 inhalation powder inhaled orally once daily for 52 weeks
223655744|NCT04518358|BEHAVIORAL|Use of Expert Guiding Technology (GAINS) to Improve Live and Vocational Skills for Individuals with Developmental Challenges|During the GAINS sessions, the Direct Support Professional (DSP) will follow the pre-programmed teaching protocol in the expert guiding technology. The system will provide step-by-step verbal prompts to the DSP throughout sessions. This includes which prompt to use for each step of the target skill, when to provide reinforcers, and which target task to work on. The system will also monitor the participant's (adults with ASD/ID) progress and notify the DSP if the target skill is mastered.
223655745|NCT05346068|DEVICE|OPN™ NCB Super High Pressure PCI Balloon|"In order to permit advancement of the studied medical devices - OPN™ NCB or Shockwave™ IVL balloon catheter - initial lesion preparation using small SCBs or NCBs (≤2mm) or rotablation (Boston Scientific, Marlborough, MA, United States) is allowed, but will be documented. This may be required in selected cases with very calcified and tight lesions.~As per protocol, lesion preparation will be performed using either the super-high pressure PCI balloon OPN™ NCB or the Shockwave™ IVL balloon catheter according to random treatment assignment after matching the angiographic and/or OCT inclusion criteria.~Following successful lesion preparation all patients will be treated with a latest generation durable polymer everolimus-eluting stent (Xience™ Sierra or Skypoint, Abbott Vascular Inc., Santa Clara, CA, United States) to allow comparison of stent expansion."
223768168|NCT04747236|DRUG|Gemcitabine|Gemcitabine, 1000 mg/m2 as an intravenous infusion over 30 minutes on Days 1, 8, and 15 of a 28 day cycle.
223768169|NCT05500365|PROCEDURE|Catheter ablation therapy|Pace mapping procedure performed during catheter ablation therapy
223768170|NCT04060329|BEHAVIORAL|coopeRATE Prompt|The coopeRATE Prompt intervention is a set of two questions delivered to patients immediately before the clinical encounter that elicit their concerns and goals.
223768171|NCT00658281|PROCEDURE|CBCT Scan|Cone Beam Computed Tomography (CBCT) scan performed once a week.
223768172|NCT00658281|PROCEDURE|OBI KV Imaging|On Board Imager kilovoltage (OBI KV) Imaging performed once a week.
223655746|NCT05346068|DEVICE|Shockwave™ C2 IVL Catheter|"In order to permit advancement of the studied medical devices - OPN™ NCB or Shockwave™ IVL balloon catheter - initial lesion preparation using small SCBs or NCBs (≤2mm) or rotablation (Boston Scientific, Marlborough, MA, United States) is allowed, but will be documented. This may be required in selected cases with very calcified and tight lesions.~As per protocol, lesion preparation will be performed using either the super-high pressure PCI balloon OPN™ NCB or the Shockwave™ IVL balloon catheter according to random treatment assignment after matching the angiographic and/or OCT inclusion criteria.~Following successful lesion preparation all patients will be treated with a latest generation durable polymer everolimus-eluting stent (Xience™ Sierra or Skypoint, Abbott Vascular Inc., Santa Clara, CA, United States) to allow comparison of stent expansion."
223768173|NCT06095843|PROCEDURE|placement of dental implants|placement of dental implants in mandibular reconstruction.
223768174|NCT00261716|BEHAVIORAL|IPS|Individual Placement and Support Evidence based supported employment
224238973|NCT02566824|BEHAVIORAL|Cognitive Behavioural & Skills Training|This will be administered in groups of 10 participants in 12 sessions each lasting 1.5 hours. Each session will focus on a new topic- Modules will be introduced via role play illustrating the topic, followed by Q\&A. Strategies will be introduced to address the problems illustrated. Adolescents will practice using these strategies via planned activities or games. Obstacles to applying the skills in everyday life will be discussed and a physical reminder will be provided for each skill. A homework activity will be assigned to help participants practice the skill during the week. Each session will begin with homework review. Adolescents will also receive individual telephone coaching twice a week during the 12 weeks, which will taper off during the follow-up phase. Parents will also attend their own support group.
224320998|NCT06351371|PROCEDURE|Biopsy Procedure|Undergo tumor biopsy
223655747|NCT05915481|DRUG|Cadonilimab|Participants will receive SBRT combined with Cadonilimab. Cadonilimab will be administered, 6mg/kg, twice a week, intravenous until disease progression or intolerable toxicities or death. The first cycle of Cadonilimab was started within 3 days before and after the first fraction of SBRT treatment.
223655748|NCT05915481|RADIATION|Stereotactic body radiotherapy|Participants will receive SBRT to one lesion or more lesions.
223655749|NCT04436848|OTHER|This is a non-interventional study|This is a non-interventional study
224320999|NCT06351371|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223655750|NCT03192553|BEHAVIORAL|Double Gloving Procedure|Participants will doff PPE using a double gloving procedure after coating with Glogerm fluorescent dye +/- staphylococcus epidermidis
223655751|NCT03192553|BEHAVIORAL|Intensified Hand Hygiene Procedure|Participants will doff PPE using an intensified hand hygiene procedure after coating with Glogerm fluorescent dye +/- staphylococcus epidermidis
223655752|NCT03192553|BEHAVIORAL|One Step Procedure|Participants will doff PPE using a one-step procedure after coating with Glogerm fluorescent dye +/- staphylococcus epidermidis
223655753|NCT03192553|BEHAVIORAL|CDC Procedure|Participants will doff PPE using a CDC recommended procedure after coating with Glogerm fluorescent dye +/- staphylococcus epidermidis
223768175|NCT00261716|BEHAVIORAL|IE|Four sessions of manualized illness education about schizophrenia/schizoaffective disorder (tailored to the participant diagnosis) prior to each course of a job search
223768176|NCT00261716|BEHAVIORAL|VOMI|Four sessions of manualized motivational interviewing oriented to employment goals and concerns prior to each course of a job search
223768177|NCT04793880|BEHAVIORAL|Medication Cost Information|This version of the HFrEF medication checklist includes patient-specific estimated monthly out-of-pocket cost for each medication. TailorMed, a company designed to provide financial counseling and planning for patients, will generate the patients' out-of-pocket cost based on insurance status. The costs for non-generic HFrEF medications will then be populated onto a checklist of recommended heart failure medications so that patients and their clinicians will have this information available during their clinical encounter.
224321000|NCT06351371|PROCEDURE|Computed Tomography|Undergo CT
224321001|NCT06351371|DRUG|Erdafitinib|Given orally
224321002|NCT06351371|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
224238974|NCT02566824|BEHAVIORAL|Supportive Group Therapy|This will be administered in groups of 10 participants in 12 sessions each session lasting 1.5 hours. During the initial session group members will be asked to identify a specific goal to address during the program. Each session will review the previous week's events (challenges and positive accomplishments) and psychoeducation on a topic relating to ADHD (topics will be elicited from group members at the outset of each session). Adolescents will also receive a telephone coaching at the same frequency as the CBT+S group participants. These phone calls will deal with issues a given participant had raised in the preceding session, and the approach will emphasize support and unconditional positive regard. Parents will also attend their own support group.
224238975|NCT02566824|OTHER|Treatment as Usual - community resources|The treatment as usual group reflects what patients currently receive in the community (mainly medication). Participants will be stabilized on optimal medication (if they choose to be on medication) and referred back to the community for follow-up. Participants are free to seek out any additional interventions that they feel are required. These participants will be evaluated at the same intervals as the two therapy groups. They will receive a follow-up phone call from the study coordinator at two-month intervals in-between evaluation points. If participants indicate during the phone call that they require services, they will be referred to services in the community.
224238976|NCT02566824|DRUG|Methylphenidate or amphetamine product|Medication is titrated over a 4-week period with stepwise increments each week. Participants, parents and teachers complete ADHD symptom scales at baseline and before each medication visit. They will also complete side effects scales at baseline and before each medication visit. The gradual increase will continue until there is no further improvement in symptoms and in the Clinical Global Improvement Scale or side effects are such that further increases are not indicated. Once the optimal dose is reached, the participants remain on this dose for the remainder of the study.
224238977|NCT04452734|PROCEDURE|Platelet Rich Plasma (PRP)|PRP was prepared by withdrawing 8-10 ml of patients own blood (IV from antecubiodal area and collected in a vacuum tube coated with anticoagulant (Na citrate). For activation 1 ml of calcium chloride was added to Platelet Rich Plasma. This layer of approximately 2 ml of PRP was then taken into the residual bone cavity along with gel sponge to stimulate regeneration in wound healing after surgical extraction of mandibular third molar tooth followed by sutures
224238978|NCT04452734|PROCEDURE|Surgical Extraction|Surgical extraction procedure under Local anesthesia on dental chair, followed by spongstone (gel sponge) and suture placement.
224238979|NCT04876378|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
224238980|NCT04876378|OTHER|Questionnaire Administration|Complete questionnaires
224238981|NCT02754401|OTHER|16 Items|Patients took part in the questionnaire and were examined using the PSI (periodontal screening index).
224238982|NCT02754401|OTHER|PSI|The PSI scores (0 to 4) were recorded: score 0=healthy, score 1=bleeding, score 2=supra-/subgingival calculus, score 3=probing depths from 3.5mm to max. 5.5mm, score 4=probing depths greater than 5.5mm. Only the highest finding was noted for each sextant. Persons with findings of code 0 to code 2 were classified as non-periodontitis persons (group 1), whereby codes 3 and 4 were considered a probable periodontitis persons (group 2).
224238983|NCT05627427|DRUG|Surufatinib|250mg, p.o., qd, q3w, until disease progression or other treatment termination criteria
224238984|NCT05627427|DRUG|Sintilimab|200mg, IV, D1, q3w, until disease progression or other treatment termination criteria
224238985|NCT03806062|DRUG|domperidone|10 mg domperidone 3 times a day after meals
224238986|NCT03806062|DEVICE|He-Ne laser (Bravo TrezaSerie) device|The laser scan beam was adjusted to the size of the treated breast for 10 minutes with wave length 632.8 nm and power output 25 mw after the end of treatment session
224238987|NCT03806062|DEVICE|faradic current|faradic stimulation (Body shaping System, model B-333, made in China) , at the following acupuncture points on both sides: Spleen 6 (Sanyinjiao), Liver 3 (Taichong) and Small Intestine 1 (Shaoze)
224238988|NCT03884166|DIAGNOSTIC_TEST|bronchoscopy|Patients will undergo bronchoscopy to sample respiratory tissue in different heights in order to analyze mucociliary clearance
224238989|NCT02462330|DRUG|Autologous MSC from bone marrow|After bone-marrow aspiration by an authorized person, MSCs were isolated and cultured during 17±2 days by the French Blood Establishment. Then, patients receive intramyocardial injections of MSCs using the electromechanical NOGA-XP system.
224238990|NCT02462330|DRUG|Placebo comparator|injections of human albumin
224238991|NCT04525248|PROCEDURE|Laparoscopic total colectomy + low resection of rectum|Laparoscopic total colectomy + low resection of rectum
224238992|NCT04525248|PROCEDURE|Laparoscopic total colectomy + High resection of rectum|Laparoscopic total colectomy + High resection of rectum
224238993|NCT01352325|BEHAVIORAL|system constellations seminar|individual-centered intervention in a group setting, duration 3 days
224238994|NCT01352325|BEHAVIORAL|system constellations seminar|individual-centered intervention in a group setting, duration 3 days
224321003|NCT04838223|OTHER|Hyperosmolar Response|A single drop of hypertonic sodium chloride solution at room temperature will be instilled in each eye and change in pain/other symptoms after up to 90 seconds of application (to account for any initial irritation symptoms) will be observed.
223655754|NCT06313918|OTHER|High intensity training (HIT)|Please see information already included in the arm descriptions.
223655755|NCT01583296|BEHAVIORAL|Music Relaxation Therapy (MRT)|music relaxation therapy and breathing at resting respiration rate
223655756|NCT01583296|BEHAVIORAL|CBT and HRVB|cognitive behavioral therapy and heart rate variability biofeedback
223655757|NCT01047553|DRUG|Formoterol (OT)|9 μg/dose, Inhaled, twice daily for 52 weeks
223655758|NCT02111304|DRUG|iOWH032|
223655759|NCT01063283|DRUG|Pemetrexed|Pemetrexed 500 mg/m\^2 intravenously over 10 minutes
223655760|NCT01063283|DRUG|Carboplatin|Carboplatin at a dose calculated to produce an area under the concentration-time curve of 6 mg/ml•min intravenously over 30 minutes
223655761|NCT01063283|DRUG|Bevacizumab 7.5 mg/kg|Bevacizumab at 7.5 mg/kg intravenously over 90 minutes
223655762|NCT01063283|DRUG|Bevacizumab 15 mg/kg|Bevacizumab at 15 mg/kg intravenously over 90 minutes
223655763|NCT03179319|BEHAVIORAL|MyChoices|Access to the MyChoices mobile app which includes the HIV test plan with reminders, STI information, PrEP resources, links to testing and PrEP sites, and geo-location features.
223768178|NCT04793880|BEHAVIORAL|Heart Failure Medicines Checklist|The Heart Failure Medicines Checklist is an evidence-based medication checklist that describes guideline-recommended medications for HFrEF. This tool is used during the clinical encounter to facilitate a discussion about medications that may be most appropriate for the patient.
224238995|NCT04408404|PROCEDURE|Acute aortic dissection|Acute aortic dissection treatment include Bentall procedure, Tyrone David procedure, Yacoub procedure or ascendant aortic replacement with or without aortic valve replacement, ascendant aortic root remodelling (all are standard of care procedures)
224238996|NCT02161913|BEHAVIORAL|Multi-Family Group Treatment|
224238997|NCT02161913|BEHAVIORAL|SCI Education Control Group|
224238998|NCT03492580|DRUG|Canagliflozin|No intervention or treatment assignment imposed by this study. Participants received canagliflozin as a part of routine clinical practice.
224238999|NCT03492580|DRUG|Empagliflozin|No intervention or treatment assignment imposed by this study. Participants received empagliflozin as a part of routine clinical practice.
224239000|NCT03492580|DRUG|Dapagliflozin|No intervention or treatment assignment imposed by this study. Participants received dapagliflozin as a part of routine clinical practice.
224239001|NCT03492580|DRUG|Dipeptidyl Peptidase-4 (DPP-4) Inhibitors|No intervention or treatment assignment imposed by this study. Participants received DPP-4 inhibitor as a part of routine clinical practice. DPP-4 inhibitors includes: alogliptin, linagliptin, saxagliptin, sitagliptin, vildagliptin.
224239002|NCT03492580|DRUG|Glucagon-like Peptide-1 (GLP-1) Agonist|No intervention or treatment assignment imposed by this study. Participants received GLP-1 agonist as a part of routine clinical practice. GLP-1 agonists includes: albiglutide, dulaglutide, exenatide, liraglutide, lixisenatide.
224239003|NCT03492580|DRUG|Anti-hyperglycemic Agents (AHA)|No intervention or treatment assignment imposed by this study. Participants received other selected AHA as a part of routine clinical practice. Other select AHAs includes: acarbose, bromocriptine, miglitol, nateglinide, repaglinide.
223655764|NCT03292367|PROCEDURE|ldTRA|After puncture of left distal radial artery, coronary angiography and percutaneous coronary intervention, if needed, will be performed.
223655765|NCT05358769|DIETARY_SUPPLEMENT|Incoxil food supplement and pelvic floor muscle exercise|"Incoxil supplement group receives standardized written and verbal instructions on how to perform PFME and are asked to perform the pelvic floor muscle exercises 3 times per day, with 15 repetitions per set, daily for 6 weeks. Women perform PFME at an intensity of at least 65-75% of one repetition maximum. (Repetition maximum load is the maximum weight or force an individual can exert in a single lift.) In addition participants receive Incoxil food supplement and take the supplement once a day.~Incoxil composition: creatine, l-leucine, zinc, calcium and magnesium. Incoxil is specifically designed to contain ingredients that help strengthen muscles during regular resistance training of moderate intensity."
223655766|NCT05358769|OTHER|Pelvic floor muscle exercise|Group receives standardized written and verbal instructions on how to perform PFME and are asked to perform the pelvic floor muscle exercises 3 times per day, with 15 repetitions per set, daily for 6 weeks. Women perform PFME at an intensity of at least 65-75% of one repetition maximum. (Repetition maximum load is the maximum weight or force an individual can exert in a single lift.) In addition participants receive placebo food supplement to take once a day.
223655767|NCT03613961|DRUG|Anesthetics|The ANS plays an important role in the regulation of hemodynamics during anesthesia. Manually blous of propofol during induction anesthesia is reported to reduce both sympathetic and parasympathetic tone; however, it is not clear whether the changes in heart rate variability are associated with propofol concentration. We will observe the relationship of anesthetics and HRV dynamics.
223655768|NCT03651401|DEVICE|Scapular muscle endurance test|The SME test, developed by Edmondston et al. 17, is based on an exercise used to improve the performance of the serratus anterior and trapezius muscles. The test was carried out while the subjects were facing the wall in standing position and with their shoulders and elbows flexed to 90 degrees. While both scapulae were in neutral position, an appropriate size of stick (18-36 cm) was selected and placed between the elbows, and they were asked to hold the dynamometer (Feta 137 F0202 1 kg/10 N) between their hands.
223655769|NCT03651401|OTHER|Pain intensity|"Pain intensity assessment was performed by questioning rest, activity, night, and measuremant pain using a visual analogue scale (VAS) on a 10 cm line with marks at both ends to define the limits of the pain experience as no pain (0) and maximum pain experienced (10), with higher scores indicating greater pain 20."
223768179|NCT03844451|DRUG|Liposomal Bupivacaine|At the conclusion of the procedure, liposomal bupivacaine will be administered as a V2 nerve block.
223768180|NCT03844451|DRUG|Bupivacaine and Epinephrine|At the start of the procedure, 0.5% bupivacaine and 1:200,000 epinephrine as a surgical field block.
223768181|NCT01772498|BEHAVIORAL|heart rate variability biofeedback|
223768182|NCT00702130|DRUG|Pravastatin|pravastatin 40mg per os once daily
224239004|NCT03492580|DRUG|Thiazolidinediones (TZD)|No intervention or treatment assignment imposed by this study. Participants received TZD as a part of routine clinical practice. TZDs includes: pioglitazone, rosiglitazone, troglitazone.
224239005|NCT03492580|DRUG|Sulfonylureas (SU)|No intervention or treatment assignment imposed by this study. Participants received SU as a part of routine clinical practice. SUs includes: glipizide, glyburide, glimepiride, chlorpropamide, tolazamide, tolbutamide, acetohexamide
224239006|NCT03492580|DRUG|Insulin|No intervention or treatment assignment imposed by this study. Participants received Insulin as a part of routine clinical practice.
224321004|NCT04838223|OTHER|Proparacaine Challenge Test|A single drop of Proparacaine hydrochloride ophthalmic solution, (Alcaine®, 0.5%) will be used on each eye respectively and any change in pain/other symptoms will be noted after 90 seconds (to account for initial discomfort from the preservative in Proparacaine solution).
224321005|NCT04838223|OTHER|Contact Lens Dry Eye Questionnaire-8 (CLDEQ-8) Optional; only for Contact Lens Wearers|The CLDEQ-8 is a validated eight-item scaled questionnaire developed to reflect the overall opinion of soft contact lenses.
224321006|NCT04838223|OTHER|Ocular Pain Assessment Survey (OPAS)|Twenty seven-item quantitative questionnaire designed to provide an assessment of the symptoms and quality of life effect of ocular pain \[18\]. The 27 items of the OPAS questionnaire are graded on a scale of 0 to 10, or 10 to 100, where 0 indicates none and 10 or 100 indicate maximum.
223768183|NCT03380468|DRUG|cisplatin plus pemetrexed|cisplatin 75mg/m2 iv; pemetrexed 500mg/m2 iv
223655770|NCT03651401|DEVICE|Upper Limb Functional Performance|The Functional Impairment Test-Hand and Neck/Shoulder/Arm (FIT-HaNSA) protocol, which was developed by MacDermid et al. 21, was used to evaluate the functional performance of the upper extremity when performing 3 tasks.
223655771|NCT01120717|DRUG|QVA149|capsules for inhalation, delivered by an SDDPI
223655772|NCT01120717|DRUG|Placebo|capsules for inhalation, delivered by an SDDPI
223655773|NCT05766696|PROCEDURE|Atraumatic Restorative Treatment (ART)|"Conventional glass-ionomer restorations are placed using the Atraumatic Restorative Treatment (ART) technique. Essentially, cavities are prepared using hand instrument excavators. Afterwards, the cavity is conditioned (using a 10% polyacrylic acid conditioner) and cleaned, with subsequent insertion of a conventional restorative glass-ionomer. During the curing phase, Vaseline will be applied to all restoration surfaces for moisture protection.~The treatment will be conducted in a class room.~As concomitant treatment, all participants will receive supervised toothbrushing during the study using 1,450 ppm fluoride toothpaste once a day."
223655774|NCT05766696|PROCEDURE|Conventional Cavity Preparation|"Conventional glass-ionomer restorations are placed after conventional cavity preparation. Essentially, cavities are prepared using rotary instruments/diamond burs. Afterwards, the cavity is conditioned (using a 10% polyacrylic acid conditioner) and cleaned, with subsequent insertion of a conventional restorative glass-ionomer. During the curing phase, Vaseline will be applied to all restoration surfaces for moisture protection.~The treatment will be conducted in a mobile clinic.~As concomitant treatment, all participants will receive supervised toothbrushing during the study using 1,450 ppm fluoride toothpaste once a day."
223655775|NCT03117140|DRUG|Ropivacaine 0.75%|Only ropivacaine 0.75% is administered for this arm of the interscalene block
223655776|NCT03117140|DRUG|Ropivacaine 0.75% + 300 mcg Buprenorphine|Ropivacaine 0.75% + 300 mcg Buprenorphine is administered for this arm of the interscalene block
223655777|NCT03117140|DRUG|Ropivacaine 0.75% + 75 mcg clonidine|Ropivacaine 0.75% + 75 mcg Clonidine is administered for this arm of the interscalene block
223655778|NCT03117140|DRUG|Ropivacaine 0.75% + 8 mg dexamethasone|Ropivacaine 0.75% + 8 mg Dexamethasone is administered for this arm of the interscalene block
223655779|NCT00356304|BEHAVIORAL|Motivational interviewing|Participants assigned to motivational interviewing will attend two 1-hour sessions of motivational interviewing over 2 consecutive weeks, followed by a third session 8 weeks later. Motivational interviewing is a type of counselling. Each session is of approximately 1 hour duration.
224239007|NCT03249584|DEVICE|OsteoCool™ RF Ablation|The OsteoCool™ RF Ablation system is indicated in the United States (US), Europe (EUR) and Canada (CAN) for patients with metastatic malignant lesions in a vertebral body, painful metastatic lesions involving bone (in the US, patients with metastatic lesions involving the bone must have failed or were not candidates for standard therapy) and benign bone tumors such as osteoid osteomas.
224239008|NCT03263637|DRUG|AZD4573|AZD4573 will be administered as a intravenous (IV) infusion.
224239009|NCT02898909|DEVICE|nuclear lens fragmentation in 8 pieces|
224239010|NCT02898909|DEVICE|nuclear lens fragmentation in 16 pieces|
224239011|NCT05727137|PROCEDURE|Single shot adductor canal block|Single shot adductor canal block on the the first and second postoperative day.
224239012|NCT05727137|PROCEDURE|Continuous adductor canal block|A catheter will be placed in the adductor canal and connected to a continuous patient-controlled analgesia pump.
224239013|NCT04909437|DIETARY_SUPPLEMENT|Mycobiotic|2 sachet/day, 21 days, oral
224239014|NCT04909437|DIETARY_SUPPLEMENT|Placebo|2 sachet/day, 21 days, oral
224239015|NCT02392793|DRUG|Talazoparib|Given orally once or twice on day 1 (depending on the dose level), then daily on days 2-6.
224239016|NCT02392793|DRUG|Irinotecan|Given intravenously daily, days 2-6 immediately following the talazoparib dose.
224239017|NCT02392793|DRUG|Temozolomide|Given orally daily. Dose to be determined after MTD established with talazoparib plus irinotecan.
223655780|NCT00356304|BEHAVIORAL|Treatment as usual|Participants will continue with their normal treatment regimen as usual.
224239018|NCT02392793|DRUG|Filgrastim|Given subcutaneously (SubQ) once per day starting 24-36 hours after last dose of chemotherapy and continuing until post-nadir ANC is \>2,000/μL, unless peg-filgrastim is given.
224239019|NCT02392793|DRUG|Peg-filgrastim|Given subcutaneously (SubQ) once per day starting 24-36 hours after last dose of chemotherapy and continuing until post-nadir ANC is \>2,000/μL, unless filgrastim is given.
224239020|NCT03677648|DRUG|SHR0302|The study drug, SHR0302, is designed to block the activity of an enzyme protein called JAK (known as a JAK inhibitor).
224239021|NCT03677648|DRUG|Placebos|Placebos
224239022|NCT02191891|DRUG|Xentuzumab|Patients received intravenous infusion of Xentuzumab 1000 milligram (mg) delivered over 60 minutes per week for 4 weeks, in combination with once daily oral treatment of Afatinib film-coated tablet.
224239023|NCT02191891|DRUG|Afatinib|Patients received intravenous infusion of Xentuzumab 1000 milligram (mg) delivered over 60 minutes per week for 4 weeks, in combination with once daily oral treatment of Afatinib film-coated tablet.
224239024|NCT03268109|OTHER|assessment of cognitive impairment|Measure of Global Deficit Score
224239025|NCT01101230|OTHER|Almonds|1.5 oz almonds/day
224239026|NCT02693210|DRUG|Cyclophosphamide|Participants will receive 750 mg infusions of cyclophosphamide on Days 3 and 17
224239027|NCT02693210|DRUG|Methotrexate|Participants will receive \>= 10 mg/week methotrexate orally up to 24 weeks
224239028|NCT02693210|OTHER|Placebo Cyclophosphamide|Participants will receive placebo in place of cyclophosphamide on Days 3 and 17
224239029|NCT02693210|OTHER|Placebo Methotrexate|Participants will receive weekly oral placebo in place of Methotrexate
224239030|NCT02693210|OTHER|Placebo Rituximab|Participants will receive placebo in place of rituximab on days 1 and 15
224239031|NCT02693210|DRUG|Rituximab|Participants will receive 1g infusions of rituximab on Days 1 and 15
224239032|NCT04586088|DRUG|Apatinib plus Camrelizumab|Subjects receive Apatinib, 250mg, QD and Camrelizumab, 200mg, D1, Q3W. Treatment was continued until confirmed disease progression, death, unacceptable toxicity, withdrawal of consent, or investigator decision.
224239033|NCT05577845|DRUG|Ramosetron|Ramosetron, 4 weeks
224239034|NCT04394676|PROCEDURE|Pressure applied during RARP|Patients will be randomly assigned to undergo RARP either at a pneumoperitoneum pressure of 12 mmHg (experimental) or 15mm Hg (standard technique).
224239035|NCT03316001|OTHER|Review of multidetector row computed tomography scans|multidetector row computed tomography scans
224239036|NCT02330848|DIETARY_SUPPLEMENT|Walnut Ad libitum diet|Participants will be provided 392 grams of walnuts per week (56g or 2 oz/day) to include in their diet. Their calorie intake will not be subsequently monitored or regulated, and thus will be allowed to float ad libitum
223655781|NCT01493076|DEVICE|Primary cannulation/precut sphincterotomie with the Baby-S|"At the papilla the ankle for cannulation was optimized due to changes of the position of the sphincterotome, its lay in the working channel and the tension of the Albaran-lever and the cutting wire. After successful cannulation, the catheter with the sphincterotome inside was slightly pushed into the duct. If necessary, the baby-sphincterotome was replaced with a guide wire and than conventional endoscopic sphincterotomie was completed with a standard traction-type sphincterotome."
223655782|NCT03465969|DRUG|tacrolimus|oral
223655783|NCT00948441|DRUG|25% ethanol|Study Lock -25% Ethanol- The ethanol lock therapy consists of placing up to 2.3 ml of 25% ethanol into the central venous catheter and allowing it to dwell for 4 to 12 hours per day.
223768184|NCT01650181|DRUG|Metformin|Patients with Steatohepatitis treated with diet, exercise and metformin
224239037|NCT02330848|DIETARY_SUPPLEMENT|Walnut Calorie controlled|The intervention group participants will meet with a registered dietitian and receive instructions and recipes for inclusion of 392 grams of walnuts per week (56g or 2 oz/day) in their meal plan for 6 months.
224239038|NCT02351466|OTHER|Observational|
224239039|NCT00902109|DEVICE|Perimetry|different perimetric devices, different perimetric grids: Octopus: New Scotoma-Oriented Perimetry (SCOPE) Using a New Fast German Adaptive Threshold Estimation (GATE) HFA: 30-2, Sita (Swedish Interactive Thresholding Algorithm) full threshold
224239040|NCT00902109|DEVICE|Confocal Scanning Laser Tomography|HRT examinations for the clinical evaluation of the optic disc.
224239041|NCT00902109|DEVICE|Optical Coherence Tomography (OCT)|imaging of the retinal nerve fiber layer
223655784|NCT00948441|OTHER|heparin lock|Placebo Lock - Heparin - These will be prepared in a sterile fashion in the Pharmacy of Children's Hospital of Pittsburgh in 10 day supplies as 1ml lock syringes utilizing 100 units/ml if the central venous catheter is accessed once daily and 10 units/ml if accessed more than once daily. The lock solution will be instilled and allowed to dwell for 4 to 12 hours.
224239042|NCT06091878|OTHER|Observation|Observational study, no intervention
224239043|NCT03447860|BEHAVIORAL|PAACC|Mindfulness based caregiver intervention that includes education , problem solving, skill building, stress management and mindfulness to help enhance compassion and acceptance of self and others
224239044|NCT03447860|BEHAVIORAL|REACH-VA|A cognitive-behavior based multi-component caregiver intervention to reduce caregiver stress
224239045|NCT01974648|DRUG|propofol|
224239046|NCT01974648|DRUG|propofol and remifentanil|
224239047|NCT04196452|DRUG|Ipilimumab|Specified dose on specified days
224239048|NCT00965653|DRUG|folic acid|\>/= 5 mg po weekly
224239049|NCT00965653|DRUG|methotrexate|7.5 - 25 mg weekly (oral or parenteral)
224239050|NCT00965653|DRUG|tocilizumab [RoActemra/Actemra]|162 mg sc weekly (QW)for 12 weeks
224239051|NCT00965653|DRUG|tocilizumab [RoActemra/Actemra]|162 mg sc every other week (Q2W) for 12 weeks
224239052|NCT02854280|BIOLOGICAL|Pedalling exercise on a cycle ergometer|At 80% of the maximal aerobic power, until exhaustion
224239053|NCT02854280|BIOLOGICAL|Isolated contractions of the quadriceps|Until exhaustion
224239054|NCT06383572|DRUG|Cyclophosphamide|Given by IV
224239055|NCT06383572|DRUG|Fludarabine phosphate|Given by IV
224239056|NCT06383572|DRUG|Decitabine|Given by IV
224239057|NCT06383572|DRUG|Dexamethasone|Given by mouth
224239058|NCT05864976|DEVICE|Support Vector Machine|Machine learning algorithm
224239059|NCT06077565|OTHER|foot-in-the-door technique and self-determination theory|the research assistant will ask about the priority the participants place on engagement in desirable health-related lifestyle practices identified in the completed behavioural risk factor survey. The participants will also be asked to choose the goal that they consider easiest to achieve, such as quitting or reducing smoking, consuming more vegetables or less fatty foods or sugary drinks, performing more exercise or reducing alcohol consumption. The participants will be encouraged to quit health-risk behaviours (or adopt a healthy lifestyle) sequentially, but they will also be able to choose to quit them simultaneously if they are confident in doing so. Each participant will then receive a brief (approximately 5 minutes), individual intervention with health advice about the selected health-related lifestyle practice. The whole intervention will last approximately 10 minutes, but slightly longer if necessary.
224239060|NCT06077565|OTHER|Follow-up booster intervention|For the first 6 months of the study period, the research assistant will deliver WhatsApp/WeChat messages about once per week. If a participant does not own a smartphone or is unable to receive WhatsApp/WeChat messages (uncommon in Hong Kong), the research assistant will make a telephone call, instead of sending a message, as a reminder for the participants to adhere to their desirable health-related lifestyle practice. Instant messaging via mobile applications has found to be effective in enhancing treatment compliance.
224239061|NCT06077565|OTHER|Control group|The control group participants will receive a brief telephone intervention based on the AWARD model and delivered by the trained research assistant, similar to that delivered to the intervention group. However, the research assistant will simply advise the participants to change their health-risk behaviours and/or adopt a healthy lifestyle practice.
223655785|NCT06214234|PROCEDURE|Band ligation|Band ligation in variceal bleeding
223655786|NCT02654769|DRUG|Ingenol Mebutate (Picato®)|Brand product
223768185|NCT01650181|DIETARY_SUPPLEMENT|Siliphos+ Selenium - Methionine + Alpha Lipoic Acid|Patients with Steatohepatitis treated with diet, exercise, metformin and Siliphos (140mg) + Selenium (15 mcg) - Methionine (3mg) + Alpha Lipoic Acid (200mg), two tablets BID
223768186|NCT01650181|DIETARY_SUPPLEMENT|Siliphos+ Selenium - Methionine + Alpha Lipoic Acid|Patients with fatty liver treated with diet, exercise, metformin and Siliphos (140mg) + Selenium (15 mcg) - Methionine (3mg) + Alpha Lipoic Acid (200mg), two tablets BID
224239062|NCT04782726|OTHER|Software Solution for Radiation Therapy Treatment|Software has been developed for individualized pre optimization evaluation of the patient anatomy and prescribed dose of radiation therapy.
224239063|NCT04782726|OTHER|Radiation therapy|Standard of Care planning for Radiation therapy is used to treat the subjects for head and neck cancer
224239064|NCT03909659|BEHAVIORAL|Dietary sodium reduction|A supply of a reduced-sodium added-potassium salt substitute
224239065|NCT05722600|OTHER|Grape juice|Hardaliye (grape juice) is a fermented, traditional non-alcoholic beverage made from fresh grapes. It is mainly produced by the fermentation of grapes, sour cherry leaves and mustard seeds. Hardaliye was purchased from traditional producers in Turkey. Hardaliye Group consumed 250 ml/day of hardaliye (grape juice) for 28 days.
224239066|NCT05722600|OTHER|Placebo drink|Placebo drink has carbohydrate, energy and sensory properties similar to hardaliye. Placebo Group consumed 250 ml/day of placebo drink
224239067|NCT01341366|OTHER|Fast-track perioperative program|Preoperative counseling, no preoperative fasting, short-acting anesthetics, continuous infiltration of wound with local anesthetic agent, non-opioid pain management, the use of chewing gum, and early postoperative feeding and mobilization
224239068|NCT01341366|OTHER|Traditional perioperative program|Preoperative fasting, standard anesthetic management with no intraoperative fluid restriction, opioid pain management, no chewing gum, feeding/mobilization according to attending surgeon
224239069|NCT02678195|DRUG|Amoxicillin|Oral amoxicillin dispersible tablets (DT), 250 mg tablets, given according to age band, two times daily
224239070|NCT02678195|DRUG|Placebo|Placebo dispersible tablets (DT), 250 mg tablets, given according to age band, two times daily
224239071|NCT01328730|DEVICE|Firebird 2 SES|The FIREBIRD2™ Rapamycin-Eluting CoCr Coronary Stent is the second generation DES of MicroPort, which based on the new cobalt chromium alloy stent platform. It uses polyolefin polymer, which makes the coating property very remarkable.
224239072|NCT01328730|DEVICE|Cypher SES|The Cypher SES is based on the 316L platform with Controlled-release, nonresorbable, elastomeric polymer coating.
224239073|NCT05078008|PROCEDURE|Physiotherapy modalities|parafango in the lumbar region 20min/day; High frequency Transcutaneous Electrical Nerve Stimulation (TENS), 100 Hz, 0,04-0,2mseg, 20 min/day; lumbar flexibility self-exercise plan
224239074|NCT05078008|PROCEDURE|Balneotherapy modalities|Immersion in a thermal pool with 15 minutes of automatic hydromassage and 15 minutes of spine flexibility exercises; thermal steam treatment to spinal column; hydromassage bath with Vichy thermal water
224239075|NCT00696449|DRUG|Adapalene|All Subjects will treat the face once daily in the evening.
224239076|NCT00696449|BEHAVIORAL|frequent visits|This group will be asked to return to the study center on weeks 1, 2, 4 and 8 for office visits (to remind the Subject to apply the study medication); in addition to the study visits on Weeks 6 and 12.
224239077|NCT00696449|BEHAVIORAL|electronic reminder|This group will receive a daily electronic reminder by email, text pager, or phone message (approximately at the same time each day) to use the study medication within a 4-hour window after the reminder and will return to the study center for study visits on Weeks 6 and 12.
224239078|NCT00696449|BEHAVIORAL|Parent reminder|In this group parents will be prompted by a daily electronic message by email, text pager, or phone message (approximately at the same time each day) to remind the Subject to use the study medication within a 4-hour window after the reminder. Parents will be instructed to then verbally deliver the message to the study Subject. Subjects will return to the study center for study visits on Weeks 6 and 12.
224239079|NCT00696449|BEHAVIORAL|Standard of care|"This group is considered to be the standard of care arm and will return to the study center for study visits on Weeks 6 and 12. This group will not receive any kind of reminders other than the instructions provided by the study staff during the study visits."
223655787|NCT02654769|DRUG|Generic Ingenol Mebutate|Generic formulated to have the same therapeutic effect of the brand
223655788|NCT02654769|DRUG|Vehicle Foam|It does not contain active ingredient. A placebo to test the sensitivity of the active treatments.
224239080|NCT04567342|OTHER|1 automated message|Parents of eligible patients will receive 1 HIPAA compliant automated call or text reminder (based on preference recorded in EHR) that their child is due for a checkup and information on how to schedule an appointment.
224239081|NCT04567342|OTHER|2 automated messages|Parents of eligible patients will receive 2 HIPAA compliant automated call or text reminders (based on preference recorded in EHR) that their child is due for a checkup and information on how to schedule an appointment.
224239082|NCT04567342|OTHER|No personal contact attempt|No personal contact attempts will be made.
224239083|NCT04567342|OTHER|1 personal contact attempt|Parents of eligible patients will receive a text from a medical assistant informing them that their child is due for a check up. This will be followed by personal call from the medical assistant to assist the parent with scheduling an appointment.
224239084|NCT01208064|DRUG|pazopanib hydrochloride|
224239085|NCT01208064|OTHER|laboratory biomarker analysis|
224239086|NCT01208064|OTHER|pharmacogenomic studies|
224239087|NCT01208064|OTHER|pharmacological study|
224239088|NCT01208064|PROCEDURE|quality-of-life assessment|
224239089|NCT06032351|OTHER|Innovation-integrated curriculum for dementia care and care management|The curriculum integration group will receive two intervention phases, including an innovation-integrated curriculum for dementia care and an innovation-integrated curriculum for care management with Entrustable Professional Activities (EPAs), lectures, Situated Simulation Learning, Team-based learning, and Objective Structured Clinical Examination(OSCE).
223655789|NCT02677519|DRUG|Aptensio XR|Orally-administered extended release formulation of methylphenidate; once daily dosing
223768187|NCT01650181|DRUG|Metformin|Patients with fatty liver treated with diet, exercise and metformin
224239090|NCT06032351|OTHER|Traditional classroom teaching course programs|The conventional teaching group will receive only traditional classroom teaching course programs.
224239091|NCT04870190|DRUG|Almonertinib|Almonertinib will be administered orally at a dose of 165 mg per time, Q.D.
224239092|NCT04870190|DRUG|Osimertinib|Osimertinib will be administered orally at a dose of 80 mg per time, Q.D.
224239093|NCT04770623|DRUG|Docetaxel|patients with gastric cancer who have disease progression after first line treatment will receive the test protocol and evaluated for efficacy and survival
224239094|NCT04770623|DRUG|Irinotecan|patients with gastric cancer who have disease progression after first line treatment will receive the test protocol and evaluated for efficacy and survival
224239095|NCT02014181|DIETARY_SUPPLEMENT|finely ground flaxseed powder|40 grams finely ground flaxseed powder daily for one month to patients with cystic fibrosis
224239096|NCT03415906|COMBINATION_PRODUCT|sacubitril+valsartan|Combined angiotensin receptor + neprilysin inhibition
224239097|NCT03415906|DRUG|valsartan|Angiotensin receptor inhibition alone
223655790|NCT03816293|DEVICE|Negative Pressure Wound Therapy|Occlusive dressing with attached Prevena incision management with 125mmHg of negative pressure and cartridge to manage secretions
223655791|NCT04945057|DEVICE|Mindpax monitoring system|All participants will use the Mindpax mobile application, wear the wrist accelerometer and fill in weekly self-assessments. All participants will obtain weekly health tips (general psychoeducation) and additional individualized targeted tips when the system detects deviation from individual mood, activity and sleep patterns, during the active 12 months of followup.
223655792|NCT02467634|BIOLOGICAL|HuCNS-SC sub-retinal transplantation|HuCNS-SC sub-retinal transplantation in subjects with bilateral GA AMD
223655793|NCT03456310|DIAGNOSTIC_TEST|transperineal ultrasound|"trans-perineal US: B mode capable 2D ultrasound system with cine loop function, a 3.5-6.0 MHz curved array transducer. A mid-sagittal and axial views is obtained by placing a transducer on the perineum (Parting of the labia can improve image quality).~Dynamic MRI:~Magnetic resonance (MR) imaging of the pelvic floor is a two-step process that includes:~analysis of anatomic damage on axial fast spin-echo (FSE) T2-weighted images. then sagittal and coronal (FSE) T2-weighted are obtained.~functional evaluation using sagittal dynamic single-shot T2-weighted sequences during straining and defecation."
223655794|NCT03159962|DEVICE|Bonded RME (Rapid Maxillary Expander) appliance|"The expansion screw was activated 1 quarter of a turn per day (0.25 mm per turn) until the palatal cusps of the maxillary posterior teeth approximated the lingual cusps of the mandibular posterior teeth.~The expander was kept in place as a passive retainer for 8 months. After expander removal, patients were followed without performing any additional treatment for 4 months."
223655795|NCT03159962|DEVICE|Banded RME (Rapid Maxillary Expander) appliance|"The expansion screw was activated 1 quarter of a turn per day (0.25 mm per turn) until the palatal cusps of the maxillary posterior teeth approximated the lingual cusps of the mandibular posterior teeth.~The expander was kept in place as a passive retainer for 8 months. After expander removal, patients were followed without performing any additional treatment for 4 months."
223655796|NCT05444257|DRUG|VX-121/TEZ/D-IVA|Fixed-dose combination tablets for oral administration.
224239098|NCT00004109|DRUG|Doxorubicin Hydrochloride|Doxorubicin dose will not exceed 20 mg/m2 per week IV over 4 days every week for 5 weeks
223655797|NCT01440777|BEHAVIORAL|Go! to Sleep|"The online program provides various tools for the delivery of the intervention including:~* Daily articles~* Daily activities to help get the sleep you need~* Daily sleep improvement recommendations~* Audio recorded relaxation exercises~* Daily e-mails from your program coach~* Personal progress charts~* An online sleep log and daily sleep score"
223655798|NCT04045028|DRUG|Tiragolumab|Administered by IV infusion at a fixed dose of 600 mg on Day 1 of each 21-day cycle (Q3W)
224239099|NCT00004109|RADIATION|Radiation Therapy (RT)|External-beam radiotherapy at a dose of 50 Gy (2.0 x 25 fractions, weeks 1-5).
224239100|NCT03510364|BEHAVIORAL|Dietary intervention|For the feeding intervention, participants consumed a meal that contains 60% of their energy daily energy requirement as a lunch time meal for 14 consecutive days under observation except during the weekends. To ensure the participant receives 60% of the daily energy requirement as a lunch meal we added a supplemental shake to the standard 1200 kcal meal.
224239101|NCT06355245|DIAGNOSTIC_TEST|Blood sampling|Collection of blood samples
224239102|NCT01891292|DRUG|Enalapril|0.25-0.35 mg/kg/day
224239103|NCT01891292|DRUG|N-Acetylcysteine|N-Acetylcysteine 0.5 mmol/kg
224239104|NCT03571048|BEHAVIORAL|Reduced Calorie Diet (RCD)|Participants will be given an individualized calorie goal. Participants in this group will also receive a 12 week comprehensive group-based behavioral weight loss program and will be instructed in specific strategies to support RCD.
224321007|NCT04838223|OTHER|Visual Analogue Questionnaire|Symptoms of ocular comfort and dryness will be graded for each eye on a scale of 0-10, where 0=extremely uncomfortable, extremely dry and 10=excellent comfort, no dryness. An average rating will be provided for the morning, afternoon and evening.
223655799|NCT04045028|DRUG|Daratumumab/rHuPH20|Administered by SC injection 1800 mg/30,000 U rHuPH20 weekly for a total of 6 doses, then every 3 weeks for a total of 16 doses (first dose given at Week 7), then every 4 weeks from Week 55 onward until disease progression
223655800|NCT04045028|DRUG|Rituximab|Administered for a total of 8 doses. Rituximab will be administered by IV infusion for the first dose at a dose of 375 mg/m\^2. After administration of at least one full infusion of IV rituximab, the SC formulation of rituximab (rituximab and rHuPH20) may be used for the remaining doses per institutional guidelines. SC rituximab will be administered at a dose of 1400 mg rituximab/23400 U rHuPH20 once weekly (QW).
223655801|NCT04045028|DRUG|Atezolizumab|Administered by IV infusion at a fixed dose of 1200 mg Q3W
223768188|NCT05320653|DIETARY_SUPPLEMENT|Medical nutrition|Nutrition therapy of the critically ill patients
223768189|NCT04103294|DIETARY_SUPPLEMENT|cowpea variety #1|two most popular varieties of cowpea currently consumed in the selected geographic area
223768190|NCT04103294|DIETARY_SUPPLEMENT|cowpea variety #2|two most popular varieties of cowpea currently consumed in the selected geographic area
223768191|NCT02479919|DEVICE|Magstim® Active TBS|Non-invasive transcranial magnetic stimulation inducing changes in cortical excitability depending on the cortical target (except for sham stimulation)
224239105|NCT03571048|BEHAVIORAL|Time Restricted Feeding (TRF)|Participants will be given an individualized calorie goal. Participants in this group will also receive a 12 week comprehensive group-based behavioral weight loss program and will be instructed in specific strategies to support RCD. Participants in this group will also instructed to eat only during a window of 10 hours, starting within 3 hours of waking. They will also be instructed in specific strategies to support TRF including: strategies to deal with hunger outside eating windows, distraction techniques, and choosing a balanced diet/appropriate portions during feeding windows.
224239106|NCT01226797|DRUG|Placebo|Take 4 capsules twice daily 12 hours apart with water. Swallow whole.
224239107|NCT01226797|DRUG|PF-04136309|Take 4 capsules twice daily 12 hours apart with water. Swallow whole.
224239108|NCT01143857|DRUG|Varenicline|Varenicline 2.0 mg/day or Placebo
224239109|NCT00963209|DRUG|tamoxifen citrate|
224239110|NCT00963209|OTHER|laboratory biomarker analysis|
224239111|NCT00963209|OTHER|pharmacological study|
223655802|NCT04932408|OTHER|Evaluation of the feasibility, psychosocial effects, influence and perception of exercise selection an experimental design of exercises performed at the hip and chest region.|A single exposure feasibility study using elastic resistance bands in older adults to challenge stability. Exercises with an elastic resistance band anchored from the ground and placed at the hip and chest region will be trialled. A semi- structured interview will identify the impact and practicalities of the intervention. The information will be used in the development of an evaluation process with key consideration of the planning phase of the intervention. Questions with verbal cues to provide perceptions of the exercise selection such as likes/dislikes, safety, confidence, difficulty, enjoyment and band placement will be asked to determine the acceptability, accessibility, appropriateness and usability of the protocol and build insights into the participant preferences.
223655803|NCT00472030|DRUG|Omalizumab|Patients will be treated with 150-375 milligrams of Omalizumab (Xolair), based on their baseline weight and serum Immunoglobulin E levels. Omalizumab will be administered subcutaneously on Day 1, and on Week 2, 4, 6, 8, 10, 12 and 14 treatment.
224239112|NCT00058292|BIOLOGICAL|filgrastim|Given at a dose of 5 μg/kg, subcutaneously daily, beginning on Day 0 (stem cell transplant day) until white blood cells measure greater than 1500/ul.
224239113|NCT00058292|BIOLOGICAL|rituximab|Intravenous infusion of 250 mg/m2 on treatment days -22 and -14 (day 0 = stem cell transplant).
223655804|NCT00472030|DRUG|prednisone|Prednisone, to a maximum dose of 0.5 mg/kg/day.
223768192|NCT02479919|DEVICE|Magstim® Sham TBS|Sham stimulation
224239114|NCT00058292|DRUG|Carmustine|Part of high dose BEAM chemotherapy given on study (a combination of carmustine, etoposide, cytarabine, and melphalan). Carmustine is given at a dose of 300 mg/m2 intravenous infusion over a 2 hour period on treatment day -6 (Day 0 = stem cell transplant).
223768193|NCT02734017|OTHER|pharmacist-led standardized medication review|the goal of this study is to assess the impact of the standardized medication review on the rate of readmissions and/or death at 30 days following initial hospitalization discharge.
223768194|NCT04844385|DRUG|Toripalimab|Toripalimab 240 mg, d1, Q3w for two cycles
224239115|NCT00058292|DRUG|cytarabine|Part of high dose BEAM chemotherapy given on study (a combination of carmustine, etoposide, cytarabine, and melphalan). Cytarabine is given at a dose of 100 mg/m2 intravenous infusion over a 1 hour period, every 12 hours on treatment days -5, -4, -3, and -2, for a total of 8 doses (Day 0 = stem cell transplant).
224239116|NCT00058292|DRUG|etoposide|Part of high dose BEAM chemotherapy given on study (a combination of carmustine, etoposide, cytarabine, and melphalan). Etoposide is given at a dose of 100 mg/m2 intravenous infusion over a 2 hour period every 12 hours on treatment days -5, -4, -3, and -2, for a total of 8 doses (Day 0 = stem cell transplant).
224239117|NCT00058292|DRUG|melphalan|Part of high dose BEAM chemotherapy given on study (a combination of carmustine, etoposide, cytarabine, and melphalan). Melphalan is given at a dose of 140 mg/m2 as an intravenous infusion over a 1 hour period on treatment day -1 (Day 0 = stem cell transplant).
224239118|NCT00058292|PROCEDURE|peripheral blood stem cell transplantation|On day 0, a minimum of 2.0 X 106 CD34+ cells/kg unselected peripheral blood progenitor cells (PBPC) will be reinfused following institutional guidelines for the reinfusion procedure.
224239119|NCT00058292|RADIATION|yttrium Y 90 ibritumomab tiuxetan|Patients will receive 90Y2B8 at a variable dose on treatment day -14 (Day 0 = stell cell transplant). The initial dose calculated to deliver no more than 100 cGy to critical organs (liver, lung). Doses will be escalated based on cohort of enrollment.
224239120|NCT03320304|DEVICE|Vagal Nerve Simulation (VNS) Therapy|A VNS Therapy System used for vagus nerve stimulation and consisting of an implantable VNS Therapy generator, lead, and external programming system.
224321008|NCT04555551|BIOLOGICAL|Infusion of MCARH109 T cells|Patients will be admitted to Memorial Hospital as inpatient prior to the infusion of CAR T cells. The T cell infusion will be planned to start at 2 days following the completion of the conditioning chemotherapy (up to 7 days is allowed if clinically indicated to delay).Cohorts of 3-6 patients each will be treated with escalating doses of modified T cells.
224321009|NCT05512234|DIETARY_SUPPLEMENT|L. reuteri|Dietary supplementation with drops containing L. reuteri once daily for 21 consecutive days
224321010|NCT05512234|DIETARY_SUPPLEMENT|Placebo|Dietary supplementation with placebo drops identical to those containing L. reuteri once daily for 21 consecutive days
223768195|NCT04844385|DRUG|Paclitaxel-albumin|Paclitaxel-albumin 260 mg/m2, d1, Q3w for two cycles
223768196|NCT04844385|DRUG|Nedaplatin|Nedaplatin 75mg/m2, d1, Q3w for two cycles
224321011|NCT04763343|DRUG|Ketamine Hydrochloride|Ketamine hydrochloride will be given as an intravenous infusion using a standard regimen given in most studies conducted: 0.5 mg/kg over 40 minutes. Ketamine infusions will be given every other day until either the subject reports clinician rated Scale for Suicidal Ideation (SSI) score of\<4, and \>50% decrease from baseline, and clinical assessment of patient not being suicidal for three consecutive pre-infusion ratings, or a maximum of six infusions have been given over the course of 2 weeks, or they have been discharged from the inpatient unit.
223655805|NCT03690297|DEVICE|Linked Color Imaging|Use of narrow band imaging with LCI for colon inspection during both insertion and withdrawal phase of colonoscopy
223768197|NCT04844385|RADIATION|radiation therapy at a total dose 60 Gy|Radiation therapy at a total dose 60 Gy
223768198|NCT04844385|DRUG|Capecitabine|Capecitabine 1000 mg/m2, bid, d1-14, q3w during radiotherapy
223768199|NCT04844385|RADIATION|radiation therapy at a total dose 50 Gy|Radiation therapy at a total dose 50 Gy
223768200|NCT00351494|PROCEDURE|contrast enhanced ultrasonography|"Three contrast-enhanced ultrasonography : before embolization, after one day and after 6 months.~Abdominal route 2.4 ml sonovue per injection / bolus"
223768201|NCT00351494|PROCEDURE|embolization|Intervention is described in the case report form for each patient
223768202|NCT04984655|DEVICE|30-minute Virtual Reality (VR) Experience delivered through Oculus Quest 2 VR headset|All participants will go through the same intervention described above
224239121|NCT04917978|DIAGNOSTIC_TEST|Hematological Phenotype Analysis|Hematological parameters were determined with an automated hematology analyzer (Sysmex, Japan), and hemoglobin analysis was performed with either high-performance liquid chromatography (Bio- Rad, USA) or capillary electrophoresis (Sebia, France and Helena, USA).
224239122|NCT05921214|BEHAVIORAL|VAULT Phase 5|This is an input-based vocabulary learning treatment based on principles of statistical learning.
223655806|NCT02841904|DEVICE|Confocal LASER Endomicroscopy|Patients scheduled for bladder endoscopic surgery under general anesthesia are offered to be included in our study. The suspicious mucosal areas are marked then examined with CLE. Tissue samples are taken based on the usual standard criterias. The samples are evaluated microscopically and compared with the results of the CLE technique. A single surgeon performs all surgeries. Biopsies are anlysed by a pathologist from Herlev and Gentofte Hospital's Pathology Department, which is affiliated CLE- study.
223768203|NCT06440070|PROCEDURE|Loop Carpal Tunnel Release|Under the guidance of ultrasound, needles are inserted above and below the transverse carpal ligament, respectively, to form a loop around the ligament. Finally, the ligament is cut by pulling the looped thread.
224239123|NCT04029610|PROCEDURE|Local anesthesia with lidocaine and adrenalin.|Local anesthesia with lidocaine and adrenalin.
224239124|NCT04029610|DRUG|lidocaine and adrenalin|lidocaine and adrenalin
224239125|NCT04029610|DRUG|lidocaine and arterial blockage|lidocaine and arterial blockage
224239126|NCT01188746|BEHAVIORAL|McGill Quality of Life Questionnaire and the European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire|Participants will be interviewed twice (if they chose to participate in the qualitative portion) and complete instruments at three time points: 1) immediately prior to the procedure, 2)within seven days after the procedure, preferably prior to discharge, and 3) three weeks after their catheter placement.
224321012|NCT04763343|DRUG|Saline|Subjects randomized to placebo will be administered a saline (0.9% sodium chloride) drip for 40 minutes. Saline placebo infusions will be given every other day until either the subject reports clinician rated Scale for Suicidal Ideation (SSI) score of\<4, and \>50% decrease from baseline, and clinical assessment of patient not being suicidal for three consecutive pre-infusion ratings, or a maximum of six infusions have been given over the course of 2 weeks, or they have been discharged from the inpatient unit.
224239127|NCT05455073|DIETARY_SUPPLEMENT|Weekly Iron and Folic Acid Supplementation (WIFA)|Weekly school provision of WIFA tablets to adolescent girls
224239128|NCT05455073|COMBINATION_PRODUCT|WASH|Ensure availability (or provision) of water, sanitation, and hygiene supplies for adolescent girls and boys
224239129|NCT05455073|COMBINATION_PRODUCT|Menstrual Hygiene Management|Support for adolescent girls' menstrual hygiene
224239130|NCT05455073|BEHAVIORAL|Nutrition Behavior Change Intervention (BCI)|Changing the knowledge, attitudes, and practices of nutrition (including dietary diversity), IFA, deworming
224239131|NCT05455073|BEHAVIORAL|MHM & WASH Behavior Change Intervention (BCI)|Changing the knowledge, attitudes, and practices of WASH and menstrual hygiene management
224239132|NCT06232252|DRUG|BI 765423|BI 765423
224239133|NCT06232252|DRUG|Placebo matching BI 765423|Placebo matching BI 765423
224239134|NCT03905486|DRUG|Pregabalin 300mg|Group 1: will receive pregabalin as a monotherapy. Pregabalin will be administered according to the treatment recommendations for fibromyalgia in the package insert \[Pfizer Inc., 2012\] starting by 50 mg twice daily increasing to 300 mg twice daily according to the efficacy and tolerability for 3 months.
224239135|NCT03905486|DRUG|Combined pregabalin 300mg and milancipran 100mg|Group 2: will receive a combined pregabalin and milancipran. Pregabalin will be administered as group 1, while milancipran will be administered according to the treatment recommendations for fibromyalgia, starting by 50 mg once daily for 1 week then increased to reach 100 mg daily (50 mg twice daily) based on efficacy and tolerability for 3 month.
224239136|NCT06230081|DRUG|Ropivacain 5 mg/ml + Clonidine|Drug used in the block
224239137|NCT04117841|OTHER|Observational|All groups will undergo observational data collection. No interventions will be made to patient care.
224239138|NCT00455351|DRUG|Vorinostat|Increasing dosing, phase I
223655807|NCT02668978|DEVICE|Hemopatch™ Sealing Hemostat|Hemopatch™ application over lung resection areas
223655808|NCT02668978|PROCEDURE|Standard surgical technique|Lung resuturing or restapling
223655809|NCT03593954|DRUG|JNJ-61393215|Participants will receive 2 oral administrations of 2 mg JNJ-61393215 as oral suspension.
223655810|NCT03593954|DRUG|Ritonavir|Participants will receive 100 mg of ritonavir tablet orally.
223768204|NCT01831310|DIETARY_SUPPLEMENT|Standard (Kabiven)|Parenteral nutrition provided 25-30 kcal/kg/day energy and 0.15-0.20 g/kg/day nitrogen. All nutrient substrates were mixed in 3 litre bags and infused in 24 h through a dedicated central venous line
224239139|NCT05745805|DEVICE|Simultaneous cortico-spinal magnetic resonance imaging, Serum|Simultaneous cortico-spinal magnetic resonance imaging data were collected in a strong magnetic field and collected the serum of participants.
224239140|NCT03938922|DRUG|Active Investigational Treatment ENT-01|"ENT-01 will be administered in tablet form, once daily.~Other Names:~ENT-01"
224239141|NCT00208286|DEVICE|PFC Sigma Fixed Bearing|PFC Sigma Fixed Bearing system for use in total knee arthroplasty
224239142|NCT00208286|DEVICE|PFC Sigma Mobile Bearing|PFC Sigma Mobile Bearing system for use in total knee arthroplasty
224239143|NCT02968186|BEHAVIORAL|Implementation program|Health professionals in the intervention arm will receive up to four training sessions in the first three months of the implementation period. Practice support will be continuously available throughout the project. Posters specifically designed for this project will be added to the primary health care units aiming to facilitate eliciting alcohol issues during the consultations, and to help professionals remembering to conduct alcohol screening and brief intervention. Leaflets to be handed-in to patients were also specifically produced for this project, aiming to aid professionals in advising at-risk drinkers to cut down. The research team will schedule with each primary health care unit regular visits for feedback on the progress of the program.
224239144|NCT01641445|DRUG|Topiramate|Topiramate (200 mg daily)
224239145|NCT01641445|DRUG|Placebo|"Matching placebo capusules (sugar pills"
224239146|NCT01974141|DRUG|Dapsone Gel|Dapsone gel applied topically to the face and to affected areas of the trunk once daily for 12 weeks.
224239147|NCT01974141|DRUG|Dapsone Gel Vehicle|Dapsone gel vehicle applied topically to the face and to affected areas of the trunk once daily for 12 weeks.
224239148|NCT02219945|OTHER|5 min exhaled breath sampling with soft nose clamp|study participants are requested to quietly sit and allow exhaled breath to be sampled through mouth piece breathing with nose clamp during 5 min while electronic data are collected in the device and later downloaded on a laptop pc
223655811|NCT04198714|PROCEDURE|Pudendal block|Administration of a pudendal block at the conclusion of vaginal surgery.
223655812|NCT06654115|DEVICE|Wireless Physiologic Monitoring|YHE® BP Doctor Pro Blood Pressure Smartwatch, which is a commericially available device. The device can monitor heart rate, blood pressure and saturation.
223655813|NCT00169065|DRUG|Clozapine|
223655814|NCT00169065|DRUG|Olanzapine|
223655815|NCT06592937|OTHER|Invasive ventilation|Invasive ventilation and respiratory support
223655816|NCT06667011|BEHAVIORAL|Feedback|learning conversation between trainee and teacher lasting 5 to 10 minutes at the end of each working day
223768205|NCT01831310|DIETARY_SUPPLEMENT|Standard-Glutamine|Parenteral nutrition (Kabiven) provided 25-30 kcal/kg/day energy and 0.15-0.20 g/kg/day nitrogen. it was 0.3-0.4 g/kg/day for glutamine dipeptide (Dipeptiven) supplementation. All nutrient substrates were mixed in 3 litre bags and infused in 24 h through a dedicated central venous line
223655817|NCT06984952|PROCEDURE|ERAS protocol|The ERAS protocol includes pre-admission patient education through audiovisual materials; reduction of perioperative fasting duration with preoperative carbohydrate loading and early postoperative oral intake; multimodal prophylaxis for postoperative nausea and vomiting; early removal of surgical drains and intravenous lines; early mobilization; and multimodal analgesia aimed at minimizing postoperative opioid use. The detailed protocol used in this study has been published previously \[https://doi.org/10.5230/jgc.2025.25.e27\].
223655818|NCT06591403|OTHER|the index and middle fingers of each participant&amp;#39;s active hand|A pulse oximeter was placed simultaneously on the index and middle fingers of each participants active hand while they were in an upright sitting position. After the pulse oximeter was placed on both fingers for one minute, stable values seen on its screen for at least three seconds were recorded. Then, the participants were placed in a supine position, and after a 10-minute rest, similar measurements were repeated with a pulse oximeter placed on the index and middle fingers of the active hand.
223655819|NCT06591078|OTHER|electropuncture|"The needle was retained for 30 minutes. During the retention period, the needle was lifted and twisted for 3 times with even small amplitude every 10 minutes, and the complement method was performed for 3 times. No manipulation before the needle, cotton ball press directly out of the needle.~④ Frequency, course and time: Start at the same time as immunotherapy, and complete 1-2 times of electroacupuncture treatment per week; Electroacupuncture was performed 4 times per 28 days. The number of electroacupuncture treatment cycles and the number of immunotherapy courses should be consistent."
223655820|NCT04509726|DRUG|EBV-specific TCR-T cell with cytokine auto-secreting element|Patients were pre-conditioned with chemotherapy and infused with EBV-specific TCR-T cells with cytokine auto-secreting element
223768206|NCT01831310|DIETARY_SUPPLEMENT|Standard-Omega 3 fatty acid|Parenteral nutrition (Kabiven) provided 25-30 kcal/kg/day energy and 0.15-0.20 g/kg/day nitrogen. The dose of omega 3 fatty acid (omegaven)supplementation was 0.1-0.2 g/kg /day. All nutrient substrates were mixed in 3 litre bags and infused in 24 h through a dedicated central venous line
223768207|NCT01831310|DIETARY_SUPPLEMENT|Standard-glutamine-omega 3|Parenteral nutrition (kabiven) provided 25-30 kcal/kg/day energy and 0.15-0.20 g/kg/day nitrogen. The dose of omega 3 fatty acid (omegaven) supplementation was 0.1-0.2 g/kg /day and it was 0.3-0.4 g/kg/day for glutamine dipeptide (dipeptiven)supplementation. All nutrient substrates were mixed in 3 litre bags and infused in 24 h through a dedicated central venous line
223768208|NCT00767676|DEVICE|HP828-101|Nine topical patch applications over 3 weeks, rest period of 2 weeks and challenge after 48 hours.
223655823|NCT06248996|RADIATION|Hyperfractionated radiotherpy|83.0 Gy in 68 fractions, 1.22 Gy per fraction, two daily fractions, five days per week to the primary tumour volume (GTVT\_83.0). To the primary tumour with an added margin (PTVT\_74.8) and to neck node metastases (PTVN\_74.8) the prescribed dose will be 74.8 Gy in 68 fractions, 1.10 Gy per fraction twice daily. To elective neck nodes (PTV 54.4) the prescribed dose will be 54.4 Gy in 68 fractions, 0.80 Gy per fraction twice daily.
223655824|NCT06248996|RADIATION|Control group|68.0 Gy in 34 fractions, 2.00 Gy per fraction per day, five or six days per week to tumour volumes and 54.4 Gy in 34 fractions, 1.60 Gy per fraction to elective neck nodes.
223655825|NCT05458713|DEVICE|Laser acupuncture|Irradiate acupoints with low power laser
223655826|NCT05283031|DIAGNOSTIC_TEST|Modified Diurnal Tension Curve|The modified diurnal tension curve (mDTC), an alternative that involves IOP measurements every 2 or 3 hours during office hours, is more feasible and may provide better information regarding the IOP profile than single IOP measurements.
223655827|NCT06896994|DRUG|esketamine group|In the esketamine group, in addition to receiving the combination of pregabalin and duloxetine, patients will also undergo a single intravenous infusion of esketamine.
223655828|NCT06896994|DRUG|control group|receiving the combination of pregabalin and duloxetine
223655831|NCT06762054|DRUG|Continue DTG-based antiretroviral therapy|Participants will continue on DTG-based ART after enrollment for up to 12 months
223655832|NCT06762054|BEHAVIORAL|Enhanced adherence counselling|Participants with VL ≥200 copies/mL will undergo enhanced adherence counselling
223768209|NCT00617240|DRUG|metformin|500mg tablets, 250mg to 2000mg/day, po, BID to TID, 26 weeks
223768210|NCT00617240|DRUG|placebo|500/0mg tablets, 250-2000mg/day divided BID to TID, po, 26 weeks
224239149|NCT01264120|BEHAVIORAL|Health Psychology Intervention|The health psychology intervention will involve a bariatric rehabilitation service (BRS) which will involve those allocated to the intervention receiving usual care plus three 50 minute sessions with a health psychologist pre-operatively (1 week before surgery), perioperatively (before they are discharged from hospital) and at 3 month follow up.
224239150|NCT01128686|OTHER|No intervention|This study is retrospective chart review
223655833|NCT06900816|DRUG|CHF 6001|CHF 6001 DPI single dose
223655834|NCT06900816|DRUG|CHF 6001|CHF 6001 DPI single dose
223655835|NCT07084168|BEHAVIORAL|Educational videos|Educational videos about genetic testing will be provided. Subjects will be asked to view one of three videos (an endometrial cancer/Lynch Syndrome video or a longer or shorter version of an ovarian cancer video) relevant to their cancer diagnosis and genetic testing.
223655836|NCT07084168|BEHAVIORAL|Survey|Subjects will be asked to complete a brief satisfaction survey.
223655837|NCT07142395|PROCEDURE|Immediate skin closure|After laparotomy wounds will be closed primarily using no. 1 vicryl suture
223655838|NCT07142395|PROCEDURE|Delayed primary closure|Deeper layers of wound will be closed after surgery and loose mattress sutures will be applied to skin with prolene. After three to five days of daily dressing with bactericidal solution, the skin will be closed
223655839|NCT06938464|DIETARY_SUPPLEMENT|Probiotics|Probiotics powder including: Resistant dextrin, inulin, oligosaccharide, erythritol, Lactobacillus plantarum VB165, Bifidobacterium lactis VB301, Lactobacillus rhamnosus VB255, acerola cherry powder, citric acid
223655840|NCT06938464|DIETARY_SUPPLEMENT|Placebo|placebo with similar appearance and smell but not containing probiotics
223655841|NCT06940778|OTHER|No Interventions|no interventions
223655842|NCT02713464|BEHAVIORAL|maternal education|Antenatal and/or postpartum Instruction on risks of neonatal jaundice, dangerous practices, technique to evaluate jaundice, early signs of ABE, when to seek care.
223655843|NCT07144163|DRUG|Atumelnant|Atumelnant, tablets, once daily by mouth
223655844|NCT07144163|DRUG|Placebo|Placebo, tablets, once daily by mouth
223655845|NCT07141251|PROCEDURE|BAO-G|Using G-iliac system to reconstruct the visceral branches of in endovascular repair of thoracoabdominal aortic aneurysm.
223655846|NCT06088160|PROCEDURE|Total Hip Arthroplasty|Total hip arthroplasty is a common surgical procedure performed in people with advanced hip osteoarthritis
223655847|NCT07156864|DRUG|1/10 therapeutic dose|5 volunteers + 1 replacement volunteer will recieve 1/10 therapeutic dose of the study drug (parenteral administration).
223655848|NCT07156864|DRUG|1/2 therapeutic dose|5 volunteers + 1 replacement volunteer will recieve 1/2 therapeutic dose of the study drug (parenteral administration).
223655849|NCT07156864|DRUG|full therapeutic dose|15 volunteers + 3 replacement volunteers will recieve full therapeutic dose of the study drug (parenteral administration).
223655850|NCT07156864|DRUG|Patients with a verified diagnosis of COVID-19|10 volunteers with a verified diagnosis of COVID-19 will recieve full therapeutic dose of the study drug (parenteral administration).
223655851|NCT07157579|DIAGNOSTIC_TEST|Detection of Notch1 mutation using real time pcr on bone marrow aspirate samples or peripheral blood samples.|Detection of Notch1 mutation using real time pcr on bone marrow aspirate samples or peripheral blood samples.
223655852|NCT07156929|DIETARY_SUPPLEMENT|Controlled-ileocolonic-release nicotinamide (CICR-NAM): 500 mg/d|Controlled-ileocolonic-release nicotinamide (CICR-NAM) film-coated tablets release 500 mg nicotinamide per tablet at a pH of 7, leading to a delayed and prolonged systemic exposure to nicotinamide and to exposure of the ileum and colon including the gut microbiome.
223655853|NCT07156929|DIETARY_SUPPLEMENT|Controlled-ileocolonic-release nicotinamide (CICR-NAM): 1000 mg/d|Controlled-ileocolonic-release nicotinamide (CICR-NAM) film-coated tablets release 500 mg nicotinamide per tablet at a pH of 7, leading to a delayed and prolonged systemic exposure to nicotinamide and to exposure of the ileum and colon including the gut microbiome.
223655854|NCT07157241|DIETARY_SUPPLEMENT|Intervention|omega-3 capsules with a concentration of 1000 mg/day for three months (NOW Foods- Ultra omega-3 500 EPA/250 DHA).
223655855|NCT07157241|DIETARY_SUPPLEMENT|Control group (placebo)|corn oil capsule /day for 3 months
223768211|NCT03741959|PROCEDURE|Experimental group|"Active self-correction exercises (20 minutes) to achieve the best possible trunk alignment the patient can achieve in the three-dimensional planes using visual, proprioceptive and EMG feedbacks.~Passive and active trunk stabilization exercises (20 minutes) to improve trunk biomechanical constraint Functional tasks (20 minutes) defined as functional exercises to train the automatic response to maintain the best alignment through the broadest possible range of challenging activities (Romano2015)."
223655857|NCT07158502|DRUG|TauroPace Cohort|"After sterile opening of the vial, the entire content of TauroPace™ will be poured into single-use sterile trays. Following skin incision, the surgical site will be irrigated with 5 mL of TauroPace™ solution.~The leads, device generator, and fixation sutures will then be thoroughly wiped using sterile gauze soaked in the solution. Once the leads are connected to the generator, the entire system will be treated again with TauroPace™ before being inserted into the pocket.~At the end of the procedure, the final surgical site will be irrigated once more with an additional 5 mL of TauroPace™ using a sterile syringe. A full 100 mL vial of the solution will be used for each patient, ensuring continuous antimicrobial coverage throughout the procedure.~Excess solution will be gently removed prior to surgical wound closure."
223655858|NCT07157085|OTHER|Comprehensive treatment|Comprehensive HCC therapies include liver resection, TACE, HAIC, targeted therapy, immunotherapy and radiotherapy
223655859|NCT07154186|OTHER|Coronary Angiographic Assessment|Coronary angiographic assessment will be performed for all patients.
223768212|NCT03741959|PROCEDURE|Control group|Training consisted of passive and active trunk mobilization (10 minutes) followed by muscle stretching, and strengthening exercises, and gait training (50 minutes)(Bartolo et. al., 2010).
223655860|NCT07156357|DIAGNOSTIC_TEST|Surface Electromyography|Tests performed to evaluate swallowing function
223655861|NCT07156357|DIAGNOSTIC_TEST|Fiberoptic Endoscopic Evaluation of Swallowing|Assessment of swallowing function
223655862|NCT07157397|BEHAVIORAL|Plant-Focused Diet Counselling|Individualized dietary counseling conducted with the use of sample meal plans and infographics to guide patients to consume a diet emphasising plant-based protein sources while meeting nutritional requirements for peritoneal dialysis patients.
223655863|NCT07157397|BEHAVIORAL|Standard Renal Diet Counselling|Individualized dietary counseling conducted with the use of sample meal plans and infographics based on current guideline recommendations, to guide patients to consume a diet emphasising animal-based protein sources while meeting nutritional requirements for peritoneal dialysis patients.
223655864|NCT07158255|OTHER|electrotherapy treatment|Patients in the electrotherapy group will receive 15 sessions of TENS, hotpack, and ultrasound, 45 minutes each, 5 days a week, for 3 weeks. The treatment program is planned for 20 minutes of TENS, 15 minutes of hotpack, and 10 minutes of ultrasound.
223768213|NCT02488512|DRUG|90Y-DOTATOC|Each patient will receive a maximum cumulative 90Y-DOTATOC activity of 11.1 GBq (300 mCi) \[45-46\], divided into 4 cycles (1.8 - 2.8 GBq for each cycle) with an interval of 6 - 8 weeks between cycles. The activity to be administered will be measured in a dose calibrator, properly calibrated for the 90Y-radionuclide.
223768214|NCT00380640|DRUG|Trimethoprim|This group will receive the active intervention (trimethoprim) first, followed by the placebo.
223655865|NCT07158255|OTHER|Exercise training|In addition to electrotherapy, the patients in the study group will receive 15 sessions (45 minutes, 5 days a week, for 3 weeks) of exercise training consistent with the literature. Exercise training includes programs to increase joint range of motion and mobility at the pain threshold and to restore functionality. Following electrotherapy, upper extremity normal range of motion exercises, anterior and posterior capsule stretching exercises, pendulum exercises, wand exercises, isometric training in 3 planes, and isotonic strengthening exercises will be applied. Five exercises will be selected each day, performed under the supervision of a physiotherapist. A 2-minute rest period will be provided after each exercise, followed by a transition to the next exercise. Care will be taken to perform the exercises within the pain threshold and to ensure that the pain does not exceed a VAS score of 2.
223655866|NCT07156318|BEHAVIORAL|2 months of drumming lessons given by a professional drummer with extensive experience working with children with Down syndrome|Drumming lessons consisting of how to use hands to drum on djembe drum, using alternating hands to drum, drumming to a metronome and to music.
223655867|NCT07156318|BEHAVIORAL|Lessons after measurement|Receiving lessons after the two lab visits should still offer any possible positive effects to participants while still allowing us to compare the Control group children's behaviors to those of the Experimental group.
223655868|NCT07156526|DIETARY_SUPPLEMENT|Qualia Iron Version A|Qualia Iron Version A manufactured by Qualia Life Sciences
223655869|NCT07156526|DIETARY_SUPPLEMENT|Qualia Iron Version B|Qualia Iron Version B manufactured by Qualia Life Sciences
223655870|NCT07156526|DIETARY_SUPPLEMENT|Placebo|Rice powder
223655871|NCT07156838|OTHER|bioflex crown|A preformed bioflex crown of similar size will be selected. Tooth preparation will be done using a tapered diamond bur to reduce the occlusal surface, including the central groove, by 1-1.5 mm. The proximal surfaces will be prepared by approximately 0.5 mm to clear the contact area, bioflex crown fitting and proper occlusion will be checked then it will be cemented using type-I glass ionomer cement, Any excess cement will be removed.
223655872|NCT07156838|OTHER|zerconia crown|"Occlusal reduction will be done by 1-1.5 mm using coarse football shaped diamond bur following the natural occlusal anatomy.~Interproximal contacts will be opened with a tapered fissure bur. The proximal space should be enough to permit the chosen crown to fit passively.~The molar will be trimmed down circumferentially 0.5-1.25 mm as needed with the use of tapered diamond burs.~•About 1 to 2 mm subgingival preparation will be done to achieve a feather-edge finish line.~Prepared tooth should be free from any blood or saliva. Try-in will be done using the pink crowns, to check the occlusion and Passive fit of the crown.~The zirconia crown will be luted with type I glass ionemer cement. Consistent firm finger pressure will be applied during cementation, Any excess cement will be removed, and proper occlusion will be verified"
223768215|NCT00380640|DRUG|Trimethoprim|This group will start the study with placebo, followed by the active intervention (trimethoprim).
223768216|NCT01611259|DRUG|Rituximab and Lenalidomide|Rituximab 375 mg/m² i.v. day 1 Lenalidomide 20 mg p.o. daily for 21 days Cycles should be repeated every 28 days. Restaging should be performed after three cycles. In case of at least stable disease, patients should receive another three courses of therapy. Patients with documented CR after 6 courses will stop therapy/study, while patients with PR or SD will be given another two cycles for a maximum of 8 cycles.
223768217|NCT04936685|BIOLOGICAL|Meningococcal Polysaccharide (Serogroups A, C, W, and Y) Tetanus Toxoid Conjugate Vaccine|Liquid solution for injection Intramuscular
223768218|NCT02527057|DEVICE|DW-MRI|Participants will perform four DW-MRI scanning as follows,before chemoradiation , at 2 weeks , 4 weeks after the start of radiotherapy and before the surgery.If participants can not receive surgery,the last scanning time will replaced at the end of radiotherapy.
223768219|NCT02143622|BIOLOGICAL|LJM716|antibody
224239151|NCT06522958|DIETARY_SUPPLEMENT|High Dissolving Transitional Food|Transitional foods are solid foods that rapidly change texture in the presence of moisture (e.g., water or saliva) or temperature change. Duration of consumption of the investigational agent will include the time of the surgery until the second post-operative evaluation. This is estimated to be approximately 1-2 months in total.
224239152|NCT05935098|DRUG|BGB-A3055|Administered intravenously
224239153|NCT05935098|DRUG|Tislelizumab|Administered intravenously
224239154|NCT05935098|DRUG|Chemotherapy|Administered in accordance with relevant local guidelines and/or prescribing information.
223768220|NCT02143622|BIOLOGICAL|cetuximab|antibody
223768221|NCT04054414|DRUG|Normal Saline along with standard treatment|The arm is for active comparison for PMZ-1620 (sovateltide), an endothelin-B receptor agonist. PMZ-1620 has the potential to be a first-in-class neuronal progenitor cell therapeutics that is likely to promote quicker recovery and improve neurological outcome in cerebral ischemic stroke patients. Normal saline (vehicle) with standard treatment will be provided.
223768222|NCT04054414|DRUG|PMZ-1620 along with standard treatment|PMZ-1620 (sovateltide) is an endothelin-B receptor agonist. PMZ-1620 has the potential to be a first-in-class neuronal progenitor cell therapeutics that is likely to promote quicker recovery and improve neurological outcome in cerebral ischemic stroke patients.
223768223|NCT02717897|OTHER|No intervention|This study is not interventional
223768224|NCT02925975|DRUG|Carvedilol|Carvedilol starts from 6.25mg daily and increase to 12.5mg once daily in next week if being tolerated.
223768225|NCT02925975|DEVICE|3D-vHPS|This 3D model of HPS is rebuilt by a software combining the anatomic information of vessels from CTA (computed tomographic angiography) and the blood stream speed of targeted vessel from Doppler Ultrasound.
224239155|NCT04656353|BEHAVIORAL|Intervention Arm|Participants randomized to the Intervention Arm will be provided with the website link to the online self-help program and a questionnaire and a distress survey. They will be asked to use the website within two weeks and then to complete these documents after using it and mail them back in a self-addressed stamped envelope. Same documents will be administered at the 3-month follow-up period, and the participant will be given two weeks to complete and return it in a self-addressed stamped envelope. Additionally, participants will also be asked in the 3-month follow-up questionnaire if they are interested in attending a focus group to elaborate on their experience with the psychosocial self-help program. Those who have expressed an interest will be contacted. The focus groups will last about 1-1.5 hours and consist of 3-4 participants. Focus groups will be audio-taped and conducted in either English or Chinese.
223655873|NCT07156838|OTHER|stainless steel crown|"An appropriately sized preformed stainless-steel crown will be selected. Tooth preparation will involve using a tapered bur to reduce the occlusal surface by 1 to 1.5 mm, with interproximal reduction made on the mesial and distal sides. The selected crown size will be checked, and a trial fit will be conducted prior to cementation. Crimping pliers will be used, and the crown will be cemented with Type 1 glass ionomer cement.~Any excess cement will be removed, and proper occlusion will be verified"
223655874|NCT07156539|DRUG|HS-20094 Injection|HS-20094 injected subcutaneously once weekly
223655875|NCT07156539|DRUG|Dulaglutide Injection|Dulaglutide injected subcutaneously once weekly
223655876|NCT07156396|DEVICE|SleeperOne®, dental Hitec, France|SleeperOne® is a computerized local anesthetic delivery system used to deliver 3% mepivacaine following application of 20% benzocaine topical gel. It is designed to reduce injection pain and improve comfort during pediatric dental procedures.
223655877|NCT07156396|PROCEDURE|Conventional Infiltration|Local anesthetic (3% mepivacaine) will be administered using a conventional dental syringe after the application of 20% benzocaine topical anesthetic.
223655878|NCT07158346|DRUG|L03RD1|1 tablet of L03RD1
223655879|NCT07158346|DRUG|L03RD2|2 tablets of L03RD2
223655880|NCT07158346|DRUG|CT-L03|1 tablet of CT-L03
223655881|NCT07156591|PROCEDURE|Esophagogastroduodenoscopy|Assess the gastric retention during esophagogastroduodenoscopy
223655882|NCT07157631|DRUG|tranexamic acid|In patients assigned to tranexamic acid, 2.0 g dissolved in 50 ml of 0.9% saline）will be given intravenously within 30 mins after skin incision.
223655883|NCT07157631|DRUG|0.9 % saline|In patients assigned to placebo, a comparable volume of 0.9% saline will be given.
223655884|NCT07156552|BEHAVIORAL|Resistance exercise training and protein supplementation|"The intervention consists of two components:~1. Resistance Exercise Training Participants will engage in a 24-week resistance training program. This program includes one supervised session per week supervised by a qualified kinesiologist, complemented by two to three additional unsupervised sessions per week performed at home.~2. Protein Supplementation~Participants will receive daily protein supplements for a total duration of 12 weeks. The dosage will be progressively increased:~* 20 grams per day during weeks 1-4~* 40 grams per day during weeks 5-8~* 60 grams per day during weeks 9-12 After the 12-week supplementation period, participants will receive additional dietary counseling sessions with a dietitian. These sessions aim to support the maintenance of adequate protein intake through dietary intake."
223655885|NCT07157995|BEHAVIORAL|BALANCE Building Active LIving and Addressing Needs for Caregiver Empowerment|The Balance intervention will include individual visits by a Caregiver Navigator and group sessions with other participants, led by the caregiver navigator. The focus will be on future planning, resources for unmet needs and support and socialization.
223655886|NCT07156435|DRUG|Vyxeos 44 MG / 100 MG Liposome Injection|Vyxeos®/CPX-351 will be infused in 90 minutes on day 1, 3 and 5 only, 3 hours after the end of clofarabine (if administered on the same day).
223655887|NCT07156435|DRUG|Clofarabine|Clofarabine infusion will be given according to the assigned dose level, over 2 hours IV, daily on day 2-6 (for 5 consecutive days).
223768226|NCT02925975|PROCEDURE|Routine endoscopic procedures|These include esophageal band ligation and tissue glue injection in the fundus of stomach by upper GI endoscopy if there are visible varies in cirrhotic patients. There routine procedures are done to prevent potential varies associated bleeding.
223655888|NCT07156669|DEVICE|Novalung ultimate kit, Xenios 2.0, and MultiSupport Ground (MSG)|Patients will receive ECLS treatment using the Novalung ultimate kit, Xenios 2.0, and MultiSupport Ground (MSG) during ground-based inter-hospital patient transport and/ or stationary treatment according to their intended use and local standards/ requirements.
223655889|NCT07157735|DRUG|dapansutrile|Dapansutrile tablets administered for 26 weeks, starting at 1,000 mg daily (500 mg twice daily) for 4 weeks, escalated to 2,000 mg daily (1,000 mg twice daily) thereafter.
223655890|NCT07157735|DRUG|placebo|Matched placebo tablets administered for 26 weeks, admistered as per the active treatment.
223655891|NCT07157475|DRUG|Treatment with SGLT2 inhibitors (flozins)|Patients received SGLT2 inhibitors (empagliflozin, dapagliflozin, canagliflozin) as part of their routine clinical care during the 12-month follow-up period after elective or urgent lower limb revascularization procedures. The study does not assign treatment; medication use occurred independently of the study protocol.
223655892|NCT07156409|DEVICE|Peripheral Embolization Coil System|Primarily used to block or reduce the blood flow velocity in the peripheral vascular system
223655893|NCT07157332|PROCEDURE|Bariatric Sleeve Surgery|Participants undergo a restrictive bariatric procedure called sleeve gastrectomy, performed by experienced surgeons. This procedure involves surgical reduction of the stomach size to aid in weight loss. The study observes outcomes related to iron metabolism, body composition, and biochemical markers over six months post-surgery. No additional interventions or treatments are applied as part of the study protocol; the surgery is part of routine clinical care.
223655894|NCT06303063|DEVICE|SINOMED IAS Stent System|Stent-assisted coiling (SAC) of intracranial aneurysms paved the way for endovascular coiling of wide-neck aneurysms, improving rates of aneurysm obliteration and recurrence.
223655895|NCT06303063|DEVICE|Neuroform Atlas Stent System|Stent-assisted coiling (SAC) of intracranial aneurysms paved the way for endovascular coiling of wide-neck aneurysms, improving rates of aneurysm obliteration and recurrence.
223655896|NCT05170919|DRUG|Mirtazapine|Patients will be prescribed a dosage of 15 mg per day. Dose will not be escalated.
223655897|NCT05170919|DRUG|Olanzapine|the participant will be prescribed a dosage of 2.5mg per day if \> 65 yrs. and 5 mg/per day if \<65 yrs. per day. Per physician discretion, participants are allowed a dose escalation of a maximum of 10mg.
223655898|NCT06030752|DRUG|Washed Microbiota Transplantation|The prepared microbiota suspension was infused into the participates' lower gut.
223768227|NCT00984854|DRUG|Juvidex|Intradermal Juvidex, 100μl of 50mM (1.41mg/100μl) administered just prior to wounding and 200μl administered 24 h later
223768228|NCT00984854|DRUG|Juvidex|Intradermal Juvidex, 100μl of 100mM (2.82mg/100μl) administered just prior to wounding and 200μl administered 24 h later
223768229|NCT00984854|DRUG|Juvidex|Intradermal Juvidex, 100μl of 200mM (5.64mg/100μl) administered just prior to wounding and 200μl administered 24 h later
223655899|NCT05106426|BEHAVIORAL|Healthy Caregivers- Healthy children|The HC2 intervention is an obesity prevention program that provides nutrition and healthy activities programs administered weekly via Zoom or in-person.
223655900|NCT05106426|BEHAVIORAL|Jump Start|The Jump Start intervention is a behavioral health and safety program that provides behavior management and safety programs administered weekly via Zoom or in-person.
223655901|NCT00202475|PROCEDURE|eythrocytapheresis|machinal collection of erythrocytes
223655902|NCT00202475|PROCEDURE|whole blood collection|collection of whole blood
223655903|NCT02923921|BIOLOGICAL|Pegilodecakin|Pegilodecakin plus FOLFOX
223655904|NCT02923921|DRUG|FOLFOX|FOLFOX Alone
223655905|NCT05310175|DEVICE|Electroacupuncture|Filiform needles (0.30×50mm, Hanyi brand, Beijing Medical Appliance, China) and the SDZ-V electric acupuncture (Suzhou Medical Appliance) apparatus will be used. After acupuncture at the acupoints group, the needle handle will be connected with the electrode of the electric acupuncture apparatus.
223655906|NCT05310175|DEVICE|Sham acupuncture|Shallow needle insertion of 2-3 mm at sham acupoints without manipulation.
223655907|NCT04177576|BIOLOGICAL|2 additional tubes of blood|2 additional tubes of blood will be collected to prepare plasma aliquots used tomeasure markers of neutrophil activation
223655908|NCT04860778|DIETARY_SUPPLEMENT|BDNF Essentials|Participants will take two capsules, twice daily with water for 84 days.
223655909|NCT00778843|DIETARY_SUPPLEMENT|Viusid|Viusid, three oral sachets daily during 24 weeks
223655910|NCT00778843|OTHER|Placebo|Placebo three oral sachets daily during 24 weeks
223655911|NCT00479687|DEVICE|SUPARTZ®|Three Supartz injections over 2 weeks into the glenohumeral joint space.
223655912|NCT00479687|DEVICE|Phosphate Buffered Saline|Three phosphate buffered saline injections over 2 weeks into the glenohumeral joint space.
223655913|NCT00295880|PROCEDURE|umbilical cord blood transplantation|The graft will be given by slow injection into each posterior iliac crest.
223655914|NCT02064413|DEVICE|ESS310 (BAY1454032)|
223655915|NCT01474239|DRUG|bevacizumab [Avastin]|10 mg/kg every 2 weeks intravenously until disease progression or unacceptable toxicity
223655916|NCT01474239|DRUG|fotemustine|75 mg/m2 intravenously on days 1, 8 and 15 followed by, after a 5 weeks interval, 100 mg/m2 on day 1 of a 3-weeks cycle. Until disease progression or unacceptable toxicity
224239156|NCT04656353|BEHAVIORAL|Control Group|Participants randomized to the Control group will receive standard care (no intervention). They will be used as a baseline to compare groups and assess the effect of the intervention (i.e., the online psychosocial program). At the two weeks following randomization (T1) and the 3-month follow-up periods (T2), they will be asked to complete the questionnaire and distress survey and return them in a self-addressed stamped envelope. Participants will be given two weeks to complete the questionnaire and distress survey. The same documents will be administered at the 3-month follow-up period (T2). Once the 3-month follow-up is completed, each participant will be provided with the website link to view the self-help program.
223655917|NCT03636464|OTHER|Blood collection|Pharmacokinetics
223655918|NCT05344196|BEHAVIORAL|Modified EAET for prediabetes|Attempts to reduce stress and improve health behavior by engaging in emotional awareness and expression leading to changes in interpersonal relationships and health behavior
223655919|NCT01009372|BEHAVIORAL|IPP|Institution of intraoperative breaks for the surgeon with release of pneumoperitoneum for patient
223655920|NCT01429025|BIOLOGICAL|rituximab|IV
223655921|NCT01429025|DRUG|bendamustine|IV
223655922|NCT01429025|DRUG|lenalidomide|PO
223655923|NCT06471283|OTHER|physical activity|Exercising physical activity during dialysis
223768230|NCT00984854|DRUG|Juvidex|Intradermal Juvidex, 100μl of 300mM (8.46mg/100μl) administered just prior to wounding and 200μl administered 24 h later
224239157|NCT04977336|DRUG|VX-548|Tablets for oral administration.
223655924|NCT01139008|DRUG|metronidazole 1% gel|Apply topically on one side of the face once daily for three weeks
223655925|NCT01139008|DRUG|azelaic acid 15% gel|Apply topically on the opposite side of the face twice daily for three weeks
223655926|NCT04546984|DRUG|HEC96719|Part 2：Mulltiple doses up to 10 days
223655927|NCT03154229|OTHER|Smartphone-based decision-support|WHO guidelines have been adapted from paper onto a smartphone referred to as a Rehydration Calculator
223655928|NCT03154229|OTHER|Paper-based decision-support|WHO guidelines presented on paper
223655929|NCT03154229|OTHER|Pre-Assessment of practices|Observation of baseline clinical practice.
223655930|NCT00347620|DEVICE|spectacles|
223655931|NCT00347620|PROCEDURE|Cataract Surgery|
223655932|NCT04567901|OTHER|Death|Mortality group
223655933|NCT04567901|OTHER|Survive|Survival group
223655934|NCT04951661|DEVICE|Virtual Reality|Participants will be set up in the VR equipment. They will engage and follow along with a 10-20 minute guided meditation through the VR. The meditation program may include simulated movement, relaxing music, and the voice of a meditation guide. The research team member will supervise the session, ensuring safety of the subject is maintained.
223655935|NCT00505778|DRUG|Mesalamine Once-Daily|Mesalamine tablets, 1.6-2.4 g/day taken orally once a day for 52 weeks
223655936|NCT00505778|DRUG|Mesalamine Twice-Daily|Mesalamine tablets, 1.6-2.4 g/day, taken twice daily for 52 weeks
223655937|NCT00116298|DRUG|stavudine, efavirenz, lamivudine|
223655938|NCT03414892|DRUG|Globalagliatin Hydrochloride|once daily, oral
223655939|NCT03414892|DRUG|Placebo|once daily, oral
223655940|NCT01785173|PROCEDURE|Endoscopic-guided gauze pledgetting|By using a transnasal endoscope as a guide and a biopsy forceps, a gauze strip soaked with decongestant and anesthesia will be delivered to a selected nasal meatus chosen by anterior rhinoscopy.
223655941|NCT01785173|PROCEDURE|Cotton-tipped applicator gauze pledgetting|In contrast to the endoscopic-guided, forceps-delivering method, a gauze strip is delivered to a selected meatus by a cotton-tipped applicator.
223655942|NCT01373671|DEVICE|SIEMENS INSPIRATION DIGITAL BREAST TOMOSYNTHESIS (DBT) SYSTEM|DBT scan
223655943|NCT04249232|DRUG|Abaloparatide 80 micrograms per Pen dose|prefilled injector pen to deliver 80 micrograms daily subcutaneously
223655944|NCT04249232|DRUG|Placebo prefilled injector pen|prefilled injector pen to deliver inactive solution daily subcutaneously
223655945|NCT05204303|DIAGNOSTIC_TEST|24-hour pH-impedance monitoring|Ambulatory transnasal reflux device to detect reflux events in the oeosphagus and pharynx.
223655946|NCT05204303|OTHER|Symptom questionnaires|Reflux Symptom Index (RSI) Gastroesophageal Reflux Disease Questionnaire (GERDQ) Short-form Esophageal Hypervigilance and Anxiety Scale (SF-EHAS)
223655947|NCT05204303|OTHER|ROME IV Diagnostic Questionnaire|A symptom-based questionnaire used to diagnose disorders of gut-brain interaction (DGBI)
223655948|NCT05367492|DRUG|Double Blind Varenicline|"For participants 16-17 years old, ≤ 55 kg:~* 0.5 mg once daily for 7 days, then~* 0.5 mg twice daily for 11 weeks~For participants 16-17 years old, \>55 kg:~* 0.5 mg once daily or 3 days,~* 0.5 mg twice daily for 4 days~* 1.0 mg twice daily for 11 weeks~For participants 18+ years old:~* 0.5 mg once daily or 3 days,~* 0.5 mg twice daily for 4 days~* 1.0 mg twice daily for 11 weeks"
223768231|NCT00984854|DRUG|Juvidex|Intradermal Juvidex, 100μl of 400mM (11.28mg/100μl) administered just prior to wounding and 200μl administered 24 h later
223655949|NCT05367492|DRUG|Double Blind Placebo|"For participants 16-17 years old, ≤ 55 kg:~* 0.5 mg once daily for 7 days, then~* 0.5 mg twice daily for 11 weeks~For participants 16-17 years old, \>55 kg:~* 0.5 mg once daily or 3 days,~* 0.5 mg twice daily for 4 days~* 1.0 mg twice daily for 11 weeks~For participants 18+ years old, regardless of weight:~* 0.5 mg once daily or 3 days,~* 0.5 mg twice daily for 4 days~* 1.0 mg twice daily for 11 weeks"
223768232|NCT00984854|DRUG|Juvidex|Intradermal Juvidex, 100μl of 600mM (16.93mg/100μl) administered just prior to wounding and 200μl administered 24 h later
223768233|NCT00984854|DRUG|Placebo|Intradermal Placebo (0.9% phosphate buffered saline, pH 7.0), 100μl administered just prior to wounding and 200μl administered 24 later
223768234|NCT04388332|PROCEDURE|Structural allograft|Subjects that have received ACDF structural allograft with plates with autograft and/or allograft comprised of cancellous and/or corticocancellous bone chips
223768235|NCT04388332|DEVICE|Tritanium C|Subjects will receive the Tritanium C anterior cervical cage which is intended to be used with autogenous or allogenic bone graft comprised of cancellous and/or corticocancellous bone graft
224239158|NCT04977336|DRUG|HB/APAP|Capsules for oral administration.
224239159|NCT04977336|DRUG|Placebo (matched to VX-548)|Placebo matched to VX-548 for oral administration.
224239160|NCT04977336|DRUG|Placebo (matched to HB/APAP)|Placebo matched to HB/APAP for oral administration.
224239161|NCT05344898|PROCEDURE|Subscap Tenotomy|Group will not have their subscapularis tendon repaired following a reverse shoulder replacement.
224239162|NCT05344898|PROCEDURE|Subscap Repair|Group will have their subscapularis tendon repaired following a reverse shoulder replacement.
224321013|NCT04763343|BEHAVIORAL|CAMS Therapy|CAMS weekly sessions will also be started immediately as an inpatient at the start of the study while receiving ketamine or saline. CAMS will be continued weekly after the patient is discharged and followed up as an outpatient. Weekly CAMS sessions will be terminated after the subject, as an outpatient, has three consecutive outpatient CAMS sessions with an overall risk \< 2 (# 6 on the SSF Core Assessment) along with a positive response regarding their thoughts/feelings and clinician indicating behavioral stability (suicidal behavior).
223655950|NCT05367492|BEHAVIORAL|QuitVaping|QuitVaping is a manualized intervention based on the American Lung Association smoking cessation program modified with adolescent appropriate content and language for vaping cessation from the vaping section of teen.smokefree.gov and the Truth Initiative. These behavioral support sessions will be delivered weekly during the 12-week treatment phase via videoconference or in- person.
223655951|NCT05367492|BEHAVIORAL|This Is Quitting|A free, publicly available text message vaping cessation program from Truth Initiative, designed specifically to help adolescents who vape nicotine quit. Participants who set a quit date receive messages for a week preceding it and 30 days afterward that include encouragement and support, skill- and self-efficacy building exercises, coping strategies, and information about the risks of vaping, benefits of quitting and cutting down to quit.
223655952|NCT02714972|DEVICE|Hyperglycemia Minimization Algorithm|The hyperglycemia minimization algorithm will be running actively on the study laptop during the night and dose insulin if the algorithm predicts hyperglycemia. If hypoglycemia is predicted, the system will suspend the pump.
223655953|NCT00344578|DEVICE|Restor IOL|
223655954|NCT00369291|BIOLOGICAL|keyhole limpet hemocyanin|KLH is a foreign protein to humans, it will be used to assess the immune response to a neo-antigen given as a single injection, 1 mg subcutaneously in the arm (per MT1999-06).
223655955|NCT00369291|BIOLOGICAL|tetanus toxoid|Tetanus toxoid booster 0.5 ml intramuscularly (IM) in the opposite arm (per MT1999-06)
223655956|NCT00001068|DRUG|Lamivudine|
223655957|NCT04901780|OTHER|pragmatic posterior capsular stretch|pragmatic posterior stretch is used to increase the length of the posterior capsule
223655958|NCT04901780|OTHER|cross body stretch|crossbody stretch performed by an individual
223655959|NCT03046862|DRUG|Durvalumab|Durvalumab 1.12 g iv on D1 every 3 weeks
223655960|NCT03046862|DRUG|Tremelimumab|Tremelimumab 75mg iv on D1 every 3 weeks
223655961|NCT03046862|DRUG|Gemcitabine|Gemcitabine 1000 mg/m2 iv on D1\& D8 every 3 weeks
223655962|NCT03046862|DRUG|Cisplatin|Cisplatin 25 mg/m2 iv on D1\& D8 every 3 weeks
223655963|NCT05070715|OTHER|Analyzing of microplastic level|Blood samples will be taken from the vein of the umbilical cord. Placental tissues will be taken from the maternal side of the placenta. Placental tissues and serum samples will be stored in the temperature set to -80 °C until analysis. Extraction methods involving chemical reactions will be used to separate and purify microplastics in placenta and cord blood samples. After the extraction process, analysis of microplastic levels in tissues and serum will be done by µ-Raman spectroscopy.
223655964|NCT05112952|DRUG|Lazertinib|Lazertinib tablet will be administered orally.
223655965|NCT01374503|BIOLOGICAL|ALX-0651|single or multiple (once daily for maximum 3 consecutive days) i.v. administration, 0.003-12 mg/kg
223768236|NCT04870840|RADIATION|Proton Beam Radiation Therapy|Undergo radiation therapy
223768237|NCT04870840|OTHER|Quality-of-Life Assessment|Ancillary studies
223768238|NCT04870840|OTHER|Questionnaire Administration|Ancillary studies
223655966|NCT01374503|BIOLOGICAL|Placebo|single or multiple i.v. administration
223655967|NCT06520410|DEVICE|Pars plana vitrectomy with a 18 mm short vitrector|Using the shorter 18 mm vitrector for various pediatric vitreoretinal surgeries
223655968|NCT00995293|DRUG|DOCETAXEL|Intravenous
223655969|NCT00995293|DRUG|CISPLATIN|Intravenous
223655970|NCT00995293|DRUG|5-FLUOROURACIL|Intravenous
223655971|NCT00551278|DEVICE|GeneSearch™ Breast Lymph Node (BLN) Assay|"For in vitro diagnostic use only.~The GeneSearch™ Breast Lymph Node (BLN) Assay is a qualitative, in vitro diagnostic test for the rapid detection of greater than 0.2 mm metastases in nodal tissue removed from sentinel lymph node biopsies of breast cancer patients. Results from the assay can be used to guide the intra-operative or post-operative decision to remove additional lymph nodes.~Post-operative histological evaluation of permanent sections of the tissue specimen, in accordance with usual diagnostic practice and using the Veridex lymph node cutting scheme, is required."
223655972|NCT03859583|DIETARY_SUPPLEMENT|Capsaicin|4 tsp of cayenne in a breakfast omelette
223655973|NCT03859583|DIETARY_SUPPLEMENT|Control|breakfast omelette without cayenne pepper
224239163|NCT04512768|BEHAVIORAL|Transdiagnostic Internet-delivered Cognitive Behaviour Therapy|All participants receive an 8-week transdiagnostic course for anxiety and depression called The Wellbeing Course, originally developed by Macquarie University, Australia. The course is comprised of 5 lessons, beginning with psychoeducation and an introduction to the cognitive behavioural model, and then introducing key skills for managing anxiety and depression, including thought challenging, de-arousal strategies, graded exposure, behavioural activation, and relapse prevention. The course also includes supplementary resources that briefly provide information on related common concerns, such as managing worry, communication, assertiveness, problem solving, and a brief resource on sleep that provides limited psychoeducation and sleep hygiene information. Participants receive weekly brief therapist support via secure message or telephone from qualified counselors (social workers, psychologists).
223655974|NCT00772317|DEVICE|High Intensity Focused Ultrasound|High Intensity Focused Ultrasound
223655975|NCT01374230|PROCEDURE|Total knee arthroplasty|Primary total knee arthroplasty surgery for the treatment of osteoarthritis.
223655976|NCT05669261|PROCEDURE|Adipose Tissue Harvest|"Local Anesthesia will be administered. A Stab wound will be created at the harvest site through which a 3.0 or 2.5 mm cannula will be inserted to suction fat using the syringe (i.e. manual) technique. A total of 100 cc of lipoaspirate will be collected by manual draw of the adipose tissue into syringes."
223655977|NCT05669261|BIOLOGICAL|ATCell|Infusion of the study medication at the rate of 575 mL/HR (500ml of LRD5 plus 75ml of ATCell suspended in LRD5) and continue until all received trial medication has been delivered.
223655978|NCT00333762|DEVICE|Smart Power Assistance Module (SPAM)|Experimental Power wheelchair utilized to traverse prescribed course
223655979|NCT00333762|DEVICE|Smart Wheelchair Component System (SWCS)|Experimental power wheelchair utilized to traverse prescribed course
223655980|NCT05346666|DRUG|Tocilizumab Prefilled Syringe [Actemra]. propofole, phenobarbital, midazolam|Tocilizumab is an immuno-modulatory drug which act as interleukin (IL)-6 receptor inhibitor that blocks IL-6-mediated signal transduction. This drug is known to improve various diseases
223655981|NCT06241391|DIAGNOSTIC_TEST|PSMA PET-CT|Prostate Specific Membrane Antigen PET-CT
223655982|NCT04140578|DRUG|Ertapenem|inject from iv drip before endoscopic cyanoacrylateinjection obliteration
223655983|NCT01022528|DRUG|Dexamethasone (0.1 mg/kg)|
223655984|NCT01022528|DRUG|Dexamethasone (0.2 mg/kg)|
223655985|NCT01022528|OTHER|Saline|
223655986|NCT03690752|DEVICE|unweighting using Alter-G Anti-Gravity Treadmill|The unweighted group (experimental) is allowed to self-select a comfortable unweighting using the weight control feature on the Alter-G Anti-Gravity Treadmill. Both groups use the same Alter-G Anti-Gravity Treadmill and both groups are about to self-select speed, incline, and duration.
223655987|NCT03690752|DEVICE|normal weight using Alter-G Anti-Gravity Treadmill|The weighted (control) group will walk at 100% their body weight using the Alter-G Anti-Gravity Treadmill. Both groups use the same Alter-G Anti-Gravity Treadmill and both groups are about to self-select speed, incline, and duration.
223655988|NCT05453669|BIOLOGICAL|CD19-CAR-DNT cells|Lentiviral vector-transducted DNT cells to express anti-CD19 CAR. Prior to cellular infusion, each patient received cyclophosphamide and fludarabine lymphodepleting chemotherapy.
223655989|NCT02089893|DEVICE|Fundus photography|Non-mydriatic fundus photographs
223655990|NCT02583737|PROCEDURE|freeze bone allograft|sinus lifting filling procedure employing freeze bone allograft from tissue bone bank.
223655991|NCT02583737|PROCEDURE|lyophilized bone allograft|sinus lifting filling procedure employing lyophilized bone allograft from tissue bone bank.
223655992|NCT00351052|DRUG|Pimecrolimus|Pimecroliums cream 1 % bid.
223655993|NCT00351052|DRUG|Placebo|Vehicle control (placebo) bid.
223655994|NCT00808080|BIOLOGICAL|AMLCTL|Ex-vivo expanded cytotoxic autologous AML-reactive T cells (CTL)
223655995|NCT01847326|DRUG|carboplatin|Given IV
223655996|NCT01847326|DRUG|paclitaxel albumin-stabilized nanoparticle formulation|Given IV
223655997|NCT01847326|DRUG|fluorouracil|Given IV
223655998|NCT01847326|DRUG|hydroxyurea|Given PO
223655999|NCT01847326|PROCEDURE|therapeutic conventional surgery|Undergo surgical resection
223656000|NCT01847326|RADIATION|radiation therapy|Undergo radiation therapy
223656001|NCT01847326|RADIATION|hyperfractionated radiation therapy|Undergo hyperfractionated radiation therapy
223656002|NCT01847326|OTHER|laboratory biomarker analysis|Correlative studies
223656003|NCT05545540|OTHER|Musical Neurostimulation|Daily exposure to musical composition found to have antiseizure properties
223656004|NCT05545540|OTHER|Placebo Musical Neurostimuloation|Daily exposure to musical composition found NOT to have antiseizure properties
223656005|NCT02935439|OTHER|Cell Phone|Participants responded to questions about their heart failure symptoms using a cell phone.
223656006|NCT05844488|DEVICE|PrecivityAD|Measure risk for amyloid plaques in the brain and will include a test for certain genetic variants (specifically, ApoE proteins in the blood revealing APOE genotype) known to be associated with Alzheimer's disease.
223656007|NCT00423917|BIOLOGICAL|bevacizumab|
223656008|NCT00423917|DRUG|fulvestrant|
223656009|NCT05555420|DEVICE|SRP+Laser|Non-surgical periodontal therapy in combination with Laser
223656010|NCT03085797|DRUG|Mepolizumab|Mepolizumab injection 100 mg/millilitre (mL) is a clear to opalescent, colorless to pale yellow to pale brown sterile solution for SC injection in a single-use, safety syringe.
223656011|NCT03085797|DRUG|Placebo|Placebo is a clear to opalescent, colorless sterile solution for SC injection in a single-use, safety syringe.
223656012|NCT03085797|DRUG|Mometasone furoate|All participants will receive mometasone furoate usually 400 micrograms (mcg), 2 actuations (50 mcg/actuation) in each nostril twice daily. Intolerant participants will use 200g (2 actuations \[50 g/actuation\] in each nostril once daily).
223656013|NCT01474252|DRUG|RSI|"All medications are administered only one dose before intubation~Anesthetics:~Propofol 2-2.5 mg/kg Thiopental 3-5mg/kg Etomidate 1-2mg/kg~Neuromuscular blocking agents:~Succinylcholine 1-1.5mg/kg Rocuronium 0.9mg/kg~Opioid:~Fentanyl 1-2ug/kg"
223656014|NCT00865540|DRUG|prednisolone acetate 1%|1 drop every 8h two days before surgery
223656015|NCT00865540|DRUG|ketorolac tromethamine 0.4%|1 drop every 8h two days before surgery
223656016|NCT00865540|DRUG|nepafenac 0.1%|1 drop every 8h two days before surgery
223656017|NCT00865540|DRUG|methylcellulose 0.5%|1 drop every 8h two days before surgery
223656018|NCT01837823|DRUG|rosuvastatin|All subjects will receive rosuvastatin 40mg/day for 8-12 weeks
223656019|NCT03128125|OTHER|clinical examination in neurology|This examination is based on the movement of the child in a standing position (forward and backward on a straight line, jumping on a foot ...), seated (visual continuation ...) and elongated (tone, patellar and achillian reflexes, superficial sensitivity ...) . This makes it possible to evaluate all the neurological systems.
223656020|NCT03128125|OTHER|neuropsychological examination|This examination is based on the use of standardized psychometric tools and validated with children, usually used in clinical practice.
223656021|NCT03128125|OTHER|anamnestic elements|Several elements will be collected during the clinical interview to inform the history of the child's development, such as neonatal data (term of pregnancy, APGAR score ...), age of appearance of the first words , seating, walking, possible care, level of education ans level of education of the parents.
223656022|NCT05062499|DEVICE|Active TENS|electrical stimulation
223656023|NCT05062499|DEVICE|Sham TENS|no stimulation
223656024|NCT01873534|DRUG|FMX-8|FMX-8 is a fusion protein of the human hemojuvelin (HJV) protein.
223656025|NCT00792493|DRUG|ORM-12741|Alternating panel multiple dose escalation
223656026|NCT03929380|OTHER|Squat protocol|60% of 1RM weight for 100 squat reps
223656027|NCT03548181|BEHAVIORAL|Virtual Autonomous Physiotherapist Agent (VAPA)|A Virtual Autonomous Physiotherapist Agent is going to gide and motivate the patient to train physically at home.
223656028|NCT00927004|DRUG|Etoricoxib (Arcoxia)|60 mg, daily dose, oral delivery, 14 days duration
223656029|NCT00927004|DRUG|Sugar pill|Daily dose (1 pill), oral delivery, 14 days
223768239|NCT04326478|DRUG|Azithromycin|Enrolled children in the intervention arm of this study will receive a single weight-based dose of azithromycin (20 mg/kg, to a maximum dose of 1 gram) administered by a trained study nurse within 12 hours of a member of their household testing positive for cholera.
223768240|NCT04326478|BIOLOGICAL|Placebo|Enrolled children in the placebo arm of this study will receive a single dose of non-antibiotic placebo administered by a trained study nurse within 12 hours of a member of their household testing positive for cholera.
224321014|NCT05592392|DEVICE|Synchronized Diaphragmatic Stimulation|Implantable Pulse Generator system providing cardiac-gaited stimulation of the diaphragm and thereby influence cardiovascular properties relevant in heart failure.
224321016|NCT04942093|DIETARY_SUPPLEMENT|With low-calorie, high-protein diet|A low-calorie, high-protein diet will be prescribed to the patient for a period of 4 weeks. The diet will be done the 4 weeks before the bariatric surgery
224321017|NCT04942093|DIETARY_SUPPLEMENT|Without low-calorie, high-protein diet|A low-calorie, high-protein diet will not be prescribed to the patient for a period of 4 weeks.
223656030|NCT03848182|DRUG|Gemcitabine|Gemcitabine will be administered on days 1, 8, 15 every 28 days
223656031|NCT03848182|BIOLOGICAL|TT vaccine booster|One human TT childhood vaccine booster will be administered on day 8
223656032|NCT01697514|DRUG|LY2940680|Capsule administered orally.
223656033|NCT01697514|DRUG|LY2940680|Powder administered orally (may be sprinkled on soft food).
223656034|NCT01132781|DRUG|Theophylline (Intervention Group)|200 mg twice daily of slow release theophylline
223656035|NCT01132781|DRUG|Placebo (Placebo Group)|200 mg twice daily of placebo drug
223656036|NCT02686723|OTHER|Clinical and biomechanical evaluations|Clinical evaluation : demographics, clinic and functional testing. Biomechanical evaluation : isokinetic, motion analysis of 2 specific motion (drop vertical jump and cutting task) and anterior tibial translation with GnRB
223656037|NCT02936648|OTHER|quality improvement intervention|The intervention activities included: assessment, planning, stakeholder engagement, education, ongoing process monitoring, program adaptation, problem identification and problem solving, data audit/feedback, program marketing, network development, among others.
223656038|NCT00004554|DRUG|naltrexone (Revia)|100mg/day
223656039|NCT00004554|DRUG|sertraline (Zoloft)|200mg/day
223656040|NCT00004554|DRUG|Placebo|Placebo
223656041|NCT00306826|DRUG|pioglitazone|
223656042|NCT00306826|DRUG|simvastatin|
223656043|NCT00306826|DRUG|pioglitazone + simvastatin|
223656044|NCT03479164|OTHER|Ultra Low-Dose CT|Ultra Low-Dose CT
223656045|NCT01934595|DIETARY_SUPPLEMENT|Beneprotein|The study will compare different protein supplementation amounts to determine if increased protein supplementation in critically ill patients improves outcomes.
223768241|NCT00811564|DRUG|fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% ophthalmic solution|1 drop of study medication taken approximately 12 hours apart, dosed 2 times a day
223768242|NCT00811564|DRUG|latanoprost 0.005%|1 drop of study medication taken once daily
223768243|NCT05701137|OTHER|EMDR-RTE|The experimental group will have EMDR recent traumatic event.
223768244|NCT05701137|OTHER|TAU|The comparator group will have usual psychological intervention.
224321018|NCT06550713|DRUG|TQB3455 tablet+Azacitidine for Injection|TQB3455 is a selective IDH2 mutant enzyme inhibitor. Azacitidine for injection is a cytosine nucleoside drug that is used for demethylation therapy.
223656046|NCT05592587|BEHAVIORAL|Evaluation of the effectiveness of eye massage device producing both vibrations and nature sounds distraction in the management of anxious pediatric patients during inferior alveolar nerve.|"The child will be provided inferior alveolar nerve during eye massage device producing both vibrations and nature sounds. Children will be assessed by using a combination of measures: Wong-Baker faces and the Children's Fear Scale (self-report), heart pulse rate and blood pressure (physiological), and behavior (using Anxiety levels using Face - Legs - Activity - Cry - Consolability FLACC scale external evaluator). Acceptance will be measured using a two-point Likert scale"
223656047|NCT05592587|BEHAVIORAL|Evaluation of the effectiveness of eye massage device producing vibratory stimulations distraction in the management of anxious pediatric patients during inferior alveolar nerve.|"The child will be provided inferior alveolar nerve during eye massage device producing vibratory stimulations. Children will be assessed by using a combination of measures: Wong-Baker faces and the Children's Fear Scale (self-report), heart pulse rate and blood pressure (physiological), and behavior (using Anxiety levels using Face - Legs - Activity - Cry - Consolability FLACC scale external evaluator). Acceptance will be measured using a two-point Likert scale"
223656048|NCT05592587|BEHAVIORAL|Evaluation of the effectiveness of basic behavior guidance techniques without using any type of distraction aids in the management of anxious pediatric patients during inferior alveolar nerve.|"The child will be provided inferior alveolar nerve during eye massage device producing vibratory stimulations. Children will be assessed by using a combination of measures: Wong-Baker faces and the Children's Fear Scale (self-report), heart pulse rate and blood pressure (physiological), and behavior (using Anxiety levels using Face - Legs - Activity - Cry - Consolability FLACC scale external evaluator). Acceptance will be measured using a two-point Likert scale"
223656049|NCT04765267|DIETARY_SUPPLEMENT|Zinc sulphate heptahydrate|Dietary supplements
223656050|NCT03213171|BEHAVIORAL|Reception staff providing handout.|Reception staff will provide an educational pamphlet to patients that have not yet registered for organ donation
223656051|NCT03213171|BEHAVIORAL|Mobile Tablet (e.g. iPad)|Patients will have the opportunity to immediately register for organ donation using an a mobile tablet (e.g. IPad)
223656052|NCT02914301|DEVICE|Babyscripts Prenatal App|The use of a mobile digital app to facilitate certain aspects of standard prenatal care.
223656053|NCT02914301|DEVICE|Placebo|No Mobile App, Usual care
223656054|NCT00549068|DRUG|Risedronate Sodium (Actonel)|
223656055|NCT06392399|DEVICE|cooled radiofrequency ,|In Cooled RF, after placement of the introducer needle, the 18 gauge internally cooled RF electrode is used for 90 seconds at a temperature of 60°C.
223768245|NCT03969212|DRUG|Baloxavir Marboxil|IPs less than 12 years old will receive either 2 mg/kg (if weight less than 20 kg) or 40 mg (if weight more than or equal to 20 kg) of Baloxavir Marboxil as oral suspension. IPs more than or equal to 12 years old will receive either 40 mg (if weight less than 80 kg) or 80 mg (if weight more than or equal to 80 kg) of Baloxavir Marboxil as tablets. HHCs of IPs will not receive study medication.
223768246|NCT03969212|DRUG|Placebo|IPs less than 12 years old will receive placebo oral suspension and those above 12 years will receive placebo tablets. HHCs of IPs will not receive study medication.
223768247|NCT05924035|DEVICE|HBOT|HBOT treatment on a multiplace chamber (OXYHeal Hyperbaric Oxygen Chamber), 100% oxygen at 2.0 atmospheres for 90 minutes - on 4 consecutive days within 3 hours of completion of exercise training (as soon as practically possible). This will occur during week 2 of data collection.
224321019|NCT00122759|DRUG|ketamine|
223768248|NCT04457674|BEHAVIORAL|Cognitive Behavioral Therapy for insomnia (CBTi)|CBTi consists of six weekly sessions of individual therapy with a trained therapist, delivered via telemedicine.
224321020|NCT01940991|DRUG|Placebo|Placebo, Dose B; dose applied to the lateral canthal lines
223656056|NCT06392399|DEVICE|conventional radiofrequency|In conventional RF group lesion will be performed at 80°C for 120 seconds.
223656057|NCT06392399|DEVICE|neurolysis of ganglion|In neurolytic block, Once the position of the needle tip confirmed, 4 - 6 mL of 8% phenol in saline will be injected followed by 1 mL of saline to avoid the deposition of phenol within the intervertebral disc material.
223656058|NCT05067699|DIAGNOSTIC_TEST|Human 25-Hydroxyvitamin D3 (HVD3) ELISA Kit (96 well)|The serum will be tested by a double-antibody sandwich enzyme-linked immunosorbent assay (ELISA) to assay the level of Human 25Dihydroxy vitamin D（25-OH-D).
223656059|NCT04192383|RADIATION|Cyberknife stereotactic radiosurgery|Hypofractionated stereotactic radiosurgery
223656060|NCT04981535|DEVICE|Head box during upper gastrointestinal endoscopy|"็Head box is an acrylic box over a patient's head who undergoing upper gastrointestinal endoscopy."
223656061|NCT00126334|PROCEDURE|Packed Red Blood Cell Transfusion|transfusion of 1 unit of PRBCs
223768249|NCT04457674|BEHAVIORAL|Sleep Hygiene Education (SHE)|SHE participants receive six weekly sessions of individual therapy with a trained therapist, delivered via telemedicine.
223768250|NCT01451346|DIETARY_SUPPLEMENT|B. Infantis 35624|One sachet daily for 12 weeks
223768251|NCT05000996|PROCEDURE|Bariatric Surgery|Roux-en-Y gastric bypass (RYGB) and vertical sleeve gastrectomy (VSG)
223768252|NCT04833166|DEVICE|CMAC D-blade videolaryngoscope with full or partial glottic view|Deliberate achieving full or partial glottic view on C MAC D-blade video laryngoscope and comparing time and ease of intubation with both arms
223768253|NCT02003625|DRUG|GCSF|
223768254|NCT02003625|DRUG|meloxicam|
224321021|NCT01940991|DRUG|Botulinum Toxin Type A|Botulinum Toxin Type A, Dose A, dose applied to the lateral canthal lines
224321022|NCT04269525|BIOLOGICAL|UC-MSCs|After enrollment, each subject will receive UC-MSCs infusion intravenously on day 1, day 3, day 5, and day 7.
224321023|NCT00610246|DRUG|Sorafenib|Sorafenib orally for one week prior to radiation, then concomitantly for two weeks with radiation and then for one week following completion of radiation. Each anatomic cohort will dose escalate independently. Dose level 1 is 200mg of sorafenib. If full oral dose (400mg orally, twice a day) is reached in a given cohort then an additional dose level will open where sorafenib treatment is extended following radiation for a total of eight weeks.
224321024|NCT01236443|DRUG|HPPH|3 mg/m2 IV
224321025|NCT05021432|OTHER|Virtual reality training group|This group will receive video based games
224239164|NCT04512768|BEHAVIORAL|Brief Internet-Delivered Cognitive Behaviour Therapy for Insomnia|A new sleep lesson will replace the existing resource, developed using a patient-oriented process, that provides information and skills to aid with insomnia. The sleep lesson includes psychoeducation on the nature of sleep problems and factors that affect sleep, such as circadian rhythm. Two key behavioural strategies are introduced: sleep restriction, which requires the patient to avoid napping and sleep on a strict schedule for several weeks until they begin to feel naturally sleepy at night; and stimulus control, which asks the participant to only spend time in bed when prepared to sleep and avoid other activities (e.g., work, TV) in bed. Patients will record how much they sleep each night and provide ratings of sleep quality and fatigue each week. Therapists will support patients in adjusting their sleep schedule. Patients are encouraged to apply skills they learn during the Wellbeing Course to sleep problems, for example, by applying thought challenging to beliefs about sleep.
223656062|NCT05941195|OTHER|Psychoeducation|"In the cognitive behavioral approach based psychoeducation given to the experimental group patients; Addiction and Its Effects, Increasing and Maintaining Motivation, The Cognitive Model and the Cognitive Model of Addiction, Automatic Thoughts That Increase Impulse to Substance Use, Dysfunctional Beliefs Regarding Substance Use, High Risk Situations and Coping Skills,  The topics of Prevention of Slippage and Recurrence and Problem Solving are included."
224239165|NCT06379009|OTHER|Training|12 week home-based training program
224239166|NCT03385746|OTHER|polyamide|metal reinforced polyamide denture base material
224239167|NCT03385746|OTHER|heat cured acrylic resin|conventional heat cured acrylic resin denture base material
224239168|NCT04538040|DRUG|Bictegravir/emtricitabine/tenofovir alafenamide + Doravirine switch|Safety and efficacy of switching from rilpivirine/emtricitabine/tenofovir alafenamide in combination with dolutegravir, to bictegravir/emtricitabine/tenofovir alafenamide in combination with doravirine in male, 45+ year old subjects. The study will also include secondary outcomes of quality of life (QOL) and weight changes.
224239169|NCT01624766|BIOLOGICAL|Anakinra|Given SC
224239170|NCT01624766|BIOLOGICAL|Denosumab|Given SC
224239171|NCT01624766|DRUG|Everolimus|Given PO
224239172|NCT05150236|DRUG|177Lu-PSMA-617|Patients will be given 7.5GBq of Lu-PSMA every 6 weeks up to 6 cycles unless there is unacceptable toxicity, commencing following result of 68Ga-PSMA PET within 28 days of registration.
223656063|NCT03870243|DEVICE|Bubble CPAP|To see the effectiveness of Bubble Continuous Positive Airway Pressure (bCPAP) in children with severe pneumonia
223656064|NCT03870243|DEVICE|Low flow oxygen|To see the effectiveness of low flow oxygen in children with severe pneumonia
223656065|NCT01782248|OTHER|Questionnary and IRM|
223656066|NCT02165267|BIOLOGICAL|VRC01|Administered IV in 100 mL of normal saline (Sodium Chloride for Injection 0.9%, USP) or administered SC by needle and syringe injection.
223656067|NCT02165267|BIOLOGICAL|SC placebo for VRC01|Sterile, buffered aqueous solution of 25 mM Sodium Citrate, 50 mM Sodium Chloride, 150 mM L-Arginine Hydrochloride, 10% Dextran 40, and 0.005% Polysorbate 80 at pH 5.8 administered SC by needle and syringe injection
223656068|NCT02165267|BIOLOGICAL|IV placebo for VRC01|Sodium Chloride for Injection 0.9%, USP administered IV in 100 mL of normal saline (Sodium Chloride for Injection 0.9%, USP)
223656069|NCT03504176|OTHER|Ventilation bundle|ventilation targets (pH, spO2, pCO2) tidal volume 3-6ml/kg peak pressures \<28-32cmH2O PEEP-FiO2 titration tables
223656070|NCT05751018|DRUG|Pyrotinib|Pyrotinib maleate is a small molecule tyrosine kinase inhibitor that can irreversibly inhibit HER1, HER2, and HER4.
223656071|NCT02137915|BIOLOGICAL|Human Central Nervous System Stem Cells|
223656072|NCT02088138|DEVICE|Functional Electrical Stimulation|Functional electrical stimulation twice per week for eight weeks totaling sixteen sessions.
223656073|NCT02088138|DEVICE|Functional Electrical Stimulation placebo|Functional electrical stimulation in the sensory threshold level, twice a week for eight weeks, totaling sixteen sessions.
223656074|NCT03777748|DEVICE|dental implants and stud attachments|
223656075|NCT01576900|BEHAVIORAL|SyBeMeP (Systemized Behavioural Modification education Program)|"* Standard video material will be developed to minimize variation of outcomes caused by differences in contents at each trial site.~* Video material will be self-study program for PC with running time around 20 minutes. Contents will cover pathophysiology, diagnosis and treatment process, and be easy to understand for everyone with variety of examples. In treatment part, it will describe general principles of behavioural therapy (Adjustment of timing of fluid intake, Reducing alcohol and caffeine, Improving sleep hygiene including moderate exercise, room temperature, noise and lighting. if necessary, compressive stocking, late afternoon nap and leg elevation would be added)~* During trial, patients will watch SYBeMeP at a specially prepared separate room with computer.~* After watching the video, check-list on take-home message will be recorded by patients at the site to confirm patients' awareness after education."
223656076|NCT03622918|DRUG|colistin and rifampin combination therapy|Colistin (100 mg, colistin sodium methanesulfonate, SCD Pharm., Seoul, Korea) will be intravenously administered with 100 mL of normal saline with 8 hours interval. Rifampin (600 mg, rifampin, Yuhan, Seoul, Korea) will be orally administered daily. Treatment should be maintained daily administration for at least 7 days and up to 28 days. Duration of antibiotics treatment will be determined through discussion by pulmonology and infection specialist.
223768255|NCT02003625|DRUG|Placebo|
224239173|NCT05150236|DRUG|Ipilimumab|Patients will be given 3mg/kg of Ipilimumab every 6 weeks up to 4 doses unless there is unacceptable toxicity, concurrently with Lu-PSMA and Nivolumab.
224239174|NCT05150236|DRUG|Nivolumab|Patients will be given 1mg/kg of Nivolumab every 3 weeks up to 8 doses, concurrently with Lu-PSMA and Ipilimumab unless there is unacceptable toxicity. Followed by 480mg nivolumab monotherapy commencing at week 32. Nivolumab monotherapy will be given to patients every 4 weeks up to 18 doses, or until disease progression or unacceptable toxicity.
224239175|NCT03541681|PROCEDURE|Glucocorticoid Injections|1 ml Dexamethasone + 0,5 ml Bupivacain
224239176|NCT03541681|PROCEDURE|Anesthetic Injections|0,5 ml Bupivacain
224239177|NCT04757415|OTHER|Traction straight leg raise technique for hamstring|traction straight leg raise technique is used along with gluteal exercises
224239178|NCT04757415|OTHER|Gluteal activation exercises,Hotpack|only gluteal activation exercises were performed without traction straight leg raise technique
224239179|NCT02161874|DEVICE|T3 with DCD tapered Prevail implant|T3 with DCD implant with Certain (internal) connection and platform-switch design
224239180|NCT02161874|DEVICE|Nanotite Certain tapered implant|Nanotite (DCD) implant with Certain (internal) connection and non- platform-switch design
224239181|NCT01968382|DRUG|IMM 124-E (Hyperimmune Bovine Colostrum)|Hyper-immune bovine colostrum enriched with anti-LPS antibodies and which has been designated by Immuron as IMM-124E.
223656077|NCT03622918|DRUG|colistin monotherapy|. Colistin (100 mg, colistin sodium methanesulfonate, SCD Pharm., Seoul, Korea) will be intravenously administered with 100 mL of normal saline with 8 hours interval. Treatment should be maintained daily administration for at least 7 days and up to 28 days. Duration of antibiotics treatment wil be determined through discussion by pulmonology and infection specialist .
223656078|NCT01757353|BEHAVIORAL|BASICS motivational interview|
223656079|NCT01757353|BEHAVIORAL|BASICS plus normative enhancement motivational interview|
223656080|NCT01757353|BEHAVIORAL|Self-directed: Information only|
223656081|NCT05202340|OTHER|No intervention|No intervention
223656082|NCT01923272|DEVICE|AlphaCore Device|Active stimulation to the vagal nerve
223768256|NCT01140425|DRUG|PF-00232798|600 mg oral solution once daily x 7 days
223768257|NCT01140425|DRUG|PF-00232798|300 mg oral solution once daily x 7 days
223768258|NCT01140425|DRUG|Placebo|Oral solution once daily x 7 days
223768259|NCT01140425|DRUG|Moxifloxacin|400 mg tablet single dose
223768260|NCT00280566|DRUG|Placebo|Oral capsule formulation: Patients will be treated initially with open-label ziprasidone in the range of 40-80 mg BID (twice a day) for at least 10 weeks and up to 16 weeks. Patients who achieve a stable treatment regimen and whose symptoms stabilize for 8 consecutive weeks by Week 16 (Week 10 at the earliest) will be randomized. Patients randomized to placebo will be tapered off the open-label ziprasidone by 20 mg BID every 2 days (in a double-blinded manner) until they are completely off ziprasidone and are on matching placebo capsules for up to 24 weeks of double-blind treatment.
223768261|NCT00280566|DRUG|Ziprasidone Oral Capsule|Oral capsule formulation: Patients will be treated initially with open-label ziprasidone in the range of 40-80 mg BID for at least 10 weeks and up to 16 weeks. Patients who achieve a stable treatment regimen and whose symptoms stabilize for 8 consecutive weeks by Week 16 (Week 10 at the earliest) will be randomized. Patients randomized to ziprasidone will continue to receive the same stable treatment regimen achieved during the open-label treatment, ie, either 40 mg BID, 60 mg BID or 80 mg BID for up to 24 weeks of double-blind treatment.
223768262|NCT01147653|BIOLOGICAL|Autologous UCB Reinfusion|Autologous umbilical cord blood (UCB) reinfusion
223768263|NCT01147653|OTHER|Placebo|Placebo
223768264|NCT05138939|OTHER|Red wine A|8 oz (237 ml) of red wine A and red wine B will be blinded and randomized between Japanese Zweigelt red wines from vintages 2015 or 2018.
223768265|NCT05138939|OTHER|Red wine B|8 oz (237 ml) of red wine A and red wine B will be blinded and randomized between Japanese Zweigelt red wines from vintages 2015 or 2018.
223768266|NCT05138939|OTHER|Control|8 oz (237 ml) of control beverage is a beverage that has similar calories to red wines.
223768267|NCT03967470|BIOLOGICAL|Bacterial spray|Bacterial spray containing bacteria that do not cause underarm malodor
224239182|NCT01968382|DRUG|Placebo (High protein milk powder)|Subjects will receive a total of 4 sachets (2 in the morning and 2 in the evening) daily
224321026|NCT05021432|OTHER|Circuit Training group|They will receive Task-oriented Circuit training exercise program
224321027|NCT03814603|PROCEDURE|PET-MR Scan|Participants will undergo PET-MR scans at baseline and two-year follow up to examine brain amyloid deposition longitudinally.
224321028|NCT03814603|DRUG|PiB|Subjects will receive a single dose of 555 MBq of PiB and perform a dynamic 30 min PiB PET-MR scan 60 min after injection.
223656083|NCT01923272|DEVICE|AlphaCore|Active AlphaCore treatment
223656084|NCT05106699|RADIATION|proton plus carbon ion radiation|All patients received whole pelvis and prostate region proton irradiation of 46 GyE in 23 fractionsfollowed by localized carbon ion irradiation of 32GyE in 8 fractions to the prostate region. The dose to metastatic LN was escalated using simultaneous integrated boost (SIB) technique. The dose was 60-62.1GyE in 23 fractions as much as dose constraints. All patients will be recommened receive 2-3 years endocrine therapy.
223656085|NCT04078646|OTHER|Intervention with soy protein isolate|"Test meals will be served to the subjects, containing soy protein isolate:~350 mL carrot/tomato juice (50:50, v/v), with 30 g added soy protein, plus 5 ml peanut oil~as morning test meal, served together with 40 g toasted bread and 20 g of cream-cheese plus 10 g margarine."
223656086|NCT04078646|OTHER|Intervention with whey protein|"Test meals will be served to the subjects, containing soy protein isolate:~350 mL carrot/tomato juice (50:50, v/v), with 30 g added whey protein isolate, plus 5 ml peanut oil~as morning test meal, served together with 40 g toasted bread and 20 g of cream-cheese plus 10 g margarine."
223768268|NCT03467269|DIAGNOSTIC_TEST|Brush sign|presence of a brush sign in MRI image in acute cerebral ischaemia
223768269|NCT00353366|BIOLOGICAL|Rotarix|Two doses of the oral vaccine
224239183|NCT04018261|DRUG|Activated T-Lymphocytes|Activated T-Lymphocytes will be infused intravenously in a single-dose
224239184|NCT01376128|DRUG|Paroxetine|
224239185|NCT04089683|OTHER|Swab stick|Swab sticks collected from Web Spaces, Scrub, Anterior Nares
224239186|NCT01004172|DRUG|carboplatin|
224239187|NCT01004172|DRUG|bevacizumab|
224239188|NCT01004172|DRUG|herceptin|
224239189|NCT03623048|OTHER|chlorhexidine|antibacterial and anti-inflammatory mouthwash
224239190|NCT03623048|OTHER|saline|anti-inflammatory cleansing mouthwash
224239191|NCT03623048|OTHER|Propolis extract|antibacterial mouthwash
224239192|NCT03623048|OTHER|pomegranate extract|antibacterial mouthwash
224239193|NCT06249399|OTHER|Aerobic Exercise|Aerobic Exercise training will be provided three days a week, 45 minutes a day, for 12 weeks. Patients will be subjected to submaximal aerobic exercise with rhythmic movements without equipment via video conference accompanied by a physiotherapist.
224239194|NCT06249399|BEHAVIORAL|Behavioral Treatment Program|Behavioral Treatment Program will be completed with an initial training period of 40 minutes, and subsequent control interviews of 20 minutes at four-week intervals.
224321029|NCT06176170|DEVICE|VividWhite Glaucoma Implant (VW-51)|Subconjunctival surgical implantation of the VW-51 implant in the study eye.
223656087|NCT04078646|OTHER|Intervention without protein addition|"Test meals will be served to the subjects, containing soy protein isolate:~350 mL carrot/tomato juice (50:50, v/v), plus 5 ml peanut oil~as morning test meal, served together with 40 g toasted bread and 20 g of cream-cheese plus 10 g margarine."
223656088|NCT00436345|DRUG|Remifentanil|analgesia in medical and post-surgical Intensive Care Unit subjects requiring mechanical ventilation
223656089|NCT00436345|DRUG|Propofol|conventional sedation in medical and post-surgical Intensive Care Unit subjects requiring mechanical
223768270|NCT00353366|OTHER|Data collection|Safety evaluation: recording of adverse events by using diary cards and by non-leading questioning.
224239195|NCT01506830|PROCEDURE|Relative isolation with cotton rolls|Cotton roll group: Moisture control was provided using a labial retractor, cotton rolls and gingival retraction cord placed into the gingival sulcus
224239196|NCT01506830|PROCEDURE|Absolute isolation with rubber dam|Rubber dam group: Moisture control was provided by a rubber dam and a gingival retraction clamp placed in the cervical area of the tooth.
224239197|NCT01904786|DRUG|Melatonin|
224239198|NCT01904786|DRUG|placebo|
224239199|NCT00913107|DRUG|Lamictal®|"The regime of prescription for Lamictal® during the clinical trials was as follows:~1. 50 mg twice daily for 10days, followed by,~2. 100 mg twice daily for the next 10days, followed by,~3. 100 mg thrice daily for the next10 days, followed by,~4. 100 mg four times daily for the final 10 days."
224239200|NCT00913107|DRUG|Tegretol®|"The regime of prescription for Tegretol® during the clinical trials was as follows:~1. 150 mg twice daily for 10days, followed by,~2. 200 mg thrice daily for the next 10days, followed by,~3. 300 mg thrice daily for the next 10 days, followed by,~4. 300 mg four times daily for the final 10 days."
224239201|NCT01107236|DRUG|IW-6118|Single dose
224239202|NCT01107236|DRUG|Matching Placebo|Single dose of matching placebo for IW-6118 and/or matching placebo for naproxen sodium
224239203|NCT01107236|DRUG|Naproxen Sodium|Single dose
224239204|NCT02471066|DEVICE|rTMS|"* Study 1 : 5 daily sessions of rTMS 1 Hz, 95% x resting motor threshold (RMT) applied on M1 / sham~* Study 2 : 3 weekly sessions of rTMS 1 Hz, 95% x RMT on M1 combined with ericksonian hypnosis session"
224239205|NCT00950872|DEVICE|Duet TRS|Patients will have their gastric pouch created with ENDO GIA staplers with Single Use Loading Units with Duet TRS.
224239206|NCT02898623|OTHER|No intervention|Evaluation of performance of immunoassays based on the detection of antibodies directed against Mycobacterium tuberculosis antigen
224239207|NCT05876195|BIOLOGICAL|Keyhole-Limpet Hemocyanin|Sub-unit Keyhole Limpet Haemocyanin (KLH, Immucothel, Biosyn, Fellbach, Germany)
224321030|NCT00963066|DEVICE|PSV - pressure suppot ventilation|Gold standard partial ventilator support: Pressure Support Ventilation performed with Servo-i® ventilator (MAQUET,Critical Care, Sweden). Different levels of pressure support ventilator assistance are tested.
224321031|NCT00963066|DEVICE|NAVA - Neurally Adjusted Ventilatory Assist|Partial ventilator support with new partial ventilation mode (NAVA) performed with Servo-i® ventilator (Maquet,Critical Care, Sweden). Different levels of neurally adjusted ventilatory assist are tested. Positive pressure, delivered by the machine, is driven using inspiratory flow trigger.
223656090|NCT03609606|DRUG|D013, D326 and D337|Daily oral administration of 1 tablet for each drug under fasting conditions for 7 days
223656091|NCT03609606|DRUG|D013|Daily oral administration of 1 tablet under fasting conditions for 7 days
223656092|NCT03609606|DRUG|D326 and D337|Daily oral administration of 1 tablet for each drug under fasting conditions for 7 days
223656093|NCT05358613|BEHAVIORAL|My Choices|"The My Choices program is an harm reduction program to modify substance use habits. It is based on the Miller \& Rollnick Motivational interviewing as well as Deci and Ryan's Self-determination theory and Bandura's social learning theory.~It is presented as a guide, divided in 6 phases. In every phase, participants will find, in the guide, some auto-observation exercises about their alcohol use habits and other aspects about their quality of life, reflexions and information about alcohol. The participants are also invited to note the number of standard units of alcohol they use on every occasion."
223768271|NCT02690961|DRUG|Kukoamine B Mesilate|Kukoamine B Mesilate or placebo single-dose and intravenous(IV) drip for 1 hour in healthy volunteers.
223768272|NCT02690961|DRUG|placebo multiple doses|
223768273|NCT03302481|OTHER|liver biopsy|the biopsies will be performed under laparoscopy and taken in the lower part of the right hepatic lobe
223768274|NCT02617316|OTHER|Barefoot|barefoot running test was 20 minutes.
223768275|NCT02617316|OTHER|In shoes|In shoes test was 20 minutes.
224239208|NCT05876195|DRUG|Saline|Placebo intervention.
224239209|NCT05876195|DRUG|Montanide ISA 51 VG|Montanide ISA-51 (Seppic, France) is a water-in-oil vaccine adjuvant
224239210|NCT05876195|DRUG|Alhydrogel|Alhydrogel is a vaccine adjuvant
224239211|NCT03874130|DRUG|Scopolamine|IV Scopolamine
224239212|NCT01139164|DRUG|Regimen A|Chronic Lymphocytic Leukemia/ Chronic Prolymphocytic Leukemia, Multiple Myeloma.
224239213|NCT01139164|DRUG|Regimen B|Other malignancies not addressed in A or C
224239214|NCT01139164|DRUG|Regimen C|B-Cell Lymphomas
224239215|NCT02003183|RADIATION|[F-18]FDDNP|Each participant was injected with \[F-18\]FDDNP, a radiolabeled molecular imaging probe, prior to receiving a PET scan.
224239216|NCT02187978|OTHER|Early total enteral feeding (ETEF)|In ETEF Group total required volume of fluid will be administered as oral feeds and no intravenous fluid will be given. Feeds will be started at 80 mL/kg and increased till 150ml/kg is attained.
224239217|NCT02187978|OTHER|Conventional enteral feeding (CEF)|CEF Group will receive some feed and some Intravenous fluids. Feeds will be slowly increased from 20 mL/kg on day 1 till full feeds 150ml/kg is attained on day 6 of life.
224239218|NCT01933607|DEVICE|TOPS System|Non-randomized study involving implantation of a TOPS via lumbar surgery to decompress and provide stability to the index level.
224239219|NCT05256628|OTHER|Early Weightbearing|Patients randomized to undergo this study intervention will bear weight, as tolerated, on the affected side straight after surgery, with crutches for additional support and stability. They will be allowed to stop using crutches in the weeks after surgery as they feel more comfortable and stable on their surgical leg.
223656094|NCT05114642|DEVICE|Skeletal Class III Malocclusion Treatment with Face Mask Group|Expanding the maxilla, which is narrower than the mandible in the transverse dimension, using a rapid maxillary expansion device and protraction of the maxilla, which is located behind in the sagittal dimension, forward using the face-mask appliance.
223656095|NCT01067092|BEHAVIORAL|Community Health Worker Intervention|A Community Health Worker makes 36 home visits to the person with diabetes over a two year period, providing diabetes education and self-management skills training. The curriculum covers recommended diabetes self-management behaviors including glucose self-monitoring, responding to abnormal blood glucose levels, working effectively with health care providers, medication adherence, foot care, daily physical activity, and reducing fat content of diet. CHWs also deliver training in behavioral skills of self-monitoring, environmental restructuring, engagement of social support, stress management, and problem-solving skills to facilitate the self-management activities.
223656096|NCT01067092|BEHAVIORAL|Educational Newsletter|Diabetes education and self-management skills training delivered via 36 bilingual diabetes education newsletters over a 2 year period. The newsletters cover recommended diabetes self-management behaviors including glucose self-monitoring, responding to abnormal blood glucose levels, working effectively with health care providers, medication adherence, foot care, daily physical activity, and reducing fat content of diet. The newsletters also describe behavioral skills of self-monitoring, environmental restructuring, engagement of social support, stress management, and problem-solving skills to facilitate the self-management activities.
223656097|NCT00568165|PROCEDURE|Mobile team|a mobile team including a cardiologist with mobile echocardiography, systematic follow up à 3 days, a dietician advice in patients hospitalized for acute heart failure in a non cardiology ward
223656098|NCT00568165|PROCEDURE|Standard care|Standard care
223656099|NCT01175083|BIOLOGICAL|GSK1024850A (Synflorix)|2, 3 or 4 intramuscular injection
224239220|NCT05256628|OTHER|Protected Weightbearing|Patients randomized to undergo this study intervention will be instructed to be touch weightbearing for 6 weeks after surgery. They will use crutches and put no more weight on the surgical side than what it takes to crack an egg. After the 6-week mark, they will be able to bear weight.
224239221|NCT04531228|PROCEDURE|TACE-HAIC plus lenvatinib|chemo-lipiodolization with EADM (30mg/m2), followed by FOLFOX-based chemotherapy artery infusion (Oxa 85mg/m2, 5-Fu 400 mg/m2, 5-Fu 1200mg/m2). Lenvatinib was administrated two or four days after TACE-HAIC, with 8mg for patients weight \<60kg, or 12mg for patients weight more than 60Kg.
224239222|NCT03055949|BEHAVIORAL|Early rehabilitation program|The investigators evaluated patients who were admitted SICU for more than 3 days for an early rehabilitation program and delivered one of 5-stepped rehabilitation program if the patient was eligible.
224239223|NCT01581957|OTHER|Specific Enteral Nutrition|Patients will receive a Specific EN. The caloric target is 25 Kcal/kg/day to be reached on the third day post-initiation of EN (early enteral nutrition).
224239224|NCT01581957|OTHER|Standard Enteral Nutrition|Patients will receive an equivalent volume and caloric intake of standard formulation. The caloric target is 25 Kcal/kg/day to be reached on the third day post-initiation of EN (early enteral nutrition).
224239225|NCT02847806|BIOLOGICAL|Estradiol (Insulin sensitivity)|
224239226|NCT02847806|BIOLOGICAL|Testosterone (Insulin sensitivity)|
224239227|NCT02363790|PROCEDURE|LVHR PFC|Information included in arm description
223656100|NCT01175083|BIOLOGICAL|Tritanrix-HepB/Hib|Intramuscular injection, 4 doses
223656101|NCT01175083|BIOLOGICAL|Polio Sabin|4 oral doses
223656102|NCT02888678|BEHAVIORAL|Economic Strengthening (Impumelelo)|Economic Strengthening (Impumelelo): This intervention consists of 15 one-hour long sessions on financial education in combination with access to appropriate youth-friendly savings mechanisms.
223656103|NCT02888678|BEHAVIORAL|HIV Prevention Education (Vhutshilo 2.2)|HIV Prevention Education (Vhutshilo 2.2): This intervention consists of 15 one-hour long sessions that are interactive, skills focused, and cover such topics as expressing one's feelings; dealing with loss and grief; decision-making; coping; gender violence; understanding HIV and other sexually transmitted infections; healthy relationships and staying safe in sexual relationships; and contraception and risks associated with unplanned pregnancy.
223656104|NCT01623713|DRUG|iloperidone|Iloperidone is being development as a treatment of schizophrenia. This trial will verify the safety and efficacy of iloperidone in patients with schizophrenia.
223656105|NCT01623713|DRUG|Risperidone|Risperidone is used for the treatment of schizophrenia.Risperidone is unique among most other atypicals in that it has high affinity for the D2 receptor whereas most other atypicals have 'loose binding' of the D2 receptor. It has actions at several 5-HT (serotonin) receptor subtypes.
223656106|NCT03574012|DEVICE|Monitoring Device|Use Fitbit tracker
223656107|NCT03574012|OTHER|Informational Intervention|Receive individualized health and fitness information from clinician, supplemented with peer support through the study's social media platform
223656108|NCT03574012|OTHER|Informational Intervention|Receive general health and fitness information from clinician
223656109|NCT03574012|OTHER|Questionnaire Administration|Ancillary studies
224239228|NCT02363790|PROCEDURE|Bridging LVHR|Information included in arm description
224239229|NCT00417209|DRUG|Larotaxel (XRP9881)|administered as a 1-hour IV infusion on Day 1 of every 3 weeks (q3w)
224239230|NCT00417209|DRUG|5-Fluorouracil|administered as IV infusion from Day 1 to Day 4
224239231|NCT00417209|DRUG|Capecitabine|administered orally from Day 1 to Day 14 q3w
224239232|NCT01737190|OTHER|PEEP guided by Esophageal pressure + Recruitment maneuver|"Upon patient recruitment Esophageal balloon will be inserted and esophageal / pleural pressure will be measured. Thereafter, Inspiratory pressures and PEEP will be adjusted according to well established criteria. Inspiratory pressure and PEEP will be adjusted to achieve the best lung compliance possible while not exceeding transpulmonary end Inspiratory pressure of 25 to 30 cm H2O, and at the same time maintaining a positive transpulmonary end expiarory pressure of not more than 5 cm H2O.~A recruitment maneuver with application of 40 cm H2O for up to 40 seconds will be performed."
224239233|NCT01148082|PROCEDURE|Self administered Surveys|
224239234|NCT01148082|PROCEDURE|Interviews|
223656110|NCT02467686|BEHAVIORAL|WHOQOL questionnaire|WHO defines Quality of Life as individuals perception of their position in life in the context of the culture and value systems in which they live and in relation to their goals, expectations, standards and concerns.
223656111|NCT02467686|BEHAVIORAL|FSFI questionnaire|FSFI questionnaire application for evaluation of sexual function at the first visit, 3-month and 6-month follow-up.
223656112|NCT02467686|BEHAVIORAL|kupperman scale|Kupperman scale is a tool to help evaluate the severity of menopausal symptoms
223656113|NCT02467686|DRUG|Cimicifuga racemosa|The Cimicifuga racemosa effects on the sexuality of women with Breast cancer
223768276|NCT00177424|DRUG|sertraline|Subjects will initially be started on either sertraline 12.5mg/d or placebo and will receive this dose for 3 days. Subjects will then be increased to 25mg/d for 4 days, then 50mg/d for 7 days, then increased to 75mg/d. Seventy-five mg per day is the target dose for the remainder of the subject's participation in the study. The study medication will not be titrated past 75mg/d.
223768277|NCT00177424|DRUG|Placebo|matching placebo tablets
223768278|NCT00907283|DRUG|Deferiprone|15 mg/Kg/twice for 1 year
223768279|NCT04955106|DIAGNOSTIC_TEST|SEM Scanner|They will perform 2 sets of 3 measures (1 on sacrum, 1 on the right heel and 1 on the left heel)for each patients
223768280|NCT00365248|DRUG|Fibrinogen human (TachoSil)|Resection of the liver with or without segmental liver transplantation
223768281|NCT06269172|BEHAVIORAL|intereviews|"An individual's experience of their breathlessness is influenced by multiple factors including their medical condition, psychology, sociological and situational circumstances which will include ethnicity. There is currently a lack of evidence exploring the impact of ethnicity in the experience and presentation of breathlessness.~The non-medical management of breathlessness in respiratory diseases includes pulmonary rehabilitation (PR). PR is a highly evidenced exercise-based intervention to help manage breathlessness, improving health-related quality of life and improving survival. Recent audits in England and Wales showed 89% of patients attending PR were recorded as having a White British ethnicity which is in contrast to national ethnicity demographics. This may be because the cultural acceptability of PR components are not fully considered."
223768282|NCT01087424|DRUG|R mini CHOP|Prednisone 40 mg/m2 D1 D2 D3 D4 D5 Rituximab 375 mg/m2 D1 Doxorubicine 25 mg/m2 D1 Cyclophosphamide 400 mg/m2 D1 Vincristine 1 mg/m2 D1
224239235|NCT01759290|DEVICE|Absorb Bioresorbable Vascular Scaffold|Subjects receiving the Absorb Bioresorbable Vascular Scaffold
224239236|NCT04374084|OTHER|Moxibustion plus Cupping|"Moxibustion: The burning of a small, thimble sized, smoldering plug of dried leaves on the skin at an acupuncture point. Usually the plugs contain leaves of mugwort or moxa. Cupping takes the pot as a tool, uses the combustion to remove the air in the pot, causes a negative pressure, and makes it adsorb on the skin of the acupoints. UseBaixiaojiumoxibustion on each acupoint for 10-15 minutes, the temperature of moxibustion should be adjusted within patient's tolerance level. Use diameter of 5-6 cm acuum cupper to cupping on each acupoint for 5-8 minutes."
223768283|NCT00000439|DRUG|sodium valproate|subjects were randomized to sodium valproate vs placebo. Serum sodium valproate was monitored. This intervention was added on treatment as usual which was defined as being on lithium carbonate and also attending individual dual recovery counseling.
224239237|NCT03080649|DEVICE|excavated with rotary bur|One of two identified caries lesions in the patient were randomly allocated to be excavated with rotary bur
224239238|NCT03080649|DEVICE|Er:YAG laser|One of two identified caries lesions in the patient were randomly allocated to be excavated with Er:YAG laser
224239239|NCT00406848|DRUG|duloxetine hydrochloride|Placebo for 1 week (double-blind placebo lead-in), then duloxetine 30 milligrams (mg) orally once daily (QD) for 1 week, followed by duloxetine 60 mg QD orally for 11 weeks. This double-blind acute treatment phase was followed by a double-blind 12 week continuation phase during which participants either remained on 60 mg QD or were eligible for dose escalation to 120 mg QD orally based on depression symptom severity.
224239240|NCT00406848|DRUG|placebo|Placebo for 13 weeks (The first week was placebo lead-in). This double-blind acute phase was followed by a double-blind 12 week continuation phase during which participants either remained on placebo or were eligible for receiving duloxetine 60 milligrams (mg) orally once daily (QD), beginning with duloxetine 30 mg QD orally for 1 week followed by duloxetine 60 mg QD orally for the remainder of the study based on depression symptom severity.
224239241|NCT03605238|BIOLOGICAL|Corticosteroids & tanCART19/20|Twelve days of high-dose IV methylprednisolone (1000mg×3 days, 500mg×3 days, 240mg×3 days, 120mg×3 days) before anti-CD19/20 CAR T cells infusion. The dose is 1E5\~2E6 anti-CD19/20-CAR positive T cells. The cells infusion process may last for 30 min.
224239242|NCT00191932|DRUG|Duloxetine|
224239243|NCT01722448|DIETARY_SUPPLEMENT|Choline|4 capsules with 480 mg choline per day
224239244|NCT01722448|DIETARY_SUPPLEMENT|Placebo|
224239245|NCT03629249|DRUG|Placebo once daily|Placebo to QAW039 once daily (one tablet blinded placebo to QAW039 150 mg and one tablet blinded placebo to QAW039 450 mg).
224239246|NCT03629249|DRUG|QAW039 150 mg once daily|QAW039 150 mg once daily (one tablet of blinded QAW039 150 mg to be given together with one tablet blinded placebo to QAW039 450 mg)
224239247|NCT03629249|DRUG|QAW039 450 mg once daily|QAW039 450 mg once daily (one tablet of blinded QAW039 450 mg to be given together with one tablet blinded placebo to QAW039 150 mg)
224239248|NCT00847548|BEHAVIORAL|substance abuse/domestic violence treatment|This intervention is comprised of 16 sessions of cognitive behavioral therapy. 8 sessions are addressing partner violence and 8 sessions are addressing substance abuse.
224239249|NCT00847548|BEHAVIORAL|CBT addressing partner violence|This treatment is comprised of 16 sessions of cognitive behavioral therapy addressing partner violence.
223656114|NCT02467686|DRUG|tamoxifen|The Cimicifuga racemosa effects on the sexuality of women with Breast cancer using tamoxifen
223656115|NCT02467686|DRUG|exemestane|The Cimicifuga racemosa effects on the sexuality of women with Breast cancer using aromatase inhibitor.
223656116|NCT00254384|DRUG|Cisplatin|Given IV
223656117|NCT00254384|DRUG|Docetaxel|Given IV
223656118|NCT00254384|DRUG|Erlotinib|Given PO
223656119|NCT00254384|DRUG|Erlotinib Hydrochloride|Given PO
223656120|NCT00254384|OTHER|Laboratory Biomarker Analysis|Correlative studies
223656121|NCT03482960|DRUG|Hyperpolarized Xenon gas|"Hyperpolarized Xenon gas~* Hyperpolarized mixture (750ml HP 129Xe and 250ml nitrogen)~* Administration: By mouthpiece attached to a single use Tedlar bag.~* Dosage: 750 mL of the 129Xe mixture up to, but not exceeding, four doses of the 129Xe.~* Frequency: 10-minute interval between doses."
223656122|NCT03482960|DRUG|PFP|"* Inhaled PFP, a gaseous contrast agent (79% PFP; 21% O2, pre-mixed, medical grade gas)~* Administration: Full-face disposable ventilation mask and a standard Douglas Bag system.~* Dosage: Two controlled breaths of the contrast gas followed by a full breath and a 12-second breath-hold and scan for image acquisition.~* Frequency: Repeated 5 times followed by an identical five cycles with room air to ensure PFP gas wash-out has occurred."
223656123|NCT00267813|DRUG|Bupropion (Zyban)|1 tablet a day increasing to 2 tablets a day after a week
224239250|NCT05427383|DRUG|KN026/Placbo Injection|IV KN026/Placebo at 30 mg/kg on D1, Q3W
224239251|NCT05427383|DRUG|Paclitaxel Injection|IV Paclitaxel at 175 mg/m² on D1, Q3W
223656124|NCT05855148|PROCEDURE|Enlistment For Lung Transplant|All included patients are enlisted for lung transplantation
223656125|NCT04494997|OTHER|Survey Questionnaire|"This Cross sectional study uses Questionnaire with Closed ended questions. The survey form is designed using Google forms program. Survey initial question seeks CONSENT from the respondent. Survey collects data under 4 sections.~Section I: Demographic details Section II: 6 Questions regarding use of your Social Media for Professional activities.~Section III: 7 Questions regarding the advantages of your Social Media use. Section IV: 5 Questions regarding the disadvantages of your Social Media use.~The Google form questionnaire survey link will be shared with the Dentists in internet via Social Media \&/Or email to seek responses. The link will be available for single response for a single respondent."
223656126|NCT01783704|DIETARY_SUPPLEMENT|Nutrition|Participants receive 2000 IU vitamin D3, 600 mg calcium, and a multivitamin daily for the duration of the study. Nutritional counseling is also provided. Participants are screened at time of randomization to assess nutritional risk using the Mini Nutritional Assessment-Short Form and contacted by a registered dietician (RD) within 7 days of randomization. Those who score ≤7 (malnourished) and participants with baseline serum albumin 2.5-3.5 g/dl receive a visit from an RD with follow-up a week later. Participants who score 8-11 (at risk of malnutrition) and have serum albumin level \>3.5 g/dl receive a phone call from the RD and may receive an in-person visit if warranted. Those screening in the normal range (12-14) and have serum albumin level \>3.5 g/dl receive a phone call from the RD. Weight is monitored every 4 weeks. Those who lose 2% or more body weight receive a call from the RD. Those who lose 5% or more body weight between baseline and follow-up may be referred to an RD.
223656127|NCT01783704|BEHAVIORAL|PUSH|Strength components of the muscle performance intervention are performed using a portable progressive resistive exercise device (Shuttle® MiniPress, Contemporary Design Company, P.O. Box 5089, Glacier, Washington 98244). Muscle performance focuses on bilateral hip extensors, hip abductors, knee extensors, and plantar flexors. Balance and strength are addressed with additional exercises performed while standing. The endurance intervention begins with 2-3 minutes of continuous upper and lower extremity active range of motion (AROM) with the participant sitting in order to increase the participants' heart rate (HR) or exertion closer to the target zone. The participant is then asked to walk on level surfaces and/or up and down steps to keep the HR within the training zone for 20 minutes.
223656128|NCT01783704|BEHAVIORAL|PULSE|During the AROM exercises, participants work to increase flexibility and range of motion. Exercises include the neck, shoulders, arms, trunk, hips, knees and ankles. During all AROM exercises, the participant focuses on deep breathing techniques. The second part of the session uses transcutaneous electrical nerve stimulation (TENS) on lower extremity muscle groups to decrease pain, thereby allowing greater ease of mobility. TENS uses low-level electrical current to stimulate superficial cutaneous nerve fibers through the skin. Flexible carbonized, disposable electrodes coated with a self-adhesive conductive polymer will be applied to the skin bilaterally near the motor points on muscle bellies (the gluteal complex, the quadriceps, and the gastrocnemius) for 7 minutes per muscle group.
223656129|NCT04159311|OTHER|Osteopathy|testing osteopathy Vs Treating osteopathy
223656130|NCT02056262|OTHER|Dental cavity evaluation|The dental cavities present will be evaluated using the ICDAS (International Caries Detection and Assessment System).
223656131|NCT02056262|BIOLOGICAL|Saliva sampling|A saliva sample will be harvested.
223656132|NCT02056262|BIOLOGICAL|Plaque sampling|Plaque samples from a healthy tooth and a tooth with a cavity will be harvested.
223656133|NCT04407949|OTHER|CPAP Treatment|Comparing events from the CPAP device with the events scored in PSG
223656134|NCT00475306|DRUG|metoclopramide 10 mg|an anti-emetic medication
223656135|NCT00475306|DRUG|Diphenhydramine 25 mg|used for prophylaxis against akathisia
224239252|NCT05427383|DRUG|Docetaxel Injection|IV Docetaxel at 75 mg/m² on D1, Q3W
224239253|NCT05427383|DRUG|Irinotecan Injection|IV Irinotecan at 125 mg/m² on D1, D8, Q3W
224239254|NCT00352690|DRUG|Paclitaxel poliglumex|
224239255|NCT00352690|DRUG|Carboplatin|
223656136|NCT00475306|DRUG|Placebo|placebo
223656137|NCT00475306|DRUG|Metoclopramide 20 mg|Metoclopramide 20 mg
223656138|NCT02637830|OTHER|Application of fluoride varnish (22600 ppm F, Duraphat) at the begining of the study|
223656139|NCT02637830|OTHER|Application of fluoride toothpaste (1500 ppm F, Crest) twice a day for 3 days of the study|
224239256|NCT00352690|RADIATION|External beam radiation therapy|
224239257|NCT04008784|DRUG|Crisaborole 2% Topical Application Ointment [EUCRISA]|Ointment
224239258|NCT04008784|DRUG|Triamcinolone Acetonide 0.1% Ointment|Topical Corticosteroid
224321032|NCT00963066|DEVICE|NAVA - EMG|Partial ventilator support with new partial ventilation mode (NAVA) performed with Servo-i® ventilator (Maquet,Critical Care, Sweden). Different levels of neurally adjusted ventilatory assist are tested. The machine applies positive pressure throughout inspiration in proportion to the electrical activity of the diaphragm (Eadi). Eadi was obtained trhough a naso-gastric tube with multiple array of electrodes placed at its distal end (Eadi catheter® , Maquet Critical Care, Sweden).
223656140|NCT02637830|OTHER|Application of placebo toothpaste (0 ppm F, Ice Fresh) twice a day for 3 days of the study|
223656141|NCT01042041|DRUG|sorafenib tosylate|Given orally
223656142|NCT01042041|DRUG|doxorubicin hydrochloride|Given via transarterial/hepatic chemoembolization
223656143|NCT01042041|DRUG|cisplatin|Given via transarterial/hepatic chemoembolization
224239259|NCT01621165|DRUG|Addition of prazosin to usual care (add-on study)|Prazosin and placebo will be gradually titrated over 10 days to a final dose of 10 mg/day, given in divided doses (three times a day). During this time subjects will be monitored for adverse effects to prazosin and manic symptoms will be monitored. Vital signs will be monitored three times a day throughout the study. If a subject receiving prazosin or placebo develops distressing adverse effects, the dose will be decreased to the next lower dose.If there is a greater than 15 mg mercury postural fall in systolic bBP, dosing will be held at the previous day's dose.Subjects who do not tolerate prazosin or placebo will be discharged from the study.
223656144|NCT01042041|DRUG|mitomycin C|Given via transarterial/hepatic chemoembolization
223656145|NCT01042041|PROCEDURE|transarterial chemoembolization|
223656146|NCT01042041|PROCEDURE|hepatic artery embolization|
223656147|NCT00985361|DIETARY_SUPPLEMENT|Vitamin D3 2000 international units daily|Vitamin D3 2000 international unit tablets once daily for 3 months
223656148|NCT00985361|DIETARY_SUPPLEMENT|Vitamin C 500mg daily|Vitamin C 500mg tablets once daily for 3 months
223656149|NCT01716052|DRUG|placebo|Lactulose
223656150|NCT01716052|DRUG|Ibuprofen|
223656151|NCT05437497|DRUG|Remimazolam Injection|The experimental group was sedated with remimazolam
223656152|NCT05437497|DRUG|Propofol Injection|The control group was sedated with propofol
223656153|NCT03544762|DRUG|18F-FES PET|18F-FES PET will be performed for each patient. All patients will receive intravenously injection of 5-8 mCi (185-296 MBq) of 18F-FES. PET imaging will be performed on PET/CT system. The 1-frame dynamic data acquisition of thoracic region including the primary tumor will be started immediately after tracer injection. Whole-body PET acquisition from skull base to upper thigh will be started 60 minutes after tracre injection.
223656154|NCT04056832|PROCEDURE|Single Strip Pericardium|The anterior pericardium is taken in accordance with the measurements made using an aortic annulus sizer or Ismail sizer. The diameter of the annulus valve is converted to circumference of the aortic valve according as a measure of the length of the pericardium. Measurement of aortic commissure height is done by measuring the distance between the lowest point of the valve attachment to the highest point on the commissure as a measure of pericardium width. The pericardium is immersed in 0.6% glutaraldehyde solution for 10 minutes, then rinsed and soaked with saline solution 3 times for 6 minutes each. After the pericardium becomes firm it is cut to be a single strip according to the length and width in the previous measurement. It is then sutured to the aortic valve annulus.
223656155|NCT04056832|PROCEDURE|Mechanical Prosthetic Valve|Median incision is performed at the surgical site. Sternal retractor is placed at the sternum after median sternotomy being performed. Aortic valve is measured using aortic annulus sizer. Pledgeted suture is performed for the mattress. Sutures are performed to attach the mechanical prosthetic to the aortic annulus.
224239260|NCT01621165|DRUG|Placebo|Prazosin and placebo will be gradually titrated over 10 days to a final dose of 10 mg/day, given in divided doses (three times a day). During this time subjects will be monitored for adverse effects to prazosin and manic symptoms will be monitored. Vital signs will be monitored three times a day throughout the study. If a subject receiving prazosin or placebo develops distressing adverse effects, the dose will be decreased to the next lower dose.If there is a greater than 15 mg mercury postural fall in systolic bBP, dosing will be held at the previous day's dose.Subjects who do not tolerate prazosin or placebo will be discharged from the study.
224239261|NCT02385396|DIETARY_SUPPLEMENT|Inofolic: myo-inositol and folic acid|4000 mg of myo-inositol and 0,4 mg of folic acid for 3 months preceding the ICSI procedure
224239262|NCT05962879|BEHAVIORAL|Resilience Training for Teens|A brief 6-session group-based behavioral intervention for high school aged teenagers at risk of a mental illness.
224239263|NCT02589171|DEVICE|Neo Close Abdominal Closure|Neo Close Abdominal Closure
224239264|NCT02589171|DEVICE|Carter Thomason Device|Carter Thomason Device
224239265|NCT04227639|PROCEDURE|T-piece trial|T-piece trial will be performed for around 1 hour with a T-piece connected to the extremity of the endotracheal tube by simply disconnecting the patient from the ventilator and by providing additional oxygen (≤ 6 L/min)
223656156|NCT05048511|BIOLOGICAL|vitamin D estimation|Serum samples to estimate vitamin D status were collected on the sixth day of stimulation
223656157|NCT03742752|OTHER|Enteral nutrition|administration of enteral nutrition
223656158|NCT03742752|OTHER|Parenteral nutrition|administration of parenteral nutrition
223656159|NCT04790565|BIOLOGICAL|FMT|Fecal microbiota in frozen capsules
223656160|NCT04342507|OTHER|conservative treatment|lid hygiene, warm compression, and dexamethasone/tobramycin ointment for at least 20 days.
223656161|NCT04342507|DIETARY_SUPPLEMENT|probiotics|use specific probiotics in addiction to conservative treatment to modify the intestinal microbiome to ameliorate the clinical course of adults chalazia by re-establishing intestinal and immune homeostasis
224239266|NCT04227639|PROCEDURE|Pressure-support trial|Pressure-Support trial will be performed for around 1 hour without disconnecting the patient from the ventilator, by using a low level of pressure-support (PS 8 cm H2O) with a FiO2 ≤ 40% and without positive end-expiratory pressure (PEEP), while continuously monitoring the respiratory rate and tidal volume on the ventilator display.
224239267|NCT02767310|DRUG|Rosuvastatin 20 mg film-coated tablets|Single oral dose of 20 mg
224239268|NCT02767310|DRUG|Crestor 20 mg film-coated tablets|Single oral dose of 20 mg
224239269|NCT04325100|BEHAVIORAL|Switch - Individual sessions|"Participants follow the Switch intervention through individual sessions (1 hour, twice a week, for around 2 months).~Participants are provided with a folder which presents the rational for each strategy. Take-home assignments are given and stored in the same folder. Participants are also given small cards (that can fit in their wallet) containing the key elements of each strategy.~The intervention manual can be obtained from the main investigator (in French)."
223656162|NCT02405442|DRUG|Andecaliximab|Andecaliximab administered via subcutaneous (SC) injection
223656163|NCT02405442|DRUG|Placebo|Placebo to match andecaliximab administered via SC injection
223656164|NCT03521778|OTHER|Fascial Distortion Model|"Patients will receive manual treatment according to FDM procedures:~1. Triggerbands - therapist put a pressure by the thumb along the presented pathway.~2. Continuum Distortions - therapist put a pressure by the thumb at the exact place of feeling of pain.~3. Folding Distortions - therapist conduct traction or compression of the affected joint.~4. Herniated Triggerpoint - therapist put a pressure by the thumb at the place where HTP occurs.~5. Cylinder Distortions - therapist compress and stretch by the hands affected area.~6. Tectonic Fixation - Therapist compress and stretch affected area by the hands or tools like vacuum bubble."
223656165|NCT03521778|OTHER|Mulligan Concept|"Patients will receive manual treatment according to Mulligan Concept procedures:~MWM- Mobilization With Movement- application can be defined as the application of a sustained passive force/glide.~NAG - Natural Apophyseal Glide - application can be defined as the oscillatory mobilization techniques from the middle to the end of the range of motion.~SNAG- Sustained Natural Apophyseal Glide- They are weight bearing techniques: all procedures are done with the patient sitting or in standing. They are mobilisations with active movement followed by passive over pressure."
223656166|NCT03521778|OTHER|Traditional physiotherapy|"Patients will receive traditional physiotherapy:~Exercises, laser treatment, magnetic field therapy, ultrasound treatment, light treatment"
223656167|NCT06208475|OTHER|Resistance exercise|Resistance exercises in the following order: squat, bench press, deadlift. Each exercise consisted of 3 sets with 7 repetitions, using a load of 70% 1RM with 120sec of rest between sets.
223656168|NCT02592057|DRUG|SOF|SOF tablets administered orally once daily based on approved prescribing information
223656169|NCT05349565|OTHER|CONVENTIONAL PHYSICAL THERAPY|"High frequency TENS for 10 mins, 3 days/week Ankle pumps for blood circulation 10 repetitions x1 set, 3 days/week. Heel slides10 repetitions x1 set, 3 days/week. Open chain knee flexion and extension 10 repetitions x1 set, 3 days/week. SLR (straight leg raise) 10 repetitions x1 set, 3 days/week. Calf stretch 10 repetitions x1 set, 3 days/week. Quad set 10 repetitions x1 set, 3 days/week.~Total 6 sessions each consisting of 30-45 minutes"
223656170|NCT05349565|OTHER|MUSCLE ENERGY TECHNIQUE|"Experimental group treated by applying Muscle energy technique along conventional physical therapy.~For MET patient is positioned at maximal comfort and lengthening while engaging the barrier and then patient is asked to perform isometric contraction with 6-10 sec hold and then release and lengthen the muscle 4-5 repetition x 1 set, 3days/week Total 6 sessions each consisting of 30-45 minutes"
223656171|NCT03476590|PROCEDURE|new model of ambulatory care with use of of non-invasive vital signs assessment and telemedicine|"The report of symptoms and physical examination will be obligatory performed by the ACP nurse. Self-condition and quality of life assessment at every visit will be based on EQ-5D questionnaire and VAS 10-points scale Hemodynamic assessment - the ACP nurse will perform impedance cardiography (cardiomonitor) and bioimpedance (scale). The parameters measured by ICG and bioimpedance will be assessed with respect to individually defined target values for: heart rate (HR), systolic and diastolic blood pressure (SBP and DBP), thoracic fluid content (TFC) and its change (delta TFC), change of body mass and total body water (delta TBW).~Supervising physician will confront ICG/bioimpedance results with the patient's clinical data and give final remote recommendations."
223656172|NCT01563653|PROCEDURE|4 diagnostic tests for surgical success|Q-tip test, Bonney maneuver, TVT maneuver, clip strip test
223656173|NCT02078960|DRUG|Omacetaxine mepesuccinate|3.5 mg omacetaxine mepesuccinate and 10 mg mannitol; The first dose of the day for cycle 1 will be administered at the investigational center. Subsequent doses (in prefilled syringes) may be administered on an outpatient basis after training takes place
223656174|NCT00267787|OTHER|genetic analysis|standard of care
223656175|NCT00093379|DRUG|Capecitabine|825 mg/m\^2 orally twice a day (BID), Mon-Fri during weeks 1, 2, 4, and 5.
223656176|NCT00093379|DRUG|Oxaliplatin|50 mg/m\^2 by vein (IV) over 2 hours on days 1, 8, 22, and 29.
223656177|NCT00093379|RADIATION|Radiation Therapy (XRT)|Undergo radiotherapy\* once daily on days 1-3, 6-10, 13-17, 20-24, 27-31, 34-38, and 41-42. \*Patients with T3-4 lesions undergo radiotherapy once daily on days 43 and 44.
223656178|NCT01171560|PROCEDURE|endotracheal intubation|The patients will be randomized to one of two groups: EZ Blocker or conventional double lume tube. After induction of anesthesia, intubation using respective device will be performed in dorsal position.
223656179|NCT05546580|DRUG|Iadademstat|iadademstat oral solution
223656180|NCT05546580|DRUG|Gilteritinib Oral Tablet|120 mg Gilteritinib
223656181|NCT06251882|OTHER|injection|10ml D5W injection for MP patients
223656182|NCT04316403|PROCEDURE|Er:YAG laser|This application was made before the onset of canine retraction in one side of the mouth
223656183|NCT03275350|DRUG|Naltrexone Injectable Suspension|Six monthly injections of extended-release naltrexone
223656184|NCT03275350|OTHER|Treatment as usual|Standard treatment for opioid use disorder provided at each HIV clinic
224239270|NCT04325100|BEHAVIORAL|Switch - Group programme|"Participants follow the Switch group programme (2 hours, twice a week, for around 2 months).~During the group sessions, a powerpoint presentation and different media are used to present the different parts of the motivation model. Participants learn the different strategies (e.g., cognitive defusion, pleasure anticipation, problem solving) through individual and group exercises.~Participants are provided with a folder which presents the rational for each strategy. Take-home assignments are given and stored in the same folder. Participants are also given small cards (that can fit in their wallet) containing the key elements of each strategy.~The intervention manual and the presentation material can be obtained from the main investigator (in French)."
224239271|NCT05116670|OTHER||this is an observation study, no intervention is needed
224239272|NCT03407365|BEHAVIORAL|10 Week Exercise Program|Subjects will complete a 10 week exercise program using DVD with instructions provided. Participants will have to do one session of exercise on 5 different days each week for a total of 5 sessions per week, for 10 weeks.
223656185|NCT04129437|DRUG|Ibuprofen|Weight based ibuprofen dosing
223656186|NCT04129437|PROCEDURE|Osteopathic manipulative treatment|Low velocity osteopathic manipulative treatment
223656187|NCT04313413|OTHER|Yoga|Yoga sessions includes sukshma vyayama (strengthening yoga expertise), stretching and relaxing postures (asana) on chair or standing, breathing and meditation practices.
223656188|NCT05753696|DRUG|Azilsartan|Azilsartan initial dose 20mg/d, if not reached the goal of hypertension; azilsartan dose 40mg/d
223656189|NCT05753696|DRUG|Losartan|losartan initial dose 40mg/d, if not reached the goal of hypertension; losartan 100mg/d
223656190|NCT00400270|PROCEDURE|Breathing and relaxation exercises: the Papworth Method|
223656191|NCT00522938|DRUG|CHR-2797 (tosedostat)|Once daily, oral ingestion of CHR-2797 capsules(PhaseI: 120mg, 160mg or 200mg depending on cohort or Phase II: recommended dose) capsules until progressive disease or withdrawal from the study
223656192|NCT00522938|DRUG|erlotinib|Once daily, oral ingestion of erlotinib tablets 150mg tablets until progressive disease or withdrawal from the study. Per protocol, the Investigator may reduce the dose of erlotinib or cease treatment with erlotinib(per label) with Sponsor approval.
223656193|NCT00888186|DRUG|levodopa/carbidopa|intestinal gel, for continuous daytime infusion
223656194|NCT00003560|DRUG|carboplatin|
223656195|NCT00003560|DRUG|docetaxel|
223656196|NCT04254770|DEVICE|ADA approved Manual Toothbrush|ADA approved Manual Toothbrush
223656197|NCT04254770|DEVICE|Marketed Power Toothbrush|Marketed Power Toothbrush
223656198|NCT05262049|OTHER|intermittent compression-decompression with glides|Patients in this group will be given only intermittent compression and decompression with glides. Traction (decompression applied at knee joint with anteroposterior glide followed by compression for about 6 minutes (30 glides, 10 seconds compression and vice versa), for the duration of 4 weeks (3 days a week, alternate days)
223656199|NCT05262049|OTHER|Conventional Physical Therapy|"In this group conventional therapy will be given according to below mentioned protocol for 4 weeks (3 days a week, alternate days).~* Hot pack /TENS for 10 minutes~* Stretching: Hamstring(10x) and calf (10x)~* Strengthening of periarticular muscles especially the quadriceps (straight leg raising, pillow squeeze-isometric and dynamic)"
223656200|NCT05262049|OTHER|conventional physical therapy and intermittent compression-decompression with glides|Patients in this group will receive the combination of conventional physical therapy and intermittent compression and decompression with glides, for 4 weeks (3 days a week, alternate days).
223656201|NCT04595890|DEVICE|Arthrex Angel System used to prepare injection of Bone Marrow Concentrate (BMC)|Participants will have bone marrow aspirated from their iliac crest, then processed using the Arthrex Angel System to produce autologous bone marrow concentrate (BMC). Then, BMC will be injected into the participant's knee with knee osteoarthritis (OA).
224239273|NCT03407365|BEHAVIORAL|DVD Program After 10 Weeks|If the DVD program shows to help participants in Group 1, the program and DVD will be provided to Group 2 participants
224239274|NCT01678547|DEVICE|Robot-assisted walking|The practice will included an add-on robot-assisted walking therapy at variable speeds for 40 min with a partial body weight support (BWS). All participants will start with 30-40% BWS and an initial treadmill speed of 1.5 km/h speed will be increased to a range of 2.2 to 2.5 km/h and the BWS % will be decreased.
224239275|NCT01678547|DEVICE|Treadmill Training|The practice will included an add-on treadmill walking therapy at variable speeds for 40 min with a partial body weight support (BWS). All participants will start with 30-40% BWS and an initial comfortable treadmill speed and the speed will be increased to a range of 1,0 to 2.5 km/h and the BWS % will be decreased.
223656202|NCT04595890|OTHER|Saline injection|Participants will have bone marrow aspirated from their iliac crest to maintain masking. Then, saline will be injected into the participant's knee with knee osteoarthritis (OA).
223656203|NCT02173509|OTHER|Multidisciplinary and multifaceted educational intervention.|Outreach visits (40 minutes) which included a PowerPoint presentation and impress materials: poster; flyers; participation certificate and articles mentioned in the presentation. This outreach visit aimed to change the knowledge-attitudes previously identified in a previous study as being associated with poor prescribing of antibiotics in the case of physicians and propensity to dispense antibiotics without medical prescription in the case of pharmacists.
223656204|NCT00951197|OTHER|Neuroimaging|Three successive MRI acquisitions to measure FA, MTR and T2 parameters.
223656205|NCT05905978|PROCEDURE|Corneal donors predisposed by CXL|Corneal donors predisposed by CXL and DALK procedure was conducted in patients
223656206|NCT05905978|PROCEDURE|Corneal donors stored in corneal storage media|Corneal donors stored in corneal storage media and DALK procedure was conducted in patients
223656207|NCT06426589|OTHER|Resistence training and mediterranean diet|"Resistance training. Subjects assigned to the experimental group participated in resistance program twice a week (on Tuesdays and Thursdays) for a period of 12 weeks, totaling 24 sessions of 60 minutes each. Each session during this time was divided into three clearly differentiated parts: i) 5-minute warm-up comprised of a series of gentle, low-intensity exercises designed to gradually prepare the muscles and joints of older adults for the main exercise.~Mediterranean Diet. In addition to the resistance intervention, the experimental group received a Mediterranean diet protocol based on the study by Ismail et al. \[34\] with the following meal plan: i) carbohydrates constituted 50% of daily intake; ii) fats repre-sented 35%; and iii) proteins accounted for 15%."
223656208|NCT00975689|DRUG|N-Acetyl Cysteine|900mg effervescent tablet; Dosed as 15 mg/kg/day (maximum dose 900 mg per day) for one week, advanced to 30 mg/kg/day (maximum dose 1800 mg per day) for the second week, and then advanced to 60 mg/kg/day (maximum dose 2700 mg) for the remainder of the trial (6 additional weeks).
223656209|NCT02155478|DEVICE|ISERT 250 (HOYA, Japan): a standard IOL|
223656210|NCT02155478|DEVICE|AMO ZCB00 IOL (Abbott Medical Optics, United States): a standard IOL|
223656211|NCT04380246|OTHER|Qualitative Interview|There is no intervention as part of this study. Clinicians will participate in a qualitative interview.
223656212|NCT04011358|OTHER|Sleeping Monitor|to evaluate obstructive sleep apnea
223656213|NCT06098742|DRUG|Antareit|A single dose of T or R drug in each of 2 periods of the study 2 h prior to food intake
224239276|NCT01678547|OTHER|Ground treatment|The practice will included ground walking therapy s for 40 min with therapist support.
224239277|NCT03947242|DRUG|Pyrotinib and Trastuzumab plus Vinorelbine|Pyrotinib:400mg orally daily Trastuzumab:8mg/kg ivgtt load followed by 6mg/kg ivgtt 3-weekly for a total of 4 cycles Vinorelbine :25mg/m2 ivgtt 3-weekly for a total of 4 cycles,d1 d8
224239278|NCT01798836|PROCEDURE|Oestradiol pre-treatment and combination of GnRH agonist/antagonist protocol|
224239279|NCT01798836|PROCEDURE|GnRH agonist or antagonist protocol without oestradiol pre-treatment|
223656214|NCT06027645|BEHAVIORAL|Crawling stimulation with a mini-skateboard (i.e. the crawliskate)|Consists of 8 weeks of daily training. Infants benefit from a 10 minutes session everyday at home with either a trained therapist or his/her parents. Parents are trained by the therapist at the begining of the 8 weeks. During each session the infant is prone wrapped on a mini-skateboard (i.e. the crawliskate) and has to produce flexion and extension movements with his four limbs in order to move forward with the assistance of the adult (therapist or parent).
223656215|NCT05867771|DRUG|PM1022|PM1022 Injection
224239280|NCT03931239|BIOLOGICAL|Study subjects will be vaccinated with 3 (three) vaccine doses. The first vaccine will be administered intramuscularly starting at 6-12 weeks of age followed by two doses at four-week interval|An openlabel, multicentric, bridging study to assess the safety of Diphtheria, Tetanus, Pertussis, Hepatitis B and Haemophilus influenzae type b Conjugate Vaccine (Adsorbed) manufactured by Serum Institute of India Pvt. Ltd in Vietnamese infants aged 6-12 weeks, given as a 3-dose regime, with 4 week intervals between the doses
224321033|NCT04587726|BEHAVIORAL|Girl's room video|"Girls Room, a body image mini-series, developed in collaboration with Lena Waithe, Dove and CAR.~Video content was informed by empirical evidence related to body image prevention and intervention. The series consists of five, 3-minute videos.~The videos follow the lives of a 5 best friends, and each video targets a key risk factor for body image:~1. Appearance comparison~2. Body appreciation~3. Body talk~4. Body functionality~5. Appearance teasing \& bullying~6. Appearance focus~The five videos aired on Instagram TV (IGTV) in March 2020."
223656216|NCT00787618|DRUG|50 mg Proellex|Single dose
223656217|NCT02250729|OTHER|intradermal pholcodine allergy test in cases|
223656218|NCT02250729|OTHER|Blood sampling|
223656219|NCT05046327|DRUG|Avatrombopag 20 mg Oral Tablet|Avatrombopag administered at a frequency to maintain a target platelet count between ≥50 and ≤150×10⁹/L
223656220|NCT02536417|DRUG|Melatonin|To determine the effectiveness of melatonin in preventing the development of delirium compared with placebo
224239281|NCT02719522|DEVICE|Pipeline™ Flex Embolization Device with Shield Technology™|"Pipeline™ Flex Embolization Device with Shield Technology™ utilizes a phosphorylcholine (PC) surface treatment to the implant combined with the PFED delivery system. The Shield Technology™ surface treatment applied to the implant is an inert polymer material created to mimic the outer membrane of a human red blood cell.~The Pipeline™ Flex Embolization Device with Shield Technology™ is intended for endovascular embolization of cerebral aneurysms and is designed to be placed across the opening (or 'neck') of a brain aneurysm and redirect blood flow away from the aneurysm, causing the blood within the aneurysm to clot."
224239282|NCT01853553|DRUG|Spironolactone|Blood pressure medication.
224239283|NCT01853553|DRUG|Sugar pill|Placebo.
224239284|NCT01113606|OTHER|Obagi New-Derm System|
224239285|NCT01113606|OTHER|Standard of Care|
224239286|NCT05432193|DRUG|[Ga-68]-PNT6555|\[Ga-68\]-PNT6555 IV administered as imaging agent for PET/CT
224239287|NCT05432193|DRUG|[Lu-177]-PNT6555|Patients with FAP-avid disease as determined by the \[Ga-68\]-PNT6555 screening PET/CT will receive \[Lu-177\]-PNT6555 at a fixed dose level for up to 6 doses at an interval of 6 weeks between each dose.
224239288|NCT00425256|DRUG|Bremelanotide|
224239289|NCT02068248|DIETARY_SUPPLEMENT|Soluble Fibre|
224239290|NCT00351845|BEHAVIORAL|Low carbohydrate diet (behavior)|
224239291|NCT04426409|DRUG|tarivid ointment|Vaseline ointment is applied to both noses.
224239292|NCT01242865|BEHAVIORAL|Attention and Interpretation Therapy|"Participants will receive a copy of the book, Train Your Brain Engage Your Heart Transform Your Life along with three handouts summarizing the contents of the book."
224239293|NCT01030965|DRUG|GSK573719 125mcg|125mcg once-daily
224321034|NCT04587726|OTHER|Control video - Chicken Girls|Chicken Girl's Episode - appearance neutral episode matched for target audience and video length
224321035|NCT03203850|DRUG|Deferasirox FCT|Taken orally once per day (QD) as a film coated tablet (FCT)
223656221|NCT02536417|DRUG|Sugar pill|To determine if placebo effect plays a part in preventing the development of delirium
224239294|NCT01030965|DRUG|GSK573719 250mcg|250mcg once-daily
224239295|NCT01030965|DRUG|GSK573719 500mcg|500mcg once-daily
224239296|NCT01030965|DRUG|Placebo|once-daily
224239297|NCT04582721|OTHER|Implantable Neurostimulator System (Spectra WaveWriter™ Spinal Cord Stimulator System), (Boston Scientific Neuromodulation Corporation, Valencia, California (CA), USA)|"the participants with chronic intractable back or back and leg pain will be implanted with the stimulation lead(s). The leads are initially connected to an external trial neurostimulator. Patients will be implanted with two epidural leads and two subcutaneous leads. A three weeks trial phase will follow. The first two days after the leads implant will be without stimulation and thereafter alternating stimulation every week will start, randomly ordering the treatments using a Williams design balanced for first-order carryover effects (i.e. incorporating 6 different treatment orders), from:~* 1\) CON-SCS with Subcutaneous stimulation~* 2\) HF-SCS~* 3\) Combination Therapy A patient's favored SCS mode, providing that there is at least 50% reduction in pain intensity on the NRS in the trial phase, will then be implanted and patients will be followed up for 12 months."
224239298|NCT03424291|DRUG|Apatinib plus chemoradiation|Apatinib 500 mg qd po Taxus + platinum or 5FU + platinum (drug dose reference to clinical) palliative radiotherapy dose ≥ 40Gy and radical radiotherapy dose (60-70Gy)
224239299|NCT05563909|OTHER|Exercise|Patients participating in the study will not receive any intervention other than exercise and splint.
223656222|NCT05086029|DIAGNOSTIC_TEST|Superb Microvascular Imaging|Superb microvascular imaging (SMI) is a new ultrasound technology that can diferen-tiate blood flow signals from artifacts by using a new algorithm.
223656223|NCT04995458|PROCEDURE|composite-ceramic|To assess the clinical performance of composite-ceramic crowns
223656224|NCT04995458|PROCEDURE|Monolithic zirconia|To assess the clinical performance of monolithic z¡irconia crowns
223656225|NCT02584556|DRUG|systemic chemotherapy|Pirarubicin(Brand Name:Pirarubicin - Main Luck Pharmaceutical, China) 30mg/m2 intravenously on Day 1 and Oxaliplatin(Brand Name: Eloxatin) 100 mg/m2 intravenously on Day 2 every 3 weeks starting 4-6 weeks after hepatic resection.
223656226|NCT02584556|DRUG|Transcatheter Arterial Chemoembolization|Lipiodol 5-10ml,Pirarubicin17mg/m2 and Oxaliplatin 30mg/m2 are infused through the right and left hepatic arteries,followed by embolization using gelatin sponge particles(Gelfoam; Guangzhou) starting 4-6 weeks after hepatic resection.
223656227|NCT02949479|BEHAVIORAL|Dissociation Investigation in Sex Offenders|prevalence of a clinical dissociative state during the offence; secondary : correlations of dissociation with childhood abuse or neglect, with significant lifetime dissociative experience, post traumatic stress disorder or dissociative disorder (DSM-5), violence and sexual estimated risk using actuarial and professional structured judgement tools
223656228|NCT00675467|BEHAVIORAL|Focus Group - Parent/Caregiver|A 1 1/2 hour group session with other parents/caregivers.
223656229|NCT00675467|BEHAVIORAL|Focus Group - Pediatric Patient|A 1 1/2 hour group session with other pediatric patients.
223656230|NCT01227135|DRUG|hydroxychloroquine|
223656231|NCT01227135|DRUG|imatinib mesylate|
223656232|NCT01227135|GENETIC|cytogenetic analysis|
223656233|NCT01227135|GENETIC|polymerase chain reaction|
223656234|NCT01227135|OTHER|laboratory biomarker analysis|
223656235|NCT01227135|OTHER|pharmacological study|
223656236|NCT06111118|DEVICE|ThermaCare HeatWraps|ThermaCare HeatWraps application
223656237|NCT01701232|BIOLOGICAL|rituximab|Patients will receive rituximab at a dose of 375 mg/m2 intravenously once a week for 4 weeks (on day 1,8,15,22)
223656238|NCT06471192|PROCEDURE|PPCI|PPCI for patients of STEMI to assess thrombus burden
223656239|NCT05136950|PROCEDURE|Secondary in-the-bag IOL fixation|The experimental group with secondary IOL fixated in the capsular bag
223656240|NCT05136950|PROCEDURE|Secondary ciliary sulcus IOL fixation|The control group with secondary IOL fixated in the ciliary sulcus
223656241|NCT02995824|OTHER|Raltegravir-based antiretroviral therapy|To analyze retrospectively the efficacy and safety of raltegravir plus 2 nucleoside reverse transcriptase inhibitors (NRTI) \[lamivudine (3TC) or emtricitabine.(FTC) plus abacavir (ABC) or tenofovir (TDF)\] \[Group 1\] versus other ART regimens including boosted PI or NNRTIs \[Group 2\] in 271 HIV/HCV-coinfected patients who underwent liver transplantation between 2002 and 2012 and were followed until December 2016.
223656242|NCT02809040|OTHER|Electrocardiogram/Echocardiography|"Electrocardiogram (ECG) is a non-invasive (does not require an incision into the body) test that records the electrical activity of the heart.~Echocardiography is a non-invasive scanning of heart images using standard two-dimensional, three-dimensional, and Doppler ultrasound to create images of the heart."
223656243|NCT02809040|OTHER|Portable digital auscultation|"Traditional Stethoscope :An acoustic medical device for auscultation, or listening to internal sounds of human body.~Digital Stethoscope :Electronic stethoscope is a passive heart sound recording device. The heart sound listening and recording will be performed by trained personnel in a way very similar to that of using conventional cardiac auscultation"
223656244|NCT02873351|DRUG|carbidopa-levodopa 25-100 mg|included in arm description
223656245|NCT02873351|DRUG|placebo for carbidopa-levodopa 25-100 mg|included in arm description
223656246|NCT05035602|OTHER|Physical activity assessment|Physical activity patterns will be obtained from google location history, using an Android phone
224239300|NCT05563909|OTHER|Wrist Splint|Patients participating in the study will not receive any intervention other than exercise and splint.
224239301|NCT05563909|OTHER|Virtual Reality Mediated Exercise|Patients participating in the study will not receive any intervention other than exercise and splint.
224239302|NCT04627376|OTHER|Multimodal education and support program for cancer related cachexia prevention|12-weeks multimodal program includes: 4 meetings (with cancer nurse and clinical dietician). In this 4 meetings (about 30 minutes) they will have blood tests (CRP, Albumin levels), body composition measurements, questionnaires, education on their diet and symptom management related to anti cancer treatment.
223656247|NCT02453347|DEVICE|CES Therapy|Cranial Electrotherapy Stimulation (CES) may serve as an effective complimentary, noninvasive/non-pharmacological treatment for this Veteran population. CES is administered through a therapeutic device (such as Alpha-Stim®) marketed and approved by the FDA to treat insomnia, depression, anxiety, and pain.
223656248|NCT03832049|BIOLOGICAL|9-valent human papillomavirus vaccine (Gardasil 9) - 3 doses|0.5mL intramuscular dose - 3 doses (0, 2 and 6 months)
223656249|NCT03832049|BIOLOGICAL|9-valent human papillomavirus vaccine (Gardasil 9) - 2 doses|0.5mL intramuscular dose - 2 doses (0 and 6 months)
223656250|NCT03832049|BIOLOGICAL|9-valent human papillomavirus vaccine (Gardasil 9) - 1 dose|0.5mL intramuscular dose - 1 doses (0 months)
223656251|NCT03890042|DRUG|Dienogest group|VISANNE 2MG Tablet once daily
223656252|NCT03890042|DRUG|Gestodene-Ethinyl Estradiol|Gynera tablet once daily
223656253|NCT03890042|RADIATION|Ultrasound|ultrasound assessment of uterine volume
223656254|NCT03890042|OTHER|visual analogue scale|visual analogue scale for assessment of pain
223656255|NCT00741845|DRUG|intravaginal metronidazole|high dose intravaginal metronidazole 750mg (with or without miconazole) to be compared to low dose intravaginal metronidazole 37.5mg
223656256|NCT01944852|DRUG|Icodextrin|
223656257|NCT03763097|DIAGNOSTIC_TEST|Pelvic floor ultrasound|Pelvic floor ultrasound will include transperineal and introital ultrasound
223656258|NCT02597478|DRUG|Fentanyl Sublingual Spray|"Low-dose Fentanyl Goup: 15-25% of the morphine equivalent daily dose (MEDD) sprayed into mouth and under tongue one hour after first Shuttle Walk Test.~High-Dose Fentanyl Group: 35-45% of the morphine equivalent daily dose (MEDD) sprayed into mouth and under tongue one hour after first Shuttle Walk Test."
223656259|NCT02597478|PROCEDURE|Shuttle Walk Test|Participants walk back and forth between 2 cones in an indoor hallway for up to 12 minutes. After one hour Fentanyl Spray delivered, then second walk test performed.
223656260|NCT02597478|BEHAVIORAL|Questionnaires|Questionnaire completed about any breathing problems or other symptoms participant may be having at baseline. End of study questionnaire asks which dose level of study drug participant thinks they received. Participant also completes a questionnaire about how study drug may have helped them and how satisfied they are with the study. It should take about 5 minutes to complete the questionnaire.
223656261|NCT02597478|BEHAVIORAL|Mental Ability Tests|After each walk test, participant completes 4 tests of their mental abilities. It should take 15 minutes total to complete these tests.
224239303|NCT06121037|PROCEDURE|proximal ultrasound-guided GON radiofrequency ablation|proximal GON radiofrequency
224239304|NCT06121037|PROCEDURE|distal ultrasound-guided GON radiofrequency ablation|distal GON radiofrequency
224239305|NCT02090439|DRUG|Silodosin|
224239306|NCT02097290|DEVICE|CRT-D|For all subjects with the AUTOGEN CRT-D, the autothreshold algorithms will be evaluated
224239307|NCT00156949|DRUG|Epoetin alfa DT|Receive drug at same frequency and dose as at the time of randomization Change dose by+/- 25% in order to maintain Hb between 11.0 - 13.0 g/dL
224239308|NCT02467621|DRUG|Pantoprazole|40 mg x 1 daily intravenously from ICU admission to ICU discharge
224239309|NCT02467621|OTHER|Saline (0.9%)|10 ml of isotonic saline x 1 daily intravenously from ICU admission to ICU discharge
224239310|NCT02449876|OTHER|Neuroscience Education|"The following topics will be discussed in the education~* Basic structure of the nervous system~* Basic physiology of the nervous system~* The function and importance of pain~* Strategies to lessen the impact of pain~The instruction will be delivered in an interactive manner so that questions are addressed immediately. At the conclusion of the session each subject will receive the book: Why Do I Hurt by Adriaan Louw to reinforce the information discussed in the session. Subjects will be asked to read the 50 page book prior to the second session.~Session 2:~The session will begin with a review of the topics discussed in Session 1 and contained in the book. Subject will be encouraged to ask questions and get clarification on any of the topics that are unclear."
223656262|NCT02597478|BEHAVIORAL|Phone Call|Thirty days study visit participant called by study staff. This call should last about 10 minutes.
223656263|NCT04860388|PROCEDURE|closed eruption technique|The impacted teeth treated with closed eruption technique firstly. Orthodontic traction started a week later the sutures were removed. When the crown of the maxillary impacted canine was fully visible in the mouth, its bracket was inserted, and aligned within the dental arch using double-arch technique. Posttreatment plaque index, gingival index, gingival bleeding index, probing depth, and keratinized and attached gingival width and gingival thickness measurements of the impacted canines and controls were performed. The measurements compared with the contralateral canines that served as control teeth.
223656264|NCT01652469|DRUG|Erlotinib|Erlotinib 150 mg/day p.o. continuously with 21 days cycle.
223656265|NCT01652469|DRUG|Docetaxel|Docetaxel 75 mg/m2 as an IV infusion every 21 days.
223656266|NCT03005015|DRUG|Lenvatinib|
223656267|NCT03005015|DRUG|Doxorubicin|
223656268|NCT01402102|DIETARY_SUPPLEMENT|Aged garlic powder|Aged garlic powder(6.0g/day)
223656269|NCT01402102|DIETARY_SUPPLEMENT|Placebo powder|Placebo powder(6.0g/day)
223656270|NCT06050824|DRUG|Comparing Load and Concomitant therapy|Levofloxacin - Omeprazole - nitazoxanide - doxycycline
223656271|NCT05873907|DRUG|AMG 592|Administered as SC injection
223656272|NCT05873907|OTHER|Placebo|Administered as SC injection
223656273|NCT00522769|BEHAVIORAL|Cognitive Behavioral Therapy|Girls enrolled in the study will either receive the 6-20 session CBT intervention at the time of enrollment or 6 months after they enroll. Assessments including questions about eating behaviors, mood, and general functioning are given on enrollment in the study, and 3- and 6-months following enrollment (also at 9- and 12-months for those in the delayed treatment condition
223656274|NCT04653597|PROCEDURE|Close monitoring|surveillance every 30 minutes of blood pressure, SpO2, respiratory rate, heart rate and GCS until the patient recovers a GCS\>8 or responds adequately to a simple order
223656275|NCT04653597|PROCEDURE|Endotracheal intubation|invasive airway management in order to avoid risk of pulmonary aspiration
223656276|NCT05043142|DIAGNOSTIC_TEST|ELISA test for the antibodies to COVID-2019.|Each subject will be assigned an individual number, which will be used for conduction of a rapid ELISA test for the antibodies to COVID-2019. Subjects will be notified of the test results.
224239311|NCT05159635|DEVICE|Active Living programme and wearable technical aids|attend 6 weeks active living programme and apply wearable technical aids for 8 weeks.
224239312|NCT05159635|DEVICE|Wearable technical aids|apply wearable technical aids for 8 weeks.
224239313|NCT00663221|DIETARY_SUPPLEMENT|Anthocyans, Calcium and Vitamin D|
224239314|NCT00663221|DIETARY_SUPPLEMENT|placebo|
223656277|NCT02697474|BIOLOGICAL|Euvax B®: Hepatitis B vaccine|0.5 mL, Intramuscular
223656278|NCT02697474|BIOLOGICAL|Euvax B®: Hepatitis B vaccine|0.5 mL, Intramuscular
223656279|NCT01334619|PROCEDURE|appropriate volume of 0.5% ropivacaine|initial concentration: 30 ml, subsequently varied at a ratio of 1: 1.2 for each consecutive patient according to the response of the previous patient, until 5 up-and-down cycles completed.
223656280|NCT02324634|DEVICE|NeuroTrac Rehab dual channel device|ES intervention twice a day, 5 days a week, for 3 months applied to the wrist extensors and wrist flexors. The therapist will identify the motor points for the forearm flexors and the extensors, and will place an electrode on these motor points using sticky pads. They will then connect the electrodes to the respective channels in the electrical stimulator. The ES will be set to deliver a 450μs pulse at a frequency of 40-60Hz (as per patient convenience). The intensity of the current will be increased to produce an alternating contraction of the flexors and extensors using a flex-hold-extend-hold pattern. A single stimulation and hold cycle will last 20 seconds and this will be cyclically repeated for 30 minutes after which the device can be removed.
223656281|NCT03885167|OTHER|Specimen Collection|No interventions take place as part of study participation- only specimen collection occurs for both cohorts.
223656282|NCT04726540|OTHER|Patient Satisfaction|Patients were then asked to grade their overdentures/dentures on a visual analog scale and written questionnaire to evaluate their overall satisfaction.
223656283|NCT01305577|DRUG|Deoxycholic acid injection|
223656284|NCT01305577|DRUG|Placebo|Phosphate buffered saline placebo for injection
223656285|NCT00718653|DIETARY_SUPPLEMENT|Lutein|Lutein (12 mg/d)
223656286|NCT00718653|DIETARY_SUPPLEMENT|Lutein plus green tea extract|lutein (12 mg/d) plus green tea extract (200 mg/d)
224239315|NCT03190486|OTHER|functional Magnetic Resonance Imaging (fMRI)|During fMRI, healthy volunteers will listen 80 baby's cry.
223656287|NCT02750241|BEHAVIORAL|Active video game-based intervention|"* Attend 12 weekly group session at the UTMB Breast Health Clinic to play the active video games using Wii Fit U or Xbox 360.~* Participate in self-paced home sessions~* Monitor daily, weekly, and monthly steps using Wii Fit Meter~* Feedback on physical activity and physical function"
223656288|NCT02750241|BEHAVIORAL|Pedometer|"* Attend 3 monthly UTMB Breast Cancer Support Group Sessions~* Monitor daily, weekly, and monthly steps using a pedometer (Digi-walker CW-700/701)~* Feedback on physical activity and physical function"
224239316|NCT05312125|PROCEDURE|backward downhill walking|Children in the intervention group will take backward downhill walking program plus to routine physiotherapy.
224239317|NCT05312125|PROCEDURE|routine physiotherapy|Children in one of the groups will take routine physiotherapy programme
223656289|NCT00207285|BEHAVIORAL|Sleep Hygiene Education|Baseline general meetings with officers in intervention districts, in which we will provide an introductory program on optimal caffeine use (caffeine re-education) and sleep hygiene, as these are cost-effective measures that may effectively address difficulties adjusting to night work, and low-grade sleep disorders such as mild shift work sleep disorder across the cohort as a whole.
223656290|NCT00207285|PROCEDURE|Screening and Treatment of Sleep Disorders|All individuals who screen positive in the questionnaires on the baseline survey will be referred to one of the physicians at Sleep HealthCenters® or other sleep clinics in Massachusetts. Individuals will be paid $40 for attending an initial consultation visit with a sleep clinician and $400 if they are then asked to undergo an overnight sleep study and they complete the sleep study. Individuals will also be asked to wear an ApneaLink device for 2 nights at home and for 1 night during the overnight visit at Sleep HealthCenters®. Subjects may be asked to wear the ApneaLink device for more than 2 nights if there are not 4 hours of usable data each night. If the data is inadequate, subjects will be asked to wear the device until 4 hours of usable data on 2 nights is achieved. The ApneaLink device is an FDA approved sleep-screening tool that is used to identify individuals that are at risk for Obstructive Sleep Apnea Syndrome.
223656291|NCT02967341|OTHER|Ciprofloxacin administration|Ciprofloxacin will be administered via the PAC directly followed by a NaCl 0.9% flush to wash the PAC. At least 1 hour afterwards 500 microliter of blood will be drawn via the PAC. Directly hereafter a blood draw of 500 microliter will be performed either via capillary blood sampling or via a venipuncture. If an anaesthesia is foreseen for another procedure (e.g. a lumbar puncture or an osseous punction), we will strive to perform the peripheral blood draw under anaesthesia.
223656292|NCT04655937|OTHER|Acceptance and Commitment Therapy|9 x two hour remote sessions (50 minutes activity + 20 minute break + 50 minutes activity). Acceptance and Commitment Therapy (ACT) is a third wave transdiagnostic cognitive-behavioural therapy that supports clients to adjust to current experiences and 'commit' to behaviours that are congruent with their personal values, in order to promote psychological well-being and prevent future mental health crisis. ACT uses a variety of experiential techniques to support this process including: mindfulness practices; exercises to identify personal values; commitment to goals for valued living.
223656293|NCT05216744|DRUG|Ceftriaxone 1000mg + doxycycline 100 mg|Study comparing the effectiveness of two combination regimens in the treatment of gonorrhea and chlamydia, including regimen A (100mg doxycycline orally twice a day for 7 days + 1 dose of 1000mg ceftriaxone intravenously) and regimen B (100mg doxycycline). orally for 7 days + 1 oral dose of 800mg cefixime)
224239318|NCT03673059|DRUG|OTC Eczema Moisturizer Regimen|Subjects were assigned to use an OTC, oatmeal-containing eczema therapy moisturizing cream twice daily on their face and entire body for the 14-day treatment period of the study, in place of any other moisturizers/emollients. Subjects were also provided with a mild cleanser to use in place of their normal body wash and/or soap (same cleanser as used by Group B) per their usual cleansing routine. After the 14-day treatment period, subjects discontinued use of the moisturizer for the 7-day regression period.
224239319|NCT03673059|OTHER|Cosmetic Moisturizer Regimen|Subjects were assigned to use a non-fragranced, dry skin daily moisturizer twice daily on their face and entire body for the 14-day treatment period of the study, in place of any other moisturizers/emollients. Subjects were also provided with a mild cleanser to use in place of their normal body wash and/or soap (same cleanser as used by Group A) per their usual cleansing routine. After the 14-day treatment period, subjects discontinued use of the moisturizer for the 7-day regression period.
224239320|NCT03392571|DRUG|NGC-Triple regimen|gemcitabine 800 mg/m2; Abraxane (nab-paclitaxel 100 mg/m2; cisplatin 25 mg/m2
224239321|NCT05487833|BIOLOGICAL|insulin|5% glucose in 0.9% NaCl with 4 IU of short acting insulin per 500 ml added, infused at a rate determined by the treating physician, treatment duration: 18 hours
224239322|NCT05487833|OTHER|standard treatment|infusion of a balanced solution, infused at a rate determined by the treating physician, treatment duration: 18 hours
224239323|NCT04437693|DRUG|Hydroxychloroquine|The treatment group that will receive Hydroxychloroquine (HCQ) 400mg twice a day on day 1 followed by 400 mg weekly for 7 weeks
224239324|NCT03144687|DRUG|Itacitinib|Itacitinib self-administered orally once daily .
224239325|NCT03144687|DRUG|Ruxolitinib|Ruxolitinib self-administered orally at the stable dose of \< 20 mg daily established before entering the study.
224239326|NCT06298435|PROCEDURE|Intermittent Positive pressure ventilation|Intermittent positive pressure ventilation during general anesthesia for non-cardiac surgery
224239327|NCT00922532|DRUG|Inhaled Nitric Oxide|Inhaled Nitric Oxide will be administered continuously starting at 20ppm through an INOvent delivery system for up to 14 days.
224239328|NCT00922532|DRUG|Placebo|Nitrogen gas will be administered in the same manor as the experimental drug
224239329|NCT01054599|DRUG|Memantine|All subjects in the treatment group will be placed on memantine. The dosage of memantine will begin at 5mg once per day (qday), and increase by 5mg every week. The titration will continue over a period of 3 weeks until a goal of 10mg bid is reached. The dosing will increase slowly, to minimize the risk of side effects. The subject will then remain on memantine at 10mg bid for 10 weeks, until the conclusion of the first phase of the study. At the conclusion of the first 13 weeks, subjects will discontinue the treatment (memantine or placebo) and enter the open label phase.
223656294|NCT05216744|DRUG|Cefixime 800mg + doxycycline 100 mg|Study comparing the effectiveness of two combination regimens in the treatment of gonorrhea and chlamydia, including regimen A (100mg doxycycline orally twice a day for 7 days + 1 dose of 1000mg ceftriaxone intravenously) and regimen B (100mg doxycycline). orally for 7 days + 1 oral dose of 800mg cefixime)
223768284|NCT01936259|DEVICE|Mini Stem|The humeral stem component is manufactured from Ti6Al4V alloy. The taper has a machine finish and accepts the taper adaptor of the humeral head component. The proximal region of the bone-contacting outer surface features a porous coating of plasma-sprayed titanium alloy, while the distal portion is polished. Seventeen stem diameters are available - 4 mm to 20 mm, in 1-mm increments.
224239330|NCT01054599|OTHER|Sugar Pill|In the control arm of the study, subjects will take one placebo sugar pill per day for one week, then increase to one tablet twice per day for the following 12 weeks. At the end of this phase of the study, subjects will enter the open-label phase (unblinded treatment with memantine).
224321036|NCT03203850|PROCEDURE|Phlebotomy|according to investigator's decision
224321037|NCT01155973|BEHAVIORAL|EDUCORE intervention|Direct exhibition of their cardiovascular risk with SCORE, visual images and documentation to the patients
223656295|NCT00914108|BEHAVIORAL|Newborn Individualized Developmental Care|The developmental care model aims to create a relationship-based developmentally supportive care environment for the preterm infant and family. The theory proposes that care implementation that takes into account infants' thresholds of disorganization is most supportive of long term outcome. Specifically, the intervention consisted of weekly neurobehavioral observations and reports of the experimental group infants' behavior with suggestions for parents and staff in ways to support each infant's development. The developmental specialists observed each infant's behavior throughout hospitalization and to 2 weeks corrected age and formulated descriptive neurobehavioral reports with suggestions to structure caregiving procedures adapted to the infant's sleep/wake cycle and in support of the infant's well-regulated behavioral balance. Parents were supported to care for their infant, encouraged to nurse and hold their infant skin-to-skin, and to cradle them during stressful procedures.
223656296|NCT02922686|DRUG|Flucloxacillin|One flucloxacillin capsule of 500mg strength taken four times daily for 7 days
223656297|NCT02922686|DRUG|Phenoxymethylpenicillin|One capsule of phenoxymethylpenicillin of 500 mg strength taken four times daily for 7 days
223656298|NCT02922686|DRUG|Placebo (for phenoxymethylpenicillin)|Over-encapsulation of phenoxymethylpenicillin will be performed by the manufacturer of the investigational medicinal products such that placebo and active phenoxymethylpenicillin are identical in size, shape, colour and smell, and are packaged in identical bottles
223656299|NCT00000303|DRUG|Baclofen|
223656300|NCT02809222|OTHER|Samples|Blood samples
223656301|NCT02809222|OTHER|Quality of life questionnaire|Questionnaire to assess the quality of life of cancer patients
223656302|NCT00905645|DEVICE|Silimed Gel-Filled Mammary Implant|
224239331|NCT01054599|DRUG|Memantine|Open label: When the blinded phase is complete (Weeks 1-13), all subjects will receive open-label treatment with memantine (Weeks 14-26). The dosage of memantine will begin at 5mg once per day (qday), and increase by 5mg every week. The titration will continue over a period of 3 weeks until a goal of 10mg bid is reached. The dosing will increase slowly, to minimize the risk of side effects. The subject will then remain on memantine at 10mg bid for 10 weeks, until the conclusion of the study. At the conclusion of the study, subjects will discontinue the treatment.
223656303|NCT02408757|PROCEDURE|Sonographic monitoring|Sonographic monitoring during weaning of cerebrospinal fluid drainage catheters
223656304|NCT01386970|DRUG|zidovudine 300mg and lamivudine 150mg as Combivir|twice daily for 12 days in the HIV-negative group and indefinitely for their care in the HIV-positive group
223656305|NCT03020940|DRUG|Cefuroxime Axetil Dispersible Tablets|"Oral. This product can be taken orally, can also be added to the amount of warm water after mixing evenly.~Adult general 0.25g (one time), 2 times a day, the general course of treatment for 5 to 10 days.~Severe Infection or suspected pneumonia, a 0.5g (once 2), 2 times a day; general urinary tract infection, a Times a 0.125g (one and a half tablets), 2 times a day; for patients with no complications of gonorrhea recommended dose of 1g (4 Tablets), a single taking.~Children generally a dose of 0.125g (one-half tablets), 2 times a day; for less than two years of age in the middle ear Inflammatory patients, a 0.125g (one half tablets), 2 times a day; for greater than two years of otitis media patients, one Times a 0.25g (one time), 2 times a day; more than 12 years of age in children, the same dose for adults"
223656306|NCT00114790|RADIATION|boronophenylalanine-based BNCT|Boronophenylalanine is infused into a peripheral vein prior to neutron irradiation.
224239332|NCT05468229|DRUG|Dorzagliatin|single oral dose of dorzagliatin 50 mg
224239333|NCT05468229|DRUG|Placebo|Matching placebo
224239334|NCT01075139|BEHAVIORAL|Brief Motivational Intervention|30 minute one-on-one meeting
224239335|NCT01075139|BEHAVIORAL|Educational information|Educational handouts/brochures
224239336|NCT00743197|DRUG|Aspirin|Aspirin 81 mg daily
223656307|NCT02766556|DRUG|dexmedetomidine|ISB with ropivacaine with dexmedetomidine or normal saline
223656308|NCT02766556|PROCEDURE|ISB|ISB with ropivacaine with dexmedetomidine or normal saline
223656309|NCT02766556|DRUG|Ropivacaine|ISB with ropivacaine with dexmedetomidine or normal saline
224239337|NCT00743197|DRUG|Lisinopril|Lisinopril 10 mg every night
224239338|NCT00743197|DRUG|Simvastatin|Simvastatin 20 mg every night
224239339|NCT00743197|DRUG|Lovaza|Lovaza 1 gram daily
224239340|NCT00743197|BEHAVIORAL|Therapeutic Lifestyle Changes|Therapeutic lifestyle changes will be initiated with the assistance of a dietician, including diet counseling, exercise recommendation, and weight maintenance/weight loss.
224239341|NCT01395953|DRUG|Buspirone|Children with Autism Spectrum Disorders will receive buspirone or matched placebo. Buspirone will be titrated to the maximum daily dose during the first four weeks of the trial (dose titration phase). Week 4 onwards subjects will be maintained on maximum achieved dose till the end of the trial (dose maintenance phase). During the titration phase total dose of buspirone will be increased at each visit by 5mg and on the 4th day after each visit by 5mg.
224239342|NCT01395953|DRUG|Placebo|Children with Autism Spectrum Disorders will receive buspirone or matched placebo. Buspirone will be titrated to the maximum daily dose during the first four weeks of the trial (dose titration phase). Week 4 onwards subjects will be maintained on maximum achieved dose till the end of the trial (dose maintenance phase). During the titration phase total dose of buspirone will be increased at each visit by 5mg and on the 4th day after each visit by 5mg.
224239343|NCT00794079|DIETARY_SUPPLEMENT|omega-3 fatty acids|4 grams per day for 8 weeks
224239344|NCT00794079|DIETARY_SUPPLEMENT|corn oil|4 grams per day for 8 weeks
224239345|NCT01564433|PROCEDURE|Device: Electromechanical gait trainer|The experimental group will be subjected to 12-30 minute session (3 per week: Monday, Wednesday, Friday) of repetitive locomotor therapy on the Gait Trainer (Reha-Stim, Berlin, Germany), followed by 20 minutes of passive joint mobilization and stretching exercises. The GT-I consists of a double crank and rocker gear system, composed of two footplates positioned on two bars (coupler), two rockers, and two cranks that provide the propulsion. While using the gait trainer, individuals are secured in a harness and positioned on two footplates, whose movements simulate stance and swing phase, with a ratio of 60% to 40% between the two phases. The body weight was initially reduced by 30% and then progressively increased.
224321038|NCT01155973|OTHER|Control group|SCORE oral information and counseling as standard practice care
224321039|NCT00429429|PROCEDURE|Sublingual immunotherapy|Drops of peanut protein placed and held under the tongue for a specific time before swallowed.
224239346|NCT01564433|PROCEDURE|Convetional control treatment|The control group will be subjected to a conventional treatment that will consist of three different sets of exercises: 1) passive joint mobilization and stretching of lower limb muscles; 2) muscle strengthening exercises; 3) gait exercises. Each set of exercises lasted 10, 15 and 15 min, respectively with 2,5 min at rest between each set for a total of 40 minutes.
224239347|NCT03114956|PROCEDURE|Gauze|Implant surface will be wiped with sterile gauze soaked alternatively in sterile saline and CHX (5 times)
223656310|NCT04931888|BEHAVIORAL|EMPOWER|EMPOWER is an adapted social emotional learning (SEL) and wellness education initiative delivered to a community of refugee families that was developed through a pre-pilot in the New Haven Afghan refugee community in 2020. Unlike traditional school-based SEL curricula, EMPOWER partners with community organizations to provide translated and trauma-informed wellness education to family units. The program combines in-person (socially distant) and remote delivery of culturally-informed physical, emotional, and medical wellness tools adapted from evidenced-based behavioral medicine, refugee trauma and recovery, and community health research.
223656311|NCT01056302|PROCEDURE|Surgical repair of mandibular fractures|Patients will undergo whatever needed surgical repair of maxillofacial trauma that is necessary. Records such as CT imaging and plaster models of the jaws will be utilized in the standard way to plan and carry out the surgery. The CT scan will also be used within the visuohaptic computational environment to develop and evaluate the user interface. The amount of time taken to work up and plan surgery using standard surgical practice and using the computational platform will be compared. Real surgical outcome will be compared to the simulated surgical outcome using the proposed software tool.
223656312|NCT02558647|BEHAVIORAL|CBT for insomnia (CBT-I)|CBT-I is an online, fully automated, interactive, and tailored web-based program that incorporates the primary tenets of face-to-face CBT-I, including sleep restriction, stimulus control, cognitive restructuring, sleep hygiene, and relapse prevention.
223656313|NCT02558647|BEHAVIORAL|Psycho-Education about Sleep (PE)|PE provides online information about insomnia symptoms; the impact, prevalence, and causes of insomnia; when to seek input from a doctor; and basic lifestyle, environmental, and behavioral strategies that may help to improve sleep.
223656314|NCT01224951|DRUG|Beclomethasone|400 microgram of beclomethasone will be given to the patients in arm 1. During the last 4 weeks, the patients will receive additional 400 microgram of Qvar.
223656315|NCT05380479|DRUG|Mirtazapine|mirtazaine15 mg tablet daily for 8 weeks.
223656316|NCT05380479|DRUG|Megestrol Acetate|megestrol acetate 160 mg tablet daily for 8 weeks.
223656317|NCT05279573|DIETARY_SUPPLEMENT|Omega-3 and/or botanical ingredient|Consumption for 60 days. Subjects should consume two capsules in the morning and two capsules in the afternoon.
223768285|NCT01936259|DEVICE|Nano|The stemless humeral component is manufactured from Ti6Al4V alloy. It consists of a central tapered region and six outer wings. The taper has a machine finish and accepts the taper adaptor of the humeral head component. A small groove is included just below the taper to accept an inserter/impactor. The bone-contacting outer surface features a porous coating of plasma-sprayed titanium alloy for cementless fixation in the proximal humerus. Six sizes are available - 30 mm, 32 mm, 34 mm, 36 mm, 38 mm, and 40 mm.
223768286|NCT05354570|RADIATION|Intensity-Modulated Pleural Radiation Therapy (IMPRINT)|Radiation therapy will be administered over approximately 6 weeks at 50.4 Gy in 28 fractions, including an optional dose-painting SIB to gross residual disease up to 60 Gy while respecting normal tissue constraints.
223768287|NCT03159884|DRUG|Conbercept|
224321040|NCT03956394|DIAGNOSTIC_TEST|UltraFast ultrasound|The patient will be hospitalized by day to perform the usual follow-up of the Takayasu disease: blood sampling and Doppler ultrasound control. Then UltraFast ultrasound doppler will be assessed.
223768288|NCT04845737|OTHER|sympathetic skin response measurement|"Sympathetic skin response(SSR) was studied with upper and lower extremity hand and foot recording of all participants, and amplitude and latency values will be recorded. SSR measurement will be made at room temperature of 25 ºC, while the patients are resting in the supine position. 6 mm silver disc electrodes will be used as the recording electrode.~The relationship between the patients' vitamin D levels and inflammatory response markers and their sympathetic skin responses will be investigated by statistical analysis."
223768289|NCT02752295|BEHAVIORAL|stress-coping week|The multidisciplinary team will offer Mindfulness-Based Stress Reduction (MBSR), group psychotherapy (resilience, Cognitive Behavioral Analysis System of Psychotherapy CBASP, psychodynamic therapy), relaxation training, nutrition course, stress-coping and physical training in a group setting.
223768290|NCT02752295|BEHAVIORAL|additional two days follow-up weekend|A two-days follow-up which recapitulates previous treatment elements.
223768291|NCT00473720|DRUG|Satraplatin|Dose escalation of 40, 60 and 80 mg/m²/day on days 1-5
223768292|NCT00473720|DRUG|Abraxane|Dose escalation of 80 and 100 mg/mm²/day on days 1,8,15,22 every 28 days
224239348|NCT03114956|PROCEDURE|Titanium brush|Titanium brush: Titanium brush (TiBrush, Straumann, Switzerland) mounted on an oscillating hand piece will be used for 1 minute.
224321041|NCT06139497|BEHAVIORAL|Physical activity programme|48-week exercise programme including aerobic, resistance, balance and flexibility exercises twice to three times per week. The sessions are supervised by a coach at least once a week during the first 6 months then monthly. The other session of the PA programme is performed at home and the overall weekly PA is reviewed with the coach at the end of the supervised session.
224321042|NCT06139497|BEHAVIORAL|Home-based physical activity|48-week exercise programme including aerobic, resistance, balance and flexibility exercises twice to three times per week. Participants have to perform the exercise programme at home exclusively. They are called every week by a research assistant to review the activities performed, collect information on their adherence and perception on the programme.
224321043|NCT00916643|DEVICE|HELP Secura (apheresis treatment)|Process is described in Arm (above).
224321044|NCT01843296|DRUG|Magnesium Sulfate|Injection of 50 mg of magnesium sulfate 50% (0.1 ml),intrathecally.
223768293|NCT03996785|BEHAVIORAL|Walking in Urban setting|Walking for 60 minutes as described above
223768294|NCT03996785|BEHAVIORAL|Walking in nature setting|Walking for 60 minutes as described above
223768295|NCT02269891|DIETARY_SUPPLEMENT|Nu Femme|Combination product of Labisia pumila and Eurycoma longifolia extracts
223768296|NCT02269891|OTHER|Placebo|
223768297|NCT06027749|DEVICE|Epitel's™ Remote EEG Monitoring System's (REMI™)|Ambulatory electroencephalography (EEG) monitoring
223656318|NCT05279573|OTHER|Control product consumption|Product with identical characteristics to the experimental product. Consumption for 60 days. Subjects should consume two capsules in the morning and two capsules in the afternoon.
223656319|NCT05367635|DRUG|SKB315 for injection|SKB315 for injection is an Antibody Drug Conjugates (ADC) drug targeting Claudin18.2. The strength of SKB315 is 200 mg/vial.
223656320|NCT06704633|DRUG|Sacubitril / Valsartan Oral Tablet|A 36-hour wash-out of ACE inhibitors before initiating ARNI will be done, because of a risk of angioedema if ARNI is started without a wash-out period. The ACE inhibitor or ARB will be switched to sacubitril/valsartan 50mg twice daily (24.3 mg sacubitril, 25.7mg valsartan) for two weeks, increased to 100mg twice daily for three weeks, followed by 200mg twice daily
223656321|NCT01900418|BEHAVIORAL|Walk with Ease|An evidence-based walking program
223656322|NCT02939807|DRUG|ABC294640|"ABC294640 500 mg orally twice daily (approximately 12 hours apart) continuously.~ABC294640 will be dosed under fasting conditions (at least 1 hour before or 2 hours after eating). A cycle is defined as 28 days."
223656323|NCT02214394|OTHER|High-performance liquid chromatography Analysis|Blood samples will be collected for HPLC analysis to compare with the breath samples.
223656324|NCT02214394|DEVICE|SMART Device|Breath collection for GC-MS analysis to compare with Blood collection.
223656325|NCT05861349|DIAGNOSTIC_TEST|Nerve conduction study|Nerve conduction study of median and ulnar nerve together with sensory comparative methods on the affected side (sides).
223656326|NCT05861349|DIAGNOSTIC_TEST|Ultrasound|Ultrasound of the median nerve on the affected side (sides).
223656327|NCT03338127|DIAGNOSTIC_TEST|renal function test|2 ml blood sample to be investigated for renal function test
223656328|NCT01698034|BEHAVIORAL|Volunteering|Weekly volunteering with elementary school children in after school programs
223768298|NCT01721590|DRUG|Tongxinluo|Tongxinluo,3 capsules/time 3times/day for 1 year
223768299|NCT01721590|DRUG|placebo|3 capsules/time，3times/day for 1 year
223768300|NCT00006482|DRUG|cisplatin|
223768301|NCT00006482|DRUG|gemcitabine hydrochloride|
223768302|NCT02566915|DEVICE|CPET submaximal with EPAP|The expiratory positive pressure is applied through silicone mask (RHDSON Vital Signs®, New Jersey, USA) containing one-way valve and a resistance mechanism expiratory positive expiratory pressure generator adjustable 5-20 cm H2O (Spring Loaded) (Vital Signs® , New Jersey, USA). The mask one headgear will be comfortably adjusted to face being used to prevent air leakage, and the pressure level gradually adjusted to the level of 10 cm H2O.
223768303|NCT01302392|DRUG|Carfilzomib|20mg/m² IV on Days 1 and 2 of Cycle 1, escalating to 27 mg/m² IV on Days 8,9,15,and 16 of Cycle 1 and continuing on Days 1,2,8,9,15,and 16 of Cycles 2 through Cycle 9. Cycles 10 and beyond will receive 27 mg/m² IV on Days 1,2,15, and 16 (alternatively, the investigator could choose to continue the dosing frequency on the original dosing days \[Days 1, 2, 8, 9, 15, 16\] for individual subjects).
223768304|NCT01302392|DRUG|Best Supportive Care|"Corticosteroid (either prednisolone 30 mg orally (PO) every other day, dexamethasone 6 mg PO every other day, or other equivalent corticosteroid).~Optional cyclophosphamide 50 mg PO once daily may be given at the Investigator's discretion (maximum of 1400 mg per 28-day cycle)."
223768305|NCT04547062|DRUG|Tocilizumab|Administration of tocilizumab at day 8 of induction following a classical induction
224239349|NCT03114956|PROCEDURE|Air powder abrasion|Air powder abrasion: One minute of air powder abrasion using Glycine prophy powder (Prophy Jet, Dentsply, USA) with overlapping passes form apical to coronal direction for 1 minute.
223656329|NCT01756170|DRUG|paclitaxel|
223656330|NCT01756170|DRUG|cisplatin|
223656331|NCT01756170|RADIATION|Radiotherapy|
223656332|NCT00805337|DEVICE|Intrabuccally-administered amplitude-modulated RFEM|Generation of amplitude-modulated electromagnetic fields: the device consists of a battery-driven radiofrequency (RF) electromagnetic field generator connected to a 1.5 meter long 50 Ohm coaxial cable, to the other end of which a spoon-shaped mouthpiece made of steel is connected with the inner conductor. The RF source of the device corresponds to a high-level amplitude-modulated class C amplifier operating at 27.12 MHz. The modulation frequency can be varied between 0.01 Hz and 150 kHz with a modulation depth of 85 ± 5%. The RF output is adjusted to 100 mW into a 50 Ohm load using a sinusoidal modulated test signal, which results in an emitting power identical to that of the device used in the treatment of insomnia (Pasche et al 1996, 19:327-336).
223656333|NCT02663544|OTHER|Limited dairy diet|Consumption of no dairy foods other than 3 servings per week of nonfat milk for 12 weeks
223656334|NCT02663544|OTHER|Low-fat dairy diet|Consumption of 3.3 servings per day of low-fat milk, yogurt, and cheese for 12 weeks
223656335|NCT02663544|OTHER|Full-fat dairy diet|Consumption of 3.3 servings per day of full-fat milk, yogurt, and cheese for 12 weeks
223656336|NCT06317129|DEVICE|Endoscopic gastric restriction and biliodigestive diversion|The BariTon™ is endoscopically implanted.
223656337|NCT04230252|DRUG|Acetaminophen|Acetaminophen tablet will be administered orally in treatment sequence 1 and 2.
223656338|NCT04553042|DRUG|Seltorexant|Seltorexant will be administered orally as per assigned treatment sequence.
223656339|NCT04601467|DRUG|AZD5718|Oral dose of AZD5718 (tablet) once daily for 12 months
223768306|NCT00259857|DRUG|Alendronate|Group-1/Year-1:Alendronate, pill, 35mg or 70mg, weekly; calcium, pill, 500mg or 1000mg daily; vitamin D, liquid, 800IU, daily, depending upon the body weight, for 12 months. Group-1/Year-2:Placebo, pill, 35mg or 70mg, weekly; calcium, pill, 500mg or 1000mg daily; vitamin D, liquid, 800IU, daily, depending upon the body weight for 12 months. Group-2/Year-1:Placebo, pill, 35mg or 70mg, weekly; calcium, pill, 500mg or 1000mg daily; vitamin D, liquid, 800IU, daily, depending upon the body weight for 12 months. Group-2/Year-2: Alendronate, pill, 35mg or 70mg, weekly; calcium, pill, 500mg or 1000mg daily; vitamin D, liquid, 800IU, daily, depending upon the body weight for 12 months.
223768307|NCT02224365|DIETARY_SUPPLEMENT|Apple|12 weeks of 75 g dried apple powder taken in 480 ml per day.
223768308|NCT02224365|DIETARY_SUPPLEMENT|Placebo|12 weeks of 75 g apple-flavored placebo powder taken in 480 ml per day.
223768309|NCT00000436|BEHAVIORAL|Self-efficacy and muscle strength training|
224239350|NCT03114956|PROCEDURE|Comprehensive|A comprehensive treatment including the use of titanium brush and air powder abrasion (as described above) and 30 seconds etching with 9.6% HF acid gel (Premier, USA) applied with a micro-applicator tip (Unipack Medical, USA), followed by copious irrigation with sterile saline.
223656340|NCT04601467|DRUG|Placebo|Oral dose of matching placebo (tablet) once daily for 12 months
224239351|NCT03970772|DRUG|Glucagon Injection|Participants will be instructed to check their blood glucose (BG) with study meter once they developed hypoglycemia symptoms, their CGM reads below 70 mg/dl, or when the CGM glucose was trending down and the participant intended to treat to prevent hypoglycemia. Participants will be instructed to check BG with meter 3 times and treat the hypoglycemia event using mini-dose glucagon when their BG in range 40-69 mg/dl according a prescribed protocol.
223656341|NCT03828201|DRUG|Delamanid|"Frequency: daily Route of administration: oral~Delamanid is a medication used to treat tuberculosis. Specifically it is used, along with other antituberculosis medications, for active multidrug-resistant tuberculosis. It is taken by mouth."
223656342|NCT03828201|DRUG|Levofloxacin|"Frequency: daily Route of administration: oral~Levofloxacin is an antibiotic used to treat a number of bacterial infections including acute bacterial sinusitis, pneumonia, urinary tract infections, chronic prostatitis, and some types of gastroenteritis. Along with other antibiotics it may be used to treat tuberculosis."
223656343|NCT03828201|DRUG|Bedaquiline|"Frequency: daily Route of administration: oral~Bedaquiline is indicated for use as part of an appropriate combination regimen for pulmonary multidrug-resistant tuberculosis (MDR-TB) in adult patients when an effective treatment regimen cannot otherwise be composed for reasons of resistance or tolerability."
224239352|NCT03970772|OTHER|Glucose Tablets|Participants will be instructed to check their blood glucose (BG) with study meter once they developed hypoglycemia symptoms, their CGM reads below 70 mg/dl, or when the CGM glucose was trending down and the participant intended to treat to prevent hypoglycemia. Participants will be instructed to check BG with meter 3 times and treat the hypoglycemia event using glucose tablets when their BG in range 40-69 mg/dl according a prescribed protocol.
224239353|NCT00313885|DRUG|eplivanserin (SR46349)|oral administration
223656344|NCT03828201|DRUG|Clofazimine|"Frequency: daily Route of administration: oral~Clofazimine has shown activity against multidrug-resistant tuberculosis (MDR-TB) and is now recommended by the World Health Organization (WHO) to treat drug resistant tuberculosis as a Group B drug. It is thought that clofazimine acts by inhibiting the formation of matrixes within the DNA and thus delaying the growth of the bacterium. Clofazimine first received FDA approval in 1986, although its use in the treatment of MDR-TB has not been approved by any stringent regulatory authorities and it is therefore used off-label for this function."
223656345|NCT03828201|DRUG|Linezolid|"Frequency: daily Route of administration: oral~Linezolid is an antibiotic used for the treatment of infections caused by Gram-positive bacteria that are resistant to other antibiotics."
223656346|NCT05551156|BEHAVIORAL|Animal-assisted interaction|Visits will occur on 3 consecutive days during your participant's inpatient hospital stay. A dog-handler team or a handler alone will visit participants with a dog for approximately 20 minutes at a convenient time for the participant. During this visit, the participant will be able to pet the dog if they wish. The handler will talk with the participants about the dog, the weather, sports, or other light topics. Participants can also suggest light topics to talk about as well.
223656347|NCT05551156|BEHAVIORAL|Conversational interaction|Visits will occur on 3 consecutive days during your participant's inpatient hospital stay. A dog-handler team or a handler alone will visit participants without a dog for approximately 20 minutes at a convenient time for the participant. During this visit, the handler will talk with the participants about the weather, sports, or other light topics. Participants can also suggest light topics to talk about as well.
223656348|NCT00005062|RADIATION|radiation therapy|
224239354|NCT00313885|DRUG|placebo|oral administration
224321045|NCT01843296|PROCEDURE|Spinal Anesthesia|Lumbar puncture was performed in sitting position,at the one level above iliac crest. Using a median approach, a 25-G Quincke needle was introduced with the needle aperture directed laterally.
224321046|NCT01843296|DRUG|Bupivacaine|
223656349|NCT06518408|DRUG|Cabotegravir Injectable Product|long-acting regimen dosed every 2-months
223656350|NCT06518408|DRUG|Rilpivirine Injectable Product|long-acting regimen dosed every 2-months
224321047|NCT01843296|DRUG|Fentanyl|
224321048|NCT06048952|BEHAVIORAL|Music Therapy|Huseyni maqam, Pentatonic music
223656351|NCT05159336|DEVICE|tACS for auditory hallucinations via single arm|a 20 weeks, weekly 40 minutes, 1mA, 10Hz-tACS protocol
223656352|NCT04101942|BEHAVIORAL|Internet-based CBT|The experimental group will go through active internet-based treatment which is delivered on a safe internet platform. Treatment is divided into four modules, each containing homework assignments. Participants in experimental group will be assigned a therapist that they can contact through a message system in the platform and expect answer within 36 hours.
223656353|NCT02334462|BIOLOGICAL|Pfs230D1M-EPA/Alhydrogel|
223656354|NCT02334462|BIOLOGICAL|Pfs25M-EPA/Alhydrogel|
223656355|NCT02334462|DRUG|TWINRIX|
223656356|NCT02334462|DRUG|Menactra|
223656357|NCT02439502|DEVICE|Fuse® system|Fuse® system will be used to perform gastro and endoscopic diagnostic procedures for upper and lower GI tract.
223656358|NCT04496570|PROCEDURE|periodontal therapy|Non surgical periodontal therapy was performed to patients with peridontitis
223656359|NCT01491984|DEVICE|Laryngoscopy order: 1) MAC, 2) Levitan|Laryngoscopy with MAC, then Levitan
223656360|NCT01491984|DEVICE|Laryngoscopy order: 1) Levitan, 2) MAC|Laryngoscopy with Levitan, then MAC
223656361|NCT05228691|OTHER|Evaluation and Education|A functional physical evaluation will be carried out and they will be informed about the characteristics of their symptoms. After the evaluation, they will be taught a guideline of exercises and recommendations.
223656362|NCT06531785|DEVICE|chest ultrasound|Lung ultrasound to early diagnose ILD among rheumatoid arthritis patients
223656363|NCT05162937|BIOLOGICAL|IL-17A antibody|Recombinant fully human IgG4 anti-IL-17A monoclonal antibody drug
223656364|NCT04095429|BEHAVIORAL|Expect Respect|Expect Respect is a 24 session curriculum designed to support middle school students to increase skills in emotion regulation, relationship skills, communication, and positive bystander intervention behaviors.
223768310|NCT00000436|PROCEDURE|High-intensity strength training|
223768311|NCT00670228|DRUG|Insulin Glargine (LANTUS)|Subcutaneous insulin glargine was initiated 90 prior to the insulin glulisine infusion discontinuation (i.e. 48 hours after randomization) and titrated as per physician preference to maintain the plasma glucose between 90-130 mg/dL
223768312|NCT00670228|DRUG|Insulin Glulisine (Apidra)|"Prior PCI, subjects received a single IV bolus of insulin glulisine. The dose was 0.025 U/kg based upon patient reported weight.~Then IV insulin glulisine infusion was started within one hour of the IV insulin glulisine bolus and administered at a minimum rate of 2 U/h for 48 hours. The infusion was titrated in order to achieve and maintain the plasma glucose between 90 and 130 mg/dL."
223768313|NCT00670228|DRUG|Standard Therapy|Standard insulin therapy titrated to blood sugar control
223768314|NCT05554861|DEVICE|Low Frequency rTMS Protocol|"It was planned to apply 1 Hz low-frequency inhibition protocol to the primary motor cortex foot area in the non-lesional hemisphere, 5 days a week for 2 weeks, for a total of 10 sessions.~After the daily rTMS session, it was planned to apply a conventional rehabilitation therapy for 60 minutes to all patients for 6 weeks (Exercise program consisting of joint range of motion exercises, strengthening exercises, balance exercises and neurophysiological exercises (Brunstroom exercises) for 45 minutes and 15 minutes of NMES application in the presence of an experienced physiotherapist)."
223768315|NCT05554861|DEVICE|Intermittent Theta Burst Stimulation (iTBS) Protocol|"It was planned to apply 50 Hz high-frequency stimulation protocol to the primary motor cortex foot area in the ipsilesional hemisphere, 5 days a week for 2 weeks, for a total of 10 sessions.~After the daily rTBS session, it was planned to apply a conventional rehabilitation therapy for 60 minutes to all patients for 6 weeks (Exercise program consisting of joint range of motion exercises, strengthening exercises, balance exercises and neurophysiological exercises (Brunstroom exercises) for 45 minutes and 15 minutes of NMES application in the presence of an experienced physiotherapist)."
223768316|NCT05554861|DEVICE|Sham rTMS Protocol|"It was planned to apply daily sham rTMS to the motor extremity area of the primary motor cortex along a 10 cm thick wood for 10 sessions.~After the daily sham rTMS session, it was planned to apply a conventional rehabilitation therapy for 60 minutes to all patients for 6 weeks (Exercise program consisting of joint range of motion exercises, strengthening exercises, balance exercises and neurophysiological exercises (Brunstroom exercises) for 45 minutes and 15 minutes of NMES application in the presence of an experienced physiotherapist)."
223768317|NCT02968732|PROCEDURE|Radical Cystectomy|
223768318|NCT05609409|BEHAVIORAL|FlexED|Intervention consists of eight 20-30 minute sessions of a digital intervention based on Acceptance and Commitment Therapy (ACT). Participants learn skills of body image flexibility by following an avatar through a story line and completing interactive exercises.
223768319|NCT06163573|BIOLOGICAL|N-TEC|Implantation of an autologous tissue engineered cartilage graft in the patellofemoral joint for treatment of osteoarthritis.
223768320|NCT06163573|BIOLOGICAL|Platelet rich plasma|"Injection of an autologous Conditioned Plasma ACP® on the basis of one injection per week for three consecutive weeks.~Conditioned Plasma ACP®, Arthrex, one injection per week for three consecutive weeks."
223656365|NCT04095429|BEHAVIORAL|Enhanced Usual Care|Participants will be connected via a warm referral to available individual behavioral health supports and resources in their community that can support them.
223656366|NCT01613898|BIOLOGICAL|Blood tests|Blood tests
223656367|NCT00482989|BIOLOGICAL|MEDI 545|"MEDI-545 is supplied as a sterile liquid containing 0.75 mL of MEDI-545 solution at a concentration of 100 mg/mL in a 3 mL single-use glass vial.~Dosage, frequency and duration: MEDI-545 (0.3, 1.0, 3.0, or 10.0 mg/kg) will be administered via infusion over at least 60 minutes every 2 weeks for 26 weeks."
223656368|NCT00482989|OTHER|Placebo|"Dosage form: Placebo is supplied as a sterile liquid containing a 0.75 mL solution in a 3 mL single-use vial.~Dosage, frequency and duration: Placebo (0.3, 1.0, 3.0, or 10.0 mg/kg) will be administered via infusion over at least 60 minutes every 2 weeks for 26 weeks."
223656369|NCT00349050|DEVICE|laboratory pain assessment|Participants will record their pain experiences every day for 2 weeks before receiving the first of 5 laboratory pain assessments. The laboratory pain assessment uses a small device, controlled by a computer and attached to the underside of the forearm, to produce different temperature stimulations. As the device reaches a level considered painful to the participant, he/she can push a button to return to a level of comfort.
223656370|NCT00349050|PROCEDURE|transcranial magnetic stimulation|"There will be two, 20-minute, 3-day TMS treatment sessions. Participants will be randomly assigned to one of two groups. Group A will receive real TMS for the first 3-day treatment and sham TMS (which does not involve real stimulation) for the second treatment. Group B will receive sham TMS for the first treatment, and real TMS for the second treatment. Regardless of the group, participants will receive both real and sham TMS."
223656371|NCT01580215|DEVICE|Zephyr Endobronchial Valve (EBV)|• Implantation of at least one Zephyr EBV following Chartis assessment
223656372|NCT00250289|DEVICE|a mucosal sticker with herbal formula|
223656373|NCT00616785|DRUG|cisplatin|
223656374|NCT00616785|DRUG|etoposide|
223656375|NCT00616785|DRUG|irinotecan hydrochloride|
223656376|NCT00616785|RADIATION|radiation therapy|
223656377|NCT01209702|BIOLOGICAL|tocilizumab|Administered intravenously (iv) every 4 weeks
223656378|NCT01209702|DRUG|Placebo|Placebo to tocilizumab administered intravenously every 4 weeks
223656379|NCT00010829|BEHAVIORAL|American Heart Association Step 1 diet|
223656380|NCT00010829|BEHAVIORAL|American Heart Association Step 2 diet + 10 g/day flax seed|
223656381|NCT00010829|BEHAVIORAL|Macrobiotic dietary intervention|
223656382|NCT03948945|RADIATION|Profile HaloTM Mixed Fractional Laser|Profile HaloTM fractional laser is the world's first hand tool with nonablative and ablative fractional laser. It includes a nonablative fractional laser with a wavelength of 1470 nm and an ablative fractional laser with a wavelength of 2940 nm. It has a good therapeutic effect on skin aging.
223656383|NCT04593264|OTHER|Self-guided pre-habilitation exercise program|A set of self-guided exercises developed by an athletic trainer to perform at home in order to optimize the knee for ACL repair surgery
223656384|NCT04593264|OTHER|Traditional pre-habilitation|Pre-habilitation exercise sessions under the direct supervision of a physical therapist.
223656385|NCT01701947|BIOLOGICAL|Hemoleven|Replacement therapy
224239355|NCT02492399|PROCEDURE|extended myectomy|The scheme of extended septal myectomy: Two parallel incisions were made into the septal bulge and connected to remove the muscle mass. Myectomy was extended to the base of the papillary muscles, when midseptal thickening was present. The papillary muscles were grasped and pushed medially to visualize the abnormal connections between the papillary muscles and the anterior wall of the ventricle. A blade was used to divide the thickened abnormal attachments. A pituitary rongeur may be used to resect a portion of the junction of the papillary and lateral wall. This reduces the diameter of the papillary muscle and allows for posterior displacement of the anterior mitral leaflet. Division of abnormal attachments and thinning of the papillary muscles is critical for the treatment of SAM.
223656386|NCT01103193|DRUG|remifentanil injected|mixture of 60% nitrous oxide and 40% oxygen is administered through a face mask. In the first group the patient receives a constant concentration of sevoflurane. In this group the remifentanil concentration will be injected via an intravenous line in a step up protocol.
223656387|NCT01103193|DRUG|sevoflurane in step up concentration|of 60% nitrous oxide and 40% oxygen is administered through a face mask.remifentanil is injected in a fixed rate and sevoflurane is administered in a step up concentration.
223656388|NCT03001817|DRUG|K-877|
223656389|NCT03001817|DRUG|Fenofibrate|
223656390|NCT03001817|DRUG|Placebo (for K-877)|
224239356|NCT02492399|PROCEDURE|myectomy by Morrow|A first myotomy is made into the septum just below the base of the right coronary leaflet at a point 2-3 mm to the right of the commissure between the left and right coronary leaflets. A second myotomy is made in the same manner, parallel to the first one and about 1 cm to the right of it. The two vertical myotomies are made and cornnected transversely in the interventricular septum. The muscle bar is then grasped with the angled rongeur and the instrument is pushed firmly toward the apex, peeling the mtusele from its anterior septal attachments. After completion of the resectioni, a rectangular channel about 1 X 1.5 cm is palpable from the valve ring toward the apex for a dis- tance of about 4 cm.
224239357|NCT00672854|DRUG|ClinOleic 20% Intravenous Emulsion|ClinOleic 20% is a lipid emulsion containing a mixture of refined olive oil (approximately 80%) and refined soybean oil (approximately 20%) corresponding to an essential fatty acid intake of approximately 20% of the total fatty acids intake.
224239358|NCT00672854|DRUG|Intralipid, 20% Intravenous Emulsion|It is made up of 20% Soybean oil, 1.2% egg yolk phospholipids, 2.25% glycerin, and water for injection
224239359|NCT03491358|DEVICE|Wright jet nebulizer|Roxon Medi-Tech, Montreal, QC, Canada
224239360|NCT03491358|DEVICE|Aerogen Solo|Aerogen Ltd., Galway, Ireland
224239361|NCT01627366|OTHER|Survivorship Care Plan|Receipt of a personalized survivorship care plan and an in-person session with a trained nurse to review the contents of the care plan.
224239362|NCT04644133|OTHER|Paper diary|Subjects will be asked to complete a 2 week paper stool diary.
223656391|NCT03001817|DRUG|Placebo (for Fenofibrate)|
223656392|NCT00995800|DRUG|Fluticasone propionate / Formoterol fumarate|2 dose strength vs. placebo
223656393|NCT03005405|PROCEDURE|Ionomer Restoration (control)|Restoration of moderate caries lesions after partial caries removal using high viscosity glass ionomer cements
224239363|NCT04644133|OTHER|Electronic APP diary|Subjects will be asked to complete a 2 week paper stool diary.
224239364|NCT03383744|DIETARY_SUPPLEMENT|vitamin A supplementation|Each child received one capsule of 200,000 IU of vitamin A
224239365|NCT04291066|DRUG|N-Acetyl cysteine|Carbonyl scavenger and multi-vitamins with minerals to neutralize reactive carbonyl groups on the lipid aldehydes in patients with TBI
224321049|NCT02934399|OTHER|27 hour subcutaneous fluid sampling|"One hour prior to the microdialysis catheter insertion the participants will be asked to receive a local anaesthetic on the injection site for the microdialysis catheter. Lignocaine 1% will be injected subcutaneously at a localised site on the abdomen covering a horizontal area of about 5cm after a brief acclimatisation period at the hospital.~A sterile linear catheter will be inserted using aseptic precautions at the anaesthetised site on the abdomen. The catheter is connected at one end to the microdialysis pump, and at the other end to the automated collection device. Subcutaneous tissue microdialysis samples will be collected regularly for the duration of the sampling period (27 hours)."
223656394|NCT03005405|PROCEDURE|Ionomer Sealant (test)|Sealing of moderate caries lesions without any caries removal or cavity opening.
223656395|NCT03005405|PROCEDURE|Oral hygiene orientation and professional fluoride application|Oral hygiene orientation and professional fluoride application
223656396|NCT03855059|DRUG|Placebos|This will be a saline solution of given IV or perineural.
223656397|NCT03855059|DRUG|Dexamethasone Sodium Phosphate|This will be the active drug solution given IV or perineural.
223656398|NCT01976741|DRUG|Rogaratinib (BAY1163877) oral solution|Participants received Rogaratinib oral solution as a single dose on Cycle 1 Day 1 (C1D1) and twice daily (BID) from Cycle 1 Day 3 (C1D3) onward for the remaining 19 days of Cycle 1. For subsequent cycles, study drug was administered twice daily for 21 days each Cycle.
223656399|NCT01976741|DRUG|Rogaratinib (BAY1163877) oral tablet|Participants received Rogaratinib oral tablet as a single dose on C1D1 and BID from C1D3 onward for the remaining 19 days of Cycle 1. For subsequent cycles, study drug was administered twice daily for 21 days each Cycle.
223656400|NCT01976741|DRUG|Rogaratinib (BAY1163877) 800 mg BID|Participants received Rogaratinib 800 mg oral tablet as a single dose on C1D1 and BID (in total 1600 mg) from C1D3 onward for the remaining 19 days of Cycle 1. For subsequent cycles, study drug was administered twice daily for 21 days each Cycle.
223656401|NCT06406543|DIETARY_SUPPLEMENT|Vitamin D3 (Cholecalciferol)|an oral solution of vitamin D in a refined olive oil solution
223656402|NCT02829801|BEHAVIORAL|AAT and cognitive stimulation and rehabilitation of social tie.|"There are 8 workshops, one workshop per week. The workshops will begin with a 15 minute introductory activity allowing the establishment of the relationship with the dog and between the participants. Activities with the dog will be offered: games, caresses, brushing.~Then, a 40 minute cognitive stimulation will be offered. Finally, 5 minutes will be devoted to the closing of the session and to say goodbye to participants and the dog (pet him, play with him ...)."
223656403|NCT02829801|BEHAVIORAL|Cognitive stimulation and rehabilitation of social tie.|"There are 8 workshops, one workshop per week. The workshops will begin with an introductory activity of 15 minutes that will establish the relationship between the participants. Different topics will be proposed to foster communication and exchange.~Then, the same cognitive stimulation in the AAT arm will be offered."
223656404|NCT01688349|OTHER|analyze the role of glucocorticoid in AT distribution.|"The purpose of this trial is to investigate the impact of cortisol on adipose tissue functions, distribution and morphology. Patient with endogenous blood cortisol excess exhibit changes in adipose tissue, with fat gain in the upper trunk, face and neck leading to visceral obesity and features of the metabolic syndrome. The aims of this study will be~* to compare the pattern of gene expression between visceral and subcutaneous adipose tissue in Cushing patients requiring an adrenalectomy as cortisol adenoma treatment;~* to compare these patterns of gene expression with those of two control populations:1/ healthy metabolic subjects having a partial nephrectomy, 2/obese patients with similar degree of insulin resistance."
223656405|NCT02752282|OTHER|Anticipatory Counseling|Anticipatory Counseling provides information on expected side-effects that may change or go away over time, or stay for the duration of the treatment. Anticipatory counseling can also help patients understand when their side-effects are normal and when to seek medical attention.
223656406|NCT02752282|OTHER|Cancer Screening Guidelines|Anticipatory Counseling on United States Preventative Services Task Force (USPSTF) updated pap screening guidelines
223656407|NCT04565704|DEVICE|Biopsy imaged by Optical imaging device.|
223656408|NCT03639909|PROCEDURE|sweating function|Sweating dysfunction by Sudoscan
223656409|NCT03639909|PROCEDURE|Cardiovascular function|Cardiovascular (CV) tests
223656410|NCT01612832|DRUG|Pregabalin|Patients in one group will receive 150 mg of PGL at 20:00 h the night before surgery and at 1.5 h before surgery, and will undergo surgery under general anesthesia (GA).
223656411|NCT01612832|OTHER|Control|pain treatment as customary in the department
223656412|NCT05970354|DRUG|EMLA Cream|Eutectic Mixture of Local Anesthetics (Lidocaine 2.5% and Prilocaine 2.5%)
224239366|NCT05249907|OTHER|Massage|"Stroking (stroking) movement will be performed on the soft tissue parallel to the muscle fibers on the origo and insertion lines. Vaseline will be preferred as an intermediate to increase the lubricity of the instrument. The frequency of patting and friction movements will be 60 repetitions per minute.~Starting from the medial side of the gastrocnemius (calf) muscle in both legs and moving it longitudinally from distal to proximal and from back to distal in a straight line within 20 seconds, for 2.5 minutes. Then this treatment will be applied to the lateral side of the gastrocnemius muscle for 2.5 minutes."
224239367|NCT04025879|BIOLOGICAL|Nivolumab|Specified dose on specified days
224239368|NCT04025879|DRUG|Carboplatin|Specified dose on specified days
224239369|NCT04025879|DRUG|Cisplatin|Specified dose on specified days
223656413|NCT05970354|DRUG|VersaPro Cream Base for Compounding|Placebo
223656414|NCT02167139|DRUG|Humira (adalimumab)|
224239370|NCT04025879|DRUG|Paclitaxel|Specified dose on specified days
224239371|NCT04025879|DRUG|Pemetrexed|Specified dose on specified days
223656415|NCT02167139|DRUG|SB5 (proposed biosimilar to adalimumab)|
223656416|NCT04721301|COMBINATION_PRODUCT|Nivolumab plus Ipilimumab plus Maraviroc|In the single treatment arm, all patients receive Nivolumab, Ipilimumab and Maraviroc
223656417|NCT01553370|OTHER|Increased Dairy Intake|3 additional servings of low fat dairy will be consumed
223656418|NCT01553370|OTHER|Supplemental carbohydrate|Maltodextrin will be provided in an amount equal to the the energy content in the 3 supplemental servings of low-fat dairy.
223656419|NCT04205383|OTHER|biological analyses|The histones H3-citrullinated, acetylated histones (Pan-histones), H1 histone as well as the free HMGB1 protein will be quantified. This choice corresponds to the histones involved in inflammation, proliferation, migration or cell differentiation and can be quantified to date.
223656420|NCT04165421|BEHAVIORAL|Family intervention group|Education and Family conversations
223656421|NCT02912858|DEVICE|geko plus R-2|"The gekoTM plus R-2 devices (acting on the common peroneal nerve) and IPC devices will be activated for 10mins prior to measuring blood flow.~The sequence of application of IPC and gekoTM plus R-2 devices will be randomly selected with 10 minutes recovery between active therapies."
223656422|NCT01819532|PROCEDURE|Milking group|"The umbilical cord will be milked toward the neonate four times prior to clamping the umbilical cord."
223656423|NCT01819532|PROCEDURE|Immediate cord clamping|The umbilical cord will be clamped and cut immediately after delivery of the neonate.
223656424|NCT05915598|OTHER|Right/left discrimination training|"Participants will use recognize app by Neuro-orthopedic institute (NOI) for daily right/left discrimination training.~The training will include visual and auditory stimuli, with tasks such as identifying the laterality of images and sounds.~Participants will engage in training for 20 minutes per day, 5 days per week, over a six-week period.~Weekly monitoring and feedback will be provided by the research team"
224239372|NCT04025879|DRUG|Placebo|Specified dose on specified days
224239373|NCT04025879|DRUG|Docetaxel|Specified dose on specified days
224239374|NCT01198236|DRUG|Itraconazole|"Itraconazole will be administered intravenously 2×200 mg/d(200mg twice a day, with 12 hours interval, and should be completed in no less than 60 minutes each time) in the first two days of treatment as a loading dose, then 200mg/d intravenously (200mg once a day with 24 hours interval and completed in no less than 60 minutes) until the end of the at-risk period.~In transplant patients, the end of at-risk period is defined as a stable engraftment of 1\*109/L neutrophil cells; in patients who have undergone chemotherapy, it is defined as the resolution of neutropenia (neutrophil cells\> 0.5\*109/L).~If needed, the patients will take itraconazole solution orally after intravenous administration."
224321050|NCT03674736|DIETARY_SUPPLEMENT|Dietary Intakes|Four levels of methionine or lysine intakes will be provided by the reference protein drinks, 3 levels of methionine from rice and wheat bread and 3 levels of lysine from chickpeas and lentils
224321051|NCT04750889|DEVICE|RFID tags|Installation of the RFID tag device wire localization)
224321052|NCT04750889|DEVICE|Wire localization|Installation of the wire localization device
223656425|NCT05915598|OTHER|usual care|"Usual care: Participants will continue their usual care management for fibromyalgia, including any prescribed medications and physician consultations. No specific right/left discrimination training will be provided to the control group.~Follow-up assessments: Participants in the control group will undergo the same follow-up assessments as the intervention group to evaluate changes in pain perception, functional disability, and cognitive function."
223656426|NCT02893956|PROCEDURE|echocardiography with postural support|
223656427|NCT02893956|PROCEDURE|echocardiography with standard condition (usual)|
223656428|NCT02397629|OTHER|This study has no intervention|
223656429|NCT04655651|OTHER|No intervention|There is no intervention for both groups.
223656430|NCT00333099|DIETARY_SUPPLEMENT|Impact (R) Enteral Nutrition|mucositis frequency, treatment tolerance
223656431|NCT00333099|OTHER|impact|"1500 calories every day :~-5 days before the begining of the chemoradiotherapy and until the last day of the treatment"
223656432|NCT01719744|DRUG|ENMD-2076|
223656433|NCT05298449|DRUG|HU-045|"HU-045 is a medicine that is injected into muscles and used to improve the look of moderate to severe frown lines between the eyebrows (glabellar lines) in adults for a short period of time (temporary). It should be reconstituted with sterile, preservative-free 0.9% saline before use.~White powder"
223656434|NCT05298449|DRUG|Xeomin®|Xeomin® is a prescription medicine that is injected into muscles and used to improve the look of moderate to severe frown lines between the eyebrows (glabellar lines) in adults for a short period of time (temporary). It should be reconstituted with sterile, preservative-free 0.9% saline before use.
223656435|NCT00781573|DRUG|Clopidogrel|Clopidogrel, 75 mg QD, for one year
223656436|NCT03545971|DRUG|IBI310|IBI310 is anti CTLA-4 antibody
223656437|NCT03545971|DRUG|Sintilimab|PD-1 monoclonal antibody
223656438|NCT05475574|OTHER|Discontinuation of contact precautions for ESBLE|Discontinuation of contact precaution : only standard precaution are implemented for any patient carrying (infected or colonized) ESBLE
223656439|NCT03649997|DRUG|JNJ-61393215|Participants will be administered JNJ-61393215 in Part 1, 2 and 3 of study as oral suspension.
223656440|NCT03649997|DRUG|Placebo|Participants will be administered JNJ-61393215-matching placebo in Part 1, 2 and 3 of study as oral suspension.
223656441|NCT03649997|DRUG|JNJ-61393215|Participants will be administered JNJ-61393215 in Part 1, 2 and 3 of study as capsule.
223656442|NCT05854784|DRUG|Afamelanotide 16 MG|Eligible patients will receive one dose of afamelanotide 16mg every 28 days (up to six doses), as a controlled-release formulation.
223656443|NCT06121544|DIAGNOSTIC_TEST|Plasma tau|Plasma levels of different p-tau and np-tau species
223656444|NCT06121544|DIAGNOSTIC_TEST|Plasma Ab42/Ab40|Plasma levels of Ab42/Ab40 ratio
223656445|NCT06121544|DIAGNOSTIC_TEST|Flutemetamol F18 Injection|Positron emission tomography (PET) imaging of amyloid-β plaques
223656446|NCT06121544|DIAGNOSTIC_TEST|[18F]-RO6958948 Injection|PET imaging of Tau aggregates
223656447|NCT06121544|DIAGNOSTIC_TEST|Magnetic resonance imaging (MRI)|Different MRI sequences relevant for brain imaging
223656449|NCT03629951|DRUG|Oral Antipsychotics (OAP)|This is an observational study. Participants enrolled in this study will continue to receive routine treatment of OAPs for example, risperidone (1 to 6 mg OD to BID), olanzapine (5 to 20 mg OD), haloperidol (5 to 20 mg OD to TID) etc, as directed by their treating physician.
223656450|NCT03977181|BEHAVIORAL|Group-based Community Health Club|GBHCs will be facilitated by trained Lay Health Counsellors (LHC). GBHCs will consist of a maximum 20 participants. GBHC sessions will held multiple times a month in each study area, allowing for flexibility for study participants. Sessions will be held at a safe and secure, centrally located area within the study community, and will be regularly monitored and assessed by the study coordinator. Participants will be invited to join a club-specific WhatsApp group to facilitate group communication and adherence support throughout the month. They will also be invited to partner up with another participant to provide mutual peer support. Permission will be sought from group-based adherence support participants before they are added to WhatsApp groups. Group adherence counsellors assigned will be members of WhatsApp groups, and will monitor all shared content to ensure that no inappropriate content or private information is shared in the group.
223656451|NCT03977181|BEHAVIORAL|Individual-based Adherence Support|IAS participants will be matched to a LHC and will schedule IAS sessions once-a-month for the duration of the study. These sessions will be held at a centralized location within the study community. The sessions will be semi-structured to allow for participant-driven discussion of any adherence challenges and key-messages. The adherence curriculum will also explore motivations for PrEP and adherence and focus on practical adherence tips, environmental cues, integration of PrEP within daily routines, short-term goal-setting, problem-solving, safe PrEP disclosure and social support, risk reduction counselling, partner communication, and HIV risk perception. A subset of IAS sessions will be audio-recorded for quality assurance by investigators and the study coordinator. These recordings are for training purposes only and will not form part of the dataset. Consent for recording IAS sessions will be sought from participants during the pre-enrolment consent process.
223656452|NCT03350672|DRUG|FTC/TAF|Participants in cohorts 1a\&b will be administered FTC/TAF for 1 to 7 consecutive days and then be followed clinically for 6 to 14 days. Cohort 2 will participate in a 1 time blood and urine collection.
223656453|NCT00003278|DRUG|dexamethasone|
224321053|NCT05203783|OTHER|McKenzie Exercises|"McKenzie exercises: The McKenzie set consists of 5 exercises.~1. Prone-lying~2. Prone-extension~3. Prone press ups~4. Progressive extension with pillows~5. Standing extension"
223656454|NCT00003278|RADIATION|radiation therapy|
223656455|NCT02321709|DRUG|SAR113244|Pharmaceutical form:solution for injection Route of administration: subcutaneous
223656456|NCT02321709|DRUG|placebo|Pharmaceutical form:solution for injection Route of administration: subcutaneous
223656457|NCT05694416|DRUG|Etoposide Plus Cisplatin|Etoposide Plus Cisplatin ivdrip d1-5
223656458|NCT04348916|BIOLOGICAL|ONCR-177|Intratumorally administered oncolytic immunotherapy comprised of a genetically engineered HSV-1
223656459|NCT04348916|BIOLOGICAL|pembrolizumab|Anti-PD-1 monoclonal antibody
223768321|NCT02545894|BEHAVIORAL|Cognitive therapy|"The tasks are:~* visually tracking a picture as it moves across the computer screen~* pressing a button every time a picture is seen on the screen~* pressing a button every time a specific picture is seen on the screen~* Pressing a button every time a specific sound is heard~* Matching objects to a picture~* Matching gestures to objects~* Matching two connected objects~* Sorting objects by categories~* Matching sounds to objects~* Complete the category and odd on out with objects~* Choosing target objects by pointing~* Choosing objects to complete the category by pointing"
223768322|NCT05071417|DRUG|Semaglutide|Usual treatment with semaglutide. Dose 0.5 - 1mg weekly, subcutaneous, weekly
223656460|NCT00773214|BEHAVIORAL|Exercise|12-week supervised exercise programme (5 times /week at 75% maximal Heart Rate)
223656461|NCT00267566|BEHAVIORAL|Strongest Families (formerly Family Help Program): Anxiety Program|Evidence-based psychological and behavioural distance intervention
223656462|NCT00416221|DRUG|Lexapro, an antidepressant medicine|
223656463|NCT00416221|BEHAVIORAL|Physical Activity|
223656464|NCT00416221|BEHAVIORAL|Mood Management Skills|
223656465|NCT00416221|BEHAVIORAL|Personalized support from a Family Nurse Practitioner|
223768323|NCT02013323|DRUG|Scaling and root planing, and Septilin for 7 days|Subjects in septilin group received Septilin tablets (Septilin tablets, Himalaya Drug Company, India), 500 mg of 2 tablets to be taken thrice daily for 7 days after scaling and root planing and checked for clinical and micrbiological parameters at baseline, 10 days, 1 month, 3 months and 6 months.
223768324|NCT02013323|DRUG|Scaling and root planing, and Placebo drug for 7 days|Subjects in placebo group received placebo tablets taken thrice daily for 7 days and checked for clinical and microbiological parameters at baseline, 10 days, 1 month, 3 months and 6 months
223768325|NCT01702233|DRUG|Traumeel S inj|Traumeel S inj. 2 ml. subacromial 3 times at days 1, 8 and 15
223768326|NCT01702233|DRUG|Fortecortin/Dexamethasone 8 mg/2 ml inj|Fortecortin/Dexamethasone 8 mg/2 ml inj. subacromial 3 times at days 1, 8 and 15
223768327|NCT01702233|DRUG|Saline inj|Saline inj. 2 ml. subacromial 3 times at days 1, 8 and 15
223768328|NCT05081661|OTHER|Motor Imagery Program|The intervention group of the study will undergo standard postoperative physical therapy treatment at their therapist. Beginning on the third day after surgery, the participant will begin an motor imagery program to be performed three times a week for four weeks. A session lasts between fifteen and twenty minutes. It begins with a body awareness phase followed by a series of three to five one-minute exercises to be repeated three times, with a one-minute break between each exercise. The program is performed independently at home using a standardized audio tape.
223768329|NCT05081661|OTHER|Placebo program|"The control group of the study will undergo standard postoperative physiotherapy treatment at their therapist. On the third day after surgery, the participant will begin a relaxation program inspired by the mindfulness tool called Bodyscan that acts as a placebo mental imagery program. Nevertheless, the program created for this technique does not follow the Bodyscan guidelines (Jon Kabat-Zinn, 2005), as we do not want there to be any effects in favor of improved body perception on the participants, which could bring an additional biai to the study. For the sake of understanding, we have used the term body visualization in the various documents distributed to the participants. The program is to be performed three times a week for four weeks. A session lasts between ten and fifteen minutes. The program is performed independently at home using a standardized audio tape."
223768330|NCT06139627|OTHER|Best Practice|Receive usual care
223768331|NCT06139627|PROCEDURE|Biospecimen Collection|Undergo blood and stool sample collection
223768332|NCT06139627|OTHER|Communication Intervention|Receive GA assessment summary and assessment-based recommendations
223768333|NCT06139627|OTHER|Comprehensive Geriatric Assessment|Complete GA
223768334|NCT06139627|OTHER|Electronic Health Record Review|Ancillary studies
223768335|NCT06139627|OTHER|Survey Administration|Ancillary studies
223768336|NCT01083030|DEVICE|Percutaneous transluminal angioplasty (PTA)|Angioplasty of superficial femoral artery (SFA)
223768337|NCT01083030|COMBINATION_PRODUCT|DCB|Drug Coated Balloon Angioplasty
223768338|NCT00529932|OTHER|CD133+ infusion|Subjects will be infused with all available autologous CD133+ cells after processing during one infusion session (during angiography).
223768339|NCT00529932|OTHER|placebo infusion|Buffered normal saline will be infused in the coronary artery during an angiography.
223656466|NCT02403440|DRUG|Hetrombopag Olamine|Hetrombopag Olamine 2.5mg, 5mg and 7.5mg
223656467|NCT06422897|OTHER|anterior segment optical coherence tomography|surgically treated corneal perforation by amniotic membrane graft and platelet rich plasma clot is assessed by anterior segment optical coherence tomography 1 month postoperative
223656468|NCT02019797|DRUG|Desflurane|Patients are assigned to desflurane group (Des) or propofol group (Prop). Des receives desflurane (1-2 MAC) inhalation between the induction of anesthesia and before cardiopulmonary bypass (CPB). After the induction of CPB, the anesthesia in Des is switched to a total intravenous anesthesia (TIVA) with propofol. Prop receives a propofol during the surgery.
223656469|NCT02640456|BIOLOGICAL|Bacteriology|Tonsillar surface swabs, tonsillar tissues, and pus aspirates.
223656470|NCT02640456|PROCEDURE|Type of surgery|Surgical approach and complications.
223656471|NCT02640456|BIOLOGICAL|Biochemistry|Amylase concentration i pus aspirates.
223656472|NCT02640456|BIOLOGICAL|Serology|Levels of antibodies against selected bacteria (F. necrophorum, F. nucleatum, and Group A streptococci) in acute and convalescent sera.
223656473|NCT01637129|DEVICE|Transcranial Magnetic Stimulation|Transcranial Magnetic Stimulation, repetitive at 1Hz
223656474|NCT01637129|DEVICE|Sham Magnetic Stimulation|Sham Magnetic Stimulation
223656475|NCT02504216|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|2.5 mg, twice daily, orally, tablet
223656476|NCT02504216|DRUG|Rivaroxaban-Placebo|matching placebo, twice daily, orally, tablet
223656477|NCT02544516|OTHER|cognitive tasks + PANSS+ IQ|Patients will have cognitive tasks: reaction time (Alert TEA, Zimmermann and Fimm, 2005), Edinburgh laterality questionnaire (Oldfield, 1971), IQ test (IQ: PM38, Raven, 1960), and the PANSS (Positive and Negative Syndrome Scale, Kay et al., 1987
223656478|NCT02544516|OTHER|cognitive tasks|Patients will have cognitive tasks: reaction time (Alert TEA, Zimmermann and Fimm, 2005), Edinburgh laterality questionnaire (Oldfield, 1971),
223656479|NCT02731105|DRUG|Acnatac® Gel left face|topical application
223656480|NCT02731105|DRUG|Epiduo® Gel right face|topical application
223656481|NCT02731105|DRUG|Acnatac® Gel right face|topical application
223656482|NCT02731105|DRUG|Epiduo® Gel left face|topical application
223656483|NCT02475694|OTHER|No intervention|No treatment
223656484|NCT02451709|DEVICE|Activated Smartinhaler or Smartturbo|Medication reminder alarms
223656485|NCT02451709|OTHER|Feedback of adherence data|Review of adherence data with action planning
223656486|NCT02451709|DEVICE|Deactivated Smartinhaler or Smartturbo|Alarms deactivated and no feedback
223768340|NCT03396783|BIOLOGICAL|blood test|during the visit, nurse will make a blood test for biological and immunological analysis
223656487|NCT03703193|OTHER|Dry Needling|A single session of modulatory interventions combined with a single session of dry needling into the shoulder muscles which active trigger points will reproduce the shoulder pain symptoms.
223656488|NCT03703193|OTHER|Physical Therapy|A single session of modulatory interventions targeting modulation of central nervous system.
223656489|NCT00223080|BIOLOGICAL|ALVAC-HIV vCP1521 + AIDSVAX|Combined dose of 600 μg (300 μg of each antigen), co-formulated and administered in alumi-um hydroxide gel at a dose of 600 μg/mL
223656490|NCT00223080|OTHER|ALVAC Placebo + AIDSVAX Placebo|ALVAC carrier, supplied as a lyophilized product, without virus and Aluminum hydroxide adjuvant, 1.2 mL per vial, given as a 1 mL injection
223656491|NCT05741619|OTHER|Long-term outcome|Autonomy, physical examination, behavioural disorders
223656492|NCT02598583|BIOLOGICAL|ALXN1210|Participants were administered ravulizumab as an IV infusion every 4 weeks.
223656493|NCT03237286|DRUG|Intravenous ketamine|Intravenous ketamine is given at a subanesthetic dose, which previous research suggests is safe and efficacious for rapid relief from depression.
223656494|NCT03237286|BEHAVIORAL|Computer-based Cognitive Training|"Computer-based Cognitive Training will be delivered following intravenous ketamine to test whether learning during a post-ketamine window of opportunity might extend relief from depression."
223656495|NCT05440552|DIAGNOSTIC_TEST|Qualitative Fecal immunochemical test + APCS score|Risk stratification using Qualitative Fecal immunochemical test and APCS score
223656496|NCT05440552|DIAGNOSTIC_TEST|Quantitative Fecal immunochemical test|Use Quantitative Fecal immunochemical only for risk stratification
223656497|NCT06265662|BEHAVIORAL|A Digital Health Program for Non-Communicable Disease Prevention in a Workplace Setting in Thailand|The program consists of two main components: (1) Participants are invited to join health courses and/or health activities in the form of seminars or group activities, and (2) Participants will have access to an application that is part of the program, where they can consult with health experts to plan lifestyle modifications and reduce behavioral risk factors over the 6-month duration of the research project, totaling four sessions, each lasting one hour.
223656498|NCT04618848|DIAGNOSTIC_TEST|Fingerstick blood draw|Each participant shall be pricked twice in order to perform CBC test
223656499|NCT05785676|DEVICE|Filter implantation|Implantation of OATF ALN vena cava filter
223656500|NCT03193593|DRUG|Placebo|Placebo- Single injection of saline into Pectoralis Muscle
223656501|NCT03193593|DRUG|EB-001|Single injection of EB-001 into Pectoralis Muscle
223656502|NCT00316043|BEHAVIORAL|Written information for parents|
223656503|NCT00316043|BEHAVIORAL|Distance learning package for General Practitioners|
223656504|NCT00316043|BEHAVIORAL|Distance learning package for practice assistants|
223656505|NCT04286048|OTHER|Weight implement|"The technique will be done by making the same movement of the launch, but with the weight implement. The physiotherapist will be next to the pitcher, noting that there is no pain or discomfort when launching. The session will be held for 15min with 30 seconds of rest between each launch, until reaching 15 pitches.~The sessions will be directed by a physiotherapist, in charge of supervising that the pitcher is correctly making the requested movement."
223656506|NCT05102032|PROCEDURE|mini invasive approach|using mini-trocars (3 trocars of 3 mm and a 5 mm-optic trocar) with insufflation pressures of less than 8 mmHg.
223656507|NCT05102032|PROCEDURE|Conventional approach|laparoscopic procedure including standard trocars (3 trocars of 5 mm and a 10 mm-optic trocar) with insufflation pressures between 10 and 12 mmHg.
223656508|NCT00056797|BIOLOGICAL|ALVAC HIV vaccine (vCP1452)|
224239375|NCT02487784|PROCEDURE|Block allograft|A cancellous block allograft plus corticocancellous particulate allograft will be used as the positive control treatment.
224239376|NCT02487784|PROCEDURE|Particulate allograft + autogenous bone chips|The test arm of this study will include a mix of particulate bone allograft and autogenous bone chips.
224239377|NCT02215577|PROCEDURE|In-situ split|The portal branches to the diseased side should be completely divided. The bile duct to the diseased side should not be divided. The parenchyma should be transected all the way through the transection plane and place a plastic sheet on the diseased transection surface.
223656509|NCT00056797|DRUG|Interleukin-2|
223656510|NCT04074408|PROCEDURE|stereotactic surgery|stereotactic aspiration surgery
223656511|NCT04074408|BIOLOGICAL|hUMSCs|single intracavitary infusion 1 day after stereotactic aspiration surgery
223656512|NCT04074408|BIOLOGICAL|placebo|single intracavitary infusion 1 day after stereotactic aspiration surgery
223656513|NCT03313817|DEVICE|Additional MRI sequences|"Patients will be hospitalized for suspicion of CRAO. An optimized MRI will be performed with specific sequences: 3D T1 MSDE (Motion Sensitized Driven Equilibrium) dark blood; 3D Optimized diffusion centered on the optic nerves; 3D PD T1 after injection. A consultation of ophthalmology and a control MRI will be carried out one month after the CRAO. Again, specific sequences will be added: 3D T1 MSDE (Motion Sensitized Driven Equilibrium) dark blood; 3D Optimized diffusion centered on the optic nerves; DTI (Diffusion Tensor Imaging); 3D PD T1 after injection."
223656514|NCT02797613|BEHAVIORAL|Restricted Reporting|An abbreviated version of the microbiology report indicating that growth is present and the physician should call the lab for further details if clinically important
223656515|NCT02121080|DRUG|REGN2222(SAR438584)|
223656516|NCT02121080|DRUG|placebo|
223656517|NCT02879188|OTHER|Physical Therapy|Patients will initiate inpatient physical therapy on the day of their surgery including attempted ambulation with an assistive device that is supervised by a physical therapist.
223656518|NCT02879188|OTHER|Standing|Patients will initiate inpatient physical therapy on postoperative day 1. On the day of their surgery they will dangle their feet over the edge of the bed with supervision of nursing.
223768341|NCT03396783|OTHER|electromyogram and walk test|during the visit, measuring the amount of functional motor units at the muscular level and the distance traveled during a 2 minute walk
223768342|NCT01786694|DEVICE|cma microdialysis catheter placement|the microdialysis catheters are sold by CMA
223768343|NCT04406805|DIAGNOSTIC_TEST|Measurement of plasma and urine trimethylamine-N-oxide concentration|Information already included in arm/group descriptions.
223768344|NCT04410575|OTHER|Standard Pharmacist Care|Standard pharmacy care (as outlined in the Alberta College of Pharmacist Standards of Practice for Pharmacist and Pharmacy technicians)
223656519|NCT05111730|DEVICE|The Shock wave Therapy.|Shockwave therapy is a multidisciplinary device used in orthopedics, physiotherapy, sports medicine, urology and veterinary medicine. Its main assets are fast pain relief and mobility restoration. Together with being a non-surgical therapy with no need for painkillers makes it an ideal therapy to speed up recovery and cure various indications causing acute or chronic pain. Shockwave is an acoustic wave which carries high energy to painful spots and myoskeletal tissues with sub-acute, sub-chronic and chronic conditions. The energy promotes regeneration and reparative processes of the bones, tendons and other soft tissues. Shockwaves are characterized by jump change in pressure, high amplitude and non-periodicity. The kinetic energy of the projectile, created by compressed air, is transferred to the transmitter at the end of the applicator and further into the tissue.
223656520|NCT00438568|DRUG|Regular Insulin|administered intra-nasally twice a day for 16 weeks
223656521|NCT00438568|DRUG|Placebo|administered intra-nasally twice a day for 16 weeks
223656522|NCT00002076|DRUG|Fluconazole|
223656523|NCT05048966|BEHAVIORAL|Group Wellness Class 1|Twelve weekly online group wellness sessions for individuals with the disability and their support person. Each class will last for approximately 2 hours.
223656524|NCT05048966|BEHAVIORAL|Group Wellness Class 2|Twelve weekly online group wellness sessions for individuals with the disability and their support person. Each class will last for approximately 2 hours.
223768345|NCT04410575|OTHER|Reviewed Questionnaire tool results with participant|Pharmacist reviews results of the patient-administered PHQ-9 and/or GAD-7 questionnaire tool, at the scheduled follow-up appointment
223768346|NCT04410575|OTHER|Patient Clinical Assessment|Pharmacist conducts clinical assessment of the participant's major depressive disorder and/or generalized anxiety, which can include: appearance, current mood, sleeping patterns, mental health, medical history, social history, family history, relationship with others, suicidal ideation, previous suicide attempts or hospitalizations, current employment status
223768347|NCT04410575|OTHER|Psychotherapy Referral|Pharmacist initiates collaboration with physician to arrange referral for psychotherapy, including: psychologist, social worker, counsellor, psychiatrist
223768348|NCT04410575|OTHER|Pharmacist initiated interim telephone follow-up with participant|Interim telephone follow-up conducted by the pharmacist since the last in-person follow-up \& a minimum of 1-2 weeks after the last in-person follow-up that involved a dose adjustment, prescribing of adjunctive medication, or discontinuation of therapy (Note: a telephone follow-up does not replace the scheduled in-person follow-up)
223768349|NCT04410575|OTHER|Communication update with physician after participant contact|Pharmacist provides communication update (fax or electronic charting) with the participant's physician after contact with the participant
223768350|NCT04410575|OTHER|Medication Counselling and Educational Support|Pharmacist provides medication related counselling and educational support to participant
223768351|NCT04410575|OTHER|Non-medication Counselling|Pharmacist provides non-medication related counselling and educational support to participant
223768352|NCT04410575|OTHER|Identification of drug interaction|Pharmacist identification of drug interaction related to medication for major depressive disorder and/or generalized anxiety
223768353|NCT04410575|OTHER|Identification of drug adverse effect|Pharmacist identification of adverse effect related to medication for major depressive disorder and/or generalized anxiety
223768354|NCT04410575|OTHER|Identification of severe deterioration|Pharmacist identification of participant severe deterioration (i.e. suicide attempt)
223768355|NCT04410575|OTHER|Pharmacist-to-physician recommendation for medication adjustment, change to alternative, add-on, or deprescribing|Pharmacist collaborates, discusses, and makes recommendations to physician re: treatment plan for MDD and/or GAD (as per CANMAT guidelines), which can include: medication dose adjustment, change to alternative medication, add-on, or deprescribing
223768356|NCT04410575|OTHER|Pharmacist initiated medication adjustment, change to alternative, add-on, or deprescribing|Pharmacist initiated alteration to treatment plan for MDD and/or GAD (as per CANMAT guidelines), which can include: medication dose adjustment, change to alternative medication, add-on, or deprescribing
223768357|NCT05764369|BEHAVIORAL|Parenting Wisely Residential Treatment (PWRT)|PWRT experimental intervention
223768358|NCT05764369|BEHAVIORAL|TAU|The TAU condition is the standard of care offered to parents in RT settings.
223768359|NCT02376907|PROCEDURE|Biliary drainage|EUS-BD or ERCP
223768360|NCT04856696|DIAGNOSTIC_TEST|PGT-A|trophectoderm biopsy in blastocyst stage for euploidy testing using next generation sequencing platform
223768361|NCT04856696|DIAGNOSTIC_TEST|non-invasive PGT-A|cell-free DNA collected from spent culture media for euploidy testing using next generation sequencing platform
223656525|NCT00947882|DRUG|Placebo|Mannitol 50 mg/mL solution
223656526|NCT00947882|DRUG|Degarelix 10 mg|10 mg degarelix, 40 mg/mL solution
223656527|NCT00947882|DRUG|Degarelix 20 mg|20 mg degarelix, 40 mg/mL solution
223656528|NCT00947882|DRUG|Degarelix 30 mg|30 mg degarelix, 40 mg/mL solution
223656529|NCT05268913|DIAGNOSTIC_TEST|MRI scan|Participants will undertake a magnetic resonance imaging scan.
223768362|NCT05035017|DEVICE|Test Lens|Daily disposable with modified lens design for 2 days
223768363|NCT05035017|DEVICE|Control Lens|Daily disposable lens for 2 days
223768364|NCT00858390|DIETARY_SUPPLEMENT|enteral feeding with Oxepa® and Glutasolve®|enteral feeding with Oxepa® and RESOURCE® GLUTASOLVE®
223768365|NCT05844696|DEVICE|Soterix MXN-5 HD-tES Model 5005A. Medtronic Percept DBS platform.|"〔Part 1〕Using Soterix MXN-5 HD-tES Model 5005A. Three treatment groups: sham control, continuous tDCS, slow-oscillatory tDCS.~〔Part 2〕Using Medtronic Percept DBS platform. Single group:Neuromodulation."
223768366|NCT04471584|DEVICE|Insertion of ILR device|All patients enrolled will be randomized to have one of three ILR devices implanted (BIOMONITOR III, Reveal LinQ, or Confirm RX) and will be given event monitoring device for concurrent evaluation.
224239378|NCT02215577|PROCEDURE|Portal embolization or ligation|Portal vein embolization is performed according to the intervention used at the different sites.
224239379|NCT02888171|DRUG|ferric citrate|Participants randomized to the ferric citrate arm will take 2 grams of ferric citrate three times a day with meals.
224239380|NCT02888171|DRUG|ferrous sulfate|Participants randomized to the ferrous sulfate arm will take 325 mg of ferrous sulfate three times a day.
224239381|NCT01136642|DRUG|Nicotrol|
224239382|NCT04192500|BIOLOGICAL|OVX836|One single administration intramuscularly at Day 1.
223656530|NCT05268913|BIOLOGICAL|Blood test|Participants will undertake a fasting blood test.
223656531|NCT02644876|DRUG|Penehyclidine inhalation|Penehyclidine inhalation will be administered by inhalation (penehyclidine hydrochloride 0.5 mg/0.5 ml, mixed with normal saline 5.5 ml) once every 12 hours from the night before surgery till the second day after surgery. The total number of inhalation is seven times. Study drug inhalation is performed with the high-flow oxygen-driven method for the non-intubated patients or with the atomizing inhalation device of ventilator for the intubated patients.
223656532|NCT02644876|DRUG|Placebo inhalation|Placebo inhalation will be administered by inhalation (water for injection 0.5 ml, mixed with normal saline 5.5 ml) once every 12 hours from the night before surgery till the second day after surgery. The total number of inhalation is seven times. Study drug inhalation is performed with the high-flow oxygen-driven method for the non-intubated patients or with the atomizing inhalation device of ventilator for the intubated patients.
223656533|NCT02219867|DRUG|Ketamine|Drug (including placebo)
223656534|NCT00687427|BEHAVIORAL|Questionnaires and motor/sensitivity testing|"Group A:~1. Full assessment (using the various measures described) will be carried out 0-3 weeks since referral.~2. Treatment will focus on the patient's needs and in accordance with the physicians requests.~3. Three months post initial treatment re-assessment will be conducted."
223656535|NCT00687427|BEHAVIORAL|Questionnaires and motor/sensitivity testing|Group B Researcher will contact by phone previous patients that were treated in the occupational therapy department in the past half year and a year, in order to get their permission to participate (retrospectively) in this research. After getting their consent, a questionnaire concerning their RTW will be posted to the subjects.
223656536|NCT00687427|BEHAVIORAL|Questionnaires and motor/sensitivity testing|Group C Researcher will contact by phone previous patients that were treated in the occupational therapy department in the past half year and a year, in order to get their permission to participate (retrospectively) in this research. After getting their consent, a questionnaire concerning their RTW will be posted to the subjects.
223656537|NCT06178601|DRUG|RC48-ADC|RC48-ADC （2.0 mg/kg，intravenous (IV) infusion，Q2W）, combined with cadonilimab（AK104）
223656538|NCT06178601|DRUG|AK104|AK104（6.0 mg/kg，intravenous (IV) infusion，Q2W）combined with RC48-ADC
223656539|NCT03220906|OTHER|Blood pressure measurement|Blood pressure will be measured in both upper and lower extremities.
223656540|NCT06518018|RADIATION|HDR brachytherapy (30Gy single fraction)|Study Group receives a novel triple combination therapy for advanced NSCLC in the second-line setting. The treatment begins with a single fraction of high-dose rate (HDR) brachytherapy, delivering 30 Gy locally to the tumor site. This is followed within 1-3 days by systemic therapy, combining immunotherapy and chemotherapy , both administered intravenously.
223656541|NCT06518018|DRUG|Immunotherapy|Control Group receives the current standard of care for second-line treatment of advanced NSCLC. This regimen consists of a combination of immunotherapy and chemotherapy , both administered intravenously
223656542|NCT02084121|BIOLOGICAL|Enriched Hematopoetic Stem Cell Infusion|Enriched Hematopoetic Stem Cell Infusion
223656543|NCT00161343|BEHAVIORAL|Health Improvement Project for Teens on HIV Prevention|Comparison of 2 facilitator-led intervention groups: (1) HIV prevention, and (2) general health promotion. Outcome measures: sexual risk behaviors in adolescent girls
223656544|NCT05751603|DRUG|sugammadex|sugammadex is administered just after extubation
223656545|NCT03615443|DIAGNOSTIC_TEST|Guardant360|Guardant360 is a comprehensive, non-invasive tumor sequencing test.
223656546|NCT00653926|DRUG|ropivacaine, ketorelac and epinephrine|In Group A, 200 mg ropivicaine, 30 mg ketorelac and 0.5 mg epinephrine (total volume 106 ml) are infiltrated by the surgeon into the soft tissues peri-articularly during the operation in the following way: Before inserting the components, 20-30 ml are injected into the posterior capsule and before closure of the wound the rest is injected into the capsule incision, the synovium, the ligament and the subcutaneous tissue After 21 postoperative hours in Group A, 150 mg ropivicaine, 30 mg ketorelac and 0.1 mg epinephrine, total volume 22 ml, are injected intraarticularly via the catheter.
223656547|NCT00653926|DRUG|saline|In Group P (placebo) no injections were given intaoperatively. All patients had a tunnelled intra-articular multihole 20-G catheter placed at the end of the operation by the surgeon.After 21 postoperative hours 22 ml of saline was injected intraarticularly via the catheter.
223656548|NCT03370432|OTHER|Observational|Information on diet, lifestyle, weight, height, medical treatment, environmental exposures, and other socio-economic factors were collected at enrolment using questionnaires and interviews
223656549|NCT01206218|DRUG|FLOT Regimen|FLOT Regimen: 5-fluorouracil, Oxaliplatin, Docetaxel
223656550|NCT01206218|DRUG|FLO Regimen or FLOT Regimen|FLO Regimen: 5-fluorouracil, Oxaliplatin FLOT Regimen: 5-fluorouracil, Oxaliplatin, Docetaxel
223656551|NCT05270252|OTHER|Learning and Care|"The educational intervention lasted 10 hours: six face-to-face and four for personal study. Three educational methodologies were combined.~The first: flipped classroom. Students received training material in their email: articles on the needs of families / cancer survivors and family nursing according to the Calgary Model (Wright \& Leahey, 2013) and experiential videos of survivors and family members. In the classroom, a week later, a nurse promoted students' self-learning and reflection.~The second: simulation clinical case. The students received by email a summary of the case and material for their personal work. Students in groups of three performed the entire clinical scenario.~The third: round table. The components were advanced practice nurse, medical oncologist, cancer survivor and a family member. The content revolved around personal experience in caring for family members and cancer survivors and the interdisciplinary work required for this care."
223656552|NCT05429385|DRUG|HLX70|Single-dose, intravenous infusion
223656553|NCT05429385|DRUG|Placebo|Single-dose, intravenous infusion
223656554|NCT02659891|BIOLOGICAL|IVIg|
224239383|NCT04192500|BIOLOGICAL|Quadrivalent seasonal influenza vaccine (Influvac TetraTM)|One single administration intramuscularly at Day 1.
223656555|NCT02659891|OTHER|Placebo|
223656556|NCT06227104|DEVICE|Convection-based Hemodiafiltration|Convection-based Hemodiafiltration with pre substitution fluid
224239384|NCT05810766|OTHER|mobilization with movement|MWM at glenohumeral joint and then we will add progression by adding glides at sternoclavicular and acromioclavicular joint.5 sets of painless glides of 10 repetitions will be given, with 3-minute rest between sets.
224239385|NCT05810766|OTHER|conventional physical therapy|Hot pack for 15 minutes
223656557|NCT01430052|DRUG|Drug: gemcitabine, S-1|Gemcitabine 1,000mg/㎡ is administered with 30 min intravenous infusion on day 1 and 8 every 3 weeks. S-1 60mg/㎡/day is administered orally for 2 consecutive weeks every 3 weeks.
223656558|NCT01430052|DRUG|gemcitabine, S-1, radiotherapy|Gemcitabine 600mg/㎡ is administered with 30 min intravenous infusion on day 1 and 8 every 3 weeks. S-1 60mg/㎡/day is administered orally for 2 consecutive weeks every 3 weeks. Concurrent radiotherapy (a total dose of 50.4Gy) was delivered in 28 fractions.
223656559|NCT04911608|OTHER|cervical spinal manipulation|High-velocity, mid-range, low amplitude force at the segment of pain and/or segmental restriction. The participant will lay comfortably in a supine position, the practitioner will then use his clinical discretion to select the most appropriate or symptomatic cervical motion segments and attempt to localize the manual thrust at those levels. A maximum of 2 attempts for each side of the cervical spine will be allowed regardless of the having achieved joint cavitation.
224239386|NCT03423225|DRUG|ADVAGRAF®|"Administration method The total daily dose of tacrolimus will be converted to 1:1 (mg:mg) and the total daily dose of ADVAGRAF® will be administered only once daily in the morning, starting from Day 1 (at least one hour before breakfast or 2 to 3 hours after breakfast).~* Dose adjustment after conversion On Day 1, the total dose will be converted to 1:1. It is recommended to check the blood concentration of tacrolimus at each visit and adjust the dose to achieve the blood concentration maintaining at 5\~8ng/ml for 0 to 3 months and then at 5ng/ml or below for 3 to 6 months of study treatment.~* Duration of treatment The investigational product will be administered for 24 weeks."
224239387|NCT00741663|DRUG|Spironolactone and furosemide|Patients in arm A will receive potassium canrenoate at the initial dose of 200 mg/day, then increased up to 400 mg/day. Non responders will be treated with 400 mg/day of potassium canrenoate and furosemide at an initial dose of 50 mg/day, then increased up to 150 mg/day.
224239388|NCT00741663|DRUG|Spironolactone and furosemide|Patients in arm B will receive at first 200 mg/day of potassium canrenoate and 50 mg/day of furosemide, then increased up to 400 mg/day and 150 mg/day, respectively.
224239389|NCT02403700|DEVICE|Cone beam computed tomography (CBCT)|Dimensional changes are documented over a healing period of 8-weeks following single tooth extraction. To document these changes over time, two methods will be applied. Firstly, two cone beam computed tomographies (CBCT) will be obtained, one directly after tooth extraction, the other one at 8 weeks of socket healing prior to implant placement. The two CBCT's will be analyzed with a novel software program (InVivo Dental). Secondly, consecutive impressions will be made at day 0 (day of extraction), day 14, 28, 42, and 56 to digitally produce virtual 3D study models. These models can be analyzed with another software program (Geomagic Studi 10) to document the variations of the soft tissue in the extraction site.
223656560|NCT04911608|OTHER|cervical spinal mobilization|Participant will lay comfortably in a prone position, the practitioner will then use his clinical discretion to select the most appropriate or symptomatic cervical motion segments and attempt to localize the manual forces at those segments.
223656561|NCT01858935|DRUG|ND-L02-s0201 Injection|Single IV infusion.
223656562|NCT01858935|DRUG|Placebo|Single IV infusion.
223656563|NCT01385527|BEHAVIORAL|Weekly Internet survey|Parents will complete a weekly online survey about medication use.
224239390|NCT02473809|DRUG|Liraglutide|Once daily
223656564|NCT01385527|DRUG|Topical Triamcinolone|Topical triamcinolone to all affected areas once daily
223656565|NCT04976543|DRUG|nadroparin calcium-warfarin sequential anticoagulation|The NWS therapy group were given a subcutaneous injection of nadroparin calcium every 12 hours for 1 month and switched to warfarin for 5 months. Warfarin was initiated at least 5 days before nadroparin calcium was stopped. International normalized ratio (INR) was detected every 3-4 days and adjusted carefully by 0.75mg dosage until achieve the target level of 2-3.
224239391|NCT02473809|DRUG|Placebo|Once daily
223768367|NCT05474144|DIETARY_SUPPLEMENT|SmartProbio C|Probiotic supplement consisting of 19 strains (Lactobacillus acidophilus NCFM, Bifidobacterium lactis, subsp. Infantis Bi-07, Lactobacillus rhamnosus LR22, Lactobacillus acidophilus LA14, Lactobacillus rhamnosus LGG, Bifidobacterium lactis HN019, Bifidobacterium lactis Bl-04, Lactobacillus acidophilus LA 11 ONLLY, Lactobacillus rhamnosus HN001, Lactobacillus plantarum LP ONLLY, Lactobacillus casei LC18, Bifidobacterium breve BB8, Lactobacillus reuteri LE16, Bifidobacterium lactis BI516, Streptococcus thermophilus ST6, Bifidobacterium animalis BA77, Bifidobacterium bifidum BB47, Bifidobacterium longum BL88 ONLLY, Bifidobacterium infantis BI211) in different ratios. Probiotic mixture enclosed in HPMC (hydroxypropylmethylcelulose) capsule, 25 billion CFU (colony-forming units) in each capsule. As a filling agent mix of inulin and maltodextrin was used. Dosage twice a day.
224239392|NCT04659538|DEVICE|CAPTIS Embolic Protection device|The CAPTIS Embolic Protection device will be deployed during standard of care TAVR procedure. The device's safety will be assessed up to one month post procedure. The device's technical performance and feasibility to capture and remove debris during the procedure will be evaluated.
224239393|NCT04882293|DRUG|Atorvastatin 20 mg / Fenofibrate 160 mg in fixed dose|1 tablet once a day, 20 mg /160 mg, Orally
224239394|NCT04882293|DRUG|Atorvastatin (Lipitor ®)|1 tablet once a day, 20 mg, Orally
223656566|NCT00272103|DRUG|Itopride (drug)|
223656567|NCT05317741|DRUG|IA-14069|Subjects received IA-14069 tablet orally on Day 1.
223656568|NCT05317741|DRUG|Placebo|Subjects received matching placebo tablet orally on Day 1.
223656569|NCT01508806|DRUG|liraglutide|Single dose of 0.75 mg, administered as a subcutaneous injection
223656570|NCT01262820|DRUG|Pazopanib|Pazopanib, 800 mg by mouth daily each 21 day cycle
223656571|NCT03327103|BEHAVIORAL|CHAMPION|An interactive mHealth decision aid that includes immediate and over time quality of life (QL) graphical summaries for advanced prostate cancer patients to enhance informed, shared decision making and will also be used to assess the CPNs' role in the decision-making process.
223656572|NCT01933685|BIOLOGICAL|AIDSVAX B/E|1 mL per injection (300 ug dose/antigen for a total of 600 ug/dose administered)
223656573|NCT01933685|BIOLOGICAL|AIDSVAX B/E Placebo|1 mL per injection
223656574|NCT02784067|DRUG|Sucraid|Study drug
223656575|NCT02784067|DRUG|Placebo|Sucraid placebo
223656576|NCT06020989|DRUG|Lazertinib+Pemetrexed+Carboplatin|Arm A will receive Lazertinib and Pemetrexed, Carboplatin combination. Lazertinib will be given 240 mg once a day daily PO until disease progression or unacceptable toxicity. Pemetrexed(500 mg/m2) will be administered IV infusion on Day 1 of each 21-day cycle until disease progression or unacceptable toxicity. Carboplatin(AUC5) will be administered IV infusions on Day 1 of each 21-day cycle until 4 cycles.
224239395|NCT02837965|DRUG|treatment with topical superpotent corticosteroid therapy|
224239396|NCT02837965|DRUG|treatment with systemic therapy (methotrexate)|
223656577|NCT06020989|DRUG|Lazertinib|Lazertinib will be given 240 mg once a day daily PO until disease progression or unacceptable toxicity.
223656578|NCT06020989|DRUG|Lazertinib|Lazertinib will be given 240 mg once a day daily PO until disease progression or unacceptable toxicity.
223656579|NCT04836780|DRUG|Dexamethasone|Dexamethasone base 6 mg once daily for seven days
223656580|NCT03059680|OTHER|High potassium diet|An increase in consumption of high potassium fruits and vegetables
223656581|NCT02211170|DRUG|BIBR 796 BS, low dose|
223656582|NCT02211170|DRUG|BIBR 796 BS, high dose|
223656583|NCT02211170|DRUG|Placebo|
223656584|NCT02211170|DRUG|Lipopolysaccharide|Lipopolysaccharide (LPS) for endotoxin challenge
223656585|NCT04656327|OTHER|No intervention|There is no intervention in this study. It is a cross-section study evaluating the oral health and nutritional statuses of community-dwelling elders dependent for care for their activities of daily living.
223656586|NCT00104520|DRUG|AZLI 75 mg two times a day (BID)/three times a day (TID)|
223656587|NCT00104520|DRUG|Placebo two times a day (BID)/three times a day (TID)|
223656588|NCT03951350|BEHAVIORAL|Lifestyle Modification Program (LMP)|"Patients will follow TAU and LMP. This program will consist of 6 weekly group sessions (lasting 90 minutes each) led by an experienced psychologist and complemented by PowerPoint presentations. The content is the following:~1. Presentation of the project and psychoeducation on depression.~2. Behavior activation.~3. Sleep hygiene habits and careful exposure to sunlight.~4. Physical activity.~5. Adherence to the Mediterranean diet.~6. Summary of previous sessions with practical final suggestions."
223656589|NCT03951350|BEHAVIORAL|Lifestyle Modification Program (LMP) + Information Communication Technologies (ICTs)|Patients will follow TAU and LMP and will be monitored using a wearable smart wristwatch that will track their daily sleep patterns and physical activity (LMP+ICTs).
223656590|NCT01151904|DRUG|brimonidine 0.2%/timolol 0.5% fixed combination ophthalmic solution|COMBIGAN® (brimonidine 0.2%/timolol 0.5% fixed combination ophthalmic solution) administered as one drop in the morning and one drop in the evening in affected eye(s) for 12 weeks.
223656591|NCT01151904|DRUG|latanoprost|Latanoprost administered in the affected eye(s) as prescribed by physician.
223656592|NCT01026324|DRUG|dinaciclib|Given IV
223656593|NCT01026324|OTHER|pharmacological study|Correlative studies
223768368|NCT05474144|DIETARY_SUPPLEMENT|Placebo|Placebo. HPMC (hydroxypropylmethylcelulose) capsule filled with maltodextrin. Dosage twice a day.
224239397|NCT02837965|DRUG|treatment systemic therapy (prednisone)|
224239398|NCT02837965|DRUG|treatment with systemic therapy (prednisone)|
224239399|NCT02837965|DRUG|treatment with systemic therapy (doxycycline)|
224239400|NCT03876561|PROCEDURE|Pelvic floor prehabilitation|The systematic pelvic floor prehabilitation will start 4 weeks before stoma closure and will include 1 session per week before stoma closure and 1 session per week during 6 weeks following stoma closure. The prehabilitation will be performed according to a predefined protocol based on a biofeedback strategy.
224239401|NCT00938210|PROCEDURE|Laparoscopic colonic surgery|Laparoscopic removal of colonic cancer
224239402|NCT05544448|OTHER|Blood sample taken at a single time point|At inclusion, a blood sample will be taken for research purpose
223656594|NCT01026324|OTHER|laboratory biomarker analysis|Correlative studies
223656595|NCT03616301|DRUG|Clavamox|Clavamox, Powder for Oral Suspension, 400 mg + 57 mg / 5 ml, manufactured by Pharmtechnology LLC, Belarus
223656596|NCT03616301|DRUG|Augmentin®|Augmentin®, Powder for Oral Suspension, 400 mg + 57 mg / 5 ml, marketed by CJSC GlaxoSmithKline Trading, Russia
223656597|NCT05188053|DRUG|HTX-011|Single dose administration periarticular 400mg bupivacaine and 12mg meloxicam extended release solution
223656598|NCT05188053|DRUG|ropivacaine , epinephrine , ketorolac diluted in sodium chloride|Single dose administration in 100cc of standard formulation, there is 225mg of ropivacaine 5mg/mL, 0.6mg epinephrine 1mg/mL, 30mg ketorolac 30mg/mL diluted in sodium chloride
223656599|NCT03182569|DEVICE|FLEXIBLE CATHETER|
223656600|NCT03182569|DEVICE|hourly rigid needle puncture|
223656601|NCT05405686|DRUG|Lutropin alfa|addition of recombinant luteinizing hormone
223656602|NCT05405686|DRUG|Follitropin alfa|recombinant follicle stimulating hormone (FSH)
223656603|NCT05405686|DIAGNOSTIC_TEST|Endometrial biopsy|pipelle de cornier biopsy
223656604|NCT02422459|BEHAVIORAL|COMMENCE|ChrOnic pain self-ManageMent support with pain science Education and exerCisE (COMMENCE) consists of two visits with a physiotherapist per week over six weeks. One of the two visits is in a group setting, where the emphasis is on pain neurophysiology education and provision of self-management strategies. The second visit each week is an individualized, one-to-one session in which the focus is on providing support for implementing self-management strategies and developing of an individualized, goal-oriented exercise program.
223656605|NCT01585857|BIOLOGICAL|Autologous adipose derived stem cells administrated for intra-articular use|Each patient will receive one single administration of the cells and will be followed for 3 months. Each patients will be follow-up during one year with routinely examinations for safety issues.
223656606|NCT01585857|BIOLOGICAL|Autologous adipose derived stem cells administrated for intra-articular use|Each patient will receive one single administration of the cells and will be followed for 3 months. Each patients will be follow-up during one year with routinely examinations for safety issues. The first patient will be followed during 12 weeks before inclusion of the second patient.
223656607|NCT00238641|DRUG|Botulinum Toxin type B|
223768369|NCT06251076|DRUG|Teclistamab|Teclistamab is an antibody therapy (bispecific T-cell engager \[BiTE\]) that binds to two target proteins on different cells; CD3 on healthy T cells and B cell maturation antigen (BCMA) on myeloma cells. This brings healthy T cells and the myeloma cells close together so the T cells can more effectively kill them. Teclistamab is approved for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least three prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody, and who have demonstrated disease progression on the last therapy.
224239403|NCT04825938|DRUG|Toripalimab , Carboplatin, Nab-paclitaxel|Patients receive toripalimab IV on day 1, paclitaxel IV on day 1 and carboplatin IV on day 1 . Treatment repeats every 21 days for up to 2 courses in the absence of disease progression or unacceptable toxicity.
223656608|NCT05895019|DRUG|Propofol|Propofol was administered using TCI pump induction with a starting target effect concentration of 1.0ug/ml. The target concentration was increased by 0.2-0.5ug/ml if the patient did not reach unconsciousness after 1 min of stabilization of the target concentration. The propofol concentration recorded at this time was the target concentration the patient was induced to unconsciousness. The state of consciousness was tested every 60 s by the investigator, and clinical trial data were collected for 5 min; after that, clinical trial data were recorded before and after induction of anesthesia at 5 min after induction of anesthesia, at intubation and skin dissection, and 1, 3, and 5 min after intubation and skin dissection, respectively.
223656609|NCT00284453|PROCEDURE|Peripheral blood sampling|blood samples will be collected within 72 hours of subjects receiving \>2, 1-2(low level) or inappropriate therapies, device data and repeat bloodwork in 3 months(+/- 4weeks).
223656610|NCT05334212|DEVICE|Surgical Theater|The surgical theater platform uses data from MRI and CT scans, creating a 3d image that can be seen by the patient.
223656611|NCT01561313|BIOLOGICAL|Adalimumab|Subcutaneously 40 mg every other week (EOW) or every week (EW) (as dosing requires)
223656612|NCT05569590|DRUG|Propolis|Vital tooth bleaching will be performed and Propolis as a desensitizing agent will be applied after bleaching to reduce dentine hypersensitivity.
223656613|NCT05569590|DRUG|hydrogen peroxide 35%|hydrogen peroxide 35%
223656614|NCT05569590|OTHER|fluoride varnish|fluoride varnish
223656615|NCT03904992|OTHER|Progressive web app|Access to a progressive web app for the promotion of healthy habits in preescholers through the participant's smatphone
223656616|NCT02433470|DEVICE|Transcranial direct current stimulation|Transcranial direct current stimulation over the motor cortex
223656617|NCT05106764|OTHER|No intervention|This is non-interventional study.
223656618|NCT03239561|DRUG|[18F]MNI-1020|Participants will receive a single intravenous bolus injection of \[18F\]MNI-1020 at a dose of not more than 10 millicurie (mCi), with a maximum mass dose of 10 microgram (mcg) and maximum volume of 10 milliliter (mL) at imaging visit.
223656619|NCT06554366|DEVICE|GentleWave|Root canals will be shaped using a Vortex Blue and ProTaper gold rotary system. Once the root canals have been shaped, the GentleWave procedure will be performed
223656620|NCT06554366|DEVICE|EdgePro laser irrigation|Root canals will be shaped using a Vortex Blue and ProTaper gold rotary system. Once the root canals have been shaped, the EdgePro procedure will be performed
223656621|NCT06554366|DEVICE|Irrisafe passive ultrasonic irrigation|Root canals will be shaped using a Vortex Blue and ProTaper gold rotary system. Once the root canals have been shaped, the passive ultrasonic irrigation procedure will be performed
223656622|NCT04393454|DRUG|Sirolimus 2mg Tablet|Sirolimus (oral) will be started at 2 mg daily. Sirolimus dosing will be titrated to meet serum trough levels of \>8 ng/ml, assayed at 7 days after starting a new dose, by chromatography/mass spectrometry. Once adequate serum levels are met (≥8 ng/ml), the same dosing will be continued until progression of disease as evidenced by imaging, or unacceptable toxicity.
224239404|NCT03231670|PROCEDURE|Blood sampling|5ml blood will be taken in addition to standard sampling
224239405|NCT01229020|OTHER|Observational study - no intervention|Observational study - no intervention. Patients underwent VRI recordings and routine V/Q scan.
224239406|NCT00469586|DRUG|inhaled human insulin|Treat-to-target dose titration scheme, pre-prandial, inhalation.
224239407|NCT00469586|DRUG|metformin|Tablets, 2000 mg/day.
224239408|NCT00469586|DRUG|glimepiride|Tablets, 4 mg/day.
224239409|NCT00469586|DRUG|inhaled human insulin|Treat-to-target dose titration scheme, post-prandial, inhalation.
224239410|NCT02170688|DRUG|Isovue 370|All contrast media doses administered for this study are within the FDA approved dose range in the package insert.
224239411|NCT02170688|OTHER|Weight calculation|
224239412|NCT01894178|DEVICE|Parker Flex-Tip® tracheal tube|
223656623|NCT04079140|DRUG|Dinoprostone|1 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia \& Upjohn, Puurs, Belgium) self-inserted by the patient 12 hours before IUD insertion.
223656624|NCT04079140|DRUG|placebo|one tablet of placebo self-inserted by the patient 12 hours before IUD insertion.
223656625|NCT02564835|OTHER|Yoga|The yoga curriculum in this study is based is based on the Integral Yoga approach that includes branches of yoga associated with cognitive and immune benefits (Hatha, Raja). Within the Integral Yoga approach, physical poses, breathing techniques and mediation practices were chosen to provide benefits to the nervous system, immune system, musculoskeletal system and gastrointestinal system. Poses will be adapted to individual needs. The number of repetitions and/or length of hold will be increased through standard progression.
223768370|NCT06251076|DRUG|Tocilizumab|Toclilzumab is an interleukin inhibitor approved for the treatment of patients with chimeric antigen receptor (CAR) T cell-induced severe or life-threatening cytokine release syndrome (CRS) and other indications.
223768371|NCT01813019|DRUG|AFQ056|mGluR5 antagonist
223768372|NCT01813019|DRUG|Placebo|Matched placebo
224239413|NCT01894178|DEVICE|Portex® Tracheal Tube|
224239414|NCT04617769|BEHAVIORAL|Psychoeducation|psychoeducational materials on trauma and safety behaviors
224239415|NCT04617769|BEHAVIORAL|Exposure|six 3-minute video exposure trials with an inter-trial interval of 2 minutes
224239416|NCT02952248|DRUG|BI 754091|
224239417|NCT05432843|DRUG|Pregabalin|Patients receive for one week Pregabalin 75 mg and 7 weeks Pregabalin 150 mg
224239418|NCT05432843|DRUG|Placebo|Patients receive a treatment with placebo for 8 weeks
224239419|NCT02787278|DRUG|SP-8203 High dose|High-dose group: 160mg will be intravenously administered as 80mg/dose twice daily (intervals of 12 hours).
224239420|NCT02787278|DRUG|SP-8203 Low dose|Low dose group: 80mg will be intravenously administered as 40mg/dose twice daily (intervals of 12 hours).
224239421|NCT02787278|DRUG|Placebo|Same dosage of SP8203. Placebo will be intravenously administered twice daily (intervals of 12 hours)
224239422|NCT03680898|DEVICE|Rectal swab collection|Patient will provide a rectal swab by following hospital-provided instructions.
224239423|NCT01471522|PROCEDURE|cardiac catheterization|Narrowed blood vessels can be opened without surgery using stents or can be bypassed with surgery. To determine which is the best approach for you the doctor needs to look at your blood vessels to see where the narrowings are and how much narrowing there is. This is done by a procedure known as a cardiac catheterization.
224239424|NCT01471522|PROCEDURE|coronary artery bypass graft surgery|"Artery narrowing is bypassed during surgery with a healthy artery or vein from another part of the body. This is known as coronary artery bypass grafting, or CABG (said, cabbage). The surgery creates new routes around narrowed and blocked heart arteries. This allows more blood flow to the heart."
224239425|NCT01471522|PROCEDURE|percutaneous coronary intervention|Percutaneous coronary intervention may be done as part of the cardiac catheterization procedure. With this procedure a small, hollow, mesh tube (stent) is inserted into the narrowed part of the artery. The stent pushes the plaque against the artery wall, and opens the vessel to allow better blood flow.
224239426|NCT01471522|BEHAVIORAL|Lifestyle|diet, physical activity, smoking cessation
224239427|NCT01471522|DRUG|Medication|antiplatelet, statin, other lipid lowering, antihypertensive, and anti-ischemic medical therapies
223656626|NCT02564835|OTHER|Physical Activity|The physical activity intervention is based on the Exercise for People Living with Cancer program. The intervention will include nine resistance exercises (e.g. squats) and 8 flexibility exercises (e.g. shoulder stretch) targeted for the whole body as well as a brief warm up and cool down (walking). Exercises will be adapted to individual needs. The number of repetitions and/or length of hold will increase through standard progression.
223656627|NCT05812729|BEHAVIORAL|resiLIR Basic|"Each module contains psychoeducational elements as well as practical exercises.~Week 1: Introduction + Stress and resilience~Week 2: Optimism~Week 3: Mindfulness~Week 4: Sense of coherence and values~Week 5: Acceptance~Week 6: Self-compassion + Conclusion"
223656628|NCT01420094|DRUG|Acetylsalicyclic acid (Fast release Aspirin, BAY1019036)|Single oral dose of fast release aspirin tablet 1000 mg (2 x 500 mg) and 2 placebo-matching acetaminophen caplets with a full glass of water (240 milliliter \[mL\]) between 1-4 hours post dental surgery.
223656629|NCT01420094|DRUG|Acetaminophen (Tylenol extra strength)|Single oral dose of acetaminophen (Tylenol extra strength) caplet 1000 mg (2 x 500 mg) and 2 placebo matching aspirin tablets with a full glass of water (240 mL) between 1-4 hours post dental surgery.
223656630|NCT01420094|DRUG|Placebo|Single oral dose of placebo (2 placebo aspirin tablets and 2 placebo acetaminophen caplets) with a full glass of water (240 mL) between 1-4 hours post dental surgery.
224239428|NCT02405195|PROCEDURE|cardiopulmonary bypass|During cardiac surgery, the subjects are routinely undergoing cardiopulmonary bypass
224239429|NCT01615081|OTHER|The acute effect of malt extract versus sucrose on the response of glucose and insulin, subjective appetite sensations and ad libitum energy intake|2-arm crossover study for investigation of the effect of malt extract vs. sucrose on glucose, insulin, subjective appetite sensations and ad libitum energy intake.
223656631|NCT05167825|DRUG|Macitentan|Macitentan will be administered orally as a tablet.
223656632|NCT01224145|DRUG|5x5cm bupivacaine collagen sponges|
223656633|NCT02230033|DRUG|JNJ-56021927|Single oral dose of JNJ-56021927 240 milligram (mg) capsule will be administered on Day 1 or Day 4 in any of the treatment.
223656634|NCT02230033|DRUG|Itraconazole|Itraconazole 200 mg (2 capsules of 100 mg) will be administered once daily orally from Day 1 until Day 32.
223656635|NCT02230033|DRUG|Gemfibrozil|Gemfibrozil 600 mg oral tablet will be administered twice daily from Day 1 until Day 32.
224239430|NCT04962685|OTHER|Rapid Maxillary Expansion|"Subjects in the experimental group (with unilateral posterior crossbite) will be treated with Maxillary Rapid Expansion using a disjunctor fixed with two bands on the upper first permanent molars and a mesh cemented to the upper first premolars or upper first primary molars (depending on the eruptive stage of the patient).~The breaker screw will be activated twice a day until a transverse overcorrection of 2 mm is achieved in the first permanent molars. When the active disjunction phase is completed, the screw will be blocked out with light-curing flowable resin and the patient will wear the cemented disjunctor as a retainer for a minimum of six months."
224239431|NCT02607319|DRUG|Bemiparin sodium|Bemiparin sodium 3,500 IU will be started on the evening of the same day of embryo transfer and until the day of pregnancy test. If the test is positive, Bemiparin will be discontinued by the end of the 12th week of gestation.
223656636|NCT03389958|OTHER|Counseling and provision of contraception|Provider training, availability of contraceptive methods
223656637|NCT02038361|GENETIC|blood draw|
223656638|NCT01906606|BEHAVIORAL|Parenting Program|A manualized, community-based 12 session group parenting program, facilitated by a locally recruited volunteer
223656639|NCT03304249|BEHAVIORAL|iAmHealthy Healthy Lifestyles Program|iAmHealthy is behavioral intervention focused on nutrition, behavior and physical activity that engages parents and children in treatment using mobile health (mHealth) technology. Meetings are approximately one hour. Participants will log in for 8 weekly group sessions, followed by 6 monthly sessions.
223656640|NCT03304249|OTHER|Newsletter|Weight loss materials delivered via a newsletter. Each newsletter will cover nutritional, exercise, and behavioral suggestions to improve the child's health. The newsletter will be sent in the mail once a month for 8 months.
223656641|NCT01866085|PROCEDURE|AdVance® sling procedure|
223656642|NCT01866085|PROCEDURE|ARGUS Sling procedure|
223656643|NCT06218498|DEVICE|ablative fractional 2940-nm Er: YAG laser|Ablative fractional 2940-nm Er: YAG laser (Dermablate MCL31, Asclepion Laser Technologies, Germany), the following parameters were used: model of N25%, energy density of 20-30J/cm2, pulse time of 300μs and one to two passes.
223656644|NCT06218498|DEVICE|non-ablative fractional 1565nm|Non-ablative fractional 1565nm (Lumenis, M22): Resur Fx len, energy of 30-35J/cm2, density of 200spot/cm2, overlap ≤10%.
223656645|NCT06218498|DRUG|5% Minoxidil|topical 5% minoxidil, 1 ml, twice daily
223656646|NCT04189224|DEVICE|JJV Investigational Multifocal Contact Lens|TEST
223656647|NCT04189224|DEVICE|1-Day Acuvue® Moist Brand Multifocal Contact Lens|CONTROL
223656648|NCT00159887|DRUG|Sildenafil citrate|
223656649|NCT04078906|OTHER|n3-LCPUFA enriched Intravenous Lipid Emulsion|To start from D0 at 1g/kg/day and increase by 1 g/kg daily till reaching 3 g/kg/day.
223656650|NCT00692263|DRUG|escitalopram and tramadol|10 mg escitalopram for 3 days 20 mg escitalopram for 6 days 150 mg tramadol as a single dose on day 9
223656651|NCT00692263|DRUG|placebo|placebo identical for 10 mg/ 20 mg escitalopram and 150 mg tramadol
223656652|NCT00692263|DRUG|placebo and tramadol|9 days of placebo equivalent to 10 / 20 mg escitalopram, one single dose of 150 mg tramadol on day 9
223768373|NCT00574860|DRUG|EN3285|Oral rinse
224321054|NCT05203783|OTHER|Kinesio Tape Application|Kinesio Tape (KT) application: Participants in the experimental group received additional taping using KT by an experience therapist with prior training in KT application. The tape was applied using the method proposed for the sacrospinalis muscle (Kase, 1996). Y-shaped tape was applied as shown in Figure 1. While the participant was in standing position, the origin of the Y-shaped tape was attached over the centre of the sacrum without stretching the tape and afterward subjects gradually bent forward. A 5-degree angle was maintained within the valley of the Y tape. The tape was changed on the fourth day
224239432|NCT02507375|DRUG|Erlotinib|Erlotinib will be administered as oral tablets.
224239433|NCT02507375|DRUG|Pertuzumab|Pertuzumab will be administered as intravenous (IV) infusion.
224239434|NCT03746353|PROCEDURE|early ileostomy closure|Assigned interventions Conventional closure of ileostomy: Surgical closure of the protective ileostomy 90 or more days after the proctectomy surgery
224239435|NCT07037550|BEHAVIORAL|Strength-based intervention|"The Strength-based intervention incorporates 8-week Ambassador-led strength-based intervention including:~1. a strength-based assessment to the patient-participant and caregiver done by the Social Worker,~2. Ambassador-assisted preparation of the strength-based biography,~3. four Ambassador-led workshops, the workshop will be delivered in group of 6-8 participants by at least 2 Ambassadors, and~4. one Social Worker-led zoom video conference delivered to the caregivers."
224239436|NCT00565305|BEHAVIORAL|Healing Touch|Healing Touch (HT) is a non-invasive therapeutic approach to healing which describes its mode of action as using touch to modulate the patient's energy system. The goal of HT is to restore harmony and balance in the patient's energy system to assist the person to self-heal.88 Healing Touch, as used here, refers to the techniques taught in Mentgen's standardized curriculum of Healing Touch offered through Healing Touch International and endorsed by the American Holistic Nurse's Association
224239437|NCT00565305|RADIATION|Standard Treatment|4-6 cycles of cytotoxic chemotherapy followed by 5040 cGy of external beam whole breast radiotherapy in 28 fractions usually followed by a boost of 1000-1600 cGy
223656653|NCT05556811|DEVICE|Dynamic Light Therapy Device, LSA-1|Dynamic Light Therapy
223656654|NCT05556811|DEVICE|Dynamic Light Therapy Device, LSA-2|Dynamic Light Therapy
224239438|NCT07035756|DEVICE|Arterial Pressure Monitoring Set Fixation Device|A newly developed fixation device designed to securely stabilize the arterial pressure monitoring set, improving patient comfort and reducing device displacement during the postoperative period in patients undergoing coronary artery bypass graft surgery.
224239439|NCT04595136|DRUG|Drug COVID19-0001-USR|COVID19-0001-USR by nebulization for patients with mild and/or moderate SARS- COV-2
223656655|NCT05556811|DEVICE|Dynamic Light Therapy Device, LSA, 3|Dynamic Light Therapy
224239440|NCT04595136|DRUG|normal saline|0.9% NS via nebulization
224239441|NCT02765321|BEHAVIORAL|Healthy lifestyle promotion|Healthy lifestyle changes (i.e., increase in physical activity levels and improvement in eating habits) will be promoted via population-based counselling through media (i.e., radio, newspapers, magazines, television, banners), cell phone applicative, workshops, specific programs at schools and companies, and community physical activity programs.
224239442|NCT06884943|BEHAVIORAL|AI-guided maintenance training with visual-acoustic biofeedback|"Participants will complete AI-guided practice in the home setting in which they will interact with a web interface of the staRt web-based software for speech practice. The staRt software will present words to practice and show a real-time visual display of the acoustic signal of speech (biofeedback). On select trials, feedback will be provided by a classifier for children's r sounds, PERCEPT. Research assistants will join sessions to facilitate but will not provide direct clinical guidance to participants."
224321055|NCT01195610|BEHAVIORAL|Dietary intervention|Instruction to diet for 6 month
224321056|NCT02166255|BIOLOGICAL|siRNA-transfected peripheral blood mononuclear cells APN401|Given IV
223656656|NCT05163275|DIAGNOSTIC_TEST|Video recording and EMG|"The visible and infrared cameras will be positioned in front of the patient (150 cm from the patient's face). EMG electrodes will also be placed on the wings of the nose and the parasternal intercostal muscles. The pressure and flow sensors will finally be positioned at the level of the airways. EMG, respiratory and video recording will begin 15 minutes before the start of the ventilatory weaning trial. Just before the weaning test, a measurement of dyspnea will be carried out. After 15 minutes of baseline recording, patients will be placed in a ventilatory bondage test. Dyspnea will be measured every 5 minutes during the weaning test. After 30 minutes of testing, the ventilatory weaning test is stopped. Patients will then be placed on ventilatory assistance with the same parameters used before the weaning test. An additional 15-minute recording after the end of the ventilatory weaning test will also be made. The recording will therefore last 1 hour in total"
223656657|NCT04643613|DIETARY_SUPPLEMENT|Protison cancer nutritional formula (PCNF)|PCNF (237 mL/Pack) for 5-6 times/day via bolus NG tube feeding for 12 weeks
223656658|NCT04185051|DRUG|JNJ-67953964|Participants will receive JNJ-67953964 as oral capsules.
223656659|NCT04185051|DRUG|Placebo|Participants will receive matching placebo oral capsules.
223656660|NCT03174938|DIAGNOSTIC_TEST|Flutemetamol F18 Injection|PET imaging of Abeta amyloid
224321057|NCT02166255|OTHER|laboratory biomarker analysis|Correlative studies
223656661|NCT03174938|DIAGNOSTIC_TEST|[18F]-RO6958948|PET imaging of Tau aggregates
223656662|NCT03174938|DIAGNOSTIC_TEST|Elecsys (Roche) Abeta42, Ttau and Ptau|Measurement of Abeta42, Ttau and Ptau in the cerebrospinal fluid
223768374|NCT00574860|DRUG|Placebo|Oral rinse
223768375|NCT00574860|OTHER|Standard of care|This will be the therapy most commonly used the the institution treating the patient
223768376|NCT02640729|DRUG|Nelotanserin|once daily, oral, 20-mg tablets
223768377|NCT02640729|DRUG|Placebo|once daily, oral, matching tablets
223768378|NCT03492333|OTHER|Gluten free diet|Gluten-free diet- Instructions provided by a dietitian
223768379|NCT00799968|DRUG|Urokinase|UK,bolus 4 400 U/kg followed by intravenous 2 200 U/kg•h for 12 hours
223656663|NCT03174938|DIAGNOSTIC_TEST|Lumipulse (Fujirebio) Abeta42, Ttau and Ptau|Measurement of Abeta42, Ttau and Ptau in the cerebrospinal fluid
223656664|NCT05348213|DRUG|Zanubrutinib plus R-ICE|Zanubrutinib 160mg/bid PO D1-21 Rituximab 375mg/m2 IV D0 Ifosfamide 1500mg/m2 IV D1-3 Carboplatin AUC×\[GFR(ml/min) + 25\] mg/d,AUC=5 IV D2 Etoposide 100 mg/m2 IV D1-3
223656665|NCT05348213|DRUG|Decitabine plus R-ICE|Decitabine 10mg/m2 IV D1-5 Rituximab 375mg/m2 IV D0 Ifosfamide 1500mg/m2 IV D1-3 Carboplatin AUC×\[GFR(ml/min) + 25\] mg/d,AUC=5 IV D2 Etoposide 100 mg/m2 IV D1-3
223656666|NCT05348213|DRUG|Chidamide plus R-ICE|Chidamide 20mg/d PO D1、4、8、11 Rituximab 375mg/m2 IV D0 Ifosfamide 1500mg/m2 IV D1-3 Carboplatin AUC×\[GFR(ml/min) + 25\] mg/d,AUC=5 IV D2 Etoposide 100 mg/m2 IV D1-3
223656667|NCT05348213|DRUG|Tofacitinib plus R-ICE|Tofacitinib 5mg/bid PO D1-10 Rituximab 375mg/m2 IV D0 Ifosfamide 1500mg/m2 IV D1-3 Carboplatin AUC×\[GFR(ml/min) + 25\] mg/d,AUC=5 IV D2 Etoposide 100 mg/m2 IV D1-3
223656668|NCT05348213|DRUG|Pomalidomide plus R-ICE|Pomalidomide 4mg/d PO D1-10 Rituximab 375mg/m2 IV D0 Ifosfamide 1500mg/m2 IV D1-3 Carboplatin AUC×\[GFR(ml/min) + 25\] mg/d,AUC=5 IV D2 Etoposide 100 mg/m2 IV D1-3
223656669|NCT02970942|DRUG|Semaglutide|Once daily administration of semaglutide subcutaneously (s.c., under the skin) in three different doses (0.1 mg, 0.2 mg and 0.4 mg)
223656670|NCT02970942|DRUG|Placebo|Once daily administration subcutaneously ( s.c., under the skin)
223656671|NCT06651905|DRUG|Dexmedetomidine|The patients were given 0.5 mcg /kg dexmedetomidine over 10 min via syringe pump, followed by 0.2-0.7 mcg/kg/hour until the end of intubation according to hemodynamics.
223656672|NCT06651905|DRUG|Superior laryngeal nerve block|The patients received an airway nerve block through bilateral superior laryngeal nerve block and trans-tracheal injection for recurrent laryngeal nerve.
223656673|NCT06655025|DRUG|Dexmedetomidine|Dexmedetomidine infusion during open heart surgery
223656674|NCT02529553|DRUG|LY3076226|Administered IV
223656675|NCT00488683|BIOLOGICAL|MenACWY-CRM|One dose (0.5 mL) of MenACWY conjugate vaccine supplied as an extemporaneous mixing just before injection of the lyophilized component (MenA) reconstituted with the liquid component (MenCWY) was administered at 2-, 4-, and 12-months as IM injections in the anterolateral area of the right thigh.
223656676|NCT00488683|BIOLOGICAL|DTaP-Hib-IPV|IM injections of 3 doses of 0.5 mL each of DTaP-Hib-IPV supplied in prefilled vial were administered at 2-, 3-, and 4-months in the anterolateral area of the left thigh.
223656677|NCT00488683|BIOLOGICAL|PCV|IM injections of 3 doses of 0.5 mL each of PCV supplied in pre-filled syringe were administered at 2-, 4-, and 12-months (Groups 2 and 3) or 13-months (Group 1) in the anterolateral area of the left thigh.
223656678|NCT00488683|BIOLOGICAL|MMR|IM injection of one dose of 0.5 mL of MMR obtained by extemporaneous mixing just before injection of powder and the solvent for solution was administered at 13 months in the anterolateral area of the left thigh.
223656679|NCT00488683|BIOLOGICAL|Hib|IM injection of one dose 0.5 mL of Hib supplied in pre-filled syringe was administered at 13 months in the anterolateral area of the right thigh.
223656680|NCT06600945|OTHER|Cataract surgery|With local anesthetic in peribulbar anesthesia
223656681|NCT06544824|OTHER|Measure gait spatiotemporal parameters and kinematics from optoelectronic system|The raw data acquired from motion capture system were processed with Smart Analyzer software (BTS Bioengineering, Milano, Italy). First, the 3D data were filtered and interpolated in case of missing data for short time. Then spatial-temporal parameters (cycle duration, cadence, gait speed, stance phase, swing phase, double-support phase, stride length and step width) and conventional kinematic parameters of traditional Davis marker-set protocols were computed.
223656682|NCT06544824|OTHER|Measure gait spatiotemporal parameters and kinematics from markerless system|The two videos were elaborated using OpenPose that returns a set of 25 2D keypoints coordinates for body pose estimation for each video. Key-points were located in relevant body landmarks and it were used to determine the 2D Cartesian coordinates on the sagittal plane and on the frontal plane. The data calculated with routines were filtered and interpolated in case of missing data. With respect to kinematic parameters, the segment and joint angles were measured from the estimated feature points of each joint. Spatiotemporal gait parameters were calculated using successive heel strike and toe-off events.
223656683|NCT07062003|PROCEDURE|Biopsy Procedure|Undergo biopsy
223656684|NCT07062003|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
223656685|NCT07062003|PROCEDURE|Computed Tomography|Undergo CT
223656686|NCT07062003|OTHER|Medical Device Usage and Evaluation|Undergo MBRT with tungsten slit collimator
224239443|NCT06884943|BEHAVIORAL|Treatment as Usual (TAU)|Participants will return to their regular community-based care. This may consist of treatment in the school setting or by a private SLP; participants who were not previously receiving treatment may return to a no-treatment condition. Data will be collected from parents/guardians to determine the frequency of treatment, if any, received during this phase.
224239444|NCT00522457|DRUG|ertumaxomab|Ertumaxomab will be intravenously administered to see if it can increase the patient's objective response rate.
223656687|NCT07062003|RADIATION|Minibeam Radiation Therapy|Undergo MBRT with tungsten slit collimator
223768380|NCT00799968|DRUG|Urokinase|UK,20 000U/kg continuously intravenous infusion for 2 hours
223768381|NCT03281369|DRUG|5-Fluorouracil (5-FU)|5-FU 2400 milligrams per square meter (mg/m\^2) by continuous intravenous (IV) infusion over 46 hours on Days 1 and 2 and Days 15 and 16 of every 28-day cycle.
223768382|NCT03281369|DRUG|Leucovorin|Leucovorin: 100 mg/m\^2 IV over 2 hours on Days 1 and 15 of every 28-day cycle.
223768383|NCT03281369|DRUG|Oxaliplatin|Oxaliplatin: 100 mg/m\^2 administered by IV infusion over 2 hours on Days 1 and 15 of every 28-day cycle.
223768384|NCT03281369|DRUG|Atezolizumab|Atezolizumab: 840 mg by IV infusion on Days 1 and 15 of every 28-day cycle.
224239445|NCT06266377|OTHER|Administration of menus of collective catering adapted to the sensory and nutritional needs of subjects with Autism Spectrum Disorder|"The AUT-MENU intervention study will be structured in two phases: a preliminary observation phase (T0), which will assess and describe the acceptance of standard meals in the context of collective catering in primary and high schools by the subjects enrolled in the study; and an intervention phase (T1) in which the acceptance of menus targeted to the nutritional and sensory needs of the same subjects enrolled at T0 will be assessed.~The revision of the standard menus will be carried 1) balancing energy and macronutrient content, 2) promoting adequate weekly food frequencies consumption and portions, to provide an adequate and sustainable menus 3) adapting the sensory characteristics of the foods offered to the sensory needs of individuals with ASD.~The acceptance of the targeted menus by the enrolled population will be evaluated through meal evaluation forms. These results will be compared with the ones collected during the first observational phase (T0)."
224321058|NCT04363580|OTHER|Auditory processing disorder screening tool|"Screening tool : a questionnaire completed by the parents and the child's teacher and a mini-battery of tests composed of verbal and nonverbal assessments.~Questions for parents are grouped into four sections:~* Reference pattern and portrait of the child.~* Auditory history.~* History of speech and language development.~* School history.~The teacher questionnaire has seven sections:~* Portrait of the child.~* Reading and writing.~* Speaking.~* Mathematics.~* Music.~* Memory.~* Listening skills and understanding:~  * Concentration and organization.~ * Environment.~Mini-battery of tests:~* Dichotic Numeric Listening Test.~* Identification test of 15 patterns of frequency-varying sounds at each ear.~* Test of 10 monosyllables in noise per ear.~* Auditory memory test by measuring the range of figures (instead of words in order to reduce the contribution of language processing)."
223768385|NCT03281369|DRUG|Cobimetinib|Cobimetinib: 60 mg by mouth once a day on Days 1-21 of every 28-day cycle
224321059|NCT01009814|DRUG|BMS-663068|BMS-663068 will be administered as a tablet formulation
224239446|NCT06266377|OTHER|Nutrition education course aimed at caregivers of individuals with Autism Spectrum Disorder|A population subgroup will also be selected whose caregivers will be invited to participate in a nutrition education course with the aim of providing parents of subjects with ASD, with knowledge tools to learn how to identify, manage and reduce their children's attitudes of food selectivity.
223656688|NCT07062783|OTHER|Breathing exercise|Volunteers participating in the study who were included in the experimental group performed breathing exercises every day for three weeks. They were taught to focus their attention on the hand on their abdominal area while breathing slowly through their nose and to increase abdominal movement while reducing chest movement. They were warned that during inspiration, as air filled their lungs, the hand on their abdomen should rise upward and the hand on their chest should not move excessively. Participants continued the training until they performed the exercise correctly. The diaphragmatic breathing exercise was performed for 10 minutes in the supine position during the first week, in the semi-sitting and/or sitting position during the second week, and in the standing position during the final week.
224239447|NCT01691248|DRUG|fidaxomicin|"Fidaxomicin 200 mg tablet once daily from the start (+/- 2 days) of condition (prior to transplantation) or at the time of Fluoroquinolone initiation. Study drug treatment will continue until 7 days after either neutrophil engraftment or the completion of any Fluoroquinolone antibiotic regimen (whichever occurs later).~Study drug treatment will stop at onset of CDAD or no longer than 40 days of duration, even if other antibiotics are still administered or neutrophil engraftment extends beyond 40 days."
224239448|NCT01691248|DRUG|Placebo|"Placebo tablet once daily from the start (+/- 2 days) of condition (prior to transplantation) or at the time of Fluoroquinolone initiation. Treatment will continue until 7 days after either neutrophil engraftment or the completion of any Fluoroquinolone antibiotic regimen (whichever occurs later).~Treatment will stop at onset of CDAD or no longer than 40 days of duration, even if other antibiotics are still administered or neutrophil engraftment extends beyond 40 days."
224239449|NCT02962128|DIETARY_SUPPLEMENT|High Linoleic Acid (LA) Diet|Volunteers will be randomly assigned to consumption of a high \[10% energy\] LA-containing diet for 12 weeks.
224239450|NCT02962128|DIETARY_SUPPLEMENT|Low Linoleic Acid (LA) Diet|Volunteers will be randomly assigned to consumption of a low \[2.5% energy\] LA-containing diet for 12 weeks.
224239451|NCT01740700|DEVICE|p-Branch®|Instead of making a large incision in the abdomen, the physician makes a small incision near each hip to insert, and guides the study device(s) into place in the aorta.
224321060|NCT01009814|DRUG|Ritonavir|Ritonavir will be administered as a capsule.
223656689|NCT07062783|OTHER|Aerobic Exercise|The ratios determined as reference values for walking training in healthy adults (reference value for women = (2.11\*height) - (2.29\*body weight) - (5.78\*age) + 667 meters - reference value for men = (7.57\*height) - (1.76\*body weight) - (5.0 2\*age) - 309 meters) was performed at 80% intensity for at least 30 minutes on at least 3 days a week for 3 weeks. Aerobic exercise was considered for 3 weeks to facilitate adaptation to exercise and sustainability.
223768386|NCT03281369|BIOLOGICAL|Ramucirumab|Ramucirumab: 8 mg/kg administered by IV infusion over 60 minutes on Days 1 and 15 of every 28-day cycle.
223768387|NCT03281369|DRUG|Paclitaxel|Paclitaxel: 80 mg/m\^2 administered by IV infusion on Days 1, 8, and 15 of every 28-day cycle.
223768388|NCT03281369|BIOLOGICAL|PEGylated recombinant human hyaluronidase (PEGPH20)|PEGPH20: 3 micrograms per kilogram (mcg/kg) administered by IV infusion on Days 1, 8, and 15 of every 21-day cycle.
224321061|NCT00618371|DRUG|Raltegravir (MK-0518)|Antiretroviral drug intensification with Raltegravir (MK0518) 400mg orally every 12 hours for 28 days in addition to the prescribed antiretroviral therapy
224321062|NCT01059461|DRUG|Cerebrolysin®|injection of cerebrolysin® 0.1ml/kg IM twice weekly for 10 injections after discharge from NICU (postneonatal)
224321063|NCT00836407|DRUG|Ipilimumab|Ipilimumab (10mg/kg) will be administered intravenously at weeks 1, 4, 7 and 10. Subjects will also be offered maintenance phase dosing every 12 weeks.
224321064|NCT00836407|BIOLOGICAL|Pancreatic Cancer Vaccine|The Pancreatic Cancer Vaccine (5E8 cells) will be administered intradermally at weeks 1, 4, 7 and 10. Subjects will also be offered maintenance phase dosing every 12 weeks.
224321065|NCT06315075|BEHAVIORAL|Dialectical behavior therapy for adolescents (DBT-A)|A 20-week DBT-A with a weekly individual session (45 minutes), a weekly session of multifamily skills training groups with a caregiver (120 minutes), and telephone consultation with individual therapists outside therapy sessions as needed. The treatment consists of four components and is delivered according to the manual except for the phone coaching that PBU offers workdays until 8 pm.
223656690|NCT06890897|DRUG|Esketamine group|Patients in the esketamine group will receive intravenous infusion of esketamine besides PRF+standardized treatment.The formula will be intravenous infusion of 0.5mg/kg of esketamine diluted in 50 mL normal saline, starting with intravenous injection of 10 mg of esketamine for 1 minute, and maintaining a dose 8 mg/h.The infusion rate will be adjusted the parameter according to the tolerance of the patients
223656691|NCT06890897|DRUG|PRF group|Patients in the control group will receive PRF+standardized treatment
223656692|NCT04829240|BEHAVIORAL|Veterans Anxiety Skills Training Intervention|Modular anxiety intervention designed for Primary Care-Mental Health Integration settings, including up to six 30-minute sessions occurring approximately every 2 weeks, in which Veterans select modules of interest to them to complete, with an emphasis on psychoeducation and cognitive-behavioral coping strategies for self management of anxiety symptoms
223656693|NCT04829240|BEHAVIORAL|PCMHI Usual Care|Appointment with Primary Care-Mental Health Integration provider at local primary care clinic for anxiety treatment; provider delivers whatever interventions they deem appropriate and collaboratively decides with patients whether and when to meet again as in routine PCMHI care
224239452|NCT04738747|BEHAVIORAL|WHOOP fitness tracker|WHOOP is a device that uses a wristband or arm band to track heart rate, heart rate variability (HRV), and sleep to calculate proprietary strain and recovery scores for its users. Heart rate variability is an important metric for correlation with acute stress
223656694|NCT06657924|DRUG|Tranexamic acid|1 gram IV bolus in 100ml of normal saline administered over 10 minutes at the start and end of the surgery for a total of 2 grams TXA
223656695|NCT05731544|DRUG|BMF-219|Investigational Product
224239453|NCT05308043|DIAGNOSTIC_TEST|Deep learning algorism|A deep learning algorism that was developed previous would be applied to identify retinoblastoma tumours on Retcam images and distinguish between active and inactive retinoblastoma tumours. The decision of two different senior ophthalmologists would be the gold standard.
224239454|NCT02863575|DRUG|Ibuprofen/Caffeine|Ibuprofen/Caffeine fixed-dose combination
224239455|NCT02863575|DRUG|Ibuprofen|Ibuprofen capsule
224239456|NCT02863575|DRUG|Placebo|Placebo treatment
223656696|NCT06539962|DIAGNOSTIC_TEST|Krebs von den Lungen-6 (KL-6)|Krebs von den Lungen-6 (KL-6) will be evaluated for ability to predict cardiovascular comorbidities among IPF patients
223656697|NCT06285201|DRUG|T|8 mg/kg IV of Test drug manufactured by I-Mab Biopharma(Hangzhou)
223656698|NCT06285201|DRUG|R|8 mg/kg IV of Test drug manufactured by Patheon Italia
224239457|NCT07076082|DRUG|Clopidogrel (Plavix) Pharmacogenetic Test Reagents|Dual antiplatelet therapy (DAPT), defined as the use of Clopidogrel (75 mg/day) (clopidogrel) and aspirin (81 mg or more/day). Single antiplatelet therapy (SAPT), defined as the use of aspirin (81 mg or more/day).
224239458|NCT06818487|DRUG|Ganyan1|During the treatment period, participants will receive the following Chinese herbal granules, including Chrysanthemum, Dendrobium, Salvia miltiorrhiza, Gypsum Fibrosum, and Goji berries, administered twice daily at a dose of 10 g per time for a duration of 4 weeks.
224239459|NCT06818487|DRUG|Sodium Hyaluronate|Participants received 0.1% sodium hyaluronate eye drop
224239460|NCT06818487|DRUG|1/2Ganyan1|During the treatment period, participants will receive the following Chinese herbal granules, including Chrysanthemum, Dendrobium, Salvia miltiorrhiza, Gypsum Fibrosum, and Goji berries, administered twice daily at a dose of 5 g per time for a duration of 4 weeks.
224239461|NCT06818487|DRUG|Placebo|Participants will receive the following placebo Chinese herbal granules, administered twice daily at a dose of 10 g per time for a duration of 4 weeks.
224239462|NCT05879367|DRUG|Eflornithine (Dose Level 1)|Eflornithine 2.3 g/m2 administered orally every 8 hours on a 2 weeks on, 2 weeks off schedule
223656699|NCT05475483|DRUG|Placebo capsules|Treatment was blind for the whole duration of the study.
223656700|NCT05475483|DRUG|SOM3355 200 mg capsules|Treatment was blind for the whole duration of the study.
223656701|NCT05475483|DRUG|SOM3355 300 mg capsules|Treatment was blind for the whole duration of the study.
223656702|NCT03969784|OTHER|blood draw, tumoral biopsy tissus|Patient will have specific blood draw and part of their tumoral tissu biopsied
223656703|NCT03425474|DRUG|Remimazolam Tosilate|Initial dose plus supplemental doses as necessary
223656704|NCT03425474|DRUG|Propofol|Initial dose plus supplemental doses as necessary
223656705|NCT01597167|DIETARY_SUPPLEMENT|Magnesium sulfate|4 grams magnesium sulfate in 100 ml IV over 4 hours
223656706|NCT02130791|BEHAVIORAL|Sleep|
223656707|NCT04628910|OTHER|Simulated Flotation Therapy|"The Zerobody is a new technology designed to simulate the effects of traditional Float-REST therapy, but without the contact with salt water. The system has a very thin membrane that cradles the body and provides a warm sensation, similar to that experienced in a traditional flotation tank. The system will be housed in a room that allows for significant reductions in light and sound to mimic the experience of a flotation tank. The room will contain an intercom that allows participants to communicate with study personnel in the event they need assistance. Participants will undergo 60 minute sessions twice a week for 3 weeks using the Zerobody, also termed dry floating, as one of the two interventions."
223656708|NCT04628910|OTHER|Traditional Float-REST Therapy|Traditional Float-REST therapy uses sensory deprivation tanks that consist of a very large warm water enclosure with a high concentration of Epsom salt to create a completely buoyant environment. This, along with a combination of temperature that is kept equal to skin temperature (94 degrees), allows the participant to eliminate the gravitational effects on the body, and along with lack of sound and low to no light (depending on comfort) allows the brain and body to completely relax for augmented physical and mental recovery. The room will contain an intercom that allows participants to communicate with study personnel in the event they need assistance. Participants will undergo 60 minute sessions twice a week for 3 weeks as one of the two interventions.
223656709|NCT05661188|DRUG|Atezolizumab plus Tiraglolumab|All patients receive atezolizumab (1200mg) plus tiragolumab (600 mg) for 2 cycles (Q3W) in concomitance with the 6 weeks of standard scheduled chemoradiotherapy (cisplatin: 60 mg/m² on days 1 and 29; 5-FU: 1000 mg/m² per day on days 1-4 and 29-32; radiotherapy: 1.8 Gy per day / total dose 54 Gy). After the concomitant phase, patients receive atezolizumab and tiragolumab for 6 additional cycles (consolidation phase).
223656710|NCT00566384|DRUG|Dehydroepiandrosterone, BAY86-5314|Treatment with daily oral intake of two capsules containing 50 mg DHEA each. Treatment duration will be 24 weeks
224239463|NCT05879367|DRUG|Eflornithine (Dose Level 2)|Eflornithine 2.8 g/m2 administered orally every 8 hours on a 2 weeks on, 2 weeks off schedule
223768389|NCT03281369|DRUG|BL-8040|BL-8040: 1.25 mg/kg administered by subcutaneous (SC) injection on Days 1-5 during the 5-day priming period prior to Cycle 1; 1.25 mg/kg administered by SC injection three times a week (Days 1, 3, 5, 8, 10, 12, 15, 17, and 19 of every 21-day cycle).
223656711|NCT00566384|DRUG|Placebo|Treatment with daily oral intake of two capsules containing Placebo. Treatment duration will be 24 weeks
223656712|NCT01865552|BIOLOGICAL|SB4|SC administration
223656713|NCT01865552|BIOLOGICAL|EU sourced Enbrel|SC administration
223656714|NCT01865552|BIOLOGICAL|US sourced Enbrel|SC administration
223656715|NCT05289518|DEVICE|Remote ischemic conditioning (RIC)|RIC is a non-invasive therapy which is performed by automated pneumatic cuffs placed on bilateral arms. The RIC protocol include five cycles of 5-min inflation to 220mmHg and 5-min deflation.
223768390|NCT03281369|DRUG|Linagliptin|Linagliptin: 5 mg orally once a day of every 21-day cycle.
223768391|NCT03281369|DRUG|Atezolizumab|Atezolizumab: 1200 mg administered by IV infusion on Day 1 of every 21-day cycle
223768392|NCT03281369|DRUG|Cobimetinib|Cobimetinib: 40 or 60 mg (depending on the recommended dose determined during the safety run-in phase) by mouth once a day on Days 1-21 of every 28-day cycle.
223768393|NCT03281369|DRUG|Cisplatin|Cisplatin: 80 mg/m\^2 administered by IV infusion on Day 1 of each 21 day cycle. Treatment will be capped after 6 doses.
224239464|NCT05879367|DRUG|Eflornithine (Dose Level -1)|Eflornithine 1.75 g/m2 administered orally every 8 hours on a 2 weeks on, 2 weeks off schedule
224239465|NCT05879367|DRUG|Temozolomide|Temozolomide 150 mg/m2 (with option to escalate per USPI maintenance phase instructions) administered orally once daily on a 5 days on, 23 days off schedule
224239466|NCT04124861|DRUG|Drug free, IS monotherapy and GC combined with IS|Follow-up intervals: Every 3 months (3th, 6th, 9th, 12th, 15th, 18th month).
224239467|NCT03941223|PROCEDURE|PECSII and paravertebral blocks|Regional anesthesia for mastectomy outcomes
224239468|NCT05189184|DRUG|Camrelizumab+Apatinib mesylate+Albumin-bound paclitaxel+cisplatin|Camrelizumab in Combination With Apatinib mesylate Plus Albumin-bound paclitaxel and cisplatin as the First Line Treatment of Recurrent or Metastatic , UnresectableHead and Neck Squamous Cell Carcinoma (HNSCC)
224239469|NCT02051309|DRUG|Guanfacine|6mg/day ER with 3-week lead-in period. Maintained at steady state throughout 8 week treatment phase. After treatment phase, given taper supply of medication. Follow up at 1 month, 2 months and 6 months.
224239470|NCT02051309|DRUG|Placebo|
224239471|NCT03654196|DRUG|HL301(Experimental)|Total 7 days of treatment and The daily dose is as follows \[Morning: HL301 1Tab + Placebo of Umkamin 1Tab\] \[Noon: Placebo of Umkamin 1Tab\] \[Evening: HL301 1Tab + Placebo of Umkamin 1Tab\]
223656716|NCT05289518|DEVICE|Sham remote ischemic conditioning (Sham-RIC)|The Sham-RIC protocol include five cycles of 5-min inflation to 60 mmHg and 5-min deflation by placing automated pneumatic cuffs on bilateral arms.
223656717|NCT01258322|DRUG|Pioglitazone|The patients were randomized divided into 2 groups; one received no pioglitazone for lowing triglyceride, one with oral pioglitazone (Actos®, Takeda®) 15mg once daily for 12 weeks. After a four-week wash out, patients then continued with the alternate therapy.
223656718|NCT02052492|DRUG|EF-022 (Modified Vitamin D Binding Protein Macrophage Activator)|
223768394|NCT03281369|DRUG|Tiragolumab|Tiragolumab: 600 mg administered by IV infusion on Day 1 of every 21 day cycle.
223768395|NCT03281369|DRUG|5-Fluorouracil (5-FU)|5-FU 800 mg/m\^2 administerd by IV infusion on Days 1-5 of each 21 day cycle.
223768396|NCT05233462|OTHER|standardized dose|intrathecal anesthesia with 10 mg of bupivacaine
224239472|NCT03654196|DRUG|Umkamin(Active Comparator)|Total 7 days of treatment and The daily dose is as follows \[Morning: Placebo of HL301 1Tab + Umkamin 1Tab\] \[Noon: Umkamin 1Tab\] \[Evening: Placebo of HL301 1Tab + Umkamin 1Tab\]
224239473|NCT03267745|DIETARY_SUPPLEMENT|Amino Acid|23.7 g amino acid 3 times daily for 28 days
224321066|NCT04603872|DRUG|CD19/BCMA Targeted CAR T-cells and dasatinib|Each subject receive CS1 Targeted CAR T-cells by intravenous infusion, and the dasatinib was combined according to the presumed regimens.
223656719|NCT03716167|DEVICE|Summus Laser|infrared laser treatment
223656720|NCT03716167|DEVICE|Summus Laser Sham|non-infrared light
223768397|NCT05233462|OTHER|adjusted dose|intrathecal anesthesia with 0.05 mg of bupivacaine par cm of patient's height
223768398|NCT04604457|OTHER|Palliative care contacts primary care|Palliative care specialist reaches out to primary care to recommend a palliative care consult. If the primary care provider agrees, he/she will write an order for a palliative care consult.
223768399|NCT01559311|DEVICE|CRT-P OFF|CRT Pacemaker
223768400|NCT01559311|DEVICE|CRT-P ON|CRT Pacemaker
223768401|NCT01559311|DEVICE|DDDR|Dual-chamber, rate-modulated pacemaker
223768402|NCT00367172|BEHAVIORAL|Directly Administered Antiretroviral Therapy|
224239474|NCT03267745|DEVICE|Breg Brace single-leg immobilization|7 days of single leg immobilization; randomized to leg; knee brace will be worn in a fixed flexion position at 140°.
224239475|NCT03267745|OTHER|Placebo|Excipient-matched placebo 3 times daily for 28 days
223768403|NCT03489395|DRUG|Edoxaban|Edoxaban 60 mg once a day for 4 weeks. Edoxaban 30 mg/day in patients with body weight ≤60 kg, or with concomitant therapy with verapamil/quinidine/dronedarone.
223768404|NCT02850003|DRUG|IDP-120 Gel|Gel
223768405|NCT02665208|OTHER|Treatment As Usual (TAU)|informational pamphlets and information from 1800 quit line + prescription for nicotine replacement therapy (NRT) based on on the quantity of baseline self-reported smoking, or nicotine replacement gum (2mg)
223768406|NCT02665208|DRUG|Nicotine Replacement Therapies|a prescription for a nicotine replacement therapy (NRT) (i.e. nicotine replacement patches based on the quantity of baseline self-reported smoking, or nicotine replacement gum (2mg)
223768407|NCT02665208|BEHAVIORAL|Text Message Intervention (TMI)|
223768408|NCT00273572|OTHER|Moderate Lifestyle Intervention|Two educational group meetings with a dietitian in the first month of intervention; One individual counselling session with a dietitian at baseline, and at 6-month and 12-month follow-up
223768409|NCT00273572|OTHER|Intensive lifestyle intervention|A monthly individual counselling session with a dietitian; A monthly group session with a dietitian; Bi-monthly group sessions with a physical activity instructor
224239476|NCT00775177|DRUG|Doxycycline monohydrate 100mg tablets|Bioequivalence Doxycycline monohydrate 100mg tablets fasting condition
224239477|NCT04872257|DRUG|Oral Vitamin D|Vitamin D 5,000 UI for 6 months (oral capsule, daily, single-dose)
224239478|NCT04872257|PROCEDURE|NB-UVB Phototherapy|NB-UVB Phototherapy twice per week for 6 months until completing 48 sessions. Initial dose of 200 mJ/cm² with a 10-20% increase to the previous session. Maximum dose for face and neck is 1500 mJ/cm² and 3000 mJ/cm² for the rest of the body.
224239479|NCT04872257|DRUG|Placebo|Administered orally daily for 6 months
223656721|NCT03796520|DIAGNOSTIC_TEST|EpiPick simplified seizure classification algorithm|"EpiPick simplified seizure classification algorithm input:~Grey matter brain lesion Exclusively nocturnal seizures First seizure at age \> 20 years Lip smacking or chewing during seizures Staring with impaired awareness, lasting less than 20s without postictal confusion Sudden irregular jerks, in isolation or brief series, if none of the following applies: Are the jerks consistently in the same limb? When resting in bed when falling asleep? Bilateral tonic-clonic seizures within 1h of awakening or immediately preceded by irregular jerks Any of the following is present: Skin turning pale pre-ictally; Loss of consciousness immediately after urination or defecation; Sudden slump with loss of awareness, lasting less than 10 seconds; Seizure lasting longer than 10 minutes, with eyes closed throughout the seizure; Severe pre-ictal headache; Episodes consisting of falls that occur always after change in posture to the upright position, or coughing or feeling pain."
223656722|NCT04058132|DRUG|Sildenafil Citrate 50Mg Tab|sildenafil citrate (Viagra®, Pfizer. Inc., NY, NY). Sildenafil citrate is designated chemically as 1-\[\[3-(6,7-dihydro-1-methyl-7-oxo-3-propyl-1Hpyrazolo\[4,3-d\]pyrimidin-5-yl)-4- ethoxyphenyl\]sulfonyl\]-4-methylpiperazine citrate. Sildenafil citrate is a white to off-white crystalline powder with a solubility of 3.5 mg/mL in water and a molecular weight of 666.7. For this study, we will use 50 mg tablets for the single dose studies.
223656723|NCT04058132|DEVICE|functional Near-infrared Spectroscopy (fNIRS)|Functional Near-Infrared Spectroscopy (fNIRS): Functional near-infrared spectroscopy (fNIRS) a noninvasive technique that can measure cerebrovascular reactivity (CVR) will be used to measure regional cerebral blood flow and cerebrovascular reactivity in the brain. The device (fNRIS100, fNIR Device LLC), uses laser emission diodes (730nm and 850nm)which in a headband that is worn on the front of the scalp and forehead. Surrounding detectors a few centimeters away detect the light as it scatters through the underlying tissues. The technique is able to detect changes in the absorption spectrum of the tissue corresponding to the concentrations of oxyhemoglobin (HbO2) and deoxyhemoglobin (HbR), and indicate local perfusion changes. fNIRS will be performed twice at each study visit, once before and once about 45 minutes after single dose administration of sildenafil 50 mg.
223656724|NCT04058132|OTHER|Carbon Dioxide (CO2) 5%|"Carbon Dioxide (CO2) 5% mixed with room air. Both the fNIRS procedure and one Magnetic Resonance Imaging (MRI) session at visits that include imaging will be done with a hypercapnia challenge for comparison.~CO2 (hypercapnia) challenge is similar to holding one's breath. Participant will wear a nose clip and a mouth breathing apparatus while in the MRI scanner or sitting in a chair during the fNIRS procedure.~During the 7-minute hypercapnia procedure, participants will breathe room air and then switch to room air mixed with 5% CO2, from one to the other for one minute each."
223656725|NCT04058132|OTHER|Neuropsychological Assessments|TBI Neuropsychological Assessments: Study participants will be administered a set of Neuropsychological Tests designed by the NINDS Common Data Elements (CDEs) initiative for TBI, in order to provide a comprehensive and broad assessment of deficits commonly found after TBI. We anticipate that the neuropsychological battery will require approximately 1 hour to complete. The measures (pencil and paper exercises, questionnaires, and interview by the examiner) to be administered are: Glasgow Outcome Scale-Extended (GOS-E). Learning trials portion of the California Verbal Learning Test (CVLT-II): The Trail Making Tests A and B (TMT): Subsets of the Wechsler Adult Intelligence Scale (WAIS-IV) (Digit Symbol and Symbol Search): Behavioral Symptoms Inventory-18: Satisfaction with Life Scale (SWLS): Word Reading subtest of Wide Range Achievement Test (WRAT)-4: Rivermead Post-Concussion Symptom Questionnaire.
223656726|NCT04058132|DRUG|Gadolinium contrast infusion|Gadolinium contrast infusion: Brain MRI with gadolinium contrast: Dynamic contrast-enhanced (DCE) MRI with intravenous gadolinium-based contrast agents (GBCAs) to measure their transfer rate between intravascular and extravascular compartments as a marker of blood-brain barrier (BBB) permeability. For the DCE sequence, the participant is injected with the contrast agent through a heplock/iv in the scanner and the sequence takes about 15 min. Half-life of gadolinium is about 1 ½ hours and 90-98% clearance from the body in 24 hours in people with normal kidney function.
223656727|NCT04058132|PROCEDURE|Blood sample collection for research purposes|Serum and plasma (5 ml each) will be collected at at each study visit 10 m or 2 tsp. per visit or up to 40 ml or 8 tsp. over the 180 day course of the study). Samples will be collected by study personnel.
223656728|NCT04058132|OTHER|Structural brain Magnetic Resonance Imaging (MRI|"Structural brain Magnetic Resonance Imaging (MRI): The scanner used is a 3.0 Tesla MR (Model 750, General Electric Healthcare), which is equipped with a high-performance gradient subsystem and a 32-channel head coil (General Electric Healthcare). These scans involve lying still in a scanner for several minutes at a time which is tube shaped, using magnetism to take images of the brain. There is no radiation in MRI. The participants will have up to 3 research brain MRIs. Healthy controls will have 1 MRI session.~Common TBI MRI techniques will be performed. Block-design BOLD fMRI during which there will be a 7 minute hypercapnia challenge will be done to assess brain blood flow and measure cerebral vascular reactivity (CVR)."
224239480|NCT03208543|DEVICE|HECT-CL|To evaluate the effectiveness, safety and feasibility of thermotherapy with the low cost Hand-held Exothermic Crystallization Thermotherapy pad in the treatment of cutaneous leishmaniasis in Quetta, Balochistan, Pakistan.
224321067|NCT04603872|DRUG|CD19/BCMA Targeted CAR T-cells|Each subject receive CS1 Targeted CAR T-cells by intravenous infusion.
224239481|NCT01781598|DEVICE|Total knee arthroplasty (TKA) (Smith &Nephew®)|
224321068|NCT04844190|DIAGNOSTIC_TEST|EndoFLIP|During pre-G-POEM upper endoscopy, an EndoLIP catheter will be inserted through the patient's mouth into the stomach and across the pylorus. Once results of EndoFLIP are obtained, the catheter will be removed (5 minutes).
223656729|NCT05094388|OTHER|Admitted to intensive care units|Admitted to intensive care units
223656730|NCT03563924|OTHER|"Setting up a specific care path AlloTC for management of TVE in patients with cancer"|"Setting up a specific care path AlloTC for management of TVE in patients with cancer with a specific coordination nurse within the AlloTC multidisciplinary team as a privileged interlocutor for health professionals and patients with the aim of simplifying the care pathways and ensuring a hospital-city interface organized in collaboration with the attending physician, to develop and publicize tools available for patients and caregivers (information documents, patient monitoring protocols, etc.)"
223656731|NCT04708314|DRUG|Golodirsen 50 MG/1 ML Intravenous Solution [VYONDYS 53]|Vyondys 53
223656732|NCT04591678|DRUG|nusinersen|SPINRAZA (nusinersen) is FDA approved to treat spinal muscular atrophy (SMA) through intrathecal injection.
223656733|NCT01757249|DRUG|Combined Oral Contraceptive Pill (Microgynon 30)|Pre-IVF treatment for 8 weeks
224239482|NCT00991445|PROCEDURE|Minimal Invasive Surgery|After a 8-10 cm skin incision, a medial parapatellar capsule incision is made. The vastus medialis muscle or the rectus tendon are not incised, nor is the patella everted. The patella is merely pushed slightly aside when the bone cuts are made and the prostheses are cemented in place. Local Infiltration Analgesia is used.
223656734|NCT01282619|DRUG|Huperzine A|Sustained-Release Tablet, 400µg once a day, 24 weeks
223656735|NCT01282619|DRUG|huperzine A|Tablet, 200µg twice a day, 24 weeks
223656736|NCT01282619|DRUG|Placebo|placebo orally twice a day
223656737|NCT01715012|BIOLOGICAL|ST266|ST266 is applied daily by spray to burn wound and skin graft donor site
223656738|NCT01715012|DRUG|Saline|Saline is applied daily by spray to burn wound and skin graft donor site
223656739|NCT05150899|DRUG|Tamsulosin Hcl 0.4Mg Cap|alpha blocker
223656740|NCT05150899|DRUG|fexofenadine 180 mg Oral tablet|antihistaminic
223656741|NCT03192371|BIOLOGICAL|Rabipur|Rabies vaccine administered as an intramuscular injection according to Zagreb or Essen regimen to subjects aged ≥6 to ≤17 years.
223656742|NCT02269579|DRUG|CPX-351|
223656743|NCT04458090|BEHAVIORAL|A decision aid for patients considering Hospice care.|A 12 page booklet and 17 min video describing hospice care
223656744|NCT04415671|BIOLOGICAL|AD-214|AD-214 is a recombinant Fc-fusion protein that selectively binds to CXCR4 to antagonise the SDF-1/CXCR4 axis.
223656745|NCT04415671|OTHER|Placebo|Placebo
223656746|NCT02120183|BEHAVIORAL|Psycho-educational support group therapy|"Weekly sessions lasting 60 minutes. Topics addressed each week:~Week 1: Coping with the diagnosis of loved one and dealing with uncertainty~Week 2: Caring for the carer 1: Feeding your body (self-care, stress management, mindfulness concepts)~Week 3: Caring for the carer 2: Feeding your mind (challenging negative thinking habits)~Week 4: The emotions of caregiving (handling emotional reactivity)"
223656747|NCT06126211|DEVICE|Assessment|"The hand grip strength of each individuals was measured by the Electronic Camry Dynamometer (Model EH101, Zhongs-han Camry Electronic Co. Ltd. China: 90 kg capacity, 356 g weight) and Jamar Hydraulic Hand Grip Dynamometer (Model J00105, Lafayette Instrument Com-pany. USA: 90 kg capacity, 727 g weight). The assessments of the upper extremity were performed bilaterally.~Camry Electronic Hand Grip Dynamometer - Measurement of Grip Strength: In the evaluation to be made with the Camry Electronic Hand Grip Dynamometer; Three different measurements will be made on bilateral upper extremities (right and left).~Jamar Hydraulic Hand Grip Dynamometer - Measurement of Grip Strength: In the evaluation to be made with the Jamar Hydraulic Hand Grip Dynamometer; Three different measurements will be made on bilateral upper extremities (right and left)."
223656748|NCT02175199|DEVICE|Lotrafilcon B contact lenses with color printing|
223656749|NCT02175199|DEVICE|Phemfilcon A contact lenses with color printing|
223656750|NCT01794143|DRUG|Sulfonylurea (glimepiride)|Used in accordance with labeling and/or usual practice.
223656751|NCT01794143|DRUG|DPP-4 inhibitor (sitagliptin)|Used in accordance with labeling and/or usual practice
223656752|NCT01794143|DRUG|GLP-1 receptor agonist (liraglutide)|Used in accordance with labeling and/or usual practice.
223656753|NCT01794143|DRUG|Insulin (glargine)|Used in accordance with labeling and/or usual practice.
223656754|NCT03257449|DIETARY_SUPPLEMENT|Viscous Fibre|Meta-analysis of Randomized Controlled Trials
223656755|NCT00459732|DIETARY_SUPPLEMENT|Zinc|25 mg of elemental zinc as zinc sulphate take once daily for 18 months
223656756|NCT00459732|DIETARY_SUPPLEMENT|Placebo|Placebo capsule, identical to the zn capsule in size, shape and color, taken once daily for 18 months
223656757|NCT01257061|DRUG|Group 1|Clemastine fumarate 1,0 mg/g + dexamethasone 0,5/g applied 2 times / day at lesion
223656758|NCT01257061|DRUG|Group 2|Dexchlorpheniramine maleate 10 mg/g applied 2 times / day at lesion
223656759|NCT00250328|DEVICE|LapCAC Laparoscopic Compression Anastomosis Clip|
223656760|NCT02789930|OTHER|"Device: Accuracy of a program and the anesthesia tape (Anästhesie-Lineal)"|Computer based comparison of the two devices based on collected patient data
223656761|NCT04502173|DEVICE|Ellavi UBT|The study team will train all obstetric healthcare staff (i.e. obstetricians, midwives, medical officers, clinical officers) involved in PPH management at the participating healthcare facilities on use of the Ellavi UBT. This will be done to gather feedback from the healthcare workers (post-training and post-PPH) to understand the barriers to and facilitators of use in order to evaluate acceptability and feasibility among facilities providing different levels of care (level 4, level 5 (county), level 6 (tertiary)).
223656762|NCT06291818|DEVICE|temporary magnetic system for tarsorrhaphy (MST)|cutting-edge technology has produced smaller magnets with stronger magnetic fields, prompting experts to revisit the use of magnets to facilitate eyelid closure
223656763|NCT05751564|BIOLOGICAL|"Ready to inject Umbilical cord-derived Mesenchymal Stromal Cell (MSC) product"|Cryopreserved thaw \& inject MSC intra-articular therapy
223656764|NCT05751564|BIOLOGICAL|Resuspended Umbilical cord-derived Mesenchymal Stromal Cell (MSC) product|Cryopreserved resuspended MSC intra-articular therapy
223656765|NCT03344770|DEVICE|Active rESWT|5,000 pulses of rESWT, with 0.16mJ/mm2 of energy at a frequency of 20Hz once a week for three weeks.
223656766|NCT03344770|DEVICE|Sham rESWT|5,000 pulses of rESWT, with 0.0 mJ/mm2 of energy at a frequency of 20Hz once a week for three weeks.
223656767|NCT04344964|OTHER|None - NA|Observational study
223656768|NCT01017380|DRUG|Celecoxib|celecoxib 400 mg 1 cap before surgery
223656769|NCT01017380|DRUG|etoricoxib|120 mg 1 tab before surgery
223656770|NCT00045461|DRUG|carboplatin|
223656771|NCT00045461|DRUG|ifosfamide|
223656772|NCT00045461|PROCEDURE|hyperthermia treatment|
223656773|NCT03933891|PROCEDURE|TIPS|TIPS: Established distributary channel between the portal vein and hepatic vein via the jugular vein, portal vein blood directly shunts into the systemic circulation to reduce portal vein pressure to effectively prevent bleeding and refractory ascites.
223656774|NCT05480111|DRUG|Local anesthesia at incision site|20 ml of 0.25% Bupivacaine will be given at incision site
223656775|NCT05480111|DRUG|Sham QL|20 mls of normal saline given at QL.The QL block will be administered on both the right and left sides. The transducer is placed transverse immediately cranial to the iliac crest and at the level of the posterior axillary line. The needle is then inserted inplane from the lateral edge of the transducer and advanced through the quadratus lumborum (QL) muscle until the needle tip penetrated the epimysium of the anterior part of the QL muscle. The anesthetic is injected after repeated negative aspiration tests for blood in the fascial interspace between the QL and psoas major (PM) muscles posterior to the transversalis fascia
223656776|NCT05480111|DRUG|Sham Local|20 mls of normal saline given at incision site
223656777|NCT05480111|DRUG|QL|QL block involves injection of 19 ml of 0.25% Bupivacaine and iml(4mg) of Decadron in a fascial place formed partly by the posterior surface of the quadratus lumborum muscle.The QL block will be administered on both the right and left sides. The transducer is placed transverse immediately cranial to the iliac crest and at the level of the posterior axillary line. The needle is then inserted inplane from the lateral edge of the transducer and advanced through the quadratus lumborum (QL) muscle until the needle tip penetrated the epimysium of the anterior part of the QL muscle. The anesthetic is injected after repeated negative aspiration tests for blood in the fascial interspace between the QL and psoas major (PM) muscles posterior to the transversalis fascia
223656778|NCT00935922|DIETARY_SUPPLEMENT|Flaxseed|Flaxseed omega-3 fatty acids and lignans
223656779|NCT04851405|BEHAVIORAL|Otago Exercise Programme+ (OEP+)|"Physiotherapists (PTs) will receive OEP and BAP training. They will provide at home visits and follow-up phone calls to the older adult participants (5 at home visits and 3 phone calls).~Older adults will have access to the OEP app."
223656780|NCT04851405|BEHAVIORAL|Otago Exercise Programme (OEP)|PTs will receive OEP training. They will provide at home visits and follow-up phone calls to the older adult participants (5 at home visits and 3 follow-up phone calls).
223656781|NCT02814500|DRUG|DP-R212|Investigational product is prescribed to all of randomized subjects
223656782|NCT02814500|DRUG|Amlodipine|Investigational product is prescribed to all of randomized subjects
223656783|NCT02814500|DRUG|Rosuvastatin|Investigational product is prescribed to all of randomized subjects
223656784|NCT01322841|OTHER|CHICA Diagnosis Module|The CHICA module helped to screen and diagnose patients with tuberculosis or iron deficiency anemia
223656785|NCT01322841|OTHER|CHICA Placebo|This was CHICA without the screening module
224239483|NCT00991445|PROCEDURE|Conventional exposure|After a 15-20 cm midline skin incision is made, a medial parapatellar capsule incision is made. The incision is carried up through the insertion of the vastus medialis and into the rectus tendon. The patella is everted. The bone cuts are made and the prostheses are cemented in place. Local Infiltration Analgesia is used.
224239484|NCT00592098|DRUG|Strontium chloride hexahydrate|Cutaneous solution, 1 ml dose per 100 sq cm of affected skin area, To be applied twice daily for 28 days.
224239485|NCT00592098|DRUG|Placebo|Cutaneous saline solution, 1 ml dose per 100 sq cm of affected skin area, To be applied twice daily for 28 days.
224321069|NCT04844190|DIAGNOSTIC_TEST|Antroduodenal Manometry|Following removal the EndoFLIP catheter, a manometry catheter will then be placed through the nose and advanced across the pylorus. Once catheter positioning is confirmed on endoscopy, the endoscope will be withdrawn. The manometry catheter will be taped to the nose and sedation stopped. The patient will be brought to the recovery area where they will wake-up with the catheter in place. In a private recovery room, the patient will have the catheter in place (no positioning or movement restrictions). When pyloric spasms are documented (0.5-4 hours), they will be given a standard small meal (water, toast/bread). Once motility is assessed with eating, the manometry catheter will be removed.
223656786|NCT04980742|PROCEDURE|acute normovolemic hemodilution|acute normovolemic hemodilution
223656787|NCT01095198|DEVICE|offer of vaginal self collection|Women assigned to the intervention group will be offered the opportunity to self collect a vaginal specimen for HPV testing. They will be sent a letter explaining that a study of self testing is being performed, and will invite her to participate in this study. The letter will state that, if the patient prefers, she can perform a vaginal self-test in addition to, or instead of Pap smear testing. Patients are told that they have the option of completing the self-test on their own or in their physician's office with the help of their physician or practice staff. The letter will be accompanied by a self collection kit consisting of: a swab and test tube, pamphlet (with written instructions and diagram outlining procedure), instructional DVD and return envelope.
224239486|NCT03229005|PROCEDURE|implant insertion|during surgery soft tissues will be measured
224239487|NCT03229005|PROCEDURE|operculectomy|during second surgery soft tissues will be measured again
224239488|NCT03229005|PROCEDURE|prosthetic rehabilitation|after three months implants will be loaded with screw retained crown
224239489|NCT02510547|PROCEDURE|CrossBoss Catheter|Upfront use of the CrossBoss catheter for CTO lesion crossing
224239490|NCT02510547|PROCEDURE|Antegrade Wire Escalation Strategy|Upfront guidewire escalation strategy for CTO lesion crossing
224239491|NCT04281563|OTHER|massage with MCT oil (group 1)|Two trained nurse took turns performing standardized massage techniques in group 1 and group 2. The difference was that in group 1, the neonates received massage with MCT oil, and in group 2, the neonates received massage without using the oil. The 10-min massage intervention consisted of two 5-min phases: tactile and kinesthetic stimulation (13), which were given three times a day for 7 consecutive days. The massage force was approximately 300 grams, and the massager practiced applying the pressure by using a food scale. The massage was given in the prone and supine positions, and the actions included gentle touching of the head, back and limbs for five 1-min periods, followed by six passive flexion/extension movements lasting 10 s apiece for each arm, then each leg, and finally both legs together for a total of five 1-min periods. Premature infants in the oil massage group received massage with 10 mL/kg/day of MCT oil divided equally into three applications.
223656788|NCT01095198|OTHER|2nd reminder letter for Pap testing|Women in both groups will receive a letter informing them that they are due for cervical screening. This is a standard letter, and is signed by the patient's individual family physicians. It will advise the patient that this is the second reminder letter that she is due for cervical cancer screening, and will invite her to phone the physician's office to obtain an appointment for Pap testing.
223656789|NCT02560545|DRUG|Cannabis oil|Cannabis oil 20% THC
223656790|NCT00283335|DRUG|gemfibrozil|
223656791|NCT00283335|OTHER|Placebo|Matching placebo tablets taken once per day
223656792|NCT05090774|BEHAVIORAL|Adapted Otago Exercise Program (OEP)|A modified version of the 8- week evidence-based Otago Exercise Program (OEP), adapted for integration into supervised exercise therapy (SET). The OEP exercises will include 12 static and dynamic standing balance movements (knee bends, backwards walking, walking and turning, sideways walking, tandem stance, tandem walk, one leg stand, heel walking, toe walking, heel-toe walking backwards, sit to stand, stair walking). The OEP also contains additional behavior change techniques embedded within the intervention protocol (i.e. feedback on behavior, self-monitoring of behavior, biofeedback).
223656793|NCT03263949|OTHER|Diagnostic|For the analysis of myocardial function, conventional 2D echocardiography and tissue doppler will be used. For the evaluation of myocardial mechanics, 2D speckle tracking, strain, strain rate and mechanical dispersion will be obtained.
223656795|NCT02767349|DRUG|MNK-155|2 or 3 tablets initial dose, followed by two tablets every twelve hours
223656796|NCT02817425|DRUG|SOX Sequential S-1|8 cycles SOX followed by S-1 monotherapy until disease progression. S-1: 40 mg/m2 bid,po, day 1 \~14 (S-1：BSA \<1.25m2, 40mg bid, 1.25m2≤BSA≤1.5m2,50mg bid, BSA\>1.5m2, 60mg bid) Oxaliplatin: 130 mg/m2 iv 2h,day 1.Every 21 days as a cycle.
223656797|NCT02817425|DRUG|SOX|S-1: 40 mg/m2 bid,po, day 1 \~14 (S-1：BSA \<1.25m2, 40mg bid, 1.25m2≤BSA≤1.5m2,50mg bid, BSA\>1.5m2, 60mg bid) Oxaliplatin: 130 mg/m2 iv 2h,day 1. Every 21 days as a cycle
223656798|NCT02817425|DRUG|TEGAFOX Sequential S-1.|6 cycles TEGAFOX followed by S-1 monotherapy until disease progression. S-1: 40 mg/m2 bid,po, day 1 \~14 (S-1：BSA \<1.25m2, 40mg bid, 1.25m2≤BSA≤1.5m2,50mg bid, BSA\>1.5m2, 60mg bid) Oxaliplatin: 130 mg/m2 iv 2h,day 1. TF 1000 mg/m2 with calcium folinate 300 mg/m2 IV infusion from Day 1 to Day 5 Every 28 days as a cycle.
223656799|NCT02122757|DEVICE|Cefaly tDCS|Cefaly tDCS (transcranial direct current stimulation) is able to modify cortical excitability, in particular anodal tDCS increases it. The side effects of tDCS are minor, especially sensations of itching and scalp paresthesias.
223656800|NCT02122757|DEVICE|sham Cefaly tDCS|2mA during 30sec
223656801|NCT01401660|OTHER|Physical Therapy|The physician will complete a physical exam as well as analyze a completed CERSR® scan study to determine the root cause of the low back pain. The physician will then prescribe a targeted physical therapy regime to address the cause of the low back pain.
223656802|NCT03983317|DEVICE|Empower Neuromodulation System|Transcutaneous electrical nerve stimulation
223656803|NCT03991897|DIETARY_SUPPLEMENT|Ketogenic diet|Ketocal, a nutritionally complete ready-to-drink liquid, is foreseen to ensure adequate amounts of vitamins and minerals will be used. After 24 weeks a Modified Atkins diet will be started.
223656804|NCT03991897|DIETARY_SUPPLEMENT|Isocaloric diet|Patients will follow an isocaloric diet
223656805|NCT03991897|DIETARY_SUPPLEMENT|Ketone ester supplementation|25g of a ketone monoester, ingested 3 times a day for a period of 12 weeks. Ingestion is separated from a meal and interspersed by at least 4 hours to ensure maximal available ketone bodies circulating in the blood.
223656806|NCT02904213|BIOLOGICAL|ComBe Five (Liquid)|
223656807|NCT01761162|DEVICE|Patients with a ProMRI Pacemaker System|Bradycardia Slow Heart Beat
223656808|NCT01761162|OTHER|Magnetic Resonance Imaging (MRI) scan|MRI scan of head and lower back.
223768410|NCT03886558|OTHER|A multicomponent intervention program was developed consisting of two 60-minute sessions per week, held on non-consecutive days, for a period of 8 months.|The sessions consisted of a warm-up phase (10') in which individuals performed joint mobility exercises and walked at a rate of 3 km/h. Afterwards, muscular strength work was carried out on the upper and lower limbs, including calisthenic exercises, and the use of dumbbells or medicine balls (1-3kg). Generally, the exercises were organized in two sets of 10-15 repetitions, resting for two minutes between sets. Communal ball games and relay games were then practiced (over a distance of 30 meters). Finally, 10 minutes were devoted to relaxation and stretching exercises. multicomponent intervention program was designed and monitored by a specialist in gerontogymnastics.
223768411|NCT06109584|DEVICE|Insertion of central venous catheter|Central venous catheter verified by ultrasound and then verified by radiography.
224239492|NCT00002725|DRUG|bryostatin 1|
224239493|NCT00002725|DRUG|chemotherapy|
224239494|NCT03155048|DRUG|oral estrogen replacement therapy|oral estradiol group for endometrial preparation
224239495|NCT03155048|DRUG|Estradiol transdermal patch|transdermal estradiol group for endometrial preparation
224239496|NCT05192330|DEVICE|Virtual Reality Glasses|After obtaining informed consent, the data collection form, Spielberger State Anxiety Scale and VAS scoring scale (pain) were applied to both groups by face to face interview during the day giving appointment for intrauterine insemination. Immediately after the questionnaires were answered, virtual reality glasses were given by the nurse researcher to intervention group for 30 minutes.
223656809|NCT02998957|DEVICE|AcuTENS|Stimulation of acupuncture point Dingchuan using transcutaneous electrical nerve stimulation (TENS) instead of needles
223656810|NCT02998957|DEVICE|Sham AcuTENS|Portable TENS electrostimulation device with no electrical output
223656811|NCT03205449|BEHAVIORAL|Masayang Pamilya Para Sa Batang Pilipino Parenting Programme (MaPa)|The MaPa programme includes the following content: 1) spending one-on-one time with children; 2) describing actions and feelings for cognitive development and socio-emotional awareness; 3) using praise and rewards to encourage positive behaviour; 4) establishing limits through effective instruction giving and consistent household rules; 5) nonviolent discipline such as ignoring negative attention seeking behaviour, and consequences for noncompliance, rule-breaking, and aggressive behaviour; 6) problem solving with children; and 7) mindfulness based stress reduction for caregivers.
223656812|NCT03205449|OTHER|Parenting Effectiveness Service|Content uses a thematic manual that includes sessions on Filipino family dynamics, early childhood development, child behaviour management, marital relationships, prevention of child maltreatment, health care, nutrition, and government anti-poverty initiatives, as well as disaster preparedness. \[12\].
223656813|NCT03565952|OTHER|Cranial massage|Manual cranial therapy consisting of massage and cranial relaxing techniques, lasting 30 minutes each session approximately, for 3 weeks and one month follow-up. Manual therapy consists of a prone and supine cranial massage.
224239497|NCT05192330|BEHAVIORAL|Therapeutic Touch|After obtaining informed consent, the data collection form, Spielberger State Anxiety Scale and VAS (pain) scoring scale were applied to both groups by face to face interview during the day giving appointment for intrauterine insemination. Immediately after the questionnaires were answered, therapeutictouch were given by the nurse researcher to intervention group for 30 minutes.
223656814|NCT03565952|OTHER|Control group|The control group does not receive treatment
223656815|NCT00941629|BEHAVIORAL|Cognitive Processing Therapy (CPT)|Patients with PTSD receive a trauma-focused, cognitive-behavioral intervention in Face-to -Face treatment.
223656816|NCT00941629|BEHAVIORAL|Cognitive Processing Therapy (CPT)|Provision of Cognitive Processing Therapy over teleconference network (telemental health; telehealth)
223656817|NCT00323011|DRUG|Fragmin, 5-Fluorouracil, Folinic Acid, irinotecan, bevacizumab|
223656818|NCT03595995|BIOLOGICAL|UB-621|Monoclonal antibody by SC injection
223656819|NCT03595995|OTHER|Placebo|The placebo is a sterile, clear and colorless or slightly yellow liquid, contains the same composition as UB-621 except drug substance. It is given by SC injection.
223656820|NCT04480970|DEVICE|Nasogastric tube placement|All patients enrolled in the study will have a nasogastric tube placed for gastric decompression.
224239498|NCT05008822|OTHER|Motor Imaginary Training Group|After the baseline assessment, the participant will receive Motor Imaginary Program
224239499|NCT05008822|OTHER|Task oriented Training Group|After the baseline assessment, the participant will receive MRP and CIMT training
224321070|NCT05546463|BEHAVIORAL|Digital games|"A digital game was played via iPad Air 2 32GB 9.7-inch wi-fi model tablet. The researcher created a folder with a range of selected games to appeal to different preferences. Children could choose from the following games: Word Travel, Talking Tom Candy Run, 384 Puzzles for Kids, Masha and The Bear, Subway Surfers, Head Ball 2 and Dream League Soccer."
223656821|NCT00271713|DRUG|ibandronate, calcium and vitamin D|1: 150 mg ibandronate monthly plus 500mg calcium and 800 UI vitamin D daily or
223656822|NCT00271713|DRUG|placebo,calcium and vitamin D|2: placebo monthly plus 500mg calcium and 800 UI vitamin D daily
223656823|NCT01541683|OTHER|PEG solution (Fortrans®) and Mentholyptus Drops (Halls®)|Patients will be instructed to drink 4 Liters of PEG solution (FORTRANS®) split into 2 days while sucking on sugar-free mentholyptus drops (2 L at 7-9 pm on the day prior to the colonoscopy while continuously sucking on Halls®, and 2 L on the day of the colonoscopy to be completed a minimum of 1.5 hours before the procedure while continuously sucking on Halls®)
223656824|NCT01541683|OTHER|PEG solution (Fortrans®)|4 liters of PEG solution (FORTRANS®) split into 2 days (2 L at 7-9 pm on the day prior to the colonoscopy, and 2 L on the day of the colonoscopy to be completed a minimum of 1.5 hours before the procedure)
223656825|NCT02741518|BIOLOGICAL|Fecal Microbiota Transplantation|This is pre-screened fecal material that has been encapsulated
223656826|NCT02741518|OTHER|Placebo|These are capsules that have no fecal material in them.
223656827|NCT01349049|DRUG|PLX3397|Maximum Tolerated Dose of PLX3397 will be administered orally, twice daily.
223656828|NCT01349049|DRUG|PLX3397|The drug product is available in capsule form, to be taken orally.
223656829|NCT03140215|DEVICE|laryngeal mask insertion (Baska)|
223656830|NCT03140215|DEVICE|laryngeal mask insertion (I-gel )|
223656831|NCT05350696|DRUG|Erector Spinae plane block (plain pubivicaine)|"The erector spinae block is achieved by injecting the local anesthetic solution (with possible adjuvants) between the erector spinae muscles (iliocostalis, longissimus, spinalis/ from lateral to medial) and the transverse process .~The technique is performed under ultrasound guidance."
223656832|NCT05350696|DRUG|Intravenous morphine group|patients will receive 0.1 mg /kg of intravenous morphine diluted to 10 ml volume using saline at the end of the operation.
223656833|NCT06092944|PROCEDURE|Catheterization|Before the operation,the patient was placed in the left lateral position.The catheter（soft tip epidural catheter 20-gauge-100 cm） was placed at the rhomboid-intercostal plane under ultrasound guidance at the T5-T6 level, followed by ultrasound-guided catheter placed in the anterior serrated muscle plane at the T7-9 level。
223656834|NCT06092944|PROCEDURE|Single nerve block|Before the operation,40milliliters of 0.3% ropivacaine was injected into the rhomboid-intercostal fascia plane and anterior serrated muscle plane respectively under the guidance of ultrasound.
223656835|NCT06092944|PROCEDURE|Continuous nerve block|After surgery,local anesthetics were injected continuously through catheters.Local anesthetic formula:Ropivacaine 300mg + normal saline, prepared into 150milliliters liquid, background dose 2milliliters/h.
224239500|NCT03106610|DRUG|Nivolumab|3 mg/kg of body weight by vein over about 60 minutes on Day 1 of Cycles 1-3.
224239501|NCT03106610|BEHAVIORAL|Questionnaires|2 quality-of-life questionnaires completed on Day 1 of Cycles 1-3, at the visit before surgery, and 4 weeks after surgery.
224239502|NCT01861210|BEHAVIORAL|Couples Voluntary HIV Counseling and Testing|
224239503|NCT01861210|BEHAVIORAL|Individual Counseling and Testing|
224321071|NCT03348631|PROCEDURE|Computed Tomography|Undergo CT scan
224321072|NCT03348631|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
224321073|NCT03348631|DRUG|Tazemetostat|Given PO
224321074|NCT02678208|DRUG|Tranexamic Acid|
224321075|NCT02678208|DRUG|5% glucose|
223656836|NCT06092944|PROCEDURE|PCIA|After surgery, the patient was given controlled intravenous analgesia. Analgesic pump drug formula:Sufentanil 50ug+ Dezocine 20mg+ Granisetron 10mg+150milliliters saline, continuous dose of 2milliliters/h intravenous pump, single injection dose of 2milliliters, locking time of 20 min
223656837|NCT02384798|OTHER|noninvasive ventilatory support|noninvasive ventilatory support with 5-minute ramp and positive end expiratory pressure (PEEP) of 5 cm H2O for 30 minutes, then there will be the interval aerobic training on a treadmill added to resistance exercises
223656838|NCT02384798|OTHER|interval training|interval training
224239504|NCT03474510|DRUG|local infiltration of liposomal bupivacaine|Those patients randomized to receive LIA of EXPAREL will have 266mg EXPAREL diluted to 100mL, and drawn into (5) 20mL syringes affixed with (5) 22-gauge needles. Investigators will administer the syringes to the tissue in small increments with the plunger held steady while withdrawn from the tissue to avoid saturating the area around the needle sticks since EXPAREL doesn't readily travel through the tissue.
224239505|NCT03474510|OTHER|continuous infusion of ropivacaine interscalene nerve block|"All patients will receive a single injection of 30mL, 0.5% preservative-free ropivacaine.~Those patients randomized to receive CINB will then have an indwelling catheter placed and held in place by Dermabond and Tegaderm. Placement will be confirmed by ultrasound. Patients will then receive 0.2% preservative-free ropivacaine at 8mL/hr beginning at the conclusion of surgery and delivered for approximately 50 hours (or finish of 400mL) via elastomeric infusion system (OnQ Pain Relief System: Select A Flow, Kimberly-Clark Corporation, Roswell, Georgia). Patients are instructed prior to discharge how to pull the catheters at home. Patients may also return to surgeon's office for catheter removal once the pain ball is empty if they prefer."
224239506|NCT00465881|DEVICE|CGM System for Type 1 and Type 2 Diabetes Mellitus|
224239507|NCT03805438|DRUG|Chloroprocaine Hcl 3% Inj|"Initial Patient (A#X) 45mg (1.5mL) of Chloroprocaine 3% (Nesacaine - Fresenius Kabi), will be drawn up into a 3 ml syringe (a 1 ml 'TB syringe' will be used to aspirate the drug in aliquots to ensure accuracy). The following additive will be added: 10 mcg (0.2ml) of fentanyl (50 mcg/ml) 0.3 ml of sterile 0.9% sodium chloride Thus the total volume in the syringe will be 2 ml. Study drugs will be prepared by one anesthesiologist (un-blinded) and administered by another anesthesiologist (blinded).~Subsequent Patient (A#X+1) The dose of Chloroprocaine 3% based on outcome from prior subject and calculations mentioned previously will be added to 10 mcg (0.2ml) of fentanyl (50 mcg/ml). Sterile 0.9% sodium chloride will be added until the total volume in the syringe is 2 ml."
224321076|NCT03613233|PROCEDURE|Glaucoma surgery|phacoemulsification
223656839|NCT01170533|DRUG|omeprazole and pantoprazole|The clopidogrel dose will be a 600mg loading dose followed by a 75mg daily maintenance dose, starting the next day for 7 days. Omeprazole will be used at a daily dose of 40mg and pantoprazole at 80mg.
223656840|NCT03647813|RADIATION|Photobiomodulation|Patients received three irradiations of laser at ʎ = 808 nm, 100 mW, 142 J/cm2 and 4 J per point.
223656841|NCT03647813|RADIATION|Placebo|The same laser protocol was followed but with the device switched off.
223656842|NCT02933450|DRUG|Patiromer 25.2 g|Single dose of Patiromer 25.2 g
224239508|NCT00610090|DEVICE|UniFit AAA Stent Graft|Endovascular repair of Abdominal Aortic Aneurysms
223656843|NCT02358291|PROCEDURE|open discectomy|The open discectomy, will be performed under general anesthesia in the prone position with horizontal. The level of the spine indicated for surgical treatment will be identified with the aid of fluoroscopy. An incision is made about the dorsal disc level involved with dissection of the paravertebral muscles on the side of disc herniation. After laminectomy and resection of part of the yellow ligament, partial discectomy is done under direct vision.
223768412|NCT04107480|PROCEDURE|Endoscopic trans-sphenoidal adenoma resection|"Neurosurgical consultation consists of at least one consult with a neurosurgeon and at least one consult with an endocrinologist with relevant experience. If the multidisciplinary team (MDT) agrees the patient is a good surgical candidate, the patient is asked consent for surgery, as is a custom part of preoperative requirements. When the patient decides not to have the surgery, (s)he will receive standard medical treatment, but will continue study follow up in the intervention group.~Surgery only takes place if both the MDT and the patient agree to it and should then be planned within three months after randomization. Surgery is performed by one or two trained neurosurgeons in the hospital where the counseling took place. A standard, semi-protocolled, endoscopic trans-sphenoidal surgical resection of the prolactinoma is performed according to standard practice."
223768413|NCT04107480|DRUG|Dopamine Agonists|"The treating physician adheres to the treatment protocol in general, but has freedom to choose treatment to his/her ideas how to deliver best care.~Current first line treatment consists of a dopamine agonists: cabergoline (currently the most used), bromocriptine or quinagolide. All dopamine agonists are taken orally, and the dosage may be raised based on its effect. It is usually titrated to achieve a normal or suppressed prolactin level and restoration of the gonadal axis. Dopamine agonist treatment is discontinued after 2 years of treatment, unless a normal prolactin level cannot be achieved. The dopamine agonist is restarted when prolactin levels rise after the medication is discontinued.~In standard care, surgical treatment is reserved for patients who don't tolerate medication, or whose adenoma fails to show a sufficient response. Patients in the control group with an intolerance for dopamine agonists or an insufficient response may be offered surgery as part of standard care."
224239509|NCT00366899|BIOLOGICAL|13-valent pneumococcal conjugate vaccine|Single 0.5 mL dose of 13vPnC given at 3, 5 and 11 months of age.
224239510|NCT00366899|BIOLOGICAL|7 valent pneumococcal conjugate vaccine|Single 0.5 mL dose of 7vPnC given at 3, 5 and 11 months of age.
224239511|NCT01174134|OTHER|Nutritional beverage|
224239512|NCT05922449|PROCEDURE|Thoracic Paravertebral Block|Patients randomly assigned to PV group will be placed in lateral position, and punctured using the out of plane technique guided by ultrasound (Shenzhen Huasheng Navi low-frequency convex array probe). 15 ml of 0.5% ropivacaine was administered to the T4 and T7 thoracic paravertebral spaces respectively, for a total of 30 ml. After injection, the pleura of the punctured segment and adjacent segments could be obviously moved down. Upon successful puncture, the patient was transferred to the supine position. After 5, 10, and 15 minutes, the range of sensory blockage was tested at T3\~T8 to cover the surgical area.
224239513|NCT03163875|OTHER|Hospital Anxiety and Depression Scale|To assess the levels of depression and anxiety, quality of sleep and quality of life (QoL) in chronic urticaria patients, using an interdisciplinary approach combining interview/questionnaire-based psychiatric and dermatological evaluations
224321077|NCT05628831|PROCEDURE|vNOTES suspension with autologous tissue|Autologous tissue will be fixated on solid points in pelvis using vNOTES.
224321078|NCT05628831|PROCEDURE|Vaginal surgery|Vaginal hysterectomy will be done with anterior and/or posterior repair depending on the judgment of the surgeon at the time of the operation. Uterosacral and cardinal ligaments will be repositioned and attached to the vaginal vault after hysterectomy at the time of vault closure. A modified McCall culdoplasty will be done in this group to prevent enterocele and further apical prolapse
223656844|NCT02358291|PROCEDURE|microendoscopic discectomy|Microendoscopic discectomy combines standard lumbar microsurgical techniques with endoscope, enabling surgeons to successfully address free-fragment disc pathologic factors and lateral recess stenosis.
223656845|NCT02358291|PROCEDURE|transforaminal endoscopic lumbar discectomy|transforaminal endoscopic lumbar discectomy removes the intervertebral disc portion through the intervertebral foramen
223656846|NCT03117452|BEHAVIORAL|Visual Training|The computerized visual training (VT) program that is being evaluated was developed by Aaron Seitz, who is a co-investigator on this project; it includes 1) ULTIMEYES, which targets broad-based visual functions, including low-level processes (e.g., visual acuity, contrast sensitivity), and 2) visual perceptual organization exercises, which target mid-level visual processes. Both elements of the program also involve higher-level visual functions, such as visual search and visual attention.
223656847|NCT03168958|DRUG|Methadone|Methadone will be provided at induction of anesthesia
223656848|NCT03168958|DRUG|Saline|Saline will be administered at induction of anesthesia
223656849|NCT01670305|PROCEDURE|Residual pockets will be treated by laser + photosensitizer|Experimental group: Residual pockets will be treated by laser + photosensitizer
224239514|NCT05717036|DEVICE|Serum Total Protein Measurement with TS Meter-DSP and Refractix DSP|The two blood samples will be centrifuged and hematocrit measured per the plasma center's standard operating procedures. One participant sample will be dispensed onto the cleared TS Meter-DSP for a serum total protein measurement. This measurement will be used, along with other pre-screening information, to determine if the participant can donate plasma. The second participant sample will be dispensed onto the investigational Refractix DSP for a serum total protein measurement. It will be compared to the sample measurement taken on the cleared TS Meter-DSP.
223768414|NCT06471036|OTHER|Care Champion Intervention|The care champion will communicate with the patient according to an algorithm and will emphasize adherence to appropriate lipid lowering therapy, LDL-C retesting, and outpatient follow-up. The care champion will also facilitate communication of any challenges or issues with the patient's outpatient care team. Of note, the care champion will NOT be responsible for prescriptions or drug management.
224239515|NCT02812849|DRUG|Cu-64 DOTATATE|
224239516|NCT01619800|DEVICE|Blended Sensor Optimization (BSO)|"At wound check (POD#1 and 1 Week F/U), histograms from device interrogation obtained from patients in the BSO group are assessed, and these patients undergo optimization. A hall walk and stair climbing exercise will be performed and MV optimized using trending data to hit the following targets:~HR at Rest: 60 HR upon slow walking: 100 HR upon brisk walking: 115-120 HR upon climbing stairs: 130-135 Patients will undergo optimization, and be instructed that their device may have been optimized."
224239517|NCT01619800|DEVICE|Accelerometer Alone (AA)|Patients in the AA group will also undergo device interrogation, and will perform a hall walk and stair climbing exercise. Afterwards, these patients will undergo a sham optimization by placing the PPM interrogation laptop device over there pacemaker, and instructing the patients that their device may have been optimized.
224239518|NCT02539485|OTHER|heating precondition|The streamlined liner of the pharynx airway (SLIPA) was heated 2 hours before use.
224239519|NCT02665013|BEHAVIORAL|Tailored|Pregnant women will be recruited to the study. The intervention will be delivered to participants prior to the child's 2 month well child visit, when the child is between 4 and 6 months of age, and when the child is 10-12 months of age. The first intervention occurs at enrollment in the study. Participants in the tailored intervention arm will receive vaccine information tailored specific to her concerns and values at each intervention point.
224239520|NCT02665013|BEHAVIORAL|Untailored|Pregnant women will be recruited to the study. The intervention will be delivered to participants prior to the child's 2 month well child visit, when the child is between 4 and 6 months of age, and when the child is 10-12 months of age. The first intervention occurs at enrollment in the study. Participants in the untailored arm will receive vaccine information at each intervention time point, but it will not be tailored to her specific concerns.
224239521|NCT04583852|OTHER|AIVÍA, Ultra-Brightening Spot Micro-needle Patch|a dissolving micro-needle patch, contains active ingredients
224239522|NCT04583852|OTHER|Placebo Micro-needle Patch|matching placebo will be provided as a dissolving micro-needle patch
224239523|NCT02927509|DRUG|TNF alpha blockers|
224239524|NCT02429271|DRUG|Ticagrelor|
224239525|NCT02429271|DRUG|Clopidogrel|
224239526|NCT02429271|PROCEDURE|Percutaneous Coronary Intervention (PCI)|
224239527|NCT02429271|PROCEDURE|Coronary Angiography|
224239528|NCT01255878|DEVICE|occlusal stabilization splint|
224239529|NCT01255878|DRUG|Gabapentine|100 mg(1 capsule)three times per day for two months
224239530|NCT00073177|DRUG|Roflumilast|
224239531|NCT02707978|DRUG|F 18 T807|Participants will receive a single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807. For those who cannot tolerate the full exam, participants will receive single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807.
224239532|NCT01186588|DRUG|Canagliflozin|One 300-mg dose of canagliflozin on Day 1
224239533|NCT00994253|DRUG|Aliskiren|Aliskiren will be prescribed at 150mg po per day. If the subjects blood pressure is not controlled by week 5 the dose will be increased to 300mg po per day. All subjects will be prescribed lisinopril 40mg and amlodipine 5mg po daily.
223656850|NCT01670305|PROCEDURE|Residual pockets will be treated only photosensitizer|Placebo Comparator: Residual pockets will be treated only photosensitizer
223656851|NCT01670305|PROCEDURE|Residual pockets will be treated scaling and root planing|Active Comparator: Residual pockets will be treated scaling and root planing
223656852|NCT01670305|PROCEDURE|laser + photosensitizer associated with scaling and root planing|Experimental group: furcation defects will be treated by laser + photosensitizer associated with scaling and root planing
223656853|NCT01670305|PROCEDURE|furcation defects will be treated by scaling and root planing|Active Comparator: furcation defects will be treated by scaling and root planing
223656854|NCT01717053|DRUG|Abiraterone acetate|1000 mg orally once a day for 6 months.
223656855|NCT01717053|DRUG|Androgen deprivation|LHRH analog (at discretion of treating physician) will be administered over 6 months (for example, leuprolide acetate 22.5mg IM or goserelin acetate 10.8mg SC given every 3 months for 2 doses).
223656856|NCT01717053|RADIATION|Radiation Therapy|Daily (Monday-Friday) for 8 weeks, final dose of 75-80 Gy
223768415|NCT05983497|OTHER|Self-Care Skill Educational Intervention|An evidence-based interactive self-care skill educational intervention that supports the clinical nurses to reduce compassion fatigue and increase the compassion satisfaction. The intervention will be delivered as 1-day activity-based educational training. The educational activity consists of the following content: the concept of compassionate fatigue, burnout awareness and recognition, eight dimensions of well-being, and followed by a demonstration of 7 guided self-care skill activities \*on practicing sleep hygiene, self-talk, gratitude practice, Journaling, breathing exercise, heartfulness relaxation, and heartfulness meditation. After the activity participants will develop their own self-care plan for practicing the self-care skills. At the end of the session, they will receive the instructional leaflet to practice the 7 self care skills that they gained from the educational activity.
223768416|NCT01462357|BIOLOGICAL|Cervarix|2 doses of 0.5 mL supplied as a liquid in individual pre-filled syringes to be administered intramuscularly in the deltoid muscle of the non-dominant arm at Day 0 and Month 6.
223768417|NCT01462357|BIOLOGICAL|Gardasil|2 or 3 doses of 0.5 mL supplied as a liquid in individual pre-filled syringes or vials to be administered intramuscularly in the deltoid muscle of the non-dominant arm at Day 0 and Month 6 (Gardasil 2 dose Group) or at Day 0, Month 2 and Month 6 (Gardasil 3 dose Group), respectively.
223656857|NCT01717053|DRUG|Prednisone|5 mg tablet once daily for 6 months.
223768418|NCT01462357|DRUG|Placebo|2 doses of 0.5 mL supplied as a liquid in individual pre-filled syringes to be administered intramuscularly in the deltoid muscle of the non-dominant arm at Month 2 to maintain blinding.
223768419|NCT02694315|OTHER|Bishop score|calculation of modified Bishop score in numbers by digital vaginal examination
223656858|NCT01812668|DRUG|cabozantinib-s-malate|Given PO
223656859|NCT01812668|RADIATION|fluorine F 18 d-FMAU|Undergo 18F PET/FMAU PET scan
223768420|NCT02694315|OTHER|cervical length|measuring cervical length by trans-vaginal ultrasound
223768421|NCT05466227|OTHER|Implementation of Modified Valsalva maneuvre|"Modified Valsalva maneuvre:~* Patient is attached to 12-lead ECG monitoring~* The patient sits in an upright position and performs forced expiration for 15 seconds by blowing on a 10 mL syringe~* Patient's legs are elevated (45°) for 15 seconds~* Afterwards, the patient is placed back in an upright position~* If not efficient, this maneuver can be repeated up to two times"
223768422|NCT01482767|DRUG|Pegylated-Interferon Alfa 2b (PEG-IFN)|1.5 mcg/kg subcutaneously (SC) once a week (based on participant's weight at entry) for up to 48 weeks depending on cirrhosis status and, in Group A, Week 8 HCV viral response.
223768423|NCT01482767|DRUG|Ribavirin (RBV)|800-1400 mg orally per day with food (based on participant's weight at entry) for up to 48 weeks depending on cirrhosis status and, in Group A, Week 8 HCV viral response.
224239534|NCT00994253|DRUG|Hydrochlorothiazide|Hydrochlorothiazide will be prescribed at 12.5 po per day. If the subjects blood pressure is not controlled by week 5 the dose will be increased to 25mg po per day. All subjects will be prescribed lisinopril 40mg and amlodipine 5mg po daily
224239535|NCT02352298|DEVICE|Dario Blood Glucose Monitoring System|Fingerstick to obtain blood sample for analysis with the Dario BGMS
223656860|NCT01812668|PROCEDURE|positron emission tomography|Undergo 18F PET/FMAU PET scan
223656861|NCT01812668|OTHER|pharmacological study|Correlative studies
223656862|NCT01812668|OTHER|laboratory biomarker analysis|Correlative studies
223656863|NCT03856281|DEVICE|Intermittent Pneumatic Compression|Participants administer an intermittent pneumatic compression device in addition to their standard lymphoedema care for a 5 week treatment period
223656864|NCT01464281|DRUG|Peginterferon alfa 2a|Group 1 : 48-week standard treatment by Peginterferon alfa 2a 180µg/week Group 2 : 96-week prolonged treatment by Peginterferon alfa 2a 180µg/week.
224239536|NCT02352298|DEVICE|YSI Analyzer|Fingerstick to obtain blood sample for analysis with YSI
224239537|NCT01110447|DRUG|VSL#3|VSL#3® is made up of 4 strains of Lactobacilli (L. paracasei, L. plantarum, L. acidophilus and L. delbrueckii subsp. bulgaricus), 3 strains of Bifidobacteria (B. longum, B. infantis, B. breve) and 1 strain of Streptococcus thermophilus. Dose would be 1 sachet per day (Each sachet containing 900 Billion CFU). The duration of treatment would be for 24 weeks
224239538|NCT01110447|OTHER|Placebo|Placebo sachets contain corn starch. Dose: 1 sachet per day Duration of treatment: 24 weeks
224239539|NCT03416777|BEHAVIORAL|Meat-based diet|Diet including 4 servings per week of red meat (1 serving = 150 g), 3 servings per week of processed meat (1 serving = 50 g), and 1 servings per week of poultry (1 serving = 150 g), for a total amount of 900 g per week of meat.
224321079|NCT05431894|BEHAVIORAL|Laguna Coach Intervention Group|Behavioral and mental support was delivered through personal interactions with Laguna Coaches via phone, video, or web chat. Behavioral and mental support was individualized to best match each patient's needs and strengths. Support was provided to participants through human interactions over approximately 30 days.
223656865|NCT05212545|DIETARY_SUPPLEMENT|Placebo|maltodextrin taken daily for 4 weeks with water
223656866|NCT05212545|DIETARY_SUPPLEMENT|Prebiotic supplement|Prebiotic supplement taken daily for 4 weeks with water
223656867|NCT05212545|DIETARY_SUPPLEMENT|Prebiotic combination|prebiotic oligosaccharides mixture taken daily for 4 weeks with water
223656868|NCT05212545|DIETARY_SUPPLEMENT|Prebiotic oligosaccharides|Prebiotic oligosaccharides taken daily for 4 weeks with water
223656869|NCT04030156|PROCEDURE|tonsillectomy|Tonsillectomy was performed under general anesthesia using cold dissection method.
223656870|NCT04681352|DEVICE|Octave-Ultherapy treatment|Micro-focused ultrasound delivered below the surface of the skin.
223768424|NCT01482767|DRUG|Boceprevir (BOC)|800 mg orally every 8 hours with food from Week 5 to up to Week 48 depending on cirrhosis status and, in Group A, Week 8 HCV viral response
223656871|NCT05722444|OTHER|Nighttime Feminine Product|"During nights while menstruating:~* Standardized nighttime feminine product + typical nighttime behaviors to prevent leak~* Standardized nighttime feminine product + refraining from nighttime behaviors to prevent leak"
223656872|NCT01039129|PROCEDURE|Endoscopic Cholecystectomy|An incision will be made in the vagina and a flexible surgical camera (endoscope) and instruments will be introduced. The surgical procedure for each given arm will be performed with the aid of an additional surgical instrument inserted through a small incision in the umbilicus.
223656873|NCT01039129|PROCEDURE|Endoscopic Appendectomy|An incision will be made in the vagina and a flexible surgical camera (endoscope) and instruments will be introduced. The surgical procedure for each given arm will be performed with the aid of an additional surgical instrument inserted through a small incision in the umbilicus
223656874|NCT01039129|PROCEDURE|Endoscopic Peritoneoscopy|A diagnostic peritoneoscopy with or without biopsy for any indication
223656875|NCT03220451|PROCEDURE|Adhesive elastic taping|Adhesive elastic taping placed around a pressure ulcer, according to a planned placement technique
223656876|NCT01643772|DRUG|Oxycodone hydrochloride|The subjects will be randomized to receive either a single dose of OxyNorm® Capsules 5, 10, 20mg, or multiple-dose OxyNorm® Capsules 10 mg for 13 times.
223656877|NCT00732446|DRUG|Moxifloxacin and Dexamethasone combined|moxifloxacin 0,5% qid and dexamethasone 0,1% qid combined
223656878|NCT00732446|DRUG|Moxifloxacin|moxifloxacin 0,5% qid and
223656879|NCT00732446|DRUG|Dexamethasone|dexamethasone 0,1% qid
223656880|NCT02439359|DRUG|CF-301|Dose escalation
223656881|NCT02439359|DRUG|Placebo|
223656882|NCT02453815|PROCEDURE|non-cardiac surgery|all surgical procedures except cardiac
223656883|NCT02453815|OTHER|arterial catheter|arterial catheter
223656884|NCT05180396|OTHER|Questionnaires|Application of a study based questionnaire described in the protocol
223656885|NCT03599232|OTHER|Formative objective structured clinical examination (OSCE)|
224239540|NCT03416777|DIETARY_SUPPLEMENT|Meat-based diet supplemented with alpha-tocopherol (MBD-T)|Dietary intervention like the MBD with supplementation of alpha-tocopherol at a dosage of 100 mg/die. Available evidence suggests that alpha-tocopherol may help prevent colon cancer by decreasing the formation of mutagens arising from the oxidation of faecal lipids, by decreasing oxidative stress in the epithelial cells of the colon and by molecular mechanisms that influence cell death, cell cycle and transcriptional events (Pierre 2013, Bastide 2016, Bastide 2017, Diallo 2016). It is important to note that 200 mg/day of tocopherol was administered to 20,000 women for 10 years without side effects (Lee et al.,2005).
224239541|NCT03416777|BEHAVIORAL|Pesco-vegetarian diet|Diet excluding fresh and processed meat, poultry but including 3 servings per week of any type of fish, excluding shellfish (1 serving = 150 g), for a total amount of 450 g per week. Diet will contain other sources of proteins (e.g. eggs, dairy, legumes/beans). There is suggestive evidence that fish and vegetable consumption has protective effects against CRC (Vieira et al., 2017).
224239542|NCT03456570|DRUG|Dydrogesterone 10 mg|Dydrogesterone 10 mg twice daily
224239543|NCT03456570|DRUG|Placebo Oral Tablet|oral tablets twice daily
223656886|NCT03457441|OTHER|Standards vision tests|Subjects vision : near visual acuity, contrast sensitivity and scotoma and metamorphopsia detection will be assessed by gold-standard tests and with the OdySight medical application
223656887|NCT03457441|DEVICE|OdySight medical application assessment|Subjects vision : near visual acuity, contrast sensitivity and scotoma and metamorphopsia detection will be assessed by gold-standard tests and with the OdySight medical application
223656888|NCT01811056|DRUG|Mifepristone|Mifepristone use outside of the center
223656889|NCT05186415|DRUG|Sulfur Hexafluoride Lipid Type A Microspheres 25 MG Injection Powder for Suspension [LUMASON]|The patient will receive the weight-based dose of Lumason of 0.03 mL/kg per injection, not to exceed 2.4 mL per injection per the FDA and manufacturer recommendations.
224239544|NCT00419770|DRUG|deferasirox|20 mg/kg enterally per day
223656890|NCT03968939|DRUG|Diphenhydramine (Benadryl)|Oral Diphenhydramine (Benadryl), 25 mg
223656891|NCT03968939|DIETARY_SUPPLEMENT|Melatonin|Oral Melatonin, 3 mg
223656892|NCT03968939|BEHAVIORAL|Sleep Hygiene Education|"Brochure containing information about getting a good night's sleep."
223656893|NCT04642001|OTHER|Photon Laser III-DMC (without radiation emission) + My First- Colgate|Positioning of the FBM (Photon Laser III / DMC) without emitting radiation, the equipment's sound was mimicked with the Beep application (Foncannon Inc, Google, © 2018), followed by the use of fluoride-free toothpaste (My First- Colgate) and brushing three times a day.
223656894|NCT04642001|OTHER|Photon Laser III-DMC (without radiation emission) + Sensodyne® Rapid Relief / GSK|Positioning of FBM (Photon Laser III / DMC) without emitting radiation, the equipment's sound was mimicked with the Beep application (Foncannon Inc, Google, © 2018), followed by the application of toothpaste containing strontium acetate (Sensodyne® Rapid Relief / GSK) and brushing three times a day.
223656895|NCT04642001|RADIATION|Photon Laser III-DMC (with irradiation emission) + My First- Colgate|Emission of FBM therapy (Photon Laser III / DMC), followed by the use of fluoride-free toothpaste (My First- Colgate) and brushing three times a day.
223656896|NCT04642001|COMBINATION_PRODUCT|Photon Laser III-DMC (with irradiation emission) +Sensodyne® Rapid Relief / GSK|Emission of FBM therapy (Photon Laser III / DMC), followed by the application of toothpaste containing strontium acetate (Sensodyne® Rapid Relief / GSK) and brushing three times a day.
223656897|NCT04397666|DIAGNOSTIC_TEST|conjunctival RT PCR|conjunctival sample in covid-19 patients
224239545|NCT00419770|DRUG|Placebo|
224239546|NCT00419770|DRUG|Liposomal amphotericin B|
224239547|NCT06148090|DIAGNOSTIC_TEST|clobetasol decreasing measurement|"At two occasions during the clobetasol decreasing measurement at 8 AM and clinical assessment by a physician:~* Visit 1: 20-40 g clobetasol twice a week for at least 1 month~* Visit 2: 20-40 g clobetasol once a week for at least 1 month"
224239548|NCT04175548|OTHER|Data extraction from medical files|Data extraction from medical files
224239549|NCT00005948|BIOLOGICAL|aldesleukin|
223656898|NCT01278940|BIOLOGICAL|Dendritic Cells (DC) malignant melanoma|The patients were assigned to intradermal or intranodal DC vaccination
224239550|NCT00005948|BIOLOGICAL|recombinant interferon alfa|
224239551|NCT00005948|BIOLOGICAL|sargramostim|
224239552|NCT00005948|DRUG|busulfan|
224239553|NCT00005948|PROCEDURE|peripheral blood stem cell transplantation|
224239554|NCT05121233|DRUG|Diclofenac|a single dose 75 mg IV diclofenac by infusion prior to the procedure
224239555|NCT05121233|DRUG|Placebo|single dose iv placebo (saline ) by infusion prior to the procedure
224239556|NCT04840251|OTHER|Well-being review and rehabiliation|"For their well-being review, patients will meet with a physiotherapist specialist in PH and discuss:~* how they are~* what they can do for themselves~* what it is challenging for them to do~* how active they are~* if they have ever exercised before The physiotherapist will then make a referral to the most suitable rehabilitation service local to the patient e.g. rehabilitation classes, physiotherapy at home, weight-loss programmes."
224239557|NCT04840251|OTHER|Qualitative Interviews|Patients who have previously undergone rehabilitation will take part in a semi-structured interview to explore their experience and the impact it has had
224239558|NCT05651230|DIETARY_SUPPLEMENT|Rhamnan sulfate|A randomized, placebo-controlled, double-blind crossover dietary supplement intervention consisting of 3 weeks each of rhamnan sulfate (Rhamnox100, Konan Chemical Manufacturing Co. LTD, Mie, Japan: 540 mg/day) or placebo with 2 weeks of washout between the interventions will be conducted. Dietary supplements (rhamnan sulfate) will be taken orally three time daily at each meal time. Rhamnan sulfate is a polysaccharide (carbohydrate) extracted from seaweeds and can be considered nutrition supplement. As each pill contains 90 mg of rhamnan sulfate or placebo, subjects will be taking 2 pills before or during each meal.
224239559|NCT01627457|DEVICE|Guided Exercise (GEx) system|30 CAD patients will wear the GEx system while they are trained during inpatient cardiac rehabilitation (phase II) in order to evaluate accuracy and safety of data like heart rate, breathing, ECG three times a week for about three weeks. In a second step these patients train at home (phase III) in order to evaluate practicability and technical problems of the GEx device three times a week for about three weeks.
224239560|NCT01705769|OTHER|Ready to Use Therapeutic Food-Centrally produced|Ready to Use Therapeutic Food-Centrally produced by an Indian company.
224239561|NCT01705769|OTHER|Ready to Use Therapeutic Food-Locally produced|Ready to Use Therapeutic Food prepared by the study team
224239562|NCT01705769|OTHER|High energy and micronutrient rich foods|High energy and micronutrient rich foods prepared by caregivers at home using ingredients provided to them
224239563|NCT03119480|DEVICE|electronic alerts|electronic alerts for AKI
224239564|NCT05411692|OTHER|Functional electrical stimulations and motor priming exercise|"One pair of surface stimulation electrodes is placed on the subject's skin above the flexor digitorum superficialis and the flexor digitorum profundus muscles to generate finger flexion. The Second pair of electrodes is placed on the subject's skin, above the median~nerve, to generate thumb flexion. The third pair of electrodes is placed on the subject's skin, above the extensor digitorum muscle, to generate finger extension. Motor priming exercises will be done (functional task practice, FTP) for 20 minutes. Participants will be asked to spend at least 20 minutesDuration of training will be 4 weeks, 5 days per week, one session per day, and one hour per session."
224239565|NCT05411692|OTHER|Functional electrical stimulations|"Stimulation parameters are (1) balanced, biphasic, current-regulated electrical pulses; (2) pulse amplitude from 8 to 50 mA (typical values 17- 26 mA); (3) pulse width 250 ms; and (4) pulse frequency from 20 to 70 Hz (18). Trancutaneous stimulation will be delivered bilaterally with surface electrodes placed on the volar aspect of each wrist targeting the distribution of the median nerve. One pair of surface stimulation electrodes is placed on the subject's skin above the flexor digitorum superficialis and the flexor digitorum profundus muscles to generate finger flexion. The Second pair of electrodes is placed on the subject's skin, above the median~nerve, to generate thumb flexion for 20 minutes"
224239566|NCT05411692|OTHER|Conventional physical therapy|a structured exercise protocol targeting strength (2 days/week) and endurance (3days/week) training
224239567|NCT02848326|DRUG|Atogepant|Atogepant capsule.
224239568|NCT02848326|DRUG|Placebo-matching Atogepant|Placebo-matching atogepant capsule.
224239569|NCT00927992|OTHER|Epidemiological Non interventional|Epidemiological Non interventional
224239570|NCT01412580|OTHER|observational follow-up|observational follow-up
224239571|NCT05023005|OTHER|Strain-Counterstrain treatment of piriformis muscle|Participant will lay prone on table with affected leg close to edge of table. Piriformis muscle tender point is identified and palpated. Then patient leg is passively moved off table and passive hip flexion, abduction, and possible internal/external rotation is added to reduce tender point by 70% or more. This is done passively. This position is held for 90 seconds and then participant is passively returned back to neutral prone position with leg on table. Tender point is palpated again to reassess for change in pain (using subjective visual analog scale). An algometer is also used pre and post to assess objective change in pressure pain threshold.
224239572|NCT03101878|DRUG|Ionis AGT-LRx|Ascending single and multiple doses of Ionis AGT-LRx administered subcutaneously
224239573|NCT03101878|DRUG|Placebo|Saline .9%
223656899|NCT01278940|PROCEDURE|IL-2|IL-2 were administrated by intranodal injection
223656900|NCT02744404|DEVICE|POC EID|
223656901|NCT06067152|DEVICE|EIT measurement|Evaluation of mechanical ventilation and ventilation distribution through EIT. Mechanical ventilation is set by the physician according to clinical protocolized criteria
223768425|NCT03676361|DRUG|Desmopressin|Subjects will complete a water deprivation test using desmopressin to aid in the determination of maximum tubular concentration capacity before and six months after uni-nephrectomy.
224239574|NCT02958111|DRUG|Capecitabine|Patients will receive capecitabine (650 mg/m2 bid, p.o.，d1-21，q3wks; continued until disease progression, unacceptable toxicity, or over 1 year).
224239575|NCT01636570|DRUG|Placebo Comparator: Sugar Pill|Placebo will be given in identical gelcaps (as microcrystalline cellulose) as 2 per day for a period of 6 months.
224239576|NCT01636570|DRUG|Vitamin D3 (cholecalciferol)|10,000 IU vitamin D3 will be given as 5000 IU gelcaps two per day for a period of 6 months.
224239577|NCT02857270|DRUG|LY3214996|Administered orally
223768426|NCT02397356|DRUG|Ketamine first AB|Nebulised ketamine 1mg/kg
223768427|NCT02397356|DRUG|Placebo first BA|Nebulised saline 1-2ml
223768428|NCT00025883|DRUG|Metreleptin|Drug treatment
224239578|NCT02857270|DRUG|Midazolam|Administered orally
223656902|NCT06067152|DEVICE|Staircase Recruitment Maneuvers with EIT guided and decremental PEEP trial|"SRMs will be performed with a standardized ventilation protocol. Patient will be sedated, paralyzed and ventilated in pressure controlled mode, FIO2 to obtain SPO2\> 92%, RR 25, I:E =1:1.5. Alarm of pressure limit will be set at 35 cmH2O. The ventilator will be equipped with inspiratory and expiratory hold taste. Inspiratory and expiratory occlusion will be held for 5 seconds, data will be stored and analyzed with the ventilator own tool.~Decremental PEEP trial will start if plateau pressure 30 cmH2O will be reached or end inspiratory transpulmonary pressure will exceed 28 cmH2O value. Once reached this level of plateau or transpulmonary pressure, PEEP will be reduced in three steps from 12, 10 and finally to 8 cmH2O every 20 minutes"
223656903|NCT06067152|DEVICE|Setting of EIT-guided mechanical ventilation|Mechanical ventilation is set according to EIT measurement
223656904|NCT06067152|DEVICE|Reevaluation after 24 h|Evaluation of mechanical ventilation and ventilation distribution through EIT after 24h of ventilation EIT-guided
223656905|NCT03112083|DIETARY_SUPPLEMENT|Nutritional counseling A|Krill powder capsules
223656906|NCT03112083|DIETARY_SUPPLEMENT|Nutritional counselling B|Placebo capsules
223656907|NCT00857714|DRUG|lapatinib|1500 mg lapatinib for 14-21 days
223656908|NCT02643134|PROCEDURE|extracorporeal shockwave lithotripsy|Patients in Group 1 undergo extracorporeal shockwave lithotripsy(ESWL).
223656909|NCT02643134|DEVICE|External Physical Vibration Lithecbole|Multi-dimensional physical harmonic vibration inertial guidance technology
224239579|NCT02857270|DRUG|Abemaciclib|Administered orally
224239580|NCT02857270|DRUG|Nab-paclitaxel|Administered IV
223656910|NCT04841642|OTHER|MANUAL THERAPY|The investigators will apply manual therapy for ten minutes a week, for 8 weeks, based on cervical mobilizations and suboccipital inhibitions.
223656911|NCT04841642|OTHER|THERAPEUTIC EXERCISE|"The exercises recommendations will be based on a simulation of the exercises in the same session of the manual therapy of each week, helped by the physiotherapist.~The access to telerehabilitation will be through a web page, through which patients could see explanatory videos of the exercises as many times as they need."
223656912|NCT01145677|DRUG|Topiramate|Topiramate 100-300 mg/day orally twice per day
223656913|NCT04785469|OTHER|Low-load eccentric training|"* Aerobic exercise training on a downhill walking treadmill with the following settings: 10% negative incline and constant speed corresponding to 75% of the average speed recorded during the initial 6-Minute walk test.~* Resistance training: 5 minutes of warm-up on the manual ergometer, then 3 sets for 10 repetitions of the leg extension (performed unilaterally in eccentric phase) with a load of 75% of 1 repetition maximum (concentric) for the first two weeks. The following two weeks, 3 sets for 10 repetitions will be performed on the leg press (performed unilaterally in the eccentric phase) with 75% load of 1 repetition maximum (concentric). In addition, patients will perform 3 upper extremity strengthening exercises (free weights or elastic bands), including 2 sets of 10 repetitions for each exercise."
223656914|NCT04785469|OTHER|Usual care|"* Aerobic exercise training using the cycle ergometer at an intensity calculated as follows: 2 minutes with load equal to 20% of maximum load, then 25 minutes with initial load at 50% of maximum load calculated as 103.217 + (30.500xGender) + (-1.613xAge) + \[0.002x6-Minute walk work (6MWW)\]. \[Sex: female = 0; male:1\] \[6MWW = 6-Minute walk distance x weight in kg\].~* Resistance training: 5 minutes of warm-up on the manual ergometer, then 5 exercises for upper and lower limbs performed with free weights or elastic bands. For the first 2 weeks will be performed 2 sets X 20 repetitions with 1 minute break between sets and a load that allows to perform no more than 20 repetitions. For the following 2 weeks, 3 sets of 10 repetitions x 10 repetitions with 2 min break between sets and a load that allows for no more than 10 repetitions."
223656915|NCT04956913|DEVICE|Mac Grath|Patients of this group were intubated using Mac Gath videolaryngoscope
223656916|NCT04956913|DEVICE|Macintosh|Patients of this group were intubated using the Macintosh Laryngoscope
223656917|NCT00484757|DRUG|Orexine A|
223768429|NCT02423265|DRUG|Ranolazine|Ranolazine: 500 mg twice day, up-titrated after 1 week to 1000 mg twice a day
223768430|NCT02423265|DRUG|Placebo|Matching placebo: up-titration after 1 week
224239581|NCT02857270|DRUG|Gemcitabine|Administered IV
224239582|NCT02857270|DRUG|Encorafenib|Administered orally
224239583|NCT02857270|DRUG|Cetuximab|Administered IV
224239584|NCT01218165|DIETARY_SUPPLEMENT|Probiotic drink|This group receives a probiotic drink daily for 6 week.
224239585|NCT01218165|OTHER|Control Group|without intervention
224239586|NCT04220151|GENETIC|DNA methylation|DNA methylation will be measured by real time polymerase chain reaction
224239587|NCT03973177|DRUG|Phenol Injection|6% aqueous phenol 2.5 mL will be mixed with 0.5 mL iopamidol 300 and will be injected at each target site with live, pulsed fluoroscopy (5-8 seconds at each location) to observe the contrast dye-tagged phenol covering the lateral margin of the femur or tibia respectively on AP and lateral views. The needles will then be removed and band-aids placed.
224239588|NCT03973177|DRUG|Methylprednisolone Injection|Methylprednisolone acetate 10 mg with 2 mL preservative saline and 0.5 mL iopamidol 300 will be injected at each of the 3 target sites with live, pulsed fluoroscopy (5-8 seconds at each location) to observe the contrast dye-tagged steroid mixture covering the lateral margin of the femur or tibia respectively on AP and lateral views; the needles will be removed and band-aids placed.
224239589|NCT04271826|PROCEDURE|laparoscopic appendectomy|cases with normal CT underwent laparoscopic appendectomy
224239590|NCT02680626|DRUG|Magnesium Sulfate|Given via transversus abdominis plane block
224239591|NCT02680626|DRUG|Ropivacaine|Given via transversus abdominis plane block
224239592|NCT02446626|PROCEDURE|Skin biopsy|Optional 2-3mm skin punch biopsies will be performed.
224239593|NCT02446626|PROCEDURE|Blood draw|Peripheral blood draws will be performed.
224239594|NCT02446626|DEVICE|Xenodiagnosis|Larval ticks will be obtained from Dr. Sam Telford from a laboratory maintained tick colony at Tufts Veterinary School. These ticks are hatched from eggs laid by ticks that have fed only on specific pathogen free laboratory animals that were purchased from established vendors. Between 25-30 larval ticks that have been aged and are known to be ready to attach will be placed on the study participant.
223656918|NCT04660097|DRUG|Alotinib Plus Durvalumab-Platinum-Etoposide in First-line Treatment Extensive Small-cell Lung Cancer|This trial is single-armed IIb stage clinical trial to study the efficacy and safety of Alotinib Plus Durvalumab-Platinum-Etoposide in First-line Treatment Extensive Small-cell Lung Cancer . We use the outcome of CASPIAN trial as control group. The primary endpoint is ORR according to the RECIST 1.1, and secondary endpoints are PFS, OS, satety and life quality.
224239595|NCT05647031|OTHER|Qualitative study. Pain in competitive athletes with physical disabilities and techniques for its management.|"This study used a qualitative, exploratory and descriptive methodology, with a semi-structured interview technique. The purpose was to respond to the specific objectives set out in this research from the perspective of competitive athletes and sports agents (physiotherapist, coach and psychologist). The thematic cores that served as a script for the interview were for the athletes and sports agents 1) sporting characteristics of the professionals; 2) perception of how pain affects this type of athlete and what repercussions it has on the development of their sporting career, and 3) knowledge of techniques and/or strategies for pain management (athlete, coach and psychologist).~The interviews were conducted via skype. After transcription of all the interviews, validation by the interviewees was applied for the reliability of the research. Two types of triangulation were applied to ensure the quality of the data."
224239596|NCT00414466|DRUG|Intraspinal Gabapentin|Surgical implantation of a drug infusion system with intrathecal (spinal) delivery of active drug (1 of 3 possible dose levels) or placebo (saline) for 22 days followed by 7 days of infusion at half dose level. Subjects may then continue in open-label treatment with study drug. Dosage in open-label may be adjusted to meet subject needs.
224239597|NCT00000566|PROCEDURE|ventilation-perfusion ratio|
223656919|NCT06319950|DRUG|Furmonertinib|Furmonertinib, 160mg po qd
223656920|NCT06319950|DRUG|Osimertinib|Osimertinib，80mg po qd
223656921|NCT02302612|BEHAVIORAL|CREATE Wellness|Patients allocated to the intervention arm will receive three group sessions with between visit contacts designed to increase activation and engagement with their care plans. They will also continue to be enrolled in the KP PHASE program
223656922|NCT02302612|OTHER|Usual Care Control|Patients allocated to the control arm will continue to receive usual care, including disease management within the KP PHASE program.
224239598|NCT00000566|PROCEDURE|angiography|
224239599|NCT06248450|OTHER|Medical yoga|Medical yoga is a therapeutic form of Kundalini yoga led by a certified yoga instructor that uses different standardized yoga programs with a combination of physical postures, breathingexercises, and relaxation/meditation.
224239600|NCT05710341|DIETARY_SUPPLEMENT|Water with added nitrate|Water with added nitrate
224239601|NCT05710341|DIETARY_SUPPLEMENT|Water without added nitrate|Water without added nitrate
223656923|NCT03010488|BEHAVIORAL|Morning Light Therapy|10,000 Lux light for 30 minutes through a light box each morning at patient's desired wake up time.
224239602|NCT05007795|DIAGNOSTIC_TEST|Targeted sequencing using the GenoScreen Deeplex assay|Targeted sequencing to be performed on DNA extracted directly from clinical sputum samples using an on-demand strategy to generate a drug resistant profile. Clinicians treating the patients will have access to this and prescribe 5 or more effective drugs to the patients within 14 days of diagnosis.
224239603|NCT00957814|BEHAVIORAL|Nutritional education|Systematic nutritional orientation program
224239604|NCT03341481|OTHER|Femaltiker|Patient had taken twice a day the product
224239605|NCT03341481|OTHER|Placebo|Patient had taken twice a day the placebo
224239606|NCT00812734|PROCEDURE|Blood sampling for genomics; harvesting of a sample of intercostal muscle for proteomics (thoracotomies only)|Blood sampling for genomics; harvesting of a sample of intercostal muscle for proteomics (thoracotomies only)
224239607|NCT04334590|PROCEDURE|Cleft Lip/Nose Repair without PSIO|Standard of care surgical repair of cleft lip/nose without PSIO.
223656924|NCT03010488|BEHAVIORAL|Assigned Sleep Times|Sleep times will be assigned to subjects that will allow them to drive their regular sleep times closer to those they determine to be optimal at study initiation.
223656925|NCT03010488|DEVICE|Goggles|Subjects will wear goggles during saliva collection and Bright Light Therapy
223656926|NCT02881567|DRUG|Daclizumab|High yield formulation
223656927|NCT00687375|PROCEDURE|Laparoscopic Inguinal Hernia Repair|Laparoscopic Inguinal Hernia Repair using Transabdominal preperitoneal (TAPP) Approach
223656928|NCT00687375|PROCEDURE|Laparoscopic Inguinal Hernia Repair|Laparoscopic Inguinal Hernia Repair using totally extra peritoneal (TEP) Approach
223656929|NCT03378713|DRUG|GROUP 1: Long testosterone|Application of testosterone in transdermal gel during the 2 cycles prior to initiation of controlled ovarian stimulation and until the onset of second menstruation (approximately 56 days). The COS begins the day after the last testosterone application
224239608|NCT04334590|PROCEDURE|Presurgical Infant Orthopedic Therapy|Standard of care surgical repair of cleft lip/nose with PSIO.
224239609|NCT05853484|OTHER|Bimodal lifestyle program|Participants will be subjected to two training periods of six weeks (or until transplantation) of a semi-supervised home-based bimodal lifestyle program. The bimodal lifestyle program consists of an exercise program combined with nutritional support. The exercise program comprises high intensity interval training and endurance training, combined with peripheral resistance training and breathing exercises
224239610|NCT06083337|DEVICE|CaRi-Heart device|Open-label treatment with atorvastatin +/- low-dose colchicine medications based on CaRi-Heart algorithm management.
224239611|NCT01975207|BEHAVIORAL|Treatment as usual|Participants will be treated as per clinic's standard treatment for depression.
223656930|NCT03378713|DRUG|GROUP 2: Short testosterone|Application of testosterone in transdermal gel begins on day 21 of menstrual cycle, from the luteal phase of the cycle prior to initiation of controlled ovarian stimulation and until menstruation (approximately 10 days). The COS begins the day after the last testosterone application.
223656931|NCT03378713|DRUG|GROUP 3: Control|The COS starts directly on the second day of the cycle without prior medication.
223656932|NCT03189238|BIOLOGICAL|Peri-urethral and clitoral injections|Peri-urethral and clitoral injections
223656933|NCT00551057|BEHAVIORAL|Expression type|to investigate the expression of different inflammatory proteins in cancer and normal pancreatic tissue
223656934|NCT06014398|DIAGNOSTIC_TEST|Dynamic testing of Pituitary Function|"Pituitary Function Assessment:~Baseline assessment of pituitary function by measuring ACTH, cortisol, FSH, LH, oestrogen (in females), testosterone (in males), sex hormone binding globulin, thyroid function tests, prolactin and IGF-1\].~Dynamic testing of pituitary function:~* Patients will undergo dynamic testing of the ACTH and growth hormone axes using a glucagon stimulation test (GST).~* Patients whose GST identifies cortisol deficiency will undergo a short synacthen test to confirm adrenal insufficiency as the GST has a false positive rate of approximately 20% for ACTH deficiency."
223656935|NCT00373113|DRUG|Capecitabine|1250 mg/m\^2, twice daily, for 2 consecutive weeks, followed by a 1-week rest period and given as 3-week cycles
223656936|NCT00373113|DRUG|Sunitinib malate|37.5 mg daily, continuous dosing
223656937|NCT02223845|OTHER|Music|Self-selected music played via headphones
223656938|NCT00472680|BEHAVIORAL|Caloric restriction, high protein|Weight loss with higher protein (35%) intake
224239612|NCT01975207|BEHAVIORAL|Internet Intervention|"One of the major treatments for mild-moderate depressive disorders is cognitive behavioural therapy (CBT). It has been possible to operationalize some of this treatment and internet-based approaches to this have been developed. The most widely examined was developed in Australia and is termed MoodGYM (https://moodgym.anu.edu.au/welcome). This program has been widely studied, and these studies have shown it is very effective for many individuals in family practice"
224239613|NCT01975207|BEHAVIORAL|Depression Treatment Pathway|"There has been a growing awareness in health care circles that certain high frequency, high cost addiction and mental health disorders may be best addressed via the systemic adoption of clinical pathways. A clinical pathway is defined as a multidisciplinary outline of anticipated care, placed in an appropriate timeframe, to help a patient with a specific condition or set of symptoms move progressively through a clinical experience to positive outcomes. A clinical pathway incorporates guidelines, protocols and evidence informed best practice into everyday use for the patient and family."
224239614|NCT05706337|DRUG|Propofol|Propofol 1-2mg / kg was for anesthesia induction. Propofol is a hypnotic agent that is used as an induction agent and as a maintenance anaesthetic delivered by continuous i.v. infusion or intermittent i.v. bolus.
224239615|NCT05706337|DRUG|Ciprofol|Ciprofol 0.2～0.5mg/kg was for anesthesia induction. Ciprofol is an intravenous sedative-hypnotic and a short-acting GABAA receptor agonist. It activates GABAergic neurons by enhancing chloride ion influx. It is used for anesthetic induction and maintenance agents include rapid induction of general anesthesia, rapid return of consciousness, minimal residual effects on the central nervous system and less injection pain.
224239616|NCT02804737|DEVICE|Aiddly (Web Site)|A website designed to better educate patients on how to prepare for their colonoscopies
224239617|NCT03746093|DIETARY_SUPPLEMENT|Water|Participants will consume a bottle of water (330 ml) every day for 12 weeks.
224239618|NCT03746093|DIETARY_SUPPLEMENT|Non-alcoholic beer|Participants will consume non-alcoholic beer (330 ml) every day for 12 weeks.
224239619|NCT00002889|DRUG|flutamide|
224239620|NCT00002889|DRUG|goserelin|
224239621|NCT00002889|DRUG|leuprolide acetate|
224239622|NCT00002889|RADIATION|low-LET photon therapy|
224239623|NCT02999178|DRUG|Nintedanib|
223656939|NCT00472680|BEHAVIORAL|Caloric restriction; normal protein|Weight loss with normal level of protein (18%) intake
223656940|NCT00472680|BEHAVIORAL|Nutrition Education|Participants will have the opportunity to speak with the dietitian about their diet by phone, or on-site twice per month
223656941|NCT04248491|DEVICE|BTL Emsella chair|Subjects will sit on the device. The Research Nurse Coordinator (RNC) will turn the device on and increase the setting gradually until the patient reaches their sensory threshold. This is the maximum sensation the patient can tolerate. The treatment threshold should be increased with every treatment until the subject reaches 100%.
223656942|NCT01373541|OTHER|InFat™ based infant formula|high sn-2 palmitic acid oil based infant formula
223656943|NCT01373541|OTHER|Standard vegetable oil based infant formula|standard vegetable oil based infant formula
223656944|NCT01737593|DRUG|Acetaminophen|
223656945|NCT01707576|BEHAVIORAL|consultation 10 days later|new depression screening
223656946|NCT03181646|DRUG|citicoline|intravenous citicoline 15 mg per kg per dose BD will be given to babies until oral feeds are established
223656947|NCT00587496|DRUG|valacyclovir hydrochloride|500 mg capsule, one per day for 30 days
224239624|NCT02999178|DRUG|Placebo|
224239625|NCT03914066|BEHAVIORAL|A group-based treatment of overweight and obesity|The intervention is a group treatment of overweight and obesity in primary care inspired by cognitive behavioural therapy. The main goal of the group treatment is for the participants to obtain and maintain healthy lifestyle habits, with emphasis on diet and physical activity. Every group has 8-12 participants and is led by two persons; the main group leader is either a primary care nurse or a physiotherapist with special training. The groups meet six times (2 hours every time) once a month over a 6-8 month period. Every group session has a set agenda with different topics, for example a healthy diet, recommended physical activity or how to deal with setbacks. Between group sessions there are home assignments. The home assignments are followed-up at the next session and participants are encouraged to share experiences with each other in order to inspire, challenge and help fellow group participants. Data is collected prior to the start of group treatment, after 6-8 and 12 months.
224239626|NCT02837757|OTHER|Biological samples|blood and tumor tissue samples
223656948|NCT00587496|DRUG|placebo|lactose placebo capsule, six per day for 30 days
223656949|NCT00587496|DRUG|valacyclovir plus aspirin|500 mg valacyclovir capsule, one per day for 30 days 325 mg acetyl salicylic acid (aspirin) capsule, three per day for 30 days placebo capsule, two per day for 30 days
223768431|NCT00496301|DRUG|Gemcitabine, Capecitabine and Sorafenib (6 cycles)|Gemcitabine: 1000 mg/m2 i.v. days 1 and 8. Capecitabine: 650 mg/m2 i.v. day 1 to 14. (change to 500mg/m2 after amendment nº2 (dated on 10/10/2007) Sorafenib:400 mg/12h v.o. day 1 to 21
223656950|NCT02340351|DEVICE|Auricular acupuncture|Auricular acupuncture according to the the NADA protocol includes the needling of five specific acupuncture points on both ears: point 51 (= Sympathetic point), point 55 (= Shen Men), point 95 (= Kidney point), point 97 (= Liver point) and point 101 (= Lung point). All points were acupunctured with fine sterile single use steel needles with the size of 0.25 x 20 millimetres. The needles were inserted about 2-3 millimetres, so that the needle point pierces the skin and is just positioned in the cartilage of the ear. They remained in position for 30 minutes.
223656951|NCT02340351|PROCEDURE|Progressive muscle relaxation|Progressive muscle relaxation was carried out by the method of Bernstein and Borkovec. All participants were asked to close eyes while sitting comfortably. Each group session included 16 main exercises of consciously tensing and relaxing specific groups of muscles.
223656952|NCT05151029|DEVICE|Elastography|new dignostic tool
223656953|NCT03928977|DIAGNOSTIC_TEST|Functional Magnetic Resonance Imaging|fMRI sequences done with motor paradigm (right and left arm), followed by resting state acquisition
223656954|NCT00257270|DRUG|gabapentin|
223656955|NCT02059096|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|
223656956|NCT03919578|BIOLOGICAL|Recombinant Hepatitis B vaccine|Recombinant Hepatitis B vaccine is an inactivated HbsAg produced in yeast cells (Hansenula polymorpha) using recombinant DNA technology. It is a whitish liquid produced by culture genetically engineered yeast cell which carry the relevant gene of the HbsAg. The inactivated HbsAg (bulk) is imported from Serum Institute of India and then formulated and filled at Bio Farma.
223656957|NCT03919578|BIOLOGICAL|Recombinant Hepatitis B (Bio Farma)|Recombinant Hepatitis B vaccine is an inactivated HbsAg produced in yeast cells (Hansenula polymorpha) using recombinant DNA technology. It is a whitish liquid produced by culture genetically engineered yeast cell which carry the relevant gene of the HbsAg. The inactivated HbsAg (bulk) is imported from The Janssen Vaccine Corp and then formulated and filled at Bio Farma.
223656958|NCT02364336|DRUG|Peginterferon alfa-2a|
223656959|NCT01731938|BIOLOGICAL|Fibrin Sealant (FS) Grifols|Fibrin Sealant (FS) Grifols: The maximum total volume of FS Grifols allowed to be applied at the target bleeding site by dripping or spraying was approximately 12 mL (equivalent to the full content of 2 FS Grifols kits).
223656960|NCT01731938|DEVICE|Surgicel®|Up to four Surgicel® sheets applied to the target bleeding site according to Package Insert instructions and the surgeon's usual clinical practice.
223656961|NCT03547024|DRUG|JNJ-55308942 High Dose|Participants will receive high dose of JNJ-55308942 orally once daily.
223656962|NCT03547024|DRUG|JNJ-55308942 Low Dose|Participants will receive low dose of JNJ-55308942 orally once daily.
223768432|NCT05028504|DRUG|Penpulimab|Penpulimab is a humanized monoclonal antibody targeting programmed cell death-1 (PD-1), which prevents PD-1 from binding to PD-L1 and PD-L2 receptors on tumor cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.
224239627|NCT05851131|OTHER|Approach to Diagnosis and Treatment of Osteoporosis Questionnaire|"The survey will use multiple-choice questions to assess primary care physicians' knowledge on the diagnosis and treatment of osteoporosis. The questions will cover various aspects, including medication options, their mechanisms of action, side effects, and recommended vitamin D supplementation dosages. The physicians will also be asked about their sources of knowledge and how they keep themselves updated on the topic, as well as their self-evaluation of their knowledge. Background information, such as their professional and demographic characteristics, will also be collected. The survey questionnaire used in other studies will be adapted for this survey based on the Updated approach for the management of osteoporosis in Turkey: a consensus report."
223656963|NCT03547024|DRUG|Levonorgestrel/Ethinyl Estradiol Fixed Dose combination (FDC)|Participants will receive 0.150 milligram (mg) levonorgestrel and 0.030 mg ethinyl estradiol FDC tablet orally.
223656964|NCT03547024|DRUG|Drug Cocktail:Midazolam (2mg)/Omeprazole (20mg)/Dextromethorphan (30mg)|Participants will receive single dose of drug cocktail consisting of midazolam (2 mg), dextromethorphan (30mg) and omeprazole (20 mg) orally.
223656965|NCT00771953|DRUG|apricoxib|Oral apricoxib tablets will be provided as white or off-white film-coated tablets available in 100mg strength to be taken every day
223656966|NCT00771953|DRUG|Placebo|Oral placebo tablets will be provided as white or off-white film-coated tablets to be taken every day
223656967|NCT00771953|DRUG|Docetaxel or Pemetrexed|Docetaxel 75mg/m2 or Pemetrexed 500mg/m2 given as an IV infusion every 21 days. TheTreating physician will determine chemotherapy drug as per his usual practice.
223656968|NCT06153303|BEHAVIORAL|Acceptance and commitment therapy|The participants will go through an active internet-based ACT treatment focused on education about endometriosis and chronic pain, value-based exposure for avoided situations, and behavior change through exercises targeting the processes mindfulness, cognitive defusion and acceptance. The treatment is delivered on a safe internet platform. Participants have planned telephone contact with their assigned psychologist 2 times during the program and can also contact their psychologist via a message system in the platform and expect answer within 48 hours.
223656969|NCT05520554|OTHER|Development of the Telerehabilitation Satisfaction Questionnaire|This study will be examined the development, validity, and reliability of the Telerehabilitation Satisfaction Questionnaire in patients with MS.
223656970|NCT01254708|DRUG|Ambisome ®|liposomal amphotericin B
223656971|NCT01254708|DRUG|Regular standard of care medication|Drug for this group is at the physician's discretion. Patients in this group receive the standard of care medication currently implemented at the Institution. Example would be voriconazole
223656972|NCT05211583|DIAGNOSTIC_TEST|Serum progesterone levels|In order to show change of serum progesterone levels, serial venous blood sampling will be done and also transvaginal ultrasonography will be performed to show ovulation.
223768433|NCT05028504|DRUG|Anlotinib|A multi-target receptor tyrosine kinase inhibitor
223768434|NCT02682420|DEVICE|everlinQ endoAVF System|
223768435|NCT01971138|OTHER|this is a survey|
223768436|NCT00844792|DIETARY_SUPPLEMENT|Lycopene, Vitamin D3, Selenium, Green Tea Extract, Vitamin E|Twice a day with meals. Lycopene - 20 mg, Vitamin D3 - 200 IU, Selenium - 100 mcg, Green Tea Extract - 75 mg, Vitamin E - 50 IU
223768437|NCT00844792|DRUG|Placebo|Twice a day with meals.
223768438|NCT03787316|DEVICE|Study group|4 weeks of custom-made insoles in the home and outside the home environment , follow the home exercise program during this process.It is planned to perform gait parameters and pain assessment before and after the treatment.
223656973|NCT06116513|DEVICE|S53P4 bioactive glass granules|During revision surgery, all infectious material would be removed and subsequently the posterior wall of the external ear canal would be reconstructed and the mastoid would be obliterated using S53P4 bioactive glass.
223656974|NCT04174404|OTHER|ICory-Circumcision|The ICory-Circumcision is specially developed for this study based on preliminary studies, other literature, and most importantly, the surgical pathway currently practiced in the study hospital. The ICory-Circumcision programme has two components: (1) the Buddy Healthcare mobile app (BuddyCare) that provides a comprehensive day-by-day perioperative guide for parents regarding their child's surgery with an interface for health care professionals to monitor parents' and their children's needs as well as communicate with them. (2) The Triumf Health mobile game app that provides emotional support and distraction to children. The ICory-Circumcision programme is designed to be a self-guided and healthcare professional-led. Participants will have access to BuddyCare for parents and Triumf Health from time of recruitment till 2 weeks after surgery while the healthcare professional would receive face-to-face training on how to use the BuddyCare dashboard.
223656975|NCT04174404|OTHER|Routine care|The routine care consists of normal consultations with the doctor, preoperative preparation, and post-operative care. During the first consultation, the child will be assessed for the need for circumcision and the doctor explains verbally to the parents about the procedure, risks, what to expect and prepare pre-operatively.
223656976|NCT05680441|OTHER|Peirodontal clinical measurements and gingival crevicular fluid sampling|The clinical periodontal examination of the healthy and periodontitis subjects consisted of plaque index (PI), probing pocket depth (PPD), clinical attachment level (CAL), and bleeding on probing (BOP) recorded. CAL was calculated by adding GR to the PPD values. Averages for full mouth PPD, CAL, and the percentage of sites with BOP were calculated for each subject. A single calibrated examiner (VO) conducted a full mouth periodontal examination of all participants.
223656977|NCT04726969|DRUG|Moxidectin 2 mg Oral Tablet|Tablets of 2 mg moxidectin
223656978|NCT04726969|DRUG|Albendazole 400 mg Oral Tablet|Tablets of 400 mg albendazole
223656979|NCT04726969|DRUG|Ivermectin 3 mg Oral Tablet|Tablets of 3 mg ivermectin
223656980|NCT00006117|DRUG|gemcitabine hydrochloride|
223656981|NCT00006117|DRUG|oxaliplatin|
223656982|NCT05787548|BEHAVIORAL|Contact information|Information on how to contact Geisinger if the patient needs care
223656983|NCT05787548|BEHAVIORAL|Urgent care map|A map of the patient's nearest Geisinger urgent care location, with information about urgent care
223656984|NCT05787548|BEHAVIORAL|Self-triage chart|A chart demonstrating what to do in response to several common conditions where the patient might be compelled to visit the ED
223656985|NCT03081936|DIETARY_SUPPLEMENT|Oral consumption of Nutricia Aptamil Stage 1 formula|Daily oral consumption of Nutricia Aptamil Stage 1 formula
223656986|NCT03081936|DIETARY_SUPPLEMENT|Oral consumption of a2® Platinum Stage 1 formula|Daily oral consumption of a2® Platinum Stage 1 formula
223656987|NCT03081936|DIETARY_SUPPLEMENT|Oral consumption of breast milk|Daily oral consumption of breast milk
223656988|NCT00856518|DEVICE|EMST|Pressure threshold device (Expiratory Muscle Strength Trainer) targeted at increase muscle force generation of expiratory and submental muscles.
223656989|NCT00856518|DEVICE|Sham|The same device just like the EMST but does not provide a load on the target muscle group
223656990|NCT02933684|DRUG|Seromycin|Seromycin (aka D-cycloserine) is an analogue of D-alanine and a partial agonist at the NMDA receptor, which facilitates the process of fear extinction.
223656991|NCT02933684|BEHAVIORAL|Virtual Reality Exposure Therapy|Allows for delivery of exposure therapy on an iPad. Participants read a speech to a virtual audience. Exposures become increasingly more difficult as the audience becomes more hostile and speeches increase in length and complexity.
223656992|NCT02933684|DRUG|Placebo|Administered in pill form.
223656993|NCT05048524|DRUG|S-1, leucovorin, oxaliplatin and gemcitabine|"Gemcitabine 800 mg/m2 on day 1, oxaliplatin 85 mg/m2 on day 1, S-1 orally 80-120 mg/day \[depending on patient's body surface area (BSA)\] on day 1 to 7 and leucovorin 30mg BID day 1 to 7 on in a 2-week cycle. The dose of S-1 is defined as follows:~* BSA \< 1.25 m2: 80 mg/day~* 1.25 m2 ≤ BSA \< 1.5 m2: 100 mg/day~* BSA ≥ 1.5 m2: 120 mg/day"
223656994|NCT00947193|DRUG|Ataluren|Oral powder
223656995|NCT05765513|DRUG|HA35(L20200708MP07707, Ministry of Health, Mongolia) was freshly manufactured by mixing hyaluronidase PH20 injectable solution (H31022111) and high-molecular-weight HA injectable solution (H20174089)|The clinical effects of gingival discomfort oritching, redness and swelling, and bleeding from the probing were observed and recorded in patients before and after 7 days of treatment.
223656996|NCT03364270|DRUG|PET/CT Imaging with [F-18] RGD-K5|PET Imaging/scan with \[F-18\] RGD-K5, PET Imaging/scan with RGD-K5, PET Imaging/scan with K5
224239628|NCT05405725|BIOLOGICAL|ENZ215|Enrolled women with postmenopausal osteoporosis will receive ENZ215 (60mg)
223656997|NCT01051154|DIETARY_SUPPLEMENT|Docosahexaenoic acid (DHA)|Children will be received either fish oil capsules (DHA group) or placebo capsules (placebo group) which is visually indistinguishable from DHA capsules (softgel). Each child will be receiving 100 mg/kg/day or placebo capsules without docosahexaenoic acid, during the first three months of treatment.
223656998|NCT01051154|DIETARY_SUPPLEMENT|Placebo|Children will be received either fish oil capsules (DHA group) or placebo capsules (placebo group) which is visually indistinguishable from DHA capsules (softgel). Each child will be receiving 100 mg/kg/day or placebo capsules without docosahexaenoic acid, during the first three months of treatment.
223656999|NCT00926029|DRUG|Fluoride|Brush twice daily
223657000|NCT00926029|DRUG|Triclosan, fluoride|Brush twice daily
223657001|NCT00926029|OTHER|Metal salt|Brush twice daily
223657002|NCT00635258|DRUG|triptorelin (Decapeptyl®, Ipsen Pharma, Barcelona, Spain)|0.1 mg/day triptorelin s.c (Decapeptyl®, Ipsen Pharma, Barcelona, Spain) was started on day 21-24 of the preceding cycle for at least 14 days to produce an agonadal state.
224239629|NCT05405725|BIOLOGICAL|Prolia|Enrolled women with postmenopausal osteoporosis will receive Prolia
224239630|NCT02060110|DEVICE|Patients that were randomized to the the cardiac resynchronization therapy with defibrillation (CRT-D) device for the study|
224239631|NCT02060110|DEVICE|MADIT-CRT ICD ONLY ARM|
224239632|NCT03192696|DEVICE|Atherectomy Catheter|Treatment of restenotic lesions within stents previously placed within the artery.
224239633|NCT00653471|DEVICE|Microcapmicro-stream device with Smart CapnoLine Plus|nasal oxygen mask tested to determine accuracy of endtidal CO2 monitoring
223657003|NCT00635258|DRUG|GnRH antagonist (Orgalutran®)|GnRH antagonist (Orgalutran®; 0,25 mg/d, sc.) commencing on day 1 of the menstrual cycle and maintained until the day of donor's hCG administration.
223657004|NCT04404400|DRUG|Investigational products administration|"Investigational products include:~* Hydrocortisone hemisuccinate 50 mg: one intravenous injection every 6 hours, and~* 9 alpha fludrocortisone 50 μg: one tablet per day via a nasogastric tube.~All treatments will be stopped after 7 days or until the patient has left the intensive care unit (whichever occurs first) without tapering off."
223657005|NCT04404400|DRUG|Placebo administration|Placebos for hydrocortisone and for fludrocortisone, administered in same manner as the active drugs in the interventional arm, for 7 days.
223657006|NCT05819255|OTHER|Non-Interventional|"This prospective, non-interventional clinical study will enroll patients with metastatic melanoma, who have been selected by their oncologist to receive standard of care dual-agent immunotherapy and monitored for treatment response using SOC FDG PET/CTs.~The primary objective of this clinical study is to investigate intent to change treatment decisions after the addition of treatment response information from the TRAQinform Immuno technology."
223657007|NCT05246514|DRUG|Trastuzumab deruxtecan|administered as an IV infusion
223657008|NCT00261261|BEHAVIORAL|ADVANCE|
223657009|NCT00261261|DRUG|Midazolam|
223657010|NCT00261261|PROCEDURE|Parental presence|
223657011|NCT00971815|DRUG|Escitalopram|first week: 10mg/day. Then, treatment with 20mg/day is continued throughout a 3 months period of time.
223657012|NCT00971815|DRUG|placebo|1/2 pill pr day first week, then 1 pill pr. day throughout a 3 months treatment period (90-118 ± 7days)
223657013|NCT05618691|DRUG|GFH312|Oral tablet, GFH312 will be administered at 3 dose levels, each patient in one of three groups will be given a dose of 40mg, 80mg, 120mg of the study drug.
223657014|NCT05618691|OTHER|Placebo|Placebo will be administered to subjects in the placebo group
223657015|NCT03031080|DEVICE|Thermoplastic Hand Splint|Thermoplastic Night splint created and moulded to the individual patients hand in-house using generic thermoplastic.
223657016|NCT02385643|BEHAVIORAL|SmartPhone Support System|
223657017|NCT01347411|PROCEDURE|CPAP|Treatment with CPAP
223657018|NCT04937465|OTHER|No intervention done|No intervention was done. This was an observational study.
223657019|NCT04154189|DRUG|Lenvatinib|"Lenvatinib 14 milligrams per square meter (mg/m\^2) capsules will be administered once daily on Days 1 to 21 of each 21-day cycle until disease progression (PD), development of unacceptable toxicity, participant request, withdrawal of consent, or discontinuation of study by the sponsor.~An extemporaneous suspension of lenvatinib capsules may be used for participants unable to swallow capsules."
223657020|NCT04154189|DRUG|Ifosfamide|Ifosfamide 3000 milligrams per square meter per day (mg/m\^2/day) intravenous infusion will be administered on Days 1 to 3 of each 21-day cycle for a total of 5 cycles.
223657021|NCT04154189|DRUG|Etoposide|Etoposide 100 mg/m\^2/day intravenous infusion will be administered on Days 1 to 3 of each 21-day cycle for a total of 5 cycles.
223657022|NCT04154189|DRUG|Lenvatinib|Lenvatinib 14 mg/m\^2 capsules will be administered once daily on Days 1 to 21 of each 21-day cycle until the next PD (per response evaluation criteria in solid tumors \[RECIST\] 1.1 as assessed by investigator), development of unacceptable toxicity, participant request, or withdrawal of consent, whichever occurs first.
223657023|NCT04048772|BEHAVIORAL|CALM IVF|The intervention will be three 1-1.5 hour interactive sessions that are scheduled throughout the participant's first in vitro fertilization cycle. These sessions will provide additional time for discussion about treatment with providers, learning opportunities on topics of interest to fertility patients, and stress reduction techniques.
223657024|NCT04048772|OTHER|Standard of Care|Patients will receive the standard of care IVF treatment at the University of Iowa.
223657025|NCT04727372|OTHER|Questionnaire|A structured questionnaire will be served to each participant of study after getting the verbal consent from him for inclusion into the study
223657026|NCT03314922|DRUG|Parsaclisib|Parsaclisib administered orally once daily for 8 weeks at the protocol-defined dose, followed by a once-weekly regimen at the same dose.
223657027|NCT04856839|DIAGNOSTIC_TEST|high throughput sequencing and electromyography|Whole Genome Sequencing, Whole Exome Sequencing, Transcriptomics, Proteomics, Metabolomics
223657028|NCT06045702|PROCEDURE|Epididymal sample|During a planned surgical procedure carried out by the Urology and Medically Assisted Reproduction (MAP) department at Brest University Hospital in the patients included in the study, a remnant epididymal sample (between ½ and ¼ of a cc) will be kept for research purposes. These patients suffer from male infertility, leading them to undergo surgery in order to check for the presence of spermatozoa in the epididymis, and to recover spermatozoa which will be frozen and flaked in the AMP department of the CHU Brest, in the event of future procreation by in vitro fertilisation.
223657029|NCT01043913|DRUG|Guarana extract|Guarana extract 50mg q12 hours for 21 days
224239634|NCT00653471|DEVICE|Microcap micro-stream device with CapnoLine|CO2 measured via nasal cannula
223657030|NCT01384149|DEVICE|external slt|Nd:YAG LASER SLT perilimbal above trabecular meshwork 180 degrees ,100 lasering dots
223657031|NCT01384149|DEVICE|standard slt|Nd:YAG LASER SLT gonioscopic laser treatment
223657032|NCT00830297|DRUG|Insulatard (long-acting insulin)|In group No.1 (study arm 1 (=A)), patients will be treated with long-acting insulin (Insulatard) as soon as the glucose-level before supper surpasses 140 mg/dl. The normoglycemic goal in this group will be from 110 to 120 mg/dl.
223657033|NCT00830297|DRUG|Conventional|In group No.2 (study arm 2 (=B)), patients will be treated conventionally according to the decisions taken by the physicians on the ward. The following suggestions will be brought to the attention of the ward in order to standardize the treatment of the patients in study arm B: 1. Treatment in this group should be initiated if the fasting glucose level surpasses the renal glucose threshold, i.e. 180 mg/dl. 2. As the proposed life-style modifications for the treatment of NODAT1 are not feasible during this very early post-transplant phase, the basis of the conventional therapy will be proposed to be sulfonyl urea drugs (i.e. Gliclazide - Diamicron®, 30 mg, not more than twice daily). 3. Short-acting insulin will be strongly recommended to be used for corrections of capillary blood glucose levels above 250 mg/dl.
223768439|NCT02908529|DRUG|Combination product of Atomoxetine and Oxybutynin|Combination product of Atomoxetine 80 mg and Oxybutynin 5 mg 2 hours before sleep
224239635|NCT00653471|DEVICE|TG-920 main-stream device (Nihon Kohden, Tokyo, Japan).|CO2 measured via nasal cannula
223657034|NCT05149235|OTHER|early mobilization group|Participants will perform exercises using only the cycle ergometer and ambulation. In this group, participants will be instructed to turn the pedals continuously, without any weight added to the equipment (only on 1st post-operative day) and training load will be determined by a fatigue level maintenance of 4 or 5 on the modified Borg scale with a maximum HR elevation of 20% on 2nd and 3rd post-operative days. Duration of exercise will be of 10 minutes (five minutes with the upper limbs and five minutes with the lower limbs). For the arm exercises, the individuals will be positioned with the head end of the bed raised to 60° above the horizontal, while ensuring that all the equipment responsible for measuring the patient's vital signs remained connected. For the leg exercises, the head end of the bed will be lowered to a 30° angle to provide better access to the pedals and avoid compensatory hip movements. Ambulation will be performed only on 3rd post-operative day (40 meters).
223657035|NCT05149235|DEVICE|physio adventure|The protocol applied to the experimental group will be the same of that applied to the early mobilization group with the use of smart move instead of cycle ergometer.
224239636|NCT05325047|PROCEDURE|Intensive speech rehabilitation|Combination an e-health device allowing the patient to self-rehabilitate with a face-to-face approach of accompaniment and support of the patient by the speech therapist.
223657036|NCT05149235|OTHER|placebo|Participants allocated to the Control group will perform respiratory physiotherapy (Flow-oriented incentive spirometer (3×15), active exercises for lower and upper limbs, with each movement being repeated 10 times in an open kinetic chain. For the upper limbs, movements of anterior flexion of the shoulder will be performed until achieving maximum range of motion, using diagonal movements starting at the contralateral iliac crest up to the maximum range of anterior flexion of the shoulder associated with supination. For the lower limbs, exercises will consist of straight leg raises, hip and knee flexion-extension exercise and ankle pumps. Sessions will be of 10 minutes duration.
223657037|NCT00610454|DRUG|Levetiracetam|
223657038|NCT04135287|DRUG|GLP-1 receptor agonist|The main objective of the study is to determine the relationship between the increase in glucose-stimulated insulin secretion and decrease in HbA1c caused by GLP-1 RA therapy in poorly controlled T2DM patients. We also will identify a cut point of an increase in beta cell function which produces a clinically meaningful decrease in HbA1c.
223657039|NCT02497742|OTHER|Basic metabolic panel|Patients blood is collected in routine fashion for basic blood chemistries
223657040|NCT00486291|DRUG|VI-0521|phentermine 15mg/topiramate 100mg
223657041|NCT00486291|DRUG|Placebo|matched placebo
223657042|NCT04220476|RADIATION|Stereotactic Body Radiation Therapy (SBRT) (50GY in 5 fractions)|Patients randomized to arm 2 will start letrozole alone, and add palbociclib on day 21, after completion of I-SBRT. They will undergo tumor Immunogenic-SBRT(I-SBRT) days 1-12 (+/-2 days, to enable inclusion of holidays). During the week preceding day 1, they will undergo simulation and planning for radiotherapy. Each oligometastatic lesion will be treated with I-SBRT every 48 hours. Treatment may be given daily (to keep the total I-SBRT treatment time to ≤ 12 days) and lesions targeted with I-SBRT will thus be alternated each day to accommodate for the 48 hour interval between fractions
224239637|NCT04529746|BEHAVIORAL|EVERYbody Project|Brief behavioral intervention (4 hours across two meetings)
223657043|NCT04220476|DRUG|Letrozole 2.5Mg Tab|All patients start standard therapy with oral letrozole (Femara), day 1 of the study.
223657044|NCT04220476|DRUG|Palbociclib 125mg|Patients randomized to arm 2 will start letrozole alone, and add palbociclib on day 21, after completion of I-SBRT.
223657045|NCT00973713|DRUG|RAD001|10mg/d
223657046|NCT02121821|BEHAVIORAL|SMS reminder messages|The study is prospective and interventional comparing differences between pregnant women who receive reminder messages via the SMS Mother Reminder system to those who are not. Pregnant women will be followed from their first ANC visit at a health facility through delivery. The study will examine the effect of the mobile phone intervention on attendance to ANC appointments and IPTP2 coverage. The intervention group will be composed of pregnant women receiving SMS reminder messages in comparison with a control group of pregnant women receiving no intervention (i.e. no SMS reminders).
223657047|NCT02163603|PROCEDURE|Pelvic osteotomy|
223657048|NCT02499133|OTHER|language and cognitive tests|The participants will undergo seven different. The tests will include different cognitive and language examinations. The main test of the study will be The Hebrew Focused Stress Test (HFST). The HFST includes three subtests. The first subtest requires identification of the stressed word in a sentence based on psychoacoustic abilities alone. The second and the third subtests require understanding the meaning of focused stress in different contexts - lexical grammatical and pragmatic/social. The test includes forty eight recorded sentences. In each sentence one word is stressed. The participants will be asked to listen to the recordings and answer a closed question regarding the stressed word.
223657049|NCT04073524|OTHER|Nature-Body-Mind-Community|The Nature-Body-Mind-Community (NBMC) approach has been developed in a pilot project over 2014-2018. The 'Wild man Programme' consists of the following main elements: 1. Nature environments and nature experiences, 2. Mind relaxation and meditation, 3. Body awareness and 4. Fire talks, storytelling and community spirit.
223657050|NCT04073524|OTHER|Treatment as usual|Treatment as usual consist of the rehabilitation offered by the hospital or municipality for the specific condition e.i. cancer, diabetes, COPD, anxiety, depression and stress
223657051|NCT00102583|DRUG|Subconjunctival Cyclosporine Implant|
223657052|NCT03739034|BEHAVIORAL|Lifestyle Medicine|Treatment modalities consist of encouraging a plant based, whole food diet, physical activity, stress management, healthy sleep, control of unhealthy habits.
223768440|NCT02908529|DRUG|Placebo, 2 tablets|Placebo 2 tablets 2 hours before sleep
223768441|NCT04395716|BIOLOGICAL|ResCure™|Patients will be treated with nebulized ResCure™
224239638|NCT00331526|BIOLOGICAL|aldesleukin|
224239639|NCT00331526|BIOLOGICAL|therapeutic autologous lymphocytes|
224239640|NCT00331526|PROCEDURE|adjuvant therapy|
224239641|NCT00331526|PROCEDURE|conventional surgery|
224239642|NCT03480425|DIAGNOSTIC_TEST|Measuring extubation force|Intubation of the esophagus of anesthetized participants who are having planned endotracheal intubate for surgery; inflation of the cuff; attachment of a force transducer to the tube connector; and gently tugging the tube out of the mouth. Then intubating the esophagus and repeating the tugging procedure. Meanwhile, the force of resistance to tugging is measured with a force transducer.
223657053|NCT02476266|OTHER|Resistance Training|Resistance training has been shown to improve balance and muscle weakness in those with PD as well as reducing the number of falls experienced, albeit not significantly. However to date no study has investigated forms of resistance training in the same study. To disentangle which form of resistance training might be more effective at reducing the risk of falls, improving balance and muscle strength, the proposed study will compare power training and conventional strength training.
223657054|NCT02010450|OTHER|Wearable Blanket (Sleep Sack)|
223657055|NCT02010450|OTHER|Incentive Item|
223657056|NCT04783090|DRUG|MT1013|bispecific peptide as a CaSR agonist and a functional OGP analogue
223657057|NCT04710472|DEVICE|Mentora App|"Participants will be invited to register their treatment side effects, symptoms, daily activities and exercise and QoL on a health app designed for this purpose.~The Mentora Health App includes a tool based on PRO-CTCAE™, a patient-reported outcome measurement system developed by the National Cancer Institute, version 1.1, that includes 80 symptoms (attachment 1) and has been translated and validated to Portuguese (Portugal) by the authoring entity. These symptoms are graded on a five-point scale from 0 (not present) to 4 (disabling) based on clinical criteria."
223657058|NCT02305810|DRUG|Everolimus 10 mg daily|everolimus is a recently approved mTOR inhibitor in advanced progressing well/moderately differentiated pancreatic neuroendocrine tumors
223657059|NCT00126490|BIOLOGICAL|Aldesleukin|Given subcutaneously
223657060|NCT00126490|BIOLOGICAL|Bevacizumab|Given IV
223657061|NCT00126490|OTHER|Laboratory Biomarker Analysis|Correlative studies
223657062|NCT00654433|BIOLOGICAL|ALD-101|A subpopulation of cord blood cells composed of cells that express a high level of the intracellular enzyme aldehyde dehydrogenase (ALDH).
223657063|NCT01931371|PROCEDURE|Anal Fistula Plug|Surgical procedure for the treatment of anal fistula with an Anal Fistula Plug
223657064|NCT01931371|PROCEDURE|Endorectal Advancement Flap|Surgical procedure for the treatment of anal fistula by an Advancement Mucosa Flap
223657065|NCT05118880|OTHER|Peer Bullying Counseling Program based on the Interpersonal Relationship Model|"The content of the program was created by the researcher in line with the issues that peer bullying children need support based on their bullying-related characteristics in the light of the relevant literature. Education topics prepared in this framework; 'Empathy', 'Peer Bullying', 'Anger Management' and 'Happy Friendship Relationships' were determined. The main nursing problem of the research is peer bullying. The main purpose of the Peer Bullying Counseling Program is to improve the empathy skills of the bullying child, to enable them to gain the right perspective towards bullying, to develop anger control, and to help them establish happy friendships. The content of the Peer Bullying Counseling Program; drawing, brainstorming, empathy demonstration, white paper activity, educational matching game, peer bullying demonstration, case studies, educational emotion puzzle game, anger control information video were applied using educational techniques."
223657066|NCT05606471|DRUG|Semaglutide Pen Injector [Ozempic]|Glucagon-like peptide 1 (GLP-1) receptor agonist
224239643|NCT02486822|PROCEDURE|Amniotomy|Amniotomy, artificial rupture of membranes, is done with initial delay of labor (in partograph: extension beyond alert line, in labor scale: when progress reaches the membrane line)
224239644|NCT02486822|DRUG|Oxytocin|Oxytocin augmentation: given with further delay of labour (according to the point of intervention of the partograph or the scale)
224239645|NCT02486822|PROCEDURE|Cesarean Section|Cesarean section: done when progress is deemed arrested (according to the definition of the partograph or the scale)
224239646|NCT06011122|PROCEDURE|Distal radius fracture ORIF with a specific volar plate|Patients who had a distal radius fracture were treated surgically : an ORIF was realised with a volar plate
224239647|NCT01658293|BEHAVIORAL|thermal stimulation|The heat and cold-water will be added to the thermal group for 30-40minutes a session daily,five sessions a week for six weeks.
223657067|NCT05606471|DIETARY_SUPPLEMENT|Very-low Calorie Diet|Total meal replacement with a limit of 800 kilocalories per day
223657068|NCT01968655|BIOLOGICAL|OBI-1|OBI-1 is a B domain deleted recombinant porcine factor VIII
223657069|NCT06480487|BEHAVIORAL|Feedback provided face to face|Feedback will be provided face-to-face.
223657070|NCT06480487|BEHAVIORAL|Feedback provided by electronic mail|Feedback will be provided by electronic mail.
223657071|NCT06480487|BEHAVIORAL|Feedback provided by researchers|Feedback will be provided by researchers.
223657072|NCT06480487|BEHAVIORAL|Feedback provided by authoritative bodies|Feedback will be provided by authoritative bodies.
224239648|NCT01658293|BEHAVIORAL|control group ergometer exercises|The control group will be given ergometer exercises with the similar duration as experimental group.
223657073|NCT06480487|BEHAVIORAL|Feedback provided with peer comparision|Feedback will be provided with peer comparison.
224239649|NCT02956772|DRUG|TACE|After the puncture of femoral artery via Seldinger method, a catheter was inserted and digital celiac axis or hepatic arteriography performed. Then a microcatheter was used to infuse chemotherapeutic agent (30 to 60 mg of pirarubicin) mixed with 5 to 20 mL of Lipiodol Ultra-Fluid. Embosphere microspheres (size of 100 to 300 um) were inserted for embolization.
224239650|NCT02956772|DRUG|Arsenic trioxide|Arsenic trioxide 10 mg is put into 500 ml saline solution and then administrated by continuous intravenous drip for 5 hours during a treatment day.
224239651|NCT03596372|DRUG|BAY1834942|"Dose escalation:~Sequential dose levels~.~Dose expansion (except for low-dose expansion):~With maximum tolerated dose (MTD) identified in dose escalation part."
224239652|NCT03100630|DRUG|RO7239361|Specified dose on specified days
223657074|NCT06480487|BEHAVIORAL|Feedback provided without peer comparision|Feedback will be provided without peer comparision.
223657075|NCT03399396|BEHAVIORAL|Practice facilitation for HPV vaccine|The practice facilitation intervention provides coaching support to pediatric practices to guide them through quality improvement projects to increase HPV vaccination rates.
223657076|NCT02124317|DRUG|nanoparticle albumin-bound paclitaxel|nanoparticle albumin-bound paclitaxel is given at 120 mg/m2 intravenously on day 1 and 8 of each 21 day cycle. Number of cycles: 6 cycles.
223657077|NCT02124317|DRUG|S-1|S-1 is orally administered (40-60 mg according to the body surface, twice a day) on day 1-14 of each 21 day cycle. Number of cycles: 6 cycles.
223657078|NCT00975780|OTHER|Enhanced Oral Care|oral brushing plus oral chlorhexidine plus upright feeding positioning
223657079|NCT00975780|OTHER|Usual oral care|Usual oral care and feeding positioning
223657080|NCT00985699|GENETIC|polymorphism analysis|
223657081|NCT00985699|OTHER|laboratory biomarker analysis|
223657082|NCT00985699|OTHER|pharmacogenomic studies|
223657083|NCT01056016|OTHER|ADHD Collaborative|This intervention includes mapping and redesign of office flow to facilitate adherence to AAP ADHD guidelines as well as didactic sessions related to diagnosis and treatment of ADHD. Didactics emphasize the importance of obtaining parent and teacher behavioral ratings (e.g. Vanderbilt ADHD Rating Scales) at the time of the initial assessment for ADHD and during follow-up after initiating medication treatment and making a DSM-IV based ADHD diagnosis. Practices are given a web-based ADHD portal to assist them in creating a patient registry and to help in obtaining parent and teacher ratings scales.
223657084|NCT02857634|DEVICE|Cellvizio dual band|Using fluorescence cytoscopy, lesions in the bladder will be resected. The samples will be immediately observed in order to keep the fluorescein effect under confocal microscopy (Cellvizio dual band). After confocal microscopy samples will be fixed in formalin and prepare for the pathologist that will confirm the diagnosis. The Cellvizio system can be used to observe a resected sample ex vivo, offering a cellular-level view of internal tissue. This technique allows the visualization of the microstructure of the tissue in real-time which may improve targeted sampling, provide earlier disease detection and help patient management. The Cellvizio system includes miniaturized optics, optical fiber bundles, high-speed scanning and advanced image processing components.
223657085|NCT00950820|DRUG|Oxaliplatin, Capecitabine, Panitumumab|"Panitumumab at a dose of 9 mg/kg BW every three weeks will be administered on day 1 of each cycle just prior to administration of chemotherapy.~The XELOX regimen is defined as a 2 hour infusion of oxaliplatin 130 mg/m² on day 1 followed by capecitabine 1000 mg/m² bid per os. Capecitabine administration will commence on the evening of day 1 and complete after the morning dose on day 15."
224239653|NCT02506582|DIETARY_SUPPLEMENT|jerusalem artichoke and fermented soybeans powder mixture|40 g jerusalem artichoke and fermented soybean powder mixture
224239654|NCT02506582|DIETARY_SUPPLEMENT|placebo|40 g powdered rice flour
223657086|NCT00950820|DRUG|Oxaliplatin, Capecitabine|The XELOX regimen is defined as a 2 hour infusion of oxaliplatin 130 mg/m² on day 1 followed by capecitabine 1000 mg/m² bid per os. Capecitabine administration will commence on the evening of day 1 and complete after the morning dose on day 15.
223657087|NCT04976582|DEVICE|dry needle|modalities including transcutaneous electrical nerve stimulation (TENS); electrical muscle stimulation (EMS); and interferential current (IFC). Physical agents including ultrasound, hot packs, and cold packs. Exercise including McKenzie exercises) will be administered.
223657088|NCT05656144|DEVICE|Cadonilimab|AK104, 6mg/kg, Q2W
223657089|NCT05494515|PROCEDURE|the early swallowing rehabilitation program|the early swallowing rehabilitation program based on the HRIM evaluation
223657090|NCT00241189|DRUG|rapamycin|
223657091|NCT00241189|DRUG|methotrexate|
223657092|NCT03051178|DEVICE|Responsive deep brain stimulation|Responsive deep brain stimulation (R-DBS) therapy will be delivered responsively based on the level of their symptoms as detected by wearable EMG and inertia (acceleration) sensors.
223657093|NCT04805398|BIOLOGICAL|CM310|300 mg every two weeks
223657094|NCT04805398|BIOLOGICAL|Placebo|300 mg every two weeks
224239655|NCT04112082|BEHAVIORAL|Mobile Neurofeedback|Home-based neurofeedback training (downtrain theta, uptrain beta; training site: Cz) 4 times weekly for a 40 of total sessions over the ten-week training period. Session duration of 21 minutes for the first 20 sessions to 30 minutes for the last 20 sessions. Positive visual and auditory feedback when brainwaves are within the desired range.
223657095|NCT04749992|PROCEDURE|Polysomnographic examination in sleep laboratory (PSG measurement)|Recording of sleep quality and quantity by sleep parameters, such as total sleep time - TST; duration of sleep stages - S1t, S2t, S3t, rapid eye movement - REMt; sleep onset latency - SL; wake after sleep onset - WASO, sleep efficiency - SE.
223657096|NCT02270294|OTHER|Thai traditional massage|Thai traditional massage treatment based on original Thai traditional massage at Wat Po was use in this study. The participants will be assigned to receive one time of Thai traditional massage one time. Thai traditional massage techniques consists of petrissage, friction, and passive stretching on head, neck, shoulders, arms, back and legs for 60 minutes.
223657097|NCT02270294|OTHER|No massage|The participants will be asked to lie down in relaxant position on bed without sleep for 60 minutes.
223657098|NCT04202042|OTHER|Psychological first aid|PFA responders (peer support workers) are trained to deliver 8 core actions: contact and engagement, safety and comfort, stabilization, information gathering, practical assistance, connection with social supports, information on coping, and linkage with collaborative services
223657099|NCT04202042|OTHER|Usual organisational intervention|Emergency intervention by workplace psychologist and limited therapeutic sessions with employee aid program
223657100|NCT03769610|OTHER|Inpatient Foley catheter|
223657101|NCT03769610|OTHER|Outpatient Foley catheter|
223657102|NCT05918471|DIETARY_SUPPLEMENT|Very Low Energy Diet with Liquid Supplementation|"The preoperative VLED protocol will utilize Optifast 900, a commercially available weight loss product sold by Nestlé Health Sciences. Optifast 900 is designed as a high-protein, low-carbohydrate, and low-fat meal replacement with complete micronutrient composition. Instructions for use are as follows:~1. Consume 4 Optifast 900 packets each day~2. Take 1 sachet of Optifast 900 once in the morning (AM), once at noon, once in the early evening (PM #1), and once later in the evening (PM #2) for three-weeks.~3. Mix 1 sachet with at least 300 mL (1 1⁄4 cups) of cold water. Shake well or blend in a blender."
223657103|NCT01598506|DRUG|Hydromorphone|Hydromorphone will be administered one time intrathecally to laboring patients to determine the ED50 for pain relief.
223657104|NCT00001027|DRUG|Pentamidine isethionate|
223657105|NCT03873792|DIAGNOSTIC_TEST|Physician diagnoses a history of asthma or eczema or allergic rhinitis or health pregnant women|Physician diagnoses a history of asthma or eczema or allergic rhinitis
223657106|NCT04249986|BEHAVIORAL|The Borg Rating of Perceived Exertion|Participants who satisfy the exclusion criteria and health assessment instrument are categorized in the lowest risk group for cardiac events and does not require medical screening for mild to moderate exercise per ACSM guidelines.
223657107|NCT02891135|OTHER|SLATE|Algorithm for collecting information required to determine if patient is eligible for immediate (same-day/same-visit) initiation of antiretroviral medications.
223657108|NCT05915156|OTHER|Post-acute home physiotherapy program|This health services research assessed the effects of a post-acute home physiotherapy program that was designed to provide physical rehabilitation services to older adults recently discharged from acute or post-acute care. Under this program, every patient was attended by a physiotherapy technologist within 48 hours of being discharged and received home physiotherapy for a minimum of three days per week for a maximum of eight weeks.
223657109|NCT06361836|BIOLOGICAL|SBT777101|Experimental treatment
223657110|NCT03452163|DEVICE|PMD-200|"the patients will be monitored by PMD-200. The technology consists of measurements of a number of nociception-related physiological parameters that corresponds with the autonomic nervous system's response to noxious stimuli, and using the company's proprietary algorithms, 'translating' these measurements into an index that represents the nociceptive response, the NoL™ (Nociception Level) Index. The NoL index is a relative index from 0 to 100, while 0 is no pain/nociception and 100 is extreme pain/nociception."
223657111|NCT03452163|DEVICE|EEG monitor|An EEG device will be connected to the patient and display the Spectral Edge Frequency (SEF) signals and values on the subject monitor.
223657112|NCT00855881|DRUG|tegafur-uracil|tegafur-uracil 1 cap, bid for 1 year
223657113|NCT02379663|DRUG|Rivaroxaban|Rivaroxaban was taken orally in a dosage of 10mg once daily
223657114|NCT02379663|DRUG|Enoxaparin|Enoxaparin was injected subcutaneously in a dosage of 40mg once daily
223657115|NCT02379663|OTHER|Normal saline|subcutaneous injection of 1 cc of normal saline once daily
223657116|NCT02321670|PROCEDURE|End-to-end|Excision of the stricture and end-to-end anastomosis of the urethra.
223657117|NCT02321670|PROCEDURE|Graft|Incision of stricture and grafting procedure with buccal mucosa where the corpus spongiosum is not divided
223657118|NCT03632486|OTHER|Bedside Ultrasound|"Patients enrolled in this study will undergo bedside ultrasound during their initial presentation to the emergency department. Ultrasound imaging protocols include the following:~* FAST Exam - Standard images will be obtained using the abdominal transducer. Images include the following: 1) sub-xyphoid 2)right upper quadrant (with right thorax) 3)left upper quadrant (with left thorax) and 4) suprapubic~* Right Upper Quadrant Exam - Standard images will be obtained using the abdominal transducer. Images include the following: 1) Long axis of the gallbladder 2) Transverse axis of the gallbladder fundus 3) Transverse axis of the gallbladder body and 4) Transverse axis of the gallbladder neck.~* Lung ultrasound to assess for pleural effusions and sonographic b lines."
223657119|NCT05741749|DEVICE|Socket Seal Abutment|Customized Healing Abutment
223657120|NCT03420352|DIAGNOSTIC_TEST|Thromboelastography|paired TEG analysis undertaken from participants with the two different needles
223657121|NCT04944199|OTHER|Physical Activity|Intervention group participants will be enrolled in a standardized step-based program to gradually increase their physical activity. Daily steps will be measured via a pedometer application on a smartphone or wearable device, with a gradual increase in the goal on a weekly basis, with a target intervention of around 4-6 weeks in total. The first week's step count will be used to calculate a baseline step count for the week. At the start of each week, the participants will be asked to increase their daily step counts by 1,000.
223657122|NCT04080167|BEHAVIORAL|InCharge Health mobile application|"The InCharge Health app features include: Daily reminders; Ability to customize content of message and time of day when the message comes; Symptom tracker to monitor daily pain and mood; 7-day streak that tracks daily adherence; Graphing adherence against pain symptoms; Communication feature allowing the patient to connect to the clinic and a health partner; Link to discussion forum where communication to other patients can occur; Education bank that provides information about SCD and hydroxyurea. Participants can delay daily push notifications. If hospitalized, participants may stop notifications. A special feature of the app is to set up a health partner, who may be a person the participant may choose from his/her contact list and who will receive notifications if it had been \<4 hours since not documenting the use of hydroxyurea. The app healthy partner will be encouraged to message the participant to remind him/her to take the medication."
223657123|NCT04080167|BEHAVIORAL|HU Toolbox mobile application|The HU Toolbox app includes algorithms for hydroxyurea use and is ready for immediate use on Apple and Android operating systems. In addition, it has the NHLBI guidelines adapted for pediatrics (guidelines/recommendations separated by age) and for adults (guidelines/ recommendations separated by organ system, laboratory, or physical exam finding). The HU Toolbox app includes the ability to search guidelines for key words and add notes. Algorithms are also included as PDF documents that can be printed out or emailed. Finally, a contact list of local SCD specialists and important contacts is included, so providers can easily contact SCD experts and expect an answer in 24 hours or less. The HU Toolbox app is easily updated with all data and resources stored on a cloud-based server that can provide instant up-to-date information to those using the app.
223657124|NCT02389153|BEHAVIORAL|collaborative care CHD|Over a time span of 6 months participants receive individualized treatment to reduce risk factors and improve quality of life, based on their preferences following a health plan, which they developed with their health coach.
223657125|NCT00520806|DRUG|Relaxin|Intravenous infusion for 48 h at 30 ug/kg/day
223657126|NCT00520806|DRUG|Placebo|Intravenous infusion for 48 h
223768442|NCT05961891|PROCEDURE|The Use of Composite Bone and Nail Bed Graft Combined With Cutaneous Flaps for Reconstruction of Finger Tip Amputations|"1. The amputated finger tip is cleaned and a composite graft including the nail bed and bone of distal phalanx is taken from the amputated part.~2. The bone of the amputated part is fixed to the remaining stump of the distal phalanx with an axial 21gauge needle or by a K-wire (0.8 mm).~3. The nail bed graft is sutured with 6-0 vicryl to the remaining nail bed.~4. A local or regional cutaneous flap is used to cover the volar aspect and tip of the distal phalanx bone e.g. V-Y advancement flap, thenar flap or cross finger flap .The flap should protrude beyond the tip, providing extra skin which is recontoured to a rounded tip.~5. The nail plate is inserted in the nail fold to prevent the formation of synechiae between the nail fold and the injured nail bed.~6. The finger is immobilized for two weeks in a below elbow dorsal slab.~7. Patients are followed up for 3 months. Postoperative complications and their management will be recorded."
223768443|NCT00976534|DRUG|AZD1386|90 mg, capsules, oral, during 3 weeks
223768444|NCT00976534|DRUG|Placebo|capsules, oral, during 3 weeks
223768445|NCT02653677|OTHER|intake of the specific kind of bread|To determine the glycemic and insulinemic responses (area-under the curve, AUCs), the satiety rate and the AUCs of free fatty acids (FFA), triglycerides and ghrelin after the ingestion of four types of breads, each containing 50g of available carbohydrates
224239656|NCT04112082|OTHER|Treatment as Usual|Treatment plan as part of regular care at the ADHD clinic, which may include pharmacological intervention, cognitive behavioral therapy (CBT), a combination of pharmacological intervention and CBT, or no intervention. Care will often include pharmacological intervention, with the specifics (e.g., type of medication, dosage) determined by psychiatrist recommendation considering such factors as response to previous interventions, participant characteristics, and practical constraints. Most pharmacological interventions will be stimulants (e.g., methylphenidate) with various release mechanisms. Each participant will receive an individualized dose titration and follow-up plan, including clinic visits as needed (generally 1-2 visits over the 10-week intervention period); interventions may be switched in accord with clinical judgment.
223768446|NCT05023694|OTHER|Video recordings|"In the first phase it will proceed to completion of the registration system by collecting data revivals and video recordings.~In a second phase, the video is displayed and analysis of the resuscitation performance will take place. We will identify and make a registration of incidents. At this point the observational descriptive analysis will take place.~Third phase: to develop preventive measures necessary to limit the number of incidents or to contain or minimize adverse effects resulting thereof: restructure and adapt the protocol."
223768447|NCT05023694|OTHER|Video recordings after corrective measures in adverse events|"Fourth phase: Training department staff on improvements to optimize performance times protocol using simulation.~Fifth stage: final implementation of corrective measures of adverse events during the performance resuscitation.~Sixth stage: successive evaluations of impact of corrective measures. With this evaluation, it will be held another descriptive case series. With the secondary formulate hypothesis after analysis of the errors, the protocol is optimized and measured if errors are minimized: analytical observational prospective cohort study."
223768448|NCT02553421|DEVICE|ivWatch Model 400|The ivWatch Model 400 is placed next to the subject's PIV site. All subjects will receive standard care for their IV sites including the normal routine assessments of the IV site by the bedside registered nurses.
223657127|NCT05634668|OTHER|Interviewing sheet|"1. . Interviewing sheet: It was designed by the researchers and used to obtain subjects' sociodemographic data; their age, menopausal age, gravidity, parity, BMI, residency, occupation, education level, hot flashes, sweating, and daily habits.~2. . Menopause specific quality of life questionnaire (MENQOL): MENQOL was designed by Hilditch and used to assess the presence of menopausal symptoms, its severity, and the degree to which they adversely affect women's life. It consisted of 29 items categorized into four domains~3. . Pittsburgh Sleep Quality Index (PSQI): The PSQI was a self-report scale consisting of 7 components and 19 questions. PSQI studies quality of sleep in the recent month."
223657128|NCT02019485|DRUG|Tapentadol Extended Release (ER) Tamper-Resistant Formulation (TRF)|Participants will receive a single dose of tapentadol ER TRF 100 mg tablet orally (by mouth) in treatment sequences AB and BA appropriately.
223657129|NCT02019485|DRUG|Tapentadol Prolonged-Release Formulation 2 (PR2)|Participants will receive a single dose of tapentadol PR2 100 mg tablet orally in treatment sequences AB and BA appropriately.
223657130|NCT03637439|OTHER|Ultrasound-guided Percutaneous Neuromodulation|It's a new intervention of sport physiotherapy. It´s an invasive technique. It is necessary an ultrasound
223657131|NCT03637439|OTHER|Ultrasound-guided Percutaneous Needle|Same protocol without electricity
224239657|NCT01909557|DRUG|Acetyl-L-carnitine|
224239658|NCT01909557|DRUG|placebo|
223657132|NCT00312195|DRUG|Buprenorphine transdermal patch|Buprenorphine transdermal patch 5, 10 or 20 mcg/h applied for 7-day wear.
223768449|NCT05146128|OTHER|Strengthening exercises|The participants had to perform specific exercices 3 times a week during 8 weeks
223768450|NCT00611702|PROCEDURE|Kidney biopsy|Kidney biopsy (recipients only) will be obtained for RT-PCR, microarray analyses and histology.
223768451|NCT02381080|DRUG|Ibrutinib|Ibrutinib capsule (at dose level of 140 or 420 or 560 mg) will be taken orally QD up to six, 28-days cycles.
223657133|NCT00312195|DRUG|Placebo to match BTDS|Placebo to match buprenorphine transdermal patch applied for 7-day wear.
223657134|NCT05739201|PROCEDURE|interscalene nerve block|Patients will receive interscalene nerve block, in which the patient will be in supine position with the head turned to the contralateral side using an ultrasound scan to identify the C5 and C6 nerve roots between the scalene muscles.15 ml of 0.25% Bupivacaine will be deposited between the C5 and C6 nerve roots, within the interscalene groove using a 22 gauge-regional block needle.
223657135|NCT05739201|PROCEDURE|anterior suprascapular nerve block|Patients will receive anterior suprascapular nerve block, in which the patient will be in supine position with the head turned to the contralateral side, using an ultrasound the nerve will be traced as it diverges from the brachial plexus to lie under the omohyoid muscle in the supraclavicular fossa. 15 ml of 0.25% Bupivacaine will be deposited lateral to the suprascapular nerve, underneath the omohyoid muscle using a 22 gauge-regional block needle.
223657136|NCT05739201|PROCEDURE|Peri-capsular nerve group block|Patients will receive PENG block, in which the patient will be in supine position and the patient's arm will be placed in external rotation and abducted at 45 degrees, using an ultrasound the humeral head, the tendon of the subscapularis muscle and the deltoid muscle over it will be defined, 15 ml of 0.25% Bupivacaine will be placed between the deltoid muscle and subscapularis tendon using a 22 gauge-regional block needle.
223768452|NCT02381080|DRUG|Erythromycin|Erythromycin 500 mg tablet will be taken orally TID (Part1 Cycle 1: on Days 5-10 and morning dose on Day 11; Part2 Cycle 1: on Days 5-17 and morning dose on Day 18).
223768453|NCT02381080|DRUG|Voriconazole|Voriconazole 200 mg tablet will be taken orally BD (Part1 Cycle 1: on Days 19-25; Part2 Cycle 1: on Days 5-17).
224239659|NCT05885165|BEHAVIORAL|Supervised team-based exercise|The intervention is a 12-week physical exercise program with five training sessions bi-weekly lasting approximately 1 hour each.
224239660|NCT05885165|BEHAVIORAL|Unsupervised exercise|The intervention is a 12-week physical exercise program with five training sessions bi-weekly lasting approximately 1 hour each. First two weeks are supervised, the following 10 weeks are unsupervised.
223657137|NCT02511106|DRUG|AZD9291 80 mg/40 mg|The initial dose of AZD9291 80 mg once daily can be reduced to 40 mg once daily.
223657138|NCT02511106|DRUG|Placebo AZD9291 80 mg/40 mg|The initial dose of Placebo AZD9291 80 mg once daily can be reduced to 40 mg once daily.
223657139|NCT02511106|DRUG|Open-label AZD9291 80 mg/40 mg|Eligible patients will be offered open-label osimertinib upon recurrence and in the absence of intervening systemic anti-cancer therapy.
223657140|NCT02885116|DEVICE|Nasal high flow (NHF) supplementation|use of NHF for 20 min/ 35 l/min, at the end of this period right heart catheterization
223657141|NCT02885116|DEVICE|oxygen supplementation|hypoxemic patients will use their normal oxygen supplementation durch right heart catheterization
223657142|NCT06425835|OTHER|VR device|"The VR device consists of a pair of VR glasses with a video previously chosen and installed. Patient preparation must be done before initiating the protocol.~The first step is to choose patient candidates for VR who are understanding and interested. Guardian approval is required; then it is necessary to explain the principle, the stages and the benefits of the care.~The intensity of pain is calculated according to the visual analog scale before, during the procedure and 30 minutes after as well as the max VAS during the procedure, the 'Children Fear Scale', the satisfaction score and any adverse effects are noted."
223657143|NCT00480467|DRUG|SAM-315|
223657144|NCT04379622|OTHER|Dietary intake, body composition, lifestyle, and CVD risk factors|Dietary intake, body composition, lifestyle, and CVD risk factors
223657145|NCT02578303|OTHER|Vascular flow measurement by PC-MRI|participants will undergo vascular flow measurement by PC-MRI at intra and extracranial levels
223657146|NCT05391490|GENETIC|KCAT19 T cells|Allogeneic, cord unit derived KCAT19 T cells
223657147|NCT04734561|OTHER|Inspiratory muscle training group|Participants will perform an inspiratory muscle training including warm-up, recovery between intervals and return to calm.
223657148|NCT04734561|OTHER|Inspiratory muscle training placebo group|Participants will perform an inspiratory muscle training including warm-up, recovery between intervals and return to calm.
223657149|NCT04734561|OTHER|Inspiratory + expiratory muscle training group|Participants will perform an inspiratory and expiratory muscle training including warm-up, recovery between intervals and return to calm.
223657150|NCT04734561|OTHER|Inspiratory + expiratory muscle training placebo group|Participants will perform an inspiratory and expiratory muscle training including warm-up, recovery between intervals and return to calm.
223657151|NCT00641368|BEHAVIORAL|R4Power Program|In the 10-lesson online R4Power Program, adolescents will learn cognitive skills (link between thoughts, feelings, and behaviors; thinking traps; challenging negative beliefs) and problem-solving skills (assertiveness; relaxation and distraction; overcoming procrastination; decision-making) in order to cope with stressful situations.
223657152|NCT00641368|OTHER|Waitlist Control|Adolescents in the waitlist control group will complete the R4Power program during the second year of the study.
223657153|NCT06332417|OTHER|Ba-Duan-Jin Based Deep Breathing Exercises|"Pressing Up to the Heavens: Deep inhales while raising arms, promoting lung expansion.~Drawing the Bow to Shoot the Eagle: Stretching exercises to improve flexibility and posture."
223657154|NCT06332417|OTHER|FET (Forced Expiratory Technique)|The forced expiratory technique sometimes referred to as a 'huff', is used to help force secretions (phlegm) up the throat so it can be removed via the mouth without the pain of coughing.
223657155|NCT00989872|DRUG|EDP-322|
223657156|NCT05322668|DEVICE|Prototypes (812A-v1), (812C-v1), (812D-v1) and (812F-v1)|"All the subjects will receive all the treatment in the same order.~On each hand 2 devices will be attributed as follow:~* Prototypes (812A-v1) will be applied on an area of the back of the patient's right hand, on healthy skin~* Prototypes (812C-v1) will be applied on an area of the back of the patient's right hand, on healthy skin~* Prototypes (812D-v1) will be applied on an area of the back of the patient's left hand, on healthy skin~* Prototypes (812F-v1) will be applied on an area of the back of the patient's left hand, on healthy skin"
223657157|NCT00488553|BEHAVIORAL|Questionnaire|Questions about cancer risk factors, medical history, and family history of cancer.
224239661|NCT04165148|DEVICE|Low Impact Laparoscopy|Low Impact Laparoscopy is a minimally invasive technique that combines low pressure insufflation (with the iFS AirSeal® system) and microcoelioscopy (with specific microtrocards and laparoscopic instruments).
223657158|NCT04106076|BIOLOGICAL|UCART123|Allogeneic engineered T-cells expressing anti-CD123 Chimeric Antigen Receptor
223657159|NCT04162860|DEVICE|Eso-SPONGE® device|Preemptive ENP therapy will be carried out with either an Eso-SPONGE® device system (Eso-SPONGE®, B. Braun Melsungen AG, Melsungen, Germany). Eso-SPONGE® consists of an open-pored polyurethane foam fitted to a gastric tube. Secretions are then continuously evacuated using a suction pump generating a negative pressure between 75 and 100 mmHg.
223657160|NCT02657408|DRUG|BI 1026706|
223657161|NCT02657408|DRUG|Placebo|
223657162|NCT00947167|DRUG|pertuzumab|840 mg, 420 mg, iv
223657163|NCT00947167|DRUG|erlotinib|150 mg, PO
223657164|NCT02801019|OTHER|E-poly|comparison of two different polyethylene plastic 0,04 mm at 3 months 0,06 at 2 years
223657165|NCT02801019|OTHER|ArComXL|comparison of two different polyethylene plastic 0,03 mm at 3 months 0,10 mm at 2 years
223657166|NCT00664001|DIETARY_SUPPLEMENT|Anti-oxidant supplementation|Daily dose of 1g L-ascorbic acid, 400 IU of alpha-tocopherol acetate, and 600mg of alpha-lipoic acid in sealed capsules as anti-oxidant supplementation.
223657167|NCT00664001|DIETARY_SUPPLEMENT|Matched placebo for anti-oxidant supplementation|Matched placebo for anti-oxidant supplementation
224239662|NCT04165148|DEVICE|conventional laparoscopy|conventional laparoscopy
223657168|NCT05398913|DRUG|Rimonabant|Rimonabant
223657169|NCT00863213|PROCEDURE|Atrial fibrillation ablation|"Atrial fibrillation ablation with radiofrequency, guided by 3D navigation map. Either 4mm or cooled tip-catheters will be used.~It will include, at least, pulmonary veins isolation; all other radiofrequency lines, including roof and mitral isthmus line, and complex fractioned electrograms ablation will be performed according to each Hospital protocol. Radiofrequency lines block will be tested."
223657170|NCT00863213|DRUG|Antiarrhythmic drug|Usual drug therapy for atrial fibrillation. In patients with structural heart disease, amiodarone is recommended, while flecainide plus diltiazem or beta-blockers are encouraged in patients without structural heart diseases.
223768454|NCT05355844|DRUG|Benzoyl peroxide|Benzoyl peroxide application in the incision area before surgery
224239663|NCT04165148|OTHER|Visual Analog Scale (VAS) for Pain|"The patient evaluates her pain using an VAS scale on arrival in the post-interventional surveillance room, then 30 minutes, 2 hours, 4 hours, 6 hours after leaving the operating roo, at the exit of post-interventional surveillance room and at the exit of the hospital.~The day after surgery, according to the usual practice, outpatients receive a telephone call from a Gynecologist. The assessment of their pain (with VAS scale) will be collected.~During the usual consultation at 1 month, the patient must evaluate her pain by means of an VAS."
223657171|NCT06464978|DEVICE|Stapler Reinforcement Patch|Participants in this group will receive gastrojejunostomy with the use of stapler reinforcement patches.
223657172|NCT06464978|DEVICE|Standard Stapler|Participants in this group will receive gastrojejunostomy with the use of Standard Stapler
223657173|NCT01693978|BEHAVIORAL|Prolonged Exposure Therapy|"Prolonged Exposure Therapy is considered the gold standard treatment for PTSD in psychiatry. It uses a cognitive-behavioral approach that repeatedly and systematically exposes patients to memories of their traumatic events to reduce fear and arousal. The PE therapy offered in this study will be based on procedures used by Foa and colleagues, described in their book-length treatment manual (Foa, Hembree, \& Rothbaum, 2007)."
223768455|NCT00192452|DRUG|MEDI-507|
223768456|NCT05318118|PROCEDURE|Medial Meniscus Arthroscopic Reconstruction Using the Fast Fix|Arthroscopic reconstruction of damaged Medial Meniscus using Fast-Fix (Smith \& Nephew) implant.
223768457|NCT05318118|PROCEDURE|Medial Meniscus Arthroscopic Reconstruction Using the Fiber Stitch|Arthroscopic reconstruction of damaged Medial Meniscus using Fiber-Stitch (Arthrex) implant
223768458|NCT05068440|DRUG|Zanubrutinib|administered orally as capsules
223768459|NCT05864274|DEVICE|Cognitive training application|Patients will participate with a cognitive training application and undergo neurocognitive testing during and after chemotherapy.
223768460|NCT06575374|DRUG|Letermovir|Given by mouth or intravenously
223768461|NCT04973488|OTHER|Therapeutic plasma exchange|The intervention is a combination between the procedure of Therapeutic plasma exchange and biological transfusion of convalescent plasma from donors that have have COVID-19
223768462|NCT00079352|DRUG|alvocidib|Given IV
223768463|NCT00079352|DRUG|gemcitabine hydrochloride|Given IV
223768464|NCT00079352|DRUG|irinotecan hydrochloride|Given IV
223768465|NCT02687906|DRUG|Vabomere|Vabomere (meropenem-vaborbactam) for IV injection
224239664|NCT04165148|OTHER|Saint-Antoine Pain Questionnaire (QDSA)|"The patient evaluates her pain using an QDSA questionnaire on arrival in the post-interventional surveillance room, then 30 minutes, 2 hours, 4 hours, 6 hours after leaving the operating roo, at the exit of post-interventional surveillance room and at the exit of the hospital.~The day after surgery, according to the usual practice, outpatients receive a telephone call from a Gynecologist. The assessment of their pain (with QDSA questionnaire) will be collected.~During the usual consultation at 1 month, the patient must evaluate her pain by means of an QDSA questionnaire."
224239665|NCT04165148|OTHER|post-operative questionnaire|The patient will fill in the antalgic intake record and the patient booklet for the collection of medical consumptions from her discharge from the hospital and during the month following the surgery.
224239666|NCT00983684|DEVICE|Intrabeam|A dose of 20 Gy at the surface of the applicator or 6 Gy at 1cm (in water) is prescribed by the radiation oncologist and delivered to the breast tissue. This takes approximately 30 minutes, depending on the size of the applicator.
223768466|NCT06152744|OTHER|Monitoring membrane lung function at different altitudes|The altitude in Beijing is 100m, while the altitude in Xining, Qinghai is 2600m. We will monitor the partial pressure of post-ML arterial oxygen in ECMO patients in these two locations and evaluate whether the normal values of membrane lung function are consistent in different altitudes.
223768467|NCT06151717|OTHER|Non-Interventional Study|Non-interventional study
223768468|NCT04127578|BIOLOGICAL|LY3884961|Participants will receive a single dose of LY3884961, administered intra-cisterna magna
224239667|NCT00983684|RADIATION|Post-operative radiotherapy|All patients randomised to receive conventional radiotherapy within this trial should be treated in accordance with a pre-specified policy. Dosage should only be applied to the breast; axillary, supra-clavicular and internal mammary nodes should not generally be irradiated by discrete fields.
223768469|NCT04127578|DRUG|Methylprednisolone|6 IV pulses administered as concomitant medication over 3 months
223768470|NCT04127578|DRUG|Sirolimus|Back-up treatment if corticosteroid is not well tolerated. Loading dose, followed by maintenance dose, followed by dose tapering; administered as concomitant medication
223768471|NCT03480737|DEVICE|Magstim Super Rapid2 stimulator, 10 Hz condition|10 Hz (2,000 pulses) at left DLPFC
223768472|NCT03480737|DEVICE|Magstim Super Rapid2 stimulator, Sham condition|sham
223768473|NCT03480737|DEVICE|Magstim Super Rapid2 stimulator, iTBS condition|50 Hz, iTBS (600 pulses) at left DLPFC
223768474|NCT05703178|BEHAVIORAL|Online Pain Coping Skills Training|The intervention is completed online, using a personal computer, tablet computer, or smartphone. It includes 8 interactive sessions, each of which teaches users a different pain coping skill. Participants are asked to practice these skills in their daily lives to manage pain and pain-related symptoms and problems. Each session takes 35 to 45 minutes to complete. Participants can take breaks during the sessions and review them at any time after completing them.
223768475|NCT05703178|OTHER|Education|Participants will receive their usual medical care and an educational booklet with information about Aromatase Inhibitors (AIs), side effects they cause including painful arthralgia, methods for managing arthralgia, and tips for talking with doctors about arthralgia and other AI side effects.
223768476|NCT02019849|DEVICE|Plasmafit® Total Hip Arthroplasty|
223768477|NCT06282926|DIAGNOSTIC_TEST|Echocardiography assessment|"Group 1 will have healthy adult volunteers recruited at the workplace following specific criteria to participate in the study. A research cardiac ultrasound protocol to assess the RV will be performed at two different visits, with a maximum interval of two weeks between them.~Group 2 will have ACHD patients with known moderate or severe pulmonary regurgitation after ToF repair, following specific criteria to participate in the study. This group of patients will be studied in two separate visits. The patients will be recruited during the first visit when attending to an existing hospital appointment for ACHD CMR. A research cardiac ultrasound protocol to assess the RV will be performed on the same day, either before or after the CMR. For all patients who will have a second follow-up visit at the ACHD outpatient clinic within a maximum interval of one year, the same research protocol will be performed, in addition to the usual cardiac ultrasound."
223768478|NCT06412107|OTHER|True acupressure|Participants will receive a 7-week true self-acupressure practice and a 12-week follow-up.
223768479|NCT06412107|OTHER|Sham acupressure|Participants will receive a 7-week sham self-acupressure practice and a 12-week follow-up.
223768480|NCT06412107|OTHER|Usual care|Routine methods of treatment and care along with an updated education booklet.
223768481|NCT04197713|DRUG|Adavosertib|Given PO
223768482|NCT04197713|DRUG|Olaparib|Given PO
223657174|NCT01693978|BEHAVIORAL|Voucher-Based Reinforcement|Those in the PE+CM condition will also be able to earn voucher-based incentives for each therapy session that they attend as scheduled, with a maximum of $480 for full adherence to all sessions. Specifically, participants will earn $30 for attending Session 1, $40 for attending Session 2, $50 for attending Session 3, and $60 for attending Sessions 4 through 9. There will be no payment for Sessions 10 through 12. Because it is very important that participants attend sessions on schedule, voucher values will be reset starting from $30 if participants miss a scheduled session. Vouchers can be exchanged for goods and services in the community (e.g., gift cards to local retailers).
223657175|NCT04286906|OTHER|Questionnaire|MultiDimensional Profile (MDP), Anxiety-Depression Hospital Scale (HADs), Nijmegen
223657176|NCT02471326|BIOLOGICAL|VRC-HIVMAB060-00-AB (VRC01)|A potent HIV-specific monoclonal antibody
223657177|NCT05613062|DRUG|Modified Huang-Lian-Jie-Du Decoction (MHLJDD)|Chinese medicine granules for 12 weeks twice daily
223657178|NCT05613062|DRUG|Placebo|Placebo granules for 12 weeks twice daily
223657179|NCT02806583|OTHER|structured support groups|Telephone-based Support Groups, information booklet and telephone-based preparatory meeting prior to the telephone-based support groups
223657180|NCT03866876|OTHER|Eucapnic pH|Collection of Biological marker (proposed by Racinet): eucapnic pH
223657181|NCT06424314|DIAGNOSTIC_TEST|Monitoring of respiratory mechanics parameters|Physiologic recording instrumentation measure maximal transdiaphragmatic pressure，twitch diaphragmatic pressure and maximal diaphragmatic electromyography
223657182|NCT05805319|OTHER|increasing total fiber intake|Patients in the intervention arm will complete a dietary survey and be counselled on increasing their total fiber intake.
223657183|NCT03162367|BIOLOGICAL|Autologous epidermal cell suspension|First skin samples taken from normal skin by 4mm punch will be send to laboratory for preparation of epidermal cell suspension and this suspension transfer to one area of second degree burn
223657184|NCT03162367|DRUG|Silver sulfadiazine ointment|the area with second degree burn dresses by silver sulfadiazine ointment and dressing change each 12 hour till 10 day
223657185|NCT00324961|DRUG|adefovir dipivoxil tablets|adefovir dipivoxil once daily 10 mg orally
223657186|NCT04193644|BEHAVIORAL|Mindfulness and Self-Compassion focussed exercises during walking training|Mindfulness and Self-Compassion focussed exercises during walking training with moderate intensity
223657187|NCT04193644|BEHAVIORAL|Walking training|Walking training with moderate intensity
223657188|NCT00597324|PROCEDURE|coronary catheterisation|Coronary angiography which may be followed by ad hoc percutaneous intervention if indicated clinically
223657189|NCT00344487|DRUG|Lopinavir/Ritonavir|Dosing of Kaletra will be per package insert and BID with food. A three-drug standard of care antiretroviral regimen will be used in this study. Subjects will enter the study already on an effective, virally-suppressive treatment regimen. One of these drugs will be substituted for Lopinavir/ritonavir (Kaletra®). However, the nucleoside/nucleotide backbone drugs that the subject is already on will remain the same.
224239668|NCT04048005|DIAGNOSTIC_TEST|Fractional flow reserve|
224239669|NCT00913705|DRUG|Neoadjuvant chemotherapy (taxol and carboplatin)|Taxol: 200mg/m2 infusion over 3 hours; Carboplatin: AUC= 6 at the end of the Taxol infusion. Administration of 3 cycles at 21-day intervals. Prior to surgery.
223657190|NCT01839669|DEVICE|Foot Orthoses Only|patients wear foot orthoses as a treatment condition - no further therapy
223657191|NCT01839669|PROCEDURE|Foot Orthoses and Eccentric Exercise|patients wear foot orthoses and they perform an additional home-based eccentric training program for the M. tibialis posterior
224239670|NCT00913705|DRUG|Adjuvant chemotherapy (taxol and carboplatin)|Taxol: 200mg/m2 infusion over 3 hours; Carboplatin: AUC= 6 at the end of the Taxol infusion. Administration of 3 cycles at 21 days interval. Post-surgery
223657192|NCT01839669|DEVICE|Sham Foot Orthoses|patient wear sham foot orthoses (control condition)
223657193|NCT05768607|PROCEDURE|Quality of Life QUESTIONNAIRE (SF36)|Units of a scale of the patients will be compared pre and postoperatively by using SF36
223657194|NCT05768607|PROCEDURE|INCONTINENCE IMPACT QUESTIONNAIRE (IIQ-7)|Units of a scale of the patients will be compared pre and postoperatively by using IIQ-7
223657195|NCT05768607|PROCEDURE|UROGENITAL DISTRESS INVENTORY (UDI - 6)|Units of a scale of the patients will be compared pre and postoperatively by using UDI - 6
223657196|NCT01148992|DRUG|Lofexidine|0.8mg alone and concurrent with IV cocaine infusions of 20 mg and 40 mg
224239671|NCT00913705|PROCEDURE|Surgery|Surgery
224239672|NCT01288131|DRUG|Cyclosporine combine with mycophenolate mofetil|Cyclosporine 100 mg BID and mycophenolate mofetil 750 mg BID for 24 weeks
224239673|NCT01288131|DRUG|Cyclophosphamide + pred|Cyclophosphamide 100 mg QD combine with prednisolon 1.0 mg/kg/day
223657197|NCT01148992|DRUG|Placebo|0mg
223657198|NCT03494907|DRUG|Seltorexant|Participants will be administered oral dose of seltorexant over-encapsulated tablets on Day 1.
223657199|NCT03494907|OTHER|Placebo Matched to Seltorexant|Participants will be administered matching placebo to seltorexant tablets on Day 1.
223657200|NCT03494907|OTHER|Placebo Matched to Moxifloxacin|Participants will be administered oral dose of moxifloxacin placebo tablet on Day 1.
223657201|NCT03494907|DRUG|Moxifloxacin Dose 1|Participants will be administered oral dose 1 of moxifloxacin on Day 1.
223657202|NCT05843669|DRUG|Guafenesin tablets|During the 12-week period of receiving treatment, patient participants will take Mucinex® 12h, 2 x 600 mg (1200 mg total) twice daily.
223657203|NCT03617016|DRUG|Domperidone|Participants will receive domperidone tablets orally.
223657204|NCT03617016|DRUG|Placebo|Participants will receive matching placebo to domperidone tablets orally.
223657205|NCT05300919|OTHER|Measurement based care|Measurement-based care based on arm.
223657206|NCT06638216|OTHER|Geriatric Assessment|"Frailty is assessed using the G8 questionnaire.~Secondary objectives include the assessment of quality of life and financial burden (EORTC-QLQ C30+ H\&N43), swallowing function, cardiopulmonary resilience (6-minute walk test) and the patient's wishes regarding a prehabilitation program. Epidemiological and disease-related data is also collected."
223657207|NCT05065424|DRUG|IV Atropine and Fentanyl Premedication Arm|"Prior to the LISA procedure, the blinded bedside nurse will infuse IV Atropine, labelled as Atropine/Placebo, over 1 minute, followed by IV fentanyl, labelled as Fentanyl/Placebo, over 20 minutes in the presence of blinded respiratory therapist and primary team provider.~After medication infusion, a primary team member will perform Less Invasive Surfactant Administration procedure. Infant vital signs, cerebral Near Infrared Spectroscopy values, pain scores will be monitored and recorded during and for 12 hours after the procedure. Level of respiratory support, oxygen requirement and subsequent need for intubation for 24 hours after the procedure will be obtained from the electronic medical record."
223657208|NCT05065424|DRUG|IV Normal Saline Placebo Arm|"Prior to the Less Invasive Surfactant Administration procedure, the blinded bedside nurse will infuse IV Normal Saline, labelled as Atropine/Placebo, over 1 minute, followed by a second infusion of IV Normal Saline, labelled as Fentanyl/Placebo, over 20 minutes in the presence of blinded respiratory therapist and primary team provider.~After Normal Saline infusion, primary team member will perform Less Invasive Surfactant Administration procedure. Infant vital signs, cerebral Near Infrared Spectroscopy values, pain scores will be monitored and recorded during and for 12 hours after the procedure. Level of respiratory support, oxygen requirement and subsequent need for intubation for 24 hours after the procedure will be obtained from the electronic medical record."
223657209|NCT04616677|DRUG|JNJ-42847922|JNJ-42847922 tablet will be administered orally.
223657210|NCT04463108|OTHER|No Intervention|No intervention will be administered as a part of this study. Both retrospective and prospective data will be collected. The retrospective data will be collected through medical chart review.
224239674|NCT03814239|OTHER|protocol|In patients of Group Protocol , basal crystalloid infusion was started at 4 ml/kg/h right after general anesthesia induction and intubation. ClearSight System (Edwards Lifesciences Cop, Irvine, CA, USA) was used to measure stroke volume variation and cardiac output, continuously and noninvasively through finger- cuffed technology. If SVV was \>15% rapid crystalloid bolus of 10ml/kg or 4ml/kg colloid bolus were administered until it reached a value of ≤15%. After two consecutive fluid boluses SVV remained \>15%, administration of noradrenaline infusion was considered.
224239675|NCT01400022|OTHER|UVA1 phototherapy|The UVA1-phototherapy is conducted 4 times per week over a period of 3 months. A UVA1-irradiation device of the company Sellamed, Gevelsberg (Germany) is used. The radiation intensity is 24 mW/cm ². The distance between radiation source and irradiation area is approximately 25 cm. Over five sessions, the UVA1 dose is increased slowly, starting with 10 J/cm ² in the first, 20 J/cm ² in the second and 30 J/cm ² in the third, 40 J/cm ² in the fourth, and from the fifth session 50 J/cm ². Additionally, a topical treatment with vaseline album once daily can be applied after irradiation (not before irradiation).
223657211|NCT04950816|BEHAVIORAL|tailored MBI (.b)|The session will include brief didactic presentations, videos, and mindfulness practice followed by inquiry. We anticipate that sessions will take place twice a week. Sessions will be held on site at the Covenant House Texas (CHT) shelter in a quiet, designated learning space to ease access to sessions for the participants and to assure access to shelter staff (e.g., social workers and case managers) and services (e.g., food and shelter). CHT has onsite, weekday clinical and mental health care and established protocols for accessing needed resources 24/7. Selection criteria for the interventionist include maintaining a personal mindfulness practice for at least two years, trained in .b, and prior experience working with high-risk youth. The interventionist will receive additional training in Trauma-Informed Care as well as study procedures.
223657212|NCT04950816|BEHAVIORAL|attention control condition|Participants will receive no training in MBI or meditation. Topics covered may include physical activity, nutrition, managing weight, understanding adolescence, personal care, avoiding tobacco, alcohol, and drugs though this will be finalized in YR-1 with the HYWG and advisory panel. The HT program will be led by a positive adult instructor with training in health education or a related field and experience working with YEH.
223657213|NCT05710627|DEVICE|TENEX|Use of TENEX device for sectioning of the gluteus medius and ITB tendons.
223657214|NCT03646396|DRUG|Sofosbuvir-daclatasvir|Sofosbuvir-daclatasvir for 3 months
223657215|NCT05518773|OTHER|Observational|Observational
223657216|NCT04373317|DRUG|Pimavanserin|Fixed-dose Pimavanserin - Pimavanserin is a new antipsychotic agent, and pure 5HT-2A inverse agonist, that was approved by the FDA recently (2016) for the treatment of PDP. It is the only FDA-approved medication for PDP, but is still not the first-line AP used in PD. All participants assigned to pimavanserin will receive the FDA-approved dose of 34 mg (equivalent to 40 mg pimavanserin tartrate) daily without titration up or down; however, because pimavanserin is blinded to quetiapine, participants will undergo sham titration based on tolerability (i.e., overall adverse event profile) and efficacy (i.e., improvement in severity of psychosis).
223657217|NCT04373317|DRUG|Quetiapine|"Flexible-dose Quetiapine - Quetiapine, which is a mixed serotonin and dopamine receptor antagonist, is by far the most commonly used AP for PDP. However, scientific evidence for the efficacy of quetiapine in PDP is almost non-existent as most of the studies were underpowered, had high drop-out rates, and possibly underdosed quetiapine. Quetiapine immediate and extended release will be titrated as shown:~Baseline visit Quetiapine: 25 mg IR QHS, All participants must be up-titrated to 50 mg/day~Week 1 call Quetiapine: 50 mg XR QHS, Up-titration to 50 mg~Week 3 visit Quetiapine: 100 mg XR QHS, Up-titration as appropriate~Week 5 visit Quetiapine: 150 mg XR QHS, Up- or down-titration as appropriate~Week 6 call Quetiapine: 200 mg XR QHS, Up- or down-titration as appropriate"
223657218|NCT05389995|DRUG|Potassium citrate|7 days potassium citrate followed by 24 hour urine collection
223657219|NCT05389995|DRUG|Crystal light|7 days crystal light followed by 24 hour urine collection
223657220|NCT05389995|DRUG|Potassium citrate + crystal light|7 days potassium citrate + crystal light followed by 24 hour urine collection
223657221|NCT04760769|DRUG|Tavapadon|Participants will receive Tavapadon at a dose of (5 to 15) mg QD, orally during a 58-week treatment period.
224239676|NCT01400022|OTHER|Cortisone|Clobetasol propionate (0.05%) in white vaseline is applied thinly once daily. The duration of treatment is 3 months.
223657224|NCT03954574|DIAGNOSTIC_TEST|assessment of pulmonary hemodynamics during exercise by right heart catheterization|all patients undergo right heart catheterization during exercise due to clinical reasons. Results of this and other Routine clinical tests will be included in the registry
223657225|NCT05040217|GENETIC|AAV2-BDNF Gene Therapy|AAV2-BDNF is a genetically engineered adeno-associated virus serotype 2 (AAV-2) that expresses the human BDNF cDNA.
223657226|NCT05040217|BIOLOGICAL|AAV2-BDNF Gene Therapy|Gene therapy is a biological therapy delivering the BDNF gene to the brain
223657230|NCT03795870|DIETARY_SUPPLEMENT|Polymeric Tube Feeds|Polymeric tube feeds will be given to HEN patients to assess the percentage of goal calories provided in comparison with blenderized tube feeds
223657231|NCT03795870|DIETARY_SUPPLEMENT|Blenderized Tube Feeds|Blenderized tube feeds will be given to HEN patients to assess the percentage of goal calories provided in comparison with polymeric tube feeds
223657232|NCT03963258|DEVICE|whole-body vibration training|The subjects were exposed to alternating vertical sinusoidal vibration using a Galileo tilting table system.The frequency of WBV ranged from 5 to 20 Hz, and the amplitude ranged from 1 to 6 mm.The subjects were kneeled on the ground, both shoulders flexed at 90 degrees, elbows slightly flexed, their trunk bent in this position and contacted on the platform board with their palms equidistant from the midpoint of the board
223657233|NCT03963258|OTHER|conventional upper limb training|compensatory techniques for activities of daily living, UE strength, therapist-guided techniques for facilitating normal UE movement patterns,and range of motion and traditional positioning
223657234|NCT04059159|DEVICE|Connected Catheter|Patients will use the Connected Catheter to empty the bladder during the course of treatment.
223657235|NCT00042003|DRUG|decitabine (5-aza-2'deoxycytidine)|
223657236|NCT04571697|DRUG|Methotrexate|No intervention or treatment will be administered as part of this study. Data of participants with first claim for a methotrexate in the patient's history are included.
223657237|NCT04571697|DRUG|Anti-TNF|No intervention or treatment will be administered as part of this study. Data of participants with first claim for an anti-TNF in the patient's history are included. Anti-TNF includes infliximab, golimumab, etanercept, certolizumab, and adalimumab.
223657238|NCT04342325|BIOLOGICAL|infusion of ADR-001 (Mesenchymal stem cell)|Once or twice with two week interval at a dose of 100 x 10 \^ 6 cells.
223657239|NCT00000716|DRUG|Zidovudine|
223657240|NCT04145661|DEVICE|Hearing aids programmed conventionally.|All participants will wear their hearing aids programmed in this way for around six weeks.
223657241|NCT04145661|DEVICE|Hearing aids programmed with compression activated.|All participants will wear their hearing aids programmed in this way for around six weeks.
223657242|NCT00567814|DRUG|Metyrapone|Twice daily
223657243|NCT00567814|DRUG|Oxazepam|Twice Daily
223657244|NCT00567814|DRUG|Placebo|Twice daily
223657245|NCT03369262|DRUG|OBE022|Oral
223657246|NCT03369262|DRUG|Placebos|Oral
223657247|NCT03369262|DRUG|Atosiban|I.V.
223657248|NCT01459497|RADIATION|Radiation Therapy|Image-Guided Radiation Therapy (IGRT)60 Gy in 15 fractions in 3 weeks
223657249|NCT01459497|RADIATION|Conventional radiation|Conventional radiation 60-66 Gy in 30-33 fractions in 6-7 weeks
223657250|NCT00135343|DRUG|Atazanvir/ritonavir + efavirenz|Capsules (ATV and RTV) Tablets (EFV), Oral, ATV 300 mg + RTV 100 mg + EFV 600 mg, Once daily, 48 weeks.
223657251|NCT00135343|DRUG|Atazanvir/ritonavir + efavirenz|Capsules (ATV and RTV) Tablets (EFV), Oral ATV 400 mg + RTV 100 mg + EFV 600 mg, Once daily, 48 weeks.
223657252|NCT01749189|DIETARY_SUPPLEMENT|Blend|22 grams of protein/day
223657253|NCT01749189|DIETARY_SUPPLEMENT|Whey|22 grams of protein/day
223657254|NCT01749189|DIETARY_SUPPLEMENT|Placebo|22 grams of carbohydrate/day
223657255|NCT02853058|RADIATION|normal PI|measurement of the PI in the uterine artery for pregnant women during labor, expressed in MoM
223657256|NCT02853058|RADIATION|pathological PI|measurement of the PI in the uterine artery for pregnant women during labor, expressed in MoM
223657257|NCT01247272|DRUG|Fluoxetine Hydrochloride|90 mg Capsules
223657258|NCT01247272|DRUG|PROZAC WEEKLY®|90 mg Capsules
223657259|NCT02781259|PROCEDURE|Axillary lymph node dissection|Lymph node dissection is performed in axillary lymph node level I and II. In case of palpable nodes in level II, additional lymph node dissection in level III is done.
223657260|NCT02781259|DRUG|Indocyanine green|10cc of 20μg/mL indocyanine green is injected at the nipple-areola complex before surgery
223657261|NCT02781259|DEVICE|Imaging devices|Near-infrared fluorescence is collected by imaging lenses and digital camera.
223657262|NCT06299332|DEVICE|Device treatment|20 heterosexual males clinically diagnosed with Erectile Dysfunction will receive 6 weekly treatments with the Forma Applicator according to the study protocol and will return for two follow up visits 1- and 3-months post treatment. Two further telephone feedback checks will be carried out 6 months and 12 months following the last treatment visit
223657263|NCT05019911|DEVICE|Polysomnography|In the cross-sectional part, the group of patients with COPD alone and the group of patients with COPD combined with sleep apnea hypopnea syndrome will be monitored by traditional sleep monitoring equipment (polysomnography) for vital signs in order to diagnose COPD combined with sleep apnea hypopnea syndrome.
223657264|NCT05019911|DEVICE|Millimeter wave radar equipment|In the cross-sectional part, the group of patients with COPD alone and the group of patients with COPD combined with sleep apnea hypopnea syndrome will be monitored by millimeter wave radar equipment for vital signs in order to diagnose COPD combined with sleep apnea hypopnea syndrome. In the cohort part, both groups of patients will be continuously monitored by millimeter wave radar equipment for vital signs for months in order to establish a model to predict acute exacerbations of COPD combined with sleep apnea hypopnea syndrome.
223657265|NCT01436929|DRUG|Silymarin|Silymarin 140mg 1tab bid for 8 weeks
223657266|NCT01436929|DRUG|Placebo|Placebo 1tab bid
223657267|NCT03815266|DIAGNOSTIC_TEST|transcranial Direct Current Stimulation (tDCS)|"transcranial Direct Current Stimulation (tDCS) is device which consist in setting up an electrode on the skull of the patient to deliver the low intensity current.~Patient will have transcranial Direct Current Stimulation (tDCS) at each session and at the same time of Computerized Mirror Therapy (CMT)."
223657268|NCT03815266|DIAGNOSTIC_TEST|Computerized Mirror Therapy (CMT)|Computerized Mirror Therapy (CMT) will be realizing by the device Intensive Visual Simulation 3 (IVS3). Patient will have Computerized Mirror Therapy (CMT) at each session and at the same time of transcranial Direct Current Stimulation (tDCS).
223657269|NCT03815266|DIAGNOSTIC_TEST|Tolerance Assessment Questionnaire|The Tolerance Assessment Questionnaire will be completed at the end of each session.
223657270|NCT03815266|DIAGNOSTIC_TEST|Ashworth's scale|Ashworth's scale evaluates the resistance to stretching. This test will be completed before the start of the program, at the end of the program and one month after.
223657271|NCT03815266|DIAGNOSTIC_TEST|Frenchay arm test|"Frenchay arm test evaluates your abilities with the affected hand to perform several actions.~This test will be completed before the start of the program, at the end of the program and one month after."
223657272|NCT03815266|DIAGNOSTIC_TEST|Abilhand questionnaire|"Abilhand questionnaire evaluates your abilities to perform several activities in the daily life with your arm affected.~This test will be completed before the start of the program, at the end of the program and one month after."
223657273|NCT03815266|DIAGNOSTIC_TEST|Fugl-Meyer test|"Fugl-Meyer test evaluates your ability to perform different movements with all the joints of your arm affected.~This test will be completed before the start of the program, at the end of the program and one month after."
223657274|NCT03815266|DIAGNOSTIC_TEST|Goal Attainment Scaling (GAS)|"Goal Attainment Scaling (GAS) sets therapeutic goals with the patient before the start of the program.~These goals will be checked at the end of the program and one month after."
223657275|NCT00052117|DRUG|capravirine|
223657276|NCT00052117|DRUG|Kaletra|
223657277|NCT00052117|DRUG|2 NRTIs|
223657278|NCT04240548|RADIATION|Regional Nodal Irradiation|
223657279|NCT01349400|OTHER|Watchful waiting|Watchful waiting means the observation of the hernia. The patient is informed about signs of deterioration or incarceration. The hernia is controlled clinically on defined follow-up visits.
223657280|NCT01349400|PROCEDURE|Hernia repair|"Open or laparoscopic hernia repair with mesh (non-absorbable or partly-absorbable alloplastic material) or with direct suture repair. For hernias measuring ≥ 3 cm mesh repair is recommended. A wide overlap of the mesh over the fascia margin on each side has to be provided.~These are all standard techniques in incisional hernia repair."
223657281|NCT04030273|DIAGNOSTIC_TEST|Diagnostic hysteroscopy|"Diagnostic hysteroscopy performed in outpatient setting, using no touch vaginoscopy technique with a 2.9 mm 30-degree rigid hysteroscope with a single inflow sheet using normal saline as distention media."
223657282|NCT05779189|BEHAVIORAL|Game-based virtual reality (Game)|Besides reading the health education flier, they also need to trained with the game-based virtual reality in Biodex Medical Systems, which is a machine, includes 4 games: Catch Game, boating, Ball Maze, and Word Search. And all of the games are balance control games. The games were implemented in person for 30 minutes one time, total is 16 times (once to twice day a week).
223657283|NCT05779189|BEHAVIORAL|Conventional health education|The health education flier was made refer to medical institutions, e.g., hospitals or clinics, the video of balance exercise was collected from the internet. Participants were assigned to read the health education flier, and follow suit the video of balance exercise at home of their free will.
223657284|NCT03530124|BIOLOGICAL|PCV13|Advisory Committee on Immunization Practices (ACIP) Recommended vaccine
223657285|NCT03530124|BIOLOGICAL|DTaP|ACIP Recommended vaccine
223657286|NCT03530124|BIOLOGICAL|HBV|ACIP Recommended vaccine
223657287|NCT03530124|BIOLOGICAL|IPV|ACIP Recommended vaccine
223768483|NCT06328894|DEVICE|Nasogastric Tube Feeding|Within 4 hours after admission, the placement of the feeding tube was conducted by professional medical staffs and after intubation, the tube was secured to the patient\&#39;s cheek with medical tape. The feeding was conducted once every 3-4 hours, with 200-300ml each time. The total feeding volume was determined based on daily requirements. The feeding content was formulated by the nutritionists based on the patient\&#39;s condition and relevant guidelines to reach the energy demand as 20-25 kcal/kg/day and protein supplementation of 1.2-2.0 g/kg/day for both two groups. For patients with limited tube feeding compliance, we made appropriate adjustments to ensure that they were not at risk of severe malnutrition as much as possible.
223768484|NCT06328894|DEVICE|Intermittent Oro-esophageal Tube Feeding|Before each feeding, inside and outside of the tube was cleaned with water. During feeding, the patient should maintain a semi-reclining or sitting position with mouth opened, and the tube was inserted slowly and smoothly into the upper part of the esophagus by medical staffs while the appropriate depth of intubation was checked with the calibration markings on the tube wall. The distance from the incisors to the head part of the tube should be between 22-25 cm. However, the specific depth should be evaluated based on patients' feedback and adjusted accordingly. After insertion, the tail part of the tube should be put into a container full of water and the absence of continuous bubbles indicated a successful intubation. Then, the feeding was to be conducted three times per day with 50 ml per minute and 400-600ml for each feeding.
223768485|NCT06328894|BEHAVIORAL|comprehensive rehabilitation therapy|"Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training.~Pulmonary function training, including standing training, cough training, and diaphragm muscle training."
223768486|NCT01330758|DRUG|AZD8931|40 mg AZD8931 wet granulation tablet formulation
223768487|NCT01330758|DRUG|AZD8931|40 mg AZD8931 roller compacted tablet formulation
223657288|NCT03530124|BIOLOGICAL|Hib|ACIP Recommended vaccine
223657289|NCT05343624|DEVICE|continuous glucose monitoring|Use of continuous glucose monitoring in inpatient and ICU settings
223657290|NCT04469335|DEVICE|mobile neurofeedback|"to maximize usability and effectiveness, we would like to conduct a study that regulates theta/beta ratio using mobile app-based Neurofeedback Training Equipment (OmniCNS).~The actual Neurofeedback training allows you to download and use the omnifit brain\_Game, an application with an audio guide. After the pre-assessment, the researcher will provide guidance to subjects and carers on how to use the application, and demonstrate how to use it in practice. For 2 weeks, 4 weeks and 6 weeks, phone calls are conducted to check whether they are used or not and for any inconvenience. After 12 weeks of Neurofeedback training, the device is returned and post-evaluated.~The application is equipped with four types of games and is instructed to use the three-day-a-week application. For Neurofeedback attention and cognitive training, use a headset with left and right frontal lobe 2 channel-EEG sensors to perform the game through feedback to see if it is concentrating well."
223657291|NCT04469335|DEVICE|Sham mobile neurofeedback|"It uses the sham devices and programs as the Neurofeedback, but it is not usually possible to obtain the expected effects of the Neurofeedback by providing random feedback regardless of actual brain waves.~In case of Sham control group, parental education is conducted the same for each clinical evaluation, and in case of Sham control group, actual Neurofeedback is applied if patients and parents want it after the end of the study."
223657292|NCT04469335|DEVICE|medication + mobile neurofeedback|The mobile needback is applied to patients who are taking methylphenidate or atomoxetine, which is a standard ADHD treatment, but have not been remissioned with more than 4 points of CGI-S.
224239677|NCT05682118|PROCEDURE|roadmap|"FFR and iFR tests using the roadmap system, or FFR and iFR tests without using the roadmap system.~Pressure wire into guiding catheter The equalization of the pressure wire with the aortic pressure(after placing the pressure wire on the tip of the guiding catheter and removal of contrast media by saline flushing) and the placement of the pressure wire on the distal of the blood vessel to measure iFR. After iFR measurement, the pressure wire was pulled back into the tip of the guiding catheter to check the presence of pressure drift. A final Pd/Pa between 0.97 and 1.03 is considered acceptable. Following confirming no pressure drift, a mode change will be done from iFR to FFR, and then a re-check of the time between the equalization of the pressure wire with the aortic pressure will be planned. In all lesions, FFR value were measured with hyperemia, achieved by intracoronary (IC) bolus injection of nicorandil (Sigmart®; Chugai Pharmaceutical Co., Ltd., Tokyo, Japan) 2 mg."
223657293|NCT04469335|DEVICE|medication + Sham mobile neurofeedback|The sham mobile needback is applied to patients who are taking methylphenidate or atomoxetine, which is a standard ADHD treatment, but have not been remissioned with more than 4 points of CGI-S.
223657294|NCT01267214|DRUG|Sodium Hyaluronate (Hyalgan)|1% Sodium Hyaluronate in prefilled syringe
223657295|NCT01267214|PROCEDURE|Osteotomy alone|no injection
223657296|NCT01145976|DRUG|Cy-ATG|"Hydration with 0.45% NaCl at 6 liters/24 hours will be started on day -5. Cy 50 mg/kg in D5W 200 ml i.v. over 1-2 hours on days -5 to -2 by pump through a central venous catheter.~Thymoglobuline 3 mg/kg in N/S 500-800 mL (less than 0.5 mg/mL) or lymphoglobuline 15 mg/kg in N/S 500-800 mL (less than 2 mg/mL) iv daily at 8 am on days -4 to -2"
223657297|NCT01145976|DRUG|Flu-ATG|Fludarabine 30 mg/m2 will be infused intravenously over 30 minutes in D5W 100 ml for 6 consecutive days (days -7 to -2) Thymoglobuline 3 mg/kg in N/S 500-800 mL (less than 0.5 mg/mL) or lymphoglobuline 15 mg/kg in N/S 500-800 mL (less than 2 mg/mL) iv daily at 8 am on days -4 to -2
223657298|NCT03061396|OTHER|Matching points PC6+CV12|Choose both Neiguan(PC6) and Zhongwan point(CV12).The needles are connected through a electro-acupuncture apparatus, the positive poles are linked to the needle, and the reference poles are located near the acupoint about 1cm with a electrode.Frequency is 2/10 hertz,the intensity of stimulation is adjusted according to the patient's tolerance, and the electric current is less than 10 milliampere. And plus 5-hydroxytryptamine-3 (5-HT3) antagonist (Ramosetron, Tropisetron，Granisetron or Ondansetron) and dexamethasone.
223657299|NCT03061396|OTHER|Single points PC6|Choose Neiguan(PC6)of double upper limb.The needles are connected through a electro-acupuncture apparatus, the positive poles are linked to the needle, and the reference poles are located near the acupoint about 1cm with a electrode.Frequency is 2/10 hertz,the intensity of stimulation is adjusted according to the patient's tolerance, and the electric current is less than 10 milliampere. And plus 5-hydroxytryptamine-3 (5-HT3) antagonist (Ramosetron, Tropisetron，Granisetron or Ondansetron) and dexamethasone.
223657300|NCT02591225|DRUG|Dabigatranetexilate|After inclusion of the subjects with LA thrombus, they are treated according to the randomization either with Dabigatran (150 mg bid) or Phenprocoumon (INR adjusted once) for the treatment period of 12 months.
223657301|NCT02591225|DRUG|Phenprocoumon|After inclusion of the subjects with LA thrombus, they are treated according to the randomization either with Dabigatran (150 mg bid) or Phenprocoumon (INR adjusted once) for the treatment period of 12 months.
223657302|NCT04539769|PROCEDURE|conventional BI|After standard laparoscopic distal gastrectomy with radical lymphadenectomy, the gastrointestinal continuity will be restored with conventional Billroth I gastroduodenostomy.
223657303|NCT04539769|PROCEDURE|long-limb BII|After standard laparoscopic distal gastrectomy with radical lymphadenectomy, the gastrointestinal continuity will be restored with Billroth II gastrojejunostomy using 100 cm-long biliopancreatic limb.
223657304|NCT04539769|PROCEDURE|long-limb RY group|After standard laparoscopic distal gastrectomy with radical lymphadenectomy, the gastrointestinal continuity will be restored with Roux-en-Y reconstruction using 100 cm-long Roux limb and standard biliopancreatic limb.
223657305|NCT05605886|DRUG|Solvazinc 50mg|Patients will receive a daily zinc supplement tablets of 50 mg in the morning after breakfast for 4 days prior to injections.
223657306|NCT05605886|DRUG|placebo|placebo
223657307|NCT00862082|DRUG|PR104 550 mg/m^2 + sorafenib|550 mg/m\^2 PR104 IV on day 1 of each 28 day cycle + 400 mg sorafenib PO twice daily. Number of Cycles: until progression or unacceptable toxicity develops.
223768488|NCT06485271|DRUG|Camrelizumab|200mg,iv,d1,Q2W/Q3W
223768489|NCT06485271|DRUG|apatinib|250mg,qd
223657308|NCT00862082|DRUG|PR104 770 mg/m^2 + sorafenib|770 mg/m\^2 PR104 IV on day 1 of each 28 day cycle + 400 mg sorafenib PO twice daily. Number of Cycles: until progression or unacceptable toxicity develops.
223657309|NCT02608671|PROCEDURE|Skin adhesive tape|
223657310|NCT05161013|DIAGNOSTIC_TEST|LINFU™|A method to detect pancreatic cancer (ductal adenocarcinoma) using ultrasound technology in those who are at significantly increased risk for developing pancreatic cancer. LINFU™ involves analysis of pancreatic fluid collected.
223657311|NCT00574522|RADIATION|Far infrared|Far infrared radiation with the wavelength between 5μm and 20μm for 30 to 40 minutes per session.
223657312|NCT01383343|BIOLOGICAL|Bevacizumab|Given IV
223657313|NCT01383343|DRUG|Fluorouracil|Given IV
223657314|NCT01383343|DRUG|Irinotecan Hydrochloride|Given IV
223657315|NCT01383343|DRUG|Leucovorin Calcium|Given IV
223657316|NCT01383343|DRUG|Sorafenib Tosylate|Given PO
223657317|NCT04949321|OTHER|Magnetic Resonance Imaging with Single dose of gadobutrol (Gd-DO3A-butrol, Gadovist® 0.1 mmol/kg, 1 mmol/mL)|Magnetic Resonance Imaging with Single dose of gadobutrol (Gd-DO3A-butrol, Gadovist® 0.1 mmol/kg, 1 mmol/mL)
223657318|NCT02486185|OTHER|SCREENING TEST|"* Skeletal muscle mass, which will be estimated by calculating values for the mid-arm muscle circumference (MAMC) from brachial perimeter (BP) and triceps skinfold thickness (TSF).~* Muscle force will be measured using a hydraulic dynamometer~* Physical performance will be estimated from the subject's Gait speed using a 4 meter gait test (Gait speed 4-m)"
223657319|NCT01486095|DEVICE|AXXESS + Biomatrix Biolimus Eluting stent|NAP
223657320|NCT01486095|DEVICE|Culotte technique with Xience V or Xience Prime stents|NAP
223657321|NCT00388193|DRUG|RITUXIMAB|375 mg/m2/d day 1
223657322|NCT05465252|DIETARY_SUPPLEMENT|Krill Oil 500 MG|Qualified subjects start to take supplementation from Day 1 in the trial. Specifically, subjects from Intervention group take 3 capsules of krill oil per day.
223657323|NCT05465252|DIETARY_SUPPLEMENT|Olive Oil 500MG|Qualified subjects start to take placebo from Day 1 in the trial. Specifically, subjects from placebo group take 3 capsules of olive oil , which has the same color and smell as the krill oil.
223657324|NCT02256709|DRUG|BIBP 5371 CL tablet|single rising daily doses
223657325|NCT02256709|DRUG|BIBP 5371 CL solution|
223657326|NCT02256709|OTHER|High fat, high caloric breakfast|
223657327|NCT02256709|DRUG|Placebo tablet|
223657328|NCT02256709|DRUG|BIBP 5371 CL tablet high dose|
223657329|NCT02256709|DRUG|Placebo drinking solution|
223657330|NCT02256709|DRUG|BIBP 5371 CL tablet low dose|
223657331|NCT04421703|BEHAVIORAL|Med-South Lifestyle Program|The Med-South Lifestyle Program is an evidence-based behavior change intervention that translates the PREDIMED (Mediterranean) dietary pattern for a Southeastern US population and includes support for increased physical activity.
223657332|NCT04837378|OTHER|Abdominal Massage|The massage starts from the left lower quadrant of the sigmoid colon. After the initial tension is removed, deep effloration, petrization and vibration maneuvers are started. Finally, the process is completed in about 15 minutes to cover the entire column.
223657333|NCT04837378|OTHER|In-bed Exercise|In-bed exercises are passive exercises performed by caregivers when the patient is dependent on the bed, that is, when he cannot actively move on his own. These are movements applied to all joints of the upper and lower extremities and in all directions. Exercises are done in all directions on finger joints of both hands, wrists, elbow and shoulder joints, finger joints of both feet, ankles, knee and hip joints.
223657334|NCT00549003|DEVICE|Rapid Diagnostic Test for P. falciparum malaria|
223657335|NCT03098004|OTHER|e-Cigarette|Participants will self-administer an experimenter-provided e-cigarette.
223657336|NCT04105504|DRUG|Glutathione|Oral glutathione capsule (500 mg), were taken once daily by the subjects.
223657337|NCT04105504|DRUG|Placebo oral tablet|Placebo oral capsule were taken once daily by the subjects.
223657338|NCT05852613|DEVICE|high power laser therapy (HPLT)|high power laser therapy (HPLT) will be produced by A LEVELASER EZ1 EASYONE device which produces a Ga Al As CW diode laser with pulsed emission 980 nm and maximum average power 5 W with a high level of energy penetration. While the patient is in a prone position and the head slightly bends to the front, The treatment will be performed at a distance of 60-70 cm, perpendicular to the cervical region, in a pulsed mode of 4 Hz, wavelength = 980 nm, radiation power density P = 4 W in the scan phase and 2 W in the acupuncture phase and energy 840 J. Patients will receive pulsed HPLT laser treatment for 8 minutes. Scanning will be performed transversely and longitudinally to the bilateral paraspinal muscles, inter-scapular area, upper trapezius and the neck region for 6 minutes followed by 2 minutes acupuncture. Protective goggles will be used to prevent direct eye contact of the laser beam.
223657339|NCT05852613|COMBINATION_PRODUCT|selected physical therapy program|hot pack, US for 5 min, exercise for 20 min.
223657340|NCT05454072|PROCEDURE|Sinonasal Microbiota Transfer|Pre-screened donor mucus, up to 15mL, will be transplanted into each diseased sinus via nasal lavage.
223657341|NCT05454072|PROCEDURE|Sham Sinonasal Microbiota Transfer|Saline, up to 15mL, will be transplanted into each diseased sinus via nasal lavage.
223657342|NCT00253162|DRUG|risperidone|
223657343|NCT00456391|PROCEDURE|Medical history|
223657344|NCT00456391|PROCEDURE|Brain CT scan|
223768490|NCT06485271|DRUG|chemotherapy|Standard treatment
223768491|NCT00095758|DRUG|Antidepressant + Placebo|Antidepressant Caps/Tablets Placebo Tablets, Oral, 2-20 mg Placebo, once daily, 6 weeks following an 8 week Prospective Treatment (Baseline) Phase.
223768492|NCT00095758|DRUG|Antidepressant + Aripiprazole|Antidepressant Caps/Tablets Aripiprazole Tablets, Oral, 2-20 mg Aripiprazole, once daily, 6 weeks following an 8 week Prospective Treatment (Baseline) Phase.
223768493|NCT06282315|DRUG|Pre-screening Phase|"The entire school population will be invited to participate in the study. The purpose of this phase is to confirm participant eligibility for enrolment in the study based on the inclusion and exclusion criteria. Given the context in which the clinical trial is being conducted, in many instances, group meetings with the parents/guardians of potential participants in the community or at school might be necessary as part of the informed consent process. This consent process may be performed up to three months before the start of the screening visit activities.~Participants and parents/guardians of subjects will be asked to confirm in writing their agreement to participate in the trial before any study-specific procedure is conducted. In addition, written assent will be sought for participants over 12 years of age."
223768494|NCT06282315|DRUG|Screenig Phase|"The purpose of the screening visit is to confirm subject eligibility for enrolment in the study based on the inclusion/exclusion criteria. Screening visits in a particular school can be performed between 14 and 7 days before the intervention (Day 0).~To continue with the screening activities, participants must have signed written consent from their parent or legal guardian, and in the case of participants aged 12 years or older, they must also have a signed assent form before any specific study procedure is performed.If the consent/assent process has not been finalized during the pre-screening phase, this can be completed during the screening visit, but always before any trial procedure.~All participants who consent to participate in the trial will be given a Participant Screening Number, which will be assigned sequentially as the informed and assent forms are signed."
223768495|NCT06282315|DRUG|Randomization|Only when the screening process is finalized in a particular school, and the list of eligible participants is closed, with at least 100 eligible participants, will the school be a candidate for randomization. Once the screening process is finalized, the investigator or designee will notify the ISGlobal Trial Statistician, who will provide the School Randomization ID allocated based on the randomization lists created before the trial starts. School Randomization ID will be assigned sequentially per site, following the order of school randomization. Additionally, the ISGlobal Trial Statistician will provide the site with the list of eligible participants per school randomly selected to participate in the Effectiveness Cohort.
223768496|NCT06282315|DRUG|Baseline Effectiveness Cohort|"Before the administration of the study drug at school, participants selected for the Effectiveness Cohort will perform an additional study visit during which they will provide the study team with a stool sample for STH analysis. A dried blood spot (DBS) sample will also be taken to test for S. stercoralis.~Sampling of the baseline effectiveness cohort will be conducted within 7 days before the start of the school study intervention. In addition to the delivery of the stool/blood sample, participants from the effectiveness cohort will be evaluated for scabies by designated study personnel following the IACs simplified criteria."
224239678|NCT05682118|PROCEDURE|iFR/FFR|Patients undergoing pressure wire test with moderate stenosis. Pressure wire into guiding catheter The equalization of the pressure wire with the aortic pressure(after placing the pressure wire on the tip of the guiding catheter and removal of contrast media by saline flushing) and the placement of the pressure wire on the distal of the blood vessel to measure iFR. After iFR measurement, the pressure wire was pulled back into the tip of the guiding catheter to check the presence of pressure drift. A final Pd/Pa between 0.97 and 1.03 is considered acceptable. Following confirming no pressure drift, a mode change will be done from iFR to FFR, and then a re-check of the time between the equalization of the pressure wire with the aortic pressure will be planned. In all lesions, FFR value were measured with hyperemia, achieved by intracoronary (IC) bolus injection of nicorandil (Sigmart®; Chugai Pharmaceutical Co., Ltd., Tokyo, Japan) 2 mg.
224239679|NCT01382290|PROCEDURE|MRI|
224239680|NCT00266006|DRUG|eptacog alfa (activated)|
224239681|NCT06381609|BEHAVIORAL|Quality life questionnaire AQoLS|Quality life questionnaire AQoLS will be completed by patients of both arms at inclusion, three and six months after inclusion
224239682|NCT06381609|BEHAVIORAL|Quality life questionnaire Euroqol EQ-5D-5L|Quality life questionnaire Euroqol EQ-5D-5L will be completed by patients of both arms at inclusion, three and six months after inclusion
223657345|NCT02578758|BEHAVIORAL|Transdiagnostic internet-based protocol|Transdiagnostic internet-based protocol is an Internet-based Protocol for ED, which will allow the individual to learn and practice adaptive ways to regulate their emotions from a transdiagnostic perspective. The protocol contains the following components: present-focused emotional awareness, cognitive flexibility, emotional avoidance and emotion-driven behaviors, interoceptive and situation-based emotion exposure, psychoeducation about emotions, motivational enhancement and relapse prevention, which are organized in 12 modules: Emotional disorders and emotion regulation; Motivation for change; Understanding the role of emotions; The acceptance of emotional experiences; Practicing the acceptance; Learning to be flexible; Practicing the cognitive flexibility; The emotional avoidance; Emotion driven behaviors; Accepting and facing physical sensations; Facing emotions in the contexts in which they occur; and Relapse Prevention.
223657346|NCT02578758|BEHAVIORAL|Transdiagnostic internet-based protocol + positive affect component|Transdiagnostic internet-based protocol + positive affect component is an Internet-based protocol for ED. This protocol contains several transdiagnostic components (present-focused emotional awareness, cognitive flexibility, emotional avoidance and emotion-driven behaviors, interoceptive and situation-based emotion exposure, psychoeducation about emotions, motivational enhancement and relapse prevention) and a specific positive affect regulation component. These components are organized in 16 treatment modules: Emotional disorders and emotion regulation; Motivation for change; Understanding the role of emotions; The acceptance of emotional experiences; Practicing the acceptance; Learning to be flexible; Practicing the cognitive flexibility; The emotional avoidance; Emotion driven behaviors; Accepting and facing physical sensations; Facing emotions in the contexts in which they occur; Learning to move on; Learning to enjoy; Learning to live; Living and learning; and Relapse Prevention.
223657347|NCT02578758|OTHER|Waiting List Control Group|Participants in a 18-week waiting list control condition. They will be offered the possibility of receiving the online treatment protocol after the wating list period.
223657348|NCT00186134|BEHAVIORAL|physical activity|
223657349|NCT00110721|DRUG|GM-CT-01 plus 5-Fluorouracil|Single use vials, combined regimen of GM-CT-01 / 5-Fluorouracil (280 mg/m2 /500 mg/m2) given for 4 consecutive days in a 28 day cycle until disease progression.
223657350|NCT05006001|DRUG|Colchicine and NSAID|Colchicine and nonsteroidal anti-inflammatory drug combination therapy
223657351|NCT05870943|PROCEDURE|Hybrid Argon Plasma Coagulation|Hybrid APC will be utilized to first ablate the gastric mucosa along the greater curve of the stomach.
223657352|NCT05870943|PROCEDURE|Endoscopic Sleeve Gastroplasty|Endoscopic full-thickness tissue acquisition and plication using 2-0 Prolene synthetic sutures via the Apollo ESG platform.
223657353|NCT00860548|DRUG|currently available therapy in the community|Participants will receive telephone calls every 3 months for approximately 44 months for the purpose of outcome surveys
223657354|NCT01405144|DRUG|5-fluoruracil|5% 5-fluoruracil cream, twice a day, during 3 weeks
224239683|NCT06381609|OTHER|Peer support consultations|"For patients included in the Peer support group, eight mandatory consultations with a peer support specialist will be performed between the inclusion visit and during the three following months.~Patients can request additional consultations with the peer support specialist during the 6 first months of follow-up"
223657355|NCT01405144|PROCEDURE|5-fluoruracil|The same 30 patients will be submitted to 4 weekly application of superficial peeling using 5% 5-fluoruracil in propyleneglycol as vehicle. The applications will be performed by physician (one of the co-investigators)
223657356|NCT05196321|OTHER|sessions with ENF (Electro Neuro Feedback).|The study evaluates patients with clinical evidence of post-surgical hematoma / seroma after hip replacement surgery. These patients will undergo ultrasound evaluation in the 4th (+/- 2) day post surgery, in which triaxial parameters of the hematoma will be measured. This evaluation will then be repeated after 5 treatment sessions with ENF (Electro Neuro Feedback).
223657357|NCT00073476|DRUG|traxiprodil (CP-101,606)|
223657358|NCT02949791|PROCEDURE|Cytoreductive surgery|Maximal surgical effort to obtain a minimal residual disease of less than 2.5 mm
223657359|NCT02949791|OTHER|Low Intra abdominal pressure HIPEC|Hyperthermic intraperitoneal chemotherapy using closed modality and intra abdominal pressure of 8-12 mmHg
223657360|NCT02949791|OTHER|High Intra abdominal pressure HIPEC|Hyperthermic intraperitoneal chemotherapy using closed modality and intra abdominal pressure of 18-22 mmHg
223657361|NCT02616796|BEHAVIORAL|Social gaze training|Appropriate social gaze behavior will be shaped using the principles of Applied Behavior Analysis.
223657362|NCT01575626|DRUG|Sevoflurane|"All active comparators of this study have the same intervention as mentioned ahead:~First IOP measurement will be performed just before anesthesia induction. Standard general anesthesia will be induced using propofol (5 mcg/ml) administered by target controlled infusion (TCI - Schnider model),fentanyl and rocuronium according to standard protocol of general anesthesia. The second IOP measurement will be performed just before tracheal intubation.~Following tracheal intubation, concentration of propofol will be decreased till 0 and anesthesia with sevoflurane will be started, followed by 3 more IOP measurements for different end-tidal sevoflurane concentrations (Consented patients will be randomly allocated to one of three groups as mentioned).~Total of 5 IOP measurements. IOP will be measured by the ophthalmologist via both TonoPen XL and Schioz devices."
223657363|NCT03985969|DRUG|elafibranor|Elafibranor 120mg is a coated tablet for oral administration
223657364|NCT03985969|DRUG|CHRONO-INDOCID|CHRONO-INDOCID 75mg is a capsule for bis in die (bid) oral administration
223657365|NCT06140030|BEHAVIORAL|Mindfulness training|Mindfulness-training mobile health application
223657366|NCT01862237|OTHER|Intervention|"* blood collection~* Completion of a pre-operative cardiac MRI.~* Completion of a coronary angiography examination~* Completion during the surgery d'une myocardial biopsy,~* Aortic echocardiographic follow-up (including post-operative ultrasound and ultrasound at 1 year~* Completion of a cardiac MRI 1 year after surgery."
223657367|NCT03830619|DIAGNOSTIC_TEST|collect samples|collect serum samples and clinical features
223657368|NCT06176911|DRUG|Teriflunomide|Starting dose of 7 mg once daily. Dose adjustments are made throughout the study based on individual platelet counts.
223657369|NCT06176911|DRUG|Danazol|200 mg twice daily.
223657370|NCT03358264|DIETARY_SUPPLEMENT|L-citrulline|Amino acid supplement
223657371|NCT02093819|DRUG|Placebo to BI 416970|single rising doses
223657372|NCT02093819|DRUG|BI 416970|single rising doses
223657373|NCT00794313|DRUG|Amantadine 300 mg|Amantadine, 300 mg, capsule, three times a day, two weeks
223657374|NCT00794313|DRUG|Topiramate|Topiramate, 25 mg, capsule, two times a day, 1 week Sugar Pill, capsule, one time a day, 1 week Topiramate, 50 mg, capsule, three times a day, 1 week
223657375|NCT00794313|DRUG|Sugar Pill|sugar pill, capsule, three times a day, 2 weeks
223657376|NCT02344524|DEVICE|Intercostal drainage|Small bore chest drains are inserted by modified Seldinger's technique. Large bore chest drains are inserted by blunt dissection technique.
223657377|NCT03629496|OTHER|Arts-based intervention|6x1 hourly facilitated art sessions during haemodialysis. Participants will be provided with an option of visual art or creative writing, the artistic materials used will include graphite pencils, colouring pencils, water colour paints and graphic pens. Participants will be provided with their own art supplies for infection control purposes. During each session participants will be allowed to self-select a subject matter or be provided with binary prompts to facilitate decision making. Participants will also have an option of displaying completed work in the reception area of the unit during their haemodialysis sessions.
223657378|NCT05381857|OTHER|Human Biological Samples|Blood, urine, nasal swab, fecal samples
223657379|NCT00752804|PROCEDURE|Dialysis during 4 hours|Blood and dialysate sampling
224239684|NCT03469297|DEVICE|Brown Glaucoma Implant|The Brown Glaucoma Implant (BGI) is an implantable device designed to lower intraocular pressure (IOP) in glaucoma patients by shunting aqueous humor from the anterior chamber of the eye to the surface of the eye. Because there are no physiologic sources of outflow resistance, the device can be engineered to target an IOP that is low enough to halt the progression to blindness in a patient suffering from glaucoma.
223657380|NCT00752804|PROCEDURE|Dialysis during 6 hours|Blood and dialysate sampling
223657381|NCT00752804|PROCEDURE|Dialysis during 8 hours|Blood and dialysate sampling
223657382|NCT02447302|DRUG|Etrasimod|
223657383|NCT02447302|DRUG|Placebo|
223657384|NCT03672890|OTHER|Telestroke|Telestroke is an audiovisual communication network that allows for coordination of stroke care from a distant 'hub' site (the telestroke provider location) to an originating 'spoke' site (patient location) in a HIPAA compliant fashion. In TELECAST, inpatient telestroke rounding will be used to oversee the urgent diagnostic stroke evaluation, secondary stroke prevention, health screening \& evaluation, and stroke education in patients admitted with stroke.
223657385|NCT01901250|DIETARY_SUPPLEMENT|Xylitol gummy bears|The children receive xylitol gummy bears 3 times/day within the supervised school environment.
224239685|NCT01471847|DRUG|BEZ235 + Trastuzumab Phase l/Phase ll)|"Phase l: Patients will receive increasing doses of oral BEZ235 (BID) together with standard weekly trastuzumab at a fixed dose. BEZ235 doses will be escalated in cohorts of 3 to 6 patients guided by an adaptive Bayesian logistic regression model with overdose control until MTD/RP2D has been established.~Phase ll: If randomized to the trastuzumab + BEZ235 arm, patients will receive standard weekly trastuzumab in combination with oral BEZ235 (BID) at the MTD or RP2D and will continue on study treatment until PD, unacceptable toxicity or until other pre-defined discontinuation criteria are met. They will have regular safety assessments and will be evaluated for response to treatment according to RECIST every 2 cycles for the first 36 weeks then every 12 weeks until disease progression (or start of new anti-neoplastic therapy)."
224239686|NCT01471847|DRUG|Lapatinib + Capecitabine (Phase II)|"If randomized to the lapatinib + capecitabine treatment arm, patients will receive standard lapatinib plus capecitabine until PD, unacceptable toxicity or until other pre-defined discontinuation criteria are met.~Patients will have regular safety assessments and will be evaluated for response to treatment according to RECIST every 2 cycles for the first 36 weeks then every 12 weeks until disease progression (or start of new anti-neoplastic therapy). After progression, survival f-up will continue.~All patients participating in the Phase II part of the study will be required to have available archival or fresh tumor tissue for biomarker analysis prior to treatment start"
224239687|NCT03416647|PROCEDURE|Duodenojejunostomy|Duodenojejunostomy with or without duodenal resection
223657386|NCT01901250|DIETARY_SUPPLEMENT|Sugar free fiber gummy bears|The children receive sugar free fiber gummy bears 3 times/day within the supervised school environment.
224239688|NCT03100305|OTHER|Collection of blood and urine|Collection of blood and urine before nutritional support, during total parenteral nutrition, during partial parenteral nutrition and during enteral nutrition
224239689|NCT01386047|OTHER|Integrated Clinical Prediction Rule (iCPR)|Integrated clinical prediction rule for Strep Pharyngitis based on Walsh clinical prediction rule (CPR) criteria and rule for Pneumonia based on Hecklering CPR criteria.
224239690|NCT02548637|PROCEDURE|Acupuncture Therapy|The standard textbook of Chinese Acupuncture and Moxibustion is the source for the name and location of the points for this study. A total of 38 points will be used, divided between two acupuncture sessions: 20 points or 37 locations in the supine position; 18 points or 36 locations in the prone position. Other than points governing vessel (GV) 20, conception vessel (CV) 6, CV 10, all points will be performed bilaterally.
224239691|NCT02424188|OTHER|TRIIUMPH Intervention|Group and individual smoking cessation and weight management counseling, pharmacotherapy with varenicline or bupropion and nicotine replacement therapy, group exercise, and text messaging support
224239692|NCT01085045|DRUG|PT003 MDI|Inhaled PT003 MDI administered as two puffs BID for 7 days
224239693|NCT01085045|DRUG|PT005 MDI|Inhaled PT005 MDI administered as two puffs BID for 7 days
224239694|NCT01085045|DRUG|Placebo MDI|Inhaled placebo administered as two puffs BID for 7 days
224239695|NCT01085045|DRUG|Tiotropium bromide 18 μg (Spiriva Handihaler®)|Inhaled tiotropium bromide 18 μg (Spiriva Handihaler®) administered QD for 7 days
224239696|NCT01085045|DRUG|Formoterol Fumarate 12 μg (Foradil® Aerolizer®)|Inhaled formoterol fumarate 12 μg (Foradil® Aerolizer®) administered BID for 7 days
224239697|NCT01085045|DRUG|PT001 MDI|Inhaled PT001 MDI administered as two puffs BID for 7 days
224239698|NCT04949698|DEVICE|plasma exchange|Plasma exchange was performed daily for five times or until platelet level returned to normal
224239699|NCT01701024|DRUG|ACYC|ACYC active, topically applied to the face for 12 weeks
224239700|NCT01701024|DRUG|ACYC vehicle|ACYC vehicle (placebo), topically applied to the face for 12 weeks
223657387|NCT01901250|BEHAVIORAL|Oral health education|Oral health education, toothbrush, and fluoride toothpaste
223657388|NCT01901250|DEVICE|Fluoride varnish|The study dentists apply the varnish on all children twice a year during the study period. The varnish is 5% sodium fluoride and contains 2.26% by weight fluoride ion in a colophony base.
223657389|NCT01901250|DEVICE|Dental sealant|The study dentists apply the sealant on the children in the second grade when the permanent first molars are fully erupted.
223657390|NCT04274946|PROCEDURE|Sentinel lymph node biopsy|Sentinel lymph node biopsy(SLNB) procedure with different mapping methods using combination of radioactive colloid, patent blue, indocyanine green associated with intraoperative ultrasound.
223657391|NCT04401683|DEVICE|Home-based rehabilitation with a digital biofeedback system|"Participants in the experimental group will perform a 12-week digital exercise program, to be performed independently at home using the SWORD Phoenix® medical device, under remote monitoring from a physical therapist.~Additionally, both groups will have access to standard medical treatments and to an educational program, specifically developed to target chronic low back pain, consisting of a booklet containing pathology-related information, causes, treatment recommendations, as well as suggestions of cognitive behavioural therapy exercises."
223657392|NCT04401683|OTHER|Conventional home-based rehabilitation|"Participants in the control group will benefit from a 12-week home-based rehabilitation program, consisting of 12 face-to-face sessions (1 per week) with a physical therapist, complemented by additional non-supervised sessions. Both supervised and unsupervised sessions will follow the same set of exercises defined for the experimental group.~Additionally, both groups will have access to standard medical treatments and to an educational program, specifically developed to target chronic low back pain, consisting of a booklet containing pathology-related information, causes, treatment recommendations, as well as suggestions of cognitive behavioural therapy exercises."
223657393|NCT00463723|DRUG|FK506 0.06% (eye drops)|
224239701|NCT05294094|BEHAVIORAL|blended learning|The blended learning course consists of two parts. The first part is an online course with case studies and instructional videos providing basic clinical diagnostic knowledge and the ability to conduct structured clinical interviews. In the second part, learners get to discuss the course content with a teacher, practice their interviewing skills with other students and make a transfer to a real face-to-face diagnostic situation with an actor simulating a patient.
224239702|NCT05294094|BEHAVIORAL|teaching format as usual|The teaching format as usual represents the usual teaching of clinical diagnostic knowledge and the ability to conduct structured clinical interviews. Also in this intervention students also have the opportunity to discuss the course content with a teacher, practice their interviewing skills with other students and conduct a structured interview with an actor simulating a patient.
224239703|NCT02086188|DRUG|Mirabegron|see detailed information in associated Arm Description
224239704|NCT02086188|DRUG|Placebo|Sugar pill manufactured to mimic Mirabegron 25mg tablet.
224239705|NCT02188641|OTHER|Diet|
223657394|NCT00006100|BIOLOGICAL|aldesleukin|
223657395|NCT00006100|BIOLOGICAL|allogeneic Epstein-Barr virus-specific cytotoxic T lymphocytes|
223657396|NCT00006100|DRUG|fludarabine phosphate|
223657397|NCT00006100|PROCEDURE|peripheral blood stem cell transplantation|
223657398|NCT03111641|DIAGNOSTIC_TEST|Lung ultrasonography|Lung ultrasound scan during preoperative anaesthesia consultation
223657399|NCT00327197|DRUG|Prednisolone|Subjects will be administered oral prednisolone at a dose of 0.5 mg/kg, up to a maximum of 40 mg per day for 14 days.
223657400|NCT00327197|PROCEDURE|Bronchoscopy|All subjects will undergo bronchoscopy assessments which will involve insertion of a standard bronchoscope.
223657401|NCT04787536|PROCEDURE|Non-cardiac surgery|Non-cardiac surgery excluding cranial neurosurgery
223657402|NCT04927624|PROCEDURE|transversus abdominis plane block|The transversus abdominis plane (TAP) block was first introduced by Rafi et al. in 2001 as a landmark-guided technique via the triangle of Petit to achieve a field block. It involves the injection of a local anesthetic solution into a plane between the internal oblique muscle and transversus abdominis muscle. Since the thoracolumbar nerves originating from the T6 to L1 spinal roots run into this plane and supply sensory nerves to the anterolateral abdominal wall , the local anesthetic spread in this plane can block the neural afferents and provide analgesia to the anterolateral abdominal wall.
223657403|NCT04927624|PROCEDURE|quoadratus lumborum block|quoadratus lumborum block
223657404|NCT04619771|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|CBT-I has a specific protocol with behavioral targets that differ significantly from standard CBT. This approach focuses on implementing sleep restriction and stimulus control interventions which are fully deployed during the first session. 5 CBT-I sessions will be delivered over the course of 8 weeks. Key recommendations include: 1) reduce time in bed; 2) get up at the same time every day; 3) do not go to bed unless sleepy; 4) do not stay in bed awake for more than 15 minutes; and 5) avoid napping. Participants are also taught relaxation strategies and cognitive therapy addresses arousal and catastrophizing.
223657405|NCT04522830|DRUG|BTL-TML-COVID|"Sublingual dosing of BTL-TML-COVID on days 1 and 2 - Day 1 - 1 drop every 15 minutes for the first hour of initiation of treatment then every hour for the balance of the day until bedtime.~Day 2 - 1 drop every 2-3 hours for a total of 6 times during the day. The parallel group assignment will only be maintained until the completion of a minimum of 48 hours of blinded study drug dosing, at which point all subjects will receive the active treatment.~Day 3 - 1 drop every 15 mins for the first hour of the day, then every hour for the balance of the day until bedtime.~Days 4 through 10 - 1 drop every 3-4 hours for a total of four times during the day."
223657406|NCT04522830|DRUG|Placebo|"Sublingual dosing of matching placebo on days 1 and 2 - Day 1 - 1 drop every 15 minutes for the first hour of initiation of treatment then every hour for the balance of the day until bedtime.~Day 2 - 1 drop every 2-3 hours for a total of 6 times during the day. The parallel group assignment will only be maintained until the completion of a minimum of 48 hours of blinded study drug dosing, at which point all subjects will receive the active treatment.~Day 3 - 1 drop every 15 mins for the first hour of the day, then every hour for the balance of the day until bedtime.~Days 4 through 10 - 1 drop every 3-4 hours for a total of four times during the day."
223657407|NCT01456897|DRUG|OPC-34712|orally administered once daily
223657408|NCT05961007|BIOLOGICAL|Intravitreal injection of IBI302(dose 1)|IBI302(dose 1) intravitreal injection given as protocol
223657409|NCT05961007|BIOLOGICAL|Intravitreal injection of IBI302(dose 2)|IBI302(dose 2) intravitreal injection given as protocol
223657410|NCT05961007|BIOLOGICAL|Intravitreal injection of IBI302(dose 3)|IBI302(dose 3) intravitreal injection given as protocol
223657411|NCT05961007|DRUG|Intravitreal injection of Aflibercept|Aflibercept intravitreal injection given as protocol
223657412|NCT05779618|OTHER|no intervention|observational study, all data collected are binary
223657413|NCT06057727|BEHAVIORAL|Pre-visit patient text messaging|Patients will be sent text message reminders 3 days and 24 hours prior to their scheduled primary care visit. The messages will inform the patient that a flu shot has been reserved for them at their upcoming appointment and encouraging the patient to ask their provider about receiving the vaccine.
223657414|NCT06057727|BEHAVIORAL|Default pended order|A default pended order for the flu vaccine will be pended to the patient's upcoming primary care encounter and will be visible to the provider during the visit encounter. Clinical staff will have the option of signing the order or dismissing it if they deem it inappropriate for a given patient.
223657415|NCT06057727|BEHAVIORAL|Monthly peer comparison feedback|Each month, clinicians will be sent an email containing what percent of their eligible patients received the flu vaccine and how that compares to other peer clinicians in the intervention.
223657416|NCT06057727|BEHAVIORAL|High risk bidirectional pre-visit text messaging|High risk patients randomized to receive the high risk intensification nudge will receive a bidirectional text messaging component prior to their visit. This intervention will query the patient about common questions or concerns about receiving the flu vaccine. If the patient responds, it will provide additional educational materials based on the patient's specific concern(s).
223657417|NCT03304938|DRUG|Lavender Oil|The intervention group pour 3 drops of Lavender essential oil on a cotton wool then smell it rhythmic and slowly for 5 minutes at bed time for 4 weeks
224239706|NCT02188641|OTHER|Exercise|
224239707|NCT02188641|OTHER|Diet and Exercise|
224239708|NCT02188641|OTHER|Healthy Lifestyle (Control) Group|
223768497|NCT06282315|DRUG|Day 0 Trial Intervention|"Within seven days after the first sample for the baseline effectiveness cohort is collected, the school's mass administration of the allocated drug will take place. All participants included in the list of eligible subjects from a particular randomized school will receive a single dose of the medication administered to their school (FDC or ALB). Before the administration, participants will be asked about any medical condition that has arisen since the last study visit, in which case information will be documented as a concomitant disease.~In case a participant vomits within one hour after the study drug intake (during the study physician observation period), the participant will continue participating in the trial and may still participate in the effectiveness cohort. If they are chosen for the day 21 or month 11 effectiveness cohort, an additional sensitivity analysis will be performed without including these participants, considered as Intervention Fail."
224239709|NCT03212222|OTHER|Peek Acuity|Cell phone application for visual acuity screening
224239710|NCT03212222|OTHER|Standard Visual Screening|Visual screening exam conducted in Duke University Eye Center
224239711|NCT04177290|DRUG|Sintilimab (M1b)|Intravenous infusion
224239712|NCT04177290|DRUG|Sintilimab (approved)|Intravenous infusion
224239713|NCT01533298|DRUG|CombiflexOmega peri|intravenously over 3 days infusion
224239714|NCT01533298|DRUG|SmofKabiven peripheral|intravenously over 3 days infusion
224239715|NCT05531422|DRUG|Inhaled fentanyl aerosol|Participants were randomized to 6 BTP episodes, in which 4 BTP episodes were treated with inhaled fentanyl aerosol (with a starting dose of 25 µg every 4 minutes until adequate pain alleviation. The maximum doses are 6×25 µg) and 2 BTP episodes with placebo(0 µg every 4 minutes until adequate pain alleviation. The maximum doses are 6×0µg) in a random sequence.
224239716|NCT05531422|DRUG|Placebo|Participants were randomized to 6 BTP episodes, in which 4 BTP episodes were treated with inhaled fentanyl aerosol (with a starting dose of 25 µg every 4 minutes until adequate pain alleviation. The maximum doses are 6×25 µg) and 2 BTP episodes with placebo(0 µg every 4 minutes until adequate pain alleviation. The maximum doses are 6×0µg) in a random sequence.
224239717|NCT01295372|DRUG|Zicronapine|7.5 mg/day; orally
224239718|NCT01295372|DRUG|Risperidone|5 mg/day; orally
224239719|NCT05290311|BEHAVIORAL|cognitive behavioural therapy|Cognitive behavioural therapy (CBT) was given according to the protocol of Safren (2004, 2005). Each participant followed one session of 60 minutes per week, for 10 to 16 weeks. Psychotherapists giving CBT had at least a master diploma.
224239720|NCT01464970|PROCEDURE|Both Superficial Inferior Artery and Vein Clamped|Perfusion assessed in Zone IV of the DIEP flap whilst both the contralateral Superficial Inferior Epigastric Artery and Vein are clamped
224239721|NCT01464970|PROCEDURE|Superficial Inferior Epigastric Vessels both unclamped|Perfusion assessed in Zone IV of the DIEP flap whilst both the contralateral Superficial Inferior Epigastric Artery and Vein are unclamped
224239722|NCT01464970|PROCEDURE|SIE Artery Unclamped, Vein Clamped|Perfusion assessed in Zone IV of the DIEP flap whilst the contralateral Superficial Inferior Epigastric Artery is unclamped and the Vein is clamped
224239723|NCT01464970|PROCEDURE|SIE Artery clamped, Vein unclamped|Perfusion assessed in Zone IV of the DIEP flap whilst the contralateral Superficial Inferior Epigastric Artery is clamped and the Vein is unclamped
224239724|NCT00416520|DRUG|MCI-196 (Colestilan(INN), Colestimide(JAN), CHOLEBINE®)|3g to 15g/day (3 times a day), Tablet, 12 weeks of flexible dose and 4 weeks of double blind
224239725|NCT00416520|DRUG|Placebo|3g to 15g/day (3 times a day), Tablet, 4 weeks of double blind
224239726|NCT00416520|DRUG|Another phosphate binder (Sevelamer)|Current approved dosing recommendations for 12 weeks
224239727|NCT04921462|PROCEDURE|Septoplasty surgery|septoplasty procedures were performed by a single surgeon using the same technique among all patients. The procedures were conducted under general anesthesia according to the standard preoperative care used in our institution.
224239728|NCT03401996|DEVICE|1 mA tDCS over bilateral SMA|"A 1mA direct current will be delivered through two 5cm x 5cm saline-soaked surface sponge electrodes by a battery-driven, constant-current stimulator (Neuroconn DC stimulator). First, the SMA will be identified based on the guidelines of the international 10-20 electrode system. The tDCS will then be applied using the following procedure:~1. The head of participants will be measured to find the 'vertex' (top) of the head. This point will be used as a landmark to locate the SMA. This region corresponds to the FCZ (e.g., Legon et al., 2013).~2. The return electrode will be placed over the mastoids. Once the electrodes are in position, cathodal tDCS will be applied at 1mA for 15 minutes, 2 times a day with a resting period of 20 minutes in between treatment periods, for 5 consecutive days."
223657418|NCT03304938|DRUG|Placebos|The placebo group pour 3 drops of Almond oil on a cotton wool then smell it rhythmic and slowly for 5 minutes at bed time for 4 weeks
223657419|NCT00493051|BIOLOGICAL|GAM501|Ad5PDGF-B formulated in a collagen gel
223657420|NCT00493051|BIOLOGICAL|Placebo|Collagen gel
223657421|NCT00493051|OTHER|Standard of care|moist dressing changes daily
223657422|NCT00930072|DRUG|Cervical Sympathetic Block (bupivicaine, clonidine)|12-15ml solution of bupivicaine .5% containing 50 mcg of clonidine for cervical sympathetic block administered in a single injection.
223657423|NCT01396070|DRUG|Brentuximab vedotin|"1.8 mg/kg by IV every 3 weeks for a maximum of 16 doses (8 cycles).~Brentuximab vedotin is an antibody conjugate, consisting of the chimeric IgG1 anti-CD30 antibody cAC10; the microtubule disrupting agent monomethyl auristatin E (MMAE); a protease-cleavable linker that covalently attaches MMAE to cAC10."
223657424|NCT02879201|PROCEDURE|Slow efficiency dialysis|Slow dialysis 4 times weekly 8 hours CVVHDF predilution mode
223657425|NCT02921334|PROCEDURE|switching between invasive and noninvasive ventilation|As defined criteria, patients are switched between invasive and noninvasive ventilation until the ventilator is successfully weaned.
223657426|NCT02152956|BIOLOGICAL|Flotetuzumab 3 ng/kg/day, 4 days on and 3 days off|Flotetuzumab is a CD123 x CD3 bispecific antibody-based molecular construct referred to as a DART® molecule.
223657427|NCT02152956|BIOLOGICAL|Flotetuzumab 10 ng/kg/day, 4 days on and 3 days off|Flotetuzumab is a CD123 x CD3 bispecific antibody-based molecular construct referred to as a DART molecule.
223657428|NCT02152956|BIOLOGICAL|Flotetuzumab 30 ng/kg/day, 4 days on and 3 days off|Flotetuzumab is a CD123 x CD3 bispecific antibody-based molecular construct referred to as a DART molecule.
223657429|NCT02152956|BIOLOGICAL|Flotetuzumab 100 ng/kg/day, 4 days on and 3 days off|Flotetuzumab is a CD123 x CD3 bispecific antibody-based molecular construct referred to as a DART molecule.
223657430|NCT02152956|BIOLOGICAL|Flotetuzumab 300 ng/kg/day, 4 days on 3 days off, after one-step lead-in dose|Flotetuzumab is a CD123 x CD3 bispecific antibody-based molecular construct referred to as a DART molecule.
223768498|NCT06282315|DRUG|Active Surveillance (study visit Day 1, Day 2 and Day 7)|Active safety surveillance will be performed at school during the trial intervention on day 0 until day 7 post-intervention. The assessment will include recording of all AEs and SAEs presented by study participants from the intake of the study drugs, and for two additional days (Day 1 and Day 2 study visits). During active surveillance, participants will be visited by a study physician at school during the study intervention, on day one and day two, and they will be questioned about any potential AE or change in a pre-existing condition. In addition, a final safety visit will be conducted to all participants at Day 7 to collect data on any potential AE occurred between day 2 and the end of the surveillance period and to perform a follow up of any AE ongoing after Day 2 visit.
224239729|NCT01798732|PROCEDURE|Selective Laser Trabeculoplasty (Tango Laser, Ellex)|One session of selective laser trabeculoplasty with the following parameters (inferior half-circumference, 50 shots, 0.8 to 1.3 mJ)
223657431|NCT02152956|BIOLOGICAL|Flotetuzumab 500 ng/kg/day, 4 days on 3 days off, after one-step lead-in dose|Flotetuzumab is a CD123 x CD3 bispecific antibody-based molecular construct referred to as a DART® molecule.
224239730|NCT01633047|OTHER|electrical stimulation|Intervention group that will be submitted to physical therapy exercises plus electrical stimulation (low frequency device with a current of 47 Hz with symmetrical, biphasic and pyramidal waveforms, with pulse duration of 1.5 s and interval of 1.8 s)
224239731|NCT01633047|OTHER|physical therapy exercises|Control group that will be submitted only to physical therapy exercises
224239732|NCT04155281|OTHER|urine analysis|New Psychoactive Substances research in urine at admission in unit care
224239733|NCT02439008|PROCEDURE|Blood samples collection before radiotherapy|"Nine blood samples (35 mL each) will be collected in each patient before, during and after radiotherapy treatment.~Before radiotherapy:~* Sample T0: after registration, in the days running up to the administration of the first fraction of radiotherapy"
224239734|NCT02439008|PROCEDURE|Blood samples collection during radiotherapy|"* Sample T1: within 15 minutes after the administration of the first fraction,~* Sample T2: within 15 minutes after the administration of the second fraction,~* Sample T3: within 15 minutes after the administration of the third fraction"
224239735|NCT02439008|PROCEDURE|Blood samples collection after radiotherapy|"* Sample T4: one week after the end of the radiotherapy,~* Samples T5 to T8: respectively 3 months, six months, 9 months and 12 months after the end of the radiotherapy."
224239736|NCT02439008|RADIATION|Radiotherapy|
224239737|NCT01492361|DRUG|AMR101|Parallel Assignment
223657432|NCT02152956|BIOLOGICAL|Flotetuzumab 500 ng/kg/day, continuous infusion, after multi-step lead-in dose|Flotetuzumab is a CD123 x CD3 bispecific antibody-based molecular construct referred to as a DART molecule.
224239738|NCT01492361|DRUG|Placebo|Parallel Assignment
224239739|NCT01492361|DRUG|Statin therapy|Stable statin therapy (± ezetimibe) for at least 28 days before lipid qualification measurement (LDL-C \>40 mg/dL and ≤100 mg/dL)
223657433|NCT02152956|BIOLOGICAL|Flotetuzumab 700 ng/kg/day, 4 days on 3 days off, after multi-step lead-in dose|Flotetuzumab is a CD123 x CD3 bispecific antibody-based molecular construct referred to as a DART molecule.
223657434|NCT02152956|BIOLOGICAL|Flotetuzumab 700 ng/kg/day, continuous infusion, after multi-step lead-in dose|Flotetuzumab is a CD123 x CD3 bispecific antibody-based molecular construct referred to as a DART molecule.
223657435|NCT02152956|DRUG|Ruxolitinib|Oral inhibitor of JAK kinase
223657436|NCT02152956|BIOLOGICAL|Flotetuzumab 300 ng/kg/day, continuous infusion, after multi-step lead-in dose|Flotetuzumab is a CD123 x CD3 bispecific antibody-based molecular construct referred to as a DART molecule.
224239740|NCT04812756|BEHAVIORAL|Step-2-It - text messaging program|participants received a pedometer and text messages to motivate them to increase walking daily for a period of 12 weeks.
224239741|NCT02837822|DEVICE|Spinal cord stimulator|Spinal cord stimulator is a reversible and minimally invasive neuromodulation device used for the treatment of various diseases related to chronic pain, including CRPS and FBSS. Briefly, this technology uses electrical pulses to generate action potentials in nerve cells that induce paresthesias (buzzing or tingling sensations) in the affected limb and can relieve pain.
224239742|NCT02837822|PROCEDURE|Implantation of a spinal cord stimulator|The electrical pulses are induced by one or more electrodes surgically implanted into the epidural space. These electrodes are usually placed under the skin in the abdomen or upper buttock.
224239743|NCT03765502|DEVICE|Nasal Glucagon Device (NG)|NG devices will be provided empty of drug product
224239744|NCT03765502|DEVICE|GEK|Used to administer glucagon intramuscularly (IM)
224239745|NCT03765502|DRUG|IM Glucagon|Administered IM via GEK
224239746|NCT01465295|DEVICE|Mechanical hemiepiphysiodesis using the HemiBridge System|Surgical application of mechanical hemiepiphysiodesis using the HemiBridge device.
224239747|NCT04090892|PROCEDURE|selective percutaneous muscle release|Children will be evaluated before and two times after they undergo a selective percutaneous myofascial release. Investigators make no determination about the need for the surgery or which muscles are released, nor do they participate in the surgery. The investigators are assess outcomes on gait and motor function.
224239748|NCT01272336|DRUG|Acute Intermittent Hypoxia (AIH)|Participants will breath intermittent low oxygen via air generators. The generators will fill reservoir bags attached to a non-rebreathing face mask. Oxygen concentration will be continuously monitored to ensure delivery of FIO2=0.09±0.02 (hypoxia) air for 15 minutes.Participants will receive treatment for up to seven visits.
224239749|NCT01272336|OTHER|SHAM-Intermittent Room Air|This is a sham intervention to the AIH intervention. Participants will breath intermittent room air via air generators. The generators will fill reservoir bags attached to a non-rebreathing face mask. Oxygen concentration will be continuously monitored to ensure delivery of FIO2=0.21±0.02 (normoxia). Participants will receive treatment for up to seven visits.
223657437|NCT02445794|DRUG|Low dose cohort|RT001 is encapsulated di-deutero synthetic homologue of linoleic acid ethyl ester. Each capsule contains 900 mg of RT001.
223657438|NCT02445794|DRUG|High dose cohort|RT001 comparator is encapsulated non-deuterated linoleic acid ethyl ester.
223657439|NCT00530387|DRUG|19 organic sunscreen filters and 5 topical NSAIDs|
223657440|NCT02081885|PROCEDURE|Tricalcium Phosphate / Chitosan|
223657441|NCT02081885|PROCEDURE|Autologous Graft|
224239750|NCT01220206|DRUG|Placebo|2 placebo capsules daily
224239751|NCT01220206|DRUG|One POMx capsule daily|One POMx capsule, one placebo capsule daily
224239752|NCT01220206|DRUG|2 POMx Capsules|2 POMx Capsules daily
224239753|NCT03919942|OTHER|OxyFlower gel|the region with pericoronitis was debrided using gauze and curettes, with copious irrigation with sterile saline solution. At this moment, the gel was applied topically under the pericoronal hood, with a standard volume of 2microIiters, using a dosing syringe. Then, participants received instructions on oral hygiene and how to use the gel at home, twice a day for one week. After 30 days, it was performed third molar removal or distal wedge removal
224239754|NCT03919942|OTHER|Chlorhexidine gel|the region with pericoronitis was debrided using gauze and curettes, with copious irrigation with sterile saline solution. At this moment, the gel was applied topically under the pericoronal hood, with a standard volume of 2microIiters, using a dosing syringe. Then, participants received instructions on oral hygiene and how to use the gel at home, twice a day for one week. After 30 days, it was performed third molar removal or distal wedge removal.
224239755|NCT03919942|OTHER|Placebo gel|the region with pericoronitis was debrided using gauze and curettes, with copious irrigation with sterile saline solution. At this moment, the gel was applied topically under the pericoronal hood, with a standard volume of 2microIiters, using a dosing syringe. Then, participants received instructions on oral hygiene and how to use the gel at home, twice a day for one week. After 30 days, it was performed third molar removal or distal wedge removal
224239756|NCT00405678|BEHAVIORAL|Exercise Training|Subjects receiving chemo with exercise training
224239757|NCT00405678|BEHAVIORAL|Chemo only|Subjects receiving chemo only
224239758|NCT02695732|DRUG|Carvedilol|Carvedilol is started at a dose of 6.25 mg/d, and titrated to a maximum dose of 12.5 mg/d.Doses are increased every 7 days until ABPsys is not less than 95 mm Hg and HR is not less than 55 bpm.
223657442|NCT00835562|PROCEDURE|Non-surgical management|Non-surgical management (physiotherapy and self-training)
223657443|NCT00835562|PROCEDURE|Osteosynthesis|Osteosynthesis with angle-stable plate followed by physiotherapy and self-training
223657444|NCT00835562|PROCEDURE|Hemiarthroplasty|Primary modular hemiarthroplasty followed by physiotherapy and self-training
223657445|NCT05131724|OTHER|Treadmill training with virtual reality|The virtual environment will be composed of obstacles, different paths, and narrow and deviated corridors. Walking through this environment will require the infant to coordinate walking behaviour and adjust the length, height, and width of steps to negotiate the obstacles on the television screen placed at the infant's eye level in front of the treadmill. The speed, orientation, size, frequency of appearance, and shape of the obstacles will be manipulated according to individual performance following a standardized protocol. The virtual system will provide visual and auditory feedback on the success or failure of the activity to enhance motor learning. In addition, the characteristics of the environment (e.g., visibility, configuration, and distractions) will be adjusted to increase the complexity of the training.
223657446|NCT05131724|OTHER|Treadmill training|The RAM870A of the Medisoft treadmill will be used. Two treadmill training sessions will be held before the onset of the intervention to familiarize the children with the equipment. During these two sessions, the treadmill training and speed will be set according to the following procedures: the ground walking speed of each child will be determined through the baseline 6MWT, then the training velocity will be set at 50% of the maximum ground speed established during the 6MWT and increased gradually based on the tolerance of each child (i.e., no complaint of fatigue, heart rate not exceeding 70% of the maximum heart rate, and a lack of gait shuffling, buckling or dragging steps more than 5 seconds during walking).
223657447|NCT04723797|OTHER|Physical activity|Physical activity program consisting of running and/or cycling
223657448|NCT00238355|DRUG|caspofungin acetate|70 mg iv x 1 on day 1 (loading dose), followed by 50 mg iv daily on day 2 through day 84.
223657449|NCT00238355|DRUG|voriconazole|6mg/kg iv q12 hours x 2 doses OR 400mg po q12hours on day 1 (loading doses. Maintenance doses on day 2 through day 84 may be either 4 mg/kg iv q12 hours, or 200 mg po q12 hours (at least one hour before or after meals).
223657450|NCT01469611|BIOLOGICAL|JX-594|Infusion Procedure:JX-594 will be administered on the designated treatment days at a dose of either 1 x 106, 1 x 107 or 3 x 107 pfu per kg. Virus infusion should occur over 60 minutes (+/- 5 minutes). The final infusion volume of virus plus diluent will be approximately 250 mL.
223657451|NCT03546205|DRUG|JNJ-64565111|All participants will receive a single SC dose of JNJ-64565111 solution on Day 1.
223657452|NCT03089918|DRUG|11C-JNJ-63779586|Participants will receive IV injection with 11C-JNJ-63779586 in Part A and Part B.
223657453|NCT01064947|DRUG|Retapamulin 1%|Apply a thin layer of Retapamulin 1% to the affected area twice daily. The treated area may be covered with a sterile bandage or gauze dressing if desired.
223657454|NCT00508196|OTHER|RVP-min|DDD pacing with long AV delay
223657455|NCT00508196|OTHER|RVP-max|DDD pacing with short AV delay
223657456|NCT06444191|DRUG|Rilzabrutinib|Rilzabrutinib tablet(s) administered orally
223657457|NCT04761328|BEHAVIORAL|cognitive behavioral therapy|Cognitive-behavioral therapy involves changing these erroneous cognitions and beliefs through cognitive restructuring, modification of behavior, and development of alternative coping skills.
224239759|NCT02695732|DEVICE|endoscopy|Patients receiving endoscopic therapy (either endoscopic ligation or cyanoacrylate injection) every 4 weeks until eradication of varices.
223657458|NCT04282330|DIAGNOSTIC_TEST|3D CEST imaging|Chemical Exchange Saturation Transfer (CEST) is an emerging MRI technique that can acquire multiple endogenous contrasts to probe cerebral metabolism.
223657459|NCT00610298|DEVICE|whole body vibration using a Galileo vibrating platform|whole body vibration at 20 hertz for 3 minutes 3 to 5 days per week for up to 12 weeks
223657460|NCT04549545|DEVICE|Vivaer ARC Stylus|The Vivaer procedure will be performed in the study clinic using the Vivaer ARC Stylus and Aerin Console. The Vivaer ARC Stylus is a disposable handheld device capable of delivering bipolar radiofrequency energy to tissue when connected to the Aerin Console radiofrequency generating device. Participants in this study will undergo bilateral treatment of the nasal valves in a single study session.
223657461|NCT04549545|DEVICE|Sham|The sham control procedure will be performed in the study clinic using the Vivaer ARC Stylus while audible sounds that accurately simulate the Aerin Console's active treatment are produced even though RF energy is not being generated or delivered. All other aspects of the procedure will be the same as used for the active treatment, including administration of anesthetic agent(s).
224239760|NCT03031054|PROCEDURE|Sono-guided injection with hyaluronic acid|Sono-guided injection with hyaluronic acid (ARTZDispo, 25 mg/2.5 ml) between carpal tunnel and median nerve
224239761|NCT03031054|PROCEDURE|Sono-guided injection with normal saline|Sono-guided injection with 2.5cc Normal saline (0.9%) between carpal tunnel and median nerve
224239762|NCT05123690|DEVICE|Neurofeedback|A device that assists in training patients in relaxing.
224239763|NCT02069626|PROCEDURE|compression time of the laparoscopic linear stapler|
224239764|NCT02009800|BIOLOGICAL|Quadrivalent HPV vaccine|One dose of Gardasil administered in the intervention group
224239765|NCT00318994|DRUG|Meropenem|
223657462|NCT04478942|DRUG|Misoprostol Oral Product|Misoprostol will be dosed using the preexisting UnityPoint Health-Meriter Protocol for oral misoprostol administration.
223657463|NCT04478942|DRUG|Intravenous Oxytocin|Intravenous oxytocin administration will also follow standard, UnityPoint Health-Meriter Protocol.
223657464|NCT05130606|BEHAVIORAL|"Culturally Targeted Narrative Video: Is My Cancer Hereditary? Rosa Visits a Genetic Counselor."|Participants randomized to the video arm will receive a link with a password by email or text message to watch the video, depending on participants' preference. Participants without internet access will receive a DVD. Participants will be instructed to watch the video alone with no interruptions. We will ask them not to share the link with others.
223657465|NCT05130606|BEHAVIORAL|FORCE Fact Sheet|Participants will receive a PDF of the fact sheet by email, text message, or a printed fact sheet by mail depending on participants' preferences. The fact sheet includes information about genes, breast cancer, risk factors for HBOC, genetic counseling and testing, and resources.
223657466|NCT04554914|BIOLOGICAL|Tabelecleucel|Tabelecleucel is being investigated as an off-the-shelf, allogeneic T-cell immunotherapy for the treatment of EBV+ malignancies and diseases.
223657467|NCT05886413|OTHER|VentilO application|"This educational application provides clinicians with combinations of tidal volume and respiratory rate based on gender, height, weight, body temperature and patient type. The algorithm used is based on published data regarding ventilatory requirements in different populations (i.e. from intubated patients for scheduled surgery to the most severe ICU patients) and anatomical and instrumental dead space.~The objective of this application is to help implement personalized protective ventilation in intubated patients according to their characteristics.~After patient data entry in the VentilO application, the investigators will compare the recommended settings (for mechanical ventilation) vs the real clinician settings done by clinician after patient admission in ICU after cardiac surgery. The investigators will evaluated the potential effect of the VentilO recommendation on the first arterial (or capillary) blood gases compared to the real settings."
223657468|NCT06015152|DRUG|Tazarotene 0.045% Topical Application Lotion [ARAZLO]|\[ARAZLO\]
223657469|NCT01006291|DRUG|insulin degludec|Injected s.c. (under the skin) once daily (alternative regimen). Dose was individually adjusted.
223657470|NCT01006291|DRUG|insulin degludec|Injected s.c. (under the skin) once daily. Dose was individually adjusted.
223657471|NCT01006291|DRUG|insulin glargine|Insulin glargine injected s.c. (under the skin) once daily. Dose was individually adjusted.
223657472|NCT00234754|PROCEDURE|TVT Surgery TOT Surgery|TVT surgery and TOT surgery
223657473|NCT03114540|DRUG|GBT440|Oral
223657474|NCT03079102|DRUG|Nitric Oxide|An endogenous gaseous signaling molecule which stimulates soluble guanylate cyclase and may act via S-nitrosation, nitrite/nitrate or nitrated fatty acid formation.
223657475|NCT03079102|DRUG|Nitrogen|Nitrogen is the carrier gas (vehicle) for iNO. Subjects receiving placebo will receive equivalent doses of nitrogen.
223657476|NCT02585661|DIETARY_SUPPLEMENT|Dairy product fortified with enriched Fe-54 salt (1)|2.5mg of Fe per 100g of product
223657477|NCT02585661|DIETARY_SUPPLEMENT|Dairy product fortified with enriched Fe-57 salt (2)|2.5mg of Fe per 100g of product
223657478|NCT01440192|BIOLOGICAL|PDA001 (cenplacel-L)|1 unit PDA001 (approximately 200 x 106 cells) IV on Days 1 \& 8
223657479|NCT02398006|OTHER|a standard arm sling|Closed reduction (re-aligning the fragments of the fracture) will be not performed because the reduced position is practically impossible to maintain.
223657480|NCT02398006|OTHER|a figure-of-eight bandage|Closed reduction (re-aligning the fragments of the fracture) will be not performed because the reduced position is practically impossible to maintain.
223657481|NCT01793870|DRUG|Tab carvedilol 25 mg|Carvedilol 25 mg immediate release tablet
223657482|NCT01793870|DRUG|Tab carvedilol 6.25 mg|Carvedilol 6.25 mg immediate release tablet
223657483|NCT01793870|DRUG|Powder carvedilol up to 2.5 mg|Carvedilol up to 2.5 mg isotopically enriched drug substance powder
223657484|NCT03982134|DRUG|PDR001|PDR001 is a humanized IgG4 antibody
223657485|NCT03982134|DRUG|Panobinostat|Panobinostat is a Histone deacetylase inhibitor (HDACi).
223657486|NCT00747734|DRUG|MNRP1685A|Escalating intravenous dose
223657487|NCT00062231|DRUG|amoxicillin-clavulanate potassium|
223657488|NCT00062231|DRUG|ciprofloxacin|
223657489|NCT00062231|DRUG|moxifloxacin hydrochloride|
223657490|NCT00062231|PROCEDURE|management of therapy complications|
223657491|NCT02810444|BIOLOGICAL|IgG Next Generation (BT595)|
223768499|NCT06282315|DRUG|Passive Surveillance|Passive surveillance will be carried out by monitoring AEs in health facilities near the schools involved in the study for six days after the intervention until Day 7 (end of the safety surveillance period). Although AE will be actively monitored during the scheduled study visits, this passive surveillance will allow for the identification of AEs and potential SAEs that might occur and remained underreported in case the participant does not attend school during the active safety surveillance period. In addition, a diary cards will be given to participants to write any AE they may have from Day 2 to Day 6 post intervention.
224239766|NCT03377881|PROCEDURE|MRI/Fusion biopsies|The intervention in the experimental arm is an MRI with targeted biopsies using fusion technique to prostate lesions. Repeat screening is offered after 2-6 years on an individualised basis.
224239767|NCT03377881|PROCEDURE|Systematic biopsies|The intervention in the control arm is traditional systematic biopsies of the prostate.
224239768|NCT05825495|DRUG|Dinalbuphine sebacate|A single dose of 150 mg dinalbuphine sebacate will be intragluteally administrated at least 12 hours before surgery.
224239769|NCT05825495|OTHER|Routine practice|Within 3 days after surgery, paracoxib will be administrated twice a day. Ketorolac will intravenously give once breakthrough pain occurring. Enteral acetaminophen will be take regularly within 14 days after surgery.
224239770|NCT04648358|DRUG|Bupivacaine|The control group will receive scalp nerve blocks with 0.5% bupivacaine with epinephrine at 1:200,000, plus normal saline 1 ml. The anesthesiologist will perform scalp nerve blocks based on the group allocation 10 mins before the incision. Scalp nerve blocks will be performed according to the technique previously described by Pinosky et al.
224239771|NCT04648358|DRUG|Dexamethasone combined with bupivacaine|The DEX4mg group will receive scalp nerve blocks with 0.5% bupivacaine with epinephrine at 1:200,000, plus 4 mg dexamethasone (1 ml). The anesthesiologist will perform scalp nerve blocks based on the group allocation 10 mins before the incision. Scalp nerve blocks will be performed according to the technique previously described by Pinosky et al.
224239772|NCT04033952|BEHAVIORAL|Strategy Training|This approach is different from traditional direct skill training, which emphasizes clinicians' responsibility on identifying their patients' challenges in performing activities and teaching patients task-specific problem-solving strategies. Strategy training, on the other hand, requires clinicians to take a role as a facilitator, guiding participants to learn through prompts and questions. In the training process, participants learn to develop their own problem-solving strategies and work through the problems they have, through which they can develop self-efficacy and confidence to manage participation challenges. Participants can also generalize the strategies they learn to other similar problems they encounter in daily life.
224239773|NCT04818242|DEVICE|Dexcom G6 CGM with GTS|CGM sensor will be placed after consent. Glucose values obtained from the CGM sensor will be sent to the CGM transmitter by Bluetooth technology and Dexcom Share2 software application to a smart phone that serves as an intermediate-transmitting (routing) device. Glucose values from the smart phone will be transmitted wirelessly to a table computer (I-Pad) using the Dexcom Follow application. Information on the CGM will activate an alarm in case of hypoglycemia or hyperglycemia events. Hypoglycemia alarm will be set to \< 85 mg/dl (for prevention for low blood glucose levels). Nursing staff will be instructed to provide 15 grams of carbohydrates in response to a hypoglycemia alarm.The hyperglycemia alarm will be set at 300 mg/dl. If this occurs, the nursing staff will assess clinical status and perform a POC glucose testing to confirm glucose values. If blood glucose (BG) \> 300 mg/dl, nursing staff will communicate the high glucose value to the primary care team.
224239774|NCT04818242|DIAGNOSTIC_TEST|POC Blood Glucose Test + Blinded CGM|Point of Care (POC) testing before meals and bedtime (standard of care). For the control group, participants will also get a CGM sensor (blinded CGM). CGM alarms are turned off, however if the POC is found to be between \<80 mg/dl by POC, 15 grams of carbohydrates will be given as a preventive measurement for hypoglycemia (standard of care).
223657492|NCT02249637|PROCEDURE|Novel technique Circumcision Incision Orchidopexy|The novel technique starts with retraction of the prepucial skin off the glans penis and double incision circumcision done with mucosal sparing, then degloving of the penis on the side of the undescended testis. Dissection via Dartos' layer into the inguinal area until the palpable testicle was identified and extracted with mobilization of the spermatic cord. Hernia sac was then separated and suture ligated as high as the area of internal ring opening. Spematic cord lengthening was done until adequate length achieved for fixation into the inferior aspect of the scrotum. Then development of the Dartos' pouch via the circumcision site was done. A double or single suture testicular fixation using Vicryl 3-0 simple interrupted sutures on the everted Dartos' pouch inner surface was done. Subsequent placement of the testicle into the Dartos' pouch was done as the inner surface was inverted. The last step was the completion of the circumcision closure using Chromic 4-0 interrupted sutures.
223657493|NCT05401058|DRUG|Droperidol Injection|About 30min before the end of operation, Droperidol 1.25mg/0.5ml will be administered by intravenous injection.
223657494|NCT05401058|DRUG|Saline|About 30min before the end of operation, Normal saline 0.5ml will be administered by intravenous injection.
223657495|NCT02785770|DRUG|PF-04447943|Single oral dose of PF-04447943 administered as an extemporaneously prepared solution
223657496|NCT02785770|DRUG|Placebo|Single oral dose of matching placebo for PF-04447943 administered as an extemporaneously prepared solution
223657497|NCT02785770|DRUG|Moxifloxacin|Single oral dose of moxifloxacin administered as tablet
223657498|NCT03488511|OTHER|FoodforCare at home|Six small protein rich meals that will be delivered twice a week for 3 weeks.
223657499|NCT02452827|OTHER|Biomechanical parameters|
223657500|NCT02452827|OTHER|MRI|MRI of cervical spine
223657501|NCT05880290|PROCEDURE|gynaecological examination in lateral decubitus|Single group: gynaecological examination in lateral decubitus, conventional repositioning if unsuccessful
223657502|NCT05481957|DRUG|Vortioxetine|5-10mg for 16 weeks
223657503|NCT05481957|DRUG|valprote|500\~1000mg for 16 weeks
223657504|NCT01624311|OTHER|Therapeutic Hypothermia|After obtaining written consent, patients are cooled to 33.5°C (+/- 1°C ) for 72 hours and and then rewarmed by 0.5°C per every 3 hours over 18 hours.
223657505|NCT01624311|OTHER|Standard of Care Therapy|Patients with hyperammonemia and encephalopathy requiring renal replacement therapy due to a urea cycle disorder or organic acidemia that were treated at Children's National Medical Center over the past 10 years.
223657506|NCT05331859|DRUG|Insulin|Topical insulin drops will be prepared by diluting 1 unit of rapid-acting insulin per 1 mL of an artificial tear with a propylene glycol base. Drops will be preserved at low temperature (2ºC) and applied four times a day.
223657507|NCT05331859|DRUG|autologous serum (AS)|Whole blood (20 ml) wll be procured by venipuncture, centrifuged at 1,500 revolutions per minute (relative centrifugal force of 25.15 × g) for 10 minutes. AS drops will be carefully prepared under a laminar airflow cabinet, and diluted with artificial tears (Systane ultra; Alcon) to 20%. AS drops will be prepared on the day of surgery and patients will be asked to keep AS drops refrigerated at about 4C.
223657508|NCT05331859|DRUG|conventional|Topical moxifloxacin 0.5% (Vigamox; Alcon Laboratories) four times per day, artificial tears (Systane ultra; Alcon) every two hours, Dexamethasone 0.1% (Maxidex; Alcon Laboratories) four times daily for one month then fluorometholone 0.1% (Efemyo; Orchidia Laboratories) four times daily for another two to four weeks depending on refraction and haze level.
223657509|NCT05423353|DEVICE|Paraffin Bath Therapy|Device named 'Fizyowax 1300' (Fizyomed, Turkey).
223657510|NCT05423353|DEVICE|Extracorporeal Shock Wave Therapy|Device named 'Elettronica Pagani,Italy' and will be used with radial probe.
223657511|NCT03704753|DRUG|Ropivacaine|Serratus anterior plane block for thoracic surgery patients and subpectoral interfascial nerve block for open heart surgery patients
224239775|NCT02256085|DEVICE|Daily rTMS with Active coil|rTMS produces strong electromagnetic fields (\~2Tesla) generated briefly (\~1ms) but repetitively (1Hz) applied for 30mins, in five sessions per week for six weeks
224239776|NCT02256085|DEVICE|Daily rTMS with Sham coil|rTMS produces strong electromagnetic fields (\~2Tesla) generated briefly (\~1ms) but repetitively (1Hz) applied for 30mins, in five sessions per week for six weeks
224239777|NCT02256085|DEVICE|Open Label Daily rTMS with Active coil|rTMS produces strong electromagnetic fields (\~2Tesla) generated briefly (\~1ms) but repetitively (1Hz) applied for 30mins, in five sessions per week for six weeks
224239778|NCT00290147|BIOLOGICAL|D1ME100 (dengue-1 premembrane/envelope DNA vaccine)|IM injection delivered by Biojector
224239779|NCT03043547|DRUG|nal-IRI|nal-IRI \[Irinotecan liposome\] (80 mg/m2 as a 1.5 hour infusion)
223768500|NCT06282315|DRUG|Post-Treatment Effectiveness Evaluation|"Post-treatment effectiveness evaluation will be performed by measuring the prevalence of STH at two time points: 21 days after the intervention (± 7 days) and 11 months after intervention (± 28 days). Additionally, the reduction in S. stercoralis seroprevalence will be evaluated 11 months after the intervention.~These participants will be tested for STH by Kato-Katz at the two post-treatment time points (day 21 and month 11) and for S. stercoralis by NIE ELISA at 11 months. The diagnostic test will be the same as in the intervention of Baseline Effectiveness Cohort.~As part of the genetic monitoring pilot study and the microbiome analysis, the same samples will be collected as described in the intervection of Baseline Effectiveness Cohort."
224239780|NCT03043547|DRUG|5-FU|5-FU \[5-Fluorouracil\] (2400 mg/m2 as 46 hour infusion)
224239781|NCT03043547|DRUG|leucovorin|leucovorin (400 mg/m2 as 0.5 hour infusion)
224239782|NCT05080751|BEHAVIORAL|Eating Behaviors|Materials to be weekly available for intervention group, following a schedule of sessions (six in total): videos, audios, booklets, films, books and other presentations. The intervention will be based online, in a asynchronous modality. Members will self-manage activities.
224239783|NCT03227445|DEVICE|ELLIPTA placebo DPI|ELLIPTA is a dry powder inhaler used via oral route. It will be a placebo DPI with two strips with 30 blisters per strip. First strip will contain lactose monohydrate and the second strip will contain lactose monohydrate blended with magnesium stearate.
223657512|NCT03704753|DRUG|Sodium chloride 0.9%|Serratus anterior plane block for thoracic surgery patients and subpectoral interfascial nerve block for open heart surgery patients (placebo).
223657513|NCT01976039|OTHER|rhinopharyngeal retrograde clearance (RRC)|The rhinopharyngeal retrograde clearance is a respiratory physical therapy technique that uses a forced inspiratory maneuver to clear the nasopharynx with the aid of saline instillation
223657514|NCT02903459|OTHER|Transversal Study so there is no intervention|
223657515|NCT04518995|DRUG|CTP-543 matching placebo|Administered as tablets.
223657516|NCT04518995|DRUG|CTP-543|Administered as tablets.
223657517|NCT04518995|DRUG|CTP-543|Administered as tablets.
223657518|NCT00345644|DRUG|risedronate|risedronate sodium 35 mg tablets (once a week dose)
223657519|NCT00345644|DRUG|risedronate placebo|placebo for risedronate tablets (once a week dose)
223657520|NCT01062373|DIETARY_SUPPLEMENT|Supplementation of lactating mothers who has delivered prematurely with DHA|Supplementation in DHA will be conducted for 1 month at the dose of 200 mg DHA per day provided by TG-DHA from Decola (products from Martek) (two soft capsules per day)
223657521|NCT01062373|DIETARY_SUPPLEMENT|Supplementation of lactating mothers who has delivered prematurely with DHA|Supplementation in DHA will be conducted for 1 month at the dose of 200 mg DHA per day provided by GPL-DHA from ASL (10 g per day) (two soft capsules per day)
223657522|NCT00639743|DRUG|placebo ( group B)|placebo ( group B)
223657523|NCT00639743|DRUG|tenecteplase (group A)|tenecteplase (group A)
223657524|NCT02835053|OTHER|Frailty|Participants will be defined as frail based on the Johns Hopkins ACG Frailty Defining Diagnoses Indicator, which will be applied to available health administrative data in the 3 years preceding index hospital admission. If no frailty defining diagnoses are present participants will be defined as not frail
223657525|NCT05950152|DRUG|Meloxicam Injection 30mg|meloxicam injection 30mg every 24 hours for up to 2 dose
223657526|NCT05950152|DRUG|Meloxicam Injection 60mg|meloxicam injection 60mg every 24 hours for up to 2 dose
223657527|NCT05950152|DRUG|Nacl 0.9%|IV Placebo every 24 hours for up to 2 doses
223657528|NCT00904410|OTHER|FDG-PET|370 MBq of FDG one hour before imaging acquisition PET just before neo-adjuvant chemotherapy and just before the second cycle
223657529|NCT05987176|DRUG|Lutathera|"Dosage:~In total 14.8 GBq (400 mCi) 177Lu-DOTATATE administered in two equally divided doses. Each dose to be infused over 30 minutes.~Duration of treatment:~Two administrations of 177Lu-DOTATATE (each treatment 7.4 GBQ (200 mCi) at 8±1-week intervals, which can be extended to 16 weeks for resolving acute toxicity."
223657530|NCT06052449|BEHAVIORAL|Social determinants of health screening assessment and referral process|Unite Us is an electronic SDoH screening and referral tool assessing: (1) financial resource strain; (2) housing stability; (3) transportation needs; and (4) food insecurity. Upon completion, the Unite Us platform identifies a list of geographically-tailored resources to connect the individual in need. A staff member will administer the SDoH screening and referral tool, review the results with the participant, and use the geographically-tailored resources to make SDoH-related referrals.
223657531|NCT06052449|BEHAVIORAL|Current practice - Community-based lunch cancer screening (LungTalk)|The current practice during community events is to offer LungTalk. LungTalk is a novel theoretically grounded health educational tool that will be delivered via iPad and is an interactive computer-based program that includes audio, video and animation segments with scripts presented from a master content library in consideration of different ways people like to learn. Informed by our prior research, LungTalk tailors its content based on smoking status and perceived barriers. In prior work, LungTalk more than doubled LCS knowledge and health beliefs (p \< 0.01), and was associated with a significant increase in deciding to screen for lung cancer compared to control group; OR 1.99; 95% Confidence Interval (CI), 1.03, 3.85, p = 0.03.
223657532|NCT06454682|DRUG|RJK002 Intrathecal injection|Eligible subjects will receive a single intrathecal administration of investigational product with dose 3E13 vg/person, 6E13 vg/person, and 1.2E14 vg/person sequentially.
223768501|NCT03026998|PROCEDURE|MRI|MRI will be performed each year during 10 years.
224239784|NCT03227445|DEVICE|DISKUS placebo DPI|DISKUS is a dry powder inhaler used via oral route. It will be a placebo DPI with one blister strip that will contain lactose monohydrate.
223657533|NCT06128538|DEVICE|Auricular acupuncture|we will implement 12 weeks of BFA. These sessions will be done every other week (total of 6 sessions over 12 weeks). During these sessions, Dr. Quinlan (Co-I) and another BFA-trained provider (Dr. Wilbur or Dr. Butler; also research team members) will perform the group BFA protocol with all 20 participants. During this 12-week acupuncture phase, participants will receive the same SMS messages twice a week to collect pain intensity scores. The group BFA protocol involves taking vitals for all patients (similar to a regular medical visit) and placing all 10 acupuncture needles (5 in each ear) while the patient remains seated in a chair. Once the acupuncture needles are placed, the patient will be asked to move around and remain in the room for 30 minutes (for any questions or medical concerns.
223768502|NCT06808204|OTHER|Questionnaire|Quality of life questionnaire : Peds QL 4.0 (Pediatric Quality of Life )
223768503|NCT06808204|OTHER|questionnaire|Physical activity level : Ricci and Gagnon questionnaire
223768504|NCT06808204|OTHER|questionnaire|Anxiety questionnaire : State and Trait Inventory
224239785|NCT03227445|DEVICE|HandiHaler placebo DPI|HandiHaler is a dry powder inhaler used via oral route. It will be a DPI with placebo capsules that will contain lactose monohydrate.
224239786|NCT03227445|OTHER|Inhaler preference questionnaires|Preference questionnaires will be given to subjects to understand the inhaler preference. There will be 2 types of questionnaire, preference questionnaires 1 and 2, which will be randomized at visit 3 (Day 56).
224239787|NCT01624376|DRUG|DLX105|10mg DLX105/injection injected into the fistula over a treatment period of 4 weeks.
224239788|NCT01624376|DRUG|Placebo|Placebo injections are administered over the treatment period of 4 weeks.
224239789|NCT02835482|PROCEDURE|Femtolaser surgery|
224239790|NCT02835482|PROCEDURE|Phacoemulsification|
224239791|NCT02025465|DRUG|Metoprolol|"The attending ED physician may use higher or lower intravenous doses depending on patient response as this is the norm in clinical practice for these two medications used for decades for AF/FL rate control.~Conversion of intravenous to oral, chronic management will be left to the discretion of the ED or managing medical team."
224239792|NCT02025465|DRUG|Diltiazem|"The attending ED physician may use higher or lower intravenous doses depending on patient response as this is the norm in clinical practice for these two medications used for decades for AF rate control.~Conversion of intravenous to oral medication for rate control for chronic management will be left to the discretion of the ED or managing medical team."
224239793|NCT01977469|BEHAVIORAL|Low intensity resistance training|The LIRT group initiated the resistance training for UL with 30% of the 1RM, with 5% increases each nine sessions; therefore, the maximum load was 45% of the 1RM. The LL training initiated with 30% of the 1RM, increasing 7% each nine sessions, thus, the maximum load was 51% of the 1RM. Each exercise session consisted of three sets of 15 repetitions, with a 2 minutes interval between sets.
224239794|NCT01977469|BEHAVIORAL|High intensity resistance training|the initial load for HIRT group was 60% of 1RM for UL with 5% increases each nine sessions; therefore, the maximum load reached 75% of the 1RM. The LL training initiated with 60% of the 1RM with 7% increments each nine sessions, as a result, the maximum load after 36 sessions was 81% of the 1RM. These patients underwent three sets of eight repetitions, with two minutes intervals between sets.
224239795|NCT01977469|BEHAVIORAL|Aerobic training|Patients underwent an aerobic training in cycle ergometer, with load intensity determined as the same load the patient presented a VO2 value of 70-80% of the peak VO2 obtained in the symptom-limited CPET. Each session of aerobic training lasted 20-30min according to patient's tolerance.
224239796|NCT01870180|DEVICE|EyeBag|fabric bag of beads which can be heated in a microwave
224239797|NCT01870180|OTHER|Placebo|
224239798|NCT05886426|DIAGNOSTIC_TEST|4DCT wrist and standard CT wrist|Dynamic CT aquistion of wrist during movement and standard static wrist CT
224239799|NCT02745522|DRUG|Oxytocin|
224239800|NCT02745522|DRUG|Placebo|
224239801|NCT00755196|DRUG|AN2728|AN2728 Ointment, 5%, twice daily for 12 weeks
223768505|NCT06808204|OTHER|questionnaire|Depression questionnaire : Child Depression Inventory
223768506|NCT06808204|OTHER|questionnaire|Child Depression Inventory
223768507|NCT06808204|OTHER|questionnaire|Quality of life of parents before and after transcatheter ablation
223768508|NCT05177042|DRUG|ARV-110 in Combination with Abiraterone|ARV-110 oral tablets in combination with abiraterone and a corticosteroid administered daily in 28 day cycles
224239802|NCT00755196|DRUG|Ointment vehicle|Ointment vehicle, twice daily for 12 weeks
224239803|NCT04878146|PROCEDURE|Sacro-spinous fixation|Uterine cervix will be attached to the sacro-spinous ligament
224239804|NCT04878146|PROCEDURE|Subtotal hysterectomy|Done on both arms
224239805|NCT04878146|PROCEDURE|Sacrocolpopexy|Uterine cervix is attached to sacral promontory with two synthetic meshes
224239806|NCT04670913|DRUG|Camrelizumab|A human anti-PD-1 monoclonal antibody
224239807|NCT04670913|DRUG|Apatinib|A tyrosine kinase inhibitor selectively targeting VEGFR-2
224239808|NCT04734964|BEHAVIORAL|exercise training|Exercise training session for 45 minutes.
224239809|NCT00677118|DRUG|Cisplatin,fluorouracil|Patients receive radical radiotherapy and cisplatin (40mg/m2 on day 1) weekly during radiotherapy, then receive cisplatin (80mg/m2 on day 1) and fluorouracil (800mg/m2 on Day 1 to 5) every four weeks for three cycles after completion of radiotherapy.
224239810|NCT00677118|DRUG|Cisplatin|Patients receive radical radiotherapy and cisplatin (40mg/m2 on day 1) weekly during radiotherapy.
224239811|NCT00002579|DRUG|CMF regimen|
224239812|NCT00002579|DRUG|cyclophosphamide|
224239813|NCT00002579|DRUG|fluorouracil|
224239814|NCT00002579|DRUG|methotrexate|
224239815|NCT00002579|DRUG|tamoxifen citrate|
224239816|NCT00002579|PROCEDURE|conventional surgery|
224239817|NCT00002579|RADIATION|radiation therapy|
224239818|NCT01703832|DRUG|Neurexan®|0.6 mg / tablet, 6 tablets, 1 tablet every 30 minutes from -180 minutes to -30 minutes
224239819|NCT01991470|DEVICE|Enlite sensors|Subject wears enlite sensor first and followed by enlite 3 sensor.
224239820|NCT05696470|DEVICE|DePuy Synthes Conduit 3D printed titanium cages|DePuy Conduit 3D printed titanium cages supplemented with SKYLINE Anterior Cervical Plate System and 1 CC DBM
224239821|NCT00243932|DRUG|coenzyme Q10|antioxidant and mitochondrial cofactor, given in capsules three times daily
224239822|NCT00243932|DRUG|Placebo|Placebo capsules, indistinguishable from CoQ10 capsules, given three times daily
223768509|NCT02259413|BEHAVIORAL|Exercise Rehabilitation|This intervention will consist of lifestyle education, home-based resistance exercise and stationary cycling during hemodialysis sessions. Duration of the intervention will be 26 weeks
223768510|NCT04850378|DRUG|Dalteparin|Drug: Dalteparin 200 units/kg once a day for 4-7 days.
223768511|NCT04850378|DRUG|Apixaban|Drug: Apixaban 5 mg twice a day for 4-7 days.
223768512|NCT05569954|BIOLOGICAL|V116|Sterile 0.5 mL solution in prefilled syringe containing 4 μg of each pneumococcal polysaccharide (PnPs) antigen 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15C, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F, and 35B.
223768513|NCT05569954|BIOLOGICAL|PPSV23|Sterile 0.5 mL solution in prefilled syringe containing 25 μg of each PnPs antigen 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F.
223768514|NCT01660412|DRUG|Standard of Care First|For the second injection, and randomly after that, Sodium Bicarbonate will be compounded with Tc-99m SC, to raise the pH up to \~7.40.
223768515|NCT01660412|DRUG|ph Altered first|For the first injection, Sodium Bicarbonate will be compounded with Tc-99m SC, to raise the pH up to \~7.40. For the second injection, the standard of care will be given, and randomly after that either standard of care, or pH altered will be given.
223768516|NCT03118128|DRUG|Metformin|Metformin 850 mg PO three times a day plus prednisone in one 7-days cycle as pre-treatment and during the 28 days induction remission treatment, consolidation therapy and maintenance
223768517|NCT02184221|DEVICE|High frequency stimulation|The parameter of DMS: alpha frequency
223768518|NCT02184221|DEVICE|Low frequency stimulation|The parameter of DMS: 0.5Hz
223768519|NCT05733949|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
223768520|NCT05733949|PROCEDURE|Computed Tomography|Undergo CT
223768521|NCT05733949|RADIATION|Stereotactic Body Radiation Therapy|Undergo ST-SBRT
223768522|NCT04920448|DRUG|N-Acetyl cysteine|Administered as specified in the treatment arm
223768523|NCT05741658|DRUG|Dapagliflozin 10mg Tab|Participants will take one Dapagliflozin 10mg tablet once per day for 4 weeks.
223768524|NCT06504082|DRUG|Letrozole|Patients in the MTX + letrozole group received letrozole tablets (Femara 2.5 mg) once daily for ten days starting from the day of MTX administration.
223768525|NCT06504082|DRUG|Methotrexate|After confirming the diagnosis of tubal ectopic pregnancy, each patient will receive a single dose of intramuscular MTX (50 mg/m² MTX) on the same day
223768526|NCT03013491|DRUG|CX-072|Solution for infusion
223768527|NCT03013491|DRUG|ipilimumab|Solution for infusion
223768528|NCT03013491|DRUG|vemurafenib|Tablet
223768529|NCT06672575|DRUG|Ivonescimab|Participante will recived an infusion by vein
223768530|NCT06616701|BEHAVIORAL|Follow up call|As part of the standard of care, caregivers of youths who present to the hospital with suicidal risk receive a follow up call approximately 5-10 business days after the hospital discharge to assist them with any challenges they may encounter in accessing mental health care, including medication access. The intervention group will receive a call 5 days after discharge. The non-intervention group will receive a call 10 days after discharge.
223768531|NCT06995300|PROCEDURE|minimally invasive decompression via the posterior approach|All patients will undergo minimally invasive isolated decompression via the posterior approach to the cervical spine.
223768532|NCT01223716|BEHAVIORAL|Perceptual learning|Research participants will be asked to practice a visual discrimination task (e.g. position acuity, contrast sensitivity, stereoacuity etc) in our laboratory for a period of time (2 hrs/day, 5 days/week).
223768533|NCT01223716|BEHAVIORAL|Video Game|"Research participants will be asked to play off-the-shelf video games in our laboratory for a period of time (2 hrs/day, 5 days/week)."
223768534|NCT01223716|BEHAVIORAL|Crossover (Occlusion therapy + Video Game)|"Phase 1. Research participants will be required to cover the good eye during the day in order to push the brain to use the amblyopic eye (2 hrs/day, 5 days/week for 2-4 weeks).~Phase 2. Research participants will be required to cover the good eye during the day in order to push the brain to use the amblyopic eye (2 hrs/day, 5 days/week for 2-4 weeks)."
224239823|NCT03937453|DIAGNOSTIC_TEST|MRI/MRCP|An MRI/MRCP with IV gadolinium contrast with high resolution imaging of the pancreas will be performed at baseline. Further imaging upon recommendation by study committee
223657534|NCT06128538|BEHAVIORAL|Visual Analog Scale for Pain|During the first 12 weeks of the trial, the research manager will collect weekly pain scores using the visual analog scale (pain scale 1-10). During the second 12 week phase of the trial, which includes the acupuncture sessions, the research manager will collect pain scores using the visual analog scale at each acupuncture session immediately before and 30 minutes after the acupuncture protocol by the research team, and then twice a week thereafter.
223657535|NCT06128538|BEHAVIORAL|Roland-Morris Disability Questionnaire|During the first 12 weeks of the trial, the research manager will collect weekly Roland -Morris Disability questionnaire data. During the second 12 week phase of the trial, which includes the acupuncture sessions, the research manager will collect disability scores using the Roland-Morris Disability Questionnaire at each acupuncture session (6 sessions in total).
223657536|NCT04978454|BIOLOGICAL|Influenza RG-A/Texas/71/2017 (H3N2) Challenge|RG-A/Texas/71/2017 (H3N2) is an infectious influenza virus and requires handling at BioSafety Level 2. The challenge virus will be administered intranasally in a volume of approximately 0.5 mL per nostril. Intranasal challenge will be carried out using the Intranasal Mucosal Atomization ( MAD Nasa(TM)) Device attached to a 1 mL syringe.
223657537|NCT04978454|OTHER|Placebo|Sucrose phosphate glutamate (SPG) inoculum
223768535|NCT05269628|DRUG|Cannabidiol (CBD)|"Epidiolex® dose will be 0.5 mL (50 mg) twice daily during the first seven days of active treatment (half of full anticipated dose), followed by 1 mL (100 mg) twice daily for the remainder of the treatment interval (full dose). If the full dose (100 mg twice daily) is not tolerated by participants, they will have the option of going down to the original half-dose (50 mg twice daily).~Participants who go back to the half-dose of Cannabidiol (50 mg twice daily) also have the option to request once-per-day dosing with study drug taken at preferred time of day. Participants who request once-per-day dosing will not exceed a total daily dose 100 mg Cannabidiol per day. Participants who are tolerating the full-dose of medication (Cannabidiol 100 mg twice daily) will not be allowed to combine these doses into one daily dose."
224239824|NCT02947009|BEHAVIORAL|Diagnostic Study|Participants will undergo laryngoscopy at baseline and with exercise challenge and will rate severity of various symptoms related to the larynx (ex. shortness of breath, voice changes, cough).
224239825|NCT06233266|DRUG|Ticagrelor-Test product|Ticagrelor Tablets 90 mg Manufactured by: Mankind Pharma Limited, India
224239826|NCT06233266|DRUG|Ticagrelor-Reference product|Ticagrelor Tablets 90 mg Manufactured by: AstraZeneca AB, Sweden
224239827|NCT00460304|DRUG|pramlintide|
224239828|NCT00460304|PROCEDURE|continuous glucose monitoring|
224239829|NCT03409601|OTHER|100% Portion Size|Meal portion size at baseline
224239830|NCT03409601|OTHER|125% Portion Size|Meal portion size 125% of baseline
224239831|NCT03409601|OTHER|150% Portion Size|Meal portion size 150% of baseline
223657538|NCT05433285|BIOLOGICAL|COVID-19 Protein Subunit Recombinant Vaccine|SARS-CoV-2 RBD subunit recombinant protein, manufactured by PT. Bio Farma
223657539|NCT05433285|BIOLOGICAL|Active Comparator|Covovax® COVID-19 vaccine is a protein-based vaccine candidate engineered from the genetic sequence of the first strain of the SARS-CoV-2 betacoronavirus
223657540|NCT05424289|DEVICE|videolaryngoscope|Videolaryngoscope is a high-resolution micro camera mounted on the tip of a curved blade connected to small portable digital monitor improves the view of the vocal cords
223657541|NCT04190888|OTHER|No intervention|No intervention - observational study
223657542|NCT01310205|DRUG|SCV-07|This is an extension of ongoing study SCI-SCV-HCV-P2-001. Subjects will be invited to participate in this extension study if they complete treatment in study SCI-SCV-HCV-P2-001 and are eligible for retreatment with peg-IFN and RBV
223657543|NCT00222664|BIOLOGICAL|Hep-V Vax|
223657544|NCT02891070|DRUG|FS VH S/D 500 s-apr|
223657545|NCT02891070|DEVICE|DuraSeal Dural Sealant|
223657546|NCT02945709|BEHAVIORAL|Personalized Attention control training (ACT)|In this intervention, participants will be trained with a personalized Dot-Probe task. Each participant will perform the task with the set of words that he or she ranked as the most threatening according to a Word Ranking Task.
223657547|NCT02945709|BEHAVIORAL|Non-personalized Attention control training (ACT)|"In this intervention, participants will be trained with the same Dot-Probe task as in the personalized condition, except that the word stimuli will be randomly fit for each participant. It should be noted that 25% out of the words in this condition will be high ranked words according to each patient's word ranking. The aim of this is to enhance similarity to a generic ACT intervention (see Badura-Brack et al., 2015), where there is some degree of exposure to what one may consider personalized stimuli (i.e., threat words that were randomly included by the researchers), although it is not deliberately set to idiosyncratic preferences."
223657548|NCT02945709|BEHAVIORAL|Control training.|In this intervention, participants will perform a computerized task, similar to the Dot-Probe task. In each trial, one neutral word will be presented at the center of the screen and participants will respond to a probe ('E' or 'f') presented following the removal of the words display. This version does not include the essential ingredients thought to reduce PTSD symptoms in the other dot-probe tasks: exposure to threat content and competition on attentional resources. Thus, this control version provides a control condition for the ACT interventions.
223657549|NCT03336437|DRUG|Estradiol vaginal ring|Estradiol 2mg vaginal ring
223657550|NCT03336437|OTHER|Placebo vaginal ring|Silicone vaginal ring without any active estradiol
223657551|NCT05173116|OTHER|Medical Outcomes Study Short Form 36 (SF 36)|completion of questionnaire quality of life SF 36 (inclusion, Month 3, Month 6).
223657552|NCT05173116|OTHER|observationnal study|data collection
223657553|NCT04702919|OTHER|Registration|Synchronized recording of BTP in ultrasound, brain activity by EEG, heart rate and blood pressure.
223657554|NCT04702919|OTHER|Auditive oddball task|Presentation of an auditory sequence, comprising 'Standard' (probability of occurrence: p = 0.90) and 'Deviants' (p = 0.10, targets) sounds via loudspeakers.
223657555|NCT05091775|DRUG|Asacol is used to treat and prevent mild to moderate acute fissure disease|Comparison of two groups after 2 weeks in fissure wound healing, pain relief, pruritus, burning, bleeding, incontinence. Preliminary results of the study show the rate of fissure improvement 6 weeks after treatment, which is observed by clinical examination. Restoration is defined by complete epithelialization of the fissure site without scarring or residual cracks, and the secondary results will be a reduction in the amount of pain and other symptoms.
223657556|NCT00085176|PROCEDURE|management of therapy complications|
223657557|NCT00085176|PROCEDURE|psychosocial assessment and care|
224239832|NCT03409601|OTHER|175% Portion Size|Meal portion size 175% of baseline
224239833|NCT03542422|DRUG|Apatinib|Metastasis after primary treatment : Apatinib + yew + platinum. Local recurrence after previous surgery/radiotherapy: Apatinib alone or in combination with platinum-based chemotherapy.
223657558|NCT01320137|PROCEDURE|Blood withdrawal|Blood sampling
223657559|NCT02934100|DEVICE|Shock Master 300|"Extracorporeal Shock Wave Therapy~In all treatments (from 1 to 10) applied number of pulses is 4500 and the frequency is based on the patients feelings (from 8 to 12 Hz). Variable is the pressure:~Treatment 1 - 2,5 Bar; Treatment 2 - 2,6 Bar; Treatment 3 - 2,7 Bar; Treatment 4 - 2,8 Bar; Treatment 5 - 3,0 Bar; Treatment 6 - 3,2 Bar; Treatment 7 - 3,4 Bar; Treatment 8 - 3,6 Bar; Treatment 9 - 3,8 Bar; Treatment 10 - 4,0 Bar.~Each patient will also receive kinesiotherapy treatment that will consist of:~* eight-minute massage of posterior lower leg muscles~* plantar aponeurosis stretching"
223657560|NCT02934100|DEVICE|Skanlab 25 BODYWAVE|"Electric field diathermy therapy - Capacitive energy transfer system (CETS)~Time of each treatment (from 1 to 15) is eight minutes. Variable is the energy:~Treatment 1 - 3; Treatment 2 - 3; Treatment 3 - 4; Treatment 4 - 4; Treatment 5 - 5; Treatment 6 - 5; Treatment 7 - 6; Treatment 8 - 6; Treatment 9 - 7; Treatment 10 - 7; Treatment 11 - 7; Treatment 12 - 7; Treatment 13 - 7; Treatment 14 - 7; Treatment 15 - 7.~Each patient will also receive kinesiotherapy treatment that will consist of:~* eight-minute massage of posterior lower leg muscles~* plantar aponeurosis stretching"
224239834|NCT01246830|RADIATION|Panoramic radiograph, Cephalometric radiograph|2D images that are used for orthodontic treatment planning
224239835|NCT01246830|RADIATION|Cone-beam computed tomography (CBCT)|CBCT data will be used in 3D cephalometric analysis softwares
224239836|NCT03247556|DRUG|Placebo|Placebo was administered once daily
224239837|NCT03247556|DRUG|400mg SPN-812|400mg SPN-812 was administered once daily and compared to Placebo
224239838|NCT03247556|DRUG|600mg SPN-812|600mg SPN-812 was administered once daily and compared to Placebo
224239839|NCT04457999|DEVICE|Lipiflow Thermal pulsation|Single vectored thermal pulsation treatment for dry eye
223657561|NCT02934100|DEVICE|EVO US13 CosmoGamma|"Ultrasound therapy~Doses applied as following:~Each treatment (from 1 to 15) is pulsed ultrasound (1MHz, pulsed 1:4). Variable is the time and intensity:~Treatment 1 - 4 minutes, 0,4 W/cm2; Treatment 2 - 5 minutes, 0,4 W/cm2; Treatment 3 - 5 minutes, 0,5 W/cm2; Treatment 4 - 6 minutes, 0,5 W/cm2; Treatment 5 - 6 minutes, 0,6 W/cm2; Treatment 6 - 6 minutes, 0,6 W/cm2; Treatment 7 - 6 minutes, 0,6 W/cm2; Treatment 8 - 6 minutes, 0,7 W/cm2; Treatment 9 - 7 minutes, 0,7 W/cm2; Treatment 10 - 7 minutes, 0,7 W/cm2; Treatment 11 - 7 minutes, 0,8 W/cm2; Treatment 12 - 8 minutes, 0,8 W/cm2; Treatment 13 - 8 minutes, 0,8 W/cm2; Treatment 14 - 8 minutes, 0,8 W/cm2; Treatment 15 - 8 minutes, 0,8 W/cm2.~Each patient will also receive kinesiotherapy treatment that will consist of:~* eight-minute massage of posterior lower leg muscles~* plantar aponeurosis stretching"
223657562|NCT02934100|DEVICE|Sham LASER CTL1106MX|"Sham laser therapy Time of each treatment (from 1 to 15) is four to five minutes. Developed is 10 points, each point takes 15 seconds. Device is unplugged and it does not emit any radiation.The patient does not know that the procedure is not really executed.~Each patient will also receive kinesiotherapy treatment that will consist of:~* eight-minute massage of posterior lower leg muscles~* plantar aponeurosis stretching"
223657563|NCT02859870|DEVICE|FUSE-TM colonoscope|Colonoscopy in conditions of normal security including patient clinical examination before leaving the hospital. Data collection by each operator.
223657564|NCT01076439|DRUG|Fluticasone Furoate Nasal Spray|Fluticasone Furoate Nasal Spray: 110mcg QD
223657565|NCT01076439|DRUG|Olopatadine Nasal Spray|Olopatadine Nasal Spray: 2660mcg BID
223657566|NCT01076439|DRUG|Saline Nasal Spray|Placebo
223657567|NCT04491604|BIOLOGICAL|Topical Beremagene Geperpavec|Topical gel of non-integrating, replication-incompetent HSV-1 expressing the human collagen VII protein
223657568|NCT04491604|OTHER|Placebo|Matching masked inactive topical gel
223657569|NCT02049541|DRUG|PI3K inhibitor BKM120|Will be supplied to each patient on the first day of each cycle. It will subsequently be self administered by the patient themselves daily on days 1-28 of every 28 day cycle
223657570|NCT02049541|BIOLOGICAL|rituximab|Given IV (intervenously) on days 2, 8, 15, and 22 of cycle 1, and subsequently on day 1 of cycles 3, 5, 7, 9, and 11.
223657571|NCT02049541|OTHER|Pharmacodynamics|Pharmacodynamic samples from peripheral blood (for those with peripheral blood involvement) and bone marrow aspirate (for all patients) are drawn at baseline.
224239840|NCT06143722|RADIATION|simultaneous with radiotherapy|Chemotherapy combined with immunotherapy simultaneous with radiotherapy
224239841|NCT06143722|RADIATION|synchronous with radiotherapy|Chemotherapy combined with immunotherapy synchronous with radiotherapy
224239842|NCT00843323|OTHER|Methylaminolevulinate - photodynamic therapy|Methylaminolevulinate cream 16% applied for 3 hours under occlusion on the face and then illuminated with red LED device
224239843|NCT01071122|DRUG|Nifedipine (Adalat, BAYA1040) and Valsartan|Combination treatment with nifedipine GITS 30mg and valsartan 80mg, Once daily
224239844|NCT01071122|DRUG|Nifedipine (Adalat, BAYA1040)|Nifedipine 60mg, Once daily
224239845|NCT01071122|DRUG|Valsartan|Valsartan 160mg, Once daily
224239846|NCT03952143|DRUG|LY900014|Administered SC
223657572|NCT02049541|OTHER|Correlative studies|Patients will undergo correlative studies to include bone marrow biopsy at study enrollment, and at the time of complete remission. In addition, patients with peripheral blood involvement at enrollment will have peripheral blood drawn for all planned research correlates.
223657573|NCT00545272|DRUG|indacaterol|Indacaterol delivered by multiple dose dry powder inhaler (TWISTHALER® device).
223657574|NCT00545272|DRUG|formoterol|Formoterol delivered by oral inhalation via AEROLIZER® inhalation device.
223657575|NCT00545272|DRUG|placebo to indacaterol|Placebo TWISTHALER® device
223657576|NCT00545272|DRUG|placebo to formoterol|Placebo AEROLIZER® device
223657577|NCT00545272|DRUG|short acting β2-agonist|100 μg/ 90 μg salbutamol/albuterol Metered Dose Inhaler (MDI) or equivalent dose of Dry Powder Inhaler (DPI).
223657578|NCT04509349|DEVICE|transcranial Altering Current Stimulation|The participant will wear an electrode cap with 5 gel-filled cup HD electrodes arranged in a 4 x 1 montage.
223657579|NCT04509349|DEVICE|Sham tACS|2 saline sponge electrodes will be attached to the upper arm contralateral to hand attached to the accelerometer.
223657580|NCT04455152|BEHAVIORAL|self-control|avoiding eating sweets as a way of building self-control strength
223657581|NCT01882608|OTHER|Mental Health Telemetry (MHT)|Ecological momentary assessment (EMA) focuses on using data collected from subjects living their daily lives in their natural environments using minimally invasive techniques to improve the quality of the data collected. MHT is an evolution of EMA. MHT was developed at Sunnybrook in partnership with the University of Toronto; it uses cell phones to collect self-report data on symptoms of illness and then transmit it in real-time to a central database. Principal advantages of MHT over EMA include the ability to time- and date-stamp data, thus eliminating retrospective record completion, and the ability to observe and monitor data flow in real-time, without having to wait for participants to upload or deliver the data (e.g., at their next doctors' appointment).
223657582|NCT01585506|OTHER|No treatment given|"Patients to complete the WHO-5 Well-being Index questionnaire"
223657583|NCT01585506|OTHER|No treatment given|"Physicians to complete two questionnaires, Demographic Data and Disease and Treatment Course and Questionnaire of Potential Difficulties in the Period of Treatment Switching from Insulin to Its Analogues"
223657584|NCT00199303|DRUG|pre-operatively followed by 30 mg three times per day after surgery|
224239847|NCT03952143|DRUG|Insulin Lispro|Administered SC
224239848|NCT03952143|DRUG|Insulin Glargine|Administered SC
224239849|NCT03952143|DRUG|Insulin Degludec|Administered SC
224239850|NCT00020826|OTHER|quality-of-life assessment|QLQ-C30 questionnaire administered. STO22 questionnaire administered.
223657585|NCT02934503|BIOLOGICAL|Pembrolizumab|200 mg IV fixed dose every 3 weeks until progression or for up to 2 years of therapy.
223657586|NCT02934503|DRUG|Cisplatin|75 mg/m2
223657587|NCT02934503|DRUG|Carboplatin|AUC 6
223657588|NCT02934503|DRUG|Etoposide|IV every 3 weeks for up to 6 cycles (minimum of 4 cycles, maximum of 6).
223657589|NCT02934503|RADIATION|Radiation therapy|Thoracic radiotherapy will be given per institutional standards(dose and duration may vary for individual participants).
223657590|NCT04280237|OTHER|Blood samples|Blood samples
223657591|NCT00262938|BEHAVIORAL|behavioral dietary intervention|Patients undergo weekly contact with a dietitian; exercise intervention for 6 months; and physician counseling at baseline and at 3, 6, and 12 months. Patients undergo quality of life assessments and clinical assessments at baseline and at 3, 6, and 12 months.
223657592|NCT00262938|OTHER|counseling intervention|Patients undergo weekly contact with a dietitian; exercise intervention for 6 months; and physician counseling at baseline and at 3, 6, and 12 months. Patients undergo quality of life assessments and clinical assessments at baseline and at 3, 6, and 12 months.
223657593|NCT00262938|OTHER|educational intervention|Patients undergo weekly contact with a dietitian; exercise intervention for 6 months; and physician counseling at baseline and at 3, 6, and 12 months. Patients undergo quality of life assessments and clinical assessments at baseline and at 3, 6, and 12 months.
223657594|NCT00262938|OTHER|preventative dietary intervention|Patients undergo weekly contact with a dietitian; exercise intervention for 6 months; and physician counseling at baseline and at 3, 6, and 12 months. Patients undergo quality of life assessments and clinical assessments at baseline and at 3, 6, and 12 months.
223657595|NCT00262938|PROCEDURE|quality-of-life assessment|Patients undergo quality of life assessments and clinical assessments at baseline and at 3, 6, and 12 months.
223657596|NCT00724867|BIOLOGICAL|Belimumab 1 mg/kg|Belimumab 1 mg/kg IV over one hour every 28 days
223657597|NCT00724867|BIOLOGICAL|Belimumab 10 mg/kg|Belimumab 10 mg/kg IV over one hour every 28 days
223657598|NCT06458816|DEVICE|Non-Invasive Knee Joint Distraction|Non-invasive Distraction device
223657599|NCT06458816|PROCEDURE|Manual Joint Distraction|no device. manual distraction.
223657600|NCT04995367|DEVICE|Implementation of a BCI system integrated to the T-FLEX lower-limb exoskeleton in post-stroke patients.|The participants will carry out 4 tasks with a BCI system integrated to the T-FLEX device. The task consists of 1 session that includes 4 conditional experiments: Active ankle movement, passive ankle movement, Motor Imagery Detection with Visual cue, and Motor Imagery Detection with Tactile Stimulation and visual cue.
224239851|NCT03606278|OTHER|Structured debriefing assisted by video|In the structured debriefing assisted by video, the process was based on the immediate review of the video, stopping and rewinding the recording as required. The debriefing session was conducted in the debriefing room of the simulation laboratory with an assigned time of 15 minutes. Each session was developed in three phases. The first phase, descriptive, in which each participant was encouraged to recount what they had lived and experienced, clarifying how the events unfolded, verifying the appropriate decisions and the errors committed in the scenario and the ways they could have solved them and corrected them. The second phase, analytical, the participant reflected on what occurred in the scenario, commenting on how their feelings were involved in the development of the case. The third phase, application or transference, in which the group was encouraged to draw conclusions from what had occurred, realizing an application of this experience in a real-life.
224239852|NCT03606278|OTHER|Structured oral debriefing|In the structured oral debriefing, the process was based by the mental search of their memories of what occurred. The debriefing session was conducted in the debriefing room of the simulation laboratory with an assigned time of 15 minutes. Each session was developed in three phases. The first phase, descriptive, in which each participant was encouraged to recount what they had lived and experienced, clarifying how the events unfolded, verifying the appropriate decisions and the errors committed in the scenario and the ways they could have solved them and corrected them. The second phase, analytical, the participant reflected on what occurred in the scenario, commenting on how their feelings were involved in the development of the case. The third phase, application or transference, in which the group was encouraged to draw conclusions from what had occurred, realizing an application of this experience in a real-life.
224239853|NCT04615793|OTHER|PILATES EXERCISES|The experimental group will receive Pilates exercises focusing on lower limb strength, flexibility and coordination in addition to exercises given to control group. Exercises or movements were done on a mat, on an exercise ball or in standing position while emphasizing on spinal and pelvic alignment, maintaining core contraction and the rhythm of respiration. All exercises were done for 10 repetitions with a rest period of two minutes before commencing the next exercise, and lasted for about 45 minutes. All the groups will receive the above mentioned interventions thrice in a week for a period of 10 week
223657601|NCT01146743|PROCEDURE|EUS-guided gallbladder drainage|EUS-guided gallbladder drainage was performed with a linear-array echoendoscope. The initial puncture was performed at the antrum of the stomach or bulb of the duodenum and was chosen to access the gallbladder body or neck and avoid visible vessels. After removal of the needle, a 6F or 7F bougie were inserted and then removed to dilate the tract. Afterward, nasobiliary drainage tube or stent was placed.
223657602|NCT01146743|PROCEDURE|percutaneous transhepatic gallbladder drainage|Under ultrasound guidance, needle punctured to gallbladder via percutaneous transhepatic route.
223657603|NCT00373893|DRUG|Lidoderm Patch|
223657604|NCT03049241|OTHER|neuromuscular fatigue|The main aim of the present protocol is to compare the effect of knee extensors and ankle plantarflexors length on the development and aetiology of neuromuscular fatigue, in children and adults
223657605|NCT04880291|DRUG|GFB-024|Peripherally acting Cannabinoid-1 receptor inverse agonist monoclonal antibody
223657606|NCT04880291|DRUG|Placebo|Matched placebo
223657607|NCT02756416|DEVICE|MRI brain|Standard MRI brain will be performed on each participant to look at brain structure and exclude complications of RCVS (if any).
223657608|NCT02756416|DEVICE|ASL-MRI brain|ASL-MRI is a non-contrast scan used to measure cortical cerebral blood flow (CBF) in areas supplied by major arteries (Circle of Willis).
223657609|NCT02756416|DEVICE|MRA brain|MR angiography scan looks at blood vessels structure. We expect to see constriction (narrowing) of the major arteries in RCVS cases.
223657610|NCT06201806|OTHER|Test food breakfast with NCS or witout NCS|"Study Intervention: 30 drops (70.8 mg) of a stevia and sucralose mix were chosen based on Ford et al. 2011, indicating a 48 mg sucralose concentration comparable to the sweetness of a standard diet soda, due to a lack of studies on the acute effects of combined non-nutritive sweeteners.~Glycemic Responses (GR): Blood samples collected using Accu-Chek® Instant glucometer, with fasting samples establishing baseline glucose concentration. Test breakfast or white bread consumed within 12 to 15 minutes, followed by capillary blood sampling at various intervals. Continuous glucose monitoring with a sensor was also implemented.~Glycemic Index (GI) Calculation: Geometric calculation of the area under the curve (AUC) for each food, excluding the baseline area. Test breakfast GI determined by expressing AUC as a percentage of the standard food AUC. Final GI value averaged across groups."
224239854|NCT01024166|BEHAVIORAL|Questionnaire and Review Session|Use PRO computer system to complete 2 questionnaires about any symptoms patient may be experiencing and their overall health, 30 minutes to complete. Review session about use of computer system and suggested changes.
224239855|NCT01024166|BEHAVIORAL|Questionnaire and Review Session|Use PRO computer system to complete 4 questionnaires about symptoms their overall health of patients, 30 minutes to complete. Review session about use of computer system and suggested changes.
224239856|NCT02255708|OTHER|Proprioceptive Neuromuscular Facilitation - PNF|
224239857|NCT00006174|DRUG|Letrozole|
224239858|NCT04718506|BEHAVIORAL|Exercise|Participants from the experimental group will complete 8 weeks of a tailored, educational and supervised multicomponent exercise program adapted from the ACSM guidelines for Chronic Obstructive Pulmonary Disease and Cardiovascular Disease. Participants will complete a 3-days-a-week concurrent training routine: two days of resistance training (50% 1RM (one-repetition maximum), 3 sets, 8 repetitions, 4 exercises \[squat, bench press, deadlift and bench pull\]) combined with Moderate Intensity Variable Training (MIVT: 4-6 x 3-5 min at 70-80% Heart Rate Reserve (HRR) / 2-3 min at 55-65% HRR), and one day of Light Intensity Continuous Training (LICT: 30-60 min, 65-70% HRR). Progressions will be individualized and consistent with patient tolerance. Sessions will be supervised by certified strength and conditioning coaches, Graduated in Sports Sciences
224239859|NCT04718506|BEHAVIORAL|Inspiratory muscle training|Participants enrolled in the inspiratory muscle training protocol will used the PowerBreath® Classic Heath Series mechanic threshold devices to perform 1 set of 30 repetitions, twice a day, every day of the week. This assumes a work intensity of approximately 62.5% ± 4.6% of the PIM (maximum inspiratory pressure). Increase in resistance will be made every two weeks by turning the load adjustment clockwise ¼ to 1 full turn, pending on participant tolerance to maintain a 12-15 RPE on modified Borg scale. The training will be preceded by a warm-up at 80% of the 30 RM load, with 2 min of rest between sets
224239860|NCT04718506|BEHAVIORAL|Controls|Controls will be advised (non-supervised) to follow the WHO guidelines: Support for Rehabilitation: Self-Management after COVID-19 Related Illness
224239861|NCT00035581|DRUG|poly I-poly C12U|200-400 mg IV infusions 2x/week for 24 weeks
224239862|NCT04421508|COMBINATION_PRODUCT|INOpulse|Subjects will be treated by means of an INOpulse device using an INOpulse nasal cannula.
224239863|NCT04421508|COMBINATION_PRODUCT|Placebo|Subjects will be treated by means of an INOpulse device using an INOpulse nasal cannula.
224239864|NCT00091052|BIOLOGICAL|sargramostim|
224239865|NCT00091052|RADIATION|radiation therapy|
224239866|NCT03141099|OTHER|Low normal MAP|The patients are randomized to recieve a Phillips M1006B blood pressure measuring module, offset by +10 %. All patients will target a MAP of 70, but due to the offset module, the patients will target an actual blood pressure of 63 mmHg.
224239867|NCT03141099|OTHER|High normal MAP|The patients are randomized to recieve a Phillips M1006B blood pressure measuring module, offset by -10 %. All patients will target a MAP of 70, but due to the offset module, the patients will target an actual blood pressure of 77mmHg.
224239868|NCT03141099|OTHER|Low normal PaO2.|The patients are randomized to a PaO2 target of 9-10 kPa (open-label).
224239869|NCT03141099|OTHER|High normal PaO2|The patients are randomized to a PaO2 target of 13-14 kPa (open-label).
224239870|NCT04559607|DRUG|Camrelizumab|Camrelizumab: 200mg, iv, Q3W
224239871|NCT04559607|DEVICE|TACE|TACE if necessary
224239872|NCT04559607|DRUG|Apatinib|Apatinib: 250m, po, QD
224239873|NCT05319665|DEVICE|Head-mounted display|The intervention is a visual and auditory contact via a head-mounted display (HMD) worn by the mother airing a live video of her newborn filmed by a 2D 360° camera during and after a caesarean section. The HMD will be worn by the new mother from the moment that her newborn is moved to an adjacent room to receive the initial care until the moment when they can be reunited again. The camera will be placed in the adjacent room where the newborn, the mother's partner and a midwife will be. The camera will film the newborn and transmit the live images and the sound to the HMD worn by the mother. The mother will be able to see and hear what happens in the next room and change her angle of view by moving her head from one side to another.
224239874|NCT06343168|OTHER|prevalence of frailty|determine the prevalence of frailty
224239875|NCT04433910|DRUG|Convalesscent Plasma|Transfusion
224239876|NCT04922424|DRUG|Atorvastatin|Subjects will ingest placebo or ingest 20 mg atorvastatin for 30 days first. We will include 30 days of washout between treatments to minimize any potential carryover effects.
224239877|NCT04922424|OTHER|placebo|Subjects will ingest placebo or ingest 20 mg atorvastatin for 30 days first. We will include 30 days of washout between treatments to minimize any potential
224239878|NCT05149118|PROCEDURE|Polydeoxyribonucleotide (PDRN)|A total 1mL of PDRN was injected along the suture line at distance of 1cm in one day and two days after the surgery.
224239879|NCT06114706|BEHAVIORAL|Physicians assess patients|Physicians are asked to assess patients following the current Swedish guideline
224239880|NCT06114706|BEHAVIORAL|Nurses assess patients|Nurses are asked to assess patients following the current Swedish guideline
224239881|NCT06114706|BEHAVIORAL|Pharmacists assess patients|Pharmacists are asked to assess patients following the current Swedish guideline
224239882|NCT00322933|PROCEDURE|renal replacement therapy (intermittent or continuous)|
224239883|NCT04212949|DEVICE|Repetitive transcranial magnetic stimulation (rTMS)|Stimulation will be performed from the contralateral M1 cortex of the painful side. Each stimulation session will consist of 1500 pulses (30 trains of 5 seconds each, with an inter-train interval of 25 seconds) delivered at a frequency of 10 Hz. The stimulation intensity will be set at 80% of the resting motor threshold.
223657611|NCT02299583|OTHER|Preventive intervention trauma-informed early intervention|Every department appoints 2-4 health care professionals as child welfare officers (CWOs) who will be responsible for carrying out the intervention at the department. Whenever a child or adolescent is present in the department a CWO will be send for. The intervention consists of four distinct elements: 1) A standardized plan of action for the appointed health care CWOs on how to conduct trauma-informed health care for children and their families shortly after exposure to a PTE, 2) a training program for CWOs on trauma-informed support and communication with children and their families, 3) a supervision program for the CWOs, and 4) three psychoeducational booklets for young children, older children, and parents. The booklets will be given to the families by the CWOs.
223657612|NCT01112449|OTHER|Placebo|no active medication
224239884|NCT04212949|DRUG|Transforaminal epidural steroid injection|"An epidural steroid injection under guidance of fluoroscopy is used to reduce inflammation at a lumbar spinal nerve root(s).~The following drugs will be used for this procedure: 80mg/2ml triamcinolone acetonide (sinakort-A) and 1 mL 0.5% bupivacaine (marcaine)"
224239885|NCT05086523|DEVICE|Programmable Hypertension Control (BackBeat Moderato)|Programmable Hypertension Control can be turned OFF without affecting regular pacing
224239886|NCT05086523|DEVICE|Pacing (BackBeat Moderato)|Programmable Hypertension Control can be turned OFF without affecting regular pacing
224239887|NCT04622709|DRUG|Furosemide (loop diuretic) Tablets|Open label dose escalation study of furosemide in people receiving maintenance hemodialysis. Participants will take furosemide oral tablets twice daily for 18 weeks. Doses will be titrated every 2 weeks for 6 weeks if safe, effective, tolerated, and accepted by the participant. First 2 weeks of the study: participants not taking oral furosemide at enrollment will take 80mg furosemide twice daily, those taking oral furosemide at enrollment will stay on their prescribed dose, and those taking another loop diuretic at enrollment will discontinue their prescription and take an equivalent oral furosemide dose. At week 4: dose escalation if tolerated (from 80mg to 120mg twice daily for the 1st group, and a 50% increased dose not \>320mg/day for the 2nd \& 3rd groups). At week 6: dose escalation if tolerated (from 120mg to 160mg twice daily for the 1st group, and a 50% increased dose not \>320mg/day for the 2nd \& 3rd groups). Final 12 weeks: all participants will take the maximum tolerated dose.
224239888|NCT05488613|DRUG|Midostaurin|Midostaurin was administered in two different dosing options. Either as 2x25mg daily or 2x50mg daily.
224239889|NCT00760266|DRUG|Aliskiren|Aliskiren 150 mg for 1 week, Aliskiren 300 mg (with or without amlodipine)for 7 weeks
224239890|NCT00760266|DRUG|Hydrochlorothiazide|Hydrochlorothiazide (HCTZ) 12.5 mg for week 1; Hydrochlorothiazide (HCTZ) 25 mg (with or without amlodipine)for 7 weeks
224239891|NCT01407536|DEVICE|Thermal stimulation system|The subjects meeting our criteria will be randomly assigned to either the experimental group (EXP) or the control group (COT). The EXP and COT received upper extremity thermal stimulation protocol for 30 minutes a day for 20 days. The TS temperature of EXP for noxious stimulation was set at 46-47°C for heat and 7-8°C for cold stimulation; the temperature of COT for innoxious stimulation was set at 40°C for warm and 20°C for cold stimulation.
224239892|NCT02066675|DRUG|Trabectedin|Each patients will receive intravenous trabectedin (1.5 mg/mq-1.3 mg/mq) over 24 hours every 3 weeks
224239893|NCT03955757|BEHAVIORAL|Boot Camp Translation|Communities in the intervention arm will participate in the Boot Camp translation process, where stakeholders will come together to develop and implement locally relevant materials to promote adolescent vaccination.
224239894|NCT03955757|OTHER|Control|No intervention. Communities will continue to behave as usual.
224239895|NCT00216437|DRUG|Capecitabine (Xeloda)|
224239896|NCT02684552|DEVICE|Non invasive ventilation|Training on treadmill with Non invasive ventilation
224239897|NCT02684552|DEVICE|Oxygen|Training on treadmill with oxygen
224239898|NCT01893957|PROCEDURE|high voltage electrical stimulation - axillary lymphadenectomy|Will be used high voltage electrical stimulation, Neurodyn High Volt Model (IBRAMED), twice a week, over the course of seven weeks,in 20-minute sessions on alternate days. The parameters are: high voltage pulsed current, monopolar (cathode), 100 Hz, synchronized mode, on/off relationship of 3:9 seconds, rise/decay 2:1 seconds, and motor threshold. The electrodes are positioned in the middle and distal thirds of the anterior surface of the forearm and arm.
224239899|NCT01893957|PROCEDURE|High voltage electrical stimulation - ( healthy women )|Will be used high voltage electrical stimulation, Neurodyn High Volt Model (IBRAMED), twice a week, over the course of seven weeks,in 20-minute sessions on alternate days. The parameters are: high voltage pulsed current, monopolar (cathode), 100 Hz, synchronized mode, on/off relationship of 3:9 seconds, rise/decay 2:1 seconds, and motor threshold. The electrodes are positioned in the middle and distal thirds of the anterior surface of the forearm and arm.
224239900|NCT01893957|DEVICE|Neurodyn High Volt Model (IBRAMED)|
224239901|NCT01132976|BEHAVIORAL|Personal Concerns Inventory|This is a pre-treatment, goal-based motivational interview which helps to patients identify their life goals, and goal-value. The interview will last approximately 2 hours and will be carried out face to face with a therapist across one or two sessions.
224239902|NCT01132976|BEHAVIORAL|Treatment as usual|No specific motivational interview
224239903|NCT02151032|BEHAVIORAL|Booklet|Participants read a booklet about colorectal cancer screening tests.
224239904|NCT02151032|BEHAVIORAL|Audio CD|Participants listen to an audio CD that will narrate the colorectal cancer screening tests booklet.
224239905|NCT02151032|BEHAVIORAL|Video with Non-Moving Images|Participants watch a video with non-moving images about colorectal cancer screening tests on an iPad.
224239906|NCT02151032|BEHAVIORAL|Video with Animated Images|Participants watch a video with animated images about colorectal cancer screening tests on an iPad.
224239907|NCT02151032|BEHAVIORAL|Questionnaires|Questionnaire completion before and after viewing the program.
223657613|NCT01112449|DIETARY_SUPPLEMENT|selenomethionine|200 µg/day of selenomethionine (SM)
223657614|NCT01112449|DIETARY_SUPPLEMENT|low dose selenized-yeast|200 µg/day of SY
223657615|NCT01112449|DIETARY_SUPPLEMENT|high dose selenized-yeast|285 µg/day of SY
223657616|NCT01454141|OTHER|Cognitive Control Training|Three sessions of CCT.
223657617|NCT01454141|OTHER|Peripheral Vision Task|Three sessions of PVT.
223657618|NCT00842491|DRUG|endostar, cisplatin, capecitabine|"Product 1: endostar~Dosing schedule: 15mg daily dose, d1-14~Mode of administration: intravenously"
223657619|NCT00842491|DRUG|capecitabine|"Product 2: capecitabine~Dosing schedule: 1000mg/m2 bid, days 1-14, every 3 weeks~Mode of administration: orally"
223657620|NCT00842491|DRUG|cisplatin|"Product 3: cisplatin~Dosing schedule: 80mg/m2, day 1 of every 3 weeks~Mode of administration: intravenously"
223657621|NCT05439213|DRUG|Adrenaline 0,33 Mg/mL Solution for Injection|adrenaline dosage
223657622|NCT05439213|DRUG|Adrenaline 1 Mg/mL Solution for Injection|adrenaline dosage
223657623|NCT01335737|BEHAVIORAL|aerobic training|12 weeks of aerobic training, 4 times/week
224239908|NCT05515926|PROCEDURE|Cranial manipulation group, or cranial osteopathic techniques (OMM)|"Cranial OMT procedure:~Subjects were relaxed and lying on the back for entire time of the research protocol (approximately 30 min). Osteopathic physician performed the osteopathic manipulations using his hands. The physician gently applied a small amount of force to the neck and head to release tissue tension until feeling a softening and warmth of tissues. Subjects experienced a sensation of slight pulling, releasing, or relaxing of the tissue."
224239909|NCT05515926|PROCEDURE|Sham manipulation|The osteopathic physician placed his hands on the skull of the subject but did not influence cranial motion.
223657624|NCT01335737|BEHAVIORAL|Wait list|wait list control condition
223657625|NCT01290913|DRUG|Omalizumab|Omalizumab is an antibody that helps decrease allergic responses in the body
223657626|NCT03284541|BEHAVIORAL|2GETHER|Communication skills, coping skills, problem-solving, acceptance, HIV prevention
223657627|NCT03284541|BEHAVIORAL|Existing Public Health Practice|HIV testing, medication adherence, HIV risk reduction
223657628|NCT05412446|DRUG|ADAPT6-SPECT|Diagnostic SPECT for HER2 expression in primary tumour and metastatic lymph nodes
223657629|NCT03457064|BEHAVIORAL|PA+Social Adherence Intervention(PASAI)|While both physical activity programs were tailored to match participants' physical needs and abilities, the PA+Social Adherence Intervention(PASAI) introduced elements to promote and strengthen self-efficacy and social interaction among participants.
224239910|NCT01807208|OTHER|Educational Tool|"A personalized health goal education and reminder tool, with 3 parts: report card showing the status of secondary prevention domains during hospitalization; questions to help prepare the patient for the follow-up visit; and potential questions for the physician."
224239911|NCT00197210|BIOLOGICAL|Rotavirus|
224239912|NCT03299400|DEVICE|Contact lens sensor|Patient will continue to wear the contact lens postoperatively for a total of 24 hours or until the patient cannot tolerate the contact lens. After removal of the contact lens sensor, the recorded profiles will be collected and visualized graphically on a computer interface.
224239913|NCT02802436|PROCEDURE|Extraction with socket graft|Extraction will be done as usual standard of care to preserve socket walls. Sockets will be measured at all 4 line angles for depth with the same periodontal probe, Buccal-Lingual dimension will be measured prior to graft placement. Graft material (mineralized cortical/cancellous Bone Powder 250-1000µ) will be used for both sites. Volume of graft used will be recorded. Both sites will be filled slightly below marginal bone level (1mm). Test site will be injected with Bioactive Agent. At 3 levels apical 1/3rd, middle 1/3rd and coronal 1/3rd. Control site will be injected with saline (or vehicle) at same levels. Occlusal orifice will be closed with Collagen plug adjusted for depth to meet free gingival margins and then sutured with 4-0 PGA (Vicryl)
224239914|NCT05618470|DRUG|Wumeiwan Jiawei Fang|orally administered Wumeiwan Jiawei Fang prescription granules, 1 dose a day, twice a day, once for 14 days, for 42 days.
224239915|NCT05618470|DRUG|botulinum toxin A|Botulinum toxin (Lanzhou Biopharmaceutical Co., LTD.) was injected into the medial side of the upper eyelid, the lateral side of the upper eyelid, the lateral side of the lower eyelid, and the temporal orbicularis oculi muscle of the lateral canthus. The botulinum toxin type A was diluted into 50IU/ML with normal saline and injected with a 1ml skin test syringe (4\\ 5-gauge needle), and 2.5IU was injected into each point. A total of 1 injection.
224239916|NCT01697878|PROCEDURE|CPAP followed by atmospheric pressure|In the PACU, Patients receive 2 hours of continuous-positive-airway-pressure (CPAP) oxygen at 30% FiO2 treatment followed by 2 hours of oxygen treatment (6 L O2/min) that is part of standard of care at Massachusetts General Hospital
224239917|NCT01697878|PROCEDURE|Atmospheric pressure followed by CPAP|In the PACU, patients receive 2 hours of Oxygen treatment (6L/min) that is part of standard-of-care at Massachusetts General Hospital, followed by 2 hours of Continuous Positive Airway Pressure (CPAP) treatment at 30% FiO2.
224239918|NCT00150007|DRUG|Enteric-coated Mycophenolate sodium (EC-MPS)|
224239919|NCT02080923|BEHAVIORAL|Brief Motivational Interview|The intervention is exclusively focused on Adolescent Dating Aggression and will always be delivered by a human interventionist. It is theory-based and its success as an intervention method for substance abuse and several other health-related issues is well established.
224239920|NCT01309607|DRUG|paclitaxel/carboplatin/lapatinib|"Drug doses for the neoadjuvant regimen:~* Paclitaxel 80mg/m2, day 1, 8, 15 of a 21-day cycle~* Carboplatin AUC of 2, day 1, 8 of a 21-day cycle~* Lapatinib 750mg daily continuously"
224239921|NCT04180007|DRUG|Apatinib|500 mg Apatinib given orally once a day for 12 wk prior to RAI (131I) treatment.
224239922|NCT04113239|DIAGNOSTIC_TEST|16S rRNA gene sequencing|Taking a stool sample for gut microbiome DNA sequencing
223657630|NCT03278353|OTHER|Exercise|"A prescription of progressive rehabilitation exercises designed to strengthen weakened muscle groups and stretch joint movements that demonstrate range of motion limitations will be provided as a home program. Treatment is based on clinical presentation and identification of impairments by the treating clinician. Participants will be seen for 3 visits over 6 weeks and a final visit 1 year post-surgery for those electing to undergo surgery.~The interventions will consist of progressive exercise (PE) in two phases with general instruction guidelines. The assigned program will be tailored per each participant's clinical presentation and progressed based on response to exercise load. The researcher will instruct, review and supervise each program initially and, at follow-up visits; as well as monitor progress, re-enforce treatment strategies and modify the respective program accordingly. Each participant will receive a home program manual as well as a program log."
223657631|NCT03278353|OTHER|Manual Therapy|Hip joint and spine manual therapy techniques applied toward the impairments of the subject.
223657632|NCT00413985|DRUG|Nutrient-enriched human milk|
223657633|NCT04335136|DRUG|RhACE2 APN01|Patients will be treated with APN01 intravenously twice daily (BID).
223657634|NCT04335136|DRUG|Physiological saline solution|Patients will be treated with placebo intravenously twice daily (BID).
223657635|NCT04466202|OTHER|Music with Structured Verbal Training|Structured verbal training on prostate biopsy was given to the intervention group before the procedure, and then patients in this group listened to the music they preferred during the procedure with headphones.
223657636|NCT01361204|DIETARY_SUPPLEMENT|Theanine|Taking 4 tablets of theanine two times daily for 16 days
223657637|NCT05688124|DRUG|IBI351|IBI351 is administered orally
223657638|NCT05688124|DRUG|Esomeprazole|Esomeprazole is administered orally
223657639|NCT03671850|BIOLOGICAL|VT-EBV-N|Epstein-barr virus human cytotoxic T lymphocytes (EBV-CTL)
223657640|NCT03671850|OTHER|Placebo|Peripheral blood mononuclear cell, PBMC
224239923|NCT04113239|GENETIC|DNA-microarray genotyping|Taking a saliva sample for genotyping
224239924|NCT05549856|PROCEDURE|Wet suction|The pancreatic solid lesions will be puncture with the 22G Acquire needle (Boston Scientific Corporation, Marlborough, MA, USA). Before puncturing the lesion, flush the needle with 5ml saline, then use a 10 ml syringe in order to replacing the column of air with fluid. After puncture, monitoring the puncture needle under US guidance in real time, the needle was moved back and forth about 10-20 times within the lesion using a fanning technique.
224239925|NCT05549856|PROCEDURE|Dry suction|The pancreatic solid lesions will be puncture with the 22G Acquire needle (Boston Scientific Corporation, Marlborough, MA, USA). The stylet is removed and a 10 ml air-filled pre-vacuum syringe is attached. After puncture, monitoring the puncture needle under US guidance in real time, the needle was moved back and forth about 10-20 times within the lesion using a fanning technique.
224239926|NCT01987271|DEVICE|Noninvasive Ventilation|A randomized plan define the order in which patients would execute the 6MWT, with or without NIV.
224239927|NCT01520857|PROCEDURE|Transabdominal Preperitoneal repair of inguinal hernia|Transabdominal Preperitoneal (TAPP) repair of inguinal hernia using CO2 pneumoperitoneum under spinal anesthesia
224239928|NCT01520857|PROCEDURE|Transabdominal Preperitoneal repair of inguinal hernia|Transabdominal Preperitoneal (TAPP) repair of inguinal hernia using CO2 pneumoperitoneum under general anesthesia
224239929|NCT03287609|DRUG|Evolocumab 140 mg/mL|Three injections with pre-filled auto-injector pen at day 1 and at week 4.
224239930|NCT03287609|DRUG|Placebo|Three injections with pre-filled auto-injector pen at day 1 and at week 4.
224239931|NCT06023147|PROCEDURE|E-TACE|The 100μm drug-loaded microspheres were loaded with 40mg-80mg anthracyclines at 1mL/2mL, and then combined with non-isoionic contrast agents to embolize the tumor supplying arteries, and then 250μm or 400μm drug-loaded microspheres were loaded with 1mL/2mL chemotherapy drugs to embolize the tumor supplying arteries at different grades and diameters.
224239932|NCT01273181|BIOLOGICAL|PG13-MAGE-A3 TCR9W11 (anti-MAGE-A3/12 TCR) Transduced Autologous Peripheral Blood Lymphocytes|
224239933|NCT01273181|DRUG|Aldesleukin|720,000 IU/kg every 8 hours for a maximum of 15 doses
224239934|NCT01273181|DRUG|Cyclophosphamide|60 mg/kg/day x 2 days intravenous (IV)over 1 hour.
224239935|NCT01273181|DRUG|Fludarabine|25 mg/m\^2/day intravenous piggy back (IVPB) daily over 30 minutes for 5 days.
224239936|NCT04366141|DEVICE|COVID-19 barrier box|Attending anesthesiologists will use a plastic proprietary barrier enclosure for intubating patients in the intervention group to protect spreading aerosolized droplets from patient to health care provider.
224239937|NCT05991726|OTHER|Other: Survey|Multiple survey rounds identifying most important outcomes for effective self-management for non-dialysis CKD
224239938|NCT03006965|DRUG|octocog alfa|Pharmacokinetic Characterization of the Hemophilia A Population in Spain using an standalone web-based software
224239939|NCT03006965|DRUG|rurioctocog alfa pegol|Pharmacokinetic Characterization of the Hemophilia A Population in Spain using an standalone web-based software
224239940|NCT00507234|DRUG|formoterol fumarate inhalation solution|
224239941|NCT04922112|DIAGNOSTIC_TEST|Obstructive sleep apnea testing|"* Functional Outcomes of Sleep Questionnaire (FOSQ-10)~* European Organization for Research and Treatment of Cancer Head and Neck Survey (EORTC HN 35)~* Epworth Sleepiness Scale (ESS)~* Adult Comorbidity Evaluation (ACE 27)~* University of Washington Quality of Life Questionnaire (UW-QOL)~* Chronic Pain Assessment Questionnaire"
224239942|NCT03157388|DRUG|Combined Vancomycin and Gentamycin and Meropenem|"The following combined antibiotic regime will be administered for eradication of gut bacteria.~7 days combined antibiotic treatment, per oral route, once daily: vancomycin 500 mg (Vancomycin Hospira), powder for concentrate and gentamycin 40 mg (Hexamycin®), solution and meropenem 500 mg (Meropenem Hospira), powder for concentrate; The three drugs are dissolved and combined in approximately 100 ml of apple juice."
224239943|NCT01118247|PROCEDURE|Uncemented primary total hip arthroplasty|Total hip prosthesis partly coated with pure Ti with and without HA are compared in a RCT.
223657641|NCT04170985|OTHER|clinical Whole Genome Sequencing|Participants will receive cWGS as well as standard of care testing. The clinician/site PI will be blinded to the cWGS results until Day 180.
223657642|NCT04313140|DIAGNOSTIC_TEST|Diagnostic test|"The intervention occurs only one time (for 2h30), the MRI examination is divided as follow:~* Cinicial MRI (50 minutes)~* Research MRI (Phosphorus Spectroscopy, Sodium Imaging)"
223657643|NCT04294056|DRUG|Ciprofol|First-stage: 0.4mg/kg, 0.6 mg/kg, 0.8 mg/kg Second-stage: 0.4mg/kg, 0.6 mg/kg, 0.8 mg/kg
223657644|NCT04294056|DRUG|Propofol|First-stage: 2.0mg/kg, 3.0 mg/kg, 4.0 mg/kg Second-stage: 2.0mg/kg, 3.0 mg/kg, 4.0 mg/kg
223657645|NCT02715440|DRUG|Immediate intervention|Gradual withdrawal of benzodiazepines or related drugs
223657646|NCT06438510|PROCEDURE|Gastric Mucosal Ablation (GMA) of the fundus with Hybrid Argon Plasma Coagulation (HybridAPC) combined with Endoscopic Sleeve Gastroplasty (ESG)|All endoscopic procedures will be performed with the patient in the supine position, under general anesthesia, with endotracheal intubation, in CO2 using a flexible endoscopic suturing system (OverStitchTM; Apollo Endosurgery, Austin, TX, USA) connected to a dual-channel endoscope (GIF-2TH180 or GIF-2TH160; Olympus, Center Valley, PA, USA ). The HybridAPC with submucosal injection and APC will be delivered by ErbeJet®2. ESG will be obtained by placing full-thickness sutures in the body gastric wall, from the angulus to the gastric fundus. Biopsy tissue will be collected from the gastric fundus and the samples will be fixed for histopathologic examination. In the next step HybridAPC to the gastric mucosa of the fundus is applied.
223657647|NCT04228029|DEVICE|Carboxytherapy|Carbon dioxide (CO2) gas in injection form
223657648|NCT04228029|DRUG|Intralesional Steroid Injection|triamcinolone acetonide 8 mg/mL
223768536|NCT05269628|DRUG|Tetrahydrocannabinol (THC)|"Dronabinol dose will be 2.5 mg twice daily during the first seven days of active treatment (half of full anticipated dose), followed by 5 mg twice daily for the remainder of the treatment interval (full dose). If the full dose (5 mg twice daily) is not tolerated by participants, they will have the option of going down to the original half-dose (2.5 mg twice daily).~Participants who go back to the half-dose of Dronabinol (2.5 mg twice daily) also have the option to request once-per-day dosing with study drug taken at preferred time of day. Participants who request once-per-day dosing will not exceed a total daily dose 5 mg Dronabinol per day. Participants who are tolerating the full-dose of medication (Dronabinol 5 mg BID) will not be allowed to combine these doses into one daily dose."
223768537|NCT05269628|DRUG|Placebo CBD|Placebo solution will be taken twice per day, using the same dosing regimen as described for Epidiolex®.
223657649|NCT05086614|DRUG|Thymosin Alpha1|Receive thymosin-alpha 1 1.6mg with subcutaneous injection, twice a week, for 6 months after radical resection.
223657650|NCT06110832|BEHAVIORAL|Mindfulness-based Meditation and Yoga program|In the mindfulness-based meditation and yoga program, mindfulness-based formal and informal interventions are conducted for 8 weeks.
223657651|NCT03935568|DRUG|PU-AD|3 cohorts receiving a single oral dose of PU-AD at one time.
223657652|NCT03935568|DRUG|Placebo|3 cohorts receiving a single oral dose of Placebo at one time
223768538|NCT05269628|DRUG|Placebo THC|Placebo capsules will be taken twice per day in the same schedule and manner as active dronabinol.
223768539|NCT05445128|BIOLOGICAL|MGTA-145|MGTA-145 will be administered as an IV infusion
223657653|NCT03935568|DRUG|Placebo|2 cohorts receiving multiple oral dose of Placebo at one time
223768540|NCT05445128|DRUG|Plerixafor|240 µg/kg administered subcutaneously
223768541|NCT07007429|OTHER|Ipsilesional Side Stimulated Occlusal Imbalance|In this group, a 1 cm thick cotton roll will be placed on the ipsilesional occlusal surfaces of the patients, and they will be instructed to hold it in place without clenching.
223768542|NCT07007429|OTHER|Contralesional Side Stimulated Occlusal Imbalance|In this group, a 1 cm thick cotton roll will be placed on the contralesional occlusal surfaces of the patients, and they will be instructed to hold it in place without clenching.
223768543|NCT07007429|OTHER|Bilateral Cotton Roll with Jaw Clenching|In this group, a 1 cm thick cotton roll will be placed on both occlusal surfaces, and the patients will then be instructed to clench their teeth.
224239944|NCT05459727|PROCEDURE|Non-surgical periodontal therapy|Non-surgical periodontal therapy includes basic oral hygiene instructions and full-mouth subgingival scaling and root planing under local anesthesia.
224239945|NCT05459727|PROCEDURE|Control periodontal treatment|Control periodontal treatment includes basic oral hygiene instructions and full-mouth supragingival ultrasonic scaling.
224239946|NCT04638153|BIOLOGICAL|Recifercept|Recifercept
224239947|NCT02707653|DRUG|Misoprostol|400 mcg sublingual misoprostol
224239948|NCT00002549|BIOLOGICAL|filgrastim|
224239949|NCT00002549|DRUG|busulfan|
224239950|NCT00002549|DRUG|cyclophosphamide|
224239951|NCT00002549|DRUG|cytarabine|
223657654|NCT03935568|DRUG|PU-AD|2 cohorts receiving multiple oral dose of PU-AD at one time
223657655|NCT02870478|DRUG|Atropine|Dosing frequency comparison, using atropine sulfate 1% solution diluted to 0.01% and 0.05% by Leiter's Compounding Pharmacy
223768544|NCT07025252|DEVICE|VersaWrap|VersaWrap is applied to the affected tendon to allow post-operative gliding.
223768545|NCT05944120|COMBINATION_PRODUCT|Aromatherapy patches|This study anticipates that Staff-reported stress levels will decrease when nurses use strategies from the Crisis Intervention Cart while at work.
223768546|NCT07039123|DIAGNOSTIC_TEST|Polygenic Risk Score for Coronary Artery Disease (PRS-CAD)|A polygenic risk score will be calculated based on genome-wide genotyping and combined with SCORE2 clinical risk factors to estimate personalized cardiovascular risk. The combined risk (PRS-CAD-SCORE2) will be communicated to participants and their healthcare providers using a standardized communication tool. Participants with elevated risk will be referred to a lipid clinic.
224239952|NCT00002549|DRUG|daunorubicin hydrochloride|
224239953|NCT00002549|DRUG|etoposide|
224239954|NCT00002549|DRUG|idarubicin|
223657656|NCT00495248|BEHAVIORAL|Group intervention inspired by Lifestyle Redesign|Group intervention inspired by Lifestyle Redesign
223657657|NCT00495248|BEHAVIORAL|Group intervention inspired by Lifestyle redesign|Lifestyle programme once a week for two hours over an intervention period of 9 months
224239955|NCT00002549|DRUG|mesna|
224239956|NCT00002549|DRUG|mitoxantrone hydrochloride|
224239957|NCT00002549|PROCEDURE|allogeneic bone marrow transplantation|
224239958|NCT00002549|PROCEDURE|autologous bone marrow transplantation|
224239959|NCT00002549|PROCEDURE|peripheral blood stem cell transplantation|
224239960|NCT00002549|RADIATION|radiation therapy|
224239961|NCT02019290|DRUG|Midazolam|Single oral doses will be given on Days 1 and 15, after an overnight fast.
224239962|NCT02019290|DRUG|bitopertin|An oral dose will be given daily in the morning from Days 2-15. On Days 14 and 15, bitopertin will be given after an overnight fast; on Days 2-13, bitopertin will be given under fed conditions.
224239963|NCT00270959|BEHAVIORAL|Cognitive Behavioral Therapy|Behavioral therapy includes standard cognitive behavioral therapy, with an emphasis on behavioral activation. Treatment is administered on the basis of the participants' individual needs and may continue for up to 12 months.
224239964|NCT00270959|BEHAVIORAL|Motivational Interviewing|Motivational interviewing is designed to address alcohol and drug use.
223657658|NCT03264729|OTHER|Isometric exercise|The isometric exercise is performed standing with the forefoot on a step. The participant is instructed to stand still with the ankle joint in neutral and hold this position. Supporting oneself for balance by placing the hands on a wall or a rail is allowed. The participant performs 5 sets of 45-second isometric holds. The load used is the heaviest possible load that the participant is able to withstand for 1 minute. As with the isotonic exercise, if the participant's body weight is inadequate the participant is fitted with a backpack with books and/or weights.
223657659|NCT03264729|OTHER|Isotonic exercise|"The isotonic exercise is performed standing with the forefoot on a step. The toes are maximally dorsi-flexed by placing a towel underneath them. The participant is instructed to perform a heel-raise to a maximal plantar flexion in the ankle joint, and afterwards to lower the heel to maximal dorsi flexion. Supporting oneself for balance by placing the hands on a wall or a rail is allowed. The participant performs 4 sets of 8 repetitions with a load of 8RM. The contraction time is 3s concentric, 2s isometric and 3s eccentric and will be guided by a metronome.~If the participant's body weight is inadequate to reach sufficient loading during the exercises the participant is fitted with a backpack with books and/or weights."
223657660|NCT03264729|OTHER|Walking|The walking will be performed barefoot and the participant will be instructed in walking at a pace similar to the pace they would use when walking around in their home. The duration of the walking session will be four minutes to match the duration during the exercises.
223657661|NCT05941871|OTHER|Dietary intervention - intervention group|"Low-calorie diet for 4 months with a different daily energy distribution according to the chronotype:~* Morning chronotype: 50% of kcal administered before lunch and 15% in the second part of the day (specifically: 40% at breakfast, 10% in the morning snack, 35% at lunch, 5% at afternoon snack and 10% at dinner)~* Evening chronotype: 15% of kcal given before lunch and 50% in the second half of the day (specifically: 10% of kcal at breakfast, 5% in the morning snack, 35% at lunch, 10% at snack time and 40% at dinner)"
223768547|NCT07039123|BEHAVIORAL|Standardized Risk Communication Tool (SCORE2)|Participants will receive risk communication based solely on clinical risk factors using the SCORE2 algorithm. The same structured communication tool will be used (without genetic data), along with general lifestyle guidance.
224239965|NCT00270959|DRUG|FDA-Approved Anti-Anxiety Medications|Participants assigned to receive the combination therapy may receive one or more of the following medications based on their individual needs: fluoxetine, sertraline, paroxetine, buspirone, propranolol, trazodone, and any of the benzodiazepines. Participants may begin receiving medication immediately or anytime within the 12 months post-injury. Form, dosage, frequency, and duration depend on patient need, but all are prescribed in accordance with standards of care.
224239966|NCT00270959|BEHAVIORAL|Standard Care Control|Standard care control includes the usual treatment for injured trauma survivors.
224239967|NCT02829970|BEHAVIORAL|SUCCEEDS Program|Participants will receive ADHD Psychoeducation, Brief Motivational Interviewing (BMI) and Behavioral Activation for Attention \& Alcohol Disorders (BAAAD).
224239968|NCT02829970|BEHAVIORAL|Living a Healthy College Lifestyle|Participants will receive ADHD Psychoeducation, BMI and Supportive Counseling (SC).
224239969|NCT03248362|DEVICE|Transcutaneous posterior tibial nerve stimulation|12 session programme (a total of 6 hours) is delivered in 30 minute sessions twice weekly over a 6 week period of tibial nerve stimulation
224239970|NCT03248362|DEVICE|Sham stimulation|12 session programme (a total of 6 hours) is delivered in 30 minute sessions twice weekly over a 6 week period of of the lateral sub-malleolar area
223657662|NCT05941871|OTHER|Dietary intervention - control group|Group that will follow a low-calorie diet with a standard daily energy distribution (20% of kcal at breakfast, 10% in the morning snack, 35% at lunch, 10% at afternoon snack and 25% at dinner) for 4 months
223657663|NCT04668027|DIAGNOSTIC_TEST|impulse oscillation（IOS）|The patient is tested for the first IOS after the screening test, and performed the second IOS test immediately after the results of BPT or BDT. The patient takes seats, body relax, make sure the mouthpiece is fully covered by mouth, then clip nose with both hands to cover both sides of the cheek, and then calms breathing one minutes.
223657664|NCT04668027|DIAGNOSTIC_TEST|bronchial provocation test(BPT)|Patient needs to cooperate with the inhalation of acetylcholine stimulants with low to high concentrations, and operates in accordance with the standard nebulized administration procedure. Measure FEV1 after each inhalation and take the high value. The interval between the inhalation of two adjacent doses is 5 minutes, until the FEV1 decrease value is ≥20% of the FEV1 base value or the highest inhalation concentration. The patient needs to cooperate to ensure that the filter is as tight as possible to prevent air leakage, and performs exhalation and inhalation with the greatest strength and fastest speed. After the examination,the patient should inhale the bronchodilator salbutamol sulfate (400ug).
223657665|NCT04668027|DIAGNOSTIC_TEST|bronchial dilation test(BDT)|The patient inhales the salbutamol sulfate (400ug). 15 minutes later, the pulmonary function tester is used for measurement. The patient needs to cooperate to ensure that the filter is as tight as possible to prevent air leakage, and to exhale and breathe with the greatest strength and fastest speed. Inhale.
223657666|NCT00617799|BIOLOGICAL|aldesleukin|
223657667|NCT00617799|GENETIC|gene expression analysis|
223657668|NCT00617799|GENETIC|mutation analysis|
223657669|NCT00617799|OTHER|flow cytometry|
223657670|NCT06273696|DEVICE|ShangRing|The ShangRing is a sterile, single use, disposable male circumcision (MC) device that consists of two concentric plastic rings, the inner of which is lined by a silicone pad, which provides a smooth and non-bio reactive surface against the surgical wound. The outer ring consists of 2 halves which are hinged together at the same end. On each side of the halves there is a locking clasp which allows for locking itself with inner ring. The ShangRing device is removed seven days after placement.
223768548|NCT06722170|GENETIC|EH002 administration|EH002 was administered into one or both ears via intracochlear injection.
223768549|NCT06893809|PROCEDURE|Epidural injection via Tuohy needle|Local anesthetic was administered entirely through the Tuohy needle.
223768550|NCT06893809|PROCEDURE|Epidural injection via catheter|Local anesthetic was administered entirely through the epidural catheter.
223768551|NCT06893809|PROCEDURE|Combined epidural injection (needle and catheter)|Half of the total local anesthetic dose was administered through the needle and half through the catheter.
224239971|NCT06155630|OTHER|mandibular implant-overdenture|Mandibular overdentures fabricated over two implants will be delivered to the patients. In the first group, the 3D printed overdentures will be given for 3 months, followed by 3-month wear of traditional overdentures. The second group will wear traditional overdenture first followed by 3 months of 3D printed overdenture.
224239972|NCT05288127|DRUG|Talazoparib|"The recommended dose is 1 mg talazoparib once daily. Patients should be treated until disease progression or unacceptable toxicity occurs. Daily dosing of talazoparib can be interrupted for recovery from toxicity for up to 28 days. For interruptions longer than 28 days, treatment at the same or a reduced dose can be considered based on the if evidence of response or clinical benefit to talazoparib is noted.~Missing dose If the patient vomits or misses a dose, an additional dose should not be taken. The next prescribed dose should be taken at the usual time.~Dose adjustments:~To manage adverse drug reactions, interruption of treatment or dose reduction based on severity and clinical presentation should be considered."
223657671|NCT03846518|DEVICE|Hyrax|Rapid maxillary expansion using the Hyrax expander. Appliance anchorage will be performed by bands adapted to the first maxillary molars and arms of the screw contoured to adapt to palatal faces of the first and second maxillary bicuspids, in wich will be bonded by resin. The screw will be positioned perpendicularly to the palate sagittal midline, between second maxillary bicuspids and first maxillary molars, and 5 mm apically from marginal gingiva of palatal face of the first maxillary molars.The activation protocol will be 2 turns a day up to obtain transverse overcorrection. After the active period of RME, the screws will be fixed with ligature wire and the appliance will be kept as a retainer for 6 months.
224239973|NCT00171821|DRUG|Deferasirox|
224239974|NCT05165056|DEVICE|Intimleds|INTIMILEDS® is a photobiomodulation device designed for intravaginal use. It's design permits an irradiation of the whole vaginal wall, the vulva, and the cervix, with a constant intensity.
224239975|NCT04019678|PROCEDURE|Omission of Axillary dissection|In Group 1 and 2: Axillary dissection won't be performed
224239976|NCT02687074|DEVICE|HFNC|patients treated with high flow nasal cannula
224239977|NCT02687074|DEVICE|NIV|patients treated with noninvasive ventilation
224239978|NCT01973348|DEVICE|4-hour AmblyZ glasses|4-hour AmblyZ glasses for moderate amblyopia
224239979|NCT01973348|DEVICE|12-hour AmblyZ glasses|12-hour AmblyZ glasses for severe amblyopia
224239980|NCT01973348|DEVICE|2-hour patching|2-hour patching for moderate amblyopia
224239981|NCT01973348|DEVICE|6-hour patching|6-hour patching for severe amblyopia
224239982|NCT04386759|OTHER|Cohort|None. Only implementation of a cohort with data collection via individual self-questionnaires and administrative services for contextual data.
224239983|NCT00874237|DRUG|Inhaled loxapine|Inhaled Staccato Loxapine 10 mg single dose
224239984|NCT00874237|DRUG|Inhaled placebo|Inhaled Staccato placebo single dose
224239985|NCT00874237|DRUG|Oral moxifloxacin|Oral moxifloxacin 400 mg
224239986|NCT00874237|DRUG|Oral placebo|Oral placebo similar in appearance to moxifloxacin 400 mg
224239987|NCT01162226|BEHAVIORAL|gait and balance training program|The intervention will be implemented via three 50-minute training sessions per week for 12 weeks. The games will be played when the subject is receiving the maximum benefit from their anti-parkinsonian medications. The control group and the intervention group will receive weekly telephone calls to inquire about medications and falls. At baseline and end of the 12 weeks, in-home testing will determine stride length and speed; standing balance eyes open and closed on flat and foam surface.
224239988|NCT02355431|DRUG|Itacitinib|tablets to be administered by mouth once daily at dose selected from safety run-in phase
224239989|NCT02355431|DRUG|erlotinib|150 mg tablets administered by mouth once daily at total daily dose of 150 mg
224239990|NCT02355431|DRUG|placebo|matching placebo tablets to be administered by mouth at dose selected from safety run-in phase
224239991|NCT03129425|BEHAVIORAL|ReNACE Psychoeducational Intervention|9 sessions in groups of 15-20 people at most so as to promote reflection and facilitate the interchange of opinions between participants about issues of interest from their day to day experience of coping with Parkinson's disease.
223768552|NCT06893198|BEHAVIORAL|Storytelling intervention|"The storytelling intervention consists of interactive, literacy-appropriate, and culturally sensitive multimedia storytelling modules for motivating behavior change through the power of patients speaking in their own voice. Based on preferences that emerged during the researchers' formative work with the partnering rural communities, the storytelling intervention will be delivered via Computerized Intervention Authoring System (CIAS) on a biweekly basis. A supplementary Learn More module of didactic material (3 minutes) provides strategies for better patient-physician communication and is coordinated with the specific patient stories will be provided via CIAS as well."
224239992|NCT03129425|OTHER|General Educational Program|5 sessions in groups of 15-20 people
224239993|NCT03077516|DEVICE|Mobi-C|Device for cervical intervertebral disc replacement at one or two contiguous levels
224239994|NCT03850639|BEHAVIORAL|Internet-based exposure therapy|The treatment is a three week long cognitive behavior therapy. It is based mainly on the principles of exposure; i.e. the participant is instructed to approach the memory of the traumatic event and situations they since the traumatic events are associated with fear and anxiety. Other interventions include psychoeducation, and breathing retraining to facilitate exposure.
224239995|NCT01257009|DRUG|Atorvastatin|6 weeks treatment with atorvastatin and studying the effect of atorvastatin on sympathetic activity
224239996|NCT03912337|DRUG|Placebo|Placebo once every 4 weeks. SC injection.
224239997|NCT03912337|DRUG|Erenumab|Erenumab once every 4 weeks. SC injection.
224239998|NCT06213688|OTHER|blood sampling|blood sampling at inclusion
224239999|NCT06213688|OTHER|urine sampling|urine sampling at inclusion
224240000|NCT03752528|DIAGNOSTIC_TEST|Blood sample collection|Determination of buprenorphine and norbuprenorphine plasma concentrations
224240001|NCT03752528|DIAGNOSTIC_TEST|Urine sample collection|Urine sample for determination of free buprenorphine and free norbuprenorphine concentrations, qualitative UDS for opioids, quantitative UDS for buprenorphine, norbuprenorphine and naloxone, and determination of creatinine concentration
223657672|NCT03846518|DEVICE|mini Hyrax|Rapid maxillary expansion using the mini Hyrax expander. Appliance anchorage will be performed by bands adapted to the first maxillary molars and arms of the screw contoured to adapt to palatal faces of the first and second maxillary bicuspids, in wich will be bonded by resin. The screw will be positioned perpendicularly to the palate sagittal midline, between second maxillary bicuspids and first maxillary molars, and 5 mm apically from marginal gingiva of palatal face of the first maxillary molars. The activation protocol will be 2 turns a day up to obtain transverse overcorrection. After the active period of RME, the screws will be fixed with ligature wire and the appliance will be kept as a retainer for 6 months.
223657673|NCT05622253|COMBINATION_PRODUCT|Combined Low-Dose Isotretenion and Long-Pulsed 1064 ND-YAG Laser|Selected patients will be treated with low-dose oral isotretinoin (10mg/day) over a period of sessions and six sessions of 1064 ND- YAG laser (Deka motous AY) using 150 J/cm2, 20-25 milliseconds pulse duration, and 5 mm spot size, at 2 weeks' interval.
223657674|NCT02834793|DRUG|Placebo|Participants will receive matching placebo in Randomization phase.
223657675|NCT02834793|DRUG|Perampanel|Participants will receive perampanel in Randomization phase, open-label Extension A, and open-label Extension B.
223657676|NCT00967824|OTHER|informational intervention|
223657677|NCT00967824|OTHER|questionnaire administration|
223657678|NCT00967824|OTHER|survey administration|
223657679|NCT03811236|OTHER|Cold exposure|Two hours of mild cold exposure using a water-perfused vest
223768553|NCT06893198|BEHAVIORAL|Home BP monitoring|Patients with hypertension will be provided blood pressure monitors and guided to self-measure their blood pressure and to record their blood pressure daily at home.
224240002|NCT06391983|OTHER|resistance training (elastic band)|The intervention group attended online group education sessions on diabetes self management, as well as resistance exercise training sessions three times weekly; the sessions were approximately 40 minutes long and included 5 minutes of warm up, followed by 30 minutes of resistance exercises and 5 minutes of cool down. The resistance training consisted of ten upper-body and lower-body exercises using elastic band. The initial sessions were 1 to 2 sets of 6 to 8 repetitions at 45% of the one-repetition maximum (1 RM). It was increased progressively to 2 to 3 sets of 8 to 12 approximately 50% -55% of 1 RM.
224240003|NCT00721747|DRUG|Docetaxel, Liposomal doxorubicine and Cyclophosphamide|4 cycles of Docetaxel 100mg/m2 iv followed by 4 cycles of Liposomal doxorubicine 60mg/m2/iv and Cyclophosphamide 600mg/m2/iv
224240004|NCT06631157|DEVICE|Essential pro|Patients in whom treatment with (Essential Pro) has been attempted
224240005|NCT01772030|OTHER|Use of the Achieve catheter followed by ICE-guided mapping catheter|
224240006|NCT00106548|DRUG|tocilizumab [RoActemra/Actemra]|4mg/kg iv / month
224240007|NCT00106548|DRUG|tocilizumab [RoActemra/Actemra]|8mg/kg iv / month
224240008|NCT00106548|DRUG|Placebo|iv / month
224240009|NCT00106548|DRUG|Methotrexate|10-25mg/week
224240010|NCT06328348|DIETARY_SUPPLEMENT|supplementation|group receiving a course of Black Cohosh, Soy Isoflavones, and SDG Lignans
224240011|NCT06328348|OTHER|placebo|placebo
224240012|NCT00537030|DRUG|Asparaginase|Given IM
224240013|NCT00537030|OTHER|Laboratory Biomarker Analysis|Correlative studies
224240014|NCT00537030|OTHER|Pharmacological Study|Correlative studies
224240015|NCT02458469|DRUG|Buspirone|The initial dose of Buspirone is 15 mg daily (7.5 mg bid.). To achieve an optimal therapeutic response, at intervals of 2 to 3 days the dosage may be increased 5 mg per day until a maximum dose 30mg/day is reached.
223657681|NCT03961698|DRUG|IPI-549 (eganelisib)|IPI-549 is an oral, selective inhibitor of phosphoinositide-3-kinase gamma (PI3K-gamma). It is an orally-administered capsule that will be dosed at either 20mg/day, 30mg/day, or 40mg/day to patients in both cohorts A and B depending on the results of the safety run-in phase for each cohort.
223657682|NCT03961698|DRUG|Atezolizumab|Atezolizumab is a fully humanized, engineered monoclonal antibody of IgG1 isotype against the protein programmed cell death-ligand 1 (PD-L1). 840 mg of the drug will be administered intravenously (IV) on days 1 and 15 in combination of each 28-day cycle for patients with TNBC. 1200mg will be administered IV on day 1 of each 21-day cycle to patients with RCC.
223657683|NCT03961698|DRUG|nab-paclitaxel|Nab-paclitaxel is a nanoparticle albumin-bound formulation of paclitaxel (Taxol), a mitotic inhibitor chemotherapy, with less toxicity than solvent-based (sb) paclitaxel and achieves a 33% higher tumor uptake in preclinical models. Nab-paclitaxel will be administered intravenously (IV) at 100 mg/m2 on days 1, 8 and 15 of each 28-day cycle for patients with TNBC.
223657684|NCT03961698|DRUG|Bevacizumab|Bevacizumab is an anti-vascular endothelial growth factor (anti-VEGF) recombinant monoclonal antibody that is approved by the FDA for the treatment of multiple solid tumors in combination with chemotherapy. It will be administered at 15 mg/kg IV on day 1 of each 21-day cycle to patients with RCC.
223657685|NCT00960726|DRUG|NOV-002|60 mg delivered daily subcutaneously for up to 12 months.
223657686|NCT03701035|BEHAVIORAL|Aerobic Training & UL Motor Training|Aerobic training at 40%-59% Heart Rate Reserve (AT) increasing from personal maximum time (if \< 40 mins) to 40 minutes followed by UL motor training with the Armeo®Spring/Senso/Pablo X2®
223657687|NCT03701035|BEHAVIORAL|Non-aerobic training & UL Motor Training|40 minutes non-aerobic gait \& balance circuit training followed by UL motor training with the Armeo®Spring/Senso/Pablo X2®
224240016|NCT02458469|DRUG|Trazodone|100 mg dose before bed-time
224240017|NCT02458469|DRUG|Placebo|One placebo pill before bed-time
224240018|NCT03682159|OTHER|manual lymphatic drainage|The intervention group received the same conventional postoperative cares as the control group, but also underwent 5 sessions of manual lymphatic drainage (MLD)
224240019|NCT04795154|OTHER|Yoga excercise|Yoga exercise in pre-eclampsia \>20 weeks of pregnancy woman, treatment number was 4 times.
224240020|NCT02524197|DRUG|CR845 0.25 mg|Subjects will dose orally twice a day with CR845 0.25 mg tablets for two weeks. A diary will be kept for recording the individual's pain scores and dosing accountability.
224240021|NCT02524197|DRUG|CR845 0.50 mg|Subjects will dose orally twice a day with CR845 0.50 mg tablets for two weeks. A diary will be kept for recording the individual's pain scores and dosing accountability.
224240022|NCT02524197|DRUG|CR845 1 mg|Subjects will dose orally twice a day with CR845 1 mg tablets for two weeks. A diary will be kept for recording the individual's pain scores and dosing accountability.
223657688|NCT03246386|DRUG|Posaconazole Injection [Noxafil] 300mg|Single dose by intravenous infusion 300mg
223657689|NCT03246386|DRUG|Posaconazole Injection [Noxafil] 400mg|Single dose by intravenous infusion 400mg
223657690|NCT05946356|OTHER|no intervention - cross-sectional observational only|no intervention - cross-sectional observational only
223657691|NCT01049009|DRUG|Nebivolol|"Subjects will be randomized to either nebivolol or metoprolol xl, and remain on the study drug for 10 weeks. They will then cross over to take 10 weeks of the comparator drug."
223657692|NCT01049009|DRUG|Metoprolol XL|"Subjects will be randomized to either nebivolol or metoprolol xl, and remain on the study drug for 10 weeks. They will then cross over to take 10 weeks of the comparator drug."
223657693|NCT00229424|DRUG|Lafutidine|Oral administration of lafutidine by 20mg/day along with famotidine placebo
223657694|NCT00229424|DRUG|Famotidine|Oral administration of famotidine by 40mg/day along with lafutidine placebo
223657695|NCT00229424|OTHER|Placebo|Oral administration of lafutidine placebo along with famotidine placebo
223657696|NCT05657574|DRUG|D377|oral, once daily, 8 weeks
223657697|NCT05657574|DRUG|CKD-331|oral, once daily, 8 weeks
223657698|NCT05657574|DRUG|D086|oral, once daily, 8 weeks
223657699|NCT05657574|DRUG|Placebo (for D377)|oral, once daily, 8 weeks
223657700|NCT05657574|DRUG|Placebo (for CKD-331)|oral, once daily, 8 weeks
223657701|NCT05657574|DRUG|Placebo (for D086)|oral, once daily, 8 weeks
223657702|NCT04384081|DRUG|BI 456906|Solution for injection
223657703|NCT04384081|DRUG|Placebo|Solution for injection
224240023|NCT02524197|DRUG|CR845 5 mg|Subjects will dose orally twice a day with CR845 5 mg tablets for two weeks. A diary will be kept for recording the individual's pain scores and dosing accountability.
224240024|NCT06470880|DRUG|Adaptive Therapy|A blood test that measures the amount of tumour DNA circulating in the patient's blood (known as ctDNA) will be conducted every two weeks to check if the cancer cells are still present, and if they are becoming active. The result of this test will allow doctors to monitor the activity of the tumour and judge when to pause and resume encorafenib and binimetinib treatment. This intermittent treatment is called 'adaptive therapy'.
224240025|NCT06470880|DRUG|Standard of Care|Encorafenib and binimetinib delivered to UK standard of care.
224240026|NCT02156739|PROCEDURE|Contrast-enhanced Magnetic Resonance Imaging|Undergo contrast-enhanced MRI
224240027|NCT02156739|DRUG|Gadobutrol|Given IV
224240028|NCT02156739|DRUG|Gadoxetate Disodium|Given IV
224240029|NCT01081730|BIOLOGICAL|anti-TNF biologics|as prescribed
224240030|NCT01081730|OTHER|general population|non-treated cohort
224240031|NCT01081730|BIOLOGICAL|non-anti-TNF biologics|as prescribed
223657704|NCT04709133|PROCEDURE|multi-ligament knee surgery|a chart review will be performed to identify patients who underwent surgical treatment for multi-ligamentous knee injuries at Assiut University Hospital performed by one of sports medicine orthopaedic surgeons at Assiut arthroscopy and sport unit.
223657705|NCT05573269|DIETARY_SUPPLEMENT|FOPE (fish oil + pine extract)|During the experiment period the participants will receive a capsule of pine bark extract (Oligopin® 100mg) and a capsule of fish oil (EPA 350mg + DHA 250mg) a day. Blood collecting (biomedical parameters and antioxidative status) and cognitive function evaluation will be examined at the 0, 12, 24th week. Body composition, 24-hour dietary recall and blood pressure measurement will be measured at 0, 4, 8, 12, 16, 20, 24th week.
223657706|NCT05573269|OTHER|FO (fish oil +placebo)|During the experiment period the participants will receive a capsule of placebo (maltodextrin + magnesium stearate) and a capsule of fish oil (EPA 350mg + DHA 250mg) a day. Blood collecting (biomedical parameters and antioxidative status) and cognitive function evaluation will be examined at the 0, 12, 24th week. Body composition, 24-hour dietary recall and blood pressure measurement will be measured at 0, 4, 8, 12, 16, 20, 24th week.
223657707|NCT03843671|DRUG|Hyperbaric oxygen|Hyperbaric oxygen therapy
223657708|NCT03843671|DEVICE|Hyperbaric chamber|Hyperbaric chamber
223657709|NCT02423902|BIOLOGICAL|Ad-RTS-hIL-12|Approximately 1.0x10\^12 viral particles (vp) per injection
223657710|NCT02423902|DRUG|Veledimex|7 oral doses of veledimex
223657711|NCT02136069|DRUG|Etrolizumab|105 mg administered by subcutaneous (SC) injection once every 4 weeks (Q4W) until Week 52.
223657712|NCT02136069|DRUG|Infliximab|5 mg/kg of infliximab will be administered by intravenous (IV) infusion at Weeks 0, 2, and 6 and then every 8 weeks until Week 46.
224240032|NCT01081730|BIOLOGICAL|ustekinumab|as prescribed
224240033|NCT01081730|DRUG|systemic non-biological treatments|as prescribed
223657713|NCT02136069|OTHER|Placebo (IV)|Administered by (IV) infusion at Weeks 0, 2, and 6 and then every 8 weeks until Week 46.
223657714|NCT02136069|OTHER|Placebo (Injection)|Administered by SC injection Q4W until Week 52
223657715|NCT00778661|DRUG|amoxicillin 400mg + clovalunic acid 57.5mg tablets|
223657716|NCT05395273|DEVICE|Game Ready cryocompression|Cryotherapy on the coldest tolerable level and intermittend compression on the knee
223657717|NCT04538144|OTHER|Hot and Humid Trial|Individuals will be exposed to a simulated heat wave (hot and humid) condition.
223657718|NCT04538144|OTHER|Hot and Dry Trial|Individuals will be exposed to a simulated heat wave (hot and dry) condition.
223657719|NCT05627323|BIOLOGICAL|CHM-1101 CAR-T cells|Administered via ICT/ICV dual delivery
223657720|NCT05612932|OTHER|immediate orthodontic retainer delivery|post orthodontic treatment patients will be given orthodontic retainer immediately after debonding
223657721|NCT05612932|OTHER|delayed orthodontic retainer delivery|post orthodontic treatment patients will be given orthodontic retainer after 7 days of debonding
223657722|NCT01871740|DRUG|Enalapril maleate and folic acid tablets|Enalapril maleate and folic acid tablets, (10mg/0.8mg)/tablet, taken orally and once daily for a maximum of 5 years. Combination with other anti-hypertension drugs are allowed.
223657723|NCT01871740|DRUG|Enalapril maleate|Enalapril, 10mg/tablet, taken orally once daily for a maximum of 5 consecutive years. Combination with other anti-hypertension drugs are allowed.
223657724|NCT06310720|OTHER|Video Education|12-minute educational video covering postpartum topics of hemorrhage, infection, hypertension, and depression. Created by Cicatelli Associates Inc.
223657725|NCT04323787|OTHER|observational|No Intervention
224240034|NCT06002971|DEVICE|Blood pressure measurement|Serial blood pressure measurements to compare reference auscultatory sphygmomanometer to CONNEQT Pulse according to ISO 81060-2.
223657726|NCT05140876|BEHAVIORAL|START mHealth Intervention|The START mHealth intervention is a mobile application that will be downloaded by participants through their mobile phones. The application targets information, motivation, and behavioral skills relevant to ART adherence. Participants will have access to this application for 6 months.
223657727|NCT06743282|BEHAVIORAL|Waitlist|Subjects will have monthly check-in meetings with the Integrated Behavioral Healthcare manager, complete monthly urine tests for substance use, the Timeline Follow Back (TLFB) to gather substance abuse history, and complete baseline questionnaires.
224240035|NCT03259763|DEVICE|Lumen-apposing metal stent|In this technique, the gastric wall and its adjacent small intestine are punctured by a needle to make a connection between the stomach and small intestine. Then a lumen-apposing metal stent is deployed at the puncture site to keep the stomach-small intestine connection open.
224240036|NCT03259763|DEVICE|Self-expandable metal stent|In this technique, under endoscopic visualization, a guidewire will be advanced through the obstructed part of the stomach. Then an enteral self-expandable metal stent will be deployed under direct endoscopic visualization and fluoroscopic guidance.
224240037|NCT05660642|DRUG|BPL-003|Experimental BPL-003 arms: will investigate one of two doses of BPL-003 (Part 1) and two doses of BPL-003 (Part 2)
224240038|NCT06542081|BEHAVIORAL|Descriptive information form, psychological resilience scale and disaster preparedness scale were completed by the parents of hearing impaired children.|Descriptive information form, psychological resilience scale and disaster preparedness scale were completed by the parents of hearing impaired children.
224240039|NCT03561883|DRUG|IW-3718|oral tablet
224240040|NCT03561883|DRUG|placebo|oral tablet
223657728|NCT06743282|BEHAVIORAL|Senyo App|Subjects will engage with the Senyo Health platform for 12 weeks to deliver Integrated Behavioral Healthcare (IBH) treatment. The Senyo Health platform consists of asynchronous cognitive behavioral therapy modules and weekly check-ins with the IBH care manager. Subjects will also complete a monthly urine test for substances, the Timeline Follow Back (TLFB) to gather substance abuse history, and complete weekly questionnaires.
223657729|NCT06743282|BEHAVIORAL|Follow-up|Subjects will have monthly check-in meetings with the Integrated Behavioral Healthcare manager, complete monthly urine tests for substance use, the Timeline Follow Back (TLFB) to gather substance abuse history, and complete monthly questionnaires.
223657730|NCT03571685|BEHAVIORAL|Sustainable Early Episode Clinic Model of Care|The first 8 weeks is the education phase. Participants attend classes every week for up to 6 hours. From 9 weeks to 10 months participants attend classes for 5 hours every other week. Based on individual progress. Participants can move to the maintenance phase. This phase provides minimal intervention but ongoing support/evaluation.
223657731|NCT04607850|BIOLOGICAL|ChAdOx1-HPV|Trial vaccine
223657732|NCT04607850|BIOLOGICAL|MVA-HPV|Trial vaccine
223657733|NCT04607850|BIOLOGICAL|Placebo|Saline placebo vaccine
223768554|NCT06893198|BEHAVIORAL|Expanded community health worker services|A training program will be implemented for community health workers for the intervention arm regarding hypertension management at the community level so that they can assist patients better managing their blood pressure at home.
224240041|NCT03561883|DRUG|Standard-dose PPIs QD|background therapy
224240042|NCT06370312|PROCEDURE|Trapeziectomy|Patients scheduled for trapeziectomy due to thumb basal joint osteoarthritis are invited to participate. Synovial fluid is aspirated before the joint is opened. Bone and cartilage are collected. Blood samples are obtained preop. Patients are measured with grip strength, pinch strength, range of thumb motion, body mass index, central obesity and blood pressure.
224240043|NCT00524758|DEVICE|ologen (oculusgen) collagen matrix|Implant ologen collagen matrix on the top of sclera flap after loose stiched the sclera flap. The traditional trabeculectomy is performed.
224240044|NCT00524758|DRUG|MMC in Trabeculectomy|MMC in Trabeculectomy
224240045|NCT01283919|DRUG|Pantoprazole Sodium|Pantoprazole Sodium DR Tablets 40 mg
224240046|NCT02256007|OTHER|Paper and Pencil Assessments|Videogame Assessments
224240047|NCT06275191|BEHAVIORAL|Multicomponent intervention|The multicomponent intervention consists of (1) a single 45-60-minute academic detailing session with provider participants, plus (2) provision of patient post-extraction instruction materials and (3) provision of blister-packaged acetaminophen and ibuprofen for distribution to adolescent/young adult patients after tooth extraction in the course of clinical practice
224240048|NCT06275191|OTHER|Usual care|No intervention.
224240049|NCT06354270|DRUG|Stannous fluoride toothpaste|Toothpaste containing 0.454 % weight/weight (w/w) SnF2.
223768555|NCT06893198|BEHAVIORAL|"Learn More module only"|"A supplementary Learn More module of didactic material (3 minutes) provides strategies for better patient-physician communication, which will be delivered via Computerized Intervention Authoring System (CIAS) at baseline and at 3, 6, and 9 months after enrollment."
223768556|NCT06761937|PROCEDURE|Thermotherapy|Thermotherapy will be given once a week after a radiotherapy fraction
224240050|NCT06354270|DRUG|Regular fluoride toothpaste (Crest Cavity Protection)|Regular fluoride toothpaste containing 1100 parts per million (ppm) fluoride.
224240051|NCT06137183|DRUG|Vixarelimab|Vixarelimab will be administered as per the schedule specified in the respective arms.
224240052|NCT06137183|DRUG|Placebo|Vixarelimab matching placebo will be administered as per the schedule specified in the respective arms.
224240053|NCT05245695|OTHER|Observational study, no intervention|Observational study, no intervention
224240054|NCT03092856|BIOLOGICAL|Anti-OX40 Antibody PF-04518600|Given IV
223657734|NCT03422328|DRUG|macitentan|macitentan 10 mg, film-coated tablet, oral use
223657735|NCT01620931|DRUG|Placebo|Single doses, iv or sc
223657736|NCT01620931|DRUG|RO5469754|Single ascending doses, iv or sc
223657737|NCT01092546|DRUG|[18F]Flutemetamol|All subjects will receive an IV dose of \[18F\]flutemetamol (less than 10 mg flutemetamol). The nominal activity of a single administration of \[18F\]flutemetamol will be 185 MBq.
223657738|NCT02185495|BEHAVIORAL|Observer nodule detection|Radiologists will detect the nodules.
223657739|NCT02185495|DEVICE|Computer-aided nodule detection|Computed-aided detection (CAD) software will be used to detect the nodules.
223657740|NCT05407662|OTHER|sMRA therapies|No drug will be provided to participants. Patients follow routine clinical practice/administration.
223657741|NCT00311129|DRUG|Fludarabine Phosphate (Fludara)|Injection of rituximab on Day 1 along with 5-consecutive day oral dosing of fludarabine phosphate from Day 1 to Day 5, followed by an observation period from Day 6 to Day 28 as 1 treatment cycle, 6 cycles will be given. As for patients who has been observed with partial response (PR) or better antitumor effect, any treatment shall not be provided in principle until the status comes to progressive disease (PD)
223657742|NCT00311129|DRUG|Rituximab|Injection of rituximab on Day 1, followed by an observation period from Day 6 to Day 28 as 1 treatment cycle, 6 cycles will be given. As for patients who has been observed with partial response (PR) or better antitumor effect, any treatment shall not be provided in principle until the status comes to progressive disease (PD)
224240055|NCT03092856|DRUG|Axitinib|Given PO
224240056|NCT03092856|OTHER|Laboratory Biomarker Analysis|Correlative studies
224240057|NCT03092856|OTHER|Placebo|Given IV
224240058|NCT02736656|DRUG|SPN-812|"Cohort 'A': Children 6-11 yrs of age take 100-400mg SPN-812 once daily by mouth and adolescents 12-17 yrs of age take 100-600mg SPN-812 once daily by mouth. Pediatric subjects in Cohort 'A' are given a choice to extend their participation in the study every 6 months for up to 72 months.~Cohort 'B': Pre-school-age children 4-5 yrs of age take 100mg SPN-812 once daily by mouth. Pediatric subjects in Cohort 'B' will be treated with 100 mg SPN-812 (100 mg capsule) for up to 6 months."
224240059|NCT06436781|DRUG|Maolactin|Once daily dose of 2 capsules containing a total of 500mg/day Maolactin
224240060|NCT06436781|DRUG|Maltodextrin|Once daily dose of 2 capsules of Maltodextrin containing a total of 0mg/day Maolactin
224240061|NCT06106555|BEHAVIORAL|Dialectibal Behaviour Therapy|Standard Dialectical Behaviour Therapy of up to 12 months as described Professor Linehan
224321080|NCT05747105|BEHAVIORAL|Sleep Extension|The 16-week protocol includes 11 total individual visits that integrate applicable elements of Cognitive Behavioral Therapy for Insomnia (CBT-I) and health behavior change theory. The first 6 weeks include weekly sessions (\~45 minutes each) focused on psychoeducation about sleep, goal-setting and self-monitoring, stimulus control, addressing cognitive and somatic arousal, sleep hygiene, and challenging negative thoughts about sleep. Sleep restriction will also be used in specific cases where sleep efficiency is low (\<85%). The remaining 10 weeks include briefer biweekly visits (5 visits, \~15-20 minutes each) to reinforce health behavior change strategies through topics such as problem-solving barriers, utilizing social support, identifying setbacks and creating an action plan, and relapse prevention. Self-reported sleep diary data and subjective sleepiness will be collected at each visit.
224321081|NCT04233294|DRUG|Chidamide|Chidamide is a novel and orally active benzamide class of HDAC inhibitor that selectively inhibits activity of HDAC1, 2, 3 and 10, which can Induce tumor-cell apoptosis, suppress cell proliferation and enhance immune surveillance.
224240062|NCT05432232|DEVICE|HistoSonics Investigational System|The HistoSonics Investigational System is intended for the non-invasive destruction of kidney tissue using histotripsy, a non-thermal mechanical process of focused ultrasound.
224240063|NCT04968249|OTHER|Observational|Observational Cohort to understand risk factors for early COPD.
224240064|NCT04675177|DRUG|Polidocanol foam sclerotherapy|"i. Patients underwent preparation, two hours before the intervention, with cleaning enema (Disodium phosphate). No antibiotic prophylaxis was prescribed.~ii. Preparation of the polidocanol (Aethoxysklerol 3%) foam according to Tessari technique immediately before application, so that the microbubbles of the foam did not disintegrate; iii. The procedure was performed in the medical office. Application according to the Blanchard technique through a disposable transparent anoscope, in jackknife position, using a 20mL disposable syringe of the mixture (polidocanol + air) and a reusable 10 cm syringe extender adapted to an intravenous needle; iv. Patients were treated in a maximum of 3 sessions, at 3 weeks intervals; v. Maximum dose per treatment session of 20mL of mixture of 4mL of polidocanol 3% with 16mL of air; i. In each session, the sclerosant was injected in one or more hemorroidary cushion;"
223657743|NCT00622440|DRUG|AIJP (Arnebia Indigo Jade Pearl)|Participants will administer their own treatment using 1/4 teaspoon of the cream twice daily for 48 weeks.
223657744|NCT00622440|DRUG|Placebo|Placebo twice daily for 48 weeks.
223657745|NCT03171467|PROCEDURE|Salpingectomy|
224321082|NCT04233294|DRUG|Camrelizumab|Camrelizumab is a humanized anti-PD-1 monoclonal antibody.
224321083|NCT04233294|DRUG|Decitabine|Decitabine is an investigational (experimental) drug that works by depleting DNA methyltransferase 1 (DNMT1), which can increase tumor antigens and HLA expression, enhances antigen processing, promotes T cell infiltration, and boosts effector T cell function.
224321084|NCT00451204|DRUG|Estriol|Estriol 8 mg capsule, once per day, duration of treatment is 2 years
224321085|NCT00451204|DRUG|Placebo|Placebo capsule, once a day, treatment duration is 2 years
224321086|NCT00451204|DRUG|Copaxone|Injection, once a day, all subjects
223657746|NCT05724511|DRUG|MIYAIRI 588|In the 3 months intervention, each subjects take 1g/package with meal, and 3 packages/day.
223657747|NCT04550598|DEVICE|HD-tCES|The high definition transcranial electrical stimulation was applied using a 1\*4 ring electrode configuration. The electrode will be applied at the left M1 or contralateral to pain side. The anodal electrode was placed on the C3/C4, and the remaining 4 cathodal electrodes were placed in a radius of approximately 7.5 cm from anode (Cz, F3, T7, and P3 on the left hemisphere or Cz, F4, T8, and P4 on the right hemisphere). HD-tCES will be applied for 20 minutes at an intensity of 1.0 mA direct current stimulation and a specific-added waveform each time, 5 times a week, lasting for 2 weeks.
223768557|NCT06761937|RADIATION|standard radiotherapy|standard radiotherapy
224321087|NCT00282529|DEVICE|High Risk Lymphedema Education and Device Intervention|
224321088|NCT04831814|DIAGNOSTIC_TEST|Near Focus NBI|Colonoscopy with near focus narrowing band imaging technology . Optical specifications include a 2 mm near field focal depth. Optical diagnosis of polyps were according to NICE and WASP, respectively.
224321089|NCT04831814|DIAGNOSTIC_TEST|Standard Focus NBI|Colonoscopy with narrow band imaging technology.Optical diagnosis of polyps were according to NICE and WASP, respectively.
224321090|NCT00000814|DRUG|Nevirapine|
224321091|NCT00000814|DRUG|Zidovudine|
224321092|NCT00000814|DRUG|Didanosine|
224321093|NCT01257178|DRUG|LY2624803|Administered orally
224321094|NCT03055624|DEVICE|Embosphere microparticles for prostate artery embolization|Pelvic angiograms will be performed and microspheres delivered to the arteries supplying the prostate to alleviate symptoms of benign prostatic hyperplasia.
224321095|NCT04726241|PROCEDURE|Biospecimen Collection|Undergo collection of blood and/or bone marrow samples
223657748|NCT04550598|DEVICE|Sham HD-tCES|The high definition transcranial electrical stimulation was applied using a 1\*4 ring electrode configuration. The electrode will be applied at the left M1 or contralateral to pain side. The anodal electrode was placed on the C3/C4, and the remaining 4 cathodal electrodes were placed in a radius of approximately 7.5 cm from anode (Cz, F3, T7, and P3 on the left hemisphere or Cz, F4, T8, and P4 on the right hemisphere). Sham HD-tCES will consist of a 5-second ramp up to 1.0 mA direct current stimulation and a specific-added waveform followed immediately by a 5-second ramp down, no current in the middle 19 minutes 40 seconds, and a ramp-up and ramp-down period during the last 10 seconds.
223768558|NCT07071311|BEHAVIORAL|Growth Mindset Intervention|"This single-session growth mindset intervention consists of reading and reflective writing activities that present mental health as something that can be improved, rather than something fixed. The goal is to show that adopting a growth mindset of mental health can encourage more proactive mental health behaviors.~To begin, participants will read stories of three employees who share their personal experiences navigating mental health challenges in the workplace. Each story highlights the employee's struggles, how they came to see mental health as changeable, and the steps they took to care for their well-being (e.g., practicing self-care or seeking therapy). After reading, participants will complete a short reflective essay in response to three prompts. These prompts guide them to examine their own mindset about mental health, endorse a growth mindset towards mental health, and outline specific actions they can take to proactively support their own mental well-being."
223768559|NCT07071311|BEHAVIORAL|Digital Technology Condition|"This single-session control exercise aims to encourage the use of digital technology in the workplace. It positions participants as experts who provide guidance to others on how to use digital tools more effectively at work.~First, participants will read stories about employees' experiences navigating their workload with the help of workplace technology. Each story highlights the employee's initial struggles with learning new digital tools and how they eventually recognized the value of these technologies. This includes examples of how they viewed digital learning as manageable and took proactive steps-such as seeking help from colleagues or setting aside time to practice. Then, participants will complete a short reflective essay in response to three writing prompts. These prompts guide them to reflect on their own experiences with digital tools and offer practical advice to others on how to use new technologies effectively in the workplace."
223768560|NCT04768101|DRUG|[11C]-PIB|\[11C\]-PIB is a PET radiotracer used to evaluate levels of Αβ burden.
223768561|NCT07082387|OTHER|External oblique and rectus abdominis plane block|Patients will receive an external oblique and rectus abdominis plane (EXORA) block using 20ml of bupivacaine 0.25%.
223768562|NCT07082387|OTHER|Quadratus lumborum block|Patients will receive a quadratus lumborum block (QLB) using 20ml of bupivacaine 0.25%.
223768563|NCT07082374|OTHER|Dual subsartorial block|Patients will receive dual subsartorial block (DSB).
223768564|NCT07082374|OTHER|Adductor canal block|Patients will receive an adductor canal block (ACB).
223768565|NCT07082374|OTHER|Femoral nerve block|Patients will receive a femoral nerve block (FNB).
224321096|NCT05131555|DRUG|Placebo: Placebo + exercise training.|Oral placebo Exercise training: Interval-based cycling exercise
223657749|NCT05571566|OTHER|Educational Book|An educational book with information about appendicitis for patients, parents and caregivers
223657750|NCT05704569|DIAGNOSTIC_TEST|measurement of multiple biomarkers|All patients were tested for glucose and cholesterol levels. The capillary blood glucose level was measured by an electrochemical method using an Accu-Chek Active by AkkuChek blood glucose meter. The DM was considered to be verified when there were criteria which the World Health Organization (WHO) set in 2001: glucose concentration in whole blood is \>6.1 mmol/l, and glucose concentration is \>11.1 mmol/l in random measurement. Plasma for the study was obtained via the standard phlebotomy technique from ethylenediaminetetraacetic acid (EDTA) anticoagulants. Plasma was aliquoted into cryovials and got frozen quickly. The samples were stored in a low-temperature refrigerator (-70°C) until the study commencement (up to 3 months). All biomarkers were measured by magnetic bead-based multiplex immunofluorescence assay through the Xmap technology using the Milliplex map Human CVD Magnetic Bead Panel 1 (Millipore)
223657751|NCT04132271|OTHER|Personalized diet|Modified texture and volumen diet according to the OD specifications
223657752|NCT04132271|OTHER|Control|Nutritional Recommendations according to the OD specifications
223657753|NCT04163172|PROCEDURE|Surgical treatment of distal humeral fracture with elbow hemiarthroplasty|Latitude anatomical elbow hemiarthroplasty (WRIGHT -Memphis, Tennessee)
223657754|NCT04163172|PROCEDURE|Surgical treatment of distal humeral fracture with double plating.|Double plating (Synthes - Switzerland and West Chester, Pennsylvania, United States)
223657755|NCT06143930|OTHER|strengthening ex with BFR training|Therapeutic strengthening training with blood flow restriction of trained limb.
223657756|NCT06143930|OTHER|strengthening ex|Therapeutic strengthening training program for lower extremities.
223768566|NCT07085962|DRUG|Calculus bovis sativus|Calculus bovis sativus 200mg qd
223768567|NCT07085962|DRUG|Placebo|Placebo 200mg qd
223768568|NCT07087067|DRUG|Aspirin 75 mg|patients received aspirin 75 mg daily prior to 12 weeks gestation
223768569|NCT07085416|DEVICE|Sensor-enabled Athletic X Ankle Brace (sXAB)|The intervention is a sensor-enabled version of the TayCo Brace, Inc. Athletic X Ankle Brace (sXAB), which integrates commercially available inertial measurement units (IMUs) into the structure of the brace. The brace is worn on the ankle of the dominant limb during functional movement tasks to evaluate its ability to produce valid gait and balance metrics compared to laboratory-grade measurement systems.
223768570|NCT07085988|OTHER|Rapid glitter|Patients with nasopharyngeal carcinoma are given rapid gamin during concurrent chemoradiotherapy
223657757|NCT02288455|DEVICE|GTU Artificial Urinary Sphincter|A totally implantable Artificial Urinary Sphincter (AUS) for the treatment of male Stress Urinary Incontinence (SUI)
223768571|NCT07086378|DEVICE|Oxygenating Bite Block|Oxygenating Bite Block will be used instead of the standard bite block.
223768572|NCT07085806|DRUG|Pentoxifylline (also known as oxpentifylline)|Intravenous injection Pentoxifylline 1 mg/kg/hr dissolved in Plasma Lyte/0.9% Normal saline from12 hours before the surgery to 72 hours after the Surgery
224321097|NCT05131555|DRUG|H1 blockade: H1 receptor antagonist + exercise training|H1 blockade: oral blockade Exercise training: Interval-based cycling exercise
224321098|NCT05131555|DRUG|H2 Blockade: H2 receptor antagonist + exercise training|H2 blockade: oral blockade Exercise training: Interval-based cycling exercise
223657758|NCT05944484|BEHAVIORAL|low caloric diet, ultrasound cavitation,Kegel exercises|"* low caloric diet (800-1200) calories/day,). According to each patient, diet contained (carbohydrate protein, fats, minerals, vitamins). 50 to 55% of total calories are carbohydrates, 10 to 15% of total calories protein. Fat limited to less than about 28% of daily total calories .Women took 1200 calories in the first month, 1000 calories in the second month, and 800 calories in the third month. Every week, each woman allowed to change the types of food to avoid boarding.~* ultrasound cavitation emits low-frequency ultrasound 40 khz for 30 minutes on abdomen twice/ week with 3 days apart for 12 weeks.~kegel exercise: Each woman in the study took the same Kegel exercise program performed the Kegel exercise for 12 weeks (3 sessions per week)"
223657759|NCT02014701|PROCEDURE|Echocardiogram|"1. Contrast echocardiography with Optison for assessment of regional wall motion. This will be performed immediately following the resting echocardiogram by a sonographer specifically trained in myocardial contrast echocardiography.~2. Contrast echocardiogram with Optison for assessment of myocardial perfusion. This will be performed using a continuous infusion of Optison using low mechanical index power-modulation imaging of the myocardium and blood pool. Myocardial perfusion will be assessed offline using video intensity analysis software."
223657760|NCT01787721|PROCEDURE|Ankle manipulation|
223657761|NCT01787721|OTHER|Sham manipulation|
223657762|NCT03328208|OTHER|Comfort Talk® app|Test app
223657763|NCT03328208|OTHER|White Noise app|White Noise app built to mimic appearance of Comfort Talk® test app
223657764|NCT01179113|DRUG|Esmolol|Esmolol group: Will receive 0.5 mg/kg IV bolus of esmolol during induction, and an infusion of esmolol at 0.3 mg/kg/hr intraoperatively.
223657765|NCT01179113|DRUG|Saline|Loading: an equivalent volume for the Esmolol group Infusion: an equivalent volume for the Esmolol group
223657766|NCT04875000|OTHER|Remineralizing agent I application|Application of UltraEZ remineralizing agent to the bleached teeth
223657767|NCT04875000|OTHER|Remineralizing agent II application|Application of 2.5% arginine solution to the bleached teeth
223657768|NCT04875000|OTHER|Remineralizing agent III application|Application of 2.5% nano-hydroxyapatite solution to the bleached teeth
223657769|NCT04729023|PROCEDURE|Pars plana vitrectomy combined with cataract surgery.|In the combined surgery group, phakic diabetes retinopathy patients over 45 years old without severe lens opacity will receive pars plana vitrectomy combined with phacoemulsification and intraocular lens (IOL) implantation at the same time.
223657770|NCT04729023|PROCEDURE|Pars plana vitrectomy with subsequent cataract surgery.|In the control group, phakic diabetes retinopathy patients over 45 years old without severe lens opacity will first receive pars plana vitrectomy and a subsequent phacoemulsification with IOL implantation will be performed at least 6 month after the PPV.
223657771|NCT03333772|BEHAVIORAL|REAL-T Intervention|Individualized lifestyle intervention conducted via internet-based videoconferencing and incorporating the following topics: Diabetes knowledge; access to healthcare; communication with healthcare providers; incorporation of diabetes self-care tasks within daily habits and routines; social support; and emotional well-being. Participants will have approximately 6-10 sessions lasting about one hour each, over a 3-month period.
223657772|NCT01667419|DRUG|Vemurafenib|4 tablets of vemurafenib 240 mg each (total 960 mg) were administered orally as per the schedule specified in the respective arm.
223657773|NCT01667419|DRUG|Placebo|Placebo matching to vemurafenib were administered orally as per the schedule specified in the respective arm.
223657774|NCT01206088|DRUG|nilotinib|administration of nilotinib as 2nd line
223657775|NCT01984528|BIOLOGICAL|four differente concentrations of Alternaria alternata allergen extract, positive control and negative control|This concentrations will be tested in every patient in duplicate on the volar surface of the forearm.
223657776|NCT01094145|OTHER|Deep brain stimulation|DBS in the Nucleus basalis Meynert
223768573|NCT07085806|OTHER|Plasmalyte|Plasmalyte
223657777|NCT02328365|OTHER|Structured medical follow-up after operation|Patients in the intervention arm are seen by a physician on the 4th or 5th postoperative day before discharge to pick up and manage any medical problems, and are furthermore seen in the cardiology clinic 1 month after operation, and in the pulmonary medicine clinic 1 and 3 months after operation
223657778|NCT05200234|DRUG|Nattokinase|Nattokinase + standard treatment
223657779|NCT05200234|DRUG|Placebo|Placebo+ standard treatment
223657780|NCT05376033|OTHER|root canal filling with Ceraseal sealer|root canal filling with Ceraseal sealer
223657781|NCT04364984|DRUG|Angiotensin converting enzyme inhibitor|routine drug intake
223657782|NCT04364984|DRUG|Angiotensin Receptor Blockers|routine drug intake
223657783|NCT04364984|DRUG|Direct renin inhibitor|routine drug intake
223657784|NCT05967507|DEVICE|Low-flow nasal supplemental oxygen with a conventional nasal cannula during tracheal intubation with the C-MAC video laryngoscope|0.2 L/kg/min FiO2 1.0 low-flow nasal supplemental oxygen with a conventional nasal cannula during tracheal intubation with the C-MAC video laryngoscope (Karl Storz, Tuttlingen, Germany) with Miller-blade or Macintosh-blade size No. 0 or No. 1.
223657785|NCT05967507|DEVICE|High-flow nasal supplemental oxygen (Fisher & Paykel, Auckland, New Zealand) during tracheal intubation with the C-MAC video laryngoscope|2 L/kg/min FiO2 1.0 high-flow nasal supplemental oxygen (Fisher \& Paykel, Auckland, New Zealand) during tracheal intubation with the C-MAC video laryngoscope (Karl Storz, Tuttlingen, Germany) with Miller-blade or Macintosh-blade size No. 0 or No. 1.
223657786|NCT04707300|DRUG|Human T Lymphoid Progenitor (HTLP) injection|The HTLP cell suspension will be injected intravenously at the time of UCB HSCT on D0
223657787|NCT05819853|DRUG|Semaglutide Injectable Product (Wegovy and/or Ozempic)|10 months of semaglutide, with dose escalation as recommended by manufacturer. Maximum dose used will be 1.7mg
223657788|NCT05377229|DEVICE|MarginProbe2.0|The MarginProbe System is an adjunctive diagnostic tool for identification of cancerous tissue at the margins of the ex-vivo lumpectomy specimen following primary excision and is indicated for intraoperative use, in conjunction with standard methods (such as intraoperative imaging and palpation) in patients undergoing breast lumpectomy surgery for previously diagnosed breast cancer.
223768574|NCT07085832|OTHER|Education (ALS provider course) in Egypt|Participants complete an ALS course, including theoretical and practical components focused on scenario based simulations for CPR and chest compressions.
223768575|NCT07085949|OTHER|5 cmH2O PEEP|5 cmH2O PEEP will be administered during mechanical ventilation
223768576|NCT07085949|OTHER|10 cmH2O PEEP|10 cmH2O PEEP will be administered during mechanical ventilation
223657789|NCT04988841|DRUG|MaaT013|study is an experimental drug , produced by MaaT Pharma, and composed of pooled-donor, full-ecosystem intestinal microbiome (455 species approximately against 274 on average)
224240065|NCT04675177|PROCEDURE|Doppler-guided hemorrhoidal artery ligation|"i. Patients underwent preparation with cleaning enema (Disodium phosphate). No antibiotic prophylaxis was prescribed.~ii. The procedure was performed in the operating room of an outpatient surgery unit, under regional anestesia.~iii. A proctoscope with a Doppler transducer in its tip was introduced inside the anal canal to search for the superior rectal artery.~iv. Each branch was ligated with suture above the dentate line. The device was rotated slowly in clockwise direction to locate further arteries at that level.~v. Rectoanal repair consisted in a continuous running suture was applied longitudinally just over every prolapsed hemorrhoid."
224240066|NCT00528281|DRUG|Lapatinib|Lapatinib was administered once daily orally. Patients will begin treatment at Dose Level 0, using a lower dose of pemetrexed, 400mg (approved dose is 500mg). Absent a DLT or need for treatment delay in cycle 1, Dose level 0 or 1, patients may be dose escalated to dose level 1 or 2, respectively in cycle 2.
224240067|NCT00528281|DRUG|Pemetrexed|Pemetrexed is administered intravenously on a 21 day schedule. Two dose levels are used in the dose escalation: 400 and 500 mg.
224240068|NCT01939197|DRUG|ABT-450/r/ABT-267|tablet
224240069|NCT01939197|DRUG|ABT-333|tablet
224240070|NCT01939197|DRUG|ribavirin|tablet
224240071|NCT04738032|OTHER|Digital Storytelling Intervention|12-minute digital storytelling intervention in Spanish, with four individuals explaining their personal Type 2 Diabetes stories.
224240072|NCT00643877|PROCEDURE|Preoperative hepatic and regional arterial chemotherapy using oxaliplatin, MMC and FUDR|PHRAC which included of two parts(common hepatic artery chemotherapy and main tumor supplying artery chemotherapy) was performed 7 days before surgery： common hepatic artery chemotherapy: FUDR 500mg, Oxaliplatin 50mg and MMC 10mg main tumor supplying artery chemotherapy: FUDR 500mg, Oxaliplatin 50mg and MMC 10mg
224240073|NCT00643877|PROCEDURE|surgery|radical surgery only
224240074|NCT01834963|DRUG|Interferon Alfa、Fluorouracil|"Hepatic Arterial Infusion of 5-fluorouracil combined with systemic administration of Interferon-alpha~Interferon Alfa 5×10⁶International Unit(IU)/body subcutaneously 3 times a week for 4 weeks~Fluorouracil 300mg/m2, day1-5,8-12, every 6 weeks"
224240075|NCT01834963|DRUG|Cisplatin、Fluorouracil|"Hepatic Arterial Infusion of 5-fluorouracil and Cisplatin (Low-dose FP)~Cisplatin 20mg/m2 ,day1,8,22,29, every 6 weeks~Fluorouracil 300mg/m2, day1-5,8-12,22-26,29-33, every 6 weeks"
223657790|NCT04988841|DRUG|Ipilimumab|Anti cytotoxicT-lymphocyte-associated protein 4 ( immunothérapy)
223657791|NCT04988841|DRUG|Nivolumab|AntiPD1 ( immunothérapy)
223657792|NCT04988841|DRUG|MoviPrep|Osmotic laxative solution : patients take a single dose of two liters of Moviprep® or equivalent the night before the first administration of experimental treatment (Fecal microbiota transfer or placebo)
224240076|NCT00004376|DRUG|guanfacine|
224240077|NCT04615156|DRUG|18F-2-fluoro-2-deoxy-D-glucose|Administration of 18F-2-fluoro-2-deoxy-D-glucose for the purposes of diagnosis.
223657793|NCT04988841|DRUG|Normacol|hypertonic enema solution
223657794|NCT04988841|DRUG|Placebo of Maat013|expérimental drug placebo of MaaT013
223657795|NCT06653543|OTHER|Mulligan mobilization with arm movement|mulligan mobilization applied on cervical spine with arm movement
223657796|NCT06653543|OTHER|conventional therapy of cevical radiculopathy|hot pack for 10 minutes, active ranges of motion (AROMs) with 3 sets of 10 repetitions and isometrics for each movement repeated 20 times with the hold of 6 to 10 seconds in each repetition
223657797|NCT03511807|OTHER|Electrical|"For the electrical stimulation:~An electrode will be inserted into the ear canal which will be stimulated."
223657798|NCT03511807|OTHER|Acoustic|"For the acoustic stimulation:~A typical sound will be presented for 6 minutes. Loudness is reported for 4 minutes after the stimulus offset to measure the presence and duration of the residual inhibition. If a successful acoustic stimulus is found, the subject will be given a series of sound files to listen to on a digital music player (CD or MP3 player) and will be asked to listen to each sound file (5 minute duration) and record their tinnitus loudness/annoyance during and after each sound stimulation. For some subjects, the investigators will use music on a digital music player (MP3 player) to see if music listening and music exercises will help reduce the intensity or annoyance level of the tinnitus (using the same surveys). These music-based exercises will involve training in recognition of musical intervals (e.g., octaves, fifths, and thirds)."
223768577|NCT07085559|DRUG|Metabolically Armed BCMA CAR-T cells.|Each subject receive metabolically armed BCMA CAR- T cells by intravenous infusion.
224240078|NCT01536223|DRUG|PF (cisplatin and 5-fluorouracil) group|the group the patients using PF(cisplatin and 5-fluorouracil )neoadjuvant chemotherapy 3 cycles of neoadjuvant chemotherapy at day1,22 and 43 with cisplatin 100mg/m2 and 5-fluorouracil 4000mg/m2 civ 120 hours And then chemoradiation using IMRT with 2 cycles of cisplatin concurrent chemotherapy at 80mg/m2.
224240079|NCT01536223|DRUG|TPF (docetaxel plus cisplatin and 5-fluorouracil) group|"3 cycles of TPF neoadjuvant chemotherapy at day1,22 and 43 with docetaxel 75mg/m2,cisplatin75mg/m2 and 5-fluorouracil 2400mg/m2 civ 96 hours .~And then chemoradiation using IMRT with 2 cycles of cisplatin concurrent chemotherapy at 80mg/m2."
224240080|NCT02126865|DRUG|Placebo to BI 1060469|tablet
224240081|NCT02126865|DRUG|BI 1060469 Healthy|tablet
224240082|NCT02126865|DRUG|Placebo to BI 1060469 asthmatics|tablet
224240083|NCT02126865|DRUG|BI 1060469 asthmatics|tablet
224240084|NCT00182806|DRUG|gemcitabine hydrochloride|IV over 30 minutes on days 2 and 9. Courses repeat every 21 days.
224240085|NCT00182806|DRUG|irinotecan hydrochloride|IV over 90 minutes on days 1 and 8. Courses repeat every 21 days.
224240086|NCT01316653|BEHAVIORAL|GROW Healthier|Group sessions that meet once weekly for 3 months (intensive phase) with choice of phone call session as preferred by participant, phone call coaching monthly for 9 months (maintenance phase), and monthly cues to action to use one's built environment for healthy activities for 24 months (sustainability phase)
224240087|NCT01316653|BEHAVIORAL|GROW Smarter|Group sessions that meet six times over the course of three years with quarterly newsletters.
224240088|NCT02451605|DRUG|Analgesic nerve blockade (Ropivacaine)|Analgesic nerve blockade (Ropivacaine) for total knee replacement surgery.
224240089|NCT02451605|PROCEDURE|Total knee replacement surgery.|Total knee replacement surgery.
224240090|NCT03159156|BEHAVIORAL|Applied Tension|Described above.
223657799|NCT06331013|RADIATION|CyberKnife ultra-hypofractionated SBRT|CyberKnife ultra-hypofractionated SBRT for localized Prostate cancer with dose-escalation to the dominant intraprostatic lesion
223657800|NCT01941186|OTHER|Patient Decision Aid|Short informational video on developmental delays and early intervention services aimed at helping parents make an informed decision about whether to pursue early intervention services.
223657801|NCT04856085|DRUG|VIR-2218|VIR-2218 given by subcutaneous injection
223657802|NCT04856085|DRUG|VIR-3434|VIR-3434 given by subcutaneous injection
223657803|NCT04856085|DRUG|PEG-IFNα|PEG-IFNα given by subcutaneous injection
223657804|NCT02918513|BEHAVIORAL|Wellness Element 1 - Exercise|1\. Daily wellness element focusing on Exercise; adherence documented online daily
223657805|NCT02918513|BEHAVIORAL|Wellness Element 2 - Mindfulness|2\. Daily wellness element focusing on Mindfulness Meditation; adherence documented online daily
223657806|NCT02918513|BEHAVIORAL|Wellness Element 3 - Sleep Hygiene|3\. Daily wellness element focusing on sleep hygiene; adherence documented online daily
223657807|NCT02918513|BEHAVIORAL|Wellness Element 4 - Social Connectedness|4\. Daily wellness element focusing on Social Connectedness; adherence documented online daily
223657808|NCT02918513|BEHAVIORAL|Wellness Element 5 - Nutrition|5\. Daily wellness element focusing on Nutrition; adherence documented online daily
223657809|NCT02918513|BEHAVIORAL|Wellness Element 6 - Wellness Exercises|6\. Daily wellness workbook exercises focusing on improving mental wellness; adherence documented online daily
223657810|NCT02918513|BEHAVIORAL|Wellness Element 7 - Motivational Messages|7\. Daily motivational emails offering information on one of the 5 wellness elements each day (Exercise, Mindfulness Meditation, Sleep, Social Connectedness, and Nutrition)
223657811|NCT00742144|DRUG|ofatumumab|Ofatumumab (GSK1841157), a clear colorless liquid, is supplied in a glass vial. Each vial contains 100mg of ofatumumab in 5mL.
223657812|NCT02722304|BIOLOGICAL|ARALAST NP 60 mg/kg|ARALAST NP is an Alpha1-Proteinase Inhibitor (A1PI) augmentation therapy
223657813|NCT02722304|BIOLOGICAL|ARALAST NP 120 mg/kg|ARALAST NP is an Alpha1-Proteinase Inhibitor (A1PI) augmentation therapy
223657814|NCT02722304|BIOLOGICAL|GLASSIA 60 mg/kg|GLASSIA is an Alpha1-Proteinase Inhibitor (A1PI) augmentation therapy
223657815|NCT02722304|BIOLOGICAL|GLASSIA 120 mg/kg|GLASSIA is an Alpha1-Proteinase Inhibitor (A1PI) augmentation therapy
223657816|NCT02722304|BIOLOGICAL|Human Albumin 2%|Human albumin 2% (by appropriate dilution with normal saline solution)
223657817|NCT01125696|DRUG|Tenofovir/lamivudine/lopinavir-ritonavir|Tenofovir/lamivudine/lopinavir-ritonavir given to mothers starting at 14-28 weeks gestation till labor/delivery and continued postpartum if maternal baseline CD4\<350
223657818|NCT01125696|DRUG|Zidovudine/lamivudine/lopinavir-ritonavir|Zidovudine/lamivudine/lopinavir-ritonavir given to mothers starting at 14-28 weeks gestation till labor/delivery and continued postpartum if maternal baseline CD4\<350
223657819|NCT04737304|DRUG|BEN2293 (0.25% or 1.0% w/w) or matching placebo|BEN2293 and placebo will be administered as a topical ointment. Both ointments contain the same excipients; placebo ointment has been manufactured in the same way except for the addition of 0.25% and 1.0% (w/w) BEN2293.
223657820|NCT02592096|DRUG|0.1% Pazufloxacin Mesilate Ear Drops|
223657821|NCT02592096|DRUG|0.3% Pazufloxacin Mesilate Ear Drops|
223657822|NCT02592096|DRUG|0.5% Pazufloxacin Mesilate Ear Drops|
223657823|NCT02592096|DRUG|Pazufloxacin mesilate injection|
223657824|NCT03018262|DEVICE|TMS - sub-study 1|TMS pulses will be applied to the motor hotspot of the surround muscle to identify the TMS-evoked potentials corresponding to motor surround inhibition (SI)
223657825|NCT03018262|DEVICE|TMS - sub-study 2|TMS will be used to stimulate the motor cortex and an inhibitory region of the inferior parietal lobe
223657826|NCT03018262|DEVICE|TMS - sub-study 3|TMS pulses will be delivered to the primary motor cortex at rest, at the onset of the motor task, or during the motor task
223657827|NCT03878849|DRUG|2X-121|2X-121 will be administered daily as 600 mg (200 mg 2X-121 morning dose + 400 mg (2 x 200 mg) 2X-121 evening dose) hard gelatin capsules in a 28 days cycle.
223657828|NCT03878849|DRUG|2X-121|2X-121 will be administered daily as 800 mg (400 mg (2 x 200 mg) 2X-121 morning dose + 400 mg (2 x 200 mg) 2X-121 evening dose) hard gelatin capsules in a 28 days cycle.
223768578|NCT07086937|DRUG|Nitazoxanide|Children were given nitazoxanide, PPI, and clarithromycin for 14 days.
224240091|NCT03159156|BEHAVIORAL|Respiration Control|Described above.
223768579|NCT07086937|DRUG|Metronidazole|Children received MTZ, PPI, and clarithromycin for 14 days.
223768580|NCT07086937|DRUG|PPI|Children were given omeprazole for 14 days.
223657829|NCT02897856|DRUG|Buccal midazolam|Study subject will receive Buccal midazolam, Intramuscular placebo.
223657830|NCT02897856|DRUG|Intramuscular midazolam|Study subject will receive Intramuscular midazolam,Buccal placebo
223657831|NCT04756908|DEVICE|Cataract Surgery|The surgical procedure in which the natural crystalline lens is removed and replaced with a lens implant.
223657832|NCT02232568|BEHAVIORAL|Feedback|
223657833|NCT05002075|OTHER|m-health cardiac rehabilitation|Participants randomized to m-Health cardiac rehabilitation will receive a 24-week home-based exercise program delivered via a previously validated, commercially available smartphone platform called Movn (Moving Analytics, California). This app includes a patient-facing iOS and Android compatible smartphone app and an integrated hospital-facing online dashboard for remote monitoring and care coordination by a trained coach
223657834|NCT01013103|DRUG|Atorvastatin, high vs low dose|In this arm patients with ischemic heart disease will be recruited. In a double-blind crossover design heart failure patients (n=30) naïve to statins treatment will be randomized to receive oral atorvastatin 10mg/day 1x1(n=15) or oral atorvastatin 40mg/day 1x1 (n=15) for 4 weeks. At the end of 4 weeks a 2-week wash out period will follow and then all patients will switch atorvastatin dose and continue treatment for 4 weeks (e.g all patients that were under atorvastatin 10mg/day will be switched to atorvastatin 40mg/day and vice versa).
223768581|NCT07086937|DRUG|Clarithromycin|Children were given clarithromycin for 14 days.
224240092|NCT03159156|BEHAVIORAL|Applied Tension/Respiration Control|Described above.
224240093|NCT02231645|DEVICE|STN DBS|The DBS device is turned on and off by the physician.
224240094|NCT03992859|PROCEDURE|Continuous serratus plane block|Peripheral nerve catheter placed by the surgeon at the end of surgery
224240095|NCT00005778|DRUG|High-dose immunoablative therapy|"1. High dose cyclophosphamide for 4 days.~2. NIH monthly IV cytoxan for 6 months followed by quarterly for 2 years."
223657835|NCT01013103|DRUG|Atorvastatin vs Placebo|In this arm, patients undergoing cardiac surgery (CABG, valve replacement or aortic surgery) that are not under statins treatment will be recruited. Patients will be randomized in a double-blind fashion to atorvastatin 40mg/day or placebo for 3 days before surgery date.
223657836|NCT01068600|DRUG|Indacaterol|Once daily via single-dose dry powder inhaler (SDDPI)
223657837|NCT01068600|DRUG|Placebo to indacaterol|Once daily via SDDPI
223657838|NCT05417763|DEVICE|Randomized physiological measurements by the two systems|To measure physiological indices (FFR, cRR and RFR), either pressure microcatheter or pressure wire enters one patient's body. Whether it is the pressure microcatheter or pressure wire firstly to enter is randomized. After completion of one system's physiological assessment, the other system will follow for its physiological assessment.
223657839|NCT02644109|DIETARY_SUPPLEMENT|Phytosterol|"Day 1: Anthropometry, laboratory test, dietary intake (24 hour recall and food frequency questionnaire) and presence of symptoms and side effects will be determined, a logbook will be provided to record product consumption, symptoms, medications and side effects. Then will be randomly assigned to one of the groups.~Days 7 \& 21: 24 hour recall, review of symptoms, side effects and adherence as registered in the logbook.~Days 15 \& 30: Anthropometry, vital signs, venous blood sample, review of symptoms, side effects and adherence to intervention as registered on logbook, dietary intake (24-hour recall), delivery of monetary compensation proportional to the study days will be given before being discharged."
224240096|NCT03847558|DIAGNOSTIC_TEST|FSH((Follicle Stimulating Hormone) and LH (Luteinizing Hormone) hormone for females and Testosterone hormone for males|assess of sexual maturation by clinical examination and hormonal studies (FSH.LH,Testosterone)
224240097|NCT05445219|DIAGNOSTIC_TEST|RespirAct|The RespirAct device is an automated breathing circuit that uses a gas bladder to control and deliver CO2 to measure cerebrovascular reactivity
224240098|NCT04232605|OTHER|GLP-1 peptide|Receive intravenous infusion of GLP-1. The dosage will be determined after a dose finding pilot study.
223657840|NCT02644109|DIETARY_SUPPLEMENT|Placebo|"Day 1: Anthropometry, laboratory test, dietary intake (24 hour recall and food frequency questionnaire) and presence of symptoms and side effects will be determined, a logbook will be provided to record product consumption, symptoms, medications and side effects. Then will be randomly assigned to one of the groups.~Days 7 \& 21: 24 hour recall, review of symptoms, side effects and adherence as registered in the logbook.~Days 15 \& 30: Anthropometry, vital signs, venous blood sample, review of symptoms, side effects and adherence to intervention as registered on logbook, dietary intake (24-hour recall), delivery of monetary compensation proportional to the study days will be given before being discharged."
224240099|NCT04232605|OTHER|Placebo|Receive intravenous infusion saline
224240100|NCT00745095|DRUG|Neostigmine|Neostigmine will be administered in 20, 40, and 60mg doses until an individualized dose-response relationship is established
223657841|NCT06026124|BEHAVIORAL|Retrieval-based word learning: Repeated Spaced Retrieval condition|"Each child will learn 8 novel nouns referring to unfamiliar plants and animals (nepp) and a related meaning (a nepp likes rain) in the context of a story book. Four of the nouns will be will be learned using repeated spaced retrieval. In this condition, they will initially hear the information and be asked to retrieve it. Thereafter, they will be asked to retrieve it after hearing 3 intervening words. After each retrieval attempt, they will hear the target information again. This procedure will occur on two consecutive days."
224240101|NCT06495762|OTHER|e-health assesment|This study is purely observational and does not forsee any intervention but only observational assesment of parents' wellbeing
224240102|NCT04010799|DRUG|CHF 6333|CHF 6333 - Part I - SAD CHF 6333 - Part II - MD
224240103|NCT04010799|DRUG|Placebo|Placebo - Part I - SAD Placebo Part II - MAD
223657842|NCT06026124|BEHAVIORAL|Retrieval-based word learning: Repeated Study condition|"Each child will learn 8 novel nouns referring to unfamiliar plants and animals (nepp) and a related meaning (a nepp likes rain) in the context of a story book. Four of the nouns will be will be learned using repeated study trials only (with no retrieval practice). In this condition, they will simply hear the information (word \& meaning) as part of the story. This procedure will occur on two consecutive days."
223657843|NCT01519869|DRUG|neoadjuvant chemotherapy|platinum-based neoadjuvant chemotherapy followed by interval surgical debulking with platinum-based adjuvant chemotherapy
223657844|NCT03023813|OTHER|Intervention|Written material provided.
223657845|NCT02575690|DIETARY_SUPPLEMENT|Spirulina|Individuals receive 2 g of spirulina daily, for 3 months.
223657846|NCT02575690|OTHER|Placebo|Individuals receive a placebo daily, for 3 months.
223657847|NCT02329418|OTHER|Explaining withholding and withdrawing life-sustaining therapies along with a written document|The document describes the law and the role of family members and medical team in the decision.
223657848|NCT02329418|OTHER|Explaining withholding and withdrawing life-sustaining therapies following standard procedure|
223657849|NCT04296838|DRUG|intravitreal injection of Conbercept|patients will receive intravitreal injection of Conbercept, and at the same time, aqueous humor sample will be obtained from the anterior chamber to measure the concentrations of cytokines.
223657850|NCT03345290|DEVICE|PET with a cerebral step|Positron Emission Tomography with a cerebral step before to carry out the standard Position Emission Tomography
223657851|NCT03345290|DEVICE|Central blood pressure measurement|Central blood pressure measurement
223657852|NCT03345290|OTHER|Neurocognitive tests|Mini Mental State Examination, MMSE, Mini International Neuropsychiatric Interview MINI and Frontal Assessment Batery FAB
224240104|NCT04351178|BEHAVIORAL|Mobile phone supported and team based rehabilitation|Participants in the intervention group will receive an 8-week mobile phone supported and team based rehabilitation intervention (F@ce 2.0).The participants will be introduced to a problem-solving strategy intended to facilitate the learning and problem-solving process to be used during the intervention. The strategy will provide a structure for healthcare professionals delivering the intervention. Three goals in daily activities will be formulated that the person wants and needs to do within the home environment. Each activity will be practiced together with the healthcare professionals and significant others. The significant others will be informed about the participant's goals and the planned strategies for reaching the goals. The participants will practice the activities in their home environment supported by mobile phone calls and text messages. In addition they will be given information about stroke.
223768582|NCT07085715|DIAGNOSTIC_TEST|Online self-sampling testing strategy to enhance pan-viral testing (HBV, HCV, HIV)|"The TESTATE website (https://testate.org/) will be expanded to include the offer of free HBV/HCV/HIV self-sampling kit. Users will log in and complete a sociodemographic, behavioral and hepB vaccination survey, which will include the HCVMOSAIC questionnaire. Users identified at HCV risk will be sent a DBS collection kit by post to detect HCV RNA, HBsAg and HIV Ab. Participants will self-collect the DBS sample by finger prick at home and send them to the laboratory by post. The results will be delivered online. All participants who return samples will receive an acceptance survey by email.~All participants recruited into the study will be provided with online information about the study and given the opportunity to ask questions and clarify queries to the field coordinator by email or phone."
223657853|NCT00577798|PROCEDURE|contrast-enhanced magnetic resonance imaging|Cardiac magnetic resonance imaging (cMRI) offers the unique advantage of being able to analyze both function and structure (myocardial changes in the form of both a functional decrease in ejection fraction and structural changes within the myocardium defined as delayed contrast uptake). Participants will have already received doxorubicin hydrochloride as standard therapy when undergoing chemotherapy for non-Hogdkin's lymphoma and Hogdkin's lymphoma.
223657854|NCT03294564|BIOLOGICAL|Typhoid Vi Polysaccharide Vaccine|Salmonella typhi capsular polysaccharide vaccine (Typhoid Vi Polysaccharide Vaccine): Each dose of 0.5ml Salmonella typhi capsular polysaccharide vaccine (Sanofi Pasteur, SA) is formulated to contain 25μg of purified Vi polysaccharide in a colorless isotonic phosphate buffered saline (pH 7±0.3), 4.150mg of sodium chloride, 0.065mg of disodium phosphate, 0.023mg of monosodium phosphate and 0.5ml of sterile water for injection. It is indicated for use by humans aged 2 years and older for protection against typhoid fever.
223657855|NCT03294564|BIOLOGICAL|Placebo|The placebo injection will consist of 0.5mL of saline.
223768583|NCT07084805|BEHAVIORAL|Diabetes Inspired Culinary Education (DICE) - Phase 1|The DICE intervention is a 10-lesson family-and community-based culinary nutrition and diabetes education program. Intervention Mapping, a protocol for developing theory- and evidence-based health promotion programs, was utilized to develop the DICE intervention. Rooted in the Social Cognitive Theory, the DICE intervention targets key personal, behavioral, and environmental constructs as mechanistic pathways for eliciting change in the consequential health outcomes of poor glycemic control in children and adolescents with type 1 diabetes.
224240105|NCT04351178|BEHAVIORAL|Rehabilitation as usual|Control group participants will receive rehabilitation as usual and in addition information about stroke.
224240106|NCT04925024|BIOLOGICAL|Lomecel-B medicinal signaling cells|A single administration of Lomecel-B will be performed via 6-10 intramyocardial injections into the right ventricle during the participant's standard of care stage II palliation. Dosing is based on body weight. Each patient will be given 2.5 x 10\^5 cells per kg of body weight. The entire dose of the cells will be roughly 600 microliters.
224240107|NCT04757259|DRUG|cerdulatinib|Participants will receive oral cerdulatinib at the starting dose he or she was receiving at completion of Study 13-601 (30, 25, 20, or 15 milligrams \[mg\] twice daily \[BID\]).
224240108|NCT04085666|DRUG|CDX 6114|CDX-6114 for oral administration is formulated in phosphate buffer, which also includes mannitol and poloxamer.The vehicle solution provided is identical to the CDX-6114 oral solution except for the active drug.
224240109|NCT04085666|OTHER|Matching Placebo|The placebo oral dosing solution will also be supplied as an approximately 240 mL oral solution and will be made up of the phosphate buffer diluent and the caramel flavoring.
224240110|NCT00618163|DRUG|Meloxicam|
224240111|NCT03288766|PROCEDURE|PICC placement with SHERLOCK 3CG™ Diamond TCS with MODUS II software|The SHERLOCK 3CG™ Diamond Tip Confirmation System (TCS) is an FDA-cleared fully-integrated magnetic tracking and ECG-based PICC tip confirmation technology, indicated for use as an alternative to chest x-ray and fluoroscopy for PICC tip placement confirmation in adult patients without any alterations of cardiac rhythms that change the normal presentation of the P-wave. A software package, MODUS II, has been developed to accurately analyze the entire ECG complex and identify the correct placement of the PICC tip based on a patient's individual ECG, in the absence of an easily identifiable P-wave. This software system is designed to provide visual and/or audio cues to notify the PICC placer of the location of the PICC tip relative to the cavoatrial junction (CAJ) of the patient.
224240112|NCT06114407|DRUG|Baricitinib 2mg|Participants of arm 'A' will be treated with tablet baricitinib 2 mg twice daily for 12 weeks
224240113|NCT06114407|DRUG|Tofacitinib 5 mg|Participants of arm 'B' getting tablet tofacitinib 5 mg twice daily for 12 weeks will be taken as historical control arm from another study on the efficacy of tofacitinib in refractory axial spondyloarthritis
224240114|NCT00958243|BIOLOGICAL|CSL's 2009 H1N1 Influenza Vaccine (CSL425)|0.5 mL intramuscular injection on Day 0 and Day 21
224240115|NCT00958243|BIOLOGICAL|CSL's 2009 H1N1 Influenza Vaccine (CSL425)|0.25 mL intramuscular injection on Day 0 and Day 21
224240116|NCT00958243|BIOLOGICAL|Placebo|Placebo
223657856|NCT06193122|DEVICE|Ultrasound imaging 3D and Spectroscopy|Ultrasound imaging and spectroscopy will consist of collecting three dimensional data. Regions of interest in each of the tumour images and in the adjacent normal tissue will be selected for analysis.
224240117|NCT02200965|OTHER|My Diabetes, My Information, My Plan Document|A structured, understandable, well designed, user friendly, user developed and approved letter has been developed and undergone user acceptability testing for this purpose. It succinctly contains all information mapping to core diabetes care processes, is simple and easy to digest and effective in encouraging self-understanding and prompting self-care and empowering informative engagement with services and care providers. The satisfaction of users with the communicating letter both in a developmental pilot phase has been assessed by user group feedback and patient questionnaire.
223657857|NCT05304533|DRUG|MYK-224|Specified dose on specified days
224240118|NCT06170268|OTHER|Routine Care Documentation|Routine Care Documentation
223657858|NCT05304533|DRUG|Itraconazole|Specified dose on specified days
223657859|NCT05304533|DRUG|Verapamil|Specified dose on specified days
223657860|NCT02188901|OTHER|Sonazoid-enhanced ultrasonography|Sonazoid (perflubutane) \[GE healthcare\]
223657861|NCT05996302|BEHAVIORAL|Relocation to sea level|Relocation to sea level by bus and stay for 2 days
223657862|NCT03193827|DEVICE|In-line filtration|In-line filtration is used during anesthesia and postoperative 96 hrs in study group to purify endovascular fluids administrations reducing postoperative phlebitis
223768584|NCT07084805|BEHAVIORAL|Diabetes Inspired Culinary Education (DICE) - Phase 2|The DICE intervention is a 10-lesson family-and community-based culinary nutrition and diabetes education program. Intervention Mapping, a protocol for developing theory- and evidence-based health promotion programs, was utilized to develop the DICE intervention. Rooted in the Social Cognitive Theory, the DICE intervention targets key personal, behavioral, and environmental constructs as mechanistic pathways for eliciting change in the consequential health outcomes of poor glycemic control in children and adolescents with type 1 diabetes.
223768585|NCT07080216|BIOLOGICAL|ZG005|ZG005 20mg/kg, intravenous infusion(IV), once every 3 weeks (Q3W)
223768586|NCT07080216|DRUG|Gecacitinib|Part 1: Cohort A：Gecacitinib is administered continuously until the end of treatment; Cohort B：Gecacitinib is administered continuously from CnD1 to D14, and discontinued from CnD15 to D21；Part 2：Gecacitinib for dose exploratory stage will commence after the Recommended Phase 2 Dose (RP2D) is determined during the dose escalation stage.
223768587|NCT07080216|BIOLOGICAL|Bevacizumab|Bevacizumab 7.5 mg/kg，intravenous infusion(IV), once every 3 weeks (Q3W)
223768588|NCT07085065|DEVICE|VR session|"Standard care: Standard care. In both the external control group and the intervention group during Period 1, painful procedures will be performed ccording to usual clinical practice by trained healthcare professionals.~VR session: The device includes a VR headset connected to a smartphone, which displays immersive visual content, along with headphones that deliver audio content. Scenarios are culturally and demographically adapted to the study population. The duration of each VR session will correspond to the time required for each painful procedure."
223768589|NCT07086066|OTHER|Diaphragm mobilization|This group underwent treatment three times a week, with each session lasting 40 to 60 minutes, over a period of six weeks. Diaphragm mobilization included techniques aimed at increasing muscle elasticity, improving postural balance, and reducing pain by stimulating the sympathetic and parasympathetic nervous systems. In each session, participants received 20 minutes of TENS and 10 minutes of cryotherapy. Following this, diaphragm mobilization was applied. During the application, participants were positioned comfortably in the supine position. The physiotherapist palpated the diaphragm, instructed the participant in diaphragmatic breathing, and asked them to take a deep diaphragmatic breath. During expiration, the diaphragm was mobilized in the posterior and inferior directions. This mobilization was performed 10 times per session. Following that, posterior glide and inferior glide techniques were performed.
224240119|NCT04916938|BEHAVIORAL|Interaction Guidance Therapy|Mother child psychotherapy based on video-feedback interaction after a free play session. The therapy usually enhances parent sensibility to the child.
224240120|NCT04916938|BEHAVIORAL|Mother's child psychotherapeutic session|Mother's representation of the event, mother's representation of the relation to her child, maternal emotions.
224240121|NCT04916938|BEHAVIORAL|Interview|History and perception of the mother's issues.
224240122|NCT04916938|BEHAVIORAL|Self-rated questionnaires|Parental Self-Questionnaire to assess the perception of the evolution of the father, mother and child
224240123|NCT00298870|DRUG|Isoniazid|Modified daily isoniazid dose : approx. 7.5 mg/kg, 5 mg/kg and 2.5 mg/kg for rapid, intermediate and slow acetylators, respectively
224240124|NCT00298870|DRUG|isoniazed|Conventional standard daily isoniazid dose : approx. 5 mg/kg b.w. for all
223657863|NCT03193827|DEVICE|Standard treatment|Patients are treated with standard intravenous solutions and vascular access management
224240125|NCT06217172|DEVICE|RHEUPP App|RHEUPP App; Monthly RAPID3 response; General recommendations for managing Flare through App and Social Monitor for appropriate orientation; 3 month consultation by telehealth.
224240126|NCT06217172|OTHER|Usual Follow-up|Usual Care in Rheumatoid Arthritis Ambulatory Service
224240127|NCT02636816|DRUG|carbetocin|drug used to increase the tone of uterine muscle to prevent post partum hemorrhage after cesarean delivery.
224240128|NCT05639634|DIETARY_SUPPLEMENT|Chlorella supplementation|Supplementation with Chlorella (1.5 g/d) in 3 capsules for 12 weeks.
224240129|NCT05639634|OTHER|12 week cardiovascular training programme|Participants will be asked to complete a 12 week cycling training programme. This will consist of 4 X 50 min sessions per week. Each exercise session will include a warm-up phase (\~ 5 min), a main physical conditioning phase (\~ 40 min), and a cool-down phase (\~ 5 min).
224240130|NCT05639634|DIETARY_SUPPLEMENT|Placebo Supplementation|Supplementation with Placebo - microcrystalline cellulose (1.5 g/d) in 3 capsules for 12 weeks.
224240131|NCT03481205|DEVICE|Ischemic conditioning device|RLIC will be done using a specialized blood pressure device ( Doctormate) that inflates to 200 mm HG for 5 minutes followed by 5 minutes deflation.
224240132|NCT00192608|DRUG|saquinavir 500 formulation|NRTIs + SQV/RTV 1000/100 mg BID using 200 mg SQV capsules switched at entry to ATV/SQV/RTV 300/1500/100 mg QD using 500 mg SQV tablet for 48 weeks with PK at days 0 and 8.
224240133|NCT00192608|DRUG|cross-over arm|either ATV/SQV/RTV 300/1500/100 QD (500 mg SQV tabs) for 7 days then after PK SQV changed to 1600 mg QD (200 mg caps) with PK day 15, or ATV/SQV/RTV 300/1600/100 QD for 7 days with switch to SQV 1500 mg QD. After day 15 PK both groups switch to ATV/SQV/RTV 300/1500/100 QD to week 48
224240134|NCT01032369|OTHER|Nutritional intervention and physical activity|"Nutritional intervention:~Subjects will be asked to attend weekly nutritional group's sessions and individual meetings with the dietician for nutritional treatment and follow up.~Physical activity:~All participants will be engaged in physical activity comprising 45-60 min training sessions 3 times a week (gym or walking)."
224321099|NCT05022264|DIAGNOSTIC_TEST|RIA-VS|Measuring vital signs with a new contactless camera technique
224321100|NCT02352818|OTHER|no study intervention|
224321101|NCT06680596|DRUG|trastuzumab derxutecan|T-DXd will be administrated as an intra-venous injection of 5.4 mg/kg every three weeks (1 cycle = 21-day treatment).
223657864|NCT01367951|PROCEDURE|Surgical fixation|"* The fractures will be reduced and stabilized by use of plates and screws~* Attempt will be made to stabilize ribs 3-7, as these are surgically accessible and most important in maintaining integrity of the chest cavity.~* Goal is not to fix all the fractures, but to fix sufficient fractures to create an internal splint and allow chest wall motion to occur as a unit. In case of fibs fractured at numerous locations, as many fragments will be reduced and stabilized as necessary to ensure movement as a unit.~* Chest tube(s) will be placed at the discretion of the treating surgeon in patients with pre-operative or intra-operative violation of the pleural cavity (ie pre-op pneumothorax/haemothorax, iatrogenic pleural injury). No post-operative drains will be inserted."
223657865|NCT01753648|DEVICE|Dynamic Vessel Analyzer|Retinal vessel diameter, total retinal blood flow (together with FD-OCT), retinal oxygen saturation
223768590|NCT07086066|OTHER|conventional physical therapy|As with the experimental group, therapy will be delivered three times per week for six weeks, with each session lasting between 40 and 60 minutes. Each session will include 20 minutes of TENS and 10 minutes of cryotherapy, followed by posterior and inferior gliding techniques on the glenohumeral joint and capsular stretching. Functional exercises will also include wand exercises (two sets of 10 repetitions) and finger ladder exercises targeting shoulder flexion and abduction, but without the addition of diaphragm mobilization techniques.
223768591|NCT07086274|DEVICE|Individualized location-based Repetitive Transcranial Magnetic Stimulation|Enhancing targeting accuracy through personalized target localization to improve the analgesic response rate of rTMS.
223657866|NCT01753648|OTHER|FDOCT|total retinal blood flow (together with DVA), retinal blood velocities
223768592|NCT07086274|DEVICE|Traditional location-based Repetitive Transcranial Magnetic Stimulation|Recent studies have shown that the dorsolateral prefrontal cortex (DLPFC) plays an inhibitory role in the human pain pathway. High-frequency repetitive transcranial magnetic stimulation (rTMS) applied to the left DLPFC has been found to improve chronic migraine.
223657867|NCT01753648|OTHER|Ocular perfusion pressure|Measurement of intraocular pressure and mean arterial blood pressure for determination of ocular perfusion pressure
223657868|NCT01805791|DRUG|HMPL-004 1800 mg/day|Subjects randomized to the arm of HMPL-004 1800 mg/day will receive HMPL-004 600 mg TID (total dose 1800 mg/day) for 56 days (8 weeks).
223657869|NCT01805791|DRUG|Placebo|Subjects randomized to the arm of Placebo will receive matching Placebo three times daily for 56 days (8 weeks).
223657870|NCT01805791|DRUG|HMPL-004 2400 mg/day|Subjects randomized to the arm of HMPL-004 2400 mg/day will receive HMPL-004 800 mg TID (total dose 2400 mg/day) for 56 days (8 weeks).
223657871|NCT00518089|DRUG|Gatifloxacin 0.5% eye drops|Day 1 = 1 drop of study medication every 2hrs up to 8 times total; day 2-5 = 1 drop twice daily
223657872|NCT00518089|DRUG|placebo eye drops|Day 1 = 1 drop of study medication every 2hrs up to 8 times total; day 2-5 = 1 drop twice daily
223657873|NCT01406613|OTHER|Observation|In this study we will examine the changes in bone density by DXA and QUS and bone turnover after stopping Bisphosphonate treatment. As we wish to measure the speed of offset of effects of treatment we have scheduled visits at 24 week intervals in order to fully assess this effect.
223657874|NCT00357669|DRUG|Brivaracetam 25 mg|"* Active Substance: Brivaracetam~* Pharmaceutical Form: Tablet~* Concentration: 25 mg~* Route of Administration: Oral use"
223657875|NCT00357669|DRUG|Brivaracetam 50 mg|"* Active Substance: Brivaracetam~* Pharmaceutical Form: Tablet~* Concentration: 50 mg~* Route of Administration: Oral use"
223768593|NCT07085364|BEHAVIORAL|Attentional focus|Every training session will include the following activities for both groups: a 5-minute warm-up; a 30-minute walking training; and a 5-minute cool-down. The walking training will be conducted within a level-ground walking field. Participants will be instructed to look at and step on specific markers/labels that will be attached along the walking paths.
223768594|NCT07085364|BEHAVIORAL|Control|Every training session will include the following activities for both groups: a 5-minute warm-up; a 30-minute walking training; and a 5-minute cool-down. The walking training will be conducted within a level-ground walking field. No markers/labels will be attached and no relevant instructions will be provided apart from the general instruction.
223768595|NCT07086287|DRUG|rhBNP and standard basic treatment|After administering a bolus of rhBNP at 1.5-2 μg/kg intravenously, a maintenance dose of 0.0075-0.01 μg/kg/min is continuously infused intravenously for 72 hours, with the dosage adjusted based on blood pressure and heart rate; the control group receives standard basic treatment.
223768596|NCT04740034|DRUG|AMG 340|AMG 340 is a bispecific antibody targeting prostate-specific membrane antigen (PSMA) on tumor cells and CD3 on T-cells
224240135|NCT01032369|OTHER|Nutritional intervention, physical activity and behavioral treatment|"Nutritional intervention:~Subjects will be asked to attend weekly nutritional group's sessions and individual meetings with the dietician for nutritional treatment and follow up.~Physical activity:~All participants will be engaged in physical activity comprising 45-60 min training sessions 3 times a week (gym or walking).~Behavioral treatment:~This group will undergo behavioral treatment focusing on self control techniques using the CBT technique (cognitive behavioral therapy) which will be conducted by a clinical psychologist from ONIM in weekly group sessions."
224240136|NCT00113425|DEVICE|V-Beam laser, Candela Corp., 595 nm wavelength|Subjects will receive a series of up to 6 laser therapy sessions with a treatment interval of from approximately 1 to 4 weeks. In all cases, laser treatment parameters will be within the guidelines normally used clinically with the V-Beam laser, and thus fluences used will not exceed 15 J/cm2.
223657876|NCT00357669|OTHER|Placebo|"* Active Substance: Placebo Pharmaceutical Form: Tablet~* Concentration: 25 mg and 50 mg~* Route of Administration: Oral use"
224240137|NCT06317246|GENETIC|Investigation of BRAF mosaicism|The study of BRAF mosaicism will be conducted on biopsy samples from patients with ECD and other neoplasms co-occurring with the BRAFV600E mutation. The samples will be labeled with anti-Pu.1-Alexa Fluor 647 antibody (which binds to macrophages), then DNA will be extracted using FACS method and amplified using MDA (Qiagen Repli-G Single-Cell kit). Quality control will be performed using Quant-it (ThermoScientific) and Agilent 4200 TapeStation. Eligible samples will undergo digital droplet PCR (ddPCR) and sequencing. ddPCR probes for wild-type and mutant alleles will be used. Sequencing will be performed using Illumina HiSeq 2500 system
224240138|NCT02319928|PROCEDURE|Colonoscopy|
224321102|NCT01582152|DRUG|TPI287|"Phase I Starting Dose: 160 mg/m2 given by vein on Day 1 every three weeks of a 42 Day cycle.~Phase II Starting Dose: Maximum Tolerated Dose (MTD) from Phase I."
223657877|NCT05055206|DIAGNOSTIC_TEST|SPECT-CT|99m-Technetium Sulfur Colloid will be injected prior to the scan.
223657878|NCT03112577|DRUG|REGN3500|Intravenous (IV) use
223657879|NCT03112577|DRUG|Dupilumab|Subcutaneous (SC) use
223657880|NCT03112577|DRUG|Placebo|Matching placebo
223657881|NCT03112577|DRUG|Fluticasone propionate|Inhalation use
223657882|NCT01956721|PROCEDURE|Exercise training,|
223657883|NCT01956721|PROCEDURE|Muscle biopsy|
223657884|NCT05044299|DEVICE|Isoped|Isoped is a mechanical device allowing movement of lower extremities in a forward and backward motion, with phone-based app to control resistance load
223657885|NCT05178719|DEVICE|PMA-zeolite|given for a total period of 4 years
223657886|NCT04477278|BEHAVIORAL|Mindfulness Meditation|The mindfulness meditation recording consisted of instruction in focused attention on breath and body sensations and metacognitive monitoring and acceptance of discursive thoughts, negative emotions, and pain.
223657887|NCT04477278|BEHAVIORAL|History of Osteopathy|The history of osteopathy recording introduced patients to the founder of osteopathy, Andrew Taylor Still, and his philosophy of healing.
223657888|NCT02487017|PROCEDURE|Transcatheter Arterial Chemoembolization (TACE)|"Transcatheter Arterial Chemoembolization (TACE):~5-FU 400mg/m2 Hepatic arterial infusion ,lipiodol amount is usually 20 ml,the perfusion time should not be less than 20 min"
223657889|NCT02487017|BIOLOGICAL|DC-CIK|"Transcatheter Arterial Chemoembolization (TACE):~5-FU 400mg/m2 Hepatic arterial infusion ,lipiodol amount is usually 20 ml, the perfusion time should not be less than 20 min~DC-CIK:~8×10\^9 DC-CIK cells for each infusion, IV (in the vein) for each infusion at least 3 cycles, each cycle received four infusions on day 14, 16, 30 and 32"
223657890|NCT05870696|DIAGNOSTIC_TEST|PrecogColo Dx test|the serum metabolite based PrecogColo Dx test for advanced colorectal neoplasia Screening, including advanced adenoma and colorectal cancer
223657891|NCT06795139|BEHAVIORAL|Trial Enrollment Diversity Dashboard Behavioral|A data management and classification algorithm tool that provides personalized enrollment diversity performance data for clinician review and which aims to overcome race-ethnic disparities in Leukemia clinical trial participation. Data inputs and the Dashboard are within existing HIPAA-complaint electronic health records systems used at Dana-Farber Cancer Institute, and utilization data metrics are collected through the Tableau software supporting the intervention.
223657892|NCT04960124|DRUG|JNJ-42847922|Participants will receive JNJ-42847922 tablet as a single oral dose (Dose 1 or Dose 2 or Dose 3) on Day 1.
223657893|NCT05379998|OTHER|Neural mobilization|Sciatic nerve mobilization (sliding technique) will be performed by a physical therapist. The sciatic nerve mobilization technique improves the nerve mobility of the hemiparetic lower limb in a nervous system patient and is helpful in increasing the ROM of the lower limbs without resistance.
223657894|NCT05379998|OTHER|PNF hold relax technique|Proprioceptive neuromuscular facilitation hold relaxation technique of hamstring muscle will be performed by the physical therapist three days a week for 6 weeks. In the hold relax technique after reaching the point of resistance, an isometric contraction is performed against the resistance to get a pain free response.
223657895|NCT05927155|DRUG|LABA|Inhalation of 4 puffs of 2,5 µg of a long-acting beta2-agonist (LABA-olodaterol) administered via a spacer device
223657896|NCT05927155|DRUG|LAMA|Inhalation of 4 puffs of 2,5 µg of a long-acting muscarinic antagonist (LAMA-tiotropium) administered via a spacer device
223657897|NCT03454360|DEVICE|ACURATE neo™ Aortic Bioprosthesis|TAVI; Transcatheter Aortic Valve Replacement. Transapical Access.
224321103|NCT01582152|DRUG|Bevacizumab|Arm A + B: 10 mg/kg by vein every 2 weeks of a 42 day cycle.
223657898|NCT00517855|BIOLOGICAL|PRTX-100 (Staphylococcal protein A)|
223657899|NCT00329797|DIETARY_SUPPLEMENT|Calcium|A single dose of 500 mg of elemental calcium orally each day for 3 years.
223657900|NCT00329797|DIETARY_SUPPLEMENT|Zoledronic acid|Patients receive IV over 15 minutes once every 6 months for 3 years. The goal dose of zoledronic acid is 4 mg, but the selection of dose is determined based on calculated creatinine clearance at baseline.
224240139|NCT03104738|OTHER|25% reduction of basal insulin dose|"Subjects will be instructed to reduce their basal insulin dose to 75% instead of our institutional 50%.~Subject must check their own blood sugar before reporting to the hospital for their surgery. If the value is less than 70 or subjects are having symptoms of hypoglycemia, subjects will be instructed to immediately ingest 4-8 oz of fruit juice (without pulp) and call their doctor or the hospital."
224240140|NCT01973049|DRUG|Daclatasvir|
224240141|NCT01973049|DRUG|Asunaprevir|
224240142|NCT01973049|DRUG|BMS-791325|
224240143|NCT01973049|DRUG|Ribavirin|
224240144|NCT01973049|DRUG|Placebo matching Ribavirin|
224240145|NCT01353495|DEVICE|APM Graft (BIOTAPE XMTM)|Patients randomized to the APM group will, following surgical debridement for their diabetic foot wounds, receive a single application of an APM graft (BIOTAPE XMTM, Wright Medical Technology, USA) with dressing changes taking place weekly. All necrotic tissue will be removed from the wound prior to application. BIOTAPE XMTM will be sutured or stapled in place under a silver-based non-adherent dressing (Silverlon, Argenta Medical). Therapy will then be followed by a moisture-retentive dressing (hydrogel bolster) until complete epithelialization has occurred.
224240146|NCT01353495|OTHER|Wound Debridement|Wounds debrided in both arms of study
224240147|NCT02068040|DIETARY_SUPPLEMENT|CocoaVia|CocoaVia contains flavanols found natrually in cocoa beans. Capsules will contain 250mg of flavanol
224240148|NCT00276757|DRUG|leucovorin calcium|
223657901|NCT00329797|RADIATION|radiation therapy|Patients must receive external beam irradiation, brachytherapy (HDR or LDR), or a combination of external beam irradiation and brachytherapy at the discretion of the treating physician. Dose/duration also will be at the discretion of the treating physician; however, dose will not exceed 45 Gy to 100% of the proximal femur, and no proximal femur will receive ≥ 60 Gy.
223657902|NCT00329797|DRUG|LHRH|LHRH therapy must take place for a minimum of one year. Choice of LHRH agonist, dose, and duration are at the discretion of the treating physician.
223657903|NCT00329797|DIETARY_SUPPLEMENT|Vitamin D|400 IU (10μg), orally each day for 3 years.
223657904|NCT01311141|DRUG|doripenem|doripenem once i.v.500mg
223657905|NCT04341519|BEHAVIORAL|PTSD|"family members: post-traumatic stress disorder (PTSD) related symptoms assessed by Impact of Event Scale Revised (IES-R) at 90 days~Patients:~post-traumatic stress disorder (PTSD) related symptoms assessed by Impact of Event Scale Revised (IES-R) at 90 days"
223657906|NCT04341519|BEHAVIORAL|Burnout|Symptoms of burnout as assessed by the Maslash Burnout Inventory
224240149|NCT00276757|DRUG|methotrexate|
224240150|NCT00276757|DRUG|prednisolone|
224240151|NCT00276757|DRUG|vinblastine sulfate|
224321104|NCT06066294|BIOLOGICAL|Regimen 1|WHO Pre-qualified rabies vaccine (Rabivax-S), WHO recommended PrEP Vaccination Schedule, 2 visits, 0.2ml 2 sites (0.1ml each site) on day 0 and day 7
224321105|NCT06066294|BIOLOGICAL|Regimen 2|WHO Pre-qualified rabies vaccine (Rabivax-S), Government of India approved vaccination schedule, 3 visits, 0.1ml 1 site on day 0, 7 and 28
224321106|NCT03494101|OTHER|Blood samples|Blood samples will be collected and analyzed at different study time points
223657907|NCT03892304|OTHER|Self-report written questionnaire|"Patient questionnaire filled-out in presence of clinical nurse. Gynecological options and contraceptive choices were recorded. Close-ended questions used (yes/no): contraception use; contraceptive pill use; contraceptive implant; intrauterine device; tubal sterilization; mechanical contraception; other type of contraception use; previous term delivery; gynecological follow-up; previous Pap smear. If Yes was noted, more details were requested (contraception name, delivery date, gynecological follow-up frequency, last Pap smear date).~Other gynecological history and management data not included in the 2014 questionnaire: age at first menstruation, menstrual cycle regularity without hormonal contraception, age at menopause, previous human papilloma virus vaccination, recurrent vulvovaginal candidiasis, urinary incontinence, fertility/infertility data, and infertility treatment with assisted reproductive technologies. Results were compared with those obtained in 2014 (121 women)."
223657908|NCT02888938|OTHER|pelvic radiography|
223657909|NCT02888938|OTHER|pelvic MRI|
223657910|NCT02888938|OTHER|pelvic CT-scan|
223657911|NCT03686007|OTHER|Informational Intervention|Receive MSM intervention handbook
223657912|NCT03686007|OTHER|Informational Intervention|Receive MSM intervention research nurse coaching
223657913|NCT03686007|OTHER|Informational Intervention|Receive ASCO print materials
223657914|NCT03686007|OTHER|Informational Intervention|Receive CRA assistance
224240152|NCT04588753|OTHER|active isolated stretch|"Active Isolated Stretch (AIS);~* The shortened hamstring muscle will be isolated.~* The hamstring will be stretched.~* This Stretches will be Repeated eight to 10 times.~* Stretch will be hold for no more than two seconds.~* Exhale on the stretch; inhale on the release. Other amputees training exercises;~* weight-shifting~* Dynamic balancing activities~* Stool stepping~* Braiding~* Gait exercises~* Climbing/descending the stairs"
224240153|NCT04588753|OTHER|Post Facilitation Stretch|"Participants of this group will receive Post Facilitation Stretch (PFS);~* The shortened hamstring muscle will be placed between a fully stretched and a fully relaxed state.~* The patient will be asked to contract the hamstring using a maximum degree of effort for 5-10 seconds while the therapist will resists thepatients force.~* The patient will be then asked to relax and release the effort, whereas the therapist will apply a rapid stretch to a new barrier and is held for 10 seconds.~* The patient relaxes for approximately 20 seconds and the procedure will be repeated to five times (8) (18).~  2\. Other amputees training exercises;~* weight-shifting~* Dynamic balancing activities~* Stool stepping~* Braiding~* Gait exercises~* Climbing/descending the stairs"
224240154|NCT01767428|DRUG|Paracetamol|500 mg immediate release paracetamol formulations
224240155|NCT00448175|DEVICE|Urgent PC Neuromodulation System|The Urgent PC Neuromodulation System is a minimally invasive neuromodulation system designed to deliver retrograde access to the sacral nerve through percutaneous electrical stimulation of the tibial nerve. The method of treatment is referred to as Percutaneous Tibial Nerve Stimulation (PTNS).
224240156|NCT00448175|DRUG|Tolterodine|
224240157|NCT03657056|DEVICE|BX Pulsar 1002|"LIFUP will be administered to the temporal region on the side to undergo surgery, within the focus producing seizures. The ultrasound will be focused on the highest activity area within the temporal lobe. Functional MRI of the brain will be obtained throughout the LIFUP session.~After the participant is fitted with the transducer they will be placed in the MRI machine and undergo a series of scans. After placing the transducer over the anterior tip of the temporal lobe the participant will undergo fMRI BOLD scans with LIFUP excitation (from (Lee et al., 2015): Tone Burst Duration = 2ms and Pulse Repetition Frequency = 250Hz) at four levels of intensity (720mW/cm2, 1440mW/cm2, 2880mW/cm2 and 5760mW/cm2). Before increasing the intensity, the transducer will be moved approximately 5mm posterior. After the last excitation scan the LIFUP parameters will be changed to inhibitory parameters (from (Yoo et al., 2011): Tone Burst Duration = 0.5ms and Pulse Repetition Frequency = 100Hz)."
224240158|NCT03806803|BIOLOGICAL|Lyophilized fecal microbiota transplant|15 capsules
224240159|NCT03806803|BIOLOGICAL|Lyophilized sterile fecal filtrate|15 capsules
224240160|NCT02701114|PROCEDURE|Proximal Adductor Canal Block|Continuous Nerve Block
224240161|NCT02701114|PROCEDURE|Distal Adductor Canal Block|Continuous Nerve Block
224240162|NCT02134522|DEVICE|Continuous positive airway pressure (CPAP).|Continuous positive airway pressure is a commonly prescribed therapy for obstructive sleep apnea which is recommended for the treatment of obstructive sleep apnea in children and adults.
224240163|NCT02029937|DRUG|Proflavine, high resolution imaging|5-10 ml of proflavine hemisulfate (0.01%) will be sprayed on the esophageal mucosa. The HRME will then be inserted through the endoscope and gently placed against the mucosa. Imaging of abnormal tissues will be performed.
224240164|NCT05343637|COMBINATION_PRODUCT|Drug: RT234 - vardenafil inhalation powder; Device: RS01 dry powder inhaler (RS01 DPI)|RT234 is a drug/device combination product composed of vardenafil hydrochloride as the drug constituent and will utilize RS01 DPI device.
224321107|NCT03494101|OTHER|Stool samples|Stool samples will be collected and analyzed at different study time points
224321108|NCT03494101|OTHER|Clinical information|Clinical information will be collected at different study time points using questionnaires
223657915|NCT03686007|OTHER|Media Intervention|View the MSM intervention videos
223657916|NCT03686007|OTHER|Media Intervention|View American Cancer Society (ACS) videos
223657917|NCT01867697|DRUG|Cetuximab|
223657918|NCT01867697|DRUG|Irinotecan|
223657919|NCT01867697|DRUG|Oxaliplatin|
223657920|NCT01867697|DRUG|Folinic Acid|
223657921|NCT01867697|DRUG|Calcium Carbonate|
223657922|NCT03736642|BIOLOGICAL|blood sampling|12 ml sample
223657923|NCT03736642|OTHER|stool sampling|20 g sample
223657924|NCT03736642|OTHER|urine sampling|18 ml sample
223657925|NCT03736642|DIAGNOSTIC_TEST|neuropsychological tests|"* Go-nogo~* flexibility~* food stroop~* implicit and explicit evaluation~* Child Depression Inventory~* Hamilton Depression Rating Scale"
223657926|NCT02752581|DEVICE|Suction drain|A suction drain is used to remove excess fluid from tissues after surgery.
223657927|NCT02752581|DEVICE|No suction drain|A suction drain is used to remove excess fluid from tissues after surgery.
223657928|NCT01745549|DEVICE|Needle for insulin pen, 4 mm long and with a diameter of 33 gauge|
223657929|NCT01745549|DEVICE|Needle for insulin pen, 4 mm long and with a diameter of 32 gauge|
223768597|NCT06929923|DEVICE|Pro-2-Cool Device|"The Pro-2-Cool Device is a non-invasive hypothermic therapy (cold therapy) device that provides localized cooling of the head and neck. Water and isopropyl alcohol cooled to 6°C by the chiller assembly circulate through the cooling garment to create conductive heat transfer from the scalp and carotid arteries, thus achieving cooling of the brain."
223768598|NCT07085494|BEHAVIORAL|neurofeedback|\- Neurofeedback Training : Feedback is based on individualized alpha band power. Participants see a game-like display (for instance, a plane) that reflects their alpha activity. Excessive EMG (muscle tension) causes performance drops, encouraging relaxation.
223768599|NCT07085494|BEHAVIORAL|Cognitive Training|\- Cogmed Training : Participants complete adaptive tasks focusing on working memory. The difficulty adjusts in real time based on performance.
223768600|NCT07085494|BEHAVIORAL|Sham feedback|The sham neurofeedback protocol was identical to the verum neurofeedback protocol except that the animation (horizontal plane movement) was based on the EEG results of another participant. EMG-based feedback will still be provided for the sham condition
223768601|NCT07087093|OTHER|Ketone ester|KetoneAid Ke4 Pro Ketone Ester：20ml, tid po
224240165|NCT06672081|PROCEDURE|Early Catheter-Interventional Treatment|Patients will undergo a catheter-interventional treatment within 60 min. after randomization. Fibrinolytic treatment will be prepared parallel to interventional treatment preparations to avoid any delay in its administration if clinically necessary. Catheter-interventional treatment may include any certified devices for the treatment of PE including aspiration thrombectomy, local fibrinolytic therapy, local ultrasound treatment as assistance to local fibrinolysis or any combination of these.Transfemoral venous access routes will be used for any catheter-directed treatment using sheath-sizes as recommended in the IFUs by the respective manufacturers. Sheaths will be withdrawn immediately after catheter-based thrombectomy or after completion of catheter-directed local fibrinolysis, typically 5 to 10 hours after initiation.
223657930|NCT00614068|BEHAVIORAL|Trauma-focused cognitive behavioral therapy (TF-CBT)|TF-CBT sessions will include trauma-focused treatment and will teach participants behavioral management and coping skills to overcome their PTSD.
223657931|NCT00614068|BEHAVIORAL|Treatment as usual (TAU)|TAU outpatient sessions will include routine community care and nontrauma-focused therapy.
223657932|NCT06517485|DRUG|upifitamab rilsodotin|"XMT-1536 will be administered once every 28 days until disease progression, unacceptable toxicity, or either the patient or study physician determines it is in the best interest of the patient to discontinue participation in the study.~For sites participating in the sub-study, patients with platinum -resistant ovarian cancer will have the option to enroll in this sub-study to evaluate potential changes in the QTc interval following administration of XMT-1536"
223657933|NCT00152919|DRUG|Meloxicam|
223657934|NCT01614483|OTHER|Yellow cassava|Daily provision of 375 g boiled yellow cassava for 18 weeks, 6 days/week Daily provision of placebo capsule for 18 weeks, 6 days/week
223657935|NCT01614483|OTHER|White cassava|Daily provision of 375 g boiled white cassava for 18 weeks, 6 days/ week Daily provision of placebo capsule for 18 weeks, 6 days/ week
223657936|NCT01614483|OTHER|White cassava|Daily provision of 375 g boiled white cassava for 18 weeks, 6 days/week Daily provision of B-carotene capsule (1400 µg B-carotene)
223657937|NCT00687141|DRUG|AZD0328|Oral solution administered orally once per day on day 1, and then day 3 through to day 14. Specific dose depends on dose panel.
223657938|NCT00687141|DRUG|Placebo|Administered orally as a solution once per day on day 1, and then day 3 through to day 14.
223657939|NCT01114399|DIETARY_SUPPLEMENT|Diet and Vascular Health|One group will consume 400g of standard broccoli each week for 12weeks; the second group will consume 400g of the high glucosinolate broccoli each week for 12weeks while the third group will consume 400g of peas each week for 12weeks. The broccoli and the peas will be consumed on top of the volunteer's standard diet.
223657940|NCT01114399|DIETARY_SUPPLEMENT|Diet and Vascular Health|One group will consume 400g of standard broccoli each week for 12weeks; the second group will consume 400g of the high glucosinolate broccoli each week for 12weeks while the third group will consume 400g of peas each week for 12weeks. The broccoli and the peas will be consumed on top of the volunteer's standard diet.
223657941|NCT01114399|DIETARY_SUPPLEMENT|Diet and Vascular Health Study|One group will consume 400g of standard broccoli each week for 12weeks; the second group will consume 400g of the high glucosinolate broccoli each week for 12weeks while the third group will consume 400g of peas each week for 12weeks. The broccoli and the peas will be consumed on top of the volunteer's standard diet.
223657942|NCT03722004|BIOLOGICAL|mOPV1|Monovalent oral poliovirus vaccine type 1 is a type-specific, live, attenuated oral poliovirus vaccine that protects against poliovirus type 1.
223657943|NCT03722004|BIOLOGICAL|bOPV|Bivalent oral poliovirus vaccine is a live, attenuated oral poliovirus vaccine that protects against poliovirus types 1 and 3.
223657944|NCT03722004|BIOLOGICAL|fIPV|Fractional dose of inactivated poliovirus vaccine that protects against types 1, 2, and 3 (all polio serotypes). Given as a 0.1 milliliter (mL) dose (fractional) by intradermal injection in lieu of the full 0.5mL dose that is given intramuscularly.
223657945|NCT01810536|DEVICE|Hi-flow nasal cannula|Different ways of providing supplemental oxygen will be compared: hi-flow nasal cannulas versus Venturi masks
223657946|NCT01810536|DEVICE|Venturi mask|
223657947|NCT02640196|DEVICE|Macintosh|The participants intubated the easy airway simulator with a double lumen tube using the Macintosh laryngoscope followed with intubating the difficult airway simulator
223657948|NCT02640196|DEVICE|GlideScope|The participants intubated the easy airway simulator with a double lumen tube using the GlideScope followed with intubating the difficult airway simulator
223768602|NCT06908759|OTHER|EXERCISE TRAINING WITH OR WITHOUT MEDICATION|In the first phase of the study all enrolled patients will perform exercise in the context of an in-hospital intesive rehabilitation after the acute event. At discharge they will be randomized in two groups: supervised exercise in the context of a cardiac rehabilitation facility or home-based exercise
223768603|NCT06908070|DRUG|Consolidation durvalumab|Patients with initially unresectable stage III NSCLC will undergo surgery after chemoradiotherapy completion when the tumor is deemed resectable by the thoracic oncology tumor board and will then receive durvalumab
223768604|NCT03977259|OTHER|Individually targeted fortification|"Abbott liquid protein and/or medium chain triglyceride are added routinely to ensure that the base milk has protein 1 g/dL and calories 67/dL."
223768605|NCT05092165|DRUG|Methylene Blue|1 mg per kilogram bolus, followed by 0.1 milligram per kilogram during renal replacement therapy
224240166|NCT06672081|DRUG|Conventional care|reperfusion treatment
224240167|NCT05277389|OTHER|START - Startle Adjuvant Rehabilitation Therapy|Application of startling acoustic stimuli during practice of movement task
223657949|NCT02640196|DEVICE|Airtraq|The participants intubated the easy airway simulator with a double lumen tube using the Airtraq followed with intubating the difficult airway simulator
223657950|NCT02640196|DEVICE|King Vision|The participants intubated the easy airway simulator with a double lumen tube using the King Vision followed with intubating the difficult airway simulator
224321109|NCT03449004|OTHER|Validation of the OPSI questionnaire|A questionnaire to measure satisfaction with online information for patients with low back pain
223657951|NCT02377739|OTHER|non-invasive ventilation|patients will undergo a nocturnal non-invasive ventilation
223657952|NCT02605265|RADIATION|Radiation|Pelvic Radiation: 50Gy/25Fx
223768606|NCT05092165|OTHER|Control|Usual care during renal replacement therapy
223768607|NCT06754280|BEHAVIORAL|RESET-CKD|RESET-CKD is a 12-week intervention that consists of four major components to support decreasing sedentary behavior: (1) health coaching, (2) feedback charts on sedentary behavior, (3) a workbook, and (4) reminders and cues.
223657953|NCT02605265|DRUG|Capecitabine|
223768608|NCT06754280|OTHER|Attention Control|CKD-related education
223657954|NCT02605265|DRUG|Irinotecan|
223657955|NCT02605265|DRUG|Oxaliplatin|
223657956|NCT04254913|DRUG|MT-1186|Suspension
224240168|NCT05277389|OTHER|Sham Control|Practice of Movement task without START
224240169|NCT06259435|BEHAVIORAL|Low-energy dense diet|Subjects will follow time-restricted eating of a low energy dense diet
224240170|NCT06259435|BEHAVIORAL|Usual diet|Subjects will follow time-restricted eating of the usual diet
224240171|NCT06149780|DEVICE|Patients treated with laser|Patients treated with laser with topical steroid Patients treated with laser with vehicle
224240172|NCT03264664|DRUG|E7386|Oral immediate release tablets.
224240173|NCT05231642|OTHER|Nutritional Interventional|Individualised postprandial glucose and vascular risk responses
224240174|NCT01570699|GENETIC|COMT polymorphism|The COMT enzyme enables the degradation of brain monoamines such as Dopamine and is encoded by a single gene for which several polymorphisms are known, including the Val158Met polymorphism which has been widely studied in various psychiatric disorders including addictions, as well as in impulsivity
223768609|NCT06908330|BEHAVIORAL|Social-emotional Skills for Thriving and Relating at School Program|The SSTRS Program is a developmentally-tailored, school-based preventive intervention focusing on children and their parents at the critical transition to kindergarten to prevent deficits in children's social-emotional skills-which are known transdiagnostic risk factors for a range of mental health problems. Children receive SSTRS programming during their regular school day for eight weeks at the beginning of the school year. Parents receive SSTRS programming via informational videos and virtual parenting groups during the same time period.
223768610|NCT06909396|DRUG|General anesthesia|Patients received general anesthesia
223768611|NCT06909396|DRUG|Intrathecal Anesthesia|Patients received intrathecal Anesthesia
223768612|NCT06909396|DRUG|Caudal block|Patients received caudal epidural anesthesia.
223768613|NCT06909188|OTHER|No intervention|No Intervention
223768614|NCT06598800|DRUG|Drug: BG-T187|Intravenous administration
223768615|NCT06917482|DRUG|BW-40202 injection|BW-40202 is a conjugate drug, dosage form is solution for injection and route of administration is subcutaneous injection
223768616|NCT06917482|OTHER|Sodium Chloride|Placebo (sodium chloride injection) will be administered as Subcutaneous injection
224240175|NCT05657899|PROCEDURE|Cerclage fixation|The intervention is by surgical open reduction and internal fixation of the fracture using two 1.0mm cerclage.
224240176|NCT05657899|PROCEDURE|Tension band wiring|The intervention is by surgical open reduction and internal fixation of the fracture using a 1.0mm cerclage and two 1.6 mm k-wires as described in AO-guidelines.
224240177|NCT04121455|DRUG|Olaptesed pegol|Olaptesed pegol continuous i.v. administration
224240178|NCT04121455|RADIATION|Radiotherapy|Radiotherapy in weeks 1-6; cumulative dose of 60 Gy in 2 Gy fractions
224240179|NCT04121455|DRUG|Bevacizumab|Bevacizumab every 2 weeks i.v. infusion
224240180|NCT04121455|DRUG|Pembrolizumab|Pembrolizumab every 3 weeks i.v. for 26 weeks
223657957|NCT02045641|PROCEDURE|pleuracentesis|Direct needle drainage of pleural effusions with dynamic ultrasound technique
223657958|NCT04621149|OTHER|chlorine dioxide|chlorine dioxide is an antimicrobial agent used for a variety of purposes including as a water purification product, a disinfectant on food, etc.
223768617|NCT07107113|OTHER|Pilates Exercise|Pilates exercises are characterized as muscle strengthening and stretching.
223768618|NCT07107113|OTHER|Aerobic exercises|Aerobic exercises are characterized as a modality that works cardiorespiratory fitness.
224240181|NCT04121455|DRUG|Temozolomide (TMZ)|oral treatment according to current SPC
224240182|NCT05135442|DRUG|Bortezomib Injection|Bortezomib should be administered immediately after each plasma exchange, and the interval between the next plasma exchange is\> 24h. Plasma exchange continued until the patient's platelet count was \>100×109/L for 2 consecutive days, and then changed to once every other day for a total of two times and then stopped.
224240183|NCT04819971|DRUG|Tirelizumab|tislelizumab (intravenously, 200 mg on day 1 of every cycle for 4 preoperative and 12 postoperative cycles)
224240184|NCT04819971|DRUG|Trastuzumab|Trastuzumab(intravenously, 8 mg/kg loading dose, then 6 mg/kg on days 1 of every cycle for 4 preoperative and 12 postoperative cycles)
224240185|NCT04819971|DRUG|Docetaxel|docetaxel (intravenously, 50 mg/m2 on day 1 of every cycle for 3 preoperative cycles)
224321110|NCT01331850|DRUG|Copegus|1000 mg or 1200 mg daily oral doses for 24 weeks
224321111|NCT01331850|DRUG|Copegus|1000 mg or 1200 mg daily oral doses for 48 weeks
224321112|NCT01331850|DRUG|Pegasys|180 microgram subcutaneously once weekly for 24 weeks
224321113|NCT01331850|DRUG|Pegasys|180 microgram subcutaneously once weekly for 48 weeks
224321114|NCT01331850|DRUG|RO5024048|1000 mg oral doses twice a day for 24 weeks
224321115|NCT01331850|DRUG|danoprevir|100 mg oral doses twice a day for 24 weeks
224321116|NCT01331850|DRUG|ritonavir|100 mg oral doses twice a day for 24 weeks
223657959|NCT04621149|DIETARY_SUPPLEMENT|zinc acetate|zinc acetate lozenges have been suggested to have antiviral properties
223657960|NCT04621149|DRUG|Famotidine|famoitidine is a histamine-2 blocker sold over the counter to reduce stomach acid
223657961|NCT04621149|OTHER|placebo|filtered water
223657962|NCT04621149|DIETARY_SUPPLEMENT|lactoferrin, green tea extract|lactoferrin and green tea extract are dietary supplements
223657963|NCT04464018|OTHER|working grup|After each student received theoretical training, they performed an intravenous injection on the model. In the study group performed hybrid simulation. After finishing the simulation application. the students went to the analysis room and watched their own application videos. The analysis session was held immediately after all the students in the group completed their applications.The IM injection success Test and Student Satisfaction and self-confidence scale were applied to the study and control groups after the laboratory application was completed.
223657964|NCT01396057|DRUG|Ranibizumab|Injections consisted of 0.5 mg/0.05 ml solution to be injected intravitreally. Ranibizumab was formulated as a sterile solution aseptically filled in a sterile glass vial. It was suitable for single use only and the content of the vial was not allowed to be split
223657965|NCT01396057|OTHER|Dexamethasone Implant|Comparator Ozurdex® (dexamethasone) was formulated as a rod shaped implant to be inserted into the eye by an applicator. The implant as well as the respective applicator were suitable for single use only.
223657966|NCT01396057|OTHER|Sham injection|Sham injection: Empty sterile syringes were provided so that masking could be maintained. Either empty syringes in the case of sham injections or pre-filled syringes in the case of ranibizumab injections were visible to the patient in the room of study drug administration
223768619|NCT07107113|OTHER|Pilates exercises plus aerobic exercise|Pilates exercises are characterized as muscle strengthening and stretching, while aerobic exercises are characterized as a modality that works cardiorespiratory fitness.
224240186|NCT04819971|DRUG|S1|S1 (orally, 400mg/m2 BID on day 1\~14 of every cycle for 3 preoperative and 3 postoperative cycles )
224240187|NCT04819971|DRUG|Oxaliplatin|Oxaliplatin(intravenously, 100 mg /m2 on day 1 of every cycle for 3 preoperative cycles ;130mg /m2 on day 1 of every cycle for 3 postoperative cycles.
224240188|NCT00926744|BEHAVIORAL|physical activity|The targets of amount of physical activity are 3.3METs•h/day (MVPA) and 10,000 step counts/day.
224240189|NCT00922597|BIOLOGICAL|Recombinant Factor VIII (Kogenate FS, BAY14-2222)|Patients undergoing surgery and receiving continuous infusion with Kogenate Bayer according to local drug information.
224240190|NCT03034226|OTHER|Glucose clamp technique|Hyperinsulinemic euglycemic and hyperinsulinemic hypoglycemic clamp procedure with infusion of insulin and glucose
224240191|NCT05052164|BEHAVIORAL|Gluten-free nutrition plan + exercise group|Menopausal or post-menopausal celiac women will follow a physical exercise program 3/4 times per week and their dietary intake will be gluten-free isocaloric
224321117|NCT05249673|OTHER|global postural reeducation|"GPR interventions will last 9 sessions, 1 hour each, with one-to-one supervision, once or twice a week according to the participant's needs. All participants will receive advice to follow written ergonomic suggestions and to repeat the exercises in the first physical therapy session at home twice a week for 15 minutes. Each group will get a home exercise program, which will differ according to the type of treatment received. Participants in the GPR group will execute one posture routine."
223657967|NCT03881215|PROCEDURE|Platelet Rich Plasma|Platelet Rich Plasma
223657968|NCT03881215|PROCEDURE|intra-uterine balloon|intra-uterine balloon
223657969|NCT04655170|DRUG|Revefenacin (YUPELRI) & Formoterol (Perforomist)|Revefenacin is a Long-acting anticholinergics (LAMAs) and Formoterol is Long-acting bronchodilators, beta-agonists (LABAs).
223657970|NCT04655170|DRUG|Albuterol Inhalation Aerosol (short-acting beta-agonists) & Ipratropium Aerosol (short-acting anticholinergic)|Albuterol Inhalation Aerosol (short-acting beta-agonists) \& Ipratropium Aerosol (short-acting anticholinergic)
223657971|NCT03412240|PROCEDURE|Induced pacing of the heart|Once the defibrillator leads have been inserted or, in the case of a box change, the old leads have been tested as per routine procedure, these pacing leads will be connected to an external pacing stimulator. The test involves electrically pacing your heart at different rates and we will be constantly monitoring you under close clinical supervision. During the test, your heart will be electrically stimulated to beat at a faster rate.
223768620|NCT06920134|DEVICE|ARC-IM Investigational System|Implantation of a stimulation lead on the low thoracic level of the spinal cord and implantation of a neurostimulator in the abdominal region.
223657972|NCT04535453|BIOLOGICAL|Ad26.COV2.S|All participants, both adults and adolescents, will receive intramuscular (IM) injections of Ad26.COV2.S.
223768621|NCT06922929|DRUG|INR101|INR101 PET/ CT
224240192|NCT05052164|BEHAVIORAL|Gluten-free nutrition plan group|Menopausal or post-menopausal celiac women will follow a gluten-free isocaloric dietary program
224240193|NCT05052164|BEHAVIORAL|Active Comparator: Celiac controls group|Menopausal or post-menopausal celiac women in whom all the tests were measured but they did not perform an intervention program with physical exercise or special follow-up of an adapted dietary-nutritional program
224240194|NCT03883607|DRUG|Elafibranor 80mg|Once daily oral intake of elafibranor 80 mg during 3 months
224240195|NCT03883607|DRUG|Elafibranor 120mg|Once daily oral intake of elafibranor 120 mg during 3 months
224240196|NCT06268522|BEHAVIORAL|Mindfulness-Oriented Recovery Enhancement: (MORE) group|Mindfulness-Oriented Recovery Enhancement (MORE) is a novel social work intervention and mental training program that unites complementary aspects of mindfulness training.
224240197|NCT06268522|BEHAVIORAL|Psychoeducation|Education on the neurobiology of pain, healthy eating, diet, sleep and stress
224240198|NCT03688373|BEHAVIORAL|Cognitive Behavioral Therapy|Each intervention will contain a 60-minute psycho-education session (PE) and two 60-minute exposure sessions (EX), conducted by a mental health professional together with a master student in psychology, who are both weekly supervised by a CBT certified psychologist. In the first (PE) session, participants learn about anxiety, specific phobias and exposure. During this session they will create a fear hierarchy (1 relating to least fearful and 10 indicating most fearful situation), formulate their cognition about the feared object or situation and determine what they want to achieve during treatment (e.g. goal situation). The next two sessions consist of exposure exercises in either big or small steps.
223657973|NCT04535453|OTHER|Placebo|Adult participants in Groups 4, 5, 6, 8, and 10, and adolescent participants in Group C will receive at least one injection of placebo.
223657974|NCT02685137|DRUG|stannsoporfin|Intramuscular injection of stannsoporfin to treat jaundice.
223657975|NCT02685137|OTHER|Sham Injection|nothing
223657976|NCT02695420|DRUG|25 mg Omecamtiv Mecarbil|oral tablet
223657977|NCT02695420|DRUG|Placebo|oral tablet
223657978|NCT02695420|DRUG|37.5 mg Omecamtiv Mecarbil|oral tablet
223657979|NCT02695420|DRUG|50 mg Omecamtiv Mecarbil|oral tablet
223657980|NCT02267798|OTHER|conventional therapy|"The conventional rehabilitation program will consist of physiotherapy sessions (100 min/day) following an individualized approach. The program aims at the restoration of mobility and daily living competence. Specific exercises for the affected upper limb will include, bilateral tasks and facilitation techniques.~The amount of treatment will to be comparable between control and experimental groups in order to avoid possible confounding factors."
223657981|NCT02267798|DEVICE|arm training combined with FES|"Arm training protocol Training sessions will last for 60 minutes. The Reo Therapy System is robot-assisted therapy; during the session the subject's affected hand is placed on or strapped onto a robotic arm and the subject is instructed to either actively reach predefined reach points, or to be guided while the robotic arm leads the arm towards these reach points.~Functional electrical stimulation protocol Experimental group will receive up to 40 minutes of FES after arm training. The device consists is a stimulator containing 5 electrodes positioned to provide reliable activation of the following muscles: extensor digitatum communis and extensor pollices brevis, flexor pollices longus, flexor digitatum superficialis, and thenar muscles."
223657982|NCT00416039|DRUG|Midazolam|0.2 mg/kg of sublingual midazolam and 0.5 mg/kg of morphine
223657983|NCT00416039|DRUG|Placebo|placebo at 0.2 mg/kg and morphine 0.5 mg/kg
223657984|NCT00925925|OTHER|Cord blood collection for analysis|Cord blood will be collected from the placentas at delivery for analysis
223657985|NCT01911962|PROCEDURE|transvaginal laparoscopic surgery|
223657986|NCT00695929|DRUG|Levosimendan|Intravenous injection
223657987|NCT00695929|DRUG|Milrinone|Intravenous injection
223657988|NCT05507112|DRUG|PD-1 inhibitor|Tislelizumab (3 cycles): 200mg i.v. q3w on day 1 of each cycle, and starting from the second week after the start of radiotherapy
223657989|NCT05507112|DRUG|Capecitabine|Capecitabine 1650mg/m2/d orally twice-daily, 5 days a week for a total of 5 weeks.
223657990|NCT05507112|RADIATION|Long-course radiation therapy|45-50 Gy/day, 5 days a week for a total of 5 weeks.
223657991|NCT03843008|DIETARY_SUPPLEMENT|Melatonin|Participants in the Melatonin Group will receive 3mg of melatonin each evening for up to seven days for a maximum total of 21mg of melatonin.
223657992|NCT01245569|DRUG|Foster® 100/6 µg/unit dose|"Foster® (beclomethasone dipropionate 100 µg plus formoterol 6 µg/unit dose), 2 inhalations b.i.d. (daily dose of BDP extrafine 400 µg plus FF 24 µg)."
223657993|NCT01245569|DRUG|Seretide Accuhaler® 500/50 µg/actuation|Seretide® Accuhaler® (fluticasone 500 μg plus salmeterol 50 μg/actuation), 1 inhalation b.i.d. (daily dose of fluticasone 1000 μg plus salmeterol 100 μg).
223657994|NCT03290924|BEHAVIORAL|Low dose high frequency health worker training approach|"* Two 4-day training sessions for skilled birth attendants~* 1-day peer practice coordinator training after first training session~* Weekly, peer-led practice sessions using MamaNatalie® and NeoNatalie™ anatomic models~* SMS reminder messages and quizzes~* Routine telephone calls between master mentors and peer practice coordinators, and between project staff and master mentors~* Health information officer training~* Data collection and use training~* Supply of simulators, newborn resuscitation equipment, and delivery sets"
223657995|NCT03290924|BEHAVIORAL|Active Comparison|Training on data collection and reporting
223657996|NCT02174822|DRUG|AVP-786|
223657997|NCT02174822|DRUG|Paroxetine|
223657998|NCT02174822|DRUG|Duloxetine|
223657999|NCT04449263|DEVICE|Lens A|Subjects will be randomized to wear Lens A (test) for 2 weeks.
223658000|NCT04449263|DEVICE|Lens B|Subjects will be randomized to wear Lens B (control) for 2 weeks.
223768622|NCT07086781|BEHAVIORAL|Virtual Family Navigation|Participants randomized to the Family Navigation condition will receive up to 4 research-based individual sessions with a trained navigator to support them in identifying and enrolling in recommended autism early intervention services. All navigation sessions will be delivered virtually via phone/Zoom.
223658001|NCT04449263|DEVICE|Habitual Lenses|All Subjects will wear their habitual lenses for 2 weeks prior to randomization of test lens and control lens.
223658002|NCT03282214|BEHAVIORAL|Self-management energy conservation|"The experimental group will receive four sessions approximately every three weeks with the PI. These sessions will correspond to the cycles of chemotherapy they will receive, with the first two sessions being during cycle 1, and sessions 3 and 4 being during cycles 2 and 3 of chemotherapy, respectively. The women will be instructed on how to assess their activity patterns by making a list prioritizing their usual activities. The journal and priority list (a to do list) provide the basis for the second session. In this session, the participant will learn to create a plan for managing valued activities to minimize the amount of energy used, to report the fatigue experienced during and after an activity done in the journal and will learn strategies to manage fatigue and optimize activity. In the third session, the participant will evaluate and revise their individualized plan. In addition, the participant will be instructed to wear a pedometer to record objective physical activity."
223658003|NCT06175949|DRUG|HRS-7085 Tablets|HRS-7085 Tablets, PO, 2mg、5mg、8mg、10mg、12mg、15mg, QD,
223658004|NCT06175949|DRUG|HRS-7085 simulant|PO, 2mg、5mg、8mg、10mg、12mg、15mg, QD
223658005|NCT00916929|DEVICE|Impedance Monitoring Feature|Algorithm in cardiac device that measures intra-thoracic impedance from the implanted leads
223658006|NCT03043105|DRUG|Thalidomide, cyclophosphamide and prednisone|"* Thalidomide: 100mg QN for 1 year; And maintained with 100mg QN for the second year;~* Cyclophosphamide: 300mg/m2 on Day 1, 8, 15, 22 every month for 1 year;~* Prednisone: 1mg/kg on Day 1-2, 8-9, 15-16, 22-23 every month for 1 year."
223768623|NCT07086781|BEHAVIORAL|Educational Materials|"The comparison condition (Educational Materials) consists of providing the participant's caregivers information about early intervention and community-based supports (i.e., infant-toddler programs, transition to school-based supports, family support groups, local organizations. Families in this condition will receive this information throughout 4 timepoints in the first 3 months after enrolling."
224240199|NCT04566159|BEHAVIORAL|CBI-CHW|2 sessions of computer delivered counseling + nicotine replacement therapy and CHW follow up post hospitalization up to twice weekly for up to 8 weeks
224240200|NCT04566159|OTHER|Standard Care|Standard tobacco treatment care offered by the inpatient care
224240201|NCT04713696|OTHER|Functional training|Functional training refers to exercises that targets the muscles of the lumbopelvic-hip complex in order for them to more appropriately support and control the spine.
223658007|NCT00888719|DRUG|CWP-0403 100mg|100mg/tablet, Twice a day, 1 tablet at a time for 12 weeks
223658008|NCT00888719|DRUG|placebo|"Tablet not containing CWP-0403 and indistinguishable from CWP-0403 50mg, 100mg tablets.~Twice a day, 1 tablet at a time for 12 weeks"
223658009|NCT00888719|DRUG|CWP-0403 50mg|50mg/tablet, Twice a day, 1 tablet at a time for 12 weeks
223658010|NCT05721599|BEHAVIORAL|Integrated care with nutrition and lifestyle counselling|The structured care includes specialist care, integrated assessment, group health education, one-on-one nutrition and lifestyle guidance, online and face-to-face support group and case management.
223658011|NCT05895474|DEVICE|Transcranial Focused Ultrasound|Using MRI-guided targeting, we will administer focused ultrasound in one of the 4 stimulation conditions
223658012|NCT05829369|OTHER|Intrinsic foot muscle strengthening exercises|participants will perform specific toe and foot motions that recruit plantar intrinsic foot muscles, 3 sets of 10 for each exercise, 5 days per week
223658013|NCT05829369|OTHER|Minimal footwear with prescribed walking|Participants will be provided minimal footwear. They will walk 30 minutes per day, 5 days per week, and be prescribed a gradual increased time in minimal footwear during daily activities (up to a maximum of 7.5 hours per day).
223768624|NCT04424992|OTHER|Observational cohort study on the natural history of hospitalized SARS-COV-2 patients.|Describe the natural history and clinical evolution of hospitalized patients over time affected by SARS-COV-2 infection, understand the pathogenesis of the disease and improve the aids and therapeutic procedures.
224240202|NCT04713696|OTHER|Routine training|Routine training refers to general exercises that perform before and after practice, including jogging, stretching and strengthening exercises for upper and lower extremities
224240203|NCT00221507|BEHAVIORAL|Reminder-Recall-Outreach|
223658014|NCT05829369|OTHER|Control|Participants will perform seated upper and lower extremity active range of motion activities 5 days per week. They will also be given a brochure on fall prevention tips.
223658015|NCT02464280|OTHER|Tomosythesis scan of the lung or the wrist|All study participants will undergo Tomosynthesis imaging of the lung or the wrist. The radiation dose of each method will be recorded.
223658016|NCT02464280|OTHER|CT scan of the lung or the wrist|All study participants will undergo CT imaging of the lung or the wrist, for which they where originally scheduled. The radiation dose of each method will be recorded.
223768625|NCT06923657|DIAGNOSTIC_TEST|PSMA PET/MRI-TRUS guided prostate targeted combined saturation biopsy|The experimental group will undergo PSMA PET/MRI examination. For those with positive PSMA PET/MRI results, a PSMA PET/MRI-TRUS guided prostate targeted biopsy will be performed based on transrectal ultrasound (TRUS) guided transperineal saturation biopsy, targeting the positive lesions. For those with negative PSMA PET/MRI results, only TRUS guided transperineal saturation biopsy will be performed. Clinical and pathological data of the patients will be collected for statistical analysis.
223768626|NCT06923657|DIAGNOSTIC_TEST|TRUS guided transperineal saturation biopsy|The control group will receive TRUS guided transperineal saturation biopsy. Clinical and pathological data of the patients will be collected for statistical analysis.
223768627|NCT07131293|PROCEDURE|Lymphatic intervention|This intervention was made as part of their clinical treatment.
223768628|NCT06932770|DIETARY_SUPPLEMENT|Food Supplement active|The food supplement active (2 soft gels) will be consumed once per day with a large glass of water.
224240204|NCT00221507|BEHAVIORAL|Case Management|
224240205|NCT00221507|BEHAVIORAL|Patient Navigator|
224240206|NCT04627506|DEVICE|Bilateral NIRS (Masimo, O3TM Regional Oximetry)|Bilateral NIRS will be used to measure rSO2 intraoperatively. The NIRS electrodes will be placed on fronto-temporal area and baseline values of rSO2 obtained according to manufacturer's guidelines in the operating room prior to induction of anesthesia. The NIRS screen will be concealed in the control group to ensure blinding.
224240207|NCT04375293|OTHER|Microbiome swabs|Swabs for analysis of microbiome
224240208|NCT05635279|OTHER||
224240209|NCT05059522|DRUG|Avelumab|oral
223658017|NCT02464280|OTHER|conventional X-ray of the lung or the wrist|All study participants will undergo conventional X-ray of the lung or the wrist, for which they where originally scheduled. The radiation dose of each method will be recorded.
223658018|NCT01755819|DEVICE|Biocomposite interference screw|
223658019|NCT01755819|DEVICE|Extracortical ACL Tightrope fixation|
223658020|NCT05493800|DRUG|MIT-001|Corresponding dose of MIT-001 IV injection during 0.5\~1hr
223658021|NCT05493800|DRUG|normal saline|normal saline IV injection
223658022|NCT03200886|DEVICE|Sinovial H-L|Patients were treated with an hybrid form of hyaluronic acid (Sinovial H-L) obtained through thermo-chemical processes from the combination of high (1100-1400 kDa) and low (80-100 kDa) MW fractions.
224240210|NCT05059522|DRUG|Lorlatanib|oral
224240211|NCT05059522|DRUG|Talazoparib|oral
224240212|NCT05059522|DRUG|Pemetrexed|IV (intravenous) infusion
224240213|NCT05059522|DRUG|Axitinib|oral
224240214|NCT05059522|DRUG|CMP 001|IT (intratumoral) or SC (subcutaneous)
224240215|NCT05059522|DRUG|Utomilumab|IV infusion
224240216|NCT05059522|DRUG|PF04518600|IV infusion
224240217|NCT03544138|DEVICE|Hummingbird Tympanostomy Tube System (H-TTS)|The H-TTS is intended to deliver a tympanostomy tube through the tympanic membrane of a patient during a tympanostomy procedure.
224240218|NCT00699322|DRUG|Sitagliptin|100mg P.O. per day for 1month
224240219|NCT00699322|DRUG|Glimepiride|2mg P.O. per day for 1 month
224321118|NCT05249673|OTHER|neck stabilization training|"Each exercise session will be comprised 10-minute warm-up exercises, 40-minute stabilization exercises, and 10-minute cool-down and stretching exercises, including neck and shoulder girdle muscles. The whole program will be carried out 3 days per week for 4 weeks.~performed. The participants will be asked to maintain the positions and contractions during the exercises and throughout the day as much as possible. The combination and progression of the exercises will be designed according to condition of the patient."
224321119|NCT02753920|OTHER|voiding trial|1 of 2 tests to assess bladder function after vaginal apex suspension surgery with or without mid-urethral sling
224321120|NCT02753920|DEVICE|Foley catheter|If subject is unable to void adequately, a Foley catheter will be placed as per protocol and the subject discharged home with catheter. The subject will follow up in the office for removal of catheter.
224321121|NCT00936247|DRUG|HES 130/0.42 + electrolyte solution|Tetraspan 6% as colloid component combined with Sterofundin ISO as electrolyte component
224321122|NCT00936247|DRUG|Albumin + electrolyte solution|Albumin 5% as colloid component and NaCl 0.9% as electrolyte component
224321123|NCT00181714|DRUG|methylphenidate HCl (Concerta)|OROS MPH will be openly prescribed to a maximum of 1.5 mg/kg/day (maximum 126 mg/day). Doses will be titrated according to clinical assessment of efficacy and tolerability.
223658023|NCT03200886|DRUG|Triamcinolone Acetonide|The patients have received two i.a. injections (at baseline and 15 days apart) of 0.5 ml of triamcinolone acetonide (Kenacort® 20 mg, Bristol-Myers Squibb Srl)
223658024|NCT01742286|DRUG|Ceritinib|"LDK378 is a capsule taken by mouth, contents can be mixed with food for pediatric patients or mixed with water and given via nasogastric/gastric (NG/G) tube. For patients in fasted group: 1-2 tablespoons (15-30 mL) of an appropriate food such as apple sauce or non-fat yogurt and a glass of water were allowed.~For patients in the fed cohort: LDK378 was taken with, or within 30 minutes after finishing a low-fat light snack containing 100-300 calories and 1.5-2 grams of fat."
223658025|NCT04335734|PROCEDURE|Nissen Fundoplication with wrap fixation|Firstly, we performed left crural dissection, division of the short gastric vessels, right crural dissection, and esophageal mobilization. Then repair of HH were made by simple cruroraphy if the size of the defect was less then 10 сm² otherwise mesh for reinforcement of cruroraphy was used. Creation of the wrap was made by passing posterior fundus behind the esophagus from left to right, followed by stitching the edges of the stomach with three interrupted sutures. Wrap was fixated to both diaphragmatic crura or to the body of stomach using two non-absorbable stitches on each side.
223658026|NCT04335734|PROCEDURE|Nissen Fundoplication without wrap fixation|Firstly, we performed left crural dissection, division of the short gastric vessels, right crural dissection, and esophageal mobilization. Then repair of HH were made by simple cruroraphy if the size of the defect was less then 10 сm² otherwise mesh for reinforcement of cruroraphy was used. Creation of the wrap was made by passing posterior fundus behind the esophagus from left to right, followed by stitching the edges of the stomach with three interrupted sutures.
223658027|NCT06522542|DRUG|systematic therapy|All patients received systematic therapy including chemotherapy, targeted therapy or immune checkpoint inhibitor. We aims to investigate the impact of bleeding on the survival and treatment-related adverse events (TRAEs) of gastric cancer patients.
223658028|NCT04530136|DRUG|Ruconest|Patients will be randomized to Ruconest or Standard of Care
223658029|NCT04152564|PROCEDURE|levo-bupivacaine infusion via Thoracic epidural catheter|The epidural catheter will be placed via a paramedian approach as close as possible to the surgical procedure via the inter-vertebral space (from T7 to T10) so that the affected dermatomes of the surgical wound would receive the benefits of bupivacaine infusion
223658030|NCT04152564|PROCEDURE|levo-bupivacaine infusion via preperitoneal catheter|At the end of surgery and after the closure of the peritoneal layer, the catheter will be allocated above the peritoneum within the musculofascial layer and secured to the skin with an occlusive dressing
224240220|NCT05554653|DIETARY_SUPPLEMENT|Leucine enriched amino acids|Leucine enriched essential amino acids (4g total, of which 1.6g are leucine). 20g carbohydrate, 2g of protein free drink powder, and 5g of Splenda.
224240221|NCT05554653|DIETARY_SUPPLEMENT|Carbohydrate Placebo|iso-caloric placebo (4g maltodextrin). 20g carbohydrate, 2g of protein free drink powder, and 5g of Splenda.
224240222|NCT01911195|DRUG|ISOFLURANE- Experimental Arm|The experimental group will be given the anesthetic isoflurane for three hours, and will undergo cognitive tests immediately following emergence from general anesthesia while connected to an EEG machine.
224240223|NCT01911195|OTHER|Control Group: Cognitive Testing|The control group will undergo cognitive testing while connected to an EEG machine following a comparable rest period, but will not receive general anesthesia.
224240224|NCT01078025|PROCEDURE|Smear test vaginally, intraabdominally|Pre- and intraoperative smear tests of the vagina and douglas are performed.
224240225|NCT01078025|PROCEDURE|Smear test vaginally, intraabdominally|Pre- and intraoperative smear tests of the vagina and douglas are performed.
224240226|NCT03268668|OTHER|Collection of thrombus that is responsible for stroke and blood sample|"A blood sample (venous or arterial) of 10 ml will be made, on ethylene Diamine Tetra-Acetic (EDTA) tube (5 ml) and citrate (5 ml).Thrombus resulting from thrombectomy will be collected at the end of the procedure. The samples will be transferred to a biobank. Treatment efficacy, etiology and prognosis of patients will be assessed using the following criteria :~A) TOAST score (etiology) B) TICI score (status of final recanalization) C) Extravasation of contrast agent on post-intervention CT (rupture of the blood-brain barrier :yes/no) D) Symptomatic haemorrhagic transformation corresponding to an increase \> 4 of the NIHSS score due to a haemorrhagic transformation identified on brain imaging 24 hours after stroke E) Decreased NIHSS score by 8 points or NIHSS score = 0 24 hours after stroke (improved neurological status: yes/no) F) Modified RANKIN score (mRS) measured at 3 months evaluating neurological prognosis"
224240227|NCT01766778|DRUG|LAF237 (vildagliptin)|Vildagliptin 50mg capsule
224240228|NCT01766778|DRUG|Metformin|Metformin maximum tolerance dose
224240229|NCT04359095|DRUG|Emtricitabine/tenofovir|Generic drug distributed by the Colombian Health System for Human Immunodeficiency Virus (HIV) positive patients It is classified as an anti infectious drug and its current indications include HIV infections.
224321124|NCT04352725|PROCEDURE|End-expiratory lung volume measurement and incremental PEEP titration|"* End expiratory lung volume measurement procedure according to the PEEP level set by the clinician, respecting a Vt at 6ml/kg IBW and Pplat\<28cmH2o~* incremental PEEP titration procedure in 5 steps starting from 5cmH2o up to 20cmH2o"
223768629|NCT06932770|DIETARY_SUPPLEMENT|Food supplement placebo|The food supplement placebo (2 soft gels) will be consumed once per day with a large glass of water.
223768630|NCT06932770|OTHER|Skin care product active|The cosmetic skin care product active will be applied twice daily to half of the face and to one volar forearm.
223658031|NCT03561467|OTHER|Observational|Evaluation of dysfunctions in the continuous city-hospital journey of a patients cohort treated by oral chemotherapy
223658032|NCT02087423|DRUG|MEDI4736|MEDI4736 (durvalumab) by intravenous infusion every two weeks. Treatment from Day 1 for a maximum of 12 months or study drug withdrawal if this occurs earlier. Patients who achieve CR, PR or SD through the end of the initial 12-month treatment period can restart treatment with MEDI4736 (durvalumab) when they eventually do progress. This retreatment period can continue for as long as the investigator considers to patient to be receiving clinical benefit.
223658033|NCT00980967|OTHER|Study of predictive factors|Identification of predictive factors for lung chronic rejection outcome in lung transplant recipients
223658034|NCT01387542|DRUG|Paliperidone extended release (ER)|Paliperidone ER 3 milligram (mg) or 6 mg or 9 mg or 12 mg oral tablets depending on investigator's discretion once daily for 10 weeks
223658035|NCT01010867|DRUG|Lactobacillus plantarum strains 299 and 299v|"Patients will receive a daily dose of Lactobacillus plantarum: 1 x10\^8 CFU/kg/day. This supplement will be supplied in sachets of powder and will be mixed in water (certain water-based liquid) that is no warmer that 37o C.~Colony forming units (CFU)"
223658036|NCT00773318|PROCEDURE|SPECT/CT guided LM/SL|Detection, localization, and removal of sentinel lymph node (s) from prostate cancer guided by an integrated SPECT/low-dose multislice CT
223658037|NCT03601117|DEVICE|Dorsolateral Prefrontal Cortex Accelerated Theta Burst Stimulation|"Participants will receive iTBS (intermittent theta burst stimulation) to the left DLPFC.~Stimulation intensity will be standardized at 80% of resting motor threshold (adjusted for cortical depth).~Stimulation will be delivered using the Brainsway TMS system."
223658038|NCT03601117|DEVICE|Anterior Cingulate Cortex Accelerated Theta Burst Stimulation|"Participants will receive iTBS (intermittent theta burst stimulation) to the anterior cingulate cortex (ACC).~Stimulation intensity will be standardized at 80% of resting motor threshold (adjusted for cortical depth).~Stimulation will be delivered using the Brainsway TMS system."
223658039|NCT04775628|PROCEDURE|Inferior glide humerus in GH joint|Supine inferior glide GH joint
223768631|NCT06932770|OTHER|Skin care product placebo|The cosmetic skin care product placebo will be applied twice daily to half of the face and to one volar forearm.
223768632|NCT03950128|BEHAVIORAL|Mindfulness-Based Skills Training (MBST)|"This intervention teaches students mindfulness-based skills to help manage their emotions when resolving conflict with their partners. The skills followed the ABCDE acronym. ABCDE stands for awareness, breathing, checking in with your feelings and thoughts, describing your experience, and expressing what you want to change. Students learned about the skills and had opportunities to practice them as well."
223768633|NCT03950128|BEHAVIORAL|Psychoeducational|This intervention is based on the Love is Not Abuse (LINA) Curriculum (Liz Claiborne Education Development Center (n.d.)). It was adapted to be given over the course of three 50-minute sessions. The selected materials covered (a) what dating abuse is, (b) the pattern of abuse and, (c) technology and dating abuse. The curriculum is interactive and includes handouts, activities, and discussion.
224240230|NCT04359095|DRUG|Colchicine Pill|Generic drug distributed by the Colombian Health System as an insurance treatment for Gout. It has been suggested that colchicine would be useful in SARS Covid 19 becouse its antiinflammatory effects through reduction of cytokine levels as well as the activation of macrophages, neutrophils, and the inflammasome
224240231|NCT04359095|DRUG|Rosuvastatin|Generic drug distribute by the Colombian Health System. It is used in people with High levels of cholesterol. An action against the main protease (Mpro) of COVID 19 virus has been described, There is evidence suggesting that statins could exert anti Covid 19 action and the infectivity of enveloped viruses
224240232|NCT04359095|OTHER|Standard treatment|Standard treatment n, multiple organ failure related to the acute infection including respiratory support (oxygen, positive end-expiration pressure with external devices or invasive ventilatory support), cardiovascular, renal, haematological or coagulation, or co-infection with bacterial or mycotic organisms, standard care to prevent pressure ulcers or other care required by the patient. No viral therapies are included.
224240233|NCT02728037|PROCEDURE|Magnesium-Based Injection Formulation|"Each study kit will include 4 10cc syringes containing 7ml of 1% lidocaine, and 3 numbered glass vials. For those in the magnesium-based injection formulation arm the glass vials will be prepared as follows; 1) 10ml of 50% magnesium sulfate, 2) 20ml of 8.4% bicarbonate, and 3) 20ml of 50% dextrose.~At the visit a study investigator will mix 2cc of vial 1, 5cc of vial 2 and 5cc of vial 3, for a total of 12cc of additive mixture. 3cc of this additive mixture will be then drawn in to each of the 4 pre-packaged lidocaine syringes, for a total of 10cc of final mixture per syringe. The concentration of components in the final mixture is 0.7% lidocaine, 0.8% sodium bicarbonate, 6.0% dextrose, and 2.5% magnesium sulfate."
224321125|NCT03437031|DEVICE|Virtual Reality device|For those patients randomized to VR, the study staff member will explain the use of the Samsung VR goggle set, and thereafter will allow the patient to use the device freely for up to 30 minutes. Intervals of 2-5 minutes is suggested for first-time use, and patients will be to allowed to discontinue it at any time as long as they are not experiencing any discomfort or side effects (dizziness, motion sickness, etc.). The study staff member will be present at all times, and will work with hospital staff as necessary to ensure the patient is receiving appropriate clinical care throughout the duration of the intervention.
224321126|NCT02794870|BIOLOGICAL|RSV LID ΔM2-2 1030s vaccine|10\^5.0 PFU; administered as nose drops
223768634|NCT06937996|DEVICE|NanoKnife|The NanoKnife, System has been commercially available since 2009, and is FDA-approved to treat soft tissue tumors. The NanoKnife System has received FDA clearance for the surgical ablation of soft tissue. It has not received clearance for the therapy or treatment of any specific disease or condition.
223768635|NCT06938802|BEHAVIORAL|Sleep coaching|Participants will receive an 8-week sleep coaching program delivered by smartphone/tablet app
223768636|NCT06938802|BEHAVIORAL|Sleep education|Participants will receive electronic access to educational information about sleep for 8 weeks
223768637|NCT06937749|DRUG|Placebo|Placebo administered subcutaneously (SC) once a week.
223768638|NCT06937749|DRUG|IBI362|IBI362 administered subcutaneously (SC) once a week.
223768639|NCT07172191|BIOLOGICAL|Fecal Microbial Transplantation|The technical implementation of FMT procedure is consistent with the methodological letter issued by the National Public Health Center of Hungary. FMT is performed via nasogastric tube with suspended fresh stool graft obtained from a pre-selected stool donor. Following FMT, the patient is observed for 24 hours at our center. The process is supervised and performed by the lead researcher.
223768640|NCT07172230|BEHAVIORAL|Immersive Virtual Reality|Immersive VR
224240234|NCT02728037|PROCEDURE|Lidocaine-Only Injection Formulation|"Each study kit will include 4 10cc syringes containing 7ml of 1% lidocaine, and 3 numbered glass vials. For those in the lidocaine-based injection formulation arm the glass vials will be prepared as follows; 1) 10ml of 0.9% sodium chloride, 2) 20ml of 0.9% sodium chloride, and 3) 20ml of 0.9% sodium chloride.~At the visit a study investigator will mix 2cc of vial 1, 5cc of vial 2 and 5cc of vial 3, for a total of 12cc of additive mixture. 3cc of this additive mixture will be then drawn in to each of the 4 pre-packaged lidocaine syringes, for a total of 10cc of final mixture per syringe. The concentration of components in the final mixture is 0.7% lidocaine."
224240235|NCT02728037|DRUG|lidocaine|
223658040|NCT06159426|OTHER|Vojta Therapy|"The subject will be placed on a stretcher with the torso uncovered. Once the adhesive electrodes have been placed in the different recording areas on the anterior part of the trunk, a recording of the activity at rest will begin, two minutes of stimulation (digital pressure), one minute of rest, two minutes of stimulation in the contralateral side and, finally, one minute of rest.~The therapy consists of the application of a stimulating pressure in the pectoral area in the pattern of the locomotion complex of reflex rolling in its first phase. For this, the subject will be placed in a supine position aligned with respect to the axial axis, with the arms along the body, the lower extremities in extension, and the head extended with a rotation of approximately 30º towards one side of the stimulation. The manual stimulation pressure will be exerted in the space between the 6th-7th or the 7th-8th rib under the mammillary line, with a force of about 2 kg."
224240236|NCT02728037|DRUG|magnesium sulfate, bicarbonate, dextrose.|
224240237|NCT03863678|OTHER|Neurodevelopemental therapy (NDT)|NDT treatment will be given for 45 minutes, 3 sessions per week in 4 weeks period (total of 12 sessions).
224240238|NCT03863678|OTHER|Neurodevelopemental therapy (NDT) and dry needling|NDT treatment will be given for 45 minutes, 3 sessions per week in 4 weeks period (total of 12 sessions). Dry needling will be applied on M. Gastrocnemius, M.Quadriceps, M.Flexor Carpi Radialis, and M.Biceps Brachii muscles, 60 seconds (sec) for each muscle groups at the end of the NDT treatment.
223768641|NCT07172230|BEHAVIORAL|No distraction Control condition|No VR during word list study phase
223768642|NCT07173387|DRUG|NALIRIFOX (liposomal irinotecan-based chemotherapy).|NALIRIFOX is a chemotherapy regimen that includes liposomal irinotecan, oxaliplatin, 5-fluorouracil (5-FU), and leucovorin, administered intravenously in 10-12 cycles every two weeks.
223768643|NCT07173387|RADIATION|Stereotactic Body Radiation Therapy (SBRT).|Stereotactic Body Radiation Therapy (SBRT) is a form of high-precision radiation therapy that delivers focused radiation beams to the tumor while minimizing damage to surrounding healthy tissue. In this study, SBRT will be applied in two different timing schedules after NALIRIFOX chemotherapy: early after 1 cycle (Cohort 1) or late after 6-8 cycles (Cohort 2). The total radiation dose will be 25-50 Gy, delivered in 5 fractions.
223768644|NCT07173959|DEVICE|GDM digital Therapy mini-program|The main functions of digital therapy products include personalized recipe recommendations, exercise and diet records and personalized analysis, blood sugar and weight monitoring, and the generation of weekly and monthly electronic comprehensive reports. The content of the electronic comprehensive reports includes the weight gain, blood sugar status, examination indicators, mood, and the proportion of diet and exercise of pregnant women in line with the system's recommendations during this period of time.
224240239|NCT04525807|DIAGNOSTIC_TEST|Multi-omics|Use multi-omics to analyze
224240240|NCT00001090|BIOLOGICAL|APL 400-047|
224240241|NCT00001090|BIOLOGICAL|ALVAC-HIV MN120TMG (vCP205)|
224240242|NCT00001090|DRUG|Sargramostim|
224240243|NCT05015556|PROCEDURE|Minimal invasive volar plating|Muscle sparing osteosynthesis, no casting postoperatively
224240244|NCT03208426|DRUG|Esomeprazole (S14)|Nexium, esomeprazole 40mg bid, 14 days
224240245|NCT03208426|DRUG|Esomeprazole (BQ10)|Nexium, esomeprazole, 40mg bid for 10 days
223768645|NCT07173959|DEVICE|Pregnancy record and education mini-program|This mini-program looks the same as digital therapy products but only has the functions of education and record-keeping
224240246|NCT03208426|DRUG|Amoxicillin (ST14)|Day 1-7 amoxicillin (Brand name: Amoxicillin Capsule) 1000mg bid for 7 days
224240247|NCT03208426|DRUG|Clarithromycin (ST14)|Klaricid-XL, clarithromycin, 500mg, bid, for 7 days, (day 8-14)
224240248|NCT03208426|DRUG|Metronidazole (ST14)|Flagyl, metronidazole, 500mg bid, for 7 days (day 8-14)
224240249|NCT03208426|DRUG|dibismuth trioxide 120mg (BQ10)|KCB F.C. TABLETS, dibismuth trioxide 120mg qid for 10 days
224240250|NCT03208426|DRUG|Metronidazole (BQ10)|Flagyl, metronidazole 500mg tid for 10 days
224240251|NCT03208426|DRUG|tetracycline (BQ10)|Tetracycline (Brand name: Tetracycline Capsule ) 500mg qid for 10 days
224240252|NCT03887689|BEHAVIORAL|Modified prolonged exposure|Participants will receive three sessions of modified prolonged exposure therapy.
224240253|NCT04209920|DEVICE|CAD-CAM milled PMMA crown|the patient will receive a full coverage restoration for hypomineralized first permanent molar in patient suffering from molar incisor hypomineralization using PMMA disks using a CAD-CAM technology.
224240254|NCT04209920|OTHER|Cast metal coping using nickel chromium alloy|the patient will receive a full coverage restoration for hypomineralized first permanent molar in patient suffering from molar incisor hypomineralization using Nickel Chromium alloy to make a Cast Coping.
224240255|NCT02184728|DEVICE|End-tidal CO2(portable capnometer)|End-tidal CO2(portable capnometer: EMMATM, Side stream capnometry module:Datex-Ohmeda S5 Anesthesia Monitor )levels were recorded at the time of arterial blood gas sampling.
224240256|NCT01478620|DRUG|Canephron® N|3x 2 coated tablets/day for 7 days p.o.
224240257|NCT03267056|DEVICE|drug eluting balloon catheter (trade name: Orchid)|use drug eluting balloon catheter(trade name: Orchid) to inflate the stenosis or occlusion in superficial femoral artery(SFA) and/or popliteal artery
224240258|NCT02139514|BEHAVIORAL|Virtual Reality Social Cognition Training|Social skills training via virtual reality with trained therapist.
224240259|NCT00152165|PROCEDURE|Radiostereometric Analysis beads inserted during surgery|
223768646|NCT07172906|BEHAVIORAL|"Patients of Group A and B both are filling out the questionnaire Mediterranean diet questionnaire (MEDAS)"|This questionnaire will be completed by patients in both groups. The aim of this questionnaire is to assess the patients' dietary choices and how beneficial they are for their health, according to the Mediterranean diet model.
223658043|NCT05438303|DRUG|AZD9833|AZD9833 tablets will be administered orally once daily on Days 1 - Day 5 (Treatment Period 2) and Day 1 (Treatment Period 3) for participants recruited to Arms A and C and Day 1 for those in Arm B
223658044|NCT05438303|DRUG|Midazolam|Midazolam will be administered orally as a syrup once on Day 1 of Treatment Periods 1 and 3; administered together with Omeprazole
224240260|NCT02527096|DRUG|dolutegravir (Tivicay®) - Phase 1|• Phase 1 (8 weeks) : switch of the third agent with dolutegravir(Tivicay®) 50 mg once a day.
224240261|NCT02527096|DRUG|lamivudine (Epivir®) - Phase 2|• Phase 2 (48 weeks): combination with lamivudine (Epivir®) 300 mg once a day + dolutegravir (Tivicay®) 50 mg once a day. Only participants with plasma HIV RNA ≤ 50 cp/mL at Week 8 will continue on phase 2.
224240262|NCT02527096|DRUG|dolutegravir (Tivicay®) - Phase 2|• Phase 2 (48 weeks): combination with lamivudine (Epivir®) 300 mg once a day + dolutegravir (Tivicay®) 50 mg once a day. Only participants with plasma HIV RNA ≤ 50 cp/mL at Week 8 will continue on phase 2.
224240263|NCT00046865|PROCEDURE|acupressure therapy|
224240264|NCT00046865|PROCEDURE|management of therapy complications|
224240265|NCT00046865|PROCEDURE|nausea and vomiting therapy|
224240266|NCT04813809|DEVICE|BARRIER EasyWarm|Application of BARRIER EasyWarm for 10 hours. The treatment with the investigational device will be according to the instruction stated on the investigational device.
224240267|NCT04620109|DRUG|KDR2-2|"KDR2-2 is a synthetic anti-angiogenic chemical compound with highly effective inhibition on vascular endothelial growth factor receptor-2 (VEGFR2), and an additional, moderate inhibitory effect on platelet-derived growth factor receptor β (PDGFRβ).~KDR2-2 suspension eye drop is in development for the treatment of corneal neovascularization."
223658045|NCT05438303|DRUG|Omeprazole|An Omeprazole capsule will be administered once on Day 1 of Treatment Periods 1 and 3; administered together with Midazolam
224240268|NCT04620109|DRUG|Placebo|Placebo : the formulation and the product process of placebo are the same as the KDR2-2 eye drops, but without API .
223658046|NCT05438303|DRUG|Dabigatran Etexilate|A Dabigatran Etexilate capsule will be administered once on Day 1 of Treatment Periods 1 and 2
224240269|NCT02057848|OTHER|low amount of carbohydrates|different regimens of carbohydrate administration to prevent hypoglycaemia during a standardized bout of moderate physical activity in patients with type 1 diabetes
224240270|NCT02057848|OTHER|high amount of carbohydrates|different regimens of carbohydrate administration to prevent hypoglycaemia during a standardized bout of moderate physical activity in patients with type 1 diabetes
224240271|NCT02057848|OTHER|Rapid-acting carbohydrates|different regimens of carbohydrate administration to prevent hypoglycaemia during a standardized bout of moderate physical activity in patients with type 1 diabetes
224240272|NCT02380183|DEVICE|Civco Needle Guidance Device|Needle guidance device will be used while nerve block is performed.
224240273|NCT00322400|DRUG|Docetaxel|Subjects assigned to Arm B, cohorts will receive 75 or 100 mg/m2 of docetaxel (based on cohort assignment) on Day 1 repeated every 21 days (1 cycle). AMG 706 will be administered concurrently on Days 3-21 of Cycle 1, and Days 1-21 of Cycle 2 and beyond.
224240274|NCT00322400|DRUG|Paclitaxel|Subjects assigned to Arm A will receive 90 mg/m2 of paclitaxel on Days 1, 8 and 15 repeated every 28 days (1 cycle). On Arm A, AMG 706 will be concurrently administered on Days 3-28 of Cycle 1, and Days 1-28 of Cycle 2 and beyond.
224240275|NCT00322400|DRUG|AMG 706|"Subjects assigned to Arm A will receive AMG 706 at 50, 75, 100 or 125 mg daily (based on cohort assignment) on Days 3-28 of Cycle 1, and Days 1-28 of Cycle 2 and beyond in combination wth paclitaxel 90 mg/m2. Paclitaxel will be administered on Days 1, 8 and 15 every 28 days.~Subjects assigned to Arm B will receive AMG 706 at 50, 75, 100 or 125 mg daily(based on cohort assignment) on Days 3-21 of Cycle 1, and Days 1-21 of Cycle 2 and beyond in combination with docetaxel. Docetaxel will be administered at either 75 mg/m2 or 100 mg/m2 on Day 1 every 21 days."
224240276|NCT00254111|DEVICE|Ultra Probe Laser System|
224240277|NCT05825300|BEHAVIORAL|Email message|Email message encourages patients to donate blood
224240278|NCT05825300|BEHAVIORAL|Social responsibility|Message specifies that there is a shortage of the patient's blood type
224240279|NCT02073630|OTHER|active cerebellar stimulation|
224240280|NCT02073630|OTHER|sham cerebellar stimulation|
224240281|NCT01411332|RADIATION|SIMRT|A total dose of 80 Gy will be delivered in 40 fractions to the Clinical Target Volume (CTV).
223658047|NCT05438303|DRUG|Celecoxib|A Celecoxib capsule will be administered once on Day 1 of Treatment Periods 1 and 3
223658048|NCT01475149|OTHER|Phlebotomy|Subjects will have blood drawn at each of the 3 study visits.
223658049|NCT04655989|DEVICE|DBB-EXA ES Hemodialysis System|The DBB-EXA ES Hemodialysis Delivery System is intended to support an optional online priming, rinseback and emergency bolus features. The appropriate priming of the hollow fiber dialyzer and blood tubing lines removes debris and air prior to device use, as well as ensuring proper rinseback.
223658050|NCT04235296|BIOLOGICAL|epidermal growth factor|Residual wounds from the same person were divided into control group and experimental group. The epidermal growth factor is used to control group. Then the foam wound dressing was selected to cover the residual wound, and the dressing was changed every 2 days.
223658051|NCT04235296|BIOLOGICAL|mesenchymal stem cell conditioned medium-derived pleiotropic factor|Residual wounds from the same person were divided into control group and experimental group. The pleiotropic factor is used to control group. Then the foam wound dressing was selected to cover the residual wound, and the dressing was changed every 2 days.
223658052|NCT04609644|OTHER|Digital Tools for Asthma Self-Management|Please see description of active study arm.
223658053|NCT02246465|DRUG|RXI-109|
223658054|NCT00026169|DRUG|imatinib mesylate|Given orally
224240282|NCT01411332|RADIATION|HTIMRT|Dose escalation to the Multiparametric MRI (MP-MRI) by dose painting at 2.35-2.40 Gy per fraction, while the rest of the Clinical Target Volume (CTV) receives 2.0 Gy a fraction to 76 Gy. The hypofractionated targeted (HT) boost region will receive an absolute dose of 89.3-91.2 Gy. Assuming an α/β ratio of 3.0, this would be equivalent to 95.5 Gy in 2.0 Gy fractions.
224240283|NCT03396133|DIAGNOSTIC_TEST|Snap|screen, transmission, and analysis ECG automated
224240284|NCT02218164|DRUG|Pegylated Interferon alpha-2b|Drug administration will occur on an outpatient basis at the infusion center at Moffitt Cancer Center. Dose will be weight-based. Starting treatment doses of 3 mcg/kg will be given subcutaneously (SC) injection in the thigh, abdominal wall, or upper arm every week for a total of 27 weeks as tolerated.
224240285|NCT02218164|DRUG|Capecitabine|Drug administration will be on an outpatient basis. Capecitabine will be administered at an initial dose of 800 mg/m\^2 by mouth twice daily on days 1-14 of a 21 day cycle with days 15-21 off. This cycle will be repeated every 21 days during the study for a maximum of 9 cycles as tolerated. Administration via feeding tube in patients unable to swallow is permitted.
224240286|NCT02218164|DRUG|5-FU|If participants are not able to acquire oral capecitabine, then treating physicians will start participants on infusional 5-FU which can be delivered via standard of care. Participants will need to have a port placed for continuous infusion treatments. 5-FU pumps will be activated in the infusion center at Moffitt Cancer Center with a starting dose of 800 mg/m\^2 days 1-4, with pump removal on day 5 at the infusion center. 5-FU pumps will be attached every 21 days (1 cycle) for a maximum of 9 cycles.
224240287|NCT03709862|DIAGNOSTIC_TEST|Whole Genome Sequencing|Residual DNA from clinical samples will be utilised for whole genome sequencing of Treponema pallidum the causative agent of syphilis
224240288|NCT04183881|DRUG|Brodalumab 210mg SC|210 mg, subcutaneous dosing, every 2 weeks
224240289|NCT06683638|DRUG|Doxycycline 200mg daily for 14 days|Doxycycline will be taken as a single dose of 200mg daily, rather than the current CDC-recommended 100mg twice daily regimen for early syphilis. The duration will still be 14 days of therapy.
224240290|NCT04885127|OTHER|Palliative Care + Digital Symptom Monitoring|Previously described in Arm description
224240291|NCT01190293|DRUG|Maraviroc|All patients (previously on an efavirenz-based therapy) will be administered maraviroc at 600mg twice-daily for 2 weeks.
224240292|NCT05670171|PROCEDURE|Debulking Atherectomy|Excimer laser atherectomy combined with drug-coated balloon angioplasty
224240293|NCT05670171|PROCEDURE|Stent Angioplasty|Nickel-titanium self-expanding bare stent
224240294|NCT07037290|DIAGNOSTIC_TEST|Ankle proprioceptive neuromuscualar facilitation technique|Proprioceptive Neuromuscular Facilitation (PNF) is a therapeutic technique that uses sensory input to enhance muscle function and improve flexibility. For the ankle, PNF techniques can be used to increase range of motion, improve balance and stability, and reduce pain associated with ankle injuries.
224240295|NCT07037290|DIAGNOSTIC_TEST|Foot core exercises along with conventional physiotherapy|This Group will be given foot core exercises which includes heel raise, toe curls, foot doming, toe spreading, balancing board, and tennis ball roll under foot along with conventional therapy which includes ultrasound, plantar fascia stretching and Achilles stretching.
224240296|NCT07036393|OTHER|Acupuncture|"Cholecystectomy involves a procedure where patients' spines are kept in position and skin around the acupoints is disinfected with 75% alcohol. Acupuncture treatment is given when patients return to units within 2 hours after surgery. The needles are inserted using disposable sterile needles and manipulated to induce a sense of De qi (soreness, numbness, distension, or heaviness). Gastrectomy involves daily acupuncture sessions for 5 consecutive days, starting on postoperative day 1. The needles are inserted perpendicular to the acupoints in the extremities to a depth of approximately 20 mm from the skin surface."
224240297|NCT07036393|OTHER|Transcutaneous electrical nerve stimulation|Patients will receive a transcutaneous electrical nerve stimulation unit (ENNRAF) for up to 48 hours post-surgery, with instructions to self-titrate intensity for pain relief. Postoperative stimulation will be 20-40 milliampere and pulse width 5
224240298|NCT07036393|OTHER|drugs|analgesics and nonsteroidal anti-inflammatory drugs
224240299|NCT07036432|DEVICE|Endosign|"The intervention involves the EndoSign® Cell collection device (Cyted Ltd), a non-endoscopic method for esophageal sampling.~Patients swallow a gelatine/HPMC capsule containing a sponge attached to a string. After \~7 minutes in the stomach for dissolution and sponge expansion, a trained nurse withdraws the sponge via the string, collecting cells. Optional throat anesthetic is offered.~It can be performed without sedation in an outpatient clinic setting by a nurse. Samples undergo central analysis for TFF3, atypia, and p53, differing from standard biopsy histopathology. This study specifically evaluates its feasibility, acceptability, and nurse-led implementation in Swedish hospitals for Barrett's surveillance."
224240300|NCT07035509|BIOLOGICAL|Pharmaceutical fresh frozen plasma|OCTAPLAS LG® has been registered with INVIMA in Colombia for five years and is used as a plasma replacement in cardiac surgery, hematologic diseases, or intensive care settings where blood bank plasma is unavailable
224321127|NCT02794870|BIOLOGICAL|Placebo|Isotonic diluent, administered as nose drops
223658055|NCT00026169|OTHER|laboratory biomarker analysis|Correlative studies
223658056|NCT00026169|OTHER|pharmacological study|Correlative studies
223658057|NCT00000921|DRUG|Prednisone|
223658058|NCT01233232|DRUG|Placebo|Oral dose bid
223658059|NCT01233232|DRUG|AZD5069 50mg|Oral dose bid
223768647|NCT07172906|BEHAVIORAL|"Patients of Group A and B both are filling out the Mini Nutritional Asessment questionnaire"|This questionnaire will be completed by patients in both groups. The aim of this questionnaire is to assess the nutritional status of the patients, their level of nutrition and appetite for food, and the potential risk of malnutrition.
224240301|NCT07035509|DRUG|Normal Saline|Bolus dose of 10 mL/kg normal saline (NS) (max. 500 mL) administered over \<15 minutes.
224240302|NCT07035509|DRUG|Ringer lactate (RL)|Bolus dose of 10 mL/kg Ringer's lactate (max. 500 mL) administered over \<15 minutes.
224321128|NCT06619106|OTHER|Cognitive test|Cognitive test based on building blocks
224321129|NCT05545124|DRUG|Donafenib + Tislelizumab|Donafenib 100mg, BID+Tislelizumab 200mg, D1; q3w
223658060|NCT01233232|DRUG|AZD5069 80mg|Oral dose bid
223658061|NCT05522491|DRUG|Olaparib|All subjects enrolled will receive olaparib.Subjects continued to take medication until disease progression, unacceptable toxicity, withdrawal of informed consent, or discontinuation of medication at the discretion of the investigator.
223658062|NCT02470000|DEVICE|Intravascular laser irradiation of blood (ILIB)|continuous-wave ILIB is performed using a 632.8nm (red light) laser beam from a He-Ne laser machine (Y-J ILIB-5, Bio Human Energy Cooperation, New Taipei City, Taiwan, R.O.C.).The participants sit on a sofa with their arms relax and supported on the table. A 24-gauge catheter is inserted to a superficial vein in upper extremity under sterile preparation, and an optic fiber channel is connected to the catheter for blood irradiation.
224240303|NCT07035483|PROCEDURE|bariatric surgery|This is a prospective observational study evaluating the metabolic and tissue-level effects of bariatric surgery in obese individuals. The intervention includes either laparoscopic sleeve gastrectomy (LSG) or Roux-en-Y gastric bypass (RYGB), performed according to standard clinical guidelines. No experimental procedures are added beyond routine care. Skeletal muscle quality and visceral fat distribution are assessed using MRI and clinical biomarkers at multiple postoperative time points (baseline, 3 months, 12 months, and annually up to 5 years). A healthy control group undergoes baseline evaluation only, without surgical intervention.
224240304|NCT07037407|PROCEDURE|IOS|Intra oral scanning
224240305|NCT07037407|PROCEDURE|WTI|window technique Impression
224240306|NCT07035444|DIETARY_SUPPLEMENT|L-Carnitine 4g|500ml enteral nutrition solution containing 4g of L-carnitine
224240307|NCT07035444|DIETARY_SUPPLEMENT|Enteral Nutrition|Enteral nutrition was given 500 ml per day for a total of 84 days.
224240308|NCT07036276|BEHAVIORAL|Co-adapted intervention|An existing co-created intervention will be adapted by researchers and 7th and 8th grade pupils and teachers during 3 to 5 design sessions in both co-adaptation intervention schools.
223658063|NCT02470000|DEVICE|Transcutaneous electrical nerve stimulation|TENS over neck for 15 minutes.
223658064|NCT02470000|OTHER|Stretching exercise|stretching exercise to the involved muscle for 15 minutes.
223658065|NCT03722277|OTHER|Variable load training|Based on symptoms/strength measured in an isometric maximum strength test at five different angles of knee flexion- and extension, participants will be training with variable load during both concentric and excentric phase of the dynamic movement. Initially participants will start at 40% of symptom limited isometric strength, this will increase to 50% during the training period.
223658066|NCT03722277|OTHER|Conventional strength training|Conventional strength training with rubber bands in knee flexion- and extension, additionally hip abduction- and adduction.
223658067|NCT02762370|DRUG|FX006 32 mg|Single 5 mL IA injection
223658068|NCT02762370|DRUG|TCA IR 40 mg|Single 1 mL IA injection
223658069|NCT06017037|DRUG|Citalopram 20mg|Citalopram 20mg tablets, encapsulated to aid blinding. To take per oral once daily for 7-9 days
223658070|NCT06017037|DRUG|Placebo|Lactose monohydrate tablets encapsulated to aid blinding. To take per oral once daily for 7-9 days
223658071|NCT03500224|DRUG|[14C]-TAK-954|\[14C\]-TAK-954 intravenous infusion.
223658072|NCT04181125|OTHER|Biodex Balance System|For the computerized evaluation of postural control, Biodex Balance System will be used.
223658073|NCT04181125|OTHER|Balance Error Scoring System (BESS)|For the clinical evaluation of postural control, the Modified Balance Error Scoring System (BESS) will be used.
223658074|NCT00268853|DRUG|CPOP-R|Cyclophosphamide 750 mg/m2, pixantrone 150 mg/m2, vincristine 1.4 mg/m2, rituximab 375 mg.m2 on Day 1 of a 21 day cycle, for 8 cycles Prednisone 100 mg/day on Day 1-5 of a 21 day cycle for 8 cycles
223658075|NCT00268853|DRUG|CHOP-R|Cyclophosphamide 750 mg/m2, doxorubicin 50 mg/m2, vincristine 1.4 mg/m2, rituximab 375 mg.m2 on Day 1 of a 21 day cycle, for 8 cycles Prednisone 100 mg/day on Day 1-5 of a 21 day cycle for 8 cycles
223658076|NCT06237478|DRUG|Glycopyrrolate|At the timepoint of 10 min after operation beginning (T1), the basic HR, MAP and the HRV frequency indexes were recorded. Then glycopyrrolate 0.006 mg/kg was injected intravenously in Group L.
223658077|NCT06237478|DRUG|Glycopyrrolate|At the timepoint of 10 min after operation beginning (T1), the basic HR, MAP and the HRV frequency indexes were recorded. Then glycopyrrolate 0.006 mg/kg was injected intravenously in Group H.
224240309|NCT07036276|BEHAVIORAL|Standard intervention|The existing co-created intervention will be implemented in the standard intervention schools. So, adolescents and school staff from the standard intervention schools will not be involved in adapting the intervention.
224240310|NCT06904508|BEHAVIORAL|Facing Your Fears (FYF) Intervention: A CBT Focused Group Treatment for Autistic Youth with Anxiety|FYF is an outpatient, multi-family, evidence-based CBT group treatment for children and adolescents ages 8-14 with average intellectual abilities, and a primary co-occurring anxiety diagnosis (social, generalized, separation anxiety, or specific phobia).
223658078|NCT00528697|DRUG|ABT-089|Subjects will take 0.5 and 1 and/or 5 and/or 10 mg ABT-089 tablets (actual dose based on weight) once daily for 8 weeks.
223658079|NCT00528697|DRUG|atomoxetine|Subjects will take 10, and/or 18 and/or 25 mg atomoxetine tablets once daily for 8 weeks.
223658080|NCT00528697|DRUG|placebo|Subject will take a tablet once daily for 8 weeks
223658081|NCT01167244|DRUG|BMS-690514|Tablets, Oral, 200 mg, once daily, until disease progression or toxicity
223658082|NCT00713297|BEHAVIORAL|satisfaction questionnaire|Satisfaction questionnaire
223658083|NCT00500214|PROCEDURE|elective ilioinguinal nerve excision|
224240311|NCT06907966|BEHAVIORAL|Engaging Families home practice app|"The intervention is a smartphone application (or app) that was developed to support caregiver home practice of intervention skills. The app was designed to support caregivers participating in the Bridges program, an evidence-based, family-based preventive intervention. Features of the app were developed to help caregivers overcome common barriers to practicing intervention skills at home."
224321130|NCT02652611|PROCEDURE|SI Screw Removal Surgery|
223658084|NCT01324401|DRUG|Peanut flour OIT|Patients will receive daily escalating dosages (Peanut flour OIT) as determined in the modified rush phase as stated in the protocol. The dosage will be escalated until a daily dose of 4000 mg is reached. A Double-blind, placebo-controlled food challenge will then consist of two challenges performed on the same day. One challenge will consist of 7 doses of peanut given every 10-20 minutes in increasing amounts up to a total of 10 grams of whole peanut (5 grams of peanut protein) masked by inclusion in vehicle food. The other challenge will consist of placebo material given similarly.
223658085|NCT01885585|DRUG|Apixaban|
223658086|NCT05969847|RADIATION|split-course hypofraction radiotherapy|After reaching a cumulative radiotherapy dose of 25Gy in the entire pelvic cavity (PTV1), the treatment field was subsequently narrowed to solely focus on the primary tumor (PTV2), with a total dose of 35Gy administered. All patients will undergo fractionated radiotherapy, following a regimen of 7Gy per fraction, delivered every 3 weeks for five cycles.
223658087|NCT05969847|DRUG|CAPOX|Drug: Oxaliplatin,130mg/m2，ivgtt，d1,for 6 cycles. Drug: Capecitabine,1000mg/m2，po，bid，d1-14, for 6 cycles.
223658088|NCT05969847|DRUG|Envafolimab|Envafolimab is administered by subcutaneous injection. The recommended dose is 300 mg per 3 weeks (Q3W) for 6 cycles.
223658089|NCT05969847|PROCEDURE|Local excision|Local full-thickness resection is employed for patients with clinical complete response (cCR) or near-clinical complete response (ncCR) following TNT.
223658090|NCT03574181|OTHER|Smartwatch to measure Blood Alcohol Level (BAL)|Subjects will wear a wristwatch with a sensor that measures blood alcohol level during a 1-hour period of consuming alcohol followed by a 5 hour observation period.
223658091|NCT03233321|OTHER|Dry cold application|Dry cold application using ice bag (Crushed ice was filled in ice bag with ½ table spoon of salt and then covered by clean linen to prevent moisture) was placed over the injection site for about 20 minutes.
223658092|NCT03233321|OTHER|sub cutaneous injection (low molecular weight heparin)|sub cutaneous injection (low molecular weight heparin) has been administered on injection site
223658093|NCT00522899|BEHAVIORAL|Group 1|Aerobic exercise plus computer-based mental activity training: both 3 days/week, 60 minutes/session for 12 weeks.
223658094|NCT00522899|BEHAVIORAL|Group 2|Aerobic exercise plus educational DVDs: both 3 days/week, 60 minutes/session for 12 weeks.
223658095|NCT00522899|BEHAVIORAL|Group 3|Stretching/toning exercise group plus computer-based mental activity training: both 3 days/week, 60 minutes/session for 12 weeks.
223658096|NCT00522899|BEHAVIORAL|Group 4|Stretching/toning exercise group plus educational DVDs: both 3 days/week, 60 minutes/session for 12 weeks.
223658097|NCT04121585|DEVICE|Total Hip Arthroplasty|Total Hip Arthroplasty using the SL-PLUS™ hydroxylapatite coated cement free hip stem
223658098|NCT01586130|OTHER|Exercise in eccentric or concentric mode|In this therapeutic field, isokinetic exercises seem to have a better efficiency than other, more frequently used, kinds of exercises such as isometric or isotonic exercises.
223658099|NCT04021693|OTHER|Handheld Ultrasound Devices|Interns in the handheld ultrasound device arm shall carry a personal handheld ultrasound device to be used for self-directed learning
223658100|NCT01122121|DRUG|Leuprorelin SR|Leuprorelin SR injection
223658101|NCT01122121|RADIATION|Radiotherapy|Radiotherapy 70 +/- 4 Gy
223658102|NCT01122121|DRUG|Flutamide|Flutamide tablets
223658103|NCT01708902|DRUG|linagliptin2.5mg/metformin1000mg|linagliptin2.5mg/metformin1000mg BID
223658104|NCT01708902|DRUG|linagliptin2.5mg/metformin1000mg|linagliptin2.5mg/metformin1000mg BID
223658105|NCT01708902|DRUG|linagliptin 5mg|linagliptin 5mg once daily
223768648|NCT07172906|BEHAVIORAL|"Patients of Group A and B both are filling out Nottingham Health Profile Scale questionnaire"|This questionnaire will be completed by patients in both groups. The aim of this questionnaire is to assess the subjective discomfort of the individual with health problems as well as the extent to which these problems affect their normal activities.
223658106|NCT01708902|DRUG|Metformin 500mg|Metformin 500mg BID
223768649|NCT07172906|BEHAVIORAL|"Patients of Group A and B both are filling out the Cardiovascular Diet Questionnaire-2"|This questionnaire will be completed by patients in both groups. The aim of this questionnaire is to assess the dietary choices of patients with cardiovascular diseases, such as the patients in this study.
224240312|NCT06907966|OTHER|Scheduling app|The Cozi Family Organizer is a smartphone application that will be given to caregivers randomized to the active control group. Cozi is a highly rated family organization app with features that include a family calendar, to do list, shopping list, and daily agenda. Cozi is available on Android and iPhone devices.
224321131|NCT02652611|PROCEDURE|Non-screw removal treatment (non-operative management)|
223658107|NCT01708902|DRUG|linagliptin2.5mg/metformin500mg|linagliptin2.5mg/metformin500mg BID
223658108|NCT01708902|DRUG|linagliptin2.5mg/metformin500mg|linagliptin2.5mg/metformin500mg BID
223658109|NCT01708902|DRUG|linagliptin 5mg|linagliptin 5mg once daily
223658110|NCT01708902|DRUG|Metformin 1000mg|Metformin 1000mg BID
223658111|NCT00224640|DRUG|Iron chelating intervention|Iron chelating intervention
223658112|NCT00725062|BIOLOGICAL|CD4+CD25+ regulatory T cells|Cohort 1 will receive 3 x 10\^6 CD4+CD25+ cells/kg, Cohort 2 will receive 1 x 10\^7 CD4+CD25+ cells/kg, Cohort 3 will receive 3 x 10\^7 CD4+CD25 cells/kg
223658113|NCT00725062|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Occurs on Day 0 of study - HLA-identical sibling donor peripheral blood progenitor cell (PBPC) transplantation
223658114|NCT03699215|DRUG|Levosimendan|Upon arrival of the patient in the Coronary Unit, he will receive, in a randomized and double-blind manner, the 24-hour infusion of Levosimendan, without a loading dose, at a dose of 0.1 μg / kg / min or placebo. If the initial dose is tolerated and a greater hemodynamic effect is needed, the infusion rate can be increased to 0.2 micrograms / kg / min. The dose of Levosimendan infusion can be reduced to 0.05 μg / kg / min in case of clinical intolerance or systolic hypotension \<90 mmHg.
223658115|NCT03699215|DRUG|Placebos|continuous perfusion of 0.1 micrograms / kg / min for 24h. If the initial dose is tolerated and a greater hemodynamic effect is needed, the infusion rate can be increased to 0.2 micrograms / kg / min.
223658116|NCT06326333|PROCEDURE|Combined parasternal block and serratus anterior plane block|"The first PSB will be applied to the patients with 7.5 ml of 0.25% bupivacaine under real-time ultrasound guidance at the level of the second intercostal space.~The second PSB will be applied to the patients with 7.5 ml of 0.25% bupivacaine under real-time ultrasound guidance at the level of the fourth intercostal space.~The SAPB will be applied to the patients with 10 ml of 0.25% bupivacaine under real-time ultrasound guidance at the level of the sixth rib in the anterior axillary line.~The block applications will be applied bilaterally."
223658117|NCT00422682|DRUG|bsi-201 + topotecan|21 day cycle
223658118|NCT00422682|DRUG|bsi-201 + temozolomide|28 day cycle
223658119|NCT00422682|DRUG|bsi-201 + gemcitabine|28 day cycle
223658120|NCT00422682|DRUG|bsi-201 + carboplatin/paclitaxel|21 day cycle
223658121|NCT04803240|DEVICE|Thealoz Duo|Non applicable
223658122|NCT01779258|DRUG|glycerol, paraffin (liquid and white soft)|1 application in the morning and in the evening
223658123|NCT01779258|DEVICE|Atopiclair®|1 application in the morning, in the afternoon and in the evening
223658124|NCT01779258|DRUG|Locatop@|"During the Run-In period:~1 application in the morning and in the evening during a maximum of 21 days"
223658125|NCT01779258|DRUG|Locapred@|"During the 3 months study treatment:~1 application in the evening in case of flare "
223658126|NCT01281332|DEVICE|Menopod|The mechanism of action of the device will not be revealed in advance.
223658127|NCT01281332|DEVICE|Inactive device|
223768650|NCT07172906|OTHER|Measurement of patient somatometric characteristics|Measurement of body weight, Body Mass Index, Fat and Water Percentage, Chest, Waist and Hip Circumference of patients using a tape measure and electronic scale-lipometer. Also, measurement of bloodless blood pressure and fasting glucose.
223768651|NCT07172906|BEHAVIORAL|Nutritional education and discussion with group B patients|Nutritional education using an information leaflet, e-mails and telephone calls to patients in group B only. Discussion regarding their dietary choices before surgery, identification of wrong habits and efforts to improve them afterwards. It will concern all the basic categories of healthy eating (preference for fruits, vegetables, proteins, healthy carbohydrates, reduction of saturated fat, salt and sugar and information about nutritional labels and how to choose foods according to them). The goal is for patients who will receive this education to improve their measurements in repeat meetings with the researcher, compared to those who will not be informed.
223768652|NCT07172269|DRUG|Sitagliptin + Metformin|Oral tablets, 50/1000 mg, taken twice daily after meals for 12 weeks
223768653|NCT07172269|DIETARY_SUPPLEMENT|mangosteen supplement|Capsules, 500 mg, taken twice daily after meals for 12 weeks
223768654|NCT07172269|BEHAVIORAL|Lifestyle Management|Diabetes education, diet counseling, and exercise guidance provided throughout the 12-week study period.
223658128|NCT05306808|OTHER|physiotherapy class|The supervised 1-hour group exercise class will be conducted twice a week, with a maximum of 8 patients in each class. Subjects will be given a home log for exercise recording. If subjects are unable to attend exercise class for any reason (eg., low counts or feeling unwell, etc.), they will be advised to continue xercises at home. On the day of one of the exercise classes each week, there will be an additional 1-hour group education/ discussion session which may be conducted by PT, OT, APN, dietician or medical social worker. Topics covered will include physical activity, management of fatigue, lymphoedema, neuropathy, brain fog, return to work, stress, nutrition, sexuality, psychosocial and caregiver issues. There will be 10 sessions of educational class in total for each subject.
223658129|NCT00357279|DRUG|denufosol tetrasodium (INS37217) Inhalation Solution|Denufosol 60 mg is administered as an inhalation solution, three times daily for six months during the double-blind portion of the study. Subsequently, denufosol 60 mg is administered for an additional six months during the open label safety extension.
223658130|NCT00357279|DRUG|Placebo - 0.9% w/v sodium chloride solution|4.2 mL of solution, allowing delivery of approximately 4 mL into the nebulizer cup for nebulization, three times daily for six months.
223658131|NCT00442364|DRUG|Polidocanol (1%) Microfoam (Varisolve)|Varisolve polidocanol 1% microfoam, maximum of 20ml injected into affected great saphenous vein.
223768655|NCT07172997|PROCEDURE|Bariatric Surgery|A surgical procedure used to manage obesity and obesity-related conditions.
223768656|NCT07172750|OTHER|Education on Urinary Catheter Care|"Urinary catheter care training based on the Roper, Logan, and Tierney Lifestyle Model was developed based on daily living activities.~A training booklet was created based on 11 daily living activities (providing and maintaining a safe environment, communication, breathing, nutrition, etc.).~To increase the effectiveness of the training, a booklet based on this model will be prepared and used as a guide in the training program."
223768657|NCT07174375|DRUG|PCSK9 inhibitor|PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) inhibitors are a class of monoclonal antibody drugs that lower low-density lipoprotein cholesterol (LDL-C) by inhibiting the PCSK9 protein, which increases the liver's ability to remove LDL-C from the blood. This intervention involves the use of established PCSK9 inhibitor agents.
223768658|NCT07172568|PROCEDURE|Blood Flow Restriction|In the intervention group, 50% of limb occlussion pressure are applied to the extremity during exercises.
223768659|NCT07172568|PROCEDURE|sham-Blood Flow Restriction|In the control group, 20 mmHg are applied to the extremity during exercises.
223768660|NCT07173712|DRUG|CSII followed by iGlarLixi|Short term intensive insulin therapy followed by Insulin Glargine and Lixisenatide Injection(iGlarLixi) for 24 weeks. After then, participants continue with the current treatment or downgrade to the original treatment before enrollment for 24 weeks based on their own will. The total follow-up period was 48 weeks.
224240313|NCT05271539|DRUG|Lucentis alone group|The Lucentis alone group received 3 monthly intravitreal injections of lucentis alone or less than 3 injections if the central foveal thickness reached 250 microns
224240314|NCT05271539|DRUG|Lucentis dexamethasone group|Lucentis dexamethasone group received intravitreal injections of combination of both lucentis and commercial dexamethasone. the second group received monthly intravitreal injections of the same dose of ranibizumab combined with 0.4 mg in 0.1 ml dexamethasone (Dexamethasone sodium phosphate, Amriya Pharmaceuticals, Cairo, Egypt) in a separate 1ml syringe with 27- gauge × ½ inch sterile injection needle, followed by 2 Intravitreal ranibizumab, 1 month apart (with dexamethasone if follow up OCT shows less than 10% improvement from baseline i.e., PRN). Treatment was stopped when CMT improved below 250 µ.
224240315|NCT04526210|DRUG|ALXN1840|ALXN1840 will be administered orally as a single dose as 4 x 15 mg enteric-coated tablets with 240 milliliters of water (fasting), for a total dose of 60 mg.
224240316|NCT04526210|DRUG|Bupropion Hydrochloride|Bupropion hydrochloride will be administered orally as a single dose as one 150 milligrams (mg) tablet with 240 milliliters of water (fasting).
224240317|NCT05471817|DRUG|Elinzanetant (BAY3427080)|Capsule, oral, single dose
223658132|NCT00442364|PROCEDURE|Endovenous Microfoam Occlusion|Varisolve® polidocanol microfoam injection under duplex guidance to fill proximal and distal great saphenous vein and varicose tributaries.
223658133|NCT00217178|DRUG|Vitamins: Folic acid, B6, B12|
224240318|NCT05471817|DRUG|Dabigatran etexilate|Capsule, oral, single dose
224240319|NCT05031884|DEVICE|MGIR3-US|MGIR3-US is an remote scanning robot which can do ultrasonic examinations.
224240320|NCT02637232|OTHER|Mirvaso® / Onreltea TM|
223658134|NCT02633020|BIOLOGICAL|AMG 714|Administered via a 120-minute IV infusion for a total of 7 times over 10 weeks.
224240321|NCT05554809|OTHER|Strecthing|Comparing the crossover-effect of dynamic versus static stretching
224240322|NCT01308593|DEVICE|Juvederm XC|Filler
224240323|NCT01308593|DRUG|Botox|26 units dosed one time
224240324|NCT01781637|DRUG|Omalizumab|subcutaneous injection
224240325|NCT01781637|DRUG|placebo|subcutaneous injection
224240326|NCT04983706|PROCEDURE|MRI/Ultrasound Fusion Saturation Biopsy|MRI/Ultrasound fusion saturation biopsy: the core number and location are designed according to the lession condition.
224240327|NCT00090857|DRUG|Letrozole|
224321132|NCT02237092|PROCEDURE|Measurement of IAP|The level of intra-abdominal pressure was measured via a Foley catheter through the urinary bladder. After the introduction of a 30 mL of warm saline. Measurement of the water column in the system was made from the zero level to the mid-axillary line, for 10 minutes, after quiet breathing pregnant at the time of expiration.
224321133|NCT04172597|DRUG|Poziotinib Hydrochloride|The poziotinib drug substance is a hydrochloride salt of poziotinib and is formulated as a tablet for oral administration.
224321134|NCT04172597|DRUG|Loperamide|Loperamide as prescribed by the physician.
224321135|NCT01542151|OTHER|Time of labor induction|Assigned time of labor induction - morning or evening
224321136|NCT00794339|DRUG|64Cu-ATSM|
224321137|NCT00794339|DRUG|FDG|
223658135|NCT02633020|BIOLOGICAL|Placebo|Administered via a 120-minute IV infusion for a total of 7 times over 10 weeks.
223658136|NCT01573234|DEVICE|MySkin patch|Hydrogel and polyurethane film
223658137|NCT01573234|DEVICE|Gauze and Patch|Traditional Dressing
223658138|NCT00530816|DRUG|carfilzomib|Intravenous (IV) injection over 2 to 10 minutes twice weekly for three weeks followed by 12 days of rest.
223658139|NCT00003206|DRUG|carboplatin|
223658140|NCT00003206|DRUG|paclitaxel|
223658141|NCT04801056|DRUG|TB006|TB006 monoclonal antibody
223658142|NCT04801056|OTHER|Placebo|Placebo i.v. infusion
223658143|NCT03791944|DEVICE|3DV+TPS/VARIAN|Use imported 3DV+TPS to map targets and develop treatment plans
223658144|NCT03791944|DEVICE|TPS / VARIAN|Use imported TPS to map targets and develop treatment plans
223658145|NCT03791944|DEVICE|3DV + TPS / Domestic Accelerator|Use domestic 3DV+TPS to delineate target areas and develop treatment plans
223658146|NCT03791944|DEVICE|TPS / Domestic Accelerator|Use domestic TPS to map targets and develop treatment plans
223658147|NCT04473287|OTHER|reflexology practice|Reflexology is a reliable and holistic complementary and alternative treatment method that means that the body's specific glands, organs and regions are stimulated by applying a special pressure with the fingers on the hands, feet and ears. When the literature is analyzed, it has been determined that reflexology is applied effectively before, during and after surgery, including different surgical procedures, and it is emphasized that one of the most important areas is patients who underwent Coronary Artery Bypass Graft (CABG) surgery. In this study, it is thought that reflexology application to patients undergoing CABG surgery on nursing care will contribute to the nursing literature by examining the effect of reflexology on pain, anxiety, fatigue, sleep and physiological parameters.
223768661|NCT07173712|DRUG|CSII followed by IDegAsp|Short term intensive insulin therapy followed by Insulin Degludec and Insulin Aspart Injection(IDegAsp) for 24 weeks. After then, participants continue with the current treatment or downgrade to the original treatment before enrollment for 24 weeks based on their own will. The total follow-up period was 48 weeks.
223768662|NCT07173712|DRUG|CSII followed by iGlar+MET|Short term intensive insulin therapy followed by Insulin Glargine Injection(iGlar） plus metformin 0.5g tid for 24 weeks. After then, participants continue with the current treatment or downgrade to the original treatment before enrollment for 24 weeks based on their own will. The total follow-up period was 48 weeks.
224240328|NCT00090857|OTHER|Placebo|
224240329|NCT02977026|BEHAVIORAL|CYD|
224240330|NCT02977026|BEHAVIORAL|AHC|
224240331|NCT00458848|DRUG|asparaginase|
224240332|NCT00458848|DRUG|daunorubicin hydrochloride|
224240333|NCT00458848|DRUG|etoposide|
224240334|NCT00458848|DRUG|idarubicin|
224321138|NCT01611857|DRUG|Tivantinib|Patients with advanced solid tumors will be treated with oral Tivantinib (120, 240, or 360 mg BID) daily for 14 days in cycles of 14 days.
224321139|NCT01611857|DRUG|FOLFOX|The FOLFOX treatment regimen is started on Day 1 of each cycle and consists of 5-Fluorouracil (5-FU) 400 mg/m\^2, 5-FU continuous IV 2400 mg/m\^2 over 46 hours, leucovorin 400 mg/m\^2 IV, and oxaliplatin 85 mg/m\^2.
224321140|NCT06399575|OTHER|Apnea Following Isocapnic Hypoxia|Decreasing end-tidal partial pressure of oxygen to 50 mmHg for five minutes, targeting 80-85% peripheral oxygen saturation. The end-tidal partial pressure of carbon dioxide will remain +1 mmHg above baseline levels. After five minutes of hypoxia, participants will complete an apnea.
223658148|NCT01136785|DEVICE|active CPAP Therapy|7 days of active CPAP therapy
223658149|NCT01136785|DEVICE|sham CPAP therapy|7 days of sham CPAP therapy
224240335|NCT00458848|DRUG|imatinib mesylate|
224240336|NCT00458848|DRUG|mercaptopurine|
224240337|NCT00458848|DRUG|methotrexate|
224240338|NCT00458848|DRUG|methylprednisolone|
224240339|NCT00458848|DRUG|mitoxantrone hydrochloride|
224240340|NCT00458848|DRUG|prednisone|
224240341|NCT00458848|DRUG|vincristine sulfate|
224240342|NCT00458848|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
224240343|NCT00458848|PROCEDURE|autologous hematopoietic stem cell transplantation|
224240344|NCT00458848|PROCEDURE|peripheral blood stem cell transplantation|
224240345|NCT00458848|RADIATION|radiation therapy|
224240346|NCT06219473|DRUG|Fascia lata membrane|novel allogenic derived acellular matrix produced from human fascia lata allograft
224240347|NCT06219473|DRUG|Platlet Rich fibrin membrane|Platelet-rich fibrin (PRF) or leukocyte- and platelet-rich fibrin (L-PRF) is a derivative of PRF where autologous platelets and leukocytes are present in a complex fibrin matrix to accelerate the healing of soft and hard tissue
224240348|NCT06219473|DRUG|subepithelial connective tissue graft|The connective tissue is generally taken from the hard palate, although it may be taken from other sites as well, such as the maxillary tuberosity area.
224240349|NCT00917657|PROCEDURE|Photorefractive keratectomy|
224240350|NCT05097326|DRUG|Mifepristone|Mifepristone 200mg taken orally
224240351|NCT05097326|DRUG|Misoprostol|Misoprostol 50 mcg taken orally, and may receive additional doses of misoprostol 50 - 100 mcg as needed
224240352|NCT06158516|DRUG|Surufatinib|Surufatinib 300 mg once a day (QD) will be orally administrated on a 28-day cycle
224240353|NCT06158516|DRUG|Placebo|Placebo 300 mg once a day (QD) will be orally administrated on a 28-day cycle
224240354|NCT06264024|PROCEDURE|Corneal collagen cross linking (CXL)|Use of Avedro Inc. KXL 1 system to stop progression of keratoconus
223658150|NCT04834089|BIOLOGICAL|AntiSARS-CoV-2 Serum|Stage A: 30 kidney transplanted participants (very high risk), where 15 will received 1 vial (5 mL) and 15 will received 2 vials (10 mL) of serum; Stage B: 30 immunocompetent participants with at least 2 risk factors for severe disease (high risk) who will receive the dose selected by stage A; Stage C: 558 participants, of very high risk and high risk, compared with placebo in allocation 2:1.
223658151|NCT04834089|OTHER|Placebo|Saline solution Administration Route: Intravenous
223658152|NCT05094778|PROCEDURE|a single-portal palm approach|a single-portal palm approach that passes superficially to palmar aponeurosis, and cut the full transverse carpal ligament.
223658153|NCT02850471|DEVICE|electroacupuncture|Transcutaneous Electric Acupoint Stimulation which is a device of electroacupuncture was used on patients in TEAS group with the stimulator parameters set as 2/100Hz, 2V, 30min.
223658154|NCT05444595|BEHAVIORAL|Behavioral plant-based dietary intervention|Participants will meet with community health workers to receive information focused on healthy eating and consuming a traditional plant-based diet in a group format for the first few months followed by individual check-ins.
223658155|NCT05444595|BEHAVIORAL|Standard care|Participants will meet with community health workers to receive general health information through individual check-ins.
223658156|NCT05430633|PROCEDURE|Appendectomy|Appendectomy - laparoscopic or open
223658157|NCT00800254|DEVICE|Neuromuscular Electrical Stimulation (NMES)|NMES 20 minutes twice a day for 6 weeks plus standard physical therapy
223658158|NCT00800254|OTHER|Standard Rehabilitation Protocol|Standard physical therapy for 8 weeks after surgery
223658159|NCT02922478|RADIATION|X-ray of the spine|Every participant will undergo X-ray of the spine so that vertebral fractures can be quantified using the Genant score.
223658160|NCT02922478|PROCEDURE|Ambulatory blood pressure monitoring (ABPM)|ABPM will be performed using the brachial, oscillometric, automated self-measurement mobil-O-Graph device (I.E.M. GmbH, Stolberg, Germany) with integrated ARCSolver®-Software (Austrian Institute of Technology Wien).
223658161|NCT02922478|RADIATION|Dual X-ray absorptiometry|Individual bone mineral density and T-Score will be determined by X-ray absorptiometry.
223658162|NCT02922478|PROCEDURE|Non-invasive procedures|Other non-invasive study procedures include structured patient interview, sampling of blood, buffy coat and spot urine (including biobanking), electrocardiogram, pulse wave velocity and analysis, transthoracic echocardiography, 4-meter gait speed test, hand grip test, questionnaires
223658163|NCT03399201|PROCEDURE|General anesthesia|induction with the intravenous anesthetic (Propofol) and maintenance with the inhalational anesthetic (Sevoflurane)
224321141|NCT03523299|PROCEDURE|Cryoablation|Cryoablation is a non-surgical, minimally invasive freezing procedure used to destroy tumors. In the breast, cryoablation is performed under ultrasound guidance. Due to the analgesic properties of freezing, no IV sedation or anesthesia is required. After administration of local anesthetic, the physician makes a 2-3 mm incision and inserts needle-like cryoprobes into the tumor, commencing a number of freeze-thaw cycles. Then the probe is removed, pressure is applied to the area, and a bandage is placed. The patient leaves the office without stitches and minimal, if any, pain. Any residual pain after the procedure is routinely treated with over the counter analgesics such as acetaminophen.
224321142|NCT01573299|OTHER|Mobilization of stroke patients|"In the first group (early vertical positioning)the patient can sit outside of the bed, the day after stroke onset. In the second group (progressively vertical positioning), the patient is progressively verticalised and is allowed to sit outside of the bed on the third day after the stroke onset."
223658164|NCT03399201|PROCEDURE|Neuraxial anesthesia|Spinal anesthesia will be applied via the local anesthetic ( Bupivacaine).
224321143|NCT02759393|DRUG|Dexlansoprazole|receiving 8-week PPI
224321144|NCT02759393|DRUG|Lansoprazole|receiving 8-week PPI
223658165|NCT03399201|DIAGNOSTIC_TEST|Spirometer|Pulmonary function will be evaluated via the portable spirometer (MIR Spirodoc, Spirodoc®, Roma, Italy)
223658166|NCT06230211|OTHER|Music Therapy|Effect of Maternal Voice and Music Therapy on Pain and Physiological Parameters During the Suction Procedure in Intubated Children: Randomized Controlled Study
223768663|NCT07173335|BEHAVIORAL|In-person physiotherapist led integrated healthy lifestyle and pain care|"Participants allocated to in-person intervention will be offered:~A) Up to four in-person physiotherapist consultations (up to one hour in duration) over 12 weeks (weeks 1, 3, 6, and 12);~B) Tailored pain education and healthy lifestyle education and resource bundles, including video content, web resources and interactive tools sent to participants via email or text;~C) Referral to telephone-based population wide health behaviour change support services, the NSW Get Healthy Coaching and information service and the Quitline for smokers, by the week 12 consultation (up to 6 telehealth consultations).~Total = up to 10 consultations over 6 months."
224240355|NCT06264024|PROCEDURE|Transepithelial phototherapeutic keratectomy (t-PTK)|Use Alcon Wavelight 500, excimer laser to remove the epithelium and some of the stroma over apex
223658167|NCT06230211|OTHER|Maternal Voice|Effect of Maternal Voice and Music Therapy on Pain and Physiological Parameters During the Suction Procedure in Intubated Children: Randomized Controlled Study
223658168|NCT01388985|BIOLOGICAL|Human Diploid Cell Vaccine (HDCV) rabies vaccine|Human Diploid Cell Vaccine (HDCV) rabies Merieux 1 ml vaccine for rabies, provided by Sanofi-Pasteur, administered zvia ID route at two sites
224240356|NCT01553838|DEVICE|MRI guided prostate biopsy and TRUS guided biopsy|MRI guided prostate biopsy
224240357|NCT00277381|BEHAVIORAL|Automated feedback regarding drug adherence|
224240358|NCT03299296|DRUG|Rivaroxaban 10 Milligrams|The first group is to be on Rivaroxaban 10 mg with dosage according to the orthopedic approved regimen (10 mg once daily 6-10 hours after the surgery; recommended total duration of therapy: 12 to 14 days; The American College of Chest Physicians (ACCP) recommendation: Minimum of 10 to 14 days; extended duration of up to 35 days suggested.
224321145|NCT02934191|DRUG|Celecoxib|Dosing will be 6mg/kg twice a day with a maximum dose of 300mg twice a day. All ages will be given the suspension (concentration 100mg/5mL) orally
224321146|NCT02934191|OTHER|Placebo|Placebo will have the same appearance, taste and consistency as celecoxib. Placebo will consist of calcium carbonate powder suspended in the same syrup as celecoxib. Dose of elemental calcium is 3 mg/kg/day.
224321147|NCT02934191|DRUG|Acetaminophen|Acetaminophen syrup at a dose of 15mg/kg/dose will be given every 4 hours for the first 5 days after surgery. After that point, is given as needed.
223658169|NCT01057589|DRUG|Pemetrexed|"Triplet Combination Therapy: 500 mg/m\^2 administered intravenously on Day 1 of 21 day cycle for up to 6 cycles~Maintenance Therapy: 500mg/m\^2 administered intravenously on Day 1 of 21 day cycle until disease progression or unacceptable toxicity"
224240359|NCT03299296|DRUG|Enoxaparin 40 Milligrams/0.4 Milliliters Prefilled Syringe|"The other group will be administered the standard of care (SOC) enoxaparin as follows:~Once-daily dosing: 40 mg once daily, with initial dose within 9 to 15 hours before surgery, and daily for at least 10 days (or up to 35 days postoperatively) or until risk of deep venous thrombosis (DVT) has diminished or the patient is adequately anticoagulated on warfarin. The American College of Chest Physicians recommends initiation ≥12 hours preoperatively or ≥12 hours postoperatively; extended duration of up to 35 days suggested."
224240360|NCT04671888|OTHER|exercises|COPD patients will be asked to wear a data logger system to collect EMG data and respiration parameters during exercise that simulate daily activity (i.e., walking, cycling)
223658170|NCT01057589|DRUG|Cetuximab|"Triplet Combination Therapy: 400 mg/m\^2 administered intravenously on Day 1 of 21 day cycle for 1 cycle; 250 mg/m\^2 administered IV infusion on Day 1 of 21 day cycle and then weekly for up to 6 cycles.~Maintenance Therapy: 250 mg/m\^2 administered intravenously on Day 1 of 21 day cycle and then weekly until disease progression or unacceptable toxicity"
223658171|NCT01057589|DRUG|Cisplatin|Triplet Combination Therapy: 75mg/m\^2 administered intravenously on Day 1 of 21 day cycle for up to 6 cycles.
224240361|NCT01483352|DEVICE|Accu-Chek DiaPort|
224240362|NCT02143765|DRUG|Mitiglinide|three times a day, orally, for 12 weeks
224240363|NCT02143765|DRUG|Acarbose|three times a day, orally, for 12 weeks
224240364|NCT02684344|DRUG|Tamsulosin|Tamsulosin may have prophylactic properties against post-operative urinary retention
224240365|NCT02684344|OTHER|Education|Education about signs and symptoms of urinary retention
224240366|NCT03970122|DRUG|GFB-887|IMP
224321148|NCT02934191|DRUG|Oxycodone|Oxycodone may be used every 4 hours post-operatively to treat breakthrough pain. The most commonly prescribed dose is 0.075mg/kg/dose (suspension) every 4 hours as needed.
223658172|NCT01057589|DIETARY_SUPPLEMENT|Folic Acid|Standard of care dietary supplements: 350 to 1000 µg orally 5 times a day for the 7 days preceding the first dose of first dose of pemetrexed and continuing throughout treatment and for 21 days after the last dose of pemetrexed.
223658173|NCT01057589|DIETARY_SUPPLEMENT|Vitamin B12|Standard of care dietary supplements: 1000 µg IM during the week preceding the first dose of pemetrexed and every 9 weeks thereafter.
223658174|NCT05842356|BEHAVIORAL|Communication Technique 2|A new communication technique.
224240367|NCT03970122|DRUG|Placebo|Matching
224240368|NCT00416481|BEHAVIORAL|quality of life questionnaires|
224240369|NCT00304447|DRUG|Mylotarg|
224240370|NCT04205942|DEVICE|Argon Plasma Jet|Cold Plasma (CP) therapy is applied in the first week of treatment on a daily schedule, in the second week CP is applied every second day. In total, 8 applications are performed with a one day schedule variance.
224240371|NCT04205942|DEVICE|Placebo|Sham Cold Plasma (sham-CP) (switched off Electric field, no plasma production, just gas) therapy is applied in the first week of treatment on a daily schedule, in the second week sham-CP is applied every second day. In total, 8 applications are performed with a one day schedule variance.
224240372|NCT00396526|DRUG|Oral Co-trimoxazole (8mg/kg/day trimithoprim) twice a day for five days vs. oral amoxycillin (20 mg/kg/day) thrice a day for three days.|
224321149|NCT01777230|PROCEDURE|SPECT-CT sentinel node mapping|sentinel node localisation using the nuclear medicine technique SPECT-CT
224321150|NCT01777230|PROCEDURE|Magnetic Resonance Lymphangiography sentinel node mapping|Sentinel node localisation using Magnetic Resonance Lymphangiography
224240373|NCT04114448|OTHER|Therapeutic exercise|Patients will perform an exercise protocol specifically designed for patients with hemophilia that will include exercises focused on improving range of movement, strength, flexibility, balance and coordination as well as diaphragmatic breathing at the start and at the beginning of each session.
224240374|NCT04114448|OTHER|Usual physical therapy care|Patients will undergo usual physical therapy treatment for hemophiliacs, based on affected self and gentle joint mobilization and stretching of muscles involved in the affected joints.
224321151|NCT01777230|PROCEDURE|Intra-operative sentinel node procedure|Open or (robot-assisted) laparoscopic sentinel node detection and resection.
224321152|NCT05083065|BIOLOGICAL|Covid-19 vaccine|"* First dose or complete cycle of Comirnaty (Pfizer/BioNTech) vaccine~* First dose or complete cycle of Spikevax (Moderna) vaccine~* First dose or complete cycle of AstraZeneca/Vaxzevria vaccine~* Complete cycle of vaccination using one type of vaccine for the first dose and a different type for the second dose~* Janssen (Johnson \& Johnson) vaccine (single dose)"
223658175|NCT03761368|PROCEDURE|Remote Ischemic Preconditioning|four cycles of 5-min inflation to 200 mmHg followed by 5-min deflation of left upper - arm cuff
223658176|NCT03761368|PROCEDURE|Sham Remote Ischemic Preconditioning|deflated cuff placed on the left arm for 40 min
223658177|NCT03435783|BEHAVIORAL|Brief Electronic Intervention|The brief electronic intervention will allow users to receive normative feedback based on their alcohol use and sexual activity. Users who show interest in changing their behavior will also be asked to create a plan to do so.
223658178|NCT03435783|BEHAVIORAL|Attention-Matched Control|Participants will view a video clip on general health promotion that is a similar length as the intervention arm.
223658179|NCT02954172|DRUG|Bevacizumab in Combination With Paclitaxel/Carboplatin|Drug Bevacizumab15mg/kg in combination with Paclitaxel/Carboplatin 6 cycles then maintains at 7.5 mg/kg
223658180|NCT02954172|DRUG|IBI305 in Combination with Paclitaxel/Carboplatin|Drug IBI305 15mg/kg in combination with Paclitaxel/Carboplatin 6 cycles then maintains at 7.5 mg/kg
223658181|NCT00853567|DRUG|Proellex|25 mg oral daily dose vs. 50 mg oral daily dose vs. placebo
223658182|NCT00853567|OTHER|placebo|Placebo
223658183|NCT00388817|BEHAVIORAL|Pharmacist intervention|
223658184|NCT05533229|DRUG|Fentanyl|The trial aims to study the quality of anesthesia and perioperative analgesia and patient's satisfaction provided by fentanyl and bupivacaine versus morphine and bupivacaine.
223658185|NCT05533229|DRUG|Morphine|The trial aims to study the quality of anesthesia, perioperative analgesia and patient's satisfaction provided by fentanyl and bupivacaine versus morphine and bupivacaine.
224240375|NCT05687630|OTHER|elastic band resisted exercise|muscle strengthening exercise, 10-15 times of each set, for 3 sets
224321153|NCT02292095|PROCEDURE|TAPB group|transverse abdominis plane block will be conducted by ultrasound and a single-injection of 20ml 0.75% ropivacaine will be conducted for nerve block at the end of surgery.After surgery,participants in this group will also receive patient controlled intravenous analgesia.
224321154|NCT02292095|PROCEDURE|PCIA group|The formula of patient controlled intravenous analgesia included tramadol 800 mg, flurbiprofenaxetil 100 mg, and dexamethasone 5 mg with saline added up to a volume of 80 ml in total, they received a loading dose of 2 ml followed by an infusion rate of 1 ml/h with bolus of 2 ml, the lock time was set at 15 min
223768664|NCT07173335|BEHAVIORAL|Virtual multidisciplinary integrated healthy lifestyle and pain care|"Participants allocated to the virtual multidisciplinary intervention will receive:~A) 10 consultations over 6 months with a multidisciplinary team, including a minimum 4 with a physiotherapist (week 1, 3, 6, 12) and remainder with a dietitian and/or psychologist, tailored to participants needs. Virtual care consultations may be individual or joint multidisciplinary sessions conducted on standard virtual care platforms used by NSW Health. Consultation will be up to one hour in duration, or use an equivalent total duration with a higher frequency schedule. Where appropriate, participants may be referred to alcohol or smoking cessation support, including individualised virtual or telephone-based counselling with access to nicotine replacement therapy;~B) Tailored pain education and healthy lifestyle education and resource bundles, including video content, web resources and interactive tools sent to participants via email or text."
223768665|NCT07172256|DRUG|CUE-101|CUE-101 will be administered by IV infusion with a commercially available syringe pump or IV infusion pump over 60 minutes on Day 1 and Day 21 after all procedures and assessments are completed. It will be administered at a dosage level of 4 mg/kg x 2
223658186|NCT01643096|OTHER|Zataria multiflora Boiss|Thermic effect of food of Zataria multiflora Boiss and comparison between hot and cold temperament people
223658187|NCT01643096|OTHER|Sumac|Thermic effect of food of Sumac and comparison between hot and cold temperament people
223658188|NCT00543530|DRUG|MK0831|
223658189|NCT02224001|PROCEDURE|The Flag Technique|"A New Concept in the Tip Plasty of Asian Rhinoplasty : The Flag Technique by Use of Only A Septal Cartilage without Septal Extension Grafts~The investigators propose the new technique, so called 'Flag Technique' by a tip-strut complex in a flag-like shape : using only the septal cartilage as an elongated columellar septal strut graft, a shield graft , bilateral mini-spreader grafts of the upper part in the elongated columellar septal strut graft without the septal extension graft to achieve the desired the result."
223658190|NCT01240824|DRUG|aminophylline|One of three escalating doses of aminophylline (3 mg/kg, 6 mg/kg and 9 mg/kg) administered intravesically
223658191|NCT01454817|BEHAVIORAL|Quality of life|Improving Quality of Life
223658192|NCT03636516|DEVICE|SWL|extracorporeal shockwave lithotripsy apply
223658193|NCT00457457|DRUG|Tamsulosin|Tamsulosin hydrochloride capsules, 0.4 mg. Tamsulosin hydrochloride is an antagonist of alpha1A adrenoceptors in the prostate
223768666|NCT07172256|DRUG|Pembrolizumab|Pembrolizumab will be administered on Day 1 and Day 21 after all procedures and assessments are completed according to the Study Calendar. Pembrolizumab will be administered as a dose of 200 mg using a 30-minute (- 5 min/+10 min) IV infusion.
223768667|NCT07172984|PROCEDURE|Anesthesia|"Receives local anesthesia with 5 cc of lidocaine before the infiltration procedure.The patient will receive breathing instructions as part of SHAM treatment, which will not allow them to achieve cardiac coherence."
223768668|NCT07172984|PROCEDURE|breathing group|The procedure will use 5 cc of saline solution instead of the usual anesthesia. Explanations for performing 5-minute breathing cycles that facilitate the achievement of cardiac coherence, with visual feedback.
223768669|NCT07174154|BEHAVIORAL|Interview|Recorded interviews
223768670|NCT07171931|PROCEDURE|IPACK block|After the general anesthesia induction, IPACK block will be performed with 0.25% bupivacaine (20 mL) using ultrasound in addition to adductor canal block.
223768671|NCT07171931|PROCEDURE|Genicular nerve block with bupivacaine|After the general anesthesia induction, genicular block will be performed with 0.25% bupivacaine (20 mL) using ultrasound in addition to adductor canal block.
223658194|NCT00457457|DRUG|UK-369,003|UK 369,003 is a highly selective and potent inhibitor of PDE5. It has increased selectivity for PDE5 over PDE6 (\>80 fold) compared to sildenafil (\~10 fold). Two recently completed trials have shown efficacy for UK-369,003 in treating subjects with ED
223658195|NCT03835364|DEVICE|Blood measurement|Single fingerprick to measure haemoglobin and haematocrit measurements using the Aptus Home, anaemia home monitoring system.
223658196|NCT00464191|DRUG|escitalopram|
223658197|NCT02507167|DIETARY_SUPPLEMENT|mixed meal|250 ml Fortimel compact (chocolate)
223658198|NCT02507167|DRUG|Rifampin|oral rifampin administration (600 mg EREMFAT®)
223658199|NCT04066231|DEVICE|VIPUN GMS|Motility is measured for 4 hours with the VIPUN Gastric Monitoring System (GMS).
223658200|NCT04066231|DRUG|Erythromycin Lactobionate|"Test model: Erythromycin has gastroprokinetic properties. The primary aim of this investigation is to validate the ability of the VIPUN GMS to discriminate between normal and pharmacologically-enhanced fasting gastric motility in healthy adults.~Erythromycin Lactobionate infusion: 200 mg i.v. infusion over a period of 20 minutes. Note: Erythromycin is not labeled as a gastroprokinetic agent in Belgium."
224240376|NCT02092922|DRUG|Filanesib, KSP (Eg5) inhibitor; intravenous|multiple dose, single schedule
224240377|NCT02092922|DRUG|Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous|standard of care
224240378|NCT05561426|OTHER|Ad libitum breakfast and dinner meals for 12 days|Ad libitum portions of breakfast and dinner meals served at the eating behaviour lab
224240379|NCT01001845|DRUG|Milk Thistle extract|1 tablet equivalent to 140 mg of silymarin, 3 times daily for 3 weeks
224240380|NCT01001845|DRUG|vit E|200 mg twice daily for 3 weeks
224240381|NCT01001845|DRUG|vit E + Milk Thistle extract|200 mg vit E twice daily + 1 tablet of Milk Thistle 3 times daily for 3 weeks
224240382|NCT05081258|PROCEDURE|passive Alveolar Molding|A passive palate plate (passive Alveolar Molding) will be inserted within the first week after birth. The pAM appliance will be modified on regular appointments and remain until surgical lip closure (6-7 months of life). After surgical lip closure, infants will receive a nostril retainer and the treatment with the pAM appliance will continue until palate closure (10-12 months of life).
224240383|NCT05081258|PROCEDURE|Nasoalveolar Molding|A passive palate plate will be inserted within the first week after birth. A nasal stent will be added to the palate plate after one week (NAM appliance). The NAM appliance will be modified on regular appointments and remain until surgical lip closure (6-7 months of life). After surgical lip closure, infants will receive a nostril retainer and will be treated with a passive palate plate without nasal stent until palate closure (10-12 months of life).
224240384|NCT04810416|OTHER|Texting- 10 minutes|Participants will practice texting for 10 minutes using smart phone.
223658201|NCT05266833|BEHAVIORAL|Slow diaphragmatic breathing|"The curriculum was based on three key breathing components that have been shown to reduce stress in adolescents: slow breathing; diaphragmatic breathing; and extended exhale breathing. Slow breathing entails breathing at a pace slower than normal breathing. Diaphragmatic breathing focuses on breaths starting from the diaphragm or abdominal areas, with abdominal, then lung, then chest expansion during the inhale and a slow, gradual, full release of air in the reverse direction on the exhale. Extended exhale breathing comprises breathing with the exhalation duration longer, often twice as long, as the inhalation.~Two versions of slow diaphragmatic extended exhale breathing were included in this study. For both, participants did the practice while seated comfortably and breathing through the nose, and were guided to increase the inhale and exhale durations over the 5 weeks. Students followed 5-minute videos for each session."
223658202|NCT02223494|DRUG|Terbogrel|
223658203|NCT05179590|OTHER|Quality of Dream|"Patients frequently report having dreams during general anesthesia, and the dreams are often reported to be pleasant dreams.~However, factors associated with the quality of dreams during general anesthesia have not been clarifed. The aim of this study was to determine the relationships between the quality of dreams during general anesthesia and perioperative factors.~This prospective observational study included patients scheduled for elective surgery under general anesthesia."
223658204|NCT04673396|DRUG|Norcantharidin Lipid Microsphere for Injection|"The test drug was added to 5% glucose injection to a final volume of 250 mL，and administered by instillation at a rate of 200 mL/h.~This product can be used alone or in combination with chemotherapy, and the dosage and time of administration vary with the chemotherapy regimen."
223658205|NCT04673396|DRUG|Sodium Demethylcantharidate Injection|Dissolve the reference drug with appropriate amount of sterile water for injection, and add 250 mL of 5% glucose injection for slow dripping.
223658206|NCT02029898|DRUG|Remifentanil|
223658207|NCT02029898|DRUG|sodium chloride 0,9%|
223658208|NCT00515268|DRUG|GSK256066|GSK256066 will be available as dry powder inhaler with dosing strengths of 12.5, 37.5, 50 micrograms per inhalation.
223658209|NCT00515268|DRUG|Placebo|Subjects will receive placebo inhaler.
223658210|NCT02738385|BEHAVIORAL|High Intensity Interval Training|Exercise will be performed at three sessions per week. All sessions will be supervised by a trained health or exercise professional.
223658211|NCT02738385|BEHAVIORAL|Moderate Intensity Interval Training|Exercise will be performed at three sessions per week. All sessions will be supervised by a trained health or exercise professional.
223658212|NCT00580671|BEHAVIORAL|MET/CBT|Weekly Individual Counseling Sessions
223658213|NCT00580671|BEHAVIORAL|CM|Abstinence-based incentives delivered contingent on drug-negative urine test results.
223658214|NCT00580671|BEHAVIORAL|BPT|Behavioral parent training involve 14 weekly counseling curriculum to improve parenting skills.
223658215|NCT00051662|DRUG|efalizumab|
223658216|NCT00633204|BIOLOGICAL|MPHOSPH1 and DEPDC1|DEPDC1-9-294, and/or MPHOSPH1-9-278 will be administered by subcutaneously injection once every week after curative surgery 8 times and BCG in bladder simultaneously. Then, DEPDC1-9-294, and/or MPHOSPH1-9-278 will be administered once every month. These peptides are determined to administer in accordance with the protein expression using immunohistochemical staining. These peptides are conjugated with Montanide ISA 51 as an adjuvant.
223658217|NCT00858104|PROCEDURE|Percutaneous Laser Ablation|Single session with standardized approach: Two fibers, up to 2 laser emissions; nodule volume up to 10 ml are treated by 800 Joules /ml and above 10 ml by 600 Joules/ml.The treatment is performed under local anesthesia and with diazepam sedation.
223658218|NCT05611190|DIAGNOSTIC_TEST|CT-FFR|CT-FFR is a type of non-invasive procedure to provide a 3D model of coronary arteries as a way to evaluate the hemodynamic significance of coronary artery lesions. CT-FFR calculates FFR from subject-specific CCTA data using computational fluid dynamics technology. CT-FFR value ≤0.80 is considered hemodynamically significant.
223658219|NCT05611190|DIAGNOSTIC_TEST|Usual Care|Participants randomized to usual care will be evaluated according to institutional standard practice.
223658220|NCT03220321|OTHER|PICN (VITA Enamic) hybrid abutment crown|Hybrid ceramic
223658221|NCT03220321|OTHER|Lithium disilicate (IPS e.max) hybrid abutment crown|Glass ceramic
223658222|NCT01170572|OTHER|No intervention|No intervention
223658223|NCT03829423|DIAGNOSTIC_TEST|Breast MRI interpretation|Analysis and interpretation of breast MRI sequences by a specially developed breast MRI interpretation algorithm
223658224|NCT04411563|OTHER|Taking biological samples|Taking blood samples for biochemical and epigenetic analysis
223658225|NCT03248791|DRUG|Phenylephrine|Phenylephrine variable infusion with a starting rate of 0.75 mcg/Kg/min.
223658226|NCT03248791|DRUG|Norepinephrine|Norepinephrine variable infusion with a starting rate of 0.1 mcg/Kg/min.
223658227|NCT03248791|DRUG|Bupivacaine|Bupivacaine will be injected in the subarachnoid space with a dose of 10 mg
223658228|NCT04824651|BIOLOGICAL|COVID-19 vaccine|Vaccination done as part of France's COVID-19 Vaccination Campaign
223658229|NCT01497366|DRUG|Sofosbuvir|Sofosbuvir 400 mg (2 × 200 mg tablets) administered orally once daily
223658230|NCT01497366|DRUG|PEG|Pegylated interferon alfa-2a (PEG) 180 μg administered once weekly by subcutaneous injection
224240385|NCT04810416|OTHER|Writing- 10 minutes|Participants will practice writing on notebook for 10 minutes.
224240386|NCT04810416|OTHER|Texting- 15 minutes|Participants will practice texting for 15 minutes using smart phone.
224240387|NCT04810416|OTHER|Writing- 15 minutes|Participants will practice writing on notebook for 15 minutes.
224240388|NCT02137993|DRUG|A-prexa|A-prexa 5-20 mg for 6 weeks
224240389|NCT02137993|DRUG|Zyprexa|Zyprexa 5-20 mg for 6 weeks
224240390|NCT05868447|PROCEDURE|Stabilization surgery|"hourly blood gas analysis and hemoglobin and hematocrit control and blood transfusion will be performed when necessary~If a low pO2 value is observed in the blood gas, the fi02 values or fresh gas flow will be increased."
224240391|NCT06443307|DRUG|Irinotecan Liposome|The experimental group will collect data from patients treated with Nal-IRI as the chemotherapy regimen. It is recommended to use according to the label, clinical practice shall prevail.
223658231|NCT01497366|DRUG|RBV|"Ribavirin (RBV) administered as 200 mg tablets up to 1200 mg in a divided daily dose~* Dose of sofosbuvir+RBV group based on baseline weight: \< 75kg = 1000 mg and ≥ 75 kg = 1200 mg~* Dose of PEG+RBV group: 800 mg"
223658232|NCT03800420|DRUG|BBT-401-1S first and then Placebo|Total 16 week treatment period: The subject takes BBT-401-1S, QD for the first 12 weeks, then placebo for the last 4 weeks.
223658233|NCT03800420|DRUG|Placebo first and then BBT-401-1S|Total 16 week treatment period: The subject takes the placebo, QD for the first 8 weeks, then BBT-401-1S for the last 8 weeks.
223658234|NCT04208607|PROCEDURE|Bronchoscopy|Role of bronchoscopy in diagnosis of bronchiectasis
223658235|NCT00001062|DRUG|Ganciclovir|
223658236|NCT03911102|BIOLOGICAL|DaxibotulinumtoxinA for injection|Intramuscular injection
223658237|NCT02152917|DRUG|Tranexamic acid|
223658238|NCT02152917|DRUG|Floseal®|
223658239|NCT04409860|RADIATION|CCRT|Radiation concurrent platinum-containing chemotherapy (cisplatin or carboplatin)
223658240|NCT04409860|DRUG|Paclitaxel, Cisplatin|The regimen of adjuvant chemotherapy following CCRT is Paclitaxel(150mg/m2 D1), Cisplatin(60mg/m2 D1) , q3w, three cycles.
223658241|NCT02014337|DRUG|Mifepristone and Eribulin in combination|Single Arm, Two Parts Part 1: Dose Escalation Phase to determine MTD and RP2D in up to 20 patients Part 2: Dose Expansion Phase at RP2D in 20 patients
223658242|NCT00419445|DRUG|GTS21/Placebo|
223658243|NCT00746512|DRUG|Prednisone 15 mg|Prednisone 15 mg tablets once daily for 15 days.
223658244|NCT00746512|DRUG|Placebo Tablets|Prednisone placebo tablets once daily for 15 days.
223658245|NCT00746512|DRUG|Prednisone 7.5 mg|Prednisone 7.5 mg over-encapsulated tablets once daily for 15 days
223658246|NCT00746512|DRUG|Placebo Over-Encapsulated Tablets|Prednisone 7.5 mg placebo over-encapsulated tablets once daily for 15 days
223658247|NCT02117557|PROCEDURE|Single incision laparoscopic surgery|
223658248|NCT02117557|PROCEDURE|Conventional laparoscopic surgery|
223658249|NCT03499535|BEHAVIORAL|Radon & Smoking Synergistic|Participants viewed health information detailing the risks of developing lung cancer from exposure to radon gas, smoking, and their synergistic effects. This intervention represents the type of information most commonly presented in radon risk communications.
223658250|NCT03499535|BEHAVIORAL|Radon Only|Participants viewed health information detailing the risks of developing lung cancer from radon exposure. No information about the risks for developing lung cancer associated with smoking or its synergistic effect with radon exposure are included.
223658251|NCT03499535|BEHAVIORAL|Radon and Smoking Isolated|Participants viewed health information detailing the risks of developing lung cancer from radon exposure and smoking. No information describing the synergistic effects of smoking and radon exposure on lung cancer risk are included.
223658252|NCT03499535|BEHAVIORAL|EPA|Health information modeled after the Environmental Protection Agency's (EPA) pamphlet on radon risk.
224240392|NCT04132557|DRUG|Methylphenidate|Methylphenidate is common ADHD medications in the United States. This is a non-interventional study and no drug will be given as part of this study. Analysis will be performed from data taken from three United States (US) health care databases and one US electronic health record database.
223658253|NCT03499535|BEHAVIORAL|Idaho|Health information modeled after the Idaho Department of Health and Human Welfare's pamphlet on radon risk.
223658254|NCT04435717|DRUG|Tocilizumab 20 MG/ML Intravenous Solution [ACTEMRA]_#1|Tocilizumab 20 MG/ML Intravenous (one dose)
223658255|NCT04435717|DRUG|Tocilizumab 20 MG/ML Intravenous Solution [ACTEMRA]_#1 (2 doses)|Tocilizumab 20 MG/ML Intravenous ( two doses)
223658256|NCT01449799|DRUG|GSK961081 800 microgram dose|To be provided via a combination of 4 inhalers - one 400 micrograms GSK961081 Diskus inhalation, a second 400 microgram GSK961081 Diskus inhalation and one inhalation each from two separate placebo Diskus inhalers
223658257|NCT01449799|DRUG|Fluticasone Propionate 500 microgram dose|To be provided via a combination of 4 inhalers - one 250 microgram fluticasone propionate Diskus inhalation, a second 250 microgram fluticasone proopionate Diskus inhalation, and one inhalation each from two separate placebo Diskus inhalers
223658258|NCT01449799|DRUG|GSK961081 800 microgram and Fluticasone Propionate 500 microgram separately|To be provided via a combination of 4 inhalers - one 400 microgram GSK961081 Diskus inhalation, a second 400 microgram GSK961081 Diskus inhalation, one 250 microgram fluticasone propionate Diskus inhalation, and a second fluticasone propionate 250 microgram Diskus inhalation
223658259|NCT01449799|DRUG|GSK961081 800 microgram Fluticasone Propionate 500 microgram in a blend|To be provided via a combination of 4 inhalers - one inhalation of a Diskus inhaler containing a blend of 400 microgram of GSK961081 and 250 microgram of fluticasone propionate per inhalation, a second inhalation of a Diskus inhaler containing a blend of 400 microgram of GSK961081 and 250 microgram of fluticasone propionate per inhalation, and one inhalation each from two separate placebo inhalers
223658260|NCT04129281|PROCEDURE|Surgery|Surgery acconding to clinical practice
223658261|NCT05069870|DRUG|SKLB1028|SKLB1028, capsule, oral
223658262|NCT05069870|DRUG|Itraconazole|Itraconazole, capsule, oral
223658263|NCT05069870|DRUG|Gemfibrozil|Gemfibrozil, capsule, oral
223658264|NCT05069870|DRUG|Rifampicin|Rifampicin, capsule, oral
223658265|NCT02745080|BIOLOGICAL|Secukinumab|Eligible subjects are randomized to one of two treatment arms in a 1:1 ratio
223658266|NCT02745080|BIOLOGICAL|Adalimumab|Eligible subjects are randomized to one of two treatment arms in a 1:1 ratio
224240393|NCT04132557|DRUG|Lisdexamfetamine|Lisdexamfetamine is common ADHD medications in the United States. This is a non-interventional study and no drug will be given as part of this study. Analysis will be performed from data taken from three US health care databases and one US electronic health record database.
224240394|NCT04132557|DRUG|Atomoxetine|Atomoxetine is common ADHD medications in the United States. This is a non-interventional study and no drug will be given as part of this study. Analysis will be performed from data taken from on three US health care databases and one US electronic health record database.
224240395|NCT04132557|DRUG|Amphetamine|Amphetamine is common ADHD medications in the United States. This is a non-interventional study and no drug will be given as part of this study. Analysis will be performed from data taken from on three US health care databases and one US electronic health record database.
223768672|NCT07173166|OTHER|Physical activity|"Patients assigned to intervention group A will follow a supervised programme of physical activity and exercise at home and during hospitalisation. All patients will follow the same exercise programme, which will be adapted to a basic, intermediate and advanced level to suit the patients' physical condition. The loads, intensity and number of sets will be adapted to each level.~Aerobic exercise will consist of walking and/or cycling at an intensity of between two and five on the Borg perceived exertion (RPE) scale. Resistance exercise will consist of one session focusing on the trunk and upper limbs, and another on the lower limbs. Both sessions will include seven exercises, performed at an intensity of between three and four on the Borg RPE scale."
224240396|NCT04132557|DRUG|Dextroamphetamine|Dextroamphetamine is common ADHD medications in the United States. This is a non-interventional study and no drug will be given as part of this study. Analysis will be performed from data taken from on three US health care databases and one US electronic health record database.
224240397|NCT03846388|DIAGNOSTIC_TEST|follicular stimulating hormone|in the serum of our patients
224321155|NCT05795322|OTHER|Sound healing with tuning forks|"Over the course of a half-hour virtual session, a specially developed triple OM track created by tuning forks was played."
223658267|NCT06144580|OTHER|Community Health and Wellbeing Worker|Each CHWW will be deployed to cover 120 households in defined geographies ('villages') in North and South Westminster. LSOAs in the bottom 20% deprivation have been identified as priority areas for the CHWWs to be deployed. All households in the villages allocated to receive the intervention will be approached by the CHWW allocated to that village, irrespective of demographic characteristics and previous needs. CHWWs will visit all households each month, building a longitudinal relationship with each household so that problems arising from one month to the next can be captured in good time.
223658268|NCT04371588|OTHER|No Response to Train of Four Stimulation|No response is observed during Train of Four stimulation monitoring during surgery
223658269|NCT04371588|OTHER|1-2 Response to Train of Four Stimulation|1 to 2 response is observed during Train of Four stimulation monitoring during surgery
223658270|NCT04381182|DEVICE|Apollo Wearable Device|Participants wear Apollo device which generates vibration frequencies on skin and can be controlled by the user
223658271|NCT01256632|DRUG|Ranibizumab|All study eyes will receive 0.5mg, of intravitreous monthly injections of ranibizumab, for four initial doses,(Day 0, Month 1, Month 2, and Month 3),with scheduled follow-up visits monthly for 12 months. Re-treatment after.
223658272|NCT01996761|DRUG|porcine brain peptide (Cerebrolysin)|
223658273|NCT01996761|DRUG|Placebo|
223658274|NCT06020872|OTHER|Health literacy program|Health literacy program was the health education related to healthy plate.
223658275|NCT02869659|BEHAVIORAL|Weight Loss Group|All participants will follow the Medifast Achieve TM 4 \& 2 \& 1 Plan® which includes the 4 MR products per day, with the addition of 2 Lean and Green™ Meals and 1 Healthy Snack
223658276|NCT02869659|BEHAVIORAL|Delayed Weight Loss|18 weekly, group dietary and exercise sessions led by the study staff in which participants will follow a modified Diabetes Prevention Program
223658277|NCT04126161|PROCEDURE|CT|standard of care CT prior to primary hip replacement
223658278|NCT04126161|DEVICE|Ultrasound|Ultrasound scan together with standard of care CT prior to primary hip replacement
224240398|NCT03846388|DIAGNOSTIC_TEST|Anti-mullerian hormone|in the serum of our patients
224240399|NCT03846388|RADIATION|Basal antral follicle count|by ultrasound
224240400|NCT02622945|DEVICE|Active tDCS plus Speech-Language Therapy|Stimulation will be delivered by a battery-driven constant current stimulator. The electrical current will be administered to a pre-specified region of the brain not affected by the lesion(perilesional areas, right hemisphere or cerebellum). The stimulation will be delivered at an intensity of 2mA (estimated current density 0.04 mA/cm2; estimated total charge 0.048C/cm2) in a ramp-like fashion for a maximum of 20 minutes. Speech-language therapy will be oral and written naming.
224240401|NCT02622945|DEVICE|Sham plus Speech-Language Therapy|Speech-Language therapy will be administered during sham stimulation. Current will be administered in a ramp-line fashion but after the ramping the intensity will drop to 0 mA. Speech-language therapy will be oral and written naming.
223658279|NCT02758184|DEVICE|ROTEM-based coagulation monitoring|
223658280|NCT02758184|PROCEDURE|Spine surgery|
224240402|NCT04902157|DIAGNOSTIC_TEST|Cycle threshold|cycle threshold number
224240403|NCT00404131|DRUG|diquafosol tetrasodium (INS365) Ophthalmic Solution|
224321156|NCT04060186|PROCEDURE|Balloninflation|Patient will inflate into a ballon made by a handglove 2-3times/h from 8:00-20:00 after evacuation of chronic subdural hematoma.
224321157|NCT03237507|DRUG|S-1|40-60mg/m\^2 bid, days 1-14, oral，every 3 weeks.
224321158|NCT03237507|DRUG|oxaliplatin|100mg/m\^2 days 1，intravenous infusion, every 3 weeks.
224321159|NCT03237507|DEVICE|Hyperthermic Intraperitoneal|hyperthermic intraperitoneal chemoperfusion
224321160|NCT03237507|DRUG|Paclitaxel|intraperitoneal perfusion
223658281|NCT00531427|DRUG|Buprenorphine|transdermal system 10 and 20 applied for 7-day wear
223658282|NCT00531427|DRUG|Placebo|transdermal system (placebo) applied for 7-day wear
223658283|NCT06322576|DRUG|177Lu-PNT2002|"10 patients will undergo DCFPyL PET/CT and 177Lu-PSMA dosimetry imaging only (single tracer dose).~If opened, Cohort 2 patients will receive 4 cycles, every 8 weeks of 177Lu-PSMA infusion. Other procedures during treatment and follow up may include: physical exam, CT/MRI, PSMA-PET, blood draws, adverse event assessment, and completion of questionnaires."
223658284|NCT02117297|DRUG|Gemtuzumab Ozogamicin|Gemtuzumab, 9.0 mg/m2, will be given IV over 2 hours two times post allogeneic transplantation.
223658285|NCT02773082|DEVICE|Reclaim™ DBS Therapy|DBS is indicated for bilateral stimulation of the ventral anterior limb of the internal capsule as an adjunct to medications and as an alternative to anterior capsulotomy for treatment of chronic, severe, treatment-resistant obsessive compulsive disorder (OCD) in adult patients who have failed at least three selective serotonin reuptake inhibitors (SSRIs). Medtronic received humanitarian device exemption (HDE) approval for Reclaim DBS Therapy for the management of OCD on February 19, 2009.
223658286|NCT06523400|DRUG|Mexiletine granules for prolonged-release oral suspension|Mexiletine PR
223658287|NCT06523400|DRUG|Placebo|Matching Placebo
223658288|NCT00773604|DEVICE|Medtronic implantable deep brain stimulation (DBS) system|surgical placement of deep brain stimulation system for treatment of dystonia
223658289|NCT06463158|DEVICE|Family Room Application|The Family Room application is a point of care tool that guides families on contributing to patient participant care by providing real time education, a sense of connection, emotional support, and resources that enable meaningful care giving. Importantly, family caregiver participants receive virtual training on comfort-focused care activities that can be done at the bedside, as well as a mechanism within the electronic health record (EHR) to measure and record the effectiveness of the care they provide.
223658290|NCT06864481|OTHER|Blood samples|one Blood sample (20 ml)
223658291|NCT06614166|OTHER|SBD111 Probiotic Medical Food|Medical food comprised of probiotics and prebiotic fibers
223658292|NCT06614166|OTHER|SBD121 Probiotic Medical Food|Probiotic medical food comprised of three lactic acid bacteria and one bacillus
223658293|NCT01545505|BEHAVIORAL|Neuropsychological assessment|"A clinical evaluation with Impact of Events Scale-Revised, Child Post-Traumatic Stress Reaction Index, State-Trait Anxiety Inventory for Children, Children Depression Inventory and Emotion, activity and sociability.~A neuropsychological assessment with a emotional Go-No/Go, a visual search task, the Trail Making Test, 3 items of the WISC III ( and the Grober and Buschke Test."
223658294|NCT06721936|COMBINATION_PRODUCT|Multimodal pelviperineal physioterapy group|"The multimodal PPT protocol includes:~Pelvic Floor Muscle Training (PFMT): This component includes techniques to raise awareness of the pelvic floor, incorporating both manual and instrumental intravaginal techniques.~Non-Ablative Radiofrequency Therapy (Model: RNG, INDIBA): Applied during all eight sessions, with each session lasting 25 minutes.~Therapeutic Pelvic Health Education: Designed to empower participants with knowledge about their condition and the pelvic-perineal area. This educational intervention aims to enhance understanding, promote self-care, and encourage behaviours that alleviate symptoms associated with GSM"
223658295|NCT06721936|DEVICE|Laser CO2 Therapy group|"The fractional laser application will be delivery with the following probes:~90° Probe for Incontinence: Maximum power of 40W; 360° Probe for Vaginal Atrophy: Maximum power of 40W and Right-Angle Probe for Vulvar Atrophy: Maximum power of 24W."
223658296|NCT06173518|BIOLOGICAL|AUTO1|Following lymphodepletion with chemotherapy (cyclophosphamide and fludarabine) patients will be treated with anti-CD19 chimeric antigen receptor (CAR) T cells
223658297|NCT06767774|DRUG|Combination therapy|"* pitavastatin 4mg~* ezetimibe 10mg"
223658298|NCT06767774|DRUG|High intensity statin monotherapy|rosuvastatin 20mg
223658299|NCT06671405|DRUG|AZD0780|Dose 1 and Dose 2
223658300|NCT06671405|DRUG|Itraconazole|"* Period 2 (itraconazole administration only).~* Period 3 (AZD0780 + itraconazole administration)."
223658301|NCT06671405|DRUG|Carbamazepine|"* Period 2 (carbamazepine administration only).~* Period 3 (AZD0780 + carbamazepine administration only)."
223658302|NCT06671405|DRUG|Midazolam|"* Period 1 (midazolam administration only).~* Period 3 (AZD0780 + midazolam administration)."
223658303|NCT06671405|DRUG|Ethinyl estradiol/levonorgestrel|"* Period 1 (EE and LNG administration only).~* Period 3 (AZD0780 + EE and LNG administration)."
223658304|NCT05552196|DRUG|Ponesimod|Ponesimod tablet will be administered orally.
223658305|NCT05552196|DRUG|Carbamazepine|Carbamazepine tablet will be administered orally.
223658306|NCT07073209|PROCEDURE|PENG Block Administration|"Policy for the PENG block administration:~30 mL of Bupivacaine 0.25% 1:200,000 epinephrine Dexamethasone 4 mg%~While these drugs are administered to participants, the intervention under evaluation is the PENG Block anesthesia technique."
223658307|NCT07073209|PROCEDURE|Femoral Block Administration|"Policy for the Femoral block administration:~30 mL of Bupivacaine 0.25% 1:200,000 epinephrine Dexamethasone 4 mg~While these drugs are administered to participants, the intervention under evaluation is the Femoral Block anesthesia technique."
224240404|NCT01556308|PROCEDURE|Taking of liquid and top of blisters|the liquid and the top of blisters will be took.
224240405|NCT04793347|DEVICE|shock master (shock waves device)|device produces shock waves
224240406|NCT02757248|DRUG|Volasertib|Volasertib 75-150mg/m2 given intravenously on days 1 and 8
224240407|NCT02757248|DRUG|Romidepsin|Romidepsin 12-14mg/m2 given intravenously on days 1, 8 and 15
224240408|NCT00614289|DEVICE|Epikeia Coatings|Topical skin coating
224240409|NCT03753425|PROCEDURE|Low volume bowel preparation in inflammatory bowel diseases|Low volume bowel preparation in inflammatory bowel diseases
224240410|NCT02042365|PROCEDURE|ERAS (Enhanced recovery after surgery)|
223658308|NCT07073209|DRUG|Bupivacaine , epinephrine Dexamethasone|30 mL of Bupivacaine 0.25% 1:200,000 epinephrine Dexamethasone 4 mg%
223658309|NCT06795191|DRUG|Triptorelin Mesylate|22.5 mg in a prefilled, ready-to-use, long-acting formulation
223768673|NCT07173166|OTHER|Physical activity and nutrition|The intervention integrates a structured physical activity programme with individualized nutritional recommendations based on the Mediterranean diet. Macronutrient distribution was 50-55% carbohydrates, 30-35% fats, and 10-15% proteins. The protocol emphasized the intake of vegetables (≥2 servings/day, 200 g each), fruits (1-2 servings/day, 150 g each), legumes (≥3 servings/week, 150 g cooked), whole grains (1-2 servings/meal, 40-60 g), and low-fat dairy products (1-2 servings/day; 200 ml milk or 125 g yoghurt). Lean meats were prescribed at 3-4 servings/week (100-125 g each), fish and seafood at 4 servings/week (150 g each), nuts at 3-7 servings/week (30 g each), and olive oil as the principal fat source (≤4 tbsp/day). Micronutrients and bioactive compounds from these foods, including antioxidants, polyphenols, and essential fatty acids, were recognized as pivotal for modulating protective mechanisms and mitigating toxicological effects.
223658311|NCT03611595|DRUG|Cabozantinib|Cabozantinib will be given orally once every day with cycles repeated every 4 weeks (28 days, +/- 3 days), with no rest periods between cycles
223658312|NCT03611595|DRUG|13-cis-retinoic acid|13-cis-retinoic acid at 80mg/m2/dose twice daily for two consecutive weeks (14 days) out of every four weeks (28 days, +/- 3 days).
223658313|NCT03390114|BEHAVIORAL|SHUTi|SHUTi consists of six, 40-minute, weekly sessions during which the intervention components of stimulus control, sleep restriction, sleep hygiene, cognitive restructuring, and relapse prevention are delivered. Each SHUTi session has the same structure: the main content, a homework screen with options, and a summary of the main points.
223658314|NCT03036215|BEHAVIORAL|PACT Experimental Arm|The study will employ a self-management program, entitled Personalized Activated Care and Training (PACT) that is a tailored 8-week progressive web-based training program supported by a health coach to enhance understanding, compliance, and success in improving TMD pain. The program provides 8 weeks of structured didactic and experiential training on exercises and cognitive- behavioral training to reduce risk factors that contribute to delayed recovery and enhance protective factors that have evidence of improving TMD pain.
223658315|NCT04427332|OTHER|Investigation of smell and taste disorders|The study consists of an epidemiological investigation by means of a prospective observational study with the aim of investigating the demographic and clinical factors related to the sense of smell and taste in patients with Sars Cov 2 infection.
223658316|NCT00644891|DRUG|cefdinir (Omnicef)|2.5 ml of strawberry cream flavored oral suspension 125 mg/5 ml
223658317|NCT00644891|DRUG|amoxicillin|2.5 ml of bubble-gum flavored amoxicillin oral suspension 125 mg/5 ml
223658318|NCT05579067|PROCEDURE|ACL Reconstruction using an autograph of the peroneus longus tendon, folded twice.|The use of a peroneus longus tendon autograft taken from the lower leg of the same limb and used as a graft to reconstruct the ACL (anterior cruciate ligament) of the knee joint.
223768674|NCT07172867|DRUG|HT-6184|2mg QD
223768675|NCT07172867|DRUG|HT-6184 Matching Placebo|2mg QD
223768676|NCT07172867|DRUG|Semaglutide 1 mg|Semaglutide 1 mg, every week
223768677|NCT04317989|OTHER|Practice Facilitation|"1. Implementing evidence-based protocols and the use of clinical algorithms (for screening, counseling, referral, and MAT) to engage the entire clinical team in a high standard delivery of care.~2. Promoting a strong use of decision support tools and templates to support the practice workflow.~3. Optimizing the use of the electronic health record (EHR) to pull clinical data on a monthly basis to guide the change process.~4. Developing patient registries (e.g., for those identified to have AUD) to identify needed care~5. Proactive, team-based care with assigned roles and responsibilities to prepare the clinical team to develop needed care and engage patients throughout the entire visit process.~6. Enhancing the understanding of available counseling and referral resources to ensure that practices are confident that they have appropriate evidence-based intervention options."
224240411|NCT02874300|OTHER|High intensity supervision arm|The higher-intensity supervision arm will comprise 6 occupational therapist (OT) home visits and 5 physiotherapist visits (1,1,2,2,6,12,18,24,30,36 and 52) plus supervised support from a rehabilitation support worker (RSW) twice a week for 3 months, once a week for 3 months, once a fortnight for 3 months and once a month for 3 months. Initially, and at review and progression points, the RSW will visit jointly with the therapists.
224240412|NCT02874300|OTHER|Moderate intensity supervision arm|The moderate-intensity supervision arm will be based on an ongoing Australian trial (83, 112). There will be 6 OT home visits and 5 physiotherapist visits (weeks 1,1,2,3,4,5,6,7,8,10,12) and three OT telephone calls (weeks 9,10,11). Participants will be expected to exercise independently in-between supervised sessions.
224240413|NCT00840138|PROCEDURE|Surgical reconstruction|"Hepaticojejunostomy~End-to-end anastomosis~Duct suture over T-tube"
224240414|NCT02683083|BIOLOGICAL|[131I]-SGMIB Anti-HER2 VHH1|
224240415|NCT05810753|BEHAVIORAL|SPOONful|Participants will be asked to consume two ONS daily, in addition to their regular diet, for three weeks. Participants will be asked to consume one ONS with their breakfast, and one with lunch.
224240416|NCT02950207|GENETIC|miRNA|miRNA extraction
224240417|NCT04441970|PROCEDURE|Neutral position|The cuff pressure will be recorded at the neutral head position.
224240418|NCT04441970|PROCEDURE|Head extension position|The cuff pressure will be recorded at the head extension position.
224240419|NCT04441970|PROCEDURE|Head flexion position|The cuff pressure will be recorded at the head flexion position.
224240420|NCT04441970|PROCEDURE|Head rotation position|The cuff pressure will be recorded at the head rotation position.
224240421|NCT00138515|DRUG|vildagliptin|
224240422|NCT01029470|DRUG|Luveris|Luveris 75IU or 150IU depending on the patient conditions, subcutaneous injection, Qd, from Day 8 till hCG Day
224240423|NCT05321316|DRUG|18F-FDG|All study participants will undergo one 18F-FDG PET/CT scan.
224240424|NCT04734184|DIAGNOSTIC_TEST|DCFPyL|Single dose injection
224240425|NCT04486066|BEHAVIORAL|Mindfulness-Based Stress Reduction|In MBSR, participants meet by video for 2 hours per week for 8 weeks in a group format and receive instruction in mindfulness meditation according to a standardized curriculum, are given daily homework, participate in group discussions, and can ask questions.
223658319|NCT05579067|PROCEDURE|ACL Reconstruction using an autograph of Hamstrings muscle tendons.|The use of Hamstring muscle tendon autograft (Semitendinus and slender muscle) taken from the lower leg of the same limb and used as a graft to reconstruct the ACL (anterior cruciate ligament) of the knee joint.
223768678|NCT03997318|BIOLOGICAL|AMDC-USR|Autologous Muscle Derived Cells for Urinary Sphincter Repair
223768679|NCT03997318|OTHER|Placebo|Placebo control is the vehicle solution used for the study product.
223768680|NCT05414409|DRUG|Metformin|Metformin is an oral medication that improves insulin sensitivity.
223768681|NCT05648565|DEVICE|Radiofrequency ablation (RFA)|The NEUROMARK device is an in-office, disposable bipolar RFA device with a treatment tip consisting of micro electrodes which delivers RF energy while monitoring appropriate tissue contact to maximize delivery to posterior nasal nerve and its variable branching. After topical anesthesia consisting of oxymetazoline and 1% lido followed by 4% lidocaine, the device will be placed in the posterior inferior turbinate under endoscopic visualization. The device will be activated per manufacturer's instructions
224240426|NCT04486066|BEHAVIORAL|Cognitive Behavioral Therapy for Chronic Pain|Cognitive Behavioral Therapy (CBT) is the most widely used non-pharmacologic intervention for chronic pain and a version of CBT specifically addressing chronic pain (CBT-CP) has been developed for use in VA with Veterans. Fundamentally, CBT is an approach that seeks to ameliorate dysfunctional relationships between an individual's thoughts, feelings, and behaviors to improve functioning and quality of life. At our site, the CBT-CP format has been adapted for clinical use (i.e., as part of usual clinical care) to 8 video sessions in a group format, while retaining all essential elements.
223658320|NCT05772351|DRUG|micronized flavonoid fraction|"Patients of the experimental group received Detralex® 1000 mg QD for 15 days before the operation, 3000 mg starting from day 1 after the surgery for 4 days, then 2000 mg for the next 3 days and 1000 mg till day 30 after surgery.~Under spinal anesthesia appropriate surgical intervention was performed. After the surgery, the patient was given a questionnaire and a scale for assessing pain at rest and during defecation within the first 2 weeks after surgery. During the hospital stay, the nurse filled out a section on the drugs used; after discharge, the patient filled out this section for 7 days after the surgery. After 30 days, the side effects section was filled out, and the quality of life was assessed on days 7 and 30. Also, the patients indicated in a separate column on which day after the surgery they were able to return to normal living or go to work."
223658321|NCT01317459|BEHAVIORAL|Guided self-determination|Group counselling
223658322|NCT01303224|DRUG|Ibodutant|Oral tablet, low dose, once daily, for 8 weeks
223658323|NCT01303224|DRUG|Ibodutant|Oral tablet, intermediate dose, once daily, for 8 weeks
223658324|NCT01303224|DRUG|Ibodutant|Oral tablet, high dose, once daily, for 8 weeks
223658325|NCT01303224|DRUG|Placebo|Oral tablet, (identical in appearance and weight to Ibodutant tablets), once daily, for 8 weeks
223658326|NCT05194371|RADIATION|definitive radiotherapy or definitive chemoradiotherapy|A total dose of radiation therapy should be more than 50Gy
223658327|NCT04075812|DEVICE|Neuromuscular Stimulator|
223658328|NCT01574183|DRUG|Vilazodone|up to 40 mg capsule daily
223658329|NCT01574183|DRUG|Placebo|up to 40 mg capsule daily
223658330|NCT00283634|DRUG|erlotinib and bortezomib|
223658331|NCT06313385|DIAGNOSTIC_TEST|Indocyanine Green Fluorescence (ICG)|The ICG will be injected intravenously and being assessed with Near-infrared (NIR) camera FLUORO4000XL 20 cm above the flap and fluorescence intensity counted with application called ImageJ
223658332|NCT06313385|DIAGNOSTIC_TEST|Temperature|Portable thermal imaging camera called Forward-looking infrared (FLIR) ONE® was used to assess flap and normal skin temperature. The FLIR ONE® device was place in perpendicular manner from the skin. The images were attained in two points of times which is direct temperature and after cold challenge test.
223658333|NCT06313385|DIAGNOSTIC_TEST|Transcutaneous oxygen and carbon dioxide pressure|The partial transcutaneous pressure is measured in flap using transcutaneous monitor (TCM) Combi probe. The probe should be cleaned using alcohol pads before use. After 5-10 minutes, the TCM 4 machine monitor should show stable transcutaneous oxygen and carbon dioxide pressure from the flap
223658334|NCT06313385|DIAGNOSTIC_TEST|Histopathology|A part of tissue from free flap is acquired and stored in 10% formalin tube. Later on, the tissue was colored with hematoxylin-eosin, neutrophile count, necrosis volume, and vessel proliferation will be assessed
223658335|NCT06313385|DIAGNOSTIC_TEST|Hypoxia inducible factor-1 (HIF-1) alpha|Peripheral tissue from distal free flap (0,5 x 0,5 cm in size) is obtained and stored in tube with dry ice. The tissue is assessed with human HIF - 1 Alpha Enzyme-Linked Immunosorbent Assay (ELISA) kit ab171577.
223658336|NCT06226389|PROCEDURE|4 different bulk-fill composite|Posterior cavities either class 1/2
224240427|NCT04486066|OTHER|Usual Care|Veterans randomized to usual care will continue to be followed by their usual care providers for all medical and mental health care. This can include continued use of medications, specialty referrals and other usual elements of care. They will be asked to not enroll in the specific MBSR or CBT-CP interventions during the 8-month study period, but can attend other groups interventions, such as CBT-Insomnia, Acceptance and Commitment Therapy for Chronic Pain, and other groups for chronic pain and PTSD as directed by their treating providers. They can also enroll in MBSR or CBT-CP at the completion of the study.
224240428|NCT06569615|OTHER|shock wave therapy|"All the participants in first week will receive the ice pack for 15 minutes 3 times a day at the lumbosacral area to reduce inflammation in the area, along with rest to reduce irritation at the lumbosacral area for the first week.~From the 2nd week:~Participants will be given Radial shockwave therapy, (Storz Medical Shock Master MP200 device) for 10 minutes/session, one session/week, for 8 weeks."
223658337|NCT06213103|PROCEDURE|Patient cohort|Collection of 6 blood tubes at the inclusion visit.
223658338|NCT06213103|PROCEDURE|Control cohort|Collection of 6 blood tubes at the inclusion visit.
223658339|NCT00843284|DRUG|Pregabalin|Capsules, 150 - 600 mg/day, 2-3 times/day, 8 weeks
223658340|NCT02773953|DEVICE|T4PTelemonitoring|addition of a Telemonitoring unit on the CPAP line to standard care.
223658341|NCT02773953|DEVICE|CPAP|CPAP treatment for treatment of obstructive sleep apnea syndrome
223658342|NCT01505764|DRUG|Anamorelin HCl|100 mg tablets; oral administration every day for 84 days, at least 1 hour before the first meal of the day.
224240429|NCT06569615|OTHER|LASER Therapy|"All the participants in first week will receive the ice pack for 15 minutes 3 times a day at the lumbosacral area to reduce inflammation in the area, along with rest to reduce irritation at the lumbosacral area for the first week.~From the 2nd week:~Participants will be given LASER, (LEVELASER EZ1 EASYONE) over the lumbosacral area for 10 minutes/Session, three session/week, for 8 weeks."
224240430|NCT06569615|OTHER|Cryotherapy|"All the participants in first week will receive the ice pack for 15 minutes 3 times a day at the lumbosacral area to reduce inflammation in the area, along with rest to reduce irritation at the lumbosacral area for the first week.~From the 2nd week:~Participants will be given Cryotherapy, (Gymna UniphyCryoflow 1000 IR Shock Master ICE-CT device) over the lumbosacral area for 10 minutes/Session, three session/week, for 8 weeks."
223658343|NCT01505764|DRUG|Placebo|Placebo tablets identical in appearance to active tablets; oral administration once a day for 84 days, at least 1 hour before the first meal of the day.
223658344|NCT01714791|OTHER|Usual care|Patients exercise at a heart rate corresponding to 65% of baseline Vo2peak. Each exercise training session takes 40-60 minutes. Exercise time is apportioned as follows: 42% on the treadmill, 33% on the circle ergometer and 25% on the arm cranking device. All patients exercise under close supervision 3 days per week for a total duration of 12 weeks.
223658345|NCT01714791|OTHER|Osteopathic treatment|"Patients receive 4 osteopathic treatments (OT). OT is performed in week 4, 5, 8 and 12 postoperative. Depending on what is found in the patient, treatments consist mostly of one or more of the following approaches:~* Structural High Velocity Low Amplitude-techniques.~* Muscle Energy Techniques.~* General osteopathic mobilisations.~* Functional techniques (Sutherland-, Jones-techniques,…) including inhibition techniques.~* Fascia techniques.~* Soft tissue- and connective tissue techniques.~* Neurovisceral and neurolymphatic reflex techniques.~* Fluidal techniques (lymphatic manipulative techniques,...).~* Visceral manipulations.~* Neurocranial and viscerocranial techniques."
223768682|NCT06482944|BEHAVIORAL|Whole Foods for Families|"This diet intervention will encourage the consumption of a whole foods dietary patterns such as a wide variety of fruits, vegetables, proteins, seafood, dairy and whole grains. During the partial feeding period (weeks 3-8), families will be asked to continue the whole foods diet with support that includes: 1) 3 weekly dinners of the families' choosing (described above), 2) rotating menus (\~3 weeks' worth) that will allow for customization (e.g., protein, vegetable, grain swaps) to support cultural/dietary preferences, and 3) dietetic support to help with customization and diet maintenance. Participants will be instructed by the registered dietitian nutritionist (RDN) on how to adhere to the diet intervention and will be provided menus and recipes. For the enrolled families in the study, the goal is to maintain complete diet adherence during the twelve-week intervention."
223768683|NCT04809129|DEVICE|Weighted vest|Patients will wear a weighted vest following bariatric surgery with weight increased incrementally to maintain baseline weight. This vest will be worn for a minimum of 8 hours a day for three months postoperatively.
223768684|NCT06192628|BEHAVIORAL|Parkinson's Exercise and Education Programme|"A 12 week programme of exercise and education~The weekly programme consists of a 45-minute exercise programme, 45-minute education sessions delivered by healthcare professionals about their role in Parkinson's management, and independent home exercise programmes completed twice weekly (determined by the registered physiotherapist only)"
223768685|NCT06192628|BEHAVIORAL|Parkinson's Exercise and Education Programme and Behavioural Change|"A 12-week programme of exercise, education and behavioural change techniques to support exercise adherence and exercise self-efficacy~The weekly programme consists of a 45-minute exercise programme, 45-minute education sessions delivered by healthcare professionals about their role in Parkinson's management, and independent home exercise programmes completed twice weekly (determined by the registered physiotherapist and participant)~Additional techniques addressing behavioural regulation include firstly, an exercise diary completed independently at home, secondly, the rationale and the intended functional benefit and expectations of the exercise programme clearly explained, thirdly individual weekly conversations to reflect on progress, expectations, solutions to barriers, and goals. Finally, peer support is strongly encouraged through the in-class support, and a social media networking group."
223768686|NCT03985553|BEHAVIORAL|Parenting Self-Management Program|
223768687|NCT05505630|DRUG|Ketamine|A single dose of IV ketamine will be administered.
223768688|NCT05505630|DRUG|Midazolam|A single dose of IV midazolam will be administered
223768689|NCT05505630|DRUG|Dexmedetomidine|A single dose of IV dexmedetomidine will be administered
223768690|NCT05505630|DRUG|Saline|A single dose of IV saline will be administered
223768691|NCT04473040|DRUG|alpelisib|Alpelisib is provided as 50 mg and 200 mg film coated tablets as individual patient supply, packaged in bottles. Alpelisib will be dosed on a flat scale of mg/day and not be adjusted to body weight or body surface area. Alpelisib will be administered at a starting dose of 300 mg orally once daily on a continuous dosing schedule and can be adjusted for toxicity per the recommendations in this treatment plan.
223658346|NCT03517345|DIETARY_SUPPLEMENT|Prebiotic|Prebiotic (Inulin+Oligofructose) consumed as 10 g/d in yogurt (200 g/d)
223658347|NCT03517345|DIETARY_SUPPLEMENT|Control|The only yogurt consumed as 200 g/d without prebiotic.
223658348|NCT01531855|OTHER|Reducing post-exercise rapid-acting insulin (insulin lispro or aspart) dose|Dosage after exercise
223658349|NCT02603666|DEVICE|Fibroscan|Ultrasound by specific wavelength developed for elastography, repeated measures according to the manufacturer's instructions.
223658350|NCT03140059|PROCEDURE|Open flap debridement|Open flap debridement will be performed to decontaminate root surface
223658351|NCT03140059|PROCEDURE|Repeated application of aPDT|Repeated application of photodynamic therapy (aPDT) at 0, 1, 2, 7 and 14 days post-operatively.
223658352|NCT00770575|DRUG|Pioglitazone and atorvastatin|"Pioglitazone 30 mg, capsules, orally, once daily and atorvastatin 20 mg, tablets, orally, once daily for 4 weeks; increase to:~Pioglitazone 45 mg, capsules, orally, once daily and atorvastatin 40 mg, tablets, orally, once daily for up to 20 weeks."
223658353|NCT00770575|DRUG|Atorvastatin|"Pioglitazone placebo-matching capsules, orally, once daily and atorvastatin 20 mg, tablets, orally, once daily for 4 weeks; increased to~Pioglitazone placebo-matching capsules, orally, once daily and atorvastatin 40 mg, tablets, orally, once daily for up to 20 weeks."
223658354|NCT02492607|OTHER|Standard treatment|"wide local excision only or wide local excision and radiotherapy or mastectomy.~+/- hormonal therapy"
223658355|NCT02492607|DEVICE|digital mammography|annual mammography
223658356|NCT02492607|RADIATION|radiotherapy|according local policy
223658357|NCT00004040|BIOLOGICAL|recombinant interferon alfa|
223768692|NCT05212259|DRUG|Collagen type II (40 mg/day)|4 capsules per day
223768693|NCT05212259|DRUG|Collagen type II (80mg/day)|4 capsules per day
223768694|NCT05212259|DRUG|Collagen type II (120 mg/day)|4 capsules per day
223768695|NCT05212259|DRUG|Glucosamine Hydrochloride with Chondroitin Sulphate (2700 mg)|4 capsules per day
223768696|NCT05212259|DRUG|Placebo|4 capsules per day
223658358|NCT00004040|BIOLOGICAL|rituximab|
223658359|NCT04939350|OTHER|questionnaire|patients will complete a vaccination questionnaire
223658360|NCT00232791|DEVICE|Cypher Select|CYPHER SELECT™ Sirolimus-eluting Coronary Stent
223658361|NCT00232791|DEVICE|Cypher|CYPHER™ Sirolimus-eluting Coronary Stent
223658362|NCT06153004|BEHAVIORAL|Healthy Activity Program (HAP)|HAP, delivered over 6-8 sessions by non-specialist healthcare workers, has behavioural activation as the core psychological strategy along with other strategies such as problem-solving and activation of social networks.
223658363|NCT06153004|DRUG|Antidepressant medication (ADM)|Patients assigned to antidepressant medication will start on fluoxetine 20 mg/day which can be raised to 40 mg/day (the maximum mandated by treatment guidelines for primary care in India) at week 3 or 6 for patients who have yet to remit. Patients who cannot tolerate fluoxetine will be switched to escitalopram.
223768697|NCT02263638|DRUG|Anakinra|One daily subcutaneous injection of a fixed dose of 100 mg will be administered at a fixed time during a five day period
223658364|NCT02501187|PROCEDURE|Levator advancement|A transcutaneous procedure in which the Levator palpebrae aponeurosis is advanced and attached to the tarsus.
223658365|NCT02501187|PROCEDURE|Müller's muscle-conjunctival resection procedure|A transconjunctival procedure in which part of the muller muscle and conjunctiva are resected.
223768698|NCT04857866|DRUG|XmAb27564|Single ascending dose of XmAb27564
223768699|NCT04857866|DRUG|Placebo|Single dose of placebo
223658366|NCT02501187|PROCEDURE|White line advancement|A transconjunctival procedure in which the Levator palpebrae aponeurosis is advanced and attached to the tarsus.
223658367|NCT04643145|PROCEDURE|Flexible ureteroscopy for renal calculi less than 20 mm|Patients with renal calculi less than 20 mm will be managed by flexible ureteroscopy. at the end of the procedure, they will be randomized to receive either temporary ureteral catheter for 2 days or indweeling double J stent for 2-4 weeks
223658368|NCT04195542|OTHER|Questionnaire|questionnaire assessing knowledge of the need to take vitamin B9 supplementation in women in the periconceptional period and the reasons why this supplementation is carried out or not
223658369|NCT00526916|DRUG|[C-11]PBR28|
223768700|NCT06146387|DIETARY_SUPPLEMENT|Investigational Formula|Participants in this arm will receive stage 1 and stage 2 investigational formulas. At the first (up to) 6 months, they will be fed with stage1 formula, and then switch to stage 2 formula until 12 months.
224240431|NCT06569615|OTHER|Exercises|The assigned exercises for all participants will include 1. Bilateral bridging, 2. Knee to chest, 3. Back extension within a pain-free range, 4. Plank, 5. Baby pose stretch, 6. Cat and camel, 7. Bilateral adductor ball squeezes and 8. Stretching exercise (Gluteal /Piriformis stretch, Quads /Hams stretch. The treatment plan involved performing three sets of exercises, with each set comprising 8 to 10 repetitions. 20-30 minutes of exercise session will be conducted three times per week over a span of 8 weeks.
223658370|NCT03135418|DEVICE|Intervention|"Patients will use virtual reality d4evice to play task oriented games like bowling, arrow shooting and home activity simulations which focuses upper extremity abduction, flexion and rotation movements. Each session will be a total of 45 minutes divided to 3 15 minute games. Sessions will held for 6 weeks each monday, wednesday and friday at same time for each patient.~In addition to the virtual reality treatment program conventional rehabilitation therapies including neurodevelopmental facilitation techniques, physiotherapy, and occupational therapy and, where necessary, speech therapy will be applied according to the needs of the patient."
223658371|NCT03135418|DEVICE|Control|The control group will be included in the virtual reality program only focusing on visual scenes without upper extremity interaction. Bobath therapy, walking exercises, upper extremity active exercises, proprioceptive neuromuscular facial techniques will be applied to the control group for 6 weeks.
223658372|NCT03855826|DRUG|Nifekalant hydrochloride|Both groups were given conventional treatment except for arrhythmia drugs.Only nyficarine hydrochloride or amiodarone hydrochloride could be used according to random results, and the antiarrhythmic drugs should be replaced according to the protocol rules.
223658373|NCT03855826|DRUG|Amiodarone|Both groups were given conventional treatment except for arrhythmia drugs.Only nyficarine hydrochloride or amiodarone hydrochloride could be used according to random results, and the antiarrhythmic drugs should be replaced according to the protocol rules.
223658374|NCT03553992|BEHAVIORAL|POP-6:|"90 days of Facebook messaging, weekly live sessions targeting tobacco use and tailored to SGM young adults~Drug: nicotine patch 14-day supply of nicotine patch"
223658375|NCT03553992|BEHAVIORAL|TSP-6:|"90 days of Facebook messaging, weekly live sessions targeting tobacco use~Drug: nicotine patch 14-day supply of nicotine patch"
223658376|NCT00798759|DRUG|Travoprost ophthalmic solution 0.004% with SofZia® preservative system (TRAVATAN Z®)|Ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension, one drop a day, dosed topically for 12 weeks (84 days). Referred to as travoprost.
223768701|NCT06146387|DIETARY_SUPPLEMENT|Control Formula|Participants in this arm will receive stage 1 and stage 2 Control formulas. At the first (up to) 6 months, they will be fed with stage1 formula, and then switch to stage 2 formula until 12 months.
223768702|NCT06146387|DIETARY_SUPPLEMENT|Breastfeeding|Exclusively breastfed for the first 4 months and continue with supplement food without any marketed infant formula.
223768703|NCT02851108|DRUG|Methylene Blue|50 patients will receive methylene blue
223768704|NCT02851108|DRUG|Primaquine|50 patients will receive primaquine
223768705|NCT04524403|DRUG|Miricorlilant|Miricorilant 600 mg (4 X 150 mg) for once-daily for oral dosing
223768706|NCT04524403|DRUG|Miricorlilant|Miricorilant 900 mg (6 X 150 mg) for once-daily for oral dosing
223768707|NCT04524403|DRUG|Placebo|Placebo for once-daily oral dosing
224240432|NCT01113268|OTHER|Cohort|Our main goal is to create a prospective cohort of 1500 patients with a first large myocardial infarction allowing us, in a second step, to identify susceptibility genes for the progression of patients towards chronic heart failure using a candidate gene/candidate pathway approach.
224240433|NCT01074710|DRUG|[2-13C] uracil|po, in the form of semi-solid meal, granules, once a period
224240434|NCT01074710|DRUG|[2-13C] uracil, placebo|po, in the form of semi-solid meal, granules, once a period
224240435|NCT05474248|BEHAVIORAL|Experimental group|Diaphragmatic Breathing Training
224240436|NCT00560235|DRUG|CP-751,871|Final dose 30 mg/kg IV on Day 1 of each 28 day cycle until either progression or toxicity
224240437|NCT01365650|DRUG|Ketorolac Tromethamine|Single intranasal dose of 30 mg ketorolac tromethamine (one 15 mg spray into each nostril) on Day 1 of Period 1
224240438|NCT01365650|DRUG|Oxymetazoline Hydrochloride|Single intranasal dose of oxymetazoline hydrochloride followed by a single intranasal dose of 30 mg ketorolac tromethamine (one 15 mg spray into each nostril) 30 minutes later on Day 1 of Period 2
224240439|NCT01365650|DRUG|Fluticasone Propionate|Seven days of treatment with intranasal fluticasone propionate (between Periods 2 and 3) followed by a single intranasal dose of 30 mg ketorolac tromethamine (one 15 mg spray into each nostril) on Day 1 of Period 3
223658377|NCT00798759|DRUG|Latanoprost ophthalmic solution 0.005% (XALATAN®)|Ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension, one drop a day, dosed topically for 12 weeks (84 days). Referred to as latanoprost.
223658378|NCT05410756|DIAGNOSTIC_TEST|Assessment of Voice Quality and Function|An acoustic voice analysis (fundamental frequency (F0), jitter, shimmer, noise to harmonic ratio (NHR), harmonic to noise ratio (HNR)) and an aerodynamic analysis (maximal phonation time (MPT)) were performed by an experienced otolaryngologist specialized in voice disorders for evaluation of objective voice quality and function. These analyses were performed on all the volunteers from both groups, and the results obtained were compared between the groups.
223658379|NCT03372759|PROCEDURE|airtamponade|airtamponade is applicated in the study group air
223658380|NCT03372759|PROCEDURE|saline|saline is left in the study Group saline
223658381|NCT04273880|DRUG|Methylphenidate|10mg of MPH taken an hour and a half before one of the testing sessions.
223658382|NCT04273880|DRUG|Vitamin C|90 mg of Vitamin C taken an hour and a half before the other testing session
224240440|NCT00532636|PROCEDURE|Ventilation|Mask ventilation in neutral and head extension position
224240441|NCT00532636|PROCEDURE|Ventilation|Mask ventilation in neutral and head extension position
223658383|NCT01677429|DEVICE|VR movie + balance challenge|Computer Assisted Rehabilitation Environment Integrated Reality System used for the challenge of balance control
223658384|NCT01677429|DEVICE|still pictures from VR|Monitoring only still pictures from the VR scene in a loop, no balance challenge
223658385|NCT01677429|BEHAVIORAL|Cognitive Behavioral Therapy|For the treatment of panic disorder
223658386|NCT00740935|BIOLOGICAL|Rotateq vaccine|"Vaccination against rotavirus~Three oral doses (2 mL) between 6 to 26 weeks of life with at least 4 weeks between each dose."
223658387|NCT05350956|DRUG|TPO-RA (Herombopag)|During the correction period, subjects will receive a dose of Herombopag starting at 5-7.5mg once daily, orally for 14 days, subject to dosing adjustment (or discontinuation) depending on their platelet response or at the investigator's discretion. In the secondary prophylaxis phase, Herombopag 5mg once daily, starting 5 days before antineoplastic therapy and continuing for 10-14 days.
223658388|NCT05350956|DRUG|TPO-RA (Herombopag) and rhTPO(Recombinant human thrombopoietin)|During the correction period, subjects will receive a combination of Herombopag and rhTPO, Herombopag starting at a recommended dose of 5mg once daily for 14 days. The recombinant human thrombopoietin dose is 300U/kg. bw/day or 15000U/day per person, once daily, for 14 consecutive days (or as determined by the investigator). In the secondary prophylaxis phase, Herombopag 5mg once daily, starting 5 days before antineoplastic therapy and continuing for 10-14 days.
223658389|NCT04331743|DRUG|Liposome-entrapped Mitoxantrone Hydrochloride Injection|Intravenous infusion
223768708|NCT00368940|BEHAVIORAL|PATH|PATH utilizes a problem solving approach based on Problem Solving Therapy (PST) and identifies problems that interfere with everyday functions and that contribute to depression and disability. The treatment then provides compensatory strategies and environmental adaptations that are designed to bypass the person's cognitive limitations and to improve adaptive functioning in the home environment. PATH also incorporates caregiver involvement to help patient reduce depression and improve functioning.
224240442|NCT01188837|OTHER|Full Kinetic Chain Manipulative Therapy|"Treatment will focus on restoring knee flexion and extension by lesser grades of mobilization and patellar mobilization along with careful high velocity low amplitude axial elongation of the knee joint.~Additionally, manipulative therapy will be applied where needed to the full kinetic chain using diversified techniques, such as HVLA manipulation or mobilization.~This group will receive a total of 6 treatments over a 3 week period. Outcome measures will be taken at baseline, prior to the 4th treatment and at the one week follow-up. A 3 month follow-up will be done by mail, phone or email."
224240443|NCT01188837|OTHER|Full Kinetic Chain Rehabilitation|"Rehabilitative therapy includes exercises, focused soft tissue treatment and stretch to the knee and the full kinetic chain where needed based upon functional assessment. Also included; patient advice, education and home exercise recommendations for managing their KOA.~This group will receive a total of 6 treatments over a 3 week period. Outcome measures will be taken at baseline, prior to the 4th treatment and at the one week follow-up. A 3 month follow-up will be done by mail, phone or email.~The rehabilitative therapy group will be required to attend the initial treatment/training, the 4th visit and 1 week follow-up. Treatments 2, 3, 5 and 6 are considered optional; they may be done at home"
223658390|NCT00724711|DRUG|emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF)|FTC 200 mg/TDF 300 mg tablet, once a day
223658391|NCT00724711|DRUG|abacavir (ABC)/lamivudine (3TC)|ABC 600 mg/3TC 300 mg tablet, once a day
223768709|NCT00368940|BEHAVIORAL|ST-CI|Supportive therapy focuses on the use of nonspecific or common factors of therapy, including facilitation of affect, helping the person feel understood, empathy, the treatment ritual, success experiences, and therapeutic optimism. In working with the participant, the therapist creates a supportive relationship and encourages the participant to consider his/her strengths and abilities rather than focusing on negative aspects of his/her character.
224240444|NCT01188837|OTHER|Full Kinetic Chain Manipulative Therapy with Rehabilitation|"This arm is a combination of the manipulative therapy arm and the rehabilitative therapy arm.~This group receives 6 treatments over a 3 week period with a one week follow-up on site and a 3 month follow-up by mail, phone or email."
224240445|NCT05960409|PROCEDURE|chest tube - emergency thoracotomy|chest tube is an inter-costal tube inserted intrathoracic in case of haemothorax and pneumothorax ,,,, emergency thoracotomy is an emergency exploration in severly injured patients
224240446|NCT04461665|OTHER|vitamin D|vitamin D supplement 10 μg daily for 2 months
224240447|NCT03408626|DRUG|Papain-based Chemo-mechanical caries removal agent|Birx 3000 and the exclusive Encapsulating Buffer Emulsifier (EBE) technology claim it has effective and selective proteolytic action to remove collagen fiber in the carious tissue. It has an antibacterial and antifungal power, thus it has an antiseptic power at the tissue level .furthermore, this gel does not contain chloramines in its formula, which enhances its toxicological safety feature.
224240448|NCT03408626|DEVICE|conventional rotary|traditional rotary method
223768710|NCT05937035|PROCEDURE|Customized allogenic bone block surgery|After studying the CBCT to regenerate the posterior sites of the mandible, the investigators will design CAD/CAM freeze- dried bone allograft to fit exactly on the defect morphology that the patients present. A full thickness flap will be released to have a correct access of the defects. Releasing incisions will be performed to achieve the correct closure of the flap. The sterile blocks have to fit perfectly on the defect and fixed by screws. Covered with resorbable membranes fixed with pines and suture. 4 months later, photographs, periapical xrays digital impressions and 2nd CBCTwill be performed. During the implant surgery, a bone trephine will be removed and sent into a Laboratory to make a histological study of the bone block for histomorphometry. After 3 months, second-stage surgery and healing caps will be placed if needed. Impressions will be taken 2 weeks after to perform the final crowns.
223768711|NCT01272167|BEHAVIORAL|Long-term grapefruit juice consumption|The main goals of this project are (1) to characterize the effect of a long-term grapefruit juice consumption on both vascular and bone protections and (2) to assess the specific role of naringin, in these potential protective effects.
223768712|NCT03992326|OTHER|TIL|Adoptive transfer of Autologous Tumor-Infiltrating Lymphocytes
223768713|NCT03992326|DRUG|Cyclophosphamide|Cyclophosphamide will be administered as an intravenous (IV) infusion for two days.
223768714|NCT03992326|DRUG|Fludarabine|Fludarabine will be administered as an intravenous (IV) infusion for five days.
223768715|NCT03992326|DRUG|Interleukin-2|After TIL infusion, IL-2 (optional) will be started as a bolus administration every eight hours, for a maximum of eight doses.
223768716|NCT03992326|OTHER|Radiotherapy|Low-dose irradiation (1Gy) will be administered using tomotherapy to up to 20 measurable tumor lesions once before TIL infusion.
223768717|NCT03609294|DRUG|Treatment A (Fimasartan, Linagliptin)|Co-administration of Fimasartan and Linagliptin
223768718|NCT03609294|DRUG|Treatment B (Fimasartan/Linagliptin)|Fixed Dose Combination of Fimasartan 120 mg/Linagliptin 5 mg
223768719|NCT04795414|BIOLOGICAL|SARS-CoV-2 Vaccine(Vero Cell), Inactivated|The subjects of Vaccination Group will receive two doses, 21 days apart of inactivated SARS-CoV-2 vaccine (4 μg of BBIBP-CorV)
223768720|NCT00002604|DRUG|O6-benzylguanine|Patients receive BG IV over 1 hour during week 1, and then BG IV over 1 hour during week 3. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.
223768721|NCT00002604|DRUG|carmustine|After one hour of receiving BG patients receive BCNU IV over 1 hour during week 3. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.
223768722|NCT00002604|DRUG|chemosensitization/potentiation therapy|
223768723|NCT03873285|GENETIC|Genetic diagnostic by mendeliome or genome|For cases not explained by a mendeliomes: genome and transcriptome on fibroblast culture
223768724|NCT03272594|OTHER|Breastfeeding|Infants will be placed in skin-to-skin contact with their mother at least five minutes prior to heel lance to allow time to settle and initiate breastfeeding. Breastfeeding position will be determined based on individual maternal preference in order to optimize feeding as well as to facilitate ease of access to the infant's foot for blood collection, while also attempting to minimize disruption of continuous EEG, heart rate, oxygen saturation, and video recording. Active breastfeeding will be facilitated to ensure it takes place for a minimum of two minutes prior to heel lance, and will continue until the procedure is completed.
223768725|NCT03272594|DRUG|24% oral sucrose|Administration of 24 percent oral sucrose will occur two minutes prior to the heel lance. Non-nutritive sucking will be offered using a gloved finger or pacifier (based on parental preference) immediately following administration of the complete 24 percent oral sucrose dose.
223768726|NCT02346565|PROCEDURE|Exercise ECG|
223768727|NCT02346565|PROCEDURE|Stress Echocardiography|
223768728|NCT02694991|OTHER|Osteopathic Manipulative Treatment|The thoracic wall is gently manipulated in conscious subjects in a supine position in order to facilitate greater diaphragmatic excursion. The thorax is palpated by applying a low pressure load directly on the skin in the direction of resistance, without any sliding over the skin or forcing of the subcutaneous tissue until it begins to yield and there is a sensation of softening. Sterile procedures are used when touching the patients near the surgical site. The treatment consists of a fixed and preordained sequence of three sessions, beginning with the costal arch on the diaphragm and then moving to the sternal area and, finally, the region of the thoracic outlet. The first two phases are performed from the right side, and the third from the head of the bed.
224240449|NCT04069637|COMBINATION_PRODUCT|Growth-sparing instrumentation and titanium levels|Patients with growth-sparing instrumentation as treatment for early onset scoliosis, will have their titanium (serum and urine) levels tested, to evaluated if they have elevated titanium levels compared to a control group.
224240450|NCT01532622|DIETARY_SUPPLEMENT|Blueberry Powder|Patients will take 30 grams of blueberry powder daily for up to 30 days
224240451|NCT01532622|OTHER|Placebo Powder|Patients will take 30 grams of placebo powder daily for up to 30 days.
224240452|NCT02845895|OTHER|Caregiver dedicated|Organization of nutrition screening with the help of a caregiver
224240453|NCT02845895|OTHER|Classic strategy|Classic organization with the training of the department team
224240454|NCT04366336|PROCEDURE|Blood Flow Restriction Training|Same as Standard PT with the exception that BFRT involves placing the pressure cuff before the start of therapeutic exercises
224321161|NCT02089607|DEVICE|Thoracoabdominal Aortic Aneurysm Arm|"The Zenith Fenestrated-Branched System is a tubular graft made of polyester fabric sewn to stainless steel stents that keep the graft open. The graft will be inserted through arteries in the leg (called endovascular repair). This procedure uses catheters that go inside the blood vessel to place a stent graft above and below the aneurysm.~The graft includes 1 to 5 small holes (fenestrations) or cuffs (side branches). The arteries to the liver, intestine, and kidneys will be have a stent (small tubular stainless steel structures) to help keep the arteries open and aligned with the fenestrations or branches."
223768729|NCT02037503|DRUG|Ketamine|
223768730|NCT02037503|DRUG|Saline|
223768731|NCT05050188|DRUG|H008|Drug administration after a minimum 10-hour overnight fasting. Subjects will be instructed to take the drugs with approximately 240 ml (8 oz) room temperature water.
223768732|NCT05050188|DRUG|H008 placebo|Drug administration after a minimum 10-hour overnight fasting. Subjects will be instructed to take the drugs with approximately 240 ml (8 oz) room temperature water
223658392|NCT04208113|BEHAVIORAL|School teacher training /.b|"The intervention is a multi-level, multi-component complex intervention. It consists of a school teacher training programme and the .b-programme to be delivered to pupils 11-15 years in the schools.~The school teacher training programme consists of three parts: 1) the establishment of own mindfulness practice by participation in the MBSR programme and sustaining mindfulness with a regular formal daily practice; 2) completion of the four days .b residential course, and 3) completion of the 3x2-days seminars on relational competences and implementation issues regarding teaching .b .~The .b programme consists of well-described, weekly 40-60 minutes classroom sessions over 10 weeks. All the sessions have a specific theme, associated teachers' notes, power points and animations. The .b programme can only be delivered with fidelity by a trained .b teacher."
223658393|NCT06321380|BEHAVIORAL|Complex span task|"The intervention consists in a computerized working memory task. This task follows the design of a complex span task, involving alternation between memorization and processing steps.~For each trial, participants have to memorize French words. These words are sequentially displayed on the screen. Between each word, participants perform a processing task consisting in a spatial location task: They have to determine if a shape is at the top or at the bottom of the screen. After each processing episode, participants have a free time (i.e., available time to maintain information in WM). At the end of each trial, participants perform an orally immediate recall. This experimental task involves several conditions in order to manipulate the opportunities for the spontaneous use of refreshing and elaborative strategies."
223658394|NCT06321380|DIAGNOSTIC_TEST|Clinical neuropsychological assessment|"As part of routine care, participants in the patient group undergo a standardized clinical neuropsychological assessment that evaluates several cognitive functions. The investigators hypothesize correlations between working memory performance during the experimental task and the results of neuropsychological tests. Thus, the investigators consider the results to several French versions of neuropsychological tests:~* MMSE (Mini-Mental State Examination)~* Digit Span Backward subtest (WAIS-IV)~* Stroop Test~* Trail Making Test (TMT)~* Rappel Libre - Rappel Indicé à 16 items or GERIA-12~* Category fluences~* Instrumental Activities of Daily Living and ADL ."
223658395|NCT06321380|DIAGNOSTIC_TEST|Clinical neurospychological assessement|"Participants in the control group undergo 2 tests clinical that evaluate cognitive functioning.~The investigators consider the results to French versions of these neuropsychological tests:~* MMSE (Mini-Mental State Examination; )~* Digit Span Backward subtest (WAIS-IV)"
223658396|NCT01945710|DRUG|Eribulin-LF|
223658397|NCT04314791|DEVICE|Ultrasound evaluation, with grayscale and color Doppler imaging|In pregnant women with previous CS and anterior low-lying or placenta previa, the following three sonographic criteria were assessed: (i) the smallest myometrial thickness in the sagittal plane; (ii) presence of placental lacunae and its grade from 0-3; (iii) bridging vessels using color Doppler. The PAI score (up to 9) was calculated for every patient as described by Rac et al.2015.
223658398|NCT00647569|PROCEDURE|Mesh repair|A Surgisis Gold Hernia repair graft (Cook Biotech Incorporated, West Lafayette, IN, U.S.A) is placed at the donor site of the rectus abdominis muscles used for the rotation flap before the abdominal fascia is sutured with continuous running suture.
223658399|NCT00647569|PROCEDURE|Conventional facial closure|The abdominal facia is closed with with continuous running suture
223658400|NCT00375609|DRUG|Betrixaban|Capsule
223658401|NCT00375609|DRUG|Enoxaparin|Administered subcutaneously
223658402|NCT05208840|DRUG|Ocrelizumab|Ocrelizumab will be given as slow intravenous infusion. Each treatment cycle has a duration of 6 months (5 cycles are planned in the study). The first cycle will consist of 2 infusions of 300 mg ocrelizumab (second infusion will be performed 14 days after first infusion). Cycles 2 through 5 will consist of one infusion of 600 mg ocrelizumab administered on Day 1 of each cycle.
223658403|NCT05554562|OTHER|Adductor strength assessment|Adductor strength will be evaluated with HHD (handheld dynamometer) and forceplates (Forceframe), both injured leg and healthy will be assess in order to compare both limbs
223658404|NCT00000724|DRUG|Trimetrexate glucuronate|
223658405|NCT00000724|DRUG|Leucovorin calcium|
223768733|NCT05050188|DRUG|Lansoprazole|Drug administration after a minimum 10-hour overnight fasting. Subjects will be instructed to take the drugs with approximately 240 ml (8 oz) room temperature water
223768734|NCT00785226|DRUG|RDEA119|Total daily doses of RDEA119 from 10 mg/day to 100 mg/day
224240455|NCT04366336|PROCEDURE|Standard Physical Therapy|Therapeutic exercise, including but not limited to: movement re-education, balance, and functional strength training; and Manual Physical Therapy including but not limited to passive range of motion (therapist will move your knee without your help), joint mobilization, soft-tissue mobilization and static stretching
224240456|NCT03757364|DRUG|Methotrexate|Methotrexate in the treatment of distal interphalangeal joint extensor tendon enthesopathy in patients with nail psoriasis
224240457|NCT02933775|GENETIC|CAR-CD19 T cells|Initial dose: A total of 1 - 10×10\^7 CAR-CD19 T cells/kg will be administered by 1 - 3 infusions. Subsequent dose will be based on the subject's response to initial dose.
223658406|NCT00979667|DRUG|Oseltamivir|75 mg twice daily for 5 days
223658407|NCT00979667|DRUG|Zanamivir|10 mg twice daily for 5 days
223658408|NCT00979667|DRUG|Placebo of Oseltamivir|twice daily for 5 days
223658409|NCT05330715|OTHER|Management|Comparison if different strategies to manage acute emergencies in the pre-hospital setting.
223768735|NCT00785226|DRUG|Sorafenib|Total daily doses of sorafenib from 400 mg/day to 800 mg/day.
223768736|NCT01023126|BEHAVIORAL|Group Psychotherapy|Group psychotherapy once a week, under a psychiatrist supervision
223768737|NCT03290508|DIAGNOSTIC_TEST|Prolaris Testing|Recently diagnosed treatment-naïve patients with early stage localized prostate cancer who undergo Prolaris testing
223768738|NCT05226104|DEVICE|MOXI|Patients will receive treatment using f1927 devices and will be treated twice over the affected areas, once each month for a total of two months.
223768739|NCT02349711|DIETARY_SUPPLEMENT|Probiotic mixture|A 350 mg capsule containing a mixture of Lactobacillus gasseri, Bifidobacterium bifidum, and Bifidobacterium longum (1.5 billion cells per capsule prior to expiration) will be taken twice daily for 8 weeks by subjects in the group receiving this supplement (group is unknown, double-blinded). Inactive ingredients include gelatin, potato starch, and silica.
223768740|NCT02349711|DIETARY_SUPPLEMENT|Placebo|Placebo will be taken as a capsule twice daily for 8 weeks by subjects in the group receiving this supplement (group is unknown, double-blinded). Supplement contains 348.25 mg of potato starch.
224240458|NCT02933775|DRUG|Fludarabine|30 mg/m\^2/day×4 days
223768741|NCT03347994|DRUG|Minnelide|Minnelide therapy may be administered for up to 12 cycles of 28 days are planned. If patients are receiving clinical benefit, treatment can continue beyond 12 cycles.
223658410|NCT03201081|OTHER|Motivational resistance-training programme|The experimental group exercised at a moderate intensity (8 to 12 repetitions). The load was increased during the 12 weeks from 65% 1-RM to 80% 1-RM. This training load was increased when the individual could perform more than the prescribed number of repetitions (12 repetitions), following the OMNI-RES scale and a hard effort perception level.74 A 1-2 minutes resting period was allowed between sets. During the sessions, the participants were verbally encouraged to perform the complete range of motion for each exercise and received motivational strategies.
223658411|NCT05864092|OTHER|Virtual Reality Goggles|We will offer patients virtual reality goggles with guided meditation software in addition to standard medical therapy (NSAID and opioid).
223658412|NCT05111301|DEVICE|Control-IQ technology 1.5|"All subjects wearing the t-slim X2 insulin pump with Control-IQ technology 1.5, and wearing the Dexcom G6 sensor.~Outcomes will be analyzed overall and subgroup analysis will be performed by Group, and by baseline A1c level."
223658413|NCT05154305|BEHAVIORAL|multidisciplinary intervention|"* individually adjusted physical program consisting of strength and endurance training \> 3 times a week, 2 times guided by a physical therapist at the University Hospital or at a private practice, and ones a week by themselves at home recorded by an activity tracker. Follow-up is foreseen on monthly basis.~* multidisciplinary coaching (discipline depending on personal needs of patient) on a monthly basis. These coaching sessions could be in small groups or individual."
223658414|NCT00985920|DRUG|tranexamic acid|"Patients will receive a solution containing either 1.5g or 3 g of tranexamic acid in 50 ml of normal saline (0.9% sodium chloride) or only 50 ml of saline without TA (placebo).~The treatment solution will be prepared under sterile conditions and coded at TWH pharmacy. In the OR the sterile bag containing the solution will be given to the scrub nurse. The contents (50 ml) will be emptied in a sterile surgical bowl. TA or placebo solution (50 ml) will be then applied to the open joint and tissues by the bulb syringe and will be left in contact with the tissues for 5 minutes. Excess solution will be subsequently suctioned by placing the suction tip on the cemented component without touching the joint and surrounding tissues."
223658415|NCT00985920|DRUG|Placebo|"Patients will receive a solution containing either 1.5g or 3 g of tranexamic acid in 50 ml of normal saline (0.9% sodium chloride) or only 50 ml of saline without TA (placebo).~The treatment solution will be prepared under sterile conditions and coded at TWH pharmacy. In the OR the sterile bag containing the solution will be given to the scrub nurse. The contents (50 ml) will be emptied in a sterile surgical bowl. TA or placebo solution (50 ml) will be then applied to the open joint and tissues by the bulb syringe and will be left in contact with the tissues for 5 minutes. Excess solution will be subsequently suctioned by placing the suction tip on the cemented component without touching the joint and surrounding tissues."
223658416|NCT01974739|DRUG|Hydrochloorthiazide|
223658417|NCT01974739|DRUG|placebo|
223658418|NCT03348189|OTHER|Pulse Oximeter|Pulse Oximeter
223658419|NCT04540510|DEVICE|OPEP therapy|Oscillatory Positive Expiratory Pressure therapy
223658420|NCT04540510|OTHER|Standard care|Standard pneumonia care
223658421|NCT02338882|DEVICE|Bi flex M multifocal intraocular lens|Multifocal intraocular lens
223658422|NCT02338882|DEVICE|Bi flex 1.8 monofocal intraocular lens|Standard monofocal intraocular lens
223658423|NCT01328405|DEVICE|Laryngeal Mask Airway (LMA)|Comparison of airway seal pressure, airway morbidity bronchoscopic view obtained between two different laryngeal mask airways.
223658424|NCT01371279|DEVICE|Intra-Cardiac Echocardiography guided atrial fibrillation ablation|8-F or 10-F phase array ICE-probe
223658425|NCT05207943|DEVICE|Non-invasive Neuromodulation|The electrodes will be placed with the help of gloves and adapted socks for 1 hour, twice a week, until 10 intervention sessions are completed. In addition, depending on the session, an adhesive electrode will be placed at the level of C7. Characteristics of microcurrents: pulsed monophasic rectangular wave with a pulse of 1.3 s and pause of 300 ms, voltage 3 millivolt and intensity 0.5 μA.
224240459|NCT02933775|DRUG|Cyclophosphamide|500 mg/m\^2/day×2 days
224240460|NCT04182737|DRUG|IgM-enriched polyclonal immunoglobulins titer-based treatment|Immunoglobulins will be administered in a personalized dose based on serum IgM-titers
223658426|NCT05207943|DEVICE|Placebo Non-invasive Neuromodulation|The same protocol described for the experimental group will be applied, but microcurrents device which will be previously manipulated and tested with an oscilloscope so that they do not emit electrical currents
223658427|NCT02216110|PROCEDURE|Surgery|Surgery for early gastric cancer includes distal gastrectomy, total gastrectomy, proximal gastrectomy, and wedge resection
223768742|NCT01479036|DRUG|docetaxel and epirubicin|docetaxel 75mg/m2, IV (in the vein) on day 1 of each 21 day cycle; epirubicin 75 mg/m2, IV (in the vein) on day 1 of each 21 day cycle, totally 3 cycles
223768743|NCT01479036|DRUG|docetaxel and epirubicin plus endostatin|docetaxel 75mg/m2, IV (in the vein) on day 1 of each 21 day cycle; epirubicin 75 mg/m2, IV (in the vein) on day 1 of each 21 day cycle; endostatin 7.5mg/m2, IV (in the vein) on 1st to 14th days of each 21 day cycle; every 3 weeks, totally 3 cycles
223768744|NCT02564198|DRUG|Ramucirumab|Administered IV
223768745|NCT03548610|OTHER|Nanofat-seeded biological scaffold on surgical defect|Nanofat-seeded biological scaffold in healing larger surgical defects (\>1.5cm) involving the lower limbs
223768746|NCT02721212|DEVICE|Armeo Spring|"All patients of experimental group were treated according to an established protocol for ARMEO Spring. In the first session the device was adjusted for patients arms. The physiotherapist controlled functional space of upper limb movement and correct position of working station.~Each training session consisted of two parts with 30 minutes per session with Armeo Spring and 30 minutes per session with conventional treatment 5 days per week, for 6 weeks."
224240461|NCT04182737|DRUG|IgM-enriched polyclonal immunoglobulins Flat treatment|Polyclonal endovenous immunoglobulins enriched in IgM administered in standard fixed dosages
223658428|NCT02381483|OTHER|Cold exposure|
224240462|NCT03365037|DRUG|Electret electrostatic physiotherapyFilm|Patients with acute soft tissue injury treated with electret electrostatic physiotherapyFilm
224240463|NCT03365037|DRUG|Fracture healing film|Patients with acute soft tissue injury treated with Fracture healing film
223768747|NCT02721212|OTHER|Conventional Rehabilitation|"The conventional treatment, under control of physiotherapist, consists of passive and active assisted mobilization of the upper limbs traditional training based on the Bobath concept (neuromuscular facilitation, postural control and proprioception exercises, verticalization and gait training).~Each training session consisted of 60 minutes with conventional treatment 5 days per week, for 6 weeks in a control group.~The conventional session in the experimental group lasted 30 minutes with the same techniques and methods."
223768748|NCT05733676|DEVICE|Resin infiltration|Base line treatment of white spot lesions in smooth surface with Resin infiltration -Icon + etch, DMG, Germany.
223768749|NCT05733676|DEVICE|Casein Phosphopeptide (CPP) - Amorphous Calcium Phosphate (ACP) - Fluoride|Base line treatment of white spot lesions in smooth surface with MI paste plus + etch , GC corporation, Germany, Europe
223768750|NCT03777124|DRUG|SHR-1210|Subjects receive SHR-1210 intravenous every 2 weeks
223768751|NCT03777124|DRUG|Apatinib|Subjects receive Apatinib orally every day
223768752|NCT03777124|DRUG|Pemetrexed|Subjects receive Pemetrexed intravenous every 3 weeks
223768753|NCT03777124|DRUG|Carboplatin|subjects receive carboplatin intravenous every 3 weeks
223768754|NCT01019655|DRUG|Nadroparin calcium|nadroparin calcium (fraxiparin®) 0.3 mL daily during pregnancy and six weeks post partum
223768755|NCT06393192|PROCEDURE|Epidural analgesia (EA) only group|The epidural needle will be inserted into the lumbar epidural space at the level of L2-3 intervertebral space.
223768756|NCT06393192|PROCEDURE|Quadratus lumborum block (QL2)|0.2% bupivacaine at a volume of thirty milliliters were administered at the specified sites on each side behind the QL muscle, resulting in a total of Sixty mL
223768757|NCT06393192|PROCEDURE|Quadratus lumborum block 3(QL3)|0.2% bupivacaine at a volume of thirty milliliters were administered at the specified sites on each side among the QL muscle and the psoas major, resulting in a total of Sixty mL
223768758|NCT06393192|PROCEDURE|Quadratus lumborum block 2+3 QL(2+3)|0.2 percent bupivacaine solution of fifteen milliliters were administered at each injection site, with the needle being inserted once on each side
223768759|NCT01285765|DRUG|RCHOP21|Prednisone-60 mg/m2: D1 D2 D3 D4 D5;Rituximab-375 mg/m2 : D1; Doxorubicin-50 mg/m2 D1;Cyclophosphamide-750 mg/m2:D1 Vincristine-1.4 mg/m2 :D1; G-CSF SC -5 microg/kg/day: D6 to D13
223768760|NCT04669210|DRUG|Ruxolitinib|Ruxolitinib administered during conditioning 5 mg tid before allogeneic hematopoietic stem cell transplantation, 5 mg tid days 5-21 and 5 mg bid days 22-150 after transplantation instead of tacrolimus and MMF.
223768761|NCT04669210|DRUG|Tacrolimus|Tacrolimus 0.03 mg/kg adjusted to concentrations 5-15 ng/ml from day+5 to +100
224240464|NCT01524653|DRUG|Rosuvastatin|20 mg po od
224240465|NCT01524653|DRUG|Placebo|20 mg po od
224240466|NCT02148302|DEVICE|Harvesting Device (CelluTome©)|Subjects who continue to meet eligibility criteria will be randomized to one of two groups: (1) Up to 3 applications of Epidermal grafting harvested utilizing the CelluTome® system at day zero, week 4 and week 8, visits plus standard of care (multi-layer compression) (2) Multilayer compression alone.
223768762|NCT04669210|DRUG|Mycophenolate Mofetil|Mycophenolate mofetil 30 mg/kg from day +5 to +35
223768763|NCT04699994|DRUG|FLOT therapy|Preoperative FLOT therapy
224240467|NCT03858712|OTHER|Active Care Team Alert|"2\) Active care team alert via office practice nurse monitoring of ePRO oral responses scored at 3, indicating moderate-severe (grade ≥3) toxicity.~Office practice nurses will monitor ePRO oral responses and respond to those scored at 3 per disease center symptom management protocol.~The ePRO oral responses from the remaining participants will additionally be monitored by office practice nurses who will respond to ePRO responses with scores of 3, indicating a moderate-severe toxicity (grade 3 or higher)."
224240468|NCT03858712|OTHER|Passive Care Team Alert|"Primary care teams are assigned an EHR inBasket pool through which PP messages are delivered. Providers will be responsible for reviewing ePRO responses via inBasket, selecting mark as reviewed button as mandated for all clinical messages within 48 hours per policy."
223768764|NCT04731441|BEHAVIORAL|Home-based Exercise Program Prior to CRS-HIPEC|Exercise Program Subjects randomized to the intervention arm should have 6 weeks of home exercise prior to surgery, with a minimum of 5 weeks and not more than 7 weeks. The program will begin with an exercise consultation appointment with a certified fitness professional. During this consultation participants will receive an exercise manual for individualized home-based exercise and a practical introduction by an exercise and cancer specialist. PowerBlock adjustable dumbbells will be used for resistance training exercises and walking or jogging will be the primary type of aerobic training. The current program design was developed and successfully used with women with breast cancer. Thus, some components may need modification for this group of patients with advanced GI cancer.
223768765|NCT04731441|BEHAVIORAL|Exercise Education|Control arm: Subjects randomized to the control arm will receive education and a handbook on the benefits of exercise and will be encouraged to have adequate protein in their diet and provided with the list of high protein foods and nutritional information. These subjects will undergo the same assessments as the intervention arm at all time points. Control subjects will be offered a 6-week home exercise program 3 months after CRS/HIPEC, as described in sections 7.2.1-7.2.3. Results and outcomes will not be recorded.
223768766|NCT02200042|RADIATION|Image Guided Radiation Therapy|Patients undergo 15 fractions of image-guided radiation therapy delivered over 19-26 or 27-34 days.
224240469|NCT01272752|DIETARY_SUPPLEMENT|IHBG-10|500 mg IHBG-10
224240470|NCT01272752|DIETARY_SUPPLEMENT|Placebo|Placebo taken 15 minutes prior to the three main meals of the day
224240471|NCT01684969|DRUG|Haloperidol|0.5 mg iv x one dose
224240472|NCT01684969|DRUG|Placebo|0.5 mg iv , one dose
224240473|NCT04605107|DRUG|Epifasi: Human chorionic gonadotrophin|IM Injection of 1 ampoule contains 5000 I.U. of Human chorionic gonadotrophin
224240474|NCT04605107|DRUG|Pregnyl: Human chorionic gonadotrophin|IM Injection of 1 ampoule contains 5000 I.U. of Human chorionic gonadotrophin
224240475|NCT03289156|BEHAVIORAL|Arousal Reappraisal|Brief readings educating about the stress response and usefulness of arousal reappraisal.
224240476|NCT03289156|BEHAVIORAL|Exercise|Three 5-minute bouts of exercise at increasing intensities (65%, 75%, and 85%) with 5-15 minute breaks in-between for recovery.
224240477|NCT00353353|PROCEDURE|consumption of fortified bread|
224240478|NCT00566800|DRUG|erlotinib hydrochloride|
224240479|NCT00566800|OTHER|laboratory biomarker analysis|
224240480|NCT00566800|PROCEDURE|biopsy|
224240481|NCT01203878|DRUG|Photodynamic therapy|Administered 4 weeks after completion of imiquimod therapy
223658429|NCT03495609|DRUG|Ovitrelle|Ovitrelle will be injected in 35 asymptomatic women with BRCA1 or BRCA2 mutation during 90 days (an extra 4 weeks in a subgroup). The gene expression of the breast epithelial cells will be characterized and compared to the gene expression of the breast epithelial cells before ovitrelle injection.
223658430|NCT04156542|BEHAVIORAL|Basic School Lunchroom Nudges|"The intervention consists of three components: 1) serving fresh fruit in attractive bowls in at least two locations on the lunch line; 2) providing descriptive names for the vegetables; and 3) increasing amount of plain milk availability by 10% and placing it in front of the chocolate milk. For the vegetable naming intervention, researchers first developed, printed, and laminated descriptive vegetable name cards (2x4). Some examples included Savory Collard Greens, and \[School Mascot\] Salad. Cafeteria staff affixed name cards to the serving line sneeze-guards in front of the vegetables for the day. For the fruit intervention, we purchased and delivered two ceramic bowls to the intervention school. The cafeteria staff filled the bowls and put them in different locations on the lunch line. For the milk intervention, cafeteria staff increased the amount of plain milk available by 10% and placed plain in front of chocolate milk in the coolers."
223658431|NCT02346773|DIETARY_SUPPLEMENT|ω-3 LC-PUFA|The intervention product was a full fat (80%) margarine.Participants were provided with one-month supply of the intervention product (including reserve products) at the onset of the intervention and received a new supply monthly. The intervention products were provided in neutral serving-sized cups, each containing 10 grams of margarine.The child's parents were instructed to have their child consume one complete portion pack (10 g) of margarine per day. The margarine had to be consumed as spread on sandwiches, crackers or bread rolls.The intervention product could be consumed on various periods over the day or all at one occasion. Every day a new portion pack had to be used, even if there was margarine left in the package of the previous day.
223658432|NCT02346773|OTHER|Placebo|The placebo product was a similar margarine with the same sensory properties, but with monounsaturated fatty acids (MUFA; refined plant oils) replacing EPA and DHA; total saturated fatty acids (SAFA) and ω-6 long chain polyunsaturated fatty acids (LC-PUFA) content were similar between the active and placebo products.
223658433|NCT05366400|DIAGNOSTIC_TEST|ECHO|Conventional routine tests and ECHO will be assessed. Biomarkers will be measured using ELISA The functional capacity was assessed by the COPD assessment test (CAT) questionnaire.
223658434|NCT00561860|DEVICE|Telemedicine Arm|Telemedicine involves the provision or support of direct clinical care via the application of electronic and communicating technology, including the remote monitoring of health status. By providing patient data early in the course of CPAP prescription, we believe that this technology would be immensely useful in improving compliance and acceptance of the device in patients with sleep apnea.
223658435|NCT02935829|OTHER|Glucose as reference food|Ten subjects (male: 6, female: 4) consumed 25g glucose diluted in 250ml water, two times, in different weeks, within 5-10 min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
223658436|NCT02935829|OTHER|White bread as reference food|Ten subjects (male: 6, female: 4) consumed 25g available carbohydrate from white bread along with 250ml water, two times, in different weeks, within 10-15 min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
223658437|NCT02935829|OTHER|Carob snack as test food|Ten subjects (male: 6, female: 4) consumed 25g available carbohydrate from carob snack along with 250ml water, one time, in different weeks, within 10-15 min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
223658438|NCT02935829|OTHER|Chocolate cookie snack as test food|Ten subjects (male: 6, female: 4) consumed 25g available carbohydrate from chocolate cookie snack along with 250ml water, one time, in different weeks, within 10-15 min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
223658439|NCT02935829|OTHER|Carob preload|Fifty healthy subjects (male: 22, female: 28) consumed a standardized breakfast (bread and honey) and 2h after were offered a preload given as snack (40g carob snack). Three hours after, subjects were given ad libitum access to a meal (lunch and dessert). The meal consisted of rice, roasted chicken breast and chocolate cake. Foods were weighed before serving and any leftovers were weighed again after meal. Fingertip capillary blood glucose samples were taken before breakfast, 120min after breakfast; before preload, 120minand 180minpost-preload consumption; before meal (lunch and dessert), 60minand 120min post-meal consumption. Subjective appetite ratings were assessed with 100mm VAS.
223658440|NCT02935829|OTHER|Chocolate cookie preload|Fifty healthy subjects (male: 22, female: 28) consumed a standardized breakfast (bread and honey) and 2h after were offered a preload given as snack (40g chocolate cookie). Three hours after, subjects were given ad libitum access to a meal (lunch and dessert). The meal consisted of rice, roasted chicken breast and chocolate cake. Foods were weighed before serving and any leftovers were weighed again after meal. Fingertip capillary blood glucose samples were taken before breakfast, 120min after breakfast; before preload, 120minand 180minpost-preload consumption; before meal (lunch and dessert), 60minand 120min post-meal consumption. Subjective appetite ratings were assessed with 100mm VAS.
223658441|NCT04745949|DRUG|Brentuximab Vedotin|Given IV
223658442|NCT04745949|DRUG|Cyclophosphamide|Given IV
223658443|NCT04745949|DRUG|Doxorubicin|Given IV
223658444|NCT04745949|BIOLOGICAL|Nivolumab|Given IV
223658445|NCT04745949|DRUG|Prednisone|Given PO
223658446|NCT04745949|OTHER|Quality-of-Life Assessment|Ancillary studies
223658447|NCT04745949|BIOLOGICAL|Rituximab|Given IV
223658448|NCT04838977|BEHAVIORAL|RESET|Therapy
223658449|NCT01600144|OTHER|digital mammography|data collection
223658450|NCT00786370|DRUG|dexmedetomidine|Propofol or dexmedetomidine infusion will be started according to the randomized treatment allocation. The propofol group will receive a bolus of 2mg midazolam and 100mcg fentanyl and then continuous propofol infusion at 50-100mcg/kg/min until a Ramsay score of 3 or Bis score of 60-80 is achieved. The dexmedetomidine group will receive a bolus of dexmedetomidine 1mcg/kg for 10 minutes and then a continuous infusion of dexmedetomidine 0.2-0.7mcg/kg/hr until a Ramsay score of 3 or a Bis score of 60-80 are achieved.
223658451|NCT00786370|DRUG|Propofol|continuous propofol infusion at 50-100mcg/kg/min until a Ramsay score of 3 or Bis score of 60-80 is achieved
224240482|NCT01203878|DRUG|Imiquimod|Imiquimod 3.75% cream, up to 2 packets, applied topically daily for two 2-week cycles separated by a no-treatment interval of 2-weeks, followed observation
223658452|NCT00786370|DRUG|Dexemedetomidine|continuous infusion of dexmedetomidine 0.2-0.7mcg/kg/hr until a Ramsay score of 3 or a Bis score of 60-80 are achieved.
223658453|NCT03323424|RADIATION|Systemic treatment + Stereotactic Body Radio-Therapy (SBRT)|"According to the usual practice, patients will receive their systemic treatment, composed of :~* Taxane + trastuzumab +pertuzumab for metastatic breast cancers;~* FOLFOX or FOLFIRI + cetuximab for metastatic colorectal cancers;~* 5FU-Platine + cetuximab for metastatic head and neck cancers; for six cycles and a maintenance of the targeted therapy until progression or unacceptable toxicity.~If progression occurs before the 6th cycles, patients could receive a different line of treatment, according to the usual practice.~In addition to the systemic treatment, patients randomized into this experimental group will receive a SBRT of 45Gy in 3 fractions for hepatic and pulmonary metastasis, 27Gy in 3 fractions for bone metastasis and 33 Gy in 3 fractions for intra-cranial metastasis."
223658454|NCT03323424|OTHER|Systemic treatment|"According to the usual practice, patients will receive their systemic treatment, composed of :~* Taxane + trastuzumab +pertuzumab for metastatic breast cancers;~* FOLFOX or FOLFIRI + cetuximab for metastatic colorectal cancers;~* 5FU-Platine + cetuximab for metastatic head and neck cancers; for six cycles and a maintenance of the targeted therapy until progression or unacceptable toxicity.~If progression occurs before the 6th cycles, patients could receive a different line of treatment, according to the usual practice."
223658455|NCT01145092|BEHAVIORAL|exercise training, endurance training|The endurance training group exercised on a cycle ergometer (90% of power output determined at the respiratory compensation point = RCP). The duration of each training unit was increased with time. The resistance group trained on 8 weight machines where the workload gradually increased every 2-3 weeks. At week 13 an additional physical examination, OGTT and spiro-ergometry for adjusting the training were performed.
223768767|NCT03260816|BEHAVIORAL|Internet-delivered Parent-Child Interaction Therapy (I-PCIT)|Families assigned to the Internet-delivered Parent-Child Interaction Therapy (I-PCIT) group will receive Internet-delivered weekly sessions of a short-term parent-training intervention emphasizing positive attention, consistency, problem-solving, and communication. Using videoconferencing, webcams, and wireless Bluetooth earpieces, I-PCIT therapists provide in-the-moment feedback to parents during live parent-child interactions.
223768768|NCT03260816|OTHER|Referrals as Usual (RAU)|Families assigned to RAU will participate in services referred by their Early Steps team, as per usual care.
223768769|NCT03637751|BEHAVIORAL|Behavioral|Trier Social Stress Test
223768770|NCT03637751|BEHAVIORAL|Control condition|In the no-stress control condition, participants will be instructed to sit in a room, read magazines, and to refrain from any stressful activities (e.g., cell-phone use will be restricted).
223658456|NCT03065972|PROCEDURE|Surgical fistula creation from patient's anatomy|Patient will be randomized via computer system, to receive the fistula or graft. If fistula, surgeon creates fistula for hemodialysis access from patient's anatomy.
223658457|NCT03065972|DEVICE|Surgical Graft implant|Patient will be randomized via computer system, to receive the fistula or graft. If graft, surgeon implants hemodialysis access using an FDA approved graft.
223768771|NCT02097134|DRUG|Melphalan|Given IA
224240483|NCT04314869|PROCEDURE|Uterus transplantation|Patient will undergo surgery in order to transplant the graft (uterus). After that, a follow-up in order to detect early rejection. After 6 months, embryo transfer will be perfomed. Labour route will be C-Section. Two pregnancies are agreed, and after the second one, a hysterectomy will be performed in order to remove the graft.
223658458|NCT05648032|COMBINATION_PRODUCT|lyophilized platelet (30ng) and triamcinolone acetonide 10mg|Ultrasound-guided injection of lyophilized platelet (30ng)+1.0 mL 1.0% Lidocaine+1.0 mL (10.0 mg/mL) Triamcinolone acetonide into the hypoechoic area of common extensor tendon (in lateral epicondylopathy) or around calcific spots (in supraspinatus calcific tendinitis)
223768772|NCT00218062|DRUG|D-Amphetamine 30mg|
223768773|NCT00218062|DRUG|D-Amphetamine 60mg|
223768774|NCT00218062|DRUG|Modafinil 200mg|
223768775|NCT00218062|DRUG|Modafinil 400mg|
223768776|NCT00218062|BEHAVIORAL|Therapy|Manual-based, cognitive-behavioral therapy was provided for 1 hour each week by master's-level therapists. The cognitive-behavioral therapy emphasized relapse prevention and coping skills.
223768777|NCT00218062|DRUG|Placebo|
223768778|NCT04824534|OTHER|Motion analysis|Motion analysis is performed in the Motionlab using Vicon systems. Surgery (in case of SI patients) is performed with iFuse implant system for sacroiliac joint fusion
223768779|NCT06426797|DRUG|Cadonilimab plus anlotinib|cadonilimab (10mg/Kg, ivgtt, d1) and anlotinib (12mg, P.O., d1-d14) on a 21-day regimen for 3 cycles
223768780|NCT02839434|PROCEDURE|Blood sample|This blood sample does not require specific puncture because it is made on the occasion of a sample justified by the patient monitoring.
224240484|NCT00162669|DRUG|bevacizumab|
224240485|NCT03904966|DEVICE|Kinesio tape|Kinesio tape will be applied on the plantar heel (the most painful area) of the patients for the treatment of plantar fasciitis, in addition to the extracorporeal shock wave therapy
224240486|NCT03904966|DEVICE|Extracorporeal shock wave therapy|Extracorporeal shock wave therapy will be used for all patients with plantar fasciitis. (5 sessions for 5-week)
224240487|NCT00815763|DRUG|ginsenoside-Rd|infusion ginsenoside-Rd 20 mg once a day and continued for 14 day
224240488|NCT00815763|DRUG|placebo|infusion placebo once a day and continued for 14 day
224240489|NCT03507335|DEVICE|chest strap and PPG-device for monitoring the rhythm|chest strap and PPG-device for monitoring the rhythm during 24 hours for both groups (atrial fibrillation and sinus)
224240490|NCT00437658|DRUG|Elagolix|Provided as tablets for oral administration
224240491|NCT00437658|DRUG|Subcutaneous depot medroxyprogesterone acetate (DMPA-SC)|Provided for subcutaneous injection in a prefilled syringe, 104 mg/0.65 mL per syringe.
224240492|NCT00437658|DRUG|Placebo to Elagolix|Matching placebo tablets for oral administration
224240493|NCT00437658|DRUG|Placebo to DMPA-SC|Matching placebo for subcutaneous injection in a pre-filled syringe
224240494|NCT02603224|DRUG|MRG-201|Intradermal injection of single ascending doses and multiple ascending doses in healthy volunteers.
223658459|NCT05648032|OTHER|lyophilized platelet (30ng)|Ultrasound-guided injection of PLT (30ng)+1.0 mL 1.0% Lidocaine+1.0 mL normal saline into the hypoechoic area of common extensor tendon (in lateral epicondylopathy) or around calcific spots (in supraspinatus calcific tendinitis)
223658460|NCT05648032|DRUG|triamcinolone acetonide 10mg|Ultrasound-guided injection of 1.0 mL 1.0% Lidocaine+1.0 mL (10.0 mg/mL) Triamcinolone acetonide into the hypoechoic area of common extensor tendon (in lateral epicondylopathy) or around calcific spots (in supraspinatus calcific tendinitis)
223658461|NCT00095940|DRUG|lapatinib ditosylate|Given orally
223658462|NCT00095940|PROCEDURE|therapeutic conventional surgery|Undergo surgery
223658463|NCT00095940|OTHER|laboratory biomarker analysis|Correlative studies
223658464|NCT00095940|OTHER|pharmacological study|Correlative studies
223658465|NCT00095940|PROCEDURE|positron emission tomography|Correlative studies
223658466|NCT00095940|PROCEDURE|magnetic resonance imaging|Correlative studies
223658467|NCT04259619|DEVICE|Low-Level Laser Therapy|The low-level laser emits monochromatic, coherent, bundled laser light. In each therapy a energy dose of 2-4 Joul (J) / centimeter (cm)\^2 is applied over a duration of about 30 seconds using level 1 (20 percent of maximum output) of the 350 milliwatt (mW) device.
223658468|NCT04259619|DEVICE|Placebo Therapy|The intervention is conducted identically to the low-level laser therapy but the placebo laser that is used emits only red light that is polychromatic, leading to a reduction in energy being emitted and therewith to no or a smaller effect.
223658469|NCT05233241|OTHER|in vitro Allergological test Allergological skin tests|"In vitro allergological tests: lymphocyte transformation test, measurement of CD154 membrane expression, ELISPOT-IFNgammma Allergological skin tests (patch tests, prick tests and intradermal tests with European standardised method) in case of negative in vitro tests."
223658470|NCT00922948|PROCEDURE|Cryoablation|Cryoneedles and one temperature probe are inserted under endoscopic and sonographic guidance.
223658471|NCT00922948|PROCEDURE|Radiofrequency ablation|Thermal injury is the predominant mechanism of action of RFA. A high-frequency alternating current emitted from the exposed noninsulated portion of the electrode generates frictional heat, agitating ions in the tissue surrounding the tip of the needle.
223658472|NCT00621062|PROCEDURE|High Ligation of the GSV|Performed in local or general anesthesia in accordance to clinical praxis and the patients own preference. After high ligation the GSV is stripped from the groin to the most distant insufficient part or just under the knee joint.All proximal branches are ligated. Including the superficial epigastric vein. The stripping instrument can be inserted in either cranial or caudal direction but all veins are stripped in the cranio-caudal direction.
223658473|NCT00621062|PROCEDURE|Endovenous Laser Ablation|Laser ablation is performed in tumescence anesthesia which is performed with a 150-200 ml (sometimes more is required, up to 400ml in patients with a poorly formed saphenous sheath) solution of lidocaine with adrenaline supplement. General sedation can be administrated as a supplement (with intravenous Propofol or Dormicum when needed). Laser is performed under duplex guidance and the catheter is inserted percutaneously into the GSV at knee level and parked distant to the saphenofemoral junction (SFJ) just distal to the superficial epigastric vein. Laser ablation is performed down to the most distal insufficient part of GSV or just below the knee joint. We use an effect of 14 Watt administration of 70-80 J / cm at a continuous mode at a speed of 1cm/5sec.
223658474|NCT00621062|PROCEDURE|Radiofrequency ablation|RF ablation is performed in tumescence anesthesia which is performed with a 150-200 ml solution (same as above) of lidocaine with adrenaline supplement. General sedation can be administrated as a supplement (with intravenous Propofol or Dormicum when needed). RF is performed under duplex guidance and the Closure-FAST catheter is inserted percutaneously into the GSV at the knee level and parked distant to the SFJ just distal to the superficial epigastric vein. Probe size and length used for RF is chosen in accordance to the manufacturer's recommendation and with a probe temperature of 120 degrees C. RF closure is performed down to the most distal insufficient part of GSV or just under the knee joint.
223768781|NCT01176825|BEHAVIORAL|cognitive-behavior therapy (CBT)|14 sessions of individual cognitive-behavior therapy. Sessions last 50-60 minutes and are held weekly. 2 optional monthly booster sessions may also be held after the end of treatment.
223768782|NCT05567731|DRUG|ultrashort GnRHa|"the patients used the ultrashort protocols with GnRH agonist (GnRH-a, and recombinant Follicle-Stimulating Hormone for controlled ovarian hyperstimulation (COH). Form the second day of menstrual cycle, 0.1 mg/d GnRHa will be injected by subcutaneous injection for 3-4 d.~Gonadotropins will be added from the third day of menstrual cycle and the initial gonadotropin doses will be 225-300 IU/d. During the treatment, gonadotropin doses will be adjusted according to guided monitoring of follicle growth and measurement of serum estradiol (E2) levels of 10 000 units of human chorionic gonadotrophin (hCG) will be administered when 43 follicles will be 418 mm"
224240495|NCT02603224|DRUG|Placebo|Intradermal injection of placebo at a second site in healthy volunteers. Each subject will serve as their own control.
224240496|NCT02932696|OTHER|Cardiac training program|"This program takes place at the Cardiovascular Rehabilitation Department at the Nîmes University Hospital and includes a combination of various physical activities: treadmill, exercise bike, rower, aerobics, gymnastics, serious games, swimming. The program begins approximately within 3 months after myocardial infarction and consists of 20 consecutive days of training. The main physical activity is aerobic interval training (AIT).~30-minute AIT sessions will occur 5x per week for 4 weeks.~1 AIT session includes a warm up for 8 minutes to reach a heart rate during exercise corresponding to 20 to 30% of maximum aerobic power determined during the initial effort test. Then interval training occurs with 4x2 min of high intensity effort (heart rate during exercise corresponding to 80% of maximum aerobic power) alternating with 2 min of active recovery at 20-30% of maximum aerobic power. Then recovery for 8 minutes."
224240497|NCT02068105|DRUG|ALKS 5461|Sublingual tablet
224240498|NCT02068105|DRUG|Placebo|Sublingual tablet
223658475|NCT00621062|PROCEDURE|Foam Sclerotherapy|Sclerosant foam consists of 2ml 3% aethoxysclerol mixed with 8ml air (Tessari method). A maximum of 10 ml is injected. Access to the vein for the sclerosant is gained by a duplex guided puncture or a mini incision mid-thigh or just above the knee and the amount of sclerosant foam used is 2,5-10 ml. Duplex is used prior to the operation in order to mark the vein and during the operation in order to control the extent of the sclerofoam. Duplex validates that foam is deposed to the whole length of the GSV. Blood from the veins is drained by means of elevation prior to the deposition of the sclerofoam. The leg is then bandaged with elastic bandage.
223768783|NCT05567731|DRUG|short GnRHa|"Buserelin acetate 100 mg five times daily and FSH will be started on the 2nd day of the menstrual cycle as short application. The dose of gonadotropin hormone will be individualized according to the patient's age and previous stimulation history or response to stimulation. Cycles will be monitored by transvaginal ultrasonography and serum estradiol (E2) levels.~Follicular maturation will be completed by the administration of 10000 IU human chorionic gonadotrophin (hCG) when at least two follicles reached a diameter of \>18 mm. Thirty-five to thirty-six hours after human chorionic gonadotrophin (hCG) administration, ovum retrieval will be performed by transvaginal echo-guided ovarian puncture."
224240499|NCT04641130|OTHER|Exposure to birch pollen in EEC|Patients are exposed to airborne birch pollen allergen. The duration of each exposure is 4h maximum.
224240500|NCT05372926|DEVICE|high flow nasal canulae|high flow nasal canulae is a oxygen therapy technic which allows the administration of warmed and humidified oxygen with a flow up to 50L/Min and a monitored FiO2. Physiological previous studies reported various effects of this technic especially on work of breathing. In our study the investigators aim to test this physiological property during exercise.
223658476|NCT00621348|DRUG|Isotonic fluid|0.9% saline with 5% dextrose at standard maintenance rate
223658477|NCT00621348|DRUG|Hypotonic fluid|Reduced volume (two thirds of standard maintenance rate) of N/5 saline in 5% dextrose
223658478|NCT00621348|DRUG|Hypotonic fluid|N/5 saline in 5% dextrose at standard maintenance rate
223658479|NCT00473733|PROCEDURE|GLP receptors expression|
223658480|NCT00473733|PROCEDURE|ESOPHAGOGASTRODUODENOSCOPY|
223658481|NCT01785992|DRUG|Irosustat|Patients will receive 40mg of Irosustat once daily in addition to the aromatase inhibitor on which they progressed until disease progression or development of unacceptable toxicities.
223658482|NCT06278818|BEHAVIORAL|Cognitive Telerehabilitation|Cognitive training specifically designed to promote cognitive functions in early stages of neurodegenerative conditions.
223658483|NCT06278818|OTHER|Control Condition|This activity is commonly used as a control condition to test the effectiveness of innovative rehabilitative treatments.
223658484|NCT06148454|BEHAVIORAL|App-based Positive Psychology Intervention (A&B)|An app-based, evidence-based positive psychology intervention focusing on two modules: (A) Awareness \& Positivity and (B) Meaning and Accomplishment
223658485|NCT06148454|BEHAVIORAL|App-based Positive Psychology Intervention (C&D)|An app-based, evidence-based positive psychology intervention focusing on two modules: (C) Rapport \& Conflict Management and (D) Compassion \& Leadership
223658486|NCT03304158|BEHAVIORAL|FCHV visit|FCHVs will visit selected households 3 times a year for providing health promotion messages and measure the blood glucose
223658487|NCT02042716|OTHER|diagnosis of white matter damage in preterm infants|Added value of supersonic shear imaging in the diagnosis of white matter damage in preterm infants
223658488|NCT02206971|OTHER|urine analyses feedback|biomarker feedback report regarding the urine sample analyzed for the tobacco chemicals, cotinine, nicotine and NNAL
223658489|NCT03073837|OTHER|Rhinovirus Challenge|Challenge with HRV-16 virus
223658490|NCT03747666|PROCEDURE|2.0 single locking miniplates|The fractured segments in the parasymphyseal region will be fixed using 2.0 single locking miniplates placed on the inferior border of the mandible.
223658491|NCT01536067|BIOLOGICAL|ofatumumab|Given IV
223658492|NCT01536067|DRUG|bortezomib|Given SC
223658493|NCT01536067|OTHER|laboratory biomarker analysis|Correlative studies
223658494|NCT03120351|DRUG|Lidoderm 5 % Topical Patch|Patients will receive Lidoderm topical 5% lidocaine patches. Those will be placed to affected area up to three patches as needed for pain 12 hours on and 12 hours off
223658495|NCT03120351|DRUG|Placebo patch|2\) Group II: Patients will receive placebo patches. Those will be placed to affected area at dose up to three patches as needed for pain 12 hours on and 12 hours off
223658496|NCT01438736|DRUG|Desogestrel 75 micrograms POP (Cerazette), Etonogestrel 68 mg implant (Nexplanon)|Desogestrel 75 micrograms POP daily for 3 monts, followed by etonogestrel 68 mg subdermal implant for following 6 months
223658497|NCT01438736|DRUG|Etonogestrel 68 mg subdermal implant|Etonogestrel 68 mg subdermal implant for 6 months
223658498|NCT01507064|DRUG|Sorafenib|tablets 200mg dosage: 400mg bid duration: 4 weeks
223658499|NCT01507064|PROCEDURE|laser ablation (LA)|"For LA, we use a commercially available system (Echolaser XVG system, Esaote El.En., Florence, Italy) and four optical fibers,inserted into the tumor through four 21-gauge needles. The tips of the needles will be positioned at a distance of 15mm from each other.~When, after LA treatments, CT or MRI findings show a residual nodule activity of 10% or less, percutaneous ethanol injection may be done. If the residual activity is of 50% or more transarterial chemoembolization may be used."
223658500|NCT04765228|DRUG|Pegylated liposomal doxorubicin|Pegylated liposomal doxorubicin 50mg/m2 intravenous infusion on the first day + Anlotinib 12mg/d orally, medication on days 8-21, one cycle every 21 days, 2\~4 cycles
223658501|NCT04765228|DRUG|Anlotinib|Anlotinib
223658502|NCT03421769|PROCEDURE|EA and AMLK|A 7-9mm diameter corneal epithelial tissue will be obtained from the fellow eye using femtosecond laser technology. This epithelial autograft (EA) is then ready for transplantation on the disease eye, following the procedure of allogeneic middle lamellar keratoplasty (AMLK).
223658503|NCT03421769|PROCEDURE|LA and AMLK|A 3-clock-hour limbal autograft (LA) will be obtained from the fellow eye. This is then ready for transplantation on the disease eye following the procedure of AMLK.
223658504|NCT01256190|BIOLOGICAL|Fibrocaps (fibrin sealant)|human thrombin and fibrinogen topical powder
223658505|NCT01256190|DEVICE|Gelatin sponge|absorbable gelatin sponge for topical use
223658506|NCT00576329|DRUG|Ketorolac|Topical use before surgery
223658507|NCT03458013|BEHAVIORAL|Mindfulness Meditation|Guided using an mp3 player and noise cancelling headphones, participants will be led through a series of mindfulness meditations lasting approximately 20 minutes each.
223658508|NCT05895526|PROCEDURE|Self etch dentin adhesive, Fluoride varnish|After an informed consent, in one group 5% sodium fluoride varnish will be applied in affected area, while the other group will receive self etch dentin adhesive.
223658509|NCT01523977|DRUG|Everolimus|Orally, daily days 1-32 per assigned dose level
223658510|NCT01523977|DRUG|Prednisone|40 mg/m2/day orally 3 x daily days 4-32
223658511|NCT01523977|DRUG|Vincristine|1.5 mg/m2 IV daily on days 4, 11, 18, and 25
223658512|NCT01523977|DRUG|PEG-Asparaginase|2,500 U/m2 IV 1 x daily on days 5 and 18
224240501|NCT05372926|DEVICE|Ventury mask|Ventury mask is a oxygen therapy technic which allows the administration with a mask of oxygen with a flow up to 15L/Min and a monitored FiO2.
223658513|NCT01523977|DRUG|Doxorubicin|30 mg/m2 IV on days 4 and 5
223658514|NCT01523977|DRUG|Dexrazoxane|300 mg/m2 IV on days 4 and 5
223658515|NCT02511223|DRUG|OLAPARIB|Olaparib 300 (mg) twice a day per os given every day until disease progression or toxicity
223658516|NCT03968133|DIETARY_SUPPLEMENT|Probiotic|Oral probiotic delivered in powdered form.
223658517|NCT03968133|DIETARY_SUPPLEMENT|Placebo|Oral placebo delivered in powdered form.
223658518|NCT06121999|BEHAVIORAL|Standard of care acceptance-based behavioral weight loss program|Evidence-based, structured weight loss program for adults with co-morbid conditions of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). Published as a workbook for participants and a clinician guide, the intervention consists of twenty-five sessions or modules with accompanying worksheets. Each session covers specific acceptance-based behavioral skills to implement and build upon in subsequent sessions.
223658519|NCT06121999|BEHAVIORAL|Occupational therapy dietary and lifestyle modifications|Occupational therapy Model of Human Occupation Screening Tool (MOHOST) and Role Checklist version 3 (RCv3) assessments identify areas of need for personalizing participant implementation of the standard of care acceptance-based behavioral weight loss program. Areas of need may include physical activity limitations to be addressed in an exercise plan or social determinants of health that are barriers to dietary and lifestyle modifications. Dietary and lifestyle modifications are based on American Gastroenterology Association (AGA) recommendations published in practice guidelines for this population. Recommendations include a Mediterranean diet, improved self-management of co-morbid chronic conditions, and a total body weight loss of five to ten percent at 1 - 2 pound weekly increments.
223658520|NCT05283577|OTHER|Electroacupuncture|EA at 13 standardized acu-points that were chosen for their therapeutic effects: Shenting (GV24), Baihui (DU20), Sinshencong (EX-HN1), Zhongwan (CV12), Guanyuan (CV4), Neiguan (PC6) bilateral, Shenmen (HT7) bilateral, Zusanli (ST36) bilateral, Sanyinjiao (SP6) bilateral, Taixi (KI3) bilateral, Zhaohai (KI6) bilateral, Hegu (LI4) bilateral, Taichong (LIV3) bilateral
223658521|NCT05283577|OTHER|Sham-Electroacupuncture|Non-disease related points with electrical stimulation: Pianli (LI6) bilateral, Wenliu (LI7) bilateral, Fuyang (BL59) bilateral, Kunlun (BL60) bilateral, Sanyangluo (TE8), Sidu (TE9) bilateral, Daheng (SP15) bilateral
223658522|NCT06958107|OTHER|Non-Metastatic and Resectable|"Blood Draw Timepoints:~* Before any treatment begins~* After Neo-adjuvant therapy (only if you receive this type of therapy)~* After local surgery~* After Adjuvant therapy (only if you receive this type of therapy)~* Follow up after adjuvant therapy: at Months 3, 6, 9, 12, 15, 18, and 24~* After evidence of recurrence or worsening of disease, and then collected at standard of care disease evaluation visits up until 24 months from the last treatment for the initial diagnosis"
223658523|NCT06958107|OTHER|Metastatic and Un-resectable|"Blood Draw Timepoints:~* Before any treatment begins~* During standard of care disease evaluation visits for up to 24 months"
223658524|NCT06958107|OTHER|No evidence of disease, under surveillance|"Blood Draw Timepoints:~* From completion of treatment- at Months 3, 6, 9, 12, 15, 18, and 24; depending on when you enroll into the study you will start at the next timepoint in this schedule~* After evidence of recurrence or worsening of disease, and then collected at standard of care disease evaluation visits up until 24 months from the last treatment for the initial diagnosis"
223658525|NCT06958107|OTHER|ALT or WDLS|"Blood Draw Timepoints:~• Collect once after surgery (up to six weeks after surgery)"
223658526|NCT05650632|DRUG|ABBV-383|Intravenous Infusion
223658527|NCT05028309|OTHER|Mechanical unloading of the Thorax using an external cuirass|External cuirass (i.e., a plastic shell over the thorax) will be used to mechanically unload the chest wall. The cuirass has different operating modes. It can generate a constant negative pressure over the chest wall (e.g., -20cmH2O) or it can be triggered off mouth flow so it can generate a negative pressure on the chest wall during inspiration (e.g., -21cmH2O) and a positive pressure during expiration (e.g., +7cmH2O).
223658528|NCT06074549|DEVICE|DynamX Novolimus-eluting Coronary Bioadaptor System|All patients will receive at least one DynamX Bioadaptor implant in a commercial setting in accordance with the product's Instructions for Use
223658529|NCT02350478|DRUG|Linagliptin|The subject will receive Linagliptin 5mg orally once daily for 12 weeks.
223658530|NCT02350478|DRUG|Placebo|The subject will receive placebo orally once daily for 12 weeks.
223658531|NCT03799042|DEVICE|Virtual Reality|Subjects will wear a 3D glass and watch 3D pictures (or video) of landscapes or tourist sites in Hong Kong.
224240502|NCT00213304|BIOLOGICAL|varicella vaccine (VARIVAX)|
224240503|NCT01126125|DIETARY_SUPPLEMENT|Iodized oil|400 mg of iodine vs 100 mg of iodine as iodized oil
224240504|NCT02188953|DRUG|ACCS100|ACCS100 is made from Hydrated Sodium Calcium Aluminosilicate, which is a substance generally recognized as safe by the U.S. FDA.
223658532|NCT03799042|BEHAVIORAL|Inter-generation interaction|Secondary school student will play games and chats with secondary school students. Games involve identifying famous landscapes or tourist sites in Hong Kong
224240505|NCT02188953|DRUG|Calcium carbonate placebo|
224240506|NCT00770445|DRUG|Pioglitazone and insulin|Pioglitazone 15 mg, tablets, orally, twice daily and metformin placebo-matching tablets, orally, twice daily and insulin glargine stable dose for up to 24 weeks.
224240507|NCT00770445|DRUG|Pioglitazone and metformin and insulin|Pioglitazone 15 mg, tablets, orally, twice daily and metformin 850 mg, tablets, orally, twice daily and insulin glargine stable dose for up to 24 weeks.
224240508|NCT00770445|DRUG|Metformin and insulin|Pioglitazone placebo-matching tablets, orally, twice daily and metformin 850 mg, tablets, orally, twice daily and insulin glargine stable dose for up to 24 weeks.
224240509|NCT04407806|DEVICE|Continous Pulse oximeter|Pulse oximeter is a small lightweight non-invasive device placed on the fingertip or toe to measure blood oxygen saturation throughout hospitalization
224240510|NCT04407806|DEVICE|Intermittent Pulse oximeter|Pulse oximeter is a small lightweight non-invasive device placed on the fingertip or toe to measure blood oxygen saturation intermittently during hospitalization
224240511|NCT04017156|PROCEDURE|implant installation|All site preparations will be performed deeper compared to the length of the implant so that the implant apex cannot reach the bottom of the osteotomy.
224240512|NCT00161356|DRUG|Ambisome|5mg/kg IV - one time dose during liver transplant
223658533|NCT05009459|BEHAVIORAL|eVIS|To facilitate individualized physical activity levels within the Swedish IPRP setting, an eVISualisation (eVIS) of physical activity and pain intervention has been systematically developed. eVIS is designed to target facilitating mechanisms for behavior change, such as outcome expectations, self-monitoring, self-evaluation, and self-efficacy, which are theoretically framed by the Social Cognitive Theory by Bandura. In eVIS, objectively measured physical activity tracking using a wrist-worn activity tracker (Fitbit Versa 2) is combined with a daily activity goal (steps/day) and daily patient reports of known important clinical outcome assessments: pain intensity and its affect on daily activities30-34 and pharmaceutical consumption. Data is collected and visualized in a purpose-developed web application, Pin And TRaining ON-line (PATRON), which can be used by the patient and the IPRP-team to follow and adjust individual physical activity levels.
223658534|NCT06535607|BIOLOGICAL|Volrustomig|IV Infusion
223658535|NCT06535607|DRUG|Cisplatin|IV Infusion
223658536|NCT06535607|DRUG|Carboplatin|IV Infusion
223658537|NCT06535607|DRUG|Paclitaxel|IV Infusion
223658538|NCT06156384|DEVICE|FITBONE® Lengthening Nail|"The patient is installed on a standard orthopaedic table, intramedullary reaming is performed through a metal working tube. The osteotomy is performed percutaneously and then an osteotome according to the postage-stamp technique. Once the FITBONE lengthening nail is placed in the desired location, it should be connected to the subcutaneous receiver. The receiver should be placed close enough to the skin surface to ensure the energy transfer from the external transmitter.~After 5 to 10 days after surgery, the lengthening mechanism is operated by the patient, using the transmitter. An elongation of approximately 1 mm/day takes place. The attending physician determines the rhythm of lengthening in each case. When the desired elongation length is reached, the consolidation phase begins, which is necessary for bone regeneration. The FITBONE lengthening nail can be removed once the bone has consolidated, approximately one to one and a half years after implantation."
223658539|NCT03646123|DRUG|brentuximab vedotin|1.2 mg/kg by IV infusion
223658540|NCT03646123|DRUG|doxorubicin|25 mg/m\^2 by IV infusion
223658541|NCT03646123|DRUG|vinblastine|6 mg/m\^2 by IV infusion
223658542|NCT03646123|DRUG|dacarbazine|375 mg/m\^2 by IV infusion
223658543|NCT03646123|DRUG|G-CSF|Granulocyte colony stimulating factor (G-CSF) primary prophylaxis administered 24-36 hours after each dose of A+AVD
223658544|NCT03646123|DRUG|nivolumab|240 mg by IV infusion
223658545|NCT05052736|DEVICE|Non-invasive Neuromodulation|"The electrodes will be placed with the help of gloves and adapted socks for 1 hour, twice a week, until 20 intervention sessions are completed. In addition, depending on the session, an adhesive electrode will be placed at the level of C7.~Characteristics of microcurrents: pulsed monophasic rectangular wave with a pulse of 1.3 s and pause of 300 ms, voltage 3 millivolt and intensity 0.5 μA."
223658546|NCT05822609|DRUG|Semaglutide|1.0 mg
223658547|NCT05822609|OTHER|Placebo|Placebo
223658548|NCT05605444|OTHER|Single bout of exercise|isometric wall squat at a knee joint angle of 100 degrees. Instruct participant to place their back against the wall with feet positioned parallel and spaced shoulder-width apart. Lower themselves down until they reached a knee joint angle of 100 degrees. Measure knee joint angle by placing a goniometer on the lateral epicondyle of the knee, in line with the femur whilst the anchor arm was in line with the lateral malleolus.
223658549|NCT04915950|DRUG|Temanogrel|Participants will receive a single oral dose of temanogrel during the treatment visit.
223658550|NCT04915950|DRUG|Placebo|Participants will receive a single oral dose of temanogrel matching placebo during the treatment visit.
223658551|NCT04458259|DRUG|PF-07265807|Given 2 weeks on/1 week off
223658552|NCT04458259|DRUG|Sasanlimab|Given SC Q3W
223658553|NCT04458259|DRUG|Axitinib|Dosed per package label starting with 5 mg PO BID
223658554|NCT06838039|PROCEDURE|Rhomboid Intercostal Block (RIB)|Rhomboid Intercostal Block (RIB) A regional anesthesia technique administered under ultrasound guidance for postoperative pain relief. This will be used as the sole intervention in Arm 1.
223658555|NCT06838039|PROCEDURE|Rhomboid Intercostal Block (RIB) + Serratus Anterior Plane Block (SAPB)|A combination of two regional anesthesia techniques, Rhomboid Intercostal Block (RIB) and Serratus Anterior Plane Block (SAPB),(THE SAPB will received within 24 hours after RIB) administered under ultrasound guidance. SAPB targets the lateral cutaneous branches of the thoracic nerves, complementing the pain relief provided by RIB. This combination is used in Arm 2 to enhance postoperative analgesia.
224240513|NCT00161356|PROCEDURE|Liver Biopsy|post drug delivery (60 min. after completion of Ambisome infusion)
224240514|NCT02513056|OTHER|MRI|MRI
224240515|NCT04713709|COMBINATION_PRODUCT|Nasus Pharma FMXIN001|A nasal spray of 4mg Naloxone Hydrochloride powder in a unit dose device
224240516|NCT04713709|COMBINATION_PRODUCT|Nasal Naloxone liquid spray|A nasal spray of 4mg/0.1mL Naloxone Hydrochloride solution in a unit dose device
224240517|NCT02465697|BEHAVIORAL|Reappraisal Training|
224240518|NCT06561750|OTHER|Rooibos tea|Participants will be subjected to 12 g of rooibos tea per 1200 ml of freshly boiled water
224240519|NCT06561750|OTHER|Control|Participants will be subjected to 12 g per 1200 ml of freshly boiled water which is equivalent to 6 cups of tea
224240520|NCT06139588|DEVICE|acellular dermal matrix implant for breast reconstruction|acellular dermal matrix implant in implant-based breast reconstruction in patients receiving radiotherapy
224240521|NCT00318383|BIOLOGICAL|NicVAX conjugate vaccine|200 mcg or 400 mcg IM in 4 doses over 6 months; 200 mcg or 400 mcg IM in 5 doses over 6 months; 200 mcg (formulation 2) IM in 5 doses over 6 months; All are adsorbed onto Alhydrogel
224240522|NCT00318383|BIOLOGICAL|Placebo|Phosphate buffered saline and ALhydrogel of identical appearance to NicVAX; IM in 4 or 5 doses over 6 months
224240523|NCT05782647|DEVICE|HeartGuide cuffless BP monitor|Wearable (watch-type) monitor: HeartGuide 6410T (Omron Healthcare, Kyoto, Japan)
223658556|NCT01786772|OTHER|Cryotherapy and compression|Cryotherapy and intermittent pneumatic compression will be applied to the knee joint using a recirculating compression unit and knee sleeve. This unit will recirculate water which is between 1-3° C. Circumferential intermittent pneumatic compression to the knee joint (5 to 50 mm Hg) will be applied in conjunction with cryotherapy. The duration of intervention will be 20 minutes.
223658557|NCT01786772|OTHER|Cryotherapy|Cryotherapy will be applied to the knee joint using a recirculating compression unit and knee sleeve. This unit will recirculate water which is between 1-3° C. The duration of intervention will be 20 minutes.
223658558|NCT00157482|DRUG|Ezetimibe|
223768784|NCT05567731|DRUG|long GnRHa|In the long protocol, daily subcutaneuous injection of Triptorelin :Decapeptyl 0.1 mg (Ferring, Switzerland) 0.1 mg started at day 21 of the cycle prior to stimulation cycle and continued till the day of hCG triggering. Gn stimulation started after fulfilling stimulation start criteria of thin endometrium \< 5 mm and low estradiol (E2) \< 50 and Luteinizing Hormone \< 5IU/l with either HMG(Menogon; Ferring, Switzerland) or rFSH (Gonal-f; Merck Serono, Germany) in a starting dose of 150-300 IU/day according to women age, day 3 Follicle-Stimulating Hormone, Anti-Müllerian Hormone and previous gonadotropin response then adjustment of the dose according to ovarian response monitored by serum estradiol (E2) and ultrasound evaluation.
223768785|NCT01982422|BEHAVIORAL|Whole Food, Nutrient-Dense Dietary Intervention|The dietary intervention will be a whole food, nutrient-dense diet which restricts processed foods high in food additives while optimizing micronutrient intake.
223768786|NCT01982422|BEHAVIORAL|Standard of Care|Normal standard-of-care for pregnancy.
224240524|NCT03415802|DRUG|Nab-paclitaxel and S-1|Nab-paclitaxel 120 mg/m2 (D1, D8, q3w) and S-1 (40mg BID for body surface area \< 1.25 m2; 50mgBID for body surface area of 1.25-1.5 m2; and 60mg BID for body surface area \>1.5 m2; D1-14, q3w)
224240525|NCT05606393|OTHER|virtual reality speech training|virtual reality speech training that focuses on receptive and expressive aspects of language, through a newly developed interactive virtual reality software
223658559|NCT00157482|DRUG|Simvastatin|
223658560|NCT05416710|DIAGNOSTIC_TEST|Invitae's 84 gene multi-cancer panel.|Invitae's Multi-Cancer panel analyzes 84 genes associated with hereditary cancers across major organ systems.
223658561|NCT01038999|BIOLOGICAL|Peripheral blood biological tests|A group and B group will be evaluated three times, at baseline, then every 12 months during 3 years. In case of initiation or changing of antiretroviral therapy, patients will be evaluated once more. Control subjects will be only evaluated at baseline.
224240526|NCT05606393|OTHER|traditional speech therapy|traditional speech therapy in current clinical use, that focuses on language comprehension, naming, fluency, repetition.
223658562|NCT02127957|OTHER|Exercise|Exercise will be prescribed by kinesiologist and will be done 3 times a week for 1 hour by subject. Every 4 weeks subject will be on supervised training session.
224240527|NCT01425060|BEHAVIORAL|Contraceptive management program|The contraceptive management program will consist of two components: (1) the World Health Organization's contraception protocol and (2) reinforced follow-up visits.
223658563|NCT04195893|DEVICE|somofilcon A|Contact Lens
223658564|NCT04195893|DEVICE|etafilcon A|Contact Lens
223768787|NCT04512937|DEVICE|Computer-assisted navigation surgery|Computer navigation-assisted surgery has two main elements; the pre-procedural planning to create accurate 3D images of the pelvis allowing the surgical team to achieve an accurate perception of the operative field, and intraoperative navigation where these images are used for anatomical guidance to enhance surgical precision. Accordingly, computer software is used in this study to outline the tumour and other pelvic organs on pre-operative images which are subsequently used for intraoperative navigation.
224240528|NCT01425060|OTHER|Usual care|The usual care condition will be given general information about contraceptive options and contact information for clinics and providers that provide contraceptive services.
224240529|NCT03368508|BEHAVIORAL|Simulating video|A 360-degree simulating video showing physiotherapy assessment in lumbar area
224240530|NCT03368508|BEHAVIORAL|Conventional video|A conventional video showing physiotherapy assessment in lumbar area
224240531|NCT03495622|BEHAVIORAL|Motivational Interviewing/Text messaging|"The intervention is a multi-component one that is tailored to the individual and will target smoking cessation. The CHW, after identifying the individual's stage of behavior change, will provide motivational interviewing and set up an automatic text messaging system with their mobile phones that are structured around a quit date chosen by the participant.~The CHW visits are pre-determined and she monitors the progress of the individual regularly. She may restart the process of determining the stage of behavior change for those who relapse or quit the intervention midway thereby reassigning them to the appropriate phase of the trial"
224240532|NCT01594203|OTHER|F18-FGD PET/CT|
223658565|NCT02873117|OTHER|Prostate biopsy, prostatectomy or prostate resection|Collection of prostate examination
223658566|NCT05827536|DIETARY_SUPPLEMENT|PKU GOLIKE|PKU GOLIKE is a food for special medicinal purposes (FSMP) for the dietary management of PKU.
223658567|NCT05827536|DIETARY_SUPPLEMENT|Standard of Care|Protein substitute
223658568|NCT06248775|BEHAVIORAL|Prehabilitation Intervention Supported with Technology (Fitbit, glucose sensor and app for diet habits)|During the VITAAAL intervention patients use the Diameter app to monitor their physical activities (in connection with a Fitbit), nutrition (using the Diameter app) and glucose levels (in connection with Freestyle Libre 2 sensors). Before the intervention starts, a three-day period of blinded baseline measurements is performed to measure current habits, motivation and possibilities. Then, individual aims for improving vitality are formulated in consultation with the NP diabetes. Afterwards, patients continue measuring their habits unblinded with the Diameter for the following weeks and weekly evaluate their goals with the nurse practitioner to receive new instructions and/or to adapt the goals
224240533|NCT01378039|DRUG|comparison of treatment effect on different markers|inhaled budesonide (400 µg BD) or placebo BD
224240534|NCT01020396|DRUG|Metronidazole|Vaginal Gel, 0.75%
224240535|NCT01020396|DRUG|Metronidazole|Vaginal Gel, 0.75%
224240536|NCT02137135|OTHER|HAD scale|The anxiety/depression scale (HAD) was used to assess anxiety and depression.
224240537|NCT02137135|OTHER|The SF 12 test|The SF 12 test (SHORT FORM 12) was used to evaluate quality of life.
224240538|NCT02137135|OTHER|Visual analogue score|Visual analogue score vas used to evaluate pain.
224240539|NCT00857935|DRUG|NatrOVA Creme Rinse - 1%|NatrOVA Creme Rinse, one or two, 10-minute topical treatments (7 days apart)
223768788|NCT02492451|OTHER|Endometrial Injury|Endometrial injury in luteal phase of preceding cycle by pipelle canula
223658569|NCT05526404|OTHER|Dieta mobile application|Mobile application that functions on mobile phones and allows for tracking of symptoms, dietary intake, and stool characteristics using logs and pictures. Users of the application track symptoms by completing questionnaires regarding stool frequency, consistency, and mental status changes. Users can track dietary intake and stool characteristics by taking time-stamped photos of all dietary intake and bowel movements.
223658570|NCT02209532|DEVICE|PINPOINT|PINPOINT® Near Infrared Fluorescence Imaging to identify lymph nodes
224240540|NCT00857935|DRUG|NIX Creme Rinse - 1% permethrin|NIX Creme Rinse: one or two, 10-minute topical treatments (7 days apart)
223658571|NCT00541801|DEVICE|Doppler-echocardiography and acoustic cardiography|Patients receive a Doppler-echocardiography and an acoustic cardiography
223658572|NCT03399929|OTHER|Post Acute Rehabiltation|
223658573|NCT03094507|DRUG|Tivicay|50 mg once daily
223658574|NCT03094507|DRUG|Rezolsta|darunavir 800 mg/cobicistat 150 mg once daily
223658575|NCT03679754|BIOLOGICAL|Ad-RTS-hIL-12|"* 2.0 x 10\^11 viral particles (vp) per injection~* intratumoral injection of Ad-RTS-hIL-12"
223658576|NCT03679754|DRUG|veledimex|"* 20mg/day~* 15 oral daily doses of veledimex"
223658577|NCT00964171|DRUG|Efavirenz 600mg|
223658578|NCT06336642|BEHAVIORAL|SPOT-ON Early Start|Participants will start treatment within 3 days of enrollment, which may include: receiving information on breathing techniques, relaxation techniques, posture techniques, and distraction techniques, and/or trying different oxygen-based therapies, such as high-flow nasal cannula, low-flow supplemental oxygen, and non-invasive ventilation with a respiratory therapist.
223658579|NCT06336642|BEHAVIORAL|SPOT-ON Delayed Start|Participants will start treatment within 3 days of enrollment, which may include: receiving information on breathing techniques, relaxation techniques, posture techniques, and distraction techniques, and/or trying different oxygen-based therapies, such as high-flow nasal cannula, low-flow supplemental oxygen, and non-invasive ventilation with a respiratory therapist.
223658580|NCT02163941|BEHAVIORAL|Compassion Training|
223658581|NCT02413151|BEHAVIORAL|Exercise training program|The exercise sessions will be hospital-based, 3 times a week for 60 minutes each, on non-consecutive days for 6 months. Selected the aerobic interval training (AIT) method for the development of cardiopulmonary system and the inclusion of resistance and sensorimotores exercises. The AIT comprises 4 interval training periods (high intensity) and 3 active pauses (moderate intensity) between interval training periods. The patient will warmup for 10 minutes at 50% to 60% of HRpeak from CPET, before walking to four 4 minutes intervals at 90 to 95% of peak HR. Each interval, including the last one, is separate by 3 minutes active pauses, walking at 60% to 70% of HRpeak. Total aerobic exercise time at this moment will be 28 minutes and will be maintain to the end of ExT intervention period.
223658582|NCT02413151|DEVICE|Cardiac resynchronization therapy (CRT)|Implantation will be performed according to standard techniques of biventricular pacing. The CRT includes a generator and three leads, used to correct ventricular dyssynchrony.
223658583|NCT03368690|DIETARY_SUPPLEMENT|Oligopin®|At the treatment period (0th to 4th week of the experiment), subjects with ADHD will receive 1\~3 capsules of polyphenolic extract from pine bark (25mg or 50 mg Oligopin per capsule) according to their body weight and age. The 5th to 6th week will be the washout period. The control group and Oligopin group will be cross-over at 7th week to 10th week of the experiment.
223658584|NCT03368690|OTHER|Placebo|At the treatment period (0th to 4th week of the experiment), subjects with ADHD will receive 1\~3 capsules of polyphenolic extract from pine bark (25mg or 50 mg Oligopin per capsule) according to their body weight and age. The 5th to 6th week will be the washout period. The control group and Oligopin group will be cross-over at 7th week to 10th week of the experiment.
223658585|NCT03156296|DRUG|Dexmedetomidine|patients will receive ultrasound guided TAP block using 0.3 ml/kg bupivacaine (0.125%) with a maximum volume of 20 ml + 0.25 mg/kg dexmedetomidine dissolved in 2 ml normal saline (0.9%)
223658586|NCT03156296|DRUG|Bupivacaine|patients will receive ultrasound guided TAP block using 0.3 ml/kg bupivacaine (0.125%) with a maximum volume of 20 ml + 2 ml normal saline (0.9%)
223658587|NCT00002618|BIOLOGICAL|filgrastim|
223658588|NCT00002618|DRUG|cytarabine|
223658589|NCT00002618|DRUG|doxorubicin hydrochloride|
223658590|NCT00002618|DRUG|leucovorin calcium|
223658591|NCT00002618|DRUG|mercaptopurine|
223658592|NCT00002618|DRUG|methotrexate|
223658593|NCT00002618|DRUG|prednisone|
223658594|NCT00002618|DRUG|vincristine sulfate|
223658595|NCT00002618|RADIATION|low-LET cobalt-60 gamma ray therapy|
223658596|NCT00002618|RADIATION|low-LET electron therapy|
223658597|NCT00002618|RADIATION|low-LET photon therapy|
223768789|NCT02492451|DRUG|progesterone (Crinone® %8 vaginal progesterone gel)|Luteal phase support with progesterone (Crinone® %8 vaginal progesterone gel) in IUI cycle Vaginal progesterone gel is administered from second day after insemination until pregnancy testing and is continued in the presence of pregnancy until the 12 weeks of pregnancy.
224240541|NCT02313688|PROCEDURE|gastrectomy|Transabdominal (include transhiatal) D2 gastrectomy according JGCA gastric cancer treatment guidelines (2010, ver.3) and with 3±0.5 cm lengthen proximal resection margin.
223768790|NCT02086435|PROCEDURE|Extracorporeal morcellation|"patients treated with protected removal by endobag and extracorporeal myoma morcellation with cold scissors and scalpel blade or with power morcellator used inside the bag itself"
224240542|NCT02313688|PROCEDURE|gastrectomy|Transabdominal (include transhiatal) D2 gastrectomy according JGCA gastric cancer treatment guidelines (2010, ver.3) and with 5±0.5 cm lengthen proximal resection margin.
224240543|NCT05932524|DRUG|Baricitinib 2 MG|Baricitinib 2 mg q.d., p.o., for 6 consecutive months.
224240544|NCT05932524|DRUG|Dexamethasone|Dexamethasone 40 mg q.d. for 4 consecutive days (the 4-day course of dexamethasone will be repeated in the case of lack of response by day 10)
224240545|NCT02017119|DRUG|Comparison between Lactulose and Lactulose-Paraffin|
224240546|NCT01498003|DRUG|tirofiban|10μg/kg bolus followed by 0.15μg/kg/min maintenance infusion for 12h
224240547|NCT01498003|DRUG|normal saline solution|same use as tirofiban
224240548|NCT01060618|OTHER|Maraviroc + Trofile ESTA® (diagnose test)|The Trofile ESTA® will be performed in those patients and once the results are obtained (within one month approximately), the patients will be treated with the medication Maraviroc
223768791|NCT02086435|PROCEDURE|Intracorporeal morcellation|patients treated with standard intracorporeal morcellation, using reusable electronic device
223768792|NCT05438082|DRUG|Antibiotic Prophylaxis|This trial will contain two arms in which patients will be randomized to receive one dose of either Trimethoprim (if \< 2 months) or Trimethoprim-Sulfamethoxazole (if ≥ 2 months) or placebo in suspension. Dosing regimen for the active treatment (Trimethoprim) will be based on weight (5mg/kg of Trimethoprim component) with a maximum dosage of 320mg
223768793|NCT05438082|OTHER|Placebo|The placebo group will receive an equal volume of placebo suspension that has been developed to have the same colour and taste as the antibiotic to preserve blinding.
224240549|NCT04180709|DEVICE|Sleepio|Sleepio is an online cognitive behavioural therapy (CBT) based intervention designed to treat insomnia, conducted is 6 sessions. The program is an automated media-rich web-based application that is driven dynamically by baseline, adherence, performance and progress data. At the beginning of each session The Prof conducts a progressive review with the participant exploring the diary data submitted the week prior that includes sleep status and pattern, as well as progress based on goals previously set by the participant. The information, support and advice are personally tailored based on underlying algorithms.
224240550|NCT00369447|PROCEDURE|External radiotherapy|Radiotherapy for first 2 weeks, 10 daily fractions of 30Gy 2 additional fractions to be added if desirable
224240551|NCT00369447|BIOLOGICAL|nimotuzumab|weekly dose until disease progression
224240552|NCT00431197|DRUG|Ketoconazole, Dexamethesone, Androgel,GnRH|
224240553|NCT01433497|DRUG|Masitinib|
224240554|NCT01433497|DRUG|Placebo|
224240555|NCT02731157|DRUG|Rejuvesol|
224240556|NCT02731157|PROCEDURE|Blood transfusion|Only transfusions necessary for the treatment of the sickle cell disease will be given for the purpose of the study.
224240557|NCT05194748|OTHER|No intervention, observational only|No intervention, observational only
224240558|NCT03291548|DIETARY_SUPPLEMENT|Quinoa biscuit|2x15g biscuits per day for 28 consecutive days (4 weeks).
224240559|NCT03291548|DIETARY_SUPPLEMENT|Control biscuit|2x15g biscuits per day for 28 consecutive days (4 weeks).
224240560|NCT06126848|DEVICE|Ambient sensor system|Main study: A contactless non-intrusive ambient sensor system including infrared motion sensors combined with a contactless Emfit bed sensor will be installed in the home of single living study patients by using a commercially available System (Domo Health®, Lausanne) after informed consent has been obtained. Sensor data are prospectively followed over 3-6 months for predefined indicators of health deterioration. If indicators for health deterioration are present, patients will be called in to the hospital for cardiology consult by the study team including blood analysis for follow-up of BNP values and if necessary, therapy adaption.
224240561|NCT01470560|BEHAVIORAL|Mindfulness-Based Stress Reduction (MBSR)|Mindfulness-Based Stress Reduction (MBSR) was developed by Jon Kabat-Zinn in 1979. MBSR is a group-based intervention, typically provided to up to 30 participants, in a class-based format of eight weekly two hour sessions.
224240562|NCT01470560|BEHAVIORAL|Sham Yoga Group|Emphasis will be placed on healthy alignment and ways to pace and adjust poses to make them safe and productive for the body.
224240563|NCT02495558|OTHER|Reflex Cough Test|Peak of Cough Expiratory Flow of the reflex cough
223658598|NCT01236976|DEVICE|Therastride Treadmill System|This device supports spinal cord injured patients to stand (suspended in a harness by an overhead pulley) on the specially designed treadmill for locomotor training. It is registered with the FDA (Regulation Number 890.5380).
223658599|NCT01236976|DEVICE|FES-assisted cycling|This intervention will be provided using a RT300 cycle (Restorative Therapies, Baltimore MD).
223658600|NCT01236976|OTHER|Trunk and upper and lower limb exercises|This intervention will comprise assisted and/or resisted movements aimed at facilitating and strengthening voluntary muscle activity and improving movement quality.
223658601|NCT01236976|OTHER|Upper body strength and fitness program|This intervention is a circuit-based exercise program incorporating resistance and cardiovascular training.
223658602|NCT01286909|DIETARY_SUPPLEMENT|LaFlavon|two tablets of LaFlavon (two x 3.5mg lycopene/25 mg soy isoflavone) daily for three months
223658603|NCT00982059|OTHER|Colonoscopic examination|All patients enrolled in the study will undergo a colonoscopic examination and complete a baseline questionnaire.
223658604|NCT01360736|BEHAVIORAL|Safety Planning - Military (SAFE MIL)|The Safety Planning Intervention (SPI) which is delivered in the SAFE MIL condition aims to help individuals lower their imminent suicide risk by having them collaborate with the study clinician to generate a detailed, hierarchically-arranged action plan for managing suicidal thoughts and urges.
223658605|NCT03308721|DRUG|NNC9204-1177 A 1.0 mg/mL|"Participants will get 1 or more injections into the skin of the stomach area once each week for 12 weeks.~Dose gradually increased to 6000 μg."
223658606|NCT03308721|DRUG|PLACEBO|Participants will get 1 or more injections into the skin of the stomach area once each week for 12 weeks.
223658607|NCT00850421|DRUG|Botulinum Toxin Type A|100 Units - Dilution: 25U/ml (4:1 BOTOX/preservative free saline)
223658608|NCT04370119|DIAGNOSTIC_TEST|Nasal swab|SARS-CoV-2 PCR
223658609|NCT04370119|DIAGNOSTIC_TEST|Serum testing|Anti-SARS-CoV2 S protein IgG ELISA, serological changes after SARS-CoV-2 vaccination
224240564|NCT03601663|BEHAVIORAL|Physical Activity Information|Participants will receive a copy of the Canadian Physical Activity Guidelines.
224240565|NCT03601663|BEHAVIORAL|Physical Activity Monitoring|Participants will receive a wearable activity tracker (Polar A300).
223658610|NCT02949895|DRUG|BMS-986012|
223658611|NCT02949895|DRUG|Cisplatin|
223658612|NCT02949895|DRUG|Etoposide|
223658613|NCT05418543|PROCEDURE|Endoscopic ultrasound with fine needle biopsy|Patients with unresectable bile duct tumors will be investigated by either CH-EUS with FNA or conventional EUS with FNA
223658614|NCT03497013|DEVICE|Active tDCS|All patients received 2-mA anodal left/cathodal right prefrontal tDCS treatment (fifteen 30-minutes sessions: Monday to Friday once daily, every other week to do a group of treatment).
223768794|NCT01075334|DIETARY_SUPPLEMENT|Porimore - A Carnitine based food supplement|A daily dose of 2 grams L-carnitine, 1 gr acetyl L-carnitine, 500mg Vitamin C, 400 IU vitamin E, 60 mg Q10, 30mg Zinc Picolinate, 500mcg Folic Acid, 200 Mcg Selenium, 100 MCG Vitamin B12.
224240566|NCT03601663|BEHAVIORAL|Autonomy-support|Participants will receive eight autonomy-supportive weekly emails containing information and activities to help them set goals and make changes to become physically active.
223658615|NCT03497013|DEVICE|Sham tDCS|For sham stimulation, the device was set to turn off after 30 seconds(study model).
224240567|NCT05833581|OTHER|New York Heart Association Classification Guide|The New York Heart Association Classification Guide is a questionnaire that assists in guiding the provider in selection of the patient's class
223658616|NCT02194374|PROCEDURE|ROR1R-CAR-T Cell Infusion|"Dose Escalation Cohort starting dose level of ROR1R-CAR-T cells/kg: 105 cell/kg infused via central venous catheter or by vein on Day 1.~Dose Expansion Cohort starting dose level of ROR1R-CAR-T cells/kg: MTD from Dose Escalation Cohort."
223658617|NCT02194374|DRUG|Fludarabine|"FCR Regimen: 25 mg/m2 by vein on Days -5, -4, and -3.~FBR Regimen: 20 mg/m2 by vein Days -5, -4, and -3."
223658618|NCT02194374|DRUG|Cyclophosphamide|FCR Regimen : 250 mg/m2 by vein on Days -5, -4, and -3.
223658619|NCT02194374|DRUG|Rituximab|"FCR and FBR Regimen: 375-500 mg/m2 by vein on Day -5.~BR Regimen: 375-500 mg/m2 by vein on Day -4."
223658620|NCT02194374|DRUG|Bendamustine|"BR Regimen: 70-90 mg/m2 by vein on Days -4 and -3.~FBR Regimen: 30-50 mg/m2 by vein on Days -5 to -3."
223658621|NCT01614678|DEVICE|Lotrafilcon B contact lens with color, automated|Silicone hydrogel contact lens with color manufactured via an automated process
224240568|NCT06110039|OTHER|Cervicothoracic Junction Mobilization|The therapist stood in back of the subject, who was seated straight on a chair. The therapist positioned the medial side of one hand's thumb. The desired level of vertebra can be strengthened by placing the index finger of the opposite hand on the spinous process. A pure transverse glide was executed from the affected side to the unaffected side.
224240569|NCT06110039|OTHER|Upper Thoracic Spine Manipulation:|The therapist placed one hand on the patient's head and the hypothenar or thenar eminence of the other hand was placed over the T1 transverse process (the therapist's left hand was used for thrusting and vice versa for treating the left T1 Transverse process). As the tissue deficiency is taken up localizing the forces, the patient was urged to breathe in and out multiple times. While holding the hand on the head steady, a minor relative rotation in the opposite direction was caused, which led to the introduction of the postero-anterior force on the transverse process of T1(29). Patients will receive three sessions a week on alternate days for three weeks and follow up data will be taken once after completion of all three sessions using data collection tools
224240570|NCT00389636|DEVICE|TheraGauze|TheraGauze
224240571|NCT00389636|DRUG|Regranex|Regranex + TheraGauze
224240572|NCT02576249|DRUG|Ropivacaine|4cc 0.5% ropivacaine
224240573|NCT02576249|DRUG|Normal saline|4cc of sterile normal saline (0.9%)
224240574|NCT02576249|DRUG|Methylprednisolone|1cc 40mg methylprednisolone
224240575|NCT00921336|DRUG|KW-2450|Dose escalation may proceed once \>= 3 subjects have completed the Day 29 blood sample to evaluate glucose. The safety of each dose level will be established prior to enrollment of subjects in the next dose level. Dose escalation will proceed sequentially with accelerated escalation. Once the criteria for completing the accelerated titration are reached, dose escalation will follow a modified Fibonacci schedule. Up to 6 subjects will be enrolled at each dose level. Enrollment will proceed until the maximum tolerated dose (MTD) has been established or the highest dose level (800 mg/day) has been reached. The Sponsor will enroll up to 12 additional subjects, in an expanded safety cohort.
224240576|NCT05133609|BIOLOGICAL|ChAdOx1 nCoV-19 vaccine (AZD1222)|ChAdOx1 nCoV-19 vaccine (AZD1222) in a standard 3-dose schedule with an interval of 12 weeks (first-second dose) and 24 weeks (second-third dose).
224240577|NCT02175264|GENETIC|Blood sample|
224240578|NCT03490721|OTHER|Clustering care|During 20 minutes, preterm infants will receive a cluster care with 2 minutes of hand containment.
224240579|NCT02154321|DEVICE|Electroencephalogram (EEG)|The electroencephalogram assesses brain electrical activity through surface recording disks (electrodes) which are placed near the participants' head using a custom designed Lycra cap. The electrodes transmit the signals which are then amplified and stored on a computer. The procedure is entirely non-invasive. Once an accurate signal is assured, the signal derived from the electrode cap is then amplified, transmitted to a computer, and stored for later analysis. Each participant will undergo the electroencephalogram (EEG) procedure only once for the duration of 30-45 minutes.
224240580|NCT04173936|BEHAVIORAL|tai chi|12-week community-based tai chi program
224240581|NCT05954650|BEHAVIORAL|Rehabilitation|Physical therapy and multisensory stimulation adjusted to the needs of each patient.
224240582|NCT04450043|BEHAVIORAL|Run-In Sessions 1-5|Session 1 explores patient goals and wishes for life after cancer treatment with a study interventionist. Sessions 2-5 focuses on learning and practicing skills to enhance post-treatment quality of life.
224240583|NCT04450043|BEHAVIORAL|RCT Transitions Program Sessions 1-5|Sessions 1-5 focuses on learning and practicing skills to enhance post-treatment quality of life.
224240584|NCT04450043|BEHAVIORAL|RCT Control Session|Participants will receive a 1-session intervention, focused on reviewing goal progress for post-treatment quality of life, providing encouragement and support, identifying any current concerns, and providing tailored recommendations and resources.
224240585|NCT01659307|DRUG|Aspirin 75mg|Subjects randomised to aspirin 75mg will receive 1 container containing aspirin 75mg and 1 container containing placebo for the morning and 2 containers containing placebo for the evening. Subjects will take one capsule from each container in the morning and one capsule from each container in the evening.
224240586|NCT01659307|DRUG|Lactose powder|Subjects randomised to placebo will receive 4 containers of placebo, 2 containers containing placebo for the morning and 2 containers containing placebo for the evening. Subjects will take one capsule from each container in the morning and one capsule from each container in the evening.
224240587|NCT01659307|DRUG|Aspirin 1200mg|Subjects randomised to aspirin 600mg 12 hourly will receive 2 containers of aspirin 300mg each for the morning and 2 containers of aspirin 300mg each for the evening. Subjects will take one capsule from each container in the morning and one capsule from each container in the evening.
224240588|NCT05150964|DEVICE|Phonak Audeo hearing aid|receiver in the canal devices with custom earmolds
223658622|NCT01614678|DEVICE|Lotrafilcon B contact lens with color, semi-automated|Silicone hydrogel contact lens with color manufactured via a semi-automated process
223658623|NCT03037580|DRUG|Oral treprostinil|Sustained-release oral tablets for TID administration
223658624|NCT03037580|DRUG|Placebo|Placebo (sugar pill) for TID oral administration
223658625|NCT00152269|DRUG|Asoprisnil|10mg Tablet, oral Daily for 12 months
223768795|NCT01075334|DIETARY_SUPPLEMENT|Zinc and Folate Supplementation|500 Mcg Folic acid, 30-60 mg Zinc tablets/ day
223658626|NCT00152269|DRUG|Asoprisnil|25mg Tablet, oral Daily for 12 months
223658627|NCT00152269|DRUG|Placebo|Placebo, Tablet, oral Daily for 12 months
223658628|NCT02327663|DRUG|Emtricitabine|emtricitabine were given to each patients at baseline and respoonse guided therapy was adopted according HBV DNA level at week 24
223658629|NCT02442804|DIETARY_SUPPLEMENT|POMx|Pomegranate supplement (1g) by mouth twice per day for 7 days
224240589|NCT00738803|PROCEDURE|Total hip replacement|Total hip replacement typically preformed for hip arthritis
223658630|NCT02442804|OTHER|Placebo|Placebo (for POMx, containing no antioxidant contents; 1g) capsule by mouth twice per day for 7 days
223768796|NCT00225355|DRUG|Rosiglitazone|
224321162|NCT02089607|DEVICE|Aortic Arch Aneurysm Arm|The endovascular graft includes the main aortic arch portion and one to three cuffs (side branches) that allow the graft to be located in the aortic arch. The number of cuffs is decided based on the anatomy of your aneurysm. The arteries in the aortic arch are the innominate artery (Zone 0), left common carotid artery (Zone 1) and the left subclavian artery (Zone 2). These arteries supply the right arm and right side of the brain, the left side of the brain and the left arm, respectively. The main aortic endovascular graft will be connected into the innominate artery, left common carotid artery and left subclavian artery using additional stents into the branch vessels.
224321163|NCT03533309|PROCEDURE|Computer guided surgical cutting guide|comprised 6 patient undergoing surgical alveolar ridge splitting using computer guided surgical cutting stent
224321164|NCT03533309|PROCEDURE|Conventional alveolar ridge splitting|comprised 6 patient undergoing surgical alveolar ridge splitting using conventional technique.
223658631|NCT04269798|OTHER|Traditional Treatment|conventional rehabilitation program for lower limb, balance and gait training
223658632|NCT02036853|DRUG|Triheptanoin|"Schedule A: Subjects previously treated with triheptanoin will continue to dose at approximately 35% of total daily calories (\~1-4g/kg/day, depending on age).~Schedule B: Subjects who are naïve to triheptanoin will begin a 2-week fixed titration schedule up until they have reached 35% of total daily calories (\~1-4 g/kg/day depending on age). If a subject has not reached the target of 35% of total daily calories, by the end of the 2-week fixed titration period, dose titration should continue until achieved or until the maximally tolerated dose has been established."
223768797|NCT00298896|DRUG|SNS-595|
223768798|NCT03394872|PROCEDURE|Drainage of the pleural effusion|
223768799|NCT02348242|DEVICE|Aqueous Gel|1 drop of Dexpanthenol® 0.2% aqueous gel in the eye every 6 hours
223768800|NCT02348242|DEVICE|Eyelid Occlusion Dressing|Eyelid occlusion using pro-ophta® eyelid occlusion dressing, dressing to be verified every 6 hours and replaced daily
223768801|NCT02348242|DEVICE|Artificial Tears|1 drop of Phylarm® artificial tears in the eye every 6 hours
223768802|NCT06273553|BIOLOGICAL|RG002 injection|In Part A, there are three dose cohorts that are 25µg,75µg and 150µg. In Part B, there will 1 or 2 dose levels according to the results of Part A. All subjects will receive a total of three RG002 Injections, administered intramuscularly at assigned dose level, with a dosing frequency of every 2 weeks (D1, D15, and D29).
223768803|NCT04922801|DIAGNOSTIC_TEST|Nuclear Medicine whole-body|Gamma-Camera Whole-body scan at 24-48 hour post-Molecular Radiotherapy (MRT).
224321165|NCT03751007|BIOLOGICAL|AG019 - Low Dose|Solid, orally administered capsule - 2 capsules per day for 1 day (single dose) or 8 weeks (repeat dose)
223658633|NCT01640834|DRUG|LY2409021|Administered orally
223658634|NCT01640834|DRUG|Placebo|Administered orally
223658635|NCT01640834|DRUG|Glucagon|Administered via intramuscular injection
223658636|NCT00254930|DRUG|risperidone|
223658637|NCT01035411|DRUG|AZD9668|2 x 30 mg batch DLE494
223658638|NCT01035411|DRUG|AZD9668|2 x 30 mg batch DLF497
223658639|NCT01035411|DRUG|AZD9668|2 x 30 mg tablet variant 1
223658640|NCT03783715|DRUG|Ketoprofen|Ketoprofen 200 mg ER, taken orally, once a day for 6 months. If medication, if obtained from a compound pharmacy, dose will be 210 mg ER, taken orally once a day for 6 months.
224240590|NCT01659203|RADIATION|IG-IMPT|Daily, Monday-Friday for about 6 weeks
224240591|NCT01659203|RADIATION|IG IMRT|Daily, Monday-Friday for about 6 weeks
224321166|NCT03751007|DRUG|Teplizumab|Daily IV infusions of Teplizumab during the first 12 days of AG019 treatment. Total cumulative dose is approximately 17mg (dose calculation based on body surface area).
223658641|NCT03415711|DIETARY_SUPPLEMENT|VSL#3®|VSL#3® 450 billion sachets
223658642|NCT03415711|DRUG|Mesalamine|Mesalamine 2.4 g/day in once daily administration.
223768804|NCT04922801|DIAGNOSTIC_TEST|SPECT/CT imaging.|SPECT/CT scan at 24-48 hr post MRT
223768805|NCT04922801|DIAGNOSTIC_TEST|PET/CT imaging.|3-6 months Pre and post-therapy PET/CT imaging
224321167|NCT03751007|DRUG|Placebo-AG019|Formulated identically to AG019 with the active ingredient removed.
224321168|NCT03751007|DRUG|Placebo-Teplizumab|Formulated identically to teplizumab with the active ingredient removed.
223658643|NCT03415711|DRUG|Placebo|sachets with maltose, cornstarch and dioxide
223658644|NCT04121793|DEVICE|Kinesia 360 and Smartphone sensors|Data will be recorded from the Kinesia 360 system and smartphone sensors using the AWARE Framework.
223658645|NCT01537614|DRUG|COLIMYCINE inhalation|2 MILLION UI
223658646|NCT01537614|DRUG|COLIMYCINE injectable|2 MILLIONS UI
223768806|NCT04922801|DEVICE|Patient-led radiation monitor (SELFIE)|"Following MRT administration, a standard whole body dosimetry measurement will be taken by medical physicist at 1 and 2 meters distance. The patient will begin to take SELFIE readings at the same time under supervision so that their records can be compared with the physicists' results.~After 28 days, patients will be asked to return the diary sheet and SELFIE monitor by post to GSTTFT in a pre-paid, pre-addressed envelope.~On completion of the 28 day exercise, patients will be asked to complete and return a feedback questionnaire."
223768807|NCT04922801|DIAGNOSTIC_TEST|LAB TEST|Biochemistry, haematology and tumour markers blood tests pre, post and during MRT.
224240592|NCT05141864|BIOLOGICAL|Acmella oleracea gel|Study group will use Acmella oleracea gel during the digital rectal examination.
224240593|NCT05141864|DRUG|Lidocaine 2 % Topical Cream|Control group will use lidocaine 2% gel during the digital rectal examination.
224240594|NCT05141864|OTHER|Ultrasound gel|Control group will use ultrasound gel during the digital rectal examination.
223768808|NCT01221441|BIOLOGICAL|TissueGene-C|Single intraarticular injection at 3 x 10e7 cells
223768809|NCT01221441|DRUG|Normal Saline|Single intraarticular injection of normal saline as a placebo control
223768810|NCT03022149|DEVICE|Doctormate® (200mmHg)|Limb ischemia was induced by Renqiao Remote Ischemic Conditioning Device (Doctormate®) inflating tourniquets to 200mmHg.
223658647|NCT03174600|OTHER|Questionnaire|The patients were questioned using the Danish Prostatic Symptom Score (DAN-PSS), and evaluated using modified Barthel index, incontinence quality of life questionnaire (I-QOL), and the Mini-Mental Test (MMT) on the 1st, 3rd and 6th months.
223658648|NCT03546452|DIAGNOSTIC_TEST|in vitro NGS-panel|cell free DNA ,which was purified from hydrothorax, is used to be tested by NGS-panel
223658649|NCT04023734|BEHAVIORAL|Reminders, habit-based strategies and/or involvement of family member|"Strategies to cope with forgetfulness include reminders, habit-based strategies and/or involvement of family members. The use of a reminder tool and pill boxes will be encouraged and a reminder app can be implemented if patients own a mobile phone. The habit-based strategy will be delivered through a printed worksheet which is tailored to patient's daily routine. Patients will be asked to identify the appropriate place and time to take their medication, and an action they conduct every day that could serve as a prompt or cue to take their medication. Patients will be asked to write coping plans to formulate their own if-then plans for all daily doses of their antihypertensive drug(s). Moreover, patients will be asked to choose a family member to become their treatment supporter. This individual will be asked to support patients to take the antihypertensive drugs. Pharmacists will remind patients to take his/her completed worksheet to the next visit."
223768811|NCT03022149|DEVICE|Doctormate® (60mmHg)|Limb ischemia was induced by Renqiao Remote Ischemic Conditioning Device (Doctormate®) inflating tourniquets to 60mmHg.
223768812|NCT02912481|PROCEDURE|posterior tibial artery|
223658650|NCT04023734|BEHAVIORAL|Counselling to increase knowledge|The content of the counselling to cope with lack of knowledge will focus on educating patients about the purpose of the medication, when and how to take the medication, the need for long-term use, the importance of medication adherence, and how to deal with possible side effects. To explore which education is needed, the patient will be asked whether they know why and how to take their medication. The teach-back method will be used, where the patient is asked to explain the pharmacist what he/she has understood after receiving the education.
223768813|NCT02912481|PROCEDURE|radial artery|
223768814|NCT02912481|PROCEDURE|dorsalis pedis artery|
223768815|NCT01086579|DEVICE|IN.PACT Falcon paclitaxel eluting balloon (Drug eluting balloon)|Coronary Artery Bypass Graft (CABG)
223768816|NCT01086579|DEVICE|Taxus (Paclitaxel eluting stent)|Percutaneous transluminal coronary angioplasty (PTCA) with stent
223768817|NCT02649972|DRUG|Cobimetinib|Cobimetinib will be administered at a dose of 60mg daily for 21 days on, then 7 days off, in a 28 day treatment cycle. Patients will have the option to discontinue treatment after 12 cycles and will be monitored for disease relapse for an additional 12 months. In the event that disease relapse occurs within the 12 month monitoring period, patients will restart treatment and continue on study. Upon restarting, the assessment schedule will restart at rechallenge cycle 1(RC-1) and all assessments will occur at the frequency and intervals. Cycle 1 Day 15 visits will not be required for patients that restart treatment after relapse. Participants will re-sign consent upon rechallenging.
223768818|NCT04837794|DEVICE|Digital Pain-Management Tool|Digital Pain-Management Tool
223768819|NCT06788964|DRUG|Loncastuximab Tesirine|Patients will receive Loncastuximab Tesirine intravenously for 1-6 cycles (every 21 days) prior to standard of care CAR-T cell therapy.
223768820|NCT06788964|DRUG|Rituximab|Rituximab is administered intravenously for 1-6 cycles (every 21 days) prior to standard of care CAR-T cell therapy.
223768821|NCT05112497|OTHER|No intervention procedure|No intervention procedure
223768822|NCT03079258|OTHER|Exercise|Previously inactive pregnant women will be asked to complete 3-4 sessions of aerobic exercise each week for 24 weeks of 15-30 minutes in duration.
223768823|NCT01845155|BEHAVIORAL|Neuro-Music-Therapy according to the Heidelberg Model|"The neuro-music therapy according to the Heidelberg Model for tinnitus is a manualized short term music therapeutic treatment lasting for nine consecutive 50-minutes sessions of individualized therapy. Therapy takes place on five consecutive days (from Monday to Friday) with two therapy sessions per day. It comprises both active and receptive forms of music therapy. The interventions are structured into the following modules Directive Counseling, Resonance Training, Neuroauditive Cortex Training, Tinnitus Reconditioning.~For more details on the music therapy see Argstatter et al. 2012"
223768824|NCT01845155|BEHAVIORAL|Counselling|Duration: single session of 50 min Tinnitus specific procedures: The counseling group receives the identical counselling procedure as the music therapy group.
223768825|NCT05644327|BEHAVIORAL|Cardiovascular training (CT)|12 weeks of CT
223768826|NCT05644327|BEHAVIORAL|Resistance training (RT)|12 weeks of RT
223768827|NCT05644327|BEHAVIORAL|Multimodal training (MT)|12 weeks of MT
223768828|NCT04385602|DRUG|Intratracheal dexmedetomidine|Thirty minutes before the end of the surgery, Dex (0.5μg/kg diluted and mixed in 1ml saline in a medical spray bottle) will be sprayed down the intratracheal tube
223768829|NCT04385602|DRUG|Saline Solution|Thirty minutes before the end of the surgery, 1ml saline in a medical spray bottle will be sprayed down the intratracheal tube
224240595|NCT04804800|OTHER|Experimental group 1 : Virtual Reality|Patients benefit from the care recommended by the HAS, the virtual reality program and time for relaxation and body scan.
224240596|NCT04804800|OTHER|Experimental group 2 : Virtual Reality + Multi Sensorial Remediation|Patients benefit from the care recommended by the HAS, the virtual reality program, the multisensory remediation, and also the body scan.
224240597|NCT04366232|DRUG|Anakinra alone (stages 2b/3)|Anakinra 300 mg 1/d Intravenous 5 days then dose tapering
224240598|NCT04366232|DRUG|Anakinra and Ruxolitinib (overcome stage 3)|Anakinra 300 mg od Intravenous (maximum14 days) Ruxolitinib 5 mg bid per os (maximum 28 days)
224240599|NCT04366232|OTHER|Standard of care|Routine clinical care for Covid-19
224240600|NCT04182152|DEVICE|Indocyanine green (ICG)|Indocyanine green (ICG) was diluted with saline to 0.5mg/mL, and injected 0.6mL/site.
224240601|NCT04182152|DEVICE|Electromagnetic navigation bronchoscopy|Electromagnetic navigation bronchoscopy (ENB) allows physicians to access peripheral lung nodules with high accuracy and provides a working channel for ICG injection.
223768830|NCT04991740|DRUG|JNJ-78306358|JNJ-78306358 will be administered.
223768831|NCT03394391|BEHAVIORAL|Daily ART-adherence SMS reminder|Interactive and tailored SMS reminders that are acceptable to the participants to remind them to take their medications and to make clinic attendance.
223768832|NCT03394391|BEHAVIORAL|Standard Adherence Counselling/Patient experience group chat|"All the participants will receive the standard adherence counselling by trained counsellors at each visit.~All participants will also be enlisted in a group chat on social media where they will discuss their experiences with the quality of HIV services rendered at their respective clinics. A specialist who will have very minimal involvement will give weekly feedback and counsel on how best to resolve prominent challenges."
223768833|NCT02081495|DRUG|DOXIL/CAELYX reference product (Treatment A)|Participants will receive DOXIL/CAELYX reference product 50 mg/m2 as an intravenous (into a vein) infusion over 90 minutes on Day 1.
223768834|NCT02081495|DRUG|DOXIL/CAELYX test product (Treatment B)|Participants will receive DOXIL/CAELYX test product 50 mg/m2 as an intravenous infusion over 90 minutes on Day 1.
223768835|NCT03909776|DRUG|Cisplatin|Cisplatin was administered intravenously or intraarterially after adequate IV hydration. For IA infusion, cisplatin was given via insertion of a catheter percutaneously by using the Seldinger technique through the brachial or femoral artery under anesthesia and usually at 120 mg/m2 as a 3-h/6-h continuous infusion; while for IV administration, it was given at 100-120 mg/m2 as 6-h infusions.
223768836|NCT03093805|DIETARY_SUPPLEMENT|Calcipotriene|Topical vitamin D cream will be applied to affected areas of the skin.
223768837|NCT04985253|OTHER|prediction of overall survival using Web based PREDICTV2.0 portal|"Predict is an online prognostication and treatment benefit tool developed in the UK, using cancer registration and survival data recorded by the Eastern Cancer Registration and Information Centre (ECRIC) for 5694 women diagnosed in East Anglia from 1999-2003.~The model was validated in a second cohort of 5468 women from the West Midlands Cancer Intelligence Unit and is available online (www.predict.nhs.uk) providing 5-and 10-year survival estimates and treatment benefit predictions. Wong et al, tested the predictive accuracy of PREDICT V1.0 in the southeast Asian population. There were 67% Chinese patients while 13% were Indians. They showed concordance in observed and predicted OS in most subgroups except for women whore less than 40 years of age."
223768838|NCT02652624|DRUG|E/C/F/TAF|150/150/200/10 mg FDC tablet administered orally once daily with food
223768839|NCT02652624|DRUG|E/C/F/TDF|150/150/200/300 mg FDC administered orally once daily with food
223768840|NCT02652624|DRUG|ATV|ATV 300 mg capsules administered orally once daily with food
223768841|NCT02652624|DRUG|RTV|RTV 100 mg tablets administered orally once daily with food
223768842|NCT02652624|DRUG|FTC/TDF|200/300 mg tablet administered orally once daily with food
223768843|NCT02652624|DRUG|B/F/TAF|50/200/25 mg FDC tablet administered orally once daily without regard to food
223768844|NCT01023659|DRUG|bupropion|bupropion, 150 mg twice daily plus weekly motivational emails for 12 weeks
223658651|NCT04023734|BEHAVIORAL|Counselling to increase motivation|The content of the counselling to cope with lack of motivation will focus on exploring and discussing their concerns and necessity beliefs. This method is called motivational interviewing. This is done by asking a first question about whether the medication bothers the patient. Follow-up on this question can focus on any concerns or low necessity beliefs (e.g., when patients are bothered by the medication because they think the medication is not needed or are afraid of side-effects).
223658652|NCT04023734|BEHAVIORAL|Explore/address other drug related problems|The content of the counselling to address other drug related problems will focus on exploring these other problems underlying the non-adherence, for example experiencing side effects, costs, polypharmacy, difficulty to refill antihypertensive drugs in time, or medication intake problems, and offering solutions/alternatives when possible.
223658653|NCT04023734|BEHAVIORAL|Usual care based on the Indonesian guideline|Patients in five CHCs randomized to the control group will receive pharmacist counselling based on the Indonesian guideline of pharmacy practice. At each visit, they will receive information about the quantity and dose of the dispensed drugs, when and how to use and store the drugs, side effects and how to deal with them, the importance of medication adherence, and confirming if the patient understands how to take medications correctly.
223658654|NCT02917122|DEVICE|active tDCS|Patients will take 12 tDCS sessions (30min for each session): first 10 consecutive sessions for two weeks (Monday to Friday), and then 2 follow-up sessions scheduled 2 and 4 weeks after the consecutive treatment.
223768845|NCT01023659|DRUG|varenicline|varenicline, 1 mg twice daily plus weekly motivational emails for 12 weeks
223768846|NCT01023659|BEHAVIORAL|motivational emails|brief motivational emails, sent weekly for 12 weeks
223768847|NCT00739336|BEHAVIORAL|Diabetes Prevention and Control|The program will be delivered over 3 months in 12 one hour weekly mid-day sessions at the worksite. The curriculum has been adapted from the Diabetes Prevention Program, the National Diabetes Education Program and Conversation maps from Healthy Interactions Inc. Topics relate to healthy eating, physical activity, coping with disease and depression, and cardiovascular disease prevention. Additional topics may be included per feedback and need of the participants. After completion of the 3 month program, there will be monthly meetings.
223768848|NCT00912405|DEVICE|Steroid-Eluting Sinexus Intranasal Splint|Intranasal drug-coated splint placed after functional endoscopic surgery (FESS)
223768849|NCT00384137|DRUG|Tacrolimus|Immunosuppression
223768850|NCT02343510|OTHER|PCR for chlamydia DNA in primary tubal cancer|PCR for presence of chlamydia DNA in paraffin blocks retrieved for tubal and ovarian tissues in all groups
223768851|NCT03067779|OTHER|mHealth Tool|"The curriculum in the mHealth tool was derived in consultation with patient safety, informatics and adult educational curricula experts, and is comprised of clinical vignettes describing common patient safety themes in CKD and includes a pre- and post-test knowledge assessment. Topics of emphasis included NSAID risk awareness, hypoglycemia awareness, avoidance of volume depletion when ill (Sick Day Protocol) and avoidance of contrast-induced nephropathy."
223768852|NCT02483234|DRUG|secukinumab|
224240602|NCT04182152|DEVICE|Hook wire|Hook wire is a puncture locating needle with a hook head that is about 1 cm in length and 30 cm metal wire behind. Through the puncture path planned based on CT scan, hook wire puncture percutaneously into the chest cavity to reach the lesion for localization.
224321169|NCT03751007|BIOLOGICAL|AG019 - High Dose|Solid, orally administered capsule - 6 capsules per day for 1 day (single dose) or 8 weeks
223658655|NCT02917122|DRUG|Sertraline|Patients will take Sertraline.
223658656|NCT02917122|DEVICE|sham tDCS|Patients will take 12 tDCS sessions (30min for each session): first 10 consecutive sessions for two weeks (Monday to Friday), and then 2 follow-up sessions scheduled 2 and 4 weeks after the consecutive treatment.
223658657|NCT00900952|OTHER|Clinical record review|
223658658|NCT03297905|BEHAVIORAL|Complementary and Integrative Therapies|Intervention time period is 3 - 6 weeks.
223658659|NCT03297905|BEHAVIORAL|Standard Rehabilitative Care|Intervention time period is 3 - 6 weeks.
223658660|NCT01224990|PROCEDURE|Whole body diffusion MRI|These studies will be performed on a 3Tesla (T) MR system (Achieva, Philips Medical Systems). A major advantage of 3T compared to 1.5 T is the improved signal to noise ratio that allows whole-body studies to be faster and without application of external antennas, which greatly improves patient comfort.
223658661|NCT02543060|DRUG|stannous fluoride toothpaste|0.454% stannous fluoride toothpaste
223658662|NCT02543060|DRUG|cavity protection toothpaste|0.243% sodium fluoride toothpaste
223658663|NCT04282408|DEVICE|Scoliosis back brace|The patients will use the traditional brace, if not already in use, for 2 weeks and then they will wear a 3D printed back brace for the following 2 weeks. Both the braces will be worn for the amount of hours per day prescribed by the physician.
223658664|NCT04696614|BEHAVIORAL|exercise|intervention groups provided different sequential modality of exercise
223658665|NCT05155189|BIOLOGICAL|C-CAR031|Targeting GPC3 armored CART cell injection (C-CAR031)
223658666|NCT05155189|DRUG|Lenvatinib|Tyrosine kinase inhibitors
223658667|NCT05155189|DRUG|PD-1(L1) monoclonal antibody|Immune checkpoint inhibitors, ICIs
223658668|NCT02105181|DEVICE|Placement of a FCMS in the biliary tract of the patients|During an ERCP procedure, a fully covered biliary metal stent (FCMS) is placed across a benign biliary stricture
223658669|NCT04001959|PROCEDURE|Silver Diamine Fluoride with Potassium Iodide|Dry the tooth for 30 seconds with air jet and apply one drop of Diamino 30% Silver Fluoride with a disposable applicator brush for 3 minutes and one drop of potassium iodide solution immediately on the treated surface, then wash.
223658670|NCT01452100|DRUG|prednisone|Patients enrolled into the study will be treated with prednisone, 20 mg/day (if body weight \<70 kg ; or 25mg/d if body weight \>70 kg) for 1 month, then tapered to 12.5 mg/d (month 2) and 7.5 mg/d (month 3) and stop. In both groups, patients will be treated according to expert advice including use of statins (according to French Health Agency recommendation), a RAS inhibitor and supportive treatment (including nutrition, treatment of heart failure, and dialysis).
223658671|NCT01452100|OTHER|placebo|• Patients enrolled into the study will be treated with placebo, 20 mg/day (if body weight \<70 kg ; or 25mg/d if body weight \>70 kg) for 1 month, then tapered to 12.5 mg/d (month 2) and 7.5 mg/d (month 3) and stop. In both groups, patients will be treated according to expert advice including use of statins (according to French Health Agency recommendation), a RAS inhibitor and supportive treatment (including nutrition, treatment of heart failure, and dialysis).
223658672|NCT01890252|DEVICE|Hyper CL|The Hyper CL is hyper osmotic contact lens that absorb fluids from the cornea and by that reduces corneal edema.
223658673|NCT01890252|DRUG|saline solution|saline solution of 5% NaCl
223658674|NCT00536497|DRUG|GW842166X|
223658675|NCT03292172|DRUG|Atezolizumab|Atezolizumab will be given intravenously (IV) at a fixed dose of 1200 mg on Day 1 of each cycle, every 3 weeks.
223658676|NCT03292172|DRUG|RO6870810|RO6870810 will be injected SC,at initial planned doses of 0.30, 0.45, or 0.65 mg/kg, QD for the first 14 days of a 21-day cycle.
223658677|NCT03060161|BEHAVIORAL|Health in the right measure|Nutritional monitoring and individual guidance on regular physical exercise.
223658678|NCT02236117|OTHER|Aerobic Training|Will be included 160 children, 80 in an experimental group and 80 in a control group of both genders. The experimental group will realize aerobic training during 10 weeks (3×40min week-1; intensity, \>80% maximal aerobic velocity - MAV), while the control group will have involved with the physical education classes two times a week for 50 minutes each class. The aerobic protocol will be composed by 2 sessions of intermittent running and 1 session by continuous.
223658679|NCT02526030|DRUG|Aripiprazole|
223658680|NCT02526030|DRUG|Quetiapine|
223658681|NCT02526030|DRUG|Ziprasidone|
223658682|NCT02901678|DEVICE|Intrusion by 400 g|using miniscrews and coil springs to apply the intrusive force on maxillary posterior segment intrusion.
224321170|NCT03751007|BIOLOGICAL|AG019 - High Dose|Solid, orally administered capsule - 6 capsules per day for 8 weeks.
223658683|NCT00163254|DRUG|abciximab|
223658684|NCT00163254|DEVICE|stent and drug eluting stent|
223658685|NCT00013156|PROCEDURE|Effectiveness of Lung Reduction Therapy|
223658686|NCT01305980|DRUG|SB injection|Infusion SBinjection of 21.87ml/m\^2, IV route, 24times for 4 months
223658687|NCT00499590|DRUG|bevasiranib|Bevasiranib (2.5mg) administered intravitreally every 8 or 12 weeks
223658688|NCT00499590|DRUG|ranibizumab|Lucentis® (0.5 mg)administered intravitreally every 4 weeks.
223658689|NCT01430169|BIOLOGICAL|AA4500|Two injections of AA4500 0.58 mg 24 hours apart
223658690|NCT01626937|OTHER|Non invasive ventilation|After nebulisation of bronchodilatators and administration of corticosteroid therapy, non invasive positive pressure ventilation will be started out of hospital and continuously in COPD patient with acute respiratory distress and respiratory acidosis, using a facial mask, with initial level of inspiratory pressure at 8 mmHg then according to VTe and/or respiratory rate; expiratory pressure at 4 mmHg then according to persistance of inspiratory work, level of FiO2 for an objective of SpO2 between 88 and 92%. In case of failure, NIV will be stopped and endotracheal intubation realized if indicate.
223658691|NCT01626937|OTHER|conventional medical treatment|Conventional medical treatment includes nebulization of bronchodilatators every 15-20 minutes until hospital and corticosteroid therapy. If indicate during out of hospital setting, endotracheale intubation will be realized. After admission in hospital, non invasive ventilation could be started.
223658692|NCT00000776|DRUG|Flucytosine|
223658693|NCT00000776|DRUG|Fluconazole|
223658694|NCT00000776|DRUG|Amphotericin B|
223658695|NCT00000776|DRUG|Dexamethasone|
223658696|NCT05661851|DRUG|Investigational Lubricating Eye Drop in a Novelia® bottle|Investigational Product
224321171|NCT00841828|DRUG|Epirubicin|
224321172|NCT00841828|DRUG|Cyclophosphamide|
223658697|NCT05661851|DRUG|Blink® Tears eye Drops|Control Product
224321173|NCT00841828|DRUG|Docetaxel|
223658698|NCT01212341|BIOLOGICAL|Allogeneic NK cells|
223658699|NCT04146636|DIAGNOSTIC_TEST|e-LIFT|Diagnostic procedure: elastography devices, blood tests (e-LIFT), liver biopsy if necessary (elstometry ≥ 8 kPa and \< 15 kPa)
223658700|NCT00583076|DRUG|AST-120|AST-120, 2grams,three times daily for 4 weeks. Responders in the second cohort of patients are eligible to receive AST-120 for up to 52 weeks.
223658701|NCT01119079|OTHER|Normal Saline|10ml Normal Saline instilled in the epidural space
223658702|NCT01119079|PROCEDURE|Administration of epidural anesthesia for labor|Standard procedure
223658703|NCT04174326|BEHAVIORAL|Immediate intervention group|Participants will be randomized to either the immediate or delayed intervention group at baseline. Participants in both groups will receive CBT for chronic pain management sequentially, once a week during the 6 week intervention period. Participants will be followed-up at 18 weeks from baseline. Two in-between sessions practice assignments will be added to each group therapy session during the the CBT program.
223658704|NCT01490489|OTHER|blood sample and doppler Ultrasound of uterine arteries|"* 36 ml of blood samples (serum and plasma) will be collected~* After a bed rest supine for 15 minutes, ultrasound Doppler from each of the uterine arteries will be performed to search for Notch"
223658705|NCT04583241|OTHER|Constitution of serum bank at D0|Blood samples at Day 0 (day of surgery)
223658706|NCT04583241|OTHER|Constitution of serum bank during follow-up|Blood samples are obtained at week 2, week 6 post-surgery, at the end of antibiotherapy and 6 months post-surgery, only for patients with staphylococcus aureus monoinfection who are follow-up during two years.
223658707|NCT04583241|OTHER|ELISA assays of serum markers of bone remodeling at D0|Assessment by ELISA assays of serum markers of bone remodelling: the osteocalcin (OC), the procollagen propeptide type 1 (PINP), the cross linked telopeptide of type 1 collagen (CTX1) and the periostin at Day 0 (day of surgery)
223658708|NCT04583241|OTHER|ELISA assays of serum markers of bone remodeling during follow-up|Assessment by ELISA assays of serum markers of bone remodelling: the osteocalcin (OC), the procollagen propeptide type 1 (PINP), the cross linked telopeptide of type 1 collagen (CTX1) and the periostin at week 2, week 6 post-surgery, at the end of antibiotherapy and 6 months post-surgery, only for patients with staphylococcus aureus monoinfection who are follow-up during two years
223658709|NCT04583241|OTHER|Analysis of bacterial gene expression at D0|Assessement of bacterial gene expression on surgery residual tissue (bone tissue, joint fluid, fragment of prostheses) collected at Day 0 (day of the surgery)
223658710|NCT04306796|DEVICE|3D printed splints|3D printed made to measure splints
223658711|NCT04306796|DEVICE|Thermoplastic splints|thermoplastic splints individually adjusted by occupational therapists
223658712|NCT01649206|PROCEDURE|Percutaneous Radiofrequency Thermal Ablation|Percutaneous Radiofrequency Thermal Ablation (RTA) by using a RITA© StarBurst Talon needle (RITA Medical Systems, Fremont, CA). RTA is performed in each patient at Time 0.
223658713|NCT01689493|BEHAVIORAL|patient education and daily SMS|The proposed intervention will be based on several conceptual frameworks (Chronic Care Model and Medication Adherence Model) and adapt elements of prior successfully adherence interventions, including: collaborative care, patient education, tailoring of medication regimens, and daily mobile phone short message service (SMS).
223658714|NCT02916537|DRUG|CTT1057|Single IV dose (370 MBq, or 10 mCi) of CTT1057 followed by combined PET/MR imaging (prostate + whole body).
223768853|NCT03302858|DEVICE|BARRX™ Anorectal Wand|"The radiofrequency ablation (RFA) or Barrx™ Ablation System used in this protocol comprises an RFA generator (Barrx™ FLEX) and the Barrx™ Anorectal Wand. The generator and wand are cleared by the FDA for human use and the wand is specifically cleared for treatment of anal neoplasia. The present FDA indication for use statement is: The Barrx™ catheters are indicated for use in the coagulation of bleeding and non-bleeding sites in the gastrointestinal tract including, but not limited to, the esophagus. Indications include esophageal ulcers, Mallory-Weiss tears, arteriovenous malformations, angiomata, Barrett's esophagus, Dieulafoy lesions, angiodysplasia, gastric antral vascular ectasia, and radiation proctitis."
223768854|NCT04410926|OTHER|Corrective exercises|The experimental and control groups performed a designed strengthening exercises included short-foot exercise, toes-spread-out exercise, toes-extension exercise and toe-curls for 60 minutes
223768855|NCT04410926|OTHER|Neuromuscular electrical stimulation|The experimental group received NMES aiming to reinforce the planter intrinsic foot muscles for 30 minutes. The surface electrodes were placed over the abductor halluces. The control group received placebo NMES with no current stimulation.
223768856|NCT00393172|BEHAVIORAL|exercise|5 days per week exercise for 4 months
223768857|NCT00894075|BIOLOGICAL|ENB-0040|1mg/kg subcutaneous injection thrice weekly for 6 months
224321174|NCT00841828|DRUG|Lapatinib|
224321175|NCT00841828|DRUG|Trastuzumab|
224321176|NCT05308628|DIAGNOSTIC_TEST|Liver Allograft Fibrosis by Using Fibrosis Panel(PRO-C3, PIIINP, TIMP-1, HA etc.)|Liver biopsies will be performed at 3 months, 6 months and 12 months post-transplant. Fibrosis was evaluated using the liver allograft fibrosis score (LAFSc) staging system. Liver Allograft Fibrosis by Using Fibrosis Panel(PRO-C3, PIIINP, TIMP-1, HA)or (FBLN3,YKL40,LECT2 etc.)
223658715|NCT02916537|PROCEDURE|Prostatectomy|Radical prostatectomy with lymph node dissection
223658716|NCT06373133|DRUG|SHR-8068|1mg/kg，ivgtt, d1, q6w or 4mg/kg，ivgtt, d1, q12w
223658717|NCT06373133|DRUG|Adebrelimab|1200mg, ivgtt, d1, q3w
223658718|NCT06373133|DRUG|BP102|7.5mg/kg, ivgtt, d1, q3w
223658719|NCT00409357|DRUG|SL77.0499-10 (alfuzosin hydrochloride)|
223658720|NCT05611333|BEHAVIORAL|Physician-Led Remote Exercise Program Intervention|The physician-led remote exercise program intervention consists of three 45-minute walking classes on Zoom per week for 4 weeks.
223658721|NCT06120829|PROCEDURE|Cryobiopsy|Use of 1.1mm ERBE 2 disposable cryoprobe for tissue sampling
223658722|NCT06120829|DEVICE|Cryobiopsy|Use of 1.1mm ERBE 2 disposable cryoprobe for tissue sampling
223658723|NCT06120829|PROCEDURE|Core Needle Biopsy|Core Needle Biopsy
223658724|NCT05740878|DIETARY_SUPPLEMENT|immunonutrients oral nutritional supplements|1 serving of ONS immunonutrients which is 57 grams of ready-to-brew powder yields 200 ml of a liquid formula containing 251 kcal energy (1.26 kcal/ml), 9 grams protein (14%), 94 mg omega-3, and 20 mg anthocyanins.
224240603|NCT04978532|OTHER|Guided Imagery|The children in the guided imagery group listened to a voice recording named 'Stroll in the Forest' before and during venipuncture. One minute before venipuncture, children wore an earphone and voice recording started. Children closed their eyes, imagined the text content, and focused on the voice recording while listening to the voice. It is a voice recording that helps the children in the guided imagery group to imagine that they are strolling in a forest and guides them.
223658725|NCT05740878|DIETARY_SUPPLEMENT|standard oral nutritional supplements|1 serving of standard ONS which is 57 grams of ready-to-brew powder yields 200 ml of liquid formula containing 258 kcal energy (1.26 kcal/ml), 5 g (7.5%) protein , 7 g (24%) fat, 43 g (68%) carbohydrate
223658726|NCT03241147|DRUG|Lu AF35700|Single dose, 10 mg film coated tablet
223658727|NCT02503137|DRUG|Topical SM04554 solution|
223658728|NCT02503137|DRUG|Topical Vehicle solution|
223658729|NCT03039946|DEVICE|Closed-Loop GDFT|Patients receive fluids in the form of 100ml boluses of crystalloid (Plasmalyte) over 6 minutes via an automated closed-loop goal-directed fluid therapy (GDFT) system guided by non-invasive flow monitoring (Clearsight system). Additional boluses of colloid or crystalloid can be administered under the attending anesthesiologist's discretion (e.g. to compensate blood loss) .
223658730|NCT03039946|OTHER|Restrictive Fluid Therapy|Patients receive fluids (Plasmalyte) via a restrictive approach with a baseline of of 4ml/kg/h. Additional boluses of colloid or crystalloid can be administered under the attending anesthesiologist's discretion (e.g. to compensate blood loss) .
223658731|NCT03564704|DRUG|Dexamethasone|Dexamethasone will be added in Pre-phase Regimen, Induction-Regimen, Consolidation-Module of PDT-ALL-LBL protocol.
223658732|NCT03564704|DRUG|vincristine|Vincristine will be added to Induction-Regimen, Consolidation-Module and Maintenance-Module of PDT-ALL-LBL protocol.
223658733|NCT03564704|DRUG|Cyclophosphamide|CTX will be added to Induction-Regimen, Consolidation-Module and Maintenance-Module of PDT-ALL-LBL protocol.
223658734|NCT03564704|DRUG|Idarubicin|IDA will be added to Induction-Regimen and Consolidation-Module of PDT-ALL-LBL protocol.
223658735|NCT03564704|DRUG|Pegaspargase|PEG-ASP will be added to Induction-Regimen and Consolidation-Module of PDT-ALL-LBL protocol.
223658736|NCT03564704|DRUG|Adriamycin|Adriamycin will be added to Consolidation-Module of PDT-ALL-LBL protocol.
223658737|NCT03564704|DRUG|Methotrexate|Methotrexate will be added to Consolidation-Module of PDT-ALL-LBL protocol.
223768858|NCT03409692|DIAGNOSTIC_TEST|Gene Expression Profiling|SkylineDx has previously developed the MMprofiler, a microarray-based diagnostic test that can subtype MM patients and reliably predict MM patient survival (prognosis). In this project, the test's clinical value will be expanded to include the prediction of treatment effectiveness in individual patients based on Gene Expression Profiling.
224240604|NCT04978532|OTHER|Control Group|No intervention was made in the children.
223658738|NCT03564704|DRUG|6-mercaptopurine.|Mercaptopurine will be added to Consolidation-Module and Maintenance-Module of PDT-ALL-LBL protocol.
223658739|NCT03564704|DRUG|Etoposide|VP-16 will be added to Consolidation-Module of PDT-ALL-LBL protocol.
223658740|NCT03564704|DRUG|Cytarabine|AraC will be added to Consolidation-Module of PDT-ALL-LBL protocol.
223658741|NCT03564704|PROCEDURE|Bone marrow aspiration|Bone marrow aspiration and additional tests will be performed in all module of PDT-ALL-LBL protocol.
223658742|NCT03564704|PROCEDURE|Intrathecal injection|Intrathecal injection of chemotherapy will be performed in PDT-ALL-LBL protocol.
223658743|NCT03564704|RADIATION|Radiation therapy|Radiation therapy will be performed for mediastinum and/or central nervous system leukemia/lymphoma in PDT-ALL-LBL protocol.
223658744|NCT03564704|GENETIC|NGS|Next-Generation-Sequencing (NGS) will be performed in PDT-ALL-LBL protocol.
223658745|NCT03564704|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Allo-HSCT will be added to LBL patients with available donor in PDT-ALL-LBL protocol.
223658746|NCT03564704|DIAGNOSTIC_TEST|Flow-MRD|Flow-MRD will be added to PDT-ALL-LBL for bone marrow and cerebrospinal fluid samples.
223658747|NCT03564704|DIAGNOSTIC_TEST|FISH|FISH will be added to PDT-ALL-LBL for bone marrow samples.
223658748|NCT03564704|DIAGNOSTIC_TEST|Flow immunophenotyping|Flow immunophenotyping will be performed in PDT-ALL-LBL protocol.
223658749|NCT03564704|DIAGNOSTIC_TEST|Karyotyping|Karyotyping will be performed in PDT-ALL-LBL protocol.
223658750|NCT03564704|DRUG|Chidamide|HDACi chidamide will be added to induction regimen, consolidation and maintenance module of PDT-ALL-LBL.
223658751|NCT03564704|DIAGNOSTIC_TEST|PET-CT scan|PET-scan will be performed for T-LBL patients for MRD assessment in PDT-ALL-LBL.
223658752|NCT03827915|DEVICE|Double sequential external defibrillation|DSED is the process of using two defibrillators near simultaneously at their highest allowed energy setting and aims to treat refractory atrial fibrillation. The first set of pads is placed in the traditional anterolateral position and the second set can be either placed adjacent to the first set (antero-lateral) or in the antero-posterior position. Shocks are then delivered simultaneously or near simultaneously
223658753|NCT00600977|DRUG|Doxorubicine|9mg/m² J1 J4 2 COURSES
223658754|NCT00600977|DRUG|Doxorubicine pegylated|40 MG/M² J1 2 courses
223658755|NCT03423199|DRUG|Palbociclib|Palbociclib, 125mg, orally once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment
223658756|NCT03423199|DRUG|Placebo|Placebo, orally once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment
223658757|NCT03423199|DRUG|Tamoxifen|Tamoxifen, 20mg, orally once daily (continuously)
223658758|NCT03423199|DRUG|Goserelin|For pre/perimenopausal patients only: Goserelin, 3.6 mg, subcutaneously every 4 weeks; or 10.8 mg, subcutaneously every 12 weeks
223658759|NCT03050229|DRUG|Empagliflozin|Empagliflozin 10mg/day once daily before or after breakfast
223658760|NCT03050229|DRUG|Placebo|Placebo once daily before or after breakfast
223768859|NCT03863366|DRUG|Prucalopride|1mg prucalopride tablet, encapsulated in white capsule
224240605|NCT05614570|DEVICE|SSVEP Device|Non-invasive, non-interventional SSVEP sensor device
224240606|NCT05614570|OTHER|SCAT5|The Sport Concussion Assessment Tool version 5
224240607|NCT00237549|PROCEDURE|optimised treatment|"The intervention targeted individual patients and the Primary Care Team. Practitioners were trained in a target driven, intensive multifactorial approach including lifestyle advice (smoking cessation, physical activity 30 min./day and healthy diet) and pharmacological treatment with the aim of reducing the complications of diabetes as described in protocol.~The training included meetings, practice visiting, written feed back reports and reminders on controls."
223658761|NCT01461109|DRUG|[18F] CFPyPB|Each subject will receive a bolus injection targeted to be 5 mCi and not to exceed 5.5 mCi (not \>10% of 5 mCi limit) of \[18F\]CFPyPB or 5 μg of CFPyPB (whichever is greatest).
224240608|NCT01783171|DRUG|Akt Inhibitor MK2206|Given PO
224240609|NCT01783171|DRUG|Dinaciclib|Given IV
224240610|NCT01783171|OTHER|Laboratory Biomarker Analysis|Correlative studies
223658762|NCT04357223|DRUG|extract from Angelica archangelica leaf|A standardized extract from Angelica archangelica leaf. Capsule, Twice Daily
223658763|NCT04357223|DRUG|Placebo|Placebo
223658764|NCT00612807|BEHAVIORAL|Weekly marital therapy|Weekly marital therapy for 6 months.
223658765|NCT00612807|DRUG|As indicated: Sertraline, bupropion, venlafaxine, mirtazepine, nortriptyline, tranylcypromine, lithium augmentation, etc.|"Study doctor may prescribe antidepressant medication for the treatment of depression. Medications will be prescribed according to empirically supported guidelines outlined in the Duke Somatic Treatment Algorithm for Geriatric Depression (STAGED Approach; Steffens, 2002).~SSRIs (daily dose of at least 20 mg for citalopram, 20 mg for fluoxetine, 100 mg for sertraline, 20 mg for paroxetine)~SNRIs (e.g., venlafaxine)~Bupropion SR (achieve dose of at least 150 mg BID)~Mirtazapine~Tricyclic antidepressants (nortriptyline with drug levels 80-120 ng/dl)~Lithium augmentation~MAOI (daily dose of at least 30 mg tranylcypromine or 45 mg of phenelzine)"
223658766|NCT00666484|DRUG|cyclophosphamide|
223658767|NCT00666484|DRUG|doxorubicin hydrochloride|
223658768|NCT00666484|DRUG|etoposide|
223658769|NCT00666484|DRUG|prednisolone|
223658770|NCT00666484|DRUG|procarbazine hydrochloride|
223658771|NCT00666484|DRUG|vincristine sulfate|
223658772|NCT00666484|RADIATION|radiation therapy|
223658773|NCT06129617|DEVICE|Hemodialysis|5 treatments with hemodialysis on day 1, 2, 3, 5 and 7
223658774|NCT06129617|DEVICE|ADVOS|5 treatments with ADVOS on day 1, 2, 3, 5 and 7
224240611|NCT01783171|OTHER|Pharmacological Study|Correlative studies
224240612|NCT04392271|DRUG|LY3372689|Administered orally.
224240613|NCT04392271|DIAGNOSTIC_TEST|[18F]LSN3316612|Administered intravenously (IV).
224240614|NCT02567838|DRUG|Lidocaine gel|Instillagel (2% lidocaine) was administered rectally prior to probe insertion.
224240615|NCT02567838|DRUG|Placebo|Placebo (Aquagel) was administered rectally prior to probe insertion.
223658775|NCT03966430|PROCEDURE|damage control surgery|"1. Emergency surgery stage, (a) the hybrid operating room restores mesenteric vascular patency. (b) excision of the necrotic intestine (c) retention of suspicious intestinal ducts, double stoma (d) establishment of catheter thrombolysis pathway (e) apply TAC to maintain open abdominal.~2. ICU phase, including (a) fluid resuscitation; (b) anti-infective and organ function support therapy; (c) continued local anticoagulation, thrombolysis (d) arrange planned re-laparotomy (e) early EN.~3. Definitive surgical procedures, including (a) Deterministic fascia closure or further removal of the necrotic intestine. (b) Intestinal stoma care and enteral nutrition support treatment. (c) An enterostomy was performed about 6 months after the first operation."
223658776|NCT03966430|PROCEDURE|non-damage control surgery|"The patients are diagnosed with AMI and treated for mesenteric thrombosis and ischemic bowel.~1. The patient retains the endoluminal catheter after the DSA was diagnosed as AMI.~2. After diagnosis, the operation is performed in the general operating room, and the intestinal fistula double or the anastomosis is performed according to the judgment of the surgeon.~3. After the operation, re-laparotomy is performed on demand."
223658777|NCT01567839|PROCEDURE|Mandibular buccal Infiltration injection|
223658778|NCT00749853|DRUG|follicle stimulating hormone|Pituitary down-regulation will be achieved using buserelin (Suprefact®, Hoechst, Frankfurt, Germany) at a fixed daily dose of 200 mg s.c., according to a long agonist protocol, starting on day 2 of the normal menstrual cycle. Treatment with r-hFSH (Gonal-F®, Serono Austria GmbH, Vienna, Austria) will be started in women with serum E2 concentrations \<200 pmol/l and no follicles \>15 mm in diameter or ovarian cysts on ultrasonographic examination. The initial r-hFSH dose will be 250 IU s.c. daily for 5 days, after which the dose will be increased to a maximum of 450 IU per day using a step-up protocol with steps of 50 IU/day.
223658779|NCT00749853|DRUG|follicle stimulating hormone|No pituitary down-regulation will be performed. Treatment with r-hFSH (Gonal-F®, Serono Austria GmbH, Vienna, Austria) will be started in women with serum E2 concentrations \<200 pmol/l and no follicles \>15 mm in diameter or ovarian cysts on ultrasonographic examination. The r-hFSH dose will be 150 IU s.c. daily for 11 consecutive days.
223658780|NCT04512612|DIAGNOSTIC_TEST|Chromoendoscopy|Participants randomised to Group A will undergo colonoscopic evaluation using dye-based chromoendoscopy
223658781|NCT04512612|DIAGNOSTIC_TEST|High definition white light colonoscopy|Participants randomised to Group B will undergo colonoscopic evaluation using high definition white light endoscopy
223658782|NCT06386016|OTHER|artificial intelligence-based stethoscope|artificial intelligence-based stethoscope
223658783|NCT04215497|OTHER|PSSE|"Physiotherapeutic Scoliosis-Specific Exercises (PSSE) group will receive exercise for 30-40 mins in a day, twice in a week, totally 8 weeks and 16 hours.~Control group will be taught the basic elements of corrective exercises and want them to do the practising during 8 weeks at home."
223658784|NCT04994002|DRUG|CERC-006|Oral solution
223658785|NCT02645019|DEVICE|Cuffed ETT|Cuffed endotracheal tube.
223658786|NCT02645019|DEVICE|Cuffed LMA|Cuffed laryngeal mask airway.
224240616|NCT05303909|DRUG|Gentamicin|a single dose of IV gentamicin at a dose of 5 mg/kg infused over 30 minutes via a peripheral vein. Followed by administration of YF17D vaccine (stamaril) 0.5mls via subcutaneous injection into the deltoid region of the right or left arm.
224240617|NCT05303909|DRUG|Placebo|100mls of 0.9% normal saline as placebo infused over 30 minutes via a peripheral vein. Followed by administration of YF17D vaccine (stamaril) 0.5mls via subcutaneous injection into the deltoid region of the right or left arm.
223658787|NCT02657785|DRUG|R-IDARAM plus intrathecal chemotherapy|R-IDARAM comprised of rituximab 375 mg/m2 (day 1), idarubicin 10 mg/m2(day 2 and 3); dexamethasone 100 mg/m2 (12 h.infusion in day 2, 3 and 4); cytarabine 1 g/m2 (1 h. infusion in day 2 and 3); methotrexate 2 g/m2 (6 h. infusion in day 4 with folinic acid rescue). Intrathecal Immunochemotherapy comprised of rituximab 10mg, MTX 15mg, dexamethasone 5mg and Ara-c 50mg once a week.
223658788|NCT02055118|BIOLOGICAL|idursulfase-IT|10mg
223658789|NCT02055118|OTHER|No IT treatment|Standard of Care
223658790|NCT04239612|BEHAVIORAL|Physical exercise|Regular physical exercise in groups. Circular training: both strength and fitness
223658791|NCT02281383|BIOLOGICAL|Bacillus Calmette-Guérin (BCG)|
223658792|NCT00000426|DRUG|Calcium supplement|
223658793|NCT04339244|OTHER|RALRP under lower mean BP|RALRP under regulation of lower mean BP
223658794|NCT04339244|OTHER|RALRP under lower mean BP|RALRP under regulation of highly normal mean BP
223658795|NCT02633696|DRUG|silybin phosphatidylcholine|
223658796|NCT02633696|DRUG|Legalón SIL|
223658797|NCT01580501|DRUG|Tadalafil and Sildenafil|PDE-5 Inhibitor; Low dosages will be 0.5mg/kg and high dosages will be 1.0mg/kg
223658798|NCT04506138|DRUG|Camrelizumab|Camrelizumab 200mg D1, D22
223658799|NCT04506138|DRUG|Paclitaxel for Injection (Albumin Bound)|Paclitaxel for Injection (Albumin Bound) 100mg/m\^2 D1, D8, D22, D29
223658800|NCT04506138|DRUG|Carboplatin|Carboplatin AUC5 D1, D22
223658801|NCT02259088|DRUG|Ranibizumab (RFB002)|Ranibizumab 0.5 mg/0.05 mL for intravitreal injection
223658802|NCT02259088|PROCEDURE|Laser|Laser photocoagulation according to Early Treatment Diabetic Retinopathy Study (ETDRS) guidelines
223658803|NCT02259088|DRUG|Sham injection|Imitation of an intravitreal injection consisting of an empty vial and an injection syringe without a needle
223658804|NCT02259088|PROCEDURE|Sham laser|Imitation of an active laser
223658805|NCT02162199|DRUG|Debio 1450|Single sentinel dosing of 40 mg per unit capsules is planned to escalate from 80 mg to 160, 320, 480, 640 and 800 mg, per respective dosing group. Doses may be modified based on review of available safety and pharmacokinetic (PK) data.
223658806|NCT02162199|DRUG|Placebo|Matching single sentinel dosing of placebo capsules is planned to escalate from 2 capsules to 4, 8, 12, 16 and 20 capsules, per respective dosing group. The number of capsules will match those delivering Debio 1450 for the group, as those doses may be modified based on review of available safety and pharmacokinetic (PK) data.
223658807|NCT06112886|OTHER|There was no intervention in this study|There was no intervention in this study
223658808|NCT04155242|DIAGNOSTIC_TEST|Cytosponge test|The Cytosponge will be administered by the study nurse prior to the participant having the endoscopy, usually as part of the same visit to hospital. The capsule along with the string is swallowed by drinking a small glass of water. The participant is asked to hold the Cytosponge in situ for 5 minutes. The sponge contained within expands and is then drawn back by the research nurse up the oesophagus by the attached string, collecting cells as it moves upwards. This device received a letter of no objection by the MHRA for use in the BEST pilot trial (LRQ 0939857) but it is not CE marked. Cytosponge and research endoscopic biopsies will be couriered to the Fitzgerald laboratory, at the MRC Cancer Cell Unit on a regular basis. The specimens will be processed in conjunction with the Cambridge University Hospitals' NHS Foundation Trust tissue bank which is accredited to GLP standards.
223658809|NCT04155242|DIAGNOSTIC_TEST|Assessment of the panel of molecular biomarkers: IM-SCORE, TFF3 protein expression, methylation panel, p53 mutation|Molecular analysis of the specimen obtained by Cytosponge or endoscopic biopsies - TFF3 protein expression, methylation panel, p53 mutation. Endoscopic biopsies will be assessed for the presence of IM (according to the IM-score).
223658810|NCT04155242|DIAGNOSTIC_TEST|Oesophagogastroduodenoscopy|"* Endoscopy will be carried out with white light and NBI with optical magnification or near focus to inspect oesophagus and GOJ.~* NBI magnification will be used to assess systematically the mucosal pit pattern at the GOJ and to look for light blue crest (LBC) sign.~* Targeted biopsies will be taken from either areas with LBC or irregular pit pattern on NBI, followed by random biopsies as per clinical standard. A maximum of 6 biopsies will be taken at the GOJ (maximum 4 targeted and 4 random.. During the first 2 post RFA follow up, at discretion of the endoscopists, neo-suqamous biopsies can be taken in line with local policies.~* Argon plasma coagulation ablation is allowed in a single island up to 5mm or up to 3 islands \<3mm within the study endoscopy as long as this does not represent an obstacle to GOJ biopsies."
223658811|NCT00329524|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|TMS will initially be targeted to asymmetric cortical activation in one hemisphere, as defined by PET-CT imaging. TMS will then be optimized by identifying the area of maximal tinnitus suppression, within the area of asymmetry, by delivering single 1-Hz pulses of TMS at the MT. The area of maximal tinnitus suppression, as reported by the patient, will then be targeted for treatment with rTMS at 1-Hz frequency, delivering 1800 pulses at 110% MT on each of 5 consecutive treatment days.If no area of maximal tinnitus suppression can be found in the hemisphere initially targeted for treatment based on PET, we will perform the optimization procedure in a homologous region of the opposite cerebral hemisphere to determine if a maximal area of suppression can be found there. Each group will then crossover to sham and active stimulation conditions, respectively, 7 days following the completion of the first treatment session.
223768860|NCT03863366|OTHER|Placebo|Lactose placebo tablet, encapsulated in white capsule
223768861|NCT05555433|OTHER|NO INTERVENTION|no intervention
223658812|NCT01234935|DRUG|dasatinib|Given orally
223658813|NCT01234935|DRUG|gemcitabine hydrochloride|Given IV
223658814|NCT01234935|OTHER|laboratory biomarker analysis|Correlative studies
223658815|NCT01234935|GENETIC|mutation analysis|Correlative studies
223658816|NCT01234935|GENETIC|nucleic acid sequencing|Correlative studies
223658817|NCT01234935|OTHER|immunohistochemistry staining method|Correlative studies
223658818|NCT02184052|DRUG|Meloxicam|7.5 mg or 15 mg
223658819|NCT04479371|DRUG|Liposomal bupivacaine|Injecting liposomal bupivacaine for a penile block for analgesia for hypospadias repair
224240618|NCT03259100|OTHER|all the data collection have done by CDC.|In this study there was no intervention, just simple data collection via CDC.
224321177|NCT01231204|PROCEDURE|Placebo (normal saline) Continuous Infusion|Patients randomized to this group will receive an initial catheter placement using the standard Ultrasound-guided Technique. For the surgical procedure they will receive 15cc of 0.5%Ropivicaine. Following the surgical procedure they will receive a pain pump filled with normal saline. The normal saline infusion will continue for the 3 days following surgery. All patients will have access to other pain relievers for break-through pain. All patients will have the outcome measures assessed.
223658820|NCT04479371|DRUG|Bupivacaine|Standard bupivacaine
223658821|NCT06518434|DRUG|Medical Cannabis|Medical cannabis oil three times daily
223658822|NCT02243462|DEVICE|Forced Air Warmer|"A forced air warmer device will be used to pre-warm patients for 10 minutes in holding bay before surgery. Air warming device is an electrically powered control unit, hose, and inflatable blanket. The control unit has an air filter and heater, which warms air entrained from the environment. The hose connects to a blanket."
223658823|NCT02243462|OTHER|No pre-op warming|No forced air warming of the patient prior to being taken in for surgery
223658824|NCT04965038|DRUG|Tenecteplase (until trial protocol V04: Alteplase)|Intravenous thrombolysis within 4.5 hours of symptom onset
223658825|NCT04239625|DRUG|ALK-001|Oral administration of a pill for up to 24 months
223658826|NCT04665089|DRUG|Erythromycin|"Before each intervention (either at inclusion: day 0) and after the end of 5 days of erythromycin or placebo (day 6), the following dosages will be performed:~* Pro-inflammatory cytokine (TNF alpha)~* Anti-inflammatory cytokine (IL-10)~* Procalcitonin (PCT) Then, analysis of the variations in the TNF/ IL-10 ratio, the blood count, CRP and PCT parameters (between Day 0 and Day 6)"
223658827|NCT06273202|OTHER|Infant Massage|Infant massage will be performed three times a day (10 minutes per session) until they reach the 35th week of post-conceptional age (35+6) by the two departmental physical therapists (ADP and ADV).
223658828|NCT06486168|PROCEDURE|NIVATS|Non-Intubated Video-Assisted Thoracic Surgery (NIVATS) is the least invasive approach available. It is part of an optimal Enhanced Recovery After Surgery (ERAS) pathway and allows for expanding surgical indications in patients with poor cardio-pulmonary function.
223658829|NCT06115148|OTHER|Feeding|Nutrition beverages will be provided to meet the nutrient needs described in the Feeding Arm.
223658830|NCT06115148|OTHER|Fasting|Water will be consumed as described during the Fasting Arm.
223658831|NCT06230900|OTHER|(3S,4S,5R)-1,3,4,5,6-pentahydroxy-hexan-2-one|(3S,4S,5R)-1,3,4,5,6-pentahydroxy-hexan-2-one ingestion
223658832|NCT06230900|COMBINATION_PRODUCT|14C-(3S,4S,5R)-1,3,4,5,6-pentahydroxy-hexan-2-one|14C (3S,4S,5R)-1,3,4,5,6-pentahydroxy-hexan-2-one ingestion
223658833|NCT05073432|OTHER|Experimental|Usability of the Discussion Prioritization Tool (DPT) by completing Geriatric Assessment and Conjoint Analysis
223658834|NCT04063098|OTHER|Oral glucose tolerance test|Oral glucose tolerance test (OGTT) after a 72-hours standardized diet. OGTT will be performed 1 month prior to as well as 1, 3, 6, and 12 months after endoscopic sleeve gastroplasty
223658835|NCT04286373|DEVICE|active stimulation then placebo stimulation|"The active VNS stimulation will be applied in the hollow of the left outer ear on the auricular branch of the vagus nerve (cymba conchae), a session of 1 hour of stimulation per week, at a weak intensity value (between 2 to 5 mA), depending on the tolerance of each patient.~A transcutaneous vagus nerve stimulator Tens Eco Plus SCHWA MEDICO™ France with the Garches Azabou-Bao vagal electrode (the G electrode) will be used in this Clinical Investigation.~VNS placebo stimulation will be performed under the same conditions and parameters as active VNS stimulation, but at a different site: the left ear lobule according to previously published methods (Fang et al. 2017, Frangos et al. 2015).~The two stimulation periods will be separated by a 4 weeks wash-out period."
224240619|NCT04666909|DIAGNOSTIC_TEST|blood pressure|"The Welch Allyn ABPM 7100 is an easy-to-use 24-hour ambulatory blood pressure monitor that is designed to help avoid the effects of white coat hypertension, provide accurate sleep blood pressure readings, and tailor drug therapy regimes to your individual patient's needs.~This device is programmed to take three BP readings a minute apart. To be eligible, participants must have an average SBP \> 135 mm Hg or DBP \> 85 mmHg (based on the average of 3 BP readings); or average SBP \> 130 mm Hg or DBP \> 80 mm hg (for those with diabetes or kidney disease) based on JNC-7 criteria for uncontrolled HTN."
223658836|NCT04286373|DEVICE|placebo stimulation then active stimulation|"VNS placebo stimulation will be performed under the same conditions and parameters as active VNS stimulation, but at a different site: the left ear lobule according to previously published methods (Fang et al. 2017, Frangos et al. 2015).~The active VNS stimulation will be applied in the hollow of the left outer ear on the auricular branch of the vagus nerve (cymba conchae), a session of 1 hour of stimulation per week, at a weak intensity value (between 2 to 5 mA), depending on the tolerance of each patient.~A transcutaneous vagus nerve stimulator Tens Eco Plus SCHWA MEDICO™ France with the Garches Azabou-Bao vagal electrode (the G electrode) will be used in this Clinical Investigation.~The two stimulation periods will be separated by a 4 weeks wash-out period."
223658837|NCT05689385|OTHER|eHealth-based cardiac rehabilitation|"The 12-wk case manager-led eHCR program includes:~1. Individualized exercise prescription according to the results of cardiopulmonary exercise test.~2. At least one session of in-person physical therapy to familiarize participants with the process of exercise training before the initiation of telerehabilitation.~3. Telerehabilitation: a 30-minute moderate aerobic exercise training with remote monitoring and instruction using video conferencing. (Frequency: twice per week in the first 4 weeks, once per week in the 5th-8th week, once every 2 weeks in the 9th-12th week)~4. Additional self-exercise to achieve the target volume of 150-minute moderate aerobic exercise and 2 sessions of resistance training per week.~5. Patient education for secondary prevention delivered regularly via a communication app on the smartphone.~6. Weekly follow-up call from a case manager via phone call or communication app."
223658838|NCT01001325|BIOLOGICAL|Fluviral influenza vaccine, 2009-2010|0.5 mL intramuscular
223658839|NCT01001325|BIOLOGICAL|Normal saline|0.5 mL intramuscular
223768862|NCT00501540|DRUG|Lithium Carbonate|Lithium 300mg PO TID escalating to a lithium level of 0.8-1.2. Lithium carbonate will be administered the first week at 300 mg flat dose three times each day. A serum lithium level will be checked after 4-5 days of treatment by drawing a blood sample prior to the morning dose of lithium. Evaluate every 8 weeks.
223658840|NCT05408078|DEVICE|SLEEPexpert|"SLEEPexpert 1.0 is the first version of an online Program to treat Insomnia. The internet-based self-help platform used for the implementation of CBT-I in this study has been developed by the University of Bern (Prof. Dr. Thomas Berger), has been used successfully in previous trials and has received a CE mark in 2018.~The device is intended for patients with mental disorders and insomnia who are treated for mental disorders in a hospital or an outpatient unit. No specific training is needed to operate the application.~There is no available clinical research data to date on exactly this product. However, the therapeutic content that is used in this study is based on Cognitive Behavioral Therapy for insomnia (CBT-I). This intervention has been found to be highly effective and without lasting adverse effects in many studies and is recommended for the treatment of insomnia in current clinical guidelines."
223658841|NCT05408078|OTHER|TAU plus sleep monitoring|Treatment aus Usual and a Sleep Monitoring App will be used. This is already described in the Arm Section
224240620|NCT05502978|BEHAVIORAL|Blended education of Infant and Young Child Feeding|Blended education is an intervention about IYCF consisting of 3 components: Education via WhatsApp group, counselling face to face, Consultation with nutritionist via WhatsApp call. In the intervention group, participants will get blended education about IYCF provided by trained cadres. Education via WhatsApp group. The implementation of this educational program was carried out for 3 meeting sessions, where previously trained cadres had distributed videos and digital booklets for IYCF material and opened a discussion session at the end of the meeting in WhatsApp group. Face to face Counselling (Home visit). The cadres conduct home visits every month when the participants have given birth until the child is 7 months old. Consultation with nutritionist via WhatsApp call. Consultations were carried out via WhatsApp calls about IYCF practice was for infants aged 1 month, 3 months, 6 and 7 months.
223658842|NCT04226196|DEVICE|Implantation of an intraocular lens|Implantation of an intraocular lens Zeiss 409 MP into the capsular bag using an injector, after removing of the human crystalline lens.
223658843|NCT05780983|BEHAVIORAL|education and coaching on developing healthy nighttime sleep and daytime activity behaviors|The intervention includes a four-session, in-person program delivered by a Master's-level provider. Each individual session will be approximately 30-45 minutes in length. Each session will include education and coaching on developing healthy nighttime sleep and daytime activity behaviors.
223658844|NCT01584440|DRUG|AVP-923-20|AVP-923-20: 20 mg of dextromethorphan and 10 mg of quinidine
223768863|NCT00519649|BIOLOGICAL|Engerix™-B Kinder|Intramuscular injection, 1 dose
224240621|NCT01611389|DEVICE|Prolonging atrioventricular (AV) delay.|Prolonging atrioventricular (AV) delay to maximum 350 ms.
224240622|NCT01611389|DEVICE|Standard atrioventricular (AV) delay.|Standard atrioventricular (AV) delay - approximately 180/140 ms depending on heart rate.
224240623|NCT03270293|DEVICE|Profhilo|
224240624|NCT04985422|BEHAVIORAL|Smartphone-based Daily Ecological Momentary Intervention|Interventions are delivered through smartphones (SMS text message + Qualtrics) at a low cost with high accessibility. Participants are prompted 6 random times a day over the set intervention period (4 weeks) to complete brief EMA and EMI intervention actions) across contexts in daily lives for the reduction of depressive symptoms, as well as rumination distress, and improve functioning.
224240625|NCT04985422|BEHAVIORAL|Smartphone-based Weekly-delivered Information|Information with simple actions for reducing depressive symptoms are delivered through smartphones (SMS text message + Qualtrics) at a low cost with high accessibility. Participants are prompted weekly with a new set of information, together with a 5-min assessment. The information includes intervention actions provided in the EMI group.
224321178|NCT01231204|PROCEDURE|Ropivicaine 0.4% Continuous Infusion|Patients randomized to this group will receive an initial catheter placement using the standard Ultrasound-guided Technique. For the surgical procedure they will receive 15cc of 0.5%Ropivicaine. Following the surgical procedure they will receive a pain pump filled with 0.4%Ropivicaine. The 0.4%Ropivicaine infusion will continue for the 3 days following surgery. All patients will have access to other pain relievers for break-through pain. All patients will have the outcome measures assessed.
223658845|NCT01584440|DRUG|Placebo|Placebo capsule
223658846|NCT01584440|DRUG|AVP-923-30|AVP-923-30: 30 mg of dextromethorphan and 10 mg of quinidine
224240626|NCT01856309|DRUG|Sirukumab 100 mg|Sirukumab 100 mg subcutaneously (SC) at Weeks 0 (administered as the last dose in CNTO136ARA3002 or CNTO136ARA3003), 2, and every 2 weeks through Week 156 for participants who completed CNTO136ARA3002 and through Week 208 for participants who completed CNTO136ARA3003.
224240627|NCT01856309|DRUG|Sirukumab 50 mg|Sirukumab 50 mg SC at Weeks 0 (administered as the last dose in CNTO136ARA3002 or CNTO136ARA3003), 4, and every 4 weeks through Week 156 for participants who completed CNTO136ARA3002 and through Week 208 for participants who completed CNTO136ARA3003.
224240628|NCT01856309|DRUG|Placebo|Between sirukumab 50 mg injections, placebo SC injections will be administered at Weeks 2, 6, and every 4 weeks until the study becomes open-label, and placebo injections are discontinued.
224321179|NCT04705272|OTHER|Questionnaire|Pregnant women will be included in the study at the time of their first or second trimester ultrasound in the Hautepierre and CMCO ultrasound department. The period of inclusion should extend from 1 October 2020 to 31 October 2021 with a duration of participation of each subject of 9 months.
223658847|NCT06453486|RADIATION|High dose radiation therapy|"High dose radiation refers to the administration of a concentrated beam of radiation to target and treat the tumor. High dose radiation therapy typically involves delivering radiation in fractions over a set period. For instance, options such as:~* 50Gy/5Fx: 50 Gray delivered over 5 fractions, administered every other day over 2 weeks.~* 67.5Gy/15Fx: 67.5 Gray delivered over 15 fractions, administered once a day over 3 weeks.~* 75Gy/25Fx: 75 Gray delivered over 25 fractions, administered once a day over 5 weeks.~These numbers denote the total dose of radiation (in Gray, abbreviated as Gy) delivered over a specific number of fractions (abbreviated as Fx), and the respective time frames for administration. The selection of radiation therapy (RT) dose levels for participants is guided by the expertise and evaluation of the radiation oncologist."
223768864|NCT01873482|BEHAVIORAL|Movement to rhythm|Movement to rhythm
223768865|NCT00130962|DRUG|ALGRX 4975|
223768866|NCT04485481|DRUG|ADX-914|Single dose from 0.1mg/kg to TBD
223768867|NCT04485481|DRUG|Placebo|Matching single dose placebo
223768868|NCT04485481|DRUG|ADX-914|Multiple dose from TBD to TBD
223768869|NCT04485481|DRUG|Placebo|Matching multiple dose placebo
224240629|NCT04946877|DIAGNOSTIC_TEST|IQ assessment using Wechsler intelligence scale for children third edition (WISC-III)|IQ assessment using Wechsler intelligence scale for children third edition (WISC-III): is consists of several subtests, each classified into a verbal or performance scale .
224240630|NCT01075711|DRUG|Prednisone|According to SPC
224240631|NCT01284205|BIOLOGICAL|Mycobacterial Cell-Wall DNA Complex|8 mg/50 mL (sterile WFI) Intravesical Administration; one weekly instillation per week for 6 week Induction Phase; three weekly instillations per month at Months 3, 6, 12, 18, and 24 followed by Maintenance Phase.
224240632|NCT01284205|BIOLOGICAL|Bacillus Calmette-Guerin|mg/50 mL (sterile saline) Intravesical Administration; one weekly instillation per week for 6 week Induction Phase; three weekly instillations per month at Months 3, 6, 12, 18, and 24 followed by Maintenance Phase.
224240633|NCT04172649|OTHER|Acupuncture|On the day before surgery, patients randomized to the intervention groups will receive routine postoperative analgesic care with application of 6 bilateral press tack needles (diameter of 0.15mm and length of 0.6mm for P-6 and Shenmen, diameter of 0.20mm and length of 1.2mm for SP-6, Seirin New Pyonex, Seirin Corp., Shizuoka City, Japan).
224240634|NCT04172649|OTHER|Acupressure|On the day before surgery, patients randomized to the intervention groups will receive routine postoperative analgesic care with application of 6 bilateral press tack placebos (knob without needle, diameter of 0.15mm and length of 0.6mm for P-6 and Shenmen, diameter of 0.20mm and length of 1.2mm for SP-6, Seirin New Pyonex, Seirin Corp., Shizuoka City, Japan).
224240635|NCT01723995|RADIATION|low-level laser on nipples|The LASER HAND WL device, manufactured by MM Optics.
224240636|NCT06025448|PROCEDURE|BIO-RSA|Patients will have a reversed shoulder arthroplasty with lateralization of the joint centre using bony lateralization (BIO-RSA).
224240637|NCT06025448|PROCEDURE|MIO-RSA|Patients will have a reversed shoulder arthroplasty with lateralization of the joint centre using metallic lateralization (MIO-RSA).
224240638|NCT06012903|OTHER|Questionnaire Welbevinden|A validated questionnaire recommended by the Flemish inspection of education to measure well-being in primary school children of the 4th, 5th and 6th grade.
223658848|NCT05512000|BEHAVIORAL|Feedback with massed trials|The participant receives feedback on their accuracy completing retrieval practice tasks. Exposures for one word are provided before moving to the next word in each session.
223658849|NCT05512000|BEHAVIORAL|Feedback with spaced trials|The participant receives feedback on their accuracy completing retrieval practice tasks. Exposures for each word are interspersed with one another (e.g., an exposure for word 1, then one for word 3, then one for word 2, etc.) in each session.
223658850|NCT05512000|BEHAVIORAL|No feedback with massed trials|The participant does not receive feedback on their accuracy completing retrieval practice tasks. Exposures for one word are provided before moving to the next word in each session.
223658851|NCT05512000|BEHAVIORAL|No feedback with spaced trials|The participant does not receive feedback on their accuracy completing retrieval practice tasks. Exposures for each word are interspersed with one another (e.g., an exposure for word 1, then one for word 3, then one for word 2, etc.) in each session.
223658852|NCT05512000|BEHAVIORAL|No teaching control|The words in this set are not taught, only assessed.
223658853|NCT06233370|BEHAVIORAL|Moderate intensity walking exercise|For each intervention arm, participants will be walking at a moderate intensity, determined based on a step rate of approximately 100 steps per minute (measured by a Fitbit)
223658854|NCT06147388|DIAGNOSTIC_TEST|Colposcopy|No surgery, observation
223658855|NCT02587273|DRUG|Fentanyl|In this study there will be no administration of an investigational product per study protocol. The dosage of fentanyl will be according to the ICU's established procedures and the treating physician's judgment. The specific dose of fentanyl given to each patient will differ extensively. By routine, the ICU's in our hospital usually dose the fentanyl infusion as 0,5 - 6 μg/kg/hrs (kg = Ideal Body Weight). The intervention in this study will be a per protocol cessation in administration of fentanyl over a 6 hours period. Arterial blood samples, urine samples, pre and post filter samples and samples from dialysate will be collected during this 6 hours. If the patient needs opioid analgesia during the period, alternative opioid analgesia will be given.
223658856|NCT03390283|OTHER|Survey Administration|Complete online survey
223658857|NCT00899431|DRUG|Lenalidomide|Starting dose 5 mg by mouth every other day; increase to 5 mg/d daily in 4-5 weeks for 6 - 12 months
223658858|NCT00899431|DRUG|Fludarabine|30 mg/m\^2 intravenously daily on days -5, -4, -3.
223658859|NCT00899431|DRUG|Rituximab|375 mg/m2 intravenously on day -13, and 1000 mg/m\^2 on days -6, +1 and +8.
223658860|NCT00899431|DRUG|Thymoglobulin|1.0 mg/kg intravenously over 4 hours (day -2 and -1).
223658861|NCT00899431|PROCEDURE|Stem Cell Transplantation|On Day 0, donor blood stem cells collected will be transplanted over 30-45 minutes.
223658862|NCT00899431|DRUG|Bendamustine|130 mg/m2/day by vein daily on day -5, -4, -3 (following Fludarabine).
223658863|NCT00899431|DRUG|Allopurinol|300 mg by mouth daily beginning at the start of lenalidomide therapy and continuing for 3 months.
223658864|NCT02759367|OTHER|High potassium diet|An increase in consumption of high potassium fruits and vegetables
223658865|NCT01193504|DRUG|Pred Forte|Pred Forte BID for 4 weeks postop
223658866|NCT01193504|DRUG|Lotemax|Lotemax BID for 4 weeks postop.
223658867|NCT05770323|DIAGNOSTIC_TEST|Uric acid level|Uric acid will be measured for all Patients with acute coronary syndrome and result will be analysed
223658868|NCT00661427|BIOLOGICAL|cetuximab|Cetuximab 500 mg/m\^2 IV over 2 hours every other week
223658869|NCT00661427|BIOLOGICAL|cetuximab|Cetuximab 750 mg/m\^2 IV over 3 hours every other week
223658870|NCT03216824|OTHER|Dressing|A dressing is maintained on the CVAD exit site.
223658871|NCT03216824|OTHER|No-Dressing|The CVAD exit site is not covered with a dressing.
223658872|NCT02860429|DRUG|Cinobufacini injection|cinobufacini injection 20ml mixed with 5% Glucose injection 500ml started at the first day of chemotherapy until seven days once a day.
223658873|NCT02860429|DRUG|chemotherapy|Chemotherapy is the oxaliplatin combination with fluorouracil regimen.
223658874|NCT06022523|DIAGNOSTIC_TEST|Data acquisition using DT-400 pulse oximetry system|Acquisition of photopleth data during profound hypoxia using a Consolidated Research DT-400 pulse oximetry system.
223658875|NCT04947982|OTHER|carbon dioxide|carbon dioxide insufflation pressure
223658876|NCT04440904|DEVICE|CT workstation (Syngo Via VB10B, Siemens, Germany)|Multiplanar reconstruction, curvature plane reconstruction, and volume rendering were used for three-dimensional reconstruction to measure the diameters and lengths of blood vessels and the distances on the body surface
223658877|NCT04867096|OTHER|Physical activity|Patients in arm A (interventional) will carry out a physical activity intervention during 3 months. Patients should perform an interval training program on cycle-ergometer during 3 sessions per week.
223658878|NCT01453062|DRUG|Arzerra|Treatment with Arzerra
223658879|NCT04483648|OTHER|Exercise|Home exercises were performed three times in a week for six weeks. Home exercises included range of motion exercises, coordination exercises and strengthening exercises. Repeats and durations of the exercises increased every week to provide progression.
223658880|NCT05438472|OTHER|data collection in healthcare professionals with COVID-19 mRNA vaccine booster|Day 3 (48 - 96h) post COVID-19 mRNA booster: data collection on symptoms (chest pain, dyspnea, myalgia, fever, chills); blood sample for cardiomyocyte injury (hs-cTnT, hs-cTnI). If elevated hs-cTnT concentration, participant has to avoid strenuous exercise. Work-up on Day 4: clinical evaluation, ECG, 2. blood sampling for hs-cTnT. If hs-cTnT \> 100 ng/l, cardiac magnetic resonance imaging is done for signs of cardiac inflammation. If hs-cTnT rises above upper limit but doesn't exceed 100 ng/l, clinical exam might be evaluated. In confirmed myocarditis, a clinical assessment (treatment, need for hospitalization, length of rhythm monitoring, rest) is evaluated by a cardiologist. Day 4: EDTA blood from all subjects with elevated troponin at day 3 post-vaccination is collected for pathomechanism of mRNA vaccine associated myocarditis. 1-month follow-up: questionnaire on predefined cardiac endpoints.
224240639|NCT06012903|OTHER|Questionnaire Vancouver symptom score for dysfunctional elimination syndrome|Vancouver symptom score for dysfunctional elimination syndrome, Dutch version, validated by 't Hoen et al. 2016.
224240640|NCT06012903|OTHER|Developmental Coordination Disorder Questionnaire|Validated Developmental Coordination Disorder Questionnaire, Dutch version includes assessment of motor functioning.
223768870|NCT05523531|OTHER|Self-administered questionnaires|"* Neuropathic Eye Pain Questionnaire~* 5-item Dry Eye Evaluation Questionnaire (DEQ-5)~* Visual Impact Assessment Questionnaire~* Concise Ophthalmic Pain Questionnaire~* Questionnaire to evaluate the effectiveness and tolerance of treatments~* Chronic pain questionnaire"
224240641|NCT06012903|OTHER|Questionnaire concerning LUTS, NDDs and treatment perceptions|Unvalidated, complementary questions including the presence of LUTS, earlier diagnosis of bladder and/or boweldysfunction and neurodevelopmental disorders and perception concerning treatment characteristics.
224240642|NCT06012903|OTHER|Questionnaire about policies and practices regarding children's toilet use and drinking habits in the classroom|These unvalidated questionnaire was based on the questionnaire developed by Ko et al. (2016) about the school's policies and practices regarding children's toilet use and drinking habits in the classroom, covering students in grades one through six. Epidemiological questions related to LUTS were added to complement the questionnaire.
224240643|NCT03657160|DRUG|Vedolizumab Placebo|Vedolizumab placebo-matching IV infusion.
224240644|NCT03657160|DRUG|Vedolizumab|Vedolizumab IV infusion.
224240645|NCT03682562|DIAGNOSTIC_TEST|DNA Integrity Index|"This test will be performed for ALL three groups:~Sample collection:~Patients will be given a sterile cup containing 5mL saline solution with which they will vigorously rinse their mouth while rubbing their tongues against the oral mucosa for 30 seconds, then spit it back into the cup. The solution will then be used for DNA extraction.~DNA integrity analysis:~The DNA integrity will be done through measuring a housekeeping gene using competitive polymerase chain reaction where the isolated DNA will be combined with DNA capture probes for sequence-specific DNA fragments. The DNA integrity index will be calculated as the ratio of the concentration of longer DNA fragments to the ratio of shorter ones."
224240646|NCT04280757|PROCEDURE|Biopsied ICSI embryos (PGS)|Biopsied ICSI embryos (PGS)
224240647|NCT05689463|BIOLOGICAL|characterisation of immunoglobulin subclasses|For patients with positive anti BP180 and/or anti BP230 serology, a characterisation of the immunoglobulin subclasses will be performed
224240648|NCT05696639|PROCEDURE|Aneurysm embolization|All patients underwent Aneurysm embolization surgery, the cerebral venous will be observed intraoperatively.
224240649|NCT02749513|DRUG|Itraconazole|
224240650|NCT02512978|DRUG|Levothyroxine|Levothyroxine is used to normalize the thyroid hormone level of patients allocated to levothyroxine.
224240651|NCT02520505|DRUG|Supraovulation clomiphene citrate|Treatment with clomiphene citrate during day 3 to 7 of the menstrual cycle.
223658881|NCT01432483|DRUG|Denileukin diftitox (ONTAK)|Given at a dose of 9 or 18mcg/kg/day by intravenous infusion over 30 to 60 minutes for 5 consecutive days every 21 days for 8 cycles.
223658882|NCT00106899|PROCEDURE|Magnetic Resonance Imaging (MRI)|MRI scans
223658883|NCT00106899|PROCEDURE|Positron Emission Tomography (PET)|PET scans
224240652|NCT02520505|BEHAVIORAL|Timed intercourse|Timing intercourse during the fertile window in the menstrual cycle. Patients may also utilize an ovulation predictor kit to determine time of ovulation.
224240653|NCT02520505|PROCEDURE|Intrauterine Insemination|Intrauterine insemination will be performed \~36 hours after the time the woman ovulates, as determined by an ovulation predictor kit.
224321180|NCT05328219|OTHER|Chewing gums with PEG solution|"Patients undergoing colonoscopy under experimental group was advised to take 2L of PEG solution and packets of sugarless sweet mint flavored chewing gums.~The patients are advised to Chew one stick of sugarless gum for at least 10 min after taking each glass of PEG solution and discard the chewing gum before taking next glass."
223658884|NCT00106899|PROCEDURE|Lumbar Puncture (LP)|collection of cerebrospinal fluid
223768871|NCT05523531|PROCEDURE|Bilateral ophthalmologic examination|"* Examination of the ocular surface and eyelids Slit lamp with fluorescein instillation: Oxford scheme and Break-up time, Schirmer's test, Oxybuprocaine test~* Lipiview® test~* Examination of corneal sensitivity with the Cochet-Bonnet esthesiometer~* In vivo morphological examination of the subepithelial nerve plexus of the cornea by confocal microscopy"
223768872|NCT05868694|DIAGNOSTIC_TEST|polysomnography|Polysomnography is mainly used to diagnose sleep breathing disorders, including sleep apnea syndrome, snoring, upper airway resistance syndrome, and also used for the auxiliary diagnosis of other sleep disorders, such as: narcolepsy, restless legs syndrome, insomnia classification, etc.
224321181|NCT05328219|OTHER|Standard of care|Standard of care
224321182|NCT02681835|DEVICE|C-MAC laryngoscope|Intubation performed using C-MAC laryngoscope
224240654|NCT06394505|OTHER|Data Collection Tools|"Safety Climate Scale: Since a customized safety climate perception measurement tool for nurses could not be found in the literature, the Safety Climate Scale (SAS), developed by Choudry et al. in 2009 and adapted to Turkish by Türen et al. in 2014, was used on healthcare workers and electronics industry workers. The scale consists of two subscales: 10 items evaluating the management's perspective and rules (YÖBAK) and 4 items evaluating colleagues and safety training (İAGE). Participants rate the statements in the scale between strongly agree (five points) and strongly disagree (one point). The total score of the scale is calculated by taking the average of the item scores, and as the average gets closer to five, the safety climate improves, and as it gets closer to one, it gets worse. The Cronbach Alpha reliability coefficient of the scale was determined as 0.93 in the study conducted by Türen et al., and in this study it was calculated as 0.82."
223658885|NCT04234412|PROCEDURE|umbilical cord blood stem cell implantation for osteoarthritis treatment|"The arthroscopic procedure is performed in the supine position after spinal anesthesia. Once the chondral lesion is identified through a standard anteromedial and lateral portal, meniscectomy, meniscal repair, and lateral retinacular release are performed if necessary. microfracture is performed using a microfracture awl.~Once both the unstable cartilage and subchondral bone are removed in the lesion area and the sclerotic bone is peeled slightly by using a burr, hole(s) are created for implantation by using a drill bit(diameter 4; depth: 4mm). After implantation is performed in the hole by injecting the mixture of sodium hyaluronate and hUCB-MSCs, it is trimmed to the height of the surrounding articular surface."
224240655|NCT01561274|DRUG|2 ml bupivacaine|2 ml bupivacaine
223658886|NCT02093195|DRUG|Bosentan|
224240656|NCT01561274|DRUG|1.5 ml bupivicaine.|1.5 ml bupivicaine.
224240657|NCT04043065|BIOLOGICAL|Liver-enriched antimicrobial peptide 2|Infusion of LEAP-2 during a 180 min grated glucose infusion.
224240658|NCT04043065|OTHER|Placebo|Saline
224240659|NCT01696097|BEHAVIORAL|DASH diet counseling|Comparison of protein source (chicken and fish vs. pork) as part of DASH diet on blood pressure regulation and blood lipids.
224240660|NCT02829268|DRUG|dantrolene sodium|"The purpose of this study is to assess the safety and tolerability of dantrolene sodium in patients with Wolfram syndrome. In addition, we will assess the efficacy of dantrolene sodium on the cardinal manifestations of Wolfram syndrome, including visual acuity, remaining beta cell functions, and neurological functions.~There is a screening period up to 56 days, a 6-month treatment period with an optional extension phase up to 24 months, and a 4-week safety follow-up period. Study assessments include medical \& medication history, physical exams, neurological exams, eye exams, endocrine exams, vital signs, height, weight, electrocardiograms, blood and urine tests, pregnancy test if applicable, and questionnaires."
224240661|NCT02977520|PROCEDURE|Printing, Three-Dimensional|To establish 3D model of cerebral aneurysms and have preoperative evaluation.
224240662|NCT02768064|DEVICE|temporary pacemaker insertion|Insertion of pacemaker electrode (Medtronic flow direct pacing catheter), connect to external pacemaker (Medtronic).
224240663|NCT04208503|DIAGNOSTIC_TEST|thyroid ultrasound|After meeting enrolment criteria the thyroid ultrasound will be performed at 32 and 36 weeks of gestation, blood test for TSH and FT4 will be obtained at 14-21 day of life, at 32 and 36 weeks of gestation
224240664|NCT00898079|OTHER|Cytology Specimen Collection Procedure|Correlative studies
224240665|NCT03097900|DRUG|Caffeine Citrate|25 patients after elective colorectal surgery will be given 100 mg caffeine citrate orally diluted in 50 ml apple flavored water three times per day starting on the morning of postoperative day 1 after surgery until flatus will occur for the first time or to a maximal period time of 7 days, whichever comes earlier.
224240666|NCT03097900|OTHER|Water|25 patients after elective colorectal surgery will be given 50 ml apple flavored water three times per day starting on the morning of postoperative day 1 after surgery until flatus will occur for the first time or to a maximal period time of 7 days, whichever comes earlier.
224240667|NCT01434693|BIOLOGICAL|Trichuris suis ova|single dose
223658887|NCT02093195|DRUG|Symbicort turbuhaler|
224240668|NCT01434693|OTHER|Placebo|
224240669|NCT04006171|DIAGNOSTIC_TEST|C type natriuretic peptide|Serum level of CNP in PCOS and healthy women
224240670|NCT01393288|DRUG|Ondansetron|8 mg ondansetron ODT or placebo, 1 hour pre-operatively, before discharge, evening of day of surgery, morning of postoperative day (POD) 1, lunch POD 1, evening POD 1, and morning of POD 2
224240671|NCT01393288|DRUG|Lorazepam|1 mg Lorazepam or placebo 1 hour preoperatively, before discharge, evening of day of surgery, morning of postoperative day (POD) 1, lunch of POD 1, evening of POD 1, and morning of POD 2.
224240672|NCT01393288|DRUG|Aprepitant|40 mg Aprepitant or placebo 1 hour preoperatively and before discharge (placebo for postoperative days 1-2)
224240673|NCT01440283|RADIATION|Intensity Modulated Radiation Therapy (IMRT)|IMRT delivery will follow current conventional volume-targeting guidelines, however, appropriate application within the abdomen will be determined by ascertaining intra-abdominal organ motion and the potential for reducing normal tissue dose, while simultaneously increasing dose delivered to target tissues, particularly when dose escalation for gross residual disease is required. Concurrent neuro-hormonal tests, cytokine analyses, functional and morphologic imaging will generate novel data describing the acute and chronic effects of radiotherapy within the abdomen.
224240674|NCT00444197|BEHAVIORAL|Mentoring and violence prevention curriculum with parental monitoring|
224240675|NCT06247657|DRUG|BL0006|Patients will be administered BL0006 via intravenous infusion at the corresponding dose level on days 1 and 8 of a 21-days treatment cycle.
224240676|NCT03138330|OTHER|this study is observational, it is not an intervention|
224321183|NCT02681835|DEVICE|Macintosh laryngoscope|Intubation performed using laryngoscope with Macintosh blade
224321184|NCT00362336|BIOLOGICAL|DTaP-IPV-HB-PRP~T|0.5 mL, Intramuscular (IM)
223658888|NCT01821560|DRUG|Baclofen|
223658889|NCT01821560|DRUG|placebo|
223658890|NCT04562051|OTHER|prophylaxis regimen|All recipients were divided into two groups: stratified prophylaxis group based on donors' and recipients' characteristics and routine prophylaxis group based on clinical experience
223658891|NCT06076967|BEHAVIORAL|Mindfulness Awareness Practices for ADHD (adapted)|The Mindful Awareness Practices (MAPs) for ADHD program is an 8-week, group-based mindfulness program for adults with ADHD.
223658892|NCT06076967|BEHAVIORAL|Services-As-Usual|Services-As-Usual includes the standard support services provided by universities
224240677|NCT00359164|DRUG|Verteporfin Photodynamic Therapy (Low Fluence) and bevacizumab|"Bevacizumab 1.25 mg with verteporfin at Low Fluence (300 mW/cm2 delivered for 83 seconds \[light dose of 25 J/cm2\]) Photodynamic Therapy.~Treatment at Baseline visit, followed by an as needed basis. Assessments monthly for bevacizumab and at 3-month intervals for combination therapy with verteporfin or sham."
224240678|NCT00359164|DRUG|Verteporfin Photodynamic Therapy (Very Low Fluence) and bevacizumab|"Bevacizumab 1.25 mg with verteporfin at Low Fluence (150 mW/cm2 delivered for 83 seconds \[light dose of 12.5 J/cm2\]) Photodynamic Therapy.~Treatment at Baseline visit, followed by an as needed basis. Assessments monthly for bevacizumab and at 3-month intervals for combination therapy with verteporfin or sham."
224240679|NCT00359164|DRUG|Verteporfin Photodynamic Therapy (SHAM) and bevacizumab|"Bevacizumab with SHAM (150 mW/cm2 delivered for 83 seconds \[light dose of 12.5 J/cm2\]) Photodynamic Therapy.~Treatment at Baseline visit, followed by an as needed basis. Assessments monthly for bevacizumab and at 3-month intervals for combination therapy with verteporfin or sham."
224240680|NCT03755609|DRUG|Oxycodone|0.1 mg/kg intravenously
224240681|NCT03755609|DRUG|fentanyl|1ug/kg intravenously
224240682|NCT03599505|PROCEDURE|localization group|Intraoperative ultrasonographic localization will be performed using an ultrasound system (HI VISON Ascendus), which is equipped with a 5-10MHz mechanical probe (EUP-OL531). The accuracy rate of localization will be evaluated using gray scale mode and elastography mode.
224240683|NCT02102425|PROCEDURE|Patients with or without bandage over exit site|
224240684|NCT02624557|DRUG|Alpelisib|Subjects will receive a single dose of 300 mg alpelisib.
224240685|NCT00376922|PROCEDURE|music therapy|music played for patient during bone marrow biopsy collection
224240686|NCT00440557|DRUG|Epoetin alfa 3 times weekly /once weekly|Epoetin alfa will be administered as a SC injections at initial dose of 50 IU/kg (3 times weekly for 22 weeks) and at initial dose of 10000 IU (once weekly for 22 weeks)
224240687|NCT00440557|DRUG|Epoetin alfa once weekly|Epoetin alfa will be administered as a SC injection at initial dose of 10000 IU (once weekly for 44 weeks).
224240688|NCT00440557|DRUG|Epoetin alfa once every two weeks|Epoetin alfa will be administered as a SC injection at initial dose of 20000 IU (once every 2 weeks for 44 weeks).
223658893|NCT06217016|PROCEDURE|ICCAUT|In this study ,the ICCAUT strategy include intermittent catheter clamping and active urination training. For patients in the ICCAUT group, intermittent catheter clamping will be initiated at 9:00 AM. The catheter will be clamped for 3 h, followed by a 5-minute release, which is one cycle. The next cycle will begin after the cycle was completed. Catheter training is to conclude at 10:00 PM on the first postoperative day, and the catheter is left open during the night. At 6:00 AM on the second postoperative day, another cycle of catheter training will be performed, with the catheter removed at 9:00 AM. During the training period, if the patient experiences a strong urge to urinate before the 3-hour clamping time is over, the clamping can be released in advance for 5 min, allowing the patient to proceed to the next cycle of bladder training. Each time the catheter is released, we will encourage the patients to actively initiate urination to facilitate complete bladder emptying.
223658894|NCT06217016|PROCEDURE|Free drainage|For patients in the free draining group, no intervention will be performed on the catheter during this period. The catheter will be removed at 9:00 AM on postoperative day two.
223658895|NCT04306484|DIAGNOSTIC_TEST|FDOPA-TEP|FDOPA-TEP performed as part of the normal management of a suspected brain tumour
223658896|NCT04107025|OTHER|HELP|Individual counseling were given to each intervention group participant. They were assisted with safety, emotional and mental support and referrals for health and financial assistance. Participants were also given handout to manage anxiety and panic situations during the legal procedures.
223658897|NCT00495898|DEVICE|CYPHER sirolimus-eluting stent|drug-eluting stent
223658898|NCT00495898|DEVICE|uncoated Bx VELOCITY balloon-expandable stent|bare metal stent
223658899|NCT04291989|DEVICE|Optimal Blood Sampling Site for Point of Care Lactate Assessment using the handled Lactate-Pro 2 device|This study aims to compare lactate levels using the Lactate Pro 2 device from the same patient at the same time with blood samples taken from three locations - fingertip, earlobe and forearm venepuncture
223658900|NCT00268255|DRUG|gefitinib|
223658901|NCT00268255|PROCEDURE|adjuvant therapy|
223658902|NCT00268255|PROCEDURE|enzyme inhibitor therapy|
223658903|NCT00268255|PROCEDURE|neoadjuvant therapy|
223658904|NCT00268255|PROCEDURE|protein tyrosine kinase inhibitor therapy|
223658905|NCT00268255|PROCEDURE|radiation therapy|
223658906|NCT00268255|PROCEDURE|radiosensitization|
223658907|NCT05513209|PROCEDURE|opioid based multimodal anesthesia|elective tonsillectomy or adenotonsillectomy surgery using opioid based multimodal anesthesia.
223658908|NCT05513209|PROCEDURE|pterygopalatine ganglion block based multimodal anesthesia)|elective tonsillectomy or adenotonsillectomy surgery using opioid free pterygopalatine ganglion block based multimodal anesthesia.
223658909|NCT01338298|DRUG|Aripiprazole|Aripiprazole dosing will begin at 5 mg/day once daily and increased to 10mg by mouth once daily at the end of week 2 and then increased to 15 mg/day once daily at the end of week 8 in women who have not yet regained their menstrual period. If a woman gets her menstrual period on the 5 or 10 mg dose she will remain on this dose for the study.
223658910|NCT01338298|DRUG|Placebo|The placebo will be sucrose filled capsules that are identical to the active medication. It is double blind so no one will know if the capsule is placebo or aripiprazole.
223658911|NCT05933252|OTHER|Augmented reality (AR)|an app on an iPad every 15 minutes
223658912|NCT02872285|DRUG|Drug: LYC-30937-EC|
224240689|NCT03206866|DIAGNOSTIC_TEST|serum regucalcin antibody|serum regucalcin antibody
223658913|NCT02872285|DRUG|Placebo|
223658914|NCT04313361|OTHER|No intervention|No drug will be administered as part of this study.
223658915|NCT03478826|OTHER|ILD|100 cc of blood collected from a total of 250 ILD patients. This includes IPF (n=100), fibrotic NSIP (n=50), chronic hypersensitivity pneumonia (n=20), sarcoidosis(n=50), progressive rheumatoid lung disease (n=10) and scleroderma lung disease (n=20)), 10 patients with other fibrosing disease (fibrosing mediastinitis), and 50 patients with lymphangioleiomyomatosis
224321185|NCT00362336|BIOLOGICAL|CombAct-HIB®|0.5 mL, IM
224321186|NCT00362336|BIOLOGICAL|Engerix B® Pediatric|0.5 mL, IM
224321187|NCT05159024|DIAGNOSTIC_TEST|CRP, PCT, and WBCs trajectories|the levels of CRP, PCT, and WBCs were assessed before surgery and after the onset of leak
223658916|NCT03478826|OTHER|Healthy|100 cc of blood collected from a total of 25 healthy volunteers in order to compare with the ILD participants.
223658917|NCT03478826|OTHER|Pneumonia|100 cc of blood collected from a total of 100 participants with a diagnosis of pneumonia in order to compare with the ILD participants.
223658918|NCT03462693|OTHER|Dry needling|The DNHS® dry-puncture technology is specifically marked for stroke patients. the muscle to be treated is placed in a submaximal position; the needle is inserted into the present tense bandage and mobilized in the inside and outside for about 1 minute or until the reaction of global spasm ceases
223658919|NCT06216925|BEHAVIORAL|#BabyLetsMove|Description of #BabyLetsMove
223658920|NCT06216925|BEHAVIORAL|WIC Antenatal Care|Description
223768873|NCT02550964|PROCEDURE|Composite Examination|First, patients will get the baseline ophthalmologic exam and medical evaluation by physicians. As a diagnostic method, the composite examination including fundus photography, fundus autofluorescence, spectral-domain optical coherence tomography, Humphrey visual field test and multifocal electroretinography will be tested once every year.
224240690|NCT04067102|DRUG|Albumin bound (nab)-paclitaxel combined with carboplatin followed by epirubicin and cyclophosphamide|Paclitaxel for injection (albumin binding)260mg/m2，I.v., d1；carboplatin AUC=5, I.v., d1； 21 days in one cycle, 4 cycles in total.Continue the protocol when evaluated as CR/PR/SD at the second cycle, Terminate the protocol paclitaxel (albumin binding) combined with carboplatin when evaluated as PD at the second cycle，and use the EC protocol in advance or decide the next treatment
224240691|NCT04067102|DRUG|paclitaxel combined with carboplatin followed by epirubicin and cyclophosphamide|Paclitaxel 175mg/m2, I.v., d1； Carboplatin injection AUC 5, I.v., d1； 21 days in one cycle, 4 cycles in total.Continue the protocol when evaluated as CR/PR/SD at the second cycle, Terminate the protocol paclitaxel (albumin binding) combined with carboplatin when evaluated as PD at the second cycle，and use the EC protocol in advance or decide the next treatment protocol by the researcher
224240692|NCT05267366|DRUG|PD-1 inhibitor, Bevacizumab, Carboplatin, Cisplatin, Pemtrexed|PD-1 inhibitor (pembrolizumab) 200mg iv, d1; bevzcizumab 15mg/kg, iv, d1; Carboplatin 5/AUC or Cisplatin 75mg/m2 iv d1; Pemtrexed 500mg/m2 iv, d1; every 21 days a cycle.
223658925|NCT04770181|DEVICE|Alpha-Stim AID CES (Active Comparator)|The Alpha-Stim® AID CES device delivers a mild electrical current (100-500 µA) to the brain via ear clips electrodes. The treatment regimen is one daily 60 minutes Alpha-Stim® CES treatment using ear clip electrodes for 6 weeks at 0.5 Hz. 50% duty cycle with a fixed current of 100 µA (subsensory level).
223658926|NCT04770181|DEVICE|Alpha-Stim AID CES (Sham Comparator)|The Alpha-Stim® AID CES sham device is inactive and does not emit electrical current to the brain via ear clip electrodes. The sham treatment regimen is one daily 60 minutes Alpha-Stim® CES treatment using ear clip electrodes for 6 weeks.
223658927|NCT02902146|DEVICE|Bougie|
223658928|NCT02902146|DEVICE|Endotracheal tube|
223658929|NCT01441232|DRUG|LX4211|400 mg of LX4211 administered as two 200 mg tablets
223658930|NCT01441232|DRUG|Januvia®|100 mg Januvia® (sitagliptin) administered as one 100 mg sitagliptin tablet
224240693|NCT00539266|BIOLOGICAL|bone marrow derived mononuclear cells|40 IM injections (calf muscle) of 1-8 10E9 mono nuclear cells
224240694|NCT00539266|BIOLOGICAL|placebo|40 IM injections (calf muscle) of placebo suspension
224240695|NCT02865564|DIETARY_SUPPLEMENT|Lactobacillus reuteri DSM 17938|
224240696|NCT02865564|DIETARY_SUPPLEMENT|Placebo|
224240697|NCT02865564|DRUG|ampicillin and gentamicin|
224240698|NCT05856903|DIAGNOSTIC_TEST|ACT|"ACT will be measured :~* after in vitro spiking with unfractionated heparin of blood samples from severe hemophilia A patients already treated with emicizumab~* after in vitro spiking with unfractionated heparin with or without emicizumab of blood samples from healthy volunteers"
224240699|NCT00377390|BIOLOGICAL|Omalizumab|Subcutaneous injections of omalizumab will be administered every 2 or 4 weeks along with standardized asthma care for 60 weeks, beginning with the Randomization Visit, as a part of ICATA (ICAC-08, NCTNCT00377572).
224240700|NCT01388270|DEVICE|a pre-heparin-coated hemodialysis filter; Hepran|Use of the pre-heparin-coated filter compared to the conventional filter in a cross over design
223658931|NCT01253577|DEVICE|Sinus Stent with drug coating|Sinus stent coated with 370 ug of the corticosteroid mometasone furoate
223658932|NCT01253577|DEVICE|Non Coated Sinus Stent|Sinus stent (visually identical) without drug coating
223658933|NCT00334113|BEHAVIORAL|TLC-PED|Telephone-Linked Care - Promoting Exercise for Diabetes (TLC-PED), a method that uses interactive voice response and speech recognition technologies, will be developed to provide individualized and personalized motivational messages using automated telephone calls for veterans with Type 2 diabetes who participate in a home based walking program.
223658934|NCT03697889|DRUG|Naproxen sodium (test product)|Participants will be administered single doses of 275 mg Naproxen sodium (test product) tablet orally.
223658935|NCT03697889|DRUG|Naproxen sodium (reference product)|Participants will be administered single doses of 275 mg Naproxen sodium (reference product - Nalgesin) tablet orally.
223658936|NCT03204240|OTHER|Neuromuscular electrical stimulation|NMES-RE will involve concentric/eccentric contractions of the quadriceps from a seated position. Briefly, each session will include four sets of 10 actions evoked using 50 Hz trains of 450 µs biphasic pulses. The protocol will be implemented using surface NMES. Upon completion of the NMES-RE session, participants will be given a short break (10-15 minutes) for recovery before starting aerobic training. NMES aerobic exercise will involve twitch electrical stimulation (pulse duration/interval=200/50 µs) applied to the quadriceps muscle via surface NMES. The current amplitude will set to 175 mA. The training will start with 10 minutes of twitch stimulation at 2 Hz. After the first weeks, the duration of the session will progressively increase up to 60 minutes at 10 Hz.
223658937|NCT02509026|BIOLOGICAL|Etanercept|50 mg subcutaneous, once weekly, 24 weeks
223658938|NCT01539460|PROCEDURE|minimally invasive surgery|Subcutaneous fat and apocrine sweat glands were removed by suction under tumescent anesthesia,and the remaining tissue and glands, tightly attached to the epidermis-dermis interface, were completely removed with scissors through the initial small incision.
223658939|NCT04963868|PROCEDURE|Stent removed by the novel strategy|The stent was removed during the last necrosectomy when the endpoint of necrosectomy was achieved；
223658940|NCT04963868|PROCEDURE|Stent removed by the conventional strategy|The stent was removed after the last necrosectomy when clinical symptoms were relieved and fluid was nearly completely resolved confirmed by CT image.
224240701|NCT04999670|PROCEDURE|Fascial closure method during caesarean section via pfannenstiel incision.|Comparison of three different methods of fascial closure.
224240702|NCT00254956|DRUG|ciclesonide (XRP1526)|
224240703|NCT02555111|DRUG|Xarelto|15mg/day oral administration during 2 to 4 years (based on the recruitment date).
224240704|NCT05110677|DEVICE|Multispectral Optoacoustic Tomography (MSOT)|non-invasive transcutaneous imaging of subcellular muscle components
224240705|NCT04763005|BEHAVIORAL|HIIT exercise intervention|The exercise intervention will be eight weeks of high-intensity interval training (HIIT) started by one warm-up week with an intensity of 75% maximum heart rate (HRmax). In the following seven weeks, the participants will perform a HIIT based on the following protocol and with a total duration of 45 minutes per session: warm-up for 10 minutes at 60-70% HRmax followed by a high-intensity interval consisting of 4x4 minutes at 80-90% HRmax with 3 minutes of active recovery at 60-70% HRmax and a 10 minutes cool-down at 60-70% HRmax. HR will be monitored during training by Polar® H7 heart rate sensors combined with Polar® M400 watches.
224240706|NCT04763005|BEHAVIORAL|Physical activity recommendations|The control group will get physical activity recommendations based on actual guidelines from the European Association of Preventive Cardiology.
224240707|NCT02869425|DRUG|arbaclofen ER Tablets|arbaclofen ER tablets, 10 mg, 15 mg, or 20 mg
224240708|NCT02869425|DRUG|Placebo for arbaclofen ER tablets|matching placebo tablets to arbaclofen ER tablets 10 mg, 15 mg or 20 mg
224240709|NCT03827863|DEVICE|TTE|TTE to detect the heart function
224240710|NCT03229018|DIAGNOSTIC_TEST|Voxel size|200 μm and 300 μm Voxel Sizes
223658941|NCT04652037|DEVICE|Acrysof IQ Vivity Toric Extended Vision Intraocular Lens Implantation|Implantation during bilateral cataract surgery of a new non-diffractive extended vision presbyopia and astigmatism correcting intraocular lens (Acrysof IQ Vivity Toric Extended Vision Intraocular Lens)
223658942|NCT03719196|OTHER|Reading glass|Participants from the experimental group have received reading glasses free of cost. Investigators hypothesize that a simple pair of eyeglasses could improve the lives of these people by enabling continued participation in the workforce, restoring productivity levels in both paid and unpaid work, and enhancing the ability to perform everyday tasks. Investigators also hypothesize that reading glasses will improve quality of life.
223658943|NCT03265652|DEVICE|Intense Pulsed Light (IPL) therapy|Intense pulsed light therapy is a non-invasive and non-laser light treatment that is FDA-approved for various conditions in dermatology. Subjects will receive a total of 4 treatments over the course of the study, at intervals of 2 weeks. Each treatment will include applications on 10-15 IPL pulses in the malar region and close to the lower eyelids, followed by meibomian gland expression. Meibomian gland expression will be implemented by squeezing the meibomian glands with the aid of two Q-tips positioned on either side of the meibomian glands, or with a meibomian gland expressor forceps.
223658944|NCT03265652|DEVICE|Sham therapy|Subjects will receive a total of 4 treatments over the course of the study, at intervals of 2 weeks. Each treatment will include a sham application of IPL on 10-15 locations in the malar region and close to the lower eyelids, followed by meibomian gland expression. Meibomian gland expression will be implemented by squeezing the meibomian glands with the aid of two Q-tips positioned on either side of the meibomian glands, or with a meibomian gland expressor forceps.
223658945|NCT05037175|BEHAVIORAL|CPT-Text|CPT is a 12-session (13 modules), trauma-focused, cognitive therapy that teaches clients to examine and change problematic beliefs about themselves and the world that were altered as a result of trauma. Each session includes psychoeducation and introduction of a new skill or module, which builds on the previous information and skills. Participants will receive psychoeducation video links via Talkspace and an electronic workbook with handouts, written explanations of the concepts and activities, and CPT worksheets, which will be embedded in the platform and sent by the therapist at the appropriate point in the protocol. Therapists encourage the client to complete each module using the provided materials and assist clients in reflecting on their beliefs through Socratic questions and feedback on their worksheets. Clients work at their own pace, with therapists sending the skill or module after the client has practiced the previous one. Brief synchronous messaging sessions can be arranged
224240711|NCT06077526|BEHAVIORAL|P.E.A.K. Rx|Pain Education + Physical Activity Group Based Intervention
224240712|NCT06077526|OTHER|Usual Care|Participants will receive the community hospital's usual care.
224240713|NCT03749369|DRUG|Salvadora Persica Root|Salvadora Persica Gel
224240714|NCT03749369|PROCEDURE|Scaling and root planing|Thorough scaling and root planing (SRP) will be performed by a single clinician. The SRP procedure will be carried out in two sittings, comprising of ultrasonic scaling in the first, and manual instrumentation and root debridement in the second.
223658946|NCT05037175|BEHAVIORAL|Culturally Informed Trauma Treatment (CITT)|CITT will be conducted by Talkspace therapists with a specialty in PTSD treatment. Based on previous research and Talkspace's analysis of TAU and the therapists' training in culturally informed trauma treatment, it is likely CITT will include culturally informed, supportive and client-centered interventions, problem solving, and elements from EBTs such as cognitive-behavioral therapy. Brief synchronous messaging sessions can be arranged.
223658947|NCT05037175|BEHAVIORAL|Retention Incentive|Participants will be told at baseline that they can earn free or discounted therapy for other individuals with PTSD who are in need of financial assistance if they remain consistently engaged in treatment. If client participants do not re-engage after 24 hours from the RAU (3 days without engagement), they will receive an automated text-message reminding them to message their therapist regularly (on average, every other business day) in order to get a discount donated it to a fund that will offer free or discounted therapy to individuals with PTSD who require financial assistance. Throughout treatment, participants will be sent reminders every other week of what the incentive is and how it can be acquired, in addition to feedback about whether they are on or off track to earn the discount.
224240715|NCT01929642|DRUG|Sirolimus|
224240716|NCT01929642|DRUG|Everolimus|
224240717|NCT02636959|OTHER|saline irrigation|HVSI (NeilMed® Sinus Rinse™) versus LVSI (Salinex®) in the early post-operative management in patients with chronic rhinosinusitis. Both are a saline rinse spray.
224240718|NCT00669942|BIOLOGICAL|AIN457|AIN457A is a fully human recombinant IgG1 antibody that targets and neutralizes IL-17A.
224240719|NCT00669942|DRUG|Placebo|Placebo to AIN457
224240720|NCT00375700|DIETARY_SUPPLEMENT|Nutritional Supplement|
224240721|NCT01988909|DRUG|WR 279,396|Paromomycin + Gentamicin Topical Cream
224240722|NCT02008305|DEVICE|protocol of optimization ALARA|
224240723|NCT02008305|DEVICE|protocol of optimization Philips|
223658948|NCT05037175|BEHAVIORAL|Reminder as Usual|As per Talkspace guidelines, therapists are available to client participants twice per day, five days per week. In the event a client participant has not engaged or messaged in 48 hours, therapists send a personalized message to the client participant to encourage them to re-engage.
223658949|NCT05741008|RADIATION|Target range|Compared with conventional radiotherapy, the target dose is unchanged and the CTV2 volume is reduced.
223658950|NCT05301608|DRUG|Psilocybin|The psilocybin used in this study is synthetically manufactured and formulated under current good manufacturing practices (cGMP). The active drug is encapsulated using a size 0 blue gelatin capsule and contains 10 mg of psilocybin.
224240724|NCT04022798|OTHER|Exercise, manual therapy|"Participants were randomly assigned into treatment (n=15) or control group (n=15). Participants in each group received 12 treatment sessions of 45 minutes each, 2 days a week for 6 consecutive weeks.~For each group, a menu of a lumbar stabilization program was designed. This program included 8 levels of exercise ( single leg knee to chest stretch, double leg knee to chest, supine piriformis stretch, supine hamstring stretch, lower trunk rotation stretch, lumbar rotation stretch, pelvic tilt, pelivic tilt with alternative legs). Exercises were tailored for each individual ability and, if possible, progressed at each session which would last approximately 30 minutes. Each single exercise was repeated many times based on the patient's clinical condition. All sessions were provided by physiotherapists."
223658951|NCT05301608|DRUG|Placebo|The placebo used in this study is microcrystalline cellulose, an inert substance, encapsulated using a size 0 blue gelatin capsule.
224240725|NCT02226952|DRUG|BILN 2061 W, low dose|
223658952|NCT06228768|OTHER|Acupressure|9 acupoints will be stimulated for 3 minutes per point
223658953|NCT06228768|OTHER|Acupressure|9 areas will be stimulated for 3 minutes per point
223658954|NCT05533866|COMBINATION_PRODUCT|APR-TD011|APR-TD011 wound cleansing spray (drug/device combination product with a 510k clearance that is commercially marketed in the US for use by or on the order of a physician. Based on its product profile, APR-TD011 has been granted an FDA Orphan Drug Designation for epidermolysis bullosa.
223658955|NCT06414291|OTHER|Plain Water|Plain water without calories, sweetener, or electolytes
223658956|NCT06414291|OTHER|Liquid IV Hydration Multiplier|Drink with 22 grams of carbohydrate, 1020 milligrams of sodium, and 760 milligrams of potassium per liter. Hydration multiplier liquid IV
223658957|NCT06414291|OTHER|Liquid IV Sugar Free|10 grams of carbohydrate, 1060 milligrams of sodium, and 760 milligrams of potassium per liter. Sugar free Liquid IV
223658958|NCT05847530|DEVICE|Potenza|Subjects will receive 1-4 treatments at approximately 1 month intervals, but other intervals from 2 to 12 weeks may take place at the PI's discretion. At the discretion of the PI, additional follow-up visits may take place to observe the time course of skin reactions after treatment and/or to assess if the skin condition continues to improve beyond 3 months after treatment.
223658959|NCT05847530|DEVICE|Icon|Subjects will receive 1-4 treatments at approximately 1 month intervals, but other intervals from 2 to 12 weeks may take place at the PI's discretion. At the discretion of the PI, additional follow-up visits may take place to observe the time course of skin reactions after treatment and/or to assess if the skin condition continues to improve beyond 3 months after treatment.
223658960|NCT05407818|DRUG|JNJ-63733657|JNJ-63733657 will be administered as an IV infusion.
223658961|NCT05716542|OTHER|Physical Activity Intervention|Fitbit wearable device, home exercise sessions, and telehealth appointments with physical therapist.
223658962|NCT04966481|DRUG|Palbociclib|Administered on an outpatient basis
223658963|NCT04966481|DRUG|Cetuximab|Given intravenously over approximately 60 minutes
223658964|NCT06102499|DEVICE|SpO2 and SaO2 comparison|Several pulse oximeter will be place on patient find few minutes before arterial blood gases. During an arterial blood sample, all SpO2 will be recorded
223658965|NCT05920135|DRUG|BBT-207|BBT-207 given orally alone
223658966|NCT06598189|DEVICE|Ear-SD|The Ear-SD is a purely EEG recording device Continuous Electroencephalogram (cEEG), Electromyogram (EMG), Electrooculogram (EOG), Photoplethysmogram (PPG), Electrodermoactivity (EDA), and Inertial Measurement Unit (IMU). The Ear-SD device rests on the ears and connects to the scalp by two sticker electrodes.
223658967|NCT06598189|DIAGNOSTIC_TEST|Electroencephalogram|Standard 21-channel scalp-continuous electroencephalogram (cEEG) with video recording and electrocardiogram (ECG)
223658968|NCT00721968|DEVICE|Glaucoma Stent Surgery (GTS400 Stent)|ab interno trabecular bypass stent surgery
223658969|NCT00721968|PROCEDURE|cataract surgery alone|Cataract surgery alone
223658970|NCT03313011|DIAGNOSTIC_TEST|Testing protocol for the study|All patients will see a Neurologist for a neuro exam and consult, see a Speech Pathologist for assessment of speech and language skills, see the Study Coordinator for neuropsych testing (brief tests of thinking, memory, visual spatial skills, etc), undergo an MRI of the brain and a DaTscan of the brain.
223658971|NCT05601544|DEVICE|ACUVUE OASYS 1-Day|Sphere CONTROL
223658972|NCT05601544|DEVICE|ACUVUE OASYS MAX 1-Day|Sphere TEST
223658973|NCT05601544|DEVICE|ACUVUE OASYS Multifocal|Multifocal CONTROL
223658974|NCT05601544|DEVICE|ACUVUE OASYS MAX 1-Day Multifocal|Multifocal TEST
223658975|NCT05601544|DEVICE|ACUVUE OASYS 1-Day for Astigmatism|Toric CONTROL
223658976|NCT05601544|DEVICE|senofilcon A based contact lens (toric) with new UV/HEV filter|Toric TEST
223658977|NCT06108583|BEHAVIORAL|TEAlimento : a multicomponent parent training behavioral program to treat feeding difficulties in children with Autism Spectrum Disorder|The program focuses on parent training. Additionally, intervention on sensory integration is implemented directly with children. The program is made up of 12 sessions, which are held weekly, combining group (1.5 hour parent training and child sensory desensitization) with individual sessions. Parent training group sessions (1,3,4,5,7,8), are focused on teaching strategies based on the principles of behavior intervention and specific techniques related to eating. Strategies involve functional behavioral assessment, antecedent-based interventions, extinction of disruptive behaviors, positive reinforcement, modeling and visual supports. Additionally, parents were trained in methods of introducing new foods, such as modifying food presentation or textures. Simultaneously, children attend a group session in a separate room to target sensory issues and receive oral-facial stimulation. Individual sessions (2,6,9) are focused on specific characteristics of each child.
223658978|NCT04940039|DRUG|Risperidone 3 mg|Participants will receive 3 mg oral risperidone tablet once daily for 3 days.
223768874|NCT06021392|PROCEDURE|Z plasty and minimal excision of pilonidal sinus|"The investigators will perform a  Z plasty  procedure and Minimal excision procedure for patients complaining of pilonidal sinus and the investigators will compare the outcomes and rate of recurrence of these two procedures"
223768875|NCT01668316|BEHAVIORAL|Weight loss|"1. Participants will be prescribed a reduced calorie diet and asked to track their diet three days per week using the online USDA MyPlate SuperTracker. This record will be accessed by the RD in order to provide diet recommendations sent by email.~2. Participants will be given an exercise prescription, and encouraged to walk briskly with a provided pedometer or exercise at the campus Recreation Center every day. Participants will be asked to record the number of steps and other physical activity in a log book.~3. Participants will meet with the research staff every other week to measure weight, waist and hip circumference, and record the steps from the pedometer.~4. Participants will be encouraged to breastfeed their baby and provided with resources for pumping breast milk at work."
223658979|NCT04940039|DRUG|Paliperidone Palmitate 50 mg eq.|Participants will receive 50 mg eq. PP1M IM injection for at least 17 weeks (maximum 25 weeks).
223658980|NCT04940039|DRUG|Paliperidone Palmitate 75 mg eq.|Participants will receive 75 mg eq. PP1M IM injection for at least 17 weeks.
223658981|NCT04940039|DRUG|Paliperidone Palmitate 100 mg eq.|Participants will receive 100 mg eq. PP1M IM injection for at least 17 weeks.
223658982|NCT04940039|DRUG|Paliperidone Palmitate 150 mg eq.|Participants will receive 150 mg eq. PP1M IM injection for at least 17 weeks.
223658983|NCT04940039|DRUG|Paliperidone Palmitate 175 mg eq.|Participants will receive 175 mg eq. PP3M IM injection up to 24 weeks.
223658984|NCT04940039|DRUG|Paliperidone Palmitate 263 mg eq.|Participants will receive 263 mg eq. PP3M IM injection up to 24 weeks.
223658985|NCT04940039|DRUG|Paliperidone Palmitate 350 mg eq.|Participants will receive 350 mg eq. PP3M IM injection up to 24 weeks.
223658986|NCT04940039|DRUG|Paliperidone Palmitate 525 mg eq.|Participants will receive 525 mg eq. PP3M IM injection up to 24 weeks.
223768876|NCT04400305|BEHAVIORAL|Digital Health Online Platform|"The website has 10 lessons that the participant will gain access to on a bi-weekly basis. Lesson titles are as follows:~Lesson 1 - Benefits of Physical Activity on Chronic Disease Lesson 2 - Mental benefits of Physical Activities Lesson 3 - Increasing Self Confidence for Physical Activities Lesson 4 - Learning about your Emotions Lesson 5 - Building Social Support Lesson 6 - Building Physical Activity Opportunity Lesson 7 - Goal Setting and Planning Lesson 8 - Self Monitoring Lesson 9 - Habit Lesson 10 - Identity"
223768877|NCT02845271|DRUG|placebo|"Pharmaceutical form:solvent for parenteral use~Route of administration: intraarticular"
223768878|NCT02845271|DRUG|GZ389988|"Pharmaceutical form:suspension for injection~Route of administration: intraarticular"
223768879|NCT02845271|DRUG|acetaminophen or paracetamol|"Pharmaceutical form: tablet~Route of administration: oral"
223768880|NCT02845271|DRUG|fixed combination of paracetamol + codeine|"Pharmaceutical form: capsule~Route of administration: oral"
223768881|NCT02845271|DRUG|fixed combination of paracetamol + tramadol hydrochloride|"Pharmaceutical form: tablet~Route of administration: oral"
223768882|NCT05996250|OTHER|Immersive virtual reality task|participants will have to wear a virtual reality headset connected to a remote control and will have to perform submersive virtual reality tasks
223768883|NCT04355416|DRUG|curcumin Oral gel|application of curcumin oral gel after scaling and root planing
223768884|NCT04355416|PROCEDURE|subgingival scaling and root planing|subgingival scaling and root planing without application of curcumin gel
223658987|NCT00081874|DRUG|RAD001|"Phase I: Starting dose 5 mg by mouth daily for 28 days.~Phase II: Maximum Tolerated Dose (MTD) from Phase I."
223658988|NCT02491632|DRUG|Dexamethasone|Given PO
223658989|NCT02491632|BEHAVIORAL|Exercise Intervention|Complete a graded resistance exercise program and a walking regimen
223658990|NCT02491632|OTHER|Laboratory Biomarker Analysis|Correlative studies
223658991|NCT02491632|OTHER|Quality-of-Life Assessment|Ancillary studies
223658992|NCT02491632|OTHER|Questionnaire Administration|Ancillary studies
223768885|NCT01108549|DIETARY_SUPPLEMENT|Ribose|Ribose 5 grams PO TID was taken daily
223658993|NCT00328107|BIOLOGICAL|Influenza Vaccine, recombinant Hemagglutinin|0.5mL dose for IM injection
223658994|NCT06221826|DRUG|Mexidol|Neurocytoprotector
223658995|NCT06124508|BEHAVIORAL|Lung Cancer Screening Education|Tailored lung cancer screening education will consist of an annual, in-person 60 minute visit of lung cancer screening education in the participant's native language with material in layman's terms about the importance of lung cancer screening, tobacco cessation, and the risk of developing a second primary lung cancer.
223658996|NCT06124508|BEHAVIORAL|Semi-Structured Interview|Participants will undergo an annual, in-person or virtual, semi-structured interviews to understand barriers and perception towards screening and cultural competencies to increase adherence to lung cancer screening. The interviews will last approximately 30 minutes at each visit.
223658997|NCT06124508|BEHAVIORAL|Standard of Care Lung Cancer Screening Program|Participants will receive standard of care referral to the University of Miami's Lung Cancer Screening Program. The standard education includes a one-time, in-person or virtual 60-minute visit with the Advanced Practice Registered Nurse (APRN) to review educational material about lung cancer screening and tobacco cessation guidelines, and to discuss the risks versus benefits of undergoing screening.
223658998|NCT04254549|DRUG|Rifaximin|550 mg by mouth three times daily for 14 days
223658999|NCT04254549|DRUG|Placebo|By mouth three times daily for 14 days
223768886|NCT02258282|DRUG|Etanercept|
223768887|NCT02258282|DRUG|Control|
223768888|NCT04879745|OTHER|MyVoice:Rheum|Participants will be given access to MyVoice:Rheum, a web-based decision aid (DA).
223768889|NCT04879745|OTHER|Pamphlet|Participants in this arm will be given a copy of an existing patient pamphlet
224240726|NCT02226952|DRUG|BILN 2061 W, medium dose|
224240727|NCT02226952|DRUG|BILN 2061 W, high dose|
223659000|NCT05744310|DEVICE|Long term mechanical ventilation support|Patients that choose life prolonging treatment with long term mechanical ventilation support
223659001|NCT05744310|DEVICE|No long term mechanical ventilation support|Patients that decline life prolonging treatment with long term mechanical ventilation support
223659002|NCT06566547|DRUG|GR1803 injection|D1 given at a dose of 30ug/kg, D4 given at a dose of 90ug/kg, D8 given at a dose of 180ug/kg, followed by weekly dosing up to cycle 9, and cycle 10 and onwards, every 2 weeks, with a dosing cycle of every 4 weeks
223659003|NCT03088644|DRUG|JNJ-54175446|JNJ-54175446 up to 600 mg suspension for oral dose administration.
223659004|NCT03088644|DRUG|18F-JNJ-64413739|18F-JNJ-64413739 fluid for injection administered intravenously.
223659005|NCT06853587|OTHER|Pharmacogenetic-guided dosing|SSRI dosing based on Clinical Pharmacogenetics Implementation Consortium's SSRI dosing guidelines.
223659006|NCT06853587|OTHER|Current prescribing guidelines/recommendations|SSRI dosing based on current prescribing guidelines/recommendations
223659007|NCT06654804|DRUG|Perflutren lipid|Bolus injection of contrast during spinal decompression surgery for the treatment of traumatic spinal cord injury. Ultrasound imaging will then be used to collect images of the spinal cord injury to record perfusion, inflow and washout.
223659008|NCT03120897|DEVICE|RAM sensor|Rainbow Acoustic Monitoring sensor for measurement of respiratory rate
223659009|NCT06843343|PROCEDURE|Intertransverse Process Block with 1.5% Lidocaine|For the ITP block, the needle will be advanced further into the intertransverse tissue complex between the T4 and T5 transverse processes, and local anesthetic will be injected just above the superior costotransverse ligament, under ultrasound guidance.
223659010|NCT06843343|PROCEDURE|Erector Spinae Plane Block with 1.5% Lidocaine|The ESP block will be performed by advancing the needle to the transverse process, under ultrasound guidance, with local anesthetic injected between the erector spinae muscle and the transverse process, targeting a caudad-cephalad spread.
223659011|NCT06843343|DRUG|1.5% Lidocaine|local anesthetic to be used in either the ITP and ESP block
223659012|NCT06064851|DEVICE|Volta System|The Volta System will be using the components of the Sparrow Ascent device: (FDA-cleared K230796) a wearable, battery-operated, neurostimulation system designed to transcutaneously stimulate nerves on and/or around the auricle. During Second Menstruation, participants will self-administer 2, 1-hour sessions of active tAN daily with the Volta System Device beginning Day 1 of second menstruation through the final day of second menstruation.
223659013|NCT05306548|PROCEDURE|Surgical carpal tunnel release|Open surgical division of the flexor retinaculum of the palm/wrist to release pressure on the median nerve
223659014|NCT05306548|DRUG|Injection, Triamcinolone Hexacetonide, Per 5 Mg|Ultrasound-guided injection of 20 mg of triamcinolone hexacetonide (or -acetonide) into the carpal tunnel space close to the median nerve
223659015|NCT06378216|DIAGNOSTIC_TEST|neurocognitive evaluations|clinical and neurocognitive evaluations neuroradiological evaluation through cerebral magnetic resonance
223659016|NCT06662383|DRUG|Retatrutide|Administered SC
223659017|NCT06662383|DRUG|Tirzepatide|Administered SC
223659018|NCT06817252|BEHAVIORAL|Mediterranean Diet Nutrition Education|Participants randomized to receive the Mediterranean Diet Nutrition Education will receive a pre-recorded education session (lasting approximately 1 hour) they can watch at home after their Baseline and 6-Week Study Visits, which will be created by the PI and Co-I's of the study (who are comprised of Professors who are either Registered Dietitian credentialed or have experience with creating nutrition/physical activity programs), including an explanation of the principles and components of a Mediterranean dietary pattern and its benefits, guidance on recommended intake of various food groups, budget-friendly strategies for incorporation, supporting resources (educational materials and online tools), and techniques for overcoming barriers to following a Mediterranean dietary pattern. Additional educational materials will be provided to participants through computer or web-based sources.
223659019|NCT06817252|BEHAVIORAL|Mediterranean Diet Nutrition Education with Baked White Potato|Participants randomized to receive the Mediterranean Diet Nutrition Education with Baked White Potatoes will similarly receive a pre-recorded education session (lasting approximately 1 hour) they can watch at home after their Baseline and 6-Week Study Visits (same as the Mediterranean Diet Nutrition Education group). They will also receive will 100 g roasted white russet potatoes with the skin and will be asked to consume the regimen as a part of their meals (breakfast, lunch, dinner) or as a snack throughout the day to contribute to a balanced meal plan. The baked white potato regimen will be pre-portioned (in 100g amounts), stored in the freezer and given in freezer-microwave safe containers. The baked white potato regimen is approximately 100 kilocalories, 22g carbohydrates, and 0.2g of fat . In order to increase participants' compliance, they will be informed of a variety of ways to consume the baked white potato regimen.
223659020|NCT03524729|DEVICE|Rocker bottom shoe|Walking shoe with a anterior posterior rocker sole.
223659021|NCT03524729|DEVICE|Ankle foot orthosis|Dynamic carbon fiber ankle brace.
223659022|NCT03524729|DEVICE|Standard walking shoe|Standard walking shoe (control shoe) with no rocker sole.
223659023|NCT02230124|DEVICE|MRE|
223659024|NCT01548833|DEVICE|Delefilcon A contact lens|Silicone hydrogel contact lens for single use, daily disposable wear.
223659025|NCT01548833|DEVICE|Narafilcon A contact lens|Silicone hydrogel contact lens for single use, daily disposable wear.
223659026|NCT01548833|DEVICE|Filcon II 3 contact lens|Silicone hydrogel contact lens for single use, daily disposable wear
223659027|NCT01235078|DEVICE|EZ-IO|powered intraosseous vascular access system
223659028|NCT06870071|OTHER|Control group|IV paracetamol (1 g, 3×1) and IV dexketoprofen (50 mg, 2×1)
223659029|NCT06870071|OTHER|Quadro iliac plane block|40 mL of 0.25% bupivacaine
223768890|NCT01651741|DIETARY_SUPPLEMENT|Seaweed and Duolac7S|"Seaweed and probiotics is composed of seaweed and Duolac7S.~Seaweed:~1. Form: brown granule~2. Dosage and frequency: 1 pack (3 g), 2 packs per day (30 min after morning, and evening meal)~3. Duration: 4 weeks of treatment period~Duolac7S:~1. The probiotics, Duolac7S, consist of 7 bacteria.~2. Ingredients: Lactobacillus acidophilus, L. plantarum, L. rhamnosus, Bifidobacterium breve, B. lactis, B. longum, Streptococcus thermophilus.~3. Dosage and frequency: 1 capsule (5✕1,000,000,000 bacteria/capsule \[7✕100,000,000 viable cells/strain\]), 2 capsules per day (30 min after morning and evening meal)~4. Duration: 4 weeks of treatment period"
223768891|NCT01651741|DIETARY_SUPPLEMENT|Seaweed and Duolac7S-P|"Seaweed and probiotics is composed of seaweed and Duolac7S-P(Placebo Duolac7S).~Seaweed:~1. Form: brown granule~2. Dosage and frequency: 1 pack (3 g), 2 packs per day (30 min after morning, and evening meal)~3. Duration: 4 weeks of treatment period~Duolac7S-P:~Duolac7S placebo has the same form, color and flavor as experimental intervention (Duolac7S). The dosage, frequency and duration is also the same as experimental intervention (Duolac7S)."
224240728|NCT02226952|DRUG|Placebo|
223659030|NCT05190744|DRUG|PB|1000mg twice daily (BID). The dose of PB inducing the maximal increase in urine osmolality will be continued for up to four weeks providing that no side effects are observed including clinical and laboratory surveillance.
223768892|NCT04491630|BEHAVIORAL|Self-Hypnosis (SH)|"Participants assigned to this condition will listen to a 20-minute recording with instructions of SH adapted from one of our team member's proposed model. First, the audio recording will introduce and orient the participant to SH. Then instruction in SH will be provided, including: (a) how to self-induce a hypnotic induction; (b) specific self-suggestions for comfort and ability to manage intense sensations; and (c) post-hypnotic suggestions that the participant will be easily able to use these hypnotic strategies on their own at a later time (i.e., in this case, during the Cold Pressor Arm Wrap procedures that will follow).~A second 5-minute audio recording with instructions to guide the participant in SH will be provided during the second cycle of Cold Pressor Arm Wrap (CPAW)."
223768893|NCT04491630|BEHAVIORAL|Mindfulness Meditation (MM)|"Participants in the MM condition will listen to a 20-minutes recording with instructions in the use and application of Vipassana MM, adapted from the manual developed by one of our team members. First, the audio recording will focus on introducing the idea of attention to their breath, and of non-judgmental monitoring and acceptance of the all events and stimuli. Then a guided MM (body scan) experience will be provided.~A second 5-minute audio recording with instructions to facilitate the MM (body scan) experience taught in the first audio recording will be provided during the second cycle of CPAW."
223768894|NCT04491630|BEHAVIORAL|Christian Prayer (CP)|"Participants in this condition will listen to a 20-minute recording with CP instructions. These instructions will be adapted from the existing on-line biblical meditations from the Society of Jesus (www.passo-a-rezar.net). First, the recording will introduce and orient the participant to CP. Then, a text of the Bible will be read twice, followed by a brief suggestion of prayer.~A second 5-minute audio recording with instructions to facilitate the CP experience taught in the first audio recording, including the recording of a text of the Bible followed by a brief suggestion of meditation and relaxing music, will be provided during the second cycle of CPAW."
223768895|NCT02529410|PROCEDURE|Cardiac Resynchronisation Therapy|
223768896|NCT04428138|DIAGNOSTIC_TEST|In-office vascular visit|Every patient will undergo a complete physical examination in order to detect any clinical or sub clinical vascular disease.
223768897|NCT04428138|DIAGNOSTIC_TEST|Echo duplex scan of arterial system|Every patient will undergo a complete echo duplex scan in order to detect any morphological or hemodynamic alteration of aorta, carotid arteries and lower limb arteries.
223768898|NCT00040404|DRUG|CEP-1347 10mg|CEP-1347 10mg, a K252a derivative, retains neuroprotective properties
223768899|NCT00040404|DRUG|CEP1347 25mg|CEP1347 25mg, a K252a derivative, retains neuroprotective properties
223768900|NCT00040404|DRUG|CEP-1347 50mg|CEP-1347 50mg, a K252a derivative, retains neuroprotective properties
224240729|NCT01683032|DRUG|MPH|a capsule containing 20 mg
224240730|NCT02312700|BEHAVIORAL|Interactive empowerment tool|
223659031|NCT06595134|OTHER|Non Interventional|Screening (Day -7 to Day -1) Visit 1 (Day 0) Visit 2 (Month 3 +/- 7 days) Visit 3 (Month 6 +/- 7 days) Visit 4 (Month 12 +/- 7 days) Visit 5 (Month 24 +/- 7 days) Visit 6 (Month 60 +/- 30 days; end of study)
223768901|NCT00040404|OTHER|Placebo Comparator|Placebo capsules matching the CEP-1347 capsules
223768902|NCT06345508|DIAGNOSTIC_TEST|Quantitative Ultrasound|Research quantitative ultrasound
223768903|NCT06345508|DIAGNOSTIC_TEST|B-mode Ultrasound|B-mode US performed according to the clinical standard of care.
223768904|NCT06345508|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|The composite reference standard includes MRI performed according to the clinical standard of care or histopathology when available.
224240731|NCT03027115|DRUG|Tamsulosin|Tamsulosin treatment for 7 days pre-operatively
224240732|NCT00882180|DRUG|ALN-VSP02|IV infusion administered every two weeks
224240733|NCT02828917|DEVICE|MedJ-01 Ridaforolimus Eluting Coronary Stent System|
224240734|NCT06405009|OTHER|Without any intervention, we only divided gastric cancer patients into two groups based on postoperative pathology, and analyzed their basic characteristics and risk factors|Without any intervention, we only divided gastric cancer patients into two groups based on postoperative pathology, and analyzed their basic characteristics and risk factors
224240735|NCT05879549|OTHER|Closed Chain Exercise Group|Closed Chain Exercise Group
224240736|NCT05879549|OTHER|Proprioceptive Exercise Group|Proprioceptive Exercise Group
223659038|NCT02626624|DEVICE|Implantation of the CarboClear Pedicle Screw System|
223659039|NCT06704841|BEHAVIORAL|Music in combination with mindfulness|Participants will attend two in-person sessions per week over two consecutive weeks. Each session will be up to one hour in duration. During each session, participants will engage in a 20-minute guided meditation while listening to instrumental music.
223659040|NCT05073146|OTHER|interview|Starting from the user as an extended starting point, through on-site visits and interviews with relevant personnel, such as personal management, professional service teams, cases, family members, other long-term care service providers (home service assistants), etc., collect relevant information and summarize successful strategies and related elements of long-term professional services (including conditions, demand analysis, service usage, professional team interaction, payment and payment systems, characteristics of case, etc.) of model cases.
224240737|NCT04173650|DRUG|AGLE-102|Extracellular vesicles from bone marrow derived mesenchymal stem cells - up to six topical administrations
224240738|NCT02514655|DEVICE|Nosten® pressure control (it's not an antibiotic, but simple device)|One experimental group with the control of the cuff pressure by Nosten® device
224240739|NCT02514655|OTHER|Manual pressure control|One control group with the manual monitoring of the cuff pressure and inflation of the balloon
223659041|NCT06708468|OTHER|Exercise|The intervention includes 12-day personalized exercise program set in a rehabilitation center, followed by a three-month digital intervention and then a second 12-day personalized exercise program in a rehabilitation center.
223659042|NCT06708468|OTHER|Usual Care|Usual care includes appointments at hospitals and in the community health system according to what has been recommended to that individual
223659043|NCT05348278|DRUG|Urea cream|apply 10% urea cream at both hands and feet twice daily
223659044|NCT06888388|PROCEDURE|Nipple Sparing Mastectomy (NSM)|Nipple sparing mastectomy (NSM) is a surgical procedure which removes all macroscopic breast glandular tissue while retaining the skin as well as the nipple areola complex.
223659045|NCT06888388|PROCEDURE|Skin-Sparing Mastectomy (SSM)|Skin sparing mastectomy (SSM) is a procedure that removes the nipple and areola complex along with all visible macroscopic breast glandular tissue.
223659046|NCT06888388|PROCEDURE|Total (Simple) Mastectomy|Total (Simple) Mastectomy is a traditional mastectomy approach that removes the breast glandular tissue with a large overlying area of skin including the nipple and areola complex to allow for flat closure.
223659047|NCT04307576|DRUG|Omitted Doxorubicin|Omission of IV Doxorubicin
223768905|NCT06345508|DIAGNOSTIC_TEST|Liver Biopsy|The composite reference standard includes MRI performed according to the clinical standard of care or histopathology when available.
223768906|NCT04364633|OTHER|Voice Handicap Questionnaire (VHI)|Voice Handicap Index (VHI) self-questionnaire
223768907|NCT00804427|DIETARY_SUPPLEMENT|Fish oil (90% triglycerides)|
223768908|NCT00804427|DIETARY_SUPPLEMENT|Fish oil (60% triglycerides)|
223768909|NCT00804427|DIETARY_SUPPLEMENT|Fish oil (ethyl esters)|
223768910|NCT00804427|DIETARY_SUPPLEMENT|Soy oil|
223768911|NCT05059457|DEVICE|Blood source: single and pooled capillary and venous blood|"* A single drop of capillary blood (blood drop #3) will be placed in a microcuvette directly from a finger/heel and tested using a HemoCue 201+.~* Pooled capillary blood will be placed in a Microtainer® tube (250-500 µL) containing EDTA and then a drop of blood placed in a microcuvette and tested using a HemoCue 201+.~* Venous blood will be collected into a 3mL Vacutainer tube containing EDTA and then a drop of blood will be placed in a microcuvette and tested using a HemoCue 201+ and autoanalyzer."
223768912|NCT05059457|DEVICE|Blood source: single capillary and venous blood|"* A single drop of capillary blood (blood drop #3) will be placed in a microcuvette directly from a finger/heel and tested using a HemoCue 201+ .~* Venous blood will be collected into a 3mL Vacutainer tube containing EDTA and then a drop of blood will be placed in a microcuvette and tested using a HemoCue 201+ and autoanalyzer."
223768913|NCT05059457|DEVICE|Blood source: pooled capillary and venous blood|"* Pooled capillary blood will be placed in a Microtainer® tube (250-500 µL) containing EDTA and then a drop of blood placed in a microcuvette and tested using a HemoCue 201+.~* Venous blood will be collected into a 3mL Vacutainer tube containing EDTA and then a drop of blood will be placed in a microcuvette and tested using a HemoCue 201+ and autoanalyzer."
223768914|NCT01540370|OTHER|No Treatment|No treatment
223768915|NCT02984995|DRUG|Quizartinib|Quizartinib was orally administered once daily every morning. Treatment with quizartinib was administered in 28-day cycles and continued until the discontinuation criteria for treatment were met.
223768916|NCT04077034|DIETARY_SUPPLEMENT|Probiotic Formula Bacillus subtilis DE111®|Probiotic Formula Bacillus subtilis DE111®, 1 billion colony forming units (CFU) per day for 8 weeks
223768917|NCT04077034|DIETARY_SUPPLEMENT|Placebo comparator|Placebo comparator, once a day for 8 weeks
223768918|NCT02483247|DRUG|BBI503|Patients in this trial will receive BBI503 orally, daily, and continuously. The dose-level of BBI503 will be assigned according to the dose-cohort open at the time the patient enrolls into a given arm. The study-arm and combination anti-cancer agent for a given patient will be determined by the investigator. BBI503 Dose Level 1: 200 mg once daily, Dose Level 2: 300 mg once daily.
223768919|NCT02483247|DRUG|Capecitabine|Capecitabine 1000 mg/m\^2 body surface area is administered orally, twice daily, on days 1-14 of each 21 day cycle.
223768920|NCT02483247|DRUG|Doxorubicin|Doxorubicin 60 mg/m\^2 body surface area is administered intravenously once every three weeks (21-days).
223659048|NCT04307576|DRUG|Omitted Vincristine+Dexamethasone pulses|Omission of Vincristine+Dexamethasone pulses
223768921|NCT02483247|DRUG|Nivolumab|Nivolumab 3 mg/kg is administered as an intravenous infusion over 60 minutes on day 1 and day 15 of each 28 day cycle.
223768922|NCT02483247|DRUG|Pembrolizumab|Pembrolizumab 2 mg/kg is administered as an intravenous infusion over 30 minutes once every three weeks (21-days).
223768923|NCT02483247|DRUG|Paclitaxel|Paclitaxel 80 mg/m\^2 body surface area is administered intravenously once weekly on day 1, day 8, and day 15 of each 28 day cycle.
223659049|NCT04307576|DRUG|Inotuzumab Ozogamicin+Standard Maintenance Therapy|Addition of IV Inotuzumab ozogamicin before Maintenance Therapy
223659050|NCT04307576|DRUG|Imatinib|p.o. Imatinib
223659051|NCT04307576|DRUG|6-tioguanine+Standard Maintenance Therapy|Addition of p.o. 6-tioguanine to Standard Maintenance Therapy
223659052|NCT04307576|DRUG|Blinatumomab|IV Blinatumomab
223768924|NCT02483247|DRUG|Sunitinib|Sunitinib 37.5 mg is administered once daily.
223768925|NCT02683759|DIETARY_SUPPLEMENT|Bio-enhanced Curcumin Soft Gelatin Capsule|"Each capsule is a bio-enhanced modification of curcumin (diferuloylmethane), which is a derivative of curcuma longa (rhizome extract)~Starting dose: 50 mg BID of Bioenhanced Curcumin Increase dose to 100 mg BID after two (2) weeks if there is no response to the drug"
224240740|NCT04168567|DIAGNOSTIC_TEST|Microbiome analysis|Samples from TIMP microbiome project will be analyzed with NGS techniques.
224240741|NCT06415201|OTHER|Interactive Artificial Intelligence|scenario based AI to assess, classify, explain and conduct supportive interviews
224240742|NCT06525831|DIAGNOSTIC_TEST|MR-elastography exam|Imaging acquisition
224240743|NCT06525831|DIAGNOSTIC_TEST|Ultrasound exam|Imaging acquisition
224240744|NCT06181825|BEHAVIORAL|COMET-BA (Common Elements Toolbox- Behavioral Activation)|COMET-BA includes 4 online weekly modules which focus on elements of behavioral activation, including positive activity scheduling, avoidance reduction, values, and change plans.
224240745|NCT02096718|DRUG|Afatinib healthy|
224240746|NCT02096718|DRUG|Afatinib severe renally impaired|
224240747|NCT02096718|DRUG|Afatinib moderate renally impaired|
224240748|NCT02818439|OTHER|evaluation of frailty|
224240749|NCT03682900|OTHER|Click City®: Tobacco|A computer-based program assigned to students designed to prevent subsequent tobacco use. Students complete one 15 to 20 minute lesson two times a week for four weeks.
224240750|NCT03682900|OTHER|Usual Tobacco Curriculum|Students complete their usual curriculum designed to prevent tobacco use.
224240751|NCT03062046|DEVICE|RF ablation|RF ablation
224240752|NCT04448886|DRUG|Pembrolizumab|(iv) fixed dose, administered once per cycle
223659053|NCT01909011|DEVICE|Active CES|The active CES treatment group will receive the following dose of CES delivered over the temples bilaterally: 2mA of alternating current qt 1Hz, 5Hz, and 15,000Hz for one 20 minute session per day for 5 times per week for four weeks.
223768926|NCT02683759|DRUG|5-Aminosalicyclic acid|Dosage is as instructed by patient's physician
223768927|NCT01953484|OTHER|Change in extracorporeal carbon dioxide removal|
223768928|NCT00476424|DRUG|efavirenz|EFV 400 mg OD for 14 days EFV 600 mg OD for 14 days
223768929|NCT03122912|DIETARY_SUPPLEMENT|Fish Oil|Capsules contain omega-3 fatty acids (fish oil). Dosage of 3180 mg of omega-3 fatty acids will be taken orally daily up to 16 weeks.
223768930|NCT03122912|DIETARY_SUPPLEMENT|Soybean Oil|Dosage will be 3000 mg of soybean oil taken orally daily for up to 16 weeks.
223659054|NCT01909011|DEVICE|Sham CES|The CES sham group will receive sham CES (device off) for 20 minutes 5 times per week for two weeks.
223659055|NCT06170047|BEHAVIORAL|Chicago Parent Program for Foster Care|CPP-FC consists of 12 two-hour sessions delivered virtually by two trained group leaders over 16 weeks (11 concurrent weeks, 1 one-month booster) in a group-based format. Foster and kinship caregivers of young children are systematically taught parenting skills through group discussions, videotaped vignettes, structured role play and weekly homework assignments.
223659056|NCT06170047|OTHER|Usual Care|The Usual Care control will receive services from the county, CHECK clinic, and for licensed caregivers, their licensing agency per usual care. Caregivers receive training and support from their county and/or private licensing agency, children are referred to community services by the caseworker when behaviors emerge, and support from behavioral health specialists is available when caregivers request them.
223768931|NCT01903278|DRUG|PEG-IFN-SA /RBV|
223768932|NCT01903278|DRUG|Pegasys /RBV|
223768933|NCT05750693|GENETIC|PIK3CA analysis|"PIK3CA will be investigated together with HER2 in pre-NAD tissue samples, in order to evaluate the correlation with response to NAD chemotherapy, with a 16-gene MYRIAPOD kit. This evaluation will be performed on all 58 patients in the study for group (responders and not responders).~Moreover 10 patient samples (5 responders and 5 non-responders) will be subjected to gene expression profile analysis. Specifically, a transcriptomic analysis will be performed on total RNA from one inch of cells (10-50 cells isolated by LCM from FFPE biopsy, RNA seq) which will allow to have the transcriptional profile for each patient of protein-coding transcripts (coding RNAs) and long non-coding RNAs.~In addition, an NGS analysis by TSO500 will be performed in parallel, on the slide following the previous one, to have the genome sequence (523 genes) on the same 10-50 cells isolated by LCM from FFPE biopsy for the identification of any mutations."
223768934|NCT06407778|OTHER|High Intensity Strength Training|"* High-intensity workouts to strengthen the quadriceps and enhance knee function;~* Knee flexion and extension 10 lbs.~* 10RM of hip flexion and extension~* 10RM hip adduction and abduction~* Standing with feet aligned for one minute\*2, standing on one leg's forefoot and the other leg's heel for two minutes\*2, standing on one foot for three seconds\*15, and walking ten meters in a straight line for four minutes~* 4-week program; 3 days/week; Conventional Treatment: Exercises for range of motion, mobility and weight bearing, muscle stretching, static quadriceps exercise, quadriceps exercise, and straight leg raising"
223768935|NCT06407778|OTHER|Muscle Energy Technique|"The Muscle Energy Technique (MET) to strengthen and flex your quadriceps and hamstrings.~* After maintaining an isometric contraction for ten seconds, a little stretch was maintained for thirty seconds.~* Four contractions every treatment, separated by three seconds of rest. Standing with feet parallel for one minute\*2, standing on one leg's forefoot and the other leg's heel for two seconds\*2, standing on the forefoot for three seconds\*15~* Move in a 10 m by 4 straight line.~* 4-week program; 3 days/week Conventional Treatment: Exercises for range of motion, mobility and weight bearing, muscle stretching, static quadriceps exercise, quadriceps exercise, and straight leg raising"
223659057|NCT06015282|BIOLOGICAL|Investigational aQIVc|Investigational Adjuvanted Cell-derived Quadrivalent Influenza vaccine, containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO (World Health Organization) for quadrivalent vaccines for the respective season.
223659058|NCT06015282|BIOLOGICAL|licensed QIVr|Recombinant Quadrivalent Influenza Vaccine (Flublok Quadrivalent/Supemtek) containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO for quadrivalent vaccines for the respective season.
223659059|NCT06015282|BIOLOGICAL|licensed aQIV|Adjuvanted, egg-derived Quadrivalent Influenza Vaccine (Fluad) containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO for quadrivalent vaccines for the respective season.
223659060|NCT07059650|DRUG|DZD8586+R-CHOP|DZD8586 at the protocol defined dose level (50 mg or 75 mg, po, qd) with R-CHOP (Rituximab: 375 mg/m2, IV, d1; Cyclophosphamide: 750 mg/m2, IV, d1; Doxorubicin: 50 mg/m2, IV, d1; Vincristine: 1.4 mg/m2, IV, d1; Prednisone: 100 mg, po, d1-5) in a 21-day cycle for 6 cycles. DZD8586 (pre-defined dose level, po, qd) as maintenance therapy for CR/PR patients.
223659061|NCT07059650|DRUG|DZD8586+R-GemOx|DZD8586 at the protocol defined dose level (50 mg or 75 mg, po, qd) with R-GemOx (Rituximab: 375 mg/m2, IV, d1; Gemcitabine: 1000 mg/m2, IV, d1; Oxaliplatin: 100 mg/m2, IV, d1) in a 21-day cycle for 8 cycles. DZD8586 (pre-defined dose level, po, qd) as maintenance therapy for CR/PR patients.
223659062|NCT07059650|DRUG|DZD8586+BR|DZD8586 at the protocol defined dose level (50 mg or 75 mg, po, qd) with BR (Bendamustine: 90 mg/m2, IV, d1-d2; Rituximab: 375 mg/m2, IV, d1) in a 21-day cycle for 6 cycles. DZD8586 (pre-defined dose level, po, qd) as maintenance therapy for CR/PR patients.
223768936|NCT00004026|DRUG|CT-2584|
223768937|NCT00004026|DRUG|chemotherapy|
223768938|NCT06312098|OTHER|remote ischemic preconditioning (RIPC)|After induction of anesthesia, the paired RIPC group took the RIPC intervention on the upper arm in the lateral position. The RIPC intervention was applied using a manual cuff inflator, which consisted of three cycles of 5-min inflation of the blood pressure cuff (to 250 mmHg, or to 50 mmHg higher than the preoperative SBP), followed by 5-min deflation of the cuff. In the no-RIPC group, a blood pressure cuff was also applied on the upper arm but was not inflated.
223768939|NCT01150695|OTHER|Placebo|Normal saline will be administered to all subjects as a control and will be given at the same visit as the vaccine (Day 0).
223768940|NCT01150695|BIOLOGICAL|Undiluted Francisella tularensis live attenuated vaccine|Undiluted Francisella tularensis live attenuated vaccine \[approximately 1x10\^9 colony forming units (cfu)/mL\] produced by Dynport Vaccine Company. Administered by scarification in the ulnar aspect of the volar surface (palm side) of the forearm midway between the wrist and the elbow.
223768941|NCT01150695|BIOLOGICAL|Undiluted Francisella tularensis live attenuated vaccine|Undiluted Francisella tularensis live attenuated vaccine (approximately 1x10\^9 cfu/mL) in use by the United States Army Medical Research Institute of Infectious Diseases. Administered by scarification in the ulnar aspect of the volar surface (palm side) of the forearm midway between the wrist and the elbow.
223768942|NCT05326139|DRUG|Tranexamic acid|TA-soaked pledgets were placed under the skin flap in such a way that both sides reach the osteotomy area and left for 5 minutes.
223659063|NCT06748443|BEHAVIORAL|Support intervention for the use of Knee Control+|Coaches will be offered a smorgasbord of support interventions that they can choose from depending on their specific needs: physical and digital workshops before and during the study, site visits to their team, digital programme material, leaflets and social media posts. Fitness coaches will be responsible for physical workshops to train the football coaches.
223659064|NCT06748443|OTHER|Information about Knee Control+|Coaches receive information about injuries in football and the efficacy of injury prevention exercise programmes at a pre-season digital workshop, and guided to access the Knee Control+ programme from the Swedish Football Association website.
223659065|NCT06760507|OTHER|Adapted Family History Screening Program|The intervention includes four key steps designed to enhance the family health screening process. Before the visit, clinics will engage in community outreach using tools such as social media, events, and promotional materials to raise awareness and drive appointment scheduling through the updated GA CORE website 2.0. During the visit, the intervention streamlines the screening process by embedding reminders into workflows and simplifying results communication and documentation. Patients receive theory-based communication materials about their results. After the visit, follow-ups are automated using the updated website 2.0, consolidating data tracking and incorporating risk-stratified communication strategies to encourage appropriate cancer screening behaviors.
223659066|NCT03818035|DRUG|Guselkumab|Participants will receive 100 mg guselkumab subcutaneously at Weeks 0, 4, 12 and 20 (group 1), at weeks 28, 36, 44, 52, 60 (group 2a and 2c), and at weeks 36 and 52 (group 2b). Group 2d and 3c are the re-treatment groups and will receive three injections after loss of disease control.
223659067|NCT03818035|DRUG|Placebo Injection|Participants of group 2b will receive matching placebo injection subcutaneously at weeks 28, 44 and 60.
223659068|NCT00982423|DRUG|Furosemide|Subjects received their clinically prescribed dose of furosemide for a 3 week stabilization period, then were assessed for cardiorenal and humoral function. Subjects then had a 50% reduction of the furosemide dose for a 3 week stabilization period, and were assessed for cardiorenal and humoral function again.
223659069|NCT05566873|BEHAVIORAL|PA Education plus human and planetary health information|One year of continuing person-level physical activity promotion and health-related information delivered primarily by mail, email, and through online scientific video presentations and exploration of freely available citizen science mobile applications
223659070|NCT05566873|BEHAVIORAL|PA Education plus Our Voice citizen science|One year of continuing person-level physical activity promotion and health-related information delivered primarily by mail and email, plus participatory citizen science activities involving neighborhood audits of the walking environment using a mobile app and remote group discussion and problem-solving around physical activity barriers
223768943|NCT05326139|OTHER|Isotonic saline|Isotonic saline -soaked pledgets were placed under the skin flap in such a way that both sides reach the osteotomy area and left for 5 minutes.
223768944|NCT05471362|DEVICE|Postpartum IUD|Postpartum IUD prevents pregnancy and short inter-pregnancy interval and allow spacing and family regulation
224240753|NCT04448886|DRUG|Sacituzumab Govitecan|(iv) fixed dose, administered twice per cycle
224240754|NCT04997993|DRUG|Leflunomide|Leflunomide, 20-50mg PO daily
223659071|NCT04842591|DIAGNOSTIC_TEST|exercise echocardiography|All patients will undergo exercise echocardiography during a symptom-limited cardiopulmonary exercise test.
223659072|NCT06925490|DRUG|Metapex|Pulpectomy using Metapex
223768945|NCT00518804|BEHAVIORAL|Functional Behavioural Skills Group and Parent Training|
223768946|NCT04586179|OTHER|Aerobic (treadmill) Exercise|"Individuals begin walking at 5.8 km/hr. (3.6 mph) at a 0.0% incline (5.1 km/hr. \[3.2 mph\] if below 5' 10 tall), the treadmill incline is increased 1 degree each minute for the first 15 minutes, then speed increased 0.64 km/hr. (0.4 mph) each minute thereafter.~Exercise will be terminated if participant a) attains 90 percent of predicted heart rate reserve (HRR=.90\*\[{208-(.7\*age)}-resting HR\]), or b) reports a symptom worsening of 3 or points (0-10 scale) for headache, dizziness, or nausea, d) a rapid progression of complaints with continued exercise, or e) a rating of perceived exertion (RPE) greater than 18.5."
223768947|NCT04586179|OTHER|Dynamic (Agility) Exercise|"Participants will begin in a center circle with equidistant cones 2.5 meters away. After the administrator presents a card, the participant touches a corresponding cone and returns to the starting position. Cards will be presented in increasing frequency in synchrony with a metronome application until exercise termination criteria are identified.~Exercise will be terminated if participant a) attains 90 percent of predicted heart rate reserve (HRR=.90\*\[{208-(.7\*age)}-resting HR\]), or b) reports a symptom worsening of 3 or points (0-10 scale) for headache, dizziness, or nausea, d) a rapid progression of complaints with continued exercise, or e) a rating of perceived exertion greater than 18.5."
223768948|NCT00594828|DEVICE|CoaguChek (Patient self testing)|Patients will test their INR at home either biweekly, weekly or every 2 weeks using a CoaguChek point of care meter and communicate with the healthcare provider via an internet based expert system
224240755|NCT06340802|DEVICE|VNS Treatment|Vagus nerve stimulation is started 2-week after the implantation
224240756|NCT03205553|PROCEDURE|SoC Staged Silo Closure|Serial reductions will be performed with silastic silo placement for staged reduction using umbilical tape ties. The silo is assessed daily on morning rounds by the surgical team. Once the abdominal contents are at the level of the fascia, the abdomen is closed in the operating room. The average day to closure historically from CHND data is 5 days.
224240757|NCT03205553|DRUG|Peritoneal Dialysis Solution/Dextrose 1.5%|Serial reductions will be performed with silastic silo placement for staged reduction with adjuvant direct peritoneal resuscitation (DPR). A JP drain will be securely placed through the top of the silo beneath the fascia at the base of the small bowel mesentery for instillation of dialysate fluid and aspiration of peritoneal fluid. The sterile syringe will then be connected to the JP drain. The dialysate fluid administered via JP drain as a bolus infusion every 6 hours until the abdominal wall is closed (generally 3-5 days), but not to exceed 7 days maximum. Fluid will be warmed at bedside using dry heat not to exceed 37°C/98°F. The initial bolus infusion will be 10 mL/kg of dialysate. If tolerated, each subsequent infusion will be increased by 10 mL/kg up to a goal infusion of 40 mL/kg (to a maximum volume of 100 mL) as tolerated. Dialysate will dwell for 1 hour after instillation of fluid. Any excess fluid will then be removed via JP drain.
224321188|NCT04414618|DRUG|Opaganib|Study participants received opaganib 2 x 250 mg capsules (500 mg) plus standard of care every 12 hours (pharmacological and/or supportive).
223659073|NCT06925490|DRUG|3Mixtatin|pulpotomy treatment when applying 3mixture of antibiotic (Metronidazole, cefixime, and Ciprofloxacin) along with simvastatin
223659074|NCT03374202|GENETIC|VRC-HIVAAV070-00-GT (AAV8-VRC07)|AAV8-VRC07 is a recombinant AAV vector expressing a HIV-1 CD4 binding site-specific neutralizing antibody, VRC07
223768949|NCT00594828|DEVICE|Anticoagulation Management Service (AMS)|Patients will attend the AMS for six months and have their INR checked every 4-6 weeks or more frequently, at the discretion of the clinician
223768950|NCT04428866|DIAGNOSTIC_TEST|Continuous Glucose Monitoring|A CGM sensor (Dexcom G4 or other professional version available at onset of study) will be placed during visit 1 in blinded (masked) mode, and will be worn for 10 days. Data will be analyzed to determine patterns of glucose during both day and night intervals.
223768951|NCT04428866|DIAGNOSTIC_TEST|activity monitor|The activity monitor (Fitbit Charge 2) will be worn by participants for 10 days to assess activity, concurrent with CGM sensor wear.
223768952|NCT04428866|DIAGNOSTIC_TEST|Mixed meal tolerance test|After an overnight fast, participants will be given a standard liquid mixed meal; blood samples will be collected at baseline (fasting) and at defined time points after a meal for metabolic and hormonal analyses.
223659079|NCT06919926|DRUG|AGB101|low-dose levetiracetam, 220 mg, extended release tablet
223659080|NCT06919926|DRUG|Placebo|placebo capsule
223659081|NCT02712047|DRUG|Fluticasone furoate (FF) (100 mcg)|First blister strip contains FF blended with lactose, 100 mcg per blister
223659082|NCT02712047|DRUG|Vilanterol (VI) (25 mcg)|Second blister strip contains vilanterol blended with lactose and magnesium stearate, 25 mcg per blister
223659083|NCT02712047|DRUG|Placebo|Matching placebo will have two blister strips, identical in appearance to the inhaler containing active study medication; one containing lactose and the second strip containing lactose and magnesium stearate
223659084|NCT06924294|OTHER|observation of renal affection in patients with liver cirrhosis|"* CBC~* Liver function test~* kidney function test (serum creatinine, BUN, eGFR (EPI equation and MDRD equation) ,~* Prothrombin time and concentration, INR,~* Serum electrolytes~* Urine analysis."
223659085|NCT02536053|PROCEDURE|Limb salvage|
223768953|NCT04428866|DIAGNOSTIC_TEST|Glucagon Sensitivity Testing|After baseline blood sampling, glucagon will be administered by injection, and blood samples will be collected for analysis of glucose and hormone responses. This will allow us to assess whether sensitivity to glucagon is altered in PBH.
223768954|NCT04428866|DIAGNOSTIC_TEST|Hypoglycemic Hyperinsulinemic Clamp|This test will assess hormonal responses to hypoglycemia. Participants will arrive after an overnight fast. After baseline blood sampling, an infusion of insulin and glucose will be started, and infusions will be adjusted to allow glucose levels to drop very gradually. Blood samples will be collected for measurement of hormonal responses to lowering of glucose. This test will allow us to determine whether secretion of hormones which counteract hypoglycemia (counterregulatory hormones) is reduced in patients with PBH as compared with other groups.
223768955|NCT04428866|DIAGNOSTIC_TEST|analysis of fecal microbiome|Participants will be asked to provide a fecal sample, collected at home, which will be analyzed to determine the types of bacteria present in the feces.
223768956|NCT01971827|BEHAVIORAL|MOVI-KIDS|MOVI-KIDS is a multidimensional intervention that consist of: a) for children, 4.5 h/week of a standardized recreative, non-competitive physical activity extracurricular program; b) informative sessions to parents and teachers about how schoolchildren can became more active, and c) interventions in the playground (environmental changes: equipment, facilities, painting, etc.) aimed to promote physical activity during recess (MOVI-Playground).
224240758|NCT03752788|BEHAVIORAL|Dual-task Training Fixed Priority|"Dual-task training fixed priority instructional set for four weeks. Balance training sessions of 45 minutes per day, 3 times a week for four weeks, so as to complete 9-12 hours of training warm-up improve the balance performance. This included 12 repetitions in each session for 30 minutes after a 10-minutes warm up.~Attention was focused on both postural and cognitive tasks throughout this session. In postural tasks, subjects were instructed to perform the following: walk narrow base of support with a cognitive task of counting backward by three walk narrow base of support with cognitive task of count forward by three, walk narrow base of support, step, sideways, backward avoiding the obstacles (holding a basket) with cognitive task to remember words."
224240759|NCT03752788|BEHAVIORAL|Dual-task Training Variable Priority|"Dual-task training variable priority instructional set for four weeks. Balance training sessions of 45 minutes per day, 3 times a week for four weeks, so as to complete 9-12 hours of training warm-up improve the balance performance. This included 12 repetitions in each session for 30 minutes after a 10-minutes warm up.~During the first half of the training session, attention was focused on postural tasks, while during the remaining half of the session, attention was focused on cognitive tasks."
224240760|NCT04598243|DIETARY_SUPPLEMENT|Smart Energy System|A nutritional /herbal combination
223659086|NCT05167071|DRUG|HBM4003|Subjects will be treated with HBM4003 on Day 1 during each 21-day cycle.
223659087|NCT05167071|DRUG|Toripalimab|Subjects will be treated with Toripalimab on Day 1 during each 21-day cycle.
223659088|NCT05167071|DRUG|Tislelizumab|Subjects will be treated with Tislelizumab on Day 1 during each 21-day cycle.
223659089|NCT06940206|DIAGNOSTIC_TEST|Multidirectional Isometric Assessment of the Hip|Participants perform isometric tests (flexion, extension, ABD, ADD) to assess isometric hip strength at different basic movements over two sessions. Data is collected to evaluate the reliability and validity of these tests for swimmers.
223659090|NCT06941428|BEHAVIORAL|Trauma-Focused Cognitive Behavioral Therapy (TF-CBT)|TF-CBT is a cognitive-behavioral individual intervention for children aged 3 to 18 years with trauma exposure and related mental health sequelae.TF-CBT core components include psychoeducation, relaxation skills, affective regulation skills, cognitive coping skills, construction of a trauma narrative to facilitate imaginal exposure and cognitive processing of the traumatic events, and in vivo exposure to trauma reminders. TF-CBT is hypothesized to operate on specific mechanisms that influence improvements in clinical outcomes.
223659091|NCT06941428|BEHAVIORAL|School-Adapted TF-CBT (S-TF)|S-TF is a version of Trauma-Focused Cognitive Behavioral Therapy modified for delivery by providers in the education sector. Although modifications will be determined by Study 1 activities, we anticipate that S-TF might modify treatment pacing, session length, or content sequencing. Regardless, the core functions of TF-CBT will be retained in the S-TF redesign.
223659092|NCT06937918|DEVICE|The AFM and Eadyn - guided resuscitation group|A fluid challenge using a stroke volume change prediction (∆SVpredict) and Eadyn guide. If the ∆SVpredict is more than 10%, isotonic crystalloid of 500 ml will be administered in 30 minutes, and the machine's response will be awaited. If ∆SVpredict is still more than 10%, continuous fluid loading was reapplied until SVV was less than 10% (fluid therapy will be stopped if ∆SVpredict is less than 10%) and dynamic arterial elastance (EAdyn) reaches the goal of 0.8-1.0 along with a vasopressor will be administered and titrated every 10 minutes until the target MAP \> 65 mmHg is reached. After MAP of 65 achieved, tissue perfusion including urine output, capillary refill time, and serum lactate will be assessed
223659093|NCT06937918|OTHER|The standard care for septic shock|"The standard of care group will be treated according to according to septic shock guidelines 2021; In brief A vasopressor with optimal ideal fluid (at least 30 ml/kg) will be given to achieve the hemodynamic target (MAP ≥ 65 mm Hg) by fluid challenge technique guided by MAP and central venous pressure (CVP) changes after fluid challenge. Fluid-responsive tests can be used as a subsidiary, depending on the attending physician. Early Norepinephrine (NE) infusion can be used with a standard dose of 0.05 mcg/k/min and titrated at the rate of 0.01-0.02 mcg/kg/min every 10 min until 0.25 mcg/kg/min was achieved; then, the second line vasopressor will be added and adjusted to the target of vasopressor. Hydrocortisone can be given according to septic shock guidelines.~After MAP of 65 achieved, tissue perfusion including urine output, capillary refill time, and serum lactate will be assessed"
224240761|NCT03366909|BEHAVIORAL|Mindfulness based relapse prevention (MBRP)|"These weekly visits include a Mindfulness Meditation session:~The sessions of meditation take place in a dedicated room. The collective sessions owed approximately of 2 hours and will approach the following themes: (1) Autopilot, (2) Facing obstacles, (3) Full awareness of breath, (4) Staying present, (5) Allow, let go (6) Thoughts are not facts, (7) How to take care of oneself, (8) Mindfulness on a daily basis."
224240762|NCT03366909|BEHAVIORAL|classic therapy|These weekly visits include usual addiction care provided during a consultation. This care includes psychotherapeutic management: brief interventions, cognitive-behavioral therapies, motivational interviews; associated with nonsystematic pharmacological management.
224240763|NCT05258942|OTHER|Observational|Blood samples will be collected within 30 days before scheduled surgical / interventional therapy for Heart Failure. The study will not impact patient treatment in any way.
224240764|NCT04604704|DRUG|Naltrexone|Naltrexone at 4.5 mg/day
224240765|NCT04604704|DIETARY_SUPPLEMENT|NAD+|NAD+ will be applied using iontophoresis patches. The patches will be provided by ready-made NAD+ solutions (400 mg) to be applied to the positive electrode of the patch and saline to the negative electrode. The patch is powered by a self-contained battery, producing an electric current to facilitate NAD+ absorption through the skin into the blood. Patches are worn for 4-6 hours once a week.
224240766|NCT00177593|BEHAVIORAL|behavioral weight loss|
224240767|NCT02602925|OTHER|Dose decrease|Treatment strategy change: dose decrease based on PASI and DLQI
224240768|NCT02602925|OTHER|Usual care|Usual care
224240769|NCT04471675|DRUG|Albumin-bound docetaxel|Albumin-bound docetaxel by intravenous infusion.
224240770|NCT05628636|DRUG|AC-OLE-01-VA|formulation of tricaprilin
223659094|NCT00212368|DRUG|Zinc acetate|
223659095|NCT01885741|DEVICE|IPBS|
223659096|NCT06943157|OTHER|No intervention|This is a descriptive, observational study. No intervention or experimental procedure was performed. Data were collected using self-administered questionnaires without influencing participant behavior or treatment.
223659097|NCT07145060|DRUG|Yiqi Yangyin Formula|Yiqi Yangyin Formula,consists of seven Chinese herbal medicines（Table 1）: Rehmanniae Radix (Sheng Di Huang), Lilium brownii (Bai He), Adenophorae Radix (Nan Sha Shen), Fructus Hordei Germinatus (Sheng Mai Ya), Artemisia annua (Qing Hao), Cimicifuga foetida (Sheng Ma) , and Bupleurum chinense(Chai Hu)
223659098|NCT07145060|DRUG|Yiqi Yangyin Formula placebo|Yiqi Yangyin Formula placebo,has the same appearance, state, and taste as YQYYF, but contains 5% of the ingredients of Yiqi Yangyin Formula
223659099|NCT07144891|GENETIC|Sperm DNA fragmentation|Estimation of sperm DFI level with sperm chromatin dispersion
223659100|NCT07145294|BIOLOGICAL|iEV|Intranasal administration of iEV, twice a week, 2 ml each time (at a concentration of 2×10¹⁰/ml), for 12 consecutive weeks.
224240771|NCT04016532|DIETARY_SUPPLEMENT|Personalized dietary management at home|"Personalized dietary management at home to improve nutritional status.~* Four (J7, J30, J60 and J90 for non-undernutrition patients) or five Home visits (J7, J15, J30 and J90 for undernutrition patients or at risk of undernutrition) by professional dietitians from Saveurs \& Vie over a period of 3 months after discharge from the hospital: personalized dietary advice and recipe sheet.~* There will be no change in medical prescriptions"
224240772|NCT03778905|OTHER|Rehabilitation|The stroke patients who admitted to post acute care(PAC) institution would undergo regular rehabilitation.
224240773|NCT00148564|DRUG|olanzapine|treatment with either Olanzapine or Ziprasidone
224240774|NCT00148564|DRUG|Ziprasidone|treatment with either Olanzapine or Ziprasidone
224240775|NCT02384174|DIETARY_SUPPLEMENT|Resistant starch|
224240776|NCT02384174|DIETARY_SUPPLEMENT|Dietary fibre (arabinogalactan, gum guar, pectin)|
224240777|NCT01502943|DRUG|Louxiangdan Tongxin granules|"TCM treatment:~Decoction: Louxiangdan Tongxin granules Herbs:Danshen 10g、Chenxiang 1g、Gualou10g、Xiebai 10g、Banxia6g、Chuanxiong 6g 、Dangshen 10g、Zhiqiao 6g、Taoren 10g、Guizhi 6g Therapeutic Principle:Invigorating Spleen to Remove Phlegm and activating blood and dissolving stasis, at least 6 kinds of TCM herbs can be chosen and their dosages be adjusted according to Syndrome Differentiation.~Usage:Once 100ml, twice per day after breakfast and supper."
224240778|NCT01502943|DRUG|TCM granules placebo|Chinese medicine granules placebo: once 100ml, twice per day after breakfast and supper.
224240779|NCT01502943|DRUG|Chixiangshen Tongxin granules|"TCM treatment:~Decoction: Chixiangshen Tongxin granules Herbs: Chishao 10g, Chenxiang 1g, Danggui 10g, Jupi 10g, Yanhusuo 6g, Chuanxiong 6g, Dangshen 10g, Huangqi 6g, Taoren 10g, Honghua 10g Therapeutic Principle:Invigorating Spleen to Replenish Qi and activating blood and dissolving stasis, at least 6 kinds of TCM herbs can be chosen and their dosages be adjusted according to Syndrome Differentiation.~Usage:Once 100ml, twice per day after breakfast and supper."
224240780|NCT01502943|DRUG|TCM granule placebo plus western basis treatment|Chinese medicine granules placebo: once 100ml, twice per day after breakfast and supper.
224240781|NCT01502943|DRUG|Western basis treatment|Aspirin: 100mg pd. P.O.( patients who have Aspirin resistance or Allergy can replaced with Piece clopidogrel 75mg pd. P.O.) Atorvastatin calcium (Lipitor): 10mg pd. P.O.( patients who have Atorvastatin calcium resistance or Allergy can replaced with Additive amount of pravastatin equal to 10mg Lipitor) Nitroglycerin: sublingual necessary.
224240782|NCT05265806|DRUG|Intranasal oxytocin|Each subject will be assigned to administration of oxytocin intranasal spray (24 IU).
224240783|NCT05265806|DRUG|Oral oxytocin|Each subject will be assigned to administration of oxytocin lingual spray (24 IU).
224240784|NCT05265806|DRUG|Placebo|An identical amount of intranasal administration of placebo (identical ingredients except the peptide - i.e. glycerine and sodium chloride) will be assigned to each subject.
223659101|NCT07145294|OTHER|Basic treatments|Basic treatments for cerebrovascular diseases such as antiplatelet aggregation, blood pressure control, blood glucose control, blood lipid control, and plaque stabilization.
223659102|NCT07146412|BEHAVIORAL|Multimodal Lifestyle Intervention|The intervention supports adoption and maintenance of healthy behaviors including healthy nutrition The Mediterranean-DASH (Dietary Approaches to Stop Hypertension) Intervention for Neurodegenerative Delay, or MIND Diet), physical activity (150 min/week of moderate activity), stress management, weight management, and adherence to doctor-prescribed medical regimens. In addition, participants will be encouraged to participate regularly in social and learning activities, and to engage in cognitive training via Posit's BrainHQ web-based training tools (brainhq.com). Participants will be supported by telephone-based health coaching. Coaches will be currently licensed allied health providers such as Registered Dietitians. Using the combination of an individual's biological data (including genomics, blood, stool, saliva, etc.), activity data, behavioral data, and other incoming streams of health information, the coach will tailor the lifestyle intervention for each participant.
223659103|NCT07144917|DIAGNOSTIC_TEST|mHLA-DR analysis|"mHLA-DR analysis will be realized on Cyto-Chex® BCT anticoagulant tubes (5mL). Each sample will be transported and centralized at the Immunology Laboratory of Edouard Herriot Hospital and analyzed by flow cytometry.~Samples will be collected :~* The day of surgery before intervention~* The day of surgery after intervention~* At postoperative day one~* At postoperative day two~* At postoperative day three~* At postoperative day four~* At postoperative day five~* At postoperative day seven"
223659104|NCT07146217|DRUG|Likmez® (metronidazole) Oral Suspension|Each patient will receive 7.5 mg/kg of Likmez® every 6 hours, with a concentration of 100 mg metronidazole/mL
223659105|NCT07146152|DEVICE|Patient Decision Aid|A Patient Decision Aid designed to help patients with CIN2 make informed decisions about wether they prefer operation (Loop Electrical Surgery) or active surveillance.
223659106|NCT07146815|DIAGNOSTIC_TEST|FibroScan|Performance of a FibroScan measurement to determine the prevalence of liver steatosis.
223659107|NCT07146815|DIAGNOSTIC_TEST|MRI PDFF|Performance of an MRI-PDFF to determine amount of liver steatosis.
223659108|NCT07145385|OTHER|multiplex digital PCR|multiplex digital PCR
223659109|NCT07146672|BIOLOGICAL|Super DC Vaccine|Super DC Cell Injection
223659110|NCT07146321|DIETARY_SUPPLEMENT|multi-vitamin, multi-nutrient|A multi-vitamin, multi-nutrient combination of approved and/or GRAS ingredients
223659111|NCT07146321|DIETARY_SUPPLEMENT|Placebo|placebo
223659112|NCT07147140|DEVICE|dorsal root ganglion stimulation cessation|Treatment of DRGS will be stopped at home and physiological parameters will be monitored with bio wearables at home. physiological parameters will be monitored during a baseline period, before stopping DRGS. While DRGS is stopped. And during the period while the DRGS is turned back on.
223659113|NCT07145424|OTHER|kinesio taping group|The original Kinesio Tape (Kinesio Tex Classic Tape) was used for taping by a physiotherapist with 15 years of experience in the field. The tape was cut into an I-shape and applied to the lower abdominal and lumbo-sacral regions where the participants experienced pain, 10 days prior to the anticipated start of menstruation (Figure 2). The tapes were renewed after four days. This procedure was performed three times and the total taping period was completed as 12 days. The tapes were removed on the third day of menstruation and all outcome measurements were performed again for the post intervention measurements
223659114|NCT07145840|OTHER|Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5)|Psychiatric interview for diagnosis of schizophrenia by SCID 5 (American Psychiatric Association, 2015), The Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) is a semi structured interview guide for making the major DSM-5 diagnoses using the chapter of schizophrenia spectrum
223659115|NCT06944314|PROCEDURE|Diagnostic procedures|Diagnostic Flexible Cystoscopy
223659116|NCT06944314|PROCEDURE|Flexible Cystoscopy|Diagnostic Flexible Cystoscopy
223659117|NCT06946316|DIETARY_SUPPLEMENT|Nutritional supplementation during a 12 month resistance training program|1% chocolate milk
223659118|NCT06946316|DIETARY_SUPPLEMENT|Nutritional supplementation during a 12 month resistance training program|pea-based beverage
223659119|NCT06946316|DIETARY_SUPPLEMENT|Nutritional supplementation during a 12 month resistance training program|almond-based beverage
223659120|NCT06947850|DRUG|Cenegermin Ophthalmic Solution [Oxervate]|Oxervate (cenegermin-bkbj) is commonly used to treat neurotrophic keratitis
223659121|NCT06947187|OTHER|Pre-bunking video|\~3 minutes educational video to improve vaccine literacy and vaccine confidence
223659122|NCT06947187|OTHER|Video on safe disposal of medication|\~3 minutes educational video on safe disposal of medication
223659123|NCT06946407|DRUG|Rituximab, Methotrexate, and Thiotepa (R-MT) Induction Followed by Etoposide and Cytarabine (EA) Consolidation|"Pre-induction Therapy (R-M regimen):~Cycle 1-2 (C1-C2):~Rituximab (R): 375 mg/m² IV, on Day 1 Methotrexate (MTX): 3.5 g/m² IV over 3 hours, on Day 2~Induction Therapy (R-MT regimen):~Cycle 3-6 (C3-C6):~Rituximab (R): 375 mg/m² IV, on Day 1 Methotrexate (MTX): 3.5 g/m² IV over 3 hours, on Day 2 Thiotepa (T): 30 mg/m² IV over 30 minutes, on Day 3~Consolidation Therapy (EA regimen):~Cycle 7-8 (C7-C8):~Etoposide (E): 5 mg/kg IV, every 12 hours on Days 1 and 2 Cytarabine (A): 2.0 g/m² IV over 2 hours, every 12 hours on Days 3 and 4"
224240785|NCT04597086|OTHER|Best Practice|Receive standard of care
224240786|NCT04597086|PROCEDURE|Bright White Light Therapy|Receive BWLT
224240787|NCT04597086|OTHER|Survey Administration|Ancillary studies
224240788|NCT02679183|DIETARY_SUPPLEMENT|Medically-Graded Honey|Honey added to the baby formula once a day for 2 weeks.
223659124|NCT06946771|DIAGNOSTIC_TEST|Advanced MRI parameters for the diagnosis of prostate cancer|This study aims to use time-dependent DWI (td-DWI) to fit and calculate quantitative information such as cellularity, cell diameter, intracellular volume fraction and cell density; use the chemical exchange saturation transfer (CEST) sequence to saturate hydrogen protons (hydroxyl (-OH), amide (-NH) and amine (-NH2) groups) in specific metabolites in the body by applying frequency-selective saturation pulses to non-invasively reflect metabolic information in the human body for the diagnosis of prostate cancer and to evaluate its diagnostic accuracy compared with traditional multi-parameter magnetic resonance imaging.
223659125|NCT06947109|DRUG|Placebo|Monitor for a minimum of 24 hours to assess whether the safety and tolerability are acceptable according to the investigator.
223659126|NCT06947109|DRUG|AK111|The study will use dose escalation scheme. Before proceeding to randomize the next group of subjects, the safety data from all subjects in the previous dose group must be reviewed and confirmed.
223659127|NCT06946173|DIETARY_SUPPLEMENT|health program|"Health children their age between 6-12 years bone and live in Gharbia governorate.~\- Legal pre mission will be taken from each school movement system to assess over weight among there school children.~\- The children and their family included in the study will be able to follow program of health intervention to prevent obesity.~Materials and methods:~1. Each children will be subjected to full history talking , clinical examination, growth assessment; weight height and body mass index (BMI) for age percentile ( Egyptians growth charts)~2. Laboratory investigation will be done which include lipid profile, serum cholesterol, triglycerides, LDL and hemoglobin level~3. Child history will be taken which include personal history~4. Dietary history of the child which include eating habits"
223659128|NCT06946589|DRUG|Carbetocin|A uterotonic agent used for the prevention of postpartum hemorrhage in Cesarian section
223659129|NCT06947629|DIAGNOSTIC_TEST|Intraoperative Frozen Section|"Intraoperative Frozen Section analysis which will include the following steps:~\- The specimen will undergo both gross and microscopic examination:~1. Gross examination: Evaluation of nodular features including, multiplicity, size, outlines, color and consistency.~2. Microscopic examination: Assessment of capsular pattern, capsular invasion, thickness of capsule, vascular invasion and number of invaded vessels and the presence or absence of papillary structures."
223659130|NCT06946212|DRUG|Dexmedetomidine|In Dexmedetomidine group: patients received an intravenous dose of dexmedetomidine at 1 mcg/kg over 10 min in 100 mL normal saline followed by continous infusion of dexmedetomidine at 0.2mcg/kg/h up to 0.7mcg/kg/hr till reaching Ramsay sedation score 2-3
223659131|NCT06946212|DRUG|Ketamine plus Midazolam|In Ketamine Midazolam group: patients received midazolam 0.02 mg /kg IV then 2 minutes later take ketamine 0.25 mg/kg IV and we will repeated this mixture till reaching Ramsay sedation score 2-3
223659132|NCT06946329|BEHAVIORAL|Aquatic Exercise|Supervised WATERinMOTION sessions (60 mins, 3x/week) in heated pool. Focus on progressive resistance and mobility exercises.
223659133|NCT06946329|BEHAVIORAL|Land-Based Rehabilitation|Matched frequency/duration land-based program emphasizing core stabilization and low-impact aerobics.
223659134|NCT06946940|DRUG|Cannabis Oil (5% THC/5% CBD)|Cannabis oil containing a balanced formulation of 5% tetrahydrocannabinol (THC) and 5% cannabidiol (CBD). Administered sublingually over a three-month period, starting with a six-week titration phase to optimize dosing, followed by maintenance.
223659135|NCT06946940|DRUG|Sham Cannabis Oil|Placebo oil visually and chemically matched to the active cannabis oil but devoid of active cannabinoids (THC/CBD). Administered sublingually over three months, mirroring the active arm's titration and maintenance schedule.
223659136|NCT06947902|DEVICE|High flow|The High Flow Nasal Cannula (HFNC) device (Vapotherm) will be placed through the nostrils for oxygen (2L/kg per min with max of 45L)
223768957|NCT04073095|OTHER|Erector spinae plane block (Group E)|"Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period.A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit. Postoperative patient evaluation will be performed by an anesthesiologist blinded to the procedure.~Postoperative pain assessment will be performed using the VAS score (0 = no pain, 10 = the most severe pain felt). The VAS scores at rest and during cough will be recorded at postoperative 1, 2, 4, 8, 16 and 24 hours. If the VAS score will be ≥ 4, 0.5 mg/ kg meperidine IV will be administered. The first time of the use of rescue analgesic, intraoperative and postoperative opioid consumption, side effects such as nausea, vomiting, itching and block related complications will be recorded."
224240789|NCT02679183|OTHER|Premature Milk Formula|Enteral feeds were provided to subjects of all groups using premature milk formula as per routine nutritional management in the neonatal intensive care unit.
224240790|NCT04448678|BEHAVIORAL|Health Insurance Education Program (HIEP)|\[See arm/group descriptions\]
224240791|NCT04448678|OTHER|Usual Care|\[See arm/group descriptions\]
224240792|NCT00162123|DRUG|Ipilimumab|Intravenous solution, 0.3, 3, or 10 mg/kg; 1 dose every 3 weeks or every 3 months until patient discontinuation
223659137|NCT06947902|DEVICE|Low Flow|The High Flow Nasal Cannula (HFNC) device (Vapotherm) will be placed through the nostrils for oxygen (0.5L/kg per min with max of 5L)
224240793|NCT02016170|DRUG|Ticagrelor 180mg|"After providing written informed consent, eligible patients on maintenance prasugrel meeting inclusion and exclusion criteria will be randomized in a 1:1:1 fashion to one of the following treatment arms:~A. Ticagrelor 180 mg loading dose (two 90mg ticagrelor tablets) followed by 90 mg BID maintenance dose for 7±2 days.~B. Ticagrelor 90 mg (one 90mg ticagrelor tablet) followed by 90 mg BID maintenance dose for 7±2 days C. Prasugrel 10 mg once daily maintenance dose for 7±2 days"
224240794|NCT02016170|DRUG|Prasugrel 10mg|"After providing written informed consent, eligible patients on maintenance prasugrel therapy meeting inclusion and exclusion criteria will be randomized in a 1:1:1 fashion to one of the following treatment arms:~A. Ticagrelor 180 mg loading dose (two 90mg ticagrelor tablets) followed by 90 mg BID maintenance dose for 7±2 days.~B. Ticagrelor 90 mg (one 90mg ticagrelor tablet) followed by 90 mg BID maintenance dose for 7±2 days C. Prasugrel 10 mg once daily MD for 7±2 days"
224240795|NCT02016170|DRUG|Ticagrelor 90mg|"After providing written informed consent, eligible patients on maintenance prasugrel therapy meeting inclusion and exclusion criteria will be randomized in a 1:1:1 fashion to one of the following treatment arms:~A. Ticagrelor 180 mg loading dose (two 90mg ticagrelor tablets) followed by 90 mg BID maintenance dose for 7±2 days.~B. Ticagrelor 90 mg (one 90mg ticagrelor tablet) followed by 90 mg BID maintenance dose for 7±2 days C. Prasugrel 10 mg once daily MD for 7±2 days"
223768958|NCT04073095|OTHER|modified-thoracolumbar interfascial plane block (Group T)|"Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period.A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit. Postoperative patient evaluation will be performed by an anesthesiologist blinded to the procedure.~Postoperative pain assessment will be performed using the VAS score (0 = no pain, 10 = the most severe pain felt). The VAS scores at rest and during cough will be recorded at postoperative 1, 2, 4, 8, 16 and 24 hours. If the VAS score will be ≥ 4, 0.5 mg/ kg meperidine IV will be administered. The first time of the use of rescue analgesic, intraoperative and postoperative opioid consumption, side effects such as nausea, vomiting, itching and block related complications will be recorded."
223768959|NCT05437757|DEVICE|Surgical implantation of the PCL Breast scaffold with autologous fat grafting|Single shot of prophylactic perioperative antibiotics is given to the patient. A suitable incision is made to provide access followed by mobilisation of the breast gland.If present, the silicone implant is removed and capsulectomy performed. The implant pocket shall be rinsed with saline or antiseptic and a surgical drain shall be placed in the pocket at the discretion of the PI. The PCL Breast scaffold shall be inserted into the pocket and fixed using 2 to 4 sutures. The incision is closed. Liposuction is performed from another area of the body and lipofilling is performed within the breast scaffold. Sterile bandaging is applied and a daily wound revision is performed whilst an inpatient. A prophylactic antibiotic shall be administered to the patient.The patients shall be hospitalized overnight for clinical observation.
223659138|NCT06947525|OTHER|Manual pressure|Before the procedure in the manual pressure group, the vein entry area will be pressed with the right hand thumb for 10 seconds. The pressure will be applied until the nail bed turns white.
223659139|NCT06947525|OTHER|Shotblocker|In the Shotblocker group, the shotblocker will be placed 2 cm above the vein entry point and will remain throughout the procedure.
223659140|NCT06947655|DEVICE|VBM Tourniquet|Perioperative VBM-Tourniquet Application with a fixation pressure of 15mmHg.
223659141|NCT06947655|DEVICE|Adaptive Cuff|Perioperative Delfi-Tourniquet Application with a fixation pressure of 15mmHg.
223659142|NCT06946901|COMBINATION_PRODUCT|Hyperthermic Intraperitoneal Chemotherapy (HIPEC) with Cisplatin + Systemic AG Chemotherapy|"* HIPEC (cisplatin 70mg/m², Day 1,3 post-surgery), 1 cycle；~* Systemic AG chemotherapy (nab-paclitaxel 125mg/m²+ gemcitabine 1000mg/m², initiated, Day 1,8,15, q4 week), 4 cycles"
223768960|NCT05355636|BEHAVIORAL|Fertility Management Counseling|counseling
224240796|NCT00188656|PROCEDURE|CT thorax|
223659143|NCT06947746|BIOLOGICAL|hiSCs|hiSCs are derived from human induced pluripotent stem cells and exhibit immunomodulatory properties.
224240797|NCT03414749|PROCEDURE|Lower Extremity First (LEF)|The intervention for the LEF group was a non-specific long-axis distraction to the ankle, knee, and hip or shoulder, elbow and wrist provided was at the discretion of the clinic doctor (over 25 years experience).
223659144|NCT06947772|BEHAVIORAL|Skill building education|This intervention includes two session. theoretical and practical. In theroretical patient will be teahc about self-care of AVF and in oracticla session they learn how to monitor their AVF. monitoring have three part. inspection, palpation and auscultation
223659145|NCT06946693|PROCEDURE|To evaluate the color stability and surface roughness of implant supported provisional restorations fabricated using conventional technique, milling, and 3D printing in mandibular posterior region.|Subjects with single stage implant placement and early non-functional loading with implant supported provisional restorations fabricated using conventional technique, milling, and 3D printing.
223659146|NCT06947564|DIAGNOSTIC_TEST|CMR|Coronary microvascular function was assessed using contrast-enhanced CMR after PCI.
223659147|NCT06946615|BIOLOGICAL|Claudin18.2-targeted CAR-T Cells|Autologous T cells genetically modified to express a chimeric antigen receptor (CAR) targeting Claudin18.2.
223659148|NCT06946615|BIOLOGICAL|Claudin18.2-targeted CAR-DCs|Autologous dendritic cells (DCs) genetically modified to express a chimeric antigen receptor (CAR) targeting Claudin18.2.
223659149|NCT06947226|DRUG|9MW2821|Subjects will receive intravenous (IV) infusion of 9MW2821 as per protocol
223659150|NCT06947226|DRUG|Other anti-cancer therapy|Subjects will receive other anticancer therapy as per protocol
223659151|NCT06946069|RADIATION|NB-UVB twice weekly|Standard phototherapy without additional systemic treatment.
223768961|NCT02537964|OTHER|washcloths impregnated with 2% chlorhexidine gluconate|All infants in the NICU eligible for the study will be assigned for bathing three times a week with washcloths impregnated with 2% chlorhexidine gluconate
223768962|NCT05600218|DRUG|No intervention - Observational study|Real life drug evaluation
223768963|NCT00482391|BIOLOGICAL|trastuzumab|
223768964|NCT00482391|DRUG|cyclophosphamide|
223768965|NCT00482391|DRUG|doxorubicin hydrochloride|
224240798|NCT03414749|PROCEDURE|Upper Extremity First (UEF)|The intervention for the UEF group was a non-specific long-axis distraction to the shoulder, elbow and wrist provided was at the discretion of the clinic doctor (over 25 years experience).
224240799|NCT05886543|BEHAVIORAL|Conventional chest physical therapy|Conventional chest physical therapy: The patients performed four series of five breath with 3 seconds of sustained breathing interspersed with periods of quite breathing followed by two or three coughs or huffs (with wound support by a pillow or his/her hands), twice a day in the first two postburned days and once a day from the third to the tenth days.
224240800|NCT05886543|BEHAVIORAL|Pilates exercise|The Pilates technique, which stretched laterally and to the back, stressed costal breathing, in which the ribs climb and drop throughout the ventilatory stream. The transverse muscle had to work harder to avoid abdominal distension, provide more support to the diaphragm to promote lower rib movement, and provide more diaphragmatic excursion, During the expiratory phase, the transversus abdominis, the multifidus and the pelvic floor musculature were contracted.
223659152|NCT06946069|OTHER|NB-UVB + dexamethasone (2.5-3 mg/week)|Combination therapy to enhance immunosuppression and repigmentation.
223659153|NCT06946667|OTHER|the UTI group|Laboratory parameters, including WBC, NLR, NEU, hs-CRP, HBP, NGAL, and ADPN levels, were measured. Midstream clean-catch urine samples from patients in the UTI group were collected for pathogen identification and antimicrobial susceptibility testing.
223768966|NCT00482391|DRUG|lapatinib ditosylate|
223768967|NCT00482391|DRUG|paclitaxel|
223768968|NCT00482391|OTHER|laboratory biomarker analysis|
223768969|NCT01448850|BIOLOGICAL|MEDI8968 600 mg IV, 300 mg SC|MEDI8968 600 mg as IV infusion on Day 1 followed by 300 mg injection SC every 4 weeks up to Week 53.
223768970|NCT01448850|OTHER|Placebo|Placebo matched to MEDI8968 as IV infusion on Day 1 followed by SC injection every 4 weeks up to Week 53.
223768971|NCT02601040|BIOLOGICAL|Attenuated Hepatitis A Vaccine, H2 Strain|6.50 lgCCID50/ml in babies aged 18-35 months\\6.50 lgCCID50/ml in children aged 3-16 years \\6.50 lgCCID50/ml in adults aged 17 up to 65 years old
223768972|NCT02601040|BIOLOGICAL|Inactivated Hepatitis A Vaccine, Lu8 Strain|320EU/Vial in babies aged 18-35 months \\320EU/Vial in children aged 3-16 years \\640EU/Vial in adults aged 17 up to 65 years old\\boost at month 6\\two-dose
223768973|NCT02601040|BIOLOGICAL|Group A Meningococcal Polysaccharide vaccine|30µg Group A Meningococcal Polysaccharide vaccine in subjects aged 18 months-65 years old
223768974|NCT02596529|DEVICE|Fixation|Fixation of the posterior malleolus with lag-screws or platefixation (usually by Drittelrohr plate).
223768975|NCT02596529|OTHER|NO Fixation|NO Fixation of the posterior malleolus.
223768976|NCT00333112|DRUG|solifenacin succinate|Oral
223659154|NCT06946667|OTHER|the Non-UTI group|Laboratory parameters, including WBC, NLR, NEU, hs-CRP, HBP, NGAL, and ADPN levels, were measured. Midstream clean-catch urine samples from patients in the UTI group were collected for pathogen identification and antimicrobial susceptibility testing.
223768977|NCT00333112|DRUG|tamsulosin|oral
223768978|NCT00333112|DRUG|placebo|oral
223768979|NCT02939404|OTHER|Cold exposure|23.25 hours inside respiratory chamber with the temperature set to19°C
223768980|NCT02939404|OTHER|Normal temperature|23.25 hours inside respiratory chamber with the temperature set to 24°C
223768981|NCT02939404|OTHER|Fixed diet|A diet that matches the participant's caloric needs
223768982|NCT02939404|OTHER|Ad libitum diet|Participants can eat as much as they want
223768983|NCT02939404|OTHER|Fasting|Participants do not eat for 12 hours before and 24 hours in chamber
223768984|NCT01420302|PROCEDURE|Nurse directed|Nurse directed insulin titration to establish glycemic control in the target range of 80-110 mg/dL
223768985|NCT01420302|PROCEDURE|LOGIC-Insulin|Blood glucose control (80-110 mg/dL) guided by the LOGIC-Insulin algorithm
223768986|NCT04441450|DRUG|[14C]ICP-022|150mg suspension containing 100μCi of \[14C\]ICP-022
223768987|NCT04634773|RADIATION|Low-dose CT|"A low-dose, or quantitative (q) CT scan will be performed on the shoulder. This CT scan will be done to assess the bony structure of the shoulder, as well as bone strength, which can influence the health of the cartilage.~Group 1 participants will complete this scan at baseline, 2-years and 4-years in the affected shoulder, and at baseline and 4-years in the opposite, unaffected shoulder.~Group 2 participants will complete this scan at baseline, 2-years and 4-years."
223768988|NCT04634773|OTHER|T1Rho MRI|"A T1Rho MRI will be performed on the shoulder. This imaging technique uses a special sequence and will be used to assess the muscles and tendons around the shoulder.~Group 1 participants will complete this scan at baseline, 2-years and 4-years in the affected shoulder, and at baseline and 4-years in the opposite, unaffected shoulder.~Group 2 participants will complete this scan at baseline, 2-years and 4-years."
223768989|NCT04634773|OTHER|Motion Analysis|"Motion analysis is the study of how joints move and which muscles fire during specific movements. In the lab, participants will be asked to perform movements that they might do during a typical day or when exercising.~Group 1 participants will complete this scan at baseline, 2-years and 4-years in the affected shoulder, and at baseline and 4-years in the opposite, unaffected shoulder.~Group 2 participants will complete this scan at baseline, 2-years and 4-years."
223659155|NCT06947863|OTHER|thermal cure|The thermal treatment and physical rehabilitation therapy were administered at the same spa center of Jbal EL Ouest, situated to the west of the city of Zaghouan, 50 km from Tunis. Patients were accommodated in the care center for 18 days. Treatments were delivered in the morning on a daily basis, except on Sundays. The thermal treatment used hot, chlorinated and sodium water. Every day, the patients received 4 out of the 5 following treatments: underwater showers (15 minutes), shower-massage (10 minutes), hydromassage (20 minutes), swimming pool rehabilitation (20 minutes) and application of heated peloid (15 minutes).
223768990|NCT05919147|DRUG|Pioglitazone 45 mg|The dose of pioglitazone will not exceed 45 mg once daily. Pioglitazone dose will titrate progressively over the first three weeks.
223768991|NCT05919147|DRUG|Placebo|Placebo will have the same appearance as the active drug.
223768992|NCT04948632|OTHER|Complete LeoMed application|Access to the complete LeoMed application on the participant's smartphone. The day before surgery, participants will receive notifications encouraging them to use the platform to help prepare for their surgery. Safety instructions will also be sent. Postoperatively, notifications will be sent to the participants every day during the first 4 days and on the 7th day. These notifications will direct them to online forms that aim to assess their condition. On the 15th and 30th postoperative day, the platform will send a follow-up form. The platform will collect this information and classify it for appropriate management of their condition.
223768993|NCT04948632|OTHER|Basic LeoMed application|Access to a partial version of the LeoMed application on the patient's smartphone during a visit to the preoperative clinic. Before surgery, participants will receive a phone call to be summoned to the hospital and to remind them of the safety instructions. Postoperatively, their follow-up will not be standardized and will vary depending on their surgeon. On the 15th and 30th postoperative day, the platform will send a follow-up form. In the event of an emergency, they will receive the contact details of the CHUM Health Infoline to ensure the continuity of their care.
223768994|NCT04304001|BEHAVIORAL|Community Health Advisor|"Intervention arm participants will receive one 45-minute face-to-face meeting followed by two phone calls in one-week intervals over a period of three weeks beginning within one month following baseline survey completion. These educational activities will include the use of National Cancer Institute colorectal cancer resources and materials, including a Screen to Save media presentation, and colorectal cancer brochures. The intervention will follow a conversation guide/standard script for intervention fidelity. Community Health Advisors will take notes following each interaction to document the call length and call details. Participants will receive an additional text message reminder once a week for an additional three weeks - with instructions for participants to text yes to confirm they received the message - for a total of six weeks of intervention delivery. The personalized text messages will include short messages about the benefits of colorectal cancer screening."
223659156|NCT06947863|OTHER|dry rehabilitation|The thermal treatment and physical rehabilitation therapy were administered at the same spa center of Jbal EL Ouest, situated to the west of the city of Zaghouan, 50 km from Tunis. Patients were accommodated in the care center for 18 days. Treatments were delivered in the morning on a daily basis, except on Sundays. The physical rehabilitation treatment was delivered in dry and included an analgesic physiotherapy based on electrotherapy (30 minutes) and muscle strengthening, as well as group rehabilitation.
223659157|NCT06946251|DEVICE|Transcutaneous Diaphragm Stimulation|"In the ICU, TEDS is administered by a physiotherapist once daily for 20 minutes, five days a week, as part of the routine treatment protocol. The stimulation is delivered using the LGT-231 model device from the LONGEST brand.~A transcutaneous current with a frequency of 30-50 Hz and a pulse width of 300-400 microseconds is applied to the diaphragm. The stimulation intensity is increased until visible muscle contraction is achieved."
223659158|NCT06946147|OTHER||
223659159|NCT06947148|OTHER|Comprehensive post hospital management based on digital health intervention(DHI)|Based on the routine HF management of standard of care (SOC), the intervention group will carry out comprehensive post hospital management based on DHI, including cognitive behavioral therapy, digital self-monitoring and ReDS™ technology, etc.
223659160|NCT06945939|PROCEDURE|Fixation of Pott's fracture b and c|Assessment of syndesmotic injury via X-ray, CT, ultrasound and intraoperative
223659161|NCT06496750|DRUG|Ketamine Hydrochloride|Participants will receive IV ketamine (0.50mg/kg) dissolved in 0.9% sodium chloride in a total volume of 100mL and administered with an infusion pump over 45 minutes. Duration of each infusion may be extended by the Study Clinician supervising study medication infusion if slower infusion rate is better tolerated.
223659162|NCT06496750|DRUG|Midazolam Hydrochloride|Participants will receive IV midazolam (0.02mg/kg) dissolved in 0.9% sodium chloride in a total volume of 100mL and administered with an infusion pump over 45 minutes. Duration of each infusion may be extended by the Study Clinician supervising study medication infusion if slower infusion rate is better tolerated.
223659163|NCT06590051|DRUG|UPLIZNA|
223659164|NCT05286749|PROCEDURE|Workshop plus Clinician-Collected Cervical Swab|clinician-collection methods using speculum and cervical swabs
223659165|NCT05286749|DEVICE|Workshop plus Participant-Collected Cervical Swab|Evalyn® Brush (Rovers® Medical Devices, Netherlands)
223659166|NCT05286749|DIAGNOSTIC_TEST|HPV testing on Participant-Collected Cervical Swab Samples|Roche Cobas4800 HPV Test System (Roche Molecular Systems Inc., Rotkreuz, Switzerland)
223659167|NCT02464046|DRUG|JNJ-42847922|Participants in arm JNJ-42847922 then Placebo will receive 2\*20 mg tablet of JNJ-42847922 orally once daily from Day 1 to Day 5 in Period 1 and participants in arm Placebo then JNJ-42847922 will receive 2\*20 mg tablet of JNJ-42847922 orally once daily from Day 1 to Day 5 in Period 2.
223659168|NCT02464046|DRUG|Placebo|Participants in arm JNJ-42847922 then Placebo will receive matching Placebo orally once daily from Day 1 to Day 5 in Period 2 and participants in arm Placebo then JNJ-42847922 will receive matching placebo orally once daily from Day 1 to Day 5 in Period 1.
223659169|NCT06493279|DRUG|RJK002 Intrathecal injection|Eligible subjects will receive a single intrathecal administration of investigational product with dose 3E13vg (3ml), 6E13vg(6ml), and 1.2E14 vg(12ml) per person sequentially.
223659170|NCT05290571|OTHER|Modified Otago Exercise Program with music|Our study attempts to establish a new home-based exercise option incorporating mOEP with video, music and lyrics. Our new approach shares the same aims with Exergames and video-supported methods - to increase the exercise motivation of elderlies, hence their physical performance. Based on the video-supported approach in one previous study, we add in the component of music therapy. Music-based exercise interventions could produce positive outcomes on both physical, such as gait, balance and fall risk and level of physical activities and psychological, including exercise adherence, perceived exertion, thus extending exercise duration. However, exact mechanisms have not been revealed and it may be limited by personal preferences on music. In our video, the music we chose is of brisk rhythm, slightly delightful melody and higher pitch, which all help to shape a cheerful and relaxing atmosphere for the elderlies.
223768995|NCT04304001|BEHAVIORAL|Usual care|Control arm participants will receive a Fecal Immunochemical Test kit, a mailed targeted colorectal cancer brochure, and complete a follow-up telephone survey at 3- and 12-months after the mailing.
223768996|NCT05607303|OTHER|Clinical estrogen therapy|No research interventions will be used as a part of the study since the research is observational. Estrogen treatment will be prescribed and followed by participant's clinical physician.
223768997|NCT04819997|OTHER|Educational Intervention|Participate in videoconference session
223768998|NCT06350864|DEVICE|High-flow nasal cannula (HFNC)|high flow cartridge and adult size nasal cannula: (flow range: 5-40L/minute, oxygen concentration (FiO2): 21-100%, temperature range: 33-39◦ C, humidity minimum of 12mg/liter)
223768999|NCT06350864|DEVICE|Conventional nasal oxygen therapy (COT)|Adult size, single use nasal cannula
223769000|NCT06350864|DEVICE|Upper gastrointestinal endoscopy (UGE) including gastroscopy|Upper gastrointestinal endoscopy (UGE) will be either diagnostic and/or therapeutic including variceal band ligation, endoscopic hemostasis as injection of bleeding peptic ulcers with adrenaline or bleeders control via either argon plasma coagulation (APC) or heater probe coagulation.
223769001|NCT06350864|DEVICE|Upper gastrointestinal endoscopy (UGE) including Endoscopic ultrasound (EUA)|Upper gastrointestinal endoscopy (UGE) will be diagnostic
223769002|NCT04927338|DIETARY_SUPPLEMENT|BacoMind® (Bacopa monnieri standardized extract)|BacoMind® (Bacopa monnieri standardized extract) 300 mg daily capsule.
223769003|NCT04927338|DRUG|Placebo|Daily placebo capsule identical in size, color, and shape to that of the Bacopa capsules.
223769004|NCT05821309|DRUG|PEG 3350|The purpose of this study is to determine if a sustained change in the fecal microbiome occurs after prolonged use of an antegrade continence enema bowel flush regimen. Patients' microbiomes will be evaluated via 16s rRNA sequencing. PEG 3350 will be compared to PEG 3350 with electrolytes
223769005|NCT05821309|DRUG|PEG-3350 with electrolytes|The purpose of this study is to determine if a sustained change in the fecal microbiome occurs after prolonged use of an antegrade continence enema bowel flush regimen. Patients' microbiomes will be evaluated via 16s rRNA sequencing. PEG 3350 will be compared to PEG 3350 with electrolytes
224240801|NCT02522806|PROCEDURE|endometrial biopsy|Endometrial biopsy (EB) between J17 and J22 of previous ovarian hyperstimulation cycle
223659171|NCT05290571|OTHER|Modified Otago Exercise Program|Otago Exercise Program (OEP) was developed by Otago Medical School in New Zealand as a tailor-made home-based fall prevention program to improve the balance performance of community-dwelling elderlies over 1 year. It comprises of 3 main components: 5 lower limb strengthening, 12 balance retraining and walking exercises. In the original program, the intensity was set as moderate with up to 4 difficulty levels for strengthening and balance exercises, in terms of ankle cuff weights and number of repetitions, and level of support respectively. It also stated that the frequency was at least 3 times a week for the former two exercises and at least 2 times per week for walking exercises; while the total duration was expected to make up to an hour, including 30-minute walking exercises.
224240802|NCT03627585|DEVICE|Personalised programming|Reprogramming protocol already test in an observation cohort will be utilised which will direct physiologists to consider pacemaker mode, base rate, utilisation of rate response, hysteresis, sleep and rest rates as well as lead outputs.
224240803|NCT02007122|OTHER|Ceftaroline in CRRT|Plasma levels of ceftaroline will be measured in patients receiving CRRT
224240804|NCT02007122|OTHER|Ceftaroline in IRRT|Ceftaroline plasma levels will be measured in patients receiving intermittent renal replacement therapy
224240805|NCT02327130|DEVICE|Isomark Canary™|Isomark, LLC is a Madison, Wisconsin-based company that has developed an investigational device, the Isomark Canary™, that is intended to determine the breath delta value of breath samples collected from critically ill patients.
224240806|NCT06144710|DRUG|SG301 SC Injection|Subcutaneous injection every two weeks
224240807|NCT06144710|DRUG|SG301 SC Placebo|Subcutaneous injection every two weeks
223659172|NCT00895206|DRUG|individual adapted immunosuppression|individual adapted immunosuppression
224240808|NCT00003706|DRUG|pemetrexed disodium|
224240809|NCT05188937|PROCEDURE|validity and reliability study|Validity and reliability assessment of the Dual-task Questionnaire
224240810|NCT02011204|DEVICE|Electrical impedance myography (EIM)|"In EIM, high-frequency alternating electrical current is applied to localized areas of muscle via surface electrodes and the consequent surface voltage patterns analyzed.~EIM is very sensitive to the compositional and structural elements of muscle. Data from both human subjects and animal disease models, including ALS, spinal muscular atrophy (SMA), and Duchenne muscular dystrophy (DMD), show that EIM may be sensitive to a variety of pathological states. It is anticipated that EIM will thus likely be able to assist in quantifying the severity of the disease affecting various muscle groups as well as in measuring changes in the disease over time."
224240811|NCT01313416|BIOLOGICAL|CT-011|3mg/kg, intravenous (IV) day 1 of each cycle over 2 hours.
223659173|NCT00895206|DRUG|golden standard therapy|golden standard therapy
223659174|NCT01868542|DRUG|insulin detemir|Insulin detemir was administered once daily to the subjects. The dose was titrated based on the previous breakfast SMPG values.
223659175|NCT02206789|DRUG|Prednisolone acetate1%,|efficacy of prednisolone acetate1%alone versus prednisolone acetate 1%and cyclosporine 2% in preventing graft rejection
223659176|NCT02206789|DRUG|Prednisolone acetate1%, cyclosporine 2%|penetrating keratoplasty--efficacy of prednisolone acetate1%alone versus prednisolone acetate 1%and cyclosporine 2% in preventing graft rejection
223659177|NCT02269189|DRUG|BIIL 284 BS, high dose|
223659178|NCT02269189|DRUG|BIIL 284 BS, low dose|
224240812|NCT01313416|DRUG|Gemcitabine|1000mg/m\^2 intravenous (IV) over 30 minutes on days 8, 15, and 22 of each cycle.
224240813|NCT02226458|DRUG|EPI-743|
224240814|NCT00721604|DRUG|fluid administration|two consecutive infusions of 6% hydroxyethyl starch at the dosage 7 ml/kg over 30 minutes (total 14 ml/kg in 60 minutes)
223659179|NCT02269189|DRUG|Placebo|
223659180|NCT00373568|DRUG|miltefosine: 2.5 mg/kg/day for 42 days|
223769006|NCT05821309|DRUG|Glycerin|Glycerin will be given to patients based on standard of care, at the discretion of the pediatric gastroenterology and pediatric surgery teams. Glycerin administration will not be randomized. For secondary analysis, the microbiomes of those who have and have not received glycerin will be compared.
223769007|NCT06423612|BEHAVIORAL|POC urine assay informed enhanced ART adherence counselling for viral suppression|Collect urine on intervention participants and screen for presence of TFV. Feedback will be provided to the participant based on the results on their ART adherence with provision of enhanced ART adherence counseling for viral suppression.
223769008|NCT04151940|PROCEDURE|Positron Emission Tomography|Undergo PET/CT scan
223769009|NCT04151940|PROCEDURE|Computed Tomography|Undergo PET/CT scan
224240815|NCT03960970|DRUG|Azithromycin 500 mg|Additional IV Azithromycin 500 mg to Standard Prophylaxis
224240816|NCT03960970|DRUG|Mefoxin 2g|Standard Prophylaxis
224240817|NCT03828942|DRUG|drug inducing hematological toxicity|Drugs susceptible to induce hematological toxicities
224240818|NCT05856045|OTHER|PNF(proprioceptive neuromuscular facilitation exercises)|"PNF involves both stretching and contracting (activation) of the muscle group being targeted in order to achieve maximum static flexibility, along with its D1\&D2 flexion/extension patterns to improve dynamic flexibility and thus improving balance and coordination.~total 8 weeks session was given to patients. 45 mins session/each day for 6 days a week."
224240819|NCT05856045|OTHER|PBBT (pertubation based balance training)|"Perturbation-based balance training (PBT) is an emerging task-specific intervention that aims to improve reactive balance control after destabilizing perturbations in a safe and controlled environment. Pertubations are given by therapist in unexpected directions to challenge patients reactive balance. In this study pertubations will be given manually and on treadmill by a harness system.~daily 45 mins of exercise session of pertuations divided into double leg foam roller, wobble board exercises and pertubations on treadmill were performed for total 8 weeks and 6 days a week."
224240820|NCT05856045|OTHER|PNF and PBBT intervention group|proprioceptive neuromuscular exercises, pertubation based balance training along with conventional physiotherapy exercises were given for 8 weeks and 6 days per week for around 45 mins.
224240821|NCT03116386|OTHER|run-in period|observational time i.e. baseline situation
224321189|NCT04414618|DRUG|Placebo|Study participants received placebo 2 x 250 mg capsules (500 mg) plus standard of care every 12 hours (pharmacological and/or supportive).
223769010|NCT04151940|DRUG|Chemotherapy|Receive standard of care chemotherapy
223769011|NCT04151940|BIOLOGICAL|Immunotherapy|Receive standard of care immunotherapy
224321190|NCT05430217|DRUG|Buspirone|1 tablet (15 mg) once per day for 28 days
223659181|NCT04299932|PROCEDURE|Electroacupuncture|BL33 is located in the third posterior sacral foramen; BL35, 0.5 cun (≈10mm) lateral to the extremity of the coccyx; and SP6 posterior to the medial border of the tibia, 3 cun superior to the prominence of the medial malleolus. BL33 will be inserted by needles of 0.30×75mm size at the angle of 45°, inward and downward, till the depth of 60-70mm. BL35 will be inserted by needles of 0.30×75mm size, slightly outward and upward, till the depth of 60-70mm. SP6 will be inserted by needles of 0.30×40mm till the depth of 25-30mm. All the needles will be lifted, thrust and twisted evenly for three times, right after insertion, to induce the sensation of deqi. Electronic acupuncture apparatus (Yingdi KWD 808 I electro pulse acupuncture therapeutic apparatus, Changzhou Yingdi Electronic Medical Device Co., Ltd) will be connected to the three pairs of needles transversally, with continuous wave of 20 Hertz (Hz), electric current of 2-6.5 milliampere (mA) for BL33 and BL35, and 1mA-3.5mA for SP6.
223659182|NCT04299932|PROCEDURE|Sham electroacupuncture|Sham BL33 is in the area of 1 cun (≈20mm) horizontally outside BL33; sham BL35, 1 cun (≈20mm) horizontally outside BL35; Sham SP6, in the middle of SP6 and tendons. The three pairs of acupoints will be inserted by needles of 0.30×40mm size to a depth of 2-3mm till the needles can stand still. No manipulations will be conducted, and the sensation of deqi will not be induced. Electronic acupuncture apparatus (Yingdi KWD 808 I electro pulse acupuncture therapeutic apparatus, Changzhou Yingdi Electronic Medical Device Co., Ltd) will be connected to the three pairs of needles transversally, with continuous wave of 20Hz and minimal electric current (ideally at a degree which participant can just percept). In about 30 seconds, the electric current will be turned down, leaving the indicator light and ticking sound on.
223659183|NCT02657473|DRUG|tobramycin inhalation solution|
223659184|NCT02657473|DRUG|Saline 0.9% inhalation solution|
223659185|NCT02609113|DEVICE|Strong Magnetic Wristband|
223659186|NCT02609113|DEVICE|Weaker Magnetic Wristband|
223659187|NCT01744535|BEHAVIORAL|"My Meal Mate (smartphone application)"|"A smartphone application called My Meal Mate (MMM) designed to facilitate weight loss. The app allows system users to set a goal for weight loss and self monitor diet and activity in an electronic diary. Users receive instant nutritional feedback and feedback via text message."
223659188|NCT01744535|BEHAVIORAL|Paper food diary|"The paper food diary is provided by a commerical slimming organisation called Weight Loss Resources. The diary allows the user to record daily food and drink consumed. It is accompanied by a book which provides a database of the nutritional content of 40,000 food and drinks. The diary also encourages participants to record their physical activity."
223659189|NCT01744535|BEHAVIORAL|Online food diary|"The online food diary is provided by a commerical slimming organisation called Weight Loss Resources. The electronic diary allows the user to record daily food and drink consumed. System users are also encouraged to record their physical activity."
223659190|NCT02558413|DRUG|BTA-C585 oral capsules|BTA-C585; Single ascending doses from 50 mg to 800 mg
223659191|NCT02558413|DRUG|BTA-C585 matching placebo|Single ascending doses to match 50 to 800 mg BTA-C585 capsules
223659192|NCT03980691|BIOLOGICAL|Chidamide with CAR-T or TCR-T cell therapy|HIV-1 specific therapy
223659193|NCT01984658|BIOLOGICAL|Alecsat|The ALECSAT CBMP will be administered as single dose at week 4, 7 and week 10 which is considered an appropriate time for ALECSAT CBMP to strengthen the immune system and thus have the ability to kill tumour cells. It is the aim that the patients will receive three doses during the study period however, if the patient wish and it is recommended by the investigator, patients may receive more than three doses, continuing until progression or as judged by the Investigator. Continued treatment after the 24 week study period is only possible under the condition that no safety issues have been discovered. The interval between injections for continued treatment will be decided based on e.g. tumour response and clinical examinations.
223659194|NCT03742466|DRUG|Ozone|After prepping and draping the area, intracarpal injection of ozone/oxygen mixture (20 ml, 25μg/ml) will be performed under sonographic guidance
223659195|NCT03742466|DRUG|methylprednisolone acetate|After prepping and draping the area, intracarpal injection of methylprednisolone acetate 40mg, and 40 mg lidocaine (20 ml, volume) will be performed under sonographic guidance
223659196|NCT00498771|BEHAVIORAL|Aquatic Exercise arm|Participants will attend 12 classes of aquatic exercise program (2-3 classes/weekly). Each one hour class is held in warm water pool which is 89 degrees and 3.5'-4'deep.Classes include low impact, dynamic movements for warm up, stretching and breathing exercises, upper and lower body resistance training, and cool down activities. Participants will be evaluated for Circumference \& volumetric measurement of the affected limb, BMI, weight and height at the baseline, at 3rd week and at 6th week. Participant will complete a quality of life survey (QOL)at baseline, 6 week, 6 and 12 month.
223659197|NCT02830685|DEVICE|DTI with Acellular Dermal Matrix (CELLIS® Breast)|After conservative mastectomy, a pre-pectoral subcutaneous reconstruction with definitive implant will be performed using an ADM (CELLIS® Breast), either completely covering the implant or simply covering the anterior surface of it. The implant could be of any shape, material and texture available with no restriction. After at least 6 months, a fat grafting procedure, using a wash and filter principle for fat handling, will be performed over the implant.
223659198|NCT02830685|DEVICE|DTI with Titanium Coated Polypropylene Mesh (TiLOOOP® Bra)|After conservative mastectomy, a pre-pectoral subcutaneous reconstruction with definitive implant will be performed using a TCPM (TiLOOOP® Bra), either completely covering the implant or simply covering the anterior surface of it.The implant could be of any shape, material and texture available with no restriction. After at least 6 months, a fat grafting procedure, using a wash and filter principle for fat handling, will be performed over the implant.
223659199|NCT05025319|RADIATION|X-ray image|Bedside x-ray at intensive unit.
223659200|NCT00122980|PROCEDURE|Red Cell Transfusions|Red Blood Cell Transfusions
223769012|NCT04151940|RADIATION|Radiation Therapy|Undergo standard of care radiation therapy
223769013|NCT04151940|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223769014|NCT04151940|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223769015|NCT06960707|RADIATION|Radiation therapy - 1 week|2600 cGy whole breast radiotherapy in five fractions (Arm 1) over 1 week
223659201|NCT00122980|PROCEDURE|Iron Chelation|Iron Chelation Therapy
223659202|NCT00122980|DRUG|Hydroxyurea|Hydroxyurea
223659203|NCT00122980|PROCEDURE|Phlebotomy|Phlebotomy
223659204|NCT06478394|DIAGNOSTIC_TEST|Laparoscopic exploration|Laparoscopic exploration
224321191|NCT05430217|DRUG|Placebo|1 placebo tablet once per day for 28 days
223769016|NCT06960707|RADIATION|Radiation therapy - 2 weeks|3200 cGy whole breast radiotherapy with a concomitant tumor bed boost to 3600 cGy in 10 fractions (Arm 2) over 2 weeks. In Arm 2, if no cavity is visible due to oncoplastic surgery, we will deliver 32 Gy to the whole breast only, without a boost.
223659205|NCT01437904|PROCEDURE|Outpatient Recovery|Patients go home following Percutaneous nephrolithotomy
223659206|NCT01437904|PROCEDURE|In hospital recovery|Patients are hospitalized following Percutaneous nephrolithotomy
223659207|NCT00547443|DRUG|carboplatin|Given IV
223659208|NCT00547443|DRUG|paclitaxel|Given IV
223659209|NCT00547443|DRUG|sorafenib tosylate|Given orally
223659210|NCT00547443|RADIATION|radiation therapy|Given 5 days a week for 7.5 weeks
223659211|NCT01124864|DRUG|AUY922|AUY922 was supplied in individual 10 mL amber colored glass ampoules containing 10 mL of a 5 mg/mL active drug substance in 5% aqueous glucose solution. AUY922 was administered intravenously (i.v.) weekly at 70 mg/m2.
223659212|NCT01243242|DRUG|Metadoxine (MG01CI)|MG01CI 1400 mg, that will be taken daily by the patients for a duration of 6 weeks.
223659213|NCT04183543|DEVICE|Pulsed Electromagnetic Fields|The PEMF device produces pulsed magnetic fields at flux densities up to 1.5 mT peak.
223659214|NCT04183543|DEVICE|Sham Therapy|Inactive Pulsed Electromagnetic Field therapy
223659215|NCT03291366|DRUG|UCMSCC|infusion of aUCMSC and conventional therapy
223659216|NCT03291366|DRUG|conventional treatment|conventional treatment
223659217|NCT00005642|DRUG|semaxanib|This is a dose-deescalation study. Patients receive SU5416 IV over 1 hour twice weekly for 4 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity. Cohorts of 6-12 patients receive deescalating doses of SU5416 until the maximum target-inhibiting dose (MTID) is determined.
223659218|NCT03180632|DRUG|Lorazepam|Patient receives one or two tablet of 0,5mg Lorazepam according to body weight
223659219|NCT03180632|OTHER|Placebo|Patient receive one of two tablet of Placebo according to body weight
223659220|NCT03060122|DEVICE|NIN|The InterX device will be applied by a trained therapist along the course of the dermatomes in the affected area, paying special attention to the location of major cutaneous nerves ensuring optimal treatment points are identified and treated within the neurologically related area.
223659221|NCT03060122|DEVICE|Sham CES|The sham CES is identical to the regular device but ear clips will emit a dose at 100 mA, a sub-sensory level.
223659222|NCT03060122|DEVICE|CES|Cranial Electrical Stimulation (CES) Alpha-Stim is a noninvasive medical treatment device that delivers a microcurrent (100 to 500 microamperes) via ear clip electrodes connected to a handheld device.
223659223|NCT06326983|DRUG|Dexmedetomidine|Dexmedetomidine (1mcg/kg bolus given intravenously at induction of anesthesia
223659224|NCT06326983|DRUG|Acetaminophen|Acetaminophen (12.5mg/kg with a maximum dose of 1 gram given intravenously at induction of anesthesia).
223659225|NCT06326983|DRUG|Ketorolac|Ketorolac 0.5mg/kg with a max dose of 30mg intravenously at the end of surgery.
223659226|NCT06326983|DRUG|Morphine|Morphine (0.1mg/kg given intravenously at induction of anesthesia)
223659227|NCT02061839|OTHER|Sunscream with visible light protection|
223659228|NCT02061839|OTHER|Sunscream|
223659229|NCT02988284|OTHER|No intervention|
223659230|NCT02803346|OTHER|Circulating blood (leukocytes)|mHLA-DR measurement (in vitro)
223659231|NCT00380653|DRUG|sapacitabine|
223769017|NCT05246605|OTHER|change in body position|changing from supine to prone position and the back to supine
223659232|NCT04122352|OTHER|Ischemic compression|Ischemic compression was performed 3 times ; after the initial evaluation, after the first week evaulation and after the second week evaulations.
223659233|NCT04122352|OTHER|Exercises (Rocabodo's 6x6 exercises and posture exercises)|Rocabodo's 6x6 exercises exercise was shown to be administered for 4 weeks. After the first week evaluation, posture exercises are added to the exercise programs of the patients.
223659234|NCT05103852|PROCEDURE|Cardiac MRI|vigilant patient installed in the MRI with compatible ECG electrodes for synchronization and monitoring, blood pressure cuff for monitoring, cardiac antenna. Sterile drape over the femoral region, femoral local anesthesia, femoral venipuncture, Swan Ganz probe venous navigation (CE marking, MRI compatible at 1.5T) with balloon inflated with 2 cc of gadolinium, navigation under real time SSFP cine sequence.
223659235|NCT05636449|OTHER|Group Suprainguinal fascia iliaca block|After the operation is completed, the fascia iliaca will be separated from the iliacus muscle. With ultrasound guidance, the local anesthetic injection will be made between the fascia and the muscle.
223659236|NCT05636449|OTHER|Group Periarticular Infiltration|A total volume of 80 ml local anesthetic will be applied to the medial and lateral capsule, the medial and lateral meniscus margins, the deep part of the medial ligament, the medial and lateral synovial space, and the patellar ligament and quadriceps tendon.
223659237|NCT00002069|DRUG|Ditiocarb sodium|
223659238|NCT05295667|DIAGNOSTIC_TEST|Doppler measurement in combination with amniotic fluid volume|Ultrasonographic evaluation
223659239|NCT01156064|DEVICE|Confocal Laser Endomicroscopy (Pentax/Optiscan)|Confocal laser endomicroscopy is performed using the Pentax/Optiscan confocal endomicroscopy and 5 ml of 10% intravenous fluorescein sodium. Photos of magnified images of the digestive mucosa are taken during the procedure.
223659240|NCT01156064|DEVICE|Narrow Band Imaging/Auto Fluorescence Imaging (Olympus)|NBI/AFI endoscope offers an alternative light source involve NBI and AFI to view digestive mucosa in real time.
223659241|NCT01511120|DRUG|Tetraspan|
223659242|NCT01511120|DRUG|acetated Ringer's solution|
223659243|NCT01037764|PROCEDURE|alloHCT|"\[ alloHCT arm \] Bu-Cy conditioning; Busulfan (Bu) 3.2 mg/kg\*/day iv daily on days -7 and -4. Cyclophosphamide (Cy) 60 mg/kg\* in D5W 200 mL iv over 1-2 hours daily on days -3 and -2.~BuFluATG conditioning; Bu 3.2 mg/kg\*/day iv daily on days -7 and -6. Fludarabine (Flu) 30 mg/m2/day in D5W 100 ml iv over 30 minutes starting at 4 pm daily on days -7, -6, -5, -4, -3, and -2.~Anti-thymocyte globulin (ATG, Thymoglobulin, Genzyme Transplant, Cambridge, MA, USA) 1.5 mg/kg/day (for HLA-matched sibling HCT) or 3.0 mg/kg/day (for HLA-matched unrelated donor HCT or HLA-mismatched familial donor HCT) in N/S 500-800 ml (less than 4 mg/ml) iv over 4 hours starting at 8 am daily on days , -3, -2 and -1."
223659244|NCT00973817|BIOLOGICAL|ELAD plus standard of care treatment|Use of ELAD plus standard of care
223659245|NCT00973817|OTHER|Standard of care|Standard of care in the treatment of AOCH will be administered
223659246|NCT01732601|BEHAVIORAL|Intensive Outpatient CBT|Sessions will be delivered 1-2 times a week for the first 4-6 weeks, based on need, and then weekly until 6 months. Therapy can continue up until one year.
223659247|NCT01732601|BEHAVIORAL|Standard Care|Treatment at step-down facilities
223659248|NCT05730803|OTHER|dietary intervention|During the iodine balance period of pregnant women, seaweed was added to lunch on the 4-6 days of the experiment, and the iodine content was about 200 μg.
223659249|NCT00788177|DRUG|Pegaptanib (Macugen®)|Pegaptanib administered to the subretinal space (first dose) and to the vitreous cavity (following doses)
223659250|NCT01856218|DRUG|UX003|
223659251|NCT05011201|DEVICE|Dual Joint Visual Feedback without Scoring|Participants will walk on the treadmill while given instantaneous anterior and posterior foot position and immediate scoring information using the DJVF interface. A pediatric physical therapist will provide (1) verbal encouragement and redirection of attention to the task as needed (2) verbal cueing to assist if difficulty in interpreting the feedback and appropriate modification is noted.
223659252|NCT05011201|DEVICE|Dual Joint Visual Feedback with Scoring|Participants will walk on the treadmill using the same DJFB with additional visual cumulative scoring on their performance. A pediatric physical therapist will provide (1) verbal encouragement and redirection of attention to the task as needed (2) verbal cueing to assist if difficulty in interpreting the feedback and appropriate modification is noted.
223659253|NCT06010043|PROCEDURE|"Suturing of ileostomy using Dumpling suture method"|"Suturing of ileostomy using Dumpling suture method"
223659254|NCT06010043|PROCEDURE|Suturing of ileostomy using Traditional suture method|Suturing of ileostomy using Traditional suture method
223659255|NCT06317545|OTHER|Mulligan Taping|Mulligan taping involves the application of tape to the lateral aspect of the elbow to offload stress during movement of the extensor tendons.
223659256|NCT00700388|DEVICE|TPEP device (UNIKO)|This technique is mainly based on a continuous low-pressure insufflation in the airways, which is likely to reduce (or even avoid) the potential pressure-related damages of other commonly used devices. This device should be used only in those individuals who are showing a normal competence of their cough reflex, thus it should be considered as a means which may help those techniques normally adopted for the individual's bronchial hygiene.
223659257|NCT00700388|PROCEDURE|MABT (Manually assisted breathing techniques)|Conventionally manually assisted breathing techniques
223659258|NCT03718091|DRUG|M6620|M6620 is a drug designed to inhibit the ATR enzyme. Inhibiting ATR may block how cancers repair their naturally damaged DNA, handle cancer cell stress, and maintain cancer cell life and health.
223659259|NCT04581707|DEVICE|Kyphoplasty Single Balloon Catheter Allevo|Vertebral compression fractures treated with Kyphoplasty Single Balloon Catheter Allevo (Joline®) and BonOs® Inject bone cement
223659260|NCT04581707|DEVICE|Quattroplasty Double Balloon Catheter Stop'n GO|Vertebral compression fractures treated with Stop'n GO double balloon kyphoplasty system (Joline®) and BonOs® Inject bone cement
223659261|NCT03664349|DEVICE|SuperEar9000|Handheld hearing amplifier, not FDA regulated.
223659262|NCT02490670|DRUG|Cephalexin|Administered orally
223659263|NCT03618355|DRUG|eRapa (encapsulated rapamycin)|"The eRapa (encapsulated rapamycin) drug product consists of sub-micron rapamycin particles incorporated into poly(methyl methacrylate) polymer (Eudragit® L 100 / S 100).~This improved formulation and better bioavailability enables eRapa to consistently provide approximately 30% more drug than sirolimus (unpublished data). Improved and predictable delivery allows for consistent and sustained lower dosing, which will result in an improved toxicity profile since the latter is proven to be related to blood concentration levels. This is a phase Ib trial in low risk (Gleason score ≤7 (3+4)) prostate cancer patients under active surveillance to establish dosage safety and treatment levels."
223659264|NCT03792828|DRUG|Duloxetine HCl 30mg|In the duloxetine group, one capsule of Duloxetine HCl 30mg (Duroceptol) is taken orally and daily from the day before the first operation to seven days after the second operation. In the control group, the patients can take painkillers except duloxetine.
223659265|NCT03629275|COMBINATION_PRODUCT|CTX0E03 Drug Product and delivery device|Includes stereotactic surgery and a burr hole drilled through the skull to allow for a one time intracerebral injection of 20 million CTX0E03 Drug Product stem cells into an area of the brain adjacent to the area affected by the stroke.
223659266|NCT03629275|DRUG|Placebo|Sham surgical comparator includes stereotactic surgery and a partial thickness burr hole drilled into the skull. No injection of any kind is made into the brain, and no other intervention is given.
223659267|NCT03387527|BEHAVIORAL|Prostate cancer decision aid|Patients will undergo standardized counseling and individualized counseling with the screening decision aid. The screening decision aid is a computer program that provides individual patients estimates of their risks of prostate cancer diagnosis, prostate cancer related death, or death from any cause
223659268|NCT01121809|DRUG|Raltegravir|Changing the dose of raltegravir from 400 mg bid to 800 mg qd
223659269|NCT01121809|DRUG|Etravirine|Changing the dose of etravirine from 200 mg bid to 400 mg qd
223659270|NCT00543959|DRUG|MK0533|Initially a 12-wk study of MK0533 30mg, switching at week 12 to a study of daily administration MK0533 5mg, MK0533 15mg, MK0533 30mg. Study period is a total of 24-wks.
223659271|NCT00543959|DRUG|Comparator: Placebo (unspecified)|MK0533 Placebo; MK0533 5mg; MK0533 15mg; MK0533 30mg. Study period is a total of 24 wks.
223659272|NCT00543959|DRUG|Comparator: pioglitazone|pioglitazone 45mg. Study period is a total of 24 wks.
223659273|NCT01077921|DRUG|Propranolol|Treatment will be with a standard propranolol dose of 40 mg every 12 hrs.Each patient will participate in 6 weeks of treatment with placebo or study drug (propranolol), followed by a 2-week wash-out period and then 6 weeks of treatment with the other modality (placebo or propranolol).
223659274|NCT01077921|DRUG|Placebo|Treatment will be with a standard propranolol dose of 40 mg every 12 hrs.Each patient will participate in 6 weeks of treatment with placebo or study drug (propranolol), followed by a 2-week wash-out period and then 6 weeks of treatment with the other modality (placebo or propranolol).
223659275|NCT00474279|DRUG|Orally active growth hormone secretagogue (MK-677)|
223659276|NCT05667077|DRUG|Amantadine|The amantadine group is treated with amantadine capsules 100mg twice a day for two weeks
223659277|NCT03637088|DEVICE|Simulated Altitude (FiO2: 15.1%)|"Inhalation of deoxygenated air through a altitude simulator (Altitrainer), for approx. 1 hour. given by a facemask."
223659278|NCT03637088|DEVICE|Shamed Hypoxia (FiO2: 20.9)|"Inhalation of unmodified air through an altitude simulator (Altitrainer) for approximately 1 hour given by a facemask"
223769018|NCT06849830|BEHAVIORAL|Narrative Medicine (NM) Workshop Series|"The Narrative Medicine (NM) Workshop Series is a structured six-week behavioral intervention designed to enhance self-expression, reflection, and resilience in adolescents and young adults recovering from eating disorders. This intervention differs from traditional psychotherapeutic or psychoeducational approaches by integrating literary analysis, creative writing, and guided discussion as therapeutic tools.~Each one-hour weekly workshop includes:~* Close reading of visual or written texts related to themes such as self-definition, resilience, kindness, and possibility~* Creative writing exercises in response to structured prompts that encourage self-reflection and personal storytelling~* Facilitated group discussions to foster connection, self-expression, and emotional processing in a supportive environment"
223769019|NCT04958694|BEHAVIORAL|CEDARS|This intervention is intended to help adolescents cope with stress and improve positive affect.
223769020|NCT04875520|OTHER|Screening testing strategy|The intervention we are evaluating is the use of weekly screening testing among students and staff.
223769021|NCT04875520|OTHER|No screening testing strategy|a group of schools will not receive screening testing.
223769022|NCT06461572|OTHER|conventional therapy|This group will receive conventional physiotherapy, which will consist of manual resistance-based neck strengthening exercises. The exercises will last 30 minutes apiece and cover cervical flexion, extension, side flexion, side flexion with rotation, and pure rotation with moderate resistance. The power ball's effect on proximal muscle control and refractive error in children with developmental delays will also be discussed.
224240822|NCT03116386|DEVICE|Control period|neither activation of any lighting environment when the resident gets up from his bed nor alert if the resident did not return to bed after 15 minutes Etolya-F ® devices will only permit detection and recording of the moment of the elderlly will leave his/her bed and recording of the moment the elderly will be found by caregivers
223769023|NCT06461572|OTHER|conventional therapy along with standard therapy and stability exercises.|"Group B: In addition to standard care, this group will engage in power ball exercises for neck stability and strengthening. Gradually, the resistance will rise.~Three mints in each position for a total of fifteen mints of ball exercises. At first, Powerball progressively strengthened the muscle and reduced the pain , and with continued development, allowed them to move in a pain-free range."
223769024|NCT02791334|DRUG|LY3300054|Administered IV
223769025|NCT02791334|DRUG|Ramucirumab|Administered IV
223769026|NCT02791334|DRUG|Abemaciclib|Administered orally
223769027|NCT02791334|DRUG|Merestinib|Administered orally
223769028|NCT02791334|DRUG|LY3321367|Administered IV
223659279|NCT04825470|PROCEDURE|Liver Transplantation|Liver Transplantation
223659280|NCT04183361|DIAGNOSTIC_TEST|ABR and salivary cortisone testing|"Three saliva samples at the workplace will be collected immediately after the morning shift. The first saliva sample was given 3 days (Tuesday) before arrival at the research place, the second sample 2 days (Wednesday) before arrival, and the third sample 1 day (Thursday) before arrival at the research site. One hour before saliva sampling, a respondent should not brush his/her teeth nor eat nor drink. Fifteen minutes prior to sample administration, the subject should rinse his/her mouth with a cold water. Samples will be analyzed using High Performance Liquid Chromatography (HPLC) at the Translational Medicine Division of the Srebrnjak Children's Hospital.~2\. Collaboration in the process of assessing hearing health at the research place. The assessment includes: otoscopy, tympanometry and audiometry. Subjects will be tested for auditory evoked brainstem response in only one ear, with a more regular hearing threshold."
223769031|NCT05889286|DRUG|[F-18]MHF|Following intravenous injection of 10 ± 2 mCi (370 ± 74 MBq) \[F-18\]MHF as a bolus, dynamic PET imaging of the lower limbs will be acquired for approximately 90 minutes. The acquired images will be processed. The uptake pattern of \[F-18\]MHF around infected orthopedic knee implant will be determined and compared with its uptake pattern around non-infected knee implants.
223769032|NCT05971758|DRUG|Fimepinostat|The study will allow us to determine the efficacy and safety of these doses in the treatment of Cushing Disease (CD) and guide dose selection for subsequent, larger studies.
223769033|NCT05151809|OTHER|Clinical information|The investigators will recruit PBC patients and collect important clinical information and laboratory investigation, together with biological samples.
223769034|NCT04793698|OTHER|Compassion meditation|10 week meditation course taught in 90-minute groups
224240823|NCT03116386|DEVICE|Etolya-F ® devices|Etolya-F ® devices will permit detection of absence in the bed, activation of a lighting environment when the resident gets up from his bed, transmission of alert to caregivers through the centralized system of sick call if the resident do not return to bed after 15 minutes and recording the time when caregivers will find the resident out of bed, distinguishing between a fall and a night wandering in the room or corridors without a fall
224240824|NCT05857332|DRUG|SG1906|Phase 1a will use an accelerated titration-Bayesian optimal interval (AT-BOIN) design with 7 dose cohorts: 0.1 mg/kg, 0.3 mg/kg, 1 mg/kg, 3 mg/kg, 6 mg/kg, 9 mg/kg, and 12 mg/kg by IV infusion. Accelerated titration (i.e., 1 patient each) will be applied to the first 2 cohorts.
223769035|NCT04793698|BEHAVIORAL|Applied relaxation|10 week applied relaxation course taught in 90-minute groups
223769036|NCT06556680|DEVICE|Optical coherence tomography|In the OCT-guided biopsy arm, n=100 study subjects will be enrolled. The investigators will conduct biopsies and imaging using our newly developed OCT catheters and real-time image processing and display algorithms.
223769037|NCT05371054|DEVICE|Vysis LSI MYC Break Apart Rearrangement Probe Kit|MYC rearrangement fluorescence in situ hybridization (FISH) testing is performed using the Vysis LSI MYC Break Apart Rearrangement Probe (Abbott Molecular, Inc.) in the Chromosome Pathology Section, Laboratory of Pathology, Center for Cancer Research (CCR), National Cancer Institute (NCI). This kit is not Food and Drug Administration (FDA) approved. It is being used as a treatment determining in-vitro diagnostic device in this study.
224240825|NCT03486613|OTHER|PROM registration via the DANBIO App on a smartphone|PROM data is reported through the DANBIO smartphone app
224240826|NCT03486613|OTHER|PROM registration via the touch screen solution|PROM data is reported through the touch screen solution
223659281|NCT03443583|OTHER|Immediate Dentin Sealing or Delayed Dentin Sealing|The main difference between the IDS and DDS technique lies in the fact that in IDS, a thin layer of bonding resin is applied immediately after tooth preparation and prior to impression taking, whereas in DDS this layer is applied immediately before cementation of the restoration.
223659282|NCT05172583|BEHAVIORAL|Control|The control groups will receive the nursing interventions that are performed daily in the adult ICU. These are orientation in time, space, and place, accompaniment of the family for two hours in the morning and two hours in the afternoon, physical therapy once a day according to the patient's condition, medication with conscious sedation, and progressive reduction analgesics. opioids and benzodiazepines.
223769038|NCT05371054|DRUG|Venetoclax|"Dose Escalation: Administered orally, days 1-10, per specified dose level; every 21 days for up to 24 cycles, or until disease progression or unacceptable toxicity.~Dose Expansion: Administered orally, days 1-10, at the recommended phase 2 dose (RP2D); every 21 days for up to 24 cycles, or until disease progression or unacceptable toxicity"
223769039|NCT05371054|DRUG|VIP152|"Dose Escalation: Administered intravenously, days 2 and 9, per specified dose level; every 21 days for up to 24 cycles, or until disease progression or unacceptable toxicity.~Dose Expansion: Administered intravenously, days 2 and 9, at the recommended phase 2 dose (RP2D); every 21 days for up to 24 cycles, or until disease progression or unacceptable toxicity."
223769040|NCT05371054|DRUG|Prednisone|Administered orally, days 1-10, at a dose of 100 mg; every 21 days for up to 24 cycles, or until disease progression or unacceptable toxicity
223769041|NCT05371054|DIAGNOSTIC_TEST|PET|Screening, pre-cycle 7, pre-cycle 13, and at end-of-treatment (post-cycle 24).
223769042|NCT05371054|DIAGNOSTIC_TEST|EKG|Screening
224240827|NCT03435198|DIAGNOSTIC_TEST|Collect exhaled breath during low and normal blood sugar|Collect exhaled breath during low and normal blood sugar to determine if there are any differences between the two in people with type 1 diabetes.
223769043|NCT05371054|DIAGNOSTIC_TEST|ECHO|Screening
223769044|NCT05371054|DIAGNOSTIC_TEST|CT neck chest, abdomen, and pelvis|Screening, pre-cycle 2, pre-cycle 3, pre-cycle 5, pre-cycle 7, pre-cycle 9, pre-cycle 11, pre-cycle 13, pre-cycle 15, pre-cycle 17, pre-cycle 19, pre-cycle 21, pre-cycle 23, and at end-of-treatment (post cycle 24).
223769045|NCT05371054|DIAGNOSTIC_TEST|MRI|As indicated. Screening, pre-cycle 2, pre-cycle 3, pre-cycle 5, pre-cycle 7, pre-cycle 9, pre-cycle 11, pre-cycle 13, pre-cycle 15, pre-cycle 17, pre-cycle 19, pre-cycle 21, pre-cycle 23, and at end-of-treatment (post cycle 24).
224240828|NCT03054103|DRUG|Midazolam + Ketamine 10 MG/ML: 0.5 ML|5 mg ketamine IV given just prior to onset of case. Then titrated midazolam up to 2 mg IV at beginning and during case.
224240829|NCT03054103|DRUG|Midazolam + Ketamine 10 MG/ML: 1 ML|10 mg ketamine IV given just prior to onset of case. Then titrated midazolam up to 2 mg IV at beginning and during case.
224240830|NCT03054103|DRUG|Midazolam + Normal saline|Preoperative control: Normal saline placebo given preoperatively. Then protocol followed for titration of midazolam up to 2 mg IV at beginning and during case.
224240831|NCT03708913|DEVICE|Hypothalamic Deep Brain Stimulation|One-year continuous hypothalamic deep brain stimulation
223769046|NCT05371054|PROCEDURE|Bone marrow aspiration/Biopsy|Baseline, post-cycle 6, post-cycle 12, and at end-of-treatment (post-cycle 24).
223769047|NCT04016870|DEVICE|Reconditioned Pacemaker|Devices from the three manufacturers below will be used.
223769048|NCT04016870|DEVICE|New Pacemaker|Devices from the four manufacturers below will be used.
223769049|NCT06472206|BEHAVIORAL|CHW Sessions|Sessions with a Community Health Worker (CHW).
223769050|NCT06472206|DEVICE|CleverCap|The CleverCap pill bottle is an innovative technology that dispenses only the prescribed amount of medication, keeps track of medications dispensed, and communicates wirelessly with the WiseApp to deliver medication adherence reminders.
223769051|NCT06228079|DRUG|Immunotherapy,Toripalimab Injection|Patients in the experimental group would be implemented with adjuvant Immunotherapy and chemotherapy after endoscopic surgery. Four to six cycles chemotherapy and 10 cycles immunotherapy,or until unacceptable side effects.
223769052|NCT06228079|DRUG|Chemotherapy,Gemcitabine based regimen|Patients in the experimental group would be implemented with adjuvant Immunotherapy and chemotherapy after endoscopic surgery. Four to six cycles chemotherapy and 10 cycles immunotherapy,or until unacceptable side effects.
223769053|NCT05768867|OTHER|FRAnçaise du PEYronie's Disease QUESTionnaire|Complete an online FRAnçaise du PEYronie's Disease QUESTionnaire
223769054|NCT05773287|BEHAVIORAL|Targeted Health Coaching Group|Participants in the THC group will receive an exercise prescription (steps/day) based on their last cardiac rehabilitation session exercise prescription. Participants will be provided a Garmin wearable device to track steps/day. Additionally, participants will partake in 6 virtual or in-person health coaching sessions lasting approximately 30-60 minutes in duration. These sessions will take place approximately every other week during the 3-month intervention period.
223769055|NCT05773287|BEHAVIORAL|Standard Care Group|Participants in the SC group will receive an exercise prescription (steps/day) based on their last cardiac rehabilitation session exercise prescription. Participants will be provided a Garmin wearable device to track steps/day. Additionally, participants will be provided with a single virtual or in-person education session, lasting approximately 30 minutes, at the beginning of the 3-month intervention period.
224240832|NCT01369277|DRUG|PF-04991532|Single dose administration of PF-04991532 (100 mg, 300 mg and 750 mg) in tablet formulation under fasted condition.
224240833|NCT01369277|DRUG|Placebo|Single dose administration of matching placebo in tablet formulation at the fasted state
224240834|NCT01369277|DRUG|PF-04991532|Single dose administration of PF-04991532 (300 mg and 750 mg) in tablet formulation under fasted condition.
224240835|NCT02343120|DRUG|Zanubrutinib|Oral administration by capsule
224240836|NCT01872143|DEVICE|transcranial Direct Current Stimulation|daily or twice-a-day administration of transcranial Direct Current Stimulation from a minimum of 10 session to a maximum of 20
224240837|NCT00413556|BIOLOGICAL|ALK Grass tablet|
224240838|NCT01986582|DRUG|Oxymetazoline|Intranasal application
224240839|NCT01986582|OTHER|Hydroxyl-propyl-methyl cellulose powder|Intranasal application
224240840|NCT01986582|OTHER|Placebo (lactose powder)|Intranasal application
224240841|NCT01930461|BIOLOGICAL|SLIT tablets of HDM allergen extracts, 3 different doses (A)|Two sublingual tablets daily for 13 months
224240842|NCT01930461|BIOLOGICAL|SLIT tablets of HDM allergen extracts, 3 different doses (B)|Two sublingual tablets daily for 13 months
223769056|NCT01801787|DEVICE|tDCS|active vs. sham tDCS left hemisphere
223769057|NCT01350128|DRUG|PT001 MDI|PT001 MDI administered as two puffs BID for 7 days
223769058|NCT01350128|DRUG|Ipratropium Bromide HFA Inhalation Aerosol|Taken as 2 inhalations of the 17 µg per actuation strength MDI QID
223769059|NCT01350128|OTHER|Placebo MDI|Matching placebo to PT001 MDI administered as two puffs BID for 7 days
223769060|NCT05388942|PROCEDURE|Virtual reality hypnosis|VRH offers predefined hypnosis sessions with no need of trained physician or nurse or caregiver mobilization. Consisting of a headset including headphones and a virtual reality screen, VRH allow patients to select a visual and sound environment (e.g.: tropical beach, space, underwater…) into which the hypnotic speech is delivered. That way, the patient's attention is distracted and muscular relaxation is obtained, a major relaxation factor. HRV is simple, quick, and presumably safe.
223769061|NCT05388942|DRUG|Nitrous oxide|inhalation of NO usually used to help with ASD reduction but inhaled NO has safety and maintenance issues.
223769062|NCT04199299|DEVICE|Heart rate and respiration rate sensors|The use of sensors to monitor physiological variables (e.g. heart rate, sleep). The design is a before-and-after comparison with respect to whether the use of sensors has changed the caregivers' practice and their (perceived) understanding of the participant. The frequency of participants' self harm or aggressive behavior after as compared to before the introduction of pulse- and respiration monitors will also be charted.
223769063|NCT05651009|PROCEDURE|TKA|Total knee artroplasty with medial parapatellar incision and mechanical alignment without navigation
224240843|NCT01930461|BIOLOGICAL|SLIT tablets of HDM allergen extracts, 3 different doses (C)|Two sublingual tablets daily for 13 months
224240844|NCT01930461|BIOLOGICAL|Placebo matching the SLIT tablets of HDM allergen extracts|Two sublingual tablets daily for 13 months
224240845|NCT00018447|DRUG|PTH 1-34|
223769064|NCT03592329|BEHAVIORAL|Stress Reduction Training A|"twice weekly booster sessions and weekly instructor-led sessions for 8 weeks plus home practice sessions"
223769065|NCT03592329|DEVICE|active tVNS|non-painful electrical stimulation of the auricle
223769066|NCT03592329|BEHAVIORAL|Stress Reduction Training B|"twice weekly booster sessions and weekly instructor-led sessions for 8 weeks plus home practice sessions"
223769067|NCT03592329|DEVICE|sham tVNS|sham stimulation
223769068|NCT02762669|DRUG|Oxytocin|Oxytocin, 10-7mol/L to 10-5mol/L
223769069|NCT04548674|OTHER|Whiteness HP 35%|Single application of 45 minutes on the buccal surfaces of third molars, with an average thickness of 1 mm
224240846|NCT00018447|DRUG|MFPSR-fluoride|
224240847|NCT00252551|PROCEDURE|Osteosynthesis|
224240848|NCT00252551|PROCEDURE|Simple surgery|Surgery without device
224240849|NCT03266237|DRUG|Vaxigrip®|To describe the humoral immune response to Vaxigrip (IM) vaccination at Day 0 (baseline) and Day 28 according to the age and frailty status at baseline (i.e. in each study group) for each Influenza strain.
224240850|NCT03120117|PROCEDURE|Cough Test following Sling Surgery|Enrolled subjects will undergo sling surgery who present with stress-dominated urinary incontinence. While in the operating room, the subject will be asked to stand and cough to determine if there is still leakage once the sling has been placed.
224240851|NCT06037200|DEVICE|Urin-based test by the DOASENSE Dipstick Device|Routinely assessed urine is tested by the DOASENSE Dipstick device for presence of direct oral anticoagulants. Readout is performed after 10 minutes visually and by a automated reader.
224240852|NCT04318561|DIAGNOSTIC_TEST|Gallium-68 NODAGA-LM3 PET/CT|Twenty patients will take this intervention. They will be further divided into two sub-groups with the same interventional radiopharmaceutical (Gallium-68 NODAGA-LM3) but different scanning protocols (Protocol A and Protocol B). The first enrolled 8 patients will go with Protocol A, who will undergo serial whole-body PET/CT scans at multiple time points (5m, 10m, 20m, 40m, 1h, 2h) after administering 40ug/150-200MBq Gallium-68 NODAGA-LM3. Baseline safety assessment will be conducted right before the study. The following 12 patients will go with Protocol B, who will undergo a whole-body PET/CT scan at 1 hour after administering 40ug/150-200MBq Gallium-68 NODAGA-LM3.
224240853|NCT04318561|DIAGNOSTIC_TEST|Gallium-68 DOTA-LM3 PET/CT|Twenty patients will take this intervention. They will be further divided into two sub-groups with the same intervention radiopharmaceutical (Gallium-68 DOTA-LM3) but different scanning protocols (Protocol C and Protocol D). The first enrolled 8 patients will go with Protocol C, who will undergo serial whole-body PET/CT scans at multiple time points (5m, 10m, 20m, 40m, 1h, 2h) after administering 40ug/150-200MBq Gallium-68 DOTA-LM3. Baseline safety assessment will be conducted right before the study. The following 12 patients will go with Protocol D, who will undergo a whole-body PET/CT scan at 1 hour after administering 40ug/150-200MBq Gallium-68 DOTA-LM3.
224240854|NCT04318561|DIAGNOSTIC_TEST|Gallium-68 DOTATATE PET/CT|All patients have to do a Gallium-68 DOTATATE PET/CT scan (40ug/150-200MBq, 1h post-injection) for comparison on the next day of LM3 scan. Safety assessment and tolerability of the previous LM3 study will be conducted right before the study.
224240855|NCT02348268|OTHER|Manual Therapy|The manual therapy techniques included: (i) anterior-posterior and side-shift of the cervical spine; (ii) muscle energy technique involving side-bending of cervical spine; (iii) neuromuscular technique for restricted C1-C2 rotation; (iv) inhibitive occipital distraction; and (v) cervical stretching: post-isometric relaxation for the upper trapezius, scalene and sternocleidomastoid muscles.
224240856|NCT02348268|OTHER|Myofascial Release Therapy|The myofascial release therapy techniques included: (i) cranial base release, adjusting the relation of the rectus capitis posterior muscles to the dura mater; (ii) gross release of the sternocleidomastoid muscle; (iii) release of the suprahyoid and infrahyoid muscles; and (iv) release of the retrohyoid fascia.
224240857|NCT02348268|DEVICE|Analgesic therapy|Analgesic therapy consisted of superficial thermotherapy by an infrared lamp (Infra 2000, Enraf Nonius) and TENS (TENSMED 911, Enraf Nonius). The 250-watts infrared lamp was focused at a distance of 50 cm on the cervical area for 15 minutes. TENS employed 80 Hz frequency, 150 µs pulse duration, with 50x50 mm electrodes (Gel-Trode, Enraf Nonius) placed on the painful or metamers areas for 20 minutes.
224240858|NCT01993875|DRUG|Lubiprostone|Liquid formulation, 12 mcg x 2 pumps administered orally twice daily (BID)
224240859|NCT01993875|DRUG|Placebo|Matching liquid placebo, 0 mcg x 2 pumps administered orally twice daily (BID)
223659283|NCT05172583|BEHAVIORAL|Interventions to reduce delirium based on DSM and scientific evidence|The interventions are designed from the structure of the Dynamic Symptoms Model (DSM), taking into account the antecedents of delirium, physiological such as the medical condition of mechanical ventilation and pain, and drug treatment with sedatives and analgesics; the psychological, social, and spiritual antecedents with stimulation in the values, life experience, personality and spirituality, and the environmental antecedents with an adaptation of the physical conditions of the ICU. In addition, previous experience with identification and care of concomitant symptoms such as fear, confusion, restlessness, loneliness, and discomfort, and with the measurement and classification of the trajectory of delirium when it occurs, will also be considered. The interventions follow the scientific evidence, mainly from the ABCDEF bundle. All interventions are non-pharmacological.
224240860|NCT02534493|DEVICE|Carpal Tunnel Tissue Manipulation Device (CTMD)|This piece of rigid, shaped, biocompatible plastic (polypropylene) rated for skin contact and a strong but safe hypoallergenic biocompatible medical adhesive which bonds the skin over the carpal tunnel to the plastic piece for a duration of 2-14 hours.
223659284|NCT00648050|DRUG|Verapamil Hydrochloride Extended-Release Capsules, 300 mg|300mg, single dose fasting
223659285|NCT00648050|DRUG|Verelan® PM Extended-Release Capsules, 300 mg|300mg, single dose fasting
224240861|NCT04578470|DRUG|Vitamin D|Daily 2000 IU cholecalciferol(two tablets) for 13 weeks,and daily 1000 IUcholecalciferol(1 tablet) foranother 13 weeks.
223659286|NCT06308705|DIAGNOSTIC_TEST|InBios Strongy Detect TM IgG ELISA|The InBios Strongy Detect TM IgG ELISA detects specific IgG antibodies to Strongyloides recombinant antigens NIE and SsIR in serum. It consists of an enzymatically amplified sandwich-type immunoassay. Positive and negative control samples are provided in the kit. The test will be run and interpreted according to the manufacturer's instruction. The results are expressed as OD and nOD. Clinical interpretation of the results will be done by analysis of the Receiver Operating Characteristics (ROC) curve generated using data from confirmed positive and confirmed negative samples.
223659287|NCT04009564|DIETARY_SUPPLEMENT|Date coffee|45 g of date seeds coffee in 280 ml of water
223659288|NCT04009564|DIETARY_SUPPLEMENT|Normal coffee|6 g of normal coffee in 280ml of water
223659289|NCT04009564|DIETARY_SUPPLEMENT|Placebo|water, food colouring and coffee flavouring
223659290|NCT01460511|DRUG|E004 (Epinephrine Inhalation Aerosol) HFA-MDI|E004 (Epinephrine Inhalation Aerosol) HFA-MDI, 125 mcg/inhalation, 2 inhalations QID
223659291|NCT01460511|DRUG|Placebo-HFA|Placebo-HFA, 0 mcg/inhalation, 2 inhalations QID
223659292|NCT01256294|DRUG|Generic Tacrolimus|Generic Sandoz tacrolimus supplied as capsules of 0.5 mg, 1 mg and 5 mg dose strengths.
223659293|NCT01256294|DRUG|Branded Tacrolimus|Capsules supplied at dose strengths of 0.5 mg, 1 mg, and 5 mg.
223659294|NCT02160899|DRUG|ISIS-APO(a)Rx|ISIS-APO(a)Rx subcutaneously: 100 mg on Days 1, 8, 15, and 22; 200 mg on Days 29, 36, 43, and 50 unless down-titrated; and 300 mg on Days 57, 64, 71, and 78 unless down-titrated.
224321192|NCT00658879|DRUG|Somavert (Pegvisomant)|"Somavert (Pegvisomant) 10, 15 or 20mg powder and solvent for solution for injection.~Dosage, Frequency : According to Japanese LPD.~Duration : According to the protocol of A6291023, the duration of the investigation for findings regarding safety and efficacy of a patient is from the first drug administration to the 5 years after the first administration."
223659295|NCT02160899|DRUG|Placebo|Normal saline as Placebo, subcutaneously on Days 1, 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78.
223659296|NCT06335745|BEHAVIORAL|PediCARE Intervention|A household material hardship intervention with monthly, direct provision of groceries and transportation. Resources will be centrally administered by the Dana-Farber Cancer Institute study team.
223659297|NCT03625843|BEHAVIORAL|Mindfulness exercises|
223659298|NCT00250198|DRUG|STA-5326|
223659299|NCT03293901|BEHAVIORAL|Exercise|Treadmill exercise for 60 minutes with load carriage (weighted vest, 30% body weight) completed three times during the 6 day kinetic period.
223659300|NCT05466370|BIOLOGICAL|Transfusion of Allogeneic Blood|Transfusion of Allogeneic Blood
223659301|NCT00749710|PROCEDURE|clopidogrel|ORIF - surgical treatment
223659302|NCT00749710|PROCEDURE|no antiaggregant therapy|ORIF - surgical treatment
223659303|NCT03776370|PROCEDURE|Preserve the left colonic artery|Preservation of left colonic artery in rectal cancer surgery.
223659304|NCT03776370|PROCEDURE|The left colonic artery is not preserved|The left colonic artery was dissected in rectal cancer surgery.
223659305|NCT03896256|DRUG|ketamine infusion|Ketamine will be used in subanesthetic doses for patients with refractory chronic migraine to see if it improves pain after a 5-day continuous infusion.
223659306|NCT05761717|DRUG|Neoantigen mRNA Personalised Cancer vaccine in combination with Stintilimab I njection|Subcutaneous Injection
223659307|NCT01876940|DEVICE|air-Q, followed by fiberoptic intubation|
223659308|NCT01876940|DEVICE|Free-hand Fiberoptic Intubation|Fiberoptic tracheal intubation will be performed without use of the air-Q and timed. Laryngeal grade of view will also be assessed
223659309|NCT03649308|DEVICE|Negative Pressure Wound Therapy|An immediate mobilization and negative pressure wound therapy (PICO) initiated after surgery.
223659310|NCT03649308|PROCEDURE|Conventional treatment|Traditional treatment with conventional wound dressing and 5 days of immobilization after surgery.
223659311|NCT01368562|DRUG|Methylnaltrexone|Methylnaltrexone will be administered as per the dose and schedule specified in the arm.
224240862|NCT04578470|DRUG|Placebo|two tablets daily for 13weeks then 1 tablet daily for13 weeks
224240863|NCT00002027|DRUG|Diclazuril|
224240864|NCT01662466|DRUG|Testosterone cream (0.5mg per gram)|Testosterone cream 2 gms per day applied transdermally to the left wrist to deliver 1.mg daily dose with estimated absorption of 100 ug per day testosterone
224240865|NCT01662466|DIETARY_SUPPLEMENT|DHEA|DHEA 25mg tid
224240866|NCT01662466|DRUG|Placebo|Carrier cream without added testosterone in the identical type of pump
224321193|NCT04290143|OTHER|Colored healing water|Patients will be treated with colored healing water for 20 minutes.
224321194|NCT04290143|OTHER|Placebo treatment (colored tap water)|Patients will be treated with colored tap water for 20 minutes.
224321195|NCT03647670|DRUG|PF-04965842|orally bioavailable small molecule that selectively inhibits JAK1 by blocking the adenosine triphosphate (ATP) binding site.
224321196|NCT03647670|DRUG|Midazolam|substrate which undergoes extensive metabolism by CYP3A4 and CYP3A5 and acts as a sensitive probe for evaluating drug interaction with respect to these isoenzymes
223659312|NCT05402605|PROCEDURE|ICSI with AOA|"Step 1: All post-ICSI oocytes will be added in the medium drop in AOA dish, these oocytes will be placed in the incubator at 37oC, 6% CO2, and 5% O2 for 20 minutes.~Step 2: After 20 minutes, calcium ionophore stock (Sigma-Aldrich - USA) will be diluted into 10µM drops in AOA dish.~Step 3: After 10 minutes of incubation, all post-ICSI oocytes will be moved to the AOA drop, then this dish will be put back in the incubator for 10 minutes.~Step 4: After 10 minutes, all the oocytes in drop AOA will be moved to another drop for rinsing and then put back in the incubator for 20 minutes.~Step 5: After 20 minutes, the oocytes will be moved into drop AOA and then put back in the incubator for 10 minutes.~Step 6: After 10 minutes, all post-ICSI oocytes will be added in the medium drop, then divided into drops with maximum 3 oocytes per drop for culturing. After that, the culture dish will be put in the K-system G185 incubator at 37oC, 6% CO2, and 5% O2"
223659313|NCT05402605|PROCEDURE|ICSI without AOA|Conventional ICSI procedure will be performed without the application of AOA.
223659314|NCT00771862|PROCEDURE|perineural ropivicaine|Subjects will be randomized to one of two groups: ropivicaine 0.2% infusion for days 0-1 then infusion with normal saline (placebo) for days 1 through catheter removal (POD 4 or 5) or ropivicaine 0.4% infusion for day 0 through catheter removal (POD 4 or 5). The infusion rate will be set at 7-11 mL/h.
223769070|NCT04548674|DEVICE|Whiteness HP 35% + LASER|A dose of LASER (60 J / cm2, for 16 seconds) was applied at two points, one point in the cervical region and another in the center of the buccal surface of the third molars, using visible infrared LASER therapy (Photon III / DMC, São Carlos, SP, Brazil), with a wavelength of 808 nm, and AsGaAl, as an active medium.
223769071|NCT04548674|OTHER|Whiteness HP 35% + CPP|Topical application of casein phosphopeptide amorphous calcium phosphate fluoride CPP-ACPF (My Paste Plus, Recaldent, GC, USA) with the aid of a microbrush (KG Sorensen, SP, Brazil) in a passive way for 5 minutes.
223769072|NCT04548674|OTHER|Whiteness HP 35% + NANO|A topical application of nanohydroxyapatite (Nano P FGM, SC, Brazil) was performed with the aid of a microbrush (KG Sorensen, SP, Brazil) in a passive way for 5 minutes after teeth whitening.
223769073|NCT06483269|PROCEDURE|PRP infiltration|"a single intra-articular infiltration of 5 mL of PRP-O will be performed by the infiltrating physician.~It is specified that the PRP-O used within the study will be produced following the guidelines and standards for the production of blood products for non-transfusion use as already in place at the Unified Metropolitan Transfusion Service IOR site.~PRP (Platelet Rich Plasma) is produced from platelet pool from donor buffy coat.~PRP contains 1,000,000 PLT/mml +/- 20%, as required by current regulations."
224240867|NCT05060900|PROCEDURE|Ligament Reconstruction with Allograft Ligament|Patients will undergo surgery for hand and wrist ligament reconstruction using allograft ligament.
224321197|NCT05620537|OTHER|observation|There are no interventions.
224321198|NCT01727037|PROCEDURE|Bronchoscopic intrabullous autologous blood instillation|
224240868|NCT02158832|DEVICE|Acupuncture + Electrical Stimulation|"2 acupuncture needles are inserted into the upper back. 10Hz, 0.5ms biphasic square wave electrical pulses are applied to needles x20 mins. Current \>sensation threshold \& maintained at a level that is comfortable/painless \& does not elicit skeletal muscle contractions (\~5mA, \<10mA).~Needle locations are in the vicinity of nerves that supply the affected upper limb:~EX-B1': Affected hemisphere, 1.5cm lateral to C5 spinous process. Insertion angle: shallow, 'inferior-lateral', \~15⁰ perpendicular to the skin, \~15⁰ lateral to the midline. Depth: \~1.5 cm (secure anchorage).~EX-HN15': Affected hemisphere, 1.5cm lateral to the C7 spinous process. Insertion angle: shallow, 'inferior-medial' \~15⁰ perpendicular to the skin, \~15⁰ medial. Depth: \~1.5 cm (secure anchorage)."
224240869|NCT05190510|OTHER|Data collection|Collection of data from preoperative imaging examinations (routine examination prescribed before the operation)
224321199|NCT00524966|PROCEDURE|Bipolar Versus Ultrasonic Hemostasis Techniques|OUTLINE: Patients undergoing thyroidectomy for thyroid cancer, thyroid nodules, hyperthyroidism and goiter will be randomized to either bipolar energy sealing system or ultrasonic coagulation.
223659315|NCT00948220|DRUG|peginterferon alfa-2a and ribavirin|standard antiviral therapy with peginterferon alfa-2a 180 µg/week and ribavirin 1000-1200 mg/d
223659316|NCT05828004|BEHAVIORAL|Whole-Course Multidisciplinary Care Intervention|On the basis of standard treatment, all patients were evaluated by senior practice nurses in the Department of Oncology in person at the time of enrollment (before radiotherapy) and once every week during radiotherapy, and once in person/over the phone at 1, 2, 3, and 6 months after radiotherapy.
223659317|NCT00558688|PROCEDURE|Photodynamic therapy|Photodynamic therapy applied to actinic keratoses
223659318|NCT01293227|PROCEDURE|Surgical treatment of distal radius fractures|Surgical repair of distal radius fracture using either intramedullary locked nail or volar locked plate
223769074|NCT01112384|DRUG|SB939|Given orally 3 times per week
223769075|NCT05548192|DEVICE|SmartPICC-1 System|The SmartPICC system is indicated for use as an alternative method to chest x-ray or fluoroscopy confirmation of PICC tip placement in adult patients when proper ECG detection is available. The SmartPICC system provides a supplemental intravascular ionic dilution feature that provides qualitative blood flow information to the user to aid catheter navigation during PICC placement.
223769076|NCT04474652|OTHER|Single Blood Draw from each participant|Health Professionals will seek informed consent and take a single blood collection from the participant. This will take place during the patient's visit to the breast one stop clinic as part of their routine urgent breast referral pathway.
223769077|NCT01015352|DRUG|Azacitidine|Azacitidine 75mg/sqm SQ per day for 5 days every 28 days
223769078|NCT01015352|DRUG|Epoetin beta|"Epoetin beta : 60000U weekly SQ injections~NeoRecormon®"
223769079|NCT01495481|DRUG|Dexmedetomidine|Dexmedetomidine 2 mcg/kg, Intravenous push
224240870|NCT05190510|PROCEDURE|collection of the carotid plaque (surgical specimen)|collection of the carotid plaque
224321200|NCT04317079|DIETARY_SUPPLEMENT|Hydroxytyrosol|Administration of hydroxytyrosol in doses 15mg and 5 mg compared to placebo for 6 months
224321201|NCT04317079|OTHER|Diet|Consultation by a dietitian was offered to all participants
224321202|NCT05624398|DEVICE|Vivity IOL|Cataract surgery with implantation of the Vivity IOL along with concurrent implantation of the Hydrus Microstent
224321203|NCT01121562|DRUG|Sunitinib|Sunitinib capsule will be given orally at continuous daily dosing with a dose of 37.5 mg in the morning (regardless fasting or non-fasting, One cycle will be 28days)
224240871|NCT05190510|OTHER|anatomopathological, histological, cellular and molecular biology examinations (metabolomics and transcriptomics) on surgical specimens|anatomopathological, histological, cellular and molecular biology examinations (metabolomics and transcriptomics) on surgical specimens
223659319|NCT06243523|BEHAVIORAL|The stress management psychoeducation program based on Neuman's Systems Model|The stress management psychoeducation program will be implemented in six sessions with individual interviews lasting approximately 45-60 minutes, three times a week for the spouses of patients in intensive care. The first session includes the meeting and introduction of the psychoeducation program. The second session includes the adaptation process to the intensive care unit. The third, fourth and fifth sessions include methods of coping with stress. The sixth session includes evaluation and termination of the psychoeducational program. Quantitative data of the research will be collected with the pre-action and post-action Psychological Distress Scale and the Stress Coping Styles Scale. Qualitative data of the research will be collected through semi-structured individual in-depth interviews conducted after the action.
223659320|NCT02506985|DRUG|rivaroxaban|Immediately following completion of alteplase infusion, patients will receive rivaroxaban 15 mg oral bid for 21 days followed by 20 mg oral daily.
223659321|NCT02506985|DRUG|warfarin|Immediately following completion of alteplase infusion, patients will continue on unfractionated heparin or low-molecular weight heparin with initiation of warfarin adjusted to INR of 2-3.
223659322|NCT04989153|DIAGNOSTIC_TEST|pepsinogen|serum pepsinogen diagnosed gastric cancer and precanceous lesion
223659323|NCT00328302|DRUG|Candesartan|
223659324|NCT00328302|DRUG|Placebo|
223659325|NCT00669409|DRUG|PF-04383119 (tanezumab)|single dose of 10 mcg/kg IV
223659326|NCT00669409|DRUG|PF-04383119 (tanezumab)|single dose of 100 mcg/kg IV
223659327|NCT00669409|DRUG|PF-04383119 (tanezumab)|single dose of 200 mcg/kg IV
223659328|NCT00669409|DRUG|PF-04383119 (tanezumab)|single dose of 25 mcg/kg IV
223659329|NCT00669409|DRUG|PF-04383119 (tanezumab)|single dose of 50 mcg/kg IV
223659330|NCT00669409|DRUG|PF-04383119 (tanezumab)|single dose of Placebo IV
223659331|NCT02226679|DEVICE|Algisyl-LVR|Algisyl-LVR™ device (implants) administered during a surgical procedure
224240872|NCT01088126|PROCEDURE|radiofrequency catheter ablation|radiofrequency catheter ablation, NavX system
224240873|NCT03254251|BEHAVIORAL|Stair climbing|Stair climbing (SC) training was 12 weeks of progressive SC program. Each training session consisted of a general warm-up (5 min: slow and fast skipping, stretching) followed by the SC training and was supervised by experienced personnel. The program began with two bouts of stair climbing four days a week in weeks 1 and 2, increasing by one climb a day every three weeks. By the last three weeks (10-12) of the study, all subjects were completing 5 climbs four days a week. During each climb participants ascended 12 flights (192 steps) divided into 3 sets of 4 flights, with a 2 min rest period between each set. There was a 5 min rest period between climbs that allowed the participants to reach the ground floor using an elevator. Subjects in the non-exercising control group did not participate in a supervised exercise program for the duration of the study.
224240874|NCT05765565|DEVICE|Octaray multi-electrode catheter|Newly designed multi-electrode catheter for creating 3D electroanatomical CARTO maps.
224240875|NCT05765565|DEVICE|Pentaray multi-electrode catheter|Current standard multi-electrode catheter for creating 3D electroanatomical CARTO maps.
224240876|NCT05310565|PROCEDURE|HVLA cervical chiropractic adjustments|Chiropractic high velocity low amplitude adjustment
224240877|NCT01521988|PROCEDURE|Atrial flutter ablation|Radiofrequency ablation of Atrial flutter
223659332|NCT05911594|DRUG|Solifenacin group|Patients in this group will receive medical treatment (Solifenacin 5 mg once or twice daily) without any second line of treatment
223769080|NCT01495481|DRUG|Adenosine|Stepwise incremental approach of adenosine starting at 0.2 mg/kg (max 6 mg) followed by 0.3 mg/kg (max 12 mg) if initial dose was unsuccessful
224240878|NCT01521988|PROCEDURE|Atrial flutter ablation and pulmonary vein isolation|Radiofrequency ablation of atrial flutter and pulmonary vein isolation using cryoablation
224240879|NCT03415997|DRUG|Iohexol|Iodinated contrast media
224240880|NCT05327166|OTHER|ED-LINC|The ED-LINC intervention provides 1) overdose education, 2) brief bedside intervention targeting motivation to engage in outpatient care, 3) a patient-centered approach to MOUD using a treatment decision support tool, 4) longitudinal and proactive care management which will proceed for 3 months, and 5) weekly caseload supervision allowing for stepped-up care targeting opioid use and comorbidity.
224240881|NCT04608643|DIAGNOSTIC_TEST|CBC _inflammatory markers _ platelet function test|CBC , Erythrocte sedimentation rate (ESR) ,CRP, platlet functions tests ( adhesions, 'aggregations ristocetin).
224240882|NCT00910364|OTHER|Exercise|Exercise
224240883|NCT02401334|DEVICE|Cook® Antimicrobial Hernia Repair Device|Device containing an antimicrobial to reinforce soft tissue during ventral or incisional hernia repair in clean-contaminated, contaminated, and dirty-infected
224240884|NCT00368953|DEVICE|Yukon Choice stent system|coronary stent implantation
224240885|NCT00368953|DEVICE|Taxus Liberté stent system|coronary stent implantation
224240886|NCT06143865|OTHER|Closed system aspiration|Aspiration catheter; it is part of the ventilator and the ventilator circuit. The catheter is stored in a protective sheath. Therefore, the catheter can be used repeatedly during the day.
224240887|NCT05441202|DEVICE|transdermal therapy|transdermal therapy with Chinese medicine
224240888|NCT02282436|OTHER|No specific intervention for this study|No specific intervention for this study
223659333|NCT05911594|PROCEDURE|Percutaneous tibial nerve stimulation group|Patients in this group will receive Percutaneous tibial nerve stimulation after failure of medical therapy
223659334|NCT05911594|DRUG|Intradetrusor BOTOX group|Patients in this group will receive Intradetrusor BOTOX after failure of medical
223659335|NCT05911594|COMBINATION_PRODUCT|Intradetrusor BOTOX combined with Percutaneous tibial nerve stimulation group|Patients in this group will receive Intradetrusor BOTOX combined with Percutaneous tibial nerve stimulation after failure of medical
223659336|NCT00738621|DRUG|Aprepitant, Dexamethasone, Ondansetron|Aprepitant oral 40mg one dose, dexamethasone IV 4mg one dose, ondansetron 4 mg one dose
223659337|NCT00738621|DRUG|Aprepitant, Dexamethasone, Placebo|Aprepitant 40mg oral one time, dexamethasone IV 4mg one time placebo one time
223659338|NCT05212870|OTHER|assessment of cognitive level, pain catastrophe, physical activity level and quality of life|assessment of cognitive level, pain catastrophe, physical activity level and quality of life
223659339|NCT02812017|BEHAVIORAL|Thirty Million Words- Well Baby|Through evidence-based strategies, the TMW-WB curriculum teaches parents how to harness the power of their words to build their child's brain and impact their child's learning trajectory.
223659340|NCT02812017|OTHER|Safety Starts at Home|A portion of the Safety Stars at Home set is shown. Demonstrating proven childproofing techniques and accident-prevention strategies, which unifies safety guidelines and shows caregivers how to take proactive measures at home. Many no- or low-cost safety alternatives are offered.
223769081|NCT03829735|OTHER|Human biological samples|Collection of capillary blood for HbsAg testing. Collection of 12 mL of blood for HbsAg positive women and 1 mL for HbsAg positive children.
224240889|NCT06981819|DIAGNOSTIC_TEST|Probe-based Confocal Laser Endomicroscopy by Experts|Confocal Laser Endomicroscopy (CLE) is an advanced in vivo imaging technique that combines confocal microscopy with endoscopy, enabling real-time, microscopic visualization of tissues at a cellular level during endoscopic procedures. Probe-based CLE (pCLE) can enter the stomach cavity through the biopsy channel of the endoscope and observe the gastric mucosa. To generate diagnostic results of pCLE, two pCLE experts dignosed independent. Any discrepancies are then resolved by a third expert.
224240890|NCT06981819|DIAGNOSTIC_TEST|magnifying endoscopy with blue laser imaging|Magnifying Endoscopy with Blue Laser Imaging (ME-BLI) is an advanced endoscopic imaging technique that combines high-resolution magnification with laser-enhanced visualization to improve the detection and characterization of gastrointestinal (GI) mucosal lesions. Developed by Fujifilm, BLI utilizes specific laser wavelengths to enhance surface and vascular patterns, making it particularly useful for diagnosing early-stage cancers and precancerous conditions in the stomach, colon, and esophagus. To generate diagnostic results of ME-BLI, two ME-BLI experts dignosed independent. Any discrepancies are then resolved by a third expert.
224240891|NCT06981819|DIAGNOSTIC_TEST|Probe-based Confocal Laser Endomicroscopy by trainees|Confocal Laser Endomicroscopy (CLE) is an advanced in vivo imaging technique that combines confocal microscopy with endoscopy, enabling real-time, microscopic visualization of tissues at a cellular level during endoscopic procedures. Probe-based CLE (pCLE) can enter the stomach cavity through the biopsy channel of the endoscope and observe the gastric mucosa. The diagnosis results of CLE trainees are generated by each trainee themselves.
224240892|NCT05686759|BIOLOGICAL|Undiluted I.V.-Hepabig inj(GC5103)|undiluted I.V.-Hepabig inj(GC5103) 10,000 International Unit
224240893|NCT05686759|BIOLOGICAL|Diluted I.V.-Hepabig inj(GC5103)|Diluted I.V.-Hepabig inj(GC5103) 10,000 International Unit
224240894|NCT01874951|DRUG|Naltrexone|1 mg of naltrexone will be given twice daily to all patients assigned to active drug.
224240895|NCT01874951|DRUG|Placebo|Placebo identical in appearance to naltrexone will be given twice daily to all patients assigned to placebo.
224240896|NCT06665178|DRUG|Sacituzumab Govitecan|Administer Sacituzumab Govitecan (SG) at 10 mg/kg as an intravenous (IV) infusion on Days 1 and 8 of a 21-day cycle. SG should not be administered as an IV push or bolus.
224240897|NCT06597214|DEVICE|AVACore Technologies, Inc. warmUP Sleeve|AVAcore Technologies's warmUP (WU-20) Temperature Management System was developed based on work with the Aquarius Medical Acrotherm device and prior human hypothermic subject data showing a rewarming rate of \~1ºC in 5 minutes when heat and vacuum application was tested. AVAcore Technologies received FDA acceptance of its Section 510(k) premarket notification for the warmUP (vH1) Temperature Management System in 2005. This product was used on over 100 patients in the US in 2005-2006 timeframe.
224240898|NCT06597214|DEVICE|Arizant Healthcare Bair Hugger®|The Arizant Healthcare Bair Hugger® Temperature Management System proposed for use in this study is a 'forced air' system providing convective warming via the circulation of warmed air through a specially designed blanket which is placed over a portion of the patient's body. This product has been in use in the US for over 20 years in a majority of hospitals.
224240899|NCT02236715|DRUG|Atrovent®|
224240900|NCT06988514|OTHER|Standardized stool collection from healthy volunteers|The only interventions are clinical examination, dietary restrictions and samples collection (stool, and urine for the pregnancy tests (when applicable).
224240901|NCT05647213|BIOLOGICAL|iPSC-CL|Autologous IPSCL
223659341|NCT00358540|DRUG|eltrombopag|Dosing of sarcoma subjects with eltrombopag after treatment with Adriamycin and Ifosfamide.
224240902|NCT01540175|OTHER|Blood samples obtained|Research participants agree to have blood samples obtained at the time of diagnosis before any chemotherapy, if available, and prior to high dose chemotherapy regimen with autologous HSCT as well as on days 14, 21, 28, week 8 and months 3, 6, 12 and 18 after autologous HSCT. Research participants with high risk neuroblastoma may also agree to have blood samples taken before and twice in the recovery period (days 0, 7 and 15-18) of Induction chemotherapy courses one and four.
223659342|NCT04734899|OTHER|Exercise program|Strengthening with resistance bands for tibialis posterior, tibialis anterior, peroneus longus, finger flexors, hip and knee muscles, sheet gathering exercises, fingertip walking exercises, Stretching exercises for gastrocnemius and soleus muscles, plantar fascia stretching, weight transfer on one leg
223769082|NCT06382233|DIAGNOSTIC_TEST|Identification of Diagnostic Biomarkers|Urinary single-cell and EVs screening to stage the intrarenal injury and repair processes in UPJO babies and identification of the whole blood gene expression profiling of babies with unilateral UPJO. Data deriving from patients with unilateral UPJO will be compared with data deriving from controls.
223659343|NCT04734899|OTHER|Foot core training|Short foot exercises with passive modeling, active assisted modeling, active modeling, functional training
223659344|NCT00152100|PROCEDURE|Stem cell transplant|
223659345|NCT00152100|DRUG|Filgrastim, Alemtuzumab|
223659346|NCT00152100|DEVICE|Miltenyi CliniMACS|
223659347|NCT05518318|DRUG|GLS-010|Participants receive GLS-010 240mg intravenously (IV) on Day 1, Q2W
223769083|NCT03296228|RADIATION|Flexibility Radiographs (supine, supine side-bend, FB)|Supine, supine side-bend, fulcrum bend
223769084|NCT03296228|RADIATION|Flexibility Radiographs (awake traction)|awake traction
223769085|NCT03296228|RADIATION|Flexibility Radiographs (STUGA)|supine traction under GA
223769086|NCT01109316|DRUG|Insulin lispro 2 day reservoir in-use|Insulin lispro 2 Day (L2D) administered by infusion pump for 8 week treatment period.
224240903|NCT06614517|OTHER|Birdwatching Intervention|Description: Participants will attend three birdwatching sessions, where they will enjoy direct contact with nature in selected environments such as forests and farms. These outings will be guided by an expert, who will also introduce participants to the use of binoculars and tools for identifying the birds observed during the excursions. During the outings, participants will learn the body scan technique, which will help them focus on physical sensations without making judgments. This exercise will encourage them to pay attention to details such as muscle tension, temperature, or surface contact, allowing them to be more present and connected to their surroundings during the birdwatching sessions. In addition to the in-person outings, participants will receive digital materials via WhatsApp to complement the intervention.Birdwatching Intervention
223769087|NCT01109316|DRUG|Insulin lispro 6 day reservoir in-use|Insulin lispro 6 Day (L6D) administered by infusion pump for 8 week treatment period.
224240904|NCT03704220|DRUG|Warfarin|Removal of anticoagulation with warfarin
224240905|NCT02851290|PROCEDURE|Caudal block anesthesia|After induction of general anesthesia, a caudal block will be performed using 0.75-1 mL/kg of 0.2% ropivacaine without epinephrine
224240906|NCT02851290|PROCEDURE|Dorsal penile nerve block anesthesia|After induction of general anesthesia, a dorsal penile nerve block will be performed using 0.75-1 mL/kg of 0.2% ropivacaine without epinephrine
224240907|NCT00101543|DEVICE|Electrical Stimulation with Intramuscular Electrodes|
223659348|NCT05518318|DRUG|Chemotherapy of Investigator's choice|Chemotherapy administered as assessed as appropriate by the investigator in accordance with the local guideline, including but not limited to DHAP,GEMOX, ESHAP , ICE , IGEV and GVD
223659349|NCT02492932|DEVICE|Ultrasonography|Ultrasonography evaluation of the internal jugular vein.
223659350|NCT02697344|DRUG|Dexamethasone|Given PO
223659351|NCT02697344|OTHER|Laboratory Biomarker Analysis|Correlative studies
223659352|NCT02697344|DRUG|Lenalidomide|Given PO
223659353|NCT02697344|OTHER|Pharmacological Study|Correlative studies
223659354|NCT02697344|DRUG|R-(-)-Gossypol Acetic Acid|Given PO
223659355|NCT00130975|DRUG|Candesartan|
223659356|NCT02245425|OTHER|Supine Thoracic Spine Manipulation|Position patient so that small amplitude quick stretch can be applied to the least mobile area of the thoracic spine that is identified during the spinal segmental mobility testing. The thoracic spine thrust manipulation will be applied at an appropriate range of motion as identified by the clinician.
223659357|NCT02245425|OTHER|Prone Thoracic Spine Manipulation|Position patient so that small amplitude quick stretch can be applied to the least mobile area of the thoracic spine that is identified during the spinal segmental mobility testing. The thoracic spine thrust manipulation will be applied at an appropriate range of motion as identified by the clinician.
223659358|NCT04903743|DRUG|bupivacaine|group B received 28ml of 0.25% bupivacaine and 2ml normal saline
223659359|NCT04903743|DRUG|magnesium sulfate|group BM received 28 ml of 0.25% bupivacaine and 2 ml magnesium sulfate 10%.
223659360|NCT04540016|DRUG|[14C]HSK7653|25 mg of \[14C\]HSK7653 (radioactivity of 80 µCi) capsules are taken under fasted condition.
223769088|NCT01109316|DRUG|Insulin aspart 6 day reservoir in-use|Insulin aspart 6 Day (A6D) administered by infusion pump for 8 week treatment period.
223769089|NCT06225258|DIETARY_SUPPLEMENT|Xanthohumol|Patients, who received Xanthohumol (Chmiel-Xn-Active, SALUTIS Pharmacy, Poland) as adjunctive therapy to treatment recommended by Surviving Sepsis Campaign. Xanthohumol is administrated by the nosogastric tube three times a day \*every 8 hours) at the dose of 2 mg.\\/kg body weight for 10 days. The first dose of Xanthohumol is administrated within 4 hours after the admission to the ICU.
223769090|NCT03666780|DEVICE|LAmbre Occluder|All patients are implanted with Lifetech LAmbre occluder device.
223769091|NCT01782651|DRUG|Lapatinib plus capecitabine|Lapatinib plus capecitabine
224240908|NCT00101543|PROCEDURE|Body Weight Supported Treadmill Training|
224321204|NCT04196881|OTHER|Knowledge Improvement Program about ADHD|This training program will cover an overview of ADHD, prevalence, causes, symptoms, risk factors, associated impairment, prognosis, and treatment options including behavioral interventions and medication.
223659361|NCT05435443|DEVICE|PowerBreathe and PEP Therosold tools|"Initially, the following data were collected from each subject in addition to basic epidemiological data:~M-mode diaphragmatic excursion measurements, both in inspiration and expiration via ultrasound; spirometry is also carried out, obtaining values of forced vital capacity (FVC or FVC), forced expiratory volume (FEV), portion of FVC (FEV1/FVC), peak expiratory flow (PEF), mean expiratory flow, peak inspiratory pressure (PIM) and peak expiratory pressure (PEM). A 30-day treatment plan was carried out in which one group (Tool Group) had to perform 5 minutes of exercise with each tool, alternating with one minute of rest between each minute of exercise, starting with the Therosold PEP® and then the PowerBreathe®. The resistances applied to the devices were marked according to the specific assessment of each subject, in relation to the spirometric values of PIM and PEM."
223659362|NCT02852616|BEHAVIORAL|Narrative Exposure Therapy|8 - 15 sessions: 1 lifeline session, 5 - 12 sessions narrative exposure, 1-2 sessions of future-oriented counselling
223659363|NCT03247452|OTHER|One-day Low fiber diet|One-day low fiber diet before colonoscopy
223659364|NCT03247452|OTHER|Three-day low fiber diet|Three days low fiber diet before colonoscopy
223659365|NCT03247452|DRUG|Polyethylene Glycol plus ascorbic acid|2 liters of Polyethylene Glycol plus ascorbic acid will be administered to both groups
223659366|NCT00002271|DRUG|Alovudine|
223659367|NCT03074019|DIETARY_SUPPLEMENT|Xylooligosaccacharide|XOS95 powder
223659368|NCT03074019|DIETARY_SUPPLEMENT|Maltodextrin|Maltodextrin powder
223659369|NCT05132322|BEHAVIORAL|Educational Outreach|Educational outreach includes staff-targeted educational materials and outreach sessions summarizing the current evidence and guideline recommendations for pulse oximetry use in bronchiolitis.
223769092|NCT05884099|PROCEDURE|Cryoanalgesia AND single-injection paravertebral block|CO2 Cryoanalgesia AND paravertebral block with Bupivacaine 0.5%
223769093|NCT05884099|PROCEDURE|Single-injection paravertebral block|Paravertebral block with Bupivacaine 0.5%
224240909|NCT01853306|DRUG|Veliparib|veliparib
223659370|NCT05132322|BEHAVIORAL|Audit & Feedback (unit level)|Weekly unit-level feedback of each hospital's guideline-concordant practice will be distributed to sites in the form of a visual dashboard that includes comparisons over time and between hospitals. The dashboard will then be shared locally on a weekly basis with clinicians in person and electronically.
223659371|NCT05132322|BEHAVIORAL|Audit & Feedback (real time, individual-level)|Real-time feedback will occur at the individual clinician level. When collecting data on an individual patient, data collectors encountering guideline-discordant continuous monitoring are empowered to briefly ask any available clinician responsible for that patient's care, in a nonjudgmental way, about indications for monitoring that patient. The clinician is ultimately responsible for deciding if any changes are indicated.
223659372|NCT05132322|BEHAVIORAL|Clinical Pathway Integrated into Electronic Health Record|Clinical pathways guide clinicians step-by-step through evidence-based care. Based on the existing guidelines for physiologic monitoring in bronchiolitis, the pathway will clearly specify (a) situations when it is appropriate to initiate intermittent SpO2 measurement instead of continuous SpO2 monitoring, and (b) when it is appropriate to discontinue continuous SpO2 monitoring altogether, and transition to intermittent SpO2 measurement. In order to be visible to clinicians as they perform patient care, the pathway will be integrated into the electronic health record at sites randomized to this intervention.
223659373|NCT02314637|DRUG|Teneligliptin|Teneligliptin for 52 weeks
223659374|NCT02314637|DRUG|Teneligliptin + Sulfonylurea|Teneligliptin for 52 weeks in combination with sulfonylurea
223659375|NCT00448318|PROCEDURE|Music Therapy|
223659376|NCT03663660|OTHER|Organizational infrastructure pediatric plan (OIPP)|Restructuration of the hospital sectors with a stratification of health care into 4 levels.
223659377|NCT04133129|BEHAVIORAL|Low Volume-High Intensity Interval Training|On a treadmill, a 2 minute warm-up will be followed by 2 bouts of 4 minutes at an intensity between 85% and 95% of Maximum Heart Rate (HRmax) interspersed by a 2 minutes recovery bout at 70% of heart rate max, followed by a 3 minutes Cool Down
223659378|NCT04133129|BEHAVIORAL|Moderate Intensity Continuous Training|On a treadmill,a 2-minute warm-up will be followed by 45 minutes at 65%-75% of Heart Rate max followed by 3 minutes cool down.
223659379|NCT05220475|DEVICE|fully covered self-expandable metal stent with an anchoring external plastic stent|Extrahepatic malignant biliary obstruction treated with fully covered self-expandable metal stent with an anchoring plastic stent
223659380|NCT05220475|DEVICE|uncovered self-expandable metal stent|Extrahepatic malignant biliary obstruction treated with uncovered self-expandable metal stent without an anchoring plastic stent
223659381|NCT00213538|DRUG|Response to anakinra associated with methotrexate|
223659382|NCT00389987|DRUG|MK0826, /Duration of Treatment : 8 Weeks|
223659383|NCT00389987|DRUG|Comparator : piperacillin sodium (+) tazobactam sodium /Duration of Treatment : 8 Weeks|
223659384|NCT02586649|DRUG|Tiotropium Bromide|Tiotropium bromide is an anticholinergic used to study bronchodilatation and improvement of pulmonary function in tetraplegic patients
223659385|NCT02586649|DRUG|Placebo|Placebo is a non-active inhalation capsule .
223659386|NCT02999438|DEVICE|Actigraph to check activity levels at home|
223659387|NCT02433951|OTHER|Cardiopulmonary exercise test|Maximal exercise test with ergospirometry.
224240910|NCT01104662|DRUG|Vancomycin|
224240911|NCT01104662|DRUG|Daptomycin|
223659388|NCT00207064|DRUG|quetiapine|flexible doses according to the clinical condition
223659389|NCT02663713|DRUG|Ticagrelor|Ticagrelor 60mg twice daily
223659390|NCT02663713|DRUG|Clopidogrel|Clopidogrel 75 mg once daily
224240912|NCT01104662|DRUG|Semi-Synthetic Penicillin|
224240913|NCT05561114|COMBINATION_PRODUCT|GIE Medical ProTractX3 TTS DCB|Paclitaxel Coated Balloon
223659391|NCT03539549|DRUG|Abicipar pegol|Abicipar pegol 2 mg administered to the study eye by intravitreal injection on Day 1 and Weeks 4, 8, 16, and 24.
223659392|NCT03303508|DIAGNOSTIC_TEST|anti-ds DNA|venous blood samples
223659393|NCT05003297|OTHER|hemogram inflammatory parameters|Neutrophil to Lymphocyte Ratio (NLR) and Platelet to Lymphocyte Ratio (PLR)
223659394|NCT00494247|DEVICE|coronary stent (Genous, OrbusNeich) with immobilised anti-CD34 antibody to capture circulating endothelial progenitor cells|coronary stent covered with anti-CD34 antobody, (Genous, R-stent, produced by OrbusNeich). 30 patients will undergo PCI with implantation of Genous stent and 30 patients will receive bare metal stent (BMS)
223659395|NCT02239549|DEVICE|Jumbo cold forceps polypectomy|The specific jumbo cold forceps used are the Olympus EndoJaw Biopsy Forceps (open jaw diameter 8.5 mm) and the Boston Scientific RJ4 Biopsy Forceps (open jaw diameter 8.8 mm).
223659396|NCT02239549|DEVICE|Cold snare polypectomy|The specific cold snares used are the Boston Scientific Captiflex Extra Small Oval Flexible Snare (loop width 11 mm), the US Endoscopy Dsnare Dimunitive Polypectomy and Suction System (loop width 9 mm), or the Boston Scientific Sensation Short Throw Oval Flexible Snare (loop width of 13 mm, 27 mm, or 30 mm).
223659397|NCT02864862|DEVICE|Immediate implant|
223659398|NCT02864862|BIOLOGICAL|SCTG|
223659399|NCT02864862|BIOLOGICAL|ADM|
224240914|NCT05561114|OTHER|Control|Standard Endoscopic Dilation
224240915|NCT00556127|DRUG|Rituximab|375 mg/m2 on day 1
224240916|NCT00556127|DRUG|Epirubicin|110 mg/m2 on day 3
224240917|NCT00556127|DRUG|Cyclophosphamide|1200 mg/m2 on day 3
224240918|NCT00556127|DRUG|Vincristine|1.4 mg/m2 (maximum 2 mg) on day 3
224240919|NCT00556127|DRUG|Prednisone|40 mg/m2 from day 1 to 5
224240920|NCT00556127|DRUG|Granulocyte-colony-stimulating factor|(G-CSF 5 μg/Kg/day) from day 5 to day 11
224240921|NCT00556127|DRUG|Mitoxantrone|8 mg/m2 for 3-day
224240922|NCT00556127|DRUG|Cytarabine ARA-C|2 g/m2/12 hours for six doses in 3-hour infusion
224240923|NCT00556127|DRUG|Dexamethasone|4 mg/m2/12 hours before ARA-C administration
224240924|NCT00556127|DRUG|Carmustine BCNU|300 mg/m2 on day -7
224240925|NCT00556127|DRUG|Etoposide|100 mg/m2/12 hours
224240926|NCT00556127|DRUG|Melphalan|140 mg/m2 on day -2
224240927|NCT00556127|RADIATION|Radiotherapy|Involved Field Radiotherapy (IF-RT)
224240928|NCT00556127|PROCEDURE|PBSC reinfusion|ASCT
224240929|NCT03797755|RADIATION|palliative radiotherapy|Radiotherapy for palliating symptoms in stage IV cancer patients
223659400|NCT02091557|DRUG|GnRH-analogue|
223769094|NCT03689764|OTHER|interactive video game-based exercise|Twenty-four patients were randomly allocated to two groups (12 participants per group). Group A received interactive video game-based exercise training for the first 6 weeks, with no intervention in the subsequent 6 weeks. Group B had no intervention for the first 6 weeks and then underwent interactive video game-based exercise training in the subsequent 6 weeks.
223769095|NCT03689764|OTHER|no intervention|Twenty-four patients were randomly assigned to two groups (12 participants per group). Group A received interactive video game-based exercise training for the first 6 weeks, with no intervention in the subsequent 6 weeks. Group B had no intervention for the first 6 weeks and then underwent interactive video game-based exercise training in the subsequent 6 weeks.
223769096|NCT06431828|OTHER|APP|The patients will download an app through which they will be able to report adverse events related to their cardiovascular health.
223769097|NCT02751151|OTHER|have Levulan Kerastick (aminolevulinic acid) solution|Levulan Kerastick (aminolevulinic acid) solution applied to the face and/or scalp (if both are needed, treated separately on back to back days); with an incubation period of 2.5 hours. Blue light photodynamic therapy utilizing the DUSA BLU-U device, illumination: 1000 seconds (16 min, 40 secs), will be administered
223769098|NCT00203203|DEVICE|Intramyocardial Injection of stem cells via NOGA Mapping|Subject is randomized to receive intramyocardial injection of stem cells (stem cell therapy) via NOGA mapping to deliver cells in the active arm of the protocol.
223659401|NCT04215302|DEVICE|laryngeal mask|the size of laryngeal mask given to the patient was based on patient's weight measurement
223769099|NCT00203203|OTHER|Control, then Stem Cell Therapy|Subject is randomized to receive a NOGA mapping and no injections (sham treatment)at time of active enrollment and treatment then offered stem cell therapy at 6 months.
223659402|NCT03828578|PROCEDURE|High flow oxygen therapy|High flow oxygen therapy delivered via Airvo2
223659403|NCT05490550|BEHAVIORAL|COAST-enhanced CBTI|Participants will receive CBTI delivered through the COAST platform by one of NOCTEM's certified and licensed COAST clinician. Communication between the participant and licensed clinician will occur primarily through COAST's HIPAA-compliant text messaging, but clinicians and patients may elect to connect via telephone calls or HIPAA-compliant secure videoconference if needed.
223769100|NCT01893424|DRUG|Sativex buccal spray|buccal spray
223769101|NCT01893424|DRUG|CBD-THC-Piperine-PNL capsule|a capsule containing Cannabidiol and Tetrahydrocannabinol combination
223769102|NCT04310761|PROCEDURE|one single blastocyst transfer, both fresh and warmed|Ultrasound guided transvaginal embryo transfer.
223769103|NCT00449293|BEHAVIORAL|standard cognitive behavioral therapy|Standard therapy to help participants with smoking cessation.
223769104|NCT00449293|BEHAVIORAL|Mindfulness Based Cognitive Therapy|A novel mind body therapy that extends basic CT principles to include the practice of mindfulness, which fosters a dispassionate approach to the experience of craving.
224240930|NCT05733195|OTHER|OGTT test|The OGTT test (75g glucose) was performed between 24 and 28 weeks of gestation. GDM will be diagnosed using the criteria of the IADPSG.
224240931|NCT02511509|DEVICE|Bifrontal electroconvulsive therapy|The centre of each electrode will be placed 4-5 cm above the outer canthus of the eye along a vertical line perpendicular to a line connecting the pupils.
224240932|NCT02511509|DEVICE|Bitemporal electroconvulsive therapy|The centre of the stimulus electrodes will be applied 2-3 cm above the midpoint of the line connecting the outer canthus of the eye and the external auditory meatus on each side of the individual's head.
224240933|NCT05337956|PROCEDURE|Erector spinae plane block catheter|All ESP blocks will be performed in lateral position after general anesthesia induction. ESPB will be performed under ultrasonographic guidance using a linear 6- to 10-MHz ultrasound probe. The linear ultrasound transducer will be placed in a longitudinal parasagittal orientation 3 cm lateral to the T6-10 spinous process. The erector spinae muscles will be identiﬁed superﬁcial to the tip of the transverse process. A 21-gauge 10-cm needle will be inserted using an in-plane superior-to-inferior approach or an out of plane approach. The tip of the needle will be placed into the fascial plane on the deep (anterior) aspect of erector spinae muscle. The location of the needle tip will be conﬁrmed by visible ﬂuid spread lifting erector spinae muscle oﬀ the bony shadow of the transverse process on Ultrasonographic imaging. A total of 10-15 ml of 0.2% ropivacaine will be injected each side. A catheter will then be placed leaving 5 cm in place.
224240934|NCT00280371|DRUG|Formoterol Fumarate|
224240935|NCT05814848|DRUG|Relmacabtagene Autoleucel Injection|For patients who had undergone at least one disease assessment after the first treatment of Relmacabtagene Autoleucel injection and whose disease status was not complete remission, the investigators decided to give the patients a second treatment of Relmacabtagene Autoleucel injection based on clinical practice, and the specific dosage was determined by the investigators according to the patient's condition and dose reserve.
224240936|NCT05978427|PROCEDURE|interscalene block|will receive a 20 ml mixture of local anesthetic solution prepared as 10 ml of bupivacaine 0.5% diluted with 10 ml normal saline 0.9% will be injected in interscalene block.
224240937|NCT05978427|PROCEDURE|superior trunk block|will receive a 20 ml mixture of local anesthetic solution prepared as 10 ml of bupivacaine 0.5% diluted with 10 ml normal saline 0.9% will be injected in superior trunk block.
223659404|NCT05490550|BEHAVIORAL|Military Treatment Facility Insomnia Care As Usual|Participants will receive the insomnia care offered at their site following current delivery practices (i.e., face-to-face or virtual; individual or group format). During the treatment phase, participants randomized to ICAU will be instructed to communicate with their clinicians as needed, according to standard procedures in place.
223659405|NCT05126251|DRUG|Tangningtongluo tablet|Tangningtongluo Tablet is an in-hospital preparation of Guizhou bailing. It is used for diabetes caused by deficiency of Qi and Yin. The symptoms include thirst, drinking, overeating, polyuria, weight loss, shortness of breath, fatigue, hand, foot and heart heat and blurred vision; Type 2 diabetes and diabetic retinopathy see the above syndrome. The present study shows that Tangningtongluo Tablet have certain hypoglycemic effects in diabetic animal models and diabetic patients, and may improve insulin sensitivity in diabetic mice.It is speculated that the drug may be effective for prediabetes. (0.4g/tablet,Plate(12 pills/plate ×3 plates/box))
223659406|NCT05126251|BEHAVIORAL|lifestyle intervention|Avoid overeating, avoid large intake of high-calorie, high-fat foods, live a regular life, avoid sitting for a long time, strengthen exercise and reduce weight.
223659407|NCT04504552|DRUG|Avelumab|Subjects will receive treatment with avelumab monotherapy 800 mg as a 60-minute IV infusion on the Day 1 (± 2 days) of a 2-week treatment cycle for 4 administrations.
223659408|NCT03841630|DRUG|LY3437943|Administered subcutaneously (SC)
223659409|NCT03841630|DRUG|Placebo|Administered SC
223659410|NCT03702881|DEVICE|Bonded Spurs associated with posterior build-ups|Twenty-five patients will be treated with bonded spurs associated with posterior build-ups. The cervical portion of the palatal surfaces of the maxillary incisors and the incisal portion of the lingual surfaces of the mandibular incisors will be pumiced, rinsed, dried, and acid etched with 37% phosphoric acid. The etched surfaces will be subsequently rinsed and carefully dried. Then, the spurs will be bonded using Transbond primer/adhesive. The positions for the spurs will be chose to prevent possible future occlusal interferences The spurs will be sharpened with a carborundum disk before bonding. In addition, posterior build-ups (resin blocks) will be cemented on the functional cusps of all maxillary posterior teeth. The treatment time will be 12 months. After this time, the posterior build ups will be removed and the bonded spurs will be maintained for 12 months more, as active retention.
223659411|NCT03702881|DEVICE|Conventional bonded spurs|Twenty-five patients will be treated only with bonded spurs. The bonding of the spurs will follow the same protocol described for the experimental group. The treatment time will be 12 months. After this time, the bonded spurs will be maintained for 12 months more, as active retention.
223659412|NCT02191865|DRUG|Nintedanib|Soft gelatine capsule
223659413|NCT02191865|DRUG|Nintedanib|Soft gelatine capsule
223659414|NCT02191865|DRUG|Nintedanib|Soft gelatine capsule
223659415|NCT02969148|PROCEDURE|Laparoscopic bursectomy and D2 lymphadenectomy|The anterior lobe of transverse mesocolon and capsula pancreatis will be dissected with the D2 lymphadenectomy according to the guidelines of National Comprehensive Cancer Network(NCCN) by laparoscopy，this is Laparoscopic bursectomy and D2 lymphadenectomy.
223659416|NCT02969148|PROCEDURE|Laparoscopic D2 lymphadenectomy|D2 lymphadenectomy is carried out according to the guidelines of National Comprehensive Cancer Network(NCCN).
223659417|NCT03799302|BEHAVIORAL|SIC Coaching|Sites receiving consultation to implement either TFCO or MDFT will also receive consultation on their implementation fidelity as measured and tracked by the SIC.
223659418|NCT04156633|DIAGNOSTIC_TEST|conventional identification method: biochemical profiling or MALDI-TOF MS|Identification of bacteria in positive blood cultures with MALDI-TOF MS from a subculture usually one day after the signal for a positive blood culture appears (from 2016 to 2018)
223659419|NCT04156633|DIAGNOSTIC_TEST|new identification method: Biofire FilmArray© BCID panel|The Biofire FilmArray© BCID Panel is performed directly from the positive blood culture without the need of subculture to reach single bacterial colonies (from 2018 and 2019)
223659420|NCT04156633|DIAGNOSTIC_TEST|new identification method: metagenomic WGS|shotgun metagenomic approach allows to sequence the whole genome (WGS) of pathogens and thereby potentially detect every potential pathogen and also resistance and virulence gene (from 2018 and 2019)
223659421|NCT02902341|DIETARY_SUPPLEMENT|Nutrition Therapy|Nutrition based on measured caloric needs.
223659422|NCT02902341|DIETARY_SUPPLEMENT|Control|Standard protocol nutrition based on calculated caloric needs.
223659423|NCT02117622|DRUG|insulin degludec|Treatment according to routine clinical practice at the discretion of the treating physician. The assignment of the patient to Tresiba® is decided in advance of this study
223659424|NCT06297772|DRUG|Decitabine|decitabine 20mg/m2 per day for consecutive 5 days
223659425|NCT06297772|DRUG|Fludarabine Injection|fludarabine 30mg/m2 per day for consecutive 5 days
223659426|NCT06297772|DRUG|Busulfan Injection|Busulfan 3.2mg/kg per day for consecutive 4 days
223659427|NCT06055543|DIETARY_SUPPLEMENT|Fortimel|2 bottles/day of the high energy ONS
223659428|NCT00124046|PROCEDURE|Surgery|Surgery for this diagnosis is a standard of care, as is the medical treatment. We are comparing the two
223659429|NCT00124046|PROCEDURE|Medical Treatment|Surgery for this diagnosis is a standard of care, as is the medical treatment. We are comparing the two
223659430|NCT04645719|OTHER|Lactate ringer group|General anesthesia only
223659431|NCT04645719|DRUG|Magnesium sulfate dose through real weight group|General anesthesia + magnesium sulfate 15 mg.kg-1.h-1 based on the patient's real weight
223659432|NCT04645719|DRUG|Magnesium sulfate dose through corrected ideal weight group|General anesthesia + magnesium sulfate 15 mg.kg-1.h-1 based on the patient's corrected ideal weight
223659433|NCT02683603|DRUG|"AS colistin and imipenem"|colimycin (colistin) powder (1 million units (MU) by flakon) by AS route in addition to imipenem
223659434|NCT02683603|DRUG|"IV colistin  and imipenem ."|colimycin (colistin) powder (1 MU by flakon) by intravenous route in addition to imipenem
223659435|NCT02683603|DRUG|AS colimycin (colistin)|nebulisation of colimycin (colistin) for 30 minutes 3 times per day during at least 14 days. Nebulisation was made via an ultrasonic vibrating plates nebulizer (Aeroneb Pro® Aerogen Nektar Corporation, Galway, Ireland).
223659436|NCT02683603|DRUG|IV colimycin (colistin)|intravenous colimycin (colistin) : 9 MU during 60 minutes followed by 4.5 million units 2 times per day
223659437|NCT02683603|DRUG|AS colistin and imipenem|IV imipenem 1 g three times per day.
223659438|NCT02683603|DRUG|IV colistin and imipenem|IV imipenem 1 g three times per day
223659439|NCT00783484|DRUG|PF-03716539|PF-03716539 10 mg oral solution, single dose
223659440|NCT00783484|DRUG|PF-03716539|PF-03716539 25 mg oral solution, single dose
223659441|NCT00783484|DRUG|PF-03716539|PF-03716539 3 mg oral solution, single dose
223659442|NCT00783484|OTHER|Placebo|Placebo for 3 mg, 10 mg and 25 mg of PF-03716539 (single dose)
223659443|NCT00783484|DRUG|PF-03716539|PF-03716539 100 mg oral solution, single dose
223659444|NCT00783484|DRUG|PF-03716539|PF-03716539 200 mg oral solution, single dose
223659445|NCT00783484|DRUG|PF-03716539|PF-03716539 50 mg oral solution, single dose
223659446|NCT00783484|OTHER|Placebo|Placebo for 50 mg, 100 mg and 200 mg of PF-03716539 (single dose)
223659447|NCT00783484|DRUG|Midazolam|Midazolam 1 mg IV, single dose
223659448|NCT00783484|DRUG|Midazolam + PF-03716539 (100 mg)|Midazolam 1 mg IV, single dose plus PF-03716539 100 mg oral solution, single dose
223659449|NCT00783484|DRUG|Midazolam + PF-03716539 (50 mg)|Midazolam 1 mg IV, single dose plus PF-03716539 50 mg oral solution, single dose
223769105|NCT01539382|PROCEDURE|Cerebral oxygenation intervention|The protocol for interventions to increase cerebral oxygenation levels above 60% optimizing pH, PaO2, PaCO2, bispectral index, central venous pressure, mean arterial pressure, venous oxygen saturation, and hematocrit. In addition, cerebral perfusion pressure of 70-80 mm Hg and flow \>2.0 l/min/m2 will be maintained during cardiopulmonary bypass. In the ICU, temperatures will be maintained below 38 degrees by administering antipyretics or cooling, and dexmedetomidine will be used if the patient is agitated.
223659450|NCT00783484|DRUG|Darunavir|Darunavir 600 mg tablet twice daily for 9 days (Days 1-9)
223659451|NCT00783484|DRUG|Darunavir + PF-03716539|Darunavir 600 mg tablet, single dose plus PF-03716539 50 mg oral solution, single dose (Day 10)
223659452|NCT00783484|DRUG|Maraviroc|Maraviroc 150 mg tablet once daily for 6 days (Days 1-6)
223659453|NCT00783484|DRUG|Maraviroc +PF-03716539|Maraviroc 150 mg tablet, single dose plus PF-03716539 100 mg oral solution, single dose (Day 7)
223659454|NCT00783484|DRUG|Maraviroc|Maraviroc 225 mg tablet once daily for 6 days (Days 1-6)
223659455|NCT00783484|DRUG|Maraviroc +PF-03716539|Maraviroc 225 mg tablet, single dose plus PF-03716539 200 mg oral solution, single dose (Day 7)
223659456|NCT03514810|COMBINATION_PRODUCT|Combined Sertraline & Ketoprofen|The first group of patients has administered sertralin (50mg)+placebo. The second group has administered sertralin (50mg)+ketoprofen (100mg) (Sertraline \& Ketoprofen) daily.
223659457|NCT03514810|OTHER|Interleukins in MDD after treatment|Some interleukine levels were estimated in the first group of patients (administered sertralin,50mg+ketoprofen,100mg) and compared with their level in the second group (administered sertralin (50mg)+placebo).
223769106|NCT06779409|OTHER|Back squat|2 sets of 3 repetitions of a back squat, set to 85% of the 1 repetition maximum weight
223659458|NCT06122311|DRUG|N Acetylcysteine|N-acetylcysteine sachets 600 mg twice daily
223659459|NCT05949502|DRUG|Beautifil II LS (Low-Shrinkage)|low shrinkage bioactive material Giomer
223659460|NCT05949502|DRUG|3M Filtek Z250 XT Universal|Universal Nano-hybrid composite
223659461|NCT05254847|DRUG|Capecitabine combined with lenvatinib and tislelizumab|Capecitabine combined with lenvatinib and tislelizumab
223659462|NCT02527044|PROCEDURE|Fractional Flow Reserve (FFR)|An FFR will be performed pre-operative to the CABG procedure
223769107|NCT06779409|OTHER|Wingate test|30 second maximal effort cycling test, with resistance at 7.5% bodyweight
223769108|NCT03638986|OTHER|No intervention planned|No Intervention planned.
223769109|NCT06117462|OTHER|Assesment of CFS|Assesment of CFS
224240938|NCT03321565|OTHER|Behavioral counseling and optional meal replacement program|Medical assessment and medical supervision of weight loss Measurements of metabolism and body composition Individualized exercise programs Personal training Support group meetings Individual psychotherapy A variety of nutritional plans including meal replacement options Nutrition education Long-term weight maintenance and relapse prevention programs
224240939|NCT02079532|DRUG|rituximab [MabThera]|1 g was given by intravenous infusion on Days 1 and 15
224240940|NCT04175951|DEVICE|Intraocular lens|Tecnis Eyhance is a monofocal IOL which give added intermediate vision without employing EDOF or multifocal technology and hence induces no glare and halos. Whereas monofocal IOLs such as RayOne do not give intermediate vision.
223659463|NCT02058524|BIOLOGICAL|fecal microbiota transplantation|
223659464|NCT05374915|COMBINATION_PRODUCT|REM-001 photodynamic therapy|Infusion of REM-001 (iv) followed by light treatment to treatment field 24 hrs after infusion of REM-001
223659465|NCT06783868|DEVICE|Catheter Ablation|Catheter Ablation is commonly performed with radiofrequency or cryotherapy to maintain a rhythm control strategy if patients can no longer tolerate their symptoms or are no longer controlled on AVNB or AAD. The procedure leads to significant symptom improvement even though there may be insignificant AF recurrence at one year. At Kansas City Heart Rhythm Institute, CA may be performed with radiofrequency ablation (Tactiflex Ablation Catheter, Abbott Cardiovascular, Minneapolis, MN) or pulsed field ablation (PulseSelectTM, Abbott Cardiovascular or FaraWaveTM, Boston Scientific, Marlborough, MA), performed with EnsiteX (Abbott Cardiovascular) or Carto3 (Biosense Webster, Irvine, CA) mapping software.
223659466|NCT06783868|DRUG|Market-approved AVNB, OAC and AAD|Used per protocol for the duration of the trial.
223659467|NCT04693234|BIOLOGICAL|Tislelizumab|200 mg administered intravenously once every 3 weeks on day 1 of each cycle
223659468|NCT04693234|BIOLOGICAL|Ociperlimab|900 mg administered intravenously once every 3 weeks on day 1 of each cycle
223659469|NCT04643158|DRUG|AZD1402|Randomised participants will receive oral inhalation of AZD1402, via DPI.
223659470|NCT04643158|DRUG|Placebo|Randomised participants will receive oral inhalation of matching placebo via DPI.
223659471|NCT04643158|DRUG|Short acting beta agonist (SABA) (rescue medication)|"In addition to study intervention, all participants will be provided with a SABA as rescue medication (eg, salbutamol/albuterol), to be used throughout the Run-in and Treatment Periods. All participants should refrain from taking a SABA as rescue medication 6 hours prior to pulmonary function tests.~Dosage levels: 100 μg per nominal dose 90 μg per nominal dose pro re nata (as required) (PRN)"
223769110|NCT01743937|PROCEDURE|Coronary occlusion with balloon inflation|
223769111|NCT06572709|DIAGNOSTIC_TEST|Parasternal intercostal muscle thickness with ultrasonography|Ultrasonographic measurements were performed of the bilateral parasternal intercostal muscle thickness in the supine position in the stroke patient group. Ultrasonographic measurements were performed of dominant side parasternal intercostal muscle thickness in the supine position in healthy individuals group. Spirometry evaluation was performed in both groups.
223769112|NCT02164396|DEVICE|Spectacle Lens|Spectacle Lens Only
224240941|NCT03346564|BEHAVIORAL|Ritual training program|Ritual training program including education and demonstration
223659472|NCT04643158|DRUG|Run-in medications (ICS-LABA combination)|"During the Run-in Period, the participants are required to maintain on their ICS-LABA dose. Controller medications (eg, ICS LABA) should remain at a stable dose and be taken after study intervention as applicable.~These drugs are used as standard of care."
224240942|NCT03346564|BEHAVIORAL|Routine care|
223769113|NCT02164396|DEVICE|Habitual Soft Contact Lens|subject's own contact lens
223769114|NCT02164396|DEVICE|Test Lens|senofilcon A or narafilcon A
223769115|NCT03783559|DRUG|TACE|TACE
223769116|NCT03783559|DRUG|chemotherapy±target therapy|chemotherapy±target therapy
223769117|NCT02270060|OTHER|Music Therapy|Patient receives a single 20-minute music therapy session with a music therapist. Patient will interact with specially composed music tailored to the patient's preferences using an iPad.
223769118|NCT02270060|OTHER|Music Listening|Patient listens to his/her preferred music on an iPod touch for 20 minutes without the presence of a music therapist.
223769119|NCT01072682|DEVICE|Selective cytopheretic device (SCD)|The selective cytopheretic device (SCD) is comprised of tubing, connectors and a hemofilter cartridge. The device is connected in series to a commercially available Continuous Renal Replacement Therapy (CRRT) device. Blood from the CRRT circuit is diverted after the CRRT hemofilter through to the extra capillary space (ECS) of the SCD. Blood circulates through this space and is returned to the patient via the venous return line of the CRRT circuit. Regional citrate anticoagulation is used for the entire CRRT and SCD blood circuits.
223769120|NCT04460664|DIAGNOSTIC_TEST|Quantra System|Diagnostic device to monitor coagulation properties of a whole blood sample at the point-of-care.
223769121|NCT04578847|DRUG|Imatinib|Initial dose - 400 mg daily. If on imatinib, the dose should be decreased to 300 mg daily on the first stage, to 200 mg daily - on the second stage.
223769122|NCT04578847|DRUG|Nilotinib|Initial dose - 300 or 400 mg twice daily. If on nilotinib to 400mg daily on the first stage, to 200 mg daily - on the second stage.
223769123|NCT04578847|DRUG|Dasatinib|Initial dose 100 or 140 mg daily. If on dasatinib then to 50 mg daily on the first stage, to 25 mg daily - on the second stage.
223769124|NCT04578847|DRUG|Bosutinib|Initial dose 500 mg daily. If on bosutinib, the dose should be reduced to 300 mg daily on the first stage, to 200 mg daily on the second stage.
223769125|NCT05035771|DEVICE|Pressure wire measurement in peripheral vascular disease|The aim of IMPACT PAD is to examine the safety and feasibility of intraprocedural flow, pressure and resistance rate changes to help predict the success of a peripheral endovascular intervention.
223769126|NCT04856033|BEHAVIORAL|TM|Transcendental Meditation instruction, 12-sessions over 3-4 months with monthly follow-up
223769127|NCT04856033|BEHAVIORAL|PCT|Present Centered Therapy, 12-sessions over 3-4 months with monthly follow-up
223769128|NCT04543552|DEVICE|Bladder scan|Bladder Scanner, or Biocon-900 is an ultrasonic imaging device that has been developed to measure post-void residual volume of the bladder non-invasively. The images and measurements are obtained by applying a probe onto the abdomen (i.e. bladder). As it scans, the scanner constructs 12 cross-sectional images at 15 degree interval using the reflection signals from urine in the bladder and extracts the position of the bladder wall as well. During urodynamic studies, the bladder scan will measure the infused volume in order to assess difference between the infused and scanned volumes.
223769129|NCT02132000|DRUG|toremifene or tamoxifen|
223769130|NCT00914615|RADIATION|Stereotactic Body Radiation|Radiation therapy will be delivered on six occasions, over two weeks. Each treatment will take approximately 30 minutes to deliver (up to an hour including all imaging and set-up procedures). You may be asked to swallow 250 cc of oral contrast before each radiation therapy treatment. Pepto Bismol (a liquid that coats the stomach and is used to treat heartburn) and/or water may be combined with the contrast to improve the quality of the stomach's image.
223769131|NCT04594096|BEHAVIORAL|Telehealth visits|Receiving telehealth visits with a medical provider (MD or NP) 2-3 days after last chemotherapy administration in the cycle
223769132|NCT04594096|BEHAVIORAL|Standard of Care|Receiving care as usual from the UC Davis Comprehensive Cancer Center
223769133|NCT02202928|BIOLOGICAL|DC-CIK|8×10\^9 autologous tumor lysate pulsed DC-CIK cells for each infusion, IV (in the vein) for four cycles, each cycle received four infusions with a 1 day interval.
223769134|NCT02202928|RADIATION|Radiotherapy|45\~50 Gy in 25-28 fractions.
223769135|NCT02202928|DRUG|Chemotherapy|Oxaliplatin 85mg/m2 IV over 2 hours, day 1; Leucovorin 400mg/m2 IV over 2 hours, day 1; 5-FU 400mg/m2 IV bolus on day 1, then 1200mg/m2/day for 2 days IV continuous infusion; Repeat every 2 weeks.
223659473|NCT06499025|BIOLOGICAL|targeted AML1-ETO neoantigen cytotoxic T cells (CTL)|After subject screening, peripheral blood mononuclear cell #PBMC# donors matching half or more of the subject's HLA matching will undergo blood collection to prepare neoantigen cytotoxic T cells. Neoantigen cytotoxic T cells preparation is expected to be 25-30 days after blood collection. In this study, the bridging therapy will be allowed before Chemotherapy preconditioning. Chemotherapy preconditioning will be performed before neoantigen cytotoxic T cells transfusion.
223769136|NCT00094653|DRUG|MDX-010 (anti-CTLA4) monoclonal antibody|3mg/kg (intravenous \[iv\] infusion over 90 minutes), every 3 weeks for 4 doses
223659474|NCT06499025|DRUG|Cyclophosphamide injection|Cyclophosphamide injection will be performed in -10 to -8d before neoantigen cytotoxic T cells transfusion
223659475|NCT06499025|DRUG|Decitabine Injection|Decitabine Injection will be performed in -12 to -8d before neoantigen cytotoxic T cells transfusion
223659476|NCT06499025|DRUG|Liposome mitoxantrone|Liposome mitoxantrone will be performed in -9 to -8d before neoantigen cytotoxic T cells transfusion
223659477|NCT06377254|BEHAVIORAL|Decreased Physical Activity|Physical activity levels will be decreased
223659478|NCT06377254|BEHAVIORAL|Increased Physical activity|Physical activity levels will be increased
223659479|NCT04540198|BEHAVIORAL|GamePlan4Care|GamePlan4Care; Experimental
223659480|NCT04540198|BEHAVIORAL|Resources4Care|R4C; Active Comparator
223659481|NCT06310291|BIOLOGICAL|VTP-1000|Intramuscular (IM) injection comprised of self-assembling nanoparticles of gluten peptides and a rapamycin component
223659482|NCT06310291|OTHER|Matched Placebo|Intramuscular (IM) injection comprised of saline solution
223659483|NCT01655004|DRUG|Exemestane|Exemestane is commercially available and will be obtained locally from the manufacturer. There are no experimental treatments in this study.
223659484|NCT01696604|DRUG|GSK2849466|GSK2849466 will be available as capsules of dose strengths 0.01, 0.1, 1.0, and 2.5 mg.
223659485|NCT01696604|DRUG|Placebo|Matching placebo capsules will be available.
223659486|NCT02888119|DEVICE|PRISMA 3T MRI scanner (Siemens Medical Solutions)|A baseline MRI exam consisting of accelerated 3D-T1p, and T2, MRI will be performed. Longitudinal follow-up MRI exams (24 months) will be repeated on the same knee on all OA patients.
224240943|NCT06337006|PROCEDURE|Placement of the laryngeal mask airway|Evaluation of patients' chest movement with manual ventilation, airway leak level, airway pressures, fingertip O2 saturation percentage, and capnogram results will be recorded and the correlation between clinical observation and measured parameters will be evaluated.
224240944|NCT04281706|DRUG|Etomidate vs Propofol as induction agent|Patients undergoing cardiac surgery were induced with Etomidate according to the standard operating procedure for induction until October 1st, 2013, afterwards a new SOP with Propofol as primary induction agent was introduced. After a washout period of 3 months, Propofol was used as sole induction agent. The rest of the standard operating procedure remained the same.
224240945|NCT02924948|PROCEDURE|Balloon inflation|EUS balloon inflation will be done before insertion through the subjects throat
224240946|NCT03057262|DEVICE|Repositioning splint|Application of repositioning splint in the study group.
223769137|NCT00094653|BIOLOGICAL|MDX-1379 (gp100) Melanoma Peptide Vaccine|2mL (2 subcutaneous injections of 2 mL each, 1 to each thigh), every 3 weeks for 4 doses.
223769138|NCT03921411|BIOLOGICAL|Nemolizumab|Participants received subcutaneous (SC) injection of 30 milligram (mg) of Nemolizumab every 4 weeks (Q4W) over a 16-week treatment period, with a loading dose of 60 mg on Day 1.
223769139|NCT04587622|DRUG|Icenticaftor|Single oral dose of 300 mg of icenticaftor (QBW251)
223769140|NCT00330551|DRUG|Oral Risperidone|Patients will be treated with oral risperidone daily, with the dosage determined by treating psychiatrist.
224240947|NCT04431271|PROCEDURE|Robot-assisted hernia repair|Inguinal hernia repair was performed using the DaVinci Xi robotic system
224240948|NCT04757090|DRUG|89Zr-trastuzumab|"-To minimize uptake of the 89Zr-trastuzumab in normal tissues, immediately prior to planned 89Zr-trastuzumab injection patients will receive a 50 mg dose of cold unlabeled trastuzumab intravenously (IV). The administration of a fixed small dose of unlabeled antibody to improve tumor-to-normal-tissue (T/N) uptake of the radiolabeled antibody is standard in this type of imaging procedure."
224240949|NCT06446180|DRUG|SsK12@Lip@GSH|SsK12@Lip@GSH powder contained 1×10\^9 CFU viable cells of SsK12@Lip@GSH as the active ingredient.
224240950|NCT02716129|DRUG|Morphine|38 patients of this group will receive 10 mg of 0.5% hyperbaric bupivacaine (Buvanest Spinal 0.5% Heavy) with 0.2 mg morphine (Infumorph - Injection 10 mg/mL) in 0.5 ml volume (total volume 2.5 mL). Patients will be preloaded with 10 ml/kg Ringer's lactate solution intravenous.
224240951|NCT02716129|DRUG|Morphine plus Nalbuphine|39 patients of this group will receive 10 mg of 0.5% hyperbaric bupivacaine (Buvanest Spinal 0.5% Heavy) with 0.5 mg morphine (Infumorph - Injection 10 mg/mL) plus 0.2 mg nalbuphine (NALUFIN 20MG/ML AMP) in 0.5 ml volume (total volume 2.5 mL). Patients will be preloaded with 10 ml/kg Ringer's lactate solution intravenous.
224240952|NCT06028607|DIETARY_SUPPLEMENT|QD-27|Oral Protein gel with greater Leucine proportion and vitamin D Consumption of 2 each day for 3 months to be taken at breakfast and lunch
223659487|NCT05214261|OTHER|Safety and efficiency of post operative analgesia between laparoscopic-assisted TAP block and epidural analgesia|"Patients in the TAP group will be given a laparoscopic-assisted TAP block with a total of 2mg/kg of 0.25% bupivacaine in the bilateral subcostal region into four spots of the bilateral subcostal region, two on both sides of the lateral abdomen between the anterior iliac spine and lower costal arch. The TAP block is performed after the first trocar placement before the insertion of other trocars and the beginning of the surgical intervention.~In the control group epidural catheters will be placed using landmark- and loss-of-resistance techniques while the patient is on the operating table. Infusions of 4ml/h containing 0.125% levobupivacaine and 5.5 μg/mL fentanyl will be started with a CADD Solis VIP-infusion pump at the time of anesthesia induction."
223659488|NCT05475730|PROCEDURE|bone and soft tissue augmentation|"A vertical full-thickness incision in the mesial aspect of the defect ridge.Microsurgery instruments is subsequently use to carefully elevate the full thickness of the mucosa.~Extreme caution must be exercised during these maneuvers to avoid tissue perforation and to maintain the integrity of the periosteum.An dermal matrix is place into the tunnel.A pouch is create between the bone and the membrane and the mixed bone chips and hyaluronic acid are inserted into the tunnel until the desirable ridge dimensions are obtained. Primary closure of the vertical incisions was achieved with single interrupted sutures."
223659489|NCT04764331|DEVICE|Revian Red All LED cap|Cap that uses two wavelengths of light, 620 nm and 660 nm will be used once a day for 10 minutes.for treatment
223659490|NCT04582253|DIAGNOSTIC_TEST|Scheimpflug Camera Corneal Tomography|Pentacam Sheimpflug system(Pentacam HR, Oculus Optikgeräte GmbH, software V.1.15r4 n7) is used for imaging of the anterior and posterior surfaces of the cornea to obtain corneal tomographic maps.
223659491|NCT05889559|DEVICE|Tissue Ultrafiltration Catheters|patients randomized to the experimental arm will have three TUF catheters placed in the anterior muscle compartment of the injured limb. The TUF catheters will be connected to a closed suction drain and will remove interstitial fluid from the muscle.
223659492|NCT04580667|OTHER|Collection of plasma samples|Collection of plasma samples - Plasma samples are collected at different times during the study for the RadTox test.
223659493|NCT06291727|DRUG|Mepivacaine|Patients will be administered a standard dose of mepivacaine 1.5% (4.5ml, 67.5mg) for total knee arthroplasty prior to surgery
223659494|NCT06291727|DRUG|Bupivacaine|Patients will be administered a standard dose of 0.75% hyperbaric bupivacaine (1.4ml, 10.5mg) for total knee arthroplasty prior to surgery
223659495|NCT05793567|DIAGNOSTIC_TEST|Coronary angiogram with coronary reactivity testing (CRT)|CRT is an angiography procedure (using X-ray) to examine the small blood vessels in the heart and how they respond to three drugs (adenosine, acetylcholine and nitroglycerin) as per clinical protocol.
223659496|NCT01551511|DRUG|Tetrahydrocannabinol|The add-on treatment consists of two phases: a step-up phase (day 1-5: 3 mg TID; day 6-10: 5 mg TID), and a stable dose phase (day 11-52: 8 mg TID). The dosage may be tapered to at least 5 mg TID, when 8 mg is not tolerated.
223659497|NCT01551511|DRUG|Placebo|Identical step-up approach to the Namisol arm.
223659498|NCT00880971|RADIATION|Postoperative 3D-CRT or IMRT|Postoperative radiotherapy using 3D-CRT or IMRT techniques, 2 Gy per fraction, total 25 fractions (50Gy) over 5 weeks.
223769141|NCT00330551|DRUG|Risperidone in Long-Acting Injectable Form (Consta)|Participants will take a 25 mg dosage of injectable risperidone (Risperidone in Long-Acting Injectable Form (Consta)) once every 2 weeks. Dosage will be adjusted if needed.
223769142|NCT05664035|BIOLOGICAL|Diagnosis of SPAD using immunization with PPV23|Diagnosis of SPAD using immunization with PPV23
223659499|NCT03689686|DEVICE|Noninvasive Respiratory Support|"Physiological crossover prospective study comparing four study trials (20 mins) delivered in computer generated random order:~1. Standard Oxygen therapy with mask~2. HFNC flow 2l/Kg~3. HFNC flow 3l/Kg~4. Helmet CPAP"
223659500|NCT00973869|DIETARY_SUPPLEMENT|curcumin|
223769143|NCT05192577|OTHER|Electrical stimulation|At the beginning of the session, an electrode will be attached to the participant's ankle. Electrical stimulation will be applied to estimate the electrical perception threshold. This threshold will be used as condition stimuli when different thermal thresholds are assessed.
223769144|NCT00472134|DRUG|bupivacaine|administered locally, 0.5% Bupivacaine (Marcaine Abbott Laboratories) or saline administered continuously for 48 hours at 2 mL/h.
223769145|NCT00472134|DEVICE|On-Q PainBuster pump|local anesthetic (bupivacaine) administered via a pain relief system consisting of a 20 gauge soaker catheter attached to an elastomeric balloon pump that is capable of infusing a set volume of local anesthetic over a wide area of surgical site for 2 to 5 days
223769146|NCT01826175|DRUG|Ticagrelor|Subjects are randomized to receive a loading dose of ticagrelor or clopidogrel, and all subjects have Optical Coherence Tomography (OCT) imaging performed at the end of their stenting procedures.
223769147|NCT01826175|DRUG|Clopidogrel|Subjects are randomized to receive a loading dose of ticagrelor or clopidogrel, and all subjects have Optical Coherence Tomography (OCT) imaging performed at the end of their stenting procedures.
223769148|NCT01826175|DEVICE|Optical Coherence Tomography|Subjects are randomized to receive a loading dose of ticagrelor or clopidogrel, and all subjects have Optical Coherence Tomography (OCT) imaging performed at the end of their stenting procedures.
223769149|NCT03306888|OTHER|Physical Activity Coaching|Physical activity coaching over 4 months
223769150|NCT04606238|OTHER|Decision Aid|Oncologists and patients will use the decision aid in the same situation (change of treatment needs to be discussed with the patient - either because of disease progression or treatment toxicity or other reasons (e.g. change of care setting).
224240953|NCT03947515|PROCEDURE|prostate biopsy|All patients included, will report to the urology department on the date previously agreed with the surgeon. The patient will be seen by the nurse and urologist on duty as part of outpatient care or, more rarely, in ambulatory care. After verification of the patient's identity, the signature of informed consent, the absence of immediate contraindications to biopsy (haemorrhagic and infectious) and the patient's proper preparation (antibiotic prophylaxis and possible enema), the patient will be installed for the taking of samples covered by the protocol (rectal swabbing and prostate biopsies, see paragraph IX). If the patient has not taken the antibiotic prophylaxis or performed the enema, he or she will be reconvened at a later date for the biopsies. After the prostatic biopsies have been performed, the patient's participation in the study ends and his follow-up resumes according to the recommendations adapted to his pathology.
224240954|NCT03947515|OTHER|Urinary sampling|It will be collected after the prostate massage performed by the surgeon in charge of the patient during his clinical examination for prostate cancer screening. After elimination of the first draft, the urine will be collected in 2 tubes with borated preservative
224240955|NCT03947515|OTHER|Rectal swabbing before biopsies are performed|A rectal swab will then be taken by the urologist on the day the prostate biopsies are taken. The analysis of the digestive microbiota will eliminate contamination of prostate biopsies by bacteria from the faecal flora during transrectal sampling
224240956|NCT03043378|BEHAVIORAL|Questionnaires|Participants complete three questionnaires at consultation visit.
224240957|NCT02498964|OTHER|Teaching,education,feedback and practice sessions to help improve as needed|Group discussion,individual attention and teaching as needed,more teaching using different modalities like powerpoint and hands on experience
223659501|NCT00973869|OTHER|high performance liquid chromatography|
223659502|NCT00973869|OTHER|laboratory biomarker analysis|
223659503|NCT00973869|OTHER|pharmacological study|
223659504|NCT00973869|PROCEDURE|diagnostic endoscopic procedure|
223659505|NCT00973869|PROCEDURE|therapeutic conventional surgery|
223659506|NCT00775008|BEHAVIORAL|electronic health information|Participants will receive weight loss information via 1 of 2 different mediums.
223659507|NCT04241055|BEHAVIORAL|Values affirmation exercise|In the experimental values affirmation condition, participants spend 10-15 minutes completing a guided reflection regarding values that are personally important (see Logel and Cohen, 2012; Brady, Griffiths, \& Cohen, in prep).
223659508|NCT04241055|BEHAVIORAL|Active control exercise|In the active control condition, participants spend 10-15 minutes completing a guided reflection regarding values that are not personally important but could be important to someone else (see Logel and Cohen, 2012; Brady, Griffiths, \& Cohen, in prep).
223769151|NCT00529841|DRUG|Hydrocortisone sodium acetate|Subcutaneous administration of medication via insulin pump
223769152|NCT05487729|OTHER|ultrasonography and functional assessment and questionnaire survey|ultrasonography and functional assessment and questionnaire survey
223769153|NCT04703452|OTHER|Indicators of central sensitisation|Indicators of central sensitisation, assessed by the Central Sensitization Inventory
223659509|NCT05658315|OTHER|ApplTree smartphone application|ApplTree is a smartphone reminder application which allows the user to enter details of future tasks and events and then prompts the user to remind them to complete these at a pre-specified time. ApplTree was designed with people who experience memory and attention difficulties in mind and has a customisable user interface design to support attention and short-term memory when entering PM tasks. ApplTree was developed by Professor Jonathan Evans and Dr Matthew Jamieson (see Jamieson et al., 2020) and is owned by the University of Glasgow.
223659510|NCT01694407|DRUG|Tenofovir (TFV) Alone Vaginal Tablet|vaginal tablet containing 40 mg of TFV
223659511|NCT01694407|DRUG|Emtricitabine (FTC) Alone Vaginal Tablet|Vaginal Tablet containing 40 mg of TFV
223659512|NCT01694407|DRUG|TFV and FTC Combined Vaginal Tablet|vaginal tablet with 40 mg TFV and 40 mg FTC
223659513|NCT01694407|DRUG|Placebo Vaginal Tablet|Vaginal Tablet containing no drug
223659514|NCT01731418|BEHAVIORAL|Narrative Exposure Therapy|Narrative Exposure Therapy (NET) is a treatment approach that was developed by a research group of the University of Konstanz (Schauer, Neuner, \& Elbert, 2005, 2011). In NET, the patient repeatedly talks about the most arousing traumatic events in detail while re-experiencing the emotions associated with this event. In the process, the patient constructs a narration of his life, focusing on the detailed report of the traumatic experiences.
223659515|NCT01731418|OTHER|Treatment-as-usual|"Treatment-as-usual was defined as the commonly used psychotherapy for abused women in Iran, such as medical therapy and/or supportive counseling.~Regarding supportive counselling, the sessions included:~Life skill education CBT techniques ACT techniques Finding resources to stop violence Discussing marital and sexual conflicts with the presence of husbands Working on their children problems Improvement of communication skills"
223659516|NCT00003690|DRUG|alvocidib|
223659517|NCT00003690|DRUG|carboplatin|
223659518|NCT00003690|DRUG|cisplatin|
223659519|NCT00616538|DEVICE|Epiceram(r)|Topical barrier repair emulsion cream
223659520|NCT00616538|DRUG|Fluticasone Propionate 0.05%|Topical mid-strength steroid
224240958|NCT02419690|BEHAVIORAL|text message intervention|Subjects will be sent 58 messages (3-5 per week) over 12 weeks, plus reminder messages for follow up interviews. The content of these messages will focus on contraception methods and effectiveness, sexually transmitted infection (STI) transmission, condom use, partner and parental communication, and healthy relationships. There will also be several text messages asking the participant if they would like to have a health educator contact them. The format will include facts, quizzes, true/false and some will have links to videos/pictures and websites, and some will request a response.
224240959|NCT00605930|DIETARY_SUPPLEMENT|Pyruvate, creatine, niacinamide|A bar of 2 gm of pyruvate and 1 gm of creatine, and a pill of 1 gm of niacinamide once a day for 24 weeks.
224240960|NCT00605930|DIETARY_SUPPLEMENT|Placebo|25% of subjects will receive a placebo bar and a placebo pill once a day for 24 weeks.
224240961|NCT01247948|PROCEDURE|navigation assisted spine surgery|navigation assisted pedicle screw placement of spine surgery
223659521|NCT05171062|DRUG|bexmarilimab (FP-1305)|standard 3+3 dose escalation trial of bexmarilimab (FP-1305)
224240962|NCT01247948|PROCEDURE|traditional spine surgery|traditional spine surgery without navigation assist
223659522|NCT05171062|DRUG|Pembrolizumab|Pembrolizumab 200mg IV is administered in 4 planned bexmarilimab dose escalation cohorts
223659523|NCT06007365|DEVICE|Z5m Dental Implants|This is an observational study, collecting data on the use of Z5m Dental Implants.
223659524|NCT01940172|DRUG|Birinapant|"Dose Escalation:~Dose Level (1) - 13 mg/m2 (twice a week for 3 of 4 weeks); Dose Level (-1) - 11 mg/m2 (twice a week for 3 of 4 weeks); Dose Level (2) - 13 mg/m2 (twice weekly for 4 weeks );"
223659525|NCT01940172|DRUG|Conatumumab|10 mg/kg IV on Day 1 and 15 of each cycle
223659526|NCT03223519|DRUG|Comboprofen|Triple combination of Ibuprofen, Magnesium and Vitamin C Powder for oral solution administered TID for 3 days
223659527|NCT03223519|DRUG|Placebo|Powder for oral solution administered TID for 3 days
223659528|NCT03223519|DRUG|Ibuprofen|Powder for oral solution administered TID for 3 days
223659529|NCT03223519|DRUG|Magnesium|Powder for oral solution administered TID for 3 days
223659530|NCT03223519|DRUG|Vitamin C|Powder for oral solution administered TID for 3 days
223659531|NCT03735524|OTHER|Exercise|Different exercises will be adopted including: repetition of different movements for ambulation and stair climbing, repetition of crossed patterns of movements for coordination, postural reactions while standing with eyes open and closed and oscillatory boards for balance, strengthening lower limb muscles, and low-intensity and long-duration static stretching of iliopsoas, rectus femoris, hamstrings, triceps surae, and lumbar spinal muscles for muscular flexibility and range of motion. In addition, advanced robotic therapy will be used to standardize rehabilitative treatment and to obtain more objective indexes of motor function. The Lokomat exoskeleton and the Biodex stability system will be used.
223659532|NCT00000156|DEVICE|Goggles|
223659533|NCT00000156|PROCEDURE|Ambient Light Reduction|
223659534|NCT02989428|PROCEDURE|Early parathyroidectomy group (EPTX-group)|Participants will undergo parathyroidectomy as soon as possible
223659535|NCT04303039|DRUG|ABP-671|ABP-671 Tablet 1.0 mg
223659536|NCT05709938|DRUG|Glargine and regular insulin versus NPH and regular insulin|"Patients with type 1 diabetes (T1DM) in group A received insulin glargine as basal therapy at night and regular insulin given prior to each main meal.~Patients in group B were given NPH and regular insulin in split and mix method in the morning and evening."
223659537|NCT01697618|DRUG|biphasic insulin aspart 30|Injected subcutaneously (s.c., under the skin) before breakfast and dinner, dosage adjusted throughout the trial according to individual needs
223769154|NCT01541826|DIETARY_SUPPLEMENT|Chokeberry Extract|Consumption of 2 x 250 mg chokeberry extract capsules daily for 12 weeks.
223659538|NCT01697618|DRUG|biphasic human insulin 30|Injected subcutaneously (s.c., under the skin) before breakfast and dinner, dosage adjusted throughout the trial according to individual needs
224240963|NCT01513070|DRUG|Quick-Acting Heart Reliever|Quick-Acting Heart Reliever，200mg，tid，po. for six months
224240964|NCT01513070|DRUG|Isosorbide Dinitrate|Isosorbide Dinitrate，10mg，tid，po. for six months
224240965|NCT01513070|DRUG|Placebo of Isosorbide Dinitrate|Placebo of Isosorbide Dinitrate，10mg，tid，po. for six months
224240966|NCT01513070|DRUG|Aspirin Enteric-coated Tablets|Aspirin Enteric-coated Tablets，100mg，qd，po. for six months
224240967|NCT01513070|DRUG|Placebo of Quick-Acting Heart Reliever|Placebo of Quick-Acting Heart Reliever，200mg，tid，po. for six months
224240968|NCT01513070|DRUG|Aspirin Enteric-coated Tablets|Aspirin Enteric-coated Tablets，100mg，qd，po. for six months
224240969|NCT05134792|DRUG|intravenous immunoglobulin|All pediatric burn patients allocated in group intra venous immunoglobulin admitted will receive 200 mg/kg IVIG once after their initial resuscitation before 48 hours passes of burn incident.
224240970|NCT01223612|DRUG|Ranibizumab|Intravitreal injection of 0.5mg in 0.05ml. One injection at baseline, 4 and 8 weeks then four-weekly as required to 44 weeks.
223659539|NCT01421355|DRUG|Atazanavir|The study design is a single arm, open label trial. Treatment is atazanavir 300 mg BID per day for 4 days. The Brigham and Women's Hospital Investigational Drug Service (IDS) will dispense study drug.
223659540|NCT02123472|DRUG|Cephalexin|Administered Orally
223659541|NCT01229696|PROCEDURE|Catheter Placed At Bifurcation|Patients randomized to this group will receive a sciatic nerve block placed at the bifurcaton of the sciatic nerve and outcome measures will be tested.
223659542|NCT01229696|PROCEDURE|Catheter Placed 5cm Above Bifurcation|Patients randomized to this group will receive a sciatic nerve block placed 5cm above the bifurcaton of the sciatic nerve and outcome measures will be tested.
223659543|NCT01852396|PROCEDURE|Retroclavicular block|Retroclavicular approach ultrasound guided regional anesthesia
223659544|NCT00811096|DRUG|Tinidazole|2gms, p.o. q.d. for 5 days
223659545|NCT00811096|DRUG|chloroquine|
223659546|NCT02049606|DRUG|LAYLA tablet|1 Tablet twice a day
223659547|NCT02049606|DRUG|CENATONE tablet|2 Tablets once a day
223659548|NCT00838084|DRUG|LY2811376|Oral capsules
223659549|NCT00838084|DRUG|Placebo|Oral capsules
223659550|NCT04096976|OTHER|logistic regression|To identify associations between factors listed in Table 1 and hospital survival, we used logistic regression
223659551|NCT02802267|DRUG|Inecalcitol|vitamin D receptor agonist
223659552|NCT02802267|DRUG|Placebo Oral Tablet|placebo
223659553|NCT02907632|DRUG|Metoclopramide|"Metoclopramide Solution 4 mg / ml; 30 ml canister (1 drop equals 0.2 mg). Dose: 0.2 mg / kg / dose (1 drop per kg) every 8 hours orally 15 minutes before lactation.~Duration: Until the child completes 40 weeks of post menstrual age."
223659554|NCT02907632|DRUG|Placebo|Oral solution: 1 drop per kg of placebo 15 minutes before lactation with identical presentation appearance, taste and color than Metoclopramide. Duration: Until the child completes 40 weeks of post menstrual age.
223659555|NCT02292836|OTHER|Questionnaire testing|Questionnaire testing on rosacea and non-rosacea dermatology outpatients
223659556|NCT04279418|DIETARY_SUPPLEMENT|Mixed functional foods supplementation|In this project, taking the method of random, double blindness and control, participants in the mixed functional foods group will take functional foods with main compositions of ginsenoside, green tea polyphenols and marine collagen peptide for three months. After that, neuropsychological tests and neuroimaging biomarkers will be compared between functional food group and placebo group.
223659557|NCT04279418|DIETARY_SUPPLEMENT|Placebo|In this project, taking the method of random, double blindness and control, participants in the placebo group will take placebo for three months. After that, cognitive changes and neuroimaging biomarkers will be compared between functional food group and placebo group.
223659558|NCT03463642|DIETARY_SUPPLEMENT|vitamin D3|100,000IU
223659559|NCT03463642|DIETARY_SUPPLEMENT|Pill|Dicalcium phosphate, microcrystalline cellulose, silicium dioxide, magnesium stearate
223659560|NCT03463642|DIETARY_SUPPLEMENT|orange syrup|100 drops orange syrup
223659561|NCT03463642|OTHER|mineral oil|Paraffinum Liquidum,Isopropyl Palmitate,Parfum
223659562|NCT03463642|DIETARY_SUPPLEMENT|Penetrator|Tangerine essential oil (10ml)
223659563|NCT01474018|DRUG|QR-bromocriptine|The study drug is added-on to patients on existing type 2 diabetes treatment with insulin +metformin+exercise/nutritional counseling. The study drug is titrated up starting at one 0.8mg tab daily for 1 week, then 2 (0.8mg) tablets for week 2, then 3 tablets for week 3, then 4 tablets for week 4, then 5 tablets for week 5, then six tablets for week 6 (total 4.8). The limiting factor is nausea at which point the patients will back down the highest tolerated dose and continue on that dose for the remainder of the 6 months of the study.
223659564|NCT04049149|OTHER|Biogenetic explanation and endocrinologist intensive managment|"* JADE report and JADE APP~* Biogenetic explanation~* First-year intensive management by endocrinologists~* Follow up by their usual care doctors for continue treatment regimen maintenance.~* Yearly DM nurses follow up for blood taking and questionnaires"
223659565|NCT04049149|OTHER|Usual care management|"* JADE report and JADE APP~* Attend their usual care clinic for ongoing treatment~* Yearly DM nurses follow up for blood taking and questionnaires"
223659566|NCT01034748|DRUG|[14C]PF00299804|Single 45 mg oral dose of radiolabelled PF-00299804
223659567|NCT02865707|DIETARY_SUPPLEMENT|Synergy-1|Synergy-1 is chicory-derived β-fructans inulin plus FOS (1:1).
223659568|NCT02865707|DIETARY_SUPPLEMENT|Maltodextrin|Maltodextrin is carbohydrate adsorbed in the small bowel.
223659569|NCT00001378|DRUG|fenretinide|
223659570|NCT06382376|PROCEDURE|Intrathecal morphine administered group, Four quadrant transversus abdominis plane block applied group|Intrathecal morphine administered group and Four quadrant transversus abdominis plane block applied group
223659571|NCT02433080|BEHAVIORAL|Shape-Up following cancer treatment|"The programme is based on Social Cognitive Theory and Control Theory. The focus of the programme lies on self-control, self-efficacy, and relapse prevention."
223659572|NCT01345357|DRUG|CEP-9722|CEP-9722 will be administered orally from day 2 through day 7 of each cycle beginning with cycle 2. The starting dose will be 150 mg twice daily. Following cycle 2, the dose will either be decreased to 150 mg daily or increased to 200 mg twice daily in a cohort of 3 to 4 new patients. Subsequent cycles will increase the dose by 100 mg twice daily in cohorts of 3 to 4 patients (with criteria to expand to 6 patients) to a maximum of 400 mg twice daily. Patients must receive CEP-9722 to remain in the study. Once treatment with CEP-9722 is discontinued, patients will withdraw from the study.
223659573|NCT01345357|DRUG|Gemcitabine|Gemcitabine will be administered at 1250 mg/m\^2 intravenously on day 1 and day 8 of each 21-day cycle. Dosage reduction may be applied on day 8 (within a cycle) or on day 1 of the next cycle based upon the grade of toxicity experienced by the patient.
223659574|NCT01345357|DRUG|Cisplatin|Cisplatin will be administered at 75 mg/m\^2 intravenously on day 1 of each cycle, after the infusion of gemcitabine. Dosage reduction may be applied on day 1 of the next cycle based upon the grade of toxicity experienced by the patient.
223659575|NCT02567604|BEHAVIORAL|Focus Groups|at least three focus groups lasting approximately one hour
223659576|NCT01965574|PROCEDURE|Trendelenburg position|
223769155|NCT01541826|DIETARY_SUPPLEMENT|Placebo capsule|Color-matched rice powder pill, 2 x 250 mg/day for 12 weeks
223769156|NCT01541826|DIETARY_SUPPLEMENT|Chokeberry extract capsule, acute|Chokeberry extract capsule, 2 x 250 mg, one-time dose.
223769157|NCT00169143|DRUG|Rituximab + ACVBP regimen plus Pegfilgrastim|
223659577|NCT03219658|BEHAVIORAL|Parenting education sessions|If assigned to the parenting education session group, families will start with the 10-week group parenting education sessions and 2-4 home visits immediately after being enrolled. During this time, they will also come in for four one-on-one check-ins with the STOMP team. Each check-in will be approximately 1 hour. At least one parent/caregiver will attend weekly parenting sessions which will take place at SickKids. The Toronto Public Health Nurse will arrange 2-4 home visits with the family during the 6 month period of the study. The home visits will focus on helping to apply the messages and skills from the group sessions in their homes, and making connections in the neighbourhood to recreational or nutrition programs or other supports for the family.
223659578|NCT02675556|DRUG|Allo-hMSCs|a single administration of allogeneic Human Mesenchymal Stem Cell (hMSCs): 100 x 10\^6 (100 million) allo-hMSCs of cells
223659579|NCT02675556|DRUG|Placebo|a placebo administration consisting of 1% human albumin serum in Plasma-Lyte A
223659580|NCT00965965|BEHAVIORAL|New colorectal cancer screening patient education document|The newly developed educational document was created accounting for health behavioral models (such as the Expanded Health Behavior Model, Social Cognitive Theory, and the Transtheoretical Model) and related research studies indicating the factors that most strongly and positively influence patients' cognitions regarding colorectal cancer screening and are, in turn, predictive of actual colorectal cancer screening behavior.
223659581|NCT00965965|BEHAVIORAL|Traditional colorectal cancer screening education document|The traditional educational document is a slightly edited version of materials freely available on the National Cancer Institute (NCI) web site, used in this study with the permission of the NCI.
223659582|NCT05395793|OTHER|Support Group|Support Group with moderator
223659583|NCT02691871|DRUG|Apatinib (250 mg/d) + Docetaxel (60 mg/m2)|
223659584|NCT02691871|DRUG|Apatinib (500 mg/d) + Docetaxel (60 mg/m2)|
223659585|NCT02691871|DRUG|Apatinib (750 mg/d) + Docetaxel (60 mg/m2)|
223659586|NCT04522700|PROCEDURE|scapular free flap|use of scapular free flap to reconstruction post maxillectomy defect to provide bony support
223659587|NCT03273218|DEVICE|Tiger catheter|
223659588|NCT03273218|DEVICE|Judkins catheter|
223659589|NCT02797002|OTHER|Assessment|
223659590|NCT05187273|BEHAVIORAL|Elastance Group|Fluids are given based on dynamic elastane value
223659591|NCT06529081|RADIATION|Palliative Radiotherapy|Standard treatment with added consolidative radiotherapy to the chest area and possibly metastatic lesions (if indicated) in doses and for palliative indications (total dose of 30 Gy in 10 daily doses of 3 Gy each).
223659592|NCT06529081|RADIATION|Radical/Ablative Radiotherapy|Standard treatment with added radical/ablative radiotherapy (total dose of 45 Gy in 15 daily fractions of 3 Gy to the chest area and total dose of 24 Gy administered in single fractions of 8 Gy every 2-3 days to the metastatic lesions) to the chest area and all metastatic lesions.
224240971|NCT01223612|PROCEDURE|Modified ETDRS laser|Argon laser therapy to the macula in accordance with the modified ETDRS protocol at baseline, 12, 24 and 36 weeks.
224240972|NCT04785937|DIAGNOSTIC_TEST|Ultrasound and Magnetic Resonance|liver ultrasound (US), including shear wave elastography (SWE) with liver stiffness measurement and US- fatty liver indicator (US-FLI), and a multiparametric unenhanced liver magnetic resonance examination including MR spectroscopy (MRS), Proton Density Fat Fraction (PDFF) and T2\* measurement with Multiecho technique, T1 mapping with Inversion Recovery method, and Intravoxel Incoherent Motion diffusion weighted imaging (IVIM-DWI), measuring different parameters.
224240973|NCT07020728|BEHAVIORAL|Solo: Unmasked Speech Stimuli|Speech stimuli recorded using non-moving speakers and mics. No masking sources present. No BSS applied to multi-channel recordings. Very high output QoS values.
223659593|NCT00830908|DEVICE|HairMax LaserComb|LaserComb to be used 3 times weekly on non-consecutive days, according to User Manual instructions. Use is preferably following a shower, prior to using any styling products on the hair or scalp. Hair may be wet or dry during treatment.
223659594|NCT05247788|BEHAVIORAL|Blood alcohol concentration (BAC) discrimination training|Subjects will receive 0.65 g/kg alcohol to yield a peak BAC of 85 mg/dl (0.085%). They will be trained to accurately estimate their BAC using the Body Scan Exercise with BAC feedback.
223659595|NCT05247788|BEHAVIORAL|Performance feedback training|This training element targets the driver's self-efficacy by increasing their awareness of the behavioral impairing effects of alcohol that are experienced at BACs at and even below the legal limit (50-80 mg/dl).
223659596|NCT05247788|BEHAVIORAL|Blood alcohol concentration (BAC) discrimination training for controls|Subjects will receive 0.65 g/kg alcohol to yield a peak BAC of 85 mg/dl (0.085%). They will be given a general Body Scan Exercise with no feedback.
223659597|NCT04145518|DRUG|Naproxen Sodium|Participants will be randomized to take either a placebo pill or a single 550 mg naproxen sodium pill.
223659598|NCT02462915|DEVICE|i-gel|"a supraglottic airway devices without cuff and the material was Styrene Ethylene Butadiene Styrene.~gastric channel to the The gastric suction channel can facilitate venting and reduce the aspiration."
224240974|NCT07020728|BEHAVIORAL|Raw: Fully masked speech--no motion stimuli|Speech stimuli recorded using non-moving speakers and mics. All masking sources present. No speech separation or extraction methods applied to multi-channel recordings. Very low output QoS values.
224240975|NCT07020728|BEHAVIORAL|StatScrub: Extracted Speech--no motion stimuli|Speech stimuli recorded using non-moving speakers and mics. All masking sources present. Joint ACES scrubbing of both noise sources applied to multi-channel recordings. Very high output QoS values.
223659599|NCT02462915|DEVICE|endotracheal tube|traditional and regularly use in many surgeries for maintaining the airway.
223659600|NCT02462915|DRUG|lidocaine, propofol, fentanyl and cisatracurium|
223659601|NCT02874703|OTHER|Cardiac MRI/MRS|
223659602|NCT06354816|DRUG|Xylocaine 10% pump spray|"First volunteers will undergo insertion of PIVC into the vessel of dorsum manus; 2-10 hours later: All volunteers will undergo insertion of PIVC into the forearm/cubita. Lidocaine spray 10 % serves as a local anesthesia is applied with a dispenser dispensing 0.1ml per pulse on the area of the skin, where the insertion of the PIVC is planned.~Exposure time is 2 min, timed with an hour glass; validated prior to the study by a stop watch. 0.5 ml (5 pulses) of 10% lidocaine spray (equals 50mg of lidocaine) are to be applied before insertion of a PIVC 18 Gauge."
223769158|NCT00169143|PROCEDURE|Autologous stem cell transplant|
223659603|NCT06354816|DRUG|Saline solution isotonic 0.9% NaCl|"First volunteers will undergo insertion of PIVC into the vessel at dorsum manus; 2-10 hours later: All volunteers will undergo insertion of PIVC into the forearm/cubita. Physiological saline solution serves as a placebo and is applied with a dispenser dispensing 0.1ml per pulse on the area of the skin, where the insertion of the PIVC is planned.~Exposure time is 2 min, timed with an hour glass; validated prior to the study by a stop watch. 0.5 ml (5 pulses) of 10% lidocaine spray (equals 50mg of lidocaine) are to be applied before insertion of a PIVC 18 Gauge."
223659604|NCT01050517|DRUG|albendazole + ivermectin + praziquantel|albendazole (400 mg one dose) + ivermectin 200 microgram/kg body weight) + praziquantel (40 mg/kg)
223659605|NCT01050517|DRUG|albendazole + ivermectin + (1 week later) praziquantel|albendazole (400 mg one dose) + ivermectin (200 microgram/kg body weight) + (1 week later) praziquantel (40 mg/kg)
223659606|NCT03152929|DRUG|Paravertebral Block|20-30 mL 0.5% Ropivacaine
223659607|NCT03152929|DRUG|Pectoral Nerve Block|20-30 mL 0.5% Ropivacaine
223659608|NCT02864654|PROCEDURE|ADRC injection|10 mL of autologous ADRC suspension will be injected intramuscularly
223659609|NCT02864654|OTHER|ADRC isolation|ADRC will be isolated according to patent pending technology based on enzymatic digestion, washing and concentration of cell pellet in 10 ml of normal saline.
223659610|NCT02864654|PROCEDURE|Liposuction|
223659611|NCT01015638|DRUG|Clindamycin and BPO 5% gel|Once-daily applications, to the randomized side of the face either left or right, of clindamycin and benzoyl peroxide (BPO) 5% gel.
223659612|NCT01015638|DRUG|Clindamycin phosphate and benzoyl peroxide 2.5% gel.|Once daily application of clindamycin phosphate and benzoyl peroxide (BPO) 2.5% gel
223659613|NCT04741126|OTHER|Manually assisted cough technique|Manually assisted cough technique will be given for four weeks. 10 to 12 repetitions of manually assisted cough technique with rest will be given in one minute 3 to 4 time of repetition in a 1 set. The result of the peak cough flow meter and incentive spirometer will be check pre and post only.3 sets will be given in one session and 2-time session will be recommended per day. The session will be given three days in a week. The Result of the Peak Cough flow meter and incentive spirometer will be check pre and post only.
224240976|NCT07020728|BEHAVIORAL|SlideSpch: Scrubbed Speech emitted from linearly moving speaker stimuli|Speech stimuli recorded using linearly moving speech source and stationary masking sources and mics. All masking sources present. Joint ACES scrubbing of both noise sources applied to multi-channel recordings. Moderately high output QoS values.
223659614|NCT04296448|DEVICE|Cellscope|Cellphone otoscope (Cellscope) to evaluate pediatric patient ears.
224240977|NCT07020728|BEHAVIORAL|SlideNoise: Speech Scrubbed from linearly moving and stationary noise stimuli|Mixed speech and noise sources recorded using a stationary speech source, a stationary noise source, and a linearly moving noise source. A valid source hypothesis of the speech source is used to extract the speech source. High output QoS values.
223659615|NCT02741973|OTHER|Yoga|
223769159|NCT00945984|PROCEDURE|Radical nephrectomy|Surgical options to treat localized renal cell carcinoma
223659616|NCT02741973|OTHER|School sport|
223659617|NCT05643859|DIETARY_SUPPLEMENT|Dietary Fiber|Given PO
223659618|NCT05643859|PROCEDURE|Proctoscopy or anoscopy with Biopsy|Undergo proctoscopy or anoscopy
223659619|NCT05643859|PROCEDURE|Colonoscopy|Undergo Colonoscopy
223659620|NCT05643859|OTHER|Questionnaire Administration|Ancillary studies
223659621|NCT05487196|DRUG|Clonidine|Clonidine belongs to the drug classification of antihypertensives
223659622|NCT05487196|DRUG|Dexmedetomidine|Dexmedetomidine belongs to the drug classification of sedatives
223659623|NCT05487196|DRUG|Fentanyl|Fentanyl belongs to the drug classification of analgesic opioid agonists and is used as the standard of care
223659624|NCT05487196|DRUG|Ropivacaine|Ropivacaine belongs to the drug classification of local or regional anesthesia for surgery and is used as standard of care
223659625|NCT03755778|DRUG|EDP-938|Subjects will receive EDP-938 once daily on Day 1 and 14 (Part 1)
223659626|NCT03755778|DRUG|EDP-938|Subjects will receive EDP-938 once daily on Day 1 and 14 (Part 2)
223659627|NCT03755778|DRUG|EDP-938|Subjects will receive EDP-938 once daily on Day 1 and 8 (Part 3)
223659628|NCT03755778|DRUG|Itraconazole|Subjects will receive itraconazole once daily from Day 5 to Day 18
223659629|NCT03755778|DRUG|Rifampin|Subjects will receive rifampin once daily from Day 5 to Day 16
223659630|NCT03755778|DRUG|Quinidine|Subjects will receive quinidine once daily from Day 5 to Day 12
223659631|NCT01670916|DIETARY_SUPPLEMENT|probiotics|Capsule with 1 x 10\*\*9 Lactobacillus rhamnosus GG and 1 x 10\*\*8 Bifidobacterium BB12. Two capsules once a day. The capsules are opened and the content is dissolved in mother's milk or water if the baby is given any milk. In tube fed infants, two drops are given in the mouth and the rest in the nasogastric tube.
223659632|NCT05829044|DEVICE|Pupillometry|Pupillometer measurement of pupil size in response to different light stimuli
223769160|NCT04321304|DEVICE|Sham transcranial direct current stimulation|Uses weak electrical current (2 mA intensity) at the beginning and the end of a given stimulation period to control for potential placebo-like effects or participant expectation bias.
223769161|NCT04321304|DEVICE|Transcranial direct current stimulation at 2 mA|Uses weak electrical current (2 mA intensity) to either increase or decrease brain excitability and improve functional or cognitive outcomes.
223769162|NCT04321304|DEVICE|Transcranial direct current stimulation at 4 mA|Uses weak electrical current (4 mA intensity) to either increase or decrease brain excitability and improve functional or cognitive outcomes.
223659633|NCT05829044|DEVICE|Light box exposure|Using a light box to produce different wavelengths and intensities of light. Exposure to red light on Night 1 and blue/green light on Night 2 to determine circadian timing and suppression of hormone (melatonin)
223659634|NCT03945617|BEHAVIORAL|Unified Treatment Protocol|The Unified Treatment Protocol (UP) is a transdiagnostic psychotherapeutic treatment manual for emotional disorders, that is based on CBT principles and focuses on changing dysfunctional emotion regulation.
223659635|NCT00910299|DRUG|Prasugrel|One time 60 milligram (mg) oral loading dose and 10 mg once daily oral maintenance dose up to 6 months.
223659636|NCT00910299|DRUG|Clopidogrel|75 mg oral daily maintenance dose up to 6 months.
223659637|NCT02618499|DRUG|Timing of administration of post partum Oxytocin|10 IU of oxytocin given IV at different times after birth
223659638|NCT00711477|DRUG|Naltrexone SR 32 mg/bupropion SR 360 mg/day|
223659639|NCT00711477|DRUG|Placebo|
223659640|NCT00711477|OTHER|fMRI scan|fMRI to assess the effects of the drug/placebo on areas of the brain
223659641|NCT03849118|DIAGNOSTIC_TEST|89Zr-girentuximab|Single IV administration on Day 0, followed by diagnostic scan on Day 5 +/- 2 days.
223659642|NCT03211572|DRUG|Tamoxifen|Participants will take endocrine therapy for 2 weeks prior to surgery.
223659643|NCT02436837|OTHER|sessions with virtual reality|sessions with virtual reality to improve the balance
223659644|NCT02657603|DRUG|Lidocaine|Lidocaine injected through the new Catheter (LAX)
223659645|NCT02657603|DRUG|Lidocaine|Lidocaine injected through the new Catheter (SAX)
223659646|NCT02657603|PROCEDURE|LAX insertion of catheter|ultra sound guided cather insertion in the long axis (LAX) of the adductor canal
223659647|NCT02657603|PROCEDURE|SAX insertion of catheter|ultra sound guided cather insertion in the short axis (SAX) of the adductor canal
223659648|NCT04858022|BEHAVIORAL|Visual Acoustic Biofeedback|In visual-acoustic biofeedback treatment, the elements of traditional articulatory treatment (i.e., auditory models and verbal descriptions of articulator placement) are enhanced with a dynamic display of the speech signal in the form of the real-time LPC (Linear Predictive Coding) spectrum. Because correct vs incorrect productions of /r/ contrast acoustically in the frequency of the third formant (F3), participants will be cued to make their real-time LPC spectrum match a visual target characterized by a low F3 frequency. They will be encouraged to attend to the visual display while adjusting the placement of their articulators and observing how those adjustments impact F3.
223659649|NCT04858022|OTHER|No treatment - waitlist|10-week period of no treatment
223659650|NCT03277339|DRUG|Paroxetine|Deroxat® (20 mg/day) 3 week; can be increase on week 2 until 50 mg.
223659651|NCT03277339|OTHER|Thermal cure|Thermal cure is realized for 3 weeks
223659652|NCT05063448|BEHAVIORAL|DadSpace|A group educational support and mentoring program for perinatal fathers.
224240978|NCT07020728|BEHAVIORAL|SlideMic: Stationary sources scrubbed from a linearly moving mic stimuli|Mixed speech and noise sources recorded using all stationary sources, and a linearly moving microphone (mic 1). Joint ACES scrubbing of both noise sources is used to reduce the response of Mic 1 to a residue of speech. Low output QoS values.
223659653|NCT02448641|BIOLOGICAL|SB623 Implant (2.5M)|2.5 million SB623 cells
223659654|NCT02448641|BIOLOGICAL|SB623 Implant (5.0M)|5 million SB623 cells
223659655|NCT02448641|PROCEDURE|Sham surgery|
223659656|NCT05170880|PROCEDURE|Primary endodontic treatment|Primary non surgical endodontic treatment will be provided to patients in treatment group.
223659657|NCT02929407|DRUG|FE 204205|"In Part 1 of the trial, each subject will receive increasing IV doses of FE 204205, given once daily as 2 hour infusion, on three consecutive days.~In Part 2 of the trial, each subject will receive a 2 hour IV infusion of the maximum tolerated dose of FE 204205 as defined in Part 1 of the trial."
224240979|NCT02393040|OTHER|PRP/Saline|"PRP/Saline: Two groups were defined: group A and group B. Group A received treatment with PRP on the right half-head and placebo on the left half-head while group B received administration of PRP on left half-head and placebo on the right half-head.~Same patient will be injected with PRP and a saline solution. Each patient will be injected on half-head."
224240980|NCT07013682|BIOLOGICAL|PRF as adjunct to non-surgical mechanical debridement|Non-surgical mechanical debridement with hand and power-driven instruments will be performed. Venous blood will be harvested from the patient and centrifuged. Immediately afterwards, the PRF will be inserted in all pockets of the allocated side of the jaw in all pockets ≥ 5 mm.
223659658|NCT02929407|DRUG|Placebo|In Part 2 of the trial, each subject will receive a 2 hour IV infusion of placebo.
223659659|NCT06111781|DRUG|Relugolix 120 MG [Orgovyx]|ORGOVYX will be initiated with a loading dose of 360 mg on the first day and continue treatment with a 120 mg dose taken orally once daily at approximately the same time each day. Total length of treatment will be 30 days.
223659660|NCT06111781|RADIATION|SBRT standard of care radiotherapy treatment|SBRT is a standard-of-care radiotherapy treatment for intermediate-risk prostate cancer.
223659661|NCT06259656|DIAGNOSTIC_TEST|COVID-19 Spike Protein IgG Quantitative Antibody (CMIA)|Maternal blood and cord blood were collected to test for COVID-19 Spike Protein IgG Quantitative Antibody (CMIA)
223659662|NCT04404933|OTHER|Treatment algorithm for OIC|Treatment Algorithm for OIC
223659663|NCT01895621|PROCEDURE|Median nerve decompression at the wrist|Surgical incision of the carpal ligament at the wrist and proximal hand to decompress the median nerve.
223659664|NCT01895621|DIETARY_SUPPLEMENT|Alpha lipoic acid post median nerve decompression|Daily supplementation of alpha lipoic acid
223659665|NCT05213728|BIOLOGICAL|VXA-G1.1-NN|Norovirus GI.1 Norwalk VP1 Vaccine (VXA-G1.1-NN) E1/E3-Deleted Replication-Defective Recombinant Adenovirus 5 with Adjuvant Oral Tablet Vaccine.
223659666|NCT02375334|OTHER|Medical Chart Review|Medical chart review by the Cancer Center ORIS and EPIC based systems
223659667|NCT05081297|OTHER|Qigong|Qigong as a traditional chinese medicine technique, composed of several types of exercises: Baduanjin, taijiquan, yijinjing, baojiangong.
223769163|NCT01652456|OTHER|Addiction support|one consultation with an addiction specialist
223659668|NCT00648960|DRUG|Clarithromycin|Single-dose 500 mg immediate-release oral tablet
223659669|NCT00648960|DRUG|Clarithromycin|Single-dose 500 mg immediate-release oral dose
223659670|NCT03351283|OTHER|Severe sodium restriction|Patients will be assigned to a diet with sodium restriction of two grams.
223659671|NCT03351283|OTHER|Moderate sodium restriction|Patients will be assigned to a diet with sodium restriction of three grams.
223659672|NCT04240132|OTHER|Adherence to Hand Hygiene|determine the colonization of microorganisms due to microbial reproduction on the external surface of the distal end of the enteral feeding tube (EFT), hub of the EFT and other feeding system components and assess the relation between the colonization and adherence to hand hygiene practices by nurses and other healthcare workers
223659673|NCT00870519|DRUG|I-123-MNI-168|Subjects will be injected with up to 5 mCi and not to exceed 5.5 mCi (not \>10% of 5 mCi limit) of 123-I MNI-168 followed by serial SPECT imaging.
223659674|NCT00870519|DRUG|123-I MNI-168|Subjects will be injected with up to 5 mCi and not to exceed 5.5 mCi (not \>10% of 5 mCi limit) of 123-I MNI-168 followed by serial SPECT imaging.
223659675|NCT00892216|DEVICE|Acupressure (BioBand)|Band will remain on from 20 minutes before surgery until the end of the hospital stay.
223659676|NCT00892216|DEVICE|Acupressure (BioBand)|Band will remain on from 20 minutes before surgery until the end of the hospital stay. The same band will be placed and turned so the beads face the corresponding point on the dorsal surface of the upper limb area.
223659677|NCT00884741|RADIATION|3-Dimensional Conformal Radiation Therapy|Undergo 3-dimentional conformal radiation therapy
223659678|NCT00884741|BIOLOGICAL|Bevacizumab|Given IV
223659679|NCT00884741|RADIATION|Intensity-Modulated Radiation Therapy|Undergo intensity-modulated radiation therapy
223659680|NCT00884741|OTHER|Laboratory Biomarker Analysis|Correlative studies
223659681|NCT00884741|OTHER|Placebo|Given IV
223659682|NCT00884741|OTHER|Quality-of-Life Assessment|Ancillary studies
223659683|NCT00884741|DRUG|Temozolomide|Given orally
223659684|NCT02052999|DRUG|PAC-14028 cream 1%|Participants received topical PAC-14028 cream 1% twice daily for 8 weeks
224240981|NCT07013682|BIOLOGICAL|Control, non-surgical mechanical debridement alone|Non-surgical mechanical debridement with hand and power-driven instruments will be performed. Venous blood will be harvested from the patient and centrifuged. Immediately afterwards, an empty sy will be inserted in all pockets of the allocated control side of the jaw in all pockets ≥ 5 mm.
223659685|NCT02052999|OTHER|Vehicle|Participants received topical Vehicle twice daily for 8 weeks
223659686|NCT02052999|DRUG|Rozex gel 0.75%|Participants received topical Rozex gel 0.75% twice daily for 8 weeks
223659687|NCT05808361|OTHER|exercises|"The complex of therapeutic exercises included exercises in the initial position lying, sitting and standing. In active and static motor modes under the control of saturation, blood pressure, heart rate and respiratory rate.~The complex included breathing exercises with the inclusion of compensatory respiratory muscles, elements of sound and drainage gymnastics, and diaphragmatic breathing. Therapeutic gymnastics was carried out in the form of individual lessons with an exercise therapy instructor, a course of 10 procedures, daily, the duration was 20 minutes."
224240982|NCT07024654|DRUG|Doxycycline Injection|Injection of doxycycline as a sclerosing agent into the genicular artery region under ultrasound guidance for the purpose of evaluating its effectiveness in reducing knee pain.
224240983|NCT07027553|BEHAVIORAL|Mobile health exercise programme|8 week personalised exercise intervention. Delivered and monitored via mobile health technology
224240984|NCT07027553|OTHER|Lifestyle maintenance|Continue current lifestyle
224240985|NCT07027670|DRUG|5-Aminolevulinic Acid hydrochloride (5-ALA)|5-ALA: supplied for oral administration as a dark green, opaque, size 0, hypromellose (HPMC) capsule containing drug alone at a dosage strength of 75mg (58.7mg as 5-ALA). There are no excipients.
224240986|NCT07027670|OTHER|Placebo|Supplied for oral administration as a dark green, opaque, size 0, HPMC capsule containing 125mg lactose. The capsule shells are of non-animal origin, and are comprised of HPMC, titanium dioxide, and a copper complex of chlorophyllins.
224240987|NCT07027670|DRUG|Sodium ferrous citrate (SFC)|SFC: supplied for oral administration as a dark green, opaque, size 0, HPMC capsule containing drug alone at a dosage strength 118mg (12.5mg as Fe). There are no excipients.
224240988|NCT07027319|OTHER|Parenting Education|The intervention group will receive 8 sessions of Triple P (positive parenting training).
224240989|NCT03953170|DRUG|Teduglutide|"Teduglutide (Gattex, Shire) was approved by the FDA in 2012 for use in adult patients with short bowel syndrome requiring parenteral support only.~The results of this study will not be used to justify a change of indication, or dose currently approved for Teduglutide, and will not be used to advertise the drug. This study meets all of the requirements for exemption from the IND regulations and an IND exemption has been confirmed by the FDA."
224240990|NCT03953170|DRUG|Placebo|Placebo
224240991|NCT01924130|OTHER|Classroom feeding|Students are fed breakfast in the classroom at the start of the school, rather than the cafeteria before school.
223659688|NCT05808361|OTHER|massage|Hardware massage in the electrostatic field with a frequency of 30/60 Hz of the chest area consisted of 10 procedures, daily, the duration of the procedure was 20 minutes.
223659689|NCT01638182|DIETARY_SUPPLEMENT|Placebo|27 participants received for three months 1 placebo capsule per day
223659690|NCT01638182|DIETARY_SUPPLEMENT|Vitamin K1-capsules|27 participants received for 3 months 1 vitamin K1-capsule per day containing 52 µg of K1/day
224240992|NCT01924130|BEHAVIORAL|Nutrition education lessons|Students receive breakfast specific nutrition education lessons.
223659691|NCT01638182|DIETARY_SUPPLEMENT|Vitamin K2-capsules|27 participants received for 3 months 1 vitamin K2-capsule per day containing 75 µg of MK-7.
223659692|NCT06314828|BIOLOGICAL|RJMty19 (CD19-CAR-DNT cells)|Lentiviral vector-transducted double negative T cells (DNT) to express anti-CD19 CAR. Prior to cellular infusion, each patient received cyclophosphamide, fludarabine and Etoposide lymphodepleting chemotherapy.
223659693|NCT01608932|PROCEDURE|Telemonitoring for frail patients with chronic diseases|"Patients are equipped with a telemonitoring kit that can be composed by a portable wrist clinic device, a digital weight scale and a glucometer for clinical parameters measuring, according to the pathologies of the patient. The equipment is completed by a gateway device for data transmission.~The patient can monitor a complete set of clinical parameters, such as pulse-oxymetry, heart rate, blood pressure, ECG, body weight and glycemia with a frequency set by the clinician in the personalized treatment plan. In the same protocol the clinician includes also the alarm thresholds that determine when the clinical measures are out-of-range. Data are transmitted to a regional eHealth centre where a group of operators keeps these information under control and alerts the general practitioner in case of worsening of symptoms."
223659694|NCT04239378|PROCEDURE|socket preservation|Autogenous dentin matrix and collagen membrane(test group) Bovine derived xenograft and collagen membrane (control group)
223659695|NCT02198118|OTHER|Domiciliary exercises for the upper limbs|Study group (SG) instructed to perform domiciliary exercises for the upper limbs.
223769164|NCT06104189|DIAGNOSTIC_TEST|MRI|MRI based classification of breast cancer histological factors and subtypes
223659696|NCT06153719|OTHER|12-weeks combined exercise intervention|This 12-week combined exercise intervention will consist of 3 supervised exercise classes per week, each one lasting 50 minutes. It will involve both aerobic and resistance training in order to follow the UK's physical activity recommendations
223659697|NCT02717806|BEHAVIORAL|PATHway|Patients will use the PATHway platform for 6 months
223659698|NCT01014910|OTHER|Continuous pulse oximetry monitoring|Placement of a pulse oximeter to monitor oxygenation status. This is usually placed on a toe, finger, or ear lobe and held in place with adhesive tape. Patients will receive continuous pulse oximetry monitoring throughout their hospital stay regardless of their need for supplemental oxygen.
223659699|NCT01014910|DEVICE|Intermittent pulse oximetry monitoring|Placement of a pulse oximeter to monitor oxygenation status. This is usually placed on a toe, finger, or ear lobe and held in place with adhesive tape. Patients will receive pulse oximetry monitoring during vital signs checks (every 4 hours) and as indicated clinically when not on supplemental oxygen. When patients require supplemental oxygen they will be continuously monitored by pulse oximetry until their oxygen requirement has resolved.
223659700|NCT02724397|DEVICE|LCI/BLI then white endoscopy|First use of Linked Color Imaging/Magnifying Blue Laser Imaging (LCI/BLI) and then White Light Endoscopy to detect colonic adenomas.
224240993|NCT01924130|BEHAVIORAL|Social Marketing|A social marketing campaign designed to promote consumption of one healthy breakfast a day. The marketing includes a healthy breakfast points-based reward program designed by the students and promotional campaigns.
224240994|NCT01924130|BEHAVIORAL|Parent outreach|A variety of communication methods that engage families and offer education that meets their needs, including school breakfast menus, parent newsletters, and information tables at parent-teacher meetings.
224240995|NCT07029308|PROCEDURE|Modified poco-poco exercise program as the home-based therapy (Intervention)|Patient will do the exercise at home 5 days/week and supervised via zoom application. Supervised via Zoom will be conducted every week. The instructor will monitor the exercise movement of the participants, if there is any mistake the instructor will pause the session and correct it immediately. The monitoring will also be done by researcher assistant to collect attendance, help ensure correct movement and operational problem. The intensity of the exercise will be evaluated and adjusted every 4 weeks.
224240996|NCT07028840|OTHER|Physiotherapy|10 sessions over 2 weeks, including TENS, cold therapy, ultrasound, and exercise therapy, 5 sessions per week.
223659701|NCT02724397|DEVICE|White endoscopy and then LCI/BLI|First use of White Light Endoscopy and then Linked Color Imaging/Magnifying Blue Laser Imaging (LCI/BLI) to detect colonic adenomas.
223659702|NCT05518747|DIETARY_SUPPLEMENT|Probiotic|In this group participants will receive probiotic supplements twice a day (morning and evening) for a period of 12 weeks.
223659703|NCT05518747|DIETARY_SUPPLEMENT|Placebo|In this group participants will receive placebo twice a day (morning and evening) for at period of 12 weeks.
223659704|NCT05262829|BIOLOGICAL|Human Umbilical Cord Mesenchymal Stem Cells|MSCs treatment by intestinal submucosal injection/MSCs treatment by intravenous drip + MSCs treatment by intestinal submucosal injection
223659705|NCT04662515|PROCEDURE|Type of surgery|surgical or non-surgical extraction one or more teeth
223659706|NCT04662515|DRUG|Dabigatran|
223659707|NCT04662515|DRUG|Rivaroxaban|
223659708|NCT04662515|DRUG|Apixaban|
223659709|NCT04662515|DRUG|Edoxaban|
223659710|NCT04662515|DRUG|Warfarin|
223659711|NCT00637702|DRUG|ARRY-334543, EGFR/ErbB2 inhibitor; oral|single dose and multiple dose, escalating
223659712|NCT04521049|DRUG|Saxagliptin 5mg|Patients would be assigned to saxagliptin (Onglyza® AstraZeneca Pharmaceuticals LP, Indiana, USA), either received a dose of 5 mg or 2.5 mg daily if patients had eGFR \<50 mL/min/1.73 m2
223659713|NCT05933239|DRUG|68GaNOTA-Anti-MMR-VHH2|Injection of the radiopharmaceutical and PET/CT imaging
223659714|NCT05499299|BEHAVIORAL|Google ads|Individuals who googled COVID-19 information in Hong Kong were randomized to see one of the seven ads and, if they clicked on the ads, the corresponding vaccine message on our website
223659715|NCT04063306|OTHER|none of intervention was given|this is an observational survey and no intervention is given
223659716|NCT06205186|BEHAVIORAL|Army Health|A whole health mobile application for Soldiers
223659717|NCT00849095|DRUG|budesonide/formoterol combination (PRN)|budesonide/formoterol combination 160/4.5 mcg 1 inhalation used as needed for a period of 52 weeks
223659718|NCT00849095|DRUG|budesonide/formoterol combination|budesonide/formoterol 160/4.5 mcg 1 inhalation bid
223659719|NCT00849095|DRUG|placebo|bid inhaled placebo
223659720|NCT00849095|DRUG|terbutaline|as needed terbutaline 500 mcg for a period of 52 weeks
223659721|NCT00145977|DRUG|Alendronate|alendronate 70 mg once weekly
223659722|NCT00145977|DIETARY_SUPPLEMENT|Calcium Citrate|600 mg of calcium citrate
223659723|NCT00145977|DIETARY_SUPPLEMENT|Vitamin D|500 mg of Vitamin D consumed with the evening meal.
224240997|NCT07028840|DEVICE|Extracorporeal Shock Wave Therapy (ESWT)|4 sessions total, applied 2 times per week for 2 weeks.
224240998|NCT07028840|DEVICE|High-Intensity Laser Therapy (HILT)|4 sessions total, applied 2 times per week for 2 weeks.
223659724|NCT01192685|PROCEDURE|Transcranial Magnetic Stimulation (TMS)|TMS will be administered to subjects 5 days a week-typically Monday through Friday, for 6 weeks.
223659725|NCT01192685|DEVICE|near infrared spectroscopy (NIRS)|near infrared spectroscopy (NIRS) will be used to measure the blood flow in the brain
223659726|NCT04813185|BEHAVIORAL|Bridging the Gap|"Bridging the Gap Bridging the Gap is a hybrid model for violence prevention which integrates a hospital-based brief violence intervention (BVI) delivered to the patient while in hospital with a wrap-around community case management prevention strategy.~Firearm Counseling Program The firearm counseling program was developed to be administered in the hospital alongside the 6-step intervention program, as well as in the patient's home after hospital discharge. The firearm safety counseling program includes 3 components aimed at understanding patient risk, reducing firearm-related violence risk-factors, and helping patients increase firearm safety practices."
223659727|NCT02408159|DRUG|Varicella Zoster Vaccine|
223659728|NCT02408159|DRUG|Placebo|
223659729|NCT05539300|DIAGNOSTIC_TEST|PSMA-PET/CT response evaluation|PSMA-PET/CT response evaluation, 2 months after starting hormonal therapy, 2 months after starting upfront enzalutamide therapy
224240999|NCT04469153|OTHER|No intervention / Evaluation of the ferritin and glycosylated ferritin by standard approved serological tests|No intervention / Evaluation of the ferritin and glycosylated ferritin by standard approved serological tests
223659730|NCT02202083|OTHER|Cook Balloon|"There are two groups. Acoording to the bishop score, one group uses the oxytocin , and the other uses the cook balloon.~This group is term gestaion,with bishop score less than 6."
223659731|NCT02966054|BEHAVIORAL|Digital Health Physical Activity Intervention Group|Print materials on exercise after cancer, Fitbit Flex for 12 weeks, and daily Text Messages for 12 weeks
223659732|NCT00275548|DRUG|Pegasys|135-180 micrograms administered sc once weekly
223659733|NCT00275548|DRUG|Copegus|400-1200 mg/day for 48 weeks
223659734|NCT00757471|PROCEDURE|Brillant Blue|Membrane Peeling with Brillant Blue
223659735|NCT00757471|PROCEDURE|Indocyanine Green|Membrane Peeling with indocyanine Green
223659736|NCT03790033|DRUG|Ucha-Shinki-Hwan|"Product name : Bosinji Granule Manufacturer : Tsumura \& Co. Ingredient : Bosinji granule 2.5g (Bosinji extract 1.523g)~Bosinji extract is composed of following proportion of ingredient~Rehmannia Root 1.7g Achyranthes Root 1.0g Cornus Fruit 1.0g Dioscorea Rhizome 1.0g Psyllium Husk 1.0g Alisma Rhizome 1.0g Hoelen 1.0g Moutan Root Bark 1.0g Cinnamon Bark 0.3g Pulvis Aconiti Tuberis Purificatum 0.3g"
223659737|NCT03790033|DRUG|Placebo|placebo granule
223659738|NCT00705549|DRUG|Gemcitabine|Gemcitabine I.V at the dose of 1000mg/m2 on Day 1 and Day 8
223659739|NCT00705549|DRUG|Cisplatin|Cisplatin I.V at the dose of 75mg/m2 on Day 1
224241000|NCT06625307|DRUG|NNC0537-1482|Administered via subcutaneous route
224241001|NCT06625307|DRUG|Placebo|Administered via subcutaneous route
224241002|NCT07025915|DRUG|[14C]SSS17|single oral dose
224241003|NCT03328793|BEHAVIORAL|Mood Assessment|Prior to and after the session, the patients will be asked to fill a VAMS (Visual Analog Mood Scale).
224241004|NCT03328793|BEHAVIORAL|Emotion Assessment|During the sessions, the patients will be videotaped and the videotapes will be reviewed by 2 independent research assistants. With the use of the Observed Emotional Rating Scale (OERS), the research assistants will be able to assess the patients's emotions at the beginning and at the end of the session (they will analyse the first 10 and the last 10 minutes of the sessions).
224241005|NCT03328793|BEHAVIORAL|Communication Assessment|During the sessions, the patients will be videotaped and the videotapes will be reviewed by 2 independent research assistants. With the use of the CODEM Scale, the research assistants will be able to assess the patients's emotions at the beginning and at the end of the session (they will analyse the first 10 and the last 10 minutes of the sessions).
224241006|NCT03328793|OTHER|Mobility assessment|If deemed to be safe, the patients will undergo a gait speed assessment as well as a TUG (timed-up-and-go) prior to and after the sessions
224241007|NCT03328793|OTHER|Music Intervention|The participants will listen to a 30 minute live music sessions which will be given by musicians (who is a volunteer)
224241008|NCT03328793|OTHER|Documentary watching|The patients will watch a documentary for 30 minutes in the presence of a volunteer
224241009|NCT06709599|OTHER|Three-Week Strength and Conditioning Program|Athletes train six days a week for three weeks, totaling approximately 15 hours of training per week. Training includes circuit training, weightlifting, technique drills, and sparring, designed to mimic typical MMA preparation.
224241010|NCT06707896|DRUG|TCR1020-CD8 T cells|TCR1020-CD8 T cells are autologous mKRAS-redirected CD8+ T cells engineered using a lentiviral vector to express a TCR with specificity for HLA-restricted mKRAS G12V epitopes restricted to the HLA-A\*11:01 molecule.
223659740|NCT00705549|DRUG|Docetaxel|Docetaxel I.V at the dose of 75mg/m2 on Day 1
223659741|NCT00705549|DRUG|Cisplatin|Cisplatin I.V at the dose of 80mg/m2 on Day 1
223659742|NCT00705549|DRUG|Vinorelbine|Vinorelbine per os 50mg every Monday, Wednesday and Friday
223659743|NCT00705549|DRUG|Pemetrexate|Pemetrexate I.V 500mg/m2 on Day 1
223659744|NCT02816385|PROCEDURE|Antegrade cardioplegia|Injection of the cardioplegia in the coronary arteries
223659745|NCT02816385|PROCEDURE|Retrograde cardioplegia|Injection of the cardioplegia in the venous system
223659746|NCT00782834|DRUG|Nilotinib|400 mg orally twice daily until disease progression, intolerability or withdrawal of consent
223659747|NCT05415917|DRUG|Gemcitabine and Capecitabine|"A chemotherapy cycle will constitute 28 days of treatment:~1. Gemcitabine: 1000 mg/m2 IV on days 1, 8, and 15 of each 28-day cycle~2. Capecitabine: 1660 mg/m2 per day orally on days 1 through 21 of each 28-day cycle."
223659748|NCT02452515|DRUG|BAY1142524|5 mg BAY1142524 or placebo given as 5 mg IR tablet twice daily for 2 weeks
223659749|NCT02452515|DRUG|BAY1142524|10 mg BAY1142524 or placebo given as 2 x 5 mg IR tablets twice daily as for 2 weeks
223659750|NCT02452515|DRUG|BAY1142524|25 mg BAY1142524 or placebo given as 5 x 5 mg IR tablets twice daily for 2 weeks
223659751|NCT02452515|DRUG|BAY1142524|50 mg BAY1142524 or placebo given 1 x 50 mg IR tablet once daily for 2 weeks
223659752|NCT02452515|DRUG|Placebo|The patients will be treated orally with combinations of IR tablets containing placebo to achieve the indicated dosages.
223659753|NCT04059588|DRUG|2141 V-11|intratumoral injection of 2141-V11
223659754|NCT05901389|DRUG|Lidocaine|After the thoracoscopic surgery, lidocaine will be transfused through the epidural tube fixed in the chest drainage tube was connected to an electronic pump whose parameters are already set up (marking the chest drain for analgesia).
223659755|NCT05901389|DRUG|normal saline|After the thoracoscopic surgery, normal saline will be transfused through the epidural tube fixed in the chest drainage tube was connected to an electronic pump whose parameters are already set up (marking the chest drain for analgesia).
223659756|NCT05420259|BEHAVIORAL|Combined Exercise and Dietary Intervention (CEDI)|The exercise program will be planned by an exercise physiologist and implemented by physiotherapists prior to rehabilitation physician assessment. In the first session patients will be evaluated by physiotherapist in order to allow personalization of exercise according to patient's age and functional capacity. In regard to diet, written materials will be given to patients and caregivers, namely a dietary plan, standard menus, recipes, and standard portions information.
223659757|NCT05420259|BEHAVIORAL|Standard Care|Standard Care
223659758|NCT03098615|DRUG|Jublia (Efinaconazole 10% Topical Solution)|Efinaconazole 10% Topical Solution will be applied to the great toenail with the DLSO and dermatophytoma.
223659759|NCT05828056|DEVICE|Wearable activity tracker|Garmin smartwatch will record features, such as activities, heart rate, sleep, through smartphone App
223659760|NCT03572127|OTHER|Diet|High protein diet derived from either animal or non-animal sources.
223659761|NCT01215097|DRUG|Linagliptin|once a day
223659762|NCT01215097|DRUG|placebo|once a day
223659763|NCT00660686|BEHAVIORAL|Resistance Exercise|60 minute sessions 3 times a week of moderate-vigorous lower and upper body free-weight strength training plus impact training (jumps). Two of the three sessions are conducted in a supervised setting at a university fitness facility and the third session is a modified version of the exercise program performed at home. Participants are in the exercise program for 12 months
223659764|NCT00660686|BEHAVIORAL|Flexibility Training|60 minute session 3 times a week focusing on whole body flexibility (stretching) and relaxation (progressive neuromuscular relaxation, focused breathing) exercises. Exercises are selected to be non-weight bearing and require minimal muscle strength in order to provide a contrast to the intervention arm. Two sessions are conducted in a supervised setting at a university fitness center and the third is a home-based version of the program performed at home.
223659765|NCT03497312|PROCEDURE|full mouth rehabilitation|full mouth rehabilitation under general anesthesia
223659766|NCT04017845|DIAGNOSTIC_TEST|FIT|Screenees were supplied with two fecal collection devices and asked to collect two specimens from two consecutive Different Bowel Movement Samples (DBMS) or, in case of infrequent bowel movements, from the Same Bowel Movement Sample (SBMS).Instruction stressed that after collection the device must be stored in refrigerator and transported in an iced pack within no more than 48h from sampling. After checking for sampling appropriateness, the received samples were analyzed by the FOB Gold/SENTiFOB method (Sentinel Diagnostics SpA, Milan, Italy), according to the previously validated procedural platform
223659767|NCT04017845|PROCEDURE|Precolonoscopy cleansing regimen|Laxative stimulant two days prior to the cleansing regimen involves the intake of one 10 mg tablet of bisacodyl (Dulcolax, Sanofi,UK) at 18:00 for two consecutive nights.The evening before colonoscopy cleansing started with 2 doses (at 16:00 and 20:00) of one sachet Sodium picosulphate preparations (PICOPREP, Ferring Pharmaceutical Co., Ltd., Zhongshan, China), dissolved in150 mL of cold water, followed with five 240 mL portions of clear liquids within 3 h. The third dose is taken in the morning about 5 h prior to colonoscopy, followed with at least three 240 mL portions of clear liquids no later than 2 h before colonoscopy.
223659768|NCT04017845|PROCEDURE|Conventional Colonoscopy|With the colonoscopists completely blinded regarding the FIT results, conventional colonoscopy examinations were conducted in the Endoscopy Unit of Al-Kindy Polyclinic. According to the five levels of competency proposed by the European guidelines, this unit is assigned as level 2, with the possibility of removing polypoid and sessile lesions \<25 mm, providing there is good access. For flat lesions, larger sessile and polypoid lesions, and smaller lesions with more difficult access, the lesions were documented appropriately with the patients referred to higher competent units in order to be safely and expertly removed.
224241011|NCT07029048|OTHER|Standard Post-COVID Rehabilitation Program|This standardized rehabilitation intervention includes a 14-day inpatient course comprising physiotherapy, therapeutic exercises, massage, and respiratory gymnastics. The program is delivered equally to all participants regardless of cognitive status and is intended to promote post-viral recovery in patients recently discharged following COVID-19 pneumonia. No specific cognitive therapy or pharmacological treatment is administered during the rehabilitation period. The intervention is used as background care, not as an experimental variable.
224241012|NCT07028320|DRUG|SAL056 (56.5μg)|Administered by subcutaneous injection once a week during treatment phase
224241013|NCT07028320|DRUG|Alendronate|70 mg tablet taken once a week during treatment phase
224241014|NCT07036029|DRUG|NAL ER|Oral tablets
224241015|NCT07036029|DRUG|Placebo|Oral tablets
223659769|NCT04017845|DIAGNOSTIC_TEST|Histopathological examinations of screen-detected lesions|Adenomas were classified according to the modified revised Vienna classification for the European Guidelines. Advanced adenoma was defined as the presence of one of the following features: \>10 mm diameter, tubulovillous or villous structure, and high-grade neoplasia. Polypoid adenocarcinomas were reported according to the TNM classification, while colorectal cancer associated with flat and/or depressed lesions were reported as non-polypoid lesions, and further classified by the Paris classification. Pathologic results of hyperplastic polyps, sessile serrated lesions or post inflammatory polyps were considered normal findings.
223659770|NCT04017845|DRUG|Tribenoside 400 mg + lidocaine 40 mg suppositories|Treatment of hemorrhoids was initiated with tribenoside 400 mg + lidocaine 40 mg suppositories, once daily for up to 2 weeks.
223659771|NCT04017845|DRUG|Diltiazem hydrochloride 2%/Nitroglycerin rectal ointment|Treatment of anal fissure was initiated with Diltiazem hydrochloride 2%/Nitroglycerin rectal ointment applied every 12 hours, for up to six weeks.
223659772|NCT02758483|OTHER|Control diet|Diet with a little quantity of sugars (30.40g; 12.7% of total carbohydrates of the diet).
223659773|NCT02758483|OTHER|Test Diet|Diet with foods containing moderate quantity of sucrose in composition (80.22g; 30.2% of total carbohydrates of the diet).
223659774|NCT05838898|DEVICE|Specular microscopy|Non-contact Specular microscopy is a non-invasive method that allows for in vivo study of corneal endothelium.
223769165|NCT04647058|PROCEDURE|Cubital tunnel release|The control group will undergo cubital tunnel release in situ. In cases of preoperative or intraoperative ulnar nerve instability, anterior transposition of the ulnar nerve will be performed.
224241016|NCT07035262|OTHER|serum metabolites|serum metabolites before and after colorectal cancer surgery
224241017|NCT07036172|DRUG|HDM1702|Initiate at a once weekly dose of 0.25 mg and followed a fixed-dose escalation regimen, with dose increases every 4 weeks (to doses of 0.5, 1.0, 1.7 and 2.4 mg per week) aiming at reaching the maintenance dose of 2.4 mg at week 16.
224241018|NCT07036172|DRUG|Wegovy ®|Initiate at a once weekly dose of 0.25 mg and followed a fixed-dose escalation regimen, with dose increases every 4 weeks (to doses of 0.5, 1.0, 1.7 and 2.4 mg per week) aiming at reaching the maintenance dose of 2.4 mg at week 16.
223659775|NCT06521905|DEVICE|intravascular lithotripsy|The intravascular lithotripsy can intermittently release acoustic pressure waves at the site of vascular calcification lesions, thereby achieving the goal of rupturing calcified plaques; After the rupture of calcified plaques, the vascular calcification lesions can be fully dilated with the help of lower balloon inflation pressure.
223659776|NCT06521905|DEVICE|high-pressure ballon|High pressure balloon dilation, as the main method for traditional treatment of insufficient stent expansion caused by calcification, has a good therapeutic effect on insufficient stent expansion caused by calcification
224241019|NCT07036094|OTHER|Manual breast milk expression|"Manual breast milk expression: Milk was expressed by hand until the milk flow stopped at the mother's breast. While the baby was suckling from one breast, milk was expressed from the other breast, and a 10 cc sample was taken from the collected milk and placed in sterile fallopian tubes.~The mothers' food records were analyzed for 3 days before the milk sample was taken and on the day the milk sample was taken."
224241020|NCT07037576|PROCEDURE|Breast Reconstruction Surgery|Breast Reconstruction Surgery (either immediate one-stage prepectoral implant reconstruction or two-stage expander/implant reconstruction) with postoperative adjuvant radiotherapy
224241021|NCT07037095|DIAGNOSTIC_TEST|Ankle plantar flexion test:|Ankle plantarflexion is valid test used to assess for gastrocnemius muscle strain . Patient is asked to actively plantarflex the foot against resistance while examiner Observe ,this action activates the gastrocnemius muscle .The reliability for ankle plantar flexion is 0.81 to 0.99. If the patient reports pain in the region of gastrocnemius, the test is positive. If there is no pain , weakness or difficulty performing plantarflexion then suggest that test is negative.
224241022|NCT07037355|COMBINATION_PRODUCT|Handgrip Strength and Hand-Eye Coordination Assessment|Children underwent standardized testing to assess functional recovery post-healing of distal radius greenstick fractures.
224241023|NCT07037316|DIAGNOSTIC_TEST|progressive resistance exercise with lymphatic taping|Participants will receive a supervised, moderate-to-vigorous intensity resistance training program designed specifically for pregnant women, The resistance training will involve the use of light barbells (1-10 lbs) and weight plates (2.5-10 lbs), targeting all major muscle groups through 50-80 repetitions per muscle group over 3-5 minutes, with short rest intervals. Exercises will be performed at a self-rated intensity level considered moderate to vigorous, following the Borg scale for perceived exertion. The training program is based on the BodyPump format but modified to suit pregnancy-related safety considerations.
224241024|NCT07037316|DIAGNOSTIC_TEST|progressive resistance exercise with compression Bandage|Participants in will receive progressive resistance exercise same as Group B and also receive thecompression bandaging as the primary intervention for the management of lower-limb oedema during pregnancy. The compression bandage will be applied in a multi-layered manner, beginning from the base of the toes and extending proximally to below the knee, ensuring graded pressure with higher compression distally and gradually reducing proximally to support venous and lymphatic return. Prior to each application, participants will be asked to lie in a supine position with their legs elevated for 15-20 minutes to reduce pre-existing swelling.
224241025|NCT07036341|OTHER|Protein-enriched diet|A protein intake of 1.5 g/kg bodyweight/day. This will be obtained by consuming protein-rich and protein-enriched foods.
224241026|NCT07036341|OTHER|Progressive resistance exercise|The intervention group will perform resistance training during three non-consecutive days with a minimum of 48 hours between the sessions. Subjects will continue the resistance training after discharge for 2 times a week, also with a minimum of 48 hours between sessions until the study period of 3 months is completed. All sessions will be supervised by physiotherapists.
224241027|NCT07037485|OTHER|Renal resistive index|"It will be measured with ultrasound-Doppler using an abdominal curvilinear probe ultrasonography by two independent, trained sonographers (who will not be involved in patient care). After visualizing the kidney in ultrasound mode and checking for renal abnormalities, an arcuate or inter-lobar artery will be localized, and three successive Doppler measurements at different positions in the kidney (high, middle, and low) will be performed. The average value for each kidney will be taken.~The renal resistive index will be calculated as follows:~(systolic peak flow velocity - diastolic minimum flow velocity)/systolic peak flow velocity"
223659777|NCT00256568|BEHAVIORAL|reporting system|Nurses and office staff were asked to report all communications with community pharmacists regarding prescription problems
223659778|NCT06086340|DRUG|Palbociclib|Palbociclib with an aromatase inhibitor therapy
223659779|NCT06086340|DRUG|Aromatase Inhibitor|Aromatase Inhibitor Therapy
223659780|NCT03171181|OTHER|Vestibular reeducation|Balance quality was registered with static and dynamic posturography. For spatial orientation is was registered Visual vertical and visual orientation perception. Vestibular disability was also assessed. Variables were registered at the beginning and at the end of a vestibular rehabilitation in UPVD participants. Vestibular rehabilitation consisted of 10 sessions of vestibular rehabilitation using dynamic posturography and visual reeducation. Duration of each session: 40 minutes. Twice a week.
223659781|NCT04752241|PROCEDURE|Inferior Mesenteric Artery Preservation|Performing left hemicolectomy the IMA was preserved ligating close to the colonic wall the sigmoids arteries.
223659782|NCT04752241|PROCEDURE|Inferior Mesenteric Artery Ligation|Performing left hemicolectomy the IMA is ligated and sectioned after the origin of left colic artery
223659783|NCT00932828|DRUG|Peanut oral immunotherapy|Defatted peanut in flour form to be used as treatment for peanut allergy
223659784|NCT02252939|RADIATION|X-Ray|X-ray as part of standard care
223659785|NCT05942235|OTHER|Education|Education
223659786|NCT05170932|PROCEDURE|CHX gel 2 % + 24% EDTA|The local drug delivery gel (24% of EDTA gel on root and bone surface and then application of 2% of chlorhexidine gel on root surface) were placed for group 2 in the periodontal pockets Filter paper were inserted into the orifice of the pocket for 1 minute. This was done in the day of surgery then after 3 days, 7 days, 14 days and 21 days after the local drug delivery to measure the gel release profile.
223659787|NCT03849625|DRUG|aspirin, NSAIDs, paracetamol|Perform skin test and/or provocation test with aspirin, paracetmol, or suspected NSAIDs in questionable cases
223659788|NCT04340271|OTHER|Extracorporeal shock wave therapy|ESWT was conducted using the Duolith SD-1® device (StorzMedical, Tägerwilen, Switzerland) with an electromagnetic cylindrical coil source for the focused shock wave (Fig. 2). ESWT was performed around the primary treatment site at 100 impulses/cm2, an energy flux density(EFD) of 0.05 to 0.30 mJ/mm2, frequency of 4Hz, and 1000 to 2000 impulses were administered at 1-week intervals for 4 sessions.
223659789|NCT04340271|OTHER|conventional occupational therapy|Standard accupational therapy consist of range of motion exercise, strengthening exercises, and activities of daily living exercises
223659790|NCT05434780|OTHER|Kinesiology taping|Kinesiology tape is an elastic tape applied to skin with specific amount of tension as per requirement. The underlying mechanism investigated by several studies is the space enhancement and skin uplifting that increases the blood flow in the targeted area and promotes healing.
223659791|NCT01033448|DRUG|COPEGUS|COPEGUS 800 mg or 1000-1200 mg po for 24 weeks
223659792|NCT01033448|DRUG|peginterferon alfa-2a [Pegasys]|PEGASYS 180 micrograms sc once weekly for 24 weeks
224241028|NCT07037485|OTHER|Renal Artery Pulsatility Index|"It will be measured using an abdominal curvilinear probe ultrasonography by two independent, trained sonographers (who will not be involved in patient care). After visualizing the kidney, the interlobular artery will be located using color Doppler mode, and the velocity of the interlobular arteries will be assessed in one or two kidneys.~The Renal Artery Pulsatility Index (RAPI) will be calculated as follows:~RAPI = \[(peak systolic velocity) - (end diastolic velocity)\] /average velocity"
224241029|NCT07037485|OTHER|Urinary oxygen tension (PUO2)|Urinary oxygen tension (PUO2) will be measured preoperatively (baseline), postoperatively just after intensive care unit admission, 12 hours after surgery, and then once daily for 7 days.
224241030|NCT07036978|OTHER|Collecting biospecimens|Collecting blood, urine, tissue, and faecal samples
224241031|NCT07035847|PROCEDURE|Echocardiography guided TAVR|Echocardiography guided TAVR
224241032|NCT07036263|OTHER|Oculomotor therapy|"Oculomotor therapy will follow and adapt the protocol for treating convergence insufficiency (CI). Procedures will be organized progressively, from easiest to most difficult. Gross convergence techniques: (1) Brock String: A 1.5-2 m cord with colored beads; the patient focuses on each bead to train binocular fusion, observing the X shape of the cord. (2) Barillé Chart: A card with paired images for each eye; the patient merges the images into one using convergence and sensory fusion. Accommodative techniques: (1) Eccentric Circles: Printed circles with eccentric marks; viewed through filters to train motor and sensory fusion by aligning them into a single 3D image. (2) Opaque Lifesaver Cards: Cards with figures on an opaque background, used with red-green filters to stimulate convergence and fixation by reducing peripheral stimuli and enhancing visual attention."
224241033|NCT07036263|OTHER|No Treatment Added|Participants in the control group will not receive any type of treatment for a period of five weeks. After this period, they will be re-evaluated
224241034|NCT06126393|DIAGNOSTIC_TEST|next generation sequencing AND Immunohistochemical examination|First, the mismatch repair (MMR) proteins were detected by immunohistochemistry, and the deletion of one or more proteins was classified as d-MMR subtype; Then the POLE gene mutation detection was performed, and the mutation Changes were classified as POLE mutation; Finally, p53 was detected by immunohistochemistry, and p53 mutant (p53 abn) and p53 wild-type (p53wt) were distinguished.
224241035|NCT07036809|DIAGNOSTIC_TEST|Antithrombin III|quantitative measurement(%)
224241036|NCT07036809|DIAGNOSTIC_TEST|Protein C|quantitative measurement(%)
224241037|NCT07036809|DIAGNOSTIC_TEST|Protein S|quantitative measurement(%)
224241038|NCT07036809|DIAGNOSTIC_TEST|D-dimer|quantitative measurement( ug/ml)
223659793|NCT01818752|DRUG|Carfilzomib|Carfilzomib was administered over 30 minutes on days 1, 2, 8, 9, 22, 23, 29, and 30 for nine 42-day cycles. Carfilzomib 20 mg/m² IV was administered on days 1 and 2 of cycle 1, followed by escalation to 36 mg/m² IV starting on day 8 of cycle 1.
223659794|NCT01818752|DRUG|Bortezomib|Bortezomib 1.3 mg/m² was administered as a bolus IV injection or as a subcutaneous injection (per investigator's choice, dose modification, or regulatory approval) on days 1, 4, 8, 11, 22, 25, 29, and 32 of cycles 1 to 4, and on days 1, 8, 22, and 29 of cycles 5 to 9.
223659795|NCT01818752|DRUG|Melphalan|Melphalan 9 mg/m² was taken orally on days 1 to 4 of all cycles.
223659796|NCT01818752|DRUG|Prednisone|Prednisone 60 mg/m² was taken orally on days 1 to 4 of all cycles.
223659797|NCT04270370|DRUG|LY3478045|Administered orally.
223659798|NCT04270370|DRUG|Placebo|Administered orally.
223659799|NCT04270370|DRUG|Atorvastatin|Administered orally.
223659800|NCT01237769|DRUG|Vitamin D3|2200 IU/day
223659801|NCT01237769|BEHAVIORAL|Lifestyle advice|Diet and exercise
223659802|NCT02709382|DRUG|Cefepime and Tazobactam combination|
224241039|NCT07036809|DIAGNOSTIC_TEST|Flow cytometry immunophenotyping|Flow cytometry immunophenotyping
224241040|NCT07037056|COMBINATION_PRODUCT|Shoulder and Neck Strengthening + Postural Correction Exercises|Physiotherapy exercises of Shoulder and Neck Strengthening + Postural Correction Exercises for shoulder and neck pain
224241041|NCT07037056|COMBINATION_PRODUCT|Shoulder and Neck Strengthening + soft tissue mobilization|Physiotherapy exercises of Shoulder and Neck Strengthening + soft tissue mobilization Exercises for shoulder and neck pain
224241042|NCT07035574|OTHER|Conventional Denture Teeth|Complete dentures fabricated using conventional techniques with prefabricated acrylic denture teeth.
224241043|NCT07035574|OTHER|3D Printed Denture Teeth|Complete dentures fabricated using additive manufacturing techniques with advanced resin materials.
224241044|NCT07037186|DEVICE|Electroencephalogram|All patients will receive intraoperative electroencephalography monitorization during general anesthesia.
224241045|NCT07036861|DRUG|Ibuprofen 2%|Reformulated Ibuprofen 2% oral suspension (Berlin-Chemie AG)
224241046|NCT07036861|DRUG|Ibuprofen 4%|Reformulated Ibuprofen 4% oral suspension (Berlin-Chemie AG)
224241047|NCT07036861|DRUG|Ibuprofen 4%|Nurofen dla dzieci Forte pomarańczowy 40 mg/mL, oral suspension (Polish brand name)
224241048|NCT02158936|DRUG|Eltrombopag|Eltrombopag will be round film-coated tablets containing eltrombopag equivalent to 50 mg (white to off-white), 200 mg and 300 mg (green) of eltrombopag free acid
224241049|NCT02158936|DRUG|Azacitidine|Subcutaneous Injection (IV if local standard)
224241050|NCT02158936|DRUG|Placebo|Eltrombopag matching placebo tablets
224241051|NCT02158936|DRUG|Placebo|Eltrombopag matching placebo tablets will be supplied
223769166|NCT04647058|PROCEDURE|Supercharged end-to-side (SETS) nerve transfer|The SETS group will undergo the same procedure as described above, with the addition of the SETS procedure consisting of a end-to-side transfer of the anterior interosseous nerve to the ulnar nerve motor branch. Decompression of Guyon's canal during the SETS procedure is at the discretion of the treating surgeon.
223769167|NCT05954234|OTHER|Postural re-education|"Each session of the experimental approach will be composed of 40 minutes of postural exercise. Participants will be asked to maintain two different postures to stretch both the anterior and posterior muscle chains. The first posture will consist of lying on the back maintaining the extension of the legs to release the respiratory diaphragm and stretch the anterior muscle chain. For the second posture, participants wiil be asked to lie on their back with their legs flexed to stretch the posterior chai. For each posture, the physical therapist will use verbal commands and manual contact to maintain alignment and make the necessary postural corrections to optimize the stretching and discourage compensatory movements.~10 sessions of the allocated intervention will be performed and organized in 2 times a week for 5 weeks."
223659803|NCT01605630|BEHAVIORAL|Family-based family cancer literacy intervention|family based counseling and materials provided in navajo/english including digital stories
223659804|NCT01605630|BEHAVIORAL|Control|standard of care
223659805|NCT00004005|DRUG|fluorouracil|
223659806|NCT00004005|DRUG|irinotecan hydrochloride|
223659807|NCT00004005|DRUG|leucovorin calcium|
223659808|NCT00004005|PROCEDURE|conventional surgery|
223659809|NCT00004005|RADIATION|radiation therapy|
223659810|NCT02948517|OTHER|Time restricted feeding|Time restricted feeding
223659811|NCT00888199|DEVICE|Experimental prosthetic foot (K3 Promoter)|Experimental prosthetic foot
223659812|NCT01324141|DRUG|Tempol|Tempol gel will be applied to the bilateral groins and the gluteal cleft, avoiding a 3 cm radius from the anal verge, immediately prior to each fraction of radiation therapy (RT).
223659813|NCT01324141|DRUG|5-Fluorouracil|5-FU will be delivered as 1000mg/m(2)/day as 96 hour continuous infusion beginning on day 1 and 29.
223769168|NCT05954234|OTHER|Spinal mobilization|"This approach will consist of 40 minutes of thoracolumbar spine mobilization. Two different mobilizations will be carried out. In the first one the patient will be in sitting position with both legs out of the bed and a mobilization in antero-posterior direction will be provide by the physiotherapist; the second one will consist in rotational mobilisation provide with the patient in lateral decubitus position.~10 sessions of the allocated intervention will be performed and organized in 2 times a week for 5 weeks."
224241052|NCT06887530|OTHER|Hand-10 questionnaire and ABILHAND-kids questionnaire|"Children and their parents included in the study will be informed about the purpose of the study and the evaluations to be made and will be asked to sign a written consent form. The questions in the data collection form will be asked to individuals in a face-to-face interview. The manual skills classification system, Hand-10 questionnaire and ABILHAND-kids questionnaire will be used.~While validating the Hand10 questionnaire in children with cerebral palsy, it was planned to use the ABILHAND-kids scale, which has been previously validated for reliability and validity in cerebral palsy. It was also planned to use the hand function classification system in the evaluations. The Hand-10 questionnaire will be filled out by the child himself. The ABILHAND-kids questionnaire will be filled out by the parent. An expert will record the manuel ability system according to the hand skills."
224241053|NCT06925373|OTHER|Indoor Air Purification|An indoor air purifier with a dual HEPA/activated carbon filter, a usage tracker, and an indoor air quality monitor will be installed in public housing residences.
224241054|NCT06925373|OTHER|Neighborhood Improvements|Improved built environment (green space, sidewalks, street lights) and social environment (educational and workforce development programs, wrap-around social services, Internet access).
223659814|NCT01324141|DRUG|Mitomycin-C|Mitomycin-C (MMC) will be delivered at a dose of 10mg/m(2) on days 1 and 29
223659815|NCT01324141|PROCEDURE|Radiation Therapy|Radiation therapy (RT) will be delivered to a total dose of 50-54 Gray (Gy) based on tumor characteristics.
223659816|NCT05376332|DEVICE|Sonomyographic Prosthesis|The sonomyographic system will include a custom-fitted test socket incorporating ultrasound transducers and controlling a TASKA prosthetic hand. All socket fittings will be performed by a board-certified prosthetist as part of this study.
223659817|NCT05376332|DEVICE|Myoelectric direct control prosthesis|The direct control system will include a custom-fitted test socket incorporating dual-site electrodes and controlling a TASKA prosthetic hand. All socket fittings will be performed by a board-certified prosthetist as part of this study.
223659818|NCT05376332|DEVICE|Myoelectric pattern recognition prosthesis|The pattern recognition system will include the subject's clinically-prescribed socket and commercially-available pattern recognition technology (IBT Sense). The pattern recognition system will not be fitted as part of this study, as subjects will already be trained users prior to enrolling in the study.
223659819|NCT06210360|DRUG|Irinotecan liposome injection|50 mg/m² on Day 1 of a 14 day cycle
223659820|NCT06210360|DRUG|Oxaliplatin|60 mg/m² on Day 1 of a 14 day cycle
223659821|NCT06210360|DRUG|5-FU|2400 mg/m² continuous IV infusion in 46 h
223659822|NCT06210360|DRUG|LV|400 mg/m² on Day 1 of a 14 day cycle
223659823|NCT05315895|OTHER|natural aging process|To observe the relationship between new cases of diseases and health status of people exposed to different factors such as life style, alcohol consumption, eating habits, etc.
223659824|NCT02515721|DEVICE|pCLE-TB|Patients will receive white-light endoscopic imaging, followed by probe-based Confocal Laser Endomicroscopy scanning on suspected lesions and 5 standardized locations. Then targeted Biopsies will be performed on locations with intestinal metaplasia, intraepithelial neoplasia, and carcinoma.
223659825|NCT02515721|DEVICE|virtual chromoendoscopy-TB|Patients will receive virtual chromoendoscopy using iScan. Standard biopsies will be performed on all suspected lesions and standardized loctaions.
223659826|NCT05386407|DIAGNOSTIC_TEST|telemedically guided oropharyngeal + nasal (OP+N) self-sampling (GSS) and nasopharyngeal (NP) or OP+N sampling performed by health care professionals (HCP)|"After giving informed consent by signing the consent form, patients will be randomized to either OP+N GSS - or to OP+N USS.~After performing either procedure, they will continue to be sampled by HCP OP+N and HCP NP."
223659827|NCT00000955|DRUG|Tuberculin Purified Protein Derivative|Administered intradermally at 5 TU per 0.1 mL
223659828|NCT05593562|DRUG|SPH3127|Oral 100 mg \[14 c\] SPH3127 mixed suspension
223659829|NCT00310661|DRUG|Sarizotan|The dose of sariztan HCI for each patient in the drug arm will be given 2mg b.i.d. orally during the first 4 weeks of treatment. If efficacy is inadequate and there are no safety concerns, the option to raise the dose to 5mg b.i.d is given. After 8 weeks of treatment, the option to raise the dose to 7mg bid is given. Dose may remain the same or may be decreased again to the previous dose.
223659830|NCT00310661|OTHER|Placebo|Placebo for each patient randomized to the placebo arm will be given placebo (oral, twice daily) in a pill form for 12 weeks
223659831|NCT03323567|DRUG|MD Muscle GUNA collagen|intramusclular injections of MD Muscle collagen
223659832|NCT03323567|DRUG|Lidocaine 2% Injectable Solution|intramuscular Lidocaine 2% injection
223659833|NCT03323567|DRUG|Saline Solution, Hypertonic|intramuscular Saline injection
223659834|NCT01710319|OTHER|blood draw|a blood specimen will be obtained from each patient in the four groups. An optional blood draw after 30 days of initial blood specimen if indicated.
223659835|NCT03723967|DRUG|Durvalumab with Carboplatin/Paclitaxel|Durvalumab associated with Carboplatin / Paclitaxel as first line treatment in patients with recurrent/metastatic SCCHN not eligible to standard chemotherapy
223659836|NCT01710813|BIOLOGICAL|alglucosidase alfa|Alglucosidase alfa IV infusion of 20 mg/kg; qow
223659837|NCT01877252|PROCEDURE|Surgical revascularization|
223659838|NCT01877252|PROCEDURE|Endovascular revascularization|
223659839|NCT01877252|OTHER|No vascular intervention|
223659840|NCT03476005|BEHAVIORAL|proficiency based progression training|proficiency based progression training supported by technology enhanced learning
223659841|NCT01221311|DEVICE|Fully covered Metallic Stent|Covered Wallflex Biliary (TM)
224241055|NCT06925373|OTHER|Housing Improvements|High-quality public housing
223659842|NCT01221311|DEVICE|Plastic Stent|Patients randomized to the PS group will be treated using a standard algorithm. Specifically, the stricture will be dilated using a passage dilator and/or dilation balloon catheter, and one or two PS will be deployed depending on the baseline characteristics of the stricture as well as the diameter of the proximal and distal bile duct (standard of care). The endoscopist will sequentially dilate and upsize the cumulative stent diameter on ensuing ERCPs, until the stricture has been obliterated using clinical and fluoroscopic criteria.
223659843|NCT00314002|DEVICE|Mechanical Thrombectomy|
223659844|NCT05744440|DRUG|allogenic NK cells|The relapsed/refractory AML after allo-HSCT patients will receive allogenic NK cells infusion up to 2 dose levels (1x10\^7/kg, 5x10\^7/kg) after chemotherapy with azacitidine
223659845|NCT01717924|PROCEDURE|peri-operative chemotherapy|Usual treatment strategy for gastric adenocarcinoma
223659846|NCT01717924|PROCEDURE|Surgery first|strategy with a surgical procedure first, without the usual peri-operative chemotherapy
223659847|NCT00870584|DRUG|Omalizumab|Omalizumab was supplied as a lyophilized, sterile powder in a single-use, 5 mL vial. The vial was designed to deliver 150 mg (1.2 mL) of omalizumab for subcutaneous (s.c.) administration after reconstitution with 1.4 mL sterile water for injection. Doses of more than 150 mg were divided among multiple injection sites to limit injections to not more than 150 mg per site.
223659848|NCT00870584|DRUG|Placebo|Placebo was supplied as a lyophilized, sterile powder in a single-use, 5 mL vial. The vial was designed to deliver 150 mg (1.2 mL) of placebo for subcutaneous (s.c.) administration after reconstitution with 1.4 mL sterile water for injection. Doses of more than 150 mg were divided among multiple injection sites to limit injections to not more than 150 mg per site.
224241056|NCT00135395|DRUG|Atazanavir+ritonavir|Capsules, Oral, 300mg/100mg, once daily, 24 weeks.
224241057|NCT00135395|DRUG|Lopinavir+ritonavir|Capsules, Oral, 800mg/200mg, twice daily, 24 weeks.
224241058|NCT01432171|DRUG|Lacosamide|Given PO
224241059|NCT01432171|OTHER|Placebo|Given PO
224241060|NCT06450002|OTHER|physical therapy|Tens and Hot packs for 20 minutes, ultrasound for 5 minutes on the back and back exercise in form of bridging exercise and core stability exercise
223659849|NCT05184829|OTHER|selective lymph node dissection|selective lymph node dissection
223659850|NCT05184829|OTHER|Systemic Lymph Node Dissection|Systemic Lymph Node Dissection
223659851|NCT02560025|DRUG|Alisertib|
223659852|NCT02560025|DRUG|Cytarabine|
223659853|NCT02560025|DRUG|Idarubicin|
223659854|NCT02560025|DRUG|Daunorubicin|Can be used in place of idarubicin
223659855|NCT03913338|PROCEDURE|LasikXtra|By randomized selection, one eye was treated with the LASIK Xtra procedure that consists of fs-LASIK treatment combined with intraoperative accelerated continuous UV-riboflavin crosslinking. After laser ablation, the corneal bed under the flap was coated with riboflavin, rinsed with saline solution, and after 90 seconds the corneal flap was repositioned. The eye was irradiated at 30 mW/cm2 for 90 seconds with continuous UVA.
223659856|NCT03913338|PROCEDURE|LASIK|Femtosecond-assisted preparation of a corneal flap and subsequently excimer-laser ablation of corneal stroma. Repositioning of the corneal flap and installation of a therapeutic contact lens.
223659857|NCT02703337|DRUG|LY900014|Administered subcutaneously (SC)
223659858|NCT02703337|DRUG|Insulin Lispro|Administered SC
223659859|NCT01886989|DIETARY_SUPPLEMENT|Cocoa polyphenols|Cocoa polyphenols (960mg) reconstituted in water
223659860|NCT03170180|DRUG|Sunitinib|sunitinib 37.5mg daily
223659861|NCT03170180|DRUG|Gefitinib|Gefitinib 250mg daily
223659862|NCT03170180|DRUG|Imatinib|Imatinib 400mg daily
224241061|NCT06739083|OTHER|e-mentoring program|The e-mentoring program is planned to last four weeks to facilitate the adaptation process of newly recruited nurses in intensive care units via the e-mentoring website.
223659863|NCT00961909|DRUG|RO5095932|cohorts receiving multiple ascending doses, sc once weekly for 4 weeks
223659864|NCT00961909|DRUG|RO5095932|dose titration to target dose, sc once weekly for 6 weeks
223659865|NCT00961909|DRUG|metformin|stable dose
223659866|NCT00961909|DRUG|placebo|sc once weekly for 4 weeks
223659867|NCT03258528|BEHAVIORAL|positioning|Positioning neonates for 6 hours either in right lateral position or supine position
223659868|NCT02644616|DRUG|tolvaptan+torasemide|tolvaptan 15mg/d po(10 days) + torasemide 20mg/d iv
223659869|NCT02644616|DRUG|placebo+torasemide|placebo 15mg/d po(10 days) +torasemide 20mg/d iv
224241062|NCT02078700|OTHER|The early palliative care programme|The intervention consists of an early integration of a palliative care programme with the standard care performed by the oncologists-pneumologists that are following the cancer patients. The intervention will be delivered by the specialised Palliative Care Unit (PCU) of the hospital. Each patient meets the professionals of the PCU by 30 days by cancer diagnosis and at least monthly thereafter in the outpatint settings.
223659870|NCT05693961|DEVICE|CART-I plus|CART-I noninvasively measures the oxygen saturation of blood in a local area by screening the bloodstream through the user's finger using PPG signals
223659871|NCT01859520|PROCEDURE|swim-up, density gradient sperm preparation techniques|Sperms are prepared by sperm washing techniques before used in assisted reproductive technologies. Most commonly used sperm preparation methods are the swim up and the density gradient. Recent studies shows that the DNA integrity status of the spermatozoa is related to the success in assisted reproduction techniques. Sperm preparation methods may theoretically cause damage sperm DNA. Therefore it is important to select the optimum method of sperm preparation causing least sperm DNA damage. Aim of our study is to investigate and compare the effect two different sperm preparation techniques on DNA fragmentation.
223659872|NCT04458480|COMBINATION_PRODUCT|Fast Inpatient Rehabilitation|Routine inpatient rehabilitation protocol, administered by licensed Physical Therapist, duration period of 1.5h-2h each time, 2 times for weekdays and 1 time for weekends, totally lasting for 1 week, are applied to the exposed group. After the fast inpatient rehabilitation for 1 week, the patients can get discharged if reaching to the rehabilitation goals of symptoms of pain and swell reduced, knee flexion ≥ 90° and knee extension ≥ 0°, quadriceps femurs and hamstrings muscle strength enhanced, recovery to aided standing and walking, and acquiring of rehabilitation training methods.
223659873|NCT02879006|DRUG|Chinese Herbal Medication|Capsules, 26 month course, starting 2 months pre-OIT
223659874|NCT02879006|DRUG|Placebo|Placebo capsules that look identical to E-B-FAHF-2, 26 month course, starting 2 months pre-OIT
223659875|NCT02879006|DRUG|Omalizumab|4 months course, starting 2 months pre-OIT through the 2 month build-up phase
224241063|NCT06036511|DRUG|Ketamine Hydrochloride|"This is a single arm, open-label, prospective cohort clinical trial.~No blinding is required for this trial.~A total of 14 adult patients with PTSD will be recruited from UNM outpatient clinics and undergo rsfMRI and behavioral assessment prior to ketamine treatment. They will complete baseline scan at day one, a preparatory session (initial part of KAP), IM ketamine treatment, then within 24 hours, an integration session to take advantage of neuroplasticity for optimal therapeutic progress. Each participant will have two complete KAP sessions (preparation, treatment, and integration) followed by rsfMRI within approximately 24 hours, and again approximately two weeks after the completion of the second KAP session. Patients will also have repeat clinical assessments after each treatment. Changes in PTSD symptoms will be correlated with changes in connectivity at each rsfMRI."
223659876|NCT02879006|DRUG|Multi OIT|24 months of multi OIT (maintenance dose of 1gm each food allergen)
223659877|NCT00064064|DRUG|gemcitabine hydrochloride|
223659878|NCT00064064|DRUG|triapine|
223659879|NCT06032013|OTHER|Cardiac rehabilitation program (PROMs)|"The program is multidisciplinary with the following components:~* Medical assessment~* Physical training and counselling on physical activity~* Identification and control of risk factors~* Nutritional assessment and counselling~* Psychological assessment and intervention~* Education and information"
223659880|NCT01751945|BEHAVIORAL|EmONC package|"The EmONC package consists of:~1. Maternal and neonatal health pack(clean delivery kit, emollient, chlorhexidine, sms messages) for safe motherhood and newborn wellbeing.~2. Enhanced trainings of community-level health care providers to provide effective maternal and neonatal health services and referral of complicated cases to health facilities and creation of linkages amongst health care providers.~3. Community mobilisation"
223659881|NCT00282308|DRUG|Rituximab|Rituximab was supplied in single-use vials.
223659882|NCT00282308|DRUG|Methotrexate|
223659883|NCT00282308|DRUG|Methylprednisone|Patients received methylprednisolone 100 mg intravenously before each infusion of rituximab.
223659884|NCT00282308|BIOLOGICAL|C. albicans|Patients received an intradermal injection of C. albicans (0.1 mL) on the volar surface of the forearm.
223659885|NCT00282308|BIOLOGICAL|Tetanus toxoid adsorbed booster vaccine|Patients received an intramuscular injection of the tetanus toxoid adsorbed booster vaccine (1 mg in 0.5 mL) in the deltoid muscle.
223659886|NCT00282308|BIOLOGICAL|23-valent pneumococcal polysaccharide vaccine|Patients received an intramuscular injection of the 23-valent pneumococcal polysaccharide vaccine (0.5 mL) in the deltoid muscle.
223659887|NCT00282308|BIOLOGICAL|Keyhole limpet hemocyanin|Patients received a subcutaneous injection of keyhole limpet hemocyanin (1 mg)
223659888|NCT06577831|DIAGNOSTIC_TEST|dynamic MRI|"* MRI sequences will be performed for patients and healthy volunteers i~* Vaginal and rectal tagging will be performed using a water-based ultrasound gel.~* The gel will be inserted by an authorized person (nurse or doctor) using a syringe with a conical tip and, optionally, a probe.~* MRI sequences.~* Data analysis and interpretation."
223659889|NCT05743946|DRUG|Trikafta|Participants will be given elexacaftor 100 mg/tezacaftor 50 mg/ivacaftor 75 mg (two pills once daily in the morning) and ivacaftor 150 mg (once daily in the evening), as the FDA-registered agent, Trikafta. Dose and schedule will be for 28 days, and otherwise identical to what has already been FDA-approved for effective treatment of cystic fibrosis.
223659890|NCT04280029|DEVICE|SELUTION SLR™ DEB|The SELUTION Sustained Limus Release (SLR)™ drug-eluting balloon (DEB) catheter is a combination product consisting of a standard percutaneous transluminal coronary angioplasty (PTCA) balloon catheter coated with a drug (Sirolimus).
223659891|NCT04280029|DEVICE|Control|POBA or FDA-approved -limus DES
224241064|NCT06802315|RADIATION|Intensity modulated total marrow irradiation|"See Treatment Regimen"
224241065|NCT06802315|DRUG|Cyclophosphamide (CTX)|This study will determine the safety of the combination of Total Marrow Irradiation (TMI) and Post-Transplant Cyclophosphamide using a myeloablative fludarabine and iv targeted busulfan (Flu/Bu4) conditioning regimen.
224241066|NCT06802315|DRUG|Fludarabine (Fludara)|chemotherapy conditioning
224241067|NCT06802315|DRUG|Busulfan (conditioning for ALLO Transplant)|chemotherapy conditioning
224241068|NCT02426957|BEHAVIORAL|motivational enhancement therapy|The intervention consists of the following components: establishing rapport, assessing motivation for change, enhancing motivation for change, envisioning the future, establishing goals, and completing goals, strategies, and change plan worksheets.
223659892|NCT06157151|BIOLOGICAL|PRGN-2009 plus Pembrolizumab|Subjects randomized will receive PRGN-2009 (5 x 10\^11 PU, subcutaneous (SC) injection) every 3 weeks for three administrations, thereafter subjects will continue to receive PRGN-2009 administrations every 6 weeks. Pembrolizumab will be administered concurrently as intravenous (IV) infusion (400 mg) every 6 weeks.
223659893|NCT06157151|DRUG|Pembrolizumab alone|Subjects randomized will receive IV infusion of pembrolizumab (400 mg) administered every 6 weeks.
223659894|NCT03878615|PROCEDURE|elective surgery, according to deprtement routine|none, descriptive study
223659895|NCT05133037|DEVICE|GE MR Scanner|"3T GE MR 750 systems MR scanner~Scanners run compatible software so pulse sequences and reconstructions can easily be supported on all systems. Reconstruction servers are networked to all scanners for reconstruction and data archiving. 3T scanner is equipped with state-of-the-art gradient systems (at least 40 mT/m Gradients / 150 mT/m/ms slew rates) and 16 or more receive channels. 3T scanner includes an assortment of RF coils including quadrature and phased-array coils designed to image brain, spine, neurovascular, torso, pelvis, cardiac, knee, foot/ankle, and hand/wrist. 3T system has several sizes of 16-channel wrap coils that are excellent for scans using parallel imaging."
223659896|NCT00166413|DRUG|CC-5013|40 mg/day orally on days 1-4 and 15-18 of each 28-day cycle
223659897|NCT03990519|DRUG|JNJ-26366821|Participants will receive sterile solution of JNJ-26366821 subcutaneously (SC).
223659898|NCT03990519|DRUG|Placebo|Participants will receive sodium chloride injection as placebo on Day 1.
223659899|NCT03477539|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo ASCT
223659900|NCT03477539|BIOLOGICAL|Daratumumab|Given IV
223659901|NCT03477539|DRUG|Lenalidomide|Given PO
223659902|NCT04408781|PROCEDURE|Ridge expansion by osseodensifcation/Ridge expansion by ridge splitting|Ridge expansion by ridge splitting using the piezotome in conjunction with simultaneous implant placement in narrow ridges.
223769169|NCT05954234|OTHER|Perineal Exercises|Perineal Exercises will be performed in both the allocated approach. The protocol will consist in 10 minutes of perineal contraction and relaxation and 10 minutes of stretch-reflex for a total of 20 minutes of perineal exercises.10 sessions of the allocated intervention will be performed and organized in 2 times a week for 5 weeks.
224241069|NCT05768269|OTHER|No Intervention|As this is a non-interventional rollover, long-term safety follow-up study, no intervention will be administered.
224241070|NCT03248063|DRUG|Cloxacillin|"Intravenous treatment by cloxacillin, 25 to 50 mg/kg every 4 or 6 hours, without doing less than the minimum daily dose of 8 g/day and without exceeding the maximum daily dose of 12 g/day, administered as a 60-minutes infusion. This treatment will be administered for at least 7 days by intravenous route.~Dosing regimen will be adapted in patients with chronic renal failure (glomerular filtration rate below 30ml/min/1.73m²) and in patient with impaired hepatic function associated with renal impairment whatever the level of the estimation of the glomerular filtration rate, according to SPC."
224241071|NCT03248063|DRUG|Cefazolin|Intravenous treatment by cefazolin, 25 to 50 mg/kg every 8 hours (without exceeding the maximum daily dose of 6 g/day), administered as a 30-minutes infusion. This treatment will be administered for 14 days by intravenous route. Dosing regimen will be adapted in case of glomerular filtration rate between 30-50ml/min according to SPC. As currently recommended, investigators will be encouraged to use the intravenous route for the entire duration of treatment. However, in order to interfere as little as possible with usual practice in each center, the antimicrobial therapy will be let to the choice of the physician in charge of the patient after a minimum of 7 days of intravenous treatment.
224241072|NCT05423210|COMBINATION_PRODUCT|Atezolizumab + FSRT radiation|Atezolizumab 840mg IV every 2 weeks Fractionated Stereotactic Radiotherapy
224241073|NCT06517225|BEHAVIORAL|Visual-acoustic biofeedback|Behavioral: Visual-acoustic biofeedback In visual-acoustic biofeedback treatment, the elements of traditional treatment (auditory models and verbal descriptions of articulator placement) are enhanced with a dynamic display of the speech signal in the form of the real-time LPC (Linear Predictive Coding) spectrum. The web-based software staRt will be used for intervention delivery.
224241074|NCT06929429|PROCEDURE|Bilateral Sphenopalatine Ganglion Block|A bilateral sphenopalatine ganglion block will be performed after induction of general anesthesia using 4 mL of 0.5% bupivacaine. The local anesthetic will be applied intranasally with a cotton-tipped applicator placed parallel to the zygomatic arch and advanced to the posterior nasal cavity. The applicator will remain in place for 15 minutes.
224241075|NCT06929429|PROCEDURE|Bilateral Infraorbital Nerve Block|A bilateral infraorbital nerve block will be performed after induction of general anesthesia using 4 mL of 0.5% bupivacaine per side. The block will be guided by linear ultrasound to identify the infraorbital foramen and administered with a 22G needle around the nerve. A 15-minute absorption period will be allowed before the surgical procedure begins.
223659903|NCT06516055|DRUG|S1B-408|Medication with multiple monoamine activities
223659904|NCT04990895|OTHER|Electronic Tumour-Specific Patient-Reported Outcomes (ePRO) questionnaires|A web-based portal that prompts participants to enter tumour-specific ePROs at regular intervals in between clinic visits
223659905|NCT05704244|DRUG|FE 999326|75 mL FE 999326 (3 x 10\^11 vp/mL) of sterile suspension instilled once every 3 months into the bladder via a urinary catheter
223659906|NCT04225845|BEHAVIORAL|Phone therapy|Weekly phone calls by lay trained personnel to deliver problem solving therapy.
223659907|NCT04225845|BEHAVIORAL|Cash transfer|One-time cash transfer of Rs.1000.
223659908|NCT06332092|DRUG|FID007|Patients will receive FID007 via IV infusion at their assigned dose on Days 1, 8, and 15 of each 28-day cycle. Starting from Cycle 2, Cetuximab will be administered every 2 weeks on Days 1 and 15 of each 28-day cycle.
223659909|NCT02694458|OTHER|Early vancomycin monitoring and bayesian dosage adjustment|Measure of vancomycin serum concentration at the 3rd hour of treatment and adjustment of vancomycin dosage at the 6th hour of treatment using a bayesian approach. Then measure of vancomycin serum concentration at the 24th hour of treatment.
223769170|NCT04029467|DRUG|Dexmedetomidine|addition of dexmedetomidine to ropivacaine as an adjuvant in ESP block to assess wether or not it prolongs its duration of action
223769171|NCT00191997|DRUG|Olanzapine|
223769172|NCT00648219|DRUG|Olmesartan Medoxomil Tablets 40 mg|40mg, single dose fed
223769173|NCT00648219|DRUG|Benicar® Tablets 40 mg|40mg, single dose fed
224241076|NCT06648252|BEHAVIORAL|Healing Minds Biofeedback and Breathing Practices Intervention|The study participant will attend ten weekly Healing Minds sessions at the Hoskinson Health and Wellness Clinic. The parent (s) or guardian will accompany the study participant and follow along with the cues during the weekly session. Each session will be approximately 60 minutes. The principal investigator/pediatrician or trained and certified health care or research staff member will deliver the intervention. Biofeedback will be implemented based on the Heart Math Protocol. Breathing practices will include a variety of yoga and qi gong techniques.
223659910|NCT02694458|OTHER|usual vancomycin dose and monitoring strategy|Vancomycin serum concentration will be measured at the 24th hour of treatment.
223659911|NCT03809325|DRUG|Paliperidone Palmitate 3-Month Formulation (PP3M)|No intervention will be administered as a part of this study. Participants who have been treated with PP3M in clinical practice will be enrolled.
223659912|NCT05563363|OTHER|Hospital-like treatment in patients' home|Hospital-like treatment in patients' home. Caregivers, medical doctors and social workers will make several visits per day to the patients' home. 24/7 contact is available.
223659913|NCT05563363|OTHER|standard inpatient treatment|Inpatient treatment on addiction ward
223659914|NCT06040541|DRUG|RMC-9805|Oral Tablets
223659915|NCT06040541|DRUG|RMC-6236|Oral Tablets
224241077|NCT06241430|DEVICE|CardioMEMS|Hemodynamic-guided optimization will be performed using the CardioMEMS CardioClip device.
224241078|NCT04655248|DEVICE|Transcatheter Aortic Valve Implantation/Replacement|The device is placed in patients heart at the level of aortic valve through a transfemoral access from femoral groin as indicated in device IFU
223659916|NCT06228599|OTHER|Treatment Plan|A matched treatment regimen will be administered for approximately 12 weeks based on recommendations made by the MTB.
223659917|NCT04303195|DRUG|NG101|Capsules
223659918|NCT04303195|DRUG|Placebo|Capsules
224241079|NCT06909357|OTHER|Quitline Treatment (QT)|Tobacco Free Florida Quitline. 10-week supply of Combination Nicotine Replacement Therapy (NRT).
224241080|NCT06909357|OTHER|App-based Treatment (mHealth)|Fully automated digitally-delivered smoking cessation intervention targeted to cancer patients. 10-week supply of Combination Nicotine Replacement Therapy (NRT).
224241081|NCT02754622|OTHER|Observational Group|Indirect calorimetry measurement during Physical Rehabilitation. Observing planned physical rehabilitation session to determine the rehabilitation activity achieved with IC utilised to determine the number of calories used per session
223769174|NCT00866632|BEHAVIORAL|Cognitive Behavioural Therapy|Cognitive behavioural therapy to be delivered in a group setting for 11 sessions, for 1 to 1.5 hours/session.
223769175|NCT00866632|BEHAVIORAL|Cognitive Behavioural Therapy|Cognitive behavioural therapy to be delivered in one-on-one via the telephone across 11 sessions, for 1 to 1.5 hours/session.
223659921|NCT06251206|BEHAVIORAL|ADL/Postoperative Instruction|This is an education video which includes demonstration of simple ADL tasks that the participant can do at home after surgery. Handout includes the same information and a QR code to watch the video.
223659922|NCT06251206|BEHAVIORAL|Postoperative Instruction|This is an education video that only includes the postoperative instructions. Handout includes the same information and a QR code to watch the video.
223769176|NCT04768647|DEVICE|TNM|TNM is a small portable head set that can be used by the participants at home to stimulate the vestibular system
223659923|NCT05672524|DRUG|Trastuzumab|Patients will then be given tucatinib (300 mg BID orally) and trastuzumab (8 mg/kg on day 1, then 6 mg/kg starting cycle 2 and every three weeks) therapy for an initial 6 week lead-in period. All patients, regardless of findings on rectal MRI will then transition to standard of care induction chemotherapy with continuation of the trastuzumab and tucatinib for a total of five additional cycles (15 extra weeks).
223659924|NCT05672524|DRUG|Tucatinib|Patients will then be given tucatinib (300 mg BID orally) and trastuzumab (8 mg/kg on day 1, then 6 mg/kg starting cycle 2 and every three weeks) therapy for an initial 6 week lead-in period. All patients, regardless of findings on rectal MRI will then transition to standard of care induction chemotherapy with continuation of the trastuzumab and tucatinib for a total of five additional cycles (15 extra weeks).
223659925|NCT01595958|DRUG|Cyclosporine A|Single intravenous bolus of cyclosporine A (2.5 mg/kg) at the onset of resuscitation
223659926|NCT01595958|PROCEDURE|cardio-pulmonary resuscitation|usual care of cardiac arrest
223659927|NCT05556902|DEVICE|Permanent Epidural Spinal Cord Stimulation|Permanent Spinal Cord Stimulation implanted in participants undergoing routine care for management of chronic neuropathic pain.
223659928|NCT04772989|DRUG|AB308|Administered intravenously (IV) as specified in the treatment arm
223659929|NCT04772989|DRUG|Zimberelimab|Administered IV as specified in the treatment arm
223769177|NCT03781518|PROCEDURE|ridge splitting in group and khoury shell technique in the other group|Mandibular ridge splitting with complete separation of the buccal cortical plate for horizontal augmentation of atrophic posterior mandible in one group and the other group will receive khoury shell technique by taking bone block from the ramus
224241082|NCT06797726|BEHAVIORAL|Cognitive behavioral therapy|Session 1: Functional analysis, motivational approach and psycho-education (advantages/disadvantages of consumption ; effect of addiction on mental disorders and interaction ADHD/behavioral addiction) Session 2: Follow-up to psycho-education session 1, treatment plan Session 3: ADHD: compensation strategies; reducing distractibility distractibility Session 4: ADHD: calendar and organization worksheet Session 5: ADHD: mood disorders and emotions Session 6: Recognizing and managing emotions Session 7: Analysis of functional elements in addictive disorder addictive disorders in patients with ADHD Session 8: Risk situations, psycho-education (emotions) Session 9: Managing craving; analysis of the functional elements of of addiction Session 10: Relapse and relapse prevention, problem solving and social pressure
224241083|NCT06916858|DEVICE|home sleep test|Apnealink air
223659930|NCT06974786|DRUG|Elranatamab|Participants will receive step up dosing of Elranatamab subcutaneously in first cycle of consolidation followed by fixed dosing for 2 additional cycles and for 12 cycles in maintenance. Arm A participants will receive additional 12 cycles of Elranatamab monotherapy if they are MRD negative after Maintenance 1 for a total of 27 cycles. Cycles will be 28 days.
223659931|NCT06974786|DRUG|Daratumumab|Participants will be given 1800 mg of Daratumumab subcutaneously every 4 weeks for up a maximum of 26 cycles.
223659932|NCT06974786|DRUG|Lenalidomide|Participants will receive 10 mg of Lenalidomide daily by mouth for 21 days of each 28-day cycle for up to a maximum of 24 cycles.
223659933|NCT06974786|PROCEDURE|autologous stem cell transplantation|Participants will undergo ASCT as standard treatment following individual site's processes and practices.
223659934|NCT07127445|DIETARY_SUPPLEMENT|OEA supplement|The supplement contains OEA, ginger extract, and lavender essential oil as its active ingredients.
223659935|NCT06457204|DRUG|Pramipexole manufactured in Ingelheim|1 tablet Sifrol® (pramipexole) manufactured in Ingelheim containing 0.088 mg pramipexole taken orally after an overnight fast of at least 10 hours.
223659936|NCT06457204|DRUG|Pramipexole manufactured in Ennigerloh|1 tablet Sifrol® (pramipexole) manufactured in Ennigerloh containing 0.088 mg pramipexole taken orally after an overnight fast of at least 10 hours.
223659937|NCT06644599|DEVICE|wireless monitoring|The monitoring wireless system will continuously monitor the heart rate, oxygen saturation (SpO2), respiratory rate, and blood pressure and in selected patients electrocardiography (ECG).
223659938|NCT05171049|BIOLOGICAL|Abelacimab|Abelacimab 150 mg
223659939|NCT05171049|DRUG|Apixaban|Apixaban 10 mg followed by 5 mg
223659940|NCT06167473|BIOLOGICAL|umbilical cord-mesenchymal stem cells|Different dosage of umbilical cord-mesenchymal stem cells through peripheral vein
223659941|NCT02510677|OTHER|myocardial perfusion scintigraphy|
224241084|NCT01459874|BEHAVIORAL|Organizational model for remote monitoring|An organizational model defining roles and behaviors of subjects involved in the remote monitoring of pacemaker and defibrillator recipients
223659942|NCT04562428|DRUG|Xiang Sha Liu Jun Zi Decoction dry powder|the principles of Chinese medicine treatment areinvigorating Pi, regulating qi, dissipating dampness and appetizing wei
223659943|NCT04562428|DRUG|XSLJZ Placebo|XSLJZ Placebo
223659944|NCT06060548|OTHER|Monitoring of patients presenting with PVCs|Patients presenting with PVCs and ventricular arrhythmias will be monitored using ILRs from the time of their initial presentation of PVCs to assess for the incidence of all cardiac arrhythmias. They will also be evaluated for clinical, biomarker and radiological evidence of myocarditis to understand association with incident arrhythmias.
223659945|NCT06812650|OTHER|Medical treatment|Patients will continue their routine medical treatment for gastroesophageal reflux disease.
223659946|NCT06812650|OTHER|Exercise|The exercise program will consist of diaphragmatic breathing exercises and progressive muscle relaxation exercises. Diaphragmatic breathing exercises will be performed for 8 weeks, 5 days a week, twice a day, for 15 minutes each time.
223659947|NCT06593119|BEHAVIORAL|Telemedicine management of Hypertension|TM-HTN intervention includes tailored and frequent self-management support, home blood pressure monitoring, pharmacotherapy, and as-needed assistance for health-related social needs provided by pharmacists, nurses, community health workers, and social workers. This will be compared with usual care
223659948|NCT06593119|BEHAVIORAL|Usual Care|This includes usual clinic based HTN care using routinely available clinic resources (e.g., community health worker, social worker). Clinicians can offer self-management support (e.g., dietician referral) or recommend a home BP monitor. These activities mirror current primary care practice.
223659949|NCT01065454|DRUG|Riociguat (Adempas, BAY63-2521)|up to 2 mg three times a day (increasing from 0.5 to 1 to 2 mg)
223659950|NCT01065454|DRUG|Riociguat (Adempas, BAY63-2521)|up to 1 mg three times a day (increasing from 0.5 to 1 mg)
223659951|NCT01065454|DRUG|Riociguat (Adempas, BAY63-2521)|fixed 0.5 mg three times a day
223659952|NCT01065454|DRUG|Placebo|Placebo three times a day
223659953|NCT06985485|DRUG|Blinatumomab and Inotuzumab Ozogamicin|Subjects who meet the study criteria during screening will receive induction therapy consisting of low-intensity chemotherapy combined with BiTE with or without TKIs. Regimen includes dexamethasone, vindesine, followed by blinatumomab dosed by body weight: pts ≥45 kg receive fixed dosing (9 µg/day days 1-7, 28 µg/day days 8-28), pts \<45 kg receive BSA-adjusted dosing (5 µg/m²/day days 1-7, 15 µg/m²/day days 8-28). Philadelphia chromosome-positive ALL pts receive second-generation TKIs, with subsequent switch to third-generation TKIs upon resistance. If morphologic remission is not achieved after initial therapy, a salvage cycle with InO will be administered. Post-remission consolidation chemotherapy includes high-dose methotrexate followed by sequential immunotherapy: BiTE (per weight-stratified dosing), then after a 2-week break, InO (0.8 mg/m² on day 1), followed by another 2-week break.This sequence is repeated for 4 cycles.
223659954|NCT06208943|OTHER|cross-sectional MRI and EEG assessments (NO INTERVENTION)|n/a there is no intervention in this observational study
223659955|NCT06546397|DRUG|17β-estradiol/dydrogesterone tablets|The medication group began taking 17β-estradiol/dydrogesterone tablets orally for 28 days starting from the first day after induced abortion surgery (taking 2mg of 17β-estradiol orally once a day for the first 14 days, and then taking 2mg of 17β-estradiol + 10mg of dydrogesterone tablets orally once a day for the next 14 days). The blank control group did not take any medication.
223659956|NCT06819813|BEHAVIORAL|Feasibility/Efficacy Testing|This digital intervention will include elements of adapted cognitive-behavioral treatment for adolescent binge eating and weight control, with a focus on self-regulation and skills use.
223659957|NCT06986928|OTHER|No intervention will be applied.|No intervention will be applied.
223659958|NCT06986928|OTHER|No intervention will be applied.|No intervention will be implemented in this study, as the questionnaires will serve an exploratory purpose.
223659959|NCT01601652|DRUG|Omegaven|1 g/kg/d iv infusion over 24h
223659960|NCT00758199|DRUG|Bromfenac|Group 1: Bromfenac BID for 3 weeks Group 2: Bromfenac BID for 6 weeks
223659961|NCT00758199|DRUG|Moxifloxacin hydrochloride|Group 1 and Group 2:Moxifloxacin hydrochloride 1 day prior to surgery-continue for six days after surgery.
223659962|NCT00758199|DRUG|Prednisolone Acetate|Group 1 and Group 2:Prednisolone Acetate for 3 weeks in a tapering schedule (week 1: TID; week 2: BID, week 3:QD).
223659963|NCT00273793|BEHAVIORAL|Contingency Management|incentives are available for reduced smoking on each study visit which occur each weekday.
223659964|NCT04321707|RADIATION|15O-H2O PET/MR|All included patients will have a 15O-H2O PET/MR scan performed at baseline and a scan performed after NAC, prior to cystectomy.
223769178|NCT01894789|DRUG|Ticagrelor|Blinded administration of ticagrelor for 10 days
224241085|NCT02295878|DIETARY_SUPPLEMENT|Treatment capsule containing seaweed extract (treatment)|400mg capsule containing seaweed extract (treatment)
224241086|NCT02295878|DIETARY_SUPPLEMENT|Placebo|
223659965|NCT04576871|DRUG|225Ac-J591|In this study, subject enrollment will be done in a re-treatment design. A single dose of 225Ac-J591 given at the specified dose per cohort. The initial planned dose level will be determined based upon prior radioactivity exposure level. Those with moderate exposure (up to 30 GBq of 177Lu) will start with 65 KBq/Kg and those with heavy prior exposure (more than 30 Gbq of 177Lu or any 225Ac) will start with 50 KBq/Kg.
223659966|NCT01740453|DRUG|ropivacaine 2 mg/ml|single
223769179|NCT01894789|DRUG|Clopidogrel|Blinded administration of clopidogrel and placebo for 10 days
223769180|NCT02600637|BEHAVIORAL|MBSR|Mindfulness-based Stress Reduction is an 8-week course designed to teach a number of mindfulness techniques to help improve stress- and depression-related symptoms.
223769181|NCT02600637|BEHAVIORAL|Brain Health class|An 8-week course on brain health will be administered to participants as an active control group.
223769182|NCT02627599|DEVICE|Breath Responsive Variable Bolus Oxygen Conserving Device|Mini Electronic Oxygen Conserving Device
223769183|NCT05304260|OTHER|clinical and radiographic examination|Prevalence of dental anomalies in deciduous dentition and risk factors associated with non-syndromic oral clefts patients: A cross-sectional study.
223769184|NCT02327923|DRUG|Lidocaine|Lidocaine intravenous 1.5mg/kg IV bolus at the time of induction followed by IV infusion @ 1.5 mg/kg/hr till the last suture.
223769185|NCT02327923|DRUG|Esmolol|Esmolol intravenous bolus 0.5 mg/kg at the time of induction followed by infusion @ 5-15 microgram/kg/min till the last suture.
223769186|NCT02327923|DRUG|Paracetamol|Inj. Paracetamol 1 gm IV at the time of induction
223769187|NCT02327923|DRUG|Lidocaine|Inj. Xylocaine 2% 3 ml will be infiltrated in skin in all port sites prior to incision.
223769188|NCT02327923|DRUG|Propofol|Inj. Propofol 2- 2.5 mg/kg will be given for induction
224241087|NCT04751578|DEVICE|IMPEDE-FX Embolization Plug|Fill an abdominal aortic aneurysm (AAA) sac outside of an endovascular aneurysm repair (EVAR) stent graft
223659967|NCT06682806|DRUG|PRT3789|PRT3789 is administered as an intravenous infusion once weekly for 3 weeks
223659968|NCT06682806|DRUG|pembrolizumab|Pembrolizumab is administered at 200 mg as an intravenous infusion over 30 min every 3 weeks
223659969|NCT06687889|OTHER|Elastography Measurements|Elastography Measurements
223769189|NCT02327923|DRUG|Fentanyl|Inj fentanyl 1.5mg/kg will be given at the time of induction.
223769190|NCT02327923|DRUG|Vecuronium|Inj Vecuronium 0.1mg/kg will be given at induction and for maintenance.
223769191|NCT02327923|DRUG|Atropine|Inj Atropine 0.4 mg IV will be given for bradycardia (HR \< 50/min)
223769192|NCT02327923|DRUG|Ephedrine|
223769193|NCT02327923|DRUG|Morphine|
223769194|NCT02327923|DRUG|Ketorolac|
224241088|NCT05928845|DIAGNOSTIC_TEST|Muscle thickness measurement|Rectus femoris and sternocleidomastoideus muscle thickness will be measured via ultrasonography in admission and on 7th day of admission
224241089|NCT03732846|DRUG|Anlotinib|Take Anlotinib 12mg once daily for two weeks, stop for one week, the program repeats every 21 days until it can not tolerate, or disease progression
223659970|NCT06687889|OTHER|Bone Mineral Density Measurement (DEXA)|Bone Mineral Density Measurement (DEXA)
223769195|NCT02327923|DRUG|Ondansetron|
223769196|NCT02327923|DRUG|Bupivacaine|Inj. Bupivacaine 0.25% 10 ml will be infiltrated at incision site after closure.
223769197|NCT02327923|DRUG|Tramadol|Inj tramadol 50 mg IV will be given on SOS basis in ward.
223769198|NCT02327923|DRUG|Neostigmine|50 mcg/kg for reversal of residual neuromuscular blockade
223769199|NCT02327923|DRUG|Glycopyrrolate|10 mcg/kg with neostigmine
223769200|NCT01148602|OTHER|LED stopwatch-clock timers|"We will attach a large, in-your-face red LED stopwatch-clock timers to the patient's stretcher at the moment of ED arrival to act as a constant visual reminder to all team members (physicians, RN's, CT technologists) of the urgency of the situation."
223769201|NCT02815228|DRUG|BAY987517|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation Code: Z43-034)
223769202|NCT06562881|OTHER|Scheduling Navigation|Participants will be connected to a scheduler to schedule a surgical consultation visit at time of recruitment. Participation does not guarantee or require surgery.
223769203|NCT06562881|OTHER|Without Scheduling Navigation|Patients will work with clinic staff in the usual fashion for their treatment for primary hyperparathyroidism. They will not be connected directly to a scheduler to help schedule a surgical consultation visit at time of recruitment. With our crossover design, if patients have not yet received surgical consultation after 3 months, they will be called and connected with a scheduler at that time. Participation does not guarantee or require surgery.
223769204|NCT01365273|DEVICE|Mepitel One|Dressing
223769205|NCT04043312|DEVICE|Magstim SuperRapid|Transcutaneous magnetic stimulation targeting the left stellate ganglion.
224241090|NCT01706926|BIOLOGICAL|Mavrilimumab 30 mg|Mavrilimumab (CAM-3001) 30 mg injection subcutaneously every 2 weeks for 24 weeks
224241091|NCT01706926|BIOLOGICAL|Mavrilimumab 100 mg|Mavrilimumab (CAM-3001) 100 mg injection subcutaneously every 2 weeks for 24 weeks.
224241092|NCT01706926|BIOLOGICAL|Mavrilimumab 150 mg|Mavrilimumab (CAM-3001) 150 mg injection subcutaneously every 2 weeks for 24 weeks.
223659971|NCT06687889|OTHER|Berg balance scale|Berg balance scale
223659972|NCT06687889|OTHER|Functional reach test|Functional reach test
223659973|NCT06687889|OTHER|Timed Up and Go Test|Timed Up and Go Test
223659974|NCT07025226|PROCEDURE|Biospecimen Collection|Undergo blood and CSF sample collection
223659975|NCT07025226|DRUG|Dasatinib|Given PO
223659976|NCT07025226|DRUG|Fisetin|Given PO
223659977|NCT07025226|DRUG|Fluorodopa F 18|Undergo 18F-DOPA-PET scan
223659978|NCT07025226|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223659979|NCT07025226|OTHER|Patient Observation|Receive rest and take no treatment
223769206|NCT04043312|DEVICE|Magstim SuperRapid|Sham transcutaneous magnetic stimulation.
223769207|NCT00504686|OTHER|manual therapy|manual therapy - thoracic spine thrust manipulation
223769208|NCT00504686|OTHER|exercise|therapeutic exercise
224241093|NCT01706926|OTHER|Placebo|Placebo matched to mavrilimumab (CAM-3001) injection subcutaneously every 2 weeks for 24 weeks.
223659980|NCT07025226|PROCEDURE|Positron Emission Tomography|Undergo 18F-DOPA-PET scan
223659981|NCT07025226|DRUG|Quercetin|Given PO
223659982|NCT07025226|DRUG|Temozolomide|Given PO
223659983|NCT04469998|DRUG|AXR-270 Low Dose|AXR-270 Topical Eyelid Cream
223659984|NCT04469998|DRUG|AXR-270 High Dose|AXR-270 Topical Eyelid Cream
223659985|NCT04469998|DRUG|AXR-270 Vehicle|AXR-270 Topical Eyelid Cream Vehicle
223659986|NCT06710938|DEVICE|The system includes the G-Branch™ thoracoabdominal aortic stent graft system, the peripheral vascular stent graft system, and the aortic extension stent graft system|The thoracoabdominal artery stent graft system is a mixed branch design with two inner branches for the visceral arteries and two outer branches for the bilateral renal arteries.
223659987|NCT06714617|DRUG|BL-M17D1|The study includes 3 parts: Part 1 Dose escalation. Part 2 Dose Finding non-randomized and Part 3 Dose expansion randomized. BL-M17D1 will be administered on Day 1 and Day 8 by intravenous infusion every 3 weeks.
223659988|NCT06718972|OTHER|Not applicable- observational study|This is a retrospective and observational study. Not Applicable
223659989|NCT07046429|DIETARY_SUPPLEMENT|Melatonin tablet 3 mg once daily|Participants will be instructed to take 3 mg regular acting (not orally dissolving) melatonin 30 minutes before their anticipated bedtime, nightly for the 30 days preceding analysis of study endpoints.
223659990|NCT07046429|DIETARY_SUPPLEMENT|Thiamine|Participants will be instructed to take 100 mg regular acting (not orally dissolving) thiamine 30 minutes before their anticipated bedtime, nightly for the 30 days preceding analysis of study endpoints.
223659991|NCT06885281|DRUG|ZL-1310|drug ZL-1310
223659992|NCT07042607|OTHER|not appicable|no intervention
223659993|NCT06923436|BEHAVIORAL|Psychological Assessment|Collection of anamnestic and socio-demographic data, test administration repeated 4 months apart to monitor any changes
223659994|NCT06003049|DRUG|OnabotulinumtoxinA|BOTOX injection series
223659995|NCT06003049|OTHER|Placebo|Placebo injection series
223659996|NCT07146386|DRUG|H077 sustained-release tablet|Subjects are administered one H077 sustained-release tablet (8 mg) orally once daily, along with one silodosin capsule (placebo) orally twice daily.
223659997|NCT07146386|DRUG|Silodosin capsules Control Group|Subjects are administered one Silodosin capsule (4 mg) twice daily, along with one H077 sustained-release tablet placebo once daily, orally.
223659998|NCT07146126|DRUG|PG-011 nasal spray 0.6%(twice daily)|2 sprays in each nostril, twice daily for 14-day treatment period.
223659999|NCT07146126|DRUG|Placebo|2 sprays in each nostril, twice daily for 14-day treatment period.
223660000|NCT07146360|BIOLOGICAL|Revelise (GENERIUM, Russia)|"1. 90-minute accelerated dosing regimen for patients who can start treatment within 6 hours after the onset of symptoms of acute myocardial infarction (AMI): Initial bolus injection: 15 mg intraveniously (IV) followed by an infusion of 50 mg over 30 minutes and then a subsequent infusion of 35 mg over 60 minutes to reach a maximum total dose of 100 mg.~   \- For patients less than 65 kg: Initial bolus injection: 15 mg IV - 0.75 mg/kg (maximum 50 mg) over 30 minutes followed by an additional infusion of 0.5 mg/kg (maximum 35 mg) over 60 minutes.~2. 3-hour dosing regimen for patients who can start treatment between 6 and 12 hours after symptom onset of AMI: Initial bolus injection: 10 mg IV followed by an infusion of 50 mg over 60 minutes and then a subsequent infusion of 40 mg over 120 minutes to achieve a maximum total dose of 100 mg.~   * For patients less than 65 kg: The cumulative dose should not exceed 1.5 mg/kg."
224241094|NCT00814099|BEHAVIORAL|Team approach to sedation management|"The team approach to sedation management includes the following:~* Team education and consensus on the use of sedatives~* Team identification of the patient's trajectory of illness and daily prescription of a sedation goal~* A nurse-implemented goal-directed comfort algorithm that guides moment-to-moment titration of opioids and benzodiazepines~* Team feedback on sedation management performance"
224241095|NCT00814099|BEHAVIORAL|Usual approach to sedation management|The pediatric ICU will continue its usual approach to sedation management.
223660001|NCT07146360|BIOLOGICAL|Actilyse® (Boehringer Ingelheim Pharma GmbH and Co.KG, Germany)|"1. 90-minute accelerated dosing regimen for patients who can start treatment within 6 hours after the onset of symptoms of acute myocardial infarction (AMI): Initial bolus injection: 15 mg intraveniously (IV) followed by an infusion of 50 mg over 30 minutes and then a subsequent infusion of 35 mg over 60 minutes to reach a maximum total dose of 100 mg.~   \- For patients less than 65 kg: Initial bolus injection: 15 mg IV - 0.75 mg/kg (maximum 50 mg) over 30 minutes followed by an additional infusion of 0.5 mg/kg (maximum 35 mg) over 60 minutes.~2. 3-hour dosing regimen for patients who can start treatment between 6 and 12 hours after symptom onset of AMI: Initial bolus injection: 10 mg IV followed by an infusion of 50 mg over 60 minutes and then a subsequent infusion of 40 mg over 120 minutes to achieve a maximum total dose of 100 mg.~   * For patients less than 65 kg: The cumulative dose should not exceed 1.5 mg/kg."
223660002|NCT06947265|DRUG|L-Arginine|get 3 gm oral tablets of L-arginine
223660003|NCT06947265|DRUG|Tadalafil 5 mg|get 5 mg oral tadalafil for 8 weeks
223660004|NCT07146399|PROCEDURE|Ischemic Preconditioning|Compression cuff width: 10CM; Compression duration: 5min/5min (ischemia/reperfusion) \*4. 220 mmHg
223660005|NCT07146399|PROCEDURE|Sham (No Treatment)|Compression cuff width: 10CM; Compression duration: 5min/5min (compression/relaxation) \*4. 20 mmHg
223660006|NCT01395524|DRUG|NKTR-118|12.5 mg oral tablet once daily
223660007|NCT01395524|DRUG|NKTR-118|25 mg oral tablet once daily
223660008|NCT01395524|DRUG|Placebo|Oral tablet intake once daily
223660009|NCT01657461|DRUG|Intravenous (IV) recombinant human tissue plasminogen activator (rtPA)|Standard therapy with Intravenous (IV) recombinant human tissue plasminogen activator (rtPA)
223660010|NCT01657461|DEVICE|Solitaire revascularization device|Clot retrieval with the Solitaire revascularization device after patients have received standard therapy with intravenous tissue plasminogen activator
223660011|NCT03159260|DEVICE|Theraworx|Subjects will be instructed to apply the topical foam they have been assigned to their entire upper and lower legs and feet using 8 pumps from the product dispenser per leg (upper thigh to foot) before retiring each evening for the next 14 days. If subjects experience leg cramps or spasms after retiring they will be instructed to reapply to 2 pumps of the foam to the affected area in response to each event. Each morning during the 14 days in which subjects apply the foam they will be asked to complete the Compliance and Symptom Log that documents the incidence and severity of night-time cramps and spasms their use of the foam and any other therapies they used to treat their night-time cramps and spasm.
223769209|NCT04437966|BEHAVIORAL|Enhanced Chronic Disease Self-management program|CDSMP workshops will last for approximately 2.5 hours and occur weekly for six weeks. Sessions will focus on appropriate diet for persons with hypertension and to facilitate weight loss; managing medications, adherence to medical clinic appointments; physical activity and stress management. Participants make weekly action plans, share experiences, and help each other solve problems they encounter in creating and carrying out their self-management program. Participants will also be given pill boxes and will be prompted by social media messages to make and keep clinic appointments as well as maintain a healthy lifestyle.
223660012|NCT03159260|OTHER|Placebo|Subjects will be instructed to apply the topical foam they have been assigned to their entire upper and lower legs and feet using 8 pumps from the product dispenser per leg (upper thigh to foot) before retiring each evening for the next 14 days. If subjects experience leg cramps or spasms after retiring they will be instructed to reapply to 2 pumps of the foam to the affected area in response to each event. Each morning during the 14 days in which subjects apply the foam they will be asked to complete the Compliance and Symptom Log that documents the incidence and severity of night-time cramps and spasms their use of the foam and any other therapies they used to treat their night-time cramps and spasm.
223660013|NCT04866745|DEVICE|Magnetotherapy plus exercise|The VARIMAG-4E magnetotherapy device will be used. It is a pulsed radiofrequency energy device. The device has a voltage of 220V, 4 amps of intensity, 50 Hz of frequency and a maximum power of 100 Gauss. For the active treatment application, the patient will be in supine position and will introduce both knees in the 50 cm coil in case of bilateral knee osteoarthritis. In the case of unilateral knee osteoarthritis, the affected knee will be introduced in the 30cm coil. The duration of the treatment will be 20 minutes, the frequency administered will be 50 Hz and a power of 100 Gauss.
223660014|NCT04866745|DEVICE|Microwave plus exercise|The application of deep heating therapy will be with the patient in a sitting position. The VARITRON 250-EP microwave device will be used with a frequency of 2450 MHz and a maximum output power of 250W. In the case of unilateral knee osteoarthritis, the circular applicator with a diameter of 170mm will be placed approximately 15 cm from the knee. The duration of the session will be 20 minutes, 10 minutes over the internal face and 10 minutes over the external face of the knee. In the case of bilateral knee osteoarthritis, the large lumbar applicator will be placed approximately 15 cm from the anterosuperior face of both knees for 20 minutes. The patient will have to perceive a moderate heat sensation.
223660015|NCT04866745|DEVICE|Sham Magnetotherapy plus exercise|The protocol and device will be the same in the active/placebo treatment. The sham device does not emit an electromagnetic field. The energy from the active device is not felt by the user, and the active device cannot be distinguished in any way from the placebo device.
223660016|NCT00608946|DIETARY_SUPPLEMENT|copper|intake of copper orotate 8 mg per day per os, once daily for one year, vs. placebo under observation of the cognitive status
223769210|NCT03044132|OTHER|DermACELL AWM|Decellularized regenerative human tissue matrix allograft (dermis) processed using proprietary Matracell® technology
223769211|NCT00560690|DRUG|Metformin|500 mg oral three times a day for 6 months
223769212|NCT00560690|DRUG|pegylated interferon|180 micrograms, or 1.5 micrograms/kg body weight weekly SQ injection for 6 or 12 months depending on genotype
223769213|NCT00560690|DRUG|Ribavirin|800-1200 mg PO given in 2 divided doses for 6 to 12 months depending on weight and genotype
223769214|NCT01120431|OTHER|Oral rehydration fluid|Oral electrolyte solution or other clinically acceptable oral rehydration fluid, 5 to 10 mL of offered with encouragement every 5 to 10 minutes
223660017|NCT00608946|DIETARY_SUPPLEMENT|placebo|placebo
223660018|NCT02491944|DRUG|AZD9291|Single oral dose of 80 mg AZD9291 tablet on Day 1 administered orally with 240 mL water following an overnight fast.
223660019|NCT02491944|DRUG|[14C]AZD9291|Each healthy male subject will also receive a single, radiolabeled, 100 μg dose of \[14C\] AZD9291 administered as an IV microdose infusion starting at 5 hours and 45 minutes after receiving the oral dose.
223660020|NCT06227598|OTHER|Procedure: Additional biopsies collection|Procedure: Additional biopsies collection We will recruit only subjects (UC, CD and NO-UC/CD) scheduled for the endoscopy and biopsies-collection according to the usual clinical practice. During the endoscopy we will collect 6 additional biopsies.
223660021|NCT00940667|DRUG|Amlodipine plus Losartan|amlodipine/losartan 5/50mg q.d.
223660022|NCT00940667|DRUG|Amlodipine|amlodipine 5mg q.d.
223660023|NCT01126047|OTHER|eCO testing|exhaled carbon monoxide testing measured in duplicate on each of 2 machines immediately prior to the carboxyhemoglobin blood draw and four minutes after the clinical measurement of DLCO
223660024|NCT04685161|PROCEDURE|Surgical extrusion|Invasive treatment option for fractured tooth
223660025|NCT04685161|DEVICE|Fibre post|Easy approach for treatment
223660026|NCT02050542|PROCEDURE|systematic biopsies|90 patients will have to undergo 12 systematic transrectal ultrasound-guided biopsies of the prostate
223660027|NCT02050542|PROCEDURE|Targeted biopsies guided by a fusion of MRI and ultrasound- images|Immediately after the 12 systematic biopsies, the same patients will have to undergo 3 additional targeted biopsies on the suspicious image detected by IRM, guided by a fusion of MRI and ultrasound- images with the Koelis ® system
223660028|NCT03610100|DRUG|Acelarin|825 mg/m2 administered intravenously over 15 to 30 minutes on days 1, 8 and 15 of a 28 day cycle. Number of Cycles: until disease progression or unacceptable toxicity develops.
223769215|NCT01120431|DRUG|Isotonic hydration fluid and recombinant human hyaluronidase|Single subcutaneous dose of 150 U recombinant human hyaluronidase, followed by infusion pump-delivered subcutaneous isotonic hydration fluid
223769216|NCT00854581|BIOLOGICAL|PEG-interferon alfa-2b|Administered subcutaneously.
223769217|NCT00854581|BIOLOGICAL|Interferon alfa-2b|Administered intravenously.
223769218|NCT00854581|DRUG|Valproic Acid|Administered orally.
223769219|NCT00854581|DRUG|Zidovudine|Administered intravenously during Induction Therapy; orally during Maintenance Therapy in all Phases (1, 2A and 2B).
223769220|NCT01339390|BEHAVIORAL|MOVE OUT|The MOVE OUT intervention builds on the high quality information provided by the nationally-developed MOVE program by adding 1) peer support; 2) convenient local access to educational sessions, which allows the material to be delivered in smaller, more easily retained aliquots; 3) convenient local exercise opportunities; and 4) open-ended availability of both education and exercise support.
223660029|NCT03610100|DRUG|Gemcitabine|1000 mg/m2 administered intravenously as a 30 minute infusion on days 1, 8 and 15 of a 28 day cycle. Number of Cycles: until disease progression or unacceptable toxicity develops.
223660030|NCT00167297|DRUG|Atomoxetine|
223660031|NCT05629065|OTHER|Clinician Nudge Email|"-Clinician nudge email encouraging discussion to initiate discussion on SIC at next visit"
223660032|NCT05629065|OTHER|Patient Nudge Letter and Share questionaire|"Involves patient nudge consists of a letter and SHARE questionnaire~\- patient nudge is a letter and a SHARE questionnaire encourages the participant to complete the SHARE questionnaire, which asks questions about the participants goals and preferences around cancer care, and discuss the questionnaire with their oncology clinician at the next visit."
223660033|NCT02524600|DEVICE|myocardial IQ-SPECT imaging applied to scintigraphic imaging|
223660034|NCT02524600|DEVICE|scintigraphic imaging|
223660035|NCT06032325|DIAGNOSTIC_TEST|Neutrophil Gelatinase and Kidney Injury Molecule-1|To assess Neutrophil Gelatinase associated Lipocalin and Kidney Injury Molecule-1 as biomarkers of acute kidney injury in children with Diabetic Ketoacidosis
223660036|NCT00643721|OTHER|dehydration|dehydration to 3% and 5% loss of total body water
223660037|NCT00942994|DRUG|Aliskiren/Amlodipine|"Amlodipine capsule (5 mg)~Aliskiren/Amlodipine tablets (150/5 mg, 300/5 mg, 300/10 mg)"
223660038|NCT00942994|DRUG|Aliskiren/Amlodipine and Hydrochlorothiazide (HCTZ)|"Aliskiren/Amlodipine tablets (150/5 mg, 300/5 mg, 300/10 mg)~HCTZ capsule (12.5 mg, 25mg)"
223660039|NCT03583385|DRUG|Glucophage XR (Test drug)|Participants received single oral dose of Glucophage® XR tablet manufactured by PT Merck Tbk, Jakarta, Indonesia (Test Drug) under fasted conditions.
223660040|NCT03583385|DRUG|Glucophage XR (Comparator drug)|Participants received single oral dose of Glucophage® XR tablet manufactured by Merck Santé, Semoy, France (Comparator Drug) under fasted conditions.
223660041|NCT03507387|DRUG|Phenylephrine|5 mg (1ml) phenylephrine intramuscular injection will be given into the gluteus maximus muscle before anesthesia.100ug (1ml) phenylephrine intravenous injection will be given after the subarachnoid injection is completed .
223660042|NCT03507387|DRUG|Normal saline|1ml 0.9% normal saline intramuscular injection will be given into the gluteus maximus muscle before anesthesia and after the subarachnoid injection is completed.
223660043|NCT03507387|DRUG|Bupivacaine|All patients will receive spinal anesthesia with bupivacaine.
223660044|NCT04780919|DEVICE|BTL-6000 FSWT|Intensity 0,12 mJ/mm2, frequency 10 Hz, total number of shocks 1300.
223660045|NCT04780919|DEVICE|BTL-6000 FSWT with sham applicator|Intensity 0,12 mJ/mm2, frequency 10 Hz, total number of shocks 1300 - applied with modified applicator which does not allow wave transmission.
223660046|NCT03914222|DEVICE|CardioSpire (Respirix) Device|Patients will blow into the device through a small tube, which analyzes the signals in the airway patterns.
223660047|NCT05715112|PROCEDURE|Graded Motor Imagery|GMI consisting of education, sensory integration of the foot using contact, flooring samples, immersion, and two point discrimination.
224241096|NCT03499847|BEHAVIORAL|standardised face-to-face counselling session|the healthcare provider will conduct a standardised face-to-face counselling session guided with subjects guided by a check-list of topics to cover regarding the Advanced Medical Directive.
224241097|NCT03499847|BEHAVIORAL|advanced medical directive pamphlet|A standardised pamphlet containing information about the Advanced Medical Directive produced by the Ministry of Health, Singapore.
223660048|NCT00706303|BEHAVIORAL|Supported self management training and support|Supported Self-management. This will consist of fortnightly individual patient sessions at home of approximately 40 minutes for two months, with home visits at a maximum frequency of 6 weeks thereafter for 1 year. Further details of the rubric of the initial training sessions are given in Appendix 1 and will use adapted versions of the Bourbeau self-management and education materials. Follow up visits will be less structured, and based on the patient's individual agenda as well as reviewing and reinforcing basic self-management messages. Patients will be provided with an individualised self-management plan and symptom diary cards to use as a monitoring aid. Patients will be trained to identify and treat exacerbations associated with purulent sputum with antibiotic and those associated with increased breathlessness, mucoid sputum and/or upper airway symptoms with Prednisolone.
223660049|NCT04126278|DRUG|Barbotage|Administered as per standard of care
223660050|NCT04126278|DRUG|Dexamethasone|4 mg of dexamethasone
223660051|NCT05189353|OTHER|Ghrelin|Ghrelin infusion
223660052|NCT05189353|OTHER|Placebo|Saline infusion
223660053|NCT03029988|DRUG|Tilmanocept (Technetium Tc 99m tilmanocept Injection)|Drug: Technetium Tc 99m tilmanocept
223660054|NCT03029988|PROCEDURE|SPECT/CT Imaging|4-6 hours post-injection SPECT/CT will be obtained in the abdominal region.
223660055|NCT01540955|BEHAVIORAL|Improving Cognition with group intervention|Participants attend 5 weekly group sessions that are 2 hours each, delivered by a trained therapist. Sessions focus on specific aspects of attention, memory, multi-tasking and encoding. Homework assignments are practiced between classes. Goals are set for improved functioning.
223660056|NCT03006861|DIETARY_SUPPLEMENT|3.5 mL/d topical creatine|
223660057|NCT03006861|DIETARY_SUPPLEMENT|3.5 mL/d topical placebo|
223660058|NCT03006861|DIETARY_SUPPLEMENT|21 g/d Oral creatine|
223660059|NCT03006861|DIETARY_SUPPLEMENT|21 g/d oral placebo|
223660060|NCT01504646|DIETARY_SUPPLEMENT|Lyprinol|8 capsules (1 capsule=50mg n-PUFA, 100mg olive oil) per day for 3 weeks
223660061|NCT01504646|DIETARY_SUPPLEMENT|Placebo (Olive Oil)|8 capsules (1 capsule = 100mg olive oil) per day for 3 weeks
223660062|NCT00001113|DRUG|Interferon alfa-2a|
223660063|NCT00001113|DRUG|Zidovudine|
223660064|NCT00001113|DRUG|Interferon alfa-n1|
223660065|NCT01221935|OTHER|Pristiq first-line treatment charts|300 charts including patients initiated on Pristiq within the past 6 months as a first-line treatment
224241098|NCT02620670|BEHAVIORAL|Physical activity of moderate intensity for 3 days|The intervencion consist in a moderate-intensity physical activity exercise is a heart rate between 60 and 70% of maximum heart beats per minute for at least 30 minutes for three days
224241099|NCT04608253|DIAGNOSTIC_TEST|11C-choline PET/CT|11C-choline PET/CT
224241100|NCT02735122|DRUG|acetaminophen Tablet|2 test acetaminophen 500 mg tablets
224241101|NCT02735122|DRUG|acetaminophen Caplet|2 commercial acetaminophen 500 mg caplets
224241102|NCT02735122|DRUG|ibuprofen Liquid-filled capsule|2 commercial ibuprofen 200 mg Liquid-filled capsules
223660066|NCT01221935|OTHER|Pristiq second-line treatment charts|800 charts including patients initiated on Pristiq within the past 6 months as a second-line treatment (following first-line treatment with a Serotonin Norepinephrine Reuptake Inhibitor (SNRI) or Selective Serotonin Reuptake Inhibitors (SSRIs)).
223660067|NCT01221935|OTHER|SNRI or SSRI first-line treatment charts|800 charts including patients initiated on a Serotonin Norepinephrine Reuptake Inhibitor (SNRI) or Selective Serotonin Reuptake Inhibitors (SSRIs) (excluding Pristiq) within the past 6 months as a first-line treatment.
223660068|NCT01221935|OTHER|SNRI or SSRI second-line treatment charts|800 charts including patients initiated on a Serotonin Norepinephrine Reuptake Inhibitor (SNRI) or Selective Serotonin Reuptake Inhibitors (SSRIs)(excluding Pristiq) within the past 6 months as a second-line treatment (following the first-line treatment with a SNRI or SSRI).
223660069|NCT06337019|OTHER|Cohort observational|Cohort observational
223660070|NCT00263289|PROCEDURE|preprocedural fasting|
223660071|NCT04602871|DIAGNOSTIC_TEST|Breath Biopsy|Breath Biopsy sampling using the ReCIVA® Breath Sampler
223660072|NCT00641641|DRUG|Tenofovir + emtricitabine + raltegravir.|TDF 300mg once daily + FTC 200mg once daily + RAL 400mg twice daily.
223660073|NCT02385422|DRUG|Carvedilol|Carvedilol is started at a dose of 6.25mg/d, and titrated to a maximum dose of 25mg/d. Doses are increased every 2-3 days until ABPsys is not less than 90 mm Hg and HR is not less than 55 bpm.
223660074|NCT02385422|DRUG|Propranolol|Patients receiving propranolol start at a dose of 30 mg/d and the dose will be increased to a maximum dose of 160 mg/d.Doses are increased every 2-3 days until ABPsys is not less than 90 mm Hg and HR is not less than 55 bpm.
223660075|NCT00856232|BIOLOGICAL|Medical Air|Compressed medical air
223660076|NCT00856232|BIOLOGICAL|Oxygen|Medical Oxygen
223660077|NCT03241030|DRUG|Sucralfate|Will receive 20mg/kg/dose up to 1 gram.
223660078|NCT03241030|OTHER|Placebo|Will received placebo solution of similar quantity to that of the weight based dose of sucralfate.
223660079|NCT03241030|DRUG|Acetaminophen|All patients will receive analgesia, either acetaminophen 15mg/kg or ibuprofen 10mg/kg depending on medication administration prior to arrival in the Emergency Department and at the discretion of the treating physician, in addition to either the experimental drug or placebo.
223660080|NCT03241030|DRUG|Ibuprofen|All patients will receive analgesia, either acetaminophen 15mg/kg or ibuprofen 10mg/kg depending on medication administration prior to arrival in the Emergency Department and at the discretion of the treating physician, in addition to either the experimental drug or placebo.
223660081|NCT02713074|DRUG|povidone-iodine|The patients will be subjected to povidone-iodine (Betadine7.5%) for vaginal cleaning before office hysteroscopy
223660082|NCT02713074|DRUG|normal saline|The patients will be subjected to normal saline (Sod. Chloride 0.9%, Nile) for vaginal cleaning
223660083|NCT00160472|PROCEDURE|removal of ovarian vessels|
223660084|NCT02553252|OTHER|Sudarshan Kriya Yoga Trauma Relief Program (SKY)|Participants in the SKY group will undergo a 12-week training course in Sudarshan Kriya Yoga (SKY) conducted by certified instructors from the Art of Living Foundation.
223660085|NCT03264053|DEVICE|Socket shield|Socket shield is the Removal of the lingual portion of the anterior root thus retaining the lingual portion
223660086|NCT03264053|PROCEDURE|Conventional immediate implantation|Conventional immediate implantation
223660087|NCT01758536|DRUG|Huatuo Zaizao Pills|A tens of herbs botanical drug product 12 gram (g) in 72 mini pills formulation. It is to be used as 12 g each time, twice daily.
223660088|NCT04249349|DEVICE|Assisted gait with a motorized ankle foot orthosis|The motorized ankle foot orthosis is a powered lower extremity assistance device with an actuated ankle joint. A novel control software has been design and implemented in this device, which allows precise joint movement and recording of data from training session.
223660089|NCT00040560|DRUG|111In-DAC|
223660090|NCT00040560|PROCEDURE|Diagnostic|
223660091|NCT01676779|BIOLOGICAL|Dendritic cell therapy|Dendritic cell therapy IV and ID
223660092|NCT01311024|BIOLOGICAL|PCV GSK1024850A|2 to 4 doses administered to the siblings in the cluster-randomized Finnish Invasive pneumococcal Disease Trial (ClinicalTrials.gov Identifier:NCT00861380)
223660093|NCT01311024|BIOLOGICAL|hepatitis B vaccine or hepatitis A vaccine|2 to 4 doses administered to the siblings in the cluster-randomized Finnish Invasive pneumococcal Disease Trial (ClinicalTrials.gov Identifier:NCT00861380)
223769221|NCT01339390|BEHAVIORAL|MOVE!|"As part of routine care at the ZVAMC, all patients who are eligible for the present study are identified by a clinical reminder. This reminder prompts the PCP to determine if the person would benefit from a weight loss program, and to refer them to MOVE if they and the patient agree that it would be beneficial. The MOVE program in Milwaukee can be tailored by the patient and PCP, but includes dietitian assessment, education, weekly weigh-ins, follow-up classes, and exercise programs."
223660094|NCT02706964|DEVICE|Positron emission tomography/x-ray computed tomography|A whole-body PET/CT will be performed to identify the site and extent of spread.
223660095|NCT02706964|DEVICE|Magnetic resonance imaging|A brain MRI will be performed.
223660096|NCT02706964|DEVICE|x-ray computed tomography (CT)|A CT scan will be performed to identify the site and extent of spread.
223660097|NCT04352972|DEVICE|Tele-monitored home exercise program|Tele-monitoring home exercise program used in the home with monitoring by physiotherapists.
223660098|NCT04352972|OTHER|Hospital-based rehabilitation program|Participants will receive a maximum of 8 sessions over 10 weeks with the option of two additional sessions. Participants will receive exercises, patient education, manual therapy and other modalities that were prescribed and progressed at the project physiotherapist's discretion. Participants will also receive a set of home exercises and they will be instructed to exercise on days when not attending rehabilitation.
223660099|NCT03078140|DIETARY_SUPPLEMENT|Triferdine|Triferdine 1 tablet daily Start from 14 weeks of gestation until delivery
224241103|NCT02735122|DRUG|Placebo Tablet|2 placebo tablets
224241104|NCT02735122|DRUG|Placebo Caplet|2 placebo caplets
223660100|NCT03078140|DIETARY_SUPPLEMENT|Triferdine/Ferli-6|"For the participants assigned to this group, urine iodine level will be checked first.~For participants with normal urine iodine level, Ferli-6 1 tab daily will be given.~For those with low urine iodine level, Triferdine 1 tab daily will be given. Medication will be started from 14 weeks of gestation until delivery."
223660101|NCT01523275|DRUG|Mitomycin -C|Topical mitomycin-C at a dosage of 0.4mg/ml will be applied to cottonoid pledgets and placed into the radial incisions for 3 minutes.
223660102|NCT01523275|OTHER|Saline application|Isotonic saline will be applied to cottonoid pledgets and placed into the patient's radial incisions for 3 minutes as the placebo intervention.
224241105|NCT02735122|DRUG|Placebo Liquid-filled capsule|2 placebo Liquid-filled capsules
224321205|NCT05316610|BEHAVIORAL|Body Confident Athletes|The Body Confident Athletes program is a five-session in-person program designed to be delivered by coaches to their athletes. Groups should be of approximately 10 girls. The organizations will work with the community partner and researchers on how to schedule the intervention over a five-week period. These sessions can replace a regular sport practice each week or an additional session can be organized by the sport organizations. Each session will take approximately 60 minutes and will consist of four phases, including The Game Plan (5 mins), The Skills (20 mins), Game Time (20 mins), and The Final Score (15 mins). A variety of activity modalities are utilized to convey learning outcomes, including group and individual activities, and discussion-, writing- and movement-based activities.
224321206|NCT02075515|BIOLOGICAL|Herpes Zoster vaccine (GSK 1437173A)|2 doses administered intramuscularly in deltoid region of non-dominant arm.
224321207|NCT02771288|DEVICE|Bioresorbable Vascular Scaffold|
223660103|NCT01863836|PROCEDURE|Fluoroscopy|
223660104|NCT01863836|PROCEDURE|Radial EBUS-guided biopsy|
223660105|NCT02265588|BEHAVIORAL|Cognitive behavioral therapy|A disease specific cognitive behavioral therapy program called PASCET-PI: The PASCET-PI model focuses on behavioral activation, cognitive restructuring and problem solving skills to change maladaptive behaviors, cognitions and coping strategies specific for IBD.
223660106|NCT02150434|DEVICE|Automated oxygen titration|Automated oxygen titration every second to maintain stable SpO2 at a predefined value (94% in the present study)
223660107|NCT02150434|DRUG|Compressed air|compressed air delivered at a fixed flow of 2 L/min
223660108|NCT02150434|DRUG|Oxygen constant flow|oxygen delivered at a fixed flow of 2L/min
223660109|NCT06173180|DEVICE|TOT|In the Transobturator Tape-TOT operation, the anterior vaginal wall is incised 2 cm sagittal 1.5 cm below the urethra in the dorsal lithotomy position and the paraurethral areas are separated by sharp and blunt dissection and the ischiopubic bone is reached with the finger. The skin is incised so as to remain 1 cm lateral to the ischiopubic ramus on the line passing through the clitoris, and the synthetic tape is placed from outside to inside with special inclined trocars, passing under the urethra close to the medial part of the obturator foramen. Cystoscopy is not performed during the procedure. The vagen mucosa is sutured and the procedure is terminated by inserting a urethral foley catheter. The urethral catheter is removed on postoperative day 1 after the investigator evaluates the patient.
223660110|NCT06173180|DEVICE|VACS-D|The VACS-Minifiks procedure is a vaginal application of a natural tissue repair procedure whose efficacy has been proven in the abdominal route. The second difference is that the procedure is performed through a single incision instead of the three incisions used in the Transobturator Tape-TOT operation. Thus, the same goal will be achieved in a less invasive way without placing an artificial permanent implant. There is no difference in parameters such as anesthesia, operation time, and discharge time.
223660111|NCT05646017|DEVICE|Intermittenly scanned continuous glucose monitoring|Use of Intermittenly scanned continuous glucose monitoring (FreeStyle Libre)
223660112|NCT01788436|BEHAVIORAL|Cognitive Test Battery 1|The Cognitive Test Battery 1 comprises the following tasks: Practice with graphics tablet, pen and screen; Digit Symbol Substitution Test (DSST); Implicit Pattern/Sequence Learning Task (PLT\_Impl); Verbal Learning Test (VLT); Figure drawing; Mirror Drawing; Explicit Pattern Learning Task (PLT\_Expl); Delayed Recall and Recognition Test; and Pursuit rotor.
223769222|NCT00000946|BIOLOGICAL|HIV p24/MF59 Vaccine|
223769223|NCT00000946|BIOLOGICAL|ALVAC-HIV MN120TMG (vCP205)|
223769224|NCT00000946|BIOLOGICAL|ALVAC-RG Rabies Glycoprotein (vCP65)|
223769225|NCT00000946|BIOLOGICAL|rgp120/HIV-1 SF-2|
223769226|NCT04847674|DRUG|TEV-53275 Dose A|subcutaneous (sc) injection
223769227|NCT04847674|DRUG|TEV-53275 Dose B|subcutaneous (sc) injection
223769228|NCT04847674|DRUG|Placebo|Matching subcutaneous (sc) placebo injection
223769229|NCT02281136|DRUG|Aminolevulinic Acid (ALA)|20% ALA applied to upper extremities for 3 hours prior to 10 J/cm2 blue light
223769230|NCT02281136|DEVICE|BLU-U|10 J/cm2 of 417 nm blue light delivered at 10 mW/cm2
223769231|NCT03254134|DRUG|Warfarin|patients treated with warfarin
224241106|NCT03348423|DRUG|DEX-IN|IN Dexmedetomidine + IV placebo
224241107|NCT03348423|DRUG|Fentanyl|IN Placebo + IV Fentanyl
224241108|NCT03348423|DRUG|Placebo|IN Placebo + IV Placebo
224241109|NCT05636241|OTHER|conventional physiotherapy program|The conventional physiotherapy program consists of stretching exercises for lower extremities, strength exercises for core, upper, and lower extremity muscles, sit to stand exercises, and balance exercises.
224241110|NCT05636241|OTHER|whole body vibration training program|The whole body vibration training program sessions consisted of three 3-min bouts of vibration of 20 Hz and a peak-to-peak amplitude of 2mm with a 3-min rest in between, in addition to conventional physiotherapy exercises for children with cerebral palsy.
224241111|NCT01917838|BEHAVIORAL|MFG plus MyMFG|"Specific aim is to utilize mHealth to improve the Design and Do process of HW within the context of the Family Groups for Youth with Behavioral Difficulties (MFG) intervention, an EBT for DBDs in youth and their families who seek assistance at outpatient mental health clinics in urban communities.~The first component focuses on delivering HW via a highly engaging, multiplayer, interactive, cooperative, and skill-building game platform aimed at improving the Design and Do process of HW. The second component focuses on targeting factors putatively related to poor HW implementation within the Do process."
223660113|NCT01788436|BEHAVIORAL|Cognitive Test Battery 2|The Cognitive Test Battery 2 comprises the following tasks: Practice with graphics tablet, pen and screen; Digit Symbol Substitution Test (DSST); Implicit Learning Retention Test; Hopkins Verbal Learning Test (HVLT); Figure drawing; Mirror Drawing; Explicit Learning Retention Test; Instrumental Learning Task; Pursuit rotor; and Sensory Motor Interception Adaptation Task.
223660114|NCT05526040|DIETARY_SUPPLEMENT|Immunonutrient-enriched oral nutrition supplementation|"Individualized dietary assessment and counselling with additional high energy, high protein, immunonutrient-enriched oral nutrition supplement; taken 3 servings per day, from 1 week prior to cancer treatment and continued throughout the cancer treatment.~Oral Impact® is an oral nutrition supplement product enriched with arginine (3.3g/sachet), omega-3 fatty acids (0.8g/sachet) and nucleotides (0.3g/sachet). The immunonutrient-enriched formula is also a complete and balanced formula, and is gluten free. The osmolality of the formula is 620 mOsm/kg water."
223660115|NCT05526040|DIETARY_SUPPLEMENT|Standard medical nutrition therapy|Individualized dietary assessment and counselling and standard nutrition supplementation via oral nutrition supplementation or enteral nutrition as necessary.
223660116|NCT04013061|OTHER|Pluridisciplinary consultation|Pharmacist-anesthesiologist team will be present during the anesthetic consultation
223660117|NCT05573386|DRUG|Filgrastim|human granulocyte colony-stimulating factor (G-CSF) protein obtained from the bacterial fermentation of a strain of E. coli. transformed with a genetically engineered plasmid containing the human G-CSF gene; administered via syringe
223660118|NCT05573386|DRUG|Pegfilgrastim|long-acting covalent conjugate of recombinant methionyl human filgrastim and monomethoxypolyethylene glycol (PEG); administered via syringe
223660119|NCT06023667|BEHAVIORAL|SMART-IBD|Daily medication and diary completion reminders are provided to participants. Additional educational content regarding self-management skills will be provided.
223660120|NCT05764707|DRUG|Acetaminophen|Patients will received 1000mg of intravenous acetaminophen within 30 minutes of skin closure.
223660121|NCT05764707|DRUG|Placebo|Patients will received 1000mg of normal saline within 30 minutes of skin closure.
223660122|NCT05353504|DIETARY_SUPPLEMENT|Inulin|28g/day delivered in 2 sachets throughout the day with main meals
223660123|NCT05353504|BEHAVIORAL|Lifestyle intervention|weekly educational sessions to improve individual's eating behaviour
223660124|NCT05353504|DIETARY_SUPPLEMENT|Placebo|equicaloric maltodextrin delivered in 2 sachets throughout the day with main meals
223660125|NCT01802073|DRUG|Oral Vancomycin|
223660126|NCT00332722|PROCEDURE|Cervical facet joint nerve blocks|
223660127|NCT03883841|DRUG|Iron Sucrose Solution for Injection|intravenous infusion of iron sucrose
223660128|NCT01929499|BIOLOGICAL|cytokine-induced killer cells|
223660129|NCT00918736|DRUG|sodium hyaluronate|3 weekly intraarticular injections of 2 ml sodium hyaluronate (Hyalgan) into the ankle joints.
223660130|NCT03142711|OTHER|No Medical Intervention|Validation of phone ePRO
223660131|NCT02230319|OTHER|Cryotherapy|
223660132|NCT02230319|DRUG|Paclitaxel|
223660133|NCT03825861|DRUG|FOLFIRINOX|Oxaliplatin 85mg/m2, Leucovorin 200mg/m2, Irinotecan 180mg/m2, 5-FU 400mg/m2 bolus followed by 2400mg/m2 continuous infusion.
223660134|NCT04820140|PROCEDURE|Lymphatic drainage|Lymphatic drainage
223660135|NCT01137604|DRUG|Lenvatinib|24 mg lenvatinib capsules orally, once daily continuously in 28-day cycles until disease progression, development of unacceptable toxicity or withdrawal of consent.
223660136|NCT01137604|DRUG|Bevacizumab|Bevacizumab 10 mg/kg administered intravenously every 2 weeks in 28-day cycles until disease progression, development of unacceptable toxicity or withdrawal of consent.
223660137|NCT02149667|DEVICE|total hip arthroplasty implant|
223660138|NCT01961726|BIOLOGICAL|Placebo|Coronary Sinus Delivery
223660139|NCT01961726|BIOLOGICAL|30 mg dose of JVS-100|Coronary Sinus Delivery
223660140|NCT01961726|BIOLOGICAL|45 mg dose of JVS-100|Coronary Sinus Delivery
223660141|NCT03138980|BEHAVIORAL|BodiMojo Buddy for IBS|"Mobile application focusing on emotional coping skills for teens and young adults with IBS. Components of the module include: mood recorder and mood cloud, with supportive feedback given based on mood choice; health behavior change support messages informed by mindfulness and self-compassion; quizzes with tailored feedback; library of meditations; an interactive coping skills advice section; and a link to an optional social support feature."
223660142|NCT03688256|DEVICE|Obalon Balloon System|6 month Obalon Intragastric Balloons
223660143|NCT06282133|BEHAVIORAL|Behavioural Experiments for Intolerance of Uncertainty|"Behavioural experiments involve selecting a specific thought to test (for example, uncertainty makes me incapable of acting) and designing a detailed experiment to challenge this thought."
223660144|NCT05352633|DRUG|Intensive BP Arm|Participants in the Intensive BP treatment group have a goal of SBP \<120 mmHg. It is recommended to provide long-acting antihypertensive medications, that is once daily, unless other medication delivery frequency is needed. The local investigator may select among the available study antihypertensive medications. Other drugs not supplied by the trial may also be used as the investigator determines appropriate. One or more medications from the following classes of agents will be provided by the study for use in managing participants in both randomization groups to achieve study goals: Angiotension converting enzyme (ACE)-inhibitors;Angiotension receptor blockers (ARBs); Thiazide-type diuretics; Loop diuretics; Potassium-sparing diuretics; Beta-blockers; Calcium channel blockers (CCBs); Direct vasodilators; Alpha1-receptor blockers; Sympatholytics
223660145|NCT05352633|DRUG|Standard BP Arm|Participants in the Standard BP treatment group have a goal of SBP \<140 mmHg. The same medications used in the Intensive BP treatment group will be used for the Standard BP treatment group.
223660146|NCT01057641|PROCEDURE|Spacer|Implantation of a percutaneously implanted interspinous device (spacer)
223660147|NCT01057641|OTHER|physiotherapy|physiotherapy
223660148|NCT00229515|OTHER|abciximab followed by implantation of bare metal stent|Patients will receive infusion of abciximab at standard regimen before undergoing intervention for STEMI and then bare metal stent implantation in the culprit lesion
223660149|NCT00229515|OTHER|abciximab and Sirolimus eluting stent|Patients will receive abciximab infusion at standard regimen followed by implantation of sirolimus-eluting stent in the culprit lesion
223769232|NCT03254134|DRUG|Dabigatran|patients treated with Dabigatran
223660150|NCT00229515|OTHER|tirofiban and bare metal stent|Patients will receive tirofiban infusion at high loading dose followed by standard infusion for 18-24 hours and subsequently they will be treated with bare metal stent implantation
223660151|NCT00229515|OTHER|tirofiban and sirolimus-eluting stent|Patients will receive tirofiban infusion at high loading dose followed by standard infusion for 18-24 hours and subsequently they will be treated with sirolimus-eluting stent implantation
223660152|NCT04022395|DIAGNOSTIC_TEST|stress cardiac MRI|pharmacological stress testing has evolved as an alternative to physical exercise for the detection of inducible myocardial ischemia
223660153|NCT04919980|DEVICE|Innovalve MR system|Innovalve MR system
223660154|NCT02857348|BEHAVIORAL|Night Shift|Night Shift is an adventure video game with the transformational goal of teaching physicians key characteristics of patients with non-representative severe injuries - injuries classified by the American College of Surgeons as life-threatening or critical but that do not fit the archetype of injuries typically requiring treatment at a trauma center. Players take on the persona of Andy Jordan, a young emergency physician who moves home after the disappearance of his estranged grandfather (Robert Jordan) and takes up a job in the local Emergency Department (ED). In the preamble, players learn they have two explicit objectives. First, they must diagnose and treat patients who present to their ED. Second they must solve the mystery of Robert's disappearance: was he murdered or has he simply chosen to disappear?
223660155|NCT02857348|BEHAVIORAL|Educational Module|The educational module consists of two separate apps, both commercially available. myATLS includes a review of each chapter of the Advanced Trauma Life Support (ATLS) textbook, a series of videos demonstrating common trauma procedures, and clinical resources including checklists for use at the bedside. Trauma Life Support MCQ Review includes 550 multiple-choice questions with correct answers and explanations. The investigators will ask physicians to review the myATLS app and then complete questions in the Trauma Life Support MCQ Review, spending at least 1 hour on the combined tasks.
223660156|NCT04036292|DRUG|OC-01 (varenicline) nasal spray|OC-01 (varenicline) nasal spray
223660157|NCT04036292|DRUG|Placebo (vehicle) nasal spray|Placebo (vehicle) nasal spray
223660158|NCT04346355|DRUG|Tocilizumab|In case of aggravation of COVID-19 pneumonia, according to protocol criteria, participants will receive 8 mg/kg IV up to a maximum of 800 mg with repetition of the same dosage after 12 hours
223660159|NCT05437250|DRUG|Non interventional study|CLL patients initiated with acalabrutinib at their physician's discretion between January 1, 2021 and December 31, 2022 . Secondary data collection
223660160|NCT03462511|BEHAVIORAL|HABIT Intervention|Dyads randomized to the intervention group will receive the HABIT intervention, which includes CHW support and tailored text messages.
223660161|NCT03462511|OTHER|Standard of Care|Standard of care used to treat patients with SCD
223660162|NCT03462511|OTHER|Education materials|Education materials provided to all patients enrolled in the trial
223660163|NCT00042471|DRUG|Pramlintide acetate|Pramlintide acetate (AC137) injection is a clear, colorless, sterile solution for injection. It consists of pramlintide in sodium acetate buffer, pH 4.0, containing 43mg/mL mannitol as an iso-osmolality modifier and 2.25 mg/mL metacresol as a preservative. The strength of pramlintide is 1.0 mg/mL for SC injection and 0.6 mg/mL for IV bolus injection.
223660164|NCT05506228|OTHER|No intervention|
224241112|NCT06485999|PROCEDURE|Biologically Oriented Preparation Technique|It is a preparation technique without a finish line, also known as the biologically oriented preparation technique (BOPT). In this protocol, the crown's anatomic emergence profile at the cementoenamel junction (CEJ) is eliminated with diamond rotary instruments to create a new prosthetic junction, adapted to the gingival margin. The aim of this protocol is to create a new anatomic crown with a prosthetic emergence profile that simulates the shape of the natural tooth.
224241113|NCT03626649|DEVICE|DiamondTemp Cardiac Ablation System|"The DiamondTemp Ablation System is the test device in this investigational study. The DiamondTemp Ablation System consists of:~* DiamondTemp Ablation Catheter~  o Unidirectional and Bidirectional models~* DiamondTemp Catheter-to RFG Cable~* DiamondTemp GenConnect Cable~* DiamondTemp FASTR Generator with Footswitch~* DiamondTemp Irrigation Pump~* DiamondTemp Irrigation Tubing Set"
224241114|NCT06344624|BEHAVIORAL|CBT group|Brief cognitive behavioral therapy
223660165|NCT02428283|DRUG|Ropivacaine|0.25% ropivacaine 2-3 ml was injected around the scalp nerves that are located on the head.
223660166|NCT02428283|DRUG|Remifentanil|Remifentanil 1 μg/kg was injected before skin incision.
223660167|NCT02428283|DRUG|Sevoflurane|Anesthesia was titrated with sevoflurane, maintaining mean arterial pressure and heart rate within 20% baseline value.
223660168|NCT03826368|DIETARY_SUPPLEMENT|Hemp-derived botanical dietary supplement|Subjects currently taking phytocannabinoid Hemp-derived botanical dietary supplements during recovery from brain injury.
223769233|NCT02563028|DEVICE|SightSaver Visual Stimulator|Evoked response photic stimulator
223660169|NCT01702493|DRUG|Cap SRT2104|Micronized free base in a 250 mg SRT2104 (active equivalents) capsule
223660170|NCT01702493|DRUG|Tab SRT2104 slow release|New 250 mg SRT2104 mesylate salt slow release tablet
223660171|NCT01702493|DRUG|Tab SRT2104 intermediate release|New 250 mg SRT2104 mesylate salt intermediate release tablet
223660172|NCT01702493|DRUG|Tab SRT2104 fast release|New 250 mg SRT2104 mesylate salt fast release tablet
223660173|NCT01702493|DRUG|Selected formulations of SRT2104 from Part 1|SRT2104 500 mg of selected formulation(s) from Part 1 in single-dose or daily for 7 days
223660174|NCT01702493|DRUG|Selected formulations of SRT2104 from Part 1 single alternative dose|SRT2104 single alternative dose (other than 500 mg, but not to exceed 2000 mg) of selected formulation(s) from Part 1
224241115|NCT06344624|BEHAVIORAL|Laughter group|Laughter yoga therapy
224241116|NCT01559324|DEVICE|ECT|Bifrontal ECT, low dosage
224241117|NCT01559324|DEVICE|ECT|Right unilateral electrode position, high dosage
224241118|NCT05621941|BEHAVIORAL|Game-Supported Goal Management Training|The investigational treatment is based on a compensatory strategy training named Goal Management Training (GMT). The investigational treatment will include GMT in combination with a compensatory strategy game which allows the patient to learn and apply the algorithm of GMT in a safe and controlled environment. This means that the multiple steps of the GMT will be learned during the treatment sessions under guidance of a therapist as well as in their own home environment by using the compensatory strategy game.
224241119|NCT05621941|BEHAVIORAL|Information Group|In the information group, patients are informed about non-specific consequences of acquired brain injury, aimed to increase patient's insight into their condition and with that improving functioning. The program consists of the following subjects: 1) cause of brain injury, 2) information processing and attention, 3) memory, 4) planning and performance, 5) fatigue, 6) changes in emotion and behavior and 7) processing and adjustments.
223660175|NCT02925416|DRUG|Oritavancin|Administered intravenously
223660176|NCT02925416|DRUG|Placebo (D5W)|Administered intravenously
223660177|NCT04705493|OTHER|fluid resuscitation with crystalloid|give two-volume of fluids initial 250ml then another 250 ml
223660178|NCT00200356|DRUG|Edaravone|Edaravone, at 30 mg, is intravenously administered by drip over 30 minutes b.i.d., in the morning and the evening.
224241120|NCT02325141|PROCEDURE|laparoscopic sleeve gastrectomy|creation of a gastric tube of 100cc using a stapler.
224241121|NCT01564511|DEVICE|Gait trainer treatment|Patients will be subjected to 40 minutes of repetitive locomotor therapy on the Gait Trainer (GTI) (Reha-Stim, Berlin, Germany), followed by 10 minutes of passive joint mobilization and stretching exercises. The first 40 min session will be divided as follow: 15 min gait training; 5 minutes at rest; 15 minutes gait training; 5 minutes at rest. The GT-I consists of a double crank and rocker gear system, composed of two footplates positioned on two bars (coupler), two rockers, and two cranks that provide the propulsion.
223660179|NCT00200356|DRUG|Sodium Ozagrel|Sodium Ozagrel, at 80 mg, is intravenously administered by drip over 2 hours b.i.d., in the morning and the evening.
223660180|NCT00137072|DRUG|Viagra (Sildenafil Citrate) 100 mg|
223660181|NCT02900989|BEHAVIORAL|Suicide screening|"Patients of the emergency unit usually do not pass this kind of questionnaire in the absence of warning signs. Then it could result in adverse effects on behavior and ideation.~The study had to be declared as an interventional study according to French law."
223660182|NCT01022008|DEVICE|Osteodistraction techniques|Treatment based on craniofacial osteotomies and osteodistraction techniques.
223660183|NCT06119750|DEVICE|NS Solution|This will be administered via skin patch.
223660184|NCT06119750|OTHER|Normal Saline|This will be administered via skin patch.
223660185|NCT06119750|OTHER|SLS|This will be administered via skin patch.
224241122|NCT01564511|OTHER|Conventional treatment|The control group will be subjected to a conventional treatment that will consist of three different sets of exercises: 1) passive joint mobilization and stretching of lower limb muscles; 2) muscle strengthening exercises; 3) gait exercises. Each set of exercises lasted 10, 15 and 15 min, respectively with 2,5 min at rest between each set for a total of 40 minutes.
224241123|NCT03288883|DEVICE|Photothermal Non-ablative Erbium:YAG-laser|Laser treatment of the vagina for GSM
224241124|NCT03288883|DEVICE|Fractional Microablative CO2-laser|Laser treatment of the vagina for GSM
224241125|NCT03422211|OTHER|Questionnaire|Will ask patients questions in regards to how many narcotics they have taken and what their pain level has been.
224241126|NCT00003528|DRUG|raltitrexed|Given IV
224241127|NCT05523271|DIAGNOSTIC_TEST|CAD EYE (Computer Aided Diagnosis ----?|CADEYE is a CAD-e system (FUJIFILM) that enables real-time video processing at the same rate as the standard procedure and and allows a real time computer aided detection of polyps with high accuracy.
223660186|NCT00770419|OTHER|medical chart review|
223660187|NCT00770419|OTHER|questionnaire administration|
223660188|NCT00770419|PROCEDURE|psychosocial assessment and care|
223660189|NCT05456685|DRUG|Mirvetuximab soravtansine|Mirvetuximab Soravtansine (MIRV) is an investigational antibody drug conjugate designed to selectively kill cancer cells. The antibody (protein) part of MIRV targets tumors by delivering a cell-killing drug to the tumor cells carrying a tumor-associated protein called FRα. It is being developed for the treatment of participants with recurrent platinum-sensitive, high grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with FRα expression. FRα positivity will be defined by the Ventana FOLR1 Assay.
223660190|NCT05456685|DRUG|Carboplatin|Carboplatin is considered to be the treatment agent of choice in relapsed PSOC.
223660191|NCT03534479|DRUG|Polyclonal IgG|Measurement of vascular reactivity before and after Infusion of plyclonal Immunoglobulins G in patients with Common variable immunodeficiency
223660192|NCT03998839|OTHER|Community distribution of Sulfadoxine-pyrimethamine (SP)|Community health workers will distribute SP to pregnant women, targeting at least three times during pregnancy.
223660193|NCT03316495|BEHAVIORAL|PAMPHLET|EXPOSURE TO PAMPHLETS
223660194|NCT00923611|DRUG|Fimasartan|
223660195|NCT01297491|DRUG|BKM120|Buparlisib was supplied as 10mg or 50mg capsules. It was administered on a continuous once daily dosing schedule at a dose of 100 mg. The patient was dosed on a flat scale of mg/day and not adjusted to body weight or body surface area.
223660196|NCT06272084|DEVICE|Therapeutic Plasma Exchange (TPE) option of multiFiltratePRO|Retrospective Data Analysis of TPE treatments with multiFiltratePRO
223660197|NCT03276091|BEHAVIORAL|Colofit+ intervention|Personnalized phone call, done by the medical student in the name of Adémas-69, organized cancers screening in the Rhône area association. This is a motivational call to encourage patients with an immunochemical fecal test positive, to realized their colonoscopy.
223660198|NCT05646849|OTHER|Connected application|Recording and sharing sessions. Exchanges and interactions with other patients. Participation in three collective challenges.
223660199|NCT00000176|DRUG|Estrogen|
223660200|NCT00000176|DRUG|Estrogen and Progesterone|
223660201|NCT01455636|OTHER|Hand Sanitizer|The water-based hand sanitizer to be used in the current project will be produced in India by Hexagon Inc. It will be dispensed via a foam dispenser, since it has been established that foam is preferable to gel because of the natural tendency to rub foam more thoroughly into one's hands.
224241128|NCT05054348|BIOLOGICAL|IO-108|IO-108 given as monotherapy
224241129|NCT05054348|BIOLOGICAL|IO-108 + pembrolizumab combination therapy|IO-108 and fixed dose pembrolizumab combination therapy
224241130|NCT05054348|BIOLOGICAL|IO-108 + cemiplimab combination therapy|IO-108 and fixed dose cemiplimab combination therapy
224241131|NCT03423849|DRUG|Vinorelbine|25mg/m2,day 1 and day 8, every 3 weeks
224241132|NCT03423849|DRUG|Gemcitabine|1250mg/m2,day 1 and day 8, every 3 weeks
224241133|NCT03423849|DRUG|Cisplatin|25mg/m2,day 1,every 3 weeks
223660202|NCT01455636|DIETARY_SUPPLEMENT|Improved Micronutrient Powder|A modified and improved formulation of MNPs will be used. The composition is specially designed to enhance appetite and growth with 17 essential micronutrients; including calcium and magnesium, as well as an increased amount of zinc (10 mg). Previously MNP formulations (including the UNICEF formulation) contained only 5 mg of zinc and did not contain magnesium and calcium, which are essential nutrients for bone formation.
223660203|NCT01455636|OTHER|No hand sanitizer|"All family members will receive hand-hygiene education with Information, Education and Communication (IEC) materials including pictorial messages describing critical points for hand-hygiene.~No placebo for the hand sanitizers will be provided to families in Groups 3 and 4 because it would be unethical if families were to use an inactive hand-hygiene product as a substitute for routine hand-washing. Nevertheless, all groups will be instructed"
223660204|NCT01455636|DIETARY_SUPPLEMENT|No Micronutrient Powder|I-MNP and placebo will be procured from a local pharmaceutical company in Dhaka, Bangladesh (Renata Pharma Ltd.). The outer-packaging of the sachets of 'I-MNP' and 'placebo-MNP' will be identical except for a different numeric code for each.
223660205|NCT03739125|DRUG|CKD-501 0.5mg|CKD-501 0.5mg, orally, 1 tablet once a day for 24weeks or 52weeks(if extension study) with D150 and D745
223660206|NCT03739125|DRUG|Placebo|orally, 1 tablet once a day for 24weeks or 52weeks(if extension study) with D150 and D745
223660207|NCT01569893|OTHER|Self-monitoring for patients with Dibetes mellitus|"Patients are equipped with a telemonitoring kit composed by a portable glucose meter and a gateway device for data transmission.~The patient can monitor his blood glucose level with a frequency set by the clinician in the personalised treatment plan. Data are transmitted to a regional eHealth centre where a group of operators keeps these information under control and alert the reference clinician in case of worsening of symptoms."
223660208|NCT04752098|DIAGNOSTIC_TEST|Vibro-acoustic analysis (VAA), based on ultrasound radiation force|The study will develop and validate a new ultrasonic method for assessment of infant bone by evaluating structural and mechanical characteristics of the infant tibia. This project will utilize a novel, non-invasive method, vibro-acoustic analysis (VAA), to evaluate infant bone properties in a wide frequency range while reducing the artifacts from soft tissue.
223660209|NCT03209128|RADIATION|Irradiation prophyllactique cérébrale|Irradiation prophyllactique cérébrale
224241134|NCT03423849|DRUG|Capecitabine|1250mg/m2,day 1 to day 14, every 3 weeks
224241135|NCT00060749|DRUG|Docosahexaenoic Acid (DHA) Dietary Supplement|
224241136|NCT00496548|PROCEDURE|Fecal calprotectin|Fecal calprotectin levels obtained and compared to urinary PGE-M and serum C-reactive protein (CRP) levels.
223660210|NCT05099263|DEVICE|Vivaer Arc Stylus|The Vivaer procedure will be performed in the study clinic using the Vivaer ARC Stylus and Aerin Console. The Vivaer ARC Stylus is a disposable handheld device capable of delivering bipolar radiofrequency energy to tissue when connected to the Aerin Console radiofrequency generating device. Participants in this study will undergo bilateral treatment of the nasal airway in a single study session.
223660211|NCT04033393|OTHER|Game based dual-task training|Participants in the experimental group will receive game based dual-task training with a treadmill
223660212|NCT04033393|OTHER|Treadmill training|Participants in the control group will receive treadmill training
223660213|NCT01838980|DEVICE|Motus GI Clean-Up Device|
223660214|NCT01237015|DEVICE|Infant Flow nasal CPAP|Infant Flow nasal CPAP 5 cm H2O
223660215|NCT02181725|BEHAVIORAL|Multimodal Rehabilitation Program|The Multimodal Rehabilitation Program is a Graded exposure based treatment. It consists of a Graded Exposure Module (GE), a Combination Module (HMGE) and a Parent Module (PM).
223660216|NCT02181725|BEHAVIORAL|Care as Usual|Care as usual is the care currently provided to adolescents with musculoskeletal chronic pain and is based on the principles of Graded Activity.
223660217|NCT00021801|PROCEDURE|Islet Cell Transplantation|
223660218|NCT02895867|OTHER|Full fat dairy|Participants will receive nutritional counseling aiming to maintain body weight from a registered dietician and will be instructed to include at least ≥3 servings of full fat dairy products into their diet
223660219|NCT02895867|OTHER|Low fat dairy|Participants will receive nutritional counseling aiming to maintain body weight from a registered dietician and will be instructed to include at least ≥3 servings of low fat dairy products into their diet
223660220|NCT02895867|OTHER|Control|Participants will receive nutritional counseling aiming to maintain body weight from a registered dietician and will not be asked to include a specified amount or type of dairy products
223660221|NCT02424578|DRUG|Diclofenac Capsules low dose|
223660222|NCT02424578|DRUG|Diclofenac Capsules high dose|
223660223|NCT03764293|DRUG|SHR-1210|Subjects receive SHR-1210 intravenously, Dosage form: lyophilised powder, Strength: 200 mg /vial
223660224|NCT03764293|DRUG|Apatinib|Subjects receive Apatinib orally, Dosage form: tablet, Strength: 250 mg/tablet
223660225|NCT03764293|DRUG|Sorafenib|Subjects receive Sorafenib orally, Dosage form: tablet, Strength: 0.2 g/tablet
223660226|NCT03695770|OTHER|kit for self-diagnosis and self-treatment|distribution of kits for malaria self-diagnosis and self-treatment after a training by health facilitators
224241137|NCT00496548|PROCEDURE|Urinary PGE-M Level|Urinary PGE-M level obtained and compared to fecal calprotectin and serum CRP levels.
223660227|NCT00540410|DRUG|Coarsucam® (artésunate (AS) + amodiaquine (AQ) as fixed dose combination)|Infants tablets: AS 25/AQ 67,5 mg Toddlers tablets: AS 50/AQ 135 mg Once daily, dose according to bodyweight range Duration of treatment: 3days Children tablets: AS 100/AQ 270 mg
223660228|NCT00540410|DRUG|Coartem® (arthemether+ lumefantrine)|"Tablets, 20/120 mg, oral route, twice daily, dose according to bodyweight range.~Duration of treatment: 3 days"
223660229|NCT03433612|OTHER|Classic Intercristal Line Technique|"Researcher will use the classic technique to estimate the L4-L5 interspace. The classic technique begins by palpating both the right and left posterior iliac crests and following the imaginary line that intersects each (intercristal line) with the non-dominant hand to the spine where it is estimated to intersect the L4 spinous process or L4-L5 interspace. A marker pen will mark an X lateral to the estimation, opposite side from the estimation of the other technique."
224241138|NCT04298177|DEVICE|Atrial fibrillation ablation using the QDOT® catheter|Atrial fibrillation ablation will be performed using the QDOT® catheter. The ablation mode will be selected according to the MDCT-derived LAWT information.
223660230|NCT03433612|OTHER|Novel SAIL Technique|"Researcher will use the novel technique to estimate the L4-L5 interspace. The SAIL technique begins by palpating the sacrum and the researcher sliding the non-dominant hand up the dorsal surface of the sacrum to the first interspace (L5-S1) and then up one more interspace to estimate the L4-L5 interspace. A marker pen will mark an X lateral to the estimation, opposite side from the estimation of the other technique."
224241139|NCT04298177|PROCEDURE|Standard atrial fibrillation ablation|Atrial fibrillation ablation will be performed using the SmartTouch® catheter. The ablation parameters will be adjusted according to the settings previously described in the CLOSE study.
224241140|NCT02125370|OTHER|Qualitative and survey|
224241141|NCT00164892|DRUG|Oral Vioxx (Rofecoxib)|
224241142|NCT03149653|DRUG|ClinOleic (baseline)|Lipid emulsion in pharmacy compounded all-in-one admixture
224241143|NCT03149653|DRUG|ClinOleic + Omegaven|Lipid emulsion in pharmacy compounded all-in-one admixture
224241144|NCT03149653|DRUG|Lipoplus (baseline)|Lipid emulsion in pharmacy compounded all-in-one admixture
224241145|NCT03149653|DRUG|Lipoplus + Omegaven|Lipid emulsion in pharmacy compounded all-in-one admixture
223660231|NCT03084783|DRUG|Dexamethasone|Participants receive dexamethasone 10mg intravenously 6 hourly for 4 days.
223660232|NCT01302145|DRUG|ASP1941|Tablet
223660233|NCT01302145|DRUG|Metformin|Tablet
223660234|NCT01302145|DRUG|Placebo|Tablet
223660235|NCT02581150|PROCEDURE|Treatment of Occlusive Arterial Disease|Regarding the intervention, the technique used during the diagnostic and/or therapeutic procedure shall be left to the operator's discretion, except the use of an arterial closure device (ACD). In the ambulatory hospitalisation arm, the ACD use will be mandatory. In the conventional hospitalisation arm, ACD will be used at the discretion of the interventionalist.
223660236|NCT05260918|OTHER|Float-REST|Participants will utilize sensory deprivation tanks.
223660237|NCT05260918|OTHER|Nappod|Participants will utilize nappod.
223660238|NCT05983081|PROCEDURE|Injection Treatment|Physical Therapy
223660239|NCT05580445|DRUG|CT-707|Focal Adhesion Kinase (FAK) inhibitor
224241146|NCT03149653|DRUG|SMOFlipid (baseline)|Lipid emulsion in pharmacy compounded all-in-one admixture
224241147|NCT03149653|DRUG|SMOFlipid + Omegaven|Lipid emulsion in pharmacy compounded all-in-one admixture
224241148|NCT00384917|DRUG|Ketoconazole|
224241149|NCT05745870|DIETARY_SUPPLEMENT|Creatine Monohydrate Supplementation|Participants will consume 5g/d creatine monohydrate + 5g/d maltodextrin for 42 consecutive days
224241150|NCT03067818|PROCEDURE|Unaffected Transcranial Magnetic Stimulation|Non-invasive brain stimulation to unaffected hemisphere site prior to practice
224241151|NCT03067818|PROCEDURE|Affected Transcranial Magnetic Stimulation|Non-invasive brain stimulation to affected hemisphere site prior to practice
224241152|NCT03067818|PROCEDURE|Control Transcranial Magnetic Stimulation|Non-invasive brain stimulation to control site prior to practice
224241153|NCT02282189|DEVICE|Oscillating Positive Expiratory Pressure (Aerobika ®)|The oPEP system combines positive expiratory pressure therapy and airway vibrations to help mobilize pulmonary secretions. oPEP therapy enforces a resistance to exhalation at the mouth, while the airway vibration technology transmits movements upstream during exhalation so that airway walls may become free from mucous. Subjects will take home the device and use four times daily during the active part of the study.
224241154|NCT00947908|BIOLOGICAL|Hymenoptera venom|Patients are treated with hymenoptera (bee or wasp) venom using subcutaneous injections. The initiation of immune therapy consists of a 52-hour-period in which patients are treated with increasing doses of hymenoptera venom. Afterwards, patients are treated with monthly subcutaneous injections with a fixed dose of hymenoptera venom. Blood will be collected directly before and 1 hour after initiation of immune therapy and after 12 months of immune therapy (directly before the next subcutaneous injection of hymenoptera venom).
224241155|NCT01139034|DEVICE|Self-designed surface functional electrical stimulator|Use the self-designed surface functional electrical stimulator to improve the shoulder joint subluxation.
224241156|NCT00898508|GENETIC|gene expression analysis|
224241157|NCT00898508|GENETIC|mutation analysis|
224241158|NCT00898508|GENETIC|proteomic profiling|
224241159|NCT00898508|GENETIC|reverse transcriptase-polymerase chain reaction|
224241160|NCT00898508|OTHER|fluorescent antibody technique|
223660240|NCT05580445|DRUG|Toripalimab|Programmed Death 1(PD-1) antibody
223660241|NCT05580445|DRUG|Gemcitabine|nucleoside inhibitor
223660242|NCT06095648|OTHER|Dose of platelet transfusion|Intervention is using a lower (5ml/kg) compared to usual (15ml/kg) dose of platelets for transfusion in non-bleeding babies born at or before 32 weeks in NICU
223660243|NCT05330104|BEHAVIORAL|Mobile Ecological Momentary Assessment|mEMA is a tool that allows for scheduled or triggered surveys to assess a participant's CIPN symptoms and/or fall risk
223660244|NCT00317278|OTHER|massage therapy|massage therapy to stable preterm infants
223660245|NCT00317278|OTHER|Sham|Sham (placebo) provided to the control group
223660246|NCT05605951|OTHER|non-interventional study|observational study
223660247|NCT03541395|DRUG|GnRH antagonist|
223660248|NCT05428124|OTHER|In vitro fertilisation|In vitro fertilisation
223660249|NCT00708084|BIOLOGICAL|CL184|CL184 20 IU/kg intramuscularly on Day 0; in conjunction with rabies vaccine on Days 0, 3, 7, 14, and 28
223660250|NCT00708084|BIOLOGICAL|HRIG|HRIG 20 IU/kg intramuscularly on Day 0; in conjunction with rabies vaccine on Days 0, 3, 7, 14, and 28
223660251|NCT04335214|OTHER|one to one interview|one to one interviews with older people from moroccon origin in Belgium
223660252|NCT01174433|DEVICE|Tryton|Percutaneous coronary intervention of a bifurcation lesion, with a Tryton bifurcation coronary stent for the side branch and a drug-eluting coronary stent for the main branch
224241161|NCT00898508|OTHER|immunohistochemistry staining method|
224241162|NCT00898508|OTHER|laboratory biomarker analysis|
224241163|NCT00898508|OTHER|liquid chromatography|
224241164|NCT00898508|OTHER|mass spectrometry|
224241165|NCT00898508|OTHER|medical chart review|
224241166|NCT00898508|PROCEDURE|quality-of-life assessment|
224241167|NCT05876156|BEHAVIORAL|Virtual Reality Physical Therapy|Participants are allowed to freely choose one game from the game list. Participant will be asked to wear a validated activity tracker - ActiGraph. Baseline heart rate will be collected for 1 minute. Participants will be wearing the ActiGraph during Physical Therapy session. Participants receiving VR intervention will be instructed to wear an Oculus Quest 2 headset (Meta, Inc., Menlo Park, CA) and participate in VR applications under the supervision of the physical therapist.
223660253|NCT01538784|DRUG|YF476|"Two groups of six subjects received single rising oral doses of YF476 capsules or matching placebo. Each subject received 2 doses of YF476 and 1 dose of placebo. 4 subjects received active and 2 placebo at each dose level, as follows:~Group A YF476 0.5, 25 and 100mg by mouth Group B YF476 5.0, 50 and 100mg by mouth~Groups A \& B were dosed alternately, at weekly intervals"
223660254|NCT06455579|BEHAVIORAL|Bedtime Stories Sleep Health Education Program for community healthcare providers (BTS-HP)|The sleep health education program includes 6 educational modules on different topics related to sleep health: (1) Basics of Sleep, 2) Sleep and Development, 3) Sleep Health, 4) Consequences of Deficient Sleep, 5) Sleep Health Disparities, and 6) Sleep Screening and Evaluation.
223660255|NCT06192017|DIAGNOSTIC_TEST|WomEC|The study will collect pipelle biopsies from post-menopausal women presenting with AUB entering to the EC diagnostic process at the clinical consultancy or emergency room. In the study an endometrial biopsy by aspiration will be collected (i.e., pipelle biopsy) and it will be used for (1) diagnostic purposes following current procedures (i.e., pathological examination and diagnosis); (2) placed in a collection tube for WomEC test.
223660256|NCT05553834|COMBINATION_PRODUCT|Alirocumab and Cemiplimab|Combination of PCSK9 inhibitor Alirocumab 150mg SC q2weeks and PD-I inhibitor Cemiplimab 350mg IV q3 weeks
223660257|NCT03732781|DRUG|Radspherin|"Radspherin® suspension consists of degradable calcium carbonate microparticles with the α-emitting radionuclide 224Ra in suspension.~Radspherin® will be provided in a R10 vial filled with 10 mL suspension of 224Ra adsorbed on 1 g calcium carbonate microparticles. The volume to be administered will contain 0.7-1 g calcium carbonate microparticles with 1-7 MBq 224Ra. 224Ra has a half-life of 3.6 days."
223660258|NCT05051631|OTHER|Intervention plus 12 months maintenance|The intervention will include 2 months of data collection in the control period, 4 months of education and awareness training, and 12 months of data collection in the maintenance time period.
223660259|NCT05051631|OTHER|Intervention plus 10 months maintenance|The intervention will include 4 months of data collection in the control period, 4 months of education and awareness training, and 10 months of data collection in the maintenance time period.
223660260|NCT05051631|OTHER|Intervention plus 8 months maintenance|The intervention will include 6 months of data collection in the control period, 4 months of education and awareness training, and 8 months of data collection in the maintenance time period.
223660261|NCT05051631|OTHER|Intervention plus 6 months maintenance|The intervention will include 8 months of data collection in the control period, 4 months of education and awareness training, and 6 months of data collection in the maintenance time period.
223660262|NCT05051631|OTHER|Intervention plus 4 months maintenance|The intervention will include 10 months of data collection in the control period, 4 months of education and awareness training, and 4 months of data collection in the maintenance time period.
223660263|NCT02503657|DRUG|MN-001|A novel, orally bioavailable small molecule compound that demonstrates anti-inflammatory and anti-fibrotic activity
223660264|NCT02503657|DRUG|Matching Placebo|Excipients of MN-001/tipelukast
223660265|NCT05357261|BEHAVIORAL|Wellness Check and Socialization|In-home delivery with opportunity for driver observation and interaction
224241168|NCT05876156|BEHAVIORAL|Traditional Physical Therapy|Participants will receive traditional Physical Therapy sessions (standard care) under the supervision of the accredited physical therapist. Participants will be wearing the Actigraph during Physical Therapy session. Participants will perform regular physical exercise, such as 20 minutes walking or biking on a stationary bike, under the supervision of a physical therapist.
224241169|NCT05118178|DIAGNOSTIC_TEST|echocardiography, computed tomography|echocardiography - including GLS and MWI computed tomography - with calcium score index
223660266|NCT05357261|OTHER|Prepared Meals|Prepared meals compliant with Older Americans Act nutrition programs guidelines
224241170|NCT01491581|DIETARY_SUPPLEMENT|food bar|milk based food bar enriched with micronutrients
224241171|NCT05357157|OTHER|Electroacupuncture|Subjects will be administered electroacupuncture as described in the electroacupuncture group description
223660267|NCT04255745|BEHAVIORAL|progressive resistance training|Individual, tailored, progressive muscle strength and function intervention
223660268|NCT04435691|DRUG|Azacitidine|Given SC or IV
223660269|NCT04435691|BIOLOGICAL|Magrolimab|Given IV
223660270|NCT04435691|DRUG|Venetoclax|Given PO
224241172|NCT05357157|DIETARY_SUPPLEMENT|Nutrition|Subjects will be administered the intervention described in the electroacupuncture nutrition and dietary supplement group description
224241173|NCT05357157|DIETARY_SUPPLEMENT|Dietary supplement|Subjects will be administered the intervention described in the electroacupuncture nutrition and dietary supplement group description
223660271|NCT05989893|BEHAVIORAL|Language-based tasks|In either the MRI suite, or the Epilepsy Monitoring Unit, or the operating room, epilepsy and tumor subjects are asked to perform a variety of language-based tasks as neural recordings are made from and/or neural stimulations are delivered to various language areas of the brain.
223660272|NCT05408637|DEVICE|Transcranial Phoobiomodulation (tPBM)|Transcranial light therapy penetrates the skin and brain using light energy; this makes transcranial light therapy noninvasive. Transcranial light therapy may activate under-stimulated brain regions.
223660273|NCT01703754|GENETIC|Ad-RTS-hIL-12 and Veledimex|Oral activator ligand with adenoviral vector injection of cancer lesions
223660274|NCT01703754|DRUG|Palifosfamide|Small molecule chemotherapy, IV administration
223769234|NCT05716828|OTHER|Balint group activities|A Balint group is a working form that focuses on the professional doctor-patient relationship. Participants in the Balint group completed Balint training for a period of at least three months, which included two lectures and 10 small group discussion sessions held once a month for one hour at a time (on Thursdays from 12 to 1 PM). Balint group is a closed group including one to two group leaders and six to twelve participants, with sessions lasting 60 to 90 minutes.
223769235|NCT03669445|DRUG|Ixazomib|21-day cycles induction and 28-day cycles consolidation
223660275|NCT05575999|DRUG|Bupivacaine alone OR Bupivacaine-Ketorolac-Ketamine (BKK) Combination|The plan will be to stratify patients in two groups: intervention group receiving 20 cc combination of BKK (Bupivacaine HCl 60 mg \[3 mg/mL\], Ketorolac Tromethamine 24 mg \[1.2mg/mL\], Ketamine HCl 24 mg \[1.2 mg/mL\]) vs the control group receiving 20 cc of 0.5% bupivacaine (Bupivacaine HCL 100 mg \[5mg/ml\]. The dose can be repeated multiple times during the procedure as per operator's discretion. The patients will be further stratified into sub-groups based on type of procedure they had undergone. Analgesia/anesthesia strategy will be local infiltration of the drug along with a sedating agent based on institutional standard of care. The dose of the medicines will be adjusted as per discretion of the operator to maintain adequate anesthesia/analgesia during and after the procedure.
223660276|NCT06370182|DEVICE|ANA Funnel Catheter|Mechanical thrombectomy using a stent retriever delivered by the ANA device that enables local flow restriction when deployed.
223660277|NCT06370182|DEVICE|Control|Mechanical thrombectomy using a stent retriever delivered by an approved guide catheter with or without an intermediate catheter and aspiration per conventional techniques.
223660278|NCT06541210|OTHER|Community Health Service|Access CoLLab Learning Health System to use any of the services
223660279|NCT06541210|OTHER|Questionnaire Administration|Ancillary studies
223660280|NCT02834936|DRUG|pyrotinib|
223660281|NCT00652106|DRUG|0.2% brimonidine/0.5% timolol fixed combination ophthalmic solution|0.2% brimonidine/0.5% timolol fixed combination ophthalmic solution 1 drop instilled in each eye twice daily (morning and evening)
223660282|NCT00652106|DRUG|Concurrent brimonidine 0.2% and Timolol 0.5% ophthalmic solution|Brimonidine 0.2% 1 drop instilled in each eye three times daily (morning, afternoon, and evening) and concurrent timolol 0.5% ophthalmic solution 1 drop instilled in each eye twice daily (morning and evening)
223660283|NCT00652106|DRUG|Brimonidine 0.2% ophthalmic solution|Brimonidine 0.2% ophthalmic solution 1 drop instilled in each eye three times daily (morning, afternoon, and evening)
223660284|NCT01688531|DRUG|CD0271 0.1%/CD1579 2.5% gel|one application (pea-sized amount according to the labelling) on a half-face, 5 to 7 days for 6 months
223660285|NCT01688531|DRUG|CD0271 0.1%/CD1579 2.5% gel vehicle|one application (pea-sized amount according to the labelling) on a half-face, 5 to 7 days for 6 months
223660286|NCT04600271|DRUG|Crystalloid Solutions|exposure
223660287|NCT04600271|DRUG|Colloid Blood Volume Expanders|exposure
223660288|NCT04600271|OTHER|blood replacement|exposure
223660289|NCT04600271|DRUG|Diuretic|exposure
224241174|NCT01714648|DRUG|Triptorelin 0.2 mg|A single bolus of 0.2 mg triptorelin given 34-36 hours before oocyte retrieval.
224241175|NCT00883090|BIOLOGICAL|FXIII Concentrate (Human)|Subjects will receive approximately 40 U/kg of FXIII every 28 days for 3 doses administered as a bolus intravenous (IV) injection at approximately 250 U/minute.
224241176|NCT04177381|PROCEDURE|Cesarean section|"1. Abdominal Incision: Pfannenstiel incision Sharp dissection will be continued through the subcutaneous layer to the fascia.~2. The fascia will be then incised sharply at the midline~3. The transversalis fascia and pre peritoneal fat will be dissected carefully~4. The peritoneum will be then incised.~5. Low Transverse Cesarean Incision. Bladder flap creation effectively moves the bladder away from the planned hysterotomy site~6. Delivery of the Fetus and placenta.~7. Uterine Repair in two layers of continuous 0-or No.1 absorbable suture."
224241177|NCT04177381|PROCEDURE|subcutanous sutures|suture closure of subcutaneous tissue with interrupted 2-0 polyglactin 910 (Vicryl).the stitch interval is 1cm
224241178|NCT04177381|DEVICE|subcutanous drain|Inthedraingroup,aclosednonvacuum drain willbeinsertedin thetissueandexitefrom theskinthroughaseparateopeningandstitchto theskin
223660290|NCT04600271|DRUG|noradrenaline|exposure
223660291|NCT04600271|DRUG|Non-Steroidal Anti-Inflammatory Analgesics|exposure
223660292|NCT05025956|DRUG|Fisetin|Oral Fisetin 20 mg/kg taken for 8 days total.
223660293|NCT05025956|DRUG|Placebo|Fisetin appearance-matched microcrystalline cellulose placebo. 20 mg/kg taken for 8 days total.
223660294|NCT06132139|DEVICE|VisAR|The study device is a Microsoft HoloLens which uses Novarad's proprietary software and is collectively known as VisAR.
223660295|NCT00173641|PROCEDURE|blood drawing|
223660296|NCT01989208|OTHER|SG1002|200 mg capsules will be administered BID for 7 days, then doubled to 2 capsules BID for 7 days and doubled again to 4 capsules BID for the final 7 days.
223660297|NCT01989208|OTHER|Placebo|200 mg capsules containing placebo will be administered BID for 7 days, then doubled to 2 capsules BID for 7 days and doubled again to 4 capsules BID for the final 7 days.
223660298|NCT06331728|DRUG|IGNX001|IGNX001 given as a single subcutaneous dose on Day 1.
223660299|NCT06331728|DRUG|Placebo|Placebo to IGNX001 given as a single subcutaneous dose on Day 1.
223660300|NCT03016741|BIOLOGICAL|GnRH agonist/antagonist|Given GnRH agonist/antagonist therapy
223660301|NCT03016741|DRUG|Prednisone|Given by mouth
223660302|NCT03016741|DRUG|Abiraterone Acetate|Given by mouth
223660303|NCT03016741|DRUG|Enzalutamide|Given by mouth
223660304|NCT05342441|PROCEDURE|QT graft|"Surgical reconstruction of primary ACL rupture with autograft harvested from the quadriceps tendon without bone block.~The QT graft is harvested through a 4-5 cm incision at the upper pole of the patella. A graft sized 10-12 mm in with and app. 6 mm in depth is harvested from the middle part of the tendon.~The femoral tunnel is placed anatomically central in the native footprint of the ACL. The tibia tunnel is also placed anatomically; the center of the tunnel being medially between the eminential spines at the level of the posterior margin of the anterior horn of the lateral meniscus.~The ST/Gr graft is fixed proximally with the RIGIDFIX® Curve Cross Pin System (DePuy Synthes) and distally with a Milagro skrew (DePuy Synthes) or similar."
223769236|NCT03669445|DRUG|Lenalidomide|21-day cycles induction and 28-day cycles consolidation and 28-day cycles maintenance therapy
223769237|NCT03669445|DRUG|Dexamethasone|21-day cycles induction and 28-day cycles consolidation
223769238|NCT03669445|DRUG|Daratumumab|21-day cycles induction and 28-day cycles consolidation
223769239|NCT01791361|OTHER|Other|No intervention other than routine medical care
223769240|NCT00378703|BIOLOGICAL|Bevacizumab|Given IV
224241179|NCT05341232|BEHAVIORAL|Lego Robot Programming Active Challenges|Participants will adapt their own Lego robot programs to achieve specific task goals.
224241180|NCT05341232|BEHAVIORAL|Lego Robot Programming Procedural Methods|Participating will undergo Lego robot programming training that engages them to follow fixed programming coding steps.
224241181|NCT05341232|BEHAVIORAL|Board Games|Participants will play board games with each other.
224241182|NCT00625911|DRUG|morphine|intravenous patient controlled analgesia, standard protocol
223660305|NCT05342441|PROCEDURE|ST/Gr graft|"Surgical reconstruction of primary ACL rupture with autograft harvested from the semitendinosus and gracilis muscles.~The ST/Gr graft is harvested through a 4-5 cm incision at the pes anserinus. Both the semitendinosus and the gracilis tendon is identified and harvested. The tendons are prepared and folded to a four-stranded graft with a total diameter of 7-10 mm.~The femoral tunnel is placed anatomically central in the native footprint of the ACL. The tibia tunnel is also placed anatomically; the center of the tunnel being medially between the eminential spines at the level of the posterior margin of the anterior horn of the lateral meniscus.~The ST/Gr graft is fixed proximally with the RIGIDFIX® Curve Cross Pin System (DePuy Synthes) and distally with a Milagro skrew (DePuy Synthes) or similar."
223660306|NCT05342441|PROCEDURE|BPTB graft|"Surgical reconstruction of primary ACL rupture with autograft harvested from the patella tendon with bone block (bone-patellar-tendon-bone).~The BPTB graft is harvested through two 4-5 cm incisions, one on the tibial tuberosity and one on the patella. The middle 10 mm of the patella tendon plus 20-30 mm bone plugs at each end from corresponding tibia and patella is harvested.~The femoral tunnel is placed anatomically central in the native footprint of the ACL. The tibia tunnel is also placed anatomically; the center of the tunnel being medially between the eminential spines at the level of the posterior margin of the anterior horn of the lateral meniscus. The BPTB graft is fixed both proximally and distally with a Milagro skrew (DePuy Synthes) or similar."
223660307|NCT06532383|DRUG|PF-07940369|Bulk powder for extemporaneous preparation for oral solutions.
223660308|NCT06532383|DRUG|Placebo|Bulk powder for extemporaneous preparation for oral solutions
223660309|NCT05021237|RADIATION|Ultra-fractionated radiation therapy|Patients enrolled in this study are planned to receive systemic therapy. Imaging based Ultra-fractionated radiation therapy using a PULSAR technique, which is 5 pulses to gross tumor in pelvis.
223660310|NCT05757960|PROCEDURE|Physiotherapy|Various physiotherapeutic techniques are used in three defined sessions. Before the first session, a dental examination is performed and a clinical functional status is obtained to assess the extent of temporomandibular dysfunction. The results are recorded on validated questionnaires.
223660311|NCT05723679|OTHER|HeO2 gas mixture|Low-density helium-oxygen gas mixture (HeO2: 21% O2 and 79% He). Participant will be breathing this gas mixture.
223660312|NCT05723679|OTHER|Room air gas mixture|Normal room air
223660313|NCT06803004|OTHER|Junior sonographer measurement of DDH|Participants will not receive visual cues from the DeepDDH system. Junior sonographer technicians will offer preliminary interpretations before these are subjected to validation and subsequent review by expert's team.
223660314|NCT06803004|OTHER|Senior sonographer measurement of DDH|Participants will not receive visual cues from the DeepDDH system. Senior sonographer technicians will offer preliminary interpretations before these are subjected to validation and subsequent review by expert's team.
223660315|NCT06803004|OTHER|Automated annotation of the DDH measurement through deep learning|Through randomization, a subset of the preliminary interpretations will be conducted by AI technology, and the study team will evaluate the degree of divergence between these AI-generated preliminary interpretations and the final interpretations.
223660316|NCT06803004|OTHER|AI-assisted junior sonographer measurement of DDH|Participants will receive visual cues from the DeepDDH system.
223660317|NCT06454409|DRUG|Azacitidine|Given IV
224241183|NCT00625911|DRUG|morphine ketamine|low dose ketamine added to 2/3 standard dose of morphine
223660318|NCT06454409|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223660319|NCT06454409|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
223660320|NCT06454409|DRUG|Regorafenib|Given PO
224241184|NCT02467036|BEHAVIORAL|Family Based Behavioral Treatment|The intervention for both groups will be a 4-month Family-Based Behavioral Treatment (FBT), which includes dietary changes, physical activity changes, and behavioral therapy. Treatment is provided in separate parent and child groups. Families will learn to reduce caloric consumption and increase caloric expenditure (physical activity). Behavior therapy includes stimulus control, self-monitoring, goal setting and contracting, parenting skills, skills for managing high-risk situations, and maintenance and relapse prevention. Families will self-monitor caloric intake, breakfast consumption, physical activity, and hunger and satiety throughout the day.
224241185|NCT05159206|PROCEDURE|CT group|This group will do a preoperative CT scan for templating. The same scan is then used for per-operative navigation. After surgery, a postoperative CT will validate the templating/navigation, and then subsequent CT scans (postoperative, 3 months, 1 and 2 years) will be done to measure prosthetic migration over time.
224241186|NCT03344510|DEVICE|Kinetic Anesthesia Device|A vibrating device held to the skin in close proximity to the lidocaine injection, intended to diminish discomfort by the gate control theory of pain
224241187|NCT03344510|OTHER|Control|One injection will be administered without the kinetic anesthesia device.
224241188|NCT04245826|OTHER|Change in LCSBs Intake|Effect of changing LCSBs intake
223660321|NCT06454409|DRUG|Venetoclax|Given PO
223660322|NCT04856462|BEHAVIORAL|Education Support|Caregivers engage in a weekly video/teleconference support group with a skilled facilitator to discuss various strategies for managing caregiving stress, challenging behaviors, and personal self-care.
223769241|NCT00378703|OTHER|Laboratory Biomarker Analysis|Correlative studies
223769242|NCT00378703|OTHER|Pharmacological Study|Correlative studies
223769243|NCT00378703|DRUG|Sorafenib Tosylate|Given PO
223769244|NCT00378703|DRUG|Temsirolimus|Given IV
224241189|NCT04245826|OTHER|Substitute LCSBs for SSBs or Water|Effect of substituting LCSBs for SSBs or Water
224241190|NCT03535168|DRUG|BAY1902607|3 different doses over the course of part 1 and 4 different doses over the course of part 2.
224241191|NCT03535168|DRUG|Matching placebo|Matching placebo for BAY1902607
224241192|NCT03535168|DRUG|Midazolam|Part 1: The subjects will initially (Day -1) receive a sub-therapeutic dose of 1 mg midazolam as solution in the morning.
224241193|NCT01475838|DRUG|PI|PI administered according to prescribing information; allowed PIs include atazanavir (ATV), darunavir (DRV), fosamprenavir (FPV), lopinavir (LPV), or saquinavir (SQV)
224241194|NCT01475838|DRUG|RTV|RTV administered according to prescribing information FTC/TDF administered according to prescribing information
223769245|NCT01193491|DRUG|IPI-493|Capsules, ascending dose, multiple schedules
223660323|NCT06543355|DEVICE|Modified Battlefield Acupuncture + National Acupuncture Detoxification Association protocol|The delivery of modified BFA + NADA will be administered in a setting designed to ensure that patients are comfortable, with their backs well-supported. With regards to needling technique, participants' ears will be cleaned, and sterile acupuncture needles will be placed on the BFA or NADA points, using proper technique. Auricular acupuncture needles are thin, between 0.12 - 0.18mm, and are less than 1 inch long. The needles will remain in the ear until the session is complete. On the alternative ear, seeds are another modality of auricular acupuncture treatment that will be used. Seeds are comprised of small circular balls comprised of a natural plant, no more than 1.5 mm diameter size. The seeds are attached to a small piece of adhesive tape and are placed on one's ear. The seeds remain on the ear and the given point can be massaged and stimulated as indicated.
223660324|NCT03891446|DRUG|Bimatoprost SR|Intraocular implant
223660325|NCT03891446|OTHER|Standard of Care|Standard of care treatment based on investigator's judgement.
223660326|NCT05372718|DRUG|Recombinant non-immunogenic staphylokinase (Fortelyzin®)|lyophilisate for preparation a solution
223769246|NCT02608112|DRUG|Methotrexate|Administered as per investigator's discretion. Investigator could also suggest any other csDMARDs instead of methotrexate.
223769247|NCT02608112|DRUG|Tocilizumab|Tocilizumab treatment will be administered SC at the discretion of the investigator in accordance with local clinical practice and local labelling.
223660327|NCT05372718|PROCEDURE|surgical methods of treatment|Endovascular intervention, open surgery and/or bypass surgery in accordance with the current National Guidelines
223660328|NCT06279195|DRUG|Relugolix (40 mg) /estradiol (1 mg)/norethisterone acetate (0.5 mg) oral tablet|All participants will be instructed to take REL-CT.
223660329|NCT04728425|DRUG|subcutaneous immunoglobulin (SCIG)|20% subcutaneous immunoglobulin
223660330|NCT04728425|DRUG|intravenous immunoglobulin + subcutaneous immunoglobulin (SCIG)|10% intravenous immunoglobulin + 20% subcutaneous immunoglobulin
223769248|NCT06539026|OTHER|fluid therapy, 300 ml of crystalloid Ringer's solution.|"300 ml by dripping within 30 minutes, the fluid will be repeated by half the amount if needed to reach equal or less than 50% collapsibility.~the fluid that will be used is sterile Ringer's solution which is an isotonic intravenous solution with pH 5.0 - 7.5 and an osmolality of 308mOsmol/kg."
223660332|NCT05913193|OTHER|Oral Nutritional Supplement (ONS)|Diabetes specific oral nutritional supplement
223769249|NCT03846258|DRUG|Low bicarbonate solution (22 mmol/L)|Participants randomized to this arm will be started on CRRT using Phoxillum as the replacement fluid.
223769250|NCT03846258|DRUG|High Bicarbonate solution (32 mmol/L)|Participants randomized to this arm will be started on CRRT using Prismasate as the replacement fluid.
223769251|NCT05069922|OTHER|Fresh Frozen Plasma|Fresh Frozen Plasma
223769252|NCT03424031|PROCEDURE|Verticalization|To allow the verticalization of hemiplegic patients, we will use a device commonly used in rehabilitation: the standing (or standing) brand Thera Trainer . This device makes it possible to keep the patient standing despite the motor and postural deficits thanks to knee, buttocks and an anterior support for the upper limbs. Verticalization with this device requires the presence of one or two caregivers (including at least one re-educator), depending on the possibilities of participation of the patient.
223660333|NCT04973436|BEHAVIORAL|Dialectical Behavioral Therapy Skills Training|LiveWell: Dialectical behavioral therapy skills training adapted for patients with metastatic lung cancer
223660334|NCT00566696|DEVICE|CliniMACS|Miltenyi Biotec CliniMACS stem cell selection device
223769253|NCT03366064|BIOLOGICAL|Pemetrexed and donor-derived NK cell infusion|Patients are administered with donor-derived NK cells one week after pemetrexed infusion
224241195|NCT01475838|DRUG|FTC/TDF|FTC/TDF (200/300 mg) administered according to prescribing information
223769254|NCT01106456|BEHAVIORAL|All Nations Breath of Life (ANBL)|ANBL consists of in-person group sessions and individual telephone calls. We have successfully conducted a pilot study of ANBL and have found very promising results. At six months and 12 months post baseline, all participants will be assessed for smoking status and smoking abstinence.
224241196|NCT01475838|DRUG|Stribild|Stribild (E/C/F/TDF) (150/150/200/300 mg) STR administered orally once daily with food
224241197|NCT03988127|DIAGNOSTIC_TEST|Perfusion index|The perfusion index (PI) is the ratio of the pulsatile to the non-pulsatile blood flow in peripheral tissue. It represents a non-invasive measure of peripheral perfusion that can be continuously obtained from a pulse oximeter. We observe changes in PI before and after painful stimulation in intubated critically ill patients.
224241198|NCT01717976|BEHAVIORAL|DISPO ED|primary care based nurse telephone support
224241199|NCT00048568|DRUG|Abatacept|Intravenous (IV) Solution, - Weight Titered (500 mg \< 60 kg); (750 mg 60-100 kg), )1 gram \> 100 kg), Day 1, Day 15, Day 29; every 28 days thereafter, 1 year
223769255|NCT01106456|BEHAVIORAL|Nontailored program (NT)|"The nontailored intervention includes the medicines listed above to all participants and targeted counseling delivered by non-American Indian counselors who have worked closely with the American Indian communities and respect the cultures, values, and traditions of the Indian people. Therefore, our intervention includes the current best practice recommendations for smoking cessation. At six months and 12 months post baseline, all participants will be assessed for smoking status and smoking abstinence."
224241200|NCT00048568|DRUG|Methotrexate|Tablets, Oral, \>= 15 mg, weekly, 1 year
224241201|NCT00048568|DRUG|Placebo|IV solution, Intravenous, D5W, Day 1, Day 15, Day 29; every 28 days thereafter, 1 year
224241202|NCT03831048|DEVICE|OCS Heart System|Preserving and assessing donor after circulatory death hearts for transplant
224241203|NCT03831048|OTHER|Cold Storage|Active comparator intervention
224241204|NCT00098878|DRUG|carboplatin|
224241205|NCT04083859|OTHER|mPATH-Lung|A web-based program that determines patients eligibility for lung cancer screening (LCS), informs them of LCS, presents them with personalized risk-benefit information, helps them make a screening decision, and helps them schedule a LCS clinic appointment.
224241206|NCT04083859|OTHER|Lung health video|Web-based video about guideline recommended exercise for lung health
223660335|NCT00566696|PROCEDURE|Stem cell transplantation|An infusion of HLA mismatched family member donor stem cells processed through the use of the investigational Miltenyi Biotec CliniMACS device.
223660336|NCT00566696|DRUG|Fludarabine|Transplant recipients will receive a conditioning regimen consisting of systemic chemotherapy and antibodies.
223660337|NCT00566696|DRUG|Thioplex®|Transplant recipients will receive a conditioning regimen consisting of systemic chemotherapy and antibodies.
223660338|NCT00566696|DRUG|L-phenylalanine mustard|Transplant recipients will receive a conditioning regimen consisting of systemic chemotherapy and antibodies.
223660339|NCT00566696|DRUG|Mycophenolate mofetil|Transplant recipients will receive a conditioning regimen consisting of systemic chemotherapy and antibodies.
223769256|NCT01106456|DRUG|Pharmacotherapy|All participants in the study will be offered pharmacotherapy (e.g. Varenicline, Bupropion, or NRT)
223660340|NCT00566696|DRUG|Rituxan™|Transplant recipients will receive a conditioning regimen consisting of systemic chemotherapy and antibodies.
223769257|NCT01930058|DRUG|MK-8876|MK-8876 10 mg or 100 mg tablets taken q.d. by mouth.
224241207|NCT06545201|BIOLOGICAL|RE001 T cell|All subjects who met the entry and exit criteria and signed the informed consent form were observed in hospital at the beginning of lymphocyte clearance chemotherapy, with the dosage of cyclophosphamide (600-800mg/m\^2/days,-5,-4 days) and fludarabine (25-30mg/m\^2/days,-5,-4,-3 days), at least two days after the completion of lymphocyte clearance chemotherapy.
224241208|NCT03576846|OTHER|Stretching and Spinal manipulative therapy|Subjects will be instructed to perform a series of progressively difficult stretching exercises for the neck and upper back muscles. In addition, subjects will be treated with Spinal manipulative therapy
224241209|NCT03576846|OTHER|Stretching|Subjects will be instructed to perform a series of progressively difficult stretching exercises for the neck and upper back muscles.
224241210|NCT01161667|DRUG|naratriptan hydrochloride|2.5 mg tablet
224241211|NCT04677764|OTHER|virtual reality|Wii Fit balance board (Nintendo Inc., Kyoto, Japan).
224241212|NCT04677764|OTHER|Standard of care|physical therapy and occupational therapy exercises either at their own home or a gym
224241213|NCT01806090|DRUG|clopidogrel|Clopidogrel 7 days prior to the endoscopic procedure (Colonoscopy)
224241214|NCT01806090|OTHER|Placebo|Placebo for 7 days prior to the endoscopic procedure (Colonoscopy)
224241215|NCT06139003|DEVICE|3d Printed implant|Occlusal stability was evaluated using occlusense device by charting amount and distribution of force over dental arch in percentage
224241216|NCT06139003|DEVICE|Conventionally constructed implant|Occlusal stability was evaluated using occlusense device by charting amount and distribution of force over dental arch in percentage
224241217|NCT01595503|PROCEDURE|rTMS with fMRI-based targeting|Inhibitory (low frequency) 1-Hz rTMS will be applied to the secondary auditory cortex during 10 daily 20-minute treatment sessions. An fMRI scan combined with a language task will be used to localize the secondary auditory cortex, followed by neuronavigation to identify the scalp location overlying the targeted cortex.
224241218|NCT01595503|PROCEDURE|rTMS with landmark-based targeting|Inhibitory (low frequency) 1-Hz rTMS will be applied over the left temporoparietal cortex (TPC) during 10 daily 20-minute treatment sessions, with the stimulating coil located midway between the left temporal (T3) and parietal (P3) scalp landmarks, using the International 10-20 system for EEG.
224241219|NCT00483899|DRUG|GW870086X|Subjects will inhale 0.25 or 1.5 mg/inhalation GW870086X for four times
224241220|NCT00483899|DRUG|Placebo|Placebo matching GW870086X will be administered by subjects
224241221|NCT03827109|BEHAVIORAL|Group educational activities|Group educational topics include nutrition, stress, IBD and school, and disease management, and are taught by experts in each content area. s.
224241222|NCT03827109|BEHAVIORAL|IBD educational website|Website with age-appropriate educational information, including information from the group educational activities.
224241223|NCT03827109|BEHAVIORAL|Monthly check-in calls from program coordinator|Phone calls from coordinator to encourage youth to do something fun with a friend (comparison group) or mentor (Mentoring Program). During the COVID-19 pandemic, virtual activities are encouraged. For those in the Mentoring Program, the coordinator will also ask about the mentee's relationship with the mentor.
224241224|NCT03827109|BEHAVIORAL|Mentor|Mentees will be matched with a mentor for a year-long, 1:1 mentee-mentor relationship. Matching mentors and mentees is based on gender (same), age, geographical proximity, ethnicity, and interests. Mentors and mentees are expected to have weekly contact (e.g., text, phone), with in-person contact 1 - 2 times per month, one of which can be attending a group activity together. Due to the COVID-19 pandemic, a modification was approved so that all study activities can be conducted virtually, e.g., the in-person mentor-mentee monthly activity can be conducted via Skype, and group activities are live streamed
224241225|NCT03827109|BEHAVIORAL|Fun group activities|"Program participants vote on fun group activities to participate in for support and to learn self-management skills through experiential opportunities and modeling. These are live streamed during the COVID-19 pandemic."
223660341|NCT00566696|DRUG|Alemtuzumab|After January 2010, due to the unavailability of muromonab, transplant recipients received a conditioning regimen consisting of systemic chemotherapy and antibodies, including alemtuzumab.
223769258|NCT02994862|OTHER|Galla Chinnesis|new Remineralizing Agent before Bonding to teeth with amelogenesis imperfecta
223769259|NCT02994862|OTHER|Conventional Bonding|Normal Bonding Protocol
223769260|NCT05543785|DRUG|Ketorolac|After confirmation of circulatory isolation of the operated limb by the inflated tourniquet, 30 mg ketorolac tromethamine diluted in normal saline in a total volume of 50 ml will be injected
223769261|NCT05543785|OTHER|Control|After confirmation of circulatory isolation of the operated limb by the inflated tourniquet, 50 ml normal saline without drugs will be injected
223769262|NCT02334228|BEHAVIORAL|In SHAPE Lifestyles|In SHAPE Lifestyles is a health promotion intervention consisting of a fitness club membership and a health promotion coach with basic certification as a fitness trainer, instruction on principles of healthy eating and nutrition, and training in tailoring individual wellness plans to the needs of persons with serious mental illness.
223769263|NCT02334228|BEHAVIORAL|Health Club Membership and Education|Fitness club membership with education in using the exercise equipment.
223660342|NCT00566696|DRUG|Cyclophosphamide|Transplant recipients will receive a conditioning regimen consisting of systemic chemotherapy and antibodies.
223660343|NCT00566696|DRUG|Anti-thymocyte globulin (Rabbit)|Transplant recipients will receive a conditioning regimen consisting of systemic chemotherapy and antibodies.
223660344|NCT00566696|DRUG|G-CSF|Transplant recipients will receive a conditioning regimen consisting of systemic chemotherapy and antibodies.
223660345|NCT00566696|DRUG|Muromonab|Prior to January 2010, transplant participants received a conditioning regimen consisting of systemic chemotherapy and antibodies, including muromonab. Muromonab became unavailable from the manufacturer at that time and was replaced by alemtuzumab.
224241226|NCT03827109|BEHAVIORAL|Parent support group|Parents participate in a social/support group facilitated by an Investigator while mentees and mentors are socializing during group events (virtually during the COVID-19 pandemic).
224241227|NCT06850090|COMBINATION_PRODUCT|TAS-102|"Radiotherapy:~1. Radiotherapy Technique: Three-dimensional conformal radiotherapy (3D-CRT), intensity-modulated radiotherapy (IMRT), or volume modulated arc therapy (VMAT);~2. Radiotherapy Dose and Fractionation Schedule: Conventional fractionation with external beam irradiation at a dose of 50 Gy delivered in 25 fractions over 5 weeks.~Synchronous Chemotherapy:~Concurrent administration of TAS-102 at a dose of 35 mg/m² twice daily at the 1st, 3rd and 5th week of radiotherapy.~Intermittent Consolidation Chemotherapy:~Oxaliplatin at 85 mg/m² on day 1 combined with TAS-102 at 35 mg/m² twice daily from day 1 to day 5, repeated every 14 days for a total of 6 cycles.~Surgery:~The operation follows the principle of TME. The type of surgery depends on the location and extent of the primary tumor.~Postoperative adjuvant therapy:~Two cycles of CapeOX (Oxaliplatin 130 mg/m2 on day 1+ capecitabine 1000 mg/m2 twice a day on days 1-14, q3w)."
224241228|NCT06850090|COMBINATION_PRODUCT|Capecitabine|"Radiotherapy:~1. Radiotherapy Technique: Three-dimensional conformal radiotherapy (3D-CRT), intensity-modulated radiotherapy (IMRT), or volume modulated arc therapy (VMAT);~2. Radiotherapy Dose and Fractionation Schedule: Conventional fractionation with external beam irradiation at a dose of 50 Gy delivered in 25 fractions over 5 weeks.~Synchronous Chemotherapy:~Capecitabine administered orally at a dose of 825 mg/m² twice daily on days of radiotherapy.~Intermittent Consolidation Chemotherapy:~Oxaliplatin at 130 mg/m² on day 1 combined with capecitabine at 1000 mg/m² twice daily from day 1 to day 14, repeated every 21 days for a total of 4 cycles.~Surgery:~The operation follows the principle of TME. The type of surgery depends on the location and extent of the primary tumor.~Postoperative adjuvant therapy: Two cycles of CapeOX (Oxaliplatin 130 mg/m2 on day 1+ capecitabine 1000 mg/m2 twice a day on days 1-14, q3w)"
223660346|NCT00802256|PROCEDURE|pulpotomy|removal of caries and cronal pulp tissue and then restoring of tooth
223660347|NCT04309864|DEVICE|Use of CMAP app for education (in-hospital)|Clinicians will use the updated CMAP system during patient education for prevention of pressure injuries with Veterans with SCI who are completing their initial rehabilitation.
223660348|NCT04309864|DEVICE|Use of CMAP app (in-home)|The Veteran will use the CMAP system at home for two weeks during their daily routines.
223660349|NCT05737355|DIETARY_SUPPLEMENT|ANKASCIN 568-P Red yeast rice capsules|Product ingredients: ANKASCIN 568-P red yeast rice product 440 mg,microcrystalline ,cellulose,Maltodextrin; capsule shell composition: HPMC (hydroxypropyl methylcellulose), purified water, titanium dioxide, gellan gum.
223660350|NCT05737355|DIETARY_SUPPLEMENT|Placebo Capsules|Maltodextrin was used as a placebo
224241229|NCT05666752|DIETARY_SUPPLEMENT|Allium Cepa L. Peel Heated Water Extract|4 capsules/day after meal(1,200 mg/day) for 8 weeks
223660351|NCT00351429|DEVICE|Polyglycolic acid suture|PGA suture used in Trabeculectomy surgery
223660352|NCT02872935|DRUG|Glycopyrrolate|.2mg of Glycopyrrolate will be given intravenously with the administration of the spinal dose
223660353|NCT02872935|DRUG|Normal Saline|1ml of normal saline will be given intravenously with the administration of the spinal dose
223660354|NCT03854877|BEHAVIORAL|Health behaviour intervention|The intervention uses the principles of acceptance-commitment therapy (ACT). It aims to increase healthy eating and good sleep. Based on personal needs participants can choose task for physical activity, relaxation, healthy eating, sleep eg. Their get regular feedback and support from their personal trainer via phone and computer.
223660355|NCT00010699|DRUG|Vitamin E|
224241230|NCT05666752|DIETARY_SUPPLEMENT|Placebo|4 capsules/day after meal(1,200 mg/day) for 8 weeks
223660356|NCT03048006|PROCEDURE|MRI with Dotarem|
224241231|NCT05065645|DRUG|Angiotensin Converting Enzyme 2|SAD: single dose; MAD: dosage 2x daily for 7 days
224241232|NCT05065645|DRUG|Sodium chloride|SAD: single dose; MAD: dosage 2x daily for 7 days
224241233|NCT04833998|DRUG|Extremecare|The product under investigation (Extremecare) will be supplied as 120g use individual tubes to be applicated in the hands and feet twice a day (once in the morning and once in the evening) beginning with the first cycle of capecitabine and continuing until the end of the fifth cycle of chemotherapy.
223660357|NCT01482052|BIOLOGICAL|meningococcal meningitis conjugate vaccine, quadrivalent|NmVac4-A/C/Y/W-135-DT™conjugate is a vaccine in liquid form composed of purified polysaccharides (PS) conjugated to diphtheria toxoid. Single intramuscular 0.5 mL dose contains 4 µg each Serogroup A, C, W-135, Y PS conjugated to approximately 16 µg total diphtheria toxoid.
223660358|NCT01482052|BIOLOGICAL|meningococcal meningitis conjugate vaccine, quadrivalent|Meningococcal (Groups A,C,Y and W-135-DT) Polysaccharide Conjugate Vaccine 0.5 mL dose, intramuscular. Single dose contains 4 µg each Serogroup A, C, W-135, Y PS conjugated to approximately 48 µg total diphtheria toxoid.
223660359|NCT04013659|OTHER|Dental Bleaching with 35% hydrogen peroxide gel + Violet LED Irradiation|After gum protection, the bleaching gel (35% hydrogen peroxide) was applied to the surface of the tooth and irradiated with VIOLET LED
223660360|NCT05743959|PROCEDURE|No intervention|No intervention
223660361|NCT01321099|OTHER|NaFeEDTA|Labeled iron as FeSO4 or NaFeEDTA added to a test meal
223660362|NCT01321099|OTHER|Phytase|Labeled iron as FeSO4 added to a test meal with or without phytase and with or without vitamin C
223660363|NCT01321099|OTHER|Vitamin C|Labeled iron as FeSO4 added to a test meal with or without vitamin C
223660364|NCT04615832|DEVICE|Toffee Full Face Mask|Full face mask for PAP therapy applied in a home environment
223660365|NCT02213861|DRUG|SHAPE|topical gel
223660366|NCT01534897|DRUG|GSK2118436|150mg twice per day orally for 28 days (42 days if Iodine-131 scan on Day 25 shows new uptake)
223660367|NCT00492128|DRUG|Losartan/amlodipine or losartan/hydrochlorothiazide|Losartan 50mg/amlodipine 5mg and the fixed dose combination drug of losartan 50mg/hydrochlorothiazide 12.5mg once a day during 12 months.
223660368|NCT06174688|DRUG|BOTOX|Intramuscular Injections
223660369|NCT06174688|DRUG|Placebo|Intramuscular Injections
223660370|NCT01276054|RADIATION|technetium Tc 99m sulfur colloid|Given intradermally and periareolarly
224241234|NCT04833998|DRUG|Placebo|Placebo cream will be supplied as 120g use individual tubes to be applicated in the hand and feet twice a day (once in the morning and once in the evening) during the fifth cycle of capecitabine therapy.
224241235|NCT02621775|BEHAVIORAL|Computer-based stress management program|The program includes 5 one hour weekly sessions that patient follow from a web site accessible from a computer in our unit. He benefits from a minimal contact with a medical member of staff before and after every session. The duration of each session is about one hour. To avoid internet connexion problem between session it is supplied to the patient, from the first session an USB key (Universal Serial Bus) containing videos, audio files, self help book, portfolio in the form of e-guide, log book with the program of the exercises to be realized between two session of the five sessions program. The patient is encouraged to practice a twenty-minutes daily exercises five or six days per week.
224241236|NCT02621775|BEHAVIORAL|Stress management in face-to-face|The program includes 5 forty-five minutes weekly session with a therapist (psychologist graduate of a master of cognitive and emotional therapy with a minimal of one year of practice in CBT and CBSM (Cognitive-Behavioral Stress Management ). Information, exercises and homework assignments are delivered by the therapist without self help support.
224241237|NCT02621775|OTHER|Waiting list|The patients are followed by their General Practitioners without change in treatment .
224241238|NCT00996320|OTHER|Reduced work hour schedule|Interns on the intervention schedule work an average of 60 hours per week over 4 weeks, with maximum shift length 16 hours.
224241239|NCT00852436|DRUG|pregabalin|Pregabalin capsules in 75 mg,dosing increment from 150, 300, to 600mg/day at weekly intervals,administered orally one (or two, or four) capsule(s), twice daily. Fixed schedule of dosing increment from 150, 300, to 600mg/day at weekly intervals, until the highest tolerated dose has been reached. A single downward dose titration will be allowed depending on tolerability, after which the patient will remain on this dosage for the rest of the study.
223660371|NCT01276054|DRUG|methylene blue|Given subcutaneously
223660372|NCT01276054|DRUG|indocyanine green solution|Given subcutaneously
223660373|NCT01276054|PROCEDURE|sentinel lymph node biopsy|Undergo sentinel lymph node biopsy
223660374|NCT01276054|PROCEDURE|axillary lymph node biopsy|Undergo axillary lymph node biopsy
223660375|NCT01276054|PROCEDURE|bioimpedance spectroscopy|Correlative studies
223660376|NCT01276054|PROCEDURE|quality-of-life assessment|Ancillary studies
223660377|NCT01276054|OTHER|lymphedema management|Undergo axillary reverse mapping
224241240|NCT00852436|DRUG|placebo|Placebo capsules in 75 mg,dosing increment from 150, 300, to 600mg/day at weekly intervals,administered orally one (or two, or four) capsule(s), twice daily. Fixed schedule of dosing increment from 150, 300, to 600mg/day at weekly intervals, until the highest tolerated dose has been reached. A single downward dose titration will be allowed depending on tolerability, after which the patient will remain on this dosage for the rest of the study.
224241241|NCT01245166|DRUG|Acarbose|Acarbose 50 mg, per orem, thrice daily
224241242|NCT01245166|DRUG|Metformin/Acarbose|Metformin HCl 500 mg plus Acarbose 50 mg Tablets, per orem, thrice daily
224241243|NCT05914103|PROCEDURE|ERAS|The primary endpoint is the rate of composite outcomes. The composite outcomes include the major adverse cardiac events (MACE), major postoperative pulmonary complication (PPCs), and acute kidney injury (AKI)
224241244|NCT02164838|DRUG|Axitinib|
224241245|NCT00055978|DRUG|celecoxib|Given orally. 400mg twice daily for 6 months.
224241246|NCT00055978|OTHER|placebo|Given orally
224241247|NCT01309945|DRUG|Duloxetine|Capsule, Oral, 30-60 mg/day, once daily (QD), 8 weeks
224241248|NCT01309945|DRUG|Placebo matching with BMS-820836|Tablet, Oral, 0.0 mg, once daily (QD), 14 weeks
223660378|NCT02512029|DRUG|18F-AV-1451|
223660379|NCT05986396|DEVICE|INSPIRIS Resilia (model 11500A)|Aortic Valve
223660380|NCT02640508|DRUG|Eribulin|Will be given by I.V. at 1.4 mg/m2 on day 1 and day 8.
223660381|NCT02640508|DRUG|Lenvatinib|Will be taken orally at 20-24 mg daily in each 21 day cycle.
223660382|NCT05071768|BEHAVIORAL|Focused ACT|Brief acceptance and commitment therapy
224241249|NCT01309945|DRUG|BMS-820836|Tablet, Oral, 0.5-2.0 mg, once daily (QD), 6 weeks
224241250|NCT01309945|DRUG|Duloxetine|Capsule, Oral, 30-60 mg/day, once daily (QD), 6 weeks
224241251|NCT01309945|DRUG|Placebo matching with Duloxetine|Tablet, Oral, 0.0 mg, once daily (QD), 8 weeks
223660383|NCT00932178|BEHAVIORAL|Calmer Life|Calmer Life is a modified version of an existing Cognitive Behavioral Treatment manual. Participants have the option of including religion and spirituality into coping skills taught as a way of treating anxiety with or without depression in older adults.
223660384|NCT02703441|OTHER|Tablet computer|Patients randomized to the intervention group will receive a tablet computer with an app-like software solution supporting nutrition and physical activity. The patients operate the computer and order their meals from the hospital menu; register dietary intake, and receive feedback informing about their current status for protein and energy intake. Likewise, the patients use small series of brief videos instructing in daily life activities for strengthening their muscles. After this, they register their performed activities and will receive informing and motivating feedback. Nudging and prompting is part of the solution.
223660385|NCT00552747|DRUG|fenofibrate|fenofibrate 160 mg capsules qd
223660386|NCT00552747|DRUG|placebo|capsules placebo
223660387|NCT03202615|DIETARY_SUPPLEMENT|L (lactoferrin)|Dietary Supplement: Pravotin sachets (Hygint, Egypt) containing bLf One sachet of Pravotin contains 100 mg of bLf. Dosage: one sachet twice a day before meals with placebo tablets
223660388|NCT03202615|DRUG|F (ferrous sulphate)|Drug: FerroGrad by Abbott Dosage: one capsule three times /day containing150 mg of dried ferrous sulfate capsules (Ferrofol capsules, Eipico, Egypt), with placebo sachets.
223660389|NCT02792829|DRUG|Lenvatinib|All participants will receive one single dose in each of the 2 treatment periods (total of 2 doses). The total duration of the treatment periods is 12 days (6 days per period) in healthy adult volunteers.
223660390|NCT03173001|DIAGNOSTIC_TEST|Parasitological examination|Three stool samples for parasitological examination will be taken from control subjects and CRC patients at 1-2 days interval.
223660391|NCT05405257|DRUG|Oxytocin|IV 1IU Oxytocin in 200 ml 0.9%NaCl over 40 minutes. Total of three infusions in three consecutive days (one per day).
223660392|NCT05405257|OTHER|Placebo|IV, 200 ml 0.9%NaCl over 40 minutes. Total of three infusions in three consecutive days (one per day).
224241252|NCT05938556|BEHAVIORAL|hybrid asynchronous-synchronous group coaching program|A hybrid asynchronous-synchronous program. The synchronous part has two weekly recorded live group coaching calls for four months. The asynchronous consist of 1) on-demand replies to recorded coaching calls, 2) Self-coaching through weekly self-study modules and worksheets, and 3) written Ask A Coach. Content modified per needs of APPs by a physician, a certified coach, and an APP who is also a Co-I. The curriculum has weekly themes that build. Month-1 consists of 1) Introduction to the Model, 2) How to Feel Better, 3) Defining Your Purpose, and 4) Living Your Purpose. Month-2 consists of 1) Growth Mindset, 2) Welcoming Feedback and Assessment Bias, 3) Feeling Valued and Belonging, and 4) How to Deal with Hidden Expectations. Month-3 consists of 1) Imposter Syndrome, 2) Perfectionism, 3) Approval Addiction, and 4) How to Change Your Thoughts. Month-4 consists of 1) How to deal with Ambiguity, 2) Confidence, 3) Self-Appreciation and Self-Compassion, and 4) Celebrate the New You.
224241253|NCT05938556|OTHER|treatment as usual group (TAU)|The treatment as usual group will consist of any structural or programmatic interventions, resources, lectures, curriculum, etc. offered at the participants' hospital of employment. Thus, this active control is designed to represent a best-case alternative to group coaching, making it a more rigorous form of control. Participants randomly assigned to TAU will also continue any structural or programmatic interventions or resources they were previously participating in.
224241254|NCT01762748|DRUG|Saccharomyces boulardii|Oral capsule with 200 mg lyophilized S. boulardii-17 (about 4x108 cells), 6 mg sucrose and 2.4 mg magnesium stearate (Floratil®).
224241255|NCT06038539|BIOLOGICAL|PERT-IJS plus trastuzumab, carboplatin and docetaxel|PERT-IJS is a monoclonal antibody, which has been developed by Biocon Biologics (earlier in collaboration with Viatris) as a proposed biosimilar to European Union (EU)-approved and United States (US) licensed Perjeta.
224241256|NCT06038539|BIOLOGICAL|Perjeta plus trastuzumab, carboplatin and docetaxel|EU Perjeta (Pertuzumab) , an antineoplastic agent, is a recombinant humanized monoclonal antibody that specifically targets sub-domain 2 of the extracellular domain of Human Epidermal Growth Factor Receptor 2 (HER2), blocking heterodimerization of HER2 with other members of the receptor family, including epidermal growth factor, Human Epidermal Growth Factor Receptor 3 (HER3) and Human Epidermal Growth Factor Receptor 4 (HER4).
224241257|NCT05871736|OTHER|Turkish version of Child Engagement in Daily Life Measure V2|Child Engagement in Daily Life Measure V2 will be performed on both groups and GMFCS and MACS levels of children with cerebral palsy will be recorded.
224241258|NCT01027780|BEHAVIORAL|Mindfulness-Based Stress Reduction|The standardized Mindfulness-Based Stress Reduction (MBSR) program is the primary training tool used to enhance mindfulness. The eight-week-long MBSR program is designed to teach subjects how to develop their inner resources in the service of taking better care of themselves. MBSR training includes the learning and refining of a range of skills aimed at increasing relaxation and awareness of physical experiences and sensations related to physical symptoms, emotions, and thoughts. Special emphasis is placed on movement, meditation, and breathing.
224241259|NCT00115882|BEHAVIORAL|MI + CBST|The HS Study intervention consisted of proactive identification and recruitment of eligible smokers (and selected nonsmokers) within the target population, and a protocol-guided series of counselor-initiated, personally-tailored telephone calls (from 1 to 10, depending on participant's interest) to eligible high school senior smokers and nonsmokers in experimental high schools. The telephone-delivered behavioral intervention integrated Motivational Interviewing and Cognitive Behavioral Skills building. Content and dose were tailored to the individual.
224241260|NCT01315249|DRUG|indacaterol and glycopyrronium (QVA149)|QVA149 capsules delivered via dry powder inhaler (SDDPI), once daily.
224241261|NCT01315249|DRUG|Placebo to fluticasone/salmeterol|Placebo to fluticasone/salmeterol delivered via Accuhaler® device, twice daily.
224241262|NCT01315249|DRUG|fluticasone/salmeterol|Fluticasone/salmeterol dry inhalation powder delivered via Accuhaler® device, twice daily.
224241263|NCT01315249|DRUG|Placebo to indacaterol and glycopyrronium (QVA149)|Placebo to QVA149 delivered via dry powder inhaler (SDDPI), once daily
224241264|NCT02511405|DRUG|VB-111 + bevacizumab|"VB-111 will be administered intravenously at a dose of 1x10e13 VPs every 2 months~Bevacizumab will be administered intravenously at a dose of 10mg/kg every 2 weeks"
224241265|NCT02511405|DRUG|Bevacizumab|Bevacizumab will be administered intravenously at a dose of 10mg/kg every 2 weeks
224241266|NCT00584311|OTHER|MRI and Ultrasound|MRI and US of the joint
224241267|NCT04988061|OTHER|counselling|Educating and Counselling with personal communication for 10-15 minutes and written information about the importance of early identification and intervention for hearing loss are provided by a physician. Also, the information about hearing screening results and an appointment date are provided by a physician.
224241268|NCT01740661|OTHER|Cryotherapy|The subjects will be exposed to a cold (\~ 12° C) water immersion tub at the umbilical level for 20 minutes.
224241269|NCT01740661|OTHER|Control|The subjects will be exposed to a non-cold (\~ 26° C) water immersion tub at the umbilical level for 20 minutes.
223660393|NCT06584383|PROCEDURE|Exablate MRgFUS subthalamotomy|Exablate MRgFUS subthalamotomy for Parkinson's Disease
223660394|NCT06584383|DRUG|Best Medical Treatment|Subjects will be managed according to conventional therapeutic guidelines (i.e., best medical treatment) for Parkinson's Disease
223660395|NCT03791099|DRUG|Metronidazole|After subgingival ultrasonic scaling is performed, metronidazole in polymer matrix is applied to the selected periodontal pockets.
223660396|NCT05367297|DIAGNOSTIC_TEST|Coronary CT Angiogram|A computerized tomography (CT) coronary angiogram is non-invasive imaging test that looks at the arteries that supply blood to your heart.
223660397|NCT00136188|DRUG|Folic Acid|oral administration of folic acid 5mg /d for 4 weeks
223660398|NCT01518764|DIETARY_SUPPLEMENT|Red Wine Polyphenols 600mg/day|
223660399|NCT01518764|DIETARY_SUPPLEMENT|placebo|
223660400|NCT03126318|DRUG|COR-001|Anti-inflammatory therapy
223660401|NCT03126318|DRUG|Placebo|Sterile water with a final buffer of 25 mM Histidine, 8.5% (w/v) trehalose and 0.05% PS80
223660402|NCT01500681|PROCEDURE|Plasma exchange (PLEX)|Regular maintenance PLEX courses, typically 3 procedures monthly
223660403|NCT02361632|DIETARY_SUPPLEMENT|Coffee with or without milk|Intervention :30 participants were randomized to 3 Groups, 10 persons in each group. All participants fasted 6 hours for solid food before gastric volume was measured by Magnetic Resonance Imagining ( MRI). 2 hours before MRI examination, each participant ingested either 175 ml black coffee, 175 ml coffee with 20% milk or 175 ml coffee with 50% milk in the order defined for the group (arm).
223660404|NCT01080365|DRUG|SKI-606 (Bosutinib)|500 mg commercial formulation film coated tablet, administered once daily
223769264|NCT04056559|DEVICE|Adaptable mouthguards|Validate a prototype of Adaptable Intra-Oral Protections patented by Bordeaux University and Bordeaux University Hospital according to 3 levels (ventilation, comfort, cervical muscle activity).
223769265|NCT02165930|DRUG|Oxycodone|One capsule of 40 mg PF-00345439 Formulation K, single dose, administered with water, under fasting conditions
223769266|NCT02165930|DRUG|Naltrexone|Single dose of 40 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before,and 12 hours after study drug administration).
223769267|NCT02165930|DRUG|Oxycodone|One capsule of 40 mg PF-00345439 Formulation K, single dose, administered with 40% ethanol, under fasting conditions
223769268|NCT02165930|DRUG|Naltrexone|Single dose of 40 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before, and 12 hours after study drug administration).
223769269|NCT00501202|DRUG|placebo|twice daily for 4 weeks
223769270|NCT00501202|DRUG|RWJ-333369 (carisbamate)|200 mg tablet twice daily for 4 weeks
223769271|NCT03494036|DIETARY_SUPPLEMENT|Synbiotic|capsule
223769272|NCT03494036|DIETARY_SUPPLEMENT|Placebo|capsule
224241270|NCT06441396|OTHER|Telerehabilitation|In the study, the VTR guru was given video footage of 15 exercises previously recorded on camera. The individuals in this group were made to do the exercises together online via the WhatsApp program. Exercises in both groups were planned for 6 weeks, 3 days a week, 25-45 minutes. The main program consists of 15 calisthenic exercises involving the lower extremity, upper extremity and trunk large muscle groups. Exercises in both groups were planned for 6 weeks, 3 days a week, 25-45 minutes. The number of repetitions of each exercise started with 10 and was increased by 5 repetitions every two weeks until it reached 20 repetitions.
224241271|NCT06441396|OTHER|Video-based rehabilitation (VTR)|In the study, the VTR guru was given video footage of 15 exercises previously recorded on camera. Participants were asked to exercise by watching these videos. In addition, these individuals were interviewed once a week to check the progress of the exercise program. Video images were sent to the intervention group for informational purposes, and the individuals in this group were made to do the exercises together online via the WhatsApp program.
224241272|NCT05558891|BEHAVIORAL|THRIVE|Toward Hope, Recovery, Interpersonal Relationships, Values and Engagement (THRIVE), is a brief, suicide-specific, narrative, recovery-focused, 60 minute intervention. THRIVE includes three components: 1) Sharing the suicide narrative; 2) Completing the Lifeline and Meaning Reconstruction; 3) Completing the Meaningful Living Plan (MLP).
224241273|NCT05558891|BEHAVIORAL|Usual Care|Care as Usual in this Crisis Stabilization Unit includes medication management, medication management, safety planning Intervention, group psychoeducation, discharge planning, and community linkages
224241274|NCT02480465|DRUG|Lobelitazone 0.5mg|Lobelitazone 0.5mg, placebo of Sitagliptin 100mg, orally, 2 tablet once a day for 24 weeks with metformin
224241275|NCT02480465|DRUG|Sitagliptin 100mg|placebo of Lobelitazone 0.5mg, Sitagliptin 100mg, orally, 2 tablet once a day for 24 weeks with metformin
224241276|NCT02631629|OTHER|Non-fortified foods|The non-fortified placebo foods are eggs, cheese, yoghurt and crisp bread (without vitamin D added).
224241277|NCT02631629|OTHER|Fortified foods|The fortified intervention foods are eggs, cheese, yoghurt and crisp bread (with about 20 mcg/day).
223660405|NCT01080365|DRUG|SKI-606 (Bosutinib)|500 mg (5 ×100 mg) phase 3 formulation film coated tablets, administered orally once daily
223660406|NCT06396104|OTHER|Mobilisation with movement|The physiotherapist places the medial edge of the thumb of one hand on the upper facet joint of the relevant segment, then applies superior-anterior slide to the facet joint by providing support with the thumb of the other hand. The 'gliding' movement is maintained while the patient actively performs the unilateral neck rotation movement and maintains it for a few seconds at the end of the movement. If joint movement is painful, attempts are made on the other facet joint of the same segment or on the spinous process. If this attempt does not immediately improve the patient's active joint motion, Mulligan Sustained Natural Apophyseal Glides (SNAG) will be applied to the upper part of the left zygapophysial joint, and in case of failure again, application will be made through the superior spinous process of the relevant segment. Painless joint movement will be applied in 6 repetitions and 3 sets.
223769273|NCT05624099|DRUG|camrelizumab|200mg intravenous drip d1q3w
223769274|NCT05624099|DRUG|Paclitaxel drugs|150mg/m2 d1 q3w
223769275|NCT05624099|DRUG|Platinum drug|Cisplatin, carboplatin, nedaplatin and other platinum drugs
223769276|NCT05624099|RADIATION|Radiation|Dose: 5040cGy/28f
223769277|NCT04664504|COMBINATION_PRODUCT|Concurrent Chemoradiotherapy Radiotherapy|50Gy in 25 fractions to the primary tumor and to mesorectal, presacral,and internal iliac lymph nodes. Concurrent chemotherapy: Capecitabine 1650 mg/m2/d.
223769278|NCT04664504|RADIATION|Short-course Radiotherapy|25Gy in 5 fractions to the primary tumor and to mesorectal, presacral,and internal iliac lymph nodes.
223769279|NCT04664504|RADIATION|Local dose increase of Short-course Radiotherapy|25Gy in 5 fractions to the of primary tumor and to mesorectal, presacral,and internal iliac lymph nodes. And 4Gy in 1 fractions to the PGTV of primary tumor and to mesorectal, presacral,and internal iliac lymph nodes.
223769280|NCT04664504|DRUG|Consolidation chemotherapy|Intravenous infusion of oxaliplatin (130 mg/m2 over 2 h) on day 1 and oral administration of capecitabine (1000 mg/m2 twice daily) from day 1 to day 14, is repeated every 3 weeks for 4 cycles. 4 courses\*3 weeks per course.
223660407|NCT06396104|OTHER|Sham mobilisation|While the patients are sitting in a chair with a supported back, the spinal segment where pain is felt in neck joint movements will be determined. Without applying a sliding movement to this segment over the facet joint, only sensory input will be given and the patient will be asked to continue the active rotation movement and wait a few seconds at the end of the movement. The application will be completed as 6 repetitions and 3 sets.
223660408|NCT00466570|DRUG|gatifloxacin, moxifloxacin|
223660409|NCT05168111|DIAGNOSTIC_TEST|Detect the serum sample|Detect the serum sample
223660410|NCT05701319|PROCEDURE|PCI|percutaneous coronary intervention
223660411|NCT04252976|BEHAVIORAL|Ethical Living|Ethical principles based on Yoga philosophy, including contents of Yamas and Niyamas.
223660412|NCT04252976|BEHAVIORAL|Yoga Exercises|Ujjaii breathing and simple yoga asanas
223660413|NCT04252976|BEHAVIORAL|Mantra Meditation|Meditation with mantras
223660414|NCT04993157|DRUG|FIA586|FIA586 capsule
223660415|NCT05744804|DRUG|-group of patients(75 patients) will receive low dose rivaroxaban myocardial infarction plus (acetylsalicylic acid 75 mg and clopidogrel 75 mg|receive low dose rivaroxaban (rivaroxaban 2.5 mg twice daily orally) for 1 month after anterior ST-segment myocardial infarction plus dual antiplatelet therapy (acetylsalicylic acid 75 mg once daily orally and clopidogrel 75 mg once daily orally)
223660416|NCT05744804|DRUG|(acetylsalicylic acid 75 mg once daily orally and clopidogrel 75 mg once daily orally only)|control group of patients: 75 Patients of anterior ST-segment myocardial infarction on dual antiplatelet therapy only
223660417|NCT00644982|DRUG|sertraline|Flexibly-titrated 50 mg tablets, 50-150 mg/day and venlafaxine placebo orally for 10 weeks.
223660418|NCT00644982|DRUG|venlafaxine XR|Flexibly-titrated 75 mg capsules, 75-225mg/day and sertraline placebo orally for 10 weeks.
223660419|NCT04298476|PROCEDURE|Placement of an adductor canal nerve block|An adductor canal nerve block will be placed in a patient undergoing a knee arthroscopy in 1 of 3 locations with local anesthetic or placebo (without location definition or local anesthetic) to assess optimal placement of local anesthetic, pain management and anxiety scores post operatively.
223769281|NCT04664504|DRUG|Adjuvant chemotherapy|2 h) on day 1 and oral administration of capecitabine (1000 mg/m2 twice daily) from day 1 to day 14, is repeated every 3 weeks for 6 cycles. 6 courses\*3 weeks per course
223660420|NCT00132548|DRUG|Pyrimethamine/sulfadoxine|
223660421|NCT00132548|DRUG|Amodiaquine|
223660422|NCT00132548|DRUG|Artesunate|
223660423|NCT04180124|OTHER|Walking|"Patients walk over ground on a mat with sensors and on a treadmill with sensors (in different conditions) to compare their movement pattern.~Also the movement pattern will be compared between walking at comfortable walking speed en fast walking.~Finally, the correlation between upper extremity impairment and arm swing will be investigated."
223660424|NCT03120195|DEVICE|The EndoRotor®|The EndoRotor® is in automated mechanical endoscopic mucosal resection system for use in the gastrointestinal tract. The EndoRotor suctions up the tissue and cuts it, automatically sending the tissue to a collection trap for histological evaluation.
223660425|NCT00452361|DRUG|Sirolimus+MMF or MPS or AZA+Steroid|Corticosteroids will be administered according to local practice, within a daily maintenance dosage range of 2.5 to15 mg for prednisone or prednisolone (2 to 12 mg/day for methylprednisolone) or the alternate day equivalent.
223769282|NCT04664504|PROCEDURE|TME|Total mesorectal excision
223769283|NCT03947151|DRUG|Degarelix injection(s)|1 or 2 degarelix injection(s)
223660426|NCT00452361|DRUG|Calcineurin Inhibitors (either cyclosporine or tacrolimus)+MMF or MPS or AZA+Steroid|"The maintenance dose of:~1. MMF will not exceed 1500 mg/day or PMS will not exceed 1080 mg/day~2. AZA will not exceed 75 mg/day~Thereafter, at the discretion of the investigator, MMF/MPS or AZA may be:~1. continued for the entire 104-week period of randomized therapy~2. subsequently discontinued~3. restarted after discontinuation"
223660427|NCT00276523|BIOLOGICAL|PEG-interferon alfa-2b|Study medication begins on Day 1 and taken subcutaneously once each week with the last dose being taken within 1 week prior to surgery or biopsy.
223660428|NCT00276523|PROCEDURE|Conventional surgery|Participants on the control arm may undergo surgery at anytime within 3 weeks of randomization, and those randomized to PEG-Intron will undergo surgery on Days 16-22 following initiation of treatment.
223660429|NCT00276523|PROCEDURE|Neoadjuvant therapy|
223660430|NCT00776919|DRUG|clindamycin / benzoyl peroxide gel|Once a day application to the face
223769284|NCT04292730|DRUG|Remdesivir|Administered as an intravenous infusion
223769285|NCT04292730|DRUG|Standard of Care|Standard of Care Treatment for COVID-19 Infection
223769286|NCT01527292|RADIATION|Stereotactic Radiation Therapy|SRT only
223769287|NCT01527292|RADIATION|SRT with Vertebral Augmentation Procedure|SRT with VAP
224241278|NCT06395857|OTHER|Visual arts-based intervention|This visual arts-based intervention is grounded on Bandura's Self-Efficacy Theory. It consists of four weekly group and face-to-face sessions delivered by a qualified facilitator. The contents of the intervention involve structured visual art-making activity, group discussion, and workbook assistance.
224241279|NCT00308529|DRUG|irinotecan|
224241280|NCT00308529|DRUG|carboplatin|
223660431|NCT00776919|DRUG|clindamycin gel|Once a day application to the face
223660432|NCT00776919|DRUG|BPO gel|Once a day application to the face
223660433|NCT00776919|DRUG|vehicle gel|Once a day application to the face
223660434|NCT01162837|DEVICE|BEAM device|A red/blue LED device for the treatment of acne
223660435|NCT01739062|GENETIC|Genetic risk assessment|
224241281|NCT00308529|DRUG|bevacizumab|
223769288|NCT02119546|OTHER|Aerobic exercise|Aerobic exercise and dual-task training
223769289|NCT02119546|OTHER|Stretch exercise|Stretch exercise \& sitting balance
223769290|NCT02501603|DRUG|afatinib|Afatinib 40mg daily oral administration
223769291|NCT02501603|DRUG|paclitaxel|Paclitaxel 80mg/m2 IV weekly (day 1,8,15)
223769292|NCT03938142|OTHER|Filling in an online survey regarding goalsettings|Patients are asked to fill in an online survey regarding their individual goalsettings.
223769293|NCT01954485|PROCEDURE|Dental implant placement with a final prosthetic abutment|
224241282|NCT00308529|PROCEDURE|Radiation Therapy|
224241283|NCT01008657|PROCEDURE|Radiofrequency ablation|Percutaneous multipolar radiofrequency ablation.
223660436|NCT01472718|DEVICE|coronary thrombectomy|coronary thrombectomy with either Angiojet device (rhelytic thrombectomy) or Export device (manual aspiration)
223660437|NCT01472718|DEVICE|standard primary PCI (with stenting, as required)|standard primary PCI (usually with stenting) for STEMI, without use of thrombectomy or distal protection devices
223660438|NCT03116152|BIOLOGICAL|IBI308|IBI308 200mg Intravenous drip every three weeks；
223660439|NCT03116152|DRUG|paclitaxel/ irinotecan|paclitaxel 175mg/㎡ Intravenous drip every three weeks or irinotecan 180mg/㎡ Intravenous drip every two weeks
223660440|NCT05949437|OTHER|Yuga|Traditional yoga body posture for 15 minutes, yoga breathing exercises for 30 minutes and meditation for 5 minutes for 12 weeks
223660441|NCT05949437|OTHER|Aerobic exercises|in form of treadmill according to the target exercise heart rate for 12 weeks
223660442|NCT01469715|DEVICE|GBP CGM|Visit 1: Screening visit to determine if subject qualifies for the study. Visit 2: Inpatient admission requiring a 25.5-hour hospital stay. Each subject will wear one active \& one mock device simultaneously during hyperglycemic \& hypoglycemic challenge conditions to observe a wide range of glucose values. Visit 3 \& 4: Subjects will return to the research center approximately 24 \& 48 hours after sensor removal, respectively, for evaluation of the postimplantation sensor site. Visit 5: Subjects will return to the research center approximately 28 days post inpatient admission. Blood samples for future testing of GBP and polyethylene Glycol neutralizing antibodies will be taken at Visit 1 \& 5.
223660443|NCT06443931|PROCEDURE|cryoablation of intercostal nerves|"Patients in the CryoINB group will undergo cryoablation of the intercostal nerves, at the end of surgery before weaning from CPB, using the ArtiCue device for 120 seconds at a temperature of -50°C to -70°C, in the intercostal spaces where the surgical approach is located, one intercostal space above and one below it. Cold leads to axonotmesis, in which the axon and myelin sheath are damaged, preventing the pain signal from traveling along the sensory nerve. However, the structural elements of the nerve are preserved, which promotes complete regeneration at a rate of 1-2 mm per day, thereby restoring normal function within several months."
223660444|NCT03705013|OTHER|Cologuard|Observational
223660445|NCT01966718|DRUG|Repository corticotropin injection|An adrenocorticotropic hormone (ACTH) analogue that stimulates the adrenal cortex to secrete cortisol, corticosterone, aldosterone, and a number of weakly androgenic substances
223660446|NCT06291519|OTHER|Multi-sensory Stimulation Method-Mother Applying the Method to the Baby|"In the multisensory stimulus method;~1. st stimulus (sense of taste): The mother breastfed the baby for 20 minutes. Breastfeeding was terminated before vaccination.~2. nd stimulus (sense of touch),: The mother applied touch - a light massage for 5 min until the vaccination process. There was a break just before the vaccination. The application was continued for another 5 min after the vaccination.~3. rd stimulus: Speech-Sound (sense of hearing): The mother spoke to the baby in a soft tone for 5 minutes until the vaccination (words, lullabies, songs, etc.). There was a break just before the vaccination. The practice was continued for 5 minutes immediately after the vaccination.~4\. Stimulus Eye contact (sense of sight): The mother made eye contact with the baby in the mother's field of vision for 5 minutes until the vaccination. There was a break just before the vaccination. The application continued for another 5 minutes after the vaccination."
223660447|NCT06291519|OTHER|Multi-sensory Stimulation Method-Nurse Applying the Method to the Baby|"In the multisensory stimulus method;~1. st stimulus (sense of taste): The mother breastfed the baby for 20 minutes. Breastfeeding was terminated 5 min before vaccination.~2. nd stimulus (sense of touch),: The nurse applied touch - a light massage for 5 minutes until the vaccination. There was a break just before the vaccination. The application was continued for another 5 min after the vaccination.~3. rd stimulus: Speech-Sound (sense of hearing): The nurse spoke to the baby in a soft tone for 5 minutes until the vaccination (words, lullabies, songs, etc.). There was a break just before the vaccination. The practice was continued for 5 minutes immediately after the vaccination.~4\. Stimulus Eye contact (sense of sight): The nurse made eye contact with the baby in the mother's field of vision for 5 minutes until the vaccination. There was a break just before the vaccination. The application continued for another 5 minutes after the vaccination."
223660448|NCT06291519|OTHER|Breastfeeding Applied Group|"Multisensory stimulus method not applied:~The baby was breastfed by its mother for 20 minutes. Breastfeeding was stopped just before the vaccination."
224241284|NCT00581646|BEHAVIORAL|survey instrument|Participants will be mailed or given a one time survey instrument and data will be collected either in person or by telephone. We expect the study survey to take approximately 35-45 minutes to complete. The domains assessed will include psychological functioning, reproductive knowledge, perception of third party reproduction and concerns, sexual functioning, and quality of life.
224241285|NCT05352386|DIAGNOSTIC_TEST|Coronary computed tomography angiography (CCTA)|Participants undergo coronary computed tomography angiography (CCTA)
224241286|NCT01185808|BIOLOGICAL|Vitamin D|Vitamin D 5000IU/day for 6 weeks
224241287|NCT03538587|BEHAVIORAL|Enhanced Mindfulness Intervention|"The 8-week EMI will consist of one initial in-person session with the participant and parent, a series of at home assignments, and two booster sessions. The psychoeducation group will be given educational material about coping with cancer."
224241288|NCT03538587|BEHAVIORAL|Psychoeducation|The psychoeducation group will be offered the opportunity to participate in the EMI 8 weeks post-baseline.
224241289|NCT03925870|DRUG|KN046|Eligible subjects will be enrolled and receive KN046 (3 mg/kg) monotherapy treatment until progressive disease according to RECIST 1.1, unacceptable toxicity, completion of 2 years' KN046 treatment, or withdrawal of informed consent, whichever comes first
224241290|NCT03802370|PROCEDURE|connective tissue grafting by Dome Technique|The dome technique addresses the placement of the CT, as it is layered over the implant and takes the shape of an inverted dome
224241291|NCT01247259|DRUG|Pangramin®|During a 4-week increasing-dose phase, the patients increased the daily dose from 1 to 5 drops of 1.6 STU/mL solution from day 1 to 10, 1 to 5 drops of 8 STU/mL solution from day 11 to 15, 1 to 5 drops of 40 STU/mL solution from day 16 to 20, 1 to 5 drops of 200 STU/mL solution from day 21 to 25, and 1 to 5 drops of 1000 STU/mL solution from day 26 to 30. After reaching the maintenance dose, 5 drops of 1000 STU/mL solution, the patients took the allergen three times per week during the maintenance phase.
224241292|NCT02925442|PROCEDURE|t-RFA|standard thermal genicular radiofrequency ablation
224241293|NCT02925442|PROCEDURE|C-RFA|Cooled radiofrequency ablation
224241294|NCT02925442|PROCEDURE|Control|Simulated radiofrequency ablation for placebo controlled group
223660449|NCT04660916|DRUG|Isotretinoin|The effects of isotretinoin on morphology, growth rate, and thickness of the nail plate
223660450|NCT02865876|PROCEDURE|Accelerated Corneal Cross-linking|All participants in this group receiving conventional therapy (moxifloxacin 0,5% for bacterial keratitis or natamycin for mycotic keratitis) plus accelerated cross-linking (Avedro Inc., Waltham, USA) under topical anesthesia using 0.1% riboflavin (Vibex, Avedro Inc, Waltham, USA) for 10 minutes and irradiation 30 mW/cm2 during 3 minutes.
223660451|NCT03714581|DEVICE|Microablative Fractional CO2 Laser Therapy|5 laser therapies intravaginally administered will be applied at monthly intervals.
223660452|NCT00430976|BEHAVIORAL|Minds in Motion|
223660453|NCT02379637|DRUG|N-acetylcysteine|
223660454|NCT02379637|DRUG|Placebo|
223660455|NCT03959397|DRUG|nab-paclitaxel|nab-paclitaxel monotherapy or combination therapeutic regimen
223660456|NCT04759326|OTHER|Hippotherapy|Hippotherapy is an emerging specialized rehabilitation approach, performed on a specially trained horse via its movement at a walk by accredited health professionals (e.g., physicians, psychologists, physical therapists, occupational therapists, psychomotor therapists, chiropractors ...). The horse is an excellent support for temporary or consolidated disabilities, providing key elements of recovery for impairment, activity limitation, and participation restriction. It is a dynamic activity where the amplitude of movement of the patient's body transmitted by the horse is similar to the human walking (micro-movements of postural muscles). Moreover, through multimodal inputs (sensory, exteroceptive, proprioceptive, interoceptive), hippotherapy has a direct action on the individual's motor capacities and cognitive abilities. The degree of change relying on neuroplasticity is linked both to the relevance of the activity and to the intensity and frequency of the elements that constitute it.
223660457|NCT04759326|OTHER|Conventional Neurorehabilitation|The neurorehabilitation therapy is an intervention from two or more disciplines (physiotherapy, occupational therapy, social work, psychology and other related disciplines, nursing) prescribed by a medical specialist (neurologist, neurosurgeon, oncologist, physiatrist). It is designed to be patient-centered, time-limited and functionally oriented, and aims to maximize activity and participation (social inclusion) using a biopsychosocial model.
223660458|NCT00665808|DRUG|insulin detemir|"Observational study on treatment satisfaction of Levemir ® versus Protaphane® during real-life usage in Germany"
224241295|NCT04238442|DEVICE|A&D TM-2657W oscillometric device|Assessing the accuracy of the A\&D TM-2657W oscillometric device using International Standards Organization validation protocol. This involves comparing the accuracy of the A\&D device to 2 observer mercury auscultation (gold standard).
224241296|NCT02270970|BIOLOGICAL|belimumab|belimumab will be given at 10 mg/kg intravenously at Week 1, Week 2, Week 4 and monthly after that as was done in Phase III trials and approved in the FDA label
223660459|NCT00665808|DRUG|isophane human insulin|"Observational study on treatment satisfaction of Levemir ® versus Protaphane® during real-life usage in Germany"
223660460|NCT00420043|DRUG|imatinib|
223660461|NCT01110148|OTHER|video-based informed consent for skin biopsies|video-based informed consent for punch and shave biopsies
223660462|NCT01110148|OTHER|traditional informed consent|traditional informed consent (standard of care) from physicians for shave and punch biopsies
223660463|NCT00003749|PROCEDURE|adjuvant therapy|
223660464|NCT00003749|PROCEDURE|conventional surgery|
223660465|NCT00003749|RADIATION|brachytherapy|
223660466|NCT00003749|RADIATION|radiation therapy|
223660467|NCT00511368|DRUG|matching placebo|
224241297|NCT00771537|BEHAVIORAL|Message Sidedness|There are 16 pairs of messages varying in sidedness. Arm 1 is a no message control condition regarding HIV testing + a no message control condition regarding trial participation. Arm 2 is control + a 1-sided message. Arm 3 is control + a trivial 2-sided message. Arm 4 is control + a major 2-sided message. Arm 5 is a 1-sided message + a control. Arm 6 is a 1-sided message + a 1-sided message. Arm 7 is a 1-sided message + a trivial 2-sided message. Arm 8 is a 1-sided message + a major2-sided message. Arm 9 is a trivial 2-sided message + a control. Arm 10 is a trivial 2-sided message + a 1-sided message. Arm 11 is a trivial 2-sided message + a trivial 2-sided message. Arm 12 is a trivial 2-sided message + a major 2-sided message. Arm 13 is a major 2-sided message + a control. Arm 14 is a major 2-sided message + a 1-sided message. Arm 15 is a major 2-sided message + a trivial 2-sided message. Arm 16 is a major 2-sided message + a major2-sided message.
224241298|NCT00893256|DRUG|Risperidone|Risperidone: tablet; oral; 4-6 mg/day; once daily; 12 weeks
224241299|NCT00893256|DRUG|risperidone|Risperidone: tablet; 4-8 mg/day; once daily; 12 weeks
224241300|NCT00893256|DRUG|Citalopram|Citalopram: tablet; oral; 20 mg/day; once daily; 12 weeks
224241301|NCT00893256|DRUG|Placebo|Placebo: once daily
224241302|NCT05911607|PROCEDURE|Low power laser|Phototherapy for extraction sockets using two different lasers.
224241303|NCT02827409|PROCEDURE|Short Delay Cord Clamping|Delay cord clamping will occur for up to 1 minute. Subject will be placed on mother's abdomen for warmth and stimulation. If the subject is depressed they will be transferred to the radiant warmer for resuscitation.
223660468|NCT00511368|DRUG|Bevirimat|
223660469|NCT00238342|GENETIC|proteomic profiling|
223660470|NCT00238342|OTHER|surface-enhanced laser desorption/ionization-time of flight mass spectrometry|
223660471|NCT00238342|PROCEDURE|biopsy|
223660472|NCT04242641|BEHAVIORAL|WW|WW is a structured lifestyle modification, weight-loss programme involving a programme for healthy eating, physical activity and positive mindset and support via attendance at local WW workshops and digital tools.
223660473|NCT03512938|PROCEDURE|Non-surgical periodontal therapy|Patients were motivated and instructed to brush with modified Bass technique and use interdental toothbrushes, dental floss. Each patient underwent quadrant scaling and root planning (SRP) under local anaesthesia over a 4-week period. Root planing (RP) was performed under local anaesthesia (2% lidocaine, epinephrine 1:100.000) and a standard curette set newly sharpened with Arkansas stone was used for each patient.
223660474|NCT02048319|DRUG|Pasireotide LAR 60 mg|Pasireotide long acting release, intramuscular injection
223660475|NCT02048319|PROCEDURE|Aspiration sclerotherapy|Percutaneous drainage of the hepatic cyst with subsequent ethanol instillation
224241304|NCT02827409|PROCEDURE|Extended Delay Cord Clamping|Extended delay cord clamping will occur for at least 5 minutes and will continue until the subjects begins breathing and/or the cord stops pulsating. Subject will be placed on mother's abdomen for warmth and stimulation. If the subject is depressed they will be transferred to the LifeStart bed for resuscitation adjacent to the mother's bedside.
224321208|NCT01297985|BEHAVIORAL|BRIDGES Peer-Led Education|The BRIDGES program is a 10-week, manualized education course designed to provide basic education about the etiology and treatment of mental illness, self-help skills, and recovery principles in order to empower participants to return to valued social roles within their communities. BRIDGES is a peer-led program and all instructors are adults with mental illnesses. For this intervention study, the BRIDGES curriculum was modified from a week course to an 8-week course, meeting for 2 1/2 hours once a week.
224321209|NCT02829476|BIOLOGICAL|Osteoblast sample|culture osteoblasts obtained from vertebrae fragments from 30 patients with AIS and from 10 control patients with secondary scoliosis
224241305|NCT05666583|OTHER|Art therapy|The intervention group is the group in which art therapy is applied. They receive chemotherapy.
224321210|NCT00378573|DRUG|docetaxel|
224321211|NCT00378573|DRUG|gemcitabine|
224321212|NCT00378573|DRUG|bevacizumab|
224321213|NCT01613430|BEHAVIORAL|Coach Training (COACH)|"Participants and their coaches receive Printed Educational Materials (PEM). Additionally, coaches will receive a 40-minute cancer-related training session led by a research staff member. The coaches will be provided basic information about different types of cancer screenings, how to schedule and keep medical visits, and how to communicate with health care providers about cancer screening. The session will be interactive, including short video presentations, role plays and exercises. Coaches will be given brochures on cancer screening for the three cancer types, a checklist for the coach and a Things to Remember diary checkup list, and resources addressing well-known barriers to cancer screening."
224321214|NCT01613430|BEHAVIORAL|Printed Educational Materials (PEM)|Participants and their coaches will be provided with educational brochures about cancer screening for colorectal, breast and cervical cancers at the completion of the baseline survey.
224321215|NCT00533312|DRUG|Comparator : placebo (unspecified) / Duraton of Treatment: 4 Weeks|
224321216|NCT00533312|DRUG|MK0524A, niacin (+) laropiprant / Duration of Treatment : 4 Weeks|
224321217|NCT00533312|DRUG|Comparator : niacin / Duraton of Treatment: 4 Weeks|
224321218|NCT06377618|DIAGNOSTIC_TEST|Resistance Training and Core Strengthening Exercises Group|The regimen includes resistance training (using bands, weights, and bodyweight for major muscle groups) and core strengthening (targeting abdominal, lower back, hip, and gluteal muscles) exercises.
224321219|NCT06377618|DIAGNOSTIC_TEST|Resistance Training and Core Strengthening Exercises Group Plus Vitamin D Supplementation|Group 1 Intervention plus Vitamin D Supplementation: Daily vitamin D supplementation, with the dosage adjusted based on initial serum 25(OH)D levels to achieve and maintain optimal vitamin D
223660476|NCT02048319|DRUG|Placebo|Saline solution, injected as placebo
223660477|NCT02791763|DRUG|1 to 4 mg tablets of GSK1278863|7.0 millimeters (mm) round, standard biconvex, white film coated tablets containing 1 mg, 2 mg, or 4 mg of GSK1278863 as active ingredient, to be orally administered once daily.
223660478|NCT02791763|DRUG|6 mg GSK1278863 tablet|9.0 mm round, standard biconvex, white film coated tablets containing 6 mg of GSK1278863 as active ingredient, to be orally administered once daily.
223660479|NCT02791763|DRUG|Epoetin beta pegol|An injectable formulation containing 25 micrograms µg, 50 µg, 75 µg, 100 µg, 150 µg, 200 µg, or 250 µg of epoetin beta pegol per syringe (0.3 mL), supplied as a glass syringe prefilled with epoetin beta pegol solution (clear colorless to pale yellow). Epoetin beta pegol will be subcutaneously administered once every 2 or 4 weeks.
223660480|NCT06035419|OTHER|education|breastfeeding education for migrant mothers
223660481|NCT03179605|DRUG|DFD06|Apply twice per day for 15 days
224241306|NCT01802697|DRUG|IdeS|
224241307|NCT01802697|DRUG|Placebo|
224241308|NCT04560881|BIOLOGICAL|Inactivated SARS-CoV-2 vaccine (Vero cell)|Immunization schedule: 2-doses of investigational vaccine or placebo are inoculated to the deltoid muscle of the upper arm according to the immunization schedule of Day 0, 21.
224241309|NCT04560881|BIOLOGICAL|Placebo/Aluminum Adjuvant of Inactivated SARS-CoV-2 vaccine|Immunization schedule: 2-doses of investigational vaccine or placebo are inoculated to the deltoid muscle of the upper arm according to the immunization schedule of Day 0, 21.
224241310|NCT00088062|DRUG|STA-5326|
224241311|NCT05653596|BEHAVIORAL|Virtual reality-based cognitive intervention|This intervention consists of 12 different VR contents that were developed for this trial. Each content includes 10-12 scenes with visual and auditory stimuli generated from nature. Participants will view 3D nature videos using a VR headset for 20 minutes every other day, three times per week for one month.
224241312|NCT01889836|BIOLOGICAL|'MenCC-Bio'|The experimental group will receive one dose of meningococcal C vaccine adsorbed produced by Bio-Manguinhos.
224241313|NCT01889836|BIOLOGICAL|MENJUGATE|The control group will receive one dose of meningococcal C vaccine adsorbed - MENJUGATE.
224241314|NCT01453075|DRUG|Valacyclovir|Valacyclovir 1.5 mg po bid
224241315|NCT01453075|DRUG|Placebo|Matching placebo twice daily
224241316|NCT00527800|DRUG|Dihydroartemisinin-piperaquine|Once daily for 3 days, given in fixed dose tablets (40 mg dihydroartemisinin + 320 mg piperaquine) according to weight-based guidelines
224321220|NCT06004791|DRUG|Herombopag + CsA|Herombopag（10mg/d）+CsA(3-5 mg/kg/d, adjust the grain concentration 100-200ng/ml)
224321221|NCT06004791|DRUG|rhTPO combined with Herombopag + CsA|rhTPO (15000U, subcutaneous injection, once a day for 7 days, once a month for 3 months)，Herombopag（10mg/d）+CsA(3-5 mg/kg/d, adjust the grain concentration 100-200ng/ml)
223660482|NCT01319604|DEVICE|SENSIMED Triggerfish|Soft contact lens-based device for the continuous monitoring of IOP fluctuations
223660483|NCT01319604|DEVICE|Tonometer|Tonometric assessment of IOP
223660484|NCT00635999|BEHAVIORAL|Applied relaxation and self-control desensitization|Applied relaxation and self-control desensitization sessions will teach participants relaxation techniques and the use of imagery for coping with anxiety. Treatment will include 14 weekly sessions.
223660485|NCT00635999|OTHER|Cognitive therapy (CT)|CT sessions will teach participants to identify ways in which they perceive themselves and the world and how to modify these thoughts to reduce anxiety. CT will include 14 weekly sessions.
223660486|NCT00635999|BEHAVIORAL|Cognitive-Behavioral Therapy|Includes all of the techniques in the other 2 interventions.
223660487|NCT04692636|DIAGNOSTIC_TEST|Measure: BP measurements, inter-dialysis BP variability, intra-dialysis hypotension|BP will be measured at the beginning and end of each dialysis session in a seated position by a trained dialysis nurse in accordance with the routine unit practice and entered into an electronic database. BP was measured using validated oscillometric BP monitor equipped in hemodialysis machines (Fresenius 4008S or Nikisso DBB-05), which were maintained as per dialysis unit protocols.
223660488|NCT05282134|PROCEDURE|Wet cupping therapy|Wet cupping therapy is a bloodletting application done by cups on the skin
223660489|NCT05282134|PROCEDURE|Acupuncture|Acupuncture is a complementary application of TCM done by needles
223660490|NCT02254954|DRUG|Macitentan in combination with RT and TMZ|Escalating doses of macitentan in combination with RT and TMZ, and maintenance TMZ.
223660491|NCT02001636|DRUG|Resource Instant Protein 88|Protein product: Resource Instant Protein 88, Nestlé Health Nutrition; postoperative intake of 30 - 35 g powder per day over 6 months.
223660492|NCT02001636|DRUG|Resource Maltodextrin|Placebo product (Resource Maltodextrin, Nestlé Health Nutrition). Postoperative intake of 30 - 35 g powder per day over 6 months.
223660493|NCT04500262|DEVICE|Open-tip pulsed needle biopsy (NeoNavia Biopsy System)|Ultrasound-guided biopsy using 14G open-tip pulsed biopsy needle
223660494|NCT04500262|DEVICE|Core needle biopsy (CNB)|Ultrasound-guided biopsy using standard of care core needle biopsy
223660495|NCT00888043|DRUG|CNTO 95 and avastin|"STAGE 1 (Dose escalation) Cohort # subjects CNTO 95 Bevacizumab~* 2 3-6 2.5 mg/kg IV Q3 weeks 7.5 mg/kg IV Q3 weeks~* 1 3-6 2.5 mg/kg IV Q3 weeks 15 mg/kg IV Q3 weeks~  1. 3-6 5 mg/kg IV Q3weeks 15 mg/kg IV Q3 weeks~ 2. 3-6 10 mg/kg IV Q3 weeks 15 mg/kg IV Q3 weeks STAGE 2 (Biomarker) Cohort # subjects CNTO 95 Bevacizumab~ 3. 20 Recommended Phase II Dose Recommended Phase II Dose"
223660496|NCT05587686|OTHER|VentilO application|"This educational application provides clinicians with combinations of tidal volume and respiratory rate based on gender, height, weight, body temperature and patient type. The algorithm used is based on published data regarding ventilatory requirements in different populations (i.e. from intubated patients for scheduled surgery to the most severe ICU patients) and anatomical and instrumental dead space.~The objective of this application is to help implement personalized protective ventilation in intubated patients according to their characteristics.~After patient data entry in the VentilO appllication we will compare the recommended settings (for mechanical ventilation) vs the real clinicial settings done by clinician after patient intubation.We will evaluated the potential effect of the VentilO recommendation on the first arterial (or capillary) blood gases compared to the real settings."
223660497|NCT04514380|OTHER|Carbohydrate fluid|400 mL carbohydrate fluid
223660498|NCT04514380|OTHER|Non-carbohydrate fluid|0 mL carbohydrate fluid
223660499|NCT05028244|DIAGNOSTIC_TEST|venous ultrasound of lower extremity|Patients are explored for deep vein thrombosis in femoral-popliteal and distal veins of the legs with ultrasound compression and doppler flow evaluation
223660500|NCT02400983|DEVICE|Pacemaker, ICD|
223660501|NCT04519242|PROCEDURE|Surgery|"ORIF will be done by using bridge plate (variable angle locking plate and/or locking plate and/or dynamic compression plate - 3.5mm, 2.7mm or 2.4mm) and/or transarticular screw osteosynthesis (4.0mm cannulated screws and/or solid small fragment screws and/or HCS). For fixation TMT4 and/or TMT5 K-wires (1.6 or 2.0mm) can be used instead.~PA will be done by removal of articular surface and subsequent stabilization with bridge plate (variable angle locking plate and/or locking plate and/or dynamic compression plate - 3.5mm, 2.7mm or 2.4mm) and/or transarticular screw osteosynthesis (4.0mm cannulated screws and/or solid small fragment screws and/or HCS).~Type and sequence of fixation of the involved rays as needed, partial or complete fixation as needed, judgement by treating surgeon."
223660502|NCT02465424|OTHER|quality of life questionnaires|Randomised allocation of 4 validated quality of life questionnaires followed by study specific overview questionnaire
223660503|NCT05861713|DRUG|Hydrating Cream|The experimental group will apply the Hydrating Cream to the affected skin area at least twice daily with a cotton swab, while the other limb was the control group.
223660504|NCT05950386|OTHER|Lead exposure|The lead-acid battery factory workers will exposure to lead via Inhalation of lead particles, ingestion of lead-contaminated dust and water.
223660505|NCT03123406|DRUG|Cinacalcet HCl|Administer Cinacalcet HCL to all subjects from 1st to 32nd week. Subjects choose to buy and take Cinacalcet HCL in real-world period from 33rd to 52nd week.
223660506|NCT02410343|DRUG|TV-1106|A starting dose of 5.0 mg was expected to be appropriate for most patients because the daily recommended starting dose of recombinant human growth hormone (rhGH) treatments (e.g. somatropin) is 0.2 mg/day, and the conversion factor was 28. Dosage could be titrated by an unblinded central reader on weeks 4, 8, 12 and 16 until the participant's insulin-like growth factor 1 (IGF-1) standard deviation score (SDS) was within the range of -0.5 to +1.5.
223660507|NCT02410343|DRUG|Placebo|Placebo treatment was administered in a blinded fashion and titrated on weeks 4, 8, 12 and 16 to mimic the active treatment.
223660508|NCT00799214|DRUG|Placebo|1 gram emollient cream to be inserted intravaginally qhs (once before bed) for 10 days or less if intolerable side effects occur.
223660509|NCT00799214|DRUG|Boric acid|Boric acid = 600 mg boric acid compounded in emollient cream (1 gram total) to be inserted intravaginally qhs (once before bed) for 10 days or less if intolerable side effects occur.
223660510|NCT00799214|DRUG|Metronidazole|Metronidazole = 10 % intravaginal cream (Sanofi-Aventis Canada Inc Product DIN 01926861) (for a total of 37.5 mg metronidazole) to be inserted intravaginally qhs (once before bed) for 10 days or less if intolerable side effects occur.
223660511|NCT04006275|DRUG|Sonovue and Sonazoid|"Subjects were randomized to receive SonoVue firstly and Sonazid secondly after wash out period. Between the wash out period(at least 30min) and after whole trial, the patients was carefully observed at our department for at least 30min.~contast agent dose: Sonazoid (0.12 μL/kg of perflubutane microbubbles) or SonoVue (2.4 mL) in a 1:1 ratio."
223660512|NCT04006275|DRUG|Sonazoid and Sonovue|"Subjects were randomized to receive Sonazoid firstly and SonoVue secondly after wash out period. Between the wash out period(at least 30min) and after whole trial, the patients was carefully observed at our department for at least 30min.~contast agent dose: Sonazoid (0.12 μL/kg of perflubutane microbubbles) or SonoVue (2.4 mL) in a 1:1 ratio."
224321222|NCT00611546|OTHER|Photo-protection|Parenteral solutions are protected from day light using aluminum covers
224241317|NCT00527800|DRUG|Artemether-lumefantrine|Dosed twice daily for 3 days, given in fixed dose tablets (20 mg artemether + 120 mg lumefantrine) according to weight-based guidelines
224241318|NCT00527800|DRUG|Trimethoprim-sulfamethoxazole|Once daily dosing according to weight based guidelines
224241319|NCT04682002|OTHER|Osteopathic manipulative treatment|"OMT will be used to treat pregnancy women after having performed a manual osteopathic assessment. The first osteopathic evaluation is carried out during the 12th week, with the possibility to undertake a personalized treatment built on the needs of the single patient; the chosen techniques are based on the collected data by the operator. A black-box type of treatment is undertaken."
224241320|NCT04682002|OTHER|Usual care|Administration of routine care based on international guidelines
224241321|NCT04682002|OTHER|Mindfulness|Mindfulness group weekly meetings. Mindfulness practices consist of cognitive and behavioral treatments for depression and anxiety, including mindfulness-based stress reduction and mindfulness-based cognitive therapy.
224241322|NCT04682002|OTHER|Yoga|Weekly yoga group meetings. Yoga is a mind-body practice that encompasses a system of postures, deep breathing, and meditation. In this context, yoga practice is adapted to pregnancy with the aim of benefit women who suffer from anxiety, depression, stress, low back pain, and sleep disturbances.
224321223|NCT00611546|OTHER|Photo-exposure|Perenteral nutrition bottles and tubings are allowed to be exposed to day light.
224321224|NCT05376644|DRUG|99mTc-ADAPT6|One single injection of 99mTc-ADAPT6, followed by gamma camera imaging 2 hours after injection.
224321225|NCT05376644|DRUG|99mTc-DARPinG3|One single injection of 99mTc-DARPinG3, followed by gamma camera imaging 4 hours after injection.
224321226|NCT01190631|DEVICE|Acrysof IQ (SN60WF) IOL|Acrysof IQ (SN60WF) intraocular lens implanted in the capsular bag of the eye during cataract surgery. The IOL is intended for the lifetime of the patient. Unilateral (one eye only) implantation is planned.
224321227|NCT01527409|BEHAVIORAL|Tailored health partnership program|"When intervention group participate in the tailored program, they can receive various information which is related with three strategic areas (exercise, diet, and posttraumatic growth).~Three areas are based on the transtheoretical model (TTM), social cognitive theory, PRECEDE-PROCEED model, and Health behavior model.~Patients will be received tailored manual and workbook for health tele-coaching that help them to lead their healthy life.~The health tele-coaching will be operated sixteen times for 24 weeks. Intervention group will be provided three contents (exercise, diet, and posttraumatic growth) from health partners. The health partners took a certificate that is related with health, leadership and coaching.~Also, patients will be provided a workshop for leadership that is dealt with controlling their healthy life. It will be proceeded for four hours. Three hours is for the leadership, and the last one hour is for presentation of their health mission statement."
223660513|NCT00228553|DRUG|Armodafinil 100 to 250 mg/day|Armodafinil 100-250 mg: once daily in the morning for patients with obstructive sleep apnea/hypopnea syndrome (OSAHS) or narcolepsy, once daily only on nights worked for patients with shift worker sleep disorder (SWSD).
223660514|NCT05359367|DIAGNOSTIC_TEST|Observational|Laboratory movement analysis, navigated transcranial magnetic stimulation and clinical aspects of gait function and walking.
223660515|NCT02878798|DRUG|topiramate|Oral topiramate at a target dose of 50mg twice daily.
223660516|NCT02878798|OTHER|Placebo|overencapsulated placebo of identical color, shape and packaging to topiramate
223660517|NCT02720042|DEVICE|Phasix™ Mesh|A resorbable mesh prepared from poly-4-hydroxybutyrate (P4HB)
223660518|NCT05367089|DRUG|Fluconazole|"Way of administration: oral capsules. One capsule at the same day of the week.~Dosage:~As treatment for active RVVC- in the first week on day 1 one capsule 150 mg Fluconazole, on day 4 one capsule 150 mg Fluconazole and on day 7 one capsule 150 mg Fluconazole.~As prophylaxis to prevent a new RVVC episode: one capsule Fluconazol 150 mg per week for a duration of 6 months."
223660519|NCT05367089|DEVICE|L-Mesitran|"Way of administration: intra-vaginal application using an applicator.~Dosage:~As treatment for active RVVC - Single daily application (5 grams) for 1 month. As prophylaxis to prevent a new RVVC episode: Single weekly (5 grams) application for 5 months."
223660520|NCT00959725|DRUG|Infliximab (intravitreal, 2.0mg/0.05ml)|One injection of intravitreal infliximab (2.0mg/0.05ml).
224241323|NCT04682002|OTHER|Clinical nutrition|Nutritional advice to all women participating in the study at 12 weeks of pregnancy, with the possibility of starting an individualized path.
224241324|NCT04682002|OTHER|Coaching|There will be five personalized coaching sessions during the pregnancy.
224241325|NCT04449484|DRUG|MEDI1341|Intravenous infusion over 60 minutes
223660521|NCT03834272|COMBINATION_PRODUCT|LUM Imaging System|Patients will be injected with one of 3 study doses of LUM015 and tissue will be imaged in vivo with the LUM imaging device. Some patients may be imaged with an additional imaging device.
224241326|NCT04449484|OTHER|Placebo|Intravenous infusion over 60 minutes
224241327|NCT00166842|DRUG|sirolimus, cyclosporine, tacrolimus|
224241328|NCT01909869|DEVICE|EXCEL-Ⅱ|A PILOT First-In-Man Study to evaluate safety and efficacy of the EXCEL-Ⅱ with New Cobalt ChRomium Alloys Sirolimus Eluting BioDegradable Polymer Stent In the Treatment of Patients with de novo Coronary Artery Lesions
224241329|NCT04099888|DRUG|Fimaporfin and Gemcitabine|PCI treatment consists of IV administration of Amphinex solution for injection (investigational product) at 0.22 mg/kg dose of fimaporfin, followed 4 days later by a standard dose of gemcitabine infusion (1000 mg/m²) and intraluminal laser light application. Up to 2 PCI treatments will be given.
224241330|NCT04099888|DRUG|Gemcitabine/Cisplatin chemotherapy|Up to 8 cycles of gemcitabine/cisplatin combination chemotherapy will be administered.
224241331|NCT04095871|OTHER|Observational study|No intervention, patients record the time of CISC
224241332|NCT06235398|BIOLOGICAL|Hematopoietic stem-cell transplantation|Upfront related donor transplantation
224241333|NCT04538170|BEHAVIORAL|pain after surgery|
224241334|NCT05739045|DRUG|nivolumab combined with SOX|nivolumab + SOX (3 cycles) before surgery → radical surgery (D2) → nivolumab + SOX (3 cycles) after surgery → nivolumab monotherapy maintenance (11 cycles);
224241335|NCT01373970|DRUG|Placebo|Placebo, one tablet daily for 12 weeks
223660522|NCT03572608|OTHER|Acupuncture treatment|Classical acupuncture points will be used without a formal traditional Chinese medicine diagnosis in the intervention group. Neither manual needle stimulation nor moxibustion will used. The needles will left in place for 30 min and de qi was not sought. The points will be selected bilateral Heart-7, bilateral Large Intestine-4, Governing Vessel-20 and ear shenmen for the first session. Bilateral Conception Vessel-3,4,6, bilateral Liver-3, bilateral Stomach-30, bilateral Spleen-6, bilateral Governing Vessel-20 will be used for the second session. Bilateral Large Intestine-4, bilateral Spleen-6,9, bilateral Stomach-36 will be used for the last session. All acupuncture points will be selected and localized on the basis of the WHO Standardised Acupuncture Point Location.
224241336|NCT01373970|DRUG|Pantoprazole + Placebo|Pantoprazole 40 mg, one tablet daily in eight weeks followed by a blinded cross over to placebo, one tablet daily for four weeks
224241337|NCT06261853|RADIATION|3D-CBCT|CBCT provides a three-dimensional image of the hard tissue structures and their anatomical relationships such as the root of the wisdom tooth and the inferior dental canal. CBCT radiation doses are typically in the range of 60 microSv.
224241338|NCT06261853|RADIATION|2D-OPG|An OPG provides a two-dimensional image of the hard tissue structures and their anatomical relationships such as the root of the wisdom tooth and the inferior dental canal. OPG radiation doses are typically in the range of 20 microSv.
224241339|NCT03213886|DRUG|Calcifediol (Vitamin D)|"After surgical treatment, participants with vitamin D deficiency (25OHD \< 30 ng/mL) will be randomly allocated to an intervention group or control group.~For the intervention group, participants will receive 16. 000 U oral Calcifediol daily for 5 days.~For the control group, participants will receive 16.000 U oral Calcifediol weekly for 5 weeks.~Both groups:~1. Will follow the usual hip fracture rehabilitation pathway.~2. 25OHD serum levels will be measured after 4 weeks. Depending on the serum 25OHD level, the patients will receive different vitamin D strategies (according to the protocol) Patients will be monitored for up to 12 months after the discharge from the hospital, with 3 clinic visits at 3, 6 and 12 months (to determine serum vitamin D levels and to evaluate functional status)"
224241340|NCT00144625|DRUG|MRA(Tocilizumab)|8mg/kg/4weeks
224241341|NCT02529280|BEHAVIORAL|Intervention|Intervention includes 1) a 30-minute computer-based video (in English/Spanish), featuring instructional screens, graphics and animation to help participants understand the concepts presented. It will feature breast cancer patients who have participated in CTs, patients talking to their doctor or nurse and a bilingual narrator to guide participants. Video content will address common barriers and concerns regarding clinical trials, as well as the informed consent process, and how clinical trials are monitored and reviewed; 2) a bilingual easy to understand booklet with tailored information on clinical trials. The booklet will include many of the elements and messages featured in the video program; and 3) assistance from a trained, bilingual, bicultural, nurse navigator.
224241342|NCT00637299|OTHER|Active osteopathic treatment (OMT+PR): Active Comparator|The treatment was done once a week for 4 weeks and lasted 30 minutes.The examination was done according to the following scheme: anamnesis; physical examination (evaluation of the posture, palpation, tests for passive and active motion of areas linked to altered respiratory function); cranic-sacral evaluation (by means of a palpation of the cranic-sacral mechanism).
224241343|NCT00637299|OTHER|sham osteopathic treatment (SOT+PR)|Only soft manipulation was performed
224241344|NCT02850770|BEHAVIORAL|Pedometers and Walking Logs|Participants were recommended to use the pedometer and walking log to self-monitor how many steps participants walked each day. Participants were recommended to gradually increase daily steps over the course of 12 weeks until reaching 10,000 steps per day. Participants were also recommended to walk at a brisk pace for 3000 of these steps, which roughly translates to 30 minutes per day.
224241345|NCT02850770|BEHAVIORAL|Phone Messaging|Participants received short text or voice messages (depending on participant preference) as reminders to review daily step goals and to self-monitor; explaining the benefits of regular physical activity, importance of regular physical activity to daily life, and ways to overcome commonly identified barriers to physical activity; asking participants to report on their physical activity performance; providing feedback based on responses.
224241346|NCT02850770|BEHAVIORAL|Family/Friend Support|Participants identified a family member or close friend (FF) to receive short text or voice messages (depending on FF preference) with suggested behaviors that are perceived as supportive by individuals making physical activity behavior changes.
224241347|NCT01357278|PROCEDURE|Rehabilitation and patient education|"Supervised rehabilitation consists of exercises for strength, balance and coordination twice weekly, and a home-training programme once weekly.~Patient education will be offered every eight week."
223660523|NCT00029770|PROCEDURE|Chiropractic spinal manipulation|
223660524|NCT00029770|DRUG|Acetaminophen|
223660525|NCT00029770|BEHAVIORAL|Self-care|
223660526|NCT00029770|DRUG|Non-Steroidal anti-inflammatory drugs (NSAIDS)|
224321228|NCT01527409|BEHAVIORAL|Usual care and health education workshop|"While intervention group participate in the tailored health partnership program, control group can receive various information which is related with ten contents for health management (smoke and drinking, diet, exercise, posttraumatic growth, distress, pain, comorbidity, sleep disturbance, pain, and energy conservation). They will be provided a workshop and booklet for a health education for four hours.~Twelve month later, they will be provided the tailored health partnership program which is especially dealing with exercise, diet, and posttraumatic growth as same as the intervention group."
223660527|NCT00029770|DRUG|Tylenol with codeine|
223660528|NCT05589558|PROCEDURE|consequently performed 4 biopsy methods (TRUS-guided biopsy, cognitive, fusion and transperineal template mapping biopsy)|TRUS-guided biopsy - extensive number of biopsies taken transrectally involving peripheral and transitional zones (8-12 cores); cognitive biopsy - targeted biopsy with MRI information and TRUS guidance but without fusion technology (2-4 cores); fusion biopsy - targeted biopsy with MRI information using MRI/TRUS fusion technology (2-4 core); transperineal template mapping biopsy - systematic transperineal TRUS-guided biopsy with special template use to aid accurate placement of biopsy needles (more than 20 cores).
223660529|NCT00125528|DRUG|D-cycloserine|D-cycloserine 50 mg bid; D-cycloserine 100 mg bid; D-cycloserine 200 mg bid
223660530|NCT00125528|DRUG|placebo|placebo bid
223660531|NCT00101452|DRUG|S-adenosyl-l-methionine|1600 mg per day with possibility of increasing to 3200 mg per day at 6 weeks
223660532|NCT00101452|DRUG|Escitalopram|10 mg per day, with possibility of increasing to 20 mg/day at 6 weeks
224241348|NCT04118478|BEHAVIORAL|multi-component phased training program|The experimental group will develop a program that consists of three progressive phases with the predominance of one physical quality over the others. The first phase will have as its main objective to develop strength, through exercises with overload and in turn, it will be subdivided into 3 blocks of 3 weeks each: Neuromuscular adaptation, muscular power, muscular resistance. The second phase will have as its main objective to develop cardiorespiratory capacity through intermittent gait training and, in turn, will be subdivided into 3 blocks of 3 weeks each: Static gait, dynamic gait and dynamic gait with changes of direction. The last phase will have as its main objective to develop balance and flexibility, by strengthening the stabilizing muscles and range of motion. In turn, this phase will be subdivided into 3 blocks of 3 weeks each: Balance / static flexibility, balance / dynamic flexibility and balance / flexibility with a double task.
224241349|NCT06521983|OTHER|Whole body vibration|Whole body vibration will be applied while standing with a frequency of 30 Hz and an intensity of 2 mm by vibration machine
224241350|NCT06350656|OTHER|Clinical data collection|Post-retrieval from the medical record
224241351|NCT06350656|OTHER|Therapeutic data collection|Post-retrieval from the medical record
224241352|NCT06350656|OTHER|IntraCranial Pression (ICP) values collection|Post-retrieval of ICP values from the monitor
224241353|NCT04234100|OTHER|Orange juice rich in hesperidin and narirutin|The product is a concentrated orange juice provided by the CITRUS Department of Florida (USA: www.FloridaCitrus.org).
224241354|NCT01206153|DRUG|metformin|
224241355|NCT00936260|DRUG|alendronate|several duration of treatment
224241356|NCT01213901|PROCEDURE|Lispro insulin|Each patient will receive 2 insulin injections in the abdomen: Once using a pinch method and once using a spread method.
224241357|NCT03369860|BEHAVIORAL|Interactivity of Experimental Condition|The neurofunctional correlates of motor control will be compared between a collaborative and non-interactive condition.
224241358|NCT02400957|OTHER|Silver nanoparticles|Half of the mouth was applied silver nanoparticles. Allocation was randomized. Evaluate the effectiveness of silver nanoparticles incorporated into the primer orthodontic Transbond XT in preventing enamel demineralization adjacent to brackets.
224241359|NCT02400957|OTHER|Placebo|Half of the mouth was applied placebo. Allocation was randomized. Evaluate the effectiveness of silver nanoparticles incorporated into the primer orthodontic Transbond XT in preventing enamel demineralization adjacent to brackets.
224241360|NCT03678038|DRUG|Triamcinolone (Shincort) injection to rotator interval|via rotator interval.
224241361|NCT03678038|DRUG|Triamcinolone (Shincort) injection to posterior glenuhumeral recess|via posterior glenuhumeral recess
224241362|NCT06091007|DIETARY_SUPPLEMENT|Magnesium|Magnesium citrate of either 200mg or 400 mg will be taken by the participant with food in the morning.
224241363|NCT00274937|DRUG|Amifostine|Given subcutaneously
224241364|NCT00274937|DRUG|Cisplatin|Given IV
224241365|NCT00274937|DRUG|Fluorouracil|Given IV
224241366|NCT00274937|OTHER|Laboratory Biomarker Analysis|Correlative studies
224241367|NCT00274937|RADIATION|Radiation Therapy|Undergo radiotherapy
224241368|NCT03222817|BEHAVIORAL|HPV self-sampling|Participants will be provided with education regarding cervical cancer screening, as well as instructions regarding how to use the HPV self-sampler. Participants will also receive referrals to trans-competent healthcare providers for follow-up screening and care.
224241369|NCT03672604|DRUG|NLY01|NLY01, a PEGylated form of the anti-diabetic peptide exenatide
224241370|NCT01741844|DRUG|No intervention|This is an observational study. Etravirine 200 mg will be adminstered twice daily in patients with Acquired Immune Deficiency Syndrome (AIDS).
224241371|NCT01883271|OTHER|High intensity aerobic interval training|Supervised aerobic interval training will be performed on bicycles 4 times per week for 8 weeks. Each training session will last 40 minutes and will consist of 10-minute warm up at 70% of maximal heart rate (HRmax), four 4-minute intervals at 90% of HRmax with 3-min active recovery at 70% of HRmax and 5-minute cool down at 70% of HRmax.
224241372|NCT01883271|OTHER|Continuous moderate intensity exercise|Supervised exercise training will be performed on bicycles 4 times per week for 8 weeks. Each training session will last 47 minutes and will consist of continuous moderate intensity cycling at 70% of HRmax.
224241373|NCT02410928|DEVICE|direct laringoscopy|the vocal cords will be visualized after extubation with direct laringoscopy
224241374|NCT02410928|DEVICE|fiberoptic nasal laringoscopy|the vocal cords will be visualized after extubation with fiberoptic nasal laringoscopy
224241375|NCT02410928|DEVICE|ultrasonograph|the vocal cords will be visualized after extubation with fiberoptic ultrasonography
224241376|NCT00429234|DRUG|Dasatinib|Starting dose 70 mg by mouth daily for Week 1. Cycle is 28 days, except Cycle 1 which is 8 weeks.
223660533|NCT00101452|DRUG|Placebo|placebo capsules look like escitalopram capsules and SAMe capsules
224241377|NCT00429234|DRUG|Gemcitabine|Starting dose of 800 mg/m\^2 by vein once weekly over 30 minutes beginning Cycle 1 Day 1. All other cycles once weekly for 7 weeks on Days 8, 15, 22, 29, 36, and 43. Cycle is 28 days, except Cycle 1 which is 8 weeks.
224241378|NCT00894283|DRUG|Enoxaparin|Patients will receive enoxaparin 40mg subcutaneously twice daily during perioperative period of bariatric surgery. Patients will be encouraged to ambulate and compression stockings while in bed.
224241379|NCT00894283|DRUG|Fondaparinux|Fondaparinux 5mg subcutaneously 6 hours following surgery, fondaparinux 5mg subcutaneously once daily during hospitalization. Patients will be encouraged to ambulate and compression stockings while in bed.
224241380|NCT02030353|BEHAVIORAL|Self-regulation plus activity monitoring|Individual in-person session, digital smart scale, online intervention, and an activity monitor.
224241381|NCT02030353|BEHAVIORAL|Self-regulation|Individual in-person session, digital smart scale, and online intervention.
224321229|NCT00676260|DRUG|Pioglitazone|Pioglitazone 15 mg to 30 mg, tablets, orally, once daily for up to 10 weeks
224321230|NCT00676260|DRUG|Placebo|Pioglitazone placebo-matching tablets, orally, once daily for up to 10 weeks
224321231|NCT02088801|DEVICE|Airtraq, blade without channel for tracheal tube intubation|Intubation
224321232|NCT02088801|DEVICE|KingVision , blade without channel for tracheal tube intubation|
224321233|NCT02088801|DEVICE|A.P. Advance, blade without channel for tracheal tube intubation|
224321234|NCT02088801|DEVICE|Macintosh|
223660534|NCT06416579|OTHER|Schroth Exercise Group|Exercises will be given in lying, sitting and standing positions. In each exercise, elongation of the spine will be ensured and the person will be positioned according to the type of scoliosis. Exercises will be given progressively in supine, prone, side sitting, sitting and standing positions. In each exercise, elongation of the spine will be ensured and the person will be positioned according to the upper and lower extremities. The exercise program will be divided into 4 phases: 0-4, 5-8, 9-12, 12-24. Progress in the exercises will be made positionally by increasing the number of repetitions and the number of rotational breathing during the exercise.
223660535|NCT06416579|OTHER|Schroth Method Based Virtual Reality Group|During Schroth method-based virtual reality exercises, continuity in stabilization will be ensured by using external focus and muscular activation in positions appropriate to the Schroth method and in corrected posture. Sessions will last 40 minutes in total, including 5 minutes of warm-up, 30 minutes of balance and sports games, and 5 minutes of cool-down. Warm-up and cool-down will consist of aerobic games available in Nitendo wii. Balance games will consist of Penguin Slide, Soccer Heading, Table Tilt, Balance Bubble, Ski Slalom, Ski Jump, Tilt City and Snowboard Slalom. Among the sports games, Bowling, Boxing, Tennis and Baseball will be included in the program. Progression will be made by difficulty level and positional in all games. The exercises will be made more difficult by side sitting, side sitting on a stool, sitting position, knight position, standing, sitting on a balance ball, standing on a soft floor, on a bosu ball and moving towards the balance board.
223660536|NCT06416579|OTHER|Control Group|Participants in the control group will be placed on a waiting list for 24 weeks. Participants will not receive any exercise intervention for 24 weeks and will be able to continue their routine physical activities.
223660537|NCT02215980|DRUG|Lenalidomide|
223660538|NCT02215980|DRUG|Dexamethasone|
223660539|NCT00409370|DEVICE|SOMA safe enclosure|
223660540|NCT05368701|BEHAVIORAL|Volitional Help Sheet for self-harm|"The volitional help sheet (VHS) is a brief psychosocial intervention that significantly reduces thoughts and acts of self-harm in adults admitted to hospital following an initial episode of self-harm. It is based on IF-THEN statements that help people link critical situations to alternative appropriate responses. An example is: If I feel the urge to self-harm when I want to get relief from a terrible state of mind, then I will do something else instead of self-harming. IF-THEN statements are intended to act as automatic coping responses, especially in cases where people may feel the urge to self-harm.~The VHS has previously been successful in reducing self-harm in people recently admitted to hospital for self-harm. Recent data have also demonstrated that a web-based version of the VHS was acceptable among a large representative sample of UK adults with self-harm experiences. However, it is yet to be known whether this intervention is effective and acceptable among adolescents."
223660541|NCT05750771|DEVICE|DES|Second-generation drug-eluting stents
223660542|NCT05750771|DEVICE|DCB|Drug-coated balloon with paclitaxel as drug coating
223660543|NCT05928546|DRUG|Quercetin|"Intra-pocket application of quercetin nanoemulgel :~* After conventional periodontal treatment, the teeth were isolated by cotton rolls for intra pocket application of the gel.~* That gel was injected in periodontal pocket using syringe with blunt cannula till the gel excess exit from the pocket ."
223660544|NCT05928546|DEVICE|scaling and root planing|\- Full-mouth scaling and root planing was performed in 1-2 sessions within 2 weeks using manual scalers and curettes or ultrasonic scaler and local anesthesia was used in case of need for patient comfort.
223660545|NCT02172534|DRUG|Tiotropium bromide low|
223660546|NCT02172534|DRUG|Tiotropium bromide medium|
223769294|NCT06143475|DEVICE|FPS group|"Vibration frequency ranged from 0 to 100 Hz. There were 3 modes of FPS application during rehabilitation course. 1) anti-spasticity mode (FV): the stimulators were placed in the middle of the muscles of the affected limb (i.e. unilaterally); 2) bilateral mode of proprioceptive facilitation; and 3) the unilateral mode of the proprioceptive facilitation.~The 2 first sessions were realized with bilateral FPS stimulations plus the anti-spasticity FV mode to reduce the level of hypertonia. Then for 6 consecutive sessions unilateral FPS stimulations of the affected sides imitating the drawing of a straight lines (horizontal, vertical, diagonal), preparing for writing (drawing a circle, triangle, square, spiral) were realized. At last, the 4 remaining FPS sessions were realized unilaterally imitating and promoting the realization of everyday life activities."
224241382|NCT04606420|BEHAVIORAL|Lifestyle medicine|"Diet: A low fat (10-15%) whole foods vegan diet, high in complex carbs and low in refined carbs (fruits, vegetables, whole grains, legumes, soy, seeds \& nuts). Calories unrestricted. Multivitamin, fish oil, curcumin, vitamin C, B12, CoQ10, lion's mane, probiotic, and magnesium. 21 meals/week and supplements provided to participants and caregivers at no cost to them.~Exercise: Aerobic (e.g., walking) and strength training 30 minutes/day based on a personalized prescription from an exercise physiologist or certified personal trainer and registered nurse.~Stress Management: Meditation, gentle yoga-based poses, progressive relaxation, breathing exercises, and meditation (with optional glasses) 1 hour per day, supervised by a certified stress management specialist.~Group Support: Participants and their spouses/caregivers participate in a support group one hour/session, 3 days/week, supervised by a licensed mental health professional in a supportive, safe environment."
224241383|NCT04714307|DIAGNOSTIC_TEST|SCA3/MJD molecular diagnosis|Double-blind molecular diagnosis for determination of the presence of the mutation.
223660547|NCT02172534|DRUG|Tiotropium bromide high|
223660548|NCT02172534|DRUG|Placebo|
223660549|NCT02707263|DRUG|intravenous continuous infusion of heparin (IV UFH)|
224241384|NCT04714307|DIAGNOSTIC_TEST|Cognitive Testing|"Cross-sectional Cognitive evaluation with~* CCAS Scale~* Trail-Making Test parts A and B~* Stroop Color-Word Test"
223660550|NCT02707263|DRUG|Subcutaneous Heparin|
223660551|NCT01269242|DRUG|bindarit|300 mg bid, that is one 300 mg tablet twice a day for 6 months;
223660552|NCT01269242|DRUG|bindarit|600 mg bid, that is two 300 mg tablets twice a day for 6 months
223660553|NCT01269242|DRUG|placebo|bindarit-matching placebo tablets for 6 months.
223660554|NCT04413682|BEHAVIORAL|Structured Supervised Exercise|Structured Exercise Program under the supervision of Physical Therapist
224241385|NCT04714307|DIAGNOSTIC_TEST|Psychiatric Evaluation|Cross-sectional Psychiatric evaluation with Hamilton-Anxiety and Hamilton-Depression rating scales.
224241386|NCT04714307|DIAGNOSTIC_TEST|Clinical Neurological Evaluation|Cross-sectional neurological evaluation with standardized clinical scales - SARA, SCAFI and CCFS.
223660555|NCT04413682|BEHAVIORAL|Structured telerehabilitation|Structured Exercise Program checked and controlled through telerehabilitation
223660556|NCT05879094|OTHER|Morton extension|A Morton extension with a height of 5 mm was insert from the proximal area of the first metatarsal head to the base of the proximal phalanx of the Hallux of the subjects' bare feet using a paper bandage. The material, shape, size, and thickness of the Morton Extension were the same.
223660557|NCT03521440|BEHAVIORAL|Psychomotor Massage|Sessions will be conducted by a graduated therapist, experienced in Psychomotor Massage and weekly supervised by a specialist in this therapeutic approach. The Psychomotor Massage involves smoothly touching the head, upper and lower limbs, followed by micro-stretching and slow mobilisations of upper and lower limbs.
223660558|NCT03521440|BEHAVIORAL|Progressive Muscle Relaxation|Sessions will be conducted by a graduated therapist, experienced in Progressive Muscle Relaxation, and weekly supervised by a specialist in this therapeutic approach. The Progressive Muscle Relaxation protocol consists in tensing and releasing 16 muscle groups for several seconds, following a specific order.
223660559|NCT06327841|OTHER|sesame oil|15min of oil pulling with 15ml sesame oil for 8 weeks
223660560|NCT06327841|OTHER|distilled water|15min rinsing with 15ml distilled water for 8 weeks
223660561|NCT04828317|OTHER|Pork Challenge|Double blind oral challenges comparing wild-type and alpha-gal free pork.
223660562|NCT00263185|DIETARY_SUPPLEMENT|Vitamin D|
223660563|NCT00263185|DIETARY_SUPPLEMENT|Calcium carbonate|
223660564|NCT00263185|DRUG|Vitamin D|
223660565|NCT00263185|OTHER|Placebo|
223660566|NCT02570048|DEVICE|Mutebutton intervention|Participants are asked to use the MuteButton daily for 30-40 minutes.They receive 'pink noise' through headphones and transcutaneous stimulation on the tongue using a 'lollypop' sensor that sits on the anterior section (tip) of the tongue.
223660567|NCT01196403|OTHER|questionnaire administration|
223660568|NCT01196403|PROCEDURE|quality-of-life assessment|
223769295|NCT06143475|OTHER|Conventional therapy group|Patients received sessions of traditional physical therapy: individual therapy sessions including exercises to strengthen muscles, stretching, reflex exercises for large, medium and small muscle groups of the upper limbs (ontogeny-oriented kinesiotherapy (OOKT), PNF - proprioceptive neuro-muscle facilitation, training and practice of functional rational self-service tasks). 12 sessions in total were realized 5 times a week and lasted 40 minutes each.
223769296|NCT00806546|DRUG|NP101|NP101 study patch four hour application
223769297|NCT03234738|DRUG|TP-271|multiple oral doses of TP-271 or placebo, dosed once daily for 7 days, randomized 3:1, doses escalating as 0.5 mg/kg, 1.0 mg/kg, 2.0 mg/kg, 2.5 mg/kg, and 3.0 mg/kg
223660569|NCT01196403|PROCEDURE|robot-assisted laparoscopic surgery|
223660570|NCT01196403|PROCEDURE|therapeutic conventional surgery|
223769298|NCT03234738|DRUG|Placebo|Placebo is sterile 0.45% saline randomized 3:1 to receive
224241387|NCT04714307|DIAGNOSTIC_TEST|Emotional Attribution Evaluation|Cross-sectional emotional attribution evaluation by means of the Reading the Mind in the Eyes Test (RMET).
224241388|NCT04714307|DIAGNOSTIC_TEST|Activities of Daily Living|Cross-sectional evaluation of Activities of Daily Living (ADLs) by means of Friedreich Ataxia Rating Scale Part II.
223660571|NCT01196403|PROCEDURE|therapeutic laparoscopic surgery|
223660572|NCT06343519|DEVICE|Echocardiography|Measuring echocardiographic parameters (cardiac index, speckle tracking, tissue Doppler indices)
223660573|NCT03601884|BEHAVIORAL|Optimal Health Program|The Optimal Health Program (OHP) is a self-management psychosocial program that promotes patients to be actively involved in their own healthcare and overall well-being. Sessions include Optimal Health, I-CAN-DO Model, Medication \& Metabolic Monitoring, Collaborative \& Strategies, Change enhancement, Visioning \& Goal Setting and Maintain Well-being.
223660574|NCT03601884|OTHER|Treatment as Usual|"Treatment-as-usual TAU is the pharmacological treatment received or prescribed by the patients' attending doctor.~To ensure standardization of treatment, attending doctors will be reminded to manage patients in accordance with the Clinical practice Guideline in Managing Diabetes Melllitus in adult patients."
223660575|NCT02587377|OTHER|Non Standard of Care blood samples collection|According to Belgian Law of 07MAY2004, if non standard of care interventions are performed as per protocol, the study must be classified as Interventional Study.
223660576|NCT01333930|OTHER|Active O2|oxygenised table water containing at least 20 mg O2 per 500 ml (15-fold higher content in comparison to placebo), further excipients: natural mineral water: carbonic acid, oxygen, sodium, potassium, magnesium, calcium, fluoride, chloride, nitrate, sulfate, hydrocarbonate (according to the summary of analysis)
223660577|NCT01333930|OTHER|Adelholzener Mineralwasser|natural mineral water containing the following ingredients: carbonic acid, sodium, potassium, magnesium, calcium, fluoride, chloride, nitrate, sulphate, hydrocarbonate (according to the summary of analysis)
223660578|NCT02659397|DRUG|ETC-1002|Blinded ETC-1002 180 mg tablet once daily for 4 weeks (Weeks 1 to 4)
223660579|NCT02659397|DRUG|Atorvastatin|Atorvastatin 80 mg tablet once daily for 8 weeks (Weeks -4 to 4)
223660580|NCT02659397|DRUG|Placebo|Blinded ETC-1002-matched placebo tablet once daily for 4 weeks (Weeks 1 to 4)
223660581|NCT03753113|DRUG|Topical Herbal Solution|Use Topical Herbal Solution every day in scalp hair loss areas for 36 weeks.
223660582|NCT03753113|DRUG|Topical Minoxidil 5%|Use Minoxidil 5% solution every day in scalp hair loss areas for 36 weeks.
223660583|NCT01918748|DEVICE|Haptic Master|The Haptic Master (HM) is a haptic device controlled according to the principles of 'admittance control'. In admittance control 'force' applied to the system (i.e. the HM arm) is measured, while 'position' (of the HM arm) is the end result.
223660584|NCT04293744|DEVICE|Colloid priming solution for ECC circuit|Prospective, multi-center, double-blinded, randomized, controlled clinical trial
224241389|NCT00383656|DRUG|GnRH|75 ng/kg GnRH IV
224241390|NCT00383656|DEVICE|Pump|portable, infusion pump for GnRH
224241391|NCT03503578|DRUG|Sevoflurane|Subjects will received sevoflurane for approximately 60 minutes.
224241392|NCT03503578|DRUG|Ketamine|Subjects will received sevoflurane and ketamine for approximately 60 minutes.
224241393|NCT02337309|DRUG|SF1126|SF1126 in IV form with be given to patients on this study.
224241394|NCT01974297|DRUG|Atorvastatin 10mg, fenofibric acid 135mg|Atorvastatin 10mg, fenofibric acid 135mg/day PO for 12 weeks
224241395|NCT01974297|DRUG|atorvastatin 20mg|Atorvastatin 20mg/day PO for 12weeks
223769299|NCT04325529|DEVICE|Aversive stimuli|Electrotactile stimulation will be used as the aversive stimulus. The aversive stimulus is delivered in the form of a mild half-second stimulation to the ankle, calibrated to a subjective threshold that is uncomfortable but not painful. This stimulation is delivered by Digitimer DS8R Constant Current Stimulator (Digitimer North America, LLC. Ft. Lauderdale, FL). Its previous model DS71 has been safely implemented in studies with previously MGH-approved IRB's (Milad et al., 2013).
223660585|NCT04293744|DEVICE|Standard priming solution for ECC circuit|Prospective, multi-center, double-blinded, randomized, controlled clinical trial
223769300|NCT05878548|PROCEDURE|corrective osteotomy and intramedullary telescoping nail for deformed femur and Wagner technique to fix NOF fracture|corrective osteotomy and intramedullary telescoping nail for deformed femur and Wagner technique to fix NOF fracture
223769301|NCT02362165|DRUG|Cyclophosphamide|500mg/d,once-weekly,per oral.
223769302|NCT02362165|DRUG|Bortezomib|1.3mg/㎡,once-weekly,subcutaneous injection
223769303|NCT02362165|DRUG|Dexamethasone|40mg/d,once-weekly,per oral
223769304|NCT02362165|DRUG|Doxorubicin|9mg/㎡,d1-4
223660586|NCT01441362|PROCEDURE|90 degrees rotation|Double-lumen tube intubation with 90 degrees rotation
224241396|NCT03656783|DRUG|Biktarvy|Open-label, multicenter, single-arm study to Evaluate the Safety and Efficacy of Switching from Regimens Consisting of Abacavir/Lamivudine/Dolutegravir (ABC/3TC/DTG) to the Bictegravir/ Emtricitabine/Tenofovir Alafenamide (B/F/TAF) Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV-Infected Adult Subjects
224241397|NCT00864097|BIOLOGICAL|tanezumab|IV tanezumab 10 mg every 8 weeks (through Week 16)
224241398|NCT00864097|DRUG|diclofenac|Oral diclofenac SR 75 mg BID for 32 weeks
224241399|NCT00864097|BIOLOGICAL|tanezumab|IV tanezumab 5 mg every 8 weeks (through Week 16)
224241400|NCT00864097|DRUG|diclofenac|Oral diclofenac SR 75 mg BID for 32 weeks
224241401|NCT00864097|BIOLOGICAL|tanezumab|IV tanezumab 2.5 mg every 8 weeks (through Week 16)
224241402|NCT00864097|DRUG|diclofenac|Oral diclofenac SR 75 mg BID for 32 weeks
224241403|NCT00864097|DRUG|diclofenac|Oral diclofenac SR 75 mg BID for 32 weeks
224241404|NCT00864097|OTHER|IV placebo|IV placebo to match tanezumab every 8 weeks (through Week 16)
223660587|NCT01441362|PROCEDURE|180 degrees rotation|Double-lumen tube intubation with 180 degrees rotation
224241405|NCT03675828|BEHAVIORAL|Virtual Visit|The Cleveland Clinic Express Care Online application will be used in this intervention. The subjects will have a virtual consult with a clinician from the study team that will mirror an experience had at an outpatient post-discharge visit, including review of systems and medications.
224241406|NCT00880568|DRUG|MK-1496|MK-1496 (20 to 120 mg), orally, administered on Day 1 of each 21-day cycle
224241407|NCT00880568|DRUG|MK-1496|MK-1496 (20 to 120 mg), orally, administered on Days 1 and 3 each week for 3 weeks (Days 1, 3, 8, 10, 15 and 17) of each 28-day cycle
224241408|NCT03962673|RADIATION|NB-UVB light exposure|Participants are exposed to three low dose Narrow Band UVB light.
223660588|NCT01764139|PROCEDURE|Blood sampling|
223660589|NCT05591235|DRUG|Metformin|After the screening period, eligible subjects took the hyperinsulinemic euglycemic clamp test and were then admitted to insulin with metformin for 4 weeks. During this timeframe, all patients were instructed to change the insulin pump infusion site and provide one profile of 7-point self-monitored blood glucose every three days. The insulin doses were titrated every day by physicians to achieve the glycemic goal. Participants who failed to attain the glycemic target in three consecutive times or could not afford the side effects of hypoglycemic medications were excluded from this study. On the last day of week 4, a FreeStyle Libre Pro Sensor (FGM system) was inserted to record the glycemic data for up to 14 days. At the end of week 5, all antidiabetic agents were stopped and the hyperinsulinemic euglycemic clamp test was performed again for remaining subjects.
223769305|NCT00423969|DRUG|Galantamine|
223769306|NCT00423969|DRUG|Escitalopram|
223769307|NCT00758511|PROCEDURE|25% Sucrose|orally administrated 25%Sucrose before, during and after heel stick
223769308|NCT00758511|PROCEDURE|facilitated tucking|facilitated tucking before, during and after heel stick
223769309|NCT00758511|PROCEDURE|Sucrose and facilitated tucking|orally administrated 25%sucrose and facilitated tucking before, during and after heel stick
223769310|NCT01703637|DRUG|Sitagliptin|"* before breakfast：a tablet of sitagliptin; a tablet of vildagliptin's dummy; a tablet of saxagliptin's dummy~* before dinner：a tablet of sitagliptin's dummy; a tablet of vildagliptin's dummy; a tablet of saxagliptin's dummy"
223769311|NCT01703637|DRUG|Vildagliptin|"* before breakfast：a tablet of vildagliptin; a tablet of sitagliptin's dummy; a tablet of saxagliptin's dummy~* before dinner：a tablet of vildagliptin; a tablet of sitagliptin's dummy; a tablet of saxagliptin's dummy"
223769312|NCT01703637|DRUG|Saxagliptin|"* before breakfast：a tablet of saxagliptin; a tablet of vildagliptin's dummy; a tablet of sitagliptin's dummy~* before dinner：a tablet of saxagliptin's dummy; a tablet of vildagliptin's dummy; a tablet of sitagliptin's dummy"
224241409|NCT05194839|DRUG|RIST4721|RIST4721 tablets, 100 mg are blue, oval, biconvex film-coated tablets
224241410|NCT05194839|DRUG|Placebo|Matching placebo
224241411|NCT02700750|DEVICE|OCT exam|OCT exam
224241412|NCT04135027|OTHER|no interventions|no interventions
224241413|NCT01470482|PROCEDURE|No use of tourniquet|Tourniquet is not applied i 25 pts
224241414|NCT01470482|PROCEDURE|Tourniquet|Use of tourniquet
224241415|NCT00233194|PROCEDURE|Observational follow-up study of adenotonsillectomy|Studies of sleep, behavior, cognition, and daytime sleepiness
224241416|NCT02911662|DRUG|Cephalexin|Cephalexin will be prescribed for women with a positive urine culture but no symptoms of urinary tract infection.
224241417|NCT02911662|DRUG|Nitrofurantoin|Macrobid will be prescribed for women allergic to penicillin with a positive urine culture but no symptoms of urinary tract infection.
224241418|NCT02775565|DEVICE|AngioVac|
224321235|NCT03545204|OTHER|Kangaroo Mother Care Package|"The KMC package will include creation of KMC Champions from within the community, social mobilization to create awareness and its acceptance with families using powerful IEC tools such as docudrama, flip charts, pictorials in local languages; engagement of community and community leaders, capacity building of health care providers on Kangaroo mother care, essential newborn care ENC, policy dialogues with stake holders in the public and private sectors and delivery of a KMC kit  to the pregnant female by the Implementation team"
223660590|NCT05591235|DRUG|Dapagliflozin|After the screening period, eligible subjects took the hyperinsulinemic euglycemic clamp test and were then admitted to insulin with dapagliflozin (100mg one day) for 4 weeks. During this timeframe, all patients were instructed to change the insulin pump infusion site and provide one profile of 7-point self-monitored blood glucose every three days. The insulin doses were titrated every day by physicians to achieve the glycemic goal. Participants who failed to attain the glycemic target in three consecutive times or could not afford the side effects of hypoglycemic medications were excluded from this study. On the last day of week 4, a FreeStyle Libre Pro Sensor (FGM system) was inserted to record the glycemic data for up to 14 days. At the end of week 5, all antidiabetic agents were stopped and the hyperinsulinemic euglycemic clamp test was performed again for remaining subjects.
223660591|NCT05591235|DRUG|Fixed-dose combination of metformin and pioglitazone (500mg metformin plus 15mg pioglitazone)|After the screening period, eligible subjects took the hyperinsulinemic euglycemic clamp test and were then admitted to insulin with fixed-dose combination of metformin and pioglitazone (two tablets of 500mg metformin plus 15mg pioglitazone) for 4 weeks. During this timeframe, all patients were instructed to change the insulin pump infusion site and provide one profile of 7-point self-monitored blood glucose every three days. The insulin doses were titrated every day by physicians to achieve the glycemic goal. Participants who failed to attain the glycemic target in three consecutive times or could not afford the side effects of hypoglycemic medications were excluded from this study. On the last day of week 4, a FreeStyle Libre Pro Sensor (FGM system) was inserted to record the glycemic data for up to 14 days. At the end of week 5, all antidiabetic agents were stopped and the hyperinsulinemic euglycemic clamp test was performed again for remaining subjects.
223660592|NCT02586779|OTHER|whatsApp|whatsApp application will be used for consultations.
223660593|NCT02586779|OTHER|without whatsApp|whatsApp application will be not used for consultations.
223660594|NCT01516034|DEVICE|Cupola Tattoo Removal device|Up to 6 treatments with the device every 2-3 weeks to the tattoo area.
223660595|NCT03485300|DIAGNOSTIC_TEST|Liver and kidney function tests for patients with chronic liver or kidney diseases|Tests will be done to patients with history suggestive of chronic liver or renal diseases or for patients clinically suspected
223660596|NCT03485300|BEHAVIORAL|Non compliance of the patient|I will order all my patients to take the drug at 10 am and assure the daily in taking of the dose and they will be followed up
223660597|NCT03485300|DRUG|Drug or food interactions|The patient will be in contact with the researcher for any drug added with warfarin in case of other co morbidity conditions and follow up his/her CBC and INR for measuring its effect on warfarin finding out the effect of food on warfarin therapeutic outcome
223660598|NCT03149744|DEVICE|RespiraSense Sleep Screener|RespiraSense will be worn at the same time as the standard of care SomnoScreen and it's results will be masked to the site team
223660599|NCT03048513|OTHER|Patient who presented with melioidosis in head and neck|Investigators assess the patients who had the pus culture positive with Burkholderia pseudomallei.
223660600|NCT03562988|DIETARY_SUPPLEMENT|Vitamin C gummy|vitamin C
224241419|NCT00890526|OTHER|Sound Therapy (Tinnitus Retraining Therapy)|The conventional sound therapy will be achieved with commercially available noise generators. Our clinic uses General Hearing Instruments (OHI) model Tranquil devices as noise sources for TRT. These flexible devices offer an adjustable volume control, with a frequency response extending from \~500 to 8000 Hz. Matched devices will be fitted binaurally and adjusted to each individual ear to achieve audibility of the noise sources (assessed by slight threshold shifts. typically 10- 15 dB, across the audiometric frequency range above 500 Hz). The sound pressure level output and frequency response of each noise source will be measured and documented using both real ear and standard electroacoustic methodologies. Each subject will be carefully instructed as to care of the instruments and correct volume setting. The bilateral noise generators will be used chronically during the intervention period except during sleep.
224241420|NCT00890526|OTHER|Counseling (Tinnitus Retraining Therapy)|The directive counseling to be used will include an in-depth participatory discussion with the patient to review audiometric and functional test results, along with the anatomy and physiology of the auditory system. A minimum of two hours will be scheduled to impart this information to the patients so that they will have a clear understanding of the disorder based upon the most current scientific data. The counseling will be focused on educating the patient, neutralizing their negative emotional association with the hyperacusis, and discussing their treatment.
224241421|NCT00890526|OTHER|No Counseling|Patients who are enrolled in Arms 3 and 4 of this study will not be offered directive counseling, but will be fitted with either conventional or placebo noise generators for their sound therapy components. These patients will be told only that their treatment for hyperacusis uses sound therapy. Otherwise, in the instrument fitting appointment (either for the conventional instrument or the placebo device), these patients will receive the same instruction in the care and use of sound generators as those patients enrolled in Treatment Arms 1 and 2 of the clinical trial.
223660601|NCT03562988|DIETARY_SUPPLEMENT|Vitamin C tablet|vitamin C
223660602|NCT00464971|DRUG|estradiol, 25 mcg|
223660603|NCT01924416|BEHAVIORAL|Enhanced Care (intervention group and comparison group)|Decision aid coupled with immediate QL-PRO results
223660604|NCT01924416|BEHAVIORAL|Usual care (routine chemotherapy cycles and imaging studies)|Usual care does not receive intervention
223660605|NCT00538811|DRUG|interferon alpha-2b, ribavirin, interferon-gamma,|
223660606|NCT00538811|DRUG|interferon alpha-2b, ribavirin, amantadine|
224241422|NCT00890526|OTHER|Placebo Sound Therapy|The placebo sound therapy will use factory-modified GHI Tranquil noise generators, which will appear identical to the conventional Tranquil devices. The placebo Tranquil devices will have a control sensor installed to detect insertion of the device in the ear canal. When the sensor detects the insertion of the placebo device into the ear canal it will trigger gradual decay of the sound output from the placebo device, The time constant of the decaying noise output will be sufficiently long to allow the clinician time to set the volume of each binaural set of devices and to instruct the patient in their use before any noticeable sound attenuation occurs.
224241423|NCT05286957|DRUG|adjuvant tislelizumab and chemotherapy for MRD+ patients|"MRD+ patients receive adjuvant tislelizumab and chemotherapy while MRD- patients just is recommended receive adjuvant chemotherapy untill be detected MRD+~adjuvant tislelizumab and chemotherapy (cisplatin/carboplatin + paclitaxel or cisplatin/carboplatin + pemetrexed,dependent on tumor histology and at investigator's discretion)"
224321236|NCT03545204|OTHER|Routine Standard Care|Routine Standard Care ( essential Newborn care )ENC
223660607|NCT02106819|BEHAVIORAL|Testing of emotional communication ability|Assessment of comprehension and expression of emotional facial and prosodic expressions and assessment of emotional reactivity via ratings of emotionally evocative pictures and words.
223660608|NCT02106819|PROCEDURE|magnetic resonance imaging (MRI) of the brain|Cerebellar participants who score at least 1 and a 1/2 standard deviations below the mean on the Florida Affect Battery and who have no contra-indications to scanning will be given an MRI. Healthy control participants who are willing and able to be scanned will also be given an MRI of the brain to use for analysis comparison.
223660609|NCT02897570|DIETARY_SUPPLEMENT|Glucose|50g of glucose dissolved in 250 to 300ml of water was drunk. Prior and upon completion of each glucose tolerance test, an EEG was performed.
223660610|NCT02897570|DIETARY_SUPPLEMENT|Milk & Cereals|A breakfast (B1) including a glass of milk (125ml) and 30 g-corn flakes was consumed. Prior and upon completion of each tolerance test, an EEG was performed
223660611|NCT02897570|DIETARY_SUPPLEMENT|Milk, apple & snack|A breakfast (B2) including a glass of milk (220ml), an apple (200g), a cream chocolate filled sponge cake (30g) was consumed. Prior and upon completion of each meal tolerance test, an EEG was performed.
223660612|NCT02897570|DIETARY_SUPPLEMENT|Milk, apple & bread w/ cream|A breakfast (B3) including a glass of milk (125ml), an apple (150g), bread (50g, hazelnut chocolate cream (15g) was consumed. Prior and upon completion of each meal tolerance test, an EEG was performed.
223660613|NCT02897570|DEVICE|EEG_pre|Electroencephalography (EEG) was performed prior each tolerance test to assess frontal P300-evoked potentials
223660614|NCT02897570|DEVICE|EEG_post|Electroencephalography (EEG) was performed upon completion of each tolerance test to assess frontal P300-evoked potentials
223660615|NCT01142804|BEHAVIORAL|Group|Walking programs with various levels of support will be administered to determine which one is most effective.
223660616|NCT03407716|DRUG|American Ginseng|Given PO
223660617|NCT03407716|OTHER|Laboratory Biomarker Analysis|Correlative studies
223660618|NCT03407716|OTHER|Placebo|Given PO
223660619|NCT03407716|OTHER|Questionnaire Administration|Correlative studies
223660620|NCT03229694|DRUG|Tracleer 125Mg Tablet|Tracleer was administered orally at two hours before surgery and six hours after surgery.
223660621|NCT03229694|DRUG|Placebo|Placebo was administered orally at two hour before surgery and six hours after surgery.
223660622|NCT05571332|DRUG|Avatrombopag 20 MG Oral Tablet|p-ATG and CsA in combination with Avatrombopag to treat
223660623|NCT03028519|DRUG|Vitamin D3|Vitamin D3
223660624|NCT02496052|PROCEDURE|dried biological amnion graft|Uterine application of amnion membrane following hysteroscopic adhesiolysis. Other Name: Human amnion membrane
223660625|NCT02496052|DEVICE|Foley balloon|Device: Foley balloon Uterine application of Foley balloon
223660626|NCT02496052|DRUG|estradiol valerate tablets+dydrogesterone Tablets|oral estradiol valerate tablets+dydrogesterone Tablets
223660627|NCT01254760|DEVICE|Nelfilcon A multifocal contact lens, investigational|Investigational, soft, multifocal contact lens for daily wear, daily disposable use.
223660628|NCT01254760|DEVICE|Nelfilcon A multifocal contact lens, commercial|Commercially marketed, soft, multifocal contact lens FDA-approved for daily wear, daily disposable use.
223660629|NCT02182388|DRUG|Placebo|
223660630|NCT02182388|DRUG|BI 207127 NA powder for solution|
224241424|NCT05286957|DRUG|adjuvant tislelizumab and chemotherapy for MRD+ patients|patients receive adjuvant tislelizumab and chemotherapy regardless of MRD status
224241425|NCT05286957|DRUG|adjuvant chemotherapy for MRD- patients|MRD- patients just be recommended receive adjuvant chemotherapy untill be detected cisplatin/carboplatin + paclitaxel or cisplatin/carboplatin + pemetrexed,dependent on tumor histology and at investigator's discretion, limited to ≤4 cycles
223660631|NCT02182388|DRUG|BI 207127 NA tablet|
223660632|NCT03196362|DRUG|Pioglitazone + Metformin|One tablet of fixed dose of Pioglitazone/ Metformin (15mg/30mg) will be given twice daily
223660633|NCT03196362|DRUG|Placebo Oral Tablet|One tablet of placebo will be given twice daily
223660634|NCT00351858|DRUG|ertumaxomab|
223660635|NCT01892839|OTHER|low dialysate flow, smaller dialyzer|The subject will receive dialysis on the usual schedule and for the usual time but with a lower than usual dialysate flow and small dialyzer.
223660636|NCT01892839|OTHER|high dialysate flow, larger dialyzer|The subject will receive dialysis on the usual schedule and for the usual time but with a higher than usual dialysate flow and large dialyzer.
223660637|NCT02024789|DRUG|Placebo|Orally twice daily, 26 weeks
223660638|NCT02024789|DRUG|RG1662|120 mg (80 mg for subjects 12 and 13 years of age) orally twice daily, 26 weeks
223660639|NCT02024789|DRUG|RG1662|240 mg (160 mg for subjects 12 and 13 years of age) orally twice daily, 26 weeks
223660640|NCT05917873|DIETARY_SUPPLEMENT|LaKe Ester|Lactate and ketone body ester (one equivalent of S-lactate and one equivalent of 1,3-butanediol / D-β-hydroxybutyrate)
223660641|NCT05917873|DIETARY_SUPPLEMENT|Placebo|Taste and appearance matched noncaloric placebo
223660642|NCT01983410|BEHAVIORAL|The risk assessment questionnaire|
223660643|NCT01983410|OTHER|Blood specimens|
223660644|NCT01983410|OTHER|tumor tissue samples will be requested|
223660645|NCT05477108|DRUG|Treatment A (BGF MDI HFO with oral activated charcoal)|Subject will receive 4 inhalations as a single dose with oral activated charcoal - test formulation; administered during 1 Treatment Period.
223660646|NCT05477108|DRUG|Treatment B (BGF MDI HFA with oral activated charcoal)|Subject will received 4 inhalations as a single dose with oral activated charcoal - reference formulation; administered during 2 Treatment Periods.
223660647|NCT05854914|PROCEDURE|Use of hypnosis videos|Hypnosis on smartphone will be used to manage pain for emergent coelioscopy surgery of patients with acute and complicated appendicitis, with generalized peritonitis
223660648|NCT06054659|DEVICE|Real Time Continuous Glucose Monitoring (rt-CGM)|Participants randomized to rt-CGM will have CGM placed before hospital discharge. They will also receive teaching from the research team on the proper use of their CGM sensor and reader. The study team will provide CGM devices, but subjects may use their glucometer for FBG testing as needed for CGM calibration.
223660649|NCT06054659|OTHER|Fingerstick blood glucose (FBG) monitoring|Participants will use their own glucometer for FBG testing as advised by their treating provider (usually primary care or diabetes doctor).
224241426|NCT00890422|BIOLOGICAL|FSME vaccination (FSME-Immun)|intra muscular 0.5 ml
223660650|NCT06054659|BEHAVIORAL|Diabetes Education|Participants will receive standard-of-care diabetes education with a certified diabetes educator (CDE) prior to discharge (with the approval of the treating inpatient team).
223660651|NCT02660983|DRUG|Donepezil hydrochloride|
223660652|NCT02660983|DRUG|Donepezil matching placebo|
223660653|NCT02660983|DRUG|Donepezil hydrochloride|
223660654|NCT05210777|DEVICE|observation|no intervention
223660655|NCT05489133|BEHAVIORAL|Modified prolonged exposure|Imaginary and in vivo expo, in addition to psychoeducation
223660656|NCT04462770|DRUG|Clemizole HCl|Clemizole HCl will be administered as an oral solution.
223660657|NCT04462770|DRUG|Placebo|Placebo will be administered as an oral solution.
223660658|NCT03814304|OTHER|Personalized tDCS|The participant will receive 20, 20-minute sessions of personalized tDCS on Monday-Friday, at approximately the same time of day, over four consecutive weeks.
223769313|NCT04561401|DEVICE|Repeated Transcranial Magnetic Stimulation (rTMS)|rTMS will be applied at 10 Hz. Each train will consist of 40 supra threshold (120% resting motor threshold) pulses over 4 seconds with an inter-train interval of 26 seconds. Treatment sessions will last 37.5 minutes (75 trains/3,000 pulses), and occur at the same time of day on every weekday for a period of three weeks (15 days total). During TMS, only passive activities will be allowed (i.e., watching movies or TV, listening to music). Three weeks of treatment was selected based on existing rTMS evidence in youth with treatment resistant major depressive disorder.
223769314|NCT04561401|OTHER|Intensive Pain Rehabilitation Program (IPRP)|The paediatric Intensive Pain Rehabilitation Program (IPRP) in Canada was established to target youth with severe chronic pain and consequent functional disability who do not respond to standard outpatient pain therapies. The IPRP at the Alberta Children's Hospital (ACH) involves three- to six-weeks of day-treatment rehabilitation, provided by an interdisciplinary team (e.g. Psychology, Physiotherapy, Family Therapy). This rehabilitative program teaches self-management strategies with the goal of helping youth and their families resume normal daily functioning.
223769315|NCT05508412|BEHAVIORAL|CancerPEP|CancerPEP
223769316|NCT02751983|BEHAVIORAL|ACT for Life|A novel protocol detailing the application of Acceptance and Commitment Therapy (ACT) to recovery from suicidal crises. Consists of three modules designed to be delivered in three to four 60-minute individual talk therapy sessions. Nearly all of the metaphors and experiential exercises are adaptations of core ACT techniques included in various empirically-supported applications of ACT to other health conditions. Additionally, the adjunctive intervention is designed to augment safety planning (a hierarchical list of strategies to recognize and cope with a suicidal crisis).
224241427|NCT03682263|BEHAVIORAL|Full Service|Receive Individual Placement and Support (IPS) model of employment services, behavioral health services, care management services, and Medication Management Support provided by a Nurse Care Coordinator (NCC).
224241428|NCT03682263|BEHAVIORAL|Basic Service|Receive Individual Placement and Support (IPS) model of employment services, behavioral health services, and care management services.
224241429|NCT04463602|DRUG|Desidustat|100 mg once daily
224241430|NCT04463602|OTHER|Standard of Care|Standard of care as per local authority
224241431|NCT05342285|DIAGNOSTIC_TEST|Flow mediated dilation|flow mediated dilation in brachial artery
224241432|NCT03156062|DRUG|Topical corticosteroids with salicylic acid|comparison between climatotherapy and topical combination of corticosteroids and salicylic acid in treatment of psoriasis
224241433|NCT06354166|PROCEDURE|Unscheduled hospital admissions|Unscheduled short-stay geriatric hospitalisations of people aged over 75 to their homes
224241434|NCT00527657|DRUG|Lomustine|Starting dose 30 mg/m\^2 by mouth daily on Day 1 and 29.
224241435|NCT00527657|DRUG|Temozolomide|75 mg/m\^2 by mouth daily on Days 1 to 42.
224241436|NCT00527657|DRUG|Thalidomide|200 mg/m\^2 by mouth daily.
223660659|NCT03814304|OTHER|Active-Sham|The participant will receive 20, 20-minute sessions of active-sham stimulation on Monday-Friday, at approximately the same time of day, over four consecutive weeks.
223660660|NCT05238922|DRUG|INCB0123667|25 mg tablets
223660661|NCT05238922|DRUG|Palbociclib|Palbociclib will be administered at protocol defined dose.
223769317|NCT02751983|OTHER|Treatment as usual|All participants will be able to engage in treatment as usual. Psychiatric inpatient care typically consists of behavioral mental health group and/or individual therapy and pharmacological treatment. Outpatient care is offered upon discharge. This typically consists of both group and individual therapy and medication management.
223769318|NCT05709171|DRUG|18F-FDG|PET/CT scan approximately 60 min after injection of 18F-FDG
223769319|NCT05709171|DRUG|64Cu-Dotatate|PET/CT scan approximately 60 min after injection of 64Cu-Dotatate
224241437|NCT01677962|BIOLOGICAL|Poly-ICLC|
224241438|NCT01677962|BIOLOGICAL|dendritic cell|
224241439|NCT00849901|DRUG|duloxetine|30-120 mg, PO, QD, for up to 38 weeks
224241440|NCT00849901|DRUG|Placebo|Capsules identical in appearance, color, taste and smell to study drug, orally (PO), once daily (QD). Dose: placebo, 6 capsules, QD for 10 weeks
224241441|NCT00849901|DRUG|fluoxetine|10-40 milligram (mg), PO, QD, for up to 38 weeks
224321237|NCT03170063|PROCEDURE|Procedure/Surgery: Biofluid samplings|Biofluid samplings (blood and cerebrospinal fluid (CSF))
223660662|NCT05238922|DRUG|Bevacizumab|Bevacizumab will be administered at protocol defined dose.
223660663|NCT05238922|DRUG|Olaparib|Olaparib will be administered at protocol defined dose.
223660664|NCT05238922|DRUG|Paclitaxel|Paclitaxel will be administered at protocol defined dose.
223660665|NCT05238922|DRUG|Ribociclib|Ribociclib will be administered at protocol defined dose.
223660666|NCT05238922|DRUG|Fulvestrant|Fulvestrant will be administered at protocol defined dose.
223660667|NCT02083861|DEVICE|Sam Ultrasonic Diathermy Device|Patients apply the Sam Ultrasonic Diathermy Device daily for 4 hours of continuous therapeutic ultrasound at 3 megahertz (MHz) frequency and 0.132 Watts/cm2.
223660668|NCT03376295|DRUG|LABA and the LAMA tiotropium (LABA-TIO)|combinational drug
223660669|NCT03376295|DRUG|LABA and an ICS (LABA-ICS)|combinational drug
223660670|NCT03665519|DIETARY_SUPPLEMENT|Sublimated mare milk|The dietary supplement mare milk product, which is obtained from fresh mare milk (few hours) through sublimation process.
223660671|NCT03665519|DRUG|Ursodeoxycholic Acid|Ursodeoxycholic acid treatment will be given for 3 months.
224241442|NCT03136666|DRUG|Nifedipine gastrointestinal therapeutic system (GITS) (Adalat LA, BAY a1040) + Candesartan cilexetil|Candesartan and nifedipine were administered together as loose combination with 240 mL non-sparkling water in the morning after a fasting period of at least 10 hours.
224241443|NCT00076934|DRUG|RG2077 (CTLA4-IgG4m)|RG2077
224241444|NCT03462524|PROCEDURE|Esophagectomy|FEV1, FVC and DLCO will be assessed at baseline and one month post induction therapy. Radiation induced lung injury (RILI EORTC grade≥2), CCI, Clavien-Dindo, and pulmonary complications will be monitored. Changes in pulmonary function will be compared with cardiorespiratory symptoms and HR-QL among disease-free survivors.
224241445|NCT00842595|DRUG|rituximab|6 courses every 28 days
224241446|NCT00842595|DRUG|vinorelbine|6 courses every 28 days
224241447|NCT00842595|DRUG|ifosfamide|6 courses every 28 days
223660672|NCT05685251|OTHER|Health Coaching|Participants will receive a health coach telehealth/video visit or phone call every 2 weeks for 4 months, for a total of 8 calls. After these initial 8 calls, at approximately 6 months postpartum, the health coach will schedule maintenance calls 1 per month until approximately 12 months postpartum, for a total of 6 additional calls.
223660673|NCT05685251|OTHER|Home Blood Pressure Monitoring|Participants will be provided an A\&D UA-651 (BT) home blood pressure monitor with an appropriate cuff size, they will be asked to take their blood pressure at least three days a week, 2 measurements each time
223660674|NCT04164511|DIETARY_SUPPLEMENT|2 daily standard doses of vanilla-chocolate ice cream (cryotherapy)|The patients will receive 2 daily standard doses of vanilla-chocolate ice cream (cryotherapy) for 2 weeks post-op, with amount of analgesic consumption and subjective pain levels recorded on a VAS scale.
223660675|NCT03049007|DIAGNOSTIC_TEST|Survey|Completion of surveys with diagnostic measurements (e.g., PGD, depression, anxiety, PTSD).
223660676|NCT05662982|DEVICE|Northwestern University Flexible Subischial Suction Socket (NU-FlexSIS)|A custom-made prosthetic socket for transfemoral amputation that consists of proximal trimlines that do not interact with the pelvis.
223660677|NCT05692453|DIAGNOSTIC_TEST|Arterial blood gas with co-oximetry|1 mL blood sample for ABG-CoOx analysis to obtain co-oximetry measured arterial oxygen saturation (SaO2C) and standard ABG derived arterial oxygen saturation (SaO2S).
223660678|NCT06053242|DRUG|CELZ-201-DDT|Subjects enrolled in the trial will receive CELZ-201-DDT at the specified dose into the lumbar paraspinal musculature. Each subject will receive a total of six injections, three injections on each side, under direct ultrasound guidance.
223660679|NCT06053242|OTHER|Placebo|Subjects will receive a placbeo injection into the lumbar paraspinal musculature. Each subject will receive a total of six injections, three injections on each side, under direct ultrasound guidance.
223660680|NCT05322954|DRUG|Psilocybin|25mg orally followed by 25 mg or 50 mg orally
223660681|NCT03606499|DRUG|Ustekinumab|No study treatment will be administered as a part of this study. Participants who are initiating the treatment with ustekinumab, will be observed according to standard clinical practice.
223660682|NCT06505837|DRUG|JS001sc (360mg Subcutaneous injection) and pemetrexed/platinum-containing chemotherapy|The combination therapy of JS001sc and pemetrexed/platinum lasted for 4 cycles, after which subjects who did not progress continued to receive JS001sc and pemetrexed maintenance therapy, and the cumulative treatment of JS001sc did not exceed 35 cycles (Each cycle is 21 days).
223660683|NCT06505837|DRUG|JS001 (240mg intravenous infusion) and pemetrexed/platinum-containing chemotherapy|The combination therapy of JS001 and pemetrexed/platinum lasted for 4 cycles, after which subjects who did not progress continued to receive JS001 and pemetrexed maintenance therapy, and the cumulative treatment of JS001 did not exceed 35 cycles (Each cycle is 21 days).
223660684|NCT05582850|DRUG|DT-9081 - dose escalation|Patients will be dosed orally once daily. The schedule might be adjusted in case of toxicities.
223660685|NCT05582850|DRUG|DT-9081 - expansion|A homogeneous patient population will receive DT-9081 at up to 3 dose levels.
223660686|NCT06289413|OTHER|Development of AD/OI after BS|"OI is a type of AD that results in chronic supine-to-standing hypotension and disabling dizziness, lightheadedness, and even syncope. Whether arising from malabsorption, vagus nerve damage, or splanchnic vasodilation, the pathophysiology of OI in bariatric surgery is not clear and requires more investigation.~Treatment of OI usually consists of dietary and lifestyle changes, which may include compression stockings and abdominal binders. Medical options include peripheral vasoconstrictors and mineralocorticoids; some patients may be referred to Cardiology for further testing. Management is difficult and endurance and tilt training, inflatable abdominal bands, and beta-blockers have been proposed. One recent study demonstrated the treatment of refractory OI with Droxidopa. Yet, the success of treatment is individualized and necessitates more novel approaches."
223660687|NCT04703114|DIAGNOSTIC_TEST|Blood count|Blood count at each visit
223660688|NCT04703114|DIAGNOSTIC_TEST|Blood collection|Blood collection to understanding of the immunological profile at each visit
223660689|NCT04703114|DIAGNOSTIC_TEST|Nasopharyngeal swab|Research of SARS-CoV-2 infection in nasopharyngeal swab by RT-PCR at day 8 and day 15
223660690|NCT04703114|DIAGNOSTIC_TEST|Saliva samples|Research of SARS-CoV-2 infection in saliva samples at each visit (excepted inclusion)
223660691|NCT04703114|DIAGNOSTIC_TEST|Faeces samples|Research of SARS-CoV-2 infection in faeces samples at day 3, day 15 and day 90
223660692|NCT04703114|GENETIC|Genetic blood collection|Collection to further research at each visit
224241448|NCT00842595|DRUG|Mitoxantrone|6 courses every 28 days
224241449|NCT00842595|DRUG|Prednisone|6 courses every 28 days
224241450|NCT00262223|BEHAVIORAL|Seeking Safety|Seeking Safety cognitive-behavioral treatment intervention for comorbid PTSD and substance use disorders
224241451|NCT00262223|DRUG|Sertraline|An anti-depressant medication, selective serotonin reuptake inhibitor (SSRI) type
224241452|NCT00262223|DRUG|Pill placebo|
224241453|NCT03828734|DEVICE|Theta TMS|TMS will be administered at the frequency of each subject's endogenous theta oscillation (4-7Hz)
223660693|NCT04703114|OTHER|Data collection|Demographics, symptoms, biological constants
224241454|NCT03828734|DEVICE|Alpha TMS|TMS will be administered at the frequency of each subject's endogenous alpha oscillation (8-12 Hz)
224241455|NCT03828734|DEVICE|Arrhythmic TMS|TMS will be administered arrhythmically; i.e. a sequence of pulses with randomized timing
224241456|NCT02476799|PROCEDURE|Rectus sheath block|Ultrasound-guided bilateral rectus sheath block of RSB group using 0.25% Ropivacaine
223660694|NCT01165216|DRUG|Ipilimumab, 3 mg|Intervenous (IV) injection, administered every 3 weeks for up to 6 cycles
223660695|NCT01165216|DRUG|Ipilimumab, 10 mg|IV injection, administered every 3 weeks for up to 6 cycles
223660696|NCT01165216|DRUG|Paclitaxel|IV injection, 175 mg/m\^2, administered every 3 weeks for up to 6 cycles
223660697|NCT01165216|DRUG|Carboplatin|IV injection, AUC=6, administered every 3 weeks for up to 6 cycles. (AUC=area under the concentration curve)
223660698|NCT01966848|DEVICE|Wich prosthesis is used|
223660699|NCT00141791|DRUG|Etanercept|
223660700|NCT00564668|DRUG|biphasic insulin aspart|
223660701|NCT00167219|BIOLOGICAL|Stem Cell Transplant|Transplantation on Day 0.
223660702|NCT00167219|DRUG|Preparative Regimen|"* Busulfan~* Cyclophosphamide~* Mesna~* Melphalan~* Anti-thymocyte Globulin (ATG)"
223660703|NCT01962363|DRUG|EPI-743|EPI-743 (alpha-tocotrienol quinone) is a small molecule therapeutic that was rationally designed to replete reduced glutathione through NQO1-catalyzed electron transfer from NADPH.
223660704|NCT03666715|DRUG|Oral Antipsychotics (OAPs)|No study treatment will be administered as a part of this study. Participants will receive OAPs (such as olanzapine, risperidone, paliperidone, aripiprazole or quetiapine) as per their usual clinical practice.
223660705|NCT03666715|DRUG|Paliperidone Palmitate 1-Month Formulation (PP1M)|No study treatment will be administered as a part of this study. Participants will receive PP1M as per their usual clinical practice.
223660706|NCT06412939|DEVICE|Agile Nail|Intramedullary implantation of the Agile intramedullary rigid nail in femur to provide bone fixation
223660707|NCT04895735|BIOLOGICAL|Pembrolizumab|Given IV
223660708|NCT04895735|DRUG|Pemetrexed Disodium|Given IV
223660709|NCT04895735|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223769320|NCT02378766|BEHAVIORAL|Website A|"Patients assigned to this arm will be invited to complete a web-based tailored intervention called TAVIE en santé (TAVIE : Traitement, Assistance Virtuelle Infirmière et Enseignement).~TAVIE en santé is a web-based tailored multicomponent intervention addressing smoking cessation, physical activity and healthy eating. Each component consists of seven interactive computer sessions lasting 5-10 minutes. The sessions, hosted by a virtual nurse, aims to develop and strengthen skills required for behavior change."
224241457|NCT02476799|DRUG|Ropivacaine|Ultrasound-guided bilateral rectus sheath block of RSB group using 0.25% Ropivacaine
224241458|NCT02476799|OTHER|Bandage|After the surgery, a bandage will be attached on injection site where is same as the incision site of surgery.
223660710|NCT04895735|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
223660711|NCT04895735|PROCEDURE|Positron Emission Tomography|Undergo PET
223660712|NCT04895735|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223660713|NCT04895735|PROCEDURE|PSMA PET Scan|Undergo PSMA PET
223660714|NCT05197062|DRUG|14C-aticaprant|14C-aticaprant will be administered orally as capsule on Day 1.
223660715|NCT04848792|DIETARY_SUPPLEMENT|Sulforaphane|Myrosinase-active whole broccoli sprout material
223660716|NCT04848792|DIETARY_SUPPLEMENT|Placebo capsules|Placebo capsules
223769321|NCT02378766|OTHER|Website B|Patients assigned to this arm will be invited to consult a validated list of five predetermined websites offering information about the health behavior they chose: being physically active, following a healthy diet or quitting smoking. These websites offers reliable information and their content were validated by experts.
223769322|NCT02437565|OTHER|Stainless steel crown|Placement of stainless steel crowns for teeth that have undergone pulpotomy for the treatment of pulpitis induced by severe early childhood caries under general anesthesia
223769323|NCT02437565|OTHER|Occlusal Template|Use of an occlusal template for the placement of stainless steel crowns under general anesthesia
224241459|NCT02476799|DRUG|IV-PCA containing Fentanyl and Ketorolac|All patients will use total 100 ml of IV-PCA containing 800 µg of fentanyl and 150 mg of ketorolac for 48 hours postoperatively.
224241460|NCT01804270|DEVICE|Repetitive transcranial magnetic stimulation (rTMS)|Active treatments with repetitive transcranial magnetic stimulation (rTMS) consists of treatment settings of 120% magnetic field intensity relative to the patient's resting motor threshold, at 10 pulses per second (10 Hz) for 4 seconds, with an intertrain interval of 26 seconds for a total of 75 trains per treatment session.
224241461|NCT00816569|DEVICE|Orthokeratology contact lenses|Wearing Orthokeratology lens in one eye of a keratoconus patient
223660717|NCT06455319|DRUG|Anti-thymocyte globulin (ATG)|ATG (brand name Thymoglobulin) a polyclonal T cell antibody preparation. It will be given at low doses (0.5 mg/kg Day 1 then 2 mg/kg Day 2).
223660718|NCT06455319|DRUG|verapamil extended release capsule|Open label administration at 120, 240 or 360 mg daily based on weight and ECG findings
223660719|NCT06455319|DRUG|Placebo|I.V. Saline
223660720|NCT06230679|DEVICE|Non-invasive Neuromodulation|Patients receive non-invasive neurostimulation through the Nesa device
223660721|NCT06230679|DEVICE|Placebo Non-invasive Neuromodulation|The same protocol described for the experimental group will be applied, but electrical stimulation device which will be previously manipulated and tested with an oscilloscope so that they do not emit electrical currents.
223660722|NCT06805838|DEVICE|Sotair|"The device is a durable plastic connector with a silicone flap inside it requiring no special handling. There are no patients involved, only a simulated lung that also requires no special handling. Adult Sotair® device has FDA clearance as a Class II device through the 510(k) pathway (K212905) for the intended use of Flow-limiting, safe, and optimal manual ventilation to minimize gastric insufflation."
223660723|NCT06199570|BEHAVIORAL|Adapted Stress Management Program|Participants will receive a 15-minute orientation session in-person or remotely to introduce the program and to receive the study materials, including the instructional sheet, small booklet, and study tablet that will be used to promote practice of stress management exercises and for completing study assessments. They will complete self-guided web modules with stress management activities/skills on tablet devices, and will rate the modules' acceptability and perceived helpfulness. After visiting each module, they will be asked to practice at least one skill daily. In a second coaching session, they will be reminded about the skills, make a plan for using them, and troubleshoot questions about using the materials. Participants will attend scans and scan result appointments with their oncologist as usual. In a third coaching session, the stress management plan will be revisited for new concerns.
223660724|NCT06199570|BEHAVIORAL|Enhanced Usual Care|Enhanced usual care includes a resource list, tablet for study assessments, and reminder calls.
223660725|NCT05469360|DRUG|NIO752|A single intrathecal (cerebrospinal) injection of NIO752 of Dose A
223660726|NCT05469360|DRUG|NIO752|A single intrathecal (cerebrospinal) injection of NIO752 at dose B
223660727|NCT05469360|DRUG|Matching placebo|A single intrathecal injection of matching placebo
223660728|NCT05469360|DRUG|NIO752|Multiple intrathecal injections of NIO752 of Dose A
223660729|NCT05469360|DRUG|NIO752|Two intrathecal injections of NIO752 at dose C
223660730|NCT05469360|DRUG|NIO752|Single intrathecal injection of NIO752 at dose C
223660731|NCT05469360|DRUG|Matching placebo|Two intrathecal injections of matching placebo
223660732|NCT06176183|PROCEDURE|Arthroscopic meniscus repair|"A traditional two-portal arthroscopic approach is utilized. The meniscal edges are examined using a probe, and any meniscal tears that are not stable are evaluated for potential repair. For meniscus repair, sutures have been made using the all-inside or outside-inside and inside-outside techniques.~If the procedure involving the addition of a fibrin clot is being carried out, a volume of approximately 60 milliliters of blood is taken and thereafter transferred into a basin. An assistant is able to stir the blood using a glass syringe for approximately fifteen minutes to ensure sufficient coagulation surrounding the syringe. After a sufficient clot has developed at the end of the syringe, a grasper is used to insert the clot through the anterolateral arthroscopy portal. The meniscal sutures are intentionally loosened to accommodate the clot in the meniscus, ensuring optimal contact with the lesion. Subsequently, the sutures are fastened and knotted."
223660733|NCT05738837|BEHAVIORAL|A-EAAA Sexual Assault Resistance Education Program immediately|Adapted from the EAAA program created for university women, A-EAAA is designed for teen girls of all sexual identities and experience levels. It focuses on resisting sexual assault (SA) committed by male acquaintances with 4, 3-hour units: Unit 1(Assess) strengthens girls' ability to detect risk in contexts involving male acquaintances and helps develop strategies to reduce it. Unit 2(Acknowledge) helps girls explore ways to overcome their own emotional barriers preventing them from acknowledging risk and employing effective resistance strategies with males they know. Unit 3(Act) provides evidence on effectiveness of various resistance strategies and teaches verbal and physical self-defense focused on common acquaintance SA situations. Unit 4 (Relationships\&Sexuality) is an adaptation of Our Whole Lives curriculum and aims to increase girls' comfort talking about sex/sexuality and identify their sexual values/desires and explore possibilities for sexual practices beyond intercourse.
223660734|NCT05738837|BEHAVIORAL|Usual care + A-EAAA at 6 months|Participants assigned to the waitlist control group will immediately receive a brief educational session on sexual assault that represents the current 'standard of care' at Canadian high schools (often presented by local Sexual Assault Centres or Public Health nurses). This 30-min session will involve a brief 15 - 20-minute presentation on sexual consent, respect in relationships, and sexual assault (e.g., definitions, prevalence statistics). This will be conducted by a well-trained and knowledgeable Research Assistant. Following the presentation, participants will be invited to take and read brochures provided on sexual assault, and to ask questions about the content of the presentation and brochures. At 6-months, participants will be scheduled to receive A-EAAA.
223660735|NCT06795178|DRUG|FP-014|11.25 mg in a prefilled, ready-to-use, long-acting formulation
224241462|NCT04464330|OTHER|no intervention|This is an observation study, with no intervention
224241463|NCT00709566|BEHAVIORAL|Exercise therapy|Participants will attend an exercise based programme once a week for 8 weeks. This will be supplemented by a home based exercise programme.
223660738|NCT02902601|DRUG|JNJ-54175446, 600 mg|Participants will receive JNJ-54175446, 600 mg as an oral suspension.
223660739|NCT02902601|DRUG|JNJ-54175446, 150 mg|Participants will receive JNJ-54175446, 150 mg as an oral suspension.
223660740|NCT02902601|OTHER|Placebo|Matching placebo to JNJ-54175446
224241464|NCT00709566|BEHAVIORAL|Combined exercise and manual therapy|Patients will attend physiotherapy once a week for 8 weeks, where they will receive a combination of exercise therapy and manual therapy. Exercise will be supplemented by a home based exercise programme
223660741|NCT06227572|BEHAVIORAL|CATNAP MI|"Three motivational interviewing (MI) sessions will be facilitated by trained MI staff and will focus on improving participants' knowledge about their OSA diagnosis, understanding of sleep health, and increasing PAP use. Sessions will also provide information about health benefits associated with good sleep and will help participants create an action plan regarding their PAP use and indicators of success, when appropriate.~Electronic messaging will be standardized for frequency and content but personalized to participants' preferred mode of delivery. Messages will focus on PAP adherence or non-adherence."
223660742|NCT03155022|DEVICE|Remote ischemic conditioning and intracoronary ischemic conditioning|"RIC: Four cycles of \[5 min brachial cuff inflation at 200 mmHg followed by 5 min of cuff deflation\] started as soon as possible prior to PCI reperfusion. At least one full cycle (inflation + deflation) has to be completed before PCI reperfusion.~ICIC: Four cycles of \[1 min balloon inflation followed by 1 min balloon deflation\] started as soon as possible after reopening of the culprit coronary artery (maximum within 3 minutes after reflow). The balloon will be placed carefully above the culprit lesion so as to minimize potential micro-embolization."
223660743|NCT03155022|DEVICE|Patients with no remote ischemic conditioning and no intracoronary ischemic conditioning|Brachial cuff is positioned during 40 minutes but not inflated. No intracoronary balloon inflation.
223660744|NCT06729970|DRUG|Xanomeline/Trospium Chloride|Specified dose on specified days
223660745|NCT06729970|DRUG|Lithium|Specified dose on specified days
223660746|NCT06729970|DRUG|Valproic Acid|Specified dose on specified days
223660747|NCT06729970|DRUG|Lamotrigine|Specified dose on specified days
223660748|NCT06853522|DRUG|exosomes derived from human umbilical cord mesenchymal stem cells|The corresponding exosome content of 60×10\^6 umbilical cord mesenchymal stem cells was given
223660749|NCT06853522|DRUG|saline +5% albumin|Equal amount of saline +5% albumin was given
224241465|NCT02260830|DRUG|Lu AF11167|
224241466|NCT00978822|DRUG|Clevidipine butyrate injectable emulsion|Clevidipine butyrate injectable emulsion infusion starting at 2 mg/hour and titrating up for effect till 32 mg/h for up to 24 hours starting in the emergency department and continued in the critical care units.
224241467|NCT00270322|DRUG|Marcaine 0.166% + Fentanyl 3.33 mcg/ml|
224241468|NCT00270322|DRUG|Morphine sulphate|
223660750|NCT06855043|DRUG|Calfactant|Participants will receive 3 daily doses of Calfactant (1.5ml/kg) administered intratracheally
223660751|NCT06855043|DRUG|Budesonide|Participants will receive 3 daily doses of Budesonide (0.25mg/kg) administered intratracheally.
223660752|NCT06599658|BIOLOGICAL|Inactivated influenza vaccine (IIV) at baseline|National Advisory Committee on Immunization (NACI) recommended seasonal inactivated influenza vaccine for moderate to severely immunocompromised patients by age at baseline
223660753|NCT06599658|BIOLOGICAL|COVID-19 Vaccines at a 3-month interval|Updated NACI recommended COVID-19 booster for moderate to severely immunocompromised patients at a 3-month interval
223660754|NCT06599658|BIOLOGICAL|Inactivated influenza vaccine at Month 1|National Advisory Committee on Immunization (NACI) recommended seasonal inactivated influenza vaccine for moderate to severely immunocompromised patients by age 1-month following initial COVID-19 booster
223660755|NCT06599658|BIOLOGICAL|COVID-19 Vaccines at a 6-month interval|Updated NACI recommended COVID-19 booster for moderate to severely immunocompromised patients at a 6-month interval
223660756|NCT04133246|BEHAVIORAL|Focus group|Groups of 6 to 10 patients and spouses led by the psychologist about their parenthood lasting 2 hours
223660757|NCT04133246|BEHAVIORAL|Individual interview|Interview led by the psychologist about the patient's parenthood
223660758|NCT06655038|BEHAVIORAL|Advocacy coalition|"* set up a task force composed of school stakeholders (students, teachers, educators, principle,...). These stakeholders will meet 4 times a year to improve the implementation and enforcement of TFSP through rules that are accepted, adopted and to which all school actors adhere.~* share of good practices in implementation with the other schools of the intervention arm through a sharing platform and two annual meetings.~* support to reffer nicotine-dependant students and staff members to smoking cessation programs.~* support in the implementation of TFSP and in getting all school actors on board, by the research team, but also by local health promotion partners."
223660759|NCT06655038|BEHAVIORAL|Feedback|Feedback on the basis of the audit and the surveys
223660760|NCT05751252|DRUG|Ganirelix|An intra-venous cannula will be inserted and blood will be sampled at 10-min intervals for a 4-h baseline period commencing at 0800 h. Ganirelix will be then administered subcutaneously at single-dose regimen at 0.0625 mg (n = 10 women with PCOS). After Ganirelix administration sampling will continue at 10-min intervals for 4 h.
223660761|NCT05751252|DRUG|Ganirelix|An intra-venous cannula will be inserted and blood will be sampled at 10-min intervals for a 4-h baseline period commencing at 0800 h. Ganirelix will be then administered subcutaneously at single-dose regimen at 0.025 mg (n = 10 women with PCOS). After Ganirelix administration sampling will continue at 10-min intervals for 4 h.
223660762|NCT06606860|DRUG|Oxantel Pamoate|Oxantel Pamoate tablet, 250mg
223660763|NCT06606860|DRUG|Placebo|Placebo tablet
223660764|NCT06984679|OTHER|Physical Evaluations in Children with Cystic Fibrosis|In this study, dyspnea, functional capacity, muscle strength, urinary incontinence and quality of life will be evaluated in children and adolescents with cystic fibrosis. The data to be obtained through all these evaluations will be done face to face within 45-60 minutes.
223660765|NCT06984679|OTHER|Physical Evaluations in Healthy Children|In this study, dyspnea, functional capacity, muscle strength, urinary incontinence and quality of life will be evaluated in healthy children and adolescents. The data to be obtained from all these assessments will be made face to face within 45-60 minutes.
223660766|NCT05688670|PROCEDURE|Regional Anesthesia|Bilateral pecto-intercostal fascial plane block (PIFB) and unilateral rectus sheath block (RSB) with Ropivacaine 0.2%
223660767|NCT05688670|PROCEDURE|Wound infiltration|Surgeon-delivered wound infiltration with Ropivacaine 0.2%
223660768|NCT05688670|DRUG|Ropivacaine 0.2% Injectable Solution|Ropivacaine 1.5 mL/kg will be used for both interventions
223660769|NCT06594393|DRUG|TCP-25 gel|Topical gel
223660770|NCT06594393|DRUG|Vehicle (placebo)|Placebo gel
223660771|NCT04007354|OTHER|Ventilation method|Depending on the group assignment, mechanical ventilation or spontaneous breathing was performed.
223660772|NCT04516954|BIOLOGICAL|Convalescent COVID 19 Plasma|A total of 500 ml of convalescent COVID 19 plasma will be transfused intravenously per subject
223660773|NCT06991322|DEVICE|A-FLUX Reducer System|The VahatiCor A-FLUX Reducer System is an implantable, self-expanding dense-cell nitinol coronary sinus flow restrictor device pre-loaded into the A-FLUX Delivery Catheter.
223769324|NCT04518891|BEHAVIORAL|Cognitive Functional Therapy (CFT)|Cognitive functional therapy (CFT) is an intervention that deals with potentially modifiable multidimensional aspects of pain (e.g. provocative cognitive, movement and lifestyle behaviours). Treatment with CFT will be individualised, the physiotherapist will listen to the complete patient pain history and the intervention will be focused on individual needs. A detailed examination will be crucial in identifying the modifiable multidimensional mediators of pain and disability (provocative cognitive, pain, movement and lifestyle behaviors) of each participant.
223660774|NCT06997744|DEVICE|Low-frequency(2HZ) TENS|Participants receive transcutaneous electrical nerve stimulation (TENS) at a frequency of 2Hz. The stimulation is delivered using surface electrodes placed on the affected upper limb. Each session lasts 30 minutes and is conducted three times per week for a total of 8 weeks. Intensity is gradually increased from 1 mA to 3 mA during each session.
223660775|NCT06997744|DEVICE|High-frequency(100HZ) TENS|Participants receive TENS at a frequency of 100Hz using the same electrode placement and schedule as the 2Hz group. Sessions last 30 minutes, three times weekly for 8 weeks, with intensity increasing from 1 mA to 3 mA across the session. This group represents high-frequency stimulation.
223660776|NCT06997744|DEVICE|Placebo TENS|Participants use a TENS device identical in appearance to the active treatment units. The power light is on, but no electrical stimulation is delivered due to internal circuit disconnection. Sessions follow the same schedule and duration as the active groups.
223660777|NCT06616987|DRUG|Sacituzumab Govitecan with pegfilgrastim|"▪ Sacituzumab Govitecan group~\- Sacituzumab Govitecan 10mg/kg IV on CnD1 and D8 + Pegfilgrastim 6mg SC QD on CnD9"
223660778|NCT03332849|BIOLOGICAL|HM12470|HM12470 is a long-acting insulin analogue
223660779|NCT05933850|BEHAVIORAL|Strong Families Programme Intervention|This is a family skills programme providing an evidence-informed prevention to support caregivers to be better parents and strengthen positive age-specific and age-appropriate family functioning and interactions to help prevent drug use, violence and other negative social consequences in their children.
223660780|NCT07028684|OTHER|Reflexology Massage|"Reflexology massage will be applied twice a week for 30 minutes per session, for a total of 10 sessions. The treatment will begin by relaxing the ankle with a few passive movements. Reflexology massage will be applied to the right foot first and then to the left foot.~Target Areas to be Applied to the Right Foot: Brain, Pineal, Hypophysis, Hypothalamus and Thalamus, Temples, Eye area and Optic nerve, Ear area, Middle ear and Balance point, Neck.~Other areas to be applied to the right foot: Thyroid and Parathyroid, Lung, Liver, Face area, Speech center and Thymus, Teeth, Diaphragm, Vertebra, Extremities.~Areas to be applied to the left foot: Kidney, Diaphragm, Intestines, Neck, Vertebra, Extremities.~The session is completed from the left foot by applying to the lymph inlet, lymph channel and diaphragm from both feet."
223660781|NCT06520085|OTHER|interactive mHealth application for patients undergoing RSA|Patients will receive interactive information via an mHealth application tailored to their needs and progress during the rehabilitation period after RSA.
223660782|NCT07033481|DRUG|Neflamapimod|Neflamapimod is a highly specific inhibitor of the intra-cellular enzyme mitogen-activated protein kinase14 (p38α) provided in 40 mg capsules
224241469|NCT00724230|DRUG|PegIntron (peginterferon alfa-2b; SCH 54031)|"PegIntron administered in accordance with approved labeling~Subcutaneous injection once weekly for 24 weeks."
224241470|NCT00724230|DRUG|Rebetol (ribavirin; SCH 18908)|Rebetol administered orally twice daily in accordance with approved labeling. Dosing duration 24 weeks.
224241471|NCT03146130|BIOLOGICAL|Variation of behaviors of Parkinson's disease|Variation of hyper dopaminergic behaviors of Parkinson's disease
224241472|NCT04231838|OTHER|TOBACCO CIGARETTES|Participants in Arm A will continue smoking their own cigarette brand as usual.
224241473|NCT04231838|OTHER|COMBUSTION-FREE NICOTINE DELIVERY SYSTEMS (C-F NDS)|Participants in Arm B will trial and familiarize with their allocated products to select the C-F NDS of their preference. They will be trained and counselled on the chosen C-F NDS; participants will also have the option to try and choose among a selection of either 3 e-liquids or 3 tobacco sticks (depending on the C-F NDS they have chosen). Participants wishing to use a heated tobacco device (HTD) will receive one kit and a full 1 week supply of tobacco sticks of their choice (they will receive a number of tobacco sticks/day corresponding to the number of cigarettes smoked at baseline); those wishing to use a vaping product will receive one vaping kit and a full 1 week supply of e-liquids of their choice (they will receive 4 x 10 ml refill containers).
224241474|NCT03152981|DRUG|Desflurane|In desflurane group, desflurane 6-8 vol% and remifentanil (target controlled infusion 2-3 ng / ml) are used for maintenance of anesthesia during surgical procedure. In propofol group, propofol 3-4 ug/ml and remifentanil 2-3 n /ml using target Controlled Infusion are used for maintenance of anesthesia during surgical procedure
224241475|NCT03152981|DRUG|propofol|In desflurane group, desflurane 6-8 vol% and remifentanil (target controlled infusion 2-3 ng / ml) are used for maintenance of anesthesia during surgical procedure. In propofol group, propofol 3-4 ug/ml and remifentanil 2-3 n /ml using target Controlled Infusion are used for maintenance of anesthesia during surgical procedure
224241476|NCT03152981|DRUG|remifentanil|In desflurane group, desflurane 6-8 vol% and remifentanil (target controlled infusion 2-3 ng / ml) are used for maintenance of anesthesia during surgical procedure. In propofol group, propofol 3-4 ug/ml and remifentanil 2-3 n /ml using target Controlled Infusion are used for maintenance of anesthesia during surgical procedure
224241477|NCT01406418|BIOLOGICAL|CR6261 2 mg/kg|Administered as a single 2-hour intravenous infusion
224241478|NCT01406418|BIOLOGICAL|CR6261 5 mg/kg|Administered as a single 2-hour intravenous infusion
224241479|NCT01406418|BIOLOGICAL|CR6261 15 mg/kg|Administered as a single 2-hour intravenous infusion
224241480|NCT01406418|BIOLOGICAL|CR6261 30 mg/kg|Administered as a single 2-hour intravenous infusion
224241481|NCT01406418|BIOLOGICAL|CR6261 50 mg/kg|Administered as a single 2-hour intravenous infusion
224241482|NCT01406418|BIOLOGICAL|Placebo|Administered as a single 2-hour intravenous infusion
224241483|NCT00000221|DRUG|Buprenorphine|
224241484|NCT01856205|DRUG|Intravenous immunoglobulin [ImmunoRel™ (batch 20081217)]|"IVIG group received 400mg/kg/day intravenous at the rate of 0.01 to 0.02 ml/kg body weight/minute for 5 days or appearance of side effect or adverse events.~Placebo group received 0.9% saline intravenous at similar rate."
224241485|NCT00233597|DRUG|ferumoxytol or oral iron|
223660783|NCT07033481|DRUG|Placebo|Placebo is a capsule that looks just like neflamapimod but without the active ingredients
223660784|NCT07032558|DRUG|DW-1021|DW-1021 is a fixed-dose combination tablet containing Pelubiprofen 45 mg and Tramadol 45.9 mg (as a salt), formulated as a controlled-release film-coated tablet. It is administered as a single oral dose with 150 mL of water under fasting conditions for the evaluation of pharmacokinetics in healthy adult male volunteers.
223660785|NCT07032558|DRUG|Pelubi CR + Zytram CR|The reference treatment consists of two separate controlled-release film-coated tablets: Pelubi CR (Pelubiprofen 45 mg) and Zytram CR (Tramadol HCl 75 mg). These are co-administered as a single oral dose with 150 mL of water under fasting conditions to compare the pharmacokinetic profile against the fixed-dose combination DW-1021.
223660786|NCT07037940|OTHER|OpenEvidence|Medical information platform which uses retrieval-augmented generation to access medical literature
223660787|NCT07037940|OTHER|GPT-4|A chatbot application developed that uses GPT-4, a large language model, to engage in conversational interactions with users.
224241486|NCT03894605|DEVICE|thalassemia|thalassemic patient use chelator and thaladssemic patient with frequent blood transfusion
223660788|NCT02553356|DRUG|PT2385|
224241487|NCT06073548|OTHER|Questionnaires and interviews|Patients wiill be asked to fulfill questionnaires at inclusion and 6 months after. An interview will be offered to a sub-sample of patients (approximately 20 patients).
224241488|NCT02152566|DEVICE|Nasal High flow therapy device|Nasal high flow therapy via nasal cannula.
224241489|NCT01568476|PROCEDURE|Distal|Blockade of both terminal branches of Sciatic nerve separately, distal to bifurcation
224241490|NCT01568476|PROCEDURE|Interneural|Sciatic nerve blockade at the site of bifurcation
224241491|NCT01230580|DRUG|Protease Inhibitor|Switch to a regimen comprising a single ritonavir-boosted Protease Inhibitor
224241492|NCT01230580|DRUG|Standard-of-care Antiretroviral therapy|Regimen should consist of 3 drugs: 2 nucleoside reverse transcriptase inhibitors with either a non-nucleoside reverse transcriptase inhibitor or a protease inhibitor
223660789|NCT06924151|PROCEDURE|surgical aortic valve replacement|SAVR
223660790|NCT06924151|PROCEDURE|Transcatheter aortic valve replacement|TAVR
223769325|NCT04518891|DEVICE|Sham intervention|Due to the impossibility of applying placebo exercise, the control intervention in this study will be based on successful reports of placebo intervention in patients with chronic low back pain in the literature (Placebo photobiomodulation + neutral talking control)
223769326|NCT05582330|OTHER|Cultural adaptation, reliability and validity|Cross-cultural Adaptation, Reliability and Validity of the Turkish Version of Telephone Based ABILOCO-Stroke
223769327|NCT01393769|DRUG|Melphalan|The usual number of chemotherapy cycles will be 3. First treatment with Melphalan will be initiated as soon as possible, once the patients are selected for the study. Once the first treatment has been completed, day 0, successive treatments will be considered, second and third (days 21 and 42). In those cases in which some patients could be considered for an additional treatments after the third cycle, these will be administrated in intervals at least of 21 days.Dosage range from 3 to 5 mg, depending of patient's weight and estimated tumour volume.
223660794|NCT06033092|DRUG|Tamoxifen 10 mg Tablet|One tablet of Tamoxifen 10 mg every other day for 6 months
223660795|NCT06033092|OTHER|Intermittent caloric restriction|"5:2 diet: 5 days a week at regular energy intake and 2 days/week at 75% energy deficit (diet will be restricted at 500-800 kcal corresponding to a 75% reduction compared to normal size)"
223660796|NCT06033092|BEHAVIORAL|Step counter Device|Participants will receive personal advice on healthy lifestyle and a step counter
223660797|NCT01784822|DEVICE|Zenapro™ Hybrid Hernia Repair Device|Device will be placed during open or laparoscopic hernia repair.
223660798|NCT03425253|DRUG|BELKYRA®|BELKYRA® was injected into preplatysma fat tissue in the submental area (at least 1 plus up to 5 optional treatments, for maximum of 6 treatments 8 weeks apart).
223660799|NCT03425253|DEVICE|Juvéderm® VOLUMA™ with Lidocaine|Juvéderm® VOLUMA™ with Lidocaine VOLUMA™ was injected along the mandibular border.
223660800|NCT03581916|DRUG|18F-JNJ-64326067|18F-JNJ-64326067 will be administered intravenously between a dose of 185 Megabecquerel (MBq) to 370 MBq.
223660801|NCT03510741|DRUG|Sodium Benzoate|Sodium Benzoate will be administered at 1000mg daily
223660802|NCT03510741|DRUG|N-Acetylcysteine|N-Acetylcysteine 1000 mgs twice daily dose
223660803|NCT03510741|DRUG|Placebo|Placebo added to TAU
223660804|NCT03510741|DRUG|Sodium Benzoate Plus N-Acetylcysteine|Sodium Benzoate will be administered at 1000mg daily and NAC 1000 mgs twice daily dose
223660805|NCT06757920|PROCEDURE|bronchoscopic argon plasma coagulation|Argon Plasma Cogulation for Debulking Endobronchial Carcinoid Using Fiberoptic Bronchoscopy
223769328|NCT02099214|DEVICE|3Tesla cardiac MRI|
223769329|NCT02099214|DEVICE|Electrocardiogram (EKG)|
223660806|NCT07123025|PROCEDURE|Partial Pulpotomy in Moderate Pulpitis|"Procedure/Surgery: Outcome of partial pulpotomy in teeth with clinical signs indicative of Moderate Pulpitis.~After caries removal and pulp exposure pulp tissue is amputated and pulpal wound will be irrigated with 3% NaOCl, and bleeding will be controlled by placing a cotton pellet soaked with 3% NaOCl over the pulpal wound for 2 to 3 minutes and will be repeated if required. Root canal therapy will be initiated in cases in which haemostasis is not achieved even after 10 minutes. Followed by capping with 2-3mm layer of MTA. A layer of RMGIC will be placed over the MTA. Then the tooth will be permanently restored with composite resin."
223660807|NCT07123025|PROCEDURE|Partial Pulpotomy in Severe Pulpitis|Description: Procedure/Surgery: Outcome of partial pulpotomy in teeth with clinical signs indicative of Severe Pulpitis. After caries removal and pulp exposure pulp tissue is amputated and pulpal wound will be irrigated with 3% NaOCl, and bleeding will be controlled by placing a cotton pellet soaked with 3% NaOCl over the pulpal wound for 2 to 3 minutes and will be repeated if required. Root canal therapy will be initiated in cases in which haemostasis is not achieved even after 10 minutes. Followed by capping with 2-3mm layer of MTA. A layer of RMGIC will be placed over the MTA. Then the tooth will be permanently restored with composite resin
223660808|NCT07084883|DEVICE|No intervention.|No intervention. Evaluate the automated AMD screening software.
223660809|NCT04083612|PROCEDURE|Venapuncture|Blood samples will be collected to determine the serum trough levels and anti-drug antibodies of ixekizumab
223660810|NCT04083612|OTHER|Patient questionnaires|The study participant will complete the Dermatology Quality of Life Index (DLQI) and EQ5D5L questionnaires at each study visit.
223660811|NCT07146048|DRUG|Secondary Prophylaxis|Continue standard of care with continued secondary antibiotic prophylaxis
223660812|NCT07145489|DEVICE|photobiomodulation|a hat with infrared lights will be worn for 30 minutes daily for 6 months
223660813|NCT06946004|DEVICE|Normobaric oxygen therapy|Patient's exposure to NBO conditions in group 1 (aNBO) including: oxygen levels of 32-40% (compared to about 21% in the atmosphere), pressure maintained at 1,500 hPa (about 1,000 hPa outside), carbon dioxide levels between 0.7-1.9% (compared to 0.03% in the atmosphere, and hydrogen levels between 0.5-1% (which is 10 to 20 thousand times higher than in the atmosphere). Exposure time in the NBO chamber will be the standard 2 hours with an additional 20 minutes for preparation and adaptation and 10 minutes for finalization and the decompression period.
223660814|NCT06946004|DEVICE|Normobaric oxygen therapy|Patients' exposure to atmospheric conditions in the same NBO chamber (without normobaric conditions to provide placebo intervention as the study comparator) in group 2 (pNBO): oxygen levels about 21%, pressure maintained at about 1,000 hPa, carbon dioxide levels about o 0.03%, and hydrogen levels about 0.00005% (0.5 parts per million, like in the atmos-phere).
223660815|NCT04254991|DIAGNOSTIC_TEST|ImmunoXpert™|The ImmunoXpert™ technology employs a biochemical assay that measures a proprietary combination of three biomarkers of the immune system coupled with pattern recognition algorithms that classify the source of an infection as bacterial or viral
223660816|NCT01217307|DRUG|Metformin|Metformin 500mg twice daily during 4 months
223769330|NCT02099214|BIOLOGICAL|Iron and cardiac markers|Serum iron, serum transferrin, transferrin saturation, serum ferritin, NT-proBNP
223660817|NCT01217307|DRUG|Placebo|Placebo twice daily during 4 months
223660818|NCT02205554|DRUG|Omnitram|Nine 20 mg doses administered every 6 hours
223660819|NCT02205554|DRUG|Tramadol|Nine 50 mg doses administered every 6 hours.
223769331|NCT02099214|BIOLOGICAL|Pregnancy test|Beta-hCG
223769332|NCT02099214|DEVICE|Echocardiography at rest|Transthoracic echocardiograph
223769333|NCT02099214|BIOLOGICAL|Urinary pregnancy test|
223769334|NCT02099214|DEVICE|3Tesla abdominal MRI|
223769335|NCT05149417|OTHER|SMS reminding|patients received SMS at day 2 , day 4 and day 7 after emergency departement discharge to remind them to take their treatment .
223769336|NCT05149417|OTHER|telemonitoring|Patients received a phone call on day 2 and day 4 to evaluate the adherence , to detect any problem that can affect the adherence to the treatment and modify the analgesic protocol treatment if needed.
223769337|NCT00096044|BIOLOGICAL|rituximab|IV
223769338|NCT00096044|DRUG|lenalidomide|Oral
223660820|NCT02205554|DRUG|Placebo|Nine doses administered every 6 hours.
223660821|NCT04240795|DIETARY_SUPPLEMENT|Low lubricity (LL) hydrogels containing fibre-based beads|The preload is made from kappa-carrageenan and alginate beads of 450 μm size. It contains no additional macronutrient but has food-grade watermelon flavor, color, and non-nutritive sweetener.
223660822|NCT00073853|PROCEDURE|Autologous Incubated Macrophages (cell therapy)|
223660823|NCT03730792|BEHAVIORAL|SHIFT Onboard Intervention|A 12-month onboarding process and social challenge supported with goal setting, computer-based training, self-monitoring, and group motivational interviewing.
223660824|NCT00929396|BIOLOGICAL|50 microg. antigen + adjuvant (500 nmol KLK + 20 nmol ODN1a)|o,5 mL suspension for injection x 2 with 2 months interval
223660825|NCT00929396|BIOLOGICAL|50 microg. antigen + adjuvant (500 nmol KLK + 20 nmol ODN1a)|o,5 mL suspension for injection x 2 with 2 months interval
223769339|NCT00366392|DEVICE|Optical Aids|
223769340|NCT06175143|BIOLOGICAL|GR2002 injection|TSLP monoclonal antibody
223769341|NCT03139916|DRUG|Temozolomide|Temozolomide causes cell death and shrinks and kills the cancer cells
223769342|NCT03139916|DRUG|Bavituximab|Bavituximab may activate (cause) the immune system to attack the cancer cells
223660826|NCT03093662|DEVICE|Ventilation with nasal cannula|Subject is fitted with a face mask and undergoes three continuous minutes of positive pressure ventilation (Respironics AF521, EE with CapStrap headgear) while simultaneously wearing nasal cannula (Carefusion AirLife Standard Nasal Cannula) with 15 L/min oxygen flow. Subject then removes mask and immediately exhales into an oxygen sensor (Maxtec Max-250E).
223660827|NCT03093662|DEVICE|Ventilation without nasal cannula|Subject is fitted with a face mask and undergoes three continuous minutes of positive pressure ventilation (Respironics AF521, EE with CapStrap headgear). Subject then removes mask and immediately exhales into an oxygen sensor (Maxtec Max-250E).
223660828|NCT02728492|DRUG|Quisinostat|
223769343|NCT03139916|RADIATION|Radiation|Radiation causes cell death and shrinks and kills the cancer cells.
223660829|NCT02728492|DRUG|Paclitaxel|
223660830|NCT02728492|DRUG|Carboplatin|
223660831|NCT02728492|DRUG|Gemcitabine|
223660832|NCT02728492|DRUG|Cisplatin|
223660833|NCT01934270|OTHER|Anaerobic Test|To evaluate the secretion of growth hormone in response to anaerobic exercise in children.
223660834|NCT01048632|DRUG|Oxandrolone|2.5 mg oxandrolone tablets.Based upon the patient's body weight, the coordinator, PI or sub-PI will determine the appropriate dose of oxandrolone (0.1 mg/kg/dose twice daily via the buccal mucosa.)
223769344|NCT00003002|BIOLOGICAL|HER-2/neu peptide vaccine|
223769345|NCT00003002|BIOLOGICAL|sargramostim|
223769346|NCT01620580|BEHAVIORAL|Self-management|"Participants in the intervention group will receive printed self management strategies each of the 5 symptoms, a symptom diary with the self-management strategies and a 15 minutes discussion. The intervention script will instruct participants on how to use the printed strategies by PI and RA #1.~Week 3"
223660835|NCT00632606|DRUG|magnesium sulfate|magnesium sulfate 2 grams intravenously; both groups will receive acetaminophen (Tylenol®) 1 gram orally
223660836|NCT00632606|DRUG|metoclopramide|metoclopramide 10 mg intravenously; both groups will receive acetaminophen (Tylenol®) 1 gram orally
223660837|NCT02889367|DRUG|Odalasvir 100 mg|Participants will receive odalasvir 2\*50 mg tablet, orally once on Day 1.
223660838|NCT02889367|DRUG|Placebo|Participants will receive odalasvir matching placebo, tablet, orally once on Day 1.
223660839|NCT02889367|DRUG|Odalasvir 500 mg|Participants will receive odalasvir 10\*50 mg tablet, orally once on Day 1.
223660840|NCT02889367|DRUG|Odalasvir (Up to maximum 1000 mg)|Participants will receive odalasvir to be decided up to maximum of 20\*50 mg tablet, orally once on Day 1.
223660841|NCT03314571|OTHER|analgesia for labor|A prospective database to study the determinants of labor pain and the resulting maternal non satisfaction.
223660842|NCT05194423|DEVICE|Tricuspid Valve Replacement System via jugular vein|To eliminate the tricuspid regurgitation through orthotopically replacing tricuspid valve with LuX-Valve system via jugular vein.
223769347|NCT01620580|BEHAVIORAL|Dietary Information|The control or usual care group will receive a symptom diary designed for the control group without any strategies and a 5 minutes discussion on how to complete the diary from RA# 1. The PI will make weekly follow up calls on the same schedule as the intervention group starting week 4 until week 7 for a total of 4 calls focusing on enhancing healthy eating skills \& adherence to renal diet and fluid restriction without discussing any intervention with the group.
223769348|NCT03320239|BEHAVIORAL|HIV risk assessment and tailored suggestions|The intervention contains: HIV risk investigation, tailored suggestions and free HIV testing link
223769349|NCT03320239|BEHAVIORAL|HIV risk behavior assessment|It only contains HIV risk behavior assessment and routine education
223769350|NCT03320239|BEHAVIORAL|placebo control|It only contains HIV/AIDS knowledge assessment and routine education
223769351|NCT05668065|BIOLOGICAL|CoronaVac/CoronaVac|Two doses at 21-day +/- 3 days. Each innoculation dose is 0.5 ml containing 600 SU in-house unit (equals to 3μg) of SARS-CoV-2 antigen.
223769352|NCT05668065|BIOLOGICAL|CoronaVac/BNT162b2|"First dose of Coronavac. Each innoculation dose is 0.5 ml containing 600 SU in-house unit (equals to 3μg) of SARS-CoV-2 antigen.~Second dose of BNT162b2 at 21-day +/- 3 days. Each dose of the Pfizer-BioNTech COVID-19 Vaccine is 0.3 ml. Each prefilled syringe contains 30 mcg of a nucleoside-modified messenger RNA (modRNA) encoding the viral spike (S) glycoprotein of SARS-CoV-2"
223769353|NCT02064738|BEHAVIORAL|Restricting daily intake of omega-6 fatty acids to less than 4 grams and increasing omega-3 fatty acids to 3 grams|
223769354|NCT00813358|DEVICE|Zenith TX2® TAA Endovascular Graft|Endovascular treatment with the study device
223769355|NCT00004031|BIOLOGICAL|rituximab|375 mg/m2 IV every 21 days
223769356|NCT00004031|DRUG|CHOP regimen|
223769357|NCT00004031|DRUG|carmustine|
224241493|NCT04937348|DIAGNOSTIC_TEST|Acquisition and analysis of milk samples|"In order to ensure reproducible results, breast milk samples were collected using a breast pump. Samples were taken in the morning, after the newborn was breastfed. The entire breast was emptied. In order to ensure the stability of the microbiological and nutritional composition, the milk samples were cooled immediately after collection, and then divided into test tubes and frozen (-80 C) until the laboratory tests were made.~The concentrations of macronutrients (protein, fat, carbohydrate) in breast milk were determined using a Human Milk Analyzer (HMA; Miris, Uppsala). Tissue hormones, e.g. adipokines: visfatin, omentin-1 were determined by ELISA method using commercial reagent kits."
223660843|NCT02878187|DEVICE|Doppler|"Color Doppler ultrasound will be used to demonstrate the main ascending branches of left and right uterine arteries as they cross over the hypogastric vessels just before they enter the uterus at the uterine-cervical junction. The high pass filter was set at 125 Hz and the uterine artery will be obtained immediately after the crossing of the hypogastric artery. The sample volume will be placed on the artery with an angle of about 0°. After detection of blood flow and visu¬alization of the waveform of the uterine artery, five blood flow indices will be automatically cal¬culated:~The pulsatility index The resistance index The peak systolic velocity ; The end-diastolic velocity The time-averaged maximum"
224241494|NCT04937348|DIAGNOSTIC_TEST|Collection, preparation and analysis of mother's blood samples.|Blood samples were collected from the mothers (fasting if possible) on the day the milk samples were taken. After collection, fasting glucose and insulin, as well as glycated hemoglobin were marked, and the other samples were centrifuged and frozen until analyzed (-80 C). Determination of adipokines was performed by ELISA method, using commercial reagent kits.
223660844|NCT01671579|PROCEDURE|Bowel ultrasound|The ultrasound imaging will take place prior to the clinically ordered MRE exam. The subject will be asked to lie on the ultrasound table for approximately 60 minutes while a variety of ultrasound images are completed.
223660845|NCT01671579|PROCEDURE|magnetic resonance enterography (MRE)|The subject will have a small intravenous (IV) catheter placed in on of their arms before the MRE exam. Medications called Glucagon and MultiHance will be given thru the IV catheter during the imaging study. The glucagon will decrease the movement of the intestines, which helps provide better images of the bowel. MultiHance is a contrast that helps create clearer MRE images. In addition to the MultiHance, the subject will be given an oral contrast medication called VoLumen to drink approximately 45 minutes before the MRE imaging is started. These medications are used for all clinically necessary MRE studies performed in children and adults at the UMHS. The MRE will take approximately 50 to 60 minutes to complete.
223660846|NCT05235490|OTHER|Non intervention|"Data study with inclusion of patients and retrospective clinical data collection, combining :~* Proofreading by radiologist of the CT scan performed (within 2 months prior to surgical intervention)~* Proofreading by iBiopsy® of the CT scan performed (within 2 months prior to surgical intervention)~* Proofreading of tumor sample slides by pathologists~* Patients follow-up (imaging, clinical)~* Recurrence-free survival"
223660847|NCT04671732|PROCEDURE|Fenestrated endovascular aortic aneurysm repair|Fenestrated endovascular aortic aneurysm repair consists in excluding a juxtrenal or suprarenal aneurysm by deploying a covered stent (stent graft) in the aorta so as to created sealing zones on both sides of the aneurysm. Since the proximal sealing is located in the visceral segment of the aorta, fenestrations are created to maintain blod flow in renal and visceral arteries. These fenestrations are custom made for each patient. Brindging covered stents are deployed between each fenestration and corresponding target arteries in order to insure sealing of the system.
223660848|NCT04671732|PROCEDURE|open repair of abdominal aortic aneurysm.|Open repair of abdominal aortic aneurysms consists in cross-clamping the aorta on both sides of the aneurysm and replace the diseased segment by a prosthetic graft.
223660849|NCT04129151|DRUG|Palbociclib|Oral, per protocol pre determined dosage, once a day for 21 days
223660850|NCT04129151|DRUG|Ganitumab|-Intravenous, per protocol predetermined dosage, twice per cycle
223660851|NCT03034551|BEHAVIORAL|Financial Incentive, Mobile Phone App, and Cellular Scale|Subjects will be provided a cellular-connected digital scale and will be offered $150 to use the app each day to log one daily self-weighing and one medication check-in. Medication check-ins consist of uploading daily photos of pills at the time of self-administration through the Wellth app. If a 2 lb or greater daily increase in weight, or a 5 lb weekly increase in weight is detected in any patient, a UMCPP physician or nurse will be alerted via automatic email and text. A physician or a nurse will then call the patient to assess the patient's symptoms. If there are increasing heart failure symptoms, the physician or nurse will suggest the patient see their doctor within the next 48 hours and will notify the patient's primary care physician and cardiologist.
223660852|NCT03950921|BEHAVIORAL|Patient Safety Display|Digital display of catheter and pressure injury information in patient hospital room
223660853|NCT02809716|OTHER|Biomarker Analysis|Correlative studies
223660854|NCT02809716|OTHER|Cytology Specimen Collection Procedure|Undergo collection of blood and tissue samples
223660855|NCT05910671|BEHAVIORAL|Physical Activity Phone Calls and Notebook|This intervention encouraged parents to model physical activity behaviors and co-participate in physical activity with their young child. Each week behavioral strategies for promoting physical activity change will be discussed to help parents work towards meeting their activity goals. As part of the physical activity intervention parents will receive a physical activity notebook that has newsletters, suggested activities that can be done with their child, and other material that will help the parent and child be active active together. The behavioral strategies and the information in the notebook will will be discussed weekly for 30 minutes via telephone.
223660856|NCT06429553|PROCEDURE|Minimally invasive hematoma aspiration drainage combined with urokinase injection|Minimally invasive hematoma aspiration drainage combined with urokinase injection
223660857|NCT06013813|PROCEDURE|Radial Artery approach on percutaneous coronary intervention (PCI)|"* Randomized patients with a right patent radial artery.~* The outcomes of the distal radial approach will be compared with those of the conventional radial approach.~* Technique and devices (introducer and compression devices) are the same in both approaches."
223769358|NCT00004031|DRUG|cyclophosphamide|
223769359|NCT00004031|DRUG|doxorubicin hydrochloride|
223769360|NCT00004031|DRUG|etoposide|
223769361|NCT00004031|DRUG|prednisone|
223769362|NCT00004031|DRUG|vincristine sulfate|
223769363|NCT00004031|PROCEDURE|bone marrow ablation with stem cell support|
223660858|NCT02730195|DRUG|Pioglitazone|Given PO
223660859|NCT02730195|DRUG|Tyrosine Kinase Inhibitor (TKI)|Given TKI therapy
223660860|NCT02031328|RADIATION|Stereotactic Ablative Radiation|
223660861|NCT00906737|DEVICE|Ankle-bot|The Ankle-bot is a piece of robotic therapy equipment for the ankle. In this study, it will be used to guide and assist the subject into ankle flexion, extension, inversion and eversion.
223660862|NCT00906737|OTHER|Conventional focused ankle therapy|Conventional focused ankle therapy will be performed by a physical therapist.
223660863|NCT02150694|PROCEDURE|Forearm venous occlusion plethysmography|Forearm venous occlusion plethysmography to study to measure forearm blood flow during intra-arterial infusion of the apelin peptides.
223660864|NCT02150694|PROCEDURE|Aellig hand vein technique|Hand vein measurements will be used to assess the response to apelin peptides and apelin receptor blocker in the human hand vein vascular bed.
223660865|NCT02150694|OTHER|Apelin agonist infusion|Escalating doses of apelin (1/10/100nmol/min) will be administered.
223660866|NCT02150694|OTHER|Apelin receptor antagonist infusion|Dose finding study (range 1-300nmol/min) and co-infusion study with apelin peptides
223660867|NCT01795768|DRUG|AZD 4547|
223660868|NCT00523263|DEVICE|heparin-bonded and collagen coated polyster|femoro-popliteal bypass
223660869|NCT00523263|DEVICE|Human umbilical vein femoro-popliteal bypass|
223660870|NCT01539044|DRUG|Neostigmine, atropine|0.05 mg/KG NEOSTIGMINE AND 0.02 MG/ KG ATROPINE at TOF 2
223660871|NCT01539044|DRUG|Sugammadex|4 mg/kg sugammadex will be given stat at the end of surgery at PTC 1-2
223660872|NCT06351384|DEVICE|miRNA detection test|miRNA sequencing based on Next-Generation Sequencing (NGS) technology
223660873|NCT03406091|DRUG|Plerixafor|Plerixafor (AMD3100) is a selective, reversible inhibitor of the receptor chemokine (C-X-C motif) receptor 4 (CXCR4) and prevents binding of its cognate ligand stromal cell derived factor-1α (SDF-1α), also known as chemokine (C-X-C motif) ligand 12 (CXCL12) \[3\]. CXCR4 is a co-receptor, along with CD4, for the binding of human immunodeficiency virus, type 1 (HIV-1) to its receptor cells.
223660874|NCT00106509|DRUG|tolevamer potassium-sodium (GT267-004)|
223660875|NCT01822314|DRUG|Abraxane|Abraxane at the dosage of 125 mg/m2 will be delivered over 30 minutes on week 1, 2 and 3 followed by 1 week rest. week rest and will be repeated for 4 cycles followed by AC or EC (adriamycin or epirubicin and cyclophosphamide) on day 1 every 3 weeks for 4 cycles or FEC (fluorouracil, epirubicin, and cyclophosphamide) on day 1 every three weeks for 4 cycles
223660876|NCT01822314|DRUG|Paclitaxel|Paclitaxel at the dosage of 90 mg/m2 diluted in 250 mL of water for injection (WFI) over 1 hour given week 1, 2 and 3 followed by 1 week rest and will be repeated for 4 cycles followed by AC or EC (adriamycin or epirubicin and cyclophosphamide) on day 1 every 3 weeks for 4 cycles or FEC (fluorouracil, epirubicin, and cyclophosphamide) on day 1 every three weeks for 4 cycles
223660877|NCT05181280|OTHER|Intervention Group|"Exposure session will consist of 15 social media ideal body message posts."
223769364|NCT00004031|PROCEDURE|peripheral blood stem cell transplantation|
223769365|NCT00004031|RADIATION|radiation therapy|
223660878|NCT05181280|OTHER|Control Group|Exposure will consist of 15 social media posts on infant feeding tips.
223660879|NCT05373069|PROCEDURE|Mechanical ischemic preconditioning of diep-type flap|"Mechanical ischemic preconditioning: Performing series of reperfusion ischemia on the flap pedicle, before cold ischemia of the flap (flap harvesting before vascular mechanical anastomoses at the recipient site)~* 10 min of clamping with single-use microvascular forceps~* 10 min declamping~* 10 min of tightening with pliers~* 10 min declamping Either preconditioning for 40 minutes, simulating 2 cycles of ischemia reperfusion prior to flap harvesting and cold ischemia before revascularization."
223660880|NCT01463007|RADIATION|Accelerated partial breast irradiation|Accuboost APBI 34.0 Gy in 10 fractions
223660881|NCT01463007|OTHER|Extended Follow up|This arm extends follow up at the Rhode Island Hospital location to 5 years. Annual mammograms and additional documentation is required to be submitted only if completed.
223660882|NCT05948384|OTHER|PNF|For the PNF intervention, we applied a lower extremity hip extension-abduction-internal rotation with knee extension pattern, together with the rhythmic initiation of a repeated stretch and a combination of isotonic techniques. By this we'll target rectus femoris, medial gastrocnemius, lateral gastrocnemius, biceps femoris and semitendinosus musculature of the patient. The session will be given in 2 sets of 5 repetitions with rest of 45 seconds
223660883|NCT04521504|DEVICE|Kinematic biofeedback with ISEO motion analysis system|Exercises are performed with the help of the ISEO motion analysis system, that provides a real-time biofeedback of shoulder kinematics. All exercises are administered by the Physical Therapist.
223660884|NCT03486626|DRUG|Metformin|Metformin to increase pregnancy rate in polycystic ovarian syndrome patients
223660885|NCT05409534|OTHER|Backward Walking (Exercise group)|The participant will apply a maximum of 40-50 minutes of exercise, including 10 minutes of warm-up exercise, 30 minutes of backward walking training and 10 minutes of cooling-off exercise. The maximum time to do backward walking training will be 30 minutes. In the backward walking exercise, 1 set will take 5 minutes. The maximum number of sets that can be made will be 6 sets. No more than 6 sets will be made.
223660886|NCT05409534|OTHER|Forward Walking (Control Group)|The participant will apply a maximum of 40-50 minutes of exercise, including 10 minutes of warm-up exercise, 30 minutes of forward walking training and 10 minutes of cooling-off exercise as the home exercise programme.
223660887|NCT04327193|PROCEDURE|Titrated PEEP based on driving pressure|Alveolar recruitment and PEEP titration is performed at three time points: after intubation, after Trendelenburg, and after supine after CO2 deflation. The level of PEEP which makes the driving pressure lowest is selected and applied during the operation.
223660888|NCT04327193|PROCEDURE|Conventional PEEP|Alveolar recruitment is performed at three time points: after intubation, after Trendelenburg, and after supine after CO2 deflation. Conventional PEEP (5cmH2O) is applied during the operation.
223660889|NCT02801266|BEHAVIORAL|Evidence informed birth control counseling|Counselors underwent training on the use of 10 best practices for contraceptive counseling.
223660890|NCT00689117|DRUG|CT Gel|Topical gel consisting of clindamycin 1% and tretinoin 0.025%, applied once daily in the evening for 12 weeks
223660891|NCT00689117|DRUG|Clindamycin Gel (clindamycin )|Clindamycin 1% gel applied topically once daily in the evening for 12 weeks
223660892|NCT00689117|DRUG|Tretinoin Gel (tretinoin)|Tretinoin 0.025% gel applied topically once daily in the evening for 12 weeks
223660893|NCT00689117|DRUG|Vehicle Gel|Topical gel without clindamycin or tretinoin applied topically once daily in the evening for 12 weeks
223660894|NCT01206322|DRUG|Intranasal insulin|The acute effects of a single 40-IU dose of intranasal insulin
223660895|NCT01206322|DRUG|Placebo|The acute effects of intranasal sterile saline.
223660896|NCT02828670|BIOLOGICAL|blood sample|
223660897|NCT02828670|PROCEDURE|spleen sample|
223660898|NCT03635658|PROCEDURE|titanium mesh|the non resorbable titanium mesh is used to fix the 1:1 mixture of autograft and xenograft particulate bone on the severely atrophies maxillary ridge.
223660899|NCT03635658|PROCEDURE|collagen membrane (Sausage technique)|the resorbable collagen membrane is used to fix the 1:1 mixture of autograft and xenograft particulate bone on the severely atrophies maxillary ridge.
224241495|NCT04937348|DIAGNOSTIC_TEST|Body composition assessment|The body composition of newborns was determined by a non-invasive electrical bioimpedance method using the body composition analyzer.
224241496|NCT04937348|OTHER|Anthropometric measurements|"Based on the mother's medical records, maternal height and pregnancy weight changes were recorded. On the day the biological material is collected, the mother was weighed.~From the baby's documentation, measurements of the length, head circumference and body weight taken after delivery and during the hospitalization were recorded. These measurements were repeated on the days of the body composition analysis."
223660900|NCT00472758|BIOLOGICAL|MEDI 545|IV dosed at 1.0 mg/kg, 3.0,g/kg, 10.0mg/kg and 30.0mg/kg
223660901|NCT00472758|OTHER|Placebo|IV Placebo dosed at 1.0 mg/kg, 3.0,g/kg, 10.0mg/kg and 30.0mg/kg
223660902|NCT00802113|DRUG|Fludarabine|Fludarabine 30 mg/m2 x 5 days
223660903|NCT00802113|DRUG|Busulfan|Busulfan 3.2 mg/kg/day x 2 days
223660904|NCT00802113|DRUG|Anti-Thymocyte Globulin|Anti-Thymocyte Globulin 2.0 mg/kg/day x 4 days
223660905|NCT00859638|BEHAVIORAL|Physiotherapy|group self-management classes
223660906|NCT00859638|BEHAVIORAL|Occupational Therapy|group self-management classes
223660907|NCT00859638|BEHAVIORAL|Capacity Building|workshops and case reviews with primary health care team members
223660908|NCT01488123|BEHAVIORAL|Individualized manualized Ayurvedic intervention|The manualized intervention will begin with an initial clinic visit (approximately 90 minutes) with the Ayurvedic practitioner in which the patient's diagnosis will be determined, an overview of Ayurveda will be given, and the initial treatment will be recommended based on the Ayurvedic diagnosis. Follow-up visits will range between 30 and 60 minutes in duration. The treatment modalities employed in the study will include nutrition, lifestyle, yoga, and marma (a treatment similar to acupressure).
223660909|NCT02299739|DRUG|Herbal medicine|Herbal medicine was taken 3 times daily in dried powder (2g) and water-base decoction form (120ml) (Ostericum koreanum, Eucommia ulmoides, Acanthopanax sessiliflorus, Achyranthes bidentata, Psoralea corylifolia, Peucedanum japonicum, Cibotium barometz, Lycium chinense, Boschniakia rossica, Cuscuta chinensis, and Atractylodes japonica).
223660910|NCT02299739|PROCEDURE|Acupuncture|Acupuncture treatment was administered 1-2 times daily using mainly Ah-shi points and local acupuncture points.
223660911|NCT02299739|PROCEDURE|Pharmacopuncture|Select ingredients similar to those included in the oral herbal medicine (Ostericum koreanum, Eucommia ulmoides, Acanthopanax Sessiliflorus, Achyranthes bidentata, Psoralea corylifolia, Peucedanum japonicum, Cibotium barometz, Lycium chinense, Boschniakia rossica, Cuscuta chinensis, and Atractylodes japonica) were freeze dried into powder form after decoction, then diluted in normal saline and adjusted for acidity and pH to be used in injections. The pharmacopuncture injections were injected once daily to the amount of 1 cc and Ah-shi points and local acupuncture points (CPL, 1 cc, 26G x 1.5 syringe, Shinchang medical co., Korea).
223660912|NCT02299739|PROCEDURE|Bee venom pharmacopuncture|Bee venom pharmacopuncture was applied after confirming a negative reaction to the hypersensitivity skin test. Diluted bee venom (saline:bee venom ratio, 10,000:1) was injected at 4-5 acupoints at the physician's discretion. Each acupuncture point was injected with approximately 0.2 cc to a total of 0.5-1 cc using disposable injection needles (CPL, 1 cc, 26G x 1.5 syringe, Shinchang medical co., Korea).
223660913|NCT02299739|PROCEDURE|Chuna manipulation|Chuna was administered 3-5 times a week. Chuna is a Korean version of spinal manipulation that incorporates conventional spinal manipulation techniques for mobilization involving high-velocity, low amplitude thrusts to joints slightly beyond the passive range of motion and gentle force to joints within the passive range of movement.
223660914|NCT00745589|DRUG|sevelamer hydrochloride|First-line higher dose (that is, 800mg TDS and up to a maximum of 1200mg TDS) sevelamer hydrochloride will be compared against low dose second-line sevelamer hydrochloride (that is, fixed dose of 400mg TDS)
223660915|NCT02969408|DRUG|Albuterol Sulfate|Albuterol sulfate will be administered as per the dose and schedule specified in the arm.
223660916|NCT02150902|PROCEDURE|Wide area circumferential catheter ablation|All subjects in the control arm of the trial will undergo wide area circumferential catheter ablation (WACA; lesions delivered 1-2 cm away from the pulmonary vein ostium) around all four pulmonary veins to the endpoint of electrical isolation (demonstrated by entry and exit block using differential pacing). Catheter ablation will be performed using contact force (CF) and electroanatomical mapping system guidance (average CF \>10g, FTI \> 500 g-sec and minimum ablation duration \>10 sec). Dormant pulmonary vein conduction will be tested using adenosine, after completion of the lesion set, and additional lesions will be delivered to eliminate dormant PV conduction.
224241497|NCT05908266|OTHER|Reaching movements|Participants will be instructed to perform reaching movements by moving the handle of a robotic arm mounted with a virtual reality display.
224241498|NCT05908266|OTHER|Disease Assessment|Disease stage assessed by trained professionals
224241499|NCT06048146|DRUG|Experimental: FOLFOXIRI and Lateral lymph node dissection|Irinotecan 150mg /m2, d1, oxaliplatin 85mg/m2, d1, 5-Fu, 2400mg/m2, pumped continuously for 46 hours and repeated for 14 days
224241500|NCT06048146|DRUG|Preoperative long-term concurrent chemoradiotherapy and Lateral lymph node dissection|Radiotherapy was administered five days a week (pelvic 2 Gy/ time, GT50 Gy) for five weeks with capecitabine (1650mg/m2/ day, orally divided into two doses). Intensity modulated radiotherapy (IMRT) was used
224241501|NCT03079050|DRUG|Dexlansoprazole 60 MG|This drug will be given to 34 random patients during the 2nd, 3rd, and 4th weeks of the month of Ramadan to assess its ability to relieve GERD symptoms
223660917|NCT02150902|PROCEDURE|Augmented- wide area circumferential ablation procedure|Subjects in this group will have WACA performed as described for WACA. Following completion of the WACA procedure a second set of circumferential ablation lesions will be delivered around the first set of ablation lesions. The ablation catheter tip will be positioned at each of the ablation lesions along the first WACA line and then moved away (from the PV ostia) until healthy, non ablated tissue is recorded from the catheter tip. Energy will be delivered using CF and FTI data as described previously. Once the first WACA ablation line has been completely duplicated the procedure will be deemed complete. In case PV isolation is not achieved after the first WACA lesion set repeat electrophysiologic testing will be performed to determine whether the augmented-WACA procedure was successful in achieving PV isolation.
223660918|NCT00977301|DRUG|fosamprenavir/ritonavir|16 days 700mg/100mg RTV BID
223660919|NCT00977301|DRUG|olanzapine|15 mg olanzapine single dose
223660920|NCT00977301|DRUG|olanzapine|10 mg olanzapine single dose
223660921|NCT00973297|OTHER|Multidisciplinary falls prevention|Group education on falls risk and mobility and transfers safety; Physical therapy at the subjects' bedside consisting of balance training; Medical assessment - medications use (anxiolytics/hypnotics, neuroleptics, antihypertensives, antiarrhythmics and other vasodilators) with effort to discontinue or reduce dose when possible; orthostatic hypotension - discontinue/reduce dose of related medications; urinary frequency/incontinence - evaluation and treatment; delirium - evaluation and treatment; visual pathology - evaluation and treatment
223660922|NCT06435065|DRUG|Biodentine|DIRECT PULP CAPPINGWILL BE DONE USING BIODENTINE
223660923|NCT06435065|DRUG|Mineral Tri-Oxide Aggregate|DIRECT PULP CAPPINGWILL BE DONE USING MTA
223660924|NCT06435065|DRUG|THERACAL LC|DIRECT PULP CAPPINGWILL BE DONE USING THERACAL LC
223660925|NCT06435065|DRUG|TRISTRONTIUM ALUMINATE|DIRECT PULP CAPPINGWILL BE DONE USING TRISTRONTIUM ALUMINATE
223660926|NCT03268070|DEVICE|Repetitive TMS over contralateral premotor cortex.|Repetitive Transcranial magnetic stimulation (rTMS) will be applied over contralateral premotor cortex during motor training. TMS uses magnetism to excite neurons near the surface of the brain. Frequency of rTMS: 0.1 Hz; time of rTMS: 50 milliseconds before the onset of movement-related electromyography (EMG); device: Super Rapid 2 Transcranial Magnetic Stimulator.
223660927|NCT03268070|DEVICE|Repetitive TMS over ipsilateral premotor cortex.|Repetitive Transcranial magnetic stimulation (rTMS) will be applied over ipsilateral premotor cortex during motor training. TMS uses magnetism to excite neurons near the surface of the brain. Frequency of rTMS: 0.1 Hz; time of rTMS: 50 milliseconds before the onset of movement-related electromyography (EMG); device: Super Rapid 2 Transcranial Magnetic Stimulator.
223660928|NCT03268070|DEVICE|Repetitive TMS over contralateral primary motor cortex.|Repetitive Transcranial magnetic stimulation (rTMS) will be applied over contralateral primary motor cortex during motor training. TMS uses magnetism to excite neurons near the surface of the brain.Frequency of rTMS: 0.1 Hz; time of rTMS: 50 milliseconds before the onset of movement-related electromyography (EMG); device: Super Rapid 2 Transcranial Magnetic Stimulator.
223660929|NCT03268070|DEVICE|Sham Repetitive TMS over contralateral premotor cortex.|Sham rTMS will be applied over contralateral premotor cortex. TMS uses magnetism to excite neurons near the surface of the brain. Frequency of rTMS: 0.1 Hz; time of rTMS: 50 milliseconds before the onset of movement-related electromyography (EMG); device: Super Rapid 2 Transcranial Magnetic Stimulator.
223660930|NCT03268070|DEVICE|Single TMS over extensor carpi ulnaris spot of motor cortex|Single-pulse TMS will be applied over the extensor carpi ulnaris (ECU) hotspot of primary motor cortex (M1) during motor training.TMS uses magnetism to excite neurons near the surface of the brain. TMS pulses will be applied at different strengths (30%-80% maximum stimulator output) and record subsequent activity of the ECU muscle using electromyography (EMG).
223660931|NCT05477082|OTHER|Observational group|Includes blood draws and data collection only
223660932|NCT02779556|OTHER|ACP Living with Diabetes Guide|American Colleges of Physicians (ACP) Living Well with Diabetes Guide
223660933|NCT02779556|OTHER|ADA Living Well with Diabetes Workbook|American Diabetes Association (ADA) Living Well with Diabetes Workbook
223660934|NCT01344525|PROCEDURE|Laparoscopic gastric sleeve|Laparoscopic gastric sleeve
223660935|NCT01344525|PROCEDURE|Gastric Banding|Gastric Banding
223769366|NCT04809909|PROCEDURE|Peripheral stimulation of acupuncture points (PSAP)|Electrode leads will be implanted at Bladder 25-bilateral (BL25), the acupoint commonly used for relief of chronic Low Back Pain in standardized acupuncture.
223769367|NCT04809909|PROCEDURE|Peripheral nerve field stimulation (PNFS)|Electrode leads will be implanted at the region of pain.
223769368|NCT06114264|BEHAVIORAL|Multimodal + Resistance Programs|"Exercise: will focus on working the all body by performing functional tasks. Behaviour change: An 'idle alert' of the wrist-worn activity prompter will be set to vibrate after 45 min without movement. Participants will be encouraged to take a 1-2 min activity break.~Education: The basic contents will explain to the patient the main mechanism of chronic pain (pain as a protective system, consequences, etc).~The Mindfulness Based Stress Reduction (MBSR) program will strictly follow the protocol developed by Jon Kabat Zinn. Each session will include three activities: the presentation of a topic, moments of dialogue and exploration in group and a Mindfulness practice.~Resistance functional exercises will replicate functional movements, such as standing from a bed, carrying bags, picking up groceries from the ground, etc."
223769369|NCT06114264|OTHER|Control group|No experimental intervention. The group will receive the same multimodal intervention as the experimental group when the experimental period is over.
223769370|NCT03490370|DEVICE|Electro-muscular stimulation using NeuroTrac MyoPlus 2/4|In this pilot study we aim to determine if change in the muscle metabolism can resolve insulin resistance in NAFLD through muscle stimulation by using electro-stimulation. We hypothesise that 6x35 minute sessions per week over a 12 week time scale would mimic effects of resistance exercise on metabolic parameters associated with NAFLD and hepatic steatosis. All 20 participants will have the electro-stimulation intervention.
223660936|NCT01344525|PROCEDURE|Multidisciplinary lifstyle intervention|Multidisciplinary lifstyle intervention (OPTIFAST®52-program)
223660937|NCT01344525|PROCEDURE|Roux-en-Y Bypass|Roux-en-Y Bypass
223660938|NCT04631211|BIOLOGICAL|Thrombosomes|Human platelet derived lyophilized hemostatic
223769371|NCT03261583|OTHER|Thoracis Surgery - Common care|Observational study. It is only a matter of collecting clinical data.
223660939|NCT04631211|BIOLOGICAL|Liquid Stored Platelets (LSP)|Leukocyte reduced apheresis platelets or whole blood derived pooled platelet concentrate equivalent (4-6 units)
223660940|NCT05857696|OTHER|walking quantified analysis|Test to measure anthropometry, joint amplitudes, muscle strength and spasticity of the lower limbs on a treadmill.
223660941|NCT01145586|DRUG|Lactase Oral Tablets|3 tablets/day for 42 days Take with breakfast, lunch and dinner
224241502|NCT05820958|OTHER|Shantali massage|"The tactile contact of a mother with the newborn was intensified by means of Shantali massage applied at least 2 times a day, 10 min. Additional, spontaneous sessions were allowed as well. This started on the 3rd day after delivery and lasted until the end of the 12th week after delivery. A total of 169 mandatory sessions should have been provided plus spontaneous sessions, if any.~The order of application:~* face and chest; 4 types of movements 10reps each;~* upper extremity; 4 types of movements, 10 reps each (left and right separately);~* abdomen; 2 types of movements, 10 reps each;~* lower extremity; 3 types of movements, 10 reps each (left and right separately);~* back; 2 types of movements, 10 reps each;~* final integration; 3 types of movements, 10 reps each."
224241503|NCT03953950|DRUG|Spironolactone|Spironolactone Starting dose: 25 mg/day Target dose: 100 mg/day Titration: every 1-2 weeks, based on BP (keep\< 140/90 mmHg, but avoid hypotension \<90/60 mmHg), and serum potassium level (\<5.5 milliequivalent /liter)
223660942|NCT02216604|BEHAVIORAL|Multimodal Exercise Intervention|During their inpatient hospitalization the participants perform 3-5x weekly guided training sessions about 15-30min. The intervention includes: game console-based training using Nintendo Wii® (endurance, strength endurance and balance), age-specific resistance training and sessions of body awareness. During the outpatient phases the participants perform a home-based exercise training 3-5x weekly using a training manual. In addition, the patients obtain a movement diary and a pedometer for documenting their activity level.
223660943|NCT02223377|DRUG|Morphine|1st dose: syringe of 0.04mg/kg morphine units (rounding off to the nearest 1 ml or 0.5 ml); with a maximum of 3 mg of morphine equivalents is administered. Repeat doses: 0.02 mg/kg morphine units every 5-10 minutes to titrate for analgesia and side effects (rounding off to the nearest 1 ml or 0.5 ml)
223660944|NCT02223377|DRUG|Hydromorphone|1st dose: syringe of 0.04mg/kg morphine units (rounding off to the nearest 1 ml or 0.5 ml); with a maximum of 3 mg of morphine equivalents is administered. Repeat doses: 0.02 mg/kg morphine units every 5-10 minutes to titrate for analgesia and side effects (rounding off to the nearest 1 ml or 0.5 ml)
223660945|NCT00942526|DRUG|Mycostatin oral suspension|peroperative Mycostatin oral suspension ( 0.1MU/cc, 24cc/bt; 5cc qid)for 7 days
223660946|NCT00942526|OTHER|Water|perioperative gargling with water
223660947|NCT05808569|BEHAVIORAL|Test|A specific self-test composed by 16 questions , will be administered to BC patients undergoing adjuvant RT.
223660948|NCT06547138|DEVICE|Prophylactic mesh|Prevention of incisional hernia after a prophylactic mesh in high-risk patients
223660949|NCT03972943|PROCEDURE|Continuous Positive Airway Pressure|Receive CPAP treatment
223660950|NCT03972943|OTHER|Patient Observation|Undergo observation
223660951|NCT03972943|OTHER|Questionnaire Administration|Ancillary studies
223660952|NCT02901704|DEVICE|Renal Denervation System (AngioCare)|After a renal angiography according to standard procedures, subjects remain blinded and are immediately treated with the renal denervation procedure after randomization.
223660953|NCT02901704|PROCEDURE|Sham procedure|After a renal angiography according to standard procedures, subjects remain blinded and remain on the catheterization lab table for at least 10 minutes prior to introducer sheath removal.
223660954|NCT00462397|DRUG|carboplatin|
223660955|NCT00462397|DRUG|cisplatin|
223660956|NCT00462397|DRUG|paclitaxel|
223769372|NCT01556542|DEVICE|paclitaxel-eluting balloon angioplasty followed by nitinol stent implantation|paclitaxel-eluting balloon angioplasty followed by nitinol stent implantation
223660957|NCT00462397|PROCEDURE|neoadjuvant therapy|
223660958|NCT00462397|RADIATION|brachytherapy|
223660959|NCT00462397|RADIATION|radiation therapy|
223660960|NCT06110169|DEVICE|Anodal Transcranial Direct Current Stimulation (Anodal tDCS)|Battery driven tDCS will be applied at 2 mA intensity to the dorsolateral prefrontal cortex and primary motor cortex for 20 minutes.
223660961|NCT06110169|DEVICE|Sham Transcranial Direct Current Stimulation (tDCS)|Participants will receive 20 minutes of sham anodal tDCS
223660962|NCT03139591|DRUG|lidocaine inhalation; intravenous dexamethasone|1.5 mg/kg body weight (BW) of 2% lidocaine inhalation, diluted with 2-3 ml of normal saline until the total volume was 6 ml, and intravenous normal saline injection; Intravenous dexamethasone group: normal saline inhalation and 10 mg of intravenous dexamethasone.
223660963|NCT00846963|DRUG|Ursodiol|"Ursodiol is given by mouth, three times a day from second value of elevated conjugated bilirubin (\>33mmol/L) to the resolution of cholestasis (conjugated bilirubin \<34mmol/L) If Nil per os, 3,3mg/kg/dose is given. If Nil per os is required (e.g. pre-surgery, or necrotizing enterocolitis), none is given.~If enteral feeding is under 100mL/kg/day, 6,7 mg/kg/day is given. If enteral feeding exceeds 100mL/kg/day, 10 mg/kg/day is given."
223660964|NCT00846963|DRUG|placebo|Placebo given in the same amount that ursodiol would be given, depending on enteral feeding and weight. It is also given three times a day, until cholestasis resolution.
223660965|NCT00221468|DRUG|quetiapine|100mg of quetiapine on day 1 and titrated to a maximum dose of 400mg by day 4, with flexible dosing to 600mg by day 28. The total duration of treatment will be 84 days (12 weeks).
223769373|NCT01556542|DEVICE|nitinol stent implantation|nitinol stent implantation
224241504|NCT03953950|DRUG|Losartan|Losartan Starting dose: 50 mg/day Target dose: 100 mg/day Titration: every 1-2 weeks, based on BP (keep\< 140/90 mmHg, but avoid hypotension \<90/60 mmHg), and serum potassium level (\<5.5 milliequivalent /liter)
223660966|NCT04497051|DIAGNOSTIC_TEST|CT-DSA|CTA before and after embolization
223660967|NCT03236662|DRUG|(-)-Epicatechin|
223660968|NCT00194493|BEHAVIORAL|ESRA-C|Graphical summary of patient symptoms and quality of life
223660969|NCT02086396|DIETARY_SUPPLEMENT|pumpkin seed flour|The pumpkin seed flour group received 20g/day of pumpkin seed flour during 12 weeks
223660970|NCT02086396|DIETARY_SUPPLEMENT|Placebo (cassava flavored flour)|The group placebo (cassava flour flavored) received 20g/day of cassava flour flavored during 12 weeks.
223769374|NCT03314467|DIAGNOSTIC_TEST|polysomnography|"* classical polysomnography~* non invasive measurement of blood pressure~* blood test: determination of HbA1c, glucose, C-peptide, hemoglobin, white blood cell count, trombocytes"
223660971|NCT02948036|OTHER|Mobile-device, plasticity-based adaptive cognitive treatment|This study employs a mobile-device delivered treatment program. Participants will be asked to use the assigned treatment program for approximately 30 minutes per session, up to seven sessions per week, over 6 weeks (42 total sessions).
223660972|NCT00892736|OTHER|Laboratory Biomarker Analysis|Correlative studies
223660973|NCT00892736|OTHER|Pharmacological Study|Correlative studies
223660974|NCT00892736|DRUG|Veliparib|Given PO
223660975|NCT03616808|OTHER|Thromboelastometry-guided haemostatic treatment|Administration of blood products and/or procoagulants is based on thromboelastometric assays.
223660976|NCT03110770|BIOLOGICAL|VRC-ZKADNA090-00-VP|VRC-ZKADNA090-00-VP is composed of a single closed-circular DNA plasmid (VRC 5283) that encodes with wild type (wt) precursor transmembrane M (prM) and envelope (E) proteins from the H/PF/2013 strain of ZIKV
223660977|NCT03110770|OTHER|VRC-PBSPLA043-00-VP|A sterile phosphate-buffered saline (PBS) prepared for human administration as a placebo
223660978|NCT00260962|DRUG|Olanzapine|After a 2-week baseline period, olanzapine was administered for 10 weeks (weeks 3-12 of the study). Olanzapine was prescribed according to a flexible dose regimen, starting at the minimum dose of at 2.5 mg/day and titrated slowly by increments of 2.5 mg/week to a maximum dose of of 10 mg/day.
223660979|NCT00260962|BEHAVIORAL|Day Hospital|Day hospital program involved attendance 4 days a week from 9:00 am to 6:00 pm for 12 to 14 weeks, and supervised meals and group therapy.
223660980|NCT04748367|DEVICE|Virtual Reality Headset|Virtual Reality Headset running SILVER software
223660981|NCT01623557|BIOLOGICAL|ChAd63-MVA CS|1 dose of ChAd63 CS 5 x 10\^10 vp intramuscularly and 1 dose MVA CS 2 x 10\^8 pfu intramuscularly 8 weeks later.
223660982|NCT01623557|BIOLOGICAL|ChAd63-MVA ME-TRAP|1 dose of ChAd63 ME-TRAP 5 x 10\^10 vp intramuscularly and 1 dose MVA ME-TRAP 2 x 10\^8 pfu intramuscularly 8 weeks later.
223660983|NCT01623557|OTHER|Controlled Human Malaria Infection Administered by Mosquito Bite|Approximately 3 weeks post MVA dosing
223660984|NCT05713149|OTHER|Surgical flap and anti-bacterial agents|Surgical flap and anti-bacterial agents
223660985|NCT04441541|OTHER|Treadmill with auditory feedback|Participants will receive training 3 times per week for 4 weeks (12 sessions).
223769375|NCT00895180|BIOLOGICAL|olaratumab|Given IV
223769376|NCT00895180|BIOLOGICAL|ramucirumab|Given IV
223769377|NCT03766763|DRUG|Venetoclax|"Venetoclax is administered according to the usual schedule an escalating dose from 20 milligram per day the first week, then 50 milligram per day the second week, 100 milligram per day the third week, 200 milligram per day the fourth week and then 400 milligram per day.~* For patient achieving a Compete Response with Minimal Residual Disease inferior to 0,01 percent in bone marrow at month 12, treatment will be stopped at month18 (18 months for total duration of treatment ).~* For responding patients at month12 (Complete Response or Partial Response) with bone marrow Minimal Residual Disease inferior to 0.01 percent, treatment will be continued until month 24 (24 months for total duration of treatment)."
223769378|NCT03851016|BEHAVIORAL|Life Story Book|Life story Book is intended to allow a person the opportunity to reminisce chronologically through their life and capture their life stories into a book.
223660986|NCT04441541|OTHER|Treadmill with visual feedback|Participants will receive training 3 times per week for 4 weeks (12 sessions).
223660987|NCT04441541|OTHER|Treadmill with auditory and visual feedback|Participants will receive training 3 times per week for 4 weeks (12 sessions).
223660988|NCT04441541|OTHER|Treadmill training|Participants will receive training 3 times per week for 4 weeks (12 sessions).
223660989|NCT04709627|DEVICE|enFlow IV Fluid and Blood Warming System|The enFlow IV fluid/blood warming system's intended use is for warming blood, blood products and intravenous solutions prior to administration.
223660990|NCT01254162|DRUG|MTC896 Gel|0.75% w/w gel applied daily for 28 days to the forehead
223660991|NCT01086358|DRUG|Triptan|Usual prescribed triptans may include:sumatriptan, rizatriptan, naratriptan, almotriptan, eletriptan, zolmitriptan
223660992|NCT01086358|DRUG|Treximet 85Mg-500Mg Tablet|Treximet is 85 mg sumatriptan plus 500 mg naproxen sodium
223660993|NCT04375462|DEVICE|AspireAssist device|"Allows for aspiration of gastric contents into a receptacle or the toilet to prevent symptoms of nausea, vomiting, and to prevent aspiration.~Device is placed endoscopically in an identical fashion to a standard PEG tube G 1-2 days after enrollment"
223660994|NCT04375462|DEVICE|Standard decompressive PEG tube|"Allows for gastric drainage to prevent symptoms of nausea, vomiting, and to prevent aspiration.~Device is placed endoscopically 1-2 days after enrollment"
223660995|NCT04375462|OTHER|gastric outlet obstruction scoring system (GOOSS) questionnaire|"Gastric outlet obstruction scoring system (GOOSS) questionnaire~Both groups will receive the questionnaires via a phone call"
223769379|NCT03851016|BEHAVIORAL|Usual Care|Three weeks of Usual Care with no visits from research team
223769380|NCT02531165|DRUG|Fentanyl|Analgesia protocol using Fentanyl (initial dose: 50-100 mcg, additional doses of 25 mcg every 2-5 minutes to achieve adequate sedation, if required).
223769381|NCT02531165|DRUG|Morphine|Analgesia protocol using Morphine (initial dose: 4-8 mg, additional doses of 2 mg every 5-15 minutes to achieve adequate sedation, if required).
223769382|NCT02531165|DRUG|Ticagrelor|Pre-hospital Ticagrelor loading dose of 180 mg administered orally, followed by 90 mg bid
223769383|NCT02531165|DRUG|Aspirin|500 mg loading dose orally (or intravenously), followed by 100 mg od
223769384|NCT02531165|DRUG|Unfractioned Heparin|5'000 IU loading dose intravenously, additional doses to achieve an ACT \>250 sec during PCI are allowed.
223769385|NCT02531165|PROCEDURE|Primary PCI|Primary PCI with stent implantation according to the guidelines of the European Society of Cardiology.
223769386|NCT01619670|DEVICE|Apligraf|non adhesive layer
223769387|NCT03497559|OTHER|Music|Classical music
223769388|NCT00586469|BIOLOGICAL|Fluviral|One dose, Intramuscular injection
223769389|NCT00998634|DRUG|LITHIUM CARBONATE|Lithium Carbonate will be dosed based on lithiemy, which will be in the range 0.9-1.2 mEq/L. Maximum allowed dose will be 1500mg/day.
223769390|NCT03429491|DIETARY_SUPPLEMENT|Placebo|Protein-free, LC n-3 PUFA-free juice based supplement
223769391|NCT03429491|DIETARY_SUPPLEMENT|Leucine-enriched protein|Leucine-enriched whey protein
223660996|NCT04375462|OTHER|Modified Gastroparesis Cardinal Symptom Index (GCSI) questionnaire|"Modified Gastroparesis Cardinal Symptom Index (GCSI) questionnaire~Both groups will receive the questionnaires via a phone call"
223660997|NCT04375462|OTHER|Patient satisfaction and ease of use survey|"Patient satisfaction and ease of use survey~Both groups will receive the questionnaires via a phone call"
223660998|NCT00461474|BEHAVIORAL|Shoulder strengthening exercises|
223660999|NCT00461474|BEHAVIORAL|Movement Optimization|
223661000|NCT06092918|RADIATION|EXTERNAL RADIOTHERAPY|EXTERNAL RADIOTHERAPY
223661001|NCT01767142|DEVICE|The Zeltiq System with Modified Belt Applicator|Non-invasive cooling is applied to the treatment area with a defined cooling rate and duration.
223661002|NCT05693012|DIAGNOSTIC_TEST|cfDNA methylation assessment|An exploratory study to establish the early detection and prognosis models of multiple myeloma patients in China based on plasma cf DNA methylation assessment
223661003|NCT05637528|DIAGNOSTIC_TEST|MRI|Patients will undergo an MRI and mammography one year after MagTrace injections
223661004|NCT03753945|DIAGNOSTIC_TEST|MRI of the spine|Perform a clinically indicated MRI of the spine in DBS patients
223661005|NCT04975230|BEHAVIORAL|Sleep Self-Management|Intervention delivered by a sleep coach will include 1) initial in-person 50 min consultation; 2) brief 5 min weekly follow ups in a format TBD; and 3) in-person 30 min booster sessions every 3 weeks (total 13 sessions).
223769392|NCT03429491|DIETARY_SUPPLEMENT|LC n-3 PUFA|LC n-3 PUFA
223769393|NCT02295748|DRUG|Deflazacort|Deflazacort, a glucocorticoid with anti-inflammatory and immunosuppressive effects, is used in treating a variety of diseases. Pharmacologically it is an inactive pro-drug which is metabolized rapidly to the active drug 21-desacetyldeflazacort.
223769394|NCT02617550|DRUG|Vericiguat (BAY1021189)|Vericiguat up-titration from 2.5 mg to 10 mg in an interval of 14 +/- 3 days: 2.5 mg vericiguat for 14 +/-3 days given as 2 x 1.25 mg tablets followed by 5 mg vericiguat for 14 +/-3 days given as 1 x 5 mg tablet followed by 10 mg vericiguat for 14 +/-3 days given as 2 x 5 mg tablets
223769395|NCT02617550|DRUG|Placebo|Placebo for 14 +/-3 days given as 1 or 2 tablets \[o.d.\].
223769396|NCT02617550|DRUG|Nitroglycerin|0.4 mg nitroglycerin spray administered at 2.5 hours before treatment (vericiguat \[trough\] or placebo) on day 12, day 26 and day 40 at 4 hours after treatment (vericiguat \[peak\] or placebo) on day 13, day 27 and day 41
223769397|NCT04596150|DRUG|CX-2009|Intravenous administration of the CX-2009 of 6 mg/kg administered every 3 weeks (Q3W)
223769398|NCT04596150|DRUG|CX-072|Intravenous administration of the CX-072 of 1200 mg administered every 3 weeks (Q3W)
223661006|NCT06157840|DEVICE|mHealth application and sleep health education|Study participants will download the mHealth app to their smartphones and complete the intervention within 6 weeks. They will be required to complete daily electronic sleep diaries for the following 6 weeks. Each week, they will be asked to complete a short assessment of their experiences from the previous week and their current insomnia severity
223769399|NCT04423042|BIOLOGICAL|Tocilizumab|Tocilizumab binds to both soluble and membrane-bound interleukin-6 receptors and has been shown to inhibit interleukin 6-mediated signalling.
223769400|NCT00832351|PROCEDURE|Mobilisation|Mobilisation
223661007|NCT06157840|DEVICE|Simplified mHealth application and sleep health education|Study participants will download the mHealth app to their smartphones and complete the intervention within 6 weeks. They will receive a simplified version of the app with sleep hygiene instructions and will be required to complete daily electronic sleep diaries for the following 6 weeks. Each week, they will be asked to complete a short assessment of their experiences from the previous week and their current insomnia severity.
224241505|NCT02276339|OTHER|Exercise|The exercise intervention will consist of an individual home-based progressive eccentric-concentric strengthening programme. Patients will be reviewed every two weeks during their rehabilitation; exercises will be progressed accordingly by their physiotherapist.
224241506|NCT05502484|BEHAVIORAL|Integrative Dialectical Behavioural Therapy (DBT)|8 weeks outpatient pre-treatment DBT followed by integrative, inpatient DBT of 40 weeks, using standard DBT, augmented with an experience-oriented, body-oriented skills training based on DBT-principles by trained DBT-therapists, and a follow-up phase of 12 weeks outpatient aftercare (maximal 8 sessions individual DBT and 4 booster sessions) and 12 weeks no DBT. The inpatient treatment takes place in a living environment that is based on the principles of DBT and takes into account several aspects of autism.
223661008|NCT03206281|DIAGNOSTIC_TEST|Fetal wight estimation|We will estimate the fetal weight by sonographic and clinical estimation
223661009|NCT04494100|PROCEDURE|TRONC|injection of 3 to 7 mL of Ropivacaine 3.75 mg/ml per nerve (median and ulnar nerves) and infiltration of 2 ml of Ropivacaine 3.75 mg/ml laterally above the flexion fold of the wrist in order to block the branches of the lateral cutaneous nerve of the forearm, the terminal sensory branch of the musculocutaneous nerve.
223661010|NCT04494100|PROCEDURE|WALANT|infiltration with 3 to 7 ml of 1% lidocaine (10 mg/ml) combined with 0.005 mg/ml epinephrine and 8.4% sodium bicarbonate in the subcutaneous area in front of the transverse ligament, between the thenar and hypothenar eminences, from the flexion fold of the wrist over a length of 5 cm.
223661011|NCT04494100|PROCEDURE|Tourniquet|inflation pressure 75 to 100 mmHg above systolic blood pressure.
223661012|NCT04494100|DRUG|Ropivacaine|troncular blocks with Ropivacaine 3.75 mg/ml
223661013|NCT04494100|DRUG|Lidocaine + Epinephrine|WALANT technique with 1% lidocaine (10 mg/ml) combined with 0.005 mg/ml epinephrine
223661014|NCT04655196|OTHER|SOLUS-D + weekly feedback by a coach|internet-based self-help
223769401|NCT05731934|DRUG|HX301|At starting dose of 40 mg, followed by 4 dose levels of 80 mg, 120 mg, 160 mg, and 200 mg
223661015|NCT04655196|OTHER|SOLUS-D + weekly automated messages|internet-based self-help
223661016|NCT00154089|DRUG|EM-1421|EM-1421 administered intravaginally every 3 weeks as 45 mg (1% w/w) EM-1421 or 90 mg (2% w/w) EM-1421
223661017|NCT02508558|OTHER|motion perception and locomotor operation performance measurements|
223661018|NCT02508558|OTHER|parabolic flight|
223661019|NCT00742833|DRUG|KUC-7483|
223661020|NCT00742833|DRUG|Placebo|
223661021|NCT03142685|DEVICE|Bowel Ultrasound|Subjects randomized to Arm B will undergo a bowel ultrasound q24 for 48 hours after time of clinical suspicion of NEC. This is in addition to the standard of care KUBs which patients in both arms will get.
223661022|NCT01919281|BEHAVIORAL|strength training|
223661023|NCT01919281|BEHAVIORAL|interval training|
223769402|NCT00990483|DEVICE|3D mammograpgy system|In addition to the standard care diagnostic imaging, all participants underwent two experimental acquisitions, in two projections (Cranio-Caudal and Mediolateral Oblique) on the breast of concern: one acquisition in Mode A (narrow angle acquisition) and one acquisition in Mode B (wide angle acquisition). The experimental imaging is compared to the standard of care imaging
223769403|NCT06104267|BEHAVIORAL|7-Form of Medical Tai Chi Exercise Healing for Colon cancer patients|"The programme is based on the 7-Form of Medical Tai Chi Exercise Healing for Colon cancer patients that lasted 60 minutes three times a week for eight weeks and is led by a Tai Chi instructor with more than 5 years of teaching experience. Each session included a warm-up, movement instruction, breathing techniques, and relaxation. To ensure that each participant is proficient in Tai Chi, they will take at least 2 sessions of 60-minute Tai Chi training before the start of the intervention, until they are able to perform all Tai Chi movements correctly and successfully, and record a video to be used in software for practice at home. The enrolled patients, Tai Chi instructors and relevant staff of the subject group set up a WeChat group, and the enrolled patients, outside of the prescribed practice time each week, can practice at home or outdoors by themselves. They can send the video of the practice to the WeChat group."
223769404|NCT00218348|DRUG|Dextro-Amphetamine Sulfate|
223769405|NCT06383949|DEVICE|Synergy Cervical Disc system|motion preservation disc
223769406|NCT02515539|DEVICE|CardiAQ TMVI System (Transapical & Transfemoral DS)|CardiAQ TMVI System using either the Transapical or Transfemoral Delivery System
223769407|NCT05911620|DEVICE|Magnetic resonance elastography (MRE)|Magnetic Resonance Imaging (MRI) imaging with low-frequency vibrations to create a visual map (elastogram) that shows stiffness of body tissues
223769408|NCT04213898|DRUG|SHR-1210+Albumin-bound paclitaxel + epirubicin|Neoadjuvant therapy：SHR-1210, 200mg,iv, q3w, for 6 cycles; Albumin-bound paclitaxel: 125 mg/m2, iv, d1, d8, and d15, 21 days as a cycle, for 6 cycles; Epirubicin: 75mg / m2, iv, d1, 21 days as a cycle, for 6 cycles; The surgery was performed 3-4 weeks after the completion of neoadjuvant chemotherapy.
223769409|NCT04099524|DEVICE|tDCS|tDCS (LPG/C3-anode, orbitofrontal cortex/Fp2-cathode) will be administered for 4 weeks (1 session per weekday for 2 weeks, and then 2 sessions per week for 2 weeks, for a total of 14 sessions). All subjects will receive anodal tDCS stimulation for 20 minutes per session, on C3 and the cathode electrode on Fp2 using 10/20 EEG system. tDCS will be applied with a pair of 35 cm2 single-use sponges soaked in approximately 4mL of saline solution on each side (\~8mL per sponge) connected to the stimulator. During the 20-minute tDCS session, we will use online tDCS design (i.e., a subject will simultaneously work on the visual attention-oriented task.
223769410|NCT03211195|DRUG|Sotagliflozin (SAR439954)|"Pharmaceutical form: tablet~Route of administration: oral"
224241507|NCT04109417|PROCEDURE|osteotomy filled with PRP-gel and covered with PRP-biomembrane|
224241508|NCT04109417|PROCEDURE|osteotomy site following the surgical intervention was left empty|
224241509|NCT02006160|DRUG|dalfampridine|10 mg bid
224241510|NCT02006160|DRUG|placebo|10 mg bid
224241511|NCT05908864|DRUG|Magnesium sulfate|Blood pressure, respiratory rate, pulse, peak expiratory flow rate (PEFR) measurement using a peak flowmeter, Fischl index and need for hospitalization in patients with acute bronchial asthma were done
224241512|NCT02696694|OTHER|Progesterone 25-75|Impact of serum progesterone concentrations \[25-75\] on the day of embryo transfer in egg donation cycles under hormonal replacement therapy
224241513|NCT02696694|OTHER|Progesterone <25, >75|Impact of serum progesterone concentrations (\<25, \>75) on the day of embryo transfer in egg donation cycles under hormonal replacement therapy
224241514|NCT03694782|BEHAVIORAL|Food diary supply|Each participant was issued with a food supply diary to record details of their household food supply and related trips over 1-mo period. Household food supply included food purchases, food gift/donation, and potential crops from the garden. Away-from-home food consumption was not recorded. For each food purchase, participants provided details of date, place of purchase, foods purchased (name, quantity and expense incurred), and trip made (origin/where the trip started, destination/where the trip ended, and mode of transportation). When till receipts were available in grocery stores or supermarkets, participants were asked to collect them in an envelope placed at the end of the food supply diary. To facilitate data entry, all family members were encouraged to help filling out the diary.
224241515|NCT03694782|BEHAVIORAL|Actigraph|Participants were instructed to wear a triaxial accelerometer (wGT3X-BT or wActiSleep-BT, Actigraph, Pensacola, FL, USA) fitted with an elastic strap on right side of the hip for 9 consecutive days, except for bathing and performing activities in the water. The Actigraph was accompanied by an activity logbook in which participants were required to daily record time when awake and sleeping, and, if any, time and duration of workout or device removal
224241516|NCT03694782|BEHAVIORAL|Questionnaire|Participants received by email a link to complete an online questionnaire about mental and social health, sensibility to food waste, and connection with nature
224241517|NCT02254174|DRUG|Tiotropium/Salmeterol|Fixed dose combination of tiotropium 7.5 μg and salmeterol 25 μg inhalation powder, PE capsule via HandiHaler®
224241518|NCT02254174|DRUG|Serevent® Diskus®|
224241519|NCT02254174|DRUG|Spiriva®|
223661024|NCT05873166|OTHER|Bilateral pressure release in Flexor Brevis Digitorum in subjects with latent trigger point|Bilateral pressure release in Flexor Brevis Digitorum in subjects with latent trigger point
223661025|NCT05873166|OTHER|Bilateral non emission Laser in latent trigger points of the Flexor digitorum Brevis Muscle|Bilateral non emission Laser in latent trigger points of the Flexor digitorum Brevis Muscle
223661026|NCT02820532|DEVICE|Protura Treatment table|The treatment couch will be moved according to the respiratory motion of the patient. As a reference first the respiration will be measured without couch motion, than the couch will be switched on and we will evaluate if the respiration changes due to the motion of the couch. This procedure will be repeated once.
223661027|NCT03206788|DRUG|Losartan|25 mg or 50 mg (based on patient's weight) Losartan tablets taken by mouth daily in the morning for week 1 followed by twice daily (one in the morning and one in the evening) on Weeks 2-12.
223661028|NCT03206788|DRUG|placebo|Placebo tablets, matching the Losartan intervention, taken by mouth daily in the morning for week 1 followed by twice daily (one in the morning and one in the evening) on Weeks 2-12.
223661029|NCT01122056|OTHER|Physical exercise training|Two 2-hours long interactive training to perform safe and efficient aerobic exercise for patients with multiple sclerosis
224241520|NCT01469767|DRUG|Fluocinonide cream|Fluocinonide cream 0.1% applied twice daily for 5 days.
224241521|NCT04751734|BIOLOGICAL|Covid vaccines|women within Priority groups for coronavirus (COVID-19) vaccination
224241522|NCT01219322|DRUG|Sodium bicarbonate|single use of sodium bicarbonate and sterile water for injection 1:1 concentration 50 cc
224241523|NCT01219322|DRUG|normal saline|intravenous normal saline volume equivalent to sodium bicarbonate
224241524|NCT01413581|DRUG|rhBSSL (recombinant human bile-salt-stimulated lipase)|rhBSSL added to infant formula/pasteurized breast milk during a 4 week treatment period.
223661030|NCT02082340|BEHAVIORAL|TB knowledge and socio-psychological counseling session|TB patients and their family members will participate in one-day counseling session provided by a trained psychologist and a TB nurse
223661031|NCT02082340|OTHER|SMS text messages|TB patients will receive SMS text messages every morning (except Sunday) during the whole ambulatory TB treatment phase as a reminder for taking the TB medication prescribed and provided by the TB physician
223661032|NCT02082340|OTHER|phone calls|Family members of the TB patients will receive phone calls every evening (except Sunday) during the whole ambulatory TB treatment phase to assure that the patient takes the medication prescribed and provided by the TB physician and to collect information on treatment adherence and possible side effects.
223661033|NCT02082340|BEHAVIORAL|Self-administered drug intake strategy|Once a week TB patients will receive the TB medication from their local outpatient TB centers and will use the medication every day (six days a week, except Sunday according to the TB treatment protocol) at home under supervision of a family member in charge.
223661034|NCT02082340|BEHAVIORAL|Educational leaflet|Educational leaflet containing information on TB infection; infection control measures; importance of TB treatment adherence and family support will be provided to all TB patients at the end of the counselling session
223661035|NCT01814709|DRUG|GDC-0032|Oral doses of GDC-0032
224241525|NCT01413581|DRUG|Placebo|Placebo added to infant formula/pasteurized breast milk during a 4 week treatment period.
224241526|NCT03452501|DRUG|Infliximab|A vial containing powder for concentrate for solution for infusion. Each vial contains: Infliximab 100 mg
224241527|NCT01066182|DIETARY_SUPPLEMENT|DHA (docosahexaenoic acid)|3 x 500 mg capsules per day orally, each capsule providing 200 mg of DHA as a triglyceride. The liquid fill contains DHASCO®-S oil, derived from the microalgae, Schizochytrium sp., high-oleic sunflower oil, natural mixed tocopherols, ascorbyl palmitate, and rosemary extract (flavouring). The gelatin shell contains glycerin, water, and colouring (carmel, carmine, turmeric).
224241528|NCT01066182|DIETARY_SUPPLEMENT|Sunflower oil capsules|The placebo will consist of 3 x 500 mg capsules per day orally containing high-oleic sunflower oil. The dimensions, taste, appearance and colour will be identical to those of the DHA capsules. The shell of the capsule will be the same as the DHA capsule. The liquid fill contains high-oleic sunflower oil, natural mixed tocopherols, ascorbyl palmitat and rosemary extract (flavouring).
223661036|NCT01814709|DRUG|Itraconazole|Oral doses of Itraconazole
223661037|NCT01814709|DRUG|Rifampin|Oral doses of Rifampin
223661038|NCT05935826|DRUG|Essential Amino Acid Supplement by Amino Co|2 months of twice daily consumption of Purity (EAA), followed by 10 months open label extension of EAA
223661039|NCT05935826|OTHER|Placebo|2 months of twice daily consumption of Placebo, followed by 10 months open label extension of EAA
223661040|NCT05491512|DIAGNOSTIC_TEST|18 F-FMISO PET/CT|The 18F-FMISO PET/CT Scan Protocol consists first of an IV bolus injection of approximately 5-10 mCi of the radiotracer. At between 150-180 mins post injection, 18F-FMISO images will be acquired.
223661041|NCT05491512|RADIATION|Radiation|Total Radiation Dose (over 3 weeks) 30Gy\*\* in 2 Gy per fraction
223661042|NCT05491512|DRUG|Cisplatin|Concurrent chemotherapy (2 cycles) will be given. At the start of week 1 of radiation, subjects will receive cisplatin 100 mg/m2 intravenously. They may be given for 2 consecutive days (50 mg/m2 each day for a total dose 100 mg/m2 ), typically on days 1 and 2, or as a single dose, typically on day 1.
223661043|NCT05491512|DRUG|Carboplatin|"If cisplatin cannot be given at 100 mg/m2 for either cycle 1 or cycle 2, the investigator may use a regimen with carboplatin and 5-Fluorouracil in its place. Carboplatin will be given at a dose of AUC 1.25 intravenously daily x 4 days starting on day 1 of the cycle (total dose of AUC 5). 5-Fluorouracil will be given at a dose of 600 mg/m2 intravenous infusion over 24 hours daily x 4 days (total dose of 2400 mg/m2 intravenous infusion over 96 hours).~(Cohort B to start carboplatin (AUC 1.5) and paclitaxel 45 mg/m2 at the start of RT)"
223661044|NCT05491512|DRUG|5-fluorouracil|If cisplatin cannot be given at 100 mg/m2 for either cycle 1 or cycle 2, the investigator may use a regimen with carboplatin and 5-Fluorouracil in its place. Carboplatin will be given at a dose of AUC 1.25 intravenously daily x 4 days starting on day 1 of the cycle (total dose of AUC 5). 5-Fluorouracil will be given at a dose of 600 mg/m2 intravenous infusion over 24 hours daily x 4 days (total dose of 2400 mg/m2 intravenous infusion over 96 hours).
223661045|NCT05464940|OTHER|Intravenous caffeine|"Group assigned to receive caffeine will receive intravenous(IV) caffeine and sodium benzoate infusion starting at 250-500 mg.~This method will use an automated algorithm that adjusts the flow of the infusion depending on the individual's sex and weight and then in a serial fashion in response to blood caffeine measurements. Serial blood caffeine measurements at pre-determined intervals according to the algorithm will be until a steady state is obtained."
223769411|NCT03151356|DEVICE|Measurement of Prostate Health Index (PHI)|Use of a diagnostic tool to predict prostate biopsy outcome: measurement of total and free PSA as well as the \[-2\]proPSA and calculation of The Prostate Health Index according to the following formula: Prostate Health Index (PHI) = \[p2PSA /fPSA\] x √tPSA
224321238|NCT01372748|OTHER|Standard CPR|30:2 CPR consists of 3 cycles of standard CPR with each cycle consisting of 30 chest compressions with a pause for 2 ventilations at a compression:ventilation ratio of 30:2. CCC consists of a series of three cycles of continuous chest compressions without pauses for ventilation. In either group, each cycle will be followed by rhythm analysis until three cycles are completed or restoration of spontaneous circulation (ROSC), whichever occurs first.
224321239|NCT01372748|OTHER|Continuous chest compressions|Continuous chest compressions during the first 6 minutes of the resuscitation.
223769412|NCT04230642|DEVICE|The Quantum Surgical device|Robotic platform for needle placement
223769413|NCT01632501|DEVICE|Coronary stent - Tsunami|A coronary angioplasty was done
223769414|NCT00649181|DRUG|Metolazone Tablets 5 mg|2x5mg, single dose fasting
223769415|NCT00649181|DRUG|Zaroloxyn® Tablets 5 mg|2x5mg, single dose fasting
224241529|NCT01354860|OTHER|Moxibustion treatment plus usual care|"Treatment group received moxibustion treatment three times a week for 4 consecutive weeks, totally 12 sessions of treatment in addition to usual care to manage their knee OA.~Moxibustion points include six local acupuncture points on affected knee joint. Up to two additional tender points will be allowed, if necessary. If participants feel knee pain on both knee joints, study practitioners will provide treatment on both knee.~We will use smokeless indirect moxibustion made of wormwood with a diameter of 1.9 centirmeter and a length of 2.1 centimeter in a cylindrical form for this study (Haitnim Bosung Inc, Korea). Free participant-practitioner interaction will be allowed during the treatment session. Expected total time of each treatment session will be 40 - 60 minutes."
224241530|NCT01354860|OTHER|Usual care alone group|"Usual care alone group can receive or use any kind of treatment other than moxibustion treatment provided as study intervention, which includes surgery, conventional medication, physical treatment, acupuncture, herbal medicine, over-the-counter drugs and other active treatment. This also applies to the moxibustion treatment group.~Education material of information on knee osteoarthritis and current management option and self-exercise sheet with a yoga-mat to enhance regular exercise will be provided in both groups at baseline."
224241531|NCT00972218|BIOLOGICAL|Adalimumab|Adalimumab subcutaneous injections 40 mg dose every other week for 24 weeks
224241532|NCT05879471|DIAGNOSTIC_TEST|68Ga-NY104 PET/CT|Participants will be administered a single, intravenous bolus of 68Ga-NY104 The recommended administered activity of 68Ga-NY104 is 1.8-2.2 MBq per kilogram bodyweight, subject to variation that may be required owing to variable elution efficiencies obtained during the lifetime of the 68Ga / 68Ga generator The CT and PET imaging session will begin approximately 45 to 75 minutes after 68Ga-NY104 administration.
223661046|NCT05464940|OTHER|Masked Placebo|"The patients assigned to the masked placebo will receive 5% dextrose in 0.45% saline using the same infusion protocol for a random length of time that was within 1 standard deviation(SD) of the mean time to achieve a steady state using the caffeine protocol (17+4 min).~To maintain blinding, caffeine blood concentration measurements that will be randomly generated within 2 SDs of the predicted values calculated by the algorithm will be used and verbally communicated for placebo infusions."
224241533|NCT01328093|DRUG|LY2140023|Administered orally
224241534|NCT01328093|DRUG|Aripiprazole|Administered orally
224241535|NCT01133353|DRUG|Tetrabenazine MR|Modified-Release (MR) tablets containing 15 mg or 30 mg tetrabenazine, dose-escalating up to a maximum of 150 mg depending on weight, once per day for 12 weeks
224241536|NCT01133353|DRUG|Placebo|1 to 5 tablets once per day depending on weight for 12 weeks
224321240|NCT04110210|DRUG|Bilateral Ultrasound-Guided Erector Spinae Plane Block|Following skin sterilization and local anesthetic infiltration of the superficial tissues, an echogenic 22-G block needle is inserted in-plane to the ultrasound beam in a cranial-to-caudal direction until contact was made with the transverse process. Correct location of the needle tip in the fascial plane deep to erector spinae muscle is confirmed by injecting 0.5-1 ml saline and seeing the fluid lifting the erector spinae muscle off the transverse process while not distending the muscle. A total of 20ml bupivacaine 0.25% are then injected into the ESP. The procedure is repeated on the contralateral side.
223661047|NCT06376045|DRUG|Rocatinlimab|Rocatinlimab will be administered by SC injection.
223661048|NCT06376045|DRUG|Placebo|Placebo will be administered by SC injection.
223661049|NCT05770609|DRUG|SPH3127 Tablets with Dose A|See Arm description
223661050|NCT05770609|DRUG|SPH3127 Tablets with Dose B|See Arm description
223661051|NCT05770609|DRUG|SPH3127 Tablets placebo|See Arm description
223661052|NCT00354276|DRUG|cytarabine|
223661053|NCT00354276|DRUG|laromustine|
223661054|NCT03777891|COMBINATION_PRODUCT|phonophoresis with different material|phonophoresis with Silicone gel for group A, , Group B: 15 patients (8 males and 7 females) received phonophoresis with Contractubex gel and Group C: 15 patients (9 males and 6 females) received Corticosteroid phonophoresis.
223661055|NCT00536913|DRUG|Budesonide/formoterol pMDI 40/2.25ug + spacer|
223661056|NCT00536913|DRUG|Budesonide/formoterol pMDI 40/2.25 ug|
223661057|NCT02829190|DEVICE|Magnetic Resonance Imaging (MRI),|Magnetic Resonance Imaging (MRI) of flow using phase contrast (PC) methods
223661058|NCT03903224|PROCEDURE|Combined Modified Pectoralis and Transversus Plane Blocks|"Modified pectoralis nerve block (Pecs II) aims to block at least the pectoral nerves, the intercostobrachial, intercostals III-IV-V-VI. This will cover dermatomes T2, T3 and T4. The probe is positioned under the lateral third of the clavicle .After locating the subclavian muscle, the axillary artery and the axillary vein we move the probe distally towards the axilla, until the pectoralis minor is identified. We start counting the ribs , from r1 under the axillary artery, we move distally and laterally until the lateral border of pectoralis minor is reached. The serratus anterior muscle which covers r2, r3, r4 is the point of entrance into the axilla.~Blocking of multiple anterior branches of intercostal nerves (Th2-6) using a transversus thoracic muscle plane (TTP) block is used as an additive to pecs II to cover the internal mammary region"
223661059|NCT03903224|PROCEDURE|Erector Spinae block|The patient is placed in a sitting position and The T5 spinous process is located by palpating and counting down from the C7 spinous process. Under complete aseptic conditions a linear ultrasound probe is then placed in a transverse orientation at the level of the T5 transverse process. The tip of the transverse process is centred on the ultrasound screen and the probe is then rotated into a longitudinal orientation to produce a parasagittal view. From T1 to T5 the erector spinae, rhomboid major and trapezius muscles are visible posterior and superficial to the transverse processes.
223661060|NCT01999517|DRUG|Intravenous Nitroglycerin|
223661061|NCT01999517|DRUG|IV Fluids|
223661062|NCT04846413|OTHER|Speech task|Speech task which consists of a sustained emission of the vowel /e/.
223661063|NCT04201808|DRUG|Tenofovir Alafenamide 25 MG|All patients will receive Tenofovir Alafenamide, 25mg PO, to treat chronic hepatitis B and their previous suboptimal response over the study duration of 48 weeks. Patients will be followed every 12 weeks for medication adherence, medication refill, and follow up as per standard of care.
223769416|NCT06008925|DRUG|Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell))|Intratumoral injection only. Dosing days may be Day 1 or Days 1-3 only.
223661064|NCT03133416|OTHER|PRP preparation|
223661065|NCT03133416|DEVICE|Physiotherapy|
223661066|NCT03133416|OTHER|PRP and physiotherapy|
223661067|NCT02739971|BEHAVIORAL|Low AGEs diet|Oral and written instructions on how to reduce AGEs in diet, mainly by changing cooking methods in addition to standard of care dietary guidance for type 2 diabetes
223661068|NCT02739971|BEHAVIORAL|Standard of care dietary guidance for Type 2 diabetes|Oral and written instructions for standard of care dietary guidance for type 2 diabetes
223661069|NCT05536271|DRUG|Bisoprolol Fumarate|antihypertensive medicine prescribed for acute coronary syndrome patients
223661070|NCT02291016|DRUG|Formoterol|Comparison of dosage administered via a nebulizer versus dosage administered via a dry powder inhaler. 12 µg Formoterol with the dry powder inhaler and 20 µg (solution form) of Formoterol with the nebulizer. Patients will receive formoterol and placebo at both study visit #1 and visit #2.
223661071|NCT02291016|OTHER|Placebo|Comparison of drug administered via a nebulizer versus a dry powder inhaler. The placebo used will be sterile, preservative free, normal saline for inhalation for the nebulizer and a matched capsule without active drug for the dry powder inhaler. All patients will receive 2 ml of normal saline with the nebulizer to match the volume of nebulized formoterol solution. Patients will receive formoterol and placebo at both study visit #1 and visit #2.
223661072|NCT01412489|DEVICE|HYALOBARRIER Gel|For each patient, the HYALOBARRIER Gel was introduced into the uterine cavity with the canula after hysteroscopic myomectomy procedure
223661073|NCT04872140|DIETARY_SUPPLEMENT|Low phytate pea powder|Exercise performance with low phytate pea powder
223661074|NCT04872140|DIETARY_SUPPLEMENT|Regular pea powder|Exercise performance with regular pea powder
223661075|NCT04872140|DIETARY_SUPPLEMENT|Placebo (maltodextrin)|Exercise performance with placebo (maltodextrin)
223661076|NCT05194579|COMBINATION_PRODUCT|PF-06881894 by on-body injector|PF-06881894 given by on-body injector (OBI), 6 mg administered as a single SC injection
223661077|NCT05194579|COMBINATION_PRODUCT|PF-06881894 by prefilled syringe|PF-06881894 given by prefilled syringe (PFS), 6 mg administered as a single SC injection
223661078|NCT03595228|BIOLOGICAL|BN-Brachyury plus radiation|MVA-BN-Brachyury injections will be given on day 0 and 14. FPV-Brachyury injection will be given on day 28, followed by radiation on days 42 through approximately day 70. FPV-Brachyury will then be given two weeks after radiation then every 6-12 weeks through 110 weeks after radiation is complete.
223661079|NCT03716154|RADIATION|Diode laser|Diode laser 810nm, 2W, 20sec, 20 HZ
223661080|NCT02811874|BEHAVIORAL|diabetes education|Diabetes education program includes: 4 theoretical sessions, 60 minutes long, taught once a week for 4 weeks, developed in the form of group classes, and given by one of the authors. The educational program content comprises (1) definition of diabetes, and identification of modifiable risk factors for type 2 diabetes, (2) non-pharmacological treatment, with emphasis on diet and exercise, (3) pharmacological therapy, including mechanism of action and side effects of anti-diabetic medications provided by the Brazilian public health system and (4) an overview of chronic diabetes complications.
223661081|NCT02811874|BEHAVIORAL|education in other areas|Four theoretical sessions related to education in other health areas, not related to diabetes, administered during 4 weeks
223661082|NCT01298908|PROCEDURE|Operative treatment|In operative treatment the great saphenous vein will be removed after flush ligation by femoral vein and stripping of the trunk.
223661083|NCT01298908|PROCEDURE|Laser ablation|In intravenous laser treatment a thin laser fiber is inserted through a tiny distal entry point. The probe is guided into place using ultrasound and the procedure is performed under local tumescence anesthesia. Laser energy is delivered to seal the faulty vein.
223661084|NCT01298908|PROCEDURE|Foam sclerotherapy|Ultrasound guided foam sclerotherapy involves an injection of foam (sodium tetradecyl sulfate mixed with air according to the Thessari method) directly into the venous trunk under ultrasound control.
223661085|NCT02711241|DRUG|Dipyrone|1 gram by slow IV infusion
223661086|NCT02711241|DRUG|Papaverine|80 mg by slow intravenous infusion
223661087|NCT02036151|DRUG|xylitol|Mothers in the experimental group were instructed to chew 1 pellet of xylitol gum (Fennobon Oy, Yrittäjäntie, Finneland -gum, 3 times ) for a period of 3 months. control mothers did not receive any medications. All mothers received oral hygiene instructions and restorative treatment when needed. Offspring of both the experimental and control groups did not receive any medication and were followed for at 6,12, 18 and 24 month from initiation of mothers consumption. month
223661088|NCT02036151|DRUG|fluoride varnish application|The control group participated in a preventive program under the supervision of the Pediatric Dentistry Department. The program activities consisted of oral hygiene instructions, fluoride varnish application (Duraphat 5% Na F ,Ultradent Products, Utah, USA) and restorative treatment when needed.
223661089|NCT06533995|DEVICE|Visuprime|Visuprime is a medical device (class IIa sterile) with ophtalmic indication, consisting on a 10 ml multidose bottle
223661090|NCT06533995|OTHER|Placebo|placebo eyedrop isotonic buffered saline solution
223661091|NCT01415414|DRUG|Iopromide (Ultravist, BAY86-4877)|CT enhancement for abdominal or pelvic scan. Generally doses of up to 1.5 g iodine per kg body weight are well tolerated
223661092|NCT05985460|DEVICE|Intervention: motion-sensor video game|The experimental arm is a 1-2 mins motion-sensoring video game, which can accommodate 1-4 individuals, engaging their entire bodies in the physical motions involved. It aims to increase PA intention by increasing their motivation, as well as personal and family well-being by increasing the interaction with family members. Assessments will be conducted at two different time points, immediately following the intervention (T2) and after 1-month follow-up (T3).
223661093|NCT05985460|DEVICE|Placebo: mobile APP game (without motion-sensoring)|The placebo arm is a 1-2 mins mobile app game, which allows 1-4 participants to play together with a duration of 1-2 minutes. It aims to increase participants' family and personal well-being by increasing the interaction of family members. Assessments will be conducted at two different time points, immediately following the intervention (T2) and after 1-month follow-up (T3).
223661094|NCT01757990|DIETARY_SUPPLEMENT|Effect of Stevioside and Rebaudioside on plaque pH|After measuring baseline plaque pH, the subjects rinsed for 1 minute with the sucrose solution. Plaque pH was then measured at 5, 10, 15, 30, 45 and 60 min after the mouth rinse.
223661095|NCT06154577|DIAGNOSTIC_TEST|Ultrasonography|Assessment of tongue morphology and posterior airway space using ultrasonography (AmCAD-UO, CE mark NB1639)
224241537|NCT01162603|DEVICE|Goldmann and Perkins applanation tonometry|IOP values will be assessed by the means of Goldmann or Perkins applanation tonometry at the following time-points: 10AM (± 1 hour), 2PM (± 1 hour), 6PM (± 1 hour), 10PM (± 1 hour), 2AM (± 1 hour) and 6AM (± 1 hour) after three months of treatment
223661096|NCT03495856|BEHAVIORAL|Mindfulness Training For Chronic Pain|4-week group Mindfulness training program for adults with chronic pain
223661097|NCT01980589|DRUG|Carfilzomib|Carfilzomib administered as a 30-minute intravenous (IV) infusion on Days 1, 2, 8, 9, 15, and 16 of each 28-day cycle. On Days 1 and 2 of Cycle 1, all participants received carfilzomib at 20 mg/m².
223661098|NCT01980589|DRUG|Cyclophosphamide|Cyclophosphamide administered orally (PO) at the dose of 300 mg/m² on Days 1, 8, and 15 of each 28-day cycle.
223661099|NCT01980589|DRUG|Dexamethasone|Dexamethasone administered PO or IV at 40 mg on Days 1, 8, 15, and 22 of each 28-day cycle.
223661100|NCT01860183|DRUG|Mycophenolate mofetil|Mycophenolate will be administered to all study patients at dose of 3 g daily for the first seven days posttransplant. Afterwards, study patients will continue, as randomized, on either 3 g, or 2 g MMF daily.
223661101|NCT02619162|DRUG|Nintedanib|Tablets of 100 mg. or 150 mg.
223661102|NCT02619162|DRUG|Letrozole|Tablet of 2.5 mg.
223661103|NCT03629314|OTHER|Educational pamphlet arm|Educational pamphlets will be provided to review and questionnaire will be provided to complete before and after review of the pamphlet
223661104|NCT00966914|DRUG|Tavocept(BNP7787) in combination with cisplatin and either docetaxel or paclitaxel|Paclitaxel 200 mg/m2 IV or Docetaxel 75mg/m2 IV every 3 weeks plus Cisplatin 80 mg/m2 IV every 3weeks plus Tavocept(BNP7787) 18.4gm/m2 IV every 3 weeks
223661105|NCT00966914|DRUG|Placebo in combination with cisplatin and docetaxel or paclitaxel|Paclitaxel 200 mg/m2 IV or Docetaxel 75mg/m2 IV every 3 weeks plus Cisplatin 80 mg/m2 IV every 3weeks plus Placebo IV every 3 weeks
223769417|NCT06008925|DRUG|Nivolumab Injection|Administered once at 3 mg/kg intravenously on Days 8 and 22 of each cycle.
223661106|NCT04598191|DRUG|Iloprost|"Participants in Iloprost group will be administered aerosolized 20 μg iloprost in 15 min through a nebulizer connected to the inspiratory limb of the respiratory system when the internal mammary artery harvesting is done."
223661107|NCT04598191|DRUG|Control (Normal saline)|"Participants in Control group will be administered aerosolized 5 ml of normal saline in 15 min through a nebulizer connected to the inspiratory limb of the respiratory system when the internal mammary artery harvesting is done."
224241538|NCT01162603|DRUG|TAFLUPROST 0.0015% EYEDROPS|Tafluprost 0.0015% preservative-free ophthalmic solution
223661108|NCT05986201|DEVICE|TachoSil®|TachoSil®, a carrier-bound fibrin sealant (CBFS), is a haemostatic tissue sealant composed of a collagen sponge, made from horse tendons, coated on one side with dried human fibrinogen and human thrombin.
224241539|NCT01162603|DRUG|LATANOPROST 0.005% EYEDROPS|Latanoprost 0.005% preservative-added ophthalmic solution
224241540|NCT05488834|OTHER|Critical-Care Pain Observation Tool|"The Critical Care Pain Observation Tool (CPOT) was created to help assess pain in critically ill patients who were unable to self-report pain.~The CPOT instrument evaluates facial expression, body movement, muscle tension, and compliance with ventilator or vocalisation to evaluate an individual's pain. The total score ranges from 0 to 8, where 8 is the worst pain. Patients are observed for 60 seconds while resting and during nociceptive procedures such as turning or wound dressings to detect any change in behaviour that could indicate pain. Further, the patient must be observed before and at the peak of analgesia medications administered to evaluate pain treatment effectiveness."
224241541|NCT05075798|OTHER|No intervention,|pure observational study
224241542|NCT04667494|COMBINATION_PRODUCT|Sonotherapy|Use of high mechanical index ultrasound therapy with intravenous Definity contrast infusion
224241543|NCT02997150|DRUG|IL-2 Low dose|"Patients receive low doses of Interleukin 2: 0.5 million UI/m²/ injection subcutaneously.~The treatment is initiated with an induction phase of one injection per day for 5 consecutive days, followed by a maintenance phase in which patients will receive one injection every 14 days for 6 months.~At the same time, corticoid treatment will be tapered until its complete withdrawal no later than 3 months from the first injection"
224241544|NCT02417636|OTHER|Task Shifting|Participants will be screened for eligibility for ART and the study and then enrolled initiated on ART by a Nursing Officers and then followed and monitored for ART adherence on a monthly basis for 12months. Quarterly, sexual behavior and quality of life questionnaires will be administered. CBC, CD4, HIV-1 Viral load, renal and liver function test will be done biannually. Nursing Officers will be free to consult with clinicians on the management of patients.
223661109|NCT00435045|DRUG|Lovaza (omega-3-acid ethyl esters) [formerly known as Omacor] plus atorvastatin|Lovaza + atorvastatin
223661110|NCT00435045|DRUG|atorvastatin|atorvastatin + placebo
223769418|NCT01731704|RADIATION|Stereotactic radiosurgery (SRS)|
223769419|NCT01731704|RADIATION|Whole brain radiation therapy (WBRT)|External beam whole-brain radiation therapy 30 Gy in 10 fractions. Treatment will be delivered once daily, 5 fractions per week, over 2 to 2.5 weeks
224241545|NCT05083299|DRUG|Sarpogrelate|Anpl-one SR
224241546|NCT00832377|DRUG|timolol/dorzolamide combination|Timolol/Dorzolamide, 1 drop, twice daily, for 12 weeks
223661111|NCT05075005|OTHER|Treatment Cohort|Subjects will walk on a specified University of Florida Natural Area Teaching Laboratory's (NATL) nature trail for approximately 30 minutes, three times per week for 8 weeks while wearing the minimalist shoes provided by the study team. Time, distance, and GPS walking route will be recorded utilizing the MapMyRun smartphone application, which is free to download and easy to use. The study team will assist each subject with downloading the application onto their smartphone and provide a brief training on app use at their pre-trial visit. Subjects will be asked to save each training session within the app to report to the study team upon completion of the 8-week training protocol. Subjects will be instructed to walk at a comfortable pace and to stop if they begin experiencing increased pain or discomfort.
223769420|NCT05721417|PROCEDURE|Tricuspid valve surgery|Surgical treatment of tricuspid regurgitation, that may be performed by repair or replacement
224241547|NCT04558151|BEHAVIORAL|preoperative inspiratory muscle training|Physiotherapists will measure the maximal inspiration pressure (MIP) with the POWER®breathe device of each single patient. Patients will then be instructed to perform inspiratory muscle training at the level of 60% of their individual MIP. Patients are instructed to perform the training containing of 30 breaths twice a day for 14-18 days before surgery. The devices are able to register the performance of each single training session and training results are monitored.
224241548|NCT01022047|DRUG|Noex|The patients shall use the Noex drug only once a day (one application in each nostril) during the 12 weeks of treatment
224241549|NCT01022047|DRUG|Budecort Aqua|The patients shall use the Budecort Aqua drug only once a day (one application in each nostril) during the 12 weeks of treatment.
224241550|NCT02297451|PROCEDURE|Proximal radial/ulnar artery as inflow|Proximal radial/ulnar artery used as inflow
224241551|NCT04926883|OTHER|bulk-fill composite resin restorations|bulk-fill composite resin restorations up to 5mm layer thickness
224241552|NCT02513797|DEVICE|LARIAT + PVI|Left Atrial Appendage ligation with the LARIAT System initially performed followed by adjunctive pulmonary vein isolation catheter ablation in staged procedures
224241553|NCT02513797|DEVICE|Pulmonary Vein Isolation|Perform pulmonary vein isolation (PVI) catheter ablation procedure using a contact force sensing, irrigated radiofrequency catheter approved by FDA for the treatment of atrial fibrillation.
224241554|NCT05866497|DIAGNOSTIC_TEST|clinical periodontal measurements|"Periodontal parameters such as PI, GI, BOP, PD, and CAL were measured using the Williams periodontal probe (Hu-Friedy, Chicago IL). PD and CAL were calculated at six surfaces per tooth, whereas PI and GI were measured at four surfaces per tooth.~The periodontal status of patients was determined based on the Classification of Periodontal and Peri-Implant Diseases and Conditions stated in 2017 World Workshop"
224241555|NCT05866497|DIAGNOSTIC_TEST|CAVI measurements|"Arterial stiffness of the participants included in this study were assessed by CAVI index using VaSera (VS-1500N) CAVI device (Fukuda Denshi Co. Ltd., Tokyo, Japan) between both arms and ankles in a supine position.~Right and left CAVI values were calculated separately."
224241556|NCT05995470|BEHAVIORAL|Internet-based dialectical behaviour therapy-informed skills training|Adaptive applications of DBT-ST for drinkers with psychological distress
224241557|NCT05995470|BEHAVIORAL|Monthly health education|General health information and sharing sessions
224241558|NCT03661528|DRUG|andexanet alfa|Andexanet alfa is a recombinant version of human FXa
224241559|NCT03661528|DRUG|Usual Care|Usual care will consist of any treatment(s) (including no treatment) other than andexanet alfa administered within 3 hours post-randomization that the Investigator and/or other treating physicians consider to be appropriate.
224241560|NCT01880034|OTHER|Lipid Emulsion Survey|
223661112|NCT05075005|OTHER|Control Cohort|Subjects will walk on hardscapes (e.g. sidewalk, asphalt, track, etc) for approximately 30 minutes, three times per week for 8 weeks while wearing the minimalist shoes provided by the study team. Similarly to the treatment group, subjects will be asked to utilize the MapMyRun smartphone application to record their training sessions. Subjects will be instructed to walk at a comfortable pace and to stop if they begin experiencing increased pain or discomfort.
223661113|NCT03469778|DEVICE|Robotic Therapy|Robotic Therapy
223661114|NCT02120040|OTHER|evaluation of anxiety with psychosocial scales|
224241561|NCT00488865|DEVICE|Intravascular Filter Device|Vena cava filter which is implanted into the inferior vena cava of patients to prevent recurrent pulmonary embolism. The filter can be utilized as a permanent or retrievable device.
224241562|NCT04403880|OTHER|Sample collection|"* Optional nasal specimen(s)~* Blood collection"
224241563|NCT00002260|DRUG|Alovudine|
224241564|NCT00281866|DRUG|erlotinib hydrochloride|
224241565|NCT02629757|DRUG|β-elemene|β-elemene 600mg/d,ivdrip,d1-14,every 28 days for 1 cycle, totally 6 cycles
224241566|NCT06246474|PROCEDURE|physical therapy program|Arm Description: Adolescents in study group (B) will received the same designed physical therapy program for the control group in addition to Kinesio taping.
224241567|NCT00925769|DRUG|bevacizumab [Avastin]|Escalating doses of 5/10mg/kg q2w
223661115|NCT02524613|OTHER|Pelvis CT scan|
223661116|NCT02166944|DRUG|tamoxifen 40 mg daily for one year|both arms with riluzole daily
223661117|NCT00567255|DRUG|Naltrexone SR 32 mg/bupropion SR 360 mg/day|
223661118|NCT00567255|DRUG|Placebo|
223661119|NCT00567255|BEHAVIORAL|Ancillary therapy|Ancillary therapy consisting of diet instruction, advice on behavior modification, and exercise counseling
223661120|NCT00108368|DRUG|Risperidone|
223661121|NCT00108368|DRUG|Olanzapine|
223661122|NCT04276376|DRUG|Atezolizumab|Fc-engineered, humanized, Ig G1 monoclonal antibody against PDL-1 1200mg q3w
223661123|NCT04276376|DRUG|Rucaparib|Inhibitor of poly-adenosine diphosphate \[ADP\] ribose polymerase (PARP) 600mg BID
223661124|NCT05387434|BEHAVIORAL|Diabetes Prevention Program-Remote (DPP-R)|The DPP is an evidenced based lifestyle intervention that includes topics on nutrition and physical activity delivered over Zoom.
223661125|NCT05387434|BEHAVIORAL|Diabetes Prevention Program-Facebook (DPP-FB)|The DPP is an evidenced based lifestyle intervention that includes topics on nutrition and physical activity delivered over Facebook.
223661126|NCT01567709|DRUG|Alisertib|Given PO
223661127|NCT01567709|OTHER|Laboratory Biomarker Analysis|Correlative studies
223661128|NCT01567709|OTHER|Pharmacological Study|Correlative studies
223661129|NCT01567709|DRUG|Vorinostat|Given PO
224241568|NCT00925769|DRUG|capecitabine [Xeloda]|Escalating doses of 500/650/750/900mg/m2 bid
224241569|NCT00925769|DRUG|erlotinib [Tarceva]|Escalating doses of 100/150mg daily
224241570|NCT02017964|DRUG|Carboplatin|Given IV
224241571|NCT02017964|OTHER|Cognitive Assessment|Optional ancillary studies
224241572|NCT02017964|DRUG|Cyclophosphamide|Given IV
224241573|NCT02017964|DRUG|Etoposide|Given IV
224241574|NCT02017964|OTHER|Laboratory Biomarker Analysis|Correlative studies
224241575|NCT02017964|DRUG|Methotrexate|Given IV
224241576|NCT02017964|DRUG|Vincristine Sulfate|Given IV
224241577|NCT02005536|BIOLOGICAL|IMOVAX POLIO®: Inactive Poliovirus Vaccine|0.5 mL, Subcutaneous
224241578|NCT04345965|PROCEDURE|Endovascular procedure|Endovascular therapies for erectile dysfunction
224241579|NCT04480073|PROCEDURE|Customized CAD-CAM Titanium Mesh (Y-xoss CBR® by Reoss -Filderstadt - Germany) for Guided Bone Regeneration of atrophic alveolar ridges|"Step one:1) exposure of atrophic areas; 2) bone harvesting from mandible or calvarium; 3) filling the meshes with a mixture of the autogenous bone and particulated xenograft in a 1:1 ratio; 4) stabilization of the mesh with titanium micro-screws.~A post-operative cone-beam computed tomography (CBCT) will be done in all patients to have a reference point for the following controls.~6 months later, patients are re-evaluated with a new CBCT to check bone volumes of the regenerated tissues and to plan implant placement.~Step two: 1) removal of the meshes; 2) preparation of implant sites (one of which will be randomly chosen to obtain a bone biopsy for histomorphometric analysis); 3) implant placement.~3 months later, implants will be uncovered and the prosthetic phases will start.~Patients will be recalled 3, 6, and 12 months later, to assess peri-implant hard and soft tissue conditions, the stability of the reconstructed bone, and the onset of implant-related complications."
223661130|NCT02166671|BIOLOGICAL|HBV booster vaccination 1dose|
224241580|NCT05494567|DRUG|Tadalafil 5mg|patients with BPH/OAB will be treated with combination therapy of tadalafil plus solifenacin for 12 weeks in group 1
224241581|NCT05494567|DRUG|Tamsulosin Hcl 0.4 mg|patients with BPH/OAB will be treated with combination therapy of tamsulosin plus solifenacin for 12 weeks in group 2
224241582|NCT05494567|DRUG|solifenacin 10 mg|patients with BPH/OAB will be treated with combination therapy of tadalafil plus solifenacin in group 1 and tamsulosin plus solifenacin in group 2 for 12 weeks
223661131|NCT04309097|BEHAVIORAL|Digital intervention|"REAP is a live-streaming platform that allows users to shoot short videos or photos related to their physical exercise or eye relaxation (e.g., staring out of the window) using their smartphones. The app has been optimised to be used with the iPhone or Android.~When taking a online course recess, students will have access to the REAP platform that allows them to watch stay-at-home workout videos developed by exercise physiologists. Students will then be asked to create their own workout videos/photos and upload them to the live-streaming platform. When upload is completed, students will receive instant motivational messages to increase their engagement with the program."
223661132|NCT04309097|BEHAVIORAL|Information-only intervention|Participants will have access to online health information and stay-at-home workout videos.
223661133|NCT03083990|BIOLOGICAL|IBI305(Bevacizumab Biosimilar)|3mg/kg, infusion in 90minutes
223661134|NCT03083990|DRUG|Avastin(Bevacizumab)|3mg/kg, infusion in 90minutes
223661135|NCT00984620|DRUG|BI 201335|BI 201335
224241583|NCT00213421|DRUG|Dermoval|group 1 elevated corticosteroids : attack treatment 2 tubes of 10g (4t/d) decreasing treatment : one month: 2 tubes/J (2t/d); 2 months : 2 tubes 1d sur 2 (1d/j); 4 months : 2 tubes 2 fois /week (0,6t/d); 4 months : 2 tubes 1 fois /week (0,3t/d)fois /week (0,3t/d) group 2 low corticosteroids : for paucibullous form with weight \< 45kg attack treatment 1 tubes of 10g (1t/d)decreasing treatment 1 month : 1 tube every 2d (0,5t/d; 1 month : 1 tubes 2 fois /week (0,3t/d) 1 month : 1 tubes 1 fois/week (0,15t/d); for paucibullous form with weight \> 45kg or for multibullous form with weight \< 45kg attack treatment 2 tubes of 10g (2t/d)decreasing treatment 1 month : 2 tubes every 2j (1t/d; 1 month : 2 tubes 2 fois /week (0,6t/d) 1 month : 2 tubes 1 fois /week (0,3t/d)and for multibullous form attack with weigth \> 45kg treatment 3 tubes of 10g (3t/d)decreasing treatment 1 month : 3 tubes every 2days (1,5t/d) 1 month : 3 tubes 2 fois /week (1t/j)1 mois : 3 tubes 1 fois /week (0,45t/d)
224241584|NCT01881321|BEHAVIORAL|Counseling Intervention|20-40 minute contraceptive counseling session based on the principles of motivational interviewing
224241585|NCT01390337|DRUG|AC220|Oral Liquid
224241586|NCT01390337|DRUG|daunorubicin|Intravenous Infusion
224241587|NCT01390337|DRUG|cytarabine|Intravenous Infusion
224241588|NCT05108571|DRUG|DA-5210 10/1000mg|single dose administration (one tablet once a day)
224241589|NCT05108571|DRUG|DA-5210-R 10/1000mg|single dose administration (one tablet once a day)
224241590|NCT02879682|PROCEDURE|nTMS data available for the surgeon|the preoperatively acquired map of the motor cortex by nTMS will be available for the surgeon
224241591|NCT02879682|PROCEDURE|nTMS data not available for the surgeon|the preoperatively acquired map of the motor cortex by nTMS will not be available for the surgeon
224241592|NCT01220076|DRUG|tamoxifen|
224241593|NCT00122629|DRUG|peg-interferon alfa-2b|
224241594|NCT00122629|DRUG|ribavirin|
224241595|NCT00122629|DRUG|amantadine|
223661136|NCT00984620|DRUG|BI 201335|BI 201335
223661137|NCT00984620|DRUG|Pegylated Interferon-alpha (IFN)|Pegylated Interferon-alpha
223661138|NCT00984620|DRUG|Ribavirin (RBV)|Ribavirin (RBV)
223661139|NCT00732719|DEVICE|Prototype device (unnamed) worn-no pressure given (placebo) from inflatable cuffs|
223661140|NCT00732719|DEVICE|Prototype device(unnamed)-A battery operated inflatable pneumatic cuffs|
223661141|NCT00732719|DEVICE|Prototype device(unnamed)-A battery operated inflatable pneumatic cuffs|
223661142|NCT00732719|DEVICE|Prototype device(unnamed)-A battery operated inflatable pneumatic cuffs|
223661143|NCT00732719|DEVICE|Prototype device(unnamed)-A battery operated inflatable pneumatic cuffs|
223661144|NCT00732719|DEVICE|Prototype device(unnamed)-A battery operated inflatable pneumatic cuffs|
224241596|NCT01449630|DRUG|LY3031207|Administered orally
224241597|NCT01449630|DRUG|Placebo|Administered orally
224241598|NCT01449630|DRUG|Celecoxib|Administered orally
224241599|NCT01888263|DRUG|Lamotrigine|Lamotrigine Extended Release Tablets, 25mg, 50mg, 100mg, 200mg and 300 mg
223661145|NCT00732719|DEVICE|Prototype device(unnamed)-A battery operated inflatable pneumatic cuffs|
223661146|NCT04489069|DIAGNOSTIC_TEST|MRI|Magnetic Resonance Imaging (sturctural MRI, fMRI resting state and task related, DTI)
223661147|NCT04489069|DIAGNOSTIC_TEST|Clinical and Neuropsychological evaluations|Clinical interviews and neuropsychological tests (paper/pencil and computer based)
223661148|NCT04489069|DIAGNOSTIC_TEST|Drawing DNA sample|Saliva sample
223661149|NCT01018810|DRUG|LY2525623 Intravenous|administered intravenously at randomization and every 2 weeks for 6 weeks
223661150|NCT01018810|DRUG|LY2525623 Subcutaneous|administered subcutaneously at randomization and every 2 weeks for 6 weeks
223661151|NCT01018810|DRUG|Placebo Intravenous|administered intravenously at randomization and every 2 weeks for 6 weeks
223661152|NCT01018810|DRUG|Placebo Subcutaneous|administered subcutaneously at randomization and every 2 weeks for 6 weeks
223661153|NCT00662467|DRUG|aspirin + clopidogrel|Dual therapy
223661154|NCT00662467|DRUG|aspirin + clopidogrel + warfarin|Triple therapy
223661155|NCT05025436|DEVICE|Acupoint stimulation with low energy laser (Erger laser pen)|Each subject was given the same main acupoints (5 acupoints) and physique matching acupoints (1-2 acupoints) interventional low-energy laser (Erger laser pen) acupoint stimulation, set wavelength 810nm +/-10%, The power is 200mW, and the Bahr parameter (B2: 1199 Hz; B3: 2398 Hz) module is selected according to the acupoints. The treatment time is 30 seconds per acupoint, and the treatment dose is 3 joules per acupoint three times a week. After a period of 4 weeks, after a 2-week pause, After the two groups crossed for 4 weeks, each subject was given the same main acupoints (5 acupoints) and physique matching acupoints (1-2 acupoints) with low-energy laser (Erjie laser pen) acupoint stimulation. Set wavelength 810nm +/-10%, power 200mW, select Bahr parameter (B2: 1199 Hz; B3: 2398 Hz) module according to acupoints, treatment time is 30 seconds per acupoint, and treatment dose is 3 joules per acupoint three times a week for a period of time 4 weeks.
223661156|NCT04618796|OTHER|vaccine|Effect of COVID-19 pandemic on vaccination compliance among children attending Assiut University Children Hospital and what is the degree of that.
223661157|NCT03684369|DEVICE|Transcutaneous electrical nerve stimulation|Commercially available device will be used to apply weak electrical currents to arm and leg muscles in each of 18 treatment sessions.
223661158|NCT02619916|BEHAVIORAL|Mindfulness-Based Cognitive Therapy (MBCT)|The intervention consists of 8 weekly individual sessions of MBCT. Each session will be administered individually and will last 60 minutes
223661159|NCT02619916|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|The intervention consists of 8 weekly individual sessions of CBT. Each session will be administered individually and will last 60 minutes.
223661160|NCT00004368|DRUG|colchicine|
223661161|NCT00470834|DRUG|dutasteride|0.5mg dutasteride (Investigation Product)
223661162|NCT00470834|DRUG|placebo|making placebo
223661163|NCT00470834|DRUG|bicalutamide|50 mg Casodex or generic equivalent
223661164|NCT03157700|BEHAVIORAL|REAL media curriculum|REAL media is a 5-level, interactive, self-paced, e-learning media literacy curriculum to prevent youth substance use.
224241600|NCT04692610|BEHAVIORAL|Stoma prehabilitation|A stoma pouch was attached to the marked stoma site on the patient's abdominal surface after stoma education (only in group C). EST nurse filled 250 ml water into the pouch. Patients lived with these pouches until surgery. They experienced walking, sitting, sleeping, changing clothes with a pouch. They learned how to empty it. When a leak occurred, the pouch was changed by the nurse
224241601|NCT04692610|BEHAVIORAL|preoperative stoma education|A consultation period for stoma education by an EST nurse was approximately 45 minutes. Patients were shown pictures of a stoma. The stoma-care equipments and a pouch were also shown to the patients and they were informed about these equipments. They were also provided information about daily living with a stoma.
223661165|NCT05152225|DIAGNOSTIC_TEST|Brain MRI|Brain MRI performed routinely in patients with EI
223661166|NCT05152225|DIAGNOSTIC_TEST|digital subtraction angiography (DSA)|Digital Subtraction Angiography (DSA) performed routinely in patients with EI
223661167|NCT03492567|BIOLOGICAL|Blood test|Blood draw (max 15 ml)
223661168|NCT05871450|BEHAVIORAL|Inclusive events|Inclusive events such as inclusive sport festivals, citizen festivals or working groups at school are organized
223661169|NCT05290064|OTHER|Ultra-processed food, high energy density|Ultra-processed diet that is high in non-beverage energy density and low in hyperpalatable foods
223661170|NCT05290064|OTHER|Ultra-processed food, both low|Ultra-processed diet that is low in both non-beverage energy density and hyperpalatable foods
224241602|NCT04692610|BEHAVIORAL|postoperative stoma education|A consultation period for stoma education by an EST nurse was approximately 45 minutes. Patients were shown pictures of a stoma. The stoma-care equipments and a pouch were also shown to the patients and they were informed about these equipments. They were also provided information about daily living with a stoma.
224241603|NCT04692610|BEHAVIORAL|Postoperative stoma care|Usual stoma care given by enterostomal therapy nurse after a surgery with fecal diversion
224241604|NCT02016612|DEVICE|Seri Surgical Scaffold|An FDA approved Bioabsorbable mesh Seri Surgical Scaffold will be utilized in the study as an internal hammock mesh support of the breast.
224241605|NCT02854579|BIOLOGICAL|neural progenitor cell|Neural progenitor cells are derived from the same aborted human fetal forebrain.
224241606|NCT02854579|BIOLOGICAL|Paracrine factors|The factors obtained from cultured human mesenchymal stem cells were concentrated 50 times
224241607|NCT02854579|BIOLOGICAL|progenitor cell and paracrine factors|Neural progenitor cells will be received after paracrine factors therapy
223661171|NCT05290064|OTHER|Ultra-processed food, both high|Ultra-processed diet that is high in both non-beverage energy density and hyperpalatable foods
223661172|NCT05290064|OTHER|Unprocessed food diet|Unprocessed diet that is low in both non-beverage energy density and hyperpalatable foods
223661173|NCT02765009|DRUG|diuretics|Used to reduce fluid overload as evidenced by weight gain
223661174|NCT02765009|DRUG|albumin|Used to reduce fluid overload in addition with diuretics in hypoalbuminemic patients
223661175|NCT02765009|OTHER|fluid restriction|Used to reduce fluid overload
223661176|NCT02765009|DEVICE|renal replacement|Used to reduce fluid overload in patients with renal replacement
223661177|NCT04509622|DRUG|Venetoclax|Tablet; Oral
223661178|NCT04509622|DRUG|Cytarabine|Subcutaneous Injection
223661179|NCT06363942|OTHER|SAFE program (exercise intervention)|Participants will be asked to carry out the SAFE program with the help of a caregiver. Our healthcare professionals will visit them during the first week to explain to them and their caregivers how to perform the exercises correctly while using our website. All exercises will be performed using video capsules available on our website (https://safe-seniors.com/fr). The exercises are divided into 4 levels of difficulty: level 1 (light); level 2 (moderate); level 3 (moderate to vigorous); and level 4 (vigorous). Each level lasts 25 to 30 minutes and includes 5 exercise categories split into 5 videos: warm-up, strength, balance, flexibility, and endurance. The exercise intervention will include 3 sessions per week over 12 weeks.
223661180|NCT05750446|DRUG|Riociguat (BAY 63-2521)|A selective stimulator of soluble guanylate cyclase (sGC)
224241608|NCT04097600|DRUG|Oral semaglutide|Oral semaglutide current formulation and oral semaglutide new formulation, each in 3 different strengths, administered once daily during 6 treatment periods, each lasting 12 weeks
224241609|NCT03256942|DEVICE|Etermis 4®|Etermis 4® is a sterile non-pyrogenic physiological gel made of reticulated hyaluronic acid (HA) of non-animal origin.
224241610|NCT04064632|DRUG|Rilpivirine + darunavir/cobicistat|Switch to a dual ART
224241611|NCT02979015|DRUG|alirocumab SAR236553 (REGN727)|"Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous"
224241612|NCT02979015|DRUG|placebo|"Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous"
224241613|NCT04250662|DEVICE|Active tDCS with guided imagery|The subject will be positioned in the sitting/reclining position in a quiet room with the lights dimmed. The tDCS device and audio headphones will be placed on the subject's head. The tDCS device to be used is the Soterix Medical 1X1 device using 2.0 mA of current. The electrodes that will be used will be standard sponge electrodes. The subject will listen to a scripted guided imagery CD specifically developed for women with chronic pelvic pain through the audio headphones. The guided imagery plus active tDCS arm will have 20 minutes of stimulation with 25 minutes of guided imagery.
224241614|NCT04250662|DEVICE|Active tDCS alone (no guided imagery)|The subject will be positioned in the sitting/reclining position in a quiet room with the lights dimmed. The tDCS device will be placed on the subject's head. The tDCS device to be used is the Soterix Medical 1X1 device using 2.0 mA of current. The electrodes that will be used will be standard sponge electrodes. Active tDCS arm alone without guided imagery, will have 20 minutes of tDCS stimulation without guided imagery.
224241615|NCT04250662|DEVICE|Sham tDCS with guided imagery|The subject will be positioned in the sitting/reclining position in a quiet room with the lights dimmed. The tDCS device and audio headphones will be placed on the subject's head. The tDCS device to be used is the Soterix Medical 1X1 device using 2.0 mA of current. The electrodes that will be used will be standard sponge electrodes. The subject will listen to a scripted guided imagery CD specifically developed for women with chronic pelvic pain through the audio headphones. The guided imagery plus sham tDCS arm will have 30 seconds of tDCS stimulation with 25 minutes of guided imagery.
224241616|NCT04250662|DEVICE|Sham tDCS alone (no guided imagery)|The subject will be positioned in the sitting/reclining position in a quiet room with the lights dimmed. The tDCS device will be placed on the subject's head. The tDCS device to be used is the Soterix Medical 1X1 device using 2.0 mA of current. The electrodes that will be used will be standard sponge electrodes. Sham tDCS alone arm will have 30 seconds of tDCS stimulation without guided imagery.
224241617|NCT03799029|OTHER|Cognitive training|Participants will train at home during 25 sessions (about 45 minutes each) over a maximum of 5 weeks. Investigators will verify compliance via Internet and call participants and their legal guardians once a week. A reward system will be established with participants. Five sessions of metacognition (1 hour each) are added.
224241618|NCT01735630|DRUG|ELND005|
224241619|NCT01735630|DRUG|Placebo|
223661181|NCT05750446|OTHER|Placebo|Placebo
223661182|NCT05840757|DEVICE|HemoSphere ClearSight Module|The Clear Sight system consists of a finger cuff connected to a monitor It will be applied to the patients finger before and removed after the TAVI procedure.
223661183|NCT03867318|DRUG|Atorvastatin|Atorvastatin administered orally QD as 10 mg tablets.
223661184|NCT03867318|DRUG|Ezetimibe|Ezetimibe administered orally QD as 10 mg tablets
223661185|NCT03867318|DRUG|Placebo for Ezetimibe|Single placebo tablet administered orally QD
223661186|NCT03867318|DRUG|Placebo for Atorvastatin|Single placebo tablet administered orally QD
223661187|NCT03783624|BEHAVIORAL|Hypnosis|A 6 session course of individual hypnosis therapy will be offered.
223661188|NCT03783624|BEHAVIORAL|Open label placebo|Ritual intake of 2 placebo capsules twice a day
223661189|NCT02707575|DRUG|Ranibizumab|Three monthly consecutive injections of 0.5-mg ranibizumab will be performed. Aqueous humor samples will be taken each time an intravitreal injection in indicated and performed.
223661190|NCT02776397|DIETARY_SUPPLEMENT|Vitamin E|Two hundred patients will be recruited to a pilot randomized controlled trial (RCT), stratified by Hp 2-2 phenotype status (100 Hp 2-2 and 100 non-Hp 2-2), and randomly allocated in a 1:1 ratio to either vitamin E 400 IU supplementation daily for 6 months or a placebo group. The trial will determine whether vitamin E improves the aforementioned surrogate markers in the Hp phenotype strata.
223661191|NCT02776397|OTHER|Placebo|Placebo arm
223661192|NCT04780997|OTHER|Virtual Reality|Microsoft Xbox Kinect® was used for virtual reality exercises
223661193|NCT00126724|GENETIC|tgAAC94 gene therapy vector|Single Dose 1x10\^11 DRP/mL
223661194|NCT00126724|GENETIC|tgAAC94 gene therapy vector|Second dose of 1x10\^11 DRP/mL tgAAC94 administered once target joint reaches predetermined criteria for re-injection (on or after Week 12) at the same concentration as initial dose.
223661195|NCT00126724|GENETIC|tgAAC94 placebo|placebo
223661196|NCT00126724|GENETIC|tgAAC94 gene therapy vector|Single Dose 1x10\^12 DRP/mL tgAAC94
223661197|NCT00126724|GENETIC|tgAAC94 gene therapy vector|Second dose of 1x10\^12 DRP/mL tgAAC94 administered once target joint reaches predetermined criteria for re-injection (on or after Week 12) at the same concentration as initial dose.
223661198|NCT00126724|GENETIC|tgAAC94 gene therapy vector|Single Dose 1x10\^13 DRP/mL tgAAC94
223661199|NCT00126724|GENETIC|tgAAC94 gene therapy vector|Second dose of 1x10\^13 DRP/mL tgAAC94 administered once target joint reaches predetermined criteria for re-injection (on or after Week 12) at the same concentration as initial dose.
223661200|NCT03573271|DEVICE|MCD|Micro-coring skin removal with automated coring device
223661201|NCT04587609|BEHAVIORAL|Free Phone Mounts|Participants will receive free phone mounts
223661202|NCT04587609|BEHAVIORAL|Commitment Contract|Participants will develop and sign a personalized commitment contract where they will create their own weekly goals for phone use reduction, and plan potential future obstacles that may hinder them from reaching their goal and how and plan to overcome that obstacle.
223661203|NCT04587609|BEHAVIORAL|Personalized Habit Tips|Participants will receive weekly habit formation tips by text message. These messages will be tailored to encourage use of phone mounts, setting up do not disturb while driving, and include their personal obstacles and plans they developed to overcome.
223769421|NCT04919967|BEHAVIORAL|Virtual implementation protocol|Participants assigned to the virtual implementation protocol plus e-learning/toolkit group will take the e-learning course and also receive additional assistance through Virtual Implementation support. The Virtual Implementation strategy will be provided through virtual assistance, training, and toolkits to help obstetric practices integrate perinatal mental health and obstetric care and is delivered over 2-3 months and includes two 1-hour virtual implementation e-meetings. Implementation will occur within the practice where a champion is identified who establishes a quality improvement team to implement the practice's change plan to achieve their goals of addressing perinatal mental health conditions.
223769422|NCT04919967|BEHAVIORAL|e-learning toolkit|A toolkit given to obstetric care providers to enhance knowledge about and screening for perinatal mood and anxiety disorders. Participants assigned to the e-learning/toolkit alone group will take an e-learning course.This four-part online learning course aims to help obstetric care practitioners address perinatal mental health conditions such as depression, anxiety, PTSD and bipolar disorder.
223769423|NCT01435005|OTHER|Moderate Volume|Moderate volume (150 minutes per week) aerobic exercise
223661204|NCT04587609|BEHAVIORAL|Social Gamification Feedback|"Each week of the intervention period, the participant will be notified whether they met their prior week's goal, stayed about the same, or backslid. Participants will all start with 100 points, and can gain/maintain/lose points each week in the intervention period. Levels are as follows:~Copper: 0-40 points Bronze: 50-80 points Silver: 90-120 points Gold: 130-160 points Platinum: 170-200 points~Social competition: participants will be placed in groups of 10 based on similarity of baseline phone use. Weekly leaderboard reports will be sent via email, with SMS reminder. In the leaderboard they'll see themselves as You."
223661205|NCT04587609|BEHAVIORAL|"Contest Financial Incentives"|"Participants who finish in the platinum level will receive equal share of a prize, or a small amount will be awarded each week over the course of the intervention period to the weekly Safest Driver in each of the social competition cohorts."
223661206|NCT03305497|BEHAVIORAL|Mobile Phone Application|110 persons will be equipped with a mobile phone application, trained in overdose prevention, and equipped with naloxone. The mobile phone app will allow persons witnessing an overdose to signal persons in the vicinity to respond with naloxone.
223661207|NCT04802577|DIAGNOSTIC_TEST|FACT-F questionnaire|The questionnaire, based on patient report outcome data in which the presence of fatique is investigated in participants.
223661208|NCT04802577|DIAGNOSTIC_TEST|Beck Depression Inventory|The questionnaire, based on patient report outcome data in which the presence of depression is investigated in participants.
223661209|NCT04802577|DIAGNOSTIC_TEST|Beck Anxiety Inventory|The questionnaire, based on patient report outcome data in which the presence of anxiety is investigated in participants.
223661210|NCT04802577|DIAGNOSTIC_TEST|Insomnia severity index.|The questionnaire, based on patient report outcome data in which the presence of insomnia is investigated in participants.
223661211|NCT04802577|OTHER|ESSPRI|The questionnaire, based on patient report outcome data in which the severity of Sjögren's syndrome is investigated in participants.
223661212|NCT04802577|OTHER|ESSDAI|Activity scale in which the activity of Sjögren's syndrome is evaluated based on the laboratory and imaging tests of the patients and the examination findings of the evaluator.
223661213|NCT04802577|OTHER|Pain Detect Questionnaire|The questionnaire, based on patient report outcome data in which the severity and extent of pain in the body are investigated in participants.
223769424|NCT01435005|OTHER|High Volume|Participate in one-year high volume (300 minutes per week)aerobic exercise.
223769425|NCT03788733|DRUG|Melatonin 3 mg|1 time a day for 8 weeks
223769426|NCT03788733|DRUG|Placebo Oral|1 time a day for 8 weeks
223769427|NCT04733157|DRUG|Tranexamic acid injection|Tranexamic 1g administered intravenously at the onset of skin incision at caesarean section
223769428|NCT04733157|OTHER|Normal saline placebo|10ml of normal saline will be administered intravenously at onset of skin incision at caesarean section to the placebo group
223769429|NCT00648297|DRUG|Nadolol/Bendroflumethiazide Tablets 80 mg/5 mg|80/5mg, single dose fed
223769430|NCT00648297|DRUG|Corzide® Tablets 80 mg/5 mg|80/5mg, single dose fed
223661214|NCT05504642|DRUG|Pre-Chemo-radio-immunotherapy Treatment (Nivolumab/Ipilimumab)|Two weeks before start of Chemo-radio-immunotherapy one administration of Nivolumab 3 mg/kg and Ipilimumab 1 mg/kg IV over 30 minutes, with a 30 minute break between Nivolumab and Ipilimumab.
223661215|NCT05504642|DRUG|Concurrent Chemo-radio-immunotherapy (Nivolumab/Ipilimumab)|In week 1-7, standard administration of concurrent Cisplatin mono 40mg/m2 body surface area d1, 8, 15, 22, 29 (Monday of each treatment week) during radiotherapy. Simultaneous application of Nivolumab 3mg/kg week 1, 3, 5, 7 (on Thursday) and Ipilimumab 1mg/kg in week 5 (on Thursday).
223769431|NCT01814176|DEVICE|Intubation with GlideScope Video Laryngoscope or Macintosh Direct Laryngoscope|
223769432|NCT02056171|DRUG|quetiapine|Patients who are diagnosed with delirium and assigned to the intervention arm will receive quetiapine.
223769433|NCT02056171|OTHER|Placebo|Patients who are diagnosed with delirium and assigned to the placebo arm will receive placebo.
224241620|NCT04203030|BEHAVIORAL|Physical Activity|Participants will meet in a weekly group session to discuss a topic related to physical activity and physical function and participate in group-based physical activity. Participants will also have instructions to participate in physical activity outside of the weekly sessions, incrementally increasing their total physical activity over the intervention period.
223769434|NCT05287191|DRUG|Magnesium sulfate and then Digoxin|We will test MgSO4 and then digoxin IV (in 3 divided dose) as second line therapy with amiodarone IV as third line. Digoxin will be protocolised to commence between 30 minutes and 12 hours after MgSO4 if fast Atrial Fibrillation persists as initially designated (dose 1). Undiluted IV digoxin (12 mcg/kg) will be administered in 3 divided doses (6, 3 and 3 mcg/kg) separated by approximately 6 hrs (i.e. dose 1 at 30 mins - 12 hours after MgSO4, followed by dose 2 at -6 hrs and dose 3 at the approximately 12 hrs). Patients with renal dysfunction (creatinine clearance \<60 ml/min measured by the Modification of diet in renal disease formula) will receive a reduced dose of 8 mcg/kg in 3 divided doses (4, 2, and 2 mcg/kg) separated by the same time intervals. In the trial intervention group, amiodarone will be given approximately 120 mins after digoxin if necessary whilst completing the digoxin dose. Amiodarone as a 150 mg infusion over 10 minutes followed by 900 mg over 24 hours.
224241621|NCT01820923|DEVICE|Transcranial direct current stimulation (tDCS)|2 mA of intensity, 20 minutes of stimulation over the left fronto-temporal prefrontal cortex.
224241622|NCT01820923|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|Frequency of stimulation: 10Hz. Interstimulus interval: 1 min. Number of stimuli per session: 300. Number of sessions per week: 4 Total number of stimuli: 1.200
223661216|NCT05504642|PROCEDURE|Maintenance Treatment (Nivolumab/Ipilimumab)|For six months after Chemo-radio-immunotherapy, Nivolumab 3mg/kg every two weeks x12 (week +2, +4, +6, +8, +10, +12, +14, +16, +18, +20, +22, +24 (twelve applications), each application over 30 minutes and Ipilimumab every six weeks x4 (week +6,+12, +18, +24).
224241623|NCT01820923|DEVICE|Transcranial Direct Current Stimulation (SHAM)|The electrodes of stimulation will be applied in the left fronto-temporal prefrontal cortex, but the device will be turned off.
223661217|NCT00764764|PROCEDURE|shoulder treatment|shoulder exercise, joint mobilization, home program, posture
223661218|NCT00764764|PROCEDURE|Shoulder AND cervical treatment|Cervical and shoulder joint mobilization, exercise, posture, and home program
223661219|NCT04045002|OTHER|'MyPinkMom' educational intervention|"The intervention will be carried out for 2 weeks. There will be three sessions of 'MyPinkMom' that will be delivered to respondents per week. In each session, a respective 'MyPinkMom' video with audio explanation will be delivered to respondents in intervention group through WhatsApp application. It will be delivered every alternate day per week and each video will take about 3 minutes duration. Each session has its own objective and different content.~Each of the respondent in the intervention group will be given 'MyPinkMom' diary in which they are required to document time of iron tablet intake daily as well as time of reading of 'MyPinkMom' material in each session. At the end of the intervention, a meeting with all the respondents from the intervention group will be held for question and answer session."
223661220|NCT04454853|OTHER|Lung cancer|Paraneoplastic neurological syndrome (PNS) is a clinical syndrome that affects the central nervous system, peripheral nerves, neuromuscular junctions and muscles by the distant influence of the tumor. No tumor cells are visible at the neuropathy site.
223661221|NCT04454853|OTHER|Suspected lung cancer|Paraneoplastic neurological syndrome (PNS) is a clinical syndrome that affects the central nervous system, peripheral nerves, neuromuscular junctions and muscles by the distant influence of the tumor. No tumor cells are visible at the neuropathy site.
223661222|NCT04454853|OTHER|Positive methylated DNA|Tumor-free DNA (cfDNA) methylation detection is to determine the cancer condition and cancer type of the subject by detecting the methylation of free DNA released by tumor cells.
223661223|NCT03795272|DRUG|Rucaparib|2:1 randomization to receive rucaparib/placebo twice daily for 24 month
223661224|NCT03795272|DRUG|Placebo|placebo
223661225|NCT00862641|DRUG|Regadenoson|IV
223661226|NCT00862641|DRUG|Placebo|IV
223661227|NCT05149521|OTHER|None - this is a consensus group study to develop an intervention|None - this is a consensus group study to develop an intervention
223661228|NCT02176252|DRUG|AZD1722|
223661229|NCT02176252|DRUG|Placebo|
223661230|NCT05816499|DRUG|Cadonilimab|Given IV, 10mg/kg Q3W
224241624|NCT01820923|DEVICE|Repetitive Transcranial Magnetic Stimulation (SHAM)|The coil will be applied on the left fronto-temporal prefrontal cortex, but the device will be turned off.
223661231|NCT05816499|DRUG|Anlotinib|oral，6mg/8mg/10mg qd 2W/3W
223661232|NCT05816499|DRUG|Docetaxel|Given IV, 60-75mg/m2 Q3W
223661233|NCT02365480|DRUG|Berberine Chloride|Given PO
223661234|NCT02365480|OTHER|Laboratory Biomarker Analysis|Correlative studies
223661235|NCT02365480|OTHER|Placebo Administration|Given PO
223661236|NCT03238014|DEVICE|Noninvasive positive pressure ventilation|Noninvasive positive pressure ventilation used assist/control mode treat severe stable chronic obstructive pulmonary disease.
223661237|NCT02086513|DRUG|LDE225|Treatment with LDE225
223661238|NCT05243693|DRUG|Brentuximab vedotin|3 cycles of Brentuximab vedotin and DHAP
223661239|NCT04534686|BEHAVIORAL|CogXergaming|The participant will play four of the six balance board games Table tilt, Tightrope, Soccer, Balance bubble, Light Run and Basic Step (each game is max 1.5 minutes). Each game will be superimposed with any 3 of the 6 cognitive tasks (word list generation consisting of verbal fluency (VF) and category fluency (CF), digit recall (DR), analogies (AN), mental arithmetic (MA), repeated letter (RL). The cognitive tasks will be randomized making sure that all the cognitive tasks are played with all the games. The cognitive and balance board game scores will be noted on the scoring sheet for each session. A total 10 minutes rest interval between every sub-session will be mandatorily provided.
223661240|NCT04534686|BEHAVIORAL|Matter of Balance Training|The program emphasizes practical coping strategies that include group discussions, mutual problem solving, exercises to improve strength, coordination and balance, and, a home safety evaluation.
223661241|NCT03941704|DIETARY_SUPPLEMENT|Pulse-based diet|Low Glycemic Index
224241625|NCT03621579|PROCEDURE|cataract surgery|To measure the RNFLT and CMT in congenital cataracts before and after the cataract extraction with IOL implantation surgery
224241626|NCT03099538|DRUG|Ixekizumab|Subcutaneous injection
223661242|NCT03941704|DIETARY_SUPPLEMENT|Regular diet|Moderate Glycemic Index
223661243|NCT01284036|DRUG|PF-05230905|Single dose subcutaneous or intravenous (IV) administration of PF-05230905 or placebo
223661244|NCT03111862|DIAGNOSTIC_TEST|NSTEMI Rule-Out according to hs-TnT|Rule-Out according to the rapid rule-out protocol of the current ESC Guidelines
223661245|NCT00097604|DIETARY_SUPPLEMENT|Valerian root extract|Valerian root extract, 100 mg softgels, 3 softgels each night for 2 weeks, 30 minutes before bedtime
224241627|NCT05090332|OTHER|Facial Gun|Vibration massage applied for five Minutes directly on the trigger point
224241628|NCT05090332|OTHER|Dry Needling|For dry needling the outer skin should be clean with alcohol and the taut band should be placed between thumb and index finger. Without damaging any nerve or artery the needle is passed though the muscle into the trigger point and breaking it to relief pain
224241629|NCT06266052|PROCEDURE|Triangular Flap|Triangular flap is a type of flap that is made in the retromolar region, from the distal of the 2nd molar tooth towards the ramus and up to the distal gingival sulcus of the 2nd molar, and includes a vertical releasing incision added from the distobuccal sulcus of the 2nd molar tooth. The auxiliary vertical incision made in this flap type allows the wound to be closed without tension.
224241630|NCT06266052|PROCEDURE|Berwick Flap|Berwick described a type of flap whose base is in the distolingual direction of the second molar tooth, in which the tongue-shaped vestibular wing extends to the buccal part of the mandible. In this modification, the incision line is not over the bone defect created by the extraction.
223661246|NCT04762719|DRUG|PET/CT Scan with 11C-ER176|Subjects will have a low-dose, non-gated, non-contrast-enhanced, free-breathing CT from the orbits to upper thigh for attenuation correction (CTAC) and anatomic co-localization. Immediately following the start of the PET scan, 518 MBq (14 mCi) (range 370-666 MBq; 10-18 mCi) of 11C-ER 176 will be administered intravenously followed by a saline flush. A whole-body PET scan from the orbits to upper thigh will then be acquired.
223661247|NCT04762719|DIAGNOSTIC_TEST|Core biopsy of gastric muscle|The echoendoscope (Aloka Arietta 850; Olympus, Center Valley, PA) will be advanced into the gastric lumen and a site targeted for EUS-guided core biopsies based on findings of the PET scan. Fine needle biopsy of the gastric wall will be performed.
223661248|NCT01630538|DRUG|Cyclophosphamide|Cyclophosphamide 1.5 mg/kg orally daily for 180 days adjusted for renal function
223661249|NCT02340871|GENETIC|Genetic testing|Patients suspected of harboring a genetic neurological disease will be summoned to take a blood test. DNA will be extracted from the blood and sent to the collaborating hospital labs for next generation sequencing.
223661250|NCT05071248|DEVICE|VEMO (Reactive Robotics GmbH)|The robot used for early mobilization is able to verticalize the patients in their bed without transfer and to generate a movement of the legs that measures and supports the patients' own movement. The device meets the requirements for mobilizing critically ill patients in an intensive care unit, maintaining hygiene standards and providing the best possible support for the patient's own movement.
223661251|NCT01929811|DRUG|Metformin|Metformin: 500mg tid, orally (500mg daily in first cycle) on day 1 to day 21 of each 21 day cycle
223661252|NCT01929811|DRUG|Docetaxel|75 mg/m2, IV (in the vein) on day 1 of each 21 day cycle; 6 cycles.
223661253|NCT01929811|DRUG|Epirubicin|75 mg/m2, IV (in the vein) on day 1 of each 21 day cycle; 6 cycles.
223661254|NCT01929811|DRUG|cyclophosphomide|500 mg/m2, IV (in the vein) on day 1 of each 21 day cycle; 6 cycles.
223661255|NCT05726188|PROCEDURE|Colonic resection|Elective or urgent colonic resection; minimally-invasive or open surgery; completion surgery for endoscopically resected pT1 colon cancer with high risk features
223661256|NCT02739685|DEVICE|Everolimus-eluting bioresorbable vascular scaffold|Implantation of everolimus-eluting bioresorbable vascular scaffold in chronic total occlusion
223661257|NCT02739685|DEVICE|Everolimus-eluting stent|Implantation of everolimus-eluting stent in chronic total occlusion
223661258|NCT01781299|DEVICE|AlloDerm RTU|
223661259|NCT01781299|DEVICE|SurgiMend PRS|
223661260|NCT06532149|DRUG|Alectinib|Alectinib 600 mg/BID
223661261|NCT06532149|DRUG|Brigatinib|180 mg/daily
223661262|NCT06532149|DRUG|Lorlatinib 100 mg|100 mg/daily
223661263|NCT06532149|DRUG|Osimertinib|80 mg/daily
223661264|NCT06532149|DRUG|Sotorasib|960 mg/daily
223661265|NCT06532149|DRUG|Dabrafenib|150 mg/BID
223661266|NCT06532149|DRUG|Trametinib|2 mg/daily
224241631|NCT06266052|PROCEDURE|Saurez Flap|In the modified flap type he used, Suarez combined the crestal incision (marginal incision) from the distobuccal corner of the second molar tooth, following the line where the retromolar area meets the buccal bone, with a releasing incision made at the mesial and distal ends of the incision.
224241632|NCT06266052|PROCEDURE|Heitz Flap|Heitz used the incision line extending from the distobuccal corner of the 2nd molar tooth to the buccal face of the 2nd molar tooth and downwards, by rotating it towards the angulus mandible on the buccal bone.
224241633|NCT01067885|DEVICE|MARIS-stent (Invatec)|stenting of SFA with Maris nitinol stent/s
224241634|NCT03044171|DEVICE|Low Level Laser Therapy|Laser therapy: it was used the infrared spectrum with wavelength of 808 nm in its active environment AsGaAl, in two points: cervical and central-medial region of the incisors, canines and premolars.
224241635|NCT03044171|DRUG|1.1% Sodium Fluoride|Fluoride therapy: 1.1% sodium fluoride 5000 ppm was applied for 5 minutes on the vestibular surface of all pre-bleached dental elements.
224241636|NCT03044171|DRUG|In-office dental bleaching|Both groups received the in-office bleaching treatment. Three 15-minute applications of the 35% hydrogen peroxide gel were performed, totaling 45 minutes in each of the 4 sessions, with a 7-day interval.
223661267|NCT06532149|DRUG|Selpercatinib|160 mg/BID
223661268|NCT06532149|DRUG|Pembrolizumab|200 mg intravenous every 21 days
223661269|NCT06532149|DRUG|Cemiplimab|350 mg intravenous every 21 days
223661270|NCT06532149|DRUG|Nivolumab|240 mg intravenous every 14 days
223661271|NCT06532149|DRUG|Carboplatin|AUC4/AU5 intravenous every 21 days
223661272|NCT06532149|DRUG|Pemetrexed|500 mg/mq intravenous every 21 days
223661273|NCT06532149|DRUG|Paclitaxel|175 mg/mq intravenous every 21 days
223661274|NCT01099449|DRUG|calcium gluconate|Given IV
223661275|NCT01099449|DRUG|magnesium sulfate|Given IV
223661276|NCT01099449|OTHER|placebo|Given IV
223661277|NCT01099449|DRUG|oxaliplatin|
223661278|NCT01798849|DRUG|MK-8892|
223661279|NCT01798849|DRUG|Placebo for MK-8892|
223661280|NCT02636361|DRUG|LY900014|Administered subcutaneously (SC)
223661281|NCT02636361|DRUG|Insulin lispro (Humalog)|Administered SC
223661282|NCT02032238|DEVICE|laser photocoagulation|Standard bevacizumab Injections will be combined with laser photocoagulation in a pre-defined manner
223661283|NCT01612806|DEVICE|PriMatrix|fetal bovine dermal scaffold
223661284|NCT01612806|DEVICE|PriMatrix Ag|fetal bovine dermal scaffold with Ag
223661285|NCT01612806|PROCEDURE|moist wound therapy|standard of care moist wound therapy
223661286|NCT03692819|DRUG|Placebo Oral Tablet|Non-surgical periodontal treatment will be performed by means of periodontal debridement in a single session.
223661287|NCT03692819|DRUG|Amoxicillin 500 Mg|Non-surgical periodontal treatment will be performed by means of periodontal debridement in a single session after the therapy will be administered the antibiotic (Metronidazole 400mg + Amoxicillin 500mg) every 8 hours for 7 days
223769435|NCT05287191|DRUG|Amiodarone|We will test Amiodarone (150mg IV then 900mg IV over the next 24 hours ) as first line treatment in the standard of care group. No more than 2g MgSO4 be delivered over 2 hours maximum for this group in the first 24 hours after randomisation unless clinically indicated for measured hypomagnesaemia (a value below the index hospital laboratories lower limit of normal).
223769436|NCT03747081|DRUG|Rivaroxaban|Rivaroxaban will administrate to patient with CVT. In first day, enoxaparin is injected to patients and the next day, patients will receive Rivaroxaban and enoxaparin discontinue. Then, patients receive Rivaroxaban for 3 months daily.
223769437|NCT03747081|DRUG|Warfarin|Warfarin as a antocoagolant drug will administrate to patient with CVT. In first day, Warfarin plus enoxaparin until adjusting INR index to 2-3. Then, patients receive warfarin for 3 months daily.
223769438|NCT02816216|BEHAVIORAL|CampAir|An empirically-based dynamic e-health intervention (based on the evidence-based ASMA) to assist adolescents with uncontrolled asthma to learn how to manage their illness and improve their asthma control.
223769439|NCT01455324|DEVICE|Novel conformable woven inner socket|Prosthetic socket liner fabricated from novel materials to allow passive conformability for the user
223661288|NCT03692819|DRUG|Lactobacillus reuteri Oral Drops|Non-surgical periodontal treatment will be performed by means of periodontal debridement in a single session after the therapy will be administered the probiotic (Lactobacillus reuteri oral drops ) twice a day for 21 days.
223661289|NCT03114319|DRUG|TNO155|TNO155 for oral administration
223661290|NCT03114319|DRUG|TNO155 in combination with EGF816 (nazartinib)|TNO155 for oral administration; EGF816 (nazartinib) for oral administration
223769440|NCT03337724|DRUG|Ipatasertib|Ipatasertib, 400 milligrams (mg), administered orally once a day (QD) on Days 1-21 of each 28-day cycle until disease progression, intolerable toxicity, elective withdrawal from the study, or study completion or termination.
223769441|NCT03337724|DRUG|Paclitaxel|Paclitaxel, 80 mg/square meter (m\^2), administered intravenously (IV) on Days 1, 8, and 15 of each 28-day cycle until disease progression, intolerable toxicity, elective withdrawal from the study, or study completion or termination.
223769442|NCT03337724|DRUG|Placebo|Matching placebo, administered orally QD on Days 1-21 of each 28-day cycle until disease progression, intolerable toxicity, elective withdrawal from the study, or study completion or termination.
223769443|NCT05713123|OTHER|A SPECT-CT whole body is added in VERITON-CT camera|A SPECT-CT whole body in VERITON-CT camera is added after the conventional procedure recorded in Anger camera
223769444|NCT05176652|RADIATION|ultrasound|ultrasonographic assessment of optic nerve sheath diameter
223769445|NCT02970838|OTHER|Structured weight-loss program|"During the fasting phase, daily consumption consists of five sachets fully replacing normal food and corresponded to an energy content of 800 kcal. This fasting phase is followed by a four-week refeeding phase, during which regular food will be reintroduced and formula diet is gradually replaced until a daily total intake of 1200 kcal is reached. During the last five weeks of the program, energy intake is gradually increased to an individual level between 1200 kcal and 1500 kcal that allowed subjects to keep their weight stable.~Once a week participants visit the study center to monitor health status and taking part in supervised exercises and a nutritional and behavioral counseling."
223769446|NCT01831375|BEHAVIORAL|Speak Up|Intervention group\_treatment group
223769447|NCT01831375|BEHAVIORAL|Get connected|Participants will learn to be connected with social resources in the community.
223769448|NCT00501891|DRUG|Bevacizumab|Bevacizumab administered intravenously 10mg/kg every other week.
223769449|NCT00501891|DRUG|Metronomic Temozolomide|Temozolomide 50mg/m2 given orally on a daily basis.
223661291|NCT06518395|OTHER|Questionnaire for The degree of knowledge and attitude.|Questionnaire for The degree of knowledge and attitude of Egyptian nurses regarding the emergency treatment of traumatic dental injuries
223661292|NCT04978103|DRUG|Gum Arabic|A dietary supplement (Powdered exudates of Acacia Senegal (Gum Arabic E-414))
223769450|NCT05555381|BEHAVIORAL|young-D program|"* needs detection by means of survey and interviews (mixed-methods)~* 6 week program (1 hour) on a weekly basis including cognitive behavioural therapy, sleep/stress hygiene education, heart coherence exercises, mindfulness and relaxation exercises"
223769451|NCT02544893|DRUG|bupivacaine|21 ml 0.5 %bupivacaine is applied paravertebral space
223769452|NCT02544893|DRUG|dexmedetomidin|1 ml dexmedetomidin + 20 ml 0.5 % bupivacaine are applied paravertebral space
223769453|NCT02544893|DRUG|serum physiologic|21 ml serum physiologic is applied paravertebral space
223769454|NCT01678534|DRUG|Allogenic mesenchymal stem cells from adipose tissue|
223769455|NCT01678534|DRUG|Placebo|
223769456|NCT06243133|DRUG|clopidogrel for 90 days combined with aspirin for 90 days|Clopidogrel 300mg on the first day, then 75mg/day for 90 consecutive days; Aspirin 100mg/day for 90 days
223769457|NCT06243133|DRUG|clopidogrel for 30 days combined with aspirin for 90 days|Clopidogrel 300mg on the first day, then 75mg/ day for 30 consecutive days; Aspirin 100mg/ day for 90 days
223769458|NCT01276899|PROCEDURE|Needle core biopsies|"No investigational products will be administered to subjects as part of this translational research study. Needle core biopsies will be done to collect tumor samples.~A taxane-based regimen will be administered as per the standard of care at each treating institution. Tissue samples from primary tumors will be collected and banked before the start of chemotherapy, after chemotherapy and at the time of surgery. Additionally, blood samples will be drawn before treatment initiation (baseline) and at different time points during treatment and stored in the tissue biobank."
223769459|NCT01276899|PROCEDURE|Needle core biopsies of metastatic lesion|"No investigational products will be administered to subjects as part of this translational research study. Needle core biopsies will be done to collect metastasis tumor samples.~Chemotherapy will be administered as per the standard of care at each treating institution. Tissue samples from metastatic tumors lesions will be collected and banked before the start of chemotherapy and at the time of progression. Additionally, blood samples will be drawn before treatment initiation (baseline) and at different time points during treatment and stored in the tissue biobank."
223769460|NCT06641687|OTHER|24% Sucrose|Participants will be given either sugar water (24% sucrose) randomly
223661293|NCT05178797|OTHER|Kinesiology taping technique with exercise therapy|Kinesiology tape is a latex-free fiber that stretches longitudinally \& elastic with an acrylic adhesive. It is used to stimulate dermal mechanoreceptors, encourages sensory and mechanical stimuli resulting in reduction of clogging lymphatic flow which limits the circumference of the affected limb in the region where it is applied due to its flexibility and acts over the lymphatic system. However, exercise therapy is systematic movement program to strengthen muscles.
223661294|NCT05178797|OTHER|Compression decongestive therapy|"It consists of two phases: First is the intensive phase (volume reduction phase), in this phase short stretch bandage, manual lymphatic drainage, skincare and exercises will be given for a period of 4 weeks.~In the second phase (maintenance phase), compression garments and exercises will be given to the patient for maintaining the limb volume or to reduce the risk of lymphedma."
223661295|NCT03892278|BEHAVIORAL|Water-based aerobic training|Participants who will be randomized for the intervention in the aerobic training group will carry out exercises with no interval for exercise change. Intensity will be increased every mesocycle and participants will carry out three 3-minute series of each exercise. In the first mesocycle (weeks 1-2) the intensity will correspond to 80-85% of heart rate corresponding to the anaerobic threshold (HRat). In the second mesocycle (weeks 3-4) the intensity will correspond to 85-90% of HRat. In the third mesocycle, the intensity will correspond to 90-95% of HRat from weeks 5-7. In the fourth mesocycle, the intensity will correspond to 95-100% of HRat from weeks 8-10. In the fifth mesocycle (weeks 11-13) the intensity will correspond to the 100-105% of HRat for 2 minutes and \<85% of HRat for 1 minute. The last mesocycle (weeks 14-16) the intensity will correspond to the 105-110% of HRat for 2 minutes and \<85% of HRat for 1 minute.
223661296|NCT03892278|BEHAVIORAL|Water-based aerobic and combined training|Participants who will be randomized for the intervention in the aerobic and combined training group will perform 8 weeks of aerobic training and more 8 weeks of aerobic and resistance training in same session. In aerobic training the participants will perform three 3-min series of each exercise. The intensity will correspond to 80-85% of heart rate of anaerobic threshold (HRat) (weeks 1-2), 85-90% of HRat (weeks 3-4), 90-95% of HRat (weeks 5-7), 95-100% of HRat (weeks 8-10), 100-105% for 2 min and \<85% of HRat for 1 min (weeks 11-13) and 105-110% for 2 min and \<85% of HRat for 1 min (weeks 14-16). Resistance training will be divide into two blocks of exercises perform each repetition at maximal effort, speed and amplitude. Participants will perform 2 sets of 30 s for each block in the first mesocycle (weeks 9-10), 3 sets of 20 s in the second mesocycle (weeks 11-13) and 4 sets of 15 s in the third mesocycle (weeks 14-16).
223661297|NCT03892278|BEHAVIORAL|Control group|The control group will perform a weekly session composed of 30 minutes of therapeutic and playfull exercises in the aquatic environment, involving games, relaxation, massage and conversation.The participants will receive instructions to perform the movements as slowly as possible to avoid physical effort.
223769461|NCT06641687|OTHER|Sterile water|Participants will be given sterile water randomly
223769462|NCT05356884|BEHAVIORAL|Diabetes Intervention|A 12-session group-based intervention that will target diabetes knowledge and leadership and communication skills through facilitated discussion and experiential learning.
223769463|NCT05356884|BEHAVIORAL|Leadership & Life Skills|A 12-session group based intervention that will teach leadership and life skills (planning strategies, leadership values, emotional awareness, effective reasoning skills)
223769464|NCT03313362|DEVICE|SPEAC System|Seizure Monitoring and Alerting System
223769465|NCT03313362|DEVICE|video EEG|The Video EEG Monitoring Test (VEEG) is a high specialized form of an EEG test in where the patient is continuosly monitored by using a video recorder. This allows doctors to observe brainwaves activity during the time a seizure or spell is occurring.
223769466|NCT04921514|BEHAVIORAL|SASRQ questionnaire|"During an interview with a trained psychologist, the presence of acute stress will be assessed by the SASRQ test within one week of the occurrence of a sudden recovered death.~The diagnosis of acute post-traumatic stress disorder is made according to the presence of at least three dissociative symptoms out of five, and other symptoms of re-experiencing, avoidance or marked anxiety or hypervigilance. Each symptom is thus evaluated dichotomously. A symptom is present if the intensity of the response is 3 or more (0 from 0 to 2 and 1 from 3 to 5)."
223769467|NCT04921514|BEHAVIORAL|PCL-5 with LEC-5 questionnaire|"This questionnaire will be completed during an interview with a psychologist trained in the protocol, 3 months after the sudden death.~The PCL-5 is a 20-item self-report questionnaire that assesses the 20 symptoms of PTSD according to the DSM-V. It is associated with the LEC-5 questionnaire.~The self-reported scale uses ratings of 0 to 4 to assess each of the symptoms.~A threshold of 38 on the PCL-5 seems reasonable to suggest the presence of PTSD."
223769468|NCT06821945|DRUG|BR5402A|Subjects take the investigational products once a day
223769469|NCT06821945|DRUG|BR5402A-1|Subjects take the investigational products once a day
223769470|NCT06821945|DRUG|BR5402B|Subjects take the investigational products once a day
223769471|NCT06821945|DRUG|BR5402B-1|Subjects take the investigational products once a day
223661298|NCT03386838|BIOLOGICAL|Nivolumab|Specified dose on specified days
223661299|NCT03386838|DRUG|BMS-986205|Administered 100mg orally once daily for a maximum of 104 weeks
223661300|NCT03386838|BIOLOGICAL|Cetuximab|400 mg/m² intravenous administration once only, then 250 mg/m² weekly maintenance until disease progression, unacceptable toxicity, withdrawal of informed consent, or other reason
223769472|NCT06821945|DRUG|BR5402C|Subjects take the investigational products once a day
223769473|NCT06821945|DRUG|BR5402C-1|Subjects take the investigational products once a day
223769474|NCT06821945|DRUG|BR5402D|Subjects take the investigational products once a day
223769475|NCT06821945|DRUG|BR5402D-1|Subjects take the investigational products once a day
223769476|NCT01550874|BEHAVIORAL|Physical activity behavior-change counselling|Participants in the experimental group will be motivated by augmented behavior modification strategies aiming to increase performance by: (i) having access to the pedometer web page that allows them to view their automatically calculated goals, and (ii) get feedback about performance toward goals.
223769477|NCT01013233|BEHAVIORAL|cognitive training|cognitive training over 6 weeks, consist of 6 meetings (a 45minutes), three sessions focus on concentration tasks and three sessions on memory problems.
223769478|NCT01013233|OTHER|control group|no intervention
224241637|NCT05964777|DEVICE|Repetitive Transcranial magnetic stimulation and transcranial alternating current stimulation|with the rapid development of neuroregulatory technology, rTMS and tACS have a profound impact on cognitive impairment. The damaged neural circuit of DLPFC-DACC may lead to impaired cognitive function in bipolar disorder.We used DTI imaging technology to calculate the DLPFC cortical region corresponding to the strongest point of dlpfc and DACC fiber connection as the stimulus site.Using high-frequency rTMS and high-precision tACS stimulation,thus affect the nerve ring pathway , thereby rapidly, effectively and safely improving cognitive impairment with bipolar disorder in remission.
224241638|NCT01276730|DRUG|Interferon, Retinoic Acid and radiation|Interferon-α2b will be administered 3 times a week for four weeks at a dose of 3 x 106 IU subcutaneously concomitant with radiotherapy. The first dose will be administered on the day the subject starts radiotherapy; 13-cis-retinoic acid will be administered orally at a dose of 40 mg/day for 1 month starting from day 1 of radiotherapy; a total of 40 to 45 Gy whole pelvis irradiation will be delivered in conventional fractions to both the study group and the control group. Additional parametrial dosages will be delivered to complete 55 Gy. This will be followed by two intracavitary applications of approximately 40-50 Gy, depending on the volume.
224241639|NCT01276730|DRUG|Cisplatin and radiation|Weekly cisplatin will be administered concurrent with external beam radiation at a dose of 40mg/m2/week for 5 weeks; a total of 40 to 45 Gy whole pelvis irradiation will be delivered in conventional fractions. Additional parametrial dosages will be delivered to complete 55 Gy. This will be followed by two intracavitary applications of approximately 40-50 Gy, depending on the volume.
223661301|NCT03386838|DRUG|Cisplatin|Cisplatin (100 mg/m2) every 3 weeks (Up to 6 cycles)
223661302|NCT03386838|DRUG|Carboplatin|Carboplatin (AUC of 5 mg per milliliter per minute) every 3 weeks (Up to 6 cycles)
223661303|NCT03386838|DRUG|Fluorouracil|1000 mg/m² per day for 4 days, every 3 weeks (Up to 6 cycles)
223661304|NCT01238484|OTHER|Standard of care|shoe modification home stretching exercises
223661305|NCT01238484|DEVICE|Dynasplint|shoe modification home stretching exercises Ankle Dorsiflexion Dynasplint
223661306|NCT02428478|DRUG|Desipramine|200 mg administered 2 hours before normal sleep time
223661307|NCT02428478|DRUG|Placebo|Placebo-matching desipramine administered 2 hours before normal sleep time
223661308|NCT02663934|BEHAVIORAL|Exercise|The resistance exercise training component will follow aerobic exercise and will consist of 4 upper and 3 lower body routines. A combination of guided-motion machines and free weights will be used. Voluntary maximum strength will be measured during the first 4 sessions on each exercise station. The program will initially consist of 1-2 sets of each exercise while lifting a weight that causes muscle fatigue after 8-10 repetitions. The trainer will monitor each participant's exercise response, and when the participant can comfortably lift the weight for 12 repetitions on any exercise, the weight will be increased to cause the muscle group to fatigue after 8 repetitions. This progressive 8-12 repetition cycle is repeated for each exercise over 26 weeks.
223661309|NCT02663934|BEHAVIORAL|Stretching and Social Interaction|Participants will receive instructions on stretching, range of motion, limbering, and toning. Activities will focus on flexibility enhancement. Along with the stretching and flexibility, this group will have a social interaction component. They will have discussions and interact with trainers and coordinators during all their sessions. These participants will be supervised by the same trainer and will receive the same amount of attention and class interaction as participants in the EXS program.
223661310|NCT06344897|OTHER|Kinesio taping|After appendicitis surgery, children will receive Kinesio taping in addition to the standard pain management applied in the clinic.
224241640|NCT05738525|DEVICE|APD-RPM|"APD mode is recommended but not limited to continuous circulating peritoneal dialysis (CCPD); (2) Dialysis dose ranges from 5 to 10 liters per day and depends on previous APD prescription and dialysis adequacy; (3) Glucose concentration starts from low concentration (1.5%) and depends on previous dialysis prescription.~Remote monitoring includes dynamic changes of the overall treatment situation, warning or any abnormal notes, and drainage, retention and duration of APD per day."
224241641|NCT00949312|GENETIC|RNA marker analysis of lymph node and primary tumors|
224241642|NCT00949312|GENETIC|microarray profiling of primary tumors|
224241643|NCT00949312|GENETIC|reverse transcriptase-polymerase chain reaction of lymph node specimens|
224241644|NCT00949312|OTHER|diagnostic laboratory RNA and DNA biomarker analysis of primary tumors|
224241645|NCT00949312|PROCEDURE|regional lymph node dissection|
224241646|NCT00949312|OTHER|lymph node staining for H&E and pancytokeratin IHC|
224241647|NCT03195374|OTHER|Prescription Opioid Misus Index|Opioid misuse will be assessed by the Prescription Opioid Misuse Index (POMI) scale. A score ≥ 2 is considered positive and will define a misuse behavior.
224241648|NCT01829308|BEHAVIORAL|The brief interventions are delivered by behavioral health counselors (Specialist)|Behavioral Health Specialists perform the brief intervention. The screening and referral to treatment processes remain the same as with the Generalist condition.
224241649|NCT01829308|BEHAVIORAL|The brief interventions are delivered by the primary care provider (Generalist)|Primary care providers perform the brief intervention. The screening and referral to treatment processes remain the same as with the Specialist condition.
224241650|NCT04407962|BEHAVIORAL|SMS group|The experimental treatment will consist of health promoting text messages addressing metabolic risk factors associated with cardiovascular disorders in patients with hypertension. The text messages will be developed to support healthy life style changes i.e. regarding general cardiovascular health, tobacco use, physical activity and diet.
224241651|NCT01720264|DRUG|Sitagliptin|Sitagliptin q 12 hours PO starting on Day -1 then given every 12 hours (total 10 doses) on Day 0, Day +1, +2 and Day +3.
224241652|NCT00306371|DEVICE|1450nm diode laser|
223661311|NCT01563133|PROCEDURE|EUS-FNA|Endoscopic ultrasound fine needle aspiration: ultrasound endoscopy of a lesion with aspiration of the lesion fluid through a needle
223661312|NCT01563133|DEVICE|nCLE|needle-based Confocal Laser Endomicroscopy
223661313|NCT04423341|DRUG|Cannabidiol Oral Solution [Epidiolex]|100 mg BID for three months Placebo oral solution for three months
223661314|NCT05339997|OTHER|6 minute walk test,|submaximal exercise test used to evaluate the functional capacity of patients
223769479|NCT01024400|BIOLOGICAL|Non-adjuvanted A(H1N1)v influenza vaccine|15 mcg HA/0.5 ml
223769480|NCT00758628|DRUG|Bromefenac|Bromfenac BID 3 months
223769481|NCT00758628|DRUG|Blink|Blink BID for 3 months
223769482|NCT06239961|BEHAVIORAL|Social Connection|6 weekly Behavioral Activation Intervention calls with a 1 hour duration for each call.
223769483|NCT06239961|BEHAVIORAL|Nutritional Coaching|4 weekly nutritional coaching calls with a Registered Dietician with a 1 hour duration for each call.
223769484|NCT06239961|BEHAVIORAL|Physical Activity Coaching|4 weekly physical activity coaching sessions with a 1 hour duration for each call.
223769485|NCT02705690|DEVICE|iOS Balance Application|"We have designed an iOS application and a belt. The application uses accelerometer data to calculate postural sway. Steps:~The phone is kept stable against the lower back of the participant using the belt.~The iOS application gives instructions to user to adopt the correct stance (eg: Standing Unsupported, legs side by side) Once the stance is adopted, the application turns on the accelerometer in the phone to sample acceleration along x (media lateral) and z (anterior posterior) axis.~These displacements from the mean are used to calculate the Root Mean Square of a person which acts a proxy score for Postural Sway. (Postural sway is defined as the phenomenon of constant displacement and correction of the position of the center of gravity within the base of support)"
223769486|NCT06639490|DEVICE|RUS GA|he RUS GA (Endoscopic Imaging Treatment Planning Software, E04010.01(2)) is an endoscopic imaging treatment planning software program. It creates a patient-specific simulation of the actual intra-abdominal surgical environment, allowing for the visualization of vascular structures and intra-abdominal organs during the surgical planning process and the operation. RUS GA utilizes preoperative CT images of the patient to segment organs and blood vessels and reconstructs them into a 3D model. Although there is no direct intervention with the patient, the surgeon uses RUS GA as a surgical navigation tool to simulate the surgery before performing the actual procedure.
223769487|NCT06639490|PROCEDURE|standard treatment|Only standard treatment is performed.(Robot-assisted gastrectomy will be performed using without software RUS GA.)
223769488|NCT06664086|BEHAVIORAL|economic and psychological burden|measuring the economic and psychological burden of infertility
223769489|NCT06824181|BIOLOGICAL|PCV21 vaccine|Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular
223769490|NCT06824181|BIOLOGICAL|Prevnar 20 vaccine|Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular
223769491|NCT06824181|BIOLOGICAL|M-M-R II vaccine|Pharmaceutical form:Powder, lyophilized, for suspension for reconstitution-Route of administration:Subcutaneous or Intramuscular
224241653|NCT00924326|DRUG|Fludarabine|Days -5 to -1 (after administration of cyclophosphamide): 25 mg/m\^2 intravenous (IV) over 30 minutes
223661315|NCT03492918|DRUG|Pembrolizumab|"Trial treatment should be administered on Day 1 of each cycle after all procedures/assessments have been completed as detailed on the Trial Flow Chart. Trial treatment may be administered up to 3 days before or after the scheduled Day 1 of each cycle due to administrative reasons.~All trial treatments will be administered on an outpatient basis. Pembrolizumab 200 mg will be administered as a 30 minute IV infusion every 3 weeks. Sites should make every effort to target infusion timing to be as close to 30 minutes as possible. However, given the variability of infusion pumps from site to site, a window of -5 minutes and +10 minutes is permitted (i.e., infusion time is 30 minutes: -5 min/+10 min)."
223661316|NCT02396472|BEHAVIORAL|Order by time and topic|
223661317|NCT02396472|BEHAVIORAL|Order by information relevance|
223661318|NCT02396472|BEHAVIORAL|Order by social relationship|
223661319|NCT02396472|BEHAVIORAL|Order by help giving|
223769492|NCT06824181|BIOLOGICAL|Rotarix|Pharmaceutical form:Solution-Route of administration:Oral
223769493|NCT06824181|BIOLOGICAL|RotaTeq|Pharmaceutical form:Solution-Route of administration:Oral
223769494|NCT06824181|BIOLOGICAL|Vaxelis vaccine|Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular
223769495|NCT06824181|BIOLOGICAL|Varivax|Pharmaceutical form:Powder, lyophilized, for suspension for reconstitution-Route of administration:Subcutaneous or Intramuscular
224241654|NCT00924326|DRUG|Cyclophosphamide|Days -5 to -4: 60mg/kg intravenous (IV) over 60 minutes
224241655|NCT00924326|BIOLOGICAL|Anti-cluster of differentiation 19 (CD19)-CAR PBL|"Anti-cluster of differentiation 19 (CD19) chimeric antigen receptor (CAR) peripheral blood lymphocytes ( PBL).~Day 0 (two to four days after the last dose of fludarabine); Cells will be infused via intravenous (IV) on the Patient Care Unit over 20-30 minutes."
224241656|NCT00924326|DRUG|Aldesleukin|Day 0: 720,000 IU/kg intravenously (IV) every 8 hours for a maximum of 15 doses.
224241657|NCT00924326|DRUG|Fludarabine|Days -5 to -3 (after administration of cyclophosphamide): 30 mg/m\^2 intravenous (IV) over 30 minutes
224241658|NCT00924326|DRUG|Cyclophosphamide|Days -5 to -3: 300mg/m\^2 intravenous (IV) over 60 minutes
223661320|NCT02396472|BEHAVIORAL|Order by self-disclosure|
223661321|NCT03706248|OTHER|Blood Draw|20 ml of blood will be drawn from subjects via venipuncture
223661322|NCT03811860|DIAGNOSTIC_TEST|Lithium level|The level of lithium in the serum
223661323|NCT03811860|DIAGNOSTIC_TEST|Serum Creatinine|The level of creatinine (as an indicator of kidney function, to approximate GFR) in the serum
223661324|NCT00004930|DRUG|doxorubicin hydrochloride|
223661325|NCT02692391|DRUG|Indomethacin|Rectal indomethacin will be administered as 100 mg loading doses following by 5 maintenance doses of 50 mg at internals of 8 hours for total of 48 hours.
223661326|NCT02692391|DRUG|Placebo|Glycerin placebo suppositories which are identical in shape, size, color, and packaging to rectal indomethacin
223769496|NCT06824181|BIOLOGICAL|Priorix|Pharmaceutical form:Lyophilized, for suspension for reconstitution-Route of administration:Subcutaneous
223769497|NCT06824181|BIOLOGICAL|VAQTA|Pharmaceutical form:Suspension for Injection-Route of administration:Intramuscular
223769498|NCT06824181|BIOLOGICAL|Havrix|Pharmaceutical form:Suspension for Injection-Route of administration:Intramuscular
223769499|NCT03551210|DRUG|Nemonoxacin|Solution for infusion, 500 mg (250 ml)
223769500|NCT03551210|DRUG|Nemonoxacin|Capsules, 250 mg
223769501|NCT03551210|DRUG|Tavanic|Solution for infusion, 500 mg (100 ml)
223769502|NCT03551210|DRUG|Tavanic|Film coated tablets (each tablet is placed into a capsule shell (overencapsulated) for blinding purposes), 250 mg
223769503|NCT03551210|DRUG|Placebo (250 ml)|0.9% NaCl (250 ml), solution for infusion
223769504|NCT03551210|DRUG|Placebo (100 ml)|0.9% NaCl (100 ml), solution for infusion
223769505|NCT06670339|OTHER|No Cooling|Participants will not be pre-cooled prior to completing a 60-minute moderate-intensity exercise bout in the heat.
223661327|NCT03381976|OTHER|Intervention 2X/week (G2X)|Participants performed resistance training (RT) composed of eight exercises performed for one set of 10-15 repetition maximum (RM). The rest interval between exercises was 2-3 min. Participants were instructed to control the speed of movement in the ratio of 1:2 for concentric and eccentric muscle actions, respectively. The progression of training loads in each exercise occurred, when a participant completed 15 repetitions in two consecutive sessions, with increases of 2-5% in exercises for the upper limbs, and 5-10% in exercises for the lower limbs. At the end of each session, one static stretching exercise at the point of discomfort for 15 seconds was performed for all major muscle groups for a total of exercises. Participants were asked not to perform any other type of organized physical exercise during the entire study period.
223661328|NCT03381976|OTHER|Intervention 3X/week (G3X)|Participants performed resistance training (RT) composed of eight exercises performed for one set of 10-15 repetition maximum (RM). The rest interval between exercises was 2-3 min. Participants were instructed to control the speed of movement in the ratio of 1:2 for concentric and eccentric muscle actions, respectively. The progression of training loads in each exercise occurred, when a participant completed 15 repetitions in two consecutive sessions, with increases of 2-5% in exercises for the upper limbs, and 5-10% in exercises for the lower limbs. At the end of each session, one static stretching exercise at the point of discomfort for 15 seconds was performed for all major muscle groups for a total of exercises. Participants were asked not to perform any other type of organized physical exercise during the entire study period.
223661329|NCT04952935|PROCEDURE|True Acupuncture|Delivery of four acupuncture seeds (no needles involved) to the head and neck area at true acupuncture points.
223661330|NCT04952935|PROCEDURE|Sham Acupuncture|Delivery of four acupuncture seeds (no needles involved) to the head and neck area at non-acupuncture points.
223661331|NCT02356900|PROCEDURE|Hyperoxic hyperbaric interval exercise training|Six 30-min high-intensity interval training sessions completed 3-times a week while at 1.4 ATA of oxygen in a hyperbaric chamber.
223661332|NCT02356900|PROCEDURE|Normoxic, normobaric, interval exercise training|Six 30-min high-intensity interval training sessions completed 3-times a week.
223661333|NCT02356900|DRUG|Oxygen|Used in Hyperoxic hyperbaric interval exercise training intervention
223661334|NCT03894397|DEVICE|Electrical stimulation of the BNST|Electrical stimulation of the BNST
223661335|NCT06081933|DRUG|intranasal dexmedetomidine|Patients will receive 1.5 micro g/kg intranasal dexmedetomidine diluted with saline + infusion saline
223661336|NCT06081933|DRUG|intravenous dexmedetomidine|patients will receive 0.1- 0.4 micro g/kg intravenous infusion dexmedetomidine + intranasal saline.
223661337|NCT01110642|DRUG|Lovastatin|Topical lovastatin applied to red, rashy areas two times daily for 12 months
223661338|NCT00504530|DRUG|Emfilermin, recombinant human leukemia inhibitory factor (r-hLIF)|
223661339|NCT06415500|DRUG|NK042|NK042 intraperitoneal infusion on Days 0,7 and 14.
223661340|NCT00246740|DRUG|Periostat|In addition to standard care, patients received oral administration of 20 mg of doxycycline twice a day at least 2 days prior to surgery, on the day of surgery, and on postoperative days 1, 2, and 3.
224241659|NCT00662740|DRUG|Tiotropium/Salmeterol QD|Tiotropium/Salmeterol Inhalation Powder, Hard Polyethylene Capsule
224241660|NCT00662740|DRUG|Placebo|Placebo Inhalation Powder, hard PE capsule / hard gelatine capsule
224241661|NCT00662740|DRUG|Salmeterol|Salmeterol Inhalation Powder, hard PE capsule
224241662|NCT00662740|DRUG|Tiotropium/Salmeterol QD+ Salmeterol|Tiotropium/Salmeterol Inhalation Powder, Hard Polyethylene Capsule, plus Salmeterol Inhalation Powder, hard PE capsule
224241663|NCT00662740|DRUG|Tiotropium (Spiriva®)|Tiotropium, Spiriva®
224241664|NCT05598658|PROCEDURE|Remote ischemic conditioning|Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflations of a blood pressure cuff to 200 mm Hg.
223661341|NCT00246740|DRUG|Placebo Oral Tablet|In addition to standard care, patients received oral administration of placebo twice a day at least 2 days prior to surgery, on the day of surgery, and on postoperative days 1, 2, and 3.
223661342|NCT03484793|OTHER|AESOP service system|Investigators develop an electronic reminder in CPOE system which notifies physicians when there appears to be an inappropriate prescription. At the time, a physician saves a typed prescription, our system analyzes the patient's medications, diseases and uses the knowledge base to determine whether a medication is uncommonly prescribed to all diseases in a given prescription. If the system detects the common associations of medications and diseases in a given prescription, it considers an appropriate prescription, and, if not, an actionable reminder is shown onscreen. To the right of each suggested uncommon medication is a reason why the reminder is appearing. Physicians can accept the reminder or ignore the reminder.
223661343|NCT05519722|BEHAVIORAL|Expectation-focused online intervention|Patients receive an expectation-focused online intervention (around 30 minutes) consisting of a video with general information about psychotherapy, a video with reports of patients' therapy experiences, questions on the content of the videos as well as open questions on personal strengths, fears and expectations in the context of therapy. This intervention aims to optimize patients' expectations by focusing on positive and realistic expectations regarding the psychotherapeutic process.
223661344|NCT00977119|OTHER|Side-effect questionnaires|Paper or telephone questionnaire to report specific side-effects associated with their breast cancer treatment weekly
223661345|NCT00977119|OTHER|research blood samples|Blood samples for research on DNA before starting treatment and after 4 cycles of treatment
223769506|NCT06670339|OTHER|Pre-Cooling|Participants will be immersed in cold (\~17°C) water to elicit a decrease in rectal temperature by 0.5°C from baseline values prior to completing a 60-min moderate-intensity exercise bout in the heat.
223769507|NCT06671015|DEVICE|Airvo 3|Provides effective therapy for acute hypoxemic respiratory failure and post-extubation respiratory support for 24 hours post-extubation.
223769508|NCT06998056|DRUG|ARQ-151 cream 0.05%|ARQ-151 Cream 0.05% is applied once daily for 4 weeks in infants with atopic dermatitis (eczema).
224241665|NCT05598658|PROCEDURE|Sham remote ischemic conditioning|Sham remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflations of a blood pressure cuff to 60 mm Hg.
224241666|NCT02072486|OTHER|Laboratory Biomarker Analysis|Correlative studies
224241667|NCT02072486|DRUG|Sorafenib Tosylate|Given PO
223661346|NCT04343105|PROCEDURE|pecto-intercostal plane block|under ultrasound guidance, pecto-intercostal plane block will be performed between 3rd and 4th rib 2 cm lateral to sternal border in supine position at the interfascial plane between pectoralis major muscle and intercostal muscles
223661347|NCT03632954|DEVICE|ACell Arm|Cytal® Wound Matrix and/or MicroMatrix®
223661348|NCT04027478|DIETARY_SUPPLEMENT|FMD|fasting mimicking diet
223661349|NCT02969655|DRUG|Daprodustat small|Available as 7.0 millimeter (mm) round, standard biconvex, white film coated tablets containing 1 mg, 2 mg, or 4 mg of daprodustat as active ingredient
223661350|NCT02969655|DRUG|Daprodustat small placebo|Available as 7.0 mm round, standard biconvex, white film coated tablets containing no daprodustat
224241668|NCT00615069|DEVICE|31 mm GORE EXCLUDER® AAA Endoprosthesis|GORE EXCLUDER® AAA Endoprosthesis - 31 mm device implanted for the primary treatment of infrarenal abdominal aortic aneurysms (AAA)
224241669|NCT02148484|BEHAVIORAL|Prolonged Exposure for Adolescents|
223661351|NCT02969655|DRUG|Daprodustat large|Available as 9.0 mm round, standard biconvex, white film coated tablets containing 6 mg of daprodustat as active ingredient
223661352|NCT02969655|DRUG|Daprodustat large placebo|Available as 9.0 mm round, standard biconvex, white film coated tablets containing no daprodustat
223661353|NCT02969655|DRUG|Darbepoetin alfa|Available as 0.5 mL plastic prefilled syringes (PFS) for IV injection each containing 10, 15, 20, 30, 40 or 60 mcg of darbepoetin alfa in a clear and colorless solution.
223661354|NCT02969655|DRUG|Darbepoetin alfa placebo|Available as 0.5 mL plastic PFS for IV injection containing no darbepoetin alfa in a clear and colorless solution.
223661355|NCT00236704|DRUG|topiramate|
223661356|NCT06164990|OTHER|PEKK framework|PEKK (Pekkton) framework in mandibular implant-supported complete fixed dental prostheses with All-on-four treatment concept
223661357|NCT02402660|DRUG|ALK-001|Daily, oral administration for 24 months
223661358|NCT02402660|DRUG|Placebo|Daily, oral administration for 24 months
223661359|NCT01510769|DRUG|Lesinurad|Tablets, 400 mg once daily (QD)
223661360|NCT01510769|DRUG|Lesinurad|Tablets, 200 mg QD
223661361|NCT01510769|DRUG|Placebo|Tablets, Placebo QD
223661362|NCT01510769|DRUG|Febuxostat|80 mg
223661363|NCT06803628|OTHER|Point of care ultrasound|"OCCLUS-POCUS will include patients with suspected SBO, with low or moderate Gestalt probability who meet the inclusion criteria During the patient's visit to the ED, the investigating physician will present the study and the importance of evaluating the value of POCUS in the diagnosis of exclusion of SBO. Once oral non-opposition to the study has been obtained, the participation of the patient lasts 28 days.~POCUS is performed only for patients with low or moderate Gestalt probability. It will be performed by trained emergency physicians (EP) using a curvilinear probe . After POCUS realization, the EP will:~* determine if there is presence or absence of SBO.~* collect POCUS duration, difficulty and investigator's characteristics.~* Realization of CT which will be the gold standard for SBO presence or absence.~* The study protocol procedure ends when the report of the CT is available and the physician establish its diagnosis.~* The study ends at D28 with a phone call"
223661364|NCT03815318|DRUG|Recombinant Human Coagulation FVIII|Participant received SCT800 for prophylaxis with 25 - 50 IU/kg injection once every other day or three times per week for 6 months.
223661365|NCT00964210|DRUG|Licensed quadrivalent HPV vaccine, Gardasil|The dose of the four valent (4v) HPV vaccine is 0.5ml administered by intramuscular (IM)injection. The recommended schedule is 0, 2 and 6 months.
223661366|NCT04516785|DIAGNOSTIC_TEST|FIT and VOC|Stool sample (FIT) analysed for blood in faeces and urine sample (VOC) analysed for the presence of volatile organic compounds
224241670|NCT02148484|BEHAVIORAL|Client Centered Therapy|
224241671|NCT06215352|OTHER|Chrono-nutrition factors|Dietary records would be used to assess the chrono-nutrition factors such as night eating, breakfast skipping, meal frequency, and daily fasting.
224241672|NCT00000961|DRUG|Anti-HIV Immune Serum Globulin (Human)|
224241673|NCT00000961|DRUG|Zidovudine|
224241674|NCT04056182|DRUG|Lofexidine 0.18 MG|Lofexidine prescribed as three 0.18mg tablets taken orally 4 times daily at 4-to 6-hour intervals for 2-10 days for the management of opioid withdrawal symptoms prior to receiving Vivitrol.
224241675|NCT01708824|BEHAVIORAL|Dietary|"Dietary intervention to meet the target of~1. \<5 servings of red/processed meat weekly; \<2 servings would be processed meat~2. 2 servings of refined grains daily"
224241676|NCT01708824|BEHAVIORAL|Physical activity|"Physical activity intervention with the following targets:~1. General health target - 30 minutes of moderate-to-vigorous physical activity (MVPA) 5 days per week (i.e. 10 MET-hours/week);~2. Cancer outcome target - 60 minutes of MVPA 5 days per week (i.e. 18-20 MET-hours/week)"
224241677|NCT00259012|DRUG|pantoprazole sodium enteric-coated spheroid suspension|pediatric suspension taken daily x 7 days
224241678|NCT02916290|DRUG|Fuzhenghuayu|
224241679|NCT02916290|DRUG|UDCA|
224241680|NCT06214364|DEVICE|Active Transcranial Direct Current Stimulation|"Active Anodal Transcranial Direct Current Stimulation (a-tDCS) will be applied over the Primary Motor Cortex of the affected or most affected hemisphere during 10 20 minute-sessions at 2 miliamps.~The tDCS stimulator device will be used by an experienced physical therapist by a saline-soak pair of surface electrodes. The anode electrode will be placed over C3 (EEG 10/20 system) and the cathode electrode over the contralateral supraorbital area (Fp2), in order to enhance the excitability of M1.~While the tDCS stimulation is administered, virtual reality upper limb exercises will be conducted. Virtual reality program will continue for another 20 minutes after the tDCS stimulation."
224241681|NCT06214364|DEVICE|Sham Transcranial Direct Current Stimulation|"The electrodes will be placed in the same position as for the Primary Motor Cortex stimulation, as in the experimental group. Current will be applied for 30 seconds in the beginning and at the end for securing the blinding.~While the sham tDCS stimulation is administered virtual reality upper limb exercises will be conducted. Virtual reality program will continue for another 20 minutes after the tDCS stimulation."
224241682|NCT03533270|PROCEDURE|Urethroplasty|Surgical repair of Urethral injury
224241683|NCT01612871|DRUG|Tamoxifen, Letrozole , Anastrozole, Exemestane|"Current first line metastatic hormone therapy treatment in hormone dependent breast cancer :~Tamoxifen 20 mg/day, Letrozole 2.5 mg/day, Anastrozole 1 mg/day, Exemestane 25mg/day"
223661367|NCT02230917|DRUG|Sotatercept|
223769509|NCT06991699|OTHER|Milled PEEK Stent|A CBCT will be performed to assess the anatomy of the subnasal area and plan the position, size, shape and thickness of the PEEK Stent. These data will be transferred to a 3D planning software to generate a digital model. Eventually, the PEEK stents will be milled in a milling machine and sterilized in ethylene oxide before the surgery. Local anesthesia will be administered into the vestibular mucosa along the extension of the anterior maxilla. VISTA technique begins with a vestibular access incision in the midline frenum and 2 bilateral incisions at premolar area. A periosteal elevator will be introduced through the incision and inserted between the bone and periosteum to elevate the tissue, creating a subperiosteal tunnel, extending distally based on the dynamic of the smile. The PEEK stent will be in one piece. They will be placed onto the bone and stabilized with 2 bone graft screw for each side. The midline incision and the lateral incisions will be sutured primarily.
223661368|NCT02230917|DRUG|Placebo|
223661369|NCT02185924|DRUG|Parecoxib|
223661370|NCT02185924|DRUG|CONTINUOUS FEMORAL BLOCK WITH ROPIVACAINE 0,2%|
223661371|NCT02185924|DRUG|N/S 0.9%|
223661372|NCT01898351|OTHER|Fava bean, Lupin, Beef meat, Green pea, Hemp, Buckwheat|"The intervention visit involves a test meal to be consumed by subjects attending the Human Nutrition Unit in the morning, following an overnight fast. The meal will be consumed within 15 minutes and blood (69 mL) and urine samples will be collected during 24 hours.~The test meals are designed to contain the same amount of proteins. Alternative protein meals: a number of bread buns for each meal containing individual alternative protein flours (green pea, lupin, hemp, buckwheat, fava beans). These will deliver 30 g of protein, the remainder being provided by white flour. The control (meat) meal: a lean beef steak containing 30 g of protein and a bun containing the same amount of white flour as used for the alternative protein bread buns.~The semi structured interview guide: will take place within the Human Nutrition Unit during one of the scheduled visits, once initial screening has taken place and participants have been selected. All interviews will be digitally recorded."
223661373|NCT01017913|OTHER|TENS|The TENS equipment was calibrated on 20 hertz frequency, and a pulse width of 330 ms (standing in control number seven) with two channels.
223661374|NCT01017913|OTHER|Interferential currents|The IFC was adjusted to a base frequency of 4000 Hz, with a modulation frequency range of 20 Hz, ∆F of 10 Hz and slope of 1/1, in quadripolar mode.
223661375|NCT04388462|OTHER|Finite element analysis|Biomechanical study to describe micromotion
223661376|NCT05927337|BEHAVIORAL|Cognitive Behavioral Therapy (CBT) for managing Obesity|Patients included in the intervention group will be treated with a tailored cognitive behavioural therapy programme for obesity management. The programme is designed and adapted from the Individualised Cognitive Behavioural Therapy for Obesity Management programme (Dalle Grave et al., 2018), which is divided into six content modules aimed at weight loss and weight maintenance. For the purpose of the research, an abbreviated programme will be designed and used, and the content modules will remain the same as in the original version of the programme.
223661377|NCT01656265|DRUG|ARQ 197|Daily repeating dose of oral ARQ 197, twice a day just after meals. Dose of ARQ 197 will be escalated according to 3+3 rule.
223661378|NCT01442844|DEVICE|Micrografting|Several small pieces of skin, each measuring 1.75 mm in diameter will be harvested from a normal pigmented area using a commercially available suction blister device. This will be attached to a sterile dressing that will be placed on the surgical wound.
224241684|NCT04267627|BEHAVIORAL|Comprehensive Assistance: Rural Interventions, Nursing, and Guidance (CARING)|Cancer-related distress will be assessed using the NCCN Distress Thermometer amended to include HNC-specific areas of distress. For those participants experiencing high rates of distress, the nurse will provide targeted distress education. Education for participants exhibiting successful distress self-management, or with distress that has already resolved will focus on reinforcing surveillance and health promotion information contained in the Survivorship Care Plan. When indicated, the nurse will discuss potential referrals to support services with the patient, and they will decide jointly which referrals will be beneficial. Following the visits, the nurse will make agreed upon referrals using existing cancer center pathways, documenting these in the medical record. The nurse will follow-up with the patient via telephone 6 weeks following the telemedicine visit to determine uptake of the referral, documenting all referral information in the electronic medical record.
223661379|NCT00335764|DRUG|sorafenib tosylate|given orally
223661380|NCT00335764|DRUG|erlotinib hydrochloride|given orally
223661381|NCT00335764|DRUG|tipifarnib|given orally
223661382|NCT00335764|DRUG|temsirolimus|IV administration
223661383|NCT01383148|BIOLOGICAL|TG4010|"TG4010 • TG4010 will be administered starting on Day 1 (D1) of Cycle 1 of chemotherapy and will be administered weekly for 6 weeks by subcutaneous (SC) injections and then once every 3 weeks until progression or discontinuation due to any reason.~Chemotherapy (and bevacizumab if prescribed), will be given as 21-day cycles for a minimum of 4 cycles and up to 6 cycles.~First line therapy:~* Non-squamous carcinoma: pemetrexed + cisplatin or paclitaxel + carboplatin +/- bevacizumab~* Squamous carcinoma: gemcitabine + cisplatin or paclitaxel + carboplatin~Maintenance therapy:~• Pemetrexed or erlotinib for eligible patients and according to labeling."
223661384|NCT01383148|DRUG|placebo|"Placebo will be administered starting on D1 of Cycle 1 of chemotherapy and will be administered weekly for 6 weeks by SC injections and then once every 3 weeks until progression or discontinuation due to any reason.~* First line therapy: as in Arm 1~* Maintenance therapy: as in Arm 1"
223661385|NCT02269540|DRUG|Sertraline|selective serotonin reuptake inhibitor
223769510|NCT03265119|DRUG|AEVI-001|Oral doses of 100 mg, 200 mg or 400 mg of AEVI-001 will be administered twice daily during the treatment period.
224241685|NCT05532527|DRUG|Microwave ablation combined with Camrelizumab and chemotherapy|Microwave ablation combined with Camrelizumab and chemotherapy
224241686|NCT02167165|DRUG|Digoxin Injection|Patients consulting the ED for Acute onset AF received 0.5 mg digoxin by oral root
223661386|NCT02269540|DRUG|Citalopram|selective serotonin reuptake inhibitor
223661387|NCT02269540|DRUG|N-acetylcysteine (NAC)|natural health product
223769511|NCT03265119|DRUG|Placebo|Oral doses of 100 mg, 200 mg or 400 mg of Placebo will be administered twice daily during the treatment period.
224241687|NCT03148886|OTHER|PA intervention|"The program is individualized according to age, fitness level, place of residence, access to adapted specific training group or associations, PA preferences and wishes of each participant. Patients are informed of the recommendations in terms of PA, and the target of 150min per week in order to maintain health benefits. Patients are asked to walk at least 30 minutes per day and increase their activities into daily routine. Several individual strategies are established with the patients to attain their objectives and increase their daily life PA.~Withings® PA trackers have been used to provide an incentive effect to increase PA, to measure the number of steps per day and make people think about their PA. Patients wore a Withings Go® wristband PA tracker throughout the whole study and had in real time a feedback on their number of steps per day.~A 7 mL blood sample is collected at baseline (D1) and at the end of the 6-month study (M6) for the biological study."
224241688|NCT05807932|DRUG|Venetoclax|Study treatment consists of the conditioning therapy including 6 or 8 days of Venetoclax treatment.
224241689|NCT05807932|DRUG|Amsacrine|Amsacrine is part of the conditioning therapy and is administered on day -10 to -7 before allogeneic blood stem cell transplantation
224241690|NCT05807932|DRUG|Ara-C|Ara-C is part of the conditioning therapy and is administered on day -10 to -7 before allogeneic blood stem cell transplantation
223661388|NCT02269540|DRUG|Existing depression medication treatment|Continuation of depression medication treatment already taken prior to study enrollment except for drugs with affinity for MAO-A or potentially influencing MAO-A levels, including phenelzine, tranylcypromine, moclobemide, cytomel and lithium
223661389|NCT02466659|DEVICE|CIAO therapy Amblyz glasses|3-hour CIAO Therapy Amblyz glasses
223661390|NCT02212184|OTHER|Manual Diaphragm Release Technique|The therapist performs manual contact (pisiform, ulnar edge and the last three fingers) with the underside of the costal cartilage of the 7th, 8th, 9th and 10th rib, and guiding forearms toward the shoulders of the corresponding side. During inspiration, pulls the points of contact with both hands, in the direction of the head, accompanying the elevation movement of the ribs. During exhalation, deepens contact toward the inner costal, maintaining resistance. 2 sets x 10 breaths (1 min interval). Treatment will last two weeks (6 sessions) All patients will undertake four evaluations throughout treatment: Baseline Day 1 and post Day 1; Baseline Day 6 and post Day 6.
223661391|NCT02212184|OTHER|Manual Diaphragm release technique (sham)|Manual Diaphragm release technique (sham) In attempt to execute the sham protocol the therapist performs manual contact (pisiform, ulnar edge and the last three fingers) with the underside of the costal cartilage of the 7th, 8th, 9th and 10th rib. The therapist will hold only light touch in the landmarks, without exerting pressure or traction. The maneuver will be performed in two sets of ten deep breaths, with an one minute interval between them.
223661392|NCT01980485|BEHAVIORAL|Lung Age feedback and exhaled carbon monoxide|"In the intervention group, if the lung age is equal to or less than the individual's chronological age, he or she will be briefly informed that the test result was normal and that it is important to avoid potential future lung problems by stopping smoking. For those in the intervention group with a normal FEV-1, the intervention will focus on their exhaled carbon-monoxide.~If their lung age is greater than their chronological age, they will be given their lung age in years, and provided with a graph describing the possible decline in lung age if they continued to smoke and a full explanation.~Those in the Intervention Group will have their exhaled carbon-monoxide (CO) result explained in more detail. Non-smokers typically have an exhaled carbon-monoxide level of 0-4 parts per million, whereas smokers typically have a CO level of 8-50 ppm. CO levels return to normal within a few days of stopping smoking. Participants are provided with a full explanation."
223661393|NCT01980485|BEHAVIORAL|No Lung Age Feedback|Those allocated to the control group will simply be informed of their scores on the spirometry.
223661394|NCT05413174|BEHAVIORAL|Hypnoanalgésia|"Use of Ericksonienne hypnosis in the medical field, aiming to dissociate the patient from the intervention in order to modify his or her perception of pain and limit anxiety.~Ericksonienne hypnosis will use during ultrasound-guided biopsy in radiology ward."
223661395|NCT04541771|DRUG|Lactobacillus Reuteri DSM 17938|The trial group will receive their usual feeds plus daily probiotic addition 1 drop/kg/dose twice daily added in expressed breast milk/formula milk from the beginning of enteral feedings till the baby attain full feeds
223661396|NCT04541771|DRUG|Placebo|expressed breast milk/formula milk plus normal saline drop from the beginning of enteral feedings till the baby attain full feeds
223661397|NCT01536392|DRUG|Granisetron|34.3 mg of granisetron formulated in a transdermal patch replaced every 7 days. At cycle 1, participants receive granisetron by vein prior to IV cisplatin and prior to administration of transdermal patch.
223661398|NCT01536392|DRUG|Ondansetron|8 mg of ondansetron by mouth three times a day starting with cisplatin administration and continued for 72 hours after chemotherapy infusion.
223661399|NCT01536392|BEHAVIORAL|Questionnaires|Completion of 3 questionnaires at study visits taking about 5 minutes each time.
223661400|NCT01536392|BEHAVIORAL|Study Drug Diary|Study drug diary to record times that study drugs taken, and to record any nausea or vomiting experienced.
223661401|NCT00375206|BIOLOGICAL|Trivalent DNA Vaccine (PIA0601) with or without DEI-LT (pPJV2012)|
223661402|NCT03195309|DRUG|Ropivacaine|Compare different concentration of ropivacaine and fentanyl for elective Cesarean delivery post operative pain control.
224241691|NCT05807932|DRUG|Tacrolimus|Tacrolimus is used for prophylaxis of acute and chronic graft-versus-host-disease according to institutional standards.
224241692|NCT05807932|DRUG|Mycophenolate Mofetil|Mycophenolate Mofetil is used for prophylaxis of acute and chronic graft-versus-host-disease according to institutional standards.
224241693|NCT01245907|BEHAVIORAL|Applied relaxation|Applied relaxation given by Internet during 10 weeks as a number of text-documents, audio-files and e-mail mediated support from therapists
224241694|NCT04901377|COMBINATION_PRODUCT|Estradiol valerate/ Dienogest|Combined hormonal contraceptive (combined oral contraceptives, COCs)
224241695|NCT06234189|DEVICE|Defocus Incorporated Multiple Segment Spectacle Lenses (DIMS)|30 minutes without DIMS and 30 minutes with DIMS
224241696|NCT06577779|DRUG|Methylphenidate Hydrochloride Extended Release Capsule|Subjects will start at dose of 40mg (DR/ER-MPH) day with titrations of 20mg leading to a maximum dose of 100mg (DR/ER-MPH).
224241697|NCT00716495|BIOLOGICAL|AGI-101H Vaccine|Each patient will receive one dose of AGI - 101H containing 5 x 107 viable cells, administered s.c. for up to 26 weeks.
223661403|NCT03195309|DRUG|Fentanyl|Compare different concentration of ropivacaine and fentanyl for elective Cesarean delivery post operative pain control.
223661404|NCT02747472|DRUG|GIP-A|GIP receptor antagonist
223661405|NCT02747472|DRUG|GIP(1-42)|GIP receptor agonist
223661406|NCT02747472|OTHER|Saline|Placebo
223661407|NCT04039009|DIAGNOSTIC_TEST|Pelvic Organ Prolapse Quantification system|The Pelvic Organ Prolapse Quantification system assessment tool measures nine anatomical points and distances in the vagina. The hymen is the reference point to which the other points are compared. The prolapsed organs are measured in centimeters to the hymen with an examination ruler.
223661408|NCT04636983|DRUG|BV100|Rifabutin IV
223661409|NCT04636983|DRUG|Placebo|Saline
223661410|NCT03929094|DRUG|Paclitaxel for Injection（Albumin Bound）|Patients firstly receive nab-paclitaxel 100 mg/m\^2 (iv, 30 minutes) on days 1, 8, and 15 for 3 weeks, followed by one week without treatment. Treatment repeats every 4 weeks until the disease recurrence or unacceptable toxicity，death or begin a novel therapeutic.
223661411|NCT03929094|DRUG|Gemcitabine|Patients secondly receive gemcitabine 1000 mg/m\^2 (iv, 30 minutes) on days 1, 8, and 15 for 3 weeks, followed by one week without treatment. Treatment repeats every 4 weeks until the disease recurrence or unacceptable toxicity，death or begin a novel therapeutic.
223661412|NCT00747357|DEVICE|Drug Eluting Balloon SeQuent Please|Drug Eluting Balloon is followed by Bare Metal Stent
223661413|NCT00747357|DEVICE|Drug Eluting Balloon SeQuent Please|Bare Metal Stent followed by Drug Eluting Balloon
223661414|NCT04942977|DEVICE|telemonitoring|"The system consists of the following elements:~1. Professional website at the hospital, which allows:~   * To set up an individualised care plan~  * To establish the patient's risk profile and targets for improvement.~  * Long-term monitoring of the evolution of cardiovascular risk factors and events that occurred~  * Advise the patient on self-management strategies.~2. Mobile application software with the following functions:~   * Scheduled exercise sessions~  * Medication reminder~  * Measurement reminder (weight, blood pressure, heart rate, waist circumference, etc.)~  * Messages: Inbox folder for system messages and messages generated by professionals for a specific patient or video conference.~  * Training monitor: guides the patient in the performance of their exercise.~  * Access to certified health information for patients"
223661415|NCT04942977|OTHER|Centre-based cardiac rehabilitation|The physical activity consisted of a workout routine and aerobic cycling training. Patients are instructed to perform 150 minutes per week of moderate physical activity when the hospital phase finishes.
223661416|NCT02750020|OTHER|Questionnaire|Current study is a retrospective telephone survey based on questionnaires. It aims to investigate the level of public support on current and future tobacco control measures and taxation policies and to address the timely impacts of smoke-free policies, substantiate public support on further tobacco control measures and assist COSH in shaping policy direction for government. The telephone survey will be conducted by a telephone survey agent under the monitor of applicants.
223661417|NCT06156709|PROCEDURE|Group I: Lower Volume with Higher Anaesthetic Concentration|10 ml of a solution containing 0,1% of bupivacaine and 2 mcg/ml fentanyl through the epidural cathether, maintained by programmed intermittant epidural (PIE) boluses of 7,5 ml of the same solution once in every hour, starting 1 hour after the loading dose. patient controlled epidural analgesia (PCEA) will be programmed so that 8 ml of the same solution with a lock-time of 10 ml may be administered
224241698|NCT03143400|DRUG|Lactobacillus salivarius BL 3123|Two classic forms will be tested (powder and pill). An innovative galenic form (pill with retarded release), developed to enhance intestinal viability and probiotic efficacy, will also be tested.
224241699|NCT01173770|DRUG|ADC3680B|Escalating single doses ADC3680B or Placebo over 5 study periods
224241700|NCT01173770|DRUG|ADC3680B|ADC3680B or Placebo for 7 days
224241701|NCT01173770|DRUG|ADC3680B|Single doses ADC3680B over 2 study periods under fasted and fed conditions
224241702|NCT03009448|OTHER|Interview|Each subject will be interviewed using a semi constructed interview.
224241703|NCT02461771|DRUG|Pegcetacoplan|On treatment day, subjects will be administered a single 100 μL IVT injection of pegcetacoplan at the dose corresponding to their treatment assignment.
224241704|NCT04963309|OTHER|endotracheal tube extubation in the operating room|endotracheal tube extubation in the operating room
224241705|NCT05777707|DRUG|PD-1 blockade|PD-1 blockade (Sintilimab/Camrelizumab/Toripalimab/Tislelizumab), 200 mg, IV., every 3 weeks, 2-3 cycles.
224241706|NCT05777707|DRUG|Albumin paclitaxel|Albumin paclitaxel, 300 mg/m2, IV., every 3 weeks, 2-3 cycles.
224241707|NCT05777707|DRUG|Carboplatin/Nedaplatin|Carboplatin/Nedaplatin, area under the curve = 5, IV., every 3 weeks, 2-3 cycles.
223661418|NCT06156709|PROCEDURE|Group II: Higher Volume with LowerAnaesthetic Concentration|20 ml of a solution containing 0,0625% of bupivacaine and 2 mcg/ml fentanyl through the epidural cathether, maintained by programmed intermittant epidural boluses of 15 ml of the same solution once in every hour, starting 1 hour after the loading dose. patient controlled epidural analgesia (PCEA) will be programmed so that 8 ml of the same solution with a lock-time of 10 ml may be administered
224241708|NCT04191980|OTHER|Comparison of prostate multi-zone segmentation obtained with an automatic deep learning-based algorithm and two expert radiologists|"The algorithm is used to perform a multizone segmentation of the prostate including delineation of : the whole prostate contours, the transition zone contours, the anterior fibromuscular stroma.~The contours is independently corrected by 2 radiologists. The corrected contours of the different zones will be stored and for each zone 6 different metrics will be used to evaluate the difference between the initial and corrected contours:~* Mean Mesh Distance: Average Boundary Distance (ABD) for each point of the reference segmentation. The distance to the closest point of the compared segmentation is first computed. Then the average of all these distances is computed and gives the ABD~* General Hausdorff distance (HD)~* 95% percentile (P) of the HD and the 95th (P) of the asymmetric HD distribution~* 95% HD modified (HD95\_1): different approach by first computing the 95th (P) of the asymmetric HD then taking the maximum~* Dice coefficient~* Difference in volumes"
224241709|NCT00383890|DRUG|Dexmedetomidine HCL Injection|
224241710|NCT00383890|DRUG|Placebo|
224241711|NCT00154414|DRUG|liraglutide|
224241712|NCT03436680|OTHER|Best Practice|Receive standard of care
224241713|NCT03436680|BEHAVIORAL|Neurofeedback|Complete neurofeedback training sessions
224241714|NCT03436680|OTHER|Quality-of-Life Assessment|Ancillary studies
224241715|NCT03436680|OTHER|Questionnaire Administration|Ancillary studies
223661419|NCT02685982|DEVICE|Rhythmic Sensory Stimulation|"The stimulation consists of 30 minutes of daily stimulation with specially composed relaxing music tracks embedded with gamma frequency sounds of 30-70 Hz range.~In this study, the stimuli will be delivered with a portable sound device called Sound Oasis Vibroacoustic Therapy System (VTS-1000) unit, which is a low-voltage consumer product that has two built in mid to high frequency speakers and one built in low frequency (subwoofer-type) speaker. The low frequency sounds played by the subwoofer speaker is experienced as vibrotactile vibration. Although the Intervention of Interest in this study is the Rhythmic Sensory Stimulation with low-frequency sounds, the efficacy of the Sound Oasis VTS-1000 device to deliver the intervention will also be subject to observation."
223661420|NCT00934440|DRUG|Bevacizumab|"* First treatment: 10 milligram per kilograms (MG/KG) intravenously (IV) on Day 1every two weeks over 90 minutes.~* Second treatment: 10 MG/KG IV on Day 1 every two weeks over 60 minutes.~* Third and subsequent treatments: 10 MG/KG IV on Day 1 every two weeks over 30 minutes (minimum of two cycles)."
223661421|NCT00934440|DRUG|Azacitidine|"* Dose level 1: 35 mg/m2/day for 7 days.~* Dose level 2: 55 mg/m2/day for 7 days.~* Dose level 3: 75 mg/m2/day for 7 days.~  * mg/m2/day = dose based on height and weight"
223661422|NCT02141737|DRUG|Lidocaine Hydrochloride Injection|Lidocaine injection should be give before the injection of etomidate. In groups L1 and L2, 20 mg and 30 mg lidocaine injection will be diluted to 2ml separately.
223661423|NCT02141737|DRUG|Etomidate Fat Emulsion Injection|1 minute after the injection of lidocaine, 0.3 mg/kg etomidate will be given in 30 to 60 s.
223661424|NCT02141737|DRUG|normal saline|2 ml normal saline will be given 1 minute before the injection of etomidate in patients in group C, and in group L1 and L2, normal saline is used to dilute lidocaine injection to 2 ml.
224241716|NCT01891409|DEVICE|Male circumcision using the Shang Ring device|
224241717|NCT02980978|BEHAVIORAL|Coaching|Focus on nutrition, activity and appropriate medication use and adherence
223661425|NCT02141737|DRUG|Midazolam Injection|0.02 mg/kg midazolam will be given to the patients in all groups 90 s after the injection of etomidate.
223661426|NCT02141737|DRUG|Fentanyl Citrate Injection|3 μg/kg fentanyl will be given to patients in all groups after the injection of midazolam.
223661427|NCT02141737|DRUG|Rocuronium Injection|0.6 mg/kg rocuronium will be given to patients in all groups after the injection of fentanyl.
223661428|NCT00037089|DRUG|UFT (Tegafur/Uracil)|
223661429|NCT01494623|DEVICE|repetitive Transcranial Magnetic Stimulation|Magnetic pulses to specified brain regions.
223661430|NCT03307655|OTHER|Control (fertile semen donors)|"The sperm will be capacitated in the presence and absence of follicular fluid (FF). In a first set of experiments, the FF will be supplemented with L-Arginine and the NOS inhibitor L-NAME. In another set of experiments the same supplementations to the capacitation medium will be examined, but without using FF.~Changes in NOS expression, protein nitrosylation, PKA activity, tyrosine phosphorylation and tyrosine nitration in sperm will be determined."
224241718|NCT01968265|DRUG|ISIS-GCCRRx|3 doses on alternate days during the first week and then once weekly for 5 weeks + daily metformin
223661431|NCT03307655|OTHER|Patients (subfertile men)|"The sperm will be capacitated in the presence and absence of follicular fluid (FF). In a first set of experiments, the FF will be supplemented with L-Arginine and the NOS inhibitor L-NAME. In another set of experiments the same supplementations to the capacitation medium will be examined, but without using FF.~Changes in NOS expression, protein nitrosylation, PKA activity, tyrosine phosphorylation and tyrosine nitration in sperm will be determined."
223661432|NCT02200640|DRUG|High dose of Micardis®, once daily|
223661433|NCT02200640|DRUG|Low dose of Micardis®, once daily|
224241719|NCT01968265|DRUG|Placebo|3 doses on alternate days during the first week and then once weekly for 5 weeks + daily metformin
224241720|NCT02222766|BEHAVIORAL|Parents and Tots Together Program|Group-based parenting program, 9 sessions offered weekly
223661434|NCT02200640|DRUG|Low dose of COZAAR®, once daily|
224241721|NCT02222766|BEHAVIORAL|Control|Minimal attention control- 9 weekly mailed information on general child development
224241722|NCT01941030|DEVICE|Orbital Atherectomy System|Orbital atherectomy (OA) is performed prior to adjunctive balloon angioplasty (BA)
224241723|NCT01941030|DEVICE|Balloon Angioplasty|Type of balloon selected is driven by preference of the operator.
224241724|NCT04047095|DIETARY_SUPPLEMENT|Immunonutrients + normal daily meal|"Glutamine Plus by Fresenius Kabi (one sachet composition: glutamine 10 g, carbohydrate 10 g, β-carotene 1.7 mg, vitamin E 83 mg, vitamin C 250 mg, zinc 3.4 mg, selenium 50 μg, and fibre 1.2 g)."
224241725|NCT04047095|DIETARY_SUPPLEMENT|Normal daily meal|Normal daily meal (75-80 g protein)
224241726|NCT02178826|DEVICE|Rapid Maxillary Expansion|The Rapid Maxillary Expander will over 10-14 days create a palatal expansion of about 5mm.
224241727|NCT02178826|DEVICE|Placebo Appliance|The Placebo Appliance looks exactly like the Rapid maxillary Expander but the expansion screw does not work. When the expansion screw is activated it does not create a palatal expansion.
224241728|NCT00281125|DRUG|PTK787 and Pemetrexed with or without Cisplatin|
223661435|NCT02200640|DRUG|High dose of COZAAR®, once daily|
223661436|NCT02200640|DRUG|Placebo|
223661437|NCT04904224|DEVICE|Panintestinal video capsule endoscopy|Performing a video capsule endoscopy using the Pill Cam Crohn's capsule from Medtronic
223661438|NCT04904224|DEVICE|Colonoscopy|Performing a standard colonoscopy using the colonoscope available in the study center
223661439|NCT06516926|DRUG|SHR-4602|Intravenous infusion, cycle every 21 days;
223661440|NCT03419585|DEVICE|Intervention systematic light exposure|30 minutes of intervention systematic light exposure daily
223661441|NCT03419585|DEVICE|Comparison systematic light exposure|30 minutes of comparison systematic light exposure daily
224241729|NCT00486109|DEVICE|I-Port(TM) Injection Port|
224241730|NCT01835678|DRUG|Linagliptin|orally 5 mg/d for 4 weeks
224241731|NCT01835678|DRUG|Placebo|orally once a day for 4 weeks
224241732|NCT01345149|BEHAVIORAL|Diet + Exercise|"Diet: Intensive counselling about calorie restriction to reduce weight gain by dietician.~Exercise: Individual counselling"
224241733|NCT01819623|OTHER|Non-pharmacological therapy|It consists of a weekly two-hour session. During the first hour yoga classes will taught by teacher, during second hour supervised cognitive training by a psychologist based on Memory Program designed by Memory Unit of Madrid
224241734|NCT03635125|DRUG|Nebivolol I|Low dose treatment phase: Nebivolol 10 mg or Metoprolol 50 mg High dose treatment phase: Nebivolol 20 mg or Metoprolol 100mg
223661442|NCT05360862|PROCEDURE|Prone positioning session|To perform respiratory measurements before, during and after a prone positioning session.
223661443|NCT00178113|DRUG|- Lyc-O-Mato (dietary supplement, 30 mg lycopene/day)|
223661444|NCT00178113|DRUG|- Certagen (multivitamins with minerals)|
223661445|NCT03617224|RADIATION|TSEBT|"The regimen includes a rule-based 3+3 design for escalating regimen intensity of combined TSEBT and pembrolizumab."
223661446|NCT03617224|DRUG|TSEBT and pembrolizumab|Dose regimens are sequential therapy of TSEBT with Pembrolizumab.
223661447|NCT01155128|BEHAVIORAL|exercise aerobic|The intervention will consist of physical exercise sessions for approximately 60 minutes and two weekly sessions. The classes will consist of an initial part to exercises heating joint flexibility and lasting 10 minutes, a major part consists of aerobic exercise, lasting 20-30 minutes, and a piece of muscular endurance with exercises upper and lower limbs and abdomen, lasting 10-20 minutes. The intensity will be controlled through the Subjective Perception Scale Borg
223661448|NCT03060551|PROCEDURE|SVF injection|SVF is increasingly recognised as an easily accessible source of regenerative cells with therapeutic potential in ischaemic or autoimmune disease. We aimed to measure for the first time the safety, tolerability and potential efficacy of autologous SVF cells local injections in patients with systemic sclerosis
223661449|NCT04735484|DEVICE|Gait analysis|Collecting movement data whilst participants walk
223661450|NCT00250146|BEHAVIORAL|Gluten (behaviour)|
223661451|NCT02125591|DEVICE|Active CN-NINM PoNS|Delivery of active stimulation of the tongue during in-person therapy sessions (1 hour) and during two home sessions (40 minutes) daily on 6 of 7 days per week (120 total sessions). Stimulation sessions will be separated by at least 4 hours.
223661452|NCT02125591|DEVICE|Sham CN-NINM PoNS|Delivery of sham stimulation of the tongue during in-person therapy sessions (1 hour) and during two home sessions (40 minutes) daily on 6 of 7 days per week (120 total sessions). Stimulation sessions will be separated by at least 4 hours.
223661453|NCT03382340|DRUG|Imx-110|a nanoparticle encapsulating a Stat3/NF-kB/poly-tyrosine kinase inhibitor and low-dose doxorubicin
223661454|NCT00003280|BIOLOGICAL|rituximab|
223661455|NCT04999449|DRUG|Scopolamine|Intranasal scopolamine at 0.2 mg or 0.4 mg
223661456|NCT04999449|DRUG|Placebo|Intranasal saline placebo
223661457|NCT06230523|DRUG|LY3841136|Administered SC.
224241735|NCT03635125|DRUG|Nebivolol II|Low dose treatment phase: Nebivolol 10 mg or Metoprolol 50 mg High dose treatment phase: Nebivolol 20mg or Metoprolol 100mg
224241736|NCT03635125|OTHER|Baseline Washout Phase|2 to 4 week Baseline Washout Phase
224241737|NCT02625454|DRUG|Intravenous Acetaminophen|1000 mg Acetaminophen q 6 hours, given intravenously
224241738|NCT02625454|DRUG|Oral Acetaminophen|1000 mg Acetaminophen q 6 hours given orally
224241739|NCT00582088|BIOLOGICAL|VEE C-84|Subjects will receive a 0.5 mL subcutaneous injection in the upper outer aspect of arm; maximum of four boosters in 1 year if titer \<1:20.
224241740|NCT05048992|OTHER|ELDOA method|group A will receive
224241741|NCT05048992|OTHER|Post-facilitation stretching|Group B will receive
224241742|NCT05654779|BIOLOGICAL|LCAR-AMDR Cells Product|Subjects will receive a conditioning regimen before treatment with LCAR-AMDR cells
224241743|NCT00018252|BEHAVIORAL|exercise|
224241744|NCT01301573|BIOLOGICAL|rAAV-GAD|
224241745|NCT06093425|DRUG|TST001, CapOx or mFOLFOX6 and NIVO or (Substudy) TST001, Oxaliplatin and capecitabine or 5-fluorouracil (5-FU)|All medications administered intravenously
224241746|NCT06093425|DRUG|Placebo CapOx or mFOLFOX6 and NIVO or (Substudy) Placebo, Oxaliplatin and capecitabine or 5-fluorouracil (5-FU)|All medications administered intravenously
224241747|NCT02173236|OTHER|platform-switched implants|
224241748|NCT02173236|OTHER|platform-matched implant|
224241749|NCT00473356|DIETARY_SUPPLEMENT|receive amino acid supplement|Receive amino acid supplement
224241750|NCT05877170|DIETARY_SUPPLEMENT|Palmitoyletinolamide|Taking a once-daily supplement containing PEA in an oral formulation (tablets), to be taken away from meals
224241751|NCT05877170|DRUG|Placebo|Taking a placebo in an oral formulation (tablets), to be taken away from meals
224241752|NCT00534703|GENETIC|AAV1/SERCA2a|AAV1/SERCA2a will be delivered by a percutaneous method in the catheter laboratory. Dose: 1x 10\^13 DRP (DNase resistant particles)
224241753|NCT00534703|DRUG|Placebo|Placebo aliquots will be of the same composition as the investigational medicinal product with the absence of the active ingredient and will be visually indistinguishable from the medicinal product. Placebo is prepared and handled exactly as above in a blinded fashion.
224241754|NCT00582400|DRUG|arsenic trioxide|"Trisenox will be diluted with 100 to 250 mL 0.9% Sodium Chloride injection, USP, using proper aseptic technique, immediately after withdrawal from the ampule. The Trisenox ampule is single-use and does not contain any preservatives. Unused portions of each ampule should be discarded properly. Trisenox is not to be mixed with other medications.~The loading dose of Trisenox will be administered intravenously over 2 hours. The infusion duration may be extended up to 4 hours if acute vasomotor reactions are observed. The drug will be administered IV through a functional peripheral or central venous line. Trisenox is not a vesicant, and may be a mild irritant if administered into the skin without dilution."
224241755|NCT01245322|DRUG|lactobacilli|women were given a seven days course of daily 2% vaginal clindamycin cream (Dalacin vaginal cream 2%, Pfizer Norway Ltd) together with oral clindamycin 300 mg BID for 7 days (Dalacin 300 mg, Pfizer Norway Ltd). Oral clindamycin treatment was also given to the patient's sexual partner.
224241756|NCT05077566|OTHER|Exercise at 60% vo2|15 minutes of exercise at 60% VO2 max.
224241757|NCT05077566|OTHER|Exercise at 90% vo2|15 minutes of exercise at 90% VO2 max.
223661458|NCT06230523|DRUG|Placebo|Administered SC.
223661459|NCT06445166|DRUG|Propranolol Hydrochloride|"Dosing is as follows:~* Patients who weigh 40 to 59.9 kg:~  * 40 mg BID (target)~ * 20 mg BID (half the target)~* Patients who weigh ≥ 60 kg:~  * 60 mg BID (target)~ * 30 mg BID (half the target)"
223661460|NCT04553133|DRUG|PF-07104091 monotherapy dose escalation|PF-07104091 will be administered orally
223661461|NCT04553133|DRUG|PF-07104091 + palbociclib + fulvestrant|PF-07104091 will be administered orally in combination with palbociclib and fulvestrant
223661462|NCT04553133|DRUG|PF-07104091 + palbociclib + letrozole|PF-07104091 will be administered orally in combination with palbociclib and letrozole
223661463|NCT04553133|DRUG|PF-07104091 monotherapy dose expansion (ovarian)|PF-07104091 will be administered orally
223661464|NCT04553133|DRUG|PF-07104091 monotherapy dose expansion (SCLC)|PF-07104091 will be administered orally
223661465|NCT04553133|DRUG|PF-07104091 + Fulvestrant (post CDK4/6)|PF-07104091 will be administered orally in combination with fulvestrant
223661466|NCT04553133|DRUG|PF-0704091 + Fulvestrant (post CDK4/6)|PF-07104091 + fulvestrant (post 4/6) dose expansion
223661467|NCT03391739|BIOLOGICAL|CART-19 cells|CART-19 cells treat
223661468|NCT05612139|DEVICE|JTIN implantation surgery|The JTIN is a self-extending intramedullary nail (telescopic rod) designed to provide fixation of femoral and/or tibial fractures, osteotomies, malunions and non-unions. The design of the JTIN includes a female and a male component, which are anchored to the proximal cortex and distal epiphysis through screw-type fixation. These two components slide from each other, allowing for extension of the JTIN as the bone structures remodel and patient growth occurs.
223661469|NCT04066907|OTHER|Integrated Disease Management|Multidisciplinary intervention comprising of patient education, self management strategies and medication optimization
224241758|NCT06063005|PROCEDURE|Translocation ILM Flap|After vitrectomy, the ILM was dissected from the macula to the vascular arch, and the retina in the fissure area was fully released to make an MH-centered, approximately 2DD-square, ILM flap with a tip (approximately 500μm wide) above; the ILM flap was transposed approximately 25-30 degrees along the tip to the inferior temporal area with the assistance of heavy water, and a total of 1ml of perfluorodecalin fluid (heavy water) was injected to cover the MH area with the ILM flap, and the original ILM defect area corresponding to the MH was transposed to the outside of the MH. The heavy water is replaced by liquid/gas exchange. Ophthalmic 13% perfluoropropane gas (AL.CHI.MI.A. Srl) was chosen as the postoperative intraocular filling.
224241759|NCT06063005|PROCEDURE|ILM Peeling|After vitrectomy, internal limiting membrane peeling up to the vascular arcade, thorough loosening of the macular hole area of the retina, and fluid/gas exchange. An eye-specific 13% perfluoropropane gas (AL.CHI.MI.A. Srl) was chosen for intraocular tamponade after the operation.
224241760|NCT05627141|OTHER|Photobiomodulation; Cryotherapy, Massage|"Photobiomodulation: the 20 participants will receive active photobiomodulation or sham immediately after the muscle damage and fatigue induction protocol in a randomized and crossover manner, with an interval of 15 days between each evaluation session. Cryotherapy combined with compression: the 20 participants will receive effective cryotherapy (10-12°C for 20 min) combined with high compression, or sham (25°C for 20 min) combined with light compression, on the lower limbs, immediately after the protocol. induction of muscle damage and fatigue. Effective cryotherapy or sham will be applied in a randomized and crossover manner, with an interval of 15 days between each evaluation session.~Massage: the 20 participants will receive the effective massage or sham immediately after the muscle damage and fatigue induction protocol in a randomized and crossover manner, with an interval of 15 days between each evaluation session."
224241761|NCT05436756|OTHER|Biological sampling and collection|"* Biological sampling and collection:~  * whole blood: 1 dry tube for IgG and IgM anti-leptospirosis serology (volume depending on the patient's weight)~ * urine: 1 bottle of 30ml~* Freezing of serum after centrifugation~* Storage~* Collection of clinico-biological data on a dedicated eCRF"
224241762|NCT02161848|OTHER|Magnetic Resonance Imaging|MRI of eye muscles, lower bag muscles, thigh muscles and calf muscles.
224241763|NCT04438057|BIOLOGICAL|CCP|Randomized open label study to receive 2:1 CCP to standard of care
224241764|NCT03257085|OTHER|Low-carbohydrate, high-fat|Participants following low-carbohydrate, high-fat diet for 8 weeks.
224241765|NCT03257085|OTHER|High-carbohydrate, moderate-fat|Participants following high-carbohydrate, moderate-fat diet (UK dietary guidelines) for 8 weeks.
224241766|NCT01479439|DRUG|Losartan|Form: suspension, tablet. Dosage \& frequency: age 6-16 = 0.7mg/kg once daily; age \>16 = 50mg once daily. Duration: 6 months
224241767|NCT00193622|DRUG|Bevacizumab|
224241768|NCT00193622|DRUG|Erlotinib|
224241769|NCT01936948|PROCEDURE|Clip closure|Patients will be randomized to either closing the mucosal defect after polyp removal or not closing the mucosal defect using clips (main intervention and comparison). The resection margins will be approximated using clips. Complete closure is defined as approximated margins with less than 1cm gap between clips. All patients will further be randomized to two different settings of electrocautery (EndoCut or Coagulation) to standardize otherwise variable electrocautery practice, and for explorative analysis.
224241770|NCT02365207|DRUG|BCG strain of Mycobacterium bovis|Invasive bladder cancer treated with 3-6 weeks of intravesical BCG
224241771|NCT01924078|DRUG|Capecitabine|metronomic use: capecitabine 500mg/tid
224241772|NCT01924078|DRUG|aromatase Inhibitors (AIs)|Anastrozole 1mg/day p.o,Exemestane 25mg/day,Letrozole 2.5mg/day p.o.
224241773|NCT05352360|DIAGNOSTIC_TEST|Pilates Exercises|Exercises with Kinesio Taping
224241774|NCT05352360|DIAGNOSTIC_TEST|Muscle Energy Technique|Exercises with Kinesio Taping
224241775|NCT05823090|DEVICE|light box (Carex DayLight Classic Model)|The active light box is a white fluorescent 4000 Kelvin unit that emits 10,000 lux and measures 33cm x 40cm. The placebo box emits 50 lux dim red light and appears identical to the active unit. Subjects were instructed to position themselves 30-36 cm from the box with their faces fully exposed to the light. The actigraphy device is a Phillips Spectrum Plus Actigraphy watch which collects activity level and sleep information along with multiple light measurements and wearer adherence.
224241776|NCT01340430|DRUG|Trastuzumab|neoadjuvant FEC (fluorouracil, epirubicin, cyclophosphamide) followed by weekly paclitaxel and concomitant trastuzumab
224241777|NCT02721264|BIOLOGICAL|Fecal Microbiota Transplant|
224241778|NCT02721264|OTHER|Standard Medical Treatment|
224241779|NCT04835246|DEVICE|Spectra IMDx system|The Spectra IMDx system is intended to be used in conjunction with conventional white light endoscopy in upper gastrointestinal endoscopic procedure to identify patients with high risk of developing and/or having gastric cancer and it is intended for use on patients above and equal to the age of 18.
224241780|NCT04908332|BEHAVIORAL|Kangaroo Baby Massage|The Kangaroo Baby Massage is an intervention that arose from nursing practice in 1996. It is a therapy that does not require an incubator, fuses massage, kangaroo position and music. KBM is available on video
223769512|NCT07017816|DRUG|SGT-53|SGT-53 is a novel cationic liposome encapsulating a normal human wild type TP53 cDNA sequence in a plasmid backbone. The liposome is decorated on its surface with an anti- transferrin receptor (TfR) single chain antibody fragment (scFv) that is designed to target cancer cells through the binding of the TfRscFv to the transferrin receptor. This complex has been shown to efficiently and specifically deliver the TP53 complementary DNA (cDNA) to the tumor cells via receptor-mediated endocytosis of the cationic liposomal complex. Introduction of the TP53 cDNA sequence restores wild-type p53 (wtp53) function in the apoptotic pathway.
223769513|NCT07017816|RADIATION|hypofractionated radiotherapy with immunotherapy|Re-irradiation has rapidly grown into a primary consideration in the context of recurrent pediatric CNS malignancies. While not thought to be curative by itself, it has often resulted in temporary symptomatic improvement as well as occasional radiographic regression or stabilization, although as with any irradiation, may also cause some adverse events.
223769514|NCT07017816|DRUG|Nivolumab|Given the poor prognosis for children with recurrent CNS malignancies and the importance of p53 function in these tumors, we propose a pilot study of SGT-53 in combination with re-irradiation and checkpoint inhibition followed by maintenance therapy with SGT-53 in combination with nivolumab to evaluate the safety, feasibility and preliminary efficacy. SGT-53 will be added to a salvage regimen utilized in patients with recurrent tumors of re- irradiation and nivolumab followed by combination therapy with SGT-53 and nivolumab.
223769515|NCT06875752|DRUG|no luteal support|In one arm of the study the patients receive no luteal support as part of their modified natural cycle frozen embryo transfer.
223769516|NCT06875752|DRUG|Vaginal Progesterone|In the 2nd arm the patient receives 2x200 mg vaginal progesterone as luteal support.
224241781|NCT02589223|OTHER|Multisensory Stimulation|Subjects assigned to the multisensory stimulation group will receive the multisensory stimulation protocol designed for the study, which will include a variety of techniques designed to awaken the individual. Stimulus provided may include: visual activities (i.e. presenting the individual with objects/pictures to look at), auditory information (i.e. playing music or speaking), tactile stimuli (i.e. touching the individual with materials of different textures), taste and smell stimuli (i.e. offering items for the individual to taste or smell).
224241782|NCT02589223|OTHER|Control|Intervention sessions will occur 3 times per week, for approximately 30 minutes per session for a total of 4 weeks. During each session, subjects will be played a pre-recorded reading of complex material for 30 minutes, in order to assist with control/blinding.
224241783|NCT03663803|BEHAVIORAL|Brief theory-based health promotion intervention (group-based)|The intervention is depicted using a PaT Plot in the published paper: Juul, L et al. Effectiveness of a brief theory-based health promotion intervention among adults at high risk of type 2 diabetes: One-year results from a randomised trial in a community setting. Primary Care Diabetes 1 0 ( 2 0 1 6 ) 111-120.
224241784|NCT03299907|DIAGNOSTIC_TEST|Spirometry|
224241785|NCT01066806|BEHAVIORAL|counseling on increasing calcium intake|The American Academy of Pediatrics recommends that adolescents ingest at least four servings of dairy food and at least 1300 mg calcium per day.
224241786|NCT01066806|OTHER|observation|observe normal dairy intake
224241787|NCT00284674|DEVICE|Hip prosthesis (re-cap, m2a-magnum and C2a-taper)|
224241788|NCT05836805|DRUG|[14C]XZP-3621|Extemporaneously compounded oral suspension solution of \[14C\]XZP-3621 (400 mg/200 µCi)
224241789|NCT03494322|DRUG|Avelumab|Avelumab 10 mg/kg given IV
224241790|NCT03494322|DRUG|Cetuximab|"Cetuximab 500\* mg/m2 given IV~\*Cetuximab dose will be dependent on outcome of safety run-in."
224241791|NCT02930005|DRUG|Meclofenamic acid|
224241792|NCT02930005|DRUG|Pentosan polysulfate sodium|
224241793|NCT01515826|DRUG|Moxifloxacin 0.5%/Dexamethasone Phosphate 0.075% Ophthalmic Gel (VIGADEXA Gel)|One ribbon (approximately 1-1.5 cm) administered topically in the conjunctival sac of the study eye three times daily (TID), starting the day before surgery (Day -1) and continuing on the day of surgery and for 15 days following surgery.
224241794|NCT01515826|DRUG|Moxifloxacin 0.5%/Dexamethasone Phosphate 0.1% Ophthalmic Solution (VIGADEXA Solution)|One drop administered topically in the conjunctival sac of the study eye four times daily (QID), starting the day before surgery (Day -1) and continuing on the day of surgery and for 15 days following surgery.
224241795|NCT05039190|DRUG|HBM9161 Injection (680mg)|HBM9161 Injection
224241796|NCT05039190|DRUG|Placebo|Placebo Injection
224241797|NCT05273866|OTHER|Virtual reality|Virtual Reality video application reduces pain by distracting. The intervention group was watched video during the procedure, starting before the procedure.
224241798|NCT01054534|PROCEDURE|Placement of interstim lead|Placement of insterstim lead using US image fusion technology
224241799|NCT05689762|BEHAVIORAL|Healthy lifestyle counseling and E-health support|Promotion of healthy lifestyle behaviors through counseling and access to E-health platform
224241800|NCT05299047|OTHER|Group US-guided|An ultrasound system with a 5-2 MHz curved transducer will be used. The division of the abdominal aorta into the common iliac arteries was located using oblique sonography. Then, the transducer will image the body of the fifth lumbar vertebra, at which level bilateral common iliac vessels will be seen leaving a space in the midline. a 20 cm long, 22 gauge Chiba needle will be introduced into the hypogastrium, with out-of-plane technique to access the fifth lumbar vertebral body at its anterior-most point, so that injected drug spreads equally bilaterally along the anterior curvature of the fifth lumbar vertebral body.Suction was applied to the needle to confirm that it was not within a vessel and 10 ml of 50% ethanol will be injected for neurolysis.
224241801|NCT05299047|OTHER|Group fluoroscopy-guided|The patient will be placed in the supine position. The L5-S1 inter-discal space was identified under fluoroscopy.After providing local cutaneous and subcutaneous anesthesia with 2% Lignocaine solution nearly 3-4 cm below the umbilicus, a 20 cm long, 22 gauges Chiba needle is advanced to the anterior portion of the 5th vertebral body under ongoing fluoroscopic guidance. Once bony resistance is reached, gently inject 2-5 ml contrast which typical reveals a characteristic triangular blob of contrast with no vascular opacification.Before injection the needle is aspirated to confirm there is no blood. A preliminary test dose of about 3 cc of 0.5% bupivacaine is then injected. If there is no change in heart rate or neurological status, rest of the 20 cc phenol 10% is injected slowly with intermittent aspiration.
224241802|NCT02406898|DEVICE|morcellator uterine system (MH)Karl Storz, Tuttligen- Germany|
223661470|NCT06988163|BEHAVIORAL|OACareTools+|OACareTools+ is a healthcare provider intervention that combines healthcare provider education, customized patient and clinical resources, and technical support from a national organization to facilitate provider counseling on and referral to as well as patient engagement in Walk With Ease. There are 2 main parts to this intervention: 1) Healthcare provider education: The study team will deliver the provider education and resources (including information about Walk With Ease and the established referral process/smartphrase) in a presentation providers at a weekly clinician meeting and in follow-up emails. 2) Implementation: Providers will use the resources to briefly counsel patients about physical activity and Walk With Ease and use the smartphrase to refer patients to Walk With Ease. Patients will register for and participate in the online Walk With Ease program. Patients and providers can seek assistance from the national organization as needed during these processes.
223661471|NCT06651242|OTHER|Decision-making information aids|Provide a decision-making information aids to assist patients and their parents in treatment decision making.
223661472|NCT06651242|OTHER|Routine care|Routine care
223661473|NCT06660277|DEVICE|Super High-Flux Dialyzer|A hemodialysis filter (known as a dialyzer) that is currently approved by Health Canada and available for use across Canada. This filter has larger pores than a high-flux dialyzer that allow for greater removal of potential toxins and wastes in the blood that would regularly be filtered out by healthy kidneys.
223661474|NCT06660277|DEVICE|High-Flux Dialyzer|A hemodialysis filter (known as a dialyzer) that is that is widely used across Canada for hemodialysis treatments.
223661475|NCT03839537|OTHER|Exposure measurement|"* 2 measurements per subject (in warm season and in cold season)~* Devices placed inside taxi vehicles on the passenger seat in a sampling bag"
223661476|NCT03839537|OTHER|Spirometry test|"* 2 measurements per subject - before and after the work shift - in warm and cold seasons~* Subject will inhale and exhale in the device"
223661477|NCT03839537|DIAGNOSTIC_TEST|Exhaled carbon monoxide test|"* 2 measurements per subject - before and after the work shift - in warm and cold seasons~* Subject will exhale in the device"
223661478|NCT03839537|DIAGNOSTIC_TEST|Skin allergy test|\- Performed by a physician during the inclusion clinical examination
223661479|NCT03839537|DIAGNOSTIC_TEST|Spirometry test|\- Performed by a physician during the inclusion clinical examination
223661480|NCT03839537|DIAGNOSTIC_TEST|Fractional Exhaled Nitric Oxide Testing|\- Performed by a physician during the inclusion clinical examination
223769517|NCT06875752|DRUG|Progesterone plus HCG|In the 3rd arm the patients receive 2x200 mg vaginal progesteroen plus 125 mcg recombinant HCG s.c. on the day of embryo transfer and 62.5 mcg recombinant HCG s.c. 4 days later.
223769518|NCT05393713|BIOLOGICAL|Anti-PD-L1 Monoclonal Antibody IMC-001|Given intra-lymphatically via DoseConnect device
223769519|NCT05393713|PROCEDURE|Punch Biopsy|Undergo punch biopsy
223769520|NCT07025668|OTHER|Eccentric Exercise|In the eccentric exercise group, in addition to strengthening exercises for the periscapular muscles and stretching exercises for the biceps brachii muscle, eccentric strengthening exercises for the biceps brachii muscle will be given. Participants will do the exercises in the groups they were randomized to every day for 12 weeks. They will be called to the clinic once a week for exercise checks.
224241803|NCT05728385|DIETARY_SUPPLEMENT|Modified Specific carbohydrate diet for 3 months|"All children at the start of the study will be subjected to:~1. Full history taking including demographic and medical history~2. Full nutritional assessment including: Through clinical examination for any signs of vitamins and mineral deficiency, with full chest examination.~3. Laboratory tests: Complete blood picture with differential white blood cells, and Serum IgE level~4. At the beginning of the study and at the end~   1. The patients will be assessed using the childhood-asthma control test (C-ACT) as a subjective method~  2. Pulmonary function tests will be performed using spirometry (Spirostik, Geratherm) that includes Forced vital capacity (FVC), forced expiratory volume in the first second of FVC (FEV1), and FEV1/FVC.~  3. Anthropometric measurements: Weight, Height, and Body mass index (BMI). All measures will be plotted on specific percentile curves for age and Z score"
224241804|NCT02874586|OTHER|Plasma exchange combination of immunosuppressive regimens|
224241805|NCT05431166|BEHAVIORAL|Virtual Yoga at First 8 weeks|1 hour per week of virtual yoga delivered by an active movement therapist at the VA during the first 8 weeks of the study
224241806|NCT05431166|BEHAVIORAL|Virtual Yoga at Second 8 weeks|1 hour per week of virtual yoga delivered by an active movement therapist at the VA during the second 8 weeks of the study
223661481|NCT06664164|PROCEDURE|ANTERİOR QUADRATUS LUMBORUM BLOCK|Patients are placed in the lateral decubitus position. The area where the block will be applied is disinfected with povidine iodine. A convex ultrasound probe is placed on the midaxillary line above the iliac crest. By visualizing the transverse process adjacent to the psoas major and quadratus lumborum muscles, using the in-plane technique, using a 22 gauge 80 mm peripheral block needle after negative aspiration into the anterior layer of the thoracolumbar fascia anterior to the quadratus lumborum muscle muscle, 0.5-1 ml of serum After observing hydrodissection with physiological, 20 ml of 0.25% bupivacaine is injected.
223769521|NCT07025668|OTHER|Combined Exercise|In the combined exercise group, in addition to strengthening exercises for the periscapular muscles and stretching exercises for the biceps brachii muscle, progressive isometric, isotonic and plyometric strengthening training will be given to the biceps brachii muscle. Participants will do the exercises in the groups they were randomized to every day for 12 weeks. They will be called to the clinic once a week for exercise checks.
224241807|NCT05826262|PROCEDURE|diagnostic laparoscopy|diagnosis and management of patients with penetrating anterior abdominal wall injuries
224241808|NCT01293422|DRUG|Rifampicin|Rifampicin 600 mg daily for a week
224241809|NCT02781727|DRUG|Once weekly subcutaneous injection of TransCon hGH|Once weekly subcutaneous injection
223769522|NCT07025668|OTHER|Control Group Exercise|In the control group, strengthening exercises for the periscapular muscles and stretching exercises for the biceps brachii muscle will be given. Strengthening exercises for the biceps brachii muscle will not be given in this group. Participants will do the exercises in the groups they were randomized to every day for 12 weeks. They will be called to the clinic once a week for exercise checks.
223769523|NCT07025694|DEVICE|A eHealth application on a computer tablet contected to a secure severer with an interface on a computer to deliver exercise interventions.|Feasibility, acceptability and usability testing of delivering home-based exercise MICT and HIIT via a Vidoe-call at fixed time-points. Tuesday, Thursday, Saturday during the 3 week-period of supervision via zoom.
223661482|NCT06664164|PROCEDURE|ANTERİOR QUADRATUS LUMBORUM BLOCK WİTH ADJUVANT|Patients are placed in the lateral decubitus position. The area where the block will be applied is disinfected with povidine iodine. A convex ultrasound probe is placed on the midaxillary line above the iliac crest. By visualizing the transverse process adjacent to the psoas major and quadratus lumborum muscles, using the in-plane technique, using a 22 gauge 80 mm peripheral block needle after negative aspiration into the anterior layer of the thoracolumbar fascia anterior to the quadratus lumborum muscle muscle, 0.5-1 ml of serum After observing hydrodissection with physiological, 20 ml of 0.25% bupivacaine and 8 mg de-xamethasone are injected.
223661483|NCT06996990|OTHER|Physical evaluations in Volleyball Players|This study will evaluate pain, fatigue, muscle strength, balance and quality of life in volleyball players. All these measurements will be completed in two sessions lasting 45-60 minutes.
223661484|NCT06862219|DRUG|Enfortumab Vedotin|Intravenous Infusion
223769524|NCT07025694|DEVICE|A eHealth application on a computer tablet contected to a secure severer with an interface on a computer to deliver exercise interventions|Feasibility, acceptability and usability testing of delivering home-based exercise MICT and HIIT via a pre-recorded videos at convenient time-point with at least one day in between during the periods of video-supervision
224241810|NCT02781727|DRUG|Once daily subcutaneous injection of Genotropin|Once daily subcutaneous injection
223661485|NCT00027989|DRUG|gemcitabine hydrochloride|
223661486|NCT00027989|DRUG|pegylated liposomal doxorubicin hydrochloride|
223661487|NCT06342193|DEVICE|virtual reality group|This group will use virtual reality glasses as distraction during cystoscopy.
224241811|NCT04362891|PROCEDURE|Cosmetic lip augmentation|The primary study treatment site will be the vermilion (body of the lip); additional areas (vermilion borders, Cupid's bow, philtral columns, and/or oral commissures) will be treated if deemed appropriate by the treating physician. Treatment will be administered through intradermal, subdermal, and/or intramuscular injection within the orbicularis oris muscle. Injection techniques for each area will include linear threading, serial puncture, fanning, and/or cross-hatching. The treating physician will determine the appropriate volume to inject based on clinical experience and the subject's goals for lip augmentation.
224241812|NCT01793194|OTHER|Compression Stockings|20-30mmg Hg maternity pantyhose compression stockings
224241813|NCT00493831|DRUG|nicotine polacrilex, transdermal system or inhaler|on label use of Nicotine replacement therapy (NRT)
224241814|NCT05473975|PROCEDURE|Placement of the EGG|Placement of the EGG before the beginning of the thrombectomy
224241815|NCT03393858|DRUG|Anti-PD-1 antibody|Patients will receive pembrolizumab 100mg every three weeks until disease progression, unacceptable toxicity or patient refusal.
224241816|NCT03393858|BIOLOGICAL|DC-CIK Immunotherapy|Mononuclear cells were collected from 50ml peripheral blood , and cultured DC-CIK cells for 15-20 days. Cells were infused back to the patients in 3 times via intravenous infusion .Patients will received at least 2 cycles of DC-CIK Immunotherapy along with 4 dosage of anti-PD-1 antibody treatment. If the evaluation of the treatment is partial response or stable disease, additional cycles were eligible.
224241817|NCT03393858|DEVICE|Thermotron RF-8EX|Hyperthermia for 40 minutes, with maximum temperature setted on 42℃ ± 0.5℃ as upper limit, twice a week since the 1st week of pembrolizumab for a total of 10 times.
224241818|NCT06431594|DRUG|GSK5733584|GSK5733584 will be administered
224241819|NCT05720572|DRUG|Antazoline|Participants assigned to the antazoline group will be administered antazoline in boluses in boluses of 100 mg diluted to 20 cm3 every 10 minutes up to a total dose of 300 mg diluted to 60 cm3 or conversion of AF to SR. Drug administration will also be stopped in case of an adverse event or conversion of AF to a different supraventricular arrhythmia. BP will be measured before every injection.
224241820|NCT05720572|DRUG|Propafenone|Patients assigned to the propafenone group were administered three 20-cm3 boluses every 10 minutes up to 60 cm3 or conversion of AF to SR. Each of the first two boluses included 70 mg propafenone (total dose 140 mg), and the third bolus contained only 20-cm3 0.9% NaCl. Drug administration will be stopped in case of an adverse event or conversion of AF to a different supraventricular arrhythmia. BP will be measured before every injection.
224241821|NCT00495326|DRUG|Nevirapine based therapy|"* Patients below 60 kg: 1 tablet twice a day of Triomune30®, including NVP 200 mg, 3TC 150 mg and D4T 30mg~* Patients above 60kg: 1 tablet twice a day of Triomune40®, including NVP 200 mg, 3TC 150 mg and D4T 40 mg)"
224241822|NCT00495326|DRUG|Efavirenz based therapy|Efavirenz EFV 200 mg (3 tablets/d) Lamivudine 3TC 300mg (2 tablets of 150mg/d) D4T generic 30mg or 40mg (2 tablets/d)
224241823|NCT00495326|DRUG|Rifampicin (RMP) Ethambutol (E) Isoniazid (H) Pyrazinamid (Z)|"* Intensive phase: 2 months daily E(RMP)HZ. PTB smear positive patients at month 2 will receive 1 more month intensive phase.~* Continuation phase: 4 months daily H(RMP).~* Patients with meningitis will receive Streptomycin instead of E during intensive phase."
224241824|NCT00933751|DEVICE|Central vein catheterization|Blood samplings from IVC catheter
224241825|NCT05602519|DRUG|propofol, rocuronium and fentanyl|In fentanyl group (36 patients), 50 ug of fentanyl, and in oxycodone group, 4 mg of oxycodone will be administered 20 minutes before the end of the surgery, in triple blind manner.
224241826|NCT05783284|DEVICE|Holocare Studio 2 (HS2)|3D HV
223661488|NCT00975897|BIOLOGICAL|bevacizumab|
223661489|NCT00975897|BIOLOGICAL|cetuximab|
223661490|NCT00975897|DRUG|fluorouracil|
223661491|NCT00975897|DRUG|irinotecan hydrochloride|
223661492|NCT00975897|DRUG|leucovorin calcium|
223661493|NCT00975897|DRUG|oxaliplatin|
223661494|NCT00975897|GENETIC|RNA analysis|
223661495|NCT00975897|GENETIC|cytogenetic analysis|
223661496|NCT00975897|GENETIC|fluorescence in situ hybridization|
223661497|NCT00975897|GENETIC|gene expression analysis|
223661498|NCT00975897|GENETIC|mutation analysis|
223661499|NCT00975897|GENETIC|protein expression analysis|
223661500|NCT00975897|OTHER|diagnostic laboratory biomarker analysis|
223661501|NCT00975897|OTHER|immunohistochemistry staining method|
223661502|NCT00975897|OTHER|questionnaire administration|
223661503|NCT00975897|PROCEDURE|cognitive assessment|
223661504|NCT06870760|OTHER|Monoclonal Gammopathy|Whole blood will be collected at the Baseline visit to evaluate for monoclonal gammopathy through SPEP, immunofixation, and free light chains.
223661505|NCT06870760|OTHER|Complete Blood Count with differential (CBC w/ diff)|Whole blood will be collected at the Baseline visit for CBC with differential which may inform a diagnosis of a plasma cell disorder or other hematological disorder.
223661506|NCT06870760|OTHER|Clonal hematopoiesis (CHIP)|Whole blood will be collected at the Baseline visit to be evaluated using next generation sequencing (NGS) detection of CHIP. Deep NGS to identify mutations associated with myeloid neoplasms and CHIP will be performed using an error-correcting next generation sequencing multi-gene panel targeting genes most frequently mutated in CHIP.
223661507|NCT05576480|RADIATION|Short-course radiotherapy|5×5Gy in Week 1
223661508|NCT05576480|DRUG|Penpulimab|Apply once in the first week, then every 3 weeks from the third week for four cycles
223661509|NCT05576480|DRUG|CAPEOX|Apply every 3 weeks from week 3 for 4 cycles
223661510|NCT05576480|PROCEDURE|TME surgery|Patient will receive radical rectal cancer surgery
223661511|NCT04219085|DEVICE|Continuous Glucose Monitor|Wearing of a continuous glucose monitor to monitor blood glucose levels in women with gestational diabetes
223661512|NCT04219085|OTHER|Routine Care|Use of a glucometer to monitor blood glucose levels in women with gestational diabetes
223661513|NCT07008911|BEHAVIORAL|CardioHeartConnect|Participants in the CardioHeartConnect group engage in an eight-week digital cardiac rehabilitation program using the commercially available Peloton app. The intervention includes two daily modules (10-25 minutes total) on weekdays, focused on walking, strength, low-intensity cardio, yoga, pilates, and stretching. Modules progress in intensity over time. The program is delivered through the Ortus-iHealth platform, which prompts daily participation and integrates survey responses and smartwatch data. The intervention is designed to support physical activity, functional capacity, quality of life, and cardiovascular health among patients recovering from Transcatheter Aortic Valve Replacement (TAVR).
223661514|NCT07008911|BEHAVIORAL|CardioHeartEd|CardioHeartEd is the control condition in which participants receive weekly cardiac rehabilitation-related educational resources through the Ortus-iHealth platform for eight weeks. The content is created by the American College of Cardiology and is designed to promote cardiovascular health following TAVR. Participants also receive a smartwatch to wear for self-monitoring, but do not receive structured exercise content. The CHE group controls for access to technology and general education about heart health.
223661515|NCT07011524|BIOLOGICAL|CM512 injection|subcutaneous injection
223661516|NCT07011524|DRUG|Placebo|subcutaneous injection
223661517|NCT07013903|OTHER|Standard rehabilitation plus cold water hydrotherapy|Cold water hydrotherapy (5-10 minutes each), twice daily during the 3-week multimodal inpatient rehabilitation program and once daily during the 6-month follow-up period
223661518|NCT07013903|OTHER|Standard rehabilitation only|same rehabilitation program than the experimental group but without hydrotherapy
223769525|NCT07025694|OTHER|Moderate Intensity Continues Training|The MICT exercise training on a spinning-bike will consist of moderate intensity-longer (60%Wpeak) duration exercise carried out 3 times per week. Tuesday, Thursday, Saturday during the 3 week-period of supervision via zoom, and at time-point with at least one day in between during the periods of video-supervision. Exercise will consist of continuous biking at an individualized workload based on pre-exercise testing, for a total time of 30 minutes.
224321241|NCT04110210|DRUG|Morphine Consumption|After operation, patients will be transferred to post anesthesia care unit (PACU) for complete recovery and monitoring. The pain VAS scores between the studied groups will be registered every 4 hours for 24 hours postoperatively. A standard postoperative analgesia regimen will be prescribed as paracetamol 1gm every 6 hours and ketorolac 30mg every 8 hours in the first 24 hours postoperatively. Morphine 2.5 mg will be given as a rescue analgesic dose if visual analogue score was ≥ 3 or when patient suffering from pain between the assessment intervals in both groups not exceeding 0.1 mg/kg in a period of 6 hours. Metoclopramide 0.15 mg/kg IV will be prescribed for patients complaining of nausea or vomiting.
224321242|NCT00134901|DRUG|Memantine|Memantine
224321243|NCT00134901|DRUG|placebo|placebo
224321244|NCT04098510|DIETARY_SUPPLEMENT|MitoQ|Subjects ingest 8x20 mg MitoQ capsules
224321245|NCT00659243|DRUG|rhBSSL|0.15 g/L rhBSSL added to pasteurized breast milk; one week treatment
224321246|NCT00659243|DRUG|Placebo|One week treatment
223661519|NCT05830084|DRUG|regorafenib tablet|"Regorafenib will be escalated/de-escalated, starting at DL0:~* DL1: 82 mg/m\^2 once daily for 21 days/28 days (max 160mg) (100% of the RP2D)~* DL0 (starting dose): 66 mg/m\^2 once daily for 21 days/28 days (max 120mg) (80% of the RP2D)~* DL-1: 50 mg/m\^2 once daily for 21 days/28 days (max 80mg) (60% of the RP2D)"
223661520|NCT03711695|DEVICE|iBeat wristwatch device|The participant will be asked to wear one iBeat wristwatch device on each arm during the planned procedure.
223661521|NCT00658164|OTHER|Iron depletion treatment|Effect of iron depletion by phlebotomy plus lifestyle changes vs. lifestyle changes alone on liver damage in patients with nonalcoholic fatty liver disease with increased iron stores
223661522|NCT07018830|BEHAVIORAL|Behavioral Treatment|Participants will be provided 11, 60 - 90 minute group sessions. They will receive behavioral strategies to address each of the lifestyle behaviors. These strategies are based on the Social Cognitive Theory and Self Determination Theory. Topics will include, but are not limited to, self-monitoring, goal setting, social support, cues, problem solving, and relapse prevention. Groups may occur both in-person and virtually.
223661523|NCT06331702|BIOLOGICAL|Vero cell-drived inactive Japanese encephalitis vaccine|0.5ml for each dose, manufactured by Liaoning Chengda Biotechnology CO., LTD, administered in the deltoid area of lateral arm by intramuscular injection.
223661524|NCT06331702|BIOLOGICAL|Measles-Mumps-Rubella Vaccine|0.5ml for each dose (after dissolving), manufactured by Shanghai Institute of Biological Products CO., LTD, administered in the lower part of the deltoid area of lateral arm, by subcutaneous injection.
223661525|NCT02897661|PROCEDURE|WMT|Washed microbiota transplantation (WMT) through mid-gut
223661526|NCT02897661|DIETARY_SUPPLEMENT|EEN|Exclusive enteral nutrition (EEN) through feeding tube
223661527|NCT06867081|OTHER|The intervention will be the BRILLIANT Platform, an online platform which provides five Modules aimed at increasing coordination of care and direct rehabilitation time|The BRILLIANT Platform provides five Modules aimed at increasing coordination of care and direct rehabilitation time: 1) Standardized measures: provided consistently with scoring and reminders to complete assessments, across all stages of recovery and care settings to guide and evaluate treatment effectiveness of clinical outcomes, performance based outcomes, patient reported outcome measures; 2) Communication Module: clinicians can communicate together and with patient/family to clarify patient-related information and update colleagues for time sensitive information, synchronously and asynchronously; 3) Shared intervention goals and plan: personalized and dynamic care trajectory and intervention plan guided by standardized assessments, reminders, and evidence-based interventions recommendations to direct patients and caregivers to the right services and interventions at the right time based on clinical and social profile and best practices; and 2 other related topics.
223769526|NCT07025694|OTHER|High intensity interval training|The HIIT exercise training on a spinning-bike will begin by using a protocol consisting of bouts of high-intensity (95%Wpeak) exercise lasting for 60 seconds. These bouts will be interspersed by 4 minutes of low intensity exercising (40%Wpeak). There will be 5 bouts per session. Exercise will consist of continuous biking at individualized workloads based on pre-exercise testing. The exercise will be carried out 3 times per week. Tuesday, Thursday, Saturday during the 3 week-period of supervision via zoom, and at time-point with at least one day in between during the periods of video-supervision.
223769527|NCT07024290|BEHAVIORAL|HITT|The experimental group completed a 4-week HIIT-boxing protocol, in addition to regular boxing sessions. HIIT consisted of three weekly sessions, each including three blocks of five 30-second all-out punching intervals on a heavy bag, with 6-second rest between efforts and 1-minute rest between blocks. Heart rate was monitored throughout, confirming training intensities of 88-92% HRmax, consistent with high-intensity training standards in combat sports.
223661528|NCT07017400|PROCEDURE|Local Anesthetic Injection|combination of regional blocks for TKA postoperative analgesia
223769528|NCT07024290|OTHER|Regular training|Participants in control groups followed a boxing training program for a period of four weeks, with sessions conducted three times per week. Each session lasted 90 min and was structured in alignment with the established training principles for amateur boxing. The training began with a 15-minute general warm-up phase, including dynamic mobility drills and calisthenics, to elevate core temperature and enhance neuromuscular readiness.
223769529|NCT07024095|BEHAVIORAL|Inspiratory Muscle Training (IMT)|"Participants in the intervention group will receive, in addition to the standard postoperative follow-up for 8 weeks (3 days per week), a home-based exercise program including diaphragmatic breathing exercises, stretching exercises targeting kyphotic posture, and strengthening exercises for the thoracic region. These exercises will be taught to the patients and their caregivers by a licensed physiotherapist before hospital discharge.~In addition, inspiratory muscle training (IMT) will be performed every day for 8 weeks. To ensure progressive workload, maximal inspiratory pressure (MIP) will be reassessed weekly, and the IMT device will be adjusted accordingly."
223769530|NCT07024095|BEHAVIORAL|control group|"Participants in the control group will receive, similar to the intervention group, a home-based exercise program for 8 weeks (3 days per week), including diaphragmatic breathing exercises, stretching exercises for kyphotic posture, and strengthening exercises for the thoracic region, in addition to standard postoperative follow-up. These exercises will be demonstrated to the patients and their caregivers by a licensed physiotherapist before hospital discharge.~Unlike the intervention group, participants in this group will not receive inspiratory muscle training (IMT)."
223769531|NCT07024394|DRUG|Luvometinib Tablets|5mg/m² (Maximum dose does not exceed 8mg, the recommended oral dose for adults), orally, once daily, until disease progression or study completion, whichever occurs first
223769532|NCT07023991|DRUG|Bupivacaine|Bupivacaine will be used in an ESP block to provide postoperative analgesia.
223769533|NCT07023991|DRUG|Dexmedetomidine|Dexmedetomidine will be added to bupivacaine in the ESP block to evaluate its effect on duration of postoperative analgesia.
224241827|NCT04641559|OTHER|Personalized nutrition group|"A digital environment which combines biological information, personal habits and preference to provide nutritional recommendations. This digital environment is composed by the follow softwares:1. The recommender system: software that combine the behavioral and biological information about the volunteer and generates personalized nutritional recommendations; 2. The ALDI microsite: A microsite that retrieves the personalized recommendations for the volunteer from the recommender system. The ALDI microsite matches food categories with products of the ALDI catalogue. As a result, the volunteer receives a list of products classified under different food categories that are recommended for him/her. Next to each food category, the number of servings recommended (weekly or daily) is also shown.~The ALDI microsite is a tool only to elaborate a shopping list through personalized recommendations. Therefore, volunteers can choose to buy their food shopping list at wherever store other from ALDI."
223769534|NCT07024849|DIETARY_SUPPLEMENT|Ecological nutritional intervention|Patients in the intervention arm will receive a 4-week nutrition management program(1 week for patients more than 4 months post-surgery), which includes providing nutritional guidelines, home delivery of personalized care foods, encouragement of physical activity using a wearable device, and weekly phone calls to check on nutritional goals and symptoms. Management services are also available through the mobile application.
224241828|NCT04641559|OTHER|Personalized Plan group|Participants will use the same software described in for the Personalized nutrition group together with a behavioral change program designed to increase the adherence to the recommendations provided by the ALDI microsite by promoting a proper attitude by means of a series of personalized, goal-orientated, friendly, achievable actions delivered periodically to the volunteer. The behavioral change program will be fed with the results of behavior questionnaires. The personalized messages will be delivered through the ALDI microsite. These personalized messages will be available only for those subjects engaged in the Personalized Plan group.
224241829|NCT04641559|OTHER|Control group|The participants in the control group will not have personalized recommendations. These participants will have access to a restricted version of the ALDI microsite where the list of recommended products correspond to categories that are general recommendations according to Mediterranean diet.
224241830|NCT00988624|DRUG|Dimebon IR Tablet|Pharmacokinetics of a single oral dose of 10 mg dimebon immediate release tablet will be assessed on Day 1 - 3.
224241831|NCT00988624|DRUG|Dimebon MR1|Pharmacokinetics of a single oral dose of 10 mg dimebon modified release formulation, MR1, will be assessed on Day 1 - 3.
224241832|NCT00988624|DRUG|Dimebon MR2|Pharmacokinetics of a single oral dose of 10 mg dimebon modified release formulation, MR2, will be assessed on Day 1 - 3.
224241833|NCT00988624|DRUG|Dimebon MR3|Pharmacokinetics of a single oral dose of 10 mg dimebon modified release formulation, MR3, will be assessed on Day 1 - 3.
224241834|NCT00988624|DRUG|Dimebon MR4|Pharmacokinetics of a single oral dose of 10 mg dimebon modified release formulation, MR4, will be assessed on Day 1 - 3.
224321247|NCT06158919|DRUG|Fruquintinib、Nivolumab、Sintilimab、Oxaliplatin、Teysuno、Capecitabine|"Combined treatment period: A total of 6 cycles of combined treatment Fruquintinib: 4 mg/d, qd po, d1-14, q3w. Nivolumab: 360mg iv.gtt d1, q3w or Sintilimab: 200mg iv.gtt d1, q3w SOX : Oxaliplatin 130mg/m2 iv.gtt d1, Teysuno 40mg/m2 p.o.b.i.d. d1\~ 14q3w. Or XELOX regimen: oxaliplatin 130mg/m2 iv.gtt d1 Capecitabine 1000mg/m2 p.o. b.i.d. d1\~ 14q3w.~Maintenance treatment period:~Fruquintinib: 4 mg/d, qd po, d1-14, q3w. Nivolumab: 360mg iv.gtt d1, q3w or Sintilimab: 200mg iv.gtt d1, q3w Teysuno 40mg/m2 p.o.b.i.d. d1\~14 q3w or Capecitabine 1000mg/m2 p.o.b.i.d. d1\~14 q3w.~Maintenance of treatment until disease progression or toxicity becomes intolerable."
224321248|NCT01554319|DRUG|SB010|"Three ascending dose groups are planned (Groups A, B, C), each consisting of 12 male subjects. Each of the 3 dose groups will be divided into 2 subgroups. First subgroup: 4 subjects (n=3 active compound, n=1 placebo); second subgroup: 8 subjects (n=6 active compound, n=2 placebo).~Each dose group will be investigated with a new group of 12 subjects (n=9 active compound, n=3 placebo). Dose escalation to next dose level will occur after satisfactory review of safety and tolerability and after review of the pharmacokinetic data (exposure control) of the preceding dose cohorts by the Safety Board.~Dose group A : 5 mg hgd40/2 mL; Dose group B: 10 mg hgd40/2 mL; Dose group C: 20 mg hgd40/2 mL."
224321249|NCT01554319|DRUG|Placebo (phosphate-buffered saline)|"Three ascending dose groups are planned (Groups A, B, C), each consisting of 12 male subjects. Each of the 3 dose groups will be divided into 2 subgroups. First subgroup: 4 subjects (n=3 active compound, n=1 placebo); second subgroup: 8 subjects (n=6 active compound, n=2 placebo).~Each dose group will be investigated with a new group of 12 subjects (n=9 active compound, n=3 placebo). Dose escalation to next dose level will occur after satisfactory review of safety and tolerability and after review of the pharmacokinetic data (exposure control) of the preceding dose cohorts by the Safety Board."
224321250|NCT03503695|DEVICE|Sterile acupuncture semi-permanent (ASP) gold needles|
224321251|NCT03135002|OTHER|Other|
224321252|NCT06263192|PROCEDURE|Intrauterine insemination|Intrauterine insemination with sperm donors
224241835|NCT01288664|DRUG|ADVAGRAF|Tacrolimus Sustained-release Capsules (ADVAGRAF) Started: 0.05-0.1mg/kg/d, one time per day, the blood level:5-10ng/ml in induction phase.
224241836|NCT02450981|DRUG|Bevacizumab (BCD-021)|Bevacizumab is a monoclonal antibody against vascular endothelial growth factor A (VEGF-A)
224241837|NCT00319358|DIETARY_SUPPLEMENT|Antioxidants|600microgm selenium, 0.54g vitamin C, 9000IU beta-carotene, 270IU vitamin E, 2g methionine per day, daily, in divided doses for 6 months
224241838|NCT00319358|DIETARY_SUPPLEMENT|Placebo|placebo
224241839|NCT01918800|BEHAVIORAL|Fatigue: Take control|Fatigue: Take Control, is the first formal education program modeled on the MS-related fatigue guideline
223769535|NCT07025239|DRUG|QL1706|QL1706 will be administered by IV infusion at 5mg/kg on Day 1 of each 21-day cycle until disease progression (PD), intolerable toxicity, initiation of a new anti-tumor therapy, death, withdrawal of informed consent, loss to follow-up or other conditions requiring termination of the treatment (whichever occurs first). The administration of QL1706 lasts for up to 2 years.
224241840|NCT01918800|BEHAVIORAL|MS: Take Control|MS: Take Control includes topics of interest to people with MS other than fatigue.
223661531|NCT01762137|PROCEDURE|Flow Diversion|Endovascular flow diverter placement
223661532|NCT01762137|PROCEDURE|Coiling|Endovascular coil placement
224241841|NCT02609464|DEVICE|Interrupted Knotted Sutures|
224241842|NCT02609464|DEVICE|STRATAFIX Symmetric PDS PLUS Knotless Tissue Control Devices|
224241843|NCT04285749|DRUG|Fluvastatin|Fluvastatin PO 80mg QD for 2 weeks
224241844|NCT04285749|OTHER|RNA-sequencing|RNA-sequencing will be completed on the original diagnostic biopsy and the final melanoma excision
224241845|NCT04285749|OTHER|Gene expression profiling|Gene expression profiling will be completed on the original diagnostic biopsy and the final melanoma excision
224241846|NCT02566278|OTHER|Upper airway collapsibility (Pcrit)|To measure passive Pcrit, patients sleep with a mask over their nose or nose and mouth, and CPAP is applied using a custom made machine that can rapidly change mask pressures in research setting. The idea is that rapid changes in airway pressure produce a clear step change in airflow that will be observed quickly. In contrast, during clinical titrations, the CPAP machines change pressure much more slowly to help promote patient comfort. Passive Pcrit will be measured using both research and clinical equipment in the same patients and the Pcrit result using clinical CPAP titration equipment will be compared to the gold standard: Pcrit measurement done through research equipment that changes CPAP pressure rapidly.
224241847|NCT02601482|BEHAVIORAL|CON|
224241848|NCT02601482|BEHAVIORAL|IW-60|
224241849|NCT02601482|BEHAVIORAL|IW-45|
224241850|NCT02409472|OTHER|surveillance program after completion of primary treatment|These are two different surveillance programs for Dukes B2-C colorectal cancer patients who have no evidence of disease at the end of their front line treatment (surgery and adjuvant radio-chemotherapy, if indicated). These programs differ greatly in the frequency of diagnostic imaging. They had similar schedules of physical examinations and carcinoembryonic antigen (CEA) assessments.
224241851|NCT03122522|DRUG|ipilimumab|ipilimumab 3mg/kg
224241852|NCT03122522|DRUG|nivolumab|nivolumab 1mg/kg
224241853|NCT03432845|OTHER|compare reversal agents|compare effect of two different approved reversal agents on postoperative and post-discharge nausea and vomiting
224241854|NCT01378975|DRUG|Vemurafenib|960 mg oral doses twice daily until disease progression, unacceptable toxicity or consent withdrawal.
224241855|NCT06640192|DRUG|Standardised triple antiretroviral therapy|patients have to use Triple therapy antiretroviral drugs on their usual regimen containing an integrase inhibitor. There are many types of drugs within this group, so they are not specified.
224241856|NCT06640192|DRUG|High doses Triple therapy antiretroviral drugs|dolutegravir 50 mg/12 h, maraviroc 300 mg/12 h and lamivudine 300 mg/12 h
224241857|NCT04663152|BEHAVIORAL|INSTACARE|CHWs will provide participants with support via phone calls, home-visits, and accompaniment to clinic visits to improve medication management and HIV viral suppression. CHWs will contact participants at least once per week for three months.
223661533|NCT07136610|BEHAVIORAL|SMART Tool|The intervention in this implementation study involves (1) integrating the SMART Tool into electronic health records (EPIC), (2) educating all NICU staff (about 850 nurses, lactation consultants, speech-language pathologists, and physicians), and (3) Quality improvement to reinforce learning.
223661534|NCT07136623|DIAGNOSTIC_TEST|Eko CORE 500 phonocardiogram (PCG) recording|Noninvasive acquisition of heart sound (phonocardiogram, PCG) recordings using the FDA (U.S. Food and Drug Administration)-cleared Eko CORE 500 digital stethoscope. At least four 15-second recordings are collected at standard auscultation sites (aortic, pulmonic, tricuspid, mitral). Recordings are used solely for investigational algorithm development and are not used for diagnostic or clinical decision-making.
224241858|NCT05969197|OTHER|Match Play Training|15 participants will be in Match play training group giving the Match play exercise protocol along with warm-up sessions for 6 weeks, measuring values before giving them protocol and after protocol.
224241859|NCT05969197|OTHER|Plyometric Training|15 participants will be in Plyometric training group giving isotonic exercise protocol along with warm-up sessions for 6 weeks, measuring values before giving them protocol and after protocol.
224241860|NCT04659681|DIAGNOSTIC_TEST|PVI Guided fluid management during surgery for (PVI<12) colloid bolus will be given .|PVI probe attached to finger in PVI Group
224241861|NCT04659681|DIAGNOSTIC_TEST|CVP Guided Fluid management during surgery for CVP<10 cms H2O colloid bolus will be given|Placement of central venous catheter
224241862|NCT02281942|BEHAVIORAL|Yoga|
223661535|NCT07136623|DIAGNOSTIC_TEST|Eko CORE 500 three-lead electrocardiogram (ECG) recording|Noninvasive acquisition of three-lead electrocardiogram (ECG) signals using the FDA-cleared Eko CORE 500 digital stethoscope. Recordings are obtained simultaneously with PCG at auscultation sites. Data are used solely for investigational algorithm development and are not intended for diagnostic use.
223661536|NCT06714006|DRUG|PYC-003|A peptide-phosphorodiamidate morpholino oligonucleotide conjugate administered as a single intravenous infusion
223661537|NCT05065411|DRUG|Enobosarm & Abemaciclib Combo|Subjects will receive a combo of Enobosarm \& Abemaciclib
223661538|NCT05065411|DRUG|non-steroidal AI, or steroidal AI (exemestane with or without everolimus) or Fulvestrant|Non-steroidal AI, a steroidal AI (exemestane with or without everolimus), OR fulvestrant
223661539|NCT06719258|DEVICE|MR850|This humidifier will be used straight away for patients whose intubation is expected to last longer than 24 hours.
223661540|NCT06719258|DEVICE|FP950|This humidifier will be used straight away for patients whose intubation is expected to last longer than 24 hours.
223661541|NCT06500273|GENETIC|cemacabtagene ansegedleucel|An allogeneic CAR T cell therapy targeting CD19
224241863|NCT02281942|BEHAVIORAL|Education|
223661542|NCT06500273|DRUG|Fludarabine|Chemotherapy for lymphodepletion
223661543|NCT06500273|DRUG|Cyclophosphamide|Chemotherapy for lymphodepletion
223661544|NCT06500273|DEVICE|Foresight CLARITY™ IUO MRD test, powered by PhasED-Seq™|A diagnostic test intended to identify patients with minimal residual disease at the end of first line treatment for LBCL.
223661545|NCT06888011|BEHAVIORAL|Participants: iAmHealthy|Families will take part in an educational group program with parents and their children. These one-hour meetings will be focused on living healthy lifestyles and engaging in healthy habits as a family and will occur weekly for three months and monthly for three months. Each family will also have the opportunity to receive individual health coaching sessions every other week that will last approximately 30 minutes to address concerns and health behaviors specific to each pair. There will be additional opportunities to demonstrate and apply learned concepts.
223661546|NCT06888011|BEHAVIORAL|Participants: Newsletter|Families assigned to the newsletter control intervention will receive the AAP Healthy Children Newsletter (HealthyChildren.org) every month for six months.
224241864|NCT02097446|DEVICE|Guardix-FL|
224241865|NCT02097446|DEVICE|Interceed|
224241866|NCT02032368|PROCEDURE|transarterial chemoembolization (TACE)|
224241867|NCT03010748|DEVICE|Scheimpflug tomography system (Pentacam) measurement|The Scheimpflug tomography system (Pentacam,Oculus GmbH, Wetzlar, Germany) is a rotating Scheimpflug camera that measures 138,000 true elevation points to compute corneal topography. Patients were asked to blink twice and then look at the fixation device. Image acquisition was a 2-second scan of 50 rotational Scheimpflug images through the corneal sighting point, the point where the ray of light from the fovea to the fixation device crossed the cornea. All measurements were performed just after a blink to minimize the effect of tear film alteration on the data. Acceptable maps had at least 10.0 mm of corneal coverage with no extrapolated data in the central 9.0 mm zone.
224321253|NCT06372574|DRUG|RO7617991|RO7617991 will be administered by intravenous (IV) infusion. Treatment will continue until unacceptable toxicity or loss of clinical benefit as determined by the investigator.
224241868|NCT03947580|OTHER|Use of the Dvectis Single pad|"Change in pain intensity - range of VAS (mm) between Visit 1 and Visit 2 Dvectis Single pads compared to without using a pad."
224241869|NCT03947580|OTHER|Use of the Dvectis Double pad|"Change in pain intensity - range of VAS (mm) between Visit 1 and Visit 2 Dvectis Double pad compared to without using a pad,~* Categorisation of adverse events,~* Categorisation of deficiencies of a medical device in patients enrolled in treatment groups using Dvectis Single and Dvectis Double pad,~* Number of patients with adverse events,~* Number of patients with deficiencies of medical device enrolled in treatment groups using Dvectis Single and Dvectis Double"
224241870|NCT03947580|OTHER|Use of no pad|Description is not needed
224241871|NCT03788265|DEVICE|Lipogems|harvest and inject micro-fragment adipose tissue
224321254|NCT06372574|DRUG|Tocilizumab|Tocilizumab 8 mg/kg IV will be administered to patients when necessary to treat potential cytokine release syndrome (CRS), as described in the protocol.
224321255|NCT04148573|DRUG|NFX88 - 1|3 times a day
224321256|NCT04148573|DRUG|NFX88 - 2|3 times a day
224321257|NCT04148573|DRUG|NFX88 - 3|3 times a day
224321258|NCT04148573|DRUG|PLACEBO - 4|3 times a day
224241872|NCT05985330|OTHER|Measurement of FeNO|Before the first immunotherapy infusion and at the follow-up visit after the 4th course of immunotherapy
224241873|NCT00347503|DRUG|ketorolac 0.4%, bromfenac 0.09%|
223661547|NCT06888011|OTHER|Clinics: Healthy Clinics|Healthy Clinics is a clinic level intervention designed to improve provider office processes using a bundled intervention of provider prompts, skills training and intervention tools implemented with performance feedback. Each clinic receives Healthy Clinics at some point in the intervention.
223661548|NCT02415036|DEVICE|Delcath Hepatic Delivery System|
223661549|NCT02415036|DRUG|Melphalan|
223661550|NCT06883045|OTHER|MyChildCMC app (an app designed to facilitate home monitoring of CMC's health status)|MyChildCMC is an app designed to support remote monitoring of CMC crosscutting symptoms to identify signs of CMC's health deterioration early to change their care early to avoid progression and prevent ED/hospital admissions. The app includes the following features: 1) automated reminders, 2) vital sign/symptom monitoring, 3) real-time feedback system, 4) automated and real-time summary reports with longitudinal graphs, 5) automated alerts to a care coordinator, and 6) clinic dashboard connecting patients to clinics and allowing access to patient data to support care coordination.
223661551|NCT01273753|OTHER|Intradialytic exercise|Patients will exercise using a stationary foot pedal cycle for 20 minutes at the beginning of hemodialysis.
223661552|NCT03064061|DEVICE|Virtual reality|a device with virtual reality is given to the patients with a film of 18 minutes
223661553|NCT07054216|OTHER|Probiotic|Given daily from 14 days of age until 9 months of age
223661554|NCT07054216|DIETARY_SUPPLEMENT|Placebo|Given daily from 14 days of age until 9 months of age
223661555|NCT07051538|DRUG|SHR-1139 Injections|SHR-1139 injections.
223661556|NCT07051538|DRUG|SHR-1139 Injections Placebo|SHR-1139 injections placebo
224241874|NCT01765530|DEVICE|ETT cleaning maneuver|"EndOclear device will be used for ETT cleaning maneuver. This is a commercially available device. It consists of an ETT cleaning apparatus with a flexible central tube and a cleaning device at its distal end. The cleaning device has a mechanically expandable mesh structure which can be adapted to selectively move between a radially-collapsed position and a radially-expanded one. In operation, the collapsed cleaning apparatus is inserted into the ETT through a Y-shaped connector. The device is then expanded by a safety toggle protected trigger mechanism that, when fired, presses the device's smooth silicone disc against the inside surface of the ETT. The cleaning apparatus is then pulled out of the ETT removing mucus deposits and secretions.~We will add endOclear to the standard ICU practice, scheduling the systematic use of the device every 8 hours for the whole intubation period."
224241875|NCT01136538|DRUG|Valacyclovir Hydrochloride|Valacyclovir Hydrochloride Tablets, 1000 mg of Dr. Reddy's Laboratories Limited
223661557|NCT07054385|BEHAVIORAL|Brain CareNotes|The Brain CareNotes mobile telehealth app is used by unpaid caregivers for BPSD management. It includes remote communication with an external human support person-a care coach-as well as features for users to independently perform health-related activities.
223661558|NCT07054385|BEHAVIORAL|Dementia Guide Expert|"Dementia Guide Expert provides education only and no interactive BPSD management support, coaching, assessment, or external response. It contains evidence-based expert information on what dementia is, types, contributing factors, risks, symptoms, stages, diagnosis, tests, treatment, management, communication techniques, and links to resources and support services."
223661559|NCT00695097|DRUG|Rituximab|Rituximab infusion on Day 1 and Day 15
223661560|NCT00695097|DRUG|No Rituximab|No Rituximab
223661561|NCT04948983|OTHER|Decision aid (DA) for breast cancer screening|The online DA for breast cancer screening is a web-based education material to inform women about the benefits and risks associated with the screening. The contents of the DA are: 1) Assessing breast cancer; 2) What is breast cancer screening?; 3) What will happen if I diagnosed with breast cancer?; 4) What is overdiagnosis?; 5) What is false positive?; 6) the statistics of breast cancer screening; 7) Now is my turn, do I want to take it?
223661562|NCT04948983|OTHER|Standarised information for breast cancer screening|Information provided by the Chilean Ministry of Health in regards to access to breast cancer screening (Age, frequency and costs)
224241876|NCT00486083|DRUG|Atomoxetine Hydrochloride|
224241877|NCT00486083|DRUG|Methylphenidate Hydrochloride|
224241878|NCT01882140|OTHER|Electrical Stimulation by Capacitive Field|
224241879|NCT01882140|OTHER|Electrical Stimulation by Capacitive Field Placebo Sham|
224241880|NCT06404307|BEHAVIORAL|Self-administration|patients will self administer their antimicrobial treatment
224241881|NCT05903326|OTHER|Dexmedetomidine|this was an observational study only based on a change of practice
224241882|NCT03991494|DRUG|[14C]-pamiparib|During the treatment phase, pamiparib 60 mg administered orally twice daily
223661563|NCT04020861|DEVICE|Active PBM|To active photobiomodulation therapy (PBMT) the patient will be oriented to lie preferably in prone. The treatment area will be defined according to painful area. In the active group will be used the followings parameters: low-level laser therapy, 808 nm, 4 infrared diodes, 180 mW, 9 J. In the placebo PBMT will be performed a simulation of laser application. The cluster probe will be positioned on painful area during the same time of active PBMT, the equipment will be turned on and set, however the trigger will be not actived and no beam will be applied.
224241883|NCT03375242|DRUG|crizotinib|"XALKORI® Capsule 200 mg／XALKORI® Capsule 250 mg Frequency and duration are according to Package Insert as follows.  The recommended dose schedule of crizotinib is 250 mg taken orally twice daily. Dosing interruption and/or dose reduction may be required based on patients' clinical status. "
224241884|NCT00855556|GENETIC|blood draw|"The blood collection is designed to obtain blood samples as a source of DNA for genotyping and to establish a plasma and serum storage repository for future assays. GCRC nurses will perform all blood draws associated with this study. The following procedures are designed to standardize sample collection:~1. Blood will be collected with the participant in the seated position with the reclining position reserved for those with a history of fainting during blood collection.~2. Participants will be instructed to drink plenty of water (e.g., at least 8 large glasses of water) prior to the clinic visit as this facilitates easier collection.~3. No fasting, activity or medication restrictions are required prior to or following blood collection.~4. Blood collection will follow completion of the questionnaires. They will be performed by a nurse or technician with documented class time and experience in phlebotomy. Technician certification will occur prior to blood collection."
224241885|NCT01170442|DRUG|vitamin D3 2000 IU|vitamin D3 2000 IU orally, daily for 6 months
223661564|NCT04020861|DEVICE|Active TENS|To active transcutaneous electrical nerve stimulation (TENS) the patient will be oriented to lie preferably in prone. Two or four electrodes standard square self-adhesive electrodes (5 × 5 cm2) will be positioned according to the painful area related by patient. It will be used the following parameters: frequency of 100 Hz, pulse duration of 125 µs (positive phase), 30 minutes of current stimulation and the pulse amplitude will be increased until the patient reports a strong but comfortable paresthesia (including motor level stimulation but no painful TENS). The amplitude will be adjusted (if necessary) each 5 minutes to keep a strong but comfortable paresthesia.
223661565|NCT04020861|DEVICE|Placebo PBM|In the placebo PBMT will be performed a simulation of laser application. The cluster probe will be positioned on painful area during the same time of active PBMT, the equipment will be turned on and set, however the trigger will be not actived and no beam will be applied.
223769536|NCT07025239|DRUG|Bevacizumab|Bevacizumab will be administered by IV infusion at 7.5mg/kg on Day 1 of each 21-day cycle until disease progression (PD), intolerable toxicity, initiation of a new anti-tumor therapy, death, withdrawal of informed consent, loss to follow-up or other conditions requiring termination of the treatment (whichever occurs first). The administration of Bevacizumab lasts for up to 2 years.
223769537|NCT07025239|DRUG|Oxaliplatin|Oxaliplatin will be administered by IV infusion at 130 mg/m2 on Day 1 of each 21-day cycle up to 8 treatment cycles.
223769538|NCT07025239|DRUG|Capecitabine|Capecitabine will be administered orally at 1000 mg/m2 twice daily for 2 consecutive weeks, followed by one-week rest in each 21-day cycle until disease progression (PD), intolerable toxicity, initiation of a new anti-tumor therapy, death, withdrawal of informed consent, loss to follow-up or other conditions requiring termination of the treatment (whichever occurs first). The administration of Capecitabine lasts for up to 2 years.
223769539|NCT07025239|DRUG|Placebo|Placebo will be administered by IV infusion at 5mg/kg on Day 1 of each 21-day cycle until disease progression (PD), intolerable toxicity, initiation of a new anti-tumor therapy, death, withdrawal of informed consent, loss to follow-up or other conditions requiring termination of the treatment (whichever occurs first). The administration of Placebo lasts for up to 2 years.
223769540|NCT07025512|DRUG|177Lu-PSMA-617|Given by IV
223769541|NCT07032298|DRUG|SSGJ-612|Intravenous injection
223769542|NCT07038902|DEVICE|Group A: Modified Miniscrew-Assisted Rapid Palatal Expander (MARPE)|A skeletal anchorage-supported with miniscrews inserted into the palate using a self-drilling technique.
223769543|NCT07038902|DEVICE|Group B: Modified Rapid Palatal Expander (RPE)|A tooth-borne anchorage focusing on molar distalization .
223769544|NCT06884423|DEVICE|FETO with GoldBAL2 Balloon and BALTACCIBDPE100 Catheter|Fetoscopic Endoluminal Tracheal Occlusion (FETO) in CDH with GoldBAL2 Detachable Balloon and BALTACCIBDPE100 Delivery Catheter
223769545|NCT03108248|DRUG|ethiodized oil; doxorubicin;Gelfoam;|Conventional TACE was performed in both groups as follows. First, multiple angiographies were performed to detect the hepatic arterial anatomy and the possible feeding arteries of tumor, selective catheterization of the artery feeding the tumors was performed. A mixture of ethiodized oil was injected, followed by injection of Gelfoam particles.
223769546|NCT03108248|DEVICE|stent; idoine-125|In the ISP-TACE group, stent placement was performed one week before TACE. Under fluoroscopic and ultrasonic guidance, the outer stent was firstly placed at the site of the obstructed portal vein, and a self-expandable nitinol stent was immediately followed through a same 10-F sheath.
223769547|NCT07049081|BIOLOGICAL|LUCAR-G79 T cells|Prior to infusion of the LUCAR-G79 T cells, subjects will receive a conditioning premedication regimen consisting of cyclophosphamide and fludarabine.
223769548|NCT06771843|BEHAVIORAL|Kisoboka|"Intervention activities:~Financial goal setting (developing delayed rewards), Text message reminders of savings goals (increase salience of delayed rewards), Substance-free activities (alternative reinforcers), Mobile money savings and work payments (constraints on buying alcohol), Social support \& role models for financial goals and substance-free activities (delayed rewards, alternative reinforcers), Financial literacy, Develop motivation \& confidence for change, Goal setting for alcohol reduction \& ART adherence, Alcohol harms \& defining low risk drinking Discuss challenges to change and maintain alcohol risk reduction and improved adherence, Developing \& reinforcing discrepancy between savings/life goals and drinking/poor adherence, Developing discrepancy activity: goals for savings and healthy living and weekly, monthly, yearly spending on alcohol Self-monitoring of savings \& spending Text message reminders to reinforce discrepancy between unhealthy behavior \& goals"
224241886|NCT01170442|DRUG|vitamin D3 5000 IU|vitamin D3 5000 IU orally, daily for 6 months
224241887|NCT01170442|DRUG|Placebo|placebo orally, daily for six months
224241888|NCT02141256|DIETARY_SUPPLEMENT|Protein enriched products|Newly developed products with extra protein. Specially developed for elderly.
224241889|NCT02924038|BIOLOGICAL|IMA950|IMA950 vaccine
224241890|NCT02924038|BIOLOGICAL|poly-ICLC|poly-ICLC vaccine
224241891|NCT02924038|BIOLOGICAL|Varlilumab|Intravenous solution
224241892|NCT02836847|PROCEDURE|biological test|mutation and signal pathway activation status analysis
224241893|NCT02836847|DRUG|GEMOX|Conventional chemotherapy:gemcitabine and oxaliplatin
224241894|NCT02836847|DRUG|Cetuximab|
224241895|NCT02836847|DRUG|Trastuzumab|
224241896|NCT02836847|DRUG|Gefitinib|
224241897|NCT02836847|DRUG|Lapatinib|
224241898|NCT02836847|DRUG|Everolimus|
224241899|NCT02836847|DRUG|Sorafenib|
224241900|NCT02836847|DRUG|Crizotinib|
224241901|NCT00218205|DRUG|Epirubicin|
224241902|NCT00218205|DRUG|Estramustine Phosphate|
224241903|NCT00218205|DRUG|Celecoxib|
224241904|NCT03202277|BEHAVIORAL|BeWell24 smartphone app|This app delivers an evidence-based suite of lifestyle interventions targeting behavior change in sleep, sedentary behavior, physical activity, and dietary intake. The app connects with a commercially available activity monitor to provide real-time feedback on behaviors over time.
224241905|NCT03202277|BEHAVIORAL|Health education app|This app delivers basic health education and hygiene content related to sleep, sedentary behavior, physical activity, and dietary intake.
224241906|NCT05752994|OTHER|Training in the multisensory room environment|The children will start with the swing follow with the scheduled activities and tabletop activity. The session will end in the relaxation room such as bubble tube, fiberoptic cascade, fiberoptic carpet and aurora projector bundle while the therapist has the interactive communication with children
224241907|NCT05752994|OTHER|Home program|Home program
223661566|NCT04020861|DEVICE|Placebo TENS|To placebo transcutaneous electrical nerve stimulation (TENS) Two or four electrodes standard square self-adhesive electrodes (5 × 5 cm2) will be positioned according to the painful area related by patient. This device was customized to deliver a current for 30 seconds (both channels) and then ramp off over the next 15 seconds so that it will be active for a total of 45 seconds. This will permit the patient to fell the TENS sensation while applying the settings.
223661567|NCT03103477|OTHER|Urine stability|This study is proposing to assess PAF and PAF-AH activity in urine after using various handling methods of the urine specimen. Better understanding of PAF stability will allow for better design of future experiments involving PAF in interstitial cystitis patients.
223661568|NCT06750536|DEVICE|MiniLung petite kit combined with the Xenios console|Veno-venous (VV) and veno-arterial (VA) Extracorporeal Membrane Oxygenation (ECMO) treatment will be performed using the MiniLung petite kit combined with the Xenios console according to their intended use and local standards/requirements.
223661569|NCT04994808|DRUG|Clofarabine|Given IV
223769549|NCT06771843|BEHAVIORAL|Behavioral Economics|"Intervention activities:~Financial goal setting (developing delayed rewards), Text message reminders of savings goals (increase salience of delayed rewards), Substance free activities (alternative reinforcers), Mobile money savings and work payments (constraints on buying alcohol/ decrease reward value of alcohol), Social support \& role models for financial goals and substance free activities (delayed rewards, alternative reinforcers), Financial literacy"
223661570|NCT04994808|DRUG|Fludarabine|Given IV
223661571|NCT04994808|PROCEDURE|Hematopoietic Cell Transplantation|Undergo HCT
223661572|NCT04994808|RADIATION|Total-Body Irradiation|Undergo TBI
223661573|NCT04994808|DRUG|Treosulfan|Given IV
223661574|NCT04994808|PROCEDURE|Echocardiography Test|Undergo ECHO
223769550|NCT06771843|BEHAVIORAL|Motivational Interviewing|"Intervention activities:~Develop motivation and confidence for change, Specific goal setting for alcohol reduction and ART adherence, Alcohol harms \& defining low risk drinking, Discuss challenges to change and to maintain alcohol risk reduction and improved adherence/care engagement"
223769551|NCT06771843|BEHAVIORAL|Screening and Referral|"Brief feedback on their Alcohol Use Disorders Identification Test (AUDIT) score per the AUDIT brief intervention manual, a referral for alcohol counseling, and brief guidance on the importance of HIV care engagement and adherence following the Ugandan Ministry of Health protocol. A referral coupon with details of the clinic name and location will be provided to each participant and participants will be asked to submit the referral note to the alcohol and/or HIV counselor."
223769552|NCT07065851|DEVICE|Extracorporeal Shock Wave Therapy (ESWT)|Non-invasive therapy delivering high-energy shock waves to stimulate healing in musculoskeletal tissues, targeting the hamstring muscles and related structures, administered 2 times per week for 4 weeks, alongside core exercises.
223661575|NCT04994808|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
223661576|NCT04994808|PROCEDURE|Lumbar Puncture|Undergo lumbar puncture
223769553|NCT07065851|BEHAVIORAL|Exercise Program|Structured exercises focusing on hamstring flexibility, lumbar stabilization, and core exercises, administered 3 times per week for 3 weeks, with sessions lasting 30-45 minutes.
224241908|NCT03859466|DEVICE|Shockwave Therapy|The cardiac shockwave system consists of a table-top device (Nonvasiv Medical GmbH, Konstanz, Germany) and a sterile single-use applicator releasing electrohydraulic shockwaves (Heart Regeneration Technologies GmbH, Innsbruck, Austria). Prior to use, the applicator is inserted into a sterile cover containing ultrasound gel. In order to ensure acoustic coupling between the applicator and the myocardium, continuous saline rinsing is applied throughout the procedure.
224241909|NCT03619408|DRUG|Antacids|Omeprazole 1 mg/kg/dose BID or Omeprazole 1mg/kg/dose BID plus Ranitidine 3 mg/kg/dose BID
224241910|NCT01231490|DRUG|Placebo|Placebo
223661577|NCT04994808|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
223661578|NCT04994808|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
223661579|NCT04994808|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
223661580|NCT06882356|DEVICE|AI-based glaucoma screening|AI analysis of fundus photographs to detect signs of glaucoma, added to AI-based diabetic eye disease screening performed for routine clinical care
223661581|NCT06882356|DEVICE|IOP measurement|Intraocular pressure measurement by Icare tonometer
223661582|NCT06882356|DEVICE|Virtual Reality Visual Field Testing|Virtual Reality Visual Field Testing by the Olleyes device for participants suspected of having glaucoma
223661583|NCT06756113|BEHAVIORAL|Digital Dyadic Empowerment|"The Digital Dyadic Empowerment Intervention utilizes LINE, a prominent instant messaging App in Taiwan, integrated with an extended application to deliver comprehensive lifestyle modification support to Chronic Kidney Disease (CKD) dyads. Key features of this intervention include:~1. Access to CKD Health Education Information;~2. Supportive Information for Significant Others;~3. Physiological Values Logging for Self-Monitoring;~4. Reminders for Clinical Appointments and Daily Self-Management Tasks;~5. Kidney Health Diary for Lifestyle Modification Progress Tracking;~6. Frequently Asked Questions (FAQs) and Consultation with Healthcare Providers.~This intervention aims to enhance the overall well-being of CKD dyads by promoting education, self-monitoring, adherence to appointments, and efficient communication with healthcare providers."
223661584|NCT06756113|BEHAVIORAL|Usual Care|All patients in this study received regular nephrology care at National Cheng Kung University Hospital. Nephrologists conducted routine examinations and provided diagnoses based on test results. The patient's condition (e.g., changes in kidney function), treatment plan, prognosis, and risks were explained to both the patient and family members. The treatment plan included medication, monitoring blood pressure, dietary and exercise at home, and consultations with the Health Education Center for kidney care or nutrition advice.
223661585|NCT06763939|OTHER|RT00401-GO0046|Cosmetic care product
223661586|NCT06763939|OTHER|RT00401-GA0677|Placebo cosmetic care product
223661587|NCT07060508|BIOLOGICAL|Single dose of 1800 mg L9LS SC|A human monoclonal antibody to protect against Plasmodium falciparum.
223661588|NCT07060508|OTHER|Placebo|Normal saline
223661589|NCT07060209|DRUG|DW-1021|A fixed-dose combination controlled release film-coated tablet containing pelubiprofen 45 mg and tramadol 45.9 mg (salt form), administered as a single oral dose under fasting and fed conditions in a two-period, two-sequence crossover design. Each subject receives the intervention once under each condition with a 14-day washout period.
224241911|NCT01231490|DRUG|Naproxen|Capsule
223661590|NCT06758245|PROCEDURE|femoral and anterior sciatic nerve block|First, in the supine position, the USG probe is placed below the inguinal crease. The femoral nerve is located lateral to the femoral artery, above the iliopsoas muscle. Once the needle tip reaches the nerve, simultaneous nerve stimulation is applied. Patellar movement is observed due to quadriceps muscle contraction upon needle placement. After a negative aspiration test, 20 ml of local anesthetic is injected.For the anterior sciatic block, while the patient was in the supine position, a convex ultrasound (USG) probe was placed transversely approximately 10 cm distal to the inguinal ligament. After visualizing the sciatic nerve as a hyperechoic flat structure, the nerve stimulator was set to 1-1.5 mA, 0.1 ms, and 1 Hz. Using an in-plane technique, the block needle was advanced. Upon reaching the sciatic nerve, when contractions in the calf, foot, or big toe continued at a current of 0.3-0.5 mA, 20 ml of 0.5% bupivacaine was administered following a negative aspiration test.
223661591|NCT06758245|PROCEDURE|femoral and popliteal sciatic nerve block|The ultrasound probe is placed transversely at the popliteal crease. The first structure seen is the popliteal artery. Just above and lateral to the artery, the tibial nerve appears as a hyperechoic, oval, and round structure. After identifying the tibial and peroneal nerves, the probe is moved proximally, and it is observed that the nerves join about 5-10 cm above the popliteal crease. The needle is advanced using an in-plane technique. After obtaining the first sciatic nerve stimulation, 20 cc of 0.5% bupivacaine is injected following a negative aspiration test.
223661592|NCT04614324|DEVICE|RhinAer ARC Stylus|The RhinAer procedure incorporates use of the RhinAer Stylus (Model FG815), which is a cleared (FDA - K192471) disposable handheld device capable of delivering bipolar radiofrequency energy to tissue. RhinAer has CE Marking in EU. The Aerin Console (Model FG226) RF generator with temperature control capable of delivering very low doses of energy was cleared for use in the US (FDA - K162810) and has CE Marking in the EU (CE639608).
223661593|NCT06759350|DIETARY_SUPPLEMENT|Soy isoflavone supplement|2 capsules containing 10 mg natural tocotrienols, 40 mg soy isoflavonoids, 540 mg calcium, vitamin D IU.
223661594|NCT06759350|OTHER|Control (placebo) group|2 placebo capsules containing a multivitamin compound.
223661595|NCT06571773|PROCEDURE|intraoperative implantation of Capsular Tension Ring|The Capsular Tension Ring(ACPi-11; Bausch + Lomb, Rochester, New York, USA) is a device made of PMMA with blunt-tipped eyelets at its ends. It can be inserted at any point during cataract surgery, following the creation of a strong anterior capsulotomy via capsulorhexis
223661596|NCT06571773|PROCEDURE|none intraoperative implantation of CTR|the surgeon did a surgery without the intraoperative implantation of CTR
223661597|NCT06734065|BEHAVIORAL|ReDS-guided heart failure management program|"Remote dielectric sensing (ReDS) system (Sensible Medical Innovations Ltd., Netanya, Israel) is a novel electromagnetic energy-based technology that accurately quantifies changes in lung fluid concentration non-invasively.~Patients in the intervention group will receive a three-month, ReDS-guided heart failure management program in addition to usual care.~The program, led by nurses, will integrate algorithms for diuretic use, a structured follow-up schedule, and self-care support tailored to pulmonary fluid levels assessed by ReDS."
223661598|NCT05289037|DRUG|AS03|AS03 oil-in-water emulsion adjuvant.
223661599|NCT05289037|BIOLOGICAL|BNT162b2|A nucleoside-modified messenger RNA (modRNA) encoding the viral spike glycoprotein (S) of SARS-CoV-2.
223661600|NCT05289037|BIOLOGICAL|BNT162b2 (B.1.1.529)|A preservative-free, sterile dispersion of RNA formulated in LNP in aqueous cryoprotectant buffer contains mRNA that encodes for the prefusion stabilized S protein of the B.1.1.529 (Omicron) variant SARS-CoV-2 strain.
223661601|NCT05289037|BIOLOGICAL|BNT162b2 (B.1.351)|A preservative-free, sterile dispersion of RNA formulated in LNP in aqueous cryoprotectant buffer contains mRNA that encodes for the prefusion stabilized S protein of the B.1.351 (Beta) variant SARS-CoV-2 strain.
223661602|NCT05289037|BIOLOGICAL|BNT162b2 bivalent (wildtype and Omicron BA.1)|A preservative-free, sterile dispersion of RNA formulated in LNP in aqueous cryoprotectant buffer. Contains mRNA that encodes for the prefusion stabilized S protein of the Omicron BA.1 variant SARS-CoV-2 strain and the ancestral strain of SARS-CoV-2.
223661603|NCT05289037|BIOLOGICAL|BNT162b2 bivalent (wildtype and Omicron BA.4/BA.5)|A preservative-free, sterile dispersion of RNA formulated in LNP in aqueous cryoprotectant buffer. Contains mRNA that encodes for the prefusion stabilized S protein of the Omicron BA.4/BA.5 variant SARS-CoV-2 strain and the ancestral strain of SARS-CoV-2.
223661604|NCT05289037|BIOLOGICAL|CoV2 preS dTM [B.1.351]|Is a liquid formulation made of recombinant protein placed in a formulation buffer that contains the spike protein sequence of the B.1.351 (Beta) variant SARS-CoV-2 strain.
223661605|NCT05289037|BIOLOGICAL|CoV2 preS dTM/D614|Is a liquid formulation made of recombinant protein placed in a formulation buffer. The antigen solution contains the spike protein sequence of the ancestral strain of SARS-CoV-2.
223661606|NCT05289037|BIOLOGICAL|CoV2 preS dTM/D614+B.1.351|Is a liquid formulation made of recombinant protein placed in a formulation buffer contains the spike protein sequences of the ancestral and B.1.351 (Beta) variant SARS-CoV-2 strains
223661607|NCT05289037|BIOLOGICAL|mRNA-1273|Lipid nanoparticle (LNP) dispersion containing an mRNA that encodes for the prefusion stabilized spike (S) protein of the 2019 novel coronavirus (2019-nCoV).
223661608|NCT05289037|BIOLOGICAL|mRNA-1273.351|Lipid nanoparticle (LNP) dispersion containing an mRNA that encodes for the pre fusion stabilized spike (S) protein of the B.1.351 variant SARS-CoV-2 strain.
223661609|NCT05289037|BIOLOGICAL|mRNA-1273.529|Lipid nanoparticle (LNP) dispersion containing an mRNA that encodes for the prefusion stabilized S protein of the B.1.1.529 (Omicron) variant SARS-CoV-2 strain.
223661610|NCT05289037|BIOLOGICAL|mRNA-1273.617.2|Lipid nanoparticle (LNP) dispersion containing an mRNA that encodes for the prefusion stabilized S protein of the B.1.617.2 (Delta) variant SARS-CoV-2 strain.
223661611|NCT05289037|OTHER|Sodium Chloride, 0.9%|0.9% Sodium Chloride Injection
223661612|NCT06247995|DRUG|[68Ga]Ga-NeoB|68Ga\]Ga-NeoB serves as a radioactive imaging compound to be used for PET imaging for localization of GRPR positive lesions.
223769554|NCT06336343|DRUG|Bimekizumab|Bimekizumab 320 mg via subcutaneous injections. Bimekizumab is a humanized immunoglobulin G1 monoclonal antibody that selectively binds to and neutralizes the biologic functions of both interleukin-17A (IL-17A) and IL-17F, which are known to increase inflammation.
223769555|NCT06761131|DRUG|Linezolid (LZD)|compare the incidence and magnitude of Linezolid induced thrombocytopenia
223769556|NCT03865472|OTHER|Questionnaire Administration|Ancillary studies
223769557|NCT03865472|PROCEDURE|Repetitive Transcranial Magnetic Stimulation|Undergo rTMS
223769558|NCT03865472|PROCEDURE|Sham Intervention|Undergo sham rTMS
223661613|NCT06247995|DRUG|[177Lu]Lu-NeoB|\[177Lu\]Lu-NeoB is a radioligand therapy drug.
223661614|NCT06247995|DRUG|Capecitabine|Capecitabine is a chemotherapy drug.
223661615|NCT06250582|OTHER|virtual reality therapy|A virtual reality therapy will be applied for 30 minutes. Patients will be wearing the glasses while lying in bed/chair during their regular dialysis session. Vital signs will be monitored repeatedly. At defined times, patients are asked to answer various questionnaires about their physical and mental health.
223661616|NCT05110937|OTHER|Blood sampling|Blood sampling
223661617|NCT07070661|DEVICE|Fixed-Dose Radial Pressure Wave Therapy.|Radial pressure wave therapy will be delivered using the BTL-6000 device. Parameters such as frequency and pressure will remain constant throughout each session. Each participant will receive one session per week for three weeks. The treatment will follow a standardized protocol previously established in the literature and based on patient tolerance.
223661618|NCT07070661|DEVICE|Modulated-Dose Radial Pressure Wave Therapy.|The BTL-6000 device will be used to deliver therapy with dynamic modulation of frequency and/or pressure within each session, following a structured protocol aiming to optimize clinical response.
223661619|NCT06806982|DRUG|VRN101099|Oral capsules
223661620|NCT06751810|DIETARY_SUPPLEMENT|Food supplement|"The nutritional composition of the food supplement comprises:~sodium butyrate, inactivated Lactobacillus rhamnosus GG Perilla frutescens dry extract quercetin fructo-oligosaccharides Vitamin D3 omega 3 polyunsaturated acids sorbitol sucralose silicon dioxide aroma"
223661621|NCT06751810|OTHER|Placebo|Placebo
223661622|NCT07073157|DRUG|HRS-8427 injection plus furosemide|HRS-8427 injection plus furosemide
223661623|NCT07073157|DRUG|HRS-8427 injection plus metformin|HRS-8427 injection plus metformin
223661624|NCT06141473|DRUG|Frexalimab|SAR441344 Solution for IV infusion
223661625|NCT06141473|DRUG|Teriflunomide|Aubagio oral tablet
223661626|NCT06141473|DRUG|Placebo infusion|Solution for IV infusion
223661627|NCT06141473|DRUG|Placebo tablet|Oral tablet
223661628|NCT06141473|DRUG|MRI contrast-enhancing agents|IV, as per respective label
223661629|NCT06141473|DRUG|Cholestyramine|oral, 8 g 3 times daily for 11 days for accelerated elimination procedure (4 g 3 times daily for 11 days in case of intolerance). The teriflunomide local label should be followed.
223661630|NCT06141473|DRUG|Activated charcoal|oral, 50 g every 12 hours for 11 days for accelerated elimination procedure. The teriflunomide local label should be followed.
223661631|NCT05970978|DRUG|regular treatment|IBI112 200mg s.c. at week 0, 12, 24 and 36.
223661632|NCT05970978|DRUG|Intensive treatment|IBI112 200mg s.c. at week 0, 4, 8, 20 and 32.
223661633|NCT05554354|DRUG|Binimetinib|Given PO
223661634|NCT05554354|PROCEDURE|Biopsy Procedure|Undergo tumor biopsy
223661635|NCT05554354|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223661636|NCT05554354|PROCEDURE|Bone Scan|Undergo bone scan
223661637|NCT05554354|PROCEDURE|Computed Tomography|Undergo CT scan
223661638|NCT05554354|PROCEDURE|Echocardiography Test|Undergo ECHO
223661639|NCT05554354|DRUG|Fulvestrant|Given IM
223661640|NCT05554354|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223661641|NCT05554354|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
223661642|NCT06660979|BEHAVIORAL|Reinforcement learning|The intervention is a reinforcement learning program that personalizes EHR-based tools for PCPs to promote deprescribing high-risk medications over follow-up. The reinforcement learning intervention selects a tool for each provider based on an algorithm from an inventory of EHR tools and chooses tools that are predicted to motivate action for the individual provider. The inventory of EHR tools from which the algorithm will choose include the following potential factors: open encounter, order entry, cold-state outreach, simplification, and risk framing.
223661643|NCT06811363|OTHER|Metabolic / prescribed diet|Instructed diet (400 mg Ca, 800 mg P, 100 mEq Na) and two liters of distilled water daily for three days (equilibration period), followed by a constant standardized meal with the same composition of Ca, P, and Na for one day. After 240hr urine sample collection patient fasted the preceding evening except for 300 ml of distilled water at 9 pm and 11 pm. On test days, 600 ml distilled water given and fasting blood obtained.
223661644|NCT06811363|OTHER|KCit Load (40 meq)|Potassium citrate load of 40meq will be given after fasting blood has been obtained
223661645|NCT06811363|DRUG|Anti-resorptive agents|Zoledronic acid or Denosumab (as prescribed by their physician)
223769559|NCT07079254|PROCEDURE|Meniscus suture|The meniscus bucket-handle injury will either be treated with meniscus suture or partial meniscectomy
223769560|NCT07079254|PROCEDURE|Partial meniscectomy|The meniscus bucket-handle injury wil be treated with either meniscus suture or partial meniscectomy
223661646|NCT06811363|DRUG|Anabolic Agents|Romosozumab (as prescribed by their physician)
223661647|NCT06568484|DRUG|Bedaquiline|"CCs (Close Contacts) of DS-TB Index Patients and PLHIV at high risk of developing TBD~1. Children 0 to \<5 years old who are HIV negative, regardless of latent tuberculosis infection (LTBI) result by TST (tuberculin skin test) or IGRA (interferon-gamma release assay)~2. Adults, pregnant people, adolescents, and children ≥5 years old who are HIV negative and LTBI positive (by IGRA)~3. Adults and adolescents ≥15 years of age who are living with HIV regardless of LTBI status, regardless of whether the participant is a CC~CCs of RR-TB Index Patients at high risk of developing TBD~1. Children 0 to \<5 years old, regardless of HIV status or LTBI result (by TST or IGRA)~2. Adults, adolescents, and children ≥5 years old who are HIV negative and LTBI positive (by IGRA)~3. Adults, pregnant people, adolescents, and children ≥5 years old who are living with HIV regardless of LTBI status~Bedaquiline based on weight and/or age at Enrollment daily for four weeks (28 doses)"
223661648|NCT06568484|COMBINATION_PRODUCT|Isoniazid, rifapentine|"CCs of DS-TB Index Patients and PLHIV at high risk of developing TBD~1. Children 0 to \<5 years old who are HIV status negative, regardless of latent tuberculosis infection (LTBI) result (tuberculin skin test \[TST\] or interferon-gamma release assay \[IGRA\])~2. Adults, pregnant people, adolescents, and children ≥5 years old who are HIV status negative and LTBI positive (by IGRA)~3. Adults and adolescents ≥15 years of age who are living with HIV regardless of LTBI status, regardless of whether the participant is a CC~3HP: 3 months of weekly isoniazid (H) and rifapentine (P) (12 doses)~1HP: 1 month of daily isoniazid (H) and rifapentine (P) (28 doses)"
223769561|NCT06596252|DRUG|Budesonide|Twice daily intake of the tablet 30 min after a meal
223661649|NCT06568484|DRUG|Levofloxacin|"CCs of RR-TB Index Patients at high risk of developing TBD~1. Children 0 to \<5 years old, regardless of HIV status or LTBI result (by TST or IGRA)~2. Adults, adolescents, and children ≥5 years old who are HIV status negative and LTBI positive (by IGRA)~3. Adults, pregnant people, adolescents, and children ≥5 years old who are living with HIV regardless of LTBI status~Levofloxacin (LFX) based on weight at Enrollment daily for 6 months (182 doses)"
223661650|NCT06930768|OTHER|Standard of Care|Wound cleansing, Sharps debridement, Dressing for moisture balance, Offloading
223661651|NCT06930768|OTHER|NeoThelium FT|NeoThelium FT is a dehydrated wound covering derived from donated human placental tissue. NeoThelium FT is a dual-layer membrane with amnion and chorion combination layers.
223661652|NCT06195631|BEHAVIORAL|Standardized Checklist for Optimizing Procedural Ergonomics in Endoscopy (SCOPE- E) Bundle|The SCOPE-E bundle is a multicomponent intervention designed to improve endoscopy ergonomics. The bundle is composed of one core intervention and 5 evidence-based implementation strategies which are defined as methods to enhance the adoption, implementation and sustainment of the core intervention. The core intervention is a pre-endoscopy ergonomic time-out checklist. The implementation strategies are endoscopist education, checklist documentation, visual reminders, nursing engagement and leadership support.
223661653|NCT05138068|DRUG|MDMA|Two 8-hour experimental sessions will occur within the 11-session intervention in which participants will take a dose of MDMA. In the first Experimental Session, the initial dose will be 80 mg MDMA, with a supplemental dose of 40 mg 1.5 to 2 hours later unless contraindicated. In the second Experimental Session, the initial dose may be increased to 120 mg MDMA unless contraindicated with an additional dose of 40 mg 1.5 to 2 hours after the initial dose is given unless contraindicated.
223661654|NCT05138068|BEHAVIORAL|Psychotherapy|Adjunctive, manualized psychotherapy will be provided by a team of two therapists during the MDMA-assisted therapy sessions
223661655|NCT04453085|DRUG|JR-171|Intravenous (IV) infusion
223661656|NCT05811897|BEHAVIORAL|Self-Managed Online Treatment|"Self-help online cognitive-behavioural therapy focusing on post-traumatic stress, sleep and mood. The content is divided into three modules :~* Coping with my trauma: psychoeducation about PTSD, cognitive restructuring prolonged exposure to avoided situations and memories (14 sessions)~* Sleeping better: psychoeducation about, sleep management strategies (restriction of time in bed, stimulus control, sleep hygiene education), Imagery Rehearsal Therapy (10 sessions)~* Improving my mood: psychoeducation about depression, behavioural activation; relaxation and mindfulness exercises; problem-solving strategies (6 sessions)~A small portion of material is unlocked each week, and access to one module will be accessible after the completion of a previous one. Access to the online material will be unlimited in time. Participants complete self-report questionnaires after each module, the platform then provides feedback and suggests corresponding modules."
223661657|NCT05811897|BEHAVIORAL|Therapist-Assisted Online Treatment|Same online intervention. Supervised graduate psychology students will provide brief regular weekly contacts for up to 30 weeks by video chat or phone, according to the participant's preference.
223661658|NCT04791540|DIAGNOSTIC_TEST|handgrip strenght|Muscle strenght measured with a handheld dynamometer, at admission (T0) and at decannulation time (T1)
223661659|NCT04791540|DIAGNOSTIC_TEST|Bioelectrical Impedance Analysis (BIA)|Muscle mass evaluated by Bioelectrical Impedance Analysis (BIA), at admission (T0) and at decannulation time (T1)
223661660|NCT04791540|DIAGNOSTIC_TEST|MUST|Malnutrition risk assessed by Malnutrition Universal Screening Tool (MUST), at admission (T0) and at decannulation time (T1)
223661661|NCT04791540|DIAGNOSTIC_TEST|GLIM|Malnutrition diagnosis performed by Global Leadership Initiative on Malnutrition (GLIM) criteria, at admission (T0) and at decannulation time (T1)
224241912|NCT05343143|DEVICE|NeuraGen 3D Nerve Guide Matrix|Integra NeuraGen 3D Nerve Guide Matrix is a resorbable implant for the repair of peripheral nerve gaps.
223661662|NCT04791540|BIOLOGICAL|Gut microbiota|A fecal sample obtained at admission (T0) and at decannulation time (T1)
223661663|NCT04791540|BIOLOGICAL|Blood Sample|A Blood sample obtained at admission (T0) and at decannulation time (T1)
223661664|NCT04791540|OTHER|Anthropometric measures|Measurement of weight and height (assessed only at admission) to calculate the Body Mass Index (BMI), at admission (T0) and at decannulation time (T1)
223661665|NCT07132736|DEVICE|Hubbard tank|women will perform pelvic floor exercise and core stability exercise under water each session will be for 30 min
223661666|NCT07132736|OTHER|Mat on the ground|women will perform core stability exercise and pelvic floor exercise on the mat for 30 min
223661667|NCT07137754|OTHER|Advanced practice physiotherapy|Physiotherapists undergoing post-graduate education as advanced practice physiotherapists will independently diagnose, manage and discharge patients.
223661668|NCT07137754|OTHER|Usual Care|Nurses and physicians in the emergency department will diagnose, manage and discharge patients as usual
223661669|NCT07137546|PROCEDURE|Fundus-First Laparoscopic Cholecystectomy ( FFLC)|"* Standard 4-port laparoscopic setup~* Carbon dioxide (CO₂) pneumoperitoneum (12-15 mmHg)~* Dissection begins at gallbladder fundus~* Peritoneum incised from infundibulum to fundus along liver bed~* Gallbladder dissected from fundus toward infundibulum~* Cystic artery and duct identified and divided last~* Critical view of safety achieved before vessel division"
223661670|NCT07137546|PROCEDURE|Classical Laparoscopic Cholecystectomy (CLC)|"* Standard 4-port laparoscopic setup~* Carbon dioxide (CO₂) pneumoperitoneum (12-15 mmHg)~* Dissection begins at Calot's triangle~* Critical view of safety achieved first~* Cystic artery and duct divided before gallbladder bed dissection~* Gallbladder dissected from liver bed"
223769562|NCT07086456|DRUG|Surufatinib|Administered orally at 200 mg once daily d1-d14, starting at the initiation of each radiotherapy phase, for 14 consecutive days. Six weeks after completion of concurrent chemoradiotherapy, patients meeting the eligibility criteria will receive consolidation therapy with surufatinib 200 mg orally once daily on Days 1-14 of each 21-day cycle
224241913|NCT03733197|BEHAVIORAL|Culture Specific|We anticipate the culture-specific arm developed minimally will include two core components: barbers as motivational interviewers, and (2) fecal immunochemical test (FIT) kits distributed by barbers. If we choose this route for the culture-specific arm, preliminary data from our barbers suggest I teach the barbers the MI technique using content that stems from Aim 1 findings. Additional components for this arm may be developed during the APEASE process.
224241914|NCT03733197|BEHAVIORAL|Control|the (control) arm will include an informational CRC screening brochure developed by the American Cancer Society plus a FIT kit distributed by the barbers.
223769563|NCT07086456|DRUG|Tislelizumab|200 mg administered via intravenous drip one day prior to the start of each radiotherapy phase. Six weeks after completion of concurrent chemoradiotherapy, patients meeting the eligibility criteria will receive consolidation therapy with tislelizumab 200 mg administered via intravenous drip on Day 1 of each cycle (Q3W), for up to 12 months.
223769564|NCT07086456|DRUG|Concurrent Chemotherapy|Albumin-bound paclitaxel 50 mg/m² plus cisplatin 25 mg/m², administered weekly (QW).
223661671|NCT07094555|BEHAVIORAL|Animal Assisted Practice|The animal-assisted intervention group initiated interaction with a goldfish in a portable aquarium during the preoperative period and accompanied them until they reached the operating room.
224241915|NCT03269409|OTHER|Lactated Ringers|Approximately 5 mls of lactated ringers will be injected after decompression into the hip that does not receive adipose derived regenerative cells.
223661672|NCT07094555|BEHAVIORAL|Kaleidoscope|The kaleidoscope group was distracted with a kaleidoscope during the preoperative period and continued this intervention until they reached the operating room.
223661673|NCT06927713|OTHER|Bloodletting Acupuncture|Bloodletting was applied to the right hand ﬁrst and then the left hand in the order of Shaoshang (LU 11), Shangyang (LI 1), Zhongchong (PC 9), Guanchong (TE 1), Shaochong (HT 9) and Shaoze (SI 1).
223661674|NCT06927713|DEVICE|Transcutaneous electrical stimulation|Transcutaneous electrical acupoint stimulation at hand twelve jing-well points.
223769565|NCT07086456|RADIATION|Radiotherapy|definitive hypofractionated radiotherapy
223769566|NCT07076498|BIOLOGICAL|M032|M032 is a genetically engineered type 1 herpes simplex virus (HSV-1) that has been demonstrated to be aneurovirulent secondary to deletions of both copies of the γ134.5 gene and modified to express human interleukin-12 (IL-12). Each patient will receive a single intratumoral injection of M032.
224241916|NCT03269409|DEVICE|The Celution 800/GP System (Cytori Therapeutics)|The Celution 800/GP System will be used for the preparation of adipose derived regenerative cells from lipoaspirate. The adipose derived regenerative cells will then be transplanted into the hip, post decompression.
224241917|NCT03269409|BIOLOGICAL|Adipose Derived Regenerative Cells (ADRC)|Subjects in this arm will have Adipose Derived Regenerative Cells (ADRC)harvested through autologous liposuction and processed outside the body using The Celution 800/GP System (Cytori Therapeutics) before having approximately 5 mls. of ADRCs transplanted into the femoral head after standard of care hip decompression.
224241918|NCT01008878|BEHAVIORAL|interdisciplinary intervention|
224241919|NCT01108094|DRUG|Itraconazole|"* Cohort A: oral itraconazole 400 mg as 200 mg twice daily; for 1 month~* Cohort B: oral itraconazole 200 mg as 100 mg twice daily; for up to 3 months"
224241920|NCT02683967|PROCEDURE|acupuncture|patients received a Delphi acupuncture at least 3 times during their fertility treatment cycle.
224241921|NCT00633399|DRUG|Ziprasidone|20mg-80mg a day. Dose increases of 20mg per day may occur at three study visits as directed by clinician. Maximum; 80mg per day per patient.
224241922|NCT00633399|DRUG|Placebo|"0mg Placebo per day (1-4 tablets per day). Dose increases and dose decreases may occur, but patient will remain at 0mg placebo."
224241923|NCT01759277|DRUG|Control: Femoral perineural local anesthetic infusion|The control group will receive a femoral nerve block and postoperative ropivacaine 0.2% infusion
224241924|NCT01759277|DRUG|Experimental: Adductor Canal perineural local anesthetic infusion|The control group will receive an adductor canal nerve block and postoperative ropivacaine 0.2% infusion
224241925|NCT02108119|DIETARY_SUPPLEMENT|Probiotics|
224241926|NCT02108119|DIETARY_SUPPLEMENT|Control placebo|
224241927|NCT02452164|OTHER|Teaching|
224241928|NCT02452164|DEVICE|(CellScopeOTO)|
224241929|NCT01137539|DEVICE|Gynecare TVT-SECUR system|All patients in the study will receive the Gynecare TVT-SECUR to treat stress urinary incontinence
224241930|NCT05512442|PROCEDURE|the centric relation|All participants were recorded the centric relation registrations according to the technique of the gothic tracing method and the neuromuscular method separately.
224241931|NCT05187949|OTHER|Mixed-method approach|Quantitative survey (cross-sectional design) and qualitative analysis (focus groups)
223661675|NCT07094113|DRUG|AMG 410|Administered as an oral tablet.
223661676|NCT07094113|DRUG|Pembrolizumab|Administered as an intravenous (IV) infusion.
223661677|NCT07094113|DRUG|Panitumumab|Administered as an IV infusion.
223661678|NCT00336648|DRUG|Avastin (Bevacizumab)|10mg/kg by vein (IV) on Days 1, 2, 15 and 29 the adjuvant therapy every two weeks starting approximately 6 weeks after surgery for three months.
223661679|NCT00336648|DRUG|Gemcitabine|400 mg/m2 IV once a week on Days 1, 2, 8,15, 22, 29, 36 +/-2 days (Saturdays)
223661680|NCT00336648|PROCEDURE|Radiation Therapy|Day 3 +/-2 days (Monday) Start Radiation therapy, Mon -Fri x 28 days; 50.4 Gy prescribed to the 95% isodose at 1.8 Gy/fraction (28 fractions)
223661681|NCT07096024|DRUG|palbociclib plus fulvestrant|Patients treated with the combination of palbociclib and fulvestrant
223661682|NCT07096024|DRUG|fulvestrant|Patients treated with fulvestrant alone
223661683|NCT03838016|BEHAVIORAL|Babble Boot Camp|The Babble Boot Camp is an experimental study to investigate whether earliest and proactive activities and routines can positively influence the speech and language development of children who were diagnosed with classic galactosemia at birth. A speech-language pathologists implements the intervention by teaching parents to foster and expand earliest signals of communication, prespeech activities such as coo and babble, vocabulary growth, sentence complexity, and use of language to communicate. Examples are intentional eye contact, reinforcing babble with rewarding play activities, and repeating a child's rudimentary sentence with slight expansions to scaffold longer sentences.
224241932|NCT03290326|DEVICE|Transcranial Alternating Current Stimulation (tACS)|tACS will be applied at a frequency of 40Hz and targeting the area of maximal tracer uptake on amyloid PET imaging using an individualized multielectrode design to maximize the induced electrical current to the target region.
224241933|NCT05115357|PROCEDURE|Pecto-Intercostal Fascial Block|A high-frequency (7-12 Mhz) linear ultrasound transducer will be placed approximately 2 cm lateral to sternal edge in the 4th or 5th intercostal space. A 22-gauge, 50-mm needle will be inserted in-plane under ultrasound guidance. The needle will be advanced through the pectoralis major muscle, and the drug will be deposited in the pecto-intercostal fascial plane located between the pectoralis major muscle and the external intercostal muscles. The separation of the fascial plane and the spread of the drug could be observed on the ultrasound image .The procedure will be repeated on the other side of sternotomy to achieve bilateral blockade.
224321259|NCT05472246|DEVICE|Wearing a virtual reality headset|VR group will be shown relaxing videos (nature scenes) by wearing a VR headset in addition to the routine anesthesia procedure
224241934|NCT05115357|PROCEDURE|Transversus Thoracis Muscle Plane Block|The ultrasound probe will be placed in the longitudinal plane 1 cm lateral to the sterna border. the T4-T5 intercostal space will be identified under US. A parasternal sagittal view of the internal intercostal muscle and the transverses thoracis muscle between the 4th and 5th rib will be visualized above the pleura. A 22-gauge, 50-mm needle will be inserted inplane until the tip of the needle is located in the transversus thoracis muscle plane between the internal intercostal and transversus thoracis muscles . After excluding intravascular and intrapleural placement, local anesthetic will be administered in 5mL aliquots with intermittent aspiration.
224321260|NCT03296501|BIOLOGICAL|Cell-based therapy of autologous adipose derived regenerative cells transplanted intraspinally and intrathecally in ALS patients|3 injections of ADRC: 1 intraspinal and 2 intrathecal
224321261|NCT06128486|DEVICE|Soft Contact Lens|Vision Correction
224321262|NCT00445432|BIOLOGICAL|adalimumab|Subcutaneous injection of 40 mg adalimumab (0.8 mL/injection) every other week (eow)
224321263|NCT00445432|OTHER|Placebo|Subcutaneous injection of placebo (0.8 mL/injection) every other week (eow)
224321264|NCT00273988|DRUG|nevirapine|
224321265|NCT02291991|DRUG|GX-E2|Investigational drug(GX-E2 or Placebo) will be administered to healthy volunteers by the intravenous route.
224321266|NCT02291991|DRUG|GX-E2|Investigational drug(GX-E2 or Placebo) will be administered to healthy volunteers by the intravenous route.
224321267|NCT00000846|BIOLOGICAL|HIV-1 Peptide Vaccine, Microparticulate Monovalent|
224321268|NCT00000846|BIOLOGICAL|HIV-1 Peptide Immunogen, Multivalent|
224321269|NCT00534950|RADIATION|5 vs 6 weekly fraction of RT|Chemotherapy
224321270|NCT05866965|OTHER|PRF|centrifuge patient's blood to collect 1 block of yellowish condensed fibrin, which is platelet-rich fibrin
224321271|NCT05866965|OTHER|standard third molar surgical removal|standard third molar surgery following surgical protocol of Department of Oral Surgery, University of Medicine and Pharmacy
224241935|NCT06038019|DIAGNOSTIC_TEST|Oral food challenge|Patients will undergo oral food challenge with increasing amounts of food allergen
224241936|NCT00637117|BIOLOGICAL|Autologous dendritic cells generated using GM-CSF, interferon alpha and LPS|Day 1 and Day 2: 2 Gy Radiation on Day 1 and Day 2 to tumor site. Day 4, 8, 11, 18: 0.5mL injection of Autologous dendritic cells generated using GM-CSF, interferon alpha and LPS.
224241937|NCT05086835|OTHER|Working Memory Task|A smartphone-based visual-spatial working memory task that will be optimized in the Stage 1A phase of this study.
224241938|NCT05086835|OTHER|Visual Search Task|A smartphone-based visual search task that will be optimized in the Stage 1A phase of this study.
224241939|NCT03558945|BIOLOGICAL|Personalized neoantigen vaccine|Patients will have complete resection of primary tumor without preoperative chemotherapy. Patients will receive postoperative chemotherapy and subsequently personalized vaccines on days 1, 4, 8, 15, 22 (priming phase) and weeks 12, 20 (boosting phase). Personalized vaccines will consist of several distinct peptides (the dose is 0.3 mg/peptide) that are grouped into 2-4 pools and 0.5 mg of poly-ICLC as the adjuvant for each pool. Injection sites will be 2-4 separate sites of the subject's thighs.
224241940|NCT02833389|DRUG|Placebo|UTTR1147A matching placebo will be administered SC.
224241941|NCT02833389|DRUG|UTTR1147A|UTTR1147A will be administered SC.
224241942|NCT06074289|BEHAVIORAL|Family connections program|Caregivers meet weekly for 90 minute sessions led by two trained psychologists. The program includes six modules: 1. Introduction, 2. Family Education, 3. Relationship Mindfulness Skills, 4. Family Environment Skills, 5. Validation Skills, 6. Problem Management Skills.
224241943|NCT01659580|DRUG|T89 high dose|225mg bid
224241944|NCT01659580|DRUG|T89 Low dose|150mg bid
224241945|NCT01659580|DRUG|Sanqi+Bingpian|225 mg bid
224241946|NCT01659580|DRUG|Placebo|225mg bid
224321272|NCT01288716|DRUG|Arbaclofen|
224241947|NCT01781325|DEVICE|IBEHR|physical therapy device to educate patients in physical therapy exercise performance
224241948|NCT05060926|PROCEDURE|Awake prone positioning|Awake prone position as long as possible according to the patients' tolerance
224241949|NCT05388318|BEHAVIORAL|Prolonged nightly fasting|14 hour nightly fast from caloric food and beverage; followed by 10 hour eating window. 8-week intervention duration.
224241950|NCT05388318|BEHAVIORAL|Health Education Control|Weekly health education video viewing related to general health topics
224241951|NCT04370639|DEVICE|AccuFlow sensor|AccuFlow sensor will be worn and survey completed
224321273|NCT03810716|DEVICE|Interactive Platform|The participants will see the interactive platform.
224321274|NCT06383455|PROCEDURE|Non-surgical periodontal therapy|An ultrasonic device (Cavitron Plus, Dentsply®, Duisburg, Germany) and periodontal hand instruments (periodontal curettes; Chicago, IL) were used for non-surgical periodontal treatment. The treatment procedure also included detailed oral hygiene instructions and full-mouth scaling and root planing. Scaling and root planing (SRP) was applied to all four quadrants under local anesthesia in a single appointment. No medication or mouthwash was prescribed to the patients.
224321275|NCT02827955|DEVICE|Gamma Knife® radiosurgery bilateral|
224321276|NCT06281015|DIAGNOSTIC_TEST|Whole-body bone single photon emission tomography (SPECT) for detection or follow-up of bone metastasis|Cancer patients referred to fast whole-body bone for detection or follow-up of bone metastasis were retrospectively included in this study.
224321277|NCT01818115|DEVICE|Hydrus Implant|
224321278|NCT01818115|PROCEDURE|IOL placement|
224321279|NCT01699815|DRUG|Acetaminophen|
224321280|NCT02779244|PROCEDURE|Early Weight bearing + Cam Boot|Patients will be transitioned to weight bearing as tolerated in a cam boot.
224321281|NCT02779244|PROCEDURE|Non-Weight Bearing + Cam Boot|Subject will be transitioned to non weight bearing cam boot, standard treatment.
224321282|NCT03353701|BEHAVIORAL|Contingency Management (CM)|A reinforcement delivery method that involves financial incentive to participants for sustained alcohol abstinence. CM will start after the participants complete the baseline measures and last for at least 30 days and up to 90 days.
224321283|NCT04168892|DRUG|150 IU of HMG in patients with age ≤ 35 years|The use of a different starting dose, based on the female age, derives from the necessity to control the effect of a variable starting dose on the primary outcome.
224241952|NCT04370639|OTHER|Survey|Patients will be asked to complete a survey regarding device tolerability after completing their cesarean section.
224241953|NCT02994810|OTHER|Breastfeeding guidance|Breastfeeding guidance
223769567|NCT05505188|OTHER|Questionnaire|"Self-questionnaires are completed by the patient at the time of this consultation:~* Neuropathic pain: NPSI in screening~* Anxiety/depression: HADS in screening~* Quality of life: EORTC (QLQC30 and H\&N43)~* Fatigue: MFI-20 hese self-questionnaires will be retrieved by the Clinical Research Associate (CRA) for verification.~Depending on the result of the NPSI questionnaire can be completed to better characterize neuropathic pain.~Depending on the result of the HADS, the MADRS questionnaire can be completed to quantify the degree of depression.~Individuals diagnosed with neuropathic pain or other depressive symptoms during the 6-month inclusion period will be referred to and managed by specialized practitioners. This assistance will be indicated in follow-up report"
224241954|NCT00001018|DRUG|Letrazuril|
224241955|NCT04277390|OTHER|clinical intervention for microbial analysis and MIR155 as biomarker|Subgingival plaque was collected with sterile curette and placental tissue sample(postpartum with surgical blade with the help of gynecologist. all the samples were subjected to RTPCR for analysis of microorganisms likeTannerella forsythia(Tf), Treponema denticola(Td), Porphyromonas gingivalis(Pg), Prevotella intermedia(Pi), Fusobacterium nucleatum(Fn). Herpes Simplex Virus(HSV), Ebstein Barr Virus(EBV), Human Cytomegalovirus(HCMV). and MIR155 levels were also estimated
224241956|NCT00005877|DRUG|rubitecan|
224241957|NCT03422653|DRUG|CR845 0.5 mcg/kg|IV medication delivered three times/week
224241958|NCT03422653|DRUG|Placebo|IV medication delivered three times/week
224241959|NCT03199547|DRUG|Azithromycin|The women will be randomized to receive a single dose of Azithromycin or Placebo
224241960|NCT03199547|DRUG|Placebo Oral Tablet|The women will be randomized to receive a single dose of Azithromycin or Placebo
224241961|NCT02769715|DEVICE|Laser-sintered removable partial denture|The master cast was scanned using 3D scanner. In the digital file, the path of insertion was determined using a special software. The survey line was drawn and all undesirable undercuts were eliminated. After that, the entire framework design was built virtually 3 dimensionally using a special software (3Shape Software) according to the specified design in three steps: deciding the contour of the component, building the tissue surface then creating the polished surface. The file was saved in STL file and was transferred to rapid prototyping machine. Framework was produced by selective laser sintering technique using the alloy powder (Sintech Metal).
224241962|NCT02769715|OTHER|cast removable partial dentures|The denture was fabricated traditionally using lost-wax casting technique.
224241963|NCT05439109|DEVICE|Topographical landmark technique of endotracheal tube placement|An endotracheal tube will be placed inside the trachea after measuring the individual's estimated tracheal dimensions.
224241964|NCT05439109|DEVICE|Intubation guide mark technique of endotracheal tube placement|An endotracheal tube will be placed in this group by using the intubation guide mark.
224241965|NCT00985894|OTHER|Online Teledermatology Care|Patients randomized to the intervention group will have their scheduled follow-up visits online via store and forward teledermatology.
224241966|NCT00985894|OTHER|Conventional in Office Care|Patients randomized to the control group will have their scheduled follow-up visits via conventional in office care.
224241967|NCT03265522|BEHAVIORAL|"ThinkMed resource at baseline"|"The ThinkMed resource contains an information booklet, recipe books, menu plan cards, shopping list cards and goal setting cards. Participants will receive this resource on one occasion at baseline."
224241968|NCT03265522|BEHAVIORAL|Standard Care Control|"Participants will continue with the standard care provided by their physician. Participants will receive the ThinkMed resource after their final 6 month study visit (i.e. delayed intervention)."
224241969|NCT03265522|BEHAVIORAL|"ThinkMed resource (staged)"|"This group of participants will receive the ThinkMed resource at monthly intervals for 5 months accompanied by telephone feedback from the research dietitian"
224241970|NCT01101022|DRUG|SPD489|1 capsule per day (30, 50 or 70 mg), daily throughout the double-blind treatment period (10 weeks)
224241971|NCT01101022|OTHER|Placebo|1 capsule per day, daily throughout the double-blind treatment period (10 weeks)
224241972|NCT01519661|DRUG|TBM100|Tobramycin inhalation powder was assigned as four capsules at 28mg dosage strength. It was inhaled b.i.d in the morning and in the evening via the T-326 Inhaler.
224241973|NCT01139047|DRUG|metronidazole 1% gel|Apply topically once daily on one side of the face for three weeks
224321284|NCT04168892|DRUG|225 IU of HMG in patients with age > 35 years|The use of a different starting dose, based on the female age, derives from the necessity to control the effect of a variable starting dose on the primary outcome.
224241974|NCT01139047|DRUG|azelaic acid 15% gel|Apply topically twice daily on the opposite side of the face for three weeks
224241975|NCT06504056|BIOLOGICAL|Diagnosis of NVM|The term 'left ventricular non-compaction' (LVNC) has been used to describe a ventricular phenotype characterized by prominent LV trabeculae and deep intertrabecular recesses. The myocardial wall is often thickened with a thin,compacted epicardial layer and a thickened myocardial layer. In some patients, this abnormal trabecular architecture is associated with LV dilatation and systolic dysfunction. Left ventricular non-compaction is frequently a familial trait and is associated with variants in a range of genes, including those encoding proteins of the sarcomere, Z-disc, cytoskeleton, and nuclear envelope.
224241976|NCT06504056|BIOLOGICAL|Diagnosis of NVM|The term 'left ventricular non-compaction' (LVNC) has been used to describe a ventricular phenotype characterized by prominent LV trabeculae and deep intertrabecular recesses. The myocardial wall is often thickened with a thin,compacted epicardial layer and a thickened myocardial layer. In some patients, this abnormal trabecular architecture is associated with LV dilatation and systolic dysfunction. Left ventricular non-compaction is frequently a familial trait and is associated with variants in a range of genes, including those encoding proteins of the sarcomere, Z-disc, cytoskeleton, and nuclear envelope.
224241977|NCT06504056|BIOLOGICAL|Diagnosis of NVM|The term 'left ventricular non-compaction' (LVNC) has been used to describe a ventricular phenotype characterized by prominent LV trabeculae and deep intertrabecular recesses. The myocardial wall is often thickened with a thin,compacted epicardial layer and a thickened myocardial layer. In some patients, this abnormal trabecular architecture is associated with LV dilatation and systolic dysfunction. Left ventricular non-compaction is frequently a familial trait and is associated with variants in a range of genes, including those encoding proteins of the sarcomere, Z-disc, cytoskeleton, and nuclear envelope.
223769568|NCT07109050|DEVICE|VR Headset|VR will be offered on either an individual or joint-experience basis, whereby the participant(s) wear a VR headset with 360 degree views, to explore various VR experiences of their choice for up to 3 sessions on a weekly basis. Goals for using VR will be ascertained by completing the goal based measure with the patient who is accessing specialist palliative care. This will define the purpose of the VR intervention in future sessions. The participant will be shown a list of VR experience options so they are aware of these prior to the next session. Pre-VR and post-VR questionnaires will be completed.
223769569|NCT05744375|DRUG|Trastuzumab deruxtecan|"All patients enrolled will be treated with trastuzumab deruxtecan (T-DXd) 5.4 mg/kg IV every 3 weeks (± 3 days).~The subject's weight at baseline will be used to calculate the initial dose. If during the course of treatment the subject's weight changes by ± 10% of the baseline weight, the subject's dose will be recalculated based on the subject's updated weight.~Patients will receive T-DXd until unacceptable toxicity, progressive disease (PD), informed consent withdrawal, or other discontinuation criterion is met."
223769570|NCT07116291|OTHER|Karate|karate practice
223769571|NCT04659785|DRUG|Fluzoparib|Take Fluzoparib orally（either at 50,100mg bid）until disease progression or appearance of unbearable toxicity
223769572|NCT04659785|DRUG|Apatinib|Take apatinib orally (either at 375mg、500mg、750mg qd）until disease progression or appearance of unbearable toxicity
223769573|NCT06924632|DRUG|Minoxidil|2.5 mg Sublingual Minoxidil Tablet
224321285|NCT04453540|DIAGNOSTIC_TEST|FilmArray PCR on respiratory samples|Molecular test performed on respiratory samples realized for microbiological routine testing as part of the care
224321286|NCT00356525|DRUG|pemetrexed|500 mg/m2, intravenous (IV), every 14 days x 6 cycles or until disease progression
224321287|NCT00356525|DRUG|gemcitabine|1500 mg/m2, intravenous (IV), every 14 days x 6 cycles or until disease progression
224321288|NCT00356525|DRUG|carboplatin|area under the curve (AUC) 5, intravenous (IV), every 21 days x 6 cycles or until disease progression
224321289|NCT00356525|DRUG|Pemetrexed|500 mg/m2, intravenous (IV), every 21 days x 6 cycles or until disease progression
224321290|NCT03717181|DRUG|Lixivaptan|Daily dose of lixivaptan optimized using a predetermined titration protocol.
224321291|NCT04097145|DEVICE|Edwards PASCAL System|Transcatheter tricuspid valve repair with the Edwards PASCAL System in patients on optimal medical therapy
224321292|NCT04097145|DRUG|Optimal Medical Therapy|Optimal Medical Therapy alone in patients with tricuspid regurgitation
224321293|NCT04097145|DEVICE|Edwards PASCAL System|Transcatheter tricuspid valve repair with the Edwards PASCAL System in conjunction with OMT
224321294|NCT04097145|DEVICE|Edwards PASCAL System|Transcatheter tricuspid valve repair with the Edwards PASCAL system in patients on optimal medical therapy (OMT) with tricuspid regurgitation
224321295|NCT06279572|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
224321296|NCT06279572|PROCEDURE|Bone Marrow Aspirate|Undergo bone marrow aspirate
224321297|NCT06279572|OTHER|Electronic Health Record Review|Medical records are reviewed
224321298|NCT05992415|OTHER|Virtual Automated Navigator Intervention with Health Education|Consented participants referred for follow-up to in-office appointments from the 10 developments randomized to the Virtual Automated Navigator Intervention with Health Education Arm will receive text messaging support via REDCAP with all aspects of follow-up appointments at either Columbia University Irving Medical Center or Harlem Hospital, specifically appointment scheduling and education about hypertension and/or glaucoma/suspect over a 1 year period.
224321299|NCT05992415|OTHER|Usual Care|Consented participants referred for follow-up to in-office appointments from the 4 developments randomized to the Usual Care Arm will only be scheduled for their initial appointments at either Columbia University Irving Medical Center or Harlem Hospital. They will not receive enhanced support. Scheduling this initial appointment will allow tracking of adherence. Arm 2 represents a realistic choice available for participants following screening over a 1 year period.
224321300|NCT06294392|BEHAVIORAL|KEEP-CK|The KEEP-CK model focuses on optimizing the role of kinship parents as the agents of positive change for children and youth. KEEP-CK groups for kinship parents are delivered by two co-group leaders for 16 weeks. Sessions are 90 minutes each week. The same group of 8-12 kinship parents attends each week. Each KEEP-CK group follows a manualized curriculum that emphasizes tailoring the content to the unique needs and cultures of the parent in the group and the youth in their care. The key parenting principles of the model include: (a) reinforce normative and prosocial behavior, (b) incentivize the behavior that parents want to promote, (c) build cooperation, (d) teach new behaviors, (e) use non-harsh effective limit setting, and (f) manage emotions while parenting. The key services connection elements of the model include: (a) parent discussions of services they are using or have used and (b) KEEP-CK group leaders share examples from a list of statewide and national services.
224321301|NCT03749057|DRUG|Rivaroxaban|Rivaroxaban 15-20 mg daily
223661684|NCT06820216|DRUG|Rectointercostal facial plane block using bupivacaine 0.25%|Ultrasound guided bilateral recto-intercostal facial plane block will be done after induction of general anesthesia using bupivacaine 0.25%. A linear ultrasound transducer Philips CX50 (5-14 MHz) will be placed 2-3 cm lateral and caudal to the xiphoid in the epigastric area. The rectus abdominis muscle and its insertion, 6th and 7th cartilage ribs will be visualized. The needle will be inserted between rectus abdominis muscle and the costal cartilages with an in-plane technique in a caudal-cranial way. Hydro-dissection will be performed with 5 ml saline for confirmation needle tip position, 20 ml of 0.25% bupivacaine will be injected, the same procedure will be then repeated with 20 ml 0.25% bupivacaine on the contra-lateral side (a total of 40 ml bilaterally).
223661685|NCT06820216|OTHER|No Intervention as a control|General anesthesia without performing any block.
223661686|NCT05141448|DEVICE|1-Day Acuvue Moist|Run-in Contact Lens
223769574|NCT06924632|DRUG|Placebo|Placebo
223661687|NCT05141448|DEVICE|EMO-118|Test Lens1
223661688|NCT05141448|DEVICE|EMO-114|Test Lens2
223661689|NCT05141448|DEVICE|MiSight® 1 day|Control Lens
224241978|NCT01521533|DRUG|NOX-A12|"Pilot Group (NOX A12 single agent, and combined with VD):~* 3 cohorts of 3 patients will receive treatment with NOX A12 alone at a single dose of 1, 2 or 4 mg/kg i.v. 2 weeks before the combination treatment of NOX A12 and VD will start. The combination of NOX A12 and VD will follow a dose titration design beginning at 1 mg/kg NOX A12 (cycle 1) proceeding to dose levels of 2 mg/kg (cycle 2) and 4 mg/kg (cycle 3) NOX A12 in combination with VD. This is followed by consolidation in cycles 4-8 when NOX-A12 will be kept at the highest individually titrated dose.~Expansion Group (NOX A12 in combination with VD):~* Expansion patients will not receive single agent NOX-A12, but will receive combination treatment as for the pilot group."
224241979|NCT03864575|DRUG|Celecoxib 400 mg|Celecoxib 400 mg/day in combination with nivolumab fixed dose
224241980|NCT05349695|DEVICE|Spinal cord stimulation|Eligible patients will undergo a SCS trial period for three weeks (as legally defined by the reimbursement authorities). The leads can be placed both surgically of percutaneously with an external trial stimulator. Surgical implantation of an implanted pulse generator (IPG) is performed if the patient achieves at least 50% pain reduction and a reduced pain medication use (reimbursement requirements) during the trial period. Subsequently, the implanted devices are programmed to the optimal parameters in collaboration with a nurse specialized in SCS treatment. The patients are educated on the use of the patient programmer.
224241981|NCT00739947|OTHER|Observational study of the surgical outcome|Subjects return for 7 follow-up visits following arthroscopic repair of their rotator cuff. During the follow-up visits subjects undergo imaging with MRI and ultrasound.
224241982|NCT05729594|DRUG|Bimatoprost Ophthalmic|eyedrops
224321302|NCT00609999|DRUG|Erlotinib and Dasatinib|You will begin study drug regimen on day 1 of cycle 1 w Dasatinib. If you are undergoing Dasatinib pharmacokinetic blood analysis, Dasatinib will be taken alone until initial PK assessments are collected. Erlotinib will be begin after initial Dasatinib PK assessments are collected \& will continue to be administered w Dasatinib on continuous daily dosing schedule. Initial Dasatinib PK assessments will be collected over 24hrs between days 3-7 of cycle 1 \& at end of cycle 1. If you are not undergoing Dasatinib PK collections you will begin both Dasatinib \& Erlotinib together on day 1 of cycle 1. Both drugs will be given in continuous daily oral manner. Cycle is defined as Dasatinib \& Erlotinib given daily for 28 days for purpose of scheduling evaluations.
224321303|NCT04724941|OTHER|No intervention|No intervention
224321304|NCT01044264|DRUG|1% Clindamycin/5% Benzoyl Peroxide Topical Gel|Topical Gel
224321305|NCT01044264|DRUG|Placebo|Placebo
224321306|NCT01724450|DRUG|Carvedilol|50mg/day for 24 weeks. The dose of carvedilol will be up titrate before the dose of 50mg/day
224321307|NCT01724450|DRUG|Placebo|Placebo similar to the carvedilol up titration but wit no active drug.
224321308|NCT04821193|DRUG|Skin antisepsis with 5% NaHCO3 water solution|In-vitro analysis of the solutions was done first. Then solutions were applied, and peripheric intravenous catheter was installed
224321309|NCT04821193|DRUG|Skin antisepsis with 2% Chlorhexidine Gluconate solution|In-vitro analysis of the solutions was done first. Then solutions were applied, and peripheric intravenous catheter was installed
224321310|NCT02542956|DRUG|Exparel|receive Exparel by injection
224321311|NCT02542956|DRUG|Marcaine|receive Marcaine in a pain pump
224241983|NCT05289674|DIETARY_SUPPLEMENT|High Calorie Formula|The high calorie formula is given as much as 300 kcal/day for 90 days after the subject were diagnosed with tuberculosis (TB) or urinary tract infection (UTI), determine as day 1. the diagnosis were determined by pediatrician. Before the intervention (day 0) and after the intervention (day 61), the subjects were taken the blood by laboratory employee of the private hospital in Surabaya, Indonesia
224321312|NCT02542956|DRUG|Marcaine|receive Marcaine by injection
224321313|NCT05298345|OTHER|Family Champions Project Primary Services|"Primary Services: participants receive 12 hours of TYRO Leadership curricula, 6 hours of Core Communication curricula.~Support Services (optional): participants choose from a menu of classes (1-3 hours) at the walk-in mini clinic to meet a variety of self-identified needs."
224321314|NCT02233439|DIETARY_SUPPLEMENT|Herbal galactagogue|
224321315|NCT02233439|DIETARY_SUPPLEMENT|Placebo|
224321316|NCT05240209|OTHER|The researcher will give training to the training group about skin cancer, skin self-examination and sun protection behaviors.|Materials used in education; Colorful brochures on the subject will be given to reinforce the slide show and post-training information.
224321317|NCT00655772|OTHER|Chlorine Dioxide|Experimental mouthwash (ClO2 Fresh®): 0.16% sodium chlorite (NaClO2) with an efficacy of 0.1% chlorine dioxide (ClO2),Placebo mouthwash: glycerin, mint oil and distilled water, contents are almost the same as those in the experimental mouthwash except ClO2.
224321318|NCT00365092|PROCEDURE|Insertion of tympanostomy tubes|
224321319|NCT04151667|DRUG|Daratumumab Injection|Patient will receive daratumumab (1800 mg in 15 ml) administered by manual subcutaneous injections weekly for the first 8 weeks, every other week for the next 16 weeks and every 4 weeks after.
224321320|NCT04151667|DRUG|Dexamethasone Oral|The dexamethasone starting dose will be 20 mg PO once a week. Commercial dexamethasone will be used. Dexamethasone is often supplied in 4 mg tablets. Accordingly, patients will take 5 (4 mg tablets) one day of the week prior to the administration of daratumumab if this corresponds to a daratumumab dosing days. In non daratumumab dosing days, dexamethasone will be taken by the patient at home, usually in the morning with breakfast.
224321321|NCT04151667|DRUG|Lenalidomide Pill|"Lenalidomide will be given orally on days 1-21 of a 28 days cycle. The starting dose of lenalidomide will be based on the patient creatinine clearance per the package insert.~Specifically patients with a creatinine clearance ≥ 50 ml/min will receive 25 mg of lenalidomide PO Days 1-21. Patients with a creatinine clearance ≥ 30 but less than 50 ml/min will receive 10 mg of lenalidomide.~Patients with a creatinine clearance \< 30 ml/min are not eligible but patients who experience a deterioration in the renal function during screening or treatment may continue on lenalidomide therapy as long as the risk / benefit profile is deemed acceptable, that study therapy is in the best interest of the patient and after discussion with the study principal investigator / sponsor."
223661690|NCT06825403|BEHAVIORAL|Olfactory Memory Training|Participants will complete 48 OMT sessions at home lasting approximately 10 minutes each over 3 months.
223769575|NCT07116694|DRUG|BXCL501 Sublingual Film|Single dose BXCL501 120 mcg
223769576|NCT02373124|DRUG|infusion of NMDA antagonist|52 minute infusion
223769577|NCT02128841|DRUG|Rivaroxaban|Direct Factor Xa Inhibitor
224241984|NCT00247195|BEHAVIORAL|Culturally Congruent Assessment and Treatment|Referral, engagement, and treatment is done following the cultural formulation model in DSM-IV in which patients' views and expectations about depression treatment are included in the assessment and treatment process.
224241985|NCT05628675|OTHER|Baby CHAT|Baby CHAT is an approximately 90-minute group intervention to be delivered during pregnancy. The group is comprised of psychoeducational material about a baby's social development after birth and while the baby is growing in the womb. Attendees are encouraged to think about when an infant's social development begins and consider whether this occurs before or after birth. Participants are then shown a video clip of Reissland et al.'s (2016) study showing 4D ultrasound images of foetuses mouthing in response to sounds that are presented to them outside the womb. During Baby CHAT, parents are encouraged to reflect on this information in the context of their own baby's development, including their likes and dislikes, routine and personality. The final section of the group involves generating ideas for social activities that parents can try with their baby prior to birth, such as singing to, massaging or reading to their baby.
224241986|NCT01941095|DRUG|Azathioprine|Participants may receive azathioprine as a concomitant therapy with tocilizumab as per physician's judgment at a stable dose that was initiated at least 4 weeks prior to baseline.
224241987|NCT01941095|DRUG|Chloroquine|Participants may receive chloroquine as a concomitant therapy with tocilizumab as per physician's judgment at a stable dose that was initiated at least 4 weeks prior to baseline.
224241988|NCT01941095|DRUG|Hydroxychloroquine|Participants may receive hydroxychloroquine as a concomitant therapy with tocilizumab as per physician's judgment at a stable dose that was initiated at least 4 weeks prior to baseline.
224241989|NCT01941095|DRUG|Leflunomide|Participants may receive leflunomide as a concomitant therapy with tocilizumab as per physician's judgment at a stable dose that was initiated at least 4 weeks prior to baseline.
223661691|NCT06825403|BEHAVIORAL|Visual Memory Training|Participants will complete 48 VMT sessions at home lasting approximately 10 minutes each over 3 months.
223661692|NCT06827028|OTHER|N/A, no intervention, participation in survey|N/A, no intervention, participation in survey
223661693|NCT04627285|DRUG|Lacosamide|"* Pharmaceutical form: Oral-solution~* Route of administration: Oral use~Subjects will receive lacosamide in a pre-specified sequence during the Treatment Period."
223661695|NCT05259839|DRUG|Etentamig|Intravenous (IV) Infusion
223661696|NCT05259839|DRUG|Dexamethasone|Oral; Tablet or IV Infusion
223661697|NCT05259839|DRUG|Lenalidomide|Oral; Capsule
223661698|NCT05259839|DRUG|Pomalidomide|Oral; Capsule
223661699|NCT05259839|DRUG|Daratumumab|Subcutaneous Injection (SC)
223661700|NCT06869564|OTHER|blood sampling|At the time of blood sampling for biological tests, 2 additional tubes of blood will be taken.
223661701|NCT03235219|DRUG|JNJ-64565111|Participants will receive JNJ-64565111 subcutaneously in the abdomen on Days 1, 8, 15 and 22.
223661702|NCT03235219|DRUG|Placebo|Participants will receive placebo subcutaneously in the abdomen on Days 1, 8, 15 and 22.
223661703|NCT07124494|PROCEDURE|Regional anethesia|This single-center, prospective, randomized controlled trial aims to compare the effects of three different postoperative analgesia techniques following spinal anesthesia in patients undergoing total knee arthroplasty (TKA). The study will assess the impact of combined spinal-epidural anesthesia, adductor canal block, and multimodal intravenous analgesia on postoperative knee range of motion (ROM). Secondary outcomes include patient satisfaction, opioid consumption, Oxford Knee Score (OKS), activity levels, and visual analog scale (VAS) pain scores.
223661704|NCT07127549|OTHER|Muscle strength, endurance and balance assessment|All participants were administered a demographic assessment form; the International Physical Activity Questionnaire-Short Form (IPAQ-SF) to assess physical activity level; the Pelvic Floor Distress Inventory (PFDI-20) and all of its subscales to evaluate the severity of symptoms associated with pelvic floor distress; urodynamic measurement; a pad test to assess the severity of UI; a perineometer device to evaluate pelvic floor muscle (PFM) strength; the Sahrmann five-level core stabilization test and the Stabilizer Pressure Biofeedback Unit to assess core muscle strength; McGill's Trunk Endurance Tests for core endurance; and the Y Balance Test to assess balance.
223661705|NCT07131540|DRUG|umbilical cord Mesenchymal Stem Cell|To test the safety and tolerability of ucMSC 1 million/kg will be given intra-venously once a week for 4 week in 10 ACLF patients. 250 ml normal saline will be infused 30 minutes prior to ucMSCs infusion. The fresh ucMSCs will be taken from ILBS cGMP facility and will be infused through IV canula peripherally over 30 minutes followed by a further 250 ml normal saline over 20-30 minutes.
223661706|NCT07134387|OTHER|N/A, no intervention, participation in survey|"A unified questionnaire will be utilized for all participants, irrespective of their group assignment. Participants will be assigned to the BPD or comparison group retrospectively, based on their answers defining the BPD-status. To enhance comprehension, the questionnaire avoids using the term BPD wherever feasible and instead employs a more general reference to lung problems."
223661707|NCT07123103|DRUG|XB371|Intravenous (IV) infusion.
223661708|NCT06934356|DEVICE|EEG|Participants will have scalp EEG recorded with the international 10-20 system sampled at 256Hz using EEG amplifiers for purposes of surface event related potential analysis
223661709|NCT06934356|DEVICE|Eye Tracking|An eye-tracking device may be used during the perceptual awareness task. Pupillary and gaze location measurements are recorded using either a ViewPoint\~VoltagePro.EyeLink 1000 Plus system, or Argus Science ETVision system. If using the ViewPoint\~VoltagePro system or the Argus Science ETVision system, participants will be asked to wear an eye tracker during the perceptual awareness task (similar to wearing sunglasses). If using the EyeLink 1000 Plus system, participants may be asked to place their head inside of a padded head-chin rest to stabilize head position
223661710|NCT06934356|DEVICE|Behavioral task|For the visual perceptual awareness task, the participant will be presented with barely perceptible visual stimuli. After a variable delay, the participant will be asked to report perception of each stimulus and identify its location.
223661711|NCT07137091|OTHER|Gyrokinesis exercise|"1. Warm-Up:~   * Begin with gentle seated movements to prepare the body.~  * Focus on awakening the spine with small circles and undulating motions, coordinating with deep breathing.~2. Seated Exercises:~   * Perform a series of exercises on a stool or chair.~  * Emphasize spinal articulation, pelvic tilts, and side bends while maintaining rhythmic breathing.~3. Floor Work:~   * Transition to mat-based exercises focusing on core strength and flexibility.~  * Incorporate movements like leg lifts, spirals, and arching motions to engage different muscle groups.~4. Standing Series:~   * Conclude with standing exercises to enhance balance and full-body integration.~  * Use spiral movements and weight shifts to energize the body and improve posture."
223661712|NCT06412913|DEVICE|MJ-Flex The New Metaizeau Nail|Intramedullary implantation of the MJ-Flex elastic nail in long bones to provide bone fixation
223769578|NCT05698095|DRUG|5-methoxy-N,N-dimethyltryptamine succinate salt|The 5-MeO-DMT drug product is comprised of the appropriate concentration of 5-MeO-DMT succinate salt drug substance in solution with 0.9% sodium chloride injection solution (USP) in a 5 mL glass vial, and is administered intramuscularly.
223769579|NCT05698095|DRUG|Placebo|The placebo is commercially available 0.9% sodium chloride solution (USP) for injection. The placebo is provided by the pharmacy in single-use sterile syringes of the appropriate dose.
223769580|NCT05857657|OTHER|: lower leg kinesiotaping|Kinesiotaping will be applied on tibialis anterior for 30 minutes for one session
223769581|NCT05857657|OTHER|propriocepticve neuromuscular facilitation|:Proprioceptive neuromuscular facilitation hold relax technique will be applied to ankle with 15-30 repititions on affected side for one session
223769582|NCT05857657|OTHER|propriocepticve neuromuscular facilitation with lower leg kinesiotaping|Kinesiotaping will be applied on tibialis anterior for 30 minutes with proprioceptive neuromuscular facilitation hold relax technique will be applied to ankle with 15-30 repititions on affected side for one session
223769583|NCT05107986|PROCEDURE|laparoscopic repair|All patients of cohort underwent laparoscopic repair.
223769584|NCT00991302|BEHAVIORAL|CAP-IT|Interventions designed to improve medication adherence, modified to specifically target people first starting highly active antiretroviral therapy (HAART)
223769585|NCT02553681|DEVICE|roflufocon D contact lenses|HPT treated rigid contact lenses
224241990|NCT01941095|DRUG|Methotrexate|Participants may receive methotrexate as a concomitant therapy with tocilizumab as per physician's judgment at a stable dose that was initiated at least 4 weeks prior to baseline.
224241991|NCT01941095|DRUG|Sulfasalazine|Participants may receive sulfasalazine as a concomitant therapy with tocilizumab as per physician's judgment at a stable dose that was initiated at least 4 weeks prior to baseline.
224241992|NCT01941095|DRUG|Tocilizumab|Participants will receive tocilizumab at a fixed dose of 162 mg SC QW either as monotherapy or in combination with non-biologic DMARDs.
224241993|NCT01924858|DRUG|GSK2647544 oral|GSK2647544 100 mg will be supplied as a size 0 swedish orange hard gelatin capsules filled with white/slightly colored granule. Subjects will receive a single oral dose of GSK2647544 100 mg (2 X 50mg capsules) with 150 mL of tepid water approximately 2 hours prior to the IV infusion of \[18F\]-GSK2647544 and a PET scan.
223661713|NCT06936618|DEVICE|Electrical Impedance Tomography (EIT), Enlight 2100|Patients will undergo ventilator adjustments using EIT-guided PEEP titration to optimize mechanical power and lung mechanics.
223769586|NCT02553681|DEVICE|RGP contact lenses made from roflufocon D|
223769587|NCT03787849|DRUG|Sevoflurane|All children will receive inhalation anesthesia with sevoflurane through facial mask in concentrations between 3-8% for anesthesia induction. After induction and peripheral vein puncture, the anesthesia will be maintained only with sevoflurane 3% until completion of the procedure.
223769588|NCT03787849|DRUG|Propofol|All children will receive inhalation anesthesia with sevoflurane through facial mask in concentrations between 3-8% until lost of conscience and peripheral vein puncture. After that, sevoflurane will be turned off and its clearance will be analyzed through gas analyzer monitor. From here, anesthesia will be maintained as total venous with continuous propofol infusion 100 mcg.kg.min-1 until completion of the procedure.
223769589|NCT01709318|DRUG|Nomegestrol acetate (NOMAC)|Daily release of 500, 700, or 900 μg.
223769590|NCT01709318|DRUG|Etonogestrel (ENG)|Daily release of 75, 100, 120 or 125 μg
223769591|NCT01709318|DRUG|Ethinyl estradiol (EE)|Daily release of 15 μg
223769592|NCT01709318|DRUG|Estradiol (E2)|Daily release of 300 μg
223769593|NCT06085417|DRUG|Bupivacaine + dexamethasone|"Vital signs were recorded before the block. Peripheral vascular access was established with a 20-gauge catheter and 0.9% NaCl crystalloid solution infusion was started. For sedation, all patients were routinely administered 1mg midazolam intravenously before the procedure. Patients' ASA score, demographic data (age, height, weight), systolic blood pressure (SBP), diastolic blood pressure (DBP), mean arterial pressure (MAP), heart rate (HR), SpO₂, sensory and motor block onset times , need for additional sedation, side effects and complications, if any, were recorded. The patients' postoperative sensory block and motor block resolution times, VAS scores at the 0th, 3rd, 6th, 12th and 24th postoperative hours, total opioid and NSAID requirements in the first 24 hours, and analgesia durations were recorded.~During the perioperative period, all patients were monitored for side effects such as nausea, vomiting, tinnitus, metallic taste in the mouth, and drug allergy."
224241994|NCT01924858|DRUG|[18F]GSK2647544 IV bolus|\[18F\]GSK2647544 will be supplied as a clear, colourless solution free from visible particle. A maximum dose up to 2 mg with a maximum dose volume of 25 mL will be administered as IV bolus over 60 seconds.
224241995|NCT01724502|BEHAVIORAL|Exercise and muscle biopsies|Subjects will undergo a euglycemic clamp, VO\_2 max determination, exercise periods and muscle biopsies.
223661714|NCT06941259|PROCEDURE|Rectus sheath and ilioinguinal nerve block with physiological saline|Rectus sheath and ilioinguinal nerve block without local anaesthesia
224241996|NCT04549584|DIAGNOSTIC_TEST|Vimentin/pan CK stain|Vimentin/pan CK stain positive/negative
224241997|NCT03927066|OTHER|Assigned Interventions|Simulated hypovolemia by applied suction to lower extremities to cause venous pooling.
224241998|NCT01183585|DRUG|RO4917838 and Rosuvastatin|multiple oral doses of RO4917838 and single oral dose of Rosuvastatin
223661715|NCT06941259|PROCEDURE|Rectus sheath and ilioinguinal nerve block with local anaesthesia|Rectus sheath and ilioinguinal nerve block with local anaesthesia
223661716|NCT06940921|RADIATION|Low-Dose Radiation(LDRT) + Stereotactic body radiotherapy (SBRT)|"Radiation: Stereotactic Body Radiation Therapy (SBRT)~* Stereotactic Body Radiation Therapy (SBRT) will be performed first at a total dose of 20-50 Gy, delivered in 3-5 fractions of 6-10 Gy each. And the target area was specifically selected based on the location and size of the patient's tumor.~Radiation: low-dose radiotherapy (LDRT)~* Whole-abdominal low-dose radiotherapy will be initiated within 10 days of the end of SBRT with a total dose of 7-15 Gy at 0.5-2.0 Gy twice daily. And the target area included all suspicious tumor tissues and potential metastatic foci in the abdominal cavity."
223661717|NCT06940921|DRUG|Cadonilimab|· Cadonilimab: 6 mg/kg IV, D1, Q2W, until disease progression, death, toxicity intolerance or withdrawal of informed consent
223661718|NCT06941740|OTHER|immediate verbal memory after low glycemic index breakfast inducing no reactive hypoglycaemia|\- Difference in immediate verbal memory after low GI breakfast without reactive hypoglycaemia at 90minutes
223661719|NCT06941740|OTHER|immediate verbal memory after low glycemic index breakfast causing reactive hypoglycaemia|\- Difference in immediate verbal memory after low GI breakfast causing reactive hypoglycaemia at 90 minutes
223661720|NCT06942767|DRUG|QLS31905 for Injection|QLS31905 for Injection
223661721|NCT06942767|DRUG|QL2107 Injection|QL2107 Injection
223661722|NCT06942767|DRUG|Oxaliplatin Injection|Oxaliplatin Injection
223661723|NCT06942767|DRUG|Capecitabine Tablets|Capecitabine Tablets
223661724|NCT06384664|DEVICE|Atricure's crysoSPHERE probe|Cryoablation is a procedure that is used to freeze and burn away tissue cells via a device called a cryosphere which emits a freezing gas.
223661725|NCT06384664|PROCEDURE|Standard of Care|An intercostal nerve block involves injecting anesthetic medications into nerves around the thoracic incision to provide temporary longer term pain relief after surgery.
223661726|NCT07143656|BIOLOGICAL|Imaging and Clinical Reports|Inclusion of existing imaging data (MRI, EMG reports) and standard clinical documentation, where available.
223661727|NCT07144176|DRUG|DWJ1511|Test drug: DWJ1511
223661728|NCT07144176|DRUG|DWC202501|Comparator: DWC202501
223661729|NCT06945094|DEVICE|caIMR|"caIMR will be measured by pressure sensors which are produced by Suzhou Rainmed Medical Technology Co., Ltd.~caIMR is calculated based on angiography images and Hyperemic Pa estimated from resting Pa according to prespecified equation"
223661730|NCT06945328|PROCEDURE|Upper endoscopy|All patients will do gastroscopy (upper endoscopy) within the first 24 hour of admission and specific elements of bleeding
223661731|NCT06942637|BEHAVIORAL|INSPIRE (Integrated Network for Student Psychosocial Intervention, Resilience, and Education)|The INSPIRE intervention is an 8-week school-based program aimed at enhancing adolescent mental health, attitudes towards mental health and help-seeking behaviors, mental health literacy, resilience and addressing depression and anxiety. Trained school counsellors deliver this structured curriculum using comprehensive materials including lesson plans, activities, and visual aids. the program provides supplementary resources for both participating students and their parents .
223661732|NCT06943989|OTHER|Ozone Exposure|6.6 hour exposure to 0.07 ppm ozone while at rest
223661733|NCT06943989|OTHER|Clean air (0.0 ppm ozone)|6.6 hour exposure to clean air (0.00 ppm ozone) while at rest
223661734|NCT07136051|PROCEDURE|Ethcing|Etching: After polishing all teeth included in the study with a polishing brush, Vococid (Voca, Germany) etching gel will be applied to the surface and left for 15 seconds, then rinsed and dried.
223661735|NCT07136051|PROCEDURE|Deproteinization|The teeth randomly assigned to Group B will receive 5.25% NaOCl applied with a sterile cotton pellet for 60 seconds after acid etching, followed by rinsing and drying.
223661736|NCT07136051|PROCEDURE|Bonding|The teeth randomly assigned to Group C will receive Futurabond® M+ (Voco, Germany) applied with a brush following acid etching. After gently drying with air for 5 seconds, the bonding step will be completed by light-curing for 10 seconds.
223661737|NCT07136051|PROCEDURE|Application of resin-based fissure sealant|After completing the pretreatment steps for all groups, Grandio Seal (Voco GmbH, Germany) will be applied to the pits and fissures on the tooth surface and light-cured for 20 seconds. The procedure will be completed after checking the surface.
223661738|NCT06939647|DRUG|Treprostinil Palmitil|Treprostinil Palmitil Inhalation Powder
223661739|NCT07145814|DRUG|dexmedetomidine 0.3 µg/kg/h|Following Anesthesia induction, dexmedetomidine (DEX) Low Dose group received a DEX loading dose (0.5 µg/kg over 10 min), followed by continuous infusions of 0.3 µg/kg/h, respectively, until 30 minutes before the end of the operation.
223661740|NCT07145814|DRUG|dexmedetomidine 0.5 µg/kg/h|Following Anesthesia induction, dexmedetomidine (DEX) high dose group received a DEX loading dose (0.5 µg/kg over 10 min), followed by continuous infusions of 0.5 µg/kg/h, respectively, until 30 minutes before the end of the operation.
223661741|NCT07145814|DRUG|0.9 % saline|Placebo group received an equivalent volume of 0.9% saline.
223661742|NCT07145346|DRUG|Suzetrigine (SUZ)|The intervention arm will receive oral suzetrigine (100 mg loading dose followed by 50 mg every 12 hours).
223661743|NCT07145346|DRUG|Placebo|The control arm will receive placebo capsules matched to suzetrigine for oral administration.
223661744|NCT07146633|BEHAVIORAL|A-EMDR|Participants in the treatment group will receive Autonomous Eye movement desensitization and reprocessing (A-EMDR) therapy delivered through an app on their device. Participants will be asked to complete 3 sessions per week for 4 consecutive weeks. During the treatment period, participants will also attend clinical sessions which will focus on factors such as the therapeutic alliance, assessing the participant's current state, reviewing recent alcohol and drug use, reviewing PTSD symptoms, providing a brief counseling intervention, enhancing positive expectancies, inspiring hope, and encouraging adherence to the study protocol.
223661745|NCT07146633|OTHER|Treatment as Usual (TAU)|Participants are advised to continue seeking mental health care as usual and will be added to a waitlist for A-EMDR. They will also attend two clinical sessions. Sessions may last 15 to 60 minutes and will focus on factors such as the therapeutic alliance, assessing the participant's current state, reviewing recent alcohol and drug use, reviewing PTSD symptoms, providing a brief counseling intervention, enhancing positive expectancies, inspiring hope, and encouraging adherence to the study protocol. Participants will continue to receive any usual healthcare services as per local standard of care. TAU and other medical appointments will be checked for attendance throughout the study period.
224241999|NCT03368755|DIAGNOSTIC_TEST|Cardiopulmonary Exercise Testing|Pimax, Pemax, airway pressure at 100 msec after occlusion (P0.1), and Ti and Ttot will be measured by the Micro 5000 device (Medisoft, Sorinnes, Belgium). TTImus will be calculated as (Pimean / Pimax) x (Ti / Ttot), where Pimean is the mean airway pressure resulting from the formula Pimean = 5 x P0.1 x Ti9. RM function will be determined a) prior to CPET, b) during CPET when the anaerobic threshold (AT) will be reached, and c) after CPET, when heart rate (HR) and oxygen consumption will be normalized.
224242000|NCT03368755|DIAGNOSTIC_TEST|Respiratory Muscle Strength and Endurance|CPET will be performed by the Ultima CPX system (Medgraphics, St. Paul, USA), using a cycle ergometer and according to a standardized protocol. The following parameters will be recorded: total work in Watts, maximum HR, maximum oxygen consumption (VO2max), AT indices (work, HR, VO2 ) and duration of recovery.
224242001|NCT02463695|PROCEDURE|cortical vestibular evoked potentials (CVEPs)|CVEPs utilise an existing method used to interrogate cortical projections from the auditory system in which sound waves stimulate the inner ear and the resulting electrical responses from the brain are recorded (known as Cortical Auditory Evoked Potentials CAEPs)
224242002|NCT00726739|BIOLOGICAL|aldesleukin|IL-2 Alone - administer 10 x 10\^6 International Units subcutaneously (SQ) will be given on day 1 and day 2 every 4 weeks until disease progression or for a maximum of 12 treatment cycles.
224242003|NCT00726739|BIOLOGICAL|allogeneic large multivalent immunogen vaccine|Allogeneic tumor cell membrane-coated large multivalent immunogen (LMI \[1 x 10\^7, 5-μm silica spheres\]) will be given as an intradermal injection every 4 weeks for up to 12 injections. Each vaccine dose will be 0.2 ml.
224242004|NCT00724542|DRUG|Voglibose tablets|0.2mg Tid
224242005|NCT01537861|DRUG|Filgrastim|
224242006|NCT01537861|DRUG|Bortezomib|
224242007|NCT01537861|DRUG|Carfilzomib|
224242008|NCT01537861|DRUG|Dexamethasone|
224242009|NCT01537861|DRUG|Cyclophosphamide|
224242010|NCT01537861|DRUG|Thalidomide|
224242011|NCT01537861|DRUG|Lenalidomide|
224242012|NCT01537861|DRUG|Pomalidomide|
224242013|NCT02149745|PROCEDURE|Calling the patient's name|calling the patient's name during anesthesia reversal
224242014|NCT02149745|PROCEDURE|Not calling the patient's name|giving verbal stimulus other than the patient's name during anesthesia reversal
224242015|NCT00003040|PROCEDURE|laser surgery|CO2 supraglottic laryngectomy within 28 days following registration with neck dissection as needed
224242016|NCT00003040|RADIATION|radiation therapy|200 cGy per day, five days per week for approximately 6 weeks, to begin 14 days after laser surgery
224242017|NCT02918877|DRUG|Sevoflurane|Volatile Anesthetic
224242018|NCT02918877|DRUG|Propofol|Intravenous Anesthetic
224242019|NCT02811523|DRUG|Doxorubicin|Doxorubicin by In Vivo Lung Perfusion
224242020|NCT00079625|DRUG|Th2/Tc2 Cells|
224321322|NCT04151667|DRUG|Bortezomib Injection|Bortezomib will be given weekly subcutaneously in an effort to decrease the toxicity of the therapy. Specifically patients will receive a starting dose of bortezomib of 1.3 mg/m\^2 Days 1,8,15 of a 28 day cycle. Bortezomib will be administered in the cancer center per standard of care procedures.
223661746|NCT07146165|DEVICE|EndoTEM resection platform and technique|EndoTEM is a flexible transanally introduced port system that allows the insertion of a second instrument alongside the flexible endoscope. A curved rigid grasping instrument has been developed, with a 2 cm long tip that can be rotated and angled in all directions.
223661747|NCT07146009|PROCEDURE|Nerve Surgery|Patients undergoing prophylactic nerve surgery (RPNI) during second-stage implant exchange after tissue expander based breast reconstruction.
224242021|NCT05818137|BIOLOGICAL|Sotatercept|SC injection at a starting dose of 0.3 mg/kg with a target dose of 0.7 mg/kg every 21 days plus background PAH therapy.
224242022|NCT04925089|OTHER|Blood and Tissue collection|Blood and tissue will be collected and analyzed for detection of ctDNA and genetic change
224242023|NCT01699607|DRUG|Amphetamine|All subjects will receive amphetamine to induce elevated dopamine levels in the brain at 0.5mg/kg
224242024|NCT01035528|DRUG|insulin glargine|antidiabetic treatment with insulin glargine sc o.d. titrated to the target fasting glucose type 2 diabetes ≤110 mg/dl
224321323|NCT03985852|OTHER|Patient Directed Standard of Care|The pre-test genetic counseling visit will be conducted through access to an automated genetics education assistant accessed through the patient portal. The automated approach will address all the components of the pre-test counseling and contains content designed by the genetic counselors at the University of Utah and NYU. Patients will have the option to contact genetic counselors through the patient portal, by phone, or in person but this will not be required. All results will be reviewed by a genetic counselor. Negative results will be returned by the automated genetics education assistant. Genetic counselors will return results for pathogenic variants and variants of uncertain significance via phone.
224321324|NCT04345913|PROCEDURE|Biopsy Procedure|Undergo biopsy
223661748|NCT07146009|OTHER|Standard of Care (Investigator Choice)|Patients receiving standard medical therapies for PMPS prevention (e.g., pharmacologic pain management, physical therapy).
224242025|NCT01035528|DRUG|metformin|use of oral metformin o.d or b.d titrated up to 2000 mg daily for to the target fasting glucose ≤110 mg/dl
224242026|NCT00464165|DRUG|rimonabant|
224242027|NCT05632640|OTHER|Standard of Care|Following the participants procedure, standard of care will be given in the recovery area.
224242028|NCT05632640|DEVICE|Weighted blanket|Following the participants procedure once in the recovery area, the nursing staff will place a weighted blanket on the participants. Different weighted blanket sizes will be used based on participants weight.
224242029|NCT01648166|OTHER|Environmental sampling|Soil, water, blood, urine, hair and radon testing in homes in Appalachia
224242030|NCT05631366|BEHAVIORAL|Alcohol Avoidance Training|Participants are instructed to react with a joystick to the tilt of pictures, presented on a computer screen. For instance, participants make an approach movement (pull) with left-tilted pictures, and make an avoidance movement (push) with right-tilted pictures. After the correct movement is made, the pictures disappear, otherwise they do not, until the correct response is made.
224321325|NCT04345913|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
224321326|NCT04345913|PROCEDURE|Computed Tomography|Undergo CT scan
224321327|NCT04345913|DRUG|Copanlisib Hydrochloride|Given IV
224321328|NCT04345913|DRUG|Eribulin Mesylate|Given IV
224321329|NCT04345913|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223769594|NCT06085417|DRUG|Bupivacaine + magnesium sulphate|"Vital signs were recorded before the block. Peripheral vascular access was established with a 20-gauge catheter and 0.9% NaCl crystalloid solution infusion was started. For sedation, all patients were routinely administered 1mg midazolam intravenously before the procedure. Patients' ASA score, demographic data (age, height, weight), systolic blood pressure (SBP), diastolic blood pressure (DBP), mean arterial pressure (MAP), heart rate (HR), SpO₂, sensory and motor block onset times , need for additional sedation, side effects and complications, if any, were recorded. The patients' postoperative sensory block and motor block resolution times, VAS scores at the 0th, 3rd, 6th, 12th and 24th postoperative hours, total opioid and NSAID requirements in the first 24 hours, and analgesia durations were recorded.~During the perioperative period, all patients were monitored for side effects such as nausea, vomiting, tinnitus, metallic taste in the mouth, and drug allergy."
223769595|NCT06085417|DRUG|bupivacaine|bupivacaine
223769596|NCT03062800|DRUG|Thalidomide|100-200mg/d,oral ,qn
223769597|NCT03062800|DRUG|pemetrexed|(500mg/m\^2) on day 1 of 21-days cycle,ivgtt
223769598|NCT03062800|DRUG|cisplatin|(75mg/m\^2) on day 1 of 21-days cycle, ivgtt
223769599|NCT03062800|DRUG|carboplatin|(AUC=5) on day 1 of 21-days cycle, ivgtt
223769600|NCT04250324|BIOLOGICAL|BZ019|A treatment program will include lymphodepleting chemotherapy with fludarabine and cyclophosphamide (flu/cy) followed by single-dose of BZ019 administered intravenously (IV).
223769601|NCT04499404|OTHER|Breastfeeding related information delivered by WeChat|Participants in the intervention group will be asked to follow our WeChat public account immoderately after randomization. They will receive breastfeeding related messages three times a week from WeChat, including preparation for breastfeeding after birth and the health benefits of breastfeeding, from baseline until childbirth. After childbirth, intervention group mothers will continue to receive information, which is mainly about breastfeeding, once a week for 6 months. WeChat will send push notifications to remind mothers about the importance of exclusive breastfeeding, build confidence and motivate them to continue exclusive breastfeeding.
223769602|NCT04499404|OTHER|Non-breastfeeding related information delivered by WeChat|Participants in the control group will be asked to follow our WeChat public account immoderately after randomization. They will receive messages mainly on topics of healthy lifestyle and nutrition during pregnancy, from baseline until childbirth. After childbirth, they will continue to receive information on other topics of interest to mothers, such as immunization, safety, infant growth, and etc., until 6 months postpartum.
224242031|NCT03047226|OTHER|next-generation sequencing|Use next-generation sequencing to test germline mutation and microsatellite instability.
224242032|NCT01683175|DRUG|Erlotinib|
224242033|NCT01683175|DRUG|cis-platinum|
224242034|NCT01683175|DRUG|Vinorelbine|
223661749|NCT05148195|DRUG|Envofolimab|300mg，Q3W (arm A,B and C)or 200mg, Q2W(arm D)
223661750|NCT05148195|DRUG|BD0801|2mg/kg，Q3W(armA, B and C) or 2mg/kg，Q2W
223661751|NCT05148195|DRUG|Docetaxel|75mg/m2，Q3W
223661752|NCT05148195|DRUG|Irinotecan|180 mg/m2，Q2W
223661753|NCT05148195|DRUG|Leucovorin calcium|400mg/m2，Q2W
223661754|NCT05148195|DRUG|5-Fluorouridine|2400 mg/m2，Q2W
223661755|NCT06233669|OTHER|Analysis of Burnout|No intervention used.
223661756|NCT03027544|RADIATION|tomotherapy|"Tomotherapy: The regular fraction modes were as follows: a. lesions≥3 cm:52Gy/4Gy/13f or 52.5Gy/3.5Gy/15f; b. lesions\<2cm:36Gy/12Gy/3f or 24Gy/24Gy/1f; for lesions located in function areas, it would be adjusted to 40Gy/8Gy/5f; c. lesions 2-3cm: 40-48Gy/8-10Gy/6-4f; d. lesions located in brainstem:50-60Gy/2.5-3Gy/20f; 3. multiple lesions with large lesion: whole brain radiation (WBRT) with 40Gy/2Gy/20f and concurrent boost of 60Gy/3Gy/20f of the lesions.~TMZ is used if necessary: concomitant TMZ: 75mg/m2 adjuvant TMZ: 150mg/ m2\*5d, q28d, up to 6cycles."
223661757|NCT06023836|DEVICE|ESWT|Patients in this group received three sessions of ESWT (MASTERPLUS MP 200 ENERGY 2 trademarked ESWT device) at an energy density of 2 bars and a frequency of 2,000 shocks/min at 12 Hz for three weeks, each session once a week. Each of the five most sensitive and painful points was given 400 pulses in the supine position
223661758|NCT06023836|PROCEDURE|Dry needling|Dry needling with Seirin branded 0.6\*50 mm acupuncture needles will be performed for 3 sessions with one week intervals for the trigger point detected by manual palpation in the medial gastrocnemius, lateral gastrocnemius, soleus, flexor digitorum brevis, quadratus plantae, abductor hallucis brevis muscles of the patients in the group.
223661759|NCT04788368|PROCEDURE|Surgical resection|Surgical resection with either of the above mentioned techniques
223661760|NCT03574519|BEHAVIORAL|Non-contingent incentives|Incentives are provided for participation
223661761|NCT03574519|BEHAVIORAL|Contingent incentives|Incentives are provided for attaining daily goals
223661762|NCT03574519|BEHAVIORAL|Weekly feedback|Text message feedback is delivered weekly summarizing the past week's progress
223661763|NCT03574519|BEHAVIORAL|Daily feedback|Text message feedback is delivered daily summarizing the current day's progress
223661764|NCT04606329|DRUG|LuminoMark inj.(Conc. for fluorescence)|Injection LuminoMark inj. (Conc. for fluorescence) 0.2mL once in this study.
223661765|NCT04606329|DRUG|Charcotrace Inj.|Injection Charcotrace Inj. about 0.3\~1mL once in this study.
223661766|NCT04012164|BIOLOGICAL|blood sampling|5ml blood sampling
223661767|NCT04012164|BIOLOGICAL|stool collection|self stool collection (2g)
223661768|NCT04012164|OTHER|Participatory activity and contact investigation|30 human subjects will self-report daily activities and contacts with selected wild and domesticated animals for five months.
224242035|NCT02444403|BEHAVIORAL|Police Education Program designed to align law enforcement and HIV prevention in Tijuana|"The 3.5-hour PEP course consists of 3 modules. Module I covers basic epidemiology, prevention and treatment of HIV, viral hepatitis and STIs, safe syringe disposal and fundamentals of addiction. Post-exposure protocols and appropriate follow-up procedures are outlined. Module II covers key provisions of Mexico's national drug policy (narcomenudeo, which defines amounts of drugs allowed for personal possession), as well as other legal provisions pertinent to HIV prevention, including the legality of syringe and condom possession. Module III covers public health-based interventions targeting PWID (SEPs, OST) and deconstructs myths typical among law enforcement (i.e., drug users do not care about their health, SEPs increase the risk of NSIs).~A sub-cohort sample will be invited to undergo pre- and post-PEP surveys with semi-annual follow-up for 2 years to assess self-reported NSIs (Aim 1), attitudinal and behavior changes (Aim 2) and mediators/moderators (Aim 3)."
223661769|NCT04012164|OTHER|Anthropological and historical interviews|Oral interviews on current and past practices and engagements with wild and domesticated animals will be conducted with the 30 human subjects who are recruited to self-report their activities (Participatory activity and contact investigation) and to provide blood and stool samples. Another 30 human subjects will be recruited only to participate in the same type of interviews, addressing past and present activities and relations with wild and domesticated animals.
223661770|NCT01043939|OTHER|Purple Grape Juice|6 ounces of purple grape juice consumed twice daily either during first or second 4 week supplementation period, depending on sequence randomization
223661771|NCT01043939|OTHER|Apple Juice|6 ounces of clear apple juice consumed twice daily either during first or second 4 week supplementation period, depending on sequence randomization
223661772|NCT03726450|DIETARY_SUPPLEMENT|Andrositol Plus|Myo-inositol
223661773|NCT03726450|DIETARY_SUPPLEMENT|Andrositol Plus|N-Acetyl-Cysteine
223661774|NCT03726450|DIETARY_SUPPLEMENT|Andrositol Plus|Folic Acid
223661775|NCT03726450|DIETARY_SUPPLEMENT|Andrositol Plus|Selenium
224242036|NCT02532764|DRUG|QR-010|Single-stranded RNA antisense oligonucleotide in aqueous solution for oral inhalaton
224242037|NCT02532764|DRUG|Placebo|Normal Saline
224242038|NCT04456361|BIOLOGICAL|Mesenchymal Stem Cells derived from Wharton Jelly of Umbilical cords|Mesenchymal Stem Cells as a single-dose therapy via IV infusion at a dose of 1 X 10 8 cells.
223661776|NCT03726450|DIETARY_SUPPLEMENT|Andrositol Plus|L-arginine
223661777|NCT03726450|DIETARY_SUPPLEMENT|Andrositol Plus|L-carnitine
224242039|NCT03527745|DRUG|Albendazole|Single dose of albendazole (200mg, dependent on treatment cohort)
224242040|NCT03527745|DRUG|Albendazole|Single dose of albendazole (400mg, dependent on treatment cohort)
224242041|NCT03527745|DRUG|Albendazole|Single dose of albendazole (600mg, dependent on treatment cohort)
224242042|NCT03527745|DRUG|Albendazole|Single dose of albendazole (800mg, dependent on treatment cohort)
224242043|NCT03527745|DRUG|Placebo|Matching placebo tablets will be obtained from Fagron, Germany.
224242044|NCT00706745|DIETARY_SUPPLEMENT|oil rich in cis9, trans11 conjugated linoleic acid|An oil rich in cis9, trans11 conjugated linoleic acid (cis9,trans11-CLA). Of the total amount of CLA in the oil, 80% is cis9, trans11-CLA and 20% trans10, cis12-CLA. In total 4 grams of oil will be given daily. The oil will be taken in the form of soft gel capsules. Two capsules will be taken in the morning and two in the evening.
224242045|NCT00706745|DIETARY_SUPPLEMENT|placebo|identical placebo capsules.
223661778|NCT03726450|DIETARY_SUPPLEMENT|Andrositol Plus|Vitamin E
223661779|NCT00086268|DRUG|zoledronic acid|
223661780|NCT00086268|DRUG|Taxotere|
223661781|NCT00086268|DRUG|Carboplatin|
223661782|NCT02051933|DRUG|Botulinum toxin type A|"At the time of definitive fixation, the hospital's investigational pharmacy will provide four syringes containing 0.5mL Botulinum toxin type A. The dose of botulinum toxin will be calculated based on the patient's weight in kilograms, such that a total dose of 200U of Botox will be used for a 70kg individual. The dosage will scale linearly in proportion to the patient's body weight, such that each kilogram change results in a 3U change in Botox (rounded to the nearest 30U interval change from 200U, with a maximum of 300U).~45-55 kg: 140U 55-65 kg: 170U 65-75 kg: 200U 75-85 kg: 230U 85-95 kg: 260U 95-105 kg: 290U 105-115 kg: 300U"
223661783|NCT02051933|DRUG|sodium chloride|"At the time of definitive fixation, the hospital's investigational pharmacy will provide four syringes containing 0.5mL 0.9% sodium chloride solution . The dose of 0.9% sodium chloride will be calculated based on the patient's weight in kilograms, such that a total dose of 200U of Placebo will be used for a 70kg individual. The dosage will scale linearly in proportion to the patient's body weight, such that each kilogram change results in a 3U change in placebo(rounded to the nearest 30U interval change from 200U, with a maximum of 300U).~45-55 kg: 140U 55-65 kg: 170U 65-75 kg: 200U 75-85 kg: 230U 85-95 kg: 260U 95-105 kg: 290U 105-115 kg: 300U"
223661784|NCT00147368|DRUG|intravenous (IV) arginine|
223661785|NCT05917431|COMBINATION_PRODUCT|SBRT plus tislelizumab and regorafenib|Participants will receive SBRT plus tislelizumab and regorafenib concurrently
223661786|NCT00748852|DRUG|JTT-302|JTT-302, 100 mg tablets, 400 mg dose, oral, 30 minutes after the start of the morning meal
223661787|NCT03522623|OTHER|Non-interventional study|Non-interventional study
223661788|NCT05019118|OTHER|Experimental milk|UNICLA milk naturally enriched in selenium and omega-3.
223661789|NCT05019118|OTHER|Experimental yogur|UNICLA yogur naturally enriched in selenium and omega-3.
224242046|NCT04699422|PROCEDURE|Serratus anterior plane block|The needle will be introduced in-plane from supero-anterior to postero-inferior until the needle tip is positioned in the plane underneath the serratus muscle (deep compartment). Under continuous ultrasound guidance,30 cc Bupivacaine 0.25% will be injected in the deep compartment. After the deep component of the SAP is completed, the needle will be withdrawn to the subcutaneous tissues. The needle will be flattened and advanced in-plane to the plane superficial to the serratus muscles. 10 cc Bupivacaine 0.25% will be injected superficial to the serratus muscles after correct placement of the needle tip is confirmed on ultrasound
224242047|NCT04699422|DRUG|PCIA with Piritramide|A patient controlled intravenous analgesia system (IVAC PCAM®, Cardinal Health or CADD pump) with piritramide (Dipidolor®, Janssen) using following settings: bolus 2 mg and lockout interval 15 min.
224242048|NCT05676866|PROCEDURE|Targeted axillary lymph node dissection|Targeted axillary lymph node dissection is done by marking suspicious node with metallic clip prior to neo adjuvant therapy ,then neo adjuvant therapy is given and after complete axillary response (proved by radiological and clinical examination) , targeted axillary lymph node dissection of clipped node is done along with sentinel lymph node dissection
224242049|NCT03862248|DRUG|6EH³RZ|New high-dose isoniazid retreatment regimen (6EH³RZ) - H 15mg/kg
224242050|NCT03862248|DRUG|6EHR³Z|New high-dose rifampicin retreatment regimen (6EHR³Z) - R 30mg/kg
224242051|NCT03862248|DRUG|6EHRZLfx|WHO levofloxacin-strengthened regimen (6EHRZLfx)
224242052|NCT04066361|OTHER|Chatbot|Interactive text chat designed to mirror the educational components of a traditional genetic counseling visit
224242053|NCT04066361|OTHER|Video Education|Brief video designed to mirror the educational components of a traditional genetic counseling visit
223769603|NCT02383758|DRUG|Glycerin Suppository|Nursing staff will administer one glycerin suppository in the bathroom if there is no continent bowl movement in the first 30 minutes. Subjects will be taken to the bathroom 5 minutes after the suppository is administered for a 30 minute sit or until a continent void occurs. If continent bowel movements maintain on two subsequent days (after bisacodyl suppositories are discontinued) the glycerin suppository will be discontinued. At least one primary caregiver will be trained on all components of intervention still in use on the last day their child's admission. Four weekly follow-up appointments will be used to support them as they continue to implement the protocol at home, including continuing to fade out the use of medications for participants who are at least partially continent but not fully independent at the time of discharge.
223769604|NCT02383758|DRUG|Bisacodyl suppository|If a subject does not have a bowel movement during the 30 minute sit following administration of the glycerin suppository, they will be given a 1 hour break, after which a bisacodyl suppository will be administered. The participant will then sit for an additional 30 minutes.If continent bowel movements maintain for two subsequent days (after senna is discontinued) bisacodyl suppositories will be discontinued if it was required. At least one primary caregiver will be trained on all components of intervention still in use on the last day their child's admission. Four weekly follow-up appointments will be used to support them as they continue to implement the protocol at home, including continuing to fade out the use of medications for participants who are at least partially continent but not fully independent at the time of discharge.
223769605|NCT02383758|DRUG|Senna|If no continent bowel movements occur for two consecutive treatment days, caregivers will be asked to administer senna each evening thereafter until medication tapering begins. Once there have been two successive days with continent bowel movements, senna will be removed from the intervention if it was required.
224242054|NCT05956678|BEHAVIORAL|Standard Transdiagnostic Intervention for Sleep and Circadian Dysfunction (TranS-C)|TranS-C is a psychosocial treatment designed to improve sleep and circadian functioning. It is a modular, psychosocial, skills-based approach. In this study, two version of TranS-C will be tested: Standard and Adapted.
224242055|NCT05956678|BEHAVIORAL|Adapted Transdiagnostic Intervention for Sleep and Circadian Dysfunction (TranS-C)|The Adapted version was derived from Standard TranS-C. It was developed to improve the fit of the treatment with the CMHC context.
224242056|NCT05052138|OTHER|Tactile massage|Tactile massage will receive two 15-min tactile massages(hand massage) per week for 4weeks
224242057|NCT05129098|DEVICE|Left bundle branch pacing lead (Select Secure 3830 lead)|Implantation of a left bundle branch pacing lead via sheath
224242058|NCT05129098|DEVICE|Right ventricular active fixation lead|Active fixation lead (standard)
224242059|NCT00000588|DRUG|Chelation therapy|After an initial 21 day balance study to demonstrate that a selected dose of PIH produced sufficient iron excretion, patients were begun on chronic therapy. PIH or placebo were given on days 4 to 9 and days 13 to 18 in a randomized, double-blind, cross-over design.
223769606|NCT06469047|DIAGNOSTIC_TEST|Enzyme-linked immunosorbent assay|Serum N/OFQ , IL-1β and NE levels were detected.
223769607|NCT00273364|PROCEDURE|Hematopoietic Stem Cell Therapy|After mobilization and harvest of stem cells, stem cells will be infused following conditioning regimen
224242060|NCT00000588|OTHER|Placebo|Placebo given at same time points as the Intervetnion for each clinical condition.
224242061|NCT06261892|DIAGNOSTIC_TEST|Collect HPV DNA from urine|Use a sample collector to collect urine
224242062|NCT05381623|PROCEDURE|Simplified suture-less approach|Immediately after the harvest of a free gingival graft from hard palate, at least a half carpule of local anesthetic (articaine 4% 1:100.000 epinephrine) will be infiltrated within the apical border of the harvesting site and another half mesially and distally to the harvesting site. At the end of the mucogingival procedure, the donor site will be evaluated to inquire regarding the presence of a competent coagulum over the wound area. In such a case, no additional procedure will be performed at the recipient site.
223661790|NCT05019118|OTHER|Experimental fresh cheese|UNICLA fresh cheese naturally enriched in selenium and omega-3.
223661791|NCT05019118|OTHER|Placebo milk|Conventional milk
223661792|NCT05019118|OTHER|Placebo yogur|Conventional yogur
223661793|NCT05019118|OTHER|Placebo fresh cheese|Conventional fresh cheese
223661794|NCT02594995|DRUG|NBP|
223661795|NCT00391209|DRUG|simplified diabetes regimen starting with a fixed dose of Human Insulin Inhalation Powder|patient specific dose, inhaled, before meals,6 months
223661796|NCT00391209|DRUG|intensive diabetes management starting with an adjusted dose of Human Insulin Inhalation Powder|patient specific dose, inhaled, before meals, 6 months
223661797|NCT05326854|OTHER|supportive care|After Medical Termination Navigation Assisted Care Program admission to the service will be held in the form of three interviews in the clinic before and after termination. The planned training will be given in three sessions and a different training module will be applied in each meeting. After the patient is discharged, three sessions will be held remotely via telephone.
223661798|NCT04830098|OTHER|Spinal stabilization exercises|It will be given stabilization exercises for a total of 18 sessions, 3 times a week for 6 weeks, each session for 45 minutes.
223661799|NCT04830098|OTHER|Chiropractic manipulation|It will be applied high-speed low-amplitude (HVLA) chiropractic manipulation for a total of 6 sessions, once a week for 6 weeks.
223661800|NCT01221285|BIOLOGICAL|German cockroach (Blattella germanica) allergenic extract|Participants received weekly escalating doses of glycerinated German cockroach allergenic extract administered via the subcutaneous route up to a Maximum Study Dose of 0.6 mL of extract at a concentration of 1:20 wt/vol.
223661801|NCT02123251|BEHAVIORAL|Financial Incentives|This intervention will examine the effects of incentives on improving adult diabetic Medicaid beneficiaries' health outcomes and reducing associated costs through healthy behavior changes in their diabetes self-management. Incentives focus on improving self-management of diabetes, compliance with ADA recommended preventive, treatment and management measures, primary biometric measures of diabetes, and eliminating barriers to a healthy lifestyle
223661802|NCT04503187|BEHAVIORAL|Visuomotor leg reaching task|Similar to a hand reaching task in which participants were asked to reach to a tea-cup, in a visuomotor leg reaching task, participants will be seated and given real-time visual feedback about their leg movements via a cursor display on a computer screen. The task is to control a foot mouse/marker attached to the foot and move the cursor from a start location to the target displayed on a wall screen. Three different targets, equidistant from the start location at top, top-left, and top-right screen positions, will be used for leg reaching. In each trial, one of three targets will be randomly presented and subjects will be instructed to make forward, or rightward, or leftward foot reaches to guide the cursor to one of the targets. Throughout the entire experiment, subjects are blocked from viewing leg movements by a cardboard.
223661803|NCT02300636|OTHER|Training|Co-contraction training at 60 knee flexion angle by using isokinetic dynamometer
223661804|NCT02300636|OTHER|Training|Co-contraction training at 60 knee flexion angle by using leg press machine
223661805|NCT02300636|OTHER|Training|Standard ACL rehabilitation
223661806|NCT05949034|DEVICE|JUUL E-Cigarette Device|We will use the commercially available and popular JUUL e-cigarette device and e-cigarette solutions.
223661807|NCT02265159|PROCEDURE|Focal Therapy Using High Intensity Focused Ultrasound|
223661808|NCT03007251|OTHER|"Eurythmy Therapy Movement R"|
223661809|NCT03007251|OTHER|"Eurythmy Therapy Movement L"|
223661810|NCT03007251|OTHER|"Eurythmy Therapy Movement B"|
223661811|NCT03007251|OTHER|Normal movements during walking or standing|
223661812|NCT02775929|DRUG|FTC-TDF PrEP|FTC-TDF PrEP for HIV-1 uninfected partners
223661813|NCT02775929|DRUG|ART|ART for HIV-1 infected partners
223661814|NCT04111562|PROCEDURE|Cranioplasty|Bone grafts
223661815|NCT01904773|DRUG|AZD5213 and placebo|low dose AZD5213 capsules; high dose AZD5213 capsules; placebo capsules
223661816|NCT04582123|PROCEDURE|crossed pin configuration|comparison of two crossed pin fixation methods
223661817|NCT00207324|DEVICE|Silver Leaf Dressing|
223661818|NCT06480162|PROCEDURE|Mechanical ventilation|After replacing the electrode, we'll monitor the EEG activity of the hippocampus and other cortex regions while weaning off mechanical ventilation.
223661819|NCT03861988|DRUG|Ketamine|0.5 mg/kg over 40 minutes, intravenous.
223661820|NCT03861988|DRUG|Normal saline (placebo)|Normal saline infusion over 40 minutes, equivalent volume to ketamine infusion.
223661821|NCT00220779|DRUG|Immune Globulin IV [Human], 10% Caprylate/Chromatography Purified|
223661822|NCT00220779|DRUG|Albumin (Human) 25%, United States Pharmacopeia (USP)|
223661823|NCT01300533|DRUG|BIND-014|
223661824|NCT01464957|BEHAVIORAL|Semi-tailored newsletter|Delivered over 3 consecutive years, in the spring
223661825|NCT03331471|PROCEDURE|alveolar recruitment maneuver|applying alveolar recruitment maneuver using the anesthesia machine
223661826|NCT03331471|PROCEDURE|conventional ventilation|conventional ventilation using the anesthesia machine
223769608|NCT00273364|DRUG|Standard treatment with a conventional drug|Standard treatment with a conventional drug is the treatment with one of the following drugs: Avonex (interferon beta 1a), Betaseron (interferon beta 1b), Copaxone (glatiramer acetate), Aubagio (teriflunomide), Tysabri (natalizumab), or Gilenya (fingolimod)
223769609|NCT03269279|DRUG|Mifepristone|Medication used in conjunction with misoprostol for abortion
223769610|NCT03269279|DRUG|Misoprostol|Medication used in conjunction with mifepristone for abortion
223661827|NCT01857596|DRUG|bupropion, Lorexys low-dose, Lorexys moderate-dose|Lorexys is a proprietary fixed-dose combination of two agents
223661828|NCT02248675|BEHAVIORAL|CBT-I|Cognitive Behavioral Therapy for Insomnia (CBT-I), an evidence-based insomnia treatment. In this study it will be delivered in four individual sessions.
223769611|NCT05894265|OTHER|ActiveMatrix® Dosage A|This group will receive ActiveMatrix® (AM) product dosage A (1cc AM diluted to 3cc with saline)
223769612|NCT05894265|OTHER|ActiveMatrix® Dosage B|Group 2 will receive ActiveMatrix® product dosage B (2cc AM diluted to 3cc with saline)
223769613|NCT05894265|PROCEDURE|Saline injection|Group 3 will receive saline injection
223661829|NCT02248675|OTHER|TAU|Treatment as Usual: All participants will be encouraged to begin or continue treatment of co-occurring conditions as recommended by treatment providers. This may include treatment within the primary care teams, through behavioral telehealth, and/or specialty outpatient mental health. Participants randomized to TAU may receive pharmacotherapy for insomnia, though CBT-I will be precluded until after the post-treatment assessments.
223661830|NCT04565327|DRUG|Hyperpolarized Carbon C 13 Pyruvate|Given IV prior to imaging
223661831|NCT04565327|PROCEDURE|Magnetic Resonance Imaging (MRI)|Undergo MRI
223661832|NCT01097200|DEVICE|Elevate mesh|The correction of the prolapse can be made by this new technique.
223661833|NCT01097200|DEVICE|Sacrocolpopexy|Attach a mesh between the vagina and the promontorium.
223661834|NCT00102401|BEHAVIORAL|Internet-based Dyspnea Self-Management Program|
223661835|NCT00102401|BEHAVIORAL|Face-to-face Dyspnea Self-Management Program|
223661836|NCT03390101|DRUG|BCD-085 Q2W|"In Arm 1, the test drug BCD-085 will be used at a dose of 120 mg given as two SC injections according to the following schedule: once a week for the first 3 weeks (induction treatment) and then once every 2 weeks through Week 10.~On Week 12, the treatment efficacy will be assessed with a PASI75 score, and the therapies will be unblinded. During the open-label patients will receive BCD-085 through week 50. The follow-up will continue through week 54."
223661837|NCT03390101|DRUG|BCD-085 Q4W|In Arm 2, and then once every 4 weeks through Week 10. On Week 12, the treatment efficacy will be assessed with a PASI75 score, and the therapies will be unblinded. During the open-label period, patients from Arm 2 will be given BCD-085 once every 4 weeks through week 50. The follow-up will continue through week 54.
223661838|NCT03390101|DRUG|Placebo|"In Arm 3, patients will be given two SC injections of placebo (1.0 mL each) according to the following schedule: on Day 1 of weeks 0, 1, 2 and then once every 2 weeks through Week 10.~On Week 12, the treatment efficacy will be assessed with a PASI75 score, and the therapies will be unblinded. During the open-label period, patients from Arm 3 will receive BCD-085 at weeks 12, 13, 14 and then once every 4 weeks through week 50. The follow-up will continue through week 54."
223661839|NCT01282970|DRUG|BI 135585|oral doses given to approximately 5-6 parallel groups of 12 subjects (9 on active and 3 on placebo) over 14 days
223661840|NCT01282970|DRUG|Placebo to BI 135585|oral doses given to approximately 5-6 parallel groups of 12 subjects (9 on active and 3 on placebo) over 14 days
223661841|NCT03699969|RADIATION|Hypofractionated dose escalated VMAT|measure the local control, progression free survival and overall survival
223661842|NCT02512627|BEHAVIORAL|Cognitive training|visuospatial, attention, memory, and executive abilities
223661843|NCT02512627|BEHAVIORAL|Physical exercise|endurance, balance, and mobility
223661844|NCT01701752|BIOLOGICAL|FP-01.1 + Placebo|
223661845|NCT01701752|BIOLOGICAL|FP-01.1 + TIV|
223661846|NCT01701752|BIOLOGICAL|FP-01.1-Adjuvant + Placebo|
223661847|NCT01701752|BIOLOGICAL|FP-01.1-Adjuvant + TIV|
223661848|NCT01701752|BIOLOGICAL|Adjuvant + TIV|
223661849|NCT01701752|BIOLOGICAL|Placebo + TIV|
223661850|NCT01701752|BIOLOGICAL|FP-01.1|
223661851|NCT01701752|BIOLOGICAL|FP-01.1-Adjuvant|
223661852|NCT01701752|OTHER|Placebo|
223661853|NCT04708171|PROCEDURE|Awake mapping under local anesthesia|During an awake craniotomy, the patient is awake and cooperative during the resection of the tumor while the surgeon uses electro(sub)cortical mapping to prevent damage to eloquent areas.
223661854|NCT04708171|PROCEDURE|Asleep mapping under general anesthesia|During asleep mapping under general anesthesia, the surgeon uses electro(sub)cortical mapping with evoked potentials (MEPs, SSEPs or continuous dynamic mapping) to prevent damage to eloquent areas.
223661855|NCT04708171|PROCEDURE|Resection under general anesthesia without mapping|During resection under general anesthesia without mapping, the surgeon does not use any intraoperative stimulation mapping techniques to identify eloquent areas.
223661856|NCT00395057|DRUG|AGN 211745|AGN 211745 Solution 1000µg injection at Day 1, Month 1, Month 2
224242063|NCT05381623|PROCEDURE|Application of hemostatic sponges and compressive sutures|Immediately after the harvest of a free gingival graft from hard palate, hemostatic collagen sponges will be applied over the harvesting site and a series of tooth suspended external mattress sutures (PGA 5/0) will be applied over the area, in order to provide a compressive effect.
224242064|NCT01416766|OTHER|Self-monitoring-nurse-primary care provider feedback loop|Intervention participants will receive an Omron BP monitor and assistance in setting it up to upload BP data to Reliant Medical Group from a home/work or clinic-based computer. They will be encouraged to upload readings at least once/month. Diabetes management nurses will receive the readings and, if a participant's mean BP is not at target, will follow protocols to address this, contacting PCPs as indicated by protocols.
224242065|NCT01604850|DRUG|SOF|Sofosbuvir (SOF) 400 mg tablet was administered orally once daily.
224242066|NCT01604850|DRUG|RBV|Ribavirin (RBV) tablets was administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg).
224242067|NCT01604850|DRUG|Placebo to match SOF|Placebo to match SOF was administered orally once daily.
224242068|NCT01604850|DRUG|Placebo to match RBV|Placebo to match RBV was administered orally twice daily.
224242069|NCT03201302|OTHER|School physical education class|Children participated only in school physical education classes only.
224242070|NCT03201302|OTHER|Taekwondo|Children participated only in taekwondo training only.
223661857|NCT00395057|DRUG|AGN 211745|AGN 211745 Solution 300µg injections, Day 1, Month 1, Month 2
223661858|NCT00395057|DRUG|AGN 211745|AGN 211745 Solution 100µg injections, Day 1, Month 1, Month 2
223661859|NCT00395057|DRUG|Ranibizumab 500µg|Ranibizumab 500µg injections at Day 1, Month 1, Month 2
223661860|NCT06371183|DEVICE|Colonoscope|Endoscopy for lower GIT
223661861|NCT05232370|DRUG|Angiotensin converting enzyme inhibitor|Angiotensin-converting enzyme inhibitors after Kidney Transplant
223661862|NCT05232370|DRUG|Angiotensin Receptor Blockers|Angiotensin receptor blockers after Kidney Transplant
223661863|NCT00338975|BEHAVIORAL|Cognitive Behavioral Social Skills Training (CBSST)|There are 36 weekly group sessions, each session is 2 hours in length, with a half-hour break after the first hour. The intervention integrates CBT and SST techniques and neurocognitive compensatory aids. All participants are asked to identify a goal. The SST components are based, in part, on a pre-packaged SST intervention available from Psychiatric Rehabilitation Consultants. The CBT components are based on techniques developed for CBT in general and techniques developed specifically for patients with schizophrenia. Cognitive therapy is combined with role-play practice of communication skills and problem-solving training.
223661864|NCT00338975|BEHAVIORAL|Goal-focused supportive contact (GFSC)|"There are 36 weekly group sessions, each 2 hours in length, with a half-hour break after the first hour. GFSC has a number of specific goals and interventions, including providing a safe environment where the patient can discuss her/his feelings and concerns; to validate these feelings and concerns; and to provide support and guidance to the client so that she/he can make progress to solving problems or alleviating concerns and worries. Psychotic symptoms and cognition are not directly targeted. Therapists utilize non-specific therapeutic techniques, including providing unconditional positive regard, reflective listening, encouraging, paraphrasing, and summarizing. Therapists do not develop a formulation or teach skills."
223661865|NCT00338975|BEHAVIORAL|Social Skills Training|The SST components are based, in part, on a pre-packaged SST intervention available from Psychiatric Rehabilitation Consultants. Participants engage in role plays and problem solving.
223769614|NCT05134376|OTHER|During Episiotomy Repair, Women Will Be Watching Virtual Reality Glasses Accompanied by Music|Unlike the experimental group, only video and music application will not be applied to the pregnant women included in the control group. Other applications will be done exactly.
224242071|NCT03201302|OTHER|Martial arts|Children participated only in martial arts training only.
224242072|NCT03201302|OTHER|Climbing|Children participated only in climbing training only.
224242073|NCT03201302|OTHER|Volleyball|Children participated only in volleyball training only.
224242074|NCT03201302|OTHER|Artistic gymnastics|Children participated only in artistic gymnastics training only.
224242075|NCT03201302|OTHER|Swimming|Children participated only in swimming training only.
224242076|NCT03201302|OTHER|Dance|Children participated only in dance training only.
224242077|NCT03201302|OTHER|Basketball|Children participated only in basketball training only.
224242078|NCT03201302|OTHER|Wrestling|Children participated only in wrestling training only.
224242079|NCT03201302|OTHER|Football (soccer)|Children participated only in football (soccer) training only.
224242080|NCT03201302|OTHER|Rhythmic gymnastics|Children participated only in rhythmic gymnastics training only.
224242081|NCT03201302|OTHER|Track and field|Children participated only in track and field training only.
224242082|NCT03201302|OTHER|Tennis|Children participated only in tennis training only.
224242083|NCT03201302|OTHER|Combination of activities 1|Children participated in two weight-bearing activities.
224242084|NCT03201302|OTHER|Combination of activities 2|Children participated in one weight-bearing activity and in one non weight-bearing activity.
224242085|NCT06545253|DIAGNOSTIC_TEST|microRNAs analysis|Patients will undergo routinary ophthalmological examination, multimodal retinal imaging and blood sampling
223661866|NCT00338975|BEHAVIORAL|Goal Setting|All participants are asked to identify a personally meaningful goal as soon as possible in therapy. Over the 36 weeks, participants in CBSST learn skills related to goal attainment, while participants in GFSC do not receive skills aimed at goal attainment, but are encouraged to discuss their goals .
223661867|NCT00281658|DRUG|Lapatinib (GW572016) oral tablets|1500 mg oral daily continuously
223661868|NCT00281658|DRUG|Paclitaxel infusion|Paclitaxel 80 mg/m2 every 3 weeks, 4th week rest for minimum 6 months
223769615|NCT04926753|DRUG|5-Fluorouracil, Cisplatin, Toripalimab|Drug: FP combined with Toripalimab Combination drugs: 5-Fluorouracil(F), Cisplatin/Carboplatin(P) and Toripalimab every 21 days for 2 cycles This is a single-arm study with all patients receiving these three drugs.
224242086|NCT05405998|OTHER|Proactive care pathway|"Patient participation in a specific therapeutic education program, as soon as the therapeutic decision is made.~The reinforced cooperation of the expert centers with the homecare providers on 2 different times:~1. before the installation of the pump, i.e. before the episode of hospitalization dedicated to the starting of the treatment;~2. after the installation of the pump following the above mentioned hospitalization."
224242087|NCT01187862|DRUG|caffeine, efavirenz, losartan, omeprazole, metoprolol, chlorzoxazone and midazolam|
224242088|NCT04002388|BEHAVIORAL|activity monitor group|will receive a FitBit and will be asked to wear this for one year
223661869|NCT00281658|DRUG|Placebo|Paclitaxel Matching Placebo
223661870|NCT04013243|DRUG|Magnesium Sulfate|magnesium sulphate 50mg/kg in normal saline 50ml infusion for 10minutes for loading dose followed by 15mg/kg/hr for continuous infusion
223769616|NCT04771741|DRUG|Acetominophen|1,000 mg every 6 hours
224242089|NCT04002388|BEHAVIORAL|usual care group|will NOT receive a FitBit
224242090|NCT03621748|PROCEDURE|Awake Anesthesia Protocol|Awake is defined as the patient being awake with electrical brain stimulation mapping during the critical portions of the procedure.
224242091|NCT03621748|PROCEDURE|Non-awake Anesthesia Protocol|Non-awake is general anesthesia as per convention with intubation.
224242092|NCT02465658|OTHER|Medical records were reviewed.|retrospective study
223661871|NCT04013243|DRUG|Placebo|Normal Saline 50ml infusion for loading dose followed by continuous infusion for same dose of magnesium.
224242093|NCT00947258|OTHER|Stretching|Participants were divided into 3 groups. The group was referred to stretching 3 weekly for 4 consecutive weeks. Group B went 4 weeks without any intervention and held only one stretch before the re-test. And the group C performed passive knee mobilization. All participants were assessed for goniometry of the knee in flexion and extension and peak torque and power on the isokinetic dynamometer.
223661872|NCT03913416|DEVICE|3D printed model|Before surgery, the surgeon will have a 3D printed model of the pulmonary malformation as well as the lung, the rib cage and the tracheal trunk based on the initial scanner images. He will then be able to train and plan the surgical strategy, as well as to discuss the pulmonary exclusion with the anesthetist.
223661873|NCT03913416|OTHER|Control group|The control group is composed of patients operated with standard surgery
223661874|NCT02828891|DEVICE|Two-Dimensional Transcranial Doppler|Transcranial Doppler will be used to measure CSF pressure.
223769617|NCT04771741|DRUG|Toradol|10 mg every 6 hours, days 0-3
223769618|NCT04771741|DRUG|Meloxicam|15 mg once daily, beginning post-op day 4
224242094|NCT02857842|DRUG|Prednisolone|
224242095|NCT04549844|DRUG|Bupivacaine|"After adequate pre-oxygenation, Induction will be accomplished with the injection of propofol 2 mg/kg and Fentanyl 1 µg/kg IV. Endotracheal intubation will be facilitated by the intravenous injection of 0.5 mg/kg atracurium. General anesthesia will be maintained by mechanical ventilation with oxygen and air (50:50), isoflurane.~Patients in peribulbar block group will receive lidocaine 2%, bupivacaine 0.5% and hyaluronidase with total volume 0.06 ml/kg keeping the ratio 1: 1 between lidocaine combined with hyaluronidase and bupivacaine by 24 Gauge needle after induction of general anesthesia and before start of surgery."
224242096|NCT02171754|DRUG|BIBW 2992|
224242097|NCT02171754|DRUG|Ritonavir|
224242098|NCT02769637|DRUG|PPI treatment|PPI treatment or no PPI treatment
224242099|NCT05487274|PROCEDURE|Total Shoulder Arthroplasty + augmented glenoid component|Replacement of the shoulder joint (ball and socket, or humeral head and glenoid) using prosthetic components. A prosthetic component is also implanted to correct for the amount of bone loss in the shoulder and restore stability.
224242100|NCT05487274|PROCEDURE|Reverse Shoulder Arthroplasty|Replacement of the shoulder joint like the TSA, however the orientation of the ball and socket is reversed.
224242101|NCT01097993|OTHER|1-fermented dairy product|Arm 1 - Intervention 1 (probiotics)
224242102|NCT01097993|OTHER|2- milk-based non-fermented dairy product (control product)|Arm 2 - Intervention 2 (control)
224242103|NCT05047107|OTHER|No intervention|Non-interventional study
224242104|NCT00867542|OTHER|no intervention|no intervention
224242105|NCT03002597|DEVICE|BrainPort V200 Device|To see if the device can be used in a pediatric population by measuring the subjects' improvement over baseline in any of the following areas: light detection, light localization, movement perception, and standardized object recognition tasks after use of the BrainPort.
223661875|NCT05011279|OTHER|Move Together app/Garmin Activity Tracker|"* The Move Together app allows users to set daily goals for increasing physical activity and decreasing sedentary time, track progress on goals, message their buddy, and access external educational infographics and other resource links.~* Garmin activity tracker in this study is for participants to track their steps and sedentary time."
223661876|NCT04054427|DEVICE|IOL implantation experimental|Implantation of trifocal IOL POD L GF consisting of hydrophobic material
223661877|NCT00310453|BIOLOGICAL|ALK Grass tablet|
223661878|NCT02800876|OTHER|CT-acquisition|
223661879|NCT02634476|BEHAVIORAL|Alcohol approach/avoidance task|The approach-bias modification is a computerised alcohol approach/avoidance task (alcohol-AAT) in which participants are instructed to respond with an approach movement (pulling a joystick) to pictures in landscape orientation and an avoidance movement (pushing a joystick) to pictures in portrait orientation. The size of the image is increased and decreased by pulling and pushing the joystick respectively, generating a sensation of approach or avoidance. Pictures include images of 20 alcoholic and 20 non-alcoholic drinks presented in a fixed orientation such that participants are in effect instructed to respond to pictures of alcohol by making an avoidance movement (pushing the joystick) and to pictures of non-alcoholic soft drinks by making an approach movement (pulling the joystick).
223661880|NCT02634476|BEHAVIORAL|Sham approach/avoidance task|The computerised training for the sham condition is the same as for the experimental condition, except that in the sham approach/avoidance task, both landscape and portrait pictures all contain neutral (non-alcohol related).
223661881|NCT03830905|DRUG|XC221|Participants will receive 200 mg XC221 once a day during 3 days
223661882|NCT03830905|DRUG|Placebo|Participants will receive Placebo once a day during 3 days
223661883|NCT04153734|DRUG|Pembrolizumab|Pembrolizumab at 200 mg (day 1) will be administered to patients with non-squamous cell carcinoma at 3-week intervals. To those with squamous cell carcinoma, Pembrolizumab at 200 mg (day 1) will be administered at 3-week intervals until disease progression or intolerable toxicity. Pembrolizumab administration should be continued for 2 years involving induction and maintenance therapies or until the 35th course.
223661884|NCT04153734|DRUG|Cis Platinum|In patients with non-squamous histology, cisplatin (75 mg/m2) will be administered every 3 weeks until 4 cycles with pemetrexed and pembrolizumab.
223661885|NCT04153734|DRUG|Carboplatin|In cisplatin-intolerable patients, carboplatin (AUC=6) will be administered every 3 weeks until 4 cycles with pemetrexed and pembrolizumab.
223661886|NCT04153734|DRUG|Pemetrexed|In patients with non-squamous histology, pemetrexed (500 mg/m2) will be administered every 3 weeks until progression or 2 years after initiation (35 cycles) with pembrolizumab.
223661887|NCT04153734|DRUG|nab paclitaxel|In patients with squamous histology, nab-paclitaxel (100 mg/m2, day 1, 8, 15, tri-weekly) will be administered until 4 cycles with pembrolizumab.
223661888|NCT00813943|DRUG|Cilengitide (2-times weekly)|Cilengitide 2000 milligram (mg) will be administered intravenously twice weekly over 1 hour infusion from Weeks -1 to 77 or until occurrence of progressive disease, unacceptable toxicity, or withdrawal for any other reason. If considered beneficial in the opinion of the Investigator, continuation of cilengitide treatment will be optional in subjects without disease progression and after Week 77 since start of treatment.
223661889|NCT00813943|DRUG|cilengitide (5-times weekly)|Cilengitide 2000 milligram (mg) will be administered intravenously 5-times weekly over 1 hour infusion from Weeks -1 to 77 or until occurrence of progressive disease, unacceptable toxicity, or withdrawal for any other reason. If considered beneficial in the opinion of the Investigator, continuation of cilengitide treatment will be optional in subjects without disease progression and after Week 77 since start of treatment.
223661890|NCT00813943|DRUG|Temozolomide|Temozolomide (TMZ) 75 milligram per square meter \[mg/m\^2\] will be administered intravenously once daily from Week 1 to 6. From Week 11 onwards, TMZ will be given as maintenance treatment at a dose of 150-200 mg/m\^2 for consecutive 5 days every 4 weeks until Week 34 or until disease progression.
223661891|NCT00813943|RADIATION|Radiotherapy|Radiation therapy (RTX) at a dose of 2 gray (Gy) per fraction will be given once daily, 5 days per week from Week 1 to 6, total dose 60 Gy.
223661892|NCT06955481|PROCEDURE|Navigated Total Knee Arthroplasty|The OrthoPilot® Software Pheno4u TKA Level 1 is an application software for computer aided navigation of surgical instruments and serves (in combination with compatible hardware and compatible navigated instruments) as an optional aid for the surgeon during the preparation of the implant site for a compatible knee endoprosthesis.
223661893|NCT02529228|OTHER|Meal (Eating) Frequency|Dividing meal intake into 2 or 6 meals with equal energy content
223661894|NCT02529228|OTHER|Protein Composition|Consuming meals with higher or lower protein.
223661895|NCT04277923|DRUG|SMOFlipid|the lipid of all-in-one is less than 4g/kg.d
223661896|NCT04277923|DRUG|Lipofundin|the lipid of all-in-one is less than 4g/kg.d
223661897|NCT06071078|BEHAVIORAL|Training of professionals according to the DISCUSS announcement protocol|"The emergency services will be divided into 4 clusters (2 or 3 services per cluster). Each cluster will belong successively to the control arm and then to the intervention arm according to a 5 successive steps of 4 months duration (stepped wedge method). The deployment of the training will therefore not be done simultaneously in the different services.~Individuals in this group will have received a decision of withholding and withdrawing life-sustaining treatments according to the DISCUSS announcement protocol, by a professional trained in this procedure."
223661898|NCT03841916|DIAGNOSTIC_TEST|transvaginal ultrasound|transvaginal ultrasound to measure endometrial thickness
223661899|NCT01235598|OTHER|Placebo|Placebo provided for the first subcutaneous injection in single-use vials at Week 0 (2 vials required), then Certolizumab Pegol (CZP) 400 mg at Weeks 2, 4 and 6, followed by Certolizumab Pegol (CZP) 200 mg every 2 weeks from Week 8 to Week 40
223661900|NCT01235598|BIOLOGICAL|Certolizumab Pegol (CZP) 200 mg|Placebo, saline solution for subcutaneous injection at Week 0 followed by Certolizumab Pegol (CZP) 400 mg at Weeks 2, 4, and 6, then Certolizumab Pegol (CZP) 200 mg 2-weekly from Week 8 to Week 40
223661901|NCT01235598|BIOLOGICAL|Certolizumab Pegol (CZP) 400 mg|Placebo, saline solution for subcutaneous injection at Week 0 followed by Certolizumab Pegol (CZP) 400 mg at Weeks 2, 4, and 6, then Certolizumab Pegol (CZP) 200 mg 2-weekly from Week 8 to Week 40
223661902|NCT04742582|DIETARY_SUPPLEMENT|Preterm Infants - fed fermented formula|Feeding infants with fermented formula supplemented with the fermentation products of the probiotic L. paracasei CBA L74 (800 mg / 100 ml of milk) (84 kcal and 2.9 g protein per 100 ml)
224242106|NCT04280263|DRUG|Caffeine|caffeine tables containing 150mg caffeine will be provided to patients with instructions to take twice per day
224242107|NCT04280263|DRUG|Placebo oral tablet|oral placebo tablets matching the caffeine tablets and will be provided to patients with instructions to take twice per day
224242108|NCT02923635|PROCEDURE|Standard wide local excision.|Excision of breast cancer without integration of plastic technique
224242109|NCT02923635|PROCEDURE|oncoplastic breast surgery.|Integration of plastic techniques with oncological surgery for resection of breast cancer.
224242110|NCT01471093|DRUG|OPC-12759 Ophthalmic solution|2％ OPC-12759 Ophthalmic solution
224242111|NCT01471093|DRUG|OPC-12759 Ophthalmic suspension|2％ OPC-12759 Ophthalmic suspension
224242112|NCT00604877|BEHAVIORAL|Treadmill Exercise|3 times per week for 6 months, with target of 45 minutes at 60-70% heart rate range
224242113|NCT00604877|BEHAVIORAL|Stretching/ROM|3 times per week for 6 months, passive and active stretching and range of motion (ROM) exercises for the upper and lower extremities
224242114|NCT03460951|DIAGNOSTIC_TEST|cervical MRI|Cervical MRI will be performed in all of the patients and controls on a 3.0-T scanner (Discovery MR750, General Electric (GE) Medical Systems, Milwaukee, WI, USA)
224242115|NCT03105830|DRUG|iv paracetamol|iv paracetamol
224242116|NCT05778448|DEVICE|Brain Computer Interface/ Functional Electrical Stimulation/ Virtual Reality|A BCI system involves 3 main components - (1) brain activity collection, (2) external devices triggered by specific features of brain activity, and (3) a processor which decodes the brain activity signal and then translates it into computerized commands to control external devices such as virtual games and functional electrical stimulation (FES).
223661903|NCT04742582|OTHER|Preterm Infants - fed standard formula|Feeding infants with standard formula with the addition of skimmed milk powder in order to provide the same protein and energy amount of the supplemented formula (84 kcal and 2.9 g protein per 100 ml)
224242117|NCT02475954|BEHAVIORAL|TH-CBT|The TH-CBT group will receive the study intervention and standard care. The study treatment has been previously manualized and modified for remote administration, as described in the introduction to the revised application.12 PD Veterans will receive 10 weekly individual sessions (60 minutes each) of CBT, delivered via Video-to-Home (V2H).
224242118|NCT02475954|OTHER|Standard Care|Standard Care is defined as medical and psychiatric treatment provided by patients' personal doctors (e.g., neurologists, psychiatrists, therapists). Veterans will continue to receive routine clinical care and will remain on all depression treatments that they were receiving prior to their study (e.g., stable anti-depressant medications, established psychotherapy, clinical monitoring).
224242119|NCT04892511|OTHER|Adjusted medication|"In patients randomized to perfusion optimization, medication will be adjusted to maintain blood pressure according to the degree of recanalization:~* Patients with TICI 2b: systolic blood pressure 140-160 mmHg.~* Patients with TICI 2c-3: systolic blood pressure \<140 mmHg.~Hypotensive drugs will be used when necessary. Intravenous labetalol is the treatment of choice, administered as a bolus or intravenous infusion. Alternative: urapidil (bolus or continuous infusion pump). If both drugs cannot be used or are insufficient, sodium nitroprusside can be used.~Hypertensive drugs for TICI2b patients whose target pressure is 140-160mmHg and are below this range. Initially, a bolus of physiological saline or 100cc Plasmalyte® will be administered. If this treatment is not effective enough (blood pressure measurements persist \<140 mmHg), intravenous phenylephrine will be administered."
224321330|NCT05686512|BEHAVIORAL|Step-by-Step|"The Step-by-Step follows a stepped care approach, were all children (and caregivers) complete the first step (a brief group intervention followed by an individual session). Those with more needs are offered to continue to step 2 where individual CBT is given. See Figure 1 for a schematic representation of the stepped care approach, and Table 2 for an overview of session content.~Step 1 Session 1-4: Group sessions including psychoeducation, parenting skills and mapping stress and vulnerability factors, exposure and coping skills (90 minutes) Session 5: Individual session - If ending after step 1 a maintenance plan is completed. If continuing to step 2 continued exposure and selection of optional focus areas such as emotion regulation, social skills, stress- and vulnerability factors, child worry or parental worry. (45 minutes)~Step 2 Session 6-8: Individual sessions - Exposure and selected focus areas. (45 minutes)"
223661904|NCT04742582|OTHER|Pre-term Infants - breastfed|Breastfeeding infants - Reference group
223661905|NCT06343857|DIAGNOSTIC_TEST|self-assessment questionnaire|Completion of the anatomical site-specific self-assessment questionnaire.
223661906|NCT02551991|DRUG|nal-IRI|
223661907|NCT02551991|DRUG|5 fluorouracil|
223661908|NCT02551991|DRUG|Leucovorin|
223661909|NCT02551991|DRUG|Oxaliplatin|
223661910|NCT03689309|PROCEDURE|High Flow Oxygen SBT|The patient is disconnected from the ventilator and remains 30 minutes without support but high flow oxygen delivered through a dedicated piece that is usually connected on tracheotomy.
223661911|NCT05676775|OTHER|No intervenetion|Observational inception cohort, with remote follow-up via participants and data record linkage
223661912|NCT03540550|OTHER|Diet based on inulin-rich vegetables|During two weeks, healthy subjects were instructed to adhere to a controlled diet based on ITF-rich vegetables (±15 g ITF/day).
223661913|NCT05120063|DEVICE|SPS monoblock stem, Symbios|hip prosthesis
223661914|NCT05120063|DEVICE|Quadra-H, Medacta|hip prosthesis
224242120|NCT05376007|BEHAVIORAL|Serious game 'Broodles'|The serious game 'Broodles' is a newly developed web-based, educational game that can be played by siblings on a computer or tablet without support from an adult. The game discusses the nine domains of sibling quality of life (Moyson \& Roeyers, 2012) in eight 20-minute levels. The main characters of the game are the Broodles, which are little monster creatures that experience things that siblings of children with ID and/or VI can also experience. The game includes animations, videos of siblings talking about their experiences, quizzes and mini-games. These elements are focussed on emotions, thoughts and difficult situations that siblings can experience. In addition to the game, siblings make offline worksheets and parents receive an information brochure. Siblings complete the game in four weeks.
224242121|NCT02932878|DRUG|DSXS topical|topical treatment
223769619|NCT04771741|DRUG|Cyclobenzaprine|10 mg every 8 hours
223769620|NCT04771741|DRUG|Lyrica|75 mg every 12 hours
223661915|NCT05120063|PROCEDURE|3D planning of THR|primary total-hip replacement (THR) planned on 3-dimensional images (computer tomography)
223769621|NCT04801524|BEHAVIORAL|Self-benefit|Participants will be reminded that the vaccine helps protect themselves from COVID.
223769622|NCT04801524|BEHAVIORAL|Prosocial-benefit|Participants will be reminded that the vaccine helps protect their family, friends, and community from COVID
224242122|NCT01918397|DRUG|Levofloxacin|Levofloxacin is a quinolone antibiotic used to treat lung, sinus, skin, and urinary tract infections caused by bacteria. The chemical name is (-)-(S)-9fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido\[1,2,3-de\]-1,4benzoxazine-6-carboxylic acid hemihydrate.
224242123|NCT01918397|DRUG|Optimized background regimen (OBR)|"For this study OBR will mean optimized background regimen, not including a quinolone. OBR will be selected at the discretion of the study investigator to conform with standards of care and local site guidelines. In general, the OBR regimen should include at least 3 drugs (other than levofloxacin) to which the patient's isolate is not expected to be resistant, with one of these being an injectable agent, at the usual recommended doses."
224242124|NCT01961973|PROCEDURE|Cultured Chondrocytes|This method has two stages. In the first stage, a knee arthroscopy is done to harvest viable cartilage cells which are then sent to a lab to be cultured for 6 weeks. In the second stage, an arthrotomy is performed. The area of cartilage deficiency is prepared and the cultured cells are transplanted onto it. After discharge from the hospital, the patient is advised partial weight bearing on the operated leg for 6 weeks after the surgery.
224242125|NCT01961973|PROCEDURE|Cultured BMAC|This method also has two major stages. The first stage involves harvesting BMAC from the patient's iliac crest (hip bone), which are then sent to the laboratory for culture for 3 weeks. Simultaneously, an arthroscopy is performed on the affected knee and the area of cartilage deficiency is debrided and microfractured. In the second stage, the cultured BMAC are injected into the affected knee and cells attach themselves to the microfractured area. The patient is then recalled at 4, 5 and 6 weeks from the first stage for an injection of Hyaluronic Acid into the operated knee.
223661916|NCT05120063|PROCEDURE|2D planning of THR|primary total-hip replacement (THR) planned on 2-dimensional images (anteroposteiros pelciv x-ray)
223661917|NCT00265148|DRUG|Rosiglitazone|Extended Release Tablets
224242126|NCT00620022|DRUG|Indacaterol 300 μg|Indacaterol was supplied in powder filled capsules together with a single dose dry powder inhaler (SDDPI) device.
224242127|NCT00620022|DRUG|Placebo|Placebo was supplied in powder filled capsules together with a single dose dry powder inhaler (SDDPI) device.
223661918|NCT00265148|OTHER|Placebo|Placebo dummy to match
223661919|NCT02842554|OTHER|EPT|
223661920|NCT02842554|DRUG|Drug Placebo Administration|
223661921|NCT02842554|OTHER|C|No Intervention
223661922|NCT03759808|BEHAVIORAL|Psychological Intervention|Psychological treatment protocol designed to treat anxiety and avoidance in an adolescent/young adult population. The focus of treatment will be to address cognitive and behavioral factors associated with prolonged symptoms. Cognitive factors that may be addressed include, but are not limited to, catastrophizing, black or white thinking, and false expectations. Behavior factors that may be addressed include, but are not limited to, avoidance, relaxation, and behavioral activation. The psychological intervention is also designed to help reduce psychophysiological arousal associated with anxiety and stress. Participants will also be taught controlled shallow breathing exercises designed to normalize the ratio of sympathetic/parasympathetic activity.
223769623|NCT04801524|BEHAVIORAL|Early access|Participants will be reminded that they have early access to COVID-19 vaccine.
223661923|NCT02909387|BEHAVIORAL|Project UPLIFT|UPLIFT is an 8-week distance-delivered mindfulness-based cognitive therapy intervention.
223661924|NCT03101111|BIOLOGICAL|MV-CHIK|Lyophilized, life attenuated, measles vectored Chikungunya vaccine; 5E+05 TCID50 (+/- 0.5 log) per dose
223661925|NCT03101111|BIOLOGICAL|MMR-vaccine|Lyophilized mixture of life attenuated Measles, Mumps, and Rubella viruses; 1000, 12500, and 1000, respectively, TCID50 per dose
223661926|NCT01801345|OTHER|Fatigued|
223661927|NCT01801345|OTHER|Rested|
223661928|NCT05525078|BEHAVIORAL|e-cigarette|Participants will select a Target Switch on which they will stop smoking cigarettes and switch entirely to the e-cigarette product.
223661929|NCT05525078|OTHER|Nicotine patch, Nicotine lozenge|Participants will select a Target Quit Date on which they will stop smoking, using the patches and lozenges provided.
223661930|NCT03073551|OTHER|Wii Group|Participants in the Wii group will be given a Wii console and video game to take home. The console includes a Wii balance board and remote controller. The Wii Fit game allows participants to choose different types of exercise such as yoga, aerobics, balance training, and more. Participant movements are shown on screen as they move with the balance board and remote control.
223661931|NCT01504906|DRUG|cyclosporine|Oral tablets, 600 mg , single dose
223661932|NCT01504906|DRUG|ticagrelor|Oral tablets, 180 mg, single dose
223769624|NCT04801524|BEHAVIORAL|Fresh start|Participants will be reminded that the vaccine offers the promise of a fresh start and chart a new path forward.
223769625|NCT03195413|PROCEDURE|Ultrasound-guided forearm nerve block|An ultrasound machine will be used to identify the median, radial, and ulnar nerves in the forearm, so that a needle may be used to apply lidocaine into the soft tissue space around those nerves.
223661933|NCT00387790|DRUG|motexafin gadolinium|Given IV
223661934|NCT00387790|RADIATION|3-dimensional conformal radiation therapy|Undergo focal cranial radiotherapy
223769626|NCT03195413|DRUG|1:1 volume measured solution of: 1% lidocaine without epinephrine and 0.5% bupivacaine without epinephrine|This is the anesthetic solution that will be administered during the ultrasound-guided nerve block
223769627|NCT03195413|DEVICE|Bedside ultrasound machine|This is the device that will be used to visualize tissues during the ultrasound-guided nerve block.
223769628|NCT01429896|OTHER|Food challenge|Double blind placebo controlled peanut challenge. Each challenge given with or without extrinsic factors exercise or sleep restriction.
224321331|NCT05686512|BEHAVIORAL|Cool Kids|"The Cool Kids Program is an Australian manualized group CBT treatment of child anxiety, which has been broadly implemented in Sweden. Several studies have found evidence of its efficacy.~Session 1-10: Group sessions including psychoeducation, cognitive restructuring (gather evidence to reevaluate anxiety related thoughts), parent skills, exposure, social skills, coping skills (cognitive and behavioral strategies to handle anxiety reactions, learning problem-solving skills). (120 minutes)"
223661935|NCT06954051|OTHER|REThink Life|REThink Life is a therapeutic game developed by David and collaborators (2019) and it is composed of four levels, each training a different emotion regulation ability (emotion recognition, mindfulness, distinguishing between rational and irrational thoughts, and positive attention bias).
223661936|NCT06078943|DEVICE|method comparison|to quantify the relationship using comparison measurement from the same sample between ABL90 FLEX PLUS and the predicate device within the reportable range for all ctBil and FHbF in heparinized arterial and venous neonatal whole blood in syringe measuring mode (S65, SP65) and heparinized mixed venous/arterial whole blood samples in capillary measuring mode (C65)
224242128|NCT05414760|DEVICE|Womed Leaf|Womed Leaf™ is a sterile, degradable film of poly(D,L-lactide) (PLA) and poly(ethylene oxide) (PEO). PEO is a biocompatible polymer with anti-adhesion and swelling properties. It is polymerized with hydrophobic PLA to form a degradable film. Womed Leaf™ is inserted in the uterine cavity by a gynaecologist surgeon with a 5 mm diameter flexible inserter. Once released, the film unfolds and grows into the uterine cavity to create a mechanical barrier and keep the uterine walls separated for approximately one week. It is then degraded and discharged naturally through the cervix.
224242129|NCT04714294|DRUG|HPP737 or placebo|HPP737 or placebo will be randomized to assign to subjects
224242130|NCT01207986|RADIATION|Low dose computed tomography (CT)|
224242131|NCT01279902|DRUG|Rituximab plus CHOP Immunochemotherapy|The R-CHOP treatment will continue up to 3 cycles with interval of 21 days: Each cycle consists of rituximab 375mg/m2 (iv, on day 1), cyclophosphamide 750 mg/m2 (iv, on day 1), doxorubicin 50mg/m2 (iv, on day 1), vincristine 1.4mg/m2 (iv, on day 1), and prednisolone 100mg (po, on day 1-5).
224242132|NCT01428830|PROCEDURE|7-day catheterization following fistula repair surgery|This group will have an indwelling urethral catheter for 7 days following fistula repair surgery.
224242133|NCT01428830|PROCEDURE|14 day catheterization|This group will have an indwelling urethral catheter for 14 days following fistula repair surgery.
224242134|NCT01846585|BEHAVIORAL|Arousal Based Therapy for Insomnia|Intervention includes education about sleep and a desensitization technique to reduce sleep interfering arousal
224242135|NCT01846585|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|Intervention includes education about sleep and behavioral and cognitive strategies to improve sleep
224242136|NCT03918486|DEVICE|Caretaker|Application of Caretaker device to subjects that are scheduled for elective surgeries.
224242137|NCT00115128|DRUG|filgrastim|Normal donors being treated with filgrastim for PBPC mobilization and collection
224242138|NCT03393728|DRUG|Propanolol|72-hour propanolol before specific treatment of hyperthyroidism
224242139|NCT02109692|OTHER|blood sample|dosage of miRNA
224242140|NCT01645839|DRUG|Liposomal Cytarabine|50mg (5 mL) by slow intrathecal injection (1-5 minutes) directly into the cerebrospinal fluid (CSF) via a ventricular catheter directly into the lumbar sac during a lumbar puncture.
224242141|NCT04065035|OTHER|Topical Body Firming Moisturizer|Moisturizer composed of a patent-pending blend of botanical extracts, bioavailable peptides, antioxidants, and a prebiotic innovation
224242142|NCT04065035|OTHER|Body Cleanser|Body cleanser to be used by study participants
224242143|NCT04065035|OTHER|Sunscreen|Sunscreen to be applied after application of moisturizer
224242144|NCT04065035|OTHER|Placebo Moisturizer|Placebo moisturizer is the vehicle control of the topical body firming moisturizer
224242145|NCT05746897|DRUG|NM1F Injection|"This is a Phase 1, multicenter, open-label, two-parts, FIH study to evaluate the tolerability, safety, PK/PD, and preliminary anti-tumor activity of NM1F as monotherapy and in combination with pembrolizumab (Keytruda®) in subjects with unresectable locally advanced, or metastatic solid tumors.~The study consists of two parts: NM1F monotherapy dose escalation (Phase 1a), NM1F dose escalation in combination with a fixed dose of pembrolizumab (Phase 1b). For each subject in the two parts, the study will include a screening period (up to 28 days), a treatment period (until treatment discontinuation), and a follow-up period."
224242146|NCT05746897|DRUG|Pembrolizumab injection|"This is a Phase 1, multicenter, open-label, two-parts, FIH study to evaluate the tolerability, safety, PK/PD, and preliminary anti-tumor activity of NM1F as monotherapy and in combination with pembrolizumab (Keytruda®) in subjects with unresectable locally advanced, or metastatic solid tumors.~The study consists of two parts: NM1F monotherapy dose escalation (Phase 1a), NM1F dose escalation in combination with a fixed dose of pembrolizumab (Phase 1b). For each subject in the two parts, the study will include a screening period (up to 28 days), a treatment period (until treatment discontinuation), and a follow-up period."
224242147|NCT00380198|DRUG|Apadenoson|
224242148|NCT03478397|OTHER|Multicomponent mHealth Intervention|Women with HPV self-collected tests will receive a multicomponent intervention which includes SMS text messages to remind them to attend triage. In addition, CHWs will receive reminders via e-mails to contact women if after 60 days from the HPV-results HPV+ they have not performed triage
224242149|NCT04799314|DRUG|PD-1 Inhibitor Tislelizumab maintenance therapy|PD-1 Inhibitor Tislelizumab maintenance therapy
224242150|NCT00486395|DEVICE|CPAP|"CPAP administered via Bubble method or Infant Flow Driver"
224242151|NCT00486395|DEVICE|Mechanical ventilation|Volume guarantee strategy
224242152|NCT01223820|DRUG|Capsaicin|5x nasal application in one day, 1 hour between each application
224242153|NCT03827291|DRUG|Exparel|Bilateral administration on each side of 30 ml aliquot containing 10 ml of liposomal bupivacaine (133 mg) and 20 ml of 0.25% bupivacaine (50 mg) in the fascial plane between the QL and psoas major muscles.
223661937|NCT04470076|DRUG|Neoadjuvant treatment: Afatinib, pemetrexed, gemcitabine, cisplatin, carboplatin|"① Eligible patients with non-squamous cell lung cancer will receive pemetrexed 500mg/m2, IV on day 1 and cisplatin 75mg/m2 or carboplatin area under curve (AUC) =5, on day 1 of a 3-week schedule for 3 cycles.~② Eligible patients with squamous cell lung cancer will receive gemcitabine 1250mg/m2 IV on day 1 and day 8, and cisplatin 75mg/m2 or carboplatin AUC =5 on day 1 of a 3-week schedule for 3 cycles .~③Patient will take afatinib at dosage of 30mg per day 48 hours after chemotherapy and will stop 24 hours before next cycle of chemotherapy."
223661938|NCT04470076|PROCEDURE|Surgical treatment|The patients who respond to neoadjuvant treatment (CR+PR) and the patients who do not respond to therapy but could still undergo surgery (SD and PD) will receive radical lung resection 3-4 weeks later after neoadjuvant.
223661939|NCT04470076|DRUG|Adjuvant treatment:afatinib|The CR, PR and SD patients who have been treated surgically will take afatinib at a dosage of 30mg per day for 2 year.
224242154|NCT03827291|OTHER|Thoracic epidural analgesia|Historical cohort that received thoracic epidural analgesia
224242155|NCT01036360|OTHER|metabolic chamber|20 adolescent boys (10 obese and 10 leans) and 20 men (10 obese and 10 lean) will complete a sub-maximal test on a ergo cycle to draw their linear relationship between VO2 and Fc. Then they will enter a metabolic chamber three times, for 24 hours each
223661940|NCT00296296|DRUG|Cyclosporin|Dose adjustment to pre-established targets
223661941|NCT00296296|DRUG|Tacrolimus|Dose adjustment to pre-established targets
223661942|NCT00296296|BEHAVIORAL|'Diabetes Education / Management'|therapeutic adjustment to target ADA criteria
223661943|NCT01874340|DRUG|Placebo|Placebo will be administered at predefined visits over the 6-month treatment phase.
223661944|NCT01874340|DRUG|AIN457|AIN457 will be administered at predefined visits over the 6-month treatment phase.
223661945|NCT05390619|PROCEDURE|50% dose of photodynamic therapy|Verteporfin (Visudyne; Novartis, Switzerland) was administrated intravenously over 10 minutes with 50% doses based on the randomization . Fifteen minutes after commencing the verteporfin infusion, a contact lens (Volk® area centralis) was positioned on the affected eye, the treatment area was exposed to a 689 nm laser with a fluence of 600 mw/cm2 for 83 seconds and a total laser energy of 50 J/cm2.
223661946|NCT05390619|PROCEDURE|70% dose of photodynamic therapy|Verteporfin (Visudyne; Novartis, Switzerland) was administrated intravenously over 10 minutes with 70% doses based on the randomization . Fifteen minutes after commencing the verteporfin infusion, a contact lens (Volk® area centralis) was positioned on the affected eye, the treatment area was exposed to a 689 nm laser with a fluence of 600 mw/cm2 for 83 seconds and a total laser energy of 50 J/cm2.
223661947|NCT03736915|PROCEDURE|Injection using 1 cc of NaCl 0.9%|The injection will be using SIMPLE block technique using 1 cc of NaCl 0.9% solution under the injection speed of 30 seconds/cc.
223661948|NCT03736915|OTHER|Patient Preference Question|Patient is asked at the end of each injection which injection they prefer
223661949|NCT03736915|OTHER|Questionnaires|Patient is asked to answer questionairres at the end of each injection
223661950|NCT01421472|DRUG|MM-121|MM-121 IV at 40 mg/mg loading dose on Cycle 1, Week 1 followed by 20 mg/mg weekly for all subsequent doses
223661951|NCT01421472|DRUG|Paclitaxel|Standard dosing of paclitaxel IV, followed by standard dosing of doxorubicin IV plus cyclophosphamide IV, followed by surgery.
224242156|NCT02942264|DRUG|Zotiraciclib (TG02)|"Phase I: Two treatment arms and several dose levels are planned; In the maximum tolerated dose (MTD) finding part, Temozolomide (TMZ) with two alternate schedules (dose dense (dd) and metronomic (mn) in combination with Zotiraciclib (TG02) will be administered;~--A cohort extension of both arms will be performed at each MTD and the treatment arm with a better progression free survival at 4 months (PFS4) will be selected for the combination treatment arm for Phase II; Patients will be randomized between two competing treatment arms: (winner of dd vs mn) TMZ + Zotiraciclib (TG02) versus dd/mn TMZ alone using a Bayesian clinical trial design. The dosage for the combination arm will be derived from the MTD determined in the Phase I component of the study."
223661952|NCT03540836|DRUG|Relacorilant (3x100 mg softgel capsules)|A single relacorilant 300mg dose (3x100 mg softgel capsules) will be given once on Day 1 of one of three treatment periods.
223661953|NCT03540836|DRUG|Relacorilant (3x100 mg hard-shell capsules)|A single relacorilant 300mg dose (3x100 mg hard-shell capsules) will be given once on Day 1 of one of three treatment periods.
223661954|NCT03540836|DRUG|Relacorilant (6x50mg hard-shell capsules)|A single relacorilant 300mg dose (6x50mg hard-shell capsules) will be given once on Day 1 of one of three treatment periods.
223661955|NCT01437306|DRUG|Lofexidine HCl|400 mcg (2 x 200 mcg tablets) administered orally as a single dose
223661956|NCT06131099|OTHER|Dohsa hou exercises|Dohsa hou is a type of psychomotor therapy that helps improve psychological problems by using bodily movements, sensation and relaxation experience.
224242157|NCT02942264|DRUG|Temozolomide (TMZ)|"Phase I: In the maximum tolerated dose (MTD) finding part, Temozolomide (TMZ) with two alternate schedules (dose dense (dd) and metronomic (mn) in combination with Zotiraciclib (TG02) will be administered; A cohort extension of both arms will be performed at each MTD and the treatment arm with a better progression free survival at 4 months (PFS4) will be selected for the combination treatment arm for Phase II; Patients will be randomized between two competing treatment arms: (winner of dd vs mn) TMZ + Zotiraciclib (TG02) versus dd/mn TMZ alone using a Bayesian clinical trial design."
224242158|NCT02482090|DRUG|Cyclophosphamide|Cyclophosphamide 60 mg/kg is administered i.v. on day -7 and day -6.
223661957|NCT06131099|OTHER|Standard treatment protocal|Standard treatment including soft tissue massage therapy, task specific training interventions, bicycle training and aerobic exercises.
223661958|NCT05274295|DEVICE|Diabetic leg ulcer treatment with adipous SVF|The Celution® System isolates approximately maximum 30 million SVF cells per 100 mL of adipose tissue to be processed. Approximately 1-3 million cells per injection (total 8-30) will be administered locally, in the target ulcer.
223661959|NCT00753246|DRUG|nimotuzumab|monoclonal antibody
223661960|NCT01068964|DRUG|0.03% Bimatoprost/0.5% Timolol Ophthalmic Solution|One drop from each bottle, administered once daily in the evening for 4 weeks Bottle 1: 0.03% Bimatoprost/0.5% Timolol Ophthalmic Solution Bottle 2: Vehicle Ophthalmic Solution
223769629|NCT03085927|BEHAVIORAL|Active Music Engagement|Three 45-minute sessions with a board-certified music therapist delivered over three days. Sessions are delivered in a private setting during in-patient hospitalization. During the first visit, parent and child will receive information on common responses of young children to cancer treatment and how parents can use music play activities to support their child during treatment. The music therapist will lead parent and child in a variety of music play activities. Parent and child will receive a music kit that includes items such as hand-held rhythm instruments, puppets, and a music CD. During the second and third visit the music therapist will lead parent and child child through the music play activities, answer questions, and make suggestions for using these activities in the hospital and at home.
223769630|NCT03085927|BEHAVIORAL|Audio Storybooks|Three 45-minute sessions with a board-certified music therapist delivered over three days. Sessions are delivered in a private setting during in-patient hospitalization. Each session children/parents will choose and listen to one of three illustrated children's books with audio recorded narration.
223769631|NCT03475160|DRUG|Sildenafil Citrate vaginal suppositories|Sildenafil citrate vaginal suppositories. Uterine artery Doppler before treatment. Uterine artery Doppler after treatment.
223769632|NCT03475160|DRUG|Placebo vaginal suppositories|Placebo vaginal suppositories. Uterine artery Doppler before treatment. Uterine artery Doppler after treatment.
223769633|NCT03475160|PROCEDURE|Uterine artery Doppler before treatment|Uterine artery Doppler before treatment: Uterine artery Doppler indices; PI and RI at cycle days 21-23 of the cycle preceding the pregnancy
223769634|NCT03475160|PROCEDURE|Uterine artery Doppler after treatment|Uterine artery Doppler after treatment: Uterine artery Doppler indices; PI and RI at the twelfth week of gestation
224242159|NCT02482090|DRUG|Fludarabine|Fludarabine 25 mg/m2 is administered on day -5 to day -1.
224242160|NCT02482090|BIOLOGICAL|TIL infusion|The maximum number of expanded TILs are infused over 30-45 minutes on day 0.
224242161|NCT02482090|DRUG|Interleukin-2|Interleukin-2 is administered as a continous i.v. infusion in a decrescendo regimen (18 MIU/m3 IL-2 over 6 hours, 18 MIU/m2 IL-2 over 12 hours, 18 MIU/m2 IL-2 over 24 hours followed by 4,5 MIU/m2 IL-2 over another 24 hours for three days).
224242162|NCT00954395|OTHER|D-dimer|D-dimer is performed at the time of anticoagulation suspension. If above or below age and gender specific cut-offs, anticoagulation is stopped and D- dimer repeated after 15, 30, 60 and 90 days.
224242163|NCT03893318|DRUG|IV lidocaine|an amide-type, short-acting local anesthetic and delivered as an aqueous solution for intravenous administration. It has a half-life of 1.5-2 hours. A traditional method of administration is via epidural delivery. Epidural lidocaine is effective and this effect is due, in part, to systemic absorption. Systemic (intravenous) administration of lidocaine is a Food and Drug Administration approved method of delivery. Low plasma levels are needed for effective use, 0.5µg/mL to 5.0µg/mL. Given this low concentration required and the short half-life, continuous infusion of lidocaine is thought to be generally safe with low risk of complication.
223661961|NCT01068964|DRUG|0.03% Bimatoprost Ophthalmic Solution and 0.5% Timolol Ophthalmic Solution|One drop from each bottle, administered once daily in the evening for 4 weeks Bottle 1: 0.03% Bimatoprost Ophthalmic Solution Bottle 2: 0.5% Timolol Ophthalmic Solution
223661962|NCT03630770|DRUG|Medium-Chain Triglyceride (MCT) Oil|Infants receive 0.5 ml/oz of MCT oil to their prescribed feedings for 21 days or until hospital discharge.
223661963|NCT00170378|DRUG|Enoxaparin|
223769635|NCT02012387|BIOLOGICAL|Active|Two injections will be administered every four weeks for four months, we will administer 4 doses within 16 weeks
223769636|NCT02012387|BIOLOGICAL|Placebo|Two injections will be administered every four weeks for four months, we will administer 4 doses within 16 weeks
223769637|NCT02012387|BIOLOGICAL|Open labeled|Two injections will be administered every four weeks for 8 months, we will administer 4 doses within 32 weeks
223769638|NCT02692989|PROCEDURE|Hip fracture surgery and anesthesia|any operative fixation for hip fracture whether under General Anesthesia or Regional anesthesia
223769639|NCT02192450|DRUG|Insulin aspart/glargine|
224242164|NCT03893318|DRUG|Placebos|Saline
224242165|NCT01516983|DRUG|icotinib|"Level 1: Standard whole brain radiation therapy plus icotinib 125 mg Tid (375 mg per day) from day1 until disease progression or intolerable toxicity.~Level 2: Standard whole brain radiation therapy plus icotinib 250 mg Tid (750 mg per day) from day1 until disease progression or intolerable toxicity.~Level 3: Standard whole brain radiation therapy plus icotinib 375 mg Tid (1125 mg per day) from day1 until disease progression or intolerable toxicity.~Level 4:Standard whole brain radiation therapy plus icotinib 500 mg Tid (1500 mg per day) from day1 until disease progression or intolerable toxicity."
224242166|NCT01516983|RADIATION|Whole brain radiotherapy|Whole Brain Radiation Therapy (WBRT) for total dose of 37.5Gy in 15 daily fractions beginning after Day 7.
223661964|NCT02469545|DRUG|Lactobacillus Plantarum 299v|Administering antidepressant drug (SSRI - selective serotonin reuptake inhibitor) and probiotic - 2x1 caps. per day of Lactobacillus Plantarum 299V (10mld colony forming units in 1 caps.) for 8 weeks.
223769640|NCT02192450|DRUG|Insulin aspart/degludec|
224242167|NCT06221319|OTHER|sacral erectör spinae plane group|sacral erectör spinae plane will be applied to patients in Group S
224242168|NCT04664621|DIAGNOSTIC_TEST|HepQuant|Patients undergoing TIPS procedure will receive a HepQuant test prior to and then after TIPS.
224242169|NCT02334722|DRUG|Levetiracetam|
223661965|NCT02469545|DRUG|Crystalline cellulose powder|Administering antidepressant drug (SSRI - selective serotonin reuptake inhibitor) and placebo of probiotic - 2x1 placebo caps. filled with micro-crystalline cellulose powder for 8 weeks.
223661966|NCT02469545|DRUG|Escitalopram|5-20mg daily
223661967|NCT02469545|DRUG|Sertraline|50-100mg daily
223769641|NCT02039531|BIOLOGICAL|Plasma rich in growth factors|
223769642|NCT02039531|DRUG|Hyaluronic Acid|
223769643|NCT06245070|DEVICE|Active transcranial direct current stimulation|HD electrodes (diameter of 1.2 cm) will be placed on the participants' skull using an HD-tDCS cap (Soterix Medical Inc. New York) and based on 5-10 international montage. Active stimulations will be delivered by a 9 MxN Soterix HD-tES device for 20 minutes( 2 mA) per day for 5 days.
224242170|NCT01118936|DIETARY_SUPPLEMENT|Magnesium supplement (magnesium hydroxide/ -oxide)|3 tablets of Mablet (360 mg per tablet) daily for 12 weeks Produced by: Gunnar Kjems APS
223661968|NCT04870580|DIAGNOSTIC_TEST|Fluorodopa PET tracer|PET/CT scan using fluorodopa tracer
223661969|NCT00775047|OTHER|Pharmacist-administered|women will receive their injections at a pharmacy by a clinical pharmacist
223661970|NCT00775047|OTHER|clinic-administered injections|women will return for their injections to the clinic where recruitment took place. They will receive one at 3 months and 6 months.
223661971|NCT00755638|BIOLOGICAL|ACE-031|single subcutaneous dose of ACE-031
223661972|NCT05197660|PROCEDURE|surgical procedures|number of hospital stays
223661973|NCT05222672|OTHER|His Bundle Pacing|Pacing of the His bundle
223661974|NCT00444678|DRUG|Cetuximab|500 mg/m2, IV every two weeks
223661975|NCT00444678|DRUG|Oxaliplatin|85 mg/m2, IV, q 2 weeks
223661976|NCT00444678|DRUG|Capecitabine|2500 mg, po bid x 7 days every two weeks
223661977|NCT03260049|PROCEDURE|pars plana vitrectomy|pars plana vitrectomy
223661978|NCT04170972|OTHER|Acute exercise|One hour of acute one-legged knee-extensor exercise followed by 3 hours recovery and 2 hours insulin (1.5 mU/min/kg) stimulation.
223661979|NCT06044051|OTHER|Blood sample|An additionnal volume of blood will be collected at inclusion and at each follow-up visit
223661980|NCT06044051|OTHER|Expectoration|Expectoration will be collected at inclusion and at each follow-up visit
223661981|NCT06044051|OTHER|Nasopharyngeal swab|A nasopharyngeal swab will be collected at inclusion and at each follow-up visit after an induced sputum
223661982|NCT02463890|OTHER|Training|
223661983|NCT02463890|OTHER|Control|
223661984|NCT02794675|DRUG|Cesium 131|The number sources and activity will be based on the target volume to deliver total radiation dose, this will vary per patient.
223661985|NCT02735135|DEVICE|AIRSOFT DUO for 1 day|The patient is placed on an AIRSOFT DUO mattress for 1 day.
223661986|NCT02735135|DEVICE|SENTRY 1200 for 1 month|The patient is placed on a SENTRY 1200 mattress for 1 month.
223661987|NCT02735135|DEVICE|SENTRY 1200 for 1 day|The patient is placed on a SENTRY 1200 mattress for 1 day.
223661988|NCT02735135|DEVICE|AIRSOFT DUO for 1 month|The patient is placed on an AIRSOFT DUO mattress for 1 month.
223661989|NCT03354507|DIETARY_SUPPLEMENT|Sodium bicarbonate|Sodium bicarbonate. See arms.
223661990|NCT03224559|DEVICE|Transcranial Electrical Stimulation|Transcranial Electrical Stimulation
223661991|NCT02747433|DEVICE|Robot-Assisted Therapy (RT)|Highly repetitive robot-assisted therapy for paretic arm with Armeo (1 hr sessions, 3x week for 3 weeks) followed by robot-assisted therapy for hand motions with Amadeo (3x week for 3 weeks). Robot training to be accompanied with ALPS motor learning program directed toward UE self management and transfer of training to daily activities in home \& community.
223661992|NCT02747433|DEVICE|Robot & Task-Oriented Training (RT-TOT)|Highly repetitive robot-assisted therapy for paretic arm with Armeo (30 min sessions, 3x week for 3 weeks) followed by robot-assisted therapy for hand motions with Amadeo (3x week for 3 weeks). Task oriented training will be delivered for remaining 30 mins of each treatment session. Robot and task oriented training to be accompanied with ALPS motor learning program directed toward UE self management and transfer of training to daily activities in home \& community.
223661993|NCT00606905|BIOLOGICAL|Gamimune N or Gamunex 10%|500 mg/kg administered in the follicular phase of the menstrual cycle. With conception, infusions every four weeks until 18-20 weeks of gestation.
223661994|NCT00606905|OTHER|normal saline|equivalent volume of normal saline
223661995|NCT03870594|DIAGNOSTIC_TEST|glycated hemoglobin|hemoglobin A1c level in blood
224242171|NCT01118936|DIETARY_SUPPLEMENT|Placebo|3 tablets of placebo daily for 12 weeks
224242172|NCT00911235|DRUG|Fesoterodine|Single 8 mg oral dose of fesoterodine
223661996|NCT02224885|DEVICE|CT-guided percutaneous biopsy or ablation|Standard interventional radiology procedure for a biopsy or ablation in the liver or in the lung
223661997|NCT03922113|OTHER|Patient follow up|Patient follow up during one month
223661998|NCT00564057|DRUG|candesartan|tablet 8-16 mg once daily, one year
223661999|NCT00564057|DRUG|lercanidipine|tablets 10-20 mg once daily, one year
223662000|NCT03596541|DEVICE|Heart and Respiratory Auscultation of an open real-time tele-stethoscopy system (EHAS-Fundatel digital stethoscope)|We compare the respiratory and heart auscultation of clinicians using the EHAS-Fundatel digital stethoscope and a conventional stethoscope and we will observe; inter-observer and intra-observer differences by two auscultation methods.
223662001|NCT04352426|OTHER|Exercise Test|Tests were conducted to evaluate exercise capacity.
223662002|NCT05729867|PROCEDURE|Endoscpic biliary drainage using fully covered metal stent|"After selective cannulation of the bile duct, cholangiography is obtained using contrast agent.~A guide wire is passed through the stricture, and then fully-covered metal stent is inserted under fluoroscopy guidance during ERCP."
223662003|NCT00227708|DRUG|docetaxel|
223662004|NCT00227708|PROCEDURE|quality-of-life assessment|
223662005|NCT03264118|PROCEDURE|Scaling and root planing|Furcation treatment by scaling and root planing
223662006|NCT03264118|DRUG|Toluidine Blue O|Antimicrobial photodynamic therapy with toluidine blue O (10mg/ml) and red laser.
223662007|NCT04143178|OTHER|Expressive Writing|The expressive writing is a form of writing therapy developed primarily by James W. Pennebaker in the late 1980s consisting of writing about stressful and traumatic experience for 15-20 min for 3 consecutive days, including one's thoughts and feelings. The expressive writing allows people to express and process emotions, feelings, and thoughts related to the life events and consequent changes and this may favor a mental reorganization of the negative events, a greater expression and regulation of the emotions related to them. This intervention could provoke social, emotional, and consequently, psychophysical changes as is showed in patients with chronic diseases and cancer. In the present study, to all participants in the writing group, 5 days after the transplant, has been asked to write for 3 consecutive days, 20 minutes each days about their deepest emotions and feelings related to the chronic failure, the transplant and their expectations after that.
223662008|NCT04143178|OTHER|Neutral Writing|Five days after the transplant, to the control group participants has been asked to write for 3 consecutive days 20 minutes a day on an assigned neutral theme (eg. describe 1 object in the room) as objectively as possible, without mentioning their emotions or thoughts related to it.
223769644|NCT06245070|DEVICE|Sham transcranial direct current stimulation|HD electrodes (diameter of 1.2 cm) will be placed on the participants' skull using an HD-tDCS cap (Soterix Medical Inc. New York) and based on 5-10 international montage. Sham stimulations will be delivered by a 9 MxN Soterix HD-tES device. In the sham tDCS condition, the current is only on for 30 seconds before it is ramped back down to 0 milliamps (mA), although the electrodes are still worn for 20 minutes.
223662009|NCT06093074|BEHAVIORAL|self-management program after traumatic injuries|The self-management support (SMS) program is manualized and will include eight weekly 2.5-hour sessions in groups of 5-7 participants. This feasibility trial will assess both face-to-face delivered program and a tele-health program via electronic devices. The tele-health intervention will be delivered with the same SMS content, frequency, and in-group mode.
223769645|NCT04381104|DRUG|Paracetamol|The intervention arm will receive 2 capsules of paracetamols of 500mg.
224242173|NCT00911235|DRUG|fesoterodine plus fluconazole|On Day 1, fluconazole (200 mg oral dose) will be given 1 hour before and approximately 11 hour following a single 8 mg oral dose of fesoterodine (fesoterodine SD). Fluconazole will also be administered 200 mg BID on the Day 2 (ie, at approximately 24 and 36 hours following the fesoterodine SD treatment given on Day 1)
224242174|NCT04175366|OTHER|Shared Decision Making|Shared Decision Making including adapted decision aid.
224242175|NCT02305225|BEHAVIORAL|Sleep Deprivation|
224242176|NCT00856388|DRUG|fludarabine phosphate|Given IV
224242177|NCT00856388|DRUG|melphalan|Given IV
224242178|NCT00856388|RADIATION|total-body irradiation|Undergo total-body irradiation
224242179|NCT00856388|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Undergo allogeneic stem cell transplantation
224242180|NCT00856388|BIOLOGICAL|anti-thymocyte globulin|Given IV
224242181|NCT05688306|DRUG|Recombinant Human Interleukin-11 for Injection|received rhIL-11 injection for at least 5 consecutive days
224242182|NCT01975064|DRUG|Propofol|Propofol will be infused individually for a sufficient level of anesthesia during the entire surgical procedure.
224242183|NCT01975064|DRUG|Sevoflurane|Sevoflurane will be administered by vaporizer individually for a sufficient level of anesthesia during the entire surgical procedure.
224242184|NCT03527017|OTHER|Survey on Use of Tobacco Products in the General Population|Face-to-face survey to estimate the prevalence of current tobacco use status in the general population of Germany.
224242185|NCT03527017|OTHER|Survey on Use of Tobacco Products in IQOS Users|Online survey to describe patterns of use in adult IQOS users residing in Germany.
224242186|NCT02485522|OTHER|No Intervention|No intervention
224242187|NCT02278835|OTHER|breathing exercises|3 sets of 10 repetitions of deep breathing exercises
224242188|NCT02278835|DEVICE|incentive spirometry|3 sets of 10 repetitions of deep breathing exercises with incentive spirometry
224242189|NCT02278835|DEVICE|Intermittent positive pressure breathing|20 minutes breathing with intermittent positive pressure
224242190|NCT02278835|DEVICE|Continuous positive airway pressure|20 minutes breathing with continuous positive airway pressure
224242191|NCT01051193|DRUG|Oxcarbazepine|
224242192|NCT03644147|DRUG|Acetaminophen|Acetaminophen will be intravenously administrated to treatment group after the end of surgery.
224242193|NCT04085107|BEHAVIORAL|Face-to-face interviews|243 PwMCI will receive two face-to-face interviews to complete two sets of questionnaires, of which 30 participants will be recruited attend a 1-hour semi-structured interview.
224242194|NCT04805411|BIOLOGICAL|CM310|IL-4Rα monoclonal antibody
223662010|NCT04241978|OTHER|Patient Decision Aid (PtDA)|Patient Decision Aid (PtDA) are tools that enables to promote and facilitate patients' involvement in medical decisions concerning their health
223662011|NCT04241978|OTHER|Brochure with general information about osteoarthritis|Participants of the control group will be given a brochure with general information about osteoarthritis of the hip, knee, ankle and foot instead of the PtDA
223662012|NCT00006233|BIOLOGICAL|therapeutic allogeneic lymphocytes|
223662013|NCT00006233|DRUG|cyclosporine|
223662014|NCT00006233|DRUG|fludarabine phosphate|
223662015|NCT00006233|DRUG|mycophenolate mofetil|
223662016|NCT00006233|PROCEDURE|peripheral blood stem cell transplantation|
223662017|NCT00006233|RADIATION|radiation therapy|
223662018|NCT00680238|DRUG|Human derived FSH|Customized for each patient
223769646|NCT06531603|DRUG|bupivacaine wound infilteration|drug was given at the end of surgery
224242195|NCT04805411|BIOLOGICAL|Placebo|Placebo
224242196|NCT06094517|OTHER|Interview|Persistent Lower Back Pain Patients on waiting list under going a usual care pathway following referral to Physiotherapy will be interviewed for views on sleep health
223662019|NCT03179202|DEVICE|SPRINT Peripheral Nerve Stimulation (PNS) System|"The SPRINT PNS System is a device which delivers mild electrical stimulation to the muscles in the low back. The System includes up to four small wires (called Leads) that are placed through the skin into the muscles in the low back. The wires attach to device(s) worn on the body that deliver stimulation (called Stimulators). The PNS System was approved by the FDA for up to 60 days of use for the management of acute and chronic pain, including back pain."
223769647|NCT06531603|DRUG|Bupivacaine plus dexmedetomidine wound infilteration|drug was given at the end of surgery
224242197|NCT00643578|DRUG|formoterol|a single dose of 24 mcg of formoterol delivered by dry powder inhaler (Twisthaler)
224242198|NCT00643578|DRUG|formoterol|a single dose of 12 mcg of formoterol delivered by dry powder inhaler (Twisthaler)
224242199|NCT00643578|DEVICE|Dry Powder Inhaler (Twisthaler)|subjects inhaled deeply and forcefully and held their breath for 10 seconds for each dose
224242200|NCT03998865|DEVICE|Provisional abutment material|The effect of the provisional abutment material on the characteristics of the bacterial microbiota will be assessed by using PEEK (experimental) or Titanium (active comparator) provisional abutments.
224242201|NCT00695162|OTHER|quiet|no noise
224242202|NCT00695162|OTHER|non-speech noise|noise without speech
224242203|NCT00695162|OTHER|speech noise|noise with speech present
224242204|NCT00242866|DRUG|GW274150|The tablets used in this study will contain either 5mg or 30mg of GW274150
223769648|NCT03526224|DRUG|Dimethyl Fumarate|Individuals with MS treated with dimethyl fumarate (Tecfidera)
223769649|NCT03526224|DRUG|Teriflunomide|Individuals with MS treated with teriflunomide (Aubagio)
224242205|NCT00242866|OTHER|Placebo|Placebo to Match GW274150
223662020|NCT06125470|BEHAVIORAL|Uptake of quality Reproductive health and Family planning products, information and Services|Strengthening capacity of health facilities and outreach to deliver quality reproductive and family planning services and address demand side barriers to the uptake of the services
223662021|NCT06125470|BEHAVIORAL|Capacity building of facility based and community based healthcare providers (public and private sector) on FP /SRH|"Training sessions on FP / SRH including FP Methods - LARC, PPIUD - Task Sharing \& Shifting for facility based healthcare providers at provincial level for Master Trainers with trickle down sessions at district level.~Training on Sayana Press, ECP, Balance Counselling Strategy and Life Skills Based Education for community-based healthcare providers including LHWs at district level."
223662022|NCT06125470|BEHAVIORAL|Adolescent Engagement|Identification of adolescent-friendly spaces through community based platforms including LHW health houses for girls and village health committees for boys with context-appropriate arrangements for LSBE and SRH counselling.
223662023|NCT06125470|BEHAVIORAL|Renovation and Refurbishment of selected healthcare facilities|Identification and improvement/ renovation of public and private healthcare facilities to strengthen the quality, provision and delivery of FP/SRH services, especially counselling, to catchment population
223662024|NCT06125470|BEHAVIORAL|Use of Data for Effective Decision-making|Improvement in data recording at the source level with reporting at existing platforms i.e. DHIS and LHW-MIS and use of this data for local decision making
223662025|NCT06125470|BEHAVIORAL|Procurement of FP/SRH medical supplies and equipment|Provision of commodities / supplies for shortest-time possible in facilities having stock-outs
223769650|NCT00194012|DRUG|Aripiprazole|Addressed in arm description.
223769651|NCT00194012|DRUG|Placebo|Addressed in arm description.
223769652|NCT01516268|DRUG|Sufentanyl|"As intervention 1cc sufentanyl is added to bupivacain in case group for TAP block.~As comparator 1cc normal saline is added to bupivacain in control group for Tap block."
223769653|NCT01595516|DRUG|Nebivolol|5 mg tablet to be taken by mouth once per day for 12 weeks
223769654|NCT01595516|DRUG|Metoprolol|100 mg tablet to be taken by mouth once per day for 12 weeks
223769655|NCT01595516|DRUG|Placebo|Gelatin capsule to be taken by mouth once per day for 12 weeks
224242206|NCT06059326|DRUG|HSK7653 10 mg|Tablet, HSK7653 10 mg Q2W, 12 weeks
224242207|NCT06059326|DRUG|HSK7653 25 mg|Tablet, HSK7653 25 mg Q2W, 12 weeks
223769656|NCT01595516|OTHER|Bradykinin|Bradykinin is infused into the brachial artery at doses of 12.5, 25.0 and 50.0 ng/100 mL of forearm tissue /min. BDK stimulates the endothelial cells to release tissue type plasminogen activator (t-PA). Blood flow in mL/100 mL tissue/min is also measured to BDK.
223769657|NCT01595516|OTHER|Saline|Baseline or resting forearm blood flow is measured in response to saline for 5 minutes before each drug infusion. t-PA release in response to the saline is also measured.
223769658|NCT01595516|OTHER|Vitamin C|The acute effects of into-arterial vitamin C on the ability of the endothelium to release t-PA was determined before and after the nebivolol and metoprolol intervention. After allowing sufficient time (\~20 minutes) for FBF and plasma t-PA concentrations to return to baseline following the initial infusion of BDK, vitamin C (24 mg/min) was infused at a constant rate while the BDK dose-response curves were repeated. t-PA and FBF were measured.
223769659|NCT00678600|OTHER|Standard (static) Computer Alerts|Static Computer Alerts on Patient's EMR webpage.
223769660|NCT00678600|OTHER|Enhanced Computer Alerts|Population level and asynchronous alerts with enhanced functionality
224242208|NCT06059326|DRUG|HSK7653 50 mg|Tablet, HSK7653 50 mg Q2W, 12 weeks
224242209|NCT06059326|DRUG|Placebo|Tablet, 0 mg Q2W, 12 weeks
224242210|NCT05809765|OTHER|8-week breath training program|The participants were asked to be seated comfortably and raise their heads by 30° with the guidance of the investigator. During the inspiration process, the participants' abdomens bulged. They then held their breaths for 5 seconds before exhaling from their mouths for twice the duration of inspiration. Breath training was performed five times each hour throughout the three-hour duration of each dialysis session. In sum, the experimental group performed Triflow breath training 15 times during each dialysis session. The experimental group and the control group were randomly assigned by a coin toss.
224242211|NCT04504396|DRUG|GLP-1 receptor agonist|PB-119 is an investigational pegylated human glucagon-like peptide-1 (GLP-1) receptor agonist. The dosing regimen is 150μg once every week as subcutaneous administration. Patients in PB-119 group will be administered the active drugs for 52 weeks (24+28).
224242212|NCT04504396|DRUG|Placebo|PB-119 matched placebo will be used once every week as subcutaneous administration to placebo group for 24 weeks.
224242213|NCT03200067|BEHAVIORAL|Personalized health care service|Personalized health care service, such as rehabilitation exercise recommendation, lifestyle activity coaching, health data monitoring
224242214|NCT01132963|OTHER|Outdoor Shoes|Patient will be wearing sturdy outdoor shoes to complete balance tests
223662026|NCT03255629|DRUG|glucagon|novel, stable non-aqueous glucagon formulation provided by Xeris Pharmaceuticals
223662027|NCT03255629|DEVICE|Closed loop glucagon pump|a novel closed-loop glucagon system (CLG) incorporating a novel, stable non-aqueous glucagon formulation together with an infusion pump system (Omnipod) guided by real-time continuous glucose monitoring (Dexcom) that is triggered by a hypoglycemia alert algorithm.
223662028|NCT02781740|DEVICE|Continous Positive Air Pressure Device|
223662029|NCT03189290|PROCEDURE|posterior Quadratus Lumborum Block (QLB)|Procedure (experimental): ultrasound guided posterior Quadratus Lumborum Block (QLB) Procedure (experimental): Sham Block
223662030|NCT05291169|DEVICE|Omeza® OCM™|"Omeza® OCM™ is a wound care matrix comprised of coldwater fish peptides (device) and cod liver oil (drug).~OCM™is supplied in a sterile single use vial."
223662031|NCT02826720|OTHER|No intervention was applied|No intervention was applied
224242215|NCT01132963|OTHER|Pillow Paw Slippers|Patient will be wearing Pillow Paws slippers to complete balance tests which are issued to patients who do not have shoes in NHS hospitals in the UK
223662032|NCT04800952|OTHER|blood samples and filtered fluid will be collected.|"Arterial blood samples will be collected just before the commencement of continuous venovenous haemofiltration (CVVHF) and 1 h after the termination of CVVHF.~Prefilter and post-filter venous blood samples and filtered fluid will be collected 1 and 3 h after the commencement of CVVHF and at the end of CVVHF."
223662033|NCT02910505|DEVICE|enLighten Laser|Laser for tattoo removal
223662034|NCT00125125|DRUG|Fluvastatin|
223662035|NCT00539175|DEVICE|infrared light|pulsed infrared light will be applied to feet, ankles and popliteal fossae of patients with diabetic neuropathy
223662036|NCT00539175|DEVICE|infrared light; placebo|patients will be exposed to the same machine used to provide pulsed infrared light, but the light emitting diodes will not be activated. All other aspects of the treatment will be the same. The patient and investigator will be blind to treatment assignment.
223662037|NCT02694432|BEHAVIORAL|GOALS|16 weeks of online support to improve blood pressure using traditional behavioral lifestyle approaches and medication adherence support.
223662038|NCT02694432|BEHAVIORAL|Minding GOALS|16 weeks of online support to improve blood pressure using traditional behavioral lifestyle approaches and medication adherence support, coupled with a mind-body-behavior program to further enhance improvements in blood pressure.
223662039|NCT02762773|PROCEDURE|non-dissection of inferior rectus sheath|Non-dissection of inferior rectus sheath
223769661|NCT01312545|DEVICE|3DP|intervention involving local made implant with different fabricating technique-3-dimensional printing (3DP) technique.
224242216|NCT02199392|DRUG|Lenvatinib|subjects will take a single oral dose of 24 mg lenvatinib on three separate occasions (Period 1, Day 1; Period 2, Day 15; and Period 3, Day 43). In Period 2, Day 15, subjects will also take a single oral dose of 600 mg po rifampin. In Period 3, subjects will receive 600 mg rifampin po daily for 21 days (Period 3, Days 29 to 49). On Day 43 of Period 3, subjects will take 24 mg lenvatinib in addition to the rifampin.
224242217|NCT01617668|DRUG|LCL161|LCL161 was available as 300 mg, tablets, which was supplied in child-resistant bottles.
224242218|NCT01617668|DRUG|paclitaxel|"Commercially available paclitaxel was sourced locally by each study site. Generic paclitaxel could be used for study treatment.~iv 80mg/m2"
224242219|NCT00016419|BIOLOGICAL|anti-thymocyte globulin|3.5 mg/kg/d IV over 12 hrs day 1
223662040|NCT02762773|PROCEDURE|control|Dissection of inferior and superior aspect of the rectus sheath
223662041|NCT03480464|BEHAVIORAL|App-technology to increase physical activity|The application will send daily reminders to register and notices with information about the health benefit of physical activity, medication, supplementary vitamins and diet after surgery
223662042|NCT05896280|PROCEDURE|EST|Stones are taken by cutting the papillary sphincter
223662043|NCT05896280|PROCEDURE|ECPP|During ERCP, a generous biliary sphincterotomy (\>1 cm) will be performed to facilitate large stone extraction by use of a lithotripsy basket and a stone extraction balloon. After all stone fragments were cleared from the bile duct, this group will undergo ECPP after EST. A single-pigtail biliary stent will be placed (suspended overlength biliary stent, 7F × 20 cm). Then the rotatable repeatable opening and closing of soft tissue clamps (referred to as harmony clips, Mico-Tech, ROCC-D-26-195) should be applied to extend the bile duct axially, linear clamp the incised duodenal papilla, taking care to avoid clamping the bile duct stent, and removing the bile duct stent 3 weeks after ECPP.
223662044|NCT01147627|DRUG|exenatide injection|Patients in exenatide group will be treated with exenatide (Byetta®, Eli Lilly and Company) 5 µg BID for the first 4 weeks and then 10 µg BID thereafter.
223769662|NCT01312545|DEVICE|Medpor|commercial porous polyethylene
224242220|NCT00016419|DRUG|cyclosporine|3 mg/kg bid days 5-94 then taper to 0 at day 124 PO
224242221|NCT01867723|OTHER|Internet communication application|Intervention 1 Effect of internet support program will be tested on cancer patients and their family caregivers No intervention
224242222|NCT00406913|DRUG|mupirocin ointment|
224242223|NCT00406913|OTHER|SOC sterilization|
224242224|NCT03450564|BEHAVIORAL|Women Education|This intervention intends to provide health education message for women enhance FP utilization in pastoralist community. It was cognizant that, Ethiopia is the second most populous country in Africa. And there is a great discrepancy between contraceptive use, unmet need for FP and maternal and child morbidity and mortality between the pastoralist and agrarian community. Pastoralist community in the country expressed as low contraceptive users, a high unmet need for FP and highest maternal and child morbidity and mortality. The previous study indicates that only 5.4% of the women use contraceptive. The most common reason mentioned for not using of contraceptive are lack of awareness, demand for a large number of children and male dominance in all decision making power in general and FP in particular. In light of this, the study hypothesized that working with men and educating women towards the use of FP could enhance the use of family planning utilization.
223662045|NCT01147627|DRUG|Mixed Protamine Zinc Recombinant Human Insulin Lispro 25R|Patients in insulin group will be treated with premixed insulin analog (Humalog Mix 25, Eli Lilly and Company). The initial insulin doses are 0.4 IU/kg per day(50% before breakfast and 50% before dinner). Insulin doses are titrated following a forced schedule according to blood glucose before breakfast and dinner.
223662046|NCT01147627|DRUG|Pioglitazone|Patients in thiazolidinedione group will be treated with Pioglitazone 30mg daily as single dose. The dose will be increased to 45mg daily after 4 weeks.
223662047|NCT00000460|BEHAVIORAL|Low intensity exercise|
223662048|NCT00000460|BEHAVIORAL|High intensity exercise|
223662049|NCT03924895|DRUG|Pembrolizumab|Pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle.
223662050|NCT03924895|PROCEDURE|Surgery (radical cystectomy (RC) plus Pelvic Lymph Node Dissection [PLND])|Surgical RC+PLND will be done in accordance with the American Urological Association (AUA)/American Society of Clinical Oncology (ASCO)/American Society for Radiation Oncology (ASTRO)/Society of Urologic Oncology (SUO) guidelines.
223769663|NCT04912505|DRUG|Aspirin|Run-in phase during one week with daily aspirin intake at 8 AM; visit 1: blood sampling at H24 and H2; intermediate phase (two weeks): daily aspirin intake at 8 PM; visit 2: blood sampling at H12; then daily intake of aspirin at the time preferred by the patient and study end visit 2 weeks after visit 2
223769664|NCT05059158|RADIATION|positron emission tomography (PET)|18-Flutemetamol PET (clinical indicated) is going to be performed at the visit.
223769665|NCT02497664|OTHER|Active Breathing Control|
223662051|NCT03924895|DRUG|Enfortumab Vedotin|Enfortumab vedotin 1.25 mg/kg by intravenous (IV) infusion, given on Days 1 and 8 of each 21-day cycle.
223662052|NCT05701280|DEVICE|Deep Brain Stimulation|Deep Brain Stimulation (DBS) of the dentate nucleus area of the cerebellum plus motor rehabilitation to improve upper-extremity function.
224242225|NCT03450564|BEHAVIORAL|Male Involvement|Male involvement was a feature of intervention in this arm. Comprehensive health education about FP was given in addition to the video message about FP. In pastoralist community the most reason mentioned for not using of FP are husband objection and religion influence. And most of the decisions are in the palm of husband to seek care for reproductive, maternal and neonatal health in general and FP in particular. Besides, the pastoralist community manifested by high total fertility rate and maternal and child morbidity and mortality.
223662053|NCT05701280|OTHER|Rehabilitation|Motor rehabilitation to improve upper-extremity function.
223662054|NCT00858338|PROCEDURE|Potentially curative surgery|"Surgery:~Week 1: Potentially curative surgery. If the tumor successfully resected (microscopically disease-free margins, Ro, with regional lymphadenectomy for proper staging), the ip catheter in place.~Weeks 2-4: Recovery. Then continue to adjuvant IP chemotherapy."
223662055|NCT00858338|DRUG|Floxuridine (IP)|"Adjuvant IP Chemotherapy:~week 1: ip Floxuridine 3 gm/day, days 1,2,3. week 2: 1 week without treatment. week 3: ip Floxuridine 3 gm/day protocol days 15,16,17. week 4: 1 week without treatment. Then continue to chemoradiation therapy."
223662056|NCT00858338|PROCEDURE|Adjuvant Chemoradiation therapy|"Adjuvant Chemoradiation therapy:~week 1: 5-FU 425 mg/m2/day x 5 days + Leucovorin (LV) 20 mg/m2/day x 5days; weeks 2-4: recovery; weeks 5-9: radiation, 150 cGy x 5 fractions/week x 5 weeks; week 5: 5-FU 400 mg/m2 + LV 20 mg/m2 each day on days 1-4; week 9: 5-FU 400 mg/m2 + LV 20 mg/m2 each day on days 1-3; week 14: 5-FU 425 mg/m2/day x 5 days + Leucovorin (LV) 20 mg/m2/day x 5days; week 19: 5-FU 425 mg/m2/day x 5 days + Leucovorin (LV) 20 mg/m2/day x 5days."
223662057|NCT05354362|COMBINATION_PRODUCT|ATG-010 and ATG-008|Patients enrolled will receive consecutive daily treatment at assigned dose level. The starting dose of ATG-010 at the dose escalation phase will be 60 mg QW, which could be escalated to 80 mg QW, 100 mg QW, 60 mg BIW. In case 60 mg QW of ATG-010 with any dose of ATG-008 is NOT tolerable, 40 mg QW ATG-010 could be explored. The starting dose of ATG-008 will be 15 mg QD, which could be escalated to 20 mg QD, with maximum of 30 mg QD. SRC will be consulted before each dose escalation starts.
223662058|NCT05099367|DIAGNOSTIC_TEST|Microdialysis, current induced vasodilation|"CIV will be applied over all microdialysis fibers: one perfused with saline, one perfused with a preferential COX-1 blocker; and one perfused with a preferential COX-2 blocker.~CIV will be applied over all fibers in the following conditions: one perfused with saline, one perfused with fluconazole and L-NMMA, and the last one perfused with lidocaine.Dialysate collection will be performed after each CIV: dermal PGI2 metabolite (6-ketoPGF1α) and other COX-dependent prostanoids or metabolite (e.g. 11-dehydroTXB2) will be collected in the dialysate fluid and quantified. One hour after the last condition, treprostinil will be perfused over all fibers."
223662059|NCT05099367|DIAGNOSTIC_TEST|Skin biopsy|Skin biopsy will be proposed. It will be performed on the internal superior calf (medial gastrocnemius), at a reasonable distance from the foot
223662060|NCT05099367|DIAGNOSTIC_TEST|peri-ulcerated skin biopsy|Non-ulcerated skin from the peri-wound area will be collected. These patient will not undergo all the procedures included in this protocol.
223662061|NCT01996839|DRUG|Loteprednol Etabonate Gel (BID)|One drop of LE gel instilled into the study eye two times per day (BID) for 14 days
223662062|NCT01996839|DRUG|Loteprednol Etabonate Gel (TID)|One drop of LE gel instilled into the study eye three times per day (TID) for 14 days.
223662063|NCT01996839|DRUG|Vehicle (BID)|One drop of vehicle instilled into the study eye two times per day (BID) for 14 days
223662064|NCT01996839|DRUG|Vehicle (TID)|One drop of vehicle instilled into the study eye three times per day (TID) for 14 days
223662065|NCT04613843|OTHER|Water Stirring|Following an active heating protocol, the cooling intervention includes vigorous water stirring throughout cold water immersion.
223662066|NCT04613843|OTHER|No Water Stirring|Following an active heating protocol, the cooling intervention includes no water stirring throughout cold water immersion.
223662067|NCT01625260|BIOLOGICAL|ALT-801|Intravenous infusion: 2 treatment courses and 1 maintenance course; on Day 3, 5, 8 and 15 of each course.
223662068|NCT01625260|DRUG|Gemcitabine|Intravenous infusion: 2 treatment courses and 1 maintenance course; on Day 1 and 8 of each course.
223662069|NCT06185751|BIOLOGICAL|WS-CART-CS1|-Subject will be hospitalized for 7 days
223662070|NCT06185751|DRUG|Lymphodepleting chemotherapy|"* Cyclophosphamide 500 mg/m\^2 IV on Days -5, -4, and -3~* Fludarabine 30 mg/m\^2 IV on Days -5, -4, and -3"
223662071|NCT05903885|OTHER|On-site Fecal Immunochemical Test (FIT) Kit Distribution|Participants will receive home based Fecal Immunochemical Test (FIT) kit directly at the Department of Motor Vehicles (DMV) location at 4606 N 56th St Suite 100, Omaha, NE 68104, by research staff.
223769666|NCT00623220|OTHER|N2O|EMONO
223769667|NCT00623220|OTHER|oxygen|oxygen
223769668|NCT04987359|BEHAVIORAL|Multimodal Lifestyle Program|The multimodal lifestyle program will utilize intensive behavioral therapy with structured exercise training and nutritional counseling.
223769669|NCT01513317|DRUG|Siltuximab|15 mg/kg administered as a 1-hour intravenous infusion every 4 weeks
223769670|NCT01513317|DRUG|Placebo|Administered as a 1-hour intravenous infusion every 4 weeks
223769671|NCT01513317|DRUG|Best supportive care (BSC)|Best supportive care according to local standards and guidelines
223769672|NCT00585949|PROCEDURE|Percutaneous Coronary Angioplasty|This is a procedure by which the blood vessels of the heart are imaged with an insertion of a catheter in the groin and blocked arteries are opened.
223662072|NCT05903885|OTHER|On-site With Social Media Advertising Fecal Immunochemical Test (FIT) Kit Distribution|Participants will receive home-based Fecal Immunochemical Test (FIT) kits directly at the Department of Motor Vehicles (DMV) location at 4606 N 56th St Suite 100, Omaha, NE 68104, by research staff supplemented by exposure to targeted social media advertisements.
223662073|NCT06095596|DRUG|Upadacitinib|Oral upadacitinib 45mg/d for 8 weeks in the induction therapy.
223662074|NCT06095596|DRUG|Vedolizumab|Vedolizumab 300mg intravenously on weeks 1, 2, 6, and then on every 8-week interval.
223662075|NCT03899805|DRUG|Eribulin|The ability of chemotherapy to kill cancer cells depends on its ability to halt cell division. Usually, the drugs work by damaging the RNA or DNA that tells the cell how to copy itself in division. If the cells are unable to divide, they die. The faster the cells are dividing, the more likely it is that chemotherapy will kill the cells, causing the tumor to shrink. They also induce cell suicide (self-death or apoptosis).
223769673|NCT00585949|PROCEDURE|Angiography|Angiography is an imaging technique to see coronary blood vessels.
223769674|NCT05786456|PROCEDURE|Discussion|Participate in group and web-based self-study sessions
223769675|NCT05786456|OTHER|Informational Intervention|Receive handouts
223769676|NCT05786456|OTHER|Media Intervention|View videos
223769677|NCT05786456|OTHER|Questionnaire Administration|Ancillary studies
223769678|NCT05786456|BEHAVIORAL|Telephone-Based Intervention|Participate in check-in calls
223769679|NCT06957821|DRUG|Pegulicianine|Pegulicianine (LUMISIGHT) Inflammatory activity
224242226|NCT03450564|OTHER|Control group|The third group in this community based intervention was following the community without provision of male iand married women education. In this group there was no intervention by the researchers. However, the activities performed by the government about family planning provision was maintained.
224242227|NCT00595608|DRUG|Sterimar Spray|Post-op nasal spray, three times a day
224242228|NCT00595608|DRUG|Generic homemade nasal saline spray (salt and water)|post op nasal saline spray in syringe, three times a day
224242229|NCT06484933|BEHAVIORAL|Focus groups of health professionals and users of primary care|"2 phases of Focus Group will be organized :~* the participants of the first 4 Focus Groups will propose an operational definition of the notion of a professional team in primary care (validation by consensus based on the definitions in the literature)~* 12 subsequent Focus Groups will be organized in 12 primary care teams to describe the ways in which risks are managed in primary care"
224242230|NCT04590300|OTHER|QUESTIONNAIRES|"1 questionnaire at the beginning of the study, before FTE program~1 questionnaire at the end of FTE"
224242231|NCT00686959|DRUG|Pemetrexed|infusion over 10 minutes
224242232|NCT00686959|DRUG|Cisplatin|infusion over 60 minutes with adequate anti-emetic treatment and appropriate hydration per local practice guidelines
224242233|NCT00686959|DRUG|Etoposide|administered per local practice guidelines over a minimum of 30 minutes
224242234|NCT00686959|DRUG|Vinorelbine|administered over 6-10 minutes infusion per local practice guidelines
224242235|NCT00686959|DRUG|Paclitaxel|administered as a 3-hour infusion
224242236|NCT00686959|DRUG|Carboplatin|administered per local practice guidelines over 30 minutes
224242237|NCT00686959|RADIATION|Thoracic Radiation Therapy (TRT)|
224242238|NCT01357707|GENETIC|DNA preparation|Taking blood or saliva from the patient to prepare DNA therefrom
224242239|NCT00193037|DRUG|Liposomal Doxorubicin|Liposomal Doxorubicin
224242240|NCT00193037|DRUG|Docetaxel|Docetaxel
224242241|NCT02303678|DRUG|D2C7-IT|D2C7-IT is a single-chain fragment variable (scFv) monoclonal antibody (Mab) fragment immunotoxin with high binding affinity for both EGFRwt- and EGFRvIII-expressing glioblastoma multiforme (GBM) cells.
224242242|NCT03336411|BEHAVIORAL|mHealth|Behavioral weight loss intervention using behavioral counseling focusing on physical activity and a one-size-fits-all, calorie-restricted, diet.
224242243|NCT03336411|BEHAVIORAL|Personalized mHealth|Behavioral weight loss intervention with personalized dietary recommendations based on machine learning algorithm that integrates gut microbiota, dietary intake, physical activity and various blood parameters to predict postprandial glycemic response.
224242244|NCT00759928|DRUG|Erlotinib|150 mg once daily by mouth
224242245|NCT00759928|DRUG|Sorafenib|400 mg twice daily by mouth
223662076|NCT03899805|DRUG|Pembrolizumab|The drug blocks the PD-1 receptor, preventing binding and activation of PD-L1 and PD-L2. This mechanism causes the activation of T-cell mediated immune responses against tumor cells.
223662077|NCT03317405|DRUG|Endoxifen Hydrochloride|Apply to the skin
223662078|NCT03317405|OTHER|Placebo Administration|Apply to the skin
223662079|NCT03317405|OTHER|Questionnaire Administration|Ancillary studies
223662080|NCT05315414|DEVICE|PrimeTaper EV implant|Tapered dental implant developed by Dentsply Sirona
223662081|NCT06567769|DRUG|GC1130A|ICV injection
223662082|NCT05477537|OTHER|Adapted physical activity program|subjects with Anorexia Nervosa (AN) involved in a day hospital or an inpatient program following HAS guidelines for anorexia nervosa treatment (treatment as usual) who will receive in addition an adapted physical activity program (one lesson per week, during 8 weeks) Adapted Physical Activity program, including psychoeducation on both problematic physical activity and consequences in terms of physical activity good practice leads to a better outcome among persons suffering from anorexia nervosa.
223662083|NCT05477537|OTHER|Treatment as usual group|Subjects with Anorexia Nervosa involved in a day hospital or an inpatient program following HAS guidelines for AN treatment (treatment as usual)
223662084|NCT01458041|DRUG|Iloprost (Ilomedin, BAYQ6256)|Prescription and treatment of Iloprost will be decided by physicians
223662085|NCT06523699|DRUG|Recombinant glycosylated human interleukin-7|Provided by RevImmune
223662086|NCT06523699|DRUG|Melphalan|Standard of care
223662087|NCT06523699|PROCEDURE|Autologous hematopoietic cell transplant|Standard of care
223769680|NCT06957821|OTHER|Placebo|Control group for the study
223769681|NCT02111616|BEHAVIORAL|Survivorship Care Plan (SCP)|Cancer Survivorship Care Plan (SCP) adapted from JourneyForward template. Each SCP is individualized to patient's care regimen. SCP is delivered at the conclusion of cancer treatment and during the patient's transition visit with nurse practitioner or physician assistant.
223769682|NCT02111616|BEHAVIORAL|Coordinated PCP visit|Visit with PCP scheduled on behalf of patient at the conclusion of cancer treatment and patient's transition visit.
223769683|NCT05172505|DEVICE|prefrontal tDCS|2 mA prefrontal tDCS (anode over F3, cathode over F4 10/20 EEG System) for 6 weeks, 5x/week in a home treatment Setting (self application) for 30 mins.
224242246|NCT05328804|DRUG|rhTPO|subcutaneous injection
224242247|NCT05328804|DRUG|Herombopag|Orally by mouth
223662088|NCT04024189|OTHER|Survey|Patients were given a questionnaire/survey to complete in respect of their satisfaction of the consent process for their surgical procedure
223662089|NCT02835976|DRUG|Olesoxime|Olesoxime will be given orally on Day 1 as a 600-mg liquid suspension within 30 minutes after starting a standardized high-fat breakfast.
223662090|NCT01766258|DRUG|ODM-101 65mg Carbidopa|
223662091|NCT01766258|DRUG|ODM-101 105mg Carbidopa|
223662092|NCT01766258|DRUG|Stalevo|
223662093|NCT00673530|BEHAVIORAL|evidence based clinical nutrition concept|The evidence based nutrition concept comprise a routine malnutrition screening for hospitalized patients, the implementation of an evidence based guideline for clinical nutrition in the participating hospital, education training of the clinical staff and thereby optimal clinical nutrition for malnourished hospitalized patients.
223662094|NCT00673530|BEHAVIORAL|care as usual|Unchanged treatment of hospital patients without interference by the study.
223662095|NCT03633539|PROCEDURE|Single-incision Laparoscopic Surgery|Patients undergo single-incision laparoscopic surgery. In this group，the surgery is performed through a transumbilical port. The surgeon will adjust surgical position to expose the operative field with the help of gravity. Besides，hand over hand cross and parallel techniques are needed to achieve the SILS. All the other operative procedures are the same as conventional laparoscopic surgery.
223662096|NCT03633539|PROCEDURE|Conventional Laparoscopic Surgery|Patients undergo conventional laparoscopic surgery. In this group，the surgery is performed through 3-5 ports according to the surgeons habits and specific conditions.
223662097|NCT06067672|OTHER|Observations to investigate the current practices of communication and decision-making during Nurse-patient consultations|No intervention
223662098|NCT01024309|PROCEDURE|Mini-Posterior surgical approach for total hip arthroplasty|Mini-Posterior surgical approach for total hip arthroplasty
223662099|NCT01024309|PROCEDURE|Direct Anterior surgical approach for total hip arthroplasty|Direct Anterior surgical approach for total hip arthroplasty
223662100|NCT00239252|DRUG|Interferon alfacon-1|
223662101|NCT00155675|DRUG|GUSUIBU|
223662102|NCT05067309|DRUG|Letrozole 2.5mg|Missed abortion received letrozole then misoprostol
223662103|NCT04382014|DIETARY_SUPPLEMENT|MAG fish oil + Curcumin OR Rice bran oil + Curcumin OR Curcumin extract|"The intervention is a randomized double blind cross over design testing the pharmacokinetics of 1) curcumin combined with MAG fish oil as a carrier, 2) curcumin combined with rice bran oil as a carrier, and 3) curcumin extract.~Treatments are randomly assigned on days 1, 8 and 15 of the clinical study. Blood samples will be collected at time 0, 1, 2, 3, 4, 5, 6, 8, 10 and 24h after taking the supplement. Each participant will perform all three treatments, with a minimum of 7 days between treatments. A questionnaire will document the side effects felt by participants."
223662104|NCT02737891|DRUG|Tesofensine/Metoprolol|Tesofensine 0.5 mg + Metoprolol 100 mg
224242248|NCT03202914|BEHAVIORAL|Usual protein and phosphorus diet|Diet intervention
224242249|NCT03202914|BEHAVIORAL|Low protein and phosphorus diet|Diet intervention
224242250|NCT03202914|BEHAVIORAL|Very low protein and phosphorus|Diet intervention
224242251|NCT06127498|BIOLOGICAL|A8G6 SARS-CoV-2 Neutralization Antibody combination nasal spray|Subjects in each cohort were randomly assigned 5:1 to two parallel administration groups, one of which served as a control. Each cohort was given either the experimental drug or placebo by nasal spray at different doses and intervals, and blood was collected on an empty stomach before the first dose. Right nostril and nasal swabs were collected for immunotoxicity, immunogenicity (immunogenicity collection and detection in cohorts 3 and 4 only), and drug concentration detection. Subjects in the first three cohort were required to return to the study Center 3±1 days after the last dose for blood samples, bilateral nostril and nasal swabs for drug concentration, immunotoxicity, physical examination, vital signs, and safety laboratory indicators (blood routine, blood biochemical, and urine routine). Subjects in cohort 4 returned to the study center 7±2 days after the last dose.
223662105|NCT02737891|DRUG|Placebo|
223662106|NCT05166837|DRUG|STSA-1002 injection|Intravenous injection
223662107|NCT05166837|DRUG|Placebo|Intravenous injection
223662108|NCT05166837|DRUG|STSA-1002 injection|Intravenous injection
223662109|NCT05166837|DRUG|Placebo|Intravenous injection
223662110|NCT05166837|DRUG|STSA-1002 injection|Intravenous injection
223662111|NCT05166837|DRUG|Placebo|Intravenous injection
223662112|NCT05166837|DRUG|STSA-1002 injection|Intravenous injection
223662113|NCT05166837|DRUG|Placebo|Intravenous injection
223662114|NCT05166837|DRUG|STSA-1002 injection|Intravenous injection
223662115|NCT05166837|DRUG|Placebo|Intravenous injection
223662116|NCT00165815|DRUG|ARICEPT|
223662117|NCT02073344|PROCEDURE|Renal replacement therapy|intermittent hemodialysis or peritoneal dialysis
223662118|NCT02073344|OTHER|no intervention|no renal replacement therapy
223662119|NCT04459208|DEVICE|Manta|plug-based vascular closure
223662120|NCT04459208|DEVICE|ProGlide|suture-based vascular closure
223662121|NCT02895126|BEHAVIORAL|"Appui Parental program"|
223662122|NCT02895126|BEHAVIORAL|Regular parental support|
223662123|NCT02152280|DRUG|Danhong Injection|Danhong Injection 40 ml add 250 ml of 0.9% sodium chloride solution, injection intravenous drip, 1 time a day, for 10 days.
223662124|NCT02152280|DRUG|Normal Saline|0.9% sodium chloride solution 40 ml add 250 ml of 0.9% sodium chloride solution, injection intravenous drip, 1 time a day, for 10 days;
223662125|NCT05830617|DEVICE|real tACS|The effect of transcranial alternating current stimulation (tACS) will be investigated in WP3. Patients will undergo standard intensive rehabilitation plus gamma tACS for two weeks.
223662126|NCT05830617|DEVICE|sham tACS|In WP3, patients will undergo standard intensive rehabilitation plus sham tACS for two weeks.
223662127|NCT02368561|DRUG|"Injection of Hyaluronic Acid - SYNVISC (hylan G-F 20)"|US guided weekly injection of sodium hyaluronate administered for 3 week in adult subjects with insertional achilles tendinopathy
223662128|NCT01639729|DRUG|Treatment A: Sufentanil IV|Sufenta IV (50 mcg/mL) 15 mcg push over 1 minute (IV)
223662129|NCT01639729|DRUG|Treatment B: Sufentanil NanoTab Sublingual|Single Sufentanil NanoTab 15 mcg given sublingually (SL)
223662130|NCT01639729|DRUG|Treatment C: Sufentanil NanoTab Buccal|Treatment C: Single Sufentanil NanoTab 15 mcg given buccally (BU)
223662131|NCT01639729|DRUG|Treatment D: Sufentanil NanoTab Oral|Single Sufentanil NanoTab 15 mcg swallowed (PO)
224242252|NCT06127498|OTHER|A8G6 SARS-CoV-2 Neutralization Antibody nasal excipient|Subjects in each cohort were randomly assigned 5:1 to two parallel administration groups, one of which served as a control. Each cohort was given either the experimental drug or placebo by nasal spray at different doses and intervals, and blood was collected on an empty stomach before the first dose. Right nostril and nasal swabs were collected for immunotoxicity, immunogenicity (immunogenicity collection and detection in cohorts 3 and 4 only), and drug concentration detection. Subjects in the first three cohort were required to return to the study Center 3±1 days after the last dose for blood samples, bilateral nostril and nasal swabs for drug concentration, immunotoxicity, physical examination, vital signs, and safety laboratory indicators (blood routine, blood biochemical, and urine routine). Subjects in cohort 4 returned to the study center 7±2 days after the last dose.
224242253|NCT02625558|DRUG|Riociguat|Patients will initiated on 0.5 mg tid and titrated every 2 weeks to a maximum of 2.5 mg three times a day
224242254|NCT02625558|DRUG|Placebo|Placebo given three times a day
224242255|NCT00150462|DRUG|Carfilzomib|Administered as an IV bolus dose
224242256|NCT00150462|DRUG|Dexamethasone|Administered orally prior to carfilzomib
224242257|NCT06342076|PROCEDURE|Patients undergoing subcostal transversus abdominis plane block and posterior transversus abdominis plane block|To prevent postoperative pain, the researchers applied a subcostal transversus abdominis plane block in addition to the posterior transversus abdominis plane block to a group of patients who underwent surgery with a midline incision due to major gynecological cancer.
224242258|NCT06342076|PROCEDURE|Patients undergoing rectus sheat block and posterior transversus abdominis plane block|To prevent postoperative pain, the researchers applied a rectus sheath block in addition to the posterior transversus abdominis plane block to a group of patients who were operated on through a midline incision due to major gynecological cancer.
224242259|NCT01212874|DRUG|nitroglycerin|nitroglycerin administered as an infusion following a step up/step down protocol to treat hypertension in patients undergoing cardiac surgery.
223662132|NCT02373085|OTHER|Antibiotic adjusted to antibiogram|A course of 3-14 days of antimicrobial treatment, according to the antibiogram results, will be prescribed for every episode of asymptomatic bacteriuria during the first 2 years after transplantation.
223662133|NCT02825797|DRUG|3BNC117|Intravenous infusion of 3BNC117
223662134|NCT02825797|DRUG|10-1074|Intravenous infusion of 10-1074
224242260|NCT01212874|DRUG|esmolol|esmolol will be administered by infusion following a step up / step down protocol to control hypertension.
223662135|NCT02825797|OTHER|Analytical treatment interruption|Analytical treatment interruption
224242261|NCT00569374|DRUG|Modafinil|subjects attend clinic for the first week in order to receive meds; oral, 200mg/day doses for three days for initiation doses; increased to oral 400mg/day for the remainder of the trial (weeks 2-6); washout period during week 7
223662136|NCT02825797|DRUG|Placebo|Intravenous infusion of placebo (sterile saline)
223662137|NCT02607748|OTHER|18F-NaF PET and coronary CTA imaging|
223662138|NCT02074891|DRUG|coformulated TDF/FTC|Daily oral dose of coformulated TDF/FTC
223662139|NCT05642650|DEVICE|novel wearable device|Patients with a novel wearable device for monitoring and uploading data daily to collect monitoring data such as jugular vein pressure and exercise steps after discharge.
223769684|NCT01434823|OTHER|Nocturnal coverage|"The investigators will randomize, by week, nocturnal coverage. During the intervention weeks, intensivists will be in the MICU from 7pm until 7am.~For the Intensivist Sleep and Work sub-study:~Measurements of Daytime Intensivist work hours, sleep, and attention will be measured with actigraphy, PVT, Sleep and Work Diaries, and Surveys. Results will be compared between periods with standard staffing to periods with overnight intensivist coverage."
223769685|NCT05161676|DIETARY_SUPPLEMENT|Ketone monoester|Commercially available ketone supplement
224242262|NCT01872546|DRUG|HUMIRA 40mg|
224242263|NCT02166138|PROCEDURE|Non-Abilative Laser treatment|Patients in this group will be given the laser treatment with the non-abilative 1540 nm wavelength. Patients will be blinded to this procedure as they will be wearing protective eye wear and noise canceling headphones. These patients will undergo the treatment 3 times, one at day of discharge, second at the 4 week follow up visit, and third at the 8 week follow up visit. After the 8 week follow up visit, patients will be asked to come in for the 3 month follow up visit and 1 year follow up visit for an evaluation. At each visit, the patient's scar will be photograph for evaluation. Each patient will also be asked to fill out the POSAS, and KOOS at each follow up visits.
224242264|NCT03428594|BIOLOGICAL|CKD-11101|
224242265|NCT03428594|BIOLOGICAL|NESP|
224242266|NCT02197195|DIETARY_SUPPLEMENT|Chocolate Milk|
223769686|NCT05161676|DIETARY_SUPPLEMENT|Placebo drink|Isocaloric placebo
224242267|NCT02197195|DIETARY_SUPPLEMENT|Fruit Drink|
224242268|NCT02197195|BEHAVIORAL|Exercise|
224242269|NCT03589534|DIAGNOSTIC_TEST|home pregnancy test|Each participant will use 4 different home pregnancy tests
223769687|NCT03780179|BIOLOGICAL|MMRvaxpro|MMRvaxpro vaccine
224242270|NCT00041496|DRUG|SB-207266|White, oval, biconvex tablets containing either 10mg, 25mg or 40mg
223662142|NCT01780220|DRUG|Abiraterone|Abiraterone acetate 1000mg/day + prednisone alone for one month before initiating the sequence of radiotherapy
223662143|NCT06243562|OTHER|combined exercises and progressive muscle relaxation group|Participants in the intervention group will receive a combined exercise program that will last 45-60 minutes, 3 days a week for 8 weeks, and progressive muscle relaxation training that will last 10-15 minutes, under the supervision of a therapist.
223662144|NCT06243562|OTHER|combined exercises group|Patients in the control group will perform a combined exercise consisting of aerobic, strengthening and stretching exercises, which will last 45-60 minutes, 3 days a week for 8 weeks, under the supervision of a physiotherapist. At the end of the combined exercise program, they will rest in the relaxation position for 10-15 minutes each session.
223662145|NCT05236868|DRUG|Seltorexant|Seltorexant will be administered orally as a tablet and as an intravenous infusion of 14C-seltorexant.
223662146|NCT05037578|BEHAVIORAL|Project Grace|A multilevel church-based intervention to encourage cognitive screens and brain health.
224242271|NCT00041496|OTHER|Placebo|Placebo to match SB-207266
223769688|NCT03780179|BIOLOGICAL|Placebo|Placebo
223769689|NCT01797536|DRUG|Elbasvir|
223769690|NCT01376011|DIETARY_SUPPLEMENT|quercetin/placebo|Quercetin 500mg once per day versus placebo
223769691|NCT01379326|DRUG|Mebendazole|All children providing stool samples will be treated with mebendazole single table of 500mg under supervision (chewing + water).
223769692|NCT01040429|DRUG|Clonidine|"Day 1-56 (week 1-8): 25 microgram (1 capsula) x 2/day for patients \< 35 kg; 50 microgram (2 capsula) x 2/day for patients \> 35 kg.~Day 57-63 (week 9): 25 microgram (1 capsula) x 1/day for patients \< 35 kg; 25 microgram (2 capsula) x 2/day for patients \> 35 kg."
223769693|NCT01040429|DRUG|Lactose capsula|"Day 1-56 (week 1-8): 1 capsula x 2/day for patients \< 35 kg; 2 capsula x 2/day for patients \> 35 kg.~Day 57-63 (week 9): 1 capsula x 1/day for patients \< 35 kg; 1 capsula x 2/day for patients \> 35 kg"
223769694|NCT01285739|OTHER|WBC, biomarkers, TBA, chest X ray|The above cited parameters were recorded and investigated every six months; chest X ray when needed.
223769695|NCT01285739|OTHER|WBC, biomarkers, TBA, chest X ray|The above cited parameters were recorded and investigated every six months; chest X ray when needed.
223769696|NCT02484105|BEHAVIORAL|Comforting Conversation|Pain management, distraction, diversion, empathy. Dependent on qualitative study results.
223662147|NCT04678076|DRUG|Ketoprofen Lysine|A single oral dose of test product - ketoprofen 25 mg/5 ml oral gel stick pack - will be administered to healthy male and female volunteers under fed conditions in two consecutive study periods with a wash-out interval of at least 7 days between the two administrations.
223662148|NCT04678076|DRUG|Ketoprofen Oral Product|A single oral dose of reference product as a single dose of half of a bipartite sachet of OKi® 80 mg granules for oral solution will be administered to healthy male and female volunteers under fed conditions in two consecutive study periods with a wash-out interval of at least 7 days between the two administrations.
223662149|NCT02868827|DRUG|Cholecalciferol|400000 international Units of cholecalciferol will be dissolved in 45 ml of fresh milk (Nestle) and it will be given to interventional group patients through enteral route within 24 hours of ICU admission as a single dose.
223662150|NCT02868827|OTHER|Milk (Nestle)|45 ml of Nestle milk will given to patients assigned as placebo
223662151|NCT03141996|OTHER|Vibration to upper posterior neck muscles|Vibration to upper posterior neck muscles using a vibrational tool.
223662152|NCT03141996|OTHER|Standard of Care|Standard of care treatment
223662153|NCT05282745|OTHER|Follow-up|Participants will be followed up at 6, 12 and 24 months with HPV viral load tests, Thinprep cytologic tests (TCT) and vaginal secretion tests.
223662154|NCT01515020|DRUG|vancomycin monotherapy|intravenous therapy by vancomycin
223662155|NCT01515020|DRUG|daptomycin monotherapy|intravenous therapy by daptomycin
223662156|NCT01116778|BIOLOGICAL|eN-Lac®|One capsule with 2x10\^9 colony forming unit (cfu) LP GMNL-32, once daily, po
223662157|NCT01116778|OTHER|Placebo|One placebo capsule, once daily, po
223662158|NCT01088607|DRUG|ursodeoxycholic acid (UDCA)|Pediatric PSC patients already receiving UDCA therapy will enter a four-phase trial consisting of baseline data collection (phase I, 4 weeks), 50% reduction in UDCA dose (phase II, 4 weeks), discontinuation of UDCA (phase III, 8 weeks) and reinstitution of therapy at a dose of 20 mg/kg/day (phase IV, 8 weeks). Surveillance and endpoint evaluation for each phase will include liver chemistries and clinical data. Comparisons will be made between baseline and the end of phase III (primary outcome) and between the end of phase III and the end of phase IV (secondary outcome). Serum cytokine biomarkers will be measured and compared between baseline and the end of phase III and between the end of phases III and IV.
223662159|NCT05624333|OTHER|Vegan diet (intervention)|The intervention diet will be a fully controlled vegan diet that will be consumed for a duration of 10 days. No animal-based food products will be included in the diet.
223662160|NCT05624333|OTHER|Omnivorous diet (control)|The control diet will be an a priori composed controlled omnivorous diet with a duration of 10 days. The omnivorous diet and the vegan diet will be isocaloric and isonitrogenous.
223662161|NCT01692821|DRUG|100% oxygen breathing|100% oxygen breathing - 30 minutes
223662162|NCT01692821|DRUG|15% oxygen in N2 breathing|15% oxygen in N2 breathing - 30 minutes
223662163|NCT01692821|DRUG|12% oxygen in N2 breathing|12% oxygen in N2 breathing - 30 minutes
223662164|NCT03162900|DRUG|Glasdegib Therapeutic Exposure|Subjects Receive a single 150 mg dose of Glasdegib followed by ECG and PK assessments.
223662165|NCT03162900|DRUG|Glasdegib Supra-therapeutic Exposure|Subjects receive a single 300 mg dose of glasdegib followed by ECG and PK assessments.
223662166|NCT03162900|DRUG|Positive Control (Moxifloxacin)|Subjects will receive a single 400 mg dose of moxifloxacin followed by ECG and PK assessments.
223662167|NCT03162900|OTHER|Placebo Control|Subjects will receive placebo dose followed by ECG and PK assessments.
223662168|NCT01093703|OTHER|Medication Adjustment|"1. Awake SBP≤135/85mmHg and patient is on once daily medications: Switch BP medications to pm period.~2. Awake SBP SBP≤135/85mmHg and patient is on bid medications (e.g. metoprolol bid): Increase pm dose of the medication. If medication is already is at maximal dose or there is contraindication for increasing the dose (e.g. bradycardia), add another BP medicine in the evening time.~3. Awake SBP≤135/85mmHg and patient is not on anti-hypertensive medications: Add BP medication at the pm period.~4. Awake SBP\>135/85mmHg: increase dose of antihypertensive medications or add more medications. All medications to be given in the evening time."
223662169|NCT00077090|DRUG|hyperbaric oxygen|
223769697|NCT02484105|BEHAVIORAL|Standard Communication|Information on procedure type, duration, findings, key landmarks, possibility of analgesic treatment, pause in procedure.
223769698|NCT00062426|BIOLOGICAL|bevacizumab|
223769699|NCT00062426|DRUG|capecitabine|
223769700|NCT00062426|DRUG|fluorouracil|
223769701|NCT00062426|DRUG|leucovorin calcium|
223769702|NCT00062426|DRUG|oxaliplatin|
223769703|NCT00263523|DRUG|[11C] (-)-RWAY|
223769704|NCT00120042|DRUG|Misoprostol|600 mcg misoprostol swallowed after delivery of fetus
223662170|NCT02942732|DIETARY_SUPPLEMENT|cholecalciferol (Euro-Pharm International, Canada)|All assigned patients received a supplement of 10,000 IU cholecalciferol (Euro-Pharm International, Canada) to be taken three times per week. The treatment was led for a period of 6 months.
223662171|NCT05971706|DEVICE|Ozone therapy using a device (Ozone DTA Ozone Generator, Denta Tec Dental AS, Norway)|Ozone therapy procedures will be performed immediately after non-surgical periodontal treatment and three times (every third day) within one week using a device equipped with a periodontal tip according to equipment producer recommendations. The periodontal tip will be halted 1 mm short of the pocket depth. Ozone will be applied only to the pockets; which depth is equal to or greater than 5 mm. Ozone application time to the pockets will be 30 seconds at a fixed concentration of 2,100 ppm (80% oxygen) through a connected handpiece.
223662172|NCT05971706|PROCEDURE|Non-surgical periodontal treatment|Non-surgical periodontal treatment consists of oral hygiene instructions, full mouth supragingival scaling using hand instruments, ultrasonic devices, polishing, and subgingival debridement under local anesthesia with sharp Gracey and Universal curettes and ultrasonic instruments in a single appointment.
223662173|NCT02262208|OTHER|Aerobic Exercises|"Exercise intensity for each individual by a heart rate monitor (Polar F1 TM, Polar Electro Oy, Helsinki, Finland), and a Borg 0-10 scale used to register individuals' perceived exertion every 5 minutes throughout the experimental sessions.~Aerobic session will consist of 40 min of lower limb bicycle at 70% of the peak heart rate, as determined in the incremental exercise test."
223769705|NCT00120042|DRUG|Oxytocin|10 units oxytocin administered intramuscularly after delivery fetus
223769706|NCT06448234|OTHER|Standart supplementation therapy group|Participants receive supplement prescriptions from a physician based on current standard practices, which include biochemical markers, genetic data, and metabolic profiles
223769707|NCT06448234|OTHER|AI-guided supplementation therapy group|Participants receive DS prescriptions determined by an AI system, which considers genetic data, metabolic profiles, biochemical markers, and patient history.
223769708|NCT01810978|DIETARY_SUPPLEMENT|Bifidobacterium lactis plus inulin|5 billion unit Bifidobacterium lactis plus 900 mg inulin per day will be given
223769709|NCT01810978|DIETARY_SUPPLEMENT|Maltodextrin|same amount of maltodextrin per day will be given as placebo
223769710|NCT06129812|DRUG|Neoadjuvant treatment|Intravenous gemcitabine-based combination regimens or FOLFIRINOX were included in NAC.
223769711|NCT06100068|BEHAVIORAL|Mental Exercises and Temporal Alteration|Mental exercises during L-DIBH to distort the awareness of passage of time
223769712|NCT06572696|DIAGNOSTIC_TEST|Shulder Ultrasound|"Ultrasound Shoulder Pathology Rating Scale (USPRS) will be used in the evaluation. While the participants are in a sitting position; A total of 5 variables, including bicipital tendinopathy, supraspinatus tendinopathy, greater tuberculum cortical surface irregularity, supraspinatus dynamic and subscapularis dynamic examination, are evaluated and scored according to the level of pathology; The total USPRS score is obtained by adding the scores of all variables.~Another parameter evaluated by ultrasonography in this study is the acromiohumeral distance measurement. In AH distance measurement with MSK-US, two measurements will be made with all participants in a neutral resting position and their hands at the top of the circle with the elbow angle of 110 °. In both positions, the probe will be placed longitudinally at the lateral point of the acromion determined by palpation, the distance determined between the acromion and the humeral head will be displayed and measured."
223769713|NCT04027660|DEVICE|Immediate Zirconia Dental Implant|"For the Exposed Group the Intervention will be the following~The Surgical procedure will envolve :~1. Administration of Articain 1:200.000~2. No flap procedure~3. Place a Zirconia Implant on the alveolar post extraction socket~4. Place xenograft biomaterial in the jumping gap~5. Place a provisional crown/individualized healing abutment~The Prosthodontic procedure will evolve:~* Final Impression with a IOS~* Placement of the Final Crown~* 3 month post crown post op~  3 IOS will be made for volumetric evaluation :~ 1. before tooth extraction~ 2. 3 month of Osseointegration for final impression~ 3. 3 month after final crown is placed~Final STL evaluation will be performed on a specialized software for volumetric measurements"
223769714|NCT06131411|OTHER|Health promotion|Co-created culture-tailored intervention of health promotion aimed to increase healthy diet, physical activity and compliance with treatment protocols for diabetes.
223769715|NCT06131411|OTHER|Usual care|Health promotion activities routinely performed by Diabetes clinics at the recruiting centres.
223769716|NCT03271437|BEHAVIORAL|PC-based Flash|Progressive counting with Flash technique
224242272|NCT02654912|DRUG|Reactive Focal Drug Administration|This is the experimental arm and is described by a reactive response to passively detected index case of malaria. The reactive response consists of treating all individuals within a defined radius of each RDT-confirmed incident malaria case with dihydroartemisinin-piperaquine (DHAP).
223769717|NCT03271437|BEHAVIORAL|EMDR-based Flash|Eye movement desensitization and reprocessing with Flash technique
223769718|NCT05356559|DIETARY_SUPPLEMENT|Intervention|12.5g (twice daily) Blue Whiting Protein Hydrolysates daily for 8 weeks
224242273|NCT00002349|DRUG|Stavudine|
224242274|NCT01464866|OTHER|Nutritional Supplement|Liquid, pediatric nutritional supplement. 1-2 bottles/day for up to 28 days.
224242275|NCT01464866|OTHER|Hospital food|Typical hospital food given daily at meals
224242276|NCT04896164|DRUG|Curcumin Lozenges|Curcumin lozenges (each containing 100 mg of curcumin) will be given at a dose of 4 lozenges (total dose 400 mg curcumin) BD. Formulation is Solid Lipid Curcumin Particle (SLCP). Oral curcumin lozenges will be given from two days prior to receiving high dose chemotherapy till day+28 of transplant.
224242277|NCT04896164|OTHER|Placebo Lozenges|Placebo lozenges will be given from two days prior to receiving high dose chemotherapy till day+28 of transplant.
224242278|NCT01444443|DEVICE|Closed-loop control|Blood glucose controlled by algorithm
224242279|NCT01444443|OTHER|Open-loop control|Blood glucose controlled by patient
224242280|NCT00193284|DRUG|Gefitinib|
224242281|NCT00193284|DRUG|Docetaxel|
224242282|NCT00193284|DRUG|Carboplatin|
224242283|NCT00193284|DRUG|Fluorouracil|
224242284|NCT03004300|PROCEDURE|Rapid maxillary expansion|Device
224242285|NCT03004300|PROCEDURE|Adenotonsillectomy|Surgery
224242286|NCT00740493|DRUG|warfarin|18 months of warfarin therapy
224242287|NCT00740493|DRUG|placebo of warfarin|18 months of placebo of warfarin therapy
224242288|NCT00912288|DRUG|Dimebon 20 mg po TID|Dimebon 10 mg po TID for 1 week followed by Dimebon 20 mg TID for 25 weeks
223662174|NCT02262208|OTHER|Eccentric Exercise|Eccentric session will consist of 40 min of one lower -limb exercises (leg press) with 6 sets of 10 repetitions at 120% of 1-RM.
223662175|NCT02262208|DEVICE|Continuous glucose monitoring system (Guardian, Medtronic, Northridge, USA)|Subjects will be admitted to the laboratory in the morning at approximately 9:00 a.m., 24 h before the exercise session, when the glucose sensor (Sof-SensorTM, Medtronic Mini-Med, Northridge, USA) will be inserted subcutaneously. The sensor is a glucose oxidase based platinum electrode that is inserted through a needle into the subcutaneous tissue of the anterior abdominal wall, using a spring-loaded device (Senserter, Medtronic, Northridge, USA). Glucose profiles will be collected the day before (day 1), the day of (day 2), and the day following (day 3) and 40 min of exercise. Each sensor will be used continuously for up to 72 h.
224242289|NCT00912288|DRUG|Placebo po TID|Placebo (matched to Dimebon) po for 26 weeks
223662176|NCT02340637|BEHAVIORAL|Coping Kids|The first half (10 sessions) of Coping Kids focuses on building skills that are common to both anxiety and depression. The children practice strategies to regulate their mood, learn problem-solving, and behavioral activation is used to break the cycle of withdrawal. The second half of Coping Kids (10 sessions) is focused on the youth's specific problem; for depressive symptoms, building a positive self-schema and behavioral activation; for anxiety problems, gradual exposure to fear-inducing situations. Cognitive restructuring directed at different maladaptive thoughts is also emphasized.
223662177|NCT02340637|BEHAVIORAL|TAU|Treatment as usual
223662178|NCT01640314|BIOLOGICAL|Cell derived subunit trivalent nonadjuvanted vaccine|A single 0.5 mL dose of the cell derived subunit trivalent nonadjuvated influenza vaccine (TIVc) supplied in prefilled syringes and administered intramuscularly in the deltoid muscle (preferably) of the non dominant arm.
223662179|NCT03672097|DRUG|Prasugrel|Prasugrel, oral tablets, containing 3.75 mg per tablet
223662180|NCT01290796|DEVICE|Ajust Adjustable Single-Incision Sling|The Ajust™ Adjustable Single-Incision Sling is a minimally invasive suburethral sling indicated for the treatment of female SUI resulting from urethral hypermobility and/or intrinsic sphincter deficiency (ISD). The system consists of a unique adjustable polypropylene mesh sling with permanent, self-fixating, polypropylene anchors, an introducer, and a flexible stylet for securing the mesh sling after adjustment.
223662181|NCT03346642|DRUG|Decitabine|Decitabine is an investigational (experimental) drug that works by depleting DNA methyltransferase 1 (DNMT1), which can increase tumor antigens and histocompatibility leukocyte antigen (HLA) expression, enhances antigen processing, promotes T cell infiltration, and boosts effector T cell function.
223662182|NCT03346642|DRUG|GVD chemotherapy|GVD regimen is a chemotherapy regimen consisted by Gemcitabine, Vinorelbine and Doxorubicine. Patients will be administrated with Gemcitabine 0.8 g/m2, Vinorelbine 30mg and Doxorubicin 20mg/m2 intravenously infusion.
223662183|NCT03346642|DRUG|SHR-1210|SHR-1210 is a humanized anti-PD-1 monoclonal antibody.
223662184|NCT02753257|OTHER|Non-Interventional|Non-Interventional
223662185|NCT04765085|BEHAVIORAL|comprehensive behavioral intervention therapy (CBIT)|"Comprehensive behavioral intervention for tics is an extension of habit reversal training. It includes an expanded set of strategies, such as psycho-education about tic disorders, tic awareness training, competing response training, relaxation training, and functional analysis.~According to the CBIT treatment manual (translated by sun Jinhua and Xu Wen, the author were Douglas W. woods et al., Oxford University Press, New York). The treatments consisted of 8 sessions for 10 weeks The first two phases were 1.5 hours, the last six stages were 1 hour.The treatment process was regularly supervised by a treatment supervisor."
223662186|NCT04765085|DRUG|Aripiprazole 5Mg Oral Tablet|Considering the patients with chronic tic disorder (chronic motor or vocal tic disorder or Tourette's disorder), aripiprazole was selected as a single drug with constant dose during the treatment. In case of extrapyramidal side effects, benhexol was given to reduce the extrapyramidal side effects, and the dosage and duration of medication were recorded
223662187|NCT03087617|DEVICE|Imbio Smoking Cessation Report|Research coordinators at the University of Michigan and HealthPartners will be provided access to the research version of LDA via an Imbio website. Following consent and lung screen, research coordinators will manually upload the study participants' images and download a resulting Report. Radiologists have been designated at both sites to review and approve the Report prior to mailing to participants. The Report will include information including the percent of damaged lung volume.
223662188|NCT03087617|BEHAVIORAL|Smoking Cessation Counseling|45 minute counseling session with a tobacco treatment specialist.
223662189|NCT03087617|OTHER|Usual Care|Usual Care for Lung Cancer Screening patients.
223662190|NCT01896206|DEVICE|CNAP monitor|Patients undergoing bariatric surgery and being monitored using the CNAP monitor.
223662191|NCT01920685|OTHER|Anxiety intervention|
224242290|NCT02506309|DEVICE|TOT - inside-out trans-obturator tape/sling|Patients were randomized by envelope technique at the time of surgery indication to either TOT or SIS anti-incontinence surgical procedure with mid-urethral slings (MUS)
223662192|NCT04450381|DEVICE|Rad-67 Pulse oximeter & DCI Mini sensor|Noninvasive pulse oximeter that measures hemoglobin
223662193|NCT05311813|DRUG|Enoxaparin, Hydroxychloroquine|To compare efficiency and safety of Enoxaparin and Hydroxychloroquine as monotherapy versus Polytherapy
223662194|NCT03899467|DRUG|GT0918|anti-tumor activity
223662195|NCT05788471|OTHER|conventional Treatment|It consists of Superficial heat, Ultrasound therapy and stretching exercise to lumbrical muscles of the hand.
224242291|NCT02506309|DEVICE|SIS - Innovative fixation single incision sling|Patients were randomized by envelope technique at the time of surgery indication to either TOT or SIS anti-incontinence surgical procedure with mid-urethral slings (MUS)
224242292|NCT04564482|RADIATION|CRT|50 Gy in 2 Gy fractions over 25 working days + capecitabine 1650 mg/m2/d PO
224242293|NCT04564482|RADIATION|SCPRT|25 Gy in 5 Gy fractions over 5 working days
224242294|NCT04564482|RADIATION|CROSS Protocol|41.4 Gy in 1.8 Gy fractions over 23 working days + carboplatin AUC of 2 mg/ml/min + paclitaxel 50 mg/m2 IV Q1W
224242295|NCT04564482|DIAGNOSTIC_TEST|PD-L1 PET|10 mg atezolizumab IV followed by 37 MBq 89Zr-atezolizumab IV. PET imaging will be done before neoadjuvant CRT/SCPRT (day 0) and between day 10-14 during CRT/SCPRT.
223662196|NCT05788471|OTHER|Neurodynamic mobilization|It is the mobilisation of the nervous system as an approach to physical treatment of pain. The treatment and or assessment relies on influencing pain physiology via the mechanical treatment of neural tissues and non-neural structures surrounding the nervous system.
223662197|NCT05755061|BEHAVIORAL|GEMS Plus|12-months of home-based walking exercise that occurs 3-5 days per week. The program will progress up to intensities that exceed the published physical activity guidelines for adults with MS
223662198|NCT05755061|BEHAVIORAL|GEMS|12-months of home-based walking exercise that occurs 3-5 days per week. The program will progress up to intensities that meet the published physical activity guidelines for adults with MS
224242296|NCT04574648|DEVICE|ActionADE|"ActionADE is a software application that allows healthcare providers to document standardized adverse drug event and non-adherence information in a user-friendly and standardized manner. We integrated ActionADE uni-directionally with PharmaNet, a secure province-wide network that links all pharmacies in British Columbia to a central data system. This allows care providers to pull in demographic information and visualize their patient's medication dispensing history.~In 2020, we enabled bi-directional integration with PharmaNet allowing clinicians to transmit standardized information back to the PharmaNet database. The three dominant community pharmacy systems in the geographic area of the trial will display non-adherence information in their systems."
224242297|NCT05425381|BEHAVIORAL|Enhanced version of Interconnected Systems Framework|"* District-community Leadership Team to support district-wide implementation and dissemination (Swain-Bradway et al., 2015)~* Detailed memoranda of understanding between schools and collaborating mental health centers~* Community mental health clinicians meaningfully participate in MTSS teams~* Twice-monthly MTSS meetings using systematic teaming strategies (Newton et al., 2012)~* Universal screening of students' social, emotional, behavioral, and academic functioning~* Data-based decision-making using screening data and data on school and academic functioning for students with and without disabilities~* Student-level discipline and intervention data (Blake et al., 2011; Smolkowski et al., 2016) addressed through iterative problem-solving approaches (McIntosh et al., 2018)~* Team fidelity measures taken at the start and end of each school year, augmented with monthly fidelity monitoring of Tier 2 and 3 services~* A Community of Practice (Wenger, 2010) among the ISFE schools"
224242298|NCT05425381|BEHAVIORAL|Positive Behavioral Interventions and Supports with Co-located School Mental Health|"* PBIS, including previously established data-based decision making, teaming, and evidence-based practices at three tiers: universal prevention; early identification and intervention for students with emerging risk; and intensive intervention for students with established problems and/or disabilities (Sugai \& Horner, 2006; Sugai et al., 2014). Most PBIS schools struggle with intervention (Hawken et al., 2009) and the emphasis is typically on behavior, not internalizing student needs, including depression, anxiety, and trauma (Weist et al., 2018).~* SMH using a co-located approach, with clinicians implementing treatment separate from the schools' MTSS (Barrett et al., 2013). Research has shown that even when PBIS and community-supported SMH operate in the same school building, in most cases there is no functional collaboration, (Splett et al., 2014). Under this model, SMH services are provided reactively, and students are often in crisis when referred (Dowdy et al., 2010)."
224242299|NCT00172055|DRUG|Zoledronic acid|
224242300|NCT04999709|DEVICE|VeNS|The VeNS device utilizes a technology called galvanic vestibular stimulation (GVS) (sometimes termed vestibular nerve stimulation (VeNS)). The device will be placed on the head in a manner analogous to headphones and will deliver a small electrical current to the skin behind the ears, over the mastoid processes. Participants will be advised to use the device at home for 1 hour per day.
224242301|NCT03601962|DIETARY_SUPPLEMENT|Aqualief|400mg oral mucoadesive tablets
224242302|NCT03601962|OTHER|Placebo|400mg Placebo oral mucoadesive tablets
224242303|NCT06383962|DEVICE|Synergy cervical spine disc replacement|motion preservation disc
224242304|NCT01388465|BEHAVIORAL|Mobile phone text messaging|Daily assessment followed by feedback
224242305|NCT01941966|DRUG|Capecitabine|Capecitabine, PO, 825mg/m2, on days: 1, 2, 3, 4, 5, 8, 9, 10, 11, 12, 15, 16, 17, 18, 19, 22, 23, 24, 25, 26, 29, 30, 31, 32, 33, 36, 37, 38, 39 and 40 of radiotherapy period.
224242306|NCT01941966|DRUG|Mitomycins|15 mg/m2, IV, bolus, single dose on day 1 of radiotherapy
224242307|NCT01941966|RADIATION|Radiotherapy|Dose: 50,4-54 Gy 28 to 30 fractions during 5 to 6 weeks
224242308|NCT03820466|DRUG|Aspirin|Once daily application of platelet inhibiting medication
224242309|NCT03820466|DRUG|Atorvastatin|Once daily application of lipid lowering medication
224242310|NCT03820466|DRUG|Placebo Aspirin|Once daily application of placebo
224242311|NCT03820466|DRUG|Placebo Atorvastatin|Once daily application of placebo
224242312|NCT00716248|DRUG|bucillamine|bucillamine 100 mg, twice a day
224242313|NCT00716248|DRUG|methotrexate|methotrexate 6 mg or more per week
224242314|NCT05354648|PROCEDURE|Hypoxic-hyperoxic preconditioning|Patients were intubated and mechanically ventilated with the target values of PaO2 and PaCO2 (80 - 120 mm Hg and 35 - 45 mm Hg, respectively) under the inhalation anesthesia. HHP was carried out as follows: breathing with a hypoxic gas mixture for 10 min with the development of hypoxemia, then breathing with a hyperoxic gas mixture for 30 minutes, then a period of breathing with atmospheric air (normoxia and normocapnia) until the cardio-pulmonary bypass is connected.
224242315|NCT05354648|PROCEDURE|Placebo|Patients were intubated and mechanically ventilated with the target values of PaO2 and PaCO2 (80 - 120 mm Hg and 35 - 45 mm Hg, respectively) under the inhalation anesthesia until the cardio-pulmonary bypass is connected.
223662199|NCT01386866|DRUG|AMG 706|Single oral dose of 125 mg AMG 706 (motesanib) containing 100 μCi of \[14C\]-AMG 706 followed by option to continue onto a treatment extension phase for potential treatment benefit. Subjects will be administered motesanib 125 mg (5 x 25 mg tablets) on a daily basis until subjects experience a dose-limiting toxicity (DLT), an unacceptable AE, disease progression, or voluntary withdrawal.
223662200|NCT04332861|OTHER|Initial clinical and laboratory evaluation|"Initial evaluation, prior to administration of any antibiotics if possible, includes history, physical exam, and labs including:~* Urinalysis~* Urine culture~* Blood cultures~* Complete blood count with differential~* Comprehensive metabolic panel~* Lactate~* Procalcitonin~* Other inflammatory markers"
223662201|NCT03122951|DIAGNOSTIC_TEST|ovulation test use|Normal use of The Clearblue® Advanced Ovulation Test according to Information for use instructions
223662202|NCT02909608|OTHER|No interventions / observations only|This is an observational study only
223662203|NCT06396910|DIAGNOSTIC_TEST|Spatial transcriptomics|Localize immune transcripts in the pulmonary lessions of sarcoidosis and tuberculosis patients. This is done in biopsies from pathological libraries.
223662204|NCT03785223|DRUG|Methylphenidate Hydrochloride Controlled-Release Capsules|"25 mg methylphenidate hydrochloride- titrated as tolerated up to a maximum 4 capsules daily (25 mg- 100 mg total dose)~At Week 0 or Week 7, dosing will start at 1 capsule/day for one week, and be titrated to 2 capsules/day for Week 2. 50 mg of methylphenidate hydrochloride per day (i.e. 2 capsules/day) is the minimum dose that must be achieved. The dose may be titrated to 75 mg/day for Week 3 and to 100 mg/day for Week 4 if participants are tolerating their current dose, are experiencing no adverse events, and have not fully responded. By Week 4 or Week 11, no further dose changes will occur."
223662205|NCT03785223|DRUG|Placebo Capsule|At Week 0 or Week 7, dosing will start at 1 capsule/day for one week, and be titrated to 2 capsules/day for Week 2. The dose may be titrated to 75 mg/day for Week 3 and to 100 mg/day for Week 4 if participants are tolerating their current dose, are experiencing no adverse events, and have not fully responded. By Week 4 or Week 11 no further dose changes will occur.
223662206|NCT05659160|PROCEDURE|Endovascular Therapy|"Endovascular therapy, as an adjunct to standard stroke therapy, may be beneficial for a very select population of patients who present with an acute ischemic stroke and have a proven large, proximal occlusion on imaging.~Endovascular therapy includes any one or more of the following:~Intra-arterial thrombolytic therapy, aspiration, stent retrieval, or a combination of multiple mechanical devices."
223662207|NCT00254189|DRUG|Levonorgestrel|
223662208|NCT00254189|DRUG|Ethinyl Estradiol|
223662209|NCT01515644|OTHER|Powder based infant formula|Powder based infant formula with Inulin I
223662210|NCT01515644|OTHER|Powder based infant formula|Powder based infant formula with Inulin II
223662211|NCT01515644|OTHER|Powder based infant formula|Powder based infant formula without Inulin
224242316|NCT05061290|OTHER|Control Porridge|Maize porridge containing 54Fe as iron sulfate
223662212|NCT05953233|OTHER|Active classroom HEPA cleaner|Commercially available portable HEPA cleaner
224242317|NCT05061290|OTHER|Reference Porridge A|Maize porridge counting 58Fe as iron sulfate with ascorbic acid
224242318|NCT05061290|OTHER|Test Porridge B|Maize porridge containing 57Fe and fortified with Moringa leaf powder as iron source
224242319|NCT05061290|OTHER|Test Porridge C|Maize porridge containing 57Fe and fortified with Boabab fruit powder as iron source
223662213|NCT05953233|OTHER|Sham classroom HEPA cleaner|Commercially available portable HEPA cleaner with filtration device removed
223662214|NCT00244140|DRUG|Iopromide 370 mg I/mL|Iopromide (Ultravist 370 mg I/mL) administered intravenously
223662215|NCT00244140|DRUG|Iopromide 300 mg I/mL|Iopromide (Ultravist 300 mg I/mL) administered intravenously
223662216|NCT04708236|DRUG|ORTD-1 low dose|ORTD-1 will be administered intravenously once daily for 5 consecutive days.
223662217|NCT04708236|DRUG|ORTD-1 mid dose|ORTD-1 will be administered intravenously once daily for 5 consecutive days.
223662218|NCT04708236|DRUG|ORTD-1 high dose|ORTD-1 will be administered intravenously once daily for 5 consecutive days.
223662219|NCT04708236|OTHER|Vehicle control|Vehicle Control will be administered intravenously once daily for 5 consecutive days.
223662220|NCT06405308|PROCEDURE|R-NOSES group|robotic natural orifice specimen extraction surgery
223662221|NCT06405308|PROCEDURE|R-TSES group|robotic transabdominal specimen extraction surgery
223662222|NCT04248283|DEVICE|Adjustable Continence Therapy for Women (ACT)|Two ACT devices are implanted in each patient. The devices are intended for implantation in the paraurethral space, with the balloons located on each side of the urethra near the bladder neck. The ports are placed subcutaneously in the labia majora. The balloons are filled after implantation with an isotonic solution via needle injection into the port. The ACT implant can be placed using local, spinal or general anesthesia with the surgical instruments (provided separately).
223662223|NCT06531980|OTHER|Modi|"The Modi course, an eight-week mobile application intervention for adolescents with anxiety symptoms, is based on cognitive therapy. Guided by a rule-based chatbot named Anna, users navigate through predefined options and responses, learning about anxiety and recording their challenges. The app includes animated videos, illustrations, and audio files to enhance engagement. Modi consists of six chapters, with a focus on psychoeducation, the cognitive triangle, and exposure exercises. Participants receive guidance from two Modi therapists who provide weekly support via messages and scheduled phone calls, ensuring personalized assistance and addressing any issues throughout the course."
223662224|NCT06531980|OTHER|Treatment as usual|Participants receive usual treatment at their local Child and Family Services. This treatment, known as Treatment as Usual (TAU), is not standardized but reflects the care they would receive in regular practice. It aligns with national clinical guidelines and includes individual therapy, parental counseling, and assessments. Typically, the treatment is provided by a therapist trained in cognitive behavioral therapy (CBT) or a psychologist
223662225|NCT04107389|BEHAVIORAL|Art Psychotherapy, Art Therapy|Art Therapy is a form of psychotherapy, based upon the premise of utilising art materials as a form of expression and communication; the roots of the theoretical approach lie in a psychodynamic approach to working with the unconscious.
223662226|NCT04107389|BEHAVIORAL|Wait List|Wait list control group. Participants randomised to Wait List group or Intervention group.
223769719|NCT05356559|OTHER|Control|Isocalorific Maltodextrin Citrus Flavoured Powder for 8 weeks
223769720|NCT01946308|OTHER|Conformational positioning system|The conformational positioning system will be compared to the standard infant crib mattress.
224242320|NCT05061290|OTHER|Test Porridge D|Maize porridge containing 54Fe and fortified with Moringa leaf and Baobab fruit powder as iron source
224242321|NCT02491346|PROCEDURE|conventional empirical glycemic control|the patients' blood glucose is controlled by physician according to their experience through insulin subcutaneous injection or insulin continuous infusion whose dosage is determinated by the physician.
224242322|NCT02491346|PROCEDURE|SGC directed glycemic control|the patients' blood glucose is controlled by SGC system through insulin continuous infusion whose dosage is determinated by SGC.
224242323|NCT06318702|OTHER|Education|is an education program implemented to raise women's awareness about reproductive health and to help them adopt healthy habits.
224242324|NCT00968552|PROCEDURE|Self-expandable stent placement via endoscopy|Self-expandable stent placement via endoscopy
223662227|NCT05192447|BEHAVIORAL|Exercise treatment|Patients selected to EG will carry out complementary cognitive and physical training under supervision of rehabilitation staff. For neuropsychological exercises, the investigators will use the RehaCom system - high quality scientific neurocognitive disorder therapy programs and software. (Time: 30 min./5 times/week per patient during RT). In this time, EG patients will do physical training (such as cycling, running on properly calibrated equipment for the circulatory system parameter measurement (1hour/ 5 days/ week), and neuromuscular and cognitive reeducation exercises using a technically advanced tool - Neuroforma computer software - 30 min/ 5 times/ week). After the end of RT, patients in EG will do a special exercise training at home under supervision of staff from the Department of Rehabilitation, and cognitive training using special tasks (3 times an hour/per week) at home, and two times/week using RehaCom and Neuroforma (60 min/sesion) in our cancer ceter.
224242325|NCT04672291|DRUG|Poly-ICLC (Hiltonol®) or Placebo|The safety cohort (Cohort A) consists of 13 patients who will be randomized to receive 2 cycles of the study drug (N10) or 2 placebo cycles (N3).
224242326|NCT04672291|DRUG|Poly-ICLC (Hiltonol®) or Placebo|The expansion cohort will receive 3 cycles of therapy. A total of 30 patients will be accrued and randomized 4:1 to receive drug (N=24) or placebo (N=6).
224242327|NCT00516880|DRUG|rosiglitazone|
224242328|NCT05000619|BEHAVIORAL|Outreach mailer|Postcard or letter
224242329|NCT05000619|BEHAVIORAL|Humor/Salience|Funny cartoon
224242330|NCT05000619|BEHAVIORAL|Doctor's authority|Letter from a doctor
224242331|NCT05000619|BEHAVIORAL|Information|Information about benefits of the appointment
224242332|NCT03232008|DIETARY_SUPPLEMENT|Canderel drink|1.4% aspartame and 0.95% acesulfame-k and 95% maltodextrin; 3g dissolved in 250ml of water
224242333|NCT03232008|DIETARY_SUPPLEMENT|Canderel+Lyle's Golden Syrup drink|Canderel: 1.4% aspartame and 0.95% acesulfame-k and 95% maltodextrin; 3g dissolved in 250ml of water Lyle's Golden Syrup: 35 g (27g of glucose and fructose)
224242334|NCT01980732|DRUG|68Ga-DOTA TATE|Patients with somatostatin receptor positive tumors will be evaluated with 68Ga-DOTA TATE PET/CT in addition to conventional imaging.
224242335|NCT00877032|BIOLOGICAL|RN6G|intravenous, single dose, dose ranging from 0.3mg/kg up to a maximum of 40 mg/kg.
224242336|NCT00877032|BIOLOGICAL|Placebo|intravenous, single dose with experimental dose.
224242337|NCT06031792|PROCEDURE|Piezo endodontic surgery|Osteotomy will be done with Piezosurgery touch. After the soft tissue curettage and uncovering the root apex, the last 3 mm of the root apex will be resected perpendicular to the long axis of the tooth using piezotome. apical preparation will be performed and Biodentine®retrograde filling material will be placed. The flap will be re-approximated and interrupted suture using non-absorbable monofilament suture will be applied. Finally, Post-operative parallel Digital view.
224242338|NCT06031792|PROCEDURE|Conventional endodontic surgery|After the soft tissue curettage and exposure of the root apex, the osteotomy will be performed using a conventional surgical handpiece. The same steps will be followed to prepare and restore the root, as well as to reposition the flap.
224242339|NCT02786030|BEHAVIORAL|Outreach education training|Printed copies of the patient management tool (PMT) and outreach education training
224242340|NCT02786030|BEHAVIORAL|No outreach education training|Printed copies of the patient management tool (PMT) without outreach education training
224242341|NCT02301325|BEHAVIORAL|Smoking research cigarettes with or without NRT|
224242342|NCT03803800|OTHER|Classic, progressive endurance training|Moderate intensity endurance training will be performed following a sequence of 5 training sessions every 2 weeks throughout the 12-week intervention. Sessions will include 60min of cycling on a stationary bicycle. Exercise intensity will match 60-80% of the maximal heart rate (HRmax)
224242343|NCT03803800|OTHER|Periodized exercise training|Throughout the 12-week periodized intervention, subjects will perform four recurrent 3-week cycles of moderate endurance training (week 1,three sessions, 60min/session, 60-80% HRmax), high intensity interval training (week 2, three sessions, 10min/session, 3x20sec supramaximal sprint interspersed with recovery intervals of 2min), and recovery weeks (week 3, one high intense interval session as described above)
224242344|NCT03803800|DIETARY_SUPPLEMENT|beta-alanine|Some subjects will receive the ergogenic supplement beta-alanine.
224242345|NCT01646788|DEVICE|NMB Paclitaxel Drug Ejecting Balloon|NMB's PTA Balloon catheter with drug
223662228|NCT05682222|DRUG|EDP1815|EDP1815 is an essentially non-viable, non-replicating pharmaceutical preparation of a single strain of Prevotella histicola, a naturally occurring human commensal microbe.
223662229|NCT05682222|DRUG|EDP2939|EDP2939 is a pharmaceutical preparation of extracellular vesicles.
223662230|NCT05682222|DRUG|Placebo oral capsule|Placebo.
223662231|NCT02668471|PROCEDURE|Ultrasound|ultrasound at radial site and measure the size and depth of radial artery and perform radial artery cannulation
223662232|NCT02668471|PROCEDURE|traditional method|Radial artery catheters will be placed by the palpation technique only.
223662233|NCT05922670|BEHAVIORAL|The Behavioral Health-Works Suicide Prevention Program for Sexual and Gender Minority Youth|BH-Works is a web-based, comprehensive program for suicide prevention. The BH-Works program is a systems-level intervention that provides tools and resources to make organization adoption more feasible.
224242346|NCT03221374|BEHAVIORAL|Mindfulness Based Stress Reduction|8-week mindfulness based stress reduction course intended to develop mind-body awareness through mindfulness practices.
224242347|NCT02077270|PROCEDURE|electroacupuncture|Patients allocated to this arm will receive electro-acupuncture bilaterally on the following points which are considered relevant both for sedation and abdominal distention:LI4 (Hegu),ii. St36 (Zusanli), Sp6 (Sanyinjiao), St25 (Tianshuv),. Du20 (Baihui),
224242348|NCT05067647|DEVICE|ENSEAL X1 Curved Jaw Tissue Sealer|ENSEAL X1 curved jaw tissue sealer is used for transecting and sealing vessels during thoracic, urologic, or ENT procedures according to instructions for use.
224242349|NCT04166032|DEVICE|Alertgy non-invasive continuous glucose monitoring device (ANICGM)|Alertgy non-invasive continuous glucose monitoring device (ANICGM)
224242350|NCT01524718|RADIATION|Imaging with two X-ray image intensifiers|Two fluoroscopy apparatus one in the AP plane and the other as the axial plane.
224242351|NCT04587557|BEHAVIORAL|Storytelling with social contextual information|Four out of 100 stories from a storytelling app (SAHK, 2013) that incorporated social contextual information, and inter-personal skills were selected. The intervention was in small group format, consisted of eight sessions across four weeks, two sessions per week, 30 minutes per session.
224242352|NCT04587557|BEHAVIORAL|Storytelling without social contextual information|Four out of 100 stories from a storytelling app (SAHK, 2013) without social contextual information, and inter-personal skills were selected. The intervention was in small group format, consisted of eight sessions across four weeks, two sessions per week, 30 minutes per session.
224242353|NCT04587557|OTHER|Children with ASD|Four out of 100 stories from a storytelling app (SAHK, 2013) were selected for children with ASD.
224242354|NCT04587557|OTHER|Children with TD|Four out of 100 stories from a storytelling app (SAHK, 2013) were selected for children with TD.
224242355|NCT05003635|DEVICE|EVEBRA device|Wear 2 weeks pre-operatively for a total duration of 200 hours. Wear 2 weeks post-operatively for 10 hours a day.
224242356|NCT00138385|BIOLOGICAL|FluMist|
224242357|NCT00138385|BIOLOGICAL|Fluzone|
224242358|NCT04193566|DRUG|Forxiga|"Forxiga®, dapagliflozin 10 mg film-coated tablet.~For further information please refer to:~https://www.ema.europa.eu/en/documents/product-information/forxiga-epar-product-information\_en.pdf.~Common side effects include hypoglycemia, hypotension, elevated hematocrite, dyslipidemia, back pain, dizziness, skin rash, urinary tract infection, vulvovaginitis and dehydration. Very rare incidents of ketoacidosis have been observed. Side effects have only been observed after use in longer periods and not in single-dose usage, as planned in the present study. A dose of 50 mg has been chosen to achieve optimal efficacy. Once-per-day doses of dapagliflozin for 12 weeks of 2.5 mg, 5 mg, 10 mg, 20 mg and 50 mg have been demonstrated to be relatively safe across the mentioned doses (20) and no apparent risk is expected from instituting two single-doses of 50 mg dapagliflozin."
223662234|NCT00079365|DRUG|fluorouracil|
223662235|NCT00079365|DRUG|gemcitabine hydrochloride|
224242359|NCT06062771|DEVICE|FIDIAL PLUS|1.8% solution of sodium hyaluronate that is derived from a bacterial fermentation (not of animal origin).
224242360|NCT06062771|DEVICE|IAL®-F|Animal derived 1.8% sodium hyaluronate equivalent to FIDIAL PLUS
224242361|NCT02463513|DIETARY_SUPPLEMENT|Placebo comparator|2 week placebo washout + 16 weeks intervention (placebo)
224242362|NCT02463513|DIETARY_SUPPLEMENT|1.6mg riboflavin (Vitamin B2)|2 week placebo washout + 16 weeks intervention (1.6mg riboflavin per day)
224242363|NCT02463513|DIETARY_SUPPLEMENT|10mg riboflavin (Vitamin B2)|2 week placebo washout + 16 weeks intervention (10mg riboflavin per day)
223769721|NCT02476565|DEVICE|LMA-Supreme supraglottic device|The fiberscope (with the Aintree loaded on top of it) will be advanced through the supraglottic device into the trachea. Next, the supraglottic device will be removed and the endotracheal tube will be advanced into the airway over the Aintree airway intubation catheter. Finally, the Aintree catheter is removed and the endotracheal tube will be left in the airway.
223769722|NCT02476565|DEVICE|I-gel supraglottic device|The fiberscope (with the Aintree loaded on top of it) will be advanced through the supraglottic device into the trachea. Next, the supraglottic device will be removed and the endotracheal tube will be advanced into the airway over the Aintree airway intubation catheter. Finally, the Aintree catheter is removed and the endotracheal tube will be left in the airway.
224242364|NCT04347837|DEVICE|Titan SGS stapler|Stapler for the longitudinal resection of the stomach
224242365|NCT01106326|BEHAVIORAL|Intervention|"Teens participating in this study will have:~1. directly observed administration of their daily preventive asthma medication at school, by the school nurse, for the first 6-8 weeks of the study~2. three counseling sessions with a study nurse trained in principles of motivational interviewing (MI), that are designed to enhance the teen's motivation to change health behaviors, with a focus on adherence to evidence-based preventive care guidelines (e.g.; preventive medications)."
224242366|NCT02545946|DEVICE|vessel loop|using the vessel loop to hold the place of the surgical wound that is made during I\&D
224242367|NCT02545946|OTHER|traditional I&D with or without packing|abscess will be drained with a traditional I\&D with or without packing (as deemed appropriate by ER doctor)
224242368|NCT03033420|DEVICE|A smartphone-based monitoring system including a) an integrated feedback loop between patients and clinicians and b) context-aware CBT modules|A smartphone-based monitoring system including a) an integrated feedback loop between patients and clinicians and b) context-aware CBT modules
224242369|NCT02945215|DRUG|IBI301|IBI301 375mg/㎡
224242370|NCT02945215|DRUG|Rituximab|Rituximab 375mg/㎡
224242371|NCT04292561|DRUG|Low MAC|To maintain a target of sevoflurane inhalation concentration 0.8 MAC.
223662236|NCT00079365|RADIATION|brachytherapy|
223662237|NCT00079365|RADIATION|phosphorus P32|
224242372|NCT04292561|DRUG|High MAC|To maintain a target of sevoflurane inhalation concentration 1.0 MAC.
224242373|NCT06545149|DIETARY_SUPPLEMENT|BioNutri AR-1,|intervention with fermented and nutritionally balanced food twice a day
224242374|NCT04792749|DRUG|Metformin|Patients are given 750, 1500, and 2000 mgs of metformin per os daily (dose increases weekly, then maintain at 2000 mgs) in addition to 500 mgs of medroxyprogesterone acetate per os daily and levonorgestrel-releasing intrauterine device for the treatment of early stage endometrial cancer.
223662238|NCT00079365|RADIATION|radiation therapy|
223662239|NCT06322030|DIETARY_SUPPLEMENT|FOCUS-15 Lifestyle Management Program|15 week weight management program
223662240|NCT06322030|BEHAVIORAL|Exercise Training|15 weeks of progressive exercise training
223662241|NCT02693132|BEHAVIORAL|Supervised (SUP-PA)|Weight loss intervention that involves an energy restricted diet plus the inclusion of 150 minutes per week of supervised moderate-to-vigorous intensity physical activity.
223662242|NCT02693132|BEHAVIORAL|Unsupervised (UNSUP-PA)|Weight loss intervention that involves an energy restricted diet plus the inclusion of 150 minutes per week of unsupervised moderate-to-vigorous intensity physical activity.
223662243|NCT02693132|BEHAVIORAL|Step-based (STEP)|"Weight loss intervention that involves an energy restricted diet plus the inclusion of physical activity in the form of 10,000 steps/day with 2,500 brisk steps/day."
223662244|NCT04376866|DRUG|Toripalimab|anti-PD-1 antibody
223662245|NCT06425692|BEHAVIORAL|Education|Education on basic palliative care via e-learning + webinar to deepen knowledge.
223662246|NCT04492332|DIAGNOSTIC_TEST|standard lumbar puncture|Subjects underwent a standard lumbar puncture to measure the intracranial pressure (ICP). ICP was measured invasively through lumbar space in the morning.
223769723|NCT00248222|BEHAVIORAL|Supervised aerobic training|
223769724|NCT00124150|DRUG|Intravenous magnesium sulfate infusion|80mg per day
224242375|NCT03741348|PROCEDURE|Erector Spinae Plane Block|In (ES) group After skin sterilization, ESPB was performed in sitting position at the level of T9 linear ultrasound (US) transducer (Phillips-Saronno Italy) was placed vertically 3cm lateral to midline to visualize the muscles of the back, transverse process and simmering pleura in between the two transverse processes. After local infiltration of needle insertion site with 2-3ml of 2% lidocaine, a 22-gauge Short bevel needle (Spinocan, B.Braun Melsungen AG, Germany) was inserted in cranial-caudal direction towards transverse process (TP) in-plane to the US transducer until needle touched the TP crossing all the muscles. Then, up to 20 ml of bupivacaine 0.5% was injected. The procedure was repeated following the same steps on the other side of back.
224242376|NCT03741348|PROCEDURE|control|in control group, Erector Spinae Plane Block will not be done
224242377|NCT05425147|OTHER|Perioperative autonomic function assessment|Patients will have BRS and HRV measurements taken for approximately 20 minutes, one day before surgery and on the day of surgery. We use LiDCO rapid to conduct non-invasive pulse and beat-to-beat blood pressure monitoring.
224242378|NCT01278056|DRUG|Exjade|Two dose escalating cohorts of oral administration in Phase I. Phase II: oral administration of the maximum tolerated dose.
224242379|NCT01447563|DRUG|Clopidogrel bisulfate|subjects received a single 75 mg tablet of the reference formulation, given with 250 mL water
224242380|NCT01447563|DRUG|Clopidogrel|subjects received a single 75 mg tablet of the test formulation, given with 250 mL water
224242381|NCT02696681|BEHAVIORAL|Cognitive Behavioral Therapy|Integrating CBT for mental health and substance issues concern with CBT for health behavior change
224242382|NCT01210456|DRUG|Physiological Saline, N-Acetylcysteine and Sodium Bicarbonate|"All patients receive N-Acetylcysteine(NAC) and sodium chloride. NAC is given orally at a dose of 700mg twice daily, on the day before and on the day of administration of the contrast media, for a total of two days.~154mEq/L of sodium chloride is given intravenously. The initial intravenous bolus is 3ml/kg per hour for 1 hour immediately before contrast injection. And then, patients receive the same fluid at 1ml/kg per hour during the contrast exposure and for 6 hours after the procedure.~In addition, intervention arms receive sodium bicarbonate.1000mEq/L of sodium bicarbonate is given intravenously twice at a dose of 40ml immediately before the contrast exposure and immediately after the procedure."
224242383|NCT00870870|DRUG|Gemcitabine|"1000 milligrams per square meter (mg/m\^2) on Days 1 and 8 of each cycle~\[First 6 cycles (18 weeks)\]"
224242384|NCT00870870|DRUG|Cisplatin|"75 mg/m\^2 on Day 1 of each cycle~\[First 6 cycles (18 weeks)\]"
224242385|NCT00870870|BIOLOGICAL|IMC-A12 (cixutumumab)|"6 milligrams per kilogram (mg/kg) intravenous (IV) infusion, administered once per week (on Days 1, 8, and 15 of each cycle)~\[First 6 cycles (18 weeks)\]"
224242386|NCT00870870|BIOLOGICAL|Cetuximab|"400 mg/m\^2 IV infusion, administered on Day 1 of Cycle 1, 250 mg/m\^2 once per week thereafter~\[First 6 cycles (18 weeks)\]"
224242387|NCT00870870|BIOLOGICAL|IMC-A12 (cixutumumab)|"10 mg/kg IV infusion, administered once every 2 weeks~(Maintenance therapy)"
224242388|NCT00870870|BIOLOGICAL|Cetuximab|"500 mg/m\^2 IV infusion, administered once every 2 weeks~(Maintenance therapy)"
224242389|NCT00870870|DRUG|Carboplatin|"Area under the curve (AUC) = 5, Day 1 of each cycle~\[First 6 cycles (18 weeks)\]~\*Carboplatin will be replaced by Cisplatin"
224242390|NCT04438005|DRUG|ICP-022|ICP-022 is a white, round, uncoated tablet, 50 mg. It is administered orally at the dose of 150 mg/day from day 1 to day 28 of each cycle for up to a total of 6 cycles or until progression.
224242391|NCT05017857|DEVICE|RepetiveTranscrainal Magnetic Stimulation (rTMS)|RepetiveTranscrainal Magnetic Stimulation (rTMS): rTMS is a non-invasive electromagnetic stimulation of the brain. A train of electric pulses is delivered at the same intensity over a set period of time to a targeted region of the brain. The current stimulates or suppresses neuronal activity based on the frequency and inter-train interval between the pulses.
224242392|NCT05017857|BEHAVIORAL|Problem-Solving Training (PST)|Problem-Solving Training (PST) is a metacognitive strategy training in which patients are guided through a process of conscious self-assessment resulting in problem identification, generation of solutions, development of specific goals and action plans, and evaluation and revision of plans as needed. PST thus helps to circumvent impulsive or unrealistic problem-solving attempts that lead to failure, discouragement, and feelings of helplessness.
224242393|NCT02125266|DRUG|V404|Sustained Release
224242394|NCT04468802|OTHER|Case fatality rate|Mortality rate caused by SARS CoV-2
224242395|NCT03104166|DEVICE|Medium Cut-Off (MCO) dialysis membrane|Patients will be treated with a CE-certified dialysis membrane that provide enhanced clearance for middle-sized molecules, call Medium Cut-Off membrane.
223662247|NCT03584880|DEVICE|Diode laser disinfection|Root canal disinfection using a 940 nm dental laser after the removal of root canal filling of failed endodontic cases.
223662248|NCT03584880|DEVICE|Pseudo diode laser disinfection|Without activating laser energy, same procedure as experimental group was performed (Sham laser application)
223769725|NCT01788501|DRUG|Tacrolimus|D-1\~D20: iv infusion, q24hr (first daily dose: 0.03mg/kg) D20\~D100: po q12hr (first daily dose: the quadruple of last iv dose) Dose modification according to TDM (10-20ng/ml)
223769726|NCT01788501|DRUG|Cyclosporine|D-1\~D20: iv infusion, q24hr (first daily dose: 3mg/kg) D20\~D100: po q12hr (first daily dose: the 3 times of last iv dose) Dose modification according to TDM (200-300ng/ml)
223769727|NCT01788501|DRUG|Methotrexate|D1: 15mg/m2 iv push D3,6,(11): 10mg/m2 iv push
223769728|NCT05044741|PROCEDURE|Emergency surgical enterostomy|Emergency surgical enterostomy
223769729|NCT05191498|DEVICE|QuiremSpheres®|Intratumoral injection of QuiremSpheres® up to a dose of 150 Gy.
223769730|NCT01263873|DEVICE|Mallinckrodt (ETT)|7.0 millimeter internal diameter for female 8.0 millimeter internal diameter for male
223769731|NCT01263873|DEVICE|Parker Flex-Tip (ETT)|7.0 millimeter internal diameter for female 8.0 millimeter internal diameter for male
224242396|NCT03104166|DEVICE|High-Flux dialysis membrane|Control: Patients will be treated with a CE-certified High-Flux dialysis membrane.
224321332|NCT05789589|DRUG|Azeliragon|"Dosing will begin on Day 0 with the loading dose and continue daily through Day 7. Starting on Day 8, dosing will resume with the continuous dose until disease progression or 8 weeks. If there is evidence of antitumor effect at 8 weeks, dosing may continue for up 2 two years.~All doses are taken orally. There are three levels of dosing, including a starting dose and two lower levels of dosing. Participants will start with the starting dose, and in the event of the dose limiting toxicities, the dose will be reduced as described below.~Starting Dose Level: 30 mg twice daily (Loading Dose) or 20 mg once daily (Continuous Dose) Dose Level -1: 15 mg twice daily (Loading Dose) or 10 mg once daily (Continuous Dose) Dose Level -2: 15 mg once daily (Loading Dose) or 5 mg once daily (Continuous Dose)"
224242397|NCT00487669|DRUG|paclitaxel poliglumex, pemetrexed|The first 6 eligible patients will be enrolled at a dose of 135 mg/m2 paclitaxel poliglumex in combination with 500 mg/m2 of pemetrexed. Patients who experience disease progression without dose-limiting adverse events after the initial cycle will be replaced. Dose escalation to the next dose level can occur provided that no more than 1 of 6 patients experience in initial dose limiting toxicity (IDLT) following 2 cycles of therapy. If ≥ 2 of 6 patients experience IDLTs at the 135 mg/m2 dose, the maximally tolerated dose (MTD) was surpassed and the study will be discontinued
224321333|NCT05789589|RADIATION|Stereotactic radiosurgery|Patients will undergo standard of care SRS as per the treating facility's policies.
224321334|NCT05789589|DRUG|Corticosteroid|"Two corticosteroid regimens are used depending on the study cohort. Cohorts 1 and 2 will receive the loading dose (LD). Only Cohort 1 will receive the corticosteroid taper (CT).~LD: Oral (8 mg) or IV bolus dose (10 mg) of dexamethasone or 40 to 80 mg of methylprednisolone on the day of SRS CT: Oral 2-4 mg of dexamethasone twice daily for 5 days and then 2-4 mg daily for 5 days at the discretion of the treating physician (concurrent use of a proton pump inhibitor or H2 receptor antagonists are encouraged during the CT)."
224321335|NCT06976060|BEHAVIORAL|High-Intensity Interval Training|High-intensity interval training (HIIT) sessions will occur twice per week, on non-consecutive days. Each training session will last 45-60 minutes and consist of eight functional movement exercises incorporating the entire body (upper body, lower body, core/stability, cycling, and agility). Participants will complete two rounds of the 8-exercise circuit with 2-minutes of rest between rounds. The load/resistance used for each exercise will be self-selected by the participants that equates to 15-18 on the RPE scale. During each round, participants will have 1 minute to complete as many repetitions as possible of a given exercise and then have 1 minute of rest before completing the next exercise - giving the participants a 1:1 exercise-to-rest ratio.
224321336|NCT06101264|DEVICE|Control|Control patients following spinal fusion for adolescent idiopathic scoliosis that receive no virtual reality sessions.
224321337|NCT06101264|DEVICE|Virtual Reality|Patients will undergo a 20 minute virtual reality session prior to each physical therapy session following spinal fusion for adolescent idiopathic scoliosis. Virtual reality sessions will continue until functionally cleared by physical therapy.
223662249|NCT06033755|OTHER|Norwegian psychomotor physiotherapy|"The intervention consisted predominantly of Norwegian Psychomotor Physiotherapy (NPMP) in which participants received individually tailored treatment based on the body examination and reported respiratory distress. NPMP addresses bodily tension, postural de-alignments and dysfunctional breathing patterns. The consultations also included a cognitive dimension, that is a conversation, in which thoughts and behaviours about training and competing were addressed and where participants were provided with self help measures that could improve breathing during training and competing. A rehabilitation plan for each participant was designed to limit further impairments and maintaining aerobic capacity without intensifying EILO symptoms. The intervention lasted 5 months."
223662250|NCT02410889|OTHER|EEG-fMRI scanning|Patients undergo EEG-fMRI scanning
223662251|NCT00756535|PROCEDURE|Exercise training|Group-based exercise training 5 days a week during hospitalization
223662252|NCT00756535|PROCEDURE|usual treatment and rehabilitation|usual treatment and rehabilitation
223662253|NCT04556383|DRUG|GB004|oral tablet
224242398|NCT05936710|DEVICE|ACETATE based dialysate|Intermittent hemodialysis with an acetate based dialysate.
224242399|NCT05936710|DEVICE|CITRATE based dialysate|Intermittent hemodialysis with an citrate based dialysate.
224242400|NCT03005522|DRUG|oral dexamethasone|Patient will be dosed with either placebo or with the study drug, 10mg oral dexamethasone, to be administered by mouth one time in the ED
223662254|NCT04556383|DRUG|Placebo|oral tablet
223662255|NCT00935246|DRUG|Escitalopram|Antidepressant administration of Escitalopram for 8 weeks under therapeutic dose
223662256|NCT01146457|DRUG|Morphine|Active dosage
223662257|NCT01146457|DRUG|Saline|Saline Control
224242401|NCT03005522|DRUG|Placebo Oral Capsule|dosed with placebo
224242402|NCT01895296|DRUG|Pasireotide|somatostatin analogue pasireotide
224242403|NCT01895296|DRUG|Placebo|placebo s.c.
224242404|NCT04012632|OTHER|this study was an observational study and no interventions were given to the participants|the participants were recruited and the data as well as blood sample were collected.
224242405|NCT01806805|DRUG|zonegran|
224321338|NCT01350583|DRUG|Sodium Bicarbonate (NaHCO3)|Treatment consisted of 0.15 g/kg/day Sodium Bicarbonate (NaHCO3) increasing to 0.3 g/kg/day after 1 week if well tolerated. Further dose increment to 0.6 g/kg/day was to be done after 2 weeks of starting sodium bicarbonate if prior dose levels were well tolerated.
224321339|NCT04405830|PROCEDURE|Renal replacement therapy|Renal replacement therapy (RRT) refers to modalities of treatment that are used to replace the waste filtering functions of a normal kidney.
224321340|NCT03510962|OTHER|Group 1: no intervention|Unstimulated saliva samples are collected from the subject to measure the pH of saliva after 5, 15, 30, 45 and 60 minutes of consumption of the test mixed fruit juice without any intervention.
224321341|NCT03510962|OTHER|Group 2: tap water gargle|The subject will use 10 ml of tap water as mouth rinse to swish for 60 seconds and spit. Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes the gargle as an intervention.
224242406|NCT01806805|DRUG|placebo|
224242407|NCT00822926|DRUG|Botulinum Toxin Type A|Patients receive a subcutaneous injection of Botulinum Toxin Type A into the scar tissue
224242408|NCT00822926|DRUG|Saline|Subcutaneous injection of saline into scar tissue
224242409|NCT05352087|PROCEDURE|Laparoscopic cholecystectomy|Laparoscopic cholecystectomy is minimally invasive surgery to remove the gallbladder.
224242410|NCT04185935|OTHER|Biospecimen Collection|Provide a sample of blood, a saliva sample, a sample of eyebrow plucks, a sample of urine, and/or stored tumor or healthy tissue
224242411|NCT04185935|OTHER|Questionnaire Administration|Ancillary studies
224242412|NCT01540032|BEHAVIORAL|Low salicylate diet|Patients will avoid foods from the 'high salicylate' group completely. They can eat foods from the 'low salicylate' group freely and just eat foods from the medium group occasionally, and not in large amounts.
224242413|NCT01540032|BEHAVIORAL|Normal diet|Patients will eat their usual diet.
224242414|NCT03776903|OTHER|ZIKV Detect™ 2.0 IgM Capture ELISA|De-identified archive specimens are tested by ELISA and compared to reference testing (RT-PCR and CDC MAC-ELISA)
224242415|NCT01124396|DRUG|DSP-3025|
224242416|NCT01124396|DRUG|Placebo|
224242417|NCT02304432|DRUG|D-cycloserine|Both participants received open label D-cycloserine (seromycin), 50 mg/d capsule, x 8 weeks.
224242418|NCT02304432|DRUG|DCS or placebo|Double-blind placebo-controlled exposures to DCS or placebo x 6 weeks. One participant received exposure to DCS x 6 weeks and then received placebo dosing x 6 weeks. The other participant received exposure to placebo dosing x 6 weeks and then DCS x 6 weeks.
224242419|NCT02304432|DRUG|D-cycloserine|Both participants received second open label D-cycloserine (seromycin), 50 mg/d capsule, x 8 weeks.
224242420|NCT01636609|DRUG|Azacitidine|Given IV or SC
224242421|NCT01636609|DRUG|Cytarabine|Given SC
224242422|NCT01636609|DRUG|Tosedostat|Given PO
224242423|NCT06347042|OTHER|qigong exercise + routine medical treatment +Anti-inflammatory diet|1\. Qigong exercise is from traditional Chinese medicine exercise . Qigong is system coordinating slow-flowing movement, deep rhythmic breathing, and a calm meditative state of min Frequency of exercise 3 days a week and 60 min a day, including a 15 min warm up, 40 min and 5min cool down.
224242424|NCT06347042|OTHER|routine medical treatment +Anti-inflammatory diet only|"1. Anti-inflammatory diet is characterized by the exclusion of potential inflammatory foods, such as gluten, dairy, free sugar, and ultra-processed food, rich in sugar, hydrogenated fat, and food additives. are some foods with recognized anti-inflammatory potential~2. routine medical treatment"
224242425|NCT00322803|DRUG|ELB139|
224242426|NCT00948519|DEVICE|Laser + ICG|ICG arm- will be defined as local application on a pledget soaked with ICG with a concentration of 200µg, upon removal of the pledget a NIR diode laser set at 6W with light emittance introduced intranasally with a 30mm diffuser fiber capable of radiating light circumferentially allowing the light energy to reach all treatable areas. Laser will be activated for 180 seconds. Assuming an approximate radius of the nasal cavity is 3mm, energy density will be around 200J/cm². Treatment will be repeated twice, 5-7 day apart. Cultures will be collected at the end of all treatments
224242427|NCT00948519|DEVICE|Laser only|same only without ICG
224242428|NCT05786222|BEHAVIORAL|CSH-Delivered Overdose Prevention Support|Corporation for Supportive Housing (CSH) will deliver technical support for overdose (OD) prevention in the participating PSH buildings using a package of core implementation strategies: PSH Overdose Prevention (POP) Toolkit (an implementation manual/blueprint for overdose prevention practices); Implementation Champions (staff and tenants in each PSH building will be selected as implementation champions who support implementation and sustainment of OD prevention practices in their buildings); practice facilitation (the practice facilitator \[a trained CSH employee\] will work with the tenant and staff champions in small group workshops and coaching sessions, building their capacity and supporting their work toward implementation of building OD prevention practices); learning collaboratives (PSH buildings starting the intervention at the same time will attend learning collaborative meetings).
224242429|NCT03239145|DRUG|Pembrolizumab|Pembrolizumab is designed to augment the natural ability of the immune system to recognize and target cancer cells
224242430|NCT03239145|DRUG|Trebananib|AMG386 is a drug that may kill tumor cells and blocks blood vessels that supply the tumor with nutrients and oxygen
224242431|NCT04536805|DRUG|Metformin|Metformin: 850 mg per day (day -15 to day 0) 1700 mg per day (day 1 to day 75)
224242432|NCT04536805|RADIATION|Stereotactic Body Radiation Therapy (SBRT) 30 Gray (Gy)|Stereotactic Body Radiation Therapy (SBRT): Dose escalation 5 x 6 Gy day 0 to day 10
224242433|NCT04536805|RADIATION|Stereotactic Body Radiation Therapy (SBRT) 36 Gy|Stereotactic Body Radiation Therapy (SBRT): Dose escalation 6 x 6 Gy day 0 to day 12
223662258|NCT03309176|DRUG|Medroxyprogesterone Acetate 10 MG|Patients in the standard arm will receive Medroxyprogesterone Acetate 10mg daily for 10 days prior to the first ovulation induction cycle and in between anovulatory cycles.
223662259|NCT03309176|OTHER|Stair step protocol without Medroxyprogesterone Acetate|No administration of Medroxyprogesterone Acetate prior to each cycle. Stair step method: rapidly increasing the dose of clomiphene citrate in case of no follicular response
223662260|NCT06171477|DEVICE|Ventilation 20-40-60|The respiratory rate during mechanical ventilation will be altered from 20 to 40 and finally to 60 breaths per minute.
223662261|NCT06171477|DEVICE|Ventilation 60-40-20|The respiratory rate during mechanical ventilation will be altered from 60 to 40 and finally to 20 breaths per minute.
224242434|NCT04536805|RADIATION|Stereotactic Body Radiation Therapy (SBRT) 25 Gy|Stereotactic Body Radiation Therapy (SBRT): Dose escalation 5x 5 Gy day 0 to day 10
224242435|NCT00098371|DRUG|alvocidib|
224242436|NCT01314742|DRUG|Biotene OralBalance® gel|Biotene OralBalance® gel is dispensed as 42gm, patient specific tube from hospital's Central Pharmacy. One pea-size oral application every 4 hours, or at touch time, to gums and tongue, as long as the subject remains mechanically ventilated for the duration of hospitalization.
223662262|NCT06171477|DEVICE|Ventilation 40-60-20|The respiratory rate during mechanical ventilation will be altered from 40 to 60 and finally to 20 breaths per minute.
224242437|NCT01314742|OTHER|Sterile Water moisten cotton tipped applicator|One oral care application will be performed every 4 hours, or at touch times, to gums and tongue, as long as the subject remains mechanically ventilated for the duration of hospitalization.
224242438|NCT03767192|DEVICE|Active Stimulation|SPG stimulation and standard of care
224242439|NCT03767192|DEVICE|Sham Stimulation|Sham SPG stimulation and standard of care
224242440|NCT00003898|DIETARY_SUPPLEMENT|glutamine|Oral
224242441|NCT02268500|BIOLOGICAL|Influenza vaccine|Influenza vaccine
224242442|NCT05618119|DRUG|[18F]MC225|\[18F\]MC225 PET scan
224242443|NCT01230151|DEVICE|GUIDE software, Version 0.1|The GUIDE software uses computer-based models to determine the spread of stimulation from DBS therapy into surrounding nuclei of the brain. The software models stimulation and is not used to program or communicate with the patient's implanted DBS System. The software was recently validated in a multi-center clinical study.
224242444|NCT01230151|DEVICE|Clinically defined stimulation parameters|Stimulation parameters clinically determined prior to start of clinical study
224242445|NCT05811156|BEHAVIORAL|Hybrid Multimodal digital intervention|Multimodal digital intervention, including an internet-delivered CBT treatment based on a biopsychosocial exposure treatment, tailored explicitly for Exhaustion due to persistent non-traumatic stress.
224242446|NCT01439893|DRUG|rhNRG-1|day1\~day10:0.6ug/kg/day,10hours per day for vein infusion
224242447|NCT01439893|DRUG|Placebo|day1\~day10:0.6ug/kg/day,10hours per day for vein infusion
224242448|NCT02425579|DRUG|Inhaled Carbon Monoxide at 100ppm (4 participants)|Inhaled Carbon Monoxide at 100ppm for up to 90 minutes daily for 5 days
224242449|NCT02425579|DRUG|Placebo for Inhaled Carbon Monoxide at 100ppm (2 participants)|Inhaled Medical Air for up to 90 minutes daily for 5 days
224242450|NCT02425579|DRUG|Inhaled Carbon Monoxide at 200ppm (4 participants)|Inhaled Carbon Monoxide at 200ppm for 90 minutes daily for 5 days
224242451|NCT02425579|DRUG|Placebo for Inhaled Carbon Monoxide at 200ppm (2 participants)|Inhaled Medical Air for up to 90 minutes daily for 5 days
224242452|NCT01517256|BEHAVIORAL|Living Everyday Above-and-beyond Pain (LEAP)|8-week multidisciplinary group therapy aiming consisting of education about the nature of chronic pain, pacing and goal setting, mindfulness medication techniques, cognitive reflections on beliefs, impulses and obsessions, physical activation, and medication management.
224242453|NCT01517256|OTHER|Wait-listed|Patients are wait-listed while awaiting participation to the LEAP program.
224242454|NCT00905853|PROCEDURE|Catheter Ablation|Intracardiac electrode catheters are placed via central vasculature to identify myocardial scar, and surviving conduction channels within the scar which form the substrate for ventricular tachycardia. Radiofrequency energy is applied to these sites, interrupting the VT circuits.
223662263|NCT02009540|DRUG|Botulinum toxin injected to bladder body|arm will receive 100u of onaBoNT-A in 20x1ml aliquots (5u/ml). 20 injections will be given into the bladder wall, sparing the trigone. Injections will be given through all layers of the bladder eg suburothelially and intradetrusor. The intervention will be performed under local anaesthetic using a flexible cystoscope.
223662264|NCT02009540|DRUG|Botulinum toxin injected into trigone|Arm B will receive 100u onaBoNT-A injected into 10x1ml suburothelial peri-trigonal sites (aliquot dose 10u/ml). The procedure will be performed under local anaesthetic by flexible cystoscopy.
223769732|NCT02065128|OTHER|Capsaicin cough challenge test|The capsaicin cough challenge testing will be conducted in the pulmonary function laboratory at SMH by a pulmonary function technologist. The test involves having the participant inhale increasing concentrations of capsaicin solutions and assessing their response. The tidal breathing method and solution preparation presented by Nejla, et al. 12 will be used to conduct this testing. The tidal breathing method is preferred to the alternative dosimeter method as it produces similar results with lower capsaicin concentrations thereby resulting in less throat irritation for the participant. The technique is detailed in the following sections.
223769733|NCT02760394|DEVICE|HBOT|40 daily sessions, 90 minutes of 100% oxygen at pressure of 2 ATA each, five days a week for 8 weeks.
223769734|NCT00047463|DEVICE|continuous positive airway pressure (CPAP)|a mask treatment for sleep apnea
223769735|NCT00047463|DEVICE|Placebo-CPAP|Placebo-CPAP
224242455|NCT00905853|DRUG|Escalated Antiarrhythmic Therapy|"Patients who have 'failed' antiarrhythmic therapy (except amiodarone) will be prescribed: Amiodarone 400 mg twice daily for 2 weeks, followed by 400 mg/day for 4 weeks, followed by 200 mg/day thereafter.~Patients who 'failed' amiodarone (less than 300mg/day) will be prescribed: Amiodarone 400 mg three times a day for 2 weeks, followed by 400 mg/day for 1 week and 300 mg/day thereafter.~Patients who 'failed' amiodarone (greater or equal to 300mg/day) will be prescribed: Amiodarone at the current dose with the addition of mexiletine 400 to 800 mg/day"
224242456|NCT03418441|OTHER|Community-acquired CNS infections|Prospective observational registration of clinical characteristics and outcome
224242457|NCT01880333|OTHER|Modified Atkin Diet|Eligible children will be started on Modified Atkins diet with help of trained dietician. Carbohydrates intake will be restricted to 5 grams/ day in children\<18 mo and 10grams/day in children 18mo- 3 years.Carbohydrate values of various food items will be explained in detail. Fats (e.g. cream, butter, oils, and ghee) will be encouraged. Proteins (cheese, fish, eggs, chicken, and soya products) will be unrestricted. Calcium and multivitamin supplementation will be done. Syrups will be restricted. Clear carbohydrates free fluids- will not be restricted. Medications will be changed to carbohydrate free preparations, wherever available. Diary of events will be recorded including seizure frequency and any adverse or positive effect. Urine ketones chart will be maintained.
224242458|NCT06659549|DRUG|GAL-101|Patient will apply daily 2 eye drops of GAL-101 at 5 minutes interval
224242459|NCT06659549|DRUG|Placebo|Patient will apply daily 2 eye drops of Placebo at 5 minutes interval
224242460|NCT03664973|PROCEDURE|Serratus plane block|Local anesthetic infusion though a peripheral nerve catheter placed on the 5th rib under the serratus plane
224242461|NCT01614730|DEVICE|Modified Neurotech Vital Device|verify no contraction is stimulated in the Modified Neurotech Vital.
223662265|NCT05981053|DIETARY_SUPPLEMENT|Wine enriched with Resveratrol|Wine enriched with Resveratrol
223662266|NCT01994889|DRUG|Tafamidis|Tafamidis 20 mg in soft gel capsules administered once a day for 30 months
223769736|NCT03398993|DRUG|Clomiphene Citrate|50 mg twice daily from3rd day of cycle till 7th day of cycle
224242462|NCT01614730|DEVICE|Neurotech Vital Device|Checking there is a contraction of the pelvic floor muscle when the treatment is administered with the Neurotech Vital Device
224242463|NCT00002005|DRUG|CD4 Antigens|
224242464|NCT05546827|PROCEDURE|Surgical resection|Surgical resection after receiving neodjuvant combination immunotherapy followed by radiation therapy.
224242465|NCT05768776|PROCEDURE|HoLEP patients without MOSES(TM) 2.0 effect (open label)|HoLEP surgery for the treatment of Benign Prostate Hyperthrophy, without using MOSES technology
224242466|NCT05768776|PROCEDURE|HoLEP patients with MOSES(TM) 2.0 effect (open label)|HoLEP surgery for the treatment of Benign Prostate Hyperthrophy, with the use of MOSES technology
223662267|NCT01994889|DRUG|Tafamidis|Tafamidis 80 mg in soft gel capsules administered once a day for 30 months
223662268|NCT01994889|DRUG|Placebo|Placebo in soft gel capsules administered once a day for 30 months
223662269|NCT03767790|DEVICE|iAPS|The AID system (iAPS) is comprised of an insulin pump, a Dexcom G6 continuous glucose monitoring sensor, and a smart phone that contains the algorithm and communicates with the other devices.
223662270|NCT03153722|PROCEDURE|Pediatric discharge process interventions|"As this is an iterative quality improvement process, interventions will be evidence-based and chosen to test effectiveness for addressing areas of discharge bottlenecks or inefficiency within our specific hospital's context. Examples of possible interventions may include implementation of a discharge risk assessment (as in Statile et al, Pediatrics 2016), institution of a medications-in-hand policy on hospital discharge (as in Sauers-Ford et al, Pediatrics 2016), or initiation of a ward discharge coordinator who will help coordinate outpatient follow-up for patients. Interventions will be implemented in a stepwise fashion, utilizing successive plan-do-study-act cycles, with a minimum 2 month period between interventions to monitor outcomes."
223662271|NCT00929643|OTHER|no intervention|success of the initial empiric treatment
223662272|NCT00163917|DEVICE|Virtual reality relaxation|
223662273|NCT01700309|BEHAVIORAL|Young and Active|The intervention will consist of three meetings between the adolescent, the parents and the researchers, and weekly web-based health-counselling. The adolescents will set goals and make an individual activity plan on the web-page. During the study period all activity will be registered by the adolescents. The researchers will perform weekly counseling based on Selfdetermination Theory and Motivational Interviewing. The webiste also allows for the adolescents to communicate with eacother and with the counsler through a blog.
223662274|NCT01748240|DRUG|Azacitidine and oral vorinostat|In patients still responding after six cycles, the drugs will continue to be supplied, and follow up until death or unacceptable tolerance will be continued in all patients.
224242467|NCT03069274|BEHAVIORAL|Intervention|General nutritional recommendations, change drinking habits
223662275|NCT04206241|DIAGNOSTIC_TEST|Point of care early infant diagnosis (POC EID)|HIV testing where the blood sample is processed at either the facility itself or a nearby site that is closer to the facility than a laboratory. With POC EID, blood samples do not have to travel to the laboratory for processing.
223662276|NCT01012089|DRUG|Daptomycin|Daptomycin IV 5 mg/kg one time dose
223662277|NCT01895478|BEHAVIORAL|PACCI-ED use|Attending physicians were allowed to view the patient's PACCI-ED prior to completing the assessment form. Attendings were told at the time of the child's ED visit that the PACCI-ED is used to assess a child's asthma control and medication adherence, and that they could use it to complete the outcomes assessment form.
223662278|NCT01812278|BEHAVIORAL|ACT|
223662279|NCT01812278|BEHAVIORAL|CBT|
223662280|NCT02237222|OTHER|Gait rehabilitation|
223769737|NCT03398993|DRUG|Human chorionic gonadotropin|75 IU dail;y from 6th day of cycle till 8th of cycle once daily
224242468|NCT03069274|BEHAVIORAL|General nutritional recommendations|Only general nutritional recommendations were given
223662281|NCT04650867|DEVICE|Multispectral Optoacoustic Tomography (MSOT)|Non-invasive transcutaneous MSOT imaging of the bowel wall (terminal ileum, ascending caecum/colon, transverse colon, descending colon, and sigmoid colon).
223662282|NCT00744042|BIOLOGICAL|asfotase alfa|
223662283|NCT01559740|DRUG|Bupivacaine|This is being used as the local anesthetic for the TAP blocks at either 0.25% or 0.125%. The block will be done once during the procedure.
223662284|NCT01573052|DRUG|Chlordiazepoxide|25mg four times daily x 3 days then tapered over 3 days
223662285|NCT01573052|DRUG|Gabapentin|300mg four times daily x 3 days then tapered over 3 days
223662286|NCT03944252|DRUG|Avelumab|avelumab 10 mg/kg iv day 1; To be repeated every 2 weeks (14 days) until progression of disease, refuse or inacceptable toxicity.
223662287|NCT03944252|DRUG|Cetuximab|cetuximab 500 mg/m2 plus avelumab 10 mg/kg iv day 1. To be repeated every 2 weeks (14 days) until progression of disease, refuse or inacceptable toxicity.
223662288|NCT01630993|OTHER|Umbilical Cord Milking|At birth, the infant will be held below the level of the placenta and umbilical cord will be milked 5 times after birth and before clamping the cord.
223662289|NCT01955629|DRUG|Aflibercept AVE0005|Pharmaceutical form: Concentrate for solution for infusion; Route of administration: Intravenous
223662290|NCT01955629|DRUG|Oxaliplatin|Pharmaceutical form: Concentrate for solution for infusion; Route of administration: Intravenous
223662291|NCT01955629|DRUG|Capecitabine|Pharmaceutical form: Tablets; Route of administration: Oral
223662292|NCT03158285|DRUG|Guselkumab|Participants will receive 100 mg of guselkumab as a sterile liquid for SC injection.
223662293|NCT03158285|DRUG|Placebo|Participants will receive matching placebo as SC injection.
223662294|NCT05529095|DRUG|Apomorphine Sublingual Film|Sublingual Apomorphine initial dose 10 mg, titrated depending on symptomatic response.
224242469|NCT02519322|BIOLOGICAL|Ipilimumab|Given IV
223662295|NCT05529095|DRUG|Placebo|Placebo (sugar pill)
223662296|NCT05675488|DIAGNOSTIC_TEST|Ultrasound|Thickness of flexor tendon and A1 pulley at MCP joint level
224242470|NCT02519322|OTHER|Laboratory Biomarker Analysis|Correlative studies
224242471|NCT02519322|BIOLOGICAL|Nivolumab|Given IV
224242472|NCT02519322|BIOLOGICAL|Relatlimab|Given IV
224242473|NCT02519322|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
224242474|NCT01706536|DRUG|Placebo|EP-101 Placebo AM + EP-101 Placebo PM
224242475|NCT01706536|DRUG|EP-101 12.5 mcg|EP-101 12.5 mcg AM + EP-101 12.5 mcg PM
224242476|NCT01706536|DRUG|EP-101 25 mcg|EP-101 25 mcg AM + EP-101 25 mcg PM
224242477|NCT01706536|DRUG|EP-101 50 mcg|EP-101 50 mcg AM + EP-101 50 mcg PM
224242478|NCT01706536|DRUG|EP-101 100 mcg|EP-101 100 mcg AM + EP-101 100 mcg PM
224242479|NCT04190693|DRUG|IMCY-0098 or placebo|Long-term follow-up
224242480|NCT06241378|DEVICE|perineometer device for physiotherapy|measuring the vaginal pressure for stress urinary incontinence patients
224242481|NCT05331664|PROCEDURE|Pars plana vitrectomy|Standard of care surgery
224242482|NCT05331664|DRUG|Triamcinolone Acetonide 40mg/mL|Sub-tenon injection of triamcinolone acetonide (40mg/mL) at the time of surgery
224242483|NCT05331664|DRUG|Moxifloxacin 0.5% or Polymyxin/Trimethoprim if patient is allergic to moxifloxacin|Antibiotic eye drop 4 times per day for 1 week after surgery
223662297|NCT04587765|BEHAVIORAL|Extra-curricular sports|The group follows the schedule of school teaching programme. Extra-curricular sports classes will be organized and provided in this group of schools in the afternoon after school until 6 p.m. (Monday to Friday).
224242484|NCT05331664|DRUG|Prednisolone 1%|Steroid eye drop 4 times per day tapered by one drop weekly for 4 weeks (4/3/2/1 taper) after surgery
223662298|NCT00043797|DRUG|Lidorestat (IDD 676)|
224242485|NCT05331664|DRUG|Atropine 1%|Eye drop daily for 1 week after surgery
224242486|NCT05005156|BIOLOGICAL|Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) (Ad5-nCoV)|All participants will receive two doses vaccine and will be followed to monitor vaccine candidate safety, immunogenicity, and efficacy for a duration of 52 weeks. Fifty four days after the first vaccination, all participants will receive a second injection.
224242487|NCT02459704|PROCEDURE|Semilunar coronally positioned flap|Semilunar coronally positioned flap with enamel matrix derivative (Emdogain) or alone.
224242488|NCT02459704|DEVICE|Enamel matrix derivative (Emdogain)|Enamel matrix derivative associated to semilunar coronally positioned flap (SCPF + EMD - test group)
224242489|NCT00860314|PROCEDURE|external electrical cardioversion (with antero-posterior electrode position)|external biphasic electrical cardioversion with step-up-protocol of 50-75-100-150-200 Joules if necessary with antero-posterior electrode position until restoration of normal sinus rhythm
224242490|NCT00860314|PROCEDURE|external electrical cardioversion (with antero-lateral electrode position)|external biphasic electrical cardioversion with step-up protocol of 50-75-100-150-200 Joules if necessary with antero-lateral electrode position until restoration of normal sinus rhythm
224321342|NCT03510962|DRUG|Group 3: 0.2% Chlorhexidine|The subject will use 10 ml of 0.2% Chlorhexidine mouth rinse (Rexidine®, Indoco Remidies Ltd, Mumbai, India) to swish for 60 seconds and spit. Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes the gargle as an intervention.
223662299|NCT02228980|BIOLOGICAL|Shenzhen trivalent influenza vaccine (split virion, inactivated) North Hemisphere (NH) formulation|0.25 mL Intramuscular (2 doses given 28 days apart)
223662300|NCT02228980|BIOLOGICAL|Shenzhen trivalent influenza vaccine (split virion, inactivated) North Hemisphere (NH) formulation|0.5 mL Intramuscular
223662301|NCT02228980|BIOLOGICAL|Shenzhen trivalent influenza vaccine (split virion, inactivated) North Hemisphere (NH) formulation|0.5 mL Intramuscular
223662302|NCT02228980|BIOLOGICAL|Shenzhen trivalent influenza vaccine (split virion, inactivated) North Hemisphere (NH) formulation|0.5 mL Intramuscular
223662303|NCT04629066|BEHAVIORAL|Remote Cardiac Rehabilitation (CR)|"Patients randomized to remote CR will be asked to use an app for cardiac rehabilitation a minimum of 3 times a week. Patients will be given an exercise prescription provided by a certified exercise physiologist.~The exercise prescription will change each week based on refreshed data from the prior week.~Instructional videos for each exercise are provided in the app. Patients will not be told to perform the exercise at a particular time. Instead they will be asked to complete a certain amount of exercise per week at whatever time is convenient for them. Patients randomized to remote CR will also receive App based reminders to take their medications, resources to guide healthy eating habits, and other behavioral health advice as is done as standard of care in both remote based and clinic based CR."
223662304|NCT03464539|DIETARY_SUPPLEMENT|PG low molecular weight chitosan|The product 1000 mg of Polyglucosamine was administered three times per day before and in between main meals
223662305|NCT03218800|COMBINATION_PRODUCT|Ertapenem|"Dose: 1g per day if creatinine clearance \> 30mL/min or 500 mg per day if creatinine clearance \< 30mL/min.~Dilution: 50 ml saline solution. Duration 30 minutes."
223662306|NCT02756429|OTHER|blood samples|Patients with atrial fibrillation for whom electrophysiology exploration or ablation are programmed; All blood samples will be taken through the exploration catheter. For the peripheral blood sample, blood will be taken at the introduction of the catheter into the femoral vein. Then the blood samples in the coronary sinus and in the left atrium will be made at progressively exploration.
223769738|NCT03398993|DEVICE|Endometrial scratch|"The procedure was carried out in preovulatory day (known when dominant follicle reached 18\_20 mm in diameter), usually, done around day 14-day of the cycle.~In the theatre, Patients put in a lithotomy position, sterilization was performed with the presence of good source of light., the procedure was carried out using a thin pipelle tube as follow :- A cuscoe's speculum was inserted into the vagina in order to visualize the cervix.~Cervix was grasped by vollselum upwards backwards, then pipelle tube passed through the cervix and uterine cavity, then moved up and down to make a single induced scratch two times in the lining endometrium of posterior wall of uterus.~The procedure took approximately 15minutes to complete"
224242491|NCT00006259|RADIATION|stereotactic radiosurgery|Patients undergo stereotactic head frame placement, followed by stereotactic radiosurgery using Gamma Knife, on day 1.
224242492|NCT02226328|DRUG|Propofol sedation|
224242493|NCT02226328|DRUG|Midazolam and Fentanyl sedation|
224242494|NCT03537781|BEHAVIORAL|Food labelling versus no food labelling|Food labelling availability and satiety status
224242495|NCT05658367|PROCEDURE|Aromatherapy massage with sesame- lavender oil mixed|After the surgery, 3 hours after the painkiller application, the patients will massage their arms with sesame- lavender oil mixed for 15 minutes with classical massage manipulations.
224242496|NCT05658367|PROCEDURE|Aromatherapy massage with sesame oil|After the surgery, 3 hours after the painkiller application, the patients will massage their arms with sesame oil for 15 minutes with classical massage manipulations.
224242497|NCT05658367|PROCEDURE|Massage with parraffin oil|After the surgery, 3 hours after the painkiller application, the patients will massage their arms with paraffin oil for 15 minutes with classical massage manipulations.
224242498|NCT01813461|DRUG|14C-labeled prodrug isavuconazonium sulfate|oral
224242499|NCT06203314|OTHER|Diagnostic test: EBV antibody tests|Participants underwent several EBV antibody tests, including VCA-IgA, EBNA1-IgA, etc.
223662307|NCT04228133|BEHAVIORAL|Attention Control Training (ACT)|A home-delivered version of ACT will be administered in this study. ACT will be comprised of 8 sessions with a variation of the dot-probe task in which the target probe replaces the neutral and threat stimuli with an equal probability to reduce attention bias variability (ABV). In addition, sessions will include video conference with the experimenter. This condition has found to be more effective in PTSD symptom reduction compared to ABM.
223662308|NCT04228133|BEHAVIORAL|Attention Bias Modification (ABM)|A home-delivered version of ABM will be administered in this study. ABM will be comprised of 8 sessions with a variation of the dot-probe task in which the target probe always replaces the threat stimuli to induce diversion of attention away from threat. In addition, sessions will include video conference with the experimenter. This condition has found to be have an inferior effect on PTSD symptom reduction compared to ACT, and thus, this ABM condition has been chosen as a control condition.
223662309|NCT04105491|DEVICE|IInvisalign® Aligners|Clear aligner orthodontic treatment
223662310|NCT03018483|DEVICE|Variable PSV|"Pressure support is to a targeted mean tidal volume of 6 to 8 ml/kg; the maximal inspiratory pressure ≤40 cmH2O; the flow trigger is set at 2 l/min; inspiratory cycling-off at 25% of peak flow; PEEP and FiO2 for oxygen saturation SaO2 ≥92%, with PEEP ≥5 cmH2O.~In patients ventilated with variable PSV, the pressure support variability is as high as possible (up to 100%), while not exceeding the maximal inspiratory pressure determined by the treating physician."
223662311|NCT03018483|DEVICE|Conventional PSV|Pressure support is to a targeted mean tidal volume of 6 to 8 ml/kg; the maximal inspiratory pressure ≤40 cmH2O; the flow trigger is set at 2 l/min; inspiratory cycling-off at 25% of peak flow; PEEP and FiO2 for oxygen saturation SaO2 ≥92%, with PEEP ≥5 cmH2O. The adjustment of pressure support until extubation follows these rules for both non-variable and variable PSV groups: pressure support is gradually adjusted in decrements (or increments) of 0 to 5 cmH2O. PEEP is decreased in steps of 0 to 5 cmH2O; PEEP and FiO2 are adjusted to achieve a SaO2 ≥92%, with a PEEP ≥5 cmH2O.
223662312|NCT03018483|DEVICE|Automated PSV|Pressure support is to a targeted mean tidal volume of 6 to 8 ml/kg; the maximal inspiratory pressure ≤40 cmH2O; the flow trigger is set at 2 l/min; inspiratory cycling-off at 25% of peak flow; PEEP and FiO2 for oxygen saturation SaO2 ≥92%, with PEEP ≥5 cmH2O.Smart CareTM as total automated procedure will be used.
223662313|NCT03018483|DEVICE|NAVA|NAVA level is to a targeted mean tidal volume of 6 to 8 ml/kg; the maximal inspiratory pressure ≤40 cmH2O; the Edi level was increased by step of 0,2 cm/h2o/ mcvolt, PEEP and FiO2 for oxygen saturation SaO2 ≥92%, with PEEP ≥5 cmH2O.
223662314|NCT03842020|OTHER|Blood pharmacokinetic samples|1 or 3 sample(s) will be taken in the following time windows: \[H0-H3\]; \[H5-H9\] and just before the next set \[H24\], depending if the child is or is not admitted to hospital
223662315|NCT03622476|DRUG|concentrated FVIII|Intervention if the assessment considers that the treatment is inadequate
223662316|NCT04922385|OTHER|Cognitive Behavioural Therapy|This study is an open waitlist control study. Eligible participants will be assigned to a treating clinician and will complete 4 weeks of treatment, followed by a post-treatment assessment (2 weeks later). If a treating clinician is not immediately available, participants will be placed on their waitlist for 4 weeks. They will then be assessed after 4 weeks and undergo the 4 week treatment, followed by the post-treatment assessment (2 weeks later).
223769739|NCT04203719|DRUG|AK105|AK105 is a humanized monoclonal antibody that specifically binds to PD-1. AK105 has a typical antibody structure and is composed of two lgG1 subtype heavy chains and two kappa subtypes light chains covalently linked by disulfide bonds.
224242500|NCT03759821|BEHAVIORAL|Nutrition, mothers|Nutrition-related social and behavior change (SBC) messages and activities for mothers focused on infant and young child feeding (IYCF), dietary diversity, water, sanitation, and hygiene (WASH), food access (use of income and home-grown foods), psychosocial well-being, gender equity, intra-household resource allocation, partner communication and household decision-making
224242501|NCT03759821|BEHAVIORAL|Nutrition, mothers and fathers|Nutrition-related social and behavior change (SBC) messages and activities for mothers and fathers focused on infant and young child feeding (IYCF), dietary diversity, water, sanitation, and hygiene (WASH), food access (use of income and home-grown foods), psychosocial well-being, gender equity, intra-household resource allocation, partner communication and household decision-making
224242502|NCT03759821|BEHAVIORAL|Nutrition+parenting, mothers|Nutrition- and parenting-related social and behavior change (SBC) messages and activities for mothers focused on infant and young child feeding (IYCF), dietary diversity, responsive caregiving and child stimulation (play and communication), water, sanitation, and hygiene (WASH), food access (use of income and home-grown foods), psychosocial well-being, gender equity, intra-household resource allocation, partner communication and household decision-making
224242503|NCT03759821|BEHAVIORAL|Nutrition+parenting, mothers and fathers|Nutrition- and parenting-related social and behavior change (SBC) messages and activities for mothers and fathers focused on infant and young child feeding (IYCF), dietary diversity, responsive caregiving and child stimulation (play and communication), water, sanitation, and hygiene (WASH), food access (use of income and home-grown foods), psychosocial well-being, gender equity, intra-household resource allocation, partner communication and household decision-making
224242504|NCT04130256|DEVICE|Electronic Pill Bottle|Electronic bottles that can beep and blink to send medication use reminders, record medication use data, and upload medication use data to a secure server.
224242505|NCT00993187|DRUG|Sitagliptin/Metformin FDC|Sitagliptin phosphate plus metformin hydrochloride combination tablet (MK-0431A) orally up to 50/1000 mg BID for 30 weeks
224242506|NCT00993187|DRUG|Comparator: Glimepiride|Glimepiride tablet orally up to 6 mg daily for 30 Weeks
224242507|NCT00993187|DRUG|Matching placebo to Sitagliptin/Metformin FDC|Matching placebo to Sitagliptin/Metformin FDC 50/1000 mg orally BID for 30 weeks
223769740|NCT04203719|DRUG|Anlotinib|a multi-target receptor tyrosine kinase inhibitor
224242508|NCT00993187|DRUG|Matching placebo to glimepiride|Matching placebo to glimepiride tablet orally daily for 30 weeks
224242509|NCT00245713|DRUG|levetiracetam|
224242510|NCT04164771|OTHER|Aerobic training and Moringa Oleifera|Aerobic exercises/training refers to any type of rhythmic, continuous physical activities that use large group of muscles like walking, running, cycling, and swimming consuming additional amount of energy while Moringa Oleifera a plant from the family Moringacea, its products are used as a health supplement introduced in Africa and south Asian countries to cure many diseases and improve health status
223769741|NCT04690608|DRUG|Triamcinolone Acetonide 40Mg/Ml Inj,Susp_#1|suprachoroidal injection of the drug in cases of resistant diabetic macular edema and central retinal vein occlusion
223769742|NCT04589559|BEHAVIORAL|Heart Rate Variability Biofeedback Training|First, participants are taught how to do relaxed, abdominal breathing. Second, they are taught how to breathe at a slow rate of 0.1 Hz (i.e., one completed breath cycle every 10 seconds). Third, they are taught how to monitor their heart rate variability (HRV) in real time using the smartphone app, which receives data wirelessly via Bluetooth from the heart rate monitor. Participants are instructed that their goal is to increase their HRV during the three weeks of at-home practice.
224242511|NCT00683293|PROCEDURE|Conventional Laparoscopic Hysterectomy|Removal of uterus via standard laparoscopic techniques
223662317|NCT02714322|BIOLOGICAL|MYL-1401A (Adalimumab)|MYL-1401A initial dose of 80 mg administered subcutaneously (sc), followed by 40 mg sc given every other week starting 1 week after the initial dose
223662318|NCT02714322|BIOLOGICAL|Humira® (Adalimumab)|Humira® initial dose of 80 mg administered sc, followed by 40 mg sc given every other week starting 1 week after the initial dose
223662319|NCT02276417|OTHER|Blood collection|Blood will be collected from patient at baseline, day 1, day 4, day 7 and weekly until week 6 as long as the patient is still hospitalized. Blood will also be collected at the one year appointment.
224242512|NCT00683293|PROCEDURE|Robot-assisted (Da Vinci®) laparoscopic hysterectomy|Removal of uterus by robot-assisted laparoscopic technique
224242513|NCT03741595|BEHAVIORAL|Item spacing|Spatial proximity of items to one another
224242514|NCT01630980|OTHER|Tree nuts|Almonds, Brazil nuts, cashews, hazelnuts, macadamia nuts, pecans, pine nuts, pistachios and walnuts in whole, meal, or flour form
224242515|NCT06544668|OTHER|Breast cancer patients with bone metastasis|This study is an observational study
223662320|NCT02276417|OTHER|Urine collection|Urine will be collected from patient at baseline, day 1, day 4, day 7 and weekly until week 6 as long as the patient is still hospitalized. Urine will also be collected at the one year appointment.
223769743|NCT00956150|PROCEDURE|Lactulose Breath Test|Test will begin with a baseline breath sample followed by ingestion of 10g of lactulose (Xactdose, South Beloit, IL) in 100ml of water. Breath samples will be collected every 15 min for 180 min. Gas samples will be analyzed for hydrogen and methane using a gas chromatograph (Model SC, Quintron Instruments, Milwaukee, WI).
224242516|NCT06544668|OTHER|Breast cancer patients without bone metastasis|This study is an observational study
224242517|NCT00274326|DRUG|SR121463B|
224242518|NCT03686358|PROCEDURE|Renal artery angioplasty|"Patients meeting the inclusion criteria were selected from the medical records of renal angioplasty performed at the Rennes University Hospital between 01/01/2010 and 12/31/2013. Each selected patient will receive a notice by mail of information. In the absence of opposition from them within a two weeks, the processing of their data will begin :~* Evaluation of the results at 3 years of renal angioplasty on atherosclerotic stenosis performed at Rennes University Hospital~* Evaluation of indications of renal angioplasty on stenosis atherosclerosis performed after 2009 at Rennes University Hospital~* Identification of prognostic factors"
224242519|NCT00681720|DRUG|AZD7325|Single dose of oral solution or capsule. 3 times per subject.
224242520|NCT00681720|DRUG|Radioligand (11C) flumazenil|Single dose of i.v solution. 4 times per subject. (3 times together with AZD7325)
223769744|NCT00956150|DRUG|Rifaximin|Rifaximin 600 mg three times a day by mouth (TID PO) x 10 days
223769745|NCT00956150|DRUG|Placebo|Placebo TID PO x 10 days
223769746|NCT03705039|OTHER|Pulsed Ultrasound Treatment|Patients will receive treatment with 1 MHz probe with the intensity of 1w/cm2, pulsed at a ratio of 1:4 for 10 minutes and at an interval of 3 sessions per week during 8 weeks, a total of 24 sessions.
224242521|NCT06546410|DEVICE|BioEP|All patient's EEG will have the BioEP score conducted on it
224242522|NCT06483581|OTHER|M-TAPA block with bupivacaine 25%|Following sterile conditions for bilateral M-TAPA block application, the transducer will be inserted on the chondrium in the sagittal plane at the 9-10th rib level. Subsequently, a deep angle will be created with the probe for visualization of the underside of the costochondrium. The sonovisible needle tip will be placed just below the chondrium and saline (5 ml) will be injected for site confirmation. After the confirmation, 20 ml of 0.25% bupivacaine will be administered for each group for a total of 40 ml of local anesthetic. Blocks will be applied using an 80 mm sonovisible needle with a 6-10 MHz linear probe under the guidance of a portable ultrasound. M-TAPA block with the same standard technique and drug dose will be applied to the contralateral side for each group of M-TAPA patients.
224321343|NCT03510962|OTHER|Group 4: Fluoridated tooth paste|"The subject will Brush with fluoridated toothpaste-(Colgate Total®, Colgate-Palmolive Company, Mumbai, India) for 2 minutes using soft brush.~Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes using tooth paste as an intervention."
224321344|NCT03510962|OTHER|Group 5: Polyol containing gum|"The subject will chew polyol containing gum (Orbit®, WrigleyCompany) for 5 minutes and spit.~Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes chewing as an intervention."
223662321|NCT02276417|OTHER|Bioimpedance Analysis|The bioimpedance analysis will be performed at baseline, day 14 or discharge from hospitalization, month 3, month 6, and month 12.
223662322|NCT02276417|OTHER|Cognitive Function Tests|Cognitive function tests will be administered at 3, 6 and 12 months.
223662323|NCT02276417|OTHER|Quality-of-life Questionnaires|Quality-of-life questionnaires will be administered at baseline, 3, 6 and 12 months.
223662324|NCT02276417|OTHER|Physical Function Tests|Physical function tests will be administered at baseline, day 14 or discharge from hospital 3, 6 and 12 months.
223662325|NCT02276417|OTHER|Blood Collection|The healthy volunteer participants will donate a blood sample. These controls will allow the investigators to determine if the values obtained are accurate, reliable, and repeatable.
223662326|NCT03009396|DRUG|RHB-104 (fixed-dose combination: 95 mg clarithromycin, 45 mg rifabutin, and 10 mg clofazimine)|For patients on ACTIVE or PLACEBO in the parent study (RHB-104-01), who were not in remission after 26 weeks
223662327|NCT00530504|DEVICE|PROTÉGÉ™ GPS™ and PROTÉGÉ™ RX Carotid Stent Systems and SpiderFX™ Embolic Protection Device|Carotid artery stenting with distal embolic protection.
223662328|NCT00811486|DRUG|Spironolactone and conivaptan|Tablet, 50 mg to 200 mg, daily, orally 20 mg intravenously one time over 30 minutes
223662329|NCT00610480|DRUG|1st visit Optive, then 2nd visit Systane|"First visit: Instillation of Optive followed by evaporometry assessment after 30 minutes.~Second visit: Instillation of Systane followed by evaporometry assessment after 30 minutes."
223662330|NCT00610480|DRUG|1st visit Systane, then 2nd visit Optive|"First visit: Instillation of Systane followed by evaporometry assessment after 30 minutes.~Second visit: Instillation of Optive followed by evaporometry assessment after 30 minutes."
223662331|NCT00501904|DRUG|Metformin|
223662332|NCT00539968|DRUG|Docetaxel plus lonafarnib|"Docetaxel: 60-75 mg/m2~Lonafarnib: 150-375 mg PO BID"
223662333|NCT02465099|DEVICE|Ultrasonic Dissection (UD)|Ultrasonic energy will be used as the primary means for soft tissue dissection in patients diagnosed with adolescent scoliosis undergoing multilevel (\>=6) PSF
223662334|NCT02465099|DEVICE|Electrocautery Dissection (ED)|Electrocautery dissection will be used as the primary means for soft tissue dissection in patients diagnosed with adolescent scoliosis undergoing multilevel (\>=6) PSF
223662335|NCT00582075|DRUG|temozolomide|TMZ 200mg/m2 days 1-5 repeat q28 days. Patients who have received prior chemotherapy will receive 150 mg/m2 days 1-5
223662336|NCT03438071|OTHER|Videoconferencing|Daily videoconference updates using Skype between parents of preterm infants hospitalized in NICU and the nurse taking care of their child, lasting 5 to 10 minutes, to check with her for the daily news and then see their child through the camera.
224242523|NCT06483581|OTHER|TAP block with bupivacaine 25%|After the necessary sterilization conditions established, the linear ultrasound probe will be placed in the middle of the iliac crest with the end limit of the ribs. Starting with skin, the layers in descending order, subcutaneous adipose tissue, external oblique muscle, internal oblique muscle, transversus abdominis muscle, and peritoneum will be identified. As the tip of the 80 mm sonovisible needle passes through the muscular layers and fascia, the needle will be advanced in a controlled manner. After receiving the click sensation (passage of the fascia of the internal oblique muscle), the location of the needle will be fixed and 20 ml of 0.25% bupivacaine will be injected between internal oblique and transversus abdominis muscles. Same procedure will be performed to the other site. (40 ml local anesthetics in total)
224321345|NCT03510962|OTHER|Group 6: 1% sodium bicarbonate solution|"The subject will use 10 ml freshly prepared 1% sodium bicarbonate w/v solution to swish for 60 seconds and spit.~Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes the gargle as an intervention."
224321346|NCT00182247|PROCEDURE|venogram|
223662337|NCT02983929|PROCEDURE|Rehabilitation after total knee arthroplasty|All the included patients followed a rehabilitation program in the Polyvalent Geriatric Rehabilitation Clinic after total knee arthroplasty.
223662338|NCT06429735|DEVICE|N1 Implant|The N1 Implant is a type of implantable brain-computer interface
224242524|NCT02453425|OTHER|MAP 60 mmHg|Norepinephrine adjusted to reach MAP 60 mmHg
224242525|NCT02453425|OTHER|MAP 75 mmHg|Norepinephrine adjusted to reach MAP 75 mmHg
224242526|NCT02453425|OTHER|MAP 90 mmHg|Norepinephrine adjusted to reach MAP 90 mmHg
224242527|NCT00191009|DRUG|atomoxetine hydrochloride|
224242528|NCT00191009|DRUG|placebo|
224242529|NCT06673706|OTHER|Front-of-package label|Participants will see packaged food-and-beverage items displayed with labels as specified by their assigned group
224242530|NCT03262012|DRUG|BGF MDI (PT010)|Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol, BGF MDI, PT010
224242531|NCT03262012|DRUG|GFF MDI (PT003)|Glycopyrronium and Formoterol Fumarate Inhalation Aerosol, GFF MDI, PT003
224242532|NCT03262012|DRUG|BFF MDI (PT009)|Budesonide and Formoterol Fumarate Inhalation Aerosol, BFF MDI, PT009
224242533|NCT03262012|DRUG|Symbicort® Turbohaler® Inhalation Powder|Budesonide and Formoterol Fumarate Inhalation Powder, Symbicort® Turbohaler® Inhalation Powder, Symbicort Turbohaler
224242534|NCT02756325|DEVICE|MRI|Imaging will be performed using a clinical whole-body MRI and a pelvic phased-array coil. No intravenous contrast will be administered. Sequences will include Diffusion weighted imaging (DWI), T2 mapping, arterial spin labeling, and spectroscopy. The acquisition is expected to take approximately one hour
224321347|NCT05454670|PROCEDURE|Two-flap palatoplasty|Two-flap palatoplasty used to correct cleft palate defect. The cleft palate is closed by separation of the nasal and the oral mucosa layers. Then approximation of the nasal mucosa layer, muscle layer is secured in the posterior palate and then the oral mucosa layer is secured
224321348|NCT01900951|DRUG|Temozolomide|
224242535|NCT07008885|BIOLOGICAL|CAR19TIF cells|"Phase 1 dose escalation/decline (3+3) :~starting dose: 5×10\^5 cells/kg, According to effective expansion and clinical efficacy data, a descending dose escalation model will be adopted: such as 1×10\^5 cells/kg, 5×10\^4 cells/kg.~If the 5×10\^5 cells/kg dose group does not achieve efficient expansion and clinical benefit, an ascending dose escalation model will be adopted, such as 2×10\^6 cells/kg, 6×10\^6 cells/kg.~Phase 2 : dose of RP2D."
224242536|NCT07008885|DRUG|Fludarabine|"Intravenous fludarabine 25\~30 mg/m\^2/day on days~-5, -4, and -3."
224242537|NCT07008885|DRUG|Cyclophosphamide|Intravenous cyclophosphamide 250\~500 mg/m\^2/day on days -5, -4, and -3.
224242538|NCT01362634|BEHAVIORAL|Trans-theoretical Process of Change Model-self|self-administered, computer-based intervention
224242539|NCT01362634|BEHAVIORAL|Trans-theoretical Process of Change Model - interviewer|interviewer-administered intervention
224242540|NCT03057392|OTHER|immersion|participants will sit in a 34-35C while receive dialysis
224242541|NCT03057392|OTHER|sham session|dialysis while sitting in the dialysis chair
224321349|NCT01406444|DRUG|rhIGF-1|Study participants will be started at a dose of 30 mcg/kg BID and will be titrated.
224321350|NCT01406444|DRUG|Risedronate|Risedronate 35mg PO one time weekly
223662339|NCT06429735|DEVICE|R1 Robot|The R1 Robot is a robotic electrode thread inserter that implants the N1 Implant.
223662340|NCT00052624|BIOLOGICAL|transferrin-CRM107|
223662341|NCT04578821|OTHER|Educational intervention|Educational intervention
223662342|NCT01358955|OTHER|group cognitive intervention|The cognitive training will be administered twice a week for 12 weeks, located in hospital-based outpatient memory clinics. Each session will last approximately 90 minutes. The cognitive training programs will be offered in group sessions consisted of 5 participants.
223662343|NCT01358955|OTHER|Home-based cognitive intervention|The participants will do their paper and pencil homework for 30 minutes every business days for 12 weeks.
223769747|NCT03705039|OTHER|Control group|Sham US will be applied to control group for the same times and periods as treatment group. A home exercise program will be given to both of two groups which contains knee range of motion and isometric strengthening exercises.
223769748|NCT03000465|PROCEDURE|Laparoscopic colorectal surgery|Minimizing intra-abdominal insufflation pressure in laparoscopic colorectal surgery as an individualized strategy
223769749|NCT01401530|BIOLOGICAL|denileukin diftitox (E7777)|E7777 will be administered by intravenous (IV) infusion for 5 days from Day 1 through 5 of each cycle (21 days/cycle) with 8 cycles in maximum for E7777 alone therapy. E7777 dose will be escalated from 6 micro-g/kg/day to 12, 15 and then to 18 in a stepwise fashion.
223769750|NCT00578773|DRUG|Moxidex otic solution|4 drops into the infected ear(s) twice daily (morning and evening) for 7 days
223769751|NCT00578773|DRUG|Moxifloxacin otic solution|4 drops into the infected ear(s) twice daily (morning and evening) for 7 days
223662349|NCT05448885|DRUG|Tislelizumab|Patients receive neoadjuvant therapy with gemcitabine(1000mg per square meter on day 1,8) , cisplatin (25mg per square meter on day 1-3) and tislelizumab(200mg) every three weeks for 2 cycles before radiotherapy, then followed by concurrent IMRT and cisplatin (100mg per square meter) concurrent every three weeks during radiotherapy ,then followed by adjuvant therapy with tislelizumab(200mg) every three weeks for 13 cycles after radiotherapy
223662350|NCT06072456|PROCEDURE|laparoscopic lateral suspension|Lateral suspension involves the lateral attachment or suspension of vaginal tissue to a stable structure, often using mesh or sutures, to provide support and stability to the pelvic organs. Control groups consist of hysterectomized women without cuff prolapse and nulliparous women.
223769752|NCT00578773|DEVICE|Tympanostomy tubes|Tubes surgically inserted through the ear drum for the treatment of recurrent otitis media in children
224242542|NCT03494595|PROCEDURE|Pediatric Liver transplantation|Pediatric Liver transplantation
224242543|NCT01762358|OTHER|Khalifa's therapy|One hour of Khalifa's therapy which is specially applied pressure to the skin
224242544|NCT01762358|OTHER|Physiotherapy|Twelve times standardized Physiotherapy
224242545|NCT04623736|BEHAVIORAL|quitSTART|"All participants will have access to the Smokefree.gov Initiative smoking cessation smartphone application, quitSTART. This app is available, at no cost, to anyone who owns a smartphone and is interested in quitting smoking. All smokers who download quitSTART are asked to provide basic information about themselves (e.g., age, sex, reason to quit smoking, triggers to smoke, when users typically smoke, how users plan to celebrate success, smoking frequency, age when started smoking regularly, ethnicity, race, cigarettes smoked per day), and set a quit date. Information about cessation and challenges to help support quitting are available, as well as games and tracking features. While using the app, users can proactively report cigarette cravings, if they slipped, if they are feeling down or feeling great. If a user reports a craving, they have the option to mark the timing or location of the craving and request a reminder to resist future cravings at the same time or location."
224242546|NCT03734965|DEVICE|AWAKEN INTUBATION|Intubation
224242547|NCT01469546|DRUG|Axitinib (AG-013736)|The subjects will be started on treatment with 5 mg of Axitinib twice a day continuously, with subsequent dose escalation to 7 mg and then 10 mg twice a day in the absence of grade 2 or worse toxicities. This will be followed by clinical and/or radiologic response assessment after 8 weeks and subsequently every 2 months until disease progression (defined per RECIST \[Response Evaluation Criteria In Solid Tumors\] criteria, or obvious progression on clinical or laryngoscopic/endoscopic exam) or intolerable toxicity (defined as below). During treatment on this protocol, all patients will be evaluated for safety. Correlative biomarker analysis will also be conducted.
224242548|NCT00003148|BIOLOGICAL|aldesleukin|
224242549|NCT04190290|OTHER|Physiotherapy Adapted Program|3 days / week mobilisations and respiratory exercises and body image exercises
224242550|NCT04190290|DIAGNOSTIC_TEST|Evaluation and Control|Manual muscle test MRC score, peak-expiratory-flow test, hand strength test, 6 minutes walking test, SF-36, EDI-3 and EDQOL
224242551|NCT03154658|DRUG|Ropivacaine 0.35%|The serratus plane block is used to supplement the pain management of a patient receiving a surgical procedure of the chest wall or breast.
224242552|NCT05282654|BEHAVIORAL|ePRO Application|The intervention consists of a patient portal, EHR-integrated web-app to communicate risk of post-discharge adverse events using patient-reported outcome questionnaires, discharge preparation checklist during hospitalization. After discharge, the intervention will provide real-time symptom monitoring using ePROs and facilitate communication with clinicians based on prediction model-informed ePRO score trends exceeding escalation thresholds.
224242553|NCT04238767|DRUG|Dolutegravir|Eligibility to receive DTG-based ART at enrolment (i.e., initiation or offer to initiate DTG-based ART)
224242554|NCT05742633|OTHER|Active release technique|"Active Release Technique was applied to patient in prone lying, knee flexed at 90. The therapist placed his elbow tip on taut band of piriformis and direct pressure applied, patient wias then asked to do internal rotation of hip, in order to achieve lengthening of the muscle. This was repeated 5-7 times.~A total of 18 sessions was given over a period of 6 weeks (3 sessions per week)"
224242555|NCT05742633|OTHER|Self-myofascial release|"Patient position in prone lying Therapist was standing beside the patient at the waistline, working on the contralateral side.~Piriformis muscle was located by an imaginary line drawn between the midpoint of the lateral aspect of the sacrum and the greater trochanter. A contact was established in the gluteal area about 3 cm from the sacrum. Patent was guided to use a foam roller followed by a massage ball.~A total of 18 sessions were given over a period of 6 weeks (3 sessions per week)"
224242556|NCT04987164|DIETARY_SUPPLEMENT|Feminabiane CBU|EXTRACTS OF CRANBERRY, CINNAMON AND MICROBIOTIC STRAINS
224242557|NCT04297228|BEHAVIORAL|Step by Step: A Family-Centered Healthy Lifestyle Intervention|
224321351|NCT01406444|DRUG|Placebo|Placebo injections 30 mcg/kg BID, Placebo tablet PO once weekly
224242558|NCT02710201|BEHAVIORAL|Descriptive Social Norm|
224242559|NCT02710201|BEHAVIORAL|Descriptive-plus-Injunctive Social Norm|
224321352|NCT01119573|GENETIC|RNA analysis|
224321353|NCT01119573|GENETIC|microarray analysis|
224321354|NCT01119573|GENETIC|reverse transcriptase-polymerase chain reaction|
224321355|NCT01119573|OTHER|laboratory biomarker analysis|
223662351|NCT06072456|PROCEDURE|laparoscopic pectopexy|Pectopexy involves attaching or suspending the vaginal vault to the pectineal ligament, which is a strong ligament in the pelvis. Control groups consist of hysterectomized women without cuff prolapse and nulliparous women.
223662352|NCT06072456|PROCEDURE|Sacrospinous ligament fixation|Sacrospinous ligament fixation entails the attachment or fixation of the vaginal vault to the sacrospinous ligament, which is a strong fibrous band located in the pelvis
223662353|NCT04410133|DRUG|18F fluciclovine|18F fluciclovine injection, 185 MBq (5 mCi) ± 20%, delivered as an intravenous bolus
223662354|NCT06077227|DEVICE|virtual reality therapy|6 2 times weekly sessions of 30-minute VR therapy in the office with pre- and post-intervention surveys
223662355|NCT06077227|OTHER|matched control group|taking the same surveys as the VR intervention group on a weekly basis for 6 weeks
223662356|NCT04784065|DEVICE|Hand orthosis|An orthosis applied to a hand affected by osteoarthritis with the expectation that it will improve symptoms and possibly structural progression.
223662357|NCT03682380|DRUG|Seltorexant High Dose|In Part 1, Part 2, and Part 3 (3A and 3C), Seltorexant high dose (either a high dose tablet or two low dose tablets) will be administered orally.
223662358|NCT03682380|DRUG|Seltorexant Low Dose|In Part 3 (3B and 3C), Seltorexant low dose will be administered orally.
223662359|NCT00557856|DRUG|PF-03446962|To determine the maximum tolerated dose (MTD), and recommended Phase 2 dose (RP2D) of PF-03446962 administered in patients with advanced solid tumors.
223662360|NCT00726011|BIOLOGICAL|Tetrodotoxin|30 µg twice daily for 4 days; repeated every two weeks as long as there is a meaningful analgesic response
223662361|NCT03759353|DIAGNOSTIC_TEST|Baseline ferritin level|At enrollment, baseline serum ferritin level will be assessed to quantify iron deficiency.
223662362|NCT03759353|DRUG|Lactoferrin|lactoferrin 100 mg one sachet twice daily for 30 days to be dissolved in 1/4 glass of water before meals (Pravotin, Hygint pharmaceuticals).
223662363|NCT03759353|DRUG|Ferrous Sulfate|200 mg of dried ferrous sulphate tablet once daily for 30 days on empty stomach but may be taken with meals to avoid stomach upset.
223662364|NCT03759353|DIAGNOSTIC_TEST|Follow up ferritin level|Four weeks after treatment, serum ferritin level will be assessed to quantify effect if treatment on iron status.
223662365|NCT02358941|BEHAVIORAL|Neurofeedback training|In neurofeedback training, EEG-activity is visualized and fed back to the participant online on a computer screen. Successful regulation is rewarded by bonus points. The aim is to gain control over one's brain activity and to be able to switch to or to maintain a more wakeful, alert or focussed state.
223662366|NCT02358941|BEHAVIORAL|Computerized cognitive training|In computerized cognitive training, impaired neuropsychological functions, such as inhibition, working memory, distractibility, are directly trained by adaptive computerized software programs. We use training programs from a scientifically based training system for patients presenting problems with sustained, focussed or selective attention, working memory, inhibition, processing speed. Good performance / improvements are rewarded with bonus points.
223662367|NCT06102200|BEHAVIORAL|CBT4CBT|This condition will integrate the standard of care and CBT4CBT interventions. The CBT4CBT is an 8-session (module) system for teaching with one module on the basics of buprenorphine and the other modules on the seven CBT core skills tailored around issues related to buprenorphine and OUD and other SUDs: (1) Introduction to functional analysis of substance use; (2) strategies for recognizing and coping with craving; (3) refusal skills and assertiveness; (4) training in problem-solving skills; (5) strategies for recognizing and changing thoughts; (6) decision-making skills; (7) how to use CBT skills to reduce HIV/ HCV risk. Each module takes 30 minutes to complete and has a format, which includes on-screen narration, animation, quizzes, and interactive exercises to teach and model effective use of skills. Modules end with a practice exercise.
223662368|NCT06102200|BEHAVIORAL|RC|Peer recovery coaching services involve a form of nonclinical, peer support aimed at helping individuals with substance use disorders to achieve and maintain recovery. Recovery coaches are individuals with experience with substance use and successful recovery. In addition to their lived experience, recovery coaches obtain formal training on substance use coaching and receive ongoing supervision. The recovery coaches use an assertive engagement approach to provide holistic, person-centered, and strength-based support.
223662369|NCT06102200|BEHAVIORAL|Sandard of care|Participants in the standard of care condition will receive the standard treatment at the recovery program, which consists of weekly, bi-weekly or monthly visits (at the discretion of the provider) in-person or virtually. This condition will be matched with the other conditions in terms of the number of research visits.
223662370|NCT06389799|DRUG|Pemigatinib|selective fibroblast growth factor receptor (FGFR) inhibitor, oral tablet
223662371|NCT06389799|DRUG|Retifanlimab|PD-1 inhibitor, Intravenous infusion
223662372|NCT01252225|DRUG|10 % Lidocaine|600 mg Nebulised Lidocaine ( 6 mls of 10 % Lidocaine) one-off dose
223662373|NCT01252225|DRUG|10 % Lidocaine|100 mg Lidocaine ( 1 ml of 10 % Lidocaine) given as one-off throat spray.
223662374|NCT01252225|DRUG|0.9% saline|6 mls of 0.9% saline nebulised followed by 1 ml of 0.9% saline as throat spray
223662375|NCT06151210|DRUG|DA-5219|1 tablet/day
223662376|NCT06151210|DRUG|Stillen® Tab|3 tablets/day
223662377|NCT06151210|DRUG|DA-5219 Placebo|1 tablet/day
223662378|NCT06151210|DRUG|Stillen® Tab Placebo|3 tablets/day
223662379|NCT05737342|DIETARY_SUPPLEMENT|ANKASCIN 568-P Red yeast rice capsules|Product ingredients: ANKASCIN 568-P red yeast rice product 440 mg,microcrystalline ,cellulose,Maltodextrin; capsule shell composition: HPMC (hydroxypropyl methylcellulose), purified water, titanium dioxide, gellan gum.
223662380|NCT05737342|DIETARY_SUPPLEMENT|Placebo Capsules|Maltodextrin was used as a placebo
223662381|NCT06291623|DRUG|Glycyrrhizin|used as intracanal medication for one week
223662382|NCT05365139|OTHER|Structured clinical diagnostic interview for PGD (PGD-I)|"Participants were administered the Structured clinical diagnostic interview for PGD (PGD-I) and screened with clinical interviews for PTSD, anxiety and depression. Whether the Aarhus PGD-scale should be answered before or after the interview was randomized.~The PGD-I and self-report scale were readministered to 50 participants 7-14 days after the initial administration."
223662383|NCT01229293|PROCEDURE|Articular Surface Replacement (ASR)|Articular surface replacement, DePuy, posterolateral approach used
223662384|NCT01229293|PROCEDURE|Standard Total Hip Arthroplasty (THA)|Device: Biomet 28mm
223769753|NCT02726815|OTHER|Questionnaire|Questionnaire based study using a symptom assessment tool
224242560|NCT05982860|BEHAVIORAL|MIND diet|Mediterranean-DASH Intervention for Neurodegenerative Delay (MIND) diet has been established by Morris et al. (2015) to improve brain health, and reduce the risk or slow progression of neurodegenerative diseases. In this diet model, which is similar to the Mediterranean diet, the diet score changes according to the frequency of consumption of some foods. The more consumption of foods such as green leafy vegetables, other vegetables, berries, nuts, whole grains, fish (not fried), beans, poultry (not fried), and the limited consumption of butter/margarine, cheese, red meat and products, fast fried foods, and pastries \& sweets ensure more score. Also, regular consumption of wine (1 glass/d) and using olive oil as primary oil in meals increases the score. Berries, fish, and hardaliye (instead of wine) will be supplied to players as well as recommendations for consumption frequencies of food components in MIND diet to increase total score.
224242561|NCT00113789|OTHER|PI Discretion|PI Discretion
224242562|NCT02366949|DRUG|BAY1217389|"BAY1217389 will be given orally, with a starting dose of 0.25 mg twice daily, on D1, D2, D8, D9, D15 and D16 of a 28 day cycle. BAY1217389 will be dosed in combination with paclitaxel in Arm 1 (Experimental Treatment) and from Cycle 2 onwards in Arm 2 (Standard Treatment).~After Maximum tolerated dose (MTD) has been defined, expansion cohorts will be conducted at the MTD dose of BAY1217389 and paclitaxel following an intermittent dosing schedule as defined in the dose escalation phase. Up to 12 to 15 breast cancer (triple negative) subjects are planned to be enrolled in the expansion cohort.~In a higher dose level Cohort 4 \> (or equal to) a relative bioavailability assessment of BAY1217389 liquid capsule formulation compared to BAY1217389 oral solution will be performed."
224242563|NCT02366949|DRUG|Paclitaxel|Paclitaxel will be given once per week IV at 90 mg/m\^2 on D1, D8, and D15 of a 28 day cycle. Paclitaxel will be dosed as a single-agent in Cycle 1 of Arm 2 (Standard Treatment Arm), and in combination with BAY1217389 in Arm 1 (Experimental Treatment Arm) and from Cycle 2 onwards in Arm 2 (Standard Treatment Arm). After Maximum tolerated dose (MTD) has been defined, expansion cohorts will be conducted at the MTD dose of BAY1217389 and paclitaxel following an intermittent dosing schedule as defined in the dose escalation phase. Up to 12 to 15 breast cancer (triple negative) subjects are planned to be enrolled in the expansion cohort.
224242564|NCT07003399|OTHER|Diaphragmatic Ultrasound and EMG Assessment|Non-invasive assessment of diaphragmatic morphofunction and respiratory drive using ultrasound imaging and diaphragm electromyography (EMG). This evaluation will be performed once per participant without any therapeutic intervention.
224242565|NCT03476980|PROCEDURE|Randomized to Umbilical Cord Milking at birth|The subjects in this group were randomized to UCM X4 at birth. This procedure infuses a placental transfusion of blood by milking the umbilical cord towards the infant at birth.
224242566|NCT03476980|PROCEDURE|Randomized to Delayed Cord Clamping at birth|The subjects in this group were randomized to DCC at birth. At delivery, the obstetrician was instructed to delay clamping of the umbilical cord for 60 seconds.
224242567|NCT01342328|OTHER|Normal saline infusion|Normal saline infusion
224242568|NCT01342328|DRUG|Dexmedetomidine|"Infusion of Dexmedetomidine will be administrated during the overnight sleep study. An initial target concentration of 0.25 ng/ml will be selected. After 5 min, the sedative point will be assessed and the concentration will be adjusted stepwise by increments and decrements of 0.05 ng/ml. This process will be repeated until the target sedative state is achieved. Using the Richmond Agitation Sedation Scale (RASS) infusion rates, using known pharmacokinetic parameters will be adjusted to achieve equivalent levels of sedation (RASS -3) for both DEX and propofol sessions.~We aim to achieve an RASS of -3 so that the subjects are moderately sedated. This state of sedation will be maintained for 3-4 hours."
224242569|NCT01342328|DRUG|Propofol|"For propofol, an initial concentration of 0.75 ng/ml will be targeted. Depending on the score achieved, the infusion rate will be increased or decreased every 5 min by 0.2 ng/ml until the target sedative state is achieved.~Note that the target sedative state (RASS score of -3) is the same for both DEX and propofol sessions, with the investigator being unaware of which drug is being administered. To ensure the investigator is not aware of the type of drug being administered, all drug delivery systems will be covered.~Intravenous drug delivery will be continued throughout the scanning period for 3-4 hours to maintain equivalent levels of sedation for both DEX and propofol."
224242570|NCT05047003|DIAGNOSTIC_TEST|EyeBOX Model EBX-4 (Portable version)|The portable EyeBOX takes less than 4 minutes to complete and involves watching a video move around the perimeter of an LCD monitor positioned in front of the patient while a high-speed camera continuously records gaze positions. The Portable EyeBOX software detects subtle changes in eye movements consistent with concussion and calculates a BOX score.
224242571|NCT03544632|DRUG|Acellular Adipose Tissue (AAT)|"Participants (n=15) will be administered between 5cc and 20cc of AAT, depending on their assigned treatment group, via sterile subcutaneous injection into the target defect. The injection is intended to be permanent. After the 3-month study follow-up visit, participants will have the option to undergo additional AAT injection (up to 20cc per treatment) in order to fully correct the defect. Total injected AAT volume per patient will not exceed 40cc. Additional injection is dependent upon study- and patient-specific adverse / unanticipated events to date.~Each vial contains a 2 milliliter (mL) dose of the injectable AAT. This volume is similar to other commonly used injectable filler materials intended for soft tissue correction."
224242572|NCT07009002|BIOLOGICAL|CAR19TIF cells|"Phase 1 dose escalation/decline (3+3) : starting dose:~5×10\^5 cells/kg, According to effective expansion and clinical efficacy data, a descending dose escalation model will be adopted: such as 1×10\^5 cells/kg, 5×10\^4 cells/kg. If the 5×10\^5 cells/kg dose group does not achieve efficient expansion and clinical benefit, an ascending dose escalation model will be adopted, such as 2×10\^6 cells/kg, 6×10\^6 cells/kg. Phase 2 : dose of RP2D."
223662385|NCT03124004|PROCEDURE|periodontal debridement|with ultrasonic device supragingival and subgingival full-mouth debridement is provided
223662386|NCT03727724|DRUG|Afatinib|Tablet
223662387|NCT03727724|DRUG|Cetuximab|Injection
223662388|NCT03230019|PROCEDURE|chest tube|VATS with chest tube placement
223662389|NCT03230019|PROCEDURE|two-lumen catheterization|VATS with two-lumen catheterization long the midclavicular line, second intercostal space
223662390|NCT03230019|DEVICE|two-lumen catheter|central venous catheter(two-lumen 7-Fr-20cm)
223662391|NCT04423198|BEHAVIORAL|Cognitive Assessment|Self administered cognitive battery
223662392|NCT04423198|BEHAVIORAL|Patient Reported Neurological Outcome Assessments|Standard neurocognitive and neuropsychological tests
223662393|NCT04423198|PROCEDURE|Blood Draw|Specimen collection of whole blood, serum, RNA
223662394|NCT02035254|OTHER|Web-based Wellness Program|Web-based educational modules and physical activity and/or health weight challenges
223662395|NCT06981585|OTHER|Physical Evaluations of Patients with Chronic Kidney Failure|In this study, data from children and adolescents with chronic kidney disease will be collected through face-to-face assessments. Grip strength, cough strength, physical activity, sleep quality and quality of life will be assessed in children and adolescents who meet the inclusion criteria. All data obtained through these assessments will be collected from participants face-to-face at one time and for a maximum of approximately 1 hour.
223662396|NCT06981585|OTHER|Physical Evaluations of Healthy Children|In this study, data from healthy children and adolescents will be collected through face-to-face assessments. Grip strength, cough strength, physical activity, sleep quality and quality of life will be assessed in children and adolescents who meet the inclusion criteria. Data obtained through all these assessments will be collected from participants face-to-face at once and for a maximum of approximately 1 hour.
223662397|NCT06075628|OTHER|Left Atrial Appendage Occlusion|Acute ischemic stroke is a major cause of morbidity and mortality in non-valvular Atrial Fibrillation (AF). Oral Anticoagulation (OAC) with Warfarin and Direct oral anticoagulants (DOACs) has been the mainstay to prevent systemic thromboembolism (STE) in this patient population. It is estimated that around 50% of patients who have AF with indication for OAC end up being not on OAC due to bleeding complications leaving them at high risk for developing STE. Left atrial appendage occlusion (LAAO) offers an option in such population.
223662398|NCT06853912|DRUG|Psilocybin 25 mg|Botanical drug product PEX010(25) contains the drug substance, PYEX, which is primarily composed of psilocybin (delivered in a capsule)
223662399|NCT06853912|DRUG|Maltodextrin (Placebo)|25 mg of Maltodextrin (delivered in a capsule)
223769754|NCT05632952|DEVICE|Intraperitoneal Onlay Mesh positioning Plus|"Intraperitoneal Onlay Mesh (IPOM) Plus with closure of the hernia defect will be performed according to the common recommendations.~The closure of the wall defect will be decided according to the surgeon evaluations: hernia size and choice of technique will be recorded in the database. The mesh will have an overlap of at least 5 cm on all sides of the defect. Dimension of the mesh will be sized to overlap the hernia orifice by at least five centimetres and placed in the intraperitoneal position. Using non-articulating laparoscopic fixation devices, 5.1-mm non-absorbable or absorbable tacks will be then positioned around the circumference of the prosthesis in a 3-row manner or 2-row manner based on the intraoperative findings, the patient's specific situation and the operating surgeon's decision."
224242573|NCT07009002|DRUG|Fludarabine|"Intravenous fludarabine 25\~30 mg/m\^2/day on days~-5, -4, and -3."
223662400|NCT05482776|OTHER|High intensity functional training|"HIFT is an exercise modality that emphasizes functional movements through exercises that involve a large amount of muscle mass and that can be adapted to the level of physical condition of each subject. Although it has similarities and is compared to HIIT, they are different.~In this discipline, functional exercises with an external load such as squats, pull-ups, or functional exercises with our own weight, are mixed with other aerobics such as running, rowing or cycling. This mix results in a high-intensity training that improves parameters of physical condition in general and performance."
223662401|NCT05482776|OTHER|classic training group|This intervention consists of carrying out their conventional weekly physiotherapy training sessions where strength, coordination and balance are trained.
223662402|NCT06354660|DRUG|Retatrutide|Administered SC.
223662403|NCT06354660|DRUG|Placebo|Administered SC.
223662404|NCT03159793|BEHAVIORAL|Live Modelling Technique|Direct observation is the term used to describe both the filmed and live modelling technique. These techniques depend on familiarizing the patient with the dental environment and allowing the patient to ask the questions he/she wants to ask. The patients are shown a film or are permitted to directly observe a cooperative patient undergoing dental treatment. These techniques have no contra indications they simply may be used with any patient.
223662405|NCT03159793|BEHAVIORAL|Filmed Modelling technique|Direct observation is the term used to describe both the filmed and live modelling technique. These techniques depend on familiarizing the patient with the dental environment and allowing the patient to ask the questions he/she wants to ask. The patients are shown a film or are permitted to directly observe a cooperative patient undergoing dental treatment. These techniques have no contra indications they simply may be used with any patient.
223662406|NCT02537015|DRUG|Bimatoprost|Bimatoprost Ocular Insert in each eye used continuously for 12 weeks, then replaced with a new Bimatoprost Ocular Insert in each eye used continuously for another 26 weeks.
223662407|NCT05704595|OTHER|Initial outpatient management strategy, including outpatient IV diuretics in clinic|Management strategy including IV diuretic in the outpatient clinic
223769755|NCT00046345|DRUG|Atazanavir (BMS-232632)|
223769756|NCT06068205|DIAGNOSTIC_TEST|Blood test - atomic force microscopy in the force spectroscopy mode|A single blood test to be analysed through atomic force microscopy in the force spectroscopy mode
223769757|NCT01699425|DEVICE|Ajust sling|
224242574|NCT07009002|DRUG|Cyclophosphamide|Intravenous cyclophosphamide 250\~500 mg/m\^2/day on days -5, -4, and -3.
223662408|NCT05704595|OTHER|Initial hospitalization-based management strategy|Direct admission to the hospital
223662409|NCT06516653|DEVICE|VasQ|External support implant for the arteriovenous fistula
224242575|NCT02753335|BEHAVIORAL|GMI and Desensitization|"Graded Motor Imagery (GMI) is used to treat chronic pain conditions and movement problems related to alterations in the nervous system such as CRPS, postamputation limb pain and back pain. The patient is trained in monitored steps. The three treatment components include left/right discrimination training, motor imagery exercises and mirror observations of the unaffected limb, appearing as the affected limb. They are performed sequentially, but require a flexible approach to suit the individual patient. The imagined movements have been demonstrated to activate motor cortical areas similar to those activated in the actual execution of that movement.~Desensitization (D) is used to decrease hyperalgesia by repeated tactile stimulation of the affected area with various materials."
224242576|NCT02753335|BEHAVIORAL|Desensitization|Desensitization (D) is used to decrease hyperalgesia and allodynia by repeated tactile stimulation of the affected area with various materials.
224242577|NCT05551078|BIOLOGICAL|thrombophilia screening|In the IUGR group systematic thrombophilia screening had already been performed.
223662410|NCT06516653|PROCEDURE|Arteriovenous fistula creation for dialysis vascular access|End to side fistula creation in the arm for dialysis vascular access
223662411|NCT06607783|DIAGNOSTIC_TEST|MRI|Standard MRI using phantom.
223662412|NCT06998355|OTHER|Registry|observational data collection
223662413|NCT06318299|DIETARY_SUPPLEMENT|Ketone Ester|Commercially available ketone ester drink (KetoneAid, Virginia, USA)
223662414|NCT06318299|OTHER|Placebo|Taste and appearance matched noncaloric placebo drink
223662415|NCT05650073|OTHER|Immersive soundscapes|Audio technology used to create a three-dimensional sound experience in which the user is immersed in a virtual soundscape
223662416|NCT05822908|DRUG|VO659|VO659 is an antisense oligonucleotide targeting CAG repeats in mRNA transcripts
223662417|NCT02230228|DRUG|ALK-001 (No generic name)|Daily, oral administration of ALK-001 capsules.
223662418|NCT05758935|OTHER|Rule-based chatbot intervention with therapist-guidance|The intervention is a mobile application designed as a rule-based chatbot. The chatbot will present psychoeducational text, videos and ask questions based on cognitive behavioral techniques. The adolescents will receive weekly therapist support within the mobile application, in addition to weekly contact by phone. The intervention has a duration of six weeks, with a total of six modules.
224321356|NCT05056038|PROCEDURE|Lateral Quadratus Lumborum block|Local anesthetic may spread to the T6-L1 spinal nerves and paravertebral area by spreading through the lateral QLB to the transversus abdominis plane, and posteriorly via the anterior thoracolumbar fascia.
223662419|NCT06672861|OTHER|Kansas City Cardiac Dysautonomia Questionnaire (KCDysQ)|To compare in patients with cardiac dysautonomia, newly developed disease specific questionnaire to established generalized SF-36 and EQ-5d questionnaires, as there are no disease specific questionnaires for comparison. These novel and established questionnaires will then be compared among groups who have relatively stable disease or stable symptoms with patients who will be expected to have a change in symptoms and QoL.
223662420|NCT03520504|RADIATION|Proton craniospinal irradiation (CSI)|Patients will be enrolled to receive 30Gy (RBE) in 3Gy (RBE) or 25Gy (RBE) in 2.5Gy (RBE) fractions course of proton CSI.
223662421|NCT01808092|DRUG|ceftazidim-avibactam (CAZ-AVI, experimental product)|2000mg ceftazidime plus 500mg avibactam
223662422|NCT01808092|DRUG|meropenem (active comparator)|1000mg of Meropenem
223662423|NCT07134361|PROCEDURE|Open Carpal Tunnel Release|All patients included in the cohort will undergo open carpal tunnel release as part of routine clinical care. The study does not assign the surgical procedure as an investigational intervention; however, it will observe clinical and ultrasonographic outcomes before and after surgery to assess prognostic factors.
223662424|NCT04279106|PROCEDURE|0.05%chlorhexidine mouthwash|All subjects were instructed to rinse once a day, in the morning, with 15 ml solution for 60 seconds, after which they expectorated. Subsequent rinsing with water was not allowed.
223662425|NCT04279106|PROCEDURE|0.05% sodium fluoride mouthwash|All subjects were instructed to rinse once a day, in the morning, with 15 ml solution for 60 seconds, after which they expectorated. Subsequent rinsing with water was not allowed.
223662426|NCT04279106|PROCEDURE|alcohol free essential oils mouthwash|All subjects were instructed to rinse once a day, in the morning, with 15 ml solution for 60 seconds, after which they expectorated. Subsequent rinsing with water was not allowed.
223662427|NCT04279106|PROCEDURE|Placebo|All subjects were instructed to rinse once a day, in the morning, with 15 ml solution for 60 seconds, after which they expectorated. Subsequent rinsing with water was not allowed.
223662428|NCT07003451|DIAGNOSTIC_TEST|Calprotectin Level|Measurement of calprotectin level to presence and severity of ILD asessed via Warrick's score
223662429|NCT04242238|DRUG|DCC-3014|DCC-3014 will be administered in pill form. Start Day 1 on first cycle and continue with dosing of DCC-3014.
223662430|NCT04242238|DRUG|Avelumab|Start Day 1 on first cycle with further infusions of avelumab every 14 days
223662431|NCT03952039|DRUG|FEDRATINIB|A potent and selective inhibitor of JAK2 kinase activity
223662432|NCT03952039|DRUG|Best Available Therapy (BAT)|Best available therapy (BAT)
223662433|NCT05437393|DEVICE|Deep brain stimulation|Deep brain stimulation of the centromedian nucleus (bilateral)
223769758|NCT01699425|DEVICE|Classical transobturator sling|Control group
223769759|NCT05541718|BEHAVIORAL|Reiki|Reiki will be provided by a trained Reiki master with the aim of balancing the flow of energy in the patient's body.
223769760|NCT05541718|BEHAVIORAL|Sham Reiki|Sham Reiki will be delivered by an individual trained to simulate the Reiki interventionist's movements, but they will not visualize patient healing
223662434|NCT06746688|BIOLOGICAL|ES2B-C001|Vaccine; Administration with or without \[adjuvant\] every third week for a total of five vaccinations.
223662435|NCT06746688|OTHER|ISA 51 VD|Adjuvant; Administration together with ES2B-C001 every third week for a total of five vaccinations.
223662436|NCT05009979|DRUG|F18-FDG|Within approximately 2 weeks of each piflufolastat F-18 (18F-DCFPyL) positron emission tomography/ computed tomography (PET/CT) scan, participants will be scanned with a fludeoxyglucose F 18 (18F-FDG) PET/CT imaging at the NIH Clinical Center using standard procedures. The 18F-FDG PET/CT imaging performed will allow the localization of viable tumor sites and characterize their FDG metabolism for comparison with 18F-DCFPyL imaging. The 18F-FDG PET/CT imaging will consist of an 18F-FDG injection and PET/CT imaging performed approximately 1 hour post 18F-FDG injection. A corresponding low dose CT scan for attenuation correction and co-registration purposes will be performed prior to the PET image.
223662437|NCT05009979|DEVICE|MRI|A standard of care computed tomography (CT) and/or magnetic resonance imaging (MRI) will be performed within 2 months of each piflufolastat F-18 (18F-DCFPyL) positron emission tomography (PET/CT).
223662438|NCT05009979|DEVICE|CT|A standard of care computed tomography (CT) and/or magnetic resonance imaging (MRI) will be performed within 2 months of each piflufolastat F-18 (18F-DCFPyL) positron emission tomography (PET/CT).
223769761|NCT05541718|BEHAVIORAL|Mindfulness Meditation|The mindfulness meditation intervention will be adapted from a standardized mindfulness induction script validated in prior research. The mindfulness practice will guide patients to focus attention on breath and body sensations while monitoring and accepting discursive thoughts, negative emotions, and pain. The MM interventionist will be a trained mindfulness provider and have experience using MM in medical settings.
223662439|NCT05009979|DRUG|F18-DCFPyL|Each subject will receive a single intravenous (IV) dose of piflufolastat F-18 (18F-DCFPyL) by bolus injection at a rate of approximately 1 ml/3-5 sec. The maximum amount of injected active drug will be less than 4.02 microgram. The target administered activity will be 9 mCi. The 18F-DCFPyL positron emission tomography and computed tomography (PET/CT) imaging will consist of the 18F-DCFPyL injection, followed by approximately 45 min dynamic CT imaging of a single bed position (including the liver lesion), and a static whole-body PET/CT imaging (top of head to mid-thighs) performed at 1 hour (+/-10 minutes) post 18F-DCFPyL injection. Only a single injection of 18F-DCFPyL is required. The initial 45 minutes dynamic regional scan will be used to determine the kinetics of 18F-DCFPyL within the tumor as compared with normal liver and other background.
223662440|NCT05009979|PROCEDURE|Tumor biopsy|Principal investigator discretion pre-treatment or during surgical resection.
223662441|NCT07076459|DRUG|HR091506 tablet|In each period under fed conditions, subjects received oral administration of either HR091506 tablet（T1）, HR091506 tablet（T2）, or HR091506 tablet（R）.
223769762|NCT00210652|DRUG|RWJ 333369:|Open-Label Extension: One 250mg tablet twice daily up to a total of 1200mg/day up until RWJ-33369 is available by prescription or study is terminated by sponsor
223769763|NCT03930017|BIOLOGICAL|Seasonal influenza vaccine - VAXIGRIP TETRA influenza vaccine (quadrivalent, split virion, inactivated)|Influenza virus (quadrivalent, split virion, inactivated) of the strains that comply with the World Health Organization (WHO) recommendations (Northern Hemisphere) and European Union (EU) decision for the 2018/2019 season. The quadrivalent vaccine is propagated in fertilised hens' eggs from healthy chicken flocks.
223769764|NCT06053216|OTHER|Indirect calorimetry|Weekly indirect calorimetry measurements using the Q-NRG+ device will be used to guide energy delivery up to day 28 of hospital admission.
224242578|NCT06627738|RADIATION|Cyberknife irradiation|Additional Cyberknife irradiation after a doublet of Platinum Salts-based chemotherapy and concomitant radiotherapy in inoperable patients with locally advanced non-small cell lung carcinoma
224242579|NCT06631547|DRUG|Progesterone|Hormonal treatment
224242580|NCT06631547|DRUG|The usual head trauma care|the basic treatment
224242581|NCT07027800|DIETARY_SUPPLEMENT|Creatine Monohydrate|20 gram loading of creatine monohdyrate for 5 days, followed by 5 grams per day for 6 weeks
224242582|NCT07027800|DIETARY_SUPPLEMENT|Placebo|20 grams daily of non-caloric placebo + 5 grams daily non-caloric placebo for 6 weeks
224242583|NCT07029516|OTHER|Cosmetic patch containing urea applicated daily for 3 months|Daily application of the patch on toes, 3 months treatment
224242584|NCT07029516|OTHER|Placebo patch application|Daily application of a placebo patch on toes for a 3 months treatment
224242585|NCT03815838|DIAGNOSTIC_TEST|PET imaging|Positron emission tomography imaging using 18F-Fallypride and 18F-FDOPA
224242586|NCT07030725|DRUG|Menthol Gel|Menthol (5% L-menthol) will be applied to the anterior thorax.
224242587|NCT07030725|DRUG|Sham|Sham gel applied to the anterior thorax.
224242588|NCT07030725|BEHAVIORAL|Time control|No gel applied to anterior thorax.
224242589|NCT07036289|PROCEDURE|Mechanical Treatment|manual quadrant scaling and root planing followed by dental prophylaxis within 4 weekly sections and oral hygiene instructions
224242590|NCT07037329|DIAGNOSTIC_TEST|Transcutaneous Electrical Nerve Stimulation (TENS)|TENS is a non-invasive electrotherapy technique used to manage pain and modulate physiological responses such as blood pressure. In this study, patients in Group 1 received TENS therapy as the primary intervention.
224242591|NCT07037329|DIAGNOSTIC_TEST|Electrical Muscle Stimulation (EMS)|EMS is a form of electrotherapy that causes muscle contractions through electrical impulses delivered via surface electrodes. In this study, patients in Group 2 received EMS therapy to investigate its effect on hemodynamic parameters in individuals with hypertension.
223662442|NCT07086261|OTHER|Spaced Retrieval Training|This study adopted a quasi-experimental research design with two groups of pre- and post-tests. The sample was recruited by convenient sampling. The experimental group used the time extraction training program to intervene and perform relevant water drinking training, 40 minutes each time, 3 times a week, for a total of 8 weeks of intervention measures, while the control group used routine care for general water drinking. Both groups collected pre-test data before the time extraction training intervention program activities in the first week, and conducted post-test data tracking and analysis in the 4th and 8th weeks after the intervention activities.
223662443|NCT03445949|DRUG|short postimplantation dual antiplatelet therapy|continuing dual antiplatelet therapy up until 6 months after left atrial appendage occlusion with Amplatzer or WATCHMAN device
224242592|NCT07035366|PROCEDURE|stabled resection|diaphragmatic plication of sever eventration by stabled resection
224242593|NCT07035366|PROCEDURE|running sutures|plication of diaphragmatic eventration by running sutures
224242594|NCT07036016|DRUG|EGFR-TKI|epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs)-including gefitinib, erlotinib, afatinib, and osimertinib
224242595|NCT07036016|DRUG|PD-1/PD-L1 inhibitor|ICIs such as nivolumab, pembrolizumab, and atezolizumab-targeting the programmed cell death 1 (PD-1) or its ligand (PD-L1)
224242596|NCT07036016|DRUG|EGFR-TKI combined with PD-1/PD-L1|epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs)-including gefitinib, erlotinib, afatinib, and osimertinib combined with ICIs such as nivolumab, pembrolizumab, and atezolizumab-targeting the programmed cell death 1 (PD-1) or its ligand (PD-L1)
224242597|NCT07035834|DRUG|Gliflozin|Our study will enroll non diabetic patients affected by chronic kidney disease secondary to lupus nephritis and ANCA associated vasculitis. Other studies have so far investigated only diabetic patients affected by the above mentioned diseases.
224242598|NCT07035899|DRUG|Caesarean Section|Cesarean section was performed as routine surgical procedure
224242599|NCT07036471|BEHAVIORAL|myCare Start|The service consists of two 10-minute, semi-structured and tailored consultations delivered by community pharmacists during the first 6 weeks of a patient initiating a new long-term medication, followed by tailored feedback to the patient's physician.
224242600|NCT07037537|PROCEDURE|Endoscopic assisted NSM+breast reconstruction+simultaneous fat transplantation|Laparoscopic assisted mastectomy with preservation of nipple and areola, combined with chest muscle anterior prosthesis and patch, immediate one-step breast reconstruction and simultaneous autologous fat transplantation
224242601|NCT07036237|DRUG|Tramadol group|Drug used as final irrigant
224242602|NCT07036237|DRUG|Dexamethasone Group|drug used as a final irrigant
223662444|NCT03445949|DRUG|extended postimplantation dual antiplatelet therapy|stopping dual antiplatelet therapy after 30 days after left atrial appendage occlusion with Amplatzer or WATCHMAN device
223662445|NCT03445949|DRUG|long-term treatment with a single antiplatelet agent|continuing long-term treatment with single antiplatelet agent
223662446|NCT03445949|DRUG|6 months treatment with a single antiplatelet agent|continuing single antiplatelet agent up until 6 months
223662447|NCT07099638|DRUG|Varenicline (VAR)|13 weeks of varenicline
223662448|NCT07099638|DRUG|Nicotine lozenge (NRT)|12 weeks of nicotine lozenges
223662449|NCT07099638|BEHAVIORAL|Smartphone intervention with adherence components (ADHERE)|Smartphone-based smoking cessation intervention with adherence components
223662450|NCT07099638|BEHAVIORAL|Smartphone intervention without adherence components (NO ADHERE)|Smartphone-based smoking cessation intervention without adherence components
223662451|NCT07099638|BEHAVIORAL|Telephone Counseling|Up to 6 telephone counseling sessions with a tobacco treatment specialist
223662452|NCT01243684|DEVICE|DTI - Diffusor Tensor Imaging|Radiology intervention
223662453|NCT06923800|BEHAVIORAL|Combined Exercise Program + A specific nutritional plan for individuals with IBS|60-minute sessions three times per week for 4 months, incorporating moderate aerobic, resistance, and flexibility exercises
223662454|NCT06923800|BEHAVIORAL|Aerobic Exercise + A specific nutritional plan for individuals with IBS|60-minute sessions, three times a week for 4 months, with low-impact, non-weight-bearing aerobic activities at 60-75% of max heart rate.
223662455|NCT05629676|BEHAVIORAL|BMT-VR|BMT-VR is a novel psychosocial intervention that addresses the supportive care needs of patients undergoing BMT. BMT-VR includes six sections focused on: 1) psychoeducation to help patients increase their awareness to stress and challenges that may accompany the BMT journey; 2) supportive psychotherapy strategies to help patients adjust to the intense BMT hospitalization; 3) psychosocial skill building to promote mindfulness, acceptance and gratitude while living with uncertainty; 4) psychoeducation to manage expectations and enhance preparedness for extended hospitalization; 5) psychosocial skill-building to promote effective coping; and 6) an overview of psychosocial skills grounded in cognitive behavior therapy, mindfulness, and positive psychology
223662456|NCT06936787|DRUG|IGT001|Study drugs
223769765|NCT06053216|OTHER|Indirect calorimetry (Standard care nutrition arm)|Weekly indirect calorimetry measurements using the Q-NRG+ device will be conducted up to day 28 of hospital admission. In the standard care nutrition arm, clinicians will be blinded to indirect calorimetry measurements.
224242603|NCT07037251|OTHER|there is no intervention|there is no intervention only observation
223662457|NCT06942481|BEHAVIORAL|Girls Invest|The Girls Invest intervention involved: 1) app-based trainings on topics related to financial literacy, gender equity, and health and 2) financial resources/incentives supporting girls' education/career.
223662458|NCT06942481|BEHAVIORAL|Waitlist control|Participants receive Girls Invest after they complete the 6 month follow-up survey.
223662459|NCT06940375|OTHER|Abdominal ultrasound , Fibroscan and body composition analysis examination|Abdominal ultrasound and Fibroscan examinations were conducted to obtain LSM, CAP, and calculate the FAST score. Bioelectrical impedance analysis was performed to obtain the content of subcutaneous and visceral fat.
223769766|NCT01045564|BIOLOGICAL|GSK influenza virus H5N1 vaccine 1557484A|Three doses of GSK 1557484A administered intramuscularly (IM), the first and third in the deltoid region of the non-dominant arm and the second in the deltoid region of the dominant arm
224242604|NCT07037212|BEHAVIORAL|Intensive Medical Nutrition Therapy (MNT)|Participants will receive individualized intensive medical nutrition therapy (MNT) with weekly dietary counseling and follow-ups for 12 weeks. The intervention focuses on improving glycemic control, reducing systemic inflammation, and enhancing gut barrier function.
224242605|NCT07037212|BEHAVIORAL|Standard Dietary Counseling|Participants will receive standard dietary advice in a single counseling session at baseline. No further dietary intervention will be provided.
224242606|NCT07036367|DRUG|Sublingual Melatonin|Participants in this group received 3 mg of sublingual melatonin, administered 60 minutes before cataract surgery. The melatonin was given in the form of a rapidly dissolving sublingual tablet to enhance bioavailability and ensure consistent preoperative absorption. The goal of the intervention was to reduce preoperative anxiety, improve sedation level, and stabilize hemodynamic parameters. The melatonin tablets were indistinguishable in appearance from the placebo and were prepared and dispensed by a pharmacy technician not involved in data collection or patient care
224242607|NCT07036367|DRUG|Sublingual Placebo|Participants in this group received an identical-appearing sublingual placebo tablet containing inert ingredients, administered 60 minutes before cataract surgery. The placebo was visually indistinguishable from the melatonin tablets and was used to maintain double blinding in the trial. Tablets were prepared by the pharmacy team to ensure concealment and eliminate bias. This group was designed to serve as a control to evaluate the effectiveness of sublingual melatonin on anxiety and sedation levels in elderly patients
224242608|NCT07036640|OTHER|Heat exposure|Heat exposure during exercise
224242609|NCT07035860|RADIATION|Carbon ion radiotherapy|Patients will receive platinum-based doublet chemotherapy and immunotherapy, followed by carbon iron radiotherapy and immunotherapy. The concrete immune checkpoint inhibitor includes durvalumab, sugemalimab, atezolizumab, benmelstobart, pembrolizumab, camrelizumab, toripalimab, tislelizumab, sintilimab, nivolumab, serplulimab, or penpulimab.
223769767|NCT04663555|DRUG|Dexamethasone|Patients in the intervention group after randomization will receive dexamethasone 20 mg intravenously once daily on day 1-5, followed by dexamethasone 10 mg intravenously once daily on day 6-10. If successful extubation occurs before day 10, treatment with dexamethasone is withdrawn.
223769768|NCT06010394|OTHER|conventional physiotherapy|ultrasound electrotherapy cold applications
223662460|NCT07145073|DEVICE|DC-Stimulator MC|Experimental：Participants will receive 10 days of repeated transcranial alternating current stimulation treatment in hospital.
223662461|NCT07145073|DEVICE|DC-Stimulator MC|Sham Comparator：Participants will receive 10 days of repeated transcranial alternating current stimulation treatment (no active stimulation) in hospital.
223769769|NCT06010394|OTHER|exercises for the knee area|range of motion exercises strengthening exercises exercises to reduce edema
223769770|NCT06010394|OTHER|payment oriented massage|10 / 15-minute massage treatments to reduce payment
223662462|NCT07145216|OTHER|Interfrential stimulation|The participant will be positioned in semi-Fowler's position. Interferential therapy was given using the quadripolar method. Two electrodes were placed on the lower abdomen just above the outer half of the inguinal ligament, and another two on the inner aspect of the thigh near the origin of the adductor muscle. At the first treatment session, every participant will be examined for pelvic floor contraction by the finger palpation method using sterilized gloves to ensure the correct position of the electrodes. It will be set with intensity up to the tolerable limit of subjects, carrier frequency of 2000Hz, vector 900, rhythmic sweep frequency of 10-100Hz, and duration 20 minutes. Interferential therapy will be applied for the treatment procedure of all women in both groups for 20 minutes, 3days per week for 8 weeks.
223769771|NCT01178229|OTHER|Physiotherapy|"The physiotherapeutic intervention was based on the Awareness through Movement technique. Ten sessions were planed. Each session lasted three hours.~The children of the experimental group and their parents were guided by two physiotherapist and the sessions took place in a room rounded by mirrors.~Each session developed as follows: presentation to the parents of the somatic awareness technique for each day; movements, games, motor tales and exercises performed by the children; in each session, a guide book with cartoons was given to the children and their parents to reinforce the exercises at home to keep a long-term result.~All the children assisted together to all the sessions and the instructions and instruments given to the children and their parents were the same for all of them."
223769772|NCT01670162|DRUG|Aflibercept|Intravitreal Injection 2mg/0.05mL Aflibercept
223769773|NCT03376997|DRUG|Perampanel|IV infusion
223769774|NCT03376997|DRUG|Perampanel|Oral tablet
223769775|NCT06363916|DEVICE|Insulin Management System in Manual mode of operation|"MEDTRUM A8 TouchCare® Insulin Management system which includes:~* Patch pump: Pump base integrated with Hybrid Close Loop (HCL) algorithm not activated~* Reservoir Patches~* Continuous glucose monitoring (CGM): Glucose Sensor + Transmitter~* Personal Diabetes Manager (PDM) and/or EasyPatch® App~* EasyFollow® App, EasyView® website System is in conformity with EC marking n° HD 601 357 110001- TUV Rheinland dated February 19th of year 2019 and completed by system DoC 881160 dated June 30th of year 2020.~EasyPatch mobile application is in conformity with EC marking n°709972 - BSI - dated March 6th 2020"
223769776|NCT06363916|DEVICE|Insulin Management System in Automatic mode of operation|"MEDTRUM A8 TouchCare® Insulin Management system which includes:~* Patch pump: Pump base integrated with Hybrid Close Loop (HCL) algorithm activated~* Reservoir Patches~* Continuous glucose monitoring (CGM): Glucose Sensor + Transmitter~* Personal Diabetes Manager (PDM) and/or EasyPatch® App~* EasyFollow® App, EasyView® website System is in conformity with EC marking n° HD 601 357 110001- TUV Rheinland dated February 19th of year 2019 and completed by system DoC 881160 dated June 30th of year 2020.~EasyPatch mobile application is in conformity with EC marking n°709972 - BSI - dated March 6th 2020"
223769777|NCT00000410|PROCEDURE|Diskectomy|The surgeon will leave the nerve root freely mobile and undamaged following the procedure. During the procedure, the surgeon may consider using loop magnification or a microscope. The surgical incision will be midline and, after reflecting the paraspinous muscles, the interlaminar level will be identified and entered. The nerve root will be clearly identified and mobilized and then gently retracted to prepare for the discectomy. Removal of the medial border of the superior facet may, in some cases, be necessary in order to have a clear view of the lateral border of the involved nerve root. Following the clear view of the nerve root and mobilization, the IDH will be approached by making a small annular incision if necessary, the fragment of disc will then be removed (i.e., limited disc excision). A search of the canal will follow removal of the fragment, along with probing of the intervertebral-foramen for residual disc or bony pathology.
223769778|NCT00000410|PROCEDURE|Non-surgical treatments|Active physical therapy modality, Education/Counseling with home exercise instruction, and an NSAID if tolerated
224242610|NCT07035860|DRUG|Chemotherapy|platinum-based doublet chemotherapy
224242611|NCT07035860|DRUG|Immunotherapy|The concrete immune checkpoint inhibitor includes durvalumab, sugemalimab, atezolizumab, benmelstobart, pembrolizumab, camrelizumab, toripalimab, tislelizumab, sintilimab, nivolumab, serplulimab, or penpulimab.
224242612|NCT07037563|OTHER|An AI pharmacy chatbot offering information related to HA-prescribed medication for hyperglycaemia, hypertension, and hyperlipidaemia|It is a chatbot for HA-prescribed medication used for treating hyperglycaemia, hypertension, and hyperlipidaemia, available through WhatsApp. All the responses will be extracted from a database, in which the content was obtained from and validated by pharmacists from the Chief Pharmacist's Office of the Hospital Authority in Hong Kong. The intervention period will last for 7 days.
224242613|NCT07037472|DIAGNOSTIC_TEST|Multi-modal photoacoustic/ultrasonic (PA/US) imaging system|The multi-modal PA/US imaging system is equipped with a handheld PA/US probe, and able to provide data of dual-wavelength PA imaging of DM skin lesions, in addition to real-time 2D conventioanl US imaging
224242614|NCT07037472|DRUG|Drug treatment|The multi-modal PA/US imaging system is equipped with a handheld PA/US probe, and able to provide data of dual-wavelength PA imaging of DM skin lesions, in addition to real-time 2D conventional US imaging. The histopathological biopsy results before and after treatment are combined as indicators for evaluating therapeutic efficacy and predicting treatment outcomes.
224242615|NCT07035704|DIETARY_SUPPLEMENT|MeD enriched with mushrooms|Patients will receive the MeD personalized plan plus commercial mushrooms
224242616|NCT07035704|DIETARY_SUPPLEMENT|MeD enriched the Lebanese herbal mixture Za'atar|Patients will receive the MeD personalized plan plus natural products/extracts of endemic plants (olive oil, herbs like Lebanese Za'atar).
224242617|NCT07035704|DIETARY_SUPPLEMENT|MeD Diet + semaglutinine or compatible treatment+ Za'atar or Mushroom (to be defined)|Patients will receive counselling and personalized dietary strategy aimed at increasing the adherence to Mediterranean diet by means of use of visual communication (e.g., comics, cartoons, videos) and digital tools (i.e., games, apps), including a physical activity program with a personal trainer + semaglutinine or compatible treatment+ Za'atar or Mushroom (to be defined)
224242618|NCT07035639|BEHAVIORAL|The Baduanjin intervention was designed following traditional Chinese health preservation principles and conducted under the guidance of certified instructors. The training sessions were led by nation|The Baduanjin group received training guided by national-level social sports instructors certified by the Institute of Sports Medicine, General Administration of Sport of China. The intervention consisted of Baduanjin training 4 times per week for 8 consecutive weeks, with a total duration (including warm-up and breaks) of ≥30 minutes per session. The training protocol included 16 minutes of Baduanjin exercise, a 2-minute break, and an additional 16 minutes of Baduanjin exercise.
223662463|NCT07145216|OTHER|Knack pelvic floor training|"The knack technique (Fitz et al., 2021):~* The patient will be instructed to lie in supine lying position with flexed knees.~* Ask the patient to contract the pelvic floor muscles for 2-4 seconds and relax for 4 seconds for 15 repetitions with 3 sets before and during coughing or sneezing .~* Contract the PFM before and during all daily activities involving effort, before and during coughing, sneezing, laughing, walking up and down stairs, jumping, running, bending, lifting a weight from the floor, holding a child, pushing furniture to prevent urine leakage.~* Contract PFM and hold for 2-4 seconds, relax 4 seconds, with 3 sets of 15 repetitions."
223662464|NCT07144826|PROCEDURE|Biospecimen Collection|Undergo blood and vaginal sample collection
223662465|NCT07144826|DRUG|Placebo Administration|Given PO
223662466|NCT07144826|DIETARY_SUPPLEMENT|Probiotic|Given PO
223662467|NCT07144826|OTHER|Questionnaire Administration|Ancillary studies
223662468|NCT07146074|RADIATION|Preventive radiotherapy|Either conventional radiotherapy (single dose of 8 Gy) or Stereotactic Ablative Body Radiation (either 1x20 Gy, 2x12 Gy, 3x10 Gy or 5x8 Gy) will be delivered depending on the participant's prognostic outcome.
223662469|NCT07146074|DRUG|Systemic therapy (Standard of Care)/Observation|It concerns systemic therapy if applicable according to the standard of care or only observation.
223662470|NCT07146685|DRUG|Bupivacaine|We are comparing two concentrations of the same drug: 10 ml of 0.5% and 20 ml of 0.25%; We will use the same milligram dose (50 mg).
223662471|NCT07144787|OTHER|implant retained complete Overdenture|four implant retained complete Overdenture versus Fixed-detachable prosthesis
223662472|NCT07144787|OTHER|Fixed-detachable prosthesis|four implant retained complete Overdenture versus Fixed-detachable prosthesis.
223662473|NCT07144930|OTHER|MCIT program|"The MCIT program combines motor and cognitive training, progressing independently with increasing difficulty.~* Motor training, based on traditional physical therapy for stroke patients, includes upper and lower extremity exercises, bed mobility, strengthening (core and extremities), and balance training, progressing from static to dynamic tasks.~* Cognitive incorporative component, adapted from previous stroke studies, supports cognitive recovery and overall well-being. Training starts with attention and short-term memory tasks, advancing to working memory and inhibitory control with increasing difficulty. Progression requires an 80% success rate; if not achieved, tasks are simplified by reducing memory span or providing additional guidance."
223662474|NCT07144930|OTHER|Motor training program|Based on traditional physical therapy for stroke patients, includes upper and lower extremity exercises, bed mobility, strengthening (core and extremities), and balance training, progressing from static to dynamic tasks. Progression is guided by core action goals (Table 2) and depends on stable vital signs, balance, and minimal assistance. If participants are unable to progress, simpler tasks are provided.
223662475|NCT07145879|DRUG|Lidocaine hydrochloride 2% with epinephrine 1:100 000|Patient were received infiltrative anesthesia with Lidocaine (Jetokain, Adeka Ilaç, Samsun, Türkiye): Active ingredient: Each 1 ml contains 20 mg lidocaine hydrochloride (HCL) and 0.012 mg epinephrine base. Excipients: Sodium metabisulfite, sodium chloride, water for injection.
223662476|NCT07145879|DRUG|Articaine 4% with epinephrine 1:100,000|Patients were received Infiltrative anesthesia with Articaine (Ultracain DS Forte, Sanofi Aventis İlaçları, Istanbul, Türkiye): Active ingredient: 40 mg articaine HCL and 0.012 mg epinephrine per 1 ml. Excipients: Sodium chloride, sodium metabisulfite, hydrochloric acid, water for injection
223662477|NCT07145879|PROCEDURE|Free gingival graft (FGG)|FGG surgery was performed around natural teeth and implants where keratinized gingival tissue was inadequate.
223769779|NCT01147419|DEVICE|stent|Before operation, take aspirin 100mg every day. During the operation, stent is delivered by a catheter and positioned through the narrowing in the artery. The stent is then expanded against the wall of the blood vessel to provide a wider channel for blood. At last, use balloon dilate the stent.
223769780|NCT01147419|DEVICE|femoral-popliteal bypass with artificial blood vessel|Before operation, take aspirin 100mg every day. Groin and suprageniculate incision, PTFE graft with end to side anastomoses.
223769781|NCT01648309|OTHER|Neuropsychological testing|This is an observational study
223769782|NCT04607226|OTHER|Active transcutaneous vagus nerve stimulation|respiratory-gated non-painful electrical stimulation of the auricle for 30 minutes
223769783|NCT04607226|OTHER|Sham transcutaneous vagus nerve stimulation|stimulation of the auricle for 30 minutes
224242619|NCT07036302|PROCEDURE|35% TCA combined with croton oil peel|3 sections every 30 days of 35% TCA combined with croton oil peel
224242620|NCT07036302|PROCEDURE|Isolate 35% TCA peel|3 sections every 30 days of isolate 35% TCA peel
224242621|NCT07036302|RADIATION|Erbium-YAG laser|3 sections every 30 days of Er-YAG laser
224242622|NCT07036302|RADIATION|Neodymium -YAG laser Q-switched|3 sections every 30 days of ND-YAG laser
224242623|NCT07037199|DRUG|SHR-A1811 + dalpiciclib+ endocrine therapy|sequential SHR-A1811 followed by dalpiciclib plus endocrine therapy (fulvestrant or aromatase inhibitors)
224242624|NCT07037303|DEVICE|Active Cycle of Breathing Technique (ACBT) and Oscillatory Positive Expiratory Pressure (OPEP) group|Patients with bronchiectasis using ACT and OPEP simultaneously
224242625|NCT07037303|DEVICE|Active Cycle of Breathing Technique (ACBT) group|Patients will receive only ACBT for airway clearance.
224242626|NCT07037602|OTHER|Sexual Health Education|After the Personal Information Form, Sexual Myths Scale and Sexual Self-Awareness Scale are applied as a pre-test to all women, sexual health training will be given to the women in the experimental group. The training will be given in 4 sessions over 2 weeks. Demonstration, powerpoint, feedback and brainstorming methods will be used in the training.
224242627|NCT07037602|OTHER|No Interventions|No intervention will be made.
224242628|NCT07036770|DIAGNOSTIC_TEST|Coronary CT scan using photon-counting CT|A dedicated cardiac UHR PCCT will be conducted within a maximum of 24 hours in ACS subjects and 72 hours in CCS subjects prior to the invasive CAG. Additionally, patients are also eligible for inclusion in case no PCCT is conducted prior to CAG, as long as no PCI is performed during the initial CAG. In these cases, the PCCT must be conducted within 24 hours for ACS patients and within 72 hours for CCS patients.
224242629|NCT07035184|PROCEDURE|Spinal Anesthesia with Bupivacaine|Group A (n=30) will receive spinal anesthesia according to the weight-based dosing calculation of bupivacaine.
224242630|NCT07035184|PROCEDURE|Spinal Anesthesia with Bupivacaine|Group B (n=30) will receive spinal anesthesia according to the age-based dosing calculation of bupivacaine.
223662478|NCT07144982|BEHAVIORAL|Counselling session|Each enrolled parent received a single, standardized counselling session (\~15 minutes) delivered in the ambulatory unit by a certified tobacco counsellor. The session followed a fixed script and covered: (1) types of tobacco smoke exposure (primary, secondary and tertiary), (2) health consequences for children with emphasis on perioperative respiratory and anaesthetic risks, (3) practical measures to reduce household exposure (smoke-free home/car rules, behavioural strategies), and (4) brief advice on initial cessation steps and referral options. Structured handouts and signposting to support services were offered when appropriate.
224242631|NCT07035964|DIETARY_SUPPLEMENT|human lactoferrin|effera human lactoferrin
224242632|NCT07035964|DIETARY_SUPPLEMENT|Placebo|Placebo Control
223662479|NCT07146646|DRUG|Trifluridine/tipiracil|FTD/TPI will be taken by mouth on Days 1-5 of the 14-day treatment cycle. The starting does is 25mg/m2 twice per day.
223662480|NCT07146646|DRUG|Oxaliplatin|Oxaliplatin is given on Day 1 of each 14-day cycle. It is given intravenously (by IV) over 2 hours.
223662481|NCT07145021|BEHAVIORAL|Breathing Exercise Intervention|Participants will receive guided breathing exercise training conducted by a certified breathing coach. The intervention consists of weekly 40-minute sessions over a 6-week period, aimed at reducing test anxiety and improving academic performance. Participants will also maintain a breathing exercise log throughout the study.
223662482|NCT07145866|DRUG|varenicline|"Dosing of this FDA-approved medication will follow the below schedule, which follows the clinical standard:~0.5 mg once daily or 3 days, 0.5 mg twice daily for 4 days 1.0 mg twice daily for 11 weeks"
223662483|NCT07145866|DEVICE|Transcranial Magnetic Stimulation|Transcranial magnetic stimulation (TMS) is a noninvasive FDA-approved technique that is commonly used as a treatment for depression and has been approved for use in smoking cessation. In this study, TMS will be administered within FDA-approved guidelines under the supervision of a physician with experience in administering the treatment and monitoring for complications. Following an accelerated model, it will consist of 5 hourly treatments for 5 consecutive days.
223662484|NCT07145866|DEVICE|Transcranial Magnetic Stimulation Sham|Transcranial magnetic stimulation (TMS) is a noninvasive FDA-approved technique that is commonly used as a treatment for depression and has been approved for use in smoking cessation. In this study, TMS will be administered within FDA-approved guidelines under the supervision of a physician with experience in administering the treatment and monitoring for complications. Following an accelerated model, it will consist of 5 hourly treatments for 5 consecutive days. The sham setting will deliver no magnetic field to the brain but will deliver electrical current to the scalp to mimic the feel of active treatment.
223662485|NCT07145866|BEHAVIORAL|Nicotine Cessation Counseling|Each participant will receive 6 sessions of brief nicotine cessation counseling by a trained study staff member. This will be provided at the weekly follow-up visits, spread out throughout the study. This counseling, while not the main aim of the study, should help participants manage their expectations of quitting and provide support and quitting strategies throughout the process.
223662486|NCT07145645|DRUG|Voltaren Topical Gel|Topical diclofenac emulgel (Voltaren) 11.6 mg/g. Dosing is based on weight bands: 25 kg: 2 grams/dose, ≥25 kg - \<40 kg: 3 grams/dose; and \>40 kg: 4 grams/dose. ATC code: M02A A15.
223662487|NCT07145645|DRUG|Ibuprofen Oral Suspension 100 mg/5mL|Children's Ibuprofen Oral suspension (Motrin) 100mg/5 mL . Dosing is 10 mg/kg to a maximum of 600mg.
223662488|NCT07145645|DRUG|ORA-Blend Oral Suspension|Oral Ibuprofen suspension (labelled as ibuprofen) given at 10 mg/kg to a maximum of 600mg each dose.
223662489|NCT07145645|DRUG|VersaPro Cream Base for Compounding|"Topical Versapro Cream emulgel (labeled as diclofenac diethylamine). Dose is based on the following weight bands: 25 kg: 2 grams/dose;~≥25 kg - \<40 kg: 3 grams/dose; and \>40 kg: 4 grams/dose."
223662490|NCT07145632|DEVICE|App-based education and training of inhalation technique|The use of MDI or DPI requires different inhalation techniques and flows, which makes correct inhalation technique more challenging if patient use different types of inhaler devices. Healthcare providers may assess inhalation technique by observation and in addition PIF may be measured by manual meter. However, this does not capture all relevant information about patient's ability to correctly inhale medication and handle prescribed inhaler(s) and do not give instant and automated feedback on the inhalation technique to user. For instance, DPI users should reached a sufficiently high PIF within the first 0.4 seconds \[18\] and MDI users inhalation time should exceed 4 seconds in adults (2-3 seconds in children) in order to optimize lung deposition of the aerosol during a low PIF \[19\]. The app-based inhalation medical device gives automated feedback on inspiratory flows that are specific DPI and MDI devices.
223662491|NCT07145125|DRUG|Brentuximab-Vedotin associated with Bendamustine|Patient having received at least one course of the association Brentuximab-Vedotin and Bendamustine
223662492|NCT07145411|OTHER|Bone Marrow Transplant with Ossium's HPC, Marrow (bone marrow recovered from deceased organ and tissue donors)|The HOPE Program does not include any investigational drugs. The medicines and procedures in this program are standard of care for a transplant. Bone marrow cells from a deceased organ and tissue donor for use in your transplant is the only product offered to you by Ossium Health.
223662493|NCT07146295|DRUG|Technetium (99mTc)|A radiopharmaceutical tracer consisting of technetium-99m (99mTc)-labelled nanocolloid used for sentinel lymph node mapping. In this study, 99mTc-nanocolloid is administered via periareolar injection with an activity of 40 MBq for the one-day protocol or 100 MBq for the two-day protocol, according to local hospital practice. Injection is performed either on the day of surgery or the afternoon before surgery. Preoperative lymphoscintigraphy is carried out to visualize lymphatic drainage. During surgery, a gamma-detection probe is used to locate and remove the sentinel lymph node(s) identified by 99mTc uptake.
223662494|NCT07146295|DRUG|Indocyanine Green|Indocyanine Green (ICG) is a fluorescent dye used for intraoperative sentinel lymph node mapping. In this study, a total dose of 5 mg (2 mL) of ICG is administered via periareolar injection after induction of general anesthesia and prior to axillary incision. During surgery, near-infrared fluorescence imaging is used to visualize lymphatic drainage and identify the sentinel lymph node(s). The identified node(s) are surgically removed under fluorescence guidance. In the transition phase, fluorescence findings are cross-checked against 99mTc uptake to ensure accuracy and safety.
224321357|NCT05056038|PROCEDURE|Posterior Quadratus Lumborum Block|In posterior QLB, the local anesthetic can spread on the anterior and lateral cutaneous branches of T4-L1 spinal nerves by administration of the agent to the lateral interfascial triangle.
224321358|NCT00794508|BIOLOGICAL|ADA gene transfer|Autologous CD34+ cells transduced with the retroviral vector MND-ADA, carrying the human ADA gene.
223769784|NCT00731328|PROCEDURE|nonmyeloablative allogeneic hematopoietic stem cell transplantation|infusion of mobilized donor hematopoietic progenitor cells
223769785|NCT06435247|BEHAVIORAL|With or without accompaniment in the recovery anaesthetic area|one grup will have family accompaniment in the recovery area and the other group will not in both groups the QoR15 scale will be used to measure the quality of anesthetic recovery
223769786|NCT04660357|OTHER|survey study|survey study
223769787|NCT04910867|BEHAVIORAL|Components of Genetic Counseling|"The APOL1 testing program is designed to help living donor candidates to reduce their decisional conflict and enhance their informed consent regarding living donation. This intervention component entails: (1) an artificial intelligence-based conversational agent chatbot providing foundational information about the relationship between APOL1 and kidney disease and living donor outcomes, and APOL1 testing. The chatbot helps to relieve the workload on clinicians and scale up information giving. (2) The transplant nephrologist counseling component includes discussion about the APOL1 test results and shared decision making about donation, in a culturally competent manner, so as to enhance donor candidates' informed consent for living donation."
224242633|NCT06876207|DEVICE|Tandem t:slim X2 with Control-IQ technology|Control-IQ is one of the second-generation AID technologies currently available worldwide and is approved for people \> 6 years. Control-IQ can predict glucose levels 30 minutes in advance and automatically adjust basal insulin delivery, providing corrective boluses if needed. The system can prevent hypoglycemia by suspending insulin delivery if glucose is predicted to drop below 70 mg/dl (8). Additionally, the device offers specific settings for circumstances such as sleep or exercise. When the exercise mode is activated, the system temporarily raises the minimum glucose target from 112.5 to 140 mg/dl to minimize the risk of hypoglycemia, a common effect of physical activity.
224242634|NCT07036601|DRUG|THDBH120 injection|Participants received THDBH120 by subcutaneous injection.
224242635|NCT07036601|DRUG|Placebo of THDBH120 injection|Participants received placebo by subcutaneous injection.
224242636|NCT07037368|BEHAVIORAL|Impact of Delivery Mode|investigates the impact of delivery mode vaginal delivery versus cesarean section on the prevalence and severity of three postpartum musculoskeletal complications: coccydynia, pelvic girdle pain (PGP), and rectus diastasis (RD). Conducted on postpartum females
224242637|NCT07037069|COMBINATION_PRODUCT|Desensitization Training|Participants in this group received desensitization training aimed at reducing hypersensitivity and pain perception through progressive exposure to different tactile stimuli. Use of soft and coarse textures (cotton, wool, Velcro, brush). Rubbing, tapping, rolling over the affected wrist and hand.
224242638|NCT07037069|COMBINATION_PRODUCT|Graded Motor Imagery (GMI)|Training Sample Size: 20 participants Participants underwent a progressive 3-phase motor training program designed to target cortical reorganization and improve movement without provoking pain. Phases: Laterality Recognition - identifying left/right hand images (Recognise™ app or cards). Explicit Motor Imagery - visualizing wrist movements without actual motion. Mirror Therapy - using a mirror box to simulate movement of the affected wrist. Sessions: 30-45 minutes/day, 5 times/week, for 4 weeks.
224242639|NCT07037173|COMBINATION_PRODUCT|Kinesiology Taping|Elastic therapeutic tape applied over the SiJ region using a standardized protocol. Therapy sessions were supervised and conducted at a rehabilitation center three times per week for six weeks.
224242640|NCT07037173|COMBINATION_PRODUCT|Yoga Therapy|A structured yoga program including asanas, pranayama, and mindfulness practices focused on enhancing flexibility, core strength, and posture. conducted at a yoga center
224242641|NCT07036926|OTHER|Artificial Intelligence Video Education Arm|A novel, AI-generated, interactive peri-operative video education program. AI videos will be personalized using medical record chart data, specifically the patient's name, surgery date, and past medical history.
224242642|NCT07036315|OTHER|Music intervention|Participants will be asked to select different music clips based on meaning, enjoyment and preference.
224242643|NCT06719375|DEVICE|Gait Analysis Using IMU Sensor|Inertial Measurement Unit (IMU) sensor-based 3D gait analysis to assess spasticity and gait impairment. This intervention aims to provide quantitative data on gait parameters in DCM patients before and after surgery.
224242644|NCT06713590|DRUG|Axatilimab|Axatilimab will be administered at protocol defined dose.
224242645|NCT07035496|OTHER|Benson's relaxation exercise|The Benson's relaxation exercise is based on the principle of choosing a word that is meaningful to the individual and focusing on it, breathing deeply and relaxing all the muscles in the body.The Benson relaxation exercise is a simple and easy-to-learn method.
224242646|NCT07036965|DEVICE|CardiPulse|abc
224242647|NCT07036965|DEVICE|FaraPulse|bcd
224242648|NCT06723041|PROCEDURE|Acupressure Therapy|Undergo true acupressure
224242649|NCT06723041|PROCEDURE|Acupressure Therapy - placebo|Undergo sham acupressure
224242650|NCT06723041|PROCEDURE|Acupressure Therapy - self-administered|Undergo self-administered acupressure
224242651|NCT06723041|OTHER|Health Promotion and Education|Receive educational handouts
224242652|NCT06723041|OTHER|Survey Administration|Ancillary studies
224242653|NCT04201171|DEVICE|CSII and CGM|use of CSII as insulin delivery or CGM as glucose monitoring
224242654|NCT04217551|DEVICE|Therapeutic Hypothermia|Participants will receive therapeutic hypothermia for the assigned number of hours with controlled rewarming, using a closed-loop temperature control device.
224242655|NCT05819398|DRUG|Spesolimab Formulation 1|Spesolimab Formulation 1
224242656|NCT05819398|DRUG|Spesolimab Formulation 2|Spesolimab Formulation 2
224242657|NCT05819398|DRUG|Placebo matching Spesolimab Formulation 1|Placebo matching Spesolimab Formulation 1
224242658|NCT05819398|DRUG|Placebo matching Spesolimab Formulation 2|Placebo matching Spesolimab Formulation 2
224242659|NCT06927869|OTHER|designed physical therapy , pully system exercise|Participants assigned to the intervention group will engage in a specially designed physical therapy program focusing on pulley system exercises. The program is scheduled to occur three times per week, which is frequent enough to potentially induce meaningful improvements while allowing adequate rest between sessions to prevent fatigue and overtraining
223662495|NCT07146295|PROCEDURE|Sentinel lymph node biopsy|Sentinel lymph node biopsy (SLNB) is a surgical procedure used to identify and remove the first lymph node(s) that drain lymph from a tumor area. In this study, SLNB is performed through a small axillary incision after mapping the sentinel lymph node(s) using either radioisotope technetium-labeled (99mTc)-nanocolloid, indocyanine green (ICG) fluorescence imaging, or a combination of both. The identified lymph node(s) are excised and sent for pathological examination to determine the presence of cancer cells. The procedure is carried out under general anesthesia as part of breast cancer surgery.
223662496|NCT07146906|BIOLOGICAL|zigakibart|zigakibart 600 mg sc injections every second week for 104 weeks (2 years)
223662497|NCT07146919|DRUG|Bemarituzumab|"Part 1 Dose escalation part :~IV infusion, every 3 weeks with the dose :~DL1 = 15 mg/kg cycle 1 day 1, then 11 mg/kg thereafter from cycle 2 day 1 DL2 = 22 mg/kg cycle 1 day 1, then 15 mg/kg thereafter from cycle 2 day 1 DL3 = 30 mg/kg cycle 1 day 1, then 22 mg/kg thereafter from cycle 2 day 1~Part 2 Extension part :~IV infusion, every 3 weeks with the dose defined in the phase I dose escalation~Treatment with both study drugs will continue until disease progression according to RECIST v1.1, unacceptable toxicity, death, patient or physician decision to withdraw, or pregnancy, whichever occurs first"
223662498|NCT07146919|DRUG|Bevacizumab|IV infusion, 15mg/kg, every 3 weeks. Treatment with both study drugs will continue until disease progression according to RECIST v1.1, unacceptable toxicity, death, patient or physician decision to withdraw, or pregnancy, whichever occurs first
223662499|NCT07145151|DRUG|UBT251|UBT251 administered subcutaneously (SC) once a week.
223662500|NCT07145151|DRUG|Placebo|Placebo,SC,once a week for 48 weeks
223769788|NCT04910867|DIAGNOSTIC_TEST|APOL1 genetic testing|APOL1 genetic testing will be performed while live kidney donor candidates are undergoing donor evaluation to identify whether they are at elevated risk of kidney disease post-donation. This risk information is expected to better enable donor candidates to make meaningful informed decisions about donating.
223769789|NCT04910867|OTHER|EHR integration|APOL1 genetic test results will be integrated into the electronic health record to provide clinical decision support to transplant nephrologists in evaluating donor candidates.
223769790|NCT03860389|OTHER|Exercise|An exercise programme will be delivered in the school for a period of up to 16 weeks. Exercise classes will take place 3 times a week and will be of 60 minutes duration.
223769791|NCT04055129|OTHER|No interventions|Observational. Data will be gathered and analyzed on ligament laxity, EMG, kinetics and kinematics during a landing and jumping activity
223769792|NCT00647855|DRUG|Levothyroxine Sodium Tablets 300 μg|2x300mcg, single dose fasting
223769793|NCT00647855|DRUG|Synthroid® Tablets 300 μg|2x300mcg, single dose fasting
223769794|NCT04506554|DRUG|AMVAC + Nivolumab|Nivolumab 240mg will be administered intravenously for 3 doses - on days 1, 15 and 29. AMVAC will be dosed intravenously every 2 weeks for 3 doses on days 1, 15 and 29 with Neulasta or equivalent. Standard AMVAC dose is as follows: methotrexate 30mg/m2, vinblastine 3mg/m2, doxorubicin 30mg/m2, and cisplatin 70mg/m2.
223769795|NCT04539028|PROCEDURE|Emergency Abdominal surgery|Emergency Abdominal surgery
223769796|NCT03842787|OTHER|Biological analysis|"Biological and research analysis:~Quantification of ficolin-3, anti-ficolin-3 antibodies, ficolin-2, anti-ficolin-2 antibodies~Purification of patients' antibodies (anti-ficolin-3 and -2)~Evaluation of effects of anti-ficolin-3 and anti-ficolin-2 purified antibodies Investigation of ficolin-3 and ficolin-2 deposition in renal biopsy"
223769797|NCT01590914|PROCEDURE|Fed Condition|Subjects will consume a 250ml liquid test meal (250kcal) before undergoing a 40min fMRI scan to assess the BOLD signal responses to visual and auditory responses to food and non-food cues.
223662501|NCT07145463|DEVICE|Transcatheter Aortic Valve Replacement|Transcatheter Aortic Valve Implantation/Replacement (TAVI/TAVR) has gradually emerged as a new treatment option for patients with severe aortic stenosis who are ineligible for open-heart valve replacement or at high surgical risk.
223662502|NCT07146516|PROCEDURE|Prophylactic (non-invasive) Laser Retinopexy|Prophylactic laser retinopexy to prevent RD in participants with SS using the indirect ophthalmoscopy (IDO) to place approximately 1800 to 2400 moderate intensity burns to produce encircling grid pattern, placed one burn width apart from 2 MM anterior to the ora serrata, extending to and between the vortex vein ampullae.
223769798|NCT01590914|PROCEDURE|Fasted Condition|Subjects will consume a 250ml control (water) before undergoing a 40min fMRI scan to assess BOLD signal response to visual and auditory food and non-food cues
223769799|NCT06023095|DRUG|LY3502970|Administered orally.
223769800|NCT06023095|DRUG|Placebo|Administered orally.
223769801|NCT04212416|DRUG|Leflunomide|Given PO
223769802|NCT04871607|BIOLOGICAL|Basiliximab|Given IV
223769803|NCT04871607|DRUG|Carmustine|Given IV
223769804|NCT04871607|DRUG|Cytarabine|Given IV
223769805|NCT04871607|DRUG|Etoposide|Given IV
223769806|NCT04871607|BIOLOGICAL|Genetically Engineered Hematopoietic Stem Progenitor Cells|Given via infusion
224242660|NCT06105047|BEHAVIORAL|Cognitive tests|". Patients will perform experimental task in four conditions : control, mime, emotion, dual In a control condition : they will be asked to read the sentence aloud; in a motor-only condition, they will also be asked to mime the sentence; in an emotional-only condition, they will be asked to read the sentence while listening to music; in a dual condition, they will be asked to both mime and listen to music. Immediately after each condition, they will realize a recognition task~* quiz : Geneva Music Induced Checklist, GMIAC, Coutinho \& Scherer, 2017"
224242661|NCT06630247|DRUG|XL495|oral doses of XL495
224242662|NCT06630247|DRUG|ADC cytotoxic agents|intravenous infusion of anti-cancer combination agent
223769807|NCT04871607|BIOLOGICAL|Recombinant Granulocyte Colony-Stimulating Factor|Given SC or IV
224242663|NCT06903403|OTHER|Front-of-package label|Participants will see packaged food and beverage items displayed with labels as specified by their assigned group
223662507|NCT07146607|BEHAVIORAL|Audiology text-message protocol|Florence is an interactive text messaging service, endorsed by NHS England, designed to improve clinical outcomes for patients. An audiology text-message protocol, delivered via Florence, will prepare, inform and support new NHS hearing aid users as they are prescribed, receive, and start to use their hearing aid(s).
223662508|NCT07145268|DRUG|Entecavir (ETV)|"Standard antiviral therapy with Entecavir 0.5 mg orally once daily for 6 months.(control group)"
223662509|NCT07145268|DRUG|Zinc (zinc sulphate)|"Zinc sulfate 220 mg orally once daily (50 mg elemental zinc) in addition to Entecavir 0.5 mg, for 6 months."
223662510|NCT07145450|BIOLOGICAL|ANOC-001 (TCR-T cells targeting KRAS G12V mutation presented by specific HLA alleles)|"The cells will be gene edited and administered by a single IV infusion on Day 1.~Drugs: Cyclophosphamide and Fludarabine will be used as a lymphodepleting chemotherapy."
223662511|NCT07145450|BIOLOGICAL|ANOC-002 (TCR-T cells targeting KRAS G12V mutation presented by specific HLA alleles)|The cells will be gene edited and administered by a single IV infusion on Day 1. Drugs: Cyclophosphamide and Fludarabine will be used as a lymphodepleting chemotherapy.
224242664|NCT04709809|DEVICE|Retinal Vessel Analyzer recordings with electrocardiographic (ECG) gating|Video recordings of ocular fundus, an analysis of dynamic vessel diameters and putting them in ECG context.
223662512|NCT07145450|BIOLOGICAL|ANOC-003 (TCR-T cells targeting KRAS G12D mutation presented by specific HLA alleles)|The cells will be gene edited and administered by a single IV infusion on Day 1. Drugs: Cyclophosphamide and Fludarabine will be used as a lymphodepleting chemotherapy
224242665|NCT06818461|OTHER|Corvis St Before and after lasik, PRK, CXL|corneal biomechanics measurment using corvis St
224242666|NCT06930703|DRUG|Cannabidiol|Cannabidiol (CBD) twice daily taken orally for 4-weeks
224242667|NCT06930703|DRUG|Placebo|Placebo equivalent twice daily taken orally for 4-weeks
224242668|NCT02417805|PROCEDURE|Intervention: Remote Ischemic Preconditioning|Remote Ischemik Preconditioning is performed using a Blood Pressure Cuff with a pressure slightly above patients' blood pressure on the upper arm.
224242669|NCT00868010|DRUG|donepezil|5 mg or 10 mg, titrated per drug insert. Participants may remain in the study at 5 mg if unable to tolerate 10 mg.
224242670|NCT00868010|DRUG|placebo|Participants will receive a placebo pill for 12 weeks if randomized to this treatment.
224242671|NCT01845662|OTHER|Surgical or non-surgical management|Retrospective surgical (splenectomy) or non-surgical management (embolization or conservative management)
224242672|NCT00115726|DRUG|furosemide|for patients on chronic furosemide therapy, patients are randomized to furosemide (at their previous dose) or placebo (given in identical form to ensure masking)
224242673|NCT00115726|DRUG|placebo|patients will be given placebo capsules (identical to experimental arm in color) at the equivalent dose as to their chronic furosemide therapy.
224242674|NCT03601637|DRUG|LUM|Fixed Dose Combination (FDC) granules (LUM/IVA).
224242675|NCT03601637|DRUG|IVA|FDC granules (LUM/IVA).
224242676|NCT01497652|DRUG|Rasagiline/Placebo|Will receive placebo pills each day for the entire 14 weeks.
224242677|NCT01497652|DRUG|Rasagiline|0.5 mg for two weeks, then 1 mg for 12 weeks.
224242678|NCT03797547|OTHER|AFLIBERCEPT|Patients will be treated following a real life protocol and according to the French recommendation
224242679|NCT03164889|DRUG|Granulocyte Macrophage-colony Stimulating Factor|The intervention drug was used as an immunomodulator in order to improve rates of HBsAg loss and HBeAg loss.
224242680|NCT03164889|DRUG|Entecavir|Antiviral drug for hepatitis b virus (HBV)
224242681|NCT05872217|OTHER|conventional upper extremity therapeutic program|"• This group will receive conventional UE therapeutic program for 60 minutes each session including:~* Exercises based on neurodevelopment technique .~* Gentle manual stretching for tight muscles of the affected UE from proximal to distal segments for 5minutes.~* Weight-bearing exercises for 10minutes for UE from prone lying, side sitting and quadriped position.~* Strengthening exercises for 10 minutes for muscles of UE as push-up from prone lying position, quadriped position, 3 point exercise, walk on hand, climbing, hanging on a bar, squeeze stress balls, cutting usescissors to strengthen hand .~* Goal directed training for 10 minutes the child will practice specific tasks that are needed for everyday life and which they find a challenge like (3 daily tasks as cleaning mirror, dressing and undressing, using pen and ruler to draw shapes, brushing teeth .~* Fine motor activities as reach, grasp, carry and release activities."
224242682|NCT05872217|OTHER|full immersive VRapeutic software gaming technology|• Children in this group will receive the same conventional UE therapeutic program as control group for 60 minutes in addition to virtual reality session using VRapeutic software gaming technology, Archeeko module (figure 3) for 30 min/3 sessions/week for 8 weeks
224242683|NCT01854008|OTHER|rehabilitation more the urban circuit|"included in a standard rehabilitation program + the urban circuit. A total of 32 urban walking circuits were developed jointly with the town hall of Mataró(124,000 in habitants)and were included in a triptych called A PEU, FEM SALUT! Itineraris urbans per Mataró http://www.mataro.cat/web/portal/ca/salut/salut\_publica/itineraris/index"
224242684|NCT01854008|OTHER|rehabilitation program but not given urbane circuits|Only rehabilitation program and general recommendations on physical activity and lifestyle . No urbans circuits.
223662513|NCT07145658|DIETARY_SUPPLEMENT|Placebo Capsule(s)|Placebo - identical capsules containing inert colour matched power
223662514|NCT07145658|DIETARY_SUPPLEMENT|multivitamin|20-ingredient multivitamin
223662515|NCT07145593|DEVICE|Application tACS- 80 Hz|In this study, a single 20-minute session of tACS will be administered over the bilateral dorsolateral prefrontal cortex (DLPFC) at various gamma frequencies (80 Hz).The anodal surface electrode will be placed over the left DLPFC (F3 according to the 10-20 system), and the cathodal electrode over the right DLPFC (F4).
223662516|NCT07145593|DEVICE|Application tACS -40 Hz|In this study, a single 20-minute session of tACS will be administered over the bilateral dorsolateral prefrontal cortex (DLPFC) at gamma frequencies (40 Hz). The anodal surface electrode will be placed over the left DLPFC (F3 according to the 10-20 system), and the cathodal electrode over the right DLPFC (F4).
223662517|NCT07145593|DEVICE|Application TACS - (6-80 Hz)|In this study, a single 20-minute session of tACS will be administered over the bilateral dorsolateral prefrontal cortex (DLPFC) at theta- gamma coupling frequencies ( 6-80 Hz). The anodal surface electrode will be placed over the left DLPFC (F3 according to the 10-20 system), and the cathodal electrode over the right DLPFC (F4).
224242685|NCT05107323|BEHAVIORAL|Compassionate Mind Training for Teachers|Compassionate Mind Training for Teachers is a biopsychosocial evidence-based approach that aims to foster compassion, affect regulation, prosocial qualities and wellbeing in teachers.
224242686|NCT04756752|OTHER|Fit and Vitaal program|Intervention type: training
224242687|NCT00736970|DRUG|ridaforolimus|10 mg oral tablets administered at 40 mg once daily for 5 consecutive days each week, followed by 2 days without ridaforolimus.
223662518|NCT07145593|DEVICE|Application TACS- Individual Gamma Hz|In this study, a single 20-minute session of tACS will be administered over the bilateral dorsolateral prefrontal cortex (DLPFC) at individual gamma frequencies . The anodal surface electrode will be placed over the left DLPFC (F3 according to the 10-20 system), and the cathodal electrode over the right DLPFC (F4).
223662519|NCT07145593|DEVICE|Application TACS- Sham|In this study, a single 20-min tACS session will be applied over the bilateral dorsolateral prefrontal cortex (DLPFC) in a sham application. The anodal surface electrode will be placed over the left DLPFC (F3 of the 10-20 system) and the cathodal electrode will be placed over the right DLPFC (F4).
223662520|NCT07146451|OTHER|Self-administered parental questionnaire|A self-administered parental questionnaire, completed online or on paper, to assess different dimension of neurodevelopment
224242688|NCT00736970|DRUG|trastuzumab|single intravenous infusion every week; initial dose of 4 mg/kg over 90 minutes, then 2 mg/kg over 30 minutes
224242689|NCT00206583|DRUG|EV/DNG (Qlaira, BAY86-5027, SH T00658ID)|GA: Estradiolvalerate (EV)/Dienogest (DNG) Tablet p.o. (oral) Tablet, p.o. (oral)
224242690|NCT03003871|DEVICE|Powered toothbrush|Oral-B® AdvancePowerTM 400 series
224242691|NCT03003871|DEVICE|Manual toothbrush|Oral-B® Pro-Health All-In-One
224242692|NCT03003871|OTHER|Toothpaste|Colgate Maximum Cavity Protection®
224242693|NCT03003871|OTHER|0.2% chlorhexidine gluconate mouth rinse|CorsodylPTMP
224242694|NCT05088005|PROCEDURE|Hyperbaric oxygen therapy|Patients with any symptoms and signs were treated with HBO2. During the first HBO2, initial compression was performed to 2.8 atmospheres absolute (ATA) for 45 min, followed by 2.0 ATA for 60 min. If an additional HBO2 was possible within 24 h, then 2.0 ATA was administered for 90 min.
224242695|NCT04715477|BEHAVIORAL|Hospital Anxiety Depression Measure|Hospital Anxiety Depression Measure
224242696|NCT00479258|DRUG|Inhaled insulin (Exubera)|Inhaled insulin with dose adjusted according to premeal blood glucose
224242697|NCT00479258|DRUG|Subcutaneous Insulin (subject's prescribed)|Subcutaneous insulin with dose adjusted according to premeal blood glucose
223662521|NCT07146451|OTHER|A short psychological assessment performed online|"NEMI-3: an intelligence test administered by a psychologist measuring a fluid and crystallised intelligence. The test consists of 117 spoken and visual questions, for a total administration time of 45 min. Results are expressed in the form of standard indices (mean 100, standard deviation 15) that facilitate comparisons with the results obtained on other intelligence scales.~Results will be classified as normal, mild delay (between 1 and \<2 standard deviation \[SD\] below the mean) or severe delay (≥2 SD)."
223662522|NCT07146256|OTHER|Non-interventional observational study|No intervention will be studied
223662523|NCT07146737|DIAGNOSTIC_TEST|Corneal tomography generation model after ICL surgery|The ICL procedures collected would be assessed by the corneal tomography generation model. The performance of the model would be assessed, including accuracy,AUC, sensitivity and specificity.
223769808|NCT04871607|BIOLOGICAL|Yttrium Y 90 Basiliximab|Given IV
223769809|NCT06460168|OTHER|Mulligan(MWM) MobilizationTechnique|"Mulligan Mobilization program in MWM , a therapist-applied pain free accessory gliding force combined with active movement.~No Of Sessions Per Week: 3 Per Weeks for 6 weeks (50 Min per Session) No of repetitions; 3 sets for 10 repetitions with 1 minute rest between sets."
224242698|NCT00373217|BIOLOGICAL|MAGE-A1, Her-2/neu, FBP peptides ovarian cancer vaccine|Given intradermally or subcutaneously
224242699|NCT00373217|BIOLOGICAL|tetanus toxoid helper peptide|Given intradermally or subcutaneously
224242700|NCT00373217|DRUG|carboplatin|Given IV
224242701|NCT00373217|DRUG|paclitaxel|Given IV
224242702|NCT00373217|PROCEDURE|conventional surgery|Patients undergo primary optimal cytoreductive surgery
224242703|NCT05033834|OTHER|covid-19 vaccines registered in Egypt|Astra Zeneka vaccine, Sinopharm vaccine, Sinovac vaccine, Jonson and Jonson vaccine, Spotnic V vaccine
224242704|NCT06278545|DRUG|modified FOLFORINOX|"One treatment every 14 days :~* Irinotecan 180mg/m² as a 2-hour IV infusion~* Oxaliplatin 85 mg/m² as a 2-hour IV infusion~* Folinic acid 400 mg/m² as 2-hour IV infusion, in Y with oxaliplatin~* 5-FU 2400 mg/m² as a continuous IV infusion over 46 hours"
224242705|NCT06278545|DRUG|Modified FOLFOX|"One treatment every 14 days:~* Oxaliplatin 85 mg/m by IV infusion over 2 hours~* Folinic acid: 400 mg/m² or 200 mg/m² if laevorotatory form by IV infusion over 2 hours, in Y with oxaliplatin~* 5FU bolus: 400 mg/m² per 10-minute IV infusion~* 5 FU continuous 2400 mg/m² by IV infusion over 46 hours"
224242706|NCT03141398|DIAGNOSTIC_TEST|Continuous Glucose Monitoring (CGM)|Where a pager-sized device fixed to the patient's forearm by a diabetic educator and it will connect to his/her body with the sensor, which measures blood glucose for three days. Patients' may experience little pain from needle prick when a sensor is introduced.
224242707|NCT03141398|DIAGNOSTIC_TEST|Oral Glucose Tolerance Test (OGTT)|Oral glucose tolerance test requires the patient to be fasting and checking of blood sugar after 8 to 10 hours overnight fasting the blood sugar will be checked three times When you arrive to the lab then twice one hour, apart you can have pain due to needle prick or little bleeding at the puncture site.
224242708|NCT03141398|DIAGNOSTIC_TEST|T2* MRI of the Pancreas|MRI \[Magnetic resonance imaging\] of the pancreas which is safe and takes around 30 minutes.
224242709|NCT02942953|DEVICE|Diaphragmatic Pacer|The surgical procedure of DP implantation consists in placing four intramuscular electrodes, using a conventional abdominal laparoscopy with four ports. It consists in locating the optimum point for electrode insertion. The process involves mapping between 30 and 50 different points in each hemidiaphragm by applying an electric stimulus of 2-24 mA at 100 µsec pulse widths11. It results in both qualitative and quantitative assessment of diaphragmatic movement. Site of main electrode is identified as the location of each hemidiaphragm's change of maximum pressure and site of secondary electrode as replica of main site. Once the sites are identified intramuscular electrode placement phase is initiated. Finally the electrodes are tunneled out to the corresponding percutaneous exit site.
224242710|NCT03456947|DRUG|Pregabalin|the patients receive 150mg or 300mg pregabalin 60 minutes prior to the surgery
224242711|NCT03073330|DIAGNOSTIC_TEST|GDM screening with 75 g 2 hour GTT|Patients will be diagnosed with gestational diabetes if they have one abnormal value: Fasting ≥ 92; 2 hour ≥ 180 mg/dl;1 hour ≥ 153 mg/dl.
224242712|NCT03073330|DIAGNOSTIC_TEST|GDM screening with two step approach|1 hour glucola with 50 g glucose load followed by 100 g glucose load if 1 hour glucola positive
224242713|NCT02126137|DRUG|Ezetimibe|
223662524|NCT07145671|OTHER|Transition program|"Transition Consultation:~Pediatric HCP introduces the transition process to AYA and family. A contact person is assigned (ideally the AYA's trusted HCP), along with someone from the AYA's personal network. Key points are recorded in the Individualized Transition Plan (ITP).~Independent Visit:~AYA has a solo consultation (parents briefly step out). They complete the Ready Steady Go checklist. The ITP is updated, and concerns are discussed.~Joint Consultation:~Pediatric and adult HCPs meet with the AYA. A new adult contact is assigned, and the AYA picks a pediatric contact for feedback. Checklist is completed again.~Feedback Moment:~After transfer, the pediatric contact checks in. The checklist guides discussion; feedback is shared across teams, and follow-up arranged if needed."
223662525|NCT07145307|DEVICE|Sidekick|An app for adolescents used to plan, complete and evaluate exposure exercises completed between sessions at a children and adolescent mental health clinic (BUP)
223662526|NCT07145281|DRUG|Estradiol (E2)|"Participants receive estradiol 2 mg/day. In the experimental arm, estradiol is administered sublingually in four divided doses (0.5 mg each).~In the active comparator arm, estradiol is administered orally, in combination with cyproterone acetate, for 6 months.~All participants are treatment-naive."
223662527|NCT07145281|DRUG|Cyproterone Acetate (Androcur, BAY94-8367)|"Participants in the active comparator arm receive cyproterone acetate (CPA) 10 mg orally, once daily, in combination with oral estradiol, for 6 months.~All participants are treatment-naive."
223662528|NCT07145684|BEHAVIORAL|A culturally tailored medical nutrition therapy|This MNT intervention combines evidence-based menu plans based on the 4A framework of food security with individual nutrition counseling and group diabetes education.
223662529|NCT07145606|BEHAVIORAL|Standard Rehabilitation|Standardized postoperative ACL rehabilitation only. Begins \~2 weeks after surgery; supervised \~3 sessions/week for 6 weeks. Includes progressive range of motion, quadriceps activation/strengthening, functional drills, and return-to-activity progressions delivered per protocol.
224242714|NCT02185872|OTHER|High-Intensity Functional Training|Participants were instructed to work as hard as they could while maintaining safe technique and proper form to achieve as many reps or rounds as possible in the prescribed time frame. As HIFT participants became accustomed to specific movements, less time was dedicated to practicing movements and technique.
224242715|NCT02185872|OTHER|Aerobic and Resistance Training|The protocol was based upon current guidelines of 150 minutes moderate-intensity aerobic activity and 2 days of muscle strengthening per week.
224242716|NCT02236494|BEHAVIORAL|Brief Negotiated Interview|As per arm
224242717|NCT02236494|BEHAVIORAL|General Health Information|As per arm (this is the active comparator)
223662530|NCT07145606|BEHAVIORAL|Blood Flow Restriction (BFR) Training|Low-load resistance exercises performed with individualized limb occlusion pressure (LOP) determined each session; target %LOP per protocol. Progresses from isometric to dynamic open/closed-chain tasks. Delivered under supervision \~3 sessions/week for 6 weeks; monitoring of tolerance and adverse events per safety LOP.
223662531|NCT07145606|BEHAVIORAL|sEMG Biofeedback|Real-time surface electromyography biofeedback to optimize quadriceps recruitment during targeted tasks (e.g., isometric contractions, straight-leg raise, sit-to-stand, mini-squat, gait drills). Visual and/or auditory feedback with progressive targets. Supervised \~3 sessions/week for 6 weeks; outcome assessors remain blinded.
223662532|NCT07146139|DEVICE|MyPrEP Plus Package|Participants receiving the MyPrEP Plus Package will utilize the interactive MyPrEP website to learn about PrEP and the various kinds of PrEP available as well as information about Doxy-PEP. While on PrEP, participants will be able sign up for PrEPmate, a tool designed to support PrEP adherence.
224242718|NCT03726866|DRUG|Sequence 1|D326, D337 or CKD-828 for 9 days
223662533|NCT07146139|BEHAVIORAL|Standard of Care (SOC)|Participants in the control condition will receive PrEP support according to local standard of care while using the website pleaseprepme.org.
223662534|NCT06946979|OTHER|Spinal Manipulation|"Spinal Manipulation Therapy The treatment consists of two standardized steps: tendon adjustment techniques and bone-setting techniques.~The total duration for both steps is approximately 15 minutes, conducted three times per week for two consecutive weeks."
223662535|NCT06946979|OTHER|Medication|Patients in both groups will receive celecoxib (one tablet, twice daily) for two weeks, with detailed records maintained.
223662536|NCT06946303|OTHER|Survey|Pre and post survey on confidence and knowledge of falls
224242719|NCT03726866|DRUG|Sequence 2|D326, D337 or CKD-828 for 9 days
224242720|NCT03726866|DRUG|Sequence 3|D326, D337 or CKD-828 for 9 days
224242721|NCT03726866|DRUG|Sequence 4|D326, D337 or CKD-828 for 9 days
224242722|NCT03726866|DRUG|Sequence 5|D326, D337 or CKD-828 for 9 days
223662537|NCT06946303|OTHER|Interview|Interview on the learning from the falls ambassador programme
223662538|NCT06946303|OTHER|Observation|Observation of falls ambassador workshops
223769810|NCT06460168|OTHER|Maitland Mobilization technique|"will receive (Maitland mobilization program manipulative physiotherapy in which chain of oscillatory joint mobilization grades l-lV based on the pathological limit of tissue are used) In this, the exercises will be performed in 3 sets and 10 repetitions with 5-10s hold and 30s to 1min rest between repetitions.~No Of Sessions Per Week: 3 Per Weeks for 6 weeks (50 Min per Session)"
223769811|NCT05112835|OTHER|brolucizumab|There is no treatment allocation. The decision to administer brolucizumab is made by the treating physician independent of the study, prior to the inclusion of the patient into the study
224242723|NCT03726866|DRUG|Sequence 6|D326, D337 or CKD-828 for 9 days
224242724|NCT02822820|DEVICE|Ligasure-Covidien|Vessel sealing device Ligasure-Covidien used during laparoscopic hysterectomy and pelvic lymphadenectomy
224242725|NCT02822820|DEVICE|RoBi forceps-Karl Storz|Vessel sealing device RoBi forceps-Karl Storz used during laparoscopic hysterectomy and pelvic lymphadenectomy
224242726|NCT02403791|DEVICE|Linear Ultrasonic Sounder|Lung ultrasound evaluation is performed after clinical assessment and before chest radiography
224242727|NCT02403791|DEVICE|Bedside X-ray Machine|Chest Radiography is performed after clinical evaluation without using ultrasound assessment.
224242728|NCT01796886|OTHER|pupillometry data|
224242729|NCT06410222|PROCEDURE|Recurrence after undergo spinal cord stimulation|"1. To investigate the pain relief and recurrence of patients with herpes zoster neuralgia after spinal cord stimulation treatment.~2. To analyze the risk factors related to recurrence after spinal cord stimulation treatment in patients with herpes zoster neuralgia, and build a recurrence prediction model."
224242730|NCT06366581|DIAGNOSTIC_TEST|Transcriptomic analysis|high-throughput sequencing technology
224242731|NCT03744364|DRUG|Misoprostol 25 mcg|To determine efficacy and safety of vaginal 'Misoprostol 25 mcg' every 4 hours with a maximum of 6 doses for induction of labor.
224242732|NCT03744364|DRUG|Dinoprostone 10mg|To determine efficacy and safety of 'Dinoprostone 10mg' vaginal insert for induction of labor.
223662539|NCT06947239|PROCEDURE|Mirror therapy along with conventional therapy|"The experimental group will receive 20 minutes of conventional therapy followed by 20 minutes of mirror therapy training including 3 minutes of rest period between the interventions.~WEEK OF INTERVENTION:~TASK PERFORM IN FRONT OF MIRROR:~WEEK :1-2~ACTIVE SHOULDER ROM:~flexion, abduction, external-internal rotation movements of the intact extremity~Increase the number of repetition according to the patient progression~WEEK:3-4~ACTIVITIES TARGETING SHOULDER ROM:~Cleaning the mirror with a towel(internal rotation+ abduction)~Lifting a glass to drink ( flexion + abduction)~Holding a brush to comb hair (external rotation~WEEK:5-6~Overhead reaching~(pasting stickers on the~mirror)(internal rotation~/ abduction)~Lifting a bottle overhead.~( flexion/abduction)~Throwing a ball (external~rotation)~PROGRESSION OF TASK SPECIFIC MIRROR THERAPY:~WEEK: 1-2 Increase the number of repetition according to the patient progression WEEK:3-4 Add water in glass Transfer glass"
223662540|NCT06947239|PROCEDURE|Control Group|"Details: Weeks wise:~The control group will receive 20 mints of conventional therapy .~1. Heat pack \& TENS to alleviate pain for 15 minutes~2. Shoulder isometric exercises 10 reps~3. Active and passive Range of Motion exercises 10 reps each~4. Codman exercises 10 reps each~5. Wand exercises 10 reps each"
223662541|NCT06946563|DEVICE|Fetoscopic Neural Tube Defect Repair Devices|Fetoscopic NTD repair will be performed on enrolled participants. An incision will be made to gain exposure and access to the uterus. The amniotic cavity is entered using a needle to administer fetal anesthesia. Then, the initial trocar is inserted into the amniotic cavity. The major steps of the procedure are neural placode dissection, myofascial flaps creation, and closure of the neural tube defect.
223662542|NCT06946095|DRUG|Chinese patent medicine|This study aims to investigate whether the addition of Xinyue Capsule to conventional Western medical therapy significantly improves cardiac function and reduces the level of heart failure biomarker NT-proBNP in patients with Heart Failure with Preserved Ejection Fraction (HFpEF).
223662543|NCT06946719|OTHER|pulp lavage Octenidine|Use of Octenidine as a pulp irrigation solution in pulp capping for mature permanent teeth
223662544|NCT06946719|OTHER|pulp lavage NaOCl|Use of NaOCl as a pulp irrigation solution in pulp capping for mature permanent teeth
223662545|NCT06946134|OTHER|FIT SA|self-adhesive flowable giomer restorative material
223662546|NCT06946134|OTHER|Beautifil Flow Plus F00|Conventional flowable giomer restorative material
223662547|NCT06947616|DRUG|Mild therapeutic hypothermia|Patients received mild therapeutic hypothermia (MTH) to 33°C for 24-36 h
223662548|NCT06947733|BEHAVIORAL|pre-class videos|This project aims to evaluate the impact of pre-class videos on enhancing ultrasound teaching effectiveness, particularly comparing videos shot with a first-person perspective (POV) to those shot with a face-to-face perspective.
223662549|NCT06947733|BEHAVIORAL|no pre-class videos|the control group (who will not watch any videos)
223662550|NCT06947330|PROCEDURE|Unilateral Erector Spinae group|On injecting 30 ml of bupivacaine 0.25% with 20 mcg Dexamedetomidine into the interfacial plane below erector spinae; a manifest linear pattern will be visualized uplifting the muscle.
224242733|NCT00003114|BIOLOGICAL|filgrastim|Filgrastim (granulocyte colony-stimulating factor) is given subcutaneously on days 5-21 and 33-42.The course is repeated every 6 weeks. A complete or partial response after 1 course of treatment receive two additional courses, but lomustine is omitted in the second course.
224242734|NCT00003114|DRUG|cyclophosphamide|Oral cyclophosphamide on days 22-31. The course is repeated every 6 weeks. A complete or partial response after 1 course of treatment receive two additional courses, but lomustine is omitted in the second course.
224242735|NCT00003114|DRUG|etoposide|Oral etoposide on days 1-3. The course is repeated every 6 weeks. A complete or partial response after 1 course of treatment receive two additional courses, but lomustine is omitted in the second course.
224242736|NCT00003114|DRUG|lomustine|Patients receive oral lomustine on day 1.
224242737|NCT00003114|DRUG|procarbazine hydrochloride|Oral and procarbazine on days 22-31. The course is repeated every 6 weeks. A complete or partial response after 1 course of treatment receive two additional courses, but lomustine is omitted in the second course.
224242738|NCT00003114|RADIATION|radiation therapy|Patients with partial response or stable disease receive radiation therapy and/or continued chemotherapy.
224242739|NCT04826679|DRUG|Camrelizumab, nab-paclitaxel, cisplatin|"Patients receive Camrelizumab IV on day 1, nab-paclitaxel IV on day 1 and cisplatin IV on day 1.~Treatment repeats every 21 days for up to 3 courses in the absence of disease progression or unacceptable toxicity."
223662551|NCT06947330|PROCEDURE|Unilateral Serratus Anterior group|Once the needle will be in perfect position, confirmed by hydro-dissection on injecting 2-3 ml of normal saline, then 30 ml of bupivacaine 0.25% with 20 mcg Dexamedetomidine.
224242740|NCT01662284|DRUG|124I-NM404|124I-NM404 administered at either 5mCi or 3mCi on day 1. If PET/CT images are diagnostically inadequate and there are no dose-limiting toxicities at current dose, next patients will receive the next higher level of 7.5 or 10 mCi.
224242741|NCT05059249|PROCEDURE|Hot Pack|Superficial Heating
224242742|NCT05059249|PROCEDURE|Manual Traction|Manual Traction for 10 minutes
224242743|NCT05059249|PROCEDURE|Mechanical Traction|Mechanical Traction for 10 minutes
224242744|NCT05059249|PROCEDURE|Joint Mobilization|3 sets of slow gentle segmental mobilizations (unilateral and posterior-anterior) with at least 10 to 15 repetitions
224242745|NCT05059249|PROCEDURE|TENS|TENS for 10 minutes with hot pack
224242746|NCT05221242|PROCEDURE|Conventional Resin Cement vs Preheated Resin Composite|For this study, variolink esthetic resin cement will be used to bond ceramic partial laminate veneers in one side of the maxillary anterior teeth (left or right upper incisors and canines), while, the other side will receive ceramic partial laminate veneers bonded with a preheated resin composite
224242747|NCT05125419|DIAGNOSTIC_TEST|Homocysteine level|diagnostic test
224242748|NCT01012635|OTHER|Hypnosis|Hypnosis Training: Verbal suggestions from an audio recording (via headphones).
224242749|NCT01012635|OTHER|Meditation|"Meditation: focus on a single word (one) for the entire session."
223662552|NCT06946017|DIETARY_SUPPLEMENT|Fermented dairy protein with prebiotic fiber supplement|Both the intervention and placebo products contain a serving of 15g with \~53Kcal, 0.5g Fats, 5g Carbohydrate, 7.5g Protein that need to be dissolved as powder in water in a protein shaker that will be provided. The intervention product contains whey protein concentrate and a prebiotic fiber. All ingredients that are designated by the FDA as Generally Recognized as Safe (GRAS). Participants will be asked to take the supplement daily before breakfast.
223662553|NCT06946017|DIETARY_SUPPLEMENT|Control placebo|Both the intervention and placebo products contain a serving of 15g with \~53Kcal, 0.5g Fats, 5g Carbohydrate, 7.5g Protein that need to be dissolved as powder in water in a protein shaker that will be provided. The placebo product is calorically matched to the intervention product and the main ingredients are protein and carbohydrate. All ingredients that are designated by the FDA as Generally Recognized as Safe (GRAS). Participants will be asked to take the supplement daily before breakfast.
223662554|NCT06946342|BEHAVIORAL|"Aquatic Exercise Group"|"Structured WATERinMOTION aquatic exercise program (3x/week for 8 weeks) in a heated pool (30-32°C), including warm-up, aerobic conditioning, resistance training with water equipment (e.g., dumbbells, noodles), and cool-down. Sessions are group-based and led by certified instructors."
223662555|NCT06946342|BEHAVIORAL|"Land-Based Rehabilitation Group"|"60-minute land-based sessions (3x/week for 8 weeks), including core stabilization, low-impact aerobics, and stretching."
223662556|NCT06946706|DIAGNOSTIC_TEST|hydrogen and methane breath testing|The hydrogen and methane breath testingt(HMBT) is a non-invasive method based on gas analysis of gut microbiota metabolomics.Normal human metabolic processes do not produce methane and hydrogen, and all methane and hydrogen in exhaled breath come from metabolites produced during the fermentation of substrates by gut microbiota. About 14-21% of the gas can diffuse through the intestinal mucosa to the bloodstream, circulate through the bloodstream to the alveoli, and be exhaled through gas exchange.Based on substrate properties, separate and measure methane and hydrogen concentrations from exhaled breath for non-invasive, convenient, and accurate diagnosis of microbial imbalance/small intestine bacterial overgrowth (SIBO)
223662557|NCT06946849|RADIATION|radiotherapy|Radiotherapy
223662558|NCT06946849|DRUG|FOLFIRI or FOLFOX or Regorafenib|FOLFIRI or FOLFOX or Regorafenib
223662559|NCT06947057|PROCEDURE|Guided implant placement|The four types of fully guided surgical guides (bilateral tooth-supported guides, unilateral tooth-supported guides, mucosa-supported full arch guides and stackable guides)
223662560|NCT06947096|DIAGNOSTIC_TEST|Radiomics-Based AI Imaging Analysis|This intervention involves the development and application of a radiomics-based artificial intelligence (AI) model to analyze preoperative abdominal CT images of patients with gastric cancer. The AI algorithm extracts high-dimensional imaging features from the para-aortic region to predict the presence or absence of para-aortic lymph node metastasis (PALNM). This non-invasive method aims to assist clinicians in preoperative risk stratification and treatment planning. The model will be trained and validated using manually segmented lymph node regions and correlated with postoperative pathological findings to ensure accuracy and clinical relevance.
223662561|NCT06946381|PROCEDURE|Evar|Branch Evar with the e-liac device
223662562|NCT06946732|DEVICE|Acostream aspiration|The pulmonary thrombus removal by Acostream.
223662563|NCT06946420|RADIATION|SBRT or RT on primary pancreatic and/or metastatic distant lesions before chemotherapy|This group of patients will first undergo radiotherapy on the primary pancreatic lesion and stereotactic treatment on the metastatic sites before being started on standard systemic therapy (chemotherapy)
223662564|NCT06946420|DRUG|Standard systemic therapy (chemotherapy) without RT/SBRT|This group of patients will undergo standard systemic therapy (chemotherapy drugs chosen by oncologist) without radiotherapy treatment
223662565|NCT06947070|PROCEDURE|To evaluate the surface topography and color stability of 3D printing provisional material.|Subjects with single stage implant placement followed by early non-functional loading with implant supported provisional restorations fabricated using 3D printing provisional material.
223769812|NCT05160805|DRUG|ONL1204 Ophthalmic solution (Dose A)|Liquid formulation administered by intravitreal (IVT) injection
223769813|NCT05160805|DRUG|ONL1204 Ophthalmic solution (Dose B)|Liquid formulation administered by intravitreal (IVT) injection
223769814|NCT05160805|PROCEDURE|Sham procedure|A sham procedure looks like a real injection into the eye but does not penetrate the eye and it does not have any study drug. The procedure is done by touching the eye surface with a syringe without a needle.
224242750|NCT01012635|OTHER|Neurofeedback training|Neurofeedback Training: Two electrodes will be placed on your scalp, and one electrode clipped on your head. There is no risk of electrical shock.
224242751|NCT01012635|OTHER|Two different levels of tDCS|Direct stimulation of the brain by using a weak electrical current. There is no risk of electrical shock.
224242752|NCT01542190|DRUG|Ketorolac Tromethamine|ketorolac tromethamine 0.4%
224242753|NCT05926570|DRUG|Cinacalcet|calcimimetic
224242754|NCT02407275|OTHER|Biological sample|
223769815|NCT04846140|DEVICE|transcranial electrical stimulation (tES)|Transcranial electrical stimulation (tES) is a form of neuromodulation that uses constant, low direct current delivered via the electrodes on the skull. Three types of tES will be applied in this study, include a-tDCS, tACS, and tRNS. Additionally, sham stimulation will be applied as a placebo-controlled intervention.
223769816|NCT06331208|DIAGNOSTIC_TEST|non-contrast chest CT|patients who undergo clinically indicated evaluation of pulmonary circulation (right heart catheterisation - RHC) will undergo non-contrast CT of the chest, blood sampling from pulmonary artery and spirometry with DLCO analysis.
224242755|NCT01356693|DRUG|Bromelin|Ananas comosus extract (3,3g) on vehicle: methylparaben, propylparaben, honey from Apis mellifera, sodium benzoate, ethilic alcohol, water) 5ml. Given in single dose.
224242756|NCT01356693|DRUG|Placebo|Placebo with mimicking characteristics of experimental drug
224242757|NCT04715152|DRUG|ACB group|Patients will receive ultrasound-guided (USG) ACB with bupivacaine and dexamethasone 30 minutes before spinal anesthesia and sham intra-articular normal saline
224242758|NCT04715152|DRUG|IA group|Patients will receive intra-articular bupivacaine and dexamethasone at the end of surgery and sham USG-ACB with normal saline
224242759|NCT00528905|DRUG|AZD3480|oral capsule
224242760|NCT01630733|DRUG|Custirsen|Custirsen: Three loading doses of custirsen 640 mg IV over 2 hours administered in 5 to 9 days prior to Day 1 of Cycle 1, then custirsen 640 mg IV weekly every 21-day cycle
223662566|NCT06946459|OTHER|Exercise|Participants in the Hip Strength Exercise Training group performed structured hip strengthening exercises using resistance bands in addition to their regular handball and strength training programs. The training was implemented three times per week for 8 weeks, with one rest day between sessions, and was conducted before regular handball practices. The exercises focused on activating and strengthening the hip muscles through simple, well-structured movements. Resistance bands were chosen due to their portability, cost-effectiveness, and suitability for adolescent athletes. This method ensured a safe training environment, reduced the risk of overload, and allowed for proper execution and control of the exercises.
223662567|NCT06947759|RADIATION|PET/MRI|"This single-center prospective observational study targets patients pathologically diagnosed with nasopharyngeal carcinoma (NPC) and clinically staged as cT3-4/N2-N3. Participants will first undergo standard whole-body 18F-FDG PET/CT, followed by localized 18F-FDG PET/MRI of the head and neck within 4 hours. Both imaging procedures will be performed according to standard clinical protocols to ensure data consistency and comparability.~PET/MRI data will be independently interpreted by an experienced nuclear medicine physician and a radiologist. The sensitivity, specificity, and staging accuracy for detecting distant metastases will be analyzed. In cases of disagreement, a third physician will mediate to reach a consensus.~The study team will also record the operational time, direct costs, and potential issues encountered during the examination process for both imaging modalities. All participants will be followed for at least one year to validate imaging results and assess correlation"
223662568|NCT06947590|DRUG|mavacamten|Patients in this group were treated with Mavacamten, starting at an initial dose of 2.5 mg, administered orally once daily. Subsequent doses were adjusted based on changes in pressure gradients and cardiac function observed during follow-up.
223662569|NCT06947798|BEHAVIORAL|motivational interviewing|motivational interviewing four times
223662570|NCT06947798|OTHER|Diet|A calorie-restricted diet was implemented in both the intervention and control groups.
223662571|NCT06947798|BEHAVIORAL|Physical exercise|A moderate-intensity aerobic exercise program, consisting of 30-minute sessions five days per week, was implemented in both groups
223662572|NCT06946628|DRUG|Group A (triple combination therapy group)|1\) Initiate with Semaglutide 0.25 mg once weekly (qw) + Empagliflozin 10 mg once daily (qd) + Pioglitazone 15 mg once daily (qd); 2) After 1 month, if blood glucose is not controlled, adjust to Semaglutide 0.5 mg qw + Empagliflozin 20 mg qd + Pioglitazone 30 mg qd. If Semaglutide is well-tolerated, increase to 1 mg qw after 1 week; 3)If blood glucose remains uncontrolled after 1 month, add basal insulin therapy.
223662573|NCT06946628|DRUG|Group B (standard therapy group)|metformin-based treatment is recommended when not contraindicated. 1).Initiate with Metformin monotherapy, titrate to the target dose of 1000 mg twice daily (bid) within 1 month or to the maximum tolerated dose (if Metformin is not tolerated, switch to Linagliptin 5 mg qd); 2) After 1 month, if blood glucose is not controlled, add a second antidiabetic drug, Empagliflozin 20 mg qd; 3) After another month, if blood glucose remains uncontrolled, add Semaglutide 0.25 mg qw, then increase to 0.5 mg qw after 1 month. If well-tolerated, increase to 1.0 mg qw after 1 week; 4) If blood glucose remains uncontrolled after 1 month, add basal insulin therapy.
223662574|NCT07146971|DRUG|OTC Drug for Atopic Dermatitis in Cream form|OTC Cosmetic Cream Formulation
223662575|NCT06947005|BEHAVIORAL|Intervention 1|The students in the serious game group were asked to download the drug applications serious game to their phones. They were asked to play the game for two weeks. The students continued to play the game at any time and as often as they wanted until they won at least one gold medal for each application. At the end of the 2nd week, a questionnaire form and VAS scale were applied to the students to evaluate the post-test data and their satisfaction levels with the game. The collected data were analysed to understand the different dimensions of game satisfaction and to assess overall satisfaction levels.
223662576|NCT06947005|BEHAVIORAL|Intervention 2|A WhatsApp group was established to maintain communication with the students in the video-supported education group. After the pre-test data were collected, the students were introduced to the ed-puzzle web page where they could watch the application videos and were asked to register to the system. No fee was paid to register to the ed-puzzle web page. Students were given the opportunity to watch the videos on the ed-puzzle web page for 2 weeks and answer the questions. Each student was allowed to watch the videos at least once until they answered all the questions correctly. The number of videos watched was monitored by the researcher. At the end of the 2nd week, post-test data were collected from the students.
223662577|NCT06955195|BEHAVIORAL|School-based intervention program on improving adolescent mental wellbeing|Students participating in the intervention program will attend the school talk and workshops about mental health. They are also required to organize whole-school activities to promote peer mental wellbeing at school. All attended students will be guided by registered social workers and trained research personnel throughout the intervention program.
223662578|NCT06955195|OTHER|Control-no treatment|Students participating at control group will not receive intervention program during the academic year compared with their counterparts in active comparator group. They will live and attend the class as usual at school. After the academic year, they will receive the intervention program on the alternative academic year.
223662579|NCT07147088|DRUG|SHR-1701|SHR-1701 will be administered by IV, 1200mg on day 1 of each 21 day cycle until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
223662580|NCT07147088|DRUG|Famitinib|Famitinib will be administered at 15 mg orally daily until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
223662581|NCT07147088|PROCEDURE|Cryoablation|Cryoablation will be performed with a two-cycle freeze-thaw phase protocol; US or non-contrast CT images will be obtained to visualize the evolving ablation zone. SHR-1701 plus famitinib will be administered 1-3 days after cryoablation.
223769817|NCT06331208|DIAGNOSTIC_TEST|spirometry with diffusing lung capacity for carbon monoxide (DLCO) analysis|patients who undergo clinically indicated evaluation of pulmonary circulation (RHC) will undergo non-contrast CT of the chest, blood sampling from pulmonary artery and spirometry with DLCO analysis.
224242761|NCT01630733|DRUG|Docetaxel|Docetaxel: 75 mg/m2 IV over 1 hour on Day 1 of every 21-day cycle
224242762|NCT03329326|OTHER|Functional tests and self-reported questionnaires|In this observational study no intervention is initiated. Patients included are only assessed with the non-invasive tests described earlier.
224242763|NCT04411966|DIAGNOSTIC_TEST|18F-fluorothymidine|Patients receive fluorothymidine F-18 IV over 1 minute and undergo PET scan over 60 minutes at least 10 days prior to systemic chemotherapy, and at least 10 days after first and second cycles of systemic chemotherapy.
224242764|NCT02489526|DRUG|VVZ-149 Injections|Experimental group will receive a loading dose of 1.8 mg/kg VVZ-149 intravenous infusion for 0.5 hour followed by a maintenance dose of 1.3 mg/kg/h VVZ-149 intravenous infusion for 7.5 hours.
224242765|NCT02489526|DRUG|Placebo|Placebo group will receive the corresponding amount of placebo.
223662582|NCT07147010|DEVICE|MIB Breath Analyzer|"Going through visit-specific blood glucose excursions by the administration of glucose and insulin (clamp), monitoring physiological processes, and measuring reference blood glucose values and VOC measurements in the breath using a GC-IMS and the MIBs (investigational devices).~Going through visit-specific blood glucose excursions by consuming a standardized meal, monitoring physiological processes, and measuring reference blood glucose values and VOC measurements in the breath using a GC-IMS and the MIBs (investigational devices)~Imitating the glucose excursion from the meal excursion by infusing glucose and insulin (clamp), monitoring physiological processes, and measuring reference blood glucose values and VOC measurements in the breath using a GC-IMS and the MIBs (investigational devices)."
223769818|NCT06331208|DIAGNOSTIC_TEST|Omics analysis of blood plasma obtained from pulmonary artery or peripheral blood|patients who undergo clinically indicated evaluation of pulmonary circulation (RHC) will undergo non-contrast CT of the chest, blood sampling from pulmonary artery and spirometry with DLCO analysis.
223769819|NCT06331208|DIAGNOSTIC_TEST|supine bike exercise during right heart catheterisation|subgroup of HF subjects who undergo right heart catheterisation will perform short supine bike exercise during RHC
223769820|NCT06331208|DIAGNOSTIC_TEST|Lung ventilation/perfusion SPECT|subgroup of HF subjects will undergo ventilation/perfusion SPECT
224242766|NCT04040426|OTHER|Human split thickness skin allograft|Application of a fenestrated human skin graft
224242767|NCT04040426|OTHER|Additional Outer Dressing Applicaiton|Application of Moisture retentive dressing, and a multi-layer compression dressing
224242768|NCT04040426|OTHER|Offloading|Patient will be offloaded in a diabetic camboot after treatment, or total contact cast if patient cannot be fit with diabetic offloading boot
224242769|NCT04040426|OTHER|Fibracol Wound Dressing|Application of Collagen Alginate Dressing
224242770|NCT03261310|DRUG|Acetaminophen or Placebo|"Study subject will receive either 1000mg of acetaminophen in 100ml own diluent, or 100ml of saline during their intra-operative period and an order will be placed in their chart/Essentris order for No acetaminophen for 6 hours post operatively."
224242771|NCT03514420|DRUG|AKCEA-ANGPTL3-LRx|AKCEA-ANGPTL3-LRx solution for SC injection.
224242772|NCT04953676|PROCEDURE|round tunnel technique|Both the femoral tunnel and tibial tunnel were drilled by 8-mm cannulated drill
224242773|NCT04953676|PROCEDURE|flat tunnel technique|Both the femoral tunnel and tibial tunnel were dimension of 5×11-mm rounded-rectangular, which was created by initially drilling a round tunnel with a 5-mm cannulated drill and reshaped by use of a bone rasp and custom-made dilator.
223769821|NCT05511844|DRUG|ORM-5029|Intravenous infusion
223769822|NCT03533075|BEHAVIORAL|Teachable Moment Brief Intervention|Behavioral intervention informed by Collaborative Assessment and Management of Suicidality and Dialectical Behavior Therapy/Cognitive Behavior Therapy to assist in positive recovery trajectory following a suicide attempt
223769823|NCT04319315|OTHER|survey|online survey
223769824|NCT02214147|DRUG|Alisertib|Alisertib will be supplied as enteric coated tablets.
223769825|NCT03204942|DEVICE|PRF on DRG|RF will be performed with the patient in a prone position with mild flexion of the spine. Fluoroscopy beam positioned in an antero-posterior direction. A 10 cm RF needle 20 G with a 10 mm active tip.The needle is inserted in a slightly medial-cephalad direction under the transverse processes, and using lateral fluoroscopic imaging, incrementally walking into the thoracic intervertebral foramen. So the location of the needle tip confirmed by sensory stimulation at 50 Hz. The point of maximum stimulation is at 0.5 V intensity and this is designated to be the location of the DRG. Slight redirection can be done to optimize the stimulation; injection of contrast reveals epidural uptake. After establishing the site for the RF, 1 ml 2% lidocaine should be injected through the needle.
224242774|NCT03374462|BEHAVIORAL|Telemedicine Intervention|Home-based telemedicine visits
224242775|NCT02088463|PROCEDURE|mobilization (manual therapy)|mobilization is one of the manual therapy or treatments with the application of a gentle oscillatory passive movement to the spinal region specifically at the level of L3 in this study at the posterio-anterior direction.
224242776|NCT02088463|PROCEDURE|Placebo mobilization|placebo mobilization is a tactile stimulation at the same level L3 without application of any force.
224242777|NCT02088463|DEVICE|Ultrasound and infrared devices|ultrasound and infrared are the traditional treatment for low back pain , they are electrical modalities used in the field of physiotherapy to decrease the inflammation and the pain in musculoskeletal systems
224242778|NCT00630149|DRUG|Pemetrexed (Alimta)|500 mg/m2 in Cycle 1, every 3 weeks, with folic acid and vitamin B12 supplementation.
224242779|NCT01372033|BEHAVIORAL|Cognitive Behavioral Therapy|18 sessions of CBT, twice weekly
223769826|NCT03204942|DEVICE|TRF on DRG|"Similar to the group of  PRF on DRG, but the types of the waves will be different as previously described"
224242780|NCT01372033|BEHAVIORAL|Cognitive Behavioral Therapy|18 sessions with goals groups drug testing
224242781|NCT01507051|DRUG|Warfarin (Coumadin)|Days -6 and -5: 10 mg warfarin (Coumadin) once daily, dosage lower if the INR is already high on day -5; Days -4 to -1 (could be prolonged by two days): 2.5, 5, 10, 12.5 or 15 mg warfarin (Coumadin) once daily, dosage depending on INR
224242782|NCT01507051|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Days 0 to 3: 20 mg rivaroxaban once daily
224242783|NCT01507051|DRUG|Placebo|Days 0 to 3: 1 tablet placebo, identical to active tablet
224242784|NCT01507051|DRUG|Vitamin K (Konakion)|Day 5: 10 mg vitamin K (Konakion) once daily
224242785|NCT00371722|PROCEDURE|Appendectomy|
224242786|NCT05792072|DEVICE|rTMS|High-frequency rTMS
224242787|NCT05792072|DEVICE|Sham rTMS|sham rTMS
224242788|NCT03377894|PROCEDURE|blunt uterine incision expansion|blunt uterine incision expansion
224242789|NCT03377894|PROCEDURE|sharp uterine incision expansion|sharp uterine incision expansion
224242790|NCT00420303|DRUG|Etanercept|50 mg injection once weekly
224242791|NCT00420303|OTHER|Placebo|placebo
223662583|NCT07145541|DEVICE|Aion Tempshield Device|The AION BIOSYSTEMS, INC. tempshield is a skin-applied, continuous temperature monitor. It is battery powered, communicates using Bluetooth LE to a smartphone, then to a clinician dashboard, and is designed to be worn continuously for up to 60 days. Its primary use is for patient monitoring in hospital or post-discharge from a healthcare facility. Through the tempshield system, clinicians can be notified if a patient's temperature exceeds a given threshold. The tempshield system is centered around a non-invasive temperature sensor placed against the patient's skin, in the pectoral region just below the collar bone. The temperature sensor is held in place with a silicone adhesive tape similar to a custom shaped piece of medical tape. The silicone adhesive tape is hypoallergenic.
223662584|NCT07146594|DRUG|Modified bismuth-containing eradication treatment|"After the confirmation of Helicobacter pylori infection, eligible patients whether first line or rescue therapy will be assigned to receive:~\- A modified and optimized bismuth quadruple therapy that comprises: 40 mg of esomeprazole bid, amoxicillin 1g tds, metronidazole 500mg tds and bismuth subcitrate 240mg bid, all medications taken for 14 days.~Esomeprazole will be given at least 30 minutes before meals every 12 hours. Antibiotics will be given after meals every 8 hours and bismuth subcitrate at least 2 hours far from meals every 12 hours."
223662585|NCT07145554|OTHER|Focal extracorporeal schock wave therapy|Participants in this group will receive a total of 5 sessions of focal extracorporeal shock wave therapy. Each session will deliver 1000 pulses per cm² to the affected piriformis muscle.
223662586|NCT07145554|PROCEDURE|Steroid Injection|Participants in this group will receive a single injection of corticosteroid into the piriformis muscle.
223662587|NCT07146087|BIOLOGICAL|MSC-Derived Exosomes|Purified, sterile, acellular extracellular vesicles (exosomes) isolated from culture supernatant of GLP-manufactured allogeneic human bone-marrow-derived MSCs. Release criteria include particle size distribution 30-150 nm (nanoparticle tracking analysis), particle count, sterility/endotoxin testing, mycoplasma negative, and predefined protein/marker profile (e.g., CD9/CD63/CD81 positive).
223662588|NCT07146087|BIOLOGICAL|Placebo (Normal Saline)|0.9% sodium chloride solution matched to the experimental product in volume, appearance, infusion set-up, and administration procedures.
223769827|NCT03204942|DRUG|Corticosteroid injection|Similar to the previous groups, but without applying any type of Radio-frequency but just injecting steroids and local anesthetics as previously described
224242792|NCT01446094|DRUG|regadenoson|Intravenous administration of 0.4 mg dose of Regadenoson using per routine CMR, as indicated in the package insert.
224242793|NCT00000310|DRUG|Risperidone|
224242794|NCT02885285|BEHAVIORAL|Spinning Class|Spinning Class twice a week for six weeks.
224242795|NCT02885285|BEHAVIORAL|Yoga Class|Yoga Class twice a week for six weeks.
224242796|NCT02885285|BEHAVIORAL|Dance Class|Dance Class twice a week for six weeks.
224242797|NCT02885285|OTHER|No Exercise Class|No exercise class. Subject will continue regular activities for six weeks.
224242798|NCT02071303|DRUG|Tramadol|Tramadol 100mg will be given to 70 women before the procedure.
224242799|NCT02071303|DRUG|Celecoxib|Celecoxib 200mg will be given to 70 women before the procedure.
224242800|NCT02071303|DRUG|Placebo|A placebo will be given to 70 women before the procedure.
224242801|NCT05383794|OTHER|Observation of Evaluation of gingival crevicular fluid miRNA 7a-5p, miRNA 21-3p, miRNA 21-5p, miRNA 200b-3p, miRNA 200b-5p, miRNA 100-5p, miRNA 125-5p levels.|Evaluation of gingival crevicular fluid miRNA 7a-5p, miRNA 21-3p, miRNA 21-5p, miRNA 200b-3p, miRNA 200b-5p, miRNA 100-5p, miRNA 125-5p levels.
224242802|NCT01978743|DRUG|Raltegravir|Switch from Atripla to Raltegravir 400mg BID + Truvada (FTC/TDF) for total of 8 weeks
224242803|NCT01107093|DRUG|CDB-2914 (ulipristal acetate)|single oral dose of 30 mg
224242804|NCT01107093|DRUG|Placebo|single oral dose
224242805|NCT00745420|BIOLOGICAL|Hematopoietic Stem Cell Transplantation|"The stem cell transplant preparative regimen is listed below. Day 0 is the day of the transplant. The - sign is the number of days before and the + sign is the number of days after the transplant.~* Alemtuzumab: Children weighing 10 kg or more will receive 10 mg, 15 mg, and 20 mg intravenously (IV) on Days -21, -20, and -19, respectively~* Fludarabine: 30 mg/m\^2/day IV on Days -8 through -4~* Melphalan: 140 mg/m\^2 IV on Day -3~* Rest on Days -2 and -1~* Transplant occurs on Day 0~* GVHD prophylaxis: Tacrolimus or cyclosporine beginning Day -3, methotrexate (7.5 mg/m2/day) Day 1, 3 and 6 and methylprednisolone/prednisone on Day +7 to +28 followed by a taper if there is no GVHD"
224242806|NCT04598984|DIAGNOSTIC_TEST|serum adipokines|Level of serum adipokines will be measured with flow cytometry
223769828|NCT02316197|DRUG|MSC2490484A (M3814)|Participants received MSC2490484A capsules at escalated dose from 100 mg to 400 mg orally from Day 1 to Day 21 of each treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent, and/or occurrence of any criterion for withdrawal from study or M3814.
223769829|NCT01915277|DRUG|Dexmedetomidine|
223769830|NCT05234398|BIOLOGICAL|Blood and saliva samplings|At each protocol visits, on the occasion of a care collection, additional blood and saliva samples will be taken specifically for the study, with a total volume of blood of 38 mL, and a saliva sample of 1.5 to 2 mL per visit (inclusion, month 1, month 4, month 6, month 9 and month 12), corresponding to routine care.
224242807|NCT02264106|DRUG|Lefradafiban tablet|
224242808|NCT02264106|DRUG|Lefradafiban double chamber sachet|
224242809|NCT02264106|DRUG|Pantoprazole|
224242810|NCT02172105|DRUG|BI 1744 CL|
224242811|NCT02172105|DRUG|Placebo|
224242812|NCT00885456|BEHAVIORAL|PREVENT program|12-week program of aerobic/strengthening exercises and education designed to induce physiological and behavioral changes deemed necessary to reduce vascular risk
224242813|NCT00885456|BEHAVIORAL|Usual Care|Three or more out-patient visits to the neurovascular clinic for assessment, counseling and referral to appropriate health care professionals.
224242814|NCT04527575|BIOLOGICAL|EpiVacCorona (EpiVacCorona vaccine based on peptide antigens for the prevention of COVID-19)|EpiVacCorona vaccine is intended to prevent COVID-19. The vaccine relies on chemically synthesized peptide antigens of SARS-CoV-2 proteins, conjugated to a carrier protein and adsorbed on an aluminum-containing adjuvant (aluminum hydroxide). The EpiVacCorona vaccine contributes to the development of protective immunity against SARS-CoV-2 coronavirus following two intramuscular administrations spaced 21-28 days apart.
224242815|NCT04527575|OTHER|Placebo (sodium chloride bufus, solvent for the preparation of dosage forms for injection 0.9%)|The use of placebo: intramuscularly, twice, spaced 21 days apart, at a dose of 0.5 ml (43 volunteers)
224242816|NCT00000229|DRUG|Buprenorphine|
224242817|NCT02772289|BIOLOGICAL|Mesenchyme Stem Cells low-dose group|Participants will receive transdermal one dose of 1\*10\^6 cells of Perinatal Tissue Mesenchyme Stem Cells in the gel once a day for continuous three days and then receive transdermal placebo without of Perinatal Tissue Mesenchyme Stem Cells in the gel once a day for continuous next three days.
223662589|NCT07145970|OTHER|Neuropsychological assessment tests for spatial neglect|"Standardized administration of four paper-and-pencil tests designed to assess different forms of spatial neglect:~* Apples Cancellation Test (Birmingham Cognitive Screen) for egocentric and allocentric neglect,~* Simplified Comb and Razor Test for personal and motor neglect,~* Line Bisection Test (30 cm ruler, blind version) for tactile neglect,~* Dot Test for visual exploration.~The purpose is to establish normative reference scores in healthy French-speaking adults according to age, sex, and professional qualification. No therapeutic intervention or patient population is involved."
223662590|NCT05887596|OTHER|Patient education|The education given to the intervention group included preoperative preparation, operating room environment, breathing exercises, cough exercises, etc. to be performed after surgery, non-pharmacological methods related to pain management (cold application, positioning, distraction), and pharmacological methods related to pain management.
223662591|NCT05047445|BIOLOGICAL|COVIDITY (SCOV1 and SCOV2) administered via needle-free intradermal injection|Two 0.2 mg doses of the plasmid DNA vaccine SCOV1 (administered on Day 1 and Day 29), followed by two 0.2 mg doses of the plasmid DNA vaccine SCOV2 (not before Days 113 and 141 \[doses 4 weeks apart\]).
223662592|NCT05047445|BIOLOGICAL|COVIDITY (SCOV1 and SCOV2) administered via needle-free intramuscular injection|Two 1.0 mg doses of the plasmid DNA vaccine SCOV1 (administered on Day 1 and Day 29), followed by two 1.0 mg doses of the plasmid DNA vaccine SCOV2 (not before Days 113 and 141 \[doses 4 weeks apart\]).
223662593|NCT05047445|BIOLOGICAL|COVIDITY (SCOV2 only) administered via needle-free intradermal injection to vaccine naive and/or previously vaccinated participants|Two 0.8 mg doses of the plasmid DNA vaccine SCOV2 administered on Day 1 and Day 29
223662594|NCT05047445|BIOLOGICAL|COVIDITY (SCOV2 only) administered via needle-free intramuscular injection to vaccine naive and/or previously vaccinated participants|Two 4.0 mg doses of the plasmid DNA vaccine SCOV2 administered on Day 1 and Day 29
223662595|NCT05047445|BIOLOGICAL|COVIDITY (SCOV2 only) administered via needle-free intradermal injection to previously infected participants|A single 0.8 mg dose of the plasmid DNA vaccine SCOV2 administered on Day 1
223662596|NCT05047445|BIOLOGICAL|COVIDITY (SCOV2 only) administered via needle-free intramuscular injection to previously infected participants|A single 4.0 mg dose of the plasmid DNA vaccine SCOV2 administered on Day 1
223662597|NCT01410617|PROCEDURE|hemodialysis|3 sessions hemodialysis before CABG
223662598|NCT01888432|DRUG|Everolimus + reduced tacrolimus|Everolimus was initiated at Week 4 post transplantation. The dose was adjusted to maintain the everolimus trough blood levels between 3-8 ng/mL for the duration of the study. Tacrolimus was reduced to 3-5 ng/mL.
223662599|NCT01888432|DRUG|Standard tacrolimus|Tacrolimus was initiated as soon as possible after transplantation according to approved labeling recommendations. The trough level should've been 5-15 ng/mL until randomization, 8-12 ng/mL from randomization until month 4 and after month 4 until end of study reduced to 6 -10 ng/mL.
223662600|NCT00000771|DRUG|Paromomycin sulfate|
223662601|NCT03085849|DRUG|Durvalumab|1500 mg IV on day 8 (flat dose) until progression
224242818|NCT02772289|BIOLOGICAL|Mesenchyme Stem Cells high-dose group|Participants will receive transdermal one dose of 1\*10\^6 cells of Perinatal Tissue Mesenchyme Stem Cells in the gel once a day for continuous six days.
224242819|NCT02772289|BIOLOGICAL|Placebo|Participants will receive transdermal placebo without of Perinatal Tissue Mesenchyme Stem Cells in the gel once a day for continuous six days.
223662602|NCT03085849|DRUG|Tremelimumab|75 mg IV on day 8 (flat dose) x 4 doses
223662603|NCT03085849|DRUG|SGI-110|"SC daily for 5 days (days 1-5) until progression or toxicity~Dose escalation scheme:~Dose level -1 - SGI-110 20 mg/m2 SC daily; Dose level 0 - SGI-110 30 mg/m2 SC daily; Dose level 1 - SGI-110 45 mg/m2 SC daily; and SGI-110 given on days 1-5 of every 28 day cycle"
223662604|NCT03054129|OTHER|Rehabilitation and balance training|"Stretching will be applied as hold-relax technique in Proprioceptive Neuromuscular Facilitation for shoulder flexion, abduction, internal and external rotations. Isotonic exercises will be done with elastic bands for strengthening.~Home exercises will include postural, stretching and strengthening exercises. Balance exercises will receive as non-supervised program."
223662605|NCT03054129|OTHER|Rehabilitation program|Rehabilitation program will be same in this group except balance exercises.
223662606|NCT02711917|DRUG|MAC 0.5|0.5 MAC Sevoflurane
223662607|NCT02711917|DRUG|MAC 0.75|0.75 MAC Sevoflurane
223662608|NCT02711917|DRUG|MAC 1.0|1.0 MAC Sevoflurane
223662609|NCT02711917|DRUG|Propofol|Propofol consumption
223662610|NCT02711917|DRUG|Etomidate|Etomidate consumption
223662611|NCT02711917|DRUG|Rocuronium|Consumption of Rocuronium
223769831|NCT02664038|BEHAVIORAL|Cognitive Remediation Training|Up to 65 hours of computer based cognitive training of attention, verbal and visual memory, verbal and visual working memory, and executive functions
223662612|NCT00130247|DRUG|Ethambutol|Mycobacteriostatic agent given to prevent emergence of drug resistance to other 1st line drugs; dosages are 15-25 milligram (mg)/ kilogram (kg)/day (d).
223662613|NCT00130247|DRUG|Isoniazid|Hydrazide of isonicotininc acid; antimicrobial activity is limited to mycobacteria where it inhibits the synthesis of mycolic acids.
223662614|NCT00130247|DRUG|Pyrazinamide|1st line bactericidal agent; dosages are 15-30 mg/kg/d, up to 2 grams (gm)/d.
223662615|NCT00130247|DRUG|Rifampin|1st line bactericidal agent which inhibits deoxyribonucleic acid (DNA)-dependent ribonucleic acid (RNA) polymerase; dosages are 10 mg/kg/d (up to 600 mg/d).
224242820|NCT01532141|DRUG|BIA 9-1067|50 mg BIA 9-1067 (single-dose)
224242821|NCT01532141|DRUG|Rasagiline|1 mg rasagiline (single-dose)
224242822|NCT01789385|DRUG|Dexmedetomidine|Starting with a 1 mg kg-1min-1 loading dose and than continued with a0.2-0.8 mg kg-1h-1 infusion rate.
224242823|NCT03625856|DIETARY_SUPPLEMENT|Chlorella Vulgaris|Chlorella capsules 1500 mg/day
224242824|NCT03625856|DIETARY_SUPPLEMENT|Placebo|Starch 1500 mg
224242825|NCT00416845|DRUG|FTY720|
224242826|NCT02658045|DEVICE|Standard Oximeter|Oxygen saturation will be measured by standard oximeter
223662616|NCT04278105|DEVICE|HD-tCES|The positions of the lesion side primary motor cortex were defined as C3/C4 according to the international 10-20 system of electroencephalograms. HD-tCES will be applied for 20 minutes at an intensity of 1.0 mA direct current stimulation and a specific-added waveform each time, 3 times a week, lasting for 4 weeks.
223662617|NCT04278105|DEVICE|Sham HD-tCES|The positions of the lesion side primary motor cortex were defined as C3/C4 according to the international 10-20 system of electroencephalograms. Sham HD-tCES will consist of a 5-second ramp up to 1.0 mA direct current stimulation and a specific-added waveform followed immediately by a 5-second ramp down, no current in the middle 19 minutes 40 seconds, and a ramp-up and ramp-down period during the last 10 seconds.
224242827|NCT02658045|DEVICE|Oxitone oximeter|Oxygen saturation will be measured by Oxitone oximeter
224242828|NCT00437138|BEHAVIORAL|Exposure to dilute diesel exhaust (300µg/m3) or filtered air|
224242829|NCT00088829|DRUG|paclitaxel|subjects will receive paclitaxel neoadjuvantly
223662618|NCT04278105|OTHER|Upper extremity rehabilitation|Upper extremity rehabilitation programs will be selected and graded in accordance with each patient's upper extremity function and specific aims of activities of daily living. Upper extremity rehabilitation will be provided for 30 minutes each time, 3 times a week, lasting for 4 weeks.
223662619|NCT04486001|BIOLOGICAL|PSC-04|adipose stem cells derived from screened donor lipoaspirate and culture expanded.
223662620|NCT01930331|DRUG|artemisinin/naphthoquine|"Each tablet of ARCO (artemisinin/naphthoquine) contains 125 mg artemisinin and 50 mg of naphthoquine. The total dose for adults will be 1000mg of artemisinin and 400mg of naphthoquine in a fixed oral dose (ARCO tablet).~The regimen for children will be calculated according to the body weight (20mg artemisinin + 8mg naphthoquine per kg body weight in a fixed oral dose(ARCO tablet))."
223662621|NCT01930331|DRUG|dihydroartemisinin/piperaquine phosphate|Eurartesim (dihydroartemisinin/piperaquine phosphate) is a fixed dose preparation with two dose-strengths (20 mg dihydroartemisinin and 160mg of piperaquine phosphate and 40mg dihydroartemisinin and 320mg of piperaquine phosphate. The regimen for patients with body weight of 36-75kg is three tablets of 40mg dihydroartemisinin and 320mg of piperaquine phosphate once daily for three consecutive days. Those beyond or below this range the regimen will be calculated based on the body weight.
223662622|NCT05841173|DIETARY_SUPPLEMENT|"PanTrek"|"The intervention is represented by the investigational product PanTrek, shots with liquid, 25 ml each (TU 10.89.19-01-44850857-2020). The composition of the product PanTrek (per 1 dose):~* Ginseng dry extract (Panax ginseng Meyer) all parts of the plant - 125 mg (the amount of ginsenosides in one vial is 9.0 mg ± 3.5 mg);~* Melissa officinalis dry extract (Melissa officinalis L) all parts of the plant - 340 mg (the amount of hydroxycinnamic acids is 19.50 mg / vial ± 10% in one vial);~* Apple juice concentrated 2.5% - 7,5 g;~* Potassium beta-hydroxybutyrate - 4,5 g;~* Magnesium beta-hydroxybutyrate - 500 mg;~* E211 sodium benzoate - no more than 5 mg;~* E202 Potassium sorbate - no more than 3,6 mg;~* Water purified - up to 25 ml. The product has registered as diet supplement in the Unified Register of Certificates of State Registration N RU.77.99.11.003.R.001152.04.21 from 05.04.2021."
223662623|NCT05841173|BEHAVIORAL|Physical Trainings|Physical activity is represented by 2 workouts lasting 45 minutes per week on an antigravity treadmill Alter-G M320 (AlterG, USA) and 2 sessions of reoxygenation lasting 30 minutes on a normobaric hypoxic therapy device ReOxy (Bitmos GmbH, Germany).
223662624|NCT05841173|OTHER|Placebo|The placebo is represented by concentrated apple juice 2.5% - 7.5 g, potassium chloride - 2.405 g, MgCl2 - 0.382 g, sodium benzoate (E211) - 5 mg and potassium sorbate (E202) - 3.6 mg, brought to 25 ml of distilled water.
223662625|NCT05841173|BEHAVIORAL|Diet|The studied diet is a low-calorie diet with an average energy value of 1730.16 kcal / day and a certain chemical composition (proteins - 108.80 g / day, fats - 68.10 g / day, carbohydrates - 162.60 g / day), including the main groups products (meat and poultry dishes, fish dishes, dairy products, cereals, vegetables and fruits). On average, 0.96-1.05 g of protein accounted for 1 kg of body weight of the subjects.
223662626|NCT04608461|DRUG|Pumpkin seed extract containing cream|Pumpkin seeds extract, white wax, white petrolium, stearyl alcohol
223662627|NCT01660958|DIETARY_SUPPLEMENT|MNP|The formulation of the multiple micronutrient powder (MNP) was based on low micronutrient intake, low bioavailability of iron and zinc in the Indian diet, and current World Health Organization (WHO)and Indian recommendations regarding fortification and age-specific nutrient requirements. The MNP formulations were produced by a certified company in India and include: Iron, Vitamin A, Vitamin C, Folic Acid, Zinc, Vitamin B12 Vitamin B2, plus filler (maltodextrin). Placebo included riboflavin and maltodextrin.
223662628|NCT01660958|BEHAVIORAL|Early Learning|• Infant will benefit from interventions that are based on responsive parenting, whereby caregivers respond to children's cues, provide opportunities for exploration, and engage in nurturant and reciprocal communication.
223662629|NCT01039662|DIETARY_SUPPLEMENT|L-arabinose and indigestible dextrin|
223662630|NCT01039662|DIETARY_SUPPLEMENT|Placebo|
223662631|NCT05491460|DRUG|Apixaban 5 MG Tab|oral intake
223662632|NCT05491460|DRUG|Dabigatran 150 MG Tab|oral intake
223662633|NCT05491460|DRUG|Edoxaban 60Mg Tab|oral intake
223662634|NCT05491460|DRUG|Rivaroxaban 20 MG Tab|oral intake
223662635|NCT05637060|DRUG|Test Drug|One single dose of Vaptor 20 mg will be administered to subjects after at least 10 hours fast together with 240 mL of ambient temperature water at their scheduled dosing time.
224242830|NCT00088829|GENETIC|microarray analysis|subjects will have a biopsy to collect tissue for gene microarray analysis
224242831|NCT00088829|PROCEDURE|biopsy|All subjects will have a biopsy to collect tissue
224242832|NCT00088829|PROCEDURE|neoadjuvant therapy|paclitaxel is given neoadjuvantly
224242833|NCT00088829|DRUG|Paclitaxel|All patients will receive paclitaxel neoadjuvantly
224242834|NCT01194648|OTHER|questionnaire administration|
224242835|NCT01194648|PROCEDURE|assessment of therapy complications|
224242836|NCT01194648|PROCEDURE|high-intensity focused ultrasound ablation|
224242837|NCT01194648|PROCEDURE|multiparametric magnetic resonance imaging|
224242838|NCT01194648|PROCEDURE|quality-of-life assessment|
224242839|NCT01194648|PROCEDURE|transperineal prostate biopsy|
224242840|NCT01194648|PROCEDURE|transrectal prostate biopsy|
224242841|NCT01358344|DRUG|Pantoprazole|40 mg delayed-release tablet administered orally in the morning of Days 1-7
223662636|NCT05637060|DRUG|Reference Drug|One single dose of Crestor 20 mg will be administered to subjects after at least 10 hours fast together with 240 mL of ambient temperature water at their scheduled dosing time.
223662637|NCT00003013|DRUG|CMF regimen|
223662638|NCT00003013|DRUG|cyclophosphamide|
223662639|NCT00003013|DRUG|doxorubicin hydrochloride|
223662640|NCT00003013|DRUG|fluorouracil|
223662641|NCT00003013|DRUG|methotrexate|
223662642|NCT00003013|DRUG|paclitaxel|
223662643|NCT00003013|DRUG|tamoxifen citrate|
223662644|NCT00003013|PROCEDURE|conventional surgery|
223662645|NCT00003013|RADIATION|radiation therapy|
223769832|NCT06156228|BEHAVIORAL|Multilevel Intervention|Clinic patients from the randomly assigned intervention clinics will be provided with additional vaccine information and will have the opportunity to ask any questions they might have about any of the 4 study focused vaccines (COVID-19, Shingles, Pneumococcal, Influenza). Health educators will provide them with additional information, address any misinformation and disinformation and will offer to schedule their vaccine appointment(s) for them.
224242842|NCT01358344|DRUG|SCH 530348 (high percentage)|2.5 mg tablet containing \~46% active pharmaceutical ingredient (API) as free base (46+5%) administered orally on the morning of Day 5
223662646|NCT05498415|BEHAVIORAL|Education|Participants will receive standard of care education information on physical activity, sedentary behavior, and sleep via a mobile app for 8 weeks.
223662647|NCT05498415|BEHAVIORAL|Health coaching|Participants will meet with a health coach weekly for 8 weeks
223769833|NCT05116852|OTHER|Survey|All study participants will be asked to complete two surveys relevant to their personal experience either losing a loved one to opioid-related death, supporting a loved on in recovery for Opioid Use Disorder, or both.
224242843|NCT01358344|DRUG|SCH 530348 (standard percentage)|2.5 mg tablet containing \~23% API as free base (STANDARD) administered orally on the morning of Day 5
224242844|NCT02857322|OTHER|Accompanying patient's specific perioperative|
224242845|NCT01209793|BIOLOGICAL|REGN846|5 IV cohorts (Dose 1, 2, 3, 4, 5)
224242846|NCT06062277|DRUG|Colchicine 0.5 MG|one oral tablet daily for 30 days
223662648|NCT05498415|BEHAVIORAL|Activity Monitor|Participants will receive a Fitbit activity monitor to support goal setting and self monitoring of behaviors.
223662649|NCT00434239|DRUG|Lenalidomide + Ancestim|Dose level 1. Lenalidomide 10mg orally daily days 1-21/ 28 day cycle Ancestim 10mc/kg subcutaneously daily for 7 days for cycle 3 only 10mg orally daily days 1-21/ 28 day cycle. Dose level 2 Ancestim 20mc/kg subcutaneously daily for 7 days for cycle 3 only 10mg orally daily days 1-21/ 28 day cycle
223662650|NCT02664948|PROCEDURE|Early geriatric follow-up after discharge|Multidisciplinary assessement and intervention by physician, nurse and physiotherapist
223662651|NCT03329014|DRUG|Remimazolam|For induction and maintenance of sedation
224242847|NCT04349852|BEHAVIORAL|BrainHQ Cognitive Training Modules|The BrainHQ is a computerized training program developed from Posit Science designed to improve multiple cognitive domains. The subtests exercises include 6 modules for the experimental group: 1) Sound Sweeps: which is identify whether sound pitches are going up or down; 2) Memory Grids: matching pairs of words; 3) Syllable Stack: recognition of sequences of confusable syllables; 4) Fine Tuning: recognition of the order of confusable syllables; 5) To-Do List Training: reconstruction of sequences of verbal instructions; 6) In The Know: identification of details in a verbally presented story. Since the intervention is presented both visually and verbally through the computer, participants will be asked to complete their training in a quiet space and time to complete these activities.
223662652|NCT03329014|DRUG|Placebo|Control arm
223662653|NCT00036842|DRUG|arsenic trioxide|
223662654|NCT03844945|DRUG|Netarsudil Ophthalmic Solution 0.01%|Topical sterile ophthalmic solution
223662655|NCT03844945|DRUG|Netarsudil Ophthalmic Solution 0.02%|Topical sterile ophthalmic solution
223662656|NCT03844945|DRUG|Netarsudil Ophthalmic Solution 0.04%|Topical sterile ophthalmic solution
223662657|NCT03844945|OTHER|Netarsudil Ophthalmic Solution Placebo|Topical sterile ophthalmic solution
223662658|NCT04137445|OTHER|Baby Foods|Commercially available baby foods
223662659|NCT04137445|OTHER|Foods from the home|Caregiver will provide participant with usual foods from the home
223662660|NCT03165604|OTHER|standard information|The participates will be given a standard information regarding the water drink before physical activity
223662661|NCT03165604|OTHER|positive information|"The participates will be given positive information (the drink will be presented as an energy drink) regarding the drink before physical activity"
223662662|NCT02604901|BEHAVIORAL|Screening and Brief Intervention (BI)|Rite Aid® pharmacists screened patients at the time of the initial fill with the Adherence Estimator™ and using the screening results, provided the behavioral intervention, Brief Intervention using motivational interviewing principles based on POLAR\*S (BI). BI was considered an active intervention method.
223662663|NCT02604901|BEHAVIORAL|Pill Box (PB)|Rite Aid® pharmacists provided patients with a Pill Box (PB) and information about their medications. However, pharmacists did not use motivational interviewing principles for engaging patients in direct interventions to modify behavior. PB was considered a passive intervention method.
223662664|NCT02871752|BEHAVIORAL|Health promotion|mindfulness-based stress reduction
223662665|NCT05654077|BIOLOGICAL|CAR-T Cell Injection|intravenously once, and the dose group was 3.0 × 10\^6cells/kg、9.0 × 10\^6cells/kg、1.5 × 10\^7cells/kg。
223662666|NCT05654077|DRUG|Fludarabine|Fludarabine 25\~30mg/m2/d was infused intravenously for 3 consecutive days. (- 5 days to - 3 days)
223662667|NCT05654077|DRUG|cyclophosphamide|250\~350mg/m2/d cyclophosphamide was infused intravenously for 3 consecutive days. (- 5 days to - 3 days)
223662668|NCT01947413|OTHER|intermittent theta burst stimulation|In intermittent theta burst stimulation pattern (iTBS) will intermittently give a 2 s train of TBS every 10s for a total of 20 times (low pulse: 600 pulses in total)
223662669|NCT01947413|OTHER|continuous theta burst stimulation|In continuous burst stimulation pattern (cTBS) will intermittently give a cTBS treatment consists of a continuous train of TBS for 40 seconds(low pulse: 600 pulses in total).
223769834|NCT06349083|DRUG|Psilocybin|One 25 mg capsule and one 5 mg capsule (30 mg total) administered once orally
223769835|NCT06349083|OTHER|Inactive Placebo|Two matching placebo capsules administered once orally
223662670|NCT01947413|OTHER|sham theta burst stimulation|In sham burst stimulation pattern (sham TBS) will intermittently give a sham TBS treatment consists of a continuous train of TBS for 40 seconds(almost no pulse: 600 pulses in total).
223662671|NCT03963271|DIAGNOSTIC_TEST|ECG-Imaging|A body surface potential mapping and a cardiac + low dose CT-scan.
223662672|NCT05363254|OTHER|Marlboro Gold Box|A combustible cigarette
223662673|NCT05363254|OTHER|Newport Box|A combustible cigarette
223662674|NCT05363254|OTHER|Non-combusted cigarette variant 42001401|A menthol flavor variant of a non-combusted cigarette (42001401)
223662675|NCT05363254|OTHER|Non-combusted cigarette variant 42001399|A menthol flavor variant of a non-combusted cigarette (42001399)
223662676|NCT05363254|OTHER|Non-combusted cigarette variant 40007386|A menthol flavor variant of a non-combusted cigarette (40007386)
223662677|NCT05363254|OTHER|Non-combusted cigarette variant 42001402|A non-menthol flavor variant of a non-combusted cigarette (42001402)
223662678|NCT06057961|OTHER|Art Therapy|8 meetings in 1 year
223662679|NCT06166121|OTHER|ShenJu|One package per time, twice a day, 90 days of treatment
223662680|NCT06166121|OTHER|Placebo|One package per time, twice a day, 90 days of treatment (the placebo was basically the same as ShenJu in terms of appearance, shape, color, taste, etc.)
223662681|NCT06246006|OTHER|Gene sequencing|Next generation sequencing of candidate genes (JAK2, cMPL, CALR, ASXL1 and NF-E2)
223662682|NCT02754700|OTHER|Neuromuscular Training|Standardized, comprehensive neuromuscular training
223662683|NCT02754700|OTHER|Hip Focused ROBUST Training|Biofeedback training focused on the hip extensors
223662684|NCT02754700|OTHER|Knee Focused ROBUST Training|Biofeedback training focused on knee abduction
223662685|NCT02559700|BEHAVIORAL|Brain training programme|An online package of brain training programmes
223662686|NCT05998889|BEHAVIORAL|Experimental group|Education, Graded Pain Exposure Exercises and Graded Motor Imagery. One supervision a week/9 weeks + exercises at home + encourage returning relevant activities despite pain
223662687|NCT05998889|BEHAVIORAL|Control group|Graded Motor Imagery following the GRaMI protocol, One supervision a week/9 weeks + exercises at home, activities encourage but pain contingency.
223662688|NCT03968640|DIETARY_SUPPLEMENT|CoQ10|The intervention will consist of a loading dose of reduced form CoQ10 of 1,800 mg/day tid for 4 weeks to be followed by a maintenance dose of 600 mg/day once daily from weeks 5 to 12. The intervention or allocation-controlled placebo will be administered by 72 hours after injury and will continue until 12 weeks after injury or until death or discharge, whichever comes first. Oral tablets (600 mg/tablet) will be administered to CoQ10 subjects who can swallow while a liquid form (100 mg/mL) will be administered to CoQ10 subjects requiring an enteral tube for nutrition.
223662689|NCT03968640|DIETARY_SUPPLEMENT|Placebo|The intervention will consist of a loading dose of reduced form CoQ10 of 1,800 mg/day tid for 4 weeks to be followed by a maintenance dose of 600 mg/day once daily from weeks 5 to 12. The intervention or allocation-controlled placebo will be administered by 72 hours after injury and will continue until 12 weeks after injury or until death or discharge, whichever comes first. Oral tablets (600 mg/tablet) will be administered to CoQ10 subjects who can swallow while a liquid form (100 mg/mL) will be administered to CoQ10 subjects requiring an enteral tube for nutrition.
223662690|NCT00693082|DIETARY_SUPPLEMENT|flaxseed|1 tablespoon a day for first three days, increasing to two tablespoons a day for the next three days. On the 7th day start with 3 tablespoons per day and maintain dose throughout the duration of the study (11 weeks).
224242848|NCT04349852|BEHAVIORAL|BrainHQ People Skills Modules|The BrainHQ is a computerized training program developed from Posit Science designed to improve multiple cognitive domains. The BrainHQ will provide 3 training modules for the control group: 1) Recognition: a picture of a face is presented briefly and then the subject picks the recognized face from 3 pictures. 2) Face to Face: matching the emotional expression of 3 pictures to the emotional expression of the picture previously presented; 3) Face Facts: recalling 3 facts about a person that was previously presented. Participants will spend 45 minutes at each training session. Since the intervention is presented both visually and verbally through the computer, participants will be asked to complete their training in a quiet space and time to complete these activities.
223662691|NCT04473235|BEHAVIORAL|Literacy training|Teaching adults how to read and write using the analytical and phonemic method
223662692|NCT04473235|BEHAVIORAL|Non-Literacy training|Attending classes in geography, history, sciences, without receiving the specific training in literacy
223662693|NCT06515808|DEVICE|Direct Laryngoscope|Patient receiving tracheal intubation with direct laryngoscope, GlideScope or Airway Scope
223662694|NCT05724693|DRUG|Bemnifosbuvir (BEM)|Day 1: A single dose of BEM will be administered
223662695|NCT01754402|DRUG|Bendamustine|Bendamustine will be administered intravenously over 1 hour (if using Treanda) or over 10 minutes (if using Bendeka) on day 1, every 28 days for 12 cycles.
223662696|NCT01754402|DRUG|Pomalidomide|Pomalidomide will be administered once daily orally (PO) on days 1-21, every 28 days until disease progression or death.
223662697|NCT01754402|DRUG|Dexamethasone|Dexamethasone will be administered weekly orally or intravenously on days 1, 8, 15, and 22 every 28 days until disease progression or death. After 6 cycles of treatment, the dose may be reduced to 20mg at investigator's discretion. For subjects ≥ 75 years of age, the starting dose of dexamethasone is 20 mg/day on Days 1, 8, 15 and 22 of each 28-day treatment cycle.
223662698|NCT03448484|DIETARY_SUPPLEMENT|Intervention (integrated package)|"Provided to all intervention households:~* Soap (for daily hand washing)~* Chlorine solution (for daily drinking water treatment)~* 8 birds of chicken (child consumes 1 egg/day)~* Vegetable seeds (red onion, indigenous managu and sukuma)~* Monthly trainings to all farmers on nutrition and WASH~* Micronutrient powder (MixMe, 1g sachet every third day)~* Oral rehydration solution (ORS) + zinc (to be used to treat acute diarrhoea: 20 mg zinc tablets; ORS sachets (10.3 g/sachet))~All families in the intervention group will receive the same agriculture-focused package (see section 'control intervention' below) as those in the control group."
223769836|NCT06349083|BEHAVIORAL|Supportive therapy sessions|Participants will receive three supportive therapy sessions of manual-based treatment from a Center for Psychedelic Medicine (CPM) clinician, accompanied by a Silver Hill Hospital (SHH) therapist who has an ongoing therapeutic relationship with the participant. The CPM clinician will be a licensed physician, clinical psychologist, or nurse practitioner who will be solely responsible for the content of the intervention. The SHH therapist will provide additional support and continuity with clinical treatment.
223662699|NCT03448484|OTHER|Control|"Active control: The families living in the control clusters will receive the agriculture-focused package that is already in place in all participating clusters through the 1AF programme. The control intervention is the same for study 1 and study 2. This agriculture-focused package consists of:~* Agricultural training (every 2 weeks on average) for all~* Free to enrol for the following products on credit:~  * Compost boosters~ * Cook stoves~ * Seeds (onions, maize, indigenous greens, beans)~ * Maize storage bags~ * Drying tarps~ * Trees~ * Solar lights~ * Fertilizer~ * Actellic dust (insecticide)~ * Re-usable sanitary pads"
223769837|NCT05167695|BEHAVIORAL|Habit-based Sleep Health Intervention|A novel low-cost approach derived by leveraging the science of habit formation
223769838|NCT05167695|BEHAVIORAL|Text messaging intervention|In addition to the Habit-based Sleep Health Intervention, the participants will also receive the text messaging intervention.
223662700|NCT01282463|DRUG|Docetaxel|Docetaxel: 75 milligram/square meter (mg/m2) on Day 1 of each 21-day cycle
223662701|NCT01282463|BIOLOGICAL|Ramucirumab DP|Ramucirumab (DP): 10 milligram/kilogram (mg/kg) intravenous (IV) on day 1 of each 21-day cycle
223662702|NCT01282463|BIOLOGICAL|Icrucumab|12 mg/kg I.V. on day 1 and Day 8 of each 21-day cycle
223662703|NCT02726542|DRUG|somatropin|Norditropin (growth hormone) given by injection using a pen-device
223662704|NCT01437475|BIOLOGICAL|Sci-B-Vac|10 microgram/ml hepatitis B surface antigen, 1 ml given intramuscularly
223662705|NCT05249478|PROCEDURE|bupivacaine and fentanyl|bupivacaine and fentanyl will be infused through the catheter
223662706|NCT03010371|BEHAVIORAL|Positive Psychotherapy|Positive Psychotherapy (PP) is designed to treat cancer survivors with moderate/severe adaptation difficulties after completing cancer treatments (Ochoa et al., 2010). The objectives are the facilitation and promotion of post-traumatic growth and quality of life, and the reduction of emotional distress (anxiety, depression and post-traumatic symptoms). Secondary consequences of this psychological improvement is a better transition to daily life and the restoration of a good psychosocial functioning (labor reincorporation, adherence to treatments and follow-up, and the adoption of healthy lifestyles). The program consists of twelve sessions of 90 minutes per week in a closed group (5 to 7 participants). Each session focuses on the different topics and tasks defined in the Positive Psychotherapy for cancer survivors (Ochoa et al., 2010).
223662707|NCT03010371|BEHAVIORAL|Positive Online Psychotherapy|The Positive Online Psychotherapy (POP) is based on the PP program, but being adapted to an online version. Patients in this experimental condition will have access to a secure virtual platform (supervised and dependent from the Catalan Health Department). The POP consists of twelve weekly sessions of 90 minutes, in a closed-group format (5-7 participants). Patients have a simultaneous group-connection to the online platform, together with a clinical psychologist who lead the tasks according to the focuses of each session.
223662708|NCT03010371|BEHAVIORAL|Cognitive Behavioral Therapy|"The Cognitive Behavioral Therapy (CBT) is based on the Cognitive Behavioral Stress Management (Antoni, 2003) and the training program derived from it, Breast Cancer Stress Management and Relaxation Training (B-SMART) by Antoni Michael (2003). In its Spanish version, it is a 10-session therapy aimed to reduce cancer-related emotional distress, facilitating adjustment to illness and greater quality of life. Stress management and relaxation techniques help patients to identify their own stress responses and learn alternative ways of thinking and acting in response to the demands they perceive as highly stressful."
223662709|NCT01449942|BIOLOGICAL|DNAzyme targeting EBV-LMP1 (DZ1)|"DZ1 in saline is administrated by intratumoral injection two hours prior to radiation therapy from week 1 to week 7 on Monday and Thursday. Dosage for each injection is 12 mg in 0.1 mL (200 micrograms per kilogram body weight.~The radical radiotherapy is given to patients 5 times per week with 2 Gy of each treatment. The entire procedure lasts seven weeks."
223769839|NCT04145791|OTHER|Ice|ice packs
224242849|NCT04126811|DRUG|Apatinib Mesylate, Pirarubicin, Ifosfamide|Apatinib 500mg, orally, once a day. One cycle every 4 weeks. Pirarubicin 75mg/m2 D1, intravenous infusion for 1-2 hours; every 4 weeks. Ifosfamide 2g/m2/d D1-D5, intravenously for 4-6 hours, 1 cycle every 4 weeks.
223662710|NCT01449942|OTHER|Saline|"0.1 mL of saline is administrated by intratumoral injection two hours prior to radiation therapy from week 1 to week 7 on Monday and Thursday.~The radical radiotherapy is given to patients 5 times per week with 2 Gy of each treatment. The entire procedure lasts seven weeks."
223662711|NCT01779817|BEHAVIORAL|Assessment of intellectual development, capacities of attention, learning process and degree of hyperactivity of the children between 6 and 9 years.|
223769840|NCT05464628|DRUG|Atorvastatin|Atorvastatin followed by ASC42 daily followed by separate co-administration of atorvastatin
223769841|NCT05464628|DRUG|ASC42|Atorvastatin followed by ASC42 daily followed by separate co-administration of atorvastatin
223769842|NCT02494700|RADIATION|External Beam Radiation Therapy|Undergo orbital EBRT
223769843|NCT02494700|DRUG|Orbital Radiation|Participants receive radiation to entire involved orbit for a total dose of 4 Gy in 2 fractions over two consecutive days with external beam radiotherapy. If there is stable disease or progressive disease, an additional 20 Gy administered to involved site. If there are two consecutive evaluations with no change in disease burden then an additional 20 Gy administered. At one year if there is persistent disease, an additional 20 Gy administered to involved site.
223769844|NCT02063165|DIETARY_SUPPLEMENT|High Linoleic Safflower Oil|2 tsp per day (\~10g of oil)
223769845|NCT05421078|DRUG|Obicetrapib|tablet
224242850|NCT04126811|DRUG|Apatinib Mesylate|Apatinib 500mg, orally, once a day. One cycle every 4 weeks.
224242851|NCT04126811|DRUG|Pirarubicin, Ifosfamide|Pirarubicin 75mg/m2 D1, intravenous infusion for 1-2 hours; every 4 weeks. Ifosfamide 2g/m2/d D1-D5, intravenously for 4-6 hours, 1 cycle every 4 weeks
224242852|NCT00219297|DRUG|Patupilone|
224242853|NCT04455633|DRUG|LX9211|Oral Tablets
223769846|NCT05421078|DRUG|Placebo|No active ingredient
223769847|NCT06164873|DRUG|IBI362|Once-weekly injections of gradually increased doses of IBI362
223769848|NCT06164873|DRUG|Placebo|Once-weekly injections of volume-matched placebo
223769849|NCT02917993|DRUG|Itacitinib|In Phase 1, itacitinib at a protocol-defined starting dose, with subsequent dose escalation based on protocol-specific criteria. In Phase 2, itacitinib at the recommended dose from Phase 1.
224242854|NCT04455633|DRUG|LX9211 Matching Placebo|Oral Tablets
224242855|NCT00379548|BEHAVIORAL|2 groups of population responding to 2 types of diets|Intervention groups include: Asian intervention and Caucasian intervention- both these groups switch from an Asian diet to a Western diet halfway through the study.
224242856|NCT06543966|DRUG|Aprepitant Injection|Before anesthesia induction, 4.4ml(32mg） was given by a single intravenous injection, which was completed within 30 seconds
223662712|NCT02509234|DRUG|Combined chemotherapy with trabectedin followed by irinotecan|"Day 1:~Trabectedin 1,1 - 1,5 mg/m²/day i.v.~Day 3-5 and 10-12:~Irinotecan 30- 90 mg/m²/day p.o. or i.v."
223662713|NCT01802164|DEVICE|A non-absorbable composite mesh (Ethicon Physiomesh)|To compare prophylactic mesh implantation to conventional abdominal wall closure in patients undergoing emergency laparotomy for peritonitis.
223662714|NCT02069275|OTHER|Immediate mobilization|Patients are mobilized immediate after coronary angiography and percutaneous coronary intervention via femoral access and closed with Angio-seal closing device. Heparin reverted with Protaminsulphate
223662715|NCT02069275|OTHER|Two hours bedrest|Patients is following the usual regimen, two hours bedrest after coronary angiography and percutaneous coronary intervention via femoral access and closed with Angio-seal closing device before mobilization. Heparin is reverted with Protaminsulphate
223662716|NCT00301184|BIOLOGICAL|pGA2/JS7 DNA|DNA Vaccine
223662717|NCT00301184|BIOLOGICAL|Modified vaccinia Ankara/HIV62|Recombinant Modified Ankara Vaccine
223662718|NCT00974584|DRUG|GDC-0941|The GDC-0941 at a starting dose of 60 milligrams (mg) will be administered once daily orally for 14 consecutive days (Days 1 to 14) in 3-week cycles except for the first cycle that has Day 1 of single-agent GDC-0941 preceding Day 2 with combination chemotherapy.\\n\\n\\n\\n\\n\\n
223662719|NCT00974584|DRUG|bevacizumab|Bevacizumab 15 milligrams per kilograms (mg/kg) intravenously (IV) on Day 1 of every 3-week cycle.
223662720|NCT00974584|DRUG|carboplatin|Carboplation IV on Day 1 of every 3-week cycle, at a dose to achieve an area under concentration time curve of 6 milligrams per milliliter\*minute (mg/mL\*min).\\n
223662721|NCT00974584|DRUG|cisplatin|Cisplatin 75 milligrams per square meter (mg/m\^2) IV on Day 1 of every 3-week cycle.\\n
223662722|NCT00974584|DRUG|paclitaxel|Paclitaxel 200 mg/m\^2 IV on Day 1 of every 3-week cycle.\\n\\n
223662723|NCT00974584|DRUG|pemetrexed|Pemetrexed 500 mg/m\^2 IV on Day 1 of every 3-week cycle.
223662724|NCT00407381|DRUG|Ranibizumab|Ranibizumab for intravitreal injection. .05ml dosing at 30 day intervals and pro re nata (PRN) with dosing criteria.
223662725|NCT00407381|PROCEDURE|Laser photocoagulation|Laser photocoagulation in either focal or grid pattern as determined by investigator.
223662726|NCT02872844|DEVICE|ICS AirCal3|Each patient will undergo a 30-minute heat stress to one ear. For randomization, the left ear will be treated in patients with a registration number ending with an odd number and the right for even numbers. An ICS AirCal3 Research Strategy (Otometrics) system attached to an Intel Core 15vPro Thinkpad (IBM) laptop is used within the audiometry department of a separate outpatient clinic. The patients will be reclined and the hot air caloric at 50°C applied by a licensed, unblinded audiologist for 30 minutes. The patients will be allowed to fixate and use whatever means they prefer for entertainment during the intervention.
223662727|NCT04865367|OTHER|Exposure to culture media|Exposure to culture media
223662728|NCT00588861|DEVICE|Answer® hip stem|Total hip replacement using Palacos® bone cement, the Answer® hip stem and the Ranawat/Burnstein® acetabular shell.
223662729|NCT00588861|DEVICE|Answer® hip stem|Total hip replacement using Simplex® bone cement, the Answer® hip stem and the Ranawat/Burnstein® acetabular shell.
223662730|NCT03636841|DEVICE|medical device with CE marking (Ultravision ©)|Ultravision © is a medical device that is used during laparoscopy to reduce the discomfort caused by surgical smoke produced by the electrical section of tissue. It works by using the principle of electrostatic precipitation, that is to say it causes the precipitation of suspended smoke droplets on the organs and walls of the abdomen.
223662731|NCT05563870|PROCEDURE|Endoluminal radiofrequency ablation|Endoluminal Radiofrequency ablation (RFA) of the entire stricture length will be performed using the Habib probe. A current of 7W will be delivered for 90s intervals at a time. If multiple ablation sessions are needed in order to ablate the entire stricture lenght, there will be an overlap of ablated areas in order to ensure proper stricture treatment. Dilation of the stricture prior to RFA delivery will be performed if required. After RFA treatment, biliary drainage of all hepatic territories will be ensured.
224242857|NCT06543966|DRUG|Aprepitant Injection Placebo|Before anesthesia induction, 4.4ml(0mg） was given by a single intravenous injection, which was completed within 30 seconds
224242858|NCT03946501|OTHER|Data collection|
224242859|NCT06130735|BEHAVIORAL|Cognitive Computerized Training|Participants will log into ABI Wellness Platform five days per week (M-T-W-Th-F) and train using the Symbol Relations module for 45 to 60 minutes. Every other week, participants will meet with their training facilitator via zoom to review training progress and troubleshoot any training-related questions.
223662732|NCT05563870|PROCEDURE|Endoscopic biliary stenting|Endoscopic biliary stenting will be performed via ERCP using multiple plastic stents, in order to ensure propper drainage of all accessed hepatic territories.
223662733|NCT01239992|DRUG|Niacin/ Laropiprant|1000/ 20 mg first 4 weeks, 2000/40 mg next 8 weeks; daily
223662734|NCT05012670|DRUG|[14C]-Paxalisib Capsule|Each subject will receive a single dose 15 mg (NMT 3.5 MBq), administered orally in the fasted state with with 240 mL water.
223662735|NCT01601600|DRUG|BYM338|BYM338
223769850|NCT02917993|DRUG|Osimertinib|Osimertinib 80 mg once daily (QD)
223662736|NCT01601600|DRUG|Placebo|BYM338 Placebo
223662737|NCT04698577|BEHAVIORAL|Attention Training|The training was delivered face-to-face in groups of three participants. Participants were involved in a game of table tennis with two players and one spectator. The roles were rotated every 5 minutes so that each participant experienced 10 minutes of play and 5 minutes of observation. The game was played as normal with one point awarded to the player for every score achieved. All 3 players were asked to keep the score of the game in their minds during each 5-minute round. Participants had two objectives 1) to play and win the game and 2) to silently keep the score of the game. The researcher watched the game and accurately kept score, using a notepad. At the end of every 5-minute round, the researcher paused play and asked each child to write down the score they were holding in their mind. The researcher then revealed the true score, asked participants to swap roles and commence another round.
223769851|NCT06169267|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration/biopsy
224242860|NCT03282136|DRUG|Incretin Effect|The patients will receive incretins therapy.
224242861|NCT03282136|DEVICE|Cardiac Resynchronization therapy defibrillator device|The patients will receive a Cardiac Resynchronization therapy defibrillator device
224242862|NCT03282136|DRUG|SGLT-2 inhibitor|The patients will receive SGLT2i therapy.
224242863|NCT05781282|DEVICE|Atrial fibrillation ablation|Pulmonary vein deconnection. PV antra visualization by ICE
223662738|NCT04698577|BEHAVIORAL|Active Control|The control group was the same as the training group except for the core training mechanism; children were not required to mentally keep score. The researcher kept score by continually calling out the updated score as each point was won. The observing child was simply told to wait his/her turn.
224242864|NCT04249973|OTHER|Collection of urine and feces|Urine and feces are collected at the families home. A short questionnaire is filled in by the parents
224242865|NCT04071444|OTHER|Baduanjin program|The entire program continued for 6 months (December, 2018 to July, 2019), and the intervention was performed for 60 min 3 times per week; particular attention was paid to the disease characteristics of the patients with chronic schizophrenia and to preventing excessive fatigue. Every session began with a 20-min warm-up, followed by 20 min of Baduanjin program, and ended with a cool-down session. The participants were instructed, with the assistance of a video, to practice Baduanjin program in a group by two authors who are experienced in the psychiatric nurses and had been trained in this program.
224242866|NCT06486246|PROCEDURE|Adductor canal block|Injection of the local anesthetic prior to the surgery, either in the the adductor canal or in the genicular nerves by the anesthesiologist under ultrasound guidance.
224242867|NCT05817916|PROCEDURE|ESP block|ESP block: ultrasound guided erector spina plane block
223662739|NCT03648866|OTHER|interview|"Initial interview and potential follow-up interviews and focus group with Florida Hospital employees.~Interview participants in compassion rounds"
223662740|NCT02702297|OTHER|single arm|Daily monitoring of vaginal fluid IL6 and fetal ECG. Daily maternal monitoring and delivery according to standard operating procedure. Post partum diagnosis of FIRS or EOS by analysing of fetal cord blood IL6 and clinical signs of sepsis. Diagnosis of histologic amniotic infection by histological analysis.
223662741|NCT00334178|DRUG|Laxymig ER (drug)|
223662742|NCT04960839|RADIATION|Prophylactic contralateral breast irradiation|The whole contralateral breast will be irradiated once daily, 5 days a week, for 5-6 weeks, using 1.8-2 Gy/fx to a total dose of 45-50 Gy.
223662743|NCT00849316|DRUG|insulin aspart|Safety and effectiveness data collection in connection with the use of the drug NovoRapid™ in patients with coexisting diabetes and chronic kidney disease in daily clinical practice.
223662744|NCT00754221|DRUG|[S,S]-Reboxetine|Once a day, oral treatment, of 4, 6, 8 or 10 mg
223662745|NCT02689921|DRUG|Exemestane|Aromatase inhibitor
223662746|NCT02689921|DRUG|Letrozole|Aromatase inhibitor
223662747|NCT02689921|DRUG|Anastrozole|Aromatase inhibitor
223769852|NCT06169267|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow aspiration/biopsy
223769853|NCT06169267|PROCEDURE|Music Therapy|Listen to music
223769854|NCT06169267|OTHER|Questionnaire Administration|Ancillary studies
224242868|NCT05817916|PROCEDURE|LP block|LP block: ultrasound guided lumbar plexus block
223662748|NCT02689921|DRUG|Leuprolide Acetate|Luteinizing Hormone-Releasing Hormone agonist
223662749|NCT02689921|DRUG|Pertuzumab|Monoclonal antibody (HER2/neu receptor antagonist)
223662750|NCT02689921|DRUG|Trastuzumab|Monoclonal antibody (HER2/neu receptor antagonist)
223662751|NCT03645343|DEVICE|Activator|This appliance is constructed in one piece to guide the position of the mandible on closure
223662752|NCT03645343|DEVICE|Twin Block|This appliance is constructed in two pieces to guide the position of the mandible on closure
223662753|NCT01594801|DEVICE|InsuPad|Use of the InsuPad for at least 3 times a day.
223662754|NCT02763943|BEHAVIORAL|Pharmacist-led, technology enabled education intervention|Prospective, non-randomized, pilot study assessing the feasibility and potential efficacy of a 6-month, pharmacist-led, technology enabled education intervention on improving medication safety and cardiovascular risk factor control in adult solitary kidney transplant recipients with a secondary aim of assessing if the impact of the intervention varies by race.
223662755|NCT03496714|BEHAVIORAL|Psychoeducation on trauma reactions|The psychoeducation handout and video on trauma symptoms will discuss reactions that are common after experiencing a trauma.
223662756|NCT03496714|BEHAVIORAL|Psychoeducation on safety behaviors|The psychoeducation handout and video on safety behaviors will discuss safety behaviors that are common in PTSD and tips for how to eliminate them.
223662757|NCT02165839|BEHAVIORAL|Brief Behavioral Therapy for Insomnia (BBT-I)|
223662758|NCT02165839|BEHAVIORAL|Healthy Eating Education Learning (HEAL)|
223662759|NCT04340219|OTHER|Survey administration|Covid-19 Peritraumatic Distress Index, Depression Anxiety Stress Scale-21, WHO Quality of Life-BREF
223662760|NCT01957670|DEVICE|Lacrima medical Prototypes|
223662761|NCT01055652|DRUG|Dapagliflozin|10mg, oral, once daily
223662762|NCT03605602|OTHER|No treatment is included in this protocol.|No drug intervention or tissue sampling will be included in this study.
223662763|NCT05317780|DRUG|rAAV9-CB6-AspA|This study is an open label, expanded access trial of a simultaneous, single intravenous (IV) and intracerebroventricular (ICV) administration of rAAV9-CB6-AspA in a child with Canavan disease. The subject will also receive an immunosuppression protocol to prevent reaction to ASPA and vector capsids.
223662764|NCT02848729|DRUG|Oral Acetaminophen|Acetaminophen for oral administration (2 tablets, 500 mg/tablet)
223662765|NCT02848729|DRUG|IV Acetaminophen|Acetaminophen for intravenous (IV) administration (1,000 mg/100 mL)
223769855|NCT02606136|DRUG|Pamrevlumab|Pamrevlumab, 10 milligrams (mg)/milliliter (mL), single dose vials
224242869|NCT02565095|PROCEDURE|Stimulation of the carotid baroreceptors with a pressure system|In each decubitus, trains of stimuli 8 (-80, -60, -40, -20, 0, 10, 20 and 40 Torr), with a duration of 500 milliseconds each, will be applied using a positive and negative pressure system placed around the neck of the subject.
224242870|NCT01064349|DRUG|Anti-erbB2 therapy as part of a treatment regimen for either brain metastases or primary breast cancer|Trastuzumab or Lapatinib
224242871|NCT05020847|DIETARY_SUPPLEMENT|Standard F75|F-75 contains 75 kcal and 0.9 g protein per 100 ml
224242872|NCT05020847|DIETARY_SUPPLEMENT|Alternative F75 with CMV|Alternative F75 With CMV contains cereal flour, oil, sugar, powdered milk with complex mineral-vitamin (CMV)
223662766|NCT02848729|DRUG|IV Morphine|Morphine for IV administration (0.125 mg/kg)
223662767|NCT02848729|DRUG|Placebo Tablets|Placebo tablets matching oral acetaminophen
223662768|NCT02848729|DRUG|Saline|Saline placebo matching IV acetaminophen
223662769|NCT03873675|DIAGNOSTIC_TEST|parathyroid hormone|10-20ml blood samples taken from the arterial catheter every 12 hours to obtain parathyroid hormone serum concentration. 6-8 samples per patient
223662770|NCT04544215|BIOLOGICAL|Dosage 1 of MPCs-derived exosomes|7 times aerosol inhalation of MPCs-derived exosomes (8.0\*108 nano vesicles/3 ml at Day 1, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7).
223662771|NCT04544215|BIOLOGICAL|Dosage 2 of MPCs-derived exosomes|7 times aerosol inhalation of MPCs-derived exosomes (16.0\*108 nano vesicles/3 ml at Day 1, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7).
223662772|NCT04544215|BIOLOGICAL|No MPCs-derived exosomes|No aerosol inhalation of MPCs-derived exosomes
223662773|NCT00866008|DRUG|Ovarian stimulation|"1. Conventional regimen with a daily dose of 225 IU recombinant FSH and GnRH agonist long protocol co-treatment~2. Mild ovarian stimulation regimen using the endogenous FSH production by starting treatment on day 5 of the menstrual cycle with 150 IU / d recFSH with GnRH antagonist co treatment starting on day 6. As soon as two follicles reach 12 mm, treatment is continued with 200 IU / d rec hCG."
223662774|NCT04802629|DEVICE|Near-infrared spectroscopy|For NIRS measurements the t-NIRS 1 and NIRO 200 NX (Hamamatsu, Japan) will be used. A cerebral sensor will be placed and fixed with a CPAP (Continuous Positive Airway Pressure) cap on the left forehead and a peripheral sensor on the right forearm. Duration of measurement will be two hours.
223662775|NCT05790161|DRUG|Caffeine|2mg/kg, once before night 6 and once before the scan (either on week 1 or 2, alternating with placebo)
223662776|NCT06074042|OTHER|previous pulmonary tuberculosis|Previous pulmonary tuberculosis is comprehensively evaluated by the self-reported medical history, T-SPOT.TB test and radiological findings.
223662777|NCT00170001|DRUG|Nexium|40 mg bid dosing
223662778|NCT00170001|DRUG|Sugar Pill|40 mg BID
223662779|NCT01106469|DRUG|JNJ-41443532|25mg tablet once daily
223662780|NCT01106469|DRUG|JNJ-41443532|250mg tablet once daily
223662781|NCT01106469|DRUG|JNJ-41443532|1500mg once daily (with 250mg tablets)
223662782|NCT01106469|DRUG|JNJ-41443532|100mg tablet once daily
223662783|NCT01106469|DRUG|JNJ-41443532|1000mg once daily (with 250mg tablets)
223662784|NCT01106469|DRUG|Placebo|Matching placebo
223662785|NCT01106469|DRUG|JNJ-41443532|500mg once daily (with 250mg tablets)
223662786|NCT00791076|DRUG|Placebo|2pmol/kg-1/min-1 placebo infused continuously over 72 hours.
223662787|NCT00791076|DRUG|Pancreatic Polypeptide (PP)|2pmol/kg-1/min-1 PP infused continuously over 72 hours.
223662788|NCT05291468|RADIATION|FDG-PET/CT|Patients will be randomized in a 1:1 ratio to either receive a combination of doxycycline and azithromycin or placebo during 3 months, after which the inflammatory state of disease is measured by FDG-PET/CT and serum biomarkers. If patients have cutaneous sarcoidosis, a skin biopsy will be performed at baseline and at the end of the study.
223662789|NCT04404218|DIETARY_SUPPLEMENT|Açaí palm berry extract - natural product|Patients will be prescribed to take 1 capsule (520mg) of Açaí Palm Berry every 8 hours for a total of 3 capsules a day, during 30 days. Total dose: 1,560mg/day of Açaí Berry extract.
223662790|NCT04404218|OTHER|Placebo|Patients will take 1 placebo pill every 8 hours (total of 3 capsules a day) for 30 days.
224242873|NCT05020847|DIETARY_SUPPLEMENT|Alternative F75 without CMV|Alternative F75 without CMV contains cereal flour, oil, sugar, powdered milk without complex mineral vitamin (CMV).
223662791|NCT06237192|DRUG|blinatumomab for B-ALL, venetoclax for T-ALL|MRD-associated based therapy for Ph-negative acute lymphoblastic leukemia
223662792|NCT00210938|DRUG|Doripenem|
223769856|NCT03296696|DRUG|AMG 596|Drug
223769857|NCT03296696|DRUG|AMG 404|Drug
223769858|NCT06013904|PROCEDURE|Difficult PIV placement personnel|Patients randomized to this group will have their difficult PIV placed following the usual protocol for pediatric ED patients.
223769859|NCT06013904|PROCEDURE|US-trained PEM Fellows|US-trained PEM Fellows
224242874|NCT03305237|OTHER|Big Breakfast|Weight loss diet (Calories fed to measured RMR) with calories distributed predominantly at breakfast (percent daily calories split between breakfast, lunch and dinner as 45-35-20%). The diet will be high protein (30% protein, 35% fat and 35% CHO) with all meals provided.
224242875|NCT03305237|OTHER|Big Dinner|Weight loss diet (Calories fed to measured RMR) with calories distributed predominantly at dinner (percent daily calories split between breakfast, lunch and dinner as 20-35-45%). The diet will be high protein (30% protein, 35% fat and 35% CHO) with all meals provided.
223662793|NCT03561532|OTHER|Fecal microbiota transplantation (FMT)|FMT administered into the cecum of the patient in colonoscopy.
223662794|NCT03561532|OTHER|Placebo|Autologous FMT (fecal suspension made of patients own feces) administered into the cecum of the patient in colonoscopy.
223662795|NCT01024621|DEVICE|Endomicroscope|Pentax EC3870K, Tokyo, Japan
223662796|NCT01024621|DEVICE|Standard endoscopy|Pentax EG-2931 gastroscope
223662797|NCT00773227|PROCEDURE|Autologous myoblasts transplantation and myotomy|Graft of autologous cell muscles (myoblasts) isolated from unaffected limb muscles into the pharyngeal muscles of patients diagnosed as suffering from OPMD and surgical procedure (myotomy)
223662798|NCT02697110|BEHAVIORAL|Edutainment based intervention|Edutainment intervention package
223662799|NCT01109056|DRUG|cyclosporine ophthalmic emulsion 0.05%|One drop in the study eye (or eyes) administered four times daily (QID)
223662800|NCT01109056|DRUG|Vehicle|One drop in the study eye (or eyes) administered four times daily (QID)
223769860|NCT05728892|DRUG|Melatonin 3 MG|Preopertive melatonin adminstration oral 0.2 mg /kg 45 min before general anaethesia.
223769861|NCT05728892|OTHER|Placebo|Placebo medication will be given to control group
223769862|NCT06051773|OTHER|muscle involvement|evaluation of muscle involvement
223769863|NCT05304949|OTHER|Lucentis|There was no treatment allocation. Patients administered Lucentis by prescription were enrolled.
224242876|NCT04635618|BEHAVIORAL|Cognitive Behavioral Brief-Telepsychotherapy|Four sections of Cognitive Behavioral Brief-Telepsychotherapy plus personalized pre-recorded videos
223662801|NCT02052414|DRUG|Gabapentin ER|"Patient who are on gralise will report efficacy by rating his or her pain rating on a digital pain scale (11 points) from 0 to 10 on each scheduled clinical visits, which will be compared to their pain level at baseline.~In addition, patients will also record the doses and any adverse effects that might arise during the trial in a diary provided by the study. All information will be recorded in a paper diary that will be followed by coordinator during each follow up visits."
223662802|NCT02912143|OTHER|documentation only|
223662803|NCT01303003|DRUG|Dexamethasone|40 cc. 0.125% bupivicaine + 0.5cc. dexamethasone (2mg.) per side.
223662804|NCT01303003|PROCEDURE|TAP block|Bilateral TAP block of 40cc. of 0.125% bupivicaine + 0.5cc. sterile saline per side
223662805|NCT05741606|DRUG|Sodium pentaborate pentahydrate|Capsules containing sodium pentaborate pentahydrate 200, 400, 600, 800, and 1000 mg
223662806|NCT05741606|DRUG|Placebo|Placebo capsules
223662807|NCT00679445|DEVICE|NeoVista Ophthalmic System|A single procedure using the NeoVioasta Ophthalmic System plus an injection of Lucentis.
223662808|NCT02704143|OTHER|combination of Cyberknife with S-1|Radiation therapy combined with chemotherapy
223662809|NCT02151773|DRUG|Freeze-dried live attenuated measles and rubella combined vaccine (Schwarz FF-8 strain/TO-336 strain)|Freeze-dried live attenuated measles and rubella combined vaccine (Schwarz FF-8 strain/TO-336 strain)
223662810|NCT00395343|DRUG|sitagliptin phosphate|sitagliptin 100 mg tablet qd for a 24-wk treatment period.
223662811|NCT00395343|DRUG|Comparator : placebo (unspecified)|sitagliptin 100 mg Pbo tablet qd for a 24-wk treatment period.
223662812|NCT00917215|DEVICE|Disposable stainless steel acupuncture (0.2mmx4mm)|"For active acupuncture group, needles were inserted into nine acupoints (CV22 and bilateral LU5, ST40, BL13, EXB1)with De-qi three times a week for 4 weeks.~For sham acupuncture group, Nine non-acupoints corresponded with each active acupoint were treated with minimal penetration into skin three times a week for 4 weeks."
224242877|NCT04635618|BEHAVIORAL|Brief Interpersonal Telepsychotherapy|Four sections of Brief Interpersonal Telepsychotherapy plus personalized pre-recorded videos
224242878|NCT04635618|BEHAVIORAL|Telepsychoeducation|A single session psychoeducation group plus weekly personalized pre-recorded videos for 4 weeks
224242879|NCT00232336|DRUG|quetiapine|
224242880|NCT04465188|PROCEDURE|Encircling scleral buckle surgical procedure|Encircling scleral buckle surgical procedure under general anesthesia
223662813|NCT04982601|OTHER|Yoga Exercises|Yoga-based exercises are Hatha yoga-based sessions consisting of breathing exercises, warm-up exercises, relaxation, asanas exercises.
223662814|NCT03619811|DIAGNOSTIC_TEST|Reflux Band® Upper Esophageal Sphincter (UES) Assist Device|UES augmentation via the UES assist device is effective in true Reflux associated laryngeal symptoms. In our first pilot trial with the UES assist device, patients had significant symptom reduction following 2 weeks of UES assist device use. Based on our preliminary work, we theorize that the UES assist device is effective in Reflux associated laryngeal symptoms.
223662815|NCT02507960|DEVICE|The Gamma Pod|Immobilization of breast during radiation.
223662816|NCT02507960|DEVICE|CT simulation|See arm description
223662817|NCT05696028|DEVICE|Gamma counter|DTpA
223662818|NCT04605991|DRUG|LY900014|Administered SC
223662819|NCT04605991|DRUG|Insulin Glargine|Administered SC
223662820|NCT03263702|DEVICE|Computational Mapping Algorithm|This software enables high resolution temporospatial mapping of atria for the identification of drivers of AF. CMA receives data from standard of care, commercially available 3D Mapping Systems (St. Jude Ensite System) and catheters and processes the data in a unique way. Electrogram and anatomy data are fed from the commercially available 3D Mapping System to an adjacent laptop computer, via an Ethernet connection, that is running CMA. CMA then processes the electrogram data and generates a map of where the potential AF driver domains are located and superimposes those potential AF driver domain targets onto the 3D geometry of the anatomy (provided by the 3D mapping system).
223662821|NCT04958395|DIAGNOSTIC_TEST|FFR and d-FFR|Measure FFR and d-FFR
223662822|NCT00102778|DRUG|GW873140|
224242881|NCT06297889|BEHAVIORAL|core strength training 1-6weeks|Behaviour: core strength training intervention for 1-6 weeks. Experimental: The experimental group performed core strength training during weeks 1-3. Subjects were first provided with basic information, familiarised with the content of the first phase of core strength training and watched a core strength video to understand its importance. The initial intervention was designed to ensure that subjects were proficient in core strength training, including warm-up and stretching patterns. During weeks 4-6, subjects will be supervised and assisted and a test will be organised at the end of week 6. Variables related to physical fitness and skills were recorded to assess whether core strength training improved physical fitness and skills.
224321359|NCT03935438|OTHER|Cardiac rehabilitation|The training program of cardiac rehabilitation, depending on the results of the patient's medical qualification, will consist of the following: free active exercises, isometric exercises, active exercises in relief with resistance, isotonic exercises, isokinetic exercises, active breathing exercises, active breathing exercises with resistance, balance exercises, general exercises- individual and in groups, interval training on a treadmill or cycling cycloergometer, continuous training on a treadmill or cycling cycloergometer, circuit training, walking training, march training with accessories, autogenic training, walking. The training program will last an average 2 weeks.
223662823|NCT00102778|DRUG|Kaletra (lopinavir/ritonavir)|
223662824|NCT03976804|OTHER|low dose CT scan|Lung cancer screening will be based on the analysis of a low dose CT scan
223662825|NCT03976804|OTHER|blood sample collection|establish a phenotyping of immunity, blood inflammation and digestive and tumour microbiota
223662826|NCT03976804|OTHER|faecal sample collection|establish a phenotyping of immunity, blood inflammation and digestive and tumour microbiota
223662827|NCT00458770|PROCEDURE|position emission transaxial tomography|cerebral position emission transaxial tomography using 18Fluorodeoxyglucose
223662828|NCT01734889|DRUG|Nitisinone|Oral suspension
223662829|NCT00966875|BIOLOGICAL|LY2439821|Subcutaneous
223662830|NCT00966875|DRUG|Placebo|Subcutaneous
223662831|NCT05919836|PROCEDURE|Laparoscopic assisted hernia|Percutaneous assisted laparoscopic hernia
223662832|NCT05919836|PROCEDURE|Laparoscopic hernia by purse string closure|Laparoscopic purse string closure of hernial sac
223662833|NCT05919836|PROCEDURE|Total laparoscopic dissection of hernial sac|Total laparoscopic dissection of hernial sac
224242882|NCT06297889|BEHAVIORAL|core strength training 7-12weeks|"Behaviour: core strength training intervention #7-12 weeks#.~Experimental: Weeks 7-9 were the experimental group:~Continued to warm up before each training session. The training content will increase in difficulty during this phase, and the supervisor should explain the training content and watch videos of the movements prior to training and prepare the training equipment in advance to protect the athlete from injury. Weeks 10-12: This is an advanced stage, requiring equipment and difficult movements to complete, please supervisors to arrange personnel to do a good job of protection to ensure that the subjects can complete the training tasks. A test will be conducted the day after Week 12 to measure the athlete's physical fitness and skills."
223662834|NCT02886403|OTHER|Standard adhesive strip|A standard adhesive strip (hydrocolloid)
223662835|NCT02886403|OTHER|New adhesive strip|A newly developed adhesive strip
223662836|NCT06073483|DEVICE|Toumai Endoscopic surgery System|5G remote gastrectomy on subjects using the Toumai endoscopic surgery system
223769864|NCT04694131|DEVICE|TMS|The intervention of interest will be TMS delivered to the region of the left posterior parietal cortex with the greatest connectivity with the left hippocampus derived from the baseline resting-state fMRI session. This region was chosen because of its dense connections with the hippocampus, allowing stimulation of this location to modulate function of the hippocampal-cortical network. The control intervention target will be vertex, a commonly used active control site which does not influence neural or behavioral activity.
223769865|NCT05761873|OTHER|Provision of audit and feedback via email and paper|Provision of A\&F reports by paper via the post (new intervention being trialled) and email (standard practice) to allocated practices depending on randomisation status.
223769866|NCT05761873|OTHER|Provision of audit and feedback via paper only|Provision of A\&F reports by email (standard practice in the region) to allocated practices depending on randomisation status.
223769867|NCT05340686|BEHAVIORAL|Aerobic Physical Exercise|Moderate to vigorous physical exercise 30-45 minutes in a group setting led by psychiatric staff, 3 times per week for 6 weeks
223769868|NCT05340686|BEHAVIORAL|Relaxing Physical Exercise|Relaxing exercises (stretching, light yoga) 30-45 minutes in a group setting led by psychiatric staff, 3 times per week for 6 weeks
223769869|NCT05340686|BEHAVIORAL|Information about physical exercise|Written and oral information about physical exercise recommendations, on one occasion, by researcher
223769870|NCT01333488|DEVICE|Arctic Sun|Core Body Temperature will be lowered using an Arctic Sun device to 34C. Bladder probe will monitor core temperature.
224242883|NCT02789306|PROCEDURE|Epidemiological study on the incidence of peri-implantitis|Clinical and radiographic examination in the routine based protocol
224242884|NCT03488342|PROCEDURE|Repair for primary inguinal hernia|Repair for primary inguinal hernia
224242885|NCT00727571|OTHER|Observations|This is a non-interventional, observational study; no investigational product is being used
223769871|NCT01333488|DRUG|Magnesium Sulfate|IVI drug levels of Magnesium Sulfate targeted to plasma levels of magnesium of 2.5-3.5 mEq/Liter.(1.25-1.75mmol/L; or 3.04 - 4.26mg/dL)for 72 hours.
223769872|NCT04792112|BEHAVIORAL|Decision support tool|Decision support tool for late preterm antenatal corticosteroids
224242886|NCT02831569|DRUG|Loxoprofen sodium|
224242887|NCT02831569|DRUG|Methocarbamol|
224242888|NCT05167357|BIOLOGICAL|COVID19|"Intervention in experimental group (COVID+ group) is the disease itself, compared to the control group (COVID- group). At inclusion, subjects have been asked if they have suffered COVID19 in the 12 months before inclusion, during whichever wave, attested by a positive PCR, positive serology test or positive chest CT scan.~Moreover, the Richalet test is a cardiorespiratory exercise test on an ergocycle (an electrically braked cycloergometer), whilst continuous measurement by a 12-lead ECG, a blood pressure cuff, a metabograph and an ear pulse oximeter. This, to assess cardiac response, ventilatory response and relevant metabolic parameters (CF, RR, SpO2, volume, BP). Subjects breathes through a mask connected to a gas mixer, which provides a gas mixture with 11,5% oxygen (corresponding to ambient air at an altitude of 4800m) in the hypoxia phases."
224242889|NCT03164772|DRUG|Durvalumab|anti-PD-L1
224242890|NCT03164772|DRUG|Tremelimumab|anti-CTLA-4
223769873|NCT01352494|DRUG|docetaxel|docetaxel - 75 mg/m2, IV (in the vein), every 3 weeks, 4 cycles
223769874|NCT01352494|DRUG|gemcitabine|gemcitabine - 100 mg/m2, IV (in the vein) on day 1 and 8 day of each 28 day cycle, 4 cycles
223769875|NCT05414903|BEHAVIORAL|Dynamic Visual Acuity|"First, participants will report the direction of the open portion of a Landolt C (right, left, up, or down) with the head still. Ten targets at 5 acuity levels (LogMAR -0.3, 0, 0.3, 0.7, 1.0, corresponding to Snellen visual acuity of 20/10, 20/20, 20/40, 20/100, 20/200) will be identified. Next, a rate sensor will be placed on the subject's head in the plane of the horizontal canals and htDVA will be measured. The Landolt C will be presented automatically when the examiner has moved the subject's head \> 150˚/sec. htDVA scores will be the LogMAR at which the subject fails to correctly identify 50% of the visual targets or reaches a LogMAR of -0.3. The overall htDVA score is calculated by subtracting the head still LogMAR from the htDVA LogMAR. htDVA scores will be calculated for right and left head movements separately."
224242891|NCT03164772|BIOLOGICAL|BI 1361849|mRNA Vaccine
224242892|NCT03164772|DEVICE|PharmaJet Tropis® device|The PharmaJet Tropis® device was used for the intradermal administration of the BI 1361849 vaccine components.
224242893|NCT03034083|BEHAVIORAL|Elevate|Study participants receive needs assessment and 8 hours of classes over a 4-week period in healthy couple functioning behaviors, relationship quality/stability, and parenting skills.
223662837|NCT06085456|DIAGNOSTIC_TEST|Hematologic features|Hematologic features including blood routine tests, blood biochemical indicators, and tumor markers before surgery
223662838|NCT04602234|DIAGNOSTIC_TEST|Lung ultrasonography|Investigators performed lung ultrasonography on patients
223662839|NCT04647981|OTHER|Xpert® Bladder Cancer Monitor Test|The urine sample is analyzed with the Xpert® Bladder Cancer Monitor test.
223662840|NCT03505840|DIAGNOSTIC_TEST|Ultrasound with Doppler and 3D technology|ultrasound will be made to pregnant females in 3rd trimester with doppler and 3D technology
224242894|NCT00051025|DRUG|ONTAK|
224242895|NCT02189941|DRUG|Deferiprone sustained-release|Deferiprone sustained-release tablets
224242896|NCT02189941|DRUG|Deferiprone immediate-release|Deferiprone immediate-release tablets
224242897|NCT00538421|DRUG|Propofol|Infusion intravenously (IV) 0-10 mg/kg/h
224242898|NCT00538421|DRUG|Sevoflurane|0,7-1,5 MAC
224321360|NCT01357148|DRUG|Sitagliptin Phosphate/Metformin HCl (JANUMET®)|Participants prescribed Sitagliptin Phosphate/Metformin HCl (JANUMET®) in routine clinical practice.
224321361|NCT04210050|DEVICE|Home noninvasive nocturnal ventilation with Breas VIVO 50 home ventilator or newer model as available, Breas Medical.|"In the usual care plus NIPPV group, those able to undergo attended PSG will be titrated with volume targeted pressure support mode, aiming to lower the baseline TcCO2 by 10 mmHg. In some cases, the CO2 cannot be lowered by that amount on a single titration, but rather will decrease over time.~For those unable to undergo lab titration (too frail, no transportation, decline/refuse), NIPPV will be initiated with empiric settings based on nighttime home CO2 tracking and daytime ABG monitoring."
224242899|NCT01652079|DRUG|CRLX101|q 14 days
224242900|NCT04526964|BEHAVIORAL|Self-management curriculum|The Intervention starts during inpatient phase after relocation of potential study participants from the intensive care unit to normal ward and after informed consent to participate. Those subjects assigned to the CGr by randomization code receive standard care at the respective center. Subjects assigned to the IGr received, in addition to standard care, a multi-modular self-management training carried out at the respective center. The content of the self-management training should be deepened and consolidated through a supplementary app. Training is performed during inpatient post-implant phase, as well as one refresher session about six weeks after discharge during regular outpatient follow-up. The intervention lasts 3 months, plus a 9-month follow-up per subject. The content of the self-management training is based on current evidence and was written in a curriculum to achieve the highest possible standardization, taking into account the center specifics.
224321362|NCT04210050|DIAGNOSTIC_TEST|Arterial blood gas (ABG) and serum bicarbonate level|Will be obtained at baseline (before randomization), then at 3, 6 and 12 months into the study
224321363|NCT04210050|DIAGNOSTIC_TEST|Overnight home oximetry and transcutaneous CO2 monitoring|will be conducted at 1 and 6 months into the study (for subjects in the NIPPV plus usual care group, testing will be done while using the ventilator.
224321364|NCT06017050|BEHAVIORAL|BullyDown|BullyDown is an 8 week, text messaging-based prevention program aimed to prevent bullying behaviors among middle school-aged youth. Message content is based upon the social-emotional learning model.
223662841|NCT01589653|DRUG|biphasic insulin aspart 30|Dose individually adjusted by the subjects themselves according to the titration algorithm every second week. Administered subcutaneously (s.c., under the skin) twice daily.
223662842|NCT01589653|DRUG|biphasic insulin aspart 30|Dose individually adjusted according to the directions given by the investigator. Administered subcutaneously (s.c., under the skin) twice daily.
223662843|NCT03463005|OTHER|Royal jelly|The study subjects in the Royal jelly group used 10 ml of the vaginal Royal jell few minutes before and few minutes after intercourse one day after the end of menstruation for two weeks.
223662844|NCT03463005|PROCEDURE|IUI|Subjects in IUI group received 75 units of FSH from the second day of the cycle.
223662845|NCT01473680|OTHER|EEG, Neuropsychological Evaluation, Psychological Questionnaires, Medical Questionnaire|Participants will complete a medical/psychiatric history questionnaire, and a standardized battery of neuropsychological (NP) tests and psychological instruments. EEG recording will be made as participants engage in tasks of basic perceptual or pre-attentive processes and selective attention. Following chemotherapy (and a matched interval for the no-chemotherapy and healthy control groups), the standardized battery of NP tests, psychological instruments, and EEG will be repeated.
223662846|NCT01473680|OTHER|EEG, Neuropsychological Evaluation, Psychological Questionnaires, Medical Questionnaire|Participants will complete a medical/psychiatric history questionnaire, and a standardized battery of neuropsychological (NP) tests and psychological instruments. EEG recording will be made as participants engage in tasks of basic perceptual or pre-attentive processes and selective attention. Following chemotherapy (and a matched interval for the no-chemotherapy and healthy control groups), the standardized battery of NP tests, psychological instruments, and EEG will be repeated.
223662847|NCT01473680|OTHER|EEG, Neuropsychological Evaluation, Psychological Questionnaires, Medical Questionnaire|Participants will complete a medical/psychiatric history questionnaire, and a standardized battery of neuropsychological (NP) tests and psychological instruments. EEG recording will be made as participants engage in tasks of basic perceptual or pre-attentive processes and selective attention. Following chemotherapy (and a matched interval for the no-chemotherapy and healthy control groups), the standardized battery of NP tests, psychological instruments, and EEG will be repeated.
223662848|NCT00288899|OTHER|"Enhanced surgical iMedConsent process (with repeat back)"|"Consent process engages patient in discussion about why they are having procedure, risks, benefits, alternatives. Then provider asks patient to repeat backwhat they understand."
223662849|NCT00288899|OTHER|standard surgical iMedConsent process|Patients are consented in standard VA consent process, where are not necessarily asked to repeat back and no discussion is necessarily documented.
224321365|NCT06017050|BEHAVIORAL|Attention-matched control|The attention-matched control will receive the messages for the same number of days as the intervention. Content will talk about 'healthy lifestyle' topics, such as fitness and healthy social media use.
223662850|NCT01788813|DRUG|GSK2245035|Nasal spray solution, to be given intranasal, 80 ng/20 ng once weekly for 8 weeks
223662851|NCT01788813|DRUG|Placebo|Nasal Spray Solution, to be given intranasal, once weekly for 8 weeks
223662852|NCT01680198|DRUG|Paracalcitol|Patients in the experimental arm received 2 micrograms Paricalcitol capsules daily, for 12 weeks. This dose was adjusted based on clinical laboratory parameters and the maximum dose was 2 micrograms daily.
223662853|NCT01680198|DRUG|placebo|
223662854|NCT03557840|DRUG|temocillin|Drug dosing and blood sampling as per the protocol
223662855|NCT00408941|DRUG|Propofol|
224321366|NCT05093764|DEVICE|VIV TAVR with BVF using TCEP|The insertion and retrieval of the SENTINEL device is performed at the time of the patients TAVR procedure in the same setting while they are sedated under moderate sedation or general anesthesia depending on the case. The device is inserted at the initiation of the procedure through 6F right radial artery access and the filters are positioned in the left common carotid artery and brachiocephalic artery. After deployment, the usual TAVR procedure is performed. At the conclusion of the procedure, the SENTINEL device is extracted and hemostasis is achieved at the radial access site in the usual fashion with patent hemostasis.
223662856|NCT00408941|DRUG|Prilocaine|
224242901|NCT05992805|OTHER|N/A - non-interventional study|N/A - non-interventional study. Data collection only.
223662857|NCT04753151|DRUG|Tranexamic acid|The study will be designed as a prospective, double-blinded clinical trial, compared to placebo (0.9% saline) in combination with conventional treatment. Patients will receive intravenous administration of 10 mg / kg tranexamic acid or placebo (0.9% saline) for 10 minutes in the 20 minutes prior to the estimated skin incision. Right after the skin incision, a maintenance dose of 1 mg / kg / h of tranexamic acid (or equivalent infusion rate of 0.9% saline) will be started, remaining until the end of the suture of the surgical wound.
223662858|NCT04657666|DRUG|Nabiximols|oromucosal spray
223662859|NCT04657666|DRUG|Placebo|oromucosal spray
223662860|NCT02591498|BEHAVIORAL|Computerized cognitive training|
223662861|NCT02386189|BEHAVIORAL|Patient Care Coordination Training|Veterans in this group will share a comprehensive list of all of their providers (VA and non-VA) at future appointments. He/she will also be trained on how to create a VA Health Summary in My HealtheVet to share with their non-VA providers and how to use their community portals (if available) to share information back to VA providers. A VA and non-VA provider visit will be evaluated.
223662862|NCT05804617|PROCEDURE|Dome-type (Modified C-incision) manual morcellation|Morcellation performed by surgeon or trainee
223662863|NCT00291044|OTHER|testing for HSV 1 and 2 IgG type specific antibosy|
223662864|NCT02654964|DRUG|Combination Drug Therapy|"Up to 3 of 73 possible interventions from the drug classes listed below will be selected based on their potency against CSCs, potential for synergy without cross-reactive toxicities, drug safety profiles, pharmacokinetics, and drug-drug interactions. Those patients that have GBM that has recurred (as defined by RANO (45)), and for whom HTS was successfully completed, will be eligible to continue to the treatment component of the study to receive the drug cocktail comprised from the following drug classes:~Antineoplastic Anti-infective Antiemetic Antihyperlipidemic Anti-inflammatory Antihistamine Antihypertensive Antidepressant Cardiotonic Alcohol antagonist Diuretic Antipsychotic NMDA receptor antagonist Antidiabetic Immunosuppressant Anticonvulsant Antimethemoglobinemic Sclerosing agent"
223662865|NCT03223168|DEVICE|Hayek RTX ventilator|Participants will receive Noninvasive negative pressure from the Hayek RTX ventilator for 30 minutes during diagnostic catheterization procedure.
223662866|NCT01651806|DRUG|Tranexamic Acid standard dose|Uniform 1 gram dosing
223662867|NCT01651806|DRUG|Females Tranexamic Acid weighted dose|Weighted dose--20mg/kg of the drug will be given
223662868|NCT01651806|DRUG|Females receiving a uniform dose of TA|Patients will receive a uniform 1 gm dose of tranexamic acid prior to tourniquet release during a primary TKA.
223662869|NCT01651806|DRUG|Males Weighted Dose TA|Weighted dose--20mg/kg of the drug will be given
223662870|NCT01790243|DEVICE|Lutonix Drug Coated Balloon|Use of the Lutonix Drug Coated Balloon (DCB) for the treatment of stenosis or occlusion of the femoropopliteal arteries.
223662871|NCT01790243|DEVICE|Standard PTA Balloon|Use of Standard PTA Balloon in the treatment of stenosis or occlusion of the femoropopliteal arteries.
223662872|NCT01558128|DRUG|Amiodarone|Bolus given 150mg IV, then IV drip 1mg per hour infused for 6 hours, 0.5mg per hour infused for 18 hours.
223662873|NCT01558128|PROCEDURE|Cardioversion|Cardioversion done if atrial fibrillation continues following 24 hour infusion of amiodarone. Cardioversion done following hospital protocol.
223662874|NCT00447070|DRUG|ATAZANAVIR|
223769876|NCT05414903|BEHAVIORAL|Reading Outcomes|"The TOSWRF will be used to assess reading fluency. Children get 3 minutes to identify as many words as possible by drawing boundaries between successive unrelated words.~The TOSCRF will be used to assess reading fluency. Children are allowed 3 minutes to identify as many contextually related words as possible by drawing boundaries between successive words.~The TILLS will be used to assess reading comprehension. Each subject will read a short passage and answer 3 yes/no questions assessing reading comprehension.~A computer based MNREAD Test will be used to assess reading acuity, critical print size and Reading Accessibility Index.~During the TILLS and MNRead test, eye tracking (Eye Link 1000+ eye tracker) will be used to record fixation duration, saccade length, regression frequency, and total time spent."
224242902|NCT00163605|DEVICE|Macroporous Biphasic Calcium Phosphate-Fibrin Sealant Vapor Heated Solvent/Detergent Treated 4 IU/ML Thrombin (MBCP-FS)|
224242903|NCT00778505|DRUG|Propofol|closed-loop administration using bispectral index as the controller
224242904|NCT00778505|DRUG|remifentanil|closed-loop administration using bispectral index as the controller
224242905|NCT00778505|DRUG|Propofol|manual administration according bispectral index values
224242906|NCT00778505|DRUG|Remifentanil|manual administration according bispectral index values
224242907|NCT01381705|BIOLOGICAL|rituximab|
224242908|NCT01381705|GENETIC|DNA analysis|
224242909|NCT01381705|GENETIC|gene expression analysis|
224242910|NCT01381705|GENETIC|polymorphism analysis|
224242911|NCT01381705|OTHER|laboratory biomarker analysis|
224242912|NCT01381705|OTHER|medical chart review|
224242913|NCT05596877|BEHAVIORAL|Music therapy|Performing music therapy during a course of pulmonary rehabilitation (25 mins)
224242914|NCT00445003|DRUG|Ranibizumab|Intravitreal injection of 0.5 mg ranibizumab at baseline and 4 weeks
224321367|NCT00598572|DRUG|Deferoxamine Mesylate|Various dose-regimens ranging from 7 mg/kg to 125 mg/kg (with a maximum allowable total daily dose of 6000 mg at any of the tested dose tiers, regardless of patient's weight), administered daily by IV infusion for three consecutive days.
224242915|NCT00445003|DRUG|Triamcinolone Acetonide|Intravitreal injection of 4 mg triamcinolone acetonide at baseline and sham injection at 4 weeks
224242916|NCT00445003|BEHAVIORAL|Sham injection|Sham injection at baseline and 4 weeks
224242917|NCT00445003|PROCEDURE|Focal/grid laser|Focal/grid laser for diabetic macular edema was performed 3 days to 10 days after the injection for all treatment groups.
224321368|NCT04914234|DRUG|Atenolol Succinate Oral Tablet|Atenolol 50 mg
224242918|NCT02027909|DEVICE|Reprogramming dual chamber pacemaker|Reprogramming rate response feature in the Medtronic pacemaker to each arm with crossover
224242919|NCT05371444|BEHAVIORAL|Training with restriction of the DoF|The intervention is based in the training of a single DoF of the upper extremity with restriction of the rest DoF of the arm and trunk that aren't being trained being restrained by an exoskeleton
224242920|NCT05371444|BEHAVIORAL|Training without restriction of the DoF|The intrevention is based in the training of the upper extremity movements without the restriction of DoF
223662875|NCT04193514|OTHER|Acceptance and Commitment Therapy|The intervention is a 7-day self-guided acceptance-based intervention using a published Acceptance and Commitment Therapy self-help work book. This therapy is based on the theory that rigid attempts to control internal states, thoughts and feelings, and other forms of experiential avoidance contribute to symptom development and maintenance of depression, anxiety and/or stress. The therapy includes two components: (a) educating patients about the exacerbation of stress and negative affect through rigid attempts at experiential avoidance, and (b) introducing acceptance and the willingness to experience pregnancy-related sensations and cognitions as an alternative to experiential control, through the practice of intentional and non-judgmental paying attention to one's thoughts, feelings, images and bodily sensations (including aversive symptoms) and learning to see thoughts as an ongoing process distinct from self rather than merely an event with literal meaning.
223662876|NCT00043329|DRUG|Actimmune Registry|as administered by physician
223662877|NCT04120103|BEHAVIORAL|Doll therapy|The patient will then be given the doll to be used in the research by the caregiver and the researcher. Intervention group (accepting the baby) will be evaluated in terms of interaction with the baby, communication with employees and other patients and participation in daily life activities for 60 days. In addition, the agitation symptoms of the patients during the 60 days they spend with the baby will be evaluated by CMAI and cognitive level by MMSE.
223662878|NCT04120103|OTHER|Routine nursing care|The nursing care provided by the institution was applied to the dementia patients in the routine nursing care group. Routine nursing care group interventions in the institution; Monitoring of life signs, application of drug treatments, participation in social activities such as listening to music, reading prayer, initiatives such as assisting patients in performing daily living activities.
223662879|NCT05925543|PROCEDURE|Kasai portoenterostomy operation.|Kasai portoenterostomy operation for biliary atresia patients.
223662880|NCT06163378|DEVICE|Rubato Life App|An algorithmically enhanced personalized music-based intervention
223662881|NCT00551928|DRUG|Melphalan|High dose Melphalan 200mg/sm with autologous stem cell support
223662882|NCT00551928|DRUG|Lenalidomide|Six months of oral therapy with Lenalidomide 10mg/day given 21 days in every 28 days cycle with the combination ofMelphalan and steroids (day 22 to 28), for 6 cycles every 28 days.
223662883|NCT00551928|DRUG|Prednisone|Given orally at the dose of 2 mg/Kg for 4 days followed by a 24 day rest period (days 5 to 28), for 6 cycles every 28 days
223769877|NCT05414903|BEHAVIORAL|Static Visual Acuity|"The subject's head will be in a headrest. Static visual acuity will be assessed in 9 domains (3 levels of visual target complexity x 3 levels of presentation complexity). The 3 levels of visual target complexity are identifying: 1) colors, 2) the direction of the open prongs of the Landolt C (right, left, up, or down), which does not require alphabet knowledge, and 3) single letters (C, D, H, K, O, N, S, R, V, and Z; NIH Toolbox, Li 2014)). The 3 levels of presentation complexity are identifying: 1) 1-visual optotype, 2) a successive row of 5 visual optotypes flashed for 3 seconds (Hillman 1999), and 3) successive rows of optotypes in paragraph form as quickly as possible (i.e., rapid automatized naming). Outcome parameters will be %-correct at each acuity level and reaction time. Fixation duration, saccade length, saccade frequency, regression frequency, and total time spent will be collected via an eye tracker (Eye Link 1000+ eye tracker \[SR Research, EyeLink, Ontario, Canada\])."
223662884|NCT00551928|DRUG|Melphalan|Melphalan will be given orally at the dose of 0.18 mg/Kg for 4 days, followed by a 24 days rest period (day 5 to 28)for 6 cycles every 28 days
223662885|NCT03946696|OTHER|Interactions with therapy-animals|How people interact with humans and non-humans animals during and outside visits from therapy-animal teams.
223769878|NCT00390975|DRUG|Tegaserod|
223769879|NCT01637688|DIETARY_SUPPLEMENT|Comparison of treatment with different amino acid formulas|Growth and amino acid status of a newly innovated amino acid formula (NAAF) and a commercial amino acid formula (AAF)
223769880|NCT00754182|DEVICE|Octylcyanoacrylate (Dermabond)|Synthetic glue for surgical use (skin closure)
224242921|NCT06366906|DIAGNOSTIC_TEST|The Resnet50 deep learning (DL) model|The predictive capability of the above Resnet50 deep learning (DL) model was validated in the test set. Based on the AUC and ACC, the best prediction model was identified. To explore the robust of the selected model, ROC analysis was performed the in the external validation set. Moreover, the Log-rank test was applied to evaluate the prognostic value of the model.
224321369|NCT04914234|DRUG|Metoprolol Succinate Oral Tablet|Metoprolol 100 mg
224321370|NCT02925104|DRUG|INC280|
224321371|NCT00315796|DEVICE|Biophilic Nature Scene and Sound|
224321372|NCT06133127|OTHER|Frailty assessment|Assessments for all patients : isometric quadriceps strength, malnutrition by RFH-NPT and MNA questionnaires, body composition by circumference and triceps skinfold, frailty by LFI and SPPB, muscle cramps by Cramp questionnaire.
224321373|NCT00934687|DRUG|clostridium botulinum toxin type A neurotoxin complex|A total of 20-50 U of clostridium botulinum toxin type A neurotoxin complex (Allergan) will be injected at four to six sites in the glabella region according to standard protocols of cosmetic botulinum toxin applications.
224321374|NCT00934687|OTHER|0.9% NaCl solution|0.9% NaCl solution will be injected in analogy to clostridium botulinum toxin type A neurotoxin complex as a placebo comparator.
223662886|NCT04813367|PROCEDURE|Surgery of twisted fallopian tubes|Patients diagnosed with twisted fallopian tube go through surgery.
223662887|NCT02711228|BIOLOGICAL|Subcutaneous Immune Globulin (Human) (Hizentra)|Hizentra, Subcutaneous Immune Globulin (Human) (SCIg), is a ready to use, polyvalent human normal Immunoglobulin G (IgG) for subcutaneous administration. Hizentra is a 20% IgG protein solution, is prepared from large pools of human plasma, and is stabilized by L-Proline.
223662888|NCT04321447|OTHER|Clinical practice guideline for prevention and management of extravasation injury|Implementation of an evidence-based clinical practice guideline and delivery of an educational programme for nurses
223662889|NCT01199367|DRUG|KW-2450 in combination with lapatinib and letrozole|Three subjects will be assigned to each of 4 sequential cohorts. Dose escalation may proceed once at least 3 subjects have completed 30 days of study treatment. Subjects who withdraw prior to completing Day 30 for reasons other than DLT will be replaced. If a DLT is observed, additional subjects may be enrolled so that up to 6 subjects are enrolled at that dose level.
223662890|NCT05132803|DRUG|HPV 16 TA-CIN|No dose escalation or reduction
224321375|NCT01322230|OTHER|Control|Multimedia Control
224321376|NCT01322230|OTHER|WISEMD Original|Current WISEMD
224321377|NCT01322230|OTHER|Social Networking|Social networking feature
223662891|NCT01725659|OTHER|Motor Learning|training of the hemiplegic upper limb with motor learning
223662892|NCT01725659|OTHER|Robotics|subjects perform training of hemiplegic arm using an upper extremity robot
223662893|NCT01725659|OTHER|surface FES|subjects are provided with surface FES to the hemiplegic upper limb
223662894|NCT03287206|BIOLOGICAL|blood samples from children|CGH array, Fragile-X syndrome screening, DI459 panel, WES
223662895|NCT03287206|BIOLOGICAL|blood samples from parents|secondary controls for children's analyses
223662896|NCT05411627|DEVICE|Shockwave Therapy|Participants will receive shockwave therapy once per week for three weeks.
223662897|NCT00985777|DRUG|Vitamin E δ-Tocotrienol|Vitamin E δ-Tocotrienol is supplied as 100-mg, 200-mg, and 400-mg capsules. The investigator (or designee) will have records of the number of participants treated within a specific cohort and will determine which treatment cohort to assign newly enrolled participants.
224242922|NCT06412549|BEHAVIORAL|Health care practices and routines|"The scope of the project includes a diagnostic visit to participating hospitals, conducted by the coordinating center team, to understand existing protocols related to the management of invasive central nervous system devices (such as intracranial pressure monitoring catheters or external ventricular drains), as well as the physical infrastructure, human resources, and other precautions taken for the prevention and treatment of central nervous system infections. All recommendations in the intervention bundle for patient care will align with the guidelines of the National Health Surveillance Agency (ANVISA) and the best available scientific evidence for preventing infections associated with central nervous system devices.~* Provide the best care for patients with ICP and/or EVD, based on the best available evidence, with regard to the insertion and maintenance of catheters, as well as diagnosis and treatment in the presence of infection.~* Training of the multidisciplinary team."
223662898|NCT02551510|PROCEDURE|Suture|Skin incision closure with standard subcuticular technique
224242923|NCT03981341|DRUG|Duavive (0.45 estrogens mg and 20 mg bazedoxifene)|Drug given for 3 months in each participant
224242924|NCT03236207|OTHER|Test extensively hydrolyzed formula|extensively hydrolyzed formula with HMOs
224242925|NCT03236207|OTHER|Control extensively hydrolyzed formula|extensively hydrolyzed formula without HMOs
224242926|NCT04234256|OTHER|Static stretching exercise|Standing quadriceps stretch, Gastrocnemius stretch, Standing split, Adductor stretch, Half kneeling groin stretch, Hamstring stretch on the bench, Prayer squat, Seated adductor and hamstring stretch, Hurdle seat, Seated glute stretch, Lying glute stretch, Seated groin abduction, Soleus stretch, Half kneeling quad stretch, Split hamstring stretch
224242927|NCT04234256|OTHER|Dynamic stretching exercise|Downward dog to runner's lunge, Dynamic squat stretch, Crescent to hamstring stretch, Half kneeling hamstring stretch, Side to side lunge with reach, Standing calf and hamstring stretch, Hurdles, Side to side lunge with step, IT band stretch, Walking quad stretch, Swing the leg forward and back, Swing the leg cross, Knee pull, Standing quat stretch, Standing gluteus stretch
224242928|NCT02458482|DEVICE|AccuPAP|The AccuPAP device used by participants will give 2.5mg and 0.5mg nebulized Albuterol and Ipratropium over 5 minutes. Inspiratory and expiratory pressures to be set at 6 and 12 cm H20 respectively. This therapy is repeated at 20 and 40 minutes for a total of three AccuPAP treatments.
224242929|NCT02458482|DRUG|Albuterol and Ipratropium Continuous Nebulizer|10mg Albuterol and 1.5mg Ipratropium continuous nebulizer treatment will be administered to a Control group over a one hour period.
224242930|NCT01631565|BEHAVIORAL|Early allocation to palliative care|Symptoms management (e.g. Pain, nausea, dehydration management).
224242931|NCT01631565|BEHAVIORAL|Nutritional counseling|Nutritional status evaluation and dietary supplementation according to the patient requirements.
224242932|NCT01631565|BEHAVIORAL|Psychoeducation.|Patient and care-taker psychoeducation, depression and anxiety evaluation.
224242933|NCT01367340|BEHAVIORAL|Loaded sit-to-stand resistance exercise|Loaded STS exercise at home, 3 times a week for 6 weeks
224242934|NCT01367340|BEHAVIORAL|Physical activity intervention|The intervention is based on the social cognitive theory and the transtheoretical model. There are two principle components, the individual consultation and the small group PA activities. In the individual consultation, assessment of current stage of readiness for PA will be performed first. Then, individualized, stage-matched feedback will be sent to the participants. Small group PA activities will be held every 2 weeks in order to increase learning opportunity by peer interaction, make exercise fun, and introduce a role model.
224242935|NCT03318796|DEVICE|Coronary Artery Stenting|Interventional coronary artery stent placement in De novo bifurcation lesions of the MB \& SB
223662899|NCT02551510|DEVICE|Experimental: Histoacryl®|Skin incision closure with topic skin adhesive Histoacryl® Flexible (n-Butyl-2-Cyanoacrylate Monomer)
223662900|NCT01004198|DRUG|MP4OX|4.3 g/dL PEG-Hb solution in lactated electrolyte solution
223662901|NCT01004198|DRUG|MP4OX|4.3 g/dL PEG-Hb solution in lactated electrolyte solution
223662902|NCT01004198|DRUG|Ringers Lactate solution|Ringers Lactate solution for Injection
223662903|NCT04955678|DRUG|Calcium, hydrolysed divinylbenzene-Me 2-fluoro-2-propenoate-1, 7-octadiene polymer sorbitol complexes|ZG-801 is powder for suspension. In Run-in period, ZG-801 is taken once a day for 4 or 5 weeks. In Double-blind period, ZG-801 is taken once a day for 4 weeks.
223662904|NCT04955678|DRUG|Placebo|Placebo is powder for suspension. In Double-blind period, Placebo is taken once a day for 4 weeks.
224242936|NCT01297036|DRUG|Donepezil, ODT 10 mg|Test- Donepezil Hydrochloride 10 mg Tablet single dose
224242937|NCT01297036|DRUG|Donepezil, 10 mg tablet|Reference: Donepezil Hydrochloride 10 mg Tablet
224321378|NCT01322230|OTHER|Social Networking plus Emotional Design|social networking features plus user interface enhancements
224321379|NCT04428450|DEVICE|Deprexis|CBT-based, integrative online self-help program
224321380|NCT03364842|DRUG|Furosemide|Administering furosemide
224321381|NCT03437070|DRUG|Trabectedin|Administered intravenously per protocol on Day 1 for 21-day cycles.
223662905|NCT03963167|DRUG|BDP/FF/G fixed combination|Fixed combination of Inhaled Corticosteroid (ICS) / Long-acting β2-agonist (LABA) / long-acting muscarinic antagonist (LAMA) that contains Beclometasone dipropionate (BDP), Formoterol fumarate (FF) and Glycopyrronium (G).
223662906|NCT01649453|DEVICE|Pathwork® Tissue of Origin Test|
223769881|NCT00754182|DEVICE|Subcuticular reabsorbable suture (Caprosyn)|Every stitch is positioned in the subcuticular tissue by a continuous technique
223662907|NCT05367258|OTHER|Patients satisfaction after medical and surgical treatment for umbilical endometriosis|It is a retrospectively evaluation of cases of umbilical endometriosis in our clinic over the last 30 years, based on the review of medical records and on outpatient follow-up visits. The questionnaire are filled in routinely by patients attending the endometriosis center of this institute every 6 months. We will collect data relating to these questionnaires referring prospectively to the study period. If the questionnaires have not already been filled in by the patient, she will be contacted to fill them in, after signing the informed consent of the study.
223662908|NCT05607212|OTHER|Kettlebell Swing|Participants will perform two-handed kettlebell swings using the interval training protocol outlined in the study carried out by Jay et. al. (2011). The protocol calls for 30 seconds of work, followed by 30-60 seconds of rest for a total of 10 intervals. The mechanics of the kettlebell swing will follow those outlined in the study carried out by McGill et. al. (2012). All male participants will perform the intervention with a 16kg kettlebell and all female participants will perform the intervention with a 12kg kettlebell to assure reliability. The weight is higher than previous and similar study by Brandon et al to ensure measurable differences between experimental and comparison groups.
223662909|NCT05607212|OTHER|Isometric Hold|Participants will perform an isometric hold of a kettlebell for 30 seconds followed by 30 seconds of rest for a total of 10 intervals. Participants will mimic initial kettlebell swing position by standing shoulder width apart with their back straight, and hips and knees flexed. Participants will be cued to squeeze their glutes and look straight ahead while they hold the weight for the 30 second interval. All male participants will perform the intervention with a 16kg kettlebell and all female participants will perform the intervention with a 12kg kettlebell to assure reliability.
223662910|NCT05607212|OTHER|Control|Control group: participants will be educated on the benefit of a kettlebell swing.
223662911|NCT02933229|DEVICE|biopsy|patients enrolled in the study will receive gastroscopy and biopsies in order to evaluate status of pathology.
223662912|NCT02933229|DRUG|H. pylori eradication|"H. pylori eradication therapy comprising esomeprazole, amoxicillin,clarithromycin and colloidal bismuth pectin.~If failed in eradicating H. pylori, a culture based antimicrobial susceptibility test will be used to guide H. pylori eradication."
223662913|NCT03994029|DIETARY_SUPPLEMENT|Effect of polyphenols on hepatic steatosis and vascular elastography and intima media thickness|Measurement of effect of polyphenol supplementation vs placebo on hepatic steatosis and vascular elastography and intima media thickness
223662914|NCT00625664|DRUG|larotaxel (XRP9881)|administered on day 1 as a 1-hour infusion
223662915|NCT00625664|DRUG|gemcitabine|administered on day 1, 8 and 15 as a 30-minute infusion
223662916|NCT00625664|DRUG|cisplatin|1 hour infusion administered on day 1, 30 minutes after the other treatment
223662917|NCT05307913|OTHER|EIT-guided PEEP|PEEP setting according to EIT
223662918|NCT05307913|OTHER|Table-guided PEEP|PEEP setting according to the lower PEEP/FiO2 table
223769882|NCT04911725|DEVICE|Elastic Compression Prototype|Elastic Compression device - No medical, surgical or laboratory procedure is implied in the use of the IMD.
223769883|NCT01252290|DRUG|Lovaza™|4 capsules daily for 6 months
223769884|NCT06237153|DRUG|Triamcinolone Acetonide extended release suspension|Active steroid
224242938|NCT04942756|DEVICE|Continuous Glucose Monitoring|"FSL2 is an integrated continuous glucose monitoring (CGM) system that provides continuous glucose measurements every minute to provide glucose levels, trends and alerts. It is composed by a sensor and a reader. The Sensor, to apply on the back of the arm, continuously measures glucose concentration in interstitial fluid and has an 8-hour memory capacity. The Sensor is factory calibrated, does not require finger stick calibration and can be worn for up to 14 days.~The reader is a small handheld device that monitors glucose values in real-time to provide alerts and alarms which, when enabled, warn the user of Low Glucose, High Glucose or Signal Loss and prompt the user to scan the Sensor.~The FSL 2 System is CE mark, it is commercially available and in the current study it is being used in accordance with approved labeling. No modifications of FSL2 System have been performed for the utilization in the current study."
224242939|NCT04942756|DEVICE|Standard Care|"The control group is represented by the usual standard way for blood glucose (BG) monitoring. The control group will use a lancing device for finger samples for collection of blood drop to be put in the test strips to be read in the Glucose meter. Lancing devices, lancets and test strips used in the comparison groups are CE marked and are used according to the user's instructions.~Monitoring and/or self-monitoring of blood glucose using glucose meters and test strips provides quantitative measurements of fingerstick blood glucose at a single point in time for patients and their healthcare providers to monitor the effectiveness of glycemic control and make more immediate treatment with the right dosage of insulin. The usual standard routine for blood glucose monitoring in patients with DM and with insulin therapy is represented by at least three finger pricks/die according to the usual standards routine of each center."
224321382|NCT03437070|DRUG|Doxorubicin|Administered intravenously per protocol on Day 1 for 21-day cycles.
223662919|NCT03700684|BEHAVIORAL|Lee Silverman Voice Treatment|Persons with Parkinson's disease receive sixteen hours of voice treatment over a four week period. Participants will practice the vocal exercises at home for an additional four weeks.
223662920|NCT03700684|DEVICE|SpeechVive|Persons with Parkinson's disease wear the SpeechVive device several hours a day over an eight week period during opportunities for communication.
223662921|NCT03700684|BEHAVIORAL|Control|Persons assigned to the non-treatment control group will not participate in voice treatment.
223662922|NCT02721394|BEHAVIORAL|Functional Communication Training|Functional Communication Training (which aims to teach the child a communicative alternative to challenging behaviour) implemented by either the researcher or family carer.
223662923|NCT02236182|DRUG|Ipratropium Bromide low dose|
223662924|NCT02236182|DRUG|Placebo|
223662925|NCT02236182|DRUG|Ipratropium Bromide high dose|
223662926|NCT06174142|DEVICE|High-Frequency ESWT|Participants will receive extracorporeal shock wave therapy at a frequency of 15 Hz and intensity/pressure level 3, with a total of 1800 impulses per session. This intervention will be conducted once per week for six weeks, alongside a standard physical therapy regimen
223662927|NCT06174142|DEVICE|Low-Frequency ESWT Group|"Participants will be treated with extracorporeal shock wave therapy at a frequency of 10 Hz and intensity/pressure level 4, also with a total of 1800 impulses per session. This protocol will be delivered weekly for six sessions, accompanied by standardized physical therapy exercises."
224242940|NCT02992678|DRUG|Pentoxifylline|Pentoxifylline, 400 mg, 3 times daily by mouth the day before ERCP procedure. Subjects received up to a maximum of 3 doses.
223662928|NCT06174142|DEVICE|Sham ESWT Control Group|"Participants in this control group will undergo a sham ESWT procedure that mimics the treatment experience without actual therapeutic effects, ensuring the blinding of participants. This sham therapy will be scheduled once a week for six weeks, in conjunction with the same physical therapy program as the other groups."
223662929|NCT04693052|OTHER|No interventions|This is a self-reported survey study about receiving mental health care during the COVID-19 pandemic
223662930|NCT01718418|OTHER|test meal|
223662931|NCT01718418|OTHER|reference|
223662932|NCT00321581|DRUG|Cediranib, AZD2171, RECENTIN|
223662933|NCT04348968|DEVICE|Total hip arthroplasty|"The THA surgical procedure involves replacing the head of the femur and acetabulum or socket with an artificial prosthesis. This system is composed of a femoral stem that is inserted into the femoral canal, a ball that attaches to the femoral stem, and an acetabular component or shell that replaces the acetabulum.~In this study, the acetabular component is the Zimmer Maxera Cup, which is a monoblock construct consisting of a pre-assembled shell and liner. The ceramic liner articulates with a ceramic femoral head for a ceramic-on-ceramic large diameter head articulation. The Maxera Cup is intended for single use only and is designed for reconstruction of the hip joint for conditions described in the inclusion and exclusion section of this protocol."
223662934|NCT05739084|RADIATION|pre-operative radiation|As per standard of care and institutional guidelines
223662935|NCT05739084|PROCEDURE|Standard surgery after rpreoprative radiation|As per standard of care and institutional guidelines
224242941|NCT02992678|DRUG|Placebo|Placebo, 400 mg, 3 times daily by mouth by mouth the day before ERCP procedure. . Subjects received up to a maximum of 3 doses.
224242942|NCT05948891|DRUG|Beclometasone/Formoterol/Glycopyrronium 88 µg/5 µg/9 µg DPI (Trimbow® 88 µg/5 µg/9 µg in NEXThaler device)|observational, prospective, multicentric, international, cohort study
224242943|NCT01196052|DRUG|Trastuzumab emtansine|Trastuzumab emtansine was provided as a single-use lyophilized formulation in a glass vial.
224242944|NCT05313425|OTHER|Ectohylo (R) eye drops|using Ectohylo eye drops post operative after PRK in the right eyes of the patients
224242945|NCT01908725|DRUG|Lamazym|ERT, i.v. infusions weekly
224242946|NCT02178722|DRUG|MK-3475|IV infusion
224242947|NCT02178722|DRUG|INCB024360|Oral daily dosing
224242948|NCT05567874|OTHER|Nosocomial SARS-COV 2 Infection proportion|Proportion of Nosocomial SARS-COV 2 Infections in Patients Hospitalized at the Metz-Thionville Regional Hospital in 2021
224242949|NCT03037372|DRUG|ART, Atorvastatin|ART, Atorvastatin
224242950|NCT03037372|DRUG|ART, Rosuvastatin|ART, Rosuvastatin
224242951|NCT03037372|DRUG|ART, No statin|ART, No statin
224242952|NCT03037372|DRUG|Healthy-HIV-negative|Age-matched, Healthy HIV-negative
224242953|NCT05561335|DEVICE|hearing aid -novel program|novel microphone configuration
224242954|NCT05561335|DEVICE|hearing aid - standard program|standard microphone configuration
224242955|NCT04225663|BEHAVIORAL|Guided Meditation|Participants will meditate in response to the guidance provided by a trained meditation coach in person.
224242956|NCT00828035|PROCEDURE|laparoscopic surgery|comparison of two different laparoscopic surgeries : robot versus human
223662936|NCT05869357|OTHER|cream containing 2.5% sericin and 2%turmeric|Sample is applied 2 times/day for 6 days. Then, use of the sample is stopped for 7 to 10 days. After that, sample is applied 2 times/day for 3days.
223662937|NCT05869357|OTHER|cream containing 5%sericin and 2%turmeric|Sample is applied 2 times/day for 6 days. Then, use of the sample is stopped for 7 to 10 days. After that, sample is applied 2 times/day for 3days.
223662938|NCT05869357|OTHER|cream containing 10%sericin and 2%turmeric|Sample is applied 2 times/day for 6 days. Then, use of the sample is stopped for 7 to 10 days. After that, sample is applied 2 times/day for 3days.
223662939|NCT05869357|OTHER|cream base|Sample is applied 2 times/day for 6 days. Then, use of the sample is stopped for 7 to 10 days. After that, sample is applied 2 times/day for 3days.
223662940|NCT03118908|DIETARY_SUPPLEMENT|Amberen|Amberen is a succinate-based dietary supplement previously shown to help provide relief for common menopausal symptoms.
224242957|NCT02381210|DEVICE|Congo Red Dot Test|The Congo Red Dot test is a simple test has been developed to detect unfolded or misfolded proteins in urine.
224242958|NCT03061526|OTHER|optical coherence tomography|measurement of reflectivity in different retinal layers based on optical coherence tomography findings
224242959|NCT03512366|PROCEDURE|Desarda's technique|It will be performed by separating a strip from the upper leaf of the external oblique aponeurosis in continuity with the muscle and suturing it with the inguinal ligament below and the newly formed upper leaf of EOA above behind the spermatic cord to form the new inguinal floor. This strip will be put under tension by muscular contraction and works as a shield to prevent recurrence.
224242960|NCT03512366|PROCEDURE|Lichtenstein's technique|A 6 × 11 cm polypropylene mesh will be fashioned to fit the posterior wall of the inguinal canal and sutured to the fibro-periosteum of the pubic bone and continued laterally, suturing the inferior edge of the mesh to the shelving edge of the inguinal ligament to a point 2 cm lateral to the internal ring.
224242961|NCT02995057|DEVICE|Gold- or silver-coated, or uncoated nickel microneedles|The stratum corneum of the participants will be breached with the gold- and silver-coated, or uncoated nickel microneedles.
224242962|NCT03340727|DRUG|Caffeine Citrate|The study intervention is caffeine citrate given once daily at 10 mg/kg/day. It is given orally, before hospital discharge and 28 days after discharge.
224242963|NCT03340727|DRUG|Placebo|The study intervention is placebo given once daily at a volume equivalent to 10 mg/kg of caffeine citrate. It is given orally, before hospital discharge and 28 days after discharge.
224242964|NCT04247308|OTHER|Sensory Stimulation|Auditory, tactile, visual, vestibular and oro motor stimulation
224321383|NCT03437070|DRUG|Olaratumab|Administered intravenously per protocol
224321384|NCT06008275|DRUG|Neratinib Oral Tablet|240mg oral daily. Dosing will follow standard dose escalation procedures
224321385|NCT06008275|DRUG|Ruxolitinib Oral Tablet|20mg oral twice daily. Dosing will follow standard initial dose recommendation procedure
223662941|NCT03118908|DIETARY_SUPPLEMENT|Smart B|Smart B contains vitamins B1, B2, B6, B9, B12 and sodium fumarate.
223662942|NCT03118908|DIETARY_SUPPLEMENT|Placebo|Placebo capsules are identical to Amberen and Smart B capsules.
223662943|NCT02126345|DEVICE|MASTER SL femoral stem and DELTA TT acetabular cup|
224242965|NCT04247308|OTHER|Movement therapy|Passive range of movements, antigravity movements in prone and supine
224242966|NCT04247308|OTHER|Routine hospital care|Maintaining the vitals
223662944|NCT05779371|BEHAVIORAL|Integrated-based Laughing Qigong Program|The protocol of the Integrated-based Laughing Qigong Program (IB-LQP) combined laughter intervention and mental health promotion courses. It was a two-hour community activity held twice a week for six weeks. The content was 50-60 minutes of a laughter practice program and 50 minutes of mental health lectures, separated by a 10-minute break.
223662945|NCT03014232|PROCEDURE|SLED-f with HCO dialyzer|Online SLED-f with high cut-off dialyzers were performed using the Fresenius 5008S hemodiafiltration machines (Fresenius Medical Care, Bad Homburg, Germany). Super-flux, Sureflux 150FH (Nipro Corporation, Osaka, Japan; cellulose triacetate material, pore size 78 A◦, Kuf 66.9 mL/hr/mmHg, surface area 1.5 m2) were used. Dialysis time and blood flow rate were 6 hours and 200 mL/min, respectively. The predilution reinfusion fluid rate and dialysate flow rate were 80 and 220 mL/min, respectively (the total dialysis fluid flow rate was 300 mL/min).
223662946|NCT03014232|PROCEDURE|SLED-f with HF dialyzer|Online SLED-f with standard high-flux dialyzers were performed using the same Fresenius 5008S hemodiafiltration machines (Fresenius Medical Care, Bad Homburg, Germany). High-flux ELISIO 150H (Nipro Corporation, Osaka, Japan; polynephron material, pore size 50-60 A◦, Kuf 67 mL/hr/mmHg, surface area 1.5 m2) were used. Dialysis time and blood flow rate were 6 hours and 200 mL/min, respectively. The predilution reinfusion fluid rate and dialysate flow rate were 80 and 220 mL/min, respectively (the total dialysis fluid flow rate was 300 mL/min).
223662947|NCT03319745|BIOLOGICAL|Pembrolizumab|Given IV
223662948|NCT01317550|DRUG|Armodafinil|150 mg by mouth once a day for a 10 week cycle.
223662949|NCT01317550|OTHER|Placebo|Capsules taken by mouth once a day for a 10 week cycle.
223662950|NCT01317550|DRUG|Minocycline|100 mg by mouth twice a day for a 10 week cycle.
223662951|NCT01317550|BEHAVIORAL|Questionnaires|Completion of symptom questionnaire before chemoradiation, then once a week during Weeks 1-16, takes up to 5 minutes to complete.
223662952|NCT05356156|PROCEDURE|Closure of the mesenteric defects|The surgically created mesenteric defects will be closed after radical gastrectomy with D1+/D2 lymph node dissection.
223662953|NCT05356156|PROCEDURE|Non-closure of the mesenteric defects|The surgically created mesenteric defects will not be closed after radical gastrectomy with D1+/D2 lymph node dissection.
223662954|NCT03872076|OTHER|Experimental|"The Drom Jump technique with the legs flexed will be performed with the patient standing in front of a bench 30 cm high by 100 cm wide. The physiotherapist will be placed lateral to the athlete. The subject will be asked to jump up from the box or bench, with the hip and knees in semi-reflexion, with his hands on his hip and he will be asked for an explosive jump, followed by a jump downwards falling the floor of the same way.~The technique of lateral jumps on cones will be carried out by means of unipodal jumps, achieving a distance of 50 cm between cones. The physiotherapist will stand in front of the athlete. The subject will be asked to perform a lateral unipodal explosive jump by flexing the hip and knee."
223662955|NCT03872076|OTHER|Control|"Elastic bands will be combined with isometric exercises in 3 sets of 10 repetitions each. The exercises they will perform are front squat. On the one hand, separating the legs at the height of the shoulders with hip and knee flexion, with the elastic band above the knees, maintaining the position 20 seconds.~In the following exercise, with the elastic band on the ankle, in unipodal support at the same time that the contralateral limb is free of support, the hip will be flexed at 45º with full knee extension, requesting the athlete to keep the tension 20 seconds, performing 3 sets of 10 repetitions."
223662956|NCT03830723|DRUG|Follitropin delta|Study medication doses during all 3 insemination will be personalized using a suggested algorithm
223662957|NCT00870103|DRUG|Vigadexa (moxifloxacin 0.5% and dexamethasone 0.1%) eye drops|1 drop every 6 hours into the study eye
223662958|NCT00121862|BIOLOGICAL|Leish-111f + MPL-SE vaccine|
224242967|NCT01743326|PROCEDURE|Radio Frequency Denervation|
224242968|NCT01743326|PROCEDURE|Local Anesthesia|
224242969|NCT03553823|PROCEDURE|Skin biopsies|At Baseline, two 6-mm punch biopsies were taken, one from the identified active plaque (TCS ≥ 6) and one from never-lesional skin. At the End-of-study Visit, one biopsy was taken from the same area of the active plaque sampled at Baseline.
224242970|NCT01572948|DRUG|roflumilast|The study drug (roflumilast, Daliresp™, Forest Laboratories, Inc.) is a targeted inhibitor of phosphodiesterase 4 and is given once daily via oral route. There is proven anti-inflammatory and anti-oxidant potential in both animal and human models
224242971|NCT01572948|DRUG|placebo|The placebo (Forest Laboratories, Inc) is manufactured as an odorless and otherwise equivalent tablet to the roflumilast tablet, but contains no active ingredient
224242972|NCT04043884|OTHER|sEmg biofeedback training|Volunteers will perform scapular strengthening and stabilization exercises added to sEMG biofeedback in the upper trapezius (TS), Trapezius (TM), Lower Trapezius (TI), and Serratil Anterior (AS) muscles in real time displayed in a Computer screen.
224242973|NCT04043884|OTHER|Strength training|The volunteers will perform a strengthening protocol with elbow flexion exercises, medial and lateral shoulder rotation, scapular retraction and push up plus.
224242974|NCT03603314|DRUG|SENS-401|29 mg dose group: tablets of 14.5 mg, oral route, by mouth, twice a day, during 4 weeks
224242975|NCT03603314|OTHER|Placebo Oral Tablet|placebo, oral route, by mouth, twice a day, during 4 weeks
224242976|NCT03603314|DRUG|SENS-401|43.5 mg dose groupe: tablets of 14.5 mg, oral route, by mouth, twice a day, during 4 weeks
224242977|NCT05468021|OTHER|Educational intervention|Randomized Clinical Trial (study design) to evaluate the effectiveness of an educational intervention to increase vaccine uptake among socioeconomically disadvantaged adults. The intervention will consist of a health promoter with an educational toolkit addressing misinformation, distrust, and hesitancy regarding the COVID-19 vaccine. An educational website with videos addressing COVID-19 vaccine will be available to study participants to boost information provided in the educational toolkit.
224242978|NCT05687864|DIAGNOSTIC_TEST|Polysaccharide superparamagnetic ferric oxide injection|The polysaccharide superparamagnetic ferric oxide injection is a clinical diagnostic reagent
224242979|NCT02598479|OTHER|IPTLD and nutrition therapy|The measurement of Quality of Life in patients who choose to use Insulin Potentiation Low Dose Therapy and Nutritional Therapy in the treatment of cancer
224242980|NCT04901221|DEVICE|Extrusion arch|one couple force system is applied; a custom-made extrusion wire from 0.016x0.022 stainless steel wire with helical bends placed 2-5 mm mesial to the molar tube placed in the upper and lower arches and tied distal to the lateral incisors
224242981|NCT05037006|DRUG|Sevoflurane - Neostigmine 30|Neostigmine 30 mcg/kg and atropine 15 mcg/kg when TOFc 3
224242982|NCT05037006|DRUG|Sevoflurane - Neostigmine 50|Neostigmine 50 mcg/kg and atropine 25 mcg/kg when TOFc 3
224242983|NCT05037006|DRUG|Sevoflurane - Neostigmine 70|Neostigmine 70 mcg/kg and atropine 35 mcg/kg when TOFc 3
224242984|NCT05037006|DRUG|TIVA - Neostigmine 30|Neostigmine 30 mcg/kg and atropine 15 mcg/kg when TOFc 3
224242985|NCT05037006|DRUG|TIVA - Neostigmine 50|Neostigmine 50 mcg/kg and atropine 25 mcg/kg when TOFc 3
223662959|NCT06078800|DRUG|YL-17231|After a screening period of approximately 14 days, eligible patients will receive oral YL-17231 once or twice daily until documented disease progression, unacceptable AEs, intercurrent illness preventing further administrations of study treatment, investigator's decision to withdrawal, the patient's consent of withdrawal, pregnancy, or for administrative reasons. Following the end of treatment, patients will continue to be followed for safety for 30 days. Patients who permanently discontinue study treatment for reasons other than disease progression will have post-treatment follow-up for disease assessment until start of new anticancer treatment, patient's consent of withdrawal, lost to follow-up, death, or until the Sponsor stops the study, whichever comes first.
223662960|NCT03287271|DRUG|VS-6063|"Phase 1:~* First 3 patient cohort: VS-6063 200 mg PO twice daily~* IF TOLERATED, Second 3 patient cohort: VS-6063 400 mg PO twice daily,~Phase 2:~VS-6063 400 mg PO twice daily of a 28 day cycle until disease progression or unacceptable toxicity."
223662961|NCT03287271|DRUG|Paclitaxel|"Phase 1:~* First 3 patient cohort: paclitaxel 80 mg/m2 infused IV continuously over 1 hour on days 1, 8, and 15 of a 28 day cycle.~* IF TOLERATED, Second 3 patient cohort: paclitaxel 80 mg/m2 infused IV continuously over 1 hour on days 1, 8, and 15 of a 28 day cycle.~Phase 2:~Paclitaxel 80 mg/m2 infused continuously over 1 hour on days 1, 8, and 15 of a 28 day cycle until disease progression or unacceptable toxicity."
223662962|NCT03287271|DRUG|Carboplatin|"Phase 1:~* First 3 patient cohort: carboplatin (AUC of 5 mg/mL/min) IV infused continuously over 1 hour on day 1 of a 28 day cycle.~* IF TOLERATED, Second 3 patient cohort: carboplatin (AUC of 5 mg/mL/min) IV infused continuously over 1 hour on day 1 of a 28 day cycle.~Phase 2: carboplatin (AUC of 5 mg/mL/min) infused continuously over 1 hour on day 1 of a 28 day cycle until disease progression or unacceptable toxicity."
223662963|NCT06466408|DIETARY_SUPPLEMENT|Supplementation Protocol|After the pre-test, the enzyme group consumed 30 mL of vegetable and fruit enzymes (The contents include needle-leaf cherries, cherries, apples, cranberries, blackberries, black currants, blueberries, beets, broccoli, cabbage, carrots, Concord grapes, cranberries, elderberries, kale, oranges, peaches, papayas, parsley, pineapples, raspberries, red currants, spinach, and tomatoes, etc.)(Enzyme Village, Chiayi, Taiwan) mixed with 150 mL of water twice a day (at breakfast and dinner) for 14 consecutive days. The placebo group followed the same protocol but consumed malt syrup (Amazon, USA) instead until the end of the study. Participants returned to the laboratory each morning to receive the daily supplement, which was administered on-site. Following supplementation, participants reported their dinner intake to the researchers, ensuring compliance with the prescribed supplementation regimen.
223662964|NCT06466408|DIAGNOSTIC_TEST|Blood Lactate Test|The blood lactate was measured at five time points: before exercise, after the fourth and eighth bouts of exercise, and at 5 and 10 minutes after exercise. The blood lactate were analyzed using a Biosen Cline blood analysis system (EKF-diagnostic, Germany). Capillary blood samples of 10 μL were collected and added to red blood cell lysis reagent and stored at low temperature until analyzed. Prior to analysis, instrument standardization and test calibration were performed, and the coefficient of variation was determined to be ≤1.5%. The detection range for blood lactate was 0.5-40 mM
223662965|NCT06466408|DIAGNOSTIC_TEST|Training Impulse|In this study, the exercise load was represented by the TRIMP \[32\], which is calculated as the product of exercise intensity and duration. To accommodate the convenience of the experiment, two different TRIMP calculation methods were used, including % HRmax (objective) and RPE (subjective). At the end of each exercise bout (8 bouts in total) and during the recovery period before the next bout (7 bouts in total), participants were asked to report their RPE, and their heart rate was recorded. This process was repeated 8 times.
224242986|NCT05037006|DRUG|TIVA - Neostigmine 70|Neostigmine 70 mcg/kg and atropine 35 mcg/kg when TOFc 3
224242987|NCT03450070|DEVICE|Light Therapy Mask Cream|test panel
224242988|NCT03733509|PROCEDURE|Intraoperative Block|One shot adductor canal nerve block with 20ml of bupivacaine 0.25% through surgical incision
224242989|NCT03733509|PROCEDURE|Ultrasound Block|One shot adductor canal nerve block with 20ml of bupivacaine 0.25% mid-thigh
224242990|NCT03733509|PROCEDURE|Intraoperative Placebo|One shot adductor canal nerve infusion with 20ml of saline solution through surgical incision
224242991|NCT03733509|PROCEDURE|Ultrasound Placebo|One shot adductor canal nerve infusion with 20ml of saline solution mid-thigh
224242992|NCT02183688|DRUG|Low dose ASA|
224242993|NCT02183688|DRUG|High dose ASA|
224242994|NCT02183688|DRUG|Low dose paracetamol|
224242995|NCT02183688|DRUG|High dose paracetamol|
224242996|NCT02183688|DRUG|Caffeine|
224242997|NCT02183688|DRUG|Placebo|
224242998|NCT03737578|OTHER|Delivery of a connected pedometer / accelerometer|"Delivery of a connected pedometer / accelerometer that the patient will be asked to wear at least 7 consecutive days / month.~Quality of life and leg restless syndrome questionnaires (auto questionnaire) completed by the patients every 3 months"
224242999|NCT03608215|DEVICE|Active tDCS|The anode and cathode sponge electrode (51 cm2) will be placed over C3 and FP2 (10-20 system) respectively. 2 mA current will be applied continuously for 20 minutes.
224243000|NCT03608215|DEVICE|Sham tDCS|The anode and cathode sponge electrode (51 cm2) will be placed over C3 and FP2 (10-20 system) respectively. 2 mA current will be applied for 30 seconds at the beginning.
224243001|NCT00999037|DRUG|Sevelamer Carbonate|Daily renvela (800 mg tid with meals) x 12 weeks
224243002|NCT00999037|OTHER|Placebo|1 inert tablet tid x 12 weeks
224243003|NCT00002361|DRUG|Indinavir sulfate|
224243004|NCT00002361|DRUG|Ritonavir|
224243005|NCT03643328|BIOLOGICAL|blood samples|Blood samples will be collected at inclusion, at 6 months and 12 months for hematological and immunological analyses.
223662966|NCT06466408|DIAGNOSTIC_TEST|Exergaming HIIE Test|The sensor system utilized two Nintendo controllers: one mounted on the exercise ring and the other secured to the participant's thigh to enhance gameplay interaction. Through the Ring-Con, participants engaged in diverse physical activities such as weightlifting, yoga, and aerobic exercises. The fitness ring sensor accurately captures and integrates players' movements into the game. The gameplay involves unlocking levels and engaging in fitness challenges that are achieved through actual physical activities. It offers a wide range of exercise routines targeting various muscle groups and provides engaging gaming challenges. The exercise protocol included eight sets of 20-second high-effort exercises, interspersed with 30-second rest intervals, totaling 370 seconds of active exercise time. Specifically, the fitness game mode used was the Adventure Mode in 'Ring Fit Adventure,' comprising exercises targeting the pectoralis major, latissimus dorsi, deltoids, and quadriceps muscles.
223662967|NCT06394362|OTHER|Bispectral index monitor|Bispectral Index (BIS), that was introduced in 1992, is a tool that monitors the depth level of hypnosis through data processing of an electroencephalogram using computer algorithm and presented in the form of processed EEG. Utilizing BIS as a monitoring tool has shown effectiveness in reducing recovery time, prevent awareness, and bring down the amount of anesthesia agent however, as of now, it has not been incorporated into the 2020 American Society of Anesthesiologists (ASA) standard procedure on anesthesia monitoring. aims to comparing the deep hypnotic time duration on two group of geriatric patients which undergoes general anesthesia with BIS monitoring compared to standard monitoring.
223662968|NCT01523847|DRUG|MBVD (Myocet+BVD)|"MBVD will be scheduled as follows:~Myocet 25 mg/mq i.v. day 1 and 15 Bleomycin 10 mg/mq i.v. day 1 and 15 Vinblastine 6 mg/mq i.v. day 1 and 15 Dacarbazine 375 mg/mq i.v. day 1 and 15"
223662969|NCT06074731|DIAGNOSTIC_TEST|SS-OCT system Plex Elite 9000|We will use a commercially available SS-OCT system (Plex Elite 9000; Carl Zeiss Meditec).
223662970|NCT02065427|BEHAVIORAL|Social Support|a) PHCT professionals: standardized training to implement caregivers intervention. b) Caregivers: 1 individualized counselling session, 1 family session, and 4 educational group sessions conducted by participating PHCT professionals; in addition to usual home health care visits, periodic telephone follow-up contact and unlimited telephone support.
223662971|NCT04858178|DIAGNOSTIC_TEST|Tests of sympathetic inhibition|Bolus phenylephrine infusion using the Oxford technique will generate the need to inhibit sympathetic activity. Similarly, resting state Mayer waves will be assessed with regard to heart rate and blood pressure responses.
223662972|NCT04858178|DIAGNOSTIC_TEST|Tests of sympathetic activation|Cold pressor test of the hand will be used to cause sympathetic activation. Valsalva's maneuver will assess the ability to buffer against blood pressure fall (phase II).
223662973|NCT04858178|DIAGNOSTIC_TEST|Testing of autonomic dysreflexia|Cold pressor test of the foot and bladder pressor response (in individuals with SCI) will be tested.
223662974|NCT04858178|DEVICE|Transcutaneous spinal cord stimulation|Transcutaneous spinal cord stimulation will be applied at T7-L1 spinal segments to assess alterations in autonomic neuroregulation.
223769885|NCT03098511|DIAGNOSTIC_TEST|Neurological Diagnostic Evaluation|"Clinical Data:~* Demographic data~* Daily data (clinical exams, laboratory data)~* Drug administration~* Additional clinical or ancillary neurological determination test~Diagnostic Intervention:~* CT-Perfusion~* CT-Angiography reconstructions~Reference Standard:~\- Clinical Neurological Exam~Blood Samples (Pharmacokinetics, Inflammatory \& Nanovesicles Parameters):~* At the time of patient enrolment~* 6 hours after patient enrolment~* At the time of the clinical neurological exam~Secondary Outcome measures at 6 months:~* extended Glasgow Outcome Scale (GOSe)~* modified Rankin Scale (mRS)"
224243006|NCT03643328|BIOLOGICAL|nasal swabs|Two nasal swabs will be collected at inclusion, at 6 months and 12 months for virology analyses.
224243007|NCT04259528|DEVICE|Pediatric endoscopic ultrasound|endoscopic ultrasound at the esophageal stricture site to assess echo texture and esophageal layers
224243008|NCT05137483|OTHER|Functional tests|We will apply upper extremity performance tests, hand grip measurements, and scales measuring fatigue and quality of life to the groups.
223662975|NCT03359018|DRUG|Apatinib|Every patients will received apatinib 250mg or 500mg orally daily according to their body surface area (BSA) until disease progression or intolerance to side effects.
223662976|NCT03359018|DRUG|SHR-1210|Every patients will received SHR-1210 3mg/kg (no more than 200mg) iv every 2 weeks until disease progression or intolerance to side effects.
224243009|NCT06484647|PROCEDURE|Percutaneous Coronary Intervention|"Percutaneous coronary intervention is a procedure that require coronary stenosis dilatation with dilatation catheter balloon and generally stent implantation.~The study involve coronary stenosis at bifurcation level that require complex coronary techniques such as External Minicrush or TAP technique."
224243010|NCT03563105|DEVICE|The Ox-Imager Mini (Desaturation)|Vascular Occlusion Test
224243011|NCT02588677|DRUG|Masitinib (4.5)|4.5 mg/kg/day
224243012|NCT02588677|DRUG|Riluzole|
224243013|NCT02588677|DRUG|Placebo|
224243014|NCT02588677|DRUG|Masitinib (3.0)|3 mg/kg/day
224243015|NCT00721305|DRUG|Lovastatin|Lovastatin 40 mg daily (2 tablets of 20 mg each, p.o.), during twelve months until the end of the study, or before the end of the study if any AIDS defining disease or toxicity appear
224243016|NCT00721305|OTHER|placebo|Placebo will be administered daily (2 tablets which will look externally identical to intervention: wrapped in the same way, with the same size, shape and color), during twelve months until the end of the study, or before the end of the study if any AIDS defining disease or toxicity appear
224243017|NCT01876576|OTHER|Clear liquids|Clear liquids
224243018|NCT01876576|OTHER|Low residue breakfast and lunch|Low residue
224243019|NCT02389491|DIETARY_SUPPLEMENT|normal density formula (Necocate)|In control group,there are 32 infants
224243020|NCT02389491|DIETARY_SUPPLEMENT|high density formula(Infatrini)|In intervention group,there are 32 infants
224243021|NCT01450462|DIETARY_SUPPLEMENT|Vitamin D3 (cholecalciferol)|Women in the vitamin D arm take 50,000 international units (IU) of vitamin D3 (cholecalciferol) weekly for four weeks (end of week 1, week 2, week 3 and week 4), then every 4 weeks through 24 weeks of follow-up (end of week 8, week 12, week 16, week 20 and week 24) for a total of 9 treatments
224321386|NCT05812534|DRUG|Cadonilimab|Subjects who met the study population conditions were treated with Cadonilimab 10mg/kg + bevacizumab 7.5 mg/kg + carboplatin (AUC 5) + pemetrexed 500mg/m2. Every 3 weeks is a cycle, with a total of 4-6 cycles (the number of chemotherapy cycles is determined by the researchers). Cadonilimab 10mg/kg, bevacizumab 7.5 mg/kg and pemetrexed 500mg/m2 were then maintained until disease progression, intolerable toxicity or other causes specified in the regimen occurred. When the subject first has imaging disease progression, if the researcher judges that it is clinically beneficial and tolerant to the test drug, he will be allowed to continue treatment.
224321387|NCT03637426|OTHER|Laser|GLASER received the laser application using the infrared light spectrum with wavelength of 808 nm with its active AsGaAl medium in two points of the vestibular face of the hypersensitive teeth. It was applied at each point 60 J / cm², for 16 seconds. The laser was applied in 2 sessions with a time interval of 24 hours.
224243022|NCT01450462|DIETARY_SUPPLEMENT|Placebo|Women in the placebo arm will take their matching supplement weekly for four weeks (end of week 1, week 2, week 3 and week 4), then every 4 weeks through 24 weeks of follow-up (end of week 8, week 12, week 16, week 20 and week 24) for a total of 9 treatments
224243023|NCT01582126|OTHER|Group balance training|Balance training i group with focus on core stability exercises and dual attention activities.
224321388|NCT03637426|OTHER|nano-hydroxyapatite|The GnHAP volunteers were submitted to the application of Desensibilize Nano P on the vestibular surfaces of hypersensitive teeth with the aid of a Microbrush applicator (Microbrush, 3M ESPE, São Paulo, Brazil) for 10 minutes. Then, a rubber cup (Unid Microdont, São Paulo, SP, Brazil) mounted on a low speed handpiece (Dabi Atlante, Ribeirão Preto, SO, Brazil) was used to scrub the desensitizing gel on teeth for 20 seconds in each tooth, according to the manufacturer's specifications
224243024|NCT03657329|DIAGNOSTIC_TEST|Dreem|Dreem Band to be worn by each participant while undergoing in-lab sleep study with PSG. Pursuant to the physician-ordered diagnostic study, clinical staff may determine a split-night study with CPAP to be appropriate for any participant, simultaneous with the PSG and Dreem.
224243025|NCT00693966|BIOLOGICAL|MEDI-517 HPV-16/18 VLP AS04 vaccine (Formulation 1)|IM injection
224321389|NCT03637426|OTHER|Laser + nano-hydroxyapatite|GLASERnHAP first received laser application and subsequently the application of nanohydroxyapatite according to the manufacturer's recommendations.
224321390|NCT03637426|OTHER|PLACEBO|In this group, a toothpaste without addition of fluoride or any other desensitizing agent (Natural, Contente®, Uberlândia, MG, Brazil) was applied to hypersensitive dentine. The GPLACEBO volunteers were submitted to the application of placebo dentifrice on the vestibular surfaces of hypersensitive teeth with the aid of a Microbrush applicator (Microbrush, 3M ESPE, São Paulo, Brazil) for 10 minutes. Then, a rubber cup (Unid Microdont, São Paulo, SP, Brazil) mounted on a low speed handpiece (Dabi Atlante, Ribeirão Preto, SO, Brazil) was used to scrub the desensitizing gel on teeth for 20 seconds on each tooth.
224321391|NCT03334461|COMBINATION_PRODUCT|Exposure to oral antiseptics or enamel remineralisation agent|
224243026|NCT00693966|BIOLOGICAL|MEDI-517 HPV-16/18 VLP AS04 vaccine (Formulation 2)|IM injection
224321392|NCT00005195|PROCEDURE|Catheter ablation|
224321393|NCT04487067|DRUG|Atezolizumab|Atezolizumab 1200 mg IV infusion q3w
224321394|NCT04487067|DRUG|Bevacizumab|Bevacizumab 15 mg/kg IV Q3W
224243027|NCT00693966|BIOLOGICAL|MEDI-517 HPV-16/18 VLP AS04 vaccine (Formulation 3)|IM injection
224243028|NCT00693966|BIOLOGICAL|MEDI-517 HPV-16/18 VLP with Al(OH)3 (Formulation 4)|IM injection
224243029|NCT01926548|DRUG|CJ Imatinib mesylate tablet|
224243030|NCT01926548|DRUG|Gleevec film-coated tablet 2 x 100mg|
224243031|NCT03607097|PROCEDURE|Secondary prevention program for drug related problems|The interventions consists of three stages: 1) actions aimed at improving the chronic prescription of the patient, 2) actions aimed at improving the therapeutic adherence and 3) actions aimed at improving the assistance healthcare levels coordination
224243032|NCT04738084|BEHAVIORAL|Meru Health Program|Each week of the 12 week program follows a different theme. Patients and therapists interact asynchronously after their initial Zoom-based intake call. Psychiatrists and medical doctors are available for consults if needed.
224243033|NCT01194609|BIOLOGICAL|Immune cell|InnoLak two consecutive weeks every 3 weeks for 3 times
224243034|NCT01194609|RADIATION|Low dose radiation|20cGy whole body radiation every three weeks for three times
224243035|NCT00130988|BEHAVIORAL|DEPENAS cognitive and behavioural techniques|
224243036|NCT00841178|PROCEDURE|Surgery|Saphenopopliteal junction ligation, stripping of the Short Saphenous vein where possible, perforator ligation and ambulatory phlebectomy, where necessary.
224243037|NCT00841178|PROCEDURE|EVLT|EVLT of the Short saphenous vein with perforator ligation and / or ambulatory phlebectomy as required.
224243038|NCT05160350|DRUG|Probiotic|Each probiotic capsule contained combination of lactobacillus and Bifidobacterium species.
224243039|NCT04136899|OTHER|Dukes scale|collection of questionnaires
224243040|NCT00354198|DRUG|pentoxifylline|intravenous pentoxifylline (0.33-0.66 mg/kg/h from days 1 to 7) followed by oral pentoxifylline 400-800 mg/day (from days 8-90). The dose of intravenous pentoxifylline will be determined by estimated GFR, patients whose GFRs are 30-59 ml/min/1.73 m2 will be given 0.66 mg/kg/h, and those below 30 ml/min/1.73 m2 will be given 0.33 mg/kg/h. The oral dose of pentoxifylline will also be determined by estimated GFR. Patients whose estimated GFRs are between 30-59 ml/min/1.73 m2 will be given 800 mg/day, and those below 30 ml/min/1.73 m2 will be given 400 mg/day.
224243041|NCT00354198|DRUG|corticosteroids|intravenous methylprednisolone (15 mg/kg/day or a maximum of 1 g/day) x 3 days + oral prednisolone (0.5-1.0 mg/kg/day) for 27 days\] x 3 courses
224243042|NCT04389320|DRUG|Hydroxychloroquine|assess its role in the coarse of covid 19 virus infection
224243043|NCT02581748|DRUG|HLX02|
224243044|NCT02581748|DRUG|Herceptin|
224243045|NCT00932750|DIETARY_SUPPLEMENT|Coffee mannooligosaccharide|2 beverages daily providing either 4 g of coffee mannooligosaccharide or placebo.
223662977|NCT01827683|OTHER|Hyperbaric oxygen|8-week, 5 times a week administration of 100% O2 for 90 minutes at a pressure of 2 ATA.
224243046|NCT00932750|DIETARY_SUPPLEMENT|Coffee mannooligosaccharides|Subjects consume 2 beverages daily providing 4 g of coffee mannooligosaccharides or placebo
223662978|NCT04307342|PROCEDURE|MIPO with Extra-articular Distal Humeral Anatomical Plate|MIPO with Extra-articular Distal Humeral Anatomical Plate
223662979|NCT05273502|BEHAVIORAL|Citizen Science intervention|Intervention generated by a participatory research process (co-creation) in the elderly population living in rural areas to co-create solutions to improve their lifestyles, quality of life and health.
223662980|NCT01120782|DEVICE|etafilcon A toric contact lens with new wetting agent|Investigational toric contact lens made of etafilcon A material with a new wetting agent.
223662981|NCT01120782|DEVICE|etafilcon A toric contact lens|Marketed toric contact lens made of etafilcon A material.
223662982|NCT03095196|DEVICE|Multipolar CRT-d, plus conventional drug therapy for HF.|A random CRT-d implant performed via multipolar left ventricle lead, in failing heart patients treated by maximal drug therapy.
223662983|NCT03095196|DEVICE|Bipolar CRT-d, plus conventional drug therapy for HF.|A random CRT-d implant performed via bipolar left ventricle lead (group B), in failing heart patients treated by maximal drug therapy.
223662984|NCT03095196|DRUG|HF drugs|full medical therapy to treat HF symptoms and its progression.
223662985|NCT00463021|DRUG|Hectorol (doxercalciferol capsules)|
223662986|NCT00463021|DRUG|Zemplar (paricalcitol injection)|
223662987|NCT04670250|DIAGNOSTIC_TEST|non invasive markers|non invasive markers (IL6, serum ferritin, fecal lactoferrin) used for monitoring of newly diagnosed patients with ulcerative colitis
223662988|NCT00977847|OTHER|Electronic Health Portals for collecting Family History data|Comparison of multiple portals for integrating patient generated family history data into the electronic health record.
223662989|NCT00255424|DRUG|ferumoxytol or oral iron|
223662990|NCT00314587|PROCEDURE|1 or 2 elastic stable intramedullary nails|
223662991|NCT05190926|BEHAVIORAL|Smart-Treatment for Anorexia Nervosa Recovery (STAR)|"Adolescents will use their smartphone to access short 5-10 minute modules that teach them about the function of emotions, ways to regulate challenging emotions, and strategies to improve negative thinking, mood, and reduce eating-disorder symptoms. Module content will include text, images, videos, and interactive questions and quizzes."
223662992|NCT05190926|BEHAVIORAL|Present-focused Anorexia Nervosa Coping Treatment (PACT)|Adolescents will use their smartphone to access two brief psychoeducational modules that teach about the common symptoms of AN, common reactions and problems associated with AN, and goals for treatment. Starting in Week 3, adolescents will complete a Daily Diary that will ask them to record life stressors, challenges, and problems, which will serve as a launching point for discussion with their outpatient therapist.
224243047|NCT05404386|OTHER|Training booklet prepared by the researchers on healthy lifestyle behaviors, bladder training, and Kegel exercises related to urinary incontinence.|After the participants enrolled in the study, a training booklet prepared by the researchers on healthy lifestyle behaviors, bladder training, and Kegel exercises related to urinary incontinence will be given to the participants.
223662993|NCT05533580|DRUG|Remimazolam|The experimental group was sedated with remimazolam.
223662994|NCT05533580|DRUG|Propofol|The control group was sedated with propofol.
223662995|NCT05541796|DEVICE|Intraocular lens|"Tecnis Symfony Optiblue (Johnson \& Johnson Vision, Santa Ana, CA, Unites States) is a violet light filtering extended depth of focus IOL that provides a continuous range of clear vision at far and intermediate.~Tecnis Synergy™ IOL (Johnson \& Johnson Vision, Santa Ana, CA, Unites States) is another latest United States Food and Drug Administration (USFDA) approved IOL, designed to provide good acuity at far through near distances, reducing the need for spectacles."
223662996|NCT03635671|DIAGNOSTIC_TEST|Optical Coherence Tomography Angiography|Retinal scans will be acquired at each follow up visit
223662997|NCT05478031|DRUG|REM0046127 High Dose|"Each subject will start with a 14-day placebo run-in period, followed by a 28-day treatment period and 7-day follow-up period.~REM0046127 high dose: 1400mg (700mg bid) oral suspension per day for 28 days"
224243048|NCT05404386|OTHER|3 months follow-up|Follow-ups will be made 3 times in total, on the basis of pre-test (baseline), intermediate follow-up test (6th week), and post-test (12th week).
224243049|NCT05404386|BEHAVIORAL|"Mobile application which named as My Fighting with Incontinence"|"The mobile application My Fighting with Incontinence aims to reduce incontinence symptoms of women with UI, ensure compliance with Kegel exercises, increase health belief and quality of life regarding UI and kegel exercises, and also allow researchers to be included in the awareness and management process."
224243050|NCT03808064|BEHAVIORAL|FCHV home visit|Behavioral: FCHV visit Female Community Health Volunteer will visit selected households 3 times a year for providing health promotion messages Other Name: FCHV Home Visit
224243051|NCT05266521|DEVICE|zLOCK Facet Stabilization System|zLOCK Facet Stabilization System is a device intended to provide posterior stability in lumbar spine in order to reduce lumbar back pains
224243052|NCT03843593|BEHAVIORAL|Demographics Questionnaire|A brief questionnaire will collect basic demographic information (i.e., age, gender, racial background, ethnicity, employment status, marital status) at time of enrollment.
223662998|NCT05478031|DRUG|REM0046127 Low Dose|"Each subject will start with a 14-day placebo run-in period, followed by a 28-day treatment period and 7-day follow-up period.~REM0046127 low dose: 350mg (175mg bid) oral suspension per day for 28 days"
223662999|NCT05478031|DRUG|Placebo|"Each subject will start with a 14-day placebo run-in period, followed by a 28-day treatment period and 7-day follow-up period.~Placebo: placebo oral suspension bid for 28 days and during the 14-days run-in phase"
223663000|NCT03502356|DRUG|Azithromycin|In this group, patients will receive standard antibiotic prophylaxis CEFAZOLIN (at a dose of 1 g) and azithromycin (at a dose of 1g) 2 hours preoperative.
223663001|NCT00749112|DRUG|Alemtuzumab, Rituximab|Alemtuzumab 10 mg each 24 hrs subcutaneous for 3 days. Rituximab 100 mg IV every week for 4 weeks.
223663002|NCT03058328|OTHER|Cognitive testing, testing of heart rate variability and blood samples|No intervention. Registration of ECG, cognitive testing and blood sampling is performed in the perioperative period and during follow up.
223663003|NCT04229732|DEVICE|ClearMateTM|Passive isocapnic hyperventilation breathing circuit.
223663004|NCT05712707|DRUG|BXCL501 (180 micrograms)|Throughout the 7-day inpatient study (Figure 1; Table 1), participants will receive sublingual BXCL501 or placebo twice daily and lofexidine or placebo 4 times daily using a double-blind, double-dummy design.
223663005|NCT05712707|DRUG|BXCL501 (240 micrograms)|Throughout the 7-day inpatient study (Figure 1; Table 1), participants will receive sublingual BXCL501 or placebo twice daily and lofexidine or placebo 4 times daily using a double-blind, double-dummy design.
223663006|NCT05712707|OTHER|Placebo|Throughout the 7-day inpatient study (Figure 1; Table 1), participants will receive sublingual BXCL501 or placebo twice daily and lofexidine or placebo 4 times daily using a double-blind, double-dummy design.
223663007|NCT05712707|OTHER|Lofexidine (Positive Control)|Throughout the 7-day inpatient study (Figure 1; Table 1), participants will receive sublingual BXCL501 or placebo twice daily and lofexidine or placebo 4 times daily using a double-blind, double-dummy design.
223663008|NCT02992444|OTHER|Standard adhesive strip|This is a standard adhesive strip (hydrocolloid)
223663009|NCT02992444|OTHER|Experimental adhesive strip|This is a strip of a newly developed adhesive.
223663010|NCT04975438|DRUG|GSK1070806|GSK1070806 will be administered
223663011|NCT04975438|DRUG|Placebo|Placebo will be administered
223663012|NCT03251313|COMBINATION_PRODUCT|JS001 120mg+GP|In this arm, JS001 120mg will be given at d1; Gem 1000mg/m2 d2,9; DDP(cisplatin) 75mg/m2 d2
223663013|NCT03251313|COMBINATION_PRODUCT|JS001 240mg+GP|In this arm, JS001 240mg will be given at d1; Gem 1000mg/m2 d2,9; DDP 75mg/m2 d2
223663014|NCT03251313|COMBINATION_PRODUCT|JS001 480mg+GP|In this arm, JS001 480mg will be given at d1; Gem 1000mg/m2 d2,9; DDP 75mg/m2 d2
223663015|NCT03251313|COMBINATION_PRODUCT|GP followed by JS001|In this arm,Patients receive 6 cycles of GP without JS001 and then receive JS001 maintenance therapy for up to approximately 2 years. JS001 will be given at RP2D.
223663016|NCT04145232|BIOLOGICAL|Collection of biopsy (FFPE), blood (PBMC) and stool|Patients receiving routine treatment (immunotherapy using anti-PD1 / anti-PDL1 and / or anti CTLA4 antibodies), financed by the Polish National Health Fund (NFZ).
223663017|NCT01462253|DRUG|Clofarabine, Cyclophosphamide|The proposed treatment schedule consists of a combination of Clofarabine plus Cyclophosphamide administered over 5 consecutive days (Treatment scheme).
223663018|NCT02065258|OTHER|Breathing exercise|"It will be based on Yoga´s breathing technique (Eliade, 1996) and will be focus on to stimulate nasal and diaphragmatic breathings, to increase expiratory time, to slow respiratory flow and to regulate the breathing rhythm. Breathing exercises will be divided into 3 phases (lasting one month each) with progressive intensity every 8 sessions.~All participants will be required to maintain their normal medical regimens during the interventions. Will be part of the routine of breathing exercises the following exercises: I) Kapalabhati, II) Uddhiyana"
223663019|NCT02065258|OTHER|Aerobic exercise|Exercise will be performed on a treadmill (Imbramed Export Plus, Brazil) with the initial intensity of 60% of the maximum predicted heart rate for patient´s age (Tanaka et al, 2001) reaching a maximal of 80% during the training. The intensity values will be calculated using Karvonen's formule (1957). Exercise intensity will be increased if the patient do not present any increase in asthma symptoms during the exercise for 2 consecutive training days. Before and after every session, patients will perform a peak expiratory flow test and if values were lower than 70% of the patient´s maximum value, they will be advised to use the rescue dose of bronchodilator prescribed the their physician
223663020|NCT00534482|BEHAVIORAL|Enhanced Office|Clinicians and office staff personally engage in AIM-HI fitness program, and promote program to patients
223663021|NCT00534482|BEHAVIORAL|Conventional Office|Conventional office: Clinicians and office staff are not personally engaged in the AIM-HI fitness program, but promote program to patients.
223663022|NCT00534482|BEHAVIORAL|AIM-HI program with enhanced feedback|Patient receives feedback on two novel indicators of their individual cardiovascular risk that: 1)appear to relate to obesity and lack of physical activity, and 2) may show relatively rapid change with improvements in these areas. These are the Homeostatic Assay - Insulin Resistance or HOMA-IR and Nuclear Molecular Resonance (NMR) lipoprotein profiles (NMRLP). These patients and their physicians also will receive periodic feedback on other outcome measures, including BMI, blood pressure, a 3-minute step test, eating assessment, physical activity assessment, and emotional well-being assessment.
223663023|NCT00534482|BEHAVIORAL|AIM-HI program and regular feedback|Patients will not receive feedback on two specific cardiovascular risk indicators (ie, Homeostatic Assay - Insulin Resistance, Nuclear Molecular Resonance lipoprotein profiles). However, patients will receive feedback on Body Mass Index, blood pressure, a 3-minute step test, eating assessment, physical activity assessment, and emotional well-being assessment.
223663024|NCT03555019|DIETARY_SUPPLEMENT|Formulaid|Supplementation with ARA and DHA
223663025|NCT03555019|DIETARY_SUPPLEMENT|MCT-oil|Supplementation with medium chain fatty acids
223663026|NCT03924856|DRUG|Pembrolizumab|Pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle
223663027|NCT03924856|DRUG|Gemcitabine|Gemcitabine 1000 mg/m\^2, IV infusion on Days 1 and 8 of each 21-day cycle
223663028|NCT03924856|DRUG|Cisplatin|Cisplatin 70 mg/m\^2, IV infusion on Day 1 of each 21-day cycle
224243053|NCT03843593|BEHAVIORAL|Adjuvant Treatment Beliefs Scale10|This brief PRO measure asks patients to indicate the likelihood, using a 5-point Likert type scale (1 \[definitely not\], 2 \[probably not\], 3 \[maybe\], 4 \[probably\], 5 \[definitely\]) of six positive (e.g., reduced risk of recurrence, greater chance of being cured) and five negative outcomes (e.g., side effects, health status) of adjuvant treatment.
224243054|NCT03843593|BEHAVIORAL|Functional Assessment of Cancer Therapy - Melanoma (FACT-M)11|FACT-M is a 51-item patient-self report measure for the assessment of quality of life (QOL) in patients with American Joint Committee on Cancer stages I through IV melanoma.
224243055|NCT03843593|BEHAVIORAL|Functional Assessment of Chronic Illness Therapy - Treatment Satisfaction - General (FACIT-TS-G)13|FACIT-TS-G is a brief, 8-item self-administered measure designed to assess general treatment satisfaction in patients.
223663029|NCT03924856|PROCEDURE|Surgery (radical cystectomy (RC) plus Pelvic Lymph Node Dissection [PLND])|Surgical RC+PLND will be done in accordance with the American Urological Association (AUA)/American Society of Clinical Oncology (ASCO)/American Society for Radiation Oncology (ASTRO)/Society of Urologic Oncology (SUO) guidelines.
223663030|NCT03924856|DRUG|Placebo|Placebo to pembrolizumab by IV infusion, given on Day 1 of each 21-day cycle
224243056|NCT03843593|BEHAVIORAL|Decisional Regret14|This is a set of 5 questions examining level of regret for treatment decisions (in this case, decision to pursue adjuvant therapy), with answers scored on a 5-point Likert-type scale (i.e., 1 \[Strongly Agree\], 2 \[Agree\], 3 \[Neither Agree Nor Disagree\], 4 \[Disagree\], 5 \[Strongly Disagree\].
223663031|NCT04551209|PROCEDURE|Maintaining apical patency|In apical patency group, a size 10 K file will be passed beyond the apical foramen between each instrument change to maintain apical patency while in Non apical patency group, K file will be carried up to the working length only. A final peri-apical radiograph will be taken in the group A with the 10 K patency file 01mm beyond the apical foramen to confirm patency.
223663032|NCT00010452|DRUG|picibanil|Up to .2 mg per injection, given intralesionally every 6-8 weeks
223663033|NCT03279640|DEVICE|rTMS on ipsilesional M1|
223663034|NCT03279640|DEVICE|tDCS on contralesional M1|
223663035|NCT00787267|DRUG|Dasatinib|70 mg PO twice daily until progression. Re-assess radiographically every 6 weeks.
223663036|NCT03455231|RADIATION|Short course radiotherapy|An accelerated hypo-fractionation radiotherapy is delivered for palliation in patients with complicated bone metastases
223663037|NCT00226759|DRUG|OMS103HP|Maximum of 39 liters of OMS103HP irrigation solution over a maximum of 2 hours.
223663038|NCT00226759|DRUG|Vehicle|Maximum of 39 liters of vehicle irrigation solution over a maximum of 2 hours
223663039|NCT00865280|DRUG|PTK 0796|PTK 0796 100 mg for injection; PTK 0796 tablet 150 mg
223663040|NCT00865280|DRUG|linezolid|For gram positive treatment: Linezolid 600 mg tablets and pre-mixed 600 mg IV infusion solution; For gram negative treatment: Moxifloxacin 400 mg tablets and pre-mixed 400mg IV infusion solution
223663041|NCT00865280|DRUG|moxifloxacin|moxifloxacin 400 mg tablet; moxifloxacin 400 mg IV infusion solution
223663042|NCT01518270|OTHER|No treatment|No treatment will be provided
223663043|NCT06341920|BEHAVIORAL|Experimental: BoneFit intervention|Exercise, nutrition and psychological support provided in 8 weeks prior to surgery
223663044|NCT06341920|BEHAVIORAL|Placebo Comparator: Control|Control group receive usual care (zero intervention)
223663045|NCT01098643|OTHER|computer-assisted intervention|
223663046|NCT01098643|OTHER|medical chart review|
223663047|NCT01098643|OTHER|questionnaire administration|
223663048|NCT01098643|OTHER|survey administration|
223663049|NCT04162691|DIAGNOSTIC_TEST|Tissue|Four 4-5 mm tissues of the thymoma
223663050|NCT00620529|DIETARY_SUPPLEMENT|Ocean Nutrition 2050|1000mg capsules, 4 capsules/day for 8 weeks
223663051|NCT00620529|DIETARY_SUPPLEMENT|Olive oil capsules|Olive oil capsules, 4 per day for 8 weeks
223663052|NCT01168986|OTHER|Pulstar Multiple Impulse Therapy|Use of the PulStar Multiple Impulse Therapy (Sense Technology). A mechanical manual therapy device.
223663053|NCT01168986|OTHER|Exercise|Participants perform an exercise to strengthen the deep neck flexors
223663054|NCT02842190|DEVICE|NIPPV|after ekstubation
223663055|NCT00079027|DRUG|doxorubicin hydrochloride|
223663056|NCT00079027|PROCEDURE|hepatic artery embolization|
223663057|NCT03739021|DRUG|Exparel|Single shot of the Bupivacaine Liposome, and then we follow up with patient in the recovery room with traditional common pain management. MME (milligram morphine equivalent) will be collected.
223663058|NCT03739021|DRUG|Ropivacaine|Continuous infusion of Ropivacaine via catheter, and then we follow up with patient in the recovery room with traditional common pain management. MME (milligram morphine equivalent) will be collected.
223663059|NCT00220129|DRUG|Epirubicin, Cisplatin, Capecitabine|
223663060|NCT00220129|PROCEDURE|Surgical Resection|
223663061|NCT04267484|DEVICE|GPS and travel diary|WP1: GPS tracker for 2 weeks and a daily diary about activity (travel diary).
223663062|NCT04267484|OTHER|e-decision support platform|WP2 and WP3: An e-decision support platform that will foster shared decision making about options to stay safe at home for the older adult.
223663063|NCT01417494|DRUG|Chemotherapy ( FOLFIRI regimen, FOLFOX regimen or LV5FU2 regimen)|
223663064|NCT01417494|DRUG|Chemotherapy ( FOLFIRI regimen, FOLFOX regimen or LV5FU2 regimen) + bevacizumab|
223663065|NCT01280877|DEVICE|tACS|Transorbital alternating current stimulation (tACS) is applied with a multi-channel device with paraorbital montage of 4 stimulation electrodes generating weak current pulses in predetermined firing bursts of 8 to 14 pulses. The amplitude of each current pulse was below 1000 microA. Current intensity was individually adjusted according to how well patients perceived phosphenes, i.e. any sensation of flickering light in response to the rtACS stimulation.
223663066|NCT01280877|DEVICE|Sham stimulation|tACS is applied with the same device with equal electrodes set-up procedures but only one of four channels actually delivers current. The current intensity of this channel is individually adjusted (preselected on the side of lesioned eye) according with patient able to clearly perceive single phosphenes or any skin irritation phenomena (like weak sense of needles or vibration) whenever a single pulse is applied. The amplitude of pulses is always below 1000 microA. Current pulses are given as 1 pulse per minute during 25-35 min of session time. Session duration is equal for verum and sham patients. The perception of the single pulses leaves sham patients at the impression that they might receive the verum intervention, but total number of pulses is less than 0,5% of verum tACS.
223663067|NCT02246413|BEHAVIORAL|RAINBOW Intervention Program|Integrated lifestyle intervention with as-needed antidepressant pharmacotherapy to treat coexisting obesity and depression in adults in primary care
223663068|NCT05241977|PROCEDURE|anterior supra scapular nerve block|nerve block for postoperative pain
223663069|NCT06287177|DRUG|Inclisiran|Injection
223663070|NCT06516419|DRUG|Concentrated secretome Injection 2mL|The secretome used in this research comes from mesenchymal stem cells from adipose tissue produced by IPT RSCM Stem Cell Medical Technology. The secretome produced by mesenchymal stem cells is collected, centrifuged to separate it from debris, and followed by filtration with a 0.22 μm pore filter to ensure sterility. Next, the concentration process is carried out using tangential flow filtration with the Spin-X UF 500® concentrator, packaged, and stored at -80 degrees Celsius. The product used is a sterile product, which is tested for sterility and total protein content. When it is to be used, the secretome is removed from the freezer, warmed (thawing), and injected into the patient according to a predetermined method.
223769886|NCT04452188|OTHER|Normoxia (with controlled re-oxygenation)|"Participants will receive lower levels of oxygen during surgery and after surgery on the ventilator.~As cardiopulmonary bypass is being weaned, anesthesia will initiate mechanical ventilation with an FiO2 of 50% or less (unless clinically necessary) to achieve oxygen saturation and PaO2 goals that fit within the expected range for the participant's physiology:~1. Single ventricle patients (PaO2:35-45 and oxygen saturation 75%-85%)~2. Two ventricle patients (PaO2: 60-100 and oxygen saturation \>92%)"
223769887|NCT04452188|OTHER|Standard of care ventilation|As cardiopulmonary bypass is being weaned, anesthesia will initiate mechanical ventilation per standard protocols. Ventilation will be continued in the ICU and adjusted per standard goals per the intensivist.
223769888|NCT04409028|PROCEDURE|Coronal restoration|A restorative material like composite resin is condensed into the cavity of teeth.
224321395|NCT06285292|DEVICE|EMY|"Patients in the intervention group (rehabilitation with the EMY medical device) will undergo 2 rehabilitation sessions with a physiotherapist trained in pelviperineology between M0 and M2. The aim of these sessions will be to learn proper perineal contraction and combat the deficits identified during the physiotherapist's assessment. They will have to perform pelvic-perineal re-education exercises with the EMY device on 3 different days a week, for 15 minutes, over a period of 3 months. Then, for a further 3 months, their program can be modified for free, on-demand use (e.g. 2 x 10 minutes per week). After the main criterion at M6, they will be free to modify their rehabilitation program in the application according to their symptoms, and follow their program until the end of the study"
224321396|NCT04267432|DIETARY_SUPPLEMENT|Placebo|Blank
224321397|NCT04267432|DIETARY_SUPPLEMENT|TCI633|Probiotics
224321398|NCT04267432|DRUG|Type 2 collagen|Positive control group
224321399|NCT03852732|DEVICE|PoNS Treatment|"PoNS Treatment will consist of three stages: an in-clinic training program, a home training program, and an extended home training program. During all stages of the study, subjects will complete three training sessions per day, morning, afternoon and evening, 6 days per week.~Daily Training Program: The same daily training program will be performed during all stages with the exception of the morning BAT session, which is not performed during stage 2 or 3:~Morning:~Warm Up Exercises without the PoNS Balance Training with PoNS Gait Training with PoNS Breathing and Awareness Training (BAT) with PoNS 3- to 4-hour break between morning and afternoon sessions~Afternoon:~Balance Training with PoNS Movement Control Training without PoNS Gait Training with PoNS~Evening:~Breathing and Awareness Training with PoNS To be performed at home during all stages"
224321400|NCT03924687|BEHAVIORAL|Acceptance and Commitment Therapy (ACT) bibliotherapy for chronic pain|"The intervention consisted of the book Libérez-vous de la douleur par la méditation et l'ACT (Dionne, 2014) and a participant workbook, along with two phone calls of approximately 15 minutes each and weekly e-mails presenting the week's content. Participants also had access to audio meditation exercises on the book's website (http://liberezvousdeladouleur.com/meditations/)."
224321401|NCT03905577|BEHAVIORAL|Action Observation|Action Observation training
224321402|NCT03905577|BEHAVIORAL|Motor imagery|Motor imagery protocol
224321403|NCT03905577|BEHAVIORAL|Placebo Action observation|Placebo Action Observation
224321404|NCT02211417|DRUG|Oral DS107|
224321405|NCT02211417|DRUG|Placebo|
224321406|NCT05746832|PROCEDURE|Endoscopic stenting Retrograde Cholangiopancreatography (ERCP)|Assessment of the differences in stone size and the largest CBD diameter before and after stenting in one or two sessions. Stone clearance and complications were also determined with the ERCP, and factors associated with complete clearance were evaluated in patients with difficult CBD stones (a large \[≥ 20 mm\] or multiple \[≥ 3 sized ≥ 15 mm\] CBD stones). And also compared the outcomes with conventional procedure of open surgery.
224321407|NCT06805305|BIOLOGICAL|DOC1021|Double-loaded dendritic cell vaccine, loaded with tumor lysate and mRNA using proprietary method
224321408|NCT06805305|PROCEDURE|Tumor resection|SOC brain tumor resection
224321409|NCT06805305|DRUG|Temodar (Temozolomide)|SOC concomitant temozolomide during radiation and adjuvant temozolomide after radiation
224321410|NCT06805305|RADIATION|SOC cranial radiation|60Gy radiation over 6 weeks in 2Gy fractions
224321411|NCT03166098|DIAGNOSTIC_TEST|Cognitive Function Assessments|The NIMH-Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) is a consensus battery that is considered state-of-the art in the evaluation of cognitive skills for schizophrenia research.(Burton et al., 2013, Harvey, 2014) The complete cognitive battery takes about one hour to administer, and is comprised of 10 subtests measuring seven essential domains of function, with very good reliability and validity.(Nuechterlein 2008, August et al., 2012) The MATRICS subtests have been incorporated into the cognitive battery described below, with supplementary subtests included where indicated within each domain.
224321412|NCT02495662|DRUG|PEG-liposomal prednisolone sodium phosphate|Liposomal prednisolone
224321413|NCT02495662|DRUG|Placebo|0.9% normal saline
224321414|NCT00437697|DRUG|dalteparin|
224321415|NCT01959061|DRUG|Raltitrexed|4mg, every 4 weeks,transhepatic arterial infusion
224321416|NCT01959061|DRUG|Oxaliplatin|100\~150mg, every 4 weeks, transhepatic arterial infusion
224321417|NCT01959061|DRUG|lipiodol|5-20ml, every 4 weeks, hepatic artery embolization
223769889|NCT00650949|DRUG|CYT997|Escalating doses (100mg/m\^2 to 150mg/m\^2), 24-hour intravenous infusion on Day 2 of a 21-day cycle (Phase Ib component). Dose selected in Phase Ib component to be used for Phase II component.
223769890|NCT00650949|DRUG|Carboplatin|Intravenous infusion over 1 hour at area under the concentration-time curve (AUC)=5 on Day 1 of a 21-day cycle
223769891|NCT01670929|DRUG|Progesterone|
223769892|NCT01670929|OTHER|Placebo|
224243057|NCT03843593|BEHAVIORAL|Clinician Preference for Treatment|This is a single item to be completed by Medical Oncologists that will indicate their preference as to whether they prefer that their patient accepts adjuvant therapy.
224243058|NCT04712071|DRUG|Ketamine Hydrochloride|Patients with a diagnosis of Gulf War Illness using Kansas Criteria will be enrolled to receive a single 40 minute infusion of 0.5 mg/kg ketamine.
224243059|NCT00581971|DRUG|celecoxib|400mg bid starting 1 week before radiotherapy and taken through radiotherapy.
224243060|NCT00581971|DRUG|Carboplatin|IV, AUC 2.0, weekly for weeks 1 through 7
224243061|NCT00581971|DRUG|Paclitaxel|IV 30 mg/m2, weekly for weeks 1 through 7
224243062|NCT00581971|RADIATION|Radiation Therapy|70.2Gy, at 1.8Gy qd, Monday through Friday
224321418|NCT00257621|DRUG|GW640385|
224321419|NCT00257621|DRUG|Ritonavir|
224321420|NCT01755091|DRUG|Dronabinol|
224321421|NCT01755091|DRUG|Placebo (for Dronabinol)|
224321422|NCT03936803|BEHAVIORAL|aerobic interval training exercise .|Its consisted of cycle ergometer training, 3 days a week for 6 weeks. Aerobic interval training consisted of ( 8 )minutes warm-up, followed by 4 times of 4-minute intervals with HR at 85% of sub maximum HR, with active pauses of 3 minutes of walking at 60% of sub maximum HR. The exercise session was terminated by 5 minutes cool-down
223663071|NCT06516419|DRUG|Tranexamic acid injection|"1. Tranexamic acid 25 mg/ml is prepared by taking tranexamic acid in a vial 250 mg/5 ml as much as 0.5 ml (25 mg) using a 1 ml syringe and diluted with 0.5 ml 0.9% NaCl solution just before being injected into the SP.~2. Tranexamic acid 10 mg/ml is prepared by taking 0.2 ml (10 mg) of AT in a 250 mg/5 ml vial using a 1 ml syringe and diluting it with 0.8 ml of 0.9% NaCl solution for a moment. before injection into the Subject~2\. Tranexamic acid 10 mg/ml is prepared by taking 0.2 ml (10 mg) of AT in a 250 mg/5 ml vial using a 1 ml syringe and diluting it with 0.9% normal saline (NS) 0.8 ml just before injection into the Subject"
223663072|NCT06516419|DRUG|Triple Combination Cream|"1. Apply sunscreen SPF ≥30 in the morning on 2 knuckles~2. Apply triple combination cream (Refaquin) containing hydroquinone 40 mg, tretinoin 0.5 mg, and fluocinolone acetonide 0.1 mg at night all over the face except the area around the eyes, 1 fingertip unit (FTU) or 1 knuckle."
223663073|NCT03279562|DRUG|Nalmefene|Educational and behaviorally oriented drug counseling
223663074|NCT03966638|PROCEDURE|Intra-meniscal injection of platelet-rich plasma|Intra-meniscal injection of platelet-rich plasma under echographic control
223663075|NCT00918788|OTHER|biologic sample preservation procedure|Ex vivo samples of normal and malignant breast tissue; biopsy specimens are then fixed in formalin and submitted for histopathologic studies
223663076|NCT00918788|OTHER|immunohistochemistry staining method|The biopsy specimens are then fixed in formalin and submitted for histopathologic studies using standard light microscopy techniques (i.e., H\&E staining and IHC). Additional histochemical, immunohistochemical, and fluorescent in situ stains may be performed to support the diagnosis or to better understand the spectroscopy results.
223663077|NCT00918788|OTHER|light microscopy|The biopsy specimens are then fixed in formalin and submitted for histopathologic studies using standard light microscopy techniques (i.e., H\&E staining and IHC).
223663078|NCT00918788|OTHER|medical chart review|Medical records are reviewed to obtain information from the pathology report on patient demographics, pathological characteristics of the surgical specimen, and clinical indication for the surgical procedure.
223663079|NCT00918788|PROCEDURE|histopathologic examination|The biopsy specimens are then fixed in formalin and submitted for histopathologic studies using standard light microscopy techniques (i.e., H\&E staining and IHC). Additional histochemical, immunohistochemical, and fluorescent in situ stains may be performed to support the diagnosis or to better understand the spectroscopy results.
223663080|NCT00918788|PROCEDURE|needle biopsy|Tissue spectra are measured using a portable clinical spectroscopy device with front- and side-viewing optical fiber probes that are inserted into the breast tissue through a hollow biopsy needle.
223663081|NCT00918788|PROCEDURE|spectroscopy|Optical spectra are acquired from ex vivo samples of normal and malignant breast tissue using diffuse reflectance, fluorescence, and Raman spectroscopy. Tissue spectra are measured using a portable clinical spectroscopy device with front- and side-viewing optical fiber probes that are inserted into the breast tissue through a hollow biopsy needle. After the probes are withdrawn through the needle, cutting biopsies are obtained and the tissue is marked at the site of the spectral measurements.
223663082|NCT05938205|DIETARY_SUPPLEMENT|AA-1|low dose aminoacids
223663083|NCT05938205|DIETARY_SUPPLEMENT|AA-2|high dose aminoacids
223663084|NCT05938205|BEHAVIORAL|Placebo|Nutritional Placebo
223663085|NCT05938205|BEHAVIORAL|Exe-H|high intensity physical exercise
223663086|NCT03453138|DEVICE|LMA Protector|LMA Protector will be inserted by a blind researcher after standart anesthesia induction. The view of the larynx will be assessed using fiberoptic grading scale
223663087|NCT03453138|DEVICE|Tracheal Intubation|tracheal intubation will be perform after standart anaesthetic induction and heamodynamic variables including blood pressure heart rate and possible complications will be observed
223663088|NCT04695808|BEHAVIORAL|yoga|Yoga practice will be done two days a week for 10 weeks.
223663089|NCT01950013|BEHAVIORAL|Auditory training program|Previous experiments performed under laboratory settings using a novel word-based auditory-training regimen have demonstrated substantial improvements in open-set recognition of words and sentences in noise. The current proposed study will investigate the effectiveness of the training regimen when used in a patient's home setting with their own hearing aids.
223663090|NCT01950013|BEHAVIORAL|Sham Comparator: Active Control|This is a sham intervention in which the patient listens to audio books following the same regimen as the patients receiving the auditory training.
223663091|NCT02672293|DRUG|Phoslax|Oral sodium phosphate solution (monobasic sodium phosphate 2.4 g and dibasic sodium phosphate 0.9g / 5 mL).
223663092|NCT00851227|DRUG|conivaptan hydrochloride|intravenous
223663093|NCT02751385|DRUG|Microgynon|
223663094|NCT02751385|DRUG|Nintedanib|
223663095|NCT06143904|DRUG|Genz-112638|Pharmaceutical form:Solution-Route of administration:IV
223663096|NCT06143904|DRUG|Genz-112638|Pharmaceutical form:Capsule-Route of administration:Oral
223663097|NCT06143904|DRUG|[14C]-Genz-112638|Pharmaceutical form:Solution-Route of administration:Oral
223663098|NCT04360382|OTHER|ERACS|Pregnant women scheduled for cesarean section will be subjected to preoperative, intra-operative and postoperative nurse care aiming at early recovery.
224321423|NCT03936803|DEVICE|electro acupuncture|"electroacupuncture (EA) of (2 Hz, 4 mA) was applied at points of:liver 3 LR3,liver 14 LR 14, gall bladder 34 (GB 34) and stomach 36 (ST36) .~Duration of the session was 15 min / each, three sessions per week for six weeks"
223663099|NCT04360382|OTHER|Regular care|Usual care for all cases subjected to cesarean section at our hospital.
223663100|NCT05525806|OTHER|Education Materials for MyProstateScore|These materials detail what the test does, how it is used, the validity and specifications of the test, and how to read its test report.
223663101|NCT03091348|DRUG|Testosterone|Testosterone cypionate injection
223663102|NCT03334786|DRUG|FLX-787-ODT|Oral Disintegrating Tablet
223663103|NCT03617328|BIOLOGICAL|6MHP|6 melanoma helper vaccine comprised of 6 class II MHC-restricted helper peptides
223663104|NCT03617328|DRUG|Montanide ISA-51|Montanide ISA-51 (Incomplete Freund's Adjuvant), local adjuvant
223663105|NCT03617328|DRUG|polyICLC|polyICLC, local adjuvant
223663106|NCT03617328|DRUG|CDX-1127|CDX-1127, anti-CD27 monoclonal antibody
223663107|NCT01716403|BIOLOGICAL|Diagnostic: protocol designed to evaluate one or more interventions aimed at identifying a disease or health condition|
223663108|NCT04354597|DRUG|HCQ & AZ|Subjects will receive weekly HCQ 400mg PO and AZ PO 500mg X 3 Days; weekly for 16 weeks.
223663109|NCT02722018|DRUG|GDC-0810 Phase II Tablet|Participants will receive dose level A (in Parts 1 and 2) or dose level B (in Part 3) tablets.
223663110|NCT02722018|DRUG|GDC-0810 Phase III Prototype Tablet|Participants will receive dose level A (in Parts 1 and 2) or dose level B (in Part 3) tablets.
223663111|NCT03144934|DRUG|GX-I7|Interleukin-7 (IL-7) is T cell growth factor that can be used for treating lymphopenia patients. GX-I7 is a protein drug recombining human IL-7 and hybrid Fc (hyFc). HyFc made by Genexine is composed of hinge-CH2 region of Immunoglobulin D (IgD) and CH2-CH3 region of Immunoglobulin G4 (IgG4). The recombined region is not exposed and each region's characteristics can reduce immunogenicity and improve the efficacy of drug. Consequently, it will be able to treat the patients with lymphopenia in effective ways.
223663112|NCT03144934|DRUG|Placebo|This is the placebo of GX-I7 described above.
223663113|NCT00706342|DRUG|Fostamatinib Disodium / R935788|R935788 tablets
223663114|NCT01034670|DEVICE|Dual axis endoscopic microscope|This is a device that is used in the accessory port of a standard endoscope and allows visualization of microscopic areas of mucosa.
223663115|NCT01034670|DEVICE|wide field fluorescence system|This is a modification to the existing narrow band endoscope from Olympus that incorporates different filters on the source and collecting optics to enable fluorescence imaging. It is used as is a standard endoscope.
223663116|NCT01034670|DEVICE|CellVizio|Minimicroscope--this is an FDA approved fiber-based microscope that we will use according to the manufacturers protocols.
223663117|NCT01034670|DRUG|fluorescent Peptide|microdosing; Topical through the endoscope
224243063|NCT05232877|OTHER|SHAM tDCS|The control group will follow cognitive training with a combined sham tDCS. Intervention will last for 4-week with 3 sessions per week (12 sessions).
224243064|NCT05232877|OTHER|tDCS|The intervention group will follow sessions of tDCS combined with a simultaneous cognitive training on tablet
223663118|NCT01034670|DRUG|fluorescein|100 mcg topical
223663119|NCT01034670|DRUG|indocyanine green|100 mcg topical
223663120|NCT04383418|DRUG|dexmedetomidine nasal spray|dexmedetomidine nasal spray
223663121|NCT04383418|DRUG|dexmedetomidine hydrochloride nasal spray blank preparation|dexmedetomidine hydrochloride nasal spray blank preparation
223663122|NCT03899181|DEVICE|Translumbosacral Neuromodulation Therapy (TNT)|A probe with 2 pairs of bipolar steel ring electrodes, will be placed in the rectum. At each site a mapping procedure is performed with single stimulus coil to assess the motor threshold intensity, defined as the minimum level of magnetic stimulation intensity required to achieve an anal and rectal MEP response of 10 microvolts and an anterior tibialis MEP of 20 microvolts with 50% of trials.The intensity for TNT at each site is capped at a maximum of 150% above this threshold to comply with safety guidelines. Thus, intensity of magnetic stimulations will be individualized. Bilateral lumbar stimulations (rTLMS) are administered at L2/L3 disc space, and sacral stimulations (rTSMS) at S2/S3 level. Next a 70 mm double air film self-cooling coil is positioned randomly over one of the 4 sites, held in place by a coil fixator and 300 or 450 stimulations are delivered. After a 5 min rest the cycle is repeated (Total =600-900/site).The coil is moved to the opposite side and it is repeated.
223663123|NCT03899181|OTHER|Sham TNT Therapy|This is the sham TNT treatment as mentioned in the different ARMs using the fake coil with no magnetic stimulations.
223663124|NCT01419197|DRUG|Trastuzumab emtansine|The dose was calculated based on the patient's Baseline weight on Day 1 of each 3-week treatment cycle. The same dose was administered in subsequent cycles if the patient's weight stayed within 10% of the Baseline weight. If there was a weight change \> 10%, the dose was adjusted accordingly and the recorded weight became the new Baseline weight. Trastuzumab emtansine was provided as a single-use lyophilized formulation.
223663125|NCT01419197|DRUG|Treatment of physician's choice|"The treatment of physician's choice (TPC) was a protocol-specified approved or standard of care therapy or combination of therapies, based on frequently used regimens for late-line HER2-positive metastatic breast cancer treatment after receipt of both trastuzumab- and lapatinib-containing regimens. The therapies included single-agent chemotherapy, single-agent (e.g., tamoxifen or aromatase inhibitor) or dual-agent (e.g., aromatase inhibitor with luteinizing hormone releasing hormone \[LHRH\] agonist) hormonal therapy for hormone receptor positive-disease, and HER2-directed therapy.~Participants who had documented progressive disease (PD) were eligible to switch treatment to receive trastuzumab emtansine 3.6 mg/kg. Participants who switched treatment remained on trastuzumab emtansine treatment until another PD event or unmanageable toxicity.~The formulation, storage, and preparation of all TPC were as per the appropriate package insert or national prescribing information."
223663126|NCT03528499|OTHER|Scapular Movement Training|Orientation about the proper scapular position and movement and training to modify the scapular movement pattern.
223663127|NCT03528499|OTHER|General Exercises|Strengthening and stretching exercises.
223769893|NCT04863976|OTHER|Dynamic stretching|Dynamic movements of the joints controlled by the quadriceps muscle (hip and knee)
223769894|NCT04863976|OTHER|Passive stretching|passive stretching of the quadriceps muscle
223769895|NCT04863976|OTHER|Self-stretching|Self-stretching of the quadriceps muscle
224243065|NCT01804777|DRUG|Amiloride|"Amiloride 10 mg taken every day for two weeks, along with adherence to specified diet.~On day 14 titrate dose up to Amiloride 20 mg, take every day for two weeks after completion of two week intake of Amiloride 10 mg, along with adherence to specified diet."
224243066|NCT01804777|DRUG|HCTZ|"HCTZ 12.5 mg taken every day for two weeks, along with adherence to specified diet.~On day 14 titrate dose up to HCTZ 25 mg taken every day for two weeks after completion of two week intake of HCTZ 12.5 mg, along with adherence to specified diet"
224243067|NCT05868564|DEVICE|Atherectomy+Drug-coated balloon|Patients in experimental group will undergo endovascular treatment for femoropopliteal lesions. The lesion will be treated by atherectomy+drug-coated balloon in the experimental group
224243068|NCT05868564|DEVICE|Drug-coated balloon|drug-coated balloon only in the active comparator group.
224243069|NCT01954264|PROCEDURE|Capillary blood sample|Capillary blood sample (up to 200µL) for determination of PP (blood slides).
223663128|NCT00146848|DEVICE|Atrial support pacing through cardiac resynchronization therapy. Device: RENEWAL family of CRT-D devices|"All subjects in this trial receive the same device. For the purpose of this trial, intervention is programming mode and lower rate limit to deliver atrial support pacing in the two treatment arms, while the control arm will receive programming where limited atrial support pacing is delivered. DDD-70 and DDDR-40 are the treatment arms programmed to receive atrial support pacing and will be compared to the DDD-40 arm."
223663129|NCT02451384|PROCEDURE|routine surgery|To observe if the surgeries can influence the countings of circulating tumor cells of the patients.
223663130|NCT02451384|PROCEDURE|no-touch surgery|
223663131|NCT02451384|PROCEDURE|laparoscopic surgery|
223663132|NCT05318742|PROCEDURE|laser|Endolaser photocoagulation during PPV
223663133|NCT04500561|DRUG|YY-20394|Yy-20394 combined with Gemcitabine and Oxaliplatin was used as a cycle for 21 days. The dose of YY-20394 was 80mg/ day as recommended in phase 2, and the dose of Gemcitabine and Oxaliplatin was treated according to clinical standards.
223663134|NCT03730090|DEVICE|zero flux skin termometer|Core temperature is monitored continously, non-invasively
223663135|NCT04915378|OTHER|hypoxia altitude simulation test (HAST) at 760m|Normobaric hypoxia at a FiO2 of 15.1% will be generated by the Everest Summit II altitude generator (Hypoxico Altitude Training Systems, Bickenbach, Germany) and delivered to the patients face via tubes and a tightly fitted mask. Patients will be seated comfortably in a chair and fitted with a full-face mask equipped with a one-way valve. After a baseline period of quiet rest of 5-10 min with ambient air breathing and installation of equipment, patients will breath the hypoxic air mixture via a tightly fitted facial mask. They will be monitored with a finger-tip pulseoximetry to continuously assess SpO2 and heart rate. After at least 15' and steady-state values of the SpO2 (±1%) for at least 5' arterial blood gases will be drawn from a radial artery and immediately analyzed (RapidPoint 500, Siemens, Zürich, Switzerland).
223663136|NCT04915378|PROCEDURE|High Altitude (3100m)|High Altitude (3100m) exposure for 2 days
223663137|NCT03385772|PROCEDURE|Sphenopalatine ganglion block|The patient will be placed supine, with head in sniffing position. Two long cotton-tipped applicators will be soaked in 4% lidocaine for 30 seconds. An anesthesia provider, after visually inspecting each nostril for any sign of deformity or blockage, will perform the block. A cotton tipped applicator will be inserted into one nostril at an angle perpendicular to the face, and will be advanced to the back of the nasopharynx until resistance is met. The procedure will be repeated in the other nostril. If the patient experiences any pain or discomfort, the physician will stop and redirect the applicator. The applicators will be left in place for 10 minutes, and then removed by the anesthesia provider.
223663138|NCT00922727|BIOLOGICAL|L. reuteri|The oil drops contains 10\^8 CFU (colony forming units). As suggested by the manufacturer in the Certificate of Analysis the daily dose given to each patient will be 5 x 10\^8 CFU/ 5 drops. The dose given is within the release limit which is greater than 2 x 10\^8 CFU/ 5 drops and less than 8 x 10\^8 CFU/ 5 drops.
224243070|NCT01954264|OTHER|Data collection|Prospective data collection at the study visit by the internet based Electronic Case Report Form (eCRF)
224321424|NCT00727103|DRUG|Varenicline|Varenicline will be dispensed in 0.5 mg and 1 mg tablets taken orally. During the first 3 days of medication, participants will take one 0.5 mg tablet of varenicline daily. If the medication is well-tolerated, the dose will be increased to 0.5 mg po twice daily for 4 days. On day 8, the dose will be increased again to the standard dosing schedule of 1 mg (1 tablet) po twice daily. At the end of the 8th week, varenicline will be discontinued.
223663139|NCT00922727|BIOLOGICAL|Sunflower Oil|As suggested by the manufacturer in the Certificate of Analysis the daily dose given to each patient will be 5 x 10\^8 CFU/ 5 drops.
223663140|NCT05224804|BEHAVIORAL|knwoledge|Knowledge and Attitudes about ADRs Reporting
223663141|NCT01801267|PROCEDURE|Endoscopic third ventriculostomy (ETV)|Pediatric patients in need of CSF-diversion surgery will undergo an endoscopic third ventriculostomy (ETV). A neurosurgeon will make a small hole in the third ventricle (a fluid space in the brain) to allow CSF to flow out of the ventricles.
223663142|NCT01801267|PROCEDURE|Ventricular shunt|Pediatric patients in need of CSF-diversion surgery will undergo ventricular shunt placement or revision. A neurosurgeon will insert a small tube into the ventricle (a fluid space in the brain) and connect this tube to another location in the body so that CSF can flow out of the brain and be absorbed elsewhere in the body - the belly, the top of the heart or the side of the lung. If a patient already has a shunt which is not working, a neurosurgeon will fix or replace it. This will serve as the Control arm of the study.
223663143|NCT01380626|PROCEDURE|exercise training|strength and endurance training, 5 time per week.
223663144|NCT02925949|BEHAVIORAL|DuoPACT|6 couple-based intervention sessions are administered weekly by a counselor.
223663145|NCT02925949|BEHAVIORAL|LifeSteps|3 individual-based intervention sessions are administered weekly by a counselor.
223663146|NCT04179292|OTHER|Hand Therapy by Physiotherapist|"stretching exercises; all finger joints, wrist and supination-pronation direction strengthening exercises; finger and wrist functional exercises retrograde massage; starting from the distal phalanx to the elbow sensory education; desentilation training (cotton…) breathing exercises 5 days / week, 8 weeks in total~* 3 days / week with physiotherapist~* 2 days / week as home program 30 minutes / day 12 repetitions"
224243071|NCT01390233|DRUG|Prepidil Gel|Pre-induction cervical ripening using dinoprostone gel in the vagina.
224243072|NCT01390233|DEVICE|Urinary Balloon Catheter|Pre-induction cervical ripening using a urinary balloon catheter device.
223769896|NCT00807534|DRUG|ipratropium bromide|ipratropium bromide nebulization
223769897|NCT00807534|DRUG|placebo|placebo nebulization
223769898|NCT00807534|BEHAVIORAL|constant rate step test|nebulization of 500ug
223769899|NCT00807534|BEHAVIORAL|constant rate shuttle walk test|nebulization of 500ug
224243073|NCT01390233|OTHER|Combined Urinary Catheter & Prepidil Gel|Pre-induction cervical ripening using dinoprostone gel injected through a urinary balloon catheter placed in the lower uterine segment.
224243074|NCT01496183|DRUG|Olanzapine|Olanzapine 5mg capsule administered orally at bedtime for 7 days followed by Olanzapine 10 mg capsule administered orally at bedtime for 7 days.
224243075|NCT01496183|DRUG|Placebo|Placebo capsule administered orally at bedtime for 14 days
224243076|NCT02479893|PROCEDURE|polypectomy|Polyps size up to 0.8 cm will removed from the left colon.Re examination in 6 months period with biopsy from the scar of polypectomy.
224243077|NCT04258150|DRUG|Nivolumab|6 mg/kg IV q4w
223663147|NCT04179292|OTHER|Hand Therapy as home program|"stretching exercises; all finger joints, wrist and supination-pronation direction strengthening exercises; finger and wrist functional exercises retrograde massage; starting from the distal phalanx to the elbow sensory education; desentilation training (cotton…) breathing exercises 5 days / week, 8 weeks in total~* 3 days / week with physiotherapist~* 2 days / week as home program 30 minutes / day 12 repetitions"
223663148|NCT02352285|DRUG|Tolvaptan|Start with 15mg to titrate upwards to 30mg to 60mg, once a daily
223663149|NCT02352285|DRUG|Placebo|Start with 15mg to titrate upwards to 30mg to 60mg, once a daily
223663150|NCT04944264|BEHAVIORAL|Stress Management and Resiliency Training (SMART) program|The Stress Management and Resiliency Training (SMART) program (bensonhenryinstitute.org) is well validated comprehensive stress management program. It is designed to cultivate both the early recognition of stress in the mind and body, develop skills to mitigate stress and evoke the relaxation response and cultivate resiliency. It is an 8 session program, typically run in a live group setting. In this study's case it was delivered via a videoconferencing platform.
224243078|NCT04258150|DRUG|Ipilimumab|1 mg/kg IV twice q6w
223663151|NCT05861817|DEVICE|Laser theapy|participants were randomized into either the LLLT group or sham treatment group by a computer-generated random number. The participants were treated using LLLT (904nm and 2.5 J/ sinus). treatment was delivered for one month
223663152|NCT03891238|DRUG|Avelumab|Patients will receive avelumab at standard dosage of 10 mg/kg as a 1-hour intravenous infusion once every 2 weeks (Q2W).
223663153|NCT04189185|PROCEDURE|Suture fixation|The fracture is reduced. A 2.5 mm hole is drilled in the dorsal olecranon 15mm from the fracture. A suture is passed through the hole and is fixed to the triceps muscle. A second suture is fixed to the triceps muscle in a figure 8 configuration.
223663154|NCT05692336|OTHER|vestibular training|balance training in the form of vestibular training
223663155|NCT05692336|OTHER|dual task training|balance training in the form of dual task training
223663156|NCT05675644|DRUG|Drospirenone-only pill|Single dose based on adaptive dose-finding design
223663157|NCT01715441|DRUG|Sorafenib and irinotecan combination|
223663158|NCT01715441|DRUG|Sorafenib monotherapy|
223769900|NCT04871334|DRUG|TWP-101|IV infusion Q2W for 4 weeks (28-day cycles)
223769901|NCT03710278|DEVICE|LPat Device|Performing Lumbar Puncture utilizing LPat device
223769902|NCT04469361|OTHER|Navicular drop measurement|The difference in navicular height between sitting and standing positions was recorded (mm) as the amount of navicular drop.
223769903|NCT04469361|OTHER|Measurement of venous return parameters in supine|Venous return parameters of posterior tibial vein was measured when participant applied force equivalent to their own body weight on plantar surface of their right leg in supine position
224243079|NCT04258150|DRUG|Tocilizumab|8 mg/kg IV q4w
224243080|NCT04258150|RADIATION|SBRT|"* A total dose of 15 Gy as a single fraction is prescribed as the mean dose to the PTV.~* PTV should be covered by 95% isodose (PTV D99% \> 95%)."
224243081|NCT03002077|DRUG|Rapastinel|Rapastinel pre-filled syringes for IV injections.
223663159|NCT01715441|DRUG|Irinotecan monotherapy|
224243082|NCT01013467|BEHAVIORAL|"CoCo colour coded blood pressure control"|The patients in the intervention group will receive a colour-coded blood pressure record booklet. The corresponding colour coded areas are divided into three areas of green, yellow and red following a traffic light system. The green area covers blood pressure readings up to a maximum of 140/90 mmHg, the yellow area includes systolic readings over 140 to 180 mm Hg and diastolic readings over 90 to 110 mmHg. The red area covers systolic readings over 180 mmHg and diastolic readings over 110 mmHg.
224243083|NCT04591717|BIOLOGICAL|hAd5-S-Fusion+N-ETSD vaccine|The hAd5-S-Fusion+N-ETSD Vaccine is a human adenovirus serotype 5 (hAd5) vector with E1/E2b/E3 deletions expressing SARS-CoV-2 viral antigen spike fusion protein and nucleocapsid with an enhanced T-cell stimulation domain.
224243084|NCT00738868|BIOLOGICAL|cetuximab|
224243085|NCT00738868|RADIATION|stereotactic body radiation therapy|
224321425|NCT00727103|DRUG|Placebo|Placebo will be dispensed in color-coded capsules. Blue capsules will contain 0.5 mg glucose (placebo), red capsules will contain 1 mg glucose (placebo).
224321426|NCT04264325|OTHER|diaphragmatic ultrasound measure|patients with lung neoplasms and malignant pleural effusions who need a diagnostic or therapeutic thoracocentesis
223663160|NCT00119678|DRUG|Abatacept|Injectable, intravenous, 10 mg/kg, abatacept every 28 days, 12 months
223663161|NCT00119678|DRUG|Placebo|Injectable, intravenous, 0 mg, every 28 days, 12 months
223663162|NCT00119678|DRUG|Prednisone|Tablets, oral, 30 mg, daily for 28 days then taper off, 12 months
223663163|NCT00119678|DRUG|Abatacept|Injectable, intravenous, 10 mg/kg, every 28 days
223663164|NCT05343767|DIETARY_SUPPLEMENT|Natural Wellness Low-Glu low dose|The contents of 4 capsules of NW Low-Glu were equally distributed and inserted into 6 capsules size 0, and administered in 3 daily doses
223663165|NCT05343767|DIETARY_SUPPLEMENT|Natural Wellness Low-Glu high dose|The contents of 5 capsules of NW Low-Glu were equally distributed and inserted into 6 capsules size 0, and administered in 3 daily doses
223663166|NCT05343767|OTHER|Metformin|A total dose of 2000 mg was administered per day.
223663167|NCT01761240|DRUG|MORAb-066|MORAb-066 infusion.
223663168|NCT03479333|DEVICE|Short implant|Short implant will be placed depending on the previous randomization. For that, a surgical access will be done, and the implant will be placed, cover screw will be installed and the access closed. The patient will receive the definitive crown after five months after the short implant installation.
223769904|NCT04469361|OTHER|Measurement of venous return parameters in standing|In standing, venous return parameters was measured of posterior tibial vein when participants shift all of their weight to the right leg for 3 second with their leg muscles as relaxed as possible and their knee joint in full extension.
223769905|NCT04469361|OTHER|measurement of midfoot pressure distrubition|In standing, midfoot pressure distrubution was measured when participants shift all of their weight to the right leg
224321427|NCT05677035|DRUG|LINO-1713 1 tablet|LINO-1713 1 tablet is administered once. Oral administration with 200mL of water
223769906|NCT01038271|OTHER|Standard Palliative Care Group|Participant is referred to the Palliative Care Team at any time.
224321428|NCT05677035|DRUG|LINO-1713 once a day for 24 days|Oral administration is performed with 200 mL of water. Instruct subjects to take the drug at the same time as possible.
224243086|NCT06293872|DEVICE|12*2 mm length miniscrew|"Prior to mini-inplant insertion the patient will instructed to rinse mouth with chlorhexidine mouthwash, then local anesthesia will be applied.~The clinical implication for miniscrew insertion in the IZ crest of adults is 14 to 16 mm above the maxillary occlusal plane and the maxillary first molar.~The self-drilling screw is directed at 90° to the occlusal plane at this point. After the initial notch in the bone is created after couple of turns to the driver, the bone screw driver direction is changed by 55°-70° toward the tooth, downward, which aid in bypassing the roots of the teeth and directing the screw to the infra-zygomatic area of the maxilla. The bone screw is screwed until only the head of the screw is visible outside the alveolar mucosa.~Follow-up: C.B.C.T will be performed after surgery to verify the implant position relative to the adjacent roots"
224243087|NCT06336733|DRUG|ANAKINRA|On demand Anakinra 100 mg/j from the prodromal phase of the attack until 24 hours of remission (during 7 days maximum) + colchicine + on demand analgesics
224243088|NCT06196242|DIAGNOSTIC_TEST|MRI and CT scan|"An MRI scan of the head in about 30 minutes. During the scan, MRI thermometry will be performed to monitor for possible lead heating due to the interaction of the MRI radiofrequency field and the implanted devices.~An CT plain scan of the head in about 10 minutes."
224243089|NCT01599338|DRUG|Liraglutide|3 months of treatment by Liraglutide (self-administration). The initial dose was 0.6 mg/day subcutaneously during five days, then uptitrated to a daily dose of 1.2 mg during three months.
224321429|NCT00490841|DEVICE|Herculink Elite Renal Stent System|This is a prospective, non-randomized, single arm, multi-center study to evaluate the safety and effectiveness of the RX Herculink Elite Renal Stent System in patients with sub-optimal renal PTA results in de novo or restenotic renal artery lesions. Patients who satisfy the inclusion/exclusion criteria will be enrolled at sites in the United States. Patients will have follow up visits for evaluation.
224321430|NCT05870059|DRUG|Propolis mouthwash|After scaling and root planning at the baseline visit, patients were prescribed to use 5ml of propolis mouthwash twice a day for 6 weeks. patients were also prescribed to not eat and drink anything for half an hour after the rinse.
224321431|NCT05870059|DRUG|Chlorhexidine mouthwash|After scaling and root planning at the baseline visit, patients were prescribed to use chlorhexidine mouthwash twice a day for 6 weeks. patients were also prescribed to not eat and drink anything for half an hour after the rinse.
224321432|NCT05973799|OTHER|Fasting|Subjects remain fasted prior to insulin-induced hypoglycemia.
224321433|NCT05973799|OTHER|Feeding|Subjects eat a normal breakfast and lunch prior to insulin-induced hypoglycemia.
224243090|NCT04625114|DRUG|Camostat|Standard of care (SOC) + Camostat mesilate (Foipan) 100mg 3 tablets 3 times a day for 5 consecutive days (D1-\>D5);
224243091|NCT04625114|DRUG|Placebo|SOC + placebo 500 mg 3 tablets 3 times a day for five consecutive days (D1-\>D5).
224243092|NCT04625114|DRUG|Camostat|Standard of care (SOC) + Camostat mesilate (Foipan) 100mg 3 tablets 3 times a day for 5 consecutive days (D6-\>D10);
224243093|NCT04625114|DRUG|Placebo|SOC + placebo 500 mg 3 tablets 3 times a day for five consecutive days (D6-\>D10).
224243094|NCT00193141|DRUG|Paclitaxel|
224243095|NCT00193141|DRUG|Carboplatin|
224243096|NCT00193141|DRUG|5-Fluorouracil|
224243097|NCT04701619|OTHER|Immuno-inflammatory profile description in patients with ischemic stroke|Patients will be evaluated for inflammatory biomarkers at inclusion, at 24-48 hours of reperfusion treatment , at 72 hours, at 7 days or at discharge if before D7, at discharge if after D7, at 3 months and at 1 year.The biomarkers will be measured using ELISA panels for inflammatory biomarkers
224321434|NCT06134726|DIAGNOSTIC_TEST|seropositivity of rheumatoid factor|All participants were tested for seropositivity of rheumatoid factor and anticitrullinated protein antibodies
224321435|NCT05532150|PROCEDURE|Arthroscopic Bankart repair|Participants in this group will undergo minimally invasive surgery to repair their shoulder with a technique called a Bankart repair.
224321436|NCT05532150|PROCEDURE|Physical therapy|Participants in this group will follow a specific physical therapy rehabilitation protocol
224321437|NCT05497791|DEVICE|transcranial laser stimulation associated with NMES|"The cluster was applied on the skin covering the head. NMES of the paretic limbs was programmed to generate, alternately, ankle dorsiflexion and wrist extension.~The NMES was started, after 5 minutes the transcranial laser stimulation (active or placebo-treatment) was started. Then, the therapies were combined. After finishing the transcranial laser stimulation (active or placebo-treatment), the NMES was continued until completing 30 minutes."
224321438|NCT05497791|OTHER|Placebo|The transcranial laser was applied identically for all groups, but the null dose was used in the placebo group. NMES of the paretic limbs was programmed to generate, alternately, ankle dorsiflexion and wrist extension.
224243098|NCT04887077|DEVICE|Kiplin|"The Kiplin intervention will be composed of four components within a smartphone application: a) a gamification of Physical Activity through multiple games called animations, b) a remote adapted physical activity program with telecoaching sessions, c) an interface for exchange and conversation and, d) an activity monitoring tool."
224243099|NCT04887077|BEHAVIORAL|face-to-face|three-month program of face-to-face adapted physical activity, three sessions a week, for a total of 36 sessions.
224243100|NCT06360653|RADIATION|Stereotactic Post-operative Radiotherapy for Endometrial Cancer|Patients candidate to receive adjuvant radiotherapy will be assigned to a shorter schedule of 30 Gy in 5 sessions.
224243101|NCT05589818|DRUG|Pembrolizumab|Patients will be treated with the standard dose of pembrolizumab for the first 12 weeks of the study. After week 12 assessments, patients without objective progression of disease are eligible to transition to Q6W dosing of pembrolizumab 400mg IV. Patients will be offered this schedule, also an FDA-approved option, at the discretion of the treating physician, based on tolerability of the q3week regimen and clinician assessment of need for closer follow up intervals. Pembrolizumab will be continued until disease progression, unacceptable toxicity, withdrawal of consent, or death.
224243102|NCT06032299|PROCEDURE|Single Distal Femur Implant|Single implant constructs will be either a retrograde intramedullary nail with interlocking screws or a single plate and screw construct.
224243103|NCT06032299|PROCEDURE|Dual Distal Femur Implant|Dual implant constructs will either be an intramedullary nail with an additional plate and screw construct or dual (two plates in any orientation) plate and screw construct.
224321439|NCT05755971|OTHER|Combination taping|Elastic and rigid tapes applied together for six weeks
224321440|NCT04604613|PROCEDURE|Bilateral Salpingectomy with Oophorectomy|Undergo standard of care bilateral salpingo-oophorectomy
223663169|NCT03479333|DEVICE|Standard implant with sinus lift|First, a surgical access will be performed, followed by sinus lift procedure. Next, a standard implant will be placed, cover screw will be installed and the access closed. The patient will receive the definitive crown after five months after the short implant installation.
223663170|NCT00509145|DRUG|Laquinimod|Laquinimod 0.6 mg capsule, oral, once daily
223663171|NCT00509145|OTHER|Placebo|oral, once daily, capsule
223663172|NCT01685151|DRUG|Ramelteon SL (Dose 1)|Ramelteon tablets for sublingual administration
223663173|NCT01685151|DRUG|Ramelteon SL (Dose 2)|Ramelteon tablets for sublingual administration
223663174|NCT01685151|DRUG|Placebo|Placebo
223663175|NCT05155254|DRUG|IO102-IO103|IO102-IO103 comprises IDO peptide antigen (IO102) and PD-L1 peptide antigen (IO103) emulsified with adjuvant (Montanide ISA 51 VG) administered subcutaneously
223663176|NCT05155254|DRUG|Pembrolizumab|Pembrolizumab administered intravenously
223663177|NCT03687944|OTHER|Validity and reliability|Test-retest method and concurrent validity
224243104|NCT02576925|OTHER|Clinical, ophthalmological and neurological evaluation|Clinical : questionnaire about the symptoms and about the vascular risk factors Imagery :Cerebral MRI, MRI angiography of the supra-aortic trunks, ECG, Holter, transthoracic echocardiography, Biology : blood count, erythrocytes sedimentation rate, C reactive protein Ophthalomogy : visual field, optical coherence tomography, retinography
224243105|NCT02546167|BIOLOGICAL|CART-BCMA|
224243106|NCT02688556|DRUG|cyclosporine|
224243107|NCT02688556|DRUG|vehicle of OTX-101|
224243108|NCT00399581|PROCEDURE|High Frequency Oscillatory Ventilation-Hi|HFOV will be conducted with recruitment maneuvers and with a table of mPaw and FiO2s that include higher mPaw's.
224243109|NCT00399581|PROCEDURE|High Frequency Oscillatory Ventilation-Lo|HFOV will be conducted without routine recruitment maneuvers and with a table of mPaw and FiO2s that include relatively low mPaw's.
224243110|NCT03348943|BEHAVIORAL|Right hemiparesis, right upper limb.|Individuals with right hemiparesis Cerebral Palsy that will perform the tasks with the affected upper limb.
224243111|NCT03348943|BEHAVIORAL|Right hemiparesis, left upper limb|Individuals with right hemiparesis Cerebral Palsy that will perform the tasks with the non-affected upper limb.
224243112|NCT03348943|BEHAVIORAL|Left hemiparesis, left upper limb|Individuals with left hemiparesis Cerebral Palsy that will perform the tasks with the affected upper limb.
224243113|NCT03348943|BEHAVIORAL|Left hemiparesis, right upper limb|Individuals with left hemiparesis Cerebral Palsy that will perform the tasks with the non-affected upper limb.
224243114|NCT02403752|BEHAVIORAL|Paired PLIE Program|Integrative exercise as described above
224243115|NCT02849652|BEHAVIORAL|ATTOC Intervention|ATTOC is implemented in a systematic 3-phase process with 10 steps to guide sites through cultural change and implementation of evidence-based practice.
224243116|NCT02849652|BEHAVIORAL|UC Intervention|Sites randomized to UC will not receive an organizational intervention to address TUD treatment. To ensure standardization across UC sites, study personnel will provide a 1-day training seminar that will include written materials describing recommended treatments for TUD to UC personnel consistent with established treatment guidelines.
224243117|NCT01955590|BEHAVIORAL|Metacognitive therapy|8-12 sessions of manualized metacognitive therapy
223663178|NCT03853278|BEHAVIORAL|colorectal cancer self-management|The intervention includes a colorectal cancer self-management information booklet, a DVD, two individual skill training and 12 follow-up telephone calls. These are to establish participants' self-management skills and healthy lifestyle, including physical activity and healthy eating fruits and vegetables.
223663179|NCT06225869|BEHAVIORAL|Assessments in ON and OFF levodopa state|Neurological assessment, neuropsychological assessment, and fMRI in ON and OFF levodopa state
224243118|NCT01955590|BEHAVIORAL|EMDR|8-12 sessions of manualized EMDR
224243119|NCT01955590|BEHAVIORAL|Treatment as usual|8-12 sessions of treatment of usual
224243120|NCT01863745|DRUG|nilotinib|Nilotinib was administered daily as hard gelatin capsules for oral use. The starting dose of nilotinib was same as the last dose given in the parent nilotinib study. After this, the dose of nilotinib was based on the investigator's judgment. The total daily dose was up to 800 mg.
224243121|NCT00472290|DRUG|Romiplostim (formerly AMG 531)|"Subjects will begin the study at an initial dose of 750 µg.~Except for:~* Subject whose doses were escalated to doses higher than 750 µg AMG 531 weekly, and maintained a response per IWG guidelines for platelet response.~* Subjects who were stable at a lower dose of AMG 531 on the previous study. Doses will be adjusted throughout the study based on individual subject's platelet count."
223663180|NCT00460291|DEVICE|Implantation of the ProVena vein graft during bypass surgery|
223663181|NCT00363701|DRUG|esomeprazole|
223663182|NCT02937402|PROCEDURE|Bronchoscopy with Bronchoalveolar Lavage|Undergo bronchoscopy with bronchoalveolar lavage
223663183|NCT02937402|OTHER|Laboratory Biomarker Analysis|Laboratory Biomarker Analysis
223663184|NCT00744302|DRUG|physiological (1.25 mmol/L ) calcium dialysate|Using the physiological calcium dialysate (1.25 mmol/L calcium dialysate)for Stable haemodialysis treatment for more than 3 months, undergoing 2 to 3 times haemodialysis a week for 4 to 5 hours per session
224321441|NCT04604613|PROCEDURE|Biospecimen Collection|Undergo collection of blood and tissue samples
224321442|NCT04604613|PROCEDURE|Hysterectomy|Undergo standard of care hysterectomy
224321443|NCT04604613|OTHER|Laboratory Biomarker Analysis|Correlative studies
223663185|NCT03844204|DEVICE|Thermal servo-controlled system|All patients will be positioned under the infant warmer. In the treatment group, a probe positioned on the skin of the neonate will guide the thermal exposure in a servo-controlled modality. In the control group, thermal exposure will be determined manually by setting the power of the heater at the maximum output.
223663186|NCT00272025|DRUG|Escitalopram|10mg to 20mg tablet daily for 6 weeks
223663187|NCT00272025|DRUG|placebo|
224321444|NCT04604613|PROCEDURE|Lymph Node Mapping|Undergo sentinel lymph node mapping
224321445|NCT04604613|PROCEDURE|Sentinel Lymph Node Biopsy|Undergo sentinel lymph node biopsy
224321446|NCT06385483|DRUG|Afatinib|Given PO
224321447|NCT06385483|PROCEDURE|Biopsy Procedure|Undergo biopsy
224321448|NCT06385483|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
224321449|NCT06385483|PROCEDURE|Computed Tomography|Undergo CT scan
224321450|NCT06385483|PROCEDURE|Echocardiography Test|Undergo ECHO
224243122|NCT05293054|OTHER|Application of autologous fibrin matrix (Obsidian)|"When the patient is anaesthetized, 120 ml venous blood is collected for preparation of the autologous fibrin matrix. The blood is processed in the Vivostat® unit for 30 minutes making a 5-6 ml concentrate ready for application by use of a specific endoscopic kit device.~When the rectal cancer resection is completed and the specimen is extracted, the Obsidian will be applied using minimal invasive technique and the endoscopic kit device.~Step 1: 1.5-2ml. Obsidian is applied onto the rectal stump, with the circular stapler device inserted into the rectal stump. The circular stapler is then closed, but not yet fired.~Step 2: 2.5-3ml Obsidian is applied 360 degrees around the anastomosis, while taking care not to increase tension on the anal intestine end. The circular stapler is then fired and removed. The water-air-leak test is performed according to standard clinical practice. Step 3: The remaining part of the Obsidian is then sealed 360 degrees around the anastomosis."
224243123|NCT05891977|OTHER|Intervention A - Tomato paste|Participants will consume a daily amount of 0.5 g of tomato paste / kg of body weight following the regular diet plus consumption of low to moderate tomato or tomato-based products and lycopene containing foods
224243124|NCT05891977|OTHER|Intervention B - Control|Participants will consume the regular diet plus consumption of low to moderate tomato or tomato-based products and lycopene containing foods
224243125|NCT01325675|BEHAVIORAL|Interval training|Aerobic interval training will be performed with 4 times of 4 minutes intervals at an intensity of 90-95% of maximum heart rate and active pauses of 3 minutes between intervals. 3 times a week for 12 weeks.
224243126|NCT00777829|DRUG|zolpidem|Participants will receive one dose of 10 mg before each nap.
224243127|NCT00777829|DRUG|Placebo|Participants will receive a dose of placebo before each nap.
224243128|NCT04834037|BEHAVIORAL|Behavioral|The provision of information and supportive nursing care is recommended to alleviate anxiety, stress and agitation in COPD patients treated with NIV.
224243129|NCT00071136|DRUG|pemetrexed|
224243130|NCT00071136|DRUG|gemcitabine|
224321451|NCT06385483|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
224321452|NCT06385483|PROCEDURE|Radionuclide Imaging|Undergo nuclear study
224321453|NCT03448497|OTHER|Non-interventional|Non-interventional
224321454|NCT02274831|OTHER|Email Reminder of need to follow up with primary physician|
224321455|NCT07134998|DRUG|HRS-6093|HRS-6093
224243131|NCT01575509|OTHER|Berry product|Sugar infused dried lingonberry
224321456|NCT07134790|DRUG|VE818|VE818, is an 11-strain bacterial consortium rationally designed by Vedanta Biosciences Inc., to displace enteropathogens and reduce intestinal inflammation in pregnant women
224243132|NCT01575509|OTHER|Bread product|Brown bread
224243133|NCT01575509|OTHER|Bread product|Whole grain bread
223663188|NCT05149885|DEVICE|SenseGuard monitoring|All subjects that recruited to the study will undergo MCT as usual with the addition of SG measurement after each Methacholine dose and spirometry test.
224243134|NCT01575509|OTHER|Glucose control solution|Glucose solution with a corresponding amount of carbohydrates as provided by the bread test products
224243135|NCT01575509|OTHER|Glucose-fructose control solution|Control solution with a similar carbohydrate content as provided by the dried lingonberry test product
224243136|NCT03665649|PROCEDURE|CD133+ cells isolation|Hematopoietic precursors from human donors will be mobilized by administering Colony Stimulating Factors (G-CSF) for 5 days (according to the clinical standard administration) and subsequently CD133+ cells will be isolated and transferred in a murine model.
224243137|NCT02877056|PROCEDURE|Endoscopy|Tissue samples taken from tumor and normal colorectal tissue during standard endoscopy before therapy.
224243138|NCT03344445|OTHER|video-assisted pre anesthesia explain|Anesthesiologist will visit all study patients, and only the experimental group will read the video.
223663189|NCT01986556|DRUG|Lesinurad 400 mg (Site 1)|
223663190|NCT01986556|DRUG|Lesinurad 400 mg (Site 2, Lot A)|
224243139|NCT05223556|DEVICE|Full Self-Diagnostic device in a remote diagnostic imaging site|Full Self-Diagnostic CRP+OCT imaging, followed by online consultation
224243140|NCT05223556|DEVICE|Human imager operated diagnostic device in the hospital|Human imager operated CRP imaging with dilated pupils, followed by face-to-face consultation
223663191|NCT01986556|DRUG|Lesinurad 400 mg (Site 2, Lot B)|
223769907|NCT01038271|OTHER|Integrated Palliative Care Intervention|Participant meets with the Palliative Care Team within 3 weeks of being randomized
224321457|NCT07134790|DRUG|Placebo|Enteric capsules filled with approximately 400mg of microcrystalline cellulose (bulking agent)
224243141|NCT00692653|BEHAVIORAL|P4|Tailored online decision support system for prostate cancer treatment decision making
224243142|NCT02001948|DRUG|intrathecal morphine 0.1 mg combined with intrathecal heavy bupivacaine 7.5 mg|
224243143|NCT02001948|DRUG|intrathecal morphine 0.4 mg combined with intrathecal heavy bupivacaine 7.5 mg|
224243144|NCT02001948|DEVICE|standard monitoring with Datex Ohmeda anesthesia monitor, GE, Finland|electrocardiography, heart rate, pulse oximetry and noninvasive arterial blood pressure
224243145|NCT02001948|DRUG|intravenous cannulation and premedication|18-gauge intravenous cannula was inserted at the forearm opposite to the surgical side and routine iv premedication (midazolam 0.03 mg/kg) was given
224243146|NCT06206395|DEVICE|Two dimensions speckle tracking and three dimension echocardiography and cardiac magnetic resonance imaging|"2D speckle tracking echo will be performed before chemotherapy and after mid-cycle and after completion of treatment.~3D echo and CMR will be performed before and after chemotherapy treatment."
224243147|NCT02359305|DRUG|Acetaminophen|Acetaminophen given by IV
224243148|NCT02359305|DRUG|Acetaminophen|Acetaminophen suppository given rectally
224321458|NCT07134790|DRUG|Oral Vancomycin|Oral vancomycin in capsule form will be administered three times daily for 5 days at 250mg per dose. Because oral vancomycin is a non-absorbable antibiotic, the likelihood of systemic absorption is minimal and therefore, it is not associated with the adverse events attributable to the intravenous formulation
224321459|NCT01098487|DRUG|Eltrombopag olamine|Thrombopoietin receptor agonist
224321460|NCT05223140|BEHAVIORAL|Birth within 7 minutes of rumping|Birth within 7 minutes of rumping (+3 station), within 5 minutes of birth of pelvis, within 3 minutes of birth of umbilicus
224321461|NCT05223140|BEHAVIORAL|Premature cord clamping|Umbilical cord clamping \<1 minute following birth
224321462|NCT00345631|OTHER|Manual Compression|Manual compression
223663192|NCT04287582|OTHER|Electromyographic device|An 8-channel surface EMG system (DELSYS Trigno Wireless System) will be used to measure signals from muscles during stair climbing activity by surface electromyography measurements.Surface EMG measurements will be carried out during stair climbing activity without any intervention in the body. Surface EMG electrodes will be placed bilaterally in the vastus lateralis, biceps femoris, tibialis anterior and gastrocnemius medialis muscles.
223663193|NCT04119466|BEHAVIORAL|Stabilizing training|The training will include the activation of the lumbar multifidus muscle (m. multifudus) and the transverse abdominal muscle (m. transversus abdominis). The performance of the individual stages of the training will be based on Richardson's methodology. One session will comprise 4 sets in which the patient will be asked to do pelvic tilts (draw-in) with simultaneous full exhalation, thus activating the aforementioned muscle groups in different positions: a) prone b) supine with lower extremities flexed c) quadruped d) standing back to the wall. The subjects will perform 3 series consisting of 10 repeats, each of which will last ca. 10 seconds.
223663194|NCT03050385|DEVICE|transcranial direct current stimulation|
223663195|NCT00351871|DRUG|PEG-Intron Plus REBETOL|
223663196|NCT02923440|BIOLOGICAL|blood sample|
223769908|NCT05199857|BEHAVIORAL|WE BEAT Group Wellness Education program - phase 1|Participants will be assigned into a small group with 3-6 other participants and will participate in a weekly, 45-50 minute intervention session for 5 weeks, delivered by a licensed clinical psychologist or limited licensed clinical psychology fellow using University of Michigan (UM) Zoom. Each session will focus on a particular skill related to wellness and resiliency. There will also be a short battery of questionnaires to complete.
223769909|NCT05199857|BEHAVIORAL|HEART Club Home Exercise program - phase 2|This is an individualized home exercise program adapted from the exercise programs used in traditional, hospital-based cardiac rehabilitation. A complete cardiopulmonary exercise test (CPET) may be completed if needed for a baseline and one will be done at the last visit. The exercise physiology team will discuss participants exercise goals, interests, and available resources to help develop the exercise plan for the research study. Once the program is designed, participants will complete the exercise activities in the plan. Over time, participants will advance through various stages in the program and then will be gradually introduced to the principles of exercise rehabilitation and more intense physical exercise. Participants will be asked to wear a wearable activity tracker and have scheduled video check-ins with the exercise physiology team. Throughout the program participants will complete a short battery of surveys.
223663197|NCT06462105|DRUG|Irinotecan Hydrochloride Liposome Injection；Carboplatin Injection；Serplulimab Injection|"Cohort 1: Liposomal irinotecan: 50mg/m2, ivgtt, d1; Carboplatin AUC=5, ivgtt, d1; Serplulimab: 4.5mg/kg, ivgtt, d1; The drug was administered once every three weeks for a total of 4 cycles. After 4 cycles, serplulimab is maintained until disease progression or toxicity becomes intolerable.~Cohort 2: Etoposide: 100 mg/m2, ivgtt, d1-3; Carboplatin AUC=5, ivgtt, d1; Serplulimab: 4.5mg/kg, ivgtt, d1; The drug was administered once every three weeks for a total of 4 cycles. After 4 cycles, serplulimab is maintained until disease progression or toxicity becomes intolerable."
223663198|NCT00466141|BEHAVIORAL|Increased Exercise for weight loss maintenance|
223663199|NCT00466141|BEHAVIORAL|Daily Self-weighing for weight loss maintenance|
223663200|NCT00466141|BEHAVIORAL|Education for weight loss maintenance|
223769910|NCT01978431|DRUG|cocaine hydrochloride|
224243149|NCT03719222|OTHER|non intervention|It is an non-interventional retrospective observational study by using archived paraffin-embedded tumor specimens
224243150|NCT06001034|DEVICE|Occlusion training|Impact of supervised occlusive training for 2 days per week for 10 weeks on quality of life and functional autonomy in participants with fibromyalgia.
224243151|NCT02242292|DRUG|Hyoscine butylbromide|
224243152|NCT02242292|DRUG|Placebo|
224243153|NCT00169195|DRUG|Gemcitabine-Oxaliplatin plus Rituximab (R-GEMOX)|
224243154|NCT03267628|PROCEDURE|Intrathecal morphine as well as local anaesthetic in Blocks|A Quadratus lumborum type 2 block will be performed under ultrasound with 25 ml 0.375% ropivacaine deposited posterior to the quadratus lumborum muscle. 150mcg morphine will be added to the spinal anaesthetic.
224243155|NCT03267628|PROCEDURE|Intrathecal morphine as well as saline in Block|150mcg morphine will be added to the spinal anaesthetic. 25 ml saline will be used on each side during a quadratus lumborum type 2 block.
224243156|NCT03267628|PROCEDURE|Saline intrathecal as well as saline in Blocks|0.3 ml saline will be added to the spinal anaesthetic. 25 ml saline will be used on each side during a quadratus lumborum type 2 block.
223663201|NCT00339001|DRUG|erythropoietin and early iron supplements|
223663202|NCT01029106|PROCEDURE|Gynecare TVT Secur|Implant of the Gynecare TVT Secur
223663203|NCT02613026|DRUG|Pirarubicin|
223663204|NCT02613026|DRUG|Docetaxel|
223663205|NCT02613026|DRUG|Cyclophosphamide|
223769911|NCT01978431|DRUG|methylphenidate|
223769912|NCT02561507|BEHAVIORAL|Survey|
223769913|NCT01987323|DRUG|Subconjunctival injection of liposomal latanoprost|
223769914|NCT02155595|OTHER|500 without BP treatment|lab tests, X-ray, bone scan or MRI, as needed
223769915|NCT02155595|OTHER|500 with BP treatment|lab tests, X-ray, bone scan or MRI, as needed (90 of these individuals can opt for iliac crest bone biopsy)
223769916|NCT02621970|DRUG|Cisplatin 1|Cisplatin 25 mg/m2, D1-3
223769917|NCT02621970|DRUG|Cisplatin 2|Cisplatin 100 mg/m2, D1
223769918|NCT02621970|DRUG|Docetaxel|Docetaxel 60mg/m2, D1
224243157|NCT03267628|PROCEDURE|Saline intrathecal as well as local anaesthetic in Blocks|0.3 ml saline will be added to the spinal anaesthetic. A Quadratus lumborum type 2 block will be performed under ultrasound with 25 ml 0.375% ropivacaine deposited posterior to the quadratus lumborum muscle.
224243158|NCT04096703|PROCEDURE|Pneumatic dilation|The patients randomized to the pneumatic dilation cohort will undergo an initial pneumatic dilation with a 30mm Rigiflex (Boston Scientific). If the Eckardt score four weeks after initial dilation is \> 4, then the patient will be scheduled for a second dilation with a 35mm Rigiflex balloon (Boston Scientific).
224243159|NCT01582672|DRUG|Standard Treatment|Standard treatment for Renal Cell Carcinoma
224243160|NCT01582672|BIOLOGICAL|AGS-003|Autologous Dendritic Cell product. Intradermal injections; 8 injections in the 1st year followed by quarterly boosters.
224243161|NCT03210636|DEVICE|LapSpace|use of atraumatic laparoscopic retractor for patients undergoing laparoscopic surgery
223663206|NCT06385782|OTHER|Antarctic environment|. According to the different work content of the scientific expedition team members, and taking the average outdoor working time of 2 hours/day as the node, the scientific expedition team members are divided into outdoor groups (n=12) and indoor groups (n=10). Participants will be assessed on the day they enter the Antarctic station and leave.
223663207|NCT04032509|OTHER|2 x 5 mL blood sample|2 x 5 mL blood sample to determine the performance of the automated VIDAS BTI platform in assessing serum concentrations of GFAP and UCH-L1 to rule out the need for a CT-scan after mTBI.
223663208|NCT03464175|DEVICE|Aerogen Solo®|Aerosol particles are generated by a vibrating-mesh nebulizer specifically designed for mechanical ventilation
223663209|NCT03464175|DEVICE|Heated-humidified circuit|It will be left on during the transfer and the nebulization in group 1
224243162|NCT05617703|DRUG|Glass Ionomer with Advanced Glass Hybrid Technology (Equia forte HT fil, GC, Japan)|Advanced Glass Hybrid technology (AGH) was achieved through introduction of ultra-fine highly reactive glass and high-molecular weight polyacrylic acid powders within conventional glass using particles and fillers with close refractive indexes
224243163|NCT03980288|DRUG|CAR-GPC3 T Cells|Pretreatment with fludarabine and cyclophosphamide CAR-GPC3 T Cells infusion
224243164|NCT01756937|DRUG|Imotun|300.03mg/cap,orally, 1 capsule once daily for 24 weeks
224243165|NCT01756937|DRUG|Placebo|1 capsule once daily for 24 weeks
223663210|NCT03464175|DEVICE|Heated-humidified circuit|It will be turned off 30 minutes before the nebulization (nebulization ended max 45 minutes after turning off the heated-humidifier).
224243166|NCT00275353|BEHAVIORAL|Individualized Symptom Education|
223663211|NCT03464175|DEVICE|Dry ventilator circuit specific for aerosol therapy|Streamlined components, specific position for the nebulizer at 30 cm of a V-shaped Y piece
223663212|NCT03464175|DEVICE|Conventional dry ventilator circuit with HME filter|The nebulizer is placed between the filter and the endotracheal tube.
223663213|NCT04346719|DEVICE|10 kHz stimulation (Myomed 932, Enraf-Nonius)|"A charge-balanced, symmetric, biphasic sinusoidal current without modulation will be delivered at a frequency of 10 kHz. The stimulation intensity will be defined as that sufficient to produce a strong but comfortable sensation, just below motor threshold, over the median nerve through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft,Netherlands)"
223663214|NCT04346719|DEVICE|20 kHz stimulation (Myomed 932, Enraf-Nonius)|"A charge-balanced, symmetric, biphasic sinusoidal current without modulation will be delivered at a frequency of 20 kHz. The stimulation intensity will be defined as that sufficient to produce a strong but comfortable sensation, just below motor threshold, over the median nerve through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft,Netherlands)"
223663215|NCT04346719|DEVICE|Sham stimulation (Myomed 932, Enraf-Nonius)|Sham stimulation will be delivered at a frequency of 10 kHz only during the first 30 seconds.
223663216|NCT04735640|BEHAVIORAL|nurse-led teleconsultation|Patients assigned to this group will receive personalized dietary and physical activity advice during 9 months. Behavioural goals and action plans will be developed in a stepwise manner in accordance with baseline levels of nutritional and physical activity adherence to recommendations.
223663217|NCT04735640|BEHAVIORAL|SMS|Patients assigned to this group will receive a total of 150 text messages (4 to 5 messages per week during weekdays) throughout the intervention period (9 months). The content of the text messages includes advice on diet and exercise.
223663218|NCT00864695|OTHER|Supportive care|protocol designed to evaluate one or more interventions where the primary intent is to maximize comfort, minimize side effects or mitigate against a decline in the subject's health or function. In general, supportive care interventions are not intended to cure a disease.
223663219|NCT00171522|DRUG|Tegaserod and Polyethylene Glycol 3350|
223663220|NCT00750152|DRUG|NAFT-500|topical cream application up to 4 weeks
223663221|NCT00750152|DRUG|Placebo|placebo cream applied for up to 4 weeks
223663222|NCT04620876|OTHER|Bimodal high resolution imaging of the retina|The protocol consists of performing an Optical coherence tomography and Scanning laser ophthalmoscope system using adaptive optics (AO-SLO-OCT).The participant is asked to put his forehead against the temple supports and his chin on a chin rest. The subject will be asked to fix a test pattern in the form of a cross. The pattern is positioned according to the desired eccentricity with respect to the fovea. The actual acquisition lasts a few seconds, possibly repeated to cover the field of the desired eye. The acquisition protocol depends on the subjects, their pathology and the system used; the area examined will be modified on a case by case basis. The total duration of each exam can be estimated at less than half an hour, with frequent breaks.
223663223|NCT01642615|DRUG|Dexlansoprazole|Dexlansoprazole capsules
223663224|NCT01642615|DRUG|Dexlansoprazole|Dexlansoprazole capsules
223769919|NCT02621970|DRUG|Xeloda|Xeloda 2000mg/m2, D1-14 in concurrent chemotherapy and Xeloda 2500mg/m2, D1-14 in adjuvant chemotherapy
223663225|NCT01642615|DRUG|Placebo|Dexlansoprazole placebo-matching capsules
223663226|NCT04716296|DRUG|Ketamine|Ketamine will be given for the second stage of the DBS surgery.
223663227|NCT04716296|DRUG|Saline|Saline will be given for the second stage of the DBS surgery.
223663228|NCT00912184|DEVICE|Standard polyamide high flux membrane|Standard haemofiltration; CVVH; blood flow 200 ml/min, ultrafiltrate 25 ml/kg/hr, anticoagulation as clinically indicated, bicarbonate buffered replacement fluid
223663229|NCT00912184|DEVICE|High cut-off (super high flux) polyamide membrane|CVVH with standard haemofiltration settings; blood flow 200 ml/min, ultrafiltrate 25 ml/kg/hour, anticoagulation as clinically indicated, bicarbonate-buffered replacement fluid
223769920|NCT02621970|RADIATION|Intensity-modulated radiotherapy|Intensity-modulated radiotherapy
223769921|NCT05136729|BEHAVIORAL|Self-Natural Posture Exercise training|SNPE training will be provided face-to-face or online by certified instructors. The SNPE exercise training involves the use of special belts to align and stabilize posture and joints. Up to 4 belts can be used, placed around the hips, around the thighs, below the knees, and above the ankles. Myofascial release is part of the training, which is self-performed with SNPE equipment.
224243167|NCT04299178|DEVICE|X-PLO2R POC|Portable Oxygen Concentrator (POC)
224243168|NCT04862078|DIAGNOSTIC_TEST|Shared decision making|"Shared decision making and decide surveillance strategy between standard follow-up according to the institutional practice and decide what to do advanced imagings for surveillance and guideline-based surveillance"
224243169|NCT04862078|DIAGNOSTIC_TEST|Usual care|standard follow-up according to the institutional practice
224243170|NCT03699644|DEVICE|Spectral-Domain Optical Coherence Tomography (SD-OCT)|Each participant in this study will undergo Optical coherence tomography (OCT), a non-invasive imaging test of the eye, one time. OCT uses light waves to take cross-section pictures of the retina, which are generated using scattered light waves.
224243171|NCT03699644|DEVICE|Magnetic Resonance Imaging (MRI)|Each participant in this study will undergo a single Magnetic resonance imaging (MRI) scan, a scanning technique for creating detailed images of the human body. The scan uses a magnetic field and radio waves to generate images of the brain.
223663230|NCT02057081|BEHAVIORAL|Multifamily Group for mTBI for Couples|MFG-mTBI-C uses a structured problem-solving and skills training approach to provide Veterans and partners with tools and information to improve coping and help couples reconnect through positive behavioral exchanges.
223663231|NCT02057081|BEHAVIORAL|Group Health Education (GHE)|GHE is a 14-session, highly structured educational intervention providing general information on health problems that are common among the general OEF/OIF cohort including sleep and sleep problems, physical activity and exercise, and alcohol and drug use, as well as guidelines for improving health behavior in these areas.
223663232|NCT03545425|PROCEDURE|Biofluid samplings|Blood and Urine
224243172|NCT03699644|DEVICE|Positron Emission Tomography (PET)|Each participant in this study will undergo a single Positron emission tomography (PET) scan of the brain. PET is a nuclear medicine functional imaging technique that is used to observe metabolic processes in the brain as an aid to the diagnosis of disease using the combination of a radioactive tracer, camera, and a computer.
224243173|NCT03699644|DIAGNOSTIC_TEST|Comprehensive Ophthalmic Examination|Each participant in this study will receive one comprehensive eye examination which will be performed by a licensed ophthalmologist at the University of Michigan. This examination will include the assessment of the participant's visual acuity, a slit lamp examination which will look at the anterior and posterior tissues of the eye including the retina using various lights and lenses, and intraocular pressures.
224243174|NCT03699644|DEVICE|Fundus Photography|Each participant in this study will undergo fundus photography of each eye. Fundus photography involves the use of a retinal camera coupled with a low power microscope to capture photographs of the retina.
224243175|NCT00258271|BIOLOGICAL|filgrastim|
224243176|NCT00258271|DRUG|cladribine|
224243177|NCT00258271|DRUG|cytarabine|
223663233|NCT04221776|OTHER|Group toilet training in daycare|During the training, children wore underpants, were informed about potty training, were encouraged to drink often and were asked regularly if they felt the need to void. Tutors looked for elimination signals in the child and quickly responded by putting the child on the potty when he/she expressed the need to void or to defecate. Children were positively rewarded. Parents received a leaflet containing practical tips concerning TT and their child's successes of the past two days. They were asked to continue TT at home during the following weekend and longer if necessary. Daycare workers were asked to pay more attention on the TT during the following days and weeks to ensure the effect of the intervention.
223663234|NCT04221776|OTHER|Individual toilet training at home|Parents were encouraged to start TT their child, because they were considered as being ready to initiate TT. Children did not receive any intervention, but parents were asked to start TT in their own manner. Parents were allowed to search for information on methods of TT with their relatives, internet, books,...
224243178|NCT00258271|DRUG|imatinib mesylate|
224243179|NCT05679648|DIAGNOSTIC_TEST|ultrasonography|studying degree of steatosis
224243180|NCT02567968|DRUG|Caffeine|Anesthetized volunteers will be allowed to wake after injection of caffeine (15 mg/ kg). The time to wake will be measured.
224243181|NCT02567968|DRUG|Placebo Control|Anesthetized volunteers will be allowed to wake after injection of saline (placebo control). The time to wake will be measured.
223663235|NCT03859362|DRUG|Ertapenem Injection|1 g of ertapenem q24h, 30 min infusion
223663236|NCT00410098|BEHAVIORAL|Bikram Yoga|
223663237|NCT06329895|DRUG|BAY2927088|Oral administration.
223663238|NCT06329895|DRUG|Dabigatran etexilate|Oral administration.
223663239|NCT06329895|DRUG|Rosuvastatin|Oral administration.
223663240|NCT01028300|DEVICE|ProDisc™-L Total Disc Replacement (TDR)|The design is based on a ball and socket articulation, one surface being metal and the other an ultra-high molecular weight polyethylene (UHMWPE). Three components comprise this modular prosthesis.
223769922|NCT01552538|DEVICE|Cyberonics VNS System|Stimulation with an active implantable electrical vagal nerve stimulation device
223769923|NCT00375193|DRUG|Amrubicin|Amrubicin 40mg/m\<2\> IV days 1, 2, 3 of each 21-day cycle until Cycle 6 or no longer beneficial
224243182|NCT05719090|DEVICE|Delfi Personal Tourniquet Systems|Measure within \& between differences in acute vascular compliance from pre- to post-training with autoregulated BFR, nonautoregulated BFR and no BFR conditions.
224243183|NCT00014105|DRUG|carboplatin|
224243184|NCT00014105|DRUG|temozolomide|
224243185|NCT05140070|DIETARY_SUPPLEMENT|Vegetable and fruit mousse enriched with a fiber preparation from potato starch with prebiotic properties|All children in the intervention group will consume on daily basis vegetable and fruit mousse enriched with a fiber preparation from potato starch with prebiotic properties for six months
224243186|NCT05140070|DIETARY_SUPPLEMENT|Vegetable and fruit mousse|All children in the control group will consume on daily basis vegetable and fruit mousse for six months
224243187|NCT05140070|BEHAVIORAL|Dietary and physical activity counselling|All children in the study will obtain 4 dietary and physical activity advice during the course of the study
224243188|NCT01024439|PROCEDURE|transumbilical single incision laparoscopic appendicectomy|"Patients will undergo transumbilical single incision laparoscopic appendicectomy. A single incision is made on umbilicus within the margin of umbilical skin ring. Peritoneal cavity is entered by open method and the fascia layer can be extended up to 2.5cm in length. A single incision laparoscopic device (Olympus) will be inserted. Conventional laparoscopic instruments will be used. Umbilical fascia will be closed by PDS-1 J-shape needle. Marcain 0.5% should be infiltrated into the fascial layers as well as the skin layers with dosage up to 20ml. The umbilicus is reconstructed by interrupted 3-0 nylon by tacking the skin onto the fascia layers.~Three non-transparent dressings will be placed as if conventional laparoscopic appendicectomy has been done."
224321463|NCT00345631|DEVICE|Vascular Closure Device|Investigational vascular closure device
224321464|NCT05866185|BEHAVIORAL|Therapy|The standard of care procedures for adults with clinically elevated anxiety and/or depression from their mental health provider.
223663241|NCT00845091|BEHAVIORAL|Exercise|moderate-intensity, low-impact, supervised, aerobic exercise
223663242|NCT00845091|BEHAVIORAL|Heart Healthy Education|Educational topics related to heart health (e.g., nutrition, smoking, sleep)
223663243|NCT03702413|PROCEDURE|Endovascular treatment|Acute thrombectomy
223663244|NCT02140593|DRUG|Group STANDARD: Rocuronium 0.6 mg/kg followed by bolus rocuronium according to standard treatment combined with saline infusion (placebo).|
223663245|NCT02140593|DRUG|Group DEEP: Rocuronium 0.6 mg/kg followed by rocuronium infusion with target level PTC 0-1 combined with bolus saline (placebo) mimicking standard treatment.|
223663246|NCT05805618|BIOLOGICAL|Recombinant Norovirus Hexavalent Vaccine|To prevent acute gastroenteritis caused by norovirus of genotypes GI.1, GII.2, GII.3, GII.4, GII.6, and GII.17
223663247|NCT05805618|OTHER|Matching Placebo|matching placebo for Recombinant Norovirus Hexavalent Vaccine / KH002
223663248|NCT01214395|DRUG|5% tea tree oil nasal ointment|daily for 5 days then weekly for 6 months
223663249|NCT04166240|BEHAVIORAL|SAFER TRACKS Intervention|SAFER Change Package delivered using a Virtual Breakthrough Series \[VBTS\] Collaborative supplemented with automated surveillance data on test results.
223663250|NCT02238184|DRUG|Atrovent®|
223663251|NCT02238184|DRUG|Ventilat®|
223663252|NCT00715910|BIOLOGICAL|Nimenrix|One dose, as intramuscular injection
224243189|NCT01024439|PROCEDURE|conventional laparoscopic appendicectomy|"Patients will undergo conventional laparoscopic appendicectomy. A 10-mm subumbilical port will be inserted by open method. Two 5-mm working ports will be inserted under laparoscopic view at patient's left lower quadrant and suprapubic area. Umbilical fascia will be closed by PDS-1 J-shape needle.~Local anaesthetic agent , Marcain 0.5% should be infiltrated into the fascial layers as well as the skin layers with dosage up to 20ml. All skin wound will be approximated with 3-0 nylon interrupted stitches and covered with non-transparent dressings."
224243190|NCT03818230|OTHER|None (observational study)|None (observational study)
224243191|NCT01483508|OTHER|Flavanol- and procyanidins-containing drink|Single oral intake of a cocoa-based dairy drink containing flavanols \[monomer\] and procyanidins \[dimers to decamers\]
224321465|NCT05866185|BEHAVIORAL|Therapy + Adhere.ly|Participants receive therapy as usual enhanced with a simple, HIPAA-compliant, web-based application to help mental health providers implement homework during therapy for adults with elevated anxiety and/or depression. The three major components of the app help providers to (1) Practice interactive, digitized therapeutic exercises with patients in-session; (2) Remind patients to practice exercises for homework, and (3) Review homework during the next session.
223663253|NCT00715910|PROCEDURE|Blood sampling|Blood samples will be collected from subjects 10-25 years of age as per enrollment in primary study and from subjects in the Nimerix Naive Group at Month 60 (Year 5) and 1 month post booster vaccination (Month 61).
223663254|NCT06067620|PROCEDURE|Robotic right hemicolectomy|Robotic right hemicolectomy with intracorporeal anastomosis and extraction through a C-section, using the Da Vinci Xi.
223663255|NCT06067620|PROCEDURE|Laparoscopic right hemicolectomy|Laparoscopic right hemicolectomy with extracorporeal anastomosis and extraction through midline.
223663256|NCT04136782|DRUG|Albumin-bound paclitaxel combined with carboplatin|Albumin-bound paclitaxel combined with carboplatin: Albumin-bound paclitaxel (Abraxis BioScience, LLC., Mclrose Park, IL, USA; certificate number: H20091059) will be intravenously administered at 125 mg/m2 for 30 minutes on days 1 and 8 of each 21-day session of treatment. There will be six 21-day sessions of treatment. At the same time, carboplatin (Qilu Pharmaceutical Co., Ltd., Jinan, Shandong Province, China; National Drug Approval Number: H20020181) will be intravenously administered at AUC = 2 mg•min/mL for 120 minutes on days 1 and 8 of each 21-day session of treatment. Carboplatin must be hydrated for 3 days before use to prevent nephrotoxicity.
223663257|NCT04136782|DRUG|Epirubicin combined with docetaxel|Epirubicin (Pfizer Pharmaceutical (Wuxi) Co., Ltd., China; National Drug Approval Number: H20000496) will be intravenously administered at 90 mg/m2 for 120 minutes on day 1 of each 21-day session of treatment. At the same time, docetaxel (Sanofi-aventis Deutschland GmbH, Frankfurt am Main, Germany; National Drug Approval Number: J20150083) will be intravenously administered at 75 mg/m2 for 120 minutes. Drug administration will be performed once every other 3 weeks for four times.
223769924|NCT02665728|DRUG|BLI400 Laxative|
223663258|NCT03854994|BIOLOGICAL|Anti-CD19 CAR-T Cells Injection|Autologous genetically modified anti-CD19 CAR transduced T cells
223769925|NCT04820816|OTHER|pelvic tilt effect on balance, sensory integration and risk of fall|BIODEX balance system, Limits of stability test, Risk of Fall test, m-CTSIB test
223769926|NCT04141462|GENETIC|blood sample|blood test
224243192|NCT01483508|OTHER|Procyanidins-containing drink|Single oral intake of a ocoa-based dairy drink containing procyanidins \[dimers to decamers\]
224243193|NCT01483508|OTHER|Flavanol-containing drink|Single oral intake of a cocoa-based dairy drink containing flavanols \[monomers\]
224243194|NCT04281992|BIOLOGICAL|AUP1602-C|AUP1602-C is topically applied on chronic wounds and covered by wound dressing.
224321466|NCT01716975|DRUG|EVP-6124|Arms 1, 2
224321467|NCT01716975|DRUG|Placebo|Arm 3
224321468|NCT01301729|DRUG|Docetaxel|100 mg/m2 iv every 3 weeks, 6 cycles (18 weeks)
224321469|NCT01301729|DRUG|Paclitaxel|90 mg/kg iv (+/-10%) every 3 weeks for 6 3-week cycles (18 weeks)
223769927|NCT02028299|PROCEDURE|2D doppler echo with Definity solution|Correlate right heart catheterization results with results from 2D doppler echo with Definity Solution
223769928|NCT01178970|BEHAVIORAL|Resistance training|
223769929|NCT01251484|DRUG|BIBF1120|Tablet 200 mg twice daily until progression
223769930|NCT00567788|DRUG|Latanoprost-Bimatoprost|latanoprost 0.005% once daily followed by bimatoprost 0.03%
223769931|NCT00567788|DRUG|Bimatoporost-Latanoprost|bimatoprost 0.03% once daily followed by latanoprost 0.005%
223769932|NCT02129361|BEHAVIORAL|Adapted Screening and Brief Intervention (Adapted SBI)|
223769933|NCT02129361|BEHAVIORAL|Screening & Education Attention Control|
224243195|NCT00336479|DRUG|Telaprevir|tablet
224243196|NCT00336479|DRUG|Ribavirin|tablet
224243197|NCT00336479|DRUG|Pegylated Interferon Alfa 2a|Solution for injection
224243198|NCT00336479|OTHER|Placebo|matching placebo tablet
224243199|NCT02501057|BEHAVIORAL|Clinician's Guide|An evidence-based, NIAAA-advocated approach to brief intervention for heavy drinking in primary care settings.
223663259|NCT04950478|OTHER|Virtual Reality|5 minutes before the procedure, they were recorded on 'Child and Parent Information Form', State-Trait Anxiety Inventory for Children and FPS-R. Their heart rate and oxygen saturation values were read and recorded. Children wore the virtual reality headset and game was started one minute before the venipuncture. As soon as the injector inserted, the researcher turned on a stopwatch and read and recorded heart rate and oxygen saturation values. When the injector was removed, the researcher stopped the stopwatch and recorded the duration of the procedure.When the injector was removed, the stopwatch was stopped and heart rate and oxygen saturation were recorded. The children took off the virtual reality headset and were asked to evaluate their pain level through FPS-R and their responses were recorded.
223663260|NCT02047721|BEHAVIORAL|Exercise|The intervention gradually increases EE from 150-200 kcal/day 5 days per week to a target of 400 kcal/d 5 days per week and will last a total of 12 weeks.
223663261|NCT02047721|BEHAVIORAL|Diet|A supervised diet program which has been successfully implemented by our group with a goal being to reduce energy intake by \~2000 kcal/week.
223663262|NCT02034409|DEVICE|Pulsed Low Intensity Ultrasound|20 minutes daily for 48 weeks
223663263|NCT02034409|DEVICE|Sham Comparator|20 minutes daily for 48 weeks
223663264|NCT02215018|DRUG|BI 44370 TA solution|
224243200|NCT02501057|BEHAVIORAL|Enhanced Motivational Interviewing|Brief motivational interview plus the use of a smart phone application to monitor alcohol use and health behaviors.
223663265|NCT02215018|DRUG|BI 44370 TA tablet|
224243201|NCT02501057|BEHAVIORAL|Enhanced Clinician's Guide|An evidence-based, NIAAA-advocated approach to brief intervention for heavy drinking in primary care settings plus the use of a smart phone application to monitor alcohol use and health behaviors.
224243202|NCT00547677|RADIATION|stereotactic radiosurgery|
224243203|NCT00377871|DEVICE|biological heart valve prosthesis|Two heart valve designs
224243204|NCT04845165|OTHER|Biopsy|Biopsy of subcutaneous adipose tissue
224243205|NCT00429000|DEVICE|thermospot|
224243206|NCT01962337|DRUG|FPA008|Infusion
224243207|NCT01962337|DRUG|Placebo|Infusion
224243208|NCT01541150|BEHAVIORAL|neuropsychological questionnaires|Due to this study population (inmates), the investigators have decided to classify the protocol as and interventionnal study.
224243209|NCT01692405|DEVICE|NaviGo Bx™|The NaviGoBx™ system is a device and method that enables an accurate reporting of the exact longitudinal location and direction of the biopsy specimen along the needle notch as well as the accurate length of the specimen. Acquiring this information during the biopsy extraction session provides an accurate designation of the location of any later region of interest within the specimen itself to the longitudinal position along the needle mandrel.
224321470|NCT01301729|DRUG|Trastuzumab|4 mg/kg iv loading dose on Day 1, 2 mg/kg iv on Day 8 and weekly thereafter
223663266|NCT02215018|DRUG|Placebo solution|
223663267|NCT02215018|DRUG|Placebo tablet|
223663268|NCT05453149|BEHAVIORAL|Integrated Physical Activity and Behavioural Change Intervention|"Physical Activity (PA) Component: A group-based PA program geared to the level of injury and mobility delivered through web conferencing software. Participants select at three sessions weekly over 10 weeks. Sessions include 45 mins of exercise (i.e boxercise; aerobics; yoga) and 15 mins of social interaction with the group.~Behavioural Change Component: Participants will also receive synchronous 1:1 sessions (approximately 20 mins/week) with a trained clinician on behavioural strategies to initiate and maintain engagement in PA over the 10-week period. Content of the sessions includes: providing information on PA and the self-management of impairments and related symptoms; evaluating barriers to engagement (e.g. fear of injury); and behavioural strategies."
224243210|NCT01692405|PROCEDURE|biopsy sponge pad|the biopsy core is downloaded onto a biopsy sponge pad which is than entered into a biopsy cassette.
224243211|NCT01722877|DEVICE|JetStream Navitus|Study to use Jetstream device for use of in-stent restenosis in femoral popliteal artery.
224243212|NCT02597101|DRUG|Metformin|background drug
224243213|NCT02597101|DRUG|saxagliptin|background drug
224243214|NCT02597101|DRUG|AZD9668|study drug
224243215|NCT02597101|DRUG|placebo|placebo for AZD9668 to be added to background drugs
224243216|NCT01900080|OTHER|Same-Day HIV testing and ART initiation|Same-day HIV testing and ART initiation
224243217|NCT01900080|OTHER|Standard ART Initiation|Standard ART Initiation
224243218|NCT01900080|OTHER|Sub-Study: Same-Day ART, CD4 Count >500|Same-day CD4 count and ART initiation for patients with CD4 count \>500 cells/mm3 (CD4 count within 7 days of HIV test)
224243219|NCT01900080|OTHER|Sub-Study: Standard Pre-ART Care, CD4 Count >500|Standard pre-ART care for patients with CD4 count \>500 cells/mm3
224243220|NCT01092351|DRUG|Nitrofurantoin|100 mg retard capsules to be taken twice daily for seven days
224243221|NCT01395030|DIAGNOSTIC_TEST|Computed Tomography|Undergo FCH PET/CT
224243222|NCT01395030|DRUG|18F-fluoromethylcholine|Undergo FCH PET/CT
224243223|NCT01395030|DIAGNOSTIC_TEST|Positron Emission Tomography|Undergo FCH PET/CT
224243224|NCT02079766|DRUG|florbetapir F 18|370 megabecquerel (MBq) IV single-dose
224243225|NCT02079766|DRUG|Flortaucipir F18|370 megabecquerel (MBq) IV single-dose
224243226|NCT06165562|PROCEDURE|PSV|Pressure support ventilation applied from the start of subcutaneous suture until extubation.
224243227|NCT06165562|PROCEDURE|Intermittent Manual Assistance|Volume-controlled mode during surgery, with intermittent manual assistance from the end of surgery until extubation.
224243228|NCT06165562|PROCEDURE|EEG-Guidance|Extubation criteria based on EEG findings:Zipper opening pattern observed in the spectrogram 95% spectral edge frequency (SEF) ≥ 23 Patient state index (PSI) ≥ 64
224321471|NCT05638061|OTHER|Soy protein|Soy foods or isolated soy protein
224321472|NCT06259188|DEVICE|Respiratory Muscle Training Device|In the both groups the initial pressure load will be set to the resistance level corresponding to the 40% of the MIP and MEP measurement. Participants will be asked to rest following 5 breathing cycles and repeat the training for 10 sets. In each set, there will be a one-minute rest break between repetitions. In breathing exercise device group participants will be able to practice both inspiratory and expiratory respiratory muscle training in a single breathing cycle. In IMT+EMT group, patients will be able to practice different to device. As the progression progresses, the perceived exertion level will be increased by 5-10% every week, to be in the range of 4-6 according to the Modified Borg scale.
223663269|NCT01030666|DRUG|Doxycycline|The patients of the doxycycline group will take 200 mg doxycycline once a day for 7 days after regenerative therapy of an infrabony defects.
223663270|NCT01030666|DRUG|Placebo|The patients of the doxycycline group will take 200 mg placebo once a day for 7 days after regenerative therapy of an infrabony defects.
223663271|NCT01030666|PROCEDURE|modified/simplified papilla preservation flap; scaling|Following an intra-crevicular incision a mucoperiosteal flap was reflected to a height of 5 mm exposing the bony margin of the defect and allowing complete visualization of the infrabony lesion. The flap was designed according to the modified or simplified papilla preservation technique to obtain primary closure of the wound and the membrane respectively. The flap was extended at least one tooth mesially and distally of the defect side. After complete removal of inflammatory granulation tissue, the root surfaces were thoroughly scaled and root planed.
223663272|NCT01030666|BIOLOGICAL|Prefgel/Emdogain|When using EMD the root surfaces facing the infrabony defect were conditioned with EDTA (prefgel; Institut Straumann AG, Basel, Switzerland) for 2 min. first. Then the EDTA was washed out with plenty of saline. After drying the surfaces EMD was applied starting at the bottom of the defect and proceeding coronally.
223663273|NCT01030666|DRUG|0.12% chlorhexidine gluconate solution|Furthermore, all patients were advised to rinse with a 0.12% chlorhexidine gluconate solution (ParoEx; Butler, Kriftel, Germany) for 2 min. twice daily for 5-7 weeksafter surgery.
223663274|NCT01030666|DRUG|Ibuprofen 400 mg (if necessary)|400 mg ibuprofen qd was prescribed for patient's comfort if necessary.
223663275|NCT01030666|DRUG|1% chlorhexidine gluconate gel (if necessary)|If soft tissue dehiscence was noted the patient was advised to use a 1% chlorhexidine gluconate gel (Chlorhexamed 1% Gel; GlaxoSmithKline, Bühl, Germany) twice daily
223663276|NCT02335814|DRUG|FLX925|
223663277|NCT03365843|DEVICE|Montage bone putty|Application of bone putty on cut sternal surfaces prior to application of conventional wires for closure of sternum during cardiac surgery.
223663278|NCT03365843|OTHER|Conventional Sternal Closure|Closure of sternum with standard wire cerclage.
223769934|NCT02075437|BEHAVIORAL|Feeling and Body Investigators with Functional Abdominal Pain|"Investigator's ten session intervention trains children to be Feeling and Body Investigators. Half of the sessions will be done in clinic and half at home via web-camera to facilitate generalization. During the treatment child/caregiver dyads will 1) gather body clues (Learn), 2) investigate (Experience: perform interoceptive mystery missions to explore a body sensation), 3) organize body clues (Contextualize: recall other context that evoke similar sensations), and 4) go on increasingly daring missions (Challenge: decrease avoidance and safety behaviors).~If successful, young children with FAP who complete the FBI early intervention will learn to experience changes in the viscera as fun and fascinating, rather than scary, and will develop new capacities for pain management, adaptive functioning, and emotion regulation."
223769935|NCT02075437|BEHAVIORAL|Treatment Strategies|"1. identify strategies with unique patterns of neural circuit maturation associated with early visceral pain on the gut-brain axis:~2. adapt acceptance-based behavioral strategies used to address psychopathology in older children to younger children;~3. incorporate caregivers as role models and facilitators based on attachment research."
223769936|NCT02047110|DRUG|placebo for risankizumab|Placebo for risankizumab administered by subcutaneous (SC) injection
223769937|NCT02047110|DRUG|risankizumab|Risankizumab administered by subcutaneous (SC) injection
223769938|NCT05291390|DRUG|Pyronaridine Tetraphosphate|Via oral capsules.
223769939|NCT00191893|DRUG|teriparatide|
223769940|NCT05219136|OTHER|Modified Fasting Group|a new fasting protocol is applied to subjects.
223769941|NCT05219136|OTHER|Conventional Fasting Group|a conventional fasting protocol is applied to subjects.
223769942|NCT04439240|DRUG|FGFR Inhibitor AZD4547|Given PO
223769943|NCT03150342|DIAGNOSTIC_TEST|myocardial perfusion imaging|dipyridamole-stressed MPI scan using thallium-201
223769944|NCT05304559|DRUG|S-Ketamine|S-Ketamine0.1mg/kg was injected intravenously during anesthesia induction and S-Ketamine0.1mg/ (kg.h) was injected intravenously during anesthesia maintenance.S-Ketamine was put into the analgesia pump as an adjuvant for continuous analgesia until 2 days after operation.
224243229|NCT06165562|PROCEDURE|Obey Command|Extubation criteria include obeying commands (eye-opening or handgrip).
224243230|NCT06165562|PROCEDURE|Spontaneous Respiration|"Extubation criteria include:~Tidal volume \> 5 ml/kg End-tidal carbon dioxide (ETCO2) \< 45 mmHg Spontaneous respiratory rate (RR) 10 to 20 breaths/min"
224243231|NCT02373098|DRUG|Fingolimod 0.5 mg|66 relapsing remitting MS (RRMS) patients were recruited. Patients who met all inclusion and none of the exclusion criteria were treated by Fingolimod 0.5 mg.
224243232|NCT02265783|DEVICE|Nellcor USB Pulse Oximeter Monitor Interface Cable|Volunteers are subjected to certain simulated, sensor removal conditions known to represent challenges to the sensor-off feature. Such conditions include exposing the sensor to an ambient light source, sensor slipping off the finger with the light emitter and detector facing each other or a sensor slipping off under a blanket.
224243233|NCT02177981|PROCEDURE|Remote ischemic preconditioning|A blood pressure cuff will be placed on the left arm and three cycles of 5 min ischemia followed by 5 min reperfusion will be applied.
223663279|NCT00239135|DRUG|PEP005|
223663280|NCT05128708|PROCEDURE|combined medial and caudal approach right hemicolectomy open and laparoscopic|resection of right colon cancer by this radical approach
223663281|NCT06408753|PROCEDURE|sterotatic body radiotherapy|checkpoint inhibitors with or without sterotatic body radiotherapy
223663282|NCT01699867|DEVICE|Optical coherence tomography|Optical coherence tomography was used to image ex vivo breast tissue specimens.
223663283|NCT06532240|DRUG|Methylene Blue|Methylene Blue 100mg will be diluted in 40ml 5% dextrose solution.The patient will receive Methylene Blue bolus with a dose of 1 mg/kg (Ideal Body Weight) over 30 minutes,followed by 0.25mg/kg/h as a continuous infusion for 6 hours for 5 days or discontinution of norepinephrine or until ICU discharge, whichever occurred first.
223663284|NCT06532240|DRUG|Placebo|An identical volume of 5% dextrose solution from the placebo drug bag will be administered to patients using the same protocol as intervention arm.
223663285|NCT05673798|OTHER|initial chemotherapy response|Initial chemotherapy response is the first imaging examination of SCLC patient after starting chemotherapy
223663286|NCT02938715|OTHER|teledermatology feedback|subject provided feedback to continue or discontinue their cream (based on actinic keratoses grading and lesion counting)
224243234|NCT02177981|PROCEDURE|Control|The cuff will be placed around the arm but not inflated.
223663287|NCT05201664|PROCEDURE|Surgical Extrusion|Relocation of the remaining tooth structure to a more coronal position within the same original socket.
224243235|NCT03379103|DRUG|Sevoflurane|Patients will receive 1 MAC sevoflurane for 15 minutes before the installation of member ischemia by tourniquete
224243236|NCT03379103|DRUG|Propofol|Patients will receive propofol for 15 minutes before the installation of member ischemia by tourniquete
224243237|NCT01658228|DRUG|Donepezil|Donepezil 5mg will be given for 6 weeks and if tolerated, the dose will be increased to 10 mg per day. The dose range of 5 to 10 mg per day is the recommended dose for donepezil in the treatment of mild to moderate Alzheimer's disease.
224243238|NCT01658228|DRUG|Placebo|A placebo capsule will be given to randomized subjects for the starting at week 16 and continuing for the remainder of the study. This group will not receive donepezil as treatment.
223663288|NCT00897819|GENETIC|DNA methylation analysis|
223663289|NCT00897819|GENETIC|loss of heterozygosity analysis|
223663290|NCT00897819|GENETIC|microsatellite instability analysis|
224243239|NCT01658228|DRUG|Citalopram|Citalopram tablet will be given to subjects during an 8 week flexible dosing open treatment. If subjects respond to citalopram treatment they will be randomized to add-on donepezil/placebo.
223663291|NCT00897819|OTHER|laboratory biomarker analysis|
223663292|NCT02551549|DRUG|CD101 IV|antifungal
223663293|NCT02551549|DRUG|Placebo|Normal saline
224243240|NCT01658228|DRUG|Venlafaxine|Venlafaxine tablet will be given to subjects during an 8 week flexible dosing open treatment if they did not respond to citalopram. If subjects respond to venlafaxine treatment they will be randomized to add-on donepezil/placebo.
224243241|NCT01852435|DRUG|R-CEOP-70|
224243242|NCT01852435|DRUG|R-CEOP-90|
224243243|NCT01852435|DRUG|R-CHOP-50|
224243244|NCT01486121|OTHER|Therapy strategy|Sedation \& mechanical ventilation
224243245|NCT03666585|OTHER|mobile application actuated rehabilitation exercise guidance|Mobile applications (also known as mobile apps) are software programs developed for mobile devices such as smartphones and tablets, to teach full function following injury and involves restoring strength, flexibility, endurance, and power.
224243246|NCT03666585|OTHER|routine rehabilitation exercise guidance|the teach to practice full function following injury and involves restoring strength, flexibility, endurance, and power. It is achieved through various exercises and drills
224243247|NCT01884740|DRUG|SIACI of Erbitux and Bevacizumab|Subjects will receive a single intra-arterial dose of Cetuximab (200 mg/m\^2) and Bevacizumab (15 mg/kg) via Superselective Intraarterial Cerebral Infusion (SIACI).
224243248|NCT02348983|BEHAVIORAL|Health Coaching via Telephone|Health coaching arm to assess feasibility of intervention among truck driving population. Coaching will be weekly with emphasis on both diet and physical activity. No medication or treatment devices are administered.
224243249|NCT00002654|DRUG|chemotherapy|
224243250|NCT00002654|DRUG|cisplatin|
224243251|NCT00002654|RADIATION|low-LET cobalt-60 gamma ray therapy|
224243252|NCT00002654|RADIATION|low-LET electron therapy|
224243253|NCT00002654|RADIATION|low-LET photon therapy|
224321473|NCT06259188|DEVICE|Personalized Breathing Exercise Device|Personalized Breathing Exercise Device
223663294|NCT04046614|DRUG|nintedanib-nivolumab combination therapy|"Safety run-in - Dose finding stage The safety-run in phase will be designed as a standard 3+3 design for dose escalation/de-escalation and 3 to 6 patients will be enrolled in each cohort sequentially, depending on occurrence of dose limiting toxicities. The recommended phase 2 dose (RP2D) will be the highest dose in which the frequency of DLTs is less than 33% if no other safety or feasibility considerations prevail.~Expansion phase: Nintedanib RP2D + nivolumab 240 mg Q2W until progression of disease."
223663295|NCT01209013|DEVICE|Medlight PDT Balloon|Medlight PDT Balloon will be used once to apply the laser light treatment
223663296|NCT01209013|PROCEDURE|Endoscopy|Endoscopy will be performed to confirm eligibility, apply photodynamic therapy, assess esophageal condition and effectiveness of the therapy
224243254|NCT04414605|DRUG|Gu Ben Hua Yu Fang decoction (Chinese herbal medicine)|Chinese herbal formula (Gu Ben Hua Yu Fang) decoction will be orally administrated twice daily. One pack of Gu Ben Hua Yu Fang will be taken for each time. Chinese herbal medicine (Gu Ben Hua Yu Fang) will not be used on the day of receiving secukinumab injection.
224243255|NCT04414605|DRUG|Secukinumab Auto-Injector [Cosentyx]|Secukinumab will be administered by subcutaneous injection. The required dose (300 mg) is divided into two doses of 150 mg (contained in two separate syringes), which are injected at the same time. The first five doses (each consisting of 2 injections of 150 mg) are given at weekly intervals, with subsequent treatment given monthly (2 injections of 150 mg).
224243256|NCT04341285|PROCEDURE|ECMO Implantation|Insertion of Extracorporal Membrane Oxygenation (ECMO) within 24 hours of referral to an Intensive Care Unit.
224243257|NCT00791947|DRUG|CHOEP + G-CSF followed by BEAM|"CHOEP:~Cyclophosphamide: 750 mg/m2 i.v. day1 Hydroxydaunorubicin: 50 mg/m2 i.v. day1 Vincristine: 1.4 mg/m2 (max 2 mg) i.v. day 1 Etoposide: 100 mg/m2 i.v. day 1-3 Prednisone: 100 mg daily p.o. day 1-5~BEAM:~Carmustine: 300 mg/m2 i.v. day 1 Etoposide: 100 mg/m2 i.v. x2 daily day 2-5 Cytosine arabinoside: 200 mg/m2 i.v. x2 daily or 400 mg/m2 as continuous 24 hrs i.v. infusion, day 2-5 Melphalan: 140 mg/m2 i.v. day 6"
224321474|NCT00567905|DIETARY_SUPPLEMENT|Green tea extract|main content is epigallocatechin gallate (EGCG, 58%)
223663297|NCT01209013|PROCEDURE|Endoscopy with biopsy|Endoscopy with collection of esophageal tissue will be performed at screening to confirm eligibility and at Week 13 (final visit) to assess effectiveness
223663298|NCT01209013|PROCEDURE|Electrocardiogram|Resting electrocardiogram will be performed at screening (unless one has been performed within 30 days prior to screening) to measure heart function
223663299|NCT01209013|PROCEDURE|Chest x-ray|A chest X-ray will be performed at screening (unless one has been performed within 90 days prior to screening) to provide several pictures of the chest to rule out any lung abnormalities
223663300|NCT01209013|PROCEDURE|Blood collection|Blood samples for laboratory tests will be taken to assess the overall condition
223663301|NCT01209013|PROCEDURE|Tissue sample collection|Esophageal tissue samples will be collected before the porfimer sodium injection and on four separate occasions after the injection (22-26 hour-, 40-50 hour-, 96-120 hour-intervals, and 13 weeks) to measure concentrations of oligomers in a subgroup of 12 patients.
223663302|NCT00006289|DRUG|Placebo|4 tabs b.i.d.
223663303|NCT00006289|DRUG|Neurotropin|4 tabs b.i.d.
223663304|NCT02973438|DEVICE|Intermittent Hypoxia (IH)|Administered over a period of 5 consecutive days involving daily, hour long sessions of alternating 6-minute hypoxic intervals (FIO2 = 0.09-0.12) with 3-minute normoxic intervals (FIO2 = 0.21). During hypoxic intervals, oxygen concentration may be adjusted to maintain participants SpO2 levels between 75-90%.
224243258|NCT05921955|DEVICE|Optiflow high-flow nasal cannula system|Using the Optiflow high-flow nasal cannula system to supply oxygen for maternal.
224243259|NCT02904837|BEHAVIORAL|Experimental training|"Each block of MP consists of 5 mental walking attempts with 10 imagined steps. Participants, seated comfortably, eyes closed, will be asked to imagine themselves walking as of a first-person perspective, without any overt physical movement, in four different conditions: habitual speed, as fast as possible, overcoming obstacles and memorizing a name of a specific medication.~Each block of PP consists of 5 physical walking attempts, with 10 steps. Participants will be asked to walk in 4 different conditions: habitual speed,as fast as possible, overcoming obstacles and memorizing a name of a specific medication."
224243260|NCT02904837|BEHAVIORAL|Control training|"Each block of MP consists of 5 mental walking attempts with 10 imagined steps. Participants, seated comfortably, eyes closed, will be asked to imagine themselves seated appreciating a beautiful landscape as of a first-person perspective, without any overt physical movement, in four different contexts: in a carriage, in a hot air balloon, in a boat and in a zepelin.~Each block of PP consists of 5 physical walking attempts, with 10 steps. Participants will be asked to walk in 4 different conditions: habitual speed,as fast as possible, overcoming obstacles and memorizing a name of a specific medication."
224243261|NCT02461823|DEVICE|Zirconia crown|patients will receive a Zirconia crown, the Zirconia crown will cover the natural crown.
224243262|NCT02461823|DEVICE|Porcelain metal crown|patients will receive a porcelain fused to metal crown, the Porcelain metal crown will cover the natural crown.
224243263|NCT02420444|BIOLOGICAL|BCG SSI|The dose volume administered for BCG was 0.1 mL, and the mode of administration was ID injection to the deltoid area.
224243264|NCT02420444|BIOLOGICAL|Placebo|This is the identical buffer solution in which H4:IC31 was formulated. The dose volume administered for Placebo was 0.5mL, and the mode of administration was an IM injection.
224243265|NCT02420444|BIOLOGICAL|AERAS-404|AERAS-404 vaccine was reconstituted on site by adding 0.2 mL H4 antigen solution to 0.8 mL IC31 adjuvant solution. The dose volume administered for AERAS-404 was 0.5mL, and the mode of administration was an IM injection.
224243266|NCT01740219|BEHAVIORAL|Capacity Enhancement|Churches in the Capacity Enhancement intervention will be invited to work with CRUZA staff over the course of a three month intervention to implement health promotion activities in their church and participate in capacity-building educational workshops. Participants may also receive technical assistance from Health Educators in order to implement their cancer education activities.
224243267|NCT01740219|BEHAVIORAL|Standard Dissemination|Churches in the Standard Dissemination arm will receive program materials with information about cancer prevention/early detection and health resources.
224243268|NCT04785677|BEHAVIORAL|Resiliency in Stressful Experiences (RISE) Program|The Resiliency in Stressful Experiences (RISE) Program is a multi-phased comprehensive trauma based reentry program designed based on the transitional nature of reentry. Participants will receive up to 4 sessions prior to release and up tp 15 session post release from prison. The RISE program is a trauma intervention paired with reentry services, including housing support and employment assistance.
224243269|NCT04759885|DRUG|Phase II: NTC015 low dose|Participants should self administer the preparation within 30 minutes and drink clear liquid according to local practice at the centre to prevent dehydration
224243270|NCT04759885|DRUG|Phase II: NTC015 medium dose|Participants should self administer the preparation within 30 minutes and drink clear liquid according to local practice at the centre to prevent dehydration
224243271|NCT04759885|DRUG|Phase II: NTC015 high dose|Participants should self administer the preparation within 60 minutes and drink clear liquid according to local practice at the centre to prevent dehydration
224243272|NCT04759885|DRUG|Phase III: NTC015 selected dose|Participants should self administer the preparation within 30 minutes and drink clear liquid according to local practice at the centre to prevent dehydration
224243273|NCT04759885|DRUG|Phase III: Polyethylene glycol plus ascorbate solution (2L PEG ASC)|"The instructions for product administration are followed according to the Summary of Product Characteristics.~One treatment consists of two litres of Moviprep® taken according to split-dose regimen.~The first litre of Moviprep® is prepared by dissolving one sachet A and one sachet B together in water to make one litre of solution. The reconstituted solution must be drunk over a period of one to two hours the evening before colonoscopy. About half a litre of clear liquid should be drunk in the next hour to prevent dehydration according to local practice at the centre. This process should be repeated with a second litre of Moviprep® prepared by dissolving one sachet A and one sachet B together in water to make one litre of solution in the early morning of the day of the procedure."
224243274|NCT05247658|OTHER|Therapeutic lens alone|Therapeutic lens will be apposed on patient's dominant eye after bilateral PRK. Therapeutic lens will be maintained without interruption until the first postoperative visit when it will be removed by the surgeon.
224243275|NCT05247658|OTHER|Therapeutic lens + amniotic membrane (Visio-AMTRIX)|Amniotic membrane (Visio-AMTRIX) will be apposed under therapeutic lens on patient's non-dominant eye after bilateral PRK. Amniotic membrane and therapeutic lens will be maintained without interruption until the first postoperative visit when it will be removed by the surgeon.
224243276|NCT05214560|DEVICE|Spinal needle|Insertion of a spinal needle to perform the neuraxial procedure.
224243277|NCT00050856|DRUG|Enfuvirtide T/20/Ro 29,9800, HIV-1 Infusion Inhibitor|
224243278|NCT05764044|DRUG|cisplatin, gemcitabine|Two additional cycles of cisplatin-based adjuvant chemotherapy 50mg/m2 D1 and gemcitabine 1000mg/m2 D1 and D8 at every 21 days.
223663305|NCT02973438|DEVICE|SHAM|Administered over a period of 5 consecutive days involving daily, hour long sessions of alternating 6-minute normoxic intervals (FIO2 = 0.21) with 3-minute normoxic intervals (FIO2 = 0.21).
223663306|NCT02873949|BIOLOGICAL|Crevicular samples (1-10µl)|"In periodontitis patients: from 2 sites affected by periodontitis and 1 healthy site, 2 samples/site, before and after treatment~In non-periodontitis individuals: 2 samples from 1 site"
223663307|NCT02873949|BIOLOGICAL|Saliva samples (1ml)|
223663308|NCT02873949|OTHER|Etiologic treatment|education on oral hygiene, scaling and root planing
223663309|NCT02873949|OTHER|Psychometric tests|Spielberger State-Trait Anxiety Inventory and Cohen Perceived Stress Scale
223663310|NCT06464783|OTHER|Comprehensive Corrective Exercise Program|"Week 1st to 2nd: Corrective exercises +Core strengthening (2 sets 10 reps). Stretchings (30 sec hold, 3 reps).~Week 3rd to 5th: Corrective exercises +Core strengthening (3 sets 15 reps). Stretchings (30 sec hold, 3 reps).~Week 5th to 8th: Corrective exercises +Core strengthening (3 sets 20 reps). Stretchings (30 sec hold, 3 reps)."
223663311|NCT06464783|OTHER|Thoracic Exercise Program|"Week 1st to 2nd: Thoracic extension (2 sets 10 reps). Mobilization (60 sec 2 reps). Stretching (30 sec hold and 3 reps).~Week 3rd to 5th: Thoracic extension (2 sets 15 reps). T W Y I thoracic exercise in prone (2 sets 15 reps). Self-mobilization (60 seconds 2 reps). Stretching (30 sec hold and 3 reps)~Week 5th to 8th. Thoracic extension (3 sets 20 reps). T W Y I thoracic exercise in prone position (3 sets 20 reps). Self-mobilization (60 sec 2 reps). Stretching (30 sec hold and 3 reps)"
223663312|NCT02098668|OTHER|Fertility treatment|Fertility treatment
223663313|NCT04241419|BEHAVIORAL|High Intensity Walking|Participants will then undergo a 12 session intervention, with two sessions scheduled per week for six weeks. These will be 45 minute sessions, including 15 minutes of a warm-up and cool-down period as well as 30 minutes of walking. The intervention will include various types of over ground walking and stair work.
223663314|NCT03211052|DRUG|TAK-700 and LHRH agonist|TAK-700 for 6 months 300mg BD with Leuprorelin Acetate Injections prior to planned prostatectomy
223663315|NCT03211052|PROCEDURE|prostatectomy|SURGICAL REMOVAL OF THE PROSTATE
223663316|NCT06522594|DRUG|Esmolol|A vey cardioselective, short-acting betablocker, with an ultra-short half life time.
223663317|NCT03807375|OTHER|CPAP preoxygenation|During preoxygenation, the ventilator device will be placed in spontaneous mode and set as CPAP: 5 cmH2O.
223663318|NCT02079272|OTHER|Helical tomotherapy for breast cancer|"1. At baseline, before helical tomotherapy is performed, for each included woman will have:~   * measures of biomarkers of cardiac injury based on blood samples (including CRP, NT-Pro BNP, …, microparticles and miRNA)~  * cardiologic examination including echocardiography for measurement of strain and strain rate~  * a CT coronary angiogram for measurement of coronary plaque indexes~2. Helical tomotherapy will be performed for all women included in the cohort.~3. At the end of tomotherapy, follow-up will include:~   * measures of biomarkers: at the end of radiotherapy, 6 months and 24 months after radiotherapy~  * cardiologic examinations including a echocardiography 6 and 24 months after radiotherapy~  * A CT coronary angiogram 24 months after radiotherapy"
223663319|NCT03718780|OTHER|simultaneous determination of PaCO2 and PtCO2|"Patients in intensive care, equipped, for their routine clinical management, with an arterial catheter blood line, will have a simultaneous determination of PaCO2 and PtCO2:~* 1\) at rest; 2 arterial CO2/PtCO2 determinations will be carried out, 10 minutes apart~* 2\) During the muscular exercise part of their routine rehabilitation program (whatever it might be, limbs active mobilization, walking, etc...) : several arterial /PtCO2 samples will be collected during the first minutes of their muscular routine: 30 sec, 1 minute, 1 ½ minute, 2, 2 ½ , 3, 4, 5 minutes, 10 minutes (end of exercise). This will generate several couples of blood/transcutaneous CO2 determinations"
223663320|NCT03718780|OTHER|Hyperventilation test|Repeated pairs of PtCO2 and PaCO2 (through arterialized capillary sampling), will be measured at the following timing: rest (0), then 30 sec post beginning of hyperventilation (breathing with accelerated frequency e.g. 30/min), 1 minute, 1 ½ minute 2, 2 ½ , 3, , 4, 5 minutes; recovery of this hyperventilation will be followed, for 5 minutes, with the PtCO2, during 3 minutes
223769945|NCT05304559|DEVICE|Continuous iliac fascia space block|After admission, the iliac fascia space block and catheterization were performed under the guidance of ultrasound, and the analgesia was continued until two days after operation.
223769946|NCT05304559|DRUG|Normal saline|Normal saline0.1ml/kg was injected intravenously during anesthesia induction and Normal saline0.1ml/ (kg.h) was injected intravenously during anesthesia maintenance.Normal saline was put into the analgesia pump as an adjuvant for continuous analgesia until 2 days after operation.
223769947|NCT06021236|BEHAVIORAL|mindfulness-based intervention|Diet meditation breath awareness body scan mindfulness yoga Compassionate blessing
224243279|NCT05764044|OTHER|Follow-up|Patients will be followed with plasma cfDNA-HPV, computed tomography (CT) scan of the thorax and magnetic resonance (MRI) of abdomen and pelvis and clinical and gynecological examination at every four months.
224243280|NCT03117569|DRUG|glecaprevir (300mg)/pibrentasvir (120mg)|glecaprevir (300mg)/pibrentasvir (120mg) for 8 weeks
224243281|NCT05602064|DRUG|Ibuprofen|Ibuprofen is a non-steroidal anti-inflammatory drug which acts by reducing the production of cyclo-oxygenases (COX-1 and COX-2)- derived prostanoids in the blood
224243282|NCT05602064|DRUG|Paracetamol|Paracetamol is an analgesic that acts peripherally; although its primary site of action is still debatable, it is thought to inhibit prostaglandins in the hypothalamus
224243283|NCT05602064|OTHER|Placebo|A placebo solution will be freshly prepared by an assistant in a manner to match the color and odor of the analgesics
224243284|NCT03639311|DRUG|CAB LA|Administered CAB LA (600 mg) Q2M, as intramuscular injection.
223769948|NCT06021236|OTHER|CIED procedure routine care|CIED procedure home care guidance
224243285|NCT03639311|DRUG|RPV LA|Administered RPV LA (900 mg), Q2M, as intramuscular injection.
224243286|NCT03639311|DRUG|RPV|Oral dose of RPV 25 mg, administered once daily from Day 1 up to Month 12
224243287|NCT03639311|DRUG|DTG|Oral dose of DTG 50 mg administered once daily from Day 1 up to Month 12.
224243288|NCT01101802|DRUG|Mycophenolate mofetil|Arm 1 patients were given 1 gm bd mycophenolate mofetil for 8 weeks, The mycophenolate was dispensed as 500mg tablets.
224243289|NCT01101802|DRUG|sugar pill|Arm 2 patients were given 2 sugar pills bd for 8 weeks
224243290|NCT01190163|DRUG|Dinoprostone|
224243291|NCT01190163|DRUG|Oxytocin|
224243292|NCT00032903|DRUG|Gimatecan® (ST 1481)|
224243293|NCT06080321|OTHER|WhatsApp reminders|"Patients will receive active oral hygiene reminders in the form of WhatsApp messages one weekday each week. The standardized text message will be: This is a message from the Orthodontic Clinic at Faculty of Dentistry, Alexandria reminding you that it is extremely important to brush your teeth for 2 minutes after every meal or at least 3 times daily. Cleaning your teeth will help to keep them healthy and beautiful."
224243294|NCT06080321|OTHER|Instagram reminders|"Patients will receive active oral hygiene reminders in the form of Instagram messages one weekday each week. The standardized text message will be: This is a message from the Orthodontic Clinic at Faculty of Dentistry, Alexandria reminding you that it is extremely important to brush your teeth for 2 minutes after every meal or at least 3 times daily. Cleaning your teeth will help to keep them healthy and beautiful."
223663321|NCT03718780|OTHER|Exercise test|an exercise test, according to the routine protocol used in the clinic: initial phase of 3 minutes gentle pedaling (10 to 50 watts, according to subject capabilities), then stepwise increase in the workload, by increments of 20-40 watts every minute, until maximum tolerated workload (VO2max). Repeated pairs of PtCO2 and PaCO2 (through arterialized capillary sampling), will be measured at the following timing: rest -10 minutes, 0, then 30 sec post beginning of exercise, 1 minute, 1 ½ minute 2, 2 ½, 3 minutes, then 3 ½ minutes, then at mid-point of every step increase in workload, until maximum tolerated workload. Recovery will be followed with the PtCO2, for 5 minutes
223663322|NCT04721587|DEVICE|Virtual Reality|"The patients of the VR Group will be subjected to the same hysteroscopy technique as the Standard of Care Group, but additionally a VR device will be applied where a distraction VR environment (Underwater Game) will be reproduced during the exploration"
223663323|NCT03817697|OTHER|Questionnaire|The socio-demographic characteristics of patients, their current and past drug use as well as their knowledge of hepatitis B and vaccination, will be collected via a questionnaire, conducted by the service's addictologists at the beginning of the consultation.
223663324|NCT03013309|BEHAVIORAL|Family Check-Up 4 Health|A parent-training intervention to improve child health and prevent/manage obesity
223663325|NCT03013309|OTHER|Treatment as usual|Treatment as usual
224243295|NCT06080321|OTHER|Phone calls|"Patients will receive active oral hygiene reminders in the form of phone calls one weekday each week. The structured phone call will be: This is a message from the Orthodontic Clinic at Faculty of Dentistry, Alexandria reminding you that it is extremely important to brush your teeth for 2 minutes after every meal or at least 3 times daily. Cleaning your teeth will help to keep them healthy and beautiful."
224243296|NCT06080321|OTHER|Application alerts|"Patients will download an app on their mobile phones which has cleaning tips, demonstrations and alerts. The structured message will be: This is a message from the Orthodontic Clinic at Faculty of Dentistry, Alexandria reminding you that it is extremely important to brush your teeth for 2 minutes after every meal or at least 3 times daily. Cleaning your teeth will help to keep them healthy and beautiful."
223663326|NCT00002272|DRUG|Foscarnet sodium|
223663327|NCT00851162|BIOLOGICAL|Trinity multipotent stem cells|Enough to fill voids which vary in size
224243297|NCT05297032|DIETARY_SUPPLEMENT|Quercetin Phytosome|All participants will ingest 1 capsule of Quercetin Phytosome (250 mg) three times daily with meals for 90 days.
223663328|NCT00851162|BIOLOGICAL|Demineralized bone matrix(DBM)|Enough DBM to fill a bone void defect
223663329|NCT06646614|BEHAVIORAL|Group Advance Care Planning Education|Those assigned to the group ACP arm will receive usual care and the intervention which consists of 2 virtual or in-person sessions for a total of 2 hours by a trained community health worker/health educator. Sessions will introduce advanced care planning, help veterans discuss their goals of care with their care teams and learn how to discuss with their families and oncologist, and filing an advanced directive. Participants will be surveyed and interviewed at baseline and again at 8 months post-enrollment.
223663330|NCT07066709|COMBINATION_PRODUCT|FDG PET/MRI|Participants will undergo an FDG PET/MRI
223663331|NCT07145398|BEHAVIORAL|Mandala Coloring|Children hospitalized in the burn unit will participate in structured mandala coloring sessions. Each session will last approximately 30 minutes and will be conducted once daily for 7 consecutive days. Children will be provided with printed mandala patterns and coloring materials, and the sessions will be supervised by the research team. The purpose of the intervention is to reduce pain and stress levels and improve sleep quality in burn patients.
223663332|NCT07145398|OTHER|Control - Standard Care|Children in the control group will receive routine burn unit care without any additional interventions. No mandala coloring sessions will be provided.
223663333|NCT07146035|DEVICE|CP369 Feasibility of a newly developed ostomy prototype (only one intervention)|The study is an open-label, single-arm, comparative study, investigating the feasibility of the prototype in subjects with ileostomy. The study is comparing the prototype exposed only to sweat (abdominal side) with the prototype exposed to sweat and output (peristomal side). Meaning, subjects are their own control.
223663334|NCT06944912|PROCEDURE|Transversalis fascia plane block and transversus abdominis plane block|20 ml local anesthetics for Transversus Abdominis Plane block and 10 ml local anesthetics for Trasnversalis fascia plane block
223663335|NCT06944912|PROCEDURE|Intrathecal Morphine|100 mcg morphine with local anesthetics injected intrathecally
223663336|NCT06947200|OTHER|Fibromyalgia|no intervention
223663337|NCT06947343|PROCEDURE|ACTION OBSERVATION THERAPY|functional AOT with visual feedback and physical training after watching a video 30mins session, 3times/week total 8weeks 3mins for observation phase, 2min for action execution Stage 1, sitting position (static and dynamic balance) exercises for trunk flexion, upper and lower trunk rotation multidirectional reaching to pick up any object from different directions, forward, lateral, and diagonal reaching Stage 2, sit to stand and stand to sit from sitting to standing, trunk flexed, hips and knees 90 degree flexed, feet behind knee, 15cm apart, then standing, trunk extension hips knees extend feet apart and vice vers 4phases of sit to stand, seat off, standing, seat on, sitting in sitting position dorsiflexion training, flexion extension training knee joint the right hand touches the left foot and viceversa pick up an object from floor stage3, standing balance weight shifting, front, back, sideways, left and right head and trunk movements in different directions while standing
223769949|NCT02630771|PROCEDURE|Pressure pain threshold|Pressure algometry over thenar eminence, bilateral masseter muscles measured at baseline and during conditioned pain modulation
224243298|NCT02155205|DRUG|Telotristat etiprate|1500 mg telotristat etiprate (six 250 mg tablets)
224243299|NCT02155205|DRUG|Placebo|Matching placebo
224243300|NCT02155205|DRUG|Moxifloxacin|400 mg moxifloxacin (one 400 mg tablet)
223769950|NCT04006158|DEVICE|LED bed|Low risk FDA cleared full body LED bed
223769951|NCT05848388|OTHER|Molar incisor malformation presence|the presence of radiographic features of molar incisor malformation
223663338|NCT06947343|PROCEDURE|MOTOR RELEARNING PROGRAM|Motor relearning program, interventional group B, based on task-oriented training 30mins, 3times/week total 8weeks stage 1, balanced sitting exercises for trunk flexion and rotation, feet and knees 15cm apart multidirectional reaching while seated forward, lateral and diagonal reaching to pick up any thing from different directions butt walking scooting on bed stage 2, standing up and sitting down transition from a seated position on a firm flat surface with no armrests to standing with an upright posture, upper body vertical and feet placed backward followed by sitting down by flexing hips,knees and ankle prerequisited of sit to stand, 4phases in sitting dorsiflexion training, flexion extension training of knee joint right hand touch to left foot and viceversa picking up objects from floor stage3, balanced standing weight shifting head and trunk movemnts while standing with feetapart standing unsupported with eyes closed multidirectional reaching
223663339|NCT06946264|DRUG|Albuterol Sulfate, 2.5 Mg/3 mL (0.083%) Inhalation Solution|Children with bronchiolitis will be randomized to an intervention arm to be administered as a nebulization (albuterol sulfate 2.5mg/ 3mL inhalation solution). The intervention drug will be placed in a sealed manila envelope, randomized in advance by a Nemours Investigational Drug Pharmacist, and stored in the ED pyxis.
223663340|NCT06946264|DRUG|Sodium Chloride 0.9% Inhl 3Ml|Children with bronchiolitis will be randomized to an intervention arm to be administered as a nebulization (sodium chloride 0.9% 3mL inhalation solution). The intervention drug will be placed in a sealed manila envelope, randomized in advance by a Nemours Investigational Drug Pharmacist, and stored in the ED pyxis.
223663341|NCT06947421|BEHAVIORAL|McKenzie Exercise|"Exercises will be performed in seated or supine positions, 15 repetitions per session, twice daily, for a total duration of 6 weeks. The program will begin with physiotherapist-supervised sessions and continue at home with guidance via a digital training manual. Weekly follow-up and progress will be ensured through individual exercise diaries. Participants missing two consecutive days of exercise will be excluded from the study. Includes:~* Cervical retraction in sitting and supine positions~* Cervical rotation to both sides~* Lateral flexion of the neck~* Combined chin rotation toward the shoulder"
223663342|NCT06947421|BEHAVIORAL|Standard Neck Exercise|"The protocol includes chin tucks, chin drop stretches, scapular retraction with resistance, and both unilateral and bilateral pectoral stretching. Exercises will be performed twice daily, 15 repetitions per session, over a period of 6 weeks. Exercise progression will be adapted biweekly based on participant tolerance. Includes:~* Chin tucks in supine with progressive hold durations~* Chin drop stretch in sitting with optional manual assistance~* Scapular retraction using theraband or weights~* Pectoral muscle stretching using doorway and seated techniques"
223663343|NCT06947603|PROCEDURE|inula viscosa extract|the topical gel of inula viscosa was applied to one side after the extraction of the impacted molar in each patient, while the other side was left without the application of any pharmaceutical substance after extraction
223663344|NCT06947603|PROCEDURE|no inula viscosa extract|the other side of patient was left without the application of inula viscosa extract after lower third molar extraction.
224243301|NCT02615847|DRUG|Memantinhydrochlorid|"Memantin Mepha® Lactabs (memantinehydrochlorid) will be provided as 5 mg, 10 mg, 15 mg and 20 mg tablets, packed in blister.~The study drug will be taken once a day per os, during 12 month."
224243302|NCT05449249|PROCEDURE|Long-term fasting|The participants will undergo a fasting program that includes the daily intake of 250 kcal under medical supervision.
223663347|NCT06946108|DIAGNOSTIC_TEST|Detection of Pancreatic Exocrine Function in Patients with Chronic Pancreatitis (CP)|For CP patients who are hospitalized, they are recruited to voluntarily preserve their feces for the detection of fecal elastase-1 (FE-1) so as to evaluate the pancreatic exocrine function.
223663348|NCT06946121|DRUG|Lignocaine|50 women undergoing diagnostic outpatient office hysteroscopy proceeded by infusions of intrauterine lidocaine 2% and normal saline at room temperature.
223663349|NCT06946121|DRUG|Saline|50 women undergoing diagnostic outpatient office hysteroscopy using warmed normal saline distention medium.
223663350|NCT06946953|BIOLOGICAL|P63+ lung progenitors|"1. Patient Screening and Cell Collection:~   Eligible patients will undergo sample collection at the study center or authorized tertiary hospitals. The operator will collect samples via bronchial brushing from three healthy segments of the patient's 3-5 level bronchi. The samples will be transported to a cooperative production facility for isolation and preparation. The cell preparation cycle is approximately 4-8 weeks. Patients will bear the costs of this process.~2. Transplantation Therapy:~   Transplantation therapy will be conducted at Ruijin Hainan Hospital. The cell preparation will be administered via fiberoptic bronchoscopy to each lung segment, with one dose per patient. After infusion, patients are advised to remain hospitalized for 24-48 hours for observation.~3. Post-Treatment Follow-Up:~Patients are advised to return for examination and evaluation at 4 and 24 weeks post-treatment."
224243303|NCT00493142|OTHER|Exercise|
224243304|NCT00493142|OTHER|Usual care|
224243305|NCT00555230|DRUG|Rosuvastatin|5mg daily for 4 weeks then step up to 10mg or matching placebo for 52 weeks
224243306|NCT00555230|DRUG|Placebo|5mg daily for 4 weeks then step up to 10mg or matching placebo for 52 weeks
224243307|NCT02717390|BEHAVIORAL|Bright By Three (BB3)|The purpose of the BB3 intervention (annual home visit, written materials, and BB3 mobile application 'app') is to increase parental talking, reading, playing, and praise (TRPP) behaviors and improves children's social-emotional and language development at ages 2, 3, and 4 years.
224243308|NCT02717390|BEHAVIORAL|Texts for Child Safety (TCS)|The purpose of the injury prevention arm is to reduce the prevalence of safety hazards in the home and car environments, decrease the number of self-reported and medically-attended injuries among children, and increase caregiver's self-reported safety behaviors and knowledge of child safety. The Investigators will compare the results of our tailored child safety intervention (Texts for Child Safety \[TCS\]) among participants in the injury prevention arm with those randomized to the BB3 arm.
224321475|NCT04519073|BIOLOGICAL|V-306 candidate vaccine|"Each V-306 monomer consists of the following elements:~1. A Lipopeptide Building Block that contains an optimized, artificially designed coiled-coil domain, which self-assembles into highly stable trimers.~2. A 'universal' T-helper epitope fused at the C-terminus of the coiled-coil domain.~3. A lipid component di-palmitoyl-S-glyceryl cysteine (Pam2C), fused at the N-terminus.~4. A mimetic of the Palivizumab epitope, referred to RSV F-protein site II antigen mimetic (FsIIm), which is coupled near the C-terminus of the Lipopeptide Building Block via a short maleimide-PEG-oxime linker."
223663351|NCT06947889|OTHER|RAGT|Biofeedback based system development to enhance Robotic Assisted Gait Training in cerebral palsy pediatric patients
223663352|NCT06947941|DRUG|KarXT|Specified dose on specified days
224243309|NCT01886326|OTHER|Consumption of 42 grams of peanuts daily|Consumption of the given 42 grams of peanuts daily without instructions for use (i.e. with/without meals, etc.)
224243310|NCT01891266|PROCEDURE|Non-tourniquet assisted TKA|The intervention group will undergo non-tourniquet assisted total knee arthroplasty, which means that blood flow to the lower limb is maintained throughout surgery.
224243311|NCT01891266|PROCEDURE|Tourniquet assisted TKA|The procedure involves the use of a tourniquet around the thigh. During surgery the tourniquet will be inflated above the systolic blood pressure to ensure a complete bloodless surgical field.
224243312|NCT03018249|DRUG|Entinostat|Given PO
224243313|NCT03018249|PROCEDURE|Hysterectomy|Undergo hysterectomy
224243314|NCT03018249|OTHER|Laboratory Biomarker Analysis|Correlative studies
224243315|NCT03018249|DRUG|Medroxyprogesterone Acetate|Given IM
224243316|NCT00699491|BIOLOGICAL|Cixutumumab|Given IV
223663353|NCT06947941|DRUG|KarX-EC|Specified dose on specified days
223663354|NCT06947941|DRUG|KarXT + KarX-EC Arm Matching Placebo|Specified dose on specified days
223663355|NCT06945991|OTHER|observation group|the observation group was additionally managed with an integrated nursing and medical approach.
223663356|NCT06945991|OTHER|control group|The control group received routine nursing care
224243317|NCT00699491|OTHER|Laboratory Biomarker Analysis|Correlative studies
223663357|NCT06946498|PROCEDURE|Local Anesthesia Thoracoscopy|"The patient is placed in a lateral decubitus, with the affected hemithorax upwards. Ensuring a venous line and full monitoring of vital functions. Mild sedation is given and a dose of Ceftriaxone is given 30 minutes before. Local anesthesia is injected in layers, starting from the skin and working up to the intercostal muscles, intercostal nerve, and periosteum of the rib.~Development of pneumothorax is done using a 16-gauge Boutin needle. 15 spontaneous breaths are sufficient to create a pneumothorax, and entry of rigid thoracoscope into the hemithorax through a 11-13 mm Trocar. Multiple biopsies from the parietal pleura are taken and pleurodesis is made according to operator judgment. A chest drain 20-22 G is placed and sutured.~A chest X-ray is performed 2-8 hours later after the patient is transferred to the ward. Chest drain is removed after 24h if fluid production is \<250ml and lung re-expansion."
223663358|NCT06946498|DEVICE|Pleuroscopy with Rigid Thoracoscope and Forceps biopsies|A video thoracoscope with an external light source, outer diameter 10 mm (Karl Storz), is inserted into the pleural cavity through a uniportal incision (1 - 1.5 cm) and complete inspection of the pleural cavity is performed. Parietal pleural biopsies are taken with a rigid 40 mm forceps (Karl Storz).
223663359|NCT07145320|OTHER|Oral Cryotherapy Group (Group 1)|Participants were educated about oral cryotherapy before their first chemotherapy cycle. Individually portioned ice bags (15 mL per cube) were prepared and provided free of charge for home use (6 bags per cycle). Patients were instructed to apply the ice intra-orally for 30 minutes at a time, 6-10 times daily, beginning at the start of Adriamycin infusion. A Cryotherapy Application Log Form was used to record date, start, and end times for each session.
223663360|NCT07145320|OTHER|Chewing Gum Group (Group 2)|Patients received standardized, tasteless, single-use chewing gum (6 boxes per cycle) and were instructed to chew a piece for 20-30 minutes before and during chemotherapy infusion. A new piece was provided midway through the session. Usage was recorded in a Chewing Gum Application Log Form, capturing date and timing details.
223663361|NCT07146269|DEVICE|tDCS|Transcranial Direct Current Stimulation delivered at an intensity of 2 mA over electrodes at F3/F4 (bifrontal, over DLPFC), for 30 minutes a day, Monday to Friday, for a total 20 sessions.
223663362|NCT07146269|DEVICE|VR-based relaxation therapy|Nature exposure via a Virtual Reality (VR) headset, for 30 minutes daily concurrently to tDCS, Monday to Friday, for a total of 20 sessions.
223663363|NCT06947044|PROCEDURE|RBC transfusion strategy|RBC transfusion strategy to maintain a hemoglobin level of at least 110 g/L.
223663364|NCT07144943|RADIATION|For subjects on SSRIs: bone densitometry|"For subjects on SSRIs:~Bone densitometry is one of the additional examinations considered. This assessment is part of the routine monitoring for subjects on androgens."
223663365|NCT07146828|DEVICE|Binocular Wavefront Optometry Machine (BWFOM, Ai-Zhitong Medical Technology Co., Ltd., Zhejiang, China)|The 0.05 D refraction group had their infusion rates precisely calibrated using 0.05 D refraction by the Binocular Wavefront Optometry Machine
223769952|NCT01350206|PROCEDURE|hepatic resection|HR was carried out under general anesthesia using a right subcostal incision with a midline extension. Intraoperative ultrasound was routinely performed. Pringle's maneuver was routinely used with a clamp/unclamp time of 10 minutes/5 minutes.Thrombectomy was performed according to the location and extent of PVTT. The en bloc technique was used for patients if the portal vein branch could be ligated with a sufficient safety margin between its root and the tip of the thrombus
223769953|NCT01350206|PROCEDURE|TACE|TACE with chemotherapy drugs (EADM 50mg, lobaplatin 50mg, and MMC 6mg )mixed with iodized oil lipidol
224243318|NCT00699491|OTHER|Pharmacological Study|Correlative studies
224243319|NCT00699491|DRUG|Temsirolimus|Given IV
224243320|NCT00338481|DRUG|Morphine p.o.|"Morphine p.o. in red morphine drops calculated as 1/12 of the 24 hours opioid consumption converted to morphine p.o., max. 24 mg morphine p.o.and isotonic sodium chloride s.c."
224243321|NCT00338481|DRUG|Morphine s.c.|"False red morphine drops without morphine p.o. and 60% of 1/12 of the 24 hours opioid consumption converted to morphine p.o. but given s.c., max. 14,4 mg"
224243322|NCT03943433|PROCEDURE|FiO2_1.0|Alveolar recruitment is performed with 100% oxygen concentration after general anesthesia induction, after position change to Trendelenburg, after position change to supine, and at the end of operation.
224243323|NCT03943433|PROCEDURE|FiO2_0.4|Alveolar recruitment is performed with 40% oxygen concentration after general anesthesia induction, after position change to Trendelenburg, after position change to supine, and at the end of operation.
224243324|NCT06291792|OTHER|telerehabilitation otago exercise program|telerehabilitation otago exercise program
224243325|NCT06291792|OTHER|face to face otago exercise program|face to face otago exercise program
224243326|NCT04758260|DIETARY_SUPPLEMENT|Antioxidant|Oral antioxidant oral intake in the 3 months prior to inclusion in the study
224243327|NCT04607863|DIAGNOSTIC_TEST|Case control|Is a case-control research
223663366|NCT07145359|OTHER|Virtual Reality Intervention|This intervention is distinguished by its integration of a structured, nurse-led virtual reality (VR) protocol specifically designed for symptom management during hematopoietic stem cell transplantation (HSCT). Unlike general VR distraction methods used in oncology, this intervention employs video content created by the research team in accordance with Attention Restoration Theory (ART), offering five preselected nature-themed options tailored to patient preferences. Prior to the procedure, eligible patients are introduced to the intervention one day in advance and given the opportunity to trial the VR equipment, ask questions, and select their preferred video. During the infusion, VR is initiated exactly one minute before the stem cell procedure and ends at the 15th minute, as recommended by the literature. Symptom assessments are conducted immediately before and after the intervention using validated tools, including the Distress Thermometer, State Anxiety Inventory, and the Edmonto
223663367|NCT06947369|OTHER|Experimental Group|Within the scope of the research, the pregnant women in the experimental group will be given a training program based on Joyce Travelbee's human-to-human relations theory, one session per week for 30-45 minutes, for a total of five sessions, while the control group will continue their routine follow-up.
224243328|NCT04334798|OTHER|Active exercises of the pelvic floor muscles & Electrostimulation & Biofeedback|See information included in arm/group descriptions.
223663368|NCT06946277|DRUG|Preemptive Analgesia Of Dexmedetomidine|Preemptive Analgesia Of Dexmedetomidine 1.5 μg · kg-1·h-1 before operation
223663369|NCT06954064|OTHER|No intervention will be applied.|No intervention will be implemented in this study, as the questionnaires will serve an exploratory purpose.
223663370|NCT06955130|DRUG|Glycerol|Subjects will receive an infusion of glycerol and glucagon.
223663371|NCT06955130|DRUG|Lactate|Subjects will receive an infusion of lactate and glucagon.
224243329|NCT04334798|OTHER|Active exercises of the pelvic floor muscles & Biofeedback|See information included in arm/group descriptions.
224243330|NCT04334798|OTHER|Active exercises of the pelvic floor muscles & Transabdominal US Biofeedback|See information included in arm/group descriptions.
224243331|NCT04334798|OTHER|Active exercises of the pelvic floor muscles & Electrostimulation &Transabdominal US Biofeedback|See information included in arm/group descriptions.
224243332|NCT04616066|OTHER|Dates|The effect of date phytoestrogens on HbA1C and fasting blood glucose in patients with type 2 diabetes
224243333|NCT04616066|OTHER|Raisins|The effect of raisins phytoestrogens on HbA1C and fasting blood glucose in patients with type 2 diabetes
224243334|NCT02803398|OTHER|Compression bandages application and interface pressure measurements|Bandages, which are applied in a spiral pattern on the leg, are composed of Biflex 16 (Thuasne) and/or Rosidal K (Lohmann \& Rauscher).
224243335|NCT06237023|OTHER|epidemyolojical|The aim of the study is to compare emergency orthopedic trauma admissions between the pre-pandemic and pandemic periods, and to identify changes in the epidemiology of orthopedic trauma.
224243336|NCT00006370|RADIATION|yttrium Y 90-edotreotide|
223663372|NCT06955130|DRUG|Glucose|Subjects will receive an infusion of glucose and glucagon.
223663373|NCT06947395|DIAGNOSTIC_TEST|PancreaSure|Serum-based biomarker test comprised of ELISA-based analyte readings of 4 protein biomarkers (ICAM-1, TIMP1, THSB1, and CTSD) and CA19-9 summed by a mathematical algorithm with associated coefficients where a pre-defined cutoff establishes a positive or negative detection of PDAC.
223663374|NCT07146841|PROCEDURE|Round window insertion|Insertion of the electrode array via the round window.
223663375|NCT07146841|PROCEDURE|Cochleostomy insertion|Insertion of the electrode array via cochleostomy.
223663376|NCT07146841|DEVICE|Lateral wall array|Lateral wall electrode array from Advanced Bionics.
224243337|NCT04675580|BEHAVIORAL|Toy Talk|Language modeling strategy encouraging caregivers to (1) talk about the toys the child is playing with, including the states, actions, and properties of the toys and (2) give the object its name using a lexical noun phrase.
224243338|NCT05939180|DRUG|Venetoclax Oral Tablet|VA regimen: azacytidine, 75mg/m2, subcutaneously, on days 1-7; venetoclax, orally, once a day, 100mg, d1; 200mg, d2; 400mg, days 3-28.
224243339|NCT05939180|DRUG|Daunorubicin|DA regimen: daunorubicin (60mg/m2) on days 1-3, intraveneously injection, and cytarabine (100mg/m2) on days 1-7, intraveneously injection, for 1 cycle.
223663377|NCT07146841|DEVICE|Periomodiolar electrode array|Perimodiolar MidScala electrode array from Advanced Bionics.
224243340|NCT02059746|OTHER|Questionnaires sent by mail|The questionnaires necessary for the study are mailed to patients at 3 and 12 months post-partum.
224243341|NCT03858257|DEVICE|High flow nasal oxygen|The Optiflow device (Fisher and Paykel Healthcare, Auckland, New Zealand) will be used.
224243342|NCT03858257|DEVICE|Standard oxygenation|Supplemental oxygen through a facemask.
224243343|NCT03811080|DRUG|DWP14012 A mg|The participants will receive treatment of DWP14012 A mg, tablet, orally, once daily and DWP14012 B mg placebo-matching tablet, orally, once daily for up to 4 weeks.
224243344|NCT03811080|DRUG|DWP14012 B mg|The participants will receive treatment of DWP14012 B mg, tablet, orally, once daily and DWP14012 A mg placebo-matching tablet, orally, once daily for up to 4 weeks.
224243345|NCT03811080|DRUG|Placebo|The participants will receive treatment of DWP14012 A mg placebo-matching tablet, orally, once daily and DWP14012 B mg placebo-matching tablet, orally, once daily for up to 4 weeks.
224243346|NCT00301769|DRUG|SJG-136|Given IV
224243347|NCT01023074|BEHAVIORAL|Auditory training|the study was originally set up so that half of the MS subjects would received auditory training. This intervention has since been discontinued.
224243348|NCT01023074|OTHER|MS: Control Activity|MS group not receiving auditory training, doing control activity
223663378|NCT07145047|BIOLOGICAL|oncolytic virus|Intratumoral injection of oncolytic virus.
223663379|NCT07145697|DRUG|Dexmedetomidine|Escalating concentrations until loss of responsiveness
223663380|NCT07145775|DRUG|sufentanil-ropivacaine combination|Epidural labor analgesia will be conducted using the sufentanil-ropivacaine combination (0.4 microgram/ml sufentanil + 0.072% ropivacaine).
223769954|NCT05735002|DIAGNOSTIC_TEST|13C-butyrate breath test|breath test
224243349|NCT03125200|DRUG|ADCT-502|Intravenous Infusion
224243350|NCT00119379|DRUG|NucleomaxX|NucleomaxX 36 grams TID every other day
224243351|NCT00119379|DRUG|Tenofovir Disoproxil Fumarate|Switch of thymidine nucleoside reverse transcriptase inhibitors to Tenofovir Disoproxil Fumarate
224243352|NCT00028691|DRUG|chlorambucil|
223663381|NCT07145775|DRUG|dexmedetomidine-esketamine-ropivacaine combination 1|Epidural labor analgesia will be conducted using the dexmedetomidine-esketamine-ropivacaine combination 1 (0.4 microgram/ml dexmedetomidine + 0.15 mg/ml esketamine + 0.036% ropivacaine).
224243353|NCT00028691|RADIATION|radiation therapy|
224243354|NCT00970697|DRUG|becaplermin gel|the amount of the gel to be applied was determined based on ulcer area at inclusion and remains identical during all the treatment The posology was identical to what is recommended for Regranex gel®: a single 15g-tube is enough to treat a 5 cm2-wound during 6 weeks (1 cm of gel is applied daily for 5 cm2) Wound was then recovered by a moist saline gauze and a bandage. Becaplermin gel is packaged into masked 15g-tubes.
224243355|NCT00970697|DRUG|Duoderm Hydrogel™|The amount of the gel to be applied was determined based on ulcer area at inclusion, and remains identical during all the treatment. The posology was identical to what is recommended for Regranex gel®: a single 15g-tube is enough to treat a 5 cm2-wound during 6 weeks (1 cm of gel is applied daily for 5 cm2) Wound was then recovered by a moist saline gauze and a bandage. Hydrogel dressing is identical in appearance, color, consistency, and odor than becaplermin gel, and packaged in similar masked15g-tubes.
224243356|NCT01575223|DEVICE|NeilMed sinus rinse|High volume saline irrigation
224243357|NCT01575223|DEVICE|Salinex|Low volume saline irrigation
224243358|NCT00709553|DRUG|midazolam|
224243359|NCT00709553|DRUG|ZD4054|ZD4054 10 mg od
224243360|NCT06015126|DRUG|metronomic oral vinorelbine plus anlotinib|To clarify the efficacy and safety of metronomic oral vinorelbine plus anlotinib in HER2-negative metastatic breast cancer patients, adding new data for the posterior treatment of HER2-negative advanced breast cancer
224243361|NCT01312922|DRUG|PNB01 fixed dose combination of pipamperone and citalopram|oral once daily administration
223663382|NCT07145775|DRUG|dexmedetomidine-esketamine-ropivacaine combination 2|Epidural labor analgesia will be conducted using the dexmedetomidine-esketamine-ropivacaine combination 2 (0.4 microgram/ml dexmedetomidine + 0.2 mg/ml esketamine + 0.036% ropivacaine).
223663383|NCT07144904|DRUG|Indocyanine Green (ICG)-Assisted Ureteral Identification|A temporary ureteral stent will be placed unilaterally (left or right) prior to robotic procedures in participants undergoing robot-assisted single-site surgery for advanced-stage endometriosis. Indocyanine green (ICG) will be administered through the stent to enable real-time fluorescence imaging for intraoperative ureter identification. The contralateral ureter will be identified using standard visualization techniques without ICG. Side allocation (ICG vs. control) will be determined by computer-generated block randomization.
223663384|NCT07144904|PROCEDURE|Standard Ureteral Identification without ICG|Ureter identification will be performed using standard intraoperative visualization techniques without the use of indocyanine green (ICG) fluorescence imaging. This will be done on the contralateral side to the randomized ICG-assisted ureteral identification during robot-assisted single-site surgery for advanced-stage endometriosis.
223663385|NCT07146945|DRUG|S1-221|S1-221 will be administered orally to participants.
223663386|NCT07146945|DRUG|Placebo|Matching placebo will be administered orally to participants.
223663387|NCT07146945|DRUG|THC|A single dose of THC will be administered to participants orally.
224243362|NCT01312922|DRUG|Citalopram|oral once daily administration
224243363|NCT01312922|DRUG|Pipamperone|oral once daily administration
224243364|NCT00694551|BIOLOGICAL|Peptide Vaccine|Peptide vaccine (PSMA and TARP peptide vaccine with Poly IC-LC adjuvant). Pilot study using three treatment arms of increasing peptide dose levels (100 mcg, 300 mcg, and 1 mg) with a fixed dose of Poly IC-LC as an adjuvant. Patients were randomly assigned to one of the 3 arms upon enrollment.
224243365|NCT00694551|DRUG|Poly IC-LC|Administered subcutaneously, one 2 mg/ml vial,(divided into two equal portions for each injection site).
224243366|NCT01038791|DEVICE|heated humidification|temperature 35°
224243367|NCT01038791|DEVICE|heat and moisture exchanger|single patient device
224243368|NCT01038791|DEVICE|usual mechanical ventilation without humidification|mechanical ventilation with usual parameters
224243369|NCT01938586|OTHER|Steri-Strip|
224243370|NCT01938586|OTHER|Superficial sutures|
224243371|NCT03236753|PROCEDURE|Thread-embedding Acupuncture (TEA)|"The acupoints and size of TEA are as follows:~1. Both EX-B2 of herniated intervertebral disc level, its upper level and its lower level (6 acupoints): perpendicular insertion, 4cm~2. Both BL24: transverse insertion toward L1 level along the erector muscle of spine, 6cm~3. Both BL25: transverse insertion toward iliac crest, 4cm~4. Both BL26: transverse insertion toward L1 level along the erector muscle of spine, 6cm~5. Both BL26: oblique insertion toward iliolumbar ligament, 6cm~6. Both EX-B7: oblique insertion toward gluteus medius muscle, 6cm~7. Both BL28: oblique insertion toward sacroiliac ligament, 6cm~8. Both GB30: perpendicular insertion, 6cm~9. Symptomatic side GB34, BL57 and ST36: oblique insertion toward foot, 4cm"
224243372|NCT03236753|PROCEDURE|Sham Thread-embedding Acupuncture (STEA)|All procedure of STEA group, including acupoints and size of TEA will be same as that of TEA group. However, thread-removed TEA will be used for STEA group instead of normal TEA, and removing procedure of thread will be performed aseptic and secretly for patient-blinding and prevention of infection.
223663388|NCT07145008|DRUG|Suprachoroidal triamcinolone acetonide injection|For suprachoroidal injection, we developed a custom-made delivery system to access the potential suprachoroidal space. A 1 mL tuberculin syringe fitted with a 27-gauge needle was prepared, and a plastic sleeve from a 24-26 G IV cannula was placed over the needle as a spacer to control penetration depth.
224243373|NCT02227121|DEVICE|Defibrillation following induction of VT/VF|Up to 10 VT/VF induction attempts followed by shock(s) delivered by an externally placed ICD and/or external defibrillator.
224243374|NCT03236766|OTHER|Citizens' panels|This study is exploratory in nature, designed to capture lay Pacific Islanders' thoughts and beliefs about existing service engagement approaches. Therefore, there are no study arms to list.
224243375|NCT03231956|DEVICE|ClearSight™ / EV1000NI Clinical Platform|Noninvasive Hemodynamic Monitoring utilizing ClearSight TM System
224243376|NCT03929367|DRUG|Oxytocin|Single IV administration of oxytocin
224243377|NCT04898062|DEVICE|CRP-apheresis|The major advantages of depleting C-reactive protein by therapeutic apheresis are the selective removal of the damaging agent by the highly specific ligand and the good controllability of the procedure, since the plasma can be passed over the column as often as necessary to achieve the desired reduction. In addition, treatment can be interrupted or discontinued at any time.
224243378|NCT02120053|DEVICE|Conventional protocol|Teeth extractions and conventional immediate complete denture placement
223663389|NCT07146373|OTHER|Inspiratoty Muscle training|Participants will follow an IMT program through a threshold IMT device which consists of 5 set/6 breaths at 50-60% MIP for 3 months along with their usual physical and cogntive training
224243379|NCT02120053|DEVICE|Bone substitute material group|Teeth extractions and sockets filling with bone replacement material before immediate complete denture placement
224243380|NCT01937390|DRUG|Tiotropium 2x2.5µg tiotropium (equivalent to 2x3.154µg tiotropium bromide monohydrate) Respimat® inhaler and cartridge Solution for inhalation|Respimat® inhaler and cartridge Solution for inhalation
224243381|NCT01937390|DRUG|Indacterol 300 µg|inhalation powder
223663390|NCT07146373|OTHER|Usual Care|Physical and cognitive training
223663391|NCT07145749|BEHAVIORAL|Transtheoretical theory-based education|Transtheoretical theory-based education will be provided to individuals with substance use disorders face-to-face in 8 modes and each lesson will last 45 minutes. Weekly education stages of transtheoretical theory-based education: Week 1; Stage 1 (not thinking); Weeks 2 and 3, Stage 2 (Thinking/Intention); Weeks 4 and 5, Stage 3 (Preparation); Weeks 6 and 7, Stage 4 (taking action); Week 8, Stage 5 (Maintenance/Continuing).
223663392|NCT07145749|OTHER|Pre-test-after-test-re-test|Information Form, Sexual Risk Taking Scale, AIDS Knowledge Scale and AIDS Prevention Self-Efficacy Scale
223663393|NCT07144969|DIETARY_SUPPLEMENT|Honey|Group B patients were asked to eat one half tablespoon of natural honey every 4 hours
223663394|NCT07144969|DIETARY_SUPPLEMENT|gum chewing|Group A patients were asked to chew gum for 5 minutes every 4 hours
223663395|NCT07147166|DEVICE|Brijjit® BP100-6 and BP-75|Brijjit® BP-100 and BP-75 are a non-invasive, flexible devices that acts as a force modulating tissue bridge (FMTB) to aid in wound healing. BP-100 and BP-75 simply refer to different sizes of the Brijjit device.
223663396|NCT07147166|OTHER|Control: Standard of care and normal wound dressing|The control chest side will receive only standard of care and normal wound dressing.
223663397|NCT05552352|OTHER|Virtual Reality assisted information|Patients in the intervention group receive a VR instructional application in the patient's room the day before TAVI implantation and in the operational suite during TAVI implantation the next day. In this application, the patient is guided through different VR parts that repeat the indication, the procedure, the localities and the post-interventional phase of the implantation with the corresponding safety instructions.
223663398|NCT03703297|DRUG|Durvalumab|Durvalumab IV (intravenous infusion)
223663399|NCT03703297|DRUG|Tremelimumab|Tremelimumab IV (intravenous infusion)
223663400|NCT03703297|OTHER|Placebo|Placebo IV (intravenous infusion)
224243382|NCT01937390|DRUG|Tiotropium 18µg (equivalent to 22.5µg tiotropium bromide monohydrate) HandiHaler® device Inhalation powder, hard capsule|HandiHaler® device Inhalation powder, hard capsule
224243383|NCT01937390|DRUG|Indacterol 150 µg|inhalation powder
224243384|NCT00636896|DRUG|Olanzapine plus modafinil|Olanzapine 10 mg/d plus modafinil 200 mg/d
224243385|NCT00636896|DRUG|Olanzapine plus placebo|Olanzapine 10 mg/d plus placebo
224243386|NCT00515203|DRUG|Placebo|Starting dose of 1.0 ug/kg. Dose adjustments are made throughout the study based on individual platelet counts.
224243387|NCT00515203|DRUG|AMG 531|Starting dose of 1.0 ug/kg. Dose adjustments are made throughout the study based on individual platelet counts.
224243388|NCT00411203|DRUG|Tamoxifen Citrate|
224243389|NCT00411203|DRUG|Placebo|
223663401|NCT04876820|OTHER|Pharmacist intervention|"In the intervention arm, the patient meets with the pharmacist. Pharmaceutical intervention (H1) about anti-epileptic drugs prescribed will be done: information on when to take the medication, what to do if you forget to take it or vomit, and an explanation of adverse events. The aim is to improve medication adherence and patient knowledge. A report will be sent to the community pharmacist.~An assessment of medication adherence to antiepileptic drug by MPR at H1 3 months and 6 months (phone call to community pharmacist) will be done. The health insurance score will also be done.~An assessment of patient knowledge by a self-made knowledge questionnaire (10 items) at H1 in pre- post interview -, 3 and 6 months (phone call to patient) will be done.~An assessment of pharmacists' satisfaction about community hospital network by a satisfaction questionnaire will be done."
223663402|NCT04876820|OTHER|Standard of care|An assessment of medication adherence to antiepileptic drug by MPR at the inclusion then 3 months and 6 months later will be done by a phone call to the community pharmacist. An assessment of patient knowledge by a self-made knowledge questionnaire (10 items) at the inclusion then 3 and 6 months later will be done by a phone call to the patient. The health insurance score will be also done during this call.
223769955|NCT02138851|DIETARY_SUPPLEMENT|Ficus Carica (300g/day)|Ficus Carica (300g/day), parallel design
223769956|NCT02138851|DIETARY_SUPPLEMENT|Placebo (300g/day)|Placebo (300g/day), parallel design
224243390|NCT00733616|DRUG|DOX: Docetaxel, oxaliplatin, Capecitabine|"* Docetaxel 40 mg/m2, iv infusion 60 minutes, day 1~* Oxaliplatin 80 mg/m2, iv infusion 120 minutes, day 1~* Capecitabine 625 mg/m2, bid, oral, continuous~  6 cycles, every 3 weeks~Capecitabine will be given same dose (625mg/m2/bid) continuous in case no toxicity (no dose adjustment)"
224243391|NCT03354104|DEVICE|The tunnel technique for root coverage with Emdogain|The tunnel technique for root coverage with Emdogain
224243392|NCT03354104|DEVICE|The tunnel technique for root coverage without Emdogain|The tunnel technique for root coverage without Emdogain
224243393|NCT03061734|DRUG|Naltrexone and Acetaminophen|Naltrexone plus acetaminophen
224243394|NCT03061734|DRUG|Naltrexone and Acetaminophen-High Dose|Naltrexon (high dose) plus acetaminophen
224243395|NCT03061734|DRUG|Naltrexone Alone (regular dose)|Naltrexone Alone plus Placebo
224243396|NCT03061734|DRUG|Acetaminophen Alone|Acetaminophen Alone plus Placebo
224243397|NCT03061734|DRUG|Matching Placebo|Two Placebo capsules
224321476|NCT01281605|BEHAVIORAL|Active titration algorithm|Patients in active titration algorithm group will contact with investigator by telephone weekly to self-adjust the insulin dose till they achieve the target of FPG(\<110mg/dl).
224321477|NCT01281605|BEHAVIORAL|Usual titration algorithm|All patients will be instructed to self-measure fasting capillary blood glucose. The dose of insulin detemir will be adjusted based on the average of three consecutive FPG values. the daily insulin dose should be increased by 2 IU/day if the FPG\>=110mg/dL, and by 4 IU/day if the FPG\>=180 mg/dL without any intervening hypoglycemic episodes; or it should be decreased by 2 or 4 IU/day if the FPG \< 70 mg/dL.
224243398|NCT06880588|BEHAVIORAL|Brief Infant Sleep Questionnaire|"The Brief Infant Sleep Questionnaire will be used to assess sleep. Infant sleep problems are among the most common problems presented to healthcare professionals. The extended version of the Brief Infant Sleep Questionnaire is a questionnaire developed by Sadeh to assess sleep problems and their causes in early childhood. This questionnaire has been translated into Turkish and assessed sleep environment and sleep problems in infants. It consists of 33 items, is based on parent reports of infant or toddler sleep patterns and is used to validate the data. It is associated with daily records and parent reports of sleep. Its sensitivity in documenting developmental sleep trends is well established"
224243399|NCT06880588|BEHAVIORAL|Test of Sensory Function in Infants|It was planned to use the Test of Sensory Function in Infants to evaluate the sensory development of infants. Test of Sensory Function in Infants is frequently used to evaluate the sensory processing
223663403|NCT03278067|OTHER|Enhanced vaccine safety surveillance|Routinely collected primary care data from up to ten general practices to support passive surveillance. Additionally, this passive surveillance will be enhanced by the use of a customized card-based ADR reporting system.
223663404|NCT02782156|OTHER|Process evaluation|Adherence to screening and action algorithm
223663405|NCT00446680|DRUG|Mannitol|400mg BD for 6 months followed by a 6 month open label period
223663406|NCT00446680|DRUG|placebo|placebo BD for 6 months
224243400|NCT06880588|BEHAVIORAL|Peabody Motor Development Scale-2|It was planned to use the Peabody Motor Development Scale-2 to evaluate motor development. The Peabody Motor Development Scale-2 was designed to determine developmental delays in children aged 0-72 months.
223663407|NCT05615025|DRUG|Sevoflurane|Anesthesia will be maintained by sevoflurane.
223663408|NCT05615025|DRUG|Propofol|Anesthesia will be maintained by propofol.
223663409|NCT02156271|DRUG|ramelteon|
223663410|NCT02156271|DRUG|placebo|
223663411|NCT03320824|DEVICE|New Dermal Filler|hyaluronic acid
223663412|NCT03320824|DEVICE|Device: FDA Approved Dermal Filler|hyaluronic acid
223663413|NCT05206656|DRUG|Eribulin Mesylate|Eribulin mesylate injection is performed on Day 1 and Day 8 of each treatment cycle (21 days per cycle). Patients were treated for six cycles, except disease progression (PD) or treatment stop for other reasons, such as severe adverse effects.
223663414|NCT05206656|DRUG|Anlotinib|12 mg Anlotinib is administered for continuous 14 days in 21 day cycles. Patients received Anlotinib untill disease progression.
223663415|NCT03387111|DRUG|Aldoxorubicin HCl|Aldoxorubicin hydrochloride
223663416|NCT03387111|BIOLOGICAL|ETBX-011|Ad5 \[E1-, E2b-\]-CEA
223769957|NCT00545831|DEVICE|Taurolidine|2 mL of taurolidine instillate on the intravascular catheter after each parenteral nutrition session for a duration of 6 months
223769958|NCT00545831|DEVICE|Physiologic Serum|2 mL of physiologic serum instillate on the intravascular catheter after each parenteral nutrition session for a duration of 6 months
223769959|NCT03814694|DIETARY_SUPPLEMENT|CRHP Diet|Dietary macronutrient composition of 30 E% from carbohydrate, 30 E% from protein and 40 E% from fat
223769960|NCT03814694|DIETARY_SUPPLEMENT|CD Diet|Dietary macronutrient composition of 50 E% from carbohydrate, 17 E% from protein and 33 E% from fat
224243401|NCT05879328|PROCEDURE|Liver Transplantation|Liver transplantation (LT) is an accepted surgical therapy for hepatocellular carcinoma (HCC) in patients who achieve effective and sustained tumor downstaging; in this study liver transplantation will be performed in patients undergoing a successful hepatocellular carcinoma (HCC) downstaging with the combination of atezolizumab and bevacizumab.
223663417|NCT03387111|BIOLOGICAL|ETBX-021|Ad5 \[E1-, E2b-\]-HER2
223663418|NCT03387111|BIOLOGICAL|ETBX-051|Ad5 \[E1-, E2b-\]-Brachyury vaccine
223663419|NCT03387111|BIOLOGICAL|ETBX-061|Ad5 \[E1-, E2b-\]-MUC1
223663420|NCT03387111|BIOLOGICAL|GI-4000|Vaccine derived from recombinant Saccharomyces cerevisiae yeast expressing mutant Ras proteins
223663421|NCT03387111|BIOLOGICAL|GI-6207|Vaccine derived from recombinant Saccharomyces cerevisiae yeast expressing mutant CEA proteins
223663422|NCT03387111|BIOLOGICAL|GI-6301|Vaccine derived from recombinant Saccharomyces cerevisiae yeast expressing mutant Brachyury yeast proteins
223663423|NCT03387111|BIOLOGICAL|haNK for infusion|NK-92 \[CD16.158V, ER IL-2\]
223663424|NCT03387111|DRUG|Avelumab|Recombinant human anti-PD-L1 IgG1 monoclonal antibody
223663425|NCT03387111|DRUG|bevacizumab|Recombinant human anti-VEGF IgG1 monoclonal
223663426|NCT03387111|DRUG|Capecitabine|5'-deoxy-5-fluoro-N-\[(pentyloxy) carbonyl\]-cytidine
223663427|NCT03387111|DRUG|Cetuximab|Cetuximab is an epidermal growth factor receptor (EGFR) antagonist.
223663428|NCT03387111|DRUG|Cisplatin|cis-diamminedichloroplatinum(II)
223769961|NCT01993264|OTHER|Fetal Echocardiogram|Subjects will then have sequential, abbreviated fetal echocardiograms performed by designated, highly trained, and experienced sonographers every 4 weeks, from 20-36 weeks.
223769962|NCT04040101|DEVICE|smartphone-based balance training system|use smartphone application to training balance
223663429|NCT03387111|DRUG|Cyclophosphamide|2-\[bis(2-chloroethyl)amino\]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
223663430|NCT03387111|DRUG|Fluorouracil|5-fluoro-2,4 (1H,3H)-pyrimidinedione
223663431|NCT03387111|DRUG|Leucovorin|L-Glutamic acid, N-\[4-\[\[(2-amino-5-formyl-1,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)methyl\]amino\]benzoyl\]-, calcium salt
223663432|NCT03387111|DRUG|nab-Paclitaxel|Benzenepropanoic acid, β-(benzoylamino)-α-hydroxy-(2aR, 4S, 4aS, 6R, 9S, 11S, 12S, 12aR, 12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a, 3, 4, 4a, 5, 6, 9, 10, 11, 12, 12a, 12b-dodecahydro-4,11-dihydroxy-4a, 8, 13, 13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca\[3,4\]benz\[1,2-b\]oxet-9-y1ester,(αR,βS)-(9CI) bound to albumin
223663433|NCT03387111|DRUG|Necitumumab|Necitumumab is a recombinant human lgG1 monoclonal antibody.
223663434|NCT03387111|PROCEDURE|SBRT|Stereotactic Body Radiation Therapy
223663435|NCT03387111|BIOLOGICAL|N-803|Recombinant human superagonist interleukin-15 (IL-15) complex \[also known as IL-15N72D:IL-15RuSu/IgGI Fe complex1)
223663436|NCT04271618|OTHER|TheraTogs Orthotic Undergarment|Strapping undergarment made from a lightweight, breathable fabric that is velcro sensitive. It consists of sleeveless vest (tank-Top), two shorts (Hipster) each with two thigh cuffs and limb cuffs
223663437|NCT03459391|DRUG|XC221 60 mg|The volunteers received the study drug once, and then continued daily intake for 5 days after a 6-day break.
224243402|NCT04279639|BEHAVIORAL|qigong|Patients of the Pain Management Unit either experience usual treatment, or usual treatment plus qigong practice.
223663438|NCT03459391|DRUG|XC221 200 mg|The volunteers received the study drug once, and then continued daily intake for 5 days after a 6-day break.
224243403|NCT03559387|DRUG|ANF-RHO™|"Subjects randomized to the ANF-RHO™ treatment arm will receive the investigational product on Day 1(day of chemotherapy treatment) of each Chemotherapy cycle. ANF-RHO™ will be administered to the subjects as a subcutaneous injection. Subjects will receive the ANF-RHO™ dose with a volume equivalent to 10 µg/kg, 20 µg/kg and 30 µg/kg.~ANF-RHO™ is provided as a single-use glass vial containing 1.0 ml of solution at a concentration of 5 mg/ml"
224243404|NCT03559387|DRUG|Neulasta®|"Subjects randomized to the Neulasta® treatment arm will receive the comparator drug on Day 2(day after chemotherapy treatment) of each Chemotherapy cycle. Neulasta® will be administered to the subjects at a standard dose of 6.0 mg in 0.6 ml as a subcutaneous injection.~Neulasta® is also provided as a single-use pre-filled syringe."
224243405|NCT06379841|PROCEDURE|Green Draping Procedure|The green draping will include only an under-buttock. After normal hand hygiene and scrub, the green draping procedure will have the surgeons don only a single pair of sterile gloves.
224243406|NCT06379841|PROCEDURE|Full Draping Procedure|The full draping will include under-buttocks, two-leg drapes, blue towels, and a top drape. After normal hand hygiene and scrub, the draping procedure will have the surgeon don a surgical gown and two sets of sterile gloves for the surgeon.
223663439|NCT03459391|DRUG|Placebo|The volunteers received the study drug once, and then continued daily intake for 5 days after a 6-day break.
223663440|NCT00588159|DRUG|Gabapentin|gabapentin 600 mg orally within 2 hours preoperatively, epidural infusion of 0.075% bupivacaine with 10 mcg/ml of hydromorphone at 6 ml/hour, fentanyl intravenous patient controlled analgesia at 10 mcg every 10 minutes as needed with a 200 mcg 4 hour lockout, oral acetaminophen 650 mg orally every 6 hours as needed for pain, intravenous ketorolac 15 mg every 6 hours as needed for pain.
223663441|NCT00588159|DRUG|Diphenhydramine|Diphenhydramine 12.5 mg orally within 2 hours preoperatively, epidural infusion of 0.075% bupivacaine with 10 mcg/ml of hydromorphone at 6 ml/hour, fentanyl intravenous patient controlled analgesia at 10 mcg every 10 minutes as needed with a 200 mcg 4 hour lockout, oral acetaminophen 650 mg orally every 6 hours as needed for pain, intravenous ketorolac 15 mg every 6 hours as needed for pain.
223663442|NCT05909800|DRUG|Phenofibrate|Administred orally, once daily, for 12 months.
223663443|NCT05909800|DRUG|Placebo|Administred orally, once daily, for 12 months.
223663444|NCT06081322|DRUG|PRRT with 177Lu-EB-FAPI|PRRT with 177Lu-Fibroblast activation protein inhibitor and modified by Evans blue
223663445|NCT02610504|DEVICE|Durolane|single injection of 3ml
223663446|NCT02735824|PROCEDURE|blood sampling and skin biopsy|Nucleated blood cells and/or fibroblasts from skin biopsy will be used for genetic testing and functional assays. Blood serum will be used for antibody and cytokine measurement.
223663447|NCT02735824|PROCEDURE|blood sampling or mouth swap|specimen will be used for genetic testing, results compared to patients
223663448|NCT02735824|PROCEDURE|blood sampling|Nucleated blood cells and/or fibroblasts from skin biopsy will be used for genetic testing and functional assays. Blood serum will be used for antibody and cytokine measurement.
223663449|NCT03219710|DRUG|Ondansetron|Ondansetron will be given at a dosage of 0.15mg/kg IV/PO q8h.
223663450|NCT03219710|DRUG|Dexamethasone|Dexamethasone will be given as 3mg/m2 IV/PO q8h.
223769963|NCT01190540|BEHAVIORAL|Training and supervision|On-Site-Support (OSS) service training will occur monthly for a period of 9 months. This training and supervision will support the proper utilization of newly learned clinical skills.
223769964|NCT01190540|BEHAVIORAL|Training and Supervision|On-Site-Support (OSS) service training will occur monthly for a period of 9 to 15 months. This training and supervision will support the proper utilization of newly learned clinical skills and continuous quality improvement of processes of care. For the control group, the OSS training will occur during phase 2, after a randomly assigned wait list control period.
223769965|NCT01190540|BEHAVIORAL|Integrated Management of Infectious Disease (IMID)|The IMID is a 9-month training program that begins with a three-week course at the Infectious Diseases Institute (IDI) in Kampala Uganda. After the course participants engage in 12 weeks of distance learning followed by a one-week boost course at the IDI. Then the engage in 12 more weeks of distance learning and a final one-week boost course. This intervention is offered to two clinicians (clinical officers or registered nurses or midwives) at every OSS Phase 1 and OSS Phase 2 site.
224243407|NCT06112535|DEVICE|Versius Surgical System|"Transoral robotic surgery (TORS) using Versius Surgical System. Versius is a robot designed to help surgeons perform surgery. It consists of a set of robotic arms: one of the arms has a camera and a light source on it while the other arms each have a small surgical instrument attached at the end. The surgeon controls each of the arms with hand controllers (joysticks) and can perform surgery with them, while seeing the surgical area on a screen in front of him/her.~The camera and instruments are inserted into the mouth and throat in order to cut out a cancerous tumour."
224321478|NCT07133906|DEVICE|Continuous glucose monitoring|A blinded Abbott Freestyle Libre 3 Pro will be placed on the newborn
224321479|NCT07133906|DEVICE|Cerebral near-infrared spectroscopy|Blinded cerebral near infrared spectroscopy will be assessed
224321480|NCT06619405|DIAGNOSTIC_TEST|Streetlab VR|Streetlab VR is a virtual reality headset that is warn to simulate walking through a maze at different light levels.
223663451|NCT03219710|DRUG|Aprepitant|Aprepitant will be given as per the weight. weight (15-40kg) - Day1 to Day 3 - 80 mg PO weight (\>40 kg) - Day 1 -125mg , Day 2 \& Day 3 - 80 mg PO
223663452|NCT03219710|DRUG|Olanzapine|olanzapine will be given as 0.14mg/kg PO (rounded off to nearest 2.5 mg )
223663453|NCT02438358|DRUG|LUM015|
223663454|NCT02438358|DEVICE|LUM 2.6 Imaging Device|
223663455|NCT00265356|PROCEDURE|PET diagnostic imaging|PET diagnostic imaging
223663456|NCT02329340|BEHAVIORAL|Am Academy of Pediatrics print materials|Print materials of injury prevention content.
223663457|NCT02329340|BEHAVIORAL|Family safety 1-2-3|Theoretically based school-aged childhood injury prevention videos for families
223663458|NCT05090176|OTHER|povidone-soaked suture|suture soak with povidone solution for 3 mins
223663459|NCT05090176|OTHER|ordinary suture|suture no need to soak with povidone solution
223663460|NCT00057980|DRUG|celecoxib|
223663461|NCT00057980|DRUG|epirubicin hydrochloride|
223663462|NCT01466257|BIOLOGICAL|cetuximab|
223663463|NCT01466257|DRUG|cisplatin|
223663464|NCT01466257|GENETIC|DNA analysis|
223663465|NCT01466257|GENETIC|gene expression analysis|
223663466|NCT01466257|GENETIC|mutation analysis|
223663467|NCT01466257|OTHER|laboratory biomarker analysis|
223663468|NCT02617485|DRUG|Rituximab|375 mg/m2 IV on day 1 of each 21 days chemotherapy cycle. Number of Cycles: 8.
223663469|NCT02617485|DRUG|Doxorubicin|50 mg of doxorubicin per square meter administrated IV on day 1 of each chemotherapy cycle
223663470|NCT02617485|DRUG|Vincristine|1.4 mg of vincristine per square meter, up to a maximal dose of 2 mg, administrated IV on day 1 of each chemotherapy cycle
223663471|NCT02617485|DRUG|Cyclophosphamide|750 mg of cyclophosphamide per square meter of body-surface area administrated IV on day 1 of each chemotherapy cycle
223663472|NCT02617485|DRUG|prednisone|100 mg of prednisone administrated PO per day for five days, day 1-5 of each chemotherapy cycle
223663473|NCT03650946|DIAGNOSTIC_TEST|Ga-68 PSMA PET|Ga-68 PSMA PET
223663474|NCT03660085|BEHAVIORAL|PC-PEP|"The 6 months at home program focuses on aerobic and strength training, pelvic floor muscle exercises, meditation, social connection, and overall healthy lifestyle practices supported with daily text message/email reminders. The aerobic (5 times/week) and strength (2 times/week) program will comprise of a single 30-minute session daily and will be individualized to each participant. Pelvic floor muscle training will include three, 10-minute sessions and mediation for 10 minutes daily. Intimacy and Connection component of PC-PEP consists of engaging in at least one form of intimacy practice prescribed, per day. Social connection will be fostered by pairing participants up with peers from the study. To encourage program compliance, study participants will receive 3 daily reminders to do their pelvic floor muscle exercises per day plus an additional motivational email daily containing helpful tips."
223663475|NCT04963842|BEHAVIORAL|Use of bio-plastic food packaging material and avoidance of plastic food packaging material|The bio-plastic food packaging material will be used by the study participants for 5 days and no plastic packaged food will be consumed.
223663476|NCT00480987|DRUG|Oxaliplatin|30 mg/m\^2 IV days 1-4
223663477|NCT00480987|DRUG|Fludarabine|30 mg/m\^2 IV days 2-6
223663478|NCT00480987|DRUG|Cytarabine|500 mg/m\^2 by IV continuous infusion days 2-6
223663479|NCT03348592|DIETARY_SUPPLEMENT|Oligofructose-enriched inulin (p-inulin)|
223769966|NCT01190540|BEHAVIORAL|Integrated Management of Infectious Disease (IMID)|The IMID is a 9-month training program that begins with a three-week course at the Infectious Diseases Institute (IDI) in Kampala Uganda. After the course participants engage in 12 weeks of distance learning followed by a one-week boost course at the IDI. Then the engage in 12 more weeks of distance learning and a final one-week boost course. This intervention is offered to two clinicians (clinical officers or registered nurses or midwives) at every OSS Phase 1 and OSS Phase 2 site.
224243408|NCT03187002|DEVICE|Transcutaneous electrical nerve stimulation (TENS)|Transcutaneous electrical nerve-stimulation (TENS) is a nonpharmacologic means of pain control that delivers electrical currents through the skin. These pulses of electrical current reduce pain by peripheral and central mechanisms, TENS actives descending inhibitory systems in the central nervous system to reduce sensitivity to pain (hypoalgesia). Assessment of previous TENS research identifies intensity as a critical factor in efficacy-documenting high intensity as the best means of pain control, as the higher pulse allows for deeper tissue afferents to be activated. TENS has been researched in a number of settings as pain control, including cancer pain, lower back pain, labor, and a range of gynecologic procedures and disorders.
224243409|NCT03187002|DRUG|Moderate IV Sedation|IV sedation with fentanyl and versed
224243410|NCT03187002|OTHER|SHAM: Transcutaneous electrical nerve stimulation (TENS)|Sham Transcutaneous electrical nerve stimulation (TENS) to ensure blinding
224243411|NCT03187002|OTHER|SHAM: Moderate IV Sedation|Sham IV to ensure blinding
223663480|NCT03348592|OTHER|No treatment|Patients do not take a supplement during the first 8 weeks or the last 8 weeks of the study.
223663481|NCT04369820|OTHER|draw blood|40 mL blood sample will be taken within the first three days of hospitalization, a second sample will be taken between the 5th and 10th day of hospitalization and a third sample will be taken on the 10th day of hospitalization or the day of discharge if earlier.
223663482|NCT02648633|RADIATION|Stereotactic Radiosurgery|Subjects will receive a single large dose of radiation to one or more lesions.
223663483|NCT02648633|DRUG|Nivolumab|3 mg/kg of nivolumab will be administered through IV infusion every two weeks following stereotactic radiosurgery.
223663484|NCT02648633|DRUG|Valproate|Subjects will begin regimen of valproate prior to radiosurgery and continue to receive therapy concurrently with nivolumab. Subjects will receive valproate daily with a target serum level of 75-100 μg/ml.
223663485|NCT04590248|DRUG|Adavosertib|The subjects will receive oral adavosertib 300 mg, once daily on Days 1 to 5 and Days 8 to 12 of a 21-day treatment cycle.
223663486|NCT00586781|DEVICE|Scandinavian Total Ankle Replacement (STAR)|The device has three parts: two metal bearing surfaces (cobalt-chromium alloy) plates with bars that fit into the bone and one plastic (polyethylene) spacer that moves between the metal plates like a ball bearing. The materials in the S.T.A.R. device are the same materials used in total hip and knee implants.
223663487|NCT01533740|DRUG|fluorouracil/irinotecan/levo-folinic acid/bevacizumab|standard first line chemotherapy with: bevacizumab 5 mg/kg intravenous (i.v.) infusion on day 1; irinotecan 180 mg/m2 i.v. infusion on day 1, levo-folinic acid 200 mg/m2 i.v. infusion on day 1, 5-fluorouracil 400 mg/m2 i.v. bolus on day 1 and 2,400 mg/m2 i.v. infusion over 46 hours; infusions repeated every 2 weeks
223663488|NCT05546203|OTHER|Ischemic compression|"IC was applied over the detected MTrPs and the participant was asked to describe the pressure and pain she felt . It was started with moderate tolerable pressure (7/10) and then severity was increased. The color of the thumb pulp was observed to control the pressure. The pressure was continued for 90 sec. The patient's pain sensation continued to be questioned and the pressure was controlled to a level at comfortable pain"
223663489|NCT05546203|DEVICE|Low-level laser therapy|LLLT was applied for 90 sec at each MTrPs with a frequency of 2000 Hz (3 J) using a GaAs diode laser instrument (Roland Serie Elettronica Pagani, wavelength 904 nm, the frequency range of 5-7000 Hz and maximum peak power of 27, 50 or 2764 W) . The laser probe was held perpendicular to the MTrPs in skin contact without pressure.
223769967|NCT01291927|PROCEDURE|Pancreas-sparing duodenectomy|Pancreas-sparing duodenectomy for periampullary carcinoma is defined as resection of the descending segment of duodenum; resection of papilla of Vater; reimplantation of bile and pancreatic ducts and reconstruction of duodenum.The Japan Pancreatic Society (JPS) system for numbering of lymph node stations was adopted for accurate description of the surgery and pathological assessment.The standard lymph node groups removed as part of PSD were the anterior pancreatoduodenal groups (JPS LN17), the posterior pancreatoduodenal groups (JPS LN13), the dextroinferior nodes of the hepatoduodenal ligament node groups (JPS LN12), the infrapyloric node (JPS LN6), the nodes around the anterior aspect of the common hepatic artery (JPS LN8) and the nodes on the right side of the SMA (JPS LN14).
223769968|NCT01291927|PROCEDURE|Pancreaticoduodenectomy|The surgical technique used for standard PD has been described before. Standard PD included clearance of all soft tissues and lymphatics immediately to the left of the superior mesenteric artery, as well as removal of the lymphoareolar tissue along the proximal hepatic artery.
224243412|NCT05822518|DIETARY_SUPPLEMENT|Neo-mune powder (otsuka pharmaceutical)|"* Preoperative: Neo-mune (otsuka pharmaceutical) powder 60 gm o.d. orally (contains glutamine, arginine and fish oil) for 3 days.~* Postoperative: Neo-mune (otsuka pharmaceutical) powder 60 gm o.d. orally (contains glutamine, arginine and fish oil) for 2 weeks starting when the intestinal sounds are audible."
224243413|NCT05822518|DRUG|Dipeptiven solution (Fresenius Kabi pharmaceutical)|Dipeptiven (Fresenius Kabi pharmaceutical) solution 50 mg o.d IV ( contains L-ananyl-L-glutamine dipeptide) post operatively for 5 days starting from the operation day.
223663490|NCT05546203|BEHAVIORAL|Standardized exercise program|The standardized exercise program included stretching and pilates exercises for core stabilization. All exercises were supervised by the same physiotherapist whom certificated by The Australian Physiotherapy and Pilates Institute (APPI). Pilates exercises were selected from APPI's mat-work exercises and performed in accordance with APPI principles. In addition, patients performed stretching exercises for 5 days a week and pilates exercises for 3 days a week at home.
223663491|NCT04010578|DIETARY_SUPPLEMENT|MK-7 and vitamin D3|Patients will receive 400 micro-grams of Menaquinone-7 and 80 micro-grams of vitamin D3 per day.
223663492|NCT04010578|OTHER|Placebo|Patients will receive a placebo each day.
223663493|NCT03590964|PROCEDURE|Open sinus lift using chin bone graft|Patients with atrophied posterior maxilla will undergo open sinus lift with chin bone graft according to standardized surgical approach.
223663494|NCT03590964|PROCEDURE|Sinus lift using bone ring containing the implant.|Patients with atrophied posterior maxilla will undergo sinus lift with chin bone ring containing the implant.
223663495|NCT00615901|DRUG|cyclophosphamide, methotrexate, fluorouracil, PEG-filgrastim|C (cyclophosphamide) 600 mg/m2 M (methotrexate) 40 mg/m2 F (fluorouracil) 600 mg/m2 P (PEG-filgrastim ) 6 mg. Eight doses of CMF q 14 days with PEG-filgrastim administered approximately 24 hours after chemotherapy. Day 14, is also considered day 1 of the next cycle.
223663496|NCT01809587|DEVICE|IQP-PO-101|
223663497|NCT03598114|BEHAVIORAL|Program Sustainability Action Planning Model and Training Curricula|The Program Sustainability Action Planning Model and Training Curricula's conceptual model is driven by the theory of change and incorporates aspects of Kolb's experiential learning theory to produce a six step process: defining the program, assessing the program, developing an action plan, executing the action plan, evaluating sustainability, and reassessing and modifying. The study team will deliver in-person, hand-on workshops incorporating each of these aspects of the conceptual model. Following the workshop, intervention states will partake in technical assistance activities with the study team to track progress and troubleshooting challenges.
223663498|NCT05089422|PROCEDURE|Squint surgery|Lateral rectus recession and /or medial rectus resection
223663499|NCT04734470|DIAGNOSTIC_TEST|Flow cytometry|The study of CD19 complex expression in lymphoproliferative disorders by flowcytometry
223663500|NCT02527200|DRUG|liraglutide|Injected s.c./ subcutaneously (under the skin) This trial consists of a part A and a part B. Part A of the trial is conducted in obese adolescents with PWS. Part B of the trial is conducted in obese children with PWS. Entry into part A and part B of the trial will be sequential.
223663501|NCT02527200|DRUG|placebo|Injected s.c./ subcutaneously (under the skin) This trial consists of a part A and a part B. Part A of the trial is conducted in obese adolescents with PWS. Part B of the trial is conducted in obese children with PWS. Entry into part A and part B of the trial will be sequential.
223663502|NCT02349932|OTHER|Healthy Adults|The following samples will be collected: fecal, blood, and saliva. The samples will be tested for HBGA-reactive antigens using an immunoaffinity assay.
223663503|NCT03464292|DRUG|Capsaicin Patch 8% or 0.1% Capsaicin Cream|0.1 ml of 8% capsaicin topical patch or 0.1% capsaicin cream
223663504|NCT03464292|OTHER|Vehicle Patch|Control patch will be the same topical solution but will not contain capsaicin.
223663505|NCT06365762|DRUG|EDTA Ophthalmic Solution 2.6%|
223663506|NCT06365762|DRUG|EDTA Ophthalmic Solution 1.3%|
223663507|NCT06365762|DRUG|Saline Solution (Placebo)|
223663508|NCT02842034|DEVICE|Repetitive Transcranial Magnetic Stimulation|Stimulate the dorsomedial prefrontal cortex for 4 weeks.
223663509|NCT01324518|DRUG|ORM-12741|60mg twice a day
223663510|NCT01324518|DRUG|ORM-12741|200mg twice a day
223663511|NCT01324518|DRUG|Placebo for ORM-12741|Placebo twice a day
223663512|NCT02645838|BEHAVIORAL|Motivational interviewing|1\. Structural motivational interviewing for one section (about 20 mins)，provided by family physician;2. Follow-up telephone call，provided by family physician.
223663513|NCT00851968|PROCEDURE|Pringle's Maneuver|The entire hilar pedicle was encircled with a rubber tape to perform a Pringle maneuver with a tourniquet.
223663514|NCT00851968|PROCEDURE|Hemihepatic vascular Clamping|The portal vein,hepatic artery ,and biliary duct were dissected in the hilum by opening the peritoneal fascia. Either the right or left portal pedicle was isolated and encircled with a tourniquet or clamped with Shatinsky clamp. Separate clamping of accessory left hepatic artery was performed when present in controlling the left hemihepatic portal traid.
223769969|NCT00619697|DRUG|biphasic insulin aspart|
223769970|NCT00619697|DRUG|insulin glargine|
223769971|NCT00619697|DRUG|metformin|
223769972|NCT00619697|DRUG|glimepiride|
223769973|NCT00277602|DRUG|Riluzole|
223769974|NCT04978038|DRUG|mRNA- COVID-19|Pfizer-BioNtech mRNA- COVID-19 0.3ml dose administered intramuscularly
224243414|NCT02098993|DRUG|Unfractionated heparin|
223663515|NCT00851968|PROCEDURE|Portal vein occlusion|The proper hepatic artery was dissected first from the duodenohepatic ligament, portal pedicle was blocked with a rubber encircled through the posterior wall of proper hepatic artery and the bottom of duodenohepatic ligament.When aberrant hepatic arteries emerging from the superior mesenteric artery are found in duodenohepatic ligament ,they should be dissected and kept unobstructed.
223663516|NCT03196492|OTHER|No intervention|No intervention
223663517|NCT04752644|BIOLOGICAL|MVA-mBN294B|MVA-BN-RSV (nominal titre 5 x10\*8 Inf.U per 0.5 mL) as intramuscular injections. Liquid frozen suspension, single dose of 0.5ml.
223663518|NCT04752644|DRUG|Placebo|TBS (Placebo) as intramuscular injections (0.5ml)
223663519|NCT02578719|DRUG|bupivacaine|marcaine %0.5 20 ml flacon
223663520|NCT02578719|DRUG|saline|%0.9 sodium chloride
223663521|NCT00091325|DIETARY_SUPPLEMENT|defined green tea catechin extract|
223663522|NCT03519542|DRUG|Sunitinib|Identify prognosis and predictive biomarkers of response to sunitinib and pazopanib as first line therapy in avanced or metastatic renal cell carcinoma.
223663523|NCT01004276|OTHER|New, improved smoking cessation management module|The intervention that will be tested is an improved smoking cessation management module in an existing chronic disease management system, P-PROMPT CDMS. This module includes the following components: a) the Patient Care Status and Update Form, b) the smoking registry and c) patient prompts.
223663524|NCT02294968|OTHER|Family Startup (in Danish: Familieiværksætterne)|Manualized parenting support program; see Center for Socialt Ansvar (2013)
223663525|NCT04087330|OTHER|Group 1 Experimental group|"Stretching exercises for Achilles tendon, hamstrings, hip flexors and adductors of lower limbs, upper abdominal and pectoralis muscles.~Facilitation of postural reactions, including: facilitation of righting, equilibrium and protective reactions from sitting on ball.~Facilitation of standing and weight shift. Facilitation of standing balance by tilting the child from standing to different directions (forward, back-ward and side-way) using a balance board.~Gait training: by forward, backward, and side-way walking between parallel bars.~Whole body vibration."
223663526|NCT04087330|OTHER|Group 2 Control group|"Stretching exercises for Achilles tendon, hamstrings, hip flexors and adductors of lower limbs, upper abdominal and pectoralis muscles.~Facilitation of postural reactions, including: facilitation of righting, equilibrium and protective reactions from sitting on ball.~Facilitation of standing and weight shift. Facilitation of standing balance by tilting the child from standing to different directions (forward, back-ward and side-way) using a balance board.~Gait training: by forward, backward, and side-way walking between parallel bars."
223663527|NCT04510428|DRUG|Ocular Surface Immune Globulin (OSIG)|Ocular Surface Immune Globulin (OSIG) eye drops 4 mg/ml (0.4%) four times a day for 8 weeks
223663528|NCT04510428|DRUG|Placebo|Normal Saline Eye Drops (0.9% NaCl) four times a day for 8 weeks
223663529|NCT04250077|BEHAVIORAL|Community Reinforcement And Family Training (CRAFT)|"Community Reinforcement Approach and Family Training (CRAFT) is a scientifically based intervention designed to help concerned significant others (CSOs) to engage treatment-refusing substance abusers into treatment. This new intervention method was developed with the belief that the CSO can play a powerful role in helping to engage the substance user in treatment. It is often the substance user who reports that family pressure or influence is the reason sought treatment. CSOs benefit by becoming more independent and reducing their depression, anxiety and anger symptoms even if their loved one does not enter treatment.~CRAFT uses a positive approach versus confrontation, emphasizing learning new skills to cope with old problems. Some components include: how to stay safe, outlining the context in which substance abusing behavior occurs, teaching CSOs how to use positive reinforcers (rewards) and how to let the substance user suffer the natural consequences for their using behavior."
223663530|NCT04250077|BEHAVIORAL|We The Village Peer Community Forum|An online peer support forum with other CSOs. Members of the forum post questions or comments to weekly peer-led discussions and receive responses and feedback from other CSO forum members. Members typically express concerns regarding their IP's wellbeing and ask other members to share any strategies they have employed when dealing with their IPs. Interactions typically, are based either in 12-Step strategies members have learned (usually through Al-Anon or Nar-Anon Family Groups or Family Training Workshops provided by treatment programs) or in CRAFT skills learned (usually from treatment programs or other We The Village members). A staff member from We The Village monitors forum interactions to ensure members are interacting respectfully.
223663531|NCT03457779|DIETARY_SUPPLEMENT|Glucose|"The first 4 patients enrolled on trial will undergo the research core biopsies of their TNBC without the 13C glucose infusion; these samples will serve as control tissue that will be processed identically to the tissues obtained from patients who received the glucose isotope.~The following 12 patients will receive 6 grams (g) of \[1,2-13C\] glucose as an IV"
223663532|NCT03954340|DEVICE|iRemember Neurofeedback (NFB)|"Neurofeedback (NFB) is a treatment technique based on learning with operant conditioning, in which a feedback (or a reward) is given in proportion with the desired physiological activity in order to improve cognition and/or behavior. This research will focus on EEG-NF where electrical activity measured with EEG serves as the physiological activity to be influenced.~EEG-NFB has been successfully used as a clinical tool for over 40 years treating various disorders from Autism , ADHD , Epilepsy , OCD and depression Electroencephalography (EEG) equipment is used to measure the electrical activity representing the neuronal activity of different parts of the brain.~During the treatment, electrode(s) are placed in predetermined location. Audio and visual rewards are given when the activity is measured to be within the desired frequency range."
223769975|NCT04978038|DRUG|Prevnar13|Pfizer Prevnar-13 pneumococcal vaccine 0.5ml dose administered intramuscularly
223663533|NCT03199443|DIAGNOSTIC_TEST|EMG pelvic floor|EMG activity during tined lead test procedures will be monitored and the response on needle stimulation will be evaluated
223663534|NCT05962567|OTHER|Non surgical periodontal therapy|scaling and subgingival debridement
223769976|NCT03120650|OTHER|Scalp acupuncture|Acupoint selection: Shenting (DU24; Baihui (DU20; and upper 1/5 and middle 2/5 in the contralateral motor area (upper: 0.5 cm posterior to the midpoint of the front and rear midline; middle 2/5: intersection between the eyebrow line and the leading edge of the temple hairline.
223769977|NCT03120650|OTHER|Conventional rehabilitation|Rehabilitation plans will be made according to the Guidelines for Stroke Rehabilitation in China (Cerebrovascular Disease Association and the Neurological Rehabilitation Association of Neurology Branch of the Chinese Medical Association, 2012), including physical therapy and occupational therapy.
223663535|NCT01022398|DRUG|cholecalciferol/placebo|10,000 IU by mouth weekly for 6 months
223663536|NCT02651909|OTHER|blood sampling|blood sampling for TEG analysis, Thrombin time, thrombin generation, PT with neoplastine, ecarin chromogenic assay, anti-factor Xa (rivaroxaban assay
223663537|NCT05330910|PROCEDURE|Laparoscopic sleeve gastrectomy with concomitant hiatal hernia repair arm|Surgical technique will be standardized and will be performed by the study team. The bougie size for the LSG will be 40Fr, and a standard 5-port LSG will be performed. Standard protocolized postoperative recovery for all bariatric patients will be employed, including liquid diet with vitamins for the first 2 weeks postoperatively, followed by introduction of solid foods after. A hiatal dissection will also be performed during initial surgery, followed by a cruroplasty with Ethibon 0 sutures, in an interrupted manner.
223663538|NCT05330910|PROCEDURE|Laparoscopic sleeve gastrectomy arm|Surgical technique will be standardized and will be performed by the study team. The bougie size for the LSG will be 40Fr, and a standard 5-port LSG will be performed. Standard protocolized postoperative recovery for all bariatric patients will be employed, including liquid diet with vitamins for the first 2 weeks postoperatively, followed by introduction of solid foods after.
223663539|NCT04301310|DRUG|BMS-986235 (Treatment A)|Specified dose on specified days
223663540|NCT04301310|DRUG|Rifampin (Treatment B)|Specified dose on specified days
223663541|NCT03848299|OTHER|Experimental: Single Arm|"All participants will have to consume the same standardized breakfasts from the second to the seventh day, except the ones that are intolerant or allergic to lactose or/and gluten. In those cases, they will follow an adapted diet for their intolerance or allergies.~Day 2 and 3: 110 g white bread.~Day 4 and 5 : 110 g white bread and 30 g butter or 55 g white bread, 50 g dark chocolate for lactose intolerant.~Day 6 and 7: Glucose drink (50g).~The bread will be replaced by gluten-free bread for gluten intolerant participants."
223769978|NCT05494255|OTHER|Recruitment maneuver|In Group RM (intervention group) after skin closure, mechanical ventilation settings will be set to FiO2:100%, I:E=1:1, respiratory rate: 6, and then tidal volume will be increased gradually by 150 ml until reaching a plato pressure of 30 mmHg. After 3 breaths in this state, RM will be considered accomplished. LUS evaluation will be made just before and after the RM.
223769979|NCT00673452|DRUG|duloxetine hydrochloride|60-120 mg, oral, every day, 12 weeks (acute blinded phase followed by a 12 week blinded continuation phase).
223769980|NCT00673452|DRUG|placebo|oral, daily, 12 weeks (acute blinded phase followed by 12 weeks of blinded duloxetine treatment)
223769981|NCT00813124|DRUG|Fludarabine|40 mg/m\^2 by vein over 60 minutes on Day -5 through Day -2.
224243415|NCT00522613|BEHAVIORAL|Recovery Group Project|Recovery Group Workbook \& Group Sessions
223663542|NCT03717428|DEVICE|Daily Weighing Group|The Experimental group will weigh themselves everyday
223663543|NCT03717428|DEVICE|Control group|This group will be weighed and measured at the beginning and end of the study and will not be weighing themselves daily
223663544|NCT00969982|DRUG|mifepristone+misoprostol|single dose of 200 mg mifepristone followed 24 hours later by 800 mcg misoprostol administered buccally and repeated every 3 hours for a maximum of 5 doses per 24 hours up to 48 hours.
223663545|NCT00969982|DRUG|misoprostol+placebo|placebo resembling mifepristone followed 24 hours later by 800 mcg buccal misoprostol repeated every 3 hours for a maximum of 5 doses per 24 hours up to 48 hours.
223663546|NCT00322985|DRUG|Lenalidomide|25 mg/day, orally for 21 days with 7 days rest (28 day cycle). Dosing will be in the morning at approximately the same time each day.
223769982|NCT00813124|DRUG|Busulfan|Busulfan administered at the dose calculated to achieve an area under curve (AUC) of 4000 µMol-min + 12% based on the pharmacokinetic studies (days -5, -4, -3, and -2).
223769983|NCT00813124|DRUG|Thymoglobulin|2.5 mg/kg by vein over about 4-6 hours on Day -3 through Day -1.
224243416|NCT04989036|PROCEDURE|pulpotomy|Pulpotomy refers to the removal of the entire coronal pulp to the level of the root canal orifice(s) or as much as 2-3 mm apical to the orifices. Pulpotomy has indications similar to those of a partial pulpotomy except that the pulp in question is likely to have more extensive inflammation. Since pulpal inflammation is unlikely to extend past the canal orifices, pulpotomy is similar to a partial pulpotomy except that the entire mass of coronal pulp tissue is removed
224243417|NCT02845258|PROCEDURE|Pancreatic pseudocyst drainage with a plastic or self-expandable metallic stent (SEMS)|"Pancreatic pseudocyst drainage with a plastic or self-expandable metallic stent (SEMS):~This procedure is to be regarded as a clinical routine procedure since a couple of years back. The type of stent (material? length? thickness?), the cyst appearance (large? infected? cyst wall thickness?) and the type of access (transgastric? transduodenal?) may however vary from patient to patient.~In this study we perform EUS-drainage using different types of equipment on a wide range of pancreatic pseudocysts of different appearance and character. All procedures are performed as recommended. The very aim of the study is to investigate which technique and Equipment is to be preferred in different scenarios."
223663547|NCT00862420|DRUG|clopidogrel (SR25990)|oral administration (tablets)
223769984|NCT00813124|DRUG|Azacitidine|Start cycles of 32 mg/m\^2 daily as an injection under the skin once a day over 5 days in a row, starting about 5 weeks after the transplant. This may be repeated once a month for up to 4 months after the transplant.
224243418|NCT01195259|DRUG|allocation of treatment with metformin or rosiglitazone|Subjects from ADOPT that are included in this meta-analysis were randomly allocated to receive metformin or rosiglitazone. Subjects from RECORD that are included in this meta-analysis were taking one of three sulfonylureas (glibenclamide, gliclazide or glimepiride) and were randomly allocated metformin or rosiglitazone to use as add-on treament to background sulfonylurea.
223663548|NCT00862420|DRUG|ticlopidine|oral administration (tablets)
223769985|NCT00813124|PROCEDURE|Stem Cell Transplant|Stem cell infusion on day 0 administered by vein after collected from donor.
223769986|NCT00365326|BIOLOGICAL|Catheter-based intracoronary injection|This Phase I single arm clinical study, was designed to assess the safety and feasibility of a dose escalating intracoronary infusion of autologous bone marrow (BM)-derived CD133+ stem cell therapy to the patients with chronic total occlusion (CTO) and ischemia. Nine patients were received CD133+ cells into epicardial vessels supplying collateral flow to areas of viable ischemic myocardium in the distribution of the CTO.
223769987|NCT03262272|DEVICE|VIE A Hemodialyzer|polysulfon membrane coated with vitamin E
224243419|NCT03167671|DEVICE|AposTherapy|AposTherapy® is a home-based exercise program utilizing footwear that causes exercise with normal daily activity
223663549|NCT05277948|OTHER|active thumbtack needle|"The following 12 acupoints including conception vessel (CV) 4, CV3, bilateral ovary acupoints, bilateral spleen (SP) 6, bilateral stomach (ST) 36, bilateral bladder (BL) 23 and bilateral EX-B7 will be used. Eight points of CV4, CV3, SP6, ST36 and BL23 were treated by the sterile thumbtack needle for single use (Hangzhou Zhuomai Medical Technology Co., LTD., model: ZM2-6YDL), and four points of bilateral ovary acupoints and bilateral EX-B7 were treated by disposable sterile electro-thumbtack needle (Hangzhou Zhuomai Medical Technology Co., LTD., model: ZM3-ZY).~The patients were receive a treatment of 2 menstrual cycles"
223663550|NCT05277948|OTHER|sham thumbtack needle|"The following 12 acupoints including conception vessel (CV) 4, CV3, bilateral ovary acupoints, bilateral spleen (SP) 6, bilateral stomach (ST) 36, bilateral bladder (BL) 23 and bilateral EX-B7 will be used. Eight points of CV4, CV3, SP6, ST36 and BL23 were treated by the sterile sham thumbtack needle for single use (Hangzhou Zhuomai Medical Technology Co., LTD., model: ZM2-6YDL), and four points of bilateral ovary acupoints and bilateral EX-B7 were treated by disposable sterile sham electro-thumbtack needle (Hangzhou Zhuomai Medical Technology Co., LTD., model: ZM3-ZY).~The patients were receive a treatment of 2 menstrual cycles"
223663551|NCT02404090|RADIATION|CT-osteoarbsorptiometry|Conventional CT-scan analyzed by means of a specific tool (Analyze, Mayo Clinic).
223663552|NCT04059536|DEVICE|Roxwood Anchoring Catheters|Anchoring catheters
223663553|NCT04059536|DRUG|Acetylsalicylic Acid|Oral Tablet
223663554|NCT04059536|DRUG|Heparin|Intravenous Injection
223663555|NCT00640224|DRUG|rosiglitazone|4 mg daily for 6 months
223663556|NCT00640224|DRUG|drospirenone/ethinyl estradiol|1 tab (3mg/30mcg) daily for 6 months
223663557|NCT02535156|DRUG|Risperidone|1 mg Risperidone
223663558|NCT02535156|DRUG|Placebo|Lactose Placebo
223663559|NCT03613142|PROCEDURE|Double tract anatomosis|After the proximal gastrectomy, the purse-string suture is tied at the esophagus stump, and the anvil head is inserted into the esophagus stump using an anvil clamp. A Roux-en-Y esophagojejunostomy (E-stomy) is performed by intracorporeal anastomosis with a circular stapler, and the jejunal stump is closed with a linear stapler. Next, side-to-side gastrojejunostomy (G-stomy), 15 cm below the E-stomy, is performed using 2 linear staplers. Finally, end-to-side jejunojejunostomy (J-stomy), 20 cm below the G-stomy, is performed by 2 linear staplers.
223663560|NCT03613142|PROCEDURE|Esophagogastrostomy|After the proximal gastrectomy, the purse-string suture is tied at the esophagus stump, and the anvil head is inserted into the esophagus stump using an anvil clamp. Next, end-to-end or side to end esophagogastrostomy is performed with a circular stapler.
223663561|NCT00015834|DRUG|imatinib mesylate|Given PO
224243420|NCT03167671|OTHER|Traditional Physical Therapy|Up to 20 sessions of traditional physical therapy
224243421|NCT03917771|OTHER|Early lymphedema detection|Face-to-face consultation in Rehabilitation for early detection of lymphedema after surgery (1,6,12 months). Lower Limb measurement and care education
223663562|NCT00015834|DRUG|cytarabine|Given IV
223663563|NCT01331213|DRUG|Pregabalin|FDA approved medication (capsules) at 200mg dose.
224243422|NCT03917771|OTHER|Usual follow-up|Usual follow-up carried out in GO consultation
223663564|NCT01331213|DRUG|Placebo|Placebo capsules
223663565|NCT02011724|DEVICE|Apligraf|
223663566|NCT04442035|BEHAVIORAL|5-element music therapy|participants were treated by TCM five-phase music therapy for not less than 30 minutes per day, and group music therapy was performed every three weeks. In addition, the therapeutic schedule is composed of treatment time (1pm-2pm, 9pm-11pm), frequency treatment (two times a day), intervention (10-15 minutes in the afternoon, 30 minutes in the evening) and content (individuals: dialectical selection of music; groups: community singing, every three weeks).
223663567|NCT01343381|DRUG|Hepalean Heparin|400 units per kilogram bolus prior to initiation of CPB
223663568|NCT01343381|DRUG|PPC Heparin|400 unit per kilogram bolus prior to initiation of CPB
223663569|NCT04586387|DEVICE|intermittent theta burst stimulation (iTBS) with sham and then active stimulation over bicep muscle|repetitive non-invasive brain stimulation protocol which feels like many quick, light taps on your head
223663570|NCT04586387|DEVICE|intermittent theta burst stimulation (iTBS) with sham and then active stimulation over finger muscle|repetitive non-invasive brain stimulation protocol which feels like many quick, light taps on your head
223663571|NCT05981781|PROCEDURE|ultrasound guided peng block in paediatric hip surgery|"On the supine position, under strict aseptic technique, a linear, high-frequency transducer (5-13 MHz) of a Sonosite (M-Turbo; Sonosite Inc, Bothell, W, USA) portable US machine will be placed in the transverse plane along the anterior inferior iliac spine (AIIS) to identify the iliopsoas muscle, femoral artery, and femoral nerve. The probe will be then rotated, and aligned with the pubic ramus to visualize the AIIS, iliopubic eminence (IPE), femoral artery, psoas muscle, and the superior pubic ramus.~Under direct visualization, a needle will be advanced in-plane, lateral to medial between the psoas tendon and pubic ramus until the needle contacts the IPE. The needle will be slightly withdrawn, and following negative aspiration, 0.5 ml/kg of bupivacaine 0.25% will be injected."
223769988|NCT03262272|DEVICE|Rexsys 27H hemodialyzer|polyethersulfon membrane with large surface area : 2,7m²
223769989|NCT03262272|DEVICE|Leoceed 21HX hemodialyzer|polyslfon membrane with gamma sterilization
223769990|NCT03262272|DEVICE|Polypure 22S+ hemodialyzer|polysulfon membrane with steam sterilization
224243423|NCT03556566|BIOLOGICAL|Tableted vaccine (V3-OVA) containing ovarian cancer antigens|One pill of V3-OVA per day for three months
223769991|NCT06027827|PROCEDURE|Addition of fusion device lateral bone graft|In addition to the central bone graft of the fusion cage, the lateral bone graft of the fusion cage was added.
223769992|NCT04929561|BEHAVIORAL|Video-conferencing group|No intervention
224243424|NCT05245643|DEVICE|Abbott Infinity Deep Brain Stimulation System|DBS is robot-assisted, with 3D intraoperative imaging control, under general anesthesia. Target is defined thanks to preoperative dedicated MRI with 2 independent experts' assessment.
224243425|NCT00002012|DRUG|Interferon alfa-n3|
224243426|NCT01740609|DRUG|Placebo|Placebo
224243427|NCT01740609|BIOLOGICAL|PF-06342674 Dose A|Single SC Dose
223663572|NCT05981781|PROCEDURE|ultrasound guided caudal epidural block in paediatric hip surgery|On lateral decubitus position, under strict aseptic technique, the sacral hiatus will be visualized at the level of the sacral cornua by employing a linear, high-frequency transducer (5-13 MHz) of a Sonosite (M-Turbo; Sonosite Inc, Bothell, W, USA) portable US machine will be placed transversely at the midline to obtain a transverse view of the two cornua, sacrococcygeal ligament, sacral bone, and sacral hiatus. At this level, the ultrasound transducer will be rotated to 90 degree to obtain longitudinal views of the sacrococcygeal ligament and sacral hiatus and subsequently placed between the two cornua. A needle will be advanced toward the upper third of the sacrococcygeal ligament. The needle advancement will be terminated immediately after penetrating the sacrococcygeal ligament. (17) At this level, after confirming absence of blood or cerebrospinal fluid on aspiration, bupivacaine 0.25% (0.5 mL/kg) will be injected over 1 minute while observing an ultrasound longitudinal image.
223663573|NCT04015375|DRUG|Dapsone gel 7.5% (Torrent Pharmaceuticals Ltd)|Topical gel
223663574|NCT04015375|DRUG|ACZONE® (dapsone) gel, 7.5% (Allergan, INC.)|Topical gel
223663575|NCT04015375|OTHER|Placebo for Dapsone gel 7.5% (Torrent Pharmaceuticals Ltd)|Topical gel
223663576|NCT02379130|BEHAVIORAL|Family Nurture Intervention|The intervention begins with Block play. The child will be asked to play blocks with the mother during a eight minute video acquisition which will be coded for mother child interaction analysis. At the end of the video period the child will sit on the mother's lap. The pair will be asked to talk and play with each other as they customarily do. If the child becomes restless the mother will be coached by the nurture specialist to further engage the child with soothing and calming; the mother will be helped to bring the child back into a calm state through sustained physical contact, comfort touch, soothing words, and eye contact. The mother will also be helped to verbally express her feelings toward her child and to tolerate her child's full range of feeling.
223663577|NCT02379130|BEHAVIORAL|Play and Nutrition Intervention|The intervention begins with Block play. The child will be asked to play blocks with the mother during a eight minute video acquisition which will be coded for mother child interaction analysis. At the end of the video period, the child and mother will play nutrition-focused games using the Healthy Habits for Life program designed by Michelle Obama.
223663578|NCT00718588|DRUG|MTRX1011A|Subcutaneous and intravenous single and repeating dose
223663579|NCT04356261|BEHAVIORAL|Gamified Personalized Normative Feedback|Each week, all players will answer 3 questions of interest about first-year students' attitudes and behaviors (e.g., drinking, partying, exercising, studying, dorm life, etc.) generated by the student players. They will also guess how the typical same-sex student at their University answered the same questions and wager points on how close to the correct answer (group norm) each of their guesses is. Further, they will rate (e.g., thumbs up/thumbs down) the reported behaviors of other players and, then, submit and vote on questions for subsequent rounds. At the end of each week, players will receive enhanced personalized normative feedback feedback on two of the three questions, and receive feedback on how other students rated the answer they reported (preferred-sex injunctive norms).
223769993|NCT03282084|DIAGNOSTIC_TEST|EGD with biopsy|Stop PPI and schedule for EGD with biopsy and Wireless pH capsule testing for 7-10 days later. Consider gastric emptying scan or high resolution esophageal manometry
223769994|NCT03282084|DIAGNOSTIC_TEST|EGD and impedance-pH study on PPI|Continue PPI and schedule EGD and Impedance-pH study on PPI. Consider gastric emptying scan or high resolution esophageal manometry
223769995|NCT01593618|BEHAVIORAL|UMFollowUp|Web-based internet resource for self-reported treatment summaries and psychosocial and physical well-being.
223769996|NCT01593618|OTHER|Standard of Care|Patients will receive information regarding their diagnosis, treatments, and ongoing health needs from their provider, but will not be provided access to the website.
223769997|NCT02211833|DRUG|BI 2536|
223769998|NCT02211833|DRUG|Pemetrexed|
223769999|NCT04166305|GENETIC|Genetic study for SCN1A c.3184 A/G and CCL2-2518G>A polymorphism:|"DNA analysis: Genomic DNA will be extracted from EDTA-anticoagulated peripheral blood (QIAamp DNA Blood mini kit,QIAGEN).~Genotyping of SCN1A c.3184 A/G(rs2298771) polymorphism"
223770000|NCT06249308|OTHER|Blood collection|Blood sample will be collected
223770001|NCT01248117|DRUG|ranibizumab 2.0mg|Monthly, intravitreal injection 0.05ml
223770002|NCT00821626|DEVICE|BD Directigen EZ Flu A+B|Naso-pharyngeal swab and rapid flu test
223770003|NCT00821626|OTHER|Control|No rapid flu test
223770004|NCT01271543|DEVICE|Endotracheal Intubation|General anesthesia will be induced with fentanyl 1-2 mcg/kg, 2-3 mg/kg propofol and maintained with 50% air /50% oxygen and isoflurane. Neuromuscular blockade will be obtained with rocuronium 0.5 mg/kg. Laryngoscopy will be performed with Shikani optical stylet (SOS) (one size) or MacIntosh laryngoscope blade size 3 for women and size 4 for men. Endotracheal intubation will be performed with an endotracheal tube of internal diameter of 7.0 mm l for female patients and 8 mm for male in both groups. Noninvasive blood pressure and heart rate will be recorded preinduction, preintubation, and every min for the first 5 min after successful intubation. The patients will be questioned post-operatively about symptoms of a sore throat, hoarseness, dysphonia or dysphagia in the Post Anesthesia Care Unit and again 24 hours after surgery.
223770005|NCT02268097|PROCEDURE|Patellar resurfacing with freehand technique|Preparing patellar resurfacing during total knee arthroplasty with freehand
223770006|NCT02268097|PROCEDURE|Patellar resurfacing with resection guide technique|Preparing patellar resurfacing during total knee arthroplasty with a resection guide
223770007|NCT04981041|DRUG|Prasugrel or Ticagrelor|Escalated antiplatelet therapy with a potent P2Y12- inhibitor for one month in patients with atrial fibrillation and indication for treatment non-vitamin K antagonist oral anticoagulants (NOACs)
223770008|NCT04981041|DRUG|Clopidogrel|Clopidogrel and NOAC
223770009|NCT00691236|DRUG|Zoledronic acid|4mg IV 3 weekly for 6 doses
223770010|NCT00691236|DRUG|Standard chemotherapy|Adriamycin + Cisplatinum and Ifosfamide
223770011|NCT02305303|PROCEDURE|Diary|A diary written prospectively during the ICU stay by the staff and relatives
223770012|NCT01374113|DRUG|50mg safinamide|50 mg safinamide on Day 1
224243428|NCT01740609|BIOLOGICAL|PF-06342674 Dose B|Single SC Dose
224243429|NCT01740609|BIOLOGICAL|PF-06342674 Dose C|Single SC Dose
224243430|NCT01740609|BIOLOGICAL|PF-06342674 Dose D|Single SC Dose
224243431|NCT01740609|BIOLOGICAL|PF-06342674 Dose E|Single SC Dose
224243432|NCT01740609|BIOLOGICAL|PF-06342674 Dose F|Single IV Dose
223663580|NCT03262311|OTHER|Hypoxia marker|Single oral dose of pimonidazole 500 mg/m2
223663581|NCT02937584|DRUG|GP MDI (PT001) 14.4 μg|Glycopyrronium
223663582|NCT02937584|DRUG|FF MDI (PT005) 9.6 μg|Formoterol Fumarate
223663583|NCT05987995|PROCEDURE|Endometrial injury|A pipelle endometrial sampler was introduced gently into the uterine cavity. The inner piston of the catheter was withdrawn to create suction, and injury (scratching) of the endometrium was done by moving the pipelle catheter up and down within the uterine cavity
223663584|NCT00838032|DRUG|Quetiapine fumarate|Quetiapine fumarate should be initiated on Day 1 and titrated to at least 600 mg/day before Day 7 according to clinical experience and prescribe information. After Day 7, the dose of quetiapine fumarate should be adjusted between 600 mg/day to 750 mg/day at the discretion of the investigator.
223663585|NCT00838032|DRUG|Haloperidol|Haloperidol should be initiated with the dose range from 5 mg/day to 15 mg/day from Day 1 to Day 5 (using injection) according to the clinical experience and prescribe information. After Day 7, the dose of haloperidol should be adjusted between 8 mg/day to 20 mg/day (change from injection to oral formulation between Day 6 to Day 7) at the discretion of the investigator.
223663586|NCT02274909|OTHER|TRAINING PROGRAM|Sixty healthy elderly women were randomly divided into 3 groups: Pilates group (PG), PNF group (PNFG) and Control group (CG). Pilates and PNF groups underwent one-month training program with Pilates and PNF methods, respectively. CG received no intervention along the one month.
223663587|NCT01855646|OTHER|Structured Sign Out Form|
223663588|NCT00003021|DRUG|bizelesin|
223663589|NCT01521312|DRUG|saxagliptin|5mg a day for 11-14 weeks
223663590|NCT01521312|OTHER|placebo pill|one tablet a day for 11-14 weeks
223663591|NCT04724122|OTHER|Observational / Assessment only|The results of this assessment will determine the needs for future interventions
223663592|NCT02646241|PROCEDURE|unroofing biopsy|Unroofing biopsy menas that the mucosa is resected with endoscopic mucosal resection and biopsies are done repeatedly for the exposed tumor with a conventional forcep. It will be performed for the patients with a suspected upper gastrointestinal subepithelial tumor after EUS-FNB. After unroofing biopsy, the final histopathological result will be used to determine diagnostic accuracy.
223663593|NCT02646241|PROCEDURE|EUS-FNB(endoscopic ultrasonography guided fine needle biopsy)|EUS-FNB will be performed for the same patients who have a gastrointestinal subepithelail tumor before unroofing biopsy. EUS-FNB is called when the tissue is obtained by puncutre of a tumor, the tissue whithin the lumen of the fine needle being detached by rotatin, and the needle withdrawn. The pathological result will be also used to compare diagnostic accuracy between EUS-FNB \& unroofing biopsy.
224243433|NCT01740609|BIOLOGICAL|PF-06342674 Dose G|Single SC Dose
224243434|NCT01740609|BIOLOGICAL|PF-06342674 Dose H|Single IV Dose
223663594|NCT02575027|RADIATION|Palliative Radiation Therapy|Undergo 4pi palliative radiotherapy
223663595|NCT02575027|OTHER|Questionnaire Administration|Ancillary studies
223663596|NCT02575027|RADIATION|Radiation Therapy Treatment Planning and Simulation|Undergo 4pi radiation simulation and planning
223663597|NCT02535390|BEHAVIORAL|Action based cognitive remediation|This is a novel form of cognitive remediation in which participants engage in simulated real world tasks in groups and receive therapist feedback in addition to receiving standard cognitive remediation.
223663598|NCT02535390|BEHAVIORAL|Cognitive remediation|Cognitive remediation engages participants in computerized exercises meant to improve cognitive functions and provides therapist feedback for how these improvements manifest in everyday life.
223663599|NCT04721080|OTHER|Functional Outcome Measurements|Dyspnea Exercise capacity Quality of life assessment
223663600|NCT04143464|BEHAVIORAL|Kyphosis-specific exercise class and kyphosis-specific exercise videos|"The kyphosis-specific exercise is based on the protocol published by Katzman and team in 2016. It includes warm-up, back muscle strength training, spine mobility training, spine alignment training, and stretching. The class will last around 60 minutes.~The exercise videos have the same content as the kyphosis-specific exercise class. The participants are asked to practice everyday at home following the videos."
223663601|NCT01755000|PROCEDURE|USCOM scan|
223663602|NCT01755000|PROCEDURE|Fluid Bolus|
223663603|NCT03725228|DRUG|Magnesium Sulfate|Magnesium Sulfate 15mg/kg/h
224243435|NCT01740609|BIOLOGICAL|PF-06342674 Dose I|Single SC Dose
224243436|NCT01740609|BIOLOGICAL|PF-06342674 Dose J|Single IV Dose
224243437|NCT01623128|BEHAVIORAL|Prenatal video|Participants are randomized to view either the intervention video or a sham video.
224243438|NCT01245790|DRUG|fostamatinib|Oral tablets, single dose
224243439|NCT02920996|DRUG|Merestinib|Merestinib is a potent and selective type II MET/RON kinase inhibitor with the ability to achieve inhibition of MET activity both in vitro and in vivo.
224243440|NCT01471366|DIETARY_SUPPLEMENT|Frozen capsule|Two frozen fish oil capsules (300 mg EPA/DHA per capsule) by mouth three times daily with 8 ounces of water without food or dairy products.
224243441|NCT01471366|DIETARY_SUPPLEMENT|Capsule with food|Two room temperature fish oil capsules (300 mg EPA/DHA per capsule) by mouth three times daily with 8 ounces of water with food but no dairy products
224243442|NCT01471366|DIETARY_SUPPLEMENT|Capsule without food|Two room temperature fish oil capsules (300 mg EPA/DHA per capsule) by mouth three times daily with 8 ounces of water with no food or dairy products
223663604|NCT03725228|DRUG|Lidocaine|Lidocaine 1,5mg/kg/h
223663605|NCT02323607|DRUG|Pacritinib|Given PO
223663606|NCT02323607|DRUG|Cytarabine|Given IV
223663607|NCT02323607|DRUG|Daunorubicin Hydrochloride|Given IV
223663608|NCT02323607|DRUG|Decitabine|Given IV
223663609|NCT02323607|OTHER|Laboratory Biomarker Analysis|Correlative studies
223663610|NCT02323607|OTHER|Pharmacological Study|Correlative studies
223663611|NCT00028652|BIOLOGICAL|interleukin-12 gene|
223663612|NCT00280384|DRUG|E2014 (Botulinum toxin type B)|A single-dose injection solution containing 20 units (U), 100 U, or 500 U/ 0.2 milliliters (mL) of E2014 was administered to extensor digitorum brevis (EDB) muscle in the left lower limb to Japanese and Caucasian participants. Duration of treatment lasted for 12 weeks: from Day -1 to Week 12. Participants were hospitalized from a day before study treatment to Day 8 for 9 nights and 10 days, and visited at the medical institution on Days 10 and 14, and Weeks 4 and 12.
223663613|NCT00280384|DRUG|E2014 (Botulinum toxin type B) Placebo|A single-dose injection solution of E2014 Placebo was administered to extensor digitorum brevis (EDB) muscle in the left lower limb to Japanese and Caucasian participants. Duration of treatment lasted for 12 weeks: from Day -1 to Week 12. Participants were hospitalized from a day before study treatment to Day 8 for 9 nights and 10 days, and visited at the medical institution on Days 10 and 14, and Weeks 4 and 12.
223663614|NCT00426452|DRUG|Vatalinib|
223663615|NCT04229407|DIETARY_SUPPLEMENT|Dietary supplement|MRI eligibility evaluation Dietary supplement drink powder dissolved in 150 c.c. warm water oral intake twice daily at every morning and night (30 minutes after exercise if do exercise) for 12 weeks subjects will be instructed to do 45-minute exercise once a week following the training program of the study trainer at gym, and 30-minute exercise (per exercise manual) at least twice a week at home.
223663616|NCT04229407|DIETARY_SUPPLEMENT|vitamin B|MRI eligibility evaluation vitamin B drink powder dissolved in 150 c.c. warm water oral intake twice daily at every morning and night (30 minutes after exercise if do exercise)for 12 weeks subjects will be instructed to do 45-minute exercise once a week following the training program of the study trainer at gym, and 30-minute exercise (per exercise manual) at least twice a week at home.
223663617|NCT00217659|DRUG|anastrozole|
223663618|NCT00217659|DRUG|goserelin acetate|
223663619|NCT05454917|DEVICE|Measure of ventilation/perfusion (V/Q) mismatch using Beacon ALPE (Automatic Lung Paramether Estimator)|Evaluation of intraoperative V/Q mismatch using the Beacon ALPE during anesthesia.
223663620|NCT00694148|DRUG|NT 201|"A Botulinum neurotoxin type A, free of complexing proteins~Detailed described in study protocol"
223663621|NCT04090801|DRUG|Topical minoxidil 5% in 90% ethanol and 5% propylene glycol|
224243443|NCT01471366|DIETARY_SUPPLEMENT|Capsule with milk|Two room temperature fish oil capsules (300 mg EPA/DHA per capsule) by mouth three times daily with 8 ounces of milk with no food or additional dairy products
224243444|NCT00216502|DRUG|galantamine hydrobromide|
224243445|NCT00912353|DRUG|AZD7268|Single Oral
224243446|NCT00912353|DRUG|Placebo|Single Oral
224243447|NCT06159803|BEHAVIORAL|Qualitative Interview|One-to-one semi-structured interviews and Think Aloud interviews
223663622|NCT04090801|DRUG|Topical minoxidil 5% in pure ethanol alone|The treatment will be continued twice daily.for six months with regular visits at 3 months intervals.
223663623|NCT04090801|OTHER|Placebo (Ethanol)|The treatment will be continued twice daily.for six months with regular visits at 3 months intervals.
223663624|NCT00299429|PROCEDURE|Stenting and minimally invasive bypass surgery|
223663625|NCT00299429|PROCEDURE|PCI with DES|PCI with DES
223663626|NCT02628080|DRUG|Atovaquone|Atovaquone has an EU marketing authorisation (held by Glaxo Wellcome UK Ltd) and is indicated for acute treatment of mild to moderate Pneumocystis pneumonia (PCP). It is also used in combination with proguanil for malaria prophylaxis.
223663627|NCT04075734|BEHAVIORAL|Managing Your Health: Self-Management + Peer Mentoring|"The online educational component consists of 5 self-management educational modules:~(1) Understanding Your Survivorship Care Plan; (2) Managing Your Healthcare; (3) Family and Significant Other Involvement in Your Healthcare; (4) Emotions about Your Health and Follow-Up Care; (5) Staying Healthy.~Participants will be matched with a peer mentor and complete a total of six calls. The first call is to build a rapport and identify the participant's self-management strengths, weaknesses, and goals. The next five calls align with the topic of each module, which the mentee is expected to complete prior to their scheduled call."
223663628|NCT06520644|DEVICE|Wii-based interactive training program|include step basic, hula hoop, table tilt, jogging, jumping, single limb extension. Single limb extension
223770013|NCT05256433|OTHER|Group-A|IASTM Certified IASTM practitioner will be performing the technique with emollient lubricant in which brushing and sweeping stroke will be applied for plantar fascia and fanning and sweeping stroke technique for calf muscles for the duration of 10 minutes to eliminate the inflammation. Active calf stretching and passive plantar fascia stretching will be performed for the correction of shortened tissue, and to prevent re-injury. The frequency stretching will be 5 repetitions for each with 10 seconds hold.
223770014|NCT05256433|OTHER|Group-B|Manual massage includes transverse friction massage for plantar fascia, flexor digitorum brevis, and deep massage for calf muscle for the duration of 10 minutes to eliminate the tightness and increase the blood flow. Active calf stretching and passive plantar fascia stretching will be performed for the correction of shortened tissue, and to prevent re-injury.
223770015|NCT00410696|DRUG|Filgrastim|5 mcg/kg/day sc from day +1 after transplantation to hemopoietic reconstitution
223770016|NCT00410696|DRUG|Pegfilgrastim|6 mg/day sc at day +1
223770017|NCT00079274|DRUG|irinotecan hydrochloride|Given IV
224243448|NCT01096290|DRUG|lubiprostone|24mcg BID, capsule, oral 30days
224243449|NCT01096290|DRUG|Matched placebo|Twice daily for 30days, oral
224243450|NCT00357448|BIOLOGICAL|denileukin diftitox|Given IP at 3 dose levels: 5mcg/kg of ONTAK, 15mcg/kg of ONTAK, or 25mcg/kg of ONTAK
224243451|NCT00357448|PROCEDURE|intraperitoneal administration|After completion of I.P. normal saline infusion, the I.P. catheter will be capped and patients will be turned/rotated for 1 hour to help facilitate I.P. bathing w/ONTAK; patients will be turned/rotated every 15 minutes in 4 different positions for a total of 1 hour
224243452|NCT00357448|OTHER|laboratory biomarker analysis|Correlative studies
224243453|NCT00357448|OTHER|enzyme-linked immunosorbent assay|Correlative studies
224243454|NCT00357448|OTHER|flow cytometry|Correlative studies
223770018|NCT00079274|DRUG|oxaliplatin|Given IV
223770019|NCT00079274|DRUG|leucovorin calcium|Given IV
223770020|NCT00079274|DRUG|fluorouracil|Given IV
223770021|NCT00079274|BIOLOGICAL|cetuximab|Given IV
224243455|NCT01402947|DRUG|Ciprofloxacin XR + MMX Placebo|MMX Mesalazine/mesalamine placebo dosed once-a-day (QD) orally for 3 days, then a single oral 500 mg dose of ciprofloxacin XR + a single oral dose of MMX Mesalazine/mesalamine placebo on day 4
224243456|NCT01402947|DRUG|MMX Mesalazine/mesalamine + Ciprofloxacin XR|MMX Mesalazine/mesalamine 4.8 g QD orally for 3 days, then a single oral 500 mg dose of ciprofloxacin XR + a single oral dose 4.8 g of MMX Mesalazine/mesalamine on day 4
224243457|NCT05697471|DRUG|Dienogest|Dienogest 2 mg per day
224243458|NCT05697471|DRUG|Danazol|Danzol 200MG per day
223663629|NCT06520644|OTHER|Traditional physical therapy program|Facilitation of balance reactions from standing position including; standing on balance board, standing on one leg, weights shifting from standing position and stoops and recover from standing,Facilitation of counterpoising mechanism through instructing the child to kick ball from standing position as well as catching and throwing ball with his hands,Gait training activities including: walking on balance board, walking using different obstacles (rolls, wedges, stepper) and walking up and down stairs,Facilitation of protective reaction from standing position by pushing the child in different directions.Facilitation of rising mechanism through changing position e.g.: from lying to standing and from sitting to standing,Strengthening exercises for back and abdominal muscles as well as upper and lower limbs,Jumping in place and jumping a board.
223663630|NCT04708249|DIETARY_SUPPLEMENT|D-chiroinositol|Supplementation with 600 mg of D-chiroinositol, two-times daily on an empty stomach, for 30 days.
223663631|NCT04380272|DIAGNOSTIC_TEST|The ROC analysis|The Brodsky clinical stage and ultrasonographic data of the participants will be matched, and the diagnostic value of the submental US in the classification of tonsil hypertrophy as non-obstructive and obstructive will be evaluated. A ROC analysis will be used to determine the optimal cut-off value.
223663632|NCT00749567|DRUG|Erlotinib|Erlotinib 150mg daily, continuously, until disease progression or the appearance of unacceptable toxicity
223663633|NCT00749567|DRUG|Bevacizumab|Bevacizumab (IV) 15 mgr/Kgr on day 1 every 3 weeks until disease progression or the appearance of unacceptable toxicity
223663634|NCT04113213|BEHAVIORAL|Lifestyle Prescription (LRx)|Lifestyle prescription, based on the UK WP10 medicinal prescription form. Includes advice and guidance regarding physical activity, diet, smoking and alcohol consumption.
223663635|NCT06412614|OTHER|disease phenotype|evaluation of SSc phenotypes
223663636|NCT04351789|OTHER|Psychoeducational intervention|"The written and verbal information provided at discharge to patients in the intervention arm will consist of:~An explanation of the normal recovery period after hospitalization due to COVID-19. What can the patient expect physically, psychologically and emotionally, and what coping mechanism might be appropriate Social support in the recovery period and how this can be used constructively. In case of worsening of symptoms - physically or psychologically, where can the patient get help after discharge from hospital.~These points are based on crisis psychology, enhancing the patients empowerment and self-management after discharge from hospital."
223663637|NCT03745599|DRUG|Diclofenac|All patients were instructed to take one capsule orally every 8 h and apply the spray (4 puffs to the pericoronitis area) every 4 h for 7 days, commencing immediately after the clinical examination.
223663638|NCT03745599|DRUG|Flurbiprofen|All patients were instructed to take one capsule orally every 8 h and apply the spray (4 puffs to the pericoronitis area) every 4 h for 7 days, commencing immediately after the clinical examination.
223663639|NCT03745599|DRUG|Benzydamine|All patients were instructed to take one capsule orally every 8 h and apply the spray (4 puffs to the pericoronitis area) every 4 h for 7 days, commencing immediately after the clinical examination.
223663640|NCT05541536|OTHER|Consultation meeting|Study team member will approach mothers \< 24 hrs (up to 5 min prior) of CRC approach for NRN trial. During the consultation meeting (5 minutes), the study team member will review the pamphlet and answer any questions. Visits will ideally occur in person. If the mother is not at bedside, 1 attempt will be made to reach the mother by phone in which case the pamphlet will be forwarded by mail.
223663641|NCT05541536|OTHER|Pamphlet|Study team member will distribute pamphlet to beside nurse to give to mother. The pamphlet provides information about Learning Health Care (LHC) and clinical research.
223663642|NCT05541536|OTHER|Usual Care|Study participants will not receive the general information pamphlet or consultation.
223663643|NCT04308967|OTHER|balance exercises|Three-stage progressive balance exercises will be applied.
223663644|NCT03615040|DRUG|MSTT1041A|"MSTT1041A (RO7187807; formerly made by Amgen \[AMG\] and referred to as AMG 282) is a novel biopharmaceutical that blocks signaling of interleukin (IL)-33, an inflammatory cytokine of the IL-1 family and member of the newly discovered alarmin class of molecules. IL-33 is released from airway epithelial cells in response to allergens, irritants, and infection. IL-33 release can trigger acute exacerbations in both asthma and COPD. MSTT1041A has the ability to block inflammation,prevent exacerbations, and improve lung function and quality of life.~Anti-ST2 is presented as sterile, clear, and colourless to slightly yellow liquid. Each sterile vial is filled with a 1 mL deliverable volume of 70 mg/mL. It is formulated with 15 mM sodium acetate, 9.0% (w/v) sucrose, 0.01% (w/v) polysorbate 20, pH 5.2."
223663645|NCT03615040|DRUG|Placebo|Placebo for Anti-ST2 (MSTT1041A) is formulated with 10 mM sodium acetate, 9.0% (w/v) sucrose, 0.004% (w/v) polysorbate 20, pH 5.2, and is supplied in an identical vial configuration.
223663646|NCT06174090|OTHER|Coronary bypass graft surgery video education|It includes information about surgical process and handling issues within the first few days of surgery.
223663647|NCT01776307|DRUG|BBI608|BBI608 is administered at 500 mg po bid continuously.
223663648|NCT01776307|DRUG|Panitumumab|Panitumumab will be administered IV on day 8 and 22 of each 28 day cycle at 6 mg/kg over 60 minutes.
223770022|NCT00079274|DRUG|Locally Directed Therapy|Patients determined to have mutated KRAS (or KRAS not evaluable) will be assigned to an event monitoring arm in which adjuvant therapy will be determined and assigned by the treating oncologist. The determination of the type of therapy, duration of treatment, and dose modification will be the responsibility of the treating oncologists.
223770023|NCT04454385|DIAGNOSTIC_TEST|Patients with well controlled asthma|"Patients with well controlled asthma~The following parameters are to be evaluated:~Blood eosinophils FeNO Findings on lung function test"
224243459|NCT03220867|DRUG|Risperidone: Xian Risperdal (test)|Participants will receive 1\*1 mg tablet of Xian Risperdal under fasting or fed condition.
223663649|NCT01776307|DRUG|Capecitabine|Capecitabine will be administered orally at 1000 mg/m2 bid daily on days 8-21 every three weeks.
223663650|NCT01776307|DRUG|Cetuximab|Cetuximab will be administered IV on day 5 at 400 mg/m2 intravenous infusion over 120 minutes as the initial dose, then weekly at 250mg/m2 over 60-minutes at subsequent cycles.
224243460|NCT03220867|DRUG|Risperidone: Gurabo Risperdal (reference)|Participants will receive 1\*1 mg tablet of Gurabo Risperdal under fasting or fed condition.
224243461|NCT00385684|DRUG|hydrocodone/APAP w placebo PRN|Hydrocodone/acetaminophen 2.5/167 mg per 5 ml liquid three times daily (TID). With liquid placebo available PRN.
224243462|NCT00385684|DRUG|hydrocodone/APAP|Participants judged as responders during Phase A continue the same dose of study medication (hydrocodone/acetaminophen 2.5/167 mg per 5 ml liquid TID). Otherwise, moved to a higher dose (hydrocodone/acetaminophen 5/500mg TID or the most appropriate formulary alternative). Participant can also receive up to 2 PRN administrations at the same dose levels as listed above, but not to exceed 2.5g of acetaminophen.
224243463|NCT00385684|DRUG|placebo with hydrocodone/APAP PRN|Liquid placebo PRN. Also available PRN is Hydrocodone/acetaminophen 2.5/167 mg per 5 ml liquid.
223663651|NCT02292069|DRUG|Amlodipine besylate/Atorvastatin calcium|Amlodipine besylate/Atorvastatin calcium 10/80 mg
223663652|NCT01105546|DRUG|recombinant activated factor VII|90 µg/kg/day i.v.
223663653|NCT01105546|DRUG|recombinant activated factor VII|treatment of bleeding episodes with 270 µg/kg (first/single dose) or 90 µg/kg i.v. every 2-3 hours until bleeding resolution
223663654|NCT02870322|BEHAVIORAL|Fruit and Vegetable CSA Prescription|Study Participants will collect and use fruit and vegetable CSA boxes given to them weekly for 10 weeks.
223663655|NCT02870322|BEHAVIORAL|Bikeshare Prescription|Study participants will use bikeshare for transportation and physical activity for 10 weeks
223663656|NCT03438370|OTHER|Three monthly ART supply at CAGs|Sites where three monthly ART supply will be provided at outreaches
223663657|NCT03438370|OTHER|Six monthly ART supply at outreaches|Sites where six monthly ART will supply will be provided at outreaches
223663658|NCT00017329|DRUG|bortezomib|
223663659|NCT02656225|DRUG|Ejiao compound|20ml,twice daily, orally after breakfast Duration:4 weeks
223663660|NCT02656225|DRUG|Niferex|one tablet,once daily, orally after breakfast Duration:4 weeks
223663661|NCT00845793|BEHAVIORAL|Nutritional guidance|The guidance will be performed using the food tray during the hospitalization and will consist of meeting the nutritionist and receiving brochures along with the meal tray focusing on constituents and elements of the diet. The served meals will consist of elements recommended for patients with T2DM (such as whole grains, low fat dairy products and canola oil).
223663662|NCT02462642|DIETARY_SUPPLEMENT|Brahmi|Brahmi extract - 225 mg filled in each hard gelatin capsule. Two such capsules per day, to be taken by the subjects for 12 weeks.
223663663|NCT02462642|OTHER|Placebo|Dry maize starch filled in identical hear gelatin capsule. Two such capsules will be taken by each subject per day for 12 weeks.
223770024|NCT02671123|PROCEDURE|Coronary PCI with OCT with Co Registration|Co-Registration is an online tool used to take measurements during a stent procedure ( PCI-percutaneous coronary intervention) as part of the OCT ( Optical Coherence Tomography intravascular system. Co Registration software may provide additional imaging details during stent implantation when using OCT.
223770025|NCT02671123|PROCEDURE|Coronary PCI with OCT without Co Registration|Coronary PCI will be performed using OCT ( Optical Coherence Tomography intravascular system) guidance without the Co Registration software tool enabled.
223770026|NCT02353481|OTHER|Heart Failure Management|
223770027|NCT05856292|OTHER|Teach Back|Standard cancer pain educational intervention enhanced with teach-back method
223770028|NCT05856292|OTHER|Placebo|Standard cancer pain educational intervention without enhancement
223770029|NCT06464939|DRUG|KH001|Applications of KH001 over a 1 or 2-week period, and application of placebo
224243464|NCT07003074|DRUG|TQB2102 for Injection|TQB2102 is a next-generation HER2 Antibody-Drug Conjugate drug proposed for patients with HER2 positive Recurrent/Metastatic Breast Cancer.
224243465|NCT07003074|DRUG|Docetaxel combined + Trastuzumab +Pertuzumab|Positive control.
223663664|NCT02462642|DIETARY_SUPPLEMENT|Brahmi|Brahmi Extract 225 mg filled in hard gelatin capsule. Two such capsules will be consumed by the subjects each day for 84 days.
223663665|NCT02462642|OTHER|Placebo|Placebo capsules - Dry starch filled in identical hard gelatin capsules
223663666|NCT02685059|DRUG|MEDI4736 (Anti PD-L1)|"MEDI4736 1.5g total i.v. every 4 weeks~As monotherapy for the first two weeks (0.75g absolute) (part 1) followed by:~MEDI4736 in combination with nab-paclitaxel 125 mg/m² every week for 12 weeks (part 2) followed by~MEDI4736 in combination with epirubicin 90mg/m² plus cyclophosphamide 600 mg/m² every 2 weeks for 4 cycles (part 3)."
223663667|NCT02685059|DRUG|Placebo|"Placebo i.v. every 4 weeks~As monotherapy for the first two weeks (0.75g absolute) (part 1) followed by:~Placebo in combination with nab-paclitaxel 125 mg/m² every week for 12 weeks (part 2) followed by~MEDI4736/Placebo in combination with epirubicin 90mg/m² plus cyclophosphamide 600 mg/m² every 2 weeks for 4 cycles (part 3)."
223663668|NCT02685059|DRUG|nab-Paclitaxel|nab-Paclitaxel 125 mg/m² weekly for 12 weeks
223663669|NCT02685059|DRUG|Epirubicin|Epirubicin 90 mg/m² 2-weekly for 8 weeks
223663670|NCT02685059|DRUG|Cyclophosphamide|Cyclophosphamide 600 mg/m² 2-weekly for 8 weeks
223663671|NCT04042090|DEVICE|Reducept, virtual reality|The VR serious game Reducept is a novel psychological VR intervention for treating chronic pain. It incorporates several psychological therapies into one application: hypnotherapy, mindfulness, ACT and EMDR. Reducept has been made in co-creation with patients, researchers, psychologists and developers and can be installed and played on a VR goggles. It consists of an education module and three games.
223663672|NCT02420015|DRUG|Nicotine replacement therapy|Participants will be prescribed NRT patch and one nicotine rescue method (e.g., nicotine gum, lozenge, inhaler) for use during the post-quit phase of the study. Participants will be given the choice between nicotine gum, nicotine inhaler, or nicotine nasal spray, and will be instructed to use the rescue method as needed to reduce cigarette cravings
223663673|NCT02420015|DRUG|Bupropion|All participants who are medically eligible will be prescribed bupropion, which they will start two weeks prior to their quit day. Dosage will be 150 mg/daily for days 1-7 and 300 mg/daily (administered in two daily doses) until the 3-month follow-up
223663674|NCT02420015|BEHAVIORAL|cognitive-behavioral smoking cessation counseling|Participants will receive four 20-minute smoking cessation counseling sessions and a participant manual. The four sessions are based on standard cognitive-behavioral therapy techniques shown to be efficacious for smoking cessation.
224243466|NCT02801877|BEHAVIORAL|IntelliCare|
224243467|NCT02801877|BEHAVIORAL|Hub App with the Recommender System|
224243468|NCT02801877|BEHAVIORAL|Coaching|
224243469|NCT04008979|DRUG|Aspirin|Aspirin - lipid complex
224243470|NCT00154102|DRUG|Cetuximab|Cetuximab intravenous infusion of 400mg/m\^2 for the first infusion then weekly intravenous infusion of 250mg/m\^2. Number of Cycles: until progression or unacceptable toxicity develops
223663675|NCT02420015|BEHAVIORAL|Mobile Contingency Management|Participants will be asked to provide video recordings of themselves taking carbon monoxide readings in order to confirm smoking abstinence. Participants are asked to upload these videos to the study's secured server, and are provided monetary reward for videos that suggest smoking abstinence.
223663676|NCT02420015|BEHAVIORAL|Stay Quit Coach|Stay Quit Coach is a smart phone application that serves as a source of readily available support and information for adults who are already in treatment to quit smoking and to help them stay quit after treatment. The app guides user in creating tailored plans that include their personal reasons for quitting, interactive tools to help users cope with urges to smoke, motivational messages, support contacts to help users stay smoke free and how to address lapses. Participants assigned to this condition will be asked to use Stay Quit Coach from Session 2 through the 6-month follow-up.
223663677|NCT02420015|BEHAVIORAL|SMS text messaging|Patients assigned to this condition will receive text messages relevant to their current status in their smoking quit attempt, including messages reminding participants to take their smoking cessation medication.
223663678|NCT02200809|DEVICE|MR-guided focal laser ablation|
223770030|NCT06464939|DRUG|Placebo|Applications of water for injection
223663679|NCT01835509|BEHAVIORAL|Intervention, Camp plus reunions|
223663680|NCT00669123|DRUG|Chondroitin sulphate|Chondroitin sulphate 800 mg/day
223663681|NCT00669123|DRUG|Placebo|
223663682|NCT06123234|DIETARY_SUPPLEMENT|Verum|Food supplement in single-dose vials
223663683|NCT06123234|OTHER|Placebo|Food supplement in single-dose vials
223663684|NCT01584544|DRUG|capecitabine|oral pills, 1000mg/m2/d, split in two times, d1-14, d22-35 combined with concurrent pelvic radiation
223663685|NCT01584544|DRUG|Capecitabine|oral pills, 1200mg/m2/d, split in two times, d1-14, d22-35 combined with concurrent pelvic radiation
223663686|NCT01584544|DRUG|Capecitabine|oral pills, 1350mg/m2/d, split in two times, d1-14, d22-35 combined with concurrent pelvic radiation
224243471|NCT00154102|DRUG|FOLFIRI (5-Fluorouracil, Folinic acid, Irinotecan)|Bi-weekly Irinotecan infusion of 180mg/m\^2, Folinic Acid infusion of 400mg/m\^2 (racemic) or 200mg/m\^2 (L-form), 5-Fluorouracil bolus of 400mg/m\^2 followed by a 46-hour continuous infusion of 2400mg/m\^2 Number of Cycles: until progression or unacceptable toxicity develops
223663687|NCT01584544|DRUG|Capecitabine|oral pills, 1500mg/m2/d, split in two times, d1-14, d22-35 combined with concurrent pelvic radiation
223770031|NCT02075320|DEVICE|Stationary Digital Chest Tomosynthesis|"The study scan, s-DCT, will be performed within two weeks of his/her clinical evaluations by chest CT and CR. There cannot be any intervening therapies or procedures (i.e. biopsy or excision of lesions) done in between the SOC imaging and the s-DCT. In the event that CRs are not included in the SOC imaging or are unusable (outside of acceptable window or poor quality), the scout image acquired by CT will be used in place of a CR.~Images will be acquired by a trained radiologist technologist. The technologist will comfortably position the patient in the supine position on the imaging table. Then, all patients will have a breath held s-DCT scan in an anterior-posterior direction."
223770032|NCT00075335|DRUG|AMD3100 (Mozobil plerixafor)|AMD 3100 (Mozobil plerixafor)mobilized peripheral blood hematopoietic progenitor cells from healthy volunteers will be characterized by cellular content and immunological properties.
224243472|NCT00331578|DEVICE|Excel drug-eluting coronary artery stent|
224243473|NCT03772496|DIAGNOSTIC_TEST|circulating tumor cells test|10 ml Peripheral blood are drawn from patients enrolled before surgery/FNAB and centrifuged to collect the peripheral blood mononuclear cells. Then, negative and positive immunomagnetic selections are used to exclude white blood cells and enrich tumor cells. After isolating mRNA, RT-PCR array is used to measure expression of target genes.
223663688|NCT01584544|DRUG|Capecitabine|oral pills, 1650mg/m2/d, split in two times, d1-14, d22-35 combined with concurrent pelvic radiation
223663689|NCT04074161|DRUG|Semaglutide|Dose gradually increased to 2.4 mg administered once weekly for 68 weeks
223663690|NCT04074161|DRUG|Placebo (semaglutide)|Administered once weekly for 68 weeks
223663691|NCT04074161|DRUG|Liraglutide|Dose gradually increased to 3.0 mg administered once daily for 68 weeks
223770033|NCT04620148|DRUG|TAK-242|TAK-242 concentrate solution 80 mg/mL for dilution and infusion
224243474|NCT03772496|DIAGNOSTIC_TEST|Fine needle aspiration biopsy|patients with potential malignant thyroid nodules are performed fine needle aspiration biopsy with the aid of ultrasound. The result of FNAB were classified by Bethesda rating system.
224243475|NCT07025395|BEHAVIORAL|- Core Training Protocol|This structured training intervention incorporates progressive core exercises designed to enhance neuromuscular activation, balance, and muscle hypertrophy. Participants perform eight exercise triads per session, progressing from core stability drills to high-intensity power movements over eight weeks.
223663692|NCT04074161|DRUG|Placebo (liraglutide)|Administered once daily for 68 weeks
223663693|NCT03236155|DRUG|opioid pain pills|patient will receive their pain pill prescription
223663694|NCT04769700|BEHAVIORAL|Edinburgh Postnatal Depression Scale|The Edinburgh Postnatal Depression Scale is a self-administered questionnaire made up of 10 items scored using a four-point Likert scale (0-3) designed to screen for symptoms of postpartum depression. Postpartum depression represents the end of a continuum of severity of symptoms. The present study used a cutoff point for depressive symptomatology risk of higher than 12.
223663695|NCT04769700|BEHAVIORAL|Breast Feeding Adherence|This will be addressed according to the breastfeeding initiation practices according to the WHO.
223663696|NCT04769700|BEHAVIORAL|Fear of Covid-19 Scale|The Fear of Covid-19 Scale is a questionnaire that evaluates fear of the global pandemic caused by the SARS-CoV-2. It consists of seven items, each with a five-point Likert scale of options. The participant is instructed to choose the option that best represents their perception about the statement presented. The maximum possible total is 35 points. The scale's authors indicate that the higher the score is, the higher is the level of the participants' fear of COVID-19.
223663697|NCT06445452|BEHAVIORAL|Direct SNAP-Ed|Six in-home SNAP-Ed lessons are delivered to participants in the SNAP-Ed arm. Lessons are offered weekly and directed by a bilingual and bicultural community health worker.
223663698|NCT03236324|DEVICE|ultrasound-guided nerve block|Transversalis fascia plane (TFP) block, ultrasound-guided
223663699|NCT03236324|DRUG|Saline|20 mL 0.9% saline administered on each side as bilateral TFP blocks
223663700|NCT03236324|DRUG|Bupivacaine-epinephrine|20 mL bupivacaine 0.25% with epinephrine 2.5 mcg/mL to a maximum of 2.5mg/kg administered on each side as bilateral TFP blocks
223663701|NCT00561626|DIETARY_SUPPLEMENT|high fat diet followed by low fat diet|High fat diet : 40 Energy (En)% fat, 45 En% carbohydrates, 15 En% proteins, 250 mg cholesterol,4 weeks, daily Low fat diet : 20 Energy (En)% fat, 65 En% carbohydrates, 15 En% proteins, 250 mg cholesterol,4 weeks, daily
223663702|NCT00561626|DIETARY_SUPPLEMENT|low fat diet followed by high fat diet|Low fat diet : 20 Energy (En)% fat, 65 En% carbohydrates, 15 En% proteins, 250 mg cholesterol,4 weeks, daily High fat diet : 40 Energy (En)% fat, 45 En% carbohydrates, 15 En% proteins, 250 mg cholesterol,4 weeks, daily
223663703|NCT04950296|OTHER|Group I: L. plantarum UALp-05TM,|One capsule to be taken orally before lunch with a glass of water. In case the dose is missed, advise participant to take before dinner.
223663704|NCT04950296|OTHER|Group II: L. plantarum UALp-05TM,|One capsule to be taken orally before lunch with a glass of water. In case the dose is missed, advise participant to take before dinner.
223663705|NCT04950296|OTHER|Microcrystalline cellulose|One capsule to be taken orally before lunch with a glass of water. In case the dose is missed, advise participant to take before dinner.
223663706|NCT05741554|OTHER|Rate of myometrial involvement in the population of 28 low grade serous ovarian carcinoma.|Presence of uterine myometrial metastasis at pathology examination after cytoreductive surgery
223663707|NCT04036370|PROCEDURE|PECS group|Pecs block performed using ultrasound guidance. Standard pain follow up and monitorization will be performed.
223663708|NCT04036370|OTHER|Control group|Standard pain follow up and monitorization will be performed.
223663709|NCT00450125|OTHER|Six-Minute Walk Test|Six-Minute walk tests at least one hour after vigorous exertion (such as exercise stress test) and at least 20 minutes in between the first and second six-minute walk tests
223770034|NCT04620148|DRUG|Placebo|Matching placebo concentrate solution
223770035|NCT03773757|BEHAVIORAL|IN-PEACE Dementia Care Coordination|Patient/Caregivers assigned to the intervention arm will have monthly phone calls with a Nurse or Social Worker, in the capacity of a Dementia care coordinator (DCC) to identify symptoms and behavior problems the person with memory problems is having, including: pain, sadness, or other symptoms. The Dementia Care Coordinator will consult with the project clinical team to develop a plan of care utilizing standardized protocols to reduce the burdens of disease associated symptoms and behaviors. In addition, education and support materials will be provided to the caregiver in the role caring and management of a patient with dementia.
223770036|NCT01267903|BIOLOGICAL|vaccine against EV71 of 320U/0.5ml|inactivated vaccine(vero cell) against EV71 of 320U/0.5ml on day0,28,modern medicines
223770037|NCT01267903|BIOLOGICAL|vaccine against EV71 of 640U/0.5ml|inactivated vaccine(vero cell) against EV71 of 640U/0.5ml on day0,28
223770038|NCT01267903|BIOLOGICAL|vaccine against EV71 of 160U/0.5ml|inactivated vaccine(vero cell) against EV71 of 160U/0.5ml on 0,28 day
223663710|NCT00450125|OTHER|Exercise stress test|Scheduled gold standard exercise test, i.e. stress test, cycle ergometry with incremental workloads or oxygen consumption exercise studies
223663711|NCT04264832|OTHER|Clinical data collection|"Basic characteristics: Participants were carefully characterized with regard to a general health history, a medical history, clinical, demographic and anthropomorphic measurements, skin problems (hirsutism is modified by Ferriman-Gallwey (mF-G) score , global acne score and premature alopecia).~A transvaginal ultrasound scan was performed on every participant during a clinical examination to determine the number of follicles and ovarian volume.~Metabolic and other assessments: General gynecological examination, prolactin, thyroid, androgen, LH, FSH, DA, 5-HT, metabonomics, glucose, insulin, triglyceride (TG), LDL and HDL were determined, OGTT was performed.~Questionnaires: The perceived stress scale(Chinese 14-item PSS), self-rating anxiety scale (SAS）, self-rating depressive scale(SDS) were used to assess the participants' mental health status. The MOS item short from health survey (SF-36) was used to assess the quality of life ."
223663712|NCT01988584|BIOLOGICAL|umbilical cord blood (hUCB) cells|Autologous umbilical cord blood banked with the Cord Blood Registry.
223663713|NCT01988584|DRUG|Saline Infusion (Placebo)|A total of 10 children (5 from each cohort) will be randomized to a placebo infusion at the baseline visit and then have the opportunity to cross-over to stem cell treatment at the 1yr. visit.
223663714|NCT01988584|BIOLOGICAL|bone marrow derived mononuclear cells (BMMNCs)|Autologous stem cells from bone marrow harvest.
223663715|NCT05271500|DEVICE|laser acupuncture|gallium-aluminum arsenide diode laser with a continuous wave and a wavelength of 850nm will be used for laser acupuncture. it will be applied for three times per week for 12 weeks
223663716|NCT01529138|DRUG|Axitinib|Combination treatment with temsirolimus and axitinib
223663717|NCT01529138|DRUG|Temsirolimus|Combination treatment with temsirolimus and axitinib
223663718|NCT03890666|DRUG|Albuterol eMDPI DS|"Albuterol sulfate electronic multidose dry powder inhaler (Albuterol eMDPI) DS with 4 component devices:~* Device 1: Albuterol eMDPI~* Device 2: Albuterol eMDPI Patient-facing smart device application (App)~* Device 3: DHP Cloud solution)~* Device 4: Provider-facing dashboard (dashboard)"
223663719|NCT03890666|DRUG|albuterol|Standard of care albuterol-administering rescue inhaler
223663720|NCT00131053|DRUG|Methotrexate|
223770039|NCT01267903|BIOLOGICAL|vaccine against EV71 of 320U/0.5ml|inactivated vaccine(vero cell) against EV71 of 320U/0.5ml on day0,28
223770040|NCT01267903|BIOLOGICAL|vaccine against EV71 of 640U/0.5ml|inactivated vaccine(vero cell) against EV71 of 640U/0.5ml on day0,28
223770041|NCT06224920|DIAGNOSTIC_TEST|magnetic resonance imaging|MRI data acquisition was performed on a 3 Tesla MRI scanner with parallel transmission and reception technology (Skyra Magnetom, Siemens Healthcare, Erlangen, Germany). Imaging is performed with a maximum gradient strength of 45mT/m and a maximum slew rate of 200 T/m/s and a 64-element head coil.
223770042|NCT06224920|OTHER|electroencephalography|A 20-channel resting EEG (Brain Products, Gilching, Germany) is recorded as part of routine clinical diagnostics in the Department of Psychiatry and Psychotherapy at the LMU to rule out focal neurophysiological pathologies. Within the scope of the present study, an extended examination will be carried out, which includes a 64-channel EEG, including a passive visual paradigm. After completion of the clinical evaluation, the neurophysiological changes in resting activity will be scientifically analyzed in comparison to the MRI and PET data.
223770043|NCT06224920|DIAGNOSTIC_TEST|blood and CSF biomarker|Aβ1-42 and 1-40, total tau protein and phosphorylated tau protein 181 (p-Tau), apolipoprotein E (APOE), soluble TREM2 protein, neurofilament light chain and glial fibrillary protein (GFAP) will be determined.
223770044|NCT06224920|DIAGNOSTIC_TEST|positron emission tomography|According to an established and standardized protocol, PET scans are performed with the TSPO receptor ligand \[18F\]-GE-180, \[18F\]flutemetamol for assessment of fibrillar Aβ 162 accumulation and the Tau ligand \[18F\]-PI-2620. In brief, \[18F\]GE-180 TSPO PET images (mean dose: 177 ± 17 MBq) with an emission window of 60-80 min after injection will be acquired to measure the activation of glial cells. \[18F\]Flutemetamol Aβ PET images (average dose: 182 ± 11 MBq) are acquired with an emission window of 90-110 min after injection to assess fibrillar Aβ accumulation. Dynamic \[18F\]PI-2620 tau PET (average dose: 186 ± 14 MBq) with an emission window of 0-60 minutes after injection are performed for quantification of tau aggregation. Static images of the late phase (20-40 min) are reconstructed. These images are used for further processing and analysis.
223770045|NCT06224920|DIAGNOSTIC_TEST|neuropsychological test|Trained psychologists at the Memory Clinic of the LMU Hospital administered the CDR, CERAD-NB and Mini-Mental State Examination (MMSE). The CERAD-NB battery was used to generate a total score for the six subscales: semantic fluency (animals/60 s), modified Boston naming test, lexical items, construction practice, lexical items retrieval, and lexical items discrimination, with higher scores indicating better performance.
224243476|NCT07025395|BEHAVIORAL|Control Group Core Routine|Control group participants engage in general core activation exercises twice per week, without progressive intensity or specialized neuromuscular adaptation.
224243477|NCT07029321|PROCEDURE|Modified poco-poco exercises|Participants performed modified poco-poco exercises for 12 weeks
224243478|NCT07028996|DEVICE|Daily use of the PEASY urine collection device for 5 days|"The PEASY device features a non-adhesive attachment system to the penis, unlike penile sheaths which are used for the same indications and whose attachment system is based on an adhesive system. Fixation of the PEASY device to the penis involves the use of a clamp on the foreskin. The clamp has a certain elasticity and has been developed to be atraumatic.~The medical device comprises a glans cup which covers the urinary meatus. This cup therefore rests on the glans."
224243479|NCT07028996|OTHER|Daily collection of patient feedback using a visual analog scale (0-100)|Daily collection of patient feedback using a visual analog scale (0-100) and any suggestions for improving the device during an open interview at the end of the test period.
224243480|NCT07036380|DRUG|MP0317 + Gemcitabine + Cisplatine + Durvalumab|"* MP0317: 3 mg/kg IV(intraveinous), day 1, every 3 weeks for a maximum of 5 administrations~* Immuno-chemotherapy (ICT): cycle 1-5~  * Durvalumab 1500 mg IV, day 8 every 3 weeks~ * Gemcitabine 1000 mg/m² IV, days 8 and 15 every 3 weeks~ * Cisplatin 25 mg/m² IV, days 8 and 15 every 3 weeks~* Immuno-chemotherapy (ICT): cycle 6-8~  * Durvalumab 1500 mg IV every 3 weeks~ * Gemcitabine 1000 mg/m² at day 1, 8 every 21 days~ * Cisplatin 25 mg/m² at day 1, 8 every 21 days~* Then durvalumab (1500 mg IV) will be administrated in monotherapy maintenance every 4 weeks until progression or unacceptable toxicity."
224243481|NCT07036380|PROCEDURE|CT-Scan|at baseline, every 6 weeks (± 1 week) for the first 24 weeks and then every 8 weeks until progression, at end of treatment visit, At each follow-up visit : Only for patients who have not progressed during treatment phase
224243482|NCT07036380|DRUG|Gemcitabine + Cisplatin + Durvalumab|"* Immuno-chemotherapy (ICT) for 8 cycles :~  * Durvalumab 1500 mg IV, day 1 every 3 weeks~ * Gemcitabine 1000 mg/m² IV, days 1 and 8 every 3 weeks~ * Cisplatin 25 mg/m² IV, days 1 and 8 every 3 weeks~* Then durvalumab (1500 mg IV) will be administrated in monotherapy maintenance every 4 weeks until progression or unacceptable toxicity."
224243483|NCT07035210|BEHAVIORAL|Group and 1:1 occupational therapy sessions|Patients will be educated on the goal setting process and setting self-directed goals aimed at occupations they identified as important in both group and 1:1 treatment sessions.
224243484|NCT07037394|DRUG|Probiotic plus lactulose|Probiotic and lactulose will be administered per the dose and schedule specified in the arms.
224243485|NCT07037394|DRUG|Rifaximin plus lactulose|Rifaximin and lactulose will be administered per the dose and schedule specified in the arms.
224243486|NCT07037394|DRUG|L-ornithine-L-aspartate plus latulose|LOLA and lactulose will be administered per the dose and schedule specified in the arms.
224243487|NCT07037394|DRUG|Lactulose|Lactulose will be administered per the dose and schedule specified in the arms.
224243488|NCT07037160|COMBINATION_PRODUCT|Kegel exercises|Kegel exercises, also known as pelvic floor exercises, involve contracting and relaxing the muscles of the pelvic floor to strengthen them. These exercises can help improve urinary and fecal continence, potentially enhance sexual function, and are recommended for both men and women.
224243489|NCT07037160|COMBINATION_PRODUCT|Kegel exercises with Foam Rolling|Foam rolling can be a helpful tool to prepare for or complement Kegel exercises by releasing tension in surrounding muscles and improving overall pelvic floor function. Foam rolling can help address tight muscles in the hips and lower back that can contribute to pelvic floor dysfunction. By releasing these tight areas, foam rolling can allow for better engagement and control of the pelvic floor muscles during Kegel exercises.
224243490|NCT07035743|OTHER|Exercise|5 minutes of constant workload exercise at 60% of peak oxygen uptake from cardiopulmonary exercise testing
224243491|NCT07035743|OTHER|Exercise|15 minutes of constant workload exercise at 60% of peak oxygen uptake from cardiopulmonary exercise testing
224243492|NCT07037524|RADIATION|Radiation Therapy|Low single-dose wholw-heart radiotherapy
223663721|NCT00131053|DRUG|Prednisolone|
223663722|NCT00131053|DRUG|Dexamethasone|
223663723|NCT00131053|DRUG|Vincristine|
224243493|NCT07037654|DRUG|ondansetron lingual film|8 mg of the lingual film form of ondansetron, given 15 minutes before spinal anesthesia
224243494|NCT07037654|DRUG|Placebo|a placebo lingual film form, given 15 minutes before spinal anesthesia
224243495|NCT07035301|DRUG|Normal Saline (Placebo)|During anesthesia induction, an equal volume of normal saline was used instead of rocuronium for anesthesia.
223663724|NCT00131053|DRUG|Pirarubicin|
223663725|NCT00131053|DRUG|Cyclophosphamide|
223663726|NCT00131053|DRUG|L-asparaginase|
223663727|NCT00131053|DRUG|Cytarabine|
223663728|NCT00131053|DRUG|Hydrocortisone|
223663729|NCT00131053|DRUG|Mercaptopurine|
224243496|NCT07035301|DRUG|Lidocaine Intravenous Infusion|Lidocaine was administered at a dose of 0.5mg/kg for the induction of anesthesia.
224243497|NCT07035301|DRUG|Remimazolam Tosilate|Remimazolam was administered at a dose of 0.2 mg/kg for the induction of anesthesia.
224243498|NCT07035301|DRUG|Remifentanil|Remifentanil was administered at a dose of 3 micrograms per kilogram for the induction of anesthesia.
224243499|NCT07035301|DRUG|Rocuronium (0.15mg/kg/body mass)|Rocuronium was administered at a dose of 0.15mg/kg for the induction of anesthesia.
224243500|NCT07036939|PROCEDURE|Immediate LVA|Bilateral cervical lymphatic-venous anastomosis (LVA) performed within 2 weeks after baseline assessments.
224243501|NCT07036939|PROCEDURE|Delayed LVA|Identical LVA procedure performed at 6 months (±2 weeks) post-baseline
224243502|NCT07037342|OTHER|Manual acupuncture|Manual acupuncture on acupoint (ST32, ST34, ST36, SP10) the needles will be inserted perpendicularly for 20 minutes.
224243503|NCT07037342|OTHER|Electro acupuncture|Electro acupuncture on acupoint (ST32, ST34, ST36, and SP10) for 20 minutes.
224243504|NCT07037342|OTHER|Sham acupuncture|Is a needle insertion at wrong points or non-points (locations that are not known acupuncture points)
224243505|NCT07037030|BEHAVIORAL|Guided deep breathing|Children will complete a brief, 5-minute, deep breathing intervention using the Domi tool to help maintain a 5-second breath pace
224243506|NCT07035912|COMBINATION_PRODUCT|PIONEER Protocol|"* Oral nutritive stimulus with every feed (minimum 5mL)~* Esophageal stimulation with up to 15 stimulations given at least 5 times per week with stimulation catheter~* High resolution esophageal manometry as much as weekly if feasible throughout protocol~* Parent biofeedback (during manometry studies) and education on at least a weekly basis with focus on their participation in oral feeding"
224243507|NCT07037108|COMBINATION_PRODUCT|Reflexology + Generalized Stretching|Participants in Group 1 received a combination of foot reflexology and generalized stretching exercises. focusing on specific reflex points related to the endocrine, nervous, and reproductive systems. Each reflexology session lasted for 20 minutes, conducted three times per week for 6 weeks.
223663730|NCT00586092|DRUG|bevacizumab, ABT-510|"* Stage 1 (Cohorts -1, 2, 2, 3) ABT-510: 25, 50, 50, 100 mg SC BID\*, bevacizumab: 5, 5, 10, 10 mg/kg IV every 14 days\*~* Stage 2 (RPTD) ABT-510: X mg SC BID\*\*, bevacizumab: Y mg/kg IV every 14 days\*\*~  * Stage I is the dose escalation stage. Stage II will include an additional 20 patients (10 patients in each group) enrolled at the RPTD in two different schedules to better assess safety and biomarker correlates.~    * \*Both agents begin on Day 1 of Cycle 1.~      * \*\*At the RPTD, ½ the patients will begin ABT-510 (Dose X) on Day 1 and bevacizumab (Dose Y) on Day 15 and the other ½ of the patients will begin bevacizumab on Day 1 and ABT-510 on Day 15. This will allow for a collection of some preliminary data of wound angiogenesis effects of ABT-510 alone versus the combination and bevacizumab alone versus the combination."
224243508|NCT07037108|COMBINATION_PRODUCT|Stretching Only|Generalized Stretching Only Method: Generalized Stretching Exercises Details: Participants in Group 2 received only generalized stretching exercises without any reflexology treatment. The stretching protocol included exercises for major muscle groups such as the neck, shoulders, back, hips, hamstrings, and calves. Each session will last for 20-25 minutes, which included a 5-minute warm-up, 15-20 minutes of static stretching, and a 5-minute cool-down.
223663731|NCT03232333|DEVICE|Biologic wound graft|Diabetic foot ulcer will be treated by grafting with MIRODERM Biologic Wound Matrix
223663732|NCT00120757|DRUG|Alendronate|
223770046|NCT01282593|OTHER|Impact of CD9 expression level on motility assays|"1\) Assess of the impact of CD9 expression level on motility assays (migration and adhesion) We have initiated motility assays (fibronectin adhesion experiments and CXCL12 chemoattracted migration tests with modified Boyden chamber technique) using the CD9 positive TEL/AML1-positive cell line REH and the CD9 negative cell line RAJI (wild or transfected with CD9 cDNA). Data will be analyzed in combination with blocking antibodies and chemical antagonist according to the level of CD9 (transcript and protein) and of CXCR4. Protein quantifications will be performed by flow cytometry and Western Blot. Interactions will be explored by confocal microscopy and biological pathways by immunoblot.~Adhesion results will be validated on patient samples of B-ALL."
224243509|NCT07036887|DIAGNOSTIC_TEST|First Rib Mobilization + Respiratory Physiotherapy|Patients were given post isometric relaxation for restricted first rib in sitting position and therefore the affected elevated first rib, opposite foot of therapist was placed on the table and patient non affected arm is 'dropped' on the therapist flexed knee. The practitioner's conjointly flexes the elbow on the non-affected side placed anterior to shoulder with the hand supporting the patient facet of head. Then therapist makes contact with the tubercle of the first rib with fingers or thumb of affected side (patient) disposing of available soft tissue. slack as steady force is applied in inferior direction. The therapist eases his flexed leg and uses his supported hand to encourage patient's neck into a side flexion and rotation to affected side thus unloading the scalene tension thereon side and encourage the first rib to move anteriorly and inferiorly
224243510|NCT07036887|COMBINATION_PRODUCT|Scalene Muscle Energy Technique (MET) + Respiratory Physiotherapy|MET for the scalene muscle, the participants were made to lie supine with a cushion or towel under the upper thoracic area. The PT placed his hand on the side of the participant's face/forehead to resist the isometric contraction and the other hand on the sternum. The participants were asked to perform the action of the anterior scalene muscle against PT resistance and hold it for 7-8 seconds followed by relaxation. (42) Along with the same respiratory physiotherapy protocol used in Group A. The treatment protocol was given for three sessions per week for four weeks
224243511|NCT07035314|PROCEDURE|Dexamethasone|1- First group: will receive local infiltration of steroids (dexamethasone) in tonsillar bed and paracetamol.
224243512|NCT07035314|DRUG|NSAIDs|2- Second group: will receive systemic nonsteroidal anti-inflammatory drugs in the analgesic and anti-inflammatory dosage and paracetamol.
224243513|NCT07035314|DRUG|Control (Standard treatment)|3- Third group: control group will receive NSAIDs, steroids and paracetamol as standard post tonsillectomy medications in our department.
224243514|NCT00756080|DRUG|citrulline|0.06 G/kg three times/day during 7 days
224243515|NCT00756080|DRUG|placebo|placebo (equimolar mixture of 6 non essential amino acids: alanine, aspartate, glycine, histidine, proline, serine) 0,006 g/kg 3 times/day during 7 days
224243516|NCT01248247|DRUG|Erlotinib|150 mg by mouth each day of a 28 day cycle.
224243517|NCT01248247|DRUG|AZD6244|100 mg by mouth daily of a 28 day cycle.
224243518|NCT01248247|DRUG|MK-2206|100 mg by mouth every week of a 28 day cycle.
223663733|NCT00607490|BEHAVIORAL|Cognitive-Behavioral Therapy|Behavioral, cognitive, sex therapy and relaxation interventions administered to teach self-management skills for pain control.
224243519|NCT01248247|DRUG|Sorafenib|400 mg by mouth twice a day for a 28 day cycle.
224243520|NCT01248247|DRUG|Erlotinib|150 mg by mouth daily of a 28 day cycle.
224243521|NCT01248247|DRUG|MK-2206|135 mg by mouth every week of a 28 day cycle.
224243522|NCT03962023|OTHER|Echocardiography and MRI|Analysis of echocardiography and MRI parameters
224243523|NCT03363503|DRUG|Salmeterol/Fluticasone Capsair®|Salmeterol/Fluticasone 50/500 mcg Inhalation Powder (1 puff) twice daily (approximately every 12 hr) via Capsair® for 8 weeks
224243524|NCT03363503|DRUG|Salmeterol/Fluticasone Diskus®|Salmeterol/Fluticasone 50/500 mcg Inhalation Powder (1 puff) twice daily (approximately every 12 hr) via Diskus® for 8 weeks
223663734|NCT00607490|BEHAVIORAL|Supportive Psychotherapy|Patient-centered talk therapy to assist participants in expressing their thoughts and feelings.
223663735|NCT04847336|OTHER|No intervention is planned|No intervention is planned
223663736|NCT05246865|DRUG|oral androgen challenge with dehydroepiandrosterone (DHEA)|The oral androgen challenge is a safe and well-validated means of studying the androgen generation profiles of different study groups.
223663737|NCT05145270|DIETARY_SUPPLEMENT|Escitalopram+Sulforaphane|Escitalopram(No-specified) 10-20mg/d, once per day; Sulforaphane(ZHIYINGUOSU, Shenzhen Fushan Biotech Co. Ltd.). 40-70kg, 4 tablets/day (containing 274μmol of glucosinolates); 70-90kg, 6 tablets/day .
223663738|NCT05145270|DEVICE|Escitalopram+rTMS|Escitalopram(No-specified) 10-20mg/d, once per day; rTMS: rTMS is delivered to the left dorsolateral prefrontal lobe position. Stimulation parameters are set to be 80 stimulation strings of 10Hz with an interval of 12 seconds. Each stimulation string includes 30 stimulations lasting for 3 seconds. One session includes 2400 stimulation strings lasting for 19 minutes and 40 seconds. The course of rTMS treatment includes 20 sessions, once a day or twice a day.
223663739|NCT05145270|DRUG|Escitalopram|Escitalopram(No-specified) 10-20mg/d, once per day.
223663740|NCT00196092|DEVICE|Roll-in|Proctored entry.
223663741|NCT00196092|DEVICE|Surgical|Surgery
223663742|NCT00196092|DEVICE|Standard Risk|Standard Endovascular repair
223663743|NCT00196092|DEVICE|High Risk|High Risk Endovascular repair.
223663744|NCT00196092|DEVICE|Compassionate Use|Endovascular repair for compassionate use patients.
223663745|NCT00196092|DEVICE|Treatment for females|Endovascular repair in female patients
223663746|NCT00196092|DEVICE|Standard Risk Continued Access|Continued Access Endovascular repair for standard risk patients.
223663747|NCT00196092|DEVICE|High Risk Continued Access|Continued Access Endovascular Repair for High Risk Patients.
223663748|NCT03052426|DEVICE|Ergotron WorkFit - TL|A sit to stand work station.
223663749|NCT05620693|BIOLOGICAL|NY-ESO-1 TCR-T|NY-ESO-1 TCR-T treatment
223663750|NCT04502680|DRUG|Eribulin Mesylate|Eribulin mesylate 1.4mg/m2, administered intravenously on Days 1 and 8 of each 21 day cycle.
223663751|NCT02961101|DRUG|Anti-PD-1 antibody|Anti-PD-1 antibody will be given at 1-3mg/kg on day8 by IV every three weeks
223663752|NCT02961101|DRUG|Decitabine|Decitabine will be given at 10mg/d on day 1to 5 by IV every three weeks
223663753|NCT02961101|DRUG|Chemotherapy|Chemotherapy be given depends on the cancer type and treatment regimen before enrollment.
223663754|NCT00907179|DRUG|LBH 589|"LBH589 three-times-a-week (doses will be at least 2 days apart, e.g. Monday, Wednesday, Friday), until disease progression or intolerable toxicities LBH589 will start the week prior to the first pemetrexed cycle and PD studies will be performed (week -1).~Dose level: 1 LBH589: 10 mg Pemetrexed: 500 mg/m2~Dose level: 2 LBH589: 15 mg Pemetrexed: 500 mg/m2~Dose level: 3 LBH589: 20 mg Pemetrexed: 500 mg/m2~Dose level: 4 LBH589: 30 mg Pemetrexed: 500 mg/m2"
223663755|NCT00907179|DRUG|Pemetrexed|Pemetrexed 500mg/m2 IV, day 1, every 21 days, on the first day of the week LBH589 is given.
223663756|NCT00911885|BEHAVIORAL|Dietary Intervention|The efficacy of the two dietary change interventions will be compared in a randomized controlled trial, with 120 patients per group. The two approaches are 1) the American Heart Association (AHA) Dietary Guidelines; and 2) a simple dietary change condition that focuses on increasing fiber. Patients in both conditions will receive intensive dietary instruction for 3 months, followed by a 9 month maintenance phase. Both conditions will receive dietary instructions via individual and group sessions led by registered dietitians.
223663757|NCT02780011|DRUG|Brentuximab Vedotin|Antibody-drug conjugate composed of the anti-CD30 chimeric immunoglobulin G1 monoclonal antibody cAC10 and the antimicrotubule drug monomethyl auristatin E connected by a protease-cleavable linker.
223663758|NCT02780011|DRUG|Alsertib|Aurora A kinase inhibitor
223663759|NCT00029510|DRUG|Magnesium|
223663760|NCT04218565|BIOLOGICAL|Golimumab (GOL)|Patients with refractory BD associated uveitis will receive Golimumab therapy, the efficacy and corticosteroids-sparing effects will be evaluated.
223663761|NCT02031965|BIOLOGICAL|oncolytic HSV-1716|Given IT
223663762|NCT02031965|DRUG|dexamethasone|Given IV
223663763|NCT02031965|PROCEDURE|therapeutic conventional surgery|Undergo surgical resection
224243525|NCT03318471|DRUG|MgSo4|50 mg/kg MgSo4 in 100 ml 0.9 sodium Chloride 15 minutes prior to anesthesia induction over 15 minutes
223663764|NCT02031965|OTHER|laboratory biomarker analysis|Correlative studies
223663765|NCT03207165|DRUG|Milrinone|Patients will be initiated on Milrinone at 0.125 mcg/kg/min \[stage 1\] and will be titrated according to a blinded protocol from stages 2 to 5 \[0.250, 0.375, 0.5 and \>0.5 ug/kg/min\]. All orders to initiate and titrate the dose of the allocated inotrope will be written in the chart as follows: 'Study inotrope dose to be \[increased/decreased/maintained\] at stage \[1-5\]' so as to ensure that treating physicians remain blinded to the allocated drug.
223663766|NCT03207165|DRUG|Dobutamine|Patients will be initiated on Dobutamine at 2.5 mcg/kg/min \[stage 1\] and will be titrated according to a blinded protocol from stages 2 to 5 \[5.0, 7.5, 10 and \>10 ug/kg/min\]. All orders to initiate and titrate the dose of the allocated inotrope will be written in the chart as follows: 'Study inotrope dose to be \[increased/decreased/maintained\] at stage \[1-5\]' so as to ensure that treating physicians remain blinded to the allocated drug.
224243526|NCT03318471|DRUG|0.9% NaCl|100 ml 0.9% NaCl 15 minutes prior to anesthesia induction over 15 minutes
224243527|NCT05689905|DIAGNOSTIC_TEST|HLA typing of the children|The HLA typing is made on a mouth swab of the children, that is a painless non-invasive procedure.
224243528|NCT02877147|OTHER|SEBTC|SEBTC benefits were issued on EBT cards using either the existing EBT delivery systems for the Supplemental Nutrition Assistance Program (SNAP) or Supplemental Nutrition Assistance Program for Women Infants and Children (WIC). Sites selected only one of the two EBT systems to be used to implement SEBTC prior to random assignment; households were not randomized to a specific delivery system.
224243529|NCT03172351|DEVICE|EDoF1|extended depth of focus IOL - EDoF1
224243530|NCT03172351|DEVICE|Monofocal|Monofocal IOL
224243531|NCT03172351|DEVICE|EDoF2|Comparison EDoF2 IOL
224243532|NCT05940909|DRUG|Perindopril/Indapamide/Amlodipine 8 mg/2.5 mg/10 mg tablet / Triplixam® 10 mg/2.5 mg/10 mg tablet|"Perindopril/Indapamide/Amlodipine is manufactured by Pharmtechnology LLC, Republic of Belarus. Each tablet contains 8 mg of perindopril erbumine, 2.5 mg of indapamide and 10 mg of amlodipine.~Triplixam® is manufactured by Les Laboratoires Servier Industrie, France. Each tablet contains 10 mg of perindopril arginine, 2.5 mg of indapamide and 10 mg of amlodipine."
224243533|NCT03326180|DRUG|Liposomal bupivacaine|266mg/20ml vial of EXPAREL
224243534|NCT03326180|DRUG|Bupivacaine hydrochloride|100mg/20ml 0.5% bupivacaine hydrochloride. Branded or generic, must be plain (cannot contain adrenaline/epinephrine)
224243535|NCT02808702|BEHAVIORAL|Cognitive-behavioral therapy|Twelve weekly sessions of individual cognitive-behavioral therapy
224243536|NCT01860105|DRUG|MDCO-157|intravenous administration
224243537|NCT01860105|DRUG|PLAVIX|oral administration
224243538|NCT03838393|OTHER|multidisciplinary management|pharmacological and non.pharmacological treatment (specially trained nurses, psychologists and physiologists)
224243539|NCT04349917|DRUG|Methylphenidate|A single, low dose of methylphenidate (0.3 mg/kg) will be administered on the drug day.
224243540|NCT04349917|OTHER|Placebo|A matching placebo pill will be administered on the placebo day.
224321481|NCT07134829|BEHAVIORAL|Stroboscopic Visual Conditions|Participants will perform walking trials under three visual conditions: high-frequency stroboscopic glasses, low-frequency stroboscopic glasses, and no-glasses control. Each participant will complete three 5-meter walking trials per condition, with the order of conditions randomized. Gait parameters will be recorded using the GAITRite walkway system, and muscle activity will be measured using surface electromyography.
224321482|NCT07134478|DRUG|HSK31858 Tablets On the morning of Day 1, a single dose of HSK31858 tablets 40 mg will be administered. Rifampicin capsules After a 5-day washout period, a single dose of rifampicin capsules 600 mg wi|"HSK31858 Tablets On the morning of Day 1, a single dose of HSK31858 tablets 40 mg will be administered.~Rifampicin capsules After a 5-day washout period, a single dose of rifampicin capsules 600 mg will be administered every morning from Day 6 to Day 14. On the morning of Day 15, rifampicin capsules 600 mg and HSK31858 tablets 40 mg will be co-administered."
224321483|NCT07133893|BEHAVIORAL|Attention bias assessment and modification|Attention bias assessment and modification involve two versions of the dot-probe task. These tasks are based on the premise that repeated attention shifts can retrain attentional biases, with the expectation that reducing attentional bias toward threats will alleviate sub-clinical anxiety symptoms.
224321484|NCT07133893|DEVICE|Transcranial photobiomodulation|Participants will receive near-infrared light at 1064 nanometers to the right side of the forehead for 8 minutes. The investigators have introduced this form of transcranial photobiomodulation (tPBM) as a means of human cognitive enhancement, and as an adjunct for attention bias modification for the reduction of symptoms of depression. In the present study, the investigators wish to extend these findings to the use of attention bias modification for the reduction of sub-clinical anxiety.
224321485|NCT04936399|BIOLOGICAL|Nivolumab|Participants will receive Nivolumab after prior chemotherapy as part of an early access to medicines scheme (EAMS) program in the United Kingdom (UK)
224321486|NCT06270303|PROCEDURE|Access flap & surgical debridement|Following surgical exposure, roots are carefully debrided.
224321487|NCT06270303|PROCEDURE|Application of bone substitute material (BioOss Collagen)|Following surgical debridement, the bone substitute material is applied to the furcation defect.
224321488|NCT04302012|PROCEDURE|Color fundus photography|Subjects will undergo fundus photography before and/or after administration of mydriatic agent
224321489|NCT04302012|DRUG|Mydriatic Agent|Subjects may be administered mydriatic medication to dilate their pupils.
224321490|NCT03161340|DRUG|Rapamycin|Patients will take Rapamycin 2 days before IVF until 15 days after IVF
224321491|NCT06604091|OTHER|Treatment protocol|Treatment options for ovarian stimulation include long-acting and antagonist regimens and other ovulation induction regimens. Options for frozen embryo transfer include natural protocols, mild ovarian stimulation regimens, hormone replacement therapy (HRT) regimens, and down-regulated combined HRT regimens. The treatment regimen is refined in the above protocol. The treatment of patients follows the principles of real-world clinical practice.
223663767|NCT03030846|OTHER|Stabilization exercise|18 sessions during 6 consecutive weeks, three times per week, 30 or 40 minutes per session including: Twenty minutes for receiving hot pack and TENS and 10 or 20 minutes for training the exercises in 7 level : 1.Train the specific contraction of the deep abdominal muscles, multifidus and pelvic floor muscles(PFM). 2.Train the specific contraction of deep abdominal muscles with coactivation of multifidus and PFM in supine, prone, sitting, standing and quadruped position. 3. Segmental control exercises in close kinematic chain. 4. Segmental control exercises in open kinematic chain with limb loading, emphasis on abdominal muscles. 5. Segmental control exercises in open kinematic chain with limb loading, emphasis on back extensor muscles. 6. Progress exercises to functional task. 7. Coactivation of abdominal and multifidus muscles with limb loading in aerobic tasks.
223663768|NCT03030846|OTHER|Control group|8 sessions during 6 consecutive weeks, three times per week, per session including: Twenty minutes for receiving hot pack and TENS
224243541|NCT01861379|PROCEDURE|Ghost Ileostomy|At the end of Laparoscopic Anterior Rectal Resection, once the colorectal anastomosis was performed, the terminal ileum was identified and a window in the mesentery was created to pass a rubber tube (we usually use an urinary catheter) around the intestinal loop. The tube was subsequently exteriorized trough the trocar incision in the right flank.
224243542|NCT00441467|DRUG|Glufosfamide|5000 mg/m2 of glufosfamide on Day 1 of each three-week cycle for up to 6 cycles.
224321492|NCT07021989|DRUG|Pembrolizumab|Given intravenously
224321493|NCT07021989|RADIATION|Non-investigational, involved site radiotherapy (ISRT)|Undergo possible, standard of care, non-investigational radiation therapy
224321494|NCT07021989|DRUG|Gemcitabine|Given IV
224243543|NCT03776422|BEHAVIORAL|Mobile self-help intervention|Participants receive several apps on their phone including IntelliCare apps, which are based on principles of cognitive-behavioral therapy. Participants also receive the Pocket Helper app, which has been designed for this study. The tools within the Pocket Helper app include a crisis text line that is available 24/7, the Illinois Warm Line which is available Monday through Friday from 8am to 5pm, directions to call 911 in the case of an emergency, the Koko web app that provides crowdsourced emotional support, brief cognitive-behavioral interventions, daily tips, and daily surveys. Phones will also include the StreetLight Chicago app, which provides homeless individuals with up-to-date information on shelters, health clinics, emergency contacts, mental health services, and more.
224243544|NCT00410865|GENETIC|INGN 201|Mouth rinse given one time on the first day and two times on Days 2-5 of each course of INGN 201. The injection and rinse (first day of each cycle), or the two rinses (Days 2-5 of each cycle), will be separated by at least two hours.
224243545|NCT01042522|BIOLOGICAL|Bleomycin Sulfate|Given IV
224243546|NCT01042522|DRUG|Carboplatin|Given IV
224243547|NCT01042522|DRUG|Cisplatin|Given IV
224243548|NCT01042522|DRUG|Etoposide Phosphate|Given IV
224243549|NCT01042522|OTHER|Laboratory Biomarker Analysis|Correlative studies
224243550|NCT01042522|DRUG|Paclitaxel|Given IV
224243551|NCT06217224|OTHER|Preventive photobiomodulation Therapy (PBMT)|The application of preventive TLBP will be performed with a laser device containing an aluminum phosphide and indium gallium diode (InGaAlP) emitting radiation in the red region of the electromagnetic spectrum (660 nm) with a power of 100mW and a beam area of 0.03 cm2 . An energy of 1J/point and an energy density of 33.3 J/cm2/point were determined, which will be applied punctually, with a distance between the points of 1cm, for 10s per point, totaling 9 points per region.
224243552|NCT00675935|OTHER|Fall Prevention Tool Kit prototype using a randomized design|Based on the results from Phase 1, Phase 2 and consistent with the literature that suggests that multifaceted, tailored interventions are most effective against inpatient falls, the FPTK prototype will be comprised of two interrelated components 1) The Fall Risk Alert and Communication Plan (translates an individual patient's fall risk assessment into a decision support intervention that communicates fall risk status to team members.) and 2) The Patient Safety Plan of Care PSPOC (translates an individual patient's fall risk assessment into a decision support intervention that creates a tailored evidence-based plan of care). The goal of the FPTK Intervention is to communicate risk status and recommended tailored discipline specific-interventions to prevent falls.
224243553|NCT04891120|DIAGNOSTIC_TEST|Treadmill test (Bruce protocol)|Treadmill test performed with and without a mask.
224243554|NCT06196515|DRUG|Calcium hydroxide|placement of intracanal medication for the three groups will be done after cleaning and shaping of the root canals and it will be left for one week.
224243555|NCT06196515|DRUG|nano calcium hydroxide|placement of intracanal medication for the three groups will be done after cleaning and shaping of the root canals and it will be left for one week.
224243556|NCT00081848|DRUG|rV-CEA(6D)/TRICOM-rF-CEA(6D)/TRICOM|
224243557|NCT00081848|DRUG|rF-CEA(6D)/TRICOM|
224243558|NCT00081848|DRUG|Recombinant Fowlpox-GM-CSF|
224243559|NCT00081848|DRUG|Celecoxib|
224243560|NCT00312039|DRUG|Elvucitabine|Elvucitabine 10 mg QD for 14days
224243561|NCT00312039|DRUG|Lamivudine|Lamivudine 300 mg QD for 14 days
224243562|NCT04915053|DIETARY_SUPPLEMENT|ABG+ Black Garlin|Daily tablet intake during three months
224243563|NCT04915053|DIETARY_SUPPLEMENT|Crystalline Cellulose|Daily tablet intake during three months
224243564|NCT06242613|PROCEDURE|Robot-Assisted Gastrectomy|Gastrectomy performed with a robotic system.
224243565|NCT06242613|PROCEDURE|Laparoscopic Gastrectomy|Gastrectomy performed with conventional laparoscopic approach.
224243566|NCT02548234|OTHER|Mirror therapy|Mirror therapy group received training for 1.5 hours/day, 3 days/week, for 4 weeks and home programs for 30-40 min/day, 5 days/week.
224243567|NCT02548234|OTHER|Bilateral arm training|Bilateral arm training group received training for 1.5 hours/day, 3 days/week, for 4 weeks and home programs for 30-40 min/day, 5 days/week.
224243568|NCT06534996|DRUG|SCD-2101|Tradictional Chinese Medicine formula (SCD-2101)
224243569|NCT04991779|DIAGNOSTIC_TEST|AI-assisted cEEG detection tool|"This study is an observational study to evaluate the accuracy of AI-assisted cEEG diagnostic tool with routine care. All patients from the cohort accept cEEG monitoring and AI-assisted cEEG detection tool.~The tool included a quantitive EEG neural signal processing pipeline to extract features from the original signal datasets, machine learning models based on gradient boosted model for prediction.~The reference standard is the electrographic seizures interpreted by 3 clinicians who had attended the uniformly training program and were certified by the Chinese Anti-Epilepsy Association."
224243570|NCT04900584|OTHER|Checklist|Checklist of guideline-based treatment before discharge
224243571|NCT04900584|OTHER|Education|Heart failure education before discharge
224243572|NCT04900584|OTHER|Telephone monitoring|Telephone monitoring after discharge
224243573|NCT03169348|DRUG|sofosbuvir daclatasvir|oral tablets
224243574|NCT03169348|DRUG|Ledipasvir/sofosbuvir|oral tablets
224243575|NCT02063841|DEVICE|lead-free protective drape containing bismuth and antimony (RADPAD®)|
224243576|NCT02063841|DEVICE|sterile identical sham drape|
224243577|NCT04177368|DIETARY_SUPPLEMENT|Theragran 60ml|history,examination and biochemical values
224243578|NCT00485472|DRUG|lacosamide|50 or 100mg tablet, 400mg daily, for 12 weeks
224243579|NCT00485472|OTHER|Placebo|50 or 100mg tablet, 400mg daily, for 12 weeks, matched to Lacosamide
224243580|NCT02639741|DRUG|Melatonin|Preoperative melatonin tablet will be given and postoperative pain scores will be evaluated
224243581|NCT02639741|DRUG|Vitamin C|Preoperative vitamin C tablet will be given and postoperative pain scores will be evaluated
224243582|NCT02639741|OTHER|Placebo|Preoperative placebo tablet will be given and postoperative pain scores will be evaluated
224321495|NCT07021989|DRUG|Vinorelbine|Given IV
224321496|NCT07021989|DRUG|Liposomal Doxorubicin|Given IV
224321497|NCT07021989|DEVICE|Foresight CLARITY™ LDT|Foresight CLARITY LDT, a laboratory-developed test (LDT),by Foresight Diagnostics, is an ultra-sensitive liquid biopsy and tissue platform that detects MRD in patients with B-cell lymphomas
224321498|NCT07021989|DRUG|Pegfilgrastim|Given IV for supportive care
223770047|NCT01282593|OTHER|Post-transcriptional regulation of CD9|"2\) Post-transcriptional regulation of CD9 in TEL/AML1-positive ALL To identify miRNAs that are potentially deregulated in TEL/AML1-positive acute lymphoblastic leukaemia and especially to screen for CD9 -targeted miRNAs, we will use a TaqMan ®MicroRNA Arrays approach allowing the simultaneous measurement of about 760 human miRNA.~Small RNA will be extracted from bone marrow samples of twenty childhood B-ALL to screen miRNAs which are differentially expressed between CD9-positive and CD9-negative ALL and further compared with miRNAs which were predicted to target CD9 in databases. Validation of the selection will be performed by single Q-PCR for selected miRNAs using a novel cohort of ten bone marrow samples."
223770048|NCT04542070|DRUG|Cabotegravir Tablets|CAB tablets were available as film coated tablets for oral administration.
223770049|NCT04542070|DRUG|Cabotegravir Injectable Suspension (CAB LA)|CAB LA was available as sterile suspension for injection in GSK1265744 for administration as IM injection.
223770050|NCT04542070|DRUG|Rilpivirine Tablets|RPV was administered as tablets for oral administration.
223770051|NCT04542070|DRUG|Rilpivirine Injectable Suspension (RPV LA)|RPV LA was available as a sterile suspension of RPV to be administered as an IM injection.
223770052|NCT04542070|DRUG|BIKTARVY Tablets (BIK)|BIK was a three-drug fixed dose combination product BIC, FTC, and TAF for oral administration.
223770053|NCT00677495|DIETARY_SUPPLEMENT|Gluten-free diet|Gluten-free diet
223770054|NCT03083691|DRUG|Nivolumab, Ipilimumab|Cohort 1: addition of ipilimumab in case of progression on nivolumab monotherapy.
224243583|NCT05767619|DIAGNOSTIC_TEST|Troponin hs-cTnI|One sample of Troponin (hs-cTnI) is obtained and analyzed at the scene. Capillary blood sample or venous (lithium heparin) if peripheral venous catheter is inserted for standard care reasons. The sample is disposed after the result has been recorded in the clinical report form. The clinicians participating in the study are instructed and have been educated about the study to only collect the data (report form with measurements) and provide care as constituted by the guidelines. Patients will be monitored by board members that standard clinical care is provided.
224243584|NCT05767619|DIAGNOSTIC_TEST|Plasma glucose|One sample of plasma glucose is obtained and analyzed at the scene. The sample is then disposed and the measured value is recorded in the clinical report form. P-glucose measurement is clinical practice in standard care and is measured on all patients with diabetes and patients with altered mental status or at the ambulance nurse discretion.
224243585|NCT02711449|DRUG|Methylprednisolone|125 mg methylprednisolone as an intravenously bolus injection approximately 30 minutes prior to skin incision.
224243586|NCT02711449|DRUG|0.9% Saline|0,9% Saline as an intravenously bolus injection approximately 30 minutes prior to skin incision.
224243587|NCT06627699|DEVICE|Total Knee Arthroplasty|Post-Market Surveillance of the Freedom Total Knee System for Primary TKA
224243588|NCT06547190|BEHAVIORAL|High AGEs diet|Participants sequentially consumed a diet that was high in AGEs and low in AGEs just be altering their cooking method. The High AGEs diet was cooked for example by baking and grilling.
224243589|NCT06547190|BEHAVIORAL|Low AGEs diet|Participants sequentially consumed a diet that was high in AGEs and low in AGEs just be altering their cooking method. The low AGEs diet was cooked for example by steaming and boiling.
224243590|NCT02215161|DRUG|Selinexor|Given PO
224243591|NCT05749172|OTHER|Strength group|4 sets of strength training exercises with 10 repetitions determined from ACSM two days a week, with a minimum of 72 hours between these days. In this exercise protocol, the movements of back squat, seated leg extension, seated leg curls, machine hip adductions, machine hip abductions, standing calf raises, back lat pulldowns, seated rows, bench press, incline bench press, biceps curls, triceps pushdowns, back press, back extension, pushup, pullup, squats and sit-ups will be performed.
224243592|NCT05749172|OTHER|Controlled group|Two hours of parkour training for two days a week.
224243593|NCT05806203|DEVICE|Low intensity shockwave treatment to pelvic floor region plus typical physical therapy|Treatment dose: 1,000 - 1,500 shocks, 2.5-3.0 Hz, 0.06-0.10 mJ/mm2 (Intensity of 6-8), 8 to 12 minutes
224243594|NCT05806203|DEVICE|Sham shockwave treatment plus typical physical therapy|Inactive dose of shockwave treatment
224243595|NCT04986332|BEHAVIORAL|Physical activity program|24-weeks moderate-intensity physical activity program
224243596|NCT04986332|OTHER|Global therapeutic remodeling|Re-assessing and therapeutic optimization of the whole burden of chronic pathologic conditions
224243597|NCT04015232|COMBINATION_PRODUCT|INTP5|INTP5, a pegfilgrastim biosimilar to US Neulasta.
224243598|NCT04015232|COMBINATION_PRODUCT|US Neulasta|US Neulasta: FDA approved pegfilgrastim innovator product.
224243599|NCT01512407|PROCEDURE|Transarterial chemoembolisation using cisplatin-lipiodol mixture|Cisplatin-lipiodol mixture was infused through catheter placed at hepatic artery followed by gelfoam embolisation. This is performed 4 to 6 weeks after surgery
224243600|NCT04602507|DRUG|Ivermectin|Routinary care offered in the hospital plus ivermectin 400 µg/kg (2 drops per kg) orally in a single dose.
224243601|NCT04602507|OTHER|Placebo|Routinary care offered in the hospital plus placebo (2 drops per kg) orally in a single dose
224243602|NCT02822781|OTHER|No intervention|There is no intervention. The patients will receive common questionnaire usually used by doctors (SNOT 22). Some Data to describe the population are collected then.
224243603|NCT02091882|DRUG|Placebo|Oral placebo-embedded IEM tablet.
224243604|NCT02091882|COMBINATION_PRODUCT|Combination product of Aripiprazole + IEM + Sensor + MIND1 Application|Combination product of aripiprazole tablet embedded with sensor and wearable patch with MIND1 system on smartphone
223770055|NCT03083691|DRUG|Nivolumab, Ipilimumab|Cohort 2: upfront combination therapy of nivolumab and ipilimumab for four cycles, followed by nivolumab monotherapy.
223770056|NCT00806468|DRUG|Desmotabs|Desmotabs encapsulated, 0,2 mg once daily for one week, 0,2 mg bid for one week
224243605|NCT00813046|BIOLOGICAL|gpASIT+TM|oral administration of entero-coated capsules containing increasing doses of gpASIT+TM (25 to 1600µg), one dose per day for 4 days
224243606|NCT04287426|DRUG|Rocuronium 0.6 mg/kg|Rocuronium 0.6 mg/kg is compared to patients with 2 µg/kg remifentanil
224243607|NCT04287426|DRUG|Remifentanil 2 µg/kg|Rocuronium 0.6 mg/kg is compared to patients with 2 µg/kg remifentanil
223770057|NCT02633475|GENETIC|IL-10 polymorphism|The IL-10 genotype will determined by polymerase chain reaction (PCR) amplication and restriction length fragment polymorphisms.
223770058|NCT03679260|OTHER|Carbohydrate restricted diet|20 grams total carbs/day
224321499|NCT07021989|PROCEDURE|Fluorodeoxyglucose (FDG) Positron Emission Tomography (PET)/Computerized tomography (CT)|Undergo imaging
224321500|NCT07026318|DRUG|Tirofiban|After endovascular treatment, tirofiban is infused at a rate of 0.4 μg/kg/min for 30 minutes, followed by a maintenance infusion at 0.1 μg/kg/min until 24 hours postoperatively.
224321501|NCT07026318|DRUG|Placebo|Following endovascular treatment, patients receive normal saline placebo, with the dosage calculated in the same manner as that of tirofiban in the experimental group.
224321502|NCT01885195|DRUG|MEK162|MEK162 will be dosed on a flat scale of 45 mg twice daily on a continuous dosing schedule.
224321503|NCT06875310|DRUG|Adagrasib|Specified dose on specified days
224321504|NCT06875310|DRUG|Pembrolizumab|Specified dose on specified days
224321505|NCT06875310|DRUG|Carboplatin|Specified dose on specified days
224321506|NCT06875310|DRUG|Pemetrexed|Specified dose on specified days
224321507|NCT06875310|DRUG|Placebo|Specified dose on specified days
224321508|NCT06875310|DRUG|Cisplatin|Specified dose on specified days
224321509|NCT04700137|OTHER|Caring Contacts Plus Introductory Phone Call (CC+)|One introductory semi-structured caring phone conversation with a follow-up specialist to check-in, establish a personal connection, and provide resources at the 0-2 week time-point followed by 11 non-demanding, caring text or email messages sent over the course of 6 months.
224321510|NCT04700137|OTHER|Caring Contacts without an introductory phone call (CC)|Eleven non-demanding, caring text or email messages sent over the course of 6 months. Participants will not know or have spoken to the follow-up specialist who sends the caring messages.
224321511|NCT07036679|DIETARY_SUPPLEMENT|Energy Active Product|Participants will use their Energy Active Product as directed for a period of 6 weeks.
224321512|NCT07036679|DIETARY_SUPPLEMENT|Energy Placebo Control|Participants will use their Energy Placebo Control as directed for a period of 6 weeks.
224321513|NCT05890534|DRUG|Pycnogenol®|Single center, quadruple blind randomized controlled trial comparing Pycnogenol® versus Placebo.
224321514|NCT05890534|DRUG|Placebo|Single center, quadruple blind randomized controlled trial comparing Pycnogenol® versus Placebo.
223663769|NCT05763355|PROCEDURE|Biopsy|Biopsies will be performed under local anaesthesia. In all patients with a suspicious lesion (PIRADSv2.1 3-5) noted on the mp-MRI, the software-based image fusion biopsies will be obtained collecting 3 to 5 cores per target area according to its volume, 10-12 systematic cores of the remaining areas of the prostate will be collected from sectors specified in the PIRADSv2.1 prostate map.
223663770|NCT01012674|DRUG|Dotarem|Each subject will receive one injection of Dotarem 0.2ml/kg
224243608|NCT02788448|DEVICE|VIVASURE CLOSURE DEVICE|Large hole closure device
224243609|NCT03097120|DRUG|0.625 mg of conjugated equine estrogen|one tablet containing 0.625 mg of conjugated equine estrogen and a placebo tablet daily
224243610|NCT03097120|DRUG|0.625 mg of conjugated equine estrogen plus 2.5 mg of medroxyprogesterone acetate|one tablet of 0.625 mg of conjugated equine estrogen plus one tablet 2.5 mg of medroxyprogesterone acetate daily
224243611|NCT03097120|DRUG|placebo tablets|two placebo tablets daily
224243612|NCT06096740|BEHAVIORAL|Cognitive Processing Therapy|"Cognitive processing therapy is a widely-utilized, empirically-supported treatment developed for PTSD. It is based on a cognitive theory of trauma which emphasizes the impact of trauma on belief systems and the development of stuck points, which are unhealthy, unrealistic, and maladaptive ways of thinking that serve to maintain unhealthy beliefs and reinforce PTSD symptoms."
224243613|NCT05227625|BEHAVIORAL|body dissatisfaction management group|"Our group is composed of 10 weekly session of 2 hours led by a psychologist trained in the management of ED and ACT therapy.~Each group will be composed of 5 to 10 people. First of all, the group will lead the participants to better know and understand the impact of BD on the symptomatology of ED by teaching current scientific knowledge on the subject. In a second step, the group will guide the patients in the acquisition of psychological skills to deal with events related to BD and to engage in actions towards the values that give meaning to their existence."
224243614|NCT05227625|BEHAVIORAL|Relaxation Group|Participants will be included in a standardized relaxation program consisting of a weekly 2 hour session for 10 weeks. The group will be led by a psychologist trained in relaxation and in particular in abdominal and muscular relaxation techniques. Each group will be composed of 5 to 10 people. Initially, the therapy will lead the participants to recognize the signs of anxiety and to understand the physiological mechanisms involved. Classic techniques of anxiety management will then be introduced (cardiac coherence, abdominal and muscular relaxation, Jacobson technique, Schultz autogenic training). These techniques will be tested in session. Participants will be encouraged to practice these techniques at home.
224243615|NCT03160352|OTHER|Exergame|In total, 10 sessions were accomplished including baseline and post intervention measurements. The remaining eight exercise sessions lasted 40 minutes, with an actual training duration of 20 minutes. This resulted in a cumulative total intervention exercise time of 160 minutes.
224243616|NCT00421005|DRUG|fluvastatin|Fluvastatin 80 mg (Arm 1) vs. Fluvastatin 20 mg (Arm 2) increased according with LDL concentrations
224321515|NCT04460560|DRUG|Terlipressin|"For the first dose of terlipressin, each vial will be reconstituted with 5 mL of sterile 0.9% sodium chloride solution and administered intravenously as a bolus injection and given over 1 minute at a dose of 0.5 mg.~For continuous infusion, the dose of terlipressin is to be dissolved in 0.9% sodium chloride solution and infused with a pump"
224321516|NCT02765425|DEVICE|AMES|Subjects will be trained while seated on the AMES device. As the footplate of the device rotates the ankle ±15 deg in dorsiflexion and plantarflexion, the participant will assist that motion. Vibration (2-3 mm at 60 pulses/s) will be applied to the tibialis anterior tendon during plantarflexion and to the Achilles tendon during dorsiflexion. To assist participants in the assisted movement task, the AMES biofeedback screen will provide real-time visual feedback of the volitional ankle torque that the participants actively apply to the AMES device. Each training session will include 15 min of training of each ankle; training sessions will be conducted 3 times/week over a 12-week period, for a total of 9 hours of training on each ankle.
224321517|NCT05755776|DRUG|TMF|switch ETV to TMF
224321518|NCT02647827|OTHER|Lifestyle management|All women will receive lifestyle management instructions at the baseline visit, before randomization. The lifestyle management involves one initial counselling session in connection with the baseline visit, which includes information about the importance of weight management, healthy diet and physical activity.
224243617|NCT01029353|PROCEDURE|Laparotomy|Initial laparotomy will be performed. Standard procedures will be used, including inspection of the bowel with removal of diseased areas, creation of stoma(s), and other procedures deemed indicated by the surgeon.
224243618|NCT01029353|PROCEDURE|Drainage|Initial drainage will involve placing a Penrose drain in the abdomen.
224243619|NCT00954915|BIOLOGICAL|teplizumab|Cohorts 1-5: escalating doses of subcutaneously administered teplizumab; cohort 6: intravenous administration of maximum tolerated subcutaneous dose.
224243620|NCT01287013|DEVICE|Cone-beam computed tomography (CT)|Imaging
224243621|NCT01287013|DEVICE|Conventional Computed Tomography (CT)|Imaging
224243622|NCT05146596|DEVICE|use low level light therapy,The Dr.Tai's energy cap|30 minutes each time, three times a week, a total of 12 times.
224243623|NCT01832701|OTHER|Coffee|coffee versus placebo
224243624|NCT01832701|OTHER|Placebo comparator|maltodextrine with caffeine
224321519|NCT02647827|DEVICE|Acupuncture|Disposable, single-use, sterilized CE marked needles made of stainless steel, 0.25 x 30 mm and 0.30 x 40/50 mm will be inserted to a depth of 15-40 mm in segmental acupuncture points located in abdominal and leg muscles, with innervations corresponding to the ovaries and the pancreas. Two sets of acupuncture points will be alternated every second treatment.
224321520|NCT02647827|DRUG|Metformin|Oral metformin 500 mg three times daily, in total 1500 mg per day. To reduce gastrointestinal side-effects of metformin, the dose will be slowly escalated starting with 500 mg daily during the first week, increasing to 500 mg twice per day during the second the week, and 500 mg three times daily, morning, lunch and dinner from the third week in total 16 weeks including the 3 weeks step-up phase (i.e. 4 months).
224321521|NCT00516373|DRUG|KU-0059436 (AZD2281)(PARP inhibitor)|oral
224321522|NCT03062163|OTHER|Resveratrol lipoic Acid|Transdermal patch loaded with resveratrol and lipoic acid
224321523|NCT03062163|OTHER|Placebo|Transdermal patch loaded with normal saline
224321524|NCT02757573|PROCEDURE|Hypercarbia|PaCO2 is elevated from 5 to 7.5 kPa by controlled ventilation.
224321525|NCT00506792|DRUG|QAU145|
224321526|NCT00506792|DRUG|Placebo|
224321527|NCT02424110|PROCEDURE|argon beam coagulator ablation|The investigators plan to use argon beam coagulator ablation plus bipolar radiofrequency ablation in the argon beam coagulator ablation group.
224321528|NCT02424110|PROCEDURE|bipolar radiofrequency ablation|The investigators only use bipolar radiofrequency ablation in the left and right atrial radiofrequency ablation.
224321529|NCT02424110|DEVICE|argon beam coagulator （American，Valleylab）|Argon beam coagulator（American，Valleylab）will be used in the argon beam coagulator ablation group
223770059|NCT03679260|OTHER|Non-restricted diet|Subject follows normal diet
223770060|NCT03679260|OTHER|Phone counseling with dietitian|Weekly calls with dietitian
224321530|NCT02424110|DEVICE|bipolar radiofrequency (AtricuteTM)|The investigators plan to use bipolar radiofrequency(AtricuteTM) in the bipolar radiofrequency group
224321531|NCT01138982|BEHAVIORAL|Youth Mentoring program|
223770061|NCT02875106|DEVICE|12-point-ECG|routine recording will be 300 seconds
223770062|NCT02875106|DEVICE|Polar V800|routine recording will be 300 seconds
224243625|NCT03328260|DEVICE|HIFU|Transvaginal high intensity focused ultrasound to ablate uterine myoma
224243626|NCT01900730|DRUG|Placebo|Patient takes placebo capsule 3 times a day by mouth for 10 weeks.
224243627|NCT01900730|DRUG|Valproic Acid (VPA)|Patients initially receive daily oral VPA 15 mg/kg/day divided in three doses. If patient tolerates the reduced dose for 10 consecutive days, then the VPA dose will increase to 30 mg/kg/day divided into three doses. Patients treated for 10 weeks.
224243628|NCT01900730|BEHAVIORAL|Questionnaires|Questionnaires completed at baseline, weeks 2, 6, and 10.
224243629|NCT01900730|BEHAVIORAL|Pill Diary|Patient given a pill diary to record the time each dose taken.
224243630|NCT01900730|BEHAVIORAL|Drainage Diary|Patient completes daily diary of drainage with the date and amount of fluid drained each day at home. Drained fluid from the day before brought to each clinic visit to give to the research team.
224321532|NCT01307176|BEHAVIORAL|Home exercise program|The home exercise program uses standard physical therapy exercises that have never been rigorously tested for people with cerebellar ataxia. These include sitting balance exercises (e.g. sitting on a peanut-shaped exercise ball and moving arms or legs), standing balance exercises (e.g. weight shifting, moving arms and legs), and walking exercises (e.g. walking heel-to-toe). The exercises are in a progression, going from less to more challenging. Though the exercises are standard, they are the intervention that we are testing and we will consider them experimental.
224321533|NCT02204306|GENETIC|TSER|TS gene will be genotyped for each patients prior to chemotherapy. Patients will be assigned to different arms according to specific TSER genotype.
224321534|NCT00789997|DRUG|Prednisone|prednisone 40 mg daily for 10 days or placebo prednisone
224321535|NCT00789997|DRUG|Etanercept|etanercept 50 mg subcutaneous given on the day of randomization and one week later or placebo subcutaneous injection
223770063|NCT02875106|DEVICE|360° eMotion FAROS SET + Belt|routine recording will be 300 seconds
223770064|NCT02875106|DEVICE|Adidas Micoach smart run|routine recording will be 300 seconds
224243631|NCT02109042|DRUG|Blosozumab|Administered subcutaneously
224243632|NCT02589964|DIETARY_SUPPLEMENT|Florajen-3|The probiotic treatment is the experimental aspect of the study. Treatment will be initiated within 48 hours of the first antibiotic and will be administered twice a day for 20 days.
224243633|NCT02589964|OTHER|Placebo|The placebo treatment is the experimental aspect of the study. Treatment will be initiated within 48 hours of the first antibiotic and will be administered twice a day for 20 days.
224321536|NCT00789997|DRUG|levofloxacin|Levofloxacin 750 mg daily for 10 days.
224321537|NCT00919854|DRUG|Darunavir|Darunavir oral suspension (100 mg/mL) will be administered as 20 mg per kg body weight twice daily for children weighing between 10 and \<20 kg before dose adjustment. Darunavir oral suspension will be administered 25 mg per kg body weight twice daily if weight less than 15 kg, and fixed dose of 375 mg darunavir tablets twice daily if weight more than or equal to 15 kg after dose adjustment.
224321538|NCT00919854|DRUG|Ritonavir|Ritonavir oral solution (80 mg/mL) will be administered as 3 mg per kg body weight twice daily before dose adjustment and after dose adjustment fixed dose of 50 mg twice daily if weight more than or equal to 15 kg.
224321539|NCT01484327|DRUG|Carvedilol|Minimum dosage 3.125 mg Χ 2, Maximum dosage 50 mg
223663771|NCT01012674|OTHER|TOF MRA|Each subject will undergo a Time Of Flight Magnetic Resonance Angiography (TOF MRA)
224243634|NCT03203447|DRUG|suprachoroidal CLS-TA|suprachoroidal injection of CLS-TA
224243635|NCT03203447|DRUG|suprachoroidal sham|sham suprachoroidal procedure
224243636|NCT03203447|DRUG|Lucentis or Avastin|IVT anti-VEGF agent. Either a 0.5 mg intravitreal injection of Lucentis or 1.25 mg intravitreal injection of Avastin
223663772|NCT04699136|OTHER|6 minutes step test (ST6)|Performing a 6 minutes step test at different intervals and comparing with respect with the 6 minutes walk test and cardiac stress test
223663773|NCT01650870|DRUG|Crystalline Lactulose|
223663774|NCT03965000|OTHER|Mixed-meal-tolerance-test|To assess the dynamics of the glucagon-incretin axis we need to perform the MMTT. Thereby the patients need to consume a body weight adjusted, standardized meal and we draw blood at fixed time points over 4 hours.
224243637|NCT04140188|DIAGNOSTIC_TEST|Senti-Scint (99mTc- pertechnetate combined with human albumin)|Senti-Scint will be injected via intradermal route to the breast with history of previous NSM.
223663775|NCT01264575|DRUG|intrathecal bupivacaine 6 mg with 100 mcg of epinephrine|intrathecal bupivacaine 6 mg with 100 mcg of epinephrine
223663776|NCT01264575|DRUG|intrathecal bupivacaine 7 mg with 100 mcg of epinephrine|intrathecal bupivacaine 7 mg with 100 mcg of epinephrine
223663777|NCT01264575|DRUG|intrathecal bupivacaine 8 mg with 100 mcg of epinephrine|intrathecal bupivacaine 8 mg with 100 mcg of epinephrine
223663778|NCT01264575|DRUG|intrathecal bupivacaine 9 mg with 100 mcg of epinephrine|intrathecal bupivacaine 9 mg with 100 mcg of epinephrine
223663779|NCT01264575|DRUG|intrathecal bupivacaine 10 mg with 100 mcg of epinephrine|intrathecal bupivacaine 10 mg with 100 mcg of epinephrine
223663780|NCT01264575|DRUG|intrathecal bupivacaine 11 mg with epinephrine 100 mcg|intrathecal bupivacaine 11 mg with epinephrine 100 mcg
223663781|NCT01264575|DRUG|intrathecal bupivacaine 6 mg with 200 mcg of epinephrine|intrathecal bupivacaine 6 mg with 200 mcg of epinephrine
223770065|NCT02875106|DEVICE|TomTom Runner Cardio HRM|routine recording will be 300 seconds
224243638|NCT00662571|DRUG|acamprosate|acamprosate 333mg tabs, 2tabs 3times per day = 1998mg/day
224243639|NCT00936871|DRUG|Lersivirine|Lersivirine 2400 mg single dose
224243640|NCT00936871|DRUG|Placebo|Placebo single dose
224243641|NCT00936871|DRUG|Lersivirine (if necessary)|Lersivirine 2100 mg single dose (if necessary)
224243642|NCT00936871|DRUG|Lersivirine|Lersivirine 2400 mg single dose (dose may be decreased pending Part A tolerability results)
224243643|NCT00936871|DRUG|Placebo|Placebo single dose
224243644|NCT00936871|DRUG|Moxifloxacin|Moxifloxacin 400 mg single dose
224243645|NCT03581422|DRUG|hCG administration before embryo transfer|Thawed embryo transfer with ovulation triggered by hCG
224243646|NCT01192230|DRUG|Endostatins|7.5mg/m2 qd \*14d,q3w
224243647|NCT01192230|DRUG|Docetaxel|75mg/m2 D1, q3w,4-6cycles
224243648|NCT04990817|OTHER|Average American Diet With SoFAS Replaced With Avocado|Replacing energy from solid fats and added sugars (SoFAS) with Avocado as part of an average American diet
224243649|NCT04990817|OTHER|Average American Diet|Average American diet based on macronutrient analyses from the most recent Nutrition and Health Examination Survey.
224243650|NCT02134405|DRUG|Rebamipide|Rebamipide 100mg tid
224321540|NCT00985491|DEVICE|Endobarrier Liner|Medical device placed endoscopically in the duodenum
224321541|NCT02687529|DEVICE|CST001|
224321542|NCT05551663|OTHER|Isometric exercise training|Participants randomised to the intervention will perform a 4-week programme of isometric exercise training.
223663782|NCT01264575|DRUG|intrathecal bupivacaine 7 mg with 200 mcg of epinephrine|intrathecal bupivacaine 7 mg with 200 mcg of epinephrine
223663783|NCT01264575|DRUG|intrathecal bupivacaine 8 mg with 200 mcg of epinephrine|intrathecal bupivacaine 8 mg with 200 mcg of epinephrine
223663784|NCT01264575|DRUG|intrathecal bupivacaine 9 mg with 200 mcg of epinephrine|intrathecal bupivacaine 9 mg with 200 mcg of epinephrine
223663785|NCT01264575|DRUG|intrathecal bupivacaine 10 mg with 200 mcg of epinephrine|intrathecal bupivacaine 10 mg with 200 mcg of epinephrine
223663786|NCT01264575|DRUG|intrathecal bupivacaine 11 mg with 200 mcg of epinephrine|intrathecal bupivacaine 11 mg with 200 mcg of epinephrine
223663787|NCT05246085|DIAGNOSTIC_TEST|Cortisol level|Cortisol levels will be checked in both groups to screen for adrenal insufficiency.
223663788|NCT00104598|DRUG|Bupropion|
223663789|NCT00104598|BEHAVIORAL|Smoking Abstinence Program|This investigation was a randomized controlled study of two framed message conditions for smoking cessation in combination with open label bupropion SR (300 mg/day). Two hundred fifty-eight cigarette smokers were randomly assigned to receive either gain- or loss-framed video and printed messages encouraging smoking abstinence. Preproduced video and printed information were chosen as the intervention media because of their reliability in delivering specific framed messages. All participants were seen at a community mental health center for 6 months and received a 7-week supply of bupropion SR.
223663790|NCT06516445|RADIATION|SCRT|5×5Gy，5Gy/d，QD，D1-D5
224243651|NCT02134405|DRUG|Placebo (for Esomeprazole)|Sugar pill manufactured to mimic Esomeprazole
224243652|NCT02134405|DRUG|Esomeprazole|Esomeprazole tablets 20mg o.d. for 8 weeks
224243653|NCT03839303|DEVICE|Infra-zygomatic Mini Implant Supported Appliance|"1. leveling and alignment of the four maxillary incisors~2. infra zygomatic mini-implant will be placed bilaterally~3. wire frame work that is designed resembling the inner bow of headgear will be adapted to the upper arch~4. a heavy arch wire engaging the 4 incisors will be attached to the wire frame work~5. orthopedic force will be delivered from the mini-implants to the wire frame work"
224243654|NCT03839303|DEVICE|high pull head gear|"1. acrylic maxillary splint is made with flying tubes~2. high pull head gear is adapted to be inserted in the flying tubes"
224243655|NCT02291562|DRUG|Tetrahydrocannabinol|10 mg Tetrahydrocannabinol (capsule, once) oral intake
224243656|NCT02291562|DRUG|Cannabidiol|600 mg Cannabidiol (capsule, once) oral intake
224243657|NCT02291562|DRUG|placebo|placebo (capsule, once) oral intake
224243658|NCT05286593|DRUG|Slow Infusion of Rubidium-82|Normal volunteers will receive weight based doses of Rb-82 infused as a slow infusion
224321543|NCT05868512|DIAGNOSTIC_TEST|Dry needling|Dry Needling Along With Routine Physical Therapy for Chronic Neck Pain
224243659|NCT05286593|DRUG|Slow Infusion of Rubidium-82|Clinical patients will receive weight based doses of Rb-82 infused as a slow infusion
224243660|NCT05286593|DRUG|Slow Infusion of Rubidium-82|Infarct volunteers will receive weight based doses of Rb-82 infused as a slow infusion
224243661|NCT00528606|BIOLOGICAL|collagenase clostridium histolyticum|Subjects could have received up to three injections of AA4500 into the cord of the affected hand. Each injection was separated by at least 30 days. Individual cords may have received up to a maximum of three injections.
224243662|NCT00528606|BIOLOGICAL|Placebo|Subjects could have received up to three injections of placebo into the cord of the affected hand. Each injection was separated by at least 30 days. Individual cords may have received up to a maximum of three injections.
224243663|NCT03764709|DEVICE|Vital signs wireless monitoring system|WIN@Hospital wireless remote monitoring is a modern light monitoring medical device with no need for continuous presence of a dedicated person. WIN@Hospital is based on an innovative modular and wearable device laid out for remote monitoring of several vital parameters 24/7. Dexcom G6 is a continuous glucose monitoring system which measures interstitial fluid glucose levels in people with diabetes from a sensor applied to the skin as an alternative to routine finger-prick blood glucose testing, and can produce a -continuous record of measurements which can be checked using an App. It can also indicate glucose level trends over time. Monitoring devices will be applied to all patients randomly assigned to the wireless monitoring arm, with a continuous monitoring setting over the first 5 days after the initiation of monitoring, corresponding to the starting of the observation (i.e. transition to subacute unit for GROUP A, discharge for GROUP B).
224243664|NCT00020397|BIOLOGICAL|NY-ESO-1 peptide vaccine|
224243665|NCT00020397|BIOLOGICAL|aldesleukin|
224243666|NCT02332148|DRUG|3VM1001|3VM1001 topical cream for treatment of osteoarthritis of the knee
224243667|NCT02332148|DRUG|Placebo for 3VM1001|Topical cream placebo for 3VM1001; cream without 3VM1001
224243668|NCT04470180|BEHAVIORAL|Virtual Teach to Goal|Participants will complete inhaler education on a tablet device.
224243669|NCT04470180|BEHAVIORAL|Brief Instruction|Participants will be read out loud instruction on how to use their inhaler.
224321544|NCT05868512|DIAGNOSTIC_TEST|Therapeutic ultrasound|Therapeutic ultrasound Along With Routine Physical Therapy for Chronic Neck Pain
224321545|NCT01747746|DRUG|Rivaroxaban|Rivaroxaban versus Historical controlled Anticoagulation with Warfarin and Enoxaparin
224321546|NCT01747746|DRUG|Warfarin and Enoxaparin|Historical Control
224321547|NCT01178710|DRUG|Simvastatin|20 mg per day, start at 5 days before surgery and continue for one year. For some congenital heart diseases which other drugs such as digoxin, antistone, furosemide were prescribed less than half year, simvastatin will be prescribed less than half year.
224321548|NCT00656266|DRUG|mycophenolate mofetil|immunosuppresion medication called mycophenolate mofetil, also known as MMF or CellCept
224321549|NCT00656266|OTHER|placebo medication|medication that looks like mycophenolate mofetil
224321550|NCT05778903|OTHER|Nerve block|Suprazygomatic maxillary nerve block
224321551|NCT01970800|DRUG|Growth Hormone|Will obtain daily injections and will evaluate the IGF-1 and IGFBP3 every 3 months
224321552|NCT02374138|BEHAVIORAL|Parental stress management|"The intervention for this study is a multi-dimensional stress management program designed to be responsive to parent and other stakeholder preferences. The intervention will have two separate yet coordinated components: one-on-one stress management sessions and peer group sessions led by community wellness coaches."
224321553|NCT02374138|OTHER|Usual Care|IMPACT DC Asthma Clinic intervention of guideline-based clinical care, education, and short-term care coordination
224321554|NCT05393479|BEHAVIORAL|Thinking Healthy Programme|The Thinking Healthy Programme (THP) is a psychological treatment recommended by the World Health Organization for perinatal depression. The THP is based on the basic tenets of cognitive behavioural therapy (CBT) that aims to identify unhealthy thoughts and the vicious effects it has on the emotions and behaviour of a person and transform to healthy thinking style that ultimately impacts one's emotions and behaviour, too. The intervention aims to bring positive outcomes in three areas - a) mother's health, b) the mother-baby relationship, and c) the mother's relationship with others. A randomized controlled trial (RCT) showed that the intervention was effective in reducing depressive symptoms and disability and improving functioning. Additionally, women receiving THP had higher rate of exclusive breastfeeding, and engaging more with their infants. Similarly, infants of these women were also less likely to have diarrhoeal episode and more likely to complete immunization.
224321555|NCT03020537|BIOLOGICAL|Fluzone|Fluzone (Influenza Virus Vaccine) Suspension for Intramuscular Injection 2013-2014 Formula.
223663791|NCT06516445|DRUG|Camrelizumab|200mg, D1, ivgtt, Q3W, C1-4
223663792|NCT06516445|DRUG|Fluzoparib|100mg, BID, PO, Q3W, C1-4
224243670|NCT00874887|DRUG|moxifloxacin 0.5% HCI ophthalmic solution|1 drop in study eye three times a day for 14 days
224243671|NCT00874887|DRUG|gatifloxacin ophthalmic solution 0.3%|1 drop in study eye four times a day for 14 days
224243672|NCT06083389|BEHAVIORAL|kabat technique for rehabilitation of facial palsy|To evaluate the comparative effectiveness of the Kabat rehabilitation technique with conventional physical therapy along with electrical stimulation in both, for reducing facial disability in patients with Bell's palsy.
224321556|NCT04293900|OTHER|24-hour dietary recall|Dietary intake assessment conducted by a Registered Dietitian Nutritionist. This assessment will occur prior to starting R-CHOP chemotherapy, during the clinic visits for each round of R-CHOP chemotherapy, and again at the end of the scheduled course of R-CHOP chemotherapy.
223663793|NCT06516445|DRUG|CAPEOX|Capecitabine: 1000 mg/m2, BID, PO，D1-14, Q3W, C1-C4； Oxaliplatin: 130mg/m2, D1, ivgtt, 0-2h，Q3W，C1-4
223663794|NCT03956238|BEHAVIORAL|Alcohol intoxication|Men and women assigned to moderate alcohol dose condition (target BAC .08%) or placebo control condition with NIAAA approved alcohol administration procedures
223663795|NCT03956238|BEHAVIORAL|Objectification|Women assigned to objectifying gazes condition or eye contact control condition
223663796|NCT03728283|PROCEDURE|implant placement in combination with connective tissue grafting|A connective tissue graft of standardised dimensions was harvested from the palate under local anaesthesia and was stabilised over the implant's neck
224243673|NCT06083389|DEVICE|electrotherapy|electrical stimulation of facial nerve supplied muscles.3 sessions per week.
224243674|NCT00142662|BEHAVIORAL|diet|
224243675|NCT00142662|BEHAVIORAL|financial incentives|
224243676|NCT02600286|DRUG|EllaOne|"* 5 mg/per os of EllaOne every day through 12 months.~* 10 mg/per os of EllaOne every day through 12 months.~* EllaOne placebo/per os every day through 12 months."
224243677|NCT02600286|DRUG|EllaOne placebo|"* 5 mg/per os of EllaOne every day through 12 months.~* 10 mg/per os of EllaOne every day through 12 months.~* EllaOne placebo/per os every day through 12 months."
224243678|NCT03728296|BIOLOGICAL|islet body|Transplanting islet bodies under the diaphragm
224243679|NCT00711360|DEVICE|Intrathoracic impedance measurement|Intrathoracic impedance measurement by cardiac resynchronization therapy (CRT) devices and implantable cardioverter defibrillators (ICDs) (Lumax 540)
224243680|NCT00000190|PROCEDURE|Parotid Gland|
224243681|NCT05558930|DEVICE|iTBS stimulation|standard iTBS burst pattern:3 pulses at 50-Hz repeated at a rate of 5-Hz; 20 trains of 10 bursts given with 8-s intervals. 600 pulses on both side of cerebellar with an interval of 5 minutes.
224243682|NCT05558930|DEVICE|sham stimulation|Participants receive a sound stimulation with the same pattern with iTBS stimulation,but without magnetic field
224243683|NCT02066207|DRUG|Fenofibrate|
224243684|NCT02066207|DRUG|Atorvastatin|
224243685|NCT02495415|DRUG|Fenretinide|Fenretinide intravenous emulsion administered as a continuous intravenous infusion for 5 days, once every 3 weeks in relapsed/refractory PTCL patients.
224243686|NCT02226185|DRUG|Berberine hydrochloride|supplement of Berberine hydrochloride 0.3g two times per day for 2-3 years
224321557|NCT04293900|OTHER|Hand grip strength|Measurement of grip strength using a hand dynamometer. This will test occur prior to starting R-CHOP chemotherapy, during the clinic visits for each round of R-CHOP chemotherapy, and again at the end of the scheduled course of R-CHOP chemotherapy.
223663797|NCT03728283|OTHER|Implant placement|Implants were placed following teh manufacturer's instructions
224243687|NCT02226185|DRUG|placebo|supplement of placebo two times per day for 2-3 years
224243688|NCT01541891|DRUG|PRO-148 Ophthalmic Solution|PRO-148 Ophthalmic Solution applied four times per day (c/6 hours) during 60 days.
224243689|NCT01541891|DRUG|Active Comparator: SYSTANE ® Ophthalmic Solution|Sterile solution containing polyethylene glycol 400, propylene glycol, hydroxypropyl-guar, boric acid, calcium chloride, magnesium chloride, potassium chloride, sodium chloride, zinc chloride and polyquad (polidronium chloride) 0,001%. four times per day (c/6 hours) during 60 days.
224243690|NCT05998265|DEVICE|FeetMe rehabilitation|Home based rehabilitation program with real time biofeedback using a connected device
224243691|NCT05998265|OTHER|Physiotherapy|Conventional physiotherapy as prescribed by the neurologists
224243692|NCT02775357|BEHAVIORAL|Measurement and communication of HIV risk|Measurement and communication of HIV risk in the context of HIV testing and counseling to inform HIV risk reduction counseling
224243693|NCT02775357|BEHAVIORAL|Standard HIV testing and counseling|Participants received HIV testing and counseling following standard Ministry of Health guidelines
224243694|NCT06390501|DRUG|Semaglutide|Solution for subcutaneous (s.c. - under the skin) injection. 0.25 mg semaglutide once weekly for four weeks, 0.5 mg semaglutide once weekly for four weeks, 0.1 mg semaglutide once weekly for four weeks, 1.7 mg semaglutide once weekly for four weeks followed by 2.4 mg semaglutide once weekly for eight weeks
224243695|NCT06390501|DRUG|Placebo|Solution for subcutaneous (s.c. - under the skin) injection
224243696|NCT01160926|DRUG|AZD6244|"Dose finding trial AZD6244 cohort 1 - 50mg bd AZD6244 cohort 2 - 75mg bd~Capsule form, given for 10 days as single agent then for 35 days in combination with standard chemoradiotherapy"
224243697|NCT01160926|DRUG|Cediranib (AZD2171)|"10 days single agent dosing with Cediranib then 35 days in combination with standard chemoradiotherapy AZD2171 cohort 1 - 15mg od AZD2171 cohort 2 - 20mg od AZD2171 cohort 3 - 30mg od~Oral tablets"
224243698|NCT03824119|DRUG|Ibuprofen 600 mg|Standard postpartum care (including administration of NSAIDs)
224243699|NCT03824119|OTHER|Standard Postpartum Care without NSAIDs|NSAID administration will be withheld from this group.
224243700|NCT02925247|BEHAVIORAL|Adherence to oral anticoagulant treatment|The adherence will be evaluated by biological results
224243701|NCT03290820|RADIATION|Radiotherapy|Technique: intensity-modulated radiotherapy; Dose: GTVnx 6810cGy/30Fr, GTVnd 6400-6600cGy/30Fr, CTV1 6000cGy, CTV2 5400cGy.
224243702|NCT03290820|DRUG|Concurrent chemotherapy|Nedaplatin 80mg/m2 d1+5-flurouracil 500mg/m2 d2-5, every 3 weeks; a total of 2-3 cycles.
224243703|NCT03290820|DRUG|Aspirin|Daily aspirin of 75mg, from the starting date of radiotherapy.
224243704|NCT03798262|OTHER|Gluten|Tereos
223663798|NCT04145219|BIOLOGICAL|Sublingual allergy immunotherapy tablet|For daily administration (1 tablet per day)
223663799|NCT04145219|OTHER|Placebo|For daily administration (1 tablet per day)
223663800|NCT02173093|BIOLOGICAL|IL-2|Given SC
224243705|NCT03798262|OTHER|Placebo|Whey protein from Nestlé Healthy Science
224243706|NCT04821401|DIETARY_SUPPLEMENT|Rejuvant|"Rejuvant tablets are sustained release tablets that release the active ingredients over 8-12 hours. Both product tablets are 0.500 round and 0.290 thick.~AKG and AKG salts are grandfathered as GRAS compounds because these compounds were supplements prior to the Dietary Supplement Health and Education Act of 1994 (DSHEA). AKG and AKG salts are currently sold in the United States as supplements.~The other components of the tablets are Vitamin A for the men's product and Vitamin D3 for the women's product. Vitamin A and Vitamin D are GRAS compounds per the FDA"
224321558|NCT04293900|OTHER|International Physical Activity Questionnaire|Survey about physical activity over the previous 7 days. This survey will be administered prior to starting R-CHOP chemotherapy, during the clinic visits for each round of R-CHOP chemotherapy, and again at the end of the scheduled course of R-CHOP chemotherapy.
223663801|NCT02173093|BIOLOGICAL|GD2Bi-aATC|Given IV
223663802|NCT02173093|BIOLOGICAL|GM-CSF|Given SC
223663803|NCT02173093|OTHER|laboratory evaluations of immune responses|Correlative studies
223663804|NCT00830895|DRUG|RAD001|RAD001 10mg/day
223663805|NCT02709538|DRUG|GSP 301 NS|FDC of olopatadine HCl and mometasone furoate: 2 spray in each nostril twice daily for 52 weeks
223663806|NCT02709538|DRUG|GSP 301 Placebo NS pH 3.7|2 spray in each nostril twice daily for 52 weeks
224321559|NCT04293900|OTHER|Patient-reported outcomes survey|Survey about symptoms and side effects experienced during cancer treatment. This will be administered prior to starting R-CHOP chemotherapy, during the clinic visits for each round of R-CHOP chemotherapy, and again at the end of the scheduled course of R-CHOP chemotherapy.
224321560|NCT04293900|OTHER|Pittsburgh Sleep Quality Index|Survey about sleep habits and quality over the past month. This will be administered prior to starting R-CHOP chemotherapy, during the clinic visits for each round of R-CHOP chemotherapy, and again at the end of the scheduled course of R-CHOP chemotherapy.
224243707|NCT04821401|DIETARY_SUPPLEMENT|Placebo|Matching placebo tablets are composed of Cellulose, Carnauba wax and/or rice bran wax (to match the specs), stearic acid, magnesium stearate and silica.
224243708|NCT02136290|BEHAVIORAL|Prepackaged meals|Portion-controlled prepackaged meals
224321561|NCT04293900|OTHER|Functional Assessment of Cancer Treatment - Lymphoma|Survey about quality of life for people with a diagnosis of lymphoma. This will be administered prior to starting R-CHOP chemotherapy, during the clinic visits for each round of R-CHOP chemotherapy, and again at the end of the scheduled course of R-CHOP chemotherapy.
224321562|NCT04293900|OTHER|urine sample (optional)|Collect three urine samples either in the clinic or at home. This specimen collection will occur prior to starting R-CHOP chemotherapy, after the third round of R-CHOP chemotherapy, and again at the end of the scheduled course of R-CHOP chemotherapy.
224321563|NCT04293900|OTHER|fecal sample (optional)|Collect a fecal sample either in the clinic or at home. This sample collection will occur prior to starting R-CHOP chemotherapy, after the third round of R-CHOP chemotherapy, and again at the end of the scheduled course of R-CHOP chemotherapy.
224321564|NCT05006547|OTHER|Electromyograph Biofeedback training of the peroneal muscle|The exercise will be performed with the subject sitting in front of a computer monitor, on an elevated chair, and his feet will be in the air. The examiner will ask the subject to perform a maximum contraction of the paronal muscles, in an open kinematic chain. After reference, the subject will begin a five-minute practice. The practice will be divided into rounds of: eight seconds of muscle work and 15 seconds rest.
224321565|NCT02849483|DRUG|Ramosetron|Administer 2 ml of normal saline iv before induction. Inject ramosetron 0.3 mg iv at the end of surgery. Add ramosetron 0.6 mg to the iv PCA.
224321566|NCT02849483|DRUG|Normal saline|Administer dexamethasone 10 mg iv before induction. Inject 2 ml of normal saline iv at the end of surgery. Add 4 ml of normal saline to the iv PCA.
224321567|NCT05706883|PROCEDURE|Needle or forceps biopsy of cervical and/or supraclavicular lymph nodes|Patients with evidence of enlarged and/or PET positive cervical and/or supraclavicular lymph nodes suspected of being metastasis from lung cancer will be submitted to the biopsy from this location.
224321568|NCT05706883|PROCEDURE|Needle, forceps or surgical biopsy of any lesion other than cervical and/or supraclavicular lymph nodes|Patients without evidence of enlarged and/or PET positive cervical and/or supraclavicular lymph nodes will be submitted to the biopsy considered less invasive and effective based on imaging data and clinical health status.
224321569|NCT05405582|COMBINATION_PRODUCT|Community-based differentiated HIV prevention incl.PrEP with SRH|Community-based model of care, that consists of social mobilisation by area-based peer-navigator into decentralised sexual reproductive health (SRH) and HIV care (incl. PrEP).
223663807|NCT02709538|DRUG|GSP 301 Placebo NS pH 7.0|2 spray in each nostril twice daily for 52 weeks
224243709|NCT02136290|BEHAVIORAL|Usual Care|Usual care dietary counseling
224243710|NCT02664103|DRUG|Fixed-dose combination of capecitabine and cyclophosphamide SAR439281|Pharmaceutical form:Tablet Route of administration: Oral
224243711|NCT01901705|DRUG|Indigo naturalis ointment|The Indigo naturalis ointment was composed of a 1:10 mixture of Indigo naturalis powder and a vehicle consisting of Vaseline: microcrystalline wax: olive oil (5:6:9 ratio)
224243712|NCT01901705|DRUG|Placebo|The placebo was a mixture of blue dye powder (54.8% Indigo carmine aluminum lake \[Blue #32\] and 45.2% Allura Red AC aluminum lake \[Red #40\] powders), Vaseline, microcrystalline wax, and olive oil.
224243713|NCT05630586|DRUG|Semaglutide|Subcutaneous Semaglutide, 0.5 mg weekly for 4 weeks. First dose given at inclusion.
224243714|NCT05630586|OTHER|Standard care|Treatment according to Danish national clinical guidelines on stroke treatment, including reperfusion therapy if eligible.
224243715|NCT03162315|PROCEDURE|Freeze all|
224243716|NCT03933956|DRUG|Empagliflozin 10 MG|Oral empagliflozin 10mg daily for 30 days
224243717|NCT00050778|BIOLOGICAL|Interferon beta-1a|Interferon beta-1a 44 microgram (mcg) subcutaneously 3-times weekly for 36 months.
224243718|NCT00050778|BIOLOGICAL|Alemtuzumab 12 mg|Alemtuzumab 12 milligram per day (mg/day) was given by intravenous infusion on 5 consecutive days during the first month and on 3 consecutive days at months 12 and 24 (the latter at the treating physicians' discretion if the cluster of differentiation 4+ \[CD4+\] T-cell count was \>=100\*10\^6 cells per liter).
224243719|NCT00050778|BIOLOGICAL|Alemtuzumab 24 mg|Alemtuzumab 24 mg/day was given by intravenous infusion on 5 consecutive days during the first month and on 3 consecutive days at months 12 and 24 (the latter at the treating physicians' discretion if the CD4+ T-cell count was \>=100\*10\^6 cells per liter).
224243720|NCT03538405|OTHER|Supporting cushions|Cushions were placed in a way that the head and four limbs were well supported, without leaving empty space between body and cushions or mattress.
224243721|NCT03538405|OTHER|Harmonic techniques|Harmonic techniques (HT) is a group of manual techniques described by Lederman (2000).The goal of this techniques in this study was to reduce the muscle tone and additionally/subsequently increase the ROM.
224243722|NCT01346397|DRUG|cyclosporine or tacrolimus|after alemtuzumab, cyclosporine or tacrolimus was administered
224243723|NCT03366805|BEHAVIORAL|Pain Management Patient Education Video|Patient education video that were created in-house specifically for this project.
223663808|NCT06001359|OTHER|No intervention|No intervention
223663809|NCT04264624|DEVICE|Perioflow and Erythritol powder and ultrasonic debridement|Airflow and Perioflow combined with Erythritol powder will be used as an adjunct therapy
223663810|NCT04264624|DEVICE|Airflow and Erythritol powder and ultrasonic debridement|Airflow combined with Erythritol powder will be used as an adjunct therapy
223663811|NCT02059291|DRUG|Canakinumab|Canakinumab solution for subcutaneous injection in vial which contained 150mg/mL canakinumab in 1 mL solution.
223663812|NCT02059291|DRUG|Placebo|Matching placebo to canakinumab solution for subcutaneous injection
224321570|NCT05405582|OTHER|Primary Health Clinic based HIV prevention and care|Primary Health Clinic (PHC) based initiation and follow-up with HIV testing and standard HIV prevention and treatment package. Family planning support and syndromic management for STIs as per South African National Department of Health Guideline.
224321571|NCT06516003|DEVICE|Immersive Virtual Reality Goggles|Immersive Virtual Reality goggles are a head mounted device placed over a patient's head and eyes that allows them to play in a virtual reality game.
224321572|NCT06516003|BEHAVIORAL|Standard of Care|Distraction techniques like tablet, phone, television, parent, child life specialist
224321573|NCT05327673|OTHER|questionnaire|"* quality of life score: FACT-BMT~* decisional conflict scale~* Discreet Choice Experiment questionnaire"
224321574|NCT03005912|DEVICE|Conventional acoustic telephony|Quantification of speech comprehension by means of the Hochmair-Schulz-Moser sentence test.
224321575|NCT03005912|DEVICE|Conventional bluetooth telephony|Quantification of speech comprehension by means of the Hochmair-Schulz-Moser sentence test.
224321576|NCT03005912|DEVICE|VoIP acoustic telephony|Quantification of speech comprehension by means of the Hochmair-Schulz-Moser sentence test.
224243724|NCT03366805|BEHAVIORAL|Wound Care Patient Education Video|Patient education video that were created in-house specifically for this project.
224321577|NCT03005912|DEVICE|VoIP bluetooth telephony|Quantification of speech comprehension by means of the Hochmair-Schulz-Moser sentence test.
224321578|NCT04386616|DRUG|MSTT1041A|Participants received one intravenous (IV) infusion of MSTT1041A 700 milligrams (mg) on Day 1. A second IV dose of MSTT1041A 350 mg was given on Day 15 if the participant remained hospitalized with a requirement for supplemental oxygen.
224321579|NCT04386616|DRUG|MSTT1041A-matched Placebo|Participants received up to 2 intravenous infusions of MSTT1041A-matched placebo.
224321580|NCT04386616|DRUG|UTTR1147A|Participants received one intravenous (IV) infusion of UTTR1147A 90 micrograms/kilogram body weight (μg/kg) on Day 1. A second IV dose of UTTR1147A 90 μg/kg was given on Day 15 if the participant remained hospitalized with a requirement for supplemental oxygen.
224321581|NCT04386616|DRUG|UTTR1147A-matched Placebo|Participants received up to 2 intravenous infusions of UTTR1147A-matched placebo.
224321582|NCT01862484|DIETARY_SUPPLEMENT|Restricted Diet|Child is on an additive, gluten free diet. Child receives daily snacks which conform to the restrictive diet.
224243725|NCT00064753|DRUG|High Dose Multivitamin|Vitamin B6 (Pyridoxine HCl): 50 mg Folic acid: 5.0 mg Vitamin B12: 1.0 mg Vitamin B1 (Thiamine HNO3): 1.5 mg Vitamin B2 (Riboflavin): 1.5 mg Vitamin C (Ascorbic Acid): 60 mg d-Biotin: 300 mcg Niacinamide: 20 mg Pantothenic Acid Calcium Pantothenate): 10 mg
224243726|NCT00064753|DEVICE|Low Dose Multivitamin|Vitamin B6 (Pyridoxine HCl): 1.4 mg Folic acid: 0.0 mg Vitamin B12: 2.0 mcg Vitamin B1 (Thiamine HNO3): 1.5 mg Vitamin B2 (Riboflavin): 1.5 mg Vitamin C (Ascorbic Acid): 60 mg d-Biotin: 300 mcg Niacinamide: 20 mg Pantothenic Acid Calcium Pantothenate): 10 mg
224243727|NCT03333291|DIETARY_SUPPLEMENT|fecal suspension|helathy donor fecal suspension administered by duodenal scope
224243728|NCT06061666|OTHER|Tilia tomentosa Concentrated - Glycerine macerate (C-GM) vs Placebo (1 gtt/10 kg/day before bedtime for 15 days)|Self-administration of the food supplement or placebo (1 gtt/10 kg/day before bedtime for 15 days)
224243729|NCT03389438|BIOLOGICAL|autologous Tcm cells immunotherapy|Autologous Tcm cells immunotherapy is to collect patient's own immune cells and infuse back into the patient's body after culture in vitro that can activate the anti-tumor immune response and achieve the purpose of cancer treatment.
224243730|NCT03436225|DRUG|Dexamethasone orally.|Administered orally (0.15mg /kg / dose) twice daily for 3 to 5 days.
224243731|NCT03436225|DRUG|Dexamethasone parenteral.|Administered parenteral (0.15mg /kg / dose) twice daily for 3 to 5 days.
224243732|NCT03436225|DRUG|Inhaled nebulized Budesonide.|Administered for inhalation (1 mg/ 2ml) twice daily for 3 to 5 days.
224243733|NCT03436225|DRUG|Inhaled nebulized salbutamol.|Administered for inhalation (0.15mg /kg / dose) daily every 6-8hrs
224243734|NCT02210390|BEHAVIORAL|Psycho education|Psycho-education Sessions will be offered weekly basis
224243735|NCT00784823|DRUG|Bortezomib 1 mg/m2|"* Bortezomib is administered by rapid I.V. push (over 3-5 seconds) via a central or peripheral vein into a flowing saline line~* Bortezomib will be administered any time on day -4 and 24 hrs after the start of the melphalan infusion on day -1~* Dosing will be based on actual body weight Patient weight must be measured within seven days of the start of the treatment regimen"
224321583|NCT01862484|DIETARY_SUPPLEMENT|Ruse Diet|Child is on an additive, gluten free diet. Child receives daily snacks which violate the restrictive diet
224321584|NCT04423887|OTHER|Lower Extremity Resistance Exercise Training|"Treadmill walking 5-10 min for warm up Strength training: (80% of 8RM)~3 times supervised exercise for 4 weeks Warm up (Self Paced walking for 10 minutes) leg press, leg extension, Sit to stand squat (mini squats) Stationary Cycling (Maximum Resistance as per patient tolerance till failure)~3 sets 8 reps 10-15 s rep rest interval 1-2 min set rest interval"
224321585|NCT04423887|OTHER|Home Exercise Plan|"2 sets of 10 repetitions/day of~AROM isolated knee extension and knee flexion Isometric isolated knee extension and knee flexion Isometric terminal knee extension Sit to stand squat Isometric knee terminal extension"
224321586|NCT04423887|DEVICE|Electrotherapy + Heating|Interferential Current therapy (2P), in combination with heating pad for 20 minutes
224321587|NCT04423887|PROCEDURE|Joint Mobilization|Tibio-femoral Anterior Glide Tibio-femoral Posterior Glide Patellofemoral Joint Mobilization
224321588|NCT04423887|DIETARY_SUPPLEMENT|Creatine Supplementation|Creatine Supplementation 20g/day for 1 week followed by 5 g/day for 3 weeks
224321589|NCT00364000|DRUG|Calcium acetate|Calcium acetate in 240 chronic HD patients
224321590|NCT00364000|DRUG|Sevelamer|label sevelamer (RenagelR) 800 mg tablets
224243736|NCT00784823|DRUG|Bortezomib 1.3 mg/m2|"* Bortezomib is administered by rapid I.V. push (over 3-5 seconds) via a central or peripheral vein into a flowing saline line~* Bortezomib will be administered any time on day -4 and 24 hrs after the start of the melphalan infusion on day -1~* Dosing will be based on actual body weight Patient weight must be measured within seven days of the start of the treatment regimen"
224243737|NCT00784823|DRUG|Bortezomib 1.6 mg/m2|"* Bortezomib is administered by rapid I.V. push (over 3-5 seconds) via a central or peripheral vein into a flowing saline line~* Bortezomib will be administered any time on day -4 and 24 hrs after the start of the melphalan infusion on day -1~* Dosing will be based on actual body weight Patient weight must be measured within seven days of the start of the treatment regimen"
224243738|NCT00784823|DRUG|Melphalan|"* Melphalan is administered by rapid intravenous infusion via a central or peripheral vein over one hour~* Melphalan will be dissolved with 10 ml of diluent to a concentration of 5 mg/mL which is then immediately diluted in 0.9% normal saline to a concentration NOT exceeding 0.45 mg/mL prior to administration~* The final dilution of melphalan is physically and chemically stable for 60 minutes and therefore will be administered within that time period~* Melphalan will be given as a single dose (not split over 2 or more days)~* Dosing will be based body surface area calculated using actual body weight"
224243739|NCT04455581|DRUG|SHR-1209|SHR-1209 administered by subcutaneous injection Atorvastatin or Rosuvastatin combined with Ezetimibe oral
224321591|NCT06040151|DEVICE|Digizorg mobile app (quality evaluation study)|Erasmus Medical Center is developing a state-of-the-art, mobile-based patient portal that combines up-to-date medication lists from all healthcare providers involved in a patient's care. Other functionalities include: accessing health information, viewing and planning appointments, teleconsulting, sending messages, filling in questionnaires, reporting self-measurements, and reading background information on diseases, medication, and other interventions. The patient portal will primarily be implemented in Erasmus Medical Center, and is ultimately intended for every patient, regardless of underlying condition.
224321592|NCT00553176|OTHER|No intervention|At six-month intervals (January and July), physicians will document disease characteristics, changes in Crohn's therapy, disease progression, key events, the use of ancillary services, and hospitalizations
224321593|NCT04094727|DRUG|Presumptive treatment with Artemether-lumefantrine (AL)|All eligible HRPs will be presumptively treated with artemether-lumefantrine (AL) at two timepoints, separated by at least one month. All individuals who have provided informed consent, meet eligibility criteria, are not pregnant or breastfeeding, and who do not have symptoms associated with severe malaria or another severe illness, will be offered an age-appropriate course of AL (age-specific blister packages). AL is currently the first line drug used for uncomplicated malaria in Namibia, and has been used previously in northern Namibia for focal mass drug administration and has no severe adverse effects and is well-tolerated, with high adherence and acceptability in this context. AL requires two daily doses for three consecutive days, for a total of six doses. The first antimalarial dose will be delivered by directly observed therapy (DOT) and subsequent doses will be left with the subject, with instructions to self-administer them.
224321594|NCT04094727|OTHER|Enhanced vector control|"The mop up indoor residual spraying (IRS) campaign will be targeted to farms and cattle posts/kraals in intervention areas in December 2019 to fill gaps from the routine spray campaign (September to November 2019) and utilize the same insecticides and protocols as the national campaign. The team will spray each unsprayed structure with the recommended solution of dichloro-diphenyl-trichloroethane (DDT) for traditional structures and/or Actellic for modern structures, tarps and tents.~Alternative vector control interventions, including LLINs (long-lasting insecticide treated bed nets), sprayed tents/tarps and topical repellents will be distributed to eligible HRPs between November and January 2020 during one round."
224321595|NCT01632280|DEVICE|Transcranial Direct Current Stimulation (tDCS)|"tDCS is a well-established, safe and noninvasive neuromodulation technique that is based on the application of a weak direct current to the scalp that flows between two electrodes-anode and cathode. Although there is substantial shunting of current in the scalp, sufficient current penetrates the brain to modify the transmembrane neuronal potential, and thus influence the level of excitability and modulate the firing rate of individual neurons.~In this study, participants will receive 10 daily sessions of tDCS (sham/real) over a period of two weeks."
224321596|NCT06055829|DRUG|Insulin injection and blood glucose|The FreeStyle Libre sensor continuously measures glucose every minute and saves the glucose data. Scan the sensor at least every 8 hours for a full glycemic profile. The below data is displayed after a typical 1-second scan of the FreeStyle LibreLink app or FreeStyle Libre reader via the sensor:
224321597|NCT05972148|OTHER|Digital scanning|Five intraoral scans, one for each arch before the insertion of scanbodies, were obtained. The implant locations were then marked, and the software trimmed a 6mm diameter circular section of the scan from the implant locations to allow the scanbodies to be added. Abutment-level polyetheretherketone (PEEK) scanbodies were hand-tightened onto each implant and not moved for the remainder of the scans. Scanbodies were scanned using a circular scan path, and scanning was finalized.
224321598|NCT05972148|OTHER|Photogrammetry|Rectangular-shaped titanium photogrammetry scanbodies were hand-tightened onto the Implants. Scanbodies were not moved before completing all scans for each arch. A total of five scans of each arch were obtained using a photogrammetry device. Measurements were successfully recorded by turning them green on the computer screen.
223663813|NCT01433289|DRUG|Polyphenon E|There will be 3 dose levels and for each dose level, there will be 6 subjects who will receive the study drug and 2 subjects who will be randomized to take placebo. Dosing will be escalated sequentially contingent on the safety profile of previous doses. Safety data from all participants receiving Polyphenon® E in the preceding dose level will be evaluated and considered acceptable prior to escalation to the next higher dose. PK analyses will be also performed as each dose level is completed. It is necessary to confirm EGCG pharmacokinetics in the event that the primary outcome measure of virologic response is not observed for each arm. For each PK visit on Study Days 1 and 14, a total of 10 blood samples will be obtained per subject.
223663814|NCT01433289|DRUG|Placebo|
224243740|NCT04869787|DEVICE|Selective Cytopheretic Device|SCD in line with CRRT extracorporeal device
224243741|NCT05110209|OTHER|Aflibercept|intravitreal injection
224321599|NCT00993421|DRUG|LY377604|Given daily, orally for 24 weeks
224321600|NCT00993421|DRUG|Sibutramine|given daily, orally for 24 weeks
224321601|NCT00993421|DRUG|Metoprolol|given daily, orally for 24 weeks (100 mg for 1 week followed by 200 mg for 23 weeks. Patients unable to tolerate 200 mg will be dose reduced to 100 mg), followed by a 2 week taper (1 week at 100 mg/day followed by 1 week at 50 mg/day).
224321602|NCT00993421|DRUG|Placebo sibutramine|given daily, orally for 24 weeks
223663815|NCT06333600|DRUG|Topical minoxidil|Therapeutic intervention
223663816|NCT06333600|DRUG|Topical Vitamin D|Therapeutic intervention
224243742|NCT05110209|OTHER|Ranibizumab|intravitreal injection
224243743|NCT05110209|OTHER|Bevacizumab|intravitreal injection
224243744|NCT03056937|OTHER|Bariatric surgery|evaluations pre and post bariatric surgery.
224243745|NCT03056937|OTHER|Control|without intervention, it will be performed only evaluations
224243746|NCT03834870|BEHAVIORAL|Virtual cOaching in making Informed Choices on Elder Mistreatment Self-Disclosure (VOICES)|Virtual cOaching in making Informed Choices on Elder Mistreatment Self-Disclosure (VOICES) screening tool.
224243747|NCT02550678|BIOLOGICAL|ASN-002|ASN-002, is made of a suspension of recombinant adenoviral particles carrying a gene coding for the human interferon-gamma (IFN). Study participants will receive protocol defined dose of ASN-002 as intra-tumoral injections.
224243748|NCT02550678|DRUG|5-FU|5-FU is chemotherapeutic agent used to treat various cancers.
224243749|NCT01985893|DRUG|Lapatinib plus trastuzumab|Comparison of the safety and efficacy of lapatinib plus trastuzumab and lapatinib plus capecitabine.
224243750|NCT00813293|DRUG|Sorafenib|
224243751|NCT00813293|PROCEDURE|radiofrequency ablation|
224243752|NCT00004907|DRUG|busulfan|
224321603|NCT00993421|DRUG|Placebo Metoprolol|given daily, orally for 26 weeks (24 weeks plus 2 weeks of taper)
224321604|NCT00993421|DRUG|Placebo LY377604|given daily, orally for 24 weeks
224321605|NCT00716794|DRUG|HE3235|HE3235 will be administered orally in 28 day cycles.
224321606|NCT04357080|PROCEDURE|Urethroplasty|Augmentation Anterior Urethroplasty Using Dorsal Onlay Buccal Mucosal Graft
224321607|NCT03101176|DRUG|SonoVue|The ultrasound contrast agent used for the CEUS specific ultrasound mode
223663817|NCT06333600|DRUG|Saline spray|placebo
224243753|NCT00004907|DRUG|cyclophosphamide|
224243754|NCT00004907|DRUG|etoposide|
224243755|NCT00004907|PROCEDURE|allogeneic bone marrow transplantation|
224243756|NCT00004907|PROCEDURE|bone marrow ablation with stem cell support|
224243757|NCT00004907|PROCEDURE|peripheral blood stem cell transplantation|
224243758|NCT00004907|RADIATION|radiation therapy|
224243759|NCT03205254|OTHER|Mediterranean Diet|four days of participant-scaled isocaloric Mediterranean meals
224243760|NCT03205254|OTHER|Fast food diet|four days of participant-scaled isocaloric fast food meals
224243761|NCT04348162|OTHER|Cocoa flavanols and berries anthocyanins|Effect of cocoa flavanols and berries anthocyanins on cardiovascular and cognitive health
224243762|NCT02867930|DRUG|Dexmedetomidine|drug for moderate sedation in trans-esophageal echocardiography
224243763|NCT02867930|DRUG|Ketofol(ketamine+propofol)|drug for moderate sedation in trans-esophageal echocardiography
224243764|NCT04053348|PROCEDURE|Home-based rehabilitation program using mobile app|Home-based rehabilitation program
224243765|NCT03343730|DIAGNOSTIC_TEST|Non-mydriatic color fundus photography with the RetinaVue camera|This hand-held device allows the primary care physician to capture an image of the patient's retina and transmit the image to a board-certified ophthalmologist for interpretation.
224243766|NCT03343730|DIAGNOSTIC_TEST|Referral for dilated eye exam with an eye care professional|All patients will be given a referral to an eye care professional for a routine, dilated, diabetic eye exam.
224243767|NCT04175964|BEHAVIORAL|ketogenic diet|The ketogenic diet will be designed according to the BMI for each participant by a consultant nutritionist. All participants will be prescribed this diet for 8 weeks.
224321608|NCT06633120|OTHER|IVM|Immature oocytes will be retrieved from small ovarian follicles and matured overnight in the laboratory prior to undergoing fertilization and embryo culture.
224321609|NCT00003198|DRUG|ifosfamide|
224321610|NCT00003198|DRUG|topotecan hydrochloride|
224321611|NCT01561261|OTHER|Continuous tissue perfusion monitoring by near-infrared spectroscopy (NIRS) and intramuscular pressure (IMP)|Continuous monitoring of tissue perfusion using NIRS in all 4 leg muscle compartments and IMP via indwelling catheters in anterior and deep posterior compartments. These measures will not provided in real time to treating physicians. All clinical care, including the diagnosis of ACS, will be according to the current standard-of-care practiced at each institution, Clinicians may use the indwelling IMP monitor to obtain up to 2 discrete measures of IMP if they encounter a clinical situation in which they would normally measure IMP as an adjunct in their normal standard-of-care for the monitoring and diagnosis of compartment syndrome. Patients who undergo fasciotomy will also have NIRS and IMP values recorded from all 4 leg compartments immediately before and after fasciotomy.
224321612|NCT04825340|BIOLOGICAL|Nasal Spray Lyophilized Live Attenuated Influenza Vaccine|0.2 ml/vial, 0.2ml/dose/per person
224321613|NCT01428154|DRUG|Darbepoetin alfa|A single 1.5 μg/kg subcutaneous (SC) dose administration on day 1
223663818|NCT02284932|OTHER|No specific intervention for this study|No specific intervention for this study
223663819|NCT05253391|OTHER|Routine care|"The investigator takes care of the patient according to the protocol in force in his department and decides on the final orientation of the patient (transfer to intensive care unit/ICU, hospitalization or home discharge).~No recommendations or instructions are given to the investigators. Each investigator is free to decide on his care and the terms of transfer, hospitalization and discharge."
223663820|NCT01425580|DRUG|liraglutide|1.8 mg s.c. (QD)
224243768|NCT04175964|COMBINATION_PRODUCT|caloric diet with Metformin|The caloric diet will be designed according to the BMI for each participant by a consultant nutritionist. All participants will be prescribed this diet with Metformin for 8 weeks.
224243769|NCT04175964|BEHAVIORAL|caloric diet|The caloric diet will be designed according to the BMI for each participant by a consultant nutritionist. All participants will be prescribed this diet for 8 weeks.
224243770|NCT03088670|DRUG|Gosogliptin|20 mg per day, dose titration to 30 mg per day at Week 4 as required Administration: orally
224243771|NCT03088670|DRUG|Vildagliptin|50 mg per day, dose titration to 100 mg per day at Week 4 as required (50 mg twice a day) Administration: orally
224243772|NCT03088670|DRUG|Metformin|"1000 mg per day starting Week 12 (500 mg twice a day), dose titration to 2000 mg per day at Week 16 as required (1000 mg twice a day).~Administration: orally"
224321614|NCT06282783|DRUG|Topiramate|Single dose of 400mg
223663821|NCT01425580|DRUG|glimepiride|4 mg p.o. (QD)
223663822|NCT01425580|DRUG|Metformin|500 mg p.o. (BID)
223663823|NCT02482831|PROCEDURE|Subgluteal sciatic nerve block|All patients (either diabetic or non-diabetic patients) received an ultrasound-guided (nerve stimulator assisted) subgluteal sciatic nerve block with 0.75% ropivacaine 20ml.
223663824|NCT00522132|DRUG|Artesunate|intravenous application
223663825|NCT02313961|OTHER|Remote ischaemic conditioning|Remote ischaemic conditioning is induced by 3 cycles of manual inflation of a blood pressure cuff placed on the left lower limb to 200 mmHg for 5 minutes and then deflation to 0 mmHg for another 5 minutes.
223663826|NCT03665727|BEHAVIORAL|Mindfulness|The 15 minute mindfulness session is a scripted mindfulness exercise that incorporates mindfulness principles of intentionally paying attention to present-moment experience in a non-judgmental fashion.
223663827|NCT03665727|BEHAVIORAL|Suggestion|The 15 minute suggestion session is a scripted suggestion exercise that incorporates imagery and suggestions for changes in cognition, emotion, and body sensations.
223663828|NCT03665727|BEHAVIORAL|Psychoeducation|The 15 minute psychoeducation session is a supportive session in which behavioral coping strategies for pain management are discussed.
223663829|NCT02215811|BIOLOGICAL|Mesenchymal stromal cells|
223663830|NCT02106858|DRUG|Regorafenib (Stivarga,BAY73-4506)|Patients treated by Physician with Stivarga under approved local prescriptions
223663831|NCT00882297|PROCEDURE|Echoguided vein puncture|Puncture with echographic visualization of vein in transversal and longitudinal way.
223663832|NCT01125488|DEVICE|LNG-IUS|levonorgestrel-releasing intrauterine system (LNG-IUS) 52mg, duration 5 years
223663833|NCT01125488|DRUG|GnRH agonist (triptorelin)|GnRH agonist (triptorelin 3.75 mg, sc q28day)
223663834|NCT05243732|BEHAVIORAL|Mindful Music Listening|"Participants will be instructed to self-administer this intervention daily, five days a week, for four weeks, 20 to 60 minutes per day at any time that is convenient for them.~During the intervention period, participants will be recommended to listen to music in a private setting that is quiet, where they will not be disturbed or distracted so they can fully focus on the music.~Participants in the mindful listening group will be given specific instructions on how to listen and follow mindfulness."
223663835|NCT05243732|BEHAVIORAL|Music Listening|"Participants will be instructed to self-administer this intervention daily, five days a week, for four weeks, 20 to 60 minutes per day at any time that is convenient for them.~During the intervention period, participants will be recommended to listen to music in a private setting that is quiet, where they will not be disturbed or distracted so they can fully focus on the music. No other specific music listening instructions will be given"
223663836|NCT01481194|DRUG|Doxorubicin|50 mg/m2 IV on day 1 of a 21-day cycle
223663837|NCT01481194|DRUG|Bortezomib|1.3 mg/m2 IV push on days 2 and 9 of a 21-day cycle
223663838|NCT01481194|DRUG|Lenalidomide|15 mg orally on days 1-14 of a 21-day cycle
223663839|NCT01481194|DRUG|Dexamethasone|20 mg orally on days 2, 3, 9, and 10 of a 21-day cycle
223663840|NCT01481194|DRUG|Cyclophosphamide|750 mg/m2 IV on day 1 of a 21-day cycle
223663841|NCT04961411|PROCEDURE|operation or non-operative treatment|type of operation or if possible non-operative treatment
223663842|NCT04343235|DRUG|furosemide|five day course of furosemide 20mg QD
223663843|NCT04343235|DRUG|labetalol|200mg labetalol BID
223663844|NCT04159753|DEVICE|Spinal Cord Stimulator|We will record patient's experience on the 30-Day FDA approved Burst Spinal Cord Stimulator Trial (BurstDR™, Abbott Saint Jude Medical).
224243773|NCT00768742|DEVICE|VizAblate Intrauterine Ultrasound-Guided RF Ablation|VizAblate enables a minimally invasive procedure to visualize, target and treat uterine fibroids using ultrasound visualization and RF energy.
224243774|NCT02914600|DRUG|Filgotinib|Tablet administered orally once a day
223663845|NCT01763996|DRUG|Febuxostat|Febuxostat capsules
223663846|NCT01763996|DRUG|Febuxostat placebo|Febuxostat placebo-matching capsules
223663847|NCT02280018|DRUG|JNJ-49122944, 5 milligram (mg)|Participants will receive single dose of 5 mg JNJ-49122944, administered as a 22.2 mL IV infusion over 45 minutes on Day 1.
223663848|NCT02280018|DRUG|Placebo|Participants will receive placebo matched to JNJ-49122944, administered as a 22.2 mL IV infusion over 45 minutes on Day 1.
223663849|NCT06521528|DEVICE|nProfiler I Stomach Cancer Assay Kit|nProfiler I Stomach Cancer Assay Kit (Novomics Co., Korea)
223663850|NCT04412785|DRUG|Cyclosporine|• The initial dose will be 9 mg/kg/day oral divided q12h. For IV, the dose will be 3mg/kg/day by continuous IV infusion.
223663851|NCT05826171|BEHAVIORAL|High-Intensity Aerobic Exercise Prior to Balance Training|20-30 minutes of high intensity aerobic exercise followed by 20-30 minutes of individualized balance training over telehealth twice weekly, for 8 weeks (16 sessions total). For the aerobic component, participants will be instructed in a 20-30-minute exercise program, using available equipment already located in the participant's home (eg. stationary cycle, elliptical trainer, etc). Exercise intensity is moderate-to-high (between 50-85% Heart Rate Reserve. Participants will be placed on a ramped protocol which increases in intensity slowly over the course of the intervention period. For the balance training component, exercises will consist of steady state, proative, and reactive balance activities that involve sensory integration of vision, proprioception, and vestibular senses. Exercises will be individualized based on baseline assessment outcomes and severity of ataxia as rated by the SARAHome.
223663852|NCT05826171|BEHAVIORAL|Low-Intensity Exercise Prior to Balance Training|"20-30 minutes of light intensity warm-up type exercises, followed by 20-30 minutes of individualized balance training over telehealth twice weekly, for 8 week (16 sessions total). For the warm-up exercise component, exercises will consist of stretching and core training. For the balance training component, exercises will consist of steady state, proactive, and reactive balance activities that involve sensory integration of vision, proprioception, and vestibular senses throughout. Exercises will be individualized based on baseline assessment outcomes and severity of ataxia as rated by the SARAHome.~Both groups are matched for time and frequency of intervention components."
223663853|NCT00512980|DRUG|prednisone|
224243775|NCT02914600|DRUG|Placebo|Tablet administered orally once a day
224243776|NCT01292330|PROCEDURE|nutritional support before operation|nutritional support before operation for more than 4 days
224243777|NCT01327690|BEHAVIORAL|CBT (Cognitive Behavior Therapy)|CBT group therapy sessions
224243778|NCT01327690|BEHAVIORAL|EFT (Emotional Freedom Techniques)|Group therapy sessions using EFT
223663854|NCT00512980|DRUG|vinblastine|
223663855|NCT00512980|DRUG|doxorubicin|
223663856|NCT00512980|DRUG|gemcitabine|
223663857|NCT02371941|DRUG|oral cromolyn sodium|Oral cromolyn sodium
223663858|NCT02371941|DRUG|Placebo|Saline
223663859|NCT01788215|DRUG|doxycycline|200mg/day in divided doses of 100mg twice daily
223663860|NCT01788215|OTHER|Sugar Pill|1 pill twice a day
223663861|NCT02481128|PROCEDURE|without preoperative access to lymphoscintigraphy findings|axillary sentinel lymph node biopsy without access to lymphoscintigraphy findings
223663862|NCT02129088|DRUG|Esketamine|Esketamine 14 mg will be self-administered by participants as intranasal spray into each nostril on Day 1 to cohort 1 and cohort 2 in a fixed sequence.
223663863|NCT02129088|DRUG|Placebo|Placebo will be self-administered as intranasal spray by participants after 5 and 10 minutes of esketamine administration into each nostril on Day 1 of Treatment period 2 to Cohort 2.
223663864|NCT03803319|DIETARY_SUPPLEMENT|Fibre 1 (combined fibres)|Dietary fibre supplement
223663865|NCT03803319|DIETARY_SUPPLEMENT|Fibre 2 (natural fibres)|Dietary fibre supplement
223663866|NCT03803319|DIETARY_SUPPLEMENT|Dietary Supplement: placebo|Dietary supplement
223663867|NCT02745015|PROCEDURE|non-surgical periodontal treatment|full-mouth scaling and root planing
223663868|NCT01794286|OTHER|Provider bulletins|
223663869|NCT01794286|OTHER|Trigger alerts|
223663870|NCT00275340|OTHER|Peer Support|
223663871|NCT00004908|DRUG|cyclophosphamide|
223663872|NCT00004908|PROCEDURE|peripheral blood stem cell transplantation|
223663873|NCT00004908|RADIATION|radiation therapy|
223663874|NCT00002771|BIOLOGICAL|recombinant interferon alfa|
223663875|NCT00002771|DRUG|busulfan|
223663876|NCT00002771|DRUG|cytarabine|
223663877|NCT00002771|DRUG|hydroxyurea|
223663878|NCT00002771|DRUG|idarubicin|
223663879|NCT00002771|PROCEDURE|allogeneic bone marrow transplantation|
223663880|NCT00002771|PROCEDURE|autologous bone marrow transplantation|
223663881|NCT00002771|PROCEDURE|peripheral blood stem cell transplantation|
223663882|NCT00002771|RADIATION|radiation therapy|
223663883|NCT02299791|OTHER|ALL|"This clinic-level intervention involves a toolkit of decision support tools. These tools are listed below.~1. EHR tools to expedite identification~   a. EHR automated point-of-care alerts (Best Practice Alerts)~2. EHR tools to expedite prescribing~   1. EHR order sets~  2. EHR text shortcuts for notation~  3. patient education materials (handout, poster)~3. EHR-based outreach support tools a. EHR registries"
223663884|NCT02299791|OTHER|ALL|These clinics got the same exact intervention, but one year later, as this was a staggered randomized trial.
223663885|NCT06240416|PROCEDURE|Low speed drilling without irrigation|Low-speed drilling (50 rpm) irrigation to perform the osteotomy
223663886|NCT06240416|PROCEDURE|High speed drilling with irrigation|High-speed drilling (800 rpm) irrigation to perform the osteotomy
223663887|NCT03163017|DEVICE|2D Fluoroscopy|Patients with syndesmotic instability will undergo reduction of the syndesmosis followed by provisional fixation with a clamp or Kirshner wire. The reduction quality will be initially compared to the contralateral ankle mortise and talar-dome lateral radiographs using the technique of Summers et al i.e. 2D Fluoroscopy using device Ziehm Vision RFD 3D image-intensified fluoroscopic x-ray system.
223663888|NCT03163017|DEVICE|3D Fluoroscopy|After the attending surgeon is satisfied with the reduction quality from 2D Fluoroscopy, 3D fluoroscopy using device Ziehm Vision RFD 3D image-intensified fluoroscopic x-ray system will be used to generate additional images to assess syndesmotic and fibular reductions.
223663889|NCT05625555|DRUG|Ketamine|IV Ketamine infusion 0.5mg/kg over 40 minutes
223663890|NCT05625555|DRUG|Midazolam|IV Midazolam infusion 30μg/kg over 40 minutes
223663891|NCT00815555|OTHER|There is no intervention - this is an observational study|
223663892|NCT06060327|DRUG|Tranexamic acid|Giving oxytocin only, or oxytocin in addition to Tranexamic acid, Misoprostol or Carbetocin the mentioned doses and by the mention routes, then comparing the estimated blood loss in each group.
223663893|NCT03535298|DRUG|Early Highly Effective Therapies Group|Highly Effective MS Therapy group of medications
223663894|NCT03535298|DRUG|Escalation Therapies Group|Escalation MS Therapy group of medications
223663895|NCT00612105|DRUG|Retigabine|150mg/day up to 900mg/day
223663896|NCT00612105|DRUG|Placebo|daily
223663897|NCT03803241|DRUG|CD133+ infusion|Infusion of cells cd133+
223663898|NCT03803241|OTHER|portal vein embolization|portal vein embolization
223663899|NCT04090372|DEVICE|evaluation of pre-op planning using Traumacad|The study will be compare pre-op planning with standard condition or with TraumaCad
223663900|NCT00770159|DRUG|odanacatib|Panel A: MK0822 tablets 25 mg once weekly for 3 weeks. Panel B: MK0822 tablets 50 mg once weekly for 3 weeks. Panel C: MK0822 tablets 100 mg once weekly for 3 weeks. Panel D: MK0822 tablets 5 mg once weekly for 3 weeks. Panel E: MK0822 tablets 100 mg once weekly for 6 weeks.
223663901|NCT00770159|DRUG|Comparator: placebo to MK0822|Panel A: placebo to MK0822 tablets 25 mg once weekly for 3 weeks. Panel B: placebo to MK0822 tablets 50 mg once weekly for 3 weeks. Panel C: placebo to MK0822 tablets 100 mg once weekly for 3 weeks. Panel D: placebo to MK0822 tablets 5 mg once weekly for 3 weeks. Panel E: placebo to MK0822 tablets 100 mg once weekly for 6 weeks.
223663902|NCT01105767|DRUG|Chlorhexidine gluconate|Self applied chlorhexidine body wash (4% chlorhexidine gluconate, Hibiclens®, Mӧlnlycke Heath Care, Norcross, Georgia) once a week to wash/cover the body (except the face and genitalia).
223663903|NCT01105767|OTHER|Supplemental training, education and hygiene|Supplemental SSTI education for trainees and drill sergeants included pocket cards and posters. Drill sergeants received briefings on SSTI and skin inspection/minor wound care. Trainees were instructed to take an additional 10-minute shower with soap and a wash cloth every week. They were also issued a first aid kit.
223663904|NCT04786834|PROCEDURE|Vesico urethral anastomosis on chicken model|Performance of a vesico urethral anastomosis on a chicken model with Da Vinci robotic system
223663905|NCT04772833|OTHER|Autopsy|The subjects deceased will undergo an autopsy to analyze the histopathological, ultrastructural and microbiological findings, related to the COVID-19 disease.
224243779|NCT02649803|BEHAVIORAL|asthma APP|Subjects diagnosed as pediatric asthma at Shanghai Children's Medical Center will be consecutively screened and eligible patients will be recruited (enrolment visit, V1). The subject will be assigned to the nearest community hospital or Shanghai Children's Medical Center, whichever is nearer to the subject's home, for their future onsite visits (V2-V5). The patient's caregiver will be instructed to install the asthma APP at their smart phone and learn how to use this APP.
223663906|NCT00743106|DRUG|Fenoldopam|Fenoldopam (0.1 \~g/kg/min)started during surgery and lasting for a total of 24 hours
223663907|NCT00743106|DRUG|Placebo|Placebo infusion(0.9% Nacl) beginning during surgery and lasting for up 24 hours post surgery
223663908|NCT03730142|DRUG|WXFL10030390|WXFL10030390 is a tablet in the form of 0.1mg and 0.5mg, oral, once a day.
223663909|NCT04611490|PROCEDURE|Spine Fusion|Each patient will undergo a spine fusion for a evolutive idiopathic scoliosis with the help of the surgivisio system.
223663910|NCT04771091|DIAGNOSTIC_TEST|Mesure of head-perineum distance by transperineal ultrasound|A mesure of head-perineum distance by ultrasound will be realized at the beginning of maternal pushing efforts by a junior gynecologist
223663911|NCT05960630|PROCEDURE|MIRRORS Protocol|Diagnostic laparoscopic assessment proceeding to either robotic (if considered appropriate following laparoscopic assessment) or open Interval cytoreductive surgery with conversion to open at any point should this be required to remove all visible disease.
223663912|NCT05960630|PROCEDURE|Standard Open Cytoreductive Surgery|Extended midline incision. Open surgical approach to interval cytoreductive surgery with the aim of removing all visible disease.
223663913|NCT00900588|BIOLOGICAL|split-virion pandemic influenza vaccine (H5N1 strain NIBRG-14)|
223663914|NCT04865900|DIAGNOSTIC_TEST|Laboratory Blood Tests|Blood tests to determine liver and kidney functioning, total blood count, and troponin levels
223663915|NCT04865900|DIAGNOSTIC_TEST|ECG|ECG to determine heart rate and functioning
223663916|NCT04865900|DIAGNOSTIC_TEST|PCR|PCR test to determine whether patient has Covid19
223663917|NCT04865900|DIAGNOSTIC_TEST|Antibody test|Antibody test to determine level of antibodies to Covid19
223663918|NCT04865900|DIAGNOSTIC_TEST|Echocardiography|If Troponin level elevated echocardiography to determine heart function
223663919|NCT04865900|DIAGNOSTIC_TEST|MRI|If Troponin level elevated MRI to determine heart function
223663920|NCT04408560|DRUG|Rhus toxicodendron 9 CH + Ruta graveolens 5 CH (Homeopathic Granules)|Rhus toxicodendron 9 CH + Ruta graveolens 5 CH
223663921|NCT04408560|OTHER|paracetamol (drug analgesic class1)|paracetamol (drug analgesic class1)
223663922|NCT03497351|DRUG|Nicardipine|The patients in Group N were infused the 130/0.4 hydroxyethyl starch and sodium chloride injection ( 7 ml/kg, 0.4 ml/kg/min) after anesthesi induction and before skin incision. Then the HR, SAP, DAP, MAP, CO, CI, SV, SVI, PPV and SVV were recorded. When the circulation was stability, Nicardipine was given, and the the 130/0.4 hydroxyethyl starch and sodium chloride injection was infused again.
223663923|NCT03497351|DRUG|Urapidil|The patients in Group N were infused the 130/0.4 hydroxyethyl starch and sodium chloride injection ( 7 ml/kg, 0.4 ml/kg/min) after anesthesi induction and before skin incision. Then the HR, SAP, DAP, MAP, CO, CI, SV, SVI, PPV and SVV were recorded. When the circulation was stability, Urapidil was given, and the the 130/0.4 hydroxyethyl starch and sodium chloride injection was infused again.
223663924|NCT00230867|DEVICE|iontophoretic acyclovir|
223663925|NCT01115322|DRUG|Tazarotene Foam without irradiation|"Each subject will be exposed to a patch with tazarotene foam during a single, 24 hour application period.~This patch will then be removed and those sites will serve as nonirradiated control. Patch sites will be evaluated for signs of inflammatory skin responses (eg, erythema and local skin reactions) and superficial effects 1 ±0.25 hour after patch removal, and during follow-up visits at 24 ±1 hours, 48 ±2 hours, and 72 ±2 hours after patch removal."
223663926|NCT01115322|DRUG|Tazarotene Foam with UVA and UVB irradiation|"Each subject will be exposed to a patch with tazarotene foam during a single, 24 hour application period. The patch will be removed and that site will be exposed to ultraviolet A (UVA) and to UVA/ultraviolet B (UVB) radiation wavelengths (UV only).~Patch sites will be evaluated for signs of inflammatory skin responses (eg, erythema and local skin reactions) and superficial effects 1 ±0.25 hour after patch removal, and during follow-up visits at 24 ±1 hours, 48 ±2 hours, and 72 ±2 hours after patch removal."
223663927|NCT01115322|DRUG|Tazarotene Foam with UVA, UVB, and visible light|"Each subject will be exposed to a patch with tazarotene foam during a single, 24 hour application period. The patch will be removed and that site will be exposed to UVA, UVA/UVB, and visible light (VIS) wavelengths (UV plus VIS).~Patch sites will be evaluated for signs of inflammatory skin responses (eg, erythema and local skin reactions) and superficial effects 1 ±0.25 hour after patch removal, and during follow-up visits at 24 ±1 hours, 48 ±2 hours, and 72 ±2 hours after patch removal."
223663928|NCT01115322|DRUG|Vehicle Foam without irradiation|Each subject will be exposed to a patch with vehicle foam during a single, 24 hour application period. This patch will then be removed and those sites will serve as nonirradiated control. Patch sites will be evaluated for signs of inflammatory skin responses (eg, erythema and local skin reactions) and superficial effects 1 ±0.25 hour after patch removal, and during follow-up visits at 24 ±1 hours, 48 ±2 hours, and 72 ±2 hours after patch removal.
224243780|NCT03522675|DEVICE|NeoMatriX Wound MatriX Collagen Dressing|Collagen wound dressing
224243781|NCT01586611|DRUG|5FU, leucovorin, oxaliplatin|Oxaliplatin 100 mg/m2 IV day 1 Leucovorin 400 mg/m2 IV day 1 5-FUl 400 mg/m2 IV day 1 5-FU 2400 mg/m2 IV continuous infusion over 46 hours starting day 1
224243782|NCT01586611|DRUG|Gemcitabine|1000 mg/m2 IV weekly for 3 weeks then one week off
224243783|NCT02171637|DRUG|BIBW 2992|escalating doses
224243784|NCT00707161|RADIATION|Radiation Therapy|Radiation therapy will be delivered concurrent with cisplatin chemotherapy as outlined in table 2. Radiation therapy dose will be 50 Gy (2.5 Gy per day, 5 days per week, for 20 treatments).
224243785|NCT00707161|DRUG|Cisplatin|Cisplatin dose will be 100 mg/m2 given i.v. every 3 weeks for a total of 2 doses (days 1 and 22) during radiation.
224243786|NCT00707161|PROCEDURE|Surgical resection|Surgical resection of residual (or recurrent) melanoma for cure or for palliation may be performed following chemoradiation if deemed appropriate by the treating physicians (surgical resection may be planned following pre-operative chemoradiation or may be performed for salvage due to inadequate response to chemoradiation or for relapse following chemoradiation). Surgical resection will not be performed until at least 4 weeks following chemoradiation (unless deemed emergent by the treating physicians).
224243787|NCT04269460|DRUG|Bupivacaine Hydrochloride 0.25% Injection Solution [MARCAINE]|preoperative ultrasound guided subcostal TAP block and Quadratus lumborum block using 1 ml/kg of Bupivacaine Hydrochloride 0.25%in pediatric patients undergoing pyeloplasty surgeries.
224243788|NCT06303726|PROCEDURE|ACL reconstruction single bundle|We will do surgery of ACL reconstruction with patellar ligament.
223663929|NCT01115322|DRUG|Vehicle Foam with UVA and UVB irradiation|"Each subject will be exposed to a patch with vehicle foam during a single, 24 hour application period. The patch will be removed and that site will be exposed to ultraviolet A (UVA) and to UVA/ultraviolet B (UVB) radiation wavelengths (UV only).~Patch sites will be evaluated for signs of inflammatory skin responses (eg, erythema and local skin reactions) and superficial effects 1 ±0.25 hour after patch removal, and during follow-up visits at 24 ±1 hours, 48 ±2 hours, and 72 ±2 hours after patch removal."
223663930|NCT01115322|DRUG|Vehicle Foam with UVA and UVB and visible light irradiation|"Each subject will be exposed to a patch with vehicle foam during a single, 24 hour application period. The patch will be removed and that site will be exposed to UVA, UVA/UVB, and visible light (VIS) wavelengths (UV plus VIS).~Patch sites will be evaluated for signs of inflammatory skin responses (eg, erythema and local skin reactions) and superficial effects 1 ±0.25 hour after patch removal, and during follow-up visits at 24 ±1 hours, 48 ±2 hours, and 72 ±2 hours after patch removal."
223663931|NCT01115322|DRUG|No Treatment without irradiation|Each subject will be exposed to a blank patch during a single, 24 hour application period. This patch will then be removed and those sites will serve as nonirradiated control. Patch sites will be evaluated for signs of inflammatory skin responses (eg, erythema and local skin reactions) and superficial effects 1 ±0.25 hour after patch removal, and during follow-up visits at 24 ±1 hours, 48 ±2 hours, and 72 ±2 hours after patch removal.
223663932|NCT01115322|DRUG|No Treatment with UVA and UVB irradiation|"Each subject will be exposed to a blank patch during a single, 24 hour application period. The patch will be removed and that site will be exposed to ultraviolet A (UVA) and to UVA/ultraviolet B (UVB) radiation wavelengths (UV only).~Patch sites will be evaluated for signs of inflammatory skin responses (eg, erythema and local skin reactions) and superficial effects 1 ±0.25 hour after patch removal, and during follow-up visits at 24 ±1 hours, 48 ±2 hours, and 72 ±2 hours after patch removal."
223663933|NCT01115322|DRUG|No Treatment with UVA and UVB and visible light irradiation|"Each subject will be exposed to a blank patch during a single, 24 hour application period. The patch will be removed and that site will be exposed to UVA, UVA/UVB, and visible light (VIS) wavelengths (UV plus VIS).~Patch sites will be evaluated for signs of inflammatory skin responses (eg, erythema and local skin reactions) and superficial effects 1 ±0.25 hour after patch removal, and during follow-up visits at 24 ±1 hours, 48 ±2 hours, and 72 ±2 hours after patch removal."
223663934|NCT00824733|DRUG|Trastuzumab|IV at 2 mg/kg over 30 minutes on day 1 of each weekly cycle. Patients who have not received trastuzumab for 4 weeks or more will receive a loading dose of 4 mg/kg over 90 minutes day 1 of the first cycle. The dose of trastuzumab will be based on the patient's actual weight at the start of each 4 week treatment cycle.
223663935|NCT00824733|DRUG|PF03512676|Patients also receive PF03512676 subcutaneously on days 15 and 22 of course 1 and on days 1, 8, 15, and 22 of all subsequent courses.
223663936|NCT00824733|OTHER|Correlative Studies|Blood for performing the correlative studies will be drawn on week 1, 2, 6, 12 and 18.
223663937|NCT00651729|BIOLOGICAL|Botulinum Toxin Type A|Each patient received from 1 to 5 treatments, with a minimum of 12 weeks between treatments. For each treatment, a total dose of 200 U to 400 U botulinum toxin Type A was injected into the wrist and finger flexor muscles of the affected upper limb, not to exceed 6 U/kg
223663938|NCT04713397|DIAGNOSTIC_TEST|Leg Length Discrepancy Scoliometer Test|"A scoliometer used as an indirect and quantitative method to evaluate LLD for the first time in this study, and described it as Leg Length Discrepancy Scoliometer Test. Scoliometer were used on Adams' forward bending position and the level of the pelvis accepted as equal when the scoliometer degree pointed zero on the sacral basis (angle of trunk rotation on sacrum). When considering pelvis level is high on the longer side and is low on the shorter side, if the angle of the scoliometer on the sacrum is negative (slope to the left), the left extremity was considered as shorter. In order to determine its correlation with an indirect method, scoliometer degree on the sacral basis was recorded then wooden blocks were added to the unequal leg side on the sacral basis until the pelvic equality was achieved on the scoliometer. Afterward, a correlation between the first measurement of ATRsacrum and the height of the wooden block which provides ATRsacrum to reach zero was investigated."
223663939|NCT00444561|DRUG|pramlintide acetate|Clear, colorless, sterile solution for SC administration
223663940|NCT02377661|DRUG|Olmesartan medoxomil, amlodipine, hydrochlorothiazide|Up-titration of antihypertensive therapy with single pill combinations (comprising an angiotensin receptor blocker, calcium channel blocker and hydrochlorothiazide) in 4-week intervals if the target blood pressure of \< 140/90 mmHg is not reached at the respective follow-up
223663941|NCT05379010|PROCEDURE|Endodontic Microsurgery|Surgical removal of 3 millimeters of the root-end, removal of the apical pathology, Root-end preparation and retrograde filling. The entire procedure is done under magnification.
223663942|NCT00136513|DRUG|SB-743921|
224243789|NCT06303726|PROCEDURE|ACL reconstruction double bundle|We will do surgery of ACL reconstruction with hamstring ligament.
224243790|NCT02763865|DEVICE|MagVenture MagProx100 Stimulator with a Cool-B65 A/P coil|"Active rTMS administration (1Hz, 1,200sec, 110% resting motor threshold (rMT); 1200 pulses total.~Resting motor threshold assessment the TMS machine will initially be set to 50% of its maximal output."
224243791|NCT02763865|DEVICE|eSHAM system|implemented in conjunction with the Cool-B65 A/P coil to effectively blind participants to rTMS treatment (active or sham)
224243792|NCT01933373|PROCEDURE|Toupet|Laparoscopic posterior partial fundoplication plus myotomy.
224243793|NCT01933373|PROCEDURE|Dor|Anterior partial fundoplication plus myotomy.
223663943|NCT02674204|DRUG|Atorvastatin|Atorvastatin calcium, a synthetic lipid-lowering agent, is an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase. This enzyme catalyzes the conversion of HMG-CoA to mevalonate, an early and rate-limiting step in cholesterol biosynthesis.
223663944|NCT02674204|DRUG|Placebo|A substance that has no therapeutic effect, and will be used as a control in testing the study agent.
223663945|NCT00437008|DRUG|Benfotiamine 1050mg, 3 days|
223663946|NCT00437008|BEHAVIORAL|high-AGE vs. low-AGE meal|
223663947|NCT01912313|PROCEDURE|Rectal biopsies from IBS patients or healthy subjects will be taken during proctoscopy|
223663948|NCT00274833|DRUG|erlotinib hydrochloride|Erlotinib is available as 25 mg, 100 mg, and 150 mg tablets. It should be administered orally once daily at the prescribed dose specified in the clinical study protocol per dose escalation schema. Preferably, erlotinib should be taken in the morning with up to 200 mL of water at least 1 hour before or 2 hours after a meal.
223663949|NCT00274833|DRUG|temozolomide|TMZ is supplied in white opaque, preservative-free, two piece hard gelatin capsules of the following sizes: 100mg capsules, 20mg capsules, and 5mg capsules. TMZ will be a once a day orally administered (75 mg/m2 x BSA x 42 days)set of capsules taken at least two hours after and one hour before a meal.
223663950|NCT00274833|RADIATION|radiation therapy|Concomitant focal RT will be delivered once daily at 2 Gy per fraction, 5 d/wk, for a total of 60 Gy. (6 weeks) as mentioned in therapeutic modalities.
223663951|NCT02646371|BIOLOGICAL|Flexyn2a|2 doses of 10 μg of Flexyn2a will be injected intramuscularly 4 weeks apart
223663952|NCT02646371|BIOLOGICAL|Placebo|2 doses of TBS solution will be injected intramuscularly 4 weeks apart
223663953|NCT00933556|DIETARY_SUPPLEMENT|VSL#3|6 gms of powder formulation to be given once a day for 4 weeks
223663954|NCT00933556|DIETARY_SUPPLEMENT|sugar pill (placebo)|placebo identical to the active product will be given
223663955|NCT00508664|RADIATION|Radiation|Radiation start in week 11
223663956|NCT00508664|DRUG|Cetuximab|Day 1 400mg/m2 i.v. than weekly 250 mg/m2 i.v. for 16 weeks
223663957|NCT00508664|DRUG|Docetaxel|75 mg/m2 i.v. day 1 3 times
223663958|NCT00508664|DRUG|Cisplatin (TP)|75 mg/m2 i.v. day 1 3 times
223663959|NCT00508664|DRUG|5-Fluorouracil (TPF) (only until Feb 2009)|Only patients recruited until Feb 2009: 750 mg/m2 i.v. day 1-5, 3 times
223663960|NCT02290743|OTHER|Kinesio tape|Application of one Kinesio tape with 0-30 % tension over the muscle fibers of the quadriceps femoris in a stretched position. The tape can be divided into several tails to cover the whole muscle from origin to insertion.
223663961|NCT01937429|DEVICE|Colonoscopy with blue Indigo Carmin®|
223663962|NCT01937429|DEVICE|Standard colonoscopy with insufflation of air|
223663963|NCT01792544|OTHER|Statement|
223663964|NCT01792544|OTHER|No Statement|
223663965|NCT02874144|DRUG|AZ compound|40 mg three times daily po for 12 weeks
223663966|NCT02874144|OTHER|Collection of Biological Specimens|collection of biomarkers for analysis of nasal disease
223663967|NCT02874144|DRUG|Intranasal corticosteroid|QD Nasal Spray
223663968|NCT02874144|DRUG|Placebo|looks like AZ compound, made by same company, double blind. 40 mg three times daily po for 12 weeks
223663969|NCT03370705|DRUG|Sulodexide|Sulodexide 250 ULS twice daily per oral route
223663970|NCT03370705|DRUG|Statin|Statin 20mg once daily per oral route,
223663971|NCT03370705|DRUG|Antiplatelet Agents|Antiplatelet therapy 75mg once daily per oral route
223663972|NCT03370705|DRUG|ACE inhibitor|ACE inhibitor 20mg once daily per oral route
223663973|NCT02540278|BEHAVIORAL|Positive Prevention PLUS|PP+ has elven 45 minute lessons: (1) Getting Started, (2) Life Planning, (3) Healthy Relationships, (4) Relationship Violence, (5) Family Planning and Contraceptives, (6) Myths and Stereotypes, (7) HIV Disease and AIDS, (8) Recognizing and Reducing Risk, (9) Peer and Media Pressures, (10) Human Immunodeficiency Virus (HIV)/Sexually Transmitted Disease (STD) Testing and Community Resources, and (11) Steps to Success.
224243794|NCT04869722|BEHAVIORAL|Liquid Model|Whey protein beverages will be used, with the amount of protein varied to study the effect on perception of the products (using sensory methods rating mouthdrying and discrimination tests 'which sample is more mouthdrying') all measured at home.
223663974|NCT00486811|DRUG|Tapentadol ER (100 to 250 mg twice daily)|50, 100, 150, 200, 250 mg twice a day (BID) during 15 weeks (3 weeks titration and 12 weeks maintenance)
223663975|NCT00486811|DRUG|Matching Placebo (twice daily)|Matching Placebo during 15 weeks (3 weeks titration and 12 weeks maintenance)
223663976|NCT00486811|DRUG|Oxycodone CR (20 to 50 mg twice daily)|10, 20, 30, 40, 50 mg twice a day (BID) during 15 weeks (3 weeks titration and 12 weeks maintenance)
223663977|NCT02659748|DIETARY_SUPPLEMENT|Milk Fat|Three daily servings of whole yogurt (3.25% fat).
223663978|NCT02659748|DIETARY_SUPPLEMENT|Control Fat|Three daily servings of fat-free yogurt supplemented with a control fat.
223663979|NCT03753789|DEVICE|Microwave Ablation|NEUWAVE microwave ablation of soft tissue liver lesions will be performed percutaneously by an interventional radiologist while the patient is under general anesthesia or deep conscious sedation.
223663980|NCT01146587|DEVICE|GangTrainer GT1|30 minutes of treatment on the GangTrainer GT1 and 30 minutes of Conventional Physiotherapy every workday for 8 weeks
223663981|NCT01146587|DEVICE|Lokomat|30 minutes of treatment on the Lokomat and 30 minutes of Conventional Physiotherapy every workday for 8 weeks
223663982|NCT01146587|OTHER|Conventional Physiotherapy|60 minutes of Conventional Physiotherapy every workday for 8 weeks
223663983|NCT02928263|OTHER|Non-Interventional|Other
223663984|NCT02975557|DRUG|Brimonidine 0.15%|Brimonidine 0.15% eye drops 2 times a day for 12 weeks
223663985|NCT02975557|DRUG|Brimonidine 0.075%|Brimonidine 0.075% (1:1 dilution will be performed using 0.15% Alphagan-P solution with Refresh Plus Artificial Tears solution) eye drops 2 times a day for 12 weeks.
223663986|NCT02975557|DRUG|Placebo|Placebo (Refresh plus Artificial Tear) dispensed in Brimonidine bottles 2 times a day for 12 weeks.
223663987|NCT04273906|PROCEDURE|End-range mobilization|End-range mobilization performed in end-range of the tibiofemoral joints' flexion and extension
223663988|NCT04273906|PROCEDURE|Placebo technique|Hands-on technique performed in end-range of the tibiofemoral joints' flexion and extension
223663989|NCT05731349|OTHER|2018 Surviving Sepsis Campaign Hour-1 Bundle|"1. Measure lactate~2. Obtain blood cultures before administering antibiotics~3. Administer broad-spectrum antibiotics based on local guidelines~4. Begin fluid resuscitation with up to 30 mL/kg crystalloid for hypotension or lactate level ≥ 4 mmol/L.~5. Apply vasopressors if hypotensive during or after fluid resuscitation to maintain the MAP ≥ 65 mm Hg"
223663990|NCT02845167|OTHER|Preoperative exercise|Patients will perform 3 consecutive days of 60 min submaximal cycling exercise at a moderate exercise intensity. During the 60 min of exercise, patients will be provided with three equally spaced 3min rest periods
224243795|NCT04869722|BEHAVIORAL|Solid Model|Protein fortified scones will be used, with the amount of fat varied to study the effect on perception of the products (using sensory methods rating mouthdrying and discrimination tests 'which sample is more mouthdrying') all measured at home.
224243796|NCT01237522|DRUG|Metformin|A single dose study with one tablet of metformin 500 mg, time frame 24 hours
224243797|NCT04195022|PROCEDURE|Dental Restoration with Chemically activated Composite resin Alkasite|Selective removal of dental caries with manual instruments, under relative isolation, application of universal adhesive system and restoration with chemically activated composite resin Alkasite.
224243798|NCT04195022|PROCEDURE|Dental Restoration with Bulk fill resin composite|Selective removal of dental caries with manual instruments, under relative isolation, application of universal adhesive system and restoration with bulk fill resin composite.
224243799|NCT01972204|BEHAVIORAL|Intensive adherence instruction|Instruction with educational brochure
224243800|NCT01972204|BEHAVIORAL|Control|Instruction as per usual practice
224243801|NCT05122286|PROCEDURE|Bailout angioplasty|Use balloons or stents for bailout angioplasty
224243802|NCT05122286|PROCEDURE|Standard therapy|Stop the endovascular recanalization procedure or to perform further recanalization attempts using stent-retrievers and/or aspiration catheters
224243803|NCT04048369|DIAGNOSTIC_TEST|Rapid diagnosis of influenza in the emergency medical service|Comparison at the University Hospital of Clermont-Ferrand of a test performed in the Adult Emergencies Department by the nursing staff (point-of-care testing) to a test carried out in the core laboratory (classical testing).
224243804|NCT00601302|DRUG|Amlodipine|
224321615|NCT03997773|BEHAVIORAL|Face-it Intervention|The Face-it intervention is a health promotion intervention consisting of 3 major components: 1) active involvement of health visitors, 2) digital health technology and coaching, and 3) a structured cross-sectoral communication system in the healthcare system. The intervention will begin at time approx. 3 months (after the baseline data collection, i.e. 10-14 weeks postpartum), and continues until 12 months
224321616|NCT02215967|DRUG|Cyclophosphamide|300 mg/m\^2 intravenous (IV) over 30 minutes on days -5, -4, and -3
224321617|NCT02215967|DRUG|Fludarabine|30 mg/m\^2 intravenous (IV) over 30 minutes immediately following the cyclophosphamide on day -5, -4, and -3
223663991|NCT01821976|PROCEDURE|Ertl Procedure|
223663992|NCT01821976|PROCEDURE|Burgess Procedure|
223663993|NCT00597597|DRUG|Erlotinib|During the treatment period, subjects will receive single agent erlotinib, 150mg/day.
223663994|NCT02249000|DEVICE|BIOVALVE prosthesis|Transcatheter Aortic Valve Replacement (TAVR)
223663995|NCT03229642|DEVICE|Active rTMS|The stimulator device was a Magstim super rapid magnetic stimulator (Magstim Company, Ltd., Wales, United Kingdom) with 4 booster modules equipped with a 70-mm air-cooled figure-eight-shaped coil. We performed rTMS on the left dorsolateral prefrontal cortex (DLPFC).The TMS parameters were as follows: 15Hz frequency, pulse intensity 100% of the rMT, 60 pulses per train, inter train pause of 26 sec, 40 stimulation trains, and 2400 total pulses for a total duration of 20 min. The patients received one rTMS session per day during the first five days of treatment, and then twice a week for the following three weeks, for a total of 11 rTMS sessions. The sham group was administered rTMS with the same parameters, but using a figure-of-eight sham coil.
223663996|NCT03229642|DEVICE|Sham rTMS|The stimulator device was a Magstim super rapid magnetic stimulator (Magstim Company, Ltd., Wales, United Kingdom) with 4 booster modules equipped with a 70-mm air-cooled figure-eight-shaped coil. We performed rTMS on the left dorsolateral prefrontal cortex (DLPFC).The TMS parameters were as follows: 15Hz frequency, pulse intensity 100% of the rMT, 60 pulses per train, inter train pause of 26 sec, 40 stimulation trains, and 2400 total pulses for a total duration of 20 min. The patients received one rTMS session per day during the first five days of treatment, and then twice a week for the following three weeks, for a total of 11 rTMS sessions. The sham group was administered rTMS with the same parameters, but using a figure-of-eight sham coil.
223663997|NCT02911831|DRUG|Tranexamic Acid|
223663998|NCT02911831|DRUG|Sodium Chloride|
223663999|NCT00139789|DRUG|Kemstro|
223664000|NCT02027090|DRUG|Routine dose icotinib|Icotinib is administered 125 mg three times daily.
223664001|NCT02027090|DRUG|Higher dose icotinib|After 8-week induction of icotinib with a dose of 125 mg three times daily, icotinib is administered 375 mg three times per day.
223664002|NCT01212380|DRUG|carfilzomib|Given IV infusion lasting 30 minutes. Will be administered IV at a specified dose in mg/m2 QDx2 weekly for 3 weeks (days 1, 2, 8, 9, 15, and 16). The first and second dose will always be administered at 20 mg/m2.
223664003|NCT01212380|OTHER|Cytokine Assessment|TNF-α,IFN-γ,IL-6,IL-8,IL-10,and IL-1β pre-dose, completion, 30 minutes, 2 hours, 6 hours, and approximately 24 hours from initiation of therapy on days 1 and 8 of treatment. These will be assessed utilizing standard ELISA or flow cytometry methodology. Other cytokines or soluble factors may be assessed that relate to drug toxicity or response. After 6 patients are examined in each group, the time points or number of cytokines examined may be changed to decrease time points examined. Cytokines will be examined by a multiplex flow cytometry assay or ELISA. Other cytokines, chemokines, or soluble factors may be assessed on residual material not used for these studies.
223664004|NCT01212380|OTHER|Pharmacodynamic Studies|Based upon our preliminary data changes occuring in vivo during carfilzomib treatment will be determined and if their occurrence correlates with both clinical response and development of cytokine release. These studies will be performed from CD19 selected CLL cells at screening, pre-treatment, 4 hours, and 24 hours post-therapy on days 1 and 8 of treatment; end of therapy evaluation, and at time of relapse (in responding patients). These studies will include assessment of NF-κB (p50/p65 binding; I-κB level, P-I-κB level, select target genes), p53 (p53 nuclear levels, p53 nuclear binding, and select target genes), p73, and ER stress response. Standard Western Blot, EMSA, RT-PCR will be done to complete these studies.
223664005|NCT01212380|OTHER|Proteosome Inhibition Assessment|Proteosome inhibition on CLL cells will be examined at screening, pre-treatment and post-treatment (immediately after completion of drug) days 1, pre-treatment day 2, day 3 (optional), day 5 (optional),pre and post-treatment days 8, pre and post-treatment days 9, day 10 (optional),day 12 (optional), and day 15 (optional).
223664006|NCT01212380|OTHER|Pharmacogenomic Studies|Germ line DNA from a buccal swab and bone marrow fibroblasts will be obtained at baseline screening for possible examination of SNP polymorphisms that may correlate with response and toxicity to carfilzomib therapy. Tumor DNA will be derived from samples obtained at baseline for the p53 mutational studies. SNPs related to drug metabolism, response, or toxicity to therapy, cytokine release, and tumor biology may be examined. Other SNPs may be used in the future. Given the potential for contamination in the recipient, recipient DNA from a buccal swab and/or saliva will be obtained at baseline screening for examination of SNP polymorphisms that may correlate with response, toxicity, and pharmacokinetics.
223664007|NCT01578850|DRUG|Etanercept|etanercept 50mg once weekly + methotrexate with or without other DMARDs
223664008|NCT01578850|DRUG|placebo|etanercept placebo once weekly + methotrexate with or without other DMARDs
223664009|NCT05205889|BEHAVIORAL|Mobile intervention on values and goals in patients with chronic pain.|The protocol consists of 10 daily sessions, 10-20 Minutes each. After each session participants will complete daily measures. Participants will learn about values and a values based life. Further they will identify their own values and are encouraged to set a goal to pursue those values. Based on this, barriers to achieving goals are explained and a corresponding commitment will be made.
223664010|NCT00761644|DRUG|Doxil|Day 1 of each 21 day cycle, beginning dose level 10 mg/m\^2 by vein over 3 hours.
223664011|NCT00761644|DRUG|Bevacizumab|Day 1 of each 21 day cycle, beginning dose level 5 mg/kg by vein over 90 minutes.
223664012|NCT00761644|DRUG|Temsirolimus|Days 1, 8 \& 15 of 21 Day Cycle, beginning dose level 12.5 mg by vein over 30 to 60 minutes.
223664013|NCT06123351|DEVICE|Denneroll cervical traction orthodontic|traction for 3 to 15 minutes once daily
223664014|NCT06123351|OTHER|stretching and strengthening exercises|strengthening exercises with 10 repetitions twice per day 3 times per week stretching exercises with hold for 20 to 30 seconds 3 repetitions daily
223664015|NCT06123351|DEVICE|Vacuum-formed soft occlusal splint|2 mm thick elastic rubber sheets
223664016|NCT01032109|DRUG|Bevacizumab|A single intravitreal injection of 1.25 mg of bevacizumab (0.05 mL of solution prepared from Avastin, 100 mg/4 mL vial) was performed within 2 weeks after PDT treatment.
223770066|NCT04646616|OTHER|Community popular opinion leader (POL) based intervention|A community popular opinion leader (POL) based intervention to promote measures to reduce COVID-19 risk, transmission, access to testing and treatment, reduction of the impact of COVID-19, and addressing the Substance Abuse, Violence, HIV/AIDS, and MEntal health (SAVAME) syndemic in the community. POLs will interact within their networks counseling regarding COVID-19 and SAVAME factors. The POLs will refer individuals to appropriate community services. POLs will record basic sociodemographic characteristics of all community contacts, the issue addressed, and their response to it. The first 300 community contacts will be invited to complete a baseline and 3-month follow up surveys (via internet or phone). The content of the surveys includes: 1) COVID-19 related questions (knowledge, impact, symptoms, risk factors, access to testing and care, acceptability contact tracing, vaccine) 2) Biological risk factors, 3) Social determinants of health, 4) SAVAME outcomes and access to services.
223770067|NCT03976986|DEVICE|continuous-flow portable oxygen concentrator (cPOC)|SeQal Eclipse 3® on continuous-flow (SeQual,Ball Ground,GA): flow rate 2 litre per minute (lpm).
223770068|NCT03976986|DEVICE|pulsed-flow portable oxygen concentrator (pPOC)|InogenOne G3® (Inogen,Goleta,CA) on pulsed-flow mode: setting 2 (flow rate 420 ml/min, 16.8 ml +/- 3ml per bolus at 25 rpm).
223770069|NCT03049813|BEHAVIORAL|Virtual Reality Job Interview Training|Job interview training using virtual reality software created by SIMmersion, Inc, in addition to standard supported employment services.
223664017|NCT06153680|DEVICE|Insoles|"Device : Insoles~At Day 0, the patient received the insoles and adapted them to his shoes.~The patient filled the quality-of-life's questionnaire at Day 0 and the same at Day14.~The patient filled the rapid relief's questionnaire at Day7 and a usability's questionnaire at Day14."
224243805|NCT05956366|BEHAVIORAL|Family-based treatment|Open-end family therapy ad modum The Maudsley model
224243806|NCT01577303|BEHAVIORAL|Cognitive bias modification training program variant 1|Computerized, internet-based training program for implicit modification of cognitive bias of attention, variant 1. Participant is exposed to two words -- either neutral-negative, neutral-positive, or negative-positive -- for 500ms-1000ms, followed by a probe (\< or \>) in the previous position of ONE of these words and is then asked to press the corresponding arrow button on a keyboard. A total of 192 word pairs are shown during a session, of one third is the neutral-negative, one third is neutral-positive, and one third is negative-positive. The probe always follows the more positive word.
224321618|NCT02215967|BIOLOGICAL|Anti-B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T cells|0.3x10\^6- 15.0x10\^6 CAR+ T cells per kg of recipient bodyweight one time dose on day 0
223770070|NCT03049813|OTHER|Supported Employment (Services as Usual)|Standard supported employment services.
223770071|NCT02369497|DEVICE|HRA|Humeral head resurfacing with the HRA device
223770072|NCT04698824|PROCEDURE|Hypnosis session|"At least one session of hypnosis in the internal medicine unit at the hospital Groupe Hospitalier Mutualiste de Grenoble"
223770073|NCT00550836|BIOLOGICAL|panitumumab|Given IV
223770074|NCT00550836|DRUG|erlotinib hydrochloride|Given orally
223770075|NCT00550836|DRUG|gemcitabine hydrochloride|Given IV
223770076|NCT01145079|DEVICE|Zotarolimus-eluting stent|Zotarolimus-eluting stent
223770077|NCT01145079|DEVICE|Zotarolimus-eluting stent for ACS and DM|Zotarolimus-eluting stent for ACS and DM
223770078|NCT01145079|DEVICE|Everolimus-eluting stent for long lesion|Everolimus-eluting stent for long lesion
223770079|NCT01145079|DEVICE|Sirolimus-eluting stent for short lesion|Sirolimus-eluting stent for short lesion
223770080|NCT06572956|BIOLOGICAL|CAR-T/CAR-NK cell injection|One to two days after completion of eluvial chemotherapy, CAR-T/CAR-NK cells were transfused in subjects assessed by the investigators as eligible for infusion. The CAR-T/CAR-NK dose is calculated according to the patient's body weight, and the total number of cells transfused is about 1-2x106 /kg. Single intravenous infusion.
223770081|NCT06155045|PROCEDURE|Modified Carbo-dissection Technique|This technique comes the C02 blower with electrocautery. Thereby, producing vasodilatation due to the gas and dissection aided by the electrocautery.
223770082|NCT06155045|PROCEDURE|Conventional Arm|This technique uses only the electrocautery as conventional model
223770083|NCT05351008|OTHER|Cognitive Functional Therapy|A physicaltheapy approach combining cognitive techniques, func-tional movement training, functional integration and Lifestyle Changes.
223770084|NCT05351008|OTHER|Exercise program:|Core strengthening program
223770085|NCT05941026|OTHER|Structured education|"The educational content of the research was created by the researcher in line with the literature and expert opinions and covers the following topics.~Educational subjects~1. Culture and Concepts Related to Culture~2. Culture/Cultural Characteristics and Cultural Elements in Terms of Social Structure~3. Cultural Factors Affecting Health and Disease~4. Concepts and Practices Related to the Field of Study~The training is an online training and continued via video conference, and a session invitation was sent to the participants before each session. In addition, after the training, brochures containing the training topics of each week were prepared and delivered to the participants. The trainings were conducted by the researcher in a total of four sessions (each session 20 minutes) once a week during the training process. During the training, the questions of the participants were answered."
223770086|NCT02063997|DRUG|Arhalofenate 600 mg|Arhalofenate 600 mg tablets once daily for 12 weeks
223770087|NCT02063997|DRUG|Allopurinol 300 mg|Allopurinol 300 mg tablets once daily for 12 weeks
223770088|NCT02063997|DRUG|Colchicine 0.6 mg|Colchicine 0.6 mg over-encapsulated tablets once daily for 12 weeks
223770089|NCT02063997|DRUG|Placebo|Placebo tablets once daily for 12 weeks
223770090|NCT02063997|DRUG|Arhalofenate 800 mg|Arhalofenate 800 mg tablets once daily for 12 weeks
223770091|NCT06568003|DEVICE|Transcatheter Tricuspid Valve Intervention|Due to unsustainable effect of medical therapy and high risks of surgical treatment, transcatheter tricuspid valve intervention (TTVI) has been a major field of study in the world in the last 10 years. TTVI could potentially reduce TR with lower periprocedural risk and improve the patient's clinical status and prognosis. Per the ESC guidelines for surgical and interventional treatment of tricuspid regurgitation (2021 ESC/EACTS Guidelines for the Management of Valvular Heart Disease), Transcatheter intervention for symptomatic secondary severe TR may be considered in inoperable patients at a Heart Valve Centre with expertise in the treatment of tricuspid valve disease (Class IIb). 20 Transcatheter tricuspid treatment options can be divided into categories based on their mechanism of action: coaptation enhancement (edge-to-edge repair and spacer device), annuloplasty devices, caval valve implantation and valve replacement.
223770092|NCT00002183|DRUG|Abacavir sulfate|
223770093|NCT00002183|DRUG|Amprenavir|
224243807|NCT01577303|BEHAVIORAL|Cognitive bias modification training program variant 2|Computerized, internet-based training program for implicit modification of cognitive bias of attention, variant 2. Participant is exposed to a pair of words or a pair of faces -- either neutral-negative, neutral-positive, or negative-positive -- for 500ms-1000ms, followed by a probe (\< or \>) in the previous position of ONE of these words or faces and is then asked to press the corresponding arrow button on a keyboard. A total of 96 word pairs and 96 face pairs are shown during a session. One third is neutral-negative, one third is neutral-positive, and one third is negative-positive. The probe always follows the more positive word or face.
224321619|NCT05286866|PROCEDURE|Dental implant bed preparation|Drilling an osteotomy for placement of a dental implant
224321620|NCT06741865|BEHAVIORAL|Lifestyle Intervention|This arm involves interventions like health coaching, dietary changes, exercise programs, and other lifestyle modifications.
224321621|NCT06741865|OTHER|Standard Health Education|Participants in the Standard of Care Arm will receive basic educational materials focused on general cognitive and physical health maintenance.
223770094|NCT00002183|DRUG|Lamivudine|
223770095|NCT00002183|DRUG|Zidovudine|
223770096|NCT03120013|DEVICE|Anodal cerebellar and cathodal spinal tDCS|10 sessions of anodal cerebellar and cathodal spinal transcranial direct current stimulation (5 days/week for 2 weeks)
223770097|NCT03120013|DEVICE|Sham cerebellar and sham spinal tDCS|10 sessions of sham cerebellar and sham spinal transcranial direct current stimulation (5 days/week for 2 weeks)
223770098|NCT05776108|DRUG|Cabotegravir IR Formulation (reference)|Cabotegravir IR Formulation (reference) will be administered.
223770099|NCT05776108|DRUG|Cabotegravir DT Formulation (test 1)|Cabotegravir DT Formulation (test 1) will be administered.
224321622|NCT05695066|PROCEDURE|Preoperative fasting instruction|Patients parents instructed to stop enteral feeding at a specified time before predicted anesthesia induction
224321623|NCT06769412|DRUG|aflibercept 2 mg|No study-specific investigations for this descriptive observational study
224321624|NCT02254265|DRUG|OTX-101 0.05%|OTX-101 0.05% Ophthalmic Solution
223664018|NCT00601952|BEHAVIORAL|Attention Bias Modification (ABM)|The ABM comprised a probe detection paradigm described above, modified to facilitate the allocation of attention away from threatening material. In this task, the probe always replaced the neutral word. Stimuli comprised a different set of 12 threat-neutral word pairs different than those used in the attention bias assessment. Participants completed 288 training trials: 2 (probe type) x 2 (probe location) x 2 (threat location) x 12 (threat-neutral word pairs) x 3 (repetition). Thus, although there were no explicit instructions to direct attention away from threat words, on all trials, the position of the neutral word indicated the position of the probe.
223664019|NCT00601952|BEHAVIORAL|Attention Control Condition (ACC)|The ACC condition was identical to the ABM procedure with the exception that the probe appeared with equal frequency in the position of the threat and neutral words, such that attention was neither trained towards nor away from threat.
223664020|NCT00254345|PROCEDURE|coating a dental restoration material ,polymethylmethacrylate, with liquid polish resin|
223664021|NCT03276455|GENETIC|Autologous CD34+ cells genetically modified|Autologous hematopoietic stem cell transduced with lentiviral vector encoding the therapeutic beta-globin gene. The target dose in the transduced product is 3x10\^6 cells/Kg CD34+ cells, with a minimum dose of 2 x 10\^6/Kg and a maximum dose of 20 x 10\^6/Kg, depending on the yield of cells. The product will be injected intraosseously following intravenous BU ±Flu ±Cy.
223770100|NCT05776108|DRUG|Cabotegravir DT Formulation (test 2)|Cabotegravir DT Formulation (test 2) will be administered.
223770101|NCT00580424|DRUG|Norethindrone|Norethindrone 0.35 mg orally daily
224243808|NCT01577303|BEHAVIORAL|CBM training program variant 3|Computerized, internet-based training program for implicit modification of cognitive bias of attention, variant 3. Participant is exposed to two words -- either neutral-negative, neutral-positive, or negative-positive -- for 500ms-1000ms, followed by a probe (\< or \>) in the previous position of ONE of these words and is then asked to press the corresponding arrow button on a keyboard. A total of 192 word pairs are shown during a session. One third is neutral-negative, one third is neutral-positive, and one third is negative-positive. The probe always follows the more negative word.
224243809|NCT01577303|BEHAVIORAL|CBM training program variant 4|Computerized, internet-based training program for implicit modification of cognitive bias of attention, variant 4. Participant is exposed to a pair of words or a pair of faces -- either neutral-negative, neutral-positive, or negative-positive -- for 500ms-1000ms, followed by a probe (\< or \>) in the previous position of ONE of these words or faces and is then asked to press the corresponding arrow button on a keyboard. A total of 96 word pairs and 96 face pairs are shown during a session. One third is neutral-negative, one third is neutral-positive, and one third is negative-positive. The probe always follows the more negative word or face.
224243810|NCT01577303|BEHAVIORAL|Control training variant 1|Computerized, internet-based training program for implicit modification of cognitive bias of attention, variant 1. Participant is exposed to a pair of words -- either neutral-negative, neutral-positive, or negative-positive -- for 500ms-1000ms, followed by a probe (\< or \>) in the previous position of ONE of these words and is then asked to press the corresponding arrow button on a keyboard. A total of 192 word pairs are shown during a session. One third is neutral-negative, one third is neutral-positive, and one third is negative-positive. The probe follows the more positive word and the more negative word with equal frequency..
224243811|NCT01577303|BEHAVIORAL|Control training variant 2|Computerized, internet-based control training program, variant 2. Participant is exposed to a pair of words or a pair of faces -- either neutral-negative, neutral-positive, or negative-positive -- for 500ms-1000ms, followed by a probe (\< or \>) in the previous position of ONE of these words or faces and is then asked to press the corresponding arrow button on a keyboard. A total of 96 word pairs and 96 face pairs are shown during a session. One third is neutral-negative, one third is neutral-positive, and one third is negative-positive. The probe follows the more positive stimulus and the more negative stimulus with equal frequency.
224243812|NCT02038608|DEVICE|PET|
224243813|NCT03241784|BIOLOGICAL|Autologous T-regulatory lymphocytes|intravenous administration of Autologous T-regulatory lymphocytes at a dose of 1x10 to the sixth /kg.
224243814|NCT03241784|BIOLOGICAL|Interleukin-2|Subcutaneous Interleukin-2 at a dose of 2x10 to the fifth IU/m2, three times a week.
224243815|NCT05275179|OTHER|Posaconazole Therapeutic Drug Monitoring|Therapeutic Drug Monitoring is performed by measuring posaconazole concentrations in serum on seven consecutive days (anticipated).
224243816|NCT04005859|DRUG|Exparel|"2\. Liposomal bupivacaine TAP block (experimental arm)~1. Block will be administered after induction of anesthesia and before incision by a specifically trained attending surgeon or surgical fellow with the colorectal service.~2. A single vial of liposomal bupivacaine (20 mL 1.3%, 13.3mg/mL, 266 mg) will be diluted in 50cc bupivacaine to a volume of 60cc prior to administration. This will be divided into 2 doses for bilateral TAP blocks.~3. The LB will be administered under ultrasound guidance in the transversus abdominis plain per manufacturer recommendations.~4. Adhesive tapes will be applied at the level of the TAP block puncture sites."
224243817|NCT04005859|DRUG|IV Lidocaine|"1\. Intravenous Lidocaine infusion (control arm, current standard of care)~1. 100 mg/5mL intravenous bolus of lidocaine 2% PF 5mL will be initiated by anesthesia service prior to general anesthesia induction.~2. 1.5 mg/kg/hr to begin prior to incision and continue until discontinued 1 hr postoperatively in PACU. Patients will be monitored in PACU for at least 30 minutes after discontinuation of lidocaine drip.~3. Adhesive tapes will be applied at the presumed level of TAP block puncture sites."
224243818|NCT02832752|PROCEDURE|ECPR Protocol|The regional protocol is activated for eligible patients who remain pulseless after 3 cycles of resuscitation, and intubation. The hospital team is activated at this time, which includes the emergency department team, a perfusionist, and a cardiovascular surgeon. A mechanical CPR device (Lucas chest compression device) is applied at this time and the patient is transported to hospital. The goal times from first professional CPR to ECMO flows is \< 60 minutes, and from emergency department (ED) arrival to ECMO flows \< 30 minutes.
224243819|NCT03341585|OTHER|expiration lente prolongée|l'Expiration Lente Prolongée (ELPr) is a passive technique to enhance the expiration used in infants, obtained by a slow and increasing manual thoraco-abdominal pression applied at the end of a spontaneous expiration till the residual volume. The aim is to obtain a bigger expired volume compared to a normal expiration and drain the mucus out of the airways (Postiaux 2003). This technique has been invented by Guy Postiaux and is used in the Chest Physiotherapy (CPT).
224243820|NCT04772807|DEVICE|Kinocardiograph|Measure with the Kinocardiograph device and the Okcardio application installed on a smartphone
224243821|NCT00819507|DRUG|Fluocinonide|Fluocinonide 0.1% cream topical daily for two weeks
224243822|NCT04879888|BIOLOGICAL|Peptide pulsed Dendritic cell|Intradermal vaccination with peptide-pulsed autologous dendritic cells in 200 µL of patient's serum in six doses weekly after surgery.
224243823|NCT00097383|DRUG|ALIMTA plus Epirubicin|
224243824|NCT00535054|DRUG|Tears Again|Liposome Eye Spray
224243825|NCT01259583|PROCEDURE|CO2|CO2 insufflation
224243826|NCT01259583|PROCEDURE|Warm water|warm water irrigation
224243827|NCT03265977|BIOLOGICAL|H56:IC31|The H56 antigen is a fusion protein created from 3 Mtb antigens: antigen 85B (Ag85B), ESAT-6, and Rv2660c.
224243828|NCT03265977|OTHER|Placebo|Normal saline
224243829|NCT02052947|RADIATION|SPECT-DaTscan|"* Measurement of fixation of DaTscan® in the caudate and lenticular nucleus~* LP (Lumbar Puncture): the LP will follow the last guidelines published in 2011 (Armand Perret-Liaudet is co-author of these guidelines; Perret-Liaudet A. et al, Cerebrospinal Fluid Collection Tubes: a critical issue for Alzheimer Disease diagnosis. Clin Chem, 2012, accepted)."
224243830|NCT01789905|DRUG|Tigecycline (Tygacil)|Tigecycline 50 mg intravenously. Therapy conducted according to Japanese LPD of Tygacil. Tygacil will be dosed according to labeling. The administration and duration of the therapy will be determined by the treating physician to meet the patient individual needs for treatment.
224321625|NCT02254265|DRUG|OTX-101 0.09%|OTX-101 0.09% Ophthalmic Solution
224321626|NCT02254265|DRUG|Vehicle|Vehicle of OTX-101 Ophthalmic Solution
224321627|NCT02762461|PROCEDURE|IVF or ICSI|
224243831|NCT02661295|DRUG|Ferric Citrate|Study participants will receive ferric citrate at a starting dose of 2 tablets with each meal if serum phosphorus levels are ≥ 6.0 mg/dL calcium levels are in the normal range, Tsat ≥ 20 and \< 50% and ferritin ≥ 200 and \< 500 ng/ml after a 2 week wash out period.
224243832|NCT02829762|OTHER|Program of geriatric and Social intervention associated techniques of Domotic and Remote assistance|Implementation of social aids, a monthly social monitoring and home improvement with domotic techniques and remote assistance
224243833|NCT01364194|DRUG|0.25% Bupivacaine|Periarticular injection with 20 ml of 0.25% bupivacaine before wound closure.
224243834|NCT01364194|DRUG|0.9% normal saline|Periarticular injection with 20 ml of 0.9% normal saline before wound closure.
224243835|NCT02722980|DIETARY_SUPPLEMENT|Placebo|The intervention consists of capsules containing placebo.
223664022|NCT00646269|BEHAVIORAL|Standard intervention protocol|The control group involves a standardized medical follow-up of patients with Alzheimer's disease and a psychoeducative group program for caregivers of patients.
224243836|NCT02722980|DIETARY_SUPPLEMENT|: Probiotic capsules|The intervention consists of capsules containing probiotics.
224243837|NCT05037422|PROCEDURE|STARR surgery|"This intervention is carried out under general anesthesia or spinal anesthesia. It consists of the circular resection of the surplus of rectal mucosa. Rectal resection and suturing is performed using automatic mechanical forceps introduced through the anus."
224243838|NCT02549092|DRUG|Optimized Medical Treatment|Oral, sublingual or transdermal anti-PD medications and medications to treat NMS per Investigator discretion and/or in accordance with approved product label of the prescribed medications.
223664023|NCT00646269|BEHAVIORAL|Standard intervention protocol + Cognitive training therapy|"Cognitive training therapy is provided in small groups of 5 to 8 patients. It consists in classroom type sessions designed to provide general cognitive stimulation. A set of standard cognitive exercises (involving memory, attention, or problem-solving…) related to activities of daily living is realized at each session."
224243839|NCT02549092|DRUG|Levodopa-Carbidopa Intestinal Gel|
224243840|NCT02549092|DEVICE|Nasojejunal (NJ) tube|optional prior to PEG-J placement
224243841|NCT02549092|DEVICE|Percutaneous endoscopic gastrostomy with a jejunal (PEG-J) tube|
224243842|NCT04540523|BEHAVIORAL|Exergaming intervention group|In addition to usual daily activity, the parent and child from each family will receive 3 game consoles (Wii, Kinect, and LeapTV) and various exergames (e.g., Nickelodeon Fit, Dance and Sports, Just Dance) with all necessary peripherals to play the games. Specifically, they will receive one game console and related exergames every 2 months to experience the variety of exergames and maintain interest in the games over time. Each parent will receive a booklet (established in our pilots studies) provides a standardized gameplay curriculum to play during each session, and attend training workshops at baseline and 3rd month in the PI's lab. The parent will be instructed to have the child perform exergaming at home for 30 minutes/session, 5 times per week, for 6 months. The games will be age appropriate for children 4-5-years-old. The games have been easy for children to learn and use in our pilot studies.
224243843|NCT04540523|BEHAVIORAL|Traditional physical activity comparison|Home-based behavioral (e.g., nutrition/PA) interventions for young children usually only target parent for multiple reasons. In this study, group workshop sessions will offered to parents at baseline, 3rd month and 6th month, including information concerning how to promote PA and reduce sedentary behaviors. Identical curricular contents (e.g., dance/sports) for home PA will be offered to parents at baseline and 3rd month in the PI's lab. Parents will also learn about PA and sedentary behavior and their impact on health and cognition. Meanwhile, the intervention staff will encourage parents to increase their lifestyle activity such as taking stairs instead of the elevator and housecleaning. Parents will also learn to shape their child and their PA and sedentary behaviors to attain the following goals: 2 hour or less screen time and at least 180 min. PA per day for children; and at least 150 min. moderate PA for parents per week.
223664024|NCT00646269|BEHAVIORAL|Standard intervention protocol + Reminiscence therapy|"Reminiscence therapy is provided in small groups of 5 to 8 patients. This therapy involves the discussion of past activities, events and experiences enhanced by aids such as photographs, familiar items, songs, or personal recordings. A particular topic of life (i.e. a wedding) is discussed at each session."
224243844|NCT04713137|DIETARY_SUPPLEMENT|Erythritol|50g erythritol dissolved in 300mL tap water.
224243845|NCT04713137|DIETARY_SUPPLEMENT|Sucrose|33.5g sucrose dissolved in 300mL tap water.
224243846|NCT04713137|DIETARY_SUPPLEMENT|Sucralose|0.0558g sucralose dissolved in 300mL tap water.
224243847|NCT04713137|DIETARY_SUPPLEMENT|Water|300mL tap water.
224243848|NCT04128943|OTHER|symptom questionnaire|"A weekly filled in symptom questionnaire for reported symptoms of AA and/or PNH (yes/no, grade, date). Grading according to current grading systems (Common Terminology Criteria for Adverse Events,CTCAE).~Data collection and processing via the ePRO application by Kaiku Health Ltd"
224243849|NCT04128943|OTHER|recording of vital signs|Record function for vital parameters (blood pressure, temperature and pulse); Data collection and processing via the ePRO application by Kaiku Health Ltd
224243850|NCT04128943|OTHER|European Organisation for Research and Treatment of Cancer (EORTC) quality of life questionnaire (QLQ)-C30 questionnaire|The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue, Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties). All of the scales range in score from 0 to 100. A high score for a functional scale represents a high/healthy level of functioning whereas a high score for a symptom scale or item represents a high level of symptomatology or problems.
224321628|NCT06764160|DRUG|Eculizumab|Participants will receive Eculizumab via intravenous (IV) infusion.
223664025|NCT00646269|BEHAVIORAL|"Standard intervention protocol + Made-to-measure program"|"The made to measure program involves no systematic intervention. The psychologist is asked to choose among the two possible therapies (Cognitive training therapy or Reminiscence therapy) the one more suitable for the patient after considering his clinical characteristics including socio-demographic characteristics, disease severity or cognitive and behavioural disturbance. It is an individualized approach emphasizing the importance of flexibility to allow adjustment to individual needs."
223770102|NCT01411306|OTHER|Toronto Bedside Swallowing Screening Test (TOR-BSST©)|All enrolled patients will be screened for dysphagia by two blinded screeners using the TOR-BSST©.
224243851|NCT04128943|OTHER|interview|Interview with the patients and responsible medical team by phone or during hospital visit about functional problems regarding the application (duration: 15-30 min) to avoid incorrect use of the application, at week 3 and month 3 and month 6
224243852|NCT00743964|DRUG|Epirubicin|Epirubicin 50 mg/m2 iv on day 1
224243853|NCT00743964|DRUG|Cisplatin, capecitabine|Cisplatin 70 mg/m2 IV on day 1 of each 21 day cycle. Capecitabine 2000 mg/m2 on days 1 to 14.
224243854|NCT01623726|PROCEDURE|Transcranial Direct Current Stimulation (tDCS)|"Transcranial Direct Current Stimulation. Daily sessions with a total of 10 days intervention. Each intervention will take place with a 2mA intensity during 20 minutes. The current will be delivered by Chattanooga Iontophoresis Dual Channel Delivery Device, that stands for a 2-channels tDCS device in which previous dosage can be set as default to maintain frequently used treatment parameters. Main features include (a) Beeping alerts if electrode fault for open current or high impedance, low battery, treatment completion or power left on; (b)automatic 30 second current ramp up and down during power on/off keeps patient comfortable; (c) Current can be set in 0.1 mA increments between 0.5 mA and 4 mA."
224243855|NCT03627091|DRUG|Ontamalimab|SC injection of 25 mg or 75 mg ontamalimab will be administered using a prefilled syringe.
224321629|NCT05528471|OTHER|Dietary intervention|To compare an iso-caloric, low fructose diet (\~5% of total energy intake (TEI); HFCS max: 10-15% of total fructose intake) to an iso-caloric, higher fructose diet (\~10% of TEI; HFCS max 20-30% of total fructose intake) in adolescents with NAFLD. The 10% higher fructose diet is part of standard of care and is NOT the intervention.
224321630|NCT05491213|BEHAVIORAL|TELESCOPE, Remote Decision Coaching with Navigation Intervention|The TELESCOPE intervention involves three complementary components: 1) decision aid and coaching for LCS, 2) referral of current smokers to evidence-based smoking cessation services, and 3) for participants interested in screening, navigation to complete LCS and diagnostic testing and oncology care as needed
224243856|NCT03627091|OTHER|Placebo|SC injection of placebo matched with ontamalimab will be administered using a prefilled syringe.
224321631|NCT07135037|DRUG|Sildenafil 25 MG|Sildenafil is a vasodilator drug which improve blood supply to placenta.Therefore, it should improve idiopathic oligohydramnios.
224321632|NCT07135037|DRUG|L-Arginine, 1000 Mg Oral Tablet|Aminoacid with vasodilator property which improve blood supply to placenta.Therefore, it should improve idiopathic oligohydramnios.
224321634|NCT07077850|DRUG|Dexamethasone (IV)|Intravenous administration of 8 mg dexamethasone sodium phosphate given as a single dose before surgery under spinal anesthesia. This corticosteroid is being evaluated for its potential to prevent postoperative urinary retention (POUR) by reducing inflammation and other perioperative effects.
223664026|NCT03241719|DRUG|IL-2|Subjects will receive vascularized composite allotransplantation (e.g. facial, hand and/or abdominal wall transplants) under conventional immune suppression. No sooner than 3 months after VCA, subjects will receive a protocol of daily recombinant IL-2 at low doses for 8 weeks.
223664027|NCT03882268|BEHAVIORAL|MIYCN interventions|"1. Capacity building for health providers and nutrition counselors (training on MIYCN SBCC from A\&T).~2. Dedicated room for MIYCN counseling at health facilities with standardized layouts, displays of government IYCF logo, and other specifications.~3. Availability of standardized MIYCN-specific BCC materials and job aids.~4. Standardized MIYCN counseling services (counseling on diet diversity and quantity, IFA and calcium supplementation, weight gain monitoring, exclusive and early initiation of breastfeeding, complementary feeding, and water, sanitation and health) provided by a dedicated MIYCN counselor hired by A\&T.~5. Dedicated community worker hired by A\&T to identify and mobilize beneficiaries needing services in the community (via satellite clinic outreach, distribute MIYCN flyers, and provision of MIYCN education via phone or home visits).~6. Supportive supervision of MIYCN counselors and community workers by program and facility managers, and field supervisors."
224321635|NCT07077850|DRUG|Normal Saline (0.9% NaCl)|Intravenous administration of 0.9% normal saline (placebo) given as a single dose before surgery under spinal anesthesia. This inert solution is used to compare against the active drug dexamethasone to determine its effect on postoperative urinary retention (POUR).
223664028|NCT04334577|BIOLOGICAL|live attenuated zoster vaccine|subcutaneous injection
223664029|NCT04334577|BIOLOGICAL|placebo|subcutaneous injection
223664030|NCT02562664|DRUG|CC|100 mg clomiphene Citrate (Clomid , global Napi , Egypt) CC tablets taken from day 3 to day 7 of the cycle
223664031|NCT02562664|DRUG|Placebo tablets|Placebo tablets taken twice daily continuously for three cycles.
223664032|NCT02562664|DRUG|Metformin|wMetformin (Cidophage , Amon , Egypt) 500 mg twice daily continuously for three cycles.
223664033|NCT03366519|PROCEDURE|clinical echography (CE)|clinical echography (CE) is performed in the first 24 hours following the diagnosis of PE, in emergency unit
223664034|NCT02205840|DRUG|SI-614|1 drop in each eye
223664035|NCT02205840|DRUG|Vehicle|1 drop in each eye
223664036|NCT01785485|OTHER|Integrative medicine primary care model|An integrative medicine primary medical care as defined by the Arizona Center for Integrative Medicine.
223664037|NCT04240834|DRUG|Aspirin|Comparison of 12 months of ticagrelor and low-dose aspirin versus 12 months of standard dual anti-platelet therapy (DAPT)
223664038|NCT04240834|DRUG|Ticagrelor|Comparison of 12 months of ticagrelor and low-dose aspirin versus 12 months of standard dual anti-platelet therapy (DAPT)
224243857|NCT03982862|DRUG|Triamcinolone|Triamcinolone 4mg diluted to 0.1 ml
224243858|NCT03982862|DRUG|Lidocaine|0.1ml 2% Xylocaine
224243859|NCT03982862|DRUG|Botulinum toxin A|4U Botox® diluted to 0.1 ml
224243860|NCT01603862|PROCEDURE|ThinkingFit programme|Combined physical, cognitive and social stimulation activties.
224243861|NCT05526573|DEVICE|Ultrathin bronchoscopy (MP190F; Olympus Medical Systems, Tokyo, Japan)|Fluoroscopy + RP-EBUS and consecutive lesion sampling by TBNA and/or TBB
224243862|NCT03787030|DRUG|Vitamin E Acetate ointment|Application of 1 ml of ointment to the distal anal canal, every 12 hours for an 8-week period.
224321636|NCT06930729|BEHAVIORAL|Behavioral Activation Therapy App|Moodivate focuses on tracking daily activities, recording daily mood, and identifying new activities to complete that may help improve mood. Participants will be asked to complete questionnaire measures at weeks 12, 16, 20, and 24 post-randomization.
224321637|NCT06930729|BEHAVIORAL|Telehealth Delivered Behavioral Activation|8 sessions of telehealth-delivered Behavioral Activation with a mental health provider over a 10-week period.
223664039|NCT06193109|OTHER||the patients with sepsis and septic shock were performed echocardiography for detecting right ventricular systolic function
223664040|NCT02779322|PROCEDURE|Minigastric bypass|The patient will be submitted to a minigastric bypass at the time of the operation
223664041|NCT02779322|PROCEDURE|Gastric bypass|In this case a simplified conventional gastric bypass will be performed
223664042|NCT03111186|DRUG|Oxycodone Hcl 5Mg|oxycodone HCl 5 mg up to six times daily as needed for pain
223664043|NCT03111186|DRUG|Ibuprofen 400 mg|Ibuprofen 400 mg up to six times daily as needed for pain
223664044|NCT03111186|DRUG|Acetaminophen 650 mg|Acetaminophen 650 mg up to four times daily as needed for pain
223664045|NCT00995059|PROCEDURE|nonmyeloablative allogeneic hematopoietic stem cell transplantation|Undergo transplantation
223770103|NCT01411306|PROCEDURE|Videofluoroscopic Swallow Study|All enrolled patients will undergo a videofluoroscopic assessment of swallowing within 24 hours of being screened with the TOR-BSST©.
224243863|NCT03787030|DRUG|Glyceryl trinitrate ointment|Application of 375 mg of ointment to the distal anal canal, every 12 hours for an 8-week period.
224243864|NCT01723748|DRUG|genotropin|iii) intravenous exogenous bolus of GH (0.5 mg) followed by muscle and fat biopsies.
224243865|NCT01545830|DIETARY_SUPPLEMENT|vitamin D3 (cholecalciferol)|Active intervention: 6,000 IUs taken by mouth daily for 6 months Active Comparator: 600 IUs taken by mouth daily for 6 months
224243866|NCT05375604|DRUG|CDK-004|ASO-STAT6 exosome administered Intravenously
224243867|NCT02356302|DEVICE|Vicriviroc (MK-4176) Intravaginal Ring (IVR)|Contains 182 mg vicriviroc (MK-4176).
224243868|NCT02356302|DEVICE|MK-2048 IVR|Contains 30 mg MK-2048.
224243869|NCT02356302|DEVICE|MK-2048A IVR|Contains 182 mg vicriviroc (MK-4176) and 30 mg MK-2048.
224243870|NCT02356302|DEVICE|Placebo IVR|
224243871|NCT05398718|DRUG|Sotrovimab|collect local clinical evidence for sotrovimab effect in the real-life setting
224243872|NCT01273779|DRUG|Talactoferrin alfa|15 mL of an oral solution of 100mg/mL (1.5 g) given 3 times a day for up to 28 days or until discharge from the intensive care unit
224243873|NCT01273779|DRUG|Placebo|15 mL of oral solution of placebo given 3 times a day for up to 28 days or until discharge from the intensive care unit
224243874|NCT03959683|DEVICE|Trilogy Lithotrite|The Trilogy has been FDA cleared for fragmentation of urinary tract calculi in the kidney, ureter, and bladder. Trilogy is a combined piezoelectric/pneumatic device capable of fragmenting calculi and aspirating stone debris. The novel technology in Trilogy has been demonstrated in bench testing to more quickly disintegrate stones compared to other devices.
224243875|NCT03959683|DEVICE|The ShockPulse-SE Lithotripsy System|The ShockPulse-SE System is an electromechanical device capable of fragmenting calculi and aspirating stone debris. The novel technology in the ShockPulse-SE Lithotripsy System uses a single transducer and proprietary ShockPulse technology to generate both low-frequency mechanical impacts and high-frequency ultrasonic energy which quickly disintegrates stones.
223664046|NCT00995059|PROCEDURE|allogeneic bone marrow transplantation|Undergo transplantation
223664047|NCT00995059|DRUG|bortezomib|Given IV
223664048|NCT00995059|DRUG|melphalan|Given IV
223664049|NCT00995059|DRUG|anti-thymocyte globulin|Given IV
223664050|NCT00995059|DRUG|sirolimus|Given orally
223664051|NCT00995059|DRUG|tacrolimus|Given oral or IV
223664052|NCT00995059|RADIATION|total-body irradiation|Undergo total-body irradiation
223664053|NCT05800301|BIOLOGICAL|Wharton's jelly derived mesenchymal stemcells|The WJ-MSCs suspension from the culture was delivered to the operating room by cold chain and used within 24 h. A total of 1.5 ml of the WJ-MSC suspension was immediately injected into the deep subtenon space of each eye.
223664054|NCT05800301|DEVICE|Magnovision|Specifically designed helmets producing high-frequency repetitive electromagnetic stimulation (MagnovisionTM, Bioretina Biotechnology, Ankara, Türkiye) stimulated the retinas and visual pathways in both eyes.
224243876|NCT02495467|DRUG|Glyceryl trinitrate|At least 4 applications of MED2005 prior to intercourse over a period of 4 weeks
224243877|NCT02495467|DRUG|MED Placebo|At least 4 applications of MED2005 prior to intercourse over a period of 4 weeks
224243878|NCT02976662|PROCEDURE|Artificial shrinkage|Artificially eliminated blastocoelic fluid before vitrification procedures.
224243879|NCT05184426|DIAGNOSTIC_TEST|Echocardiogram|Ultrasound study to assess cardiac anatomy and function
224243880|NCT05184426|DIAGNOSTIC_TEST|Cardiac magnetic resonance|MR to assess cardiac anatomy, function and tissue damage
224243881|NCT05184426|DIAGNOSTIC_TEST|Coronary angiography|Cathteterization to assess coronary anatomy. Intravascular ultrasound to obtained a detailed assessment of vessels anatomy. Guidewire pressure to assess microcirculation
224243882|NCT05184426|DIAGNOSTIC_TEST|Endomyocardial biopsy|Optic microscopy, immunofluorescence, transmission electron microscopy
224243883|NCT02605148|DIETARY_SUPPLEMENT|Gluten free diet|Gluten free diet during 18 months.
224243884|NCT02605148|DIETARY_SUPPLEMENT|Omega 3 fatty acid|Omega 3 fatty acid
223664055|NCT01189019|DRUG|ranibizumab|2mg intravitreal injection monthly
223664056|NCT01189019|DRUG|ranibizumab|2mg monthly x 3 doses, then as needed based on recurrence of activity on OCT
223664057|NCT04408222|OTHER|Awake proning|Prone positioning of awake, as tolerated, for up to 24 hours daily.
223664058|NCT01836978|OTHER|Prehabilitation|Patients in this group will follow the multimodal protocol consisting of nutritional counseling with Immunocal® whey protein supplementation, an individualized physical exercise program and stress reduction strategies.
224243885|NCT02605148|DIETARY_SUPPLEMENT|Vitamin D|Vitamin D 800 U/day
224243886|NCT02605148|DIETARY_SUPPLEMENT|Probiotics|Probiotics
224243887|NCT02324725|DRUG|Naltrexone|Up to three monthly injections of 380 mg of naltrexone suspended in dissolvable polymer microspheres and administered intramuscularly
224243888|NCT04037839|OTHER|Questionnaire|"Medical records of children aged 0-18 years who were prescribed a HFNC device at Schneider Children's between 2014-2018 for use in the home setting will be reviewed retrospectively. As part of the telephone consent process, parents will be offered to opt out at the beginning of the interview."
224243889|NCT05293886|OTHER|Classical Pelvic Floor Muscle Training|In the first 2 weeks of classical pelvic floor muscle training, individuals will perform 3 sets of 10 maximal voluntary pelvic floor muscle contraction exercises and 20 submaximal voluntary pelvic floor muscle contraction exercises per day. In every 2-week control, the number of sets will be increased by one set.
224243890|NCT05293886|OTHER|Functional Pelvic Floor Muscle Training|Functional pelvic floor muscle training will be started with 3 exercises (toe tap, bridge and clamshall exercises), each exercise will be performed with 1 set and 30 repetitions. In every 2-week control, the number of exercises will be increased by one. Cat-cow exercise will be added at 3-4th weeks, squats will be added at 5-6th weeks, and lunges will be added at 7-8th weeks.
224243891|NCT03064334|PROCEDURE|Total Knee Arthroplasty|surgical knee joints Arthroplasty
223664059|NCT00541814|DRUG|Cyclosporine|Target drug level 50-100 ng/ml or cyclosporine withdrawal
224243892|NCT01357863|DRUG|Treatment|Patients treated with Lapatinib-capecitabine after Trastuzumab progression
224243893|NCT02646865|BEHAVIORAL|Self-Compassion Enhanced Cognitive-Behavioral Therapy|12 group sessions of CBT for social anxiety based on Heimberg \& Becker's (2002) protocol with additional self-compassion exercises integrated into the treatment
223664060|NCT02929498|DRUG|GSK2879552|GSK2879552 will be administered orally as continuous daily dosing.
223664061|NCT02929498|DRUG|Azacitidine|Azacitidine will be administered at 75 mg/m2 from Day 1 to Day 7 of each 28 day cycle by intravenous (iv) infusion or subcutaneous (sc) injection.
223664062|NCT03666364|OTHER|Sperm preparation for ICSI|A new protocol for sperm preparation for ICSI cycles with teratozoospermia in over 35 years old women
223664063|NCT01398917|PROCEDURE|plastic endoprosthesis|one 10 Fr Plastic endoprosthesis or 2 7 Fr plastic endoprosthesis inserted through dominant stricture(s), to be extracted after 1-2 weeks
223664064|NCT01398917|PROCEDURE|balloon dilatation|4 cm 6 mm biliary dilatation balloon to be inflated for 2 minutes in dominant stricture(s)
223664065|NCT02862340|GENETIC|Genetic test|
223664066|NCT02744040|DRUG|ART initiation at time of HIV diagnosis|Immediate ART initiation
223664067|NCT02744040|DRUG|ART at 24 weeks|ART initiation 24 weeks after enrollment
223664068|NCT00243165|BEHAVIORAL|Lifemel honey intake every day|
223664069|NCT01415336|DRUG|Doxorubicin, Cyclophosphamide|doxorubicin 60 mg/m², iv, day 1; Cyclophosphamide 600 mg/m², iv, day 1; every 3 weeks for 4 cycles
223664070|NCT01415336|DRUG|doxorubicin, Capecitabine|doxorubicin 60 mg/m², iv, day 1; capecitabine 950 mg/m2, twice a day, via oral intake, day 1 to day 14; every 3 weeks for 4 cycles
223664071|NCT01646489|DRUG|Miravirsen sodium|Miravirsen 7 mg/kg to be administered as single subcutaneous injections for a total of 5 doses over a 5 week treatment period.
223664072|NCT01646489|DRUG|Telaprevir|Telaprevir 750 mg to be administered as single and multiple oral doses over two 7 day treatment periods.
223664073|NCT05032469|OTHER|Reflexology|Reflexology is a method that creates nervous, hormonal and energetic effects in the body using pressure, rubbing and stretching applied with special hand and finger techniques to reflex points corresponding to all parts, organs and systems of the body in the ears, hands and feet
224243894|NCT02646865|BEHAVIORAL|Cognitive-Behavioral Therapy|12 group sessions of CBT for social anxiety based on Heimberg \& Becker's (2002) protocol
224243895|NCT04539470|DRUG|Efmarodocokin Alfa|Efmarodocokin Alfa will be administered intravenously (IV) per the dosage specified in each dose escalation cohort.
224243896|NCT01826409|DIETARY_SUPPLEMENT|Fermented Red Ginseng|Fermented red ginseng 2.7g/day for 4 weeks
223664074|NCT00096356|DIETARY_SUPPLEMENT|CoQ10 & Vitamin E|
223664075|NCT00096356|DIETARY_SUPPLEMENT|Placebo & Vitamin E|
223664076|NCT01576068|OTHER|Spirometry|Spirometry done in high-risk customers of community-pharmacies to detect airflow limitation
223664077|NCT04499352|DRUG|BI 754091|BI 754091
223664078|NCT04499352|DRUG|BI 836880|BI 836880
223664079|NCT03519191|BEHAVIORAL|Healthy Relationships Education (HRE)|Healthy Relationships and Economic Pathways involves formal classes in Healthy Relationship Education (HRE), comprehensive case management, and support services and referrals to services.
223664080|NCT03519191|BEHAVIORAL|HRE+Technology Bootcamp|HRE + Technology Bootcamp involves formal classes in Healthy Relationships Education (HRE), comprehensive case management, support services and referral to services, 6-week intensive website and professional development training, and paid work experience developing a website for a local small business and mentorship.
224243897|NCT01826409|DIETARY_SUPPLEMENT|Placebo|Placebo 2.7g/day for 4 weeks
224243898|NCT00656305|DEVICE|ExAblate MRfFUS|MR guided focused ultrasound.
224243899|NCT00656305|DEVICE|Sham|sham comparator
224243900|NCT04710381|DRUG|IMUNOR|The intervention consists of the administration of IMUNOR as prevention against COVID-19 disease
224243901|NCT01667627|DIETARY_SUPPLEMENT|Bio-25|"Each capsule of the multispecies probiotic combination Bio-25 consists of 25 billion live bacteria.~Each type of bio-25 contains billions of live lactic acid bacteria in defined ratios of lyophilized Bifidobacterium breve, Bifidobacterium longum, Bifidobacterium infantis, Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus paracasein, Lactobacillus casei, Bifidobacterium bifidum,Lactobacillus lactis, Lactobacillus rhamnosus,and Streptococcus thermophilus."
224243902|NCT01667627|OTHER|Placebo|Identical placebo
224243903|NCT01139320|GENETIC|DNA analysis|
224243904|NCT01139320|GENETIC|polymerase chain reaction|
223770104|NCT06461650|BEHAVIORAL|Nicotine cessation program|Participants will complete up to 4 sessions of a nicotine cessation program over either 12-24 weeks if receiving neoadjuvant therapy (i.e. chemotherapy or hormonal/endocrine therapy) prior to surgery or over 4-6 weeks if not receiving neoadjuvant therapy prior to surgery. Each session will be 30-60 minutes long. Participants receiving neoadjuvant therapy will also be eligible for nicotine replacement therapy; however, it must be stopped 6 weeks before surgery.
224243905|NCT01139320|OTHER|laboratory biomarker analysis|
224243906|NCT01139320|OTHER|pharmacological study|
224243907|NCT02193165|DRUG|triclosan/fluoride toothpaste + cetylpyridinium chloride Mouthwash|Brush whole mouth with Total toothpaste for 1 minute, 2 times/day for 6 weeks (study duration) using a Total 360 toothbrush. Immediately after each toothbrushing, rinse whole mouth with 20 ml of mouthwash for 30 seconds.
224243908|NCT02193165|DRUG|stannous fluoride toothpaste + cetylpyridinium chloride Mouthwash|Brush whole mouth with Crest Pro-Health toothpaste for 1 minute, 2 times/day for 6 weeks (study duration) using an Oral B Pro-Health toothbrush. Immediately after each toothbrushing, rinse whole mouth with 20 ml of Crest Pro-Health Multi-Protection mouthwash for 30 seconds.
224243909|NCT02193165|DRUG|fluoride toothpaste + fluoride Mouthwash|Brush whole mouth with Crest Cavity Protection toothpaste for 1 minute, 2 times/day for 6 weeks (study duration) using an Oral B Indicator toothbrush. Immediately after each toothbrushing, rinse whole mouth with 20 ml of Crest Pro-Health For Me Breezy Mint mouthwash for 30 seconds.
224243910|NCT05439148|DRUG|OPC-61815 injection|Intravenous administration of OPC-61815 at 8 mg or 16 mg. 8mg group will be intravenously administered only on D1, once a day. 16mg group will be intravenously administered on D1，D3-D9, once a day.
224243911|NCT01778517|OTHER|Group Psychotherapy|
223664081|NCT04664699|DEVICE|Plethymographic Variability Index|"All patients were monitored with the electrocardiogram (ECG), Non Invasive Blood Pressure (NIBP), Pulse oximetry (SpO2) and invasively with an arterial line and central venous line as per institutional protocol. In the PVI group, a pulse oximetry probe was connected to the fourth finger of the hand that did not have an arterial cannulation. The pulse oximeter was connected to a monitor The Massimo ® pulse oximeter (Massimo Corp., Irvine, CA, USA), which has a module for PVI measurements.~PVI ≥13% indicates volume responsiveness, and PVI \< 13% indicates adequate volume"
223664082|NCT04664699|DEVICE|Standard Monitoring|All patients were monitored with the electrocardiogram (ECG), Non Invasive Blood Pressure (NIBP), Pulse oximetry (SpO2) and invasively with an arterial line and central venous line as per institutional protocol. Patients were resuscitated according to mean arterial pressure/ heart rate and urine output.
223664083|NCT02878057|DRUG|Apatinib|Dosing regimen: apatinib tablets: 500 mg, Po, QD; 4 weeks as a cycle, continuous treatment until disease progression, death or intolerable toxicity (giving endocrine therapy simultaneously if hormone receptor positive)
223664084|NCT01192009|DIETARY_SUPPLEMENT|Leucine|7.2 g of leucine during 2 weeks
223664085|NCT01192009|DIETARY_SUPPLEMENT|Placebo|7.2 g of alanine during 2 weeks
223664086|NCT04599530|DEVICE|Talaris Demonstrator|The Talaris Demonstrator will be evaluated during daily activities and compared to the current prosthesis
223664087|NCT03336593|BIOLOGICAL|Quadrivalent Influenza Vaccine|1 or 2 doses of Quadrivalent Influenza Vaccine depends on age
223664088|NCT03336593|BIOLOGICAL|Trivalent Influenza Vaccine|1 dose of Trivalent Influenza Vaccine
223664089|NCT01622309|DIETARY_SUPPLEMENT|eggplant meal|13 g meal of eggplant/day, being 6,5 g in breakfast and 6,5g in dinner
223664090|NCT01622309|OTHER|cassava meal|13g cassava meal/day,being 6,5 g in breakfast and 6,5g in dinner
223664091|NCT02414256|OTHER|regional anesthesia in breast surgery|In the Hospitals involved in this study are performed routinely wall blocks (PECS I-II blocks and serratus block) during breast surgery
223664092|NCT03904056|PROCEDURE|ISQ-RP|"Patients were treated with single-spot targeted retinal photocoagulation directed toward areas of retinal nonperfusion detected by fluorescein angiography. In this group, laser treatment was performed in two sessions (week 0 and 2), with a shot duration of 100 ms, but spots were placed 1/2 burn apart and power modulated in order to generate moderately white spots on the retina.~Retinal photocoagulation was performed with single-spot full-scatter PRP using Purepoint green diode laser (Alcon, Fortworth, Texas) with an Ocular Mainster PRP 165 lens with a dynamic field of view of 180 degrees, and a 200 micron spot size (which produces a 392 micron spot size on the retina). Intravitreal injection of 0.5 mg (0.05 ml) ranibizumab (Lucentis®) (IVR) were performed 180 minutes after the first laser session (week 0) by a single retina specialist."
223664093|NCT03904056|PROCEDURE|ETDRS-PRP group|Panretinal photocoagulation (PRP) as described in ETDRS Study combined with intravitreal injection of ranibizumab
223664094|NCT00796926|DRUG|Systane Ultra eyedrops|Four times a day
223664095|NCT00796926|DRUG|Refresh eye drops|Four times a day
223664096|NCT02594020|PROCEDURE|air abrasion|already used intervention to prepare micro cavities of the dental to be treated by a photopolymerizable resin
223770105|NCT00002188|DRUG|Alitretinoin|
223770106|NCT03199027|OTHER|Adherence Club|Participants will be referred to an Adherence Club at 4 months post-ART initiation. Adherence club visits occur 2-4 monthly at a community hall near the Community Health Centre (CHC). At routine visits, which last 1-2 hours, community health workers provide health education, weigh patients, ask about symptoms and dispense pre-packed ART. Symptomatic patients are sent back to the ART clinic for clinician assessment. An assigned nurse takes blood tests annually at each club, and then returns on the subsequent visit to perform a clinical assessment and check the results. Patients requiring more follow-up or with high viral loads are referred back to the ART clinic at the CHC by the nurse.
224243912|NCT01778517|OTHER|Cognitive behavior therapy based on self help|
224243913|NCT03541941|DRUG|Exparel|Solution of: 266mg of Bupivacaine Liposome Injectable Suspension (Exparel) mixed with 150mg of Bupivacaine Hydrochloride 0.25% expanded with 60cc of Normal Saline (Nacl0.9%) administered intraoperatively through a transversus abdominis plane (TAP) block
224243914|NCT03541941|DRUG|Bupivacaine Hcl 0.25% Inj|Solution of: 150mg of Bupivacaine Hydrochloride 0.25% expanded with 60cc of Normal Saline (Nacl0.9%) administered intraoperatively through a transversus abdominis plane (TAP) block
224243915|NCT03541941|DRUG|Placebo|Normal saline administered intraoperatively through a transversus abdominis plane (TAP) block
223664097|NCT02594020|PROCEDURE|sono abrasion|already used intervention to prepare micro cavities of the dental to be treated by a photopolymerizable resin
223664098|NCT02594020|PROCEDURE|dental bur|already used intervention to prepare micro cavities of the dental to be treated by a photopolymerizable resin
223664099|NCT02739178|OTHER|GSF Intervention|Intervention utilizes community-based demand generation matched with supply side improvements to improve access and use of sanitation facilities in rural communities. This is complimented with multi-stakeholder engagement to promote cooperation and coordination with national, state, and local stakeholders.
223664100|NCT05825157|DEVICE|BioBridge|Fibralign BioBridge is a thread-like, multi-lumen scaffold consisting of highly aligned collagen fibrils, optimized to encourage the endothelial cell attachment,alignment and migration that are prerequisites to new vessel formation. BioBridge is a device made from highly purified, medical-grade porcine collagen.
223664101|NCT04049877|OTHER|None - Observational study|None - Observational study
223664102|NCT05509868|DRUG|PBK_L1704 0.35mg|The subject will receive PBK\_L1704 0.35mg/ml by PCA
223664103|NCT05509868|DRUG|PBK_L1704 0.5mg|The subject will receive PBK\_L1704 0.5mg/ml by PCA
223664104|NCT05509868|DRUG|Placebo|The subject will receive placebo by PCA
223664105|NCT06478381|DRUG|L218CAR19|L218CAR19 is intravenously administered at three dose levels.
223664106|NCT05956444|OTHER|Neurodevelopmental Therapy (NDT)|In the treatment program; vestibular and proprioceptive training on the balance board; dynamic balance training in sitting with eyes open and closed, kneeling upright and standing; balance exercises in front of the mirror; standing on one leg with eyes open and closed to increase proprioceptive input; vestibular and proprioceptive training on exercise balls of the appropriate size; balance training on the trampoline; footpad sensory stimulation with different materials; weight-bearing training in sitting, crawling, kneeling and standing positions; functional reaching and throwing-holding exercises in different positions; multitasking pieces of training; gait exercises in various ways and training for climbing and descending stairs appropriate to the child's situation (assisted, unaided, symmetrical, reciprocal) took place.
223664107|NCT05956444|OTHER|Conventional Physiotherapy|Classical physiotherapy applications for balance.
223664108|NCT03391245|DIAGNOSTIC_TEST|3- Serum 25-Hydroxy Vitamin D level will be measured by Competitive ELISA technique|Serum 25-Hydroxy Vitamin D level will be measured by Competitive ELISA technique using CALBIOTECH (A life science company) kit, Catalog No.: VD220B
223664109|NCT01859546|BEHAVIORAL|Short message service|Short message service reminders on cell phones in improving the compliance of subsequent visits for routine immunization for children
223664110|NCT03302182|DRUG|Ritonavir for cycle1 and NORVIR for cycle 2|During the study session, healthy subjects will be administered a single dose of Ritonavir Tablet 100mg in cycle 1 and NORVIR tablet 100mg in cycle 2 .
223664111|NCT03302182|DRUG|NORVIR for cycle 1 and Ritonavir for cycle 2|During the study session, healthy subjects will be administered a single dose of NORVIR Tablet 100mg in cycle 1 and Ritonavir tablet 100mg in cycle 2 .
223770107|NCT03499392|OTHER|psychological tests|psychological tests psychological interviews
223770108|NCT02188238|OTHER|Saliva Sample Collection|Saliva samples will be collected from healthy volunteers recruited locally. Stimulated whole mouth saliva is collected through stimulation by inert gum, and collecting the saliva by gently spitting into a sterile tube.
223770109|NCT03331068|BEHAVIORAL|online questionnaire of MAX-PC|Scale measuring of the anxiety specific of prostate cancer, French version.
224243916|NCT01125137|PROCEDURE|Removal of Keloid|Keloid will be excised by Henry Ford Hospital Dermatologist, Dermatosurgeon or Plastic Surgeon.
224243917|NCT01486147|BEHAVIORAL|Visual nutrient profiling tool|Shown color coded fiber and protein 2x2 plot, selected fiber and protein ratings from boxes on the plot.
224243918|NCT01486147|BEHAVIORAL|Nutrient ratings table|Showed nutrition information and had to match to fiber and protein ratings from a table.
224243919|NCT00202605|DRUG|Neutral salts of dextroamphetamine sulfate, USP, amphetamine sulfate, USP, d-amphetamine saccharate, d,I-amphetamine aspartate monohydrate|
224243920|NCT04658745|DEVICE|Intermittent theta burst stimulation|iTBS (20 trains of ten bursts at eight-second intervals, 600 stimuli, 200-second per session) will be delivered to the ipsilesional hemisphere in stroke patients, by using a butterfly shape coil.
224243921|NCT04658745|BEHAVIORAL|Mirror Therapy|Participants will practice the movements with the non-affected hand and try moving the affected arm at the same time to synchronize with the non-affected hand (illusion on the mirror). The movement practice will involve 5 table-top tasks and the participant will be instructed to perform as many trials as possible in each session with a maximum of 30 trials per task, giving a total of 150 trials per session, lasting for 20 minutes.
224243922|NCT04658745|DEVICE|Sham intermittent theta burst stimulation|iTBS (20 trains of ten bursts at eight-second intervals, 600 stimuli, 200-second per session) will be delivered to the ipsilesional hemisphere in stroke patients. However, a sham coil will be used, which is not associated with any stimulation effect on the brain.
223664112|NCT02479646|BIOLOGICAL|MYL-1401H|
223664113|NCT02479646|BIOLOGICAL|EU-Neulasta|
223664114|NCT02479646|BIOLOGICAL|US-Neulasta|
223664115|NCT05291312|PROCEDURE|Adenoidectomy with endoscopic assisted coblation (EACA) and Adenoidectomy with conventional curettage (CCA)|IN the (EACA) group slight head flexion position will be given to the patients and Boyle-Davis retractor will be placed to keep the mouth open. The soft palate will be elevated upward by inserting a plastic feeding catheter.. IN the (CCA) group, by orotracheal intubation , Boyle-Davis mouth retractor will be used to provide mouth opening
223664116|NCT04427982|BEHAVIORAL|dance|Participants will attend a 2-month weekly light-to-moderate intensity dance workshop.
223664117|NCT04427982|BEHAVIORAL|diabetes education|The dance classes will be followed by a brief diabetes education and discussion session.
223664118|NCT03593616|PROCEDURE|Phacoemulsification|insertion of intra-ocular lens after emulsification of catractous lens
223664119|NCT02681354|OTHER|Biorescue training|
223664120|NCT05225805|DRUG|Lefamulin|Antibiotic
224243923|NCT04658745|BEHAVIORAL|Sham mirror Therapy|In sham mirror therapy, the mirror will be covered. Participants will practice the movements with the non-affected hand and try moving the affected arm at the same time to move the non-affected hand. The participants cannot receive mirror visual feedback of the paretic upper extremity movement during the therapy. Same as mirror therapy, the movement practice will involve 5 table-top tasks and the participant will be instructed to perform as many trials as possible in each session with a maximum of 30 trials per task, giving a total of 150 trials per session, lasting for 20 minutes.
224243924|NCT03203980|OTHER|Triple antithrombotic therapy|patients who are prescribed double antiplatelets agents and oral anticoagulation (except VKA)
224243925|NCT03325426|DEVICE|FitBit|Daily use of physical activity tracker coupled with biweekly provider telemonitoring and feedback for 6 months and then additionally without feedback for an additional 6 months
224243926|NCT01498120|DRUG|Rotigotine|"Optimal dose after titration period~0.5 mg/24 h (2.5 cm\^2)- 1 mg/24 h (5 cm\^2)- 2 mg/24 h (10 cm\^2)- 3 mg/24 h (15 cm\^2)~1 patch /day"
224243927|NCT04058080|OTHER|Bikram Yoga|Participants in the Bikram yoga group were asked to attend two classes per week for 8 weeks (16 classes in total) at a local affiliated Bikram yoga studio. Certified Bikram yoga teachers instructed all classes using a scripted instructional dialogue. Each 90-min class was held in a temperature-controlled room (40.6C, 40% humidity). The yoga studio regularly offered 22 class times per week, all of which were accessible to participants.
224243928|NCT04058080|OTHER|Aerobic Exercise|Participants in the aerobic exercise group were asked to attend two group aerobic exercise classes per week for 8 weeks (16 classes in total) at the Kingston Family YMCA. They were provided with a modified schedule of the YMCA group classes, which included only classes with a strong aerobic component and excluded those involving yoga, pilates, or cycling. Classes involving the following components were available to participants: choreography-based cardio, aerobics, light muscular conditioning, and stretching; cardio, plyometric, and strength training exercises; high intensity aerobic exercise with intermittent rest periods; circuit-based cardio and strength training exercises; stepper-based exercises; and Latin-inspired dance/fitness. Classes were 50-60 minutes in duration. Participants were able to attend any of the offered classes each week. Participants had approximately 18-22 classes in total to choose from each week.
224243929|NCT01173692|DRUG|Minocycline|100 mg twice daily (200 mg) by mouth , every day for 7 weeks starting first day of radiation therapy.
224243930|NCT01173692|DRUG|Placebo|Twice daily by mouth, every day for 7 weeks starting at first day of radiation therapy.
224243931|NCT01240291|DIETARY_SUPPLEMENT|Dipeptiven|Intravenous alanyl-glutamine (0.5 g/kg body weight; i.e. 0.35 g L-glutamine / kg body weight; continuous infusion (20-24 hr/day) via central venous access for a maximum duration of 3 weeks.
224243932|NCT01240291|DIETARY_SUPPLEMENT|normal saline|0.5 g/kg bod weight /day, continuous infusion (20-24 hr/day) via central venous access for a maximum duration of 3 weeks
224243933|NCT05482893|DRUG|Spevatamig (PT886)|Spevatamig (PT886) monotherapy, a novel bispecific antibody that targets Claudin 18.2 and CD47.
224243934|NCT05482893|DRUG|Paclitaxel|Chemotherapy as a combination partner to Spevatamig (PT886) in Part C: Cohort C1
224243935|NCT05482893|DRUG|Gemcitabine|Chemotherapy as a combination partner to Abraxane and Spevatamig (PT886) in Part C: Cohort C2
224243936|NCT05482893|DRUG|Abraxane|Chemotherapy as a combination partner to Gemcitabine and Spevatamig (PT886) in Part C: Cohort C2
224243937|NCT05482893|DRUG|KEYTRUDA® (pembrolizumab)|Immune checkpoint inhibitor as a combination partner to Spevatamig (PT886) in Part D: Cohort D2, D3 and D4.
224243938|NCT05482893|DRUG|Oxaliplatin|Chemotherapy as a combination partner to KEYTRUDA® (pembrolizumab) and Spevatamig (PT886) in Part D: Cohort D4
224243939|NCT05482893|DRUG|Leucovorin|Chemotherapy as a combination partner to KEYTRUDA® (pembrolizumab) and Spevatamig (PT886) in Part D: Cohort D4
224243940|NCT05482893|DRUG|Fluorouracil|Chemotherapy as a combination partner to KEYTRUDA® (pembrolizumab) and Spevatamig (PT886) in Part D: Cohort D4
224243941|NCT05482893|DRUG|Capecitabine|Chemotherapy as a combination partner to KEYTRUDA® (pembrolizumab) and Spevatamig (PT886) in Part D: Cohort D4
224243942|NCT05482893|DRUG|FOLFIRINOX|Chemotherapy as a combination partner to Spevatamig (PT886) in Part C: Cohort C3
224243943|NCT05658783|OTHER|Hot water foot bath|Keeping keep in 42oC (42 Degrees Celsius) hot water for 20 minutes
224243944|NCT03435796|GENETIC|Gene-modified (GM) T cell therapy|No investigational product will be administered
224243945|NCT05672264|OTHER|Whole-Body Electromyostimulation|Consistently supervised, video-guided WB-EMS application 1.5 times per week for 28 weeks. Bipolar electric current with a frequency of 85Hz, an impulse-width of 350 µs will be used in an interval approach with 6 sec of EMS stimulation with a direct impulse boost and 4 sec of rest. Low intensity movements or exercises in a standing position were performed during the 6 s stimulation period.
224243946|NCT05672264|OTHER|Physiotherapy|Six standardised physiotherapy sessions (20 min each)
224243947|NCT00196651|DRUG|IL-2|
224243948|NCT00196651|BIOLOGICAL|LIPO-6T|
224243949|NCT00196651|BIOLOGICAL|ALVAC VIH 1433|
224243950|NCT03785301|DEVICE|Freestyle Libre Flash Glucose Monitoring|Freestyle Libre Flash Glucose Monitoring will be used in diabetic patients once a month for therr months to monitor glucose level. Patients could scan the sensor to get the glucose level at any time as they want. They could alter thier diet and exercise according to the glucose levels. Patients will be required to keep track of food and exercise during wearing FGM sensor. Physicians would adjust patients' medication according their glucose profile provided by FGM, A1c, and diet and exercise every month.
224243951|NCT05200663|DRUG|Tab Tamoxifen 10 mg|Tablet tamoxifen 10mg twice a day for 6 months.
224243952|NCT05200663|DRUG|Tab Tamoxifen 10mg,Cap vitamin E 400mg|Tab tamoxifen 10 mg is given twice a day and cap vit E 400mg is given once a day for 6 months
224243953|NCT00678639|OTHER|Observation unit care, coupled with cardiac MRI|After Emergency Department (ED) evaluation, patients are randomized to Observation unit care or standard inpatient care. Patients in the observation unit will also undergo a stress cardiac MRI. Patients in the usual care arm may undergo any desired testing, including cardiac MRI, as determined by their treating physician.
223664121|NCT00456170|PROCEDURE|Performing Vaginal hysterectomy with Harmonic Scalpel|
223664122|NCT00380380|DRUG|Vildagliptin|
223664123|NCT00624169|PROCEDURE|An optimized perioperative course|A number of interventions before, during and after surgery
224243954|NCT03611608|DRUG|LY3316531|Administered IV
224243955|NCT03611608|DRUG|Placebo|Administered IV
224243956|NCT00045877|DRUG|Recombinant Human Interleukin-2 and Rituximab|
224243957|NCT01243996|DRUG|Ibuprofen|Treatment with high (20-10-10 mg/kg/day)or standard dose(10-5-5 mg/kg/day) ibuprofen
224243958|NCT04060823|OTHER|Easy Breathing program|Easy Breathing is a longstanding, nationally recognized program that translates asthma management guidelines into a standardized and usable format for healthcare providers. As part of the program primary healthcare providers will identify children at-risk for adverse asthma outcomes and provide care coordination services. Patients receive a tailored, comprehensive Asthma Treatment Plan with information regarding daily medication use and management of acute symptoms based on asthma severity.
224243959|NCT03679377|DEVICE|Mandibular slotplate|Mandibular slotplates are placed during the osteosynthesis phase of the BSSO surgery. After testing of the plates they are removed and the osteotomy is fixated with three bicortical screws.
224243960|NCT05796310|DIAGNOSTIC_TEST|Salivary collection|Collection of saliva via swab for miRNA processing
224243961|NCT05796310|DIAGNOSTIC_TEST|eye-tracking recorder|Administration of eye-tracking session recording Saccadic Eye Movements, fixation duration and pupillary response.
224243962|NCT05796310|DIAGNOSTIC_TEST|neuropsychological assessment|Administration of neuropsychological tests and collected patient medical history
224243963|NCT03803865|BEHAVIORAL|Mindfulness Training|Guided mindfulness meditation and stress management training
224243964|NCT03803865|BEHAVIORAL|Reflection and Problem Solving|Guided reflection,problem solving,and analytical thinking training
224243965|NCT04255719|PROCEDURE|DBS|Unilateral DBS for treatment of patients with PD
224243966|NCT05622461|BEHAVIORAL|Road-to-recovery|R2R-TBI is a self-guided web-based intervention that targets caregiver psychological functioning, parenting behaviors, and family functioning in the first three months following pediatric traumatic brain injury.
223664124|NCT01750749|BIOLOGICAL|Autologous BMDC implantation at the venous ulcer|An autologous bone marrow derived cell concentrate is obtained by bone marrow harvest (300 ml) from the iliac crest and subsequent processing using 6% hydroxyethyl starch to concentrate nucleated cells. The cells are injected using a 27 Gauge needle, in aliquots of 0.2 ml, along the venous ulcer edge. SOC treatment consisting of advanced wound management plus pressure therapy is administered simultaneously.
223664125|NCT01085006|DRUG|Tranexamic acid|Tranexamic acid in cases, normal saline in controls
223664126|NCT01085006|DRUG|Normal saline|Tranexamic acid in cases, normal saline in controls
223770110|NCT01456442|DEVICE|anorectal manometry|High-resolution anorectal manometry is done under standard clinical conditions with a 10 cm catheter inserted into the rectum loaded with pressure transducers at a distance of 6 mm in the sphincter area and an attached latex balloon at the catheter tip. It will measure the length of the anal sphincter, the static pressure and the clamping pressure during at least 3 over 40 seconds sustained maneuvers according to a standardized protocol. Mean and maximum pressure increase over the resting pressure during the first 30 seconds of the squeeze and the maximum possible squeeze time will be documented. Moreover, the initial anorectal perception threshold, the perception of urge to defecate and maximum tolerable volume balloon will be documented.
223770111|NCT01456442|DEVICE|barostat|For the barostat study a balloon will be attached to the catheter. Instead of a barostat machine a 60ml syringe and a sphygmomanometer will be connected to the catheter and the catheter will be positioned in the rectum. The balloon is then dilated gradually to assess perception, urge and discomfort threshold in relation to rectal volume.
223770112|NCT00000537|BEHAVIORAL|meditation|
223770113|NCT00000537|BEHAVIORAL|relaxation|
223770114|NCT03856762|DIETARY_SUPPLEMENT|traditional Jiangnan diet|traditional Jiangnan diet supplement from Monday to Friday for six months
224243967|NCT01148095|DRUG|AZD2516|Oral, single, daily, 11 days
224243968|NCT01148095|DRUG|Placebo|
224243969|NCT05898919|OTHER|Acupuncture|Acupuncture is a technique that inserts a needle into the acupuncture point to treat a condition. In this trial, we will use acupuncture to treat postoperative urinary retention.
224243970|NCT05898919|OTHER|Sham acupuncture|Participants will receive sham acupuncture at sham points.
224243971|NCT05898919|DRUG|Neostigmine Injectable Product|Neostigmine was injected once after postoperative urinary retention.
224243972|NCT01866449|DRUG|Cabazitaxel|
224243973|NCT03090932|OTHER|Blood draw|Research subjects will have two tubes of blood drawn, approximately 20mL.
224243974|NCT01671514|DIETARY_SUPPLEMENT|Epicatechin-enriched dark chocolate|For experimental purposes, subjects will take one square of epicatechin-enriched dark chocolate per day for 90 days.
224243975|NCT01671514|OTHER|Low-epicatechin dark chocolate|As a placebo control, subjects will take 1 square of low-epicatechin chocolate per day for 90 days.
224243976|NCT04342481|OTHER|Educational Screening tool|Educational Screening tool
224243977|NCT02099981|DRUG|Aminoguanidine|
224243978|NCT03609983|OTHER|Daily weighing with daily feedback on weight|"Participants will weigh themselves using a Yunmai SE Scale one time each day upon rising from bed beginning in one week, every day for four weeks. After 2 weights have been collected, participants will begin to receive daily feedback on their change in weight and suggestions to maintain energy balance. They will receive an email stating, Your weight today is \_\_\_\_\_\_\_. Your weight has (increased/decreased) \_\_\_\_\_ pounds since yesterday. If their weight has increased, the email will include one example of how to decrease their energy balance by 150 calories. If participants' weight has decreased, the email will include one example of how to increase energy balance by 150 calories."
224243979|NCT03609983|OTHER|Weekly weighing with weekly feedback on weight|"Participants will weigh themselves using a Yunmai SE Scale one time each week upon rising from bed beginning the following day for four weeks. After 2 weights have been collected, participants will begin to receive weekly feedback on their change in weight and suggestions to maintain energy balance. They will receive an email stating, Your weight today is \_\_\_\_\_\_\_. Your weight has (increased/decreased) \_\_\_\_\_ pounds since last week. If their weight has increased, the email will include one example of how to decrease their energy balance by 150 calories. If participants' weight has decreased, the email will include one example of how to increase energy balance by 150 calories."
224243980|NCT00986245|DRUG|Ropinirole Prolonged release|Change Ropinirole immediate release or Pramipexole immediate release to Ropinirole prolonged release (PR) once-daily or twice-daily
223664127|NCT04077788|OTHER|muscle energy technique|"Muscle energy technique:~1. Application of MET for bone of pelvis:~   I) Pubis:~  1. Cranial Os pubis.~  2. Caudal os pubis.~   II) ileum:~  1. Anterior ileum.~  2. Posterior ileum.~  3. External Rotation (In flare) Lesion.~  4. Internal Rotation (Out flare) Lesion.~   III) sacrum:~  1. Forward torsion of sacrum.~  2. Backward torsion of sacrum.~2. Muscle energy technique for specific muscles of pelvis and spine:~   1. Stretch of the Psoas Major.~  2. Stretch of the paravertebral muscle.~  3. Stretch of the piriforms."
223664128|NCT04359901|BIOLOGICAL|SARILUMAB|Single dose of 400 mg subcutaneous sarilumab
224243981|NCT06558162|BEHAVIORAL|Mindfetalness|"They will be instructed to lie on their left side and focus on the fetal movements for 15 minutes every day while the foetus is awake. They will also be instructed to monitor the character, strength and frequency of fetal movements (not to count them) and to seek medical advice if they feel any change in this pattern.~After two weeks, the pregnant women will be invited back to the organisation for a follow-up interview to check whether they have performed the practice and recorded correctly. An interview will be conducted again after four weeks."
223664129|NCT00690144|DEVICE|High-fidelity high-fidelity mannequin simulator (SimMan, Laerdal, Stavanger, Norway).|Critical care training using high-fidelity simulation. The case scenarios were simulated by a high-fidelity mannequin simulator (SimMan, Laerdal, Stavanger, Norway).
223664130|NCT03320577|BEHAVIORAL|Class instruction of breathing exercises|Pranayama Breathing exercises practiced at least 5 times a week and log practice times
223664131|NCT03320577|BEHAVIORAL|DVD instruction of breathing exercises|Pranayama Breathing exercises practiced at least 5 times a week and log practice times
223664132|NCT03320577|BEHAVIORAL|Control|Log dinner times
223664133|NCT05092360|BIOLOGICAL|Nemvaleukin and Pembrolizumab Combination|Nemvaleukin: 6 µg/kg/day; Days 1 through 5 of 21-day cycles; IV infusion over 30 minutes and Pembrolizumab: 200 mg; Day 1 of 21-day cycles; IV infusion over 30 minutes
223664134|NCT05092360|BIOLOGICAL|Pembrolizumab|Pembrolizumab: 200 mg; Day 1 of 21-day cycles; IV infusion over 30 minutes
223664135|NCT05092360|BIOLOGICAL|Nemvaleukin|Nemvaleukin: 6 µg/kg/day; Days 1 through 5 of 21-day cycles; IV infusion over 30 minutes
223664136|NCT05092360|DRUG|Pegylated Liposomal Doxorubicin (PLD)|40 mg/m2; Day 1 of 28-day cycles; IV infusion; 1 mg/min (Cycle 1); 60 min infusion (Cycles 2+)
223664137|NCT05092360|DRUG|Paclitaxel|80 mg/m2; Days 1, 8, 15, and 22 of 28-day cycles; IV infusion over 60 min
223664138|NCT05092360|DRUG|Topotecan|4 mg/m2; Days 1, 8, and 15 of 28-day cycles; or 1.25 mg/m2, Days 1 through 5 of 21-day cycles; IV infusion over 30 min
223664139|NCT05092360|DRUG|Gemcitabine|1,000 mg/m2; Days 1 and 8 of 21-day cycles; IV infusion over 30 min
223664140|NCT00392145|DRUG|Standard IV rehydration|A 20 mL/kg 0.9% normal saline bolus (maximum 999 mL) will be administered over 1 hour. This will be followed by D5-0.9% normal saline at a maintenance rate (maximum 55 mL/hr).
223770115|NCT03856762|DIETARY_SUPPLEMENT|Mediterranean diet|Mediterranean diet supplement from Monday to Friday for six months
223770116|NCT03856762|DIETARY_SUPPLEMENT|Current Shanghai diet|current Shanghai diet supplement from Monday to Friday for six months
224243982|NCT06558162|BEHAVIORAL|Sadovsky|"They will be asked to continue this procedure every morning, noon or evening for one month (depending on the movements of the pregnant woman and her baby, the time will be left to the pregnant woman, but it should be at the same time every day). Since the aim of the study is to increase maternal awareness rather than to determine fetal well-being, mothers will be asked to count at least 10 movements based on the count to ten and Sadovsky method, and will be asked to record the start and completion time of the movements each time. A follow-up will be made after two weeks and a final follow-up will be made after one month"
224243983|NCT00132262|BEHAVIORAL|Brief intervention based on motivational interviewing|The intervention was an approximately 30 minute discussion about alcohol-related risk behaviors and motivation to change
223664141|NCT00392145|DRUG|Rapid intravenous rehydration (RIVR)|A 60 mL/kg 0.9% normal saline bolus (maximum 999 mL) over 1 hour will be administered. This will be followed by D5-0.9% normal saline at a maintenance rate (maximum 55 mL/hr).
223664142|NCT00830778|PROCEDURE|Pancreaticojejunostomy|Pancreaticojejunostomy (PJ) reconstruction/anastomosis
223664143|NCT00830778|PROCEDURE|Pancreaticogastrostomy|Pancreaticogastrostomy (PG) reconstruction/anastomosis
223664144|NCT05993013|OTHER|LudoFit|Game-based, technology-enabled home exercise software, done at least 3 times per week. Video games for a variety of exercises that promote balance, strength, endurance, and coordination.
223664145|NCT05090397|DEVICE|Transcranial Direct Current Stimulation|Transcranial Direct Current Stimulation (tDCS) uses a mild electrical current to make small (or subtle) changes to how the brain works (or functions).
223664146|NCT05090397|DEVICE|Sham Transcranial Direct Current Stimulation|Sham Transcranial Direct Current Stimulation
223664147|NCT06384781|BEHAVIORAL|Peer Support Checklist|Peer support specialists are Certified Peer Support Specialists (CPSS) who have lived experience with Opioid Use Disorder (OUD) and OUD recovery. Peer support specialists offer consistent personalized recovery support and generalized social support. Peer support specialists will maintain contact and provide support for the participant for six-months post-baseline. CPSS will utilize the newly developed checklist from earlier phases of the project to provide patient support.
223664148|NCT04580134|DRUG|clozapine|Biotype 1 and Biotype 2
223664149|NCT04580134|DRUG|risperidone|Biotype 1 and Biotype 2
223664150|NCT02814994|BEHAVIORAL|tidal volume guided by respiratory system compliance|ventilated with tidal volume guided by respiratory system compliance
223664151|NCT02814994|BEHAVIORAL|low tidal volume|ventilation ventilated with low tidal volume
223664152|NCT00062803|DRUG|SR34006|
223664153|NCT00062803|DRUG|(LMW)heparin|
223664154|NCT00062803|DRUG|Warfarin VKA|
223770117|NCT00094874|PROCEDURE|Acupuncture|
223664155|NCT00062803|DRUG|Acenocoumarol VKA|
223664156|NCT05219370|DRUG|Cannabis oil|administration of different cannabis oil types as compared with placebo
223664157|NCT05138952|BEHAVIORAL|Mindfulness Meditation|"30-day mediation program comprising:~1. Weekly group mediation tuition and support sessions delivered online. Sessions will last 45-60 minutes and focus on mindfulness meditation theory and techniques, and trouble shooting barriers to practice and engagement.~2. 10-minutes of daily mindfulness meditation practice with the Headspace Inc app."
223770118|NCT02705820|DRUG|Pembrolizumab|Switch maintenance pembrolizumab treatment
223664158|NCT02145013|PROCEDURE|Liver resection|Hepatectomy by either open, laparoscopic or robotic procedures
223664159|NCT04947085|DRUG|Ketamine via Intravenous|Ketamine administration in sub-dissociative doses
223664160|NCT04947085|DRUG|Ketamine via BAN|Ketamine administered via Breath-Actuated Nebulizer (BAN)
223664161|NCT02499757|DEVICE|flavor and sweetener|maltol added as sweetener to e-cigarette with flavor
223664162|NCT02499757|DEVICE|flavor and nicotine|12 mg of nicotine added to e-cigarette with flavor
223664163|NCT02499757|DEVICE|flavor, nicotine and sweetener|12 mg nicotine and maltol (sweetener) added to e-cigarette with flavor
223664164|NCT02499757|DEVICE|flavor|flavored e-cigarette stand alone without added nicotine and maltol (sweetener)
223664165|NCT06516523|PROCEDURE|PEMF and Control/Sham|Use o PEMF on test implants (treatment of peri-implantitis and bone formation) Use of PEMF on experimental implants (Bone-to-implant contact)
223664166|NCT06516523|DEVICE|PEMF and without PEMF|Use o PEMF on test implants (treatment of peri-implantitis and bone formation)
223664167|NCT05767268|DEVICE|Lokomat|gait rehabilitation
224243984|NCT00132262|BEHAVIORAL|Standard Care including referral for treatment|Standard hospital care provided the patient with information and referral for treatment as necessary.
223664168|NCT01525225|DRUG|Metformin immediate release (IR)|Tablet, Oral, 1000 mg, twice daily, 1 day
223664169|NCT01525225|DRUG|Saxagliptin|Tablet, Oral, 5 mg, single-dose, 1 day
223664170|NCT01525225|DRUG|Metformin IR|Tablet, Oral, 1000 mg, twice daily, 5 days
223664171|NCT01525225|DRUG|Saxagliptin/Metformin XR FDC|Tablet, Oral, 2.5 mg Saxagliptin/1000 mg Metformin extended release (XR), Single-dose of 2 tablets. Fixed dose combination (FDC).
223664172|NCT01525225|DRUG|Metformin XR|Tablet, Oral, 500 mg, Single-dose of 4 tablets
223664173|NCT00243841|RADIATION|Stereotactic Body Radiation|Arm A: Childs A - receive 3 fractions. Arm B: Childs B - receive 5 fractions.
223664174|NCT05878262|DRUG|ibuprofen suppository|After the induction of anesthesia was performed, the nurse delivered the ibuprofen suppository at the dose of 5-10 mg/Kg for the pre-emptive analgesia group children.
223664175|NCT03647891|DEVICE|Continuous Positive Airway Pressure|CPAP is an FDA approved therapy machine for patients diagnosed with OSA. CPAP provides positive air pressure to the patients throat to ensure the patients airway stays open during sleep. CPAP is the gold standard treatment for OSA, but there is limited research that demonstrates whether or not CPAP can improve clinical outcomes in patients with cardiovascular disease. Therefore, our investigators plan to initiate CPAP therapy in patients hospitalized for cardiovascular disease to investigate whether there is an improvement in cardiac function and clinical outcomes (e.g. mortality).
223664176|NCT00285389|DRUG|Adriblastin|
223664177|NCT00285389|DRUG|dexamethasone|
223664178|NCT00285389|DRUG|Chlorambucil|
223770119|NCT03870152|PROCEDURE|Electrocautery Ablation (EC)|For the purposes of the trial, one round of EC treatment consists of two individual EC treatments with a post-EC bronchoscopy in between to check for a response to the 1st EC treatment. Within each round, the second EC treatment will only be administered if the post-treatment bronchoscopy confirms presence of persistent high grade disease. Patients in the intervention arm will receive up to three rounds of EC treatment (no more than one round annually) to all their HGLs identified at baseline.
223770120|NCT04779866|BEHAVIORAL|Self-Administered Hypnosis|Participants randomized to the self-administered hypnosis group will receive five audio-recordings of self-administered hypnosis, specifically targeting sleep improvement, which they will use for daily home practice.
224243985|NCT01635322|DEVICE|Polyaxial posterior spinal fusion system|posterior correction and fusion of the thoraco-lumbar or lumbar spine
224243986|NCT02816788|BEHAVIORAL|Equine Assisted Therapy (EAT)|Psychotherapy incorporating use of equines (Equine Assisted Therapy; EAT) to facilitate therapy to improve the social, emotional and psychological well-being of participants and alleviate PTSD symptoms.
224243987|NCT05519800|DIETARY_SUPPLEMENT|Isomaltulose|Diet will be supplemented with a beverage containing Isomaltulose as a carbohydrate source.
224243988|NCT05519800|DIETARY_SUPPLEMENT|Maltodextrin|Diet will be supplemented using a beverage containing Maltodextrin.
224243989|NCT02158494|DEVICE|Balance and Gait Training using neurostimulation modulation.|CN-NINM uses sequenced patterns of electrical stimulation on the tongue. Our hypothesis is that CN-NINM induces neuroplasticity by noninvasive stimulation of two major cranial nerves: trigeminal, CN-V, and facial, CN-VII.
224243990|NCT02158494|DEVICE|Sham Device|The sham device is visually identical to the CN-NINM device, and offers a non-zero, minimally perceivable stimulation.
224243991|NCT01214850|BIOLOGICAL|Meningococcal B Recombinant + Outer Membrane Vesicle vaccine (rMenB+OMV NZ)|
224243992|NCT01214850|BIOLOGICAL|MenACWY-CRM conjugate vaccine|
224243993|NCT01214850|BIOLOGICAL|Japanese Encephalitis vaccine|
224243994|NCT06343805|DRUG|AJ1-11095|Type II JAK2 Inhibitor
224243995|NCT05293353|OTHER|NeoKare Breast Milk Fortifier|Powdered product made from human breast milk used to increase nutritional content of mother's own breast milk
223664179|NCT00285389|DRUG|rituximab|
223664180|NCT00285389|DRUG|cyclophosphamide|
223664181|NCT00285389|DRUG|alkeran|
223664182|NCT00285389|PROCEDURE|Total body irradiation (8Gy/4fr)|
223664183|NCT00285389|DRUG|vincristine|0,4 mg/day day 1 to day 4
223664184|NCT05819489|DIAGNOSTIC_TEST|Dynamic Vision Testing|Dynamic Vision Testing (Bertec Vision Advantage System) and Balance Error Scoring System Assessment tool and computerized tests designed to evaluate postural stability and vestibulo-ocular reflex (VOR) function while assisting with return to play decision after a sports-related concussion.
223664185|NCT04596059|OTHER|Frisolac Gold Intensive HA|Regular medical care
223664186|NCT01575535|GENETIC|gene expression analysis|
223664187|NCT01575535|OTHER|flow cytometry|
223664188|NCT01575535|OTHER|fluorescence activated cell sorting|
223664189|NCT01575535|OTHER|laboratory biomarker analysis|
223664190|NCT01575535|OTHER|medical chart review|
223664191|NCT05972057|PROCEDURE|cardiac surgery|All cardiac surgery patients who met the inclusion criteria were included in the cardiac surgery department of Renji Hospital.
223664192|NCT05518578|DRUG|SPN-817|oral capsule
223664193|NCT05974059|DRUG|Oxaliplatin|Preoperative treatment：130mg/m2，iv, 2h，d1，Q3W; Postoperative treatment：130mg/m2，iv, 2h，d1，Q3W;
223770121|NCT04779866|BEHAVIORAL|Self-Administered White Noise Hypnosis|Participants randomized to the white noise hypnosis control will receive the same information and contact with the therapist, but will be provided with audio recordings that contain white noise as a sham hypnosis condition. These recordings include instructions and the use of white noise as a hypnotic induction.
223770122|NCT01823874|PROCEDURE|virtual reality distraction|Pain distraction will be measured with both the HMD virtual reality method and the ID virtual reality method.
223770123|NCT01913366|BEHAVIORAL|CM-PST|
223770124|NCT01913366|BEHAVIORAL|SG-PST|
223770125|NCT03688321|DIETARY_SUPPLEMENT|Probiotic capsule GR-1 and RC-14|Study Group will take 2 probiotics capsules containing 1 billion colony forming unit(CFU) of Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14 each before sleep for 18 weeks starting at 28th week gestation
223770126|NCT03688321|DIETARY_SUPPLEMENT|Placebo capsule|Placebo Group will take 2 placebo capsules before sleep for 18 weeks starting at 28th week gestation
223770127|NCT06416865|DRUG|AJU-C52L, AJU-C52|"AJU-C52L+C52R1L placebo: Subjects take the investigational products once a day for 2 weeks.~AJU-C52+C52R1M placebo: Subjects take the investigational products once a day for 6 weeks."
223770128|NCT06416865|DRUG|C52R1L, C52R1M|"C52R1L+AJU-C52L placebo: Subjects take the investigational products once a day for 2 weeks.~C52R1M+AJU-C52 placebo: Subjects take the investigational products once a day for 6 weeks."
223770129|NCT02702401|BIOLOGICAL|Pembrolizumab|IV infusion
223770130|NCT02702401|DRUG|Placebo|0.90% w/v sodium chloride IV infusion
223770131|NCT02702401|OTHER|Best Supportive Care|Best supportive care will include pain management and management of other potential complications including ascites per local standards of care.
223770132|NCT05092893|OTHER|Online parental questionnaires|"The SRS-2 is a parental 65-item questionnaire to detect difficulties in social responsiveness in children with autism spectrum disorder. Four different forms are available: preschoolers (2.5-4.5 years), school-aged children (4-18 years), adults (≥ 19 years) and adults self-report. In this study, only the form for school-aged children will be used.~The DCDQ'07 is a parental 15-item questionnaire to detect the risk of DCD in children between 5 and 15 years of age. Parents are asked to compare their child's motor performance to his/her peers using a 5-point Likert scale. The total sum score is compared to age-specific cut-off scores to determine the risk of DCD. Belgian norms are available since 2007."
223770133|NCT01800617|DRUG|Liothyronine, Sodium|
223770134|NCT00012051|BIOLOGICAL|filgrastim|
223770135|NCT00012051|BIOLOGICAL|rituximab|
223770136|NCT00012051|DRUG|carmustine|
223770137|NCT00012051|DRUG|cisplatin|
223770138|NCT00012051|DRUG|cytarabine|
223770139|NCT00012051|DRUG|dexamethasone|
223770140|NCT00012051|DRUG|etoposide|
224243996|NCT06245278|OTHER|ELISA (Enzyme-Linked ImmunoSorbent Assay)|A total of 60 individuals, 15 with IBD and periodontitis, 15 with IBD and periodontal health, 15 with systemic health and periodontitis, and 15 with systemic and periodontal health, will be included in the study. At the beginning of the study, periodontal clinical measurements (gingival index, plaque index, probing depth, gingival recession, clinical attachment level, bleeding on probing) and serum, saliva and gingival samples will be obtained from all individuals. Individuals with periodontitis will receive non-surgical periodontal treatment in half jaws within 2 weeks. Clinical measurements, serum and saliva sample collection will be repeated 3 months after the treatment. Biomarker levels in serum and saliva samples will be analysed by ELISA.
224243997|NCT06812403|DEVICE|the COMBO Endoscopy Oropharyngeal Airway with High-Flow Nasal Cannula Oxygenation|Using the COMBO Endoscopy Oropharyngeal Airway with High-Flow Nasal Cannula Oxygenation in Sedated Gastrointestinal Endoscopy for Obese Patients
224243998|NCT06238986|OTHER|Non-Interventional Study|Non-interventional study
224243999|NCT00802100|DRUG|Olanzapine|Daily tablets of 10 to 30 mg
224244000|NCT00802100|DRUG|Perphenazine|Daily tablets of 8 to 24 mg
224244001|NCT00802100|DRUG|Aripiprazole|Daily tablets of 10 to 30 mg
224244002|NCT00802100|DRUG|Metformin|Daily tablets of 850 to 2550 mg
224244003|NCT00802100|DRUG|Simvastatin|Daily tablets of 20 to 40 mg
224244004|NCT00802100|DRUG|Benztropine|Daily tablets of 1 to 2 mg
224244005|NCT03968718|BEHAVIORAL|Systematic ePROMs Assessment|"Depending on the care setting, eligible patients will be asked to fill in one of the following e-PROMs assessment:~Edmonton symptom assessment scale (ESAS-r) (outpatients)~Distress Thermometer (inpatients)~An ad hoc questionnaire adapted from the Bench-Can and EURACAN projects plus the institutional customer satisfaction survey (patients followed by multidisciplinary teams)"
223770141|NCT00012051|DRUG|ifosfamide|
223770142|NCT00012051|DRUG|melphalan|
223770143|NCT00012051|DRUG|methotrexate|
223770144|NCT00012051|PROCEDURE|bone marrow ablation with stem cell support|
223770145|NCT00012051|PROCEDURE|peripheral blood stem cell transplantation|
223770146|NCT00012051|RADIATION|radiation therapy|
223770147|NCT00247728|DRUG|PI-88|Once-daily SC injection for four consecutive days per week, for 3 weeks out of every 4 weeks
223770148|NCT06082466|PROCEDURE|FRAMED Infrainguinal Venous Bypass|The harvested vein graft will be covered with a mesh.
223770149|NCT06082466|PROCEDURE|Conventional Autologous Bypass|The harvested vein graft will be used without a mesh coating.
223770150|NCT01180738|BEHAVIORAL|Body weight supported treadmill training|Training will include 10 sessions over a 2 week period, each session with 30 minutes of walking on a treadmill using a body weight support system.
223770151|NCT01180738|BEHAVIORAL|Overground walking training|Training will include 10 sessions over a 2 week period, each session with 30 minutes of walking overground.
223770152|NCT01440348|PROCEDURE|cruciate ligament reconstruction|Multiple cruciate ligament reconstructions with a single Achilles allograft with was divided into two or three strips according to the thickness and length of the allograft.
224244006|NCT03664908|OTHER|Detection of circulating anti-GBM antibodies (using chemiluminescence method and indirect immunofluorescence (IIF) method).|biological detection of circulating anti-GBM antibodies (using chemiluminescence method and indirect immunofluorescence (IIF) method) in three serum samples groups, coming from SLE patients (having Lupus Nephritis or not) and in a control group.
224244007|NCT01844219|PROCEDURE|elective or emergency aortic surgery (including ascending, arch, descending thoracic aorta)|
223770153|NCT05325463|PROCEDURE|conventional lung recruitment|The recruitment maneuver will be performed by pressure controlled mode maintaining a steady airway pressure of 15 cmH2O, with 5 cmH2O increments in positive end-expiratory pressure (PEEP) until a peak pressure of 30 cmH2O will be achieved. Each PEEP level will be maintained for 5 sec. The peak airway pressure will be maintained for 10 sec or five breaths and subsequently reduced, followed by maintenance with the previous ventilator settings.
223770154|NCT05325463|PROCEDURE|ultrasound- guided lung recruitment|The recruitment maneuver will be performed under ultrasound guidance until no collapsed lung area was visible. The strategy to increase the airway pressure will be the same as that for the conventional maneuver, although the maximal pressure limit was 40 cmH2O.
223770155|NCT01924169|DRUG|Lenalidomide|"5 mg/day by mouth on Monday, Wednesday and Friday for 3 months. Process repeated for up to 2 years.~If IgG levels do not improve, frequency of lenalidomide increased to 5 mg/day by mouth for additional 3 months and if response is achieved, lenalidomide continued at 5mg/day 3 month on/3 month off for a total of 2 years."
223664194|NCT05974059|DRUG|Capecitabine|Preoperative treatment：1000 mg /m2, PO，bid d1-14，Q3W； Postoperative treatment：1000 mg /m2, PO，bid. d1-14，Q3W；
223664195|NCT05974059|DRUG|Cadonilimab|Cadonilimab 10 mg/kg, d1, Q3W
223664196|NCT03079960|DEVICE|Electrophysiological recording and measurement devices|Externalization of DBS connectors and macroelectrodes for simultaneous STN stimulation LFP recordings by the use of electrophysiological recording and measurement devices.
223770156|NCT01924169|BIOLOGICAL|Influenza Vaccine|Administered as injection yearly, during the fall/winter season.
223770157|NCT01924169|BIOLOGICAL|Pneumovax Vaccine|Administered by injection once between month 6 and month 21. Patients, who have received the Pneumovax vaccine within last 5 years, will not receive Pneumovax vaccination.
223770158|NCT01856543|OTHER|Eucerin|
223770159|NCT01856543|OTHER|Mometasone Furoate 0.1%|
223770160|NCT01622946|DRUG|Tranexamic Acid|3g of tranexamic acid is topically applied after THA. The drugs is left for 15 minutes or 2 hours
223770161|NCT01622946|DRUG|placebo|The patients will receive 3g topical TXA for 15 minutes or 2 hours after THA. 33% of the patients will receive 3g of TXA trough a suction drain for 15 minutes after total hip arthroplasty, then the suction drain is opened. 33% will receive the same amount of TXA but the suction drain will only be opened 2 hours after application. The other patients will receive a placebo in the same manner
223770162|NCT01423448|OTHER|bulletin board|An asynchronous online bulletin board for people with experience of depression
224244008|NCT02392897|BEHAVIORAL|High Eating Frequency|Free-living participants will complete a 21-day high eating frequency (high EF) Phase in which consume all daily energy at 6 eating occasions.
224244009|NCT02392897|BEHAVIORAL|Low Eating Frequency|Free-living participants will complete a 21-day low eating frequency (low EF) Phase
223770163|NCT01844635|DRUG|Thymoglobulin|
223770164|NCT05233410|DRUG|Ruxolitinib cream|Ruxolitinib cream is a topical formulation applied as a thin film to affected areas.
223770165|NCT05233410|DRUG|Vehicle|Vehicle cream is a topical formulation applied as a thin film to affected areas.
223770166|NCT02102633|DRUG|Dabigatran|Dabigatran 150 mg orally
223770167|NCT02102633|DRUG|Bosutinib|Bosutinib 500 mg orally
224244010|NCT06139783|PROCEDURE|Exercise and dietary recommendations|Online physical exercise program and online nutritional assessment with personalized health and dietary recommendations
224244011|NCT06075667|DRUG|Tirzepatide|Administered SC
224244012|NCT06075667|DRUG|Placebo|Administered SC
224244013|NCT04777409|DRUG|Semaglutide|Oral semaglutide once-daily, dose gradually increased to 14 mg. The study will last for up to 173 weeks
224244014|NCT04777409|DRUG|Placebo (semaglutide)|Oral placebo (semaglutide) once-daily. The study will last for up to 173 weeks
224244015|NCT01229852|DEVICE|DSF-rTMS|Effective Transcranial Magnetic Stimulation
224244016|NCT04478019|DRUG|10% Povidone-iodine nasal decolonization swab plus 0.12% CHG oral rinse|2 swab sticks of 10% povidone-iodine in each nares and 0.12% CHG oral rinse
224244017|NCT02952495|BEHAVIORAL|Online alcohol educational class|"Participants will be asked to review an online alcohol education class. This is a web-based patient educational program designed to prevent hazardous and harmful drinking in older adults. The project's specific objectives are to 1) provide reliable information on the extent to which A Toast to Health in Later Life! reduces alcohol-related risks and problems among older patients who drink and 2) evaluate the extent to which these reductions are associated with increases in health-related quality of life, patient knowledge and self-efficacy and decreases in the use of health services and the costs of care."
224244018|NCT00565448|DRUG|docetaxel|"Pharmaceutical form:solution for infusion~Route of administration:intravenous"
224244019|NCT00565448|DRUG|cisplatin|"Pharmaceutical form:solution for infusion~Route of administration:intravenous"
223664197|NCT04297722|OTHER|Dairy products|Dairy consumption including total dairy, full-fat dairy, low-fat dairy, total milk, full-fat milk, low-fat milk, total yogurt, full-fat yogurt, low-fat yogurt, total cheese, hard cheese and fresh cheese
223664198|NCT00627952|DRUG|amlodipine 10 mg|amlodipine 10 mg once daily
223664199|NCT00627952|DRUG|manidipine 20 mg|manidipine 20 mg once daily
223664200|NCT00627952|DRUG|amlodipine 5 mg + delapril 30 mg|amlodipine 5 mg + delapril 30 mg once daily
223664201|NCT00627952|DRUG|manidipine 10 mg + delapril 30 mg|manidipine 10 mg + delapril 30 mg once daily
223664202|NCT05525858|DRUG|Alectinib|ALK fusion or mutations, Mutations or amplification in any of the following: RET
223664203|NCT05525858|DRUG|Atezolizumab|"MSI high status by any method Or Any mutation in any of these genes:~MLH1 or MSH2 or MSH6 or PMS2 or EPCAM Or Any of the following mutations in POLE: R150X, P286R, P286H, S297F, Y298fs, F367S, V411, L424V, P436R, S459F, R665W, L698fs, R762W, R1519C, R1826W, D316H, D316G, R409W, L474P Or Any of the following mutations in POLD1: P112fs, A930fs, S478N Or Any mutation in the following: POLE not listed above, POLD1 not listed above, POLD2, POLD3, POLD4, POLQ or PRKDC Or Any loss of function mutations in BRCA1, BRCA2, ATM, MSH3, PMS1, MLH3, EXO1, RFC1, RFC2, RFC3, RFC4, RFC5, PCNA, RPA1, PRA2, PRA3, PRA4, or SSBP1 High tumor mutational burden decided by KOSMOS-II MTB (TMB ≥20/Mb in local NGS or if 10-20/Mb, confirmed by central NGS te sting)"
223770168|NCT02102633|DRUG|Dabigatran|Dabigatran 150 mg orally
223770169|NCT05827627|OTHER|simulation|Midwifery student directing the birth of a fetus with frank breech presentation.
223664204|NCT05525858|DRUG|Erlotinib|"EGFR Exon 19 deletions in the region E746\_E759;~Any of the following EGFR mutations:~E709A, E709G, E709K, E884K, G719A, G719C, G719S, L858R, L861Q, L833V, S768I"
224244020|NCT00565448|DRUG|5-fluorouracil|"Pharmaceutical form:solution for infusion~Route of administration:intravenous"
223664205|NCT05525858|DRUG|Trastuzumab + Pertuzumab|"ERBB2 amplification, or over-expression; or presence of any of the following ERBB2 mutations:~G309A, G309E, S310F, S310Y, R678Q, I655V, D769H, D769Y, L755S, p.L75 5\_T759del, I767M, V777L, E321G, R896C; P780ins; delL755-T759 ERBB2 amplification or approved by the KOSMOS Molecular Tumor Board"
224244021|NCT06039982|OTHER|no intervention|no intervention
224244022|NCT01416246|PROCEDURE|Fractionated Stem Cell Infusions|Following enrollment patients will be treated with melphalan intravenously (IV) through a central venous catheter (CVC) over 30 minutes at 200mg/m2 or 140mg/m2 (if creatinine clearance is \< or = to 50 and/or age \> 70 years) on day -2. Following 24 hours of rest, the first dose of CD34+ stem cell will be administered on day 0 (2.5-5 x 106 CD 34+ stem cells/kg)+/- 0.5 x 106 CD34+ stem cells/kg), followed by 3 additional doses of CD 34+ stem cells (1.5-2.5 x 106 CD 34+ stem cells/kg)+/- 0.5 x 106 CD34+ stem cells/kg) on days +2, +4, and +6. Pegfilgrastim 6μg will be administered on day +1. Filgrastim 5μg/kg will be 12-24 hours after the 2nd-4th stem cell infusions. There will be a +/- 1 day window for the Day +2, +4, and +6 infusions to accommodate infusions that occur over the weekend or on holidays.
223770170|NCT03756610|DEVICE|Active tACS|Placement of stimuli electrodes will be: a) active electrode over the left DLPFC (F3), and b) reference electrode over the right parietal region (P2). The exact location of electrodes will be determined by the 10/20 EEG method with EEG cap. Subjects will have tACS sessions on consecutive days (weekends and holidays excluded). Each subject will have 10 active tACS sessions.The active tACS group will be stimulated with a 2 mA current for 20 minutes.
224244023|NCT00193609|DRUG|Oxaliplatin|130 mg/m2 IV day 1 of 21 day cycle
224244024|NCT00193609|DRUG|Capecitabine|1000 mg/m2 by mouth twice daily on days 1-14 of each 21 day cycle
223770171|NCT03756610|DEVICE|Sham tACS|Placement of stimuli electrodes will be: a) active electrode over the left DLPFC (F3), and b) reference electrode over the right parietal region (P2). The exact location of electrodes will be determined by the 10/20 EEG method with EEG cap. Subjects will have tACS sessions on consecutive days (weekends and holidays excluded). Each subject will have 10 sham tACS sessions.The sham tACS group will have stimulation lasting only 40 seconds though the electrodes will remain in place for 20 min.
223770172|NCT03756610|DEVICE|Active boosting|Placement of stimuli electrodes will be: a) active electrode over the left DLPFC (F3), and b) reference electrode over the right parietal region (P2). The exact location of electrodes will be determined by the 10/20 EEG method with EEG cap. Subjects will have tACS sessions on consecutive days (weekends and holidays excluded).One month later after initial treatment, each subject will have 5 booster sessions of active tACS.The active boosting group will be stimulated with a 2 mA current for 20 minutes.
223770173|NCT03756610|DEVICE|Sham boosting|Placement of stimuli electrodes will be: a) active electrode over the left DLPFC (F3), and b) reference electrode over the right parietal region (P2). The exact location of electrodes will be determined by the 10/20 EEG method with EEG cap. Subjects will have tACS sessions on consecutive days (weekends and holidays excluded).One month later after initial treatment, each subject will have 5 booster sessions of sham tACS.The sham boosting group will have stimulation lasting only 40 seconds though the electrodes will remain in place for 20 min.
223770174|NCT06484777|DRUG|SHR-9539 for injection|SHR-9539 for dose escalation/dose extension
223770175|NCT05395962|DRUG|Carboplatin|treatment with bleomycin and carboplatin in association with electroporation
224244025|NCT02472288|DEVICE|Electroacupuncture (EA)|The EA group receives 10 sessions of EA therapy (5 per a week, 2 weeks). After inserting needles by 5-10 mm (stainless steel, 0.25 mm in diameter and 4.0 mm in length, Dong Bang Acupuncture Inc., Korea) using the Park sham guide tube on the 8 points (BL31, BL32, BL33, and BL34, bilateral sides), de qi response is elicited. The electrical stimulation is then presented for 20 minutes by middle frequency (30 Hz) (STN-111, Stratek, Korea). Conventional treatments (western/traditional herbal medications, rehabilitation, or acupuncture without electro-stimulation for stroke, and western/traditional herbal medications or acupuncture without electro-stimulation for urinary retention) are allowed during the intervention period. The practitioner should have over 1-year clinical experiences.
224244026|NCT02472288|DEVICE|Sham electroacupuncture|The patients in sham group receive totally 10 sessions of the sham EA (5 sessions per a week, for 2 weeks). Non-penetrating needles of Park sham device are implemented on the bilateral points of BL31, BL32, BL33, and BL34 (total 8 acupoints). Then, the electro-stimulation is presented for 20 minutes by middle frequency (30 Hz) (STN-111, Stratek, Korea), even though the electrical stimulation is not delivered through the skin. Conventional treatments for stroke and urinary retention along with EAT are not eliminated. It is also necessary for the practitioner with more than 1-year experiences on the clinical field.
224244027|NCT04680364|OTHER|partnered dance|Dance classes consisted of different choreographies, which include rhythmic and simple movements typically of ballroom/standard dances (Waltz, Tango, Viennese Waltz).
224244028|NCT00370006|BIOLOGICAL|Towne CMV vaccine|
224244029|NCT03139019|BEHAVIORAL|Process incentives|Participants will receive cash based incentives for achieving process based measures (class attendance).
223664206|NCT05525858|DRUG|Trastuzumab emtansine|"ERBB2 amplification, or over-expression; or presence of any of the following ERBB2 mutations:~G309A, G309E, S310F, S310Y, R678Q, I655V, D769H, D769Y,L755S, p.L75 5\_T759del, I767M, V777L, E321G, R896C; P780ins; delL755-T759 ERBB2 oncogenic mutations; G152V, X215\_splice, D277Y, G292C, N302K, V308M, G309A, S310F, S310Y, S244C, L651V, V659E, G660D, R678Q, V697L, G727A, T733I, L755A, L755P, L755S, D769H, D769Y, A775\_G776insSVMA, A775\_G776insYVMA (i.e.,Y772\_A775dup,M774\_A775insAYVME 770delinsEAYVM), G776\_V777 \> AVCV, G776\_V777 \> AVGCV, G776\_V777 \> VCV, G776\_V777insVC, G776C, G776delinsLCT, G776L, G776dleinsVC, G776L777\_G778insC, V777L, V777M, G778\_Y779insGSP, P780\_Y781insGSP (i.e.,G778\_P780dup), L786V, N813D, R840W, V842I, T862A, R896G, E1021Q or approved by the KOSMOS Molecular Tumor Board"
223664207|NCT05525858|DRUG|Vemurafenib|BRAF\_V600E/D/K/R mutations
223664208|NCT05525858|DRUG|Bevacizumab + Erlotinib|FH inactivating mutations or approved by the KOSMOS Molecular Tumor Board
223770176|NCT05395962|DRUG|Bleomycin|treatment with bleomycin in association with electroporation
223770177|NCT01868633|DRUG|Dexamethasone|
223770178|NCT01868633|DRUG|Placebo|
224244030|NCT03139019|BEHAVIORAL|Outcome incentives|Participants will receive cash based incentives for outcome based measures (weight loss).
223664209|NCT05525858|DRUG|Entrectinib|ROS1 gene fusion using either a fluo rescence in situ hybridization (FISH) or next-generation sequencing (NGS) or approved by the KOSMOS Molecular Tumor Board
223664210|NCT05525858|DRUG|Pralsetinib|RET fusion or mutations; CCDC6 RET, RET V804L, RET V804M, RET M918T, KIF5B-RET, RET C634W or approved by the KOSMOS Molecular Tumor Board
224244031|NCT03139019|BEHAVIORAL|Process and Outcome incentives|Participants will receive cash based incentives for both achieving process based measures (class attendance) and outcome based measures (weight loss).
224244032|NCT01890382|DIETARY_SUPPLEMENT|Whey protein|30 g in total; twice a day (morning and evening)
224244033|NCT01890382|DIETARY_SUPPLEMENT|whey plus creatine|whey protein combined with creatine (30 g and 6.0 g in total; twice a day, respectively)
224244034|NCT01890382|DIETARY_SUPPLEMENT|leucine supplementation|7.5 g/d in total; three times per day
224244035|NCT01890382|DIETARY_SUPPLEMENT|soy protein|30 g in total; twice a day
224244036|NCT01890382|DIETARY_SUPPLEMENT|creatine|6.0 g in total; twice a day
224244037|NCT01890382|DIETARY_SUPPLEMENT|placebo|
224244038|NCT01157091|DRUG|pazopanib hydrochloride|Given orally
224244039|NCT01157091|OTHER|laboratory biomarker analysis|Correlative studies
224244040|NCT01157091|OTHER|immunologic technique|Correlative studies
224244041|NCT05189405|DEVICE|INVOcell IVC|Embryo development in intravaginal incubation
224244042|NCT00854308|DRUG|Erlotinib HCl|Erlotinib 150 mg oral dose once daily.
224244043|NCT00854308|DRUG|MetMAb|MetMab (a monovalent antagonist antibody to the receptor MET) 15 mg/kg in 250 CC 0.9% saline intravenous infusion every 3 weeks.
224244044|NCT00854308|DRUG|placebo (0.9 % saline)|Placebo Intravenous infusion every 3 weeks.
224244045|NCT05536518|BEHAVIORAL|Mid-Ohio Farmacy (produce prescription) + WW International Coaching (In person and/or Virtual)|All study participants are members of the Mid-Ohio Farmacy produce prescription program. All participants are food insecure and will be enrolled and participate in WW coaching sessions for 24 weeks.
224244046|NCT05928481|OTHER|Simulation-based postpartum bleeding management training|Postpartum hemorrhage management practices were applied to the students in the intervention group on a high-reality Gaumard Scientific brand, product code: S550.100 Noella simulator in the simulation laboratory of the Midwifery department.
224321638|NCT07095582|BEHAVIORAL|Internet-delivered cognitive behavioral therapy|The Wellbeing Course was developed at Macquarie University, Australia. The Wellbeing Course is a transdiagnostic Internet-delivered cognitive behavioural intervention targeting symptoms of depressive and anxiety disorders. It comprises 5 online lessons targeting: 1) symptom identification and the cognitive behavioural model; 2) thought monitoring and challenging; 3) de-arousal strategies and pleasant activity scheduling; 4) graduated exposure; and 5) relapse prevention. Materials are presented in a didactic (i.e., text-based with visual images) and case-enhanced learning format (i.e., educational stories demonstrate the application of skills) and include homework activities. Lessons are released gradually in a standardized order over 8 weeks. Phone calls will only be made if there is a significant clinical issue requiring therapist attention that cannot be addressed over email (e.g., sudden increase in symptoms). Therapists will spend \~15 mins per week/per client.
223664211|NCT00363545|BIOLOGICAL|Lyophilized formulation of HRV vaccine|Lyophilized formulation of HRV vaccine
224244047|NCT06373705|DEVICE|Cardiac simulator|A computer software cardiac simulator for surgical planning in complex Congenital Heart Disease (CHD) pediatric patients.
224244048|NCT03872999|OTHER|Functional brain imaging without any contrast agent|"During the functional magnetic resonance imaging (fMRI) protocol, the subject will perform the attentional task while whole-brain activity will be recorded using Echo Planar Imaging (EPI) that measures the Blood Oxygen Level Dependent (BOLD) signal (2x2x2 isotropic voxels, Echo Time (ET) = 30 ms, Repetition Time (RT) = 2.5 sec). The functional session will be subdivided into several parts (Runs, duration: 10-15 min). Together with the functional data, the protocol will include a structural scan (T1 weighted, 1x1x1 mm voxels; duration 5-7 min) and a field mapping sequence (duration: 1 min)."
224244049|NCT04806308|BEHAVIORAL|Otolaryngology stretching micro-breaks (OSMB)|Standardized microbreak stretch that is designed to perform intraoperatively within the sterile field at medically convenient 20-40 min intervals throughout each procedure.
224244050|NCT01180569|DRUG|lenalidomide|"Patient enrollment FNA of palpable lymph node prior to escalation phase~Escalation phase of Lenalidomide:~Lenalidomide 5 mg daily PO x 14 days Lenalidomide 10 mg daily PO x 14 days Lenalidomide 15 mg daily PO x 14 days Week of rest FNA of palpable lymph node prior to treatment phase~Treatment phase of Lenalidomide:~15 mg daily PO days 1-21 out of a 28 day cycle Repeat x 6 cycles"
224244051|NCT00003332|DRUG|cisplatin|
223664212|NCT00363545|BIOLOGICAL|Liquid formulation of HRV vaccine|Liquid formulation of HRV vaccine
223664213|NCT04162561|BEHAVIORAL|Patients with documented IHD|Assessment of patients' quality of life with the use of the Seattle Angina Questionnaire (SAQ), blood pressure levels (using the Korotkoff method, blood pressure is measured 3 times with 1-minute intervals on the hand with the higher blood pressure levels while sitting calm after a 5-minutes rest), laboratory methods (lipids, glycosylated hemoglobin levels), patients' adherence to treatment (original questionnaire), quality of patients' therapy taken at the time of visit, necessity of invasive coronary revascularization procedures (during all visits).
223664214|NCT06449001|DRUG|Danicopan|Participants will receive danicopan on a weight-based dosing regimen.
223664215|NCT02264145|DRUG|Ethanolic Solution From HFA134a-MDI - low|
223664216|NCT02264145|DRUG|Ethanolic Solution From HFA134a-MDI - medium|
223664217|NCT02264145|DRUG|Ethanolic Solution From HFA134a-MDI - high|
223664218|NCT02264145|DRUG|Ethanolic Solution From Respimat®|
223664219|NCT04197219|DRUG|Pembrolizumab|200 mg IV day 1 of each cycle every 21 days
223664220|NCT04197219|DRUG|Axitinib|5 mg PO BID continuously
224244052|NCT00003332|DRUG|gemcitabine hydrochloride|
224244053|NCT00003332|PROCEDURE|surgical procedure|
224244054|NCT00003332|RADIATION|radiation therapy|
224244055|NCT00167739|DRUG|Quinine plus sulfadoxine-pyrimethamine|
223664221|NCT01315561|OTHER|acupuncture, injection|MSAT and intramuscular injections of diclofenac(NSAID)
223664222|NCT05685173|DRUG|Odronextamab|Odronextamab will be administered by IV infusion
223664223|NCT05685173|DRUG|REGN5837|REGN5837 will be administered by IV infusion
223664224|NCT06645496|OTHER|Evaluation of ehealth literacy|All patients undergoing radiotherapy at the Clinic for Radiotherapy (Campus Virchow Klinikum, Campus Benjamin Franklin) will be informed about the possibility of participating in the study (RO\_eHEALTH I). If written consent is given, patients will be asked to complete the established questionnaires (EORTC QLQ-C30 and eHEALS) and a questionnaire to collect epidemiological data at their next visit to the respective clinics.
223664225|NCT05048576|BEHAVIORAL|Negative Reinforcement|"Terms to be used in negative reinforcement:~You've got to walk faster than that. You're so slow! Why do you walk like that? Did you learn how to walk yesterday? You're doing terrible. Who walks like that? You have potential but you don't use it. You'll never amount to anything. You're not putting very much effort into this. This is the worst pace you've had yet."
223664226|NCT05048576|BEHAVIORAL|Positive Reinforcement|"Terms to be used in positive reinforcement:~Good job, you're doing awesome! Keep up the good work! You've got this! You're almost done, just a few more minutes! That's a great pace! You're going strong! Keep it up! Nice work. Great job! Good stuff. Keep it up. You're doing an amazing job."
223664227|NCT05048576|BEHAVIORAL|Silence|No recordings will be played during this condition.
223664228|NCT05048576|BEHAVIORAL|Music|Participant's can choose their own music to play during this condition.
223664229|NCT03961438|BIOLOGICAL|ConM SOSIP.v7 gp140, adjuvanted with MPLA liposomes|Vaccine administration will be done at months 0, 2 and 6 by intramuscular injection into the deltoid muscle of the non-dominant arm. The immunogen will be used at the dosage of 100 μg and will be admixed with 500 μg MPLA formulated in liposomes.
223664230|NCT03961438|BIOLOGICAL|ConM SOSIP.v7 gp140, adjuvanted with MPLA liposomes|Vaccine administration will be done at months 0, 2 and 6 by intramuscular injection into the deltoid muscle of the non-dominant arm. The immunogen will be used at the dosage of 100 μg at months 0 and 2, and 20 μg at month 6. All immunogen dosages will be admixed with 500 μg MPLA formulated in liposomes.
223664231|NCT01379508|DRUG|telbivudine|600 mg film-coated tablets taken as 600 mg once daily
223664232|NCT01379508|DRUG|tenofovir disoproxil fumarate|300 mg tablets taken as 300 mg once daily
223664233|NCT04247867|DEVICE|medium cut-off (MCO) dialysis membrane|Medium cut-off dialysis (MCO) membrane is a dialysis membrane with a higher molecular weight retention onset and similar cut-off as standard high-flux dialysis membranes. It is capable of providing increased clearance of medium sized uremic toxins and some plasma proteins (cytokines, inflammatory mediators).
223664234|NCT04247867|DIETARY_SUPPLEMENT|Dietary fiber mixture (Plantago Psyllium and Inulin)|Dietary fiber (Psyllium 69% and Inulin 30% mixture) added to the meals in the dose of 5g BID for 4 weeks in the second phase of the study.
223664235|NCT04247867|DIETARY_SUPPLEMENT|Sodium propionate|Sodium propionate (a short-chain fatty acid) added to the meals in the dose of 500 mg BID in the second phase in the study.
223664236|NCT02854930|OTHER|questioning|
223664237|NCT00703248|PROCEDURE|Osteopathic Manipulative Treatments|"1. opening the thoracic inlet~2. pectoral traction for 1 minute bilaterally~3. rib raising for a total of 4 minutes- 2 minutes on each side of the thoracic spine \]~4. thoracic pump at a rate of 60 times per minute for a total of 5 minutes bilaterally~5. abdominal pump at a rate of 30 times per minute for a total of 5 minutes bilaterally."
223664238|NCT00343941|DRUG|Tucaresol tablets 25 mg|
223664239|NCT01798108|RADIATION|Radium-223 dichloride (BAY88-8223)|\- Single injection. Starting dose 46 kBq/kg b.w. Escalating doses 93, 163, 213 and 250 kBq/kg b.w. (9.8.2 Changes in addition to those described in amendments) After completion of the five dose levels above, the protocol was amended and the study extended to include patients to received multiple injections of Radium-223 - Re-treatment: Patients who had earlier been included in the study and received dose levels 46, 93 or 163 kBq/kg b.w. could be given a second injection, provided that the total dose did not exceed 250 kBq/kg b.w. - Fractionated dose (multiple dosing) Patients were given multiple injections in treatment: 5 injections of 50 kBq/kg b.w. at 3 weeks intervals. Patients were given multiple injections in treatment: 2 injections of 125 kBq/kg b.w. at 6 weeks interval
223664240|NCT04180540|DEVICE|Percutaneous Closure|The PerClose Proglide system will be used to deliver a suture to close the venous puncture following completion of ablation for treatment of atrial fibrillation.
223664241|NCT04180540|OTHER|Manual Compression|"Manual compression is the standard method of attaining hemostasis following ablation for treatment of atrial fibrillation. Manual compression may be performed with or without figure of eight suture for hemostasis at the discretion of the treating physician)."
223664242|NCT05726084|BIOLOGICAL|Subunit recombinant vaccine for the prevention of coronavirus infection|solution for intramuscular injection, 0.5 ml
223664243|NCT05726084|BIOLOGICAL|Placebo|solution for intramuscular injection, 0.5 ml
223664244|NCT07131813|DRUG|Tofacitinib 5 mg BID and Triamcinolone ointment|Patients in the test group will get tofacitinib 5mg capsules twice daily as an add on to triamcinolone ointment
223664245|NCT07131813|DRUG|Placebo and Triamcinolone ointment|Patients in the control group will receive identical looking capsules as placebo with triamcinolone ointment
223664246|NCT01589991|DRUG|Toothpaste|The volunteers brushed their teeth with 0.3 g of the assigned toothpastes, 3x/day.
223664247|NCT07144852|DRUG|Reformulated Levulan Kerastick containing aminolevulinic acid hydrochloride (ALA HCl), 20%|Solution for topical use
223664248|NCT07144852|OTHER|Vehicle|Solution for topical use
223664249|NCT07144852|DEVICE|Blue Light Photodynamic Therapy Illuminator device, BLU-U® model 4170E.|BLU-U® blue light PDT illuminator
223664250|NCT07145177|DRUG|177Lu-PSMA-617|Given intravenously (IV)
223664251|NCT07145177|PROCEDURE|Ablation|Undergo ablation
223664252|NCT07145177|PROCEDURE|Trans-arterial chemoembolization (TACE)|Undergo TACE
223664253|NCT07145177|PROCEDURE|Positron Emission Tomography (PET)/Computerized tomography (CT)|Undergo imaging
223664254|NCT07145177|PROCEDURE|Tumor Biopsy|Undergo biopsy
223664255|NCT07145177|OTHER|Questionnaire|Participant will complete questionnaire
223664256|NCT07144995|DRUG|Fruquintinib+Paclitaxel|(using IPD from the FRUTIGA trial, n=703) Fruquintinib：subjects received Fruquintinib orally, once daily for 3 wks on/ 1 wk off Paclitaxel：Paclitaxel 80mg/㎡ at day 1,8,15 of 4-week cycle.
223770179|NCT02353091|DEVICE|Remote Microphone Hearing Aids|The ear receivers connect wirelessly with the microphone being worn by the teacher within a range of 25m.
223770180|NCT00254007|DRUG|citalopram (celexa)|20(1 tablet)-50(2 1/2 tablets) mg/day for a period of 6 or 10 weeks
223664257|NCT07144995|DRUG|Ramucirumab+Paclitaxel|(using published AgD from RAINBOW-Asia, n=440) Ramucirumab：8 milligrams/kilogram (mg/kg) intravenous (IV) infusion on Days 1 and 15 of every 4-week cycle Paclitaxel ：Paclitaxel 80mg/㎡ at day 1,8,15 of 4-week cycle.
223664258|NCT07146061|OTHER|no other intervention|This is a observational study.
224244056|NCT04042363|DEVICE|Transorbital electrical stimulation (Eyetronic Next Wave 1.1)|"Calibration phase: The patient will use a response button to indicate the threshold from which he feels a luminous sensation (phosphene). In a second step, he will use the same answer button to indicate the stimulation frequency from which the phosphenes become continuous.~Stimulation phase: From these 2 parameters (amplitude and frequency), the stimulation session will begin for a duration of approximately 40 to 50 minutes, the settings being dependent of the individual thresholds."
224244057|NCT04042363|DEVICE|Transorbital electrical stimulation (Eyetronic Next Wave 1.1) - Sham stimulation|The calibration phase is identical to the active stimulation. During the stimulation phase, the operator will manually interrupt the stimulation 60 seconds after the start of the session.
223664259|NCT07145931|PROCEDURE|Neoadjuvant chemoimmunotherapy|"* Neoadjuvant therapy is administered every 3 weeks (Tislelizumab 200mg D1, Nab Paclitaxel 260mg/m² D1, Cisplatin 75mg/m² D1-3) for a total of 3 cycles.~* Surgical treatment is performed within 3 weeks after completing neoadjuvant therapy.~* Postoperative (chemo)radiotherapy is initiated 4-6 weeks after surgery.~* Following (chemo)radiotherapy, adjuvant immunotherapy (Tislelizumab 200mg) is administered every 3 weeks for a total of 8 cycles."
223664260|NCT07145931|DRUG|Tislelizumab Nab paclitaxel|Neoadjuvant therapy is administered every 3 weeks (Tislelizumab 200mg D1, Nab Paclitaxel 260mg/m² D1, Cisplatin 75mg/m² D1-3) for a total of 3 cycles.
223664261|NCT07145203|DEVICE|Meta Quest 2 VR headset|The VR intervention used a head-mounted VR headset with built-in headphones. Patients selected VR environments from a predefined list of four nature scenes (tropical beach, diving, forest, and snowy landscape) with relaxing music and nature sounds. Guided Meditation VR from Cubicle Ninjas (https://guidedmeditationvr.com/) featured 360-degree immersive nature environments with standardized calming background audio. VR was applied during the colonoscopy procedure, with sessions lasting 15 to 30 minutes and discontinued if the patient reported nausea, dizziness, or requested removal.
223664262|NCT07144813|DEVICE|Neuspera Implantable Sacral Neuromodulation System|Stimulation of the Sacral Nerve.
223664263|NCT07145853|OTHER|Mandala activity|"The application will last for 1-2 hours once a week for a total of 8 weeks.~For individuals aged 65 years and over who meet the inclusion criteria and are included in the intervention group, a mandala draft in A4 format (21.0 cm x 29.7 cm) consisting of 8 round patterns to be determined in advance, and a dry paint set consisting of 12 colors for ease of use will be used. Quality dry paint will be used to prevent allergies"
223664264|NCT07147075|OTHER|REACH - Hypertension|The intervention is a skills training program for doctors that includes 3 self-paced on-line learning modules and 3 coaching sessions (one in-person and 2 virtual).
223664265|NCT07145242|OTHER|Acupuncture|Intervention Description \* § Add details that will distinguish this intervention from other interventions in this or another clinical study.
223770181|NCT02457325|DRUG|Surgery with 2%Articaine first, then Surgery with 4% Articaine|First Intervention (1 day - third molar surgery with infiltration of one cartridge of 2% articaíne), Washout (1-2 months), and Second Intervention (1 day - third molar surgery with infiltration of one cartridge of 4% articaíne)
223770182|NCT02457325|DRUG|Surgery with 4%Articaine first, then Surgery with 2% Articaine|First Intervention (1 day - third molar surgery with infiltration of one cartridge of 4% articaíne), Washout (1-2 months), and Second Intervention (1 day - third molar surgery with infiltration of one cartridge of 2% articaíne)
223770183|NCT04521491|DRUG|FOLFOX4(infusional fluorouracil [FU], leucovorin [LV], and oxaliplatin [OXA]).|FOLFOX4 (OXA 85 mg/m2 intravenously \[IV\] on day 1; LV 200 mg/m2 IV from hour 0 to 2 on days 1 and 2; and FU 400 mg/m2 IV bolus at hour 2, then 600 mg/m2 over 22 hours on days 1 and 2, once every 2 weeks.All patients in the treatment group will receive FOLFOX4 at most 12 times beginning from the 4th week after liver resection.
224244058|NCT04817709|OTHER|Educational Intervention|Review workbook
224244059|NCT04817709|OTHER|Usual Care|Receive educational materials
223770184|NCT01374308|BIOLOGICAL|NASVAC|NASVAC will be administered every 2 weekly intra-nasally at a dose of 100 micro grams for 5 times followed by every 2 weekly administration of 100 micro grams intra-nasally plus 100 micro grams subcutaneously.
223770185|NCT01374308|DRUG|Pegylated interferon alpha 2b|Injection Pegylated interferon alpha 2b will be administered once weekly subcutaneously at a dose of 180 micro grams for 48 weeks
223770186|NCT02771262|OTHER|Pulmonary Rehabilitation|
223770187|NCT01541930|DRUG|GK567|Once or twice daily, for 14 days, up to 30 g per day
224244060|NCT04817709|OTHER|Media Intervention|Watch video
224244061|NCT04817709|OTHER|Medical Chart Review|Review of medical records
224244062|NCT04817709|OTHER|Questionnaire Administration|Complete questionnaires
224244063|NCT00610363|BIOLOGICAL|Rilonacept|Rilonacept 320 mg loading dose on Day 1 followed by Rilonacept 160 mg/2 mL injections qw for 17 weeks.
224244064|NCT00610363|OTHER|Placebo (for Rilonacept)|Placebo loading dose on Day 1 followed by single placebo injections (2 mL) qw for 17 weeks.
223770188|NCT02431208|DRUG|Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody|Participants will receive intravenous (IV) atezolizumab until loss of clinical benefit, withdrawal, or study end. Cohorts A to C will receive 1200 milligrams (mg) on Day 1 of each 21-day cycle. Cohorts D to F (combination with daratumumab) will receive 840 mg on Days 2 and 16 of Cycle 1 and on Days 1 and 15 of each 28-day cycle thereafter.
224244065|NCT02324803|DRUG|pazopanib|continuous treatment of 800 mg pazopanib once daily until disease progression
224244066|NCT03048500|OTHER|Laboratory Biomarker Analysis|Correlative studies
224244067|NCT03048500|DRUG|Metformin Hydrochloride|Given PO
224244068|NCT03048500|BIOLOGICAL|Nivolumab|Given IV
224244069|NCT04856449|BEHAVIORAL|Dialectical Behavioral Therapy Skills Training|DBT skills training consists of a 6 months training in mindfulness, emotion regulation, interpersonal effectiveness and distress tolerance.
224244070|NCT04856449|BEHAVIORAL|EMDR|EMDR sessions will be conducted to reprocess trauma-related memories.
224244071|NCT05664464|DRUG|Gabapentin|Weekly dose escalations over 4 weeks of daily 3 x 300 mg up to 3 x 1200 mg
224244072|NCT05664464|DRUG|Sulfasalazine|Weekly dose escalations over 3 weeks of daily 3 x 500 mg up to 3 x 1500 mg
223664266|NCT07145788|OTHER|PhYoMind|This integrative intervention method includes some specific physiotherapy techniques, ( e. g. self proprioceptive neuromuscular facilitation, self nerve gliding, self mobility, post isometric relaxation techniques) yoga postures, left nostril breathing, humming bee breathing, mindfulness practices and home exercises. Each session will be 75 minutes and focus on different parts of the body and yoga postures will be selected according to these focused areas. For each week, a specific body area will be chosen as the focus. For example, the first week will focus on the hip area and lower extremities, the second week on the upper body and upper extremities, the third week on the core and anterior line of the body, and the fourth week on the back and posterior line of the body and this sequence will continue through the eighth week. In addition to these sessions, participants in this group will also apply home exercises (aerobic+strenghtening+streching) twice a week, 60 minutes per practice.
223664267|NCT07145788|OTHER|Exercise|The control group will receive only home exercises twice a week. Big muscle groups strengthening and stretching exercises and walking planned for the patient will be given as home exercise. The walking exercise will last 30 minutes at a moderately fast pace, depending on the subject's adaptation. The strengthening exercises will last 15 minutes and will consist of 3 sets of 12 repetitions of exercises with body weight and light weights, generally targeting the back extensor muscles, core stabilization muscles, shoulder region muscles in the upper extremity and hip and knee joint muscles in the lower extremity. The stretching exercises will last 15 minutes and will include neck muscles, pectoralis major/minor, erector spina, hamstrings, quadriceps femoris muscles 1-2 times for 30 seconds each. Participants will be taught face to face with a brochure when they come for the first assessment and will be asked to do HE at home.
223664268|NCT07145762|PROCEDURE|Interventional Block|For patients who are offered interventional blocks as part of their standard of care, we will measure ANI as well as pressure pain threshold before, during, and after the block as well and at follow-up to assess correlation with treatment efficacy.
223664269|NCT07145892|DEVICE|Three-dimensional Digital Breast Tomosynthesis|Patients underwent three-dimensional digital breast tomosynthesis.
223664270|NCT07145892|DEVICE|Two-dimensional Digital Mammography|Patients underwent two-dimensional digital mammography
223664271|NCT07145736|DRUG|Moxidectin|2 mg tablets
223664272|NCT07145736|DRUG|Ivermectin|3 mg tablets
223664273|NCT07145086|BEHAVIORAL|Voice therapy with vibration|Voice therapy with a novel vibration device will be delivered for five or eight weeks depending on group allocation. All participants will receive flow phonation voice therapy.
223664274|NCT07146867|BEHAVIORAL|High intensity interval training (exercise)|One 30 minute session of high intensity interval training
223664275|NCT07146347|DRUG|GZR4 injection|GZR4 is a new ultra-long-acting insulin analog
223770189|NCT02431208|DRUG|Daratumumab|Participants will receive 16 milligrams per kilogram (mg/kg) IV daratumumab until loss of clinical benefit, withdrawal, or study end. Treatment will be per the U.S. Package Insert and given on Days 1, 8, 15, 22 of Cycles 1 and 2; on Days 1 and 15 of Cycles 3 to 6; and on Day 1 of each 28-day cycle thereafter.
223770190|NCT02431208|DRUG|Lenalidomide|Lenalidomide will be administered orally (PO) until loss of clinical benefit, withdrawal, or study end. Cohort B1 will receive 10, 15, or 25 mg, ascending-dose lenalidomide, on Days 1-14 of each 21-day cycle. Cohort C will receive 10 mg on Days 1-14 of each 21-day cycle, beginning in Cycle 4. Cohort E (combination with daratumumab) will receive 10, 15, or 25 mg on Days 1-21 of each 28-day cycle. Participants in Cohort E1 will receive ascending-dose lenalidomide, and those in Cohort E2 will receive lenalidomide at the MTD as determined in Cohort E1.
223770191|NCT02431208|DRUG|Pomalidomide|Pomalidomide will be administered PO until loss of clinical benefit, withdrawal, or study end. Cohort F (combination with daratumumab) will receive 2 or 4 mg on Days 1-21 of each 28-day cycle. Participants in Cohort F1 will receive ascending-dose pomalidomide, and those in Cohort F2 will receive pomalidomide at the MTD as determined in Cohort F1.
224244073|NCT05664464|DRUG|Memantine|Weekly dose escalations over 4 weeks of daily 1 x 5-20 mg
224244074|NCT05664464|DRUG|Temozolomide|Concomitant with radiotherapy at 75 mg/m2 daily followed by maintenance 150-200 mg/m2 on 5/28 days
224244075|NCT05664464|RADIATION|Radiotherapy|30 x 2 Gy involved field radiotherapy with concomitant temozolomide
223770192|NCT02431208|DRUG|Dexamethasone|Participants will receive either 20mg or 40mg of dexamethasone PO every 7 days from Day 1 of each cycle.
224244076|NCT00957151|DRUG|Creon|
224244077|NCT03807141|OTHER|Modified Atkins diet|This is a modified version of the ketogenic diet where-in carbohydrates are restricted without any protein or calorie restriction.
224244078|NCT04526496|DRUG|FTP-198, single dose|Single dose of FTP-198, 6 dose levels, oral suspension
224244079|NCT04526496|DRUG|Placebo, single dose|Placebo matched to FTP-198, oral suspension
224244080|NCT04526496|DRUG|FTP-198, multiple doses|Multiple doses of FTP-198, 3 dose levels, oral suspension, 7 days
224244081|NCT04526496|DRUG|Placebo, multiple doses|Placebo matched to FTP-198, oral suspension, 7 days
224244082|NCT02995070|PROCEDURE|CTG|Periodontal plastic surgery for root coverage by the trapezoidal flap plus connective tissue graft
223664276|NCT07147049|DRUG|HL-1186|HL-1186 tablet for oral administration.
223664277|NCT07147049|DRUG|HL-1186 placebo|HL-1186 placebo tablet for oral administration.
223664278|NCT07145528|OTHER|Questionary with a case-report-form|Questionary with : Gender, Age, Marital Status, medical history, Socio-économic description, skills assessment test written by R-Shankland, AUDIT-C, fargestrom, HAD, CAST, EPICE, Stroop-Test, Trail making test, Rosenberg Test
224244083|NCT02995070|DEVICE|LLLT|Low Level Laser Therapy on the buccal recipient site of connective tissue graft.
224244084|NCT02995070|DEVICE|SHAM|Simulation of GaAlAs laser to irradiation on connective tissue graft recipient site.
223664279|NCT07145476|DEVICE|Robotic arm exoskeleton integrated with cognitively engaging serious games|A specific sequence of exercises including passive and active- assisted movements, unilateral and bilateral reaching tasks with visual feedback and bimanual symmetric and asymmetric coordination tasks.
223664280|NCT07144878|DIAGNOSTIC_TEST|Parasternal Intercostal Ultrasound and RSBI Assessment|Participants underwent ultrasonographic evaluation of the parasternal intercostal muscle using a high-frequency linear probe to measure thickness and the thickening fraction during respiration. In addition, the Rapid Shallow Breathing Index was calculated from ventilator-displayed values under standardized settings: pressure support equal to zero centimeters of water and positive end-expiratory pressure equal to zero centimeters of water. Both assessments were performed immediately prior to a spontaneous breathing trial to evaluate their predictive accuracy for successful weaning from mechanical ventilation.
223664281|NCT07146178|PROCEDURE|Enhanced Recovery After Surgery|"1. Before surgery~   * Sips of water until 6 AM on the day of surgery, followed by a 200 mL carbohydrate drink~  * Pre-emptive oral analgesics (celecoxib 200mg 1 cap + acetaminophen 650mg 2 tab)~2. During surgery~   * Total intravenous anesthesia~  * Local anesthetic infiltration at the laparoscopic port site for post-operative pain control~3. After surgery~   * Sips of water and a foley catheter removal on ward arrival~  * Soft meal 4 housr after surgery~  * General diet 8 hours after surgery"
223664282|NCT07146178|PROCEDURE|Usual Care|"1. Before surgery~   * Midnight NPO~  * No pre-emptive analgesics~2. During surgery~   * Balanced anesthesia~3. After surgery~   * Sips of water 8 hours after arrival in the ward~  * Foley catheter removal one day after the surgery~  * Soft meal after gas out~  * General diet after one soft meal"
223664283|NCT07145372|OTHER|Manual therapy|It includes 10 minutes of massage and myofascial release for the trapezius and neck extensors, 10 repetitions of occiput-atlas (C0-C1) joint mobilization, occiput-atlas joint manipulation, mobilization of each segment from C2 to C7 with 10 repetitions each, C2-C7 manipulation, cervicothoracic junction (C7-T1) manipulation, thoracic region (T2-T6) manipulation, and sacroiliac joint manipulation.
223664284|NCT07145372|OTHER|Diaphragmatic relaxation technique|It includes diaphragm manual release techniques and a diaphragmatic breathing exercise program
223770193|NCT04028011|DIAGNOSTIC_TEST|Novel Wearable device|patient will wear novel wearable device overnight along with normal standard of care
224244085|NCT05517681|OTHER|non-ICG|Laparoscopic radical resection of rectal cancer was performed routinely without ICG injection. The separation should extend from the center to the left, reaching the left paracolic sulcus lateral to the genital vessels. The Superior hypogastric nerve is protected by freeing it at the angle of the common iliac artery on both sides, afterwards, the vessel is free along the surface of the plexus from caudal to cephalic side to reach the root of the IMA. Switching lymph node visualization patterns. Based on the operator's experience and the extent of lymph node visualization, the lymph nodes at the root of the IMA were removed with an ultrasonic knife . The dissection continues caudally along the IMA, preserving the arterial sheath. Expose the left colonic artery, superior rectal artery, and sigmoid artery, maximum preservation of the IMA peripheral plexus while clearing their surrounding lymph nodes.
224244086|NCT05517681|DRUG|ICG|Dilute ICG to 2.5 mg/ml with its accompanying sterilized water for injection. Slow injection with a 1ml syringe in 4 parts of the tumor，Inject 0.25ml per site . Procedure started after lymph node visualization.The operation was consistent with the control group.
224244087|NCT02866188|DEVICE|Check pulse with Smart watch on 3 parts of patient's body surface|Check pulse with smart watch on wrist, carotid artery, and eye of patients in shock or cardiac arrest state.
224244088|NCT00013351|PROCEDURE|Prevention of Falls|
224244089|NCT00302952|DRUG|Lovastatin|Two 40 mg lovastatin tablets orally once daily for a total of 12 weeks in a blinded (masked) fashion
224244090|NCT00302952|DRUG|Placebo|Two placebo tablets orally once daily for a total of 12 weeks in a blinded (masked) fashion
224244091|NCT04764565|DIETARY_SUPPLEMENT|Nuun Instant|Contains (per 11 gram serving) the following: 7 grams of carbohydrate, calcium (20mg, 2%DV), sodium (520mg, 23%DV), potassium (385mg, 8%DV), magnesium (8mg, 2%DV), chloride (250mg, 10%DV), and 100% of vitamin C (90mg) and B12 (2.4 mcg).
224244092|NCT04764565|OTHER|Water|water
224244093|NCT04764565|DIETARY_SUPPLEMENT|Nuun Electrolyte|Citric Acid, Dextrose, Sodium Bicarbonate, Potassium Bicarbonate, Sodium Carbonate, Natural Flavors, Potassium Chloride, Malic Acid, Magnesium Carbonate, Calcium Carbonate, Stevia Leaf Extract, Beet Powder Color, Safflower Oil. Nuun electrolytes contains (per tablet) the following: 3 grams of carbohydrate, calcium (15 mg, 1%DV), sodium (200 mg, 9%DV), potassium (125mg, 3%DV), magnesium (15mg, 4%DV), and chloride (75mg, 3%DV).
224244094|NCT00401778|DRUG|RAD001|Patients will be assigned to one of three treatment arms with RAD001 doses of 5, and 10 mg/day for 21-28 days sequentially taken orally in tablet form.
224244095|NCT00141466|BEHAVIORAL|Education for professionals|
224244096|NCT00141466|BEHAVIORAL|Distribution of educational materials|
224244097|NCT00141466|BEHAVIORAL|Feedback for professionals|
224244098|NCT00141466|BEHAVIORAL|Reminders for professionals|
224244099|NCT00720330|DRUG|ropivacaine|10 ml 0.5% ropivacaine plus epinephrine will be injected at T11 and L1 as described above (20 ml total) using intravenous midazolam (1-2 mg) and fentanyl (0.5-1 mcg/kg) for sedation
224244100|NCT00720330|DRUG|Lidocaine/Ketamine|Patients will receive a general anesthetic consisting of intravenous induction with lidocaine (1.5 mg/kg), propofol (1.5-2.5 mg/kg), ketamine (0.25 mg/kg), fentanyl (1 mcg/kg), and midazolam (1-2 mg).
224244101|NCT00720330|OTHER|placebo|placebo
223770194|NCT05340153|DRUG|Artemether-Lumefantrine Drug Combination|Artemether-lumefantrine is formulated as tablets and will be provided in blister packs. Each tablet contains 20 mg artemether and 120 mg lumefantrine. Every pack has a picture showing how the drug should be given and contains 1 blister of 12 tablets. It will be administered each day as two, four, six or eight tablets depending on the weight of the child.
224244102|NCT03587649|DRUG|[18F]MNI-1126|"Florbetapir PET imaging will be completed in all healthy volunteers and AD subjects as part of the screening procedures.~DaTscan SPECT imaging will be completed in those PDsubjects who have not previously had DaTscan imaging as part of the screening procedures."
224244103|NCT04599699|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|Very Low, Low, favorable, or Good Prognostic Intermediate prostate cancer:SBRT; Unfavorable, or Poor Prognostic Intermediate prostate cancer: SBRT accompanied 4 months ADT;High or Very High prostate cancer: SBRT accompanied 2 years ADT.
223664285|NCT07145372|OTHER|Shoulder ROM exercise|This group was given a home exercise program consisting of shoulder girdle range of motion (ROM) exercises that do not affect the cervical region.
223664286|NCT07147101|DRUG|Sintilimab|Sintilimab will be administered by IV, 200 mg every 3 weeks
223664287|NCT07147101|DRUG|Bevacizumab Biosimilar|Bevacizumab biosimilar will be administered by IV, 15 mg/kg every 3 weeks.
223664288|NCT07147101|DRUG|Camrelizumab|Camrelizumab will be administered by IV, 200 mg every 2 weeks.
223664289|NCT07147101|DRUG|Rivoceranib|Rivoceranib will be administered by oral 250 mg once daily.
223664290|NCT07147101|DRUG|Nivolumab|Nivolumab will be administered by IV, 1 mg/kg every 3 weeks for up to four doses, followed by nivolumab 480 mg every 4 weeks
223664291|NCT07147101|DRUG|Ipilimumab|Ipilimumab will be administered by IV, 3mg/kg every 3 weeks for up to four doses.
223664292|NCT07146711|DRUG|Tamsulosin (0.4 mg/j)|Multiple dose administration (7 days)
223664293|NCT07146711|DRUG|Omnic Ocas®,|Multiple dose administration (7 days)
223664294|NCT07146789|OTHER|occupational therapy combined with HomeGRASP program|To the present date there has been no trial combining conventional treatment with the GRASP programme as opposed to conventional treatment alone. Therefore, it is necessary to translate and adapt the materials transculturally so that it can be applied in Spain and verify the changes that occur in perceived quality of life and functionality of the affected upper limb as primary outcomes, as well as evaluating manipulative skills, use of the upper limb in ADLs and personal autonomy as secondary outcomes. All this, through the HomeGRASP programme as a complement to conventional rehabilitation in occupational therapy.
223664295|NCT07146789|OTHER|occupational therapy|It will consist solely of conventional occupational therapy treatment at the rehabilitation centre. The conventional treatment sessions will be based on: generally between 2-3 sessions a week lasting 45 minutes each at the rehabilitation centre you attend. The approaches to be used during the sessions will be based solely on mobilisations of the affected upper limb if necessary (maximum 10 minutes of the session), task-oriented training and training in ADLs.
223664296|NCT03229343|OTHER|Supportive care|supportive care, systematic and joint to pneumological consultation, monthly, starting at M0 and continuing up to M6.
223770195|NCT05340153|DRUG|Dihydroartemisinin-Piperaquine drug combination|Dihydroartemisinin-piperaquine is a formulated as tablets and will be provided in blister packs. Each tablet contains 40 mg dihydroartemisinin and 320 mg piperaquine. Every pack has a picture showing how the drug should be given and contains 1 blister of 6 tablets. It will be given each day as a half, one, two or three tablets depending on the weight of the child.
223664298|NCT04113551|DRUG|MPH (Concerta)|MPH (Concerta) is approved for the indications of ADHD and Narcolepsy in Japan. This is a non-interventional study and no drug will be given as part of this study. Analysis will be performed from data taken from Japan medical data center (JDMC) database.
223664299|NCT04113551|DRUG|MPH (Ritalin)|MPH (Ritalin) is approved for the indication of ADHD in Japan. This is a non-interventional study and no drug will be given as part of this study. Analysis will be performed from data taken from JDMC database.
223664300|NCT04113551|DRUG|Atomoxetine (ATO)|Atomoxetine (ATO) is approved for the indication of ADHD in Japan. This is a non-interventional study and no drug will be given as part of this study. Analysis will be performed from data taken from JDMC database.
223664301|NCT04113551|DRUG|Guanfacine (GFC)|Guanfacine (GFC) is approved for the indication of ADHD in Japan. This is a non-interventional study and no drug will be given as part of this study. Analysis will be performed from data taken from JDMC database.
223664302|NCT02635425|PROCEDURE|7 eggs collection|vaginal US
223664303|NCT02635425|PROCEDURE|Full eggs collection|vaginal US
223664304|NCT04236141|DRUG|Polatuzumab Vedotin|Participants will receive a total of 6 cycles (a cycle being 21 days) of 1.8mg/kg Polatuzumab Vedotin (IV infusion) on Day 2 of Cycle 1 and Day 1 of Cycles 2-6.
223770196|NCT02320890|DEVICE|YBand (YDT-201N)|transcranial Direct Current Stimulation (tDCS) 2mA for 30 min; 20 sec of ramp-up and -down; left(anode) and right (cathode) Dorsolateral prefrontal cortex (DLPFC)
223770197|NCT02320890|DEVICE|sham-YBand (YDT-201N)|transcranial Direct Current Stimulation (tDCS) 2mA for 20 sec; left (anode) and right (cathode) Dorsolateral prefrontal cortex (DLPFC)
224244104|NCT06496035|DEVICE|Blood Flow Restriction with low load exercise|Cuff/tourniquet will be applied to proximal leg at hip crease and inflated to 60-80% of limb occlusion pressure to decrease venous blood flow in the limb while performing exercise.
224244105|NCT06496035|OTHER|Therapeutic Exercise|Exercise performed at appropriate load as guided by physical therapist
224244106|NCT00804063|PROCEDURE|drawing blood sample|fasting blood sample
224244107|NCT05451030|DEVICE|remote ischemic preconditioning|The cuff of a pneumatic electronic auto-control device placed around the bilateral upper limbs was used to deliver the protocol: 5 cycles of cuff inflation (200mmHg for 5 minutes) and deflation (for 5 minutes), for a total procedure time of 50 minutes, twice daily from the first DSA to the day of carotid artery stenting.
223664305|NCT04236141|DRUG|Bendamustine|Participants will receive a total of 6 cycles (a cycle being 21 days) of 90 mg/m2 Bendamustine (IV infusion) on Days 2 and 3 of Cycle 1 and Days 1 and 2 of Cycles 2-6.
223664306|NCT04236141|DRUG|Rituximab|Participants will receive a total of 6 cycles (a cycle being 21 days) of 375 mg/m2 Rituximab (IV infusion) on Day 1 of each cycle.
223664307|NCT04236141|DRUG|Placebo|Participants will receive a total of 6 cycles (a cycle being 21 days) of Placebo (IV infusion) on Day 2 of Cycle 1 and Day 1 of Cycles 2-6.
223664308|NCT01925131|DRUG|cyclophosphamide|Given IV
223664309|NCT01925131|DRUG|vincristine sulfate|Given IV
223664310|NCT01925131|DRUG|prednisone|Given PO
223664311|NCT01925131|BIOLOGICAL|inotuzumab ozogamicin|Given IV
223664312|NCT01925131|OTHER|laboratory biomarker analysis|Correlative studies
223664313|NCT05206084|DEVICE|Sirolimus-Eluting Iron Bioresorbable Coronary Scaffold System (IBS)|Subjects in this arm will be treated with IBS
223664314|NCT05206084|DEVICE|Abbott Vascular XIENCE Everolimus Eluting Coronary Stent System|Subjects in this arm will be treated with XIENCE
223664315|NCT06540807|DEVICE|Colovac Colorectal Anastomosis Protection Device|A removable, temporary intraluminal bypass device designed to safely postpone the creation of a protective stoma until 10 days after surgery for only patients who need it (do not have a healed anastomosis)
223664316|NCT06540807|PROCEDURE|Stoma creation|Diverting loop ileostomy
223664317|NCT06080932|OTHER|Ketogenic Diet|The diet intervention will start after all baseline testing is complete
223664318|NCT06080932|OTHER|NIH Toolbox|IPAD-based assessments that examines cognitive function
223664319|NCT06080932|OTHER|gradCPT|The gradCPT contains grayscale photographs of mountain scenes and city scenes. Scene images gradually transition from one image to the next
223664320|NCT06080932|OTHER|Resting-state fMRI|Whole brain echo-planar imaging (EPI) volumes sensitive to the BOLD signal will be acquired. Images will be re-aligned, un-warped, and normalized. Confounding effects of white matter, CSF signal, and head motion will be regressed from the functional time series, followed by bandpass filtering, linear detrending and smoothing, and whole brain resting state networks will be identified (e.g., default mode network, salience network, etc).
223664321|NCT06080932|OTHER|Task-fMRI|During whole brain EPI data acquisition, participants will be presented with words and pictures and asked to make judgements about the stimuli, such as indicating whether a particular stimulus (e.g., face-name association, word, number, or letter) has been previously presented, if a presented stimulus is a city or mountain scene, the direction an arrow is pointing (left or right), if a pair of stimuli match (e.g., faces with neutral or emotional expressions; word with a face). Behavioral responses will be recorded with an MRI compatible button box.
223664322|NCT06080932|OTHER|CGM/CKM|Continuous Ketone/Glucose Monitor will be applied at the start of Test Day 1. The sensor will be checked by the study team at each test day and will be removed and replaced by a fresh sensor at \~2- week intervals during the study. The sensor will be removed at the end of the final test day.
223664323|NCT06080932|BIOLOGICAL|Blood Draw|Blood samples will be collected according to the schedule in Figure 1
223664324|NCT06080932|OTHER|Sleep Monitoring|Sleep will be assessed by ring-based acceleration with cloud technology (Oura Ring). This monitor is less burdensome than other sleep monitoring technologies and less likely to interfere with normal sleep and activity demands. Worn daily throughout intervention
223664325|NCT06080932|BIOLOGICAL|Ketone/Glucose Monitoring|KetoMojo hand-held glucometer will be used daily to monitor dietary intervention adherence.
223664326|NCT06080932|OTHER|Body Composition|DEXA Scanning will be done pre-, mid-, and post- intervention.
223664327|NCT06080932|BEHAVIORAL|PHQ-9|It is a self-assessment tool used to screen and assess the severity of depression in individuals. The PHQ-9 consists of nine questions based on the nine criteria for diagnosing major depressive disorder in the Diagnostic and Statistical Manual of Mental Disorders (DSM-5).
223664328|NCT06080932|BEHAVIORAL|WHO-5|The WHO-5, also known as the World Health Organization-Five Well-Being Index, is a self-assessment tool used to measure subjective well-being and mental health. It was developed by the World Health Organization (WHO) as a brief and reliable instrument to evaluate well-being in clinical and research settings.
223664329|NCT06080932|BEHAVIORAL|SKID|The SKID refers to the Structured Clinical Interview for DSM Disorders (SCID). It is a widely used diagnostic tool in the field of psychiatry and clinical psychology. The SCID is a semi-structured interview designed to assess and diagnose various mental disorders according to the criteria outlined in the Diagnostic and Statistical Manual of Mental Disorders (DSM), which is published by the American Psychiatric Association.
223664330|NCT00326573|BEHAVIORAL|Motivational Interviewing|
223664331|NCT03407300|DRUG|Docetaxel|To evaluate the safety and efficacy of Docetaxel alone in stage III-IV NSCLC patients
223664332|NCT03407300|DRUG|Chinese traditional medicine XH1|To evaluate the safety and efficacy of Docetaxel combined with Chinese tradition medicine XH1 in stage III-IV NSCLC patients
224244108|NCT05070286|BEHAVIORAL|Observational Study.|Semi-structured interviews.
224244109|NCT03252353|DRUG|octreotide capsules|octreotide capsules 40 mg/day, 60 mg/day, 80 mg/day (individual dose titration)
224244110|NCT03252353|DRUG|Matching placebo|Matching placebo capsules
224244111|NCT03220919|OTHER|Weight-based|Glargine titration: 0.1U/kg per day when FBG is over 8.0 mmol/L. Aspart titration: total dose 0.1U/kg per day when next pre-meal BG is over 8.0 mmol/L, which is divided into three equal parts adding to three pre-meal boluses
224244112|NCT03220919|OTHER|Glucose level-based|"Glargine titration: 4, 6, or 8 U when FBG is, respectively, within the following ranges: 8.0-8.9, 9.0-9.9, \>10.0 mmol/L.~Aspart titration: 1, 3, 5, 7 or 8 U when next pre-meal BG is, respectively, within the following ranges: 8.0-10.9, 11.0-13.9, 14.0-16.9, 17.0-19.9, \> 20 mmol/L."
224244113|NCT00473486|DRUG|pemetrexed, carboplatin, sorafenib|"Ph. 1: pemetrexed 500mg/m² iv day 1; carboplatin AUC 6 iv day 1; Sorafenib 200mg po bid days 2-19; 400mg po bid days 2-19~Ph 2: pemetrexed 500mg/m² iv day 1; carboplatin AUC 6 iv day 1;sorafenib depending on results of Ph 1"
224244114|NCT00473486|DRUG|pemetrexed, carboplatin, placebo|Ph 2: pemetrexed 500mg/m² iv day 1; carboplatin AUC 6 iv day 1; placebo day 2-19
224244115|NCT06325189|OTHER|Aerobic Interval Training|Aerobic interval training is a cardiovascular exercise that involves short bursts of high-intensity activity followed by a brief rest or low-intensity exercise. It improves cardiovascular fitness, increases lung capacity, and enhances cardiovascular endurance. It also leads to higher calorie expenditure and time efficiency, allowing for faster fitness goals.
224244116|NCT02008565|DRUG|Loperamide|Participants randomized to the loperamide group will begin with 2mg of loperamide/day. The participant will be administered the Patient Global Symptom Control rating scale (PGSC) to determine dose escalation. Participants who report inadequate control of stool leakage on the PGSC will be instructed to increase the daily dose of loperamide by 2 mg up to a maximum of 8 mg per day (1-4 capsules). Bothersome adverse events and resulting dose reduction will be based exclusively on the result of the Patient Global Tolerability Scale (PGTS). The daily dose will be decreased by 2mg to a minimum of 2mg every other day. If a PGSC score indicates inadequate control of stool leakage combined with a PGTS score indicating bothersome side effects, the participant will discontinue the study medication.
224244117|NCT02008565|DRUG|Placebo|Participants randomized to the placebo arm will begin the a dose of one capsule per day and will be dose increased or dose decreased using the same algorithm described for the loperamide arm.
223664333|NCT01410916|DRUG|Eculizumab (Soliris®)|Eculizumab 300 mg, 600 mg, 900 mg or 1200 mg will be administered intravenously
223664334|NCT05621525|DRUG|BBP-398|BBP-398 (formerly known as IACS-15509) is a potent, selective, orally active allosteric inhibitor of SHP2, a tyrosine phosphatase that plays a key role in the RTK -MAPK signal transduction pathway. Key components of the MAPK pathway include the small GTPase RAS, the serine/threonine-protein kinase RAF, mitogen-activated protein kinase (MEK) and ERK. In cells, SHP2 binds to phosphorylated tyrosine residues in the intracellular domain of RTKs such as the EGFR, leading to activation of the downstream MAPK signaling pathway.
223664335|NCT04237142|DIAGNOSTIC_TEST|Vaginal secretions collection|Vaginal secretions are collected under speculum with a swab (10 seconds of impregnation of the swab). The swab is immersed in a tube containing an extraction buffer for 10 seconds. The tube is mixed and sent to the laboratory for subsequent analysis of biomarkers (IGFBP1 T/N, PIBF, PP14) and storage.
223664336|NCT04237142|DIAGNOSTIC_TEST|Blood sample|2 tubes of blood sample were collected and sent to the laboratory for serum storage and biomarkeurs assay (PIBF and MIF)
223664337|NCT03007004|DRUG|Botulinum toxin type B (2500 units / vial)|BTX-B (E2014, Eisai, NerBloc®) was injected subcutaneously from the palmar side into seven locations around interphalangeal metacarpophalangeal joints, targeting the neurovascular bundles just proximal to the A1 pulley (the radial and ulnar sides of the first finger, the radial side of second finger, the ulnar side of the fifth finger and between the second to fifth fingers). Three locations between the second and third fingers, the third and fourth fingers, and the fourth and fifth fingers were injected with 400 U (0.2 ml) of BTX-B. In addition, the radial and ulnar sides of the first finger, the radial side of the second finger, and the ulnar side of the fifth finger were injected with half a dose of BTX-B (200 units; 0.1 ml). A total of 2000 U (1.0 ml) of BTX-B was injected into one hand. Injections were performed using a 30-gauge needle.
223664338|NCT03007004|DRUG|Physiological saline|Saline solution was injected subcutaneously from the palmar side into seven locations around interphalangeal metacarpophalangeal joints, targeting the neurovascular bundles just proximal to the A1 pulley (the radial and ulnar sides of the first finger, the radial side of second finger, the ulnar side of the fifth finger and between the second to fifth fingers). Three locations between the second and third fingers, the third and fourth fingers, and the fourth and fifth fingers were injected with saline (0.2 ml). In addition, the radial and ulnar sides of the first finger, the radial side of the second finger, and the ulnar side of the fifth finger were injected with half a dose of saline (0.1 ml). A total of 1.0 ml of saline was injected into one hand. Injections were performed using a 30-gauge needle.
223664339|NCT05960292|PROCEDURE|Laparoscopic and Vaginal Hysterectomy|To make a comparison between the Vaginal Vault complications after Hysterectomy
223664340|NCT03572205|DIETARY_SUPPLEMENT|LA|The source of linoleic acid (LA) will be sunflower oil (62-63 % LA). The study diets will be isocaloric. The allowed weight change during the study is ± 2-3 %. The amount of supplementary oil will be calculated individually based on the calculated energy expenditure and adjusted, if necessary, during the study based on body weight measurements.
223770198|NCT05738200|OTHER|Nordic Hamstring Exercise|A 4-week (10 session), progressive, NHE protocol will be used for this study. Immediately following the completion of study visit 1, patients will be informed about the nature of the NHE protocol. Those available and willing to participate will be randomized to an intervention group (NHE, control). Patients randomized to NHE will receive formal instruction about how to correctly perform the exercise, and will be asked to perform several repetitions to familiarize themselves with the exercise and verify proper technique. At this time, patients will be dismissed from study visit 1, and return visits 2-11 will be scheduled to complete the NHE protocol. Patients will return for a final study visit (12) to record post-intervention measurements within 7 days of completing the NHE protocol. A minimum of 48 hours will be used to separate study visits. To accurately assess patients' ability to perform the NHE, all exercise will be performed on a NordBord Hamstring Testing System.
223770199|NCT02148172|PROCEDURE|Standard Plyometric Training|Participants will undergo individualized practice exercises of jumping, hopping, and cutting tasks consistent with standard published exercises.
223770200|NCT02148172|PROCEDURE|Plyometric Training with BWS|Participants will undergo individualized practice exercises of jumping, hopping, and cutting tasks consistent with standard published exercises while their body weight is supported via adjustable harness.
223770201|NCT01639027|DRUG|Drotaverine|40 mg Drotaverine hydrochloride (Do-Spa) IV injection at the start of the study and repeated every 2 hours up to a maximum 3 injections.
223770202|NCT01639027|DRUG|Placebo|Women who will receive 2ml of normal physiological saline (0.9% sodium chloride) I.V at the start of the active phase of labor.
224244118|NCT02008565|BEHAVIORAL|Anal exercises with biofeedback|Participants will receive a formal anal exercises training program that can be easily applied in an office setting with minimal participant burden. Participants will attend six anal exercises with biofeedback sessions with trained personnel over a 12-week period for the 24-week study. Sessions will include introduction, standard patient education, and exercises using anal manometry-assisted biofeedback introducing concepts such as shaping, generalization and termination. The protocol uses strength and sensory training including urge resistance training. During the final twelve weeks, participants will perform anal exercises on their own. The sessions with interventionists will occur every other week for 12 weeks (total 6 supervised sessions).
224244119|NCT02008565|BEHAVIORAL|Usual Care|Usual care consists of patients receiving an educational pamphlet on fecal incontinence created by the National Institute of Diabetes and Digestive and Kidney Diseases.
223770203|NCT05561972|DEVICE|injectable multifractional intercalated hyaluronic acid [Armonia®, Regenyal, Italy]|Armonia® 2 ml was injected into the vaginal wall with a standardized injection technique called Cannulated Intravaginal Injection Technique®. In this technique, Armonia® was injected as drops at 40 different points on the entire vaginal wall using 8 different entry points
223770204|NCT00534690|PROCEDURE|One-Lung ventilation|Low Vt, High PEP
223770205|NCT00534690|PROCEDURE|One-Llung ventilation|High Vt, low PEP
223770206|NCT02911675|DEVICE|EVD/IVC and the IPM/Camino|This is an interventional device study utilizing the EVD/IVC and the IPM/Camino to provide and evaluate data for optimized treatment for the control of elevated ICP and CCP in patients with severe TBI.
223770207|NCT05264324|PROCEDURE|Maximal Exercise Capacity|Maximal Exercise Capacity in incremental ramp exercise tests.
224244120|NCT02923388|DRUG|Injection Mecobalamin,|Injection Mecobalamin (500mcg) three times a week (day 1, 3 and 5 of vincristine chemotherapy) for 5 weeks.
224244121|NCT02923388|DRUG|Tablet Pyridoxine hydrochloride|Tab. Pyridoxine hydrochloride (25 mg) 2 tablets thrice daily for 5 weeks
223664341|NCT03572205|DIETARY_SUPPLEMENT|ALA|The source of alpha-linolenic acid (ALA) will be camelina sativa oil (30-35 % ALA). The study diets will be isocaloric. The allowed weight change during the study is ± 2-3 %. The amount of supplementary oil will be calculated individually based on the calculated energy expenditure and adjusted, if necessary, during the study based on body weight measurements.
223664342|NCT04333303|OTHER|Implementation of a complex regional Advance Care Planning program|"Sustainable implementation of ACP at micro- (qualification of professional ACP facilitators to lead conversations in cooperation with family physicians), meso- (qualification of relevant co-actors, organisational development of participating institutions) and macro-level (regional ACP steering group and network), ensuring that valid ACP is encouraged, facilitated, documented, known and honored.~Core of the intervention is a modular 9-day-training for ACP facilitators. These will be preferably located in regional pools, serving more than one nursing home, and reimbursed, if certified, by German sickness funds based on recent legislation (§ 132g Social Code Book \[SGB\] V: 1 full-time facilitator for 400 residents). ACP conversations will be offered to all residents. Regional intervention at meso- and macro-level comprises various formats of specific ACP training and information for leadership and staff, and aims to support professional change management."
223664343|NCT01483339|BEHAVIORAL|Metacognitive Therapy|Metacognitive Therapy for OCD according to Wells (1997)
223664344|NCT01483339|BEHAVIORAL|Exposure and Response Prevention|Exposure and Response Prevention for OCD according to Kozak \& Foa (1997)
223664345|NCT04130308|OTHER|Retrun to run protocol|Progressive return to run protocol for patients after ACL-R
223664346|NCT06185270|DIAGNOSTIC_TEST|SPPB|Short Physical Performance Battery using the automated device (Andantefit)
223664347|NCT05055284|OTHER|Electromyographic-biofeedback guided (EMG-BF) isometric quadriceps strengthening with patellar taping five days a week for six weeks.|Patellar Taping, electromyography biofeedback (EMG-BF), Strength Training
223664348|NCT04215965|DRUG|Biphozyl (dialysate and replacement)|Replacement solution with phosphate and without calcium in CRRT with citratre-based antigoagulation
223664349|NCT04215965|DRUG|Prismocal B22 (dialysate) + phoxilium (replacement)|solution with phosphate and calcium in CRRT with citratre-based antigoagulation
223664350|NCT01696929|DRUG|Tocilizumab|"Therapeutic/Pharmacologic Class of Drug:~Tocilizumab is a recombinant humanized anti-human interleukin-6 (IL-6) receptor monoclonal antibody of the immunoglobulin (Ig) gamma-1 subclass.~Type of Dosage Form:~Concentrate for solution for infusion.~Route of Administration:~Intravenous (i.v.) infusion."
223664351|NCT00545870|DRUG|bevacizumab|intravitreal application
223664352|NCT00545870|DRUG|Ranibizumab|intravitreal application
223664353|NCT01794338|DEVICE|Strattice Arm|Biologic mesh to be placed during hernia repair surgery
223664354|NCT01794338|DEVICE|Bio-A Arm|Bioabsorbable mesh to be placed during hernia repair surgery
223664355|NCT05503745|OTHER|CBT-F+MIT|The aim is to develop healthier strategies for managing negative thoughts and feelings antecedent to ED and for engaging patients in social interactions that meet their relational basic wishes. They will thus understand that perfectionism and the need for control they experience through ED are coping strategies developed within interpersonal patterns of interaction with significant others, where low self-esteem and emotive dysregulation play a central role. MIT aims to improve individuals' capacity to make sense of their own affect and cognitions and become aware of being driven by maladaptive, rigid and biased schemas about self and others, to form a richer understanding of the mind of the others and use this knowledge to react in more adaptive ways to social difficulties or evolutionary selected wishes. MIT also enables individuals to reflect on how these schemas may act as triggers for ED behavior and to develop more effective coping strategies in face of interpersonal stressors.
223664356|NCT05503745|OTHER|CBT-E|In the first Stage, the treatment will be focused on achieving a shared understanding of the patient's eating disorder and the related maintenance factors. In this phase the patient will be helped to regulate and stabilize his eating habits and so to address his weight concerns. In the second stage, progress made is reviewed in detail. In the third stage, the sessions will be focused on the central processes that are maintaining the psychopathology of the patient's eating disorder. In particular, this involves in addressing concerns about weight and body shape, cognitive and caloric dietary restriction, events and emotions that affect nutrition. In phase three and four clinical perfection, low global self-esteem, intolerance of emotions and interpersonal difficulties are also addressed. Towards the end of the third stage and during the fourth stage, procedures will be also implemented to minimize the risk of short- and long-term relapse.
223664357|NCT02108340|PROCEDURE|Microwave radiometry|Microwave radiometry of the right lower quadrant in a room temperature of 20-24 degrees celsius, in order to record changes in the temperature of the inflamed appendix.
223664358|NCT06242353|DIAGNOSTIC_TEST|Coagulopathy parameters|"Standard coagulation tests: APT (Activated Partial Thromboplastin Time), PT/INR (Prothrombin Time Test), Protein-C, Protein-S, Fibrinogen, Antithrombin, D-dimers.~Global haemostasis assays: CAT (Calibrated Automated Thrombogram), OHP (Overall Haemostatic Potential), Fibrin clot turbidity assay, microparticle detection by flow cytometry, scanning electron microscopy.~Protein expression profile (mass spectroscopy)~Ultrasound of catheterised neck veins to detect clots"
223664359|NCT01954927|DRUG|Gabapentin|Gabapentin is supplied as an oral suspension. Patients randomized to the gabapentin arm will receive a single dose of gabapentin as soon after enrollment as feasible. The gabapentin dose will be given orally and will be approximately 15 mg/kg with a maximum dose of 900 mg.
223770208|NCT03765294|DRUG|ACT-541468|Film-coated tablet for oral use
223770209|NCT03765294|DRUG|Placebo|Film-coated tablet for oral use
223770210|NCT01563068|DRUG|Calcipotriene 0.005% Foam|Topical application applied twice a day for 15 days
224244122|NCT02923388|DRUG|Intravenous normal saline 1 ml|Normal saline 1 ml three times a week (day 1, 3 and 5 of vincristine chemotherapy) for 5 weeks
224244123|NCT02923388|DRUG|Placebo pill|Placebo pill orally thrice daily for 5 weeks
224244124|NCT06360913|DIAGNOSTIC_TEST|High resolution mass spectrometry|Metabolomics study
224244125|NCT04305782|DEVICE|Release/Relock Socket - In Lab|The participants will operate the test socket in one of two test conditions: (1) pin re-lock before panel re-lock and (2) panel re-lock before pin re-lock. Participants will test each of the two conditions in a random order, in lab, following a structured protocol. Tests will determine if the order of the re-lock mechanisms influences changes in limb volume.
223664360|NCT01954927|DRUG|Placebo|Placebo will be prepared by the SJCRH pharmacy and will be similar in appearance, quantity and taste to the gabapentin drug. Patients randomized to the placebo arm will receive a single dose of placebo as soon after enrollment as feasible. The placebo dose will be given orally and will be approximately 15 mg/kg with a maximum dose of 900mg.
223664361|NCT00660881|BIOLOGICAL|Epratuzumab|Epratuzumab at a concentration of 10 mg/mL prepared in 17.5 ml vials for slow intravenous infusion using only PBS as a vehicle/buffer for the infusion procedure.
223664362|NCT00955305|BIOLOGICAL|Bevacizumab|Given IV
223664363|NCT00955305|DRUG|Carboplatin|Given IV
223770211|NCT03892811|OTHER|Three study conditions|Continuous fluoroscopy (at 30 frames/second) will be used for intermittent periods to capture 10 swallows in the initial sucking sequence of each of three study conditions: 1) Dr. Brown's Ultra-Preemie bottle nipple, 2) Dr. Brown's Preemie bottle nipple, and 3) Dr. Brown's Level 1 bottle nipple.
224244126|NCT04305782|DEVICE|Release/Relock Socket - Out of Lab|The participants will operate the test socket in one of two test conditions: (1) pin re-lock before panel re-lock and (2) panel re-lock before pin re-lock. Participants will test each of the two conditions in a random order, out of lab, with no structured protocol. Tests will determine if the order of the re-lock mechanisms changes participant experience.
224244127|NCT04305782|DEVICE|Release/Relock Socket & Control|The participants will operate the test socket in one of two test conditions: (1) release/relock mechanisms enabled and (2) release/relock mechanisms disabled. Participants will test each of the two conditions in a random order, out of lab, with no structured protocol. Tests will determine how the novel release/relock mechanisms compare against traditional socket release methods.
223664364|NCT00955305|BIOLOGICAL|Cixutumumab|Given IV
223664365|NCT00955305|DRUG|Paclitaxel|Given IV
223664366|NCT00109590|DRUG|Didanosine, enteric-coated|once daily
223664367|NCT00109590|DRUG|Lopinavir/ritonavir|twice daily
223664368|NCT00109590|DRUG|Nevirapine|single-dose at the onset of labor
223664369|NCT00109590|DRUG|Zidovudine|twice daily
223664370|NCT00491088|DEVICE|CPAP|CPAP for 12 weeks
223664371|NCT02672696|DEVICE|FluoroMap 3D|Use of the 3D reconstruction software developed by the manufacturer of the Gamma Nail (e.g. Stryker Inc.) along with the standard fluoroscopy
223664372|NCT02270996|OTHER|Antimicrobial Stewardship Program|Twice weekly meeting with Infectious Disease and Pediatric Surgery team members to audit antibiotics prescribed and suggest role for discontinuation.
223770212|NCT01392950|DEVICE|Air Optix Aqua|Lenses will be worn on a daily wear basis (ie. removed at night and stored in solution) and worn in the normal way. Lenses will be replaced each month. Lenses should be worn for a minimum of six hours a day, four days a week. The lenses are also to be worn for a minimum of two hours before attending all follow-up visits.
224244128|NCT00391105|DRUG|Remifentanil|
224244129|NCT04091256|OTHER|Single arm clinical study|Participants will be treated with desensitizing toothpaste containing zinc-carbonate hydroxyapatite nanocrystals (Zn-CHA) for 8 weeks.
224244130|NCT00467662|DRUG|Acyclovir 5%|
224244131|NCT00467662|DRUG|Docosanol 10%|
223664373|NCT03936231|OTHER|NO Intervention|"Given the observational nature of this study, we consider that no intervention is required.~Participation in concomitant studies: given the observational condition of this study, patiens that are included in other observational and/or experimental researches, can be included in the current study."
223664374|NCT05952752|OTHER|giving dexemedetomidine 12 microgram Iv dripping|Patients in the studied groups will receive either or intravenous Dexemedetomidine 12 µg
223664375|NCT05952752|OTHER|Dexamethsone IV|4 mg IV dexamethasone
223664376|NCT00594945|DRUG|Clonazepam|1 Dose
223664377|NCT04468529|DRUG|Recombinant human Neuregulin for injection|10 hours per day i.v. drip for the first 10 days (0.6ug/kg/day)
223770213|NCT01392950|DEVICE|Clariti|Lenses will be worn on a daily wear basis (ie. removed at night and stored in solution) and worn in the normal way. Lenses will be replaced each month. Lenses should be worn for a minimum of six hours a day, four days a week. The lenses are also to be worn for a minimum of two hours before attending all follow-up visits.
223770214|NCT04187196|DRUG|Propofol|Propofol will be given at an initial dose of 0.8 mg/kg followed by 20 mg every minute after 2 minutes, if adequate sedation is not achieved
223770215|NCT04187196|DRUG|Methohexital|Methohexital will be given at an initial dose of 0.5 mg/kg, followed by 10 mg every minute after 2 minutes, if adequate sedation is not achieved
223770216|NCT00009919|DRUG|semaxanib|Given IV
224244132|NCT00467662|DEVICE|Superlysine gel|
224244133|NCT04095247|DEVICE|Vagus nerv stimulator|pulse triggered autostimulation
223664378|NCT04468529|DRUG|Placebo|10 hours per day i.v. drip for the first 10 days (0ug/kg/day)
223664379|NCT06199583|DIAGNOSTIC_TEST|Shear-wave elastography|Ultrasound shear-wave elastography
223664380|NCT00956098|DRUG|oltipraz|60mg bid 90mg qd
223664381|NCT00956098|DRUG|placebo|
223664382|NCT02412813|DEVICE|LEGION OXINIUM|Investigational Group
223664383|NCT02412813|DEVICE|LEGION Cobalt Chrome|Control Group
223664384|NCT03254108|DRUG|OPC-61815 injection 2mg|Once daily for 5 days placebo tablet will be orally administered, followed immediately by intravenous administration of OPC-61815 at 2 mg.
223664385|NCT03254108|DRUG|OPC-61815 injection 4mg|Once daily for 5 days placebo tablet will be orally administered, followed immediately by intravenous administration of OPC-61815 at 4 mg.
223664386|NCT03254108|DRUG|OPC-61815 injection 8mg|Once daily for 5 days placebo tablet will be orally administered, followed immediately by intravenous administration of OPC-61815 at 8 mg.
223664387|NCT03254108|DRUG|OPC-61815 injection 16mg|Once daily for 5 days placebo tablet will be orally administered, followed immediately by intravenous administration of OPC-61815 at 16 mg.
224244134|NCT02763085|DEVICE|Basic Filling Material|Tooth (teeth) affected by dental caries or with an existing defective filling will be restored using the materials listed (Basic Filling Material). Procedures will be done using local anesthesia. The cavity is excavated and filled according to the guidelines for ordinary restorative techniques.
224244135|NCT00801970|BEHAVIORAL|Psychological Treatment|15 weekly therapy sessions.
224244136|NCT00801970|BEHAVIORAL|Group Therapy|3 months of weekly group therapy sessions.
224244137|NCT00857623|DRUG|AZD2066|Capsule, once daily, 12 mg AZD2066 day 1-4 and 18 mg AZD2066 day 5-28.
224244138|NCT00857623|DRUG|Placebo|Capsule, once daily
223770217|NCT00360074|DRUG|Thyroxin, Triiodothyronine|
223770218|NCT04537728|BEHAVIORAL|My Healthy Brain Version 2|multimodal lifestyle intervention incorporating mindfulness skills, behavioral principles, and recent research on brain disease risk factors
223770219|NCT01556204|PROCEDURE|Robotic surgery|The technique for resection of superficial and deep endometriosis will be performed in a standard fashion. All superficial lesions suspicious for endometriosis (pigmented and non-pigmented) will be completely resected until non-diseased peritoneal margins are visualized around the defect or will be fulgurized using bipolar energy; all deep lesions suspicious for endometriosis will be completely resected until non-diseased margins are visualized in the tissue surrounding the defect. Cystectomy(ies) will be performed for endometrioma(s). The fascia of any port greater or equal to 10mm will be reapproximated. Cystoscopy would only be performed when deemed appropriate by the surgeon (e.g., to assess for lower urinary tract injury in cases that require extensive ureterolysis).
223664388|NCT03254108|DRUG|Tolvaptan tablet 15mg|Once daily for 5 days tolvaptan 15-mg tablet will be orally administered, followed immediately by 1-hour intravenous administration of placebo.
223770220|NCT01556204|PROCEDURE|Laparoscopic Surgery|The technique for resection of superficial and deep endometriosis will be performed in a standard fashion. All superficial lesions suspicious for endometriosis (pigmented and non-pigmented) will be completely resected until non-diseased peritoneal margins are visualized around the defect or will be fulgurized using bipolar energy; all deep lesions suspicious for endometriosis will be completely resected until non-diseased margins are visualized in the tissue surrounding the defect. Cystectomy(ies) will be performed for endometrioma(s). The fascia of any port greater or equal to 10mm will be reapproximated. Cystoscopy would only be performed when deemed appropriate by the surgeon (e.g., to assess for lower urinary tract injury in cases that require extensive ureterolysis).
223770221|NCT03736850|DRUG|CS3006|"In the dose escalation part, the dose levels will be escalated following a modified 3+3 dose escalation scheme.~In the dose expansion part, participants will receive CS3006 at specified dose level(s)."
223770222|NCT04078776|OTHER|No intervention|There is no intervention in this study
223770223|NCT05314946|PROCEDURE|No feeding tube placed|The experimental arm will forego placement of a feeding tube.
223770224|NCT05314946|PROCEDURE|Placement of a percutaneous feeding tube|The standard arm will have a feeding tube placed (G-tube or GJ-tube by IR; or surgically placed J-tube)
223770225|NCT05664724|BEHAVIORAL|Receives interdisciplinary sessions|"Along with usual care, participants receive six interdisciplinary sessions at 2 months and 1 month pre-operatively and 2 weeks, 6 weeks, 3 months, and 6 months post-operatively attended by an orthopedic surgeon, a physiotherapist, a patient navigator, and the patient. The pre-operative interdisciplinary sessions will outline expectations, explore patients' questions and concerns, set expectations for the next interdisciplinary session, and ensure goal congruence between all members of the team.~Along with usual care during the post-operative period, participants will receive interdisciplinary sessions that address safety and medical issues, revisit patient expectations, reinforce care team expectations, focus on a personalized rehabilitation plan, and ensure goal congruence between the various team members."
223770226|NCT00688766|DRUG|retaspimycin hydrochloride (IPI-504)|IPI-504 is a novel small molecule inhibitor of heat shock protein 90 (Hsp90). Patients will receive 400 mg/m2 of IPI-504 as a 30-minute IV infusion twice weekly for 2 weeks followed by 1 week off.
224321639|NCT07095582|BEHAVIORAL|Additional Loneliness Content|The additional Loneliness Content was developed at the Online Therapy Unit, University of Regina, Canada. Relevant sections of the resource will be included at the end of each lesson within the Wellbeing Course. The Loneliness Content provides psychoeducation and skills for loneliness using a cognitive behavioral framework. Consistent with the Wellbeing Course content, the Loneliness Content will target 1) identification of loneliness; 2) loneliness thought monitoring and challenging; 3) de-arousal strategies and pleasant activity scheduling for loneliness; 4) behaviours (conversation skills); and 5) relapse prevention.
223664389|NCT02108015|PROCEDURE|Brain Imaging (PET)|
223664390|NCT02108015|PROCEDURE|Aterial Line|
223664391|NCT02108015|PROCEDURE|Blood Sampling|
223664392|NCT00813540|BEHAVIORAL|Exercise Training|The exercise group will perform supervised stationary cycle ergometer exercise 3 times per week for 12 weeks and be progressed from 15 to 45 minutes and 60% to 110% of the power output obtained at V02peak. Resistance training will be completed twice per week and will include exercises for all major muscle groups. The training will progress from 60% to 80% of 1RM over the course of the intervention.
223664393|NCT00813540|OTHER|Usual Care|Usual Care
223664394|NCT00004581|DRUG|Lopinavir/Ritonavir|
223770227|NCT00688766|DRUG|placebo|Patients will receive a 30-minute IV infusion twice weekly for 2 weeks followed by 1 week off.
223770228|NCT00688766|OTHER|Best supportive care|Best supportive care will be according to institutional standard, but will not include administration of systemic cancer-specific therapies including chemotherapies, biologic therapies, investigational therapies, TKIs (e.g., imatinib, sunitinib, nilotinib, dasatinib), or local therapies such as surgery, radiotherapy, or lesion ablative therapies.
223770229|NCT02591628|BEHAVIORAL|HCTZ prescription conversion to chlorthalidone|The intervention is simply a prescription conversion and the main outcome is whether or not patients accept the conversion and treatment with chlorthalidone.
223770230|NCT01957475|DEVICE|Coloplast Test product Y|Coloplast Test product Y is a newly developed 2-piece convex ostomy appliance
223664395|NCT00004581|DRUG|Nevirapine|
223664396|NCT02923024|BEHAVIORAL|Patient Ping|The patient ping will be a fax sent from Oscar Health to physician that will include information on the physician's patient's trigger event and contact information for the physician to reach out to the member.
223664397|NCT00745849|DRUG|esomeprazole|40mg by mouth twice daily
223664398|NCT00745849|DRUG|placebo|
223664399|NCT03861494|BEHAVIORAL|Enhanced Stroke Education|In addition to the general stroke education materials and verbal education, the enhanced stroke education group will receive a personalized verbal and written information addressing the patient's specific risk factors including their current status and goals, laboratory values and goals, and current blood pressure and goal. Specific stroke type and etiology is discussed, medication including indication, dose, frequency, physical activity goals, smoking cessation resources, appropriate diet, stroke signs and symptoms and best practice if one sees a stroke (BE-FAST), phone number to call for non-urgent questions, and education over the importance of keeping follow up appointments including Stroke Clinic. Verbal feedback of key points is encouraged.
223664400|NCT03861494|BEHAVIORAL|Usual Stroke Education|The usual stroke education group will receive general stroke education including written and verbal information about signs and symptoms of stroke, best practice to engage medical treatment if stroke occurs, general information about heart healthy diet and need for daily physical activity as well as need for compliance with medication recommendations. The education is incorporated with routine patient care and as allowed during quiet times. On the day of discharge, the patient will receive written materials reviewing stroke symptoms, risk factors, heart healthy diet and follow up appointments. The patient will receive written and verbal information about medications including indication, dose, frequency, physical activity goal, smoking cessation resources, appropriate diet, stroke signs and symptoms and best practice if one sees a stroke (BE-FAST), phone number to call for non-urgent questions, the importance of keeping follow up appointments including Stroke Clinic.
223664401|NCT00458029|BEHAVIORAL|integrated program of nutrition, activity, behavior, and promotion|implemented across 5 half-year periods: winter/spring 2007, fall 2007, winter/spring 2007, fall 2008, winter/spring 2008
223664402|NCT03176342|OTHER|patch test|Patch test allergen from chemotechnique diagnostics, pure drug and drug as is combine with petrolatum or aqueous.
223664403|NCT05069701|DIAGNOSTIC_TEST|SVV test|SVV test will be done with virtual reality glasses.
223664404|NCT02825290|DRUG|Choriogonadotropin alfa|
223770231|NCT01957475|DEVICE|Coloplast Test product Z|Coloplast Test product Z is a newly developed 2-piece convex ostomy appliance
223770232|NCT04419116|PROCEDURE|tibial preservation bone cut|tibial preservation bone cut: removing of proximal tibial less than conventional tibial bone cut with 2mm.
223770233|NCT04473651|DRUG|Lu AG06479|capsules, orally (Part A and B)
223770234|NCT04473651|DRUG|Placebos|Placebo - capsules, orally (Part A only)
223770235|NCT01640730|DRUG|Kanglaite Injection|30gm IV infusion 5 days a week for 3 weeks every 28 days
223770236|NCT03097419|PROCEDURE|Remote post-ischemic conditioning|"A manual sphygmomanometer will be inflated over the brachial artery of the participants' arm that does not have an intravenous catheter actively infusing medications. If both arms are in use, then the participant's non-dominant arm will be used.~* The sphygmomanometer will be inflated to a pressure at least 20 mmHg greater than the participants' last recorded systolic blood pressure.~* The sphygmomanometer will be inflated for 5 minutes then rapidly deflated for 5 minutes, thereby concluding one iteration.~* Five (5) total iterations constitute the treatment.~* The left arm will be preferentially used instead of the right arm, unless the left arm is receiving medication administration."
223770237|NCT04587193|DEVICE|Robotic-assist gait training device|PD participants will walk while wearing a robotic-assist gait training device
223770238|NCT03407872|DRUG|Esketamine DPI|Participants will receive different number of consecutive Esketamine DPI inhalations, consider as a single dose. There will be dose escalation between cohorts.
224244139|NCT06231147|OTHER|HORSE RIDING SIMULATOR WITH VISUAL FEEDBACK|horse riding simulator session with mirror visual feedback. The participants will be instructed that how to perform exercises by using the horse riding simulator (HRS) system in front of mirror
224244140|NCT06231147|OTHER|HORSE RIDING SIMULATOR WITHOUT VISUAL FEEDBACK|horse riding simulator session without visual feedback. The participants will be instructed that how to perform exercises by using the horse riding simulator (HRS) system.
224244141|NCT03435081|DRUG|Baricitinib|Administered orally
224244142|NCT03435081|DRUG|Placebo|Administered orally
224244143|NCT00420238|DRUG|Etanercept (Enbrel)|50 mg injection once weekly
224244144|NCT00420238|OTHER|Placebo|placebo
224244145|NCT01799681|BEHAVIORAL|an 8-week blended indoor-outdoor exercise program|stretching, strength and functional training, Balance Dance, Modified Wing Chun, Square stepping exercise, and fall-prone activities practice
224244146|NCT01799681|BEHAVIORAL|an 8-week upper limb and hand exercise program|upper limb stretching and strengthening, hand agility exercises, knot tying and Chinese calligraphy
224244147|NCT04734665|DRUG|Niraparib-Bevacizumab|"Niraparib 200mg or 300mg (once daily\[QD\]) Bevacizumab 15mg/kg every 3 weeks (Q3W)~\*The recommended starting dosage of niraparib is 200mg QD. For patients who weigh ≥77 kg and have baseline platelet count ≥150,000/μL, the recommended starting dosage is 300 mg QD."
224244148|NCT02706236|DRUG|Pancrelipase|Oral Pancrelipase, 720,000 units spread throughout the day with meals and snacks, taken daily PO for 4 weeks
223664405|NCT02825290|DRUG|Triptorelin acetate|
223770239|NCT03407872|DRUG|Esketamine DPI|"Participants will receive different dosing sequences of Esketamine DPI inhalations, consider as a single dose. There will be dose escalation between cohorts. Number of Esketamine DPI inhalations within a dosing sequence will be defined based on results from PART A of the study.~Dose: very low, low, medium, high."
223770240|NCT03407872|DRUG|Esketamine DPI|"Participants will receive different cycle of treatment consisting of 4 dosing sequences administered within 2 weeks. There will be dose escalation between cohorts. Participants in this part will be randomized to receive Esketamine DPI or placebo in 3:1 ratio. Number of Esketamine DPI inhalations within a dosing sequence will be defined based on results from PART A and PART B of the study.~Dose: very low, low, medium, high."
223770241|NCT03407872|DRUG|Placebo DPI|"Participants will receive different cycle of treatment consisting of 4 dosing sequences administered within 2 weeks. Participants in this part will be randomized to receive Esketamine DPI or placebo in 3:1 ratio.~In each cohort, number of placebo inhalations within a dosing sequence will correspond to number of Esketamine DPI inhalations."
224244149|NCT02706236|DRUG|placebo|Placebo will consist of lactose, spread throughout the day with meals and snacks, taken daily PO for 4 weeks
224244150|NCT05778513|OTHER|Passive knee flexion-extension + Cycle ergometer exercise + 3-week body weight reduction program|Passive knee flexion-extension movements + Incremental cycle ergometer exercise + Multidisciplinary body weight reduction program with a duration of 3 weeks
224244151|NCT05778513|OTHER|Passive knee flexion-extension + Cycle ergometer exercise|Passive knee flexion-extension movements + Incremental cycle ergometer exercise
224244152|NCT03916094|DRUG|HLX22|Humanized Anti-Human Epidermal Growth Factor Receptor-2 Monoclonal Antibody
224244153|NCT01850420|DRUG|IMC-1|
224244154|NCT00499642|DRUG|Lecozotan SR|
224244155|NCT00499642|DRUG|Moxifloxacin|
223664406|NCT04308733|DEVICE|Anodal tDCS|patients will be stimulated over the contralateral pharyngeal motor cortex with anodal tDCS (2mA, 20 minutes) for 4 consecutive days
223770242|NCT03680274|DRUG|Vitamin C|Intravenous vitamin C administered in bolus doses of 50 mg/kg mixed in a 50-mL solution of either dextrose 5% in water (D5W) or normal saline (0.9% NaCl), during 30 to 60 minutes, every 6 hours for 96 hours (i.e. 200 mg/kg/day and 16 doses in total).
223770243|NCT03680274|OTHER|Control|Dextrose 5% in water (D5W) or normal saline (0.9% NaCl) in a volume to match the vitamin C.
223770244|NCT03343691|DIAGNOSTIC_TEST|Screening Population|Blood samples taken from screening population
224244156|NCT03095222|DRUG|Ketamine|To be given as intravenous infusion. Ketamine infusions will be started at 5 mg/hr and can be increased by nursing staff based on patient-reported pain relief up to a maximum hourly rate of 20 mg/hr.
224244157|NCT03095222|DRUG|Opioids|Standard of care for pain management.
224321640|NCT04326205|DEVICE|transcranial direct current stimulation, tDCS|"The participants will receive a-tDCS over the ipsilesional M1, without any active arm practice for 20 minutes.~Hence, movement extension will be achieved in the affected side while the participant will view the reflection of the normal movement patterns of their unaffected UE. Then the electrodes will be removed, and the participants will receive an additional 20 minutes of MT without tDCS followed by 30 minutes of functional task practice."
223664407|NCT06515535|DRUG|Topical tranexamic acid|Topical tranexamic acid will be applied after placental delivery on the placental bed for 5 minutes by using a sterile towel soaked with 2g tranexamic acid (Kapron, Amoun, Cairo, Egypt) (4 ampules 500ug) diluted in 100ml of sodium chloride 0.9%
223770245|NCT03343691|DIAGNOSTIC_TEST|Breast Cancer Population|Blood samples taken from Breast Cancer population
223770246|NCT03307668|DEVICE|CaReSR-1S|CaReSR-1S is a sterile, ready for use round implant based on a dense matrix of native Collagen type I.
223770247|NCT03307668|DEVICE|Microfracture|Microfracture is an articular cartilage repair surgical technique that works by creating tiny fractures in the underlying bone. This causes new cartilage to develop from a so-called super-clot.
224244158|NCT05805657|BEHAVIORAL|Standard Transdiagnostic Intervention for Sleep and Circadian Dysfunction (TranS-C)|TranS-C is a psychosocial treatment designed to improve sleep and circadian functioning. It is a modular, psychosocial, skills-based approach. In this study, two version of TranS-C will be tested: Standard and Adapted.
224244159|NCT05805657|BEHAVIORAL|Adapted Transdiagnostic Intervention for Sleep and Circadian Dysfunction (TranS-C)|The Adapted version was derived from Standard TranS-C. It was developed to improve the fit of the treatment with the CMHC context.
224244160|NCT05805657|OTHER|Usual Care Delayed Treatment|Usual care in the partner CMHCs typically starts with a case manager who co-ordinates care and refers each client for a medication review and to various rehabilitation programs (e.g., health care, housing, nutrition, finding a job, peer monitoring).
223770248|NCT03869593|GENETIC|Sample analysis|Here, to determine the importance of the mutation we will analyze the blood content of patients presenting E. coli and S. aureus bacteremia
224244161|NCT00085696|DRUG|VELCADE and rituximab|
224321641|NCT04326205|DEVICE|functional electrical stimulation, FES|"The participants will start the FES-assisted MT. During this period, participants will perform simple wrist or finger extension with their unaffected UE while the affected wrist or fingers will receive FES within the mirror-box.~Hence, movement extension will be achieved in the affected side while the participant will view the reflection of the normal movement patterns of their unaffected UE. Then the electrodes will be removed, and the participants will receive an additional 20 minutes of MT without FES followed by 30 minutes of functional task practice."
223770249|NCT02962037|OTHER|Melatonin and light therapy|
224244162|NCT04662996|BIOLOGICAL|Blood sample|one blood sample is done before beginning a first treatment line for a metastatic castration resistant prostate cancer
224244163|NCT02243930|DEVICE|Disposable distal attachment|
224244164|NCT03230149|DIAGNOSTIC_TEST|Measurements of the alpha-GAL enzyme activity|Blotting paper blood tests in order to highlight an enzyme deficiency for hemizygous males with DBS kits in order to detect Fabry disease, with genetic confirmation if an abnormality is detected. For women genotyping is mandatory.
224244165|NCT00886171|BEHAVIORAL|Social Skills Training|Social skills group will consist of one session (60 minutes) per week for 8 weeks
224244166|NCT00886171|BEHAVIORAL|Physical Activity Training|Physical activity groups consist of one session (60 minutes) per week for 8 weeks
224244167|NCT02748161|PROCEDURE|DEB-TACE|Transarterial chemoembolization with doxorubicin-eluting beads.
224244168|NCT00185705|DRUG|Telmisartan|
224244169|NCT04624412|OTHER|Continuous Aerobic Moderate Intensity Exercise|"Continuous Aerobic Moderate Intensity Exercise~* 5-10 min warm up~* 30 min moderate aerobic exercise (Treadmill walking exercise)~* Constant intensity at 50% - 70% of max HR (3-6 METS)~* 5-10 min cool down"
224244170|NCT04624412|OTHER|Continuous Aerobic (Mild intensity Exercise)|"Continuous Aerobic (Mild intensity Exercise)~* 5-10 min warm up~* 30 min mild aerobic exercise (Treadmill walking exercise)~* Constant intensity at 30-50 % of max HR (1-3 METS)~* 5-10 min cool down"
223664408|NCT06515535|DRUG|Intravenous tranexamic acid|Intravenous tranexamic acid will be given in the form of an IV infusion of 1g of tranexamic acid (2 ampules 500ug) diluted with 20 ml of 5% glucose administered just after delivery of the fetus.
223770250|NCT00503386|DRUG|Palonosetron|
223770251|NCT00503386|DRUG|Granisetron|
223770252|NCT02977234|DRUG|Isoamyl 2-Cyanoacrylate|
223770253|NCT04349722|DRUG|Hyoscine Butylbromide|Intervention is given once a participant is in established labor
223770254|NCT04349722|OTHER|Placebo|Intervention is given once a participant is in established labor
223770255|NCT01813318|DRUG|Acamprosate|The maximum dose of acamprosate to be used in this study is 1998 mg per day for those subjects weighing greater than 50kg and 1332 mg per day for those less weighing less than 50kg.
223770256|NCT01813318|DRUG|Placebo|Subjects receiving placebo will be dosed similarly to the acamprosate group.
223770257|NCT01552772|DRUG|Aripiprazole IM Depot|400 mg intramuscular injection of aripiprazole
223770258|NCT03567863|DEVICE|20-GAUGE PROCORE® first, then 22-GAUGE ACQUIRE®|The two punctures performed successively with the 20-GAUGE PROCORE® (COOK) and the 22-GAUGE ACQUIRE® (BOSTON SCIENTIFIC)
223770259|NCT03567863|DEVICE|22-GAUGE ACQUIRE® first, then 20-GAUGE PROCORE®|The two punctures performed successively with the 22-GAUGE ACQUIRE® (BOSTON SCIENTIFIC) and the 20-GAUGE PROCORE® (COOK)
223664409|NCT04925154|BEHAVIORAL|The only intervention will be the information brochure that will be given after the first questionnaire.|The information brochure will be given to both groups at the same time at 2-3 weeks after the first consultation (patients group) or after answering the first questionnaire (physicians group).
223770260|NCT03818022|PROCEDURE|Cryoneurolysis (Iovera)|Cryoneurolysis performed by radiology department 1 week prior to total knee arthroplasty
223770261|NCT03339375|DEVICE|esophageal Doppler|Goal directed fluid therapy using dynamic parameters from esophageal Doppler
223770262|NCT02915744|DRUG|NKTR-102|
223770263|NCT02915744|DRUG|Eribulin|
223770264|NCT02915744|DRUG|Ixabepilone|
223770265|NCT02915744|DRUG|Vinorelbine|
223770266|NCT02915744|DRUG|Gemcitabine|
223770267|NCT02915744|DRUG|Paclitaxel|
223770268|NCT02915744|DRUG|Docetaxel|
223770269|NCT02915744|DRUG|Nab-paclitaxel|
223770270|NCT03369938|OTHER|exercise training intervention|structured aerobic endurance/resistance training on top of usual care for 12 weeks (3x/week)
223770271|NCT03279588|DIAGNOSTIC_TEST|Bedside Ultrasound|Patients presenting to the Emergency Department with abdominal pain suspected of acute diverticulitis are evaluated with standard care by an Emergency Physician (tutor); at the time the tutor requests an imaging test performed by Radiologist (CT scan or US scan), he notifies another physicians skilled in bedside abdominal US (ultrasonographer), who evaluates the patient and performs the US scan. Ultrasonographer after completation of US and knowing blood samples results fills in a standardized form reporting the diagnostic hypotesis, the need for additional work-up (if deemed necessary), and the disposition of the patient. The standardized form completed by the ultrasonographer will be compared with the actual management of the patient.
223770272|NCT05491603|BIOLOGICAL|DBI-001|Topically administered
223770273|NCT05491603|BIOLOGICAL|DBI-002|Topically administered
223770274|NCT05491603|BIOLOGICAL|Aqueous Gel|Topically administered
223770275|NCT02994537|OTHER|Different biochemical results or pathogenesis.|Comparing the pathogenesis,clinical characteristics and treatment effects between the acute autoimmune hepatitis group and the chronic autoimmune hepatitis group. The investigators don't use special intervention.
224321642|NCT04326205|OTHER|no stimulation|Both tDCS and FES will not be used in this section.
223664410|NCT02333864|DEVICE|POGO® BGMS|SMBG
223664411|NCT02929043|OTHER|air puffs|
223664412|NCT04348227|BEHAVIORAL|Enhanced hygiene measures|Wether or not hygiene measures dictated by the pandemic of severe acute respiratory syndrome coronavirus 19 , reduce multi drug resistant pathogens isolated in endotracheal aspirates.
223770276|NCT04361526|DEVICE|Cytokine Adsorption|Cytokine adsorption will be performed through a venous hemodialysis catheter, preferably jugular or femoral. The filtration system will be established with a cytokine adsorption cartridge in an hemoperfusion system using a blood flow rate of 150 - 200 ml/min. Adsorbent therapy will last 72 hours, changing cartridges every 24 hours. Prior to start, heparinization will be stablished by a 1mg/Kg iv Na heparin bolus plus iv perfusion. Activated Partial Thromboplastin Time (aPTT) control will be performed every 6 hours, with a goal range between 60 and 80 seconds.
223770277|NCT04449367|PROCEDURE|ultrasound guided erector spinae plane block|bilatral block given to patients under general anaesthesia for thoracic spine sugery to contorl post operative pain
223770278|NCT02920983|DEVICE|somofilcon A|contact lens
223770279|NCT02920983|DEVICE|nelfilcon A II 2|contact lens
223770280|NCT02920983|DEVICE|omafilcon A ll 2|contact lens
223770281|NCT03620318|DRUG|Crenolanib besylate|
223770282|NCT04143412|DRUG|Tritace (Ramipril 10 mg)|Stratified randomized clinical trial
223770283|NCT06137443|DEVICE|Balance Training|Patients underwent treatment for eight weeks, with walking and balance exercises on Andago performed three days a week. In addition, conventional in-bed exercises, including stretching, strengthening, and mobility exercises, were administered for 40 minutes, two days a week.
223770284|NCT02839499|DEVICE|RU sleeping®|Each patient included in the study has a test by RU-sleeping. The diagnosis of obstructive sleep apnea syndrome will be asked for an index of respiratory events estimated as greater than or equal to 10.
223770285|NCT02839499|OTHER|autonomy scale (ADL and AGGIR)|autonomy data
223770286|NCT02839499|OTHER|various activity scale (IADL)|activity of life data
223770287|NCT03878134|DEVICE|PHOTON COUNTING CT Scanner|Enrolled patients will undergo the requested clinical diagnostic CT study on the investigational system using the standard detector, with or without IV and/or oral contrast as indicated and an limited scan of one body region using the PCCT detector. Both scans are able to be performed on the same scanner during the same examination.
223770288|NCT04269603|DEVICE|Take blood (TA-8V (Stago®)|Healthy volunteers will have 3 blood samples at M0, M3 and M6.
223770289|NCT02831270|PROCEDURE|Acute normovolemic hemodilution (ANH)|
223770290|NCT02831270|DRUG|hydroxyethyl starch (HES 130/0.6)|
223770291|NCT03090256|DEVICE|AcrySof® IQ PanOptix™ IOL|Multifocal intraocular lens (IOL) (near, intermediate, distance) implanted for long-term use over the lifetime of the cataract patient
223770292|NCT01813565|DRUG|Hyaluronic acid/chondroitin sulfate|Additional Hyaluronic acid/chondroitin sulfate instillation to the bladder
223770293|NCT04001153|OTHER|Dental impressions|"Children will be included in this study if they already are treatment planned to receive a Hall Technique preformed metal crown (HTPMC) to manage carious lesions in primary molars. They will have a dental impression taken before and after the HTPMC placement to find out what happens with their bite after the treatment.~The dental impressions will be cast up into stone study models so that we can track the changes that happens in children's bites after placing the HTPMC (as it increases the height of children's bite when placed) and let them know what to expect after this procedure and as part of this study, additional follow-ups will be required 2, 4, 6 and 8 weeks after the HTPMC placement to allow us to track the changes in the bite at regular intervals to see when the child's bite returns to its pre-treatment state."
223664413|NCT04043624|DRUG|Lidocaine|regimen of lidocaine administration of 1.5 mg/kg, IV bolus, followed by continuous infusion at 2 mg/kg/h
224244171|NCT03206619|OTHER|Social, Local and Mobile|Patients in a smoking cessation program will use a mobile application to receive messages and rate them from their smartphones. The messages patient will receive belong to one of the following five topics: general motivation, diet tips, physical exercise tips, personal performance, and the benefits of being a non-smoker. For each one of these topics, there will be a pool of 150 different messages with tailored information for the patient. Topics and messages were approved by a smoking cessation psychologist and a pulmonologist. The selection of the time the messages have to be sent, and the message topic is selected by an health recommender system algorithm based on the patients' user profile (demographic information, message rating information, and app interaction information).
223664414|NCT04043624|DRUG|Saline|IV bolus of saline, followed by continuous infusion of saline
223664415|NCT01263912|DIETARY_SUPPLEMENT|LCPUFA Supplement|Children 12-13 months old will be assigned at random to receive either a nutrition supplement containing LCPUFA or a placebo until 24 months-of-age
223664416|NCT01263912|DIETARY_SUPPLEMENT|Placebo|Children 12-13 months old will be assigned at random to receive either a nutrition supplement containing LCPUFA or a placebo until 24 months-of-age
223664417|NCT04868630|DEVICE|Pulsewave Health Monitor (PAD-2A) Device|This is an observational study of the average breathing rate measurement of a non-invasive wrist cuff device. The purpose of this study is to calibrate the average breathing rate measurement of the Pulsewave Health Monitor (PAD-2A) wrist cuff device with the breathing rate measurement of a standard clinical capnography device. Additionally, we will also compare the average breathing rate measurement of the capnography device with other standard clinical respiratory devices (i.e. nasal pressure transducer, thermistor, and respiratory inductance plethysmography (RIP) belts of the chest and abdomen).
224244172|NCT00054106|DRUG|buserelin|
224244173|NCT00054106|DRUG|custirsen sodium|
223664418|NCT03787381|DEVICE|Ultrasound|Vaginal ultrasound examination
224244174|NCT00054106|DRUG|flutamide|
224244175|NCT00054106|PROCEDURE|conventional surgery|
224244176|NCT00054106|PROCEDURE|neoadjuvant therapy|
224244177|NCT04734288|DIETARY_SUPPLEMENT|Vit.D3 5000 IU, Immune Active|"The subjects will receive monthly (for either 3 or 6 months):~1. Vit.D3 5000 and Immune Active. The first phase includes 3 months of treatment and the second phase includes 6 months of treatment.~2. An in-home Vit.D/ hs-CRP test kit and asked to self-administer a blood collection via fingerstick and return the kits for analysis within a few days.~3. Two online questionnaires each month and asked to fill them out within a few days. It will either be the Medical Outcomes Study (MOS) Short Form (SF)-36 and the Health Status Baseline or Health Status Follow-up Questionnaire."
224244178|NCT05493930|OTHER|The hospital where the treatment is performed|
224244179|NCT03168633|BEHAVIORAL|web-based DM2 information pages|"Each email will include information on one of the following topics:~1. The importance of physical activity~2. Correct nutrition~3. The importance of adhering to medication regimens.~Emails will be either positive (e.g., the importance of good nutrition, and what constitutes good nutrition) or negative (e.g., the risks of not adhering to medications).~The information will be provided by different approaches: medical research results, practical tips, patient testimonies.…"
223664419|NCT00353470|BEHAVIORAL|Cognitive behavioral therapy|CBT for panic disorder will include 19 to 24 sessions over 12 weeks.
223664420|NCT00353470|BEHAVIORAL|Applied relaxation training (ART)|ART with exposure protocol will include 19 to 24 sessions over 12 weeks.
223664421|NCT00353470|BEHAVIORAL|Panic focused psychodynamic psychotherapy (PFPP)|PFPP will include 19 to 24 sessions over 12 weeks.
223664422|NCT00083252|DRUG|talabostat (PT-100) tablets|
223664423|NCT00083252|DRUG|cisplatin|
223664424|NCT02604121|DEVICE|Orcellex® Rovers brush|transepithelial brushing
223664425|NCT05449483|DRUG|tislelizumab+ Paclitaxel + Cisplatin|tislelizumab combined with chemotherapy
223664426|NCT04507373|DRUG|Simvastatin 40mg|40mg oral daily for 10 weeks
223664427|NCT04613778|PROCEDURE|Laser acupuncture|Laser acupuncture is a low-level laser technique with no invasive procedure
223664428|NCT00409331|DRUG|Amifostine|500 mg in two divided doses subcutaneously given 30-60 minutes prior to IMRT.
223664429|NCT00409331|PROCEDURE|Intensity- Modulated Radiation Therapy|2.0 to 2.2 Gy delivered in 30 fractions
223664430|NCT02565134|DRUG|PAC-14028 cream 0.1%|Topical application
223664431|NCT02565134|DRUG|PAC-14028 cream 0.3%|Topical application
223664432|NCT02565134|DRUG|PAC-14028 cream 1.0%|Topical application
223664433|NCT02565134|DRUG|PAC-14028 cream vehicle|Topical application
223664434|NCT04443595|PROCEDURE|Dual-scopic pancreatic necrosectomy（DPN）|Treatment of Acute Severe Pancreatitis with DPN
223664435|NCT01546272|DEVICE|Insorb resorbable staples|Subcutanous suture using resorbable staples
223664436|NCT01546272|DEVICE|Monocryl resorbable wire|Subcutanous suture using resorbable wire
224244180|NCT03832257|OTHER|ECHO CT Intervention|weekly video conference between hospitalist and skilled nursing facilities
224244181|NCT03832257|OTHER|Matched Non-Participating Facilities|Matched Non-Participating Facilities
224244182|NCT02342054|RADIATION|MRI-TRUS fusion guided Single Frac HDR|
224244183|NCT01114022|DEVICE|Experimental 1|oeso pharyngeal device
224244184|NCT01114022|DEVICE|Experimental|oeso pharyngeal device
223664437|NCT05951465|DRUG|Esketamine|esketamine dose will be 0.3 mg/kg. Propofol dose for the first patient will be 2.5 mg/kg. Doses for the subsequent patients will increase or decrease by 0.8 mg/kg using the Dixon Up and Down method.
223664438|NCT05951465|DRUG|Esketamine|esketamine dose will be 0.6 mg/kg. Propofol dose for the first patient will be 2.0 mg/kg. Doses for the subsequent patients will increase or decrease by 0.4 mg/kg using the Dixon Up and Down method.
223664439|NCT05951465|DRUG|Propofol|propofol
223664440|NCT03989869|OTHER|Immediate treatment|Early Medical Abortion treatment, when ultrasound does not yet have conclusive signs of intrauterine pregnancy
224244185|NCT01114022|DEVICE|experimental 3|oeso pharyngeal device
224244186|NCT01114022|DEVICE|Active comparator|oeso pharyngeal device
224244187|NCT02378571|BEHAVIORAL|Medication adherence telemonitoring|The member of the study team will respond to adherence data using clinical judgment as they would if the information was obtained during clinical care. Specifically, when contacting nonadherent participants, the member of the study team will provide participants with feedback on their electronic adherence; will inquire about potential consequences of missed doses; and will assess and respond to reasons for missed doses.
223664441|NCT03712007|DEVICE|MAMP therapy with MARPE expander|Twenty patients will be submitted to MAMP therapy with MARPE expander as anchorage in the maxillary arch. The appliance anchorage will be provided by bands adapted on the maxillary first permanent molars and circumferential clamps in the maxillary canines or premolars. The maxillary and mandibular miniscrews will be placed in the same section. After a 24-hour period, parents will be oriented to activate the expander screw. Patients will be instructed to wear intermaxillary elastics connecting the maxillary first molar hooks to the mandibular mini-implants.
223664442|NCT03712007|DEVICE|MAMP therapy with Hyrax expander|Fifteen patients will be submitted to MAMP therapy with Hyrax expander as anchorage in the maxillary arch. The appliance anchorage will be provided by bands adapted on the maxillary first permanent molars and circumferential clamps in the maxillary canines or premolars. The mandibular miniscrews will be placed and after a 24-hour period, parents will be oriented to activate the expander screw. Patients will be instructed to wear intermaxillary elastics connecting the maxillary first molar hooks and the mandibular mini-implants.
223664443|NCT02793856|DRUG|Cyclophosphamide|To deplete Tregs before collecting peripheral blood
223664444|NCT02793856|OTHER|PD-1 Knockout T Cells|Autologous lymphocytes are collected and PDCD1 gene is knocked out in the laboratory. Cells are selected and expanded ex vivo. Cells are infused back to the patients for treatment
223664445|NCT04259723|OTHER|VR during TAVI|Virtual Reality (VR) glasses
223664446|NCT01511055|DRUG|EC-17|One-time dose of Folate-FITC (EC-17), 0.1mg/kg IV 2-3 hours prior to surgery.
223664447|NCT03487692|OTHER|Diabetes MESSAGES Program|Health centers in the 2018 Training Cohort will enroll groups of 10-15 patients to attend 6 monthly diabetes group visits consisting of group education, social support, goal setting, and an individual medical visit for each patient. At the same time, patients will be enrolled in a 6-month interactive diabetes text messaging program. Patients will receive quarterly booster sessions for 1-2 years after the 6-month intervention period.
223664448|NCT03487692|OTHER|Diabetes MESSAGES Program (second trial)|During the first trial period, health centers in the 2020 Training Cohort will collect data on patients receiving usual care. After the first trial period, health centers in the 2020 Training Cohort will enroll groups of 10-15 patients to attend 6 monthly diabetes group visits consisting of group education, social support, goal setting, and an individual medical visit for each patient. At the same time, patients will be enrolled in a 6-month interactive diabetes text messaging program. Patients will receive quarterly booster sessions for 1-2 years after the 6-month intervention period.
223664449|NCT02298335|DRUG|prednisone|Full-dose induction period: Prednisone 1mg/kg.day, maximum 60mg/day, orally, divided into 3 times; Protracted tapering period: orally, no ask for fract. dos.
224244188|NCT01054027|DRUG|1% phenylephrine and 0.2% cyclopentolate|given as drops, prior to eye exam
224244189|NCT01194492|RADIATION|Albumin transcapillary escape rate (125I-albumin)|Repeated measure by injection of 0.1 megabecquerel and 0.3 megabecquerel of 125-iodine labeled albumin before surgery and 2 days after surgery, respectively.
224244190|NCT00254644|PROCEDURE|Morphological and functional MRI|one time
224244191|NCT04881968|BEHAVIORAL|Hopewell Hospitalist Video Game|Hopewell Hospitalist is a customized theory-based adventure video game that uses narrative engagement to educate physician players on advance care planning to increase physicians' likelihood of engaging in and billing for ACP conversations.
224244192|NCT04067180|OTHER|allogeneic stem cell transplantation with a haplo-identical family donor graft|"The graft should preferably be bone marrow, but peripheral stem cells are also acceptable.~Pre-conditioning: thiotepa 5 mg/kg/day for two days (day -6, -5), busulfan at 3,2 mg/kg/day (i.v.) and fludarabine at 50 mg/m2 (i.v.) for three consecutive days (day -4, -3, -2). Intravenous busulfan can be replaced by orally administered busulfan at a dose of 4 mg/kg/day on 3 consecutive days (day -4, -3, -2).~GVHD prophylaxis: cyclophosphamide 50 mg/kg day +3 and +5, cyclosporin A and mycophenolate mofetil."
224244193|NCT04067180|OTHER|allogeneic stem cell transplantation with a matched unrelated donor graft|"Patients are treated according to the standard conditioning protocols developed for URD SCT at each participating center, with a recommendation to use Flu+Bu (fludarabine + busulfan, with a total Bu dose of 8-16 mg/kg body weight orally, or 6,4-12,8 mg/kg i.v.) or Bu+Cy (busulfan + cyclophosphamide, with a dose of Cy not exceeding 50 mg/kg x 2).~The standard GVHD prophylaxis at the center should be applied."
224244194|NCT01589783|OTHER|completion of a questionnaire|Completion of a questionnaire
224244195|NCT01589783|OTHER|Blood draw|A subset of 100 women will have a blood test to measure Vitamin D levels
224244196|NCT00304083|BIOLOGICAL|filgrastim|Given subcutaneously
224244197|NCT00304083|DRUG|doxorubicin hydrochloride|Given IV
224244198|NCT00304083|DRUG|etoposide|Given IV
224244199|NCT00304083|DRUG|ifosfamide|Given IV
224244200|NCT00304083|PROCEDURE|conventional surgery|Patients undergo surgery
224244201|NCT00304083|RADIATION|radiation therapy|Patients undergo radiotherapy
224244202|NCT05292651|PROCEDURE|PCI|percutaneous coronary intervention
224244203|NCT02144753|DIETARY_SUPPLEMENT|NTX-1|Investigational NTX-1 fiber to be taken as three (6g each) packets of the fiber per day, one 8g packet in the morning (one hour before eating breakfast) and the other two 8g packets in the afternoon and evening.Fasting required for the morning dose and recommended with afternoon and evening dose.
224244204|NCT02144753|DRUG|psyllium (15 g)|Psyllium (an over-the-counter fiber) to be taken as three (5g each) packets of the fiber per day, one 5g packet in the morning (one hour before eating breakfast) and the other two 5g packets in the afternoon and evening.Fasting required for the morning dose and recommended with afternoon and evening dose.
224244205|NCT00715702|DRUG|AZD5672|100 mg oral single dose
224244206|NCT02287675|DRUG|Lymphoseek|Subjects will receive a single intradermal injection of Lymphoseek followed by SPECT imaging conducted in two phases: initial sequential planar imaging at 30 to 60 second intervals for the first 60 minutes and repeated at 90 minutes and 120 minutes, as indicated, for identification of the SLN followed by SPECT/CT for higher resolution imaging in transaxial, coronal, and sagittal planes. Subjects will then proceed to surgery for lymphatic mapping. Lymphoseek positivity will be based upon radioactivity counts derived from the application of the handheld gamma probe ex vivo. Tumor resection or mastectomy will be performed according to standard procedures.
223664450|NCT00830869|DRUG|IXAZOMIB|"All participants will receive IXAZOMIB IV injection on Days 1, 4, 8, and 11 of each treatment cycle followed by a rest period of 10 days.~The first stage of the study will be initiated at a starting dose of 0.125 mg/m\^2. Subsequent doses will increase until a maximum tolerated dose (MTD) is established."
224244207|NCT02287675|DRUG|Sulfur Colloid|Subjects will receive a single intradermal injection of 99mTc-SC followed by SPECT imaging conducted in two phases: initial sequential planar imaging at 30 to 60 second intervals for the first 60 minutes and repeated at 90 minutes and 120 minutes, as indicated, for identification of the SLN followed by SPECT/CT for higher resolution imaging in transaxial, coronal, and sagittal planes. Subjects will then proceed to surgery for lymphatic mapping. 99mTc-SC positivity will be based upon radioactivity counts derived from the application of the handheld gamma probe ex vivo. Tumor resection or mastectomy will be performed according to standard procedures.
224244208|NCT01134848|DRUG|Morphine|10mg IM
224244209|NCT01134848|DRUG|Neostigmine|1mg IM
224244210|NCT01134848|DRUG|0.9% saline|0.1 ml/kg
224244211|NCT01134848|DRUG|Secretin|1 unit/kg IV
224244212|NCT01134848|DRUG|0.9% saline|1ml IM
224244213|NCT05470972|DRUG|Ethanol Injection|The AEST procedure was performed as follows: vaginal walls were cleansed using vaginal povidone-iodine, a 17 gauge, 30-cm length needle was inserted through the posterior vaginal fornix into the pouch of Douglas, and the cyst was aspirated till complete disappearance of the cyst on the ultrasound scanner. The collected cystic fluid was collected into a plastic tube without an anticoagulant. The needle was maintained in its place, the syringe was removed and the cyst was flushed with saline solution until obtaining a clear liquid. Then, 96% ethanol was injected as 60% of the volume of the aspirated fluid to guard against over distension or rupture of the cyst and/or ethanol diffusion into the pelvis. The collected fluid was divided into three sterile tubes for cytological and bacteriological examinations and the study investigations. Patients were allowed to be completely recovered and were discharged home.
224244214|NCT06035315|DIETARY_SUPPLEMENT|Multiple Micronutrients during pregnancy|Pregnant women examine since 8 weeks gestation are being followed until delivery; are given additional micronutrients (Complete multi micronutrients-Calcium-Vitamin D-DHA); and perform ultrasound examinations each trimester and additional laboratory examination (Vitamin D level-Lipid profile-Zinc)
223664451|NCT06255366|DRUG|Caroxime sodium sulfonate|Five minutes before surgery, intravenous infusion of caroxime sodium sulfonate and sodium chloride injection 100ml (80mg) (trade name: Weiluojing, 100ml, containing caroxime sodium sulfonate 80mg and sodium chloride 0.9g, Chongqing Dikang Changjiang Pharmaceutical Co., LTD.) was given, and intravenous infusion of caroxime sodium sulfonate and sodium chloride injection 100ml (80mg) was given again 1 hour after surgery.
223664452|NCT06255366|DRUG|Desmopressin|Intravenous infusion of desmopressin injection 4ug (Shenzhen Hanyu) +0.9% sodium chloride injection 100ml was given 5 minutes before surgery, and intravenous infusion of desmopressin injection 4ug (Shenzhen Hanyu) +0.9% sodium chloride injection 100ml was given again 1 hour after surgery
223664453|NCT06255366|DRUG|0.9% Sodium Chloride Injection|Intravenous infusion of 0.9% sodium chloride injection 100ml (specification 100ml, containing 0.9g sodium chloride, Sichuan Kelun Pharmaceutical Co., LTD.) was given 5 minutes before surgery, and intravenous infusion of 0.9% sodium chloride injection 100ml was given again 1 hour after surgery
223664454|NCT05150639|OTHER|IVF|Women planning to undergo frozen embryo transfer IVF procedure will be included. Samples will be obtained, but no study intervention will be applied. Pregnancy outcome data will be obtained, following frozen embryo transfer, to correlate against other data from samples (vaginal microbiome etc).
223664455|NCT01767831|BEHAVIORAL|iBOLUSED|The intervention will involve daily diary data upload and daily simulation-based feedback based on the collected diary data. Throughout the educational intervention, participants will record diary data every day through the use of a diary component in the internet-based system. Diary entries include data on meals, physical activity, history of the insulin basal rate and insulin boluses given that day, self-reported stress level, hypo- and hyperglycemic fear levels, and, if applicable, menstrual cycle and any physical illness. Participants will also upload data from the CGM via the Dexcom DM3 software or the Dexcom Studio Software.
223770294|NCT05447949|PROCEDURE|Adjuncts to levobupivacaine in Erector Spinae Plane Block|The block level will be at T5 with the patient in a sitting position and full aseptic precautions. T5 transverse process; these are recognizable as flat, squared-off acoustic shadows with only a very faint image of the pleura visible. In a longitudinal US view, in which the following layers will be visible superficial to the transverse processes: skin, subcutaneous tissue, trapezius, erector spinae muscle . Skin is topicalized, then echogenic block needle inserted in plane to the ultrasound beam in a cranial-to-caudal direction until contact is made with the T5 transverse process. After aspiration; to avoid intravascular injection, 30 ml of injectate is injected and separation will be seen. 6-13-MHz, linear transducer set for small parts and a depth of 4-6 cm will be used (18-19).
223770295|NCT01126164|BEHAVIORAL|Parent Handbook and Peer Basics|Parent and Peer delivered interventions
224244215|NCT03961425|BEHAVIORAL|NO CO2|Traditional mechanical Deairing
224244216|NCT03961425|DEVICE|CO2 Cannula|NON specific, low cost delivery system
224244217|NCT03961425|DEVICE|CO2 Cardia|Specific Commercial CO2 Diffuser
224244218|NCT03966365|DRUG|PRO-122|"* PRO-122. Timolol 0.5% / brimonidine 0.2% / dorzolamide 2% ophthalmic solution free of preservatives. Prepared by Sophia Laboratories, S.A. of C.V., Zapopan, Jalisco, Mexico.~* Route of administration: topical ophthalmic."
224244219|NCT03966365|DRUG|Krytantek Ofteno®|"* \- 1. Krytantek Ofteno®. Timolol 0.5% / brimonidine 0.2% / dorzolamide 2% ophthalmic solution. Prepared by Sophia Laboratories, S.A. of C.V., Zapopan, Jalisco, Mexico.~* \- Route of administration: topical ophthalmic."
224244220|NCT03227497|DIETARY_SUPPLEMENT|Whole Walnuts|Intervention arm includes whole walnuts taken as dietary replacement meal during the day, and between breakfast and lunch, and/or lunch and dinner. Importantly, none of the main meals, including breakfast, lunch and dinner are to be replaced by study intervention, and the study subjects are instructed to do so. Walnuts are provided with the same producer at the Belgrade market.
223664456|NCT00617669|DRUG|Docetaxel|intravenous infusion given every three weeks
223664457|NCT00617669|DRUG|ZD4054|10 mg oral once daily dose
223664458|NCT00617669|DRUG|Placebo|placebo oral tablet once daily
223664459|NCT04704804|DIAGNOSTIC_TEST|Synthetic CT Scan|method of generating CT-synthetic image from MRI
223664460|NCT01185431|DIETARY_SUPPLEMENT|Ficus carica (Fig paste)|Ficus carica paste 300g/day
223664461|NCT01185431|DIETARY_SUPPLEMENT|Placebo (Placebo paste)|Placebo composition 300g/day
223664462|NCT05184439|PROCEDURE|Adductor magnus tenodesis for recurrent patellar dislocation|In all 33 patients (39 knees) adductor magnus tenodesis was performed to stabilise the patella. Adductor magnus tendon was harvested, cut proximally and fixed to the patella with proper tension.
223664463|NCT02889744|DEVICE|Arctic Sun|Targeted temperature management for 24 hours with core temperature 36℃ or 33℃
223664464|NCT03283410|DRUG|Propofol|Propofol plasmatic concentration (Marsh)
223664465|NCT02210598|DEVICE|inpatient Foley balloon induction|The catheter will be left in place and IV oxytocin will be started per LAC+USC protocol. The foley catheter will be removed after 12 hours if not spontaneously extruded.
223664466|NCT02210598|DEVICE|outpatient Foley balloon induction|The catheter will be deflated and removed within 10 minutes of placement. The patient will then undergo a non-stress test (NST). If the patient has a reactive NST with no late or variable decelerations or uterine tachysystole, the patient will be discharged home with clear return precautions and instructions to return to the triage area in 24 hours.
223664467|NCT02210598|DRUG|Oxytocin|"When a patient randomized to the outpatient Foley Balloon induction group returns to the hospital, a sterile vaginal exam will be done and Bishop score documented. The patient will then be admitted to L\&D for inpatient continuation of induction with IV oxytocin per LAC+USC protocol.~Patients randomized to the inpatient Foley balloon induction group will have IV oxytocin initiated per LAC+USC protocol at the time of Foley balloon placement."
223664468|NCT05477472|DRUG|St John's Wort|daily intake of CERES St John's Wort mother tincture. Dose according to the treating physician.
224244221|NCT02578953|DRUG|Dutasteride-Test product|Dutasteride Capsules are oblong, opaque, dull-yellow, gelatin capsules. The capsules contain 0.5 mg dutasteride for oral administration. The capsules also contain Butylated Hydroxytoluene, Mono-di-glycerides of Caprylic/Capric Acid (MDC), Gelatin, Concentrated Glycerin, Titanium Dioxide, Iron Oxide Yellow as ingredients. This product will be manufactured by GSK, Poznan.
224244222|NCT02578953|DRUG|Dutasteride-Reference product|Dutasteride Capsules are oblong, opaque, dull-yellow, gelatin capsules. The capsules contain 0.5 mg dutasteride for oral administration. The capsules also contain Butylated Hydroxytoluene, Mono-di-glycerides of Caprylic/Capric Acid (MDC), Gelatin, Glycerin, Concentrated Glycerin, Titanium Dioxide, Iron Oxide Yellow as ingredients. This product will be manufactured by Catalent, Beinheim.
224244223|NCT01044732|DEVICE|Third Eye Retroscope|Device used with colonoscope to provide second, retrograde view of the colon
224244224|NCT03918278|BIOLOGICAL|MK-0482|IV infusion
224244225|NCT03918278|BIOLOGICAL|pembrolizumab|IV infusion
224244226|NCT03918278|DRUG|Paclitaxel|IV infusion
224244227|NCT03918278|DRUG|Nab-paclitaxel|IV infusion
224244228|NCT03918278|DRUG|Gemcitabine|IV infusion
224244229|NCT03918278|DRUG|Carboplatin|IV infusion
224244230|NCT03918278|DRUG|Pemetrexed|IV infusion
224244231|NCT06252025|COMBINATION_PRODUCT|Memo-gration|This study tailored a variety of instructional material within each virtual scenario, taking into account various memory triggers. Guidance is activated when the user is identified as making physical contact with an object or discussing a specific keyword. This encompasses textual assistance provided within the virtual environment, the display of multimedia information, and the provision of organized voice guidance. Following the system's instructions, users engaged in discussion with the caregiver, and had the freedom to terminate the conversation at their discretion and explore other topics by interacting with different items.
224244232|NCT06252025|OTHER|Picture reminiscence therapy|Picture reminiscence therapy
224244233|NCT00769041|DRUG|moxifloxacin|400mg
224244234|NCT00769041|DRUG|avanafil|100mg single dose
224244235|NCT00769041|DRUG|avanafil|800mg single dose
224244236|NCT00769041|DRUG|sugar pill|single dose
223664469|NCT00972647|PROCEDURE|Laser beam guidance|Using the laser centralizing beam to assist in position the body part prior to fluoroscopic imaging
223664470|NCT05184751|OTHER|colonoscopy|
224244237|NCT02123979|DRUG|Neupro® transdermal patch/placebo|8mg transdermal patch Neupro® transdermal patch/placebo
224244238|NCT04137211|BEHAVIORAL|Prolonged sitting with social break|Participants are required to sit for three hours (reading is permitted), with a toilet break in between. Every thirty minutes participants will have a short social break. Test day begins at 7:30 with pretest measures, followed by the intervention at about 9:00, which will end around 12:00, with subsequent posttest measures.
224244239|NCT04137211|BEHAVIORAL|Prolonged sitting with walk break|Participants are required to sit for three hours (reading is permitted), with a toilet break in between. Every thirty minutes participants will have a physical activity break, where they will perform a brisk walk for about three minutes on a treadmill at a predetermined speed and grade based on the fitness test performed during the familiarization session. Test day begins at 7:30 with pretest measures, followed by the intervention at about 9:00, which will end around 12:00, with subsequent posttest measures.
223664471|NCT00690261|OTHER||No intervention in this study
223664472|NCT03674931|BEHAVIORAL|musical practice|Intensive weekly musical keyboard training over 12 months
223664473|NCT03674931|BEHAVIORAL|music education|Recreative weekly musical courses without practice over 12 months
223664474|NCT02697669|OTHER|18F-FDG PET|Imaging
223664475|NCT03745820|DRUG|BIIB104|Administered as specified in the treatment arm
223664476|NCT03745820|OTHER|Placebo|Administered as specified in the treatment arm
223664477|NCT04829578|OTHER|Hypnosis|Chronic idiopathic pruritus is treated by hypnosis
224244240|NCT04137211|BEHAVIORAL|Prolonged sitting with simple resistance activities|Participants are required to sit for three hours (reading is permitted), with a toilet break in between. Every thirty minutes participants will have a physical activity break, where they will perform simple resistance activities following a video for about three minutes. Test day begins at 7:30 with pretest measures, followed by the intervention at about 9:00, which will end around 12:00, with subsequent posttest measures.
224244241|NCT00003961|BIOLOGICAL|sargramostim|
224244242|NCT04510077|BEHAVIORAL|SmartQuit Smoking and Tobacco Cessation Program|Use SmartQuit program
224244243|NCT04510077|OTHER|Survey Administration|Ancillary studies
224244244|NCT00081783|DRUG|Xcellerated T Cells|
224244245|NCT03455348|OTHER|catheter insertion|catheter insertion one to less than 4 four centimeters to the wrist joint (Group A) and the other, to more than four centimeters to the wrist joint. (Group B)
223770296|NCT04288622|OTHER|Weekly standardised, personalised feedback|The ESM-F group will receive standardised ESM-derived feedback immediately followed the weekly ESM data collection procedure, totalling 6 times in the entire intervention period. The feedback will be provided by the researcher in the format of written report and verbal explanation. The feedback on participants' momentary affective state in specific daily life contexts and the association with depressive symptoms will be given. The changes in positive affect level and the number of depressive complaints over the course of the ESM intervention will be shown.
224244246|NCT00258947|BIOLOGICAL|Smallpox vaccine, LISTER strain, from chick embryo cells|
224244247|NCT00899028|GENETIC|comparative genomic hybridization|
224244248|NCT00899028|GENETIC|fluorescence in situ hybridization|
224244249|NCT00899028|GENETIC|gene expression analysis|
224244250|NCT00899028|GENETIC|microarray analysis|
224244251|NCT00899028|GENETIC|protein expression analysis|
224244252|NCT00899028|OTHER|immunohistochemistry staining method|
224244253|NCT00899028|OTHER|laboratory biomarker analysis|
224321643|NCT03252743|BEHAVIORAL|Exposure-based internet-delivered CBT|"The main target in treatment is exposure for abdominal symptoms by reducing avoidance and provoking symptoms. Participants are encouraged to gradually increase the difficulty by combining multiple challenges.~The parents are taught how to reduce the risk for reinforcement of children's symptom behavior, and to support their child to complete the treatment.~All treatment content is delivered over the internet, containing texts, videos, audio-files and examples. The modules are unlocked sequentially as participants worked their way through the treatment.~Therapist support consists primarily of encouragement of any progress made in the treatment and support to find individual exercises."
223664478|NCT06484205|OTHER|WHO QualityRights e-training|WHO QualityRights training provides the necessary skills to support people with psychosocial disabilities in advocating for their rights. The QualityRights online course includes six main modules: 1) Human Rights; 2) Human rights, mental health and disability; 3) Legal capacity and the right to decide; 4) Stop coercion, violence and mistreatment; 5) Quality services and inclusion in the community; 6) Mental health, well-being and recovery and it will take approximately 8 hours for completion. QualityRights course modules can be completed at each participant's pace and needs. The training is considered concluded once the quizzes provided at the end of each of the six modules have been successfully completed and upon completion of the course it will be possible to download your official WHO certificate from the QR platform.
223770297|NCT03212963|DRUG|Halobetasol Topical Lotion|Halobetasol Lotion 0.05%, applied twice daily in subjects aged 12 to 16 years 11 months with stable plaque psoriasis.
223770298|NCT03555526|DRUG|Esomeprazole 40mg|Nexium (esomeprazole), 40mg, bid, for 14 days
224244254|NCT00899028|OTHER|matrix-assisted laser desorption/ionization time of flight mass spectrometry|
224244255|NCT00899028|OTHER|medical chart review|
224244256|NCT00899028|PROCEDURE|diagnostic bronchoscopy|
224244257|NCT01569152|DRUG|MK-8457 100 mg|MK-8457 100 mg dosed orally BID
224244258|NCT01569152|DRUG|Dose-Matched Placebo|Dose-matched placebo dosed orally BID
224244259|NCT01569152|DRUG|Methotrexate|MTX dosed at the stable dose receive upon study entry
224244260|NCT05324982|DRUG|Oral Placebo|Placebo will be orally self-administered by study participants.
224244261|NCT05324982|DRUG|Oral CBG Cannabis|CBG cannabis oil will be orally self-administered by study participants.
224244262|NCT06246032|OTHER|Modified feeding Protocol|"Initiation of feeding (fixed): 10cc/kg~Advancement based on birthweight (fixed):~\<750g: 15cc/kg/d 750-999g: 20cc/kg/d 1000-1249g: 25cc/kg/d 1250-1499g: 25cc/kg/d 1500-1749g: 35cc/kg/d 1750-2000g: 35cc/kg/d~Starting Human milk fortification when feed reach at 70cc/kg/d"
224244263|NCT00059865|DRUG|gemcitabine hydrochloride|
224244264|NCT00059865|DRUG|pemetrexed disodium|
224244265|NCT06992674|DRUG|Rimegepant|Take 75mg qd of oral sulfate remigipan orally disintegrating tablets
224244266|NCT06992674|DRUG|Placebo|Take 75mg qd of placebo
224244267|NCT04698668|DEVICE|fusion imaging|To drain a pancreatic fluid collection through the assitance of the CT-scan image that is superimposed on the radiological field
224244268|NCT01523899|DEVICE|Xpert MRSA/SA SSTI|Use of Xpert MRSA/SA SSTI assay
224244269|NCT01523899|DIAGNOSTIC_TEST|Standard culture|
224244270|NCT05666349|DRUG|Niraparib|100 mg, 200 mg, or 300mg oral niraparib once daily.
224244271|NCT05666349|RADIATION|Re-irradiation (re-RT)|Intensity modulated radiotherapy (IMRT)-based re-RT for a total dose of 35 Gy in 10 daily fractions.
224244272|NCT05451836|OTHER|Patient education leaflets|Patients who attend the emergency department with upper respiratory tract infections will be provided with patient education leaflets on appropriate antibiotic use and antimicrobial resistance. The leaflets are available in the four national languages in Singapore.
224244273|NCT05451836|OTHER|Physician feedback|All physicians working in the emergency department will receive a text message from their department head on their antibiotic prescribing rates every two months.
224244274|NCT05069636|OTHER|Lymphatic OMM|Patients receive lymphatic myofascial release and thoracic pump techniques.
224244275|NCT05069636|OTHER|Light Touch|Patients receive a series of light touch techniques.
224244276|NCT02126306|DRUG|Beta Glucosylceramide|Beta Glucosylceramide
224244277|NCT02126306|DRUG|Placebo|normal saline
224244278|NCT05412732|OTHER|prospective biomedical research study|A prospective biomedical study, in which a comparison will be made of the outcome of a specific disease (in this case, AMI).
224244279|NCT05411809|DRUG|drug adjuvant therapy|The adjuvant treatment regimens depend on the judgment of oncology physicians according to pathological type, molecular characteristics and other details of the tumor.
224244280|NCT00824265|DRUG|OFC Infusion|Ofatumumab Cycle 1-Day 1 300mg, Cycle 1-Day 8 1000mg, then Cycles 2-6 Day 1 1000mg every 28 days, Fludarabine 25mg/m2 Days 1-3 every 28 days for 6 cycles, Cyclophosphamide 250 mg/m2 Days 1-3 every 28 days for 6 cycles
224321644|NCT02310256|OTHER|Five plus exercise training|calf raise exercise
223664479|NCT06484205|OTHER|Emotional intelligence e-training|This course offers caregivers resources and knowledge so that they are able to manage their emotions and gain quality in the care they provide to others and in their own lives. The course duration is similar to that of the QualityRights online course and is intended for caregivers of people with disabilities and others interested
224244281|NCT00824265|DRUG|FC infusion|Fludarabine 25mg/m2 Days 1-3 every 28 days for 6 cycles, Cyclophosphamide 250mg/m2 Days 1-3 every 28 days for 6 cycles
224244282|NCT04752748|DRUG|Drug protocol|"The following drug scheme was carried out: The patients began with methotrexate (MTX) 15 mg / week, which was increased to 25 mg / week until week 12. Subsequent steps for patients with an insufficient response (DAS28 score\> 3.2 and the Physician's Global Assessment (PGA)\> 4.0 \[0-10 cm\]) were leflunomide 20mg / day with MTX 15 mg / week from week 12 to week 24 and adalimumab twice a month and MTX 15mg / week from week 24 to week 48. The use of 5mg folic acid was advised once a week during the 48 weeks of the study. Three treatment failures were considered over these 48 weeks:~* Failure 1: failure of the first DMARD (MTX) in week 12.~* Failure 2: failure of the second DMARD (leflunomide) at week 24~* Failure 3: failure of the first immunobiological (adalimumab) at week 48."
224244283|NCT05249413|PROCEDURE|Early 23-gauge pars-plana vitrectomy|pars-plana vitrectomy for management of acute post-operative endophthalmitis.
224244284|NCT01624220|RADIATION|Spinal SBRT (Standard Dose)|Group 1 and 2: Standard doses of radiation therapy to the normal esophagus while treating the tumor. Up to 2 groups of 10 participants enrolled.
223664480|NCT03960450|DRUG|BOS-475|topical cream
223664481|NCT03960450|DRUG|Vehicle|topical cream
223664482|NCT05512468|DRUG|carbon dye|Tattooing (marking) of biopsied node with carbon dye at the time or at a separate session of fine needle aspiration or core biopsy or separate visit under ultrasound guidance. The dye will be injected in the cortex of the node and the perinodal tissue under ultrasound guidance. Patients will undergo standard (routine) armpit surgery and may receive neoadjuvant chemotherapy as planned by the clinical team. This could be removal of a few lymph glands (sentinel node biopsy) or removal of all the lymph glands (axillary lymph node dissection) in the armpit. The surgeon will try to identify and remove the tattooed lymph gland at the time of planned armpit surgery.
223664483|NCT05657522|DEVICE|Rapid molar intruder|The rapid molar intruder was applied.
223664484|NCT01528865|DRUG|Lamivudine|"Creatinine Clearance (mL/min): ≥50, Recommended Dosage of Epivir: 150 mg twice daily or 300 mg once daily.~Creatinine Clearance (mL/min): 30-49, Recommended Dosage of Epivir: 150 mg once daily.~Subjects will be taking drug for 16 weeks."
224244285|NCT01624220|RADIATION|Spinal SBRT (Higher Dose)|Group 3 and 4: Higher dose of radiation to esophagus than group before it, if no intolerable side effects were seen. 2 groups of 10 participants enrolled in the second part of study. Only participants who will receive a single spinal SBRT treatment are eligible for second part of study.
224244286|NCT01624220|PROCEDURE|Gold Seed Implantation|4 gold seeds implanted into bones of spine: 2 gold seeds above and 2 gold seeds below the area of tumor to be treated.
223664485|NCT01528865|DRUG|Tenofovir disoproxil fumarate|300 mg once a day p.o. for 16 weeks.
223664486|NCT03878693|DRUG|Fomepizole|IV 4-MP.
223664487|NCT03878693|DRUG|APAP|Oral APAP
223664488|NCT00507728|DRUG|Bupropion|Starting dose 150 mg by mouth daily (150 mg every morning for three days; 150 mg twice a day thereafter)
223664489|NCT00507728|DRUG|Varenicline|Starting dose 0.5 mg by mouth daily (0.5 mg every morning for days 1 - 3, then 0.5 mg twice a day for days 4 - 7, then 1 mg twice a day thereafter)
223664490|NCT00507728|DRUG|Placebo|Placebo by mouth for 12 weeks.
224244287|NCT01624220|BEHAVIORAL|Questionnaires|Completion of questionnaire before radiation treatment starts, and 1 time a week for the next 4 weeks. It should take about 10 minutes to complete.
224244288|NCT00662766|DIETARY_SUPPLEMENT|black currant seed press residue|Black currant seed press residue, baked into bread
224244289|NCT00662766|DIETARY_SUPPLEMENT|Bread without black currant seed press residues|Same bread but without seeds
224244290|NCT00662766|DIETARY_SUPPLEMENT|Baseline data|No supplement was administered.
224244291|NCT06114004|DRUG|Selinexor 20 MG|After having completed the Phase I part, the recommended dose for Phase II is 60mg Selinexor
224244292|NCT06114004|DRUG|Gemcitabine|Gemcitabine will be given at the dose 1200 mg/m2 (10 mg/m2/min) days 1 and 8 every 21 days.
224244293|NCT01695551|OTHER|Data Collection Forms|Participants will be asked questions relating to pre-procedure items and be asked to complete an MMSE. Subjects receive standard of care surgery. Data collected from procedures before, during and after surgery.
224244294|NCT01226069|DRUG|Glycerine Magnesium sulphate paste|Dosage to apply adheres to the manufacturer's recommendation. Sufficient amount should cover the erythema size. Dose frequency is 12 hourly.
224244295|NCT01226069|DRUG|Mucopolysaccharide polysulphate|Dosage to apply adheres to the manufacturer's recommendation. Sufficient amount should cover the erythema size. Dose frequency is 12 hourly.
224244296|NCT01226069|OTHER|No application|No application
224244297|NCT04851301|BEHAVIORAL|Active Virtual Reality|Participants will be assigned to an immersive VR environment.
224244298|NCT04851301|BEHAVIORAL|sham Virtual Reality|Participants will be assigned to a sham VR environment without the immersive experience.
224244299|NCT04851301|OTHER|No Intervention|Participants will experience tonic pain tolerance tests without exposure to any environments.
223664491|NCT00507728|BEHAVIORAL|Smoking Cessation Counseling|Counseling over 8 months and telephone support calls.
223770299|NCT03555526|DRUG|Amoxicillin|amoxicillin, 1000mg, bid, for 7 days (day 1-day 7)
223770300|NCT03555526|DRUG|metronidazole|metronidazole, 500mg, bid, for 7 days (day 8-14)
223770301|NCT03555526|DRUG|Levofloxacin 500mg|levofloxacin 250mg, bid, for 7 days (day 8-14)
224244300|NCT04851301|DRUG|Naloxone|"4mg of Naloxone will be administered (0.1 mL of 40 mg/ml naloxone solution given intranasally).~A random allocation sequence will be independently generated by the UM Pharmacy. The Principal investigator will call for each experiment."
223770302|NCT03555526|DRUG|Clarithromycin ER|clarithromycin 500mg, bid, for 7 days (day 8-14)
223770303|NCT03555526|DRUG|Esomeprazole 40mg|Nexium (esomeprazole), 40mg, bid, for 10 days
223770304|NCT03555526|DRUG|Dibismuth trioxide|Dibismuth trioxide，KCB F.C. TABLETS，300mg，qid, for 10 days
223770305|NCT03555526|DRUG|metronidazole|metronidazole, 500mg, tid, for 10 days (day 1-10)
223770306|NCT03555526|DRUG|tetracycline|tetracycline 500mg, qid, for 10 days
224244301|NCT04851301|OTHER|Saline|"Intranasal Normal Saline (0.1 mL 0.9% sodium chloride) will be administered shortly before beginning the fMRI experiment.~A random allocation sequence will be independently generated by the UM Pharmacy. The Principal investigator will call for each experiment."
224244302|NCT04851301|OTHER|Natural history|Participants will not be provided Naloxone or Saline.
223664492|NCT03121651|DEVICE|RL-adaptive application|"Up to 6 dyads of individuals with disabilities and their caregivers will be recruited to collaborate in defining the features and content of the RL-adaptive support. The steps in developing the RL-adaptive support include having the dyads use for approximately 6 weeks each:~1. young adult uses an electronic medication pillbox that sends its pillbox openings within one hour of opening to the research team,~2. young adult uses the electronic medication pillbox + both use a commercially available medication reminder app + caregiver uses a pillbox opening notification app, and~3. young adult uses the electronic medication pillbox + the RL-adaptive support including push notifications in the form of text messages + caregiver uses the pillbox opening notification app.~The goal is to reduce the number of caregiver prompts necessary for the medication pillbox to be opened."
223664493|NCT02879045|OTHER|Elasticity Belly® oil|We will enroll about 50 Nulliparous women randomly, who are in their second trimester of pregnancy. We divide each of the volunteer's abdomen skin into two parts through medioventral line, one of the abdomen skin will receive the elasticity Belly® oil to prevent striae gravidarum, and the other side will use the Clarins® oil. Volunteers apply these two kinds of oil daily until birth. We'll take abdomen pictures before and after interventions, and the occurrence of striae on abdominal skin and its severity will be evaluated as our primary end point of the study.
223664494|NCT04590742|DRUG|melatonin 6mg|6 weeks of melatonin (6mg) given to patient
223664495|NCT04590742|DRUG|Placebo|Patient given 6 weeks of placebo tablet
223664496|NCT03467100|DRUG|XEN901|Capsule filled with XEN901
223664497|NCT03467100|DRUG|Inert Ingredients Oral Product|Placebo capsule
224321645|NCT00002200|DRUG|Abacavir sulfate|
223664498|NCT06240767|BIOLOGICAL|Granulocyte infusion|The number of single granulocytes per infusion was 2.0-5.0×10\^10, with an interval of 2±1 day and 5 continuous infusions.
223664499|NCT03680742|DEVICE|Contour Neurovascular System|The Contour Neurovascular System™ is an intrasaccular, self-expanding, embolization device intended for the treatment of unruptured intracranial aneurysms.
223664500|NCT05469698|BEHAVIORAL|Tobacco Treatment Research Program Standard Care|Participants interested in quitting tobacco will be offered standard tobacco cessation care including nicotine replacement therapy and counseling.
223664501|NCT06190054|DEVICE|MERAMIRT|"MERAMIRT®, a class IIa medical device, is indicated for hydration and lubrication of the ocular surface under conditions of eye disorders caused by environmental, visual and mechanical stress, also due to asthenopia and accommodation effort. The main component of MERAMIRT® are Hydroxypropyl-methylcellulose (HPMC 0.3%) and Inositol (0.1%).~HPMC has the property of moisturizing and lubricating the eye. Inositol is used with an antioxidant role"
223664502|NCT04023929|PROCEDURE|Cord blood sampling|A cord blood sample will be obtained after the baby has been delivered and the cord has been clamped and cut.
223664503|NCT00425178|DRUG|FGF-1|
224244303|NCT03634709|BEHAVIORAL|Memory Flexibility training (MemFlex)|MemFlex is a primarily self-guided, paper workbook-based program which aims to reduce overgeneral memory bias and improve recall of positive, specific event memories. Prior to completing one month of self-guided, workbook-based intervention, the participant will attend one 45 minute face-to-face session in which the facilitator outlines the importance of autobiographical memory in everyday life, discusses the impact of trauma on autobiographical memory, and provides information on the different types of autobiographical memories (e.g., specific, general) and their potential everyday functions. The session also introduces the cued-recall tasks which were used to train the memory skills throughout the workbook, and provides facilitator-assisted practice with the tasks. Once participants are comfortable with the training exercises, they set a schedule for completion of the eight-session workbook over the following four weeks.
224244304|NCT00591630|DRUG|Zevalin|(111In Zevalin) 5 millicurie (mCi) by vein and (90Y Zevalin) 0.4 mCI/kg by vein.
224244305|NCT00591630|DRUG|Carmustine|300 mg/m\^2 by vein.
224244306|NCT00591630|DRUG|Etoposide|200 mg/m\^2 by vein every 12 hours.
224244307|NCT00591630|DRUG|Cytarabine|200 mg/m\^2 by vein every 12 hours.
223664504|NCT00136383|DRUG|paroxetine versus duloxetine|
223664505|NCT03393533|PROCEDURE|Group I|Extraction third molar without the application of therapeutic bandaging in the face and with evaluation of edema, pain and trismus
223770307|NCT02720575|OTHER|Consumption of capsule/bread with vitamin D|
224244308|NCT00591630|DRUG|Melphalan|140 mg/m\^2 by vein.
224244309|NCT00591630|DRUG|Rituximab|"Arm 1, Arm 2 = 250 mg/m\^2 by vein;~Arm 1, Arm 2, Arm 3, Arm 4 = 1000 mg/m\^2 by vein following Stem Cell Transplant;~Arm 1, Arm 3 = 375 mg/m² by vein Maintenance Therapy."
224244310|NCT00591630|PROCEDURE|Stem Cell Transplant|Injection of stem cells (Autologous SCT)
224244311|NCT00463606|DRUG|ABT-335 and rosuvastatin calcium|ABT-335 135 mg in combination with rosuvastatin calcium 5 mg administered orally, once daily for 12 weeks
224244312|NCT00463606|DRUG|ABT-335|ABT-335 135 mg monotherapy administered orally, once daily for 12 weeks
224244313|NCT00463606|DRUG|rosuvastatin calcium|Rosuvastatin calcium 5 mg monotherapy administered orally, once daily for 12 weeks
224244314|NCT02593851|DRUG|JNJ-53718678|JNJ-53718678 oral solution will be administered once or twice daily for 7 days.
224244315|NCT02593851|DRUG|Placebo|Placebo oral solution will be administered once or twice daily for 7 days.
224244316|NCT00628160|DRUG|Terlipressin|Terlipressin 2-12 mg/24h intravenously in continuous infusion. Duration: until 24h after shock resolution.
224244317|NCT00628160|DRUG|alpha adrenergic drugs|Dopamine (1-20 µg/Kg/min) and/or norepinephrine (0.05-4 µg/Kg/min) until shock resolution
224321646|NCT06194942|OTHER|chiropractic manipulation|Chiropractic manipulation is a manual therapy technique commonly used by chiropractors. It involves the application of controlled, sudden force to a specific joint, often with the goal of improving joint function, reducing pain, and promoting overall musculoskeletal health.In the context of thoracic chiropractic manipulation, the chiropractor focuses on the vertebrae and joints in the thoracic spine.
223664506|NCT03393533|PROCEDURE|Group II|Extraction third molar with the application of therapeutic bandaging in the face and with evaluation of edema, pain and trismus
223664507|NCT02384915|DRUG|prilocaine|
223664508|NCT02384915|DRUG|mepivacaine|
223664509|NCT02384915|PROCEDURE|Sciatic-femoral Nerve Block|ultrasound-guided 25 ml 2% mepivacaine injection on both femoral and sciatic nerve
223664510|NCT02384915|PROCEDURE|Spinal anesthesia|intrathecal injection of 40 mg hyperbaric prilocaine
224244318|NCT04351516|DRUG|Hydroxychloroquine|dose of 600mg on the first day followed with 400mg/day divided in 2x200mg for 6 more days
224244319|NCT04351516|OTHER|Placebo|Placebo: Film Coated Tablette
224244320|NCT01081717|DRUG|systemic non-biological treatments|as prescribed
224244321|NCT01081717|BIOLOGICAL|anti-TNF biologics|as prescribed
224244322|NCT01081717|BIOLOGICAL|golimumab|as prescribed
223664511|NCT02384915|DEVICE|Sonoplex, Pajunk|
223664512|NCT00035113|DRUG|epothilone b|
223664513|NCT04787419|OTHER|placebo|saccharum lactis
223664514|NCT04787419|COMBINATION_PRODUCT|probiotics|Lactobacillus acidophilus, Bifidobacterium longum, Strepococcus thermophilus
223664515|NCT01410357|BEHAVIORAL|Targeted Training in Illness Management (TTIM)|This intervention blends psychoeducation, problem identification/goal-setting, behavioral modeling and reinforcement via use of Peer Educators, and health care linkage, has been adapted to the primary care setting and targeted for SMI-DM participants. Generalizability is enhanced with relatively brief in-person participation requirements and by utilizing professional staff typically found in primary care. TTIM will stress information sharing that is accessible to participants, and through a collaborative process, foster motivation for SMI-DM self-management.
223664516|NCT04140760|OTHER|Symprove|A liquid probiotic
223664517|NCT04140760|OTHER|Symprove placebo product|An inert placebo
223664518|NCT02263352|DRUG|Lycored soft gels Jagsonpal Pharma, Systemic 8mgms/day|Lycopene 8mgms taken orally ,one per day for two months.
223664519|NCT02263352|DEVICE|Scaling and root planing|Scaling and root planing, otherwise known as conventional periodontal therapy, non-surgical periodontal therapy, or deep cleaning, is the process of removing or eliminating the etiologic agents - dental plaque, its products, and calculus
223664520|NCT04972045|DRUG|CuminUP60®|4 capsules, 400 mg / capsule
223664521|NCT04972045|DRUG|Curcumin capsules|4 capsules, 400 mg / capsule
223664522|NCT00988650|OTHER|isocaloric diet|
223664523|NCT00988650|OTHER|free living conditions|
223664524|NCT03847441|DRUG|Calcipotriol|Calcipotriol ointment (0.005%)
223664525|NCT03847441|DEVICE|Narrow Band UVB|NB-UVB (311nm) phototherapy
224244323|NCT01081717|BIOLOGICAL|non-anti-TNF biologics|as prescribed
223664526|NCT03847441|DIAGNOSTIC_TEST|vitamin D3 level|vitamin D3 (ng/ml)
224244324|NCT01081717|OTHER|general population|non-treated cohort
224244325|NCT06101225|OTHER|MindRegulation Intervention|The intervention is developed in class for 15 minutes before learning activities, three times per week, for five months - 57 sessions. Six different scripts with socioemotional learning content (based on CASEL framework) for each of the three themes will be applied.
224244326|NCT06101225|OTHER|Relaxation|The relaxation condition will be developed in the same way as in RegularMente intervention, but without the guided imagery with SEL component. Relaxation exercises applied in class 15 minutes before learning activities, three times per week, for five months - in a total of 57 sessions.
223664527|NCT04395053|DRUG|SHR1459|"TR group:~The first period，the subjects will be administrated with SHR-1459 in new formulation, then conduct blood collection within 48h; 7 days washout； The second period，the subjects will be administrated with SHR-1459 in old formulation, then conduct blood collection within 48h.~RT group:~The first period，the subjects will be administrated with SHR-1459 in old formulation, then conduct blood collection within 48h; 7 days washout； The second period，the subjects will be administrated with SHR-1459 in new formulation, then conduct blood collection within 48h."
223664528|NCT03923244|DIAGNOSTIC_TEST|OSDI survey|"Normal patient consultation schedule for cataract surgery with:~* Preoperative appointment scheduled for the patient~* Post-operative appointment 1 month before surgery No additional appointments.~After geting consent and during the two consultations:~* Completion of a quality of life survey by the patient. Collection of the patient's history and general and ophthalmological treatments. Questionnaire of 12 items on quality of life to be completed. For each question, the patient must answer on the frequency of the discomfort felt, from never to all the time.~* An analysis of the ocular surface is performed by a non-invasive and non-contact device for 4 minutes. This consists of taking different photographs of the eye and eyelids, allowing each to study a part of the tears.~* Schirmer test is performed, consisting of applying the end of a small strip of blotting paper behind the lower eyelid and examining the strip after 5 minutes."
224244327|NCT06101225|OTHER|Waiting List Control Group|No Intervention.
223664529|NCT02280798|PROCEDURE|Endometrial Biopsy|4 endometrial biopsy
223664530|NCT06151509|DRUG|Alpha-Agonist|An initial infusion dose of prophylactic norepinephrine (0.05 ug/kg/min) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 0.01 ug/kg/min of prophylactic norepinephrine according to the responses of previous patients according to the up-down sequential allocation.
224244328|NCT06266962|DRUG|1% Atropine drops|Patients administered 1% Atropine drops twice a day for a week before the cataract surgery.
224244329|NCT06266962|DRUG|Epinephrine|Patients underwent the instillation of epinephrine into the anterior chamber at the beginning of the cataract surgery.
224244330|NCT00789984|DEVICE|noncontact specular microscopy|
224244331|NCT03654625|BEHAVIORAL|Standard Written Exposure|Four spaced, 30-minute sessions occurring within a period of 2 weeks. Participants write a narrative about their worst worry.
224244332|NCT03654625|BEHAVIORAL|Enhanced Written Exposure|Four spaced, 30-minute sessions occurring within a period of 2 weeks. Participants write a narrative about their worst worry and rescript it.
224244333|NCT03654625|BEHAVIORAL|Control Condition|Four spaced, 30-minute sessions occurring within a period of 2 weeks. At each session, participants write a narrative about a neutral topic.
224244334|NCT05791032|DEVICE|AtaCor EV-ICD Lead|Subjects will receive the AtaCor EV-ICD Lead being evaluated in the study.
224244335|NCT05865197|OTHER|Data collection|Data collection of clinically relevant signals using home-based sensor system
224244336|NCT02228174|DEVICE|Intrauterine Ultrasound-Guided Radiofreq. Ablation System|The Sonata System combines intrauterine ultrasound (IUUS) with radiofrequency (RF) ablation in a single handpiece. Sonata is suitable in an inpatient or outpatient setting, and is intended for diagnostic intrauterine imaging and transcervical treatment of symptomatic uterine fibroids, including those associated with heavy menstrual bleeding(HMB).
224244337|NCT00401804|DRUG|Dexamethasone, Bortezomib, Doxorubicin|
224244338|NCT01427023|DEVICE|APTIMA Trichomonas vaginalis (ATV) Assay|APTIMA Trichomonas vaginalis (ATV) Assay
224244339|NCT02373332|OTHER|omega-3 and -6 fatty acids and their 12-LOX oxylipins|platelets from healthy subjects and T2DM patients will be isolated from their blood and treated with omega-3 and -6 fatty acids and their 12-LOX oxylipins of those fatty acids followed by assessment of protection from agonist-induced platelet activation and thrombosis
224244340|NCT01732978|BEHAVIORAL|Crying record|"Recording spontaneous crying is as soon as possible after birth. Crying is recorded twice during the first week of life.~Listening tests:~Tests will be conducted playbacks with the father and mother separately, and with a staff"
224244341|NCT03863730|DIETARY_SUPPLEMENT|Profermin Plus, FSMP, probiotics|"Participants will have to supply their normal intake with Profermin Plus, FSMP, Prbiotics product twice every day for 24 weeks.~The product Profermin Plus® has changed its name to ReFerm®. The content of the product is unchanged. The change occurred after the clinical part of the study was completed."
223664531|NCT06151509|DRUG|α-adrenergic receptor agonist|An initial infusion dose of prophylactic norepinephrine (0.05 ug/kg/min) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 0.01 ug/kg/min of prophylactic norepinephrine according to the responses of previous patients according to the up-down sequential allocation.
223664532|NCT01604993|OTHER|Spinach soup|556 g of high Nitrate spinach soup that is orally consumed as a single dose for 7 days
224244342|NCT03863730|DIETARY_SUPPLEMENT|Fresubin, dietary supplement|Participants will have to supply their normal intake with the control product, Fresubin, dietary supplement twice every day for 24 weeks.
224244343|NCT05266430|OTHER|Standard of Care|Patients who are planned to receive plaque radiotherapy for the treatment of IL/CM based on the expert judgment of the investigator
224321647|NCT06194942|OTHER|sham manipulation|"Sham manipulation refers to a simulated or placebo form of a manual therapy intervention, often used in research studies, especially in clinical trials involving chiropractic or physical therapy. the term sham manipulation likely implies a procedure that mimics the physical aspects of a real chiropractic manipulation but does not involve the actual therapeutic forces or movements.~The chiropractic treatment group received thoracic chiropractic manipulations (HVLA) twice a week for a total of six sessions over three weeks, while the control group received sham manipulations."
224244344|NCT05266430|DRUG|AU-011|Previously received
224244345|NCT00438828|DRUG|dexamethasone|8mg Dexamethasone PO on days 0 (prior to radiation treatment), and days 1, 2, and 3 following radiation treatment.
224244346|NCT03109132|DEVICE|Oridion Smart CapnoLine® H Plus with Wedge cannula|The subjects will assess the comfort level of the different cannulas
224244347|NCT03109132|DEVICE|Oridion Smart CapnoLine® Plus with Non-Wedge cannula|The subjects will assess the comfort level of the different cannulas
224321648|NCT00352417|DRUG|VIA-2291|100 mg, oral dosing, 1 time daily for 12 weeks
223664533|NCT01604993|OTHER|Asparagus soup|556 grams of low nitrate asparagus soup that is orally consumed for a period of 7 days as a single does
223664534|NCT01909791|PROCEDURE|Prompt Laser|Focal/grid laser performed at baseline and as needed during follow-up
223770308|NCT05496725|DRUG|Micafungin|Pharmacokinetic study under fasting conditions
224244348|NCT03109132|DEVICE|Experimental sample line Model 3|The subjects will assess the comfort level of the different cannulas
224244349|NCT03109132|DEVICE|Experimental sample line Model 4|The subjects will assess the comfort level of the different cannulas
224244350|NCT03109132|DEVICE|Experimental sample line Model 5|The subjects will assess the comfort level of the different cannulas
224244351|NCT03109132|DEVICE|O2/CO2 cannula w/female luer (Westmed comfort plus #0504)|The subjects will assess the comfort level of the different cannulas
224244352|NCT02688257|OTHER|MRI|Functional magnetic resonance imaging
224244353|NCT02688257|OTHER|Ultrasound|Optoacoustic imaging
224244354|NCT02682602|DEVICE|DePuy Synthes total hip arthroplasty|
224244355|NCT02682602|RADIATION|Computer tomography|Computer tomography (CT) scan of the hip for creation of bone models.
224244356|NCT02682602|RADIATION|Fluoroscopy surveillance|Fluoroscopy evaluation of the hip during gait (level walking), chair rise, and ramp ascent and descent activities. Sound/vibration data will be collected simultaneously via non-invasive sensors attached to the hip joint.
224244357|NCT00922909|BEHAVIORAL|Simon task|Reaction time task
224244358|NCT07035392|DRUG|Adebrelimab|Adebrelimab 1200mg，ivgtt，D1，Q3W
224244359|NCT07035392|DRUG|chemotherapy|"Queue A (lung squamous cell carcinoma patients):~Albumin paclitaxel 260mg/m2, ivgtt，D1 , Q3W Carboplatin AUC=5, D1，Q3W~Queue B (lung adenocarcinoma patients):~Pemetrexed 500 mg/m2, ivgtt，D1，Q3W Carboplatin AUC=5, D1，Q3W"
224244360|NCT07035561|DRUG|Rituximab (Mabthera)|"In Chronic hypersensitivity pneumonitis patients with no improvement in lung function (deterioration in their FVC% predicted more than or equal 5%) after a minimum of 6 months treatment including antigen avoidance and immunosuppressive therapy. Rituximab will be administered by an intravenous infusion.~* Two doses of Rituximab will be given, the first dose at day 0 and the second dose at day 15, 1 gram of Rituximab will be given in each dose.~* Patients will be given acetaminophen and antihistamine before each infusion.~* Rituximab will be diluted in an infusion bag of either 0.9% sodium chloride or 5% dextrose.~* No other drugs will be mixed with it, and patients will be closely monitored for any infusion reactions."
224321649|NCT00352417|DRUG|Placebo|oral dosing, 1 time daily for 12 weeks
224321650|NCT07133568|OTHER|Fun Exercise for Older Adults (FEXO)|The FEXO (Fun Exercise for Older Adults) program is a 14-week, multicomponent, recreational exercise intervention designed to enhance intrinsic capacity, motivation, and adherence in community-dwelling older adults. Participants engage in three non-consecutive, supervised group sessions per week (maximum instructor-to-participant ratio 1:15), each lasting approximately 60 minutes. The program begins with a two-week familiarization phase followed by three progressive phases (4 weeks each), with exercise intensity, repetitions, and resistance levels adjusted based on functional performance assessed by the Short Physical Performance Battery (SPPB).
223664535|NCT01909791|DRUG|Prompt aflibercept|Intravitreal injection of 2.0mg aflibercept performed on the day of randomization and up to every 4 weeks using defined treatment criteria
223664536|NCT01909791|PROCEDURE|Deferred laser|Focal/grid laser is initiated while receiving anti-VEGF injections only if certain criteria are met
223664537|NCT01909791|DRUG|Deferred aflibercept|Intravitreal injection of 2.0mg aflibercept performed once certain criteria for vision loss are met and then up to every 4 weeks using defined treatment criteria
223664538|NCT04175990|DRUG|Dydrogesterone Pill|started from day 1 of menses till trigger day
223664539|NCT01268280|DRUG|Placebo|Matching placebo in capsules administered as a single oral dose.
223664540|NCT01268280|DRUG|250 mg CK-2017357|250 mg CK-2017357 in capsules administered as a single oral dose.
223664541|NCT01268280|DRUG|500 mg CK-2017357|500 mg CK-2017357 in capsules administered as a single oral dose.
223664542|NCT02893579|BEHAVIORAL|Early SR intervention|Self-directed stress reduction program delivered through a smart-phone application
223664543|NCT02893579|BEHAVIORAL|Delayed SR intervention|Activity tracking only for the first month
223664544|NCT06235255|BEHAVIORAL|Guided Imagery|The participant will complete the Guided Imagery Intervention for 21 consecutive days.
223770309|NCT00808600|BEHAVIORAL|resource-activating behavioural training programme|"Stepwise intervention based on the principles of resource-activating training (RAT) applied to the needs of patients in the process after lung transplantation.~Phase 1: Build-up of therapeutic relationship through resource-activating training for patients after transplantation during rehabilitation in the rehabilitation centre Fallingbostel following inpatient treatment. Phase 2: Continued resource-activation and transfer by means of internet-based interventions (1 per 2 weeks) as well as personal interventions by trained nurses and a clinical psychologist during regular out-patient visits (approx. 4 times per year) over one year immediately following rehabilitation. Interventions focus on strengthening individual and interpersonal resources for well-being, psychoeducation, stress management and coping with illness. Phase 3: Termination and transfer, including a detailed medical report."
223770310|NCT00808600|BEHAVIORAL|Relaxation training|Phase 1: Build-up of therapeutic relationship through resource-activating training for patients after transplantation during rehabilitation in the rehabilitation centre Fallingbostel following inpatient treatment. Phase 2: Regular relaxation training after rehabilitation by self-guided relaxation compact disk and accompanying worksheets.
223770311|NCT00808600|BEHAVIORAL|Intensified anaerobic exercise training|Phase 1: Recruitment and initiation of intensified and individualised aerobic/anaerobic exercise training based on determination of aerobic/anaerobic threshold during rehabilitation in the rehabilitation centre Fallingbostel. During rehabilitation daily training sessions with a duration of 30 minutes each are performed under medical supervision. Phase 2: Home training on an IT-assisted ergometer 3.5 times a week with interval exercise intensity above the anaerobic threshold. Work load and heart rate are stored by an ergometer-chip, lung function analyses are performed and should be transferred via phone-based telemetry. Exercise training intensities will be adapted monthly, corresponding to training results. At regular 3 months visits to the outpatient clinic a medical examination is carried out. Moreover, according to the actual functional state of the patient estimated 3 monthly training work load will be adjusted. Phase 3: Termination, evaluation after a period of 12 months.
223664545|NCT06235255|BEHAVIORAL|Cognitive Power Intervention|The investigator with the subject uses the power profile generated by the PKPCT to generate goals that will positively affect functional health.
223664546|NCT06235255|BEHAVIORAL|Combined Guided Imagery and Cognitive Power Intervention|This intervention is a combination of the Guided Imagery Intervention in tandem with the Cognitive Power Intervention
224244361|NCT07036354|OTHER|Human-Animal Interaction|HAI - participants spend a specific amount of time with a therapy dog in a controlled environment.
224244362|NCT07036354|OTHER|General Health Education|GHE - participants will be educated on strategies to assist in managing general and academic anxiety.
224244363|NCT07035418|BEHAVIORAL|Clinical Decision-Making Scenarios and Preferences Assessment|Participants complete a socio-demographic questionnaire and decision-making preferences scale, including hypothetical clinical scenarios, to identify their preferred decision-making role (active, collaborative, or passive) and the influence of providers or family. Delivered electronically via secure link; reminders sent as needed.
223664547|NCT01659554|DRUG|Cisplatin|Cisplatin (75 mg/m2) prepared in 2L normal saline.
223664548|NCT01659554|DRUG|Doxorubicin|Doxorubicin (25 mg flat dose) prepared in 500 ml dialysis fluid (glucose or icodextrin-based).
223664549|NCT01936090|DRUG|Bortezomib|Given IV
223664550|NCT01936090|RADIATION|Total-Body Irradiation|Undergo TBI
223664551|NCT01936090|DRUG|Melphalan|Given IV
223664552|NCT01936090|PROCEDURE|Autologous Bone Marrow Transplantation|Undergo autologous bone marrow transplant
223664553|NCT01936090|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous peripheral blood stem cell transplant
223664554|NCT01936090|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo autologous peripheral blood stem cell transplant
223664555|NCT01936090|OTHER|Laboratory Biomarker Analysis|Correlative studies
223664556|NCT01561703|DRUG|Antibiotic|One of seven antibiotics (amoxicillin; amoxicillin/clavulanate potassium; azithromycin; cefaclor; cephalexin; cefdinir; or clindamycin) will be given at standard dosage that may be used for 7-10 days following surgery .
223664557|NCT02730143|OTHER|Altitude exposure|Altitude exposure
223664558|NCT05630391|DEVICE|High-Fidelity Simulation Manikin|A high-fidelity simulator was developed to teach skills in nursing education, and it is sized to represent an adult male patient. The mannequin can be controlled using a computer program, it can breathe, and its vital signs can be monitored using a bedside monitor.
223664559|NCT05630391|OTHER|Education|Training for 26 nursing students who constituted the control group performed personnel protective equipment (PPE) wearing-removal practice
224244364|NCT07037667|OTHER|Pilates exercises|Single leg lifts:The participant is in supine lying position with knees bent and feet parallel and hip-width apart. Head, neck and shoulders totally relaxed and arm extended and relaxed beside the body. Then the participant is asked to inhale first without moving her leg then exhale while bringing one leg up towards chest , drawing her pelvic floor and abdominals up and in like gently tightening a belt and maintaining 90 degrees angle at the knee and then put her leg down while inhaling. One leg circle:The participant is in supine lying position with one leg raised towards the ceiling and the other leg on the floor and both knees slightly bent.Then the participant is asked to inhale first without moving her leg and to make sure to use the abdominal muscles to try to maintain a neutral pelvis while doing the exercise then makes a small circle while exhaling and inhale when she completes the circle and reaches the starting position.
224244365|NCT07037667|OTHER|Dietary recommendations|Dietary recommendations as healthy snacks that are rich in magnesium and vitamin B-6.
224244366|NCT07036731|PROCEDURE|Urine biomarker -Guided without reTURBT|Participants will proceed without reTURBT
224244367|NCT07036913|DIAGNOSTIC_TEST|somatocognitive therapy|In somatocognitive therapy which includes drawing( three days prior to menustration in first two months and the first day of menustration in third month) and music(in the first 12 hours of menustration)along with TENS(thirty minutes on abdominal region, upon the onset of dysmonarrhea).
223664560|NCT00945906|BIOLOGICAL|FXIII Concentrate (Human) (FXIII)|"Doses will be guided by the individual subject's most recent FXIII activity levels, with the objective of dosing every 28 days to maintain a trough FXIII activity level of approximately 5 to 20%.~Subjects enrolled in this study who have not received at least 3 doses of FXIII Concentrate in a previous study of this product (i.e., NCT00640289, NCT00885742, or NCT00883090) will initially receive a dose of 40 U/kg by intravenous (IV) infusion."
224244368|NCT07036913|COMBINATION_PRODUCT|Stretching exercises|Stretching exercises of abdominal, lumbar or pelvic region will be performed as a treatment. Frequency:15 minutes;three times per week.
224244369|NCT07035717|OTHER|Patient interview|A semi-structured interview with five questions will be conducted, with audio recording, which will later be transcribed verbatim.
224244370|NCT07036575|BEHAVIORAL|Standard Visual Health Education|Participants receive conventional eye health education using standard visual materials, explained by an instructor.
224244371|NCT07036575|BEHAVIORAL|Easy-Read Instructor-Guided Education|Participants receive Easy-Read health education through 16 simplified images with instructor-guided explanation using plain language and pictorial content.
224244372|NCT07036575|BEHAVIORAL|Easy-Read Audio-Based Self-Learning|Participants use a voice-assisted pen device to self-learn Easy-Read materials (16 images) with audio explanations, without additional teacher guidance.
224244373|NCT07036055|DEVICE|Transcutaneous Auricular Vagus Nerve Stimulation (taVNS)|Participants receive transcutaneous auricular vagus nerve stimulation (taVNS) via a non-invasive ear-clip device targeting the cymba conchae. The device delivers electrical pulses at 25 Hz frequency with a pulse width of 200 µs, for 30 minutes daily over 10 consecutive days. The stimulation intensity is individually adjusted to the participant's perceptual threshold. taVNS is paired with standardized mindfulness training in this arm.
224244374|NCT07036055|DEVICE|Sham Stimulation|Participants in this group use the same device as in the active taVNS condition, but the stimulation is deactivated. The ear-clip device is placed identically on the cymba conchae, with no electrical current delivered. This sham procedure mimics the look and feel of taVNS but serves as a placebo control. Sham stimulation is combined with the same mindfulness training as the experimental group.
224244375|NCT07036055|BEHAVIORAL|Mindfulness Training|Participants receive instructor-led mindfulness training conducted by a trained therapist. Each session lasts 30 minutes and focuses on breath awareness, body scanning, and non-judgmental awareness of internal experience. All participants (both taVNS and sham groups) receive this training daily for 10 consecutive days.
223664561|NCT04583709|DEVICE|ECG Belt|"ECG Belt Research System Procedure LBBP Native conduction RV pacing if available Bipolar LBBP Unipolar LBBP - nonselective and selective (different outputs) Fusion pacing with native conduction at different Atrioventricular (AV) delays~HOT-CRT Native conduction HBP / LBBP HOT-CRT AV delay optimization. Medtronic Device (pacemaker/ICD) based Holter recording during the ECG belt recording"
223664562|NCT03402464|DRUG|Icotinib combined dihydroaremisinin|Icotinib should be taken by the patients continuously until disease progressed or intolerable toxicity. On day 1-3, oral dihydroaremisinin was given at 20mg per day, the dose of dihydroaremisinin is increased to 40mg daily on day 4 to 6, and 80mg twice daily until disease progressed or intolerable toxicity.
223664563|NCT00264459|BIOLOGICAL|Grass pollen formulation|"Solution for sublingual application containing allergen extracts of 6 grass pollen species (Holcus lanatus, Dactylus glomerata, Lolium perenne, Phleum pratense, Poa pratensis, Festuca pratensis) pollen allergen extract.~The study solution was applied sublingually, kept under the tongue for 3 minutes, and swallowed thereafter."
223664564|NCT00264459|OTHER|Comparator|Solution for sublingual application containing Placebo. The study solution was applied sublingually, kept under the tongue for 3 minutes, and swallowed thereafter.
223664565|NCT05146947|DEVICE|near infrared spectroscopy|near infrared spectroscopy monitoring on kidney after reperfusion
223664566|NCT02936661|DRUG|Tranexamic Acid|
223664567|NCT02936661|DRUG|Placebo|
223664568|NCT03141294|PROCEDURE|reformative dilation technique|reformative dilation technique was used when operating tracheostomy
223664569|NCT02117128|DRUG|Tranexamic acid|
223664570|NCT01046435|PROCEDURE|metronidazole and amoxicillin|Metronidazole 250 mg three times a day per 7 days
223664571|NCT01046435|PROCEDURE|Two placebos|Two placebos 3 times a day for 7 days
223664572|NCT05863000|OTHER|Online questionnaire/survey|Participants are expected to answer a short survey based on their overall experiences with their own health. No participants will therefore be followed for more than the duration of time it takes a subject to answer the questionnaire (approx 15 minutes). Randomly selected volunteers of around 30 respondents will afterwards be invited to participate in a qualitative interview with the intend to elaborate their questionnaire responds.
224244376|NCT06093802|DIAGNOSTIC_TEST|Drug-induced Sleep Endoscopy findings (identified obstruction sites)|As described above
224244377|NCT05088577|DIETARY_SUPPLEMENT|Whole egg|Daily consumption of two whole eggs during 8 weeks
224244378|NCT05088577|DIETARY_SUPPLEMENT|Annatto-enriched egg|Daily consumption of two whole eggs enriched with annatto during 8 weeks
224244379|NCT05088577|DIETARY_SUPPLEMENT|Egg whites - Control|Daily consumption of two eggs whites during 8 weeks
224244380|NCT02311361|BIOLOGICAL|Durvalumab|10 mg/kg, mg intravenous (IV), every two weeks, or 1500 mg, IV, every four weeks.
224244381|NCT02311361|BIOLOGICAL|Tremelimumab|75 mg IV, every 4 weeks for 16 weeks
224244382|NCT02311361|RADIATION|Sterostatic body radiation therapy (SBRT)|8 Gray (Gy) x 1; 5Gy x 5
224244383|NCT05046860|DRUG|Dalbavancin|"The unit dose of dalbavancin administered via the peripheral venous route will be 1500 mg at each injection with a first injection at Day1, a second injection at Day15 and a third at Day36, which corresponds to 61 days of treatment with dalbavancin.~In case of residual dalbavancin dosage at Day15 lower than 15 mg/L (rare situation) and a minimal inhibitory concentration for dalbavancin of 0.125mg/L (less than 5% of the strains), an injection every 14 days will be necessary, i.e. Day1, Day15, Day29, Day43 and Day57, which corresponds to 71 days of dalbavancin treatment.~Rifampicin should be given orally at a dose of 600 mg on an empty stomach in the morning for patients weighing less than 70 kg and 900 mg on an empty stomach in the morning for patients weighing more than 70 kg."
224244384|NCT06559670|OTHER|Blood sampling|\- Collection and analysis of blood samples
224244385|NCT05074472|DRUG|ZB131|ZB131 will be administered once weekly by intravenous infusion with the weight at baseline used for mg/kg dose calculations.
224244386|NCT02851771|OTHER|Nasopharyngeal Swab|
224244387|NCT05539339|OTHER|Individualized intervention based on genomic alterations|Specialized tumor board recommended agents that target the specific recurrence-driving genomic alterations that are determined by serial TISF ctDNA analysis.
224244388|NCT05585957|DIAGNOSTIC_TEST|INTERLEUKIN 6|role of interleukin 6 in the diagnosis of neonatal sepsis in comparison with the routine diagnostic markers of neonatal sepsis
223664573|NCT02604329|DEVICE|"Oncolase Digi therapy laser diode"|"The athermic phototherapy laser diode will be used by scanning the entire oral mucosa, including cheek and lip mucosa, gums, palate, tongue and floor of the mouth. It will be applied uniformly every two days as long as the grade of mucositis is 2 or more, with a fluence of 4J/cm², under two wavelengths (635 nm and 815 nm).~* Cheeks will be scanned extra-orally with laser fiber during 50 seconds, at the fluence of 4J/cm², associating two wavelengths : infra-red (815 nm, 3850mW) and red (635 nm, 150mW).~* Intra-orally, the fiber will be used to scan each area of mucositis during 30 seconds per area of 2 cm2, at 1cm from the mucosa; the power at 635 nm will be 150 milliwatts and 150 milliwatts at 815 nm."
223664574|NCT04664764|DRUG|Degludec|Basal insulin comparison
223664575|NCT04664764|DRUG|Glargine|Basal insulin comparison
224244389|NCT04900090|OTHER|Epidemiological study|"* Clinical phenotypic assessment and neurosensory measures~* Biological, genetic and metabolomic evaluation~* Questionnaires (quality of life, gout, life habit, comorbidities)~* Morphological evaluation by Dual-energy CT scan"
224244390|NCT02767232|DRUG|Recombinant tissue plasminogen activator (rt-PA)|Catheter-directed thrombolysis, consisting of intrathrombus administration of rt-PA using a catheter/device.
224244391|NCT02767232|DRUG|Standard Anticoagulation Therapy|Standard anticoagulation determined by physician for a period of 3-6 months
223664576|NCT04664764|DRUG|NPH insulin|Basal insulin comparison
223664577|NCT01222156|PROCEDURE|Remote magnetic navigation|Remote magnetic navigation of electrophysiology catheters to target intracardiac anatomical sites at mapping-ablation procedures in patients with cardiac arrhythmias
223664578|NCT01222156|DEVICE|Magnetecs Catheter Guidance Control and Imaging system|Magnetecs Catheter Guidance Control and Imaging (CGCI) system
223664579|NCT06390072|BEHAVIORAL|Self-Hypnosis|Participants listened to an 8-minute audio-guided self-hypnosis related to improving their physical performance
223664580|NCT06390072|BEHAVIORAL|Ankle Education|Participants listened to an 8-minute video on ankle sprain diagnosis, prognosis, and treatment
223664581|NCT05063071|DRUG|Tenofovir Alafenamide 25 MG|After orthotopic liver transplant, all patients will receive Tenofovir Alafenamide monotherapy without HBIG for HBV Prophylaxis.
223664582|NCT04135586|OTHER|Exercise training|Exercise program for 24 weeks (with neo-adjuvant treatment), with two sessions per week including both moderate-to-intense aerobic and resistance training. The intensity of each type of exercise will range between 65% and 100% of the maximum score in the Rated Perceived Exertion (RPE) scale.
223664583|NCT04135586|OTHER|Control|Yoga + educational program
223664584|NCT00450008|DRUG|GM-CSF|fixed dose of 250 mcg/m2, 3 days per week by subcutaneous injection
224244392|NCT05737992|OTHER|Exercise in water|"Participants will do some exercises in water for 30-60 minutes. Exercises will be performed at a moderate exercise intensity (12-14 on the Borg Rate of Perceived (RPE) Scale).~All protocols are tailor-made based on each individual's needs and physical abilities."
224244393|NCT04168463|DEVICE|Two Joy for All robots (one cat and one dog)|Intervention will include the opportunity to interact with the Joy for All robot animals.
223664585|NCT00450008|DRUG|thalidomide|Thalidomide by oral administration at a fixed dose of 200 mg. Prophylactic Coumadin® by oral administration at a fixed dose of 2.5 mg to prevent thromboembolic events (DVT and TIA/stroke) during Thalidomide administration. Thalidomide and Coumadin will be given daily at bedtime without interruption.
223664586|NCT00450008|DRUG|docetaxel|Docetaxel will be administered by intravenous piggyback over 1 hour at 75mg/m² every 3 weeks. Pre-medication for the docetaxel infusion will consist of dexamethasone 8 mg administered orally 12 hours, 3 hours and 1 hour before docetaxel.
223664587|NCT02507037|DIETARY_SUPPLEMENT|gum+PEG|chew sugarless gum
223664588|NCT02507037|DRUG|polyethylene glycol|2L PEG
224244394|NCT02925364|RADIATION|magnetic resonance imaging (MRI)|all participants will undergo a functional MRI and an anatomical MRI in a single session
224244395|NCT02208726|OTHER|Sucrose pillules|Unmedicated sucrose pillules
224244396|NCT02208726|OTHER|Homeopathic homaccord|Sucrose pillules medicated with Picricum acidum and Phosphoricum acidum in potencies of 6CH, 30CH and 200CH.
224244397|NCT01979081|OTHER|Tailored advice from a physiotherapist and/or an occupational therapist through the myOSCAR patient portal|
223664589|NCT03721029|DEVICE|Intraoperative nerve monitoring,|Intraoperative nerve monitoring, via electromyography, enables real-time identification of the location of the somatic fibers in the pelvic nerves that seem crucial for urinary continence control and erectile function.
223664590|NCT03721029|PROCEDURE|standard of care robotic-assisted radical prostatectomy|With out the usage of intraoperative nerve monitoring
223664591|NCT03351205|DEVICE|disposable balloon uterine stent|The disposable balloon uterine stent is heart-shaped that resembled the shape of the uterine cavity and could fully separate the two sides of the uterine wall and the corners of the uterus compare to Foley catheter.
223664592|NCT03351205|PROCEDURE|dried biological amnion graft|"Uterine application of dried biological amnion graft following hysteroscopic adhesiolysis.~Other Name: Human amnion membrane"
223664593|NCT03351205|DRUG|estradiol valerate tablets+dydrogesterone tablets|oral estradiol valerate tablets+dydrogesterone tablets
223664594|NCT03866395|DRUG|Ivabradine|Ivabradine 5 mg twice a day
223664595|NCT00998218|DRUG|Ranolazine|Ranolazine at 1000 mg BID (or 500 mg BID if the 1000 mg dose was not tolerated) or a comparable placebo for the next 4 weeks
223664596|NCT00998218|DRUG|Placebo|Ranolazine at 1000 mg BID (or 500 mg BID if the 1000 mg dose was not tolerated) or a comparable placebo for the next 4 weeks
223664597|NCT00985036|PROCEDURE|Blood test|an additional vial of blood will be obtained at the time of MRI or at the time of routine blood tests ordered by the medical oncologist. In other words, there will be no extra needle sticks. Just an extra vial of blood will be taken during a routine blood test
223664598|NCT03643536|OTHER|12-WPEP|The 12-WPEP (week physical exercise program) was carried out in 3 sessions each 40 or 60minutes with alternate days per week during 3 months, and with an intensity between 40 to 80 percent of their VO2 max, as the AHA recommends
223664599|NCT04796870|OTHER|Online Brain and Balance Training Program|The intent of the intervention is to encompass cardiovascular conditioning, cognitive performance and balance performance improvements. To promote cardiovascular conditioning the exercises are structured to keep the participant in motion while maintaining an elevated heart rate using techniques such as squats, marching and upper extremity movements. The video provides adaptations to increase or decrease the challenge based on subject ability. To promote cognitive performance, participants will be asked to complete simple and complex cognitive tasks, such as arithmetic, spatial memory recall and attention while completing the physical exercises. To promote balance performance, the videos include single limb stance and weight shifting tasks. Videos are presented in a progressively challenging manner for all domains.
223770312|NCT00808600|BEHAVIORAL|Moderate aerobic exercise training|Phase 1: Recruitment and initiation of moderate aerobic exercise training based on 40 percent of maximal oxygen consumption in Watt during rehabilitation in the rehabilitation centre Fallingbostel. Phase 2: Moderate aerobic endurance training with the target intensity of 40 percent of the individual maximum exercise capacity will be performed 3.5 times a week with a duration of 30 minutes per session, work load will be adapted continuously according to the measures that are assessed during the repeated control examinations after periods of 3 months in the outpatient clinic of the pulmonary department of Hanover Medical School.
223770313|NCT02778581|DIETARY_SUPPLEMENT|Lipidic Blend 1|daily intake of the content of one 45 mL bottle containing the product
223770314|NCT02778581|DIETARY_SUPPLEMENT|Lipidic Blend 2|daily intake of the content of one 45 mL bottle containing the product
223770315|NCT02778581|DIETARY_SUPPLEMENT|Placebo|daily intake of the content of one 45 mL bottle containing olive oil
223770316|NCT01509794|OTHER|Low Valence|Participants in the low valence condition will participate in two photo-based simulations: first, an orientation to become familiar with the interface, and then a clinical simulation. Afterward, they will complete a written debriefing followed by an verbal debriefing with a study investigator. They will complete all activities while having their heart rate and galvanic skin response monitored using non-invasive methods.
224244398|NCT04788238|BEHAVIORAL|Dual-Task Zumba Gold|Dual-Task Zumba Gold is a 12-week program to be conducted thrice weekly for 45-60 minutes. The intervention involves the concurrent performance of cognitive tasks and physical movements during specific parts of the dance. The activity will begin with warm-up and end with cool-down periods, at 5 to 10 minutes each. Orientation training will be done during the warm-up period, by asking questions to participants about time, place, and person. In the actual dance (30 to 40 minutes), the following domains will be trained: executive function (forward and backward serial counting); perceptual-motor ability (performing arm clock positions based on instructions); memory (forward and backward repetition of number/word series), and attention (forward and backward spelling of 3- to 5-letter words). The cool-down period will incorporate memory training by reminding the participants to summarize the activities performed.
224244399|NCT00365300|DRUG|pantoprazole|
224244400|NCT00365300|DRUG|Placebo|
224244401|NCT05113056|DEVICE|Acutus Medical Pulsed Field Ablation System|All subjects will be treated using the Acutus Medical Pulsed Field Ablation System (PFA System) to treat their atrial fibrillation.
224244402|NCT03832400|BIOLOGICAL|MET-2|MET-2 is a defined consortium of human commensal bacteria derived from a healthy donor, which has the full metabolic functional capacity of fecal microbiota.
224244403|NCT03832400|DRUG|Placebo oral capsule|Placebo oral capsule which is identical to the MET-2 capsules.
224244404|NCT02896361|DEVICE|Reprogramming of spinal cord stimulator (Proclaim or Prodigy SJM internal pulse generator) parameters according to study protocol|Stimulation parameters are reprogrammed from original values to study defined ones
224244405|NCT00302705|DRUG|Valsartan, Enalapril|160 mg valsartan versus 10-20 mg enalapril
224244406|NCT00302705|DEVICE|Ambulatory blood pressure monitoring|Blood pressure measured at 20-min intervals from 07:00 to 23:00 hours and at 30-min intervals at night for 48 consecutive hours
224244407|NCT00302705|PROCEDURE|Missing one dose|Patients skip the dose the second day of monitoring
224244408|NCT05116228|DRUG|500mg RTX Group|Patients will receive 1x500mg RTX (Mabthera) at baseline (time-point of their upcoming semi-annual infusion) and at months 6, 12, 18 and 24
224244409|NCT05116228|DRUG|1000mg RTX Group|Patients will receive 1x1000mg RTX (Mabthera) at baseline (time-point of their upcoming semi-annual infusion) and at months 6, 12, 18 and 24
224244410|NCT00556049|DRUG|Gemcitabine|Intravenously on days 1 and 8 of each 21-day treatment cycle.
223664600|NCT00950885|BIOLOGICAL|Low Dose Melatonin|Melatonin and placebo will be delivered as capsules on 4 successive days. All groups will receive placebo on days 1-3. Placebo group will continue to receive placebo on days 4, while low dose group will receive 0.5mg melatonin on day 4 and high dose group will receive 3.0mg melatonin on day 4.
223664601|NCT00950885|BIOLOGICAL|Placebo|Melatonin and placebo will be delivered as capsules on 4 successive days. All groups will receive placebo on days 1-3. Placebo group will continue to receive placebo on days 4, while low dose group will receive 0.5mg melatonin on day 4 and high dose group will receive 3.0mg melatonin on day 4.
223664602|NCT00950885|BIOLOGICAL|High Dose Melatonin|Melatonin and placebo will be delivered as capsules on 4 successive days. All groups will receive placebo on days 1-3. Placebo group will continue to receive placebo on days 4, while low dose group will receive 0.5mg melatonin on day 4 and high dose group will receive 3.0mg melatonin on day 4.
223664603|NCT04231552|DRUG|Camrelizumab|Radiotherapy with CAPOX+ Camrelizumab following surgical therapy Radiation: 25 Gy/5 fractions CAPOX (2 cycles): Oxaliplatin(130mg/m2) on day 1 of each cylce and Capecitabine:Dose of 2000mg/m2,14days, q3w Camrelizumab (2 cycles): 200mg on day 1 of each cycle, q3w Surgical therapy: the resection (LAR), intersphincteric resection (ISR), or abdominoperineal resection (APR)
223664604|NCT02849353|DEVICE|Cryosurgery|Percutaneous ablation under CT or ultrasound guidance
223664605|NCT02849353|BIOLOGICAL|NK immunotherapy|Each treatment: 8\~10 billion cells in all, transfuion in 3 times, i.v.
223664606|NCT04280809|DEVICE|GaAlAs laser|GaAlAs laser (AMD Picasso, Dentsply Sirona, York, Pennsylvania, USA) with a wavelength of 810 nm was placed intraorally, at a distance of 1 cm in the position of the extracted tooth socket and circling in a 2 cm - diameter area. The power applied was 0.5 ± 20% W, continuously for 30 s. The total real energy released was 12.8 J and the real energy density applied was 4 J/cm2. Each patient was irradiated 3 times consecutively right after surgery, day 1 and day 2 after surgery
223770317|NCT01509794|OTHER|High Valence|Participants in the low valence condition will participate in two video-based simulations: first, an orientation to become familiar with the interface, and then a clinical simulation. Afterward, they will complete a written debriefing followed by an verbal debriefing with a study investigator. They will complete all activities while having their heart rate and galvanic skin response monitored using non-invasive methods.
223770318|NCT01164852|PROCEDURE|Delivery|Termination of pregnancy (delivery)after completed corticosteroids
223770319|NCT00216294|DRUG|RG1068 (Synthetic Human Secretin)|
223770320|NCT01379092|DEVICE|Trident Specimen Radiography System|MIBB images will be acquired on the standard of care device and the Trident System in the Breast Center at Hoag Hospital. BSS images will be acquired on standard of care device in the Operating Room and/or the Breast Center at Hoag Hospital and then on the Trident System. Image quality will be compared and system operation will be evaluated. Feedback will be provided to manufacturer and the Trident System further refined.
223770321|NCT01379092|DEVICE|Bioptics, Faxitron, and Full Field Digital Mammography (FFDM) Selenia|All the above devices are used for SOC BSS imaging at Hoag Hospital. The images captured from these devices will be compared to the images captured from the Trident Specimen Radiography device.
223770322|NCT06572969|OTHER|Elastic-Resistance Kick Training|Athletes used tailored Elastic Resistance training
223770323|NCT06572969|OTHER|No Elastic-Resistance Kick Training|Regular Taekwondo regimen without Elastic Resistance training
223770324|NCT00742976|DRUG|Insulin Detemir; Insulin Insulatard|Dosage is individual but fixed in study period (if possible). Detemir is given once daily, Insulatard is given twice daily.
223770325|NCT00742976|DRUG|Insulin Detemir, Insulin Insulatard|Fixed doses in study period (if possible). Insulin Detemir once daily, Insulin Insulatard twice daily.
224244411|NCT00556049|DRUG|Sunitinib|Orally on days 1-14 of each 21-day treatment cycle
224244412|NCT02859662|PROCEDURE|ruptured aortic aneurysm|All patients with ruptured abdominal aortic aneurysm may be included in this study, whatever the surgical treatment.
223664607|NCT04374227|PROCEDURE|Osteopathic Manipulative Treatment|Body regions that were treated included head, cervical, thoracic, ribs, lumbar, pelvis, sacrum, lower extremity, and upper extremity.
223770326|NCT03410225|BEHAVIORAL|CAMI-TPP|The TPP group will receive four 30-minute sessions of one-on-one coaching over 12 weeks with a MI coach; the sessions will be guided by personalized feedback aimed at increasing condom use, supporting female partners in contraceptive use, and obtaining reproductive health services and STI testing. MI counseling sessions will be conducted by phone or video call.
223770327|NCT03410225|BEHAVIORAL|CAMI-Fitness|The Fitness group will also receive four 30-minute sessions of one-on-one coaching over 12 weeks with a MI coach; these sessions will be guided by personalized feedback aimed at healthy diet, physical activity and tobacco avoidance. MI counseling sessions will be conducted by phone or video call.
223770328|NCT05893277|BEHAVIORAL|Motivational Interviewing (MI) and Behavioral Couples Therapy (BCT)|Four Motivational Interviewing sessions with the husband (wife joins for last MI session) to reduce alcohol use dependency, followed by six Behavioral Couples Therapy session with the husband and wife together to improve their relation and communication and reduce intimate partner violence. Session 1: couple establishes daily trust contract and discusses strategies to cope with reduced alcohol use. Session 2: couple revisits these coping skills and builds on additional strategies, as necessary. Session 3: they shift to improving the relationship and communication. Session 4: activity to promote caring behavior between partners. Session 5: couple reviews communication strategies learned previously, learn active listening and address any ongoing communication challenges. Session 6: review session and plans to address challenges to create long-term change.
223770329|NCT05738278|BEHAVIORAL|HR-informed change in routine|"The intervention is given for a situation occuring at least ten times and accompanied by an increase in HR at least 80% of the time, during the two-week registration period. Change in care (intervention) is introduced from week 3.~The intervention is in one of four forms:~1. changes in physiotherapy, e.g., less rigorous movement in the identified painful stretch,~2. preparations for putting on corrective cast to stabilize joint and/or stretch spastic muscles,~3. change in procedures for transportation/lifting, e.g., new technique or adaptations made to equipment, or~4. revised personal hygiene procedure."
224244413|NCT01179048|DRUG|liraglutide|Maximum dose of 1.8 mg liraglutide, injected subcutaneously (under the skin) once daily. Administered in addition to the subject's standard treatment
224244414|NCT01179048|DRUG|placebo|Maximum dose of 1.8 mg placebo, injected subcutaneously (under the skin) once daily. Administered in addition to the subject's standard treatment
223770330|NCT05738278|BEHAVIORAL|Delayed HR-informed specific change in routine|"The intervention is given for a situation occuring at least twenty times and accompanied by an increase in HR at least 80% of the time, during the four-week registration period. Change in care (intervention) is introduced from week 5.~The intervention is in one of four forms:~1. changes in physiotherapy, e.g., less rigorous movement in the identified painful stretch,~2. preparations for putting on corrective cast to stabilize joint and/or stretch spastic muscles,~3. change in procedures for transportation/lifting, e.g., new technique or adaptations made to equipment, or~4. revised personal hygiene procedure."
223770331|NCT06806228|BIOLOGICAL|S-Gboxin|Gboxin specifically inhibits the growth of human glioblastoma cells but not normal cells. Gboxin rapidly and irreversibly impairs oxygen consumption in glioblastoma cells. Its positive charge for binding to mitochondrial oxidative phosphorylation complexes is dependent on the proton gradient of the inner mitochondrial membrane, and it inhibits F 0 F 1 ATP synthase activity in tumor cells. S-Gboxin crosses the blood-brain barrier at therapeutically effective concentrations.
223770332|NCT05607953|DRUG|SD-101|SD-101 doses are administered via PRVI using the PEDD method of administration
223770333|NCT05607953|BIOLOGICAL|anti-PD-1|In the Phase 1b, anti-PD-1 will be administered together with SD-101
223770334|NCT03734198|DRUG|Ibrutinib|Ibrutinib will be given at the fixed dose of 420 mg daily for the duration of treatment.
223770335|NCT03734198|DRUG|Daratumumab|Daratumumab will be started 28 days after beginning of ibrutinib and will be administered at the standard dose of 16 mg/kg (divided over two days for the first infusion), then 16 mg/kg for the following infusions, weekly for 2 months, then every other week for 4 months and then once a month until progression or intolerance.
223770336|NCT06663397|OTHER|Laughter Yoga|Laughter Yoga sessions lasting 45 minutes each week for a total of 4 sessions. These sessions will include 30 minutes of laughter and breathing exercises, followed by 15 minutes of laughter meditation and relaxation
223664608|NCT03643978|OTHER|Decision aid|The decision aids aim to inform the patients about the diagnosis and the treatment options. They aim to help the patient prioritize and make an informed decision.
223664609|NCT05504876|DRUG|Midazolam Syrup|Administered Midazolam Syrup 5 mg orally once daily in fed state;
223664610|NCT05504876|DRUG|HEC74647PA|Administered HEC74647PA 100 mg orally once daily in fed state;
223664611|NCT05504876|DRUG|HEC110114|Administered HEC110114 600 mg orally once daily in fed state;
223664612|NCT05551442|PROCEDURE|To explore the comparative study of different positioning methods in robot assisted laparoscopic pyeloplasty.|The incidence of surgical positioning time and secondary berths, surgical time, intraoperative blood loss and intraoperative complications were compared among the three groups.
223664613|NCT05551442|DEVICE|To discuss the comparative study of different position placement methods of renal pelvis ureteroplasty on the Da Vinci robotic Xi platform|To discuss the comparative study of different position placement methods of renal pelvis ureteroplasty on the Da Vinci robotic Xi platform
223664614|NCT05937464|OTHER|Exoskeleton ExoAthlet group|This group included 16 patients who had stroke. The patients was evaluated with Functional Independence Measure (FIM), physical function with 30-second chair stand test (30-CST), functional capacity with 6-Minute Walk Test (6MWT), and their quality of life with Short Form 36 (SF36). Conventional physiotherapy program was applied to groups for eight weeks, three days a week, each session 60 minutes. Then, one group received walking exercise training with exoskeleton ExoAthlet (ExoAtlet 1 model/2019, Russia). Participants were assessed at baseline and post-intervention.
223770337|NCT06663397|OTHER|Standard Childbirth Preparation Training|the sessions will be conducted in groups of 8 participants. Various educational materials, including visual aids, will be used, and the training will involve presentations, direct instruction, video displays, and question-and-answer sessions
223770338|NCT06662552|DEVICE|whole body vibration using crazy fit machine|It will be applied on the whole body All subjects will be asked to stand in a squat position on the vibration platform with the knees bent 90 this position will be chosen because the vertical sinusoidal accelerations of the vibration platform had to be damped by the different muscles around the joints of the lower extremity) ,at a frequency of 30 Hz, 5 - 30 minutes per day, 3 times per week, for 6 weeks, and the physiotherapist will be standing beside the patient
223770339|NCT06662552|DEVICE|Pulsed electromagnetic field therapy|"EMSCULPT device (BTL Industries Inc., Boston, MA) based on HIFEM technology. It consists of an appliance, motorized bed and solenoids. The appliance will be connected to electrical mains supplying230Vat frequency of 50 or 60 Hz with earth connection, Intensity 0-100. It will be used in the treatment of patient in group B. Subjects will be positioned in a supine position, and the treatment will be performed by placing the applicator centered over their thigh region (quadriceps muscle's area), for 15 minutes per day, 3 times per week for 6 weeks, the physiotherapist will be sitting beside the patient"
224244415|NCT04343690|BEHAVIORAL|Crisis management coaching|Crisis management coaching will be offered to faculty, staff, and trainees dealing with COVID-19 pandemic
224244416|NCT04489264|DRUG|Transplant, Autologous|high dose chemotherapy followed by autologous stem cell transplantation
224244417|NCT05966571|PROCEDURE|Ovary Biopsie|Ovarian biopsy will be performed on patients meeting the inclusion criteria undergoing surgery for other reasons. Ovarian biopsy will be of a few millimeters in size and taken on only one of the ovaries.
223770340|NCT06662552|OTHER|traditional physical therapy program|In the form of splinting, stretching exercises, strengthening exercises and range of motion (ROM) exercises on quadriceps muscle 15 minutes per day, 3 times per week for 6 weeks.
224244418|NCT03171493|BIOLOGICAL|MV-NIS|Attenuated measles virus encoding NIS (MV-NIS)
224244419|NCT04433871|OTHER|No intervention, observational|No intervention, observational
224244420|NCT01836341|DRUG|Afatinib|
223664615|NCT05937464|OTHER|Lokomat Free-D group|This group included 16 patients who had stroke. The patients was evaluated with Functional Independence Measure (FIM), physical function with 30-second chair stand test (30-CST), functional capacity with 6-Minute Walk Test (6MWT), and their quality of life with Short Form 36 (SF36). Conventional physiotherapy program was applied to groups for eight weeks, three days a week, each session 60 minutes. Then, one group received walking exercise training with Lokomat Free-D (Hocoma, Lokomat Pro Free-D model/2015, Switzerland). Participants were assessed at baseline and post-intervention.
223664616|NCT05072613|OTHER|Malaria screening|Participants are screened for malaria and a dried blood spot is collected from malaria positive cases
223664617|NCT01883076|BIOLOGICAL|autologous cell-based delivery|"autologous cells (derived from self)"
223664618|NCT00440791|DEVICE|PillCam Colon capsule endoscopy|
223664619|NCT03671317|BEHAVIORAL|Medical Clowning|This arm will receive a medical clowning intervention in addition to pre and post surveys about the blood draw process.
223664620|NCT02270372|BIOLOGICAL|ONT-10, Varlilumab combination|"ONT-10 a liposomal synthetic glycopolypeptide MUC1 targeted antigen formulated with PET Lipid A adjuvant.~Varlilumab is a recombinant, fully human mAb of the IgG1κ isotype that specifically binds human CD27."
223664621|NCT03133741|OTHER|GIP-A|GIP-A (GIP receptor antagonist)
223664622|NCT03133741|OTHER|GLP-1 receptor antagonist Exendin[9-39]|Exendin\[9-39\]
223664623|NCT03133741|OTHER|Placebo|Saline (9mg/mL)
224244421|NCT01836341|DRUG|Cisplatin|
224244422|NCT01836341|DRUG|Carboplatin|
224244423|NCT01836341|DRUG|Pemetrexed|
224244424|NCT01836341|RADIATION|Radiation therapy|
224244425|NCT03649841|DRUG|Antiandrogen Therapy|Undergo ADT
224244426|NCT03649841|DRUG|Abiraterone Acetate|Undergo Abiraterone Acetate Treatment SOC
224244427|NCT03649841|DRUG|Prednisone|Undergo Prednisone Treatment SOC
224244428|NCT03649841|RADIATION|Radiation Therapy|Undergo neutron radiation therapy
224244429|NCT06140264|OTHER|Acupuncture dry needle|The muscles that have been treated iliocostalis lumborum, quadratus lumborum, gluteus medius and piriformis muscles. The patients received 2 sessions per week for 2 weeks.
224244430|NCT05847205|DRUG|r-Hirudin|100 Patients will be treated with r-Hirudin (Thrombexx) for a total of 15 days beginning with 15 mg BID s.c starting 6 hours after surgery or upon adequate hemostasis and continued until end of study.
224244431|NCT00914394|DRUG|NG-monomethyl-L-arginine (L-NMMA)|bolus 6mg/kg over 5 minutes followed by a continuous infusion of 60µg/kg/min over 15 minutes
224244432|NCT00914394|DRUG|Phenylephrine|1µg/kg/min, infusion period 20 minutes
224244433|NCT00914394|DRUG|Physiological saline solution (as placebo)|infusion period 20 minutes
224244434|NCT00914394|DEVICE|Laser Doppler Flowmetry|Measurements will be performed at the neuroretinal rim to assess ONH blood flow.
224244435|NCT00914394|DEVICE|Goldmann applanation tonometer|intraocular pressure measurements
224244436|NCT00914394|DEVICE|Suction cup|Experimental stepwise increase of intraocular pressure while measurement of optic nerve head blood flow.
224244437|NCT01529060|DRUG|Phenylbutyrate|Dosage of phenylbutyrate powder will be 500 mg/kg/day in patients weighing less than 20kg and 10 g/m2/day in larger patients in four divided doses per day, the standard UCD dose studied in our preliminary studies, for 14 days.
224244438|NCT01529060|DRUG|Placebo powder|Dosage of inactive placebo powder will be 500 mg/kg/day in patients weighing less than 20kg and 10 g/m2/day in larger patients in four divided doses per day for 14 days. Subjects will receive the same amount of powder for each arm of the study.
224244439|NCT04603209|RADIATION|Intraoperative Radiation Therapy (IORT)|IORT involving 50kV Xrays to a dose of 20 Gy during breast-conserving surgery
224244440|NCT04329988|OTHER|questionnaire|A questionnaire will be made available to all eligible patients in general practitioners waiting rooms. This questionnaire will be composed by the single question, followed by the AUDIT and FACE questionnaires, and three socio-demographic questions. This questionnaire will be anonymous. Patients who agree to fill out a questionnaire will place it in a sealed box once completed.
224244441|NCT00060307|DRUG|erlotinib hydrochloride|Given orally
224244442|NCT00060307|OTHER|laboratory biomarker analysis|Correlative studies
224244443|NCT02903888|DRUG|Levonorgestrel (Jaydess, Skyla, BAY86-5028)|Intrauterine delivery system Jaydess (13.5 mg levonorgestrel)
224244444|NCT03663478|DRUG|Ropivacaine|2 x 30 ml ropivacaine 0,2% and an elastomere pump with 200 ml ropivacaine 0,2%, infusion rate 8 ml/hour
224244445|NCT03663478|DRUG|Saline|2 x 30 mL isotonic saline and an elastomere pump with 200 ml isotonic saline, infusion rate 8 ml/hour
224244446|NCT00126906|DRUG|Monthly sulfadoxine/pyrimethamine|
224244447|NCT00126906|DRUG|2-dose sulfadoxine/pyrimethamine|
224244448|NCT05173207|DIAGNOSTIC_TEST|Videofluoroscopic swallow exam with concurrent monitoring of respiratory-swallow coordination|Participants will undergo simultaneous videofluoroscopy, nasal airflow and respiratory inductance plethysmography testing.
224244449|NCT05813340|PROCEDURE|Vascularized inter-positional periosteal connective tissue flap|It is a vascularized pedicled flap derived from the hard palate that can be used as a barrier to prevent in growth of soft tissue in guided bone regeneration and to increase soft tissue quantity
224244450|NCT00959660|BEHAVIORAL|Exercise|walking, treadmill and bicycle exercise
223664624|NCT03133741|OTHER|GIP-A + Exendin[9-39]|GIP receptor antagonist + GLP-1 receptor antagonist
223664625|NCT03873740|BIOLOGICAL|EV71 inactived vaccine（Vero cells）|The EV71 inactived vaccine（Vero cells） was manufactured by Sinovac Biotech Co., Ltd.
223664626|NCT03873740|BIOLOGICAL|EV71 inactived vaccine（Human diploid cells）|The EV71 inactived vaccine（Human diploid cells） was manufactured by Institute of Medical Biology Chinese Academy of Medical Sciences.
223664627|NCT04120298|BEHAVIORAL|Supervised exercise|An individualised exercise programme supervised by a trained instructor
223664628|NCT00150917|BEHAVIORAL|Supportive-Expressive Group Therapy|
223664629|NCT03897140|DIAGNOSTIC_TEST|Diagnostic Test: Limited Echocardiogram|STUDY SOFTWARE non-significant risk (NSR) Bay Labs EchoGPS software interfaced with the Terason uSmart 3200t FDA 510(k)-cleared, commercially available ultrasound EchoGPS software communicates with the ultrasound image formation engine of the 510(k)-cleared Terason uSmart 3200t through an application programming interface (API). EchoGPS will be used to provide visual guidance feedback to users during image acquisition. For this study, RNs will use EchoGPS to perform limited echocardiogram examinations.
223664630|NCT03124927|DEVICE|DCI pulse oximeter sensor|
223664631|NCT02576184|DEVICE|Biologic Mesh|Biologic mesh placed in retromuscular position during ileostoma closure
223664632|NCT02576184|DEVICE|Synthetic Mesh|synthetic mesh placed in retromuscular position during ileostoma closure
223664633|NCT06419530|OTHER|Probiotic formula capsule|The subjects take 4 capsules a day for 84 days.
224244451|NCT00959660|DIETARY_SUPPLEMENT|Dietary Intervention|Subjects will be provided meals and instructions for individual food selections.
224244452|NCT00959660|BEHAVIORAL|Diet and exercise|Subjects will be provided meals and instructions for individual food selections and will undergo walking, treadmill and bicycle exercise.
224244453|NCT00959660|OTHER|Attention Control|control group- continue their previously randomized life style
223664634|NCT06419530|OTHER|placebo capsule|The subjects take 4 capsules a day for 84 days.
223664635|NCT06419530|OTHER|FMT capsule|The subjects take 4 capsules a day for 84 days.
223770341|NCT00703222|BIOLOGICAL|SNJB-JF-IL2 and SJNB-JF-Lptn + Dose Level 1 SKNLP|"SJNB-JF-IL2 and SJNB-JF-Lptn at 1 x 10\^7 cells/m2~SKNLP at 1 x 10\^6 cells/m2"
223770342|NCT00703222|BIOLOGICAL|SNJB-JF-IL2 and SJNB-JF-Lptn + Dose Level 2 SKNLP|"SJNB-JF-IL2 and SJNB-JF-Lptn at 1 x 10\^7 cells/m2~SKNLP at 1 x 10\^7 cells/m2"
223770343|NCT03421288|DRUG|Atezolizumab|Day 1 q2w: 840 mg IV over 1 hour (4 cycles perioperative with FLOT) + Day 1 q3w: 1200 mg IV over 1 hour (8 additional cycles monotherapy)
223770344|NCT03421288|DRUG|5-Fluorouracil|Day 1 q2w: 2600 mg/m² IV over 24 hours
223770345|NCT03421288|DRUG|Calciumfolinat|Day 1 q2w: 200 mg/m² IV over 1 hour
224244454|NCT04768309|OTHER|Ex vivo exploration of the effect of a probiotic over precursor indole production|Fresh feces in chronic kidney patients and healthy volunteers will be collected. The feces will be instilled in artificial intestine with and without selected probiotics and production of uremic toxins will be measured.
223664636|NCT02921464|OTHER|none - registry clinic followup only|
224244455|NCT01805583|OTHER|Acceptance and Commitment Therapy (ACT)|
224244456|NCT01805583|OTHER|workplace intervention (WPI)|
223664637|NCT00614770|PROCEDURE|standard of care colonoscopy|"Standard White Light Colonoscopy~one exam per patient"
223664638|NCT00614770|PROCEDURE|colonoscopy|"Narrow Band Imaging Colonoscopy~one exam per patient"
223664639|NCT00614770|PROCEDURE|standard of care colonoscopy|"High Definition White Light Colonoscopy~one exam per patient"
223664640|NCT06531967|OTHER|No intervention|No intervention
223664641|NCT03330002|DEVICE|CE-marked MANTA vascular closure device (VCD)|Compile real word data on MANTA VCD.
223664642|NCT02114658|DRUG|Sorafenib (Nexavar,BAY43-9006)|Sorafenib 400 mg will be administered orally,twice daily in a 28 day cycle
223664643|NCT04329338|OTHER|Lactobacillus pentosus KCA1|Lactobacillus pentosus KCA1 suspended in dairy and taken orally for 14 days
223664644|NCT00635219|DRUG|Placebo|capsules; daily; orally
223664645|NCT00635219|DRUG|Vortioxetine (Lu AA21004)|2.5 mg/day; encapsulated tablets; orally
223664646|NCT00635219|DRUG|Vortioxetine (Lu AA21004)|5 mg/day; encapsulated tablets; orally
223664647|NCT00635219|DRUG|Vortioxetine (Lu AA21004)|10 mg/day; encapsulated tablets; orally
223770346|NCT03421288|DRUG|Oxaliplatin|Day 1 q2w: 85 mg/m² IV over 2 hours
223770347|NCT03421288|DRUG|Docetaxel|Day 1 q2w: 50 mg/m² IV over 1 hour
223770348|NCT02292628|DRUG|Infusion of mesenchymal stem cells from adipose tissue|
223770349|NCT02292628|OTHER|Infusion of placebo|
223770350|NCT00001249|DRUG|Yttrium-90 radiolabeled anti-Tac antibody|
223770351|NCT03613896|PROCEDURE|conventional dentures|conventional dentures
223770352|NCT03613896|PROCEDURE|3d printed denture|construction of a 3d printed denture through a recent method instead of conventional heat processing
223770353|NCT02420496|DRUG|Enteral fish oil|
223770354|NCT02420496|DRUG|Ursodeoxycholic Acid|
223770355|NCT02420496|DRUG|Placebo|
223664648|NCT00635219|DRUG|Duloxetine|60 mg/day; encapsulated capsules; orally
223664649|NCT02456363|BIOLOGICAL|TNF alpha|Depending on patient need to use different TNF alpha
223664650|NCT02456363|DRUG|NSAIDs and sulfasalazine|randomized case, combine with use of NSAIDs(-/+) and sulfasalazine(-/+)
223664651|NCT03986593|DEVICE|cryoablation|cryoablation of bone metastases by cone beam-CT image-guidance
223664652|NCT01223742|DIETARY_SUPPLEMENT|ACETYL-L-CARNITINE|2 g acetylcarnitine taken orally twice a day.
223664653|NCT01223742|DRUG|placebo|placebo twice per day
223664654|NCT05181189|DRUG|DAOIB+Omega-3|The omega-3 fatty acids dose will be adjusted every 8 weeks according to clinical evaluation.
223664655|NCT05181189|DRUG|DAOIB+Placebo|Placebo
223664656|NCT00397917|DRUG|Folic acid: 4 mg versus 0.4 mg per day|Folic acid
223664657|NCT01598129|GENETIC|ONCOS-102|GMCSF encoding 3/5 chimeric adenovirus for intratumoral and intravenous injection on day 1, 4, 8, 15, 29, 57, 85, 113 and 141 tested in three different dose cohorts (3x10E10, 1x10E11 and 3x10E11) in combination with low-dose metronomic cyclophosphamide.
223664658|NCT00505076|DRUG|MK-0777|MK-0777 GEM, 8 mg BID
223664659|NCT00505076|DRUG|MK-0777|MK-0777 GEM, 3 mg BID
223664660|NCT00505076|DRUG|placebo|2 tablets placebo BID
223664661|NCT04641884|OTHER|Not concerned|Not concerned
223664662|NCT02250703|DRUG|Midazolam|oral midazolam 0.5mg/kg upto maximum dose of 15mg
223664663|NCT02250703|DRUG|Dexmedetomidine|intranasal dexmedetomidine 2mcg/kg upto maximum dose of 100mcg
223770356|NCT07023692|BEHAVIORAL|Distraction with VR (Virtual Reality) headsets|VR headsets will be fitted and applied in consultation with the study participants. Distraction material will be selected from a range of options based on the participant's preferences, such as watching/listening to a story, an experience of being in nature, or mindfulness. When applying the VR headsets, care will be taken to ensure no light leaks into the eyes and that the headband and headphones are not perceived as too tight. This is especially important in terms of the risk for motion sickness (cyber sickness). The VR headsets will then be used throughout the examination procedure and removed once the bandage has been applied.
224244457|NCT06324682|DEVICE|Cardiac pacing - Conventional RV pacing|Implantation of devices for cardiac pacing/defibrillation
224244458|NCT06324682|DEVICE|Cardiac pacing - Conduction System Pacing|Implantation of devices for cardiac pacing/defibrillation
224244459|NCT06324682|DEVICE|Cardiac pacing - Cardiac resynchronization therapy (pacing - CRTP - or defibrillation - CRTD)|Implantation of devices for cardiac pacing/defibrillation
224244460|NCT06324682|DEVICE|Cardiac pacing - Epicardial pacing|Implantation of devices for cardiac pacing/defibrillation
224244461|NCT06324682|DEVICE|Cardiac pacing - Leadless pacing|Implantation of devices for cardiac pacing/defibrillation
224244462|NCT00012948|PROCEDURE|Telephone Care|
224244463|NCT01591122|DRUG|Placebo and prednisone|Placebo: Form=tablet, route=oral. Four tablets daily on an empty stomach. Prednisone: Type=exact number, unit=mg, number=5, form=tablet, route=oral, twice daily.
224244464|NCT01591122|DRUG|Abiraterone acetate and prednisone|Abiraterone acetate: Type=exact number, unit=mg, number=250, form=tablet, route=oral. Four tablets daily on an empty stomach Prednisone: Type=exact number, unit=mg, number=5, form=tablet, route=oral, twice daily
223664664|NCT04483401|BEHAVIORAL|Cognitive Orientation to Occupational Performance (CO-OP)|"Intervention: CO-OP is a cognitive approach to solving functional motor problems (Polatajko et al., 2001b). Therapists teach children a global problem solving strategy (Goal-Plan-Do-Check) as a framework for developing specific strategies for overcoming motor problems; these strategies are determined after a dynamic performance analysis by the therapist to determine where the breakdown is in performing the task. CO-OP intervention will be administered by occupational therapists who have been trained in the CO-OP approach. Children will be seen once weekly for one hour over 12 weeks at as per published protocol (Polatajko et al., 2001b). Parents or caregivers will be encouraged to attend treatment sessions so that therapists can instruct them how to facilitate strategy use between treatment sessions. Children will select three functional motor goals to be addressed over the course of treatment, rating their performance and satisfaction of these goals pre- and post-intervention."
223664665|NCT01672177|BEHAVIORAL|Chronic disease self-management training|Those in the intervention group will receive two hour long weekly training sessions for seven-eight months (a total of 56 hours of training).
223664666|NCT02661048|DEVICE|CyberHeart System|The CyberHeart system uses proprietary software to assist the cardiologist to contour ablation targets. Standard radiosurgical techniques are then used to accomplish ablation
223664667|NCT05615519|DIAGNOSTIC_TEST|A new technology based on 3D reconstruction and deep learning algorithm to achieve an automatic diagnosis of strabismus based on patient-sourced videos of programmatic cover tests.|Digital ruler of strabismus
223770357|NCT07025265|BEHAVIORAL|Breastfeeding Self-Efficacy-Based Education and Counseling|his intervention consists of breastfeeding self-efficacy theory-based education provided during the antenatal period. The education covers key factors affecting maternal breastfeeding self-efficacy, including previous experiences, vicarious learning, social support, and psychological responses. Weekly reminder and encouragement text messages will be sent until birth. Postpartum follow-up includes a home visit in the first week for counseling and phone-based follow-ups in the 2nd, 3rd, and 4th weeks.
223664668|NCT02231099|PROCEDURE|Prolift + M|prolapse surgery with mesh
223770358|NCT03655236|DRUG|K0706|low dose, orally, once-daily
223770359|NCT03655236|DRUG|K0706|high dose, orally, once-daily
223770360|NCT03655236|OTHER|placebo|placebo, orally, once-daily
223770361|NCT05535907|DEVICE|Intravascular Lithotripsy|Enhancing percutaneous transluminal angioplasty by utilizing delivery of IVL to disrupt calcium in below the knee lesions prior to full balloon dilatation at low pressures
224244465|NCT03943238|BIOLOGICAL|Infusion of Donor Hematopoetic Stem Cells and Recipient Tregs|Living donor kidney transplant recipients will receive after a preparatory regimen of total lymphoid irradiation, total body irradiation and anti-thymocyte globulin an infusion of purified donor CD34+ of \>10 x10\^6 cells /Kg, 100 x 10\^6 donor T cell/ Kg and and an escalated dose of recipient Tregs starting at 25 x10\^6/Kg.
224244466|NCT01297348|DRUG|90ug levonorgestrel / 20 ug ethinyl estradiol|This is a non-interventional observational database study, thus no interventions are offered to patients in the study.
224244467|NCT01297348|DRUG|Oral Contraceptives containing 20 ug of ethinyl estradiol|This is a non-interventional observational database study, thus no interventions are offered to patients in the study.
224244468|NCT00518830|OTHER|multi-component intervention|The PND-MCI included psycho-educational groups, structured pharmacotherapy if needed, and systematic monitoring of clinical progress and treatment compliance
224244469|NCT00518830|OTHER|Usual care|included all services normally available in the clinics, including antidepressant medication, brief psychotherapeutic interventions or referral for specialty treatment
224244470|NCT05343078|DRUG|Dapagliflozin 10Mg Tab|Participants will take a single-dose Dapagliflozin 10mg P.O. prior to the hemodialysis session for the single-dose pharmacokinetics protocol. In the multiple-dose protocol, Dapagliflozin 10mg P.O. will be taken daily in the morning for one week.
224244471|NCT01520909|DRUG|Eltrombopag|Thrombopoietin receptor agonist
223664669|NCT02231099|PROCEDURE|conventional vaginal prolapse surgery|conventional vaginal prolapse surgery;anterior colporrhaphy, posterior colporrhaphy
223664670|NCT01499706|BEHAVIORAL|1-session of telephone-administered motivational interviewing|Participants will receive a single session of telephone-delivered motivational interviewing to reduce sexual risk behavior.
223770362|NCT06887608|OTHER|Husband assisted rebozo application|At 4-5 cm, 6-7 cm and 8-9 cm, the pregnant woman will be given a rebozo by her husband.
223770363|NCT06887608|OTHER|Midwife assisted rebozo application|The midwife will apply rebozo to the pregnant woman at 4-5 cm, 6-7 cm and 8-9 cm.
223664671|NCT01499706|BEHAVIORAL|4-session telephone-administered motivational interviewing|Participants will receive four weekly sessions of telephone-delivered motivational interviewing to reduce sexual risk behavior.
223770364|NCT06889753|DIETARY_SUPPLEMENT|Graminex WSPE|Graminex Water Soluble Pollen Extract is standardized to 6% amino acids.
223770365|NCT06889753|DIETARY_SUPPLEMENT|Graminex LSPE|Graminex Lipid Soluble Pollen Extract is standardized to 7% phytosterols.
223770366|NCT06889753|DIETARY_SUPPLEMENT|Placebo|Placebo
223770367|NCT06763705|DRUG|Midazolam|It will not be used alone but in combination with Fentanyl in the Midazolam + Fentanyl group.
223770368|NCT06763705|DRUG|Propofol|It will used alone in Propofol group and in combination with Fentanyl in the Propofol + Fentanyl group.
223770369|NCT06763705|DRUG|Fentanyl|Fentanyl will not be used in isolation but will be used in combination with either Midazolam or Propofol in Midazolam + Fentanyl group and Propofol + Fentanyl group, respectively.
224244472|NCT01520909|DRUG|Placebo|Placebo with no active pharmaceutical ingredient
224244473|NCT01748630|DRUG|dexmedetomidine|
224244474|NCT01748630|DRUG|Midazolam|
224244475|NCT01748630|DRUG|fentanyl|
224244476|NCT02792426|DRUG|Research ENDS S-TA-U001|
224244477|NCT02792426|DRUG|Nicorette Inhalator|
224244478|NCT05508659|DRUG|Duvelisib|Duvelisib PR2D bid po. until progressive disease (PD), unacceptable toxicity, or any criterion for withdrawal from the trial.
224244479|NCT05508659|DRUG|SG001|240mg, each two weeks,iv,until progressive disease (PD), unacceptable toxicity, or any criterion for withdrawal from the trial.
224244480|NCT04865952|PROCEDURE|periodontal surgery + 24 hr buccal attached gingiva (G) biopsy|Periodontal surgery will be performed and 24 hr after the surgical procedure a 2mm punch biopsy will be harvested at the level of the buccal attache gingiva (G).
223664672|NCT02303132|OTHER|Ussing experiment|fresh colon mucosa (biopsy) of all participants will be mounted in an Ussing chamber and exposed to NSAIDs / PPI / control.
223770370|NCT07063329|DRUG|PLB1004 80mg/160mg/240mg oral once daily Combined with Platinum-Based Chemotherapy|For non-squamous NSCLC patients：Pemetrexed (500 mg/m2) plus carboplatin (AUC5) or cisplatin（75 mg/m²）on Day 1 of 21day cycles (every 3 weeks) , followed by PLB1004 80mg/160mg/240mg oral once daily。 For squamous NSCLC subjects: Docetaxel（75 mg/m² ）or paclitaxel（175 mg/mg） plus carboplatin (AUC5) or cisplatin（75 mg/m²）on Day 1 of 21day cycles (every 3 weeks) , followed by PLB1004 80mg/160mg/240mg oral once daily.
223770371|NCT07063329|DRUG|PLB1004 80mg/160mg/240mg oral once daily Combined with Platinum-Based Chemotherapy|Multiple doses of PLB1004 for oral administration. Platinum-based chemotherapy is combined and administered on Day 1 of 21days（every 3 weeks).
223770372|NCT07063329|DRUG|RP2D of PLB1004 oral once daily Combined with Platinum-Based Chemotherapy|RP2D of PLB1004 as determined during Phase Ib . Platinum-based chemotherapy is combined and administered on Day 1 of 21days（every 3 weeks）.
223770373|NCT07063329|DRUG|RP2D of PLB1004 oral once daily Combined with Platinum-Based Chemotherapy|RP2D of PLB1004 as determined during Phase Ib，patients will undergo surgical treatment after 3 cycles of combination therapy with platinum-based chemotherapy. Post-surgery, they will receive an additional cycle of platinum-based chemotherapy followed by 13 cycles of maintenance therapy with PLB1004.
223770374|NCT01752205|DRUG|Paclitaxel|45mg/m2/w,total 6 weeks
224244481|NCT04865952|OTHER|HA application|HA will be applied at the end of the surgical procedure, at the level of the vertical released incisions (VRIs) and over VRIs
224244482|NCT04487132|BEHAVIORAL|Active physical education lessons and physical education plan|Active physical education lessons and physical education plan Including importance of physical activity and health, and physical education plan; through lecture in classroom will be provided to the contyrolled group.
224244483|NCT04487132|BEHAVIORAL|Recess or lunch time activities|group intervention will be provided ti the experimental group which includes Preparing the playground by offering adequate spaces and games.Developing games and teaching children to play in recess time at-least 10-15 minutes daily(i.e.sport games, traditional games) Placing a sheet in the classroom with some reminders about being active in recess time (i.e. using a poster board encouraging playing one of the selected games )
224244484|NCT00650793|DRUG|Extended Release OROS® Paliperidone|
224244485|NCT02373319|BEHAVIORAL|CV-screening-1 plus personalized|Cardiovascular risk screening supervised by health professional - 15 minutes wash-out - Self-screening of cardiovascular risk; Communication of personalized recommendations according to the health exam results for the control of cardiovascular risk factors
224244486|NCT02373319|BEHAVIORAL|CV-screening-2 plus personalized|Self-screening of cardiovascular risk - 15 minutes wash-out - Cardiovascular risk screening supervised by health professional; Communication of personalized recommendations according to the health exam results for the control of cardiovascular risk factors
224244487|NCT02373319|BEHAVIORAL|CV-screening-1 plus standard|Cardiovascular risk screening supervised by health professional - 15 minutes wash-out - Self-screening of cardiovascular risk; Standard communication of the health exam results
224244488|NCT02373319|BEHAVIORAL|CV-screening-2 plus standard|Self-screening of cardiovascular risk - 15 minutes wash-out - Cardiovascular risk screening supervised by health professional; Standard communication of the health exam results
224244489|NCT00319345|DRUG|Mannitol, Sodium-Lactate|
224244490|NCT04465864|DRUG|Intracanalicular Dexamethasone, 0.4 mg insert|Intracanalicular Dexamethasone, 0.4 mg insert four days (+/- 1 day) prior to surgery or inserted the day of surgery.
224244491|NCT04383431|PROCEDURE|PACK-CXL|Standard epithelium-off CXL, 12 minutes soaking time with riboflavin, 8 minutes UVA corneal irradiation pulsed mode.
224244492|NCT02676024|DEVICE|Knowledge-based cognitive aid|"Trained on the use of a knowledge-based cognitive aid for pediatric cardiac arrests. Will be used by a dedicated team member (cognitive aid reader)."
224244493|NCT02676024|DEVICE|Cognitive aids with roles defined (CARD)|"Trained on the use of the cognitive aids with roles defined (CARD) system for pediatric cardiac arrests. Participants are given large identification cards to be worn, which enable the code leader to quickly recognize the individuals' purpose at the code. The card identifies specific tasks associated with the role, ensuring that the participant knows exactly what their task is. Will not have a dedicated team member during the scenario (cognitive aid reader)."
224244494|NCT02676024|DEVICE|Integrated cognitive aids|"Trained on the use of the cognitive aids with roles defined (CARD) system and also in the use of a protocol-based cognitive aid for pediatric cardiac arrests which will be used by a dedicated cognitive aid reader."
224244495|NCT04775745|DRUG|LP-168|For the dose escalation phase, LP-168 will be given once or twice daily at the following dose levels:100 mg QD,150 mg QD, 100 mg BID, 300 mg QD, 150 mg BID, 450 mg QD, 225 mg BID, 600 mg QD, 800 mg QD, and 1000 mg QD.
224244496|NCT04775745|DRUG|LP-168|For the dose expansion phase, subjects will receive once or twice daily dose of LP-168 at the Recommended Phase 2 Dose (RP2D). The RP2D may be as high as the MTD and will be determined following evaluation of Phase I Dose Escalation results.
224244497|NCT00483626|DRUG|oral sildenafil|
224244498|NCT01366079|PROCEDURE|Position change|Patients change position (cecum to hepatic flexure, left lateral; transverse colon, supine; splenic flexure and descending colon , right lateral) during colonoscopy withdrawal.
224244499|NCT01366079|PROCEDURE|Left lateral|In left lateral position group patients are positioned left lateral decubitus during colonoscopy withdrawal.
223664673|NCT00000722|DRUG|Pentamidine isethionate|
223664674|NCT00133549|DRUG|Placebo|Saline placebo administered in a volume of 0.5 ml intramuscularly.
223664675|NCT00133549|BIOLOGICAL|PNU-IMUNE®23|The 23-valent pneumococcal vaccine (PS) vaccine will contain a mixture of 25 micrograms purified, pneumococcal polysaccharide of each of 23 serotypes of Streptococcus pneumoniae per 0.5 ml dose in isotonic saline and 0.01% thimerosal. The vaccine will be administered in a volume of 0.5 ml intramuscularly.
223664676|NCT00133549|BIOLOGICAL|Nine-valent pneumococcal conjugate (PNCRM9)|Cross-reactive material 197 (CRM 197) is a product of the Corynebacterium diphtheria C7. Vaccine is prepared from pneumococcal polysaccharides of types 1, 4, 5, 9V, 14, 18C, 19F, 23F (2 mcg each) and 6B (4 mcg) covalently linked to CRM197 by reductive amination. The protein-polysaccharide combination is prepared as a lyophilized powder with aluminum phosphage which is reconsitituted before use. The vaccine will be administered in a volume of 0.5 ml intramuscularly.
223664677|NCT00591318|DRUG|ceftriaxone|2 grams of ceftriaxone given daily, Monday to Friday, excluding major holidays, for a total of 40 doses
223664678|NCT00591318|DRUG|Normal Saline|50 cc of normal saline, daily, Monday through Friday, except for major holidays, for a total of 40 normal saline infusions.
223664679|NCT04431921|DIAGNOSTIC_TEST|Functional capacity|Six minute walk test used assessment of functional capacity. For respiratory function mouth pressures, for cognitive functions MoCA scale and for pain assessment pain threshold and tolerance test assessed.
223664680|NCT04694924|OTHER|standard of care|"No other procedures than those performed during the usual care for prostate cancer patients will be done. No study medication will be provided as part of participation.~Clinical outcomes will be reported via predefined electronic forms, integrated into the electronic health record (EHR). Patient-reported outcomes will be collected electronically.~All treatment decisions will be made at the discretion of the investigator or treating physician."
223664681|NCT02482038|DEVICE|geko|neuromuscular electrostimulator
223664682|NCT03234283|DEVICE|IRRIS InfraRed - Red Intubation System|IRRIS will be attached to the patient's neck skin just beneath the laryngeal prominence. Tracheal intubation will be performed by using a video-laryngoscope in a standardized Fashion and by guiding the tracheal tube into the Larynx by following the visual Signal on the Screen that is caused by IRRIS. The handling of IRRIS and the Performance of tracheal Intubation will be recorded. Patients will be monitored for safety parameters and possible adverse events during the study until recovered and released from the postoperative care unit.
223664683|NCT02460601|DRUG|Qizhiweitong granule|
223664684|NCT02586441|DEVICE|Electroencephalography|Raw EEG signals were acquired at a sampling rate of 128Hz using a BIS-VISTATM monitor and was measured during all anesthetic period.
223664685|NCT02586441|DRUG|Propofol|intravenous 1% propofol (1.5-2.5 mg/kg)
223664686|NCT02586441|DRUG|Rocuronium bromide|intravenous rocuronium bromide (0.6 mg/kg)
223664687|NCT05520892|DRUG|intravenous immunoglobulin|To compare the efficacy of two different dosage regimens of intravenous immune globulin (IVIG) in the treatment of children with newly diagnosed immune thrombocytopenia
223664688|NCT04941170|DRUG|Bupivacain|Ultrasound-guided oblique subcostal transversus abdominis plane block will be performed in the supine position under strict aseptic precautions. placing a linear high-frequency ultrasound probe obliquely near the costal margin and xiphoid process On confirming the placement of the needle in the correct target space, 1 mL of 0.25% bupivacaine will be injected to hydro-dissect the fascia layer between the RA and TA. After confirming the separation of the transversus abdominis fascia plane, the remaining 19 mL of 0.25% bupivacaine will be administered, advancing the needle infero-laterally parallel to the subcostal margin. A similar procedure will be performed on the contralateral side of the abdomen with an injection of another 20 mL of 0.25% bupivacaine.
223664689|NCT04941170|DRUG|Bupivacaine|Ultrasound-guided erector spinae plane block will be performed in the sitting position. T7 spinous process will be located To perform the block. The tip of the T7 transverse process will be then identified using the ultrasound probe that is placed in a transverse orientation The ultrasound transducer will then be placed in a longitudinal orientation 2-3 cm lateral to the midline in a longitudinal orientation to identify the hyperechoic line of the transverse process with its associated acoustic shadow. After local anaesthetic infiltration, the block needle will be inserted in a craniocaudal direction until contact will be achieved with the T 7 transverse process where the tip will lay in the inter-fascial plane below the erector spinae muscle. A small bolus of local anaesthetic should be given through the block needle to confirm the proper needle position. A total of 20 mL bupivacaine 0.25% will be injected into the interfacial plane deep to the erector spinae muscle bilaterally.
224244500|NCT05220683|DEVICE|digital marking system|Verion or Callisto, digital marking system
224244501|NCT05167981|OTHER|RETAINWORKS|The experimental group is eligible to receive the full set of RETAINWORKS intervention activities. The program includes a combination of medical provider services, stay-at-work (SAW)/return-to-work (RTW) coordination services, and other SAW/RTW services. Participants receive intensive case management and care coordination by health and employment services RTW navigators. Financial incentives are offered to participants and medical providers for milestone attainment and training achievement.
224244502|NCT03850795|DRUG|HC-1119|oral once daily 80 mg
224244503|NCT03850795|DRUG|Enzalutamide|oral once daily 160 mg
224244504|NCT02536950|DEVICE|Fixed set point|Fixed set point arm: A fixed setpoint will be used initially. Staff will observe glucose control over 2 days while subjects remain in a hotel environment, and then over 5 more days in the same subjects in an outpatient setting. The clinical staff will adjust this target up or down by 15 mg/dl based on their glycemic control in the hotel setting.
224244505|NCT02536950|DEVICE|Variable set point|Variable set point arm: The setpoint will be variable over a 30 mg/dl range and glycemic control will be optimized based on the preceding 24-hour window.
224244506|NCT04907838|DRUG|Insulin clamp|Continous infusion insulin + glucose
224244507|NCT04907838|DRUG|BQ123|Continuous infusion of Insulin + glucose + BQ123
224244508|NCT04907838|DRUG|BQ123 + BQ788|Continous infusion of insulin + glucose + BQ123 + BQ788
224244509|NCT06416826|DEVICE|Vibroacoustic Therapy System - VTS 1000|Participants will undertake 15 self-administered sessions of RSS 40Hz low frequency sound stimulation, 30 minutes daily, over 3 weeks (5 days/week).
224244510|NCT05935631|DIETARY_SUPPLEMENT|Salt with folic acid and iodine|Assess serum and RBC folate levels in women at baseline and 1 month after ingesting salt with folic acid
224244511|NCT03748303|DRUG|Allopregnanolone|Administration of weekly IM injections of Allopregnanolone.
224244512|NCT02188303|DRUG|LY2944876|Administered SC
224244513|NCT02188303|DRUG|Placebo|Administered SC
224244514|NCT01945164|DRUG|XL999|The treatment will consist of 4-week cycles in which the subject will receive XL999 administered as a 4-hour IV infusion every other week. The subject will continue to receive 4-week cycles of XL999 in the absence of progressive disease, unacceptable drug-related toxicity, and as long as the drug is available.
223664690|NCT01641419|DRUG|Placebo|2 ml of saline added to 30 ml of ropivacaine 0.5% solution for nerve block
223664691|NCT01641419|DRUG|Dexamethasone 4 mg|2 ml of dexamethasone 4 mg solution added to 30 ml of ropivacaine 0.5% solution for nerve block
224244515|NCT02589808|DEVICE|Full TTE|Full transthoracic echocardiogram, with Doppler.
224244516|NCT02589808|DEVICE|GE Vscan|Handheld echo.
223664692|NCT01641419|DRUG|Dexamethasone 8 mg|2 ml of dexamethasone 8 mg solution added to 30 ml of ropivacaine 0.5% solution for nerve block
223664693|NCT00572130|GENETIC|Rexin-G Dose 1|Rexin-G i.v., 1 x 10e11 cfu, two times a week x 4 weeks, rest 2 weeks May be repeated if grade 1 or less toxicity
223664694|NCT00572130|GENETIC|Rexin-G Dose 2|Rexin-G i.v., 1 x 10e11 cfu, three times a week x 4 weeks; rest 2 weeks May repeated if grade 1 or less toxicity
223664695|NCT04076098|DRUG|Minocycline Hydrochloride|Administration of Periocline gel into the periodontal pockets will be carried out until it overflows the pockets
223664696|NCT05827198|OTHER|Low-sugar candies compared to regular sugar candies|Acute intake
223664697|NCT00945295|DRUG|Botulinum toxin type A, BoNT-A|Participants will receive IM injections of BoNT-A between 200 and 400 Units with the total dose not to exceed 6 U / kg. The primary targets for BoNT-A injection are the wrist and finger flexor muscles (flexor carpi radialis, flexor carpi ulnaris, flexor digitorum profundus, flexor digitorum superficialis).
223664698|NCT00945295|OTHER|Rehabilitation Therapy|Rehabilitation therapy
223664699|NCT02030899|PROCEDURE|Cage fusion|Randomized selection of surgery type
223664700|NCT02030899|PROCEDURE|Plate fusion|Randomized selection of surgery type
223664701|NCT02101710|DRUG|Elantan SR 60 mg|"* Trade Name: Elantan~* Active Substance: Isosorbide 5-mononitrate~* Pharmaceutical form: Tablet~* Concentration: 60 mg~* Route of Administration: Oral administration"
223664702|NCT02101710|DRUG|Imdur SR 60 mg|"* Trade Name: Elantan~* Active Substance: Isosorbide 5-mononitrate~* Pharmaceutical form: Tablet~* Concentration: 60 mg~* Route of Administration: Oral administration"
223664703|NCT03373903|OTHER|Placebo|oral
223664704|NCT03373903|DRUG|BEZ235|oral
223664705|NCT03373903|DRUG|BEZ235 plus everolimus (RAD001)|Oral
223664706|NCT01450852|BEHAVIORAL|Strength Training|Each Member of this group completed 12 weeks of progressive, periodized resistance training for 3d/wk.
223664707|NCT00846950|DRUG|dexchlorpheniramine, lorazepam|
223664708|NCT03835793|DIAGNOSTIC_TEST|CAC-score|Testing for possible unfavourable health effects of early surgical menopause
223664709|NCT05785819|DRUG|VLX-1005|VLX-1005, a 12-LOX enzyme inhibitor
224244517|NCT04206332|DRUG|VRC-MALMAB0100-00-AB|VRC-MALMAB0100-00-AB (CIS43LS) is a monoclonal antibody that recognizes a unique and conserved region of the Plasmodium falciparum (P. falciparum) circumsporozoite protein and incorporates an LS mutation to increase product half-life in plasma.
224244518|NCT04206332|OTHER|Plasmodium falciparum (P. falciparum) sporozoite challenge|Participants were exposed to bites on the forearm from Anopheles stephensi mosquitoes infected with P. falciparum (3D7 strain).
224244519|NCT03171285|OTHER|Less than 35 years old|Clinical and laboratory evaluations
224244520|NCT03171285|OTHER|Greater than or equal to 35 years|Clinical and laboratory evaluations
224244521|NCT05664919|DRUG|SA58 Nasal Spray|SA58 nasal spray , provided by Sinovac Life Sciences Co. , Ltd. mainly consists of neutralizing antibody of COVID-19, with 5 mg neutralizing antibody of COVID-19 per ml, 20 sprays per bottle.
224244522|NCT06337721|BEHAVIORAL|SPEAR (Strategies for Pacific Empowerment and Alcohol Reduction)|This behavioral group intervention will consist of multiple group sessions to reduce AUDs and alcohol-related harms in Pacific Islander young adults. It will infuse culturally resonant narratives, language, and elements into existing evidence-based strategies.
224244523|NCT01618097|BEHAVIORAL|DVD Decision Aid|Patients will receive the DVD decision aid to view, and follow up 3 days and 30 days post visit.
224244524|NCT01618097|BEHAVIORAL|Internet Based Decision Aid|Patients will receive the OA specific internet based decision aid to view, and follow up 3 days and 30 days post visit
224244525|NCT03059628|OTHER|Personalized Normative Feedback|"This PNF technique use information designed to correct normative misperceptions to reduce heavy drinking. Much of the alcohol consumption among college students stems from the fairly widespread perception that one's peers expect regular and sometimes extreme drinking participation (subjective drinking norms). The PNF approach is designed to counter this perception by giving students accurate figures on how much their peers actually drink (actual drinking norms). It also aims to improve students' understanding of alcohol use in general and the firmly established negative outcomes associated with short - and long-term patterns of excessive drinking."
224244526|NCT03059628|OTHER|Brief Therapeutic Intervention|BTI are brief (typically one session 20-30 mns) and incorporate some or all of the following elements:feedback on the person's alcohol use and any alcohol-related harm; clarification as to what constitutes low risk alcohol consumption; information on the harms associated with risky alcohol use; benefits of reducing intake; motivational enhancement; analysis of high risk situations for drinking and coping strategies; and the development of a personal plan to reduce consumption.
224244527|NCT03059628|OTHER|Evaluation questionnaire|The patient have to fill the same evaluation questionnaire at J0, M6 and M12
224244528|NCT00989274|BIOLOGICAL|Vaccine Sanofi A(H1N1) 15 ug & trivalent|Grup 1: day 0: Vaccine trivalent (A/Brisbane/59/2007 (H1N1)-like virus, A/Brisbane/10/2007 (H3N2)-like virus, and B/Brisbane/60/2008-like virus) Vaccine Sanofi A(H1N1) administrated 15 ug. (nonadjuvant); day 28 Vaccine Sanofi A(H1N1) administrated a 15 ug. (nonadjuvant);
223664710|NCT05785819|DRUG|Placebo|Placebo matching VLX-1005
223664711|NCT05056584|BIOLOGICAL|Glucagon infusion|One hour glucagon-clamp followed by one hour of blood sampling
223664712|NCT05056584|BIOLOGICAL|Primed tracer infusion|Infusion of primed isotopically labelled glucose, amino acids and lipids. From 2 hours prior to glucagon infusion and throughout the test day,
223664713|NCT05460091|DEVICE|PTech Device|High-frequency vibration device used on regular basis in orthodontics
223664714|NCT05460091|DEVICE|PTech Sham Device|sham device (does not vibrate)
223664715|NCT03673397|BEHAVIORAL|Aerobic exercise, bicycle ergometer|Exercise performed below individual anaerobic threshold for 30 minutes
223664716|NCT01689194|DRUG|genexolPM + cisplatin|
223664717|NCT00641511|DRUG|SYN117 (nepicastat)|120 mg per day
223664718|NCT00641511|DRUG|Placebo comparator|once per day placebo capsules
223664719|NCT00233454|DRUG|Midostaurin|Midostaurin is a broad-spectrum protein kinase inhibitor, acting on conventional PKC isoforms (α, β, γ); PDFRβ; VEGFR2; Syk; PKCη; Flk-1; Flt3; Cdk1/B; PKA; c-Kit; c-Fgr; c-Src; VEGFR1; and EGFR
223664720|NCT00583713|DRUG|BLI-800|BLI-800 oral solution (two doses)
223664721|NCT02849730|DEVICE|Fentanyl/ropivacaine based Epi-PCA|Fentanyl and ropivacaine was diluted and administered to the patients according to the clinician's determination. The clinician decided dose, infusion rate, bolus dose, lockout time and total amount of drug mixed in the Epi-PCA.
223664722|NCT04224688|DRUG|Rozanolixizumab|Study participants receive rozanolixizumab by subcutaneous infusion at pre-specified time points.
223664723|NCT04224688|OTHER|Placebo|Study participants receive placebo by subcutaneous infusion at pre-specified time points.
223664724|NCT03502551|DRUG|Ketamine|Ketamine infusion (0.5 mg/kg) over 40 minutes.
223664725|NCT04430595|BIOLOGICAL|4SCAR T cells|Infusion of 4SCAR-GD2, -Her2 and -CD44v6 CAR-T cells
223664726|NCT05484544|DIAGNOSTIC_TEST|High sensitivity troponin T|Collection of hs-cTnT samples
223664727|NCT00374829|BEHAVIORAL|An IT-based patient follow-up and reminder system|
223664728|NCT02317744|DRUG|Naltrexone and bupropion combination|
223664729|NCT02317744|OTHER|Pill Placebo|
223664730|NCT06043544|DEVICE|Hyaluronic Acid 24 MG in 3 mL Prefilled Syringe|Patients in the treatment group received two intra-articular injections with Hymovis® (24mg/3ml) a week apart from each other
223664731|NCT06043544|DRUG|Corticosteroid injection|Patients in control group received two intra-articular injections with corticosteroids a week apart from each other.
223664732|NCT03549832|DRUG|Sofosbuvir|Sofosbuvir 400 mg oral pills
223664733|NCT03549832|DRUG|Simeprevir|Simeprevir 150 mg oral pills
223664734|NCT03549832|DRUG|Daclatasvir|Daclatasvir 60 mg oral pills
224244529|NCT00989274|BIOLOGICAL|Vaccine Sanofi (H1N1) 15 ug.nonadyuvante|Grup 2: Day 0: Vaccine trivalent(A/Brisbane/59/2007 (H1N1)-like virus, A/Brisbane/10/2007 (H3N2)-like virus, y B/Brisbane/60/2008-like virus); Day 28 Vaccine Sanofi A(H1N1) administrated a 15 ug. (nonadjuvant); day 56; Vaccine Sanofi A(H1N1) administrated a 15 ug. (nonadjuvant)
223664735|NCT03549832|DRUG|Ribavirin|Ribavirin 200 mg oral pills
223664736|NCT03549832|DRUG|Ombitasvir/paritaprevir/ritonavir|Ombitasvir/paritaprevir/ritonavir oral pills
224244530|NCT00989274|BIOLOGICAL|Vaccine Sanofi A(H1N1) 7.5 ug|Grup 3: day 0: day 28 Vaccine Sanofi A(H1N1) administrated a 7.5 ug (non adjuvant); day 56; Vaccine Sanofi A(H1N1) administrated a 7.5 ug (nonadjuvant).
223664737|NCT02141477|DRUG|Omacetaxine|Phase I and Phase II Omacetaxine Dose: 1.25 mg/m2 subcutaneously every 12 hours on Days 1 - 3 of a 28 day cycle.
224244531|NCT02110953|COMBINATION_PRODUCT|irinotecan-eluting beads|Receive irinotecan hydrochloride-eluting beads via hepatic artery embolization
223664738|NCT02141477|DRUG|Decitabine|"Phase I Starting Decitabine Dose: 20 mg/m2 by vein on Days 1 - 5 of a 28 day cycle.~Phase II Starting Decitabine Dose: Maximum tolerated dose from Phase I."
223664739|NCT04760743|BIOLOGICAL|NBP2001 adjuvanted with alum (RBD 30μg/dose)|Participants will receive intramuscular (IM) injections of NBP2001(RBD 30μg/dose) on Days 0 and 28.
223664740|NCT04760743|BIOLOGICAL|NBP2001 adjuvanted with alum (RBD 50μg/dose)|Participants will receive intramuscular (IM) injections of NBP2001(RBD 50μg/dose) on Days 0 and 28.
223664741|NCT04760743|OTHER|Normal Saline|Participants will receive intramuscular (IM) injections of Normal saline on Days 0 and 28.
223664742|NCT02205489|DRUG|Alemtuzumab GZ402673|Pharmaceutical form:concentration for solution Route of administration: intravenous infusion
223770375|NCT01752205|DRUG|Erlotinib|150mg/d,days 1-42,total 6 weeks
224244532|NCT02110953|PROCEDURE|hepatic artery embolization|Receive irinotecan hydrochloride-eluting beads via hepatic artery embolization
224244533|NCT00485394|DRUG|OT-551|OT-551 0.3% ophthalmic solution, 2 drops 4 times daily
224244534|NCT00485394|DRUG|OT-551|OT-551 0.45% ophthalmic solution, 2 drops 4 times daily
224244535|NCT00485394|DRUG|vehicle placebo|OT-551 0% ophthalmic solution, 2 drops 4 times daily
223770376|NCT01752205|RADIATION|Radiation therapy|
223770377|NCT06768918|OTHER|remote physical rehabilitation|In this multisite international study, we feasibility test implementation of 4 different digital solutions for delivering interactive physical rehabilitation during or after systemic anticancer treatment. The contents of the intervention follows international recommendations for exercise during or after treatment for cancer.
223664743|NCT02205489|DRUG|cetirizine|Pharmaceutical form:tablet Route of administration: oral
223664744|NCT02205489|DRUG|ranitidine|Pharmaceutical form:tablet Route of administration: oral
223664745|NCT02205489|DRUG|methylprednisolone|Pharmaceutical form:tablet Route of administration: oral
223664746|NCT02205489|DRUG|methylprednisolone|Pharmaceutical form:solution Route of administration: intravenous
223664747|NCT02205489|DRUG|aciclovir|Pharmaceutical form:tablet Route of administration: oral
223664748|NCT02205489|DRUG|esomeprazole|Pharmaceutical form:tablet Route of administration: oral
223664749|NCT02205489|DRUG|ibuprofen|Pharmaceutical form:tablet Route of administration: oral
223664750|NCT02205489|DRUG|paracetamol|Pharmaceutical form:tablet Route of administration: oral
223664751|NCT05160142|BEHAVIORAL|DICE|10-week culinary and nutrition education program for children with type I diabetes
223664752|NCT05366868|DRUG|Imeglimin|Imeglimin 1000 mg orally twice daily in the morning and evening (2000 mg daily).
223664753|NCT05366868|DRUG|Metformin|Metformin 500 mg orally twice daily in the morning and evening (1000 mg daily). However, until 2 weeks after the start of treatment, 250 mg should be administered orally twice daily in the morning and evening. Thereafter, after 4, 8, or 12 weeks, the dose may be increased up to 750 mg twice daily (1500 mg daily) if the physician determines that the hypoglycemic effect is inadequate.
223664754|NCT05366868|DRUG|Vildagliptin|Vildagliptin 50 mg orally twice daily in the morning and evening (100 mg daily).
223664755|NCT02745145|DRUG|Abituzumab 1500 mg|Participants received Abituzumab 1500 mg administered as an intravenous infusion for 1 hour every 4 weeks up to Week 64.
223664756|NCT02745145|DRUG|Abituzumab 500 mg|Participants received Abituzumab 500 mg administered as an intravenous infusion for 1 hour every 4 weeks up to Week 64.
223664757|NCT02745145|DRUG|Placebo|Participants received Placebo matched to Abituzumab administered as an intravenous infusion for 1 hour every 4 weeks up to Week 64.
223664758|NCT01745497|DRUG|Ferrous sulfate|3mg/kg liquid
223664759|NCT01745497|DRUG|Placebo|Equivalent volume of liquid with similar color and taste.
223664760|NCT02990624|RADIATION|PUVA|36 sessions of psoralen-ultraviolet A, divided as 3 sessions weekly
224244536|NCT06201650|DIAGNOSTIC_TEST|Neurofilament light chain|Neurofilament light chain as biomarker for amyotrophic lateral sclerosis
224244537|NCT03977649|DRUG|erenumab|erenumab 140 mg sc every 4 weeks
223664761|NCT04997356|BEHAVIORAL|Hostile Bias Modification Training|Volunteers will complete a novel computer-based hostile bias modification training where they are instructed to respond to word fragments (words with missing letters) based on whether the word fragments can be completed to form aggressive or positive/neutral words. They will refrain from making words that can only form aggressive words.
224244538|NCT03977649|DRUG|placebo|placebo sc every 4 weeks
224244539|NCT04052503|BEHAVIORAL|Knowledge Broker|Tailored knowledge translation intervention that included barrier assessment and intervention mapping using the theoretical domains framework and participant engagement either fully or partially supported by the knowledge broker.
224244540|NCT00003064|BIOLOGICAL|filgrastim|
224244541|NCT00003064|DRUG|carboplatin|
224244542|NCT00003064|DRUG|etoposide phosphate|
224244543|NCT00003064|DRUG|paclitaxel|
224244544|NCT00003064|DRUG|thiotepa|
224244545|NCT00003064|DRUG|topotecan hydrochloride|
224244546|NCT00003064|PROCEDURE|peripheral blood stem cell transplantation|
224244547|NCT03289884|OTHER|MRI scan (not involving ionising radiation)|The MRI study will be conducted by a trained MR radiographer, supervised by the nominated researcher
224244548|NCT03289884|OTHER|Ultrasound scan (not involving ionising radiation)|The US scan will be conducted by a nominated researcher
223664762|NCT04997356|BEHAVIORAL|Other training|Volunteers will complete a computer-based task where they are instructed to respond to word fragments (words with missing letters) regardless of whether the fragments can make hostile or ambiguous words.
224244549|NCT03289884|OTHER|Ex vivo MRI scan of cyst fluid sample|The MRI study will be conducted by a trained MR radiographer, supervised by the nominated researcher
224244550|NCT03289884|OTHER|Aspiration of cyst fluid|For patients undergoing surgery/radiologically guided aspiration the aspiration will be performed by a surgeon (at the Royal Free Hospital) or radiologist
224244551|NCT03289884|OTHER|Blood test for confirmation of serum IgG levels consistent with hydatid infection|The blood sample will be drawn by a member of the clinical team
224244552|NCT00061321|DRUG|Nevirapine and mulitvitamins|Mothers: One dose of intrapartum nevirapine by mouth (200mg) at onset of labor Infants: One dose of liquid nevirapine by mouth within 72 hours of birth (2mg/kg) Infants: Liquid multivitamins (1ml/day) week 1 through week 6 post-partum Infants (Arm 2 Only): Liquid nevirapine (5 mg/day) by mouth, from week 1 through week 6 post-partum
224244553|NCT05855785|BEHAVIORAL|dual task exercise|8-week, 3 times a week, 60-minute group exercise sessions, which were comprised of moderate-to-high intensity exercise and simultaneous cognitive tasks
224244554|NCT05855785|BEHAVIORAL|home exercise|60-minute light intensity home exercise, 4 times a week for 8 weeks
224244555|NCT02401607|OTHER|Karasek questionnaire and Saliva prelevement|Karasek questionniare and Saliva collection will be assessed on any health care worker working in any emergency department in France at day 1 and at 5 years
224244556|NCT05246293|DRUG|Tofacitinib|"Tofacitinib in doses of 5 mg BID, in RA-ILD patients at stable doses of prednisone ≤ 10 mg/day during the last three months.~Patients who met the inclusion criteria of the study protocol will received tofacitinib 5 mg BID for 12 months"
224244557|NCT05570084|DRUG|Silodosin|Cap silodosin for medical expulsion therapy
224244558|NCT05570084|DRUG|Tamsulosin|Cap tamsulosin
224244559|NCT02997800|DRUG|Esmolol|Following induction and intubation, any increase in heart rate (HR) or mean arterial pressure (MAP) \>20% of baseline will be treated with an initial intravenous bolus of esmolol 30 mg IV (30 mg in 5 ml of normal saline). An intravenous esmolol infusion will be initiated at 5mcg/kg/min after the first intravenous bolus dose and will be titrated up by 5mcg/kg/min each time HR or MAP \>20% of baseline. An intravenous bolus of placebo (normal saline 1 ml) will be administered whenever a change to the infusion rate is made.
224244560|NCT02997800|DRUG|Labetalol|Following induction and intubation, any increase in heart rate (HR) or mean arterial pressure (MAP) \>20% of baseline will be treated with an initial intravenous bolus of labetalol 10 mg IV (10 mg in 5 ml of normal saline). Any further increases in HR or MAP \>20% of baseline will be treated with intravenous boluses of labetalol 5 mg in 1 ml every 5 minutes as needed. An intravenous placebo infusion (normal saline) will be initiated at 5 mcg/kg/min after the first intravenous bolus dose and will be titrated up by 5 mcg/kg/min each time an additional intravenous bolus is given.
224244561|NCT02997800|DRUG|Fentanyl|Following induction and intubation, any increase in heart rate (HR) or mean arterial pressure (MAP) \>20% of baseline will be treated with an initial intravenous bolus of fentanyl 50 mcg IV (50 mcg in 5 ml of normal saline). Any further increases in HR or MAP \>20% of baseline will be treated with intravenous boluses of fentanyl 25 mcg in 1 ml every 5 minutes as needed. An intravenous placebo infusion (normal saline) will be initiated at 5 mcg/kg/min after the first intravenous bolus dose and will be titrated up by 5 mcg/kg/min each time an additional intravenous bolus is given.
224244562|NCT02997800|OTHER|saline infusion|An intravenous placebo infusion (normal saline) will be initiated at 5 mcg/kg/min after the first intravenous bolus drug dose (fentanyl or labetalol depending upon randomization) and will be titrated up by 5 mcg/kg/min each time an additional intravenous bolus is given.
224244563|NCT02997800|OTHER|1 ml saline infusion|Every time the infusion rate of esmolol is changed, 1 ml of normal saline will be infused.
223664763|NCT00277875|DRUG|ALT-711 (alagebrium chloride)|
223664764|NCT04876300|OTHER|No intervention|All directions for medication usage were solely at the discretion of the investigator in accordance with their usual routine clinical practice and are assumed to be consistent with the national prescribing information of the medicinal product in the country in which the study will take place.
223664765|NCT03033550|BEHAVIORAL|brief negotiated mobile application|The intervention will supplement the standard of care with the following steps: (1) mobile- based brief negotiated Intervention ( BNI); (2) a customized companion communication vaccine report to be given before AFG sees provider; and (3) automated interactive Electronic Recall/Reminder Messages (Text messaging), including text messaging and access to a website which includes information about HPV, HPV Vaccine, and cervical cancer screening guideline.
223664766|NCT01757158|RADIATION|Cs-131 brachytherapy seeds|Cesium-131 is another radiation seed that may more effectively treat lung cancer patients. Cs-131 has been previously used in prostate cancer successfully. Cs-131 has similar energy to I-125 but has a much shorter half life (9days as compared to 60 days for I-125). Patients who receive Cs-131 radiation seeds are expected to be radioactive for 30 days (1 month) as compared to 180 days (6 months) with I-125.
223664767|NCT06376903|OTHER|Pilates exercise - pelvic floor exercise - home advices|"Group (A) (Study group): It will be consisted of thirty postmenopausal women suffering from mild and moderate stress urinary incontinence, will perform program of pilates exercises, 3 sessions/week (30 minutes a session ) for 12 weeks in addition to Kegel exercises (15min/three times per week/ for 12 weeks) and home care advices.~• Group (B) (Controlled group): It will be consisted of thirty postmenopausal women suffering from mild and moderate stress urinary incontinence, will perform kegel exercises (15min/three times per week/ for 12 weeks) and home care advices as in group (A)."
223664768|NCT04698096|OTHER|Biological sample collection|Collection of faeces, urine, saliva, and blood for biobanking, to evaluate the proteomic, metascriptomic, metabolomic, metagenomic, and metagenetic profile, and to perform routine screening
223664769|NCT04698096|OTHER|Questionnaire|Anamnestic questionnaire, 3-day food questionnaire, Food Frequency Questionnaire
223664770|NCT04698096|OTHER|Medical examination|Blood pressure measurement, abdominal and thoracic physical examination
223664771|NCT00388583|BIOLOGICAL|Split, Inactivated, Trivalent Influenza Vaccine|0.1 mL, Intradermal
223664772|NCT00388583|BIOLOGICAL|Split, Inactivated, Trivalent Influenza Vaccine|0.5 mL, Intramuscular
223664773|NCT04636216|BEHAVIORAL|COPE parent training|Weekly 1.5 hour parent training meetings for eight weeks
223664774|NCT00232869|DEVICE|drug-eluting stent|Sirolimus Coated Cordis SMART™ nitinol selfexpandable stent
223664775|NCT00232869|DEVICE|bare-metal stent|SMART™ bare-metal stent
223664776|NCT02256397|OTHER|Standard comprehensive care|Standard comprehensive care at High Risk Children's Clinic
223664777|NCT02256397|OTHER|enhanced comprehensive care|"standard comprehensive care at the High Risk Children's Clinic enhaced with new technologies:~* If between 2 and 5 years old--\> will receive Home-centered comprehensive care with the propeller~* 5 and above--\> will receive home-centered comprehensive care with propeller and PIKO"
223770378|NCT06794840|BEHAVIORAL|JomCare is a smartphone-based just-in-time adaptive intervention (JITAI) for chemsex-related harm reduction.|JomCare is a smartphone-based just-in-time adaptive intervention (JITAI) that uses an EMA-based machine learning (ML) algorithm to anticipate chemsex risk and deliver appropriate chemsex-related harm reduction and HIV prevention services when the risk is detected.
224244564|NCT04360694|PROCEDURE|Incremental hemodialysis|95 patients will start renal replacement therapy (RRT) with an incremental hemodialysis (once-weekly or twice-weekly) regimen.
224244565|NCT04360694|PROCEDURE|Conventional hemodialysis|95 patients will start renal replacement therapy (RRT) with the standard (thrice-weekly) hemodialysis regimen.
224244566|NCT04866524|OTHER|Developmental score according to The Ages & Stages Questionnaires®, Third Edition - ASQ®-3|Ages \& Stages Questionnaires®, Third Edition (ASQ®-3) is a developmental screening tool designed for use by early educators and health care professionals. It relies on parents as experts, is easy to use, family-friendly and creates the snapshot needed to catch delays and celebrate milestones.
224244567|NCT04866524|OTHER|Physical development and General Health|Physical development and General health examination
223770379|NCT06766305|DRUG|QL1706 combined with SOX|QL1706 + SOX (3 cycles) before surgery → radical surgery (D2) → QL1706 + SOX (5 cycles) after surgery → QL1706 monotherapy maintenance （up to 1 year before and after surgery); Phase 1 (initial dose cohort) ： QL1706 5mg/kg ；Phase 1 (dose escalation cohort)：QL1706 7.5mg/kg ；Phase 2：QL1706 RP2D
224244568|NCT04866524|OTHER|Developmental Red flags|Developmental Red flags Questionnaires
224244569|NCT00734019|DEVICE|P.F.C. Sigma Knee|Orthopaedic implant for primary total knee replacement with a cobalt-chrome tibial tray and a moderately cross-linked polyethylene tibial insert
224321651|NCT07133568|OTHER|OTAGO|The OTAGO Exercise Program is a structured, evidence-based intervention developed to improve lower-limb strength and balance and reduce fall risk in older adults. In this study, participants in the control group will complete three non-consecutive, supervised sessions per week for a total duration of 14 weeks. Sessions will be delivered in group settings under the supervision of a licensed physiotherapist. The program includes individualized strength training for the lower extremities, progressive balance exercises, and walking routines. Although originally designed as a home-based program, in this trial it will be implemented in indoor, climate-controlled, non-slip-floor facilities provided by local institutions. The OTAGO protocol does not include recreational, cognitive, or playful components, serving instead as a standard, structured intervention against which the FEXO program will be compared.
223664778|NCT02068898|DRUG|XS003|
223664779|NCT02068898|DRUG|Tasigna|
223664780|NCT03405233|PROCEDURE|Double vein cuffed ePTFE graft both at the inflow and outflow ends|Vein cuff is obtained from a segment of one of the arm veins (cephalic or basilica) after incising it longitudinally and wrapped around both ends of PTFE Graft
223664781|NCT03405233|PROCEDURE|single vein cuffed eTFE graft both at the inflow and outflow ends|Vein cuff is obtained from a segment of one of the arm veins (cephalic or basilica) after incising it longitudinally and wrapped around the venous end of PTFE Graft
223664782|NCT03405233|PROCEDURE|ePTFE graft without any cuff|anastmosis between arterial and venous side usinf non cuffed ePTFE graft
224244570|NCT00705003|DRUG|BCI-024: over-encapsulated Buspirone tablet 15 mg QD and BCI-049: over-encapsulated Melatonin tablet 3 mg QD|BCI-024: over-encapsulated Buspirone tablet 15 mg QD and Drug BCI-049: over-encapsulated Melatonin tablet 3 mg QD taken in combination for 6 weeks
224244571|NCT00705003|DRUG|BCI-024 (Buspirone)|Drug BCI-024 (Buspirone) taken once a day at bedtime for 6 weeks.
224244572|NCT00705003|DRUG|Matching placebo|Placebo comparator once a day at bedtime for 6 weeks.
223664783|NCT04133142|PROCEDURE|peripheral nerve block, inter fascial nerve block|regional anaesthesia by Inter fascial block, peripheral nerve block. The type of block would be the most appropriate to cover the dermatomes involved in the Herpes according to the mapping done with the higher ratio benefit risks. The choice of the block will be done by an anesthesiologist expert in regional anaesthesia techniques. local anesthetic will be ropivacaine 0.5% posology according to the type of block
223664784|NCT04257188|PROCEDURE|minimally invasive vitrectomy under subtenon anaesthesia|The safety and feasibility in terms of tolerance and pain sensation during the surgery as well as the possible perception of light and colour sensations in minimally invasive vitrectomy under sub-tenon anesthesia shall be investigated.
223664785|NCT01342237|DRUG|HDCT 1(TTC), HDCT2(MEC)|"1. TTC Topotecan (2 mg/m2 once daily i.v. on days -8, -7, -6, -5, -4) Thiotepa (300 mg/m2 once daily i.v on days -8, -7, -6) Carboplatin (500 mg/m2 once daily i.v on days -5, -4, -3) (max. 700 mg/day)~2. MEC Melphalan (140 mg/m2 once daily i.v on day -7, 70 mg/m2 once daily i.v on day -6) Etoposide (200 mg/m2 once daily i.v on days -8, -6) Carboplatin (350 mg/m2 once daily i.v on days -8, -7, -6, -5)"
223664786|NCT02113254|OTHER|Corn zeaxanthin|The treatment will consist in a daily consumption of a box of 125g of corn with strong zeaxanthin content during 10 weeks. This corresponds to a daily contribution of at least 1,2 mg of lutein and 2,2 mg de zeaxanthin
223770380|NCT07074197|OTHER|OOKIE doll|The infants who met the selection criteria were wrapped with OOCIE upon admission and remained in contact with OOCIE for approximately 24 hours without affecting their routine care and position. After 24 hours, when the mother came for the first visit, the mother and baby introductory information form, Neonatal Intensive Care Unit Parent Stress Scale, Inadequate Milk Perception Scale, Mother-Infant Attachment Scale and NICU Parental Beliefs Scale pretest were administered. During the visit, the mother received the OOKIE wrapped around her baby in the incubator and stayed with the mother for 3 days and the mother could smell her baby's odor whenever she wanted.
224244573|NCT02572921|BEHAVIORAL|Positive Psychotherapy|"The Positive Psychotherapy Group Treatment was developed by Martin Seligman and Tayyab Rashid (2013) and consists of 14 weekly group sessions of 2 hours. The strictly manualized program includes the following components:~positive orientation and introduction, character strengths, signature strengths, good vs. bad memories, forgiveness, gratitude, satisficing vs. maximising, meaningful life, posttraumatic growth, hope and optimism, positive communication, signature strengths of others, savouring and slowness, altruism and the last session is about the integration of all these components to the full life."
224244574|NCT02572921|BEHAVIORAL|Cognitive behavioral therapy|This well-established, cognitive-behavior group therapy was developed by Schaub, Roth and Goldmann (2006) and consists of 12 weekly group sessions of 2 hours. The strictly manualized program includes the following components: education, building up activities, cognitive restructuring, relapse prevention. Moreover, there are 2 sessions added to the standard program: one session concerning savouring and the other one concerning stress reduction. Thus the whole program consists of 14 sessions.
224244575|NCT03684538|OTHER|Probiotics|Patients will receive probiotics (Saccharomyces boulardii) one dose per day (250 mg)
224244576|NCT03684538|OTHER|Zinc|Patients will receive zinc (10 mg for patients less than 6 month and 20 mg for older patients) one dose per day
224244577|NCT03684538|OTHER|Probiotics & Zinc|Patients will receive a combination of probiotics (Saccharomyces boulardii 250 mg) with zinc (10 mg for patients less than 6 month and 20 mg for older patients) one dose per day
224244578|NCT03684538|OTHER|Standard care|initiation of hydration and early refeeding, in addition to the use of antimicrobials in case a pathogen was identified
224244579|NCT01233622|DRUG|Vildagliptin|
224244580|NCT01233622|DRUG|Placebo|
224244581|NCT01668264|PROCEDURE|Echocardiograph|
224244582|NCT01668264|PROCEDURE|Magnetic Resonance Imaging (MRI)|
224244583|NCT05602103|DRUG|use of anticancer drugs in monotherapy or in combination therapy|Cases of cancer therapy-related cardiac dysfunction associated with anticancer drugs will be identify and describe
223664787|NCT01787162|OTHER|Echocardiography, spiroergometry, cardiac catheterization|patients with CMPD will undergo echocardiography, spiroergometry, and right heart catheterization, if indicated
223770381|NCT07077629|PROCEDURE|morbidity and mortality|Relationship of scoring systems with postoperative morbidity and mortality in geriatric patients undergoing gynecologic cancer surgery.
224244584|NCT02535611|DRUG|Placebo|Beside the usual treatment of ischemic stroke, this group will receive placebo for 4 weeks.
224244585|NCT02535611|DRUG|Memantine|Beside the usual treatment for ischemic stroke this group will be treated by memantine.
224244586|NCT02507427|DEVICE|NIM-Eclipse|Using NIM-Eclipse, nerve monitoring and mapping are performed
224244587|NCT05393960|OTHER|Lumbosacral manual therapy mobilization, lumber mobility exercises and home based self strechings program.|Manual therapy, mobility exercise therapy and a home-based self-stretching program. Manual mobilization postero-anterior glides at lumber facets joints, Transverse glides at spinous process \& Posterior-anterior glides at SI joint. Glides will be performed 3 times with 5 repetitions. Mobility exercise therapy.
224244588|NCT05393960|OTHER|home based self strechings program only.|Home based self-stretching program includes 3 repetitions of 15 seconds duration stretch (with 20 seconds rest between each repetition). Repeat stretching exercises twice a day for 3 alternate days for 1 week. Piriformis stretch: in supine crook lying, placing the lateral side of the foot over the contralateral knee and pulling towards the chest with the hands. Quadriceps stretch: stand on your left leg, one knee touching the other, hold a chair or the wall to keep you steady if needed, grab your right foot, using your right hand, and pull it towards your butt. Hamstring stretch: To stretch the right leg, sit on the ground with the left leg bent at the knee with the foot facing inward. This is called the butterfly position. Extend the right leg, keeping it slightly bent at the knee. Bend forward at the waist, making sure to keep the back straight.
224244589|NCT05019560|DRUG|Sevoflurane|IFT response, hemodynamics and BIS value were recorded during intubation period. Then the data acquisition was stopped and the isolated forearm cuff deflated. IFT values were noted by two independent observers
224244590|NCT05019560|DRUG|TIVA|IFT response, hemodynamics and BIS value were recorded during intubation period. Then the data acquisition was stopped and the isolated forearm cuff deflated. IFT values were noted by two independent observers
224244591|NCT03824691|DRUG|Cabozantinib|cabozantinib 40 mg orally once daily
224244592|NCT03824691|DRUG|Durvalumab|1500 mg durvalumab (MEDI4736) IV infusion every 28 days
223664788|NCT03816709|DEVICE|Therapeutic Ultrasound|A therapeutic ultrasound treatment was applied to the left medial gastrocnemius muscle with the following parameters: 3 MHz, 1.0 W/cm2 for 15 minutes.
224244593|NCT05096780|OTHER|Flavored caffeinated beverage|16.9 oz (500 cc), carbonated, zero calorie
224244594|NCT06046430|OTHER|Assessment|The same assessments will be made to participants in both groups.
224244595|NCT02539589|BEHAVIORAL|BART|BART is an out of school educational program that intends to provide cognitive behavioral training to reduce HIV risk. It is intended to be implemented in 8 sessions lasting 1.5-2 hours. Sessions are to be implemented by a male and female health educator in small gender specific groups of 5-15 participants.
224244596|NCT02539589|BEHAVIORAL|Healthy Living|Healthy Living is a knowledge-based intervention that intends to provide one HIV information-only session and seven sessions on nutrition, healthy eating, body image, and exercise. It is intended to be implemented in 8 sessions lasting 1.5-2 hours. Sessions are to be implemented by a male and female health educator in small gender specific groups of 5-15 participants.
224244597|NCT03505463|OTHER|Blood samples|"Three blood samples will be collected from the injured participants. The assessment points are \<72 hours, 7 days and 365 days post-injury.~One blood sample will be collected from the healthy participants. The collection will be performed as part of clinical diagnostic at the Department of Neurology at Aarhus University Hospital.~Laboratory analysis of the collected samples comprise Flow Cytometry and assay techniques."
224244598|NCT03505463|OTHER|Cerebrospinal fluid sample|"Three cerebrospinal fluid samples will be collected from the injured participants. The assessment points are \<72 hours, 7 days and 365 days post-injury.~The collected samples will be analysed by Flow Cytometry and assay techniques. One cerebrospinal fluid sample will be collected from the healthy participants. The collection will be performed as part of clinical diagnostic at the Department of Neurology at Aarhus University Hospital.~Laboratory analysis of the collected samples comprise Flow Cytometry and assay techniques."
224244599|NCT03505463|OTHER|Clinical examination|Clinical examinations will be performed at \<72 hours, 7 days and 365 days post-injury.
224244600|NCT04883801|DIAGNOSTIC_TEST|Reviewed clinical records and laboratory results|Retrospectively reviewed clinical records and laboratory results
224244601|NCT02994186|PROCEDURE|Bariatric Surgery|These are patients who will be having either Vertical Sleeve Gastrectomy or Roux-en-Y Gastric Bypass.
224244602|NCT02994186|OTHER|Medical Weight Loss Program|These are patients who will be starting a structured medical weight loss program.
223664789|NCT04685239|DEVICE|dual mobility cup|The use of a Sunfit dual mobility cup
223664790|NCT04685239|DEVICE|unipolar cup|The use of a TMT cup
224244603|NCT01302496|BIOLOGICAL|TriMix-DC and ipilimumab|Patients will receive 5 administrations of autologous TriMix-DC, administrations 2, 3, 4 and 5 will be preceded by ipilimumab (a CTLA-4 blocking monoclonal antibody, at a dose of 10 mg/kg). Patients who are free from progression according to the irRC will be offered ipilimumab maintenance administrations of ipilimumab (10mg/kg q12wks).
224244604|NCT01171690|DRUG|Teriparatide|The dose of teriparatide will be 20 mcg twice daily for the first week and 20 mcg daily for the second week. If hypocalcemia recurs after 2nd week, teriparatide will be continued for a 3rd week and then discontinued.
224244605|NCT01038856|DRUG|Erlotinib|Erlotinib supplied as tablets; oral dose of erlotinib of 150 mg daily to be continued for 16 weeks. Responders will continue for up to 12 months, non-responders will cease taking erlotinib
224244606|NCT05091385|BIOLOGICAL|Mepolizumab given SC 100mg every 4 weeks between Dec 2017 and Dec 2019|Mepolizumab administered within the frame of a severe asthma treatment program financed by National Health Fund in Poland for patients fulfilling specific criteria of asthma severity.
224244607|NCT00125307|DRUG|tacrolimus|
224244608|NCT04522609|DEVICE|Neuromuscular electrical stimulation (NMES)|"NMES will carried out with four-channel myostimulator Beurer EM80 (Germany). Self-adhesive electrodes locates above the quadriceps, the duration of the NMES session was 60 minutes, including 5-minute periods of warm-up and warm-down. Throughout the series, rectangular pulses with a frequency of 45 Hz will modulate. As a result, tonic contraction of these muscles will induce for 12 seconds, followed by a pause of 5 seconds. The amplitude of electrical exposure will select separately for each of the four channels until good muscle contraction (visually or by palpation) without pain. Electrical stimulation: 5-6 session per week, for 12 weeks, with 60-minuite session."
224244609|NCT03681509|DRUG|Pramipexole|Pramipexole
224244610|NCT03681509|DRUG|Placebo|Lactose placebo capsule
224244611|NCT00858156|DRUG|BG9928|Oral 75 mg single dose
224244612|NCT01346163|DRUG|PF 03654746|All participants will receive 3 weeks of PF-03654746 and 3 weeks of placebo. PF-03654746 and placebo will be administered in a flexible titration regimen, beginning with 0.5 mg/d. If 0.5 mg/d is well tolerated, the dose will be increased to 1.0 mg/d after 5 days. If 1.0 mg/d is not well tolerated, the dose will be decreased to 0.5 mg/d, with the goal of achieving a stable dose of PF-03654746 within the first two weeks of dosing and avoiding further dose changes during the final week of dosing.
224244613|NCT01346163|OTHER|Placebo|Placebo will be used as a comparator to the active arm.
224244614|NCT04382937|DRUG|P1101 + Ribavirin|P1101 400 µg SC Q2W + Ribavirin 800-1400 mg PO daily
224244615|NCT04382937|DRUG|PEG-Intron + Ribavirin|PEG-Intron 1.5 µg per kg SC Q1W + Ribavirin 800-1400 mg PO daily
224244616|NCT04335578|DRUG|Zampilimab|Participants will receive zampilimab (UCB7858) at pre-specified time-points.
224244617|NCT04335578|DRUG|Placebo|Participants will receive matching placebo (PBO) at pre-specified time-points.
224244618|NCT02448927|DEVICE|balloon aortic valvuloplasty|
224244619|NCT02448927|DEVICE|Transcatheter Aortic Valve Implantation|
223664791|NCT05468073|DRUG|Proleukin|Sub-cutaneous injections of Interleukin-2 (PROLEUKIN ®) Induction phase: 5 consecutive days. A week break. Maintenance phase: once a week during 16 weeks
223664792|NCT05468073|DRUG|Placebo|Sub-cutaneous injections of placebo (NaCl) Induction phase: 5 consecutive days. A week break. Maintenance phase: once a week during 16 weeks.
223664793|NCT04158843|PROCEDURE|Radical resection|Radical resection is performed, and the cutting edge is negative.
223664794|NCT04158843|RADIATION|Radical radiotherapy|Radical local radiotherapy is feasible (cumulative radiotherapy dose is greater than or equal to 50Gy).
223664795|NCT04158843|OTHER|Palliative treatment|Including palliative internal fixation, radiotherapy, systemic chemotherapy, endocrine therapy or targeted therapy
223664796|NCT00190255|PROCEDURE|CY2PC9 genotyping|CY2PC9 genotyping
223664797|NCT01155011|BEHAVIORAL|Physical Activity|"MIPARC will focus on 3 physical activity goals:~1. increasing walking behavior through gradually increasing step goals~2. increasing attendance at available on-site and local aerobic, strength and flexibility classes, as well as prompting stair use,~3. reducing sedentary behavior. Participants will monitor their steps with a pedometer, daily step logs and progress charts. All participants will have a gradually increasing fixed step goal for each week that will result in an total increase of 3000 steps after 3 months, which they will be supported to maintain for an additional 3 months."
223664798|NCT01155011|BEHAVIORAL|Group educational sessions|Every three weeks, participants will be required to attend a group education session, where researchers will teach behavior change strategies and allow participants to share their experiences and offer support to each other. The group sessions will follow a common format including: a group exercise (e.g. quiz), group discussion of use of behavior change strategies (e.g. overcoming barriers), and will end with a behavior change strategy instruction and goal setting component.
223664799|NCT01155011|BEHAVIORAL|Phone counseling call|"To support a tailored intervention delivery, participants will receive 4 individual phone calls (in weeks 2, 5, 8, and 11) from a trained health counselor. The phone call will follow the following format:~1. health check~2. step goal check~3. barrier identification~4. problem solving~5. specific goals to achieve target step counts. Counselors will prompt participants to report any adverse events, illnesses, medication changes or counter indicative symptoms. The calls will cease during the second 3 months to allow participants to practice self help techniques while still supported by the group sessions and peer mentoring."
223664800|NCT01155011|BEHAVIORAL|Peer Mentoring|"Three peer mentors at each CCRC will be trained in intervention content and delivery, measurement support, and advocacy. The peer mentors will lead a group session once every three weeks for the 6 month intervention period and once a month for the following 6 months. The peer mentors will formulate their own ideas for these sessions but we will suggest they include group walks, group activities and trips to active locations, etc.~The peers will help study staff to answer questions from participants and assist with study compliance and retention. They will also receive advocacy training from a non-profit advocacy organization to conduct walk audits of their CCRC and help mobilize participants to make changes to their community that will increase or improve the opportunities for physical activity."
223664801|NCT01155011|BEHAVIORAL|Policy Change|In order to increase the sustainability of the project, MIPARC will focus on addressing on-site policies and neighborhood factors that are barriers to physical activity. Peers and staff will conduct site inspections to identify these barriers (e.g. lack of facilities, limited opening hours, unsafe sidewalks, etc.) which will be prioritized and presented to CCRC management and community officials.
223664802|NCT01155011|BEHAVIORAL|Support|A binder of professionally prepared materials will be provided at the beginning of the intervention and are referred to by researchers in the group sessions and phone counseling calls. The materials provide important information to encourage knowledge, self efficacy and realistic expectations.
223664803|NCT01155011|BEHAVIORAL|Tailored environmental resources|Participants will be provided with a set of printed materials relating to the residential and neighborhood environment of their CCRC. A list of step counts for key indoor routes will be provided as well as safe walking route maps for the site an local neighborhood.
223664804|NCT01155011|BEHAVIORAL|Group educational sessions|Lectures will be delivered every three weeks to match the MIPARC intervention schedule. Sessions will include topics such as medications, foot care and nutrition. Physical activity will not e discussed in these sessions but participants will receive informational pamphlets on the benefits of physical activity.
224244620|NCT05290194|RADIATION|SBRT radiotherapy + Conventionally fractionated radiotherapy|Radiotherapy was performed 3-6 weeks after the end of first-line treatment, followed by conventional fractionated radiotherapy of the primary tumor and cervical lymph node metastases, SBRT radiotherapy of distant organ metastases 3-6 weeks later.
224244621|NCT05290194|DRUG|PD-1 inhibitor|Immunotherapy of PD-1 inhibitor is used during the whole time of this trial until subjects were withdrawn from the trial or the trial complete
224244622|NCT05290194|DRUG|Capecitabine|Capecitabine is treated for patients 3-6 weeks after radiotherapy, which combines with PD-1 inhibitor as the maintenance regimen in the trial.
224244623|NCT03380819|DIAGNOSTIC_TEST|Genome sequencing|Patients will undergo exome or genome sequencing, and their referring provider will receive an interpreted report with the following categories of results: 1) results related to the indication for testing, 2) secondary monogenic results, 3) carrier status, 4) pharmacogenomics results.
224244624|NCT03405402|PROCEDURE|Blood sampling|Extra blood sampling at the time of a blood transfusion in order to perform the laboratory analysis
224244625|NCT02087904|BIOLOGICAL|ABT-981|
224244626|NCT02087904|OTHER|Placebo|
224244627|NCT02186730|BEHAVIORAL|Stressbusters|cCBT
224244628|NCT02186730|BEHAVIORAL|Websites|Self help websites
224244629|NCT05034055|DRUG|atezolizumab / tiragolumab|All patients will receive 1200mg atezolizumab administered by IV infusion on Day 1 of each 21-day cycle after completion of stereotactic body radiotherapy (SBRT) for 21(+5) days. No escalations or reductions in the dose of the investigational product will be allowed.Following the administration of atezolizumab, patients will receive 600mg tiragolumab administered by IV infusion on Day 1 of each 21-day cycle. The tiragolumab dose is fixed and is not dependent on body weight.
224244630|NCT01823965|DRUG|ranibizumab|
224244631|NCT03705065|DRUG|Bupivacaine HCl|Bupivacaine HCl without epinephrine 0.25%, 60 mL (30 mL per pectoral pocket)
224244632|NCT04343066|DEVICE|Implant insertion|"In both groups, the implants will be placed using a two-stage surgical approach at the crestal level in previously horizontally augmented bony sites.~A final crown will be placed (screw-retained on multiunit abutment) between 3- and 4-months post-implant placement.~Random allocation of implant type per site will be done by the sealed envelope method.~Follow-up measurements will be done at 6 months and 1-year post-loading. The measurements are done by a blinded investigator. Before starting the study, the examiner will be trained in a calibration process.~Exam sheets are kept confidential and anonymous. Inclusion criteria are: patient aged 20 to 65, no systematic contraindication for implant surgery, smoking \< 10 cigarettes, previous horizontal bone augmentation, FMBS \<20% and FMPS \< 20%. Exclusion criteria are: general contraindication for implant surgery, pregnant/lactating women, uncontrolled diabetics, patients not willing to sign the consent form, active periodontitis."
224244633|NCT02562365|DRUG|Etoposide, Cyclophosphamide, Carboplatin|CTX 400mg（250mg/m2）+VP-16 100mg (70mg/m2)d1-d3 iv 4w/6cycles , CBP(AUC=5)+CTX 600mg(400mg/m2)d1-d2 iv 8w/6cycles
223664805|NCT01155011|BEHAVIORAL|Health check phone call|For the first 3 months, control participants will also receive a health check phone call to match the individual attention paid to participants in the MIPARC sites.
223664806|NCT01155011|BEHAVIORAL|Pedometer|Participants will also keep the pedometer they wear during the baseline measurement week to satisfy any curiosity about the devices and the step entry criteria. They will be given instructions on its use but will not be taught the benefits of self-monitoring.
223664807|NCT02083549|OTHER|Blood collection|After transfusion of each shipment of blood products outlined in the current Massive Transfusion Protocol one 2.7mL citrated blood sample will be collected from the subject through the 5th shipment of blood products. A final sample will be collected 24 hours following the discontinuation of the massive transfusion protocol.
223664808|NCT00077129|DRUG|carboplatin|
223664809|NCT00077129|DRUG|paclitaxel|
223664810|NCT02641340|DRUG|Fentanyl Sublingual Spray|Fentanyl delivered at low, medium and high doses by sublingual spray (FSS)
223664811|NCT02641340|DRUG|Fentanyl Citrate IV|Fentanyl Citrate 50 mcg, delivered intravenously
223664812|NCT05451485|DIAGNOSTIC_TEST|Blood speckle tracking|Blood speckle tracking measurements will be acquired of the carotid artery and superficial femoral artery
223664813|NCT05451485|DIAGNOSTIC_TEST|Ultrasound particle Imaging Velocimetry|Ultrasound particle imaging velocimetry will be acquired of the carotid artery and superficial femoral artery
223664814|NCT05451485|DIAGNOSTIC_TEST|4D flow MRI|4D flow MRI will be acquired of the carotid artery and superficial femoral artery
223664815|NCT05451485|DIAGNOSTIC_TEST|Conventional duplex|Conventional duplex measurements will be acquired of the carotid artery and superficial femoral artery
223664816|NCT05120557|DEVICE|Ultrasound liver assessment|The intervention consists in an ultrasound exam performed with the ultrasound medical device subject of the research.
223664817|NCT02678494|OTHER|Neurofeedback training|
223664818|NCT05845697|OTHER|Trigger point dry needling|Filiform needle that pierces the skin and is inserted into an identified trigger point in the muscle
223664819|NCT05845697|OTHER|Sham dry needling|A validated sham dry needle that is blunted on the end and does not pierce the skin
223664820|NCT03845439|OTHER|Lumbar puncture|Lumbar puncture
224244634|NCT04258982|OTHER|no intervention|no intervention
224244635|NCT01493752|DIETARY_SUPPLEMENT|beetroot juice|250mls daily beetroot juice
224244636|NCT02910037|DEVICE|mNGS for pathogen detection|This assay is a laboratory-validated metagenomic test for comprehensive detection of viruses, bacteria, fungi, and parasites in clinical samples.
224244637|NCT04127045|PROCEDURE|IMN-Group|Most intertrochanteric fractures are managed with an intramedullary nail, which allows for impaction at the fracture site. The intramedullary nail is placed directly into the marrow canal of the bone through an opening made at the top of the greater trochanter. A lag screw is then placed through the nail and up into the neck and head of the hip. As with the compression hip screw, sliding of the lag screw and impaction of the fracture take place.
223664821|NCT00349700|PROCEDURE|Compression: 2 weeks four layer bandages, then stockings|
223664822|NCT00349700|PROCEDURE|debridement|
223664823|NCT00349700|PROCEDURE|Actisorb plus (r) + Trionic(r)/ Allevyn (r)|
223664824|NCT02734901|DIETARY_SUPPLEMENT|400 g frozen raspberries|1x daily intake of 600 mL red raspberry beverage
223664825|NCT02734901|DIETARY_SUPPLEMENT|200 g frozen raspberries|1x daily intake of 600 mL red raspberry beverage
223664826|NCT02734901|DIETARY_SUPPLEMENT|Placebo|1x daily intake of 600 mL raspberry deprived supplement
223664827|NCT02710162|DEVICE|Micro Mouth Pressure Meter|The participant will be seated with the nose occluded using a nose clip. After inhaling to total lung capacity, the participant will place his or her lips around the mouthpiece and blow out as forcefully as possible. A flanged rubber mouthpiece will be used to overcome the inability of some individuals to create tight lip seal due to facial muscle weakness. Three trials will be performed and the patients highest maximum inspiratory pressure (MIP) and maximum expiratory pressure (MEP) used.
223664828|NCT02710162|DEVICE|Iowa Oral Performance Instrument|The Iowa Oral Performance Instrument (IOPI) is a device that measures the peak pressure performance of lingual strength and endurance via the action of a bulb placed on the hard palate.
223664829|NCT02710162|DEVICE|Electrical Impedance Myography|The SFB7 Bioimpedance device measures the function of the tongue by calculating measures of reactance, resistance and phase once a custom electrode array is placed on the midline of the subject's tongue for approximately 2 seconds.
223664830|NCT02710162|DRUG|Capsaicin|"A capsaicin challenge with three randomized blocks of 0, 50, 100, 200, and 500 μM capsaicin. The capsaicin will be dissolved in a vehicle solution consisting of 80% physiological saline, and 20% ethanol. Participants will be given the instruction cough if you need to prior to capsaicin delivery.The solution will be administered automatically upon detection of an inspired breath and there will be a minimum of one minute between each trial. This is to test the reflexive cough testing for upper airway sensitivity and motor thresholds."
223664831|NCT02710162|PROCEDURE|Videofluoroscopic Swallowing Study|Videofluoroscopic swallowing study will be performed to measure the oropharyngeal swallowing.
223664832|NCT02710162|PROCEDURE|Pulmonary Function Testing|Pulmonary Function testing will be performed using conventional methods and will include the following outcomes: forced vital capacity (FVC), sniff nasal inspiratory pressure (SNIP), peak expiratory flow (PEF), forced expiratory volume (FEV1) expressed as a percentage of predicted values.
223664833|NCT02710162|OTHER|Swallowing Related Quality of Life Questionnaire|Swallowing Quality of Life Questionnaire (SWAL-QOL) will be used for participant reporting of swallow-related quality of life.
224244638|NCT04127045|PROCEDURE|HA-Group|In the older patient, the chance that the head of the femur is damaged in this way is higher. It is generally felt that for these displaced fractures, patients will do better if some of the components of the hip are replaced. In some cases, this can mean a replacement of the ball, or head of the femur (hemiarthroplasty).
224244639|NCT03867994|DRUG|Atorvastatin|
224244640|NCT03867994|DRUG|Carvedilol|
224244641|NCT03867994|DRUG|saline|
224244642|NCT05642494|DEVICE|SDF|Silver Diamine Fluoride 38% (Applied bianually)
224244643|NCT05642494|DEVICE|NaF|Sodium Fluoride Varnish (5%) (Applied at baseline and after 3 months)
224244644|NCT03047265|DRUG|Paclitaxel|Paclitaxel 135mg / m2 D1, DDP 20mg / m2 D1-4, D1,D29 of RT, a total of 2 courses.
224244645|NCT03047265|DRUG|Cisplatin|Cisplatin 100mg / m2 , D1,D22,D43 of RT, a total of 3 courses.
224244646|NCT01563965|DIETARY_SUPPLEMENT|Carbohydrate plus hydrolyzed protein beverage|The study group received 400 ml (evening drink) or 200 ml (3h prior to operation drink) of a solution containing 11% de protein (pea hydrolized proptein), 89% de carbohydrates (maltodextrin 79% and saccharose 21%) e 0% of lipids (Providextra, Fresenius Kabi, São Paulo, Brasil). All the patients fasted for solids at least 6 hours from the operation
224244647|NCT01563965|OTHER|Preoperative fasting of 8h|Conventional protocol of 8h fasting before an operation
224244648|NCT00595062|RADIATION|Intra Operative Radiation Therapy (IORT)|Quadrant High Dose Rate Intra Operative Radiation Therapy (IORT)
224244649|NCT01174680|PROCEDURE|cardiogoniometry|In the course of the project a cardiogoniometry will be carried out during the ambulant or residential hospitalization before the coronary angiography.
224244650|NCT00000957|BIOLOGICAL|gp160 Vaccine (Immuno-AG)|
224244651|NCT02770625|DRUG|ISU302|60 U/kg given intravenously
224244652|NCT01474668|DRUG|GDC-0941|Single oral dose\\n \\n\\n\\n\\n
224244653|NCT01903317|OTHER|Topical Therapy|Subjects will continue use of topical therapy (e.g. topical corticosteroids, keratolytic agents, anthralin, coal tar, vitamin D analogs, retinoids) for their psoriasis as if they were not participating in this study.
224244654|NCT01903317|OTHER|Phototherapy and Systemic Therapy|Subjects will continue use of phototherapy (e.g. ultraviolet B \[UVB\] or ultraviolet A and psoralen \[PUVA\]) and systemic therapy (e.g. methotrexate, cyclosporine) for their psoriasis as if they were not participating in this study.
224244655|NCT01903317|OTHER|Biologic Therapy|Subjects will continue use of biologic therapy (e.g. etanercept, adalimumab, ustekinumab) for their psoriasis as if they were not participating in this study.
223664834|NCT02710162|OTHER|Functional Oral Intake Scale|The Functional Oral Intake Scale (FOIS) will be used for participants to report their food intake habits.
223664835|NCT02710162|OTHER|Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised|The Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) will be used to track global disease progression in participants.
223664836|NCT02710162|OTHER|Eating Assessment Tool-10|The Eating Assessment Tool-10 will be used for participant reporting of swallowing system severity.
223664837|NCT02710162|OTHER|Communicative Effectiveness Survey|The Communication Effectiveness Survey (CES) will be used for participant reporting of communication abilities across different speech contexts.
223664838|NCT02710162|OTHER|The Center for Neurologic Studies Bulbar Function Scale|The Center for Neurologic Studies Bulbar Function Scale (CNS-BFS) will be used to report bulbar function in study participants.
223664839|NCT00477516|PROCEDURE|exposure to a high-calcium dialysate bath|Subjects are exposed to a high calcium (3.5 mEq/L) dialysate bath for 150 minutes (part 1). At defined timepoints (0, 45, 90, and 150 min) blood is sampled for calcium, PTH, phosphorous, and FGF-23. At another (later) dialysis session (part 2), the process is repeated except that the subjects are exposed to a normal calcium bath (2.5 mEq/L). For each subject, results from part 1 are compared to the results from part 2.
223664840|NCT02568891|DIETARY_SUPPLEMENT|Probiotic|multispecies probiotic
223664841|NCT02568891|DIETARY_SUPPLEMENT|Placebo|matrix
223664842|NCT00308464|DRUG|PHA-794428|
223664843|NCT00234247|OTHER|Long Term Follow-Up|Extended and enhance the follow-up of the NHLBI iNO RCT by assessing the effects of iNO use on: 1.) long term clinical and childhood developmental outcomes; 2.) family impact, and; 3.) healthcare costs of prematurity-associated respiratory failure.
223664844|NCT05403398|DIETARY_SUPPLEMENT|B. subtilis CU1|2 billion CFUs daily, for 4 weeks
223664845|NCT04355585|DRUG|Colchicine Tablets|1.8mg of Colchicine given over 1 hour (1.2 mg followed by 0.6 mg 1 hour later)
223664846|NCT04355585|DRUG|Placebo oral tablet|Placebo given over 1 hour (first tablet followed by second tablet 1 hour later)
223664847|NCT04869501|DRUG|TJ004309|Antibody to CD73
223664848|NCT04869501|DRUG|Atezolizumab|Humanized monoclonal antibody to PD-L1
223664849|NCT02635932|DEVICE|Day Splint|A thermoplastic splint was confected for each participant to stabilize the trapeziometacarpal joint, maintaining the pulp of the distal phalange of the index finger free for gripping with the other fingers and leaving the thumb in a functional position. In this group the slint was used during the daily life activities.
223664850|NCT02635932|DEVICE|Night Splint|A thermoplastic splint was confected for each participant to stabilize the trapeziometacarpal joint, maintaining the pulp of the distal phalange of the index finger free for gripping with the other fingers and leaving the thumb in a functional position. In this group the slint was used during the night.
223664851|NCT03430713|PROCEDURE|Measure of tooth color|Evaluation of agreement about measure of tooth color between clinicians using two dental shade guides and two spectrophotometers in the determination of the color of maxilary central incisors and canines.
223664852|NCT05997394|OTHER|A prayer concert will be held for the participants.|Participants who are in the experimental group will be given a prayer audience.
223664853|NCT01179685|PROCEDURE|pleural fluid tapping|Minimally invasive technique to detect malignant pleural effusion
223664854|NCT05680116|DEVICE|MYOVOLT (MyovoltTM, Myovolt Limited, Christchurch, New Zealand ) wearable vibration therapy device|Patients will wear Myovolt shoulder device twice a week and each session will continue 30minutes. This therapy will apply during the radiotherapy process. The device will be applied on the bare skin of the shoulder area. The first 10 minutes of the 30 minutes will be intermittent vibration, the other 20 minutes will be done in the sinusoidal vibration program. Both programs will be in the range of 20-100 Hz.
223664855|NCT05680116|OTHER|Home based exercise|Patients will do home based exercise during the radiotherapy process. 5 days a week. 2 sessions a day, each exercise will be 10x2 repetitions
223664856|NCT00322621|DRUG|Duloxetine|
223664857|NCT02782858|DRUG|GNbAC1|Monthly IV repeated dose
223664858|NCT02782858|DRUG|Placebo|Monthly IV repeated dose
223664859|NCT01920672|BEHAVIORAL|Timed Planned Activity|
223664860|NCT01920672|BEHAVIORAL|Home Safety and Education Program|
223664861|NCT04090775|DRUG|Opdivo Injectable Product|"Opdivo (nivolumab): PD-1 inhibitor antibody~Injectable 10mg/mL, only 1 mL injected."
223664862|NCT04090775|DRUG|Yervoy Injectable Product|"Yervoy (ipilimumab): Anti-CTLA-4 antibody~Injectable 5mg/mL, only 1 mL injected."
223664863|NCT04090775|DRUG|Cytoxan|"Cytoxan (cyclophosphamide): Chemotherapy agent~Both Injectable and Oral low dose:~Injectable 250mg/m2, only 1 mL injected. Oral low dose cyclophosphamide: option of either 50mg once daily pill or 25mg twice daily pill for two weeks on, then two weeks off, then two weeks on again."
223664864|NCT04090775|PROCEDURE|Cryosurgical freezing (cryosurgery)|Cryosurgery, also known as cryoablation, for prostate cancer works by freezing the cancer cells inside the prostate gland. Cryoablation will release intact antigens to prime the immune system.
223664865|NCT01743001|DRUG|Macitentan 10 mg|Macitentan 10 mg oral tablet once daily
223664866|NCT01743001|DRUG|Placebo|Macitentan-matching placebo oral tablet once daily
223664867|NCT03194737|DEVICE|UroLift System Procedure|Minimally invasive procedure in patients with acute urinary retention secondary to BPH.
223664868|NCT05246267|BIOLOGICAL|Dupilumab|Standard of care treatment with dupilumab
223664869|NCT01490801|GENETIC|DNA analysis|
223664870|NCT01490801|GENETIC|RNA analysis|
223664871|NCT01490801|GENETIC|cytogenetic analysis|
223664872|NCT01490801|GENETIC|in situ hybridization|
223664873|NCT01490801|GENETIC|mutation analysis|
223664874|NCT01490801|GENETIC|polymerase chain reaction|
223664875|NCT01490801|GENETIC|western blotting|
223664876|NCT01490801|OTHER|flow cytometry|
223664877|NCT01490801|OTHER|immunohistochemistry staining method|
223664878|NCT01490801|OTHER|medical chart review|
223664879|NCT01565343|DRUG|florbetapir F 18|IV injection, 370MBq (10mCi)
223664880|NCT01322282|DRUG|Cetirizine|A single 10 mg dose of an experimental Cetirizine Orodispersible Tablet (ODT), with a 7-day washout period between visits
223664881|NCT01322282|DRUG|Cetirizine|A single 10 mg dose of a marketed Cetirizine Film-Coated Tablet (FCT), with a 7-day washout period between visits
223664882|NCT03149627|OTHER|Estimates - prevalence of lifetime/chronic HBV infection|Estimation of the prevalence and correlates of lifetime HBV infection defined as hepatitis B core antibody (HBcAb) positivity and chronic HBV infection defined as HBsAg positivity.
223664883|NCT04233918|DRUG|Evinacumab|Part A: Single IV dose Part B \& C: IV dose Q4W
223664884|NCT00352352|PROCEDURE|Tongue Acupuncture (Procedure)|
223664885|NCT06099080|DRUG|SM-020 gel 1.0%|Subjects will apply the investigational product twice daily for 4 consecutive weeks. Subjects will be followed for 12 weeks post final application for a total of approximately 16 weeks of required participation in the study.
223664886|NCT01532193|OTHER|Decreased oxygen concentration|"The oxygen concentration is decreased during the in Vitro embryo culture."
223664887|NCT00424541|DRUG|SPP100 (aliskiren)|
224321652|NCT07134608|PROCEDURE|Popliteal Plexus Block with 20 ml|Different position while blocking the popliteal sciatic nerve block
223664888|NCT04091607|OTHER|Music Therapy|Subject will listen to Music using provided ear buds or headphones.
223664889|NCT00984113|DRUG|Elinogrel|100 mg elinogrel b.i.d. with aspirin q.d. for 7 days and aspirin alone for 4 days (Dose of aspirin is 81 mg in the US and 100 mg in Germany)
223664890|NCT02284841|DEVICE|Hilotherm cooling face mask|Hilotherapy - use of an external cooling device; a facial mask through which water circulates at a controlled temperature, allowing continuous cooling of the face, and is thought to reduce post-operative swelling and pain.
223664891|NCT01766505|DRUG|Candemore tablet|"Candemore tablet 8, 16, or 32mg/tab, per oral, a tablet once a day during 16 weeks.~dosage is depends on the sitting blood pressure."
223664892|NCT01766505|DRUG|Cozzar tablet|Cozzar tablet: 8mg, 16mg, 32mg/tablet, per oral, a tablet a day during 16 weeks dosage depends on sitting blood pressure
223664893|NCT01736761|DRUG|Darunavir, Ritonavir and Rilpivirine|
223664894|NCT00213694|DRUG|docetaxel and celecoxib|
223664895|NCT01998568|OTHER|Intraocular pressure measurement|Using different tonometers for intraocular pressure measurement
223664896|NCT05094518|BEHAVIORAL|Mobile phone reminders|Appointment reminders in the form of push notifications will be sent through HERA app.
223664897|NCT01875679|OTHER|Comprehensive Surgical Coaching|
223664898|NCT01875679|OTHER|Conventional Surgical Training|Surgical training as per participant's residency program
223664899|NCT02807675|DRUG|CVT-301, LIP|All subjects will receive 1 dose of CVT-301 and 1 dose of placebo inhalation powder, to be taken concomitantly with their standard oral medication in 2 dosing periods. The order of treatment will be randomized, with subjects assigned to 1 of 2 sequences CVT-301 (A) administered first, followed by placebo (B), or the reverse order (BA)
223664900|NCT02807675|OTHER|Placebo|All subjects will receive 1 dose of CVT-301 and 1 dose of placebo inhalation powder, to be taken concomitantly with their standard oral medication in 2 dosing periods. The order of treatment will be randomized, with subjects assigned to 1 of 2 sequences CVT-301 (A) administered first, followed by placebo (B), or the reverse order (BA)
223664901|NCT02539056|DEVICE|Chondron Implantation|In one vial (0.4 ml), Main ingredient: 1.2 million or more autologous chondrocytes Culture solution: Adequate amount of Dulbecco's modified Eagle medium (DMEM) The cells that fill the vial are sufficiently suspended, and a sufficient amount of suspension is grafted in the defect with fibrin glue.
223664902|NCT04590833|BEHAVIORAL|Supervised walking on a treadmill|Each participant will be provided with an individualized target heart rate zone based on his/her age. Heart rate during exercise will be measured using a finger pulse oximeter. Following baseline measures, participants will receive instructions on how to use a finger pulse oximeter by a student. For participants who are not physically fit or are just engaging in regular exercise, they will be advised to start walking on a treadmill at a comfortable pace for 5 to 10 minutes at one time.46 Exercise duration and intensity will be progressed from week 3 to week 5, until participants will walk at 40-59% of heart rate reserve based on their age, which will be maintained throughout the study.
223664903|NCT04590833|BEHAVIORAL|Supervised stretching exercise|Following baseline measures, a student will demonstrate the use of a pulse oximeter and stretching movements to these participants. Starting on week 3, participants will do the prescribed stretching exercise 3 times a week, maintaining heart rate below 40% of heart rate reserve during exercise. Stretching will target all major muscle-tendon groups including shoulder, chest, neck, truck, lower back, hips, and legs. It will also involve a slow and constant motion that accounts for any physical limitations and physician-specified precautions
223664904|NCT03820440|DIAGNOSTIC_TEST|End-expiratory occlusion test (EEOT)|The EEOT is performed by interrupting the mechanical ventilation for 30 seconds, by using and end-expiratory hold on the ventilator.
224244656|NCT01382719|DRUG|bremelanotide|"Subjects will administer drug on an as needed basis, prior to anticipated sexual activity.~Investigational product: Bremelanotide aqueous solution for subcutaneous (SC) injection, provided as pre-filled syringes containing 0.75, 1.25, or 1.75 mg in 0.3 mL volume. Subjects will self-administer bremelanotide by SC injection into the anterior thigh or abdomen.~Placebo: Same formulation as the investigation product but without the active ingredient, provided as pre-filled syringes containing 0.3 mL volume. Subjects will self-administer the placebo by SC injection in the same manner as the investigational product."
224244657|NCT03203863|DIAGNOSTIC_TEST|anthropometric measures of fatness|The aim of this study was to determine the discrimination capacity for cardiovascular risk factors of BMI, fat mass (FM), waist circumference (WC), and waist to height ratio (WHtR) in a population of Chilean children from Puente Alto County. Additionally, new cutoff points were established and compared with those described by other authors
224244658|NCT01275586|DRUG|Tasigna|Following enrollment each subject will initially receive Tasigna orally at 200 mg twice daily for two weeks. If tolerated, the dose will be increased to 300 mg twice daily after a minimum of two weeks and will be increase to a maximum dose of 400mg twice daily after an additional two weeks if tolerated.
224244659|NCT01208363|DIETARY_SUPPLEMENT|Cowpea fortified with NaFeEDTA, in form of Toubani.|66g raw Cowpea fortified with 10 mg Fe as NaFeEDTA, in form of Toubani, a cowpea snack. Ther snack will be given to the participants 3 times per week, for six month integrated in the school feeding trial.
224244660|NCT02472184|PROCEDURE|Office hysteroscopy|Office hysteroscopy is a procedure performed in the office in which a flexible hysteroscope is inserted into the uterine cavity. The patient is positioned in a dorsal lithotomy position and teh cervix is visualized with a speculum. Normal saline is used to distend the cavity, and the hysteroscope is used to visualize any abnormalities within the cavity.
224244661|NCT02472184|PROCEDURE|Endometrial biopsy|An endometrial biopsy is a procedure in which a pipelle instrument is inserted into the uterine cavity and suction from the pipelle is used to obtain endometrial tissue. This is performed with the patient in the dorsal lithotomy position and a speculum is used to visualize the cervix.
224244662|NCT04274114|DRUG|L Glutamine|Powder
224244663|NCT04274114|DRUG|Placebos|Powder
223664905|NCT03820440|DIAGNOSTIC_TEST|Lung recruitment manovre (LRM)|The LRM is performed by using a single act of mechanical ventilation in pressure-controlled mode at 30 cmH20 for 30 seconds
223664906|NCT01066390|BIOLOGICAL|TriMix-DC|eligible patients will undergo a leucapheresis for the preparation of autologous TriMix-DC vaccine.4 weeks after the leucapheresis patients will initiate therapeutic vaccination with the TriMix-DC vaccine by IV and ID administration. The vaccines will be administered at 4 different visits that will be separated with an interval of 2 weeks.
223664907|NCT04608539|DRUG|Ferric Derisomaltose|Single-dose intravenous infusion, 20 mg/kg body weight, postoperative day 1
224244664|NCT04873310|OTHER|Triple P online with professional support|The psychologist in charge will have the role of monitoring the autonomous work of the participants during the 8 sessions. The psychologist in charge will also verify that the participants are able to complete the online modules week by week, that they understand the contents taught in the module and that they are practicing the tasks and exercises assigned in each of the modules; in addition to generating an action plan in case the participants are not adhering week by week to the self-administration of the program. The follow-up and contact with the families will be carried out by phone and through a weekly email-type messaging system, implemented within the same platform on which the program material is found
224244665|NCT04873310|OTHER|Triple P online without professional support|The role of the psychologist in charge will be to keep the platform updated so that the person who self-administers the intervention does not have technical problems associated with the platform.
224244666|NCT02865746|DRUG|Bethametasone|The injections were performed with the aid of syringes fitted with ultrafine needles (BD ultrafine U-100, 0.3 x 8 mm), in the buccal mucosa, submucosally near the tooth's periapex of the periapical region of the tooth involved, by using the submucosal infiltration technique.
224244667|NCT02865746|DRUG|Placebo|The injections were performed with the aid of syringes fitted with ultrafine needles (BD ultrafine U-100, 0.3 x 8 mm), in the buccal mucosa, submucosally near the tooth's periapex of the periapical region of the tooth involved, by using the submucosal infiltration technique.
224244668|NCT03098108|RADIATION|Concurrent chemo-proton therapy|Proton therapy with simultaneous integrated boost technique Gross tumor volume 70.4 gray (Gy)/ 16 fractions and clinical target volume 44.8 Gy/16 fractions Capecitabine twice a day 825 mg/body square meter
224244669|NCT06284538|DEVICE|NOVA.EMOSTOP RE-EPITHELIZING|RE-EPITHELIZING GEL BASED ON HYALURONIC ACID
223664908|NCT04608539|DRUG|Ferrous sulfate|Oral therapy, 100 mg twice daily, from postoperative day 4 until 4-week follow-up
223664909|NCT04608539|DRUG|normal saline|Single-dose infusion (placebo), postoperative day 1
223664910|NCT00959400|DRUG|Fentanyl Transdermal|Fentanest® 25 mcg/h. Each patch delivers 25 mcg of fentanyl per hour continuously for 72 hours. Therefore paches must be changed every 3 days.
224244670|NCT01270919|DEVICE|BioDuct Meniscal Repair Device|"The BioDuct® Meniscal Repair Device is a small, cannulated, arthroscopically implanted, bioabsorbable conduit that has length sizes of 5, 7 and 9 mm. Based on the concept of trephination for treating meniscal tears in the red-white zone, the BioDuct® Meniscal Repair Device is designed to create a vascular access channel between the vascular-rich and cell-rich synovium and the meniscal tear. This channel allows for the flow of blood from the vascular to the avascular tissue to promote repair of the meniscus.~The BioDuct® Meniscal Repair Device is not used across meniscal tears, like other fixation devices. The BioDuct® Meniscal Repair Device is used in conjunction with suturing and helps provide vascular access, while the sutures help provide fixation. Based on the Inclusion Criteria of this protocol, there can be a maximum of three BioDuct® Meniscal Repair Devices utilized for the meniscal tear."
224244671|NCT01359566|DRUG|Arbaclofen placarbil 15 mg BID|arbaclofen placarbil 15 mg BID
224244672|NCT01359566|DRUG|Placebo|Placebo for arbaclofen placarbil 15, 30 and 45 mg BID
223664911|NCT02213406|DIETARY_SUPPLEMENT|yogurt|Subjects will receive yogurt with varying fat concentrations
223664912|NCT02902484|DRUG|Nintedanib|Nintedanib Monotherapy Followed by Combination Therapy of Nintedanib and Gemcitabine Plus nab-Paclitaxel
224244673|NCT01359566|DRUG|Arbaclofen placarbil 30 mg BID|arbaclofen placarbil 30 mg BID
224244674|NCT01359566|DRUG|Arbaclofen placarbil 45 mg BID|arbaclofen placarbil 45 mg BID
224244675|NCT01126736|DRUG|eribulin mesylate|Eribulin mesylate (eribulin; E7389) administered as a 2-5 minute intravenous (IV) bolus in one of two dosing schedules for both the Phase Ib and Phase 2 portions: either Days 1 and 8 of a 21 day cycle in ascending doses of 0.7, 1.1, or 1.4 mg/m2 or on Day 1 of the 21-day cycle at doses at ascending doses of 0.9, 1.4, or 2.0 mg/m2.
224244676|NCT01126736|DRUG|pemetrexed|Pemetrexed given at a dose of 500 mg/m2 as an IV infusion on Day 1 of a 21-day cycle. Patients will also receive dexamethasone and vitamin supplements as recommended in the prescribing information for pemetrexed.
224244677|NCT01126736|DRUG|Eribulin mesylate (eribulin; E7389)|Eribulin mesylate (eribulin; E7389) administered as a 2-5 minute intravenous (IV) bolus in one of two dosing schedules for both the Phase Ib and Phase 2 portions: either Days 1 and 8 of a 21 day cycle in ascending doses of 0.7, 1.1, or 1.4 mg/m2 or on Day 1 of the 21-day cycle at doses at ascending doses of 0.9, 1.4, or 2.0 mg/m2.
224244678|NCT02731365|DEVICE|Activa PC+S|The Activa PC+S is a newly developed Medtronic DBS implantable system and is available for use in clinical research. This system has a mechanism for both sensing of LFP and the ability to provide deep brain stimulation therapy. The sensing capabilities are controllable with data management using a clinician sensing tablet programmer that has a USB extension allowing for telemetry to an encrypted, locked computer.
224244679|NCT04181190|DIAGNOSTIC_TEST|Total IgE|Levels of total IgE before biological treatments and at 4±2 months of treatments
224244680|NCT04181190|DIAGNOSTIC_TEST|Blood cell counts|White Blood Cell Count and Differential (and in particular the levels of total leucocytes, lymphocytes, eosinophils and basophils)
224244681|NCT04181190|DIAGNOSTIC_TEST|Asthma control assessment|Levels of asthma control assessed by asthma control questionnaire (ACT) before initiation of biological treatments and at 4± months of treatments
224244682|NCT04181190|DIAGNOSTIC_TEST|lung function tests|Lung function tests performed before initiation of biological treatments and at 4± months of treatments
224244683|NCT00944203|DRUG|Ipomea pes-caprae ointment|Ipomea pes-caprae ointment will be applied twice a day as an add-on therapy.
224244684|NCT02015390|PROCEDURE|Autogenous RIA bone grafting|After aseptic defect and adequate soft tissue coverage have been achieved, the defect reconstruction technique will include autogenous bone grafting harvesting using Reamer-Irrigator-Aspirator (RIA) and packing it within the defect.
224244685|NCT02015390|PROCEDURE|Allogeneic bone grafting|After aseptic defect and adequate soft tissue coverage have been achieved, the defect reconstruction technique will include defect packing with allogeneic bone graft croutons combined with demineralized bone matrix (DBM).
223664913|NCT02147119|PROCEDURE|Coronary angiography|
224244686|NCT06089538|DIAGNOSTIC_TEST|mEEG battery|The 2 groups will be assessed twice : in the acute phase of acute respiratory distress syndrome (ARDS) at patient's bedside in the intensive care unit (ICU) using an mEEG battery (electrophysiological acquisition at rest and during complex cognitive stimulation), and a simple clinical neuropsychological assessment ; 6 months ± 2 weeks later using the same mEEG battery and a multi-domain clinical neurocognitive and psychological assessment battery
224244687|NCT02554370|BEHAVIORAL|Psychoeducational programme|4 sessions of psychoeducation before and 3 after surgery for subthalamic deep brain stimulation
224244688|NCT01535859|DRUG|Cabergoline|Cabergoline in 0.5mg tablet. 1 tablet daily for 8 days.
224244689|NCT01535859|DRUG|Placebo|1 tablet daily for 8 days.
224244690|NCT00998556|DRUG|Bromocriptine|Patients randomized to the study medication have to take bromocriptine orally for the first 14 days at a dose of 5 mg/day (= 2 tablets, 1 in morning, 1 in the evening). From day 15 to day 56 they will take a dose of 2.5 mg (= 1 tablet) orally in the evening. The duration of the intervention is 8 weeks. The study medication is taken on top of standard therapy for heart failure.
224244691|NCT04932252|DRUG|A4368 or placebo tablet|orally administered
224244692|NCT03855332|DRUG|Sildenafil|See above
224244693|NCT03855332|DRUG|Cilostazol|See above
224244694|NCT03855332|DRUG|Placebo|Overencapsulated placebo
224244695|NCT02683837|DRUG|Remifentanil|
223664914|NCT05902650|DIAGNOSTIC_TEST|imaging|imaging
224244696|NCT02683837|DEVICE|Pupillometry|Pupillary diameter measured every 5 minutes
224244697|NCT02683837|DRUG|Sevoflurane|Administered to maintain a Bispectral Index between 40 and 60
224244698|NCT02679053|BEHAVIORAL|Aerobic exercise|
224244699|NCT02679053|BEHAVIORAL|Placebo control|
224244700|NCT00194753|DRUG|Paclitaxel|80 mg/m2 IV for 12 weeks following completion of doxorubicin and cyclophosphamide
224244701|NCT00194753|DRUG|Doxorubicin|24 mg/m2 IV weekly x 12
224244702|NCT00194753|DRUG|Cyclophosphamide|60 mg/m2 PO daily for 12 weeks
224244703|NCT00194753|DRUG|G-CSF|5 mcg per kg subcutaneously days 2 - 7 during doxorubicin and cyclophosphamide for 12 weeks
224244704|NCT05975853|OTHER|Binaural beat music group (BBM group)|The participant sat on a chair with eyes closed and wore over-ear stereo headphones to listen to 15 minutes of Taiwanese Hokkien oldies (familiar music, can be selected by participant) with BBM embedded.
223664915|NCT02130102|DEVICE|The ModuLAAr Ambient Assisted Living System|"The system consists of the following modules which will be provided to the volunteers according to their needs:~tablet computer (digital photo album, video telephone, meal ordering system, reminder system), bodyweight scale, blood pressure meter, emergency call system, mobile phone (documentation of personal health-related data), bathroom surveillance system, blood glucose meter, house automation technologies/smart home technologies"
223664916|NCT04493528|COMBINATION_PRODUCT|Meso-Jet, 2% lidocaine(xylocaine)|Performing local dental anesthesia using needle-free liquid jet injection with different parameters (pressure, volume, injection technique). Anesthetic agent: 2% lidocaine with 1:100,000 epinephrine, dose: 0.3-2ml.
223664917|NCT04493528|COMBINATION_PRODUCT|Needle,2% lidocaine(xylocaine)|Performing local dental anesthesia using syringe and needles, same as regular clinical practice. Anesthestic agent: 2% lidocaine with 1:100,000 epinephrine,dose: 0.3-2ml.
223664918|NCT03137667|OTHER|School-located Influenza Vaccination|Children in the intervention arm are enrolled in schools in Monroe County, New York that are offering school-located influenza vaccination clinics during school hours
223664919|NCT00022347|DRUG|canfosfamide hydrochloride|
223664920|NCT02278523|DEVICE|Threshold IMT®|A device used to offer threshold load to inspiratory muscle
223664921|NCT03948477|DRUG|Pantoprazole 40mg|Proton pump inhibitor, drug action is to irreversibly block the hydrogen-potassium adenosine triphosphatase enzyme system (the 'proton pump') of the gastric parietal cell. This reduces basal and stimulated gastric acid secretion therefore raising gastric pH.
223664922|NCT03948477|DRUG|Placebo|Matched placebo
223664923|NCT00000590|DRUG|immunoglobulins|
223664924|NCT02973880|DRUG|NETILDEX™ ophthalmic gel|"1 drop of NETILDEX™ (Netilmicin Sulfate 3mg/ml / Dexamethasone Disodium Phosphate 1mg/ml) ophthalmic gel immediately after the surgery then 1 drop twice daily (b.i.d.) from Day 1 until Day 14 after surgery + 1 drop of XANTERGEL™ ophthalmic gel twice daily (b.i.d.) from Day 1 until Day 14 after surgery.~Bromfenac 0.9 mg/ml 1 drop twice daily (b.i.d.) for 3 days before cataract surgery."
223664925|NCT02973880|DRUG|NETILDEX™ eye drops solution|"1 drop of NETILDEX™ (Netilmicin Sulfate 3mg/ml / Dexamethasone Disodium Phosphate 1mg/ml) eye drops solution immediately after the surgery then 1 drop four times a day (q.i.d.) from Day 1 until Day 14 after surgery.~Bromfenac 0.9 mg/ml 1 drop twice daily (b.i.d.) for 3 days before cataract surgery."
223664926|NCT00324259|DRUG|Estradiol|
223664927|NCT04382989|DEVICE|Analysis of human milk composition by mid-infrared spectrophotometry|"Analysis of human milk macronutrient content was performed by mid-infrared spectrophotometry using a Miris Human Milk Analyser.~An immune-enzymatic ELISA assays were used to estimate lysozyme and lactoferrin concentrations in human milk."
223664928|NCT05662800|DIAGNOSTIC_TEST|Assessment of peanut, tree nuts and sesame allergy|"Children will undergo skin prick testing with the following allergens: commercial extracts for peanut, hazelnut, almond, cashew, pistachio, walnut, macadamia, sesame, Timothy grass, and birch pollen; positive and negative control; peanut butter and tahini (sesame) paste.~Specific IgE levels will be quantified to all the above-listed tree nuts, peanuts, sesame seed and peanut components (Ara h 1, Ara h 2, Ara h 3, Ara h 6, Ara h 8, Ara h 9).~Children will undertake cumulative or incremental oral food challenge with peanut, sesame and tree nuts, depending on the risk assessment based on patient's medical history and results of diagnostic tests."
223664929|NCT05661747|DEVICE|Vivos Grow/Vivos Way Device|Children already using the device will be monitored to determined whether it improves symptoms of SDB
223664930|NCT05214079|DEVICE|Left paratracheal pressure|Applying Left Paratracheal pressure and testing its effectiveness using gastric tube . in addition , by using the dynamometer , the CP 50 is defined.
223664931|NCT02310334|OTHER|Guided Exercise Session|Participants will be provided a pace based upon their current (estimated) physiological strain index (PSI) - a measure of thermal work strain, the time, and the distance completed already.
223664932|NCT02310334|OTHER|Unguided Exercise Session|Participants will be instructed to complete 5 miles within 60 minutes and finish in as cool (lower body temperature) a state as possible.
223664933|NCT03021993|DRUG|Nivolumab|Nivolumab will be administered on days 1, 15 and 29. If disease has progressed at day 29, the subject will proceed to surgery. If a response or stable disease is present after the third dose, a fourth dose will be given on day 43, then the subject will proceed to surgery.
223664934|NCT04122651|PROCEDURE|'Off the shelf' toric lens|'Off the shelf' toric lens (either 2.00D or 4.00D) and combined limbal relaxing incisions and/or off-axis inttaocular lens rotation
223664935|NCT04122651|PROCEDURE|Tailored Toric lens|Fully targeted toric intraocular lens correction for corneal astigmatism
224244705|NCT05975853|OTHER|Control group|The participant sat on a chair with eyes closed and wore over-ear stereo headphones to listen to 15 minutes of Taiwanese Hokkien oldies (familiar music, can be selected by participant) without BBM embedded.
224244706|NCT00535951|DRUG|LBH589|
224244707|NCT00987805|DIETARY_SUPPLEMENT|Banhasasim-tang|Form : granules Contents : It consists of seven Herbs. It contains Rhizoma Pinelliae, Radix Scutellariae, Zingiberis Rhizoma, Panax ginseng, Glycyrrhiza uralensis Fisch, Zizyphi Fructus and Coptidis Rhizoma Dosage and frequency : 9g per day (three times a day) Route of administration : Oral Administration duration : 42 days in the study
224244708|NCT00987805|DIETARY_SUPPLEMENT|Corn-starch granules|This placebo has the same form, color, and flavor as experimental intervention.The dosage, frequency and duration is also same as experimental intervention.
224244709|NCT04857697|PROCEDURE|Biopsy|Undergo biopsy
224244710|NCT04857697|PROCEDURE|Biospecimen Collection|Undergo collection of blood, stool, and tissue samples
224244711|NCT04857697|DRUG|Probiotic|Given PO
223664936|NCT05171556|OTHER|Cosmetic product|RV4942A is a face balm product
223664937|NCT01463085|OTHER|Low-fat dairy|Dietary Intervention of 3 servings per day of low-fat dairy
223664938|NCT01163227|DRUG|Placebo (single and multiple doses)|
223664939|NCT01163227|DRUG|AQW051 2 mg (single and multiple doses)|
223664940|NCT01163227|DRUG|AQW051 15mg (single and multiple doses)|
223664941|NCT01163227|DRUG|AQW051 100mg (single dose), and 50mg (multiple doses)|
223664942|NCT02824796|BEHAVIORAL|Schema Parent Behavioral Training|A novel protocol for parent whose children suffer from ADHD and comorbidities. The protocol combines elements from Schema Focus Therapy (SFT) and Parent Behavioral Training (PBT)
223664943|NCT02824796|BEHAVIORAL|Parent Behavioral Training|A state of the art Parent Behavioral Treatment (PBT) for Children who suffer from ADHD symptoms
223664944|NCT03881527|DEVICE|Aortic valve replacement using a nitinol blade|A circular nitinol blade will be inserted by to cut the aortic valve leaflets during conventional aortic valve replacement procedure
223664945|NCT03881527|PROCEDURE|aortic valve replacement|Aortic valve replacement in a standard fashion
223664946|NCT00874419|DRUG|erlotinib|erlotinib 150 mg oral, once a day
223770382|NCT07080580|BEHAVIORAL|Core exercises performed simultaneously on a whole body vibration platform|"It's a method where individuals stand on a vibration-generating platform and the vibration is transmitted from the soles of their feet to the entire body. Its use in combination with exercise has become popular in recent years due to the hypergravity it creates, aiming to increase muscle strength and reduce pain.~There is no standardized protocol for the frequency, amplitude, and frequency of vibration application. However, it is known that when applied at frequencies between 10-30 Hz, it has no negative side effects and is beneficial in managing pain. In our study, core exercises will be performed on a vibration platform at a frequency of 14 Hz with an amplitude of 8 mm."
223770383|NCT06858774|BEHAVIORAL|Circadian Reset Technology|Circadian reset technology is a software used on a VR headset in this intervention. The software is a passive viewing experience like a guided meditation that presents visual images.
223770384|NCT06858774|BEHAVIORAL|VR Headset|The software used on a VR headset in this intervention is a passive viewing experience like a guided meditation that presents neutral images that mimics the sequence used in the CRT software.
223770385|NCT07077278|DRUG|Low sodium oxybate (LXB)|Participants will continue take low sodium oxybate (LXB) for two weeks after completing an open-label titration and dose optimization period of low sodium oxybate (LXB).
223770386|NCT07077278|DRUG|Placebo|Participants will take placebo for two weeks after completing an open-label titration and dose optimization period of low sodium oxybate (LXB).
223770387|NCT06786039|PROCEDURE|Non-invasive NAVA|"Initiate respiratory assist with NIV-NAVA within 48 hours. The setting of respiratory support will be adjusted based on clinical conditions of each subject. NIV-NAVA could be switched to nasal continuous airway pressure or high flow nasal cannula, and it also could be stopped after initial stabilization.~In cases of respiratory distress syndrome, lung surfactant will be administered via the less invasive surfactant administration (LISA) method and avoid endotracheal intubation whenever possible. For who intubated in the delivery room, extubation with NIV-NAVA should be considered as soon as possible. Endotracheal intubation with invasive ventilation could be applied when clinical deteriorations happens."
224244712|NCT04857697|PROCEDURE|Therapeutic Conventional Surgery|Undergo standard of care surgery
224244713|NCT01914497|DEVICE|Acutus Medical System Mapping|
224244714|NCT04107454|DEVICE|Active microablative fractional CO2 laser designed as SmartXide Touch C60, CO2 laser system for MonaLisa Touch, DEKA, Florence|Active application of laser radiation on the vulvar skin. The laser setting is: Power 24 W, exposure time 400 microsec, density 6,4 %, pulse energy 23,2 mJ, fluenz 1,18J/cm2, emission mode DP, DOZ Dwell 400, DOT spacing 1000.
224244715|NCT04107454|DEVICE|Sham microablative fractional CO2 laser designed as SmartXide Touch C60, CO2 laser system for MonaLisa Touch, DEKA, Florence|Sham application of laser radiation on the vulvar skin. Laser setting is a sham dose:power 0, 5 W, exposure time 400 microsec, DOT spacing 1000
224244716|NCT04925817|OTHER|Electronic Health Record Review|Medical record reviewed
223664947|NCT00874419|DRUG|gemcitabine/carboplatin|gemcitabine 1000mg/m2 on d1,8 with carboplatin AUC=5 on d1 intravenously, every 3 weeks, up to 4 cycles
223664948|NCT02906605|DRUG|JNJ-809|JNJ-809 (1\*10\^9) colony forming units (CFU) given as an infusion.
223664949|NCT02906605|DRUG|Apalutamide|Apalutamide 240 mg orally daily.
223664950|NCT03779490|DEVICE|Transcatheter Tricuspid Valve Repair|Transcatheter Tricuspid Valve Repair with Edwards Cardioband TR
223664951|NCT00710216|DRUG|Lamivudine|100 mg/day
223664952|NCT00710216|DRUG|Telbivudine|600 mg/day
224244717|NCT04925817|PROCEDURE|Ultrasound Microvessel Imaging|Undergo 3D ultrasound microvessel imaging
224244718|NCT02819934|DRUG|KD101|after 10 min KD101 administered, 14C KD101 3.52ug/1ml administrated. both of them will be administrate for oral
224244719|NCT04031131|DRUG|Instillagel|Topical Anaesthetic Gel (Instillagel) licensed for rectal administration.
224244720|NCT04031131|OTHER|KY Gel|Lubricant Gel
224244721|NCT02193880|DEVICE|Alpha-beta depleted T-cell infusion after post-transplant cyclophosphamide.|Post-transplant alpha-beta depleted T-cell infusion after post-transplant cyclophosphamide.
224244722|NCT02544594|DEVICE|Extra-Corporal Life Support (ECLS)|Extra-Corporal Life Support (ECLS) (from Sorin)
224244723|NCT02951962|DRUG|Twynsta 80/5mg|Hypertension
224244724|NCT02951962|DRUG|Crestor 20mg|Hyperlipidemia
224244725|NCT02039362|DRUG|Tenofovir DF|Tenofovir DF will be started at week 28 of pregnancy and stopped or not, according to the physician's decision, at week 12 after birth
223664953|NCT02527772|DRUG|Liposomal Doxorubicin+Gemcitabine|Gemcitabine 1000mg/m2,d1,8,iv; Liposomal Doxorubicin 30mg/m2,d1,iv.q4w of each 28 day cycle. 6 of Cycles: until progression or unacceptable toxicity develops or Progressive Disease.
223664954|NCT02527772|DRUG|FOLFOX4|Oxaliplatin 85 mg/m2 intravenously on day 1; Leucovorin 200 mg/m2 IV(in vein) from hour 0 to 2 on days 1 and 2; and Fluorouracil 400 mg/m2 IV bolus at hour 2, then 600mg/m2 over 22 hours on days 1 and 2, once every 2 weeks until progression or unacceptable toxicity develops or Progressive Disease.
223664955|NCT03272776|DEVICE|Protector Laryngeal Mask airway|Evaluate the time of insertion, performance, security and insertion success rate of the Protector Laryngeal Mask in patients under general anasthesia.
223664956|NCT01339520|BEHAVIORAL|Scorecard|Points were assigned for blood pressure, HbA1c level, LDL-cholesterol level, aspirin use and exercise level.
223664957|NCT01339520|BEHAVIORAL|Control|Standard of care for diabetes subjects
223664958|NCT04110535|DRUG|Remimazolam|IV administration over 1 minute
223664959|NCT04110535|DRUG|Midazolam|IV administration over 1 minute
223664960|NCT04110535|OTHER|Saline|IV administration over 1 minute
223770388|NCT07076264|OTHER|AquOTic|AquOTic is an evidence-based, occupational therapy-led intervention designed to enhance water competency and swim safety skills in children on the autism spectrum. The 10-week program consists of weekly 60-minute group sessions, each including six children paired in a 1:1 ratio with an interventionist. Sessions follow a structured routine involving six rotating stations, targeting various swim and safety skills, with the flexibility for individualized support by the interventionist.
223770389|NCT07078825|OTHER|Training Supported by Metaverse and Virtual Reality (VR) in the Digital Breastfeeding Museum Group|The pregnant women in this group received training supported by Metaverse and virtual reality (VR) in the digital breastfeeding museum. The training began when pregnant women wore VR headsets (Meta Quest 2) and entered the digital museum using hand controllers. To prevent physical risks like falling or bumping, they navigated the environment safely from where they were seated. Educational content was accessed via personalized avatars. Participants moved between rooms by walking virtually or clicking on circular transition portals. The researcher provided guidance when needed. Video durations varied by topic, totaling around 40 minutes. Mothers could rewatch videos and pause/resume the training on the same day. They engaged with visual, auditory, and written materials, spending approximately one hour in the museum.
223770390|NCT07086326|DRUG|Ivonescimab+Chemo|Ivonescimab (AK112) + platinum-based doublet chemotherapy
223770391|NCT07086326|DRUG|Penpulimab+Chemo|Penpulimab (AK105) + platinum-based doublet chemotherapy
224244726|NCT03548389|OTHER|Skin to skin contact|By assistance of the researcher, intervention infants were placed undressed in a prone position against their mothers' bare chest between breasts immediately after birth and before placental delivery and suturing of tears or episiotomy. The Apgar score was determined, the infant's nose and mouth were suctioned while on the mother's chest, it was well dried, and both mother and infant were covered with a pre-warmed blanket. To prevent heat loss, the infant's head was covered with a dry cap that was replaced when it became damp. Dressing and measuring of the infant were postponed to an hour after the delivery by registered midwife.
224244727|NCT03136380|DRUG|GSK1325756H|Danirixin will be available as 10 and 50 milligram (mg) white film coated, round and oval tablets intended for oral administration. It will be administered with 240 mL of water.
224244728|NCT03136380|DRUG|Placebo|Subjects will receive visually matching danirixin placebo tablets. It will be administered with 240 mL of water.
224244729|NCT01924091|DRUG|Dapivirine gel|
224244730|NCT01924091|DRUG|Dapivirine film|
224244731|NCT04556240|DEVICE|VitalConnect Platform|The VitalConnect Platform is a wireless remote monitoring system intended for use by healthcare professionals for continuous collection of physiological and irregular heart rhythm data in home and healthcare settings. This includes heart rate, electrocardiogram (ECG), heart rate variability (R-R interval), breathing rate, arrhythmia detection, body temperature, skin temperature, activity (including step count), and posture (body position relative to gravity including fall). Data is transmitted wirelessly to a central location where it is stored for analysis. The VitalConnect Platform can be configured by authorized persons to notify healthcare professionals when physiological data falls outside selected parameters
224244732|NCT02698982|DEVICE|Depth of anesthesia monitoring (BIS, Covidien USA) and Continus non invasive blood pressure monitoring (Clearsight, Edwards LifeScience, USA)|
224244733|NCT02698982|PROCEDURE|moderate risk surgery|
224244734|NCT02550340|OTHER|acute alcohol intake|Smart phone based ECG recording
224244735|NCT02620930|DEVICE|All market approved CRT-D or ICD systems endowed with the APNEA Scan algorithm|
224244736|NCT01361048|DRUG|oral metronidazole|2 gm oral once
224244737|NCT01361048|DRUG|neo penotran forte|neo penotran forte intravaginal twice a day for 7 days
224244738|NCT01361048|DRUG|neo penotran forte once a day|neo penotran forte intravaginally once a day for 7 days
224244739|NCT02778165|OTHER|MyCaRe (my cardiac recovery Android application)|Android application \& Fitbit Inspire 2 activity monitor
224244740|NCT04625348|DEVICE|Ultracore Repose® mattress|residents will be placed on the Ultracore Repose® mattress for the daily care during 14 days
224244741|NCT04625348|OTHER|experiences and perceptions of healthcare workers|Three focus groups will be set- up at the end of the study to provide insights into how caregivers think about the product and to provide a deeper understanding of the difference between the use of the Ultracore Repose® mattress (versus the Repose overlay mattress® and an alternating air mattress)
223664961|NCT01658306|PROCEDURE|remote ischemic preconditioning|RIPC consists of five 5-min cycles of right upper arm ischemia/reperfusion, induced by an automated cuff-inflator placed on the right upper arm which is inflated to 200 mmHg for 5mins followed by deflating the cuff for 5mins, each patient in the RIPC group will have the treatment twice a day for two weeks.
223664962|NCT01658306|PROCEDURE|sham remote ischemic preconditioning|Sham RIPC consists of five 5-min cycles of right upper arm ischemia/reperfusion, induced by an automated cuff-inflator placed on the right upper arm which is inflated to 50 mmHg for 5mins followed by deflating the cuff for 5mins, each patient in the placebo RIPC group will have the treatment twice a day for two weeks.
223664963|NCT02940041|PROCEDURE|Pre-surgical diagnosis of uterine malignant tumors|All patientes who fit inclusion criteria will undergo a gynecologic sonography, pelvic MRI, determination of LDH, as in regular practice. No additional interventions will be done to any patient.
223664964|NCT01443624|DRUG|critical care patients venofer|100mg IV in one hour (in critically ill patients the injection could be repeated on day 2 (200mg) and 4 (100mg) depending on treatment
223664965|NCT02840617|DRUG|Indocyanine Green (ICG)|
223664966|NCT00993226|DRUG|SABER-Bupivacaine Treatment 1a|5.0 ml
223664967|NCT00993226|DRUG|Placebo SABER-Bupivacaine Treatment 1b|5.0 ml
223664968|NCT00993226|DRUG|Bupivacaine HCl Treatment 1c|40 ml
223770392|NCT07084974|DEVICE|Adjustment and practice session|During the adjustment and practice session, participants will perform the lifting task with each exoskeleton after they are properly fitted. They will also perform the measurement sequence as to limit learning effects during lifting task sessions. The lifting task is a box transfer tasks from the ground to a table adjusted at the participant's hip height. The task rhythm is 7 cycles per minute. The box weight is equivalent to 10% of their maximal lifting strength. Total session duration is about 3 hours.
223770393|NCT07084974|DEVICE|No trunk assistance|This lifting task session is performed without any trunk assistance exoskeleton. Participants perform 3 blocks of 20 minutes of the lifting task. The lifting task is a box transfer tasks from the ground to a table adjusted at the participant's hip height. The task rhythm is 7 cycles per minute. The box weight is equivalent to 10% of their maximal lifting strength. Total session duration is about 3 hours.
223770394|NCT07084974|DEVICE|Uplift Lite exoskeleton|This lifting task session is performed with the Mawashi Uplift Lite trunk assistance exoskeleton. Participants will perform 3 blocks of 20 minutes of the lifting task. The lifting task is a box transfer tasks from the ground to a table adjusted at the participant's hip height. The task rhythm is 7 cycles per minute. The box weight is equivalent to 10% of their maximal lifting strength. Total session duration is about 3 hours.
223770395|NCT07084974|DEVICE|Biolift exoskeleton|This lifting task session is performed with the Biolift trunk assistance exoskeleton. Participants perform 3 blocks of 20 minutes of the lifting task. The lifting task is a box transfer tasks from the ground to a table adjusted at the participant's hip height. The task rhythm is 7 cycles per minute. The box weight is equivalent to 10% of their maximal lifting strength. Total session duration is about 3 hours.
223770396|NCT07084974|DEVICE|Laevo Flex exoskeleton|This lifting task session is performed with the Leavo Flex trunk assistance exoskeleton. Participants perform 3 blocks of 20 minutes of the lifting task. The lifting task is a box transfer tasks from the ground to a table adjusted at the participant's hip height. The task rhythm is 7 cycles per minute. The box weight is equivalent to 10% of their maximal lifting strength. Total session duration is about 3 hours.
223770397|NCT07085182|DRUG|SBRT combined with Tislelizumab followed by Tislelizumab|SBRT:3-10Gy/F, once daily, 5 times a week; Tislelizumab(200mg,iv,q3w):Tislelizumab was added after five sessions of SBRT radiotherapy.
223770398|NCT07086144|DIAGNOSTIC_TEST|Determination of viral genome, bacterial serology, and markers of inflammation in pediatrics diagnosed with myocarditis|N=15 patients from 2025, in which management and treatment of arrhythmias and or myocardial dysfunction were driven by the panel
223770399|NCT07086612|DIAGNOSTIC_TEST|over nigtht ventilatory polysomnograph test|Every patient will have an overnight polysomnography test.
223770400|NCT07085676|BIOLOGICAL|HBI0101 CART|HBI0101 CART is defined as autologous T cells transduced ex-vivo with anti-BCMA CAR retroviral vector encoding the chimeric antigen receptor (CAR) targeted to human BCMA. The HBI0101 CART may be provided fresh or cryopreserved.
223664969|NCT00993226|DRUG|SABER-Bupivacaine Treatment 2a|7.5 ml
223664970|NCT00993226|DRUG|Placebo SABER-Bupivacaine Treatment 2b|7.5 ml
223664971|NCT00993226|DRUG|Bupivacaine HCl Treatment 2c|40 ml
223664972|NCT00817596|DEVICE|Infusion Pump (Prometra)|Implantation of pump/catheter for infusion of morphine into the intrathecal space
223664973|NCT02282241|DRUG|Melatonin|
223664974|NCT02282241|OTHER|Placebo|
223664975|NCT00294619|DRUG|growth hormone|subcutaneous injection, once-weekly
223664976|NCT04185116|DEVICE|3D Optic System (Olympus VISERA Elite II 3D)|"Use of the 3D Optic System Olympus VISERA Elite II 3D"
223664977|NCT02379689|DRUG|Injectable placental tissue extract called BioDGenesis (Active Product)|
223664978|NCT02379689|DRUG|Placebo|
223664979|NCT03794830|OTHER|manipulation group (MG)|Patients were treated with sacroiliac joint osteopathic semidirect manipulation twice a week every 3 to 4 days over a period of time of 3 weeks
223664980|NCT03794830|OTHER|electrotheraphy group (EG)|Patients were treated with micro-waves (circular antenna in lumbar area, pulsating-mode 120W for 12 minutes) and later conventional analgesic TENS (80Hz frequency, 30 minutes) 5 days per week over a period of time of 3 weeks (15 sessions)
223664981|NCT00829192|DRUG|Afamelanotide (CUV1647)|16 mg subcutaneous implant administered every 60 days
223664982|NCT00829192|DRUG|Placebo|Placebo subcutaneous implant administered every 60 days
223664983|NCT03449641|DEVICE|Positive airway pressure (PAP)|Positive airway pressure (PAP) is a mode of respiratory ventilation used in the treatment of sleep apnea.
223664984|NCT00572767|DRUG|Dextro-Amphetamin|After a two week baseline phase the patients will receive a dose of 10mg Dexamphetamine on two days per week for five weeks. Within a time frame of one to three hours they should receive physiotherapy focusing on neurodevelopmental (NDT) for one hour.
223664985|NCT00572767|OTHER|Glucose|"After a two week baseline phase the patients will receive a dose of 10mg of a placebo (same appearance as the experimental drug) on two days per week for five weeks. Within a time frame of one to three hours they should receive physiotherapy focusing on neurodevelopmental (NDT) for one hour.~The treatment of the control group will be the same as for the experimental group except the content of the drug capsule."
223664986|NCT05552417|OTHER|Pectointercostal facial plan block|Pectointercostal facial group (PI) (n=--) where --children will have bilateral Pectointercostal Block.
223664987|NCT05926518|PROCEDURE|blood sampling|Blood sampling for the determination of anti-Xa peak levels 4 hours after administration of nadroparin sc.
224244742|NCT02208492|DRUG|Levetiracetam|Levetiracetam is a second-generation antiepileptic drug that has been approved for the treatment of epilepsy in both children and adults. This anticonvulsant works by binding to the synaptic vesicle protein 2A resulting in a possible effect on neurotransmitter release from presynaptic vesicles, while the exact mechanism of action is still unclear. In both adults and children, levetiracetam treatment in has a proven efficacy in both localization-related and generalized epilepsies. In contrast to first generation, levetiracetam reports less side effects of somnolence or lethargy, but behavioral adverse events, such as changed mood state, aggression, and irritability are noted, but only a few studies have reported such effects in a systemic fashion.
224244743|NCT02208492|DRUG|Carabamazepine|Carbamazepine, a first-generation antiepileptic medication, stabilizes the inactivated state of voltage-gated sodium channels, making fewer of these channels available to subsequently open, which leaves the affected cells less excitable and less seizure prone. It is approved for both focal seizures and generalized tonic-clonic or combined seizures for adults and children.
224244744|NCT01020734|BIOLOGICAL|anti-thymocyte globulin|
224244745|NCT01020734|DRUG|busulfan|
224244746|NCT01020734|DRUG|cyclophosphamide|
224244747|NCT01020734|DRUG|cyclosporine|
224244748|NCT01020734|DRUG|fludarabine phosphate|
224244749|NCT01020734|DRUG|methotrexate|
224244750|NCT01020734|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
224244751|NCT01661686|DEVICE|Partially covered SEMS|Boston Scientific, Natick, United States diameter 18 mm, lengths of 10, 12 and 15 cm available
224244752|NCT01661686|DEVICE|Fully covered SEMS|Boston Scientific, Natick, United States diameter 18 mm, lengths of 10, 12 and 15 cm available
224244753|NCT04753710|DRUG|Ocular gel|Instillation
224244754|NCT04349735|OTHER|Assessment of inhalation technique|Assessment of inhalation technique by 3 methods in every patient
224244755|NCT03110302|BEHAVIORAL|Prolonged exposure|PE is a manualized treatment developed by Dr. Edna Foa and her colleagues. In all three treatment modalities, 7-15 weekly, 90 minute individual sessions of PE will be provided. PE is based on emotional processing theory, which proposes that avoidance and negative thoughts about the self and the world maintain PTSD symptoms over time. According to emotional processing theory, effective treatment requires repeated activation of the trauma memory (as through memory and in vivo exposure) and incorporation of corrective information into the trauma fear structure. PE has several primary components: (1) psychoeducation about PTSD and avoidance; (2) imaginal exposure with processing, wherein the participant describes the traumatic memory aloud many times and discusses it with the therapist afterward; and (3) in-vivo exposure, wherein the participant engages in feared, but safe, activities that have been avoided since the traumatic event (e.g., crowded places, driving).
224244756|NCT05088252|DRUG|Desflurane|After induction, anesthesia will be maintained with 0.7-1.0 MAC desflurane and 0.05-0.3 μg/kg/min remifentanil.
223664988|NCT00618085|BEHAVIORAL|Motor imagery practice|During motor imagery practice a person imagines performing a skill or movement with all its sensory consequences without actually moving. In this study the therapists follow a motor imagery guideline designed for rehabilitation of skills and movement performance in subjects with neurological disease or damage. The guideline offers therapists structure and a strategy to deliver subject-specific imagery. The guideline is based on three major frameworks, namely; principles of motor learning, phased process of human movement and a training guide for sports coaches and performers from the National Coaching Foundation.
223664989|NCT00618085|OTHER|Standard physiotherapy and occupational therapy|Patients with neurological disease or damage will receive standard physiotherapy and occupational therapy.
223770401|NCT07086963|PROCEDURE|Repaired with standard TIP repair as described by Snodgrass|"Urethroplasty was performed over a 6-8 Fr Nelaton catheter (according to patient age and glans size) using 7/0 subcuticular continuous suture. Adequate meatus was left around the urethral catheter at the glans tip, followed by spongioplasty and a second-layer dartos fascia coverage.~Mucosal collar approximation and skin closure Glanular closure was then initiated with deep but superficial stitches using 7/0 or 6/0 polyglactin suture, and mucosal suture closure. Skin closure was achieved by preparing viable skin while avoiding midline skin closure by preparing a vascularized preputial skin flap to avoid skin coverage complications with subsequent UCF"
224244757|NCT05088252|DRUG|Propofol|After induction, anesthesia will be maintained with 4-6mg/kg/h propofol and 0.05- 0.3 μg/kg/min remifentanil.
224244758|NCT01675232|OTHER|Soak and smear|Corticosteroid ointment applied to wet skin once a day and dry skin once a day.
224244759|NCT01675232|OTHER|Dry Smear|Corticosteroid ointment applied to dry skin twice a day.
224244760|NCT03535207|RADIATION|high dose chemoradiotherapy|"Radiation therapy: 50 Gy at 2 Gy/Fx/d on weeks 1-5,followed by 36 Gy in 30 fractions of 1.2 Gy, twice per day,on weeks 6-8 to a total dose of 86 Gy.~concurrent chemotherapy: weekly carboplatin area under the curve (AUC) 1.5-2 and paclitaxel 45-50 mg/m2 over the duration (8 weeks) of radiation therapy.~Adjuvant chemotherapy after high dose chemoradiation is optional."
224244761|NCT01453556|PROCEDURE|Laparoscopic right colectomy|Laparoscopic right colectomy with mechanical ileo-colon anastomosis L-L
224244762|NCT03514771|DEVICE|Fraxel DUAL 1550/1927|
224244763|NCT03514771|DRUG|oral isotretinoin|oral isotretinoin
224244764|NCT03514771|DRUG|oral valacyclovir|Oral valacyclovir
224244765|NCT02857088|BEHAVIORAL|olfactory assessment|determination of olfactory sensitivity through olfactory threshold assessment (butanol) determination of hedonicity and intensity of 16 usual odors
224244766|NCT02857088|BEHAVIORAL|image visualization|20 images (from the IAPS-international affective picture systems) are presented to the subject. He has to determine the hedonicity of each picture.
224244767|NCT02857088|BEHAVIORAL|psychophysiological assessment|during the olfaction assessment and the image visualization, skin conductance reactivity (SCR) is recorded to assess unconscious emotional reactivity
224244768|NCT00672178|RADIATION|Stereotactic body radiation|Stereotactic body radiotherapy will be given in three cohorts of increasingly higher dose levels: Cohort 1: 6 Gy/fraction x 3 fractions (total=18 Gy) over 5 days; Cohort 2: 8 Gy/fraction x 3 fractions over 5 days; Cohort 3: 10 Gy/fraction x 3 fractions over 5 days.
224244769|NCT02419937|DRUG|Tocilizumab|162 mg subcutaneously once (vs. 0.9% normal saline placebo injection once in placebo arm)
224244770|NCT02419937|DRUG|Placebo|Saline injection
223664990|NCT00575484|DRUG|Hypertonic saline, then oral sodium chloride|2mL/kg hypertonic saline (4.4% NaCl if serum sodium \</=135, else 2.8% NaCl) infused over 30min BID and dosed simultaneously with IV bolus furosemide BID (latter dose per treating physician) until patient is switched to oral loop diuretic. After switch to oral diuretic, subject will receive oral 0.75gm sodium (NaCL) capsule dosed BID with loop diuretic (latter dose per treating physician) until 60d after discharge.
224244771|NCT00553280|DRUG|pregabalin|Dosage: 150-600 mg/day (75-300 mg bid), oral administration, Treatment duration: 52 weeks
224244772|NCT03874871|PROCEDURE|Function preserving gastrectomy|Function preserving gastrectomy include pylorus preserving gastrectomy, proximal gastrectomy, and partial gastrectomy.
224244773|NCT03874871|PROCEDURE|Standard gastrectomy|Standard gastrectomy include distal gastrectomy and total gastrectomy with standard lymphadenectomy according to the Japanese gastric cancer treatment guideline.
223664991|NCT00575484|DRUG|Normal saline, then oral placebo capsule|20mL normal saline infusion X 30min BID dosed simultaneously with IV bolus furosemide BID (latter dose per treating physician) PLUS 2gm sodium diet PLUS 1.5L fluid restriction. After switch to oral diuretic, begin oral placebo capsule BID, dosed with loop diuretic (dose per treating physician) PLUS 2gm sodium diet PLUS 1.5L fluid restriction.
223664992|NCT00301613|DRUG|Mycophenolate mofetil|MMF,1.0g/d
223664993|NCT02512835|OTHER|Community vital signs|We will present clinicians with information about their patients' communities
223664994|NCT05822765|DRUG|Epinephrine concentration of 1:1000000|Tumescence fluid contained Epinephrine concentration of 1:1000000 (one ampoule 1 mg per liter) lidocaine 500 mg and sodium bicarbonate 8.4% 10 ml per liter
223770402|NCT07086963|PROCEDURE|Repaired with TIP with GIP using preputial graft|"The urethral plate was deeply incised from the glans tip, extending downwards beyond the junction between the plate and the hypospadiac meatus Graft fixation The graft was then spread to cover the raw area and fixed to the edges of the urethral plate.~Urethroplasty was performed over a 6-8 Fr Nelaton catheter (according to patient age and glans size) using 7/0 subcuticular continuous suture. Adequate meatus was left around the urethral catheter at the glans tip, followed by spongioplasty and a second-layer dartos fascia coverage.~Mucosal collar approximation and skin closure Glanular closure was then initiated with deep but superficial stitches using 7/0 or 6/0 polyglactin suture, and mucosal suture closure. Skin closure was achieved by preparing viable skin while avoiding midline skin closure by preparing a vascularized preputial skin flap to avoid skin coverage complications with subsequent UCF"
224244774|NCT04843878|DIAGNOSTIC_TEST|COVID Detect|The study is determining the efficacy of a new rapid COVID testing method.
224244775|NCT05934071|DRUG|SGLT2 inhibitor|optimization of the medical therapy for heart failure with reduced ejection fraction with SGLT2 inhibitor, according to clinical guidelines
223664995|NCT05822765|DRUG|Epinephrine concentration of 1:500000|Tumescence fluid contained Epinephrine concentration of 1:500000 two ampoule 2 mg/liter with same lidocaine and bicarbonate dose. lidocaine 500 mg and sodium bicarbonate 8.4% 10 ml per liter
224244776|NCT05738382|DRUG|BG2109|oral administration once daily
224244777|NCT05738382|DRUG|Cetrorelix|0.25 mg, Subcutaneous injection once daily.
224244778|NCT05506462|DRUG|Ketamine Hydrochloride|Patients with a diagnosis of Major Depressive Disorder (MDD) will be enrolled to receive four 50-60 minute infusions of 60mg ketamine hydrochloride
224244779|NCT01544127|BEHAVIORAL|MI-SI+TAU|MI-SI focuses on exploring and resolving ambivalence about living. It consists of 1 or 2 in-person MI-SI sessions (50 mins.) on an inpatient unit, plus a telephone follow-up MI-SI session (30-50 mins)
224244780|NCT01544127|BEHAVIORAL|MI-SI-R+TAU|MI-SI-R focuses on resolving ambivalence about living. It consists of 1 or 2 in-person MI-SI sessions (50 mins.) on an inpatient unit, plus a telephone follow-up MI-SI session (30-50 mins)
224244781|NCT01544127|OTHER|TAU Alone|Inpatient treatment includes medication management, case management, meals and a bed, milieu therapy consisting of creative and social activities, and a safety plan. Some families of veterans also received education to create a supportive home environment. As part of Veterans Health Administration (VHA) suicide prevention policy, the care of suicidal patients is also overseen by a local Suicide Prevention Coordinator and case managers.
224244782|NCT04083846|DRUG|Reference drug|D744 Cap. 1 Cap., single oral administration under fed condition
224244783|NCT04083846|DRUG|Test drug 1|CKD-385 64 mg formulation I Tab. 1 Tab., single oral administration under fed condition
224244784|NCT04083846|DRUG|Test drug 2|CKD-385 64 mg formulation II Tab. 1 Tab., single oral administration under fed condition
224321653|NCT07134933|PROCEDURE|ESP (erector spinae plane)block|The ESP block was performed unilaterally in the direction of the surgery by the same anesthetist. Blocks were performed using an Esaote ultrasound device (Esaote My Lab 6 US machine, Florence, Italy), a multifrequency convex probe (1-8 MHz), and a 22-gauge, 50 mm facet needle (B. Braun Sonoplex, Melsungen, Germany). The block needle was placed at the level of the T4 spinal process using the in-plane approach, approximately 3 cm lateral to the T4 spinous process in the parasagittal plane. After visualizing the transverse process with the in-plane approach, the 50 mm facet needle (B. Braun Sonoplex, Melsungen, Germany) was inserted through the skin, and a test dose of 1 ml of 0.9% NaCl was injected between the fascia of the trapezius, rhomboid, and erector spinae muscles and the transverse vertebral process to confirm the location. A total of 20 ml of 0.5% bupivacaine was used as a local anesthetic.
224321654|NCT05314101|DRUG|Tislelizumab|Participants will receive Tislelizumab, 200mg, intravenously over 30 - 60 minutes, day 1 of every 3 weeks
223664996|NCT00271505|DRUG|Bevacizumab (Avastin)|15 mg/kg intravenously (IV) every 3 weeks
223664997|NCT00271505|DRUG|Carboplatin|AUC 6 IV every 3 weeks
223664998|NCT00271505|DRUG|Docetaxel|75 mg/m2 IV every 3 weeks
224244785|NCT06406491|DEVICE|active microprocessor-controlled knee|Active microprocessor-controlled knees are motorized prosthesis, actively supporting the users while walking, getting up, and climbing stairs.
224244786|NCT00206544|DRUG|Tamoxifen|40 mg daily of adjunctive tamoxifen in oral capsule
224244787|NCT00206544|DRUG|Progesterone|20 mg daily of adjunctive progesterone in oral capsule
224244788|NCT00206544|OTHER|placebo|adjunctive placebo daily in oral capsule
224244789|NCT06129227|BEHAVIORAL|Dual-task training|This group will receive 30 min of dual-task exercise training and 30 min of stretching exercises in each session. The dual-task component involves walking activities performed in conjunction with cognitive activities. For the stretching exercise component, no cognitive load will be added.
224244790|NCT06129227|BEHAVIORAL|Single-task training|This group will undergo 30 min of single-task mobility training and another 30 min of single-task cognitive activities. The cognitive and mobility exercises will be the same as those in the dual-task group, but they will be performed separately. No extra cognitive load will be imposed during the mobility exercises. No additional motor demand will be imposed during the cognitive exercises, as the participants will be sitting.
224244791|NCT06129227|BEHAVIORAL|Control group|This group will undergo 30 min of stretching exercises (same as the dual-task group) and another 30 min of upper limb strengthening exercises performed primarily in the sitting or lying position. No cognitive load will be added.
224244792|NCT04391062|DRUG|Gliolan|patient will receive 5-ALA 4 to 6 hours before surgery
224244793|NCT04391062|DEVICE|Intraoperative PDT|"The protocol requires the realization of specific procedures in addition to the usual care.~The intra-operative photodynamic therapy (intraoperative PDT) added to surgery for glioblastoma excision. The patient will receive 5-ALA ( 5-aminolevulinic acid hydrochloride),GLIOLAN drinkable 6h before surgery + lighting of the tumor bed by a red light source (laser with different J/cm²) at the end of resection (Prolonged surgery of 45 minutes)."
224244794|NCT01423526|DRUG|DWP10292|Drug: DWP10292 tablets, oral administration, single administration
224244795|NCT01423526|DRUG|Placebo|Placebo tablets, oral administration, single administrations
224244796|NCT04074174|DRUG|NNC0174-0833|NNC0174-0833 administered s.c. (subcutaneously, under the skin) once weekly for 12 weeks
224244797|NCT04074174|DRUG|Oral contraceptive (OC) tablets|1 tablet daily on days 1-8 and days 79-86
224244798|NCT04074174|DRUG|Acetaminophen|Single dose of acetaminophen as part of a standardised meal on day 1 and day 79
224244799|NCT02794974|OTHER|cervical plexus block|ultrasound-guided application of 20ml ropivacaine 0.75%
224244800|NCT02794974|OTHER|facial nerve block|ultrasound-guided application of 5ml prilocaine 1%
224244801|NCT02794974|OTHER|perivascular block|ultrasound-guided application of 5ml prilocaine 1%
224244802|NCT00533273|BIOLOGICAL|collagenase clostridium histolyticum|Subjects could have received up to three injections of AA4500 0.58 mg/placebo into the cord of the affected hand in the double-blind phase. In the open-label extension phase, subjects could have received up to five additional injections of AA4500, with each injection separated by at least 30 days. Individual joints could have received up to a maximum of three AA4500 injections.
224244803|NCT02870920|DRUG|Tremelimumab|
224321655|NCT05314101|DRUG|bevacizumab|Participants will receive bevacizumab，5mg/kg，intravenously over 60 - 90 minutes, day 1 and day 15 of every 4 weeks
223664999|NCT04812847|DIAGNOSTIC_TEST|Identification of MDR characteristics|Identification of MDR in culture media, followed by amplification of related genes from the bacterial isolates
223665000|NCT05391789|DRUG|Ulinastatin|Patients would be given 400000 or 800000units of ulinastatin (specification: 100000 units / vial) dissolved in 50 ml of 0.9% normal saline intravenously for at least 1 hour, once every 8 hours. It is evaluated by the attending doctor every day. When the patient does not have systemic inflammatory response syndrome (SIRS), halve the dose and continue to use it for 2 days, with a total course of treatment of at least 3 days
223665001|NCT05391789|DRUG|Placebo|Patients would be given 50 ml of 0.9% normal saline intravenously for at least 1 hour once every 8 hours.It is evaluated by the attending doctor every day. When the patient does not have systemic inflammatory response syndrome (SIRS), continue to use it for 2 days, with a total course of treatment of at least 3 days.
223665002|NCT00012597|PROCEDURE|Web-based telemedicine system for assessment of status of pressure ulcers|
223665003|NCT01572987|DEVICE|Radiofrequency Ablation(RFA) by HALO device.|RFA or Surveillance every 2 months for 1 year.
224244804|NCT02870920|DRUG|Durvalumab|
224244805|NCT02870920|OTHER|Best Supportive Care|
224244806|NCT06075173|DIAGNOSTIC_TEST|Resting full-cycle ration (RFR) measurments|RFR and FFR measurements in main vessel and side branch lesions
224244807|NCT00428857|PROCEDURE|non invasive ventilation|non invasive ventilation
224244808|NCT03619746|BEHAVIORAL|POCUS Educational Intervention|Midway through the study, all Pediatric Emergency Attendings and Fellows at Jacobi Medical Center will receive an educational session that describes how to properly perform a soft tissue examination using point-of-care ultrasound to differentiate between cellulitis and local allergic reaction.
224244809|NCT04969757|DEVICE|Predigraft group|"Patients in the interventional arm will use Predigraft (Class 1 medical device under MDD 93/42/EEC Cibiltech Society) to receive therapeutic education content (videos, facts sheets, short messages, questionnaires), exchange documents with their doctors and interact via messaging with them.~Physicians will be able to calculate their iBox score to predict their patients' allograft survival at 3, 5 and 7 years."
224244810|NCT01303848|OTHER|Blood Sampling|Blood Sampling over 24 hours
224244811|NCT04507425|OTHER|Standard of Care - Nasal Cannula|Standard of care. Flexible tube to provide extra oxygen when patients need a little help, but are not in respiratory distress.
224244812|NCT04507425|OTHER|High-flow nasal cannula|Same as nasal cannula, except the oxygen is heated or humidified and the flow is stronger, pushing air into the lungs to help keep the airway open.
223665004|NCT01572987|DEVICE|Endoscopic mucosal resection(EMR) by mucosectomy kit.|EMR or surveillance every 2 months.
224244813|NCT04507425|OTHER|HFNC plus non-invasive ventilation|This method uses HFNC as described above and adds noninvasive ventilation which is similar to CPAP machine and uses a mask rather than having to intubate (putting a tube down your throat to keep your airway from collapsing).
224244814|NCT03411330|DRUG|Hyaluronidase|Scalp nerves block will be done using lidocaine (2%) in a maximum dose of 300 mg and bupivacaine (0.5%) with maximum allowed dose 175 mg in group A, Hyaluronidase will be added in group H in a dose of 1500 IU (The minimum and maximum effective doses of hyaluronidase are not known. The doses used range from0.75 IU/ml to 300 IU/ml
224244815|NCT03411330|DRUG|Lidocaine|lidocaine (2%) in a maximum dose of 300 mg and bupivacaine (0.5%)
224244816|NCT03411330|DRUG|Bupivacaine|bupivacaine (0.5%)
224244817|NCT01799330|PROCEDURE|Transcutaneous Electrical Muscle Stimulation (TCEMS)|
224244818|NCT01799330|OTHER|Sham TCEMS|Patients randomized to Group 2 (Sham TCEMS) will receive the identical set-up for active TCEMS except they will receive a minimal electrical stimulus that does not produce a motor response
224321656|NCT05314101|DRUG|TAS-102|Participants will receive TAS-102, 35mg/m2, bid，d1-d5, d8-d12 of every 4 weeks
224321657|NCT02117739|DRUG|dapsone gel|Patches containing dapsone gel will be applied to the skin.
224244819|NCT05194722|BEHAVIORAL|Wysa mobile app|"Wysa is a digital mental health intervention (i.e., mobile app) that uses an artificial intelligence based chatbot and text-based conversation with master's level human coach counselors to deliver cognitive behavioral therapy, mindfulness training, and sleep tools. In this study, a customized version of Wysa will be used which is specifically designed for users with coexisting chronic pain. The customized experience includes additional features based on behavioral activation. This version is not currently commercially available."
224244820|NCT05477030|DEVICE|Medtronic MiniMed 780G with SmartGuard activation|Insulin pump implemented with alghoritm for automatic modulation of insulin delivery (to increase time in glucose range 70-180 mg/dl)
224244821|NCT05477030|DEVICE|Medtronic MiniMed 780G without SmartGuard activation|Insulin pump implemented with alghoritm for low glucose insulin suspension (to reduce hypoglycemia rate)
224244822|NCT02164448|DRUG|the dexmedetomidine group|the dexmedetomidine group: dexmedetomidine infusion from induction of anesthesia to end of surgery
224244823|NCT02164448|DRUG|the control group|saline infusion from induction of anesthesia to end of surgery
224244824|NCT03983564|OTHER|Cutoff Validation|We will validate the cutoff of the combination of BOSTON score and DES-OSA scores with the result of a polysomnography.
224244825|NCT04414072|PROCEDURE|sleeve gastrectomy with loop bipartition|operations to decrease weight
224244826|NCT02202850|DRUG|etanercept|etanercept 1 x 50 mg/week or 2 x 25mg/week
224244827|NCT02202850|DRUG|etanercept|etanercept 1 x 50 mg/week or 2 x 25mg/week
223665005|NCT01307644|BEHAVIORAL|Experimental: Web-based only (WO) weight intervention|The WO intervention included evidence-based lifestyle modification for healthy eating and activity, with self-monitoring and goal setting, and messages based on constructs from the Health Promotion Model across 3 phases. The intent of the phases was to deliver more intensive intervention during Phase 1, transitioning to less intensive intervention during phase 2, to providing support for self managed weight maintenance during Phase 3.
223665006|NCT01307644|BEHAVIORAL|Experimental: WO plus peer-led discussion board (WD)|Includes WO intervention plus asynchronous discussion board managed by peer leader, whose identity is masked. The peer leader who posted theme-based messages, called primers, that were consistent with WO themes across phases.
223665007|NCT01307644|BEHAVIORAL|Experimental: WO & professional email counseling (WE)|Includes WO intervention plus professional email counseling provided by a registered dietitian whose identity is masked. The email counselor is responsible for reviewing eating, activity, weight logs, and goals on the web-site and send e-mail feedback, in addition to responding to email questions. The e-mail process will follow the 5A's Model for Behavioral Counseling (assess, advise, agree, assist, and arrange) that was adapted for this study.
223665008|NCT02600780|DRUG|Febuxostat|Comparison of two anti-hyperuricemic molecules
223665009|NCT02600780|DRUG|Allopurinol|Comparison of two anti-hyperuricemic molecules
223665010|NCT04491071|DIAGNOSTIC_TEST|Generalized Anxiety Disorder-7 (GAD 7)|test that will evaluate persistent and excessive worry about a number of different things. People with Generalized Anxiety Disorder may anticipate disaster and may be overly concerned about money, health, family, work, or other issues. Individuals with Generalized Anxiety Disorder find it difficult to control their worry.
223665011|NCT04491071|DIAGNOSTIC_TEST|Background questionnaire|questionnaire on the living conditions, socio-professional contexts and environmental conditions of the participants
224244828|NCT00533663|PROCEDURE|Healing Touch|every other week (during their infusion)
224244829|NCT00533663|OTHER|Standard care|Adriamycin, cyclophosphamide, and paclitaxel administered as standard of care
223665012|NCT04491071|DIAGNOSTIC_TEST|Impact of COVID-19 questionnaire|status of the patient with regard to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 virus)
223665013|NCT04491071|DIAGNOSTIC_TEST|Confinement and Communication During the COVID-19 Pandemic|know the experience of containment and isolation during the pandemic
223665014|NCT04491071|DIAGNOSTIC_TEST|Mental Health questionnaire|welfare effect
224244830|NCT00533663|PROCEDURE|guided relaxation|
224244831|NCT01873586|PROCEDURE|Posterolateral Fusion|
224244832|NCT05440903|BEHAVIORAL|Headspace|A smartphone application that provides users with mindfulness and meditation sessions.
224321658|NCT02117739|DRUG|dapsone gel vehicle|Patches containing dapsone gel vehicle will be applied to the skin.
224244833|NCT05440903|BEHAVIORAL|TEDTalk|A smartphone application that provides users with psychoeducational audio recordings from TEDTalk.
224244834|NCT02883335|OTHER|Observational registry|
224244835|NCT05205759|DRUG|Bamlanivimab Etesevimab|Single intravenous infusion of bamlanivimab 700 mg and etesevimab 1400 mg, administered together \[1 bamlanivimab vial (700 mg/20 mL) and 2 etesevimab vials (700 mg/20 mL)\] in a 250-mL prefilled 0.9% Sodium Chloride infusion bag over one hour.
223665015|NCT04491071|DIAGNOSTIC_TEST|Patient Health Questionnaire (PHQ-9)|assess depression during the pandemic
223665016|NCT04491071|DIAGNOSTIC_TEST|Post Traumatic Stress Disorder questionnaire (PTSD-8)|Assessing the trauma of subjects during the pandemic
223665017|NCT04491071|DIAGNOSTIC_TEST|Experiences in Close Relationship Scale questionnaire (ECR-S)|Measuring social ties and attachment of subjects
223665018|NCT00161538|DEVICE|Pacing leads to be implanted according randomization.|
224244836|NCT05205759|DRUG|Sotrovimab|Single intravenous infusion of sotrovimab 500 mg (500 mg/8 mL), administered in 100 mL prefilled 0.9% sodium chloride injection infusion solution over 1/2 hour.
224244837|NCT05205759|DRUG|Casirivimab-Imdevimab|Single intravenous infusion of casirivimab 600 mg + imdevimab 600 mg, administered together in 250 mL prefilled 0.9% sodium chloride injection infusion solution over one hour. Casirivimab and imdevimab are each supplied in individual single use vials. Casirivimab is available as 300 mg/2.5 mL (120 mg/mL) or 1332 mg/11.1 mL (120 mg/mL). Imdevimab is available as 300 mg/2.5 mL (120 mg/mL) or 1332 mg/11.1 mL (120 mg/mL).
224244838|NCT00363506|BEHAVIORAL|Serotona Plus and dietary behavior management|
224321659|NCT07185984|DIAGNOSTIC_TEST|Sperm sellection|Small aliquots of 100 fresh human semen samples will be analysed using the SwimCount™ Harvester system, a CE-marked microfluidic technology patented by MCount and designed for routine clinical use.
223665019|NCT00161538|DEVICE|Selection 9000 prevent AF an Diagnose AF|
223665020|NCT00527241|BEHAVIORAL|Raices nuevas|8 90-minute sessions (once a week) of problem-posing and facilitated discussion on respect, anger, support, trust, negotiating, partnership with your intimate partner.
223665021|NCT04194385|PROCEDURE|Upper trunk block|Block will be applied to supraclavicular zone by 20 ml % 0.25 bupivacaine with 5 mcg/ml epinephrine .
223665022|NCT04194385|PROCEDURE|Costoclavicular block|Block will be applied to infraclavicular zone by 20 ml % 0.25 bupivacaine with 5 mcg/ml epinephrine.
223665023|NCT04194385|PROCEDURE|Diaphragmatic function assessment|Diaphragmatic excursion will be assessed under ultrasound immediately before and after regional anesthesia.
223665024|NCT04194385|PROCEDURE|Cervical plexus blockade|Block will be applied at thyroid cartilage level via 10 ml % 0.25 bupivacaine.
223665025|NCT00574236|DRUG|PS-341, doxorubicin|bortezomib:1.3 mg/m2 IVP over 3-5 sec. days 1, 4, 8, 11 of 21 day cycle doxorubicin: 20 mg/m2 IV over 3-5 min. days 1,8 (one hour after bortezomib) of 21 day cycle
223665026|NCT05676268|PROCEDURE|Implant-supported fixed dental prostheses with cantilever extension|Healthy patients in need of replacement of missing teeth with dental implants supporting partial fixed dental prostheses with cantilever extensions
223665027|NCT03537300|BEHAVIORAL|DCF muscles training using pressure biofeedback in addition to conventional exercises|DCF muscles training using pressure biofeedback in addition to conventional exercises
223665028|NCT03537300|BEHAVIORAL|conventional exercises|conventional exercises
223665029|NCT03063047|OTHER|PD21871AA|A 100s size menthol cigarette.
223665030|NCT03063047|OTHER|PD21872AA|A 100s size menthol cigarette.
223665031|NCT04075253|BEHAVIORAL|VO2 peak testing|Exercise on treadmill starts with \~4km/h at 0% inclination before inclination is increased to 4% and speed kept unchanged. Inclination will then be increased with two percent approximately after each minute until exhaustion.
223665032|NCT00054340|BIOLOGICAL|anti-thymocyte globulin|
223665033|NCT00054340|DRUG|busulfan|
224244839|NCT02433106|OTHER|GAA 15|Neuromuscular injury prevention training
224244840|NCT02433106|OTHER|Control|Usual training
224244841|NCT00454909|BIOLOGICAL|Meningococcal vaccine 134612|Single dose intramuscular injection.
224244842|NCT00454909|BIOLOGICAL|Menactra®|Single dose intramuscular injection.
224244843|NCT04819633|OTHER|Determination of serum sestrin levels|Serum sestrin levels will be determined using venous blood samples obtained from the subjects.
224244844|NCT00531856|DRUG|Inhaled carbon monoxide|0.7 mg/kg carbon monoxide/placebo over one hour administered 12-48 hours post transplant
223665034|NCT00054340|DRUG|cyclophosphamide|
223665035|NCT00054340|DRUG|cyclosporine|
223665036|NCT00054340|DRUG|methotrexate|
223665037|NCT00054340|PROCEDURE|allogeneic bone marrow transplantation|
223665038|NCT00054340|PROCEDURE|peripheral blood stem cell transplantation|
223665039|NCT05249517|OTHER|Pain Neuroscience Education|Pain Neuroscience Education (PNE) is a patient education approach that explains in detail the neurobiology, neurophysiology of pain, and the processing of pain by the nervous system in the management of chronic pain.
223665040|NCT05249517|OTHER|Progressive submaximal exercise program|It has been shown that the long-term results of the use of PNE in addition to physiotherapy are more effective in reducing pain and disability. It has been reported that progressive submaximal exercise program including cervicothoracic strengthening, endurance, flexibility, and coordination exercises has positive effects on chronic neck pain, related disability, quality of life and mood.
223665041|NCT02369744|DRUG|Silodosin|8mg tablet, 1 tab PO daily for 2 weeks
223665042|NCT02369744|DRUG|Tamsulosin|0.4 mg Tab, 1 tab PO daily for 2 weeks
223665043|NCT00924859|OTHER|ELISA Test|assess the overall accuracy of D-dimer values and FXIII activation peptide (FXIII-AP), using a newly developed ELISA test
223665044|NCT00003497|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|Antineoplaston therapy (Atengenal + Astugenal) capsules orally six to seven times a day. Treatment continues in the absence of disease progression or unacceptable toxicity. absence of disease progression or unacceptable toxicity.
223665045|NCT03361683|DEVICE|High-flow nasal oxygen|Randomized patients will receive oxygen through a high nasal flow device capable of delivering humidified, heated air at an output rate of 40 L/min
223665046|NCT03361683|DEVICE|Venturi mask|Randomized patients will receive oxygen through a Venturi mask at an air flow of 15 L/min
223665047|NCT02467426|DRUG|Chemotherapy|intraarterial infusion of cisplatin and mithoxantrone
223665048|NCT00814060|DRUG|neratinib|HKI-272
223665049|NCT01809639|DRUG|Progesterone|
223665050|NCT01809639|DRUG|Placebo|Standard placebo
223665051|NCT02940314|DRUG|HIP1503|
223665052|NCT02940314|DRUG|HGP1103|
223665053|NCT00967954|DRUG|antiandrogen therapy|
223665054|NCT00967954|DRUG|releasing hormone agonist therapy|
223665055|NCT00967954|GENETIC|DNA analysis|
223665056|NCT00967954|GENETIC|RNA analysis|
223665057|NCT00967954|GENETIC|comparative genomic hybridization|
223665058|NCT00967954|GENETIC|gene expression analysis|
223665059|NCT00967954|OTHER|laboratory biomarker analysis|
223665060|NCT00967954|PROCEDURE|diffusion-weighted magnetic resonance imaging|
223665061|NCT00967954|PROCEDURE|magnetic resonance spectroscopic imaging|
224244845|NCT00531856|DRUG|Inhaled carbon monoxide|2.0 mg/kg carbon monoxide/placebo over one hour administered 12-48 hours post transplant
224244846|NCT00531856|DRUG|Inhaled carbon monoxide|3.0 mg/kg carbon monoxide/placebo over one hour administered 12-48 hours during transplant
224244847|NCT00531856|DRUG|Inhaled Carbon Monoxide|3.5 mg/kg carbon monoxide/placebo over one hour administered 12-48 hours during transplant
224244848|NCT00531856|DRUG|Inhaled Carbon Monoxide|2.0 mg/kg carbon monoxide/placebo over one hour administered 12-48 hours during transplant.
224244849|NCT05293847|BEHAVIORAL|Telerehabilitation exercises and postural skills|12 week based postural exercises and skills were applied to participants. The exercises were done 3 times a week. The exercises about cervical and thoracal region strengthening and stretching of muscles and structures.
224244850|NCT01743547|OTHER|Yoga|Patients will be randomized to Yoga or control group. Those in Yoga intervention will receive 8 weekly yoga sessions.
223665062|NCT05014633|OTHER|EI skills training|EI training sessions were held and managed by two experienced instructors selected from medical education specialists with sufficient experience in conducting EI training. Both instructors attended the sessions, presented the content, videos, slides, and brochures with the help of each other, and managed related scenarios in each session.
223770403|NCT07086300|OTHER|Electroacupuncture (EA)|"In the electroacupuncture group, bilateral Zusanli (ST36) and Sanyinjiao (SP6) points were selected for needling. Upon achieving the deqi sensation, the electroacupuncture device was connected to the needles at both points. A dispersed-dense wave was applied with an intensity ranging from 0.5 to 2 mA, adjusted according to the patient's tolerance. The needles were retained for 20 minutes, after which they were removed."
223770404|NCT07086300|OTHER|Sham electroacupuncture|"In the sham electroacupuncture group, bilateral Zusanli (ST36) and Sanyinjiao (SP6) points were selected for sham electroacupuncture intervention, which did not receive manual manipulation. The electrode placement and other treatment settings were identical to those in the electroacupuncture group, but no skin penetration, electrical output, or needle techniques were applied to induce the sensation of deqi. No genuine electroacupuncture stimulation was administered in this group."
223770405|NCT07085013|BEHAVIORAL|Individually Trained Oral Prophylaxis (iTOP)|The iTOP intervention consists of a single, structured, 45-minute, small-group oral hygiene training session conducted by certified dental professional. The session includes personalized instruction on proper toothbrushing techniques (e.g., Bass technique), use of interdental brushes and floss, and patient motivation. At the 3-month follow-up, participants also received a short reinforcement session. Standardized oral hygiene kits (toothbrush, interdental brushes) were provided at each time point.
223770406|NCT07084909|DRUG|piflufolastat F 18|18F-DCFPyL is a fluorine-18 radiolabeled low molecular weight positron emission tomography (PET) tracer that binds to the extracellular domain of prostate-specific membrane antigen (PSMA) with high affinity.
223770407|NCT07087288|OTHER|AI-supported case|In the artificial intelligence supported case analysis course, students will listen to the audio video prepared by artificial intelligence.
223770408|NCT07087288|OTHER|Case Analysis|The case analysis will be made through the presentation prepared by the students in the group.
223770409|NCT06787430|DRUG|nicorandil|In the nicorandil group, intracoronary nicorandil 3mg dissolved in 3ml saline was given within 30 seconds at two time points, one was when the guidewire or ballon passed the lesion and the blood flow was regained, and another was the time before the stent was implanted.
223770410|NCT06787430|DRUG|Saline (NaCl 0,9 %) (placebo)|In the control group, 3ml saline was given intracoronary through the guiding catheter within 30 seconds at the same time points in nicorandil group.
223770411|NCT07086118|OTHER|0.9% normal saline|patients in group P will receive 0.9% normal saline
223770412|NCT07086118|DRUG|Metoclopramide 10mg|patients in group M will receive 10 mg metoclopramide
223770413|NCT07086118|DRUG|Dexamethasone|patients in group D will receive 8 mg dexamethasone
224244851|NCT01500876|RADIATION|4D-CT pre-treatment scan|Undergo pre-treatment 4D-CT study for treatment planning External Beam Radiation: standard fractionation (2Gy per day) or stereotactic body radiation therapy Evaluation: Repeat 4D-CT study at 3 months and 6 months post-treatment
224244852|NCT05553197|BEHAVIORAL|Cognitive Behavioural Therapy (CBT)|20 sessions of face-to-face, individual CBT
224244853|NCT05553197|OTHER|Ecological Momentary Assessment (EMA)|Two four-week blocks of twice daily ecological momentary assessment (EMA) of symptoms and inter-session processes
223665063|NCT02500940|DRUG|Cisplatin|Neoadjuvant chemotherapy regimen with cisplatin
223665064|NCT02500940|DRUG|Fluorouracil|Neoadjuvant chemotherapy regimen with Fluorouracil
223665065|NCT02500940|RADIATION|Radiation therapy|Intensity-Modulated Radiation Therapy
223665066|NCT02500940|DRUG|Leucovorin|Neoadjuvant chemotherapy regimen with Leucovorin
223665067|NCT00379301|PROCEDURE|Radiofrequency ablation|Special catheters are inserted into blood vessels in the groin, then advanced into the left atrium of the heart. Radiofrequency (heat) energy is applied to small areas of heart tissue where electrical impulses that generate AF are found.
223665068|NCT05388292|OTHER|Emergency triage decision support system|Evaluating the impact of the developed Emergency Triage Decision Support System on triage management
223770414|NCT07087119|BEHAVIORAL|utilization of artificial intelligence powered mental health support session through a web browser|utilization of artificial intelligence powered mental health support session with the software XAIA through a web browser for physicians in training to address symptoms related to depression and anxiety.
223770415|NCT07086404|DRUG|GC012F Injection infusion|GC012F Injection infusion will be performed within 48-72 hours after the end of lymphodepleting preconditioning.
223770416|NCT06050486|BEHAVIORAL|Mentalization-based treatment for children (MBT-C)|MBT-C is a time-limited intervention designed to resolve the child's emotional or behavioral problems and to promote resilience, by promoting the child's and parent's mentalizing capacities. It is composed by 1) an assessment phase, composed of 3 to 4 sessions, with the family, the child and the parent(s), 2) an intervention phase, composed of a minimum block of 12 individual sessions with the child and parallel sessions for the parent(s), that can be repeated up to three times (i.e., maximum of 36 sessions), and 3) a booster session 3 to 12 months after the last session. In this clinical trial, MBT-C will be composed of: 3 assessment sessions; 12 individual sessions with the child, plus 6 parallel individual sessions with the parent with BPD; 1 booster family session, 3 months after the last session.
224244854|NCT02996682|DRUG|SOF/VEL|400/100 mg FDC tablet administered orally once daily
224244855|NCT02996682|DRUG|RBV|Capsules administered orally in a divided daily dose
224244856|NCT02457520|DRUG|Isotretinoin|ABSORICA® (isotretinoin) capsules 0.5 mg/kg/day for 4 weeks followed by 1.0 mg/kg/day for 16 weeks
224244857|NCT03991260|DIAGNOSTIC_TEST|SPECT|One single injection of 99mTc- ADAPT6, followed by gamma camera imaging directly post-injection and after 2, 4 and 6 hours.
223665069|NCT03288142|OTHER|Hypertension Coaching Application and Home Monitor|The intervention group will have the HPCP installed on their iOS device during their initial office visit (screening/baseline) and will successfully take a reading from their HBMD
224244858|NCT04334174|DRUG|Brentuximab Vedotin|Brentuximab Vedotin will be dosed at 1.8 milligram (mg) per (/) kilogram (Kg) of participants body weight will be infused intravenously every three weeks for up to ten infusions.
224244859|NCT05165680|COMBINATION_PRODUCT|combination of aerobic exercise and healthy diet|"The 30 patients in this group will receive iron supplements, a personalized low caloric diet therapy based on Harris-Benedict equation. A restricted balanced diet will be prescribed which will be included. Perform aerobic exercise in the form of walking on electrical treadmill three times/ week day after day for 12 weeks according to following parameters.~* Type: moderate treadmill aerobic exercise~* Time: 40 minutes (5 minutes warm up phase, 30 minutes target heart rate (THR) phase, 5 minutes cooling down phase)~* Intensity: THR will be at 75% of maximum heart rate (which will be determined by submaximal graded exercise test and predicated MHR=220-age)~* Frequency: three times per week for 12 weeks"
224244860|NCT03064880|OTHER|SV maximization|Voluven solution 250 mL infusion per 5 minutes up to the platau of Flank-starling law: status to SV change \< 10% and maintained for 20 minutes
224244861|NCT01087476|DRUG|Doxycycline hyclate|Sub-microbial dose of Doxycycline hyclate or placebo (50 mg per day), immediately before the initiation of induction chemotherapy and daily during the following 21 days after chemotherapy.
224244862|NCT05070676|DIAGNOSTIC_TEST|newly developed mobile application|"The application will be developed in native Android, using Java (backend) and XML (front-end) as the programming language. The program of choice will be Android Studio®, YouTube® (video reproduction) and Firebase® (database) will be used as external APIs (Application Programming Interfaces).~The layout of the application will be developed using:~Adobe Illustrator® software. The logo, brand, objects, and shapes of the mobile application will be designed to enable to resize of the images without any loss of quality, due to the wide range of scales available in current smartphones"
224244863|NCT00257673|DRUG|MEM 1003|30 mg twice a day
224321660|NCT07185984|DIAGNOSTIC_TEST|DIAGNOSIS TOOL|"The diagnostic tool developed will be validated by analyzing small aliquots of 100 additional fresh semen samples processed with the integrated microfluidic system (SwimCount™ Harvester) and the CASA system with artificial intelligence. To evaluate the diagnostic efficiency of the tool, the results obtained from the semen quality analysis will be compared with those obtained from the analysis of these samples when processed using the reference technique, based on conventional methods employed by fertility specialists. Finally, to determine the effectiveness of the developed tool, the clinical results obtained from assisted reproduction treatment will be compared with the diagnosis predicted by the tool, with the aim of evaluating its predictive capacity.~Translated with DeepL.com (free version)"
224321661|NCT05921253|DEVICE|PARASYM neuromodulation device|Patients with breast cancer or lymphoma who have undergone chemotherapy for their disease, will have tests to determine heart function. Patients will be asked to use a handheld electrical unit (stimulator) at home to deliver vagus nerve stimulation (low level stimulation) to a preset position of one ear for a period of 1 hour for 14 days. After approximately 14 days, patients will have the same tests that they had at the beginning of the study.
223665070|NCT03288142|OTHER|Control: Tracking Application and Home Monitor|Control group participants will be provided with a home blood pressure monitoring device (HBMD) (Omron BP761N Bluetooth Smart Automatic Upper Arm Blood Pressure Monitor) and will be instructed in its use at the baseline study visit. Participants will also receive an information sheet describing home blood pressure monitoring that gives advice for how to respond to different home readings. At the baseline visit, participants will be instructed to install an Omron application to their smart phone device (to monitor use of the HBMD). Participants will continue to receive all routine care, including anti-hypertensive medications as prescribed by their regular clinicians.
223665071|NCT04580992|DRUG|Ajmaline|Ajmaline administration
223665072|NCT04332458|BEHAVIORAL|A focus group interview|this is a qualitative study using focus group interviewing.
223665073|NCT03903315|OTHER|Comparison between patients with Patients with central malignant airway obstructions undergoing medical treatment alone versus medical and endoscopic treatment|Comparison between patients with Patients with central malignant airway obstructions undergoing medical treatment alone versus medical and endoscopic treatment with reference to mortality and complications.
223665074|NCT03147157|OTHER|tacrolimus regimen guided by HLA matching rate|required low,middle and high tacrolimus concentration in high,middle and low MR group respectively
223665075|NCT01316068|DRUG|intravenous use of sulodexide followed by oral use|Patients will be given sulodexide 1200 LSU per day intravenously for 2 weeks,then receive 1000 LSU per day orally for 50 weeks.
223665076|NCT01316068|DRUG|use of sulodexide orally only|Patients receive 1000 LSU per day orally for 52 weeks
224321662|NCT05921253|DEVICE|PARASYM neuromodulation device|"Patients with breast cancer or lymphoma who have undergone chemotherapy for their disease, will have tests to determine heart function. Patients will be asked to use a handheld electrical unit (stimulator) at home to deliver vagus nerve stimulation (low level stimulation) to a different position of one ear compared to the experimental arm for a period of 1 hour for 14 days. After approximately 14 days, patients will have the same tests that they had at the beginning of the study."
224321663|NCT06071702|DEVICE|IoNIR Ridaforolimus-Eluting Coronary Stent System|The IoNIR Ridaforolimus-Eluting Coronary Stent System is a sterile single-use device/drug combination product, comprised of a cobalt chromium (CoCr) alloybased stent coated with a bioresorbable polymer mesh which is embedded with drug, mounted on a Rapid Exchange (RX) delivery system.
223665077|NCT01250444|OTHER|Inspiratory Muscle Training|Breathing exercises associated to the use of a training device with predetermined pressure load, daily, 30 minutes per day, during eight weeks.
223665078|NCT02102659|GENETIC|Upper Limit Nutrition Support Therapy|"Upper limit nutrition support therapy will be used in patens assigned to this group based on the patient's curve of apoptosis of oral mucosal epithelium"
223665079|NCT02102659|GENETIC|Formula Nutrition Support Therapy|"Formula nutrition support therapy will be used in patens assigned in this group based on Harris Bendiest Formula."
223665080|NCT05772585|OTHER|Blood collection|Blood collection (1 to 4 times for each patient) in order to perform metabolomic analyses of the plasmatic fingerprints of patients with hepatic encephalopathy
223665081|NCT00963118|DIETARY_SUPPLEMENT|plant based nutrition bar|Nutrition bars made from Angelica keiskei (5g), glycine max (5g), Angelica keiskei (2.5g) + Glycine max (2.5g) or rice powder (12g) will be supplemented twice/day for 4 wks.
223770417|NCT03175640|BEHAVIORAL|Implementation intervention|The implementation intervention includes peer-to-peer training, post-training outreach, proactive expert support, and assistance with addressing environmental barriers.
224244864|NCT00257673|DRUG|MEM 1003|90 mg MEM 1003 twice a day
224244865|NCT00257673|DRUG|Placebo for MEM 1003|Placebo twice a day
224244866|NCT05606562|PROCEDURE|Dental care|Participants will be offered free dental care
224244867|NCT01559220|DEVICE|Deep Brain Stimulation|Implanted device
224244868|NCT03923465|PROCEDURE|Procedure: Periodontal surgery with entire papilla preservation (EPP) technique|After local anesthesia injection an modified flap is designed according to minimally invasive microsurgical techniques. After flap elevation, careful removal of granulation tissues from the periodontal defects is performed. Scaling and root planing of the involved dental roots is ensured and finally suture is placed.
224244869|NCT03923465|DEVICE|EMD application|Application of Pref-Gel for 2 minutes and then the application of Enamel Matrix Derivatives (EMD) on the surgically exposed root surface.
224244870|NCT03923465|DEVICE|Bone substitutes application|Following the application of EMD, filling the bone defect with bone substitutes.
224244871|NCT03429920|DIETARY_SUPPLEMENT|Q CAN PLUS|Active powder with fermented soy , 2 pouches per day, each pouch contains 12-15 gms of fermented soy
224244872|NCT03429920|DIETARY_SUPPLEMENT|Placebo|Sprouted brown rice protein with flavor (provided by BESO Biological Research, Inc.)
224244873|NCT02006173|DRUG|Lidocaine|Xylocaine is a 2 % lidocaine hydrochloride contained liquid anesthesia
224244874|NCT02006173|DRUG|Normal Saline|
224244875|NCT02107092|DRUG|Sodium Zirconium Cyclosilicate|Oral 10g once daily with breakfast for 11 months.
224244876|NCT00282048|DRUG|AG-013736 (axitinib)|AG-013736 5 mg twice daily \[bid\] continuous dosing in 28 day cycles.
224244877|NCT02703948|DEVICE|Restylane Silk with Lidocaine|
224244878|NCT00190814|DRUG|duloxetine|
224244879|NCT00190814|DRUG|placebo|
224244880|NCT05320679|OTHER|Implementation of Questionnaire|Compartment of results of questionnaires which already been used in literature and results of developing Pain Related Avoidance of Movement Questionnaire
224244881|NCT01002638|OTHER|TEGADERM®|It consists of the occlusive application of two Tegaderm®, a plastic dressing
224244882|NCT01002638|PROCEDURE|Surgery|It consists of pulp reconstruction by a flap (for example palmar V-Y advancement flaps of Atazoy).
224244883|NCT01423006|PROCEDURE|Radio-Frequency Ablation (RFA) ENCAGE™|RFA is a minimally invasive procedure. It is an image-guided technique that heats and destroys cancer cells. In RFA, imaging techniques such as ultrasound or magnetic resonance imaging (MRI) are used to help guide a needle electrode into a cancerous tumor. High-frequency electrical currents are then passed through the electrode, destroying the cancer cells.
224244884|NCT02149888|DRUG|Tenofovir/emtricitabine|Once daily Tenofovir/emtricitabine (Truvada®)
224244885|NCT00398515|DRUG|lenalidomide|Given orally
223665082|NCT00611754|DRUG|Oxaliplatin, 5-FU|Oxaliplatin: 130 mg/m² in 500 mL of 5% glucose solution as a 2-hour intravenous (IV) infusion on Day 1 and repeated every 3 weeks; 5-FU: following oxaliplatin administration, 1000 mg/m²/day as a continuous IV infusion from Day 1 toDay 4, every 3 weeks.Dose adjustments were made if the patient experienced AEs.
223665083|NCT03101553|BEHAVIORAL|Interpretation Bias Modification|Eight 10-25 minute sessions of interpretation modification to reduce negative interpretation biases related to negative evaluation.
223665084|NCT03101553|BEHAVIORAL|Progressive Muscle Relaxation|Eight 15-minute sessions of progressive muscle relaxation (PMR).
224244886|NCT00398515|DRUG|temsirolimus|Given IV
223665085|NCT05514808|OTHER|Nutrition education modules|Nutrition education modules on sports nutrition and dietary supplements over a period of 4 weeks (1 module/week)
224244887|NCT00398515|OTHER|pharmacological study|Correlative studies
224244888|NCT00398515|OTHER|laboratory biomarker analysis|Correlative studies
224244889|NCT05681247|DRUG|ezetimibe tablet|The subjects randomly received single oral administration of ezetimibe tablet 10 mg
224244890|NCT05681247|DRUG|ezetimibe tablet(Ezetrol ®)|The subjects randomly received single oral administration of ezetimibe tablet (Ezetrol ®) 10 mg.
224244891|NCT00278980|DRUG|C-peptide|
224244892|NCT04349592|DRUG|Hydroxychloroquine|Hydroxychloroquine 200 mg tablet oral, one tablet three times a day for 7 days
224244893|NCT04349592|DRUG|Azithromycin|Azithromycin 250 mg capsules oral, 2 capsules on day one, followed by 1 capsule once a day for days 2-5.
224244894|NCT04349592|OTHER|Placebo Tablet|Oral, one tablet three times a day for 7 days
224244895|NCT04349592|OTHER|Placebo capsules|Oral 2 capsules on day one, followed by 1 capsule once a day for days 2-5.
224244896|NCT06119841|PROCEDURE|Tonsillectomy|Tonsillectomy was performed with cold dissection including the whole tonsil and capsule, and bleeding was controlled with bipolar cauterisation.
224244897|NCT06119841|PROCEDURE|Expansion sphincter pharyngoplasty|In the ESP technique, following bilateral tonsillectomy with cold dissection and bleeding control with bipolar cauterisation, the palatopharyngeus muscle was identified and a superior-based muscle flap was formed by cutting the upper two-thirds of the muscle on both sides from the lower third attachment site. By opening tunnels to the anterior plica mucosa, the dissected palatopharyngeus muscle was placed in these tunnels, and was sutured to the pterygomandibular raphe with vicryl 2-0 sutures. The mucosal cuts were closed with vicryl 3-0 sutures
224244898|NCT00006027|DRUG|cisplatin|
224244899|NCT00006027|DRUG|paclitaxel|
224244900|NCT00006027|PROCEDURE|adjuvant therapy|
224244901|NCT00006027|RADIATION|radiation therapy|
224244902|NCT05280262|DIAGNOSTIC_TEST|CogState Test|Computerized cognitive testing which provides a score/measurement of distinct cognitive functions
224244903|NCT04877080|BIOLOGICAL|Fast Dual CAR-T Injection|Fast Dual CAR-T injection is a autologous dual CAR-T targeted CD19 and BCMA. A single infusion of CART cells will be administered intravenously.
224244904|NCT02758691|DRUG|Intranasal Insulin|All participants in the devise testing portion of the study will self-administer a 20 IU dose of intranasal insulin. Half of the participants in the function Magnetic Resonance Imaging portion of the study will also self-administer a 20 IU dose of intranasal insulin.
224244905|NCT02758691|DRUG|Intranasal Saline|All participants in the devise testing portion of the study will self-administer a 20 mL dose of intranasal saline. Half of the participants in the function Magnetic Resonance Imaging portion of the study will also self-administer a 20 mL dose of intranasal saline.
223665086|NCT00946153|DRUG|Lenvatinib|In the Dose-Escalation Component of the study, lenvatinib will be administered as continuous once-daily oral dosing. Dose-escalation will occur based on safety information obtained during Cycle 1. The recommended dose for the Expansion Component of the study will use the MTD in Cycle 1.
223665087|NCT00084890|DRUG|carboplatin|30 minute infusion dosed based on glomerular filtration rate of patient
223665088|NCT00084890|DRUG|docetaxel|escalating doses ofstarting at 25 milligrams per meter squared
223665089|NCT00846183|PROCEDURE|local injury|In one group, on the day of oocyte retrieval, local injury to endometrium with a Novak curet to anterior and posterior wall of endometrium are performed
223665090|NCT04120519|DRUG|thalidomide combined with dexamethasone and cyclophosphamide|TCD
223665091|NCT04911985|DEVICE|Measurement of the Cardiac Output/ Cardiac Index|Semiinvasive Measurement of the Cardiac Output/ Cardiac Index with the Pulsion device
223665092|NCT00452192|DRUG|Telmisartan|telmisartan 80 mg daily over 2 weeks
223665093|NCT01783756|DRUG|lapatinib ditosylate|Given PO
223665094|NCT01783756|DRUG|everolimus|Given PO
223665095|NCT01783756|DRUG|capecitabine|Given PO
224244906|NCT00624065|DRUG|carvedilol controlled release/lisinopril|carvedilol CR + lisinopril given as separate pills
224244907|NCT00624065|DRUG|lisinopril + placebo|lisinopril plus placebo to match carvedilol CR
224244908|NCT00696020|DRUG|BI 1744 CL/tiotropium bromide fixed dose combination|BI 1744 CL plus tiotropium bromide fixed dose combination; Solution for inhalation via Respimat® Inhaler (A5); Oral inhalation
224244909|NCT00696020|DRUG|tiotropium bromide|tiotropium bromide; Solution for inhalation via Respimat® Inhaler (A5); Oral inhalation
224244910|NCT00696020|DEVICE|Respimat® Inhaler|
224244911|NCT01467765|OTHER|Elental|200Kcal/200mL of liquid nutrient for 15 min at 7:30 am is administered in PEG patients
224244912|NCT06340139|OTHER|conventional treatment|conventional treatment with Trampoline jumping, gym ball exercises, sensory diet (joint compressions, deep pressure, head massage
224244913|NCT06340139|OTHER|experimental treatment|1 being a fixation point and phase 2 including head and eye movements
224244914|NCT01387022|DRUG|Tenofovir, lamivudine and efavirenz|Tenofovir, 300mg daily, lifelong Lamivudine, 300mg daily, lifelong Efavirenz, 600mg daily, lifelong
224244915|NCT02076022|DEVICE|Enhanced Fat Grafting|"The stromal vascular fraction (SVF) cell suspension (device output) will be processed using the Tissue Genesis Cell Isolation System™~The Standard graft material and the stromal vascular fraction cells will be mixed and subsequently injected into the amputated stump at a concentration of 2.0 - 3.0 x 10 6 stromal vascular cells/ml of injected fat graft to each site. The volume of each injected fat graft will depend on the volume requirements for each injured extremity.~To manually combine the standard fat graft material and the SVF suspension (device output), each of the syringes will be connected via luer to luer lock. The contents of the lipoaspirate syringe are transferred to the SVF syringe and the cell suspension will be injected slowly back and forth between the two (2) syringes. The final 1 mL SVF-fat graft syringe is now considered cell-enriched and ready for injection into the subject."
224244916|NCT02076022|PROCEDURE|Standard fat graft|Aspirated fat tissue will be processed as standard graft material. It will be divided into small aliquots and centrifuged in a sterile rotor (3000 rpm for 3 minutes/1200g), and top fluid oil layer from the fat tissue fractions were removed, and transferred into 1ml syringes and injected into the amputation stump. This graft preparation will be performed in the operating room. Standard fat graft material will serve as a control treatment and will be injected into limb using specialized injection cannulas
224244917|NCT00388544|BEHAVIORAL|Activity matched to interest|Recreational activities are tailored to subject's style of interest
224244918|NCT00388544|BEHAVIORAL|Activity matched to function|Recreational activities are tailored to subjects physical and cognitive functioning
224244919|NCT00388544|BEHAVIORAL|Activity matched to both interest and function|Recreational activities are tailored to both style of interest and physical and cognitive functioning.
224244920|NCT05311501|OTHER|Non-surgical periodontal treatment|Non-Surgical periodontal Treatment was performed by removing supra and subgingival calculus and using both ultrasonic and manual instruments. Oral Hygiene Instructions (OHI) were provided throughout the experimental period. Local anesthesia was performed only when needed.
224244921|NCT03636763|DRUG|data report|"the information gliptin exposure will be reported"
224244922|NCT00312663|BIOLOGICAL|Falciparum Malaria Protein 11 with AS01B adjuvant.|malaria experimental vaccine
224244923|NCT01352663|BIOLOGICAL|Wockhardt's Insulin Analogue (Recomb)|Basal bolus Wockhardt's Recombinant Insulin Analogue to be injected subcutaneously.
224244924|NCT01352663|BIOLOGICAL|Lantus®|Basal bolus Insulin analog glargine (Lantus®) to be injected subcutaneously.
224244925|NCT02462317|DRUG|botulinum A toxin|botulinum toxin injection
224244926|NCT02462317|DRUG|Baclofen|baclofen oral tablet
224244927|NCT02462317|DRUG|Placebo toxin|placebo injection
224244928|NCT02462317|DRUG|placebo baclofen|placebo oral tablet
224244929|NCT05841316|DRUG|Sugammadex|"During the surgery, the desired level of neuromuscular block will be deep and followed by post-tetanic-count (PTC) of 1 to 3 in every 5 minutes. 0.3-1mg/kg/h rocuronium will be infused to ensure PTC of 1 to 3.~At the end of the surgery, 0,6 mg sugammadex will be given as a bolus in the first patient of the study. The duration between the completion of sugammadex injection and the first measurement of Train-of-four ratio (TOFR) of 0.4 will be recorded.~If the TOFR is achieved to 0.4 after sugammadex bolus of 0,6 mg/kg in 5 minutes, the result of reversal will be evaluated as positive. The consecutive patient will be given the same or decreased dose of sugammadex by 0,2 mg/kg according to the randomisation scheme.~If the patient fails to recover from deep neuromuscular block to superficial block in 5 minutes after a given dose of sugammadex, the consecutive patient will be administered increased dose of sugammadex by 0,2 mg/kg."
223665096|NCT01783756|OTHER|laboratory biomarker analysis|Correlative studies
223665097|NCT03801057|DIETARY_SUPPLEMENT|MPH_active|One daily intake at breakfast of supplementary marine protein hydrolysate (MPH), a dosage of 2400 mg, duration 6 weeks. The form is powder, flavored with lemon, and to be mixed with 100 ml water. Random sequence of arms.
223665098|NCT03801057|DIETARY_SUPPLEMENT|MPH_placebo|One daily intake at breakfast of supplementary placebo, a dosage of 2400 mg, duration 6 weeks. The form is powder, flavored with lemon, and to be mixed with 100 ml water.
223665099|NCT02667353|PROCEDURE|ECT|ECT was administered twice a week with a constant-current brief-pulse device (Thymatron, System IV). Motor and electroencephalographic seizures were monitored to ensure adequate duration and quality. Subjects were all treated with right unilateral (RUL) ECT with stimulus intensity 6 times the initial seizure threshold (ST), as determined by empirical dose titration at the first treatment, until remission (Montgomery-Åsberg Depression Rating Scale (MADRS) (27) \< 10 in two consecutive ratings with a week interval). Subjects who failed to respond right unilateral ECT after the sixth treatment were switched to bitemporal ECT (1.5x seizure threshold).
223665100|NCT02667353|DRUG|Etomidate|Anesthesia was achieved with intravenous administration of etomidate (0.2mg/kg).
223665101|NCT02667353|DRUG|Succinylcholine|Anesthesia was achieved with intravenous administration of succinylcholine (1mg/kg).
223665102|NCT06448767|DIETARY_SUPPLEMENT|Multispecies probiotics|Multispecies probiotics consisting of Bacillus subtilis W201, Bifidobacterium infantis W17, Bifidobacterium lactis W51, Lactobacillus acidophilus W37, Lactobacillus brevis W63, Lactobacillus rhamnosus W140, Lactococcus lactis W19, Propionibacterium freudenreichii W200 at a dose of 5x10\^9 Colony Forming Units (CFU), once daily, orally.
223665103|NCT06448767|OTHER|Placebo|Placebo identical in taste, smell and color to the multispecies probiotics.
223665104|NCT00449397|DRUG|Quetiapine Fumarate|
223665105|NCT03198065|PROCEDURE|Hand-made glove setting|The patients receive Hand-made glove setting for single-incision laparoscopic appendectomy
223665106|NCT03198065|PROCEDURE|Commercialized single-incision multiport setting|The patients receive commercialized single-incision multiport setting for single-incision laparoscopic appendectomy
223665107|NCT03973528|DRUG|traditional Chinese medicine: tonifying kidney Wan|traditional Chinese medicine : tonifying kidney Wan
223665108|NCT05323058|DRUG|tulsi extract|4% topical oral spray
223665109|NCT05323058|DRUG|Benzydamine Hydrochloride|0.15% topical oral spray
223665110|NCT00000659|DRUG|CD4 Antigens|
223665111|NCT00000659|DRUG|Zidovudine|
223665112|NCT04304599|DEVICE|LoFric Elle|The study device is commercially available (CE-marked). It is a device for female intermittent catheterization. Treatment Period will last for 2 weeks. The angulated handle available with the device must be used by each subject at least 10 times.
223665113|NCT01948193|BIOLOGICAL|Hexaxim™: DTaP-IPV-Hep B-PRP~T combined vaccine|0.5 mL, Intramuscular
223665114|NCT03130647|DEVICE|Focused ultrasound|Focused ultrasound
223665115|NCT00711178|PROCEDURE|Photodynamic therapy with methyl aminolevulinate|daylight mediated photodynamic therapy
223665116|NCT04712240|DEVICE|Respiration rate monitor|A portable continuously monitoring respiration rate monitor will be fitted to each participant. The respiration rate monitor is housed within a comfortable chest strap that be secured to the participant for the duration of the surgical procedure
223665117|NCT02711267|DRUG|5% Zovirax® cream|(manufactured by GlaxoSmithKline Pharma in Canada, distributed in the USA by Valeant Pharmaceuticals North America LCC, Bridgewater,NJ 08807)
223665118|NCT02711267|DRUG|5% Aciclostad cream|(STADA Arzneimittel GmbH, Vienna, Austria)
224244930|NCT04441463|BIOLOGICAL|Blood sampling for tryptase analysis|"3 bloods test~* One blood sample taking from the mother's vein punction, during the delivery.~* One blood sample tanking from umbilical cord.~* One blood sample taking from the baby in day 3 of life, during the Guthrie test."
224244931|NCT05326841|DRUG|Vitamin D3|cholecalciferol tablet, the dose is 5000 international unit /day for 12 weeks
224244932|NCT02426710|DEVICE|Intracardiac echocardiography|Flutter ablation will be done using intracardiac echocardiography.
224244933|NCT01165086|OTHER|Incorporating vegetables into the diet to reduce energy density|The entree portion of breakfast, lunch, and dinner meals will be manipulated to be a standard energy density, a 15% reduction in energy density, or a 25% reduction in energy density.
223665119|NCT02711267|DRUG|5% Aciclovir cream 1A Pharma|(1A Pharma GmbH, Vienna, Austria)
223665120|NCT02711267|DRUG|5% Zovirax Cold Sore Cream|(GlaxoSmithKline Consumer Health Care, Brendfort, UK; Marketing authorization holder: Beeham Group PLC, Brendfort, UK)
223665121|NCT02711267|DRUG|5% Zovirax® cream (Austria)|(GlaxoSmithKline Pharma GmbH, Vienna, Austria)
223665122|NCT02711267|PROCEDURE|OFM|Sampling method for interstitial fluid
223665123|NCT02711267|DEVICE|OFM Probe|Sampling probe used during OFM
223665124|NCT02711267|DEVICE|OFM Pump|Pump used to operate OFM probes
223665125|NCT02522624|BEHAVIORAL|Decision Aid (DA)|Participants will be shown (on a computer) a targeted, web-based decision aid focused on the topic of health insurance plans in addition to usual care.
223665126|NCT03196609|BIOLOGICAL|Collection of stool and serum samples|"During the inclusion visit (for the 5 cancer sites): Stool collection (1 tube RNA later + 1 tube DMQO-EDTA) +Blood sample (1 tube SST + 1 tube EDTA)~1 month after treatment (only for non-small cell lung cancer): Stool collection (1 tube RNA later + 1 tube DMQO-EDTA) + Blood sample (1 tube SST + 1 tube EDTA)"
224244934|NCT05165823|BEHAVIORAL|Sodium restriction|Participants will be guided in minimizing sodium intake. Guidance will be both oral and written. Bread with low sodium content will be offered to the participants.
224244935|NCT04920708|DRUG|Ipatasertib 300mg|Ipatasertib 300mg once daily. Oral administration. Treatment is continuous daily for 21 days, followed by 7 days off, to complete a 28 day cycle.
224244936|NCT04920708|DRUG|Fulvestrant 500g|Fulvestrant 500mg administered intramuscularly in the buttocks slowly (1-2 minutes per injection) as two 5-mL injections (one in each buttock). Administered days 1 and 15 of Cycle 1. For subsequent cycles, patients will receive fulvestrant as described above in the clinic on Day 1 of each cycle or approximately every 4 weeks.
223665127|NCT03337828|OTHER|Alcohol-free beer with regular composition|Subjects are provided with 2 alcohol-free beers with regular carbohydrates composition per day and healthy diet counselling during 10 weeks.
223665128|NCT03337828|OTHER|Alcohol-free beer with modified composition|Subjects are provided with 2 alcohol-free beers with modified carbohydrates composition per day and healthy diet counselling during 10 weeks.
223665129|NCT03719534|PROCEDURE|haplo-HCT|HCT will be performed with a haploidentical donor
223665130|NCT03719534|PROCEDURE|haplo-cord HCT|Haploidentical donor HCT will be performed with coinfusion of unrelated cord blood unit
223665131|NCT02606942|OTHER|Questionnaires, physical exam, US of the knee|Function and pain questioners, physical findings and sonographic study of the knee joint
223665132|NCT01180179|DRUG|Lansoprazole|30mg once daily
224244937|NCT04920708|DRUG|Palbociclib 75mg-125mg|Palboclicib 75mg-125mg once daily, dependent on toxicities. Oral administration. Treatment is continuous daily for 21 days, followed by 7 days off, to complete a 28 day cycle.
224244938|NCT04920708|DRUG|CDK4/6 Inhibitor|CDK4/6 inhibitor. As per current standard of care regime for ER+/HER2- breast cancer.
224244939|NCT06062914|DRUG|oral nutritional supplements|Only ONS was used as enteral nutrition
224244940|NCT00599664|DRUG|OMS201|OMS201 irrigation solution during surgery
224244941|NCT00599664|DRUG|Vehicle|Vehicle irrigation solution during surgery
224244942|NCT04058288|DEVICE|High-definition Transcranial Direct Current Stimulation|Stimulation sessions will be conducted on 2 different visits separated by 2-week gap. In a crossover design, Anodal HD-tDCS will be delivered either in Active/Sham mode (during the first visit) and Sham/Active during the second visit in a 4x1 ring configuration (center electrode being Anode and the surrounding 4 electrodes being cathodes) over the affected motor area.
224244943|NCT06121193|BEHAVIORAL|PREVENT tool|PREVENT is a novel Health Information Technology tool designed to promote physical activity and healthy food intake among overweight/obese patients at the point of care. PREVENT automates the delivery of personalized, evidence-based behavior change recommendations and provides an interactive map of community resources to help providers link patients to resources in their community.
224244944|NCT06121193|BEHAVIORAL|Wait-list Control|Will receive routine clinical care. After completion of follow-up measures, control participants will receive a behavior change prescription via the PREVENT tool
224244945|NCT00122577|DRUG|Tenofovir|
224244946|NCT00122577|DRUG|Atazanavir|
224244947|NCT00122577|DRUG|Ritonavir|
224244948|NCT03080597|DEVICE|PrEP Smart app|"English-speaking males, between the ages of 18-30, who are enrolled at a HBCU or identify as Black/African American, who are currently prescribed PrEP (Truvada) for HIV Prevention, and owners of either an Android or iOS smartphone, will be asked to use an application on their smart phones called PrEP Smart.an application on their smart phones called PrEP Smart."
224244949|NCT00122798|PROCEDURE|Stroke treatment|
224244950|NCT03331497|PROCEDURE|Tonsillotomy|About 2/3 of the palatine tonsil tissue is removed with coplator or bipolar knife.
224244951|NCT02646397|DRUG|Fosinopril|Fosinopril is an angiotensin-converting enzyme inhibitor.
224244952|NCT02646397|DRUG|Benidipine|Benidipine is a dihydropyridine-derived calcium channel blocker.
224244953|NCT02646397|DRUG|Hydrochlorothiazide|Hydrochlorothiazide is a diuretic medication.
224244954|NCT04321850|DRUG|Zinc Sulfate 50 Mg Tab|The tablets were manufactured specifically for this study.
224244955|NCT04321850|DRUG|Placebo oral tablet|The tablets were manufactured specifically for this study.
224244956|NCT03250286|DEVICE|EUS|"Endoscopic ultrasound (EUS) is performed with radial scanning echo endoscope (Olympus GF UE260) by four endosonographers.~EUS examination is performed first, and if there is choledocholith, ERCP is performed."
224244957|NCT03250286|DEVICE|ERCP|"Endoscopic retrograde cholangiopancreatography (ERCP) is performed with duodenoscope (Olympus JF-260V or TJF-260V) by four endoscopists.~* In the EUS-ERCP group, ERCP is used to remove bile duct stones diagnosed via EUS. Therefore, only ERCP is performed in patients with choledocholithiasis in EUS.~* In the ERCP group, diagnosis and treatment of bile duct stones are performed with ERCP."
223665133|NCT01180179|DRUG|Famotidine|40mg once daily
223665134|NCT03800394|OTHER|Observational PK study|Effect of antituberculosis treatment, age and genetic factors on intracellular TFV-DP and FTC-TP concentrations
223665135|NCT00894959|BIOLOGICAL|Heparin sodium Blausiegel 1|Heparin sodium Blausiegel 1 5.000 UI
223665136|NCT00894959|BIOLOGICAL|Heparin sodium APP|Heparin sodium APP 5.000 USP
223665137|NCT00995033|BIOLOGICAL|NicVAX vaccine|NicVAX vaccine given 6 times over 6 months
223665138|NCT00995033|BIOLOGICAL|Placebo|Phosphate buffered saline and ALhydrogel of identical appearance to NicVAX; IM in 6 doses over 6 months
223665139|NCT00995033|DRUG|Varenicline|Days 0-2: 0.5 mg once daily, Days 3-6: 0.5 mg twice daily (morning and evening), Day 7- 84: 1.0 mg twice daily (morning and evening)
223665140|NCT03698344|OTHER|Biodiesel exhaust exposure|Evaluation of sympathetic nervous system activity as assessed by microneurography recording during an acute exposure to dilute biodiesel exhaust via mask.
223665141|NCT01801371|DRUG|68Ga-BNOTA-PRGD2|Single intravenous bolus injection of nearly 111 MBq 68Ga-BNOTA-PRGD2 at 30 minutes before brain PET/CT scanning.
223665142|NCT01800175|DEVICE|Punctum Plug|
223665143|NCT00317291|PROCEDURE|Acupuncture/Moxibustion|Acupuncture/Moxibustion: 16 scheduled sessions
224244958|NCT02719223|DEVICE|NICaS|The NICaS is a non invasive device for measuring and calculating of hemodynamic parameters including mean arterial pressure (mm/Hg), cardiac index (l/min/m2) and total peripheral resistance (dynes/sec/cm5).
224244959|NCT02712827|PROCEDURE|Progrip|Self-fixating mesh
224244960|NCT02712827|PROCEDURE|Non-Progrip|Non self-fixating mesh with the use of glue
224244961|NCT06272331|OTHER|Low-protein plant-based drink|Ingestion of a low-protein plant-based drink
224244962|NCT06272331|OTHER|High-protein plant-based drink|Ingestion of a high-protein plant-based drink
224244963|NCT06272331|OTHER|Cow's milk|Ingestion of cow's milk
224244964|NCT03639662|OTHER|sophrology sessions|"Patients benefit from additional support consisting of at least 3 sessions of sophrology, one per week, from the week following the announcement of the diagnosis and until the week preceding the hospitalization for irathérapie. It will be group sessions, 1h carried out in the participating center by a nurse sophrologist who will use the techniques of sophrology such as relaxation, breath control, mastery of thoughts and visualization. Each session will be recorded in digital format and the recording will be given to the patient at the end of the session so that he can, if he wishes, reproduce it at home.~Patients will also be able to share their feelings and ask questions"
224244965|NCT00817960|DRUG|Methylphenidate|The effect of ritalin on postural stability of old adults (65 years old and over) will be measured using RCT study design
224244966|NCT04517162|DRUG|Collagen-Polyvinylpyrrolidone|1.5 mL of polymerized-type I collagen or placebo, every 12 h for 3 days and then every 24 h for 4 days (in total 10 injections in 7 days)
224244967|NCT01530620|DRUG|Propiverine hydrochloride ER (extended release)|45 mg capsule (1x1/d)
224244968|NCT01530620|DRUG|Propiverine hydrochloride IR (immediate release)|15 mg tablet (3x1/d)
224244969|NCT02360462|DEVICE|Active tDCS|The stimulation will be administered with a pair of surface electrodes, sponge coated, soaked in saline. A battery-powered constant current stimulator will be used for this purpose (tDCS device). The stimulation is performed by placing the anodal electrode in the primary motor cortex (M1) and the cathodal one in the contralateral supraorbital area and it will use a 2 mA (milliampere) current.
223770418|NCT04279444|DIETARY_SUPPLEMENT|BKR-017|BioKier, Inc. is developing colon-targeted, oral formulations of natural gut hormone secretagogues as non-prescription medical foods or supplements for nutritional use for improvement of insulin sensitivity.
223770419|NCT00600821|DRUG|Bevacizumab|Bevacizumab is available as 100 and 400 mg preservative-free, single use vials- The starting dose is 15 mg/kg, iv infusion, every 3 weeks.
223770420|NCT00600821|DRUG|Carboplatin|Carboplatin is available as pre-mixed 10mg /ml aqueous solution- The starting dose is AUC 6 mg\*min/ml, iv infusion, every 3 weeks.
224244970|NCT02360462|DEVICE|Sham tDCS|The sham tDCS consists in the same montage of the active tDCS, but the device is turned off 30 seconds after stimulation starts (without letting the patient notice it). The rest of the montage is kept identical to the active one during the 20 minutes session
224244971|NCT00301366|DRUG|alpha-1 proteinase inhibitor (human)|60 mg/kg weekly for 20 weeks
224244972|NCT03212573|COMBINATION_PRODUCT|ERAS protocol|ERAS protocol includes early oral intake and deambulation and multimodal analgesia
224244973|NCT03212573|COMBINATION_PRODUCT|Standard care|Oral intake and deambulation 24h after surgery and only intravenous analgesia.
223665144|NCT00317291|OTHER|Sham acupuncture/Placebo moxibustion|Sham acupuncture/Placebo moxibustion: 16 scheduled sessions
224244974|NCT05567965|OTHER|Home care intervention|The duration of the intervention, both for the control group and the intervention group, will be 18 months or until the user's admission to the nursing home.
224244975|NCT01510730|DRUG|eradication treatment of Helicobacter pylori infection|Eradication group receive Omeprazole sodium 20mg, amoxicillin 1g, clarithromycin 500mg orally at the same time twice daily for 7 days.
224244976|NCT01371786|DRUG|ciclesonide nasal aerosol|A radiolabeled solution of ciclesonide nasal aerosol supplied in a 37 μg/actuation canister
224244977|NCT01371786|DRUG|mometasone Aqueous (AQ) nasal spray|A radiolabeled suspension of mometasone Aqueous (AQ) nasal spray supplied in a 50 μg/actuation bottle
223665145|NCT02631382|PROCEDURE|wet cupping|"In double cupping (traditional technique): Cupping (suction) then scarification then cupping (suction).~In single cupping (Asian): puncture using auto lancet then cupping (suction). In both techniques 4 out of 6 acupoints (BL23, BL24, BL25 bilateral) will be selected."
223770421|NCT00600821|DRUG|Paclitaxel|Paclitaxel is available in multidose vials (30 mg/5ml;100mg/16.7 ml;300 mg/50ml)- The starting dose is 200 mg/m2, every 3 weeks
224244978|NCT03694665|OTHER|Lung recruitment maneuver|A Lung recruitment maneuver is aimed to resolve atelectasis during mechanical ventilation. It consists in a brief and controlled increment in airways pressure using pressure control ventilation. Positive end-expiratory pressure (PEEP) is increases every 5 centimeters of water (cmH2O), from 0 to 20 cmH2O keeping a fixed driving pressure of 20 cmH2O. A final step of 40 cmH2O of plateau pressure was maintained for 10 breaths, returning then to standard ventilatory settings.
224244979|NCT03463369|BIOLOGICAL|JNJ-64300535|Participants will receive JNJ-64300535 vaccine by electroporation-mediated IM injection on Day 1, Week 4, and Week 12.
224244980|NCT03463369|BIOLOGICAL|Placebo|Participants will receive 1 mL (0.9 percent \[%\] sodium chloride \[NaCl\]) of placebo solution matching to JNJ-64300535 electroporation-mediated IM injection on Day 1, Week 4, and Week 12.
224244981|NCT03463369|DRUG|Nucleos(t)ide Analogs (NA)|Participants will receive NA as a standard of care treatment.
224244982|NCT05345236|DRUG|Aflibercept|Intravitreal (IVT) injection
224244983|NCT00838149|DIETARY_SUPPLEMENT|Glutamine|"Glutamine group :~Glutamine would be supplemented (0.5gm/Kg ideal body weight) in the form of a water soluble commercial preparation containing 10 gm of pure L- Glutamine in the crystalline form. The patient in this group would be counseled to meet the remaining protein requirement (i.e1g/Kg/wt) by usual diet. This intervention would be made over a period of two months."
224244984|NCT00838149|DIETARY_SUPPLEMENT|Whey protein|"Whey protein group:~Whey protein would be supplemented (0.5gm/Kg ideal body weight) in the form of a water soluble whey protein concentrate containing 70 % protein. The patient in this group would be counseled to meet the remaining protein requirement (i.e1g/Kg/wt) by usual diet. This intervention would be made over a period of two months."
224244985|NCT02170311|DRUG|Z-213|
223665146|NCT05898997|BEHAVIORAL|Acupressure|Massage the following acupoints in order: Jing Ming, Zan Zhu, Mei Chong, Yu Yao, and Si Zhu Kong. Use the joint of your thumb to massage each acupoint for 30 times, and repeat the cycle at least once. Then, continue to promote the circulation of qi by gently making a fist and using the four fingers to scrape along the upper eye socket from inside to outside. Scrape each side 30 times, and do it separately for the left and right sides. It is recommended to do this process at least once in the morning and once in the evening.
223665147|NCT01661842|OTHER|conventional plus UC-MSC treatment|Received conventional treatment and taken i.v., once per 4 week, at a dose of 1×106 UC-MSC/kg body weight for 12 weeks.
223770422|NCT00600821|DRUG|AG-013736 (axitinib)|AG-013736 (axitinib) is available as 1mg, and 5 mg film-coated tablets for oral administration- The starting dose is 5 mg BID-
223770423|NCT00600821|DRUG|Carboplatin|Carboplatin is available as pre-mixed 10mg /ml aqueous solution- The starting dose is AUC 6 mg\*min/ml, iv infusion, every 3 weeks.
223770424|NCT00600821|DRUG|Paclitaxel|Paclitaxel is available in multidose vials (30 mg/5ml;100mg/16.7 ml;300 mg/50ml)- The starting dose is 200 mg/m2, every 3 weeks
223770425|NCT04949230|OTHER|No Intervention Used|There is no intervention in this study
223770426|NCT06050421|BEHAVIORAL|Radically Open Dialectical Behaviour Therapy (RO-DBT)|RO-DBT is a transdiagnostic intervention specifically designed to treat a spectrum of disorders characterized by excessive overcontrol such as resistant depression, avoidant and obsessive-compulsive personality disorders, mood disorders, anorexia nervosa and autism spectrum disorder.
224244986|NCT01434147|DRUG|preoperative induction chemotherapy in combination with bevacizumab followed by combined radiochemotherapy with capecitabine|Therapy start: Capecitabine 1000mg/ m² bid during 14 days(d1-14), oxaliplatin 130mg/m² and Bevacizumab 7.5mg/kg body weight d1, repetition day 22 and 43 (3 cycles) Radiotherapy: Followed by 5 x 5 days 1.8 Gy after 1 week of concluded 3rd cycle of induction chemotherapy Chemotherapy: Capecitabine 825 mg/m2 bid (on each therapy day of first 4 therapy weeks)
224244987|NCT01790347|BEHAVIORAL|Exercise group|"The physical conditioning program included a total of three 50-55 minute sessions per week. Pregnant women started at 9 weeks and finished at 38-39 weeks, therefore, an average of 85 training sessions were planned for each participant. All subjects wore a heart rate (HR) monitor (Polar FT7, Finland) during the training sessions to ensure that the exercise intensity was light to moderate.~Each session included 10 min of warm up and 10 min of cool down which included an specific pelvic floor muscles training. The core section of the exercise session lasted from 25 to 30 min and included moderate-intensity aerobic exercises once a week and resistance exercises twice a week."
224244988|NCT02511782|DEVICE|D-SQUAME Skin Sampling Discs|A D-SQUAME Skin Sampling Disc is a noninvasive patch that collects skin cell samples when affixed to the superficial stratum corneum (top layer of skin). The patch is applied with gentle pressure to the desired quadrant of the forearm and removed 2 minutes after application.
224244989|NCT03702894|DRUG|Clavamox|Clavamox, Film-coated Tablets, 875 mg + 125 mg, manufactured by Pharmtechnology LLC, Belarus
224244990|NCT03702894|DRUG|Augmentin®|Augmentin®, Film-coated Tablets, 875 mg + 125 mg, marketed by GlaxoSmithKline Trading CJSC, Russia
224244991|NCT06217614|OTHER|(Manuka honey-green tea)|"Manuka honey is a natural honey, and green tea are herbs Dried green tea leaves (100 gm) will be soaked into 500 ml of methanol solution for two days. Green tea plus ginger mouthwash was prepared by adding 50% green tea extract and 50% ginger extract. After extraction, the extract was filtered and taker to the vacuum evaporator to remove the solvent.~The mouthwash was prepared by adding 3 gm of each extract, 0.12 gm sodium saccharin, and one liter distilled water, then every 20 ml of Manuka honey were added in 100 ml of (green tea and ginger solution). Finally, the mixture was stirred vigorously until all the particles were dissolved. Thereafter the obtained mixture was filtered. The mouthwash then filled in sterilized amber color bottles of 250 ml each.~According to similar studies performed in this field, the patients used a 20ml of (Manuka honey-green tea- ginger) mouthwash three times a day (preferably after their meals), kept it for one minute, and then poured it out"
224244992|NCT00103623|DRUG|Plenaxis|
224244993|NCT00450190|DEVICE|Saizen® E-Device|Saizen® (recombinant human growth hormone \[r-hGH\]) injection 8 milligram (mg) per 137 milliliter (mL) will be administered using an electronic auto-injector (E-Device) subcutaneously (SC) in the evening as per local Summary of Product Characteristics (SmPC) for 60 days.
224244994|NCT05026671|PROCEDURE|Endotracheal Tube Alone|Intubating the trachea with an endotracheal tube alone ( without stylet).
224244995|NCT05026671|PROCEDURE|Endotracheal Tube+ Stylet|Intubating the trachea with an endotracheal tube + stylet.
224244996|NCT05026671|PROCEDURE|Endotracheal Tube + Video-laryngoscope|Intubating the trachea with an endotracheal tube + Video- laryngoscope
224244997|NCT05026671|PROCEDURE|Endotracheal tube + stylet with Video-laryngoscope|Intubating the trachea with an endotracheal tube + stylet + Video-laryngoscope
224244998|NCT03252509|PROCEDURE|Percutaneous radiologic gastrostomy|Percutaneous radiologic gastrostomy: Under conscious sedation and local analgesia, the ultrasound is performed to determine abdominal structures. The stomach is distended using room air through a nasogastric catheter or a 5 French (Fr) catheter. Gastropexy is performed under fluoroscopic guidance. The stomach is accessed using a 18 gauge (G) needle. Guidewire is advanced to the stomach. Progressive tract dilatations until the size of the gastrostomy tube is achieved. The catheter is advanced through the peel-away sheath. The catheter's balloon is inflated with 10ml of distilled water. Iodine contrast is injected to confirm position. After the procedure, the patient is observed for 3 hours. If there are no complications, the patient is discharged.
224244999|NCT03352518|DEVICE|WM3.4NR|The investigational medical device will collect spectral raman data from tissue.
224245000|NCT00518518|DRUG|Staloral 300|Staloral 300
224245001|NCT00518518|DRUG|placebo|placebo
223665148|NCT01661842|OTHER|Conventional plus placebo treatment|Received conventional treatment and taken i.v., once per 4 week, at 50 ml saline for 12 weeks
223665149|NCT02397018|BIOLOGICAL|allogeneic umbilical cord blood|Umbilical cord blood units will be selected from a public cord blood bank based on ABO/Rh blood type and cell dose, targeting a range of 0.5 to 5 x 10\^7 total nucleated cells per kilogram. The cord blood unit will be intravenously infused into the subject over 5-30 minutes at a rate not exceeding 5 mL/kg/hr. Subjects will not receive immunosuppressive medications or any other cytoreduction prior to infusion.
223665150|NCT00923949|DRUG|Pioglitazone|45 mg tablet daily by mouth for six weeks
223665151|NCT00490529|BIOLOGICAL|CpG-MCL vaccine|CpG-MCL vaccine is a vaccine prepared by co-culturing cells from the participant's mantle cell lymphoma suspension with 3 mcg/mL PF-3512676, then irradiated to 200 Gy. 1 x 10e8 CpG-MCL cells will be given as a subcutaneous injection.
223665152|NCT00490529|BIOLOGICAL|PF-3512676|PF-03152676 is a synthetic immunostimulatory, single-stranded oligodeoxynucleotide (oligo-DNA) moledule containing unmethylated cytosine and guanine (CpG) motifs. PF-03512676 acts as an agonist of human Toll-like receptor 9, leading to activation of antigen-presenting cells and a cascade of antitumor immune reactions.
224245002|NCT02848742|DEVICE|Dermal Cooling System|Dermal cryotherapy
224245003|NCT06486129|PROCEDURE|Noninvasive ventilation volume targetted|he aim of the present study was to evaluate the long-term effects of volume-targeted bilevel-positive airway pressure ventilation (BiPAP) on cardiac parameters and myocardial biomarkers in patients with OHS
224245004|NCT05683665|DEVICE|scintigraphy DaTSCAN|DaTSCAN™ (123I-ioflupnae) tomoscintigraphy assesses the density of dopamine transporters (DATs) on the pre-synaptic membrane of dopaminergic neurons
223665153|NCT00490529|PROCEDURE|Vaccine-primed T-cells|Vaccine primed T-cells are the post-vaccination leukapheresis harvest of peripheral blood mononuclear cells. Each collection is approx 1 x 10e10 CD3+ T-cells.
223665154|NCT00490529|PROCEDURE|Autologous hematopoietic stem cell transplant (HSCT)|Regular medical procedure
223665155|NCT00490529|DRUG|Rituximab|375 mg/m² by infusion
224245005|NCT01536574|DRUG|Requip PR|Eligible patients will be dispensed medication to uptitrate their REQUIP PR dose (2, 4, 6, 8mg respectively) during the first 4 weeks of treatment. During the 24 week treatment phase, the subjects dose will be adjusted according to the recommended schedule to achieve symptomatic control.
224245006|NCT01392430|OTHER|Discontinuation of prophylactic drugs i.e. co-trimoxazole, dapsone, fluconazole, itraconazole, azithromycin|Discontinuation of prophylaxis for opportunistic infections
224245007|NCT05668520|DIAGNOSTIC_TEST|Body composition using a hand-held body fat monitor • Resting Metabolic Rate (RMR) using a ventilated hood system|"Consent Paperwork~* Nutritional assessment using MNA and MUST questionnaires~* 24-hour dietary recall assessment Body weight, height, waist circumference, mid upper arm and calf circumference"
224245008|NCT04770857|OTHER|Visual analogue scale|Post procedural pain assessment using the visual analogue scale (VAS) will be performed in patients undergoing ERCP
224245009|NCT01376167|DRUG|Chloroquine 600mg|600mg Chloroquine given to each subject on Day 1 and Day2 of the trial
224245010|NCT01376167|DRUG|Chloroquine 300mg|300mg Chloroquine given to each subject on Day 3 of the trial
224245011|NCT01376167|DRUG|Tafenoquine 50mg|single dose 50mg Tafenoquine given to subject on treatment arm 1 on Days 1 or 2
224245012|NCT01376167|DRUG|Tafenoquine 100mg|single dose 100mg Tafenoquine given to subject on treatment arm 2 on Days 1 or 2
224245013|NCT01376167|DRUG|Tafenoquine 300mg|single dose 300mg Tafenoquine given to subject on treatment arm 3 on Days 1 or 2
224245014|NCT01376167|DRUG|Tafenoquine 600mg|single dose 600mg Tafenoquine given to subject on treatment arm 4 on Days 1 or 2
224245015|NCT01376167|DRUG|Primaquine 15mg|15mg Primaquine given once daily to subject on treatment arm 5 on Days 2 to 15.
224245016|NCT01376167|DRUG|Chloroquine 600mg (Part 2 )|600mg Chloroquine given to each subject on Day 1 and Day2 of the trial.
224245017|NCT01376167|DRUG|Chloroquine 300mg (Part 2 )|300mg Chloroquine given to each subject on Day 3 of the trial.
224245018|NCT01376167|DRUG|Tafenoquine 300mg (Part 2)|single dose 300mg Tafenoquine given to subject on treatment arm 3 on Days 1 or 2.
224245019|NCT01376167|DRUG|Primaquine 15mg (Part2 )|15mg Primaquine given once daily to subject on treatment arm 3 on Days 2 to 15.
224245020|NCT01319123|DEVICE|Drawtex dressing|The dressing is indicated for moderately to heavily exuding wounds such as venous leg ulcers
224245021|NCT01757600|OTHER|Microperimetry|
224245022|NCT01447615|BEHAVIORAL|Bridges|Each child participant in the Bridges Arm will receive the usual care in addition to a Child Development Account (CDA) to be used for secondary education by the AIDS-orphaned child. The CDA will be a matched savings account held in the child's name in a financial institution registered by the Central Bank (Bank of Uganda). The account will be matched with money from the program at a match rate of 1:1. Additionally, participants will receive: 1) twelve 1-2 hour workshops focused on asset building, future planning, and protection from risks; 2) mentorship sessions to reinforce learning and build optimism; and 3) a family income-generating /micro-enterprise promotion component for children enrolled in Bridges and their families.
224245023|NCT01447615|BEHAVIORAL|Bridges PLUS|Each child participant in the Bridges PLUS Arm will receive the usual care in addition to a Child Development Account (CDA) to be used for secondary education by the AIDS-orphaned child. The CDA will be a matched savings account held in the child's name in a financial institution registered by the Central Bank (Bank of Uganda). The account will be matched with money from the program at a match rate of 2:1. Additionally, participants will receive: 1) twelve 1-2 hour workshops focused on asset building, future planning, and protection from risks; 2) mentorship sessions to reinforce learning and build optimism; and 3) a family income-generating /micro-enterprise promotion component for children enrolled in Bridges PLUS and their families.
224245024|NCT01447615|OTHER|Usual Care|Participants in the usual care condition will receive usual care for AIDS-orphaned children in the study area. This includes: counseling, school lunches, and scholastic materials (textbooks and notebooks). Counseling will be provided by priests in the community (as is currently done).
224245025|NCT05069961|PROCEDURE|ESPB|Ropivacaine is injected near the nerves in the back
224245026|NCT05069961|PROCEDURE|TEA|Bupivacaine is injected into the space around the spinal cord.
224245027|NCT01842750|DEVICE|Endorectal Balloon insertion|
224245028|NCT04659915|DRUG|Metformin 500 mg Oral Tablets + Prednisone 20mg Tablets|"During one phase of the study: Metformin 500mg Day 1 1-0-0 Day 2 1-0-0 Day 3 1-0-1 Day 4 1-0-1 Day 5 2-0-1 Day 6 2-0-1 Day 7 4-0-0~In combination with prednisone 20mg: day 1 to day 7 1.5-0-0."
224245029|NCT04659915|DRUG|Placebo 500 mg Tablets + Prednisone 20mg Tablets|During another phase of the study: identical looking placebo pills starting day 1 500mg 1-0-0, day 2 500mg 1-0-0, day 3 500mg 1-0-1, day 4 500mg 1-0-1, day 5 500mg 2-0-1. day 6 2-0-1, day 7 4-0-0. In combination with prednisone 20mg: day 1 to day 7 1.5-0-0.
224245030|NCT03956264|DEVICE|Virtual Reality|Deepsen offers a VR platform that provides patients with immersive contents aimed to distract, inform, soften and improve the healthcare experience
224245031|NCT03956264|DRUG|Kalinox|Gas mixture composed of 50% Nitrous Oxide and 50% Oxygen
224245032|NCT03865654|OTHER|Communication Tool|Summarizes recommendations for clinicians and patients for surveillance mammography and follow-up care for breast cancer survivors
224245033|NCT03518281|DIETARY_SUPPLEMENT|Whole Cell Euglena containing Beta Glucan|Whole Cell Euglena containing \>50% Beta Glucan
223665156|NCT00490529|DRUG|Standard induction chemotherapy|Patient-specific, regular medical care treatment as determined by treating oncologist
223665157|NCT00490529|DRUG|Cyclophosphamide|Regular medical care treatment to mobilize peripheral blood progenitor cell (PBPC)
223665158|NCT00490529|DRUG|Filgrastim|Regular medical care treatment to mobilize peripheral blood progenitor cell (PBPC)
223665159|NCT00862797|OTHER|pressure measurement during swallowing|measurement of endotracheal tube cuff pressure during swallowing while recovering from anaesthesia
224245034|NCT03518281|DIETARY_SUPPLEMENT|Placebo|microcrystalline cellulose, hypromellose, titanium dioxide, water
223665160|NCT03254459|DRUG|Buprenorphine Sublingual Spray|0.5 mg Sublingual Spray
224245035|NCT04514393|DRUG|Methotrexate|Intravenous methotrexate at 3.5g/m2 (standard hydration/leucovorin support) will be given on day 1 of all cycles，for up to 4 cycles.
224245036|NCT04514393|DRUG|Ibrutinib|Oral ibrutinib will be given at a dose of 560 mg daily and will be continued daily after completion of methotrexate and temozolomide.Ibrutinib is continued until disease progression, intolerable toxicity or death.
224321664|NCT05619263|BEHAVIORAL|Disaster PrepWise-Caregiver|The Disaster PrepWise (DPW) intervention consists of five interactive modules and two supplemental sections (special topics and resources on various types of disasters). The five modules are: (1) Complete a Personal \& Household Assessment, (2) Develop a Personal Emergency Network, (3) Develop Emergency Information \& Gather Important Documents, (4) Keep a 3-5 Day Supply of Medications \& Medical Supplies, and (5) Build an Emergency Supply Kit. Through an initial visit (IV1) and a follow-up phone conversation 4 weeks later (IV2), the interventionist will develop a personalized disaster management plan and provide it to the participant for sharing with family and friends. Eight weeks after the initial session, the interventionist will make a final follow-up call (IV3) to provide any additional assistance caregivers may need.
224321665|NCT04009681|DRUG|THOR-707|Pharmaceutical form: solution for intravenous (IV) administration; Route of administration: IV administration
224321666|NCT04009681|DRUG|Checkpoint inhibitor|Pharmaceutical form: solution for IV administration; Route of administration: IV administration
224245037|NCT04514393|DRUG|Temozolomide|Oral temozolomide will be given at 150mg/m2 from day1 to day 5 every 4 of all cycles，for up to 4 cycles.
223665161|NCT03254459|DRUG|Morphine|4 mg Intravenous Injection
223665162|NCT03254459|DRUG|Oxycodone Hydrochloride|10 mg tablet
224245038|NCT01461850|DRUG|Neoadjuvant chemotherapy + Interval Debulking Surgery|Patients with suspected advanced ovarian cancer (FIGO stage IIIC) will undergo only to diagnostic laparoscopy. Omental cake, diaphragmatic or peritoneal extensive carcinomatosis, tumor diffusion to the small and large curvature of the stomach, large and/or small bowel mesentery disease, spleen and/or liver metastases will be investigated in order to obtain a laparoscopic score. After neoadjuvant chemotherapy interval debulking surgery will be performed: total hysterectomy, bilateral salpingo-oophorectomy, radical omentectomy, appendectomy, pelvic and paraaortic lymphadenectomy, eventual bowel resection, eventual bladder resection, eventual splenectomy, eventual parietal and diaphragmatic peritonectomy, eventual gastric resection, eventual hepatic resection, eventual pancreas resection, eventual cholecystectomy.
223770427|NCT06050421|OTHER|Treatment As Usual|he TAU condition will follow the standard treatment of the EDs Unit of the HSCSP for AN. This treatment consists of visits with a psychiatrist with a frequency decided according to the clinical situation and, in some cases, nursing follow-up and/or relapse prevention group that takes place twice per month
223770428|NCT06050421|OTHER|No intervention|All controls will complete data collection notebook and will undergo the same neuroimaging acquisition. There will not be follow-up for this group.
224245039|NCT01461850|PROCEDURE|Primary Debulking Surgery + Adjuvant Chemotherapy|Patients with suspected advanced ovarian cancer (FIGO stage IIIC) will undergo to diagnostic laparoscopy. Omental cake, diaphragmatic or peritoneal extensive carcinomatosis, tumor diffusion to the small and large curvature of the stomach, large and/or small bowel mesentery disease, spleen and/or liver metastases will be investigated in order to obtain a laparoscopic score. Then, an attempt of laparotomic cytoreduction will be performed: total hysterectomy, bilateral salpingo-oophorectomy, radical omentectomy, appendectomy, pelvic and paraaortic lymphadenectomy, eventual bowel resection, eventual bladder resection, eventual splenectomy, eventual parietal and diaphragmatic peritonectomy, eventual gastric resection, eventual hepatic resection, eventual pancreas resection, eventual cholecystectomy.
224245040|NCT05439824|BIOLOGICAL|SYS6006 20 μg|SARS-CoV-2 mRNA Vaccine
224245041|NCT05439824|BIOLOGICAL|SYS6006 30 μg|SARS-CoV-2 mRNA Vaccine
224245042|NCT05439824|BIOLOGICAL|Placebo|Placebo
224245043|NCT00439075|PROCEDURE|CPAP|
224245044|NCT00439075|DRUG|standard treatment|
223665163|NCT03254459|DRUG|Zofran|4 mg oral disintegrating tablet (ODT) or IV injection given at the investigator's discretion for nausea
223665164|NCT00727441|BIOLOGICAL|GVAX pancreatic cancer vaccine|Given intradermally
223770429|NCT01566136|BEHAVIORAL|Rehabilitation Model of Care|The PCRM-CI model includes the following 5 components: rehabilitation management; dementia management; delirium prevention and management; staff education and support; and family/significant other support and education.
223770430|NCT01626365|PROCEDURE|non-thermosoftening|Intubation is performed with a double-lumen tube put into normal saline at room temperature.
223665165|NCT00727441|DRUG|cyclophosphamide|Given IV (Arm B), given orally (Arm C)
223665166|NCT03038477|DRUG|Durvalumab|1500mg of Durvalumab will be given every 4 weeks (Q4W) for 12 months in patients enrolled in Arm A.
223665167|NCT04837352|OTHER|Study of the role of sociocognitive factors|Questionnaires
223665168|NCT00535288|DRUG|Esmirtazapine|Four different doses (2.25, 4.5, 9.0, and 18 mg) encapsulated esmirtazapine tablets in Swedish Orange hard gelatin DB-B capsules for blinding purposes. Encapsulated tablets were administered orally once daily in the evening prior to sleep for 12 weeks.
223665169|NCT00535288|DRUG|Placebo|Encapsulated placebo tablets in Swedish Orange hard gelatin DB-B capsules for blinding purposes. Encapsulated tablets were administered orally once daily in the evening prior to sleep for 12 weeks.
223665170|NCT06505733|BEHAVIORAL|postnatal attendant training|"Intervention Group: Training and counselling will be provided to the puerperant and companions before discharge in a quiet and stimulus-free environment using the Companion Training Guide. Research data will be collected three times: pre-test data, after the training and on the tenth day."
223665171|NCT00965640|DRUG|Botulinum Toxin - A injections|
223770431|NCT01626365|PROCEDURE|thermosoftening|Intubation is performed with a double lumen tube put into warm normal saline (40°C).
223770432|NCT01825551|DRUG|Granulocyte Colony Stimulating Factor|
223770433|NCT01825551|DRUG|Placebo|
224245045|NCT03876054|DEVICE|Spinal cord stimulation (SCS)|Subjects will be implanted with market-released Abbott SCS systems
224245046|NCT03876054|DEVICE|Dorsal root ganglion stimulation (DRG)|Subjects will be implanted with market-released Abbott DRG system
224245047|NCT01698476|DRUG|vitamin D (cholecalciferol) and PBA (sodium phenylbutyrate)|Dose of interventions: 5,000 IU of vitamin D (cholecalciferol tablets) once daily and 500 mg PBA (sodium phenylbutyrate tablets) twice daily for 16 weeks.
224245048|NCT01698476|DRUG|Placebo tablets|
223665172|NCT02480140|OTHER|Self-regulated constraint-induced movement therapy|There were 10 tasks to practice in total, they included fold laundry, put clothes on hanger, brush teeth, dress upper garment, dress lower garment in week one; and use telephone, prepare a cup of tea, sweep floor, wash towel, wash dishes in week two. In the 4 hours when the participants had their non-hemiplegic arm in the restrain, they received one hour therapist-guided training using SR strategy on task relearning as described above. Therefore, all participants received 10 one-hour therapist-guided training sessions (daily on weekdays, total two weeks). The intervention was delivered by occupational therapist. For the rest of the 3 hours in the restrain, the participants' wearing of the restrain was monitored by the nursing staff in the ward.
223770434|NCT01816620|DRUG|Lenalidomide, Dexamethasone|"12 cycles of lenalidomide and dexamethasone, each cycle lasts 28 days. For patients with Ccr equal to or higher than 30ml/min, oral lenalidomide 10mg once daily for days 1-21 out of a 28 cycle.~For patients with Ccr lower than 30ml/min, oral lenalidomide 10mg once every other day for days 1-21 out of a 28 cycle.~All the patients take Dexamethasone orally 40mg once weekly for day 1,8,15,22 out of a 28 cycle."
223770435|NCT05346510|PROCEDURE|ALND Group|ALND is performed in patients with positive axillary lymph nodes on CT scan and on AAUS. pALND is performed in patients with negative axillary lymph nodes on CT scan but positive on AAUS.SLNB will be performed for those with negative axillary lymph nodes on CT scan and on AAUS.
223770436|NCT04276272|OTHER|Imaging scan|PET/CT scan
223770437|NCT02864017|PROCEDURE|Enteral nutrition|
223770438|NCT02864017|DIETARY_SUPPLEMENT|L-Citrulline|
223770439|NCT02864017|DIETARY_SUPPLEMENT|Placebo|
223770440|NCT02805842|DRUG|Tacrolimus BID|Administration of Tacrolimus BID
223770441|NCT02805842|DRUG|Advagraf QD|administration of Advagraf QD
223770442|NCT02991209|DRUG|Testosterone|
224245049|NCT00818337|DRUG|Aspirin|Aspirin 81mg and Aspirin 325mg, non-enteric coated, take one tablet by mouth daily
224245050|NCT06280690|DRUG|SGM-101|SGM-101 is cea-targeted fluorescent dye
224245051|NCT03361228|DRUG|INCB001158|Phase 1: INCB001158 administered orally twice daily at the protocol-defined dose. Phase 2: INCB001158 administered orally twice daily at the recommended dose from Phase 1.
224245052|NCT03361228|DRUG|Epacadostat|Epacadostat at the protocol-defined dose administered orally twice daily.
224245053|NCT03361228|DRUG|Pembrolizumab|Pembrolizumab at the protocol-defined dose administered intravenously every 3 weeks.
224245054|NCT03079271|DRUG|Lacrisert, 5 Mg Ophthalmic Insert|
224245055|NCT05339802|COMBINATION_PRODUCT|9MW1411 injection 1 combined with Linezolid|After randomization, 9MW1411 injection, single dose, intravenous infusion, linezolid: 600mg, given intravenously or orally every 12 hours, for a total course of treatment not exceeding 14 days.
224245056|NCT05339802|COMBINATION_PRODUCT|9MW1411 injection 2 combined with Linezolid|After randomization, 9MW1411 injection, single dose, intravenous infusion, linezolid: 600mg, given intravenously or orally every 12 hours, for a total course of treatment not exceeding 14 days.
224245057|NCT05339802|COMBINATION_PRODUCT|9MW1411 injection placebo combined with Linezolid|After randomization, 9MW1411 injection placebo, single dose, intravenous infusion, linezolid: 600mg, given intravenously or orally every 12 hours, for a total course of treatment not exceeding 14 days.
224245058|NCT04862702|DEVICE|mechanical instrumentation using rotary file system|the mechanical preparation will be performed using rotary file system
223770443|NCT02991209|DRUG|Placebos|
223770444|NCT04841564|PROCEDURE|ultrasound approach of serratus anterior block|After induction of general anesthesia, the ultrasound probe will be placed longitudinally oblique just below the mid-clavicle. After identifying the second rib, the probe will be moved caudally and laterally (obliquely), towards the mid-axillary line to identify the 3rd, 4th and 5th ribs.. The fascial plane between the serratus anterior muscle and latissimus dorsi muscle will be identified over the 4th rib in the mid-axillary region. The block will be performed with a needle (22-G, 50-mm) introduced in-plane to enter deep to the serratus anterior muscle, and 30 ml 0.25 bupivacaine will be injected.
223770445|NCT04841564|PROCEDURE|open approach of serratus anterior block|After resection of the breast and identification of the serratus anterior muscle, the surgeon will be asked to palpate the ribs below the clavicle and localize the fourth rib. A 22-G, 50-mm needle will be introduced deep to the serratus anterior muscle contacting the rib, and 30 ml 0.25 bupivacaine will be injected.
224245059|NCT03660839|DRUG|Artefenomel (OZ439)|Pharmaceutical form: Granules for oral suspension Route of administration: Oral
224245060|NCT03660839|DRUG|Ferroquine (SSR97193)|Pharmaceutical form: Capsule Route of administration: Oral
224245061|NCT00665821|BEHAVIORAL|Classic back pain prevention education, and cognitive behavioral management.|Classic education: postural hygiene, Back Guide. Cognitive behavioral management: active management, Back Book.
224245062|NCT00665821|BEHAVIORAL|General health education|General health education: a booklet describing general norms for maintaining good health
224245063|NCT02328443|DRUG|Midazolam|
224245064|NCT02328443|DRUG|itraconazole|
224245065|NCT02328443|DRUG|rifampicin|
224245066|NCT03123237|DIAGNOSTIC_TEST|DMSA scan|We explore the possible role of DMSA to detect renal affection in diabetic \&/or hypertensive patients by detecting difference in counts using Tc 99m DMSA in control \& diabetic \&/or hypertensive patients.
224245067|NCT01358565|DRUG|Fx-1006A|A single oral 20 mg dose of Fx-1006A will be administered on Day 1 followed by 16 days of follow-up.
224245068|NCT01358565|DRUG|Fx-1006A|A single oral 20 mg dose of Fx-1006A will be administered on Day 1 followed by 16 days of follow-up.
224245069|NCT00985257|DEVICE|DIDGET (Investigational Blood Glucose Monitoring System)|Subjects with diabetes (with parent/guardian assistance, if applicable)and health care professionals (HCPs) each performed duplicate Blood Glucose (BG) tests from the subject's capillary blood on the DIDGET. To test the full range of glucose concentrations, a venipuncture was performed on some subjects to obtain enough blood for modifying (spiking or glycolyzing) to the extreme glucose concentrations. Results were compared to a laboratory glucose method - the Yellow Springs Instrument (YSI) Analyzer.
224245070|NCT05983874|BIOLOGICAL|BG505 SOSIP.664 gp140 Vaccine, Adjuvanted (3M-052 AF plus alum) Dosage|100µg Month 0 and Month 3
224245071|NCT03963063|PROCEDURE|Goal-directed fluid therapy|"Patients in the group will follow our mini-fluid challenge test goal-directed therapy protocol, maintaining:~* individualized optimised stroke volume by mini-fluid challenge first~* keep mean arterial pressure ≧65 mmHg~* keep systolic blood pressure ≦140 mmHg~* keep cardiac index ≧ 2.5 L/min/cm2"
223665173|NCT02480140|OTHER|Constraint-induced movement therapy|They practised the same 10 tasks as in the SR-CIMT and control groups. The same as the experimental intervention group (SR-CIMT), in the 4 hours when the participants had their non-hemiplegic arm in the restrain, they received one hour therapist-guided training using the strategy on task relearning as described above. Therefore, all participants received 10 one-hour therapist-guided training sessions (daily on weekdays, total two weeks). The intervention was delivered by occupational therapist. For the rest of the 3 hours in the restrain, the participants' wearing of the restrain was monitored by the nursing staff in the ward.
223665174|NCT02480140|OTHER|Conventional occupational therapy|They practised the same 10 tasks as in the SR-CIMT group described above. They received training for 2 weeks, 5 days a week (therapy days), the same as in the SR-CIMT and CIMT groups.
223665175|NCT04549402|OTHER|Mirror Therapy group|The intervention protocol will be carried out under the same environmental conditions and, as far as possible, on time. The intervention will last 4 weeks, with a periodicity of 7 weekly sessions. In total there will be 28 sessions lasting between 15 and 45 minutes depending on the number of joints affected.
223665176|NCT04549402|OTHER|Video group|The intervention protocol will be carried out under the same environmental conditions and, as far as possible, on time. The intervention will last 4 weeks, with a periodicity of 7 weekly sessions. In total there will be 28 sessions lasting between 15 and 45 minutes depending on the number of joints affected.
223665177|NCT05279391|DRUG|Dexamethasone|Dexamethasone 6-8 mg once daily
223665178|NCT05279391|DRUG|Low molecular weight heparin|Therapeutic doses of LMWH (e.g. Tinzaparin 175IU/kg)
223665179|NCT05279391|DRUG|Anakinra 100Mg/0.67Ml Inj Syringe|IV administration of Anakinra 200 mg/twice daily for 3-6 days, then 100 mg/twice daily, for up to 10 days in total.
223665180|NCT05279391|DRUG|Tocilizumab|IV administration of Tocilizumab as a single dose of 8mg/kg
223665181|NCT05279391|DRUG|Baricitinib|4 mg per os once daily, for up to 14 days (2 mg if GFR: 30 to \<60 ml/min/1.73 m2)
223665182|NCT05279391|DRUG|Dornase Alfa Inhalant Product|Inh. 2,500 U/twice daily, for up to 14 days.
223665183|NCT04313647|BIOLOGICAL|1X level of MSCs-Exo|Once aerosol inhalation of MSCs-derived exosomes (2.0\*10\^8 nano vesicles/3 ml)
223665184|NCT04313647|BIOLOGICAL|2X level of MSCs-Exo|Once aerosol inhalation of MSCs-derived exosomes (4.0\*10\^8 nano vesicles/3 ml)
223665185|NCT04313647|BIOLOGICAL|4X level of MSCs-Exo|Once aerosol inhalation of MSCs-derived exosomes (8.0\*10\^8 nano vesicles/3 ml)
223665186|NCT04313647|BIOLOGICAL|6X level of MSCs-Exo|Once aerosol inhalation of MSCs-derived exosomes (12.0\*10\^8 nano vesicles/3 ml)
223665187|NCT04313647|BIOLOGICAL|8X level of MSCs-Exo|Once aerosol inhalation of MSCs-derived exosomes (16.0\*10\^8 nano vesicles/3 ml)
223665188|NCT02102711|DIETARY_SUPPLEMENT|Vitamin A oral drops|
223665189|NCT00796887|DRUG|Extended-Release Niacin|500mg tablet once daily
223665190|NCT00796887|DRUG|Extended-Release Niacin|1000mg tablet once daily
223665191|NCT00796887|DRUG|Placebo|Placebo tablet once daily
223665192|NCT02176746|BIOLOGICAL|cancer stem cell vaccine|
223770446|NCT05683977|DRUG|durvalumab|Visits will be completed at W0 (durvalumab in combination with chemotherapy initiation) and at regular visits approximately every 6 weeks during the induction period (durvalumab + PE) (W6 and W12), then every two months during the maintenance period (durvalumab alone) for the first year and every three months up to the end of follow-up or the final visit at M36.
223770447|NCT05826964|DRUG|AI+CDK4/6i|"Participants will receive standard of care one of three available AI therapies in combination with one of three available CDK4/6i therapies:~* AI: Anastrozole, Letrozole or Exemestane~* CDK4/6i: Palbociclib, Ribociclib or Abemaciclib"
223770448|NCT05826964|DRUG|SERD+CDK4/6i|"Participants will receive standard of care SERD therapy in the form of Fulvestrant, in combination with one of three one of three available CDK4/6i therapies:~* SERD: Fulvestrant~* CDK4/6i: Palbociclib, Ribociclib or Abemaciclib"
224245072|NCT03963063|PROCEDURE|Non goal-directed fluid therapy|"Patients in the group will receive standard perioperative care at the discretion of care-giving anesthesiologist, maintaining:~* keep mean arterial pressure ≧65 mmHg~* keep systolic blood pressure ≦140 mmHg"
223665193|NCT02776748|DRUG|FTC/TDF PrEP|Daily oral directly observed FTC/TDF PrEP administered to breastfeeding HIV-uninfected women
223665194|NCT01413347|PROCEDURE|pillow|bronchoscopic confirmation of double-lumen tube position with a head on a pillow
223665195|NCT01413347|PROCEDURE|neutral|bronchoscopic confirmation of double-lumen tube position in neutral position of a head
223665196|NCT00642889|DRUG|Safinamide|
223665197|NCT00642889|DRUG|Safinamide|
223665198|NCT00642889|DRUG|Placebo|
223665199|NCT02879331|PROCEDURE|10 coils in upper lobes|
223665200|NCT02879331|PROCEDURE|15 coils in upper and lower lobes|
223665201|NCT02879331|PROCEDURE|cycloergometry|
223665202|NCT04811300|OTHER|There is no intervention|There is no intervention
223665203|NCT05223153|DIAGNOSTIC_TEST|Optical Coherence tomography angiography|Measurement retinal vessel density in the superficial and deep capillary plexuses using OCTA in children with anisometropic amblyopia
223665204|NCT01129583|DRUG|Botulinum Toxin Type A|Injection into the biceps brachii and brachialis immediately following the initial fracture surgery
223665205|NCT01129583|DRUG|Saline|Injection into the biceps brachii and brachialis immediately following the initial fracture surgery
223665206|NCT02600871|DRUG|Provodine|
224245073|NCT01702584|PROCEDURE|stent assisted embolization|stent assisted embolization and anti-thrombotic management
224245074|NCT02193178|DEVICE|comfilcon A Toric|Contact lenses
223665207|NCT02600871|PROCEDURE|Incision and Drainage|
223665208|NCT00204438|DRUG|0.15mg desogestrel /0.03mg ethinyl estradiol|
223665209|NCT04672954|DRUG|Placebo|Placebo matching to 10 mg BI 474121 administered as uncoated tablets with 240 milliliter of water after subjects fasted overnight for at least 10 hours. This arm was part of Part 1: randomised, placebo-controlled, single-blind.
224245075|NCT04219566|DEVICE|VeNS|Non-invasive electrical vestibular nerve stimulation
224245076|NCT04219566|DEVICE|Placebo device|Sham non-invasive electrical vestibular nerve stimulation
224245077|NCT02719249|OTHER|Dried blood spot test|
224245078|NCT02344784|DEVICE|SR-HLAB EMG|Prepulse inhibition test using SR-HLAB EMG device will record the acoustic startle response for each participant: with and without Methylphenidate treatment
224245079|NCT02344784|DRUG|Methylphenidate|The regular daily dose of P.O methylphenidate of each participant will be given directly after the first prepulse inhibition test
224245080|NCT04619810|OTHER|Nurse intervention program|Implementation of a specific care program for patients receiving immunotherapy for lung cancer
224245081|NCT04063358|DRUG|Lucentis|Lucentis 0.5 MG Per 0.05 ML Injection
224245082|NCT03151057|DRUG|Idelalisib 100 MG|100mg BID beginning on day 90 (+/- 10days) and continuing until day 270 post transplant.
224245083|NCT03151057|DRUG|Placebo Oral Tablet|placebo
224245084|NCT00128154|DRUG|Chromium picolinate|
224245085|NCT01596166|DRUG|Ketorolac Tromethamine|Ketorolac 0.5 mg/kg (max 30 mg) IV
224245086|NCT01596166|DRUG|Metoclopramide|Metoclopramide 0.2 mg/kg (max 10 mg) IV
224245087|NCT01809171|DRUG|Vitamin D3|ampoule
223665210|NCT04672954|DRUG|2.5 milligram (mg) BI 474121|2.5 mg BI 474121 administered as uncoated tablets (1 x 2.5 mg) with 240 milliliter of water after subjects fasted overnight for at least 10 hours. This arm was part of Part 3 of the study: randomised, open-label.
224245088|NCT01809171|DRUG|Placebo|ampoule
224245089|NCT06150027|OTHER|Systematic referral to a palliative care team|"Patients randomized in the experimental arm will be systematically referred to a palliative care team.~A follow-up in palliative care will be initiated for all within a maximum of 15 days after the date of randomization."
224245090|NCT03540056|DIAGNOSTIC_TEST|Ultrasound|We use ultrasound to measure the PRF and the testicular volumes.
224245091|NCT06282809|DEVICE|HistoSonics Edison™ System for the treatment of pancreatic adenocarcinoma using histotripsy|Histotripsy is a non-thermal, mechanical process of focused ultrasound used to mechanically destroy targeted soft tissue.
223665211|NCT04672954|DRUG|10 milligram (mg) BI 474121|10 mg BI 474121 administered as uncoated tablets (1 x 10 mg) with 240 milliliter of water after subjects fasted overnight for at least 10 hours. This arm was part of Part 3 of the study: randomised, open-label.
224245092|NCT02551445|BEHAVIORAL|Gradual exposure to food stimuli|Patients with anorexia nervosa will be encouraged to confront their fears and avoidance in relation to food and will be gradually exposed to different food items during the sessions.
224245093|NCT00168883|DRUG|Carboplatin|
224245094|NCT00168883|DRUG|Paclitaxel|
224245095|NCT00168883|DRUG|Vinorelbine|
224245096|NCT01582607|DRUG|Bupivacaine plain|2.0 mL (10mg) plain bupivacaine hydrochloride 0.5% intrathecally
224245097|NCT01582607|DRUG|Ropivacaine plain|2.0 ml (15mg) plain ropivacaine 0.75% intrathecally
224245098|NCT01582607|DRUG|Levobupivacaine plain|2.0 ml (10mg) plain levo-bupivacaine hydrochloride 0.5% intrathecally
224245099|NCT01582607|DRUG|bupivacaine plain +fentanyl|2.0 ml (10mg) plain bupivacaine 0.5% with 0.2 ml (10 μg) fentanyl intrathecally
224245100|NCT01582607|DRUG|ropivacaine plain +. fentanyl|2.0 ml (15mg) plain ropivacaine 0.75% with 0.2 ml (10 μg) fentanyl intrathecally
224245101|NCT01582607|DRUG|Levobupivacaine plain +fentanyl|2.0 ml (10mg) plain levo-bupivacaine 0.5% with 0.2 ml (10 μg) fentanyl intrathecally
224245102|NCT02161965|DRUG|Rivaroxaban|20mg or 15mg
223665212|NCT04672954|DRUG|20 milligram (mg) BI 474121|20 mg BI 474121 administered as uncoated tablets (2 x 10 mg) with 240 milliliter of water after subjects fasted overnight for at least 10 hours. This arm was part of Part 1 of the study: randomised, placebo-controlled, single-blind.
223665213|NCT04672954|DRUG|40 milligram (mg) BI 474121|40 mg BI 474121 administered as uncoated tablets (4 x 10 mg) with 240 milliliter of water after subjects fasted overnight for at least 10 hours. This arm was part of Part 2 of the study: non-randomised, open-label.
223665214|NCT04492215|BEHAVIORAL|Interaction between patient and trained general practitioners in motivational interviewing|Impact of the medical interview on the patient
223665215|NCT03515291|BIOLOGICAL|iMP cells|Immunomodulatory progenitor cells
223665216|NCT03515291|OTHER|Control injection|Cell suspension solution
223665217|NCT02363023|PROCEDURE|Collect tracheal and pulmonary secretions|Collect tracheal and pulmonary secretions (endotracheal aspirate, bronchoscopic and non-bronchoscopic bronchoalveolar lavage)
223665218|NCT04743570|DRUG|Placebo treatment|Active drug/placebo is given for the first 5 days of admission.
223665219|NCT04743570|DRUG|Methylnaltrexone treatment|Active drug/placebo is given for the first 5 days of admission.
223665220|NCT03537469|DEVICE|CTU Mega 20 real device|The CTU Mega 20 diamagnetic acceleration system discharges high-field magnetic impulses (with a duration of 5 ms and a period of 1000 ms), generating a magnetic field up to 2 Tesla, with a frequency of 7500 Hz in a volume of approximately 27 cm3.
224245103|NCT02161965|DRUG|Fluindione|
224245104|NCT02161965|DRUG|Warfarin|
224245105|NCT04007133|OTHER|Girerd test|This is a simple and quick questionnaire, composed of 6 questions with a binary yes/no answer. It allows to assess the degree of compliance with the prescribed treatment to better identify the constraints related to the treatment.
224245106|NCT01967108|OTHER|chest physiotherapy|chest physiotherapy, up to one hour from extubation, in ICU patients
224245107|NCT04361266|DEVICE|Rotium nanoscaffold|Rotium bioabsorbable nanoscaffold placed between bone-tendon interface of rotator cuff repair construct
224245108|NCT04361266|PROCEDURE|Control arm rotator cuff repair|Standard rotator cuff repair without Rotium
224245109|NCT01734291|BEHAVIORAL|Family psychoeducation|Family psychoeducational therapy every two weeks for six weeks in addition to treatment as usual administered by physicians
224245110|NCT03979703|OTHER|12 week yoga class|Intervention is a 12 week yoga class with classes twice a week. Each yoga class will last about 1 hour. Furthermore, focus group interviews will be conducted after the first and last yoga class.
224245111|NCT00214422|RADIATION|Radiation|Radiation will be given in dose escalations from 5040 Gray (cGy) to a maximum of 5900 cGy to lymph nodes.
224245112|NCT06287905|DRUG|Prazosin Oral Tablet|1-Dose and administration of prazosin: 30 μg/kg/dose of prazosin will be delivered orally every 6 hours 4 doses, in adults we shouldn't exceed 1 mg per dose. Prazosin will be delivered using a nasogastric tube while securing the patient's airway in the event of vomiting or unconsciousness. Every 30 minutes for the first three hours, every hour for the following six, and then every four hours until improvement, blood pressure, pulse rate, respiration rate, and oxygen saturation will be measured. When pain is the only symptom, prophylaxis shouldn't be given. To avoid the first-dose phenomenon, the patient should remain in a laying position for around 3 hours (even while the case is being examined) (Shoreit et al., 2019).
224245113|NCT05717257|DRUG|Dapagliflozin 10mg Tab|Dapagliflozin 10 mg will be added on top of the standard optimized medical therapy for heart failure and reduced ejection fraction
224245114|NCT03929393|BEHAVIORAL|Mindful Movement|The program focuses on enhancing individuals' mindfulness capabilities and skills, specifically attention regulation, body awareness, emotional regulation, and shifts in self-perception, by providing opportunities for education, practice, and social suppo
224245115|NCT03929393|OTHER|Keys to Health & Wellbeing|This community-based educational program provides participants useful content focused on general health related topics including common chronic conditions, social support, social participation, cancer screening, immunization and keeping active.
224245116|NCT04912739|BEHAVIORAL|Targeted health dialogues|"Before the targeted health dialogue, the participants fill in a questionnaire about health behaviors, background characteristics and self-rated health. Samples for blood glucose and total cholesterol are taken. BMI, waist-to-hip ratio and blood pressure are measured. The results are summoned in a health curve, which is discussed with specially trained healthcare personnel in a Targeted heath dialogue. In a sub-group, blood samples are collected for molecular analyses."
224245117|NCT05789238|BEHAVIORAL|ANVISA|Products carrying front-of-package labels based on Brazil's Health Regulatory Agency (ANVISA's) nutrient profile model
224245118|NCT05789238|BEHAVIORAL|PAHO|Products carrying front-of-package labels based on the Pan-American Health Organization (PAHO's) nutrient profile model
224245119|NCT06158451|COMBINATION_PRODUCT|Zinc oxide propolis|"Propolis liquid (Brazilian Green Bee Propolis Liquid Extract, Uniflora®) and Zinc oxide powder will be mixed on a glass slab with the help of a stainless -steel spatula.~• The mixing ratio of zinc oxide powder and Propolis liquid is 2:1 until a paste like consistency is reached."
224245120|NCT06158451|COMBINATION_PRODUCT|Modified triple antibiotic paste|"Chemotherapeutic agents used are metronidazole tablets 500 mg (Flagyl®, Sanofi, Egypt), ciprofloxacin tablets 500 mg (Ciprofloxacin tablets USP 39®, European pharmaceuticals, Egypt,), and clindamycin capsules 300 mg(Dalacin C™ Pfizer, Egypt).~* After the removal of enteric coating of tablets with the help of blade, the drugs are pulverized into fine powder using sterilized mortar and pestle.~* The same amount of each powdered drug (1:1:1) is mixed to form m-TAP powder which is mixed with one part of propylene glycol (P) and the same volume of macrogol (M) to form a paste like consistency"
224245121|NCT00000132|DRUG|Betaxolol|
224245122|NCT00000132|PROCEDURE|Argon Laser Trabeculoplasty|
224245123|NCT04175379|OTHER|group 40|During surgery, the TV(tidal volume) should maintain 6ml/kg (ideal body weight). After position change and OLV(one lung ventilation) for operation, each patient adjusts RR(respiratory rate) to reach target PaCO2 40 ± 5mmHg. Hemodynamic records and arterial blood tests are performed at the following times: After tracheal intubation, 15 minutes after in two lung ventilatory state at the supine position (T0), after 30 minutes reaching to the target PaCO2 by adjusting RR at the lateral position starting one lung ventilation (T1), and after 60 minutes while maintaining target PaCO2 (T2).
224245124|NCT04175379|OTHER|group 50|During surgery, the TV(tidal volume) should maintain 6ml/kg (ideal body weight). After position change and OLV(one lung ventilation) for operation, each patient adjusts RR(respiratory rate) to reach target PaCO2 50 ± 5mmHg. Hemodynamic records and arterial blood tests are performed at the following times: After tracheal intubation, 15 minutes after in two lung ventilatory state at the supine position (T0), after 30 minutes reaching to the target PaCO2 by adjusting RR at the lateral position starting one lung ventilation (T1), and after 60 minutes while maintaining target PaCO2 (T2).
224245125|NCT04175379|OTHER|group 60|During surgery, the TV(tidal volume) should maintain 6ml/kg (ideal body weight). After position change and OLV(one lung ventilation) for operation, each patient adjusts RR(respiratory rate) to reach target PaCO2 60 ± 5mmHg. Hemodynamic records and arterial blood tests are performed at the following times: After tracheal intubation, 15 minutes after in two lung ventilatory state at the supine position (T0), after 30 minutes reaching to the target PaCO2 by adjusting RR at the lateral position starting one lung ventilation (T1), and after 60 minutes while maintaining target PaCO2 (T2).
224245126|NCT02041169|OTHER|Subsequent walking performance|Subsequent walking performance
224245127|NCT00465764|OTHER|Alternate protein infant formula|Feed as per HCP directions
224245128|NCT00465764|OTHER|Standard infant formula|Feed as per HCP directions
224245129|NCT03380754|DIETARY_SUPPLEMENT|Nutricia preOp|A clear, non-carbonated lemon-flavored, iso-osmolar carbohydrate drink for preoperative surgical patients. Used in studies supporting the Enhanced Recovery After Surgery (ERAS) Society Consensus Guidelines.
224245130|NCT03380754|OTHER|Nestle Splash Lemon Flavor Water (Placebo)|Placebo control drink. PURIFIED WATER, NATURAL FLAVORS, CITRIC ACID, SODIUM POLYPHOSPHATE, POTASSIUM SORBATE (PRESERVE FRESHNESS), POTASSIUM BENZOATE (PRESERVE FRESHNESS), SUCRALOSE, ACESULFAME POTASSIUM, CALCIUM DISODIUM EDTA, MAGNESIUM SULFATE.
224245131|NCT02012153|BIOLOGICAL|Mesenchymal Stromal Cells|
224245132|NCT05614960|OTHER|Dried purple laver (Nori)|Dried purple laver (Nori) that has been test to have bioactivity vitamin B12 will be given for intervention groups.
224245133|NCT04205201|DRUG|Drugs, Investigational|To see the safety and efficacy of topical latanoprost compared with topical brimonidine in the treatment of the primary open angle
224245134|NCT04981938|PROCEDURE|Lobectomy with pulmonary artery reconstruction|"Lobectomy with pulmonary artery reconstruction under general anesthesia with selective intubation, by postero-lateral thoracotomy in the fifth intercostal space~Subgroups : different types of pulmonary artery reconstruction such as :~* Tangential vascular reconstruction with direct suture~* Circumferential resection and end-to-end anastomosis~* bypass reconstruction with heterologous biografts, synthetic grafts, or pericardium patch"
224245135|NCT04150627|OTHER|deep breathing|Deep breathing maneuver to increase parasympathetic nerve activity
224245136|NCT05859841|OTHER|Music listening|Music listening under instruction by music therapist, min 3 hours daily
224245137|NCT05859841|OTHER|Control|Standard treatment, care and rehabilitation
223665221|NCT03537469|DEVICE|CTU Mega 20 sham device|A CTU Mega 20 sham device (with an identical appearance to that of the real device) to avoid treatment identification by the patient or experimenter was used. Of course, the application of this sham device did not provide any magnetic field.
223665222|NCT00003296|BIOLOGICAL|filgrastim|
223665223|NCT00003296|DRUG|pegylated liposomal doxorubicin hydrochloride|
223665224|NCT05269121|BIOLOGICAL|Phage Therapy|Patient will undergo a DAIR procedure. After the DAIR, phage therapy will be administered in conjunction with antibiotic treatment.
224245138|NCT03750097|BEHAVIORAL|Comfortable walking velocity (CWV)|Walking for 250 Steps with self-selected comfortable walking velocity while wearing the two accelerometers (Polar M600 and ActiGraph wGT3X-BT)
224245139|NCT03750097|BEHAVIORAL|Slow walking velocity (SWV: CWV - 20%)|Walking for 250 Steps with slow walking velocity while wearing the two accelerometers (Polar M600 and ActiGraph wGT3X-BT). Slow walking consists of walking with 20% slower than the self-selected comfortable walking velocity by following a researcher who controls the walking velocity with a measuring wheel.
224245140|NCT03750097|BEHAVIORAL|Fast walking velocity (FWV: CWV + 20%)|Walking for 250 Steps with fast walking velocity while wearing the two accelerometers (Polar M600 and ActiGraph wGT3X-BT). Fast walking consists of walking with 20% faster than the self-selected comfortable walking velocity by following a researcher who controls the walking velocity with a measuring wheel.
224245141|NCT04558905|OTHER|Face-to-face medical visits|Face-to-face medical visits
224245142|NCT04558905|OTHER|Alternating face-to-face medical visits and video medical consultations|Alternating face-to-face medical visits and video medical consultations
224245143|NCT02005705|OTHER|Outpatient Management of Low-risk Patients|"* Labs will be obtained within 2-3 days of discharge from ED~* Clinic visit will be scheduled within 3 days of discharge from ED~* EGD will be scheduled within 7 days of discharge from ED~* Phone follow-up at day 7 and 30"
224245144|NCT02005705|OTHER|Inpatient Management of Low-risk Patients|"* Labs will be obtained on day of discharge or day 2-3~* EGD will be performed in the hospital~* Phone follow-up at day 7 and 30"
224245145|NCT06234163|BEHAVIORAL|Assigned intervention|"Enteral and parenteral nutrition training was given face to face, within 15-20 minutes, using oral presentation and written materials (brochures). The content of the Enteral and Parenteral Nutrition Training Guide prepared based on the literature was sent to ten experts in the field. and content validity was done. The training guide includes up-to-date information on topics such as enteral and parenteral nutrition indications and contraindications, evaluation of gastric residual volume, and nursing care in patients receiving enteral and parenteral nutrition."
224245146|NCT02628834|OTHER|Fascial mobilization|The patient will lie on prone position with knee extension and therapist put the patient's plantar surface to her femoral region. Achilles, tibialis posterior, perenous longus and brevis distal tendons, gastrocnemius proximal tendons, hamstring's distal tendons will be mobilized at first stage. The second stage of fascia mobilization included the deep fascial mobilization of posterior crural muscle trunks. After that, the skin also will be gently mobilized. During fascial mobilization, once the spastic muscles relaxation will appeared, the ankle will move to dorsiflexion gradually. FM will carry out for 15 minutes for each foot.
224245147|NCT02628834|OTHER|Stretching Exercise|Patients will receive also stretching exercises consisted of 30 s stretching and 10 s resting periods and will carry out for 15 minutes for each foot at second day after the first evaluation.
223665225|NCT05446831|DRUG|Baricitinib|Oral baricitinib was given at a dose of 4 mg daily. The decision to initiate rescue therapy was made after assessment of the extent of bleeding, patient preferences, lifestyle and activity, the complications of specific therapies, comorbidities that predisposed patients to bleeding and the tolerance of side effects. If a platelet count over 300,000/μL was observed for two consecutive tests at least 2 weeks apart, baricitinib treatment was interrupted.
223665226|NCT02050178|DRUG|OMP-54F28, Nab-Paclitaxel and Gemcitabine|
223770449|NCT05826964|DRUG|mTOR inhibitor + AI|Participants will receive standard of care mTOR inhibitor therapy (Everolimus) in combination with AI therapy (Exemestane) in Step 2 Arm 2 and Step 3. mTOR inhibitor + AI therapy administered as one of the available options for early switch from AI+CDK4/6i or SERD+CDk4/6i therapy in administered in Step 1.
223770450|NCT05826964|DRUG|mTOR inhibitor + SERD|Participants will receive standard of care mTOR inhibitor therapy (Everolimus) in combination with SERD therapy (Fulvestrant), in Step 2 Arm 2 and Step 3. mTOR inhibitor + SERD therapy administered as one of the available options for early switch from AI+CDK4/6i or SERD+CDk4/6i therapy in administered in Step 1.
224245148|NCT07035808|COMBINATION_PRODUCT|2 cycles of combined drug induction therapy: every 3 weeks for 2 cycles; After ,synchronous radiotherapy and chemotherapy combined immunotherapy|The enrolled patients first receive 2 cycles of combined drug induction therapy: paclitaxel+cisplatin/carboplatin ± bevacizumab+QL1706, every 3 weeks for 2 cycles; After induction therapy, synchronous radiotherapy and chemotherapy combined with immunotherapy: extracorporeal irradiation+post loading radiotherapy+synchronous chemotherapy+immunotherapy. During radiotherapy, single agent cisplatin/carboplatin treatment for 5 courses per week+QL1706 treatment every 3 weeks for 3 courses; After the end of radiotherapy and chemotherapy, immune maintenance therapy will be administered for six months: treatment with QL1706 every 3 weeks for 9 courses, followed by a follow-up period until the end of radiotherapy for 2 years or death.
223770451|NCT05826964|DRUG|mTOR inhibitor + Selective estrogen receptor modulator|Participants will receive standard of care mTOR inhibitor therapy (Everolimus) in combination with selective estrogen receptor modulator therapy (Tamoxifen) in Step 2 Arm 2 and Step 3. mTOR inhibitor + Selective estrogen receptor modulator therapy administered as one of the available options for early switch from AI+CDK4/6i or SERD+CDk4/6i therapy in administered in Step 1.
224321667|NCT04009681|DRUG|anti-EGFR antibody|Pharmaceutical form: solution for IV administration; Route of administration: IV administration
224321668|NCT02912559|DRUG|Atezolizumab|Given IV
223665227|NCT03869801|PROCEDURE|erector spinae plane block|Ultrasound-guided bilateral Erector spinae plane (ESP) block performed before the surgery. Perioperative and postoperative routine analgesic protocol will be performed (consist of intravenous analgesics and intravenous patient-controlled analgesia) with no additional intervention (block) Standard Pain Followup and Monitorization will be performed.
223665228|NCT03869801|PROCEDURE|quadratus lumborum block|Ultrasound-guided bilateral Quadratus lumborum (QLB) type 2 block performed before the surgery. Perioperative and postoperative routine analgesic protocol will be performed (consist of intravenous analgesics and intravenous patient-controlled analgesia) with no additional intervention (block) Standard Pain Followup and Monitorization will be performed.
223665229|NCT03381742|DRUG|Ticagrelor|ticagrelor 45 mg twice daily for 5 consecutive days at least.
223665230|NCT03381742|DRUG|ticagrelor|ticagrelor 90 mg once daily for 5 consecutive days at least.
223665231|NCT03381742|DRUG|ticagrelor|ticagrelor 90 mg twice daily for 5 consecutive days at least.
223665232|NCT03381742|DRUG|clopidogrel|clopidogrel 75 mg once daily for 5 consecutive days at least.
223665233|NCT01049945|DRUG|bendamustine hydrochloride|Given IV
223665234|NCT01049945|DRUG|lenalidomide|Given orally
223665235|NCT01049945|DRUG|dexamethasone|Given orally or IV
223770452|NCT05826964|DRUG|PI3K inhibitor + SERD|Participants will receive standard of care one PI3K inhibitor therapy (Alpelisib), in combination with SERD therapy (Fulvestrant) in Step 2 Arm 2 and Step 3. PI3K inhibitor + SERD therapy administered as one of the available options for early switch from AI+CDK4/6i or SERD+CDk4/6i therapy in administered in Step 1.
223770453|NCT05826964|DRUG|PI3K inhibitor + AI|Participants will receive standard of care a PI3K inhibitor therapy (Alpelisib), in combination with an AI therapy (Letrozole) in Step 2 Arm 2 and Step 3. PI3K inhibitor + AI therapy administered as one of the available options for early switch from SERD+CDk4/6i therapy in administered in Step 1.
224245149|NCT07035782|DEVICE|temperature monitoring|Core temperature will be measured in the distal esophagus. The esophageal probe will be inserted after intubation to the depth from the upper incisors recommended by Bloch et al,1 specifically one-quarter of the patient's height plus 4.5 cm.
224245150|NCT07035782|DRUG|Sevoflurane|Anesthesia induction will be standardized for all participants., the children will undergo inhalational induction using 8% sevoflurane with a fresh gas flow of 5 L/min in 100% oxygen. Once children loses consciousness, the sevoflurane concentration will be reduced to 3%-5% and then maintained as close as possible to 1.2 MAC, age-adjusted
224245151|NCT07036497|DRUG|Vitamin B12|Vitamin B12 treatment was initiated in male patients with vitamin B12 deficiency due to anemia etiology.
224245152|NCT07037693|DIAGNOSTIC_TEST|Comprehensive complication index (CCI)|Comprehensive complication index (CCI)
223770454|NCT05826964|DRUG|Chemotherapy|Chemotherapy administered standard of care as an alternative therapy in Step 2 Arm 2 and Step 3.
223770455|NCT05826964|DRUG|Oral SERD|Participants will receive standard of care oral SERD therapy (Elacestrant) in Step 2 Arm 2 and Step 3. Oral SERD therapy administered as one of the available options for early switch from AI+CDK4/6i or SERD+CDk4/6i therapy in administered in Step 1.
223770456|NCT05826964|DRUG|PARPi|For participants with germline breast cancer gene (BRCA) mutation(s). Participants will receive standard of care PARPi (Olaparib or Talazoparib) therapy in Step 2 and Step 3.
223770457|NCT05826964|DRUG|AKT inhibitor|For participants with tumors with one or more phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) or AKT serine/threonine kinase 1 (AKT1) or phosphatase and tensin homolog (PTEN) alterations. Participants in Step 2 and Step 3 will receive standard of care AKT inhibitor as an alternative therapy.
223665236|NCT01594437|BIOLOGICAL|TCN-202|Human monoclonal neutralizing antibody that recognizes a broadly conserved functional epitope on HCMV. One or two doses will be administered by intravenous infusion.
223665237|NCT01594437|BIOLOGICAL|Placebo|One or two doses administered by intravenous infusion.
223770458|NCT05826964|OTHER|Step 3 Arm 2|Participants will receive third-line treatment standard of care as per their treating physician's choice according to National Comprehensive Cancer Network (NCCN) guidelines.
223770459|NCT03940209|BEHAVIORAL|Basic needs navigation|Navigators will help participants address unmet basic needs for 6 months by telephone. Either party can initiate a call. On every call, navigators will: (1) review unmet needs previously reported (baseline survey for first call) and ask participants to report new needs; (2) jointly prioritize among multiple needs based on severity and resource availability; (3) identify community resources that could help solve the problem; (4) evaluate eligibility for those resources; and (5) prepare participants to interact with service agencies and/or act as an advocate on their behalf. On each subsequent call, navigators will review progress toward resolving those needs, assess emergent needs, and adapt priorities accordingly. Navigators will provide instrumental and emotional social support through regular friendly contact, and will attempt to reduce barriers to needs resolution to improve stability and security for participants longer-term.
223770460|NCT02438228|OTHER|Cardiac output measurement|Measurement of cardiac output by transpulmonary thermodilution, nine different pulse contour algorithms and esophageal doppler before, during and after a PLR-maneouvre and every 10 minutes before and after cardiopulmonary Bypass.
223770461|NCT01326780|DRUG|1.2% JNJ 10229570-AAA|1.2% JNJ 10229570-AAA 1.2% cream applied once daily to the face for 12 weeks
223770462|NCT01326780|DRUG|2.4% JNJ 10229570-AAA|2.4% JNJ 10229570-AAA 2.4% cream applied once daily to the face for 12 weeks
223770463|NCT01326780|DRUG|3.6% JNJ 10229570-AAA|3.6% JNJ 10229570-AAA 3.6% cream applied once daily to the face for 12 weeks
224245153|NCT07037693|DIAGNOSTIC_TEST|Clavien-Dindo-Classification (CDC)|Clavien-Dindo-Classification (CDC)
224245154|NCT05280132|PROCEDURE|Personalized antibiotic treatment|Personalized antibiotic treatment based on mPCR results, PCT (values and kinetics) and appearance of sputum.
224245155|NCT05280132|OTHER|Usual antibiotic treatment|The antimicrobial therapy is left at the discretion of the physicians, as in usual practice.
224245156|NCT03559023|PROCEDURE|Ultrasound Only|The anesthesia team will use ultrasound to scan on subject's upper back (thoracic spine) to identify a place to begin the epidural procedure. A pen will be used to place markings on subject's back.
224245157|NCT03559023|PROCEDURE|Manometry Only|The anesthesia team will use an extra piece of tubing to confirm the epidural space one the epidural space is established.
224245158|NCT03559023|PROCEDURE|Ultrasound Plus Manometry|The anesthesia team will use both ultrasound and manometry to assist with epidural placement.
223665238|NCT01350193|DEVICE|Manuka Honey|The use of the nasal irrigation on post-operative day #1. 30mL of the nasal irrigation will be applied to each nostril by a 60mL Toomey syringe (given to patient at pre-operative clinic visit) twice a day (once in am, once in pm). This will continue until the 6 month post-op visit.
223665239|NCT01350193|OTHER|Saline Irrigation|The use of the nasal irrigation on post-operative day #1. 30mL of the nasal irrigation will be applied to each nostril by a 60mL Toomey syringe (given to patient at pre-operative clinic visit) twice a day (once in am, once in pm). This will continue until the 6 month post-op visit.
223665240|NCT00224185|PROCEDURE|Bronchopulmonary Lung Lavage|Lung Lavage is a Washing. Bronchoscopy consists of the passage via the mouth or nose of a flexible fiberoptic bronchoscopy into the airways. During the lavage (washing) procedure, sterile 0.9% saline (5 x 20 ml aliquots in 1 to 3 sites) is instilled into the lung and immediately suctioned back, washing off cells lining the airways. Once the fluid has been collected, the fluid is centrifuged and the cells are collected and counted.
223770464|NCT01326780|OTHER|Vehicle control|Color matched cream vehicle, applied once daily to the face for 12 weeks
224321669|NCT02912559|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223665241|NCT00224185|PROCEDURE|Bronchial Brushing|Bronchoscopy consists of the passage via the mouth or nose of a flexible fiberoptic bronchoscopy into the airways. During the brushing procedure, a small cytology brush is passed through the bronchoscope, and a small area of the airway wall is brushed gently (in up to 20 different sites in the large and small airways) to obtain epithelial cells lining the airway. Cells collected by airway brushing will be washed, counted, and evaluated for viability. They will also be studied for differential cell count by standard procedures. Collected airway cells will be used to carry out studies assess expression of various genes and to study viral gene transfer.
223770465|NCT02506114|BIOLOGICAL|PROSTVAC V/F|PROSTVAC-V/F is a prostate-specific antigen(PSA)-based immunization strategy. It is intended to generate immune responses to prostate specific antigens and prostate cancer cells. It uses poxviral vectors to introduce modified PSA to the patient in an immunogenic manner to break self-tolerance, and thereby induce immune responses directed against prostate cancer cells.
224245159|NCT03559023|PROCEDURE|Usual Care/Management|"The epidural will be placed using the usual technique utilized by the anesthesiology department. The the usual care/management group will receive a sham (fake) ultrasound exam of subject's upper back with fake pen markings placed on subject's back. The ultrasound machine will not be turned on."
224245160|NCT06894355|OTHER|hydrotherapy|hydrotherapy in addition to physical therapy
224245161|NCT06894355|OTHER|control group|regular physical therapy treatments
224245162|NCT05822089|PROCEDURE|phacoemulsification and intraocular lens implantation|bilateral cataract surgery including phacoemulsification in individuals suffering from age-related cataract and intraocular lens implantation of a monofocal IOL (ZCB00) vs. an enhanced monofocal IOL (ICB00)
223665242|NCT00224185|PROCEDURE|Bronchial Wall Biopsy|This is a safe and widely used investigative method in pulmonary medicine. In this procedure, a small biopsy forceps is passed through the bronchoscope and, under direct vision, a small biopsy (in up to 5 sites) is obtained from the bronchial wall. A biopsy obtains tissue to a depth of 2-3 mm, and includes epithelial and subepithelial tissue.
224245163|NCT05822089|PROCEDURE|phacoemulsification and intraocular lens implantation|bilateral cataract surgery including phacoemulsification in individuals suffering from age-related cataract and intraocular lens implantation of a monofocal IOL (Sensar 1 AAB00) vs. an enhanced monofocal IOL (ICB00)
224245164|NCT05822089|PROCEDURE|phacoemulsification and intraocular lens implantation|bilateral cataract surgery including phacoemulsification in individuals suffering from age-related cataract and intraocular lens implantation of a monofocal IOL (Vivinex XY1) vs. an enhanced monofocal IOL (Vivinex impress)
224245165|NCT05822089|PROCEDURE|phacoemulsification and intraocular lens implantation|bilateral cataract surgery including phacoemulsification in individuals suffering from age-related cataract and intraocular lens implantation of an enhanced monofocal IOL (Vivinex impress) in both eyes
224245166|NCT05822089|PROCEDURE|phacoemulsification and intraocular lens implantation|bilateral cataract surgery including phacoemulsification in individuals suffering from age-related cataract and intraocular lens implantation of an enhanced monofocal IOL (EnVista) vs. an enhanced monofocal IOL (LuxSmart)
224245167|NCT05822089|PROCEDURE|phacoemulsification and intraocular lens implantation|bilateral cataract surgery including phacoemulsification in individuals suffering from age-related cataract and intraocular lens implantation of an extended depth of focus IOL (Acrysof IQ Vivity) in both eyes if low to moderate irregular astigmatism is observed
224245168|NCT05822089|PROCEDURE|phacoemulsification and intraocular lens implantation|bilateral cataract surgery including phacoemulsification in individuals suffering from age-related cataract and intraocular lens implantation of an extended depth of focus IOL (IC-8 Apthera) in one eye if irregular astigmatism is observed
224245169|NCT03716011|DEVICE|EXCROSSAL|a Second Generation Biodegradable Polymer Sirolimus-Eluting Stent
224245170|NCT06756607|OTHER|SUPPORT toolkit|The SUPPORT toolkit comprises of the SUPPORT CT website and interaction with a SUPPORT navigator.
223665243|NCT00291213|DRUG|levetiracetam|
223665244|NCT00291213|DRUG|placebo|
224245171|NCT04137393|COMBINATION_PRODUCT|brushing|mechanical and chemical plaque removal
224245172|NCT00633256|DRUG|Cycloserine|50 mg Cycloserine given in two separate experimental sessions separated by approximately one week.
224321670|NCT02912559|PROCEDURE|Computed Tomography|Undergo CT
224321671|NCT02912559|DRUG|Fluorouracil|Given IV
223665245|NCT01579851|DRUG|Sugammadex|"sugammadex~* 4 mg/kg : if there is no response to Train of Four stimulations and at least one response to the Post Tetanic Count~* 2 mg/kg : if there is at least two responses to Train of Four stimulations"
223770466|NCT02506114|DRUG|Ipilimumab|
224245173|NCT00633256|DRUG|Placebo|Matched placebo for subjects randomized to placebo arm. Given in two experimental sessions separated by approximately one week.
224245174|NCT00081952|DRUG|L-norleucine|
224245175|NCT01415700|DEVICE|Functional electrical stimulator|The stimulator is surgically implanted
224245176|NCT01415700|DEVICE|feet orthosis|feet orthosis specifically mold
224245177|NCT00911898|DRUG|MM-111|For Phase 1: Dose-escalation cohorts, drug is administered weekly via IV
224245178|NCT05437744|OTHER|Cyanoacrylate glue|8 sockets that will be treated by immediate implant placement and sealed by a Cyanoacrylate glue.
224245179|NCT05437744|OTHER|Platelet-rich fibrin (PRF)|8 sockets that will be treated by immediate implant placement and sealed by PRF.
224245180|NCT06131502|DEVICE|ExAblate MR-guided Focused Ultrasound Bilateral Anterior Capsulotomy|The ExAblate transcranial system combines a focused ultrasound surgery delivery system and a conventional diagnostic 3T MRI scanner. The ExAblate transcranial system provides real-time therapy planning algorithm, thermal dosimetry, and closed-loop therapy control.
224245181|NCT05843279|PROCEDURE|Myofunctional therapy|In one group, physiotherapy intervention is performed on the orofacial structures of the baby and in another group, the posture presented by the mother while breastfeeding her baby is corrected.
224321672|NCT02912559|DRUG|Leucovorin Calcium|Given IV
224321673|NCT02912559|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
224321674|NCT02912559|DRUG|Oxaliplatin|Given IV
224321675|NCT02912559|OTHER|Quality-of-Life Assessment|Ancillary studies
224321676|NCT04092283|DRUG|Carboplatin|Given IV
224321677|NCT04092283|DRUG|Cisplatin|Given IV
224321678|NCT04092283|BIOLOGICAL|Durvalumab|Given IV
224321679|NCT04092283|DRUG|Etoposide|Given IV
224321680|NCT04092283|DRUG|Paclitaxel|Given IV
224245182|NCT02214264|BEHAVIORAL|Loving-Kindness meditation training|Participants undergo training for approximately 12 minutes. Training involves guided reflections and intentions related to feeling loving-kindness towards the self and others.
223665246|NCT00121043|DEVICE|SimpleJectTM|
223665247|NCT00121043|DRUG|Kineret® (Anakinra)|
223770467|NCT03713489|PROCEDURE|platelet|Participants in platelet transfusion group will receive one unit of apheresis platelets transfusion 3 times for the first week after enrollment, then 2 times a week in the following three weeks.
223665248|NCT04494568|DEVICE|HIFU treatment|HIFU Treatment of rectal endometriosis
223665249|NCT03135119|BEHAVIORAL|TF-CBT|TF-CBT is typically described as including 3 phases, each focusing on a common goal and encompassing a third of treatment (4 sessions). The first phase focuses on skills-building and includes psychoeducation, parenting skills training, relaxation skills training, affect modulation skills training, and cognitive coping skills training. The second phase involves focused gradual exposure activities, including construction of a narrative account of the child's maltreatment experiences and cognitive processing of maladaptive thoughts. The third phase emphasizes the child's mastery over environmental reminders of the maltreatment and includes sharing the trauma narrative with the caregiver, in vivo exposure to physical stimuli, and enhancing future development.
223665250|NCT03135119|BEHAVIORAL|TF-CBT+AAT|TF-CBT, as described in the other arm, with animal-assisted therapy as an adjunct intervention. During the administration of TF-CBT, a certified service dog will be in the room and the participant may elect to interact with the dog as various points throughout the sessions.
223665251|NCT00858572|DRUG|STA-9090 (ganetespib)|Chemotherapy agent
223770468|NCT05241067|DRUG|Normal Saline|Placebo (Dose: equal volume saline) + Standard of care
223770469|NCT05241067|DRUG|Centhaquine|Centhaquine (Dose: 0.01 mg/kg) + Standard of care
223770470|NCT00287911|DRUG|cisplatin|intravenously (IV) over 1 hour on days 1, 8, 15, 22, 29, and 36
223770471|NCT00287911|DRUG|topotecan hydrochloride|intravenously continuously on days 1-5, 8-12, 15-19, 22-26, 29-33, and 36 -Cohorts of 3-6 patients receive escalating doses of topotecan until the maximum tolerated dose (MTD) is determined
223770472|NCT00287911|RADIATION|brachytherapy|Some patients may also undergo brachytherapy
223770473|NCT00287911|RADIATION|radiation therapy|once daily on days 1-5, 8-12, 15-19, 22-26, 29-33, and 36
223770474|NCT02684591|DRUG|Aramchol|Aramchol, a conjugate of Cholic acid and Arachidic acid, is a first in class member of a novel family of synthetic Fatty-Acid / Bile-Acid Conjugates (FABACs). FABACs are composed of endogenic compounds, orally administrated with potentially good safety and tolerability parameters
224245183|NCT02214264|BEHAVIORAL|Breath Awareness meditation training|Participants undergo training for approximately 12 minutes. Training involves guided awareness focused on sensations of breathing.
224245184|NCT02214264|BEHAVIORAL|Gratitude|Participants undergo training for approximately 12 minutes. Training involves reflections of gratitude for people, events, and things in one's life.
224245185|NCT02214264|BEHAVIORAL|Control|Participants will write and then think about the physical space in which they live (i.e., their home) for approximately 12 minutes.
224245186|NCT02341261|BEHAVIORAL|Standard Care Counseling|
224245187|NCT02341261|BEHAVIORAL|Supervised Exercise and Counseling|
224245188|NCT04373278|OTHER|failure of reconstruction of the mandibule by free fibula flap|description of failure of reconstruction of the mandibule by free fibula flap:delay, type of bacteria involved in the failure, treatment, outcome
224245189|NCT05254301|OTHER|Intervention group|This personalised multimodal treatment considers evidence- and practice-based elements (e.g., self-management, individual guidance \& follow-up, low-threshold activities, homebased functional training \& better follow-up guidance afterwards).
224245190|NCT05197322|DRUG|Pembrolizumab|Dose: 200mg by IV infusion on Day 1 of each treatment cycle
224245191|NCT03412357|PROCEDURE|pleurectomy/decortication|"VAT-PD is a type of keyhole surgery performed under general anaesthesia using a telescope and instruments put inside the chest. Through small incisions, or keyholes made between the ribs, the thoracic surgeon removes the hard rind of the tumour over the surface of the lung, thereby allowing the 'trapped' lung to fully expand again. Simultaneous removal of mesothelioma from the outer pleural membrane allows pleurodesis to occur."
224245192|NCT03412357|PROCEDURE|indwelling pleural catheter|A soft silicone catheter (IPC) with a one-way valve at the end is inserted a few centimetres under the skin under local anaesthesia. The inside end of the catheter is inserted into the pleural space and the outside end is connected to a vacuum drainage bottle. The IPC permits regular fluid drainage.
224245193|NCT02992938|DRUG|Acetazolamide|
224321681|NCT04092283|DRUG|Pemetrexed Disodium|Given IV
223665252|NCT03897439|DRUG|Nicotine patch|Participants will receive the 24-hour 21mg nicotine patch for up to 18 weeks of treatment.
223665253|NCT03897439|DRUG|Varenicline Tartrate|VAR will be dispensed 0.5 mg once daily on Days 1-3, 0.5 mg twice daily on Days 4-7, and 1 mg twice daily from Day 8 through the end of treatment.
223665254|NCT03897439|DRUG|Bupropion|BUP will be dispensed 150 mg once daily on Days 0-3 and then 150 mg twice daily from Day 4 through optimization or the end of treatment.
223665255|NCT03584581|DIETARY_SUPPLEMENT|Olive polyphenols|The amount of polyphenols to be supplied is within the ranges of absolute biosecurity food described by different authors and used in different studies.
223665256|NCT03584581|DIETARY_SUPPLEMENT|Control|Placebo
223770475|NCT02684591|DRUG|Placebo|Placebo
224321682|NCT02834013|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
224321683|NCT02834013|PROCEDURE|Computed Tomography|Undergo CT
223770476|NCT05477004|DRUG|Ketamine|A multi-day continuous ketamine infusion delivered intravenously at subanesthetic doses in a monitored setting
223770477|NCT06325774|RADIATION|Hypofractionated radiation therapy|54 Gy in 15 daily fractions of 3.6 Gy to the prostate bed in the absence of disease progression or unacceptable toxicity.
223770478|NCT04101526|BEHAVIORAL|Spanish-language Cognitive-Behavioral Therapy for Insomnia (CBT-I) delivered via videoconference|Six sessions of Spanish-language Cognitive-Behavioral Therapy for Insomnia (CBT-I) delivered via videoconference. Sessions address topics such as sleep education, sleep hygiene, sleep restriction, stimulus control, relapse prevention, and cognitive restructuring.
223770479|NCT04206163|DIAGNOSTIC_TEST|68Ga-DOTA-TOC PET/CT|Somatostatin receptor imaging
223770480|NCT04206163|BIOLOGICAL|Blood sample|Analysis of inflammatory biomarkers
224245194|NCT02992938|DRUG|Placebo Oral Tablet|
224245195|NCT02087514|PROCEDURE|Blood Transfusion|A routine medical procedure in which blood is given through an intravenous (IV) line a blood vessel.
224245196|NCT02087514|OTHER|Packed red blood cells|"Red blood cells that have been collected, processed, and stored in bags as blood product units available for blood transfusion.~A standard autologous leukoreduced packed red blood cell unit will be collected and stored in AS-3 solution in the Columbia University Medical Center blood bank.~The number of weeks in storage are as follows:~* 1 week~* 2 weeks~* 3 weeks~* 4 weeks~* 5 weeks~* 6 weeks"
224245197|NCT05961423|PROCEDURE|Robotic surgery|The patient group undergoing robotic surgery for the treatment of locally advanced colorectal cancer
224245198|NCT00705536|DRUG|Humalog|
224245199|NCT00705536|DRUG|Humulin-R|
224245200|NCT00705536|DRUG|Recombinant human hyaluronidase PH20 (rHuPH20)|
224245201|NCT01382641|DEVICE|Hoya AF-1 IOL|The patients will be assessed for three months
224245202|NCT01382641|DEVICE|Revital vision|The patients will be assessed for three months.
224245203|NCT04188106|DRUG|Varenicline Pill|FDA approved starter kit of varenicline (0.5 mg nightly for days 1-3, then 0.5 mg twice daily for days 4-7) followed by FDA-approved dose of varenicline (1 mg twice daily) for the remaining 11 weeks
224245204|NCT04188106|DRUG|Hydroxyzine Pill|For the first week, participants will receive 50 mg nightly for the first 3 days, then twice daily, 25 mg in the morning and 50 mg at night for the remaining 12 weeks.
223665257|NCT03278704|OTHER|RE only|8 weeks of supervised training. Three times weekly with no more than two non-consecutive days without exercise.
223665258|NCT03278704|OTHER|RE + HIIT|8 weeks of supervised training. Three times weekly with no more than two non-consecutive days without exercise. Concurrent training: RE followed by HIIT within the same session.
223665259|NCT05975398|PROCEDURE|Emergency neurosurgery|Surgical evacuation for intracerebral hemorrhage
223665260|NCT05975398|PROCEDURE|Conservative treatment|Standard treatment for intracerebral hemorrhage
223665261|NCT04605705|COMBINATION_PRODUCT|Optimization of the cardiac output, the temperature, the hemoglobin in order to have the NIRS value by up to 80%.|Several maneuvers will be performed in case the NIRS values are below 50%, such as an increase in cardiac output, temperature, hemoglobin to optimize the NIRS value by up to 80%.
223665262|NCT02047344|DRUG|Antroquinonol|patients will receive one 12 week cycle of antroquinonol 200 mg t.i.d. or until disease progression, unacceptable toxicity, non compliance or withdrawal of consent by the patient, or the investigator decides to discontinue treatment, whichever comes first.
223770481|NCT06358677|DRUG|Topical Tretinoin|Topical tretinoin will be applied to one half of the face, either left or right side. The side the topical tretinoin will be applied to will be randomized.
223770482|NCT06358677|OTHER|Placebo|A placebo (topical moisturizer) will be applied to the other half of the face, either left or right side. The side the topical tretinoin will be applied to will be randomized.
224245205|NCT02236247|DRUG|ivabradine|5 mg oral twice daily
224245206|NCT02236247|DRUG|Placebo|A placebo pill (identical to ivabradine) will be administered twice daily
224245207|NCT04763746|DEVICE|Lifelight Data Collect Sub-protocol 1|"Study nurse 1 will announce when the 60-second period of Lifelight® measurement begins and ends, guided by the timer on the software. They will observe the oxygen saturation measurements during this 60-second measurement period, noting down the first reading displayed at 0, 30 and 60 seconds. The three oxygen saturation readings should be averaged to generate a single, average oxygen saturation reading.~Study nurse 2 will operate the automatic sphygmomanometer upon hearing from study nurse 1 that the 60-second measurement period has begun. Study nurse 2 will then spend the remaining measurement period observing the heart rate measurements and note the reading displayed after 0, 30 and 60 seconds. The three heart rate readings should be averaged to generate a single, average heart rate reading.~This sub-protocol will be repeated twice more to generate three sets of blood pressure, heart rate and oxygen saturation measurements and three concurrent video datasets."
224245208|NCT04763746|DEVICE|Lifelight Data Collect Sub-protocol 2|"Study nurse 1 will announce when the 60-second period of Lifelight® measurement begins and ends, guided by the timer on the software. They will observe the oxygen saturation measurements during this 60-second measurement period noting down the first reading displayed at 0, 30 and 60 seconds timepoints. The three oxygen saturation readings should be averaged to generate a single, average oxygen saturation reading.~Study nurse 2 will be directed by the announcement of study nurse 1 to begin and end manually counting observed inspirations by watching chest rises throughout the full 60-second period. According to the results of the quality improvement initiative, Study nurse 2 may place their hand on the participant's chest to increase the accuracy of their manual counting.~This sub-protocol will be repeated once more to generate two sets of respiratory rate and oxygen saturation measurements and two concurrent video datasets."
223665263|NCT03713905|DRUG|GLS-010|Recombinant Human Anti-PD-1 Monoclonal Antibody
223665264|NCT00361634|DRUG|Etanercept|
223665265|NCT05702346|BEHAVIORAL|Enhance Physical Activity (EPA)|EPA is eight weeks with four weekly, hour-long parts: virtual group exercises, virtual group discussions, individual PA participation, and individual phone check-ins.
223665266|NCT00833417|DRUG|Vismodegib 150 mg|Vismodegib 150 mg was provided in hard gelatin capsules.
223665267|NCT05802953|OTHER|Physical assessments|Physical assessments include the presence of joint sounds (yes/no), Fonseca Anamnestic Questionnaire, tenderness/pressure pain threshold rating, muscle strengths assessments, temporomandibular joint and cervical region range of motion measurements, and pain.
223665268|NCT05802953|OTHER|Questionnaire|General Health Questionnaire-28 and SF-36 will be apply.
223665269|NCT04772326|OTHER|Questionnaire|Questionnaire
223665270|NCT05293899|DIAGNOSTIC_TEST|exome sequencing approach|Depending on the primary results in the proteomic and the metabolic profiling, this pilot study will search for genetic associations, using an exome sequencing approach to individuals. The findings will be compared to individuals without depression, and to relatives of depressed patients who suffer from autoimmune diseases.
224245209|NCT04763746|DEVICE|Lifelight Data Collect Sub-protocol 3|"The study nurse will observe the oxygen saturation measurements during this 60-second measurement period indicated by the timer on the software. They will note down the first reading displayed after 0, 30 and 60 seconds. The three oxygen saturation readings should be averaged to generate a single, average oxygen saturation reading for the 60-second period.~This sub-protocol will be repeated once more to generate two sets of oxygen saturation measurements and two concurrent video datasets."
223665271|NCT02486341|DRUG|Insulin|Continuous glucose monitoring system over 120-hour period.
224245210|NCT04763746|DEVICE|Lifelight Data Collect Sub-protocol 4|"Study nurse 1 will announce when the 60-second period of Lifelight® measurement begins and ends, guided by the timer on the software. They will manually count observed inspirations by watching chest rises throughout the 60-second period. They may place their hand on the participant's chest to increase the accuracy of manual counting.~Study nurse 2 will operate a standard automatic sphygmomanometer and clinical finger clip sensor upon hearing from Study nurse 1 that the 60-second measurement period has begun. Study nurse 2 will then spend the remaining measurement period observing these measurements and note the readings displayed after 0, 30 and 60 seconds. The three heart rate and three oxygen saturation readings will each be averaged to generate a single, average reading.~This sub-protocol will be repeated twice more to generate three sets of blood pressure, heart rate, respiratory and oxygen saturation measurements and three concurrent video datasets."
224245211|NCT02289963|DRUG|Placebo (for Alirocumab)|Solution for injection, one subcutaneous injection in the abdomen with a disposable auto-injector.
224245212|NCT02289963|DRUG|Alirocumab|Solution for injection, one subcutaneous injection in the abdomen with a disposable auto-injector.
224245213|NCT02289963|DRUG|Lipid-Modifying Therapy (LMT)|Statins (Rosuvastatin, Simvastatin or Atorvastatin) at stable dose with or without other LMT as clinically indicated.
224245214|NCT00322166|OTHER|Sunlight|Subjects in the intervention groups will be asked to undergo exposure of approximately 15% of their body (ie the face, hands and arms) usually between 9.30am - 10am daily during the year, 5 days per week.
224245215|NCT00322166|OTHER|Sunlight and calcium|Subjects in the intervention groups will be asked to undergo exposure of approximately 15% of their body (ie the face, hands and arms) usually between 9.30am - 10am daily during the year, 5 days per week. In the calcium and sunlight arm, calcium supplements (Caltrate, 600mg elemental calcium, Whitehall) will be administered to the whole group via the Blister/ Webster packs.
224245216|NCT00322166|OTHER|control|Subjects in the control group will be provided with a brochure about vitamin D deficiency and how to treat it. They will receive their usual routine care and nutrition.
224245217|NCT04471610|OTHER|Serial measurements of NT-pro BNP, potassium, sodium, and creatinine every second business day|Serial measurements of NT-proBNP, sodium, potassium, and creatinine in the NT-proBNP-group vs. no serial measurements in control group. In the intervention group the body weight, vital parameters, therapy changes and adverse events are documented the above mention serial measurement every second business day.
224245218|NCT01820208|DRUG|G-CSF|G-CSF would be given at a dose of 5 microgram/kg daily for 5 days followed by once in 3 days for a total of 12 doses.
224245219|NCT01820208|DRUG|Placebo|Placebo would be given s/c at days 1, 2, 3, 4, 5 and then every 3rd day till day 28 (total 12 doses)
224245220|NCT04140318|DRUG|sintilimab|Sintilimab 200mg, iv, 30-60min, q3w;
224245221|NCT04140318|DRUG|nab-paclitaxel|Nab-paclitaxel: 125 mg/m2 iv d1、d8, q3w
224245222|NCT00269776|DRUG|Placebo|Treatment C: Three OROS placebo tablets once daily + 1 placebo capsule 3x times/day for 7 days. Each patient will be randomized to 1 of 9 treatment sequences each consisting of 3 7-day treatment periods of Treatment A, B, and C.
224245223|NCT00269776|DRUG|OROS (methylphenidate HCl)|Treatment A: 1, 2, or 3 OROS methylphenidate 18-mg tablets + 0, 1, or 2 OROS placebo tablets (3 tablets in total) once daily + 1 placebo capsule 3x/day for 7 days. Each patient will be randomized to 1 of 9 treatment sequences each consisting of 3 7-day treatment periods of Treatment A, B, and C.
223665272|NCT00565929|DRUG|Placebo|Sterile saline (0.9%).
224245224|NCT00269776|DRUG|Ritalin (methylphenidate)|Treatment B: 5, 10, or 15-mg tablets (encapsulated/single capsule) 3 times a day + 3 OROS placebo tablets once daily for 7 days. Each patient will be randomized to 1 of 9 treatment sequences each consisting of 3 7-day treatment periods of Treatment A, B, and C.
224245225|NCT01972165|PROCEDURE|Mini-incision carpal tunnel release|
224245226|NCT01972165|PROCEDURE|Endoscopic carpal tunnel release|
224245227|NCT00793663|DRUG|Xenon|Inhalational gas; maximum dose allowed: 70 % Xenon; the duration of the treatment will be defined through anesthesia-time.
224245228|NCT00793663|DRUG|Sevoflurane|Inhalation gas; age adapted MAC-values; the duration of the treatment will be defined through anesthesia-time
223665273|NCT00565929|BIOLOGICAL|MVA-BN|The smallpox vaccine is a liquid frozen solution formulated to contain 0.605 mg Tris and 4.090 mg sodium chloride (NaCl) per 0.5 mL dose. The concentration of the virus will be 1 X 10\^8 tissue culture infectious dose 50 (TCID 50) per 0.5 mL dose and may be diluted in a solution of 0.9% saline prior to vaccination. Smallpox vaccine administered in 2 doses approximately 28 days apart in one of the following doses: 1X10\^7 or 1X10\^8 TCID 50.
223665274|NCT03933995|OTHER|no Intervention|no Intervention
224245229|NCT00793663|DRUG|Dexamethasone|Intravenous use, 4 mg, single shot
224245230|NCT00793663|DRUG|NaCl|Intravenous use; single shot
224245231|NCT00793663|DRUG|Ondansetron|Intravenous use; 4 mg; single shot
224245232|NCT00793663|DRUG|NaCl|Intravenous use; single shot
224245233|NCT00318812|DRUG|Heme Iron Polypeptide (Proferrin)|Heme iron polypeptide 11mg po tid for 6 months
224245234|NCT00318812|DRUG|Iron sucrose (Venofer)|Iron sucrose infusion IV q month x 6 months
224245235|NCT00549718|DRUG|Lurasidone HCl|Once daily
224245236|NCT06163079|BEHAVIORAL|No intervention|No intervention. This is a retrospective study. Data will be collected from routine consultations Will be collectad the following datas : Number and evolution of requests, age, background, infertility timing, parenthood context, Appointment time, ART timing, Type of ART, ART outcome, Outcome time
224245237|NCT04742283|DRUG|DE-126 Ophthalmic Solution 0.002% QD|DE-126 Ophthalmic Solution QD evening and Vehicle QD Morning
224245238|NCT04742283|DRUG|Timolol Maleate Ophthalmic Solution 0.5% BID|Timolol Maleate Ophthalmic Solution BID (morning and evening)
223665275|NCT05109455|DIETARY_SUPPLEMENT|MANOSAR®|MANOSAR® is an authorized food supplement that contains D-mannose, Proanthocyanidins, Ursolic Acis, vitamin complexes and ions, and protects against urinary tract infections.
223665276|NCT05109455|DIETARY_SUPPLEMENT|Proanthocyanidins|The comparator are Proanthocyanidins of continuous-release, which are isolated from cranberry, and prevents the adhesion of uropathogenic bacteria such a E.coli to the wall of the urothelium.
223665277|NCT04263584|DRUG|Copanlisib|Copanlisib vials 60 mg
223665278|NCT04263584|DRUG|R-CHOP Chemotherapy|Immunochemotherapy
223665279|NCT00204555|DRUG|Imiquimod|
224245239|NCT01825447|DRUG|Placebo|0.9% sodium chloride for injection x 1 dose administered intravenously (IV) push over 4 min.
224245240|NCT01825447|DRUG|Oxycodone + Naltrexone|Oxycodone hydrochloride (HCl) 20 mg IV and naltrexone HCl 2.4 mg IV administered simultaneously x 1 dose IV push over 4 min.
224245241|NCT01825447|DRUG|Oxycodone|Oxycodone HCl 20 mg for injection x 1 dose IV push over 4 min.
224245242|NCT01641068|OTHER|Cognitive Intervention|Participate in memory and thinking skills workshop
224245243|NCT01641068|OTHER|Educational Intervention|Participate in workshops focusing on increasing knowledge and education on the brain and cognition
224245244|NCT01641068|PROCEDURE|Functional Magnetic Resonance Imaging|Undergo functional neuroimaging
224245245|NCT01641068|OTHER|Memory Intervention|Participate in memory and thinking skills workshop
224245246|NCT01641068|OTHER|Quality-of-Life Assessment|Ancillary studies
224245247|NCT01641068|OTHER|Questionnaire Administration|Ancillary studies
224245248|NCT06036498|DEVICE|Near Infrared Spectrophotometry Device, Transcranial Doppler Ultrasonography|We will get signals from the NIRS probes which are positioned bitemporal region of forehead in same time testing intracranial blood flow via TCD device.
224245249|NCT05113147|OTHER|In-depth individual interviews|In-depth individual interviews were based on a semistructured script designed to investigate the perceptions of the participants about the activity they performed, the ideal working conditions, the presence of disruptive behaviors, and their management.
224245250|NCT02545205|DEVICE|Hybrid Assistive Limb (HAL)|Intensive gait training with Hybrid Assistive Limb (HAL) is performed, 1 session/day, 4 days/week during 4 weeks. Time for each session is individualised but does not exceed 60 minutes/session (effective walking time with HAL).
224245251|NCT02545205|OTHER|Conventional gait training|The conventional gait training is performed according to current best evidence based practice and may include over ground walking with assistance and/or assistant devices as well as the use of a treadmill and body weight support and training of gait function in activities of daily living.
224245252|NCT04783051|DRUG|Sulfadoxine pyrimethamine|Intermittent Preventive Treatment in pregnant women with Sulfadoxine-Pyrimethamine
224245253|NCT04783051|DRUG|Pyramax|Intermittent screening using ultra-sensitive malaria Rapid Diagnostic test and treatment using Pyronaridine - Artesunate (PYRAMAX®)
224245254|NCT03016858|PROCEDURE|Thoracoscopic Bullectomy Surgery|undergoing the Thoracoscopic Bullectomy Surgery
224245255|NCT01675622|DRUG|Oxycodone|dosage: 5mg, l0mg and 20mg dosage form: capsule frequency: every 6h, duration: 5-8 days
223665280|NCT03310333|DRUG|Propess® (dinoprostone)|"The inclusion begins after 12 hours of PROM for a pregnant woman who has an unfavourable cervix and no B streptococcus. The case is discussed during the obstetric staff every morning.~If the cervix is unfavourable (cervical Bishop's score \<6), the information of the study is given to the patient and the consent collected.~An antibiotic is started at the beginning of the inclusion by amoxicillin (or clindamycin in case of allergy of amoxicillin) to prevent choroamnionitis."
223665281|NCT03310333|DEVICE|cook cervical pipening balloon|• In dinoprostone vaginal group: the device is placed in vaginal fornix by the midwife for maximum 24 hours. If Propess ® is fallen before the first 12 hours, another one could be introduce if the cervix stayed unfavourable.
223665282|NCT04650451|BIOLOGICAL|chimeric antigen receptor (CAR) T cell therapy|HER2-targeted dual-switch CAR-T cells
223665283|NCT02639858|DRUG|Docetaxel-PM|Docetaxel PM 75mg/m2 IV infusion
224245256|NCT01675622|DRUG|Morphine|Morphine tablets 10mg and 20mg, oral every 4-6 hours
224245257|NCT00465439|DRUG|Subcutaneous Lidocaine 2% (Xylocaine) without epinephrine|10 ml subcutaneously
224245258|NCT04609722|OTHER|Solution-Focused Support Program|All participants will be given a program of 4 sessions for 4 weeks. Each session is planned to last approximately 50 minutes.
224245259|NCT03004105|DRUG|Selumetinib|"Safety Run-In - Beginning dose is Selumetinib 50 mg by mouth twice a day on Days 1 through 28 of a 28 day cycle~Intermittent Arm - Participants receive Selumetinib at 75 mg by mouth twice a day for 7 days on and 7 days off.~Continuous Arm - Participants take Selumetinib twice daily on Days 1 to 28 of a 28 day cycle. Dose determined by safety run-in."
224245260|NCT03004105|DRUG|Durvalumab|Safety Run-In, Intermittent Arm, Continuous Arm - Durvalumab 1500 mg by vein on Day 1 of a 28 day cycle.
224245261|NCT03004105|BEHAVIORAL|Phone Calls|About every 6 months, participant called by a member of the study staff to ask how participant is doing and if participant has started any new treatments outside of the study. These calls should last about 10 minutes each time.
224245262|NCT01086254|DRUG|Iniparib|"Pharmaceutical form: solution for infusion~Route of administration: 60-minute IV infusion"
224245263|NCT01086254|DRUG|gemcitabine|"Pharmaceutical form: solution for infusion~Route of administration: 30-minute IV infusion"
224245264|NCT01086254|DRUG|cisplatin|"Pharmaceutical form: solution for infusion~Route of administration: 1- to 4-hour IV infusion, according to the local standard"
224245265|NCT04032977|DEVICE|PN40082|To provide a 1-point improvement in the lip fullness grading scale score of subjects with very thin or thin lips or subjects with Fitzpatrick IV, V or VI to improve the LFGS score by 1 for 1 or both lips
224245266|NCT04032977|DEVICE|Restylane Silk|To provide a 1-point improvement in the lip fullness grading scale score of subjects with very thin or thin lips or subjects with Fitzpatrick IV, V or VI to improve the LFGS score by 1 for 1 or both lips
224245267|NCT02158572|DRUG|AG200-15|Transdermal contraceptive delivery system
224245268|NCT04262934|DRUG|Cholecalciferol 100.000 UI administration|One oral Administration - Every month
224245269|NCT04262934|OTHER|No vitamin D administration|No vitamin D administration
224245270|NCT02909478|DRUG|Aprepitant+Tropisetron|"Patients will receive the chemotherapy drugs oxaliplatin,leucovorin and 5-fluorouracil as well as the following antiemetic drugs:~aprepitant (125 mg orally on day 1 and 80 mg orally on days 2 and 3) plus Tropisetron (5mg IV of day1)"
224245271|NCT02909478|DRUG|Dexamethasone+Tropisetron|"Patients will receive the chemotherapy drugs oxaliplatin, leucovorin and 5-fluorouracil as well as the following antiemetic drugs:~Dexamethasone (10 mg IV on day 1 and 5 mg IV days 2, 3) plus Tropisetron (5mg IV of day1)"
224245272|NCT02880761|PROCEDURE|Assessment guiding surgery and puncture for AVF|Assessment guiding surgery and puncture for AVF. Assessing the parameters of vascular vessels during following-up and making suggestions on surgery and puncture of AVF
224245273|NCT06161961|DEVICE|WRL TTP|evaluation of functionality, degree of safety and reliability of the lower limb prosthesis prototype
223665284|NCT01258569|DRUG|Entereg|Alvimopan (Entereg), an oral peripherally- acting mu-opioid receptor antagonist, is the first and only drug approved by the FDA to accelerate the time to upper and lower GI recovery in after partial large or small bowel resection surgery with primary anastomosis.
223665285|NCT01258569|DRUG|Entereg|oral, 12 mg 30-300 min pre-op then BID up to 7 days (or 15 total doses)
224245274|NCT03075761|DEVICE|Fitbit|The Fitbit will be utilized in the intervention arm to improve adherence to a 12-week activity regimen.
224245275|NCT03075761|BEHAVIORAL|30-minute education session|
224245276|NCT03871361|DRUG|Abatacept 125 MG/ML Prefilled Syringe|Abatacept 125 MG/ML Prefilled Syringe \[Orencia\] weekly
224245277|NCT02093494|DEVICE|Initial Specimen Diversion Device (ISDD)|
224245278|NCT02093494|PROCEDURE|Lab standard practice (LSP)|
224245279|NCT02093494|DEVICE|Peripheral Intravenous Catheters (PIVC)|
224245280|NCT02442934|OTHER|Administration of the IPREA3 questionnaire|On the day of the ICU discharge, the bedside nurse administers to the patient the 18-item IPREA questionnaire i.e the nurse asks the patient to rate the severity of each discomfort source contained in the IPREA3 questionnaire experienced during the entire stay in the ICU
224245281|NCT02442934|OTHER|Immediate feedback through electronic reminder messages|After the nurse had administered the questionnaire, warning messages are displayed on the screen corresponding to the key points to prevent the three discomforts reported with the highest scores
224245282|NCT02442934|OTHER|Targeted interventions in each ICU to reduce discomforts|"These targeted interventions are implemented through the coordination of two local champions.~The central coordination IPREA3 team sends each month to the local champions monthly and cumulative discomfort scores of their unit (overall score of discomfort and scores for each item) and their ranking relative to other units assigned to the interventional arm i.e applying the IPREA3 program.~The local champions organize monthly meetings with the unit staff to present the results in terms of perceived discomforts measured by the IPREA questionnaire, identify main discomfort sources and actions to be conducted to reduce the discomforts reported with the highest scores in the unit and those that are most easily preventable, and assess the efficacy of already applied measures."
223665286|NCT01258569|DRUG|placebo|12 mg oral 30-300 min pre-op then BID up to 7 days (or 15 doses)
223665287|NCT05076864|OTHER|No intervention|No intervention
223665288|NCT05315908|OTHER|Community outreach method|The method includes automated call and text messaging to increase testing for COVID-19
224245283|NCT03597256|DEVICE|Restylane Defyne|Intradermal injection
223665289|NCT03254576|OTHER|Functional MRI|
223665290|NCT05885178|PROCEDURE|Endovascular Therapy|"Endovascular therapy, as an adjunct to standard stroke therapy, may be beneficial for a very select population of patients who present with an acute ischemic stroke and have a proven large, proximal occlusion on imaging.~Endovascular therapy includes any one or more of the following:~Intra-arterial thrombolytic therapy, aspiration, stent retrieval, or a combination of multiple mechanical devices."
223665291|NCT01561898|DRUG|Paliperidone extended-release (JNS007ER)|Type= range, unit= mg, number= 3-12, form= tablet, route= oral use. JNS007ER within the range of 3, 6, 9 and 12 mg will be orally administered once daily for 48 weeks.
223665292|NCT03361644|BEHAVIORAL|High-Intensity Interval Training|Participants assigned to HIIT will participate in treadmill exercise in intervals consisting of 1 minute intervals of challenging intensities with recovery periods in between, gradually increasing the number of intervals over the course of the study.
223665293|NCT03361644|BEHAVIORAL|Moderate-Intensity Continuous Training|Participants assigned to CMIT will participate in constant moderate intensity treadmill exercise, gradually increasing the duration of the exercise over the course of the study.
223665294|NCT03957460|OTHER|SpHb monitoring|Subjects receive the continuous and noninvasive hemoglobin monitoring (SpHb monitoring).
223665295|NCT00103233|BIOLOGICAL|trastuzumab|
223665296|NCT00103233|DRUG|vinorelbine tartrate|
223665297|NCT02773784|OTHER|immunohistochemistry and/or FISH|Patients with invasive breast cancer diagnosed by core needle biopsy (CNB) and not to receive neoadjuvant system therapy are eligible for this study. ER, PR, Her-2 and Ki67 are determined by immunohistochemistry (IHC) in CNB and surgical specimen. FISH analysis will be carried out in all HER2 2+ samples.
224245284|NCT06370754|DRUG|JS001|240 mg by IV infusionevery 3 weeks (Q3W), given on cycle day 1.
224245285|NCT06370754|DRUG|JS004|200 mg by IV infusion Q3W, given on cycle day 1.
224245286|NCT06370754|DRUG|JS007|3mg/kg by IV infusion Q3W, given on cycle day 1.
224245287|NCT06370754|DRUG|JS015|600mg by IV infusion Q3W, given on cycle day 1.
224245288|NCT06370754|DRUG|Irinotecan Liposome Injection|60 or 70 mg/m\^2 by IV infusion every 2 weeks (Q2W), given on cycle day 1.
224245289|NCT06370754|DRUG|5-Fluorouracil (5-FU)|2400mg/m\^2, intravenously, over 46 h on day 1, Q2W.
224245290|NCT06370754|DRUG|Leucovorin (LV)|400mg/m\^2, intravenously, over 30 min on day 1, Q2W.
224245291|NCT06370754|DRUG|Nab paclitaxel|125 mg/m\^2 by IV infusion Q3W, given on cycle day 1 and 8.
224245292|NCT06370754|DRUG|Gemcitabine|1000 mg/m\^2 by IV infusion Q3W, given on cycle day 1 and 8.
224245293|NCT05612867|DIETARY_SUPPLEMENT|Vitamin C|Due to clinical research supporting high dose vitamin C, the institution's surgical intensivists started utilizing a high IV vitamin C dose in higher total body surface area burns while continuing to use the standard PO vitamin C dose of 500 mg to 1,000 mg daily on patients with lower total body surface area burns. Looking at the initial 72 hours, patients with smaller burns were given 2,500 mg PO vitamin C and larger total body surface area burns were given 15,000 mg IV vitamin C.
224245294|NCT02106156|DRUG|Pegylated interferon alfa-2a|Pegylated interferon alfa-2a administered according to corresponding summary of product characteristics (SmPC).
224245295|NCT02106156|DRUG|Ribavirin|Ribavirin administered according to corresponding summary of product characteristics (SmPC).
224245296|NCT01907334|DRUG|Advair Diskus100/50 µg|Advair Diskus 100/50 µg
224245297|NCT01907334|DRUG|Flovent Diskus 100 µg|Flovent Diskus 100 µg
224245298|NCT01907334|DRUG|Methacholine Chloride|Methacholine Chloride in quadrupling concentrations from 0.25 to 64 mg/mL will be given based upon subject's baseline response.
224245299|NCT01907334|DRUG|Albuterol|Albuterol will be administered at the end of each methacholine challenge.
224245300|NCT00722124|DRUG|S-Adenosyl-L-Methionine|800 mg dose per day for 8 weeks
224245301|NCT00722124|DRUG|S-Adenosyl-L-Methionine|1600 mg per day for 8 weeks
223665298|NCT00294762|DRUG|Tarceva|oral tablet
223665299|NCT00294762|DRUG|carboplatin|IV
224245302|NCT00722124|OTHER|placebo|4 pills (2 in the AM and 2 in the PM) of placebos for 8 weeks
224245303|NCT05636319|BIOLOGICAL|ABO1020|Vaccine
223665300|NCT00294762|DRUG|paclitaxel|IV
223665301|NCT04208971|OTHER|AI-enabled ECG-based Screening Tool for AF|A novel artificial intelligence (AI)-enabled electrocardiogram (ECG)-based screening tool to improve atrial fibrillation diagnosis and stroke prevention.
223665302|NCT05812560|OTHER|postural changes|application of a protocol of postural changes every 30-60 min or at least two postural changes in one hour during labor.
223665303|NCT02238080|DRUG|Methoxy Polyethylene Glycol-Epoetin Beta|Methoxy polyethylene glycol-epoetin beta will be administered according to the usual standard of care and current best practice guidelines and will be observed during the study period.
223665304|NCT01738646|DRUG|Vorinostat|
223665305|NCT01738646|DRUG|Bevacizumab|
223665306|NCT04640662|BIOLOGICAL|Platelet-Rich Plasma|Single-injection of 2 ml PRP into the lesion under ultrasound-guided
223665307|NCT04640662|BIOLOGICAL|Prolotherapy|Single-injection of 2ml dextrose 16.5% into the lesion under ultrasound-guided
223665308|NCT06167811|OTHER|whole-body electrical stimulation|Performed using Miha Bodytec equipment, properly calibrated, with electrodes on the quadriceps, hamstrings, glutes, biceps, triceps, pectorals, abdomen, trapezius, latissimus dorsi and quadratus lumborum muscles.
223665309|NCT04038216|PROCEDURE|Single-stage surgery|the bone-anchored hearing implant will be inserted in one surgery
223665310|NCT04038216|OTHER|Two-stage surgery|Two-stage surgery has already been performed, data will therefore be retrospectively collected
223665311|NCT04304638|RADIATION|radiation or chemo-radiation|standard treatment for stage III lung cancer
223665312|NCT04304638|DRUG|EGFR-TKI Inhibitor|the standard treatment for stage IV lung cancer with EGFR mutation
223665313|NCT03222882|PROCEDURE|personal embryo transfer|According to the histological dating and transcriptomic profile of endometrium of hormone replacement cycle in control group, to explore the effectiveness of intervention by advanced or delayed personal embryo transfer . The establishment of standard control group: Frozen embryo transfer patients according to the inclusion and exclusion criteria were evaluated for histological dating and transcriptomic profile by endometrial biopsy on day P＋7 in an HRT cycle. After routine time transfer in the frozen embryo transfer cycle, the standard of histological dating and transcriptomic profile were determined according to the pregnancy outcome of the FET cycle .
223665314|NCT01876004|DRUG|Methotrexate|50 mg/m2, IM (intramuscularly), single dose
223665315|NCT01876004|DRUG|Placebo|Prescribed Placebo IM (intramuscularly), single dose
223665316|NCT01945918|BEHAVIORAL|Self-management support education|Same as Arm Description
223665317|NCT01945918|BEHAVIORAL|Connection to Health Interactive Behavior Change Technology|Same as Arm Description
223665318|NCT01945918|BEHAVIORAL|Connection to Health plus Coaching (CTH+C)|Same as Arm Description
223665319|NCT04093024|DRUG|Nintedanib|Capsule
223665320|NCT04093024|DRUG|Placebo|Capsule
223665321|NCT04571671|OTHER|Collect retrospectively data|Analyse the incidence of Mullerian anomalies in these populations
223665322|NCT02637349|BEHAVIORAL|POST Intervention|POST Intervention group will receive a tailored survivorship care plan (SCP) at the end of their active treatment. The SCP will be discussed with them. Patient will be asked about satisfaction with the end of treatment session.
224245304|NCT05636319|BIOLOGICAL|Placebo|Placebo
223665323|NCT02637349|BEHAVIORAL|POST Treatment as Usual|The POST control group may receive a survivorship care plan (SCP) as part of treatment as usual though it is not a usual procedure. They will be asked about their satisfaction with the end of treatment session.
223665324|NCT03561688|DEVICE|Foot orthotics|Insoles for shoes
223665325|NCT03561688|DEVICE|Standard insole|Sham foot orthotic
223665326|NCT05506241|DEVICE|Dynavision D2|Use of the Dynavision will be comprised of six 3-minute or nine 2-minute sessions with 30 seconds to one-minute rest in between. All Dynavision sessions require clients to scan the 4' by 4' vertical board and hit the lit targets one at a time. Participants will be able to depress targets with their left or right hand, in standing or sitting.
223665327|NCT02082938|DEVICE|Bracing|Twice a week, for a period of 5 weeks, before the sessions in the physiotherapy clinic the patients participating in the study were asked to walk at a self-selected speed on flat ground along a corridor 50 meters long, with the brace being used for fifteen minutes of gait retraining of the affected side.
223665328|NCT03632408|DRUG|Zopiclone|Oral, single dose, 7.5 mg
223665329|NCT03632408|BEHAVIORAL|hangover|as per subjects choice to consume alcohol
223665330|NCT03632408|DRUG|Placebo oral capsule|oral
224245305|NCT04013919|DRUG|Multiple Daily Injections of Insulin|Basal/ Bolus insulin injections
223665331|NCT00856414|BIOLOGICAL|botulinum toxin Type A|20U, up to two injections administered intramuscularly into the glabella (2 in each side of the corrugators and 1 in the procerus)
223665332|NCT00367367|PROCEDURE|Hysteroscopy and Curettage|
223665333|NCT04508218|DIETARY_SUPPLEMENT|whey protein supplementation powder (Inkospor X-TREME; France)|Protein requirements for burned adults are estimated as 1.5-2.0 g/kg/day. The participants asked to take the calculated serving of whey protein dissolved in 150ml of water two times / day in the morning and in the evening
224245306|NCT04013919|DRUG|Single insulin injections|Basal insulin injections only
224245307|NCT02485977|DEVICE|Magnetic resonance Imaging|MRI study will be performed on 1.5 Tesla magnet, during the administration of Gadolinium
224245308|NCT03751345|BEHAVIORAL|Parenting Wisely|PW is a self-administered, interactive, multimedia online program. Parents will complete computer-administered sessions during in-person appointments.The program comes with a parent workbook so that parents can gain additional exposure to and practice with the skills. The complete PW program takes from 3 to 5 hours to complete depending on the users' speed and depth of use. Parents will be given a login at enrollment so that they have the option to practice sessions or view any additional sessions at home. Individual coaching sessions will take place in-person with parents. Coaching sessions are designed to tailor the PW skills to each parent's presenting concerns.
224245309|NCT04138745|OTHER|Transverse Thoracic Plane Block|A bilateral plane block in the transverse thoracic space
224245310|NCT03059966|PROCEDURE|Microsurgery technique for root coverage|Microsurgery technique for root coverage adapted for macrosurgery
224245311|NCT03059966|BIOLOGICAL|Microsurgery technique for root coverage associated to EMD|Microsurgery technique for root coverage adapted for macrosurgery associated to Enamel Matrix Derivative
224245312|NCT03224494|DEVICE|Rapid Barostat Bag|Both healthy controls (n= 100) and IBS patients (n=100) will undergo anorectal studies using a Rapid barostat bag catheter.
224245313|NCT03224494|OTHER|IBS severity scoring system questionnaire (IBS-SSS)|We will correlate the changes to IBS symptoms using the IBS severity scoring system questionnaire (IBS-SSS). The questionnaire will be administered twice for IBS patients who have consented to return for a second study visit, at each of the two RBB studies.
224245314|NCT03224494|OTHER|HAD scale questionnaire|It is a validated anxiety and depression questionnaire
224245315|NCT00409162|DEVICE|Eraser TM device, with washing fluid|
224245316|NCT00581139|BEHAVIORAL|Preoperative Preparation Program (Child Life Specialist)|This group will receive the standard preoperative visit to the hospital with Child Life intervention
224245317|NCT00581139|DRUG|Midazolam|0.5 mg/kg oral midazolam
224245318|NCT00581139|BEHAVIORAL|Parental Presence during Induction of Anesthesia|One parent will be present during induction of anesthesia of the child. The parent will be accompanied out of the OR by a nurse once the induction is completed. These parents will have completed a parent preparation program.
224245319|NCT00581139|OTHER|PPIA preparation program PLUS Midazolam premedication|Subjects in this group will receive both interventions 2 and 3.
224245320|NCT06161623|BEHAVIORAL|Laughter Yoga Application|The intervention group took eight sessions of laughter yoga, that is, two sessions per week for 4 weeks. The participants in the intervention group were asked to fill in the data collection tools before the laughter yoga sessions, and after the 4th and 8th yoga sessions.
224245321|NCT00377416|GENETIC|rAAV2-CB-hAAT Gene Vector|Participants will attend a 5-day inpatient visit, during which they will receive a series of injections consisting of one of four different doses of rAAV2-CB-hAAT.
224245322|NCT06559735|DEVICE|CereVu Device|Observational, non-invasive measurements
224245323|NCT04638179|OTHER|Not intervention.Use retrospective case contrl study.|Use retrospective case contrl study.
224245324|NCT01332864|PROCEDURE|Osteopathic Manipulative Treatment (OMT)|O OMT applied to areas of somatic dysfunction other than the head region.
223665334|NCT04508218|OTHER|Exercise training program|After healing of the burn (6 weeks after injury), participants in group A and group C started resisted exercise program with a qualified therapist for 1 hour three times/week on nonconsecutive days over 12 weeks. In addition, aerobic exercises were conducted on the treadmill. Peak oxygen consumption was assessed for all patients by using the exercise test on treadmill before participation in aerobic exercises.
223665335|NCT04508218|OTHER|traditional burn care|ROM exercises, stretching, ADL activities and scar management
223665336|NCT01839604|DRUG|AZD9150|Intravenous infusion over 3 hours.
223665337|NCT04936984|COMBINATION_PRODUCT|abaloparatide-sMTS (Patheon)|single-dose administration of abaloparatide 300 μg applied to the thigh for 5 minutes
223665338|NCT04936984|COMBINATION_PRODUCT|abaloparatide-sMTS (Kindeva)|single-dose administration of abaloparatide 300 μg applied to the thigh for 5 minutes
223665339|NCT04936984|COMBINATION_PRODUCT|abaloparatide-sMTS (Patheon)|single-dose administration of abaloparatide 300 μg applied to the thigh for 4 minutes
223665340|NCT04936984|COMBINATION_PRODUCT|abaloparatide-sMTS (Patheon)|single-dose administration of abaloparatide 300 μg applied to the thigh for 7 minutes
224245325|NCT01332864|PROCEDURE|Light touch|Light touch applied to head region for 10 minutes with patient supine at rest.
224245326|NCT03545828|DIAGNOSTIC_TEST|Multi-channel aEEG monitoring|18 channel aEEG monitoring in comatose TTM-treated patients
224245327|NCT02982356|PROCEDURE|Fetal Selective Reduction Technology|Fetal Selective Reduction Technology will be conducted according to different gestational weeks: before 16weeks, 16\~24 weeks, 24\~27+6 weeks,\>28weeks
224245328|NCT02982356|DRUG|Potassium Chloride|
224245329|NCT02080845|DIETARY_SUPPLEMENT|no caffeine|
224245330|NCT02080845|DIETARY_SUPPLEMENT|high caffeine|
224245331|NCT02080845|DIETARY_SUPPLEMENT|no theobromine|
224245332|NCT02080845|DIETARY_SUPPLEMENT|low theobromine|
224245333|NCT02080845|DIETARY_SUPPLEMENT|high theobromine|
223665341|NCT02449746|BIOLOGICAL|Plasma Exchange|PLEX is a procedure in which the subject's blood is passed through a medical device which separates out plasma from the other blood components, and replaces the plasma with albumin or plasma or other colloid. PLEX therefore removes circulating pathogenic antibodies, and furthermore therapeutic benefit after PLEX supports an antibody mediated pathogenesis of disease. In PLEX, 200-250 mL plasma per kg body weight is exchanged typically over 7-14 days using 5% albumin as replacement, often at alternate days which increases the amount of immunoglobulin removed due to equilibrium effects. PLEX modality (centrifugation or filtration), type of anticoagulation, and dose scheduling will be determined by local centre practice.
223665342|NCT02449746|BIOLOGICAL|Intravenous immunoglobulin|"Active Comparator: Intravenous Immunoglobulin (IVIG) IVIG is a pooled blood product from 3000-100,000 human blood donors with direct immunomodulatory effects.~IVIG will be given at a dose of 2g/kg over 4 days. Dosing at 2g/kg is established in neurological disorders, with limited evidence that lower doses are less effective although adequate dosing studies have not been performed."
223665343|NCT06247189|OTHER|ICOPE Monitoring|"At inclusion set up of the ICOPE monitor program on the patient's device and evaluation (all steps) of ICOPE Monitor program.~Monthly, re-evaluation of the patient (Step 1 and others if necessary ) according to the ICOPE Monitor program"
224245334|NCT03633474|BIOLOGICAL|N. lactamica|Stocks of N. lactamica (strain Y92-1009, sequence type 3493, clonal complex 613) in Frantz medium containing 30% (v/v) glycerol have been previously prepared using the Good Manufacturing Practices pharmaceutical manufacturing facilities at Public Health England (Porton Down, United Kingdom).
224245335|NCT03633474|OTHER|PBS only|Sterile PBS only containing no bacteria
224321684|NCT02834013|PROCEDURE|Echocardiography Test|Undergo ECHO
224321685|NCT02834013|BIOLOGICAL|Ipilimumab|Given IV
224321686|NCT02834013|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
224321687|NCT02834013|BIOLOGICAL|Nivolumab|Given IV
224321688|NCT04846829|DRUG|Placebo|saline PBO will be administered intravenously using established clinical procedures. A single dose if saline PBO will be delivered intravenously under double-blind conditions via pump over a 40-minute period.
223665344|NCT02891928|DEVICE|Rocker sole shoes|Measure of walk testing Measure of standing position
223665345|NCT02891928|DEVICE|Normal shoes|Measure of walk testing Measure of standing position
223665346|NCT05317117|DIAGNOSTIC_TEST|NxTek™ Malaria P.f plus Rapid Diagnostic Test (RDT) and NxTek™ Malaria P.f/P.v RDT|"The NxTek (TM) Malaria Pf Plus, developed by Abbott, is a sensitive rapid chromatographic immunoassay for the qualitative detection of histidine-rich protein 2 (HRP2) and pLDH on a single test line of Pf malaria in human whole blood. This test is a lateral flow test for in vitro professional diagnostic use and intended as an aid to early diagnosis of Malaria infection in-patients with clinical symptoms.~The NxTek (TM) Malaria Pf/Pv Plus, developed by Abbott, is a sensitive rapid chromatographic immunoassay for the qualitative detection of histidine-rich protein 2 (HRP2) and Plasmodium lactate dehydrogenase (pLDH) of Plasmodium falciparum (Pf) on one test line and of pLDH of Plasmodium vivax (Pv) malaria on a second test line in human whole blood. This test is a lateral flow test for in vitro professional diagnostic use and intended as an aid to early diagnosis of Malaria infection in-patients with clinical symptoms."
223665347|NCT04845711|OTHER|Control group|patients will receive general anesthesia only.
223665348|NCT04845711|PROCEDURE|Erector spinae plane block group|patients will receive general anesthesia and bilateral ultrasound guided erector spinae plane block (20ml Bupivacaine 0.25%)
223665349|NCT04845711|PROCEDURE|Quadratus lumborum block group|patients will receive general anesthesia and bilateral ultrasound guided quadratus lumborum block (20 ml Bupivacaine 0.25%)
223665350|NCT01917253|DEVICE|Standard Device for peripheral vein cannulation|
223665351|NCT01917253|DEVICE|Long Catheters for peripheral vein cannulation|
223665352|NCT05707039|OTHER|Open kinetic chain exercises|In open chain exercises extremities are free to move and there is no weight bearing.
223665353|NCT05707039|OTHER|Closed kinetic chain exercises|In closed kinetic chain exercises extremities are fixed and weight bearing is done.
224245336|NCT04320420|OTHER|Adapted Physical Activity|"The APA program is defined in 3 stages:~STEP 1: during the initial chemotherapy over 3 months~* 3 supervised APA sessions/week on site:~  * two muscle strengthening sessions, stretching, flexibility in the gym~ * a cardio session (Nordic Walking: outdoors)~* at home: exercise book if the patient wishes~STEP 2: during hospitalization for the autograft, over 1 month:~* 2 sessions/week supervised by an APA engineer + exercise book and encouragement of individual work~* If the patient wishes, he can continue the exercises carried out with the APA engineer independently~STEP 3: after the transplant~* the first 3 months:~  * 2 supervised indoor sessions/week (muscle strengthening, stretching, flexibility),~ * 1-hour cardio session/week independently~* the following 3 months: 1 indoor session per week + independent exercises at home and walking or cycling sessions"
224245337|NCT01887691|DRUG|eszopiclone|Eszopiclone at a dose of 1-3 mg (lowest tolerated dose, as determined using a dose escalation schedule and side effect profile)will be taken 30 minutes before bedtime for one week.
224245338|NCT01996527|DEVICE|3-Tesla magnetic resonance imaging|3-Tesla MRI is a multiparametric imaging exam that includes MR pulse sequences for CEST-MRI, DW-MRI, DCE-MRI, and DSC-MRI
224245339|NCT01996527|DEVICE|CEST-MRI|Undergo CEST-MRI
224245340|NCT01996527|DEVICE|DW-MRI|Undergo DWI-MRI
224245341|NCT01996527|DEVICE|DCE-MRI|Undergo DCE-MRI
224245342|NCT01996527|DEVICE|DSC-MRI|Undergo DSC-MRI
224245343|NCT01996527|DRUG|IV administration of gadolinium-containing contrast agent|Gadolinium-containing paramagnetic contrast agent (Magnevist®; Berlex Lab, Wayne, New Jersey) in delivered via intravenous (IV) infusion to achieve DCE and DSC contrast
224245344|NCT03627780|DIAGNOSTIC_TEST|DNA extraction|DNA will be extracted from white cells
224245345|NCT06328491|DRUG|Erdafitinib|Protein Kinase Inhibitor
224245346|NCT05017480|DRUG|CBP-201|CBP-201 subcutaneous(SC) injection.
224245347|NCT05017480|DRUG|Placebo|subcutaneous(SC) injection
224245348|NCT03521765|OTHER|Cancer education|Those participants in the OT intervention group were given a consultation based on a CRC education handbook by an occupational therapist for discharge preparation (about 30 minutes) and after each follow-up visit to the clinic (about 15-20 minutes); the non-intervention group participants were given a CRC education handbook (the same handbook) only for discharge preparation. For the first OT consultation, in the first 15 minutes, the occupational therapist educated the participants based on the CRC education handbook chapter by chapter. The next 15 minutes, the occupational therapist interacted with the participants and provided them customized lifestyle suggestions. For the each following (second and third) consultations, occupational therapists interacted with the participants and provided customized suggestions based on the participants' lifestyle at home.
224245349|NCT01136382|DRUG|budesonide|pMDI, inhalation, bid, 6 weeks
224245350|NCT01136382|DRUG|placebo|pMDI, inhalation, bid, 6 weeks
223665354|NCT05511077|OTHER|Diet|Intervention products consist of two different oat products, one solid and one liquid. The content of oat in the products differs.
223665355|NCT00647270|DRUG|adalimumab|Pre-filled syringe. See arm for more detail
223665356|NCT00647270|DRUG|Placebo|Pre-filled syringe. See arm for more detail
223665357|NCT00647270|DRUG|adalimumab|Pre-filled syringe. See arm for more detail
223665358|NCT02523144|DRUG|Chloral Hydrate|70mg/kg chloral hydrate
223665359|NCT02523144|DRUG|Dexmedetomidine|2mcg/kg
223665360|NCT02523144|DRUG|Dexmedetomidine|3mcg/kg
223665361|NCT02523144|DRUG|Placebo|Flavored placebo syrup
223665362|NCT00262054|DRUG|Bivalirudin|bivalirudin to be administered as an intravenous bolus of 0.75 mg/kg prior to the start of the intervention, followed by infusion of 1.75 mg/kg per hour for the duration of the procedure.
224245351|NCT01794039|DRUG|Dexamethasone|Given PO
224245352|NCT01794039|DRUG|Lenalidomide|Given PO
224245353|NCT01794039|DRUG|Pomalidomide|Given PO
224245354|NCT00963482|BEHAVIORAL|Cognitive-behavioural smoking cessation program|It's a cognitive-behavioural intervention for smoking cessation. Originally based on a 6 week program designed for outpatients (Batra \& Buchkremer 2004). This program was then specifically tailored for inpatient use with additional information addressing the interaction of smoking and drinking and its consequences.
224245355|NCT00963482|BEHAVIORAL|Autogenic training|Learning and exercising of autogenic training. There's evidence that autogenic training is not effective in smoking cessation.
224245356|NCT00027053|DRUG|Trazodone|50 to 150 mg qhs
224245357|NCT00027053|DRUG|Placebo|
224245358|NCT00080951|DRUG|fluorouracil|
224245359|NCT00080951|DRUG|irinotecan hydrochloride|
223665363|NCT00262054|DRUG|Un-fractionated heparin|UFH is given as an intravenous bolus of 140 units/kg followed by infusion of placebo 1.75 mg/kg per hour for the duration of the procedure.
223665364|NCT01184950|OTHER|Trainer Curriculum|
223770483|NCT05027581|DRUG|Bone marrow mesenchymal stem cells|The bone marrow mesenchymal stem cells (BM-MSCs) in Chondrochymal® for this study was obtained from the donor recruited in Taipei Veterans General Hospital, Taiwan. Donors aged 20 to 50 and tested negative to infection of human immunodeficiency virus type 1 and 2 (HIV-1/2), hepatitis B virus (HBV), hepatitis C virus (HCV), Cytomegalovirus (CMV), Treponema pallidum (syphilis), human T-lymphotropic virus types I and II (HTLV-I/II), and Tuberculosis (TB) were enrolled. The eligible donor's bone marrow was aspirated from the iliac crest or femur. The collected BM-MSCs were then cultured, expanded and cryopreserved in a Good Tissue Practice (GTP)-complied laboratory. The qualified cells in cryopreservation meeting the release criteria will be thawed, mixed with lactated Ringer's solution, and transferred into a sterile syringe as the final product.
223770484|NCT05027581|DRUG|hyaluronic acid|(60 mg/3 mL hyaluronic acid \[HA\])
223770485|NCT03125265|OTHER|dietary intake of omega-3 and omega-6 polyunsaturated fatty acids|
224245360|NCT00080951|DRUG|leucovorin calcium|
224245361|NCT00080951|DRUG|oxaliplatin|
224245362|NCT05167760|DRUG|Apraclonidine|1-2 drops per eye every 8 hours for 2 weeks
224245363|NCT01992991|DEVICE|Transcranial direct current stimulation|Transcranial direct current stimulation of motor cortex
224245364|NCT02072577|BEHAVIORAL|Video|"The student watched the video prepared individually in the ward where they were interned.~After this step, the student demonstrated again the procedure for oral hygiene.~At this point the researcher also observed the sequence, movements and technical procedures used to analyze the steps of oral hygiene, using the same instrument for such employee initially."
224245365|NCT03387072|OTHER|Non interventional study|mental stress test and Blood (or salivary) sample
224245366|NCT02653664|BEHAVIORAL|PsychoEducation|Condition #1
224245367|NCT02653664|BEHAVIORAL|Self-Hypnosis Training|Condition #2
224245368|NCT02653664|BEHAVIORAL|Mindfulness Meditation|Condition #3
223665365|NCT02215941|DRUG|TV-45070|TV-45070 8% ointment
223770486|NCT03660046|DRUG|Depot medroxyprogesterone acetate (DMPA)|Depot medroxyprogesterone acetate (DMPA) will be dispensed from the Grady Pharmacy Service and will be administered every 12 weeks at the standard dose of 150 mg Intramuscular injection, beginning from week 3 of study enrollment and repeated every 13 weeks
223770487|NCT03660046|DRUG|Etonogestrel implant (Eng-Implant)|A standard Nexplanon rod Implant that is a subdermal implant in the arm. This will be placed at study week 3 by Dr. Haddad or a trained clinician. It contains Etonogestrel 68mg.
224245369|NCT04707040|OTHER|Neurocognitive Exercise Program|Neurocognitive Exercise Program (NEP) is defined as a multimodal exercise program including different motor coordination exercises and cognitive tasks. Exercise progression is performed from easy to difficult, and consist of simple and complex tasks. Different sports equipment (such as different sizes of balls, racket, tulle, pilates ball, eye band, rope, etc.) is used in motor coordination exercises where multiple extremities can be used in NEP. These materials are used during different exercises including cross-limb movements, throwing, jumping, walking, involving different cognitive tasks. The cognitive task used and the degree of difficulty of the task are provided by different visual (colored cards, numbered cards, gestures, etc.) or auditory (keywords, ring signal, etc.) signs. For example, showing a red card might indicate throwing a ball with the left hand, while showing a blue card indicates throwing a ball with the right hand and walking forward
224245370|NCT04660656|DIAGNOSTIC_TEST|5 repetition sit-to-stand test|"The sit-to-stand test with five repetitive movements is used as standard in our clinical routine to determine the patient's mobility objectively. The first measurement is performed preoperatively during surgery (baseline). The follow-up measurement is performed six weeks after the operation and one year after the operation in the clinic.~A stool with a fixed height is used for this purpose. The patient should cross his arms over the chest and then slowly stand up until the knees are full of space. Then the patient sits down again, of course without support of the arms. The duration of the five movements is recorded using a stopwatch. The complete movement starts after the Go command and ends when the patient is fully upright after the fifth movement. This duration is written down as the patient's score."
224245371|NCT00746798|BIOLOGICAL|ChimeriVax-WN02 vaccine|low dose, approximately 4 x 3log10, given one time subcutaneously
224245372|NCT00746798|BIOLOGICAL|ChimeriVax-WN02 vaccine|medium dose, approximately 4 x 4log10, given one time
224245373|NCT00746798|BIOLOGICAL|ChimeriVax-WN02 vaccine|high dose, approximately 4 x 5log10, given one time subcutaneously
224245374|NCT00746798|BIOLOGICAL|Placebo|0.9%Normal Saline for Injection, given one time subcutaneously
224245375|NCT02455492|OTHER|stroke or myocardial infarction or pneumonia|There are three main exposure groups with exposure defined as a binary variable (yes/no): Stroke in the six months prior to surgery; Myocardial infarction in the six months prior to surgery; Pneumonia in the six months prior to surgery
223665366|NCT02215941|DRUG|Placebo|Placebo
224245376|NCT00403715|DRUG|diquafosol tetrasodium (INS365) Ophthalmic Solution|
224245377|NCT06561399|COMBINATION_PRODUCT|TACE, Lenvatinib combination with Sintilimab sequential radiotherapy|TACE, Lenvatinib \[8mg(\<60kg)/12mg(\>60kg) orally daily\] combination with Sintilimab (200mg administered intravenous injection on Day 1 of each 21-day cycle) for 2 months. Sequential radiotherapy method and dosage are comprehensively evaluated by radiologists, hepatobiliary surgeons, and oncologists, and discussed by a multidisciplinary team
224245378|NCT01274988|PROCEDURE|Deep brain stimulation|Deep brain stimulation of bilateral nucleus accumbens
223665367|NCT05862506|BEHAVIORAL|Daily Mile|The intervention consisted of walking, jogging or running for \~ 15 min (\~ one mile) of exercise at a pace self-selected by each individual child, outside the school buildings during recess time, three times a week during 10 weeks. Children were instructed to maintain active for the full 15 min and, if necessary, to stop for resting only occasionally.
223665368|NCT00498290|PROCEDURE|enhanced recovery after surgery (ERAS) protocol|An integrated protocol aims to allow patients to recover more quickly from major surgery, avoid medium-term sequelae of conventional postoperative care (e.g. decline in nutritional status and fatigue) and reduce health care costs by reducing hospital stay
224245379|NCT01274988|OTHER|methadone maintenance treatment|methadone maintenance treatment
224245380|NCT02889848|OTHER|Saline|Saline injection
224245381|NCT02889848|DRUG|EN3835|Comparison of maximum marketed dose and multiple doses EN3835
224245382|NCT04438239|OTHER|none, this study is observational|none, this study is observational
224245383|NCT00633594|DRUG|Rituximab|"DL 1, DL 2, and DL 3: 375 mg/m2 IV Days 1, 8, and 15; Cycles 2-6: 375 mg/m2 IV Day 1~Same for DL-1."
224245384|NCT00633594|DRUG|Bortezomib|"DL 1, DL 2, and DL 3: 1.3 mg/m2 IV Days 1, 4, 8, and 11~Same for DL-1."
224245385|NCT00633594|DRUG|Lenalidomide|"DL 1: 15 mg PO daily Days 1-14 followed by 7 days of rest~DL 2: 20 mg PO daily Days 1-14 followed by 7 days of rest~DL 3: 25 mg PO daily Days 1-14 followed by 7 days of rest~DL-1: 10 mg PO daily Days 1-14 followed by 7 days of rest"
224245386|NCT04164589|DEVICE|SCENAR 1NT-02.2|The neuro-adaptative regulation will be carried out in vulvo-perineal and sacral area
224245387|NCT01887548|OTHER|Personality Traits Questionnaires|Patients are required to fill out several personality traits questionnaires. The following personality traits scores would be collected: IBDQ, IBDQ-Emotional function score, IBDQ-Social function score, IBDQ-Bowel function score, IBDQ-Systemic symptom score, Neuroticism score, Lie (social conformity/desirability) score, Hospital anxiety score, Hospital depression score, Buss-Perry score, PA (physical aggression) score, VA (verbal aggression) score, A (anger) score, H (hostility) score.
224245388|NCT03535896|OTHER|HSR|"Participants will complete a heel raise standing with the forefoot on a step. The toes are maximally dorsiflexed by placing a towel underneath them. The heel raise is performed with a raise to maximal plantar flexion and to maximal dorsi flexion.~The exercise is performed with a load as heavy as possible but no heavier than 8RM and for as many sets as possible every other day."
224245389|NCT03535896|DRUG|Corticosteroid injection|Participants receive an ultrasound-guided corticosteroid injection between 5 and 8 days after baseline. A 21-gauge, 40 mm needle is connected to a 2.5 cm3 syringe filled with 1 ml Triamcinolonhexacetonid (Lederspan, Meda) + 1 ml Lidocain 10 mg7ml (Xylocain, AstraZeneca). The skin is cleansed with Chlorhexidine alcohol 0.5 % (Medic). The needle is inserted with a medial approach under ultrasound-guidance aligned to the long axis of the ultrasound transducer. The injection is placed anterior to the plantar fascia insertion on the calcaneal bone in the region of maximal fascia thickness.
224245390|NCT04230525|DIAGNOSTIC_TEST|non invasive whole body bioimpedence system|Noninvasive hemodynamic changes will be observed by using whole-body impedance method urgent or elective cesarian section patients under general anesthesia. The whole-body bioimpedance method will be used to monitör the hemodynamic changes non invasively. This method can evaluate such as cardiac output, cardiac index, stroke volüme, stroke index, stroke volüme variations, cardiac reserve, etc. Parameters with a completely noninvasive method by using only electrots. The device consists of a laptop, a software which calculates cardiac parameters and two electrodes. The measurement is done by the following process: one of these electrodes, which looks like ECG electrodes, is stuck to the wrist and the other one to the opposite ankle or each one to two wrists.
224245391|NCT06293196|OTHER|acupressure|Massage acupoints and non-acupoint areas around the eyes.
224245392|NCT00813215|DIETARY_SUPPLEMENT|Meal challenge|Meal challenge with a test meal rich on saturated fat.
224245393|NCT00813215|DIETARY_SUPPLEMENT|Meal challenge|Meal challenge with a test meal rich on monounsaturated fat
224245394|NCT04207983|COMBINATION_PRODUCT|EYS606|EYS606 is a DNA plasmid solution administered by electrotransfection into the ciliary muscle
224245395|NCT03029663|PROCEDURE|Transurethral resection of the bladder tumour|
224245396|NCT01444703|OTHER|licorice solution|licorice (0.5 g)
224245397|NCT01444703|OTHER|sugar solution|sugar (5 g).
224245398|NCT01191320|DRUG|Placebo|Placebo capsule 1x daily for 3 months
224245399|NCT01191320|DRUG|Androxal|Capsules 12.5 mg or 25 mg 1x daily for 3 months
223665369|NCT00498290|PROCEDURE|control|normal recovery protocol as usually
223665370|NCT03303664|OTHER|IMPROVE Protocol|Comprehensive pain management protocol
223665371|NCT00002845|BIOLOGICAL|aldesleukin|
223665372|NCT00076453|DEVICE|Lateral wedge orthotic shoe inserts|Customized lateral wedge orthotic shoe inserts
223665373|NCT00076453|DEVICE|Standard orthotic shoe inserts|Neutral orthotic inserts
223665374|NCT05594745|DRUG|Lifitegrast Ophthalmic|eyedrop
223665375|NCT05594745|DRUG|Systane Free|eyedrop
223665376|NCT05594745|DEVICE|Lipiflow|thermal pulsation
223665377|NCT00901732|DEVICE|Caphosol|Oral Mouth Rinse
223665378|NCT00188383|DRUG|Amantadine|
223770488|NCT03660046|DRUG|Levonorgestrel IUD (Lng-IUD)|The Levonorgestrel Intrauterine Device (Lng-IUD) (Mirena or copper) will be placed at study week 3 by Dr. Haddad or a trained clinician.
223770489|NCT00136487|DRUG|Celecoxib|
224245400|NCT03560544|BEHAVIORAL|Breaking up sitting|"A three-part behaviour change intervention, including:~1. Supportive organisational culture and knowledge of consequence of prolonged sitting~2. Environmental Modification~3. Behavioural Changes"
224245401|NCT04915352|DRUG|Nasal provocation test - 725 Dermatophagoides Pteronyssinus|"3 different concentrations of Nasal Provocation Test are administered to patients:~* Nasal spray at 50 SBE/ml for 36 months~* Nasal spray at 500 SBE/ml for 36 months~* Nasal spray at 5000 SBE/ml for 36 months"
224245402|NCT04915352|OTHER|Negative control|Negative control using only solvent is applied in order to consider a non-specific nasal hyper reactivity.
224245403|NCT03818945|DRUG|shofu PRG barrier coat|Trilaminar structure which forms a type of stable glass ionomer allowing ion release and recharge, while protecting the glass core from the damaging effects of moisture, greatly improving long-term durability.(Na, BO3, Al, SiO3, F,Sr)
224245404|NCT03818945|DRUG|Sodium fluoride varnish|5% sodium fluoride \[22,600 ppm F-\]
224245405|NCT03503448|PROCEDURE|Osteotomy between the maxillary central incisors|Surgically Assisted Rapid Maxillary Expansion with osteotomy between the central incisors.
224245406|NCT03503448|PROCEDURE|Osteotomy between the maxillary lateral incisors and canines|Surgically Assisted Rapid Maxillary Expansion with bilateral osteotomy between the lateral incisors and canines
224245407|NCT05852847|DRUG|Baricitinib 2 MG [Olumiant]|Oral baricitinib was given at a dose of 2 mg daily for 6 months. Treatment was discontinued if very severe or life-threatening adverse events developed or at the patients' request.
224245408|NCT05852847|DRUG|Danazol|Danazol was given at a dose of 200 mg bid for 6 months
224245409|NCT00611819|DRUG|Peg interferon + Ribavirin|Peg interferon 180 mcg/weekly Ribavirin 800 mg/daily during 24 weeks
224245410|NCT00611819|DRUG|Peg interferon + Ribavirin|Peg interferon alpha 2a 180 mc/weekly Ribavirin 800 mg/daily during 48 weeks
224245411|NCT00503152|DRUG|Benazepril|After one month wash-out from previous RAS (ARB or ACE) inhibitor therapy, patients satisfying the inclusion/exclusion criteria will be randomly given equivalent doses (half the standard doses recommended by the manufacturer for blood pressure control) of benazepril (10 mg/day) or valsartan (160 mg/day) or one fourth of the standard doses of both agents in combination (benazepril 5 mg/day and valsartan 80 mg/day). If well tolerated, treatment will be up-titrated to full dose of benazepril (20 mg/day) or valsartan (320 mg/day) or one half of the standard doses of both agents in combination (benazepril 10 mg/day and valsartan 160 mg/day).
223665379|NCT02855918|OTHER|Blood sample for genetic purpose|"All the participants will performed the same evaluations and blood analysis :~* A clinical assessment by psychiatrist~* Self report questionnaires for the assessment of a potential mood disorder and history of SB, moral/physical pain, personality traits…~* A neuropsychological assessment for the evaluations of cognitive performances~* A routine blood sampling to the realization of a standard blood test~* A specific blood sampling (PAXgene® tubes) to extract total RNA of blood cells and measure the expression of ADARS RNA and editing of the PDE8A transcript."
224245412|NCT00503152|DRUG|Valsartan|After one month wash-out from previous RAS (ARB or ACE) inhibitor therapy, patients satisfying the inclusion/exclusion criteria will be randomly given equivalent doses (half the standard doses recommended by the manufacturer for blood pressure control) of benazepril (10 mg/day) or valsartan (160 mg/day) or one fourth of the standard doses of both agents in combination (benazepril 5 mg/day and valsartan 80 mg/day). If well tolerated, treatment will be up-titrated to full dose of benazepril (20 mg/day) or valsartan (320 mg/day) or one half of the standard doses of both agents in combination (benazepril 10 mg/day and valsartan 160 mg/day).
224245413|NCT00503152|DRUG|Benazepril/Valsartan|After one month wash-out from previous RAS (ARB or ACE) inhibitor therapy, patients satisfying the inclusion/exclusion criteria will be randomly given equivalent doses (half the standard doses recommended by the manufacturer for blood pressure control) of benazepril (10 mg/day) or valsartan (160 mg/day) or one fourth of the standard doses of both agents in combination (benazepril 5 mg/day and valsartan 80 mg/day). If well tolerated, treatment will be up-titrated to full dose of benazepril (20 mg/day) or valsartan (320 mg/day) or one half of the standard doses of both agents in combination (benazepril 10 mg/day and valsartan 160 mg/day).
224245414|NCT01045096|DRUG|Dexlansoprazole|Dexlansoprazole 15 mg, delayed release capsules, orally, once daily for up to 7 days.
224245415|NCT01045096|DRUG|Dexlansoprazole|Dexlansoprazole 30 mg, delayed release capsules, orally, once daily for up to 7 days
224245416|NCT01045096|DRUG|Dexlansoprazole|Dexlansoprazole 60 mg, delayed release capsules, orally, once daily for up to 7 days
223770490|NCT01816464|BIOLOGICAL|Trivalent Influenza Vaccine|"The formulation based on the WHO recommendation for influenza vaccines for 2013 for the Southern-hemisphere included the following vaccine strains:~* an A/California/7/2009 (H1N1)pdm09-like virus;~* an A/Victoria/361/2011 (H3N2)-like virus; - a B/Wisconsin/1/2010-like virus.~The vaccine to be used in the study in 2013 is Vaxigrip (Sanofi Pasteur), or other equivalent licensed vaccine should the latter not be available, which will be procured commercially in pre-filled syringes. Using aseptic technique, participants will be injected with 0.5 mL of TIV from pre-filled syringe."
223665380|NCT02468245|BEHAVIORAL|weekly telephone follow up|For the study group, at the initial education visit, a time for each phone call that is convenient for the patient will be scheduled. At each phone call, the OCN will get a pill count and discuss reasons for missed doses if applicable; grade any AE's experienced and interventions for those side effects; and answer any questions or concerns that they patient may be having. Patients will then return for the standard 4 week clinic visit.
223665381|NCT02468245|BEHAVIORAL|usual care|The control group will receive the standard chemotherapy education and will return for the standard 4 week follow up clinic visit.
223665382|NCT04493892|BEHAVIORAL|Educational Intervention|Deliver an educational intervention on harmful chemical exposures, such as phthalates, found in hair care products, developed by the research team using empirical evidence with key informant feedback. The intervention will cover phthalates 1) Exposure through HCPs 2) Potential adverse health outcomes for the mother and child 3) Ways to reduce exposure
223770491|NCT01947400|OTHER|Hospitalists|AIDET Training
224245417|NCT03673488|DEVICE|TephaFlex™ mid-urethral sling|The sling is made from P4HB material. It is placed in a similar technique to standard retropubic sling procedures, but will resorb over 18-24 months post surgery.
224245418|NCT05575180|DRUG|Acetazolamide 250Mg Tab|Oral acetazolamide
223770492|NCT00420550|BEHAVIORAL|Relaxation Response using Guided Imagery|
224245419|NCT05575180|DRUG|Methazolamide Pill|Oral Methazolamide
224245420|NCT05575180|DRUG|Placebo|Oral placebo
223770493|NCT02692833|OTHER|No intervention|No intervention. This is an observational study of how patients' renal function responds to their surgery. The groups are defined by this response. There is no difference between clinical interventions between the two groups.
223770494|NCT05850871|DRUG|CAZ/AVI plus Aztreonam|Samples of the patients will be examined such as the routine blood test, blood culture et al.
224245421|NCT03021720|PROCEDURE|Arterial access|Location of arterial puncture
224245422|NCT02298465|PROCEDURE|Supine ESWL|ESWL to distal ureteric stone is performed in the supine position with the shockwave generator placed in the patient's buttock area. The aim is to direct the shockwaves through the greater and lesser sciatic foramina to reach the distal ureter.
224245423|NCT02298465|PROCEDURE|Prone ESWL|ESWL to the distal ureteric stone is performed in the traditional prone position. The shockwave generator is placed on the patient's abdomen
224245424|NCT02298465|DEVICE|Extracorporeal Shockwave Lithotripsy (ESWL)|The ESWL machine we use is the Dornier S2 lithotriptor. ESWL is performed without any sedation or anesthesia under fluoroscopy. Painkillers are given upon request.
224245425|NCT04043871|DIAGNOSTIC_TEST|Systolic blood pressure|Systolic blood pressure measured by Foot-to-Apex Systolic Interval, conventional oscillometric measurement, and the auscultatory method
224245426|NCT06217653|BEHAVIORAL|mother baby yoga|"Yoga Video Content Plan~* Mood Regulation: Abdominal/Belly Breathing~* Warm Touch from the Heart~* Chair Posture~* Bucket Wrapping~* Bukka Bukka (Heart)~* Vortex Generation~* Fertile Falls~* One Hand Two Hands~* Tiny Stretches~* Here and Now Awareness~* Dolphin Pose Mothers were asked to choose the most suitable time of the day for the baby and herself, to have the baby fed at least 45 minutes before yoga, and to practice in a calm and dim environment, listening to music or white noise of her choice. Approximately one yoga session is 20 minutes."
224245427|NCT06113653|OTHER|Prospective study|Prospective study of outcomes and predictors of mortality among preterm infants with neonatal sepsis
223770495|NCT05850871|OTHER|Conventional treatment|Conventional treatment
223770496|NCT05410652|DIAGNOSTIC_TEST|Detection of fecal samples with diagnostic kit|The 23S rRNA mutation site of clarithromycin and gyrA mutation site of levofloxacin were detected by Helicobacter Pylori fecal Gene Mutation Detection Kit.
223770497|NCT05410652|DIAGNOSTIC_TEST|Sanger Sequencing group|Detection of gyrA and 23S rRNA mutations in H. pylori isolated from Gastric Mucosa by Sanger Sequencing
223770498|NCT05410652|DIAGNOSTIC_TEST|Bacterial culture and drug sensitivity test of gastric mucosa samples|First, a sample of the patient's gastric mucosa will be obtained through gastroscopy. Then, Helicobacter pylori culture and drug sensitivity test can be carried out. Finally, the resistance data of Helicobacter pylori to clarithromycin and levofloxacin will be obtained.
224245428|NCT00156247|DRUG|acitretin|Patients who have been taking etanercept 50 mg/week for at least 3 months (12 weeks) will take acitretin 25 mg pill once daily for 6 months.
224245429|NCT01511939|DRUG|Pennsaid|Administered 10 drops x 4 until 40 drops applied topically to index knee (and also non-index knee if osteoarthritis pain is present bilaterally) 4 times a day for a 4 week active treatment period.
224245430|NCT04568408|DEVICE|Xiaomi MiBand 5|Comparison of sleep-monitoring device against polysomnography (PSG)
223665383|NCT04606680|DEVICE|Heat application at acupoints|"1. The acupoints will be selected as Tianshu, Pishu, shenshu, zhongwan, and zusanli. The location of the acupoints were based on the national GB/T 12346-2006 acupoints standard. The hot sticker will be placed on the patient's acupoints for about 2 hours. This treatment will be applied once every other day, 3 times per week, for 4 consecutive weeks. The treatment will be delayed during the menstrual period.~2. The following lifestyle modification are recommended to help to establish healthy habits:~The proportion of three nutrients in total calories comprises of 55%-65% from carbohydrates, 20%-30% from oils and 15% from protein, and the energy of the whole day distributed to three meals will follow the proportion of 30% for breakfast, 40% for lunch and 30% for dinner. Meanwhile, low-to-moderate intensity physical activities will be instructed to them for at least 5 days per week continually, 30%-50% of the maximum heart rate reserve value will be required."
223770499|NCT00424372|DRUG|pregabalin|Dosage: 150-600 mg/day (75-300 mg bid), oral administration, Treatment duration: 52 weeks
224245431|NCT01163760|DEVICE|etafilcon A|daily disposable contact lens
224245432|NCT01163760|DEVICE|ocufilcon D|daily disposable contact lens
224245433|NCT02987491|BEHAVIORAL|Exercise|Participants will perform 2 metabolic study days of either resting or acute bout of cycling exercise in a randomized cross-over design.
224245434|NCT00324168|DRUG|Antibiotics|moxifloxacin 0.5% every one hour for 48 hours while awake and then every 2 hours until re-epithelialization
224245435|NCT00324168|DRUG|Topical corticosteroid|prednisolone phosphate 1% with preservative four times a day for 1 week, then twice a day for 1 week, and finally once a day for 1 week
224245436|NCT00324168|DRUG|Placebo|0.9% NaCl and preservative (same as in steroid) four times a day for 1 week, then twice a day for 1 week, and finally once a day for 1 week
224245437|NCT03497897|DRUG|LYS006 20 mg|LYS006 20 mg, capsules, oral administration, BID, for 12 weeks
224245438|NCT03497897|DRUG|LYS006 2 mg|LYS006 2 mg, capsules, oral administration, BID, for 12 weeks
224245439|NCT03497897|DRUG|Placebo|Matching placebo, capsules, oral administration, BID, for 12 weeks
224245440|NCT02962934|OTHER|Non CRRT group|Non CRRT group:Blood samples prior to first dose of Ceftolozane-Tazobactam and at 15, 45, 1hr, 2hr 3hr 4h 5h 6h 7h 8h.
224245441|NCT02962934|OTHER|CRRT group|"CRRT group: Pre and Post dialysis filter blood samples taken prior to first dose of Ceftolozane-tazobactam and at 15min, 45min, 1h 2h 3h 4h 5h 6h 7h 8h.~Ultrafiltrate samples at 1 hr,2h 4h 6h 8h"
224245442|NCT02841488|PROCEDURE|Continuous peripheral sciatic nerve block|Continuous infusion of local anesthetics through perineural sciatic nerve catheter
223770500|NCT03819868|PROCEDURE|High cost|Surfaces allocated to this group will be treated with a high-cost sealant (Fluroshield®, Dentsply, São Paulo, Brazil), according to the manufacturer's instructions.
224245443|NCT02841488|DRUG|Fentanyl|Use of patient controlled analgesia device with intravenous fentanyl
224245444|NCT02841488|DRUG|Ropivacaine|
224245445|NCT02841488|DEVICE|Perineural catheter|
224245446|NCT01538251|DRUG|Propionyl-L-Carnitine|Modified release tablets containing 500 mg of propionyl-L-carnitine. one tablet twice a day.
224245447|NCT01538251|DRUG|Placebo|Tablets containing 500 mg of propionyl-L-carnitine. one tablet twice a day.
224245448|NCT03735251|OTHER|Diuretic，Betaloc，antiplatelet drugs|According to international guidelines,we treated patinets who suffered from different disease
224245449|NCT04452656|PROCEDURE|bilateral erector spinae block|"An ultrasound transducer will be placed in a longitudinal orientation 3 cm lateral to the T3 spinous process corresponding to the T2 transverse process.~Three muscles; trapezius , rhomboids major , and erector spinae will be identified superior to the hyperechoic transverse process.~Using in-plane approach a 25 G needle will be inserted in caudal-cephalad direction, until the tip is deep to erector spinae muscle.~Correct needle tip location will be confirmed by injecting 3 mL of saline and visualizing the linear LA spread in the fascial plane between the erector spinae muscle and the transverse process..~0.4 ml/kg (1:1 solution of bupivacaine 0.25% and lidocaine 1%) will be injected and visualizing the linear LA spread in the fascial plane between the erector spinae muscle andthe transverse process12."
224245450|NCT01735409|DRUG|ABX + DDP|ABX 260 mg/m2 day 1 + DDP 75mg/m2 day 1
224245451|NCT01735409|DRUG|ABX + DDP|ABX 140 mg/m2 day 1,8 + DDP 75mg/m2 day 1
224245452|NCT01735409|DRUG|ABX + DDP|ABX 100 mg/m2 day 1,8,15 + DDP 75mg/m2 day 1
223770501|NCT03819868|PROCEDURE|Low Cost|Surfaces allocated to this group will be treated with a low-cost sealant (Prevent®, FGM Produtos Odontológicos, Santa Catarina, Brazil), according to the manufacturer's instructions.
223770502|NCT01636895|DRUG|Efficacy of suphladoxine/pyrimethamine as IPTp|3 tablets (single dose)given twice during pregnancy one month apart after quickening
223770503|NCT01636895|DRUG|Efficacy of suphladoxine/pyrimethamine as IPTp|2 courses of 3 tablets of 500 mg N1-(5,6-dimethoxy-4-pyrimidinyl) sulfanilamide (sulfadoxine) and 25 mg 2,4-diamino-5-(p-chlorophenyl)-6-ethylpyrimidine (pyrimethamine)administered (at least 1 month apart) as DOTs to pregnant mother after quickening
224245453|NCT02047071|DEVICE|Continuous positive airways pressure|Optimal Continuous positive airways pressure treatment every night plus standard care for OSA consisting of hygienic-dietary advice and lifestyle counseling.
224245454|NCT00783861|DRUG|Lactic Acid|Lactic Acid (Dermacyd Femina)
223770504|NCT04622254|DRUG|NT 201|Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).
223770505|NCT04622254|DRUG|Placebo|Solution for injection prepared by reconstitution of powder with percent (%) Sodium Chloride (NaCl).
224245455|NCT04503993|OTHER|Hepatitis B surface antigen, Hepatitis B core antibody, and Hepatitis B surface antibody|The hepatitis B tests are released into the electronic medical charts of at-risk patients who have never been screened for chronic hepatitis B using population health tools.
224245456|NCT00021528|DRUG|citalopram|
224245457|NCT00021528|DRUG|BuproprionSR|
224245458|NCT00021528|DRUG|buspirone|
224245459|NCT00021528|DRUG|Lithium|
224245460|NCT00021528|DRUG|mirtazapine|
223770506|NCT00700791|DIETARY_SUPPLEMENT|Natural Vitamin E Tocotrienol supplement (TCT)|Oral Vitamin E Tocotrienol Supplement (TCT)
224245461|NCT00021528|DRUG|nortriptyline|
224245462|NCT00021528|DRUG|sertraline|
224245463|NCT00021528|DRUG|tranylcypromine|
224245464|NCT00021528|DRUG|VenlafaxineXR|
224245465|NCT00021528|BEHAVIORAL|Cognitive Therapy|
224245466|NCT00021528|DRUG|T3 (Triiodothyronine)|
224245467|NCT01643005|BEHAVIORAL|Relationship Strengthening HIV Prevention Intervention|The relationship strengthening HIV intervention will build on the structure of the Nurturing Parenting Groups and will be integrated so that participants will receive the Nurturing Parenting Groups plus the relationship strengthening HIV intervention.
224245468|NCT01643005|BEHAVIORAL|Parenting Program Intervention|Nurturing Parenting curriculum delivered in a group format.
224245469|NCT03334825|OTHER|Enhanced housing placement assistance|assistance in the rapid (fast-track) acquisition of permanent housing; and participation in a 12-month support services program designed to prevent PLWHA from relapsing into homelessness, with services focused on increasing clients' capacity to live independently and maintain housing stability
224245470|NCT03334825|OTHER|Standard housing placement assistance|standard connections to services and housing programs offered by HASA, HOPWA, or Ryan White
223770507|NCT00700791|DEVICE|Natural Vitamin E Tocotrienol Cream (TCT)|Natural Vitamin E Tocotrienol(TCT)Topical Cream
223770508|NCT00700791|OTHER|Placebo|Oral Placebo
223770509|NCT00700791|OTHER|Placebo Cream|Topical Placebo Cream
223770510|NCT03292822|DIETARY_SUPPLEMENT|Licochalcone A|Licochalcone A is a chalconoid, a type of natural phenols. It can be isolated from root of Glycyrrhiza glabra (liquorice) or Glycyrrhiza inflata. It shows antimalarial, anticancer, antibacterial and antiviral (specifically against influenza neuraminidase) properties in vitro.
223770511|NCT03292822|DRUG|Paclitaxel|chemotherapeutic drug
223770512|NCT00865722|PROCEDURE|Remote Postconditioning|Lower limb compression using a cuff inflated to 200 mmHg for 5 ' followed by 5' of reperfusion fo three times during 30'
224245471|NCT04901962|DEVICE|JOBST® Confidence compression garments|JOBST® Confidence (JC) compression garments will be used for daytime treatment of leg or arm lymphedema. JC compression garments exert a specific therapeutic external, physical compression level and are therefore intended to use for the management of edema. JC comprise non-invasive medical devices with no direct contact with injured skin or mucous membranes and are intended for use on intact skin only.
224245472|NCT01604694|PROCEDURE|TAP Block|An Ultra Sound-guided TAP block is performed after induction of general anesthesia prior to surgical incision. The syringes containing either saline 20 ml (placebo group) or levobupivacaine 20 ml are prepared by the hospital pharmacy under aseptic conditions.
224245473|NCT02335840|OTHER|CAF-1|In this intervention the volunteers ingested one dose of caffeinated coffee containing 144 mg of caffeine
224245474|NCT02335840|OTHER|CAF-2|In this intervention the volunteers ingested two doses of caffeinated coffee containing 288 mg of caffeine
224245475|NCT02335840|OTHER|CAF-3|In this intervention the volunteers ingested three doses of caffeinated coffee containing 432mg of caffeine
224245476|NCT02335840|OTHER|DESC|In this intervention the volunteers ingested one dose of decaffeinated coffee containing 108 mg of caffeine
224245477|NCT06294080|OTHER|Dance|Exercise intervention
224245478|NCT06294080|OTHER|Tai Chi|Exercise intervention
224245479|NCT04299594|OTHER|Questionnaire|For each subject recruited, will be collected for the study a questionnaire looking for a history of low energy fracture, and the origins of the patient (or relatives), as well as medical history, lifestyle (alcohol and tobacco consumption), weight and height. This data will be used for the secondary outcomes.
224245480|NCT03888794|DEVICE|Magnetic Resonance Imaging|Magnetic Resonance Imaging on pregnant women after 18 weeks of pregnancy with US diagnosis of congenital CNS fetal abnormality.
224245481|NCT01672515|DEVICE|RIPC group|
224245482|NCT01672515|DEVICE|Control group|
224245483|NCT06491524|DEVICE|Using disposable 7.5Fr electronic flexible ureteroscope combined 10Fr ureteral access sheath to treat renal stone <2cm|Using disposable 7.5Fr electronic flexible ureteroscope combined 10Fr ureteral access sheath to treat renal stone \<2cm
224245484|NCT00358449|DRUG|mepolizumab|Participants received mepolizumab 0.55 milligrams (mg)/kilogram (kg), 2.5 mg/kg , or 10 mg/kg by intravenous (IV) infusion for 30 minutes on Day 1, Week 4 and Week 8.
224245485|NCT06248853|OTHER|Garston technique|the patients will receive instrumented assisted soft tissue mobilization using the Graston technique, which includes the application of a cream to the posterior calf and plantar foot from the knee to the toes to reduce friction on the skin. The Graston tools will be used to mobilize the tissues of the triceps surae and plantar foot bypassing the tools along the leg and foot
224245486|NCT06248853|OTHER|exercise program|the patients will receive pedaling an exercise bicycle for 5 min with minimal resistance to warm the tissues, gastrocnemius stretches performed on a step for three repetitions held for 30 sec each , plantar fascia stretching performed in a seated position for three repetitions held for 30 sec each, and foot intrinsic muscular strengthening using a short foot exercise. Ice will be offered as needed for pain management after each session in addition to home program exercise
224245487|NCT04416230|BEHAVIORAL|massage|The massage included 30 minutes of gentle friction, kneading, stroking, and passive touch on the infant's accessible upper extremities, lower extremities, head, face, and back.
223665384|NCT04606680|DEVICE|Medicated plaster at acupoints|"1. The acupoints will be selected as Tianshu, Pishu, shenshu, zhongwan, and zusanli. The location of the acupoints were based on the national GB/T 12346-2006 acupoints standard.The chinese traditional medicine(aconite root, dried ginger, evodia rutaecarpa, clove, cinnamon, etc)in moderation will be grinded into powder，and the powder will be added with a certain amount of flour, and finally they will be blended with ginger juice to the appearance of mud. Next, 10g of the kneaded medicine mud will be taked and applied to the bottom of the ordinary sticker. They will be placed on the patient's acupoints for about 2 hours. The sticker has the same shape as the hot sticker, but it does not have the effect of thermal stimulation and infrared radiation. This treatment will be applied once every other day, 3 times per week, for 4 consecutive weeks. The treatment will be delayed during the menstrual period.~2. Lifestyle modification:It will be performed as the same as the heat application group."
223665385|NCT04606680|DEVICE|Herb-partitioned moxibustion at acupoints|"1. The acupoints will be selected as Tianshu, Pishu, shenshu, zhongwan, and zusanli. The location of the acupoints were based on the national GB/T 12346-2006 acupoints standard\[18\]. The chinese traditional medicine(aconite root, dried ginger, evodia rutaecarpa, clove, cinnamon, etc)in moderation will be grinded into powder，and the powder will be added with a certain amount of flour, and finally they will be blended with ginger juice to the appearance of mud. Next, 10g of the kneaded medicine mud will be taked and applied to the bottom of the hot sticker. They will be placed on the patient's acupoints for about 2 hours. This treatment will be applied once every other day, 3 times per week, for 4 consecutive weeks. The treatment will be delayed during the menstrual period.~2. Lifestyle modification:It will be performed as the same as the heat application group."
223770513|NCT05074550|DRUG|PPMX-T003|As an observation and evaluation method, for each dose, in principle, inpatient observation is performed for 1 week from the day before administration, and then safety and pharmacodynamic tests are evaluated by visiting the hospital every 2 weeks.
223770514|NCT02310659|OTHER|No intervention|No intervention
224245488|NCT04416230|BEHAVIORAL|quiet time|During quiet time, the infant received a 30 minute quiet time (QT) period during which non-essential caregiving tasks were restricted. During QT, clinicians were asked to avoid direct clinical caregiving activities, i.e. activities requiring physical contact with the infant.
224245489|NCT03866330|BIOLOGICAL|Intraarticular injection of WJMSC|ultrasound guided intra-articular injection of at least 10 million of Wharton's jelly-derived mesenchymal stem cells per procedure
224245490|NCT02042664|DRUG|BYETTA treatment|
224245491|NCT02042664|DRUG|Metformine|
224245492|NCT05703048|DRUG|Esmolol Esterase|35 patients will be received i.v. received a loading dose of esmolol 0.5 mg/kg in 30 mL isotonic saline in the IV line, followed by an IV infusion of esmolol 0.05 mg/kg/min. infusion stopped immediately upon extubation.
224245493|NCT05703048|DRUG|Dexmedetomidine|35 patients will be received dexmedetomidine (Precedex; Abbott Laboratories, North Chicago, Illinois, USA) (vial = 2 ml) 100 mcg/ml at bolus dose of 1 mcg /kg slowly infused over 10 min, then continuous infusion by a rate of 0. 5 mcg /kg/h., infused by a syringe pump. infusion stopped immediately upon extubation.
224245494|NCT03084822|BEHAVIORAL|FAITH! App digital intervention|The digital app will include 10 education modules addressing the major CVD risk factors to be delivered on-demand through an innovative, interactive video series. The digital app will also support the multi-media education modules, interactive surveys/quizzes, self-monitoring (diet, physical activity), and social networking (discussion board) functionality.
224245495|NCT01367457|OTHER|Temsirolimus (Non-Interventional Study)|There is not any intervention in this study.
224245496|NCT03478748|OTHER|Dental health education|Anticipatory guidance given to mothers to promote their children's oral health.
224245497|NCT05179681|OTHER|Nasal High -Flow Oxygen Therapy|patients receiving transnasal humidified rapid-insufflation ventilatory exchange
224245498|NCT02575222|DRUG|Nivolumab|3 mg/kg, IV (in the vein) on day 1 of each 2-week cycle, for a total of 3 doses prior to nephrectomy.
224245499|NCT02170506|DEVICE|Urostim 2 stimulation|Sensory transcutaneous electrical stimulation will be started for a period of 20 minutes. It is applied by means of two surface electrodes placed under chin stimulation of both sides of the center line of the preceding side. Sensory transcutaneous electrical stimulation will inhibit the cerebral control of swallowing.
224245500|NCT02158182|DRUG|Lactulose|30 ml by mouth three times daily until melena resolved, then adjusted to dose-response to obtain two to three soft stools. Duration of therapy: 7 days
224245501|NCT02158182|DRUG|L-ornithine L-aspartate|10 grams by intravenous way for 24 hours. Duration of therapy: 7 days
224245502|NCT02158182|DRUG|Rifaximin|2 tablets (400mg) three times daily. Duration of therapy: 7 days
224245503|NCT02158182|DRUG|Placebo|"Placebo (for lactulose) 30ml of dextrose solution by mouth three times daily, for 7 days.~Placebo (for L-ornithine L-aspartate) saline solution 500ml by intravenous way for 24 hours, for 7 days.~Placebo (for rifaximin) 2 dextrose tablets three times daily for 7 days."
224245504|NCT00822822|BEHAVIORAL|First Questionnaire|Complete questionnaire before completing health history
224245505|NCT00822822|BEHAVIORAL|Health History|Complete electronic health history
224245506|NCT00822822|BEHAVIORAL|Second Questionnaire|Complete questionnaire after completing electronic health history
224245507|NCT01114048|DRUG|Thalidomide, cyclophosphamide, dexamethasone, bortezomib|"1. Induction therapy with CTD regimen for 4 cycles Thalidomide 50-100 mg P.O. HS D 1\~28 Cyclophosphamide 150 mg/m² P.O. D 1\~4 Dexamethasone 20 mg/ m² IV or P.O. D 1\~4, 15-18 Repeated every 28 days~2. Intensification with Vel-CD regimen for 4 cycles (patients who fail to achieve more than PR after 2 cycles of CTD) Velcade 1.3 mg/m2 IV D1, 4, 8, 11 Cyclophosphamide 150 mg/m² P.O. D 1\~4 Dexamethasone 20 mg/ m² IV or P.O. D1, 4, 8, 11 Repeated every 21 days~   * Bactrim prophylaxis during dexamethasone administration Acyclovir prophylaxis during velcade administration Aspirin medication during thalidomide administration"
224245508|NCT01074879|DIETARY_SUPPLEMENT|Whey protein|Dietary supplement after training
224245509|NCT01074879|DIETARY_SUPPLEMENT|Milk protein|Dietary supplement after training
224245510|NCT01074879|DIETARY_SUPPLEMENT|Carbohydrates|Dietary supplement after training
224245511|NCT05217225|PROCEDURE|Simple restorative treatment|Simple Occlusal Cavity class I then followed by final restoration
224245512|NCT02957318|DIETARY_SUPPLEMENT|FiberBind|Potato pulp consisting of 68% fiber (5.5 soluble, 76.7% insoluble and 17.8% resistant starch), 9.7% water, 0.3% fat, 7.2% protein and 14% carbohydrates (starch).
223665386|NCT05996913|OTHER|Imagery rescripting|The current project aims to explore the feasibility of intervention featuring imagery rescripting (ImRs) and grounding in the management of somatic flashbacks amongst this population. ImRs was developed as a method to help activate a traumatic memory, bring corrective information into the memory, create a more favourable outcome to the memory and to support the participant to discover and express inhibited trauma-related emotional responses (Arntz \& Weertman, 1999).
223665387|NCT02619383|DEVICE|Hyperbaric oxygen therapy|The treatment comprised 40 daily hyperbaric sessions, 5 days a week, in a multiplace hyperbaric chamber (HAUX-Life-Support GmbH). Each session consisted of 90 minutes of exposure to 100% oxygen at 2 ATA with 5 minutes air breaks every 30 minutes and 1 meter per minute compression and decompression.
223665388|NCT04626401|BEHAVIORAL|Forearm immobilization|Two days of forearm immobilization
223665389|NCT06144099|BIOLOGICAL|fresh frozen plasma|transfusion of fresh frozen plasma
223665390|NCT06144099|BIOLOGICAL|prothrombin complex concentrate|prothrombin complex concentrate administration
223665391|NCT05677685|DEVICE|VISUPRIME|twice daily
223770515|NCT05132335|OTHER|Imaging Biomarkers|"One arm: Subjects are studied under two consecutive conditions, after overnight fasting and after a liquid meal ingestion. During each condition they are examined for fatty acid uptake in subcutaneous fat and skeletal muscle by FTHA(\[18F\]-FTHA) PET/MRI as well as adipose and skeletal muscle blood perfusion by radioactive water(\[15O\]-H2O ) PET/MRI. This was done at two occasions, 2-14 days apart, to assess repeatability of the measurements.~Assigned interventions:~\[18F\]-FTHA tracer injections \[15O\]-H2O tracer injections~PET/MRI imaging~Overnight fasting Liquid meal ingestion"
223770516|NCT01560624|DRUG|Treprostinil Diolamine|Active
224245513|NCT02957318|DIETARY_SUPPLEMENT|RG-I fiber|Soluble fiber extracted from potato pulp consisting of 95% fiber and 5% water.
224245514|NCT02957318|DIETARY_SUPPLEMENT|Placebo|Low-fiber control
224245515|NCT01297179|DRUG|Mirabegron|Oral
224245516|NCT01297179|DRUG|Minidril|Oral
224245517|NCT01297179|DRUG|Placebo|Oral
224245518|NCT04036539|PROCEDURE|Placement of the mini-implant and verticalization|an orthodontic mini-implant will be installed in the retromandibular region. The site will be anesthetized. The region will be pre-drilled by about 5mm with a spear drill attached to an implant motor. Once the mini-implant has been selected, it will be locked into position using a kit-specific digital key. Being threaded clockwise until the intramucosal mini-implant is at the gingival level. After installation, a metallic orthodontic lingual will be glued to the molar mesial to be verticalized. The lingual button will be glued to the inclined molar mesial with orthodontic adhesive. A gray chain elastomeric ligature will attach the head of the mini-implant to the lingual button glued to the molar mesial. A light force of 150gr will be imposed (measured with a tensiometer) in all cases, regardless of tooth position. This chain elastic will be changed every 30 days for a period of 3 months. After 90 days of the experiment time, the mini-implants will be removed.
224245519|NCT02209285|BEHAVIORAL|Self-Management Program for Older Adults with Multimorbidity|Individuals in the intervention group will receive a six-month community intervention consisting of three components: (1) intensive case management and community navigation; (2) a maximum of two in-home visits by the care coordinator, two in-home visits by a Registered Nurse, and three in-home visits by the Occupational therapist or Physiotherapist, and six visits by a Personal Support Worker over 6 months in addition to usual home care services; and (3) monthly interprofessional team case conferences to develop an evidence-based, patient-centred community reintegration plan.
224245520|NCT04926805|DEVICE|CPAP with Mask A|CPAP mask
224245521|NCT04926805|DEVICE|CPAP with Mask B|CPAP mask
224245522|NCT05050071|DRUG|Allium Sativum|Sixty-six permanent mature necrotic incisors associated with apical periodontitis in male children were selected. Teeth were randomly divided into three groups (n=22) according to intra canal medications used; group I: Ca OH2, group II: garlic extract and group III: mixture of Ca OH2 and garlic extract. After access preparation, four microbiological samples (S) were as follows; (S1): were taken before canal instrumentation and irrigation. (S2): after cleaning and shaping, Then, the third samples (S3) and forth samples (S4) were taken after placement of the tested intracanal medications into the corresponding canals, for 7 and 14 days respectively. Total DNA was extracted from microbiological samples and relative quantitive real time PCR reactions were done to quantify the relative gene expression levels (FC) for Streptococcus and Enterococcus faecalis species.
224245523|NCT05050071|DEVICE|Polymerase chain reaction|Change in the bacterial load in response to different treatment procedures
224245524|NCT02163837|DRUG|rifaximine|
224245525|NCT02388971|DRUG|MLN1202|MLN1202 solution
224245526|NCT02388971|DRUG|Placebo|MLN1202 placebo-matching solution
224245527|NCT01626287|OTHER|Frozen perineal pad|Frozen ice pads will be provided as per participants' request
223665392|NCT05677685|DEVICE|Placebo|twice daily
223665393|NCT01466829|DRUG|Parathyroid hormone|100 microgram daily. S.c
223665394|NCT01466829|DRUG|Placebo|Placebo; saline injection.
223665395|NCT00335179|DRUG|Aldara (imiquimod 5% cream)|Imiquimod 5% cream containing 12.5 mg of imiquimod per 250 mg of cream
223665396|NCT00335179|DRUG|Vehicle cream|Vehicle cream in 250 mg
223665397|NCT05884749|BEHAVIORAL|Peer to Community (P2C) Model|The P2C model is an outreach model including peer support, occupational therapy and social work aimed at facilitating community integration through relationship building and meaningful activity engagement for individuals living with concurrent disorders following homelessness.
223665398|NCT05884749|BEHAVIORAL|Care as Usual (UC)|Participants in this group will receive care available typically in the community
223770517|NCT01560624|DRUG|Placebo|Placebo
223770518|NCT05695157|DEVICE|Suture-TOOL|Suture device for fast and standardized closure of the abdominal fascia
223770519|NCT03431194|DRUG|midodrine|oral midodrine tablets 5 mg
223770520|NCT03431194|DRUG|Placebo|
223770521|NCT02502357|OTHER|Healing Statements|"Before the patient in the experimental group is placed under general anesthesia, the study staff member will repeat 5 times:~Following this operation, \[the participant\] will feel very comfortable and \[the participant\] will heal very well.~Toward the end of the surgery, the study staff member will say 5 times:~The operation has gone very well. Following the operation, \[the participant\] will be hungry. \[The participant\] will be thirsty and urinate easily."
224245528|NCT01626287|OTHER|Warm water soaked Black Tea Bags|warm water soaked black tea bags will be provided to participants' as per their request
223665399|NCT02642224|BEHAVIORAL|Social Work Case Management|The National Network of Hospital Violence Intervention (NNHVI) suggests that intervening when gunshot victims are receiving treatment in hospital trauma services may be effective in linking high-risk individuals to appropriate case management services, and that this service linkage may lower the risk of further violence. Our adaptation of the NNHVI model will focus on the social networks of gunshot victims as well as the victims themselves. Intervention efforts will range from job training and mentoring to relocation to different communities.
224245529|NCT06423066|DIAGNOSTIC_TEST|Pleural ultrasound|Patients who examine pleural ultrasound preoperatively.
224245530|NCT02376348|BEHAVIORAL|A targeted demand creation Activities|Sites randomized to the intervention arm will receive all activities in the control arm, plus additional demand-creation communication messages that focus on the non-HIV benefits of VMMC and the voluntary nature of HIV testing prior to VMMC ii) use of already circumcised men from the community as auxiliary peer promoters, iii) separate waiting and group education areas for men aged 20 years and above during service delivery, iv) engagement of female partners in community-based demand creation and education and counselling about wound healing and post-circumcision abstinence.
223770522|NCT01469325|OTHER|Repetitive Transcranial Magnetic Stimulation|We deliver rTMS to the left prefrontal cortex at 120% motor threshold (10 Hz, 4-second train duration, and 26-second intertrain interval) for 37.5 minutes (3000 pulses per session) using a figure-eight solid-core coil
223770523|NCT01469325|OTHER|Sham rTMS|Sham rTMS using a similar coil with a metal insert blocking the magnetic field and scalp electrodes that delivered matched somatosensory sensations.
224245531|NCT04013425|PROCEDURE|Ice Cream Cone Technique|Guided bone regeneration
224245532|NCT01056861|DRUG|Botulinum Toxin A|Not exceeding a total dose of 400 units, once every three months.
223665400|NCT04782206|PROCEDURE|superior hypogastric plexus block|superior hypogastric plexus chemical neurolysis
223665401|NCT04782206|PROCEDURE|pulsed radiofrequency at S3 root plus superior hypogastric plexus block|pulsed radiofrequency neuromodulation at S3 root plus superior hypogastric plexus chemical neurolysis
223665402|NCT03133884|OTHER|acupuncture|The needles will be inserted into the acupoints and the depths will be adjusted to the standard permissible layers, then even reinforcing-reducing technique will be performed on the needles until achieving deqi sensation.The needles will be retained for 30 minutes in each session and manipulated twice every 10 minutes with intermittent stimulation. Each manipulation will last for 30 seconds.
223665403|NCT03133884|OTHER|superficial acupuncture|The selected acupoints will be punctured superficially by the depth of 1-3 mm, and the needles will be retained for 30 minutes without any manipulation.
223665404|NCT01566084|DRUG|Slow sodium tablets|The normal salt condition is maintained with 2300 mg / day in the form of slowly released salt (NaCl) tablets.
223665405|NCT01566084|OTHER|placebo|Placebo tablets are administered to maintain the low sodium condition.
223665406|NCT03878433|DRUG|Glisodin|500 mg/day between 12 weeks
223665407|NCT03878433|OTHER|placebo|Placebo group (20 patients) will receive 2 pills of placebo per day + sunscreen for 6 months
223665408|NCT00474305|BEHAVIORAL|Virtual Reality Treatment for PTSD|12 session protocol for Prolonged Exposure with Virtual Reality. All sessions 90 minutes.
223665409|NCT04287543|DRUG|Melatonin|25 mg of melatonin gel at noon and 25 mg of melatonin gel 30 minutes before sleeping for 12 months
223665410|NCT04287543|DRUG|Placebos|25 mg of placebo gel at noon and 25 mg of placebo gel 30 minutes before sleeping for 12 months
223770524|NCT02150122|DIETARY_SUPPLEMENT|Vitamin D3|
223770525|NCT00042094|BIOLOGICAL|Cell-Cultured Smallpox Vaccine compared to Dryvax®|
223770526|NCT00098839|DRUG|L-asparaginase|Given IM
223770527|NCT00098839|DRUG|doxorubicin hydrochloride|Given IV
223770528|NCT00098839|DRUG|therapeutic hydrocortisone|40 mg/m2/day PO divided BID or TID
223665411|NCT02812498|OTHER|Teleconsultation|The patients in the consultation group arranged their bookings on a website, where they could also access to web educational courses or to nutritional and psychological counselling
223665412|NCT02812498|OTHER|Standard|Group of patients followed in a traditional way
223665413|NCT02651129|OTHER|Noise measurement|We will be measuring noise levels in the operating room
223665414|NCT05867589|DRUG|68Ga/18F-FAPI-04|Subjects will receive one injection of 68Ga/18F-FAPI-04 (0.1\~0.15mCi/Kg), a PET radiopharmaceutical selective for fibroblast activation protein. 68Ga/18F-FAPI-04 injection will be followed by a 10 ml saline flush.
223665415|NCT03920644|DRUG|Scopolamine Transdermal Patch [Transderm Scop]|Current Motion Sickness treatment, 1 patch behind the ear.
223665416|NCT03920644|DRUG|Scopolamine|IND, up to 6 administration of intranasal gel.
223665417|NCT03920644|DRUG|Placebo Patch|Placebo Patch, 1 patch behind the ear.
223770529|NCT00098839|DRUG|vincristine sulfate|Given IV
223770530|NCT00098839|BIOLOGICAL|epratuzumab|Given IV
223770531|NCT00098839|DRUG|cytarabine|Given IT
224245533|NCT02434055|DEVICE|AVERT PLUS|
224245534|NCT00764777|DEVICE|iliac stenting|Absolute Pro (Abbott Vascular) or Omnilink Elite (Abbott Vascular) stents
224245535|NCT02460653|DEVICE|HFNC Flow Rate|We only change the flow rates between low, medium and high settings.
224245536|NCT02020707|BIOLOGICAL|Bevacizumab|Given IV
224245537|NCT02020707|OTHER|Laboratory Biomarker Analysis|Correlative studies
224245538|NCT02020707|DRUG|Nab-paclitaxel|Given IV
224245539|NCT02020707|OTHER|Pharmacological Study|Correlative studies
223665418|NCT03920644|DRUG|Placebo Gel|Placebo Gel,up to 6 administration of intranasal gel.
223770532|NCT00098839|DRUG|prednisone|Given orally
223770533|NCT00098839|DRUG|pegaspargase|Given IM
223770534|NCT00098839|DRUG|dexrazoxane hydrochloride|Given IV
223770535|NCT00098839|DRUG|methotrexate|Given IT
223770536|NCT00098839|DRUG|etoposide|Given IV
223770537|NCT00098839|DRUG|cyclophosphamide|Given IV
223770538|NCT00098839|DRUG|leucovorin calcium|Given IV
223770539|NCT00098839|BIOLOGICAL|filgrastim|Given SC
223770540|NCT00231608|DRUG|topiramate|
223770541|NCT00073905|DRUG|capecitabine plus gemcitabine|capecitabine plus gemcitabine
223770542|NCT03447171|DEVICE|App Vision Screening|Using GoCheck Kids App Vision Screening to detect Amblyopia Risk Factors
223770543|NCT02321579|DIETARY_SUPPLEMENT|vitamin B-6|50 mg/d
223770544|NCT02321579|DIETARY_SUPPLEMENT|Glutathione|500 mg/d
224245540|NCT03151278|PROCEDURE|Zero-fluoroscopy ablation|Catheter ablation will be performed under the guidance of one kind of three-dimensional navigation system and without fluoroscopic guidance.
224245541|NCT03151278|PROCEDURE|Conventional fluoroscopy ablation|Catheter ablation will be performed using fluoroscopy plus one kind of three-dimensional navigation system.
223665419|NCT06065085|OTHER|mobile education|"The study was conducted as a randomized controlled trial with 134 individuals with hypertension (68 experimental, 66 controlled) who applied a university hospital. The data were collected by Patient Information Form, Healthy Lifestyle Behaviour Scale II, EQ-5D General Quality of Life Scale, Mindful Attention Awareness Scale and Percieved Stress Scale were used. An education application was installed on the mobile phones of the experimental group. Individuals with hypertension were provided with a training for three months through the mobile application. Data collection forms were filled in by the individuals with hypertension in the experimental and controlled groups at the beginning and at the 3rd month via the mobile application."
223665420|NCT00313183|DRUG|pramlintide acetate|single subcutaneous doses of 15mcg and 30mcg
223665421|NCT02249897|DRUG|CHOLESTYRAMINE|CHOLESTYRAMINE CAPSULES, 6 G/DAY P.O. DURING 12 WEEKS
223665422|NCT00807560|BEHAVIORAL|FBT-PO|The goal of FBT-PO is to resolve the eating disorder and return the patient to healthy psychosocial and physiological developmental trajectories through active family involvement across three treatment phases.
223665423|NCT00807560|BEHAVIORAL|NEC|Families assigned to NEC will receive a minimal nutrition and physical activity education curriculum across 16 sessions over 24 weeks.
224245542|NCT03615300|DIAGNOSTIC_TEST|serum NGAL|serum NGAL was measured at 0, 24, 48, and 72 hours after recovery of spontaneous circulation.
223770545|NCT02321579|DIETARY_SUPPLEMENT|Dextrins|50 mg/d
223770546|NCT00797992|DRUG|Injection|Intravitreal injection of 1.25 mg bevacizumab
223770547|NCT05226962|DIETARY_SUPPLEMENT|Ketone monoester|A commercial liquid supplement ingested in a dose intended to provide \~0.35 g of ketone monoester per kg body mass of the participant
223770548|NCT05226962|OTHER|Placebo|A liquid placebo that is volume- and taste-matched to the ketone monoester supplement
223770549|NCT02180425|DRUG|Tretinoin or Adapalene|Subjects will apply a pea sized amount of topical retinoid cream once daily at night for 30 days. Subjects will return for a follow-up visit.
223770550|NCT02180425|DRUG|Isotretinoin|Subjects will take one pill once daily for 5 months. Subjects will return after 1 month and after 4-5 months of treatment for skin lipid profiling.
223770551|NCT00305617|OTHER|antitumor drug screening assay|
223770552|NCT00668681|DEVICE|EndoRefix|
223770553|NCT00323739|DRUG|bevacizumab|Bevacizumab 10mg/kg, IV infusion, every 2 weeks
223770554|NCT00323739|DRUG|RAD001|RAD001 10 mg by mouth daily
223770555|NCT06032286|DEVICE|Skinstylus microneedling device|Microneedling, also known as percutaneous collagen induction (PCI), is a minimally invasive technique where small needles create microscopic wounds in the skin inducing collagen formation.
223770556|NCT03879681|DIETARY_SUPPLEMENT|Jelly confectionary Snakes|"The participants will be randomized by computer generated randomisation to receive either the jelly snake (n=120) or no intervention (n=120) apart from standard institutional management.~All children randomised into the snake group will be offered a chewy jelly snake once alert and cooperative in PACU or on the ward once University of Michigan Sedation Scale (UMSS) is 025,26. The UMSS is a simple observational tool that assesses the level of alertness on a five-point scale ranging from 1 (wide awake) to 5 (unarousable with deep stimulation).~The children randomized into the control group will receive a chewy jelly snake as a treat at discharge."
223770557|NCT03600168|DEVICE|PuraStat®|Synthetic haemostatic material
223770558|NCT05508061|DRUG|Insulin Lispro Cartridge [Lyumjev]|Administration of Lyumjev in combination with the AP system
223770559|NCT05508061|DRUG|Insulin Lispro Cartridge|Administration of Humalog in combination with the AP system (standard therapy)
223770560|NCT01117818|BIOLOGICAL|active: AFFITOPE AD02|vaccination
223770561|NCT01117818|BIOLOGICAL|control: Placebo|vaccination
223770562|NCT01558882|DEVICE|Essure|Essure devices are deployed according to manufacturer's instructions for tubal sterilization.
223770563|NCT05621421|PROCEDURE|FFR and IVUS guided PCI|PCI to the long lesion guided with FFR and IVUS
223770564|NCT03228680|DRUG|Follitropin delta|Single daily subcutaneous administration through pre-filled injection pen
223770565|NCT03228680|DRUG|Follitropin beta|Single daily subcutaneous injection in the abdomen
223770566|NCT05406544|OTHER|FD qualitative study on quality of life|Patients will be contacted and focus groups will be organized with 6 to 8 patients presenting different types of FD: monostotic, polyostotic, with or without craniofacial damage. Several focus-groups will be conducted with men only or women only. Patients will be led in a semi-directive manner by a moderator who will use an interview grid listing all the topics to be addressed: symptoms, self-image, psychological and emotional well-being, difficulties in daily life and adaptative strategies. The discussions will be recorded and transcribed verbatim. Data will be analyzed manually by 2 investigators and with the help of a semantic analysis software. The objective is to bring out common notions about the quality of life of patients, their psychological and emotional well-being, their difficulties in daily life and their coping strategies according to their condition. Differences or similarities between men and women will be investigated.
224245543|NCT01643707|BEHAVIORAL|Evidence based guidelines and tools|Education, guidelines, tools
223665424|NCT02013258|DRUG|Intranasal oxytocin|This is a double-blind placebo controlled 2x2 study. Subjects will receive OT for 5 consecutive days during their 7 day stay. This will be followed by a wash out period of 4-6 weeks.
223665425|NCT02013258|OTHER|Placebo|This is a double-blind placebo controlled 2x2 study. Placebo will be given via intranasal spray, one spray in each nostril daily x 5 days. One month interval between arms of treatment.
224245544|NCT02300103|DRUG|SOF/VEL|400/100 mg FDC tablet administered orally once daily
224245545|NCT02300103|DRUG|RBV|Tablet (s) administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
224245546|NCT02183571|DRUG|Merck Glucophage® high dose|Part I: Treatment A
224245547|NCT02183571|DRUG|BMS Glucophage® high dose|Part I: Treatment B
224245548|NCT02183571|DRUG|Merck Glucophage® low dose|Part II: Treatment C
224245549|NCT02183571|DRUG|BMS Glucophage® low dose|Part II: Treatment D
224245550|NCT02438878|BEHAVIORAL|Baby Behavior|
224245551|NCT04091971|DRUG|Ketamine|"Subjects will undergo 4 sequential intravenous infusions of ketamine administered over a two week period.~Ketamine is administered at a dose of 0.5mg/kg intravenously as a slow continuous infusion over approximately 40 minutes, with 4 sequential infusions over an approximately two week period (two infusions per week for two weeks)."
224245552|NCT04872075|OTHER|Concert|People attending a concert in a closed area, with a mask
224245553|NCT04872075|DIAGNOSTIC_TEST|Rapid nasopharyngeal antigen test for Sars-Cov-2|A nasopharyngeal swab at inclusion (up to 3 days before concert) to confirm eligibility
224245554|NCT04872075|DIAGNOSTIC_TEST|Saliva Sample|Saliva samples sent by participant at Day0 and Day7
224245555|NCT06199297|DRUG|Atezolizumab combined with Bevacizumab|Atezolizumab 1200 mg IV d1, Q3W, combined with bevacizumab 15 mg/kg IV d1, Q3W treatment, treatment continued until disease progression, development of intolerable toxic reactions
224245556|NCT06199297|DRUG|Sintilimab combined with Bevacizumab|Sintilimab 200 mg IV d1, Q3W, combined with bevacizumab 15 mg/kg IV d1, Q3W treatment, treatment continued until disease progression, development of intolerable toxic reactions
224245557|NCT06199297|PROCEDURE|Transcatheter arterial chemoembolization and hepatic arterial infusion chemotherapy|The chemoembolization process employed 30 mg/m2 of epirubicin and 2-10 mL of lipiodol. This was followed by FOLFOX-based HAIC, including 85 mg/m2 of oxaliplatin, 400 mg/m2 of leucovorin, and an initial bolus of 400 mg/m2 of 5-FU for 2 h, which was then followed by a sustained infusion of 1200 mg/m2 5-FU for 23 h.
223665426|NCT01293071|OTHER|Antibiotic rotation|Rotation of antibiotic classes as specific preferred antibiotic class to be used for empiric treatment of ICU acquired infections.
223770567|NCT05406544|OTHER|FD quantitative sudy on quality of life and olfaction.|Participants will receive 3 questionnaires to complete: the SF36 questionnaire (quality of life), the SELF-MOQ questionnaire (olfaction evaluation) and a demographic questionnaire. Other data required for the study will be extracted from the medical record: age, weight, height, affected bone sites, Radiological/ biological activity data, sensorial deficit, medication. For each questionnaire, scores will be calculated and compared between the different FD patient populations according to sex, age and type of FD.
224245558|NCT02689297|OTHER|chlorine dioxide|First week, subjects were instructed to do regular tooth brushing. After that group A was requested to use chlorine dioxide mouthwash two time per days for three weeks in addition to tooth brushing and then, one week for combination of tooth brushing, tongue cleaning and mouth washing.
224245559|NCT02689297|OTHER|small toothbrush for tongue cleaning|First week, subjects were instructed to do regular tooth brushing. After that group B was requested to brush their tongue with small toothbrush two time per days for three weeks in addition to tooth brushing and then, one week for combination of tooth brushing, tongue cleaning and mouth washing.
224245560|NCT03016650|DRUG|Acetaminophen|Patients receive 100 mL of physiologic saline with 1 g IV paracetamol 30 minutes before the end of the operation and postoperatively 6, 12 and 18 hours after PCNL
224245561|NCT03016650|DRUG|Ibuprofen|Patients receive 100 mL of physiologic saline with 800 mg IV ibuprofen 30 minutes before the end of the operation and postoperatively 6, 12 and 18 hours after PCNL
224245562|NCT03734263|DRUG|sodium phenylbutyrate|Enrolled subjects will receive a four-week period of treatment with sodium phenylbutyrate (oral use)
224245563|NCT00905658|DIETARY_SUPPLEMENT|therapeutic nutritional supplementation|Patients receive systematic nutritional supplementation
224245564|NCT00905658|PROCEDURE|standard follow-up care|Patients undergo standard monitoring
224245565|NCT05439252|BEHAVIORAL|Exercise Snacking|Each bout of exercise snacking consists of 5 exercise. Each exercise is performed for one minute, with aim of completing as many repetitions as possible of that exercise in that minute. One minute of rest is observed between each exercise of the exercise snack. The five exercises are sit-to-stand from a chair, seated overhead arm raises, march on the spot, seated arm raises and shoulder touches, and seated calf raises. The sit-to-stand exercise is always performed first, with the number of repetitions achieved recorded, and subsequent exercises performed in any order without recording of repetitions.
224245566|NCT01568762|DRUG|VAK694|Intravenous infusion
224245567|NCT01568762|DRUG|VAK694 placebo|Intravenous infusion
223665427|NCT02546700|DRUG|Lebrikizumab|Lebrikizumab 125 milligrams (mg) will be administered subcutaneously once in every 4 weeks.
224245568|NCT01568762|DRUG|QAX576|Intravenous infusion
224245569|NCT01568762|DRUG|QAX576 placebo|Intravenous infusion
224245570|NCT05600322|DRUG|Hexaminolevulinate Hydrochloride|Enrolled patients will be instilled with 50 mL hexaminolevulinate hydrochloride as intravesical solution (Hexvix) in the bladder for one hour at Visit 2. After bladder evacuation, the cystoscopic examinations will be performed in both white and blue light.
224245571|NCT05600322|DEVICE|Richard Wolf Photodynamic Diagnostic Equipment (PDD) system|Cystoscopy in White and Blue light will be done using the Richard Wolf PDD system.
224245572|NCT01666730|DRUG|metformin hydrochloride|Given PO
224245573|NCT01666730|DRUG|oxaliplatin|Given IV
223665428|NCT02546700|DRUG|Placebo|Matching placebo will be administered subcutaneously once in every 4 weeks.
223665429|NCT01733303|BEHAVIORAL|personalized core muscle training program|Participants are allocated to the exercise group will commence the personalized core training exercise with EMG biofeedback based on their testing results in muscle quality. The program will run for 3 months with patients attending for one hour three times a week. The age-matched control group will maintain their usual daily life activities without any specific instruction. The exercise training will be run by an experienced physiotherapist, who will encourage patients individually to progress at their own pace.
223770568|NCT03670589|RADIATION|Radiosurgery gammaknife|This procedure use intense gamma ray, which are concentrated to the precise volume of the tumor that used to stop the progression of the tumor
224245574|NCT01666730|DRUG|leucovorin calcium|Given IV
224245575|NCT01666730|DRUG|fluorouracil|Given IV
224245576|NCT01666730|OTHER|laboratory biomarker analysis|Correlative studies
224245577|NCT06437691|PROCEDURE|Self-Expandable Metallic Stent Placement|
224245578|NCT06626555|DRUG|Letermovir|Letermovir 480mg PO once daily
224245579|NCT02953223|OTHER|Free amino acid infant formula|Patients who will be fed a free amino acid based infant formula
223665430|NCT01379144|DRUG|latanoprost 75 ug|"Eligible patients were randomized to receive 1 of 4 different doses of latanoprost (50, 75, 100 or 125 ug/mL).~Study medication was supplied in clear bottles. Patients were instructed to instill one drop of study medication in one or both eyes (as instructed by their investigator) once daily in the evening between 7 PM and 9 PM during the entire treatment period. The first dose of study medication was instilled in the evening of the baseline visit and the last dose was instilled in the evening before the Week 4 (Day 28) visit."
223665431|NCT01379144|DRUG|latanoprost 100 ug|"Eligible patients were randomized to receive 1 of 4 different doses of latanoprost (50, 75, 100 or 125 ug/mL).~Study medication was supplied in clear bottles. Patients were instructed to instill one drop of study medication in one or both eyes (as instructed by their investigator) once daily in the evening between 7 PM and 9 PM during the entire treatment period. The first dose of study medication was instilled in the evening of the baseline visit and the last dose was instilled in the evening before the Week 4 (Day 28) visit."
223665432|NCT01379144|DRUG|latanoprost 125 ug|"Eligible patients were randomized to receive 1 of 4 different doses of latanoprost (50, 75, 100 or 125 ug/mL).~Study medication was supplied in clear bottles. Patients were instructed to instill one drop of study medication in one or both eyes (as instructed by their investigator) once daily in the evening between 7 PM and 9 PM during the entire treatment period. The first dose of study medication was instilled in the evening of the baseline visit and the last dose was instilled in the evening before the Week 4 (Day 28) visit."
223665433|NCT01379144|DRUG|latanoprost 50 ug|"Eligible patients were randomized to receive 1 of 4 different doses of latanoprost (50, 75, 100 or 125 ug/mL).~Study medication was supplied in clear bottles. Patients were instructed to instill one drop of study medication in one or both eyes (as instructed by their investigator) once daily in the evening between 7 PM and 9 PM during the entire treatment period. The first dose of study medication was instilled in the evening of the baseline visit and the last dose was instilled in the evening before the Week 4 (Day 28) visit."
223665434|NCT03725241|DIETARY_SUPPLEMENT|Glutathione Supplement|1000 mg/day Glutathione
223665435|NCT03725241|DIETARY_SUPPLEMENT|Placebo Supplement|Crystalline cellulose
223665436|NCT04696887|BEHAVIORAL|Tele Tai Chi Intervention for Persons Aging with Long-Term Mobility Disabilities|• 8-week Tele Tai Chi intervention, participants will use a tablet or computer to join a small-group, online class (1hr, twice weekly) from home; during each session, participants will exercise as a group along with the pre-recorded video lessons and have the opportunity for social interaction (via video chat) before and after class.
224245580|NCT03135236|BEHAVIORAL|Parent training|Participants will attend 3 trainings. There will be a pre-test before training 1 and an initial post-test after training 3. There will be a final post-test 1 month after the final training.
224245581|NCT04466111|DEVICE|Intellis neurostimulator system|The study will use the commercially available IntellisTM neurostimulator and compatible SCS system components from Medtronic using stimulation parameters within the specifications approved for use in the approved indications. The study will stimulate the cervical dorsal columns of the spinal cord.
224245582|NCT02886468|OTHER|skin ultrasound|
224245583|NCT05702567|DEVICE|RF + PFMT|"During each session the patient is lying face up, with knees bent and feet resting on the stretcher.~Then, the vaginal probe is introduced into the cavity using a lubricant suitable for intracavitary use and radiofrequency. The device is started at 15% intensity and adapting to a 10-point Likert scale, at point 3 or 4 of intensity.~At the same time that the radiofrequency is applied, pelvic floor contractions are performed guided by the physiotherapist, and these contractions are three:~* 10 fast contractions of one second each, with 10 seconds of rest.~* 5 seconds of sustained contraction and 10 seconds of rest.~* 10 seconds of contraction maintained with 10 seconds of rest.~The contraction maintenance time will be adapted to what each woman can keep the pelvic floor contracted, with a view to the goal being to complete these exercises cyclically during the entire session."
224245584|NCT05702567|OTHER|PFMT + Placebo RF|"The intervention is exactly the same as the group RF + PFMT, unlike the non-functioning of the RF in the patients belonging to this group.~The patient is lying face up, with knees bent and feet resting on the stretcher. Then, the vaginal probe is introduced into the cavity using a lubricant suitable for intracavitary use and radiofrequency, the device is started at 15% intensity, but in this case, the program does not work or apply radiofrequency to the patients.~At the same time, that the radiofrequency's probe is applied, pelvic floor contractions are performed guided by the physiotherapist, and these contractions are the three named in the Radiofrequency + PFMT.~The contraction maintenance time will be adapted to what each woman can keep the pelvic floor contracted, with a view to the goal being to complete these exercises cyclically during the entire session."
224245585|NCT00758186|PROCEDURE|Emergency endoscopic colonic stenting|Colonic-stenting and elective surgery: Emergency endoscopic colonic stenting followed by elective surgery at a later date for acute left-sided malignant colonic obstruction. Patients who had successful stenting were discharged and re-admitted for elective surgery. Patients in whom stenting was unsuccessful underwent emergency surgery. The choice of surgery performed was up to the individual consultant colorectal surgeon.
224245586|NCT00758186|PROCEDURE|Emergency surgery|Patients underwent emergency surgery for acute left-sided malignant colonic obstruction. The choice of surgery performed was up to the individual consultant colorectal surgeon. Surgery included primary resection with or without defunctioning stoma and palliative diverting stoma only.
224245587|NCT00182442|DRUG|Olanzapine & Quetiapine|
224245588|NCT01716793|DRUG|Ara-C|"* Intermediate dose during induction phase to remission.~* High-dose during consolidation phase in patients with favorable cytogenetics."
224245589|NCT01716793|OTHER|Autologous transplantation|"* In patients with normal karyotype and one cycle of chemotherapy to achieve complete remission.~* In patients with other cytogenetics without HLA-Identical sibling."
224245590|NCT01716793|OTHER|Allogeneic HLA-identical sibling transplantation|"* Patients without favorable or normal karyotype(and one course to CR).~* Patients with normal karyotype who need two cycles of chemotherapy to achieve CR, and other cytogenetics."
224245591|NCT01716793|OTHER|CD34+ selection|In allotransplants, it is performed a CD34+ cell selection of peripheral blood stem cell transplantation.
224245592|NCT02830022|OTHER|physiological explorations|
223665437|NCT02366091|DRUG|Methotrexate|Administered to determine the effect of anti-inflammatory agents on coronary and systemic endothelial function in patients with coronary artery disease
223770569|NCT03670589|PROCEDURE|Microsurgery resection|Classical surgical approach with oto-neurosurgery procedures
223665438|NCT02366091|DRUG|Colchicine|Administered to determine the effect of anti-inflammatory agents on coronary and systemic endothelial function in patients with coronary artery disease.
223665439|NCT02366091|DRUG|Placebo|Prepared by Johns Hopkins Investigational Drug Service to mimic methotrexate and colchicine.
223665440|NCT00644007|DRUG|Placebo|Placebo as a substitute of SK3530 100mg
223665441|NCT00644007|DRUG|SK3530|SK3530 100 mg
223665442|NCT01764191|OTHER|18F-Fluorodeoxyglucose (18F-FDG) PET/CT|All subjects suspected of cardiac sarcoidosis will receive an intravenous dose of 18F-FDG (determined by weight, but not to exceed 521 MBq). Following an uptake phase of about 60 minutes, each subject will receive a PET/CT scan to evaluate the presence of cardiac sarcoidosis.
223665443|NCT03756493|PROCEDURE|Periodontal Surgery with OFD+ABG+L-PRF|Patients will be treated by periodontal surgical flaps with the addition of L-PRF+ Autogenous Bone Graft filling material.
223665444|NCT03756493|PROCEDURE|Periodontal Surgery with OFD+ABG|Patients will be treated by periodontal surgical flaps with the addition of Autogenous Bone Graft filling material.
223665445|NCT03756493|PROCEDURE|Periodontal Surgery OFD|Patients will be treated by Open Flap Debridement without use of filling material.
223665446|NCT05122702|DRUG|modified Shenling Baizhu San|modified Shenling Baizhu San granules, twice daily for 12 weeks.
223665447|NCT05122702|OTHER|Placebo|Placebo granules, twice daily for 12 weeks.
223770570|NCT02476396|PROCEDURE|Carotid Endarterectomy or Stenting|"Carotid endarterectomy is a procedure to treat carotid artery disease. This disease occurs when fatty, waxy deposits build up in one of the carotid arteries. The carotid arteries are blood vessels located on each side of your neck (carotid arteries).~This buildup of plaques (atherosclerosis) may restrict blood flow to your brain. Removing plaques causing the narrowing in the artery can improve blood flow in your carotid artery and reduce your risk of stroke.~In carotid endarterectomy, you an anesthetic. Your surgeon makes an incision along the front of your neck, opens your carotid artery and removes the plaques that are clogging your artery. Your surgeon then repairs the artery with stitches or a patch made with a vein or artificial material (patch graft).~Source: Mayo Clinic~Carotid stenting uses a expandable metal coil to prevent the artery from narrowing."
223770571|NCT03058068|BIOLOGICAL|Allo-hMSCs|1 peripheral intravenous infusion of allogeneic human mesenchymal stem cells (hMSCs)
223770572|NCT03058068|BIOLOGICAL|Placebo|1 peripheral intravenous infusion
224245593|NCT03021538|DEVICE|Extracorporeal Membrane Oxygenation|ECMO is used during lung transplant procedure
224245594|NCT03021538|DEVICE|Cardiopulmonary Bypass|CPB is used during lung transplant procedure
224245595|NCT02263092|BEHAVIORAL|Physical exercise|The intensity of physical exercise will be determine by the maximum heart rate (max HR) using the formula (220 - age). For the high intensity, the intensity will between 79-95% xx% of maxHR; moderate intensity, 64-76% of maxHR; mild intensity, 57-63% of maxHR. Furthermore, during the physical exercise the heart rate will be continuous evaluate by the POLAR and the rate perceived scale will be register in each 3 minutes by the modified Borg scale
224245596|NCT02263092|DEVICE|tDCS|Current will be applied by a DC stimulator (NeuroConn, Germany) using a pair of saline-soaked sponge electrodes (surface 35 and 36cm²). tDCS will be applied to Cz and Oz according to International 10-20 EEG system. In the anodal tDCS, the anode will be placed in Cz and cathode in Oz. In the cathodal tDCS the inverse position will be done. Parameters of current intensity and duration (dose) used were 2 mA stimulation intensity for 20 minutes with current ramping up and down of 10 seconds each.For sham, the same position of anodal tDCS will be assumed, however, current duration is only 30 seconds, with current ramping up and down of 10 seconds each. Moreover, the electrostimulation device is automatically turned off without patient's perception. Thus, patients experience early sensations (mild to moderate tingling) in stimulation site without inducing effect. Moreover, after each tDCS session, patients will answer adverse effects questionnaire.
224245597|NCT02263092|BEHAVIORAL|Rest|15 or 30 minutes seat without move the legs
224245598|NCT01327963|DEVICE|Transoral Incisionless Fundoplication|Transoral incisionless esophago-gastric fundoplication performed using the EsophyX (brand name) system with SerosaFuse (brand name) fasteners (EndoGastric Solutions, Inc., Redmond, Washington, USA) and following the standardized Transoral Incisionless Fundoplication 2.0 technique iteration (TIF2.0) protocol.
224245599|NCT00004314|DRUG|aminomidazole carboxamide riboside|
224245600|NCT01123681|DEVICE|Choice of endotracheal tube|Types of endotracheal tube, normal cuff without sub-glottic aspiration, normal cuff with sub-glottic aspiration, Special cuff with sub-glottic aspiration
224245601|NCT02743130|DIETARY_SUPPLEMENT|Blackcurrant Nectar|Consumption of a single dose (300 ml)
224245602|NCT02743130|DIETARY_SUPPLEMENT|Lingonberry Nectar|Consumption of a single dose (300 ml)
224245603|NCT02743130|DIETARY_SUPPLEMENT|Reference|Consumption of a single dose (300 ml)
224245604|NCT00893464|DRUG|IXAZOMIB|Patients will be administered IXAZOMIB by IV on Days 1, 8, and 15 of a 28-day cycle. The first stage of the study will be initiated at a starting dose of 0.125 mg/m2. Subsequent doses will increase until a maximum tolerated dose (MTD) is established.
223665448|NCT04663490|DIAGNOSTIC_TEST|Neutrophil to Lymphocyte Ratio|Zahorec et al. identified the neutrophil-lymphocyte ratio (NLR) as an inflammation marker in critical patients, defining as the absolute neutrophil count divided by the absolute lymphocyte count
223665449|NCT02618213|DEVICE|Optiflow Junior|Humified air are dispensed through the system. Airflow, FiO2 (Fraction of inspired oxygen) , SpO2 (peripheral capillary Oxygen saturation) and respiratory rate are noted each hour. Progression of condition might lead to change of system og mechanical ventilation. poor tolerance might lead to change of system
223665450|NCT02618213|DEVICE|Continous Positive Airway Pressure|Humified air are dispensed throug the system. Airflow, FiO2, SpO2 and respiratory rate are noted each hour. Progression of condition might lead to change of system or mechanical ventilation. Poor tolerance might lead to change of system.
224245605|NCT05287438|DIAGNOSTIC_TEST|Next-Generation DNA Sequencing|NGS is a technique of microbiological sequencing, using 16s ribosomal RNA molecular identification has been implemented to detect bacteria and fungi present in the sample
224245606|NCT05287438|DIAGNOSTIC_TEST|Standard Culture|Standard of care culture and sensitivity
223665451|NCT04062136|COMBINATION_PRODUCT|stem cell transplantation|Transplantation of umbilical cord mesenchymal stem cells
223770573|NCT03970434|OTHER|Venous blood collection|Venous blood collection
223770574|NCT03970434|OTHER|Peripheral blood collection|Peripheral blood collection
224245607|NCT01389102|DRUG|Estradiol transdermal one 90 μL spray|Estradiol transdermal spray, one 90 μL spray applied to 1 inner forearm daily for 12 weeks using a blinded applicator
224245608|NCT01389102|DRUG|Estradiol transdermal spray, two 90 μL sprays|Estradiol transdermal spray, two 90 μL spray applied to adjacent non-overlapping areas on 1 inner forearm daily for 12 weeks using a blinded applicator
224245609|NCT01389102|DRUG|Estradiol transdermal three 90 μL sprays|Estradiol transdermal spray, three 90 μL spray applied to adjacent non-overlapping areas on 1 inner forearm daily for 12 weeks using a blinded applicator
224245610|NCT01389102|DRUG|Placebo transdermal two 90 μL sprays|Placebo transdermal spray, two 90 μL spray applied to adjacent non-overlapping areas on 1 inner forearm daily for 12 weeks using a blinded applicator
224245611|NCT01389102|DRUG|Placebo transdermal three 90 μL sprays|Placebo transdermal spray, three 90 μL spray applied to adjacent non-overlapping areas on 1 inner forearm daily for 12 weeks using a blinded applicator
224245612|NCT01389102|DRUG|Placebo transdermal one 90 μL spray|Placebo transdermal spray, one 90 μL spray applied to 1 inner forearm daily for 12 weeks using a blinded applicator
224245613|NCT04903600|DIETARY_SUPPLEMENT|Probiotics fruit vegetable fiber powder product|Eat 16 g for once, and twice a day
223665452|NCT05747040|DIAGNOSTIC_TEST|monitoring|"The intervention consists of 48-h monitoring by using two types of monitoring: an objective monitoring, through a class IIa wearable medical device recording four physiological signals, and a subjective monitoring through a questionnaire developed with Microsoft Forms that can be compiled with a smartphone. The monitoring will be conducted during a motor neurorehabilitation treatment, 24 hours before and 24 hours after the treatment at the participant's home. Besides this monitoring, stratification questionnaires will be administered to each participant to be stratified in one of the three categories (absence of pain, nociceptive pain, or neuropathic pain) based on the following timeline:~t0: baseline t1: pre-treatment t2: post-treatment t3: follow-up"
223665453|NCT05537870|BEHAVIORAL|cancer nurse navigator care|oncology case manager care combined with cancer nurse navigator care
224245614|NCT04903600|DIETARY_SUPPLEMENT|Placebo|Eat 16 g for once, and twice a day
223665454|NCT05537870|BEHAVIORAL|case manager care|case manager care (usual care)
223665455|NCT05464953|DRUG|Triamcinolone Acetonide|Triamcinolone Acetonide is a corticosteroid that has antiangiogenic and anti-inflammatory effects that can inhibit the expression of VEGF and other proinflammatory cytokines, improving best-corrected visual acuity and decreasing central retinal thickness (CRT) in patients with macular edema
223665456|NCT05464953|DRUG|Formulated Triamcinolone|Formulated Triamcinolone: is triamcinolone and sodium hyaluronate and chondroitin sulfate
224245615|NCT03232437|DEVICE|Aina HbA1c Monitoring System|Monitoring test for quantitative determination of HbA1c
224245616|NCT00436553|DRUG|Verteporfin Photodynamic Therapy|After a 10-minute intravenous infusion of verteporfin at a dose of 6 mg/m\^2 body surface area, verteporfin was activated by light application of 50 J/cm\^2 (Standard Fluence rate) or 25 J/cm\^2 (Reduced Fluence rate) to the study eye, begun 15 minutes after the start of the infusion.
224245617|NCT00436553|DRUG|Ranibizumab|Ranibizumab 0.5 mg administered as an intravitreal injection.
224245618|NCT00436553|DRUG|Verteporfin Placebo|To maintain masking, as a placebo for verteporfin photodynamic therapy, patients were administered a 10-minute intravenous infusion of 5% dextrose solution, followed by light application of 50 J/cm\^2 to the study eye, begun 15 minutes after the start of infusion.
224245619|NCT00436553|DRUG|Ranibizumab Placebo|To maintain masking, patients in the combination groups received sham intravitreal injections whenever retreatment with active Ranibizumab was not warranted based on the retreatment algorithm.
224245620|NCT02379247|DRUG|BYL-719 (alpelisib)|Oral PI3K inhibitor
224245621|NCT02379247|DRUG|Nab-paclitaxel|IV taxane
224245622|NCT01056965|DRUG|davunetide (AL-108, NAP)|Subjects will be randomized 2:1 (drug:placebo). Subjects will receive twice daily treatment with davunetide 15 mg administered intranasally.
223665457|NCT00883519|BEHAVIORAL|Interpersonal Psychotherapy for Depressed Adolescents|12 psychotherapy sessions delivered over 16 weeks
223665458|NCT00883519|BEHAVIORAL|Interpersonal Psychotherapy for Depressed Adolescents and Parents|12 psychotherapy sessions delivered over 16 weeks
223665459|NCT02776319|DEVICE|Non-invasive brain stimulation (active)|Non-invasive brain stimulation (active)
223665460|NCT02776319|DEVICE|Non-invasive brain stimulation (sham)|Non-invasive brain stimulation (sham)
223665461|NCT00622271|BEHAVIORAL|Group Therapy|Self-management Group Protocol: The parent sessions will be structured by general topic area, but teaching of clinical and behavioral information will be derived from questions and problems posed by the group in order to actively meet the needs and concerns of participants. The parent sessions will be an interactive process of eliciting concerns and questions, presenting information to address those questions, and following up with a discussion to review concerns and strategies to address the behavioral aspects of the issues. The child sessions will be activity focused, with hands-on opportunities to practice the skills being taught.
223665462|NCT01302977|PROCEDURE|Fetal tracheal occlusion|Insertion of a detachable balloon inside fetal trachea by percutaneous fetoscopy
224245623|NCT01056965|DRUG|Placebo nasal spray|Subjects will be randomized 2:1 (drug:placebo). Subjects will receive twice daily treatment with placebo administered intranasally.
224245624|NCT04857125|OTHER|Patient interventions|"The multicomponent intervention consists of several elements regarding avoidance of specific pre-medications and optimising the patients condition before surgery (reducing fasting and fluid-fasting time).~Per-operative focus on using bispectral index (BIS) guided anaesthesia, Total intravenous anaesthesia (TIVA) as first choice, pain-and PONV (postoperative nausea and vomiting) prophylaxis and treatment.~Postoperative focus on: Reducing indwelling catheters, Fluid (p.o. or IV), Nutrition, Mobilisation, Sleep, Non-pharmacological interventions (Shielding, involving of relatives, orientation, optimizing of senses)"
223665463|NCT02721953|DIETARY_SUPPLEMENT|Butyrate|Butyrate
223665464|NCT02721953|OTHER|Placebo|Placebo
223665465|NCT01395290|DRUG|cholecalciferol|20.000 IU per week, oral
224245625|NCT04857125|OTHER|Staff education|Staff will be educated for at least 1-2 hours. Anaesthesiologist and nurse anaesthetists will receive a brush up on the use of bispectral index (BIS) and the intervention elements that are implemented and monitored. Staff in the PACU, as well as staff in the surgery wards, will be educated in postoperative delirium, learning to identify symptoms of delirium and how to use the screening tool CAM.
223665466|NCT05543772|DRUG|Normal saline|participant will be given 500 ml normal saline through intravenous access. blood sample will be extracted before and after giving normal saline using same intravenous catheter
223665467|NCT02160041|DRUG|BGJ398|BGJ398 was dosed on a flat scale of 125 mg (e.g., 1 x 100 mg and 1 x 25 mg capsules) once daily for the first 21 days of the 28-day cycle (3 weeks on, 1 week off in a cycle). A complete treatment cycle is defined as 28 days.
223665468|NCT01403948|DRUG|BI 836826|Monotherapy with BI 836826 at escalating dose levels administered as an intravenous infusion
223665469|NCT00132977|DEVICE|Cardiac Resynchronization Therapy|
223665470|NCT00836121|PROCEDURE|right thoracotomy|complete surgical resection
223665471|NCT01717599|DRUG|Diclofenac|Diclofenac 90mg, 2ml/A, IM(intramuscular) injection immediately after procedure of ERCP
223665472|NCT01717599|DRUG|normal saline|normal saline 2ml/A, IM(intramuscular) injection immediately after procedure of ERCP
223665473|NCT03482934|DEVICE|sphygmomanometer|device used for measurement of brachial blood pressure
223665474|NCT03482934|DEVICE|mobilogragh|device used for measurement of central blood pressure
223665475|NCT03482934|DIAGNOSTIC_TEST|ECG|Electrocardiogram
223665476|NCT03482934|DIAGNOSTIC_TEST|Echocardiography|Echocardiography
223665477|NCT01082549|DRUG|gemcitabine/carboplatin|i.v.
223665478|NCT01082549|DRUG|gemcitabine/carboplatin plus Iniparib|i.v.
224245626|NCT03192930|OTHER|Hyperbaric exposure|Hyperbaric exposure 4 ATA for 36 hours followed by 70 hours decompression
224245627|NCT01631422|DRUG|RO4602522|Single radiolabeled dose
224245628|NCT00403039|DRUG|Ranibizumab (Lucentis )|
224245629|NCT02437279|PROCEDURE|Surgery of the tumor|
224245630|NCT02437279|DRUG|Infusion with ipilimumab 3 mg/kg q3wks|
224245631|NCT02437279|DRUG|Infusion with nivolumab 1 mg/kg q3wks|
224245632|NCT04158570|PROCEDURE|Percutaneous Nephrolithotomy|"Application of different stone scoring systems :~* Guy's scoring system (GSS).~* Seoul renal stone complexity scoring system (S-ReSC).~* S.T.O.N.E. nephrolithometry scoring system.~* CROES Nomogram. These scoring systems will be applied on each patient and correlate the predictive values with the real results to know which one of the above scoring systems better predict the outcomes."
224245633|NCT01285037|DRUG|LY2801653|LY2801653 given orally once daily during 28-day cycles. Participants may continue on study drug until disease progression, unacceptable toxicity, or other withdrawal criterion is met.
224245634|NCT01285037|DRUG|Cetuximab|Cetuximab given via IV infusion once weekly, 400mg/m2 for first dose and 250mg /m2 for subsequent doses. If LY2801653 treatment is stopped due to toxicity after a minimum of 4 cycles, cetuximab may be continued until disease progression. In the event cetuximab treatment is stopped, participants may continue on study drug until disease progression, unacceptable toxicity, or other withdrawal criterion is met.
224245635|NCT01285037|DRUG|Cisplatin|Cisplatin given via IV infusion once a week for 2 weeks and then every 3 weeks. If the LY2801653 is terminated for LY2801653-related toxicity after a minimum of 4 cycles, cisplatin may be continued as monotherapy until progression of disease. Participants discontinuing cisplatin therapy may be allowed to continue single agent LY2801653 if they are receiving clinical benefit.
224245636|NCT01285037|DRUG|Gemcitabine|Gemcitabine given via IV infusion once a week for 2 weeks and then every 3 weeks. If the LY2801653 is terminated for LY2801653-related toxicity after a minimum of 4 cycles, gemcitabine may be continued as monotherapy until progression of disease. Participants discontinuing gemcitabine therapy may be allowed to continue single agent LY2801653 if they are receiving clinical benefit.
224245637|NCT01285037|DRUG|Ramucirumab|Ramucirumab given via IV infusion every 2 weeks in a 28-day treatment cycle. Treatment with ramucirumab may continue until excessive toxicity or evidence of disease progression. In the absence of disease progression, treatment with LY2801653 may continue even if ramucirumab is discontinued provided no dose limiting toxicity related to LY2801653 is present. In the event that LY2801653 is discontinued, treatment with ramucirumab may be continued if there is no dose limiting toxicity related to ramucirumab.
223665479|NCT04379128|OTHER|Attentional tasks|a neuropsychological assessment of attentional task, executive task and interview is proposed to patients or normal control
223665480|NCT00386919|PROCEDURE|CyberKnife|
223665481|NCT00763698|DEVICE|QuickFlex Micro Model 1258T Left Heart Lead|Implantation of QuickFlex Micro 1258T left heart lead in combination with a CRT-D system.
223665482|NCT02190565|DIETARY_SUPPLEMENT|Food supplement|Randomized double-blind, placebo-controlled
223665483|NCT03970915|DEVICE|Body warmer|The body warmer will be wrapped in a waterproof treatment field to avoid the risk of burns, 2 body warmer will be applied on the inguinal crease and 2 on the subclavicular fossa.
223665484|NCT03970915|DEVICE|Standard warming procedure|Warming only according to the standard procedure : survival blanket and heating in the emergency vehicle.
223665485|NCT01018784|DRUG|MORAb-009|MORAb-009 is intravenously administered to patients with solid tumor once a week for 4 weeks as 1 cycle.
223665486|NCT04529486|OTHER|Kinesio taping|Before applying the tape, it was checked whether the children were allergic. Tape was first started from the distal part of the fingers and taped with 0% tension with Kinesio Taping Functional Correction Technique. Another I tape was applied from palmar area of the hand to spina scapula for supination of the forearm and external rotation of the shoulder with %0 tension to make functional correction (Figure 2). Kinesio Taping Functional Correction method is suggested to be done with 75% of tension but for children, we applied it with 0% tension to minimize the shear effects to the skin4. Kinesio Tex Light Touch Plus tape was used for taping application (Kinesio Co., USA).
223665487|NCT04302909|OTHER|focused extracorporeal shock wave therapy|40 Patients with mild to moderate CTS will be randomized to receive either fESWT (1-session a week for 3 weeks) or sham fESWT(1-session a week for 3 weeks). All subjects will be asked to wear night splints.
223665488|NCT04302909|OTHER|sham focused extracorporeal shock wave therapy|40 Patients with mild to moderate CTS will be randomized to receive either fESWT (1-session a week for 3 weeks) or sham fESWT(1-session a week for 3 weeks). All subjects will be asked to wear night splints.
223665489|NCT04302909|OTHER|night splint|40 Patients with mild to moderate CTS will be randomized to receive either fESWT (1-session a week for 3 weeks) or sham fESWT(1-session a week for 3 weeks). All subjects will be asked to wear night splints.
223665490|NCT00492713|OTHER|dark chocolate|dark chocolate
223665491|NCT00492713|OTHER|Milk chocolate 1|Milk chocolate 1
223665492|NCT00492713|OTHER|Milk chocolate 2|Milk chocolate 2
223665493|NCT01765959|OTHER|Auricular acupuncture (AA)|Auricular acupuncture (AA) group will receive treatment twice a week for four weeks. Each session will take approximately 60 minutes in which there will be active treatment time for 40 minutes. During treatment the respondents will have 5 thin sterile, disposable steel needles superficially placed in each outer ear. Before needle insertion the outer ears will be cleaned with disinfection solution. During treatment the respondents will sit down in silence; with eyes shut and focus on a normal calm breathing. The acupuncturist will not be in the room during treatment. After 40 minutes the respondents remove the needles and put them in a box suited for disposed needles. If needed, assistance to remove needles will be given from the acupuncturist.
223665494|NCT01765959|OTHER|cognitive behavioral therapy (CBT)|"Cognitive behavioral therapy (CBT) group will receive manual based sessions for sleeping disorders. The group meets once a week during six weeks according to following program:~Session 1 - introduction, self-help concept Session 2 - biology of sleep, sleep restriction, Session 3 - stimulus control Session 4 - visualization as relaxation, Session 5 - how to deal with negative and automatic thoughts, Session 6 - how to solve problems, planning for the future"
223665495|NCT05815979|BEHAVIORAL|virtual reality|Presentation of the virtual reality glasses and an information meeting will be held for all students in the experimental group, and the working procedure of the virtual reality glasses will be introduced. Afterwards, students will monitor the practice skill at least once using virtual reality glasses. After the completed follow-up, the students will be asked to practice their nasogastric tube application skill on a simple simulation mannequin/model with low reality in the laboratory environment.
223665496|NCT04444856|DRUG|Eptacog alfa (activated)|The women included in the study population have been treated with NovoSeven® (eptacog alfa (activated)) according to local routine clinical practice at the discretion of the treating physician.
223770575|NCT06015698|PROCEDURE|Laparoscopic tubal disconnection|"1. The tube is grasped in the isthmic portion of the tube at least 2cm from the cornua. Bipolar coagulation will provide a more localized area of tubal burn so requiring at least 3cm of the tube to be coagulated~2. The electrosurgical generator should set to deliver a power of 25W in nonmodulated mode to desiccate tissue sufficiently~3. The tube should be coagulated with 2 to 3 contiguous burns to provide an area of about 3cm of coagulation. Th endpoint of coagulation is cessation of the current flow~4. Then, the tube is severed in the middle of the burn area with laparoscopic scissors~5. Ensure adequate hemostasis"
223770576|NCT06015698|PROCEDURE|Laparoscopic salpingectomy|"1. The tube will be removed from its anatomical attachements by progressive bipolar coagulation~2. Progressive coagulation and cutting of the mesosalpinx begins at the proximal isthmus of the tube and progresses to the fimbriated end using bipolar coagulation and laparoscopic scissors~3. Removal of the tube through one of the ancillary ports using artery forceps~4. Ensure adequate hemostasis"
223770577|NCT02002897|DEVICE|Fractional carbon dioxide laser|Fractional carbon dioxide laser (10,600 nm), a session once per month, total of 3 sessions with full clinical evaluation and investigations before and one month after the last session of treatment.
224245638|NCT02549651|DRUG|MEDI4736|MEDI4736 is an anti-PD-L1 monoclonal antibody (MAb) administered via intravenous infusion
224245639|NCT02549651|DRUG|tremelimumab|Tremelimumab is an anti-CTLA4 monoclonal antibody (MAb) administered via intravenous infusion
224245640|NCT02549651|DRUG|AZD9150|AZD9150 is an antisense oligonucleotide (ASO) administered via intravenous infusion
224245641|NCT01510262|BEHAVIORAL|Tailored Socio-Contextual Intervention|"1. Develop strengths based case management intervention using input from interviews with repeat STI patients, consultants, \& piloting.~2. Recruit/enroll in the intervention 500 subjects (50% women; African American focus).~3. After subjects receive STI diagnosis, treatment,\& partner notification services, randomly assign subjects to:~   A. The STI strengths-based prevention case management, or B. Standard care.~4. Assess participants' risk behavior, determinants of behavior \& quality of life. Investigators will assess the incidence of new STI \& test the efficacy of the intervention relative to control.~5. Conduct a qualitative evaluation. Investigators will sample repeaters and non-repeaters from the experimental group.~6. Conduct cost effectiveness analyses of intervention compared to the standard."
224245642|NCT01510262|BEHAVIORAL|Standard of Care|Currently, the total time spent in an STI exam w/men is 30 minutes \& 60 w/women. More time is devoted to patients with sexual assault hx. Reason for the visit, symptoms, STI hx, contraception, condom use, number/gender of partners \& number/type of sexual activities are assessed. The nurse takes a health hx and asks about typical HIV risks behavior. Due to time the risk assessment is 5 minutes. A risk reduction kit including condoms is issued. Information includes symptoms/treatment of STI, location of sexual health clinics, location of free condoms \& testing/treatment resources. Referral information is provided when needed \& more involved w/sexual assault survivors. Partner notification is conducted w/syphilis and HIV. This didactic process follows the medical model.
224245643|NCT04453462|PROCEDURE|Endoscopic carpal tunnel release under local direct median nerve block|local direct median nerve block is performed by surgeon using the 1%xylocaine with adrenaline 12 mL(5 mL subcutaneous at incision site and 7 mL over median nerve) (maximum dose 7 mg/kg) before the endoscopic carpal tunnel release(1-portal Agee technique)
224245644|NCT04453462|PROCEDURE|Endoscopic carpal tunnel release under brachial plexus block|brachial plexus block under ultrasound-guided is performed by experienced single anesthesiologist using the 1%xylocaine with adrenaline 15 mL (maximum dose 7 mg/kg) before the endoscopic carpal tunnel release(1-portal Agee technique)
224245645|NCT01878825|BIOLOGICAL|Fluviral™|1 dose administered intramuscularly in deltoid region of non-dominant arm.
224245646|NCT00830232|DEVICE|closed-cell stent (Xact stent)|"Patients enrolled in this study arm underwent for carotid stenting using closed stent cell. The graft used in this groups was the Xact closed-cell stent. This type of device is rigid device with dense conposition of the nitinol rigns.~Carotid stenting was used on standard fashion using filters as embolic protection device."
224245647|NCT00830232|DEVICE|Open-cell stent (Acculink carotid)|"Patients enrolled in this study arm underwent for carotid stenting using open stent cell stents. This type of stent is a tube shaped graft composed of flexible nitinol rings. The device used in this group was the Acculinx open-cell stent.~Stenting procedure eas performed on standard fashion.Filters were used as embolic protection device."
224245648|NCT01550900|DRUG|Metformin ER|Starting dose: 500 mg by mouth daily for 1 week with weekly increases of 250 mg daily to target dose of 1000 mg daily.
224245649|NCT01550900|OTHER|Placebo|Placebo tablets by mouth 1 time a day.
224245650|NCT01450085|OTHER|GeneXpert|Point of care GeneXpert
224245651|NCT01450085|OTHER|LED Microscopy|Point of care LED Microscopy
224245652|NCT03554707|GENETIC|SGT-53|2.1 mg DNA/m2 or 2.8 mg DNA/m2 twice weekly
224245653|NCT03554707|RADIATION|Radiation|Standard radiation plan
224245654|NCT03554707|DRUG|Irinotecan|50mg/m2/dose IV daily for five days in a 4-week cycle
224245655|NCT03554707|DRUG|Temozolomide|100mg/m2 PO daily for five days in a 4-week cycle
224245656|NCT03554707|DRUG|Bevacizumab|10mg/kg IV every two weeks in a 4-week cycle
223665497|NCT04444856|OTHER|Standard of care|The women included in the study population have been treated according to local routine clinical practice at the discretion of the treating physician.
223665498|NCT05592860|DEVICE|Mobile application|participants in intervention group will use smart phone application and update glucose level and investigator will adjust the insulin accordingly
223665499|NCT05592860|BEHAVIORAL|Daily Diary|participants will use daily diary to record glucose level
223665500|NCT04902300|OTHER|Data collection|evaluation of internet addiction
223665501|NCT00655174|DRUG|fluvoxamine|Children will be started on 12.5 mg. If there is no therapeutic effectivenss observed after eight weeks, then the child may have their dose increased. In this case, the child will be followed for an additional eight weeks.
223665502|NCT00655174|DRUG|sertraline|Children will be started on 12.5 mg. If there is no therapeutic effectivenss observed after eight weeks, then the child may have their dose increased. In this case, the child will be followed for an additional eight weeks.
223665503|NCT00655174|DRUG|Placebo|Patients in this study arm will receive capsules that appear identical to those of the two study drugs but will contain no active ingredient.
223665504|NCT00128323|DRUG|Gentian violet 1% solution|
224245657|NCT01725698|DRUG|Mesenchymal stem cell, HA-CaSO4, ¬BMP-2, and Implant|
224245658|NCT02167620|DRUG|Metformin|Metformin will be dispensed on a biweekly basis, and pill counts conducted at each visit.
224245659|NCT02167620|DRUG|Placebo|Placebo will be dispensed on a biweekly basis, and pill counts conducted at each visit.
224245660|NCT01981720|BIOLOGICAL|PRX-102 (pegunigalsidase alfa)|PRX-102 1 mg/kg every 2 weeks
224245661|NCT02830386|DEVICE|LVIS stent|Patients who meet the inclusion criteria will be treated with a low profile visualized intraluminal support (LVIS) stent with coils.
224245662|NCT01813006|DRUG|Omega-3|
224245663|NCT01813006|DRUG|placebo|
224245664|NCT04742478|PROCEDURE|Rotational Atherectomy|Rotational atherectomy (RA) has been the most used atherectomy modality since its first inception in1988. RA uses high speed rotation (140,000 - 180,000 rpm) to ablate inelastic plaque, resulting in debris averaging 5µm in size24. The main focus of RA in the era of DES stent has been on plaque modification rather that plaque debulking with more papers showing improved PCI success rates.
224245665|NCT03314298|DRUG|testosterone anastrozole|subcutaneous testosterone and anastrozole
224245666|NCT02674477|DEVICE|Therapeutic Education System (TES)|The TES program is made of modules about ways to prevent substance use, such as how to refuse drugs and alcohol, how to cope with thoughts about using, and how to make the best possible decisions for a person's mental health. Each module takes less than 30 minutes to complete. Modules may contain videos or other interactive media. At the end of each module, there are questions about the material.
224245667|NCT02674477|OTHER|Treatment as Usual (TAU)|Standard treatment comprises a psychiatrist-led interdisciplinary team as well as face-to-face group counseling for substance use and skills for improving general mental health. There will be no change to the routine care (treatment at usual \[TAU\]) provided to patients on the service.
224245668|NCT04300673|PROCEDURE|Radio guided surgery (RGS) using Indium-labelled PSMA|Approximately 24hours prior to surgery (PLND) patients receive a radiolabelled PSMA-tracer. During surgery, urologists will use a gamma-probe to detect PSMA-postitive tumour depostitions in pelvic lymph nodes.
224245669|NCT00567762|DRUG|FK506|Opthalmic suspension
223665505|NCT00128323|DRUG|Gentian violet 0.00165% solution|
223665506|NCT00128323|DRUG|Nystatin solution|
223665507|NCT00002339|DRUG|Fluconazole|
223770578|NCT02002897|DEVICE|Ultraviolet A1 phototherapy (UVA1)|localized UVA1 phototherapy (340-400 nm), low dose irradiation, at a rate of 3 sessions per week , total of 24 sessions with full clinical evaluation and investigations before and after treatment and clinical follow up one month after treatment.
223770579|NCT05802381|DIETARY_SUPPLEMENT|protein supplement|20 gram protein supplement per day
224245670|NCT00567762|DRUG|placebo|placebo eye drops
224245671|NCT04927208|OTHER|exercise and nutritional support|"resistance exercise and protein supplementation including branched chain amino acids for 12 weeks~Other: Combined exercise and nutrition intervention resistance exercise and nutritional supplementation for 12 weeks"
223665508|NCT06208956|DRUG|Dexmedetomidine|In the dexmedetomidine group, dexmedetomidine is infusion intravenously with a loading dose of 0.5 μg kg-1 for 10 min, then infusion at 0.3 μg kg-1 h-1 according to the ideal body weight of the patient until the end of colonoscopy. During the whole process, maintenance Ramsay score of 3 to 4. Propofol 10 mg will be administrated as the rescue dose if body movement occur during colonoscopy.
223665509|NCT06208956|DRUG|Propofol|Propofol is administrated 1 mg kg-1 intravenously, then titrated given by 0.5 mg kg-1 until Ramsay score reach 3. During the whole process, propofol is given intermittently to maintain Ramsay score 3 to 4. If body movement happen, propofol 10mg will be administrated every time.
223665510|NCT02929654|DEVICE|OneTouch Verio®|Colour Enhanced Blood Glucose Meter.
223665511|NCT02929654|DEVICE|OneTouch Verio® Flex|Colour Enhanced Blood Glucose Meter.
223665512|NCT02929654|DEVICE|Subject's Own Blood Glucose Meter|Subject's Own Blood Glucose Meter
224245672|NCT00524264|DRUG|ketorolac|"Ophthalmic drops, BID pre- and post-operation, and 6 doses on surgery day.~Placebo"
224245673|NCT03067207|BEHAVIORAL|MARS-A|The intervention will consist of the 8-week mindfulness meditation program designed for adolescents with chronic health conditions.MARS-A is based on two established mindfulness-based interventions for adults: MBSR and MBCT. The content of the program will be the same for in-person and e-health groups: all participants will receive eight 90-minute weekly evening sessions led by two trained and experienced mindfulness providers. Sessions will include short meditation practices, breathing exercises, guided discussion, mindful movements and inquiry, adapted to the context of chronic illness. Every session will start with a brief review of home practice and will close with a discussion of the home practice for the following week.
223770580|NCT05802381|BEHAVIORAL|nutrition counseling|nutrition counseling for guidance of food intake
223770581|NCT01938534|DRUG|Helicobacter pylori eradication|
223770582|NCT05796544|BEHAVIORAL|Remote self-care education|The intervention group will receive a total of four remote educational sessions over 2 months.
223665513|NCT03740815|PROCEDURE|Serratus plane block|Ultrasound guided injection of local anesthetic between latissimus dorsi and serratus muscles at mid axillary line.
223770583|NCT05796544|BEHAVIORAL|In-person self-care education|The active comparator group will receive a total of four in-person educational sessions over 2 months.
224245674|NCT01868971|DEVICE|EndoRings|Colonoscopy procedure, standard endo-therapy interventions will be performed in accordance with physician's evaluation
224245675|NCT01482377|DRUG|RO5479599|RO5479599 will be administered Q2W or Q3W (other regimen could be explored based on observations during dose escalation part).
224245676|NCT01482377|DRUG|Cetuximab|Cetuximab will be administered via intravenous (IV) infusion at a starting dose of 400 mg/m\^2 for the first infusion, followed by doses of 250 mg/m\^2 for subsequent infusions.
224245677|NCT01482377|DRUG|Erlotinib|Erlotinib, at a dose of 150 mg will be administered.
224245678|NCT01482377|DRUG|zirconium-89-labeled RO5479599|Single dose of radiolabeled drug will be administered.
224245679|NCT01536405|BIOLOGICAL|MMRV (AMP)|Measles, mumps, rubella, and VZV vaccine made with an alternative manufacturing process. Participants will receive two 0.5 mL subcutaneous injections.
224245680|NCT01536405|BIOLOGICAL|MMRV (2006 process)|Measles, mumps, rubella, and VZV vaccine made with the 2006 manufacturing process. Participants will receive two 0.5 mL subcutaneous injections.
224245681|NCT01292720|DRUG|Cholecalciferol|Cholecalciferol 90,000 IU followed by weekly 24,000 IU for 24 weeks of vitamin D3 (total dose: 666,000 IU)
224245682|NCT01292720|DRUG|Placebo|Placebo in matching volumes
224245683|NCT06323876|DIAGNOSTIC_TEST|HRCT|High resolution computed tomography (HRCT) scan is a medical imaging technique used to obtain detailed internal images of the body. HRCT images will be obtained at 0 and 12 months.
224245684|NCT06323876|DIAGNOSTIC_TEST|Blood Draw|During blood draw, someone uses a needle to take blood from a vein, usually in your arm.
223665514|NCT03740815|PROCEDURE|Axillary dissection|Axillary dissection is a surgical procedure that incises the axilla to identify, examine, or remove lymph nodes.
223665515|NCT03740815|PROCEDURE|Intravenous sedation|Administration of sedatives thru an intravenous access to achieve relaxion and improve operative conditions.
223665516|NCT00005779|DRUG|Interleukin-12|
223665517|NCT00005779|BIOLOGICAL|HIV-1 C4-V3 Polyvalent Peptide Vaccine|
223665518|NCT02969603|OTHER|Magnetic Resonance Imaging|Magnetic Resonance Imaging as reference
223665519|NCT02969603|OTHER|Magnetic Resonance combined with Positron Emission Tomography|Comparison with MRI only, to assess muscular activity, creation of anatomic images of muscle activity and resolution of metabolic activity distribution within exercising skeletal muscle
223665520|NCT03462901|PROCEDURE|Percutaneous intramedullary fixation of displaced midshaft clavicular fractures .|A group of 15 patients admitted to Assiut university with midshaft clavicular fractures treated by operative fixation of the fracture by single elastic rod through medial approach under image intensifier
223665521|NCT00568633|PROCEDURE|Allogeneic HSCT|Allogeneic, 5+ of 6 HLA-matched PBSC transplant from sibling, mobilized to target of 5 x 10e6 CD34+ cells/kg and \< 7 x 10e8 CD3+ cells/kg.
223665522|NCT00568633|DRUG|Anti-thymocyte globulin (ATG)|1.5 mg/kg for 5 days by IV
223665523|NCT00568633|DRUG|Cyclosporine (CSP)|6.25 mg/kg twice daily oral
223665524|NCT00568633|DRUG|Mycophenolate mofetil (MMF)|15 mg/kg twice daily oral
223770584|NCT05053386|DRUG|Idarubicin Hydrochloride for Injection|After an interventional treatment, CT and/or MRI, tumor-related markers, liver and kidney function and blood routine examinations will be reviewed every 4-6 weeks, based on the patient's response to the last treatment, changes in liver function and physical fitness, and CT And (or) dynamic enhanced MRI scan to evaluate the survival of liver tumors and determine the next TACE treatment. At least 2 cycles are applied and no more than 4 cycles are applied.
223770585|NCT05053386|DRUG|Epirubicin|After an interventional treatment, CT and/or MRI, tumor-related markers, liver and kidney function and blood routine examinations will be reviewed every 4-6 weeks, based on the patient's response to the last treatment, changes in liver function and physical fitness, and CT And (or) dynamic enhanced MRI scan to evaluate the survival of liver tumors and determine the next TACE treatment. At least 2 cycles are applied and no more than 4 cycles are applied.
224245685|NCT00003674|DRUG|dalteparin|
224245686|NCT00003674|DRUG|standard therapy|
224245687|NCT00812162|OTHER|Energy Restriction|Energy restricted diet of 750 kcal less than subjects requirement with a high protein diet.
224245688|NCT00812162|OTHER|Energy Restriction|Energy restricted diet of 750 kcal less than subjects requirement with a lower protein diet.
224245689|NCT01273974|BIOLOGICAL|intradermal influenza vaccine|0.25ml ,intradermal
223665525|NCT00568633|RADIATION|Total lymphoid irradiation (TLI)|80 cGy/fraction radiotherapy in 10 fractions.
223665526|NCT00568633|DRUG|Methylprednisolone sodium succinate|1.0 mg/kg for 5 days by IV
223665527|NCT00568633|DRUG|Best standard care|"Intervention consist of:~* Consolidation chemotherapy (3-4 cycles of cytarabine +/- an anthracycline agent, or other consolidation)~* Autologous transplantation~* Non-Myeloablative unrelated-donor transplant, +/- TLI and ATG conditioning~* Umbilical cord blood transplantation~* Haploidentical transplantation"
223665528|NCT01740505|BEHAVIORAL|Timing and Coordination|This intervention is based on progressively difficult stepping and walking patterns that promote the timing and coordination of stepping within the gait cycle. Small-group 60-minute classes twice weekly for 12 weeks.
223665529|NCT01740505|BEHAVIORAL|Aerobic Walking|Outdoor walking with progressive increases in exercise intensity. Small-group 60-minute classes twice weekly for 12 weeks.
223665530|NCT01740505|BEHAVIORAL|Stretching and Relaxation|Full-body stretching, range-of-motion exercises, and relaxation techniques. No specific gait training. Small-group 60-minute classes twice weekly for 12 weeks.
223665531|NCT03673761|OTHER|MRI, dual-energy, x-ray absorptiometry, muscle ultrasounds, blood testing|3.Dixon, T2 mapping MRI microRNAs
223665532|NCT01960907|DEVICE|CHROMED monitoring system|Optimization of patient's treatment according to the data collected by the home monitoring devices
223665533|NCT02360683|OTHER|patients with Parkinson's disease|
224245690|NCT01273974|BIOLOGICAL|intramuscular influenza vaccine|0.5ml,intramuscular
224245691|NCT04050930|OTHER|Mastication|Simultaneous recordings of postprandial thermogenesis (gas exchange), cardiac activity (ECG), masticatory muscle contraction (EMG), and blood collection, during alternating periods of no-mastication or mastication of natural foods or chewing gums of different hardness
224245692|NCT01759901|PROCEDURE|Pringle|Vascular clamp is applied across hepatoduodenal ligament intermittently in 15 minutes on / 5 minutes off interval
224245693|NCT04988763|OTHER|Opinions about tele-rehabilitation for consulting a clients with neurological impairments|Opinions about telerehabilitation for consultation purpose
224245694|NCT05351918|OTHER|acupuncture|Acupuncture points are punctured with needles.
224245695|NCT00886275|DRUG|Dexmedetomidine|The loading dose of dexmedetomidine is 0.5 mcg/kg over 10 minutes as needed. Then, continuous infusion of 0.2-0.7 mcg/kg/h dexmedetomidine is used to maintain RASS between 0 to -3.
224245696|NCT00886275|DRUG|Midazolam|The loading dose of midazolam is 0.05 mg/kg over 10 minutes as needed. Then, continuous infusion of 20-300 mcg/kg/h midazolam is used to maintain RASS between 0 to -3.
224245697|NCT00886275|DRUG|Dexmedetomidine, Midazolam|The loading doses are dexmedetomidine 0.25 mcg/kg and 0.025 mg/kg of midazolam over 10 minutes. Then, continuous infusion of 0.1-0.7 mcg/kg/h dexmedetomidine and 10-300 mcg/kg/h midazolam is used to maintain RASS between 0 to -3.
223665534|NCT04119271|OTHER|Breathe Easy at Home Kit Products|HEPA filtered upright vacuum cleaner, HEPA-filtered Air Purifier, Hypoallergenic latex free mattress cover, box spring cover, and two pillow covers, Healthier alternative to most household cleaners, Non- toxic glue type pest control devices for rodent control and a combination of safe products to locate and kill roaches.
223770586|NCT02167035|DRUG|Combigan Two Times Daily (BID)|
224245698|NCT01695720|PROCEDURE|VisionScope Imaging (VSI) Exam|The VisionScope Imaging (VSI) Exam \[the system itself\] is indicated for use in diagnostic and operative arthroscopic and endoscopic procedures to provide illumination, visualization, and the capture of still and motion pictures of an interior cavity of the body through a natural or surgical opening.
224245699|NCT00287092|BIOLOGICAL|DT5aP-IPV-Hib 5-component Pertussis vaccine|0.5 mL, IM
223770587|NCT02167035|DRUG|Simbrinza Three Times Daily (TID)|
224245700|NCT00287092|BIOLOGICAL|Infanrix® -IPV+Hib|0.5 mL, IM
224245701|NCT01779544|OTHER|Brief intervention, an educational model|The goal of the the brief intervention is to provide the patient knowledge to reduce uncertainty so that he or she can understand what is important after lumbar disc surgery so that belief in self-efficacy increases.
224245702|NCT01779544|OTHER|Exercise therapy|Patients are instructed to do prescribed exercises the first 3 months after surgery, and to log when they do these
224245703|NCT02977260|OTHER|Thin/Low Energy|Thin textured rice meal (ground rice grains) with lower energy density (0.57 kcal/g)
224245704|NCT02977260|OTHER|Thin/High Energy|Thin textured rice meal (ground rice grains) with higher energy density (1.01 kcal/g)
224245705|NCT02977260|OTHER|Thick/Low Energy|Thicker textured rice meal (whole rice grains) with lower energy density (0.57 kcal/g)
224245706|NCT02977260|OTHER|Thick/High Energy|Thicker textured rice meal (whole rice grains) and high energy density (1.01 kcal/g)
224245707|NCT00723476|BEHAVIORAL|Family Centered Advanced Care Planning (FCACP) sessions|FCACP will include three 60- to 90-minute weekly sessions. Sessions consisting of structured conversations with HIV infected adolescents, their proxies, and trained facilitators will aim to enhance quality of life by integrating effective end-of-life (EOL) care and minimizing depression and anxiety. The three sessions will consist of a structured EOL survey, an FCACP interview, and a family problem-solving lesson.
224245708|NCT00723476|BEHAVIORAL|Health education control sessions|Health education control sessions will include three 60- to 90-minute sessions and will involve adolescents with HIV/AIDS and their proxies. Topics covered during sessions will include developmental history, planning for the future, and safety tips.
224245709|NCT01838720|PROCEDURE|zero ischemia laparoscopic RFA assisted TE|
224245710|NCT01838720|PROCEDURE|ischemia|conventional laparoscopic partial nephrectomy
224245711|NCT03872674|BIOLOGICAL|high-flow humidified oxygen-delivery system (OptiFlow THRIVE)|stand oxygenation arm will receive oxygen at 5 L/min via nasal cannula, while Optiflow THRIVE arm will receive oxygen at 50 L/min via Optiflow THRIVE during the procedure.
224245712|NCT02514122|DRUG|Ketamine|Patients will receive a subcutaneous injection of ketamine (at a dose of 1mg/kg) immediately following surgery, the evening after surgery, and every 12 hours thereafter for a total of 5 injections.
224245713|NCT02514122|DRUG|Saline|Patients will receive a subcutaneous injection of saline (at a dose of 0.02cc/kg) immediately following surgery, the evening after surgery, and every 12 hours thereafter for a total of 5 injections.
224245714|NCT05026567|DRUG|2 ml of DORMICUM® Midazolam Hydrochloride (15 mg/3 mL)|Intramuscular injection
224245715|NCT05026567|COMBINATION_PRODUCT|ZENEO® Midazolam (10 mg/0.625 mL) on bare skin in thigh|Intramuscular injection
223665535|NCT03761862|PROCEDURE|Neural Therapy|Neural therapy is a form of alternative medicine in which local anesthetic is injected into certain locations of the body in an attempt to treat chronic pain and illness.
223665536|NCT00561548|PROCEDURE|rectosigmoïdal biopsies|rectosigmoïdal biopsies
223665537|NCT00003544|DRUG|irinotecan hydrochloride|
224245716|NCT05026567|COMBINATION_PRODUCT|ZENEO® Midazolam (10 mg / 0.625 mL) on bare skin in ventrogluteal area|Intramuscular injection
223665538|NCT00003544|PROCEDURE|surgical procedure|
223665539|NCT04583722|DIETARY_SUPPLEMENT|AX-olive oil-PP emulsion|single dose and plasma samples
223665540|NCT03587285|BIOLOGICAL|Tcm+ Goserelin acetate+ Bicalutamide|Autologous Tcm cells administered intravenously on Day 1 and Day 42,3.6mg goserelin acetate injection administered subcutaneously monthly,50 mg bicalutamide administered orally daily
223665541|NCT03587285|BIOLOGICAL|Tcm+Goserelin acetate+Abiraterone acetate|Tcm cells administered intravenously on Day 1 and Day 42,3.6mg goserelin acetate injection administered subcutaneously monthly,1000 mg abiraterone acetate administered orally daily plus 5 mg prednisone administered orally twice daily
223770588|NCT02148003|PROCEDURE|RFA at 90 degrees Celsius|Ablation at 90 degrees Celsius is defined as radiofrequency ablation of the lumbar facets nerve supply will be performed at 90 degrees Celsius
223770589|NCT02148003|PROCEDURE|RFA at 80 degrees Celsius|Ablation at 80 degrees Celsius is defined as radiofrequency ablation of the lumbar facets nerve supply will be performed at 80 degrees Celsius
224245717|NCT05026567|COMBINATION_PRODUCT|ZENEO® Midazolam (10 mg / 0.625 mL) through clothing in thigh|Intramuscular injection
224245718|NCT03676686|DEVICE|Nåva Foot Cream|Nåva Foot Cream is a Medical device (EU class IIa) for the treatment of tinea pedis, heal cracks, calluses and dry feet.
224245719|NCT00714090|OTHER|active venlafaxine and active rTMS-repetitive transcranial magnetic stimulator, Inomed and Alpine Biomed|"active venlafaxine LP 75 mg : 1 capsule per day for 3 days, then 2 per day for 2 to 4 weeks, if necessary 3 per day the next 2 weeks.~active rTMS : 5 sessions per week for 2 to 6 weeks"
224245720|NCT00714090|OTHER|active rTMS -repetitive transcranial magnetic stimulator, Inomed and Alpine Biomed and sham venlafaxine|active rTMS : 5 sessions per week for 2 to 6 weeks sham venlafaxine LP 75 mg : 1 capsule per day for 3 days, then 2 per day for 2 to 4 weeks, if necessary 3 per day the next 2 weeks.
223665542|NCT04744090|DRUG|Roflumilast|"1. Roflumilast 500 mcg daily for up to 28 days~2. Total follow up time will be 28 days.~3. Proinflammatory parameters will be assessed at baseline, day 7, day 14, and at the end of treatment.~4. Roflumilast will be combined with standard of care for ARDS.~5. During hospitalization, clinical and laboratory data will be recorded daily in the medical history of the patient and in data collection table of the study.~6. During hospitalization, adverse drug reaction will be monitored clinically and by laboratory tests.~7. In case of an adverse effect or a need to discontinue the treatment, roflumilast should be suspended."
223665543|NCT04744090|DRUG|Placebo|Placebo (identical to roflumilast dosage form) will be used for placebo-comparator group.
223665544|NCT00681356|DRUG|4975, 15 and 5 mg|Direct instillation into the surgical site
224245721|NCT00714090|OTHER|sham rTMS- repetitive transcranial magnetic stimulator, Inomed and Alpine Biomed and active venlafaxine|sham rTMS : 5 sessions per week for 2 to 6 weeks active venlafaxine LP 75 mg : 1 capsule per day for 3 days, then 2 per day for 2 to 4 weeks, if necessary 3 per day the next 2 weeks.
224245722|NCT04690166|OTHER|The speech records related to the reading document|"The document consists bit, bet, but words and Diyet passage. Volunteers will read the document in front of the microphone and also the speech will recorded by a computer."
224245723|NCT04809961|OTHER|I-care app|A smart phone app to enable healthcare worker peer support for improved workplace wellbeing.
224245724|NCT00159848|BEHAVIORAL|Treatment Optimization Program (educational material)|
224245725|NCT00319930|DRUG|CNF1010 (17-AAG)|
224245726|NCT05079425|DRUG|NXC736|Oral administration
224245727|NCT05079425|DRUG|Placebo|Oral administration
224245728|NCT05857085|DRUG|Semaglutide Pen Injector [Ozempic]|GLP 1 agonist
223770590|NCT02148003|DEVICE|C-arm guided 20-gauge radiofrequency needle|Needles will be adjusted to optimize sensory and motor stimulation.
223770591|NCT01618539|DRUG|propofol|varying intravenous dosages
224245729|NCT05857085|DRUG|Empagliflozin 10 MG|SGLT 2 inhibitor
224245730|NCT00687063|DRUG|insulin detemir|Start dose and frequency of insulin detemir is to be decided by physician. The choice of patient is also at the discretion of Physician
223770592|NCT03996928|OTHER|Exercise|
223770593|NCT04662346|OTHER|Difficulty score system for robotic pancreatoduodenectomy|calculate the score for patient in you cohort
223665545|NCT00681356|DRUG|Placebo Comparator|Direct instillation into the surgical site
224245731|NCT04222790|DRUG|monosialic gangliosides|The experimental group received 80 mg of monosialic gangliosides (GM1) on days -1, 1, and 2 of albumin paclitaxel (GM1 is a single infusion).
224245732|NCT04222790|OTHER|Placebo|The control group received placebo on days -1, 1, and 2 of albumin paclitaxel (placebo as a single infusion)
224245733|NCT06218108|DIAGNOSTIC_TEST|Taulí-T1 versus conventional classifications|All the slides of each case will be reviewed, selecting the one that contains the most invasive section, and this will be digitized to take measurements in micrometers with greater precision. To measure the degree of infiltration, the measurement of residual healthy submucosa (hrSB) will be used, which is the distance between the point of greatest infiltration and the muscularis propria. The total thickness of the submucosa in the tumor area will also be measured, taking as a reference the muscularis of the mucosa or, in its absence, the surface of the lesion, to calculate the percentage of infiltration of the submucosa. This percentage will be calculated as the inverse percentage of invasion with respect to the hrSB: (total thickness of the submucosa - hrSB / total thickness of the submucosa) x 100. The qualitative categories will be obtained: sm1 (\< 33.3%), sm2 (33.3% - 66.6%) and sm3 (\> 66.6%). Measurements will be also taken in micrometers for the conventional classifications.
224245734|NCT00616408|DRUG|Octreotide-LAR|Initial dose is 20 mg every 28 d for three months, then the dose is down-titrated to 10 mg/q28d if GH levels are below 1 ng/ml, up-titrated to 30 mg/q28d if GH levels are above 10 ng/ml and remains to 20 mg/q28 d if GH is between 1-10 ng/ml
224245735|NCT02783352|PROCEDURE|arthroscopic rotator cuff repair|arthroscopic rotator cuff repair
224245736|NCT02783352|PROCEDURE|autologous micro-fragmented adipose tissue|injection of autologous micro-fragmented adipose tissue (10 mL) after arthroscopic rotator cuff repair, in dry arthroscopy condition
224245737|NCT00845715|OTHER|Early motion|Early referral to physical therapy for range of motion (2 days post)
224245738|NCT00845715|OTHER|Standard motion|Standard referral to physical therapy for range of motion (4 weeks post)
224245739|NCT05984251|DRUG|CCX168|Administered orally.
224245740|NCT05984251|DRUG|Placebo|Administered orally.
224245741|NCT03115177|DRUG|Doxycycline|The treatment group will receive 100mg of doxycycline IV in addition to cefazolin within 1 hour of incision for total shoulder arthroplasty.
224245742|NCT03115177|DRUG|Cefazolin|
224245743|NCT00648947|DRUG|Clopidogrel Bisulfate Tablets 75 mg|75mg, single dose fasting
224245744|NCT00648947|DRUG|Plavix® Tablets 75 mg|75mg, single dose fasting
224321689|NCT04846829|DEVICE|intermittent theta burst stimulation|"10 sessions of treatment with cTBS to right DLPFC TBS consists of three TMS pulses given at 50 Hz, with this triplet repeated at a frequency of 5 Hz (every 200 ms).~iTBS paradigm of a 2 s train repeated every 10 seconds"
223665546|NCT00681356|DRUG|4975 - 5 mg|Direct instillation into the surgical site
223665547|NCT00080899|DRUG|fenretinide|Given orally
223665548|NCT00080899|OTHER|laboratory biomarker analysis|Correlative studies
223665549|NCT02618070|OTHER|Yogurt|
223770594|NCT02451826|DRUG|Ulipristal acetate|CVR delivering Ulipristal acetate and one tablet levonorgestrel.
223665550|NCT06085885|DEVICE|Cochlear implant|Cochlear implant
223665551|NCT04117867|BEHAVIORAL|Patiens with intraoperative hypotension|In this study, we will use four previously defined thresholds for intraoperative hypotension: two absolute thresholds (MAP less than 50 mmHg and MAP less than 60 mmHg) and two relative thresholds to the baseline MAP (a decrease of 30% or more and a decrease of 40% or more). A definition of baseline value most frequently reported was the arterial blood pressure before the induction of anesthesia. Therefore, the baseline MAP used in calculating the relative thresholds is defined as the mean MAP of all available blood pressure measurements before induction of anesthesia in the operating room.
223665552|NCT00728403|DIETARY_SUPPLEMENT|American Ginseng (Panax quinquefolius L.) and Korean Red Ginseng (steamed Panax C.A. Meyer)|1.5 grams American Ginseng and 1.5 grams Korean Red Ginseng are to be taken in capsulated form. Two capsules are taken with every meal, for a total of 6 capsules per day for 12 weeks
224245745|NCT03611374|PROCEDURE|Bilateral Erector Spinae Plane Block (ESPB)|Bilateral ESPBs will be placed after anesthesia induction in eligible and consented patients who are undergoing a sternotomy for congenital heart repair. Patients will receive a local anesthetic agent through each catheter prior to surgery start. If possible, levels of the local anesthetic will be measured during the case. After surgery, patients will be admitted to the CVICU and extubation will be managed by the CVICU team. The ESPB group will have an automatic, alternating side boluses of the local anesthetic started through their nerve block catheters. Levels of the local anesthetic will be measured at intervals.
224245746|NCT01583127|BEHAVIORAL|Positive Behavioral Interventions & Supports|Implementation of the School-Wide Positive Behavioral Interventions and Supports model across 4 school years.
224245747|NCT05195762|DRUG|NFX-179 Gel 1.50%|"Stanford University (Stanford) is studying a selective mitogen-activated protein kinase kinase (MEK) inhibitor (NFX-179) that has been chemically engineered for topical application to treat epidermal nevus syndromes (ENS).~Preclinical studies evaluating topical application of NFX-179 to human nevus sebaceous explants demonstrated that NFX-179 can penetrate the tissue and suppress the p-ERK biomarker.~It was also determined that NFX-179, when incubated with the tissues in medium, also suppressed ERK phosphorylation in human keratinocytic epidermal nevi. This clinical study is designed to evaluate the safety, tolerability, and clinical effect of NFX-179 Gel in Subjects with Epidermal Nevi."
224245748|NCT00747162|DEVICE|Measure of muscle oxygenation|The investigators will use an INVOS oxymeter for muscle oxygenation measure.
224245749|NCT00747162|DEVICE|Skin pigmentation determination|The investigators will use a DermaSpectrometer to get a reading from subjects' skin color
224245750|NCT01188135|BEHAVIORAL|Interactive voice messaging or Interactive voice messaging + psycho ed materials|Interactive voice telephone messages reminder participants to continue to take their antidepressive medications
224245751|NCT00112463|DRUG|romidepsin|DEP is administered at a dose of 13 mg/m2 as a 4-hour intravenous infusion in the outpatient setting.
224245752|NCT03287310|DRUG|GSK3511294|GSK3511294 will be available as a clear or opalescent, colorless or yellow to brown solution for injection at unit dose strength of 150 milligrams per milliliter (mg/mL). GSK3511294 will be diluted in 0.9% weight by volume (w/v) sodium chloride to achieve the desired concentration for administration. GSK3511294 will be administered by SC injection.
224245753|NCT03287310|DRUG|Placebo|Matching Placebo will consist of 0.9% w/v sodium chloride which will be administered by the SC route.
224245754|NCT03287310|DRUG|Salbutamol/albuterol|Salbutamol/albuterol will be supplied to all subjects for use as rescue medication during the study.
224245755|NCT06562855|GENETIC|Peripheral blood sampling|
224245756|NCT01118312|DRUG|Mometasone Furoate monohydrate|Intranasal mometasone, 1 spray (age \< 12 yr) or 2 sprays (age \>= 12 yrs) each nostril once a day for 6 months
224245757|NCT01118312|OTHER|Placebo|Intranasal placebo spray
224245758|NCT03544008|OTHER|The use of AXIOS in Endoscopic transmural drainage|
224245759|NCT01703975|OTHER|Training in pairs (Dyad training)|
224245760|NCT00307697|PROCEDURE|receipt of copy of psychiatic assessment letter|
224245761|NCT03065374|BIOLOGICAL|IMM-529|IMM-529
224245762|NCT03065374|OTHER|Placebo|Matching placebo
224245763|NCT05880576|DEVICE|Monitoring using resonance Raman spectroscopy, pulse oximetry, blood pressure, and near-infrared spectroscopy|Infants will have monitoring three times a day with resonance Raman spectroscopy device during arch watch period. They will have continuous monitoring with pulse oximetry and near infrared spectroscopy. They will have intermittent blood pressure monitoring.
224245764|NCT04603092|BEHAVIORAL|Digital Health Literacy Intervention|"Willing women participants will be provided equipment with instructions for the intervention, including a smartphone and a 4G Wifi gadget. The health literacy intervention, delivered to the experiment group, will last three months and will include a combination of the following four components:~Component 1: Health literacy video tutorial. Component 2: Virtual one-on-one weekly meetings. Component 3: Monthly group virtual meetings and Whatsapp group. Component 4: Provision and guidance of a self-management chart."
224245765|NCT02096510|DRUG|Solu-Cortef|administration by pump for minimum 2 weeks
224245766|NCT02096510|DRUG|Cortef|tablet treatment 2 ro 3 times per day for 14 days
224245767|NCT02469805|DRUG|Merional|On the 3rd day of menstruation women will have a vaginal ultrasound and will receive daily intramuscular 150 IU of human menopausal gonadotropins (hMG, Merional ®, IBSA, Lugano, Switzerland) starting from the 3nd day of menstruation.
224245768|NCT02469805|DRUG|Choriomon|Administration of 10000 IU of human chorionic gonadotropin (hCG; Choriomon®, IBSA) when at least 2 follicles measuring 18 mm are observed during vaginal ultrasound and is associated with serum E2 of 500-3000 Pg/mL.
224245769|NCT02469805|PROCEDURE|IUI|Semen will be processed and drawn into a shepherd catheter attached to a 1 mL syringe and injected into the uterus
224245770|NCT02469805|PROCEDURE|Ovulation detection|Women will be asked to test their morning urine specimen for luteinizing hormone daily starting 4 days before the expected day of ovulation. This will be done using a qualitative kit
224245771|NCT02469805|DEVICE|Shepherd catheter|Processes semen will be drawn into a shepherd catheter attached to a 1 mL syringe and injected into the uterus
224245772|NCT03901768|DRUG|Dexamethasone|a syringe having 4ml of 4mg/ml of dexamethasone is used for intravenous injection.
224245773|NCT03901768|DRUG|Triamcinolone|1ml of 40mg triamcinolone is mixed in the syringes containing solution for intrarticualar local infiltration. The solution is injected intraarticularly.
223665553|NCT00728403|DIETARY_SUPPLEMENT|American Ginseng (Panax quinquefolius L.)|3 grams of American Ginseng is to be taken in capsulated form. Two capsules are taken with every meal, for a total of 6 capsules per day for 12 weeks
224245774|NCT03901768|DRUG|Placebos|A syringe having 4ml of saline is used for intravenous injection. 1ml of saline is mixed in the syringes containing solution for intrarticualar local infiltration. The solution is injected intraarticularly.
223665554|NCT00728403|DIETARY_SUPPLEMENT|Wheat Bran|3 grams of Wheat Bran is to be taken in capsulated form. Two capsules are taken with every meal, for a total of 6 capsules per day for 12 weeks
223665555|NCT00644085|DRUG|aspirin|oral administration of aspirin 100 mg
223665556|NCT00644085|DRUG|placebo|oral administration of placebo
224245775|NCT02140398|PROCEDURE|Endometrial Currettage|Only Laparoscopic ovarian drilling without endometrial currettage will be performed
223665557|NCT01649089|PROCEDURE|Conization|Undergo cone biopsy
223665558|NCT01649089|OTHER|Quality-of-Life Assessment|Ancillary studies
223665559|NCT01649089|OTHER|Questionnaire Administration|Ancillary studies
223665560|NCT01649089|PROCEDURE|Therapeutic Conventional Surgery|Undergo hysterectomy
223665561|NCT01649089|PROCEDURE|Therapeutic Lymphadenectomy|Undergo lymphadenectomy
223665562|NCT01266187|PROCEDURE|adjuvant surgery + FOLFOX + cetuximab|surgery -\> 4-8 weeks rest -\> 24 weeks FOLFOX + cetuximab
223665563|NCT01266187|PROCEDURE|perioperative/Folfox + cetuximab|"12 weeks FOLFOX + cetuximab -\> 4 weeks rest -\> surgery~-\> 4-8 weeks rest -\> 12 weeks FOLFOX + cetuximab"
223665564|NCT01659476|OTHER|Methacholine(MCh) Challenge Testing|"Visit 1: High-dose methacholine challenge test~Visit 2 or 3: Will be conducted in random order and subjects will perform one of two modified single-dose methacholine challenge tests at either visit. During these modified challenges, subjects will (a) perform five DIs from functional residual capacity (FRC) to total lung capacity (TLC) back to FRC, or (b) refrain from taking DIs prior to inhaling the previously measured single PC20 dose of methacholine."
223665565|NCT01659476|OTHER|Methacholine(MCh) Challenge Testing|"Visit 1: Baseline tests, and subjects will be randomized to complete either a high-dose methacholine using maximal expiratory flow-volume loop (MEFV), or a high-dose methacholine challenge with impulse oscillometry (IOS) and partial expiratory flow-volume loop (PEFV) and MEFV at each dose step.~Visit 2: Subjects will perform the opposite protocol, based on their first visit:"
223665566|NCT05231096|OTHER|Aloe-vera gel|Aloe-Vera gel Production Aloe vera gel used in this study was 98% aloe vera gel concentration and 2% normal saline. Preparation of aloe-vera gel consists of ripen leaf of aloe vera.(26) Aloe vera leaf was washed thoroughly under water and then cut from the center and the seeping gel was collected in sterile container and was stored at 4°C until the time of application. In our research this pure Aloe vera gel was extracted by The Pakistan Council of Scientific \& Industrial Research (PCSIR) laboratory.
223665567|NCT05231096|OTHER|sidr honey|Honey collection Sidr (Beri) honey was used in this study. Honey was thick, raw and cold extracted from remote Pakistan afghan tribal forest belt of Sidr trees. It was smooth, viscous and medium to dark amber in color.
223665568|NCT05231096|PROCEDURE|Scaling ans root Debridement|non-surgical periodontal therapy was given to all the participants of all the three groups
223770595|NCT02358694|DIETARY_SUPPLEMENT|Serum-Derived Bovine Immunoglobulin|Patients who weigh less than 40 Kg will receive Serum Derived Bovine Immunoglobulin -5 g daily (2.5 g PO BID) and patients who weigh 40 Kg or more will receive Serum Derived Bovine Immunoglobulin- 10 g daily (5 g PO BID)
223770596|NCT02358694|OTHER|Placebo|"Matching placebo packets will be supplied and will appear identical to SBI with respect to volume, appearance and taste.~Patients who weigh less than 40 Kg will take one-half packet BID (2.5 g BID) Patients who weigh 40 Kg or more will take one packet BID (5 g PO BID)."
223770597|NCT02489981|DRUG|Spiriva|60 puffs
224245776|NCT00296647|DRUG|nicotine patch|Decreasing dosages from 21 to 7 mg over 12 week period
224245777|NCT00296647|DRUG|nicotine patch|Decreasing dosage from 21 to 7 mg over 12 weeks
224245778|NCT00296647|DRUG|nicotine lozenge|4 mg nicotine lozenge: dosage according to package directions for 16 weeks
224245779|NCT00296647|DRUG|bupropion|dosage according to prescription directions: 12 weeks
224245780|NCT00296647|DRUG|patch + lozenge|dosage of each according to package insert directions (12 weeks patch, 16 weeks lozenge)
223665569|NCT05219916|PROCEDURE|Blood collection.|"One additional 80 mL blood collection will be collected from HIV patients during a scheduled blood collection as part of their regular follow-up.~Samples will be transported within 3-5 hours by a carrier approved for the transportation of infectious biological samples from the Croix Rousse hospital to the P3 laboratory of the Ecole Normale Supérieure, Lyon for analysis."
223665570|NCT02943304|OTHER|Symptomatic pregnant women with positive RT-PCR ZIKV in serum or urine, or a positive serologic test specific for ZIKV|
223665571|NCT02968537|BEHAVIORAL|Alc-IT (50/50) (morning)|This alcohol-specific inhibition-training (Alc-IT) training group will operate with a Go/NoGo ratio of 50/50 (Houben et al. 2011; 2012): This original version of the Alc-inhibition-training will include 80 alcoholic NoGo trials as well as 80 non-alcoholic Go trials. In order to arrive at the same training length while keeping the number of Alc-NoGo-pairings constant and the Go/NoGo-ratio at 50/50, it will additionally include 80 neutral Go-trials as well as 80 neutral NoGo-trials. It will thus consist of 320 trials and take about 10.5 minutes to be completed. In the morning group, this training will be administered within the first 2 hours after awakening.
223770598|NCT02100592|OTHER|Early rehabilitation treatment on Erigo Hocoma|5 weekly sessions of erigo for three weeks. Expected tilt angle up to 60 °
223770599|NCT02100592|OTHER|Early rehabilitation treatment on Erigo Hocoma|Early verticalization treatment with Erigo Hocoma, a tilt table with stepping system
223770600|NCT04055636|DIAGNOSTIC_TEST|Echocardiography with speckle tracking analysis.|Transthoracic echocardiography with speckle tracking analysis.
223770601|NCT04055636|DIAGNOSTIC_TEST|48-hour ECG monitoring.|Ambulatory 48-hour electrocardiography monitoring.
223770602|NCT04055636|DIAGNOSTIC_TEST|Blood samples analysis.|Analysis of blood samples for biochemistry, biomarkers of myocardial damage, fibrosis and inflammation.
224245781|NCT00296647|DRUG|bupropion + lozenge|dosage of each according to prescription or package insert (12 weeks bupropion, 16 weeks lozenge)
224245782|NCT04360447|DEVICE|Reformer Pilates|Reformer pilates was planned, suitable for the disabled, with an instructor for the patients in the study group for 8 weeks.
223665572|NCT02968537|BEHAVIORAL|Alc-IT (75/25) (morning)|This version of the alcohol-specific inhibition-training (Alc-IT) will operate with a Go/NoGo-ratio of 75/25. It will equally include 80 Alcoholic NoGo-trials and 80 non-alcoholic Go-trials, but now 160 neutral Go-trials will complete the set. This training will also consist of 320 trials and take about 10.5 minutes. In the morning group, this training will be administered within the first 2 hours after awakening.
223665573|NCT02968537|BEHAVIORAL|Control-training (morning)|This group will receive an unspecific inhibition training. this training is of the same length and difficulty as the two Alc-inhibition-trainings. In the morning group, this training will be administered within the first 2 hours after awakening.
223665574|NCT02968537|BEHAVIORAL|Alc-IT (50/50) (afternoon)|"As in the arm Alc-IT (50/50) (morning), this alcohol-specific inhibition-training (Alc-IT) group will operate with a Go/NoGo ratio of 50/50 (Houben et al. 2011; 2012): This original version of the Alc-inhibition-training will include 80 alcoholic NoGo trials as well as 80 non-alcoholic Go trials. In order to arrive at the same training length while keeping the number of Alc-NoGo-pairings constant and the Go/NoGo-ratio at 50/50, it will additionally include 80 neutral Go-trials as well as 80 neutral NoGo-trials. It will thus consist of 320 trials and take about 10.5 minutes to be completed. In contrast to the In the morning group, this afternoon group will receive the training in the afternoon."
223665575|NCT02968537|BEHAVIORAL|Alc-IT (75/25) (afternoon)|"As in the arm Alc-IT (75/25) (morning), this version of the alcohol-specific inhibition-training (Alc-IT) will operate with a Go/NoGo-ratio of 75/25. It will equally include 80 Alcoholic NoGo-trials and 80 non-alcoholic Go-trials, but now 160 neutral Go-trials will complete the set. This training will also consist of 320 trials and take about 10.5 minutes. In contrast to the In the morning group, this afternoon group will receive the training in the afternoon."
223665576|NCT02968537|BEHAVIORAL|Control-training (afternoon)|"As in the arm Control-training (morning), this group will receive an unspecific inhibition training. This training is of the same length and difficulty as the two Alc-inhibition-trainings. In contrast to the In the morning group, this afternoon group will receive the training in the afternoon."
224245783|NCT04360447|OTHER|Home Exercise|A home exercise program with telephone monitoring was planned for the patients in the control group for 8 weeks.
224245784|NCT01985347|DEVICE|CPAP|Continuous positive airway pressure( CPAP)
223665577|NCT06044701|OTHER|Hologram Distraction Technique|Hologram fan application during blood collection process
223665578|NCT06044701|OTHER|Bubble Machine Distraction Technique|Bubble machine application during blood collection
223665579|NCT02078856|DRUG|A3384|
223665580|NCT06019442|BEHAVIORAL|Brief alcohol intervention (Health4Her-Automated)|"Embedded within the lifestyle health promotion provided in both conditions, participants randomised to the experimental condition will receive a brief alcohol intervention. The brief alcohol intervention will comprise information and behaviour-change content regarding alcohol consumption, including: messaging around alcohol risks/harms (with a focus on alcohol use and breast cancer risk), positive-framed messaging on the health benefits of reducing alcohol intake, and alcohol harm-reduction / behaviour change strategies (e.g. drink counting, goal setting, behaviour substitution, problem solving).~Post-session information will be provided via email (i.e. electronic brochure summarising brief alcohol intervention content)."
223665581|NCT06019442|BEHAVIORAL|Lifestyle health promotion|"Lifestyle health promotion, focused on physical activity and maintaining a healthy weight for reducing breast cancer risk, will be provided.~Post-session information will be provided via email (i.e. electronic brochure summarising nutrition for maintaining a healthy weight)."
223665582|NCT04802122|DRUG|Sevoflurane inhalant product|Sevoflurane 8% / O2 100% with the vital capacity breathing method (vital capacity induction, VCI) will be used for induction to anesthesia and facilitate endotracheal intubation.
223665583|NCT04802122|DRUG|Propofol Fresenius|Propofol 1,5mg/Kg, supplemented by fentanyl 2mcg/Kg and rocuronium 0,5mg/Kg and O2 100% will be for induction to anesthesia and facilitate endotracheal intubation. .
223665584|NCT06234241|OTHER|Echocardiography|Echocardiography was performed in all enrolled populations.
223665585|NCT03614208|BEHAVIORAL|Home-care rehabilitation group (HCRG)|The exercise program consists of aerobic exercise on a stationary bike, muscular endurance training of the upper limb and stretching exercises for finger joint motion. The exercise on the stationary bike and muscular endurance training will be performed on alternate days, three times a week.
223665586|NCT06228677|PROCEDURE|Selective adrenal artery embolization|Percutaneous selective adrenal artery embolization in patients with primary aldosteronism
223665587|NCT06171841|OTHER|low-intensity resistance training|4 sets of 30/15/15/15 repetitions of leg press exercise with a load of 20-30% of one-repetition maximum (weeks 1-3: 20%, weeks 4-6: 30%) in normoxic conditions performed twice a week for 6 weeks.
223770603|NCT00796861|DRUG|Sunitinib|Patients will be given Sunitinib 50 mg orally daily for four weeks, followed by a two week holiday. For patients tolerating treatment, three cycles of treatment will be given (18 weeks total).
223770604|NCT00394797|PROCEDURE|mitral valve annuloplasty|
223770605|NCT05577182|DRUG|INCA32459-101|solution for infusion
224245785|NCT01947218|PROCEDURE|bronchial biopsies|
224245786|NCT01947218|OTHER|Determination of CO in exhaled air|
224245787|NCT03235388|OTHER|Audit filters|Institutional implementation of audit filters
224245788|NCT01629381|DRUG|Rivaroxaban|10 mg os once daily for 1 week
224245789|NCT01629381|DRUG|placebo|10 mg os once daily for 1 week
224245790|NCT03846765|DRUG|Phenylephrine|"Phenylephrine will be administered continuously after intubation in order to maintain blood pressure in a range from MAPbaseline -20% to normal (preoperative) values (MAPbaseline). If MAP decreases to a value lower than MAPbaseline -20%, a higher dose of vasopressor will be administered. If MAP increases to a value above MAPbaseline, the dosing rate will be decreased.~Phenylephrine will be started at 0,2 μg/kg/min and adjusted according to the patient's hemodynamic status. The dose will be adjusted to MAP during a 30-minute study period."
224245791|NCT03846765|DRUG|Dobutamine|"Dobutamine will be administered continuously after intubation in order to maintain blood pressure in a range from MAPbaseline -20% to normal (preoperative) values (MAPbaseline). If MAP decreases to a value lower than MAPbaseline -20%, a higher dose of vasopressor will be administered. If MAP increases to a value above MAPbaseline, the dosing rate will be decreased.~Dobutamine will be started at 2 μg/kg/min; and adjusted according to the patient's hemodynamic status .The dose will be adjusted to MAP during a 30-minute study period."
224245792|NCT00021463|DRUG|Abacavir sulfate, Lamivudine and Zidovudine|
223665588|NCT06171841|OTHER|high-intensity resistance training|4 sets of 10 repetitions of leg press exercise at 70-80% one-repetition maximum (weeks 1-3: 70%, weeks 4-6: 80%) in normoxic conditions performed twice a week for 6 weeks.
223665589|NCT06171841|OTHER|low-intensity resistance training combined with blood flow restriction|4 sets of 30/15/15/15 repetitions of leg press exercise with a load of 20-30% of one-repetition maximum (weeks 1-3: 20%, weeks 4-6: 30%) in normoxic conditions with lower-limbs blood flow restriction (80% total occlusion pressure) performed twice a week for 6 weeks.
223665590|NCT06171841|OTHER|low-intensity resistance training in hypoxia condition|4 sets of 30/15/15/15 repetitions of leg press exercise with a load of 20-30% of one-repetition maximum (weeks 1-3: 20%, weeks 4-6: 30%) in hypoxia conditions (3500 meters above sea) performed twice a week for 6 weeks.
223665591|NCT06171841|OTHER|low-intensity resistance training combined with blood flow restriction in hypoxia condition|4 sets of 30/15/15/15 repetitions of leg press exercise with a load of 20-30% of one-repetition maximum (weeks 1-3: 20%, weeks 4-6: 30%) in normobaric hypoxia conditions (3500 meters above sea) with lower-limbs blood flow restriction (80% total occlusion pressure) performed twice a week for 6 weeks.
223665592|NCT03542032|OTHER|i-gel placement maneuvers|the i-gel was inserted with triple airway maneuver (mouth opening, head extension and jaw thrust) In the classic maneuver , the index finger used as a guide, pushes the back of i-gel towards the hard palate, inserting it into the pharynx till a resistance is felt and the i-gel is then fixed it its place.
223665593|NCT02980913|DEVICE|Thealoz Duo eye drops and Thealoz Duo gel|Thealoz Duo eye drops during the day + Thealoz Duo gel at night (1 drop before going to bed) for 7 days
223665594|NCT02980913|DEVICE|Thealoz Duo gel|Thealoz Duo gel during the day and at night for 7 days
223665595|NCT00717236|DRUG|Certolizumab pegol (CZP)|400 mg CZP given as two 200 mg subcutaneous (sc) injections at Weeks 0, 2, and 4, followed by 200 mg CZP given as 1 sc injection on Weeks 6, 8, and 10. At Week 12 subjects enter the open label phase and receive 200 mg of CZP every other week for a minimum 16 additional weeks until CZP is commercially available.
223665596|NCT00717236|OTHER|Placebo|Placebo (0.9% saline) given as 2 subcutaneous (sc) injections at Weeks 0, 2, and 4, followed by placebo given as 1 sc injection on Weeks 6, 8, and 10. At Week 12 subjects enter the open label phase and receive 200 mg of CZP every other week for a minimum 16 additional weeks until CZP is commercially available.
223665597|NCT00194870|PROCEDURE|EEG|computer-assisted analysis of the digitally-recorded EEG signals
223665598|NCT00475982|BEHAVIORAL|Weight Loss|Subjects undergo a weight loss intervention prior to radical prostatectomy. The intervention includes weekly visits with the dietician, DEXA scanning, blood draws, and anthropometrics.
223665599|NCT00475982|OTHER|No Weight Loss Group|These subjects do not undergo a weight loss intervention prior to radical prostatectomy. This group does undergo DEXA scanning, blood draws, and anthropometrics prior to radical prostatectomy.
224245793|NCT00021463|DRUG|Abacavir sulfate|
224245794|NCT00021463|DRUG|Efavirenz|
224245795|NCT00021463|DRUG|Nevirapine|
224245796|NCT02824484|BEHAVIORAL|GWDP|"In each writing session participants are asked to:~1. Describe memories concerning cancer illness in a chronological order, with an objective and detached attitude~2. Describe: (a) thoughts and emotions perceived during the illness experience; (b) the impact of illness on their daily lives, and how it has changed their attitudes toward life.~3. Focus on their actual situation, think about the entire illness experience, and report on the following aspects: -Their present thoughts and feelings, and how those differ from the ones felt during the illness experience. -To what extent they have come to terms with, understand and appreciate themselves to have dealt successfully with the illness."
224245797|NCT02824484|BEHAVIORAL|Control|Participants are requested to write about events of their daily routine happened during the past week; they are also asked to focus on facts, with an objective and detached attitude.
224245798|NCT05557474|OTHER|Early-stage lung cancer prognostic kit -- ELISA|blood sample with ELISA
223665600|NCT00572754|PROCEDURE|Circumcision|Circumcision by tying a ligature around the foreskin.
223665601|NCT02778113|DRUG|Nasal Glucagon|Administered intranasally.
223665602|NCT02778113|DRUG|Glucagon|Administered SC.
223665603|NCT00783198|BIOLOGICAL|SCH 39641 6 Amb a 1-U|SCH 39641 6 Amb a 1-U sublingual tablets administered once daily
224245799|NCT05557474|OTHER|Early-stage lung cancer prognostic kit -- IHC|surgical tumor part with IHC
224245800|NCT06319963|DRUG|Two IM injections Lenti-HPV-07|two Lenti-HPV-07 intramuscular injections one month apart
224245801|NCT06319963|DRUG|One IM injection Lenti-HPV-07|a single intramuscular injection prior to receiving a standard of care 28 days at least after the injection.
223665604|NCT00783198|BIOLOGICAL|SCH 39641 12 Amb a 1-U|SCH 39641 12 Amb a 1-U sublingual tablets administered once daily
223665605|NCT00783198|BIOLOGICAL|Placebo|matching placebo sublingual tablets administered once daily
223665606|NCT01318824|PROCEDURE|Nasal Intermittent Positive Pressure Ventilation (NIPPV)|The Control group receiving Nasal Intermittent Positive Pressure Ventilation (NIPPV) treatment
223665607|NCT01318824|PROCEDURE|Bi-Level Positive Airway Pressure (BIPAP)|BiPAP group receive Bi-Level Positive Airway Pressure (BIPAP) treatment
223665608|NCT05716672|DRUG|Lazertinib|Lazertinib 240mg(3tablets, 80mg/1tablet), once a day(QD), oral(PO), until disease progression or unacceptable toxicity
223665609|NCT00870376|OTHER|biomarkers|To define a biomarker or combination of overactive bladder syndrome
224245802|NCT04038710|DRUG|Triple combination therapy|Triple combination is compromised of the drugs ivacaftor, tezacaftor and Vertex's next generation modulator.
224245803|NCT01214226|DRUG|Pentoxifylline|400 mg prolonged-released tablets 3 time per day for 1 month.
224245804|NCT01214226|DRUG|placebo|prolonged-release tablets 3 time per day for 1 month
224245805|NCT02419456|DRUG|MK-2048A IVR (Low Dose)|Contains 91 mg of vicriviroc (MK-4176) and 10 mg of MK-2048.
224245806|NCT02419456|DRUG|MK-2048A IVR (Original Dose)|Contains 182 mg of vicriviroc (MK-4176) and 30 mg of MK-2048.
224245807|NCT01965522|DRUG|Melatonin|Melatonin 20mg taken orally once daily. This is in the form of one capsule which contains two pills of melatonin, 10 mg each.
224245808|NCT01965522|DRUG|Vitamin D|Vitamin D 2000 IU taken orally once daily. This is in the form of one capsule which contains two pills of vitamin D, 1000 IU each.
224245809|NCT01965522|DRUG|Placebo (melatonin)|Overencapsulated placebo capsule which contains an inert substance. The capsule appears identical to the capsule which contains melatonin tablets.
224245810|NCT01965522|DRUG|Placebo (vitamin D)|Overencapsulated placebo capsule which contains an inert substance. The capsule appears identical to the capsule which contains vitamin D tablets.
224245811|NCT02841800|DEVICE|'Intra-luminal radiofrequency ablation (Habib EndoHPB)|endobiliary radiofrequency ablation device
224245812|NCT00735904|DRUG|AG-013736|AG-013736 5 mg tablets orally, twice daily, until disease progression
224245813|NCT00735904|DRUG|gemcitabine|200-mg or 1 g lyophilized powder, to be administered as 1250 mg/m\^2 IV infusion on Day 1 and Day 8 of 21-day cycle. For a maximum of 6 cycles
224245814|NCT00735904|DRUG|cisplatin|1mg/ml solution or as lyophilized powder, to be administered as 80 mg/m\^2 IV infusion on Day 1 of 21-day cycle. For a maximum of 6 cycles
224245815|NCT01233505|DRUG|veliparib|Given PO
224245816|NCT01233505|DRUG|capecitabine|Given PO
224245817|NCT01233505|DRUG|oxaliplatin|Given IV
224245818|NCT01233505|OTHER|pharmacological study|Correlative studies
224245819|NCT01233505|OTHER|laboratory biomarker analysis|Correlative studies
224245820|NCT02808065|DRUG|Tacrolimus|Administered dose were individualized according to their own prescription
224245821|NCT02808065|DRUG|Mycophenolate mofetil|Administered dose were individualized according to their own prescription
224245822|NCT03687515|DRUG|budesonide|1mg/2ml Pulmicort Respules BIS twice daily
224321690|NCT04846829|DRUG|intravenous citalopram hydrochloride (CIT)|CIT will be administered intravenously using established clinical procedures. A single 40 mg dose of CIT diluted in 60 cc normal saline will be delivered intravenously under double-blind conditions via pump over a 40-minute period.
223665610|NCT01054833|PROCEDURE|Needleless mid-urethral sling|The Needleless® sling is intended for use in women as a tension free, sub-urethral slings for the treatment of SUI resulting from urethral hypermobility and/or intrinsic sphincter deficiency. The Needleless sling is a macroporous, monofilament, knitted polypropylene featuring 'Pocket Positioning Anchors' which allow sling placement without needle introducers; thus eliminating a complicated aspect of the surgery (TVT/TOT) and reducing the potential for bladder injury or inguinal pain that can occur during transobturator needle passage. The Needleless sling was approved by KFDA, and now is available in worldwide including Korea.
223665611|NCT03268655|DIETARY_SUPPLEMENT|Ginger extract|2000 mg ginger extract daily for 6 weeks, plus 6 weeks washout
223665612|NCT03268655|OTHER|Placebo|2000 mg ginger extract daily for 6 weeks, plus 6 weeks washout
223665613|NCT03704636|DEVICE|INVSENSOR00028|Noninvasive pulse oximeter sensor
223665614|NCT00791817|DRUG|PG-760564|200 mg capsule, single dose,fasted when dosed, duration is 4 days
223665615|NCT00791817|DRUG|PG-760564|200 mg capsule, single dose,high fat diet when dosed, duration is 4 days
223665616|NCT00539188|DRUG|N-Acetylcysteine|3000 mg PO (1200 mg AM, 1800 mg PM), 6 weeks
223665617|NCT00539188|DRUG|placebo|placebo, 2 capsules PO AM, 3 capsules PO PM, 6 weeks
223665618|NCT02989454|OTHER|Assessment of exercise capacity and cardiac energetics|Cardiopulmonary exercise testing and Magnetic Resonance Spectroscopy
223665619|NCT02345564|DEVICE|implantation of MaioRegen fleece into osteochondral lesion|arthroscopic localization of lesion, arthroscopic guided mini-arthrotomy and implantation of defect sized MaioRegen fleece
224245823|NCT03687515|DRUG|budesonide|nasal spray 256μg BID
224245824|NCT03687515|DRUG|Prednisone|oral prednisone 24mg QD
224245825|NCT02543554|PROCEDURE|lung protective ventilation|Lung protective ventilation strategy, which aims to deliver safe tidal volumes, appropriate PEEP, limit plateau pressure, and limit hyperoxia.
224245826|NCT01390844|DRUG|Boceprevir (BOC)|200 mg capsules, 800 mg three times daily by mouth
224245827|NCT01390844|DRUG|Placebo to boceprevir|200 mg placebo capsules, 800 mg three times daily by mouth
224245828|NCT01390844|DRUG|Peginterferon alfa-2b (PEG)|1.5 mcg/kg/week subcutaneously
224245829|NCT01390844|DRUG|Ribavirin (RBV)|200 mg capsules, weight-based dosing 800 to 1400 mg/day by mouth divided twice daily
224245830|NCT01390844|DRUG|Cross-Over Boceprevir Treatment|At Treatment Week 14, participants in the Placebo group with detectable HCV-RNA at Treatment Week 12 have the option to add boceprevir 800 mg three times daily to the PEG + RBV regimen for up to 32 weeks.
224245831|NCT03613259|DRUG|Fluorothymidine F-18|Given IV
224245832|NCT03613259|OTHER|Laboratory Biomarker Analysis|Correlative studies
224245833|NCT03613259|PROCEDURE|Positron Emission Tomography|Undergo fluorothymidine F-18 PET
224245834|NCT04605861|DRUG|Liraglutide|Liraglutide Injection, once a day, injected subcutaneously on the sites of abdomen, thigh or upper arm. The initial dose of Liraglutide Injection will be 0.6 mg per day. The dose is escalated every one to two weeks to reduce the gastrointestinal symptoms. At Week 7, the dose is increased to 3.0 mg per day. For the subjects who are not able to tolerate the target dose of 3.0 mg,the dose is reduced to 2.4 mg a day and escalated to the dose to 3.0 mg within two weeks. If the subjects are still unable to tolerate this dose (3.0 mg), the treatment is terminated.
224245835|NCT04605861|DRUG|Placebo|Placebo Injection, once a day, injected subcutaneously on the sites of abdomen, thigh or upper arm. The initial dose of Placebo Injection will be 0.6 mg per day. The dose is escalated every one to two weeks to reduce the gastrointestinal symptoms. At Week 7, the dose is increased to 3.0 mg per day. For the subjects who are not able to tolerate the target dose of 3.0 mg,the dose is reduced to 2.4 mg a day and escalated to the dose to 3.0 mg within two weeks. If the subjects are still unable to tolerate this dose (3.0 mg), the treatment is terminated.
224245836|NCT02042846|DEVICE|SportWelding Fiji Anchor|
224245837|NCT01642511|RADIATION|99mTc-labeled Sulfur Colloid|Control Group: Each patient received the 1 intraparenchymal injection of 99mTc-SC (0.5\~1.0 mCi/0.5mL) in the tumor quadrant. Study Group: Two syringes of 0.25\~0.5 mCi 99mTc-SC in 0.2\~1.0 mL volume were injected intraparenchymally into 2 quadrants of breast, at the 6 and 12 o'clock positions.
224245838|NCT01642511|PROCEDURE|Axillary Sentinel Lymph Node Biopsy|Sentinel lymph node biopsy
224245839|NCT01642511|DRUG|Methylthioninium|Four milliliters of methylthioninium was injected subcutaneously above the primary tumor or around the biopsy cavity 10 min before surgery
224321691|NCT04846829|DEVICE|continuous theta burst stimulation|"10 sessions of treatment with iTBS to left or cTBS to right DLPFC TBS consists of three TMS pulses given at 50 Hz, with this triplet repeated at a frequency of 5 Hz (every 200 ms).~1800 pulses of cTBS will be delivered"
224321692|NCT04164199|DRUG|Tislelizumab|Administered intravenously.
224321693|NCT04164199|DRUG|Pamiparib|Administered orally.
223665620|NCT05236088|DEVICE|Neuromuscular electrical stimulation application|It was applied with INNOVO brand (Atlantic Therapeutics, Galway, Ireland) device. It was applied for 30 minutes 3 days a week during 4 weeks
224245840|NCT01642511|DEVICE|Lymphoscintigraphy|Sequential anterior and lateral gamma imaging was performed with patients lying prone and by injection side just before surgery using a digital gamma camera computer system (Toshiba GCA-901A/HG).
224245841|NCT01642511|PROCEDURE|Axillary Lymph Node Dissection|ALND was performed consequently if axillary SLNB was failure or axillary SLNs were positive.
224245842|NCT01642511|PROCEDURE|Internal Mammary Sentinel Lymph Node Biopsy|Internal mammary sentinel lymph node biopsy
224245843|NCT00076050|DIETARY_SUPPLEMENT|Soy isoflavones|Purified soy isoflavones (phytoestrogens) in tablet form tablets; 200 mg.
224245844|NCT00076050|DIETARY_SUPPLEMENT|Placebo|Placebo soy isoflavones
224245845|NCT01316445|DRUG|nasal Midazolam|Intranasal and buccal administration of the standard IV formulation of midazolam (5mg/mL), administered via a metered dose sprayer at 0.1mL/spray (i.e. 0.5mg/spray). Administration will be via three sprays in each nostril (for nasal) or three sprays between the cheek and the gum per side (for buccal).
224245846|NCT03205241|DIETARY_SUPPLEMENT|n-3 PUFA|n-3 PUFA capsules containing EPA and DHA
224245847|NCT03205241|DIETARY_SUPPLEMENT|Placebo|Olive oil capsules
224245848|NCT02495545|PROCEDURE|CSFD and elevation of MAP|Lumbar drain placement with CSFD with elevation of MAP
224245849|NCT02495545|PROCEDURE|Maintenance of MAP|Lumbar drain placement without CSFD and with maintenance of MAP
224245850|NCT00490594|DEVICE|ACL Reconstruction (SeriACL™ Device)|Bioresorbable ACL
224245851|NCT00547781|PROCEDURE|PGD|
224245852|NCT00378690|DRUG|leuprorelin acetate|LHRH antagonist
224245853|NCT04792944|DRUG|Urokinase|Washing the subarachnoid clot induced by a subarachnoid haemorrhage aneurysmal bleeding with urokinase after aneurysm clipping
224245854|NCT04792944|PROCEDURE|Endovascular treatment|Aneurysm treatment through endovascular methods
223665621|NCT05236088|DEVICE|Sham neuromuscular electrical stimulation application|Sham group will be applied from the same device, again 3 days a week for 30 minutes during 4 weeks, but no current will be given from the device.
223665622|NCT02670148|PROCEDURE|Chiropractic manipulative therapy|We will set an a priori treatment schedule of 8 visits at a frequency of 2 visits per week over a 4 week period. CC participants will receive chiropractic manipulative therapy (CMT). CMT procedures can be broadly divided into two types, thrust and non-thrust. Thrust CMT is a high-velocity low-amplitude procedure characterized by a single, short duration thrust (ranging from 100 to 500 ms) of low amplitude force applied to a target joint that often results in an audible sound, or cavitation. Non-thrust CMT employs low-velocity and often repeated joint movements of varying amplitude. In the event that no CMT treatment is clinically indicated, treatment will not be provided.
224245855|NCT04792944|PROCEDURE|Clipping|Surgical clipping of brain aneurysms
223665623|NCT04517890|DRUG|lidocaine patch|5% lidocaine patch applied at 3 hours before the procedure
223665624|NCT04517890|DRUG|Sham patch|Sham patch containing no study medication applied 3 hours before the procedure
223665625|NCT06250361|OTHER|Questionnaire completion|A questionnaire will be completed by the participant and their gastroenterologist. Estimated completion time is 30 minutes for the patient, 10 minutes for the gastroenterologist.
223665626|NCT04784442|DRUG|180mg of ETC-1002(bempedoic acid)|180mg, tablet, once daily, for 12 weeks
223665627|NCT04784442|DRUG|120mg of ETC-1002(bempedoic acid)|120mg, tablet, once daily, for 12 weeks
224245856|NCT04792944|PROCEDURE|External ventricular drain|Insertion of an external ventricular drain to treat acute hydrocephalus
224245857|NCT04932837|BIOLOGICAL|Blood and Saliva collection|Serological, viral RNA and antigenic test
224245858|NCT04520464|DIAGNOSTIC_TEST|Cervical samples for identification of HR-HPV DNA via real-time PCTR.|Identification of HR-HPV DNA via real-time PCTR.
224245859|NCT03204539|DRUG|Wilate|Wilate® is a high-purity (i.e. 100 IU FVIII/mg total protein) pdVWF/FVIII complex concentrate.Wilate® possesses all the important features asked for in ITI, namely high purity, a very high pathogen safety profile, and an excellent protection of its FVIII by VWF - all achieved through unique, novel, and innovative techniques.
224245860|NCT04350580|DRUG|Human immunoglobulin|Human immunoglobulin 2g/kg over 4 days (0.5g/kg/d)
224245861|NCT04350580|DRUG|Placebo|Sodium chloride 0.9% in the same volume and over the same time as the immunoglobulin
224245862|NCT01624064|DRUG|Enalapril|2.5-20 mg/day
224321694|NCT04164199|DRUG|Temozolomide|Administered orally.
224321695|NCT04164199|DRUG|Sitravatinib|Administered orally.
224245863|NCT01624064|DRUG|Calcium Supplement|Calcium 2.5-20 mg/day
224245864|NCT04853459|PROCEDURE|Border modeling..Measurement|By using light cure to make border modeling in complete denture.
224245865|NCT04723602|BIOLOGICAL|cAd3-Marburg|A total of 16 healthy adults will be enrolled and vaccinated with a single dose of vaccine. Group 1 (N = 16) will receive a single injection of cAd3-Marburg at 1 x 10\^11 Particle Units (PU) vaccine.
224245866|NCT04723602|BIOLOGICAL|cAd3-EBO-S|A total of 16 healthy adults will be enrolled and vaccinated with a single dose of vaccine. Group 2 (N = 16) will receive a single injection of cAd3-EBO-S at 1 x 10\^11 Particle Units (PU) vaccine.
224245867|NCT02456948|DRUG|Minocycline|6 weeks 200mg/day Minocycline add-on
224245868|NCT02456948|DRUG|Placebo|6 weeks Placebo add-on
224245869|NCT01171963|BIOLOGICAL|GSK Biologicals' liquid human rotavirus vaccine 444563|Oral administration
224321696|NCT04164199|DRUG|Ociperlimab|Administered intravenously.
224245870|NCT01171963|BIOLOGICAL|Placebo|Oral administration
224245871|NCT01171963|BIOLOGICAL|Infanrix™|Intramuscular administration
224245872|NCT01171963|BIOLOGICAL|Institute of Medical Biology Chinese Academy of Medical Sciences' Oral poliovirus vaccine (OPV)|Oral administration
224245873|NCT03113006|PROCEDURE|Panretinal Photocoagulation|Panretinal laser treatment of the retina in patients with proliferative diabetic retinopathy.
224321697|NCT04164199|DRUG|BAT1706|Administered intravenously.
224321698|NCT04164199|DRUG|Fruquintinib|Administered orally.
224321699|NCT04164199|DRUG|BGB-15025|Administered orally.
224321700|NCT04164199|DRUG|Zanidatamab|Administered intravenously.
224321701|NCT04164199|DRUG|BGB-A445|Administered intravenously.
224321702|NCT04164199|DRUG|Surzebiclimab|Administered intravenously.
224245874|NCT01751594|BEHAVIORAL|MOVE Intervention|MOVE involves four sessions. Sessions 1 and 2 occur over a two-day time frame and are each one day long (approximately 8 hours in length). They will: lay the groundwork for the intervention; provide HIV and other sexual health-related information; introduce critical consciousness; Sessions 1 and 2 will begin the enhancement of critical consciousness and the action-reflection-action cycle. Sessions 3 and 4 are also one-day sessions each (approximately 8 hours in length) and will be administered at one month intervals following the completion of sessions 1 and 2. These sessions will be used to provide continued enhancement of critical consciousness and guided support, feedback, and social reinforcement for behavior change and self-efficacy related to increasing health-promoting behaviors and reducing HIV-related health risk behaviors.
224245875|NCT01751594|BEHAVIORAL|H4L Comparison Intervention|Health 4 Life (H4L) is a comparison intervention which will serve as the basis of comparison for Mobilizing Our Voices for Empowerment (MOVE), the treatment intervention. H4L will be a health promotion and life skills intervention to account for time and attention.
224245876|NCT05093205|DRUG|PF-06882961|Tablets
224245877|NCT05093205|DRUG|Atorvastatin|Tablets
224245878|NCT05093205|DRUG|Midazolam|Syrup
224245879|NCT05093205|DRUG|Levonorgestrel & Ethinyl Estradiol|Tablet
224245880|NCT06475924|DIAGNOSTIC_TEST|Caesarean scar defect evlauation by ultraosund|"Women will be examined in the lithotomy position with an empty bladder. The uterus will be examined in a standardized way excluding causes of abnormal uterine bleeding or pelvic pain (myoma, polyp, pelvic inflammatory disease, adenomyosis).~Upon detection of the SCD, the following will be measured:~In the midsagittal plane: the depth (the vertical distance between the base and apex of the defect), width (the length of the widest gap along the cervicoisthmic canal), residual myometrial thickness (RMT) overlying the defect, and the adjacent myometrial thickness fundal to the defect.~In the transverse plane: the length of the defect.~The uterine position will be classified as anteverted or retroverted.~Clinical symptoms of the patients will be reviewed such as :Postmenstrual spotting, Abnormal uterine bleeding, Pain, Secondary infertility."
224245881|NCT00048126|DRUG|Irinotecan|100mg/m2 iv on days 1, 8, 15 and 22 of each 6 week cycle.
224245882|NCT00048126|DRUG|capecitabine [Xeloda]|1000mg po bid
224245883|NCT00005856|DRUG|oxaliplatin|Given IV
224245884|NCT00005856|OTHER|pharmacological study|Correlative studies
224245885|NCT05822232|DEVICE|FreeStyle Libre 2 CGM|FreeStyle Libre 2 CGM is FDA-approved and will be used according to FDA-approved labeling
224245886|NCT05822232|DEVICE|FreeStyle Libre Pro blinded CGM|FreeStyle Libre Pro blinded CGM is FDA-approved and will be used according to FDA-approved labeling
224245887|NCT05822232|DEVICE|FreeStyle Precision Neo blood glucose meter|FreeStyle Precision Neo blood glucose meter is FDA-approved and will be used according to FDA-approved labeling
224245888|NCT01123265|DRUG|Methotrexate|Subjects will start Methotrexate which will be escalated from 7.5 mg weekly to 15 mg/weekly over a 3 week period.
224321703|NCT04164199|DRUG|Lenvatinib|Administered orally.
224321704|NCT04164199|DRUG|LBL-007|Administered intravenously.
224321705|NCT06778798|COMBINATION_PRODUCT|Median nerve neural mobilization and oral gabapentin|Manual therapy maneuver performed in the upper limb combined with gabapentin oral capsules.
223665628|NCT04784442|DRUG|60mg of ETC-1002(bempedoic acid)|60mg, tablet, once daily, for 12 weeks
223665629|NCT04784442|DRUG|Placebo|placebo, tablet, once daily, for 12 weeks
223665630|NCT06197919|OTHER|postural exercises|"In this study forward head posture will be defined as CVA\<49°, which was diagnosed by photogrammetry method.~The postural exercise program consisted of two strengthening (deep cervical flexors and shoulder retractors) and two stretching (cervical extensors and pectoral muscles) exercises based on Kendall et al's approach. The exercises involved~1. chin tucks ins~2. a chin drop in sitting~3. shoulder retraction~4. unilateral and bilateral pectoralis stretches Participants were instructed to complete 3 sets of 12 repetitions of the strengthening exercises and 3 stretching exercises held for 30 seconds each. This program was to be repeated 4 times per week. They also returned for a consultation every 2 weeks to be checked for exercise technique and progression, if appropriate. Progress to the next exercise level was indicated if the participant could complete 12 repetitions, 3 times easily with correct form"
223770606|NCT05022810|DRUG|New Paracetamol Oral Suspension (24 mg/ml)|After an overnight fasting for at least 10 hours, New Paracetamol Oral Suspension (24 mg/ml) in a volume of 42 ml will be administered orally via a single use syringe by a trained study person to the study participants as per the randomization schedule in each period.
224245889|NCT01123265|DRUG|Anti-TNF|Anti-TNF to be administered per standard of care within the practice.
224245890|NCT00360360|DRUG|paclitaxel|Paclitaxel 175mg/m2, 1-3 hour IV infusion,Day 1
224245891|NCT00360360|DRUG|carboplatin|Carboplatin AUC 6.0 IV Day 1
224245892|NCT00360360|DRUG|bevacizumab|Bevacizumab 15mg/kg IV infusion,Day 1
224245893|NCT00360360|DRUG|erlotinib|Erlotinib 150 mg by mouth daily
224245894|NCT05267405|OTHER|no interventions, only observation|no interventions, only observation
224245895|NCT05633485|OTHER|Animation-Supported Education|Expert support was received for the design and preparation of animation videos.
224245896|NCT01988974|BEHAVIORAL|Alert for Atrial Fibrillation Program|Participants' baseline knowledge of AF symptoms, and attitudes and beliefs about AF will be assessed using the KABAFS, and patients will receive cognitive-behavioral training directed toward survey responses associated with delay of treatment. Training will incorporate the content developed by the American College of Cardiology Foundation (ACCF), and participants will receive education about how to recognize an irregular pulse, and how to record the pulse rhythm in a daily log. The PI/RN coordinator will review the completed KABAFS to assess knowledge deficits, and identify attitudes and beliefs about AF that may hinder early treatment-seeking.
224245897|NCT01988974|BEHAVIORAL|Healthy Sleep|Participants will receive a 45 minute face to face instruction about sleep hygiene
224245898|NCT00401947|DRUG|ACH-0137171|
224245899|NCT05605301|DRUG|Oral 2-Deoxy-D-Glucose (2DG)|2DG will be formulated as an solid dosage form and administered orally.
224245900|NCT01746329|OTHER|Tea|Oral intake of tea containing 75 grams of glucose
224245901|NCT01746329|OTHER|Beet root|Oral intake of beetroot juice containing 75 grams of glucose
224321706|NCT06778798|DRUG|Gabapentin 300mg|Gabapentin oral capsules
224321707|NCT02638090|DRUG|Vorinostat|Administered per treatment arm guidelines.
224321708|NCT02638090|DRUG|Pembrolizumab|Administered per treatment arm guidelines.
224245902|NCT01746329|OTHER|Placebo|Oral intake of 75 grams of glucose in water
224245903|NCT03430830|DRUG|Ravidasvir 50mg|50mg, Tablet
224245904|NCT03430830|DRUG|Ravidasvir 200mg|200mg, Tablet
223770607|NCT05022810|DRUG|Panadol B&I Oral Suspension (24 mg/ml paracetamol)|After an overnight fasting for at least 10 hours, Panadol B\&I Oral Suspension (24 mg/ml paracetamol) in a volume of 42 ml will be administered orally via a single use syringe by a trained study person to the study participants as per the randomization schedule in each period.
224245905|NCT04589195|BEHAVIORAL|Mindfulness Training|The intervention includes four weeks of MT application use, accessed via phone or computer, consisting of 15-minute daily mindfulness practices 5 days a week.
224245906|NCT00816504|DRUG|Galactose|Oral galactose, 0.2 g/kg/dose twice daily for 28 days
224245907|NCT00003630|DRUG|arsenic trioxide|
224245908|NCT03583593|DIETARY_SUPPLEMENT|DIAMEL|Diamel is administered 6 capsules a day divided into three doses that are ingested before each meal.
224245909|NCT03583593|DIETARY_SUPPLEMENT|Placebo|Placebo is administered 6 capsules a day divided into three doses that are ingested before each meal.
224245910|NCT03163680|DRUG|Omeprazole 40 MG|Omperazole 40 mg twice daily
224245911|NCT00887263|DRUG|Budesonide|3 mg TID
224245912|NCT00887263|DRUG|Placebo|0 mg TID
224245913|NCT04844489|OTHER|Blood samples for the study of the humoral response to SARS-CoV-2 variants and of the cellular response after vaccination against COVID-19|"Blood samples at:~* D0 (the day of the injection of the SARS-CoV-2 vaccine),~* during the 2nd injection as part of the national vaccination campaign (on D28)~* during the 3rd injection for patients for whom a third injection is recommended (according to the recommendations in force)~* then to M1, M6 and M12 of the last injection"
224245914|NCT04185909|DEVICE|Renuvion Dermal System|The Renuvion® Dermal System consists of an electrosurgical generator unit, a handpiece with detachable standoffs, and a supply of helium gas. Radio Frequency (RF) energy is delivered to the handpiece by the electrosurgical generator unit and used to energize an electrode. When helium gas is passed over the energized electrode, a helium plasma is generated which allows for conduction of the RF energy from the electrode to the subject in the form of a precise helium plasma beam.
223665631|NCT06197919|OTHER|postural exercises with breathing exercises|"The postural exercise program consisted the exercises i.e chin tucks in, a chin drop in sitting, shoulder retraction. Participants were instructed to complete 3sets of 12repetitions of these exercises. This program was to be repeated 4times per week. They also returned for a consultation every 2weeks to be checked for exercise technique and progression, if appropriate. Progress to the next exercise level was indicated if the participant could complete 12repetitions, 3times easily with correct form.~For the breathing exercises in experimental group, breathing program includes respiratory muscle training, relaxation techniques, breathing techniques, e.g., deep breathing, hand controlled diaphragmatic breathing, relaxation technique, deep breathing, controlled diaphragmatic breathing, slow relaxed exhalation with pursed lips technique, and segmental breathing techniques. exercise protocol will be continued for 6 weeks with and initial, after 3weeks and final assessment of pain and CVA."
223665632|NCT06244290|DRUG|Colgate SNF|toothpaste
223665633|NCT06244290|DRUG|Sensodyne Extra Whitening|toothpaste
223665634|NCT06244290|DRUG|Colgate Fluoride (CDC)|toothpaste
223665635|NCT01893034|PROCEDURE|Arthroscopic treatment of femoroacetabular impingement|
223665636|NCT01893034|OTHER|Physiotherapy and activity modification|
223665637|NCT01037894|PROCEDURE|Acupuncture|Acupuncture from physiotherapist (with accredited training in acupuncture) in Shatin Hospital, three sessions per week for six weeks, and each session 30 minutes.
224245915|NCT04035603|DRUG|D-Cycloserine|50 mg d-cycloserine given as an augmentation agent, 70 minutes prior to three CET sessions for participants who achieved smoking cessation following open treatment.
224245916|NCT04035603|DRUG|Placebo oral tablet|matching 50 mg identical placebo given as an augmentation agent, 70 minutes prior to three CET sessions for participants who achieved smoking cessation following open treatment.
224245917|NCT04035603|BEHAVIORAL|Open Phase CBT that preceeds the randomization phase|Four sessions of weekly individual cognitive-behavior therapy (CBT: a form of psychotherapy that treats problems by helping people modify thoughts, behaviors, and emotions; in this case, for the goal of smoking cessation). Session topics include educational (e.g., health risks of smoking, effectiveness of different treatment approaches), motivational enhancement (e.g., identifying personally relevant benefits of quitting, and costs of continuing to smoke), and cognitive-behavioral elements (e.g., identifying smoking triggers, developing coping strategies for these triggers, planning for high risk situations, relapse prevention).
224245918|NCT04035603|DRUG|Open phase smoking cessation pharmacotherapy that proceeds the randomization phase|Initiating 2 weeks prior to quit date and continuing for 8 weeks after quit date, choice of one of three pharmacological smoking cessation aids: Nicotine Replacement Therapy (nicotine patch), Varenicline, or Bupropion.
224245919|NCT01395186|PROCEDURE|varicocelectomy|varicocelectomy for painful varicocele
224245920|NCT03983486|OTHER|Imaging flow cytometry in multiple myeloma|Combination of immunophenotyping by flow cytometry and FISH in suspension (IS-FISH) may provide both cytogenetic and phenotypic information for a large number of cells in a single test. In this scope, a recent study demonstrated a proof of concept for IS-FISH to detect non pathological signals with the new ImageStream X technology (ISX).1
224245921|NCT01417078|DRUG|Diazepam|single-dose; dosage in mg, based on patient body weight
224245922|NCT04458649|DEVICE|Dexcom continuous glucose monitor|Measurement of interstitial glucose
224245923|NCT00626548|DRUG|ZD4054|10 mg once daily oral dose
224245924|NCT00626548|DRUG|Palcebo|Matching Plcebo oral tablet once daily
224245925|NCT00048581|DRUG|Abatacept|Vials, intravenous (IV), \~10mg/kg abatacept, One every 2 weeks for first month then every 4 weeks thereafter, 6 months.
224245926|NCT00048581|DRUG|Placebo|Vials, IV, 0mg, One every 2 weeks for first month then every 4 weeks thereafter, 6 months.
224245927|NCT00048581|DRUG|Abatacept|Vials, IV, \~10mg/kg abatacept, every 4 weeks, 5.5 years
224245928|NCT05493007|PROCEDURE|Sandbag motion style acupuncture treatment|Motion Style Acupuncture Treatment(MSAT) is a therapeutic technique using acupuncture needle created in Jaseng Hospital. This treatment involves patients with musculoskeletal pain to move the part of their body actively during acupuncture treatment under physicians' observation.
224245929|NCT05493007|PROCEDURE|Korean medical treatment|acupuncture treatment, chuna, pharmacoacupuncture, Korean herbal medicine.
223665638|NCT01037894|PROCEDURE|Conventional rehabilitation|In-patient physiotherapy, occupational therapy and speech therapy.
224245930|NCT05677698|OTHER|Lemon oil|Lemon oil with massage
223665639|NCT00930137|OTHER|isocaloric for week diet|"Consumption of the 2 experimental diets~1. a diet rich in ruminant trans fatty acids (4.1 g/2500 kcal);~2. a control diet (minimal dietary ruminant trans fatty acids, 0.7 g/2500 kcal)."
223665640|NCT04683601|OTHER|Thoracoscopic esophagectomy in left decubitus|Making surgical field at thoracoscopic esophagectomy in left decubitus
223665641|NCT02037555|BIOLOGICAL|AT-III (Human)|AT-III (Human) is an antithrombin concentrate prepared from pooled human plasma. AT-III (Human) is provided as a freeze-dried preparation for intravenous use. The AT-III (Human) preparation is reconstituted in 10 or 20 mL of sterile water for injection prior to intravenous administration.
223665642|NCT02037555|OTHER|Placebo|0.9% Sodium Chloride for Injection, United States Pharmacopeia
223665643|NCT00461071|BEHAVIORAL|Guided Self-help for Bulimia nervosa|bibliotherapy
223665644|NCT03035877|BEHAVIORAL|Multisystemic Therapy-Emerging Adults|MST-EA is a home- and community-based treatment for emerging adults (ages 17-21) that aims to address antisocial behavior and problems caused by substance use disorders. The model also addresses co-occurring mental health problems when present. Therapists work directly with the young adult and his/her social network. This treatment also involves the use of coaches who help young people develop skills for young adulthood.
223665645|NCT03035877|BEHAVIORAL|Enhanced Treatment as Usual|With Enhanced Treatment as Usual (E-TAU), emerging adults will get the treatments that they usually receive when they have a substance use disorder and have been in trouble with the law. In addition, they will receive travel vouchers for attending services, a card with an individualized list of contacts when in crisis, and facilitation with identifying need of services and accessing those services.
223665646|NCT04109885|DRUG|Paracervical injection|1.5 mL of 0.5% bupivacaine will be will be injected bilaterally in the paraspinal musculature of the cervical spine.
223665647|NCT04109885|DRUG|prochlorperazine and diphenhydramine.(Standard Treatment)|Intravenous administration of prochlorperazine and diphenhydramine.
223665648|NCT01061255|OTHER|Evaluation of the stress|"Medical Students having to solve a medical problem in ambulatory setting (studied group) vs. in hospitalisation setting (control group).~Measures: The French version of the Anxiety Spielberger test is administered just before and after each problem solving session.~Cortisol salivary samples are taken before and after each problem solving session. Salivary cortisol levels have been shown to be correlated to stressful situations and some personality traits but with some difference according to gender."
224245931|NCT05677698|OTHER|peppermint oil|peppermint oil with massage
224245932|NCT05677698|OTHER|Almond oil|Almond oil massage
224245933|NCT00002064|DRUG|Pyrimethamine|
224245934|NCT00002064|DRUG|Clindamycin|
224245935|NCT04078048|DIETARY_SUPPLEMENT|Antioxidants (Vitamin C, E )|For eight weeks, Vitamin C group was intervened with tablet vitamin c 500 mg once a day ,vitamin E group was intervened with Tablet vitamin E 600 I U twice a day.
224245936|NCT00535808|DRUG|nitroprusside|Administration of nitroprusside
224245937|NCT00535808|DRUG|nitroglycerine|Administration of nitroglycerine
224245938|NCT00535808|DRUG|sevoflurane|Administration of Sevoflurane
224245939|NCT05703308|BIOLOGICAL|Autologous Menstrual Blood Stem Cells|The menstrual blood of patients in the MenSCs treatment group was collected in sterile menstrual cups on the second day of menstruation, and directly transferred to a class B clean room for MSC isolation and culture. All cell quality control studies were performed prior to the International Conference of Harmonization Q2 (ICH Q2) guidelines. The density of the final product was 20×106 cells/ml. 150 μl of the prepared suspension was injected intravaginally into each ovary of the patient under general anaesthesia
224245940|NCT02769208|DEVICE|Central air handling unit air purification technologies|As described in the arm descriptions, the interventions involve changing the baseline pre-filter + HEPA + ESP conditions by removing either just the ESP or both the ESP and the HEPA for a five week period.
223665649|NCT00321126|DRUG|Children in the zinc group received 20 mg of elemental zinc as acetate per day in a twice-daily dose for two weeks.|
223665650|NCT02585336|BEHAVIORAL|Brief intervention|An interviewer provides health information, elicits motivation to reduce SSB consumption, and helps participants make implementation plans. Booster phone calls occur at 1 week after the intervention visit, and at 2 weeks and 24 weeks following the date on which SSBs sales ended at the participant's work location.
223665651|NCT02001753|DEVICE|CMR|
223770608|NCT03852316|DEVICE|Click Device|A single-use device containing a polymerase chain reaction (PCR)-based nucleic acid amplification test (NAAT) for detection of deoxyribonucleic acid (DNA) from Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG), and Trichomonas vaginalis (TV) in self-collected vaginal specimens.
224245941|NCT00000482|DRUG|estrogen|
224245942|NCT00000482|DRUG|clofibrate clofibrate|
224245943|NCT00000482|DRUG|dextrothyroxine sodium|
224245944|NCT00000482|DRUG|niacin|
224245945|NCT01059903|DRUG|Rotigotine transdermal patch|Rotigotine 4.5 mg/10 cm\^2 patch applied for 24 hours
224245946|NCT03895684|DRUG|SP-2577 Seclidemstat|Dose escalation and dose expansion of SP-2577.
224245947|NCT01934673|OTHER|No treatment given|Patients will fill out a questionnaire by interview.
224245948|NCT01709474|DRUG|Vitamin D3 6000 IU|Subjects will receive 6,000 IU of vitamin D3 by mouth daily until the subject's serum 25(OH) level is ≥ 40ng/mL at which point the supplementation dose will be reduced to 4,000 IU/day. Note: Subjects weighing \<40 kilograms (kg) at study entry will receive their dose five days a week and all other subjects seven days a week.
224245949|NCT01709474|DRUG|Vitamin D3 400 IU|Subjects will receive 400 IU/day of vitamin D3 daily by mouth.
224245950|NCT01049893|DRUG|Compound AC220|Precomplexed powder in bottle formulation supplied as 135 mg in a 60 cc polyethylene terephthalate (PET) plastic bottle. Requires reconstitution by a pharmacist, must be stored securely, and protected from light.
224245951|NCT05306470|PROCEDURE|Ethyl chloride|Application of ethyl chloride for a cooling effect to numb the area for oral infiltration anesthetic
224245952|NCT05306470|PROCEDURE|5% lidocaine gel|Application of 5% lidocaine gel to numb the area for oral infiltration anesthetic
223665652|NCT01526824|DIETARY_SUPPLEMENT|omega-3 polyunsaturated fatty acids (Lovaza)|Lovaza, 1 gram orally daily
224245953|NCT05448430|DEVICE|Theta burst stimulation|a new paradigm of high frequency repetitive transcranial magnetic stimulation
224245954|NCT00385593|DRUG|Symbicort (budesonide/formoterol) Turbuhaler|
224245955|NCT00385593|DRUG|Conventional treatment|
224245956|NCT00766168|OTHER|HDS HI 1.54; pahrifocon A|Contact Lens
224245957|NCT00766168|DEVICE|FluoroPerm 30 RGP; paflufocon C|Contact lens daily wear
223665653|NCT00852371|DRUG|sulfadoxine-pyrimethamine|25 mg/kg po once on day 0
223665654|NCT00852371|DRUG|amodiaquine + sulfadoxine-pyrimethamine|Amodiaquine: 10 mg/kg po daily for 3 days (on days 0, 1, 2) SP: 25 mg/kg po once on day 0
223665655|NCT00852371|DRUG|dihydroartemisinin-piperaquine|2.1/17.1 mg/kg daily for three days (on days 0, 1, 2)
223665656|NCT00852371|OTHER|Placebo|dosed as for amodiaquine (10mg/kg po daily on days 1, 2)
223665657|NCT05466201|DRUG|Eltrombopag 25 MG Oral Tablet|Since thrombopoietin receptor agonists (TPO-RAs) have never been regularly used for promotion of cell engraftment post hematopoietic stem cell transplantation HSCT), we design this eltrombopag intervention to evaluate the safety and efficacy of TPO-RAs post HSCT.
223665658|NCT05466201|DRUG|Supportive care|Patients receive transfusion of blood products, including platelets and red blood cells.
223665659|NCT03812822|DEVICE|Insole|Custom-made insoles which support the foot at subtalar neutral position
223665660|NCT00892801|DRUG|RAD001|Taken by mouth once a day, for 15 days, one day prior to initiation of whole brain radiation therapy at 5 or 10 mg/day during the phase I component. One of these doses will be selected as the maximum tolerable dose and will be selected for the phase II component
223665661|NCT00892801|RADIATION|whole-brain radiation therapy|Standard whole brain radiation therapy (WBRT) 30 Gy will be given in ten fractions.
223665662|NCT03873090|OTHER|SBRT|hypofractionated accelerated RT for prostate cancer with FFF (Free Flattened Filter) beam. The schedule will be \[ 4 x 9.5 Gy = 38 Gy \] delivered in 5 alternative days, corresponding to an NTD2 between 95 and 119 Gy for an α/β estimate between 3 and 1.5 Gy.
223665663|NCT04520438|PROCEDURE|Leukocyte and platelet rich fibrin|L-PRF membrane and irrigation with L-PRF exudate in the same treatment session of NSPT
223665664|NCT04520438|PROCEDURE|Non-Surgical Periodontal treatment|The control group only received NSPT (scaling and root planing) in one treatment session.
223665665|NCT03137745|OTHER|thromboelastography|thromboelastography was done pre HIPEC ,post HIPEC and first and second postoperative days
223665666|NCT03697915|DEVICE|Experimental|Conventional physical therapy was administered to the control group and was aimed at achieving sitting balance in the first phase; once sitting balance could be achieved, we aimed at achieving standing balance in the second phase. Once standing balance was also achieved, supported and unsupported ambulation was commenced in the final phase.
223665667|NCT01590758|DRUG|Topical pexiganan cream 0.8%|14 days of treatment
224245958|NCT03226054|BEHAVIORAL|Lifestyle Modifications|Lifestyle Modifications to wean off of a Proton Pump Inhibitor, i.e. avoiding dietary triggers, waiting 3 hours to lie flat, and elevating the head of the bed
223665668|NCT01590758|DRUG|Topical placebo cream|14 days of treatment
223665669|NCT01590758|OTHER|Standard wound care|14 days of treatment
223665670|NCT01232803|DRUG|Tenofovir 1% gel|Entire contents of an applicator will be inserted rectally, for a total of 8 doses.
223665671|NCT01232803|DRUG|2% N-9 gel|Entire contents of an applicator will be inserted rectally, for a total of 8 doses.
223665672|NCT01232803|DRUG|HEC Placebo gel|Entire contents of an applicator will be inserted rectally, for a total of 8 doses.
223665673|NCT04525885|DRUG|Gefapixant 45 mg twice daily (BID)|Gefapixant 45 mg tablet to be administered orally BID
223665674|NCT04525885|DRUG|Gefapixant 15 mg BID|Gefapixant 15 mg tablet to be administered orally BID
223665675|NCT04525885|DRUG|Placebo|Placebo tablet administered orally BID
223665676|NCT04525885|DRUG|Gefapixant 45 mg BID|Gefapixant 45 mg tablet to be administered orally BID
223665677|NCT01779791|DRUG|PCI-32765 (Ibrutinib)|560 mg capsules administered orally once daily, continuously on a 21-day cycle until progressive disease.
224245959|NCT01840735|DRUG|GS-5737|
224245960|NCT01840735|DRUG|Placebo|
224245961|NCT00381537|DRUG|phenobarbitone|
224245962|NCT00381537|DRUG|carbamazepine|
224245963|NCT03416764|DEVICE|EFP-NF training|Experimental groups (among participants with and without steady menstrual cycle) will receive a total of 10 training sessions during 10 weeks. In addition to EFP-NF training, participants in the experimental groups will continue to be treated as usual at Clinic for Sexual Assault.
224245964|NCT05669768|DRUG|Pamiparib/Tamoxifen|Pamiparib 40mg PO BID, Tamoxifen 20mg PO BID
224245965|NCT03992586|OTHER|Wearing pink glasses|Wearing pink-colored lenses
224245966|NCT03992586|OTHER|Wearing clear glasses|Wearing clear glasses
224245967|NCT00622232|GENETIC|VRX496-transduced autologous CD4 T cells|The cell dose will consist of approximately 10 billion VRX496-transduced autologous CD4 T cells provided as a single bolus infusion.
224245968|NCT03487107|DRUG|SOF|400 mg tablet administered orally once daily
224245969|NCT03487107|DRUG|DAG181|100 mg capsule administered orally once daily
224245970|NCT02344992|DRUG|BioChaperone insulin lispro|Single dose of 0.2 U/kg body weight injected subcutaneously
224245971|NCT02344992|DRUG|Humalog®|Single dose of 0.2 U/kg body weight injected subcutaneously
224245972|NCT03132727|OTHER|Pharyngo laryngeal MRI|"Patients will be outgoing a pharyngolaryngeal MRI, with injection of gadolinium, in addition to the CT imaging. They will have this MRI in case of doubt about cartilage invasion. It will be realised during the time between the CT imaging and the day of surgery.~Device : gadolinium-based MRI contrast agent This will be realized according to the standard procedure."
223665678|NCT04707859|DIAGNOSTIC_TEST|Head to head comparison: Rubidium vs 15O-water PET|Head to head comparison with invasive FFR as reference. Adjustment for abnormal microcirculation
223770609|NCT04136834|BIOLOGICAL|PT01 (Pegtomarginase)|PT01 (Pegtomarginase) breaks down arginine in the blood stream, reducing the supply of arginine and stopping the cancer cells from growing. Normal cells can continue to make their own arginine inside the cell, so PT01 targets the rapidly growing cancer cells.
223770610|NCT06391827|DRUG|DA-7503 Single dose|Oral administration for once; Dose strength is different for each cohort(Cohort 1, 2, 3, 4 and 5).
224245973|NCT02100228|DRUG|Apixaban|Oral, 2.5 or 5 mg BID
224245974|NCT02100228|DRUG|Parenteral heparin and/or oral Vitamin K antagonist|Parenteral heparin and/or locally used oral Vitamin K antagonist e.g. warfarin (excludes other novel oral anticoagulants)
224245975|NCT02873910|DIETARY_SUPPLEMENT|IQP-AS-119|
224245976|NCT02873910|DIETARY_SUPPLEMENT|Placebo|
223665679|NCT06071585|OTHER|Formalin-fixed Paraffin-embedded (FFPE) tissue samples analysis|We will stain and analyze EoE, GERD, and controls Formalin-fixed paraffin-embedded (FFPE) tissue samples already stored in the pathological laboratory of OSR.
223665680|NCT04855084|OTHER|Monolithic FDPs: before adjustment|Before the occlusal adjustment, Occlusal relationship recording of the 3-unit monolithic FDPs which was fabricated following the complete digital work-flow.
223665681|NCT04855084|OTHER|Monolithic FDPs: after adjustment|After the occlusal adjustment, Occlusal relationship recording of the 3-unit monolithic FDPs which was fabricated following the complete digital work-flow.
223665682|NCT04855084|OTHER|Metal fused porcelain FDPs: before adjustment|Before the occlusal adjustment, Occlusal relationship recording of the 3-unit metal fused porcelain FDPs which was fabricated following the complete conventional manufacturing procedure.
223665683|NCT04855084|OTHER|Metal fused porcelain FDPs: after adjustment|After the occlusal adjustment, digital occlusal relationship recording was done of the 3-unit metal fused porcelain FDPs which was fabricated following the complete conventional manufacturing procedure.
223665684|NCT02527577|DRUG|RopivacaIne chlorhydrate|3mg/kg injection Hour (H) 0, H12 ; H24, H36 ; H48
223665685|NCT02527577|DRUG|Placebo|injection Hour (H) 0, H12 ; H24, H36 ; H48
223665686|NCT00947960|DRUG|Triheptanoin|1-2 grams triheptanoin (drug)/kilogram body weight divided into 4 equal doses per day taken with meals and a snack for 6 months followed by 1-2 grams vegetable oil (placebo)/kilogram body weight divided into 4 equal doses per day taken with meals and a snack for 6 months.
223665687|NCT00947960|OTHER|Vegetable Oil|1-2 grams vegetable oil (placebo)/kilogram body weight divided into 4 equal doses per day taken with meals and a snack for 6 months followed by 1-2 g triheptanoin (drug)/kilogram body weight for 6 months.
223770611|NCT06391827|DRUG|DA-7503 Multiple dose|Oral administration once daily for 7 days; Dose strength or target volunteer is different for each cohort(Cohort 1,2,3, and 4)
223770612|NCT06391827|DRUG|Placebo Single dose|Oral administraion for once.
223770613|NCT06391827|DRUG|Placebo Multiple dose|Oral administration once daily for 7 days
223770614|NCT03127124|DRUG|NANT-008|Paclitaxel: benzenepropanoic acid, β-(benzoylamino)-α-hydroxy-(2aR, 4S, 4aS, 6R, 9S, 11S, 12S, 12aR, 12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a, 3, 4, 4a, 5, 6, 9, 10, 11, 12, 12a, 12b-dodecahydro-4,11-dihydroxy-4a, 8, 13, 13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca\[3,4\]benz\[1,2-b\]oxet-9-y1ester,(αR,βS)-(9CI)
223770615|NCT03127124|DRUG|Fluorouracil Injectable Product|5-fluoro-2,4 (1H,3H)-pyrimidinedione.
224245977|NCT01989091|DEVICE|B-Lock|Antimicrobial Catheter Lock Solution
223770616|NCT03127124|DRUG|Avastin Injectable Product|Recombinant humanized monoclonal IgG1 antibody
223770617|NCT03127124|DRUG|Leucovorin Calcium Injection|Calcium N -\[p -\[\[\[(6RS )-2-amino-5-formyl-5,6,7,8-tetrahydro-4-hydroxy-6-pteridinyl\]methyl\]amino\]benzoyl\]-L-glutamate (1:1).
224245978|NCT01989091|DRUG|Heparin 5,000 U/mL|Standard of Care Catheter Lock Solution
223770618|NCT03127124|DRUG|Eloxatin Injectable Product|cis-\[(1 R,2 R)-1,2-cyclohexanediamine-N,N'\] \[oxalato(2-)- O,O'\] platinum.
223770619|NCT06566274|DEVICE|thumbtack needle|As a kind of intradermal needle, thumbtack needle (TTN) is a method of shallow puncture and long-term needle.After the TTN is attached into the acupoints, it will be reserved in the acupoints for 3 days. After 3 days of retention of TTN, the patient is instructed to go to the hospital, where the doctor removes the needle, disinfect the local skin of acupoints and conducts the next TTN treatment. A total of 5 treatments were applied for a duration of 15 days.
224245979|NCT03576040|DEVICE|Whole Body Dynamic 68Ga-DOTATOC PET/CT|"68Ga-DOTATOC PET-CT will be performed in the nuclear medicine department of the University Hospital of Brest on a Biograph mCT S64 machine (Siemens medical, Erlangen, Germany) Time of Flight system after intravenous injection of 150MBq of 68Ga-DOTATOC. In the usual conditions for performing this exam, the patient must remain at a strict rest for 60 minutes following the injection of the tracer and before a static 3D acquisition. For this protocol, a complementary 4D dynamic acquisition (15-60 minutes post-injection) will be performed during this usual rest period."
224245980|NCT03897998|DRUG|Naloxone|"4mg of Naloxone will be administered (0.1 mL of 40 mg/ml naloxone solution given intranasally).~A random allocation sequence will be independently generated by the UM Pharmacy. The Principal investigator will call for each experiment."
224245981|NCT03897998|OTHER|Saline|"Intranasal Normal Saline (0.1 mL 0.9% sodium chloride) will be administered shortly before beginning the fMRI experiment.~A random allocation sequence will be independently generated by the UM Pharmacy. The Principal investigator will call for each experiment."
224245982|NCT05084781|PROCEDURE|Coblation Debridement (FLOW90)|bipolar radiofrequency energy
223770620|NCT06566274|DEVICE|sham thumbtack needle|"The sham TTN used in the sham TTN group has no needle body and its appearance and shape are similar to the real TTN. But it does not produce a needle-like effect.~The acupoints of sham TN group are the same as those of TN group. The use of sham TN is the same as that of the TN group. After 3 days retention of sham TN, the patient will be instructed to go to the hospital, where the doctor remove the sham TN, and conduct the next treatment after local skin disinfection. A total of 5 treatments will be applied for a duration of 15 days."
224245983|NCT02602041|OTHER|Literature search and semi-structured interview|We will do a literature search and perform semi-structured interviews with cancer patients and their partners in order to explore knowledge, attitudes, barriers and facilitators regarding health behavior change following cancer treatment.
224245984|NCT04149964|DRUG|Acetaminophen 325 mg Oral Tablet|Standard of Care Acetaminophen 325 mg every 6 hours as needed for pain
224245985|NCT04149964|DRUG|Acetaminophen 650 mg Oral Tablet|Acetaminophen 650 mg scheduled every 6 hours round the clock for pain
224245986|NCT04149964|DRUG|OxyCODONE 5 mg Oral Tablet|Oxycodone 5 mg every 4 hours as needed for breakthrough pain
224245987|NCT04149964|DRUG|Acetaminophen/Hydrocodone 325 mg/7.5 mg oral tablet|Acetaminophen 325 mg/ Hydrocodone 7.5 mg oral tablet every 4 hours as needed for breakthrough pain
224245988|NCT04349605|BEHAVIORAL|Meditation|Meditation involves guided breathing and mindfulness training.
224245989|NCT04349605|BEHAVIORAL|Kundalini Yoga|Kundalini Yoga involves stretching, guided breathing and meditation
224245990|NCT03948347|DRUG|Liraglutide|The treatment arm will receive the starting dose of liraglutide of 0.6 mg/d subcutaneously once daily, and the dose will be increased to 1.8 mg/d in two weeks, and then continue to administrate this dose for 90 days.
224245991|NCT00500487|BEHAVIORAL|Affect Management|12-session group intervention including affect management training as well as sexual health skills training.
224245992|NCT00500487|BEHAVIORAL|HIV Prevention Skills|12-session group intervention including sexual health skills training.
224245993|NCT00500487|BEHAVIORAL|General Health Promotion|12-session group intervention including health information on a variety of health topics.
224245994|NCT01189669|DIETARY_SUPPLEMENT|LC n-3 PUFA (fish oil) Supplement|4 x 1g LC n-3 PUFA (fish oil)supplement containing 1.9g EPA and DHA given daily for 6 weeks
224245995|NCT01189669|DIETARY_SUPPLEMENT|Placebo (olive oil) supplement|4 x 1g olive oil capsules were given daily for 6 weeks
224245996|NCT05566015|OTHER|questionnaire|self-administered questionnaires as well as clinical assessment of schizophrenia symptoms and depression.
224245997|NCT01223365|DRUG|Hydrocodone ER|Hydrocodone bitartrate extended-release tablets were administered at doses of 15, 30, 45, 60, and 90 mg orally every 12 hours. During the open-label titration period, doses were adjusted until a stable pain control was achieved. In general, the dose of hydrocodone extended release tablets could be adjusted for efficacy or tolerability, as necessary, at any time during the open-label treatment period; however, participants were required to visit the study center before increasing the dose of study drug.
224245998|NCT00839605|DRUG|Dexmedetomidine|loading dose:0.3mcg/kg. Infusion of 0.3mcg/kg/hr
224245999|NCT03012178|PROCEDURE|Mitral valve surgery|ACC/AHA guideline directed mitral valve repair or replacement
224246000|NCT03567174|OTHER|Integrated care van (ICV)|Structural service delivery intervention
224246001|NCT03731598|PROCEDURE|bed rest|Volunteers will be physically inactive on bed rest at the clinical research center
224246002|NCT06751043|OTHER|Fasting|"Process: Fasting pre-procedure~Tube feeding will be stopped at least 8 hours before the patient's scheduled surgery or procedure time."
224246003|NCT06751043|OTHER|Not fasting|"Process: Not fasting pre-procedure~Tube feeding will be continued until patient transfer to the operating room/procedure area."
224246004|NCT06795893|DRUG|Anifrolumab|Anifrolumab is a human monoclonal antibody that binds to subunit 1 of the type 1 interferon receptor,which was developed based on the evidence supporting the role of type 1 interferon pathway in SLE. Clinical trial evidence from TULIP 1 and TULIP 2 have showed that monthly intravenous administration of anifrolumab led to a higher percentage of patients with a response, assessed with the British Isles Lupus Assessment Group-based Composite Lupus Assessment, compared with patients receiving placebo. Moreover, the phase II MUSE study showed that administration of anifrolumab resulted in substantially reduce disease activity, as measured by the SLE Responder Index,compared to patients receiving placebo. Anifrolumab was approved by the FDA and EMA in July 2021 and February 2022,respectively, for the treatment of adult patients with moderate to severe SLE who are receiving standard therapy.
224246005|NCT06263348|DRUG|Dorzagliatin tablets|During the study, patients should follow the dosing instructions from the investigator, which are made according to the package insert and the patients' conditions.
223665688|NCT02756806|DEVICE|Picosecond Q-switched laser|Each subject will receive laser treatments with Enlighten laser
223665689|NCT01806701|BEHAVIORAL|Trauma-focused cognitive behavioral therapy|the 'gold-standard' behavioral treatment for children/adolescents with posttraumatic stress disorder
224246006|NCT04010331|DIETARY_SUPPLEMENT|Nokyong Mixture Extract(CME-PI)|2 times a day, 2 capsule for 1 time, after breakfast/dinner meal, for 8 week
224246007|NCT04010331|DIETARY_SUPPLEMENT|Placebo|Placebo for 8 week
224246008|NCT00567177|DRUG|Restasis, Refresh Plus|Restasis 0.4ml- (in the eye) Instill one drop twice daily in morning and evening Refresh Plus 0.4ml- (in the eye) Instill one drop twice daily in morning and evening
224246009|NCT00803764|DRUG|Naproxen Tablets, 500 mg|
223665690|NCT00637988|DRUG|Esomeprazole|40mg twice daily
223665691|NCT00637988|DRUG|Aspirin|
223665692|NCT00637988|DRUG|Rofecoxib|25mg once daily
223665693|NCT03089385|OTHER|Hypertension tool|An algorithm developed by staff at UHN to help manage hypertension in hemodialysis patients.
223665694|NCT02717832|DRUG|hyperinsulinemic-euglycemic clamp|
223665695|NCT01041534|OTHER|Survey|Two surveys are sent to patients: Adjustable gastric band (AGB) Health Survey and a quality of life survey (EQ5D)
223665696|NCT02537288|DRUG|Fedovapagon|
223665697|NCT02537288|DRUG|Moxifloxacin|
223665698|NCT02537288|DRUG|Placebo (for fedovapagon)|
223665699|NCT04665869|BEHAVIORAL|Combined balance and brisk walking training|6-months of combined balance and brisk walking training
223665700|NCT04665869|BEHAVIORAL|Flexibility and strengthening exercise|6-months of flexibility and strengthening exercise
224246010|NCT02435043|OTHER|Nature based rehabilitation|ten weeks of nature-based rehabilitation, as add-on to standard management. A rehabilitation program in groups up to 8 patients in an especially designed garden at the Swedish University of Agricultural Sciences, Alnarp. The intervention was grounded in environmental psychology and occupational therapy, supported by a multimodal rehabilitation team that utilized the garden/nature for sensory stimulation, body awareness, meaningful occupations and nature experiences.
224246011|NCT02435043|OTHER|standard management after stroke|standard management after stroke is individualised.
224246012|NCT05240495|BEHAVIORAL|Internet-based Cognitive-behavioural therapy|Internet-based Cognitive-behavioural therapy protocol was based on contemporary CBT techniques adapted for adjustment disorders, and recovery from work training inspired by Hahn et al. \[50\]. The iCBT program consisted of ten modules distributed over ten weeks, with modules lasting 60-120 min per week.
224246013|NCT05240495|BEHAVIORAL|Work-focused Cognitive-behavioural therapy|The Work-focused Cognitive-behavioural therapy consisted of the exact generic iCBT-modules included in the first experimental group and of additional work-focused modules adapted for adjustment disorders. The W-iCBT added about 2-3 regular pages compared to the generic iCBT.
224246014|NCT02040376|DRUG|Metformin|Metformin doses will be 500 mg/m2 po daily given in 2 doses for one week and if there are no concerns increased to 1000 mg/m2 po daily given in 2 doses for the rest of the 12 week trial. The investigators will use the closest dose according to body surface area (250-500-750-1000) BID.
224246015|NCT02040376|DRUG|Placebo|Placebo doses will be 500 mg/m2 po daily given in 2 doses for one week and if there are no concerns increased to 1000 mg/m2 po daily given in 2 doses for the rest of the 12 week trial. The investigators will use the closest dose according to body surface area (250-500-750-1000) BID.
223665701|NCT00753740|DRUG|IT-101 (12mg/m2/dose)|Patients who satisfy the inclusion/exclusion criteria will receive a blinded infusion of IT-101 (12mg/m2/dose) every other week until disease progression.
223665702|NCT00753740|DRUG|IT-101 (15mg/m2/dose)|Patients who satisfy the inclusion/exclusion criteria will receive an infusion of IT-101 (15mg/m2) every other week until disease progression.
223665703|NCT00753740|DRUG|5% Dextrose (Placebo)|Patients who satisfy the inclusion/exclusion criteria will receive an infusion of placebo every other week until disease progression.
223665704|NCT01613170|DRUG|Toviaz|Toviaz 4mg daily
223665705|NCT01613170|DRUG|Premarin|Premarin cream 1 g per vagina twice weekly
223665706|NCT01613170|DRUG|Placebo cream|Placebo cream 1 g per vagina twice weekly, to mimic Premarin cream
223665707|NCT03822559|DRUG|A preservative-free, a clear, colorless sterile aqueous ophthalmic solution containing 0.015mg of tafluprost and 5.0mg of timolol in 1mL|One drop a time, once daily administration of DE-111A eye drops in the affected eye(s) at 8:00 am (±1h) for 3 months.
223665708|NCT03822559|DRUG|A preservative-free, a clear, colorless sterile aqueous ophthalmic solution containing 0.015mg of tafluprost in 1mL|One drop a time, once daily administration of preservative-free 0.0015% tafluprost eye drops in the affected eye(s) at 8:00 (±1h) for 3 months.
223665709|NCT00183417|BEHAVIORAL|Cognitive behavior therapy (CBT)|Participants will complete worksheets and group discussion on how to increase positive mood and activity.
223665710|NCT00183417|BEHAVIORAL|Supportive/expressive (S/E) therapy|Participants will be encouraged to express feelings and emotions without advice giving.
223665711|NCT00183417|BEHAVIORAL|Bibliotherapy|Participants will be given a book on how to increase their mood.
223665712|NCT05266729|DRUG|Polyene Phosphatidylcholine|Formulated as an injectable solution containing Polyene Phosphatidylcholine at two concentration of 25 mg/mL and 50 mg/mL.
223665713|NCT05266729|DRUG|Placebo|Phosphate buffered saline placebo for injection
223665714|NCT01008423|DRUG|Budesonide|Budesonide will be administered as per the dose and schedule specified in the respective arm.
223665715|NCT01008423|DRUG|Placebo|Placebo matching to budesonide will be administered as per the dose and schedule specified in the respective arm.
223665716|NCT03820739|OTHER|Follow-up|No investigational vaccine will be administered during this study
223770621|NCT00103792|DRUG|mycophenolate mofetil|2000 mg mycophenolate mofetil per day combined with steroids for induction remission, followed by azathioprine standard maintenance therapy
223770622|NCT00103792|DRUG|cyclophosphamide|2 mg/kg/d, combined with steroids, for remission induction, followed by standard azathioprine maintenance therapy
223770623|NCT06387784|DIETARY_SUPPLEMENT|Beetroot juice|In the morning, pregnant women with pre-eclampsia will consume a single dose of 70 ml of nitrate-rich beetroot juice containing 400 mg of nitrate. Participants will be monitored to assess the acute effects of nitrate intake for 6 hours.
224246016|NCT04472078|DIAGNOSTIC_TEST|Serological Assay or IgG for SARS-CoV-2|Serological Assay for detection of IgG for SARS-CoV-2
224246017|NCT00139178|DRUG|Different HAART regimens|
224246018|NCT04587778|DRUG|Ketamine Hydrochloride|intravenous infusion
224246019|NCT04587778|DRUG|Esketamine|intravenous infusion
224246020|NCT04587778|DRUG|Placebo|intravenous infusion
224246021|NCT04587778|DRUG|Pilot study II: Esketamine|intravenous infusion
224246022|NCT04587778|DRUG|Pilot study II: Placebo|intravenous infusion
223665717|NCT03820739|OTHER|Blood sample collection|Blood sampling to assess vaccine-induced immune responses will be conducted only in cohort 1 in a subsample consisting of approximately 102 adults and 165 children (55 from each of the three paediatric age groups that were enrolled in EBOVAC-Salone: 12-17 year olds, 4-11 year olds, and 1-3 year olds).
223665718|NCT05901844|DIAGNOSTIC_TEST|Paraffin pathological diagnosis|Perform two diagnostic methods on the same sample
223665719|NCT04103788|DIETARY_SUPPLEMENT|95% Curcuminoid Powder|1200 mg curcuminoids
223665720|NCT04103788|DIETARY_SUPPLEMENT|CurQ+|400 mg curcuminoids + coconut oil + polysorbate
223665721|NCT01522937|RADIATION|individualized Stereotactic Body Radiation Therapy (SBRT)|The individualized SBRT involves two treatment phases. The first phase of treatment involves receiving three fractions of SBRT, followed by a 1-month break and assessment of liver function with a blood test - Indocyanine Green (IC-Green). The second phase of treatment involves receiving two more fractions of SBRT, whose doses are adjusted to account for tolerance of the first phase of treatment.
224246023|NCT05172219|BEHAVIORAL|Physician Sent Outreach with Embedded Asynchronous Care in Portal Message|PCPs sent a portal message encouraging a quit attempt embedded a link to asynchronous care within a portal message encouraging a quit attempt in order to compare EMR-documented, physician-assisted quit attempts to those who received messages without the link 30 days after messages were sent.
224246024|NCT05172219|BEHAVIORAL|Physician Sent Outreach without Embedded Asynchronous Care in Portal Message|Physician sent a portal message encouraging a quit attempt without a link to asynchronous care within a portal message encouraging a quit attempt in order to compare EMR-documented, physician-assisted quit attempts to those who received messages without the link 30 days after messages were sent.
224246025|NCT05172219|BEHAVIORAL|System Sent Outreach with Embedded Asynchronous Care in Portal Message|Health System sent a portal message encouraging a quit attempt embedded a link to asynchronous care within a portal message encouraging a quit attempt in order to compare EMR-documented, physician-assisted quit attempts to those who received messages without the link 30 days after messages were sent.
224246026|NCT05172219|BEHAVIORAL|System Sent Outreach without Embedded Asynchronous Care in Portal Message|Health System sent a portal message encouraging a quit attempt without a link to asynchronous care within a portal message encouraging a quit attempt in order to compare EMR-documented, physician-assisted quit attempts to those who received messages without the link 30 days after messages were sent. Half of the messages came from the patient's PCP and the other half came from the health system to determine if communication from a patient's physician was associated with more quit attempts.
224246027|NCT01722474|DEVICE|ASI Device|
224246028|NCT03991026|BEHAVIORAL|Healthy food and Education/Cooking Classes|The intervention includes providing weekly seasonal produce and healthy foods to participants in addition to an education/cooking class that will be tailored to Diabetes Mellitus, Type II.
223665722|NCT02917564|DRUG|Triamcinolone Acetonide 1 ml of 40 mg/mL suspension|After preparation, Triamcinolone Acetonide 1 ml of 40 mg/mL suspension is injected through the superotemporal conjunctival fornix using a 25 Gauge needle, 5/8 inch length on a 3 ml syringe, following the contour of the globe with the needle, external to sclera for the full length of the needle such that the needle tip is ultimately positioned immediately posterior to the macula with the bevel down.
223665723|NCT02917564|OTHER|Sham - Participants will not recieve the Triamcinolone Acetonide|Patients will be given a sham.
223665724|NCT05847985|DEVICE|transcranial direct current stimulation (tDCS)|tDCS using electric currents to modulate underlying neurons
223665725|NCT04052256|DIAGNOSTIC_TEST|Coronary computed tomography angiography|Computational fluid dynamic model information derived from CT
223665726|NCT01798160|PROCEDURE|DEB TACE|DEB TACE every 6 weeks until either no viable tumor or endpoint reached.
223770624|NCT06387784|DIETARY_SUPPLEMENT|Placebo juice|In the morning, pregnant women with pre-eclampsia will consume 70 ml of a placebo juice. The placebo juice will be similar in appearance and taste to the nitrate-rich beetroot juice. Participants will be monitored to compare the acute effects of beetroot juice with the placebo intake for 6 hours.
224246029|NCT01316549|DRUG|Fludarabine|Given as injection
224246030|NCT05380024|DRUG|Ensartinib|Ensartinib 225mg QD 8 weeks
224246031|NCT00085150|BIOLOGICAL|LMB-2 immunotoxin|
224246032|NCT02817841|DRUG|15 mg E4/3 mg DRSP|15 mg estetrol and 3 mg drospirenone tablets administered once daily for 13 consecutive cycles following a 24/4-day regimen, i.e. one 15 mg E4/3 mg DRSP active tablet per day for 24 consecutive days followed by one placebo tablet per day for 4 consecutive days.
224246033|NCT02173418|DRUG|Phrenic nerve block with Ropivacaine|
224246034|NCT02173418|DRUG|Phrenic nerve block with saline|
224246035|NCT03762564|DRUG|Ramucirumab|Ramucirumab 8 mg/kg i.v. infusion on day 1 and 15
224246036|NCT03762564|DRUG|Paclitaxel|Paclitaxel 80 mg/m2 on day 1, 8, 15
224246037|NCT00161564|DRUG|Rituximab|
224246038|NCT04385771|DEVICE|vv-ECMO + cytokine adsorption (Cytosorb adsorber)|in COVID-19-diseased vv-ECMO patients additional treatment with cytokine adsorption using a Cytosorb adsorber will be randomized (vs. control group)
223665727|NCT01798160|PROCEDURE|SIRT|Selective Internal Radiation Therapy once at the beginning of the study. Follow up until endpoint.
223665728|NCT05664568|DRUG|Cephalexin|Participants in intervention group will receive a combination of cephalexin and amoxicillin-clavulanate for the first 2 weeks of TB treatment
223665729|NCT05664568|DRUG|Amoxicillin-Clavulanate 500 Mg-125 Mg Oral Tablet|Participants in the intervention group will receive a combination of cephalexin and amoxicillin-clavulanate for the first 2 weeks of TB treatment
223665730|NCT05664568|OTHER|Standard of care treatment of tuberculosis|The control group will be given standard of care treatment of tuberculosis consisting of rifampicin, isoniazid, pyrazinamide and ethambutol
223665731|NCT02935283|PROCEDURE|MRI|MRI, fMRI, 1H MRS, DTI
223665732|NCT02935283|BEHAVIORAL|Behavioral|Battery of executive function tasks
223665733|NCT00934843|DRUG|methylprednisolone (IVMP)|Neonates with congenital heart disease requiring surgery utilizing a cardiopulmonary bypass (CPB)machine in the first month of life that receive ONE doses intravenous methylprednisolone (IVMP) prior to heart surgery.Compare the effects and preoperative and intraoperative IVMP (2 dose steroid)to intraoperative IVMP alone (single dose steroid) on the inflammatory response to CPB cardiopulmonary bypass.
223665734|NCT00934843|DRUG|methylprednisolone (two doses IVMP)|Neonates with congenital heart disease requiring surgery utilizing a cardiopulmonary bypass (CPB)machine in the first month of life that receive TWO doses intravenous methylprednisolone (IVMP) prior to heart surgery.Compare the effects and preoperative and intraoperative IVMP to intraoperative IVMP alone on the inflammatory response to CPB cardiopulmonary bypass. The hypothesis is that neonates treated with preoperative IVMP as well as the standard intraoperative IVMP will have decreased production of pro-inflammatory cytokines.
223665735|NCT00003745|DRUG|topotecan hydrochloride|
223770625|NCT05298605|BEHAVIORAL|Faith in Action! Church-based Navigation Model|Cancer screening education and navigation by identified trained navigators in faith based settings + American Cancer Society Screening Guidelines pamphlet
223770626|NCT05298605|OTHER|Control|Presentation on healthy behaviors (physical activity, nutrition) + American Cancer Society Screening Guidelines pamphlet
223770627|NCT02409615|OTHER|Hypnosis Therapy|A technique called Wakeful Hypnosis that involves suggestions for healing given to a person while in a normal state of consciousness
223770628|NCT02409615|OTHER|Healing Touch Therapy|Healing Touch An energery based therapy that uses light body or above body touch to help balance the energy field and energy centers of the body to restore harmony within the body for greater healing.
223770629|NCT06413225|DEVICE|Synergy cervical disc system|motion preservation disc
224246039|NCT04385771|DEVICE|vv-ECMO only (no cytokine adsorption)|COVID-19-diseased treated with vv-ECMO
224246040|NCT02985593|DRUG|KHK4083|
224246041|NCT02985593|DRUG|Placebo|
224246042|NCT06043843|COMBINATION_PRODUCT|Focused diabetes tele-education and medication adjustment based on guidelines with remote monitoring from trial of fasting from before to throughout Ram|"1. Ramadan-focused online education by physician, specialist nurse, and dietitian via video conferencing~   1. Fasting and exemptions~  2. Self-monitoring of blood glucose~  3. Acute diabetes complications and treatment~  4. Ramadan nutritional plan~  5. Safe physical activity You will be taught to record~   <!-- -->~   1. Meal plans~  2. Physical activities~  3. Blood glucose monitoring, and~  4. Monitoring for diabetes complications Perform a trial fasting day prior to Ramadan.~2. Medication adjustments will be made according to the Diabetes and Ramadan Alliance guideline as well as individualized modifications based on their HbA1c as follows Baseline HbA1c Recommended dose reduction \< 8% 30% 8 to 10% 15% \> 10% None~2\) Glucose monitoring~1. up to 4 times daily Before Ramadan for 1 week During Ramadan After Ramadan for 1 week~2. uploaded into an online portal for data collection, without remote monitoring."
224246043|NCT02785003|DRUG|Placebo|Individuals enrolled into the control arm of the trial will receive a normal saline placebo infusion at a rate equivalent to the dosage of ketamine in the experimental arm.
224246044|NCT02785003|DRUG|Ketamine|All individuals randomized to the experimental arm of the trial will receive ketamine therapy at a rate of 2 mcg/kg/hr dosed based on ideal body weight.
223770630|NCT06559397|OTHER|Assessment of cervical proprioception|Cervical proprioception will be assessed using the 'head position error test' in both right and left rotation directions with the CROM device. Participants will be then divided into two groups based on the presence of proprioceptive errors (\>5°).
223770631|NCT04456699|DRUG|Olaparib|300 mg BID, oral until progressive disease or end of study
223770632|NCT04456699|DRUG|5-FU|2400 mg/m\^2 over 46 to 48 hours Q2W IV infusion until disease progression or end of study; bolus 5-FU (400mg/m2) can be added prior to infusional 5-FU, per local standards and at the investigator's discretion
223770633|NCT04456699|DRUG|Bevacizumab|5 mg/kg or 7.5 mg/kg Q2W or Q3W IV infusion until progressive disease or end of study
224246045|NCT02785003|DRUG|Acetaminophen|All patients admitted to the hospital will be placed on scheduled acetaminophen 1000mg PO q 6 hours unless signs of liver disease/impairment or creatinine clearance \< 35ml/min at which point dosage would be reduced to 650mg q 8 hours. Individuals unable to take oral medications would be placed on intravenous acetaminophen.
224246046|NCT02785003|DRUG|Opioid|"All individuals will receive as needed opiate therapy as an adjunct to the scheduled medications and ketamine/placebo solution. Choice in opiate therapy will be at the discretion of the attending faculty. Dosage and adjustments will be in accordance with the institutional policy on appropriate opiate dosage adjustment."
224246047|NCT02785003|DRUG|Alvimopan|All patients enrolled into the trial will be screened for eligibility for alvimopan utilization. Only in circumstances where patients are not on outpatient opioid medications and where they have not received any at time of arrival will alvimopan be administered. It will be given at least 30 minutes prior to surgery.
223665736|NCT01831583|DEVICE|Measurement of PPG waveforms|The ViSi Vital Signs Monitor will measure PPG waveforms for 4 hours.
223665737|NCT01831583|DEVICE|Measurement of Pulse Arrival Time (PAT)|The ViSi Vital Signs Monitor will measure PAT waveforms for 4 hours.
223665738|NCT01144299|BIOLOGICAL|Fluarix™/Influsplit SSW®|Single intramuscular dose on Day 0
223665739|NCT01024725|OTHER|Follow-up|Nasopharyngeal/oropharyngeal and blood samples, interviews, questionnaires, register data
223665740|NCT00183729|DRUG|Memantine|Memantine dosage is started at 10 mg daily and is increased at Week 1 as tolerated to 10 mg two times a day.
223665741|NCT00183729|OTHER|Placebo|Placebo distribution is planned to mimic the active drug.
224246048|NCT00934934|OTHER|Normal Saline|Normal Saline
224246049|NCT00934934|DRUG|anidulafungin|TBA
224246050|NCT00881088|DRUG|Nadroparin|nadroparin 0,3 cc once daily during immobilization period
224246051|NCT00881088|DRUG|Fondaparinux|Fondaparinux 2,5 mg daily during immobilization period
224246052|NCT05391685|OTHER|Scar release techniques + therapeutic ultrasound|Control group will be treated by therapeutic ultrasound only for2 sessions per week for two weeks Study group) will be treated by various scar release techniques in addition to therapeutic ultrasound, 2 sessions per week for two weeks.
224246053|NCT04003350|DRUG|Oxycodone|Patients are given, for up to 4 weeks, Oxycodone 5m PRN every four hours (up to 30 tablets)
224246054|NCT04003350|DRUG|Tramadol|Patients are given, for up to 4 weeks, Tramadol 50mg PRN every 6 hours (up to 30 tablets)
223665742|NCT00001272|DRUG|taxol|
223665743|NCT01615276|DEVICE|Enraf Nonius Tensmed S84 for Neuromuscular electrical stimulation (NMES)|One our of one-legged neuromuscular electrical stimulation (NMES)
223770634|NCT04456699|DRUG|Capecitabine|1000 mg/m\^2 oral capsule BID for 14 days, then 7 days off, Q3W) until progressive disease or end of study
223770635|NCT04456699|DRUG|Leucovorin/ levoleucovorin|400 mg/m\^2 (leucovorin) or 200 mg/m\^2 (levoleucovorin) may be added to Bevacizumab + 5-FU per investigator's discretion Q2W IV infusion until progressive disease or end of study
224246055|NCT04003350|DRUG|Tylenol|Tylenol 1000 mg: take as needed every 8 hours
224246056|NCT04003350|DRUG|Meloxicam|Meloxicam 15 mg as need once per day
224246057|NCT04003350|DRUG|Gabapentin|•Gabapentin 200 mg with morning and evening Tylenol dose
224246058|NCT04003350|DRUG|Metaxalone|Metaxalone 800mg TID
224246059|NCT04003350|DRUG|Esomeprazole 20mg|Esomeprazole 20mg daily
224246060|NCT01287910|OTHER|Cardiac MRI|Cardiac MRI within 30 days prior to TMR procedure and 6 months after TMR procedure.
223665744|NCT01615276|DEVICE|No Enraf Nonius Tensmed S84 for Neuromuscular electrical stimulation (NMES) NMES|No neuromuscular electrical stimulation (NMES) will be applied in the control leg
223665745|NCT00003076|DRUG|eflornithine|
223665746|NCT01624246|DRUG|Ceftaroline fosamil/Avibactam (CXL)|IV infusion of CXL (combination of ceftaroline fosamil \[600 mg\] plus avibactam \[600 mg\]) infused over 60 (± 5) minutes.
223665747|NCT05216354|DRUG|Fruquintinib|Fruquintinib will be administered as a single dose on the morning of Day 1 under fasting conditions
223665748|NCT02207426|DRUG|Tobramycin|
223665749|NCT01774409|GENETIC|Blood and tumor samples|"Genetic: Establishment of the genetic and immunologic profile~Whole blood sampling :~* 1 tube for the constitutional DNA extraction;~* 3 tubes for ancillary studies and research.~Collection of the available archival tumor sample (frozen or FFPE). If there's no available sample, the investigator will prescribe a biopsy of a reachable lesion.~With the established profile, recommendations will be given by a multidisciplinary molecular board."
223665750|NCT03698591|DEVICE|Transcranial magnetic stimulation task|Experimenters will employ a continuous theta-burst stimulation (cTBS) sequence using a figure-8 coil positioned tangentially to the scalp over the target coordinates. Experimenters have defined the target coordinates for stimulation (Montreal Neuroscience Institute coordinates -53, -53, 23) based on peak objective distancing activation in the left temporal parietal junction (TPJ) in previous fMRI studies using the same task.
224246061|NCT06118970|OTHER|Neuropsychological tasks and self-report questionnaires|Being a cross-sectional observational study, no intervention will be administered. Subjects will be assessed with neuropsychological tasks and self-report questionnaires.
224246062|NCT00062790|DRUG|Dutasteride|
224246063|NCT01546766|DEVICE|Pupillometry testing.|
224246064|NCT01113424|DRUG|Nicotine|Single-dose of a new Nicotine Replacement Therapy (NRT) product 2 mg and 4 mg
224246065|NCT01113424|DRUG|Nicorette® (Nicotine Gum)|Single-dose of marketed nicotine gum 2 mg or 4 mg
224246066|NCT04572659|OTHER|Group psychosocial intervention|Several couples attended a total of six group psychotherapy sessions conducted by a psychologist. Between 4 and 7 couples were treated in each group session.
224246067|NCT04572659|OTHER|Couple psychosocial intervention|The couple attended a total of six psychotherapy sessions conducted by a psychologist. Each couple was attended particularly.
223665751|NCT03698591|DEVICE|Sham transcranial magnetic stimulation task|A sham version of the TMS intervention where subjects will receive a small electrical stimulation on the scalp via two small electrodes in conjunction with a TMS coil activation. The TMS coil will be reoriented to stimulate into the air away from the scalp, simulating traditional TMS, without inducing any current to the subject.
223665752|NCT05373914|DRUG|Cudetaxestat (BLD-0409)|Cudetaxestat - 250mg tablets (orally)
223665753|NCT05373914|DRUG|Control: Matching Placebo|Placebo - 250mg tablets (orally)
223665754|NCT02894268|DRUG|Doxycycline|Doxycycline 100g po bid
224246068|NCT03196570|BEHAVIORAL|Physical Activity Intervention|After randomization into the intervention arm, participants will be instructed on how to use the Spanish language study website. During the six month intervention, they will complete online questionnaires to determine their stage of change towards increasing physical activity. A manual of information will be automatically generated based on their responses. Participants can read this information online, along with tip sheets related to increasing physical activity. On the website they can also set weekly goals and log their weekly PA. It will also include short videos with demonstrations for PA they can do at home and around their neighborhood. Information will also include community resources (community centers, public events, parks) where they can be physically active. Participants will also receive prompts and encouragement via text-message to encourage them to log into the website and continue to track their progress.
224246069|NCT03196570|BEHAVIORAL|Wellness Contact Control|Participants in the control arm will attend the same baseline orientation sessions and measurements as the intervention arm. After randomization into the control group, participants will complete an introductory in-person session to introduce them to a website, similar in design, with information on health topics other than physical activity, including diet and other factors associated with CVD risk. It will include information from NHLBI heart health materials for Latinos. Topics include healthy eating, increasing fruit and vegetable consumption, reducing fat and salt intake, learning about cholesterol, stress management. Participants will log onto a separate website unique to the control group and complete monthly surveys on the wellness topics and their progress. Participants will also receive prompts and encouragement text-messages to encourage them to log onto the website.
224246070|NCT03941925|DIETARY_SUPPLEMENT|Prebiotic fructans|Prebiotic group receiving the prebiotic fructans in two doses during the 4-week intervention period.
224246071|NCT03941925|DIETARY_SUPPLEMENT|Non-prebiotic maltodextrin|Placebo group receiving the non-prebiotic maltodextrin in two doses during the 4-week intervention period.
224246072|NCT01393366|OTHER|Telephone Intervention|Only for arm AMA, patient will have one phone every week to evaluate physical conditions.
224246073|NCT01393366|OTHER|Usual Practice|None, only usual practice.
224246074|NCT03280394|DIAGNOSTIC_TEST|Liquid Biopsy|Assessing whether plasma cell free DNA improves the accuracy of early prediction of cure in mature B-cell tumor patients and whether it represents an accessible source of tumor DNA for the sensitive identification of genetic biomarkers that, at disease presentation, refine the diagnostic workup in mature B-cell tumor patients and, upon treatment, early identify the emergence of resistance mutations.
224246075|NCT03175718|OTHER|Incisional Negative Pressure Wound Therapy (INPWT)|A total of 291 patients will be randomized to receive 7 days of Incisional Negative pressure wound dressing. The dressing will be removed 1 week after surgery.
223665755|NCT02894268|DRUG|Furazolidone|Furazolidone 100mg po bid
223665756|NCT02894268|DRUG|Esomeprazole|Esomeprazole 20mg po bid
223665757|NCT02894268|DRUG|Colloidal Bismuth Subcitrate|Bismuth 20mg po bid
223665758|NCT02894268|DRUG|Sensitivity antibiotics|Two antibiotics based on antibiotic sensitivity of H.pylori culture, including amoxicillin, clarithromycin, metronidazole, levofloxacin, tetracycline and furazolidone.
223665759|NCT06423274|DIAGNOSTIC_TEST|fundus photography|using artificial intelligence to identify diabetic retinopathy using fundus photography
224246076|NCT03175718|OTHER|Wound Dressing|A total of 291 patients will be randomized for standard gauze dressing. This dressing requires no pressure and is applied according to the current standard dressing procedures of the institution. The dressing will be changed every 2-3 days.
224246077|NCT02157636|DRUG|CPI-0610|
224246078|NCT01746017|DRUG|Placebo|Administered orally as capsules
224246079|NCT01746017|DRUG|LY2922470|Administered orally as capsules
224246080|NCT02372149|DRUG|10% intravenous immunoglobulin (IVIg)|
224246081|NCT02372149|DRUG|0.9% sodium chloride|
224246082|NCT00928525|DRUG|Imatinib Mesylate|800 mg p.o./day (400 mg b.i.d.) for a maximum of 24 months
224246083|NCT00397488|DRUG|sunitinib malate|
224246084|NCT01822483|DRUG|Mycophenolate sodium|The conversion will be performed abruptly for all patients. Mycophenolate mofetil will be discontinued one day before the day of conversion (Day 1). Mycophenolate sodium will be introduced on day 1 with equivalent doses.
224246085|NCT01822483|DRUG|Mycophenolate mofetil|Mycophenolate mofetil dose will be maintained or adjusted to keep 30 to 60 mg\*h ml-1.
224246086|NCT01049607|PROCEDURE|Clamp-Crush technique|The transectional line is marked and the liver capsule is cauterized. The liver parenchyma is then crushed stepwise using a regular Pèan clamp. Vessels and bile ducts are ligated or clipped. Vessels of less than 2mm diameter are coagulated with the irrigated bipolar forceps.
224246087|NCT01049607|PROCEDURE|Stapler hepatectomy|The transectional line is marked and the liver capsule is cauterized. For subsequent transection of the hepatic parenchyma, the liver tissue is fractured with a vascular clamp in a stepwise fashion and subsequently divided with endo GIA vascular staplers.
224246088|NCT04171570|PROCEDURE|Coronary angiography and or Percutaneous coronary Intervention|Radial access punture site
224246089|NCT03557632|BEHAVIORAL|Virtual Reality Cue Exposure Therapy|As above.
224246090|NCT03557632|BEHAVIORAL|Relapse Prevention Drug Education|As above.
224246091|NCT04074915|OTHER|Placebo mouth rinse|Normal saline
224246092|NCT04074915|DRUG|Chlorhexidine mouth rinse|Chlorhexidine gluconate
224246093|NCT04074915|DRUG|Test group|Chamomile mouth rinse
224246094|NCT02424097|DRUG|CPP-ACP 5% sodium fluoride varnish & 900ppm fluoride paste|"MI Paste \& MI Varnish- in-office:~varnish application once every 3 months; at baseline, at the end of month 3, 6, and 9 (4 applications)~\- at-home: brushing with regular 1,100ppm F-toothpaste, 2x per day and MI Paste Plus, home application after brushing in the evening; 3-5 minutes with in-home application tray"
224246095|NCT02424097|DRUG|1,100pm F-toothpaste and 0.5%NaF rinse|"Standard of care at-home:~Crest tooth brushing 2x per day - (recommendation OTC Fluoride-rinse in the evening at home 1x per day)"
224246096|NCT05278325|OTHER|Telephone intervention|Two planned phone call between clinical controls
224246097|NCT04132622|DRUG|Levothyroxine Sodium|Levothyroxine Sodium Tablets (50 ug, calculated by Levothyroxine Sodium ), produced by Merck KGaA, Darmstadt.
224246098|NCT04132622|DRUG|Traditional therapy|including steroids, vitamin C, hemodialysis and blood perfusion.
224246099|NCT03067753|DRUG|Monosialoganglioside Ganglioside|Monosialoganglioside ganglioside was given at 100 mg/time, once a day for 2 months.
224246100|NCT03067753|DRUG|Methylprednisolone (Steroid Hormone)|Pulse steroid, methylprednisolone, was administered by intravenous infusion over 3 consecutive days. Three grams of methylprednisolone was given in each cycle. Administration of 1 g was infused over 1 h daily for 3 days on an in-patient basis, which then tailed off in 10 days with administration of oral prednisolone.
224246101|NCT03067753|DRUG|Prednisolone|
224246102|NCT04282954|DRUG|JP-1366|JP-1366, QD
224246103|NCT04282954|DRUG|JP-1366 placebo|JP-1366 placebo, QD
224246104|NCT04282954|DRUG|Esomeprazole 40mg|Esomeprazole 40mg, QD
223665760|NCT06423274|DIAGNOSTIC_TEST|optical coherence tomography|detect diabetic retinopathy and diabetic macular edema by optical coherence tomography
223665761|NCT06423274|DIAGNOSTIC_TEST|fundus fluorescence angiography|detect diabetic retinopathy by fundus fluorescence angiography
224246105|NCT04282954|DRUG|Esomeprazole placebo|Esomeprazole placebo, QD
224246106|NCT04127656|OTHER|Amino Acid-Based Experimental Study Formula|Amino Acid-Based Formula; fed ad libitum
224246107|NCT05236634|DRUG|Phosphodiesterase 5 Inhibitors|A total of (120) patients with LUTS due to BPH fulfilling the inclusion criteria will be included in this study. Patients will be randomly divided into three groups: Group A: Forty patients with LUTS due to BPH will be given tamsulosin 0.4 mg for 12 weeks. Group B: Forty patients with LUTS due to BPH will be given tadalafil 5 mg for 12 weeks. Group C: Forty patients with LUTS due to BPH will be given combined therapy for 12 weeks.
224246108|NCT05236634|DRUG|Alpha Blockers|A total of (120) patients with LUTS due to BPH fulfilling the inclusion criteria will be included in this study. Patients will be randomly divided into three groups: Group A: Forty patients with LUTS due to BPH will be given tamsulosin 0.4 mg for 12 weeks. Group B: Forty patients with LUTS due to BPH will be given tadalafil 5 mg for 12 weeks. Group C: Forty patients with LUTS due to BPH will be given combined therapy for 12 weeks.
224246109|NCT05236634|DRUG|Combined Alpha Blockers and Phosphodiesterase 5 Inhibitors|A total of (120) patients with LUTS due to BPH fulfilling the inclusion criteria will be included in this study. Patients will be randomly divided into three groups: Group A: Forty patients with LUTS due to BPH will be given tamsulosin 0.4 mg for 12 weeks. Group B: Forty patients with LUTS due to BPH will be given tadalafil 5 mg for 12 weeks. Group C: Forty patients with LUTS due to BPH will be given combined therapy for 12 weeks.
224246110|NCT03018717|OTHER|Telemonitoring Constant|telemedicine of Constant
224246111|NCT03018717|OTHER|Standard clinical care|The patient will self-monitor heart rate, blood pressure, weight, diuresis, and capillary glycemia (in the case of diabetes)
224246112|NCT00817661|DIETARY_SUPPLEMENT|Vitamin A|10000 IU Vitamin A or placebo per week
224246113|NCT00817661|DIETARY_SUPPLEMENT|Placebo|10000 IU Vitamin A or placebo per week
224246114|NCT03808805|DRUG|Aprepitant 80 mg|oral therapy - daily dose - 14 days
224246115|NCT03808805|DRUG|Hydroxyzine 25mg|oral therapy - daily dose - 14 days
224246116|NCT03808805|DRUG|Placebo of Hydroxyzine|oral therapy - daily dose - 14 days
224246117|NCT03808805|DRUG|Placebo of Aprepitant|oral therapy - daily dose - 14 days
224246118|NCT03203876|BIOLOGICAL|Lirilumab|Specified dose on specified days
224246119|NCT03203876|BIOLOGICAL|Nivolumab|Specified dose on specified days
224246120|NCT03203876|BIOLOGICAL|Ipilimumab|Specified dose on specified days
223665762|NCT06451198|DRUG|Indobufen|Patients meeting the criteria are randomized before discharge from the hospital and given indobufen 100mg bid and ticagrelor 90mg bid the second day after randomization. The administration shall last 12 months.
223665763|NCT06451198|DRUG|Aspirin|Patients meeting the criteria are randomized before discharge from the hospital and continued aspirin 100 mg qd and ticagrelor 90mg bid. The administration shall last 12 months.
224246121|NCT01134094|PROCEDURE|Open reduction internal fixation of the ankle|The specific procedure for each patient managed operatively, both in the observational study and the RCT, will be determined by the operating surgeon. Any adverse intra-operative or post-operative event will be recorded. This includes but is not limited to death, infection and neurovascular injury. Post operatively, all patients will be NWB (non weight bearing) and placed in a POP (plaster of paris) below knee cast or walking boot. Discharge from hospital will be determined by the patient walking 25m unaided by standby assistance. The treating surgeon will review the patients after 10-14 days for a wound review, removal of sutures and change of cast to a fibreglass cast or walking boot (cam walker). The patient will be WBAT (weight bearing as tolerated) for a further 4 weeks.
224246122|NCT01134094|PROCEDURE|Non Operative|Patients who are treated non-operatively will be treated with a walking boot and allowed WBAT. Discharge from hospital will be determined by the patient walking 25m unaided by standby assistance. All patients will be reviewed between 7 and 14 days post injury with repeat x-rays by the treating surgeon.
224246123|NCT05705180|BIOLOGICAL|recombinant adjuvanted zoster vaccine|vaccination with recombinant adjuvantes zoster vaccine
224246124|NCT04486794|DEVICE|Restylane®|Hyaluronic acid
224246125|NCT06440499|DIAGNOSTIC_TEST|US|Us
224246126|NCT03670485|DEVICE|4 channel Electrical Stimulation Device|electrical stimulation at muscles which related with deglutition
224246127|NCT04092751|DRUG|PRA|Single oral 20-mg dose of PRA on Day 1 AM
224246128|NCT04092751|DRUG|SCY-078 plus PRA|Twice daily (BID), every 12 hours (Q12H) oral doses of SCY-078 750 mg on Day 1 and Day 2; and on Day 3 a single AM dose of oral SCY 078 750 mg followed by a single 20-mg dose of PRA administered one hour later
224246129|NCT02943447|DRUG|Cilofexor|Tablet(s) administered orally once daily, with food
223665764|NCT06451198|DRUG|Ticagrelor|All the patients meeting the criteria and enrolled in the study are given ticagrelor 90mg bid for 12 months.
223665765|NCT05306119|OTHER|Rehabilitation method|Application of techniques of kinesiotherapy, electrotherapy, massage in comorbid patients and patients with low back pain who had undergone myocardial revascularization surgery in main group.
223665766|NCT04708457|OTHER|VV-ECMO|Early use of VV-ECMO in SARI patients.
223665767|NCT04124679|OTHER|Transcutaneous Electrical Acupoint Stimulation|patients received Transcutaneous Electrical Acupoint Stimulation for 30 mins on the acupoints
223665768|NCT01686997|PROCEDURE|Roux-en-Y Gastric Bypass|
223665769|NCT03726229|DEVICE|Cholate assay|Labeled oral and IV cholate will be administered once to the Fontan cohort and blood specimens will be collected at baseline and timepoints thereafter.
223665770|NCT02252341|DIETARY_SUPPLEMENT|N-Acetyl-Cysteine|drug: N-Acetyl-cysteine N-Acetyl-cysteine 1800 mg a day for 12 weeks versus placebo for 12 weeks
223665771|NCT00575146|DIETARY_SUPPLEMENT|TAVARLIN|ketogenic diet, dietary supplementary products provided by TAVARLIN
224246130|NCT02943447|DRUG|Placebo to match cilofexor|Tablet(s) administered orally once daily, with food
224246131|NCT02069158|DRUG|PF-05212384|iv administrartion
224246132|NCT02069158|DRUG|Paclitaxel|iv administration
224246133|NCT02069158|DRUG|Carboplatin|iv administration
224246134|NCT02345941|OTHER|Parent Action Report|Parent Action Report will be displayed after the baseline assessment and contain educational safety messages.
224246135|NCT02345941|OTHER|Parent Portal|Parents will have access to the Parent Portal, and they will be encouraged to visit it at any time.
224246136|NCT00276848|DRUG|Fludarabine plus Cyclophosphamide|fludarabine at a dose of 25 mg/m2, administered intravenously daily over 30 minutes for 5 days, or fludarabine dosed at 30 mg/m2, administered intravenously daily over 30 minutes for 3 days, plus cyclophosphamide dosed at 250 mg/m2, administered intravenously daily over 30 minutes for 3 days, repeated every 28 days for a maximum of 6 courses
224246137|NCT00276848|DRUG|Fludarabine|fludarabine at a dose of 25 mg/m2, administered intravenously daily over 30 minutes for 5 days, or fludarabine dosed at 30 mg/m2, administered intravenously daily over 30 minutes for 3 days, , repeated every 28 days for a maximum of 6 courses
224246138|NCT00006682|DRUG|docetaxel|Docetaxel 70mg/m2 on day 1 of every 21-day cycle
224246139|NCT00006682|DRUG|vinorelbine ditartrate|Navelbine 20mg/m2 on Day 1 and D8 of a 21-day cycle
224246140|NCT02562378|DRUG|Trastuzumab and non-pegylated liposomal doxorubicin|"3 Cohorts (3+3 design):~Cohort 1- Trastuzumab 3.6 mg/kg IV on Day 1 every 3 weeks and non-pegylated liposomal doxorubicin (45 mg/m2) IV~Cohort 2- Trastuzumab 3.6 mg/kg IV on Day 1 every 3 weeks and non-pegylated liposomal doxorubicin (50 mg/m2) IV~Cohort 3- Trastuzumab 3.6 mg/kg IV on Day 1 every 3 weeks and non-pegylated liposomal doxorubicin (60 mg/m2) IV"
224246141|NCT00858793|PROCEDURE|PBSC-M87o, Gene (M87o)-modified, CD34+ peripheral blood progenitor cells (PBSC)|Patient stem cells will be mobilized with induction chemotherapy (R)-ICE and G-CSF. If sufficient cells can be mobilized, patients will be treated with high-dose chemotherapy and a transplant of autologous CD34+ cells transduced with an antiviral vector (M87o). If autologous CD34+ yield is insufficient, allogeneic gene-modified cells will be given, if a compatible donor is available. To minimize risk of transplant failure, a second unmodified CD34+ cell transplant will be given one week after the first transplant.
224246142|NCT06427161|PROCEDURE|LLLT application|The LLLT group received the laser application at 8 points, once a week, over a 2-month period, totaling 8 sessions. Each point was stimulated for 8 seconds in the soft palate, uvula, pharyngeal walls, palatine tonsils, and on the tongue base. LLLT protocol: Diode laser 810nm in continuous contact mode was used, and the radiant energy was 2J (250uw X 8 sec) for each point. Total energy was 16J (2J X 8 points) for each session.
224246143|NCT06427161|PROCEDURE|dextrose injection|25% dextrose was injected in the same 8 points; 1/2 ml for each point, total 4ml for each session. The injection was done weekly, up to 4 sessions.
224246144|NCT02152397|BEHAVIORAL|Therapist-led brief intervention (TBI)|
224246145|NCT04899089|BEHAVIORAL|Cognitive Training|The computerized training exercises and brain games help stimulate cognitive functions while providing real-time monitoring on the evolution of participants' skills.
224246146|NCT04899089|BEHAVIORAL|Trivia Training|The computerized trivia training asks participants to answer general questions related to pop culture, science, geography, etc. Participants can use online sources to search for answers and will be provided feedback on their accuracy.
224246147|NCT05163743|DIETARY_SUPPLEMENT|Low Calorie Ketogenic Diet|The very low-carbohydrate diet will be hypo caloric and aim to provide less than 50 g of carbohydrates per day. the participants will be counseled to choose vegetarian and healthy sources of fat and protein and to avoid trans fat. Then, gradual reintroduction of carbohydrates will take place following the second vaccine dose.
224246148|NCT04927013|BEHAVIORAL|Message-based Outreach Intervention for Survivors|The Georgia Cancer Registry will mail the initial recruitment containing messages intended to persuade the survivor to visit the study website as well as a unique login to access the website. In addition to the components of the standard website, an expanded website for the Message-based group will include Guidance for Talking with Close Relatives about Their Cancer Risk, and the request to enumerate each close relative and choose from a menu of options about how the survivor would prefer for their relatives to be contacted. Survivors also can select the option that they prefer a relative not be contacted. In this case, no invitation letter will be generated for these relatives. Survivors who provide mobile phone numbers will receive two SMS thanking them for accessing the website, and encouraging them to revisit the website to review information and contact relatives. The messages will occur at 3-week intervals over a 6-week time period.
223665772|NCT04137939|DEVICE|smart exercise system|The smart exercise system contains an upper extremity ergometer (UEE) and a lower extremity ergometer (LEE). The revolutions per minute (RPM) of the ergometer are instructed to maintain in 55-65. The resistance of UEE is set from level 1 at the first session, and adjusted by rating of perceived exertion (RPE) of each user after each end of the session. The resistance of LEE is set from level 2 at the first session, and adjusted by rating of perceived exertion (RPE) of each user after each end of the session.
224246149|NCT04927013|BEHAVIORAL|Standard Outreach for Survivors|The Georgia Cancer Registry will mail survivors an introductory letter modeled on the Registry's general outreach letters that will include log in information. Survivors will have access to a condensed version of the website that includes Information about Ovarian Cancer, Information about Who in Your Family is at Increased Risk, and the offer of Free Genetic Counseling with the option to schedule an appointment.
224246150|NCT04927013|BEHAVIORAL|Message-based Outreach Intervention for Close Relatives|Relatives will receive a unique website login linked to the survivor that enables access to the website. The website content will be identical to the survivor content with the exception of the addition of the Breast Cancer Genetics Referral Screening Tool (B-RST) risk assessment tool. This brief risk assessment is a validated screening tools that is clinically useful for estimating the probability of breast cancer (BRCA1/2) gene mutation and identifying women for referral to genetic counseling. Although all 1st or 2nd degree relatives of ovarian cancer survivors will screen positive on B-RST, asking relatives to complete the screener aims to raise their awareness of the factors that contribute to hereditary risk of ovarian cancer and will reinforce the salience of seeking genetic counseling. Additionally, relatives for who provide cell phone numbers will receive 3 SMS reminders over 9 weeks.
224246151|NCT04927013|BEHAVIORAL|Standard Outreach for Close Relatives|The invitation letter shared by the survivor will provide a unique login code for each relative to visit the standard website with sections specifically for relatives that include information about genetic risk, the value of completing an online short validated risk screener, and the offer of free genetic counseling with the option to schedule an appointment.
224246152|NCT05093309|BEHAVIORAL|Educational Webinar|At month 1 of the study period, the educational webinar was presented by expert speakers and consisted of 3 modules: 1) naloxone basics; 2) naloxone service implementation strategies; and 3) naloxone recommendation communication strategies. Participants were mailed naloxone nasal spray and auto-injector training devices prior to attending the online webinar so that they could follow along during demonstrations.
224246153|NCT05093309|BEHAVIORAL|Resources|After completing the baseline survey, both control and intervention groups were provided with a basic publicly available flyer about naloxone dosage forms in order to ensure all participants could provide adequate patient care.
223665773|NCT06248580|DIAGNOSTIC_TEST|Anti Delta|Anti Delta by ELISA
223665774|NCT02110459|DRUG|POL7080|Intravenous infusion
223665775|NCT03400605|OTHER|Infant feeding questionnaire|Prospective infant feeding questionnaire administered over the telephone or in-person at 2 weeks and at 2, 4 and 6 months postpartum
223665776|NCT04529356|DEVICE|Transcranial magnetic stimulation|By using different frequency of TMS, the device can generate different effects. For low frequency, such as 1HZ, it mainly generates inhibition on the brain cortex; while high frequency (usually higher than 10HZ) can generate stimulation effects. The later one could be used to treat different central nervous disease.
223665777|NCT04529356|DRUG|Acetaminophen|Acetaminophen is used as the painkiller to alleviate patients' headache before and during the clinical trial. In order to decrease the medication bias, we required these patients to only use acetaminophen instead of other non-steroid anti-inflammatory drugs. In the meantime, participants are requested to recorder the frequency and dosage of acetaminophen they used during the treatment course.
223665778|NCT05464511|OTHER|Left atrial appendage occlusion with the dual mechanism closure Amulet device using a novel steerable sheath.|Left atrial appendage occlusion with the dual mechanism closure Amulet device using a novel steerable sheath.
223665779|NCT05890755|OTHER|Mechanical pertubation|Acceleration or deacceleration of one treadmill gait belt.
223665780|NCT03631888|DIAGNOSTIC_TEST|preoperative abdominal ultrasound examination|Performing preoperative abdominal ultrasound examination in patients that will be scheduled for elective laparoscopic surgery for any gynecologic indication
223665781|NCT05036421|DRUG|Empagliflozin 10 milligram|antihyperglycemic medication
223665782|NCT00451347|DEVICE|Quadriceps strength training|
223665783|NCT00451347|DEVICE|Taping|
223665784|NCT00451347|DEVICE|Home exercise|
224246154|NCT05093309|BEHAVIORAL|Reminders|Reminders consisted of monthly emails from investigators for the purpose of retaining study engagement.
224246155|NCT02656186|DIETARY_SUPPLEMENT|Pre-intervention|First 2-weeks : keeping routine dietary habit
224246156|NCT02656186|DIETARY_SUPPLEMENT|Liquid nutritional supplement|Pre-intervention period was followed by an intervention period, during which consumed twice-daily 200 mL cartons of oral liquid nutritional supplementation (total 400 mL daily, containing 16 g protein, 12 g fat and 60 g carbohydrate and providing 400 kcal)
223665785|NCT02177149|DEVICE|Standard of Care|Patients in the standard of care arm will have their DBS programmed per standard of care which is testing multiple settings and looking for symptom relief through a trial and error process.
223665786|NCT02177149|DEVICE|DBS using Clinical Support System.|The DBS RN (Registered Nurse) will use ImageVis3D Mobile app on the iPad to program the DBS system, this software does not interact with imaging systems. The study team uses identified images provided by the Froedtert PACS system, de identifies them, adds a study code. The images are loaded into the software system and used to identify the leads locations. The Patients will be assessed for 6 months starting with the initial DBS programming session. Importantly, the investigators do not anticipate that the clinical decision support tool will provide the final DBS settings, nor do the investigators anticipate that the approach will obviate the need for motor exams. The clinical decision support system will help nurses choose good initial settings and then explore around those initial settings.
224246157|NCT00120198|DRUG|CDOP plus rituximab|
224246158|NCT04019951|DIETARY_SUPPLEMENT|Ca-propionate 1 g|1 g of Ca-propionate will be mixed in 203 mL of a standardized liquid breakfast
224246159|NCT04019951|DIETARY_SUPPLEMENT|Ca-propionate 3 g|3 g of Ca-propionate will be mixed in 203 mL of a standardized liquid breakfast
224246160|NCT04019951|DIETARY_SUPPLEMENT|Placebo|2.6 g of cellulose will be mixed in 203 mL of a standardized liquid breakfast
224246161|NCT05401786|DRUG|Ipilimumab|Anti-CTLA-4
224246162|NCT05401786|DRUG|Cemiplimab|PD-1 inhibition
224246163|NCT05401786|RADIATION|SBRT|Stereotactic Body Radiotherapy
224246164|NCT04002024|OTHER|Moisturizer with active ingredients|Moisturizer with active ingredients: 1 fingertip unit to cover one side of the face twice a day
224246165|NCT04002024|OTHER|Placebo|Placebo: 1 fingertip unit to cover one side of the face twice a day
224246166|NCT06385236|BIOLOGICAL|Dupilumab|"Dupilumab, an interleukin-4 receptor treatment, will be administered through a subcutaneous injection, the initial dose of 600 mg will be administered at two different injection sites (300 mg per injection), followed by a single dose of 300 mg administered every other week (Q2W).~Participants may self-administer injection after proper training."
224246167|NCT06385236|BIOLOGICAL|Benralizumab|"Benralizumab, an interleukin-5 receptor treatment, will be administered through a subcutaneous injection every 4 weeks (Q4W).~Participants may self-administer injection after proper training."
224246168|NCT05679024|DRUG|Apixaban 2.5 milligram Oral Tablet|Oral Tablet
224246169|NCT04657770|DEVICE|Telerehabilitation|The telerehabilitation system will deliver rehabilitation treatment sessions via a secured internet-connected computer. A major component of the system is the use of games to promote therapeutically relevant movements. The subject will perform daily assigned remote-based telerehabilitation games and exercises and 5 minutes of stroke education, all guided by the telerehabilitation system. During some of the sessions, therapists will initiate a videoconference with the subject's telerehabilitation system to discuss progress, issues, and revise treatment plans as needed.
224246170|NCT01886768|DEVICE|Double pledget nasal anesthesia (DPNA)|By using a transnasal endoscope as a guide and a biopsy forceps, two gauze strips soaked with decongestant and anesthesia will be delivered to the middle meatus followed by the inferior meatus under real-time transnasal endoscopic guidance.
224246171|NCT01886768|DEVICE|Single pledget nasal anesthesia (SPNA)|Another randomized group of patients will also receive endoscopic-guided gauze pledgetting using a transnasal endoscope as a guide and a biopsy forceps. One gauze strip soaked with decongestant and anesthesia will be delivered to either the middle meatus or inferior meatus determined by anterior rhinoscopy.
224246172|NCT02381834|PROCEDURE|Bladder stimulation technique|
224246173|NCT01805934|DRUG|RBLF|The patients in Group RBLF will receive a 14-day quadruple therapy,including rabeprazole(10mg bid),bismuth citrate(220mg bid),levofloxacin(200mg qm) and furazolidone(100mg bid).
224246174|NCT01805934|DRUG|RA|The patients in Group RA will be sent to a penicillin skin test before treatment except they were given penicillin before. They will receive a 14-day dual therapy with high doses of rabeprazole(20mg bid) and amoxicillin(1000mg tid).
224246175|NCT03071029|BEHAVIORAL|Monthly PAFP rates displayed at clinics.|Providers will receive visual and text feedback on their centre's PAFP uptake rates as they compare to the uptake rates of other centres. The feedback will be delivered monthly in a physical paper format.
224246176|NCT03157362|OTHER|Near Non-Social|Participants will be stably seated, and observed by a research assistant, as they complete an induced pain threshold task while they experience a virtual environment that reproduces the room in which they are seated.
224246177|NCT03157362|OTHER|Near Social|Participants will be stably seated, and observed by a research assistant, as they complete an induced pain threshold task while they experience a virtual environment that reproduces the room in which they are seated, and converse with a confederate represented by an avatar.
224246178|NCT03157362|OTHER|Far Non-Social|Participants will be stably seated, and observed by a research assistant, as they complete an induced pain threshold task while they experience a virtual environment that reproduces a different room.
224246179|NCT03157362|OTHER|Far Social|Participants will be stably seated, and observed by a research assistant, as they complete an induced pain threshold task while they experience a virtual environment that reproduces another room, and converse with a confederate represented by an avatar.
224246180|NCT00112645|BIOLOGICAL|anti-thymocyte globulin|
224246181|NCT00112645|DRUG|busulfan|
224246182|NCT00112645|DRUG|cyclosporine|
224246183|NCT00112645|DRUG|melphalan|
224246184|NCT00112645|DRUG|methotrexate|
224246185|NCT00112645|DRUG|methylprednisolone|
224246186|NCT00112645|PROCEDURE|allogeneic bone marrow transplantation|
224246187|NCT00112645|PROCEDURE|peripheral blood stem cell transplantation|
224246188|NCT00112645|PROCEDURE|umbilical cord blood transplantation|
224246189|NCT01502566|BEHAVIORAL|Education Intervention|Children/mothers allocated to this arm will receive an pamphlet with key information on dental caries prevention, together with oral instructions about how to avoid dental caries.
224246190|NCT03655106|DEVICE|Standard Long IV 4.78 cm 20 g catheter|Standard Long IV 4.78 cm 20 g catheter
224246191|NCT03655106|DEVICE|Ultra-Long IV 6.35 cm 20 g catheter|Ultra-Long IV 6.35 cm 20 g catheter
224246192|NCT04131751|DIAGNOSTIC_TEST|Next generation sequencing|we will investigate the sensitivity and specificity of next generation sequencing as a diagnostic tool in ascites infections.
224246193|NCT02961309|DRUG|THC|1 High-Potency THC (Dosage = 10mg) cigarette (oral smoking) on one day and 1 Placebo on the other day.
224246194|NCT05212766|BIOLOGICAL|COVID infection|Infections with COVID 19
224246195|NCT05212766|BIOLOGICAL|COVID vaccination|Vaccination against COVID 19
223665787|NCT02234895|DEVICE|Lateral wedge|This will be a randomized cross-over study where all participants will receive both orthoses over a six month period. Each intervention will last two months, separated by a two month washout period of no orthotics wear, and will be preceded and followed by a laboratory-based gait and pain assessment. Two months has been chosen as the ideal time frame to ensure maximum participant adherence, to observe clinically meaningful changes in symptoms, and to minimize degradation of the insoles.
224246196|NCT05212766|DIAGNOSTIC_TEST|Oral examination|Assessment of oral and periodontal health status
224246197|NCT01814462|DEVICE|6 months CPAP|
224246198|NCT05565664|DRUG|Ketamine hydrochloride|"Ketamine hydrochloride will be made in a 20 ml syringe in a concentration of 1.25 mg/ml. Patients will receive IV ketamine hydrochloride in a dose of 0.5 mg/kg (equivalent to 0.4 ml/kg) over 10 min.~The coordinator of the study will prepare blinded syringes for each group, while the anesthetist who will be in charge of anesthetic management during the operation will be unaware of the study medication."
224246199|NCT05565664|DRUG|Magnesium sulfate|"A 20 ml syringe will contain magnesium sulphate in a concentration 100 mg/ml (10%). Patients will receive 40 mg/kg of IV magnesium sulphate (equivalent to 0.4 ml/kg) over 10 min.~The coordinator of the study will prepare blinded syringes for each group, while the anesthetist who will be in charge of anesthetic management during the operation will be unaware of the study medication."
224246200|NCT05336708|OTHER|Acupressure Group|In the acupressure group, acupressure will be applied to the heart meridian 7th point (HT7), large intestine meridian 4th point (LI4), stomach meridian 36th point (ST36) and spleen meridian 6th point (SP6). After pressing each point for a certain period of time, a total of two minutes of rest periods will be applied by the researcher.
224246201|NCT05336708|OTHER|Sham Acupressure Group|In the sham acupressure group, acupressure will be applied on the bone region where the meridians do not pass, approximately 1-1.5 cm away from the HT7, LI4, ST36, SP6 points. The application process will continue in the same way with acupressure group and the pressure intensity will be less.
224246202|NCT00771485|DRUG|FM-602|Study of Efficacy of Bowel Preparation Before Colonoscopy
224246203|NCT00771485|DRUG|Marketed Bowel Cleanser|Marketed bowel cleanser
224246204|NCT00800709|DRUG|Memantine|Initially memantine 5mg/day, titrated within the first month to a maintenance dose of 20mg/day
224246205|NCT05008640|DEVICE|TrueLoo™|TrueLoo™ is an Internet-connected, smart toilet seat that uses computer vision technology to log and capture daily bowel movements and urinations. This data is then categorized by physical excreta characteristics to train and develop machine learning algorithms that are intended to eventually identify significant changes in stool and urine in real-time.
224246206|NCT00595166|DEVICE|Vaginal Speculum Sheath|Patients received the sheathed speculum exam: The clinician will begin to place the sheath onto the speculum. The sheath is attached to a thin piece of cardboard. The proximal end of the cardboard is placed between the speculum blades and is pushed toward the speculum handle. The blades of the speculum are simultaneously guided to enter the 2 pockets of the sleeve, like fingers going into a glove. The speculum exam will then be completed according to usual procedures. In the event the sheathed speculum exam is unsatisfactory the clinician will do standard of care (the clinician's usual routine at the bedside).
224246207|NCT01353469|DRUG|Insulin human/Insuman Comb 25 (HR1799)|"Pharmaceutical form:Suspension~Route of administration: Subcutaneous"
224246208|NCT01353469|DRUG|Insulin human/Novolin® 30R|"Pharmaceutical form:Suspension~Route of administration: Subcutaneous"
224246209|NCT02746484|OTHER|Ability platform program|The Ability program is an at home participant-tailored and technology-enhanced platform a) delivering tablet-based intensive (five days/a week for six weeks) motor and cognitive activities; b) monitoring from remote vital and physical health parameters (i.e., weight, Heart Rate, O2 saturation, daily steps, sleep activity).
224246210|NCT02746484|OTHER|Usual care program|Usual care at home program (paper and pencil cognitive activities; promotion of physical activity according to healthcare professional's advice)
224246211|NCT01249222|PROCEDURE|plasmapheresis|Plasmapheresis was done every 24-48 hours and continues up to five times. Blood samples were collected 30 minutes before and after each session of plasmapheresis to determine sequential changes in plasma levels of IL-1β, IL-6 and TNF-α. During each exchange session a volume of 25-30 ml/kg bodyweight of patient's plasma was exchanged with equal volume of 20% human albumin diluted with normal saline solution. Before and after plasmapheresis, prothrombin time, activated partial thromboplastin time (aPTT), platelet count and serum calcium level were checked. calcium gluconate 10% (10 ml) was administered even if patient had normal serum calcium in order to prevent hypocalcaemia due to administration of citrate. All drugs except for vasopressors were stopped during procedure.
224246212|NCT01249222|OTHER|plasmapheresis|plasmapheresis 5 times every 24-48 hours. the apheresis volume will be 30 ml/kg.
224246213|NCT03786965|OTHER|On-pump CABG|On-pump CABG
224246214|NCT03786965|OTHER|Off-pump CABG|Off-pump CABG
224246215|NCT03786965|OTHER|Pump-assisted CABG|Pump-assisted CABG
224246216|NCT03786965|OTHER|Valve Repair Procedure without CABG.|Valve Repair Procedure without CABG (open heart procedure).
224246217|NCT03786965|OTHER|Valve Repair Procedure with CABG.|Valve Repair Procedure with CABG (open heart procedure).
224246218|NCT05119270|DEVICE|Femtosecond laser assisted cataract surgery with Active Sentry handpiece|"The LenSx laser (Alcon Laboratories Inc., USA) automates key steps in the procedure including capsulorhexis, incision making and phaco. The Frequency Domain - Optical Coherence Tomography (FD-OCT) optical imaging system provides high-resolution, real-time visualization of ocular structures and their dimensions. The device sends the results to the interface which programs the laser and indicates the exact location, size and depth of the desired incisions.~Diagnostic tests:~1. Corneal topography: OPD-Scan Corneal topography photography, taken by specular reflection (OPD-Scan) by measuring corneal curvature, thickness and topography~2. Pachymetry: precise measurement of the thickness of the cornea using a pachymeter~3. Specular microscopy : Qualitative and quantitative analysis of the corneal endothelium."
223665788|NCT02234895|DEVICE|Lateral wedge plus medial arch support|This will be a randomized cross-over study where all participants will receive both orthoses over a six month period. Each intervention will last two months, separated by a two month washout period of no orthotics wear, and will be preceded and followed by a laboratory-based gait and pain assessment. Two months has been chosen as the ideal time frame to ensure maximum participant adherence, to observe clinically meaningful changes in symptoms, and to minimize degradation of the insoles.
223665789|NCT04216797|DRUG|Diazepam Tablets|Participants will be randomly assigned to either an oral or rectal administration of once daily 10 mg diazepam tablets for four weeks.
223665790|NCT04154813|DRUG|Topiramate|The initial dose of 25mg/d is rapidly increased to the target dose (100mg/d) or below the maximum tolerable dose if the patient can tolerate it.
223770636|NCT05607992|BEHAVIORAL|Brief exposure-based CBT|The 5-week intervention is psychologist-guided and delivered via text-based interactive online treatment modules, where patients complete weekly homework assignments and have regular online contact with psychologists with training in CBT for cardiac disease. Key components include imaginal exposure of the ACS event, interoceptive exposure through at home physical activity that stimulats the CV system, exposure in-vivo to reduce avoided situations, and activities to enhance physical activity wellbeing. Labeling (i.e., describing cardiac-related symptoms, thoughts, and feelings) will be used continuously during treatment to enhance the effect of exposure.
223770637|NCT04112810|DRUG|Tildrakizumab|100 mg will be injected subcutaneously on Day -1, Day 28 ± 3, Day 112 ± 7, Day 196 ± 14, and Day 280 ± 14.
223770638|NCT04488328|OTHER|patients received the routine medical treatment in addition to pulsed magnetic therapy and moderate-intensity aerobic exercise for 12 weeks|patients received the routine medical treatment in addition to pulsed magnetic therapy and moderate-intensity aerobic exercise for 12 weeks(3 sessions/ week)
223770639|NCT00000833|DRUG|Ribavirin|
224246219|NCT05119270|PROCEDURE|Standard phacoemulsification with the Active Sentry handpiece|"Phacoemulsification is done by using the Active Sentry handpiece to allow for a better control of the intraocular pressure throughout the surgery.~Diagnostic tests:~1. Corneal topography: OPD-Scan Corneal topography photography, taken by specular reflection (OPD-Scan) by measuring corneal curvature, thickness and topography~2. Pachymetry: precise measurement of the thickness of the cornea using a pachymeter~3. Specular microscopy : Qualitative and quantitative analysis of the corneal endothelium."
224246220|NCT05119270|PROCEDURE|Standard phacoemulsification with the OZil handpiece|"Phacoemulsification is done by using the traditional OZil handpiece that allows rotational movement of the phaco tip.~Diagnostic tests:~1. Corneal topography: OPD-Scan Corneal topography photography, taken by specular reflection (OPD-Scan) by measuring corneal curvature, thickness and topography~2. Pachymetry: precise measurement of the thickness of the cornea using a pachymeter~3. Specular microscopy : Qualitative and quantitative analysis of the corneal endothelium."
224246221|NCT05168670|COMBINATION_PRODUCT|Protection of eyes with tinted soft scleral eye shields|In subjects with dry eye disease due to meibomian gland dysfunction, protection of eyes with tinted soft scleral eye shields followed by IPL administration on eyelids
224246222|NCT00162474|DRUG|Warfarin|
224246223|NCT00162474|DRUG|Phenytoin|
224246224|NCT01375660|DRUG|Placebo|Supplement of vitamin D 400 units provided to all subjects, in addition Arm 1 will get placebo and Arm 2 will get D2 50K
224246225|NCT01375660|DRUG|50K vitamin D2|Supplement of vitamin D 400 units provided to all subjects, in addition Arm 1 will get placebo and Arm 2 will get D2 50K
224246226|NCT04914962|OTHER|glazed zirconium lithium silicate|monolithic glazed crown
224246227|NCT04914962|OTHER|polished zirconium lithium silicate|monolithic polishedcrowns
224246228|NCT00737490|OTHER|"Sequential Arm (Promote , model # 2207-36 or Atlas HF , model # V-343)"|"Echocardiographically guided optimized device programming: specifically sequential BiV pacing. Sequential Arm~Using one of the FDA approved St. Jude devices, depending on MD preference."
224246229|NCT00737490|OTHER|"Simultaneous Arm (Promote , model # 2207-36 or Atlas HF , model # V-343)"|"simultaneous BiV pacing.~Using one of the FDA approved St. Jude devices, depending on MD preference."
224246230|NCT02514941|DRUG|paracetamol|Administration of 5 ml Paracetamol Saft Hexal (= 200 mg paracetamol)
224246231|NCT02514941|DRUG|amoxicillin|Administration of 5 ml Amoxypen® 250 mg Saft (= 250 mg amoxicillin)
224246232|NCT02514941|DRUG|talinolol|Administration of 1 tablet Cordanum® 50 (= 50 mg talinolol) dissolved with 40 ml tap water
224246233|NCT02514941|PROCEDURE|gastroduodenoscopy with biopsy|Gastroduodenoscopy with biopsy of the lower duodenum before the first pharmacokinetic study period
224246234|NCT02514941|PROCEDURE|gastrojejunoscopy with biopsy|Gastrojejunoscopy with biopsy of the jejunum about one year after proximal Roux-en-Y gastric bypass
224246235|NCT02514941|PROCEDURE|proximal Roux-en-Y gastric bypass|sampling of a tissue specimen from the jejunum during the operation
224246236|NCT04446559|PROCEDURE|Sitting in chair position|For patients randomized in the chair group, we will perform the transfer to the chair immediately after the morning arterial blood gas. The chair position will be maintained for 3 hours, if the patient shows no clinical signs of discomfort or intolerance.
224246237|NCT02685462|DRUG|Rosuvastatin|
224246238|NCT02685462|DRUG|Atorvastatin|
224246239|NCT02685462|DRUG|Simvastatin|
223665791|NCT04154813|DRUG|Fluoxetine|Fluoxetine was increased from 20mg/d to the target dose (60mg/d) or below the maximum tolerable dose within 2 weeks.
223770640|NCT00000833|DRUG|Didanosine|
223770641|NCT01468896|BIOLOGICAL|Cetuximab|Given IV
223770642|NCT01468896|BIOLOGICAL|Edodekin alfa|Given SC
223770643|NCT01468896|OTHER|Laboratory Biomarker Analysis|Correlative studies
224246240|NCT02685462|DRUG|Digoxin|
224246241|NCT02685462|DRUG|Caffeine|
224246242|NCT04854330|DIETARY_SUPPLEMENT|Ketone monoesters|A Kme commercially available supplement will be given to the participants in the form of (R)-3-hydroxybutyl (R)-3-hydroxybutyrate (ΔG®; TΔS Ltd, UK, Oxford, UK; 0.30 ml.kg-1 body mass) and will be ingested with water and cherry-flavoured stevia in a total volume of 100 ml.
224246243|NCT04854330|DIETARY_SUPPLEMENT|Placebo|In the placebo condition, participants will consume 100 ml of water and cherry-flavoured stevia followed by the same 20 ml calorie-free sparkling spring water.
224246244|NCT01336322|DRUG|Metformin|Metformin 850 mg bid
224246245|NCT01336322|DRUG|Sitagliptin|Sitagliptin 100 mg qd
223665792|NCT04154813|BEHAVIORAL|cognitive behavioral therapy (CBT)|CBT psychotherapy, once a week for three months.
224246246|NCT01336322|DRUG|Sitagliptin + Metformin|sitagliptin 100mg + metformin 850mg
224246247|NCT06181175|DRUG|PEAPROSTIL 600 + Tamsulosin 0.4 mg|PEAPROSTIL 600 mg one sachet oral daily+ Tamsulosin 0.4 mg one tablet oral daily
224246248|NCT06181175|DRUG|Tamsulosin 0.4 mg|Tamsulosin 0.4 mg one tablet oral daily
224246249|NCT06181175|DRUG|PEAPROSTIL 600 mg|PEAPROSTIL 600 mg one sachet oral daily
224246250|NCT04109521|OTHER|Training, certification and marketing|The 12hr training will address the vendors (i) knowledge on hygienic handling of milk, preservation and low-cost methods for testing milk safety; (ii) business skills in record keeping, access and management of credit; (iii) milk marketing. On completion of the training and successfully passing an evaluation, vendors will be given a written certificate using a format suitable to be displayed in their premises (i.e. A4 poster, a hat or badge) indicating they have completed the training. The certification will not have legal value. Two quarterly unannounced visits will be conducted to collect a milk sample from the vendors and report back the results of microbiological quality. Vendors will have access to various milk marketing and communication items to be used in their daily operations. The materials will promote milk consumption through marketing focused on messages to consumers related to (i) good milk hygiene practices, (ii) good child nutrition practices, and (iii) household diets
223665793|NCT04154813|BEHAVIORAL|dialectical behavior therapy (DBT)|DBT psychotherapy,once a week for three months.
223665794|NCT02726854|DRUG|Apatinib|Patients with pancreatic cancer who are failed of receiving first-line chemotherapy and cannot tolerate second-line chemotherapy or unwilling to receive second-line chemotherapy will receive Apatinib Tablets (850mg once daily, orally) 30 minutes after meal with warm water. Take 28 days as a cycle, patients will receive this treatment until they have got disease progressed.
223665795|NCT02400385|DRUG|sunitinib|sunitinib 50mg/day po, 4 weeks on 2 weeks off
223665796|NCT02400385|DRUG|nivolumab|nivolumab 3mg/kg IV ever 2 weeks
223665797|NCT01675167|DRUG|Buprenorphine|Buprenorphine HCl Buccal Film at doses ranging from 150-900 mcg twice daily
223665798|NCT01675167|DRUG|Placebo|Matching Placebo Buccal Film twice daily
223665799|NCT05176171|PROCEDURE|Photorefractive Keratectomy with Corneal Cross-Linking|To our knowledge, this study is one of the first to compare the visual results of non-topography-guided and topography-guided photorefractive keratectomy (PRK) applying sequential and simultaneous corneal cross-linking (CXL) treatment for keratoconus. Considering recent advances in cross-linking and imaging in keratoconus, the outcomes of this study can lead us to several non-invasive algorithm management options.
224246251|NCT00496964|DRUG|Botulinum toxin A + exercise|Injection of 100 units Botox (Botulinum toxin type A) into the Vastus Lateralis of the study leg + 12 weeks of exercise for patellofemoral pain
224246252|NCT00496964|DRUG|Placebo|Injection of 2 cc placebo containing 0.1cc sodium bicarbonate 8.4% (1meq/cc), 0.9cc normal saline and 1 cc of lidocaine into the vastus lateralis of the study leg followed by 12 weeks of exercise for patellofemoral pain syndrome
224246253|NCT04781205|GENETIC|Mutation arrays, NGS panels, GWAS, WES, WGS,|DNA extracted from peripheral blood as well as genetic analysis of bacteria from feces
224246254|NCT04781205|DEVICE|wearable monitors|test various technologies of sensors to measure continuously various body functions and provide information to person and to physician
224246255|NCT02058498|BEHAVIORAL|Physical activity|Participants will be provided physical activity walking instructions and asked to record their daily activity on an activity log. Participants will be given the International Physical Activity Questionnaire and asked about their quality of life at baseline, at 6 weeks and at 4 months.
223665800|NCT04273035|DRUG|Midazolam oral solution|Oral Buccolam
223665801|NCT04273035|DEVICE|IPAD|Playing any game, film, clip or puzzle on a tablet till after induction of anesthesia
223665802|NCT05085301|DIAGNOSTIC_TEST|Rapid diagnostic test|The performance of three index tests and two comparator tests will be compared to reference tests and gold standard microscopy.
224246256|NCT00029198|PROCEDURE|massage|15 massage given tid
223665803|NCT04363541|DEVICE|Electric pad for human external pain therapy|An electric pad for local heat production will be put on the back of the patient for two hours
223665804|NCT00755300|PROCEDURE|Measurement of total thrombolic load|A video recording of the right atrium using TE echo will be used to quantitate the total thromboembolic load
223665805|NCT04962256|PROCEDURE|Enhanced recovery after surgery|ERAS management includes 3 parts: (1) Preoperative analgesia and airway evaluation. (2) The protection and reconstruction of the musculo-ligamentous complex during the surgery, the safe intubation, and the local infiltration anesthesia during surgery. (3) Collar free, multimodal analgesia, airway management, and early recovery after surgery.
223665806|NCT00950677|DRUG|Byetta (exenatide)|exenatide 5 mcg subcutaneously
223665807|NCT00950677|DRUG|Symlin (pramlintide)|pramlintide 60 mcg subcutaneously
223665808|NCT03769584|OTHER|Follow-up questionnaire|Online- Questionnaire investigating Follow-up of Treatment Outcome, Quality of Life, Sexual Life and Partnership After Surgery of Endometriosis
223665809|NCT03769584|OTHER|Follow- up interview|Semi- structured Interview investigating Follow-up of Treatment Outcome, Quality of Life, Sexual Life and Partnership After Surgery of Endometriosis
223665810|NCT05427877|DEVICE|Heating device (Heatwave Technology)|Heating devices will be applied to the trunk and extremities of the body during the first study visit. During each heating cycle, the temperature will increase quickly from room temperature to a high of 45C and then cycle back down. Each heating cycle is 30 minutes with a 3 minute cool down period where no heat is applied. The maximum temperature used in this study is 45 degrees C (113 degrees F). There will be a total of 3 heating cycles at the visit.
223665811|NCT00199043|DRUG|Allopurinol|
223665812|NCT00199043|DRUG|Rasburicase|
223665813|NCT03620461|DRUG|Gemcitabine - nabpaclitaxel|efficacy and safety
223665814|NCT00708487|OTHER|Embryo incubator oxygen concentration|Two concentrations of oxygen are currently used to culture the embryos of infertile patients in commercial human IVF programs - 21% and 5%.
224246257|NCT00029198|PROCEDURE|Sham massage|non-massage touch
224246258|NCT03195205|DIAGNOSTIC_TEST|OraQuick HCV Rapid Antibody Test|HCV Screening
223665815|NCT01282580|DIETARY_SUPPLEMENT|Lovaza-Omega 3 fatty acid capsules|The study will require monthly visits at 0, 1, 2 and 3 months of study intervention. At each visit a fasting serum sample will be obtained, self-report diaries (adverse events, record of omega 3 supplement doses or fish servings taken/missed) will be collected, and pill count / labels from cans of fish will be recorded. Medications and supplements will be reviewed with participants at each monthly visit. At clinic visits at 0 and 3 months, a history and physical examination and breast adipose fine needle aspiration (FNA)will be performed.Omega 3 supplements will be dispensed in monthly amounts.
223665816|NCT01282580|OTHER|Dietary fish (canned salmon, albacore)|Participants randomized to dietary fish will be asked to incorporate fish in the form of canned albacore and salmon into their diets at four 6 oz servings per week for 3 months. Participants on the dietary fish arm of the study will receive recipes using canned salmon and/or albacore. Sufficient canned salmon/albacore will be available for subjects who wish to prepare a meal for the family/household. Dietary intake will be assessed via 3 day diet records (0 and 3 months) and food frequency questionnaires (0 and 3 months). Verbal and written instructions on how to keep diet records, with food measured or weighed, will be given.
223665817|NCT04947852|DEVICE|Investigation Mask|Oronasal bilevel continuous positive airway pressure mask fitted by the investigational staff
223665818|NCT04947852|DEVICE|Comparator Mask|Oronasal bilevel continuous positive airway pressure mask fitted by the investigational staff
223665819|NCT00115583|DRUG|Drug Infusion (BQ-123)|
223665820|NCT00881868|DRUG|clobetasol propionate spray 0.05%|Apply enough product to cover affected areas topically twice daily at least 8 hours apart
223665821|NCT00881868|DRUG|Vehicle spray|Apply enough product to cover affected areas topically twice daily at least 8 hours apart
223665822|NCT03255083|DRUG|DS-1205c|DS-1205c 200 mg capsule
223665823|NCT03255083|DRUG|Osimertinib|Osimertinib 80 mg tablet
223665824|NCT03144609|PROCEDURE|low PEEP|The control group consisted of obese patients mechanically ventilated by a standardized volume-controlled breathing mode with low respiratory volume without alveolar recruitment maneuver and using low values of PEEP up to 4 cm H2O.
224246259|NCT02296177|BEHAVIORAL|Peace of Mind Program|The Peace of Mind Program (PMP) is a telephone counseling program based on the Transtheoretical Model of Change, with messages matched to readiness (assessed with a stage of change question)and barriers identified by women who are non-adherent to mammography. The program telephone protocol guides counselors to assess a woman's readiness to be screened and counsel her through barriers to increase appointment keeping.
224246260|NCT06392594|GENETIC|xpert MTB , XDR assay|To determine how accurate Xpert MTB/RIF and XDR for diagnosis of pulmonary TB and Rifampicin resistance
224246261|NCT00532974|BIOLOGICAL|EP1090|Low dose
224321709|NCT06193057|PROCEDURE|Total ankle arthroplasty|Patients who underwent ankle prosthesis implantation procedure with an anterior approach were involved in a longitudinal skin incision of about 12-15cm anterior to the tibio-tarsal joint in supine position. Once the deep layers were reached, passing through the anterior tibial tendon and extensor hallucis longus tendon sheath, the tibio-tarsal joint was then exposed. The operator proceeds to astragalic and tibial resections, once the appropriate size of implants was selected, the final components were implanted. In both groups, the basic prosthetic design approach will be 'three-component,' that is, with congruent mobile meniscus interposed between the tibial and astragalic components. At the end of the procedure, orthopedic walker boot was placed for 3 weeks, and progressive weight allowed.
224321710|NCT06826833|PROCEDURE|Erector Spinae Plane (ESP) Block|A regional anesthesia technique in which 20 mL of 0.25% bupivacaine is injected under ultrasound guidance at the T8-T10 level to provide postoperative pain relief.
224321711|NCT03706755|DRUG|Norepinephrine: 1mcg/kg|intervention:Parturients will receive Norepinephrine: a bolus of 1 mcg/Kg immediately after SA (preventive bolus) then they will receive complementary doses of Norepinephrine (half dose: 0.5 mcg/Kg) to maintain systolic blood pressure above 80 % of baseline
224321712|NCT03706755|DRUG|Norepinephrine 0,5mcg/kg|intervention: Parturients will receive Norepinephrine: a bolus of 0.5 mcg/Kg immediately after SA (preventive bolus) then they will receive complementary doses of Norepinephrine (half dose: 0.25 mcg/Kg) to maintain systolic blood pressure above 80 % of baseline
223770644|NCT02915029|OTHER|Educational and lifestyle coaching|"Educational lifestyle and patient activation is a CHR lead home visits every other week to provide education on healthy lifestyles (diet, exercise, alcohol abuse and smoking) as patient preference; Education provided on management of diabetes, hypertension and hyperlipidemia POC testing for A1C and microalbuminuria conducted at patient homes. Lifestyle and diet related Motivational messaging carried out regularly. Patient will receive group session at the clinic every quarters.~Control arm will receive their usual care provided by IHS. The control group will receive a health evaluation at the initiation of the study and at the 6-month and 12-month."
223770645|NCT01824745|OTHER|educational intervention|Receive the SCP-BCS template booklet
223770646|NCT01824745|OTHER|counseling intervention|Receive counseling sessions with a patient navigator
224246262|NCT00532974|BIOLOGICAL|EP1090|High dose
224246263|NCT02548403|DRUG|PEG-Asc|received 1 L solution of PEG-Asc at 7 p.m the evening before colonoscopy and another 1 L solution of PEG-Asc at 5 hours before procedure
224246264|NCT02548403|DRUG|PEG-Asc with simethicone|received 1 L solution of PEG-Asc at 7 p.m the evening before colonoscopy and another 1 L solution of PEG-Asc at 5 hours before procedure. Two packs (200 mg/10 mL each) of simethicone (400 mg) was mixed with last 500 mL of additional clear fluid.
224246265|NCT03799653|OTHER|No intervention|This is a prospective observational study, and there is no intervention.
224246266|NCT04982094|BEHAVIORAL|Mental Health First Aid and Relationship Building Training|"Relationship Building Training (RBT) is a 2 hour training session conducted live over zoom, that aims to equip business advisors the communications skills they need to enhance trustworthiness and quality of the relationship with their clients.~Mental Health First Aid (MHFA) is a certified training program. It requires 5-7 hours of online course work followed by 2 x 2.5 hour live zoom sessions, that aims to enhance mental health literacy and teach the skills needed to identify the signs of mental health conditions and to have a conversation with a person who may need professional help.~Two Booster sessions are delivered 1- and 3-months after the last MHFA session that aims to give participants the opportunity to consolidate their learning and share experiences applying the knowledge/skills gained.~Participants will also invite 2-3 of their small-business entrepreneur (SME) clients to join the study and complete 3 surveys to provide feedback on the success of the program."
224246267|NCT04982094|BEHAVIORAL|Mental Health First Aid|"Mental Health First Aid (MHFA) is a certified training program. It requires 5-7 hours of online course work followed by 2 x 2.5 hour live zoom sessions in addition to online reading, that aims to enhance mental health literacy and teach the skills needed to identify the signs of mental health conditions and to have a conversation with a person who may need professional help.~MHFA online training is conducted two-weeks before the two MHFA sessions (with a 1 day break in between each MHFA). Two Booster sessions are delivered 1- and 3-months after the last MHFA session. The Booster sessions aims to give participants the opportunity to consolidate their learning and share experiences applying the knowledge/skills gained.~Participants will also invite 2-3 of their small-business entrepreneur (SME) clients to join the study and complete 3 surveys to provide feedback on the success of the program."
224246268|NCT02898168|DEVICE|WA group|Conventional rehabilitation therapy and gait training with WAIntervention with WA is scheduled 40min/day, five times a week, for 8 weeks.
224246269|NCT02898168|OTHER|Control|Conventional rehabilitation therapy and gait training without WA.
224246270|NCT00763763|DRUG|Imatinib mesylate|imatinib 600 mg/day for 2 years
224246271|NCT00763763|DRUG|Interferon|45 micrograms per week during 2 years
224246272|NCT00763763|DRUG|Vincristine|2 mg IV injection repeated weekly for 4 weeks as induction and then monthly for 4 months as consolidation
224246273|NCT00763763|DRUG|Dexamethasone|40 mg PO repeated weekly for 4 weeks as induction and then monthly for 4 months as consolidation
224246274|NCT04222881|PROCEDURE|AVF anastomosis|Type of arteriovenous anastomosis
224246275|NCT04881435|DEVICE|Hydrogen gas therapy|Hydrogen gas therapy three times one day for 5 days
224246276|NCT02054845|BEHAVIORAL|Body awareness therapy|"Experimental condition: BEWARE training group The physical and psychosocial elements of the training sessions will be complementary: psychological techniques are used to induce and endure wearing-off and physical techniques are used to improve body awareness to cope with the off-periods.~Specifically the following techniques will be applied:~1. Body scan~2. Psychoeducation~3. Acceptance Commitment Therapy / Mindfulness skills (sustained attention, concentration, non-reactivity, nonjudging of experience)~4. Body Awareness Training~5. Exposure training (imaginary exposure to induce response fluctuations)~6. Training in cueing techniques to overcome problems with initiation and freezing~7. Visual Feedback training~8. Relaxation techniques"
224246277|NCT02054845|OTHER|Physical therapy|Control condition: Treatment as Usual The control group will receive treatment as usual based on the current guidelines for physical therapy in patients with Parkinson's Disease, with the same training schedule of 2x per week for 1,5 hours during 6 weeks. Group treatment will contain exercises for balance, walking, posture, transfers, arm/hand dexterity, strength, flexibility, relaxation and physical condition.
224246278|NCT05327491|DRUG|Sotorasib|Oral Tablet
224246279|NCT01108029|DRUG|memantine|2 tablets of 10 mg of memantine 1 time a day in the morning
224246280|NCT01108029|DRUG|placebo|2 tablets of placebo 1 time a day in the morning
224246281|NCT04628117|DIETARY_SUPPLEMENT|Oral nutritional supplementation for kidney disease|237 mls per day for 8 weeks.
224246282|NCT00939718|DIETARY_SUPPLEMENT|Vitamin B12|Vitamin B12 injections containing methylcobalamin 1000 mcg given once every six months along with the routine antidepressant treatment.
224246283|NCT03105141|DEVICE|Remote ischemic conditioning|"Remote ischemic conditioning is composed of 5 cycles of 5-min bilateral upper limb ischemia intervened by 5-min reperfusion, which is induced by an automated cuff-inflator (Doctormate®) placed on both upper arms and inflated to a given pressure followed by deflation, twice daily for 12 months.~Two different magnitude of limb ischemia pressure will be set: 200 mmHg and 40 mmHg above systolic pressure (60 patients for each).~Optimal inflating pressure will be determined based on the results."
224246284|NCT03105141|DEVICE|Remote ischemic conditioning|"Remote ischemic conditioning is composed of a given cycle of 5-min bilateral upper limb ischemia intervened by 5-min reperfusion, which is induced by an automated cuff-inflator (Doctormate®) placed on both upper arms and inflated to 200 mmHg pressure followed by deflation, twice daily for 12 months.~The number of cycles of limb ischemia will be set as: 4, 5 and 6 (60 patients for each).~Optimal cycles for application will be determined based on the results."
224246285|NCT03105141|DEVICE|Remote ischemic conditioning|"Remote ischemic conditioning is composed of 5 cycles of a given duration of bilateral upper limb ischemia intervened by reperfusion, which is induced by an automated cuff-inflator (Doctormate®) placed on both upper arms and inflated to 200 mmHg pressure followed by deflation, twice daily for 12 months.~The duration of each cycle for limb ischemia will be set as: 4, 5 and 6-min (60 patients for each).~Ischemia duration algorithm will be determined based on the results."
224246286|NCT03105141|DEVICE|Remote ischemic conditioning|"Remote ischemic conditioning is composed of 5 cycles of 5-min bilateral upper limb ischemia intervened by reperfusion, which is induced by an automated cuff-inflator (Doctormate®) placed on both upper arms and inflated to 200 mmHg pressure followed by deflation, once or twice daily for 12 months.~The method for application will be set as: once daily for 12 months and twice daily for 12 months (60 patients for each)."
224246287|NCT03756259|BEHAVIORAL|Mobile Health (mHealth) for Pneumonia|Audiovisual mobile based application will be used to counsel caregivers of children under five on pneumonia and its prevention. This will be coupled with text and voice message dissemination to the cell phones of caregivers and active pneumonia case finding by the LHWs which will be managed according to severity.
223770647|NCT01824745|PROCEDURE|standard follow-up care|Receive standard follow-up care
224246288|NCT05316428|DRUG|TPN171H tablet plus alcohol|10 mg TPN171H tablet QD plus 0.5 g/kg alcohol
224246289|NCT05316428|OTHER|alcohol|0.5 g/kg alcohol
224246290|NCT05316428|DRUG|TPN171H tablet|10 mg TPN171H tablet QD
224246291|NCT02142556|DRUG|Administration of quetiapine XR|The treatment was initiated with a 7-day cross-titration period. Previous antipsychotic medication was maintained at the original dose from day 1 to day 3; then reduced to 50% of the original dose from day 4 to day 7 and discontinued on day 8. Meanwhile, the patients started quetiapine XR with daily dose at 300 mg on day 1, 600 mg on day 2 and up to 800 mg after day 2. From day 8 until the end of the study, the dose of quetiapine XR was adjusted within 400-800 mg per day, depending on the clinical response and tolerability of the patients.
224246292|NCT01138540|OTHER|lateral-Trendelenburg position|lateral-Trendelenburg position of patients laying in the bed of the ICU, keeping trachea and tracheal tube horizontal, compared to the standard treatment (semirecumbent position) for the prevention of VAP
223665825|NCT03144609|PROCEDURE|ARM|The experimental groups also consisted of obese patients mechanically ventilated by a volume-controlled breathing mode with low respiratory volume 7 ml/kg ideal body mass, but with alveolar recruitment maneuver performed immediately after induction, followed every 30 minutes during the hemodynamic stable condition under operation.
223665826|NCT03144609|PROCEDURE|high PEEP|The experimental groups also consisted of obese patients mechanically ventilated by a volume-controlled breathing mode with low respiratory volume 7 ml/kg ideal body mass, but with higher PEEP, provided that the upper limit of 40 cm H20 was not exceeded.
224246293|NCT01868191|DRUG|Benfotiamine|Treatment with 600 mg/day for the first 3 months followed by 300 mg/day for 9 months
224246294|NCT01868191|DRUG|Placebo for benfotiamine|Treatment with placebo for benfotiamine 600 mg/day for the first 3 months followed by 300 mg/day for 9 months
224246295|NCT04555889|DEVICE|lung recruitment maneuver (LRM) with DrageerVN500|interventions involving device that may help to gradually lung development
224246296|NCT04362020|OTHER|Distal radial access|Distal radial access and No anticoagulation
224246297|NCT04362020|OTHER|Distal radial access|Distal radial access and ACT-guided anticoagulation
224246298|NCT02095782|DRUG|Intercalated combination of chemotherapy and erlotinib|"Primary therapy stage:~Paclitaxel Patients receive six cycles of Paclitaxel (175 mg/m² on days 1 of a 4 week cycle, intravenously) plus carboplatin (AUC=5, intravenously on day 1 of a 4 week cycle, intravenously) with sequential erlotinib (150 mg/day) on days 8-21 of each cycle.~Maintenance therapy stage:~Patients, who complete 6 cycles of therapy without progression or intolerable toxicity, receive erlotinib (150 mg/day) as maintenance therapy until progression, intolerable toxicity or death."
224246299|NCT01418586|DRUG|Torrent's Alfuzosin Extended Release Tablet|
224246300|NCT05463822|DRUG|Transvaginal botulinum toxin A (BTA) injection|Botulinum toxin A (Botox® 100 units) will be injected into the detrusor muscle of the bladder by inserting a needle through the anterior vaginal wall.
224246301|NCT03427164|PROCEDURE|Transjugular Intrahepatic Portosystemic Shunt|The TIPS procedures creates an artificial shunt from the portal vein to the hepatic vein. TIPS allows blood from the congested portal circulation to bypass the fibrotic liver and directly enter the systemic circulation.
224246302|NCT04957953|OTHER|Patient's consent|Primary enrolment will be carried out at the time of vaccination at the main vaccination sites, with the patient's consent. The agreement form filled in online includes the surname, first name, month and year of birth. This form serves as an agreement to participate in the study.
224246303|NCT04957953|OTHER|Inclusion form|"This form includes the date of the last menstrual period, vaccination data (type of vaccine, date of vaccination, 1st or 2nd injection, etc.), socio-demographic data of the pregnant woman, medical and surgical history, gynaecological and obstetrical history, a description of the current pregnancy, and the medication taken by the patient during her pregnancy....~A link to complete this form (with the unique identifier) will be sent to each woman included who has given her consent to participate."
224246304|NCT04957953|OTHER|Adverse reaction report form.|One month after each injection of the vaccine, information will be collected on any vaccination-related adverse reactions that may impact the pregnancy (fever, hypertension, etc.) or on the onset of a Covid-19 infection,
224246305|NCT04957953|DIAGNOSTIC_TEST|Follow-up report form.|In the 2 months following the expected delivery date, information will be collected on the outcome of the pregnancy (delivery, spontaneous abortion, etc.) and maternal clinical signs (pre-eclampsia, gestational hypertension, gestational diabetes, etc.). Before sending the link to this form, information will be sent to the second holder of parental authority. In the absence of opposition, data on the newborn will be collected (sex, height, weight, head circumference, Apgar, malformation, neonatal pathology, etc.)
224246306|NCT00270777|DRUG|adrenaline, promethazine, hydrocortisone|
224246307|NCT05076253|DRUG|Ivermectin|Ivermectin plus standard care
224246308|NCT05076253|DRUG|Placebo|Standard care
224246309|NCT02380560|DEVICE|Ultrasonographic examination|"An abdominal ultrasound for: Estimation of gestational age, biophysical profile (BPP), Detection of any fetal gross anomalies, Assessment of fetal growth measurement of the Amniotic Fluid Index (AFI), Detection of any abnormal placental insertion and/or uterine structural abnormalities as septate or bicornuate uterus, measuring The myometrial thickness at 4 different sites:~a) The lower uterine segment (LUS): 2cm above the reflection of the full urinary bladder (b)The anterior wall: 1cm above the maternal umbilicus. (c)Fundus: by placing the scan probe perpendicularly above the uterine fundus so that the entire curvature of the uterus is visualized.~(d)The posterior wall: through using the maternal abdominal aortic pulsation as an anatomic marker."
224246310|NCT03598101|DEVICE|TONEFITreha|The newly developed Tonefit Reha is based on the existing fitness device, the TONEFIT belt. Similar to Nordic Walking, the device aims to include upper limb activity in walking exercise to train the shoulder girdle and arm. While Nordic Walking uses poles, the existing TONEFIT belt uses body-worn resistance handles to actively involve the upper body. It is worn around the waist, like a belt. The two independent pull-push elements with non-adjustable resistance on each side allow increased intensity for strengthening and endurance training during walking, particular for upper extremities and trunk stability.
224246311|NCT01725958|DIETARY_SUPPLEMENT|Nutritional supplement and protein shakes|
224246312|NCT04547517|OTHER|Evaluation of Counselling competencies|To complete a set of questionnaires
224246313|NCT02005419|DRUG|Gemcitabine|Patients receive gemcitabine 1000 mg/m\^2 (iv, 30 minutes) on days 1, 8, and 15 for 3 weeks, followed by one week without treatment, and also receive placebo (Arm I)/ metformin (Arm II) on days 1-28. Treatment repeats every 4 weeks for up to 6 circles in the absence of disease recurrence or unacceptable toxicity.
224246314|NCT02005419|DRUG|Metformin|Metformin will be administered at a dose of 500 mg twice daily. If well tolerated, the dose will be increased to 1000 mg twice daily in the second week. Treatment repeats every 4 weeks (2 g on days 1-28) for up to 6 circles in the absence of disease recurrence or unacceptable toxicity.
224246315|NCT02005419|DRUG|placebo|Placebo will be administered at a dose of 500 mg twice daily. If well tolerated, the dose will be increased to 1000 mg twice daily in the second week. Treatment repeats every 4 weeks (2 g on days 1-28) for up to 6 circles in the absence of disease recurrence or unacceptable toxicity.
223770648|NCT01824745|PROCEDURE|quality-of-life assessment|Ancillary studies
223770649|NCT01824745|OTHER|questionnaire administration|Ancillary studies
224246316|NCT04019834|DRUG|regional nerve block with local anesthesia of bupivacaine with steroid|Patient will receive titrated sedation with a combination of fentanyl and versed prior to the start of the block. An ultrasound will be used to identify the fascial planes for either pectoral, serratus, or erector spinae nerve blocks. A block needle will be passed into the fascial plane and injectate will be deposited. The injectate in the active arm will contain a combination of bupivacaine, epinephrine and dexamethasone.
224246317|NCT04019834|OTHER|Placebo regional nerveblock with normal saline|Patients who are randomized to placebo will undergo the same procedure with the exception of injection of 10cc of normal saline into the subcutaneous tissue .
224246318|NCT04513587|BEHAVIORAL|CBT-based weight loss model|Methods of cognitive behavioral psychotherapy
224246319|NCT04513587|BEHAVIORAL|Control|Treatment as usual
224246320|NCT06407206|OTHER|Sub occipital muscle inhibition technique and conventional therapy|Patient is in supine position Therapist sits near the head of the participant and places his hand below the head of the participant With the pads of hand therapist palpates the arch of atlas between the occipital protuberance and spinous process of axis and place the middle and ring finger over it by flexing the metacarpophalangeal joint in 90 degrees of flexion, base of skull will rest on hands Pressure is exerted in upward direction towards the therapist and is maintained for two minutes so that the muscle scan relax Participants are guided to keep their eyes close in order to avoid movement which affects the tone of sub occipital muscle
224246321|NCT06407206|OTHER|conventional therapy|Transcutaneous electrical nerve stimulation at lower back and hamstring muscles (pulse rate: 4Hertz, pulse duration: 150µs for 15mins) Hot pack ( 15mins),Ankle pumps (15 reps with 5 sec hold), Knee Range of motions (flexion and extension,10 reps),Quadriceps set (10 reps,5 sec hold),Vastus Medialis oblique (10 reps 5 sec hold),Gluteus sets (10 reps, 5 sec hold),Single knee to chest (10 reps with 10 sec hold) McKenzie exercises (10 reps with 10 sec hold and 10 sec rest),Stretching of calf and hamstring muscles (passive stretching,7 reps with 5 sec hold).
224246322|NCT04433611|DRUG|2% lidocaine|"intrauterine infusion of 2% lidocaine (Rafa laboratories, Israel) just prior to HyFoSy~The VAS consisted of a 10 cm line ranging from 0 to 10 (anchored by 0=no pain and 10=very severe pain). Patients were asked to mark the number that represented their perceived level of pain. Based on the VAS scores, the pain level ratings were classified as: mild (rated 1-3), moderate (4-6) or severe (7-10)."
224246323|NCT04433611|DRUG|0.9 % normal saline|intrauterine infusion of 0.9 % normal saline
224246324|NCT04535830|DEVICE|Flash Glucose Monitoring System|During the three months experimental period,participants at the FSL group will be asked to wear a flash glucose monitoring sensor for a period of 2 weeks and have a care visit every month while people at SMBG group will receive a care visit every month.
224246325|NCT01082523|OTHER|Text message reminders|Subjects in this arm will receive twice daily automated text messages reminding them to apply their medications.
224246326|NCT01274039|DRUG|Acetazolamide for glaucoma patients to lower eye pressure|Acetazolamide tablets 3 times daily for 3 to 4 weeks
224246327|NCT05934825|BIOLOGICAL|Injectable suspension of allogeneic adult mesenchymal stem cells|Cell therapy treatment will be administered in a single dose at the beginning of the study. The treatment consists of the administration of a single dose of allogeneic adult mesenchymal stem cells from adipose tissue. The dose is 120 million cells (drug volume: 20 ml, concentrated at 6 million cels/ml).
224246328|NCT05934825|OTHER|Placebo|The placebo consists of the administration of the excipient of the suspension without cells. The excipient is a mixture of 50% hyaluronic acid, 49% DMEM without phenol red and 1% L-Alanine-L Glutamine.
224246329|NCT03187522|DEVICE|TREO Stent-Graft System|The TREO® Stent-Graft is designed for use in the management of patients with AAAs and is composed of self-expanding nitinol stents sutured to polyester vascular graft fabric.
224246330|NCT00002053|DRUG|Pentamidine isethionate|
224246331|NCT05038293|DEVICE|Automated mouthpiece-based toothbrush|One-time use during study visit.
224246332|NCT05038293|DEVICE|Manual toothbrush|One-time use during study visit.
224246333|NCT02195193|OTHER|Integrated care|an integrated care model for ACS and depression delivered by a collaborative team composed of cardiologists/internists and nurses in the same rural county hospital. The collaborative team will be able to provide medical services for the diagnosis and treatment at acute phase of ACS during hospitalization, ACS secondary prevention therapies at and after discharge, and screening and treatment of depression depressive symptom during hospitalization and after discharge. The core of the interventions includes: depressidepressive symptomon screening and classification, individual counseling and medical treatment of depression, group counseling and health education, and follow-up for ACS and depression treatments compliance, IT- system- assisting theassisted management and necessary referral.
223665827|NCT04874051|DEVICE|Experimental Group|The experimental treatment will be provided by means of the OAK system. This device consists of 1 cabinet with 2 independent balance boards, 2 monitors (one for the physiotherapist and one for the patient) and 3 wireless IMUs (one for the left lower limb, one for the right lower limb and one for the trunk). The 2 balance boards provide body weight transfer exercises, while the wireless motion sensors provide one leg stance exercises or trunk exercises in a virtual environment.
223665828|NCT04874051|OTHER|Control Group|The Control Group will perform conventional balance exercises similar to the exercises provided with the OAK system.
223665829|NCT05926115|DIAGNOSTIC_TEST|Diagnostic Ultrasound|During the initial visit, a transvaginal or transabdominal pelvic ultrasonography will be performed in all participants, based on the sexual history and consent form by trained gynecologists who are part of study investigators. A transvaginal ultrasound is the accepted and validated method to assess the ovarian morphology in the study of patients with PCOS.
223770650|NCT02075944|BEHAVIORAL|High intensity aerobic exercise|
223770651|NCT02075944|BEHAVIORAL|Low intensity aerobic exercise|
223770652|NCT01859715|DRUG|Oxycodone|Subjects given oxycodone 5mg by ED provider decision or by triage nurse randomization.
223770653|NCT01859715|DRUG|Hydrocodone|Subjects given hydrocodone/acetaminophen 5mg/500mg by ED provider decision or by triage nurse randomization.
224246334|NCT02708693|DRUG|Triamcinolone Acetonide|ultrasound-guided injection using 1ml of 10 mg (10mg/ml) triamcinolone acetonide (Shincort)
223770654|NCT01859715|DRUG|Ondansetron|Subjects given ondansetron 4mg for reported nausea or vomiting. Treatment determined either by triage nursing protocol or by provider discretion. Observational intervention only.
224246335|NCT02708693|DEVICE|thermoplastic wrist splint|thermoplastic wrist splint with wrist placed in a neutral position
224246336|NCT02708693|DRUG|lidocaine hydrochloride|ultrasound-guided injection using 1 ml of 2% lidocaine hydrochloride (Xylocaine)
224246337|NCT01171989|BIOLOGICAL|GSK2202083A vaccine|Intramuscular, one dose.
224246338|NCT01171989|BIOLOGICAL|Infanrix hexa™|Intramuscular, one dose.
223665830|NCT05926115|DIAGNOSTIC_TEST|Venous puncture|After an overnight fast of at least 6 hours (ideally), a 18 ml sample of venous blood will be collected from each study participant (i.e., the basal fasting sample). About 12 ml of the venous blood will be collected in plain tubes for serum cryopreservation and subsequent analysis, and the remainder in plain tubes for immediate glucose estimation in serum.
224246339|NCT01171989|BIOLOGICAL|Menjugate™|Intramuscular, one dose.
224246340|NCT01171989|BIOLOGICAL|NeisVac-C™|Intramuscular, one dose.
224246341|NCT01171989|BIOLOGICAL|Synflorix™|Intramuscular, one dose.
224246342|NCT02887339|OTHER|Training Website|Additional training website can be found at gtextraing.org
224246343|NCT02887339|OTHER|Control|Standard training given by OPOs and GTEx staff
224246344|NCT04166734|DRUG|Pembrolizumab|"Pembrolizumab will be continued dosed at 200 mg given every 3 weeks~Drug: Pembrolizumab Pembrolizumab in week 1 dosed at 200 mg (prior to SBRT) and then treatment with pembrolizumab will be continued dosed at 200 mg given every 3 weeks."
224246345|NCT04166734|RADIATION|Stereotactic Body Radiotherapy (SBRT)|Stereotactic Body Radiotherapy (SBRT) 30 Gy 3 fractions (#)
224321713|NCT06290648|BEHAVIORAL|Forging New Paths|The study intervention is Forging New Paths (FNP) a newly developed intervention for people with mental illness with criminal legal system involvement that is designed to be delivered in community mental health settings. FNP combines Cognitive Behavioral Treatment (CBT) techniques with social learning principles in a group format. The intervention is organized into a modular format to create a flexible intervention structure. It includes 5 treatment modules each consisting of two to four group sessions for a total of 14-16 sessions, which may be delivered over multiple meetings at the facilitators' discretion. The intervention is designed to be delivered to 8-12 people by two intervention facilitators. It can be delivered in person, virtually, or in a hybrid format.
224321714|NCT04228172|GENETIC|DNA/GeneticTesting|Subjects will be tested for GBA and LRRK2 mutation status at baseline.
224321715|NCT04228172|RADIATION|FDG PET scan|18F-Fluoro-2-deoxy-glucose (FDG) PET scan is a nuclear medicine test that measures glucose metabolism (energy) in your brain at baseline and 18 months later.
223665831|NCT00296205|DRUG|Cyclophosphamide|
223665832|NCT01182844|DIETARY_SUPPLEMENT|Lactobacillus casei Shirota|3 bottles of Yakult(R) light per day
224246346|NCT01627158|DRUG|Budesonide/formoterol Easyhaler|Budesonide/formoterol Easyhaler
224246347|NCT01627158|DRUG|Symbicort Turbuhaler|Symbicort Turbuhaler
224246348|NCT01627158|DRUG|Charcoal and Budesonide/formoterol Easyhaler|Charcoal and Budesonide/formoterol Easyhaler
224246349|NCT01627158|DRUG|Charcoal and Symbicort Turbuhaler|Charcoal and Symbicort Turbuhaler
224246350|NCT02339558|OTHER|Laboratory Biomarker Analysis|Correlative studies
224246351|NCT02339558|BIOLOGICAL|Nivolumab|Given IV
224246352|NCT06042335|DEVICE|DAISe EZ|DAISe Thrombectomy System for mechanical thrombectomy
224246353|NCT03587493|OTHER|BLOOD SAMPLE ANALYSIS|Peripheral venous blood sampling just before lung transplantation, at day 15 and at post-transplantation M1 for lymphocyte phenotyping by cytometry
224246354|NCT02259283|DEVICE|Hybrid Knife|POEM (Per oral endoscopic myotoymy) technique performed with the hybrid knife which combines injection and cutting in the same device.
224246355|NCT02697747|OTHER|Education|Educational intervention in the use of ultrasound to identify landmarks
223665833|NCT03225508|DIAGNOSTIC_TEST|Linear Ultrasound to Measure Diaphragmatic Movement|A linear 10-12 MHz ultrasound probe will be used to determine diaphragmatic excursion, by examining the zone of apposition. Diaphragmatic excursion will be measured from end inspiration to end expiration. The measurement will be repeated twice, and an average of the two will be taken. The distance between the two external skin markings, one at the end of full expiration and one at the end of full inspiration will indicate the excursion of the diaphragm.
223770655|NCT02993679|PROCEDURE|reconstruction of the ACL and anterolateral ligament|reconstruction of the ACL and anterolateral ligament
224246356|NCT00906477|PROCEDURE|Modified CI therapy|10 treatment days 3 hours a day: Shaping exercises 2 hours. Task practice 0,5 hours. Behavioral therapy (Transfer package) 0,5 hour. Encouragement to wear a restraining mitt on the least affected arm for all safe activities.
224246357|NCT04043377|DRUG|injection of 68Ga-DOTATATE|PET after injection of 68Ga-DOTATATE 2 MBq/kg (Max. 200 MBq); intra-venous; single injection, at M0 followed by a coronary CTA to localize the signal in coronary arteries Consultation and low-dose cardiac CT for coronary calcium scoring performed at M12 and M24 after inclusion.
224246358|NCT04028440|BIOLOGICAL|Autologous γδT cells|Cells will be extracted by apheresis, followed by expanding and activating. The autologous γδT cells product will be adoptive transferred.
224246359|NCT01185691|DEVICE|Impella 2.5|Impella 2.5 implant in patients with acute decompensated heart failure
224246360|NCT05310591|DRUG|Decreasing starting times for beginning nivolumab (Time to Event Continual Reassessment Method (TITE-CRM) )|"Patients included first receive a lympho-depleting chemotherapy by Fludarabine / Cyclophosphamide. tisagenlecleucel infusion should then be administered 2 to 14 days after completion of chemotherapy.~Nivolumab (Opdivo®) will be given intravenously at 3mg/kg every 2 weeks. It will include patients with MRD negative disease status.~1. Four decreasing starting times for beginning nivolumab (day 14, day 11, day 5 and day -1) will be available for testing~2. Patients will be enrolled sequentially by cohorts of 3 with escalation between cohorts based only on the limiting toxicities between infusion and D28~Nivolumab will be given until 12 months after tisagenlecleucel infusion in case of response."
224246361|NCT05310591|DRUG|Nivolumab starting at day -1|"It will include relapsed patients. Patients included first receive a lympho-depleting chemotherapy by Fludarabine / Cyclophosphamide. tisagenlecleucel infusion should then be administered 2 to 14 days after completion of chemotherapy.~Nivolumab (Opdivo®) will be given intravenously at 3mg/kg every 2 weeks.~-nivolumab starting at day -1.~Nivolumab will be given until 12 months after tisagenlecleucel infusion in case of response."
224321716|NCT04228172|OTHER|MRI scan|Magnetic Resonance Imaging (MRI) is a noninvasive scan which produces detailed pictures of the brain using a magnetic field. In addition, a special type of MRI, called resting state functional MRI (rs-fMRI), will measure and map brain activity. Conducted at baseline and 18 months later.
223665834|NCT03225508|DIAGNOSTIC_TEST|Curvilinear Ultrasound to Measure Diaphragmatic Movement|A curvilinear 2-5 MHz ultrasound probe will be used to determine diaphragmatic excursion, by examining the dome of the diaphragm. M-mode will be used to image the motion of the diaphragm from end inspiration to end expiration. The measurement will be repeated twice, and an average of the two will be taken.
223665835|NCT03225508|DIAGNOSTIC_TEST|Pulmonary function tests|Bedside pulmonary function tests to measure forced vital capacity (FVC). The FVC measures the maximal volume of gas that can be expired as forcefully and rapidly as possible after a maximal inspiration to total lung capacity. This measurement will help determine if the patient has any obstructive or restrictive diseases of the airways. Three measurements will be taken.
223665836|NCT05227040|DEVICE|Nintendo Ring Fit Adventure Exergame|Participants in the RFA group were required to exercise for 30 minutes three times per week (in adventure mode) for 4 weeks. The initial exercise intensity was set according to the instructions given by the virtual coach during the first game and was gradually adjusted according to the game instructions. The research continued to track the RFA group subjects and continued to encourage the completion of 4 weeks of physical activity training.
223665837|NCT04159298|DEVICE|Top Spin 360|The TopSpin360 is a dynamic multi-planar neuromuscular training device that has been shown to improve static and dynamic multi-planar neck strength in a healthy athletic population
224246362|NCT04253366|DEVICE|Clinical investigation device class IIa not marked CE|Patients should perform MammoWave exam. A short visit should be performed and during this visit a qualitative differentiation would be performed between patients with high density breast, and patients with low density breast. After the patients will be ready for the MammoWave exam. The exam will be composed of two phases: the data acquisition and the data processing. During the acquisition that should takes about 10 minutes the patients would be lying in a prone position, on a bed which is part of the MammoWave. The upper part of MammoWave has a container cup shape, which contains the breast, which also has the function of separate it from the internal parts of the device. After patient is on the bed and MammoWave would start to perform the acquisition. Once the acquisition is completed, the data will be processed through an imaging algorithm, which is integrated in the device. The final output will be composed by one or more images, plus one or more parameters describing the images.
224246363|NCT06264960|BEHAVIORAL|Music therapy|After the patient was admitted to the angiography laboratory, approximately 10 minutes before the angiography procedure commenced, they were seated and allowed to relax. Music was played using a digital MP3 player.
224246364|NCT06264960|BEHAVIORAL|Breathing exercise|Individuals in the breathing exercise group were made to do breathing exercises by the researcher in the patient room 30 minutes before coronary angiography. The exercises were performed in a single patient room, in a quiet and calm environment. During the first 5 minutes, the researcher explained how the exercise was done with pictures and showed it to the patient. The patient was then asked to do the exercise for 10 minutes under the supervision of the researcher.
224246365|NCT00645762|DEVICE|RS-Series Rhinosinusitis Treatment System|Single arm
224246366|NCT00645762|DEVICE|FinESS Balloon|
224246367|NCT01247701|DRUG|Busulfan|Busulfan dosing will be as follows: Patients \< 12 kg: 1.1 mg/kg/dose IV every 6 hours for 16 doses total; patients \> 12 kg: 0.8 mg/kg/dose IV every 6 hours for 16 doses. It will be given on Days -9, -8, -7 and -6.
224246368|NCT01247701|DRUG|Cyclophosphamide|Cyclophosphamide (50 mg/kg/dose) will be given IV on Days -5, - 4, -3, and -2 over 1 hour. The total dose to be given over 4 days is 200 mg/kg.
224246369|NCT01247701|DRUG|Fludarabine|Fludarabine will be given IV daily over 1 hour for 3 days. Dosing will be as follows: for patients ≤ 10 kg: 1.3 mg/kg; for patients \> 10 kg: 40 mg/m\^2.
224246370|NCT01247701|PROCEDURE|Cord Blood Stem Cell Infusion|The cord blood stem cells will be infused on Day 0.
224246371|NCT01795872|PROCEDURE|Several diagnostic procedures|No drug will be assigned, diagnostic assessment within the study.
224246372|NCT04533269|OTHER|Arnica montana, Ledum palustre|Homeopathic
224246373|NCT01608269|DRUG|Abacavir/Lamivudine|one tablet once a day
224246374|NCT04690101|OTHER|none, this is an observational study|none, this is an observational study
223665838|NCT05543993|DRUG|Bivalent COVID-19 Booster|Bivalent COVID-19 Booster by Pfizer or Moderna
223665839|NCT06811376|BEHAVIORAL|Spiritual Care Intervention #1|Experimental
223665840|NCT06811376|OTHER|Spiritual Care Intervention #2|Active Comparator
223665841|NCT01457352|DRUG|SPARC0921|
223665842|NCT01457352|DRUG|Placebo0921|
224246375|NCT02875769|PROCEDURE|Dental prophylaxis|Full mouth dental prophylaxis (FMDP) was conducted in one appointment lasting 10 minute, using an ultrasonic scaler at a frequency of 25 kHz (Cavitron Select SPC, Dentsply professional, York, PA, USA) at less than 50% power. The FMDP performed without anesthesia and in order to eliminate supragingival plaque, calculus and stainings.
224246376|NCT02875769|DRUG|Mouthwash CPC+Zn+F|The volunteer rinsed with pre-procedural mouthwash containing 0.075% cetylpyridinium chloride, 0.28% zinc lactate and 0.05% sodium fluoride in an Alcohol-free base for one minute, 20 ml of solution and then expectorated all remaining liquid.
223665843|NCT00040300|DRUG|Racivir|
223665844|NCT00529607|DRUG|contrast echocardiography|directly after PCI, at 24 h after PCI, before discharge and at 6 months
223665845|NCT00529607|PROCEDURE|2D and 3D echocardiography|directly after PCI, at 24 h after PCI, before discharge and at 6 months
223665846|NCT00529607|PROCEDURE|cardiac MRI|before discharge and after 6 months
223665847|NCT00529607|PROCEDURE|blood sampling|"routine lab work plus infarction and inflammation biomarkers~1: before PCI, after PCI, at 34 hours, at discharge, at 6 months 2 and 3: one blood sample in total before PCI in 2 and at any time in 3"
223665848|NCT03437616|BEHAVIORAL|Tulppa rehabilitation|The intervention includes health education on e.g. healthy diet, weight management, physical activity and psychosocial coping as well as peer discussions and physical exercises.
223665849|NCT01562093|DRUG|corticosteroid nasal spray|fluticasone furoate 55 µg (formula containing anhydrous glucose, dispersible cellulose, polysorbate 80, benzalkonium chloride, disodium edetate, purified water) once daily in each nostril for 3 months
223665850|NCT01562093|DRUG|placebo nasal spray|formula containing anhydrous glucose, dispersible cellulose, polysorbate 80, benzalkonium chloride, disodium edetate, and purified water, once daily in each nostril for 3 months
223665851|NCT06335004|DIAGNOSTIC_TEST|Magnetic resonance imaging|Patients will undergo a magnetic resonance imaging for clinical purposes to which additional sequences. Post gadolinium research sequences will be acquired only if intravenous gadolinium needs to be administered for clinical purposes.
223665852|NCT04424953|DEVICE|McGrath videolaryngoscope|A brand of a commonly-used videolaryngoscope which has a camera at the end of the laryngoscope to visualize the vocal cords
224246377|NCT02875769|DRUG|Mouthwash CHX|The volunteer rinsed with pre-procedural mouthwash containing 0.12% CHX with 10% alcohol for one minute, 20 ml of solution and then expectorated all remaining liquid.
224246378|NCT02875769|OTHER|No rinsing|The volunteer did not rinse with any pre-procedural mothwash.
224246379|NCT02875769|OTHER|Water|The volunteer rinsed with pre-procedural mouthwash containing water from a three-way syringe for one minute, 20 ml of water and then expectorated all remaining liquid.
224246380|NCT04166630|DEVICE|Clinical Electrical Stimulator|Conductive electrodes will be on the skin at each end of the tested muscle(s). Each subject will have two target muscle groups tested (extensor carpi radialis longus, and tibialis anterior). Each muscle will be stimulated at three separate stimulation frequencies (2 Hz, 4 Hz, and 6Hz) over 3 minutes each, for a total of 9 minutes of stimulation per muscle. The clinical electrical stimulator will deliver mild electrical stimulations to the muscle (20-100 mA).
224246381|NCT04351425|DEVICE|Weaning to crib|We weaned the infants into two groups. Group A, 1.6 kg
224246382|NCT04351425|DEVICE|Weaning from incubator|We weaned the infants into two groups. group B, 1.4 kg
224246383|NCT01628835|BEHAVIORAL|Low dietary glycemic index diet|Based on the national diet and physical activity recommendations for pregnant women (total energy intake, protein and vitamin etc.), counseling for a low dietary glycemic index diet will be provided
224246384|NCT01628835|BEHAVIORAL|National recommendation diet|Provision of food and dietary counseling according to the national prenatal nutrition recommendation without GI information
224246385|NCT04747535|DEVICE|Auto-CPAP|AIrSense 10, Auto-CPAP, Minimum pressure 5 cm water, maximum pressure 10 cm water
224246386|NCT04747535|DEVICE|CPAP since before|A CPAP the patient uses since before because of previously diagnosed obstructive sleep apnea
224246387|NCT00001135|DRUG|Nevirapine|
224246388|NCT05420896|OTHER|Manual Therapy|Upper cervical spine mobilization Posterior-anterior mobilization of the fifth cervical vertebra Suboccipital inhibition Suboccipital mobilization Trigger point application to my masseter, temporal and sternocleidomastoid muscles Intraoral and extraoral myofascial release Intraoral sphenopalatine ganglion technique TMJ mobilization Massage for chewing muscles The 45-minute treatment program, which includes applications including the techniques above, will be applied to the patients randomly assigned to the study group once a week for a total of 4 weeks.The changes in muscle activity of the masseter and anterior temporalis bilaterally will be recorded with EMG.
224246389|NCT04579770|DIETARY_SUPPLEMENT|Ketone ester|75g ketone ester in the form of a drink \[96% (R)-3-hydroxybutyl (R)-3-hydroxybutyrate, Oxfordshire, UK)\] will be provided.
224246390|NCT04579770|OTHER|Sodium bicarbonate|Sodium bicarbonate - widely accessible food ingredient will be provided.
224246391|NCT04579770|OTHER|Placebo|Placebo
224246392|NCT05176015|DEVICE|Frenzel Lens|pair of magnifying glasses (+20 dioptres) that are worn by the patient and an illuminating system. On using Frenzel goggles, the nystagmus is better seen as a result of eyes being magnified and inhibition of visual fixation.
224246393|NCT05176015|DIAGNOSTIC_TEST|Diagnostic Algorithm|"A diagnostic algorithm using the TiTrate approach: continuous, Intermittent, trigger or spontaneous.~The diagnostic algorithm use the REDCap software that include different videos to illustrate diagnostic tests and nystagmus types. Different maneuvers: HINTS+ battery, Dix-Hallpike test, Supine Roll test.~Different Particle Repositioning Techniques will be proposed according to specific tests: Epley and Gufoni maneuvers.~Risk Score is used to assess stroke risk for transient ischaemic attack (TIA): ABCD2 and the Canadian TIA Risk Score"
224246394|NCT03397251|DEVICE|AMDS|The device will be implanted during an already planned surgical intervention for aortic dissection repair. The participant will be observed and data gathered during the surgery and routine standard of care follow up visits.
224246395|NCT00096447|DRUG|lapatinib ditosylate|
223665853|NCT04424953|DEVICE|Direct laryngoscope|Classic direct laryngoscope that depends on visualization of the vocal cords by the operator
223665854|NCT02972567|DIETARY_SUPPLEMENT|Lactobacillus spp|9 log10 cfu/capsule. 1 capsule/day for 12 weeks
223665855|NCT02972567|DIETARY_SUPPLEMENT|Control|Maltodextrin
223665856|NCT00512629|DRUG|Omegaven|Omegaven is a fish based intravenous fat emulsion
223665857|NCT00512629|DRUG|Intralipid|Intralipid is a plant based intravenous fat emulsion
223665858|NCT04168736|OTHER|Feasibility and Acceptability of Genetic Counseling Materials|"To determine the feasibility and acceptability of a communication aid in sharing genetic test results with family members.~To determine the utility of a communication aid in sharing information. To determine the impact of patient focused information sheets on patient knowledge of genetic testing."
223665859|NCT02277561|PROCEDURE|diffusion tensor imaging|Undergo VB-DTI
223665860|NCT02277561|RADIATION|whole-brain radiation therapy|Undergo WBRT
224246396|NCT03696745|OTHER|autologous umbilical cord blood stem cells|autologous umbilical cord blood stem cells treatment for brain injury for safety and effect evaluation
224246397|NCT03696745|DRUG|0.9% Sodium-chloride|0.9% Sodium-chloride in control group
224246398|NCT05361330|DRUG|Shuganjieyu capsule|2 capsules each time, twice per day. According to the study progress, the intervention can be adjusted to 4 capsules each time, twice per day
224246399|NCT05361330|DRUG|Fluoxetine|Medication in basic study period: Fluoxetine (20 mg, once a day) Medication in the expanded study period: After 8 weeks of basic study period, if the reduction rate of HAMD-17 total scores is below 50 %, for the treatment group, the dosage of Fluoxetine will be adjusted to 40 mg / time, once a day.
224246400|NCT00002662|DRUG|docetaxel|
224246401|NCT00002662|DRUG|paclitaxel|
224246402|NCT05522361|DRUG|Risdiplam|administered to participants per product label insert
224246403|NCT04510545|DIAGNOSTIC_TEST|Endobrain, Computer Aided Diagnosis (CAD)|Artificial intelligence
224246404|NCT06448663|DIETARY_SUPPLEMENT|alpha-lactalbumin, fructooligosaccharides, inulin|"The first round supplementation will be administered for 3-month period (i.e. 12 weeks). One dose/day (2g sachet) is intended to be administered orally once a day after dissolving in water.~At the scheduled visits/phone contacts \[i.e., baseline, 12 weeks, and 16 weeks (post washout)\], seizure frequency and entity of the critical episodes will be recorded. Gut microbiome characterization, clinical scales and dietary intake will be assessed."
224246405|NCT06448663|DIETARY_SUPPLEMENT|alpha-lactalbumin, sodium butyrate, fructooligosaccharides, inulin|"The second round supplementation will be administered for 3-month period (i.e. 12 weeks). For participants weighing \<30 kg, a 4 g dose (i.e., one 4 g sachet) is intended to be administered orally once a day after dissolving in water. For participants weighing ≥30 kg, a 4 g dose (i.e., 4 g sachets) is intended to be administered orally twice a day (12h interval) after dissolving in water.~At the scheduled visits/phone contacts \[i.e., 28 weeks and 32 weeks (post washout)\], seizure frequency and entity of the critical episodes will be recorded. Gut microbiome characterization, clinical scales and dietary intake will be assessed."
224246406|NCT05215535|RADIATION|Abbreviated MRI of the liver/abdomen|"The MRI examinations of the liver/abdomen will be performed at the same time as the pelvic MRI. A 1,5 T scanner will be used together with a dedicated torso/abdominal coil. An abbreviated MRI liver protocol includes 3 different sequences as follows:~1. Axial T2-weighted respiratory triggered sequence with 5 mm slice thickness.~2. Axial diffusion weighted spin echo respiratory triggered sequence with fatsat with b-factors 50/800 s/mm2 and ADC calculation maps, 5 mm slice thickness~3. An axial breath-hold 3D T1-weighted gradient echo with fatsat with 4 mm slice thickness, gap 2 mm, contrast enhanced venous phase and in a 3 min equilibrium phase, using regular i.v bolus injection of gadolinium contrast medium with standard clinical dose."
224246407|NCT05215535|RADIATION|Combined single venous and 3 min equilibrium phase CT of the abdomen/liver|The CT examination of the liver will be performed as a combined examination in a single venous phase starting with the thoracic region directly followed by the abdomen down to the pelvis. An additional 3 min equilibrium phase of the liver only will end the examination. Regular iodinated low-osmolar non-ionic contrast media will be used of 350 mg I/ml using a power injector, 2-4 ml/s, 100-150 ml dependent on patient weight and kidney function. Reconstructed images in axial, coronal and sagittal plane will be performed.
224246408|NCT03601819|DRUG|Pacritinib|Patients will receive continuous treatment until progressive disease, toxicity, or until any other condition for treatment discontinuation has been met.
224246409|NCT03950336|DIETARY_SUPPLEMENT|Prebiotics|Oligofructose-enriched inulin \[a combination of shorter chain oligofructose, Degree of Polymerisation (DP) 3 - 9 and longer chain inulin (DP ≥ 10), in a 50:50 ratio ± 10 %\] 12 g/day for 6 weeks
224246410|NCT03950336|OTHER|Low n-6 PUFA Diet|The Mediterranean diet pattern (MDP) with increased n-3 PUFA, saturated fatty acids (SFA) and monounsaturated fatty acids (MUFA) and reduced n-6 PUFAs food intake will be adopted as suitable Low n-6 PUFA diet.
224246411|NCT03950336|DIETARY_SUPPLEMENT|Maltodextrin|Maltodextrin consists of D-glucose units connected in chains of variable length (DP 3-17). The glucose units are primarily linked with α(1→4) glycosidic bonds. Maltodextrin is easily hydrolyzed by the intestinal enzymes and thus does not have an effect on colonic microbiota. Maltodextrin (5 g/days for 6 weeks) will be used as a placebo for the prebiotic treatment
224321717|NCT04228172|OTHER|Clinical and neuropsychological assessments|Investigator will evaluate subjects according to the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS), the standard clinical tool used to measure the severity and progression of PD. Neuropsychological evaluation will assess how one's brain functions (via pencil and paper testing), which indirectly yields information about the structural and functional integrity of the brain. Conducted at baseline and 18 months later.
224321718|NCT06040268|DRUG|Advair HFA|6 puffs (total: salmeterol 126 ug and fluticasone 270 ug) twice daily
223665861|NCT02277561|RADIATION|stereotactic radiosurgery|Undergo SRS
223665862|NCT02277561|PROCEDURE|contrast-enhanced magnetic resonance imaging|Undergo contrast-enhanced MRI
224321719|NCT06040268|DRUG|Placebo|HFA134a inhaler
223665863|NCT02277561|PROCEDURE|diffusion-weighted magnetic resonance imaging|Undergo DW MRI
224321720|NCT04319237|OTHER|Handgrip strength test|The purpose of this test is to measure the maximum isometric strength of the hand and forearm muscles.
223770656|NCT04487327|OTHER|Dry Needling|"The dry-needling treatment will consist of inserting a sterile needle into 2-4 muscles of the participant either at the MTrP or 2 cm away from the MTrP, but within the same muscle. To assist in the reduction of infection risk and protection of the participants, the site will be cleaned with alcohol prior to treatment and investigators performing the needling treatment will wear gloves and handle needles using aseptic technique throughout the procedure. Each needle insertion will last approximately 5 seconds using a pistoning (in and out) technique."
223770657|NCT05626881|DRUG|PRP|"It will include patients with melasma treated with PRP sessions every two weeks for three months. 10 ml of venous blood will withdraw by means of a wide bore needle and a vacutainer containing an anticoagulant (Acid citrate dextrose).~Double centrifugation will be done. First centrifugation, will be done for 10 minutes. After the first centrifugation, three layers will be seen , Second centrifugation will be done for 10 min, after which the platelets separate and form a grayish pellet at the bottom of the tube and the rest will be platelet-poor plasma. About 1 ml of this platelet-poor plasma will be decanted off and the platelet pellet will be resuspended in the remaining plasma to get PRP. With 10 ml blood, about 1-1.5 ml of PRP will be obtained.~PRP is injected intralesionally at the site of melasma using a 30 G hypodermic needle through an insulin syringe."
223770658|NCT05626881|DRUG|sylimarin cream|Silymarin was manufactured with concentration of 1.4%
223665864|NCT00201552|DRUG|Statin|
223665865|NCT04174365|DRUG|Brexpiprazole|Oral tablet; take once daily
223665866|NCT04174365|DRUG|Placebo|Administered orally daily for up to Week 8.
223770659|NCT01825369|DRUG|IV L-carnitine|See arm description
223770660|NCT06158880|BEHAVIORAL|Alcoholic Beverage|Participants will consume an alcoholic beverage (vodka mixed with fruit juice) that is the equivalent of 3-4 standard alcoholic drinks based on their body weight.
223770661|NCT06158880|BEHAVIORAL|Non-alcoholic Beverage|Participants will consume a nonalcoholic beverage (fruit juice) that is the isovolemic equivalent of 3-4 standard alcoholic drinks based on their body weight.
224246412|NCT03950336|OTHER|Control Diet|"Participants who will not be assigned to Low n-6 PUFA diet will be advised to follow the Canada's Food Guide recommendations (Control diet). As Canada's Food Guide Diet is also designed with the aim to support healthy eating and prevention of metabolic and chronic disorders, this diet may not be considered as a true comparator for the Low n-6 PUFA diet intervention."
224246413|NCT03220802|DIETARY_SUPPLEMENT|OMNI-BiOTiC PPI|The study product consists of a sachet containing 4g of yellowish powder made of corn starch, maltodextrin, fructo-oligosaccharide P6, inulin P2, vegetable protein and 12 bacterial strains (Bacillus coagulans W183, Bacillus subtilus W201, Bifidobacterium bifidum W23, Bifidobacterium lactis W52, Bifidobacterium lactis W51, Lactobacillus acidophilus W37, Lactobacillus acidophilus W22, Lactobacillus casei W56, Lactobacillus salivarius W24, Lactococcus lactis W19, Propionibacterium freudenreichii W200, Lactobacillus rhamnosus W71, in a concentration of 2 x 109 cfu/g).
224246414|NCT03827356|DEVICE|Inspiratory muscle trainer (IMT)|The device incorporate a unidirectional valve independent of flow to guarantee constant resistance and included a specific pressure setting (in cm H2O).
224246415|NCT02537093|BEHAVIORAL|Psychiatric Consultation|
224246416|NCT04292873|OTHER|Vitamin D supplement|Enteral supplement of 569,600 IU vitamin D
224246417|NCT06562452|DIAGNOSTIC_TEST|Injectable platelet rich fbirin|fter the leveling and alignment phase, the canines were retracted with 150gm forces. The i-PRF was prepared from the blood of each patient then injected immediately before canine retraction on the buccal and palatal aspects of the extraction sites. Digital model were obtained at five time points: before tooth extraction (T0) and in the fourth week (T1), eighth week (T2), twelfth week (T3), sixteenth week (T4) from the beginning of distalization.
223665867|NCT06909773|BEHAVIORAL|Guideline education and implementation intervention|"The intervention is implemented at the investigator level and the patient level, consisted of 3 parts：~1. Disease education~   * Investigator level:All investigators will receive COPD and CVD disease education according to Chinese Guideline pproximately 4 weeks before the first subject is enrolled.~  * Patient level:After the subjects are enrolled, the cardiologists and pulmonologist will provide disease education on their respective disease areas,education will be provided every 4 weeks until the end of the study.~2. Treatment:Cardiologists and pulmonologists will work together to provide treatment management for subjects with CVD and COPD.~3. Follow-up management:the subjects will be followed up every 4 weeks."
223665868|NCT06556992|BEHAVIORAL|FIT Teens|This intervention will consist of 16 in-person and remote group-based sessions held twice per week over 8 weeks. Sessions last 90 minutes and will be led jointly by a psychologist/therapist and exercise trainer using manualized protocols.
224246418|NCT04675372|DRUG|Dexmedetomidine|Dexmedetomidine group (Group D) was given 1.5ug/kg/h Dexmedetomidine continuous infusion
224246419|NCT04675372|DRUG|Midazolam|Midazolam group (Group M) was continuously pumped with 0.05mg/kg/h midazolam
223665869|NCT07106788|DEVICE|Aveir DR Leadless Pacemaker Implant|Patients will undergo a dual chamber leadless pacemaker system implant wherein a leadless pacemaker will be implanted in the right ventricle and right atrium
223665870|NCT07106788|DEVICE|Single-chamber atrial Aveir patients|Patients will undergo a single chamber leadless pacemaker system implant wherein a leadless pacemaker will be implanted in the right atrium
223665871|NCT07106788|DEVICE|Upgrades|Patients with an existing single-chamber leadless pacemaker will undergo a leadless pacemaker system implant wherein an additional leadless pacemaker will be implanted in either the right ventricle or right atrium to form a dual-chamber LP system.
223665872|NCT07106788|DEVICE|Roll-over|Patients with an existing active Aveir DR leadless pacemaker system are eligible to be rolled into the Aveir Japan PMS upon consent for ongoing follow-up.
223665873|NCT07109869|DRUG|Boric acid|Boric acid vaginal inserts consisting of 600 mg boric acid drug substance filled into white, opaque hypromellose capsules with no additional excipients included in the formulation. Each vaginal insert is sealed into a clear blister cavity.
223665874|NCT07109869|OTHER|Placebo|Placebo vaginal inserts containing anhydrous lactose and 1% magnesium stearate are also manufactured and filled into white, opaque hypromellose capsules. Packaged in clear blisters.
223770662|NCT06158880|BEHAVIORAL|Partner Negative Mood Manipulation|Participants will engage in a laboratory task and will then report their own and their partner's emotions following the task.
223770663|NCT06158880|BEHAVIORAL|Partner Positive Mood Manipulation|Participants will engage in a laboratory task and will then report their own and their partner's emotions following the task.
224246420|NCT01893008|OTHER|Inspiratory Muscle Training (IMT)|"The IMT protocol is tailored individually. Inspiratory load is set at 60% of the measured maximal inspiratory pressure (Pimax). The load is incrementally increased based on the rate of perceived exertion (RPE) scored on a scale from 0 to 10 which is scored by the patient after each training session. When patients score an RPE below 7, patients increase the inspiratory load of the threshold device with 5% to guarantee overload during each training session. Patients have to complete 30 dynamic inspiratory efforts twice daily.~Patients will be instructed to train at home 7 days a week until surgery with a minimum of 2 weeks.~Training will be started after the chemoradiation period (if applicable)."
224246421|NCT06563336|OTHER|EMG-driven hand robot training|"Robot rehabilitation program was applied with Hand of Hope®(Rehab-Robotics Company, Hong Kong), and EMG-driven exoskeleton. The biggest advantage of this system is that it measures the residual muscle activity values with surface EMG(sEMG) sensors. The residual muscles activity is used by giving feedback to the patient.~This treatment program, which was applied to both groups in the study, consisted of joint range of motion (ROM) exercises, stretching exercises for burn scars, strengthening exercises using putty or bands, and fine motor training such as writing and using a chopstick."
224246422|NCT06563336|OTHER|conventional occupational training|This treatment program, which was applied to both groups in the study, consisted of joint range of motion (ROM) exercises, stretching exercises for burn scars, strengthening exercises using putty or bands, and fine motor training such as writing and using a chopstick.
224246423|NCT04995783|DIAGNOSTIC_TEST|Coral FRS test|A novel clinical test to predict autoimmune medication response
224246424|NCT04470791|BIOLOGICAL|F(ab)2 antivenom therapy (antivipmyn®).|Antivipmyn is an equine origin antivenom produced by Institute Bioclon in Mexico (Silanes Laboratories, México). The snake venoms used to create the F(ab')2 fragments are from Crotalus durissus and Bothrops asper. The number of doses of each patient depended on the classification and evolution, as indicated by the manufacturer for grade II envenoming: from 6 to 10 bottles of F(ab)2 antivenom therapy, intravenously, as an initial dose. One dose (bottle) consisted of 10 mL of polyvalent concentrated and modified horse antibodies treated by enzymatic digestion to neutralize the Bothrops asper venom to not less than 780 lethal dose 50 (LD50), and the Crotalus basiliscus venom to not less than 790 LD50.
224246425|NCT04470791|PROCEDURE|Local cryotherapy.|Interval cryotherapy consisted of applying a plastic bag (the size of the bag depending on the size of the lesion, approximately 28 x 46 cm) two-thirds filled with crushed ice (frapped) wrapped in a towel applied for 20 minutes every 4 hours at the site of the snakebite throughout the hospital stay. New ice bags were used after 4 hours.
224246426|NCT06310460|PROCEDURE|Papillectomy|Papillectomy prior to bile duct cannulation during ERCP
224246427|NCT03690960|PROCEDURE|electrospun TAP nanofibers|electrospun TAP loaded nanofibers containing modified triple antibiotic paste of clindamycin , ciprofloxacin and metronidazole by electrospinning process will be placed in the root canals. The access cavity will be sealed with temporary filling material
223665875|NCT06914765|DEVICE|Endoscopic Sleeve Gastroplasty (ESG) Procedure|The ESG procedure will be performed under general anesthesia monitored by an anesthesiologist. The device that will be used is called the Apollo Endosurgery ESG System, which is the only FDA approved device for the reduction of stomach volume through endoscopic sleeve gastroplasty for adult patients with obesity. This device works by being attached to a standard upper endoscope and is inserted through the mouth and goes into the stomach. When in the stomach, the back and front wall of the stomach will be stitched together to reduce the size of the stomach and help decrease the amount of food a patient can eat and drink at one time before feeling full.
223665876|NCT06917001|DRUG|Resomelagon|Resomelagon 100mg, orally, once daily.
223665877|NCT06917001|DRUG|Placebo|Placebo
223665878|NCT06917001|OTHER|Standard Treatment|Hydration and symptomatic therapy as indicated for Dengue fever.
223665879|NCT06749067|BEHAVIORAL|Mindfulness Based Practices|Experiment 1 Group Intervention: In the first session preparation session; face-to-face meeting with the women in the experimental group and then general information about the definition, purpose and applications of the mindfulness-based practice will be given, and the lack of information about the practice, if any, will be eliminated by receiving feedback from the women. The importance of regular and timely participation in the application will be emphasised, application days will be determined and phone numbers will be taken to contact women for online applications. Then, the pre-test data consisting of Personal Information Form, Psychological Well-Being Scale, Menopause Symptoms Assessment Scale will be filled out by obtaining voluntary consent. In the first session, before starting the Awareness Practice, women will be focused on the moment with a 3-minute breathing exercise and then continue with the raisin exercise.
223770664|NCT00086580|BIOLOGICAL|FluCAM [Fludara + Campath]|"Phase A: Escalating Doses of alemtuzumab (Campath) Alone~Day 1: alemtuzumab 3 mg intravenously (IV) over 2 hours.~Day 2: alemtuzumab 10 mg IV over 2 hours if 3 mg was tolerated, else repeat 3 mg daily until tolerated.~Day 3: alemtuzumab 30 mg IV over 2 hours if 10 mg was tolerated, else repeat 10 mg daily until tolerated.~Participants were allowed 3-14 days to escalate to 30 mg. Once 30 mg was tolerated, the participant had to begin Phase B within 7 days.~Phase B: FluCAM~Cycle 1: Days 1,2,3 fludarabine phosphate administered at 30 mg/m\^2 over 30 minutes IV, followed within 1 hour by alemtuzumab 30 mg IV over 2 hours. A similar schedule is set for Cycles 2 through 6; duration of alemtuzumab infusions vary from 2-6 hours. Each 28-day period is 1 cycle. Fludarabine phosphate dosage is based on participants' body surface area at the beginning of each cycle. FluCAM administered up to a maximum of 6 cycles, based upon participants' response to therapy and toxicity."
224246428|NCT03690960|PROCEDURE|modified TAP paste|modified TAP paste will be prepared by mixing equal proportions of CIP, MET and CLIN then placed inside the root canal, access cavity will be sealed with temporary filling
224246429|NCT04088760|DRUG|TCRαβ+/CD19+ depleted allogeneic hematopoietic stem cell transplant (HSCT)|The majority of TCRαβ+ T cells and CD19+ B cells will be removed from the allogeneic graft utilizing the CliniMACS® immunomagnetic selection device (Miltenyi Biotec). The depletion process involves two phases; cell labeling (phase 1) and the automated immunomagnetic depletion process (phase 2). The CD34+ dose may be adjusted by the need to not exceed the TCRαβ+CD3+ dose threshold.
224246430|NCT03964662|DEVICE|WeReha|Rehabilitation of stroke patients with the device WeReha
224246431|NCT00607230|BIOLOGICAL|BCG|BCG vaccination at 0 and 4 weeks
224246432|NCT00607230|BIOLOGICAL|Saline|Saline vaccination at 0 and 4 weeks
224246433|NCT01848301|DEVICE|Optical Coherence Tomography|OCT imaging of the LAD coronary artery
224246434|NCT01848301|DRUG|Acetylcholine|Infusion in the coronary artery to study endothelial function
224246435|NCT01848301|PROCEDURE|Brachial Artery Flow Mediated Dilation|Assess peripheral brachial artery endothelial function
224246436|NCT04839367|DRUG|64Cu-SAR-bisPSMA|64Cu-SAR-bisPSMA
224246437|NCT05702424|DRUG|IGM-7354|IGM-7354 is a PD-L1-targeted cytokine that is designed to regulate T and natural killer cell activation, proliferation and promote their anti-tumor effects
224246438|NCT01416753|DEVICE|UCR|BVM-based regulation of ultrafiltration and conductivity
224246439|NCT01416753|DEVICE|UTR|BVM-based regulation of ultrafiltration; regulation of temperature
224246440|NCT01391793|DRUG|Placebo|Twice daily for 3 days
224246441|NCT01391793|DRUG|Dexamethasone|0.15 mg/kg/dose twice daily for 3 days
224246442|NCT01317927|DRUG|Belinostat, Warfarin|1000 mg/m2 injection infusion given in a 30 min period plus Warfarin 5mg PO
224246443|NCT04115280|DIAGNOSTIC_TEST|Primary Hyperaldosteronism diagnostic|blood sample to obtain the aldosterone to renin ratio
224246444|NCT00105196|DRUG|Aripiprazole+ ADT|Tablets, Oral, 2 - 20 mg variable dose once daily, 14 weeks
223665880|NCT06749067|BEHAVIORAL|Occupational Practices|Experiment 2 Group Intervention: In the first session preparation session, the women in the experimental group will be introduced face-to-face and then general information will be given about the definition, purpose and applications of the occupational practice, and the lack of information about the practice will be eliminated by receiving feedback from the women. The importance of regular and timely participation in the application will be emphasised, application days will be determined and phone numbers will be taken to contact women for online applications. Then, the pre-test data consisting of Personal Information Form, Psychological Well-Being Scale, Menopause Symptoms Assessment Scale will be filled out by obtaining voluntary consent. Before starting the Busyness Practice, women will be asked to choose the practice that they can do within the scope of the busyness practice such as 'hand knitting, wood painting, charcoal, origami, bead work, jewellery design, painting tables with
223770665|NCT00086580|BIOLOGICAL|fludarabine phosphate|Fludarabine phosphate (Fludara) is administered at a dose of 25 mg/m\^2 IV over 15 to 30 minutes daily for 5 consecutive days (days 1 through 5) every 28 days (per package instructions). Each 28-day period is 1 cycle. The dose of fludarabine phosphate will be based on the participant's body surface area as calculated at the beginning of each cycle. Participants treated with fludarabine phosphate up to a maximum of 6 cycles, based upon their response to therapy and toxicity.
224246445|NCT00105196|DRUG|Placebo+ ADT|Tablets, Oral, 2 - 20 mg variable dose once daily, 14 weeks
224246446|NCT03025880|DRUG|Pembrolizumab|Pembrolizumab at a dose of 200mg as an intravenous (IV) 30 minutes infusion on day 1 of each 21-day cycle. Treatment will be repeated on day 1 of each 21-day cycle until objective disease progression, clinical progression (under investigator criteria), unacceptable toxicity, death or withdrawal of consent, whichever occurs first. Patients completing 24 months of uninterrupted treatment with pembrolizumab or 35 administrations of study medication will stop pembrolizumab treatment (though may continue with gemcitabine). Subjects who stop pembrolizumab after 24 months may be eligible for up to one year of additional pembrolizumab treatment if they progress after stopping it.
224246447|NCT03025880|DRUG|Gemcitabine|Gemcitabine at a dose of 1,250mg/m2 as an intravenous (IV) 60 minutes infusion on day 1 and 8 of each 21-day cycle. Treatment will be repeated on day 1 of each 21-day cycle until objective disease progression, clinical progression (under investigator criteria), unacceptable toxicity, death or withdrawal of consent, whichever occurs first.
224246448|NCT01371162|DRUG|RO5428029|Multiple ascending doses
224246449|NCT01371162|DRUG|placebo|multiple doses
224246450|NCT04135820|DRUG|BPI-7711|BPI-7711 180 mg
224246451|NCT01498848|DIETARY_SUPPLEMENT|Cooking oils|Families were randomized to receive either soybean or sunflower oil for cooking during 4 weeks
224246452|NCT01202448|PROCEDURE|CSF analysis|The cerebrospinal fluid will be evaluated via lumbar puncture.
224246453|NCT01787708|PROCEDURE|Red light|
224246454|NCT04350970|OTHER|High flow nasal therapy|All patients underwent two cardiopulmonary exercises with constant-load at 90% of the peak workload. The high flow nasal therapy was used during all exercise test.
224246455|NCT04350970|OTHER|Non-invasive ventilation|All patients underwent two cardiopulmonary exercises with constant-load at 90% of the peak workload. The NIV was used during all exercise test.
224246456|NCT04350970|OTHER|Control|All patients underwent two cardiopulmonary exercises with constant-load at 90% of the peak workload. The control test was performed with no additional therapy.
224246457|NCT04766281|DIETARY_SUPPLEMENT|MLC901|This consists of extracts from 9 herbal components in a dark blue/light blue capsule
224321721|NCT04319237|BEHAVIORAL|Neuropsychological Assessment - Wechsler Test of Adult Reading (WTAR)|"The Wechsler Test of Adult Reading (WTAR) is a neuropsychological assessment tool used to provide a measure of Intellectual function. Participants are presented with 50 irregularly spelled words and prompted to pronounce each; the irregular grapheme-to-phoneme translations (such as the gh in the word tough) in the prompts make it difficult to pronounce without having previously learned the word. A high WTAR score is correlated with higher general intelligence as measured by the Wechsler intelligence scales."
224321722|NCT04319237|BEHAVIORAL|Neuropsychological Assessment - Repeatable Battery for the Assessment of Status (RBANS)|The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) consists of twelve subtests which give five scores, one for each of the five domains tested (immediate memory, visuospatial/constructional, language, attention, delayed memory).
224246458|NCT04766281|GENETIC|Placebo|This consists of a dark brown powder in size 0 dark blue/light blue vegetable capsule
224246459|NCT00941837|DIETARY_SUPPLEMENT|Olive Oil, Palm Olein Oil, Coconut Oil|Effect of dietary fat type in combination with high protein on plasma homocysteine levels; 5 wk each with 2 wk wash out in between
224246460|NCT03488667|DRUG|Neoadjuvant Treatment - mFOLFOX6 & Pembrolizumab|Pembrolizumab, mFOLFOX Chemotherapy
224246461|NCT03488667|DRUG|Adjuvant Treatment - mFOLFOX & Pembrolizumab|Pembrolizumab, mFOLFOX Chemotherapy
224246462|NCT00184600|DRUG|biphasic insulin aspart|Treat-to-target (individually adjusted dose), subcutaneously (under the skin) injection, once or twice daily plus option for insulin aspart
224246463|NCT00184600|DRUG|insulin detemir|Treat-to-target (individually adjusted dose), subcutaneously (under the skin) injection, once or twice daily plus option for insulin aspart
224246464|NCT00184600|DRUG|insulin aspart|Treat-to-target (individually adjusted dose), subcutaneously (under the skin) injection, twice daily plus option for insulin detemir
224246465|NCT01987011|BIOLOGICAL|MG1109|
224246466|NCT01987011|BIOLOGICAL|Placebo|
224246467|NCT01386593|DRUG|Basel cocktail+(Fluconazole, Ciprofloxacin, Paroxetine)|
224246468|NCT01386593|DRUG|"Basel Cocktail"|
224246469|NCT01386593|DRUG|Basel cocktail + Rifampicin|
224246470|NCT05430698|DRUG|PD-1antibody plus GEMOX|"1. PD-1 antibody，200mg，D1，intravenous infusion, the administration time is 60 (+15) minutes.~2. GEMOX chemotherapy : gemcitabine 1000mg/m2,D1，D8；oxaliplatin 100mg/m2,D1，intravenous infusion.~3. Three weeks is a course of treatment,a total of 6-8 courses."
224246471|NCT00286754|BEHAVIORAL|SMI|Stage-matched intervention
224246472|NCT00286754|BEHAVIORAL|HEI|Health Education Intervention
224246473|NCT00286754|BEHAVIORAL|UC|Usual Care
224246474|NCT00286754|BEHAVIORAL|SMI|Stage-matched intervention
224246475|NCT00286754|BEHAVIORAL|HEI|Health Education Intervention
224246476|NCT00286754|BEHAVIORAL|UC|Usual Care
224246477|NCT02336165|DRUG|Durvalumab|Durvalumab is administered as an IV infusion over 60 ± 5 minutes Q2W.
223665881|NCT06749067|BEHAVIORAL|Mindfulness-Based Occupational Practice|Experiment 3 Group Intervention: In the first session preparation session, the women in the experimental group will be introduced face-to-face and then general information will be given about the definition, purpose and applications of the occupational practice, and the lack of information about the practice will be eliminated by receiving feedback from the women. The importance of regular and timely participation in the application will be emphasised, application days will be determined and phone numbers will be taken to contact women for online applications. Then, the pre-test data consisting of Personal Information Form, Psychological Well-Being Scale, Menopause Symptoms Assessment Scale will be filled out by obtaining voluntary consent. In the first session, before starting the Mindfulness-Based Engagement Practice, women will be focused on the moment with a 3-minute breathing exercise, followed by a raisin exercise.
223665882|NCT06920030|DEVICE|Subcutaneous cardiac microcurrent treatment|An implantable device that emits a weak direct (DC)-microcurrent directly to the heart, using a coil electrode that is transvenously placed in the right ventricle and a patch electrode that is placed in a left thoracic subcutaneous pocket
223665883|NCT06920030|DEVICE|Infraclavicular pocket cardiac microcurrent treatment|An implantable device that emits a weak direct (DC)-microcurrent directly to the heart, using a coil electrode that is transvenously placed in the right ventricle and a patch electrode that is placed in the same infraclavicular pocket as the device itself
224246478|NCT02336165|RADIATION|Standard radiotherapy|Focal radiotherapy is administered at 2 Gy given daily 5 days per week for a total of 60 Gy over 30 fractions per local institutional guidelines or local prescribing information. On days when radiotherapy and durvalumab overlap, radiotherapy is administered first followed by durvalumab.
224246479|NCT02336165|BIOLOGICAL|Bevacizumab|Bevacizumab is administered as an IV infusion (per local prescribing information) Q2W. When durvalumab and bevacizumab are administered together (i.e., Cohorts B2, B3, and C), durvalumab is administered first followed by a 1-hour observation period, after which, bevacizumab is infused.
223665884|NCT06920030|DEVICE|Coronary Sinus cardiac microcurrent treatment|An implantable device that emits a weak direct (DC)-microcurrent directly to the heart, using a coil electrode that is transvenously placed in the right ventricle and a coronary sinus electrode
223665885|NCT06915233|BIOLOGICAL|autologous cultured chondrocytes on porcine collagen membrane|An autologous cellularized scaffold product being studied for the repair of symptomatic, single or multiple full-thickness cartilage defects of the talus with or without bone involvement in adults.
224246480|NCT01911520|DRUG|Sugammadex 2 mg/kg|Patients receive 2 mg/kg Sugammadex.
224246481|NCT01911520|DRUG|Sugammadex. 4 mg/kg|Patients receive 4 mg/kg Sugammadex.
224246482|NCT01911520|PROCEDURE|Neuromuscular monitoring.|Neuromuscular monitoring using a TOF watch SX (Organon).
224246483|NCT01911520|PROCEDURE|Clinical evaluation of residual curarization .|Every 30 min, during the first 2 hours after the end of the surgery.
224246484|NCT01579357|OTHER|blood samples|"Draw blood samples in week 1 (day 1 and day 5), in week 4 (day 1 and day 5) and in week 7 (day 1 and day 5).~day 1: pre dose, 30,60,90,120,150,180,240,300 and 360min day 5: pre dose, 30,60,90,120min"
224246485|NCT03895957|BEHAVIORAL|Virtual Reality Exposure Therapy VR Mind+|Virtual Reality Exposure Self-Therapy led by a participant
224246486|NCT03895957|BEHAVIORAL|Virtual Reality Exposure Therapy VR Mind|Treatment with Virtual Reality Exposure Therapy led by a therapist
224246487|NCT03895957|BEHAVIORAL|Cognitive Behavioral Therapy|Standard treatment for social phobia led by a therapist
224246488|NCT03274830|DEVICE|aneXys|150 patients with the aneXys cup
224246489|NCT04336696|PROCEDURE|Total thyroidectomy and central neck dissection|
224246490|NCT00215410|DRUG|Formoterol Fumarate|
224246491|NCT02726581|BIOLOGICAL|Nivolumab|Specified dose on specified days, IV (intravenous)
224246492|NCT02726581|BIOLOGICAL|Elotuzumab|Specified dose on specified days, IV
224246493|NCT02726581|DRUG|Pomalidomide|Specified dose on specified days, PO (by mouth)
224246494|NCT02726581|DRUG|Dexamethasone|Specified dose on specified days, PO
224246495|NCT01960569|DRUG|active product ( Thrombexx) assigned to arm 1|Dispense 2-3 cm of cream or gel, 2-3 times per day and carry out a light massage until complete
224246496|NCT01960569|OTHER|Placebo assigned to arm 2|
224246497|NCT02024646|DRUG|210 mg brodalumab|210 mg brodalumab administered via subcutaneous injection.
224246498|NCT02024646|DRUG|140 mg brodalumab|140 mg brodalumab administered via subcutaneous injection.
224246499|NCT02024646|DRUG|Placebo|Placebo administered via subcutaneous injection until week 24.
224246500|NCT00552669|DRUG|Oral sirolimus|Oral sirolimus given orally during 14 days plus bare metal stent implantation was compared with DES.Oral sirolimus was given as bolus of 10 mg started day before intervention followed by 3mg per day during 13 days after PCI. 180 mg of Diltiazem was added during oral administration of sirolimus .
224246501|NCT00552669|DEVICE|Drug Eluting stent|Any Drug eluting stent
224246502|NCT01762618|BEHAVIORAL|Cognitive Behavioral Therapy Group|Therapy Groups
224246503|NCT01844375|DIETARY_SUPPLEMENT|Carbohydrate group|The patients will be given 12.5% carbohydrates drink 800 mL the night before surgery, between 1900 and 2400 h, and another 400 ml in the morning.
224246504|NCT01844375|OTHER|Control group|The patients will be given water 800 mL to drink the night before surgery, between 1900 and 2400 h, and another 400 ml in the morning.
224246505|NCT01689792|DRUG|MOVIPREP|
224246506|NCT01689792|DRUG|CitraFleet|
224246507|NCT01707134|DRUG|insulin aspart|Injected subcutaneously (s.c, under the skin) as meal time insulin
224246508|NCT01707134|DRUG|human soluble insulin|Injected subcutaneously (s.c, under the skin) as meal time insulin
224246509|NCT01707134|DRUG|insulin NPH|Will be administrated subcutaneously (s.c, under the skin) once or twice daily as basal insulin
224246510|NCT04000386|OTHER|zinc oxide nanoparticles coated socks|zinc oxide nanoparticles coated socks were given to subjects for 2 weeks
224246511|NCT04000386|OTHER|placebo socks|placebo socks were given to subjects for 2 weeks
224246512|NCT04720638|OTHER|Short fiber reinforced flowable resin composite restorations|reinforced flowable resin composite
224246513|NCT04720638|OTHER|Conventional resin composite restoration|Microhybrid resin composite
223665886|NCT06915233|PROCEDURE|Bone Marrow Stimulation|"A surgical awl or microdrill will be used to make multiple holes in the exposed base of the lesion. The microfracture procedure should result in holes that are approximately 3 to 4 mm apart.~When fat droplets can be seen coming from the marrow cavity, the appropriate depth (approximately 2 to 4 mm) has been reached.~The released marrow elements (including mesenchymal stem cells, growth factors, and other healing proteins) form a surgically induced clot that provides an enriched environment for new tissue formation."
223770666|NCT02872922|OTHER|Low intensity therapeutic ultrasound|The ultrasound equipment (Sonopulse III, 1 MHz, IBRAMED, Brazil) was calibrated with the radiation force method. In study, the head of the transducer will be positioned and applied for 5 min over the brachial artery at the same point that will be evaluated the endothelium function (Cruz et al., 2016). Continuous waveforms of ultrasound therapy (CWUT) are applied in the stationary mode for 5 minutes at a spatial averaged temporal intensity (SATA) of 0.4 W/cm2 using a transducer 1-MHz. A pulsed waveform of ultrasound therapy (PWUT) are applied (5 minutes) with a 20% duty cycle (2 ms on, 8 ms off), which represents a constant intensity of 0.08 W/cm2 SATA. In the placebo intervention, all of the procedures above are repeated, but with the ultrasound equipment powered off (Cruz et al., 2016).
224246514|NCT03020615|DRUG|Hydroxyurea|Given orally once daily.
224246515|NCT05757245|GENETIC|GMCN-508A Drug Product|Transplant of autologous hematopoietic stem and progenitor cells transduced with GMCN-508A lentiviral vector.
224246516|NCT01704677|PROCEDURE|Lumbar total disc replacement|The surgical intervention consisted of replacement of the degenerative intervertebral lumbar disc with a artificial lumbar disc device in one or two of the lover lumbal levels (L4/L5 or/and L5/S1). The ProDisc consists of three pieces, two metal endplates and a polyethylene core that is fixed to the inferior endplate when the device is implanted, and is implanted through a retroperitoneal (or transperitoneal) access.
224246517|NCT01704677|BEHAVIORAL|Multidisciplinary rehabilitation|The intervention is based on a treatment model described by Brox et al (Spine 2003;28:1913-1921) and is also described in details by Hellum et al (BMJ, May 2011). It consisted of a cognitive approach and supervised physical exercise and was delivered by a team of physiotherapists and specialists in physical medicine and rehabilitation. The rehabilitation programme lasted for about 60 hours over three to five weeks.
224246518|NCT00002905|DRUG|cyclophosphamide|
224246519|NCT00002905|DRUG|didanosine|
224246520|NCT00002905|DRUG|doxorubicin hydrochloride|
224246521|NCT00002905|DRUG|etoposide|
224246522|NCT00002905|DRUG|mitoxantrone hydrochloride|
224246523|NCT00002905|DRUG|prednimustine|
224246524|NCT00002905|DRUG|zidovudine|
224246525|NCT02336854|DRUG|Tacrobell tab. 2mg|
224246526|NCT02336854|DRUG|Prograf cap. 2mg|
224246527|NCT06305897|DEVICE|CRYONOVE (EC14_4osc)|The prototype is a variant version from that of a CE marked MD already commercialized (Cryobeauty mains, Cryobeauty Pharma SAS, France) which produces a cryogenic spray sequence (EC14). The prototype is intended to treat pigmented spots of the face (PIH spots and senile and solar lentigos).
224246528|NCT06305897|DEVICE|CRYONOVE (EC+05_1osc)|The prototype is a variant version from that of a CE marked MD already commercialized (Cryobeauty mains, Cryobeauty Pharma SAS, France) which produces a cryogenic spray sequence (EC05\_1osc). The prototype is intended to treat pigmented spots of the face (PIH spots and senile and solar lentigos).
224246529|NCT06305897|DEVICE|CRYONOVE (EC+05_2osc)|The prototype is a variant version from that of a CE marked MD already commercialized (Cryobeauty mains, Cryobeauty Pharma SAS, France) which produces a cryogenic spray sequence (EC05\_2osc). The prototype is intended to treat pigmented spots of the face (PIH spots and senile and solar lentigos).
224246530|NCT00904345|DRUG|Cetuximab|Patients will receive a single dose of cetuximab 400 mg/m (Day 0). On day 7 (+/- 1 day), a repeat biopsy will be performed. Radiation concurrent with weekly cetuximab 250 mg/m.
224321723|NCT04319237|BEHAVIORAL|Neuropsychological Assessment - Color Trails|The Color Trails test measures sustained attention and sequencing. Numbered circles are printed with vivid pink or yellow backgrounds that are perceptible to color-blind individuals. Participants rapidly connect circles numbered 1-25 in sequence and rapidly connect numbered circles in sequence, but alternates between pink and yellow. The length of time to complete each trial is recorded, along with qualitative features of performance indicative of brain dysfunction, such as near-misses, prompts, number sequence errors, and color sequence errors.
224246531|NCT00904345|RADIATION|50-60 Gy and 70 Gy|Within approximately 4 days (after single dose of Cetuximab), definitive radiation will begin (70 Gy in 35 fractions to the gross tumor, 50-60 Gy to subclinical target volumes) concurrent with weekly cetuximab 250 mg/m.
224246532|NCT04953832|BEHAVIORAL|Cognitive Training|Participants are asked to remember a series of items while solving puzzles.
224246533|NCT01590420|DEVICE|CPAP S8- Scape / Resmed|The pressure for treatment is according to PSG titration
224246534|NCT02613260|BEHAVIORAL|FIT Outreach|This arm will consist of priming patients with a postcard and a possibly a phone call two weeks prior to them being mailed a FIT kit. The FIT kits will be mailed to the patients with a letter from their clinic's care team informing them why they should complete the FIT and wordless instructions to help them complete the FIT. Two weeks after the FIT kit is mailed the patients that have not returned the kit will receive up to two reminder calls. During the phone calls the outreach workers will use health coaching techniques to encourage patients to complete the FIT. All written materials have been translated into English and Chinese and during phone calls patients will be spoken to in the language that they are most comfortable using.
224246535|NCT03247920|DRUG|Amoxicillin Clavulanate|Dose 75 mg/kg/day, (3dd 25 mg/kg). Concentration amoxicillin/clavulanic acid: 4:1
224246536|NCT03247920|DRUG|Antibiotics|Intravenous antibiotic therapy following local protocol
224246537|NCT01415557|OTHER|Non-Fortified Control Product|Non-Fortified Control Beverage
224246538|NCT01415557|OTHER|Micronutrient Fortified Test Product|Micronutrient Fortified Test Beverage
224246539|NCT03851965|DIAGNOSTIC_TEST|Soluble Urokinase Plasminogen Activator Receptor|Preoperative and postoperative determination of the Soluble Urokinase Plasminogen Activator Receptor levels in patients undergoing non-cardiac major surgery.
223770667|NCT01046916|DRUG|TAK-700|TAK-700 will be administered orally (PO) twice daily (BID) on a continuous schedule
224246540|NCT04315662|OTHER|Muscle power training with velocity loss (VL) of 10%|Subjects followed a muscle power training for 8 weeks (2 sessions per week on alternate days) using the leg extension exercise, with similar relative intensity (50% 1RM). Between weeks one and four two series will be performed per session. Then the number of series will increase to three per session. The inter-set recovery period will be always of 2-min. Velocity loss will be of 10% (VL10) in each set.
224246541|NCT04315662|OTHER|Muscle power training with velocity loss (VL) of 30%|Subjects followed a muscle power training for 8 weeks (2 sessions per week on alternate days) using the leg extension exercise, with similar relative intensity (50% 1RM). Between weeks one and four two series will be performed per session. Then the number of series will increase to three per session. The inter-set recovery period will be always of 2-min. Velocity loss will be of 30% (VL30) in each set.
224246542|NCT04859920|OTHER|Questionnaires|QLQ-C30, SF-12, HADS, SARASON, EPICES, socio-professional data
224246543|NCT04859920|OTHER|Collection of clinical data and treatments|clinical data and treatments
224246544|NCT03962686|DRUG|statin Oral Tablet plus PCSK9i|Patients in the third study cohort will receive for statin oral therapy plus 140 mg twice a month PCSK9i therapy via subcutaneous injection before to practice surgical intervention for carotid artery obstruction.
224246545|NCT00526734|BIOLOGICAL|filgrastim|
224246546|NCT00526734|BIOLOGICAL|pegfilgrastim|
224246547|NCT00526734|DRUG|melphalan|
224246548|NCT00526734|PROCEDURE|autologous hematopoietic stem cell transplantation|
224246549|NCT01760408|OTHER|all patients on Home Parenteral Nutrition|
224246550|NCT01828697|DRUG|Low dose nadroparin|"Fixed low dose nadroparin:~* \< 100 kg: 2850 IU subcutaneously once-daily~* 100 kg and above: 3800 IU subcutaneously once-daily"
224246551|NCT01828697|DRUG|Intermediate dose nadroparin|"Intermediate weight-adjusted dose nadroparin:~* \< 50 kg: 3800 IU subcutaneously once-daily;~* 50 to \< 70 kg: 5700 IU subcutaneously once-daily;~* 70 to \< 100 kg: 7600 IU subcutaneously once-daily;~* 100 kg or above: 9500 IU subcutaneously once-daily."
224246552|NCT01828697|DRUG|Low dose enoxaparin|"Fixed low dose enoxaparin:~* \< 100 kg: 40 mg subcutaneously once-daily~* 100 kg and above: 60 mg subcutaneously once-daily"
224246553|NCT01828697|DRUG|Intermediate dose enoxaparin|"Intermediate weight-adjusted dose enoxaparin:~* \< 50 kg: 60 mg subcutaneously once-daily, or;~* 50 kg to \< 70 kg: 80 mg subcutaneously once-daily, or;~* 70 kg to \< 100 kg: 100 mg subcutaneously once-daily, or;~* 100 kg or above: 120 mg subcutaneously once-daily."
224246554|NCT01828697|DRUG|Low dose dalteparin|"Fixed low dose dalteparin:~* \< 100 kg: 5000 IU subcutaneously once-daily~* 100 kg and above: 7500 IU subcutaneously once-daily"
224246555|NCT01828697|DRUG|Intermediate dose dalteparin|"Intermediate weight-adjusted dose dalteparin:~* \< 50 kg: 7500 IU subcutaneously once-daily, or;~* 50 kg to \< 70 kg: 10000 IU subcutaneously once-daily, or;~* 70 kg to \< 100 kg: 12500 IU subcutaneously once-daily, or;~* 100 kg or above: 15000 IU subcutaneously once-daily."
224246556|NCT01828697|DRUG|Fixed low dose tinzaparin|"Fixed low dose tinzaparin:~* \< 100 kg: 3500 IU subcutaneously once-daily~* 100 kg and above: 4500 IU subcutaneously once-daily"
224246557|NCT01828697|DRUG|Intermediate dose tinzaparin|"Intermediate weight-adjusted dose tinzaparin:~* \< 50 kg: 4500 IU subcutaneously once-daily, or;~* 50 kg to \< 70 kg: 7000 IU subcutaneously once-daily, or;~* 70 kg to \< 100 kg: 10000 IU subcutaneously once-daily, or;~* 100 kg or above: 12000 IU subcutaneously once-daily."
224246558|NCT01262469|DRUG|lapatinib + capecitabine|"For Lapatinib: 5 tablets of 250 mg each, once daily, until disease progression or unacceptable toxicity occurence.~For Capecitabine: 850 mg/m2 twice a day from day 1 to 14 of cycle 1 and 1000 mg/m2 twice a day from day 1 to 14 of the next cycles."
224246559|NCT01683682|DRUG|BIBF 1120|2 x 150 mg capsules, oral, daily (Start dose)
224246560|NCT01683682|DRUG|Vinorelbine|25 mg/m2 i.v. on day 1 and 8 (three-week cycle)
224246561|NCT01683682|DRUG|Carboplatin|AUC 5 i.v. on day 1 (three-week cycle)
224246562|NCT04239872|DRUG|Fluoride mouthwash|Sodium fluoride, at a concentration of 0.05% (226 parts per million (ppm) of fluoride), will be used to rinse the mouth for 1 minute and expectorated.
224246563|NCT04239872|DRUG|Calcium and fluoride mouthwash|Calcium lactate, at a concentration of 150 milimolar, will be used to rinse the mouth for 1 minute and expectorated; immediately after, a sodium fluoride rinse, at a concentration of 0.05% (226 ppm of fluoride), will be used to rinse the mouth for 1 minute, and expectorated.
224246564|NCT02365454|DEVICE|Stent Graft Placement (Nexus)|"The Nexus stent graft is introduced through a groin to the diseased location at the Aortic Arch. Depending on the patients anatomy and other medical considerations the physician may decide that blood flow to the sub-clavian artery and possibly also to the left carotid artery is required to be maintained via surgical bypass grafting, either immediately, or a few days, before the implantation. In addition to the incision for introducing the investigational stent graft, two smaller access sites are required, one at the groin on the opposite side and on into the Right Arm to the Brachial Artery.~This endovascular procedure will likely require full anesthesia. The entire procedure is assisted by an angiography imaging system."
224246565|NCT00054626|DRUG|cisplatin|
223665890|NCT07117877|DRUG|Etoposide Capsules|50 mg(25mg/pill, 2 pills at a time) orally, qd, days 1 to 14, per cycle
223665891|NCT07117877|DRUG|Bevacizumab|7.5mg/kg, i.v, q3w
224246566|NCT00054626|DRUG|gemcitabine hydrochloride|
224246567|NCT00054626|PROCEDURE|adjuvant therapy|
224246568|NCT03644264|DRUG|PA21|sucroferric oxyhydroxide is a mixture of polynuclear iron(III)-oxyhydroxide (about 33% m/m), sucrose (about 30% m/m), and starches (about 28% m/m) and contains ≤10% m/m water.
224246569|NCT03644264|DRUG|sevelamer carbonate|sevelamer carbonate tablets containing 800 mg of sevelamer carbonate.
224246570|NCT04417933|DEVICE|Tumor Electric Fields Treatment System|Patients wear two pairs of electrodes on the head for 19-22 hours a day. Each patient is required to wear the device as long as possible and not less than 6 months. The treatment has a two-day break for every four weeks.
223665892|NCT07117877|DRUG|Iparomlimab and Tuvonralimab (QL1706)|5mg/kg, i.v., q3w
223770668|NCT02965612|DEVICE|Injex|administration of Specific Immunotherapy (ITS) with car pressure injector without a needle
223770669|NCT02965612|PROCEDURE|SCIT|administration of Specific Immunotherapy (ITS) via traditional subcutaneous
223665893|NCT06836869|PROCEDURE|Laparoscopic radical hysterectomy incorporating modified tumor-free techniques|"Thoroughly examine the pelvic and abdominal cavities. Coagulation of the fallopian tubes are recommanded at the beginning of the surgery. The use of uterine manipulator is prohibited. An 8-suture at the uterine fundus is recommended. Insert a trocar 3 cm above the pubic symphysis and suspend the uterus by pulling with a needle holder. Alternative methods are also acceptable. Perform pelvic lymphadenectomy. Conduct radical hysterectomy according to the Q-M classification type C. Before incising the vagina, the upper part of the vagina must be closed (using a cable tie or suture), or the vagina can be incised transvaginally after deflating the pneumoperitoneum. Sterilized distilled water or saline solution (≥1000 mL) is used to irrigate the pelvic cavity. The vaginal stump can be sutured either laparoscopically or transvaginally."
223665894|NCT06836869|PROCEDURE|Abdominal radical hysterectomy|At the onset of surgery, comprehensively explore the pelvic and abdominal cavities. If intraperitoneal metastases are identified, radical hysterectomy should be aborted. Perform pelvic lymphadenectomy. After lymph node resection, remove the lymph nodes from the surgical field promptly. Sentinel lymph node mapping and biopsy are not performed in this study. Perform radical hysterectomy according to type C of the Q-M classification. It can be accompanied by or without bilateral salpingo - oophorectomy. For patients who retain their ovaries, bilateral ovarian transposition can be carried out. Before incising the vagina, close the upper segment of the vagina and/or the vaginal stump. This can be achieved using instruments such as a large right - angle clamp or an auricular clamp. Sterilized distilled water or saline solution (≥1000 mL) is used to irrigate the pelvic cavity.
223770670|NCT04164147|PROCEDURE|Total knee replacement|Participant will undergo total knee replacement performed via anterior parapatellar approach with either Posterior Cruciate Ligament sacrificing or retaining implant
223770671|NCT04164147|DIAGNOSTIC_TEST|CT scan|CT scans of the affected knee joint before and after the surgical procedure
224246571|NCT05084677|COMBINATION_PRODUCT|Toripalimab Combined With Concurrent Platinum-based Chemoradiotherapy|Toripalimab 240mg intravenously(IV) every 3 weeks (Q3W) concurrent with chemoradiotherapy; 6 cycles of Toripalimab 240mg intravenously(IV) every 3 weeks (Q3W) after chemoradiotherapy; Toripalimab 240mg intravenously(IV) every 6 weeks (Q6W) thereafter until the whole treatment period reached one year since the beginning.
224246572|NCT02810886|DRUG|68Ga-(HBED-CC)-PSMA|68Ga-PSMA-ligand intravenous administration duration is around one minute. Once the patient is injected, the tracer needs 60 minutes to be evenly distributed through the body. PET/CT images will then be performed.
224246573|NCT03527147|DRUG|AZD9150|AZD9150 will be administered as a 1-hour intravenous (IV) infusion on Days 1, 3, 5 of Cycle 1, followed by weekly infusions (starting Day 8 of Cycle 1 and beyond).
224246574|NCT03527147|DRUG|Acalabrutinib|Acalabrutinib will be administered orally twice daily (bid).
224246575|NCT03527147|DRUG|AZD6738|AZD6738 will be administered orally twice daily (bid).
224246576|NCT03527147|DRUG|Hu5F9-G4|HU5F9-G4 infusions will be given on Weekly (Day 1, 8, 15, and 22) during the first two 28-day cycles, then will be given every two weeks (Day 1 and Day 15) in Cycle 3 and beyond.
224246577|NCT03527147|DRUG|Rituximab|Rituximab infusions will be given Weekly starting on Day 8 (Day 8, 15, and 22) during the first 28-day cycle (4 weeks), then Day 1 of each 4 week cycle for Cycles 2-6. Starting with Cycle 8, Rituximab will be infused on Day 1 of every other cycle (every 8 weeks).
224246578|NCT03527147|DRUG|AZD5153|AZD5153 will be administered orally once per day (qd).
224246579|NCT03264898|DEVICE|Fecal immunochemical test (FIT)|FIT is a type of fecal occult blood test that uses antibodies to hemoglobin to detect blood in stool.
224246580|NCT02426762|PROCEDURE|Laparoscopic surgery|"Various laparoscopic operations are performed for participants. Once all surgical procedures are successfully applied, surgical wounds which are associated with laparoscopic surgery would be sealed by a quick sealant. In all, the following surgical wounds would be left:~* 4-5 trocar-produced incisions (5/10mm, minor incision)~* 1 sample-retrieval incision (4-5cm, small incision)"
224246581|NCT02426762|DEVICE|Skin sealant|After surgery, a quick skin sealant is applied in two layers of each wound to achieve skin closure. The sealant would be smeared twice on the wound area with 30 seconds of dry time required to form a firm seal.
224246582|NCT04060147|DRUG|Cilofexor|Tablets administered orally once daily
224246583|NCT00578552|DRUG|Placebo|Placebo pill - non active sugar pill designed to look alike to the gabapentin medication
224246584|NCT00578552|DRUG|Gabapentin - 1800 mg/day|gabapentin - 1800 mg/day for 12 weeks.
224246585|NCT00578552|DRUG|Gabapentin - 2700 mg/day|gabapentin - 2700 mg/day for 12 weeks.
224246586|NCT06092658|OTHER|No Intervention|no intervention
224246587|NCT02057458|DRUG|Sildenafil (Acute-1 hour)|Vascular function will be assessed 1 hour following oral ingestion of sildenafil (50 mg)
224246588|NCT02057458|DRUG|Sildenafil (Subchronic-4 weeks)|Vascular function will be assessed 4 weeks following 20 mg three times per day (TID) of sildenafil for four weeks
224246589|NCT02057458|DRUG|Placebo|Sugar pill designed to mimic the sildenafil treatment
224246590|NCT02149693|OTHER|high-fidelity simulation and teamwork training|
224246591|NCT02149693|OTHER|traditional resuscitation training|
224246592|NCT00510172|DRUG|Prostacyclin, PGI2|10 ng/kg/min of epoprostenol (stable PGI2)
224246593|NCT00510172|DRUG|Placebo|NaCL 0,9%
224246594|NCT03767361|BIOLOGICAL|packed red blood cells transfusion|packed red blood cells transfusion
224246595|NCT04811794|OTHER|Physical examination, diagnostic tests, laboratory tests|Physical examination, diagnostic tests (e.g. lung function test, echocardiography, audiometry), and laboratory tests (e.g. kidney parameter, hormonal levels) depend on examined organ system.
224246596|NCT04811794|OTHER|Personal history|Personal history on diagnosis, treatment, and socioeconomic factors
224246597|NCT02960594|BIOLOGICAL|INO-1400|
224246598|NCT02960594|BIOLOGICAL|INO-9012|
224246599|NCT02960594|BIOLOGICAL|INO-1401|
224246600|NCT03781739|DRUG|MANP|single subcutaneous injection of MANP and monitoring of metabolic, cardiovascular and renal parameters
224246601|NCT00100620|DRUG|Zoledronic Acid|
224246602|NCT05601674|OTHER|: Conventional flow Anesthesia|During the initial wash-in period 2 L/min Fresh gas flow will be used.
224246603|NCT05601674|OTHER|Low Flow Anesthesia|Fresh gas flow rate will be 0.5 L/min throughout the procedure.
224246604|NCT03097107|DRUG|Saroglitazar Magnesium 1 mg|Randomly assigned patients will receive saroglitazar magnesium 1 mg orally once each morning before breakfast for 12 weeks
223665895|NCT06936631|PROCEDURE|Catheter replacement|"In the intervention group, the catheter is not replaced during CAUTI treatment. Choice of antibiotic agent follows standard care guidelines, with adjustments based on culture results. In this group, catheter replacement occurs according to the patient's regular schedule.~The control group undergoes catheter replacement within 3 days of starting antibiotic therapy. Choice of antibiotic agent follows standard care guidelines, with adjustments based on culture results."
223665896|NCT06936631|PROCEDURE|Catheter retainment|In the intervention group, the catheter is not replaced during CAUTI treatment. Choice of antibiotic agent follows standard care guidelines, with adjustments based on culture results. In this group, catheter replacement occurs according to the patient's regular schedule. The control group undergoes catheter replacement within 3 days of starting antibiotic therapy. Choice of antibiotic agent follows standard care guidelines, with adjustments based on culture results.
223665897|NCT07144865|DRUG|conbercept ophthalmic injection （0.5mg）|Participants were randomly assigned to receive intravitreal injections of either faricimab (IVF, n=4) or conbercept (IVC, n=4) based on a randomisation protocol. To establish a baseline comparison, FVMs were obtained from three treatment-naive patients who served as controls. All participants underwent surgery 4 days after the intravitreal anti-VEGF injections.
223665898|NCT07144865|DRUG|Faricimab|According to the randomization protocol, participants were randomly assigned to receive intravitreal injections of faricimab (IVF, n=4) or conbercept (IVC, n=4). To establish a baseline comparison, FVMs were obtained from three treatment-naïve patients as controls. All participants underwent surgery 4 days after intravitreal anti-VEGF injection.
223770672|NCT04164147|DIAGNOSTIC_TEST|Biomechanics|Participants will be asked to perform biomechanical assesment before and following surgery at baseline, 6-8 weeks and 6-months postoperatively
224246605|NCT03097107|DRUG|Saroglitazar Magnesium 2 mg|Randomly assigned patients will receive saroglitazar magnesium 2 mg orally once each morning before breakfast for 12 weeks
224246606|NCT03097107|DRUG|Saroglitazar Magnesium 4 mg|Randomly assigned patients will receive saroglitazar magnesium 4 mg orally once each morning before breakfast for 12 weeks
224246607|NCT03097107|DRUG|Placebo|Randomly assigned patients will receive placebo orally once each morning before breakfast for 12 weeks
224246608|NCT04889586|DEVICE|EMG-biofeedback armband (REMO)|After clinical evaluation, the subjects execute an instrumental test. By wearing EMG-biofeedback device (REMO), the subjects have to perform 10 different hand gestures: thumb abduction, pinch, finger flexion, finger extension, wrist flexion, wrist extension, forearm pronation, forearm supination, radial wrist deviation and ulnar wrist deviation. The muscle activations (EMG signals) during the execution of each movements, are recorded for 3 seconds.
224246609|NCT05642286|DEVICE|ALLVAS® robotic-assisted PCI|ALLVAS® robotic-assisted PCI
224246610|NCT01334307|DEVICE|Lung Volume Reduction Coil (LVRC) (PneumRx)|Lung Volume Reduction Coil (LVRC)
224246611|NCT01334307|DEVICE|Control|Standard of Care
224246612|NCT03969693|RADIATION|Standard treatment protocol with combined chemoradiation|As for consolidative RT used in patients with early-stage Hodgkin lymphoma, the RT field must essentially include the mediastinum.
224246613|NCT06464120|OTHER|Increasing load strength training|The Smith machine was used to intervene with athletes by employing an incremental load approach.
224246614|NCT06464120|OTHER|Constant load strength training|The Smith machine was used to intervene with athletes by employing a constant load approach.
224246615|NCT04862429|OTHER|Contrast enhanced mammography guided biopsy (diagnostic procedure)|With visible contrast-enhancement, stereotactic biopsy will be performed under CESM guidance. After administration of an additional dose of iodized contrast-enhancement (Omnipaque), the insertion of the biopsy needle and the biopsy sampling will be targeted on the area of greatest enhancement in the context of calcifications. In the absence of contrast-enhancement, stereotactic biopsy Mammotome will be performed, using X-ray guidance. The insertion of the biopsy needle and biopsy will be targeted on the most suspicious calcification cluster or area. At the end of the procedure, a metal clip marker will be placed in the biopsy site; the placement will be verified with dual orthogonal mammography projection (as regular clinical practice).
224246616|NCT04862429|OTHER|Mammography guided biopsy (diagnostic procedure)|"For all lesions, stereotactic biopsy Mammotome will be performed, using X-ray guidance. The insertion of the biopsy needle and biopsy will be targeted on the most suspicious calcification cluster or area.~At the end of the procedure, a metal clip marker will be placed in the biopsy site; the placement will be verified with dual orthogonal mammography projection (as regular clinical practice)."
224246617|NCT02074605|BIOLOGICAL|Interferon alpha|
224246618|NCT00860223|DRUG|Digoxin|
224246619|NCT00860223|DRUG|Neratinib|HKI-272
224246620|NCT05436509|BIOLOGICAL|bi-4SCAR CD19/79b T cells|Infusion of bi-4SCAR-CD19/79b T cells at 10\^6 cells/kg body weight via IV
224246621|NCT03677622|DRUG|Voluven to near maximal stroke volume of the heart|Stroke volume guided fluid treatment with Voluven on the basis of restricted fluid therapy
224246622|NCT00724191|PROCEDURE|MRI|New MRI methods which measure information related to water, blood, and chemical makeup in the brain.
224246623|NCT00940693|DRUG|duloxetine|60 mg capsule once per day for 6 weeks
224246624|NCT00940693|DRUG|placebo|one capsule of placebo taken one a day for 6 weeks
224246625|NCT04391621|PROCEDURE|Autologous Adipose Derived stem cell transplantation|Through liposuction, harvested lipoaspirate will be processed in theatre through centrifugation at 1200g, then the sediment will be washed with Phosphate buffered saline and then incubated at 37 degrees celsius in 0.075% Collagenase type 1a for 1 hour. This will then be washed in an equal volume of 10% Fetal Bovine Serum then filtered through a 100 micrometer cell strainer. Red cells lysed using the Red cell lysis buffer will be performed followed by washing in Phosphate buffered Saline and centrifugation and the stromal vascular fraction cell pellet collected and diluted into 5ml normal saline solution for inflitration. This will then be infiltrated into the affected keloid.
224246626|NCT04391621|DRUG|Triamcinolone Acetonide 40Mg/Ml Inj,Susp_#1|Triamcinolone Acetanoide 40mg/ml suspension will be diluted into 1ml of 0.5% lignocaine solution and infiltrated into the selected keloid.
224246627|NCT01565096|DRUG|Metformin|Metformin 1000 mg BID
224246628|NCT01565096|DRUG|Metformin|Metformin 1000 mg BID
224246629|NCT01565096|DRUG|Vildagliptin|Vildagliptin 50 mg twice daily
224246630|NCT01565096|DRUG|Glimepiride|Glimepiride at individual dose
224246631|NCT01274364|OTHER|JADE|Patients will receive comprehensive assessments at baseline and again after 12-months. In the interim between these two time points patients will receive protocol-driven diabetes care using a web-based disease management program (JADE), delivered by a trio-team comprising of a trained doctor, nurse and physician assistant.
224246632|NCT01274364|OTHER|DIAMOND|Patients will receive comprehensive assessments at baseline and again after 12-months. In the interim between these two time points patients will be managed according to 'usual care' procedures.
224246633|NCT05564819|DRUG|Acetaminophen|When the infants woke up after surgery and were transported back to the ward, they were randomly divided into two groups immediately. The intervention group was given oral acetaminophen, once every 6 hours, for a total of 4 times.
224246634|NCT05564819|DRUG|Sterilized water|When the infants woke up after surgery and were transported back to the ward, they were randomly divided into two groups immediately. The control group was given sterilized water, once every 6 hours, for a total of 4 times.
224246635|NCT03955237|PROCEDURE|Drug: dextrose containing infusion|Drug: infusing dextrose containing or non glucose fluid according to blood glucose level
224246636|NCT06327607|OTHER|Control Group|Standard care for breast cancer
223665899|NCT07146724|OTHER|Exercise|"The intervention consists of a pilates-based exercise program specifically designed to target hamstring flexibility, plantar pressure sensitivity, and dynamic balance.~Unlike general fitness-oriented pilates, this program includes a combination of mat-based and functional pilates movements adapted to improve posterior chain flexibility and sensory feedback in the lower extremities.~The protocol includes 3 sessions per week for 8 weeks - 1 session conducted face-to-face under physiotherapist supervision and 2 sessions as a monitored home exercise. Exercise progression is standardized, and all sessions follow a validated physiotherapy protocol tailored for university-aged individuals with clinically measured hamstring shortening."
223665900|NCT03796026|DRUG|Seltorexant 40 mg|Seltorexant 40 mg capsules (over-encapsulated tablets) will be administered orally.
224246637|NCT06327607|OTHER|Psychosexological intervention|The intervention will be conducted individually and will take place once a week for one hour, for a total of 8 consecutive weeks, which must be completed within a maximum duration of 10 weeks.
224246638|NCT00748228|DIETARY_SUPPLEMENT|dietary sodium|10 mEq/day
224246639|NCT00748228|DIETARY_SUPPLEMENT|dietary sodium|300 mEq/day
224246640|NCT00748228|DIETARY_SUPPLEMENT|dietary sodium|150 mEq/day dietary sodium
224246641|NCT06051240|DRUG|Lithium|Lithium sulphate, 42 mg (6 mmol lithium)
224246642|NCT06051240|DRUG|Placebo|White round tablet, 10 mm. Identical to experimental drug (lithium)
224246643|NCT04991090|RADIATION|escalation dose of LLNs|The lymph nodes (SA ≥ 5 mm) existed at the internal iliac and obturator would be delineated, named as GTVnd, and received a radiation dose boost of 58Gy.
224246644|NCT04784598|OTHER|Insoles adapted in flip-flop sandals|participants of both groups individually received a pair of customized flip-flop sandals, with or without foot pieces, covered with smooth synthetic leather
224246645|NCT03571880|DEVICE|Biodex-assisted isometric strength testing|The maximum voluntary isometric and dynamic strength of back and abdominal muscles is measured using an isokinetic dynamometer (System 3, Biodex, Enraf-Nonius, New York).
224246646|NCT03693430|DRUG|Semaglutide|Subcutaneous (s.c., under the skin) injections of semaglutide once weekly at escalating doses (0.25 mg/week, 0.5 mg/week, 1.0 mg/week, 1.7 mg/week, 2.4 mg/week). The dose will be escalated to next level every 4 weeks
224246647|NCT03693430|DRUG|Placebo (Semaglutide)|S.c. injections of placebo once weekly at a similar dose escalation manner as semaglutide (placebo matched to semaglutide 0.25 mg/week, 0.5 mg/week, 1.0 mg/week, 1.7 mg/week, 2.4 mg/week). The dose will be escalated to next level every 4 weeks
224246648|NCT02702817|DRUG|Naproxen|pale blue oval tablets
224246649|NCT02702817|DRUG|Placebo|pale blue oval tablets with no active ingredients, identical in appearance to naproxen intervention
224246650|NCT01578694|DIAGNOSTIC_TEST|Magnetic Resonance Imaging (MRI)|T1 rho MRI is a modified pulse sequence from the standard T1 sequence used in the clinical MRI.
224246651|NCT03435705|BEHAVIORAL|maintaining of occupational therapy|8 home sessions over a 4 months period with caregivers' education, occupational therapy and care coordination for post intervention
224246652|NCT02582541|PROCEDURE|SEMS alone|The SEMS (Wallstent, Boston Scientific, USA) would be placed.
224246653|NCT02582541|PROCEDURE|SEMS plus radiofrequency ablation|The RFA catheter has an 8 F bipolar probe and two ring electrodes 8 mm apart with the distal electrode 5 mm from the leading edge, providing local coagulative necrosis over a 2.5 cm length. The catheter is compatible with standard side-viewing endoscopes (3.2 mm working channel), and could be passed over 0.035 inch guidewires. Ablation was performed by using an RFA generator (1500 RF generator; RITA Medical Systems, Fremont, Calif) delivering electrical energy at 400 kHz set at 7-10 W for 90-120 seconds. The RFA energy can be delivered repetitively at different tumor sites within one procedure. After the RFA application is completed, SEMS (Wallstent, Boston Scientific, USA) can be deployed.
224246654|NCT03365115|DRUG|Intrathecal morphine|Intrathecal morphine 100 mcg will be injected.
224246655|NCT03365115|DRUG|Intrathecal fentanyl|Intrathecal fentanyl 25 mcg will be injected.
223665901|NCT03796026|DRUG|Placebo|Matching placebo to seltorexant 40 mg capsules (over-encapsulated tablets) will be administered orally.
224246656|NCT04132908|DIETARY_SUPPLEMENT|Dietary Supplement: nutraceutical|Subjects will consume two capsules at breakfast and dinner for ten weeks.
224246657|NCT04132908|DIETARY_SUPPLEMENT|Placebo|Subjects will consume two capsules at breakfast and dinner for ten weeks.
224246658|NCT03608722|OTHER|SLUMS|A pen and paper screening tool of cognitive impairment
224246659|NCT03608722|OTHER|MMSE|A pen and paper screening tool of cognitive impairment
224246660|NCT03608722|OTHER|MoCA|A pen and paper screening tool for cognitive impairment
224246661|NCT03608722|DEVICE|BrainCheck|A computerized neurocognitive test administered via an electronic device, such as a phone, tablet or computer, that contains several assessments that will aid in establishing an individuals cognitive performance
224246662|NCT00585689|DRUG|ABI-007|ABI-007 will be administered at a dose of 260 mg/m2 over a 30 min IV infusion on day 1 of each 21 day cycle.
224246663|NCT00585689|DRUG|Carboplatin|Carboplatin will be administered at a dose of TARGET AUC=5 over a 15 min IV infusion of day 1 of each 21 day cycle.
224246664|NCT00585689|DRUG|Gemcitabine|Gemcitabine will be administered at a dose of 800 mg/m2 over a 30 min IV infusion on days 1 and 8 of each 21 day cycle.
224246665|NCT00585689|PROCEDURE|Radical Cystectomy|
224246666|NCT04231084|DRUG|Vasodilator testing (Inhaled Nitric Oxide)|Right heart catheterization with vasodilator testing with each arms' associated agent will be performed
224246667|NCT04231084|DRUG|Vasodilator testing (Inhaled Epoprostenol)|Right heart catheterization with vasodilator testing with each arms' associated agent will be performed
224246668|NCT00945165|BEHAVIORAL|Exercise intervention|various exercise characteristics
224246669|NCT00945165|BEHAVIORAL|No exercise|No exercise control period
224246670|NCT03375853|BEHAVIORAL|Computer Based Response Training Weight Loss Intervention|Participants complete four computer based training tasks each visit, over the course of a few lab visits. Participants then perform weekly booster sessions in a more natural home or community environment over the internet using the same computer based training tasks.
224246671|NCT03375853|BEHAVIORAL|Generic Response Training Control Intervention|Participants complete four computer based training tasks each visit, over the course of a few lab visits. Participants then perform weekly booster sessions in a more natural home or community environment over the internet using the same computer based training tasks.
224246672|NCT02479503|PROCEDURE|Antibiotic prophylaxis in adult heart transplantation|
224246673|NCT02704182|DEVICE|tDCS|25 patients received real anodal tDCS on the motor area for 20 minutes every day for 4 consecutive days.
224246674|NCT02704182|DEVICE|Sham tDCS|25 patients received sham anodal tDCS on the motor area for 20 minutes every day for 4 consecutive days.
224246675|NCT02045550|DRUG|Prospan Syrup|2.5 ml twice daily for 4 weeks
224246676|NCT01890239|OTHER|Care Programme for the Last Days of Life|The Care Programme essentially aims to raise awareness among geriatric health care staff of the importance for improving end-of-life care and to prepare them for a change in end-of-life care, to train staff in delivering good end-of-life care with the support of a multi-professional document called the Care Guide for the Last Days of Life, to support dying geriatric patients with the Care Guide for the Last days of Life, to regularly evaluate the delivered end-of-life care and support and to further educate the staff in delivering optimal end-of-life care. The Care Programme consists of the following documents: (1) the Care Guide for the Last Days of Life, (2) supportive documentation and (3) an implementation guide.
224246677|NCT01719731|BEHAVIORAL|Education|This group will receive the psychoeducation
224246678|NCT01719731|BEHAVIORAL|Non-Education|This group will not receive the psychoeducation
224246679|NCT00003647|DRUG|allovectin-7|
224246680|NCT00003647|DRUG|allovectin-7/dacarbazine|
224246681|NCT00003647|DRUG|dacarbazine|
224246682|NCT04520386|DRUG|OMT-111|Pre-filled Syringe
224246683|NCT00362765|DRUG|Fenofibrate|160 mg
224246684|NCT00362765|DRUG|Metformin|2000 mg
224246685|NCT00362765|DRUG|Placebo|Placebo
224246686|NCT02518581|PROCEDURE|Doubly labelled water method|DLW (doubly labeled water) method measures isotope dilution spaces and elimination rates to assess total energy expenditure (TEE). After enriching the body water of a subject with DLW (2H and 18O), it is only necessary to collect urine samples at defined time points, usually over a period of 1-2 weeks, so that the measurement can be done in individuals able to engage in their typical habits without restrictions. The resulting TEE measurement represents an integral value over the measurement period.
224246687|NCT01874756|DRUG|LY500307 150mg|LY500307 150mg daily dose (6 capsules of 25mg) for 8 weeks
224246688|NCT01874756|DRUG|LY500307 75mg|LY500307 75mg daily dose (3 capsules of 25mg and 3 capsules of placebo) for 8 weeks
224246689|NCT01874756|DRUG|Placebo|6 placebo capsules daily for 8 weeks
224246690|NCT01874756|DRUG|LY500307 25mg|LY500307 25mg daily dose (1 capsules of 25mg and 5 capsules of placebo) for 8 weeks
224246691|NCT01616602|OTHER|Prone Position|Patients were asked to lay on their abdomen for their elective colonoscopy.
224246692|NCT01616602|OTHER|Standard Position|The traditional left-lateral decubitus position
224246693|NCT03829098|OTHER|Intervantions for anastomotic leakage after esophagectomy|nil by mouth regime; antibiotic treatment according to local protocols; NG tube placement (with/without suction); NG tube repositioning (with/without suction); tube placement though anastomotic defect; endoVAC/endoSponge placement; stent placement (stent type if applicable); endoscopic clipping; nasoduodenal/nasojejunal feeding tube placement; radiologic drainage (thoracic cavity, mediastinum); bedside surgical chest tube placement; reoperation; reoperation approach; reoperation procedure (drainage only, suturing of the leak; resection of the leak and re-anastomosis; repair of anastomosis with muscle flap; disconnection and cervical esophagostomy; surgical jejunal feeding tube).
224246694|NCT01270048|DRUG|mild-ex-gwarip|three times a day, AC 30 min., 4 capsules taken each time (4capsules=2.5g), 8 weeks.
224246695|NCT01270048|OTHER|Placebo|three times a day, AC 30 min., 4 capsules taken each time (4capsules=2.5g), 8 weeks.
224321724|NCT04319237|BEHAVIORAL|Neuropsychological Assessment -Stroop Color and Word Test|The Stroop Color and Word Test is based on the observation that individuals can read words much faster than they can identify and name colors. The test-taker reads color words or names ink colors from different pages as quickly as possible within a time limit. The test yields three scores based on the number of items completed on each of the three stimulus sheets. An Interference score is useful in determining the individual's cognitive flexibility, creativity, and reaction to cognitive pressures.
224246696|NCT05834231|DRUG|Memantine|oral
224246697|NCT05834231|DRUG|Placebo|oral
224246698|NCT03148808|COMBINATION_PRODUCT|NVS Therapy|Combination Product: NVS Therapy which includes NVS Injection (investigational product) and the following investigational devices: NVS Delivery Catheter, NVS Light Fiber, and NVS Light Source.
224246699|NCT05057650|DIETARY_SUPPLEMENT|Vegan diet|Provide
224246700|NCT00319735|PROCEDURE|Radiation Therapy|External beam radiation therapy, beginning on day 1, 4500 cGy to esophagus with boost of 540 cGy at 180 cGy per fraction for 6 weeks
224246701|NCT00319735|PROCEDURE|Surgery|Surgical resection of primary tumor and adjacent mediastinal and/or celiac lymph nodes by a transthoracic approach after satisfactory hematologic and functional recovery within 8 weeks of completion of radiation therapy
224246702|NCT00319735|PROCEDURE|Tissue Sample|For patients who give their consent, fresh frozen tissue will be obtained per EUS at baseline, per EUS 2 weeks after the initiation of chemotherapy, and at the time of surgery for pathology submission
224246703|NCT04395677|DRUG|AB-106|"Stage 1: 400mg QD for 3 patients and 600mg QD for 3 patients~Stage 2: 600mg QD"
224246704|NCT04165096|BIOLOGICAL|Pembrolizumab|IV infusion
224246705|NCT04165096|BIOLOGICAL|Boserolimab|IV infusion
224246706|NCT04165096|BIOLOGICAL|MK-4830|IV infusion
224246707|NCT04165096|DRUG|diphenhydramine|PO
224246708|NCT04165096|DRUG|acetaminophen|PO
224246709|NCT04165096|BIOLOGICAL|MK-0482|IV infusion
224246710|NCT04763161|PROCEDURE|Decompressive hemicraniectomy|Decompressive hemicraniectomy in the context of a malignat sylvian ischaemic cerebral accident
224246711|NCT04763161|PROCEDURE|neurosurgical operation|neurosurgical operation on which cranial, meningeal, vascular (branch of the middle meningeal artery) or cerebral bone tissue is not preserved during the surgical approach.
224246712|NCT01320696|BIOLOGICAL|Reverse Genetic (RG) reassortant A/H9N2 influenza vaccine|Two intramuscular vaccinations; 5 dose groups: 3.75 µg, 7.5 µg, 15 µg, 30 µg or 45 µg HA antigen (strain A/H9N2/chicken/Hong Kong/G9/97; non-adjuvanted formulation
224246713|NCT02485808|OTHER|None-observational|For surgical patients, follow-up assessments will occur 3 and 12 months after the surgery. For medical patients, follow-up assessments will occur 3 and 12 months after the baseline assessment.
224246714|NCT02485808|PROCEDURE|Magnetic Resonance Imaging (MRI)|One time MRI scanning session examining brain structure and function in a resting state and after water consumption.
224246715|NCT02485808|OTHER|Multimodal Automated Sensory Testing System|Pressure pain thresholds will be assess using computer-controlled pressures delivered by a device called the Multimodal Automated Sensory Testing System (MAST) device on to the subjects thumbnail bed.
224246716|NCT02485808|OTHER|Auditory Sensitivity Test|Subjects' sensitivity to sound will be evaluated using a series of sounds delivered by a standard audiometer device.
224246717|NCT01837862|DRUG|Mebendazole|Mebendazole will be given orally twice daily for over the course of treatment (70 weeks for low-grade glioma patients, 48 weeks for high-grade glioma/pontine glioma patients). Mebendazole will be prescribed according to the particular dose cohort for each patient (50 mg/kg/day, 100 mg/kg/day, or 200 mg/kg/day).
224246718|NCT01837862|DRUG|Vincristine|Low-grade glioma patients only. Vincristine will be dosed as per the following: For patients \< 12kg: 0.05 mg/kg; for patient \> 12kg: 1.5mg/m2 (maximal dose 2.0 mg). Vincristine will be administered intravenously on Day 1 of weeks 0,1,2,3,4,5 during the 10-week induction cycle and on Day 1 of Weeks 0,1,2 of the six 10-week maintenance cycles.
224246719|NCT01837862|DRUG|Carboplatin|Low-grade glioma patients only. Carboplatin will be dosed at 175 mg/m2. Carboplatin will be administered intravenously on Day 1 of Weeks 0,1,2,3 of the 10-week Induction cycle, and on Day 1 of Weeks 0,1,2,3 during the six 10-week maintenance cycles.
224246720|NCT01837862|DRUG|Temozolomide|Low-grade glioma patients only. Temozolomide will be dosed at 200 mg/m2/day. Temozolomide will be given orally for 5 days during Week 6 of the 10-week induction cycle and for 5 days during Week 6 of the six 10-week maintenance cycles.
224246721|NCT01837862|DRUG|Bevacizumab|High-grade glioma/pontine glioma patients only. Bevacizumab will be dosed at 10mg/kg/dose. Bevacizumab will be administered intravenously on Days 1 and 15 of each maintenance cycle.
224246722|NCT01837862|DRUG|Irinotecan|High-grade glioma/pontine glioma patients only. Irinotecan will be administered at doses 125 mg/m2, 150 mg/m2, 250 mg/m2, or 300 mg/m2, depending on patient tolerance and concomitant enzyme-inducing anti-epileptic medication use. Irinotecan will be administered intravenously on Days 1 and 15 of each maintenance cycle.
224246723|NCT05543356|BIOLOGICAL|Tozinameran|A single standard dose (30mcg) will be administered on day 0 of the study.
224246724|NCT05543356|BIOLOGICAL|Elasomeran|A single standard dose (50mcg) of the intervention will be administered on day 0 of the study.
224321725|NCT04319237|BEHAVIORAL|Patient Reported Outcomes Measurement Information System-29 (PROMIS-29) Questionnaire|The PROMIS-29 questionnaire assesses each of 7 domains (Depression, Anxiety, Physical Function, Pain Interference, Fatigue, Sleep Disturbance, and Ability to Participate in Social Roles and Activities). A higher score equals more of the concept being measured.
224246725|NCT05543356|BIOLOGICAL|Tozinameran|A single standard dose (30mcg) will be administered on day 0 of the study.
224246726|NCT05543356|BIOLOGICAL|Elasomeran|A single standard dose (50mcg) of the intervention will be administered on day 0 of the study.
224246727|NCT05543356|BIOLOGICAL|Bivalent Pfizer-BioNTech|A single standard dose (BNT162b2 15μg +BNT162b2 OMI 15μg) will be administered on day 0 of the study.
224246728|NCT05543356|BIOLOGICAL|Bivalent Moderna|A single standard dose (BNT162b2 15μg + BNT162b2 OMI 15μg)will be administered on day 0 of the study.
224246729|NCT05543356|BIOLOGICAL|Bivalent Pfizer-BioNTech|A single standard dose (BNT162b2 15μg + BNT162b2 OMI 15μg) will be administered on day 0 of the study.
224246730|NCT05543356|BIOLOGICAL|Bivalent Moderna|A single standard dose (BNT162b2 15μg +BNT162b2 OMI 15μg) will be administered on day 0 of the study.
224246731|NCT00958178|DRUG|Oxygen|Experimental: Low flow Oxygen for 30 seconds then high flow for 3.5 minutes. Active comparator: High flow Oxygen for 4 minutes.
224246732|NCT02878109|DEVICE|Post-treatment phase group|4D-THRIVE and 4D-FLOW using magnetic resonance imaging (MRI)
224246733|NCT02878109|DEVICE|Pre-treatment phase group|4D-THRIVE and 4D-FLOW using magnetic resonance imaging (MRI)
224246734|NCT03820713|PROCEDURE|Concentrate of plasma coagulation factors|The plasma concentrate of coagulation factors is applied to the surgical site.
224246735|NCT03820713|PROCEDURE|0.9% saline|Control group receives an identical syringe and applicator generated by processing normal saline 0.9% instead of plasma.
224246736|NCT06375408|DEVICE|Real transcranial alternating electrical stimulation|The patients in the intervention group were treated with real tACS produced by Nexalin company. There were 3 treatment sites. According to the international 10-20 EEG system positioning method, one electrode was placed in the prefrontal lobe (Fp1, Fpz, Fp2 area, electrode size was 4.45cm×9.53cm), and the other two electrodes were placed in the left and right mastoid respectively (electrode size was 3.18cm×3.81cm). The treatment parameters were 40min twice daily with an interval of ≥4 hours for a total of 8 sessions over 4 days. tACS procedures were performed by trained and qualified full-time therapeutic nurses.
224246737|NCT06375408|DEVICE|Sham transcranial alternating electrical stimulation|The patients in the control group were treated with sham tACS produced by Nexalin company. The fake tACS does not emit current, so it does not stimulate the cerebral cortex. The appearance, button, electrode, and quality of the fake tACS are exactly the same as those of the real tACS in patients' senses. There were 3 treatment sites. According to the international 10-20 EEG system positioning method, one electrode was placed in the prefrontal lobe (Fp1, Fpz, Fp2 area, electrode size was 4.45cm×9.53cm), and the other two electrodes were placed in the left and right mastoid respectively (electrode size was 3.18cm×3.81cm). The treatment parameters were 40min twice daily with an interval of ≥4 hours for a total of 8 sessions over 4 days. tACS procedures were performed by trained and qualified full-time therapeutic nurses.
224246738|NCT00969566|DRUG|sitagliptin, metformin|sitagliptin 100mg once daily and metformin 500mg twice daily, orally, for 24 weeks.
224246739|NCT02530762|OTHER|Novel Fiber|novel fiber supplemented beverage provided in one serving
224246740|NCT02530762|OTHER|Positive Fiber control|positive control fiber supplemented beverage provided in one serving
224246741|NCT02530762|OTHER|Negative Control|No added fiber beverage
224246742|NCT03458871|DEVICE|4-week TTNS home-based protocol|"4-week TTNS home-based protocol. Electrodes 2 inch by 2 inch will be placed according to anatomic landmarks, with the negative electrode behind the internal malleolus and the positive electrode 10cm superior to the negative electrode, verified with rhythmic flexion of the toes secondary to stimulation of the flexor digitorum and hallicus brevis. The intensity level will be set to the amperage immediately under the threshold for motor contraction. If there is not contraction seen, maximal tolerable intensity will be used.~In addition, if the patient perceives pain, the intensity will be lowered until comfortable.~Stimulation frequency of 10 Hz and pulse width of 200ms in continuous mode will be used."
224246743|NCT00191295|DRUG|Atomoxetine|
224246744|NCT00191295|DRUG|Placebo|
224246745|NCT04339894|OTHER|Duplex ultrasonography (data collection by extra-corporeal non-invasive sensors)|Search for venous thrombosis and description of thrombosis
224246746|NCT05411536|OTHER|Walking trials|"All participants will complete a series of walking trials. They will first be requested to perform three practice walks followed by three walking trials on a 7.4m straight level-ground firm walkway (GW) and the other three walking trials on a 7.4m straight foam walkway (FW) in a randomised order. The dimension of the foam walkway in the FW will be 8m (length), 0.8m (width), and 0.3m (height). The starting and finishing lines of the FW will be positioned at 0.3m from each side of the FW's edges. Thus, the lengths of the FW and the GW will be identical (i.e., 7.4m). Participants will be asked to walk 7.4m and stop for each walking trial.~After a 10-minute rest break, participants will perform nine walking trials on the GW and the other nine walking trials on the FW, including three repetitions of three different attentional focus instructions (external focus \[EF\], internal focus \[IF\], and no specific focus \[NF\]) in the GW and FW in a randomised order."
224321726|NCT04319237|BEHAVIORAL|European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire|European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ C-3) and the add-on EORTC QLQ Non-Hodgkin's Lymphoma (EORTC QLQ-NHL-HG29) module. All scales range from 0-100, a high scale score represents a higher response level. For example, a high functional score represents a high level of functioning.
223665902|NCT01528267|OTHER|Autologous blood|50mls of autologous blood injected into each of 3 bronchopulmonary segments.
223665903|NCT01528267|OTHER|Normal saline|50mls of normal saline injected into each of 3 bronchopulmonary segments.
223665904|NCT02957968|DRUG|Doxorubicin|60 mg/m2 once every 2 weeks for 4 cycles.
223665905|NCT02957968|DRUG|Cyclophosphamide|cyclophosphamide 600 mg/m2 (AC) once every 2 weeks for 4 cycles.
223665906|NCT02957968|DRUG|Paclitaxel|Paclitaxel 80 mg/m2 IV once weekly for 12 weeks.
223665907|NCT02957968|DRUG|Carboplatin|carboplatin IV 1.5 area under curve (AUC) once weekly for 12 weeks.
223665908|NCT02957968|DRUG|Decitabine|Given IV
223665909|NCT02957968|DRUG|Pembrolizumab|Given IV
224246747|NCT03394209|DRUG|Favipiravir|"In first step: favipiravir tablet is orally administered. This drug will be given twice daily for a 10-day period. For the First day, the dosage is 1600 mg twice daily. Starting from the second day, the dosage is 600 mg twice daily.~In second step: favipiravir tablet is orally administered. This drug will be given twice daily for a 10-day period. For the First day, the dosage is 1800 mg twice daily. Starting from the second day, the dosage is 800 mg twice daily."
224246748|NCT03394209|DRUG|Oseltamivir 75Mg Capsule|oseltamivir will be administered at 75mg twice daily orally for 10 days
224246749|NCT00202319|PROCEDURE|Sedation management protocol|
224246750|NCT02815319|DRUG|Dexamethasone|Steroid prophylaxis
223665910|NCT04731272|DRUG|Dulaglutide 0.75Mg/0.5Ml Inj Pen|Randomized, open-label, cross-over study of 6 weeks exposure to dulaglutide 0.75 mg subcutaneous weekly or observation.
223665911|NCT06507488|DRUG|Daphnetin Capsule|Daphnetin, chemically known as 7,8-dihydroxycoumarin, also known as ZuShiMaJiaSu, is a class of coumarin derivatives derived from different Daphnetin genus plant .
223665912|NCT06507488|DRUG|Placebo|The placebo is a Daphnetin Capsule simulants
223665913|NCT01031836|DRUG|MEDI-545|"Stage I: MEDI-545 1.0 mg/kg IV, on Day 1 and once every 2 weeks from Day 29, for a total of 14 doses.~Stage II: MEDI-545 1.0 mg/kg IV once every 2 weeks for a total of 79 doses."
223665914|NCT01031836|DRUG|MEDI-545|"Stage I: MEDI-545 3.0 mg/kg IV, on Day 1 and once every 2 weeks from Day 29, for a total of 14 doses.~Stage II: MEDI-545 3.0 mg/kg IV once every 2 weeks for a total of 79 doses"
223665915|NCT01031836|DRUG|MEDI-545|"Stage I: MEDI-545 10.0 mg/kg IV, on Day 1 and once every 2 weeks from Day 29, for a total of 14 doses.~Stage II: MEDI-545 10.0 mg/kg IV once every 2 weeks for a total of 79 doses."
223665916|NCT01031836|DRUG|MEDI-545|"Stage I: MEDI-545 100 mg SC, on Day 1 and weekly or once every 2 weeks from Day 29, for a total of 14 doses.~Stage II: MEDI-545 100 mg SC once every 2 weeks for a total of 79 doses."
223665917|NCT01031836|DRUG|MEDI-545|"Stage I: MEDI-545 1,200 mg IV once every 4 weeks from Day 1 for a total of 8 doses.~Stage II: MEDI-545 1,200 mg IV once every 4 weeks for a total of 40 doses"
224321727|NCT04319237|BEHAVIORAL|Quality of Life (EQ-5D-5L) Questionnaire|The EQ-5D-5L questionnaire is a self assessed quality of life questionnaire. The scale measures quality of life on a 5 component scale including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The rater selects a number between 1-100 to describe the condition of their health, 100 being the best imaginable.
224246751|NCT04795609|OTHER|Early mobilization strategy adapted after immediate internal pudendal artery perforator flap reconstruction for abdominoperineal resection (intervention group).|"Early mobilization strategy adapted after immediate internal pudendal artery perforator flap reconstruction for abdominoperineal resection (intervention group).~1. Trunk control.~2. Orthostatism.~3. Walk training.~4. Aerobic exercises.~5. Muscle strengthening."
224246752|NCT05313698|DIAGNOSTIC_TEST|No intervention|cross-sectional study/psychometric study
224246753|NCT00308022|DEVICE|High Frequency Percussive Ventilation|
224246754|NCT03030196|DRUG|Denosumab|NaCl 0.9% injection is used as placebo
224246755|NCT03255148|DRUG|Oxytocin|Syntocinon nasal spray
224246756|NCT03255148|DRUG|Placebo|Placebo nasal spray
224246757|NCT04714047|OTHER|Progressive Resistance Training and no booster sessions|"An initial 12-week exercise intervention, consisting of 1-hour group sessions of progressive resistance training supervised by a physiotherapist 2 times per week.~The sessions consist of a 10-minute submaximal warm up on an exercise bike followed by 50 minutes of PRT with exercises targeting the muscles of the hip and knee joints; leg press, hip extension, hip abduction, hip flexion and knee extension. The progression will be in line with guidelines provided by the American College of Sports Medicine. The intensity will follow repetition maximum (RM) targets, from 12 RM for the first week towards 8 RM for the last weeks.~After the 12 weeks, this group consists of patients who are randomized to receive no further treatment. For the following 9 months, these patients are given a membership to a fitness center where they are encouraged to continue the same exercise regime."
224246758|NCT04714047|OTHER|Progressive Resistance Training and booster sessions|"An initial 12-week exercise intervention, consisting of 1-hour group sessions of progressive resistance training supervised by a physiotherapist 2 times per week.~The sessions consist of a 10-minute submaximal warm up on an exercise bike followed by 50 minutes of PRT with exercises targeting the muscles of the hip and knee joints; leg press, hip extension, hip abduction, hip flexion and knee extension. The progression will be in line with guidelines provided by the American College of Sports Medicine. The intensity will follow repetition maximum (RM) targets, from 12 RM for the first week towards 8 RM for the last weeks.~After the 12 weeks, this group consists of patients who are randomized to receive 4 booster sessions (at 1, 3, 5 and 7 months after termination of the initial 12 week intervention). Additionally, for the following 9 months, these patients are given a membership to a fitness center where they are encouraged to continue the same exercise regime without supervision."
224246759|NCT04714047|OTHER|Neuromuscular exercise and no booster sessions|"An initial 12-week exercise intervention, consisting of 1-hour group sessions of progressive resistance training supervised by a physiotherapist 2 times per week.~The sessions consist of a 10-minute submaximal warm up on an exercise bike followed by 50 minutes of NEMEX training with exercises focused on stability, postural function, postural orientation, lower extremity muscle strength, and functional exercises. Progression is made when an exercise is performed with good sensorimotor control and good quality of the performance and with minimal exertion and adequate control of the movement.~After the 12 weeks, this group consists of patients who are randomized to receive no further treatment. For the following 9 months, these patients are given equipment and encouraged to continue the same exercise regime at home without supervision."
224246760|NCT04714047|OTHER|Neuromuscular exercise and booster sessions|"An initial 12-week exercise intervention, consisting of 1-hour group sessions of progressive resistance training supervised by a physiotherapist 2 times per week.~The sessions consist of a 10-minute submaximal warm up on an exercise bike followed by 50 minutes of NEMEX training with exercises focused on stability, postural function, postural orientation, lower extremity muscle strength, and functional exercises. Progression is made when an exercise is performed with good sensorimotor control and good quality of the performance and with minimal exertion and adequate control of the movement.~After the 12 weeks, this group consists of patients who are randomized to receive 4 booster sessions (at 1, 3, 5 and 7 months after termination of the initial 12 week intervention). Additionally, for the following 9 months, these patients are given equipment and encouraged to continue the same exercise regime at home."
223665918|NCT01031836|DRUG|MEDI-545 600|"Stage I: MEDI-545 600 mg IV once every 4 weeks from Day 1 for a total of 8 doses.~Stage II: MEDI-545 600 mg IV once every 4 weeks for a total of 40 doses."
224246761|NCT02744352|DRUG|20ml bolus of 0.5% ropivicaine|Local anesthetic
224246762|NCT02744352|DRUG|0.2% of ropivacaine at 8 milliliter/hour|Local anesthetic
224246763|NCT00854100|DRUG|Antidepressant + placebo|Drug: Antidepressant (citalopram, duloxetine, escitalopram, sertraline, or venlafaxine XR) + Placebo Oral, once daily for 8 weeks following an 8 week Prospective Treatment (Baseline) Period.
224246764|NCT00854100|DRUG|Antidepressant + cariprazine (0.1-0.3 mg/day)|Drug: Antidepressant (citalopram, duloxetine, escitalopram, sertraline, or venlafaxine XR) + cariprazine (0.1-0.3 mg/d) Oral, once daily for 8 weeks following an 8 week Prospective Treatment (Baseline) Period.
224246765|NCT00854100|DRUG|Antidepressant + cariprazine (1-2 mg/d)|Drug: Antidepressant (citalopram, duloxetine, escitalopram, sertraline, or venlafaxine XR) + cariprazine (1-2 mg/d) Oral, once daily for 8 weeks following an 8 week Prospective Treatment (Baseline) Period.
224246766|NCT01975688|DRUG|Sativex|"Oromucosal spray containing THC (27 mg/mL) and CBD (25 mg/mL) in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring.~Each vial contains 10 mL; each 100 uL actuation delivers 2.7 mg THC and 2.5 mg CBD."
223665919|NCT00680641|DRUG|Simvastatin|40mg of Simvastatin once daily
224246767|NCT05055349|OTHER|corneal ring segments|ring hard segments inserted within corneal stroma using femtolaser
224246768|NCT04350086|DRUG|Treatment with Dexmedetomidine|Administration of Dexmedetomidine in continuous infusion by electric syringe pump at a dose of 0.4 µg / kg / h, with dose adjustment according to the sedation score and tolerance.
223665920|NCT00680641|DRUG|Placebo|40mg of placebo once daily
223665921|NCT00043342|DRUG|interferon gamma-1b|100 or 200 mcg, SQ, 3x per week
223770673|NCT04164147|DEVICE|one of the Persona MC Retained PCL, Persona MC Sacrificed PCL and NexGen PS total knee implant|Participant are randomly allocated to receive one of the Persona MC Retained PCL, Persona MC Sacrificed PCL and the NexGen PS total knee implant for treatment of end-stage knee osteoarthritis.
223770674|NCT02645916|DRUG|Danggui-Sayuk-Ga-Osuyu-Saenggang-tang|Usage: 3g, three times a day, each taken before or between meals Manufacturing company: HANPOONG PHARM \& FOODS Co. Ltd.
223770675|NCT02645916|DRUG|Placebo: corn starch|Usage: 3g three times a day, each taken before or between meals Manufacturing company: HANPOONG PHARM \& FOODS Co. Ltd.
223770676|NCT04438928|DIETARY_SUPPLEMENT|Elevit Pregnancy 2nd & 3rd Trimester|Once daily micronutrient plus DHA supplementation (Multi-micronutrients and docosahexaenoic acid (MMS) soft gel capsules)
224246769|NCT05250245|DRUG|Tolterodine Tartrate 4 MG|Tolterodine is actively being used in the treatment of over active bladder symptoms today
224246770|NCT05250245|OTHER|Continuous positive airway pressure therapy (CPAP)|The gold standard for the treatment of confirmed OSAS is continuous positive airway pressure (CPAP) therapy
224246771|NCT03486990|DRUG|TIMP-GLIA|intravenous infusion.
224246772|NCT01934621|BEHAVIORAL|Strategy Training|
224246773|NCT01934621|BEHAVIORAL|Attention Control|
224246774|NCT05813028|OTHER|a Mobile Application|Patients will use the mobile application for 6 weeks after receiving the first course of chemotherapy. The Multidimensional Scale of Perceived Social Support, Memorial Symptom Rating Scale, EORTC QLQ-C30 Quality of Life Scale and QLQ-CR29 Module, Beck Anxiety Scale will be administered when they come to the hospital for their 2nd course of chemotherapy. Patients will use the mobile application for 6 more weeks after receiving the second chemotherapy course. 3. The scales will be reapplied when they come to the hospital for a chemotherapy course. Patients will continue to use the mobile application for three more weeks after receiving their 4th and final cure. When the patients come to the outpatient clinic control in the 12th week, the use of the mobile application will be terminated and the Mobile Application Efficiency Evaluation Form will be applied together with the other scales.
224246775|NCT02216071|DRUG|Ciprodex®|Treatment of acute otitis externa (AOE) when administered twice daily for 7 days
224246776|NCT02216071|DRUG|EXL CDOS (Ciprofloxacin 0.3% and Dexamethasone 0.1%) Sterile Otic Suspension|Treatment of acute otitis externa (AOE) when administered twice daily for 7 days
224246777|NCT00385125|DRUG|Bendamustine|
224246778|NCT00385125|DRUG|Rituximab|
224246779|NCT00252811|DRUG|Gefitinib|
224246780|NCT04500353|OTHER|Face mask application for CPAP and/or PPV delivery|Face mask application for CPAP and/or PPV delivery
224246781|NCT02069665|OTHER|Fuxiong San|external application; 8-10cm wide, 0.3-0.5cm thick; 10mins for patient aged 1 to 3-year old; 15mins for those aged 3 to 5-year old; once daily
224246782|NCT02069665|DRUG|Xiyanping injection|ivd. 5 to 10 mg/(kg•d), plus 5% Glucose Injection, 80 to 100 ml, ivd. Once a day injection.
224246783|NCT02069665|DRUG|Ribavirin Injection|ivd. 10 to 20 mg/(kg•d), plus 5% Glucose Injection, 80 to 100 ml, ivd. Once a day injection.
224246784|NCT02069665|DRUG|Xiaoer Qingfei Heji (mixture)|children aged 6 months to 1 year old: 10 ml, orally taken three times daily; children aged 1 to 3 year old: 15 ml, orally taken three times daily; children aged 3 to 5 year old: 20 ml, orally taken three times daily;
224246785|NCT02069665|DRUG|Zhi Ke San|children aged 6 months to 1 year old: 0.5g, orally taken three times daily; children aged 1 to 3 year old: 1.5g, orally taken three times daily; children aged 3 to 5 year old: 2.0g, orally taken three times daily;
224246786|NCT02069665|DRUG|Hua Tan San|children aged 6 months to 1 year old: 0.5g, orally taken three times daily; children aged 1 to 3 year old: 1.5g, orally taken three times daily; children aged 3 to 5 year old: 2.0g, orally taken three times daily;
224246787|NCT02069665|DRUG|Guaifenesin Syrup|children aged 6 months to 1 year old: 3ml, orally taken three times daily; children aged 1 to 3 year old: 5ml, orally taken three times daily; children aged 3 to 5 year old: 8ml, orally taken three times daily;
224246788|NCT02069665|DRUG|Ibuprofen Suspension|taken under prescription
224246789|NCT02069665|DRUG|salbutamol|taken under prescription
224246790|NCT02209480|BEHAVIORAL|Alexander Technique|
224246791|NCT02209480|DEVICE|Heat pad application|
224246792|NCT02209480|BEHAVIORAL|guided imagery|
224246793|NCT05639062|BEHAVIORAL|Narrative-based card game|This intervention aims to evaluate the preliminary effects of narrative-based card game intervention on spiritual well-being, hope, anxiety, depressive symptoms, and QoL of childhood cancer patients at postintervention and at 1-, and 3-month follow-up postintervention.
224246794|NCT00389064|DRUG|Quetiapine XR|Quetiapine XR 50 mg tablets orally administered in flexible doses of 50 to 300 mg quetiapine XR once daily, in the evening for a 9-week treatment period.
224246795|NCT00389064|DRUG|Placebo|Matching placebo tablets orally administered in flexible doses of 50 to 300 mg once daily, in the evening for a 9-week treatment period.
223770677|NCT04438928|OTHER|Non-Supplement|Control study group of pregnant women non-supplemented with multi-micronutrients and docosahexaenoic acid (MMS) soft gel capsules
224246796|NCT03104101|COMBINATION_PRODUCT|TPTNS+Drug|one tablet Trospium Chloride 20 mg once daily Plus TPTNS
224246797|NCT03104101|DEVICE|TPTNS|Surface adhesive electrodes placed on the skin above medial malleolus
224246798|NCT03328936|OTHER|Laboratory Biomarker Analysis|Correlative studies
224246799|NCT03328936|DRUG|Melphalan Hydrochloride|Given personalized dose IV for predicted 3-day duration of severe neutropenia
224246800|NCT03328936|DRUG|Melphalan Hydrochloride|Given personalized dose IV for predicted 5-day duration of severe neutropenia
224246801|NCT03328936|OTHER|Pharmacological Study|Correlative studies
224246802|NCT02917902|OTHER|Food boxes|Box of approximately 50 pounds of nutritious foods provided by food pantry, including fresh fruits and vegetables as well as shelf-stable items selected for diabetic patients, along with brief education provided by food pantry staff.
224246803|NCT01007500|DRUG|Dexamethasone|Experimental: Dexamethasone 8 mg IV after induction of anesthesia, Ondansetron 4 mg IV at the end of surgery and 12 mg mix to intravenous patient controlled analgesia device.
223770678|NCT00002816|DRUG|cytarabine|Given IV
224246804|NCT01007500|DRUG|Ondansetron|Active comparator: Ondansetron 4 mg IV at the end of surgery and 12 mg mix to intravenous patient controlled analgesia device.
224246805|NCT04753437|DRUG|Clarithromycin|Clarithromycin tablets.
223770679|NCT00002816|DRUG|dexamethasone|Given IV
223770680|NCT00002816|DRUG|etoposide|Given IV
223770681|NCT00002816|DRUG|idarubicin|Given IV
223770682|NCT00002816|DRUG|ifosfamide|Given IV
223770683|NCT00002816|DRUG|leucovorin calcium|
224246806|NCT04753437|DRUG|Amoxicillin|Amoxicillin capsules.
224246807|NCT04753437|DRUG|Bismuth potassium citrate|Bismuth potassium citrate tablets.
224246808|NCT04753437|DRUG|Esomeprazole|Esomeprazole tablets.
224246809|NCT04753437|DRUG|Vonoprazan|Vonoprazan tablets.
223665922|NCT03116581|OTHER|Behavior|"Random-dots tasks: dots appear and move, most have a random trajectory but a given proportion of them move coherently to the same direction.~* Vicarious reward Each trial begins with a cue, showing 'me' or 'him' and filled rectangle filled proportionally to the payoff. The cue and the square are depicted in yellow (oneself) or blue (other), depending on the beneficiary. The moving dots are then presented and the subjects respond. At the end of dots motion, the feedback is presented. If the response was correct, a pile of coins proportional to the payoff is shown. For incorrect responses and misses, a red-colored cross is displayed.~* Audience effect Each trial begins with the display of two eyes (public) or a padlock (private). The moving dots are shown and the participant answers. Audience condition changes the information available on accuracy when submitting comments. In the observed condition, an arrow shows the response. In the observed condition, no feedback is displayed."
223665923|NCT03116581|OTHER|fMRI (functional Magnetic Resonance Imagery)|"Both behavioral task (audience effect and vicarious reward) will be studied in fMRI (functional Magnetic Resonance Imagery). The same paradigms used in the behavioral experiment will be adapted for fMRI.~Audience Effect experiment: trials will last for 10 seconds maximum. With 80 trials for each condition (public easy, public difficult, private easy and private difficult), the task will count a total of 320 trials and have a 54 minutes duration, in 3 runs of 17 minutes each.~Vicarious Reward experiment: trials will have a 10 seconds maximum duration. Using 40 trials for each condition (other low payoff, other high payoff, self low payoff, self high payoff, control condition), the task will have a total of 200 trials and last for 54 minutes, in 6 runs of 9 minutes each."
223665924|NCT03116581|OTHER|MEG (MagnetoEncephaloGraphy)|"Both behavioral task (audience effect and vicarious reward) will be studied in MEG (MagnetoEncephaloGraphy). The same paradigms used in the behavioral experiment will be used in MEG.~Audience Effect experiment: trials will last for 7 seconds maximum. With 100 trials for each condition (public easy, public difficult, private easy and private difficult), the task will count a total of 400 trials and have a 47 minutes duration. Every 100 trials (about 12 minutes of tasks), a break will be proposed to the participants.~Vicarious Reward experiment: trials will have a 7.2 seconds maximum duration. Using 75 trials for each condition (other low payoff, other high payoff, self low payoff, self high payoff, control condition), the task will have a total of 375 trials and last for 45 minutes. Every 125 trials (every 15 minutes), a break will be proposed to the participants."
223665925|NCT01563614|RADIATION|Brain radiotherapy (WBRT alone, SRT/SRS alone or WBRT plus SRT/SRS)|Brain radiotherapy concomitant to lomustine and liposomal cytarabine chemotherapy.
223665926|NCT01563614|DRUG|Lomustine|Brain radiotherapy concomitant to lomustine and liposomal cytarabine chemotherapy.
224246810|NCT05763238|OTHER|INTERVENTION GROUP|"Preoperative Protocol:~DAY 1: Incentive spirometry 1 set of 2 repetitions(each repetition includes 05 deep inhalations) 3 times a day.~Active ROMS (3 sets of 5 repetitions of both upper and lower limb thrice a day) Walk, Static marching to 10 steps thrice a day. DAY 2: Incentive spirometry 1 set of 3 repetitions (each repetition includes 08-10 deep inhalation) 3 times a day.~Active ROMS, 3 sets of 5 repetitions of both upper and lower limb thrice a day) Walk, Static marching to 15 steps thrice a day. DAY 3: Incentive spirometry,1 set of 3 repetitions(each repetition includes 10 deep inhalation) 3 times a day Active ROMS 3 sets of 5 repetitions of both upper and lower limbs thrice a day. Walk, Static marching to 20 steps thrice a day. Postoperative Protocol: Conventional protocol of respective cardiac setup"
223770684|NCT00002816|DRUG|mesna|Given IV
224246811|NCT05763238|OTHER|CONTROL GROUP|"Preoperative: Patients' parents will be educated about the disease process, surgery, it's possible complications, and precautions.~Postoperative: Conventional protocol of respective cardiac setup"
224246812|NCT04168788|OTHER|Blood test for genetic analysis|Drawing blood to realize a genetic analysis for susceptibility to hepatic VOD.
224246813|NCT01655628|DRUG|GC chemotherapy plus CIK cells (Gemcitabine, Cisplatin, Autologous CIK cells)|A total of 40 patients enrolled will be accept 4 cycles GC chemotherapy(every 4 weeks),then they will randomized divided into two groups. 20 patients will maintain autologous CIK cells for 8 cycles (every 4 weeks);the other 20 patients will not accept CIK cells treatment. Afer the all 40 patients have accomplished 4 cycles GC regimen chemotherapy plus CIK cells treatment or 4 cycles GC chemotherapy alone, the early effects will be assessed and long-term efficacy such as OS and PFS will be evaluated.
224246814|NCT01655628|DRUG|GC chemotherapy (Gemcitabine, Cisplatin)|A total of 40 patients enrolled will be accept 4 cycles GC chemotherapy(every 4 weeks),then they will randomized divided into two groups. 20 patients will maintain autologous CIK cells for 8 cycles (every 4 weeks);the other 20 patients will not accept CIK cells treatment. Afer the all 40 patients have accomplished 4 cycles GC regimen chemotherapy plus CIK cells treatment or 4 cycles GC chemotherapy alone, the early effects will be assessed and long-term efficacy such as OS and PFS will be evaluated.
224246815|NCT03447678|DRUG|Pembrolizumab|humanized antibody used in cancer immunotherapy
224246816|NCT01929122|DIETARY_SUPPLEMENT|Placebo-Control Meals and Snacks|
224246817|NCT01929122|DIETARY_SUPPLEMENT|Cooked Navy Bean Powder Meals and Snacks|
224246818|NCT01929122|DIETARY_SUPPLEMENT|Rice Bran Meals and Snacks|
224246819|NCT02164279|OTHER|Urinary sample collection|urinary sample collection will be done at the inclusion visit for the assessment of the microalbuminuria ( \< or \> than 100mg/L)
224246820|NCT00002994|BIOLOGICAL|interleukin 2|low dose: 1 million IU/square meter subq injection q day days 1-7 and 11-20 cycle 1; days 4-14 subsequent cycles Intermediate dose: 12 million IU/square meter subq injection on days 8-10 of cycle 1; days 1-3 of subsequent cycles
224246821|NCT00002994|BIOLOGICAL|rhuMAb|90 min IV infusion day 7 of each cycle
224246822|NCT02738242|DEVICE|Novus system|The Novus system is a FES based neuroprosthesis, which intended to provide ankle dorsiflexion and knee flexion or extension in individuals with foot drop and thigh muscle weakness, following an upper motor neuron injury or disease.
224246823|NCT04499170|OTHER|Muscular Energy Technique G1|Group of older (G1) - The muscular energy technique (TEM) based on Chaitow's proposal will be applied to the postural posterior muscles of the lower limbs such as gastrocnemius, soleus, ischiostibials, gluteus medius and paravertebral. During TEM, the contraction will be maintained from 7 to 10 seconds, against the resistance imposed by the therapist. After relaxation, range of motion will be gained until your new restriction barrier. This process will be repeated for 3 times.
224321728|NCT04319237|BEHAVIORAL|PROMIS Cognitive Function 4a Questionnaire|The PROMIS measures function, symptoms, behavior and feelings.
223665927|NCT01563614|DRUG|Liposomal cytarabine|Brain radiotherapy concomitant to lomustine and liposomal cytarabine chemotherapy.
223665928|NCT01823588|BEHAVIORAL|Nurse-led reminder through email.|"Both groups will receive an educational program and usual care. The educational program will consist of 1-hour sessions, during which the NCM emphasize the importance of blood pressure control and correct measurement, give advice for a correct blood pressure self-measurement; report non-pharmacological strategies for a healthy lifestyle, and instruction on how to fill the daily self-assessment form.~Educational program and usual cardiovascular prevention. The educational program will consist of 1-hour sessions, during which the NCM emphasize the importance of blood pressure control and correct measurement, give advice for a correct blood pressure self-measurement; report non-pharmacological strategies for a healthy lifestyle, and instruction on how to fill the daily self-assessment form."
223770685|NCT00002816|DRUG|pegaspargase|Given IV
223770686|NCT00002816|DRUG|therapeutic hydrocortisone|
223770687|NCT00002816|DRUG|thioguanine|
224246824|NCT04499170|OTHER|Muscular Energy Technique G2|Group of young people (G2) - The muscular energy technique (TEM) based on Chaitow's proposal will be applied to the postural posterior muscles of the lower limbs such as gastrocnemius, soleus, ischiostibials, gluteus medius and paravertebral. During TEM, the contraction will be maintained from 7 to 10 seconds, against the resistance imposed by the therapist. After relaxation, range of motion will be gained until your new restriction barrier. This process will be repeated for 3 times.
224246825|NCT00480350|BEHAVIORAL|rice based food supplement|
224246826|NCT00380445|DRUG|Vildagliptin|
224246827|NCT03306160|OTHER|48-hour blood pressure ambulatory monitoring|at first-time dialysis after enrollment, each patient will receive brachial and central blood pressure monitoring for 48 hours using a validate and commercially available device Mobil-O-Graph (IEM, Germany).
224246828|NCT03243630|DRUG|IV nicotine|Subjects in each arm will receive three infusions in a random order one hour apart. The infusions will be saline, 0.25mg/70kg and 0.5mg/70kg
224246829|NCT03243630|DRUG|Menthol flavor|American e-liquids' menthol flavor used in e-cigarettes will be used as the placebo comparator
224246830|NCT03243630|DRUG|green apple|green apple will be added to the menthol flavor
224246831|NCT03243630|DRUG|green apple and menthol|menthol and green apple will be the active intervention
224246832|NCT03153930|BEHAVIORAL|Walking breaks|In-Lab (full sample): participants will be asked to walk on a treadmill for 3 minutes every 30 minutes at a moderate pace during a 3-hour OGTT Free-living (sub-sample; N=12): participants will be prompted via an ActivPAL vtap monitor to walk for 3 minutes every time sedentary behavior lasts longer than 30 continuous minutes
224246833|NCT03153930|BEHAVIORAL|Sitting only|In-Lab (full sample): participants will remain seated for 3 hours during an OGTT Free-living (sub-sample; N=12): participants will perform their habitual sedentary behaviors
224246834|NCT04061005|PROCEDURE|Cold snare polypectomy|CSP, which does not include electrocautery to do a polypectomy with a snare.
224246835|NCT04061005|PROCEDURE|Hot snare polypectomy|HSP, which uses the electrocautery to do a polypectomy with a snare.
224246836|NCT04061005|PROCEDURE|Endoscopic margin observation method|Endoscopic margin observation method, After rinsing the polyp specimen with physiological saline, fully natural extension, fixing it to the foam board with a needle, and observing the margin with a colonoscope or a magnifying colonoscope near-focus mode to determine whether there is residual polyp tissue.
224246837|NCT02140060|DRUG|Dose Level A / Brinzolamide 1% ophthalmic suspension|Fixed combination
224246838|NCT02140060|DRUG|Dose Level B / Brinzolamide 1% ophthalmic suspension|Fixed combination
224246839|NCT02140060|DRUG|Dose Level C / Brinzolamide 1% ophthalmic suspension|Fixed combination
224246840|NCT02140060|DRUG|Brinzolamide 1% ophthalmic suspension AZOPT®|
224246841|NCT02140060|DRUG|Travoprost 0.004% ophthalmic solution TRAVATAN Z®|
224246842|NCT02140060|DRUG|Travoprost solution vehicle|Inactive ingredients used for masking purposes
224246843|NCT02140060|DRUG|Brinzolamide suspension vehicle|Inactive ingredients used for masking purposes
224246844|NCT04849520|DEVICE|High flow nasal cannula|Oxygen supplement via high flow nasal cannula at a rate of 2 liters/kg/min
224246845|NCT04849520|DEVICE|Buccal oxygenation|Oxygen supplement intra-orally via oral Ring-Adair-Elwyn endotracheal tube connected to oxygen at a rate of 0.5 liters/kg/min
224246846|NCT00279357|PROCEDURE|Narrow Band Imaging|
224246847|NCT01856426|DRUG|EDP239|
224246848|NCT01856426|DRUG|Placebo|
224246849|NCT02845739|OTHER|Kidney transplanted patients|
224246850|NCT00862550|OTHER|Acupuncture|20 Minute Acupuncture Sessions Before Radiation Therapy Treatment, 3 Days Per Week for 7 Weeks.
224246851|NCT07036757|OTHER|Meal Kit and Nutrition Education|Meal kits contain ingredients for 3 meals designed for 4 servings, along with nutrition education materials, recipes, and information on how to store and prepare the meals. Weekly educational content focused on healthy eating, food security, and meal planning will be provided, either via print materials or through an online platform (e.g., email or app-based resources).
224246852|NCT07037264|DEVICE|Non-ablative fractional laser treatment|The entire scar area is sealed with local anesthetic for 60 minutes before laser treatment. Give the study side 1565 nm non-ablative fractional laser treatment, spot diameter 10～16 mm, energy 40～45 mJ/cm2, spot density 150～200/cm2,1\~2passes.
224246853|NCT07035223|DRUG|4 µg dexmedetomidine in 0.5 mL of normal saline intrathecal (dexmedetomidine 100 µg/mL will be diluted in 12.5 ml preservative-fr|Group D: patients will receive 3 mL volume of 0.5% hyperbaric bupivacaine and 4 µg dexmedetomidine in 0.5 mL of normal saline intrathecal (dexmedetomidine 100 µg/mL will be diluted in 12.5 ml preservative-free normal saline, 0.5 ml will be withdrawn)
223770688|NCT00002816|DRUG|vincristine sulfate|Given IV
223770689|NCT00002816|RADIATION|low-LET cobalt-60 gamma ray therapy|
223770690|NCT00002816|RADIATION|low-LET electron therapy|
223770691|NCT00002816|RADIATION|low-LET photon therapy|
223770692|NCT00002816|DRUG|Methotrexate|Given IV
223770693|NCT05330650|DRUG|Coated Vicryl+|We used coated suture for : hystetrotomy reparation / aponeurosis and skin closure.
223770694|NCT05330650|DRUG|Vicryl|We used non coated suture for : hystetrotomy reparation / aponeurosis and skin closure.
224246854|NCT07035223|DRUG|fentanyl|Group F:patients will receive 3 mL volume of 0.5% hyperbaric bupivacaine with 25 µg fentanyl (0.5 mL) intrathecal.
223665929|NCT04889976|DEVICE|Double Active: Active portable transcranial stimulation (ptES) and active internet-based behavioral therapy (iBT)|ptES is delivered by the Flow device (Flow Neuroscience, Malmö, Sweden), consisting of a one-size-fits-all, transcranial direct current stimulation (tDCS) headset with circular electrodes (area = 22.9cm2). The anode is positioned over the left prefrontal cortex, and the cathode over the right prefrontal cortex. Current strength is set at 2mA (current density = 0.087mA/cm2) for 30 minutes, daily for 5 continuous days (with a 2-day pause) for the first 3 weeks, with twice-weekly sessions for the following 3 weeks (total of 21 sessions in 6 weeks). Active iBT consists of a smartphone app with an electronic therapist-avatar. The iBT sessions are delivered concomitantly to the tDCS sessions (the tDCS device connects via bluetooth to the participant's smartphone app).
223665930|NCT04889976|DEVICE|ptES-only: Active portable transcranial stimulation (ptES) and sham internet-based behavioral therapy (iBT)|ptES is delivered by the Flow device (Flow Neuroscience, Malmö, Sweden), consisting of a one-size-fits-all, transcranial direct current stimulation (tDCS) headset with circular electrodes (area = 22.9cm2). The anode is positioned over the left prefrontal cortex, and the cathode over the right prefrontal cortex. Current strength is set at 2mA (current density = 0.087mA/cm2) for 30 minutes, daily for 5 continuous days (with a 2-day pause) for the first 3 weeks, with twice-weekly sessions for the following 3 weeks (total of 21 sessions in 6 weeks). The sham iBT sessions are delivered concomitantly to the active ptES sessions (the ptES device connects via bluetooth to the participant's smartphone app).
223665931|NCT04889976|DEVICE|Double-sham: Sham portable transcranial stimulation (ptES) and sham internet-based behavioral therapy (iBT)|Sham ptES for this trial is delivered by the Flow device (Flow Neuroscience, Malmö, Sweden), consisting of a one-size-fits-all transcranial direct current stimulation (tDCS) headset, with circular electrodes (area = 22.9cm2). The anode is positioned over the left prefrontal cortex, and the cathode over the right prefrontal cortex. The sham protocol consists of a fade-in and fade-out phases of 1mA for 45 seconds, followed by a silent period in between for the remaining 28 1/2 minutes. The sham iBT sessions are delivered concomitantly to the sham ptES sessions (the ptES device connects via bluetooth to the participant's smartphone app).
223665932|NCT05249218|OTHER|Phase B - Extra 1 Phe exchange from fruits/vegetables containing Phe from 76-100mg/100g|Usual low Phe diet + 60g fruits/vegetables containing Phe from 76-100mg/100g
223665933|NCT05249218|OTHER|Phase C - Extra 2 Phe exchanges from fruits/vegetables containing Phe from 76-100mg/100g|Usual low Phe diet + 120g fruits/vegetables containing Phe from 76-100mg/100g
223665934|NCT05249218|OTHER|Phase D - Extra 1 Phe exchange from milk or yoghurt|Usual low Phe diet but 1 x 50 mg extra Phe exchange from milk or yoghurt
223665935|NCT05249218|OTHER|Phase E - Extra 2 Phe exchanges from milk or yoghurt|Usual low Phe diet but 2 x 50 mg extra Phe exchange from milk or yoghurt eaten daily
223665936|NCT00408044|PROCEDURE|cardiac surgery with sternotomy|
223665937|NCT05560308|DRUG|Trastuzumab Emtansine for Injection|3.6 mg/kg body weight (IV), administered on day 1, 21 days as a treatment cycle;
223665938|NCT05560308|DRUG|Pyrotinib Maleate Tablets|The initial dose is 320 mg (PO), administered orally within 30 minutes after meals, at the same time every day, 21 days as a treatment cycle;
223665939|NCT02695160|BIOLOGICAL|SB-FIX|Single dose of each of the 3 components of SB-FIX: ZFN1, ZFN2 and cDNA Donor.
223665940|NCT03730402|DRUG|Bupivacaine|utilizing local anesthetic to perform a regional block under laparoscopic guidance
223665941|NCT03730402|DRUG|Exparel 266 milligram Per 20 ML Injection|utilizing local anesthetic to perform a regional block under laparoscopic guidance
223665942|NCT03730402|DRUG|Saline|placebo injection of saline
223665943|NCT01685398|DRUG|0.5% timolol maleate eye drop|
223665944|NCT01685398|DRUG|Normal saline|
223665945|NCT02885571|DEVICE|SomnoDent Flex with DentiTrac|
223665946|NCT00423202|DRUG|ambrisentan|
223665947|NCT01681355|OTHER|Infant Formula|Standard cow's milk based infant formula with added prebiotic oligosaccharides, and a modified fat blend and protein composition
223665948|NCT02081755|DRUG|Everolimus|Everolimus Dosing: 1.5 mg BID (3.0 mg/day) for 12 months
223665949|NCT02081755|DRUG|Tacrolimus|Tacrolimus Dosing: 0.05 mg/kg BID for 12 months
223665950|NCT02081755|DRUG|Myfortic|Myfortic®: 360 mg to 1080 mg BID for 12 months
223665951|NCT02081755|DRUG|CellCept|CellCept: 500 mg to 1500 mg BID for 12 months
223665952|NCT02081755|DRUG|Imuran|0.5 mg/kg to 2 mg/kg QD for 12 months
223665953|NCT02980952|OTHER|High-fat overfeeding|
224246855|NCT07035587|OTHER|Serial Blood Sampling for Molecular Profiling|Cancer patients will undergo serial peripheral blood sampling at baseline (prior to surgery or chemotherapy), after treatment, and during follow-up visits. Blood samples will be analyzed for circulating tumor DNA (ctDNA), cell-free DNA (cfDNA), RNA, and protein biomarkers. The purpose is to detect variant allele frequency (VAF) and evaluate its relationship with tumor dynamics and treatment outcomes, including recurrence and survival.
224246856|NCT07035587|OTHER|One-Time Blood Sampling for Molecular Profiling|Control participants, including individuals with asymptomatic gallstones, benign polyps, or those undergoing health screening, will provide a one-time peripheral blood sample. The sample will be analyzed for cfDNA, RNA, and protein biomarkers and used as a baseline reference to compare molecular characteristics between non-cancer and cancer groups.
223665954|NCT02980952|OTHER|Forearm immobilization|
223665955|NCT02408432|OTHER|Laboratory Biomarker Analysis|Correlative studies
223665956|NCT02408432|OTHER|Standard of Care|Undergo mesenchymal stem cell infusion
223665957|NCT02408432|DRUG|Mesenchymal Stem Cell Transplantation|Undergo mesenchymal stem cell infusion
223665958|NCT00052442|DRUG|pralatrexate|
223665959|NCT02218632|OTHER|lactose-free diet|standard diet
223665960|NCT02218632|DIETARY_SUPPLEMENT|Temporary oral galactose supplements|galactose supplements in the range of physiological galactose production
223665961|NCT00576680|DRUG|RAD001|Given orally once a day
223665962|NCT00576680|DRUG|Temozolomide|Taken orally once a day for one week followed by a one-week break period
224246857|NCT07035613|DRUG|BXD treatment|The BXD extract was obtained from Sun Ten Pharmaceutical Company and is manufactured according to the standard procedures outlined in the Taiwan Herbal Pharmacopeia IV. The extract is produced using a fixed herbal composition and ratio based on the traditional BXD formula to yield a concentrated powder. The administration of BXD in this study follows the dosage and usage guidelines specified in the Pharmacopeia.
223665963|NCT04785690|DEVICE|CureSight|Subjects assigned to the binocular treatment group will be prescribed the CureSight treatment to watch for 90 minutes per day, 5 days a week for 16 weeks for the total of 120 hours. Parents of subjects will be instructed that the 90 minutes of daily treatment should be completed in a single 90-minute session, but if this is not possible for whatever reason, the treatment may be divided into two shorter sessions totaling 90 minutes per day
224321729|NCT04319237|BEHAVIORAL|Comprehensive Score for Financial Toxicity (COST) measure|The COST is a questionnaire made up of 11 statements around topics including costs, concerns and resources and is designed to measure financial toxicity. The user answers questions about their concern over finances numbered from 0-4, with 0 being not at all and 4 being very much.
223665964|NCT04785690|DEVICE|Patching|"Subjects assigned to the patching group will wear an adhesive patch over the dominant eye for 2 hours per day, 7 days per week for 16 weeks. Parents of subjects will be instructed that the 2 hours of daily patching should be completed in a single 2-hour session, but if this is not possible for whatever reason, the treatment may be divided into shorter sessions totaling 2 hours.~Parents will be asked to complete a usage diary by manually recording the patch usage time on daily basis."
223665965|NCT00321087|DRUG|T2000|Dose escalation from 600 to 1000 mg
223665966|NCT00321087|DRUG|T2000|Placebo followed by T2000 dose escalation from 600 to 1000 mg
223665967|NCT00321087|DRUG|T2000|Placebo followed by dose escalation from 600 to 1000
223665968|NCT05130671|DRUG|Standard of care|Standard of care treatment as per the hospital guidelines
223665969|NCT05130671|DIETARY_SUPPLEMENT|Investigational treatment|Combination of quercetin and curcumin as add-on to the standard of care
223665970|NCT06403488|DRUG|Letrozole 2.5mg|specific aromatase inhibitor
223665971|NCT02816164|DRUG|Neupogen|Subcutaneous injections
223665972|NCT00708253|DEVICE|Double-balloon procedure (DBE)|Double-balloon procedure (DBE): DBE is performed using the DBE T-type endoscope system (Fujinon Inc, Japan), as described in the literature. The DBE endoscope consist of a 200-cm long video endoscope with an outer diameter of 8.5 mm and a flexible overtube with a length of 145 cm and an outer diameter of 12 mm. Latex balloons are attached to both the endoscope and the overtube. These balloons are inflated and deflated during insertion, as described elsewhere in detail (2,3).
223770695|NCT03211169|PROCEDURE|Biopsies of bile duct stricture with pediatric biopsy forceps|Biopsies of the stricture will be taken to evaluate diagnostic yield of Pediatric Biopsy Forceps
224246858|NCT07036107|DEVICE|ABLE Exoskeleton|Participants will receive a 24-session rehabilitation treatment program with the ABLE Exoskeleton, 3 times a week for up to 8 weeks
224246859|NCT07036107|OTHER|Conventional therapy|"Participants will receive a 24-session conventional therapy program for gait rehabilitation, 3 times a week for up to 8 weeks.~Conventional therapy includes joint mobilizations, strengthening of paretic muscles and re-education of walking with parallel bars, making use of the technical aids and orthoses required by the patient (KAFOs, crutches and walkers)."
224246860|NCT07036133|DRUG|Pralatrexate Injection|Pralatrexate will be administered based on Child-Pugh Classification of liver impairment
224246861|NCT07037147|COMBINATION_PRODUCT|instrument assistance soft tissue mobilisation|In this group instrument assistance soft tissue mobilisation will be given followed by conventional therapy. IASTM will be given by using IASTM tool M2T blade. In this process patient will be asked to sit in a chair by resting its forearm in front of the table.
224246862|NCT07037147|COMBINATION_PRODUCT|Bowen technique|In this group Bowen technique will be given after the basic conventional therapy. For this technique patient will be asked to lie in a prone position where the neck of the patient will be supported with the help of a small pillow. Therapist thumb will be placed on the affected side of the muscle.
224246863|NCT07035600|PROCEDURE|Targeted leaderled training program|"Training program:~After inclusion and consent the patients are instructed through an online group training program consisting of specific training of levator, abdominal, quadriceps (all portions), and gluteal muscles as well as endurance training. They are given information about WHO recommendations about physical activity. The patients are asked to sign up for two specific training occasions per week where no group will be larger than 10 patients. Group based exercise sessions consist of 45-minute supervised online zoom exercise sessions. Apart from the supervised sessions patients are encouraged to perform one functional training session, unsupervised, as well as follow the WHO recommendation for aerobic exercise"
224246864|NCT07035600|PROCEDURE|Control arm with WHO recommendation on physical activity|Training will be in accordance with WHO recommendations of 30 min aerobic physical activity five times per week (150 min per week) plus strength sessions twice weekly. The patients will be individually adviced on how to perform the training at inclusion in the trial. This is considered standard care and will not include any on-line supervision, but will include a coaching/reminder by a phone call from a research nurse/short message service (by choice of the patient) at regular intervals before and after surgery
224246865|NCT07035236|PROCEDURE|maxillary sinus lifting|The schneiderian membrane will be tented using titanium mesh.
224246866|NCT07035236|PROCEDURE|Maxillary sinus lifting|The Schneiderian membrane will be elevated using bone screws
224246867|NCT03392909|DRUG|Gentamicin|Short-term intravenous gentamicin therapy should have the advantage of treating all of the patient's multiple skin wounds simultaneously. Six patients (three adults and 3 children) will receive intravenous gentamicin (7.5 mgs/kg) daily for 14 days and then stopped. Three adult patients will receive intravenous gentamicin (7.5mg/kg) biweekly for three months and then stopped.
224246868|NCT03096821|DRUG|ngFDS selected treatment|Treatment based on next-generation functional drug screening (ngFDS). Treatment with commercially available treatments (per package insert instructions) selected by functional drug screening. For drug screening tumor cells from bone marrow aspirates, peripheral blood, pleural effusion, or excised lymph node samples are purified over Ficoll gradient (bone marrow, peripheral blood, pleural effusion) (GE healthcare) or homogenized and filtered (lymph tissue).
224246869|NCT03325114|DRUG|Chlorthalidone|Chlorthalidone 12.5-5 mg by mouth daily for 4 weeks
224321730|NCT03584165|GENETIC|BIIB111|Administered as specified in the treatment arm.
224321731|NCT03584165|GENETIC|BIIB112|Administered as specified in the treatment arm.
224321732|NCT05720806|OTHER|Weight Bearing as tolerated (WBAT) immediately following surgery.|Subject will be provided standard of care physical therapy following surgical intervention, except will be able to self-select weight bearing based on pain and confidence.
224246870|NCT06949202|OTHER|breating exercises|diaphragmatic breathing
224246871|NCT05018416|BIOLOGICAL|Renal Autologous Cell Therapy (REACT)|Autologous selected renal cells (SRC)
223665973|NCT00708253|DEVICE|Single-balloon procedure (SBE)|Single-balloon procedure (SBE): SBE is performed using the SBE endoscope system (SIF-Q180, Olympus Optical Co., Ltd., Tokyo, Japan). The SBE endoscope consist of a 200-cm long video endoscope with an outer diameter of 9.2 mm and a flexible overtube with a length of 140 cm and an outer diameter of 13.2 mm. One single balloon is attached to the the tip of the overtube. The insertion process follows the method used for DBE, but instead of inflation of the endoscope balloon, the tip of the endoscope is angulated at straightening
224246872|NCT01727271|DRUG|Tenofovir|
223665974|NCT05405088|OTHER|Questionnaires|Pain Sensitive Questionnaire (PSQ) Corah's Dental Anxiety Scale (CDAS) Pain Catastrophizing Scale (PCS) Gender Eye color Hair color Blood group
223665975|NCT03859973|DRUG|BI 425809|Tablet
224246873|NCT01727271|BIOLOGICAL|Pegylated interferon alpha-2b|
224246874|NCT04487262|PROCEDURE|Cardiac surgery|Elective open heart surgery
224246875|NCT01387737|DRUG|TA-7284-Low|TA-7284-Low
224246876|NCT01387737|DRUG|TA-7284-High|TA-7284-High
224321733|NCT05720806|OTHER|Flat foot weight bearing (FFWB) immediately following surgery|Subject will be provided standard of care physcial therapy following surgical intervention except
223665976|NCT03859973|DRUG|Placebo|Tablet
224246877|NCT01360970|BIOLOGICAL|hepatitis A vaccine ( HAVRIX or EPAXAL)|1.0 ml im ( Havrix) and 0.5 ml im (Epaxal. Both vaccines are given two times with 6 months interval
224246878|NCT00060918|DRUG|carvedilol|
223665977|NCT04483388|OTHER|Training with Virtual Reality|Computed virtual reality therapy was performed using the Nintendo Wii® console equipment. This system allows interaction with the player by means of a movement detection system and the representation of his avatar graphical representation of a user in virtual reality. It has a remote control with a wireless system, responsible for capturing the speed, direction , acceleration and deceleration of movement. The movements performed by the player are captured and reproduced on a screen via an infrared light sensor, positioned above the TV. The feedback given by the TV provides the movement itself observing opportunity in real time, generating positive reinforcement and facilitating training and improved task. The software used in this study was the Nintendo Wii Sports.
223665978|NCT04483388|OTHER|Conventional Training|"It was done five types of exercises following to the protocol:~Exercise 1 (shoulder abduction); Exercise 2 (external rotation of the shoulder); Exercise 3 (elbow extension); Exercise 4 (weight transfer in upper limbs: a sitting position); Exercise 5 (function: task-oriented training)."
224246879|NCT00060918|DRUG|metoprolol|
224246880|NCT04041843|DRUG|Apixaban|Apixaban 10 mg twice daily p.o. for seven days followed by 5 mg twice daily p.o. for children and adolescents weighting ≥40 kg
223665979|NCT02855541|DEVICE|DeskCycle|A small cycling ergometer that can fit under a desk at the workplace.
223665980|NCT01417013|OTHER|Systane Ultra|Lubricant Eye Drops
223665981|NCT01417013|OTHER|Optive|Lubricant eye drops
224246881|NCT03552081|OTHER|Fragmented DNA evaluation in blood and semen samples|The objective will be to evaluate the decrease in the percentage of sperm with spermatic DNA fragmentation by the TUNEL technique following the evolution of this rate to 3 months, 6 months and 12 months after cessation of smoking by blood and semen samples.
224246882|NCT01950637|BEHAVIORAL|No treatment given|Completion of 90-item online questionnaire.
224246883|NCT01950637|BEHAVIORAL|survey|Completion of 58-item online questionnarie.
224246884|NCT04414917|DRUG|Twin block|Dental local anesthetic administered to target the jaw 'closer' muscles, temporalis and masseter
223665982|NCT01389661|BIOLOGICAL|MSV treatment|Autologous maxillary bone marrow mesenchymal stem cells (MSV-H) collected from patient, mesenchymal cells isolation and expansion under GMP conditions following the IBGM-Valladolid protocol (MSV)
224246885|NCT04414917|DEVICE|iPill dispenser|An active pill dispenser, regulated by patient's pain score entered on an iPill App installed on their smart phone (iPhone, Android) to dispense opioid (for pain corresponding to severe pain) or prescription strength ibuprofen and acetaminophen (for moderate pain), with over the counter solutions for mild pain recommended. This pill dispenser will be given to all patients, in both Twin block and Control groups, to regulate and monitor their pain experience-driven pain medication regimen. The pill dispenser will be packaged with pain medication (1 dispenser with vicodin, 1 with prescription ibuprofen, 1 with acetaminophen) that has been coencapsulated with ingestible event markers (IEMs, Proteus Discover).
224246886|NCT02982408|DIETARY_SUPPLEMENT|High carbohydrate overfeeding|"All participant's individual energy requirement will be determined in mega joules (MJ) per day. The energy requirement will be multiplied by a factor 1.5 for a low physical activity level (PAL). The MJ will be rounded up or down to the nearest whole number.~The participant will receive food corresponding to \~25% additional energy above their calculated energy requirement. The 25% extra energy will be supplied to the participants for 4 weeks in the form of food containing simple carbohydrates. The subjects will be given a daily snack package containing processed foods or refined foods such as sweets, cookies, soft drinks, juice etc. To ensure an adequate energy surplus (i.e. weight gain), physical activity has to be decreased to a low level during the 4 weeks overfeeding period."
224246887|NCT02982408|BEHAVIORAL|Exercise|"Half of the participants will be randomized to a 3-month exercise-training program.~The training program consists of combined aerobic training and strength training. The training program is performed unsupervised 3 times per week 45 minutes per session for 3 months in the local fitness center. Before engaging in the training program a maximal oxygen consumption test (VO2 max) are conducted and the maximal heartrate (HR) are determined.Participants are wearing the Polar V800 HR monitor and are asked to note their HR in a training log at the end of the last interval at each training session. The strength training program consist of 6 exercises (2 exercises paired together) involving the large muscle groups. The first training session is completed supervised at Rigshospitalet . After 6 weeks the training program is adjusted. Compliance will be ensured by phone calls, text messages and e-mails from study personnel."
224321734|NCT03735992|BEHAVIORAL|Mind-body medicine group program|The group program is mainly based on MBSR. It further integrates elements of the mind-body medicine cancer program of the Benson-Henry Mind/Body Medical Institute at Harvard Medical School which is rooted in psychoneuroendocrinology and focuses on relaxation techniques, exercise, cognitive restructuring, diet, and social support. In addition, naturopathic methods of selfregulation and self-care are incorporated.
223665983|NCT00033267|DRUG|temsirolimus|Given IV
223665984|NCT01131013|DRUG|Placebo|Matching placebo in capsules administered as a single oral dose.
223770696|NCT03211169|PROCEDURE|Biopsies of bile duct stricture with cholangioscopy-directed biopsies|Biopsies of the stricture will be taken to evaluate diagnostic yield of cholangioscopy-directed biopsies
223770697|NCT05598229|OTHER|Tik Tok|Encourage and do not restrict watching Tik Tok
223770698|NCT00354224|DRUG|capecitabine|
224246888|NCT02982408|BEHAVIORAL|Normal physical activity|"The other half of the participants will be randomized to a 3-month with normal physical activity level (control).~The participants will have to return to the physical activity level they had before entering the study (baseline level). Compliance will be ensured by phone calls and text messages from study personnel. The subjects will wear a simple pedometer on the hip showing the number of steps. Once a week a text message (SMS-track) is automatically sent asking the participants to enter the weekly number of steps. The test personnel receive the reply and contact the participant if the number of steps does not match the baseline level. During the first and the last 7 days of the exercise intervention participants are wearing 2 accelerometers measuring their physical activity behavior."
224246889|NCT03137108|DEVICE|Transcutaneous electrical spinal cord stimulation|Study intervention consists of the application of tSCS at three different frequencies (15 Hz, 30 Hz, 50 Hz) using the CE certified electrostimulator RehaMove 3. Stimulation will only be applied by an investigator during the two testing sessions. During the overground walking, the participants will be secured and assisted with the cable-driven body-weight support system FLOAT.
224246890|NCT05518890|OTHER|Diet Only|Participants caloric intake will be reduced by 5000kcal per week over 4 weeks
223770699|NCT00354224|DRUG|oxaliplatin|
223770700|NCT01000051|DRUG|Eltrombopag|Starting daily dose 50 mg orally on empty stomach (1 hour before or 2 hours after a meal) for 8 weeks. East Asians start at 25 mg daily.
224246891|NCT05518890|OTHER|Diet plus Exercise|Participants caloric intake will be reduced by 5000kcal per week over 4 weeks. Participants will also be asked to perform 5x30 minute cycling exercise sessions at home. Each week the intensity of exercise will be increased (week 1 = RPE 12, week 2 = RPE 13, week 3 = RPE 14, week 4 = RPE 15)
224246892|NCT03659006|BIOLOGICAL|Biological Collection|Blood sampling on catheter and CSF sampling from VDE, multimodal MRI at D42 and D365, Neurological and neuropsychological evaluation at one year
223665985|NCT01131013|DRUG|375 mg CK-2017357|375 mg CK-2017357 in capsules administered as a single oral dose.
223770701|NCT01000051|DRUG|Placebo|Once a day, orally for 8 weeks.
224246893|NCT01616381|DRUG|Sildenafil|PDE-5 Inhibitor
224246894|NCT01616381|DRUG|Placebo|Placebo for sildenafil 40mg x 3 daily
224246895|NCT06031766|DIETARY_SUPPLEMENT|Dietary supplement|The participation of the patients in the study will consist of performing the screening for malnutrition that is usually used in the hospital (CIPA) to which the GLIM test will be added, considered as the gold standard for this work. Subsequently, the sample of patients with a positive CIPA (as it is currently considered the screening test used in the hospital) will be implemented the therapeutic measures according to the usual protocol, while the subjects with a negative CIPA test but a positive GLIM will be studied. and constant monitoring taking the appropriate measures according to optional criteria. The patients will be followed up for the study of prognostic factors based on the variables obtained.
224246896|NCT03828981|PROCEDURE|fast-track recovery program|"Pre-operative: fast-track management counseling, fast-track educational video,tobacco cessation, daily physical activity, light meal 6 hours and clear liquids up to 2 hours before surgery, no bowel preparation, a warm blanket, medication.~Intra-operative: vaginal wound infiltrative anesthesia, early remove of urine catheter.~Post-operative: early oral intake liquids and food, early mobilization, avoiding opioids by use of pregabaline for postoperative pain."
224246897|NCT00899483|DRUG|Glucose potassium insulin solution|Enhanced glycaemic control in diabetics with glucose-potassium-insulin solution
224246898|NCT00239278|DRUG|budesonide/formoterol, 2x 200/6 microgram. 4 times daily|
224246899|NCT00239278|DRUG|prednisolone, 30 mg once daily and placebo|
224246900|NCT01458561|DEVICE|BioFoam Surgical Matrix|Surgical adjunct to control bleeding in open liver surgery
223665986|NCT01131013|DRUG|500 mg CK-2017357|500 mg CK-2017357 in capsules administered as a single oral dose.
223665987|NCT00422513|DRUG|methoxy polyethylene glycol-epoetin beta|120-360 micrograms intravenous (iv) monthly, starting dose
223665988|NCT00422513|DRUG|Epoetin alfa|As prescribed, iv, 3 times weekly
224246901|NCT01458561|DEVICE|Gelfoam Plus|Surgical adjunct in control of bleeding in open liver surgery
224246902|NCT02486445|DRUG|Rivaroxaban|Rivaroxaban 15 mg every 12 hours until the completion of the diagnostic work-up, which should not exceed 24 hours (maximum 2 tablets)
223665989|NCT00367783|DRUG|CP-741,952|
223665990|NCT03032380|DRUG|Cefiderocol|2000 mg intravenously every 8 hours for a period of 7 to14 days (dosage adjustment is necessary based on renal function)
223665991|NCT03032380|DRUG|Meropenem|2000 mg intravenously every 8 hours for a period of 7 to 14 days (dosage adjustment is necessary based on renal function)
223665992|NCT03032380|DRUG|Linezolid|600 mg of linezolid administered intravenously over 30 minutes to 2 hours, every 12 hours.
223665993|NCT00960583|OTHER|Exercise program|24 group exercise sessions during 12 weeks
223665994|NCT00960583|OTHER|Routine follow-up|Advice to stay active
223770702|NCT03501797|BEHAVIORAL|Singing-based rehabilitation|The singing-based rehabilitation is a combination of group-training (16 weeks, 1 x week, 90 min), which utilizes a novel combination of traditional senior choir singing and singing-based speech training protocols, and home training (16 weeks, ≥ 3 x week, ≥ 30 min) in which the choir material is trained with a tablet computer.
223770703|NCT03501797|OTHER|Standard care|Standard care comprises all rehabilitation and care services (e.g. speech therapy, physical and occupational therapy, neuropsychological rehabilitation) received by the patients in the Finnish health care system
223770704|NCT00317681|DRUG|Tacrolimus ointment|
223770705|NCT02247349|BIOLOGICAL|BMS-986012 (anti-fucosyl-GM1)|
223770706|NCT02247349|BIOLOGICAL|Nivolumab|
223770707|NCT02275286|DRUG|Trabectedin|"Escalating or deescalating dose of 1.3 or 1.5mg/m2, i.v 24h, once every 3 weeks.~Cohort A: unlimited cycles. Cohort B: 3 cycles. Cohort C: 3 cycles. Cohort D: cycles of trabectedin will be provided and patients will subsequently be evaluated for surgery."
223665995|NCT05273073|DIETARY_SUPPLEMENT|Probiotics|Each sachet consists of 30 billion colony-forming units (CFU) of six viable probiotic strains (Lactobacillus acidophilus BCMC® 12130 (107 mg), Lactobacillus casei subsp. BCMC® 12313 (107 mg), Lactobacillus lactis BCMC® 12451 (107 mg), Bifidobacterium bifidum BCMC® 02290 (107 mg), Bifidobacterium infantis BCMC® 02129 (107 mg), and Bifidobacterium longum BCMC® 02120 (107 mg).
224246903|NCT01215981|BIOLOGICAL|Influenza vaccine|One dose of inactivated hemagglutinins of influenza A (H1N1, H3N2) and influenza B
223665996|NCT05273073|DIETARY_SUPPLEMENT|Placebo|Placebo samples were identical to the probiotics in term of taste and texture without live microbial cells.
223665997|NCT03605628|OTHER|measuring tape|measurement of change in abdominal wall length \[cm\] during neuromuscular block with a measuring tape.
223665998|NCT03605628|OTHER|neuromuscular block|Measurement of the time course of the neuromuscular block: neuromuscular transmission is measured by assessment of the post tetanic count and the train of four ratio using acceleromyography (TOF Watch SX™, Essex Pharma GmbH, Munich, Germany) at the right adductor pollicis muscle with transcutaneous Ag/AgCl electrodes (electrocardiogram electrodes; Ambu Inc., MD 21060 USA);
223665999|NCT03605628|OTHER|Surgical rating score|"assessment of operating conditions by means of a standardized score: surgical rating score:~1. extremely poor conditions~2. poor conditions~3. acceptable conditions~4. good conditions~5. optimal conditions"
223666000|NCT03145818|OTHER|VD-HCBS|Like the participant-directed programs developed for Medicaid programs,VD-HCBS maximizes Veteran-centered care and independence. VD-HCBS provides Veterans with a monthly financial allotment based on an assessment of the extent of their need for assistance with personal care due to injury or the impact of disease
223666001|NCT05366504|COMBINATION_PRODUCT|LiST + PRP intracorporeal injection|12 LiST sessions (2 sessions per week) plus PRP (2 intracorporeal injections 3 weeks apart, after the 1st and the 7th LiST sessions) ( 30 patients).
223666002|NCT05366504|COMBINATION_PRODUCT|LiST + Placebo(normal saline intracorporeal injection)|All subjects of this group will receive 12 sessions (V3-V14) of LiST with session frequency 2/week and 2 normal saline injections with 3 weeks treatment interval (V3 and V9), 10 ml of normal saline will be injected at each session.
223666003|NCT05916599|DEVICE|ultrasound|a device which is used in intensive care units,
223666004|NCT00488306|DRUG|tigecycline|
223666005|NCT00421941|PROCEDURE|Tube feeding|
223666006|NCT01158170|RADIATION|Prophylactic cranial irradiation|25GY/10fraction
223666007|NCT01158170|DRUG|Erlotinib /Gefitinib|Erlotinib 150mg/d or Gefitinib 250mg/d until disease progression or intolerable toxicity
223666008|NCT01128621|DRUG|GSK1292263|Tablet
223666009|NCT01128621|DRUG|GSK1292263 matching placebo|Tablet
223666010|NCT01128621|DRUG|Sitagliptin|Tablet
223666011|NCT02292914|PROCEDURE|Robot-assisted surgery|Robot-assisted esophagectomy; Robot-assisted subtotal gastrectomy; Robot-assisted pancreatectomy;Robot-assisted rectal resection; Robot-assisted radical cistectomy;Robot-assisted prostatectomy;Robot-assisted Partial Nephrectomy; Robot-assisted hysterectomy;Robot-assisted Resection of malignant tumors of the mouth and orofaringolaringe; Robot-assisted lung lobectomy
223666012|NCT02292914|PROCEDURE|Conventional Surgery|Thoracoscopic Esophagectomy; Open rectal resection and rectal laparoscopy resection; Open radical cistectomy; Open prostatectomy; Open Partial Nephrectomy; Laparoscopic hysterectomy; Laparoscopic lung lobectomy
223666013|NCT02267317|DRUG|Eritoran|Pharmacologic inhibitor of TLR4 receptors.
223666014|NCT02267317|DRUG|D5W|5% Dextrose Water = Vehicle
223666015|NCT01875198|PROCEDURE|Radical Antegrade Modular Pancreatectomy with Splenectomy|
223666016|NCT01875198|PROCEDURE|Radical Antegrade Modular Pancreatectomy without splenectomy|distal pancreatectomy without pancreatectomy
223666017|NCT03472846|DRUG|Prolia, 60 Mg/mL Subcutaneous Solution|antiresorptive treatment with Prolia
223666018|NCT03472846|DRUG|Teriparatide|osteoanabolic treatment with Forsteo
223666019|NCT00036608|DRUG|Entecavir|
223666020|NCT00947791|DRUG|ketamine|a single IV infusion of ketamine, IV 0.5 mg/kg
223666021|NCT00947791|DRUG|midazolam|a single IV infusion of midazolam, 0.045 mg/kg
223666022|NCT06391632|DIAGNOSTIC_TEST|Revised Cardiac Risk Index|The Revised Cardiac Risk Index (RCRI) attempts to estimate the likelihood of cardiac complications during hospitalization in patients undergoing noncardiac surgery.The Frailty Index is a commonly used tool in clinical practice to assess the degree of frailty in patients.The Quality of Recovery-15 scale (QoR-15) is an easy-to-use score for assessing the quality of post-operative recovery.
223666023|NCT04169932|BIOLOGICAL|CD20 CAR-T|The maximum dose was determined according to the dose escalation test. Based on the number of CART cells per kg body weight which was proved to be safe and effective, all the subjects were treated with one single dose of CD20 CART cells per treatment course. The dose escalation test was designed to evaluate the four dose levels of CD20-CART (1 × 10 \^ 6 cells/kg,2 × 10 \^ 6 cells/kg,4 × 10 \^ 6 cells/kg,8 × 10 \^ 6 cells/kg).
223666024|NCT02720029|DEVICE|pH/impedance monitor|Placement of pH/impedance monitor via the nasogastric route with monitoring for 24 hours, followed by removal.
223666025|NCT06180187|DEVICE|Electrical mallet|elevation of the Schneiderian membrane of maxillary sinus using electrical mallet and place bone graft material to augment the residual alveolar ridge and then place dental implant .
223666026|NCT06180187|DEVICE|Osseo-densification burs|elevation of the Schneiderian membrane of maxillary sinus using osseodensification burs and place bone graft material to augment the residual alveolar ridge and then place dental implant .
223666027|NCT04276324|OTHER|Resistance training|Ten weeks of resistance training
223666028|NCT04276324|OTHER|Testing sessions|Testing sessions
223666029|NCT02366364|DRUG|Placebo|Single oral administration of placebo consumption on Day 1
223666030|NCT02366364|DRUG|NRX-1074 375 mg|Single oral administration of 375 mg consumption on Day 1
224246904|NCT01215981|BIOLOGICAL|Influenza vaccine|Two doses of inactivated hemagglutinins of influenza A (H1N1, H3N2) and influenza B
223666031|NCT02366364|DRUG|NRX-1074 500 mg|Single oral administration of 500 mg consumption on Day 1
223666032|NCT02366364|DRUG|NRX-1074 750 mg|Single oral administration of 750 mg consumption on Day 1
223666033|NCT00324298|BIOLOGICAL|bleomycin sulfate|
223666034|NCT00324298|DRUG|cisplatin|
223666035|NCT00324298|DRUG|etoposide|
224246905|NCT00659763|OTHER|Exclusion diagnosis|"Patient fulfill ROME III criteria No Alarmsignals Blood tests: FBC,CRP, ALAT, bilirubins, bas.phosphatases, Albumine, TSH, calcium, celiac screening, lactase gene test.~3 consecutive fecal samples for worm, ovaes and parasites Sigmoidoscopy with biopsy"
224246906|NCT00659763|OTHER|Clinical diagnosis|Patient fulfill ROME III criteria No Alarm signals Blood tests: FBC, CRP.
224246907|NCT00356785|BEHAVIORAL|health education|
224246908|NCT00356785|BEHAVIORAL|food supplementation|
224246909|NCT00356785|BEHAVIORAL|food supplementation combined with physical activity program|
224246910|NCT01688934|DRUG|V116517 50-mg tablets|Taken orally twice daily
224246911|NCT01688934|DRUG|V116517 30-mg tablets|Taken orally twice daily
224246912|NCT01688934|DRUG|Naproxen 500-mg capsules|Taken orally twice daily
224246913|NCT01688934|DRUG|Placebo|Tablets to match V116517 and/or placebo capsules to match naproxen taken orally twice daily
224246914|NCT04306133|PROCEDURE|PENG block|After performing spinal anesthesia, PENG block with 20 mL of 0.375 % Ropivacaine will be executed as described by Giron-Arongo et al with a low frequency curvilinear probe. A 22G 80 mm needle (Stimuplex Ultra 360, Braun ) will be used.
224246915|NCT04306133|PROCEDURE|Wound Infiltration|At the end of operation, the surgeon will perform wound infiltration with 20 mL of 0.375 % Ropivacaine.
224246916|NCT04167267|DRUG|DWP14012 tablet A|Period 1: DWP14012 tablet B Period 2: DWP14012 tablet A
224246917|NCT04167267|DRUG|DWP14012 tablet B|Period 1: DWP14012 tablet A Period 2: DWP14012 tablet B
224246918|NCT05378724|DEVICE|Hospital Fit 2.0, HFITAPP0, release 05, Maastricht Instruments B.V., the Netherlands|Hospital Fit consists of a smartphone app combined to the MOX accelerometer. Hospital Fit provides patients and physiotherapists direct feedback on patients' physical activity behavior. Individual goals regarding the number of minutes per day spent walking can be set by the therapist. Hospital Fit also gives patients insight into their own recovery process. During every treament, the physiotherapist will evaluate the extent of functional recovery. In addition, Hospital Fit will give physiotherapists the option of creating a patient-specific exercise program supported by videos. During every treatment session, the patient and physiotherapist will evaluate (and if necessary adapt) the amount of activity performed since the previous treatment, the extent of functional recovery and the exercise program.
224246919|NCT04298918|DRUG|Placebo|Participants will receive oral placebo in combination with trastuzumab emtansine.
224246920|NCT04298918|DRUG|Venetoclax|Participants will receive oral venetoclax.
224246921|NCT04298918|DRUG|Trastuzumab emtansine|Participants will receive intravenous (IV) trastuzumab emtansine.
224246922|NCT03421834|PROCEDURE|Catheter ablation of ventricular tachycardia|Catheter ablation with a uniform mapping system, procedural endpoint, and definition of acute procedural success.
224246923|NCT03421834|DRUG|Optimal medical treatment|Optimal guidelines-based heart failure treatment and antiarrhythmic drugs. Antiarrhythmics will be avoided if possible in the ablation group.
224246924|NCT03826745|OTHER|Plasma/Urine|Plasma of normal male and female normotensive, hypertensive, and/or resistant hypertensive subjects.
224246925|NCT02464553|OTHER|periradicular therapy (PRT)|RTG controlled periradicular therapy (PRT) is a microinvasive interventional pain release procedure. Advantage of targeted pain therapy is exact administration of effective drugs to the nerve root in the area of the thoracic, lumbar or sacral spines.
224246926|NCT02606708|RADIATION|Accelerated intensity modulated radiation therapy (AIMRT)|
224246927|NCT03267381|OTHER|Blood draw (before surgery)|Blood will be drawn before surgery
224246928|NCT03267381|OTHER|Blood draw (every 3 months)|Blood will be drawn every 3 months
224246929|NCT03267381|OTHER|Blood draw (at diagnosis)|Blood will be drawn at time of diagnosis
224246930|NCT00349843|DEVICE|Soft contact lens|
224246931|NCT00349843|DRUG|Marketed soft lens multipurpose disinfection regimen|
223666036|NCT00324298|PROCEDURE|management of therapy complications|
224246932|NCT01224535|DIETARY_SUPPLEMENT|Maize and Amaranth|80g porridge per day, 5 days a week, for 16 weeks (4 months)
224246933|NCT04551261|DRUG|GLS4|It is a new dihydropyrimidine antiviral drug that interferes the assembly of HBV core granule.
224246934|NCT04551261|DRUG|RTV|"1. It is HIV protease inhibitors indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection;~2. It is a CYP3A inhibitor combined with other drug to increase the exposure in human."
224246935|NCT04551261|DRUG|TAF|It is a hepatitis B virus (HBV) nucleoside analog reverse transcriptase inhibitor and is indicated for the treatment of chronic hepatitis B virus infection in adults with compensated liver disease.
224321735|NCT03885635|PROCEDURE|Hemiarch repair|Current standard of surgical repair consisting of ascending aortic replacement with open distal anastomosis at level of proximal arch under a period of hypothermic circulatory arrest . No surgical or endovascular intervention is carried out in the mid arch or descending aorta. Intra-operative management, including cannulation, cardioplegia, cerebral perfusion technique, and neurologic monitoring will be done according to each institution's current standard of practice.
224246936|NCT02821897|PROCEDURE|Target-controlled intravenous anaesthesia|
224246937|NCT02821897|PROCEDURE|Total anaesthesia|
224246938|NCT00840632|DRUG|Trandolapril 4 mg Tablets|1 x 4 mg, single-dose fasting
224246939|NCT00840632|DRUG|Mavik® 4 mg Tablets|1 x 4 mg, single-dose fasting
224246940|NCT03006705|DRUG|Nivolumab|Nivolumab: 360 mg solution intravenously for 30 min in every 3 weeks (maximum 1 year).
224246941|NCT03006705|DRUG|Tegafur-gimeracil-oteracil potassium|Tegafur-gimeracil-oteracil potassium combination drug 40 - 60 mg bid orally in 28 days, followed by 14 days off
224246942|NCT03006705|DRUG|Oxaliplatin|Oxaliplatin 130 mg/m2 (body surface area) solution intravenously for 2 hours once-daily, followed by 20 days off.
224246943|NCT03006705|DRUG|Capecitabine|Capecitabine 1000 mg2 (body surface area) bid orally in 14 days, followed by 7 days off.
224246944|NCT03006705|DRUG|Placebo|Placebo: 360 mg solution intravenously for 30 min in every 3 weeks (maximum 1 year).
224246945|NCT01294787|DRUG|indacaterol and glycopyrronium bromide (QVA149)|
224246946|NCT01294787|DRUG|placebo|
224246947|NCT01294787|DRUG|tiotropium|
224246948|NCT03701191|PROCEDURE|Inverted periosteal pedicle flap|The periosteum will be used as an autogenous graft after raising a partial thickness flap in group A
224246949|NCT04816253|DRUG|Normal saline|Normal saline irrigation and No other drug placed after extraction
224246950|NCT04816253|DRUG|Hyaluronic acid|Immediately after removal of impacted tooth (hyaluronic acid) placed in extraction socket
224246951|NCT04816253|DRUG|Methylprednisolone|Methylprednsolone will be injected half an hour preoperatively
223770708|NCT02275286|RADIATION|Radiotherapy|3D conformal radiotherapy (3D-CRT) or intensity modulated radiotherapy (IMRT) providing: Cohort A: 30Gy in 10 fractions (3Gy/fraction). Cohort B: 45Gy in 25 fractions (1.8Gy/fraction). Cohort C: 45Gy in 25 fractions (1.8Gy/fraction). Cohort D: 45Gy in 25 fractions (1.8Gy/fraction).
224246952|NCT04816253|DRUG|Methylprednisolone and Hyaluronic acid|Methylprednisolone will be injected half an hour preoperatively and Immediately after removal of impacted tooth (hyaluronic acid) placed in extraction socket
224246953|NCT00426647|DRUG|Buprenorphine|
224246954|NCT00426647|DRUG|Tramadol|
224246955|NCT03036085|DRUG|Liposomal bupivacaine|In the operating room after induction of general anesthesia patients will be positioned in a lateral decubitus position, prepared and draped in a sterile fashion. Under thoracoscopic guidance, a posterior intercostal nerve block will be performed with liposomal bupivacaine plus normal saline.
224246956|NCT03036085|DRUG|Bupivacaine|In the operating room after induction of general anesthesia patients will be positioned in a lateral decubitus position, prepared and draped in a sterile fashion. Under thoracoscopic guidance, a posterior intercostal nerve block will be performed with bupivacaine plus epinephrine plus normal saline.
224246957|NCT03036085|DRUG|Epinephrine|In the operating room after induction of general anesthesia patients will be positioned in a lateral decubitus position, prepared and draped in a sterile fashion. Under thoracoscopic guidance, a posterior intercostal nerve block will be performed with bupivacaine plus epinephrine plus normal saline.
224246958|NCT03036085|DRUG|Normal saline|In the operating room after induction of general anesthesia patients will be positioned in a lateral decubitus position, prepared and draped in a sterile fashion. Under thoracoscopic guidance, a posterior intercostal nerve block will be performed with liposomal bupivacaine plus normal saline or with bupivacaine plus epinephrine plus normal saline.
223666037|NCT03271645|BEHAVIORAL|Space from Depression|The structure and content of the programme modules follow evidence-based principles of CBT for the treatment of depression and anxiety (NICE, 2006, 2011, 2014). The treatment comprises cognitive, emotional and behavioural components. The treatment is delivered on a Web 2.0 platform using media-rich interactive content. Each module is structured in an identical way and incorporates introductory quizzes, videos, informational content, interactive activities, as well as homework suggestions and summaries. In addition, personal stories and accounts from other clients are incorporated into the presentation of the material.
223666038|NCT03271645|BEHAVIORAL|Space from Anxiety|The structure and content of the programme modules follow evidence-based principles of CBT for the treatment of depression and anxiety (NICE, 2006, 2011, 2014). The treatment comprises cognitive, emotional and behavioural components. The treatment is delivered on a Web 2.0 platform using media-rich interactive content. Each module is structured in an identical way and incorporates introductory quizzes, videos, informational content, interactive activities, as well as homework suggestions and summaries. In addition, personal stories and accounts from other clients are incorporated into the presentation of the material.
223770709|NCT01125423|DRUG|Milnacipran|Subject with Fibromyalgia will then be titrated onto milnacipran over 8 days to subject reported optimal pain control or a maximal dose of 100mg/day per package insert. Subjects will be permitted to increase or decrease their dosing at any time during the study per MD discretion in order to maintain optimal pain control.
223770710|NCT01125423|PROCEDURE|Skin biopsy|Subjects with Fibromyalgia will have 3 mm skin biopsies obtained from the dominant trapezius and the glabrous hypothenar area of the hand.
224246959|NCT04354974|BEHAVIORAL|Evaluation|Evaluation of a cognitive remediation program for mood disorders
224246960|NCT01148030|DRUG|3M Skin and Nasal Antiseptic|Intra-nasal dosing
224246961|NCT03978923|DEVICE|preparation of the implant site with Piezosurgery vs drill|"The surgery was always performed by the same operator (M.M.) to reduce the bias of the study. Loco-regional anesthesia was performed with Mepivacaine hydrochloride with 1:100000 adrenaline.~For the preparation of implant sites using traditional methods, the drills were used following manufacturer's protocol by the implant system in use (WINSIX®- BioSAF IN s.r.l, Trezzano Rosa, Trezzano Rosa, Milano - Italy).~For the preparation of sites was used ultrasonic device, (Surgysonic II, Esacrom S.r.l., Imola, Italy). For the final preparation and insertion of implants, 5-6 ultrasound inserts were used in sequence as follows: tip-shape 1st insert (ES012X) and 2nd insert (ES052XG), crown-shape 3rd insert (ES040), 4th insert (ES041), 5 ° insert (ES043) and 6th insert (ES044).~The implant insertion was performed with a maximum torque of 35 Ncm. Finally, the cap screws were positioned, and the flaps were sutured in Vycril® 3.0."
224246962|NCT06317454|DIAGNOSTIC_TEST|Blood and saliva analysis|Phenotyping and genotyping characterization using blood and saliva
224246963|NCT04394962|DEVICE|Virtual reality|Patients randomized to the study group, will be provided with the VR headset and sensors. The VR exposure will take place before the ET procedure, during their routine pre-transfer waiting period, in a private room. The patient will be able to choose between three different calming VR environments (3 scenes: beach sunset, palm tree patio or redwood forest) and will be exposed to the chosen VR environment for a continuous duration of 15-30 minutes. The VR exposure will be passive, and the patient can control her observation inside the environment by herself, simply by moving her head. During this period, at any time and for any reason, the patient can discontinue the use of the VR session simply by self-removing the helmet
224246964|NCT04503603|DRUG|Lanadelumab|Participants will receive lanadelumab 300 mg IV infusion on Day 1 followed by Day 4.
223770711|NCT01125423|PROCEDURE|Skin Biopsy|Control Subjects will have 3 mm skin biopsies obtained from the dominant trapezius and the glabrous hypothenar area of the hand.
223770712|NCT01959581|DEVICE|Movement Enhancing Device|Naturalistic play activities using the hands while wearing the movement enhancing device.
224246965|NCT04503603|OTHER|Placebo|Participants will receive placebo matching to lanadelumab IV infusion on Day 1 followed by Day 4.
224246966|NCT04908098|DEVICE|diode laser|It is the application of the laser tip parallel to the inner surface of the periodontal pocket
224246967|NCT04908098|PROCEDURE|scaling - root planning|Scaling is the removal of calculus and other deposits in the root of the tooth.Root planning is the removal of necrotic cementum on the tooth root surface. Scaler and gracey curettes are used for these operations.
224246968|NCT00789230|PROCEDURE|primary suture closure|primary suture closure of hernia
224246969|NCT00789230|DEVICE|mesh enforced closure|mesh enforced closure of hernia
224246970|NCT01725529|DRUG|TMC435|TMC435 100 mg or 150 mg capsules taken orally (by mouth) with food once-daily for 12 weeks (Week 12).
224246971|NCT01725529|DRUG|Peginterferon-alpha (PegIFNα-2a)|PegIFNα-2a (180 micrograms \[μg\] once weekly) administered as weekly subcutaneous (s.c.) (under the skin) injections of 0.5 mL for 24 or 48 weeks.
224246972|NCT01725529|DRUG|Ribavirin (RBV)|Ribavirin 1000 or 1200 mg/day (taken as 100 mg or 200 mg tablets) depending on body weight (If body weight is \< 75 kg the total daily dose of RBV will be 1000 mg, administered as 400 mg intake with food in the morning and 600 mg intake with food in the evening. If body weight is \> or = 75 kg the total daily dose will be 1200 mg, administered as 2 x 600 mg per intake with food, morning and evening) for 24 or 48 weeks.
224246973|NCT01725529|DRUG|Placebo|Matching placebo capsules taken orally with food once-daily for 48 weeks.
224246974|NCT01104025|DRUG|ATG, rabbit|ATG, rabbit (Thymoglobulin, Genzyme) will be dosed at 5 mg/kg/dose, given IV on 5 consecutive days (titrated over 4 to 8 hours).
224246975|NCT01104025|DRUG|Etoposide|Etoposide will be dosed at 150mg/m2, given IV. The first dose will be given 7 days (+/- 2 days) after the first dose of ATG, and be given weekly for a total of 7 doses.
224246976|NCT01104025|DRUG|Methotrexate|Intrathecal Methotrexate and hydrocortisone will be administered to CNS+ patients (CNS+ patients are those patients which have any of the following: elevated CSF (cerebral spinal fluid) protein or white count, seizures, focal or global neurologic deficit, MRI abnormalities consistent with CNS involvement by HLH.) in the following doses: age\< 1 yr: 6/8mg (MTX/HC), 1-2 yrs: 8/10mg, 2-3 yrs: 10/12mg, \>3 yrs: 12/15 mg. It will be administered (+/- 3 days) on day 7, 14, 21 and 42.
224246977|NCT01104025|DRUG|hydrocortisone|Intrathecal Methotrexate and hydrocortisone will be administered to CNS+ patients (CNS+ patients are those patients which have any of the following: elevated CSF (cerebral spinal fluid) protein or white count, seizures, focal or global neurologic deficit, MRI abnormalities consistent with CNS involvement by HLH.) in the following doses: age\< 1 yr: 6/8mg (MTX/HC), 1-2 yrs: 8/10mg, 2-3 yrs: 10/12mg, \>3 yrs: 12/15 mg. It will be administered (+/- 3 days) on day 7, 14, 21 and 42.
224246978|NCT01104025|DRUG|Dexamethasone|will be started with the ATG. It will be divided BID, given IV for at least 1 week before switching to PO. Dosing: 20mg/m2/day x7days, 10mg/m2/day x7days, 5mg/m2/day x14days, 2.5mg/m2/day x14days, 1.25mg/m2/day x14days.
224246979|NCT03306394|DRUG|Trifluridine/Tipiracil hydrochloride (S95005)|
224246980|NCT01948258|DEVICE|Clearblue Advanced Fertility Monitor|Clearblue Advanced Fertility Monitor used for one menstrual cycle in a home setting
224246981|NCT04234334|OTHER|Consume 2 eggs with spinach per day|Participants will be randomly allocated to consume either 2 eggs or 2 egg substitutes with spinach daily for 4 weeks and after a 3-week wash out, they will be allocated to the alternate treatment
224246982|NCT04234334|OTHER|Egg Subsitute with spinach per day|Egg Subsitute with spinach per day
224246983|NCT02372747|PROCEDURE|Delta-shaped anastomosis|The patients in DS group underwent Delta-shaped anastomosis after TLDG.
224246984|NCT02372747|PROCEDURE|Billroth II anastomosis|The patients in B-II group underwent Billroth-II anastomosis after TLDG.
224246985|NCT06265298|PROCEDURE|Conjunctival reconstruction|Conjunctival reconstruction using buccal mucosa taken from the patient's mouth. Following the reconstruction operation, an additional biopsy of buccal mucosa will be taken to develop a laboratory protocol for the transdifferentiation of these buccal cells into corneal epithelial stem cells.
224246986|NCT00070915|BEHAVIORAL|Tai chi|
224246987|NCT00070915|BEHAVIORAL|Mindfulness-based Stress Reduction program|
224246988|NCT00070915|PROCEDURE|Therapeutic massage|
224246989|NCT01452815|DRUG|Placebo|Two #2 oval shaped,opaque-white, hard gelatin shell capsules containing inactive ingredients taken orally once daily for 12 weeks.
224246990|NCT01452815|DRUG|10mg TZP-102|One 10mg #2 oval shaped, opaque-white, hard gelatin shell capsule containing active ingredients and one placebo capsule each taken orally once daily for 12 Weeks
224246991|NCT01452815|DRUG|20mg TZP-102|Two 10mg #2 oval shaped, opaque-white, hard gelatin shell capsules containing active ingredients
223770713|NCT02535195|DIETARY_SUPPLEMENT|Ginger supplement|
224246992|NCT02807987|DRUG|CS-3150|CS-3150 1.25 to 2.5, 5mg, orally
224246993|NCT03979768|OTHER|Diabetes risk assessment service in Norwegian community pharmacies|Two pharmacists at each pharmacy were trained to perform risk assessments and counselling. During six months, pharmacy customers equal or above 45 years old, wishing to participate contacted the pharmacy staff. Participants completed a validated diabetes risk test and a background questionnaire including a validated instrument for self-rated health.
224246994|NCT01304823|DIETARY_SUPPLEMENT|lactisole|flavoring agent/sweet taste antagonist
224246995|NCT01304823|OTHER|mixed liquid meal|Ensure Plus
224246996|NCT01730638|DRUG|• TF2 and 68 Ga-IMP-288|
224246997|NCT05267093|PROCEDURE|Acupuncture|Sterile single-use stainless steel needles (size 0.3 mm × 25 mm) will be utilized. After local skin disinfection with 75% alcohol wipes, acupuncturists will insert needles perpendicularly into the Ashi points to a depth of approximately 2-3 mm; horizontally into the Baxie points toward the wrist to a depth of 5-10 mm; and perpendicularly into Houxi (SI3) and Waiguan (TE5) to a depth of approximately 5-10 mm. The depth of needling will vary based on the participant's body sizes. After insertion, all needles except those in the Ashi points will be manually manipulated to achieve De qi sensations. All the needles will be retained for 30 min and then gently removed. Participants will take acupuncture treatment three times per week for a total of 12 sessions in 4 consecutive weeks.
223666039|NCT03271645|BEHAVIORAL|Space from Stress|The structure and content of the programme modules follow evidence-based principles of CBT for the treatment of depression and anxiety (NICE, 2006, 2011, 2014).The treatment is delivered on a Web 2.0 platform using media-rich interactive content. Each module is structured in an identical way and incorporates introductory quizzes, videos, informational content, interactive activities, as well as homework suggestions and summaries. In addition, personal stories and accounts from other clients are incorporated into the presentation of the material.
223666040|NCT03271645|BEHAVIORAL|Face-to-face counselling|Face-to-face counselling
223666041|NCT01717833|PROCEDURE|NEMS|NEMS sessions on both lower extremities (quadriceps and peroneus longus) simultaneously
223666042|NCT01717833|PROCEDURE|Sham|Sham sessions of neuromuscular electrical stimulation
223666043|NCT00109603|DRUG|Tenofovir disoproxil fumarate|
223666044|NCT04367051|DRUG|Withdrawal of Spironolactone|Other recommended medications for heart failure than spironolactone will be continued for withdrawal group.
223666045|NCT04367051|DRUG|Continuation of spironolactone|Specific dose of spironolactone for continuation group is on each physician's discretion with acceptable range of 12.5 mg - 50 mg once or twice daily.
223666046|NCT03002467|OTHER|PESI score|
223666047|NCT00796445|DRUG|GSK 2132231A|IM solution, a course of 13 injections administered over 27 months
223666048|NCT00796445|DRUG|Placebo|IM solution, a course of 13 injections administered over 27 months
223666049|NCT00233883|DRUG|enfuvirtide [Fuzeon]|90mg sc bid by Biojector 2000 NFID for 4 weeks
223666050|NCT00233883|DRUG|enfuvirtide [Fuzeon]|"90mg sc bid by 27G1/2 needle/syringe for 4 weeks"
223666051|NCT03238170|DEVICE|MRI scan|MRI scan using the Siemens Aera® (Siemens AG Healthcare, Erlangen, Germany) on the same day as their treatment planning CT scan
223666052|NCT00300547|PROCEDURE|MR colonography|Altered planned surgical procedure if MR colonoscopy reveals synchronous cancer or larger polyps
223666053|NCT00511940|DRUG|acamprosate|999 mg/day - 2997 mg/day, oral
224246998|NCT05267093|PROCEDURE|Sham acupuncture|The sham needles with blunt tips (size 0.3 mm × 25 mm) will be used in the control group. Acupuncturists will gently lift and twist the sham needles to simulate the treatment procedure, thus blinding the patients to the intervention. Acupuncturist will firstly sterilize the areas of acupoints, then apply the adhesive pads on the surface of Ashi points, Baxie points, Houxi (SI3) and Waiguan (TE5) and insert the sham needles without penetrating. The duration and frequency of treatment sessions will be the same as in the acupuncture group.
224246999|NCT03757845|OTHER|Mediterranean Diet|subjects will be asked to eat from a sub-menu items compliant with Mediterranean Diet
224247000|NCT03914365|PROCEDURE|Ultrasound-guided pudendal nerve block (PNB) and Ultrasound-guided penile nerve block (DPNB)|Our primary objective is to compare analgesia between the two blocks during and after pediatric circumcisions to minimize post-operative pain.
223666054|NCT00511940|OTHER|placebo|oral, placebo
223666055|NCT01547559|DRUG|part1:teprenone|Teprenone 50mg tid after meal for Hp negative patients.
223666056|NCT01547559|DRUG|part1:EAC-T|esomeprazole 20 mg, amoxicillin 1 g, and clarithromycin 500 mg, each twice daily followed by gastric mucosal protective therapy with teprenone 50mg three times daily for 11 weeks
224247001|NCT03502889|PROCEDURE|SPANK Block (Sensory Posterior Articular Nerves of the Knee)|Injection of local anesthetic into the tissues on the posterior aspect of the knee to provide sensory blockade of the articular nerves of the knee.
223666057|NCT01547559|DRUG|part1:EA-EMC-T|esomeprazole 20 mg plus amoxicillin 1 g, twice daily for 5 days, then esomeprazole 20 mg with clarithromycin 500 mg and metronidazole 500 mg, twice daily for another 5 consecutive days) followed by teprenone 50mg three times daily until 12 weeks
223666058|NCT01547559|DRUG|part1:teprenone|Teprenone 50mg tid after meal for Hp positive patients.
223666059|NCT01547559|DRUG|part2:GGA group|GGA 50mg three times daily plus diclofenac sodium 75mg once a day for patients with rheumatic diseases.
223666060|NCT04405466|PROCEDURE|Blood sampling|Blood samples
223666061|NCT04405466|PROCEDURE|Throat swab|Throat swab
223666062|NCT02445547|OTHER|UC-MSCs by peripheral intravenous infusion|
223666063|NCT02445547|DRUG|received hormone maintenance therapy|
223666064|NCT02208063|DRUG|Telavancin|
223666065|NCT02208063|DRUG|Vancomycin|
223666066|NCT02208063|DRUG|Daptomycin|
223666067|NCT02208063|DRUG|Synthetic penicillin|
223666068|NCT02208063|DRUG|Cefazolin|
223666069|NCT02704390|DRUG|ORADUR®-Methylphenidate|ORADUR®-Methylphenidate is available in three dosage forms, 22 mg, 33 mg or 44 mg. Subjects will continue to receive ORADUR®-Methylphenidate at the previously determined optimal dose for 24 months.
223666070|NCT00579384|DRUG|JNJ-26489112|Single oral dose of JNJ-26489112 up to 3000 mg on Day 2.
223666071|NCT00579384|DRUG|Placebo|Single dose of placebo on Day 1, and a second single dose of placebo on Day 3.
223666072|NCT02470988|BEHAVIORAL|Cognitive Behavioural Analysis System of Psychotherapy|
223666073|NCT02470988|BEHAVIORAL|CBASP Without DPI|
223666074|NCT00060359|DRUG|Carboplatin|Given IV
223666075|NCT00060359|DRUG|Paclitaxel Poliglumex|Given IV
223666076|NCT00060359|OTHER|Pharmacological Study|Correlative studies
224247002|NCT03502889|PROCEDURE|Adductor Canal Block|Injection of local anesthetic into the inner thigh under ultrasound guidance to provide sensory blockade to the anterior aspect of the knee
223666077|NCT01608022|DRUG|PF804|45 mg p.o. daily and continuously (28-day treatment as one treatment cycle)
223666078|NCT03044600|OTHER|Chart Review|Patient charts will be reviewed to collect demographic data, pre-operative and post-operative clinical and laboratory data, operative reports, and pathology reports.
223666079|NCT03044600|OTHER|HRPT2 Mutation Evaluation|Archived formalin-fixed paraffin-embedded (FFPE) tissue blocks from surgical specimens of patients stained for parafibromin to evaluate for HRPT2 mutations.
223666080|NCT00275132|DRUG|erlotinib hydrochloride|Tarceva (OSI-774, erlotinib) PO 150 mg daily
223666081|NCT00275132|DRUG|Matched placebo|Matched placebo PO daily
223666082|NCT02882750|OTHER|EORTC QLQ-C30 (version 3.0).|Quality of Life Questionnaire
223666083|NCT02882750|OTHER|PS Q18|Patients Satisfaction Questionnaire
223666084|NCT02882750|OTHER|Decision Self-Efficacy Scale|Questionnaire
224247003|NCT03502889|DRUG|Ropivacaine Hcl 0.5% Inj Vil 30Ml|Amide local anesthetic, this concentration is commonly used to achieve surgical level anesthesia. The drug itself is not being studied and the same concentration will be used in all participants.
224247004|NCT03502889|DEVICE|Pajunk sonoplex stim needle|Echogenic needle used for ultrasound guided nerve blockade.
224321736|NCT03885635|PROCEDURE|Extended arch repair|Surgical replacement of the ascending aorta along with intervention on the arch and descending aorta. Techniques for distal aspect of extended arch technique include but are not limited to total arch replacement along with TEVAR, Frozen Elephant Trunk procedure or surgical proximal arch replacement with bare metal stents in arch and descending aorta. Intra-operative management, including cannulation, cardioplegia, cerebral perfusion technique, and neurologic monitoring will be done according to each institution's current standard of practice.
224247005|NCT01548677|DRUG|trastuzumab|8 mg/kg of loading dose IV over 90 minutes for the first cycle, followed by 6 mg/kg IV over 60 minutes every 3 weeks for the 5 subsequent cycles.
224247006|NCT04355104|BEHAVIORAL|Education|"A one hour educational session per week for 4 weeks. In a total of 4 sessions of education, the content based on LBP Clinical Practice Guidelines which recommended that education and counseling strategies for patients with low back pain.~Education session will be through video lecturing as a motivated tool of education for all subject who are in experimental group, this video will repeated the same in every educational session and will be sent for all participants.~The neuroscience education will be by the therapist using interactive slide show and hand-drawing images.~In addition to the education video, slide show, we will specify the education for every patient to give him all that he need, questions and details, mention his case on real spine to explore it and to determine the expected goal from what he need and what we have."
224247007|NCT04355104|BEHAVIORAL|Standard physical therapy|Two session physical therapy per week for 4 weeks. The physical therapy will be based on patients case.
223666085|NCT02844062|BIOLOGICAL|anti-EGFRvIII CAR T cells|CAR T cells are infused intravenously to patients in a three-day split-dose regimen（day0,10%; day1, 30%; day2, 60%）with a total targeted dose.
223666086|NCT02844062|DRUG|cyclophosphamide|250 mg/m\^2 d1-3
224247008|NCT01094067|DRUG|ACT-050089|5 mg/h intravenously, Tezosentan
224247009|NCT01094067|OTHER|Placebo|Matching placebo
223666087|NCT02844062|DRUG|Fludarabine|25mg/m\^2 d1-3
223666088|NCT00917644|DRUG|Atorvastatin|A single 80 mg dose of marketed 80 mg atorvastatin tablets
223666089|NCT00917644|GENETIC|Atorvastatin|A single dose of new formulation of 80 mg atorvastatin tablets
223666090|NCT01260675|DRUG|Buprenorphine HCl/Naloxone HCl|
223666091|NCT05473078|OTHER|online anonymous exploratory study|online self-administered questionnary
224247010|NCT00929929|DIETARY_SUPPLEMENT|L-leucine.|10 g of leucine per day, during 12 weeks.
224247011|NCT00929929|DIETARY_SUPPLEMENT|Maltodextrin.|10 g of maltodextrin per day, during 12 weeks.
224247012|NCT00929929|BEHAVIORAL|Exercise program.|Progressive resistance exercise program 4 days a week, during 12 weeks.
224247013|NCT04863768|DIAGNOSTIC_TEST|Gene panel|comprehensive cancer gene panel targeting regions in 37 clinically relevant cancer genes in FFPE tumor tissue blocks
224321737|NCT05292183|OTHER|Electrical Stimulation|We will use a computer randomized stimulation of specific areas in the amygdala while showing a computer randomized set of pictures.
224321738|NCT06421532|DRUG|XYWAV|Daily before bedtime for 3 months
223666092|NCT02024178|PROCEDURE|Ultrasound Imaging|
224247014|NCT02529592|BIOLOGICAL|Endotoxin|
224247015|NCT02529592|BIOLOGICAL|Placebo|
224247016|NCT02064088|DRUG|Injection of 0,2 ml/kg of 0,2% levobupivacaine for small volume group|Ultrasound guided administration of 0,2 ml/kg of 0,2% lévobupivacaine in the plane between the internal oblique and transversus abdominis muscles
224247017|NCT02064088|DRUG|Injection of 0,4 ml/kg of 0,1% lévobupivacaine for high volume group|Ultrasound guided administration of 0,4 ml/kg of 0,1% lévobupivacaine in the plane between the internal oblique and transversus abdominis muscles
224247018|NCT06334445|BEHAVIORAL|Control group|Wearables/sensors and ePsycHeart App
224247019|NCT06334445|BEHAVIORAL|Intervention group|Wearables/sensors and ePsycHeart App and eHealtHeart
224247020|NCT00878878|DRUG|Optison (Perflutren Protein-Type A Microspheres Injectable Suspension)|"Arm A: Single intravenous (IV) injection of 0.5 mL Optison followed by single IV injection of 0.5 mL 5% dextrose.~Arm B: Single IV injection of 0.5 mL 5% dextrose followed by single IV injection of 0.5 mL Optison."
224247021|NCT00878878|DRUG|Dextrose|"Arm A: Single intravenous (IV) injection of 0.5 mL Optison followed by single IV injection of 0.5 mL 5% dextrose.~Arm B: Single IV injection of 0.5 mL 5% dextrose followed by single IV injection of 0.5 mL Optison."
224247022|NCT02071797|DEVICE|Induced Therapeutic Hypothermia|Head to head, direct comparator of two standard care devices/treatments (RhinoChill versus Blanketroll lll) to assess time to induced therapeutic hypothermia
224247023|NCT03121443|OTHER|Perfusion index|supine,prone, trendelenburg,reverse trendelenburg,45 degrees back up sitting position, 45 degrees legs lifted supine position.
224247024|NCT04318821|PROCEDURE|Laser acupuncture|Laser acupuncture is a non-invasive therapy that involves stimulation of traditional acupoints with low-intensity, non-thermal laser irradiation.
224321739|NCT06421532|DEVICE|gammaCore Sapphire|Twice daily for 3 months
224321740|NCT03325101|PROCEDURE|Cryosurgery|Undergo cryosurgery
223666093|NCT01964768|OTHER|Skin prick-test|
223666094|NCT03084380|BIOLOGICAL|Retroviral vector-transduced autologous T cells to express anti-GPC3 CARs|transcatheter arterial chemoembolization + CAR-T infusion
223666095|NCT03084380|DRUG|Fludarabine|Fludarabine will be administered at dose of 25mg/m2/d
223666096|NCT03084380|DRUG|Cyclophosphamide|Cyclophosphamide will be administered at dose of 40mg/kg for 1 day and then fludarabine will be given for the next 5 days and then the T cells will be administered
223666097|NCT02672527|DRUG|Trabectedin|
223666098|NCT02672527|DRUG|Dexamethasone|
223666099|NCT04716556|BIOLOGICAL|Convalescent plasma|Convalescent plasma will be collected by healthy donors, recovered by COVID19 and, after standard preparation and dosage of neutralizing antibodies, it will be administered to patients with SARS-CoV2 pneumonia
223666100|NCT06148844|OTHER|interactive robot group|Intervention group will receive one day pre-operative preparation intervention applied by researcher. Preparation will be 30-40 minutes long
223770714|NCT02535195|DIETARY_SUPPLEMENT|Placebo (starch)|
223666101|NCT04579887|OTHER|Brain changes triggered by PH induction in Parkinson's disease patients with presence hallucinations|Parkinsonian patients will undergo a two distinct experimental sessions, conducted in two separate days. In day 1, they will complete a series of validated and lab-tailored clinical evaluations, alongside with semi-structured interviews. These tests are designed to assess, the extent of the movement disorder, the predominance of positive symptoms and presence hallucination, potential cognitive impairment, amongst other relevant measures, for sleep assessment, loneliness, apathy and depression. In day 2 patients will perform the described robotic manipulation task in the MRI.
224247025|NCT05729529|OTHER|Lipoid acid gel|Topic lipoid acid gel used with topic oral gel used on tongue
224247026|NCT05729529|DRUG|Placebo|Placebo oral gel used on tongue
224247027|NCT01239862|OTHER|Autologous cell transplantation|Intrabronchial Instillation Of Bone Marrow Derived Mononuclear Cells
224247028|NCT04466553|DEVICE|NICO BrainPath™ System|Patients who are admitted under the neurology service in the Neurocritical Care and Medical ICU will be screened for participation in the trial by their treating physician. Once blood pressure has been stabilized and the best medical treatment has been determined, the patient will need to undergo a standard of care, repeat CT scan 6 hours after stabilization to show that there has been no increase in size of the ICH. Patients that meet eligibility criteria after this CT will be taken to the OR within 24-72 hours for a minimally invasive, navigation guided endoport based evacuation of the clot using the NICO BrainPath™ system.
224247029|NCT01395563|BEHAVIORAL|strength training|strength training, high intensity, twice up to 3 times per week
224247030|NCT05316922|DRUG|Levothyroxine|Levothyroxine is used to treat hypothyroidism (low thyroid function). This medicine is given when your thyroid does not produce enough of this hormone on its own.
224247031|NCT04365309|DRUG|Aspirin 100mg|on the bases of standard treatment for the COVID-19, low-dose aspirin (100 mg/ day), orally，is added to.
224247032|NCT06424145|DIAGNOSTIC_TEST|Superior radial artery|Upper radial artery, 1 ml of lidocaine
224247033|NCT06424145|DIAGNOSTIC_TEST|Right side of radial artery|Right side of the radial artery,1ml of lidocaine
224247034|NCT02104960|OTHER|Dermatological clinical examination|Clinical pictures, Dermatoscopy, Elastography, Sebumetry
224247035|NCT02104960|OTHER|Biopsy|Skin biopsy for examinations by confocal microscopy ex vivo and histopathology
224247036|NCT02104960|OTHER|Confocal microscopy in vivo|Examination by confocal microscopy in vivo
224247037|NCT04832399|DRUG|Natalizumab|As described in the treatment arm.
224247038|NCT00343278|DRUG|Valaciclovir Hydrochloride|
224247039|NCT00674505|DEVICE|Lumen Biomedical FiberNet Embolic Protection System|to demonstrate the safety and filter efficiency of the Lumen Biomedical FiberNet Embolic Protection System during the performance of primary renal stenting in the treatment of pts with a high grade ostial atherosclerotic renal lesion(s).
224247040|NCT00822497|BEHAVIORAL|Music-Based Imagery (MBI)|MBI is form of music-assisted relaxation with imagery. This protocol is used at the patients' bedside before and after the debridement process.
224247041|NCT00822497|BEHAVIORAL|Music Alternate Engagement (MAE)|MAE consisted of a menu of music therapy interventions aimed at engaging the patients in music and diverting them away from the debridement process.
223666102|NCT02331095|DRUG|Atorvastatin|"Atorvastatin belongs to the statin class of drugs, and is routinely used for prevention of cardiovascular diseases and/or reduction of cholesterol levels. It has been shown to decrease the risk of first venous thromboembolism in an otherwise healthy population with elevated high-sensitivity C-reactive protein (hs-CRP)."
224321741|NCT03325101|BIOLOGICAL|Pembrolizumab|IV
223666103|NCT02331095|DRUG|Anticoagulation Therapy|Warfarin is a standard anticoagulation in the treatment for venous thromboembolism. The dose will be adjusted to goal INR of 2-3.
223666104|NCT01816945|BEHAVIORAL|MOMBA web-based application|Web-based, interactive, social network application.
223666105|NCT00401180|DRUG|docetaxel|administered weekly in 5 escalating doses of 25 to 35 mg/ m(2) as a one-hour bolus intravenous infusion for 3 consecutive weeks.
223666106|NCT00401180|DRUG|temozolomide|administered orally daily for 3 weeks (escalating doses of 75 to 100 mg/m(2)). Cycles were repeated at 4 week intervals.
224247042|NCT00698230|DRUG|INCB013739|INCB013739 5 mg QD tablet
224247043|NCT00698230|DRUG|INCB013739|INCB013739 15 mg QD tablet
224247044|NCT00698230|DRUG|INCB013739|INCB013739 50 mg QD tablet
224247045|NCT00698230|DRUG|INCB013739|INCB013739 100 mg QD tablet
224247046|NCT00698230|DRUG|INCB013739|INCB013739 200 mg QD
224321742|NCT03325101|PROCEDURE|Pheresis|apheresis
224321743|NCT03325101|BIOLOGICAL|Therapeutic Autologous Dendritic Cells|Intra-tumoral injection
224247047|NCT00698230|DRUG|Placebo comparator matching INCB013739|Orally once daily tablet
224247048|NCT00698230|DRUG|Metformin|
224247049|NCT03785548|OTHER|Usage of a mirror|using a mirror during the pelvic examination
224247050|NCT02109354|BIOLOGICAL|ALVAC-HIV|Formulated as a lyophilized vaccine for injection and is reconstituted with 1.05 mL of sterile Sodium Chloride solution (0.4% NaCl) for a single 1 mL dose of \>1.0 x 106 CCID50/mL, to administer intramuscularly (IM).
224247051|NCT02109354|BIOLOGICAL|AIDSVAX B/E|300 mcg of subtype B (MN) HIV gp120 glycoprotein and 300 mcg of subtype E (A244) HIV gp120 glycoprotein adsorbed onto 600 mcg of aluminum hydroxide gel adjuvant. Each vial contains 1.2 mL of sterile suspension, to administer 1 mL IM.
224247052|NCT02109354|BIOLOGICAL|Placebo for ALVAC-HIV|A sterile, lyophilized product that consists of a mixture of virus stabilizer, and freeze drying medium and is reconstituted with 1.05 mL of sterile Sodium Chloride (0.4% NaCl) for a single 1 mL dose, to administer IM.
224247053|NCT02109354|BIOLOGICAL|Placebo for AIDSVAX B/E|Sodium Chloride for Injection, 0.9% administered IM.
224247054|NCT02109354|BIOLOGICAL|Hepatitis B vaccine|Each 1 mL dose contains 20 mcg of hepatitis B surface antigen (HBsAg) adsorbed onto 500 mcg aluminum as aluminum hydroxide, to administer IM.
224321744|NCT05274243|DRUG|2-HOBA|2-HOBA acetate (2-Hydroxybenzlamine acetate) 750mg (provided as three 250mg capsules) three times per day for 4 weeks
224321745|NCT05274243|OTHER|Placebo|Placebo (provided as three capsules) three times a day for 4 weeks
224321746|NCT05177211|DRUG|Fedratinib Pill|Participants will be given Fedratinib at a dose of 400 mg PO once daily (4-100 mg capsules). Fedratinib can be given at any time during the day, but patients are advised to take the dose at the same approximate time every day.
223666107|NCT06530979|DEVICE|Tailored nutritional education program utilizing Saudi-sign language supplied by Saudi-sign language interpreter|The program will be implemented in an experimental group composed of profoundly impaired hearing adults (91 Decibels and above). The experimental group will receive nutrition group counselling via photos, and models, and Saudi-sign language interpreter, including awareness of food groups and their nutrients, choose healthy and balanced items from supermarkets, restaurants or coffee shop menus-traffic lights on nutrition labelling and health problems or diseases related to diet and weight management
223666108|NCT01488513|DRUG|sphingosine kinase-2 inhibitor ABC294640|Given PO Starting dose of ABC294640 250 mg once on day on Days 1-28 of each 28-day cycle. Subsequent cohort doses (if reached) are as follows: 250 BID, 500 BID, 750 BID, 1,000 BID, 1,500 BID, 2,000 BID, 2,500 BID
223770715|NCT06341465|OTHER|Just Exercise|Schroth exercises are including rotational breathing, correction techniques, positioning, mobilization, and three-dimensional exercises specific to their curvature.
223770716|NCT06341465|OTHER|Exercise|Schroth exercises are including rotational breathing, correction techniques, positioning, mobilization, and three-dimensional exercises specific to their curvature.
223770717|NCT06341465|OTHER|Taping|Kinesiological taping will be applied as a tone enhancer or tone reducer according to the the concave and convex sides of the curve.
223770718|NCT03919045|DRUG|Saline injection|Half of the patients will be randomized to saline injections into the neck and head muscles
223770719|NCT03919045|PROCEDURE|Placebo|Half of the group will be treated with needle stings without injections
223770720|NCT01228240|DRUG|Metformin|
224247055|NCT02109354|BIOLOGICAL|Tetanus toxoid vaccine|The active ingredient is tetanus toxoid (≥ 40 I.U. / 0.5 mL) adsorbed on aluminium hydroxide dihydrate (600 mcg of aluminium), to administer IM.
224247056|NCT02109354|BIOLOGICAL|Placebo for hepatitis B vaccine|Sodium Chloride for Injection, 0.9% administered IM.
224247057|NCT02109354|BIOLOGICAL|Placebo for tetanus vaccine|Sodium Chloride for Injection, 0.9% administered IM.
224247058|NCT02404662|OTHER|Supportive text messages intervention|"The supportive text messages are based on existing aphorisms in the recovery literature. Each day patients will receive one message targeting mood and another message targeting abstinence from alcohol in accordance with the primary aims of our study. An example text message aimed at improving mood is: Monitor changes in your mood; develop a list of personal warning signs. An example message targeting abstinence is: Keep Sobriety as a number one priority and you will reach your goals. None of the messages will be repeated. The messages will be sent in the morning and evening, with the theme (mood/alcohol) of the messages pseudo-randomised according to delivery time, so that no more than three successive days will have the same theme sent at the same time slot."
224247059|NCT02404662|OTHER|Control group|The control group will receive treatment as usual, as well as fortnightly thank you text messages and calls to ensure that they are still using their phone.
224247060|NCT01423760|BIOLOGICAL|Tecemotide|Subjects who received tecemotide (L-BLP25) for the treatment of non-small cell lung cancer (NSCLC) or multiple myeloma in a feeder trial will continue to be treated with tecemotide (L-BLP25) and have safety assessments performed until the discontinuation criteria in the respective feeder trial protocol are met.
224247061|NCT01423760|OTHER|No intervention|Subjects who had not received tecemotide in the feeder study, or who had discontinued treatment with tecemotide (L-BLP25), will only be observed for progressive disease (PD) (if applicable) and survival in 6-month intervals and will not be provided treatment with tecemotide (L-BLP25).
224247062|NCT03222765|DRUG|Placebo, metformin, linagliptin, linagliptin + metformin|
224247063|NCT01452022|DEVICE|Inductigraft|Synthetic bone graft
224247064|NCT04993664|DRUG|Pelacarsen (TQJ230)|The first group will receive pelacarsen. Blood samples from all patients will be drawn for laboratory measurements and genetics determination. Ultrasound measurement of endothelium-dependent dilatation of the brachial artery and beta stiffness of carotid arteries will be measured.
224247065|NCT04993664|DRUG|Placebo|The second group will receive placebo. Blood samples from all patients will be drawn for laboratory measurements and genetics determination. Ultrasound measurement of endothelium-dependent dilatation of the brachial artery and beta stiffness of carotid arteries will be measured.
224247066|NCT03611478|DIETARY_SUPPLEMENT|Probiotic formulation|Probiotic capsule
224247067|NCT03611478|DIETARY_SUPPLEMENT|Placebo|Placebo capsule identical in taste and appearance to probiotic capsule
224247068|NCT02970656|BEHAVIORAL|Teens.Connect|Teens.Connect combines two internet psycho-educational programs, TEENCOPE™, an internet version of coping skills training using a graphic novel format combined with social media, and an internet diabetes problem-solving educational program (Managing Diabetes)
224247069|NCT01215266|DRUG|Sorafenib|Day 3-21 2x2 800 mg(milligram) daily
224247070|NCT01215266|DRUG|Placebo|Day 3-21 2x2 800 mg(milligram) daily
224247071|NCT01095692|PROCEDURE|Pelvic Organ Prolapse and Suburethral TOT implantation|Procedure/Surgery: Pelvic Organ Prolapse intervention and Suburethral TOT implantation
224247072|NCT01095692|PROCEDURE|Pelvic Organ Prolapse intervention|Procedure/Surgery: Pelvic Organ Prolapse intervention
224247073|NCT00511069|DRUG|Bortezomib|
224247074|NCT04697017|OTHER|The contribution of genetics to dental caries, oral habits and occlusal traits in children of multiple births|The contribution of genetics to dental caries, oral habits and occlusal traits in children of multiple births
224247075|NCT02222805|PROCEDURE|Early (≤30 seconds) cord clamping|Early (≤30 seconds) cord clamping of the umbilical cord after delivery.
224247076|NCT02222805|PROCEDURE|Delayed (≤180 seconds) cord clamping|Delayed (≤180 seconds) cord clamping of the umbilical cord after delivery.
224247077|NCT00275730|DRUG|indometacine (drug) effect on ocular blood flow|
224247078|NCT01523730|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|Subjects will undergo two testing weeks (active and sham rTMS treatment), washout period ≥ 1 month between the testing weeks. rTMS treatment sessions will take place twice daily on days 1-3 of each test week. Active treatment will be delivered at 90% resting motor threshold intensity. Stimulation will be administered at 20 Hz with 25 stimulation trains of 30 stimuli each with an inter-train interval of 30 sec at equivalent stimulation parameters as those used in our pilot trial. Stimulation Site: Advanced neuronavigation methods will be used to target rTMS to the dorsolateral prefrontal cortex following a T1 weighted MRI scan.
224247079|NCT01523730|DEVICE|Sham Repetitive Transcranial Stimulation (rTMS)|Subjects will undergo two testing weeks (active and sham rTMS treatment) administered in a randomized order, to which both experimenter and participant will be blind. There will be a washout period of at least one month between the testing weeks to ensure that any changes in cortical function induced by rTMS have returned to baseline. rTMS treatment sessions will take place twice daily on days 1-3 of each test week. Sham Condition: A single-wing tilt rTMS coil position producing somatic sensation (contraction of scalp muscles) with minimal direct brain effects will be used (same stimulation parameters and site as active condition).
224247080|NCT05318157|DRUG|AIT drops|Once a day
224247081|NCT05318157|DRUG|Clarityne, Rhinocort and Emedastine Difumarate Eye Drops|The following drugs were permitted as allergy symptoms-relieving medications according to the actual needs in groups: Clarityne, Rhinocort and Emedastine Difumarate Eye Drops, Once a day
224247082|NCT03878719|DRUG|binimetinib|taken orally
224247083|NCT03878719|DRUG|encorafenib|taken orally
224247084|NCT05309941|OTHER|Internal Cues Nutrition Messaging|Participants will view a 5 minute nutrition education video focused on intuitive eating principles.
224247085|NCT05309941|OTHER|External Cues Nutrition Messaging|Participants will view a 5 minute nutrition education video focused on traditional nutrition education principles such as label reading.
224247086|NCT01049334|DRUG|Placebo|Participants were instructed to suck one placebo lozenge during the initial two-hour clinic visit. Upon discharge, participants were instructed to use study medication lozenge every 3-6 hours as needed for pain, up to a total of 5 study lozenges in 24 hours.
224247087|NCT01049334|DRUG|Flurbiprofen|Participants were instructed to suck one flurbiprofen 8.75 mg lozenge during the initial two-hour clinic visit. Upon discharge, participants were instructed to use study medication lozenge every 3-6 hours as needed for pain, up to a total of 5 study lozenges in 24 hours.
224247088|NCT03979079|RADIATION|external beam radiation therapy|
224247089|NCT01458002|OTHER|Tailored Internet Communication with Relational Agent|"The Tailored Internet Intervention will include a relational agent component, which is an animated conversational agent that builds a working relationship with subjects over time and uses this alliance to boost intervention effectiveness and retention to the Tailored Internet Communications web site."
224247090|NCT01458002|OTHER|Tailored Internet Communications|Best practices for TTM tailored communications with two types of feedback: normative - compared to peers and ipsative - self compared to previous assessment.
224247091|NCT04769648|DRUG|Pro-ocular™ Topical Gel 1%|Pro-ocular™ is a topical gel applied dermally to forehead twice-daily
224247092|NCT04769648|DRUG|Placebo|Placebo is a vehicle topical gel without active ingredient applied dermally to forehead twice-daily
224247093|NCT05701930|BEHAVIORAL|symptom management|pecha kucha training
224247094|NCT03204266|DRUG|Arginine recovery supplement|Participants take 1 ounce (30mls) of Arginine recovery supplement four times daily 5 days preoperatively and 14 days postoperatively.
224247095|NCT03204266|DIETARY_SUPPLEMENT|Omega-3 Fatty Acids|Participants given omega-3 fatty acids, 1 gram four times a day, 4 grams total per day. This will be started 7 days preoperatively and continued 14 days postoperatively.
224247096|NCT00987948|DRUG|maraviroc (Selzentry)|dosage varies with other medications being taken; will follow package insert guidelines
224247097|NCT02436057|OTHER|AEGIS (Automated Evaluation of Gastrointestinal Symptoms)|
224247098|NCT04751669|DIETARY_SUPPLEMENT|Vitamin and trace elements|Dietary supplement oral route, once a day, during 14 days
224247099|NCT04751669|DIETARY_SUPPLEMENT|Placebo|Dietary supplement (placebo) oral route, once a day, during 14 days
224247100|NCT00002804|BIOLOGICAL|filgrastim|
224247101|NCT00002804|DRUG|doxorubicin hydrochloride|
224247102|NCT00002804|DRUG|ifosfamide|
224247103|NCT00002804|DRUG|mesna|
224247104|NCT00002804|DRUG|vincristine sulfate|
224247105|NCT00002804|PROCEDURE|conventional surgery|
224247106|NCT00002804|RADIATION|brachytherapy|
224247107|NCT00002804|RADIATION|low-LET cobalt-60 gamma ray therapy|
224247108|NCT00002804|RADIATION|low-LET electron therapy|
224247109|NCT00002804|RADIATION|low-LET photon therapy|
224247110|NCT01175616|DRUG|Creatine|Oral Creatine 5 grams daily.
224247111|NCT00003939|DRUG|trabectedin|
224247112|NCT05099822|DRUG|CC-97489|Specified dose on specified days
224247113|NCT05099822|OTHER|Placebo|Specified dose on specified days
224247114|NCT04285359|PROCEDURE|Intracranial Interventions|Neurosurgical elective intracranial interventions: supra- and infratentorial craniotomies, transnasal endoscopic interventions.
224247115|NCT03370549|BEHAVIORAL|AWARE intervention|Group psychotherapy for Asian-American women
224247116|NCT00151047|DRUG|Capecitabine|
224247117|NCT00151047|DRUG|Docetaxel|
224247118|NCT02440308|DRUG|68Ga-DOTA-Bombesin|"68Ga-DOTA-Bombesin is a gallium-68-labeled gastrin-releasing peptide receptor (GRPr) antagonist. DOTA is \[4,7,10-Tris-(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl\]-acetyl.~68Ga-DOTA-Bombesin is administered intravenously (IV)"
224247119|NCT02440308|PROCEDURE|Magnetic Resonance Imaging (MRI) scan|
224247120|NCT02440308|PROCEDURE|Positron Emission Tomography (PET) scan|
224247121|NCT01585259|DRUG|Anfibatide|Snake venom
224247122|NCT01585259|DRUG|Placebo|Saline
224247123|NCT06254677|OTHER|Retrospective review of histological features|Correlate histopathology characteristics of acute kidney injury with molecular signatures, kidney function and aetiology of acute kidney injury to derive clinically validated scoring system for acute kidney injury and acute tubular injury
224247124|NCT04257474|BEHAVIORAL|Self-Report Survey|The self-report survey will be created using the Health Services Utilization Model (HSUM)
224247125|NCT04257474|BEHAVIORAL|Qualitative Interviews|Researchers will randomly select 30 participants from group 1 and will use semi structured qualitive interviews exploring factors impacting utilization of screening breast MRI
224247126|NCT01029522|DRUG|Atorvastatin (Lipilou)|treatment of dyslipidemia administration : PO, qod
224247127|NCT01029522|DRUG|Atorvastatin (Lipitor)|treatment of dyslipidemia administration : PO, qod
224247128|NCT00517530|DRUG|Obinutuzumab|Obinutuzumab was provided in single-dose glass vials as a freeze-dried powder.
224247129|NCT00667095|DRUG|Botox Instillation|Botox instilled into the bladder via ureteral catheter and retained for up to 30 minutes then spontaneously voided.
224247130|NCT00667095|DRUG|DMSO Instillation|DMSO 50% w/w aqueous solution; 50 cubic centimeters instilled into the bladder via ureteral catheter and retained up to 30 minutes then spontaneously voided.
224247131|NCT01900964|PROCEDURE|PTFE membrane|The non-resorbable PTFE barrier membrane will be surgically placed in conjunction with a ridge preservation procedure.
223666109|NCT05324644|BEHAVIORAL|Motivational interview|In the first interviews with the students; It is planned to provide information about acquaintance and research, fill in the scales in 10-15 minutes, make CO measurements, and also conduct an average of 20-40 minutes of motivational interviews in the intervention group. In the second interview in the 1st month, it is planned to summarize the first interview, fill in the scales in 3-5 minutes, make the CO measurements in 10-15 minutes or get the measurement results and apply motivational interview in the average of 20-40 minutes. In the third interview in the 3rd month, it is planned to summarize the second interview in 3-5 min, fill in the scales in 10-15 minutes, make CO measurements or get the measurement results and to apply motivational interviews for an average of 20-40 minutes. In the last interview in the 6th month, it is planned to summarize the 3rd-month interview, to apply the scales for approximately 10-15 minutes, to make CO measurements or to get the measurement results.
224247132|NCT01900964|PROCEDURE|Collagen membrane|A resorbable collagen membrane is surgically placed in conjunction with a ridge preservation procedure.
224247133|NCT02967107|PROCEDURE|Cold snare polypectomy|Use of a polypectomy snare closed over a polyp without electrocautery
224247134|NCT02967107|PROCEDURE|Endoscopic mucosal resection|Use of injected chromogelofusine solution to raise a lesion prior to snare resection with electrocautery
224247135|NCT00242788|DRUG|Gefitinib and capecitabine|
224247136|NCT03447262|DRUG|VX-659/TEZ/IVA|Fixed-dose combination tablets for oral administration qd in the morning.
224247137|NCT03447262|DRUG|IVA|IVA tablet qd in the evening.
224247138|NCT03933748|DRUG|Teicoplanin-PMMA|Therapeutic drug monitoring of teicoplanin
224247139|NCT01199848|DIETARY_SUPPLEMENT|Placebo|whole milk shake without strawberry powder served with the high fat/carbohydrate test meal
224247140|NCT01199848|DIETARY_SUPPLEMENT|10G|whole milk shake with 10g strawberry powder served with the high fat/carbohydrate test meal
224247141|NCT01199848|DIETARY_SUPPLEMENT|20G|whole milk shake with 20 strawberry powder served with the high fat/carbohydrate test meal
224247142|NCT01199848|DIETARY_SUPPLEMENT|40G|whole milk shake with 40g strawberry powder served with the high fat/carbohydrate test meal
224247143|NCT01199848|DIETARY_SUPPLEMENT|Placebonofiber|Placebo without Fiber
224247144|NCT02160925|OTHER|Preoperative 99mTc-Sestamibi SPECT/CT|
224247145|NCT01221922|DEVICE|RevLite Q-Switched Nd:YAG Laser|Laser treatment once every 2 weeks for a total of 10 treatments.
224247146|NCT00938834|OTHER|CFQ Qigong|CFQ Qigong training session training will consist of three half days of training in the technique. Following the training sessions, participants will return to the study site on a weekly basis for the first 8 weeks.
224247147|NCT01882257|DEVICE|BiPAP|BiPAP-auto (Phillips Respironics)is a noninvasive positive pressure ventilation device worn with a mask interface of the subject's choice. It is used to treat obstructive sleep apnea.
224247148|NCT01882257|DEVICE|BiPAP/AVAPS (Phillips Respironics)|BiPAP/AVAPS (Phillips Respironics) is a noninvasive positive pressure ventilation device worn with a mask interface of the subject's choice. It is specifically designed to treat nocturnal hypoventilation due to an underlying neuromuscular disorder.
224247149|NCT00374335|PROCEDURE|abdominal ultrasound|abdominal ultrasound to detect hepatic hemangiomas
224247150|NCT00374335|OTHER|Dermatologic Examination|Complete dermatologic examination
224247151|NCT02259270|OTHER|Record review|Record review. No intervention with patient or physician. No effect on outcome.
224247152|NCT02259270|OTHER|AST-history|Checking history (period and number) of ambulatory dispensed AST from 1 year before till 1 year after hospitalisation. No intervention with patient or physician. No effect on outcome.
224247153|NCT04249271|OTHER|serum sampling|repeated serum sampling during pregnancy and thereafter
224247154|NCT04152174|PROCEDURE|Combined extracorporeal blood purification|Patients receive combined extracorporeal blood purification: CRRT in CVVHDF mode with AN 69 ST set (Baxter) and hemoadsorption with Cytosorbents Corp. CytoSorb adsorber.
224247155|NCT04152174|PROCEDURE|CRRT|Patients receive CRRT in CVVHDF mode with AN 69 ST set (Baxter)
224247156|NCT01349374|OTHER|skin biopsy|Obtention of skin micro-samples collected from healthy volunteers and diabetic patients (type 2 and MODY), intended to be used afterwards to obtain stem cell lines, in the framework of new therapeutic strategies of type 2 diabetes.
224247157|NCT04680962|BIOLOGICAL|MabionCD20 (candidate biosimilar to rituximab)|Intravenous infusion, 10 mg/ml concentrate, 500 ml
224247158|NCT04680962|BIOLOGICAL|MabThera®|Intravenous infusion, 10 mg/ml concentrate, 500 ml
224247159|NCT04680962|BIOLOGICAL|Rituxan®|Intravenous infusion, 10 mg/ml concentrate, 500 ml
224247160|NCT02371343|DIETARY_SUPPLEMENT|Fish oil, Ocean plus|Ocean Plus, 1200 mg, EPA 384 mg DHA 252 mg, total omega-3 782 mg, 50 soft gel, Ocean®, Germany
224247161|NCT02371343|DIETARY_SUPPLEMENT|Sunflower Oil|
224247162|NCT04468503|OTHER|Two differnt protien prescription (ig per kg per day and 2g per kg /day )will be assigned to each group interventional|In this study intervention will be the dose of protein, one group will be prescribed with the protein dose (1 g/kg/day) and other group will be on prescribed higher dose (2gm/kg/day) of protein according to the ASPEN guideline for critically ill and the energy requirements (other than proteins) will be 25 kcal/kg of adjusted body weight (Picolo et al.,). Each subject in the trail will provide remaining medical nutrition therapy according to the therapeutic guidelines in the field. The medical nutrition management other than protein will be adjust according to need of each patient.
224247163|NCT01832259|DRUG|Pazopanib|Pazopanib, 800 mg, orally daily for 28 days prior to radical prostatectomy.
224247164|NCT01832259|OTHER|Placebo|Placebo tablet orally, daily for 28 days prior to radical prostatectomy.
224247165|NCT03116659|DRUG|Doxycycline|Doxycycline 100 mg PO BID x 14 days
224247166|NCT03116659|DRUG|Imiquimod|up to 2 packs 3/ week x 28 days
224247167|NCT06281340|OTHER|Manual therapy|Each session will last approximately 50-60 minutes. Each session is composed of 10 techniques, 9 of which correspond to manual interventions commonly used in the field of manual therapy and adapted to patients with hemophilic arthropathy, according to the criteria previously established in studies that assess the safety of manual interventions in hemophilic arthropathy.
224247168|NCT06281340|OTHER|Placebo manual therapy|Each session will last approximately 50-60 minutes. Each session consists of the placebo application of 10 techniques, 9 of which correspond to manual interventions commonly used in the field of manual therapy and adapted to patients with hemophilic arthropathy, according to criteria previously established in studies that assess the safety of manual interventions in hemophilic arthropathy. In the techniques there will be no joint sliding, manipulations or myofascial inductions, being the only stimulus the contact of the physiotherapist with his hands and the pressure exerted with these, on the ankle.
224247169|NCT05876299|OTHER|95.1% Lean Pork|This intervention will contain 120 kcals, 4.4 g fat, and 20 g protein from low-fat ground pork.
224247170|NCT05876299|OTHER|81.16% Lean Pork|This intervention will contain 266 kcals, 20.6 g fat, and 20 g protein from high-fat ground pork.
224247171|NCT05876299|OTHER|Carbohydrate Beverage|This intervention will contain 266 kcals and 73.3 g carbohydrate from a carbohydrate beverage.
224247172|NCT05306639|OTHER|Rehabilitation|rehabilitation sessions using spinal magnetic stimulation or neuromodulation
224247173|NCT00833339|DRUG|mifepristone|600 mg/day x 1 week
224247174|NCT00833339|DRUG|placebo|placebo
224247175|NCT06314022|OTHER|Mobile application for colonoscopy preparation instructions|The APP will also consider the comorbidities and drugs of each patient. It can be adapted to the different types of laxative (4, 2 or 1 litre) and notify the need to discontinue anticoagulant and/or antiplatelet treatments by contacting with the primary care physician. Additionally, the application may ask short questions to the patient to control the laxative intake instruction. The user must confirm the appointment 48 hours in advance.
224247176|NCT05000658|DRUG|Dexamethasone phosphate|HSC injection of 4mL
223666110|NCT00852514|DEVICE|Bioelectrical impedance-guide dry weight reduction|for optimal determination of fluid status, monthly BIA was performed to monitor fluid status and avoid dehydration
223666111|NCT02407652|BEHAVIORAL|Cognitive Control Training|10 adaptive Paced Auditory Serial Addition Task (PASAT) sessions, 400 trials each
223666112|NCT02407652|BEHAVIORAL|Low Cognitive Load Training|10 low cognitive load sessions, 400 trials each
223666113|NCT02156245|OTHER|conventional rehabilitation program (including concentric cycle ergometer)|
223666114|NCT02156245|OTHER|cycling included into a conventional rehabilitation program|
223666115|NCT04380064|PROCEDURE|ILM Peeling|ILM peeling performed during primary PPV for PDR
223770721|NCT01897311|DEVICE|transcutaneous electrical nerve stimulation|
224247177|NCT05652543|BIOLOGICAL|SCTV01E|Participants will be vaccinated with SCTV01E on Day 0, and safety and immunogenicity will be monitored for 180 days after vaccination.
224247178|NCT05652543|BIOLOGICAL|Placebo (normal saline)|Participants will be vaccinated with Placebo (normal saline) on Day 0, and safety and immunogenicity will be monitored for 180 days after vaccination.
224247179|NCT04529863|DRUG|Tocilizumab|Tocilizumab claim is used as the reference group.
224247180|NCT04529863|DRUG|Abatacept|Abatacept claim is used as the exposure group.
224247181|NCT06327243|OTHER|Elastic tape ( kinesio tape)|This group will receive the tape on their quadriceps femoris muscle. First, the tape will be cut in a Y-shaped Kinesio type and then applied over the quadriceps femoris muscle. The tape will be applied at a point of 5 cm inferior to the anterior superior iliac spine to the patella (origin to insertion), with the patient in a supine position with 25% tension on the tape. Then, each patient will flex his or her knee, and the Y-shaped tape (the end of the tape) will be circled around the patella, ending at its inferior side with no tension.
224247182|NCT06327243|OTHER|Sham Taping|Sham taping will be applied horizontally across the muscle fibers without any stretching. the tape here will be applied transverse to the quadriceps femoris muscle. The patients will be in a supine position with their hips flexed at 30 degrees and their knees flexed at 60 degrees.
224247183|NCT00004905|BIOLOGICAL|filgrastim|
224247184|NCT00004905|BIOLOGICAL|recombinant interferon alfa|
224247185|NCT00004905|DRUG|cyclophosphamide|
224247186|NCT00004905|DRUG|cytarabine|
224247187|NCT00004905|DRUG|etoposide|
224247188|NCT00004905|DRUG|idarubicin|
224247189|NCT00004905|PROCEDURE|peripheral blood stem cell transplantation|
224247190|NCT00004905|RADIATION|radiation therapy|
224247191|NCT01334645|OTHER|Copeptin|"Patients with hyponatremia \< 135 mmol/L or troponin \> 1 μg/L are released study.~Blood sampling are taken for Troponine T, myoglobin, creatin kinase and copeptine analysis and 18-lead ECG was performed after 2, 4, 6 and 12 h.~Copeptin and myoglobin are measured at the end of the patients inclusion, after to be centrifugrd end frozen at -80°C at each time point.~The treatment of patients is not modified by the study. At 90 days, clinicals and paraclinicals events are collected"
224247192|NCT04264130|DRUG|Artesunate-Pyronaridine|Subjects received artesunate-pyronaridine according to their body weight once per day for three days.
224247193|NCT04264130|DRUG|Artemether-Lumefantrine|subjects received artemether-lumefantrine according to their body weight twice per day for three days.
224247194|NCT04264130|DRUG|Artefenomel-Ferroquine|Subject received a single dose of artefenomel-ferroquine according to their body weight
224247195|NCT00487565|DEVICE|Total knee arthroplasty|Total knee arthroplasty using a posterior stabilized implant
224247196|NCT02642367|DEVICE|McGrath videolaryngoscope|without use of stylet
224247197|NCT02642367|DEVICE|McGrath videolaryngoscope with Intubating stylet (Mallinckrodt)|use of stylet
224247198|NCT02642367|DRUG|rocuronium|tracehal intubation was performed 2 min after rocuronium injection with McGrath videolaryngoscope
224247199|NCT05719922|OTHER|Resistance Training|Comparing two different exercise-based treatment methodologies on the clinical outcomes of individuals with persistent knee pain.
224247200|NCT01163825|DRUG|Nerve Growth Factor|Encapsulated cell biodelivery of Nerve Growth Factor (NGF) to the basal forebrain nuclei of the brain by multiple implantable devices housing NGF-secreting human cells
224247201|NCT04128826|OTHER|Resistance Training|Using the cable machine, shoulders will be flexed to 180° for both (PROM \& FROM) groups throughout the training; FROM would train with full elbow extension (complete elbow flexion to extension) whereas PROM will train with partial elbow extension from 60° to 110°. A total of 8 sessions, 2 sessions/week for 4 weeks will be carried out by both groups. CON group will not participate in training protocol.
224247202|NCT04383366|DEVICE|Pentacam® (Oculus, Inc., Wetzlar, Germany)|Scheimpflug imaging
224247203|NCT04383366|DEVICE|Casia II (Tomey Germany, Nürnberg)|Anterior segment optical coherence tomography
224247204|NCT04383366|DEVICE|Spectralis Anterion (Heidelberg Engineering, Heidelberg, Germany)|Anterior segment optical coherence tomography
224247205|NCT01948414|PROCEDURE|electroencephalography|
224247206|NCT01948414|BIOLOGICAL|Blood sampling|
224247207|NCT01948414|BEHAVIORAL|Questionnaires regarding eating habits (TFEQ, EDI) and anxiety/depression (HAD)|
224247208|NCT03351335|DEVICE|Microfocused ultrasound with visualization|All subjects will receive an Ultherapy® treatment at dual depth using the 4-4.5mm and 7-3.0mm transducers. Treatments will be provided to the lower face, submental (under the chin) and neck area.
224247209|NCT03217903|DIAGNOSTIC_TEST|Myelogram|Bone marrow aspiration after 3 cycles of Azacytidine treatment
224247210|NCT03928691|DRUG|Magnesium Sulfate|4 gram MgSo4 diluted in 150 cc saline infused IV within 30 minutes as loading dose then the patient will receive the maintenance dose of 1gram MgSo4 per hour for 6 hours.
224247211|NCT00301691|BEHAVIORAL|behavioral dietary intervention|
224247212|NCT00301691|OTHER|educational intervention|
223666116|NCT04380064|PROCEDURE|No ILM Peeling|ILM peeling not performed during primary PPV for PDR
223666117|NCT01517360|DRUG|Oxytocin|Oxytocin 40 IU, intranasal inhalation
223666118|NCT01517360|OTHER|Placebo|Placebo, matched to Oxytocin, intranasal inhalation
223666119|NCT01517360|BEHAVIORAL|Social Cognitive Skills Training|The training utilizes skill building techniques that are commonly used in psychiatric rehabilitation. These include breaking down complex social cognitive processes into their components and automating these skills through repetition and practice. The training programs will include 12 sessions and will be administered in a small group format (6-8 participants per group) twice a week for 6 weeks. Each training session will last for about 90 minutes (1 hour training and 30 minutes between drug administration and start of training).
223666120|NCT05184010|DEVICE|ulnar nerve mini open release|the ulnar nerve mini open release was performed before arthroscopic release for elbow
223666121|NCT05184010|DEVICE|without ulnar nerve mini open release|arthroscopic release for elbow stiffness alone without ulnar nerve mini open release
223666122|NCT00613912|OTHER|Magnetic Resonance Imaging|"* Morphological sequences~* Arterial Spin Labelling (Perfusion)~* Spectroscopy: anterior cingulate cortex Naa, Cho, Cr, Myo-inositol, glutamate TE 30 Reference voxel in Parietal white matter"
223666123|NCT04368078|DRUG|Toripalimab plus Lenvatinib|"Toripalimab 240mg, every 3 weeks, intravenous infused, day 1, 6 weeks a cycle. Lenvatinib 8mg (weight\<60kg) or 12mg (weight≥60kg), once a day, oral at least 38 days of each 6 weeks cycle, day 2.~Number of cycle: until progression or unacceptable toxicity events develop"
223666124|NCT04982003|OTHER|exercise|10 weekly hour-long classes of drumming to music using large-amplitude, whole-body movements
223666125|NCT03741387|OTHER|Gain-frame questionnaire|Questionnaires focusing on the attitude of saving patients' lives were given to Rh negative blood donors in this group.
223666126|NCT03741387|OTHER|Loss-frame questionnaire|Questionnaires focusing on the attitude of preventing patients from death were given to Rh negative blood donors in this group.
224247213|NCT00301691|OTHER|preventative dietary intervention|
224247214|NCT04913376|DEVICE|Hilotherapy|Constant cooling device for hands and feet.
224247215|NCT01162694|OTHER|Remote Blood Glucose Monitoring|The subjects enrolled in the Internet Therapeutic Intervention arm receive standard care by testing their blood glucose at least 3 times daily and visit the endocrinologist every 3 months; however, they are also asked to upload their blood glucose readings online every 2 weeks for the health practitioner to view and comment upon.
224247216|NCT01162694|OTHER|Continuous Glucose Monitoring|The use of CGMS (Sensor, receiver, transmitter) (Medtronic Diabetes) plus the uploading of results to the Internet-based software utility of CareLink Personal and generating reports that can be viewed and used at the patient's own preference. This group will not receive feedback or suggestion based on the uploaded glucose data.
224247217|NCT00304603|OTHER|No intervention|No treatment was given to the patients as this is an observational study.
224247218|NCT02209441|DRUG|Phase I Dose-finding Study of Sorafenib Study|
224247219|NCT00469417|DRUG|Metvix® cream|
223666127|NCT00422084|DRUG|Pyronaridine artesunate|Oral PA (180:60mg tablets) once a day plus AL-placebo (twice a day) for 3 consecutive days (Day 0, 1, and 2)
223666128|NCT00422084|DRUG|Coartem® (artemether lumefantrine)|AL (20:120mg tablets) twice a day plus PA-placebo (once a day) for 3 consecutive days (Day 0, 1, and 2)
223666129|NCT00940472|DRUG|DMMET-01|90 days: 15 days daily dose 1050.6 mg (before dinner)+75 days dose twice a day 1050.6 mg (before breakfast) 1050.6 mg (before dinner).
223666130|NCT00940472|DRUG|Metformin Hydrochloride|90 days: 15 days daily dose 850 mg (before dinner)+ 75 days dose twice a day 850 mg (before breakfast) 850 mg (before dinner)
223666131|NCT03670420|OTHER|Medical honey|The investigators use Medihoney®, a medical honey released by the DermaSciences.
223666132|NCT00146484|DRUG|Twice Daily versus Three Times Daily Insulin Injections|
224247220|NCT00469417|PROCEDURE|Hand held liquid nitrogen spray cryotherapy|
224247221|NCT00089193|BIOLOGICAL|incomplete Freund's adjuvant|
224247222|NCT00089193|BIOLOGICAL|multi-epitope melanoma peptide vaccine|
224247223|NCT00089193|BIOLOGICAL|sargramostim|
224247224|NCT01038947|BIOLOGICAL|Uricase-PEG 20|Intramuscular injection of Uricase-PEG 20 without premedication
224247225|NCT03723993|DEVICE|Inflated cuff|After patient being draped, applying cuff inflation will be done to the upper arm not having the arterial line inserted of about 200 mmHg or 15 mmHg above patient's systolic pressure 3 cycles 5 minutes each followed by 5 minutes of pressure relieve
224247226|NCT03723993|DEVICE|Non inflated cuff|non inflated cuff around the arm for the control group
224321747|NCT05414357|DIAGNOSTIC_TEST|Functional Magnetic Resonance Imaging at rest and in activation with attentional task|"Participants complete 3 successive assessments (T1: baseline, T2: at 6 months, T3: after galvanic vestibular stimulation). Assessments include:~* Functional and Anatomic Magnetic Resonance Imaging at rest and in activation (only at T1 and T2).~* Biological and physiological measurements~* Spatial memory task~* Cognitive battery~* Questionnaires (sleep, quality of life)"
224321748|NCT05540327|DRUG|M5049 low dose|Participants will receive film-coated tablets of M5049 at a low dose orally, twice a day (BID) for up to 194 weeks.
224247227|NCT03191474|BEHAVIORAL|T-POWr Intervention|"All participants will be asked to complete a secure confidential online survey focusing on needs assessment.~Participants in the T-POWr Intervention Arm will receive a client-centered case management consultation based on how the participant responds to the online survey. The T-POWr will refer participants to assistance services based on the needs assessment, including accessing general health care, health insurance, hormone replacement therapy, housing, mental health care, domestic violence care, substance use treatment, etc. Each resource is extensively vetted to assure a trans-friendly experience and will be tailored to each geographic area across the project enrollment sites. The study facilitates referrals for services but will not provide extensive and ongoing case management."
224247228|NCT05730166|OTHER|Mechanical Conditioning stimulus|Mechanical stimulus on the upper trapezius of the non-dominant side.
224247229|NCT04792450|DEVICE|Thermography|Measure Temperature using Thermal Camera
223666133|NCT05563155|DRUG|Dexamethasone 24 mg|Dexamethasone 24 mg on day 1 after surgery.
224247230|NCT04792450|DEVICE|Tympanic Thermometer|Measure Temperature using Tympanic Thermometer
223666134|NCT05563155|DRUG|Placebo|Placebo tablet given on day 1 after surgery.
224247231|NCT04792450|DEVICE|Forehead Thermometer|Measure Temperature using Forehead Temperature
224247232|NCT04792450|DEVICE|62 Max + Infra-red thermometer|Measure Temperature using 62 Max + Infra-red thermometer
224247233|NCT03585790|DEVICE|Contact lens with Multifocal Optics|This contact lens has optics to aid the accommodative and convergence systems
224247234|NCT03585790|DEVICE|Contact lens with Single Vision Optics|This contact lens has standard single vision optics
224247235|NCT02011295|PROCEDURE|ankle arthroscopy with debridement and microfracture of the OLT|ankle arthroscopy with debridement and microfracture of the OLT
224247236|NCT02011295|OTHER|Bone Marrow Aspirate injection|
224247237|NCT04082858|DRUG|Ketamine|A sub-anaesthetic dose of ketamine will be administered in twice-weekly infusions
223666135|NCT06356428|OTHER|Physcian Attitudes toward Cardiac Rehabilitation and Referral Scale-Revised (PACRR-R)|The PACRR comprises 20 items and 1 open ended item to assess physicians' attitudes and beliefs about CR and referral (includes instructions for scale completion to respondents). Response options were 1 = strongly disagree, 2 = agree, 3 = neutral, 4 = agree, and 5 = strongly agree. Five (5) items are reverse-scored to mitigate acquiescence bias (denoted with \*), such that higher scores reflect more positive atti- tudes toward CR and referral. A mean score is computed for the total (where at least 80% of items were completed; i.e., 15/19) scale and subscales.
223666136|NCT01944280|OTHER|massage|
224247238|NCT04082858|DRUG|Midazolam|A sub-anaesthetic dose of midazolam will be administered in twice-weekly infusions
224247239|NCT03013634|DRUG|Dexmedetomidine|Dexmedetomidine infusion:loading 0.5ug/kg for 10min, then 0.5 ug/kg/h until the end of operation.
224247240|NCT03013634|DRUG|Normal saline|Equal volume normal saline substitute for dexmedetomidine
224247241|NCT05673317|OTHER|"Breastfeeding at AU Smartphone Application"|This is a free Apple-Based Smartphone Application the participant can download. In the application, there is information and tips for breastfeeding success and continuation, as well as information on additional resources both online and in the community as a whole.
224247242|NCT03790345|DRUG|Pyridoxine|Adjuvant daily treatment with 200mg of pyridoxine
224247243|NCT03790345|DRUG|Cobalamin|Adjuvant daily treatment with 2mg of cobalamin
224247244|NCT03790345|DRUG|Placebo Oral Tablet|Adjuvant daily treatment with placebo
224247245|NCT03860415|DIETARY_SUPPLEMENT|Vivomixx|Two months of 2 sachets vivomixx each morning and 2 sachets each night. Each sachet of viviomixx contains 450 billion live bacteria.
224247246|NCT03860415|DIETARY_SUPPLEMENT|Placebo|Two months of 2 sachets placebo each morning and 2 sachets each night. Each sachet of placebo contains 450 billion live bacteria.
224247247|NCT04073394|BEHAVIORAL|Standard Lifestyle Intervention|Research team will prescribe diet, exercise, behavioral plan for the participant to follow for the 12 week study. The lifestyle plan will be based on the Mayo Clinic Diet program.
224247248|NCT04073394|BEHAVIORAL|Modified Lifestyle Intervention|Research team will prescribe diet, exercise, behavioral plan for the participant to follow for the 12 week study. The lifestyle plan will be based on the participants obesity phenotype.
224247249|NCT03660384|PROCEDURE|PPV/SO|Subjects receive 1,000 centistoke silicone oil tamponade during vitrectomy
224247250|NCT03660384|PROCEDURE|PPV/C3F8|Subjects receive 16% C3F8 gas tamponade during vitrectomy
224247251|NCT00183521|BEHAVIORAL|Raise-CO2 breathing regulation training|Reverse hyperventilation (defined by low arterial CO2) is often characteristic of individuals with panic disorder. Participants will be randomly assigned to one of three groups: raise-CO2 breathing, lower-CO2 breathing, or a control group. Participants in the raise-CO2 group will be taught techniques to recover from hyperventilation faster.
224247252|NCT00183521|BEHAVIORAL|Lower-CO2 breathing regulation training|According to the false suffocation alarm theory, anxiety is experienced when an overly sensitive hypothalamic mechanism is triggered by rising pCO2. Participants in the lower-CO2 group will be taught techniques to reach hyperventilation levels, then switch to breathing techniques that reduce hyperventilation symptoms.
223666137|NCT00665314|DRUG|Plerixafor (AMD3100)|0.24mg/kg SC for 2 to 7 days.
223666138|NCT00665314|DRUG|Can be any registered nonpegylated form of G-CSF|10mcg/kg SC for 4 days followed by an additional 2 to 7 days.
223666139|NCT06049901|DRUG|Nitazoxanide|Nitazoxanide is considered a broad-spectrum anti-microbial drug with a potent activity against various helminths, anaerobic bacteria and viruses.
223770722|NCT02621164|BIOLOGICAL|NBP607-QIV|For subjects 6 months to 8 years of age, single intramuscular dose for primed subjects, two doses for unprimed subjects. For subjects 9 to 18 years of age, single intramuscular dose (0.25mL/0.5 mL)
224247253|NCT00183521|BEHAVIORAL|Control|Participants in the control group will not be taught any breathing techniques but will be included in all assessments.
224247254|NCT04767477|OTHER|Face-to-face rehabilitation|Aerobic training will be performed with 60% to 80% of the maximum VO2 obtained through the CPET. The exercise will be performed on the treadmill, with a total time of 40 minutes, with 5 minutes of warm-up, 30 minutes of conditioning, 5 minutes of cooling down. Resistance training will be performed for upper and lower limbs and the load used in the exercises will be 60% of the maximum repetition test (1RM), with load progression every six sessions. The exercises are performed in three series of 12 repetitions.
223666140|NCT04571528|BEHAVIORAL|TAU + multicomponent treatment VIRTUAL FIBROWALK|Group treatment protocol of 12 weekly 60 minute virtual sessions. All sessions include the following ingredients (approx. in the same order): - Pain neuroscience education (15 min.) - Cognitive restructuring (15 min.) - Mindfulness techniques (15 min.) - Physical exercise(15 min.) - Treatment as Usual (TAU) Standard pharmacological treatment usually provided to patients with fibromyalgia.
223666141|NCT04571528|BEHAVIORAL|Treatment as Usual (TAU)|Treatment-as-Usual (TAU) consisted of the prescribed drugs adapted to the symptomatic profile of each patient and basic face to face and written advice on PNE and aerobic exercise adapted to the physical capacities of the patients at the beginning of the study.
223666142|NCT04571528|BEHAVIORAL|TAU + Physiotherapy part of VIRTUAL FIBROWALK|Group treatment protocol of 12 weekly 60 minute virtual sessions. All sessions include the following ingredients: - Pain neuroscience education (30 min.) - Physical exercise(30 min.) - Treatment as Usual (TAU). Standard pharmacological treatment usually provided to patients with fibromyalgia.
223666143|NCT00915499|DEVICE|VPAP Adapt SV|Comparison of ASV and CPAP modes
224247255|NCT04767477|OTHER|Telerehabilitation|The telerehabilitation protocol will consist of stretching the muscles of the upper and lower limbs and accessory muscles of breathing. The conditioning phase will consist of stationary walking, side running, jumping jump and stationary running, 3 times of 40 seconds with a 30-second passive rest interval between them. Resistance training will be applied to the muscles of the upper limbs and lower limbs, with specific exercises for each musculature, using elastic bands as resistance.
224247256|NCT05410301|DEVICE|Static Magnetic and Electric (sBE) device|Home-based Static Magnetic and Electric (sBE) device that is slept in
224247257|NCT05410301|DRUG|Lomustine|Chemotherapy drug
224247258|NCT05410301|DRUG|Bevacizumab|Chemotherapy and targeted therapy drug
224247259|NCT01751048|BIOLOGICAL|GLA-SE|Glucopyranosyl Lipid A- Stable oil-in-water emulsion (GLA-SE) is formulated in a stable oil-in-water emulsion (SE) to yield the adjuvant formulation GLA-SE. The combination of GLA-SE with a recombinant protein antigen (LEISH-F3) results in a Th1-type T cell response. GLA-SE appears as a milky- white liquid. 16 subjects receive vaccine on day 0, 28, and 168 of 0.5 ml of 20 mcg of LEISH-F3 + 5 mcg GLA-SE.
224247260|NCT01751048|BIOLOGICAL|LEISH-F3|LEISH-F3 is a lyophilized formulation containing 50 mcg LEISH-F3 and excipients (mannitol, sucrose, and polysorbate 80). All subjects receive vaccine on day 0, 28, and 168 of 0.5 ml of 20 mcg of LEISH-F3.
224247261|NCT01751048|BIOLOGICAL|MPL-SE|Monophosphoryl Lipid A-Stable oil-in-water emulsion (MPL-SE) is an oil-in-water emulsion that contains Monophosphoryl Lipid A, an attenuated form of Lipid A from Salmonella Minnesota R595 in a emulsion (SE). The combination of MPL-SE with a recombinant protein antigen (LEISH-F3) results in a TH1-type T cell response. MPL-SE appears as a milky-white liquid. 16 subjects receive vaccine on day 0, 28, and 168 of 0.5 ml of 20 mcg of LEISH-F3+10 mcg MPL-SE.
224247262|NCT01751048|DRUG|SE|Stable oil-in-water Emulsion (SE) is a squalene oil-in-water emulsion that has adjuvant properties of its own, but in a Th2-dependent manner. SE appears as milky-white liquid. 16 subjects receive vaccine on day 0, 28, and 168 of 0.5 ml of 20 mcg LEISH-F3 + SE.
224247263|NCT03194139|DRUG|GC4711 30 mg IV|GC4711 will be infused IV as a single dose of 30 mg (3 mL GC4711 at 10 mg/mL) in 245 mL normal saline, totaling 250 mL, over a 60-minute period using a programmable pump
224247264|NCT03194139|DRUG|GC4711 50 mg IV|GC4711 will be infused IV as a single dose of 50 mg (5 mL GC4711 at 10 mg/mL) in 245 mL normal saline, totalling 250 mL, over a 60-minute period using a programmable pump.
224247265|NCT03194139|DRUG|GC4419 45 mg IV|GC4419 will be infused IV as a single dose of 45 mg (5 mL GC4419 at 9 mg/mL) in 245 mL normal (0.9%) saline, totalling 250 mL, over a 60-minute period using a programmable pump.
224247266|NCT06407622|OTHER|Foot Reflexology|In previous studies, no study was found investigating the effect of foot reflexology on sleep quality and bowel functions in patients undergoing surgical intervention. This study is thought to be the first to evaluate the effect of foot reflexology on sleep quality and bowel functions in surgical patients. In this respect, it is a study that will contribute to the literature.
224247267|NCT04908007|OTHER|Qualitative analysis for professionals|"3 individual interviews with the different categories of professionals most involved during the crisis in each university hospital. In the first phase, the points of improvement identified will be analyzed In the second phase, good practices and innovations will be analyzed. For these first two phases, the duration of one hour was chosen because it is difficult to mobilize the professionals for longer. Individual interviews are preferred, but group interviews are possible with no more than three people so that everyone can express himself or herself. Finally, individual interviews of 15 to 30 minutes will be conducted with some of the people interviewed previously in order to identify the costs of the dysfunctions or problems encountered during the crisis.~Questionnaires with establishments associated with the crisis management, the ARS AuRA and France Assos Santé AuRA.~Analysis of evidence documents in the university hospitals"
224247268|NCT04908007|OTHER|Quantitative analysis for Professionals|"A self-assessment of the three phases of the crisis management process (preparation, crisis management, crisis recovery) will be carried out in the participating establishments using the WHO grid with the target persons identified within the establishments.~This step will use the crisis response assessment tool developed by the WHO following the H1N1 pandemic in 2011. This grid will be adapted beforehand to the COVID-19 situation and to the local organization by the study's scientific committee. The dimensions investigated will be : Command and control, Communication, Safety and security, Triage, Surge capacity, Continuity of essential services; Human resources, Logistics and supply management, Post-disaster recovery.~The grids will be sent to the 4 university hospitals to be filled in with the target audience recommended by the WHO methodological guide.~The results of this self-assessment will be linked to and interpreted with the results of the interviews in phase 1."
224321749|NCT05540327|DRUG|M5049 medium dose|Participants will receive film-coated tablets of M5049 at a medium dose orally, BID for up to 194 weeks.
224321750|NCT05540327|DRUG|M5049 high dose|Participants will receive film-coated tablets of M5049 at a high dose orally, BID for up to 194 weeks.
224321751|NCT05540327|DRUG|Placebo|Participants will receive M5049 matching placebo orally, BID for up to 194 weeks.
224321752|NCT04305145|DRUG|Infliximab|Infusion
224321753|NCT04305145|DRUG|Methylprednisolone|Infusion
224321754|NCT04305145|DRUG|Prednisone|Orally
223666144|NCT03774823|DEVICE|RF and PEMF|RF and PEMF treatment is deployed using either a small or large handpick applied to the skin and moved slow random patterns homogeneously over the area of treatment
223666145|NCT03774823|DEVICE|Ultrasound|Ultrasound is applied to the subject by placing a probe on the treatment area and moving it rapidly and homogeneously over the treatment area
223666146|NCT01253811|DRUG|catridecacog|Intravenous injection of a single dose of recombinant factor XIII, 35 IU/kg body weight every 4th week
223666147|NCT01087736|DRUG|Topiramate|After random assignment, topiramate will be titrated up over 5 weeks. Dosing begins at 25 mg per day, and increase in the second week to 25 mg twice per day; in the third week to 50 mg twice/day; in the fourth week to 75 mg twice/day; in the 5th week to 100 mg twice/day; and in weeks 6-11 increased to and maintained at 100 mg in the morning and 200 mg at night. Patients will receive the highest dose tolerated, not to exceed 300 mg per day. Adjustments are permitted throughout titration. Once maximum tolerated dosage is reached, subjects will be asked to maintain dosage for remainder of the treatment phase. Upon completing the 6 week maintenance period subjects will taper off over a 7-day period (Week 12). If subjects experience significant side effects, the dosage may be adjusted.
223770723|NCT02621164|BIOLOGICAL|Agrippal S1|For subjects 6 months to 8 years of age, single intramuscular dose for primed subjects, two doses for unprimed subjects. For subjects 9 to 18 years of age, single intramuscular dose (0.25mL/0.5 mL)
224247269|NCT04908007|OTHER|Quantitative analysis for Patients|"A questionnaire of patients' perceptions on the same perimeter (crisis and post-crisis management, from the point of view of points of improvement and good practices) will be constructed and sent by the management of the establishments to all patients hospitalized for 48 hours or more during the first wave and who have left their email address (methods similar to the e-satis survey). The online questionnaire survey is preferred in order to get away from the emotion and for feasibility reasons. This patient experience questionnaire adapted to COVID will be co-constructed with expert/partner patients and user associations.~Four dimensions will be investigated : The perception of the quality of the information received by the patient, The nature of the information on the specific health protection protocol from which the patient benefited, The patient's consideration of the overall context, during and after, The effects of the health context on the overall management of the patient"
223770724|NCT01595620|OTHER|Thermal|Thermal sensation/pain testing
223770725|NCT01595620|OTHER|Electrical|Electrical sensation/pain testing
224247270|NCT04908007|OTHER|Tools development|"Development of tools to prepare for situations of uncertainty : In the third phase of the project, design thinking workshops will be organized (within the HCL) to develop training (in the form of simulation) in order to appropriate virtuous practices in situations of uncertainty. The purpose of these training sessions will be to improve the institution's ability to learn in a situation of uncertainty and thus to develop its reliability.~The aim of these workshops is to provide tools for raising awareness of situations of uncertainty to all hospital staff."
224247271|NCT04135235|DRUG|TAF|Propofol tenofovir fumarate
224247272|NCT04135235|DRUG|TDF|Dipirofurate fumarate tenofovir
224247273|NCT02753959|OTHER|Acute Intervention|"Patients will be set up onto their Non Invasive Ventilator and assessed for an hour prior to, during and following secretion clearance and will have the following assessed:~* Electrical impedance tomography (EIT)~* EMGpara~* SpO2~* tcCO2~* Respiratory inductance plethysmography~* EIT will be performed as 2 to 10-minutes recording of quiet breathing before and after each intervention~Interventions will be set as follows with a 30 minute washout period between modes:~* Manual techniques only~* MIE at low pressure (+30 to -30)~* MIE at high pressure (+60 to -60)"
224247274|NCT02753959|OTHER|Stable Intervention|"Patients will be set up onto their Non Invasive Ventilator and assessed for an hour prior to, during and following secretion clearance and will have the following assessed:~* Electrical impedance tomography (EIT)~* EMGpara~* SpO2~* tcCO2~* Respiratory inductance plethysmography~* EIT will be performed as 2 to 10-minutes recording of quiet breathing before and after each intervention~Interventions will be set as follows with a 30 minute washout period between modes:~* Manual techniques only~* MIE at low pressure (+30 to -30)~* MIE at high pressure (+60 to -60)"
224247275|NCT05974163|DIAGNOSTIC_TEST|radiomic of CT|Computed Tomography (CT) is often an important examination method for emergency diagnosis because of its fast examination speed and accurate localization acute respiratory distress syndrome.
224247276|NCT04106193|OTHER|Blended Facilitation|Blended facilitation consists of an External Facilitator and Internal Facilitator to support adoption of intimate partner violence screening practices for WVs treated in primary care.
224247277|NCT04106193|OTHER|Implementation as usual|Implementation as usual refers to traditional, site-initiated support for screening practices to detect intimate partner violence among WVs treated in primary care.
224247278|NCT04106193|OTHER|Toolkit|All study arms will feature a toolkit meant to guide sites' adoption of intimate partner violence screening among WVs treated in primary care.
224247279|NCT02897791|BEHAVIORAL|written evaluations|answering questions about pictures and stories
224247280|NCT03031184|DRUG|Mirtazapine|
224247281|NCT03031184|OTHER|Placebo|
224247282|NCT04574102|DEVICE|Omega Refractive Capsule with FDA approved Intraocular Lens|Omega Refractive Capsule with FDA approved Intraocular Lens
224247283|NCT04574102|DEVICE|FDA approved Intraocular lens|FDA approved Intraocular lens
224247284|NCT00834743|DRUG|Glucophage® XR 750 mg Tablets|1 x 750 mg, single-dose fasting
224247285|NCT00834743|DRUG|Metformin ER 750 mg Tablets|1 x 750 mg, single-dose fasting
224247286|NCT04855058|OTHER|online survey(or phone survey)|A questionnaire about the current symptoms and satisfaction for received treatment will be conducted over google survey(or the phone survey) for patients.
224247287|NCT02507128|DRUG|liraglutide|Liraglutide were taken 30 min before PCI.
224247288|NCT02507128|DRUG|placebo|Placebo were taken 30 min before PCI.
224247289|NCT03867721|DEVICE|Ventilator|Comparison of two ventilators for mouthpiece ventilation
224247290|NCT00558857|DEVICE|Dynamic Substrate Mapping-guided ablation|Radiofrequency ablation
223770726|NCT01595620|OTHER|Capsaicin|Intradermal Capsaicin
223770727|NCT01595620|DRUG|THC|Active THC (0.01 mg/kg) administered over 10 minutes
223770728|NCT01595620|DRUG|THC|Active THC (0.03 mg/kg) administered over 10 minutes
223770729|NCT01595620|DRUG|Placebo|Control: small amount of alcohol with no THC, administered over 10 minutes
223770730|NCT06309875|OTHER|PLAN CUIDARTE|Description Plan Cuidarte
223770731|NCT06309875|OTHER|Conventional care|Description Conventional care
224321755|NCT04069884|RADIATION|regional nodal irradiation|external-beam radiotherapy (XRT)
223666148|NCT01087736|OTHER|Placebo administration|Placebo pills will be prepared by the UCSF pharmacy which will be indistinguishable from the topiramate pills used in that arm. Both topiramate and placebo will then be delivered to the VA pharmacy. A consulting biostatistician will randomly assign participants to either the topiramate or placebo group. The dosing of placebo pills will follow the same regimen as outlined for the topiramate arm. In the event of a safety issue, there will be a procedure for unblinding only that participant.
223666149|NCT01429909|DEVICE|MAGNETOM Avanto (MRI device)|The primary purpose is to optimize the fMRI by a quantitative measurement of the T2\* in the cortex and the basal ganglia using MRI. The secondary purpose is to study the effect of age and Parkinson's disease on T2\*.
223666150|NCT01568528|DRUG|Oxytocin|OT intervention will be administration of OT intranasally at a dose of three 4 IU puffs per nostril for a total dose of 24 IU. This dose has been used in a number of other similarly designed challenge studies examining the effects of a single dose of OT (Kirsch et al. 2005; Kosfeld et al. 2005; Guastella et al. 2008a; Guastella et al. 2008b; Rimmele et al. 2009; Andari et al. 2010).
223666151|NCT01568528|DRUG|Placebo|The PBO/control will consist of the OT vehicle only delivered as 3 puffs of saline per nostril for a total of 6 puffs. Each puff contains 0.1 ml in volume, so the total delivered will be 0.6 ml intranasally.
223666152|NCT01568528|OTHER|Control|Participants who have no psychiatric diagnosis and will be controls for this project. These controls will NOT receive oxytocin or PBO. They will only receive psychiatric screening interview, MCCB Consensus Cogntive Battery assessment, urine drug screen, vision testing, and the three social cognition tasks.
224247291|NCT00864591|PROCEDURE|SPECT Imaging|Myocardial SPECT imaging will be performed 10-12 minutes after the stress injection of Tl-201, at 4 hours, and at 18-24 hours in patients with non-reversible or partially reversible defect on 4-hour imaging. Images will be obtained with a rotating single- or dual-head gamma camera equipped with low-energy high resolution collimators. Energy windows of 20% and 10% will be centered on the 70 KeV and 167 KeV peaks of Tl-201, respectively. Thirty images will be obtained (40 seconds each for the stress and 4-hour redistribution imaging, and 60 seconds each for the 18-24-hour imaging) over 180° extending from the 45° right anterior oblique to the 45° left posterior oblique projections.Localization of the disease in the left anterior descending artery (LAD), left circumflex (Cx) and right coronary artery (RCA) will be performed using a quantitative analysis software.
223666153|NCT02827656|DRUG|Decapeptyl|luteal support as described and vaginal progesterone 200 mg 3 times a day
224247292|NCT00864591|PROCEDURE|Stress Adenosine CMR|"CMR will be performed using a 3-T scanner and a dedicated eight-element cardiac phased-array coil Cine CMR will be performed using steady state free precession in the short-axis, two chamber, three chamber and four-chamber, 8 mm thick, separated by 0-mm gaps.~Adenosine perfusion CMR: Adenosine will be administered intravenously at 140 µg/kg/min over 6 min. Four minutes into the infusion (or earlier if angina is provoked), a bolus (0.1 mmol/kg at 5 ml/s) of Gadolinium DTPA will be administered. Patients will be instructed to hold their breath. Stress perfusion images will be acquired in the short axis plane (parameters and planning will be similar for stress and rest perfusion evaluation). The patients will be monitored by vector ECG, noninvasive sphygmomanometry, pulse oximetry and capnography."
224247293|NCT00000966|DRUG|Azithromycin|
224247294|NCT00000966|DRUG|Pyrimethamine|
224247295|NCT00000966|DRUG|Leucovorin calcium|
224247296|NCT05101044|BEHAVIORAL|Acceptance-based Behavioral Therapy (ABBT) Intervention|This acceptance-based behavioral therapy (ABBT) intervention intends to enhance retention in HIV care for people who use substances by targeting stigma. ABBT promotes an accepting stance towards life's challenges and encourages participants to thoughtfully disclose the serostatus and/or substance abuse problems as a behavioral step towards challenging stigmatization fears. The central hypothesis is that increased tolerance of stigmatization, facilitated through increased acceptance of HIV status and substance use behaviors, will increase PWH's longitudinal commitment to care.
224247297|NCT05298267|DEVICE|Do Not Disturb While Driving|Participants will be asked to turn on Do Not Disturb While Driving on their smartphones.
224247298|NCT00425672|BIOLOGICAL|ONTAK|Given IV
224247299|NCT00425672|OTHER|flow cytometry|Correlative studies
224247300|NCT00425672|OTHER|immunohistochemistry staining method|Correlative studies
224247301|NCT00425672|OTHER|enzyme-linked immunosorbent assay|Correlative studies
224247302|NCT00425672|OTHER|laboratory biomarker analysis|Correlative studies
224247303|NCT00425672|GENETIC|protein expression analysis|Correlative studies
224321756|NCT04069884|RADIATION|WBI|Whole Breast Irradiation
224321757|NCT04069884|RADIATION|chestwall XRT|chestwall irradiation
223666154|NCT02827656|DRUG|hCG luteal support|luteal support as described and vaginal progesterone 200 mg 3 times a day
223666155|NCT04618510|DEVICE|SEED 1-dayPure EDOF soft contact lens|Centre-distance contact lens with peripheral add power working on extended depth of focus principle to control myopia
223666156|NCT04618510|DEVICE|Single Vision Spectacles|These are the type of glasses that correct vision for a single distance
223770732|NCT03331874|DIAGNOSTIC_TEST|Reflectance Confocal Microscopy|In-vivo microscope
224247304|NCT00086996|DRUG|fluorouracil|Before surgery: 180 mg/m2/day by 24-hour infusion days 8 through 43. After surgery:180 mg/m2/day by 24-hour infusion days 1 through 36.
224247305|NCT00086996|DRUG|oxaliplatin|Before surgery: 85 mg/m2 by 2-hour IV infusion days 1, 15, and 29. After surgery: 85 mg/m2 by 2-hour IV infusion days 1, 15, and 29.
224247306|NCT00086996|PROCEDURE|conventional surgery|The surgical technique will depend upon the location and extent of tumor and individual surgeon preference.
224247307|NCT00086996|RADIATION|radiation therapy|Starting Day 8, patients will be treated 5 days/week at 180 centigray (cGy)/day times 25 fractions to a total dose of 4,500 cGy.
224247308|NCT04423263|PROCEDURE|Bilateral internal iliac artery balloon occlusion|Bilateral internal iliac artery balloon placement under fluoroscopic guidance preoperatively which will be occluded intraoperatively based on existing local protocol
224247309|NCT04423263|PROCEDURE|Control|Surgical approach similar to intervention arm, except bilateral internal iliac artery occlusion
224247310|NCT03447717|DEVICE|ActiGait|implanted device for peroneal nerve stimulation
224321758|NCT06424938|PROCEDURE|Patients who underwent epidural block|The researchers administered an epidural block to prevent post-operative pain to the epidural block group undergoing midline incision surgery for major gynecologic cancer.
223666157|NCT00958438|DRUG|Placebo|Placebo loading dose followed by placebo subcutaneous (SC) injection (2 mL) once a week for 16 weeks.
223666158|NCT00958438|DRUG|Rilonacept|Rilonacept 160 mg SC loading dose followed by Rilonacept 80 mg/2 mL SC injections once a week for 16 weeks.
223666159|NCT00958438|DRUG|Rilonacept|Rilonacept 320 mg SC loading dose followed by Rilonacept 160 mg/2 mL SC injections once a week for 16 weeks.
223666160|NCT00759564|DRUG|CP-70,429 and PF-03709270|Study Periods 1 and 2 will be separated by a minimum of 14 days. In Period 1, subjects will receive a single dose of CP-70429 (800 mg given as a 1.5 hour intravenous infusion), while in Period 2, subjects will receive a single oral dose of PF-03709270 (1000 mg).
223666161|NCT05948865|DRUG|CPO301|Administered by intravenous injection
223666162|NCT04813003|OTHER|Functional Brain Imaging and neurobehavioural tasks|"Combination of 3 neurobehavioural tasks:~Task 1 consists in subjective value rating of 64 food items. Participants are asked to rate how much they would want to eat the presented food item while fMRI (functional magnetic resonance imaging ) scanning is performed.~Task 2 consists in rating of subjective nutrient factor of the same 64 food items. Participants will answer the following four categorical questions in randomized order for each item: low or high in added sugar/protein/fat and healthy or unhealthy.~Task 3 consists of a decision-making task. Participants will be presented with two food items (out of the 64 food items), and asked to choose which of the two items they prefer to consume at the end of the experiment."
223770733|NCT06209112|DRUG|Sevoflurane|The time of reaching FAS=2% will be noted in both the groups. The time taken in seconds from Tzero to reach FAS 2% (Ttarget) will be calculated. Inspired concentration of Sevoflurane (FIS), FAS, and age-adjusted MAC will be retrieved from the automatically recorded 'trend' of parameters. FIS, FAS and age-adjusted MAC will be noted every 30 sec. starting from Tzero, till T5 and every minute thereafter until T15.
223770734|NCT04054648|OTHER|Bedtime administration of the participant's pre-existing antihypertensive medications|Changing the administration time of once daily blood pressure lowering medications, one at a time as tolerated, from morning to bedtime.
223770735|NCT00870311|DRUG|Lithium Carbonate|300mg PO, three times daily with dose titrated to obtain a therapeutic plasma level of 0.8 to 1.2meq/L) over the first week of treatment. Total duration is a minimum of 3 weeks. Medication is dispensed in the form of blinded research capsules.
223770736|NCT00485537|PROCEDURE|oocyte retrieval and ICSI procedure|
223770737|NCT03676049|DRUG|Cannabidiol|CBD will be administered as an adjunct to all current antiepileptic drugs. A dosing titration period will start with 100 mg/day, with 50mg BID dosing, and will be titrated monthly as tolerated based on clinical response, up to 300mg/day. This is based on a targeted dosing of 2.5 ---5---7.5 mg/kg/d.
224247311|NCT02983110|PROCEDURE|Anoscopy with Rectal Tissue Sampling|All subjects will provide 10 pieces of rectal tissue
224247312|NCT02983110|PROCEDURE|Phlebotomy|• Procedure: Blood plasma/serum collection Approximately 17 mL of blood will be taken from each subject just prior to tissue sampling.
224247313|NCT02983110|PROCEDURE|Female Genital Tract Sampling|Cohorts B only will have cervical cells, cervical tissue, and vaginal tissue collected
224247314|NCT05959681|DEVICE|Compression garment with Vari-pad microdots ink-printed on inside.|Initially, participants wear a garment with Vari-pads on one side (left or right) only and swap to a garment with Vari-pads on both sides if / when the participants notice a difference between the sides. Wearing garment 8 hours per 24 hours.
224247315|NCT00659321|DRUG|nicotine acid|16 weeks, randomisation with 500 mg, after 4 weeks elevation of 1000 mg, after week 8 to week 16 1500 mg study medication
224247316|NCT00659321|DRUG|placebo|16 weeks treatment with placebo
224321759|NCT06424938|PROCEDURE|Patients who underwent erector spina plane block|Researchers applied a erector spina plane block to prevent postoperative pain to the erector spina plane block group undergoing midline incision surgery for major gynecological cancer.
223666163|NCT01931215|OTHER|spinal anesthesia with intrathecal morphine|in addition to the standard spinal anesthesia drugs (bupivacaine and fentanyl), morphine is added
223666164|NCT01931215|OTHER|TAP-block with ropivacaine and clonidine|
223770738|NCT02652975|PROCEDURE|Venous occlusion plethysmography|To characterize endothelial function in vivo the effect of vasodilatating substances is measured in the forearm circuit. The substances is administered via a thin catheter placed in the Brachial artery near the elbow in local anesthesia. Once the vessels dilate, the blood flow in the forearm will increase and the flow change is a measure of the vasodilatory capacity of that substance. The change is measured with classical venous occlusion plethysmography. The method described is established at Aarhus University Hospital and has been used for several decades to illustrate the effect of vasoactive drugs on the human circulation, meaning it is a proven and well documented method.
224247317|NCT03875755|DIETARY_SUPPLEMENT|Myo Inositol|One soft gel capsule containing MI 600 mg and folic acid 200 μg twice a day, until delivery.
224247318|NCT03875755|OTHER|Placebo|One soft gel capsule of placebo (folic acid 200 μg) twice a day until delivery.
224247319|NCT00149500|BEHAVIORAL|Coaching|Patients received monthly calls to assist in behavioral change relative to asthma care
224247320|NCT04000100|PROCEDURE|ultrasound- guided supraclavicular brachial plexus block|"Patient lie down supine with head turned 45 degrees to the contralateral side and ipsilateral arm adducted gently by the assistant and the shoulder kept down with flexed elbow.~After sterile preparation of the skin and the ultrasound probe (12 MHz probe) were used, the brachial plexus was visualized by placing the transducer in the sagittal plane in the supraclavicular fossa behind the middle-third of the clavicle. Two distinct appearances of the brachial plexus was seen at the supraclavicular region, it either appeared as 3 hypoechoic circles with hyperechoic outer rings or as a grape like cluster of 5 to 6 hypoechoic circles, located lateral and superior to the subclavian artery between the anterior and middle scalene muscles at the lower cervical region figure"
224247321|NCT04898361|PROCEDURE|PFO closure|Interventional closure of a patent foramen oval preceded by an electrophysiological study
224247322|NCT01758627|DRUG|Peritoneal dialysis (PD)|PD exchanges will be customized depending on patient fluid status. At least one daily exchange of icodextrin PD solution will be provided to PD group.
224247323|NCT00004562|DRUG|Beta adrenergic blockers|Participants will receive beta adrenergic blockers.
224247324|NCT00004562|DRUG|Platelet inhibitors|Participants will receive platelet inhibitors.
224247325|NCT00004562|PROCEDURE|PTCA and stents|Participants will undergo percutaneous coronary intervention (PTCA) and coronary stenting.
223770739|NCT02652975|PROCEDURE|SphygmoCor|"Applanation tonometry (pulse wave velocity and central blood pressure/arterial stiffness): The central blood pressure and the augmentation index is estimated from the shape of the radial pulse wave measured with a tonometer.~Pulse wave velocity (PWV) is calculated from the average difference between the pulse pressure wave measured with a tonometer and the R in an ECG recorded simultaneously."
223770740|NCT02652975|PROCEDURE|24hour blood pressure|24 hour blood pressure measurement
223770741|NCT02652975|PROCEDURE|DEXA scan|Measurements of body composition: Total body fat and fat free mass is measured by Dual Energy X-ray Absorptiometry (DEXA).
223770742|NCT02652975|BIOLOGICAL|Laboratory blood samples|"Fasting blood tests are drawn from an antecubital placed catheter (albumin, ALAT/ASAT, alkaline phosphatase, bilirubin, gammaglutamyl transferase, coagulation factors, red and white blood cells, creatinin, potassium, sodium, fasting lipids, fasting glucose, hemoglobin A1C, insulin, sex hormones, von Willebrand factor, low grade inflammation markers, DNA and RNA for later analyses, including relevant coding genes).~Further more urine samples to determine possible systemic impact of cardiovascular disease.~We will create a biobank containing urine and blood samples from participants for future research, provided that the participant gives her permission.~Responsibility for the biobank lies with the project responsible physician, Anders Bonde Jensen."
223770743|NCT01487330|DEVICE|Transcatheter Aortic Valve Implantation (TAVI)|Placement of the SJM TAVI aortic valve with a transfemoral delivery system.
223770744|NCT02878993|DEVICE|Recording of diaphragm EMG|Recording of diaphragm EMG prior to extubation using surface diaphragm electromyography
223770745|NCT01032941|DRUG|Probiotic|Patients in this group will be given the probiotic VSL#3 2 packets BID for a total of 8 weeks.
223770746|NCT04157829|DEVICE|Scintilling lamp|Lamp with a standardized scintilling
224247326|NCT00004562|DRUG|ACE Inhibitors|Participants will receive ACE inhibitors.
224247327|NCT05884762|OTHER|electroencephalographic neurofeedback|"The patient is installed in a quiet, isolated room in the Physical Medicine and Rehabilitation Department. The patient sits comfortably in front of a computer. A nurse or a rehabilitator installs the EEG headset and places gel in the electrodes (x32). Connecting the amplifier and interface. Checking the correct positioning and contact of the electrodes (impedance).~* Calibration phase at rest.~* Working phase: the sessions last 24 minutes. The patient will be asked to concentrate on the affected arm, and to imagine a movement of this arm, to feel the sensations, without any real movement of the arm.~  * In the Neurofeedback group, the patient will receive visual feedback of a virtual hand moving on a computer screen in front of him/her, depending on his/her brain activations. He will also receive haptic feedback (vibrations) in the flexor muscles of his wrist."
224247328|NCT05884762|OTHER|SHAM electroencephalographic neurofeedback|"The patient is installed in a quiet, isolated room in the Physical Medicine and Rehabilitation Department. The patient sits comfortably in front of a computer. A nurse or a rehabilitator installs the EEG headset and places gel in the electrodes (x32). Connecting the amplifier and interface. Checking the correct positioning and contact of the electrodes (impedance).~* Calibration phase at rest.~* Working phase: the sessions last 24 minutes. The patient will be asked to concentrate on the affected arm, and to imagine a movement of this arm, to feel the sensations, without any real movement of the arm.~  * In the SHAM group, the visual feedback and haptic feedback are randomly generated"
224247329|NCT02964260|DRUG|Chemotherapy drug|Doxorubicin/Platinum agents
223770747|NCT04157829|DEVICE|Classic lamp|Lamp without a scintilling
223770748|NCT03808285|OTHER|mandibular osteomylitis|
223770749|NCT00003196|DRUG|chemotherapy|Undergo cytoreductive chemotherapy
223770750|NCT00003196|RADIATION|total-body irradiation|Undergo TBI
223770751|NCT00003196|PROCEDURE|peripheral blood stem cell transplantation|Undergo allogeneic PBSC transplant
223770752|NCT00003196|DRUG|cyclosporine|Given IV or PO
223770753|NCT00003196|DRUG|mycophenolate mofetil|Given PO
224247330|NCT02964260|DRUG|Embolic agents|Lipiodol/Gelatin sponge/PVA/Blank microspheres
223770754|NCT00003196|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Undergo allogeneic PBSC transplant
223770755|NCT00003196|BIOLOGICAL|therapeutic allogeneic lymphocytes|Undergo DLI
223770756|NCT05251181|DRUG|Normal Saline|Normal Saline to be Used as Vehicle in the Phase-III Study to Assess Efficacy of Centhaquine as a Resuscitative Agent for Hypovolemic Shock
223770757|NCT05251181|DRUG|Centhaquine|Phase-III Study to Assess Efficacy of Centhaquine as a Resuscitative Agent for Hypovolemic Shock
223770758|NCT00940303|DRUG|5-FU|3200mg/m2 continuous iv infusions, day 1 every 2 weeks
223770759|NCT00940303|DRUG|bevacizumab [Avastin]|5mg/kg iv infusion, day 1 every 2 weeks
223770760|NCT00940303|DRUG|irinotecan|165mg/m2 iv infusion, day 1 every 2 weeks
223770761|NCT00940303|DRUG|leucovorin|200mg/m2 iv infusion, day 1 every 2 weeks
223770762|NCT00940303|DRUG|oxaliplatin|85mg/m2 iv infusion, day 1 every 2 weeks
223770763|NCT00057746|RADIATION|Prophylactic cranial irradiation, 2.5 Gy fx|Prophylactic cranial irradiation, 2.5 Gy once daily, M-F, in 10 fractions (fx) for a total of 25 Gy
223770764|NCT00057746|RADIATION|Prophylactic cranial irradiation, 2.0 Gy fx|Prophylactic cranial irradiation, 2.0 Gy once daily, M-F, in 18 fractions (fx) for a total of 36 Gy
223770765|NCT00057746|RADIATION|Prophylactic cranial irradiation, 1.5 Gy fx|Prophylactic cranial irradiation, 1.5 Gy twice daily, M-F, in 24 fractions (fx) for a total dose of 36 Gy
224247331|NCT02964260|PROCEDURE|Simultaneously|1-3 days
224247332|NCT02964260|PROCEDURE|Sequentially|1 month
224247333|NCT02964260|DEVICE|Ablation|Radiofrequency ablation/Microwave ablation
224247334|NCT00001862|DRUG|Enbrel|
224247335|NCT05831462|DRUG|Ticagrelor 60mg|Standard vs Low dose ticagrelor in post PPCI patients
224247336|NCT03871920|OTHER|physical therapy treatment|any treatment chosen by treating physiotherapist
224247337|NCT01652794|RADIATION|stereotactic body radiation therapy|Undergo SBRT
224247338|NCT01652794|DRUG|carboplatin|Given IV
224247339|NCT01652794|DRUG|gemcitabine hydrochloride|Given IV
224247340|NCT01652794|OTHER|laboratory biomarker analysis|Optional correlative studies
224247341|NCT01652794|OTHER|pharmacogenomic studies|Optional correlative studies
224247342|NCT04104165|DEVICE|Foley Catheter|Foley catheter used for treatment of urinary retention
224247343|NCT05700565|OTHER|Extracorporeal photopheresis|ECP consists of the three steps of leukapheresis, photoactivation and reinfusion and has immunomodulatory effects (modulation of dendritic cells, change in cytokine profile, induction of T cell subpopulations). Indications are currently the treatment of Sézary syndrome, Graft-versus-host disease (GvHD), organ transplant rejection and systemic scleroderma.
224247344|NCT05700565|OTHER|Other immunosuppressive or immunomodulatory drugs|Other immunosuppressive or immunomodulatory drugs
224247345|NCT03929822|DIAGNOSTIC_TEST|Contrast-Enhanced Spectral Mammography|A standard dose of contrast material for other contrast mammography examinations and for body CT scanning, 1.5 ml/kg of Iohexol350 will be injected intravenously (IV) using a power injection (3-4 ml/s) with a maximum does of 150 ml. The IV injection is performed while the patient is in a sitting position. The mammogram will be performed in a standing position.
224247346|NCT03257722|DRUG|Pembrolizumab|Anti PD-1 immunotherapeutic agent, which blocks a protective mechanism on cancer cells to allow the immune system to destroy cancer cells. Administered intravenously (IV).
224247347|NCT03257722|DRUG|Idelalisib|Phosphatidylinositol 3-kinase (PI3K) inhibitor which promotes anti-tumor immune response. Administered orally (PO).
224247348|NCT02648334|DEVICE|IN.PACT drug coated balloon|
224247349|NCT02648334|DEVICE|Lutonix drug coated balloon|
224247350|NCT04274686|DEVICE|Tegaderm placement|Placement of perforated Tegaderm bandage over lower face, with diamond-shaped hole aligned with the patient's mouth, for use during bag-mask ventilation
224247351|NCT04274686|OTHER|No Tegaderm|Bag-mask ventilation performed in ordinary fashion, without use of Tegaderm bandage
223666165|NCT03550521|BEHAVIORAL|Mindfulness|Participants will be instructed to focus on the sensations of breathing. Subsequently, whenever their minds wander to distressing thoughts or emotions, they will be instructed to acknowledge those thoughts or emotions, and then bring their attention back to the sensations of breathing.
223666166|NCT02788279|DRUG|Atezolizumab (MPDL3280A), an Engineered Anti-PDL1 Antibody|Participants will receive atezolizumab IV at 840 mg on Day 1 and Day 15 in a 28-day cycle as a combination therapy or at 1200 mg on Day 1 in a 21-day cycle as a monotherapy until disease progression according to RECIST Version 1.1, unacceptable toxicity, death, participant's or physician decision to withdraw, or pregnancy, whichever occurs first.
223666167|NCT02788279|DRUG|Cobimetinib|Participants will receive cobimetinib 60 mg orally on Days 1 to 21 in a 28-day cycle as a combination therapy until disease progression according to RECIST Version 1.1, unacceptable toxicity, death, participant's or physician decision to withdraw, or pregnancy, whichever occurs first.
223666168|NCT02788279|DRUG|Regorafenib|Participants will receive regorafenib 160 mg orally on Days 1 to 21 in a 28-day cycle until disease progression according to RECIST Version 1.1, unacceptable toxicity, death, participant's or physician decision to withdraw, or pregnancy, whichever occurs first.
224247352|NCT00489112|DRUG|Alfuzocine XL 10 mg once a day|
224247353|NCT02326610|DRUG|Human growth hormone,ZOMACTON® (somatropin)|The initial dose will be 30µg/kg/day. The maximal dose will be 40µg/kg/day. The dose will be adjusted by monitoring the serum IGF-I level. Growth hormone will be delivered by injection.
224321760|NCT03842982|DRUG|HIPEC|"HIPEC protocol (ONLY Arm A) consisted in cisplatin 100mg/m2 intraperitoneally (IP), heated to 40°C for 90 minutes, along with an IV perfusion of sodium thiosulfate.~Administration of the dose should be according the following schedule:~* 50% of the dose at start of perfusion, 25% of the dose after 30 minutes from start of the perfusion and 25% of the dose after 60 minutes from start of the perfusion.~* The procedure takes 120 minutes with a 90-minute perfusion period. The IV perfusion of sodium thiosulfate is for renal protection. At the start of HIPEC procedure, 9 g/m2 in 200 ml of distilled water will be administered by IV over 15 to 30 minutes. It will be then followed by 12 g/m2 in 1 liter (1L) distilled water in a continuous IV for 6 hours."
224321761|NCT05573763|DEVICE|F&P Toffee|Nasal pillows mask
223770766|NCT02453295|BEHAVIORAL|Intervention Group|The IG will meet weekly for 2 hours for 8 weeks. Administration of questionnaires (Meaning of Illness, MIQ; Herth Hope Index, HHI; Short Form 12, SF-12; Lymphedema Quality of Life, LYMQOL) will be completed by phone at all timepoints. The questionnaires will also be administered at 4 weeks post-intervention (T3) and 8 weeks (T4) post-intervention. All participants will also complete a demographic questionnaire at T0, developed in S2 as well as a Workshop Evaluation 2 days following the final workshop (T2).
224247354|NCT05445310|DRUG|Furmonertinib|Furmonertinib 80mg/d
224247355|NCT00376623|DRUG|BI 2536|Intravenous Infusion
224247356|NCT02738723|RADIATION|SBRT|40 Gy for each patient. Patients receiving once-daily therapy ,4 Gy daily in 10 treatments over a period of two weeks.
224247357|NCT02738723|RADIATION|IMRT|45 Gy for each patient，Accelerated twice-daily thoracic radiotherapy involved the administration of 1.5 Gy in 30 treatments over a period of three weeks.
224247358|NCT02738723|DRUG|EP|Etoposide 75mg/m2/iv over 90min through day 1 to day 4 and cisplatin 25mg/m2/iv over 30min through day 1 to day 3, repeat Q 3weeks. Continuous administration to six cycles or to disease progression, unacceptable toxicity or patients' refusal.
224247359|NCT05899855|OTHER|No intervention|No intervention
224247360|NCT00034684|DRUG|Farnesyl Protein Transferase Inhibitor|
224247361|NCT00949585|OTHER|Dietary intake of potassium|Comparison of two diets: one contains 100 mmol potassium per day, and the other contains 40 mmol potassium per day
224247362|NCT01004237|DRUG|pravastatin, valsartan, pravastatin+valsartan|pravastatin 40 mg, valsartan 160 mg 8 weeks of treatment
224247363|NCT02561793|DRUG|DHEA|Women will receive DHEA 12 weeks before starting IVF/ICSI
224247364|NCT02561793|DRUG|Placebo|women will receive a placebo 12 weeks before starting IVF/ICSI
224247365|NCT02651753|DRUG|Lipitor + Lipidil supra|Reference Drug: Lipitor + Lipidil supra
224247366|NCT02651753|DRUG|CKD-337|Test Drug: CKD-337
224247367|NCT02409953|OTHER|Lying in a bath during 2 hours|
224247368|NCT02409953|OTHER|Lying in a bed during 2 hours|
224247369|NCT04138147|PROCEDURE|Superficial cervical plexus with auriculotemporal nerve blocks|Superficial cervical plexus block using 10 ml bupivacaine 0.5%. Auriculotemporal nerve block using 3 ml bupivacaine 0.5%.
224247370|NCT04138147|PROCEDURE|Cervical retrolaminar with auriculotemporal nerve blocks|Cervical retrolaminar block using 10 ml bupivacaine 0.5%. Auriculotemporal nerve block using 3 ml bupivacaine 0.5%.
224247371|NCT02625077|PROCEDURE|Laparoscopic gastroesophageal valvuloplasty|
224247372|NCT02625077|PROCEDURE|Laparoscopic Toupet fundoplication|
224247373|NCT01532297|DEVICE|Citrate dialysate (CiDi)|Use during chronic dialysis 3x/week
224247374|NCT01532297|DEVICE|Standard dialysate (StDi)|Use during chronic dialysis 3x/week
224247375|NCT03310697|OTHER|Collection of blood and urine samples|For each child, a toxicological screening will be carried out on the blood and urine for the research of proconvulsive molecules by conventional technique on the one hand and by gas chromatography coupled with a mass spectrograph on the other hand.
224247376|NCT03310697|OTHER|Clinical examination|The other clinical data, any other biological samples or additional examinations are done under the opinion of the clinician or the neuropediatrics.
224247377|NCT01773330|PROCEDURE|esophageal manometry|Esophageal manometry will be performed by swallowing different amounts of Gatorade depending on the protocol being followed.There will be alternate assignment of positions: supine position, semi-recumbent position,sitting position and standing up position.
224247378|NCT01773330|DIETARY_SUPPLEMENT|Gatorade|The patient will be given Gatorade to drink at various times during the study.
224247379|NCT01773330|OTHER|Supine position|Esophageal manometry will be performed by swallowing different amounts of Gatorade depending on the protocol being followed. There will be alternate assignment of positions: supine position, semi-recumbent position,sitting position and standing up position.
224247380|NCT01773330|OTHER|Semi-recumbent position|Esophageal manometry will be performed by swallowing different amounts of Gatorade depending on the protocol being followed. There will be alternate assignment of positions: supine position, semi-recumbent position,sitting position and standing up position.
224247381|NCT01773330|PROCEDURE|Sitting|Esophageal manometry will be performed by swallowing different amounts of Gatorade depending on the protocol being followed. There will be alternate assignment of positions: supine position, semi-recumbent position,sitting position and standing up position.
224247382|NCT01773330|PROCEDURE|Standing|Esophageal manometry will be performed by swallowing different amounts of Gatorade depending on the protocol being followed. There will be alternate assignment of positions: supine position, semi-recumbent position,sitting position and standing up position.
224247383|NCT00492960|DRUG|larazotide acetate|gelatin capsules
224247384|NCT00492960|DRUG|placebo|gelatin capsules
224247385|NCT00492960|DIETARY_SUPPLEMENT|900 mg gluten|gelatin capsules
224247386|NCT06326762|OTHER|comparaison|description indicate
224247387|NCT02867280|DRUG|Sorafenib|red round tablet
224247388|NCT03482427|BEHAVIORAL|Healthy Heart Score|Educational materials based on each component of the Healthy Heart Score and other lifestyle behaviors will be provided to the participants that include the following topics: Fruit and vegetable consumption, Whole grain consumption/ limiting refined grains, Healthy protein choices, Healthy dietary fats, Limiting Sugar-sweetened beverages, Importance of physical activity, Proper hydration, Stress management, Adequate Sleep, Smoking Cessation, Weekly menu example, Recipe Cards following the Mediterranean diet principals, Interactive weekly checklist to encourage participants to meet their weekly goals for consumption of fruits, vegetable, nuts and seeds. Participants will receive a check-in email or phone 6 weeks after the baseline visit. A Registered Dietitian is also available to speak with patients.
224247389|NCT05595694|OTHER|No intervention|This is a retrospective review of 1320 patients in our database who underwent elective primary and revision TJA in Queen Mary Hospital, Hong Kong from from January 2018 to December 2021. No intervention was involved.
224247390|NCT03543462|DEVICE|thoracic Drain Tube 24 Fr.|Positioning of Thoracic Drain after diaphragmatic resection and consequently diaphragmatic repair
224321762|NCT06443021|DEVICE|PD cycler|"After a training phase and a run-in period of up to 6 weeks, depending on the PD cycler used prior to the study, the interventional phase will be initiated.~* Study phase A, variation of dwell duration: Duration of short cycles (cycle 1 and 2) 30 min, 60 min, 90 min, 120 min (and 150 min depending on the patient´s constitution and at the discretion of the treating physician)~* Study phase B, variation of dialysis fluid glucose composition: 1st cycle: 1.5% glucose concentration, 2nd cycle: 2.3% glucose concentration, 3rd cycle: 1.5% glucose concentration, 4th cycle: 2.3% glucose concentration; all following cycles to be applied as prescribed by the treating physician.~* Study phase C, variation of fill volume: 60% fill volume, 80% fill volume, 100% fill volume and 120% fill volume. (Volume of 120% will only be applied in case the patient tolerates these volumes according to the IPP."
224247391|NCT04351074|PROCEDURE|LIFT|ligation of the intersphincteric fistula track
224247392|NCT04351074|PROCEDURE|fistulectomy|excision of the fistulous track with its internal and external orifices
224247393|NCT00015626|DRUG|Metformin|
224247394|NCT00015626|PROCEDURE|skin biopsy|
224247395|NCT00015626|BEHAVIORAL|diet and exercise|
224247396|NCT00015626|DRUG|pioglitazone|
224247397|NCT00015626|DRUG|rosiglitazone|
224247398|NCT05731674|OTHER|Random selection of excercises|Participants in the intervention group will train using a random selection of excercises and complete the profiency-based traning program.
224247399|NCT00550563|DIETARY_SUPPLEMENT|cholecalciferol|Oral
224247400|NCT00550563|GENETIC|polymerase chain reaction|companion study
224247401|NCT00550563|GENETIC|polymorphism analysis|companion study
224247402|NCT00550563|GENETIC|protein expression analysis|companion study
224247403|NCT00550563|GENETIC|reverse transcriptase-polymerase chain reaction|companion study
224247404|NCT00550563|GENETIC|western blotting|companion study
224247405|NCT00550563|OTHER|high performance liquid chromatography|companion study
224247406|NCT00550563|OTHER|laboratory biomarker analysis|companion study
224247407|NCT00550563|OTHER|pharmacological study|companion study
224247408|NCT00550563|PROCEDURE|adjuvant therapy|Additional therapy
224247409|NCT00550563|PROCEDURE|immunoscintigraphy|additional testing
223666169|NCT06088602|PROCEDURE|Cryoneurolysis|Local anesthesia is injected in the skin. The superficial genicular nerves, more specifically the ISN and the AFCN, are visualized. A nerve stimulator is used to verify the visualized nerves., 2-3 ml of ropivacaine 5 mg/ml is injected around the nerves. After 5-15 minutes the effect is evaluated by assessing pain in the surgical area and asking the patient whether there is a pain relief. Following this evaluation, cryoneurolysis (Cryo-S, Metrum Cryoflex, Blizne Laszczynskiego, Poland) is performed unilaterally along a treatment line, the location of which was guided by visualization and palpation of anatomic landmarks. The ISN treatment line is located along the line that connects a point located 5 cm medial to the lower pole of the patella and a point located 5 cm medial to the tibial tubercle. The AFCN treatment line is located at one-third the length of the distance from the center of the patella to the top of the femur, with a width equal to the width of the patella.
224247410|NCT06302686|DEVICE|engAGE system|The experimental group use the engAGE system at both healthcare organization and home. At the healthcare organization, the subject interacts with Pepper robot. The interaction is supervised by the formal caregivers and includes the following activities: dialoguing with the robot, storytelling, drama play, cognitive and physical games. This interaction is planned to last about 1 hour twice a week for 6 months. At home, the older user interacts with the tablet supervised by the informal caregiver. The user plays cognitive and physical games installed on MEMAS app. This activity is performed for 0.5 hour, every day for 6 months. Throughout the whole period of experimentation, the older user wears the smartwatch that measures his/her physiological parameters and the steps. Any activity performed by the seniors is assigned by formal caregiver and can be personalized taking into account the user's abilities, lifestyle, and social interactions.
224247411|NCT06302686|OTHER|Group practicing with only the support of a booklet|To the control group will be given a booklet containing information and activities on well-being to do at home.
224247412|NCT01054586|DRUG|Intervention A Standard dose|HIV subjects with HBV or HCV co-infection but normal hepatic function, defined by receipt of FPV 700mg BID/RTV 100mg BID and a baseline AST-platelet ratio index (APRI) score of \<2.0.
223666170|NCT06088602|PROCEDURE|Sham|The exact same procedure as in the cryo-group is performed, except that the nerves are not frozen with the cryoneurolysis apparatus. Sound effects from the machine are replicated to give the patient the same experience as in the active intervention group.
223666171|NCT01599364|DRUG|Atazanavir, ritonavir, lamivudine|Lamivudine 300 mg 1 pill once-a-day, atazanavir 300 mg 1 pill with ritonavir 100 mg 1 pill once-a-day, taken together orally with a light meal
223666172|NCT03257709|PROCEDURE|Arthroscopic acetabular labral repair|Acetabular labral tear will be identified and reattached using suture anchors until a stable repair is achieved. If evidence of FAI is present ie: a cam or pincer lesion is identified then this will be treated with osteochondroplasty (cam) or acetabular rim recession (pincer).
223666173|NCT03257709|PROCEDURE|Arthroscopic acetabular labral resection|The acetabular labral tear will be identified and its' limits defined. The torn portion of labrum will be resected to a stable edge. As with arm 1 there will be treatment of FAI if identified.
223666174|NCT06212258|PROCEDURE|Abdominal Laparascopy|pneumoperitoneum
223666175|NCT03697135|BEHAVIORAL|Respondent Driven Sampling|Participants are asked to invite contacts that they previously injected with to take a test for hepatitis C
223666176|NCT03970980|OTHER|fraction of inspired oxygen (FIO2)|Different group receives different (70% vs. 90%) fraction of inspired oxygen (FIO2) during the surgery.
224247413|NCT01054586|DRUG|Intervention B Reduced Dose|HIV subjects with mild hepatic impairment, defined by receipt of the recommended reduced FPV/RTV dose (700mg BID/100mg QD).
224247414|NCT01054586|DRUG|Intervention C|HIV subjects with moderate hepatic impairment, defined by receipt of FPV 450mg BID/RTV 100mg QD.
224247415|NCT01054586|DRUG|Intervention D|HIV subjects receiving the standard dose of FPV/RTV despite evidence of abnormal hepatic function according to APRI score: HIV subjects with HBV or HCV co-infection, receipt of FPV 700mg BID/RTV 100mg BID and a baseline APRI score of ≥2.0.
224247416|NCT01054586|DRUG|Intervention E|HIV subjects coinfected with HBV or HCV who have initiated standard doses of LPV 400mg/RTV 100mg and enrolled in the same cohorts as the FPV/RTV exposed subjects.
224321763|NCT00371033|DRUG|Pregabalin|Pregabalin 150 mg/d (50 mg orally 3 times daily) for 2 weeks, then 300 mg/d (100 mg orally 3 times daily) for 2 weeks, and then 600 mg/d (200 mg orally 3 times daily) for 2 weeks.
224321764|NCT00371033|DRUG|Placebo|Placebo at same frequency as pregabablin
224321765|NCT04110327|DEVICE|MicroStent|Treatment of arterial stenosis or occlusion with the MicroStent Peripheral Vascular Stent System
224247417|NCT03957239|OTHER|Cranberry Beverage|The cranberry beverage will provide 50 kcals and 4.0 grams of fiber per day from whole milled cranberries, water, cranberry natural flavor and sucralose.
224247418|NCT03957239|OTHER|Control Beverage|The control beverage will provide 50 kcals per day and is a color, taste matched sugar sweetened beverage formulated with water, sucrose, citric acid, cranberry natural flavor, malic acid, xanthum gum, sucralose and artificial color (red 40, blue 1).
224247419|NCT00910663|DRUG|Mycophenolate Mofetil|250 mg Capsule
224247420|NCT00910663|DRUG|CellCept®|250 mg Capsule
224247421|NCT02865850|DRUG|Vadadustat|Oral dose administered once daily for ≥36 weeks. Dose adjustment based on hemoglobin level as defined in the protocol.
224247422|NCT02865850|DRUG|Darbepoetin alfa|Subcutaneous or intravenous dose administered for ≥36 weeks. Initial dose based on the current package insert for investigational sites in the United States (US), and the Summary of Product Characteristics for all other investigational sites (non-US) for adult participants with chronic kidney disease not on dialysis. For participants already on Darbepoetin alfa, the initial dosing regimen in the study was based on the prior dosing regimen.
224247423|NCT01090713|DRUG|lisdexamfetamine|oral; 20-70mg/day
224247424|NCT01090713|DRUG|Placebo control|20-70mg; oral
224247425|NCT04542603|DRUG|[11C]PiB and 18F-labeled DPA-714 PET scan|One PET with \[11C\]PiB and One PET with \[18F\]DPA-714 before chemotherapy treatment begins. One more PET with \[18F\]DPA-714 after completion of 3-6 cycles of chemotherapy.
224247426|NCT00176306|DRUG|Levofloxacin 750 mg IV|PK in obesity
224247427|NCT02634437|DRUG|Ulipristal acetate|
224247428|NCT03347032|PROCEDURE|Remote ischemic preconditioning|Serial inflations and deflations as detailed in the arm/group descriptions
224247429|NCT03347032|PROCEDURE|Control|Serial inflations and deflations as detailed in the arm/group descriptions
224247430|NCT01593007|OTHER|Inspiratory muscle training|All participants were instructed to use a Threshold® trainer for 30min a day, seven times a week over 12 consecutive weeks.10 Patients in the Control Group used a Threshold ® device without resistance, making them blind to the treatment. For the treatment group, inspiratory resistance of the Threshold® trainer was 30% of MIP, adjusted on a weekly basis to remain constant.
224247431|NCT01593007|OTHER|Control group|Patients from the control group were also assessed weekly to ensure homogenization of the learning effect for the manometer maneuver.
224247432|NCT01772537|DRUG|Propofol|Intravenous anesthetic
224247433|NCT01772537|DRUG|isoflurane|
224247434|NCT03879915|PROCEDURE|Dental Implant placement|Surgical placement of dental implant not associated with prior or concurrent bone augmentation
224247435|NCT03352271|PROCEDURE|Individualized Incremental hemodialysis|Individualized Incremental hemodialysis program (twice/week, once/week, once/10days or less frequent) will be provided to incident ESRD patients according to their symptom presentation, clinical examination, investigations and daily urine volume measurement.
224247436|NCT03352271|PROCEDURE|Conventional thrice weekly hemodialysis|Thrice weekly hemodialysis program, the current standard of care for all patients, as a control
224247437|NCT06292871|BEHAVIORAL|Additional GDM management through social media|Usual care provided by a diabetes nurse educator and dietitian. Additional educational resources for dietary management care received, and for any queries to be addressed by dietitian via social media platform from baseline to one-month follow-up visit.
224247438|NCT06292871|BEHAVIORAL|Usual care|Usual care provided by a diabetes nurse educator and dietitian.
224247439|NCT04649411|DRUG|ferric citrate|oral tablets
224247440|NCT04649411|DRUG|standard of care|administered per the approved label and at the Investigator's discretion
224247441|NCT01814930|BEHAVIORAL|Brief standardized contraceptive counseling intervention|The intervention employed an in-person counseling strategy that included empowerment messaging and an instrument to clarify the participants' preferences for contraception in the context of their goals for future childbearing.
224247442|NCT06011538|OTHER|On-line, multi-media information on a specifically designed website for Same Day Discharge following Laparoscopic Hysterectomy|A patient educational website that provides clear, easily accessible, patient friendly information explaining what SDD after laparoscopic hysterectomy is, why SDD may be beneficial and what to expect from decision for surgery, through to the admission to hospital and immediate, short and long term recovery.
224247443|NCT03195491|BIOLOGICAL|Nivolumab|Intravenous infusion administered over 30 minutes at 240 mg
224247444|NCT01394562|DRUG|Ferinject (ferric carboxymaltose)|Subjects will receive ferric carboxymaltose intravenously on Day 0, Week 6, and Week 12
224247445|NCT01394562|OTHER|Standard of Care|Subjects randomised to Standard of Care may receive oral iron at Investigator's discretion however patients will not be permitted to receive IV iron
224247446|NCT00641394|BEHAVIORAL|Psychotherapy: Emotional Freedom Techniques (EFT)|A form of therapy that includes cognitive reframing with somatic reinforcement through touch or tapping of specified points on the body
224247447|NCT00641394|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|A form of therapy that focuses on negative cognitions of problems, and reframing them in positive terms, but without somatic reinforcement.
224247448|NCT03983057|DRUG|Anti-PD-1 monoclonal antibody|Accompanying with modified-FOLFIRINOX, Anti-PD-1 antibody was applied biweekly.
224247449|NCT00760448|DRUG|insulin detemir|
224247450|NCT00760448|DRUG|insulin NPH|
224247451|NCT04186182|BEHAVIORAL|CICI - Feasibility trial study group|The intervention will include 7 individualized meetings with the family (2 home visits + 5 videoconferences), 2 parent group sessions and 4 meetings with school and local care providers, delivered over a 4-5 month period.
224247452|NCT03735030|DRUG|Human hCG 10'000 IU|A single dose of 10'000 IU of human hCG will be injected in 24 healthy subject volunteers.
223666177|NCT05781880|OTHER|Oxygen 100%|NBO therapy were given 100% oxygen via a face mask (10L/min for 4h)
223666178|NCT00737399|BEHAVIORAL|Lifestyle Counseling with Emotional Freedom Techniques (EFT)|Two series of four sessions of phone support group coaching instruction in the use of EFT
223666179|NCT03708887|DRUG|Low dose omega-3 fatty acid supplementation|Omega-3 fatty acids capsules, 1.5 g/d by mouth for 1 year
223666180|NCT03708887|DRUG|High dose omega-3 fatty acid supplementation|Omega-3 fatty acids capsules, 3 g/d by mouth for 1 year
224247453|NCT03735030|DRUG|Recombinant hCG 6'500 IU|A single dose of 6'500 IU recombinant hCG will be injected in 24 healthy subject volunteers.
224247454|NCT05213273|BEHAVIORAL|nutritional guidelines to promote healthy diet and increase fish intake|"Nutritional guidelines based on the Mediterranean diet will be provided to both groups (gropu A and group B) through infographic material, recipes and menus.~Both groups will be guided to increase their fish consumption to 3 servings per week. Group A will do that through the consumption of fresh or frozen fish and group B through fresh, frozen and canned fish."
224247455|NCT01263704|DRUG|Cyclophosphamide|150 milligrams per square meter (mg/m\^2) intravenously (IV) on Days 1-3 of each 28-day cycle for 6 cycles
224247456|NCT01263704|DRUG|Fludarabine|12.5 mg/m\^2 IV on Days 1-3 of every 28-day cycle for 6 cycles
224247457|NCT01263704|DRUG|Rituximab|375 mg/m\^2 IV Day 0 of Cycle 1, 500 mg/m\^2 IV Day 1 of Cycles 2-6. Each cycle was 28 days.
224247458|NCT05634772|DEVICE|dormia basket|Use of dormia basket in management of proximal stent migration
224247459|NCT05634772|DEVICE|Extraction biliary ballon|Use of extraction biliary balloon in management of proximal stent migration
224247460|NCT03182114|OTHER|supine position|the patient will be placed in regular supine position after spinal anesthesia
224247461|NCT03182114|OTHER|left lateral tilted position|the patient will be placed in left lateral tilted position after spinal anesthesia
224247462|NCT03182114|DRUG|Bupivacaine|The patient will receive 10 mg Bupivacaine for spinal anesthesia
224247463|NCT00413764|DRUG|tibolone|tibolone (2.5 mg) over 24 weeks
224247464|NCT00413764|DRUG|estradiol-norethisterone|transdermal continuous combined E2-NETA (estradiol-norethisterone 50/140 mcg) over 24 weeks
224247465|NCT03357003|OTHER|Observational study|Comparison between O-desmethyltramadol/tramadol ratio and tramadol clinical efficiency and tolerance
224247466|NCT05188742|DRUG|mirabegron|mirabegron 50mg QD
224247467|NCT05188742|PROCEDURE|TTNS|transcutaneous tibial nerve stimulation
224247468|NCT03499171|DRUG|Citalopram 20mg|Citalopram is taken once a day as an add-on to PPI treatment (2x/d).
224247469|NCT03499171|DRUG|Placebo Oral Tablet|Placebo is taken once a day as an add-on to PPI treatment (2x/d)
224247470|NCT03292354|OTHER|Contrast media administration|All patients will receive contrast media with a concentration of 300 mg I/mL (Iopromide 300). The flowrate and volume will be calculated with help of the different formulas belonging to the three different arms.
224247471|NCT05357898|BIOLOGICAL|SQZ-eAPC-HPV|Enhanced antigen presenting cells (eAPC) cell therapy; therapeutic vaccine engineered from autologous peripheral blood mononuclear cells (PBMCs) by incorporating 5 mRNAs.
224247472|NCT05357898|BIOLOGICAL|Pembrolizumab|programmed cell death 1 (PD-1) blocking antibody
224247473|NCT00724477|DRUG|INEGY|Ezetimibe 10mg - Simvastatine 20 mg or 40 mg; Tablet - OD; Patient currently treated for INEGY for at least 4 weeks
224247474|NCT01777347|DRUG|3% Saline|Two 4 mL nebulization of 3% saline with 20 minutes interval
224247475|NCT01777347|DRUG|0.9% Normal Saline|Two 4 mL nebulization of 0.9% normal saline with 20 minutes interval
224247476|NCT00357201|DRUG|Food supplement (T1675)|
224321766|NCT05473195|DRUG|BVL-GSK098 9mg|BVL-GSK098 9 mg once daily po OD plus ethionamide 250 mg po OD (b9Eto250) BVL-GSK098 27 mg OD plus ethionamide 125 mg po OD (b27Eto125 BVL-GSK098 27 mg OD plus ethionamide 250 mg po OD (b27Eto250) BVL-GSK098 27 mg OD plus ethionamide 500 mg po OD (b27Eto500)
224321767|NCT05473195|DRUG|Ethionamide 250mg|Ethionamide 250 mg po OD (Eto250)
224321768|NCT05473195|DRUG|Ethionamide 250 mg|Ethionamide 750 mg po given in a single or divided dose (Eto750)
224321769|NCT05473195|DRUG|Isoniazid 300 MG|Isoniazid 300 mg po OD (INH)
223666181|NCT03708887|DRUG|Control drug|Matching placebo capsules,3 g/d by mouth for 1 year
224247477|NCT04458701|DEVICE|Hemodynamic monitoring|This is a comprehensive hemodynamic management strategy that would-be initiated in the operating room post-bypass and then continued for the first 12 hours in the intensive care unit
224247478|NCT00252720|DRUG|candesartan|32 mg oral tablet
224321770|NCT05875714|DRUG|Apremilast|Apremilast (Otezla), oral medication Day 1: 10 mg in the morning. Day 2: 10 mg in the morning and 10 mg in the evening. Day 3: 10 mg in the morning and 20 mg in the evening. Day 4: 20 mg in the morning and 20 mg in the evening. Day 5: 20 mg in the morning and 30 mg in the evening Day 6: 30 mg twice daily Maintenance dosing: 30 mg twice daily
224321771|NCT06015438|BEHAVIORAL|Home Exercise Program|Participants will perform a minimum of one exercise from each of the targeted muscle groups at a frequency of every other day, for a total of 3-4 days a week of exercise with a rest day. The entire strengthening exercise routine should take approximately 25-30 minutes to perform, including rest periods. Each muscle grouping of exercises is designed to progress from minimal muscle effort required to moderate to maximal effort. Participants will use a video to perform the exercises as well as a handout with specific instructions.
224321772|NCT06015438|BEHAVIORAL|Short Exercise Program|Participants in this group will attend one in-person visit expected to last about 60 minutes. The clinic visit will consist of standard of care procedures and tests for individuals with mild-to-severe HS .
224321773|NCT06233942|DRUG|BG-C9074|administered by intravenous infusion
223666182|NCT02328053|PROCEDURE|collagen crosslinking group|collagen crosslinking with riboflavin and Ultraviolet A
223666183|NCT02328053|DRUG|Topical anti-fungal therapy|topical antifungal medications like natamycin eye drops and voriconazole eye drops
224247479|NCT03060694|OTHER|diabetes|"1. a history of diabetes and using anti-diabetic medicines.~2. fasting serum glucose level greater than 7.1mmol/L, or glycosylated hemoglobin percentage greater than 6.5%."
224247480|NCT02903901|DRUG|Melatonin|10 mg liquid Melatonin IR-SL at 7 pm for 1 week
224247481|NCT02903901|DRUG|Placebo|10 mg liquid placebo at 7 pm for 1 week
224247482|NCT04970420|OTHER|Health Responsibility and Family Planning ın Immigrant Women (Ahıska Turks).|In this study, individual training, training via mobile application and telephone counseling will be given to the experimental group. During the meetings, attention will be paid to the pandemic rules.
223666184|NCT01062178|DRUG|Definity|Definity is the contrast agent which is going to be injected in a bolus and infusion forms during the ultrasound performance.
223666185|NCT02372227|DRUG|VS-5584 and VS-6063|Starting dose of VS-5584 will be 20mg taken once daily, 3x/week of each 21 day cycle. All subjects will also receive 2x/day treatment with 400mg VS-6063 in 21 day cycles. Number of Cycles: until progression or unacceptable toxicity develops.
223666186|NCT05647278|DRUG|Tegoprazan|Tegoprazan 50 mg, tablets, orally, qd given in combination with amoxicillin 750mg capsules, orally, qid for up to 2 weeks.
223666187|NCT05647278|DRUG|Esomeprazole|"esomeprazole 20 mg, tablets, orally, bid given in combination with amoxicillin 1000mg，clarithromycin 500mg bid，colloidal bismuth pectin 200mg bid for up to 2 weeks.~OR esomeprazole 20 mg, tablets, orally, bis in die given in combination with amoxicillin 750mg capsules, orally, quarter die for up to 2 weeks."
224247483|NCT04970420|OTHER|Control group|Individual training, mobile application and telephone counseling will be given to the control group after the study data is collected.
224247484|NCT01310920|OTHER|observation|genotyping
224247485|NCT02627066|BEHAVIORAL|Volume Control|Persistent reduction in post-dialysis weight and dietary sodium restriction
224247486|NCT02627066|BEHAVIORAL|Volume Control + Exercise|Volume reduction intervention and comprehensive exercise counseling
224247487|NCT06346730|DEVICE|Virtual reality glasses to intervention group|experimental and control ,a randomized pretest-posttest study to examine
224247488|NCT05901922|BEHAVIORAL|Social skills training|In this training, role-playing will be done in groups of six. In these role playing, the importance and application of the social skill specified before the session will be studied.
224247489|NCT05332496|DRUG|PD-1/PD-L1 inhibitors+VEGF-TKI/bevacizumab|PD-1/PD-L1 inhibitors: atezolizumab, sintilimab, pembrolizumab, nivolumab, camrelizumab, tislelizumab, toripalimab, durvalumab, penpulimab, and other ICIs; VEGF-TKI/bevacizumab: sorafenib, lenvatinib, donafenib, apatinib, anlotinib, bevacizumab/ bevacizumab biosimilar, and other anti-angiogenesis drugs; Both PD-1/PD-L1 inhibitors and anti-angiogenesis drugs only include marketed drugs but are not limited to HCC approval.
224247490|NCT05332496|PROCEDURE|TACE|TACE: cTACE (conventional TACE) or dTACE (drug-eluting beads TACE);
224321774|NCT06233942|DRUG|Tislelizumab|administered by intravenous infusion
223666188|NCT00329849|BIOLOGICAL|Meningococcal ACWY-CRM conjugate vaccine|MenACWY-CRM vaccine was obtained by extemporaneous mixing of the lyophilized MenA component to be resuspended with the liquid MenCWY component. One dose (0.5 mL) was administered by IM injection in the deltoid area of the arm without a BCG scar.
224247491|NCT01942863|PROCEDURE|water exchange single balloon enteroscopy|Oral enteroscopy was performed first, followed by the anal route on the same day or later. For oral route, SBE was first advanced beyond Treitz ligation with CO2 insufflation. Then the water exchange method was used for further insertion. Briefly, residual air in the lumen was suctioned, and 37°C water was infused with a peristaltic pump through the biopsy channel to obtain lumen visualization. Turbid luminal water due to residual feces was suctioned and replaced by clean water until the small bowel lumen was clearly visualized again. Thus, infused water was removed predominantly during the insertion phase. The total volume of water was not restricted. For anal route, water exchange or CO2 insufflation method was used from the beginning of insertion respectively.
224247492|NCT01942863|PROCEDURE|CO2 insufflation single balloon enteroscopy|Conventional enteroscopy was performed as CO2 insufflated during insertion. Oral enteroscopy was performed first, followed by the anal route on the same day or later.
224247493|NCT01942863|OTHER|Procedural Requirements|SBE was advanced as deeply as possible and complete small bowel visualization was attempted. When the following conditions were met, tattooing at the deepest position with India ink was performed and the endoscope was withdrawn: no further endoscopic advancement could be achieved, detection of a significant lesion and no other lesions suspected, severe stricture, obvious sedation and SBE-related adverse events happened which required termination of further intubation.
224247494|NCT01314417|DRUG|Methotrexate|400 μg/100 μL monthly injections for the first 3 months, then as needed per the treatment criteria
224247495|NCT06180512|DIETARY_SUPPLEMENT|Beta Alanine high dose|4 intakes of 5 g of beta alanine every 1 hour and 15 minutes.
224247496|NCT06180512|DIETARY_SUPPLEMENT|Beta Alanine low dose|4 intakes of 2.5 g of beta alanine every 1 hour and 15 minutes.
224247497|NCT06180512|DIETARY_SUPPLEMENT|Control group|4 intakes of 2.5 g of wheat semolina every 1 hour and 15 minutes.
224247498|NCT00938106|RADIATION|optimised magnetic resonance image-guided intra-uterine brachytherapy|Brachytherapy treatment will be planned based on the MRI test and will be individualized for each study participant,based on participant's cancer and body inside.Brachytherapy will be as an inpatient over 2-3 days. All other care will follow standard procedures.
224247499|NCT03735485|OTHER|Conventional Physiotherapy|"The conventional physiotherapy program consisted of electrotherapy and exercise approaches. The electrotherapy program consisted of infrared (for 15 minutes, from 70 cm distance), conventional Transcutaneous Electrical Nerve Stimulation (TENS) in an encircled region (for 20 minutes; with 4 electrodes, 100 Hz, 100 msec), and therapeutic Ultrasound (for 3 minutes; 1 megahertz (MHz), power: 1,5 W/cm²).~A physiotherapist supervised exercise program was performed following the electrotherapy program. Elastic resistive exercises were added at the week three. While, the first set of wand exercises and elastic resistive exercises was performed under supervision, two sets of the showed exercises were given as the home exercise program."
224247500|NCT03735485|OTHER|Shoulder Mobilization|In shoulder mobilization technique while the shoulder joint was placed in the traction, anterior, posterior, and inferior gliding and circumduction were applied to the humerus for 2-3 minutes. All mobilization applications were performed in painless range of motion (ROM) limits. The degree of traction and gliding were increased as the relaxing obtained in the tissues.
224247501|NCT03735485|OTHER|Proprioceptive Neuromuscular Facilitation|"In the Proprioceptive Neuromuscular Facilitation (PNF) program participants received PNF exercises with contract-relax technique, in the patterns of flexion-abduction-external rotation, extension-adduction-internal rotation, flexion-adduction-external rotation and extension-abduction-internal rotation along with the verbal and manual facilitation of the physiotherapist."
224247502|NCT00189956|BIOLOGICAL|IMVAMUNE (MVA-BN)|Two vaccinations of 0.5 ml MVA-BN vaccine, separated by a 4 week interval.
224247503|NCT05638971|DEVICE|ivWatch|The second half sample size PIVC will be enrolled into an alarming group. ivWatch will monitor the PIVC insertion site collecting data and sending visual and auditory notifications of any infiltration. The goals of the study on the alarming group are: a) to estimate the notification rate (the number of detected infiltration in the studied period; b) to evaluate the extension and severity of the detected infiltration at the time of the notification, so to gather if ivWatch is helpful in early diagnosis
224247504|NCT02330380|DRUG|Methotrexate|"Subjects will receive Methotrexate as detailed in the Group description."
224247505|NCT02330380|DRUG|Ustekinumab|"Subjects will receive Ustekinumab as detailed in the Group description."
224247506|NCT02330380|DRUG|Etanercept|"Subjects will receive Etanercept as detailed in the Group description."
224247507|NCT02330380|DRUG|Adalimumab|"Subjects will receive Adalimumab as detailed in the Group description."
224247508|NCT02330380|DRUG|Acitretin|"Subjects will receive Acitretin as detailed in the Group description."
224247509|NCT02330380|OTHER|UVB Excimer Laser|"Subjects will receive UVB Excimer Laser therapy as detailed in the Group description."
224247510|NCT02330380|OTHER|Narrowband UVB|"Subjects will receive Narrowband UVB as detailed in the Group description."
224247511|NCT02325531|OTHER|Low support|"EHR-based tools, built by OCHIN, activated during Year 1 TOOLKIT, paper and electronic form, includes documents to help support ALL implementation, and~BASIC WEBINAR, Annual, 1-hour, topics such as:~Talking to Clinicians About ALL, Using The Monthly Feedback Report and Integrating the Toolkit into Workflows"
224247512|NCT02325531|OTHER|Medium support|"Same as provided to the low support arm, PLUS~* STAFF TRAINING (2-day meeting in Portland, Oregon, Led by Implementation Specialists (IS), How to use the toolkit and how to train others to use it, Content guided by previous research, baseline survey results, study team and the S-N advisory group~* ADAPTIVE WEBINARS, Quarterly 1-hr webinars, Content from basic webinars, tailored to topics requested by study clinics. Forum for group discussion and best practice sharing. Open any interested clinics in Arm 2 \& 3."
223666189|NCT00329849|BIOLOGICAL|Meningococcal ACWY-PS polysaccharide vaccine|MenACWY-PS vaccine was supplied as a single dose (one vial of vaccine and one vial of diluent). One dose (0.5 mL) of MenACWY-PS vaccine was administered by SC injection in the deltoid area of the arm without a BCG scar.
224247513|NCT02325531|OTHER|High support|"Same as provided to the low and medium support arms, PLUS~\- PRACTICE FACILITATION: Site visits with support as needed, Staff presentations, Coaching on tools (how to present to clinic staff and how to use in the clinic workflow), Tailored problem-solving support to address identified barriers, Clinical questions fielded by RN practice facilitator and site clinician champion."
224247514|NCT02325531|OTHER|Comparison|No support was provided by the researchers. The EHR-based toolkit was available to all clinics in the network if they actively searched it out in the EHR.
224247515|NCT04007640|RADIATION|MRI with additional sequences|MRI with 15 min additional sequences to validate and assess pancreatic MRI sequences
224247516|NCT04007640|RADIATION|MRI|MRI with 15 min additional sequences to validate and assess pancreatic MRI sequences
224247517|NCT04007640|PROCEDURE|Left pancreatectomy or pancreaticoduodenectomy|Histological analysis :
224247518|NCT04007640|RADIATION|MRI with additional sequences|MRI with 15 min additional sequences to assess the relevance of MRI to diagnose specific pancreatic lesions in obese patients
224247519|NCT06362772|RADIATION|Iodine-125 brachytherapy|"In advance of the surgery, patients were informed about their condition, the expected efficacy of 125I seed implantation therapy, alternative treatments such as external beam radiotherapy and chemotherapy, as well as potential side effects and toxic effects. The preoperative evaluation process includes assessments of coagulation function, liver and kidney function, cardiopulmonary function, and local CT scans.~A collaborative effort between physicians and physicists was undertaken to establish a treatment regimen with a prescription dose ranging from 80 to 120 Gy. The patient accepted the treatment plan and signed an informed consent form. The CT-guided 125I seed implantation procedure was conducted according to the prescribed treatment regimen.~Efficacy evaluations were conducted at pre-surgery, 1-, 3-, and 5-month post-surgery. The evaluations focused on lesion dimensions, serum Tg, TGAb, TSH levels, pain levels, and adverse reactions."
224247520|NCT01026363|DRUG|Ergocalciferol|Ergocalciferol 50,000 IU capsule, one dose every other day x 5 doses
224247521|NCT01026363|DRUG|Calcitriol|0.25 mcg tablet once daily for 14 days
224247522|NCT05178095|DEVICE|Artificial intelligence|Colonoscopy with the aid of artificial intelligence for the detection of colonic polyps
224247523|NCT05178095|DEVICE|No Artificial Intelligence|Colonoscopy without the aid of artificial intelligence for the detection of colonic polyps
224247524|NCT04739566|DRUG|Dabrafenib|Given PO twice daily
224247525|NCT04739566|DRUG|Trametinib|Given PO once daily
224247526|NCT04340011|OTHER|Colposcopy|prospective resident education for colposcopy
223666190|NCT04286997|DEVICE|GRAIL population|each subjects included in the intervention group will receive 20 GRAIL sessions, aimed to the walking pattern improvement, associated with 20 traditional physiotherapy sessions, aimed to the stabilization of the trained competences
223666191|NCT04751214|PROCEDURE|APPENDICECTOMY|
223666192|NCT03905252|OTHER|sample analysis|blood, Random urine sample and 24-hour urine samples
223666193|NCT01705067|DEVICE|TKA with Journey II BCS Total Knee System|TKA with Journey II BCS Total Knee System
223666194|NCT00445237|DEVICE|H1 and H2 deep TMS coils|
224247527|NCT01591447|DRUG|solithromycin|A single oral dose of 1200 mg solithromycin (CEM-101)
223666195|NCT00653432|DEVICE|Monovisc®|Intra-articular injection
223666196|NCT00653432|OTHER|Saline|0.9% Sterile Saline
224247528|NCT01591447|DRUG|Solithromycin (CEM-101)|A single oral dose of 1000 mg solithromycin
224247529|NCT04818892|DIAGNOSTIC_TEST|Serological Assay for SARS-CoV-2|LabCorp's Cov2Quant IgG™ assay which uses immunoassay that uses electrochemiluminescent technology (ECL) for quantitative determination of anti-receptor binding domain (RBD) IgG antibodies specific to SARS-CoV-2.
224247530|NCT03675269|OTHER|HBOT|Standard practice
224247531|NCT03675269|BEHAVIORAL|Standard wound care|Standard wound care
224247532|NCT04543760|OTHER|Prone position|prone positioning in spontaneous ventilation
224247533|NCT04543760|OTHER|Supine position|supine positiong in spontaneous ventilation
224247534|NCT06561737|OTHER|Video|For the students in the experimental group, the application was first demonstrated on a model by the course instructor, after which each student was required to perform the application individually. While the students were performing the application, someone not part of the research team recorded them on their phones. During the application, two researchers independently assessed the student's skills using the application checklist. Afterward, the students were asked to watch their videos and evaluate themselves over a 15-day period. After 15 days, the students were called back and asked to perform the same application again. At this stage, the researchers once again evaluated the students independently.
224247535|NCT01067183|BEHAVIORAL|portable biofeedback tool and relaxation breathing technique|The intervention group were trained in relaxation breathing technique and the use of a portable biofeedback tool that informs them of the success of the technique...thus behavioral therapy using a biofeedback device
224247536|NCT04044261|PROCEDURE|Emotion induction using video|Emotions are induced in the test subjects using videos in Hindi and English. Each subject is shown three video clips for each of the emotions.
224247537|NCT03957447|OTHER|thermotherapy (application of heat): This part of the trial is on hold due to the Covid19-pandemia|Heat treatment is applied for 42 days plus a safety margin of up to 14 days, if ulcer margins have not fully collapsed and/or induration has not fully subsided. Treatment terminates earlier, if a lesion is completely closed. Thermotherapy will be applied with heat packs twice daily.
224247538|NCT05093491|DIAGNOSTIC_TEST|Spirometry and ultrasonography in stroke group|Ultrasonographic measurements were performed of the bilateral diaphragm and abdominal muscle thickness and thickening ratio in the supine position in the stroke patient group. The spirometric evaluation was also performed
223666197|NCT00848562|DRUG|Nicorandil|Oral administration of nicorandil (15 mg/day)
223666198|NCT01221740|DRUG|Savella|"The patients will be titrated to the maintenance dose of 50 mg BID over a 7-day period, and will be on the medication for 10 weeks.~12.5 mg QD on day 1 12.5 mg BID on days 2 and 3 25 mg BID on days 4, 5, 6, and 7 50 mg BID beginning day 8"
223666199|NCT04187287|OTHER|Radial Extracorporeal Shock Wave Therapy|Radial Extracorporeal Shock Wave Therapy will given for 3 weeks, 1 days in a week. moreover 10-12 minutes cold pack will apply for every session
224247539|NCT05093491|DIAGNOSTIC_TEST|Spirometry and ultrasonography in healthy group|Ultrasonographic measurements were performed of dominant side diaphragm and abdominal muscle thickness and thickening ratio in the supine position in healthy individuals group. The spirometric evaluation was also performed
224247540|NCT02642835|PROCEDURE|vaginal wall mesh|retrospective review of case series
224247541|NCT01854463|DRUG|Vitamin D3|2000IU per day
224247542|NCT01854463|DRUG|placebo|elemental calcium 200mg per day per 24 weeks
224247543|NCT00704821|DRUG|PTC299|Oral
224247544|NCT00704821|DRUG|Docetaxel|Intravenous infusion
224247545|NCT05907421|BEHAVIORAL|Acceptance mindset|Brief training of acceptance versus emotional reactivity as emotion regulation strategy.
224247546|NCT01507337|DRUG|liraglutide|A single dose of 1 mg administered subcutaneously (under the skin)
224247547|NCT06018532|DEVICE|PRESAGE CARE|PRESAGE Care informations from the application will be processed by the PRESAGE Care algorithm in real time, and may generate alerts indicating an increased risk of hospitalization or emergency department visits within 7 to 14 days. These alerts will be transmitted to a Care Manager platform, who will analyse the situation, initiate the healthcare intervention and coordinate its implementation. In practice, a care manager (coordinating nurse) will process the alert and carry out an initial assessment of the beneficiary's situation, using the information feedback platform, then by telephone, contacting the older adults beneficiary and the relative. The care manager may or may not implement preventive measures. If necessary, the patient may be offered an outpatient medical consultation, a home visit, a consultation with his or her GP and/or social or paramedical interventions.
224247548|NCT03506386|OTHER|No Intervention|As it was an observational study, no intervention was administered.
224247549|NCT05660655|DRUG|Baricitinib 4 MG Oral Tablet|baricitinib 4 mg once daily
224247550|NCT05660655|DRUG|Baricitinib 2 MG|baricitinib 4mg once daily in group A
224247551|NCT05454553|OTHER|myocardial perfusion SPECT|"For all participants, myocardial perfusion SPECT will be performed :~at 3, 6 and 12 months (post irradiation)"
224247552|NCT01390493|BEHAVIORAL|neurofeedback training|training of individual alpha frequency, 10 sessions, each 15 min
224247553|NCT05735925|DIAGNOSTIC_TEST|Skin Swab & Skin Biopsies & Blood Sample|These intervention will be necessary to phenotype the immune cells that are present in the skin and blood of HS patients
224247554|NCT05417425|COMBINATION_PRODUCT|Omeza collagen matrix, Omeza lidocaine lavage, Omeza skin protectant|The three omeza products were designed to be used in combination for the treatment of chronic wounds
224247555|NCT06426056|RADIATION|radiotherapy|Image guidance volume modulated arc therapy included 50.4 Gy in 28 fractions to the pelvis and 59.4 Gy simultaneous boost in 28 fractions to involved pelvic and para-aortic lymph nodes, and subsequent high-dose-rate intracavitary brachytherapy at a total dose of 30.0-36.0 Gy in 5-6 fractions, twice a week.
224247556|NCT06426056|DRUG|Nab paclitaxel|Concurrent chemotherapy regimen included weekly cisplatin (40 mg/m\^2) and weekly nab-paclitaxel at escalating doses (33 mg/m\^2 per week).
224247557|NCT06426056|DRUG|Cisplatin|Concurrent chemotherapy regimen included weekly cisplatin (40 mg/m\^2) and weekly nab-paclitaxel at escalating doses (33 mg/m\^2 per week).
224247558|NCT02543671|OTHER|vitamin D3 enriched, reduced-fat yellow cheese|60 grams of vitamin D3 enriched, reduced-fat yellow cheese provide 5.7 micrograms of vitamin D per day for 8 weeks
224247559|NCT02543671|OTHER|plain (non-fortified) reduced-fat yellow cheese|60 grams of plain (non-fortified), reduced-fat yellow cheese provide 0 micrograms of vitamin D per day for 8 weeks
224247560|NCT02512393|DEVICE|Active tDCS|This group will receive tDCS with a constant current of 2 mA intensity will be applied for 20 minutes once a day for five consecutive days using a pair of thick (0.3 cm) rectangular surface sponge electrodes (5 cm x 7 cm) saturated with 10 mL of saline solution. The anode electrode will be placed over M1 (C3 or C4 according to the 10-20 system for EEG electrode placement) of the hemisphere contralateral to the affected knee, and the cathode electrode will be placed over the supraorbital region (SO) ipsilateral to the affected knee (M1-SO montage).
224247561|NCT02512393|DEVICE|Sham tDCS|This group will receive tDCS with a constant current of 2 mA intensity will be applied for 30 seconds once a day for five consecutive days using a pair of thick (0.3 cm) rectangular surface sponge electrodes (5 cm x 7 cm) saturated with 10 mL of saline solution. The anode electrode will be placed over M1 (C3 or C4 according to the 10-20 system for EEG electrode placement) of the hemisphere contralateral to the affected knee, and the cathode electrode will be placed over the supraorbital region (SO) ipsilateral to the affected knee (M1-SO montage).
224247562|NCT04723810|DRUG|Indocyanine Green|The investigational drug is indocyanine green, single dose between 1-5 mg/kg diluted into sterile water for intravenous (IV) injection up to 5 days prior to resection surgery. The actual dose and timing from dose to imaging will be determined based on tumor type.
224247563|NCT04109469|DEVICE|Shark Screw® transplant|Application of a Shark Screw® transplant for osteosynthesis or arthrodesis in hand- or foot surgery
224247564|NCT02420210|DRUG|Bendamustine Hydrochloride|Given IV
224247565|NCT02420210|BIOLOGICAL|Obinutuzumab|Given IV
224247566|NCT02420210|DRUG|Dexamethasone|Given PO
224247567|NCT02420210|OTHER|Quality-of-Life Assessment|Ancillary studies
224247568|NCT02420210|OTHER|Laboratory Biomarker Analysis|Correlative studies
224247569|NCT01167205|DIETARY_SUPPLEMENT|astaxanthin|astaxanthin 20mg for 12 weeks
224247570|NCT04400123|DRUG|Famitinib malate|"TR group:~The first period，the subjects will be administrated with Famitinib malate in new formulation, then conduct blood collection within 192h; 14 days washout；The second period，the subjects will be administrated with Famitinib malate in old formulation, then conduct blood collection within 192h.~RT group:~The first period，the subjects will be administrated with Famitinib malate in old formulation, then conduct blood collection within 192h; 14 days washout；The second period，the subjects will be administrated with Famitinib malate in new formulation, then conduct blood collection within 192h."
224247571|NCT01185821|DRUG|BAF312|BAF312 was supplied in film-coated tablets in strengths of 5, 4 ,2, 1, .5 and .25 mg. The actual doses taken were 10, 2, 1.25, .5 and .25 mg taken orally once a day.
224247572|NCT03212339|OTHER|Therapeutic intervention|Therapeutic interventions will be delivered in ten 2-hour sessions over 12-15 weeks, which includes 2 research data collection sessions at the beginning of the study (pre-intervention) and at the end of the study (post-intervention). During the pre-intervention data collection session, participants will be asked to provide demographic information and complete interviews about their past experiences and current experiences as a parent, and their child's current functioning. Parents will also be video recorded interacting with their child for 10 minutes. During the post-intervention data collection session, participants will be asked to complete a similar set of interviews and will also be video recorded interacting with their child for 10 minutes.
224247573|NCT05856604|BEHAVIORAL|Music Therapy|"Weekly individual (one2one) Music Therapy intervention lasting 4 months (n=16 sessions).~Behavioral: Music Therapy Music therapy is a non-pharmacological intervention, in which music and its elements are used professionally as an intervention in medical, educational, and everyday environments with individuals, groups, families, or communities who seek to optimize their quality of life and improve their physical, social, communicative, emotional, intellectual, and spiritual health and wellbeing. This therapy has been shown to provide significant benefits for individuals with cognitive decline living in care homes, enhancing social-cognitive functions and reducing behavioural symptoms (Brotons \& Koger, 2000; Hsu et al., 2015; Zhang et al., 2017)."
224247574|NCT05856604|BEHAVIORAL|Storytelling|"Weekly individual (one2one) Storytelling intervention lasting 4 months (n=16 sessions).~Behavioural: Storytelling is a non-pharmacological activity, in which a professional activity coordinator reads different stories (e.g., poems, novels) to the participants and used them to initiate a possible conversation."
224247575|NCT03539003|DRUG|sevoflurane|anesthesia was induced with propofol (1.5 mg/kg) and target controlled infusion (TCI) of remifentanil (2-3 ng/mL of targeted effect site concentration (Ce). After intubation, inspired concentration of sevoflurane (0.8-1 MAC) and the Ce of remifentanil TCI (1.0-2.0 ng/ml) were adjusted to a BIS target level for hypnosis of 40-60 during surgery.
224247576|NCT03539003|DRUG|desflurane|anesthesia was induced with propofol (1.5 mg/kg) and target controlled infusion (TCI) of remifentanil (2-3 ng/mL of targeted effect site concentration (Ce). After intubation, inspired concentration of desflurane (0.8-1 MAC) and the Ce of remifentanil TCI (1.0-2.0 ng/ml) were adjusted to a BIS target level for hypnosis of 40-60 during surgery.
224247577|NCT03539003|DRUG|propofol and remifentanil|anesthesia was induced with an effect-site concentration of 3-4 μg/ml propofol and 2-3 ng/ml remifentanil using target-controlled infusion (TCI). After intubation, The effect site TCI of propofol (2-3 μg/ml) and remifentanil (1.0-2.0 ng/ml) was adjusted to maintain the desired hypnosis (40-60 of the BIS value) during surgery.
224247578|NCT05875597|OTHER|Physical therapy exercise programme|Carrying out a programme of therapeutic physical exercise for 12 weeks, twice a week for 45 minutes.
224247579|NCT00125086|DEVICE|autologous platelet gel|
224247580|NCT06368037|DEVICE|DragonFire Transcatheter Myocardial Radiofrequency Ablation System|The patients with hypertrophic obstructive cardiomyopathy were treated with a transcatheter myocardial radiofrequency ablation system and its guiding system under the guidance of echocardiography
224247581|NCT02590185|DRUG|cocktail probe drugs|"For the assessment of drug-metabolizing enzyme activity, the patients will be given the cocktail probe drugs, by oral route, one time during the study:~* A capsule of omeprazole ABBOTT® 10mg~* 10 mg of an oral liquid formulation of Dextrométhorphane bromhydrate (Drill Pierre FABRE MEDICAMENT® 5mg/5mL, syrup)~* 1 mg of an injectable solution of Midazolam for oral administration (Midazolam Panpharma® 1mg/mL, injectable solution)~* A tablet of fexofenadine Zentiva® 120mg"
224247582|NCT02608502|BIOLOGICAL|RSV-F Vaccine|
224247583|NCT02608502|BIOLOGICAL|Phosphate Buffer Placebo|
224247584|NCT02979353|BEHAVIORAL|Shed-Meds: A Patient-Centered Deprescribing Intervention|The goal of the intervention is to safely deprescribe medications, as defined by dose reductions and stopped medications, based on a combination of clinical criteria and patient preferences.
224247585|NCT00760110|DEVICE|blood pressure measurements based on HBP or CBP|To clarify which of HBP or CBP provides the stronger predictive power for the outcomes, the 400 patients were classified as with or without hypertension based on HBP and CBP measurements at baseline
224247586|NCT00086762|BEHAVIORAL|MR Therapy|Arm I: Participants receive Mindfulness Relaxation (MR) therapy as in the pilot phase. Instructions given on breathing techniques and other practices to help relax mind and body.
223666200|NCT04187287|OTHER|Deep Friction Massage|Deep Friction Massage will given for 3 weeks, 3 days in a week. Massage duration will be 10-15 min. for each session. Moreover 10-12 minutes cold pack will apply for every session. Also Mill's manipulation technique will applied once a week during 3 weeks.
224247587|NCT00086762|BEHAVIORAL|Relaxing Music (RM) Therapy|Participants listen to relaxing music (with no instructions on relaxation techniques) for 30 minutes before and during each chemotherapy session AND at least once daily for the entire duration of chemotherapy treatment
224247588|NCT00086762|BEHAVIORAL|Standard Symptom Management|Participants receive standard symptom management education. General information received about how to manage symptoms that develop due to the chemotherapy.
224247589|NCT00086762|BEHAVIORAL|Questionnaires|Questionnaire completion at baseline, during the middle of chemotherapy treatment, and at chemotherapy completion.
224247590|NCT00385346|BEHAVIORAL|Expressive writing|Patients in the intervention group write on three day for 20 minutes about highly emotional topics In the control group patients write on three days for 20 minutes about topics with relatively low emotional involvement such as diet, time management and sport.
224247591|NCT02853682|BIOLOGICAL|plasma|assesment of glycocalyx protein
224247592|NCT04873011|DRUG|Quinine Hydrochloride|After a stabilization period of 20 minutes and 10 minutes after the first blood collection, 10 mL of the quinine hydrochloride solution will be infused into the stomach in a randomized, double-blinded fashion
223666201|NCT00005862|DRUG|semaxanib|
223666202|NCT00493857|DRUG|Nimotuzumab Humanized Monoclonal Antibody|Nimotuzumab 400mg every week
223666203|NCT00493857|DRUG|Nimotuzumab|Nimotuzumab 400mg every 2 weeks
223666204|NCT04311593|DIAGNOSTIC_TEST|CD4, CD19, CD38, CD56 and CD11b|measuring CD markers by flowcytometry
223666205|NCT03547115|DRUG|voruciclib monotherapy|Voruciclib will be administered orally
223666206|NCT03547115|DRUG|voruciclib and venetoclax|Voruciclib and Venetoclax will be administered orally
223666207|NCT05052931|DRUG|Nab-paclitaxel combined with oxaliplatin and S-1|Nab-paclitaxel 100mg/m\^2, D1, Q3W; oxaliplatin 85 mg/m\^2, D1, Q3W; S-1 60 mg/m\^2, D1-14, Q3W; Neoadjuvant chemotherapy 2 cycles, followed by surgery, continue to receive 6 cycles of adjuvant chemotherapy.
223666208|NCT05929573|DIAGNOSTIC_TEST|Neutrophil Gelatinase-Associated Lipocalin|Neutrophil Gelatinase-Associated Lipocalin, which can be measured from serum or urine, can detect acute kidney failure that may occur after surgery in the early stages.
223770767|NCT02002234|PROCEDURE|Hemicraniotomy|Hemicraniotomy involves removing a large bone flap at least 12 cm in diameter and included parts of the frontal, temporal, parietal and occipital bones, with further craniectomy to the floor of the temporal fossa. The dura was opened widely and duraplasty was performed using periosteum and temporalis fascia. The bone flap was either stored in a subcutaneous pocket in the abdomen or placed in the bone bank.
223770768|NCT02002234|PROCEDURE|Standard medical treatment|Standard medical treatment involves elevation of the head of bed at 30°, intermittent hyperventilation administered, and intravenous mannitol. Mean arterial pressure was maintained above 90 mm Hg. Hemoglobin concentration was maintained at all times above 90 g/L.
224247593|NCT04873011|DRUG|Placebo|After a stabilization period of 20 minutes and 10 minutes after the first blood collection, 10 mL of water will be infused into the stomach in a randomized, double-blinded fashion
223666209|NCT05929573|DIAGNOSTIC_TEST|Renal Doppler Resistive Index|Renal Doppler Resistive Index (RDRI) is a non-invasive index believed to reflect renal vascular perfusion. RDRI measurement is a repeatable, inexpensive, and easy-to-apply technique. RDRI has been found to be associated with AKI in conditions such as renal dysfunction, hypertension, and post-traumatic hemorrhagic shock. Furthermore, due to the impact on renal perfusion in patients undergoing major surgery, RDRI, which reflects renal vascular resistance, can serve as an indicator of kidney perfusion.
224247594|NCT02121886|PROCEDURE|venous reconstruction with the parietal peritoneum|
224247595|NCT04189250|DEVICE|Automatized carbonmonoxide rebreathing machine - OpCO Detalo instruments|The automatized protocol (aCO) will be conducted with automated system OpCO of Detalo instruments. The intended use of the OpCO Detalo instrument is to quantify hemoglobin mass in human. The principle behind the machine is the widely used CO rebreathing technique. The machine applies automatically the desired CO dose to the patient to determine hemoglobin mass. The Detalo Instruments OpCO is certified conform to the following CE norms: Electromagentic compabilitiy: DIN EN 60601-1-2 and electrical Safety test: LVD 2014/35/EU.
223770769|NCT05211622|DRUG|1. alpha acid lipoic - tables|600 mg/die per os from 7 days before the beginning of chemotherapy and continue for other 4 days
223770770|NCT05211622|DRUG|2. ozonated oil - mouthwash|1 minute- three times/die after oral hygiene, possibly, from the beginning of chemotherapy and for 2 weeks
224247596|NCT02560194|PROCEDURE|Flexible Sigmoidoscopy|Examination of the rectal and distal colon by means of a flexible endoscope
224247597|NCT02560194|OTHER|Fecal occult blood test|Test for hemoglobin in faeces
224247598|NCT00550537|DRUG|bevacizumab|15 mg/m2 given through a vein for every 3 weeks
224247599|NCT00550537|DRUG|carboplatin|AUC = 6 given through a vein on day 1 of each cycle.
224247600|NCT00550537|DRUG|erlotinib hydrochloride|150 mg taken by mouth daily
224247601|NCT00550537|DRUG|paclitaxel|200 mg/m2 given through a vein on day 1 of each cycle.
224247602|NCT00550537|GENETIC|gene expression analysis|Blood and tissue collection.
224247603|NCT00550537|GENETIC|protein expression analysis|Blood and tissue collection.
224247604|NCT00550537|GENETIC|proteomic profiling|Blood and tissue collection.
224247605|NCT00550537|OTHER|laboratory biomarker analysis|Blood and tissue collection.
224247606|NCT01705301|DEVICE|WINCS|The experimental protocol will involve, after implantation of the DBS electrodes, the patient will have a single electrochemical recording electrode will be implanted along the same trajectory path as the electrophysiology and the DBS electrode
224247607|NCT00260039|BIOLOGICAL|Comparator: Gardasil|0.5 mL intramuscular injection administered at Day 1, Month 2 and Month 6
224247608|NCT00260039|BIOLOGICAL|Comparator: octavalent HPV Vaccine - dose formulation 1|0.5 mL octavalent HPV vaccine - intramuscular injection administered at Day 1, Month 2 and Month 6
224247609|NCT00260039|BIOLOGICAL|Comparator: octavalent HPV Vaccine - dose formulation 2|0.5 mL octavalent HPV vaccine - intramuscular injection administered at Day 1, Month 2 and Month 6
223666210|NCT04086498|OTHER|Mediterranean diet|The group received a plan for a isocaloric Mediterranean Diet
223666211|NCT04086498|OTHER|KEMEPHY|The group received a plan for a ketogenic mediterranean with herbal extracts diet
223666212|NCT04086498|OTHER|KD|The group received a plan for a low carbohydrate ketogenic diet
223770771|NCT05211622|DRUG|3. chlorhexidine 0,2% - mouthwash|1 minute- three times/die after oral hygiene, possibly, from five days after the beginning of chemotherapy and for subsequent 2 weeks
223770772|NCT05211622|DRUG|4. sodium bicarbonate 5% solution - mouthwash|1 minute- three times/die after oral hygiene, possibly, from the beginning of chemotherapy and for 3 weeks
223770773|NCT05257265|DRUG|Centanafadine Hydrochloride|Capsule
224247610|NCT00260039|BIOLOGICAL|Comparator: octavalent HPV Vaccine - dose formulation 3|0.5 mL octavalent HPV vaccine - intramuscular injection administered at Day 1, Month 2 and Month 6
224247611|NCT00268905|DRUG|E7389 + carboplatin AUC 5|Patients will receive E7389 before (Schedule A) or after (Schedule B) carboplatin AUC 5 infusion. E7389 will be administered as a 2-5 minute intravenous (IV) bolus infusion at a starting dose of 0.7 mg/m\^2 on Days 1 and 8 every 21 days. Carboplatin 5 AUC will be administered as a 30-minute IV infusion on Day 1 every 21 days. Dose escalation will be performed in cohorts of three patients per dose level per schedule.
224247612|NCT00268905|DRUG|E7389 + carboplatin AUC 6|"After MTD is reached with carboplatin AUC 5, dose escalation of E7389 in combination with carboplatin at AUC 6 will begin at one dose level below MTD, using the preferred schedule (A or B).~If carboplatin AUC 6 with E7389 is tolerated, the MTD reached will be used to enroll 20 additional patients with Stage IIIB or IV non-small cell lung cancer (NSCLC). If carboplatin AUC 6 is not tolerated, these patients will be enrolled at the MTD determined with the combination of E7389 and carboplatin AUC 5."
224247613|NCT00268905|DRUG|E7389+carboplatin AUC 6|In a population of patients who had generally received multiple prior chemotherapies, the eribulin MTD has been determined to be 1.1 mg/m2 in combination with carboplatin at an AUC of 6. The first-line NSCLC patients in the extension arm may tolerate a higher dose of eribulin, because they have not been exposed to the toxicity of other chemotherapies. To investigate this possibility, the dose of eribulin will be increased to 1.4 mg/m2 for subsequent patients, if the first six of these patients do not experience a DLT during their first cycle of eribulin at 1.1 mg/m2 and carboplatin at AUC 6 combination therapy. If no more than one of the first six patients experience a DLT during the first cycle with the 1.4 mg/m2 dose of eribulin, then the 1.4 mg/m2 dose will be considered the recommended dose for front-line NSCLC therapy and the remaining patients will be treated using this dose.
224247614|NCT03827174|OTHER|Return To Work Coordination|External and internal coordination regarding sick leave. Establishment of a common return to work plan between employer och employee.
224247615|NCT03827174|BEHAVIORAL|Behaviour Change Ability Program|"1. Return to work coordination~2. Education for employers and employees in pain neuroscience, validation and problem-solving.~3. Patient-specific goal setting for return to work~4. Exercise and behavioural skills training related to return to work"
224247616|NCT01853566|DRUG|growth hormone|GH group intervention: use of GH - initial dose of 0.5 UI/day (0.2 mg/day), with readjustments to 1.0 UI/day (0.4 mg/day) and 1.5 UI/day (0.6 mg/day) after 1 and 2 months of treatment, respectively. The last GH dose will be maintained until the end of the study. These GH dosages were based on the dose used for adults of the same age with GHD. Subjects will be re-evaluated after 6 months of GH therapy or placebo according to muscle strength and body composition .The other group received placebo using the same scheme as the GH group.
224247617|NCT04093037|DIAGNOSTIC_TEST|Time #1: Non Invasive Break-Up Time (NIBUT)|"A LacryDiag examination without dye will be realized. All measurements are made without contact. It's calculates the Non Invasive Break-Up Time (NIBUT), Tear Meniscus (TM) height (in millimeters) and number of Meibomian Gland.~These are different pictures taken with LacryDiag and analyzed."
224247618|NCT04093037|DIAGNOSTIC_TEST|Time #2: MicroInstillation Break-Up Time (MIBUT) + Oxford score|"The MicroInstillation of fluorescein Break-Up Time (MIBUT) will be calculated by manual MIBUT and LacryDiag MIBUT.~The Oxford score will be calculated. It's used to clinically determine the severity of dry eyes with minimum score at 0 (none) and maximum score at 5 (very severity)."
224247619|NCT04093037|DIAGNOSTIC_TEST|Time #3: Standard Break-Up Time (SBUT)|The Standard Break-Up Time (SBUT) with fluorescein macroinstillation will be calculated by manual SBUT and LacryDiag SBUT.
224247620|NCT04093037|DIAGNOSTIC_TEST|Time #4: Schirmer test|The Schirmer test will be performed. It consists of applying the end of a small strip of blotting paper behind the lower eyelid and examining the strip after 5 minutes.
224247621|NCT04093037|DIAGNOSTIC_TEST|Satisfaction questionnaire to the patient|A satisfaction questionnaire to the patient will be completed at the end of the participation at the study.
224247622|NCT00617305|DRUG|Ambrisentan|Ambrisentan was administered orally once daily; dose level was 5 mg for the first 4 weeks, followed by 10 mg for the remainder of the study; ambrisentan was supplied as 5-mg and 10-mg tablets.
224247623|NCT00617305|DRUG|Placebo|Placebo to match ambrisentan was administered orally once daily.
224247624|NCT00617305|DRUG|Sildenafil|Sildenafil was administered at the dose previously established for each subject (20-100 mg) orally three times daily. Sildenafil was supplied as 20-mg tablets, or formulated as sildenafil citrate in 25-, 50-, or 100-mg tablets.
224247625|NCT00617305|DRUG|Tadalafil|Tadalafil was administered at the dose previously established for each subject (not to exceed 40 mg per day) orally once daily. Tadalafil was supplied as 20-mg tablets.
223666213|NCT00794898|BIOLOGICAL|Infliximab (Remicade)|Infliximab 3 mg/kg infusions at Weeks 0, 2, and 6. All patients will continue to receive the same dose of MTX they were receiving at entry throughout the subsequent treatment period.
223666214|NCT01849744|DRUG|VS-4718|
224247626|NCT04355468|DRUG|Opioid Anesthesia|Intraoperatively, fentanyl in fractional doses of 1-3 µg∙kg-1 were applied if the heart rate (HR; Heart Rate) or mean blood pressure (MBP; Mean Blood Pressure) increased by more than 20% above the baseline value obtained just before surgery commencement.
224247627|NCT04355468|DRUG|Opioid Free Anaesthesia|"Before the induction of general anesthesia, a single-shot thoracic paravertebral block (ThPVB) was performed at the Th3-Th4 level. An insulated needle was used, connected to a peripheral nerve stimulator. 0.5% bupivacaine (0.3 ml∙kg-1) was then injected after a negative aspiration test. The efficacy of the blockade was checked after 20 min on both sides of the thorax with a plastic ampoule of saline. A difference in the sensation of cold between the sides of the thorax was assumed to indicate an effective block. Afterwards a continuous intravenous infusion of lidocaine and ketamine was started:~1. immediately after anesthesia induction, lidocaine was administered as an i.v. bolus at a dose of 1.5 mg∙kg-1 and ketamine in an i.v. bolus of 0.35 mg∙kg-1;~2. followed by an infusion of lidocaine 2.0 mg∙kg-1∙h-1 for 2 hours, continued at a dose of 1.2 mg∙kg-1∙h-1, and ketamine infusion 0.2 mg∙kg-1∙h-1 for 2 hours, continued at a dose of 0.12 mg∙kg-1∙h-1."
224247628|NCT02380807|DEVICE|Dry Needling|"Dry needling is the use of either solid filiform needles or hollow-core hypodermic needles for therapy of muscle pain, sometimes also known as intramuscular stimulation (IMS). Although dry needling originally utilized only hypodermic needles due to the concern that solid filiform needles had neither the strength or tactile feedback that hypodermic needles provided and that the solid filiform needle could be deflected by dense contraction knots."
224247629|NCT02380807|OTHER|Cross Tape Therapy|The tape consists of cross bands or strips mesh cross, nonelastic and without any medication, forming a grid-shaped patch. The cross tape will be applied on trigger points.
224247630|NCT04934618|DRUG|Carelizumab Combined With Irinotecan and Apatinib|Three-drug regimen was used in second-line treatment of Advanced gastric cancer
224247631|NCT02900443|DRUG|Mycophenolate mofetil|
224247632|NCT02900443|DRUG|Azathioprine|
223666215|NCT02540889|BEHAVIORAL|Auditory comprehension therapy.|100 hours of Auditory comprehension therapy embedded within a computer game.
223666216|NCT01481532|DRUG|Crotoxin|Intra patient dose escalation
223666217|NCT02682979|OTHER|Medical files analysis|Retrospective analysis of the medical files according to medical, social and geriatric criteria.
223666218|NCT05062954|DIETARY_SUPPLEMENT|Polyphenol-rich cranberry extract supplement standardized in proanthocyanidins|Participants will be randomly assigned to the consumption of one capsule of Polyphenol-rich cranberry extract standardized in PACs.
224247633|NCT02109250|DRUG|Caprelsa|Caprelsa® 100 mg or 300 mg film-coated oral tablets. Each film-coated tablet contains 100 mg or 300 mg of vandetanib.
224247634|NCT00449592|DRUG|Zinc|Oral Zincol 1 Tab TID from day -6/-7 until discharge
224247635|NCT00449592|DRUG|Placebo|Oral placebo 1 Tab TID from day -6/-7 until discharge
224247636|NCT02002754|DRUG|Bambuterol Hydrochloride tablets|Bambuterol Hydrochloride tablets(10mg) 3 tablets qd for three days(swallowed by warm water at 0.5-1h after each meal)
224247637|NCT05020925|DRUG|SHR-1701|Intravenous (IV) on Day 1 of each cycle
224247638|NCT05020925|DRUG|Famitinib|Famitinib, po, qd
224247639|NCT01746485|DRUG|UT-15C|
224247640|NCT03575234|DRUG|Cyclophosphamide|Given IV
224247641|NCT03575234|BIOLOGICAL|IRX-2|Given SC
224247642|NCT03575234|BIOLOGICAL|Nivolumab|Given IV
224247643|NCT03575234|PROCEDURE|Surgery|Undergo surgery
224247644|NCT03764748|DRUG|Washed Microbiota Transplantation|The prepared microbiota suspension was infused into the participates' lower gut.
224247645|NCT06561022|DRUG|Fluzoparib|Fluzoparib
224247646|NCT06561022|DRUG|Everolimus|Everolimus
224247647|NCT06561022|DRUG|Fulvestrant|Fulvestrant
224247648|NCT06561022|DRUG|Abemaciclib|Abemaciclib
224247649|NCT06562023|OTHER|Botulinum Toxin Type A|Patients will receive BTA injection within a period of 5 days after primary closure.
224247650|NCT06562023|OTHER|Mesotherapy|Patients will receive mesotherapy growth factor serum with a derma pen within a period of 5 days after primary closure.
224247651|NCT00275600|DRUG|Vitamin E, Evening Oil of Primrose, and Placebo|
224247652|NCT04443660|OTHER|Blood test|Blood samples taken to test levels of autophagy and apoptosis
224247653|NCT04510285|DRUG|Trastuzumab|Trastuzumab (8mg/kg loading dose; 6mg/kg maintenance) will be administered on day 1 of each 3-week dosing cycle (21 days).
224247654|NCT04510285|DRUG|Pembrolizumab|Pembrolizumab 200 mg IV will be administered on day 1 of each 3-week dosing cycle (21 days).
224247655|NCT02745951|OTHER|Heliox|Half of the study population will be randomly assigned to receive cardioplegia enriched with a 70:30 (Helium:Oxygen) via a D100 pediatric oxygenator. The Heliox itself will need to be administered via an oxygen regulator using a low flowmeter.
224247656|NCT02745951|OTHER|Standard of care|The other half will be randomized to Nitrogen:Oxygen mixture. This will be done through the standard of care cardioplegia apparatus. There will be no novel interventions administered in this group.
224247657|NCT00083785|DRUG|Talaporfin sodium (LS11)|
223666219|NCT05062954|DIETARY_SUPPLEMENT|Placebo supplement|Participants will be randomly assigned to the consumption of one capsule of placebo per day for 56 consecutive days.
223666220|NCT00744354|DRUG|bortezomib|Intravenous Push 1.3 mg/m2 Days 1, 4, 8, and 11
223666221|NCT00744354|DRUG|pegylated liposomal doxorubicin hydrochloride|Intravenous infusion, 30mg/m2, Day 4, each cycle
223666222|NCT00744354|DRUG|vorinostat|Oral, 300mg, Days 1, 2, 4, 5, 8, 9, 11, 12, every cycle.
223666223|NCT00793273|DRUG|insulin detemir|Effectiveness and safety data collection in connection with the use of the drug Levemir® in daily clinical practice
224247658|NCT00083785|DEVICE|LED-based light infusion device|
224247659|NCT00083785|DEVICE|Light emitting diodes (LED)|
224247660|NCT00083785|PROCEDURE|Photodynamic therapy|
224247661|NCT00083785|PROCEDURE|Phototherapy|
224247662|NCT00083785|PROCEDURE|Chemotherapy|
224247663|NCT04486196|DEVICE|Medency Primo Diode Laser Device (Medency, Vicenza, Italy)|Root canals were irradiated with 980 nm diode laser coupled with optical fiber 200 µm with setting at the average power 1.2-W in pulsed mode. 10 seconds irradiation followed by 10 seconds pause, which comprised one lasting cycle.
224247664|NCT04486196|PROCEDURE|2.5% NaOCl, %17 EDTA, Distilled water, 30-gauge, side-opening needle (Canal Clean, Biodent, South Korea),|Final conventional irrigation
224247665|NCT00379600|DRUG|rosiglitazone XR|
224247666|NCT01406795|DEVICE|Gore Viabahn Heparin Coated Stent|For subjects deemed to be suffering from chronic venous insufficiency of the femoral or popliteal veins, a Gore Viabahn stent will be implanted during a venoplasty procedure to determine whether the vein will stay open.
224247667|NCT05372666|OTHER|Standard white bread|Bread to be consumed within 10 minutes after 10h fasting
224247668|NCT05372666|OTHER|Experimental white bread|Bread to be consumed within 10 minutes after 10h fasting
224247669|NCT05372666|OTHER|Standard High-fiber bread|Bread to be consumed within 10 minutes after 10h fasting
224247670|NCT05372666|OTHER|Experimental High-fiber bread|Bread to be consumed within 10 minutes after 10h fasting
224247671|NCT06346223|BEHAVIORAL|Mindfulness and psychoeducation|The single-session mindfulness intervention includes a 90-minute group-based session containing different mindfulness practices, psychoeducation and group sharing activities in the single-session mindfulness intervention. A self-practice tool kit will be provided to the participants for home practice 20 minutes daily through an online platform and the participants will be told to develop the practice as a daily habit. All of the teaching contents will be closely related to dementia caregiving and delivered by a mindfulness teacher who has received 40 hours training in dementia caregiving. A weekly mindfulness practice reminder will be sent to the participants through SMS for 8 weeks. The caregivers will also be provided with access to a social media online platform for sharing their practice experience with their classmates online. The interventionist will address their difficulties and challenges via the platform to reinforce skill mastery.
224247672|NCT06346223|BEHAVIORAL|Psychoeducation|The caregivers in the control group will receive brief education on dementia with the same group size and of the same duration (90-minutes) as the sessions in the intervention arm. The nurse will deliver brief education (15 minutes) on dementia in the session, followed by group sharing and discussion on their daily caregiving experience. The caregivers in the control group will be provided with a toolkit with education materials about the common health problems of older adults and also be given access to a social media platform in which they can communicate and share their caregiving experiences with classmates.
224247673|NCT01384838|BEHAVIORAL|Counseling|Nutritional, lifestyle and sports counseling
224247674|NCT01384838|BEHAVIORAL|physical activity|counseling and controlled physical activity
224247675|NCT00048958|GENETIC|cytogenetic analysis|
224247676|NCT04058223|DEVICE|Hemorrhoidopexy|stapled hemorrhoidopexy
224247677|NCT00000804|DRUG|Indinavir sulfate|
223666224|NCT04685174|DEVICE|Invos Model 5100C Cerebral/Somatic Oximeter|To measure the correlation between post arterial and venous anastomoses (reperfusion) NIRS values of transplanted kidney and post-transplant graft failure as manifested in initiation of renal replacement therapy post transplant
223666225|NCT06138223|OTHER|Exercise intervention|During 12 weeks, patients will visit twice a week a trained oncology physiotherapist for one hour per session. This training includes supervised aerobic and resistance exercises to increase aerobic condition and muscle resistance, based on their own fitness level as assessed at baseline. Additionally, physiotherapists will educate participants on how to increase their daily activity. To this end, all participants will receive an activity tracker to monitor their daily activities.
223770774|NCT05257265|OTHER|Placebo|Capsule
223770775|NCT02562313|DRUG|BioChaperone insulin lispro|BioChaperone insulin lispro bolus infusion followed by test meal intake
224247678|NCT02201225|DIETARY_SUPPLEMENT|Nutritional supplement with micronutrient|Nutritional supplement powder with micronutrients packed as 27 g individual sachet, administered orally as a single serve
224247679|NCT02201225|DIETARY_SUPPLEMENT|Nutritional supplement without micronutrient|Nutritional supplement powder without micronutrients packed as 27 g individual sachet, administered orally as a single serve
224247680|NCT04702178|BIOLOGICAL|COVAC-2|Intramuscular vaccine against SARS-CoV-2
224247681|NCT04702178|BIOLOGICAL|Saline Placebo|Intramuscular injection of saline placebo
224247682|NCT05124574|OTHER|Samples concern SARS-COV-2 + pregnant women at the time of childbirth|"* nasopharyngeal PCR in the mother (performed systematically in this epidemic context),~* Blood samples: 1 EthyleneDiamineTetraacetic Acid (EDTA) tube (immunohistochemistry), 1 yellow tube (COVID + RT-qPCR serology).~* Sampling of amniotic fluid in case of cesarean section~* Sampling of the placenta for histological and virological study."
224247683|NCT05124574|OTHER|Samples concern newborns of SARS-COV-2 + mothers at birth|"* In the birth room:~  * Collection of gastric fluid (PCR SARS-COV-2),~ * Cord blood: 1 EDTA tube (immunohistochemistry), 1 yellow tube (SARS-COV-2 + RT-qPCR serology).~* In the newborn at D3 of life:~  \- 1 yellow tube (SARS-COV-2 + RT-qPCR serology) at the same time as the DNN.~* In symptomatic newborns:~  * 1 yellow tube (SARS-COV-2 + RT-qPCR serology).~ * nasopharyngeal PCR,"
224247684|NCT00950625|DRUG|lignocaine|200 mg of intraperitoneal lignocaine will be given once during surgery
224247685|NCT00950625|DRUG|bupevacaine|100 mg of bupevacaine will be given once during laparoscopic cholecystectomy
224247686|NCT00683202|DRUG|Acetylsalicylic acid|Acetylsalicylic acid 100 mg or placebo daily perorally started on the first day of ovarian gonadotrophin stimulation in in vitro fertilization or in intracytoplasmic sperm injection
224247687|NCT00683202|DRUG|Placebo|Acetylsalicylic acid 100 mg or placebo daily perorally started on the first day of ovarian gonadotrophin stimulation in in vitro fertilization or in intracytoplasmic sperm injection
223666226|NCT06138223|OTHER|Nutrition intervention|Once every two weeks patients in the intervention group will receive a nutritional assessment and intervention by a trained dietician for optimization of their nutritional intake to improve their nutritional status, following the ESPEN guideline on nutrition in cancer patients and the national guidelines of the National Nutritionists Oncology Working Group (NNOWG; in Dutch: Landelijke Werkgroep Diëtisten Oncologie, LWDO). Moreover, an amount of 15-25 grams of protein within 1-2 hours after exercise will be advised, to prevent muscle protein breakdown and enhance muscle protein synthesis.
223666227|NCT05690867|OTHER|Starting with volume controlled ventilation and changing the ventilation mode every 20 minutes|group 1 starts with volume controlled ventilation and we take three consecutive measurements in twenty minutes , after twenty minutes we change the ventilation mode to pressure controlled ventilation after letting washout we take three consecutive measurements at pressure controlled ventilation and we will repeat this protocol during surgery
223770776|NCT02562313|DRUG|Humalog®|Humalog® bolus infusion followed by test meal intake
223770777|NCT06482047|BEHAVIORAL|Moderate-intensity cycling|Moderate-intensity cycling on Ergoline Ergoselect 100
223770778|NCT06482047|BEHAVIORAL|Vigorous-intensity cycling|Vigorous-intensity cycling on Ergoline Ergoselect 100
223770779|NCT06482047|BEHAVIORAL|Uninterrupted sitting|Uninterrupted sitting in a quiet room
224247688|NCT05978479|OTHER|Teach-Back Method|No intervention will be given to the patients in the control group.
224247689|NCT05094713|OTHER|Flossing experimental group|Flossing of the tight muscles with medium wrapping pressure, which is individualized in based on the tight circumference of the participant.
224247690|NCT05094713|OTHER|Low wrapping pressure|Control group where flossing wrapping pressure is between 20 and 30 mmHg
224247691|NCT03902028|OTHER|Reinforced multidisciplinary follow-up|Reinforced multidisciplinary follow-up
224247692|NCT04691830|BEHAVIORAL|Prosody treatment program|"The prosody treatment program is an evidence-based practice targeting receptive and expressive prosodic skills in addition to speech production, intelligibility, pragmatics and phonology. The program incorporates the principles of validated prosodic rehabilitation strategies such as Dynamic Temporal and Tactile Cueing (DTTC), Melodic Intonation Therapy, Lee Silverman Voice Treatment in addition to expert professional practice.~The program was applied using a systematic approach of providing cues to help accelerate the child's learning of the prosodic skills targeted in the program. The program is divided into two sections according to the age into preschool section and school age section."
224247693|NCT04691830|BEHAVIORAL|Traditional auditory and language rehabilitation|Auditory rehabilitation therapy included activities targeting auditory skills: sound detection, discrimination, identification and auditory comprehension. Language rehabilitation targeted improving semantics, syntax, pragmatics and phonology.
224247694|NCT05480657|BIOLOGICAL|AT-1501 IV Infusion|Investigational study drug
224247695|NCT05480657|BIOLOGICAL|Isolated cadaveric islet cells|Infusion of human cadaveric islet cells into the portal vein
224247696|NCT04774757|PROCEDURE|Para-aortic lymph node dissection|Para-aortic lymph node dissection was defined as the dissection of para-aortic lymph nodes located below renal vein and above the bifurcation of iliac artery.
224247697|NCT03897088|DRUG|PART 1: Double-blind Placebo-controlled|all eligible subjects will receive either tildrakizumab or placebo
224247698|NCT03897088|DRUG|PART 2: Double-blind Active Treatment Extension|subjects initially on placebo will be switched over to receive tildrakizumab while subjects initially on tildrakizumab will continue to receive tildrakizumab as per defined schedule
224247699|NCT02048306|BEHAVIORAL|Family-based PR program|The 12-week Family-based PR program will consist of psychoeducation for patients and family members (once a week) and exercise training for patients (3 times a week). The psychoeducation component aims to empower the family with strategies to facilitate a functional and healthy adjustment to the disease and includes educational and psychosocial support components.
224247700|NCT02048306|BEHAVIORAL|Conventional PR program|The 12-week Conventional PR program will consist of psychoeducation (once a week) and exercise training (3 times a week) for patients only.
224247701|NCT00237003|BEHAVIORAL|motivational interviewing|Assessment plus motivational interview condition -- two motivational interview sessions are conducted during the first month of this six month study participation.
224247702|NCT01475396|BEHAVIORAL|exercise|
224247703|NCT04473807|DRUG|Intravenous Sotalol Administered as a Loading Dose to Initiate Oral Sotalol Therapy in Adult Patients with Atrial Fibrillation|The hypothesis to be tested is that the intravenous loading regimen followed by oral sotalol administration 4 hours after the conclusion of the IV infusion (every 12 hours thereafter) will result in sotalol peak concentrations at the end of IV loading dose (IV to oral loading) which are comparable to the steady state and maximum QTc seen on Day 3 after the last in-hospital oral dose.
224247704|NCT03971825|DRUG|CC-92252|CC-92252
224247705|NCT03971825|OTHER|Placebo|Placebo
224247706|NCT00855738|DRUG|Gabapentin, Lamotrigine, Levetiracetam, Pregabalin, Oxcarbacepine, Tiagabine, Topiramate, Zonisamide|"* Gabapentin: up to 3.600 mg/d~* Lamotrigine: up to 400 mg/d~* Levetiracetam: up to 3.000 mg/d~* Pregabalin: up to 600 mg/d~* Oxcarbazepine: up to 2.400 mg/d~* Tiagabine: up to 30 mg/d~* Topiramate: up to 400 mg/d~* Zonisamide: up to 500 mg/d"
224247707|NCT02745925|DRUG|Ibuprofen|
224247708|NCT05829122|PROCEDURE|Sutureless Intrascleral Intraocular Lens Fixation and Modified Iris Cerclage Pupilloplasty|In this study, patients with various causes of pupillary dilatation were recruited, and medical records and ophthalmology examinations, including slit-lamp examination, visual acuity, corrected visual acuity, intraocular pressure, pupil diameter, pupil area, corneal endothelial cell count fundus examination, and photophobia score, were collected. Those who met the recruitment criteria underwent modified iris cerclage. The modified iris cerclage was performed by making four clear corneal incisions, suturing the iris 3-4 times consecutively between each two incisions, completing 360 degrees of iris suturing in sequence, and finally tying the knot intraocularly to complete the iris cerclage.
224247709|NCT02215083|DIETARY_SUPPLEMENT|L-glutamine|10,000mg by mouth, twice daily for nine weeks (± 7 days) with one permitted dose escalation to a maximum of 10,000mg by mouth three times daily.
224247710|NCT03097783|DEVICE|Restylane Perlane Lidocaine|Intradermal injection
224247711|NCT00992771|DRUG|varenicline|up to 1mg BID for 8 weeks
224247712|NCT00992771|DRUG|placebo|placebo matching varenicline, up to 1mg BID for 8 weeks
224247713|NCT04046211|DRUG|Hydrogen|Gas exposure for 24, 48 or 72 hours via high flow nasal cannula.
224247714|NCT00993252|PROCEDURE|CT Scan|CT scan
224247715|NCT02751398|DRUG|Dapagliflozin 10mg|
224247716|NCT02751398|DRUG|Placebo 10mg|Matching placebo for dapagliflozin 10 mg
224247717|NCT06320977|OTHER|Static Stretching|"The static stretching protocol will include the following muscle groups of the dominant lower limb:~* Gastrocnemius - Participants will assume a bipedal position facing a wall. Then, the leg that is not being stretched will be placed forward, with the knee in semi-flexion, and the leg that is being stretched, behind, with the knee in full extension. Instructions will be given in order to keep the calcaneus on the floor;~* Tibialis anterior - Participants will be facing a wall, with the entire foot in touch with the ground and toes pointing forward. Then, they will secure themselves to a handrail and project the hips back.~These stretchings will be held in a position where the participants refer discomfort, and will be maintained for 30 seconds or 90 seconds according to the condition."
224247718|NCT04864548|BIOLOGICAL|SARS-CoV-2 virus|The SARS-COV-2 challenge virus strain was originally obtained from a nose/throat swab taken from a patient who developed respiratory symptoms consistent with COVID-19. The isolate was plaque purified to obtain a 'single' virus entity. The selected plaque, B1, was subsequently manufactured in accordance with GMP at the Great Ormond Street manufacturing suite.
224247719|NCT01205295|OTHER|Cognitive behavioural therapy|Cognitive behavioural therapy Psychologist Preoperative Efficacy of treatment
224247720|NCT03904303|DRUG|A 06 ad|Colonic cleansing before colonoscopy and CT colonografi
224247721|NCT04047147|OTHER|Enrollment in the Million Hearts CVD Risk Reduction Model|"The intervention is at a provider organization level and all eligible beneficiaries enrolled by participants will be considered exposed. Intervention organizations receive payments to:~* Risk stratify eligible Medicare FFS beneficiaries~* Provide CVD care management to high-risk beneficiaries~* Collect and report clinical data to CMS via the Million Hearts Data Registry and participate in learning system activities~Participating organizations receive payments for each eligible beneficiary they risk stratify. In model year 1, the organizations receive a fixed payment per beneficiary per month to provide cardiovascular management. In model years 2-5, the organizations receive a risk reduction payment that is scaled based on reductions in 10-year predicted risk scores among their cohort of high-risk beneficiaries."
223666228|NCT05690867|OTHER|Starting with pressure controlled ventilation and changing the ventilation mode every 20 minutes|group 2 starts with pressure controlled ventilation and we take three consecutive measurements in twenty minutes , after twenty minutes we change the ventilation mode to volume controlled ventilation after letting washout we take three consecutive measurements at volume controlled ventilation and we will repeat this protocol during surgery
223666229|NCT05378698|DRUG|Application of Tralokinumab|2 Arms 20 patients 5 healthy controls
223666230|NCT01757145|DRUG|Eltrombopag|"From day +1, start eltrombopag 100 mg/d. If primary end point not reached on day +14, then from day +15 - 150 mg/d.~If primary end point not reached on day +28 then from day +29 - 200 mg/d. If primary end point not reached on day +42 then from day +43 and on - 300 mg/d maximal dose).~If present dose not tolerated, return to last tolerated dose. Eltrombopag will be discontinued after platelet count has exceeded 50,000/microliter for 14 consecutive days without administration of platelets. In case of decline of platelet count \< 30,000/microliter within 15 days from eltrombopag discontinuation, it will be resumed for additional 4 weeks. After 4 weeks we will re-attempt to hold the drug (if the threshold of platelet count \>50,000/microliter will be reached again)."
223666231|NCT00958997|DRUG|18F-FP-DTBZ (18F-AV-133)|The subjects will receive a single IV bolus of approximately 10 mCi 18F-AV-133.(Injection will contain no more than 25 µg of non-radiolabeled 19F-AV-133).
223666232|NCT00958997|BIOLOGICAL|Arginine-hydrochloride|A bolus injection of 5g of 10% arginine-hydrochloride will be given over a period of 1 minute.
223666233|NCT04150367|DRUG|Isoniazid|Solution for injections, 100 mg/ml, 5 ml. Participants will get the dosage according to the instruction for use.
223666234|NCT04150367|DRUG|Rifampicin|Participants will get the dosage according to the instruction for use.
223666235|NCT04150367|DRUG|Ethambutol|Participants will get the dosage according to the instruction for use.
223666236|NCT04150367|DRUG|Rifampicin|Participants will get the dosage according to the instruction for use.
223666237|NCT04150367|DRUG|Isoniazid|. Participants will get the dosage according to the instruction for use.
223666238|NCT04150367|DRUG|Ethambutol|Participants will get the dosage according to the instruction for use.
223666239|NCT03489746|OTHER|ICS withdrawal protocol|A primary care intervention to support switch from ICS containing regimen to non-ICS containing regimen in appropriate patients.
224247722|NCT04047147|OTHER|Enrollment in control provider organizations|Control organizations receive payments to collect and report clinical data on their eligible Medicare FFS beneficiaries, but are not asked to calculate CVD risk scores or otherwise change their clinical care.
223666240|NCT03489746|OTHER|Standard care|Normal clinically indicated inhaled therapy
223666241|NCT02728973|OTHER|ERAS program|The main elements of this program were: preoperative advice, no colon preparation, provision of carbohydrate-rich drinks one day prior and on the morning of surgery, goal directed fluid administration, body temperature control during surgery, avoiding drainages and nasogastric tubes, early mobilization, and the taking of oral fluids in the early postoperative period.
224247723|NCT00204139|PROCEDURE|Routine midtrimester pregnany ultrasound scan|
223666242|NCT03498053|BEHAVIORAL|Marlboro|Participants smoke Marlboro during the first experimental day, ad libitum.
223770780|NCT02643524|BEHAVIORAL|Nutrition and Exercise Counseling|Patients are prescribed CAM boot and provided nutritional and upper body exercise counseling at the time the CAM boot is dispensed. Patients will be given a diary to complete their daily meal intake (optional), seated upper body physical exercise guidelines and asked to perform them three days per week and each exercise three times per session if able. They will be asked to record number of hours CAM boot is worn daily in the Patient Diary, if one is utilized. Albumin lab test will be drawn and their height and weight measured.
224247724|NCT00540020|OTHER|Rehabilitation|
224247725|NCT00761020|DRUG|Mefloquine|To determine the seroconversion rate (sensitivity) to Plasmodium falciparum Merozoite Surface Protein 1 (Pf MSP-1) antigen by ELISA assay in the infectivity control and mefloquine cohorts as part of a larger project to support the qualification of anti-MSP-1 antigen-specific antibody assays as valid surrogate endpoints for malaria infection.
224247726|NCT00761020|OTHER|Control|No Intervention
224247727|NCT04384978|BEHAVIORAL|Play Serious Games with a Social Robot (Ryan)|Active Group: Game play and physical activities with Ryan, a socially assistive robot developed at DreamFace Technologies,LLC.
223666243|NCT03498053|BEHAVIORAL|Marlboro Prime|Participants smoke Marlboro Prime during the second experimental day, ad libitum.
223666244|NCT03498053|BEHAVIORAL|Marlboro Prime (ventilation holes taped)|Participants smoke Marlboro Prime (filter ventilation holes taped) during the third experimental day, ad libitum.
223666245|NCT03997227|PROCEDURE|Erector spinae Block|After anesthesia and surgical procedures, a bilateral ESP block with ultrasound guidance will be applied from the T10 level at the middle line 3 cm lateral. Prior to the block, with povidone iodine, the T10 transverse protrusion will be determined by using linear ultrasound probe. The local anesthetic will be applied between the transverse projection and the erector spina muscle with the help of an isolated needle designed for peripheral block operations. Without local anesthesia, the location of the needle with saline will be confirmed by hydrodissection. After confirming the location of the needle, 20 ml of LA and saline mixture will be applied and the same procedure will be repeated in the control. A total of 40 ml of LA, 20 ml of bupivacaine 0.5%, 10 ml of lidocaine 2%, 10 ml of saline will be composed of saline.
223666246|NCT01781273|OTHER|Ethanol|During a 45 min period, investigators will ask participants to drink 500ml of cranberry juice, 100 ml at a time each 5 minutes. Depending of the allocation, these drinks will contain more or less alcohol. Pure ethanol will be used mixed with the beverage. The amount of alcohol to dilute in the drink will be calculated using Widmarks formula. Participants will move to the simulator room 20 minutes after having finished drinking the first 500 ml. To maintain the BAC level, investigators will use a breathalyser and provide 100 ml cranberry juice every 20 minutes with the amount of necessary alcohol. The person administrating drinks will hand over the drinks and make sure the participants breaths in before taking a sip, thereby inhaling alcohol vapour from the lid and keeping them blinded to the content.
223666247|NCT01781273|OTHER|Cranberry juice|100 mL cranberry juice is provided in a 250 ml container.
223666248|NCT04267601|DRUG|Anagliptin|Anagliptin treatment for 24weeks
223666249|NCT01246908|DRUG|Placebo|Placebo administered twice per day for six weeks.
223666250|NCT01246908|DRUG|CX157 (TriRima)|One tablet administered twice per day (total daily dose of 250 mg) for six weeks.
223666251|NCT03294577|DRUG|Pegfilgrastim|PEGFILGRASTIM is a long-acting granulocyte colony-stimulating factor that stimulates the growth of neutrophils, to reduce the incidence of fever and infection in patients with certain types of cancer who are receiving chemotherapy that affects the bone marrow.
224247728|NCT04384978|BEHAVIORAL|Play Solitary Games Without a Social Robot|Control Group: Group 2 will play solitary games (e.g., word puzzles) and activities but will have no interaction with Ryan.
224247729|NCT04630834|DRUG|Ibuprofen|Patients will receive both ibuprofen 10mg/kg weight based dosing with a max of 600mg
224247730|NCT04630834|DRUG|Acetaminophen|patients will receive acetaminophen 15 mg/kg weight based dosing with a max of 650mg
224247731|NCT04630834|DRUG|Placebo|patients will receive placebo 15mg/kg weight based dosing with a max of 650mg
224247732|NCT05905718|OTHER|assessment|Assessments of thoracic kyphosis angle, balance performance, and gait performance.
224247733|NCT02053454|DRUG|patisiran (ALN-TTR02)|Ascending doses administered by intravenous (IV) infusion
224247734|NCT02053454|DRUG|Sterile Normal Saline (0.9% NaCl)|Calculated volume to match active comparator
223666252|NCT03294577|DRUG|Plinabulin|Plinabulin (BPI-2358) is a synthetic, low molecular weight, new chemical entity that belongs to the diketopiperazine class of compounds. Plinabulin is intended for intravenous (IV) infusion and is diluted in D5W and administered for 30 minutes (± 5 minutes).
223666253|NCT03294577|OTHER|D5W Placebo|Placebo 250 ml D5W to match the administration of plinabulin diluted in 250 ml D5W
223666254|NCT03294577|DRUG|Docetaxel, doxorubicin, and cyclophosphamide (TAC)|Docetaxel is a type of chemotherapy medicine called an taxane. Doxorubicin is a type of chemotherapy medicine called an anthracycline. Cyclophosphamide is a type of chemotherapy medicine called an alkylating agent.
223666255|NCT04583137|DRUG|Lidocain|Layngeal direct fiberoptic examination transnasaly
223666256|NCT01214057|DRUG|Propofol and Remifentanyl|Anesthesia will be induced with lidocaine 0.5 mg kg, propofol infusion at 250 mcg/kg/min (to reduce visual bias of propofol infusion) and total volume infused will be adjusted for an induction dose of 2-3 mg/kg before bolus of muscle relaxant, rocuronium 0.5 mg kg in both SR and PR groups. Remifentanil infusion will be started at a rate of 0.4 mcg/kg/min 1-2 minutes before the propofol infusion and a 100 ml 0.9% normal saline bag will be used to blind surgeons in the sevoflurane group. The target mean arterial blood pressure (MAP) will be maintained at 70-80 mm Hg by adjusting the propofol concentration within their range (100-150 mg ml for propofol) according to the anaesthesiologist's judgement and by surgeon request. If this failed, the remifentanil rate will be adjusted by 0.05 mg kg min.
223666257|NCT01214057|DRUG|Sevoflurane and Remifentanyl|Sevoflurane 1-3% will be administered in group SR, and the infusion of propofol will be stopped. After intubation remifentanil infusion will be changed to 0.2 mcg/kg/min. The target mean arterial blood pressure (MAP) will be maintained at 70-80 mm Hg by adjusting the sevoflurane concentration within their range (between 1-3 vol% for sevoflurane) according to the anaesthesiologist's judgement and by surgeon request.If this failed, the remifentanil rate will be adjusted by 0.05 mg kg min.In order to limit the amount of fluids remifentanil wil be diluted at a concentration of 4 mg in 100 ml.
224247735|NCT00460733|DRUG|Risedronate sodium|Actonel® 35 mg (risedronate sodium) and 1000 mg of calcium and 400 UI of Vitamine D3
224247736|NCT00460733|DRUG|Calcium & Vitamine D3|1000 mg of calcium and 400 UI of Vitamine D3
224247737|NCT01067963|BEHAVIORAL|Computer assisted education and motivational interviewing.|9 study contact points. 3-week intervention using computer-assisted learning modules and telephone counseling using motivational interviewing.
224247738|NCT01067963|BEHAVIORAL|Group talks/social chat|9 study contact points. 3 group talk session on general topics about healthy lifestyle, printed power point handouts, telephone calls comprised of social conversation to discuss the handout content.
224247739|NCT05413096|COMBINATION_PRODUCT|Combination of diclofenac potassium and propolis|Patients will be divided into two groups: the first one will be treated with a combination of diclofenac 3% (10 mg/g, 60 g, EMS) and Propolis 5% gel and the second one is placebo group. Participants will be allocated randomly. The patients will be asked to apply gel 2 times per day. The patients will be instructed, not to eat or drink for 1 h after application of the gel
224247740|NCT05413096|OTHER|placebo|placebo
224247741|NCT03528187|OTHER|MRI|"MRI scan (not involving ionising radiation)~The MRI study will be conducted by a trained MR radiographer, supervised by the nominated researcher"
224247742|NCT03528187|OTHER|Written Consent|Student researcher or research nurses to take consent. Consent will be taken in the obesity clinic or radiology departments.
224247743|NCT01368991|DEVICE|Kryptonite|Osteoconductive biologic bone cement to be applied upon sternal closure
224247744|NCT01368991|PROCEDURE|Conventional closure|conventional closure, no kryptonite applied
223666258|NCT02402725|DRUG|Dexamethasone|(1 cycle = 28 days) D1: Dexamethasone 100mg IV; Dex 24mg PO every 6 hrs (begin immediately after IV dex) D2: Dex 24mg PO every 6 hrs D3: Dex 24mg PO every 6 hrs
224247745|NCT05146492|PROCEDURE|MRI|MRI with gadolinium contrast media injection
224247746|NCT05157477|BEHAVIORAL|CBT-based VR exporsure program|This project seeks to establish a 8-week CBT-based VR exposure program to tackle sensory problems in ASD according to the theory of exposure and desensitization (both social and non-social scenarios) as well as identifying dysfunctional thought and searching for alternative thinking. In brief, this program aims to build up the core competence of the ASD individuals in facing the sensory environment, including (1) Relaxation skills (2) Ranking the fearful sensory situations (3) Anxiety coping strategy (3) Graded exposure (4) Cognitive appraisal and restructuring: identifying the dysfunctional thought when facing the social situations and figuring out alternative thinking.
224247747|NCT06409377|DRUG|Precedex 200 MCG in 2 ML Injection|Patients received dexmedetomidine (1.5 μg/kg) as single injection over 10 minutes.
224247748|NCT06409377|OTHER|C group:|Patients received propofol (2 mg/kg), fentanyl (1 μg/kg), and atracurium (0.5 mg/kg).
224247749|NCT01811953|DRUG|Empagliflozin|medium dose oral administration
224247750|NCT01811953|DRUG|Metformin|oral administration
224247751|NCT01811953|DRUG|Empagliflozin|low dose of Empagliflozin oral administration
224247752|NCT01811953|DRUG|Empagliflozin/Metformin|low dose of Empagliflozin
223666259|NCT00002317|DRUG|Trimetrexate glucuronate|
223666260|NCT00002317|DRUG|Leucovorin calcium|
223666261|NCT03373331|BEHAVIORAL|Emotional Processing Training|Participants in the experimental group will receive computerized exercises administered on a laptop computer. They will undergo 12 sessions of 45-60 minutes each (twice a week for 6 weeks).
223666262|NCT03373331|BEHAVIORAL|Placebo Control Exercises|Participants in the control group will receive computerized control exercises administered on a laptop computer. They will undergo 12 sessions of 45-60 minutes each (twice a week for 6 weeks).
223666263|NCT00203814|DRUG|Sulfadoxine-pyrimethamine|
223666264|NCT00203814|DRUG|Artesunate plus sulfadoxine-pyrimethamine|
223770781|NCT02643524|BEHAVIORAL|Control|Patients are prescribed CAM boot. No nutritional or exercise guidelines will be provided. Patients will be given a diary to complete their daily meal intake and physician exercise (if any) and number of hours CAM boot is worn daily. Albumin lab test will be drawn and their height and weight measured.
224247753|NCT01811953|DRUG|Metformin|oral administration
224247754|NCT01811953|DRUG|Empagliflozin/Metformin|medium dose of Empagliflozin oral administration
224247755|NCT01811953|DRUG|Empagliflozin|medium dose oral administration
224247756|NCT01811953|DRUG|Metformin|oral administration
224247757|NCT01811953|DRUG|Empagliflozin/Metformin|medium dose of Empagliflozin oral administration
223666265|NCT01811264|BEHAVIORAL|Patient-Participation Aid|The PPA consists of a folder that addresses the three behaviors we hope to influence: agenda setting, asking questions, and making preferences known. The information inside contains sample questions for each section, with room for the patient to write her own questions. Each section models behavior by giving context for the items and specific example questions. It also addresses barriers to understanding by indicating that it is acceptable to ask questions when something is not clear or terms are unfamiliar.
223666266|NCT05798468|OTHER|Augmented reality|The intervention will be carried out in the Physiotherapy Degree of the Universities of Malaga and Cadiz. It will consist of the use of software and a platform that works with augmented reality. Previously a study of the demographic variable of the population that conforms the study will be carried out. During the intervention, teaching will be carried out with the support and enhancement of the use of augmented reality through Zapworks and Aumentaty. A study and analysis of the variables of the qualifications and usability of the study population will be carried out. For the qualification variable, the academic performance of the students will be taken into account and for the usability variable, the System Usability Scale will be used. Subsequently, an analysis and interpretation will be carried out to assess the correlation between both variables.
224247758|NCT05937451|OTHER|PRIME solution|The investigators will apply an AKI prediction model (PRIME solution) based on the patient's demographic. The investigators will collect data on vital signs, laboratory test results, medication history, and surgical records. The investigators provide information on whether AKI develops within 48 hours and the top 10 explanatory factors for predicting AKI to the physician.
224247759|NCT03579303|OTHER|Homoeopathic Remedies|comparison between homoeopathic treatment and integrated approach of homoeopathy and yoga in menstrual disorders of females with PCOS
224247760|NCT02110277|DEVICE|PAI/ultrasound Diagnostic Group|These patients will include women who are at risk for ovarian cancer and wish to undergo prophylactic oophorectomy, or who have an ovarian mass suggestive of a malignancy and are counseled to undergo oophorectomy.
224247761|NCT04336605|OTHER|Age & Development|Age, sex, pubertal onset and development
224247762|NCT04336605|OTHER|Socioeconomy|Family structure and economy
224247763|NCT04336605|OTHER|Traumatic Events|Violence and other traumatic events
224247764|NCT04336605|OTHER|Psychosocial conditions|Family/social support
224247765|NCT04336605|OTHER|Lifestyle|Physical activity, BMI, nutrition, smoking …
224247766|NCT04336605|OTHER|Chronic conditions|I.e. Epilepsy or juvenile rheumatoid arthritis ...
224247767|NCT04336605|OTHER|Somatic symptoms|Headache, pain, sleep disturbances ...
224247768|NCT04336605|OTHER|Psychological symptoms|PTSS, anxiety, depressive symptoms \& loneliness ...
224247769|NCT04336605|OTHER|Non-prescription analgesics|Non-prescription analgesics
224247770|NCT04336605|OTHER|Prescription drugs|Analgetic, sedative \& anxiolytic medication
224247771|NCT02007733|OTHER|Serial Weights|We will collect serial weights on all children enrolled in this study.
224247772|NCT02007733|OTHER|IVC/Aorta Ultrasound|We will perform an ultrasound assessment of the IVC and Aorta size in each child enrolled.
223666267|NCT05798468|OTHER|Control group|Traditional education will be carried out
224247773|NCT02007733|OTHER|Clinical Assessment|We will perform a clinical assessment of dehydration status in each child enrolled in the study, as well as collect data on mid-upper arm circumference, length, symptoms and demographic information.
224247774|NCT04741477|DRUG|CBD|CBD will be topically applied
224247775|NCT04741477|DRUG|THC|THC will be topically applied
224247776|NCT04741477|DRUG|Placebo|a placebo product (without cannabinoids) will be topically applied
224247777|NCT04198090|BEHAVIORAL|SGM Competency Training Program|A validated, two-hour long SGM curriculum created by the Fenway Institute and tailored for oncology
224247778|NCT00746850|PROCEDURE|early LC within 72 hours after the diagnosis with H (Harmonic)|early laparoscopic cholecystectomy within 72 hours after the diagnosis of acute cholecystitis with H (Harmonic scalpel)
224247779|NCT00746850|PROCEDURE|early LC within 72 hours after the diagnosis with MD (Monopolar Diathermy)|early laparoscopic cholecystectomy within 72 hours after the diagnosis of acute cholecystitis with MD (Monopolar Diathermy)
224247780|NCT04970368|PROCEDURE|Sentinel node procedure|Excision of ALL mapped nodes and other suspicious nodes regardless of mapping and label by anatomic location
224247781|NCT04970368|PROCEDURE|Selective staging|Intraoperative consultation (IOC)
224247782|NCT02046746|OTHER|Oral Nutritional Supplement (ONS)|renal specific commercially available ONS
224247783|NCT02286817|DRUG|NFC-1|Single-dose, open label administration to assess safety, tolerability, and pharmacokinetics in adolescents with ADHD and continuous daily administration for four weeks with weekly escalation to evaluate safety, tolerability, and impact on ADHD severity.
224247784|NCT00004359|DRUG|methoxsalen|
224247785|NCT04095117|PROCEDURE|Epidural block|"Epidural catheter will be inserted at the L3-L4 or L4-L5 interspace in obese subjects scheduled for surgery on the lower extremities under epidural anesthesia.~The sagittal abdominal diameter, BMI and skin to epidural space distance will be recorded."
224247786|NCT02380989|DEVICE|Ayurveda|Ayurveda combinations in the form of gel and patches were applied on acute pain site.
224247787|NCT02380989|DEVICE|Placebo|
223666268|NCT05253001|DEVICE|smartphone|Use the mobile chatbot approach for intervention groups to improve prenatal education.
223666269|NCT02942940|DEVICE|mobile app|The mobile app follow-up group will have no planned in-person follow-up, however these visits will be replaced with surgical site examination via submitted photos, Visual Analogue Scale (VAS), and Quality of Recovery - 9 questionnaire (QoR-9) and limb specific recovery monitoring. All information is submitted with the mobile app (QoC Health Inc, Toronto).
224247788|NCT04874389|DIAGNOSTIC_TEST|Multimodal Assessment|Participants will complete BISQ/health questionnaire and proceed to each testing station with 15 minute rest breaks in between randomly ordered assigned stations.
224247789|NCT01012934|DRUG|Alendronate Sodium Tablets, 70 mg|1 x 70 mg, single-dose fasting
224247790|NCT01012934|DRUG|Fosamax Tablets, 70 mg|1 x 70 mg, single-dose fasting
224247791|NCT04132011|DRUG|Extended Release Opioid Formulation, Shortened Intervals|Extended release opioid, individualized total daily dose, dosing interval is less than every 12 hours
224247792|NCT04132011|DRUG|Extended Release Opioid Formulation, Standard intervals|Extended release opioid, individualized total daily dose, dosing interval is every 12 hours
224247793|NCT04132011|DRUG|Placebo oral tablet|Lactose pill manufactured to mimic extended release opioid formulation
224247794|NCT06558656|DRUG|NTQ5082 capsule|"Part 1:The subjects are orally administered NT5082 capsules on an empty stomach in the first cycle and after a meal in the second cycle.~Part 2:The subjects are orally administered NT5082 capsules after a meal in the first cycle and on an empty stomach in the second cycle."
224247795|NCT02262377|BEHAVIORAL|Integrative Medicine Group Visits|Patients with chronic pain and depression attend group medical visits and use website and virtual patient advocate as part of the curriculum.
224247796|NCT05697419|BEHAVIORAL|deep breathing, muscle relaxation, and mindfulness|5-10-minute group sessions will be administered to DPT students teaching them the NIH recommended strategies of deep breathing, muscle relaxation or mindfulness.
224247797|NCT04115332|BIOLOGICAL|bio-feedback training|The aim of this study was to explore the abused PW nurses who receiving bio-feedback training as an intervention improve, and change of physiological indicators before and after intervention (3 months later), which included Respiratory Rate (RR), skin conduction (SC), heart rate variability (HRV), and resilience.
224247798|NCT06421870|DRUG|Dapagliflozin 10mg Tab|Patients will be given dapagliflozin 10 mg once daily
224247799|NCT06421870|DRUG|Pentoxifylline 400 MG|Patients will be given pentoxyifylline 400 mg twice daily
224247800|NCT05710562|OTHER|Name not applicable|In this study, we do not provide any type of intervention but only require the fulfillment of self-report tools by patients during their routine outpatients visit.
224247801|NCT02227186|OTHER|School-located Influenza Vaccination Clinic|Children in the intervention arm are enrolled in schools in Monroe County, NY that are offering school-located influenza vaccination clinics during school hours
224247802|NCT00000294|DRUG|Carvedilol|
224247803|NCT01604902|OTHER|4 mm punch biopsies|4 mm punch-biopsies from lesional and non-lesional psoriatic skin at day 0 and up to four times after treatment at the following days: 4, 14, 28 or 84.
223666270|NCT02942940|OTHER|conventional in-person|Patients in the conventional follow-up group will have a planned clinic follow-up at 2 and 6 weeks post-operatively, which is the schedule currently used by our surgeons. At these scheduled follow-up visits, patients will be asked to complete the VAS to assess pain and the QoR-9 in addition to recovery questions about their operated extremity.
223666271|NCT05185011|DRUG|TPN171H|10 mg TPN171H tablets，single dose
223666272|NCT00835211|DRUG|Desmopressin Acetate 0.2 mg Tablets|4 x 0.2 mg, single-dose fasting
223666273|NCT00835211|DRUG|DDAVP® 0.2 mg Tablets|4 x 0.2 mg, single-dose fasting
223666274|NCT02343549|DEVICE|NovoTTF100A|
223666275|NCT02343549|DRUG|Bevacizumab|
223666276|NCT02343549|DRUG|Temozolomide|
223666277|NCT00197548|DIETARY_SUPPLEMENT|Multivitamins-vitamins B-complex, C, and E|One daily oral dose of 20 mg of B1, 20 mg of B2, 25 mg of B6, 100 mg of niacin, 50 mcg of B12, 500 mg of C, and 30 mg of vitamin E from randomization until delivery. Participants may continue taking this intervention until 18 months post-partum if they are re-randomized to it after delivery.
224247804|NCT00953498|DRUG|pioglitazone|After randomization, patients will be treated by pioglitazone or rosiglitazone
223666278|NCT00197548|DIETARY_SUPPLEMENT|Placebo|One daily oral dose of a placebo pill taken from randomization until delivery. Participants may continue taking this intervention until 18 months post-partum if they are re-randomized to it after delivery.
223666279|NCT02543749|BIOLOGICAL|DC vaccine|Autologous DC pulsed with leukemia-associated peptides+adjuvant
223666280|NCT01040234|PROCEDURE|Bilateral dual TAP block|Bupivacaine 2.5 mg/ml 15 ml per injection. 4 injections per patient according to dual TAP block procedure
223666281|NCT02402998|DRUG|Eltrombopag|Eltrombopag 50 mg/daily.
223666282|NCT05483218|DEVICE|Nocturnal wrist orthosis wearing|Nocturnal wearing of one of the 2 wrist orthosis kind
223666283|NCT05253261|DIAGNOSTIC_TEST|Preoperative Cone Beam Computed Tomography (CBCT) scan|CBCT scans (Green X, Vatech, Hwaseong, Korea) are carried out prior to cystostomies. The scanning conditions are constant at 200 µm isotropic voxel size with 360° rotation, 94 kV tube voltage, 7.2 mA tube current and 9 s exposure time with a 15 × 8 cm field of view field of view (FOV).
224247805|NCT00953498|DRUG|rosiglitazone|treatment with rosiglitazone at a dose between 4mg and 8 mg/day
224247806|NCT03500003|OTHER|Acute milk intake|Food matrix: milk
223666284|NCT05253261|PROCEDURE|tooth removal and cystostomy|Surgical interventions are carried out in local anaesthesia. If it is deemed that a tooth or teeth included in the odontogenic cyst is of hopeless prognosis, it is removed at the time of cystostomy procedure. During cystostomy a bony window is created to accessthe cyst. The lining of the cyst is opened to accomodate the tube of the decompression appliance. A sample from the lining of the cyst is sent for histologic evaluation to confirm the diagnosis of odontogenic cyst.
223666285|NCT05253261|PROCEDURE|Decompression|The decompression appliances is delivered in the same sitting as the cystostomy. Patients are instructed on how to wear and clean their decompression device and are recalled for clinical examinations.
223666286|NCT05253261|DIAGNOSTIC_TEST|Postoperative Cone Beam Computed Tomography (CBCT) scan|Postoperative CBCT examination is performed six months into the decompression period using the same scanning conditions as those used for the preoperative CBCT scan.
224247807|NCT03500003|OTHER|Acute Yogurt intake|Food matrix: yogurt
224247808|NCT01721681|BIOLOGICAL|FACTOR X|
224247809|NCT00281749|PROCEDURE|TELEPHONE CALL|
224247810|NCT05338047|DRUG|Pegfilgrastim|Single 6mg dose of generic pegfilgrastim or brand name pegfilgrastim, at day +1 after autotransplant.
224247811|NCT03523039|DEVICE|CytoSorb® Hemoadsorption|The therapy is initiated within 6 hours from randomization and maintained for a minimum of 12 consecutive hours to a maximum of 24 consecutive hours.
224247812|NCT00371839|PROCEDURE|Audiological Evaluation|Tests of hearing, cognition, and speech perception
224247813|NCT06315530|DRUG|Telitacicept+SOC|160mg once a week for 48 weeks
224247814|NCT06315530|DRUG|SOC|SOC treatment includes aspirin and/or vitamin K antagonists (VKA) and/or low molecular weight heparin.
224247815|NCT05344872|OTHER|Weaning from mechanical ventilation|Weaning from mechanical ventilation post congenital cardiac surgery
224247816|NCT04712422|OTHER|Healthy subjects|"Participants will be tested for their foot dominance by means of the Waterloo footedness questionnaire-revised, their hand dominance by means of the Edinburgh inventory, and their eyedness Coren's Lateral Preference Inventory.~Participants will perform a cervical repositioning test. They will seat in a chair in front of a Plexiglas screen with the eye closed. The operator will guide the participant in four positions: at 30° right/left rotation and at 25° extension/flexion. The participant will be then asked to reproduce the angle. Each movement will be repeated four times in a random order. The whole sequence will be repeated by another second operator. Both the tests will be repeated after two weeks.~Head movements will be detected using an optoelectronic system using passive markers positioned on the head of the participant."
223666287|NCT05253261|PROCEDURE|Cyst Enucleation|Following the decompression period enucleation of the remaining cyst is carried out in local anaesthesia.
223666288|NCT00019383|BIOLOGICAL|aldesleukin|
223666289|NCT00019383|BIOLOGICAL|incomplete Freund's adjuvant|
223666290|NCT00019383|BIOLOGICAL|sargramostim|
223666291|NCT00019383|BIOLOGICAL|tyrosinase peptide|
223666292|NCT00019383|BIOLOGICAL|tyrosinase-related protein-1|
223666293|NCT01090323|DRUG|ICL670|Daily doses of ICL670 were taken orally 30 minutes before breakfast. The doses range from 5-40 mg/kg and were determined based on the patient's trend in serum ferritin over time during the core study (0109) and on the frequency of blood transfusions the patient received. The treatment duration was up to 4 years.
223666294|NCT05034822|DRUG|Ruxolitinib cream|Ruxolitinib 1.5% cream applied twice daily.
223666295|NCT00616499|DRUG|gefitinib|
223666296|NCT00616499|PROCEDURE|neoadjuvant therapy|
223666297|NCT00616499|PROCEDURE|therapeutic conventional surgery|
224247817|NCT04712422|OTHER|Pathologic group|"Clinical evaluation of the participants will be performed by means of the Myotonic Dystrophy Health Index (MDHI), the Rivermead Mobility Index (RMI), the Fall Events Questionnaire, and the Dizziness Handicap Inventory- short form (DHIsf).~Participants will perform a cervical repositioning test. Participants will seat in a chair in front of a Plexiglas screen with the eye closed. The operator will guide the participant in four positions: at 30° right/left rotation and at 25° extension/flexion. The participant will be then asked to reproduce the angle. Each movement will be repeated four times in a random order.~Head movements will be detected using an optoelectronic system using passive markers positioned on the head of the participant.~Participants will then perform test of balance in standing, using the EquiTest platform. Individuals will be requested to perform three different tasks: sensory organization test, adaptation test-upward tilt, and adaptation test-downward tilt."
224247818|NCT01830569|BEHAVIORAL|The EBMeDS system|"The EBMeDS system receives structured patient data from the electronic medical records in HealthOne and returns reminders, therapeutic suggestions and diagnosis-specific links to guidelines. Electronic forms and calculators (e.g. a calculator for glomerular filtration) are integrated in the system.~The original EBMeDS system was developed by Duodecim in Finland and covers a full spectrum of all clinical areas. Relevant reminders in all clinical areas are shown to the physicians in the intervention group."
224247819|NCT01830569|OTHER|Evidence Linker|The Evidence Linker is already integrated in Belgian routine practice since 2012 and could be considered as part of the usual care process. When entering a diagnosis coded in ICPC, relevant clinical practice guidelines are retrieved by the Evidence Linker and could by consulted on the initiative of the family physician.
223666298|NCT05498701|DRUG|Tafamidis free acid tablet (Test)|12.2 mg tafamidis free acid tablet (Test)
223666299|NCT05498701|DRUG|Tafamidis meglumine capsule (Reference)|Commercial 20 mg tafamidis meglumine capsule (Reference)
223666300|NCT01864005|DRUG|Ticagrelor|90mg tablets. loading dose of 180mg ticagrelor tablets (two 90mg tablets) taken orally, followed by 90mg of ticagrelor 12 hours after the first dose. Duration of treatment: 6 weeks.
223666301|NCT01864005|DRUG|Clopidogrel|75mg capsule. loading dose of 600mg clopidogrel capsules (eight 75mg capsules) taken orally, follow by 75mg of clopidogrel capsules orally od. Duration of treatment: 6 weeks.
223666302|NCT02451215|DEVICE|Laser Interstitial Thermotherapy (LITT)|Magnetic resonance imaging (MRI)-guided laser interstitial thermal therapy (LITT) is a minimally invasive surgical option to treat CNS tumors. LITT uses laser energy delivered to a target (i.e. CNS tumor) through a fiberoptic catheter, which results in damage to intracellular proteins and DNA, and subsequent cell death. LITT provides a sharp demarcation between ablated and unharmed tissue, which, when combined with the ability to monitor and control the ablation via MR thermal imaging, results in a high level of precision and control.
223666303|NCT03163797|DIAGNOSTIC_TEST|PET/MRI for evaluation|Before pretreatment, each enrolled patients will undergo PET/MRI and detail clinical examination, including human papillomavirus test. They will also undergo low dose chest CT on the same day before PET/MRI. In the posttreatment period, baseline whole body MRI will be obtained 3 months after chemoradiation. Thereafter, the patients will then be followed up also with alternative extend-field CT and whole body MRI by every 6 months. If tumor recurrence is confirmed or highly suspected, PET/MRI will also be performed for tumor re-staging.
223666304|NCT00380042|DEVICE|Cortical Stimulation|Cortical stimulation of prefrontal cortex
223666305|NCT00380042|DEVICE|Sham|Sham stimulation
223666306|NCT02668211|DEVICE|PROFEMUR Preserve Classic Femoral Components|
223666307|NCT00839033|DEVICE|mechanical insufflation - exsufflation|Patients will receive MI-E treatment with the following settings: insufflation pressure of at least +30 cm H2O and an exsufflation pressure ≥ -30 cm H2O. There will be at least 6 hyperinflation/exsufflation sequences per session of chest physiotherapy. There will be at least two daily sessions done routinely by the respiratory therapist at 8 hour intervals.
223666308|NCT00839033|DEVICE|Standard respiratory physiotherapy|Traditional chest physiotherapy without mechanical insufflation-exsufflation
223666309|NCT01962961|DIETARY_SUPPLEMENT|PharmaNAC (N-acetylcysteine)|"PharmaNAC is considered a nutritional supplement and can be obtained without a prescription. All participants will be asked to ingest two tablets twice per day during this trial. For those randomized to PharmaNAC 1800 mg twice daily, this will be two active tablets twice per day. For those randomized to PharmaNAC 900 mg twice daily, this will be one active tablet twice per day and one matching placebo tablet twice per day. For those randomized to placebo, this will be two matching placebo tablets twice per day.~PharmaNAC can be taken with or without food. The effervescent tablets should be dissolved in 8 oz. of water or juice prior to oral intake. Each participant will take study drug and/or matching placebo for 8 weeks (up to 60 days)."
224247820|NCT01771705|OTHER|Dose adjust group (NFAT)|If the average residual expression of the 3 cytokines is \<20%, the CNI daily dose will be reduced by 15%. If the average residual gene expression of the 3 cytokines is \> 60% the CNI daily dose will be increased by 15%.
224247821|NCT04221425|PROCEDURE|virtual reality rehabilitation system (VRRS)|experimental group is equipped with a telerehabilitation system which comprises a tablet (VRRS tablet) and a set of inertial magnetic sensors. participants are invited to follow a daily rehabilitation exercise program provided via VRRS tablet
224247822|NCT04221425|PROCEDURE|standard care|participants in the control group are invited to follow a daily rehabilitation exercise program and indications for the recovery as illustrated in the dimission booklets drawn up by the rehabilitation unit
223666310|NCT01962961|DIETARY_SUPPLEMENT|Matching placebo|Inactive pill that matches PharmaNAC on taste, color, and appearance.
224247823|NCT00063856|BIOLOGICAL|Wetvax (APSV)|
224247824|NCT00723528|DRUG|Placebo (CP)|Placebo 0.5 ml and 1.0 ml will be administered subcutaneously (SC) on Weeks 0 and 4 respectively during the controlled period (Weeks 0-12).
224247825|NCT00723528|DRUG|Ustekinumab 45 mg (CP)|Ustekinumab 45 mg (0.5 ml) and placebo (1.0 ml) will be administered SC on Weeks 0 and 4 during controlled period (Weeks 0-12).
224247826|NCT00723528|DRUG|Ustekinumab 90 mg (CP)|Ustekinumab 90 mg (1.0 ml) and placebo (0.5 ml) will be administered SC on Weeks 0 and 4 during controlled period (Weeks 0-12).
224247827|NCT00723528|DRUG|Placebo A (After CP)|After the controlled period (i.e., during the active drug treatment period \[Weeks 12-64\]), the placebo group will be randomized into 2 groups, including Placebo A, in which ustekinumab 45 mg (0.5 ml) and placebo (1.0 ml) will be administered SC at Weeks 12, 16, 28, 40, and 52.
224247828|NCT00723528|DRUG|Placebo B (After CP)|After the controlled period (i.e., during the active drug treatment period \[Weeks 12-64\]), the placebo group will be randomized into 2 groups, including Placebo B, in which ustekinumab 90 mg (1.0 ml) and placebo (0.5 ml) will be administered SC at Weeks 12, 16, 28, 40, and 52.
224247829|NCT00723528|DRUG|Ustekinumab 45 mg (After CP)|After the controlled period (i.e., during the active drug treatment period \[Weeks 12-64\]), participants in the ustekinumab 45 mg group will receive placebo (0.5 ml and 1.0 ml) SC at Week 12 followed by ustekinumab 45 mg (0.5 ml) and placebo (1.0 ml) SC at Weeks 16, 28, 40 and 52.
224247830|NCT00723528|DRUG|Ustekinumab 90 mg (After CP)|After the controlled period (i.e., during the active drug treatment period \[Weeks 12-64\]), participants in the ustekinumab 90 mg group will receive placebo (0.5 ml and 1.0 ml) SC at Week 12 followed by ustekinumab 90 mg (1.0 ml) and placebo (0.5 ml) SC at Weeks 16, 28, 40 and 52.
224247831|NCT04626856|BIOLOGICAL|Low dosage IRV on a 0- and 28-day schedule|Inactivated Rotavirus vaccine (Vero cell) of 80EU/0.5ml on day 0, 28
224247832|NCT04626856|BIOLOGICAL|Medium dosage IRV on a 0- and 28-day schedule|Inactivated Rotavirus vaccine (Vero cell) of 160EU/0.5ml on day 0, 28
224247833|NCT04626856|BIOLOGICAL|High dosage IRV on a 0- and 28-day schedule|Inactivated Rotavirus vaccine (Vero cell) of 320EU/0.5ml on day 0,28
224247834|NCT04626856|BIOLOGICAL|Low dosage IRV on a 0- and 28-day schedule|Inactivated Rotavirus vaccine (Vero cell) of 80EU/0.5ml on day 0,28
224247835|NCT04626856|BIOLOGICAL|Medium dosage IRV on a 0- and 28-day schedule|Inactivated Rotavirus vaccine (Vero cell) of 160EU/0.5ml on day 0,28
224247836|NCT04626856|BIOLOGICAL|High dosage IRV on a 0- and 28-day schedule|Inactivated Rotavirus vaccine (Vero cell) of 320EU/0.5ml on day 0,28
224247837|NCT04626856|BIOLOGICAL|Low dosage IRV on a 0- and 28-day schedule|Inactivated Rotavirus vaccine (Vero cell) of 80EU/0.5ml on day 0,28
224247838|NCT04626856|BIOLOGICAL|Medium dosage IRV on a 0- and 28-day schedule|Inactivated Rotavirus vaccine (Vero cell) of 160EU/0.5ml on day 0,28
224247839|NCT04626856|BIOLOGICAL|High dosage IRV on a 0- and 28-day schedule|Inactivated Rotavirus vaccine (Vero cell) of 320EU/0.5ml on day 0,28
224247840|NCT04626856|BIOLOGICAL|Low dosage IRV on a 0- and 28-day schedule|Inactivated Rotavirus vaccine (Vero cell) of 80EU/0.5ml on day 0,28
223666311|NCT01906996|PROCEDURE|proximal row carpectomy|excision of the scaphoid, lunate and triquetrum
224247841|NCT04626856|BIOLOGICAL|Medium dosage IRV on a 0- and 28-day schedule|Inactivated Rotavirus vaccine (Vero cell) of 160EU/0.5ml on day 0,28
223666312|NCT01906996|PROCEDURE|four corner fusion|excision of the scaphoid and stiffening of the lunate, capitate and triquetrum by a plate
224247842|NCT04626856|BIOLOGICAL|High dosage IRV on a 0- and 28-day schedule|Inactivated Rotavirus vaccine (Vero cell) of 320EU/0.5ml on day 0,28
224247843|NCT04626856|BIOLOGICAL|Low dosage IRV on a 0- , 28- and 56-day schedule|Inactivated Rotavirus vaccine (Vero cell) of 80EU/0.5ml on day 0,28,56
223666313|NCT03868644|BEHAVIORAL|Voluntary Counseling and Testing for HIV (VCT)|Youth are offered VCT conducted onsite via mobile clinics in accordance with Kenya National HIV Testing Guidelines by certified VCT counselors trained by the National AIDS and STI Control Program (NASCOP).
224247844|NCT04626856|BIOLOGICAL|Medium dosage IRV on a 0- , 28- and 56-day schedule|Inactivated Rotavirus vaccine (Vero cell) of 160EU/0.5ml on day 0,28,56
224247845|NCT04626856|BIOLOGICAL|High dosage IRV on a 0- , 28- and 56-day schedule|Inactivated Rotavirus vaccine (Vero cell) of 320EU/0.5ml on day 0,28,56
223666314|NCT03868644|BEHAVIORAL|Condoms|Youth are offered 50 packages containing 3 condoms each of Trust brand condoms free of charge.
224247846|NCT04626856|BIOLOGICAL|Placebo on day 0, 28|Two doses of placebo at the vaccination schedule of day 0,28
224247847|NCT04626856|BIOLOGICAL|Placebo on day 0, 28, 56|Three doses of placebo at the vaccination schedule of day 0, 28,56
223666315|NCT03472170|DIETARY_SUPPLEMENT|Enteral administration of bovine lactoferrin (bLf)|The pharmacy service of the hospital will provide the established dose of lactoferrin, according to the regimen of administration of 150 mg / kg / day (maximum 300 mg / day), as well as that of placebo. Both treatments will be administered in liquid form, in the least amount possible. Both the administration of lactoferrin and placebo will be carried out enterally, orally or by nasogastric tube. The intervention will be done in the first 72 hours of life, once a day, and for 4 weeks, extending to 6 weeks in the newborns with EG ≤ 28 weeks and / or birth weight ≤ 1000 gr, or until discharge if this happens before.
223666316|NCT03472170|OTHER|Enteral administration of placebo|Enteral administration of placebo with similar visual and gustatory characteristics in the first 72 hours of life, and for 4 weeks (6 weeks in the RN ≤ 1000 gr and / or EG ≤ 28 weeks).
223666317|NCT02184572|BIOLOGICAL|Priorix|1 dose administered subcutaneously in the triceps region of left arm at Day 0
224247848|NCT04719949|BEHAVIORAL|Behavioral Activation (BA) Therapy|Brief BA is a manualized individual psychotherapy adapted to a four-session structure for this pilot study. The first session provides psychoeducation about the value and reinforcement of various behaviors and treatment rationale. Three additional sessions include reviewing the youth's log of the activities they planned each week, assessing youths' values and planning further valued activities, and reviewing progress.
224247849|NCT04719949|BEHAVIORAL|Problem Solving Therapy (PST)|Brief PST is a manualized individual psychotherapy adapted to a four-session structure for this study. The first session provides psychoeducation on links between mood and managing social problems, as well as defining and identifying individual problems. Three additional sessions focus on generating solutions, decision making, implementing solutions, and evaluation and assessment of the outcomes of these solutions.
224247850|NCT02779894|OTHER|Remote control of patients|Diagnosis outside the hospital (3 Home PR) CPAP (if needed) titration at home REmote control of patient's during 3 months by video or phonoconference
224247851|NCT00406068|DRUG|Mycobacterial cell wall-DNA complex|8 mg MCC, intravesical - Induction Phase (6 weekly intravesical instillations) and Maintenance Phase (3 weekly instillations at months 3, 6, 12, 18 and 24).
224247852|NCT05564897|DRUG|H101, Camrelizumab|Patients receive a combination therapy of Camrelizumab 200 mg i.v. every 3 weeks with intravesical H101 with a dose of 5×10\*11 Vp weekly for 6 weeks for both induction and maintenance treatments up to 1 years.
224247853|NCT00164671|BEHAVIORAL|POWER|
224247854|NCT01993030|DEVICE|HQ® Matrix Medical Wound Dressing|
224247855|NCT01993030|DEVICE|Sidaiyi® wound dressing|
224247856|NCT01710657|DRUG|Lacosamide 50 mg|"* Active Substance: Lacosamide~* Pharmaceutical Form: Film-coated tablet~* Concentration: 50 mg~* Route of Administration: Oral use"
224247857|NCT01710657|DRUG|Lacosamide 100 mg|"* Active Substance: Lacosamide~* Pharmaceutical Form: Film-coated tablet~* Concentration: 100 mg~* Route of Administration: Oral use"
224247858|NCT01710657|DRUG|Placebo|Matching oral Placebo tablets twice daily for 16 weeks.
224247859|NCT05617222|OTHER|Bed rest|5 days of strict bed rest
224247860|NCT05617222|OTHER|Neuromuscular electrical stimulation|Unilateral neuromuscular electrical stimulation (m. Quadriceps)
224247861|NCT04196322|OTHER|observational study|observational study
224247862|NCT00881322|DIETARY_SUPPLEMENT|BC-130 (Gas Defense)|"Product Dosing:~Take one capsule daily, at approximately the same time of day, without regard to food (may be taken with or without food)~Gas Defense Serving Size: 1 tablet Active Ingredients: B. Coagulans, Enzyme Blend (Cellulase - Trichoderma longibrachiatum, Cellulase - Aspergillus niger, Hemicellulase, Alpha Galactosidase, Invertase) Inactive Ingredients: vegetable capsule, Magnesium Stearate, Silicon Dioxide, Maltodextrin Contains: Wheat, Fish."
224247863|NCT00881322|DIETARY_SUPPLEMENT|Placebo|"Product Dosing:~Take one capsule daily, at approximately the same time of day, without regard to food (may be taken with or without food)~Placebo - matched in size and color to the active product Inactive Ingredients: microcrystalline cellulose, FD\&C yellow #5 Lake, FD\&C blue #1 Lake, FD\&C red #46 Lake and vegetable capsule"
224247864|NCT02187562|DRUG|Meloxicam|
223666318|NCT02184572|BIOLOGICAL|M-M-R II|1 dose administered subcutaneously in the triceps region of left arm at Day 0
223666319|NCT02184572|BIOLOGICAL|Varivax|1 dose administered subcutaneously in the triceps region of right arm at Day 0
223666320|NCT02184572|BIOLOGICAL|Havrix|1 dose administered intramuscularly in the anterolateral region of the right thigh at Day 0
223666321|NCT02184572|BIOLOGICAL|Prevnar 13|1 dose administered intramuscularly in the anterolateral region of the left thigh at Day 0 to subjects recruited in US
224247865|NCT02187562|DRUG|Aspirin|
224247866|NCT00382694|DRUG|Fludarabine|
224247867|NCT03921294|DRUG|Emicizumab|bispecific monoclonal antibody binding to activated Factor IX and Factor X
224247868|NCT05865691|OTHER|biomarker assay|blood sample on the day of inclusion
224247869|NCT02601794|BEHAVIORAL|App-based Mindfulness Training|A commercially available mindfulness training app delivered to smartphone or tablet.
224247870|NCT01868529|DRUG|insulin degludec|Once daily dosing administered subcutaneously (s.c., under the skin) followed by a clamp visit. The two treatment periods will be separated by a wash-out period where the subjects will resume their normal insulin treatment.
224247871|NCT01868529|DRUG|insulin glargine|Once daily dosing administered subcutaneously (s.c., under the skin) followed by a clamp visit. The two treatment periods will be separated by a wash-out period where the subjects will resume their normal insulin treatment.
224247872|NCT00401089|DRUG|Panax Ginseng|The standardized extract of Panax Ginseng was formulated by Boehringer Ingelheim Pharmaton, Switzerland and fulfills the criteria of cGMP. Quality control and safety are monitored regularly by Boehringer Ingelheim Pharmaton.
224247873|NCT00535860|DRUG|Teriparatide|Daily for 96 days
224247874|NCT01263860|DRUG|Peginterferon alfa2a|patients receive a dose of 180 µg of PEGASYS once a week for 24 weeks
224247875|NCT01263860|DRUG|Ribavirin|patients receive a dose 800 to 1200 mg of ribavirin once a day(according to weight) for 24 weeks
224247876|NCT01263860|DRUG|Peginterferon alfa2a|patients receive a dose of 180 µg of PEGASYS once a week for 48 weeks
224247877|NCT01263860|DRUG|Ribavirin|patients receive a dose 800 to 1200 mg of ribavirin once a day(according to weight) for 48 weeks
224247878|NCT03966560|DRUG|Brimonidine Tartrate|Brimonidine tartrate 0.15% 1 eye drop, every day for 6-months
224247879|NCT03966560|DRUG|Dorzolamide (as Dorzolamide Hydrochloride) 20 Mg/mL and Timolol (as Timolol Maleate) 5 Mg/mL Eye Drops|Dorzolamide and timolol fixed combination 2 eye drops, every day for 6 months
224247880|NCT03966560|DRUG|Brinzolamide/Timolol 10 MG/1 ML-5 MG/1 ML Ophthalmic Suspension|Brinzolamide and timolol fixed combination 2 eye drops, every day for 6 months
224247881|NCT03966560|DRUG|Travoprost and Timolol|Travoprost and Timolol fixed combination 1 eye drop, every day for 6 months
224247882|NCT03966560|DRUG|Bimatoprost and Timolol|Bimatoprost and Timolol fixed combination 1 eye drop, every day for 6 months
224247883|NCT03966560|DRUG|Latanoprost|Latanoprost 0.005% 1 eye drop, every day for 6 months
224247884|NCT01033565|DRUG|Natrol|5mg of sustained released melatonin. One tablet given 30 minutes prior to bedtime.
224247885|NCT04828720|DRUG|ozonated oil|All patients in ozone group were asked to visit the clinic on a daily basis through the first week and have their allocated therapeutic medication applied to their particular palatal donor site wounds. The wounds were coated with 2 ml ozonated oil per day, with a concentration of 15 µg of ozone/ml of olive oil. Moreover, palatal wounds in control group were managed by compressing the donor site with gauze and periodontal pack was placed. Patients in ozone group used a soft stent to protect the palatal donor wound site and to retain the tested oils in the post harvested palatal wounds. Patients were instructed firmly not to shatter the stent for 1 week. The stent was removed and reseated only by the operator during the application of medications and collection of smears. One week postoperatively, the protective stents were discontinued.
224247886|NCT04769622|PROCEDURE|Non-surgical periodontal treatment|all included patients will be subjected to non-surgical periodontal therapy
223666322|NCT02495038|DRUG|10% reduction of combination of Esmeron® and Nimbex®|Patients were randomly assigned to each group by opening of sealed allocation envelope. After collection of data, allocation number was matched with each group. The participants matched at Group S were administered with NMBAs reduced 10% of each ED95. Before patients arrived in the operating room, rocuronium and cisatracurium were prepared by a nurse who was not involved in this study. Each drug dosage was determined by allocation number. The syringe containing each study drug was conveyed to the performer of this study as the status of shielding the scale. The syringes of rocuronium and cisatracurium used each other syringe.
224247887|NCT04769622|OTHER|Questionnaires|"All patients will be asked to complete a set of questionnaires regarding:~* adherence to Mediterranean Diet;~* sleep quality;~* physical activity;~* perceived stress."
224247888|NCT00893386|PROCEDURE|LV Lead Extraction|Removal of a LV lead using any tools \& techniques.
224247889|NCT05778422|DRUG|Suprascapular nerve block with bipuvacaine|Suprascapular nerve block with Bipuvacaine: a 50mm 22G needle (Stimuplex, BBraun) was introduced up to the suprascapular fossa, guided by ultrasound, and the location was confirmed by motor stimulation with contraction of the supraspinatus and infraspinatus muscles. Next, 5 ml of 0.25% bupivacaine with adrenaline was injected.
224247890|NCT05778422|PROCEDURE|Pulsed radiofrequency|After confirming the location, the needle mandrel was removed and the radiofrequency cannula was introduced through the needle, 2ml of 1% lidocaine without epinephrine was injected, followed by application of pulsed radiofrequency for 180sec at 42°C by radiofrequency (radiofrequency generator system BMS-50N, Bramsys).
224247891|NCT00152035|DRUG|Neutral salts of dextroamphetamine sulfate, USP, amphetamine sulfate, USP, d-amphetamine saccharate, d, l-amphetamine aspartate monohydrate.|
224247892|NCT03408119|DIETARY_SUPPLEMENT|Dried Plum|Dried plum fruit, 100g or 50g depending on treatment group randomized to
224247893|NCT03408119|DIETARY_SUPPLEMENT|800 IU vitamin D and 450mg elemental calcium|Supplemental vitamin D and calcium to protect against further bone loss
224247894|NCT01003002|DRUG|Levodopa (delivered intravenously)|One mg/kg/hr of Levodopa will be given intravenously during inpatient testing days from 0900 to 1100.
224247895|NCT03000296|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Hematopoietic stem cell transplantation Lymphoablation followed by hematopoietic stem cell transplantation to rescue the immune system.
224247896|NCT06340256|OTHER|Continuous spinal anesthesia|The Catheter will be then fed over the needle into the intrathecal space and Inserted 3cm cephalad into the subarachnoid space.The spinal needle and the modified Tuohy needle will be then removed, and a Luer connector and A filter previously filled with the anesthetic solution will be attached to the Catheter (priming volume 0.6ml). Plain bupivacaine 0.5% in 20ml vials will Be used CSA group received 1 ml(5 mg) of plain bupivacaine (0.5%) Together with fentanyl l25μg injected via the catheter at a rate of 0.2ml/15s. The level of the resulting sensory blockade will be tested using pin prick.
224247897|NCT06340256|OTHER|Continuous epidural anesthesia|The needle is advanced until the epidural space is identified by the loss-of-resistance technique, and then a 20G catheter is inserted 3 cm cephalad into the epidural space. a test dose of 3ml of 2% lignocaine with adrenaline (1:200000) will be injected into the catheter. Three minutes later, 10 ml of plain bupivacaine (0.5%) together with fentanyl l50μg will be injected via the catheter.
224247898|NCT05275985|DIAGNOSTIC_TEST|68Ga-FAPI Positron Emission Tomography-Computed Tomography|The patients with suspected pancreatic lesions were included. They underwent 68Ga-FAPI PET/CT to distinguish benign and malignant lesions, to evaluate the resectability of lesions and to detect distant metastasis. The treatment methods were decided according to the results of 68Ga-FAPI PET/CT.
223666323|NCT02495038|DRUG|20% reduction of combination of Esmeron® and Nimbex®|The participants matched at Group L were administered with NMBAs reduced 20% of each ED95.
223770782|NCT05899504|DEVICE|Over-The-Scope-Clip (OTSC) Stent Fix|A stent that of at least 4 cm longer than the stricture will be used to allow at least a 2-cm extension above and below the proximal and distal tumor margins. The stent positioned over a guidewire and deployed under fluoroscopy guidance and, in some cases, also under endoscopy guidance. Subsequently, the OTSC system will be loaded onto the scope and part of the upper rim of the stent will be suctioned into the transparent cap before releasing the OTSC, grasping both the SEMS and esophageal wall. We will avoid deploying the OTSC in areas of pulsations to prevent potential grasping of the vasculature structure
223666324|NCT01600625|DRUG|oral minocycline hydrochloride treatment|Orally received 50 mg minocycline (Minocin, SK chemical, Seoul, Korea) twice a day for 2 months treatment
223770783|NCT01493271|DRUG|Placebo|Placebo to RO5093151
223770784|NCT01493271|DRUG|RO5093151|oral doses twice daily for up to 28 days
223770785|NCT01093404|PROCEDURE|Thrombus aspiration|Aspiration of thrombus material before angioplasty
224247899|NCT03322709|PROCEDURE|kidney transplant|Transplantation of a kidney either by open surgery or robotic assisted laparoscopic surgery.
224247900|NCT01591785|DRUG|Retapamulin 1% ointment|Retapamulin 1% ointment for 5 days AND clobetasol propionate foam for 14 days
223666325|NCT04375540|PROCEDURE|Upper first premolars extractions|Fixed orthodontic treatment with upper first premolars extraction and space closure using 0.019X0.025 SS AW and elastic chain.
223666326|NCT04375540|PROCEDURE|Upper second premolars extraction|Fixed orthodontic treatment with upper second premolars extraction and space closure using 0.019X0.025 SS AW and elastic chain.
224247901|NCT01591785|DRUG|Placebo|Placebo ointment for 5 days AND clobetasol propionate foam for 14 days
224247902|NCT03827044|DRUG|Avelumab|Avelumab is a fully human monoclonal antibody (MoAb) of the immunoglobulin G (IgG) 1 subtype which specifically binds to the PD-L1 cell surface ligand and blocks its interaction with the PD-1 cell surface receptor.
224247903|NCT01523626|OTHER|Total body Computed Tomography.|"The CT protocol for the intervention group consists of a two-step whole-body acquisition (from vertex to pubic symphysis) starting with Head and Neck Non Enhanced CT (NECT) with arms alongside the body.~The preferred technique for the second complementary scan is a split-bolus intravenous contrast directly after repositioning of the arms alongside the head, and this second scan covers thorax, abdomen and pelvis. Participating centers however are free to choose their own technique as long as intravenous contrast is given for the chest and abdominal part of the TBCT."
224247904|NCT01523626|OTHER|Conventional imaging and selective CT scanning.|"The control group will be evaluated according to a conventional trauma protocol with X-rays (of the chest and pelvis), ultrasonography (Focused Assessment with Sonography for Trauma (FAST)) and selective CT scanning.~Indications for the selective CT scanning are pre-defined and based on the combined local protocols of the participating centers."
224247905|NCT02360982|BEHAVIORAL|propofol and esmeron(rokuronyum)|All patients were evaluated at postoperative 24th and 72th hours with laboratory tests including hemoglobin, sodium, potassium, BUN, creatinine, total protein, albumin and glucose values in blood samples and delirium tests (CAM and DRS-R-98).
224247906|NCT02360982|BEHAVIORAL|marcaine and fentanyl|All patients were evaluated at postoperative 24th and 72th hours with laboratory tests including hemoglobin, sodium, potassium, BUN, creatinine, total protein, albumin and glucose values in blood samples and delirium tests (CAM and DRS-R-98).
224247907|NCT00006365|RADIATION|brachytherapy|
224247908|NCT00006365|RADIATION|iodine I 125|
224247909|NCT00006365|RADIATION|radiation therapy|
224321775|NCT05811624|BEHAVIORAL|Physiotherapy intervention, including behavioral weight reduction program combined with pain neuroscience education and cognition-targeted exercise therapy.|"14 weeks, 18 treatment sessions~This includes:~* 3 sessions of Pain Neuroscience Education during the first two weeks (of which the second one will be held online). The aim is to to reconceptualize pain, to increase pain coping skills and to convince the patients that pain is in the brain, and that hypersensitivity of the central nervous system rather than local tissue damage contributes to their symptoms.~* 15 sessions which will focus simultaneously on cognition-targeted exercise therapy and behavioral weight reduction. The aim of the exercise program is to confront the patient with movements and activities that are feared, avoided and/or painful. The behavioral weight reduction program includes a lifestyle approach, with changes in diet, behavior, and a physical exercise weight loss program, all aiming for a caloric deficit of 500 to 700 kcal/day."
223666327|NCT04316832|BEHAVIORAL|Mindfulness based cognitive training|The mindfulness based cognitive training will include three short mindfulness exercises: a) a breathing exercise, b) a body scan exercise, and c) a mindfulness attention exercise.
223666328|NCT04316832|OTHER|Control exercise|Participants will listen to the first chapter of the audiobook The Hobbit, JRR Tolkien.
223666329|NCT00006409|BEHAVIORAL|Trial of Activity for Adolescent Girls (TAAG)|Intervention activities were designed to create (1) environmental and organizational changes supportive of physical activity and (2) cues, messages, and incentives to be more active. The intervention was designed to establish more opportunities, improve social support and norms, and increase self-efficacy, outcome expectations, and behavioral skills to foster greater moderate-vigorous physical activity (MVPA). An innovative feature of TAAG was linking school and community agencies to promote activity programs for girls. Finally, a TAAG Program Champion component was developed to foster sustainability after the 2-year staff-directed intervention. TAAG investigators recruited and trained Program Champions during the staff-directed intervention phase to promote maintenance of the program.
223666330|NCT05457621|OTHER|Effaclar serum|Effaclar serum has been formulated with an ultra-concentrated tri-acids complex for a synergetic action on skin and reinforced with soothing niacinamide for optimal tolerance. It acts in particular on imperfections and persistent marks due to acne.
223770786|NCT05234515|DIAGNOSTIC_TEST|Microbiology swab|Patients will have swabs taken from the nose, mouth, umbilical skin, groin skin, fistula(e), stoma(s) and vascular access device prior to surgery. Patients will be followed for 90 days postoperatively for surgical site infection (SSI) as defined by the centre for disease control (CDC) criteria 2021. Patients who develop an SSI will have both preoperative and postoperative samples sent for genome sequencing.
224247910|NCT06036082|OTHER|Conventional physical therapy|"* Standing with feet together .~* Step standing .~* High step standing and trying to keep balanced.~* Single leg stance unilateral standing with assistance.~* Standing on a declined surface by using wedge.~* Standing with manual locking of the knees.~* Changing position.~* Gait training.~* Static and dynamic muscle contraction."
224247911|NCT05312827|BEHAVIORAL|Training Intervention and Program of Support (TIPS) for fostering the adoption of family-centred telehealth interventions in pediatric rehabilitation|The proposed pre-post study will evaluate the implementation and effectiveness of a Training Intervention and Program of Support (TIPS) to enhance the adoption of family-centred telehealth in pediatric rehabilitation centres across Canada. TIPS is a multifaceted intervention, comprised of the following: 1) a 10-hour intensive training program offered to participating therapists at each site over a one-month period, including 4 hours of self-paced learning modules and a 6-hour mandatory interactive webinar; and 2) an 11-month program of support which is composed of monthly mentoring meetings at each site led by the local therapist champion, and a national virtual community of practice facilitated by 3 national knowledge brokers - an occupational therapist, a physiotherapist and a speech-language pathologist - experienced in family-centred telehealth in pediatric rehabilitation, offered simultaneously to all participating therapists across Canada.
223666331|NCT03367468|OTHER|Exercise|Strengthening exercises ( extrinsic and intrinsic foot muscles) Stretcthing exercises (plantar fascia, plantar flexor muscles)
223666332|NCT03367468|OTHER|Mobilization|Antero-posterior gliding, talocrural traction, metatarsal mobilization
223770787|NCT05234515|OTHER|Questionnaire|Patients will complete baseline preoperative questionnaires which will be repeated at 30 days and 90 days. These will evaluate generic and wound specific quality of life as well as decision conflict/decision regret.
223770788|NCT03208374|BEHAVIORAL|Prior Exercise Behavior Questions - Harvard Health Professionals Exercise Questionnaire|Participants will be asked how often on average over the year prior to their most recent diagnosis they participated in walking or hiking; jogging; running; calisthenics, aerobics, rowing, Nordic track; bicycling; tennis, squash, racquetball; lap swimming; weightlifting; and other aerobic exercise (e.g. heavy outdoor work), as well as their usual walking pace and flights of stairs climbed daily over the past 12 months prior to diagnosis.
224247912|NCT06377657|BEHAVIORAL|Exercise|The HIIT group underwent intervention with high intensity interval training. The second group was treated only with aloe vera supplementation for 12 weeks. A third group underwent a combination of HIIT and supplementation, while a fourth - CON group kept usual activities during the intervention duratino
224247913|NCT06377657|DIETARY_SUPPLEMENT|Aloe vera|Aloe Vera group was treated only with aloe vera supplementation for 12 weeks.
224247914|NCT03437304|BIOLOGICAL|Immunose™ FLU 1%|Quadrivalent influenza vaccine with 30 μg HA/strain and 1% Endocine™, dosing volume 200 μl, intranasal administration x 2
224247915|NCT03437304|BIOLOGICAL|Immunose™ FLU 2%, 200 μl|Quadrivalent influenza vaccine with 30 μg HA/strain and 2% Endocine™, dosing volume 200 μl, intranasal administration x 2
224247916|NCT03437304|BIOLOGICAL|Immunose™ FLU 2%, 300 μl|Quadrivalent influenza vaccine with 30 μg HA/strain and 2% Endocine™, dosing volume 300 μl, intranasal administration x 2
224247917|NCT03437304|BIOLOGICAL|Influenza antigen|Quadrivalent influenza vaccine with 30 μg HA/strain, dosing volume 200 μl, intranasal administration x 2
224247918|NCT03437304|DRUG|Placebo|NaCl dosing volume 200 μl, intranasal administration x 2
224247919|NCT03437304|BIOLOGICAL|i.m comparator|Quadrivalent influenza vaccine containing 15 μg HA/strain, 500 µl for intramuscular administration x 1
224247920|NCT00667862|DRUG|Panobinostat|
223666333|NCT00093405|DRUG|tanespimycin|
223666334|NCT05919706|BEHAVIORAL|Patient Education with Game-Based Mobile Technology and Motivational Interviewing|Education program, game-based mobile technology and motivational interview were applied to the patients in the experimental group. The patients' self-management, quality of life, and satisfaction level scores for the intervention were determined.
224247921|NCT05867095|PROCEDURE|Surgical navigation|Patients will be operated with assistance of a navigation system
224247922|NCT05867095|PROCEDURE|Conventional|Patients will be operated using the conventional technique
224247923|NCT01998217|DRUG|Remifentanil|Patients in Rem group receive sedation and analgesia with remifentanil, dose of which will be determined by the up-and-down method.
223666335|NCT03495778|OTHER|Test Granola|50.5 Test Granola
223666336|NCT03495778|OTHER|Control Granola|54.3 Control Granola
223666337|NCT04235010|DEVICE|Genius toothbrush|Patients brushed their teeth twice a day for 2 minutes. An integral timer was used in the genius toothbrush group.
223770789|NCT03208374|BEHAVIORAL|Current Exercise Behavior Questions: International Physical Activity Questionnaire Short Form (IPAQ SF)|The purpose of this questionnaire is to provide common instruments that can be used to obtain internationally comparable data on exercise exposure in adults aged 15 to 80 years old.
224247924|NCT01998217|DRUG|Flurbiprofen and remifentanil|Patients in this group receive sedation and analgesia with flurbiprofen and remifentanil, dose of which was determined by the up-and-down method.
224247925|NCT00158171|DRUG|Nicotine Replacement Therapies|Nicotine gum 2 \& 4 mg dependent on baseline smoking rate
224247926|NCT00158171|DRUG|Nicotine patch|21, 14 or 7 mg patch dependent on baseline smoking rate
224247927|NCT00158171|DIETARY_SUPPLEMENT|Folic Acid|400 mg
224247928|NCT00641420|PROCEDURE|Fractionated Laser Resurfacing|
223666338|NCT04235010|DEVICE|Manual toothbrush|Patients brushed their teeth twice a day for 2 minutes. During brushing, patients in manual group assigned to use their brushes were provided with a digital timer.
223666339|NCT04243382|BIOLOGICAL|Autologous umbilical cord blood|Single infusion of autologous umbilical cord blood cells
223666340|NCT04243382|BIOLOGICAL|Placebo|Placebo
223666341|NCT00496600|DRUG|Patupilone|RAD001 will be taken orally starting at a dose of 30 mg every week for the first cohort of patients, one hour prior to administration of patupilone. Patupilone will then be administered as an infusion, starting at 5 mg/m2 for the first cohort of patients. The dosage and scheduling of RAD001 and patupilone during each 21-day cycle will vary according to cohort assignment
224247929|NCT02713022|DEVICE|DEXA Scan|
224247930|NCT02713022|BEHAVIORAL|Godin Leisure Time Exercise Questionnaire (GLTEQ)|
224247931|NCT03958422|DRUG|cardiomyopeptidin|The main component of cardiomyopeptidin is the peptide active substance extracted from the ventricular myocytes of healthy young pigs.
224247932|NCT05174325|DRUG|Sintilimab + chemotherapy|Biological : Sintilimab 100mg: 10ml Method of administration: 200mg IV D1 Q3W. Drug: Cisplatin Injection Specification: 75mg/m2, IV D1 Q3W. Drug: Albumin Paclitaxel Injection specifications: 260mg/m2, IV D1 Q3W.
224247933|NCT04057222|OTHER|No intervention|Only propose water and wait for need to void
224247934|NCT05087524|DIAGNOSTIC_TEST|BinaxNOW Ag Card|A nasal swab specimen is collected from the participant, 6 drops of extraction reagent from a dropper bottle are added to the top hole of the swab well. The participant sample is inserted into the test card through the bottom hole of the swab well, and firmly pushed upwards until the swab tip is visible through the top hole. The swab is rotated 3 times clockwise and the card is closed, bringing the extracted sample into contact with the test strip. Test results are interpreted visually at 15 minutes based on the presence or absence of visually detectable pink/purple colored lines.
224247935|NCT00546897|DRUG|Lenalidomide|
224247936|NCT00242060|PROCEDURE|MRI|
224247937|NCT04905017|DEVICE|Transcatheter Tricuspid Valve Replacement|Replacement of the tricusupid valve using Trisol System in a transcatheter approach
224247938|NCT00846274|BIOLOGICAL|SK Antithrombin III|
224247939|NCT00126932|DEVICE|SonoPrep|
224247940|NCT00927303|DEVICE|Cirrus-Spectralis|512x128 cúbe program of Cirrus OCT first retinal volume 121 line of Spectralis OCT thereafter
224247941|NCT00927303|DEVICE|Spectralis-Cirrus|retinal volume program 121 lines Spectralis OCT first 512x128 program Cirrus OCT thereafter
224247942|NCT05229445|DEVICE|continuous glucose monitor based insulin bolus calculator|Participants will use the bolus calculator with meals to calculate their insulin bolus doses
224247943|NCT00905346|DRUG|Topiramate 25 mg Capsules|Topiramate Capsules 2 x 25 mg
224247944|NCT00905346|DRUG|Topamax® 25 mg Capsules|Topamax® Capsule 2 x 25 mg
224247945|NCT00905346|OTHER|Applesauce|Applesauce
224247946|NCT05238181|DIAGNOSTIC_TEST|Assess pyloric or pseudopyloric metaplasia of corpus by H&E stains|"The pathologists assess pyloric or pseudopyloric metaplasia. Pyloric or pseudopyloric metaplasia of corpus is defined as the presence of torturous deep glands in a pseudo-pylori pattern with focal or complete loss of parietal cells. The score of pyloric or pseudopyloric metaplasia of the corpus mucosa is ranging from 0 to 3. Score 0 is no loss of parietal cells with normal fundus gland patterns. Score 1 presents focal loss of parietal cells and scattered patterns of pyloric or pseudopyloric metaplasia with few forming pylorus-like glands. Score 2 presents focal loss of parietal cells and scattered patterns of pyloric or pseudopyloric metaplasia mixed with \>= 4 pylorus-like glands. Score 3 was clusters of pylorus-like glands; the metaplasia involves \> 60% of mucosa and extends to the lower third of mucosa."
224247947|NCT05238181|DIAGNOSTIC_TEST|Assess pyloric or pseudopyloric metaplasia of corpus by TFF2 immunohistochemistry stains|"Mouse anti-human TFF2 monoclonal antibody (R\&D Systems) is used to stain gastric corpus tissues to assess the presence and degree of SPEM. The score of TFF2 staining of the corpus mucosa is ranging from 0 to 3. Score 0 is not stained. Score 1 is a scattered pattern of TFF staining between parietal cells; the staining is limited in the middle third of the mucosa. Score 2 is TFF2-expressing cells distributed over both the middle and lower third of the glands. Score 3 is torturous gastric oxyntic glands with a diffuse expression of TFF2 into the whole glands over both the middle and lower third of the glands of the mucosa."
224247948|NCT05238181|DIAGNOSTIC_TEST|The assessment of corpus-predominant gastritis index (CGI), Operative Link for Gastritis Assessment (OLGA), and Operative Link on Gastric Intestinal Metaplasia assessment (OLGIM)|"We take five gastric mucosal biopsies in each patient under gastroscopy, including two from the antrum (at the lesser and greater curvature, 2 cm within the pylorus, respectively), two from the corpus (at the lesser curvature of the lower corpus and the greater curvature of the middle corpus, respectively), and one from the lesser curvature of the high corpus.~The pathologists assess the gastric pathology according to the updated Sydney system. Accordingly, the histological findings are translated into CGI, the Operative Link for Gastritis Assessment (OLGA), and the Operative Link on Gastric Intestinal Metaplasia Assessment (OLGIM) stages."
224247949|NCT01435265|BEHAVIORAL|Standard nurse education|Standard-of-care education from a dermatology nurse on the proper use of adalimumab
224247950|NCT01435265|BEHAVIORAL|Additional nurse education|Additional education from a nurse on the use of adalimumab. This will include discussion of the pre-study evaluation with the subject, design of an Individual Educational Plan based on the pre-study evaluation, and a 30-60 minute educational session with the nurse educator at each study visit. Additional information concerning the benefits of the local support group and National Psoriasis Foundation will be provided. Additional education on self-injection and the opportunity to practice self-injection under the supervision of a nurse will also be provided. Subjects will also receive reminder phone calls to take each scheduled dose.
224247951|NCT00946374|DRUG|Immunochemotherapy|R-CHOP: Rituximab 375 mg/m²,intravenous ( iv ), day 0 ; Cyclophosphamide 750 mg/m²,iv, day1; Vincristine 1,4 mg/m² but at the maximum 2 mg,iv,d1; Doxorubicin 50 mg/m², iv, d1; Prednisone 100 mg, peroral ( po ), day 1 to day 5
224247952|NCT00946374|DRUG|High-dose BEAM plus autologous SCT|High-dose BEAM: Carmustine 300mg/m², iv, day -7; Cytarabine 2 x 200 mg/m², iv, day -6 to day -3; Etoposide 2 x 100 mg/m², iv, day -6 to day -3; Melphalan 140 mg/m², iv, day -2 followed by Autologous stem cell transplantation ( \> 2,5 x 10e6 CD34 positive autologous stem cells, iv, day 0
224247953|NCT00946374|OTHER|HLA-identical allogenic SCT|Fludarabine 30 mg/m², iv, day -4 to day -2; Cyclosporin A 2 x 3mg/kg, iv, day -1 to day 0 plus total body irradiation with 2 Gy, day 0 followed by allogenic stem cell transplantation immediately after Radiation.
224247954|NCT05632874|BEHAVIORAL|relaxing breathing exercise|"Kumbhaka Pranayama, Sama Vritti Pranayama and box breathing breathing techniques will be applied to the patients."
224247955|NCT04381962|DRUG|Azithromycin Capsule|Azithromycin 500 mg OD PO 14 days
224247956|NCT00979303|DEVICE|Intracardiac echocardiography and 3D navigational system|Patients assigned to the intervention group will receive both intracardiac echocardiography as well as a 3D navigational system in addition to fluoroscopy during their ablation procedure.
224247957|NCT05757908|DRUG|Long-Acting Beta Agonist|The Investigator will prescribe standard of care LABA to eligible study participants. Participants will self-administer LABA once or twice daily at the maximum feasible standard of care dosage, per the time points specified in the study Schedule of Assessments. LABA should be taken within 1 to 3 hours prior to morning and evening at-home mobile Spirometry testing.
224247958|NCT00891800|DEVICE|Brachytherapy|SIR-Sphere contains radiation of Y-90.
224247959|NCT00891800|DEVICE|SIR-Sphere|Brachytherapy Radiation seeds
224247960|NCT04012112|DEVICE|thoracolumbar brace (Flexpine brace)|Patient's would wear the FLEXpine brace over 18 hours a day for the 6 month
224247961|NCT00909610|DRUG|Ursodiol|Ursodiol Tablets, 500 mg
224247962|NCT00909610|DRUG|Urso Forte™|Urso Forte™ Tablets, 500 mg
223666342|NCT00496600|DRUG|RAD001|RAD001 will be taken orally starting at a dose of 30 mg every week for the first cohort of patients, one hour prior to administration of patupilone. Patupilone will then be administered as an infusion, starting at 5 mg/m2 for the first cohort of patients. The dosage and scheduling of RAD001 and patupilone during each 21-day cycle will vary according to cohort assignment
223666343|NCT04781933|DIETARY_SUPPLEMENT|Treatment with Combo|Treatment with Combo
223666344|NCT04781933|OTHER|Treatment with placebo|Treatment with placebo
223666345|NCT00749814|DIETARY_SUPPLEMENT|Melatonin|Melatonin slow release tablets, 2 mg, 1 hour before bedtime for 7 days prior to admission to the hospital and up to 7 days after surgery.
223666346|NCT00749814|OTHER|Placebo tablets|Placebo
223666347|NCT05401942|OTHER|Tele-monitoring through mobile application|Tele-monitoring of Patient reported outcomes
223666348|NCT02350764|DRUG|nivolumab|
223666349|NCT02350764|DRUG|pilimumab|
223666350|NCT02057588|PROCEDURE|LV pacing site|Patient will be paced in VVI mode from Left ventricle specific position for a short period of time per position in order to cover spontaneous ventricular activity
224247963|NCT06279338|DRUG|Azacitidine Injection|On the basis of the conventional transplantation treatment regimen, combining azacitidine injection with BUCY2 conditioning regimen (azacitidine 75 mg/m2/d for -11 days to -5 days, cytarabine 2 g/m2 q12h for -8 days to -7 days, cyclophosphamide 1.8 g/m2/d for -6 days to -5 days, busulfan 3.2 mg/kg/d for -4 days to -2 days)
224247964|NCT05197634|OTHER|Not Applicable (observation)|Questionnaire
224247965|NCT02337218|DEVICE|SENSUS Pain Management System|An electrical stimulation device worn on a band around the leg. This device was determined to be non-significant risk by the FDA.
224247966|NCT04166552|DRUG|Patients will be randomized to receive EHP-101 or Placebo|EHP-101 or placebo will be taken once a day
224247967|NCT04166552|DRUG|Patients will be randomized to receive EHP-101 or Placebo|EHP-101 or placebo will be taken twice a day
224247968|NCT01623362|OTHER|Low-fluoride acidic dentifrice|550 ppm (mg/L) of sodium fluoride in pH 4,5; 12 months , 3 times a day.
224247969|NCT01623362|OTHER|conventional dentifrice|1100 ppm (mg/L) of sodium fluoride, pH 7 , 3 times a day for 12 months
224247970|NCT01623362|OTHER|neutral pH and low-fluoride dentifrice|500 ppm sodium fluoride, pH 7 , 3 times a day for 12 months
224247971|NCT06000709|DRUG|6% aqueous phenol|1.5 mL of aqueous phenol will be injected at each target genicular nerve under ultrasound guidance
224247972|NCT06000709|DRUG|MethylPREDNISolone 40 MG|40 mg of methylprednisolone diluted in 5 mL of 0.9% normal saline will be injected inside the knee joint capsule under ultrasound guidance
224247973|NCT06000709|DRUG|Intraarticular Knee Placebo|Single injection 1.5 mL of 0.9% normal saline outside the knee joint capsule under ultrasound guidance
223666351|NCT04193462|OTHER|Post-partum depression- Dyadic psychotherapy-|Mothers and infants will be treated with dyadic psychotherapy focused on interactions, emphasizing eye contact, body language, empathy, and social reciprocity. Dyadic psychotherapy will be administered one time a week during the 8-week trial period, at the subject's home. Each session, approximately 90 minutes long, will include videotaping mother-infant interaction, watching the last session's interaction as a part of video-feedback technique, and discussing main issues in the mother-infant relationship. In addition, each session will begin and end with a- 5-minute episode of affectionate touch and gaze synchrony between the mother and her infant. During the whole therapy-trial, the therapist will also use cognitive-behavioral approach to address the mother's perception of her infant and of herself as a mother.
223666352|NCT04193462|OTHER|Post-partum depression- Psycho-educational therapy|Mothers will receive a therapy in their homes for 8 weeks, 1.5 hours for each session by a therapist arriving at their home. Each session will address a different developmental aspects of the baby (feeding, movement, social-emotional development etc.). Therapist will ask the mother about her baby, will give information about developmental needs and expectations and will help mother to enrich child's development and deal will potential problems
223666353|NCT05549921|BIOLOGICAL|NY-ESO-1(TCR Affinity Enhancing Specific T cell Therapy)|NY-ESO-1(TCR Affinity Enhancing Specific T cell Therapy)
223666354|NCT00327821|BEHAVIORAL|calorie controlled diet|
223666355|NCT01328444|DRUG|GSK 573719 +GW642444 125/25|125mcg/ 25mcg
223666356|NCT01328444|DRUG|GSK573719 + GW642444 62.5/25|62.5mcg/25mcg
223666357|NCT01328444|DRUG|GSK 573719 125|125mcg
223666358|NCT01328444|DRUG|GSK 573719 62.5|62.5mcg
223666359|NCT01328444|DRUG|GW642444 25|25mcg
223666360|NCT01328444|DRUG|Plb|Comparator
223666361|NCT00246545|BEHAVIORAL|exercise|
223666362|NCT03614052|DRUG|Tamsulosin Hydrochloride 0.4 milligrams|Tamsulosin hydrochloride 0,4mg for 5 days before ureteroscopic treatment of urolithiasis
223666363|NCT03614052|DRUG|Placebo Oral Tablet|Placebo oral tablet 1 tablet per day for 5 days before ureteroscopic treatment of urolithiasis
223666364|NCT02161692|DRUG|Cyclophosphamide|
224247974|NCT06000709|DRUG|Genicular Nerve Placebo|1.5 mL of 0.9% normal saline will be injected subcutaneously at each target genicular nerve under ultrasound guidance
224247975|NCT04794283|OTHER|Breast milk|Milk substitute given during the first 24h
224247976|NCT05034757|OTHER|HA only|HA injection only
224247977|NCT05034757|OTHER|ESWT once|ESWT of the shoulder the patient will receives STORZ Extracorporeal Shock Wave Therapy 3000 impulses (each point) of shockwaves at 24kV (energy flux density, 0.32mJ/mm2) to the affected shoulder
224247978|NCT05034757|OTHER|ESWT twice|ESWT of the shoulder the patient will receives STORZ Extracorporeal Shock Wave Therapy 3000 impulses (each point) of shockwaves at 24kV (energy flux density, 0.32mJ/mm2) to the affected shoulder
223666365|NCT02161692|DRUG|Etoposide|
223666366|NCT02161692|DRUG|Cisplatin|
223666367|NCT02161692|DRUG|Bleomycin|
223666368|NCT02161692|DRUG|Carboplatin|High dose carboplatin
223666369|NCT03905044|OTHER|eyes with congenital cataracts|observation
223666370|NCT04475705|DRUG|propofol|intravenous propofol using Target Controlled Infusion 'Paedfusor' model 2-5 as the main anaesthetic to achieve Bispectral Index 40-60
223666371|NCT04475705|DRUG|sevoflurane|sevoflurane at Minimal Alveolar Concentration 0.7-1.3 as the main anaesthetic to achieve Bispectral Index 40-60.
223666372|NCT03347370|DRUG|SC Peginterferon beta-1a|All participants will be treated with their current SC interferon beta medication according to the Fachinformation (German equivalent to summary of product characteristics \[SmPC\]).
224247979|NCT00977522|DRUG|PF-03463275|30 mg Controlled Release tablet BID for 12 weeks
224247980|NCT00977522|DRUG|Placebo|Placebo tablet BID
224247981|NCT04786626|DIAGNOSTIC_TEST|Ultrasound evaluation|After vaginal, all patients were followed by traditional 2D US scanning and Doppler velocimetry on Days: 0, 2, 30, 60 and 90. Authors evaluated: scar diameter and Doppler velocimetry and resistance index (RI) of the uterine arteries, at their ascending branch
224247982|NCT00773422|DRUG|naltrexone|25 mg/day, with 1-week lead-in medication period. The starting dose is 0 mg/day for days 1-3, followed by 12.5mg/day for day 4, followed by 25mg/day for days 5-7, plus during the laboratory session (day 8).
224247983|NCT00773422|DRUG|varenicline|2mg/day, with 1-week lead-in medication period. The starting dose is 0.5mg/day for days 1-2, followed by 0.5mg twice daily for days 3-5, followed by 1.0 mg twice daily for days 6-7, plus during the laboratory session (day 8).
224247984|NCT00773422|DRUG|placebo|placebo
224247985|NCT05985317|PROCEDURE|Collagen membrane over BMAC/bovine graft in sinus lift|Collagen membrane to cover BMAC/bovine graft in sinus lift and evaluation of its effect on osteogenic potential of BMAC in sinus lift procedure
224247986|NCT05985317|PROCEDURE|PRF membrane over BMAC/bovine graft in sinus lift|PRF membrane to cover BMAC/bovine graft in sinus lift and evaluation of its effect on osteogenic potential of BMAC in sinus lift procedure
224247987|NCT04742790|DIAGNOSTIC_TEST|Scalp electroencephalography (EEG)|Resting EEG will be recorded before initiation of the combination treatment (visit 1) and 7-10 days after treatment (visit 2). Drug-induced sedation-related changes in the EEG frequency spectrum. Five minutes of resting EEG eyes-open will be recorded in a quiet room while participants are asked to focus on an image displayed on a wall. Then, they will be asked to close their eyes for an additional 2 minutes. The alpha power ratio eyes open/eyes closed will be computed (alpha attenuation coefficient; Kaida et al., 2006). Changes in this coefficient will be used as a measure of drug-induced sedation.
224247988|NCT04742790|DIAGNOSTIC_TEST|Laser-evoked potentials (LEPs)|Laser-evoked potentials (LEPs) will be recorded before (visit 1) and 7-10 after (visit 2) initiating the combination treatment. Short pulses (50-100 ms) of radiant heat generated by a C02 laser stimulator will be applied to the skin of the left or right hand dorm to briefly and selectively activate heat-sensitive pain receptors. A concomitant EEG recordings will be used to measure the amplitude and latency of the elicited laser-evoked potentials. Changes in LEP amplitude (expressed as percentage of change) will be used as a measure of drug-induced effects on the state of the thermonociceptive system.
224247989|NCT04742790|DIAGNOSTIC_TEST|Cognitive auditory-evoked potentials (P300)|Cognitive auditory-evoked potentials will be recorded before (visit 1) and 7-10 after (visit 2) initiating the combination treatment. Short-lasting auditory tones will be delivered using a three-stimulus oddball paradigm combining standard tones (90% of stimuli), slightly different target tones that the subject must attend and detect (10% of stimuli), and strongly different distractor non-target tones (10% of stimuli). The stimuli will be delivered binaurally using headphones. Participants will be instructed to press a button when they detect a target tone, and to ignore the standard and distractor non-target tones. The EEG recordings will be used to measure the amplitude and latency of the cognitive P3a and P3b potentials (Komerchero \& Polich 1999). Changes in P3a/P3b amplitude will be used as a measure of drug-induced effects on cognition (expressed as percentage of change).
224247990|NCT04742790|DIAGNOSTIC_TEST|Cervical somatosensory-evoked potentials|Cervical spinal-cord evoked potentials will be recorded before (visit 1) and 7-10 after (visit 2) initiating the combination treatment. The responses will be elicited by transcutaneous electrical stimulation of the median nerve. The N13 component of this response is mediated by large myelinated non-nociceptive fibers and reflects a segmental postsynaptic response of dorsal horn interneurons at the level of lumbar spinal cord (Cruccu et al., 2008). Changes in magnitude of the N13 will be used as a measure of drug-induced effects on spinal cord function (expressed as percentage of change).
224247991|NCT04742790|DIAGNOSTIC_TEST|Pupillometry|Pupillometry measurements will be performed before (visit 1) and 7-10 after (visit 2) initiating the combination treatment. Pupillometry has been proposed as a method to assess opioid pharmacodynamics. The extent of pupil dilatation can provide an index of nociceptive input via autonomic innervation of the iris muscles, while the extent of the attenuation of this pupillary response during exposure to opioid analgesics could provide an index of pharmacological effects reflecting the extent of opioid receptor occupancy in the CNS. Pupillometry (static pupil diameter, variability of pupil diameter \[variation coefficient of pupillary dilation, VCPD, Charier et al. 2017\]), light-evoked speed of pupil constriction \[maximum pupil constriction velocity, PCV, Connely et al., 2014\]) will be measured using a handheld pupillometry device routinely used for clinical evaluations.
224321776|NCT05811624|BEHAVIORAL|Physiotherapy intervention, including pain neuroscience education and cognition-targeted exercise therapy alone.|"14 weeks, 18 treatment sessions~This includes:~* 3 sessions of Pain Neuroscience Education during the first two weeks (of which the second one will be held online). The aim is to to reconceptualize pain, to increase pain coping skills and to convince the patients that pain is in the brain, and that hypersensitivity of the central nervous system rather than local tissue damage contributes to their symptoms.~* 15 sessions which will only focus on cognition-targeted exercise therapy. The aim of the exercise program is to confront the patient with movements and activities that are feared, avoided and/or painful."
223666373|NCT03347370|DRUG|SC interferon beta-1a|All participants will be treated with their current SC interferon beta medication according to the Fachinformation (German equivalent to summary of product characteristics \[SmPC\]).
223666374|NCT03347370|DRUG|SC interferon beta-1b|All participants will be treated with their current SC interferon beta medication according to the Fachinformation (German equivalent to summary of product.
223666375|NCT00700167|BIOLOGICAL|dendritic cell vaccine|"The vaccine will be split between as many as 10 injections, more or less. Each shot will be about 1/25th to 1/50th of a teaspoon (100 to 200 microliters). Each vaccine will be injected with a tiny needle just under your skin. This will usually cause a very small area of swelling at the injection site that may last for a few minutes to an hour or so. You will receive two additional booster doses of the same vaccine every 4-6 weeks. This would mean that you receive a total of three vaccines over about 2-3 months."
223666376|NCT03859947|DEVICE|Heated humidiﬁed high-flow nasal cannula|Non-invasive ventilation with a nasal cannula
224247992|NCT04742790|DIAGNOSTIC_TEST|Saccadic Peak Velocity|The saccadic peak velocity (SPV; m/s) will be measured before before (visit 1) and 7-10 after (visit 2) initiating the combination treatment. Saccadic peak velocity is one of the most sensitive parameters for sedation. Recording of eye movements will be performed in a quiet room with dimmed lightning. Average values of saccadic peak velocity (expressed as degrees/second) of all correct saccades will be measured.
224247993|NCT04742790|DIAGNOSTIC_TEST|Adaptive tracking test|The test will be performed before (visit 1) and 7-10 after (visit 2) initiating the combination treatment. Adaptive tracking is a pursuit-tracking task sensitive to impairment of eye-hand coordination by drugs. It has been proven useful for measuring CNS effects of alcohol, various other psychoactive drugs, and sleep deprivation.
224321777|NCT01282697|DRUG|Combined administration of irinotecan and rapamycin|This phase I trial is a dose escalation study of irinotecan + rapamycin with a 3+3 statistical design.
224247994|NCT04742790|DIAGNOSTIC_TEST|Body Sway Test|Body sway will be assessed before (visit 1) and 7-10 after (visit 2) initiating the combination treatment, using a body sway meter and with eyes closed. The body sway meter allows measurement of body movements in a single plane, providing a measure of postural stability. The method has been used to demonstrate effects of sleep deprivation, ethanol and psychoactive drugs. All body movements over a 2-min period are integrated and expressed as millimeters of sway.
224247995|NCT04742790|DIAGNOSTIC_TEST|N-back working memory test|"Working memory performance will be assessed before (visit 1) and 7-10 after (visit 2) initiating the combination treatment. In this test, a series of letters are shown to the participant on a computer screen. The test includes three conditions with increased working memory load. The 0-back condition simply requires to indicate whether the presented letter is the letter X or another letter. In the 1-back condition, participants are requested to indicate whether the displayed letter is identical to the preceding letter. In the 2-back condition, participants are required indicate whether the letter is repeated with one other letter in between (e.g., B … C … B)."
224247996|NCT04742790|OTHER|Patient-reported outcomes|Before (visit 1) and 7-10 after (visit 2) initiating the combination treatment, but also daily between the two visits, 14 days, 1 month, 3 months and 6 months after treatment initiation, patient-reported outcomes will be collected to assess clinical effects and side-effects of the combination treatmen These include the short form of the Brief Pain Inventory (BPI), the PROMIS PQ-NEURO score for neuropathic pain, the Stanford Sleepiness Scale (SSS), and the PROMIS Neuro-QOL self-assessment of cognitive functioning.
224247997|NCT05318365|DRUG|Polyethylene Glycol 3350|PEG3350, klysma, laxoberal and magnesia will be administered in accordance with actual guidelines for treatment of constipation in children
224247998|NCT05318365|BEHAVIORAL|Urotherapy|Information and demystification of the disorder along with behavioural modification such as timed voiding, proper voiding posture, avoidance of holding manoeuvers and balanced fluid intake
223666377|NCT01109732|OTHER|Systematic physical training with instructor|Training 3 times per week for 6 months, the first 3 months with an instructor
223666378|NCT03171753|DIAGNOSTIC_TEST|questionnaire|questionnarie will be performed before the application of headphone and after their removal.
223666379|NCT03171753|DIAGNOSTIC_TEST|laboratory test|laboratory test will be collected before the application of headphone and after their removal. the cardiac monitoring will be performed during the all study period
223666380|NCT03171753|DIAGNOSTIC_TEST|cardiac monitoring|the cardiac monitoring will be performed through study period
224247999|NCT04721795|DRUG|Atorvastatin with standard anti tuberculosis drugs|Participants will receive oral 30/40mg of atorvastatin daily for 2 months together with oral doses of standard antituberculosis drugs consisting of Rifampicin, INH, Ethambuthol and pyrazinamide for 2months. At the end of 2months, participants will continue with only standard anti tuberculosis drugs, Rifampicin and INH for 4months.Doseage of antituberculosis drugs are dependent on weight
224248000|NCT04721795|DRUG|Standard anti tuberculosis drugs only|Participants will receive oral doses of standard antituberculosis drugs consisting of Rifampicin, INH, Ethambuthol and pyrazinamide for 2months. At the end of 2months, participants will continue with only standard anti tuberculosis drugs, Rifampicin and INH for 4months.Doseage of antituberculosis drugs are dependent on weight
224248001|NCT00561834|DRUG|ranibizumab|All patients (n=15) will be treated with open label 0.5mg ranibizumab given intravitreally monthly as needed for 6 months.
224248002|NCT00944424|DRUG|Docetaxel + High dose Vitamin D2|Docetaxel + High dose Vitamin D2
224248003|NCT00944424|DRUG|Docetaxel + Standard dose Vitamin D2|Docetaxel + Standard dose Vitamin D2
224248004|NCT00530725|PROCEDURE|chest drainage|may be a chest tube of chest drainage procedure of any type (ie formal tube, pig-tail catheter, etc)
224248005|NCT00530725|OTHER|close clinical observation|close clinical observation in an operating room or intensive care unit without active intervention
224248006|NCT05612724|DEVICE|Testing for SARS CoV2 Antigen|Device: Testing for SARS CoV2 Antigen Antigen testing: Rapid Antigen testing (Point-of-care)
224248007|NCT05001022|DRUG|ALG-020572|Single or multiple doses of ALG-020572
224248008|NCT05001022|DRUG|Placebo|Single or multiple doses of Placebo
224248009|NCT05290961|OTHER||The study is an observational trial, which don't have any intervention.
224248010|NCT06376656|BEHAVIORAL|Cognitive stimulation|"The cognitive stimulation will comprise of psychoeducation, videogaming, book club and technology training workshop sessions. Participants will take part in weekly sessions that are an hour long each.~For every six months, the participants will alternate between psychoeducation, videogaming, book club and technology training workshop sessions."
224248011|NCT06376656|BEHAVIORAL|Physical activity|"The physical activity intervention will comprise of walking, Zumba, resistance exercise and aerobics sessions. Participants will take part in weekly sessions that are an hour long each.~For every six months, the participants will alternate between walking, Zumba, resistance exercise and aerobics sessions until the end of intervention period."
224248012|NCT02128997|DEVICE|Closed incision wound vacuum (Prevena)|wound vacuum to be placed on a closed incision
224321778|NCT02479204|DRUG|ACT-334441 2 mg|capsule containing ACT-334441 at a strength of 2 mg
223666381|NCT03171753|DIAGNOSTIC_TEST|skin resistance|the skin resistance monitoring will be performed through study period
223666382|NCT03171753|DEVICE|Music listening|Listening prerecorded music through an individual headset for 30 min
223666383|NCT03171753|DEVICE|No sound|No sound through an individual headset for 30 min
223666384|NCT05731011|OTHER|antioxidative stress|blood interventions
223666385|NCT05731011|DEVICE|electrotherapy|hotpack,Tens, ultrasound
223666386|NCT03531632|BIOLOGICAL|MGD007 + MGA012|MGD007 and MGA012 are administered by IV infusion.
223666387|NCT03635450|BIOLOGICAL|Infusion of hCT-MSC|Infants who meet enrollment criteria for moderate to severe hypoxic ischemic encephalopathy will receive 1 infusion of hCT-MSC within the first 48 postnatal hours. hCT-MSCs are a product of allogeneic cells manufactured from digested umbilical cord tissue that is expanded in culture, cryopreserved and banked. hCT-MSCs are manufactured from umbilical cord tissue donated to the Carolinas Cord Blood Bank, an FDA-licensed, FACT-accredited, public cord blood bank at Duke University Medical Center, after written informed consent from the baby's mother. Cord tissue is harvested from the placentas of male babies delivered by elective C-section after a normal, full- term pregnancy.
223666388|NCT00213993|DRUG|antiperspirant|antiperspirant topically once daily to one foot
224248013|NCT03644693|DIETARY_SUPPLEMENT|Nutritional Formulation Containing Exogenous Ketones|A nutritional formulation providing beta-hydroxybutyrate, 2g of carbohydrate, 1g of protein, and 9g of fat, plus minerals, per 100kcal. Given orally as food or beverage three times daily.
224248014|NCT03644693|DIETARY_SUPPLEMENT|Placebo Formulation|A placebo formulation providing similar amounts of carbohydrates, proteins and minerals as the nutritional formulation. Given orally as food or beverage three times daily.
224248015|NCT00139711|DRUG|Irinotecan|
224248016|NCT00139711|DRUG|Docetaxel|
224248017|NCT00747097|DRUG|gemcitabine + cetuximab|gemcitabine 1g/m² 3weeks/4 cetuximab 400 mg/m² the first week, then 250 mg/m², every week Every cycle is 8 weeks treatment
224248018|NCT03848286|DRUG|KL-A167 Injection|KL-A167 900 mg intravenously (IV) every-2-weeks (Q2W)
224248019|NCT03112863|DRUG|Bakuchiol|This group will receive bakuchiol
224248020|NCT03112863|DRUG|Retinol|This group will receive retinol
224248021|NCT00520923|DRUG|LY2140023|80mg, PO (by mouth) BID (twice a day) for up to 4 weeks.
224248022|NCT00520923|DRUG|LY2140023|40mg, PO (by mouth) BID (twice daily) for up to 4 weeks.
224248023|NCT00520923|DRUG|LY2140023|20mg, PO (by mouth) BID (twice daily) for up to 4 weeks.
224248024|NCT00520923|DRUG|LY2140023|5mg, PO (by mouth) BID (twice daily) for up to 4 weeks.
224248025|NCT00520923|DRUG|Olanzapine|10mg, PO (by mouth) QPM (every evening) for the first 3 days, then 15mg PO QPM, for up to 4 weeks.
224248026|NCT00520923|DRUG|Placebo|Taken PO (by mouth) QAM (every morning) for up to 4 weeks.
224248027|NCT00520923|DRUG|Placebo|Taken PO (by mouth) BID (twice daily) for up to 4 weeks.
224248028|NCT01969747|DRUG|Empagliflozin medium placebo|Empagliflozin medium placebo
224248029|NCT01969747|DRUG|Empagliflozin low placebo|Empagliflozin low placebo
224248030|NCT01969747|DRUG|Empagliflozin low placebo|Empagliflozin low placebo
224248031|NCT01969747|DRUG|Empagliflozin high placebo|Empagliflozin high placebo
224248032|NCT01969747|DRUG|Empagliflozin medium|Empagliflozin medium
224248033|NCT01969747|DRUG|Empagliflozin medium placebo|Empagliflozin medium placebo
224248034|NCT01969747|DRUG|Empagliflozin high placebo|Empagliflozin high placebo
224248035|NCT01969747|DRUG|Empagliflozin high placebo|Empagliflozin high placebo
224248036|NCT01969747|DRUG|Empagliflozin medium placebo|Empagliflozin medium placebo
224248037|NCT01969747|DRUG|Empagliflozin low placebo|Empagliflozin low placebo
224248038|NCT01969747|DRUG|Empagliflozin low|Empagliflozin low
224248039|NCT01969747|DRUG|Empagliflozin high|Empagliflozin high
224248040|NCT04123808|DEVICE|IpsiHand Treatment|The IpsiHand system utilizes a Brain-Computer Interface (BCI) as a control for a robotic hand orthosis donned on the affected upper extremity as participants are guided through a rehabilitation program on a tablet. Participants will complete 16-32 weeks of home therapy with the IpsiHand system. Motor function of their impaired upper extremity will be evaluated at baseline, at 4-week intervals, and 3 months post no-device use, to track progress.
224248041|NCT04000815|DIAGNOSTIC_TEST|C Type Natriüretic Peptide|C Type Natriuretic Peptide will be measured with elisa method
224248042|NCT03197285|OTHER|EYE-CERVICAL RE-EDUCATION PROGRAM|"Subjects received a total of ten sessions on alternate days.~This includes a total of 10 exercises that has proprioceptive reprogramming in the cervical area with the following phases:~1. To stimulate ocular mobility without including the cervical movement. The patient was placed in the supine position and the physiotherapist seated, at the height of the head.~2. To exercise cervical mobility with restricted eye movement. The patient is placed on a rotating stool. The ocular mobility is excluded with opaque glasses that allowed exclusively the foveal vision~3. Finally we stimulate eye and neck movement coordination. The patient continued to sit on the stool, this time without the glasses."
223666389|NCT04484571|DEVICE|Neuroexsos elbow module|The treatment group will be further divided into two levels (sub-groups), based on pathological severity: Level 1 corresponds to an FM score equal or below 28, and Level 2 with FM greater than 28. The two sub-groups will receive different combinations of robotically assisted passive mobilization (PM) and active mobilization (AM) treatment modalities, according to their differing clinical needs
224248043|NCT03197285|OTHER|Combined Physiotherapy Protocol|Thermotherapy (70 w continuous microwave for 10 minutes), therapeutic massage (surface rubbing for 5 minutes, 10 minutes of compression and kneading massage and 2 minutes of final surface friction), application of analgesic currents (TENS, by self-adhesive silicone electrodes 4x4 cm, symmetrical biphasic rectangular current, 200 µs width pulse, a frequency of 1 Hz for 10 minutes. The patient should notice a slight vibration, without it being painful).
224248044|NCT03174847|PROCEDURE|Adrenalectomy|Adrenalectomy for unilateral adrenal hyperplasia / adenoma
224248045|NCT03174847|DRUG|Mineralocorticoid Receptor Antagonists|Medical treatment with MRA / amiloride
224248046|NCT03934047|DRUG|Tranexamic Acid 100 MG/ML|Visual Field Infiltration of Tranexamic Acid during the operation of total knee replacement.
224248047|NCT01232647|DRUG|Phylloquinone|1.0 mg daily of vitamin K1
224248048|NCT01232647|DRUG|Menatetrenone (MK4)|Menatetrenone (MK4) 45 mg daily
224248049|NCT01232647|DRUG|placebo|placebo vitamin K1 and placebo MK4 given daily for 18 months
224248050|NCT06110377|PROCEDURE|MESOTHERAPY (INJECTIONS WITH SYRINGE AND NEEDLE)|After the anesthetic block, dutasteride will be injected using syringes and needles into the area of alopecia.
224248051|NCT06110377|PROCEDURE|MMP (INJECTIONS WITH A TATTOO MACHINE)|After the anesthetic block, dutasteride will be injected through needling performed by a tattoo machine in the area of alopecia.
224248052|NCT00239577|BIOLOGICAL|Live attenuated tetravalent dengue vaccine|Live attenuated tetravalent dengue vaccine
224248053|NCT00239577|BIOLOGICAL|Placebo|Placebo
224248054|NCT06118047|DRUG|Crisaborole Ointment|Crisaborole ointment to be applied twice daily.
224248055|NCT06118047|DRUG|Cetuximab|Cetuximab
224248056|NCT02778451|OTHER|Measurement of competence|This study is a psychometric validation of a generic assessment tool to evaluate ultrasonography competence among surgeons
224248057|NCT02631772|DRUG|Sofosbuvir/Ledipasvir x 12 weeks|
224248058|NCT02631772|DRUG|Sofosbuvir/Ledipasvir + Ribavirin x 12 weeks|
224248059|NCT03622801|DRUG|Iopromide (Ultravist, BAY86-4877)|Patients who have received Iopromide (iodine concentrations of 300 mg/mL or 370 mg/mL) either intra-venously or intra-arterially.
224248060|NCT03143686|DEVICE|ACURATE TA™ Transapical Aortic Bioprosthesis|ACURATE TA™ Transapical Aortic Bioprosthesis is intended for subjects with severe symptomatic aortic stenosis and are considered high risk for surgical conventional Aortic Valve Replacement.
224248061|NCT02811666|DEVICE|Assessment of sarcopenia by CT-Scan|
224321779|NCT02479204|DRUG|ACT-334441 4 mg|capsule containing ACT-334441 at a strength of 4 mg
224248062|NCT02811666|DEVICE|hand gauge|
224248063|NCT05852886|DEVICE|Enable Oral Hygiene System (EOHS)|The Enable Oral Hygiene System (EOHS) is a manual toothbrush comprised of a handle and shaft with multiple surfaces of synthetic bristles extending off of the shaft at one end.
224248064|NCT02659358|DEVICE|Fitbit Charge HR®|A wrist worn biosensor, the Fitbit Charge HR® has sensor capability, good battery life, water resistant, Bluetooth capabilities, and provides accessible data.
224248065|NCT00725517|DRUG|Icodextrin|Icodextrin was used instead of Dianeal for long dwell time every day for 5 weeks.
224248066|NCT01488058|OTHER|OxIGen + iCBT|OxIGen is an Internet-based intervention taking place over 1 week followed by iCBT, an Internet-based treatment for depression taking place over 10 weeks.
224248067|NCT01488058|OTHER|Waitlist Control|Waitlist will receive iCBT at week 11
224248068|NCT00439634|DRUG|AVE1625|oral administration
224248069|NCT00439634|DRUG|placebo|oral administration
224248070|NCT01931007|DRUG|Autologous Bone Marrow Aspirate Concentrate|Autologous Bone marrow aspirate will be concentrated using Magellan Cell Separator and stem cell kit according to the Standard Operating Procedures is to be injected in the treatment knee. 5ml of treatment cells will be combined with 10 ml of previously separated platelet poor bone marrow plasma and used for injection under ultrasound guidance into one of the subject's painful knees.
224248071|NCT01931007|DRUG|Sterile saline|Bacteriostatic 0.9% sodium chloride, preservative free manufactured by Hospira will be injected into the control knee.
224248072|NCT03863002|BIOLOGICAL|Mesenchymal Stem Cell|Mesenchymal stem cell transplantation via peripheral vein: 1.0-10x10\^5 MSCs/kg body weight administered via peripheral vein at week 0, 1, 2, 3 weeks
224248073|NCT02736721|DRUG|Peginterferon alfa-2a|Peginterferon alfa-2a in doses between 90 and 450 mcg will be administered subcutaneously once weekly until medically indicated as judged by the treating investigator.
224248074|NCT03988803|DRUG|BI 425809|Film coated tablet
224248075|NCT03988803|DRUG|Memantine|Film coated tablet
224248076|NCT05595590|DRUG|Tislelizumab|Administered as an intravenous (IV) infusion 200mg every 3 weeks (Q3W)
224248077|NCT05595590|RADIATION|Pulse radiation|66-70Gy/33-35Fx, 2Gy/Fx.
224248078|NCT00603187|DRUG|Acyline|20 mg GIPET enhanced oral dose, daily for 7-days
224248079|NCT00112190|DRUG|Itopride Hydrochloride|100 mg tid
224248080|NCT00112190|DRUG|itopride|100 mg three times daily
224248081|NCT02386618|PROCEDURE|Standardized endoscopic treatment of local residual neoplasia|Endoscopic treatment will be performed according to the type of local residual neoplasia (LRN): A - endoscopically negative scar and neoplastic tissue found only in biopsy specimens - treatment by argon plasmacoagulation, B - endoscopically aparent LRN \< 5 mm - forceps biopsy + argon plasmacoagulation, C - endoscopically evident LRN \> 5 mm + lifting during submucosal injection - endoscopic mucosal resectio + argon plasmacoagulation, D - endoscopically evident LRN \> 5 mm + non-lifting during submucosal injection - endoscopic submucosal disection (ESD) or surgical resection
224248082|NCT01021670|DRUG|Dapoxetine hydrochloride|One 30 mg tablet up to a maximum of one 60 mg tablet approximately 1 to 3 hours prior to prior to sexual activity once every 24 hours as needed for 12 weeks
224248083|NCT01021670|OTHER|Alternate care/non-dapoxetine hydrochloride treatment(s)|As prescribed or directed
223666390|NCT02888496|DRUG|tocilizumab|3 monthly IV infusions in PMR patients
223666391|NCT04704947|DRUG|nonselective beta blocker|nonselective beta blocker
224248084|NCT03021018|DRUG|Brivaracetam|"* Pharmaceutical Form: Solution for infusion~* Concentration: 10 mg/ml~* Route of Administration: intravenous"
224248085|NCT03021018|DRUG|Lorazepam|"* Pharmaceutical Form: Solution for injection~* Route of Administration: intravenous"
224248086|NCT00840099|DRUG|600 mg Amoxicillin/42.9 mg Clavulanate Postassium /5 mL|1 x 600 mg/42.9 mg/5 mL, single-dose fed
224248087|NCT00840099|DRUG|Augmentin ES-600™ 600 mg/42.9 mg/5 mL Suspension|1 x 600 mg/42.9 mg/5 mL, single-dose fed
224248088|NCT05364853|BEHAVIORAL|In-Person Testing|Participants will be randomly assigned to have either in-person testing of the DAYC-2 conducted. They will then cross over into the other testing condition approximately 3 weeks after their first assessment.
224248089|NCT05364853|BEHAVIORAL|Remote Testing|Participants will be randomly assigned to have either remote testing of the DAYC-2 conducted. They will then cross over into the other testing condition approximately 3 weeks after their first assessment.
224248090|NCT01173211|BIOLOGICAL|Trivalent inactivated influenza vaccine|Three licensed 2010-2011 seasonal inactivated trivalent influenza vaccines. Single intramuscular 0.5 mL dose. Each vaccine is formulated to contain 45 micrograms (mcg) hemagglutinin (HA) per 0.5 mL dose. Thimerosal is a preservative used in some vaccines. Fluzone, Agriflu and Fluarix do not contain thimerosal. For Fluarix, the tip cap and rubber plunger of the needleless prefilled syringes contain dry natural latex rubber.
224248091|NCT01173211|BIOLOGICAL|Trivalent inactivated influenza vaccine|Three licensed 2010-2011 seasonal inactivated trivalent influenza vaccines. Single intramuscular 0.5 mL dose. Each vaccine is formulated to contain 45 micrograms (mcg) hemagglutinin (HA) per 0.5 mL dose. Thimerosal is a preservative used in some vaccines. Fluzone, Agriflu and Fluarix do not contain thimerosal. For Fluarix, the tip cap and rubber plunger of the needleless prefilled syringes contain dry natural latex rubber..
224321780|NCT02479204|DRUG|Placebo|ACT-33441-matching placebo
224321781|NCT02479204|DRUG|Atenolol|film-coated tablet containing atenolol at a strength of 50 mg
224321782|NCT02479204|DRUG|Diltiazem ER|film-coated tablet containing diltiazem at a strength of of 120 mg
223666392|NCT04704947|DRUG|cardio-selective beta blocker group|cardio-selective beta blocker group
223666393|NCT04704947|DRUG|alendronate sodium|alendronate sodium
223666394|NCT01645943|PROCEDURE|Coronary angiogram|Routine coronary angiogram and revascularization if indicated
223666395|NCT02678559|OTHER|tee measurement|
223666396|NCT02678559|OTHER|flotrac measurement|
223666397|NCT02678559|OTHER|clearsight measurement|
224248092|NCT01173211|BIOLOGICAL|Trivalent inactivated influenza vaccine|Three licensed 2010-2011 seasonal inactivated trivalent influenza vaccines. Single intramuscular 0.5 mL dose. Each vaccine is formulated to contain 45 micrograms (mcg) hemagglutinin (HA) per 0.5 mL dose. Thimerosal is a preservative used in some vaccines. Fluzone®, Agriflu® and Fluarix® do not contain thimerosal. For Fluarix, the tip cap and rubber plunger of the needleless prefilled syringes contain dry natural latex rubber.
223666398|NCT00619320|BEHAVIORAL|Safer Sex Skills Building (SSB)|Test the effectiveness of an intervention for reducing sexual risk factors for HIV infection in two samples of pregnant drug-using women. The intervention, Safer Sex Skills Building (SSB)(El Bassel and Schilling (1991, 1992)), is a manual-driven, gender-specific group intervention delivered by mental health counselors. To date, its effectiveness has not been examined in pregnant, drug using women. The proposed study will examine the effectiveness of the intervention in both drug treatment (RBHA, N = 200) and prenatal care (PCC, N = 200) settings. Using a randomized clinical trial design, the study will compare the five-session SSB group intervention to a one-session standard group HIV Education session (ED). Study hypotheses: that women in the SSB intervention will have better outcomes (e.g., fewer unprotected penetrative sexual behaviors) than women in the control group (ED).
223666399|NCT01317108|DRUG|CMF Chemotherapy|
223666400|NCT00600119|DRUG|placebo|placebo, oral, once daily (QD)
223666401|NCT00600119|DRUG|NKTR-118|5 mg, 25 mg, 50 mg or 100 mg, oral,once daily (QD)
224248093|NCT00001085|DRUG|Amprenavir|
224248094|NCT00001085|DRUG|Lamivudine|
223666402|NCT06215768|DRUG|Dexmedetomidine and Midazolam|"This will be a prospective, double-blind, randomized controlled study conducted between October 2023and June 2024 .~Patients aged( 2\_12) years, American Society of Anesthesiologists class (ASA) I or II, scheduled for tonsillectomy with and without adenoidectomy will be randomized to receive intravenous dexmedetomidine 0.5 μg/kg Or intravenous midazolam 0.1 mg /kg(Group A) or (Group B) over 10 minutes after induction of anesthesia. The primary outcome is the incidence of ED within 30 minutes after extubation. Other outcomes are the incidence of pain, extubation time, post-anesthesia care unit (PACU) length of stay after extubation, adverse events, and the incidence of negative postoperative behavioral changes (NPOBCs)."
223666403|NCT03927560|PROCEDURE|Robotic Assisted Percutaneous Coronary Intervention|Robotic Assisted Percutaneous Coronary Intervention
223666404|NCT01583829|BEHAVIORAL|Neurofeedback|3 times per week for 45 minutes for a total of 40 sessions
224248095|NCT00001085|DRUG|Zidovudine|
224248096|NCT02778815|OTHER|Kindness for Mums|
224248097|NCT01032083|DRUG|Citalopram|Treatment with citalopram will be initiated at 20mg/day for the first 4 weeks (or one placebo capsule), followed by the option to increase the dose to 40mg per day (or two placebo capsules) for the remainder of the study period.
224248098|NCT01032083|DRUG|Placebo|Treatment with citalopram will be initiated at 20mg/day for the first 4 weeks (or one placebo capsule), followed by the option to increase the dose to 40mg per day (or two placebo capsules) for the remainder of the study period.
224248099|NCT01885052|BEHAVIORAL|QuitTXT Study|Assess the efficacy of a 6-8 week text message program to help young adults quit smoking.
223666405|NCT01583829|BEHAVIORAL|Cognitive Training|3 times per week for 45 minutes for a total of 40 sessions
224248100|NCT01885052|BEHAVIORAL|Low Contact|
224248101|NCT02193971|DEVICE|BS-DES (Biostable polymer drug-eluting stent)|
224248102|NCT02193971|DEVICE|BD-DES (Biodegradable polymer drug-eluting stent)|
224248103|NCT02193971|DRUG|Prasugrel 5mg|Use prasugrel 5mg daily for maintaning dose
224248104|NCT04533893|OTHER|Medical simulator (3B Scientific Lilly Pro) and Platform combining simulator sensor data with OSCE scores|Hands-on training app combining OSCE scoring criteria with sensor data retrieved from the simulator's sensors was used for hands-on performance evaluation.
224248105|NCT03110120|DRUG|0.5% levobupivacaine injectable solution with 10 ml of physiological saline|Serratus plane block realized with a mixture of 10 ml of 0.5% levobupivacaine injectable solution with 10 ml of physiological saline
223666406|NCT01583829|OTHER|Waitlist Control|6 30 minute calm breathing sessions over the course of 4 months
223666407|NCT04084119|OTHER|hypopressive abdominal exercise|Participants will perform an hypopressive abdominal exercise program consisting of 18 sessions (6 weeks), 3 times a week, 30 minutes each session.
224248106|NCT03110120|DRUG|0.5% levobupivacaine injectable solution with 10 ml of physiological saline|local infiltration of the wound with a mixture of 10 ml of 0.5% levobupivacaine injectable solution with 10 ml of physiological saline
224248107|NCT03110120|DRUG|0.5% levobupivacaine injectable solution with physiological saline|Serratus plane block realized with 20 ml of injectable solution of physiological saline
224248108|NCT03110120|DRUG|0.5% levobupivacaine injectable solution with physiological saline|local infiltration of the wound with 20 ml of injectable solution of physiological saline
224248109|NCT00706186|DRUG|Sodium Oxybate|The patient will maintain a dosage of 4.5 g/day for a duration of 7 days leading to Treatment Visit 1. After successful assessment at Treatment Visit 1, the dosage will be increased to 6 g/day for the duration of the trial. At Treatment Visit 2 (day 21), the dosage will be increased to a dosage of 9 g/day, if tolerated by the patient.
224248110|NCT03251430|PROCEDURE|gastrectomy|Distal gastrectomy, Total gastrectomy
224248111|NCT05963035|DRUG|18F-PFPN|For patients clinically suspected or confirmed clear cell sarcoma of soft tissue, integrated PET/MR or PET/CT imaging will be performed using targeted melanin-specific imaging agent 18F-PFPN. Meanwhile, multiple parameters will be compared with the general imaging agent 18F-FDG.
224248112|NCT03269838|DIAGNOSTIC_TEST|ECG|Primary Percutaneous coronary intervention
224248113|NCT05118412|OTHER|Lucerne protein concentrate shake|At three out of five test days: Lucerne protein concentrate powder will be mixed with water to obtain a shake, representing a 20g protein load.
224248114|NCT05118412|OTHER|Whey protein concentrate shake|At two out of five test days: Whey protein concentrate powder will be mixed with water to obtain a shake, representing a 20g protein load.
224248115|NCT05234502|OTHER|Adequate and balanced healthy diet program (CHO: 45-60%, protein:10-20%, fat:20-35%)|In calculating the estimated basal metabolic rate of individuals, Mifflin-St. The Jeor Equation will be used.BMR will be multiplied by the physical activity factor of the individual and 500\*700 kcal will be subtracted from the found value and the total daily energy requirement will be obtained.
224248116|NCT05234502|OTHER|Ketogenic diet program (CHO: 6%, protein:19%, fat:75%)|A ketogenic diet will be applied to Group 1 for 12 weeks simultaneously with taxane treatment.
224248117|NCT02621996|DEVICE|hammock|PN who will be positioned in hammock inside the incubator will be with the high trunk to about the 30th, and will be used a roll of restraint in the neck by keeping a slight lordosis to avoid suffocation risks. In two days of placement, should remain about 8 hours in the hammock, being removed during cleaning procedures, diet and medical evaluation and then immediately replaced in the hammock. The alternation of decubitus (right side, supine and left lateral) should be performed whenever the child is manipulated for these procedures.
224248118|NCT02621996|DEVICE|containment nest|"In the control group, the position will follow the routine procedure of the Hospital Barão de Lucena, consisting of the use of restraint nests U, made with rolled sheet placed on the mattress of the incubator and covered by another sheet. The control group incubators will also be inclined at 30 ° as routine service. During the 8 position, switching the supine will also be held, side left and side right after the baby handling to cleaning procedures, diet and medical evaluation."
224248119|NCT00095108|DRUG|Recombinant Human Interleukin-21|
224248120|NCT06267703|OTHER|Metabolomic profiling|Metabolomic profiling using serum samples was performed based on Nightingale Blood Biomarker Analysis platform; Proteomic profiling will be performed by both Scanning SWATH and OLINK® Explore 384 Oncology panel.
224248121|NCT03909620|DIAGNOSTIC_TEST|Low-dose computed tomography of chest|Eligible subjects will undergo a single round of LDCT screening. The LDCT will be considered as positive if a solid nodule or part-solid nodule of size ≥6 mm or non-solid nodule of size ≥20 mm is identified. Evaluation of positive nodules will be performed as per existing standard recommendations
224248122|NCT00068991|BEHAVIORAL|HIV skills training program and questionnaire|Two-hour weekly skills training sessions followed by evaluation questionnaire
224248123|NCT00068991|BEHAVIORAL|Community-level stigma reduction program|Two-hour training sessions focusing on anti-stigma and anti-discrimination
224248124|NCT00068991|BEHAVIORAL|Cross-sectional survey|Survey evaluation of community attitudes towards HIV
224248125|NCT01971060|DEVICE|surgery utilizing V-Loc suture|V-Loc suture will be utilized in the repair of the uterus following removal of fibroid tumors. a second look laparoscopy will be done on all subjects to evaluate scar tissue formation.
224248126|NCT03562091|OTHER|Data collection|The study is an observational evaluation that does not affect physician practices, the physician-patient relationship, or the care of subjects. The prescriptions will be decided prior to inclusion of the subject into the study. The information will be recorded using the data available in the medical file or collected during the visit (as part of the routine subject management).
224248127|NCT04123548|BIOLOGICAL|StrataGraft skin tissue|StrataGraft skin tissue was delivered as a single topical application to no more than 3 separate burn sites, totaling up to approximately 2000 cm\^2 of treatment area using no more than 20 tissues.
224321783|NCT06438874|OTHER|Exercise Test|Exercise capacity will be measured as peak oxygen consumption (peakVO2) using an incremental exercise test on a cycle ergometer with an open-circuit spirometry system (TrueOne, Parvo Medics, Sandy, UT) to analyze expired gases. Exercise testing will follow the American College of Sports Medicine and American Heart Association guidelines. The investigators will use a graded protocol, starting with a warm-up at 0 watts for 5 minutes, followed by 15 watt increments every 2 minutes until volitional fatigue.
224321784|NCT04108156|DRUG|PDS Implant Pre-Filled with 100 mg/mL Ranibizumab|Will be administered as per the schedule described in individual arm.
224321785|NCT04108156|DRUG|Intravitreal Ranibizumab 0.5 mg Injection|Will be administered as per the schedule described in individual arm.
224321786|NCT04108156|DRUG|Ranibizumab refill exchange|Will be administered as per the schedule described in individual arm.
224321787|NCT05558124|DRUG|Vyxeos|Fixed dose of Vyxeos (44 mg/m2 daunorubicin and 100 mg/m2 cytarabine) (Day 1, 3, and 5) in combination with various dose schedules of Gemtuzumab Ozogamicin (GO)
224321788|NCT05558124|DRUG|Gemtuzumab Ozogamicin|"Participants will be treated at the following dose levels:~Dose Level 1 - Gemtuzumab Ozogamicin will administered 3mg/m2 on Day 1 Dose Level 2 - Gemtuzumab Ozogamicin will administered 3mg/m2 on Day 1 and 4 Dose Level 3 - Gemtuzumab Ozogamicin will administered 3mg/m2 on Day 1, 4, 7"
224321789|NCT06629103|DIETARY_SUPPLEMENT|life's Omega 1035DS|A natural triglyceride derived from microalgae with minimum 365 mg DHA, minimum 100 mg EPA, and minimum 520 mg/g DHA + EPA. Participants receive 600mg/d of omega-3 fatty acids from the microalgal oil.
224321790|NCT06629103|DIETARY_SUPPLEMENT|Fish Oil|Commercially available fish oil product MEG-3 1812 TG with a minimum 100 mg DHA/capsule, minimum 160 mg EPA/capsule, and minimum 300 mg/g DHA+EPA. Participants receive 600mg/d of omega-3 fatty acids from the fish oil.
224321791|NCT06629103|OTHER|Placebo|The placebo capsules will be a mixture of corn and soybean oils. Participants receive 600mg/d of omega-3 fatty acids from the corn/soy placebo.
224321792|NCT06629103|DIETARY_SUPPLEMENT|life's Omega O3020DS|A natural triglyceride derived from microalgae with minimum 210 mg DHA, minimum 300 mg EPA, and minimum 510 mg/g DHA + EPA. Participants receive 600mg/d of omega-3 fatty acids from the microalgal oil.
223666408|NCT04084119|OTHER|general strengthening exercise|Participants will perform a general strengthening exercise program consisting of 18 sessions (6 weeks), 3 times a week, 30 minutes each session.
223666409|NCT01906944|DRUG|Bupivacaine 0.25%|Bupivacaine is a local anaesthetic drug belonging to the amino amide group.
223666410|NCT01906944|DRUG|Triamcinolone|Triamcinolone is a long-acting synthetic corticosteroid.
223666411|NCT05738681|DRUG|N acetyl cysteine|N acetyl cysteine 1,200 mg/day for 8 weeks in NAC group
223666412|NCT03241368|DEVICE|Capsule Endoscopy|At baseline subject will under the PillCam Crohn's Capsule Procedure
223666413|NCT01081418|BEHAVIORAL|Assertive Community Treatment (ACT)|ACT was structured and implemented according to guidelines of the Assertive Community Treatment Association (ACTA). Team members were highly educated psychosis experts consisting of a consultant psychiatrist, a psychiatrist, two psychologists, and a nurse, all of which received training in cognitive behavioral (CBT), dynamic, and/or family psychotherapy. Study participants could use all treatment options within the integrated care program such as psychoeducation groups, social skills training, family groups, motivational addiction therapy, meta-cognitive training etc.
223666414|NCT04772638|BEHAVIORAL|PLAY|This intervention focuses on promoting physical activity in preschoolers and the adults (parents and teachers) in their lives. It consists of 1) Teacher training 2) Activity trackers for children, teachers and parents and 3) text messaging with content and individualized goal setting.
223666415|NCT04772638|OTHER|Wait list control|not an active intervention
223666416|NCT00729469|DRUG|Ospemifene 60 mg|60 mg/day oral dose of ospemifene for 12 weeks - from Visit 2 (Randomization, Day 1) to Visit 4 (Week 12) plus Non-hormonal vaginal lubricant as needed
223666417|NCT00729469|DRUG|Placebo|oral dose of placebo,1 tablet/day, for 12 weeks - from Visit 2 (Randomization, Day 1) to Visit 4 (Week 12) plus Non-hormonal vaginal lubricant as needed
223666418|NCT02660840|DRUG|0.5 mg Flupentixol film-coated tablet (test treatment)|single oral dose, fasted state, day 1 in period 1 or 2
223666419|NCT02660840|DRUG|1 mg Flupentixol film-coated tablet (test treatment)|single oral dose, fasted state, day 1 in period 1 or 2
223666420|NCT02660840|DRUG|5 mg Flupentixol film-coated tablet (test treatment)|single oral dose, fasted state, day 1 in period 1 or 2
223666421|NCT02660840|DRUG|0.5 mg Flupentixol coated tablet (reference treatment)|single oral dose, fasted state, day 1 in period 1 or 2
223666422|NCT02660840|DRUG|1 mg Flupentixol coated tablet (reference treatment)|single oral dose, fasted state, day 1 in period 1 or 2
223666423|NCT02660840|DRUG|5 mg Flupentixol coated tablet (reference treatment)|single oral dose, fasted state, day 1 in period 1 or 2
224248128|NCT04064892|BEHAVIORAL|Exercise Intervention|The intervention will use peer mentors, motivational interviewing, and technology (Fitbit, Fitbit Coach App, \& Fitbit message board) to support behavior change. All participants will receive phone or video calls from their peer mentors every other week, and interact with their peer mentor and other participants through a private Fitbit message board at least weekly. Peer mentors will use Fitbit data to identify participants who need additional support to increase their activity.
224248129|NCT00557050|OTHER|Training|10-week eccentric hamstring muscle training
224248130|NCT02670772|DRUG|Stavudine|Stavudine 20mg twice daily for 96 weeks + Placebo 300mg once daily for 96 weeks + Lamivudine 150mg twice daily for 96 weeks + Efavirenz 600mg once daily for 96 weeks
224248131|NCT02670772|DRUG|Tenofovir Disoproxil Fumarate|TDF 300mg once daily + Placebo 20mg twice daily for 96 weeks + Lamivudine 150mg twice daily for 96 weeks + Efavirenz 600mg once daily for 96 weeks
224248132|NCT06279286|DRUG|HS-10506|HS-10506, tablets (10mg, 20mg, 40mg and 80mg) at night once daily from Day 1 to Day 5 in phase Ib study, and from Day 1 to Day 28 in phase II study.
224248133|NCT06279286|DRUG|Placebo|Placebo, placebo tablets matching the HS-10506 tablets
224248134|NCT04760704|BIOLOGICAL|Specific antibody and cellular immune response after anti-SARS-CoV-2 vaccine administration|Specific T cells and specific antibodies assessment
224248135|NCT04757792|OTHER|File inquiry|Data extraction out of file registry
224248136|NCT03192722|DEVICE|Colored near reading glasses|Participants are provided with colored near vision glasses.
224248137|NCT03192722|DEVICE|Lighting as determined by LuxIQ/2 or OttLite Cobra|Participants are provided preferred lighting (either OttLite or lamp with findings from LuxIQ/2)
224321793|NCT04808245|DRUG|Tecentriq 1200 MG in 20 ML Injection|One vial of Tecentriq® (1200 mg) will be administered as an intravenous (i.v.) infusion over 60 minutes every 3 weeks starting 4 weeks after radiotherapy. If the first infusion is tolerated, all subsequent infusions will be delivered over 30 minutes.
224321794|NCT04808245|BIOLOGICAL|H3K27M peptide vaccine|The H3K27M peptide vaccine is injected subcutaneously (s.c.). For a single vaccination 300 μg of the peptide will be emulsified in a total volume of 1 ml.
224248138|NCT03342157|DRUG|senna/docusate|Stimulant laxative
224248139|NCT00418184|DIETARY_SUPPLEMENT|Phosphatidylserine-Omega3|Phosphatidylserine-Omega3 conjugate capsules. Weeks 0-15: 300 mg/day. weeks 16-30: 150 mg/day and a 150 mg/day one year follow-up.
224248140|NCT00418184|OTHER|Colored cellulose tainted with fishy odor|as arm 1
224248141|NCT02296008|DEVICE|3D high resolution anorectal manometry|"Procedure will take about 15 minutes. During procedure resting, squeeze, bear down maneuver, cough, ano-anal and rectoanal inhibitory reflex will be obtained, if possible.~3D picture of pressures of anorectal will be recorded."
224248142|NCT03744481|OTHER|Questionaire|"Evaluation of psychomotor development in children with mild EAI without indication of therapeutic hypothermia.~Precise analysis of the type (motor, sensory, language, epilepsy) and the severity of sequelae by sending a questionnaire to parents.~Investigation of early, clinical and paraclinical prognostic factors of good or bad neurodevelopmental outcome.~Evaluation of the height-weight growth and the cranial perimeter"
224248143|NCT01826058|RADIATION|Stereotactic body radiation therapy|
224321795|NCT04808245|OTHER|Imiquimod (5%)|One sachet of Aldara® cream (250 mg) will be applied to an area of 5 x 5 cm around the injection site of the H3K27M peptide vaccine 15 min after vaccination and left on the skin for approximately 8 hours according to the instructions in the SmPC. 24 hours after the vaccination a second sachet of Aldara® will be applied by the patient as instructed above and left on the skin for approximately 8 hours.
224321796|NCT03631199|DRUG|canakinumab|canakinumab 200 mg subcutaneous (s.c.) injection every 3 weeks (squamous and non-squamous)
223666424|NCT03234569|PROCEDURE|sonoHSG|This procedure uses agitated saline to produce air bubbles at the time of the Sonohysterogram which optimizes fallopian tube visualization. The sonoHSG is free of radiation and use of contrast. In this study, in order to produce the air bubbles at the time of the sonohysterogram, the investigators will be using a continuous saline-air device that may produce a technically superior image. For the ultrasound images, General Electric will be supporting us by providing us the Voluson E10 and RIC5-9-D.
223666425|NCT03463200|OTHER|Functional elastic tape tensioned|Application of Kinesio Taping with tension in the erector spine muscles.
223666426|NCT03463200|OTHER|Functional elastic tape non-tensioned|Application of Kinesio Taping without tension in the erector spine muscles.
223666427|NCT03463200|OTHER|Rigid Tape|Application of Micropore tape in the erector spine muscles.
223666428|NCT02183740|BEHAVIORAL|Multifaceted educational program|
223666429|NCT00514852|DRUG|Carboxymethylcellulose and Glycerin based artificial tear|1 to 2 drops into each eye as needed but at least twice daily
223666430|NCT00514852|DRUG|Carboxymethylcellulose|1 to 2 drops into each eye as needed but at least twice daily
223666431|NCT03504046|DEVICE|Artificial Pancreas App|The portable Artificial Pancreas System App (APS APP) is an artificial pancreas system comprised primarily of an insulin pump, a continuous glucose monitor (CGM), and a cellular phone device to connect the components.
223666432|NCT01809093|BIOLOGICAL|Blood draw|3-4 tablespoons of blood will be drawn, one time.
223666433|NCT02490345|DRUG|gabapentin|gabapentin usage as adjunctive treatment for pain control
223666434|NCT02490345|DRUG|Placebo|Identical placebo
223666435|NCT03711240|DRUG|bevacizumab|5mg/kg iv day 1 every 2 weeks
224248144|NCT02376777|OTHER|Follow up|each three months during one year of follow up, general practioners will entered health data in database (hemorrhagic events, changes of medication, biological data...)
224248145|NCT00620074|DRUG|voriconazole|Subjects with creatinine clearance at least 50 ml/min will receive initial treatment with IV (loading dose of 6 mg/kg Q12h followed by maintenance dose of 4 mg/kg Q12h) or oral (loading dose of 400 mg Q12h followed by maintenance dose of 300 mg Q12h). Subjects with creatinine clearance \<50 ml/min will receive oral voriconazole (loading dose of 400 mg Q12h followed by maintenance dose of 300 mg Q12h).
224248146|NCT00620074|DRUG|anidulafungin|Loading dose of 200 mg QD followed by maintenance dose of 100 mg QD for up to a total of 28 days therapy
224248147|NCT05056974|BIOLOGICAL|UB-421|10 mg/kg, weekly UB-421 during the 8-week
223666436|NCT03711240|DRUG|Oxaliplatin|85mg/m2 2-hour iv infusion, day 1 every 2 weeks
223666437|NCT03711240|DRUG|Irinotecan|150mg/m2 1.5-hour iv infusion, day 1 every 2 weeks
223666438|NCT03711240|DRUG|Leucovorin|200mg/m2 2-hour iv infusion, day 1 every 2 weeks
223666439|NCT03711240|DRUG|5-FU|2400mg/m2 46-hour continuous iv infusion, day 1 every 2 weeks
223666440|NCT05606029|PROCEDURE|Cholecystectomy, extended cholecystectomy|Cholecystectomy and histopathological evaluation
223666441|NCT02884505|DEVICE|Pupillometry|Measures pupillary dynamics in darkness and light conditions
223666442|NCT02884505|BEHAVIORAL|Psychomotor Vigilance Task|Response time task measuring neurobehavioral alertness
223666443|NCT02884505|OTHER|Auditory Evoked Potential|Measure of electroencephalographic response to standardized auditory tones
223666444|NCT02884505|BEHAVIORAL|Hypersomnia Severity Index|Self-report measure of hypersomnolence
223666445|NCT03812237|OTHER|(EWB) Early Weight Bearing (2 Weeks Post-op)|Patient were permitted to progressively weightbear on their heel at 2 week post-op.
223666446|NCT00740610|DRUG|GS-9450|GS-9450 capsules at a dose of 1, 5, 10, and 40 mg administered orally once daily
223666447|NCT00740610|DRUG|GS-9450 Placebo|Placebo to match GS-9450 administered orally once daily
223666448|NCT02086032|DRUG|1mg 17 beta-estradiol|Comparing sleeping quality between micronized progesterone and dydrogesterone users.
223770790|NCT03178058|OTHER|Questionaire|"Prior to surgery women will be given a questionnaire detailing previous motion sickness, previous history of PONV, emesis during pregnancy, smoking history , itching history, skin atopy and allergies. After surgery details about surgery will be added: intraoperative hypotension, use of phenylepherine, intraoperative nausea and vomiting, exteriorization of uterus, extent of adhesions, need for uterotonic medications, and estimated bleeding.~Parturients will be assessed 1 hour and 24 postoperatively by attending anesthesiologist, PONV incidence will be reported using a three point ordinal scale (0 = none, 1 = nausea, 2 = retching, 3 =vomiting)."
223770791|NCT01246726|PROCEDURE|CT SCAN|Prior to radiotherapy + after radiotherapy completion
223770792|NCT01246726|PROCEDURE|MRI scan|Prior to radiotherapy + after completion of radiotherapy
223770793|NCT01246726|PROCEDURE|3D Ultrasound scan|Prior to radiotherapy + after completion of radiotherapy
224248148|NCT05056974|DRUG|chidamide|10 mg/dose, twice a week for 8 weeks
224248149|NCT04989491|DRUG|Rituximab|One single dose of rituximab intravenously (IV)
224248150|NCT04989491|OTHER|control group|No treatment
224248151|NCT01933360|DRUG|Misoprostol sublingual, 1h|Misoprostol is administered sublingually 1 hour prior to surgical termination of early pregnancy
224321797|NCT03631199|DRUG|canakinumab-matching placebo|canakinumab placebo every 3 weeks (squamous and non-squamous)
224321798|NCT03631199|DRUG|pembrolizumab|200 mg every 3 weeks (squamous and non-squamous)
224321799|NCT03631199|DRUG|carboplatin|Area Under the Curve (AUC) 5 mg/mL\*min every 3 weeks (non-squamous) or AUC 6 mg/mL\*min (squamous)
224321800|NCT03631199|DRUG|cisplatin|75 mg/m\^2 every 3 weeks (non-squamous)
223666449|NCT02086032|DRUG|Dydrogesterone|Comparing sleeping quality between micronised progesterone and dydrogesterone users.
223666450|NCT02086032|DRUG|micronized progesterone|Comparing sleeping quality between micronised progesterone and dydrogesterone users
223666451|NCT01270802|DRUG|Tenofovir/emtricitabine|Efavirenz will be switched to raltegravir 400mg orally twice daily while continuing tenofovir/emtricitabine
223666452|NCT01270802|DRUG|Tenofovir/emtricitabine/efavirenz|Continued therapy with tenofovir/emtricitabine/efavirenz
223666453|NCT01270802|DRUG|Raltegravir|Efavirenz will be switched to raltegravir 400mg orally twice daily while continuing tenofovir/emtricitabine
224248152|NCT01933360|DRUG|Placebo sublingual,1h|Placebo for misoprostol is administered sublingually 1 hour prior to surgical termination of early pregnancy
224248153|NCT01933360|DRUG|Misoprostol sublingual, 3h|Misoprostol is administered sublingually, 3 hours prior to surgical termination of early pregnancy
224248154|NCT01933360|DRUG|Misoprostol vaginal, 1h|Misoprostol is administered vaginally 1 hour prior to surgical termination of early pregnancy
224248155|NCT01933360|DRUG|Misoprostol vaginal, 3h|Misoprostol is administered vaginally 3 hours prior to surgical termination of early pregnancy
224321801|NCT03631199|DRUG|paclitaxel|200 mg/m\^2 every 3 weeks (squamous)
224321802|NCT03631199|DRUG|nab-paclitaxel|100 mg/m\^2 on Days 1, 8, and 15 of every cycle (squamous)
224321803|NCT03631199|DRUG|pemetrexed|500 mg/m\^2 every 3 weeks (non-squamous)
223666454|NCT03662581|BEHAVIORAL|Mindfulness Group Program|"The mindfulness program has the following aims (Iacono, 2018): to teach mindfulness skills for stress reduction, self-compassion, and dealing with difficult thoughts and emotions, to promote an integrative concept of health, which treats the whole person, to promote community building and positive relationships, and to capitalize on the power of groups to:~1. Foster peer-to-peer learning and support when it comes to coping with life challenges~2. Combat isolation~3. Increase efficiency, quality, and timeliness of care"
223666455|NCT03666156|OTHER|No intervention|No Intervention
223666456|NCT00909207|BEHAVIORAL|Interview|Review list of 25 cancer symptoms, 20-30 minute audio-taped personal interview and 15-20 minute questionnaire.
223666457|NCT03608358|DRUG|Dapagliflozin 10 mg|10 mg, oral tablet, once daily for 24 weeks of double-blind treatment period
223666458|NCT03608358|DRUG|Dapagliflozin 5 mg|5 mg, oral tablet, once daily for 24 weeks of double-blind treatment period
223666459|NCT03608358|DRUG|Dapagliflozin 10 mg placebo to match|10 mg, oral tablet, once daily for 24 weeks of double-blind treatment period
224248156|NCT01933360|DRUG|Placebo sublingual, 3h|Placebo for misoprostol is administered sublingually 3 hours prior to surgical termination of early pregnancy
224248157|NCT01933360|DRUG|Placebo vaginal, 1h|Placebo for misoprostol is administered vaginally 1 hour prior to surgical termination of early pregnancy
224248158|NCT01933360|DRUG|Placebo vaginal, 3h|Placebo for misoprostol is administered vaginally 3 hours prior to surgical termination of early pregnancy
224248159|NCT00836667|DRUG|Zoloft® 100 mg Tablets|1 x 100 mg, single-dose fed
224248160|NCT00836667|DRUG|Sertraline hydrochloride 100 mg Tablets|1 x 100 mg, single-dose fed
223666460|NCT03608358|DRUG|Dapagliflozin 5 mg placebo to match|5 mg, oral tablet, once daily for 24 weeks of double-blind treatment period
223666461|NCT03608358|DRUG|Saxagliptin 5 mg|5 mg, oral tablet, once daily for 24 weeks of double-blinded treatment period, and for 16 weeks of open-label treatment period in Stratum A or 8 weeks of open-label treatment period in Stratum B
223666462|NCT03608358|DRUG|Metformin|Stable dose of metformin immediate release/extended release (≥ 1500 mg/day or at a maximal tolerated dose) throughout the whole study period
223666463|NCT00799851|DEVICE|Variceal band ligation|
223770794|NCT05390489|DRUG|Cascara pulp arabica gayo coffee cream|extract of cascara pulp arabica gayo coffee
224248161|NCT03836560|DRUG|Nicotine patch|nicotine patch given for 8 weeks
224248162|NCT03836560|DRUG|Nicotine gum|nicotine gum given as requested
224248163|NCT06558669|OTHER|Fresh Sugarcane juice|Fresh sugarcane juice in different doses will be given to liver patients for 90 days
224248164|NCT03977272|DRUG|Combination drug|Accompanying with modified-FOLFIRINOX, Anti-PD-1 antibody was applied biweekly
224248165|NCT03977272|DRUG|Chemotherapy|modified-FOLFIRINOX
224248166|NCT06502340|DIAGNOSTIC_TEST|high sensitive troponin I|high-sensitive Troponin I levels
224248167|NCT01796730|DRUG|bambuterol|Patients will be randomized allocated to receive three treatment sequences I, II and III, every treatment period is separated by a washout period of 7 days.
224248168|NCT01796730|DRUG|Placebo|
224248169|NCT01239017|BIOLOGICAL|REGN475|
224248170|NCT01239017|OTHER|Placebo|
224248171|NCT03362710|DIAGNOSTIC_TEST|simplified tools|"1. Skin temperature on the back of the foot with infra-red thermometry~2. Toe saturometry~3. ABI with an automatic sphygmomanometry~4. Skin Recoloration time at the foot"
224248172|NCT01665586|DRUG|dexmedetomidine|"Spinal anesthesia regimen Group F: 6mg bupivacaine + 20mcg fentanyl (intrathecal) + o.4 cc 5% dextrose water Group C: 6mg bupivacaine + 0.4 cc normal saline + 0.4cc 5% dextrose water~dexmedetomidine 0.2\~0.8 micro gram/kg intravenous administration after the sterilization of the spinal anesthesia level, and prehydration"
224248173|NCT01142635|DRUG|Rocuronium bromide|Rocuronium, iv, 0,6 mg/kg diluted with saline to double volume, bolus, single dose
224248174|NCT01142635|DRUG|Rocuronium bromide|Rocuronium, iv, single dose, single bolus, 1.2 mg/kg
223666464|NCT00799851|DRUG|cyanoacrylate injection|cyanoacrylate injection
223666465|NCT04554056|DRUG|MW05|Recombinant (yeast secreted) human serum albumin-human granulocyte colony stimulating factor (I) fusion protein injection
223666466|NCT04554056|DRUG|PEG-rhG-CSF|PEGylated Recombinant Human Granulocyte Colony-Stimulating Factor
223666467|NCT04634305|PROCEDURE|Total elbow arthroplasty|Total elbow arthroplasty by a single operator
223666468|NCT05667337|DEVICE|CLP-PEG-MPC|Implantation of a 500 um thick biosynthetic corneal implant utilizing DALK surgical technique
223666469|NCT05667337|PROCEDURE|Human donor cornea penetrating keratoplasty|Implantation of a human donor cornea graft utilizing PKP surgical technique
223666470|NCT00484744|DRUG|Acetaminophen|
223666471|NCT00484744|DRUG|Avicel (placebo)|
224248175|NCT02723981|DEVICE|COMBO-Stent|The OrbusNeich COMBO Bio-engineered Sirolimus Eluting Stent (COMBO Stent) consists of a 316L stainless steel alloy abluminally coated with a biocompatible, biodegradable poly-mer containing sirolimus. Covalently attached to the surface of the stent is a layer of murine, monoclonal, anti-human CD34 antibody. The antibody specifically targets circulatory CD34+ cells (endothelial progenitor cells) thus favoring endothelialization.
223666472|NCT00484744|DRUG|Ibuprofen|
224248176|NCT02723981|DRUG|Clopidogrel, Vitamin K Antagonist, Rivaroxaban, Dabigatran|Anticoagulant medication after stent Implantation: (N)OAC and clopidogrel for 3 months followed by (N)OAC
224248177|NCT02723981|DEVICE|Any drug eluting stent oder bare metal sent|Implantation of traditional bare metal stents and/or drug eluting stents (any device approved on the market, implanted according to CE marking and IFU) and medication regimen in accordance with ESC Guidelines
224248178|NCT02723981|DRUG|ASA, Clopidogrel, Vitamin K Antagonist, Rivaroxaban, Dabigatran|A combination of antiplatelet and anticoagulant therapy according to ESC guidelines (2014)
224248179|NCT04102319|DIAGNOSTIC_TEST|serum hepcidin|it is a serum marker
224248180|NCT03251534|PROCEDURE|Centromedullary nailing|
224248181|NCT02412384|OTHER|Flow cytometry (FCM)|Use FCM to test PBMCs/CTCs from volunteers/patients.
224248182|NCT02412384|OTHER|RT-PCR|Use RT-PCR to test PBMCs/CTCs from volunteers/patients.
224248183|NCT06199219|OTHER|Sexual counseling, based on the extended (EX-PLISSIT)|"The EX-PLISSIT model is done in a cyclical manner. In other words, it is an interactive and repetitive model. All interventions must begin with Permission. Each stage of Limited Information, Special Recommendation and Intensive Therapy is supported by Allowing. Thus, the interaction between counselors and clients is improved (Taylor and Davis 2006; Punjani and Papathanasoglu, 2019)."
224248184|NCT04825535|BEHAVIORAL|Standard psychiatry and cognitive behavioral online intervention|The cognitive behavioral online intervention has been assessed in a prior trial. Ritvo, P, Knyahnytska, Y, Pirboglou, M, Wang, W, Tomlinson, G, Zhao, H, Linklater, R, Kirk, M., Katz, J., Harber, L., Daskalakis, ZJ An online mindfulness-based cognitive behavioural therapy intervention for youth diagnosed with major depressive disorders: J Med Internet Res 2021, Mar 17; 23 (3), e24380
224321804|NCT04127604|BEHAVIORAL|Integrated Treatment Adherence Program for Veterans (ITAP-VA)|Psychosocial support and treatment to improve treatment adherence, symptoms, and functioning.
224321805|NCT04127604|BEHAVIORAL|Safety Assessment and Follow-up Evaluation (SAFE)|Measurement-based care assessment and evaluation.
223666473|NCT01675089|DRUG|Zoledronic acid|The treatment group will receive 15-minute intravenous administration of zoledronic acid (5 mg) in a single dose at the time of kidney transplantation and vitamin D replacement. The aim of vitamin D replacement will be serum levels of 25 (OH) vitamin D above 30 ng/ml.
223666474|NCT01388556|BEHAVIORAL|Tango dancing|Twice weekly tango dance classes
223666475|NCT02226445|OTHER|Combined ADHD medication and psychosocial counseling|"The patients are offered as well ADHD medication as non-standardized psychosocial treatment, the latter including psychoeducation (i.e. information about ADHD aetiology and symptoms plus management of symptoms) and counselling regarding emotional-, family- and social rehabilitation-related problems.~ADHD medication:~First choice of medication is methylphenidate immediate release, initially 5 mg 2-3 times a day increasing with 10-20 mg per week up to stabilization of symptoms.~When stabilized a shift to extended release methylphenidate. Alternatively dexamphetamine, initially 2.5 mg 2-3 times a day increasing with 5-10 mg per week up to stabilization of symptoms.~If there is no adequate effect of central stimulants then a shift to atomoxetine, initially 18 mg a day, increasing during a period of 6-10 weeks up to max. 100 mg a day.~If the patients have a substance use, an anxiety problem or other contraindications then first choice of medication is atomoxetine."
223666476|NCT03363113|DRUG|Botulinum Toxins|Injection of botulinum toxin in the muscles affected by oromandibular dystonia
224248185|NCT04825535|BEHAVIORAL|Standard psychiatry and cognitive behavioural in-person intervention|The effectiveness of standard care office-based group CBT-MM at CAMH is indicated in a past study (n = 119) where depression symptoms reduced (after 16 weeks treatment) by 27% \[3,18 \]. The office-based groups follow a carefully conceived structure that centers on the workbook Mind Over Mood (MOM) (Guilford Press) \[41\]. Key CBT concepts and procedures are conveyed via work sheets that structure personal and group exploration.
224248186|NCT05931315|DIETARY_SUPPLEMENT|CaroRite™|One capsule to be taken immediately post-dinner / with dinner
224248187|NCT05931315|DIETARY_SUPPLEMENT|Placebo|One capsule to be taken immediately post-dinner / with dinner
224248188|NCT02615028|OTHER|Closed eyes double-leg stance|Closed eyes double-leg stance: Body relaxed with both arms naturally placed beside thighs, eyes closed for 40 seconds.
224248189|NCT03037671|DEVICE|Continuous Glucose Monitor (CGM)|Participants will wear the continuous glucose monitor (GCM) device during the peri-HSCT period for the duration of their initial hospital admission. No intervention based on results.
224248190|NCT05458583|PROCEDURE|Baseline periodontal measurements (T0)|Periodontal measurements including plaque index, gingival index and calculus index were recorded at the bonding session.
224248191|NCT05458583|PROCEDURE|Periodontal measurements (T1)|Periodontal measurements including plaque index, gingival index and calculus index were recorded at the 6 months after bonding.
224248192|NCT05458583|PROCEDURE|Periodontal measurements (T2)|Periodontal measurements including plaque index, gingival index and calculus index were recorded at the 12 months after bonding.
224248193|NCT05458583|PROCEDURE|Retainer failure rates|A retainer with at least one composite pad detachment was considered to be a failure during 1-year follow-up.
224248194|NCT06563011|OTHER|Counselling|Tailored Dietary Counselling
224248195|NCT00958451|DRUG|Paricalcitol|"1. Patients will receive 1mcg once daily orally if iPTH is less than 500pg/ml;~2. Patients will receive 2mcg once daily orally if iPTH is more than 500pg/ml. Duration of administration will be 16 weeks."
224248196|NCT00958451|DRUG|Ergocalciferol|"1. If baseline 25 OHD level is less than 5ng/mml: ergocalciferol 50,000 units once a week orally for 12 weeks, then 50,000 units monthly for total duration of 16 weeks.~2. If baseline 25 OHD is between 5 and 15mg/ml: Ergocalciferol 50,000 units once a week orally for 4 weeks, then 50,000 units once a month for total duration of 16 weeks.~3. If baseline 25 OHD level is between 16 and 30ng/ml: Ergocalciferol 50,000 units orally once every 4 weeks for 16 weeks."
224248197|NCT00477945|DRUG|clofarabine|"Cohort N Clofarabine (mg/m2/day)~1. 3-6 30~2. 3-6 40~3. 3-6 50~4. 3-6 60~5. 6-10 70"
224248198|NCT03114748|OTHER|EEG|
224248199|NCT03114748|OTHER|DBS switched OFF and ON|
224248200|NCT04294303|OTHER|web based telemonitoring system|Subjects in the telemonitoring group were given an iPad with installed iHealth application, a scale, and an electronic blood pressure monitor (a mobile web-based telemonitoring system). These devices were interconnected via Bluetooth. The iPad had permanent internet connection. Patients were taught to use the equipment to check and record their weight, blood pressure, and heart rate every morning, for 45 days after the hospital discharge. Data was automatically uploaded via iHealth application in a secure database.
224248201|NCT04294303|OTHER|Conventional|Subjects in the control group received the standard patient teaching, including an instruction to self-monitor their weight.
224248202|NCT05721586|OTHER|Self Assembling Peptide P11-4 (CURODONTTM REPAIR) + Fluoride varnish (DURAFLOR|The WSL was Acid etched with phosphoric acid gel 35-37% for 20 seconds, the tooth surface was rinsed with water and then dried afterwards application of CURODONTTM REPAIR
224248203|NCT05721586|OTHER|Fluoride varnish (DURAFLOR|A very thin coat of the DURAFLOR varnish was applied by a thin brush which was then allowed to dry for 10 seconds. The varnish hardens on contact with saliva or moisture
224248204|NCT03024086|DRUG|DWJ1252|DWJ1252 and Placebo of Gasmotin
224248205|NCT03024086|DRUG|Gasmotin|Gasmotin and Placebo of DWJ1252
224248206|NCT01838941|DRUG|Betaine|"Betaine will be given orally (mixed with food or dissolved in water, juice, milk, or formula) or through gastrostomy tube as follows:~* 6 g/day in children \< 30 kg, in 3 divided doses (2 g at meal time)~* 12 g/day in children \> 30 kg, in 4 divided doses (3 g at meal time and bed time)."
224248207|NCT02822235|OTHER|No Intervention|
224248208|NCT01346735|OTHER|No intervention|
224248209|NCT06067243|DIAGNOSTIC_TEST|T2 mapping 3T MRI + hip arthroscopy|"1. 3T MRI~2. hip arthroscopy"
224248210|NCT03214952|DRUG|Vonoprazan|Vonoprazan tablets
224248211|NCT03596294|DRUG|Clazosentan|Continuous i.v. infusion of 15 mg/h of clazosentan for 3 h
224248212|NCT03596294|DRUG|Rifampicin|Single i.v. dose of 600 mg rifampicin for 30 min
224248213|NCT03596294|OTHER|Saline (0.9% sodium chloride)|Single i.v infusion of 500 mL saline for 30 min
224248214|NCT02056691|PROCEDURE|Exercise programme|The exercise regime consists of 10 sessions of exercise against a constant load, each lasting 60 seconds, separated by 60 seconds of recovery eliciting 90% maximal heart rate. The 6 sessions are held over a 2 week period.
224321806|NCT05193396|DRUG|Hydrocortisone|Patients are randomized to oral hydrocortisone (10 mg twice daily) or placebo for 16 weeks.
223666477|NCT05254145|DIAGNOSTIC_TEST|Next Generation Sequencing|During the participants surgical procedure, a total of 3 ml of synovial fluid (joint fluid collected from the knee) will be collected per joint. Upon collection, the samples will be deidentified, stored on ice and shipped with a study ID number to MicroGenDx for Next Generation Sequencing.
224248215|NCT02056691|PROCEDURE|Muscle biopsy|muscle biopsy under local anaesthetic taken from the thigh, again for analysis and storage 3 times: before, during and after the exercise programme
224248216|NCT05952544|DRUG|essential amino acids and keto-analogues supplementation|very low protein diet plus essential amino acids and keto-analogues supplementation
223770795|NCT06535724|PROCEDURE|Chronic plantar fasciitis endoscopic debridement coupled with heel spur resection|"1. Preoperative Preparation: popliteal nerve block, patient positioning supine with the operated limb fully externally rotated, spinal anesthesia, tourniquet application.~2. Surgical Procedure:~   * Initial Marking from the heel bone arch to the calcaneal bone to locate the entry point.~  * First Incision and Portal Creation: an initial incision at the palpated site using a size 11 blade; blunt dissection to reveal the plantar fascia; arthroscope entry.~  * Secondary Entry: 3 cm distally from the initial incision; positioning of the arthroscope; additional blunt dissection and obturator insertion.~  * Operative Technique: continuous irrigation with sterile saline; 3.5-mm shaver introduced through the distal portal; meticulous debridement of inflamed and pathological tissue; removal of calcaneal spurs; thinning of the plantar fascia~3. Postoperative Care • Careful monitoring and guided rehabilitation to support optimal healing and recovery."
224248217|NCT05952544|OTHER|low protein diet|patients were on low protein diet only
224248218|NCT02968992|DRUG|rhLactoferrin|Eligible participants will be provided with Recombinant Human lactoferrin (rhLF) in 250 mg capsules along with detailed instructions for taking the study drug and they will be asked to take six 250 mg capsules twice a day and to keep a daily dosing dairy.
224248219|NCT02968992|OTHER|Placebo|Eligible participant will be provided with placebo in capsules of 250 mg along with detailed instructions for taking the placebo. Participants will be asked to take six 250 mg capsules twice a day and to keep a daily dosing dairy.
223666478|NCT03284892|BEHAVIORAL|SOC program|A once-daily, 7-day SOC program, including oral-motor exercise, sensory stimulation and lubrication, and safe-swallowing education.
223666479|NCT06089785|DEVICE|elastography|evaluation of degree of spleen stiffness in liver cell failure patient by elastography.
223666480|NCT02744950|PROCEDURE|Pulley stitches|
223666481|NCT02744950|PROCEDURE|Intermediate Repair|
223666482|NCT04471285|PROCEDURE|acupuncture|acupuncture
223666483|NCT04471285|PROCEDURE|Sham acupuncture|Sham acupuncture
223666484|NCT03995329|OTHER|IQOS|Acute effects of IQOS on pulmonary function, oxygen saturation, exhaled CO, heart rate and arterial blood pressure.
223666485|NCT02587611|OTHER|Elemental liquid diet|This is a randomized, crossover trial. Two types of test meals (200 kcal/200 mL of either the elemental diet or the semi-solid diet) are labeled with 100 mg \[13C\]sodium acetate and administered within 5 min in healthy subjects or within 15 min in gastrostomy-fed patients.
223666486|NCT02587611|OTHER|Standard semi-solid diet|This is a randomized, crossover trial. Two types of test meals (200 kcal/200 mL of either the elemental diet or the semi-solid diet) are labeled with 100 mg \[13C\]sodium acetate and administered within 5 min in healthy subjects or within 15 min in gastrostomy-fed patients.
223666487|NCT04933370|OTHER|Stimulation parameters|Different device stimulation parameters
223666488|NCT04181814|DEVICE|Ultrasound|Use ultrasound to assess gastric contents in diabetic patients before anesthesia
223666489|NCT00811213|DEVICE|SleepStyle 200 Auto Series with SensAwake|Auto adjusting Continuous Postive Aiway Pressure (CPAP) Device with SensAwake technology enabled
223666490|NCT00811213|DEVICE|SleepStyle 200 Auto Series with out SensAwake|Auto adjusting Continuous Postive Aiway Pressure (CPAP) Device with SensAwake technology disabled
223666491|NCT02183753|OTHER|wood smoke|
223770796|NCT03866174|DRUG|Psilocybin|The psilocybin used in this study is synthetically manufactured in a laboratory and meets quality specifications suitable for human research use. The active drug is encapsulated using a hydroxypropyl methylcellulose (HPMC) capsule and contains 25 mg of psilocybin.
223770797|NCT03866174|DRUG|Niacin|The active placebo is encapsulated using a HPMC capsule and contains 100 mg of pharmaceutical grade niacin.
224248220|NCT00000925|DRUG|Optimune oral nutritional supplement|
224248221|NCT01811758|BEHAVIORAL|Culturally Specific CBT|
224248222|NCT01811758|BEHAVIORAL|Standard CBT|
224248223|NCT01950715|DEVICE|sacral nerve stimulation|Sacral nerve stimulation
223666492|NCT02183753|OTHER|clean air|
223666493|NCT00329446|DRUG|Quetiapine Fumarate|
223666494|NCT00329446|DRUG|Escitalopram oxylate|
223666495|NCT06221657|DRUG|Vemlidy|1 tablet once a day, oral administration
223666496|NCT06221657|DRUG|Virreal|1 tablet once a day, oral administration
223666497|NCT01566214|BEHAVIORAL|Motivational Interview|For those subjects randomly assigned to the treatment group, information from their MIHART assessment interview and medical record review will be used to select intervention scripts optimally tailored to each subjects' unique configuration of beliefs and risk factors and they will be re-contacted by telephone at 2-weeks post-hospital discharge to deliver the Vet-HART intervention. The intervention will be administered by a trained research assistant via telephone, working from a semi-structured script tailored to each subject's representations and risk factors, the call will last about 15-30 minutes.
224248224|NCT03144050|DEVICE|SFDI Imaging|Imaging with SFDI device
224248225|NCT04039334|OTHER|Conventional Chest Physiotherapy|Conventional chest physiotherapy programme will include diaphragmatic breathing exercise, thoracic expansion exercises, incentive spirometer exercise (Triflo), teaching of respiratory control, relaxing and coughing techniques.
224248226|NCT04039334|OTHER|Creative Dance Based Exercise Training|Creative dance based exercise training will be given under the supervision of a physiotherapist who takes creative dance instructor training 2 days and 60 minutes per week.
224248227|NCT03992222|DEVICE|Physical exercise programs PEP targeted on appropriate muscle strengthening devices allows|administration of a Physical exercise program for 24 weeks.The participants will be followed at the 24 and 52nd weeks.
224248228|NCT03769896|DRUG|Nabilone 0.25 mg|capsules, 0.25 mg up to 2 mg of nabilone taken orally on a daily basis
224248229|NCT03769896|DRUG|Placebo|capsule, corn starch, daily basis
224248230|NCT00938795|OTHER|Uncertainty Management Intervention|Six 30-minute telephone calls with a nurse to discuss emotional and physical aspects of liver disease and awaiting liver transplant
224248231|NCT00938795|OTHER|Comparison Conditions for Liver Transplant|Six 30-minute telephone calls that provide structured education about liver disease.
224248232|NCT00268879|DRUG|Renzapride|Placebo Renzapride 4 mg QD Renzapride 2 mg BID
224248233|NCT04739475|PROCEDURE|Non Surgical Periodontal Therapy|"Conventional staging debridement (CSD) according to the severity of periodontal disease in 2 to 4 appointments at day 0, 7, 14 and 21.~Supra and subgingival scaling and polishing will be performed by the use of manual and ultrasonic instruments and oral hygiene instructions will be given. Patients will be instructed to use interdental brushes with appropriate size interdental brushes or dental floss when interdental embrasures will not allow for interdental brushing."
224248234|NCT02054117|OTHER|Intracerebral Hemorrhage|Spontaneous intracranial or intraparenchymal hemorrhage that occurred in a supratentorial location.
224248235|NCT00490204|DRUG|Cetirizine|
224248236|NCT00829530|DRUG|Ramipril 10 mg capsule|1 x 10 mg
224248237|NCT00829530|DRUG|Altace® 10 mg capsule|1 x 10 mg
224248238|NCT01320254|DRUG|Cisplatin, Gemcitabine, Panitumumab|Cisplatin 25mq/sq.m. at day 1+8 and Gemcitabine 1000mg/sq.m. at day 1 + 8 Panitumumab 9mg/kg BW at day 1
223666498|NCT04704362|BEHAVIORAL|Ensuring Quality in Psychological Support|Trainees are evaluated with the Enhancing Assessment of Common Therapeutic factors structured role play tool and the results are shared with trainers and/or supervisors to modify training based on strengths and weakness on the competency scores.
223666499|NCT04704362|BEHAVIORAL|Standard Training and Supervision|Trainees are trained using a manual for non-specialist-delivered psychological interventions.
223666500|NCT00456443|PROCEDURE|Historical records|
224248239|NCT01320254|DRUG|Cisplatin, Gemcitabine|Cisplatin 25mq/sq.m. at day 1+8 and Gemcitabine 1000mg/sq.m. at day 1 + 8
224248240|NCT00840866|DRUG|cefprozil|500 mg Tablet
223666501|NCT04929717|OTHER|Breastfeeding education and counseling|Breastfeeding education was applied for four weeks.
223666502|NCT04929717|OTHER|Routine postpartum breastfeeding training included in the hospital procedure|The routine breastfeeding postpartum educational training given to all women by healthcare personnel as part of the hospital procedures.
224248241|NCT00840866|DRUG|Cefzil®|500 mg Tablet
224248242|NCT04343794|DEVICE|BIOVITALS|Biovitals platform including (1) armband with multiple physiological sensor, (2) remote monitoring, and (3) Analytic platform. The arm will be worn 23 hours a day and off for 1 hour during showering for recharging battery during 24 hr quarantine period
224248243|NCT01015625|PROCEDURE|Surgery|lumpectomy or mastectomy with or without radiotherapy. Sentinel biopsy followed by axillary dissection (level I-II)
224248244|NCT01015625|PROCEDURE|Surgery on Demand|if necessary local therapy on demand
224248245|NCT05399446|BEHAVIORAL|Diabetes Body Project|The Diabetes Body Project (DBP) is an adapted version of the Body Project Prevention program designed specifically for individuals with Type 1 Diabetes. DBP consists of six weekly, one-hour long sessions. Group participants complete the exercises from the original Body Project and also new diabetes-specific content, drawn from Olmsted et al. (2002) that is delivered in a dissonance-based interactive format with Socratic questions from group leaders encourage participants to generate their own answers.
224248246|NCT05399446|BEHAVIORAL|Educational Group|We selected a T1D management/Eating disorder psychoeducational comparison condition to control for expectancy effects and demand characteristics. To match the Diabetes Body Project, the educational lectures will be delivered in 6 1-hour blocks. Topics include basic information about the various EDs, complications of ED behaviors, diabetes and body image, effects of dieting on blood glucose, and the risk of complications.
224248247|NCT04112823|DRUG|Dexamethasone 4mg|Dexamethasone 4mg + metoclopramide 10mg, intravenously
224248248|NCT04112823|DRUG|Dexamethasone 16mg|Dexamethasone 16mg + metoclopramide 10mg, intravenously
224248249|NCT06627010|OTHER|description|study of file
224248250|NCT05186571|BIOLOGICAL|Pfizer-BioNTech mRNA COVID-19 vaccination|Vaccination in children 5-11 years of age
224248251|NCT01770938|DEVICE|Effective light-emitting diode therapy|
224248252|NCT01770938|DEVICE|Placebo light-emitting diode therapy|
224248253|NCT04206410|DIETARY_SUPPLEMENT|Probiotic|Multispecies probiotic mixture administered to patients according to the randomization list
224248254|NCT04206410|DIETARY_SUPPLEMENT|Maltodextrin|Maltodextrin as placebo
224248255|NCT00625443|DRUG|Blinded (placebo)|"Placebo Orally, once daily administered under fasting conditions (at least 1 hr prior to or at least 2 hours after a meal or snack)~Duration - 6 months"
224248256|NCT00625443|DRUG|Open Label (Avatrombopag tablets)|"Dose 10 mg~Orally, once daily administered under fasting conditions (at least 1 hr prior to or at least 2 hours after a meal or snack)~Duration - 6 months"
224248257|NCT00625443|DRUG|Blinded (Avatrombopoag tablets)|"Dose: 2.5, 5, 10, or 20 mg~Orally, once daily administered under fasting conditions (at least 1 hr prior to or at least 2 hours after a meal or snack)~Duration - 6 months"
224248258|NCT05427643|PROCEDURE|study group|dental implant procedure under local anesthesia
224248259|NCT05427643|PROCEDURE|control group|dental implant procedure under local anesthesia
224248260|NCT04949932|OTHER|Mixed powder of Lens culinaris, Curcuma longa, Mentha arvensis, Azadirachta indica, and Trigonella foenumgraecum.|Study subjects were prescribed either PHP or placebo once daily at night for 3 weeks consecutively. A dose of 1-2 tea spoonfuls powder had to mixed with water to make paste. Then it was applied on face (except around the eyes) and had to wait for 20-30 minutes until it dries.Then they were washed face by using normal water.
224248261|NCT04949932|OTHER|Cicer arietinum powder|Study subjects were prescribed either PHP or placebo once daily at night for 3 weeks consecutively. A dose of 1-2 tea spoonfuls powder had to mixed with water to make paste. Then it was applied on face (except around the eyes) and had to wait for 20-30 minutes until it dries.Then they were washed face by using normal water.
224248262|NCT04327375|OTHER|Observational|Observational
224248263|NCT00649753|PROCEDURE|Category II Pelvic Blocking|Supine Orthopedic Blocking consists of placing padded wedges underneath the Ilium and greater trochanter to correct pelvic torsion and associated sacroiliac dysfunction.
224321807|NCT05193396|DRUG|Placebo|Patients are randomized to oral hydrocortisone (10 mg twice daily) or placebo for 16 weeks.
224321808|NCT05069558|DEVICE|Investigational PFO Closure Device|Occlutech Flex II PFO Closure Device
223666503|NCT01947062|DRUG|Intravenous Cisplatin & etoposide|Patients will receive standard intravenous cisplatin and etoposide based chemotherapy, for a total of six cycles, delivered at three-weekly intervals. In each cycle, the dose of cisplatin will be at 50mg/m2 on days 1 \& 2. The dose of etoposide will be 100mg/m2 on days 1, 2 \& 3.
224248264|NCT00649753|PROCEDURE|Category II Pelvic Blocking and Cranial|Supine Orthopedic Blocking consists of placing padded wedges underneath the Ilium and greater trochanter to correct pelvic torsion and associated sacroiliac dysfunction. During pelvic blocking a cranial procedure is performed using a zygomae release and sphenobasilar release. These cranial procedures are manual therapy procedures using light pressure from hand and/or finger contacts.
224248265|NCT00649753|PROCEDURE|Cranial Only|Without pelvic blocking a cranial procedure is performed using a zygomae release and sphenobasilar release. These cranial procedures are manual therapy procedures using light pressure from hand and/or finger contacts.
224248266|NCT02898545|DEVICE|SEEQ monitor|An external cardiac rhythm monitor
224248267|NCT05813548|OTHER|FASTer Way Intervention|6-weeks of exercise, building healthy nutritional habits such as intermittent fasting and carb-cycling
224248268|NCT05813548|OTHER|Control Group Intervention|6-weeks of following general exercise and nutrition guidelines from American Heart Association (AHA) and United States Department of Agriculture (USDA), respectively.
224248269|NCT03038048|PROCEDURE|Varying needle size with intravitreal ranibizumab or aflibercept|Varying gauge of needle, 33 gauge vs 30 gauge
224248270|NCT00006495|BIOLOGICAL|ALVAC(2)120(B,MN)GNP (vCP1452)|
224248271|NCT00006495|BIOLOGICAL|HIV-1 Immunogen|
224248272|NCT02472366|DRUG|ILUVIEN|
224248273|NCT02728102|PROCEDURE|Tumor Cell Collection|Patients will undergo aspiration of 30 mL of bone marrow from which myeloma cell preparations will be generated. Myeloma cells will be isolated and frozen for subsequent vaccine generation for patients randomized to the vaccine arm (randomization occurs after transplant and recovery).
224248274|NCT02728102|PROCEDURE|Autologous Stem Cell Transplant|Patients will receive an autologous graft with a minimum cell dose of 2.0 x 10\^6 CD34+ cells/kg patient actual body weight per autologous transplantation.
224248275|NCT02728102|DRUG|Melphalan|Autologous hematopoietic cell transplant will be done with high-dose melphalan of 200mg/m\^2 at the schedule and timing according to institutional practices.
224248276|NCT02728102|PROCEDURE|Leukapheresis|Blood samples will be collected through a catheter in the neck or chest and leukapheresis will be performed using standard clinical procedures.
224248277|NCT02728102|BIOLOGICAL|Myeloma vaccine|The target dose is 3 x 10\^6 fusion cells per vaccine. A minimum of 3 x 10\^6 total fusion cells will be required to proceed with vaccine administration. Patients who have \<3 x 10\^6 total fusion cells will not proceed with vaccination. Patients will receive the DC/MM fusion vaccine on day 1 of cycles 2, 3, and 4 of lenalidomide maintenance. Vaccine will be administered by subcutaneous injection in the upper thigh.
224248278|NCT02728102|DRUG|GM-CSF|100 ug GM-CSF will be given subcutaneously in the upper thigh and daily for a total of 4 days of each cycle.
223666504|NCT01947062|DRUG|Intravenous Cisplatin & etoposide along with oral cyclophosphamide|Patients will be treated with oral cyclophosphamide at a daily dose of 50mg. Patients will also receive standard intravenous cisplatin and etoposide based chemotherapy, for a total of six cycles, delivered at three-weekly intervals. In each cycle, the dose of cisplatin will be at 50mg/m2 on days 1 \& 2. The dose of etoposide will be 100mg/m2 on days 1, 2 \& 3.
223666505|NCT01246817|DRUG|Temsirolimus|temsirolimus (standard schedule: 25 mg weekly, by 1-hour i.v. infusion)
223666506|NCT05412589|DRUG|mFOLFOX7+Camrelizumab+Apatinib|"Drug: Leucovorin 200mg/m2 administered IV on Days 1 of a 21 day cycle Drug: Oxaliplatin 85 mg/m2 IV on Days 1 of a 21 day cycle. Drug: Fluorouracil 5-FU continuous infusion: 400mg/m2 on D1 and then 2400mg/m2 for 46h of each 21 day cycle.~Drug: Camrelizumab 200mg infusion on D1 for every 21 days Drug: Apatinib 250mg，po，qd for every 21 days"
223666507|NCT00179491|BEHAVIORAL|Intercessory Prayer|14 days of intercessory prayer from 3 sites
224248279|NCT02728102|DRUG|Lenalidomide|Maintenance therapy with lenalidomide will begin between 90 and 100 days after stem cell infusion. Lenalidomide will be administered initially at a dose of 10 mg per day continuously. Cycle duration during maintenance therapy is 28 days. Patients will continue lenalidomide for two years from initiation of therapy.
224248280|NCT03739749|PROCEDURE|Arthroscopic superior capsular reconstruction|The superior capsule of patients with irreparable rotator cuff tears will be reconstructed using an autograft or an allograft
224248281|NCT03142360|DRUG|Beraprost sodium (Berasil)|Within two days after successful arteriovenous graft surgery, the treatment group is randomly assigned to start taking 120 mcg of Berasil.
224248282|NCT01182415|PROCEDURE|Autologous stem cell transplant|Autologous stem cell transplant following high-dose chemotherapy
223666508|NCT02931708|OTHER|Diaphragm functional electrical stimulation|Functional electrical stimulation: 80 Hz frequency, 0.4 ms pulse, rise 1s, 1s time on, decay 2s, 1s time off, intensity as patient tolerance
223666509|NCT00164944|PROCEDURE|Colonoscopy|To determine the adenomas during colonoscopy
224248283|NCT01182415|DRUG|High-dose chemotherapy|High-dose chemotherapy with rituximab, thiotepa, busulfan, and cyclosphosphamide
224248284|NCT02535494|OTHER|Extensive training|We have developed a more in-depth education package to help participants better recognize and respond to an opioid overdose.
224248285|NCT01135927|DRUG|insulin degludec|NN1250 (insulin degludec) injected s.c. (under the skin) once daily for 6 days
224248286|NCT01135927|DRUG|insulin detemir|Insulin detemir injected s.c. (under the skin) once daily for 6 days
224248287|NCT04044326|PROCEDURE|The Solero Microwave Ablation|The Solero Microwave Ablation system (Angiodynamics Ltd, USA) with a single microwave applicator operating at a 2.45 GHz will be used to perform MWA
224248288|NCT02424266|DEVICE|None invasive imaging of the tear film (AdOM)|White light tomography imaging
224248289|NCT00175617|DRUG|Spironolactone|This study evaluates the efficacy of therapy with the anti-androgen spironolactone compared to topical minoxidil in female pattern hair loss.
224248290|NCT00175617|DRUG|Minoxidil|This study evaluates the efficacy of therapy with the anti-androgen spironolactone compared to topical minoxidil in female pattern hair loss.
224248291|NCT02742935|BIOLOGICAL|camrelizumab|A fully humanized anti-PD-1 monoclonal immunoglobulin (IgG4 subtype)
224248292|NCT05209009|BIOLOGICAL|COVAC-2|Intramuscular vaccine against SARS-CoV-2
224248293|NCT05209009|BIOLOGICAL|Saline Placebo|Intramuscular injection of saline placebo
223666510|NCT00164944|PROCEDURE|Colonoscopy|To determine the adenomas during colonoscopy
224248294|NCT05070611|DEVICE|IPL-MGX|One week after lesion incision, the E-Eye machine (E-SWIN company, France) IPL treatment was administered to the skin area below the lower eyelid.13 Before treatment, the eyes were protected with opaque goggles and ultrasound gel was applied on the patient's face from tragus to tragus including the nose to conduct the light.
224248295|NCT01846845|DEVICE|Conventional Prosthetic Transfemoral Socket System|Conventional transfemoral may include an ischial containment socket, a pin suspension socket, and/or suction suspension socket
224248296|NCT01846845|DEVICE|Novel Prosthetic transfemoral socket system|Prosthetic socket that incorporates lower socket trim-lines and transfemoral vacuum suspension
224248297|NCT01159132|DRUG|raltegravir|12 hour PK will be done on day 1 while subjects is on stable regimen with RAL 400 mg BID. After performing intensive PK, subjects will be randomized to either group A (RAL 400 mg OD) or B (RAL 800 mg OD) for 14 days and on day 15, a second 24 hour full PK will be carried out. After the intensive PK, subjects in both the groups will switched to the other dosing regimen, group A (RAL 800 mg OD) and B (RAL 400 mg OD) for another 14 days and on day 29, the third 24 hour full PK will be carried out.
224248298|NCT02993991|DRUG|Mocetinostat|Mocetinostat (MGCD0103) is a potent small molecule HDAC inhibitor that targets human HDAC isoforms. It is an orally bioavailable, second generation benzamide inhibitor of HDAC 1, 2, 3 and 11 with broad spectrum antitumor activity in vitro and in vivo.
224248299|NCT02993991|BIOLOGICAL|Durvalumab|Durvalumab is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody directed against human PD-L1. It is selective for recombinant PD-L1 and blocks the binding of recombinant PD-L1 to the PD-1 and CD80 receptors.
224248300|NCT05479110|BEHAVIORAL|Empathy experience courses and case-base clinical reasoning|Four 3-hour training sessions over 2 weeks, which included group instruction on empathy experience, clinical reasoning, and functional therapy case-oriented learning.
224248301|NCT05479110|OTHER|case studies|active control: case studies(text)
224248302|NCT01121276|DRUG|Faster-acting insulin aspart|0.2 U/kg body weight injected subcutaneously (under the skin)
224321809|NCT05069558|DEVICE|Standard of Care PFO Closure Device|Amplatzer PFO Occluder and Gore Cardioform PFO Occluder
224248303|NCT01121276|DRUG|insulin aspart|0.2 U/kg body weight injected subcutaneously (under the skin)
224248304|NCT01121276|DRUG|Faster-acting insulin aspart|0.2 U/kg body weight injected subcutaneously (under the skin)
224248305|NCT01121276|DRUG|Faster-acting insulin aspart|0.2 U/kg body weight injected subcutaneously (under the skin)
224248306|NCT01121276|DRUG|Faster-acting insulin aspart|0.2 U/kg body weight injected subcutaneously (under the skin)
224248307|NCT02587962|DRUG|Birinapant|Birinapant intravenous (IV) on Days 1 and 8 of each 21-Day Cycle. The following escalating doses of birinapant to be studied: 5.6, 11, 17, and 22 mg/m2. In the expansion phase the assigned recommended phase two dose will be administered in all cohorts
224248308|NCT02587962|DRUG|Pembrolizumab|200 mg pembrolizumab IV on Day 1 of each 21-Day Cycle
224248309|NCT03184480|DRUG|Arnuity Ellipta|The active component of Arnuity Ellipta is fluticasone furoate and it is indicated for the treatment of bronchial asthma. Post-marketing investigation of ARNUITY ELLIPTA will be carried out in this analysis.
224321810|NCT05004896|DRUG|Ketamine Hydrochloride|36 patients will receive ketamine hydrochloride, over four infusions, flexibly dosed between 0.5 mg/kg to 0.75 mg/kg
224321811|NCT05004896|DRUG|Midazolam Hydrochloride|36 patients will receive midazolam hydrochloride, over four infusions, flexibly dosed between 0.02 mg/kg to 0.03 mg/kg
223666511|NCT06334406|OTHER|Biological samples|"Blood samples will be collected at baseline, after the diagnostic TURBT, and D15 after the end of treatment in each cohort.~Tumor tissues will be collected at baseline for three patients."
224248310|NCT04990180|BEHAVIORAL|Shared Decision Making Intervention|Decision coaching will be provided to the Pulmonary Rehabilitation Specialists to provide the skills needed to facilitate shared decision making between themselves and patients (and carers). The patient decision aid will be an informational booklet which describes the available Pulmonary Rehabilitation options at the University Hospitals of Leicester. It will detail the risks and benefits of each option and provide interactive sections to engage patients with the content, guide them through it, encourage them to attribute personal meaning and preference to each one so they can make an informed and values-based decision about PR.
224248311|NCT00481520|DRUG|SAM-531|
224248312|NCT00481520|OTHER|placebo|
223666512|NCT00561977|BEHAVIORAL|High Fiber Diet|high fiber diet (≥30 grams of total fiber per day); reduction of calories to -500 from resting metabolic rate (RMR), not less than 1200 kcal per day.
223666513|NCT00561977|BEHAVIORAL|low saturated fat diet|low saturated fat diet (≤7% of total calories); -500 calories from RMR, not less than 1200 kcal/day.
223666514|NCT00561977|BEHAVIORAL|Combination diet|combination low saturated fat high fiber diet, with calorie restriction as specified.
224248313|NCT05009225|OTHER|Comprehensive ED AF management tool|Managing atrial fibrillation (AF) patients in the emergency department (ED) is complex, often requiring many separate decisions: How to best reduce the heart rate? Should emergency physicians attempt cardioversion? If so, how? Does this patient need stroke prevention? The investigators' CDSS provides emergency physicians with a one-stop, evidence-based resource that addresses all aspects of ED AF management.
224248314|NCT03685565|PROCEDURE|Dermabond and steristrips|Laceration repaired with Dermabond with underlying steristrips
224248315|NCT03685565|PROCEDURE|Dermabond|Laceration repaired with Dermabond
224248316|NCT03232372|DEVICE|External-Connection non-submerged Imp|Through a surgical procedure, we will implant implant whit external connection and non submerged to patients.
224248317|NCT03232372|DEVICE|Internal Connection Submerged implants|Through a surgical procedure, we will implant implant whit internal connection and submerged to patients.
224248318|NCT03232372|DEVICE|Internal Connection non-Submerged Impl|Through a surgical procedure, we will implant implant whit internal connection and non-submerged to patients.
224248319|NCT00148772|DRUG|Erlotinib (Tarceva)|
224248320|NCT03717350|DRUG|Meropenem|2g of meropenem diluted in 100ml of sodium chloride 0.9% within 15 minutes intravenously administered once
224248321|NCT03717350|DRUG|Placebo|100ml of sodium chloride 0.9% within 15 minutes intravenously once
224321812|NCT05787665|OTHER|phone call at 3 months|patients will be called at 3 months to know if they are alive and to know if they have been rehospitalized
224248322|NCT03828058|DRUG|Envarsus XR|Envarsus XR to be administered orally, once a day. Dosage will be adjusted as determined by trough blood levels.
224248323|NCT03828058|DRUG|Prograf|Prograf 2 mg BID to be administered orally, twice a day. Dosage will be adjusted as determined by trough blood levels.
224248324|NCT01488786|DEVICE|BrainPort Vision Device|2-3 days of training (10 hours) followed by minimum in-home use 300 minutes per month for 12 months.
224248325|NCT02522234|BIOLOGICAL|F-627 240 μg/kg|F-627 at 240 μg/kg dose enrolling 6 patients with breast cancer receiving adjuvant chemotherapy. Subjects will receive a corresponding dose of F-627 by subcutaneous injection 24 hours after each cycle（21 days） of chemotherapy drug administration. Blood samples are then collected at multiple time points during follow-up visits to evaluate the pharmacokinetics, pharmacodynamics, and safety of the drug. Dose will remain unchanged throughout the treatment period. Eligible subjects will be enrolled sequentially into the 240 μg/kg arm. And the arm should contain 6 evaluable subjects.
224248326|NCT02522234|BIOLOGICAL|F-627 320 μg/kg|F-627 at 320 μg/kg dose enrolling 6 patients with breast cancer receiving adjuvant chemotherapy. Subjects will receive a corresponding dose of F-627 by subcutaneous injection 24 hours after each cycle（21 days） of chemotherapy drug administration. Blood samples are then collected at multiple time points during follow-up visits to evaluate the pharmacokinetics, pharmacodynamics, and safety of the drug. Dose will remain unchanged throughout the treatment period. Eligible subjects will be enrolled sequentially into the 320 μg/kg arm. The arm should contain 6 evaluable subjects.
224248327|NCT00234286|BEHAVIORAL|Comfort care education intervention|Comfort care education intervention, consisting of intensive, on-site staff training together with an electronic order set for palliative care and educational materials
224248328|NCT02605395|DRUG|IDIAZOLE 20mg DR tabs|IDIAZOLE 20mg DR tabs is a delayed-release, enteric-coated tablets containing 20 mg of rabeprazole sodium.
224248329|NCT02605395|DRUG|PARIET 20 mg DR tabs|PARIET 20 mg DR tabs is a delayed-release, enteric-coated tablets containing 20 mg rabeprazole sodium.
224248330|NCT01422538|DEVICE|Ulthera® System|Focused ultrasound energy delivered below the surface of the skin on the lower face.
223666515|NCT02086643|PROCEDURE|Retroclavicular block|Retroclavicular ultrasound guided nerve block with total injection of 40 ml of a mixture of 20 ml ropivacaine 0,5% (5 mg/ml) + 20 ml mepivacaine 1,5% (15 mg/ml) + epinephrine 1 : 400 000 (2,5 mcg/ml). Incremental injections of 5 ml separated by an aspiration test.
223666516|NCT02914028|PROCEDURE|transversus abdominis plane block|A peripheric block needle is inserted entering the facia between musculus rectus abdominis and musculus transversus abdominis with ultrasonography and local anesthetics are injected in the facia.
223666517|NCT02914028|DRUG|Tramadol and paracetamol|Tramadol 100 mg and paracetamol 1000 mg are applied to the patients at the end of the surgery
223666518|NCT02535572|DEVICE|FEAST|FEAST is a new form of ECT, with directional current, rather than traditional alternating current which goes in both directions between the electrodes.
223666519|NCT02535572|DEVICE|RUL UB|This is right unilateral ultrabrief ECT, the standard of care.
223666520|NCT03685890|DRUG|Nivolumab|One infusion of nivolumab (Opdivo®) 480mg (flat dose) in NaCl (Natriumklorid Baxter Viaflo, 9 mg/ml) during 60 minutes
223666521|NCT03685890|PROCEDURE|Isolated limb perfusion (ILP)|Patients will be treated with ILP according to clinical routine at each separate site. The procedure is performed under general anaesthesia. The major artery and vein of the limb is catheterized, and a tourniquet is placed proximally on the limb. Continuous leakage monitoring is performed. The perfusate is heated to 40C and after ensuring steady state, melphalan (Alkeran®) at a dose of 13 mg/L (upper limb) or 10 mg/L (lower limb) is infused into the circulation during 20 minutes for a total perfusion time of 60 minutes. According to local routine tasonermin (Beromun®) will be added to the perfusate 30 minutes before the melphalan as a bolus dose of 1-4 mg.
224248331|NCT01422538|DRUG|Sculptra®|Injectable filler reconstituted prior to use. Injections are administered to the lower face in a combination of cross-hatching and fanning techniques. The Sculptra is injected in two treatment sessions 6 weeks apart.
224248332|NCT01422538|OTHER|Sculptra® treatment followed by Ultherapy™ treatment|Sculptra® administered in 2 injection sessions 6 weeks apart, then Ultherapy™ treatment 4 months following Sculptra.
224248333|NCT02738190|DRUG|Albumin|Albumin 5% added to blood priming solution
224248334|NCT02738190|BIOLOGICAL|Fresh Frozen Plasma|Fresh Frozen Plasma added to blood priming solution
223666522|NCT04620798|BEHAVIORAL|Immediate vs. delayed provision of antibody test results|The primary experiment will be assessing whether provision of the antibody test results leads to behavior change with respect to personal protective behaviors. To that end, we will randomize all participants to a trial arm that immediately receive results (within 24 hours) or a trial arm with a delayed provision of results (after 4 weeks).
223666523|NCT01297777|DRUG|Imatinib Mesylate|"* In patients without B or C findings and without biological progression: 300 mg/24 h p.o during one year or until progression/unacceptable toxicity.~* In patients with B or C findings or biological progression: 300 mg/24 h p.o for two weeks and then 400 mg/24 h p.o for a total of one year of therapy, or until progression/unacceptable toxicity."
223666524|NCT02872220|DRUG|SPF 50 Y65 110 (BAY987519)|Application of 200 µL in an occlusive patch of Webril (0.150 ± 0.010 mg) compared to that of a negative control (0.9% sodium chloride, NaCl) and followed by irradiation with UV A and UVB.
223666525|NCT02872220|DRUG|SPF 50 Y51 002 (BAY987519)|Application of 200 µL in an occlusive patch of Webril compared to that of a negative control (0.9% sodium chloride, NaCl) and followed by irradiation with UV A and UVB.
223666526|NCT02872220|DRUG|SPF 15 V27 104 (BAY987519)|Application of 200 µL in an occlusive patch of Webril compared to that of a negative control (0.9% sodium chloride, NaCl) and followed by irradiation with UV A and UVB.
223666527|NCT02872220|DRUG|Sodium chloride [NaCl]|Negative control (200 µL, 0.9% sodium chloride \[NaCl\]) after a single 24 h application of test materials followed by irradiation with ultraviolet A (UVA) and ultraviolet B (UVB).
224248335|NCT00553228|BIOLOGICAL|Tdap|0.5 mL IM once at visit #2
224248336|NCT00553228|BIOLOGICAL|Td|0.5 mL IM once at visit #2
224248337|NCT02770820|BIOLOGICAL|Aldesleukin|Given SC
224248338|NCT02770820|BIOLOGICAL|Autologous WT1-TCRc4 Gene-transduced CD8-positive Tcm/Tn Lymphocytes|Given IV
224248339|NCT02770820|OTHER|Laboratory Biomarker Analysis|Correlative studies
224248340|NCT05412173|DRUG|Molnupiravir|A single dose of R or T drug in each of 2 periods of the study in fasted conditions
224248341|NCT00720265|DRUG|Prograf|oral
224248342|NCT00720265|DRUG|MR4|oral
224248343|NCT03214822|DIETARY_SUPPLEMENT|H2MF|As described in the Experimental Arm description.
224248344|NCT04165239|DRUG|KH176|Oral administration of 50 mg KH176 twice daily
224248345|NCT04165239|DRUG|KH176|Oral administration of 100 mg KH176 twice daily
223666528|NCT03030742|OTHER|Survey|"A survey will be administered at two time points (time of hospital discharge and 2-4 weeks postpartum) to determine:~* Satisfaction with pain control 2-4 weeks postpartum~* Patient-reported use of opioid medication postpartum (receipt of prescription, filling of prescription, if refill was obtained, and number of opioid pills remaining at the time of follow-up)~* Patient characteristics associated with high opioid use~* Methods of storage and disposal of unused opioids"
223666529|NCT03027284|DRUG|Merestinib|Administered orally
223666530|NCT03027284|DRUG|Cisplatin|Administered IV
223666531|NCT03027284|DRUG|Gemcitabine|Administered IV
223666532|NCT04821362|DEVICE|Ultrasound group|In the ultrasound group, the nurses will insert the cannulas to the peripheral veins as horizontally and longitudinally with the linear probe.
223666533|NCT04821362|DEVICE|Near Infrared Device Group|In the near infrared device group, the nurses will insert the cannulas to the peripheral veins with AccuVein AV 400.
223666534|NCT00781352|DRUG|nitrous oxide|65% nitrous oxide administered during surgery
223666535|NCT00781352|DRUG|nitrogen|Nitrogen administration during surgery
223666536|NCT02084251|DRUG|PB-119|
223666537|NCT03554811|DEVICE|Functional electrical stimulation assisted supine cycling (FESC)|A supine cycle ergometer attached to a six-channel stimulator will be used for FESC. Surface electrodes will be applied to the hamstrings, quadriceps, and calf muscles on both legs. Muscles will be stimulated at specific stages throughout the cycling phase. Each session will start with a 1 minute motor-driven passive cycling warm-up at a rate of 20 revolutions per minute. Patients will continue with passive, active-assisted, or active cycling, according to their level of participation. If the patients stop cycling actively, the ergometer will revert to passive cycling.
223666538|NCT03554811|OTHER|Conventional early exercise and mobility interventions|These interventions will be based on the patient's alertness and medical stability, and includes activities to maintain or increase limb range of motion and strength, in and out of bed mobility, sit to stand, and transfer training, as well as assisted ambulation.
223770798|NCT03866174|OTHER|Set and Setting (SaS) Protocol|The SaS Protocol prescribes 6-8 hours of preparatory meetings with two facilitators prior to dosing, a 7-10 hour dosing session in a comfortable room under the supervision of the same two facilitators, and 4 hours of post-dose integration sessions with facilitators. During the dosing session participants are encouraged to wear eyeshades and listen to a curated playlist on headphones.
223770799|NCT00780572|BEHAVIORAL|ADE alert assistant|A note in CPRS alerting providers that patients are at risk for an adverse event based on prescription and lab value histories.
224248346|NCT04165239|DRUG|Placebo|Oral administration of matching placebo twice daily
224248347|NCT01414972|DRUG|Vitamin A|1 cap vitamin A 25000 IU/day for 3 month
224248348|NCT01414972|DRUG|placebo|1 cap placebo/day for 3 month
224248349|NCT03928886|DEVICE|bilateral two-view (CC and MLO) FFDM (full field digital mammography) using patient-assisted compression mode|Patient-assisted mode of Senographe Pristina (a commercial mammography medical device consisting of the Senographe Pristina FFDM system -2D- and Senographe Pristina DBT option -3D-) for FFDM imaging procedure. The patient-assisted compression feature enables the patient to personally refine breast compression using a hand-held remote control after the compression has been initiated by the operator, which is required to ensure proper breast positioning.
224248350|NCT03928886|DEVICE|bilateral two-view (CC and MLO) FFDM (full field digital mammography) using standard compression mode|"Standard compression mode of Senographe Pristina (a commercial mammography medical device consisting of the Senographe Pristina FFDM system -2D- and Senographe Pristina DBT option -3D-) for FFDM imaging procedure.~Study-related compressions will consist of the first and second CC and MLO compressions performed on each breast during each subject's exam."
224248351|NCT04395417|DRUG|Hyaluronic Acid|Patients were infiltrated with injection single dose 30 mg/2 ml 1500 kilodalton high molecular weight hyaluronic acid at the lateral epicondyle according to the standard technique.
224248352|NCT04395417|BIOLOGICAL|Prolotherapy|Patients were infiltrated with 5cc of dextrose 15% at the lateral epicondyle according to the standard technique. For solution, 1 cc 2% lidocaine, 5 cc 30% hypertonic dextrose and 4 cc 0.9 % isotonic were used.
224248353|NCT03525860|PROCEDURE|Acupuncture|"The subject is placed in the selected position (lying down or sitting), based on their comfort level. The areas to be needled are prepped with an alcohol swab. Mandatory standards and safety guidelines for acupuncture will be followed.~The acupuncture treatment protocol will be based on Traditional Chinese Medicine (TCM) theory. The TCM treatment strategy is designed to Benefit the Heart, Tonify Heart Qi and Blood, Calm and Sedate Cardiac Excitability and Regulate the Qi. Current literature supports the use of selected acupuncture points as possibly beneficial in regulating the autonomic nervous system, modulating Heart Rate Variability (HRV), relieving chest pain, and reducing arrhythmias.~11 sterile, single use, disposable needles will be placed one by one until all needles are in place.~Needles remain in place for additional 20 minutes or so as the patient remains in the selected position~."
223666539|NCT05648669|DRUG|Elagolix|200 mg tablet
224248354|NCT02218905|BEHAVIORAL|Sit to stand test|Subjects will be asked to sit to stand in 40 inches chair for 60 seconds.
224248355|NCT03555305|DRUG|Insulin Glargine|Administered SC
224248356|NCT03555305|DRUG|Lantus|Administered SC
224248357|NCT02023853|PROCEDURE|ultrasonic|
224248358|NCT02023853|PROCEDURE|erythritol|
224248359|NCT02023853|DRUG|metronidazole gel|
224248360|NCT01638377|DRUG|Naltrexone|50 mg/day for 24 weeks. All participants will receive medical intervention in the form of medical management (MM) which will be delivered by a trained health care professional.
224321813|NCT06253611|DRUG|Nivolumab|Nivolumab 240 mg IV; every 2 weeks
223666540|NCT05648669|DRUG|Elagolix placebo|Elagolix-matched Placebo tablet
223666541|NCT04901689|DRUG|Leronlimab|Leronlimab 700 mg
223666542|NCT04901689|DRUG|Placebo|Placebo
223666543|NCT01616693|DIETARY_SUPPLEMENT|Probiotic|A capsule that contains at least 1 x 10\^9 Lactobacillus rhamnosus GG organisms per capsule. The contents of this capsule were given once daily orally.
223666544|NCT01616693|DIETARY_SUPPLEMENT|Zinc|Zinc sulphate syrup is zinc sulphate heptahydrate (concentration 1mg/ml). 5 ml of this suspension was given once daily orally.
223666545|NCT01616693|DIETARY_SUPPLEMENT|Probiotic placebo|The probiotic placebo was manufactured by the same company that manufactured the probiotic and contained inulin powder but no Lactobacillus rhamnosus GG. The contents of the capsule were given once daily orally.
224248361|NCT01638377|DRUG|Control|Placebo (Lactose Monohydrate) for 24 weeks. All participants will receive medical intervention in the form of medical management (MM) which will be delivered by a trained health care professional.
224248362|NCT00925054|DRUG|rAvPAL-PEG 0.001 mg/kg|In Part 1, the planned starting dose levels is 0.001 mg/kg
224248363|NCT00925054|DRUG|rAvPAL-PEG 0.003 mg/kg|In Part 1, the planned starting dose levels is 0.003 mg/kg
224248364|NCT00925054|DRUG|rAvPAL-PEG 0.01 mg/kg|In Part 1, the planned starting dose levels is 0.01 mg/kg
224248365|NCT00925054|DRUG|rAvPAL-PEG 0.03 mg/kg|In Part 1, the planned starting dose levels is 0.03 mg/kg
224248366|NCT00925054|DRUG|rAvPAL-PEG 0.1 mg/kg|In Part 1, the planned starting dose levels is 0.1 mg/kg
224248367|NCT03286465|DEVICE|Pediatric phlebotomy tubes|Use of pediatric size tubes for diagnostic blood collection.
224248368|NCT03286465|DEVICE|Adult phlebotomy tubes|Use of adult size tubes for diagnostic blood collection.
224248369|NCT02478190|OTHER|Tight control: goal glucose 350 mg/dL or lower|Goal glucose at discharge will be 350 mg/dL or less.
223666546|NCT01616693|DIETARY_SUPPLEMENT|Zinc placebo|The zinc placebo excluded the zinc sulphate but contained lactose and was diluted to match the taste. 5 ml of this suspension was given orally once daily.
223666547|NCT01616693|BIOLOGICAL|Rotavirus vaccine|1 ml Rotarix®, a lyophilized human rotavirus vaccine reconstituted with calcium carbonate buffer provided orally at 6 and 10 weeks.
223666548|NCT01616693|BIOLOGICAL|Oral polio vaccine|A liquid trivalent polio vaccine provided orally at 6 and 10 weeks.
223666549|NCT00117494|DRUG|Pravastatin|
223666550|NCT00117494|DRUG|Rosuvastatin|
223666551|NCT04863911|RADIATION|combined CT and MRI|"1 mL of gadolinium-diethylenetriamine pentaacetic acid (Gd-DTPA) will be diluted with 100 mL of saline; 8 mL of this will be mixed with 7 mL of iodine solution (340 mg/cc) and 3 mL of lidocaine 2% and injected under ultrasonographic guidance.~The fixed US-guided technique, the needle will be inserted into the needle guide hole and directed toward the hip joint, targeting the femoral head-neck junction. The volume injected varies from 10 to 20 mL, with a mean of 15 mL.~Ideally CT should be performed immediately after the injection and MR should be performed within 90 minutes after the initial injection."
223770800|NCT00799812|DRUG|CHG 2% w/v & IPA 70% v/v, swabstick (3 @ once).|3 swabsticks topically applied at the same time to intact skin
224248370|NCT02478190|OTHER|Loose control: goal glucose 600 mg/dL or lower|Goal glucose at discharge will be 600 mg/dL or less.
224248371|NCT03586726|DRUG|Balovaptan|"In Period 1, balovaptan was administered alone as a once daily (qd) dose on Days 1 to 10.~In Period 2, balovaptan was administered as a qd dose on Days 7 to 16."
224248372|NCT03586726|DRUG|Rifampicin|In Period 2, 600 mg of rifampicin will be administered alone as a qd dose from Day 1 to Day 6, and as a qd dose on Days 7 to 16.
224248373|NCT04470557|DIAGNOSTIC_TEST|D-dimer,CBC.ESR,CRP,|Complete blood count (for patients and control subjects): was done on CELL-DYN 3700 (Abbott-Germany) and blood film was stained by leishman staining, the morphology of red blood cells. CRP titre estimation by latix method .ESR erythrocyte sedimentation rate estimation (1:5) by Westerngreen tube method.
223770801|NCT00799812|DRUG|CHG 2% w/v & IPA 70% v/v swab applied sequentially|Chlorhexidine gluconate 2% w/v and isopropyl alcohol 70% v/v; 3 swabsticks applied sequentially to intact skin.
224248374|NCT04470557|DIAGNOSTIC_TEST|Liver function tests ,serum ferritin and PCR for COVID-19 .|"Serum ferritin was performed for all subjects on Modular P auto analyzer (Roche Diagnostics, Mannheim, Germany),~• Liver function tests ( aspartate aminotransferase, alanine aminotransferase and alkaline phosphatase) and kidney funcrion were performed for all subjects on Modular P auto analyzer (Roche Diagnostics, Mannheim, G ermany),"
224248375|NCT04302662|DRUG|MS1819-SD|Patients will receive increasing doses from the lowest to a maximum dose of MS1819-SD on top of a stable dose of PPEs. The total treatment phase will range from 39 to 51 days.
224248376|NCT05403684|OTHER|High-volume breastmilk|Preterm infants will be given high-volume breastmilk
224248377|NCT00000171|DRUG|Melatonin|
224248378|NCT00512421|PROCEDURE|computer-assisted surgery|
224248379|NCT04888572|RADIATION|Peri-Apical X-ray|"Using a PCP UNC 15 Hu Friedy® periodontal probe and a gentle horizontal sweeping motion through the peri-implant tunnel or sulcus the examiner will assess bleeding on probing, the main factor in determining peri-implant inflammation and subsequently possible peri-implantitis. Then, using the same instrument, the author will examine whether there is an increase in the values of pocket depths compared to the initial values, highlighting an installation of peri-implant disease. Radiographically, evidence of bone loss after healing through taking a digital x-ray that will be viewed on DBSWIN® software will help authors make a diagnosis of peri-implantitis as well. It will be required that the digital film be perfectly parallel to the axis of the implant and the X-ray tube perpendicular to them in order to have an orthogonal radiograph."
224248380|NCT02209922|DEVICE|Transcranial direct current stimulation (tDCS)|Participants underwent tDCS(2mA) brain stimulation (20 minutes) and simultaneous balance training(20 minutes) for 5 consecutive days,for 1 week.
224248381|NCT02209922|DEVICE|Sham|During sham stimulation, the current ramped up for 30 seconds, ramped back down for 30 seconds, and then remained off for the duration of the stimulation then and simultaneous balance training(20 minutes) for 5 consecutive days,for 1 week.
224248382|NCT06105034|PROCEDURE|interventional techniques, the severity of placental invasion, and various placental positions and suture techniques|Clinically, severe complications of PA include severe obstetric hemorrhage leading to disseminated intravascular coagulopathy (DIC), iatrogenic injury to the ureters, bladder, bowel, respiratory distress syndrome (RDS), acute transfusion reactions, electrolyte imbalance, and renal failure. In women with PA, the expected blood loss at delivery is 3000- 5000 mL, About 90% of patients require a blood transfusion with 40% requiring more than ten units of packed cell transfusion
224248383|NCT01718886|DEVICE|Obalon Gastric Balloon|
224248384|NCT02937415|PROCEDURE|Breath carbon monoxide|Breath carbon monoxide measurement.
224248385|NCT02937415|PROCEDURE|Pulmonary function tests.|Measurement of lung functions by blowing through a tube which measures flow and volumes of participant's lungs.
224248386|NCT02937415|PROCEDURE|Oxidative stress and antioxidant status.|Measurement of parameters of oxidative stress and antioxidant status in blood samples.
224321814|NCT06253611|DRUG|FOLFOX regimen|Oxaliplatin 85 mg/m², leucovorin 400 mg/m², bolus of 5-FU 400 mg/m², continuous 5-FU 2400/m² in 46 hours; every 2 weeks
224321815|NCT06253611|BIOLOGICAL|EXL01|Orally 1 capsule/day, starting on day 1 of each FOLFOX/nivolumab treatment.
224321816|NCT06112743|DRUG|Mavacamten|Specified dose on specified days
224321817|NCT05612685|BEHAVIORAL|Healthcare provider referral to a tax filing app|Healthcare providers offer a referral to a tax filing app and briefly describe the potential benefits of tax credit receipt
224321818|NCT05877729|OTHER|Standard of Care|The SOC arm will include the current care delivery model: regularly scheduled visits with a healthcare provider and lab testing every 3-6 months or more/less frequently depending on the individual's HIV health outcomes (e.g., VL suppression). At each assessment, the investigators will review 149 SOC participant responses to examine acute need for referral for medical, psychological, or substance use services. In between assessments, the investigators will also do monthly check-ins to improve retention and check contact information.
224321819|NCT05877729|BEHAVIORAL|Video-counseling+app|"The intervention tailors the telehealth counseling according to the individual's needs. Tailoring occurs based on the participant's baseline MH, SU, and HIV knowledge/outcomes and assessment responses inform the sessions on these topics. Participants choose from a list identified in the menu sessions: HIV care, MH, SU, lifestyle, health, social support, family of origin, romantic and sexual relationships, self-identity and disclosure, subsistence needs, education and vocation, and a wildcard session.~WYZ contains 3 main features: My Health, My Team, and My Community. Tailoring is achieved based on the individual's needs at a given time (e.g., My Community may be used more if social isolation is a barrier)."
224321820|NCT03681535|RADIATION|Radiation Therapy|This phase II study will evaluate whether a reduction in the RT dose, concomitant with a decrease in the RT field size, in patients that achieve complete response and have a negative post-chemotherapy PET scan following 3 to 6 cycles of rituximab containing chemotherapy, will be associated with a low risk of in-field failure. The goal of this approach is to maintain excellent control rates while minimizing the risk of acute and late toxicity.
224321821|NCT05339074|DRUG|Ketamine Hydrochloride|60 patients will receive ketamine hydrochloride over 12 weeks, flexible dosed between 0.5 mg/kg to 1.0 mg/kg
224321822|NCT02701088|DRUG|5Fluorouracile and Mitomycin-C|All the patients will receive radiochemotherapy with two cycles of 5FU (1,000 mg/m²/d with 96-h infusion, days 1-5 and 29-33 of SIB-IMRT) and Mitomycin-C (10 mg/m², days 1 and 29).
224321823|NCT02701088|RADIATION|Simultaneously integrated boost of intensity modulated radiation therapy (SIB-IMRT) by tomotherapy|SIB-IMRT schedule of 61.2 Gy/1.7 Gy to the primary tumor, 57.60 Gy / 1.6 Gy to involved nodes, and 54 / 1.5 Gy to elective pelvic lymph nodes.
224321824|NCT05229666|OTHER|Cognitive Challenge|Cognitive challenge delivered via computer.
224248387|NCT00781586|DIETARY_SUPPLEMENT|One-A-Day Weight S.A. (Multi-Vitamins, BAY94-9350)|One A Day Weight Smart Advanced 1 tablet at 1st visit
224248388|NCT00781586|DRUG|Caffeine|Caffeine 100 mg 1 tablet at 1st visit
224248389|NCT00781586|DRUG|Placebo|Placebo 1 tablet at 1st visit
224248390|NCT03520517|DRUG|BHV-0223|BHV-0223, 40 mg BID
224248391|NCT02803450|PROCEDURE|Epidural needle|Medication administration via epidural needle.
224248392|NCT02803450|PROCEDURE|Catheter Administration|Medication administration via epidural catheter.
224248393|NCT02803450|PROCEDURE|Standard of Care Epidural Administration|Medication administered at higher concentration, lower volume via epidural catheter.
224248394|NCT02161445|DEVICE|the acoustic cardiographic parameters were calculated|STIs were measured using simultaneous recording of the electrocardiogram and acoustic cardiography signals using an analogic numeric system (Biopac Systems, Goleta, CA). A3-minute acoustic cardiographic tracing for all patients was obtained and stored electronically. We measured the electromechanical activation time (EMAT) which is the time between the initial deflection of the electrocardiographic Q wave and the first phonocardiographic complex corresponding to the first heart sound (S1). The left ventricle ejection time (LVET) defined as the interval between the peak components from the S1 and S2 complexes was measured on the same cardiac cycles. All studies were performed in patients in a semi-recumbent position with head at 30 degrees position. For each patient, the acoustic cardiographic parameters were calculated from a 10-second free of artifact recording of data averaging 8 to 12 beats measurements.
224248395|NCT06124235|COMBINATION_PRODUCT|Coated Orthodontic Miniscrews with Chlorhexidine Hexametaphosphate Nanoparticles|"insertion:~1. According to the random number generated, the corresponding envelop for left and right side by chosen.~2. The patient will be asked to brush his/her teeth.~3. The patient will rinse his/her mouth with chlorhexidine mouth rinse (0.12%) just before surgery being at least half an hour after brushing.~The miniscrews used conical shaped, self-drilling, 1.6 mm in diameter, 8mm in length made of Ti.~1. The site of insertion determined from the x-ray by using stent that will be fabricated for accurate site for OMS.~2. Infiltration LA will be administered. Approximately 0.45 mL ,injected into the alveolar mucosa above the OMS placement site, in order to provides an acceptable anesthesia, while still allowing the patient feedback in case the OMS contacting the periodontal ligament (PDL).~3. OMS will be placed manually by screw driver on buccally at an angle 90 degrees and then adjusted to the appropriate angle.~4. x-ray will be taken to confirm OMS position."
224321825|NCT02179086|RADIATION|3-Dimensional Conformal Radiation Therapy|Undergo standard-dose 3D-CRT
224321826|NCT02179086|RADIATION|Intensity-Modulated Radiation Therapy|Undergo standard-dose IMRT
223666552|NCT02080819|DRUG|levodopa/carbidopa 400/100 BID|"Levodopa dose escalation (1 week): Days 1-2, one 50/12.5 mg tablet BID; Days 3-4, one 100/25 mg tablet BID; Days 5-6, one 200/50 mg tablet BID; Day 7, one 400/100 mg tablet BID.~Maintenance phase (7 weeks): One 400/100 mg Levodopa/Carbidopa tablet BID or placebo in conjunction with once weekly individual cognitive behavioral therapy plus contingency management for attendance."
224248396|NCT06124235|COMBINATION_PRODUCT|Uncoated Miniscrew with Chlorhexidine Hexametaphosphate Nanoparticles|Non-coated orthodontic miniscrews
224248397|NCT05499572|DEVICE|Inhalation maneuver with placebo Inbrija and placebo Cyclops|Patients perform the inhalation maneuvers with placebo inhalers (Inbrija and Cyclops) during a Parkinson's off episode.
224248398|NCT04453748|OTHER|Complex diagnostic panel|Complex, multidisciplinary diagnostic panel, including blood, imaging and functional tests.
224248399|NCT00059371|PROCEDURE|male circumcision|
223666553|NCT05083832|PROCEDURE|Continuous Erector Spina Plane Block vs Continuous Serratus Anterior Plane Block|Two different catheter techniques with same doses local anesthetic infusion
223666554|NCT04971317|BEHAVIORAL|Sugar-Sweetened Beverage (SSB) Video|Participants will watch a video showing the decay of an egg in various SSBs (Coca-Cola, Sprite, Gatorade, and apple juice), followed by the evaporation of these beverages over a heat source, revealing their sugar content.
223666555|NCT04971317|BEHAVIORAL|Water Video|Participants will watch a video showing an egg maintaining its shell in water, followed by the evaporation of water.
223666556|NCT04971317|BEHAVIORAL|Control|Participants will watch a video of an egg maintaining its shell in rubbing alcohol, followed by the evaporation of rubbing alcohol.
223666557|NCT03619057|OTHER|General anesthesia with laryngeal mask i-gel|General anesthesia with laryngeal mask i-gel
223666558|NCT00832624|DRUG|sitagliptin|Sitagliptin, 100 mg, 1 Tablet, once a day, for 18 weeks
223666559|NCT03113890|GENETIC|Phlebotomy - Folate|This will be a blood draw performed at Visit 1 for Folate (one 7mL tube)
224248400|NCT04316312|DEVICE|Threshold inspiratory muscle trainer|Threshold inspiratory muscle trainer will be set between 15% to 30% of maximal inspiratory pressure.
223666560|NCT03113890|GENETIC|Cheek Swab|Participants will undergo a cheek swab to then be analyzed using the Genecept Assay created by Genomind, Inc. This will occur once during Visit 1.
223666561|NCT03113890|OTHER|Self-report surveys|At visit 1 and at visit 3 and 4, participants will be asked to complete self report diagnostic surveys and surveys related to the objective aims of the study.
223666562|NCT04814199|OTHER|Algorithm|Patients will have a printed algorithm to follow while they are in labour with an epidural for pain management.
223666563|NCT02395172|DRUG|Avelumab|Participants received 10 milligrams per kilogram (mg/kg) of avelumab as a 1-hour intravenous infusion once every 2 weeks until confirmed disease progression, significant clinical deterioration, unacceptable toxicity, or any criterion for withdrawal from the study or Investigational Medicinal Product (IMP) as defined in the study protocol was fulfilled.
223666564|NCT02395172|DRUG|Docetaxel|Participants received 75 mg per square meter (m\^2) (per label) of docetaxel by intravenous infusion once every 3 weeks until confirmed disease progression, significant clinical deterioration, unacceptable toxicity, or any criterion for withdrawal from the study or Investigational Medicinal Product (IMP) as defined in the study protocol was fulfilled.
223666565|NCT00653939|DRUG|Fosbretabulin|Arm 2 only: Fosbretabulin (60 mg/m2) on Days 7,14 and 21 for 6 cycles.
223770802|NCT00799812|DRUG|Aqueous CHG 4% w/v applied according to mfr's directions|Chlorhexidine gluconate 4% w/v in an aqueous base applied according to mfr's directions. Step 1) 5 ml of Hibiclens applied to a sterile gauze pad. Step 2) Product applied to treatment area on intact skin for 2 minutes. Area dried with sterile towel or sterile gauze. Steps 1 and 2 repeated.
224248401|NCT01491880|BEHAVIORAL|Therapist-Assisted by Telephone|Parents will receive educational workbooks and ongoing support over the phone from a child anxiety specialist to learn how to use cognitive behavioral therapy skills to manage their children's fears and worries.
224248402|NCT01491880|BEHAVIORAL|Self-Help|Parents will receive educational workbooks to learn how to use cognitive behavioral therapy skills to manage their children's fears and worries independently. Parents will have the option to access support over the phone from a child anxiety specialist.
224248403|NCT00323193|BEHAVIORAL|MOVE!|group based psychoeducation, motivation and support
224248404|NCT01779323|OTHER|Pre and Post Sling Pelvic MRI|Pre and Post Sling Pelvic MRI
223666566|NCT00653939|DRUG|Carboplatin|Chemotherapy: Carboplatin (AUC 6) on Day 1 of each 21 day cycle for 6 cycles.
223666567|NCT00653939|DRUG|Paclitaxel|Chemotherapy: Paclitaxel (20 mg/m2) on Day 1 of each 21-day cycle for 6 cycles.
224248405|NCT03708835|OTHER|Transitional care model|In this study, the feasibility and impact of a transitional care model from hospital to home for stroke patients and caregivers will be tested.
224248406|NCT04332627|DRUG|Sugammadex|sugammadex 2mg/kg or 4mg/kg according to Train-of-four count (TOF 0 : 4mg/kg, TOF 1-4 : 2mg/kg)
223666568|NCT00653939|DRUG|Bevacizumab|Bevacizumab (15 mg/kg) on Day 1 of each 21-day cycle for 6 cycles.
223666569|NCT05828537|DEVICE|endotracheal tube|pediatric extubation
223666570|NCT01651962|DRUG|Terbutaline|
223666571|NCT01651962|DRUG|Fentanyl|
223666572|NCT01651962|DRUG|0.9% NaCl|
223666573|NCT01629446|DRUG|Lofexidine hydrochloride|Single Dose = Solution containing 400 μg lofexidine HCl and a tracer amount of 14C lofexidine
223666574|NCT00432549|DRUG|Almotriptan|
223666575|NCT00432549|DRUG|Topiramate|
223666576|NCT01546623|DRUG|TAP-144-SR(6M)|
223666577|NCT01546623|DRUG|TAP-144-SR(3M)|
223666578|NCT04335305|DRUG|Tocilizumab|IV infusion over 60 minutes; 8 mg/kg (up to a maximum of 800 mg per dose); single dose
223666579|NCT04335305|BIOLOGICAL|Pembrolizumab (MK-3475)|IV infusion over 30 minutes, 200 mg; single dose
223666580|NCT05213819|OTHER|Carpal Tunnel Syndrome|
223770803|NCT00799812|OTHER|Sterile swabstick with sterile water (3 @ once)|3 sterile swabsticks wetted with sterile water topically applied to intact skin at the same time.
223770804|NCT00799812|OTHER|Sterile swabstick with sterile water (one-at-a-time)|Sterile swabsticks wetted with sterile water topically applied to intact skin one-at-a-time.
223770805|NCT00395044|DRUG|Placebo|Placebo
223666581|NCT01134705|DRUG|Beclomethasone dipropionate hydrofluoroalkane HFA Nasal Aerosol|Beclomethasone dipropionate (BDP) Hydrofluoroalkane (HFA) Nasal Aerosol
223666582|NCT01134705|DRUG|Placebo Nasal Aerosol|HFA Vehicle Aerosol
223666583|NCT00166556|DRUG|Campath-1H and Tacrolimus|
223770806|NCT00395044|DRUG|Gabapentin|
223770807|NCT06323642|DIETARY_SUPPLEMENT|probiotic containing Lactobacillus rhamnosus GG.|probiotic containing Lactobacillus rhamnosus GG will be given daily for 3 days
223770808|NCT06323642|OTHER|placebo|milk as placebo
224248407|NCT04332627|DRUG|Neostigmine|with glycopyrrolate 0.4mg, neostigmine 0.02mg/kg or 0.04mg/kg or 0.05mg/kg according to Train-of-four count (TOF 0 : wait until TOF 2, TOF2-3: 0.05mg/kg, TOF4: 0.04mg/kg)
224248408|NCT05552781|DRUG|H002 capsule|Small molecule, Capsule
224248409|NCT00291057|DRUG|MALG|30 minute application
224248410|NCT01063556|DRUG|donepezil HCl|Subjects will receive donepezil HCL 3 mg without haemodialysis. After an interval of over 15 days, the subjects will receive donepezil 3 mg with haemodialysis.
223666584|NCT03069105|OTHER|Questionnaire|Participants will complete paper and pencil or electronic questionnaires at the cancer center or in the privacy of their own homes.
223666585|NCT00078169|BEHAVIORAL|Behavior Therapy|
223666586|NCT05141877|DRUG|Propofol|The propofol group was both induced and maintained at an effect-site concentration (Ce) of 2.0-4.0 mcg/mL by a target-controlled infusion (TCI) system.
223666587|NCT05141877|DRUG|Sevoflurane|The sevoflurane group was maintained via sevoflurane vaporizer between 1% and 3% (target minimum alveolar concentration of 0.7-1.3).
223666588|NCT00645437|DRUG|Levofloxacin|
224248411|NCT01063556|DRUG|donepezil HCl|Subjects will receive donepezil HCl 3 mg with haemodialysis. After an interval of over 15 days, the subjects will receive donepezil 3 mg without haemodialysis.
224248412|NCT02879877|DRUG|UCB7858|
224248413|NCT02879877|DRUG|Placebo|
224248414|NCT01307722|OTHER|left atrial distensibility-guiding prescription of heart failure drugs|This study is a prospective, observational, and open label investigation. The guide group will be followed 1 time per 2 week at first 3 months, then 1 time per month later, and then 1 time per 3 months. Each time, the guide group should receive echocardiography, including the measurement of LA distensibility. LA distensibility-guided therapy is enabled in 2 ways. Prescriptions should be adjusted according to overall left ventricular filling pressure estimated by LA distensibility. The specified treatments after adjustment by the current LA distensibility are also allowed. Investigators individually adjust medications for each patient according to the ranges of LA distensibility. The specified therapy is based on 5 LA distensibility ranges (very low, low, optimal, high, and very high). Each range is associated with a prescription for medication dosing, sodium and fluid intake, or activity level.
224248415|NCT03992066|DRUG|Vadadustat|oral 150 mg tablet
224248416|NCT03992066|DRUG|Darbepoetin alfa|solution intravenous injection
224248417|NCT03992066|DRUG|Epoetin alfa|solution for intravenous injection
224248418|NCT01821144|BEHAVIORAL|Salt reduction|Salt reduction
224248419|NCT01821144|OTHER|Control|No salt awareness education
223666589|NCT04586842|BEHAVIORAL|Community-based Occupational Therapy|Domiciliary and Community-based Occupational Therapy on mental health and ABI intervention, developed on the basis of the Model Of Human Occupation.
224248420|NCT04181853|OTHER|exercise|aerobic exercise
224248421|NCT03420300|DRUG|EBR/GZR|Elbasvir/grazoprevir (EBR/GZR 50mg/100mg fixed dose combination \[FDC\]): 1 table per os per day for 12 weeks
224248422|NCT00322465|DRUG|Tinidazole|2 gm single dose (4 tablets orally at 500 mg each).
224248423|NCT00322465|OTHER|Placebo|Placebo capsule will be filled with lactose only and be identical in appearance to the capsule of Azithromycin, Tinidazole, Doxycycline.
224248424|NCT00322465|DRUG|Doxycycline|100 mg orally, twice daily for 7 days.
223666590|NCT04586842|BEHAVIORAL|Standard community-based intervention|Interventions received at the community, public or private level (e.g. community nursing, social education and/or psychology).
223666591|NCT06427135|BEHAVIORAL|Exercise interventions|Rehabilitation physician or rehabilitation therapist, to engage in physical exercise or patients, according to the medical examination data (including exercise test and physical strength test), according to their health, physical strength, and cardiovascular function status, with the form of a prescription for the type of exercise, intensity of exercise, exercise time and frequency of exercise, to put forward the precautions to be taken during exercise.
223666592|NCT05650918|BIOLOGICAL|MesoPher|autologous monocyte-derived dendritic cells loaded with PheraLys (tumor cell lysate)
223666593|NCT05650918|BIOLOGICAL|Mitazalimab|agonistic human monoclonal (IgG1) antibody targeting CD40
223666594|NCT03083444|DIAGNOSTIC_TEST|Ultrasound|Measurement of thickness of radial artery wall thickness by ultrasound
223666595|NCT05995067|OTHER|periodontitis challenge|control will be compared to diseased group suffering from periodontal disease.
223666596|NCT04363788|PROCEDURE|double gloves|The study was based on dying gloves used during resuscitation. The gloves were secured with disposable hermetically sealed pouches and described by one of the EMS team members - each time after resuscitation was completed.
223666597|NCT02784639|OTHER|Plasma Analysis of circulating cell free DNA|
223666598|NCT02784639|OTHER|Tumor tissue analysis of circulating cell free DNA|
223666599|NCT03353233|DRUG|Ropivacaine|Local anesthetic (numbing drug)
224248425|NCT00322465|DRUG|Azithromycin|1 gram (gm) (2 tablets orally at 500 milligrams (mg) each).
224248426|NCT02501005|PROCEDURE|VT ablation|Catheter ablation of ventricular tachycardia
223666600|NCT03353233|PROCEDURE|Interspace Between the Popliteal Artery and Capsule of the Knee (iPACK) Block|An ultrasound guided nerve block using a numbing medication called ropivacaine that numbs the nerves to the back of the knee.
223666601|NCT03353233|DRUG|Saline|An ultrasound guided nerve block using a medication that does NOT numb the nerve called saline, or salt water.
223666602|NCT03512457|BEHAVIORAL|Minimal Intervention|Women view an educational poster in changing room, and they receive a brochure.
223666603|NCT03512457|BEHAVIORAL|Intensive Intervention|Women view an educational poster in changing room, and they receive a brochure.
223666604|NCT02878161|DRUG|methotrexate(necessary)|Methotrexate will be received orally with dosage of 10mg/ week for every patient and MTX dose must be stable for at least 4 weeks.
223666605|NCT02878161|BIOLOGICAL|infliximab|infliximab :intravenous injection 200mg,every times,0,2,6,14week ,4 times)
223666606|NCT02878161|BIOLOGICAL|etanercept|Etanercept :hypodermic injection,25mg/twice a week
224248427|NCT02146495|DEVICE|Simultaneous EEG and fMRI recordings|
224248428|NCT02146495|DEVICE|Amygdala-Electrical Fingerprint (Amyg-EFP)-NF Trial|Neurofeedback training utilizing Amygdala Electrical Fingerprint (Amyg-EFP) methodology
224248429|NCT02146495|DEVICE|Amygdala-Electrical Fingerprint (Amyg-EFP)-NF Sham Trial|Sham neurofeedback training based on a randomized artificial Amyg-EFP signal.
224248430|NCT01073657|OTHER|Supported Education|Rehabilitation counseling using peers to achieve educational goals
224248431|NCT01073657|OTHER|General Peer Support|Matched peer support for any personal goal other than education
224321827|NCT02179086|RADIATION|Intensity-Modulated Radiation Therapy|Undergo dose-escalated and -intensified photon IMRT
224321828|NCT02179086|OTHER|Laboratory Biomarker Analysis|Correlative studies
224321829|NCT02179086|RADIATION|Photon Beam Radiation Therapy|Undergo dose-escalated and -intensified photon IMRT
224248432|NCT03909516|DEVICE|iovera°|"The iovera° device will be prepared by the trained Anesthesiologist User Guide. If at any time the device does not perform as expected the Investigator and Anesthesiologist will follow procedures as outlined in the User Guide. Start and end time will be recorded. Once localized anesthesia of the block area is achieved, the Anesthesiolgist, or designee, will complete the iovera° treatment. Upon completion of block, The Anesthesiologist or designee will assess the treatment areas for adverse events. Adductor Canal Block required, the formulation, or cocktail, of medications used are to be recorded in the medical record. Start and end time will be recorded.~Local Infiltration Analgesia - 20cc 0.5% ropivicaine only"
224248433|NCT01790581|BEHAVIORAL|Balance Training|This is a 4-week supervised balance training program that has been previously validated in those with CAI by improving subjective and objective measures of function. During the 4-week program, subjects will complete three 20-25 minute sessions a week for a total of twelve supervised training sessions. The specific exercises and repetitions that will be performed per training session will include: 1) hop to stabilization (10 repetitions per direction), 2) hop to stabilization and reach (5 repetitions per direction), 3) unanticipated hop to stabilization (3 repetitions), 4) progressive single limb stance balance activities (3 repetitions), and 5) progressive single limb stance activities with eyes closed (3 repetitions).
224248434|NCT01790581|BEHAVIORAL|STARS|The STARS intervention will consist of 4 unique sensory-targeted interventions: calf stretching, ankle joint traction, anterior/posterior ankle joint mobilizations, and plantar massage. These four techniques target 3 types of sensory pathways (musculotendinous, articular, and plantar cutaneous, respectively) and will be applied in the same order for all treatment sessions: 1) 60-second calf stretch, 2) 30-second ankle traction, 3) 30-second mobilization, 4) 2-minute plantar massage, 5) 30-second ankle traction, and 6) 30-second mobilization.
224248435|NCT00183794|DRUG|Docetaxel and Gemcitabine|Docetaxel 75 mg/m2 IV over 15-30 minutes on day 1 followed by Gemcitabine 800 mg/m2 IV over 30 minutes on Days 1 and 8 of each 3 weeks (21 days) cycle.
224248436|NCT00584922|PROCEDURE|Endoscopy in group I (all patients)|Post procedure endoscopy, omeprazole 40 mg BID, sucralfate 1 gm BID for 2-4 weeks.
224248437|NCT01228409|DRUG|Acitretin 17.5 mg/day|lower dose of Acitretin to 17.5 mg/day from 25 mg/day in those experiencing retinoid-related side effects
224248438|NCT04004676|BEHAVIORAL|20 km time trial performance|20 km time trial cycling test will be conducted to measure the effect of different drinks on performance time
224248439|NCT04004676|BEHAVIORAL|Glycogen lowering exercise|Glycogen will be lowered using a 10-min warm-up period at a workload of 50% max wattage power output (Wmax). Thereafter, participants will be instructed to cycle 2-min block periods at alternating workloads of 90% and 50% of Wmax, respectively. This will be continued until the participants are no longer able to complete the 2 min at 90% Wmax. That moment will be defined as the time at which the individual is unable to maintain cycling speed at 60 revolutions/min. At that moment the high-intensity block will be reduced to 80% Wmax. Again, athletes will cycle until they are unable to complete a 2-min block at 80% Wmax, after which the high-intensity block will be reduced to 70% Wmax. Finally, participants will be allowed to stop when pedalling speed could not be maintained at 70% Wmax.
224248440|NCT06981754|DRUG|Dexamethasone palmitate|Patients in the dexamethasone palmitate group will be assigned to receive intravenous injection of dexamethasone palmitate 8 mg (contains 5mg dexamethasone) after anesthesia induction and before surgical incision.
224248441|NCT06981754|DRUG|Dexamethasone|Patients in the dexamethasone group will be assigned to receive intravenous injections of dexamethasone 5 mg after anesthesia induction and before surgical incision.
224248442|NCT04355455|DRUG|Citalopram|40 mg citalopram intravenously
224248443|NCT04355455|DRUG|Placebo|Saline solution
224248444|NCT05285020|OTHER|Alter G|"It is anti-gravity treadmill treatment on Alter G. They will start with a 30-50% body weight load during the first week that will be progressively increased to 50-70% during the second (5% more each day during the 10 sessions as far as possible).~The slope will be 0% and the speed 2-3km/h the first week and 3-4 km/h the second. Treatment will be performed during 15 minutes for two weeks (10 sessions)."
224248445|NCT05285020|OTHER|Parallel bars and Scale|It is a re-education of the gait at the parallel bars with a progressive load in scale controlled by the patient during 10 minutes for two weeks.
224248446|NCT05285020|OTHER|Standard rehabilitation protocol|It is the hospital's standard protocol for that injuries once a day for two weeks.
223666607|NCT02878161|BIOLOGICAL|adalimumab|Adalimumab:hypodermic injection,40mg/twice a week
223666608|NCT02878161|DRUG|leflunomide (permitted, not necessary)|LEF will be permitted if patient had received for 1 month before enrollment and will not be changed for 14 weeks.
224248447|NCT02563197|DEVICE|T-326 Inhaler|No drug dosing,three test inhalations through the inhaler device filled with an empty capsule.
224248448|NCT04633109|PROCEDURE|taste bud biopsy|Taste buds will be surgically removed a) during a planned and medically induced elective surgery under full anesthesia; b) by local anesthesia in subjects without a medically induced surgery
224248449|NCT04633109|DIAGNOSTIC_TEST|oral glucose tolerance test|75g glucose will be applied in drinking water following blood sample collection to evaluate glucose, insulin and C-peptide level.
224248450|NCT04633109|DIAGNOSTIC_TEST|Taste sensitivity|Subjects are given taste strips with 4 concentrations per each taste quality of sweet, sour, salty, bitter and umami in a pseudo-randomized manner. Subjects are asked to identify the taste quality, state the intensity, preference and certainty.
224248451|NCT04633109|DIAGNOSTIC_TEST|olfactory function|Subjects will be presented 16 different sniffing sticks in a randomized order, each for about 4seconds. People are then asked to identify the smell by choosing one out of 4 options (forced choice).
223666609|NCT02878161|DRUG|NSAIDs (permitted,not necessary)|NSAIDs will be allowed if patient had received for 1 month before enrollment and will not be changed for 14 weeks.
223666610|NCT02878161|DRUG|Glucocorticoids (permitted,not necessary)|Glucocorticoids (prednisone less than 10mg/day, or equal dosage of other similar drugs) will be permitted if the patient had received for 1 month before enrollment and the dosage will not be changed during the period.
223666611|NCT02390791|OTHER|enhanced myADHDportal.com|Version of the myADHDportal.com web software enhanced with family-management support to enable parents to be active partners in optimizing and maintaining medication continuity for their child
223666612|NCT02390791|OTHER|treatment as usual standard portal|Standard version of myADHDportal.com web software
224248452|NCT04633109|DIAGNOSTIC_TEST|taste bud density|The number of taste buds on the anterior tongue will be determined by colouring the tongue surface with food colour. Taste buds will apply more reddish as compared to non-taste tissue. Based on a digital photography the number of taste buds per subjects is counted manually.
224248453|NCT04633109|DIAGNOSTIC_TEST|anthropometry|Anthropometric data collection will include measures of body height, body weight, arm-, upper- and lower leg circumferences, waist- and hip circumferences and a bioimpedance analysis to obtain data about body composition.
224248454|NCT04633109|OTHER|biospecimen collection|Blood and saliva samples will be taken as well as a tongue swab.
223666613|NCT01789398|DRUG|BF2.649|BF2.649 is provided in capsules. Patients should take 1 capsules per day with a glass of water. They will be instructed to take 1 capsule in the morning (after waking up, before breakfast).
224248455|NCT04633109|OTHER|questionnaires|Through the use of several questionnaires, data about eating behavior, food preferences, life style factors and other will be obtained.
224248456|NCT04960488|PROCEDURE|carotid endarterectomy and coronary artery bypass grafting|carotid endarterectomy and coronary artery bypass grafting
224248457|NCT05277753|BIOLOGICAL|Antigen-specific T cells CAR-T/CTL and DCvac|Antigen-specific T cells CAR-T/CTL and DCvac cells to treat T-ALL
224248458|NCT01295853|PROCEDURE|t3 sympathicotomy|The sympathetic chain was identified at the level of the crossing of the third or fourth costal heads after dissection of the parietal pleura and completely divided about 1 cm wide at the upper margin of the rib. With assistance of anaesthesia team we reinflate the lung totally in sequence with removal of the trocars. The same procedure was performed on the opposite side and ablation of the sympathetic chain overlying the rib was performed bilaterally. At the end of surgery, a postoperative chest x-ray was routinely taken to rule out pneumothorax or hemothorax.
224248459|NCT01295853|PROCEDURE|t4 symapthicotomy|The sympathetic chain was identified at the level of the crossing of the third or fourth costal heads after dissection of the parietal pleura and completely divided about 1 cm wide at the upper margin of the rib. With assistance of anaesthesia team we reinflate the lung totally in sequence with removal of the trocars. The same procedure was performed on the opposite side and ablation of the sympathetic chain overlying the rib was performed bilaterally. At the end of surgery, a postoperative chest x-ray was routinely taken to rule out pneumothorax or hemothorax.
224248460|NCT02398071|DEVICE|A water pressure threshold device (BreatheMAX)|BreatheMAX®, the water pressure threshold breathing device contributed in our laboratory will be used. This device is small, simple, easy to use and also inexpensive since the device is developed and manufactured in Thailand. The depth of water in the body of the device provides the flow resistance during exhalation through the inlet tube in a water cylinder.
224248461|NCT03079128|BEHAVIORAL|Intervention|Weight Watchers Intervention
224248462|NCT06146153|DIAGNOSTIC_TEST|digital impression|intra oral scanning
224248463|NCT02359474|DRUG|Trabectedin|
224248464|NCT02359474|GENETIC|DNA double-strand breaks|"The rationale for combining Tr and RHT is based on immune mechanisms induced by local heating of which are independent of the anti-tumor effects of Tr. Recent results demonstrate that an acute inflammation at the site of the heated tumor area and danger signals are responsible for immune reactions against tumor and metastases (Frey 2012). Abscopal effects after local radiation of tumors with response of distant metastases are induced by similar mechanisms like heat stress (Formenti 2013, Golden 2015). The long-term results for soft-tissue sarcoma are consistent with abscopal effects induced by RHT in a randomized trial compared to chemotherapy alone (Issels 2018)."
224248465|NCT02512952|PROCEDURE|Open flap debridement (OFD)|Oral prophylaxis followed by Open flap debridement (OFD)
224248466|NCT02512952|PROCEDURE|OFD with Platelet rich fibrin (PRF)|Oral prophylaxis followed by Open flap debridement (OFD) with Platelet rich fibrin (PRF) placement into the bone defect
224248467|NCT02512952|PROCEDURE|OFD with Titanium Platelet rich fibrin (TPRF)|Oral prophylaxis followed by Open flap debridement (OFD) with Titanium Platelet rich fibrin (TPRF) placement into the bone defect
224248468|NCT05608161|DIAGNOSTIC_TEST|speech in noise test|The noise masker was a stream of steady-state speech-spectrum noise, whose spectrum was representative of the average spectrum of target sentences. The speech masker was a 47-s loop of digitally combined continuous recordings for Chinese nonsense sentences. Patients from the idiopathic sudden sensorineural hearing loss (ISSNHL) group and control group were tested bilateral (left, right) speech-in-noise (SIN) perception of various signal-to-noise ratios (SNRs) under speech and noise masking conditions. Each participant has to complete four consequent levels of SNRs (-12, -8, -4, 0 decibel (dB) for most of control group, -8, -4, 0, 4 dB for ISSNHL group). In addition, the benefits of spatial separation cues under these two types of masking were analyzed.
224248469|NCT00762307|DEVICE|Zeltiq Dermal Cooling Device|Noninvasive cooling is applied to the treatment area with a defined cooling rate and duration.
224248470|NCT02478957|DRUG|PA101|40 mg PA101 administered via inhalation three times daily for 6 weeks
224248471|NCT02478957|DRUG|Placebo|matching placebo administered via inhalation three times daily for 6 weeks
224248472|NCT03607032|DEVICE|Respin Pad|RespinPad slid into the back of the patient sitting at 45° in the armchair or bed.
223666614|NCT03927378|DRUG|S-ketamine|S-ketamine (0.2 mg/kg in 20 ml normal saline) is administered by intravenous infusion in 40 minutes after childbirth.
223666615|NCT03927378|DRUG|Placebo|Placebo (20 ml normal saline) is administered by intravenous infusion in 40 minutes after childbirth.
223666616|NCT01375075|DRUG|LY2484595|Administered orally
223770809|NCT02263066|BIOLOGICAL|BAY14-2222_Kogenate-FS FVIII|Depends on Doctor's decision
223770810|NCT01469065|DRUG|PF-04991532|Oral administration of PF-04991532; 25 mg given twice a day (BID) for 14 days
224248473|NCT03607032|OTHER|usual treatment|medical aerosol session followed by aspiration or not, as required
224248474|NCT00359489|DEVICE|cardiac echosonography|
224248475|NCT04995822|DEVICE|hip arthroplasty|Hip prosthesis surgery
224248476|NCT02264054|DRUG|[14C]talsaclidine, oral|
224248477|NCT02264054|DRUG|[14C]talsaclidine, iv|
223666617|NCT01375075|DRUG|Placebo|Administered orally
223666618|NCT01375075|DRUG|Atorvastatin|Administered orally
223666619|NCT02369172|DRUG|Bupropion|
223666620|NCT02369172|DRUG|ASP2151|
223666621|NCT04371458|DRUG|Intraoperative providone-iodine lavage|Intraoperative providone-iodine lavage during resection
223666622|NCT05681143|OTHER|Crisis Prevention Arm|The crisis prevention program involves a 3-session model. Each session lasts up to 60 minutes. They take place via telehealth with a licensed clinical therapist. Sessions involve case formulation, provision of prevention strategies, connecting with professional and lay resources, what to do if a crisis occurs, and strategies to prevent the re-occurrence of a crisis, should one occur. Each session involves use of checklists, a community resource guide, and homework. Implementation is standardized using two different manuals, one for the parent and the other for the provider.
224248478|NCT00336622|DEVICE|Splint fabricated by an OT versus an off-the-shelf splint|"Experimental:~Custom-made splint and tendon-nerve gliding exercises Custom-made splint and no tendon-nerve gliding exercises~Control:~Control: Off-the-shelf splint and tendon-nerve gliding exercises Off-the-shelf splint and no tendon-nerve gliding exercises"
224248479|NCT05589311|OTHER|Transformative Learning principles|Transformative Learning principles are incorporated into the pain education workshop to stimulate critical reflection and critical discourse during the learning process.
223666623|NCT05681143|OTHER|Control|The control condition will involve sending families the Autism Speaks Challenging Behavior Toolkit. It offers a complimentary set of recommendations. It is freely available and can be found here: https://www.autismspeaks.org/tool-kit/challenging-behaviors-tool-kit. There is no interaction with the clinician in the controlcondition. After the study observation period, we will provide them with the crisis manual (for parents) used in the active treatment arm.
224248480|NCT05589311|OTHER|Conventional didactic approach|The conventional didactic approach focuses on lecture-based instruction as the teaching center, emphasizing the delivery of syllabus and concept.
224248481|NCT01064128|PROCEDURE|conventional laparoscopic hysterectomy|conventional 3 or 4 ports laparoscopic hysterectomy
224248482|NCT01064128|PROCEDURE|SPA laparoscopic hysterectomy|single-port access laparoscopic hysterectomy
224248483|NCT01701128|OTHER|Walking on treadmill|3 sessions/week, 24 weeks. The heart rate does not exceed 75% of maximum heart rate (220-age) of the participant and that blood pressure does not exceed 250/115 mmHg. During the first week, the TT velocity was adjusted to 80% of preferential walking speed of the participant. The following week, the participant was encouraged to reach 90% and 100% in the third week. From the fourth week, subjects in the Speed TT had an increase in speed, depending on exercise tolerance of each participant. The TT velocity was increased by 0,2 km/h when the participant reached criteria.
224248484|NCT01701128|OTHER|Walking on treadmill|3 sessions/week, 24 weeks. The heart rate does not exceed 75% of maximum heart rate (220-age) of the participant and that blood pressure does not exceed 250/115 mmHg. During the first week, the TT velocity was adjusted to 80% of preferential walking speed of the participant. The following week, the participant was encouraged to reach 90% and 100% in the third week. From the fourth week, the TT velocity was increased by 0,2 km/h or the incline of the walking surface of TT was increased by 1% alternately when the progression criteria were met.
224248485|NCT01701128|OTHER|Control group|Training of the control group was characterized by light intensity exercises. For the first three months, participants performed regular exercise involving full range of motion to enhance their flexibility. For the last three months of the training programme, participants learned elements of Tai Chi and rhythmic movements of latin dance. Participants attended two 1-h supervised sessions per week and were asked to perform each week a third session at home, based on instructions in a document offered to the control group participants
224248486|NCT05122208|DRUG|Famotidine Tablets|160 mg/day Famotidine
224248487|NCT01820793|DRUG|Cefoxitin|proof of concept study to evaluate the efficacy of cefoxitin (2 grams every 6 hours for 10 days) in 40 women presenting acute ESBL-producing E.coli pyelonephritis without severity symptoms and to perform on half of the participants repeated measurements of cefoxitin serum levels (6 blood samples within 6 hours following an injection).
224248488|NCT04972656|DRUG|Ambrisentan|"Titration:~Monotherapy using ambrisentan will be initialized at a beginning dose of 5 mg (once daily). Drug intake is scheduled at the morning. After 4 weeks monitoring, the dose of ambrisentan will be uptitrated to 10 mg once daily. Otherwise, if intolerability is indicated, a dose of 5 mg (once daily) will be maintained through the study duration.~Maximum dose allowed: not to exceed 10 mg/day.~Administration:~Ambrisentan will be administered orally with or without food intake."
224248489|NCT04972656|DRUG|Placebo|"Placebo tablet (one to two tablets corresponding to one to two verum tablets).~Administration:~Placebo will be administrated orally with or without food intake in the morning."
224248490|NCT06215079|DEVICE|The Magstim Rapid2 Plus Magnetic Stimulator (Magstim, Whitland, Dyfed, UK)|Transcranial Magnetic Stimulation (rTMS) is a non-invasive brain stimulation method that modulates the cortical excitability of the targeted motor area. While single-pulse TMS is generally used to explore the functioning of the brain, repetitive TMS is employed to induce lasting changes in brain activity. High-frequency rTMS leads to an increase in excitability in the motor cortex, whereas low-frequency application results in inhibition of motor cortical excitability. Theta-burst stimulation (TBS) is a form of rTMS that can be delivered continuously (cTBS) or intermittently (iTBS), thus modulating the excitability of corticospinal neurons beneath the stimulation area to either decrease or increase. rTMS is a growing research area in pain management, proven to be a safe and well-tolerated method. Studies have shown that rTMS applied to the motor cortex is a promising treatment method for chronic pain
224248491|NCT06215079|DEVICE|Sham transcranial magnetic stimulation|Patients in the control group will receive sham transcranial magnetic stimulation with sham coil for 35 minutes a day, 5 sessions in total, together with conventional rehabilitation.
224248492|NCT06215079|DEVICE|conventional rehabilitation program|Patients will receive 5 minutes of continuous ultrasound (1MHz, 2W/cm2, 1:4)), followed by a 20-minute contrast bath, and 15 minutes of TENS (frequency: 100 Hz; pulse duration: 50-100 ms; and amplitude adjusted to avoid discomfort or muscle contraction to the patient).
224321830|NCT02179086|RADIATION|Proton Beam Radiation Therapy|Undergo dose-escalated and -intensified proton beam radiation therapy
224321831|NCT02179086|OTHER|Quality-of-Life Assessment|Ancillary studies
224321832|NCT02179086|OTHER|Questionnaire Administration|Ancillary studies
223666624|NCT01011309|BIOLOGICAL|LEISH-F2 + MPL-SE|10 μg LEISH-F2 + 25 μg MPL-SE on Days 0, 28 and 56
223666625|NCT01011309|DRUG|Sodium stibogluconate|20 mg/kg/day IV daily for 20 days
223666626|NCT05032924|COMBINATION_PRODUCT|PPR group with ESWT|extracorporeal shock wave (ESWT) (STORZ MEDICAL Extracorporeal Shock Wave Therapy) (3000 impulse, each point, 24 KV, 0.32 mJ/mm2) one week after PRP or HA injection
223666627|NCT05032924|COMBINATION_PRODUCT|PPR group without ESWT|PRP or HA injection only
224248493|NCT05586256|RADIATION|ultra-hypofractionated whole breast irradiation|"All enrolled patients will be treated with an ultra-ipofractionated whole breast irradiation schedule (26 Gy delivered in 5 consecutive fractions, single dose 5.2 Gy), according to FAST-Forward trial. Whole bresat irradiation should be followed or not by a tumor bed boost (sequential: 7.6 Gy in 2 consecutive fractions, single dose 3.8 Gy or simultaneous intergrated boost: 30 Gy in 5 consecutive fractions, single dose 6 Gy). Either three-dimensional conformal radiotherapy (3DCRT), intensity-modulated radiotherapy (IMRT), volumetric modulated arc therapy (VMAT) or helicoildal techniques are allowed. Breath control techniques may be used at the discretion of each partecipating centre.~Main exclusion critereria are mastectomy and regional nodal irradiation. Neoadjuvant and/or adjuvant systemic therapies are allowed."
224248494|NCT02395003|OTHER|Palmitate Diet|Subject with high VAT/SAT ratio will be randomized to a high or low palmitate oil diet.
224248495|NCT01520623|OTHER|Serum concentration /Serum inflammatory|Allografted patients with myeloablative conditioning for an haematological malignancy. Patients will be followed for at least 12 months after transplantation and blood samples drawn before conditioning and once a week for 12 weeks after transplantation to analyze the serum concentration of Complement factors (C3, C4, B factor), Complement regulatory proteins (C1-inhibitor, I and H Factors) and analysis of the surface expression of Complement regulatory molecules such as CD46, CD55 and CD59 and the serum inflammatory cytokine levels
224248496|NCT03500692|DEVICE|MitraClip NT System|Percutaneous mitral valve repair using MitraClip NT System
224248497|NCT04347642|PROCEDURE|Umbilical port placement|The port will be inserted in the midline at the level of the umbilicus.
224248498|NCT04347642|PROCEDURE|Paraumbilical port placement|The port will be inserted 3-4cm laterally to the midline at the level of the umbilicus.
224248499|NCT01900236|BEHAVIORAL|Based on behavioral motivational interviewing (MI) technique|In addition to receiving standard clinic care, the intervention will have a tailored, interactive agenda for each of the 4 sessions based on behavioral motivational interviewing (MI) technique. The goal of this intervention is for the participant to establish early behaviors that help him/her to arrive at scheduled medical appointments and learn to take medications as prescribed during the initial year of HIV care in order to in order to achieve viral suppression and improve overall health.
224248500|NCT02449707|PROCEDURE|Lateral Window Technique Augmentation for Maxillary Sinus|Maxillary sinus augmentation will be performed using the lateral window technique
224248501|NCT02449707|DEVICE|Ultrasound activated resorbable poly-D-L-lactide pins|The titanium membrane placed during the maxillary sinus augmentation procedure will be stabilized using ultrasound activated resorbable poly-D-L-lactide pins
224248502|NCT02449707|DEVICE|Purus® Cancellous Allograft|Allograft material placed in the sinus to acheive sinus augmentation
224248503|NCT02449707|DEVICE|Resorb X Membrane|The membrane placed over the graft material before placement of the ultrasound activated pins
224248504|NCT02449707|DEVICE|Biomend|Collagen healing membrane placed over the graft material on the side where no ultrasound activated pins are being used
224248505|NCT02449707|PROCEDURE|Cone Beam CT image of the Sinus|Cone beam CT will used to assess the thickness of bone formation after the placement of the graft
224248506|NCT02449707|PROCEDURE|Trephine Biopsy|Trephine Biopsy will be performed at the time of the placement of implant to study the quality of bone formed
224248507|NCT05063500|DRUG|bicyclol, 25mg/ tablet|Experimental group: each oral bicyclol 50mg, three times daily for 4 weeks.
224248508|NCT05063500|DRUG|polyene phosphatidylcholine capsules, 228mg/ particle.|Control group: each oral polyene phosphatidylcholine 456mg, three times daily for 4 weeks.
224248509|NCT04770883|BEHAVIORAL|Internet based cognitive behavioral therapy.|Patients will receive iCBT for 10 weeks, divided into five successive steps. The iCBT will be guided by online therapists and emphasizes acceptance of symptoms through exposure training. Patients have to report that they have worked through a treatment step to get access to the next. Patients will be encouraged to work through steps 1-4 during the first half of the treatment and to spend the latter half on step 5, in which exposure exercises will be introduced. The treatment aims to break the vicious cycle between avoidance behavior, symptom severity and functional impairment.
224248510|NCT04770883|DIETARY_SUPPLEMENT|Low FODMAP diet therapy|Patients will receive 10 weeks of standardized treatment with low FODMAP diet consisting of 3 stages: FODMAP restriction; FODMAP reintroduction and FODMAP personalization. These stages will be covered in at least three appointments by primary care dieticians in Region Örebro County.
223666628|NCT05032924|COMBINATION_PRODUCT|HA group with ESWT|extracorporeal shock wave (ESWT) (STORZ MEDICAL Extracorporeal Shock Wave Therapy)
223666629|NCT05032924|COMBINATION_PRODUCT|HA group without ESWT|PRP or HA injection only
223666630|NCT00831493|RADIATION|Chemoradiation (Radiation Therapy)|Dose of 50.4 Gy in 1.8 Gy fractions in 28 fractions, Monday to Friday, Weeks 1 to 6.
223666631|NCT00831493|DRUG|Vorinostat|Starting Dose of 200 mg orally once daily, Monday to Friday, Weeks 1 to 6.
223666632|NCT05902052|OTHER|Care Protocol|Evaluation of patients' pain in the extubated period with the Visual Anolog Scale Active participation of the patient in pain reporting Regular questioning of the patient's pain Questioning pain at rest and movement Implementing nursing interventions in painful condition (VAS≤ 4)
223666633|NCT03893695|DRUG|GT90001 and Nivolumab|Stage1:Dose de-escalation. Stage2:the expansion cohort where one or no DLT takes place in planned study cohort.
224248511|NCT00731926|DIETARY_SUPPLEMENT|Oligomerized litchi fruit extract|100mg at once twice a day for 1 month
224248512|NCT00731926|DIETARY_SUPPLEMENT|VItamin C + Vitamin E mixture|Vitamin C 400mg + Vitamin E 160IU at once twice a day for 1 month
224248513|NCT00731926|OTHER|placebo|twice a day for 1 month
224248514|NCT01371409|OTHER|continuous theta burst stimulation|80% active motor threshold, 600 pulses
224248515|NCT03451201|BEHAVIORAL|High Intensity Interval Training|High Intensity Interval Exercise Training in cycle ergometer, exercising at 80% of maximal capacity during one minute alternated with exercise at 50% of maximal capacity during 4 minutes intervals, for a total of 30 minutes. Three times a week for 8 weeks
224248516|NCT03451201|BEHAVIORAL|Moderate Continuous Exercise Training|Moderate Continuous Exercise Training 3 times a week for 8 weeks at 50% of maximal capacity
224248517|NCT03451201|OTHER|Non-exercise|Conventional care for sedentary Type 1 Diabetes Controls. No intervention.
224321833|NCT02179086|DRUG|Temozolomide|Given PO
223666634|NCT00620503|DRUG|Proellex 25 mg formulation A|One Proellex 25 mg formulation A capsule
223666635|NCT00620503|DRUG|Proellex 25 mg formulation B|One 25 mg Proellex capsule formulation B administered both fed and fasted
223770811|NCT01469065|DRUG|PF-04991532|Oral administration of PF-04991532; 75 mg given twice a day (BID) for 14 days
224248518|NCT02613156|PROCEDURE|laparoscopic resection|The surgical instruments used for the laparoscopic group included conventional laparoscopic instruments (three 5 mm trocars, two 10 mm trocars, and two damage-free laparoscopic clamps), the STORZ high-resolution laparoscopic operating system (Germany), the GEN300 ultrasonic scalpel system (Johnson \& Johnson, USA), a laparoscopic linear cutter stapler (Johnson \& Johnson, USA), a laparoscopic ultrasound device, LigaSure, bipolar coagulation, titanium laparoscopic clips, and absorbable hemostatic gauze.
223770812|NCT01469065|DRUG|PF-04991532|Oral administration of PF-04991532; 150 mg given twice a day (BID) for 14 days
224248519|NCT02992093|OTHER|all the indicators|BMI、WHR、FSH、LH、PRL、T、E2、TG、CHOL、LDL-C、HDL-C、FBG、OGTT、FINS、insulin release test、HOMA index、identification of metabolites
224248520|NCT03438253|PROCEDURE|spinal anaesthesia|
224248521|NCT02658604|OTHER|Home medication review by a pharmacist|Patients will receive a home visit from a pharmacist, including a medication review and the identification and addressing of drug therapy problems through patient education, the provision of pharmacologic and/or non-pharmacologic advice, or the adaptation of therapy or communication of recommendations to prescribers. All activities are within the current scope of practice for pharmacists in Ontario. A detailed assessment of the patient's medication inventory and organization/storage practices will be conducted, followed by a medication cabinet cleanup to help the patient organize their medications and discard any expired or discontinued medications. A list of inappropriate medications found in the home will be documented, detailing the reasons why they are inappropriate and if/how the patient is currently using these medications. With patient consent, inappropriate medications will be removed from the home and returned to the pharmacy for safe disposal.
224248522|NCT04235881|BEHAVIORAL|Mindfulness-based stress reduction program|Mindfulness training through an adaptation of the standardized MBSR program. This program was conducted in person and in a group, with a maximum of 25 participants per group and a total duration of 8 weeks. The training was carried out in 8 sessions, one each week, with a duration of 2 h each session.
224248523|NCT04235881|BEHAVIORAL|App REM volver a casa|"The intervention was carried out through the computer application for mobile phone REM volver a casa. This application has been developed to carry out training in the emotional regulation program based on mindfulness, autonomously. The application is designed to carry out the program in 8 weeks."
224248524|NCT04875793|DIAGNOSTIC_TEST|Stool for Occult Blood Test and Colonoscopy with comprehensive medical checkups|participants will be drawn from all public government institutions inside Tabuk city(outreach). The institution head will be requested to give wellness cards to the eligible employee to receive comprehensive testing for free in addition to CRC test in selected public health centres.
224248525|NCT05522062|PROCEDURE|surgical treatment for humerus shaft fracture|surgical treatment for humerus shaft fracture
223666636|NCT01896791|PROCEDURE|Transcranial Direct Current Stimulation|Active Transcranial Direct Current Stimulation : the anode electrode is placed in the area of the motor cortex M1 C3 or C4 position of the dominant hemisphere (International 10-20 EEG System). The cathode electrode is placed over the contralateral supraorbital region to the anode electrode. Treatment time and intensity of the stimulus: tDCS: 2 mili Ampere, 20min, 10 days.
223666637|NCT01896791|PROCEDURE|Sham Stimulation|Sham Stimulation- appliance off during the entire period without active stimulation, with the position of the electrodes in the same sites of active stimulation
223666638|NCT02121613|DRUG|Permixon® 160 mg|Oral administration - 160 mg twice daily.
223770813|NCT01469065|DRUG|PF-0499132|Oral administration of PF-04991532; 300 mg given twice a day (BID) for 14 days
223770814|NCT01469065|DRUG|Placebo|Oral administration of PF-04991532 Matching Placebo; given twice a day (BID) for 14 days
224248526|NCT02296515|PROCEDURE|Intrathecal pump refill:|Two different experienced clinicians will perform one time the blind technique andTwo different experienced clinicians will perform one time the blind technique andtwo times the ultrasound-guided technique on all patients.
224248527|NCT03280797|PROCEDURE|Blood sample|2ml blood taken into TruCulture tube
224248528|NCT02629094|DRUG|Inspra /Eplerenone|Eplerenone is provided as 25- or 50-mg tablets that are to be taken orally. Subjects will be dosed at 25 mg daily for 1 week, and then 50 mg daily for 23 weeks. The total duration of dosing for each subject is 24 weeks.
224248529|NCT06433141|PROCEDURE|treatment option for primary second molar|final restoration for primary second molars
224321834|NCT04666311|DIAGNOSTIC_TEST|Accuracy of CAD4TB and Afinion CRP assay for pulmonary TB|"CAD4TB version 6 and 7: Software tool for detecting lung abnormalities in computer tomogram images (pulmonary abnormalities) and frontal chest radiograph images (tuberculosis abnormalities) ; availability is guaranteed by Delft Imaging System; EC 0344 Certificate (vs.6); CE mark pending (vs.7). Will be performed by a registered and qualified radiographer in accordance with national regulations.~Afinion AS100 Analyzer and Afinion CRP: In vitro diagnostic to determine the amount of CRP in human whole blood, serum or plasma; CE-mark ; Will be performed by qualified, GCP-trained study personnel."
223770815|NCT04047017|DRUG|Apatinib|250mg, po, qd
223770816|NCT04047017|DRUG|Camrelizumab|200mg, q2w
223666639|NCT02121613|DRUG|Tamsulosine LP|Oral administration - 0.4 mg daily.
223666640|NCT02121613|DRUG|Placebo matching Permixon® 160 mg|Oral administration - twice daily.
223666641|NCT02121613|DRUG|Placebo matching Tamsulosine LP|Oral administration - daily.
223770817|NCT04053374|OTHER|Blood sampling|Blood sampling +/- CSF sampling
223770818|NCT00179413|DRUG|PEG -Intron|
223770819|NCT00179413|DRUG|Colchicine|0.6mg twice a day
223770820|NCT02144675|DRUG|choline magnesium trisalicylate|Given PO
223770821|NCT02144675|DRUG|idarubicin|Given IV
223770822|NCT02144675|DRUG|cytarabine|Given IV
223770823|NCT02144675|OTHER|laboratory biomarker analysis|Correlative studies
223770824|NCT04640025|DRUG|itacitinib|Participants will self-administer itacitinib orally using intact tablets with water and without regard to food.
224248530|NCT02644434|PROCEDURE|Conventional Strategy|"Jailed wire technique: Both MV and SB are wired. The MV is stented with wire protection in SB. The SB is not further treated unless there is threatened SB closure, severe ostial pinching of SB (\>90%), TIMI flow grade decrease in SB, or SB dissection greater than type A. If one of these criteria exists, the SB would be rewired and a kissing balloon inflation is undertaken.~Provisional two-stent strategy: Lesion preparation and MV stenting are the same as the jailed wire technique. Provisional T stenting of the SB could be undertaken if one of the following criteria exists after SB rewiring and a kissing balloon inflation is undertaken: threatened SB closure, severe ostial pinching of SB (\>90%), TIMI flow grade decrease in SB, or SB dissection greater than type A."
224248531|NCT02644434|PROCEDURE|Intentional strategy|"Jailed balloon technique: The technique has been detailed in previous studies. A monorail balloon that is angiographically sized to approximate the Side Branch (SB) vessel diameter is advanced into the SB. If there is TIMI flow grade decrease in the SB after MV stenting, the SB balloon is inflated to simulate attempt to reopen the SB. The procedure would be completed with the standard kissing balloon technique no matter there is SB compromise or not.~Elective two-stent strategy: Patients in this subgroup would undergo crush procedure or any other elective two-stent strategy which stenting SB before MV stenting."
224248532|NCT00229645|DRUG|Quetiapine Fumarate (Seroquel®)|
224248533|NCT06433674|DRUG|Zinc Sulfate|The pharmacy will be the one preparing the Zinc sulfate. The zinc sulfate comes in 220 mg tablets which are then mixed with 1 ml of Oral plus (a common suspending agent) as well as 9 ml of Sterile water. This then makes a Zinc Sulfate 22 mg/ml oral suspension which will be dispensed in an amber syringe.
224248534|NCT06433674|OTHER|Sterile Water|The placebo group with will receive a similar amount of sterile water in a colored syringe
224248535|NCT01617954|DEVICE|MammaPrint|All subjects
224248536|NCT04024007|DIAGNOSTIC_TEST|Citrate dosage|Patients are dialysed according to the standard of care. Biological variables are measured in pre-filter, post-filter and dialysate 30 minutes after the dialysis is initiated.
224248537|NCT02960568|DRUG|Primaquine|30 mg oral primaquine one time
224248538|NCT07035353|DRUG|T-DXd (DS8201) 5.4 mg/kg, IVD, 1 cycle every 21 days.|The treatment plan will be recommended to the subject by the treating physician in accordance with current clinical practice guidelines and clinical practice, and the patient's decision to receive T-DXd (DS8201) should precede enrollment in this study. The strategy for administering a particular treatment to a subject is not determined a priori by the trial protocol, but should be in accordance with current clinical practice. Because of the non-interventional nature of this study, this study does not alter or interfere with the patient's actual current medical practice.
224248539|NCT07036588|DEVICE|Modified Transanal Drainage Tube|Patients with rectal adenocarcinoma will undergo elective laparoscopic/robotic low anterior resection. After the anastomosis is completed and the air leak test is confirmed to be negative, a modified TDT (occlusive balloon catheter) will be inserted. The balloon will be placed 5 cm above the anastomosis and filled under laparoscopic visualization (approximately 25 ml) to slightly dilate the intestinal lumen and occlude the intestinal cavity (under laparoscopic monitoring to ensure it does not affect the blood supply of the intestine). The external part of the tube will be sutured to the perianal skin and further secured with a 3M transparent dressing on the outside. It will be connected to a drainage bag (with an inner diameter greater than 8 mm) and left in place for 7 days, or until the drainage function is lost due to obvious defecation around the anal tube, at which point the catheter will be removed.
224248540|NCT07036510|DRUG|TimoD implant|Consists of 1 TimoD implant administration in the study eye.
223666642|NCT02298660|DRUG|BOTOX|"BOTOX® Total dose per patient: 200U Number of cycles:1 cycle~200 units of BOTOX® will be injected per procedure. BOTOX® will be diluted in 15mL saline to 20U/mL. BOTOX® injections will be performed with a normal 22 FF rigid cystoscopy or flexible 6Fr injection needle. BOTOX® will be injected into the detrusor muscle at 20 sites (10U per site), sparing the trigone. A local anaesthesia with instillation of 50 ml lidocaine 2% into the bladder will be done prior to the procedure to avoid autonomic dysreflexia."
223666643|NCT02122068|BEHAVIORAL|Mentalizing Imagery Therapy|4 week long meditation and mindfulness intervention
223666644|NCT02122068|BEHAVIORAL|Relaxation cd|
223770825|NCT05913063|DEVICE|Structured Light Imaging Microscopy|Conducting the psychophysical task on the perception of OAM-coupled polarized light created using the experimental setup - Structured Light Imaging Microscopy (SLIM). Four types of vortex orbital angular momentum, differing by the number of fringes l=5;10; 15;20, will be presented for 0.5s per trial during which an azimuthally varying entoptic profile rotated clockwise or counterclockwise. A circular mask with a varying radius will be placed at fixation, thus the task will be performed at varying eccentricities. Circular obstruction of the area will be achieved due to the high refresh-rate structured light modulator. The threshold mask size will be changed by a 2up/1down staircase method (71% accuracy for the estimation of mask size).
223770826|NCT01234623|OTHER|UCS eyedrops|1 ml UCS eyedrops/day topically applied 8 times/day 1 drop/eye for 28 days
224248541|NCT07036510|DEVICE|Injector system|"This is a CE-marked injector intended for intraocular lens (IOL) delivery. In this study, the injector is used as anintraocular implant injection system outside of its scope of intended use."
224248542|NCT06781853|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|The intervention consists of 12 weekly one-on-one online CBT sessions, each lasting 50 minutes, delivered via Microsoft Teams. The sessions will focus on addressing symptoms of muscle dysmorphia (MD), maladaptive thought patterns, and behaviors associated with steroid and performance-enhancing drug (PED) use. The therapy is based on structured CBT techniques and will include psychoeducation, cognitive restructuring, behavioral experiments, and relapse prevention strategies. The sessions will be conducted by trained clinical psychology master's students under the supervision of experienced clinical psychologists and a psychiatrist. The intervention is designed to reduce MD symptoms and improve psychological well-being.
224248543|NCT03098277|OTHER|Accelerometer|Wear Microsoft Band 2
223666645|NCT03207035|PROCEDURE|Axillary brachial plexus block|Ultrasound guided axillary brachial plexus block with local anaesthetic lidocaine with epinephrine
223770827|NCT03075644|DRUG|somapacitan|Once weekly subcutaneous injections (s.c., under the skin)
224248544|NCT03098277|OTHER|Laboratory Biomarker Analysis|Correlative studies
223666646|NCT02862067|OTHER|Assessment of cardiorespiratory fitness|Assessment of cardiorespiratory fitness
223666647|NCT02172417|DRUG|Cimetidine + Tiotropium|
223666648|NCT02172417|DRUG|Ranitidine + Tiotropium|
224248545|NCT03098277|OTHER|Physical Activity Measurement|Perform physical activities recorded by Microsoft Kinect 2
224248546|NCT03098277|BEHAVIORAL|Telephone-Based Intervention|Complete PRO questionnaires
224248547|NCT06326684|DRUG|Alcohol|The pharmacodynamic effects of alcohol (0.2 and 0.4 g/kg) will be determined.
224248548|NCT06326684|DRUG|Placebo|The effects of placebo will be determined.
224248549|NCT06326684|DRUG|Suvorexant|The effects of suvorexant dose 1 will be determined.
224248550|NCT06326684|DRUG|Suvorexant|The effects of suvorexant dose 2 will be determined.
224248551|NCT00047606|DRUG|IOP Lowering Medications|
224248552|NCT05363111|BIOLOGICAL|Actinium Ac 225-DOTA-Daratumumab|Given IV
224248553|NCT05363111|BIOLOGICAL|Daratumumab|Given IV
224248554|NCT05363111|BIOLOGICAL|Indium In 111-DOTA-Daratumumab|Given IV
224248555|NCT06551584|DRUG|ORCA-T|On Day 0, participants will receive an infusion of Orca-T HSPCs and Orca-T Tregs. On Day +2 or +3 (between approximately 48 to 72 hours of Day 0), patients will receive an infusion of the Orca-T Tcons. There is no dose escalation or de-escalation planned for the Orca-T investigational product.
224248556|NCT05782478|DIAGNOSTIC_TEST|Point of care Ultrasound according to study protocol|An emergency medicine specialist or resident will according to a structured protocol perform a structured ultrasound examination of the heart, the inferior vena cava and the lungs.
224248557|NCT04907370|DRUG|PD-1 blocking antibody|"1. IC phase of PD-1 blocking antibody: every 3 weeks × 3 cycles; 240 mg, day 1; start on day 1 of the first cycle IC and continue every 3 weeks for 3 cycles till the end of IC.~2. IMRT phase of PD-1 blocking antibody: every 3 weeks × 3 cycles; 240 mg, day 1; start on day 1 of IMRT or CCRT and continue every 3 weeks for 3 cycles till the end of IMRT.~3. Adjuvant PD-1 blocking antibody: every 3 weeks × 11 cycles; 240 mg, day 1"
224248558|NCT04907370|DRUG|Gemcitabine|Gemcitabine as induction chemotherapy, 1000 mg/m2 day 1, 8 per cycle, every 3 weeks for 3 cycles
224248559|NCT04907370|DRUG|Cisplatin (80mg/m2)|Cisplatin as induction chemotherapy, 80 mg/m2 day 1 per cycle, every 3 weeks for 3 cycles
224248560|NCT04907370|DRUG|Cisplatin (100mg/m2)|Cisplatin as concurrent chemotherapy, 100 mg/m2 day 1 per cycle, every 3 weeks for 2 cycles
224248561|NCT04907370|RADIATION|Intensity-modulated radiotherapy|Definitive IMRT of 70 Gy, 33 fractions, 5 fractions/week, 1 fraction/day
224248562|NCT04952610|DRUG|Etripamil NS 70 mg|Etripamil will be administered via the Aptar Pharma Nasal Spray Bidose System.
224248563|NCT04952610|DEVICE|Aptar Pharma Nasal Spray Bidose System|Aptar Pharma Nasal Spray Bidose System will be supplied as prefilled devices packaged into child-resistant boxes with instructions for use provided in the study drug box.
224248564|NCT04937153|BIOLOGICAL|Acasunlimab|Acasunlimab will be administered intravenously (IV) once every 21 days.
223666649|NCT02172417|DRUG|Tiotropium|
223666650|NCT02224248|BEHAVIORAL|Health checks with fitness testing|Fitness testing as part of a preventive health check compose the intervention in this trial. Thus, the intervention group will receive preventive health checks with fitness testing.
223666651|NCT02224248|BEHAVIORAL|Health checks without fitness testing|The active comparator will not receive fitness testing as part of the preventive health checks. With the exception of fitness testing, the preventive health checks in the active comparator group and the intervention group are identical.
223666652|NCT03745885|DRUG|Supaglutide injection|Administered SC in the Supaglutide arms.
224248565|NCT04937153|BIOLOGICAL|Pembrolizumab|Pembrolizumab will be administered IV once every 21 days.
223666653|NCT03745885|DRUG|Placebo|Administered SC in the placebo arms and to maintain the blind in the Supaglutide injection arms.
223666654|NCT00299611|DRUG|Sertraline|Tablets, 50mg each, (1-3TABLETS/DAY) during the Open-label phase for first 8 wks.
223666655|NCT00299611|DRUG|Levetiracetam|Tablets, dosage 500mg each tablet (1-4tablets/day)for 8 wks during the 2nd phase of the study.
223666656|NCT00299611|DRUG|Placebo|Tablets, No active ingredient, (1-4tablets/day) for 8 wks during the 2nd phase of the study.
223666657|NCT03840434|DIAGNOSTIC_TEST|MyotonPRO|Each patient will perform a stress test to trigger the painful. Measurements will be done by intramuscular punction as usually, and by non invasive tool : MyotonPRO
224248566|NCT03179904|DRUG|Anastrozole|Given PO
224248567|NCT03179904|DRUG|Denifanstat|Given PO
224248568|NCT03179904|DRUG|Exemestane|Given PO
224248569|NCT03179904|DRUG|Fulvestrant|Given IM
224248570|NCT03179904|PROCEDURE|Echocardiography|Undergo ECHO
224248571|NCT03179904|DRUG|Letrozole|Given PO
224248572|NCT03179904|DRUG|Paclitaxel|Given IV
224248573|NCT03179904|BIOLOGICAL|Trastuzumab|Given IV
224248574|NCT03179904|PROCEDURE|Computed Tomography|Undergo CT
224248575|NCT03179904|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
224248576|NCT03179904|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
224248577|NCT03179904|PROCEDURE|Biopsy|Undergo biopsy
224248578|NCT06358820|DRUG|Amino acid peritoneal dialysis solution|Each subject received treatment with 1 bag of amino acid peritoneal dialysis daily and 2-4 bags of glucose peritoneal dialysis solution daily for 6 months
224248579|NCT04815954|PROCEDURE|Urinary catheter removal|Removal of urinary catheter which was placed during kidney transplantation.
224248580|NCT06101238|DIETARY_SUPPLEMENT|supplementation with low dose elemental iron|65mg daily
224248581|NCT04475861|DIETARY_SUPPLEMENT|L-arginine supplements and nutritional supports|The enrolled subjects will then be randomized into two groups. The subjects will receive either L-arginine (the study group) or another amino acid supplement (the control group), with 60 patients in each group. All the food intake of the subjects during the 4 weeks of the study will be recorded and supervised by responsible dietitians.
224248582|NCT04201353|BEHAVIORAL|Conditional Cash Transfer|The intervention is a monthly cash transfer of 22,500 Tanzanian Shillings (\~$10) for up to 6 months conditional on visit attendance.
224248583|NCT05627739|DRUG|Mycophenolate Mofetil|Glucocorticoid is started at a dose of 0.5-0.8 mg/kg/day, and 60 mg daily was the highest dose. Mycophenolate mofetilwas is started at a dose of 0.5-1.0g bid.
224248584|NCT01832350|DRUG|Nuedexta (20/10)|Drug: Nuedexta (20/10) administered orally, two times a day, every 12 hours, during a 26-week period.
224248585|NCT04690881|BEHAVIORAL|Psychodrama group psychotherapy|In order to reduce the fear of cihildbirth, pregnant women are given 90 minutes right after the training in addition to the routine pregnancy training. In the psychodrama-based pregnancy education program, fear of childbirth were assesment by sociometric measurement in order to increase the awareness of pregnant women about birth fear levels in the first week. Afterwards, they were given the opportunity to express themselves about the factors that may cause fear in pregnant women (their previous traumatic experiences, negative prejudices about childbirth, etc). The group members shared about their process in the first session and the session was ended. The session was evaluated with other researchers. In the following sessions, in order to strengthen their coping with the fear of childbirth, besides psychodrama warm-up games, the basic techniques of psychodrama, role switching, matching and mirror were used in protogonist works.
224248586|NCT05162664|OTHER|Pressure pain thresholds|PPT will be performed firstly at the anterior tibial muscle halfway between the most superior attachment to the tibia and its tendon in the upper one third of the muscle belly (13) and secondly at the middle of the temporalis muscle (12), using a digital algometer (Wagner FPX 50) with a 1 cm2 rubber tip. The pressure algometer will apply a perpendicular increasing pressure (1kg/s) at the different test locations until the participant reports the first feeling of pain. The PPT of 4 series of ascending stimulus intensities, with an inter-stimulus interval (ISI) of 20sec between the different stimuli and an ISI of 60sec between the 2 locations, will be measured. The first stimulus is a familiarization stimulus. Afterwards the mean of the 3 subsequent stimuli will be calculated.
224248587|NCT05162664|OTHER|Thermal detection and pain thresholds|The thermal tests will be performed unilateral at tibial anterior, thenar and the forehead, using a TSA-2 (Neuro Sensory Analyzer, MEDOC). At first cold and heat detection thresholds will be measured. The patient will be asked to indicate when they feel a change in temperature. Afterwards the patient will be asked to indicate when the stimulus becomes painful to determine the cold and heat pain thresholds. The thresholds of 4 series of stimuli will be measured. The first stimulus is a familiarization stimulus. Afterwards the mean of the 3 subsequent stimuli will be calculated for every location. The subject will push a button when the thresholds are reached. The baseline temperature will be 32°C and the stimuli will increase with 1°C/s (14).
224248588|NCT05162664|OTHER|Temporal summation|The temporal summation will be assessed at the thenar eminence (19,20) using a ramp and hold protocol with the TSA-2 (Neuro Sensory Analyzer, MEDOC). Heat stimuli will be applied for a duration of 15sec. The stimulus temperature will increase from a baseline temperature of 35°C for 9sec at a sensitivity-adjusted rate of about 1,5°C/s until the HTP 5/10 of the thenar is reached. Afterwards the temperature will remain steady for the next 6 seconds. The maximal pain rating should be 50 ± 10 NRS. Subjects rate the pain intensity at the end of the ramp (9sec) and at the end of the hold procedure (15sec) using the NRS. Afterwards the ramp and hold aftersensations are measured. The subjects have to rate the pain intensity every 5sec for 30sec after the termination of the heat stimulus.
224248589|NCT05162664|OTHER|Conditioned pain modulation|CPM will be assessed by comparing heat pain thresholds and pressure pain thresholds before and after giving a conditioning stimulus at a pain free distant zone by using a second thermode of the TSA-2 (17). The conditioning stimulus (HPT 4/10 (18) at the TA) will be applied for 120 seconds. The first test stimulus will be applied at the forehead 30 seconds after the start of the conditioning stimulus (17). The HPT will be measured twice with an ISI of 20 seconds. Immediately after the end of the application of the conditioning stimulus (120 seconds), the HPT at the forehead will be measured again twice, with an ISI of 20 seconds. Afterwards, there will be 10 minutes of rest to avoid bias.
224248590|NCT01066143|DRUG|Seroquel XR|Seroquel XR tablets will be flexibly dosed and begun at a target dose of 50 mg on day 1, 100 mg on day 2, 150 mg on day 3 and 200 mg on day 4 with a maximal daily dose of 400 mg on subsequent days.
224248591|NCT02773134|OTHER|Brace Group|"All eligible patients will undergo a Posterior Spine Instrumented Fusion (PSIF) with the use of autologous local and iliac crest bone graft, and all pedicle screw instrumentation. A deep wound drain will be placed in all patients for 48 hours.~All patients will complete the Oswestry Disability Index (ODI) questionnaire, the SF-12v2 General Health Survey and the Visual Analogue Scale (VAS) for back pain at baseline visit (preoperatively) and post-operatively at 6 weeks and 3 months follow up. Clinical and radiographic assessments will be performed by independent blinded observers not involved in patient care."
224321835|NCT04666311|DIAGNOSTIC_TEST|CAD4COVID+WBC and COVID-19 RDT for SARS-CoV-2 infection|"CAD4COVID: Non-commercial product. Software tool for detecting pneumonia-related features to be expected in COVID-19 patients; availability is guaranteed by Delft Imaging System; CE certified. Will be performed by a registered and qualified radiographer/health professional in accordance with national regulations. Analysis in combination with differential white blood cell count.~SD Biosensor, STANDARDTM Q COVID-19 Ag Test (rapid chromatographic immunoassay for the qualitative detection of specific antigens to SARS-CoV-2)"
224321836|NCT02628067|BIOLOGICAL|pembrolizumab|intravenous infusion
224321837|NCT02628067|BIOLOGICAL|pembrolizumab|intravenous infusion
224321838|NCT05216432|DRUG|RLY-2608|RLY-2608 is a mutant-selective, oral PI3Kα inhibitor.
224321839|NCT05216432|DRUG|Fulvestrant|500 mg fulvestrant is administered intramuscularly on Cycle 1 Day 1, Day 15, and Day 1 of each subsequent cycle (where a cycle is 28 days).
223666658|NCT05072067|PROCEDURE|the sleeve gastroplasty with the endoscopic system Overstich SX|the sleeve gastroplasty with the endoscopic system Overstich SX
224321840|NCT05216432|DRUG|Palbociclib 125mg|125mg palbociclib is taken orally once daily for 28-day cycles that include 21 days of treatment followed by 7 days off treatment.
223666659|NCT00123669|DRUG|500 mg of depot hydroxy-progesterone|An intramuscular injection of 500 mg of depot hydroxy-progesterone 5 to 15 days prior to surgery.
223770828|NCT03075644|DRUG|Norditropin|Daily subcutaneous injections (s.c., under the skin)
223770829|NCT05265949|BEHAVIORAL|diet and physical activity intervention|Dietary intervention: Preparation and follow-up of diet program Physical activity intervention: Step count monitoring
223770830|NCT03377621|DEVICE|Whole Body Vibration|Whole Body Vibration Machine from the company Confidence Fitness
223666660|NCT05857865|BEHAVIORAL|SPYKids|SSIs will be tailored to the parent areas of primary concern as identified in the pre-questionnaire. Participants will meet with the parent coach in a virtual 90-minute session to discuss coping strategies relevant to the identified concerns. Content will be informed by the baseline questionnaire and include psychoeducation with an explanation of 1 or 2 skills to manage a primary mental health issue (e.g., Emotion Regulation, Distress Tolerance, Communication), a brief practice of the skills (as appropriate), and an action plan for the family to apply the skills at home. Families will also be provided with recommendations for relevant services from our family-focused resource list. Please note, the session length may be extended to 120 minutes if an interpreter is required in order to provide equal opportunity for understanding the session content.
223666661|NCT05857865|OTHER|Services as Usual (SAU)|Participants will receive links to the Manitoba 211 websites and a local organization's resource website with resources for adults and children. This resource is used to locate crisis, distress, and support phone lines, and counselling. Following completion of the 3-month survey, participants will receive a lab-developed comprehensive list of resources (also provided to participants in the SPYKids arm).
224248592|NCT02773134|OTHER|Control Group|"All eligible patients will undergo a Posterior Spine Instrumented Fusion (PSIF) with the use of autologous local and iliac crest bone graft, and all pedicle screw instrumentation. A deep wound drain will be placed in all patients for 48 hours.~Bracing will not be prescribed postoperatively for this group. All patients will the Oswestry Disability Index (ODI) questionnaire, the SF-12v2 General Health Survey and the Visual Analogue Scale (VAS) for back pain at baseline visit (pre-operatively) and post-operatively at 6 weeks and 3 months follow up. Clinical and radiographic assessments will be performed by independent blinded observers not involved in patient care."
224248593|NCT02640521|BEHAVIORAL|Chart Reminders & New York State Quit line referral system|Investigators at New York University Medical School, Bellevue and Lincoln Hospital will work closely to (1) develop chart reminders appropriate for each of their clinics (2) to prompt providers to ask about in home smoking at every medical visit and (3) to establish a New York Quit line referral system in the pediatric practice, including clearly defined roles and responsibilities for each step. The New York State Quit line service includes proactive telephone calls with mailings of self-help material, free nicotine replacement therapy for those who qualify, and referrals to local treatment programs, ensuring that health literacy levels of materials is maximized, amending the training curriculum for providers as necessary, and modifying patient education materials that are part of the provider tool kit to focus on the negative impact of secondhand smoke.
224248594|NCT03708991|DIAGNOSTIC_TEST|IVF combined with PGT-A|trophectoderm biopsy to test the ploidy state of the IVF embryos
224248595|NCT03708991|DIAGNOSTIC_TEST|ICSI combined with PGT-A|trophectoderm biopsy to test the ploidy state of the ICSI embryos
224248596|NCT00005591|BIOLOGICAL|cetuximab|
224248597|NCT00005591|DRUG|gemcitabine hydrochloride|
224248598|NCT02728856|OTHER|Sunscreen Spray SPF50 Z15-034(BAY987516)|Study staff will administer the control in one eye and a test sunscreen in the other eye according to the assigned randomization schedule.
224248599|NCT02728856|OTHER|Shampoo Control|Study staff will administer the control in one eye and a test sunscreen in the other eye according to the assigned randomization schedule.
224248600|NCT02728856|OTHER|Sunscreen Spray SPF50 Z15-038(BAY987516)|Study staff will administer the control in one eye and a test sunscreen in the other eye according to the assigned randomization schedule.
224248601|NCT03183037|PROCEDURE|Acupuncture|The acupuncture group will undergo 8 weeks of outpatient acupuncture or sham acupuncture treatments (twice weekly for 2 weeks, then weekly for 6 weeks, 10 treatments in total). The investigators have designed this approach to standardize acupuncture treatment for future broad use; it is based on the understanding that CIPN is a global symptom complex rather than individual isolated or local symptoms.
224248602|NCT03183037|PROCEDURE|Sham Acupuncture|Subjects in this group will receive the sham acupuncture procedure on the same schedule as subjects in the real acupuncture group. In both groups, patients' eyes will be covered with patches so they cannot observe the treatment procedure. To improve incentive to join and stay in the study, we will unblind all patients at Week 12, and offer those randomized to the Sham group 8 weeks of Acu (real) treatment. All points used will be documented.
224248603|NCT03183037|OTHER|Usual Care Group|Patients go to clinic three times during the study, at Baseline, Week 8, and Week 12 to undergo QST and CPM tests. Patients will complete all questionnaires (CIPN severity by 0-10 11-point numeric rating scale, FACT/GOG-Ntx-11, NPS) and their pain medication use at these time points. Week 4 questionnaires can be completed over the phone. As an incentive for patients to join the study - and for those randomized to control to stay in the study - controls will be offered 8 weeks of Acu (real) treatment once they have completed Week 12 assessments.
224248604|NCT03183037|BEHAVIORAL|questionnaires|FACT/GOG-Ntx, Neuropathic Pain Scale (NPS),Treatment Expectancy Scale (TES), Quantitative Sensory Testing (QST), Insomnia Severity Index (ISI), Hospital Anxiety and Depression Scale (HADS), Brief Fatigue Inventory (BFI)
224248605|NCT00520988|BEHAVIORAL|Use of telephone-based Interactive Voice Recognition system|Use of telephone-based Interactive Voice Recognition system, for reporting of health information and blood pressure measurements
224248606|NCT04192162|OTHER|Mud therapy application|Aplication the mud pack therapy from 20 minutes
224248607|NCT04192162|OTHER|Sulfur water application|Aplication the sulfur water in bath from 20 minutes
224248608|NCT04192162|OTHER|Hygienic water|Exercise in hygienic water
224248609|NCT00804960|DRUG|Letrozole|1\) Letrozole 5 mg starting on cycle day 2, which will be continued until the day of trigger. Recombinant FSH at doses 100-225 units, as determined by BMI, AFC, age, and ovarian reserve markers will be added on cycle day 4. The dose will be adjusted based on the response. An antagonist will be administered once the lead follicle reaches 14-mm in diameter or when estradiol level reaches 250 pg/mL. Oocyte maturation will be triggered by 20 iu of leuprolide acetate.
224321841|NCT05216432|DRUG|Ribociclib 400mg|400mg ribociclib is taken orally once daily for 28-day cycles that include 21 days of treatment followed by 7 days off treatment.
224321842|NCT05216432|DRUG|Ribociclib 600mg|600mg ribociclib is taken orally once daily for 28-day cycles that include 21 days of treatment followed by 7 days off treatment.
224321843|NCT05216432|DRUG|PF-07220060 100mg|PF-07220060 100 mg is taken orally twice daily at the same time with RLY-2608 during each 28-day cycle.
224321844|NCT05216432|DRUG|PF-07220060 300 mg|PF-07220060 300 mg is taken orally twice daily at the same time with RLY-2608 during each 28-day cycle.
223666662|NCT06341985|RADIATION|Exclusive radiotherapy|Curative radiotherapy treatment using 3D conformal or Intensity Modulated Radiation Therapy (IMRT) techniques.
223666663|NCT00990418|DRUG|Separated (Two Part) E-TRANS (fentanyl HCl) System; Integrated E-TRANS (fentanyl HCl) System|
223666664|NCT03114852|DIAGNOSTIC_TEST|blood collection|They will have blood tested to renal genetic diseases
223666665|NCT05261529|DIETARY_SUPPLEMENT|Extra Virgin Olive Oil (EVOO)|Daily intake of 40ml EVOO added to the normal intake of EVOO of the participants.
223666666|NCT05261529|BEHAVIORAL|Physical Exercise Program|Besides the EVOO supplementation in the same conditions as the 'Intervention 1 Group', participants will add the follow-up of a Multimodal Physical Exercise (MFE) program during the remaining 12 weeks of intervention, 3 days per week, online and face-to-face group sessions on non-consecutive days. Continuous and intervalic cardiovascular exercise at moderate-intense intensity, controlled by the HR in reserve, with a duration of 15-45 minutes, also including sympathetic modulation exercises (stretching, breathing and meditation) and methods to promote recovery, with a duration of 10-30 minutes.
223666667|NCT05291715|DEVICE|Ozone generator device (Ozone DTA-APOZAa-enterprize CO9-Taiwan, R.0.C)|Gaseous ozone ( O3-triatomic oxygen) activates the neuroprotective systems, improve the blood circulation, oxygen delivery, stimulate the immunocompetent cells and enhance the release of growth factors. Moreover, ozone therapy showed to increase the quality of life post-operatively to a free gingival graft harvesting and decrease post-operative pain sensation ( Tasdemir et al, 2016)
223666668|NCT02605460|DRUG|Busulfan|12mg/kg, Oral, divided in 4 days, 3mg/kg/day Oral, during days -7, -6, -5 y -4.
223666669|NCT02605460|DRUG|Cyclophosphamide|80mg/kg, Intravenous (IV), divided in 2 days, 40mg/kg/day IV, during days -3 y -2.
223666670|NCT02605460|DRUG|CXCR4 Antagonist|24mg, Subcutaneous (SC), in one day, 24mg/day SC, during day -4.
224248610|NCT00804960|DRUG|Std IVF Protocol|2\) Long protocol with luteal phase GnRHa suppression with gonadotropin dose at 200-450 IU. Oocyte maturation will be triggered by 250 micg of ovidrel.
223666671|NCT02605460|PROCEDURE|Hematopoietic Stem Cell Transplantation|Peripheral blood HSC (autologous HSCT) or Bone Marrow HSC (allogeneic HSCT) transfusion, day 0
224248611|NCT06219044|PROCEDURE|laparoscopic endometrioma laser vaporization|laser vaporization of ovarian endometrioma using a DWLS diode laser during a laparoscopy
224248612|NCT06071299|BEHAVIORAL|FCC|Children evaluated for abusive injuries. Caregiver offered meeting with IPV advocate during visit (survivor-centered care, immediate access to services; continued engagement with advocate for ongoing needs). Referral to Child-Study center for trauma follow up. Connection to pediatrician. Use of motivational interviewing to address IPV.
224248613|NCT06071299|BEHAVIORAL|CCC|Children evaluated for abusive injuries. Medical provider offers IPV resources to caregiver. Referral to Child-Study center for trauma follow up. Connection to pediatrician. Use of motivational interviewing to address IPV.
224248614|NCT05376319|DRUG|Obinutuzumab|1000 mg per infusion given approximately two weeks apart, on day 1 and on day 15
224248615|NCT05376319|DRUG|Rituximab|1000 mg per infusion given approximately two weeks apart, on day 1 and on day 15
224248616|NCT03421717|DEVICE|Chitosan brush|If inflammation (Bleeding on probing) and deep pockets (4 mm or more) is present at the control - maintenance is performed according to allocation
224248617|NCT01124175|DRUG|Losartan|100 mg Tablets
224248618|NCT01124175|DRUG|Cozaar®|100 mg Tablets
224248619|NCT04456842|OTHER|Patient Registry Data|To set data on demographic characteristics,documenting antithrombotic therapy, describe the INR control level of VKA users, discontinuation rates and clinical outcomes, such as stroke, hemorrhage and death.
224248620|NCT05839470|DRUG|cadonilimab|Cadonilimab (6mg/kg, iv, Q2W, Day1)
224248621|NCT05839470|DRUG|irinotecan|irinotecan\* 165 mg/m² iv continue for 1.5 hours, D1
224248622|NCT05839470|DRUG|Oxaliplatin|oxaliplatin 85 mg/m² iv continue for 2 hours,
223770831|NCT00647192|DRUG|Eplerenone|50 mg per day
224248623|NCT05839470|DRUG|leucovorin or levoleucovorin|leucovorin 400 or levoleucovorin 200 mg/m² iv continue for 2 hours
224248624|NCT05839470|DRUG|5-FU|5-FU 2400 mg/m² cont. inf. 46h
224248625|NCT06017635|OTHER|Exposure factors|"1. General information Name, gender, age, weight (kg), major diseases~2. Clinical data:~Non-contrast CT scan results of cranial CT on the first day of admission, serum SUR1, trpm4 and MMP-9 expression on the 1st, 4th, 7th and 14th days of admission, S100-β and NSE values on the 1st, 4th, 7th, and 14th days of admission, disturbance coefficient on the 1st, 4th, 7th, and 14th days of admission, Glasgow coma score on the 1st, 4th, 7th, and 14th days of admission, GOS-E score and Merriam-Webster Intelligence Scale score at 3 months of discharge."
224248626|NCT00486863|DRUG|Praziquantel|60 mg/kg administered orally given in split dose (30/mg/kg each) separated by 3 hours; over-encapsulated in gelatin capsules. Two capsule sizes will be made which will be differentiated by color; these will contain 300 mg or 150 mg to allow for best dosing by weight.
224248627|NCT00486863|OTHER|Placebo|Made with the same color coded gelatin capsules with the inert compound dextrose.
224248628|NCT03040648|DEVICE|DSA|DSA was used for detection of intravascular injection
224248629|NCT03040648|DEVICE|RTF|RTF was used for detection of intravascular injection
224248630|NCT00039286|PROCEDURE|positron emission tomography|
224248631|NCT00039286|PROCEDURE|radionuclide imaging|
224248632|NCT00039286|RADIATION|fludeoxyglucose F 18|
224248633|NCT00942968|DRUG|dalteparin|Daily subcutaneous injection 200IU/kg dalteparin
224248634|NCT06558981|RADIATION|Radiotherapy|Ppatients would receive external radiation therapy within 6 weeks after surgery, using intensity-modulated radiation therapy (IMRT) or volume modulated radiation therapy (VMAT) techniques. RAI would be administered as standard care. The treatment window is within 6 months after surgery.
224248635|NCT06558981|OTHER|radioiodine treatment|RAI would be delivered based on the condition of residual lesions after surgery. The treatment window is within 6 months after surgery.
224248636|NCT04330534|DRUG|BCX9930|BCX9930 capsules for oral administration
224248637|NCT04330534|DRUG|Placebo|placebo to match BCX9930 capsules for oral administration
224248638|NCT00501397|DRUG|ketoconazole|
224248639|NCT00501397|DRUG|GSK189075|
224248640|NCT00355797|DEVICE|Closed Loop Stimulation (CLS)|Comparison of different pacing modes available on the Cylos pacemaker device. In this intervention group, subjects were programmed to the Closed Loop Stimulation (DDD-CLS or VVI-CLS) pacing mode for the long-term follow-up portion of this study.
224248641|NCT00355797|DEVICE|Standard Rate Adaptive (R) Technology|Comparison of different pacing modes available on the Cylos pacemaker device. In this intervention group, subjects were programmed to the standard are adaptive pacing mode (DDDR or VVIR) for the long-term follow-up portion of this study.
224248642|NCT00355797|DEVICE|Non-rate adaptive (DDD) pacing|Comparison of different pacing modes available on the Cylos pacemaker device. In this intervention group, subjects were programmed to the non-rate adaptive pacing mode (DDD or VVI) for the long-term follow-up portion of this study.
224248643|NCT02856347|OTHER|18F-DOPA|Injection of 18F-DOPA and PET / CT-scan assessment
224248644|NCT03405454|DRUG|durvalumab|Durvalumab will be given at 1500mg fixed dose every 4 weeks for 24 months or until the appearance of significant treatment-related toxicity or disease progression
224248645|NCT03405454|DRUG|standard chemotherapy|chemotherapy treatment will be administered as per local institutional guidelines
224248646|NCT01686451|DRUG|XueZhiKang|Participants will receive 600mg of XueZhiKang twice a day for 4 weeks.
224248647|NCT01686451|DRUG|simvastatin|Participants will receive 20mg of simvastatin daily for 4 weeks.
224248648|NCT00218257|DRUG|Progesterone|200mg progesterone twice daily
224248649|NCT00218257|OTHER|Placebo|placebo
224248650|NCT01400087|DEVICE|Cap-attached Colonoscopy Versus Regular Colonoscopy|Trainees were divided into two group; Cap-attached Colonoscopy group or Regular Colonoscopy group. Trainees allocated to the former group undergo colonoscopy with cap for all cases, the latter without cap.
224248651|NCT02470247|OTHER|Remote Ischemic Preconditioning (RIPC)|"RIPC is accomplished by performing 4 cycles of alternating 5-minute inflation and 5-minute deflation of a standard upper-arm blood pressure cuff, to induce transient and repetitive arm ischemia and reperfusion.~RIPC will be started just before the CTA, and the time between the last inflation cycle and the beginning of the CTA will be less than 45 minutes."
224248652|NCT02470247|OTHER|SHAM Remote Ischemic Preconditioning (SHAM RIPC)|"The SHAM Remote Ischemic Preconditioning (SHAM RIPC) will be carried out with the same number of cycles that the RIPC but cuff will be inflated to the diastolic pressure of the subject and the cuff will be deflated to10 mmHg in order to maintain a non- ischemic compression (blind patient protocol)."
224248653|NCT01466166|BIOLOGICAL|Pegloticase|Pegloticase 8 mg intravenous every 2 weeks
224248654|NCT00834535|DRUG|Cefdinir Capsules 300 mg|1 x 300 mg, single-dose non-fasting
224248655|NCT00834535|DRUG|OMNICEF® Capsule 300 mg|1 x 300 mg, single-dose non-fasting
224248656|NCT03733158|DEVICE|the standard Bougie stylet for difficult intubation|intubation with the standard Bougie stylet for difficult intubation and endotracheal tube 7.0 internal diameter
224248657|NCT03733158|DEVICE|The new Flexible Tip Bougie catheter|intubation with The new Flexible Tip Bougie catheter and endotracheal tube 7.0 internal diameter
224248658|NCT01163435|DRUG|high dose dual therapy|rabeprazole 20 mg qid,amoxicillin 750 mg qid for 14 days
224248659|NCT01163435|DRUG|sequential therapy|rabeprazole 20 mg, amoxicillin 1000 mg, bid for 5 days, then rabeprazole 20 mg , metronidazole 500 mg, clarithromycin 500 mg, bid for next 5 days
224248660|NCT01163435|DRUG|clarithromycin-based triple therapy|rabeprazole 20 mg, amoxicillin 1000 mg, clarithromycin 500 mg, bid for 7 days
224248661|NCT01163435|DRUG|levofloxacin-based triple therapy|rabeprazole 20 mg, amoxicillin 1000 mg, levofloxacin 250 mg, bid for 7 days
224248662|NCT03296722|BEHAVIORAL|The Transtheoretical Model|Intervention with the Transtheoretical Model, through group and individual sessions with topics of healthy eating habits taught by a dietician, physical activity and exercise manual taught by a physical therapist, preparation of healthy food with menu taught by graduates in gastronomy, confrontation of barriers given by a psychologist. This group had a monthly monitoring during 3 months. The food plan that was prescribed to the intervention group was with the characteristics of the DASH diet, according to the most recent international guides of the ACC and AHA, for the reduction of cardiovascular risk.
224248663|NCT04408586|DRUG|Phentermine-Topiramate Extended Release|Dosing of 3.75/23 mg daily for 15 days, increased to 7.5/46 mg daily
224248664|NCT04408586|DRUG|Placebo|Placebo looks exactly like the study drug, but it contains no active ingredient
224248665|NCT04408586|OTHER|Online support system|VitalCare (VitalTech Affiliates LLC) is a digital health platform that allows remote collection of date from the wearable tracker and digital wellness devices used as part of this study. It also will allow subjects to document study medication compliance and will allow the remote visits to be conducted through a video conference between subjects and appropriate study team members.
224248666|NCT05329922|BEHAVIORAL|ALICE: Audiological rehabilitation|Persons who are randomised into this arm of the study will be asked to train their listening and communication skills using the ALICE app.
224248667|NCT04625153|BIOLOGICAL|RC18 160mg|RC18 160mg is injected subcutaneously once a week for 48 times.
224248668|NCT04625153|BIOLOGICAL|RC18 240mg|RC18 240mg is injected subcutaneously once a week for 48 times.
224248669|NCT05954741|OTHER|Motor rehabilitation alone|Participants will undergo motor training consisting of a walking session (20 minutes), balance exercises, postural control exercises, proprioceptive exercises, joint mobilization exercises, and muscle strengthening exercises for a total of 25 minutes. A muscle relaxation session will follow (45 minutes).
224248670|NCT05954741|OTHER|Motor rehabilitation and Cognitive rehabilitation (paper-based)|Group 2 will perform motor training, with an analogous modality of Group 1 (45 minutes) and a standard cognitive intervention, with the execution of cognitive exercises in the domains of attention, memory, executive function, visuo-spatial abilities, space-time orientation, by paper-pencil support (45 minutes per day).
224248671|NCT05954741|OTHER|Motor rehabilitation and cognitive rehabilitation (digital-based)|Group 3 will perform motor training, with an analogous modality of Group 1 (45 minutes) and a digital cognitive intervention, with the execution of cognitive exercises on attention, memory, executive functions, visual-spatial ability, space-time orientation, employing device support (tablet) with interactive exercises presented by specific software (VRRS Home tablet Khymeia Srl) (45 minutes).
224248672|NCT02060747|BEHAVIORAL|Coordinator-based post fracture program|
224248673|NCT06561906|OTHER|Multimodal magnetic resonance imaging scanning, behavioral, genetic and plasma biomarker testing|Multimodal magnetic resonance imaging scanning, including 3DT1, 3DT2, 3DFLAIR, functional MRI, DTI, NODDI, ASL, QSM behavioral testing, such as olfaction and spatial navigation genetic testing, such as APOE, BDNF plasma biomarker testing, such as ptau, Aβ42/40、NfL、GFAP
224248674|NCT04274374|DIETARY_SUPPLEMENT|Gluten-Free Diet|Dietary supplement without gluten
224248675|NCT04274374|DIETARY_SUPPLEMENT|Gluten Diet|Dietary supplement with gluten
224248676|NCT05013463|DRUG|Hydroxychloroquine Pill|Oral Hydroxychloroquine, 200mg BID
224248677|NCT05013463|DRUG|Indapamide Pill|Oral Indapamide, 2.5 mg OD
224248678|NCT06485531|OTHER|Pranamaya|Pranamaya
224248679|NCT06485531|OTHER|Pursed Lips Breathing|Pursed Lips Breathing
224248680|NCT06626815|BEHAVIORAL|Lateral Kangaroo Position|Newborns in the lateral kangaroo position group will be positioned diagonally on their mothers chests, with their heads placed between the mothers breast and collarbone.
224248681|NCT06626815|BEHAVIORAL|Reverse Kangaroo Position|Newborns in the reverse kangaroo position group will be positioned vertically with their backs in contact with the mothers chest.
224248682|NCT05302128|OTHER|Cold vapor|Before surgery, the socio-demographic data of the patients will be recorded. After surgery, patients will be evaluated in the recovery room for their suitability to participate in the study with the Ramsay sedation scale and the Modified Aldrete Scale. Cold vapor will be applied to the patients for 15 minutes in the recovery room during the postoperative period. The parameters to be set on the device for the cold vapor to be applied to the patients in the early postoperative period will be vapor intensity level 5, air blowing intensity 5, heater intensity 1 (+10C), and timer 15 minutes. The patients will be evaluated by the researchers in terms of nausea and vomiting before and 15 minutes after the cold vapor application in the recovery room and at the 2nd, 6th,12th, and 24th hours after the cold vapor application in the postoperative service.
224248683|NCT01079585|DIETARY_SUPPLEMENT|Nutrigal Okara - 100|
224248684|NCT02681939|DRUG|Tulsi(Ocimum sanctum Linn.) capsules|
224321845|NCT05525390|BEHAVIORAL|Extended Reality-Enhanced Behavioral Activation|"Participants will choose at least four activities to complete in Oculus extended reality over the course of the week. These activities are chosen from the Oculus and may include video 360, social interactions, gaming, etc."
224321846|NCT05525390|BEHAVIORAL|Traditional Behavioral Activation|Participants will choose at least four pleasurable and/or mastery activities to complete over the course of the week in real life.
224321847|NCT05102747|RADIATION|Hypofractionated SRT (stereotactic radiotherapy)|3\*10Gy over 1 week
223666672|NCT03976648|DRUG|GLPG1690|film-coated tablets of GLPG1690 to be administered orally
223666673|NCT02980575|OTHER|Music|
223666674|NCT02980575|OTHER|Exercise|
223666675|NCT01981551|DRUG|PF-03084014|Treatment with the selective small-molecule \>=-secretase inhibitor PF- 3084014 caused significant tumor shrinkage in patients with unresectable desmoid tumors in an early-phase clinical trial.
223666676|NCT01046409|OTHER|Measuring collateral flow|Measuring collateral flow using pressure and/or velocity coronary wire
223666677|NCT00439816|BEHAVIORAL|Group Visits|
223666678|NCT04963985|DRUG|Tafamidis Pill|Oral
223666679|NCT00960570|DRUG|Efavirenz 600 mg|Efavirenz 600 mg administered as a single oral dose on the morning of Day 1.
223666680|NCT00960570|DRUG|Efavirenz 600 mg|Co-administered single oral doses of Efavirenz 600 mg and Fenofibric Acid 105 mg on Day 31.
223666681|NCT00960570|DRUG|Fenofibric Acid|Co-administered single oral doses of Efavirenz 600 mg and Fenofibric Acid 105 mg on Day 31.
223666682|NCT01451437|DRUG|MK-8242|MK-8242 capsules, orally, once per day on Days 1-7 and Days 15-21 of each 28-day cycle (except Cycle 1 Day 7) up to a maximum of 12 cycles. Starting dose will be 30 mg and will be escalated in successive cohorts until maximum tolerated dose (MTD) is established. Beginning at a dose level of ≥120 mg total daily dose (TDD), the dosing regimen will switch to twice daily (BID). Amendment 4 added a 21-day dosing cycle in which MK-8242 would be given BID on Days 1-7 of each cycle, at the assigned dose level.
223666683|NCT00602199|DRUG|ABT-510|
223666684|NCT00602199|OTHER|immunoenzyme technique|
223666685|NCT00602199|OTHER|immunohistochemistry staining method|
223666686|NCT00602199|OTHER|laboratory biomarker analysis|
223666687|NCT00602199|OTHER|pharmacological study|
223666688|NCT00602199|PROCEDURE|biopsy|
224321848|NCT05102747|RADIATION|Historical single-dose SRS (stereotactic radiosurgery)|20 to 25Gy/1 fraction
224321849|NCT04151043|BEHAVIORAL|Suggestions|Verbal suggestions or no suggestions about treatment outcome
223666689|NCT02422199|DRUG|pyrotinib|
223666690|NCT02422199|DRUG|Lapatinib|
223666691|NCT02422199|DRUG|capecitabine|
223666692|NCT06654531|DRUG|Dexmedetomidine|"Under a sterile technique, spinal anesthesia will be carried out using a 22-G Quincke spinal needle after skin infiltration with 2% lidocaine 3 ml a t the L3-L4 level, a midline approach in the sitting position, and then in the supine position.~Th e time of spinal injection will be considered time zero (T0). The I.V drug regimen will be started according to the group to which patients will be assigned.patients will receive intrathecal 15 mg hyperbaric bupivacaine together with 5 μg Dexmedetomidine in group 2"
223666693|NCT00824837|OTHER|Larger pore haemodialysis membrane|Patients receive haemodialysis sessions 3 times a week. They are randomized to start with either treatment A (experimental arm) or treatment B (active comparator arm) and continue for 2 weeks, followed by a 1-week washout period. The patients then cross-over and receive the other treatment (either B or A) for 2 weeks.
223666694|NCT00824837|OTHER|Standard haemodialysis membrane|Patients receive haemodialysis sessions 3 times a week. They are randomized to start with either treatment A (experimental arm) or treatment B (active comparator arm) and continue for 2 weeks, followed by a 1-week washout period. The patients then cross-over and receive the other treatment (either B or A) for 2 weeks.
223666695|NCT04985552|PROCEDURE|DIEP Breast Reconstruction|All patients enrolled in the study will undergo DIEP breast reconstruction and have their abdominal incision sutured according to routine clinical practice: 3-0 VICRYL ® suture (Ethicon, USA) for deep fascia closure, 4-0 MONOCRYL® suture (Ethicon, USA) for deep dermal closure, and 5-0 MONOCRYL® suture (Ethicon, USA) for subcuticular closure.
223666696|NCT04985552|DEVICE|ciNPT|Following closure of the abdominal donor site, the closed incision will be dressed with the ciNPT system \[V.A.C.ULTA™ Negative Pressure Wound Therapy System (KCI, USA)\] applied by the operating surgeon in a sterile fashion. The ciNPT device will be set at -125mmHg of continuous negative pressure for a period of 7 days or until patient discharge from hospital. Removal of the ciNPT dressing will be performed by the surgical team at the time of discharge. Following removal, no additional dressings will be applied to the abdominal incision unless clinically indicated secondary to dehiscence.
224248685|NCT04501003|DEVICE|Bipolar cutting electrode (26040 BL1 Karl Storz, Tuttlingen)|With the bipolar cutting electrode (26040 BL1 Karl Storz, Tuttlingen. Germany), a single incision was made from the bottom of the ostium onto the lateral walls up to the isthmus, with both lateral horns perpendicular to myometrium. The depth of the incision was between 5 and 7 mm. The cavity was widened to be triangular and symmetrical. Both tubal ostium surgeries were clearly observed at the end of the surgery. All patients were discharged on the day of surgery and no hormonal therapy and intrauterine balloon was applied after surgery. Approximately 3 months after the hysteroscopic T-shaped operation, an office hysteroscopy operation was planned to control patients in the secretory phase, to perform uterine cavity and post-operative fly control and to receive post-operative control endometrial biopsy specimens.
224248686|NCT00428298|DRUG|Valacyclovir|Subjects take two 500 mg capsules twice daily for 16 weeks.
224248687|NCT00428298|DRUG|Placebo|Subjects take two 500 mg capsules twice daily for 16 weeks.
224248688|NCT01340495|RADIATION|Proton Radiation|45-50.4 Gy(RBE) to the chest wall and 45-50.5 Gy(RBE) once daily, 5 days per week, for approximately 5 1/2 weeks
224248689|NCT06345053|BEHAVIORAL|Narrative Exposure Therapy|The intervention period will be from (May 2021- October 2024). All patients will participate in standard treatment at MBS. Dialectical Behaviour Therapy -Substance Use Disorder skills training (DBT-SUD skills) will be offered to all patients at MBS in the project period that experience difficulties in emotion regulation and manage to commit to participating in the DBT- skills training evaluated by their DBT therapist. Narrative Exposure Therapy (NET) will be offered to all patients with relevant traumatic experience and symptoms of PTSD depending on clinical evaluation.
224248690|NCT00070291|DRUG|cyclosporine|Cyclosporine doses will be based on actual body weight unless actual body weight is \> 15 kg higher than the ideal body weight. Cyclosporine dose will be adjusted to maintain a trough whole blood level of 250-450 ng/mL during the high dose period (weeks 1 -6, starting dose will begin at cyclosporine 3 mg/kg by mouth two times a day (PO BID)) and 150-250 ng/mL during the maintenance period (weeks 7-36, maintenance dose will begin at cyclosporine 2 mg/kg PO BID) in the absence of renal toxicity
224248691|NCT01783535|DRUG|vincristine|Given via minibag/gravity flow.
223666697|NCT04985552|OTHER|Conventional Tape Dressings|Following closure of the abdominal donor site, the closed abdominal incision will be dressed with 1-inch Micropore™ Surgical Tape (3M, USA) with an alcohol swab applied to the tape for additional adhesion, by the operating surgeon in a sterile fashion. This dressing will remain in-situ for up to 7 days or until patient discharge from hospital. Removal of the traditional tape dressing will be performed by the surgical team at the time of discharge. Following removal, no additional dressings will be applied unless clinically indicated secondary to dehiscence.
223666698|NCT01252732|DRUG|Single-Dose IV Oritavancin Diphosphate|Intravenous oritavancin and IV placebo or IV vancomycin will be administered for a minimum of 7 days up to a maximum of 10 days.
223666699|NCT01252732|DRUG|IV Vancomycin|Intravenous oritavancin and IV placebo or IV vancomycin will be administered for a minimum of 7 days up to a maximum of 10 days.
223666700|NCT02220088|PROCEDURE|TAI of FOLFOX|Retreatment with TAI: administration of Oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries
223666701|NCT02220088|DRUG|Sorafenib|Accept sorafenib.
223666702|NCT03894007|DRUG|Docetaxel|75 mg/m2 iv, escalated to 100 mg/m2 if tolerated, day 1 every third week, 4 courses preoperatively.
223770832|NCT00647192|DRUG|Placebo|50 mg per day
224248692|NCT01783535|DRUG|topotecan|Given IV over 30 minutes.
224248693|NCT01783535|DRUG|filgrastim|Given subcutaneously 24-36 hours after chemotherapy for 7-10 days, until absolute neutrophil count (ANC) is \>2,000/µL on one occasion after the expected nadir.
224248694|NCT01783535|DRUG|PEG-filgrastim|Given subcutaneously 24-36 hours after chemotherapy for 7-10 days, until ANC is \>2,000/µL on one occasion after the expected nadir.
223666703|NCT03894007|DRUG|Carboplatin|AUC 6 iv, day 1 every third week, 4 courses preoperatively.
223666704|NCT03894007|DRUG|Trastuzumab|600 mg sc, day 1 every third week, 4 courses preoperatively. 14 courses postoperatively if complete response.
223666705|NCT03894007|DRUG|Pertuzumab|840 mg iv starting dose, thereafter 420 mg, day 1 every third week. 14 courses postoperatively if complete response in patients with baseline high risk tumours.
224248695|NCT01783535|DRUG|carboplatin|Given IV over 60 minutes. Given periocular (subtenon/subconjunctival).
224248696|NCT01783535|OTHER|focal therapy|Focal treatments will be administered at the discretion of the treating team to strata A, B and D. In select cases of very early stage retinoblastoma (Stratum A), participants may receive focal therapies only and chemotherapy will be held at the discretion of the treating team. If there is any evidence of progression or unsatisfactory results, the participant will begin chemotherapy as per Stratum A. For selected participants an effort will be made to perform sequential chemo-thermotherapy. In these cases, carboplatin will be administered one or two hours prior to thermotherapy.
223666706|NCT03894007|DRUG|Epirubicin|90 mg/m2 iv, escalated to 100 mg/m2 if tolerated, day 1 every third week, 3 courses preoperatively
223666707|NCT03894007|DRUG|Cyclophosphamide|600 mg/m2 iv, day 1 every third week, 3 courses preoperatively
223770833|NCT01159418|DRUG|Panobinostat (LBH589), Carboplatin and Paclitaxel|"1. Panobinostat (LBH589) p.o. on days 1,4,8 and 11 of each cycle (20mg-45mg).Carboplatin i.v.on day 1 at a total dose corresponding to a AUC of 5 µg/ml.h. Paclitaxel as 3 hour infusion on day 1 (135 mg/m2).~2. Panobinostat (LBH589) p.o. on days 1, 4, 15 and 18 of each cycle (20mg-30mg).Carboplatin i.v. on day 8 at a total dose corresponding to a AUC of 5 µg/ml.h.Paclitaxel as a 3 hour infusion on day 8 (135mg/m2-175mg/m2).~3. Once the MTD is achieved:Panobinostat (LBH589) p.o. on days 1 and 4 of each cycle(20mg-30 mg). Carboplatin i.v. on day 8 at a total dose corresponding to a AUC of 5 µg/ml.h.Paclitaxel as a 3 hour infusion on day 8 (135mg/m2-175 mg/m2).~The treatment will be repeated every three weeks until disease progression."
223666708|NCT03894007|DRUG|Atezolizumab|840 mg iv, day 1 every third week, 3 courses preoperatively if randomised to arm A.
223666709|NCT03894007|DRUG|Trastuzumab emtansine|3.6 mg/kg iv, day 1 every third week, 14 courses postoperatively if not complete response.
223666710|NCT03894007|DRUG|Paclitaxel|80 mg/m2 iv, day 1 weekly, 12 weeks (4 cycles), in case of (anticipated) unmanageable toxicity related to docetaxel.
223770834|NCT03565185|OTHER|robot-assisted gait training|Investigators will use robot-assisted gait training for rehabilitation of stroke
223770835|NCT03565185|OTHER|placebo|Investigators will use only conventional treatment without robot-assisted gait training
223666711|NCT03219775|BIOLOGICAL|Nivolumab/Ipilimumab|"* Induction: Mono-Therapy with Nivolumab (240 mg i.V. / Q2W x 4)~* If CR/PR: Nivolumab Maintenance Mono-Therapy (240 mg i.V. / Q2W)~* If SD/PD: Nivolumab/Ipilimumab Boost 1+2-Combination Therapy (Nivo1 mg/kg i.V. and Ipi3 mg/kg i.V. / Q3W x 2)\*~* If CR/PR: Nivolumab Maintenance Mono-Therapy (240 mg i.V. / Q2W)~* If SD/PD: Nivolumab/Ipilimumab Boost 3+4-Combination Therapy (Nivo 1 mg/kg i.V. and Ipi 3 mg/kg i.V. / Q3W x 2)~* If CR/PR/SD: Nivolumab Maintenance Mono-Therapy (240 mg i.V. / Q2W)~  * since June 5, 2019, the treatment in all four boost cycles (1+2) and (3+4) is performed with nivolumab 1 mg/kg + ipilimumab 3 mg/kg (NIVO1/IPI3)"
224248697|NCT01783535|DRUG|etoposide|Given IV. Participants who cannot tolerate etoposide may be given etoposide phosphate (Etopophos(R)).
224248698|NCT01783535|DRUG|cyclophosphamide|Given IV.
224248699|NCT01783535|DRUG|MESNA|Given IV before CYCLO and at 3, 6 and 9 hours after CYCLO.
224248700|NCT01783535|DRUG|doxorubicin|Given IV on Day 1 of Cycles 2, 4 and 6 in Stratum C high-risk.
224248701|NCT01783535|PROCEDURE|enucleation|Eye removal due to advanced disease in Strata C and D participants.
224248702|NCT01783535|RADIATION|external beam radiation or proton beam radiation|EBRT or proton beam radiation will be administered to any eye in which the disease is considered to be not controllable with focal treatments alone, and in participants with enucleated eyes in which high risk of orbital and/or central nervous system disease is documented histologically (high-risk group with disease extension beyond the sclera or cornea, or beyond the cut end of the optic nerve). EBRT will be administered using standard techniques practices with the objective of limiting dose to normal tissues including the hypothalamic-pituitary unit, supratentorial brain, orbit, cochleae and contralateral eye when indicated. Participants will be evaluated on an individual basis to determine whether they might benefit from referral for proton therapy.
224248703|NCT00507117|DRUG|Lunesta|Lunesta 3mg prior to PSG
224248704|NCT00507117|DRUG|Placebo control|matching placebo
224248705|NCT05883215|OTHER|Pain catastrophizing scale|"The pain catastrophizing scale is a self-report questionnaire used to assess an individual's tendency to engage in catastrophic thinking when experiencing pain. It measures the extent to which a person magnifies, feels helpless, and feels unable to cope with pain. The scale typically consists of several items that ask individuals to rate the degree to which they experience specific thoughts or emotions related to pain catastrophizing, such as I worry all the time about whether the pain will end or I feel like I can't stand it anymore. Participants provide responses on a Likert scale indicating the intensity or frequency of their agreement with each statement. The scale helps researchers and healthcare professionals gain insights into an individual's cognitive and emotional responses to pain, which can have implications for pain management strategies and overall well-being."
224248706|NCT05883215|OTHER|Beck Anxiety Inventory|"Beck Anxiety Inventory (BAI), which is designed to measure the severity of anxiety symptoms in individuals. The BAI is a self-report questionnaire consisting of 21 items that assess various symptoms of anxiety, such as nervousness, fear, and physiological manifestations of anxiety. Participants rate the intensity of their symptoms over the past week on a scale ranging from 0 (not at all) to 3 (severely). The scores obtained on the BAI can help clinicians and researchers evaluate the presence and severity of anxiety symptoms, monitor changes over time, and guide treatment decisions. It is important to note that the BAI is not a diagnostic tool but rather a measure of self-reported anxiety symptoms."
224248707|NCT05883215|OTHER|Social Media Use Integration Scale|The Social Media Use Integration Scale (SMUIS) is a self-report measure that assesses the degree to which individuals integrate social media into their daily lives. It aims to capture the extent to which individuals incorporate social media use into various aspects of their routines, behaviors, and identity. The scale typically consists of items that assess factors such as the frequency and duration of social media use, the importance and impact of social media on personal relationships, the integration of social media into daily activities, and the emotional connection to social media.
224248708|NCT05883215|OTHER|Fibromyalgia Impact Questionnaire|"The Fibromyalgia Impact Questionnaire (FIQ) is a widely used self-report measure specifically designed to assess the impact of fibromyalgia on various aspects of a person's life. It is a multidimensional questionnaire that evaluates the physical functioning, social functioning, and overall well-being of individuals with fibromyalgia.~The FIQ typically consists of items that ask individuals to rate the impact of fibromyalgia on their ability to perform daily activities, such as work, household chores, and recreational activities. It also assesses the severity of fibromyalgia symptoms, including pain, fatigue, sleep disturbances, and cognitive difficulties. Additionally, the questionnaire may include items related to emotional well-being, social support, and overall quality of life."
224248709|NCT05996926|DIAGNOSTIC_TEST|Three-Dimensional Transvaginal Ultrasound (3D TVS)|"In this study, Three-Dimensional Transvaginal Ultrasound will be employed as one of the interventions to evaluate Cesarean Scar Defects (CSD) and associated complications in symptomatic patients with a history of cesarean section.~Procedure: A specialized ultrasound machine (Samsung WS80A) equipped with a transvaginal 2-11 MHz probe will be used for the Three-Dimensional Transvaginal Ultrasound examination. The examination will be conducted in the 1st half of the menstrual cycle. The ultrasound probe will be introduced into the posterior fornix of the vagina to capture three-dimensional images of the uterus and scar area. The examiner will identify and measure the characteristics of the Cesarean Scar Defects (CSD), including length, depth, width, volume, residual myometrial thickness, adjacent myometrial thickness, and presence of any branches."
224248710|NCT05996926|DIAGNOSTIC_TEST|Saline-Infused Sonography (Sonohystrography)|The Sonohystrography will be performed using a Toshiba ECCO CEE SSA-340A ultrasound equipment with a 7.5 MHz transvaginal probe. A sterile vaginal speculum will be inserted, the cervix cleansed with an antiseptic solution, and a thin Foley's catheter inserted into the cervical os. Sterile saline solution will be infused into the uterus through the catheter to distend the uterine cavity. The examiner will use the ultrasound probe to visualize and assess the uterine cavity, focusing on identifying and measuring Cesarean Scar Defects (CSD) characteristics, including depth, width, volume, and myometrial thickness.
224248711|NCT04621552|DEVICE|WEB embolization|Treatment of intracranial aneurysms with WEB with the use of the virtual simulation before implantation of the device
224248712|NCT01174225|DEVICE|Flexi T 380(+) IUD|The intrauterine device is placed in the uterus immediately post-abortion. Participant is counseled that she may leave the device in for up to five years.
224248713|NCT01174225|DEVICE|Nova T IUD|The intrauterine device is placed in the uterus immediately post-abortion. Participant is counseled that she may leave the device in for up to five years.
224248714|NCT02821728|DIETARY_SUPPLEMENT|Dietary intervention|Participants in this group will consume three portions of broccoli and stilton soup per week for a minimum of four weeks before their scheduled template prostate biopsy. The soup will be made with a specially cultivated broccoli known as Beneforte, which contains an enhanced dose of a substance called glucoraphanin.
224248715|NCT02821728|OTHER|Normal diet|Participants in this group will continue with their normal diet up until the day of their scheduled template prostate biopsy.
224248716|NCT02055963|DRUG|Minocycline|100 mg given orally every 12 hours on Day -2, (i.e., 2 days prior to surgery) and continuing for 3 weeks postsurgery.
224248717|NCT02055963|DRUG|Placebo|Placebo 100 mg given orally every 12 hours on Day -2, (i.e., 2 days prior to surgery) and continuing for 3 weeks postsurgery.
224248718|NCT02055963|BEHAVIORAL|Questionnaires|Questionnaire completion 2 days before surgery, on day of surgery, 1 and 3 days after surgery, then twice a week until follow up visit on day 21.
224248719|NCT01268787|BIOLOGICAL|EV71 vaccine|Two-vaccination 0.25ml or 0.5ml dose assigned to two groups.
224248720|NCT03217539|DIAGNOSTIC_TEST|Imaging|
224248721|NCT03491072|DEVICE|Transcutaneous electrical nerve stimulation|Patients will receive IV fentanyl 1µg /Kg with the application of conventional TENS in which constant mode will be chosen. Assessment of pain will be done using visual analogue scale (VAS), every 10 minutes. If VAS ≥ 3 this indicates giving IV increments of 20µg of fentanyl.
224248722|NCT03491072|DRUG|Fentanyl|Patients will receive IV fentanyl
224248723|NCT02131363|DEVICE|Ingrowing Toenail Treatment Kit|detailed in arm description
224248724|NCT00777972|DRUG|Fosinopril sodium and hydrochlorothiazide 20-12.5 mg tablets|
224248725|NCT02028715|DRUG|Placebo|Normal saline (100cc) will be given IV as the placebo medication every six hours for a total of eight doses with the first dose being given at time of anesthesia induction.
224248726|NCT02028715|DRUG|IV acetaminophen|IV acetaminophen (1,000mg) will be given every six hours for a total of eight doses with the first dose being given at time of anesthesia induction.
224248727|NCT03547622|DRUG|MAT taper with galantamine|Following taper from MAT (methadone or buprenorphine) participants will be given galantamine daily with access to a CBT4CBT computer program
224248728|NCT03547622|DRUG|MAT taper with placebo|Following taper from MAT (methadone or buprenorphine) participants will be given placebo daily with access to a CBT4CBT computer program
224248729|NCT00520130|BIOLOGICAL|Rituximab|Rituximab: 375 mg/m(2) intravenous (IV), day 1 for patients with cluster of differentiation 20 (CD20)-positive disease.
224248730|NCT00520130|DRUG|Cyclosporine|Cyclosporine: IV over 2 hours or orally every 12 hours on days -1 to 100, followed by a taper if graft versus host disease (GVHD) does not develop.
224248731|NCT00520130|DRUG|Allogenic stem cell transplant (ASCT)|Allogenic stem cell transplant
224248732|NCT00520130|DRUG|Conditioning Chemotherapy|"Fludarabine:30 mg/m(2) per day IV infusion over 30 minutes, daily. On days -6, -5, -4, and -3.~Cyclophosphamide:1200 mg/m(2) per day IV infusion over 2 hours on Days 6, -5, -4, -3 Mesna: 1200 mg/m(2) per day IV infusion, Daily on days 6, -5,-4, and -3"
224248733|NCT00520130|DRUG|TMS|Tacrolimus: starting day -3 before transplant, given initially at 0.02 mg/kg/day CIV. Continue IV and then switch to an equivalent oral dose (when patient taking po) titrated for a goal level of 5 to 10 ng/ml; Sirolimus: given as an initial loading dose of 12 mg p.o. on day -3 pre-transplant, 4 mg starting day -2 pre-transplant and titrated for levels 3-12 ng/ml; Methotrexate 5 mg/m2 IV on days +1, +3, +6, and +11 post-transplant. Tacrolimus and sirolimus will be tapered at day +63, day +119 and day +180 post-transplant as tolerated.
223666712|NCT01956916|DIETARY_SUPPLEMENT|Lactobacillus rhamnosus GG|"Capsules containing lyophilized 6x10\^9 Colony Forming Units (CFU)/die LGG, (60mg) maltodextrin (163 mg), gelatine capsule (75 mg), magnesium stearate (2 mg)~1 cps/die for 12 months"
223666713|NCT01956916|DIETARY_SUPPLEMENT|placebo|"Capsules containing maltodextrin (163 mg), gelatine capsule (75 mg), magnesium stearate (2 mg)~1 cps/die for 12 months"
223666714|NCT00324597|DRUG|gemcitabine hydrochloride|
223666715|NCT00324597|DRUG|motesanib diphosphate|
223666716|NCT00324597|OTHER|pharmacological study|
223666717|NCT03939741|BIOLOGICAL|SVF Containg Autologous Non Expanded ADSC|5 ml of SVF containing Autologous Non Expanded ADSC will be injected intravenously and outcome will be observed over the period of 1(one) year.
223770836|NCT01066559|PROCEDURE|High flux polymethylmetacrylate membrane|Patients will be hemodialysed with high flux polymethylmetacrylate membranes
223770837|NCT01066559|PROCEDURE|Polysulfone membrane|Patients be hemodialysed with polysulfone membranes
223770838|NCT01066559|BIOLOGICAL|Hepatitis B serological control|It will be assessed at week 16, week 20 and week 40
223770839|NCT01066559|BIOLOGICAL|Seric sCD40 level|Ir will be measured at inclusion and week 12 by ELISA test according to the manufacturer instructions.
224248734|NCT00520130|DRUG|FLAG|Fludarabine:25 mg/m(2) per day IV over 30 minutes, Daily on days 1-5 Cytarabine: 2,000 mg/m(2) IV over 4 hours,on Days 1, 2, 3, 4, 5 Filgrastim: 5 mcg/kg per day subcutaneous (SC) beginning 24 hours PRIOR to initiation of chemotherapy
224248735|NCT00520130|DRUG|EPOCH-F|Fludarabine:25 mg/m(2) per day IV infusion over 30 minutes, daily on days 1-4 Etoposide :50 mg/m(2) per day continuous IV infusion over 24 hours on days 1-4 Doxorubicin:10 mg/m(2)/day CIV, days 1-4 Vincristine:0.4 mg/m(2) per day continuous IV infusion over 24 hours daily on days 1-4 Cyclophosphamide:750 mg/m(2) IV infusion over 30 minutes on day 5
224248736|NCT00520130|BIOLOGICAL|Alemtuzumab|Alemtuzumab:20 mg/day IV over 8 h on days 8 to 4 pre-transplant.
224248737|NCT01762605|OTHER|Supportive Care|
224248738|NCT01762605|PROCEDURE|Cast|
224248739|NCT05058638|DRUG|Aquamin|Participants will take a 90-day supply of Aquamin®, 4 capsules per day; 2 to be taken in the morning and 2 in the evening (containing approximately 800 mg calcium/day).
224248740|NCT00820326|DRUG|Dolasetron|Patients will receive dolasetron at a dose of 12.5 mg / day for 4 days at J0, M1, M2 and M3
224248741|NCT00820326|DRUG|Placebo|Patients will receive placebo everyday for 4 days at J0, M1, M2 and M3
224248742|NCT05077124|DEVICE|CytoSorb|Sorbent hemoperfusion system
224248743|NCT04915755|DRUG|Niraparib|Niraparib will be administered.
224248744|NCT04915755|DRUG|Placebo|Matching placebo will be administered
224248745|NCT06501040|OTHER|Web-based Educational Intervention|View web-based educational video
224248746|NCT06501040|OTHER|Questionnaire Administration|Pre video baseline survey and a post video educational survey
224248747|NCT04189614|DRUG|Cofetuzumab Pelidotin|Intravenous (IV) infusion
224248748|NCT05654103|DEVICE|endoAVF|The device will be used according to manufactures instructions and medical facilities standard of care. EndoAVF has a high likelihood of requiring additional procedures that would not have been required if they had undergone surgAVF.
224248749|NCT05654103|PROCEDURE|surgAVF|The surgAAVF procedure will be done according to the medical facilities standard of care. SurgAVF can also require additional procedures to help with the fistula being useable.
224248750|NCT06092125|DEVICE|PET/MR|PET/MR device is used for pre-treatment evaluation and efficacy follow-up of four types of diseases
224248751|NCT05946083|DIETARY_SUPPLEMENT|Inulin Intervention|For 6 weeks, 23 binge drinkers will be given a daily dose (divided into three times a day) of 15g of a dietary fiber with benefits for intestinal bacteria (inulin).
223666718|NCT01305798|OTHER|Scheduling and Active Choice for Biometric Participation|The control group will be informed via e-mail of the window of dates during which they can take part in the on-site screening and will be given instructions for scheduling an appointment. The active choice and default option arm will be informed via e-mail of a preselected time and date for their screening, which we will have generated randomly. This group will be asked to accept the default time, schedule a different time, defer the scheduling decision, or decline to receive a screening by clicking the appropriate option in the email. The active choice only arm will be given the same information as the control group, but they will also be asked to make an appointment immediately, defer the scheduling decision, or decline to receive a screening.
224248752|NCT05946083|DIETARY_SUPPLEMENT|Maltodextrin Intervention|For 6 weeks, 23 binge drinkers will be given a daily dose (divided into three times a day) of 15g of dietary fiber with no specific benefits for the intestinal microbiome (maltodextrin).
224248753|NCT06413290|OTHER|PIFP block group|Ultrasound-guided PIFP block will be performed approximately 30 minutes before surgery in patients undergoing cardiac surgery
224248754|NCT06413290|OTHER|Control group|No intervention
224248755|NCT02273622|DIETARY_SUPPLEMENT|hydroxytyrosol|Pilot study with 20 participants, each participant will alternately by the two arms of the study (hydroxytyrosol 5 mg and 20 mg) and control, during 6 weeks.
224248756|NCT02273622|DIETARY_SUPPLEMENT|placebo|
224248757|NCT00812266|DRUG|topotecan + cisplatin|topotecan IV 2 mg/sqm d1-3 + cisplatin IV 50 mg/sqm d3 q3W
224248758|NCT00812266|DRUG|Etoposide + carboplatin|Etoposide 120 mg/sqm IV d 1-3 + carboplatin AUC 5 d1 q3W
224248759|NCT06054581|BEHAVIORAL|health seeking behavior|health seeking behavior in the form of wound management and receving anti rabies immunization
224248760|NCT01819597|PROCEDURE|Encephaloduroarteriosynangiosis (EDAS)|The operation is a form of indirect revascularization or EC-IC bypass, performed under general endotracheal anesthesia, with intraoperative electroencephalographic monitoring. The surgery consists in the dissection and relocation of the superficial temporal artery (STA) and middle meningeal artery (MMA) branches, which are separated from their surrounding tissues under microscopic visualization and re-routed through a craniotomy to be placed intracranially in close proximity to the branches of the middle cerebral artery (MCA). The MCA branches are dissected in the arachnoid space and the STA and MMA are kept in position with microsutures to the arachnoid or MMA dural cuffs, maintaining close contact between the EC and MCA branches.
224248761|NCT02945891|DEVICE|HPV testing of Evalyn®Brush, FloqSwab and Colli-Pee specimens|Each woman use the self-sampling devices in an advised order the day before they go to the hospital. There will be change of sampling order with every patient so that 50% of women will use Evalyn®Brush (Rovers Medical Devices, Oss, The Netherlands) first and 50% a FloqSwab (Coban Flock Technologies, Italy) first. In addition women are asked to provide a first void urine sample using a Colli-PeeTM (Novosanis, Belgium) on the same morning as the hospital visit. At the hospital clinician will take an additional specimen for which the performance of different self-sampling devices will be compared to.
224248762|NCT02495857|DEVICE|Hyaluronate Injectable Viscosupplement|Test product of a 1% sodium hyaluronate for injection
223770840|NCT05696015|BEHAVIORAL|Standard education|Without telehealth education, this group has only postdischarge education.
224248763|NCT02495857|DEVICE|Euflexxa IA injection|Brand product of a 1% sodium hyaluronate for injection
224248764|NCT02495857|DEVICE|Placebo|0.9% sodium chloride, sterile
224248765|NCT02991404|PROCEDURE|Multimodal Peripheral Nerve Block Injection|After successful placement of the adductor canal catheter placed in standard fashion , the patient will receive a one-time 20 ml bolus of 0.25% bupivacaine, 1.67 mcg/ml of clonidine, and 1:400,000 epinephrine followed by a continuous infusion of 0.125% bupivacaine set at 10ml/hour.
224248766|NCT02991404|PROCEDURE|Single Shot Adductor Canal Block|A total of 20 ml of solution containing a combination of 0.25% bupivacaine, 1.67 mcg/ml of clonidine, 150 micrograms of buprenorphine, 2 mg of dexamethasone, and 1:400,000 epinephrine will be administered underneath the Sartorius muscle. A sham catheter will then be placed subcutaneously into the Sartorius muscle, secured in typical fashion, and connected to a pump containing saline to provide similar shape and weight with an opaque bag covering the pump. The pump will be run at the lowest possible ml/hour rate, which is currently 0.1 ml/hour with the current pump used in our hospital.
223666719|NCT03219970|DRUG|Osimertinib|80mg oral daily
223770841|NCT05696015|BEHAVIORAL|Ampiled Education|With telehealth education, in addition of discharge education.
223770842|NCT02012946|DRUG|Levosimendan|patient receiving levosimendan
223770843|NCT02012946|DRUG|Dobutamine|patient receiving dobutamine
224248767|NCT02991404|DRUG|Initial Bolus|20 ml bolus of 0.25% bupivacaine, 1.67 mcg/ml of clonidine, and 1:400,000 epinephrine
224248768|NCT02991404|DRUG|Continuous infusion|Continuous infusion of 0.125% bupivacaine
224248769|NCT05599438|OTHER|No intervention|No intervention
224248770|NCT04816838|DRUG|Osimertinib|"\* Osimertinib 80mg once a day(QD) oral(PO)~Neoadjuvant Period -If there is no disease progression or unacceptable toxicity, treatment is performed for 2cycles at 1 cycle (28 days) interval~Adjuvant Period~\- If there is no disease progression of unacceptable toxicity, treatment fis performed for 3years at intervals of 1cycle(28days)"
224248771|NCT00396279|BIOLOGICAL|Denosumab|Administered by subcutaneous injection
224248772|NCT00396279|DIETARY_SUPPLEMENT|Calcium/Vitamin D|
224248773|NCT04825808|OTHER|usual care|according to recommendations
224248774|NCT02883452|BIOLOGICAL|CT-P13|CT-P13 (5 mg/kg) by IV infusion administered as a 2-hour IV infusion per dose every 8 weeks (Part 1)
223666720|NCT00457106|DRUG|Paroxetine|
223666721|NCT00457106|DRUG|Risperidone|
223666722|NCT03339154|OTHER|Dietary Intakes|Four levels of methionine intakes will be provided by the reference protein drinks, 3 levels of methionine from chickpeas and 3 levels from chickpeas with rice.
223770844|NCT01458171|BIOLOGICAL|Immune globulin subcutaneous (Human)|IgPro20 is a 20% (weight per volume \[w/v\]) liquid formulation of human immunoglobulin for subcutaneous (SC) use. Subjects will receive weekly infusions of IgPro20 for a total of 24 weeks at a dose based on the subject's IgPro20 dose in the pivotal study ZLB06\_002CR (NCT01199705).
223770845|NCT02432365|DRUG|paclitaxel|7-day cycle schedule of paclitaxel (60 mg/m2)
223770846|NCT02432365|DRUG|cisplatin|7-day cycle schedule of cisplatin (40 mg/m2)
224248775|NCT02883452|BIOLOGICAL|CT-P13|CT-P13 (120 mg) by single SC injection every 2 weeks (Part 1)
224248776|NCT02883452|BIOLOGICAL|CT-P13|CT-P13 (180 mg) by double SC 90 mg injections every 2 weeks (Part 1)
224248777|NCT02883452|BIOLOGICAL|CT-P13|CT-P13 (240 mg) by double SC 120 mg injections every 2 weeks (Part 1)
224248778|NCT02883452|BIOLOGICAL|CT-P13|CT-P13 (120 mg) by single SC injection every 2 weeks in patients with body weight less than 80 kg, and CT-P13 (240 mg) by double SC 120 mg injections in patients with body weight at or above 80 kg based on body weight at Week 6 (Part 2)
224248779|NCT02883452|BIOLOGICAL|CT-P13|CT-P13 (5 mg/kg) by IV infusion administered as a 2-hour IV infusion per dose every 8 weeks up to Week 22. From Week 30, CT-P13 (120 mg) by single SC injection every 2 weeks in patients with body weight less than 80 kg, and CT-P13 (240 mg) by double SC 120 mg injections in patients with body weight at or above 80 kg based on body weight at Week 30 (Part 2)
224248780|NCT03350347|DRUG|Molidustat (BAY85-3934)|Starting dose of 25 mg or 50 mg molidustat once daily (OD) will be titrated based on the subject's Hb response
224248781|NCT03350347|DRUG|Darbepoetin alfa|Starting dose and frequency of darbepoetin alfa are based on previous ESA. The dose will be titrated based on the subject's Hb response
224248782|NCT03439982|BIOLOGICAL|FMT|FMT processed from routinely screened donors
224248783|NCT03026348|BIOLOGICAL|RSV F Vaccine with Aluminum Phosphate Adjuvant|
224248784|NCT03026348|BIOLOGICAL|RSV F Vaccine|
224248785|NCT03026348|BIOLOGICAL|Matrix-M1 Adjuvant|
224248786|NCT03026348|OTHER|Phosphate Buffer|
223666723|NCT00630383|BIOLOGICAL|Live Hookworm Larvae|25 live hookworm will be applied to the arm and will infect transdermally. They will be eradicated after 48 weeks.
223666724|NCT00630383|OTHER|Histamine|0.01% histamine solution is pipetted onto a plaster dressing.
223666725|NCT05738590|PROCEDURE|muscle biopsy|true cut needle biopsy
223666726|NCT05094310|DEVICE|Acupuncture|Patients with breast cancer who experienced fatigue were measured by the Brief Fatigue Inventory(BFI) scale and other Fatigue related questionnaire. Breast cancer patients diagnosed with cancer related fatigue are included in our clinical study，and those patients will receive acupuncture treatment. The position of acupuncture refers to the principle of acupuncture treatment of traditional Chinese medicine. According to ICD-10-CD code R53.0, the diagnosis of CRF is determined by the experience of diminished energy or other physical and psychological symptoms every day or almost every day for two consecutive weeks in the past month. We collected patients' blood to detect fatigue related SNP.
223666727|NCT03048383|DRUG|OnabotulinumtoxinA Injectable Product|Administered to treat facial synkinesis
223666728|NCT03048383|DRUG|AbobotulinumtoxinA Injectable Product|Administered to treat facial synkinesis
223770847|NCT02432365|PROCEDURE|Radical hysterectomy and bilateral pelvic lymphadenectomy|2 weeks after last course of neoadjuvant chemotherapy
224248787|NCT03135743|OTHER|Show an increase in incidence of cancers in patients with synchronous lymphoma|Show an increase in incidence of cancers in patients with synchronous lymphoma
224248788|NCT01194388|DEVICE|MicroFx™ PGLA COILS|. This observational evaluation will evaluate early experience using the Axium™ MicroFx™ Detachable Coils as compared to published literature of coils with electrolytic, thermal or hydraulic detachment process or the Axium™ bare Detachable Coils arm obtained from previous evaluation conducted following the same protocol.
224248789|NCT01050088|DIETARY_SUPPLEMENT|sucrose solution|5cc 5% sucrose solution P/O
224248790|NCT01050088|DIETARY_SUPPLEMENT|Saline|5cc saline p/o
224248791|NCT05986448|BEHAVIORAL|Tai-chi exercise|Traditional Chinese Tai Chi Movement
224248792|NCT03598374|DIETARY_SUPPLEMENT|Inositol + Folic acid|"Daily oral supplementation of for 6 months or until pregnancy conception:~Myo-Inositol: 1100 mg D-chiro-inositol: 27.6 mg Folic acid: 400 mcg"
224248793|NCT03598374|DIETARY_SUPPLEMENT|Folic acid|"Daily oral supplementation of for 6 months:~Folic acid: 400 mcg"
224248794|NCT03598374|BEHAVIORAL|Regular intercourses|Couples are required to have regular intercourses with the aim to achieve a spontaneous conception.
224248795|NCT00830206|OTHER|Azithromycin|Oral Suspension
223666729|NCT03048383|DRUG|Incobotulinumtoxin A Injectable Product|Administered to treat facial synkinesis
223666730|NCT05364359|DIETARY_SUPPLEMENT|Taste-test|Patients will receive a dietary counseling based on a simple taste-test
223666731|NCT05364359|OTHER|Standard care|Patients will receive a dietary counseling based on a standard dietary counseling for the patient group
223770848|NCT01391117|DRUG|placebo.|panel 1: 2 participants receive placebo at a q24h regimen.
223770849|NCT01391117|DRUG|placebo.|panel 3: 2 participants receive placebo. Actual dose and dose regimen (q12h or q24h) to be selected based on the results of the panels 1 and 2.
223770850|NCT01391117|DRUG|TMC649128.|panel 2, arm 1: 8 participants receive a q12h regimen of TMC649128 at a selected dose based on results of panel 1.
224248796|NCT00830206|DRUG|Zithromax®|Oral Suspension
224248797|NCT05983562|DIETARY_SUPPLEMENT|Dietary Supplement: D-β-hydroxybutyric acid with R-1,3-butanediol|Pre-intervention (baseline) and post-intervention measurements will be obtained before and after the 90-day period respectively.
224248798|NCT05983562|OTHER|Inert placebo|Pre-intervention (baseline) and post-intervention measurements will be obtained before and after the 90-day period respectively
224321850|NCT04151043|DEVICE|Deep brain stimulation|Regulation of deep brain stimulation intensity
224321851|NCT05002933|DRUG|Insulin glargine 300 U/ml|Solution for injection Subcutaneous injection
224248799|NCT01253590|BEHAVIORAL|questionnaire about the use of ECG device|Patients will be fitted with a continuous ECG monitor and blood pressure device. Data on every heart beat, including episodes of atrial fibrillation, for 4-6 weeks of continuous monitoring will be collected and transmitted wirelessly. Based on this information and blood pressure readings performed by patients in their home setting, clinicians can adjust oral coagulant dosage. Participants will attend 2 follow-up outpatient visits at the MSKCC outpatient cardiology practice upon the cardiologist's recommendation. Upon completion of the study, 4-6 weeks, a questionnaire will be sent via mail, including a pre-paid envelope, to participants to assess feasibility, acceptance, and overall experience with remote cardiac monitoring.
224248800|NCT01942746|DIETARY_SUPPLEMENT|Blueberry Juice S2|Blueberry Juice S2 was commercially prepared single strength blueberry juice composed of a 50:50 blend of Rubel (Vaccinium corymbosum L.) and Tifblue (Vaccinium ashei Reade) cultivars. Colorimetric analysis showed that S2 juice contained 6.04 (SD=0.20) mg anthocyanins (C3G) eq/g dry mass.
224248801|NCT01942746|DIETARY_SUPPLEMENT|Blueberry Capsules S2|Commercially prepared single strength blueberry juice composed of a 50:50 blend of Rubel (Vaccinium corymbosum L.) and Tifblue (Vaccinium ashei Reade) cultivars was freeze dried then powdered and encapsulated in gelatin capsules. Colorimetric analysis indicated an anthocyanin concentration in the powder of 2.37(SD=0.18) mg C3G eq per capsule.
223666732|NCT03472547|DRUG|diacerein 1% ointment|All subjects were exposed to diacerein 1% ointment, vehicle ointment, and 0.9% saline (negative control) at 3 randomly assigned, adjacent skin sites on the infrascapular area of the back 3 times weekly for 3 weeks (9 applications) during the Induction Phase, and one time during the Challenge Phase (10 times in total).
223666733|NCT06435897|BIOLOGICAL|fetal MSCs combined with 4SCAR T cells|Infusion of 4SCAR T cells at 10\^6 cells/kg body weight and MSCs at 3x10\^6 cells via IV
223666734|NCT03400267|DRUG|Paracetamol|Patients are randomized to paracetamol 1000 mg iv or fentanyl 1-2 mcg/kg with a maximum of 4 mcg/kg iv.
223666735|NCT03400267|DRUG|Fentanyl|Patients are randomized to paracetamol 1000 mg iv or fentanyl 1-2 mcg/kg with a maximum of 4 mcg/kg iv.
223666736|NCT07146204|DEVICE|Robotic-assisted percutaneous coronary intervention|Patients with coronary artery disease will be treated usiing the R-Star robotic system for a robotic-assisted percutaneous coronary intervention
223666737|NCT06943287|BEHAVIORAL|Pharmacist Intervention|If the patient is randomized to the intervention group, they will complete a series of phone calls with the research pharmacist. These will occur at baseline (within 1 to 2 days of enrollment), 2-weeks, 4-weeks, 6-weeks, 8-weeks, 10-weeks, and 12-weeks. During these calls, the research pharmacist will ask the patient about any past quit attempts; when they had their last cigarette; if they have been prescribed any cessation medications; if they have picked up their medication; if they have started the medication; they will assess their stage of change for quitting; discuss pros, cons, and barriers of quitting; behavioral responses to triggers/urges; and make any necessary nicotine replacement therapy (NRT; i.e., nicotine patches, gums, lozenges, inhalers, and/or nasal sprays) changes. Each call is expected to take 20-30 minutes.
223770851|NCT01391117|DRUG|placebo.|panel 2, arm 2: 2 participants receive placebo at a q24h regimen.
224248802|NCT01942746|DIETARY_SUPPLEMENT|Placebo Capsule S2|Placebo Capsule S2 (containing no anthocyanins) were prepared by freeze drying red beets and grinding them to fine powder before encapsulating in gelatine capsules. Red beets do not contain anthocyanins.
223770852|NCT01391117|DRUG|placebo|panel 4, arm 1: 10 participants receive PegIFN a-2a/RBV in combination with placebo, administered q12h or q24h, for 14 days. Actual dose and dose regimen (12h or 24h) is to be selected based on panels 1, 2 and 3.
224248803|NCT01942746|DIETARY_SUPPLEMENT|Placebo Juice L1|Placebo juice was prepared from water, sugars, citric acid, sodium citrate, and artificial colors and flavours, then pasteurized. The placebo juice contains no anthocyanins.
224248804|NCT01942746|DIETARY_SUPPLEMENT|Blueberry Juice L1|Blueberry Juice L1 was commercially prepared single strength blueberry juice composed of a 50:50 blend of Rubel (Vaccinium corymbosum L.) and Tifblue (Vaccinium ashei Reade) cultivars. Colorimetric analysis showed that L1 juice contained 6.83 (SD=0.20) mg cyanidin-3-glucoside equivalents (C3GE)/g dry mass at the start of the study, declining to 5.52 (SD=0.09) mg C3GE/g dry mass after 3 months refrigerated storage.
224248805|NCT03518905|DEVICE|Radiofrequency ablation|Radiofrequency ablation is performed using the Barrx Channel endoscopic catheter (Medtronic, Dublin, Republic of Ireland) generating an energy density level of 12 Joule/cm2. The energy is applied using a simplified protocol of three ablations without removal of coagulated tissue. The device is used on a routinely basis all around the world and already approved. The ablation catheter is applied through the working channel of the endoscope.
224248806|NCT03518905|PROCEDURE|esophagoscopy|Patients receive an esophagoscopy without radiofrequency ablation under sedation
224248807|NCT02467205|OTHER|pedometer supported walking and education|"A Physical activity; pedometer will be given to each person in the intervention group at the first education session. Participants will be encouraged to use the pedometer for a 6 month period.~The strength exercises will be performed at home. Education will incorporate the behavioural change techniques (BCTs) known to be effective in increasing physical activity (Goal setting,Self-monitoring of behaviour,Feedback on outcomes of behaviour,Problem solving,Relapse Prevention (RP) and social support)."
224248808|NCT03821545|OTHER|Lidocaine|Lidocaine will be administered at a dose of 1.5 mg/kg prior to surgical incision followed by an infusion at a rate of 1.5-2 mg/kg/hr until the end of surgery.
223666738|NCT06945913|BEHAVIORAL|Exercise|HIIT Group
223770853|NCT01391117|DRUG|TMC649128|panel 4, arm 2: 10 participants receive PegIFN a-2a/RBV in combination with TMC649128, administered q12h or q24h, for 14 days. Actual dose and dose regimen (12h or 24h) is to be selected based on panels 1, 2 and 3.
223770854|NCT01391117|DRUG|TMC649128.|panel 2, arm 2: 8 participants receive a q24h regimen TMC649128 at a dose based on results of panel 1.
223770855|NCT01391117|DRUG|TMC649128|panel 3: 8 participants receive TMC649128. Actual dose and dose regimen (q12h or q24h) to be selected based on the results of the panels 1 and 2.
223770856|NCT01391117|DRUG|TMC649128.|panel 1: 8 participants receive a q24h regimen at 1000 mg of TMC649128.
223770857|NCT01391117|DRUG|placebo.|panel 2, arm 1: 2 participants receive placebo at a q12h regimen.
223770858|NCT04307238|DIAGNOSTIC_TEST|PLR|PLR measurements will be performed within the first 2 postoperative hours.
223770859|NCT04307238|DIAGNOSTIC_TEST|Alertness testing|Preoperative (baseline) and every 30 minutes postoperative computer based alertness testing will be performed.
223770860|NCT04307238|PROCEDURE|Propofol anesthesia|Maintenance of anesthesia will be performed using propofol.
223770861|NCT04307238|PROCEDURE|Sevoflurane anesthesia|Maintenance of anesthesia will be performed using sevoflurane.
223770862|NCT00575848|DIETARY_SUPPLEMENT|Glycine|Subjects will consume glycine twice daily, once with breakfast and once with dinner. The medication is in liquid form. They will be instructed to refrigerate the liquid until the time that they take it. Subjects start by taking 10g per day for the first 2 days. Starting on the 3rd day, subjects take 0.2g/kg (15g for a 75kg adult) per day, and increase dosage by 0.2g/kg every two days, until they reach 0.8g/kg per day, which they take for the remainder of the 6-week period.
223770863|NCT00575848|DIETARY_SUPPLEMENT|Placebo|Subjects will consume placebo twice daily, once with breakfast and once with dinner. The placebo is in liquid form. They will be instructed to refrigerate the liquid until the time that they take it. Subjects start by taking 10g per day for the first 2 days. Starting on the 3rd day, subjects take 0.2g/kg (15g for a 75kg adult) per day, and increase dosage by 0.2g/kg every two days, until they reach 0.8g/kg per day, which they take for the remainder of the 6-week period.
224248809|NCT03821545|OTHER|Ketamine|Ketamine will be administered at a dose of 0.5 mg/kg in a bolus prior to surgical incision followed by an infusion at a rate of 0.1-0.2 mg/kg/hr until the end of surgery.
224248810|NCT03821545|OTHER|Lidocaine and Ketamine|Lidocaine will be administered at a dose of 1.5 mg/kg prior to surgical incision followed by an infusion at a rate of 1.5-2 mg/kg/hr until the end of surgery. Ketamine will be administered at a dose of 0.5 mg/kg in a bolus prior to surgical incision followed by an infusion at a rate of 0.1-0.2 mg/kg/hr until the end of surgery.
224248811|NCT03821545|OTHER|Placebo (0.9% NaCl)|Bolus and continuous placebo infusion (0.9% NaCl) will be equally administered at the same dose as the aforementioned anesthetics until the end of the surgery.
224248812|NCT00654030|DRUG|1650-G Vaccine|.6ml injection administered intradermally in the thigh at week 0 and week 4
224248813|NCT04758130|OTHER|Zamplo Digital Health Platform|This application will be provided to patients and provide them with a method to track various data related to their metabolic disease.
224248814|NCT03408691|DIETARY_SUPPLEMENT|Fresh fermented dairy drink containing probiotic strain|Fresh fermented dairy drink containing probiotic strain consumed as follows: one bottle (100g) BID for 6 weeks.
224248815|NCT03408691|OTHER|Acidified dairy drink without ferment|Acidified dairy drink without ferment consumed as follows: one bottle (100g) BID for 6 weeks.
224248816|NCT02010320|OTHER|Computer dosing|Pharmacokinetic population model for individual dose estimations of tacrolimus based on concentrations measurements and inclusion of relevant covariates
224248817|NCT02010320|OTHER|Standard dose determination|Tacrolimus dose determination according to trough concentrations and standard TDM at the clinic
224248818|NCT03301948|OTHER|Overfeed|Participants consume energy intakes that are 50% higher than their estimated requirements instead of consuming energy intakes equal to their estimated requirements
224248819|NCT03301948|OTHER|Energy Balance|Participants consume energy intakes equal to their estimated requirements instead of consuming intakes that are 50% higher than their estimated requirements
224248820|NCT00688363|PROCEDURE|weekly blood glucose profile|once daily self-control of urinary-glucose
224248821|NCT00688363|PROCEDURE|three-monthly haemoglobin A1c|once daily self-control of urinary-glucose
223770864|NCT04897542|DRUG|Gallium-68 NODAGA-JR11|Each patient receive a single intravenous injection of Gallium-68 NODAGA-JR11 (40ug/150-200MBq) PET/CT, and undergo PET/CT scan at 40-60 min post-injection.
223770865|NCT00626262|DRUG|Esomeprazole|Oral and Intravenous
224248822|NCT00688363|PROCEDURE|no blood-glucose self-control|once daily self-control of urinary-glucose
224248823|NCT05886101|BEHAVIORAL|Health Education|Health education will be provided to the intervention group on health literacy, self care, productivity improvement
224248824|NCT01469650|DIETARY_SUPPLEMENT|cholecalciferal|400 IU/day
224248825|NCT01469650|DIETARY_SUPPLEMENT|cholecalciferol|800 IU/day D3
224248826|NCT01082926|BIOLOGICAL|therapeutic allogeneic lymphocytes|Given intratumorally
224248827|NCT01082926|BIOLOGICAL|aldesleukin|Given intratumorally
224248828|NCT01082926|OTHER|laboratory biomarker analysis|Optional correlative studies
224248829|NCT01082926|PROCEDURE|positron emission tomography|Optional correlative studies
224248830|NCT05488808|DEVICE|repetitive Transcranial Magnetic Stimulation|Deep rTMS is delivered with the Brainsway H7-coil (Brainsway, Jerusalem, Israel) applied via a helmet placed on the head targeting the primary motor cortex of the leg.
224248831|NCT03396120|DIAGNOSTIC_TEST|Pulmonary function test|forced vital capacity and diffusing capacity
224248832|NCT04605094|BIOLOGICAL|Benralizumab|Benralizumab by subcutaneous injection until Week 16, and then benralizumab by subcutaneous injection during the extension period.
224248833|NCT04605094|BIOLOGICAL|Placebo / Benralizumab|Placebo by subcutaneous injection until Week 16, then benralizumab by subcutaneous injection until Week 52.
224248834|NCT06200220|DRUG|Venetoclax|Observational study
224248835|NCT01900691|DEVICE|Evolution® Esophageal Stent - Fully Covered|Placement of the Evolution® Esophageal Stent for benign or malignant strictures, fistulas, perforations or leaks with the intention of removal
224248836|NCT02724462|BEHAVIORAL|Smartphone-delivered Intervention (SmartQuit)|The experimental arm includes an intervention using a novel smartphone smoking cessation app.
224248837|NCT02724462|BEHAVIORAL|: Smartphone-delivered Intervention (Standard of care app)|The control intervention uses a standard of care smartphone smoking cessation app.
224248838|NCT04113265|DEVICE|SUNEKOS ® Body|SUNEKOS ® Body is a medical device (class III). The study product was injected at level of the inner thighs, knees and arms by needle (29 G) using the interstitial fluid technique (IFT)
223770866|NCT01696032|DRUG|SGI-110|
224248839|NCT01699191|DIETARY_SUPPLEMENT|Probiotic|
224248840|NCT01699191|DIETARY_SUPPLEMENT|Placebo|
224248841|NCT00731744|PROCEDURE|Normal full-term deliveries|Normal full-term deliveries by standard procedures according to institutional guidelines
224248842|NCT06391606|DIETARY_SUPPLEMENT|Coenzyme Q10|2 pills/day of 150 mg CoQ10 phytosome (i.e. 300 mg CoQ10 phytosome per day)
224248843|NCT06391606|OTHER|Placebo|2 pills/day
224248844|NCT04391933|DIAGNOSTIC_TEST|MRI 3 tesla|MRI of colon cancer. Sensitivity, specificity, positivity predictive values and negative predictive values are calculated form the histopathological surgical specimen. This will be the endpoint for both CT and MRI.
224248845|NCT00242970|DEVICE|3-Dimensional Color Scanning|Color imaging of the face and neck.
224248846|NCT02059070|DRUG|Ropivacaine|Post-operative epidural 0.125% Ropivacaine Interscalene brachial plexus block, 20-28 hrs post surgery.
223666739|NCT06946394|DRUG|Pegmolesatide|Pegmolesatide Injection: Specification 1mL: 4.0mg (National Medical Products Administration Approval No. H20230020), administered once every 4 weeks
224248847|NCT02059070|DRUG|Bupivacaine|Post-operative epidural 0.125% Bupivacaine Interscalene brachial plexus block, 20-28 hrs post surgery.
224248848|NCT06378242|DRUG|Disitamab Vedotin for injection|Intravesical instiliations into the bladder
224248849|NCT04403997|PROCEDURE|Chromoendoscopy|Chromoendoscopy is an endoscopic technique used in the follow-up of inflammatory bowel disease of long evolution. Chromoendoscopy, through the application of specific dyes used directly on the intestinal mucosa, promotes the visualization of mucosal lesions.
224248850|NCT01980693|DEVICE|SonicBone ultrasound|The device measure BA using ultrasound technology by measurement of speed of sound in three different sites : wrist bones, Phalanx III, Metacarpal bones.The device sends a short US pulse and measures the distance between a transmitter probe and a receiver probe, located at the bone measured area.The US probe converts electrical pulse to US pulse and US wave via tested bone arrives from transmitter to Receiver. Simultaneously with US pulse, controller start timer to calculate time between US pulse and the moment that US wave arrives to receiver. The accepted US signal of selected probe via amplifiers arrives to comparators that read timer value. The microcontroller calculates SOS using distance between probes and US time of flight.
224248851|NCT05225597|PROCEDURE|Intracameral administration of epinephrine and carbachol during cataract surgery|All surgeries were performed by the same surgeon using a similar technique, under topical anesthesia (0.05% proparacaine HCL), and with a 2.8 mm temporal clear corneal incision. After making the incision, 0.2 mL of preservative-free epinephrine (1:5000) was injected into the epinephrine group only. After complete hydrodissection, the nucleus was removed using the stop and chop technique. Phacoemulsification time (range: 30-60 s) was similar in all patients, while the phacoemulsification strength was set to 35%-40% for all operations. The cortex was aspirated. Before implanting a one-piece foldable hydrophobic acrylic intraocular lens (IOL) into the capsular bag, 1% sodium hyaluronate (ophthalmic viscosurgical device, Healon) was injected into the capsular bag. After removal of the viscoelastic material, only the carbachol group was given 0.5 ml of 0.01% carbachol solution intracamerally. Hydration with balanced salt solution was used to close the corneal incisions.
224248852|NCT01954394|DRUG|Alirocumab|Solution for injection, one subcutaneous injection in the abdomen, thigh, or outer area of upper arm with a pre-filled syringe.
224248853|NCT01954394|DRUG|Lipid-Modifying Therapy (LMT)|Statin (rosuvastatin, simvastatin or atorvastatin) at stable dose with or without other LMT as clinically indicated.
224248854|NCT06046846|DEVICE|Asensei app|The study will compare the delivery of a prehabilitation programme via a mHealth application against standard preoperative care for patients undergoing surgery for oesophago-gastric cancer
224248855|NCT04111263|DIETARY_SUPPLEMENT|FP|Fiber and polyphenol blend
224248856|NCT04111263|DIETARY_SUPPLEMENT|Placebo|Matched placebo
224248857|NCT04111263|OTHER|High altitude|Simulated high altitude in altitude chamber using hypobaric hypoxia
224248858|NCT04111263|OTHER|Sea level|Sea level environment in altitude chamber
224248859|NCT01975623|DEVICE|HARMONIC ACE®+ Shears (HS)|We plan to evaluate the efficacy of the HS for the sealing of PAs in an ex-vivo human model. Efficacy will be measured and compared using the bursting pressure point following vascular energy sealing. Energy sealing may be superior to stapling devices as it eliminates the need for excessive tissue dissection around the pulmonary vessels, which in turn decrease the incidence of vascular injuries during VATS anatomical lung resection. All vessels will be sealed ex-vivo using the HARMONIC ACE®+ Shears (Ethicon, Cincinnati, Ohio, USA).
224248860|NCT02071108|DEVICE|Shockwave Lithoplasty System|
224248861|NCT01026623|BIOLOGICAL|Cixutumumab|Given IV
224248862|NCT01026623|OTHER|Diagnostic Laboratory Biomarker Analysis|Correlative studies
223666740|NCT06946745|OTHER|tissue biopsy|By performing single-cell sequencing on tumor tissues at baseline and post-treatment (cycle 2) across all patients, we will conduct pseudotime trajectory analysis to study the differentiation dynamics of cellular populations.
224248863|NCT01026623|DRUG|Temsirolimus|Given IV
224248864|NCT03770598|BEHAVIORAL|Standard of Care Distressed in study Arm Distressed|Social worker evaluation and possible referral to Psychiatry/Psychology for evaluation and further treatment.
224248865|NCT03770598|BEHAVIORAL|Psycho-Education|Mindfulness based stress reduction class, yoga and education material
224248866|NCT03770598|BEHAVIORAL|Team Based Care|Psychiatrist, Oncologist, clinical social worker, study coordinator
224248867|NCT03770598|BEHAVIORAL|Standard of Care Non-Distressed|No psycho-education about wellness promotion or health. These patients will be monitored only.
223666741|NCT04679415|DRUG|hzVSF-v13|Dosage form: hzVSF-v13 40 mg/mL in a 5 mL vial Frequency: Dose at Day 1, 3, 7
223666742|NCT04679415|DRUG|Placebo (Normal saline solution)|Dosage form: 0.9% NaCl Solution Frequency: Dose at Day 1, 3, 7
223666743|NCT04835675|DEVICE|Multi-cancer early detection test|Blood collection and multi-cancer early detection testing
223666744|NCT02908542|GENETIC|genetic analysis with massively parallel sequencing|
223666745|NCT03225859|BEHAVIORAL|Self-Management Program|This therapist-assisted self-management program will increase Veterans' self-efficacy for managing their PTSD, enable the maintenance or building upon gains made in trauma-focused therapy, and encourage engagement in meaningful activities. Patients will have four contacts with their providers over the ten weeks following trauma-focused therapy completion. The intervention will help patients: 1)self-monitor symptoms, 2) continue to practice skills learned in trauma-focused therapy, 3) acquire and apply additional coping skills, 4) engage in meaningful activities, and 5) set goals
223666746|NCT04193618|PROCEDURE|Conservative surgery for placenta accretta|Uterine devasculrization and transverse compressing sutures before placental delivery
223666747|NCT02423967|BIOLOGICAL|Transplant uses frozen anonymous stool|The intervention is using frozen anonymous donor stool instead of fresh stool from family members for the fecal microbial transplant to treat recurrent CDI.
224248868|NCT00008515|DRUG|Fluocinolone|
224248869|NCT06560515|DRUG|Vaginal Dinoprostone|induction of labour in women with postdate pregnancy with vaginal dinoprostone vs. vaginal misoprostol
224248870|NCT03481998|DRUG|SHR6390|SHR6390 150 mg, orally once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment
224248871|NCT03481998|DRUG|Letrozole or anastrozole or Fulvestrant|Letrozole 2.5mg or anastrozole 1mg, orally once daily (continuously)， or Fulvestrant 500mg intramuscular injection on day 1 and day 15 for the first cycle and then on day 1 for every cycle until progressive disease
224248872|NCT03423680|DRUG|Abilify 2, 5, 10, 15mg (Tablet)|Randomized subjects will take 1 tablet of aripiprazole or placebo orally once daily from the baseline visit (Visit 2) to Visit 8 (Week 8 visit or discontinuation visit). The initial dose of aripiprazole, the investigational product, is 2 mg once daily (irrespective of meals), which the investigators can maintain, increase or decrease within a range of 2 - 15 mg at each scheduled study visit, depending on the subject's clinical response and tolerability.
224248873|NCT03423680|DRUG|Placebo of Abilify 2, 5, 10, 15mg (Tablet)|Randomized subjects will take 1 tablet of aripiprazole or placebo orally once daily from the baseline visit (Visit 2) to Visit 8 (Week 8 visit or discontinuation visit). The initial dose of aripiprazole, the investigational product, is 2 mg once daily (irrespective of meals), which the investigators can maintain, increase or decrease within a range of 2 - 15 mg at each scheduled study visit, depending on the subject's clinical response and tolerability.
224248874|NCT06020924|OTHER|No intervention|This study is a retrospective observational study without intervention.
224248875|NCT03548519|BEHAVIORAL|OCAT-only|online-contingent Attention Training without prior psychoeducation
224248876|NCT03548519|BEHAVIORAL|OCAT-sham|Placebo version of Online contingent Attention Training without prior psychoeducation
224248877|NCT03548519|BEHAVIORAL|OCAT-combo|Online contingent Attention Training with prior psychoeducation
224248878|NCT03169595|PROCEDURE|Surgery|Patients affected by epithelioid hemangioma treated with surgery
224248879|NCT04847323|DEVICE|V-bend Bonded Retainer|Traditional stainless steel retainer commonly bonded in the anterior teeth of the mandibular arch to maintain their alignment after orthodontic treatment.
224248880|NCT04847323|DEVICE|Vacuum-formed Retainer|Removable retainers made of plastic and derivatives. Currently gaining popularity due to the increased use of esthetic aligners. These clear retainers have the objective to maintain stable the results obtained after orthodontic treatment. They cover all the surfaces of the teeth up to the first or second molars.
224248881|NCT02035306|OTHER|non invasive co-oximetry haemaglobin measurement|
224248882|NCT05105945|PROCEDURE|Single-Port Inflatable Mediastinoscopy Combined With Laparoscopic-Assisted Small Incision Surgery|"Single-Port Inflatable Mediastinoscopy Combined With Laparoscopic-Assisted Small Incision Surgery dissects, dissociates and removes the esophagus in the mediastinum through an inflatable endoscopy. Detailed surgical procedures and related instructions have been published in Single-Port Inflatable Mediastinoscopy Combined With Laparoscopic-Assisted Small Incision Surgery for Radical Esophagectomy Is an Effective and Safe Treatment for Esophageal Cancer J Gastrointest Surg. 2019 Aug;23(8):1533-1540. doi: 10.1007/s11605-018-04069-w. Epub 2019 Jan 11."
224248883|NCT05105945|PROCEDURE|Thoracoscopy Combined With Laparoscopic Surgery|Patients will receive a standardized thoracoscopy and laparoscopy combined radical esophageal cancer surgery
224248884|NCT01959750|BEHAVIORAL|problem-based sessions|weekly sessions for small groups of caregivers, led by two psychologists acting as moderators and using a systemic approach, as suggested in other peer-support groups using a problem-based method
224248885|NCT00054301|PROCEDURE|adjuvant therapy|
224248886|NCT00054301|PROCEDURE|conventional surgery|Patients undergo excisional biopsy or surgery.
224248887|NCT00054301|RADIATION|intraoperative radiation therapy|Patients undergo excisional biopsy or surgery followed by an intraoperative dose of radiation to the tumor cavity.
224248888|NCT05796869|BEHAVIORAL|Assigned Interventions|The laughter therapy session will be administered to the application group face to face for 25-30 minutes once a week for 2 months by a researcher with a laughter therapy certificate. In the laughter therapy session, introducing the practitioner and introducing the therapy, breathing exercises for a healthy life, maintaining the rhythm with music, turning laughter that starts like a child's play into reality and meditation practices will be carried out.
224248889|NCT00184522|DRUG|Aflurax|
224248890|NCT00184522|DRUG|esomeprazole|
223666748|NCT02423967|BIOLOGICAL|Transplant uses fresh familial stool|The intervention is using fresh familial donor stool for the fecal microbial transplant to treat recurrent CDI
223666749|NCT06315790|DRUG|Botulinum toxin A|Subcutaneously injections are given unilaterally in the face at predefined injection sites.
223666750|NCT06315790|OTHER|Isotonic saline|Subcutaneously injections are given unilaterally in the face at predefined injection sites.
223666751|NCT00038389|DRUG|Vioxx|Starting dose for patients age 3-14 years 10.0 mg/1.73 m2 and for patients above 14 years of age 12.5 mg for 5 days per week for 6 weeks during radiation treatment, and 7 days per week for 6 months after radiation treatment.
223666752|NCT02043899|DRUG|[124I]meta-Iodobenzylguanidine|Single intravenous administration of \[124I\]mIBG Solution for Injection on Day 1 with a maximum radioactive dose of 1.42 MBq/kg (±10%) and a maximum injected dose of 50 MBq \[124I\]mIBG equating to a maximum chemical dose of 10 micrograms of stable mIBG. The activity to paediatric patients will be scaled by weight based upon the EANM paediatric dose card (Lassmann et al., 2007). This will result in an activity between 10 MBq and 50 MBq depending on the patient's weight.
224248891|NCT02584439|DRUG|ivabradine|It is a cross over study with two arms : either ivabradine-placebo or placebo-ivabradine. The capsules containing the placebo or ivabradine are completely identical.
224248892|NCT02584439|DRUG|lactose capsule (placebo)|It is a cross over study with two arms : either ivabradine-placebo or placebo-ivabradine. The capsules containing the placebo or ivabradine are completely identical.
224248893|NCT00770822|DEVICE|HIFU (Sonablate® 500)|High Intensity Focused Ultrasound
224248894|NCT00770822|DEVICE|Brachytherapy|Standard of care
224248895|NCT06392438|DRUG|CycloSPORINE Ophthalmic|Unidose of Cequa provided without charge to the participant. 1 drop in each eye morning and evening.
224248896|NCT06392438|PROCEDURE|Intense Pulsed Light|Appropriate eye patches and IPL gel will be applied. 15 triggers per passage will be applied from the right temple to the left temple (7 shots from the right temple to the right nose wing, 1 on the nose bridge and 7 shots from the left nose wing to the left temple). 2 passage/session will be applied.
223666753|NCT02043340|DRUG|indocyanine green|ICG group - scaling and root planing with application of 810 nm diode laser and ICG at a concentration of 5 mg/mL. Primary parameters included estimation of decrease in percentage of viable bacteria at baseline, immediate post treatment and end of 1 week and Lactate dehydrogenase (LDH) levels at baseline and end of 1 week. Secondary parameters included site-specific measures of plaque, gingivitis, pocket depth (PD) and clinical attachment loss (CAL) at specific time intervals.
223666754|NCT02043340|DEVICE|LASER|LASER group - scaling and root planing with application of 810 nm diode laser Primary parameters included estimation of decrease in percentage of viable bacteria at baseline, immediate post treatment and end of 1 week and Lactate dehydrogenase (LDH) levels at baseline and end of 1 week. Secondary parameters included site-specific measures of plaque, gingivitis, pocket depth (PD) and clinical attachment loss (CAL) at specific time intervals.
223666755|NCT02043340|PROCEDURE|Scaling and Root Planing|SRP group - scaling and root planning. Primary parameters included estimation of decrease in percentage of viable bacteria at baseline, immediate post treatment and end of 1 week and Lactate dehydrogenase (LDH) levels at baseline and end of 1 week. Secondary parameters included site-specific measures of plaque, gingivitis, pocket depth (PD) and clinical attachment loss (CAL) at specific time intervals.
223666756|NCT06022289|DRUG|Pemigatinib|Pemigatinib will be treated according to the treatment plan of 2 weeks of administration/1 week of discontinuation, with oral administration of 1 capsule, 13.5mg, QD, and a cycle of 21 days. Meanwhile, the molecular testing results of the patient are analyzed and interpreted by the MTB team, and appropriate combination therapy(Pemigatinib+) strategies are proposed based on the patient's previous treatment history, physical condition, drug accessibility, and economic status.
223666757|NCT02856191|OTHER|Holter|
223666758|NCT06141356|DRUG|[18F]Florbetazine ([18F]92)|Participants will receive a single intravenous bolus injection of 10 mCi ± 20% of the investigational radiotracer \[18F\]Florbetazine and will undergo a PET/CT scan.
223666759|NCT06141356|DRUG|[11C]PIB|Participants will receive a single intravenous bolus injection of 6.0-20.0mCi of the investigational radiotracer \[11C\]PIB and will undergo a PET/CT scan.
223666760|NCT01325337|DRUG|bimatoprost Formulation A|Approximately one mL dose applied evenly onto pre-specified area on scalp, once daily for 6 months.
223666761|NCT01325337|DRUG|bimatoprost Formulation B|Approximately one mL dose applied evenly onto pre-specified area on scalp, once daily for 6 months.
224248897|NCT06392438|PROCEDURE|Sham Intense Pulse Light|Appropriate eye patches and IPL gel will be applied. 15 triggers per passage will be applied with the plastic blocker mounted on the IPL prism from the right temple to the left temple (7 shots from the right temple to the right nose wing, 1 on the nose bridge and 7 shots from the left nose wing to the left temple). 2 passage/session will be applied.
224248898|NCT01644058|PROCEDURE|Immediate loading|
224248899|NCT03429634|PROCEDURE|Balloon-Stent Kissing technique|All patients underwent coronary angiogram that confirmed true bifurcation lesions, and received PCI treatment,Balloon-Stent Kissing Technique (BSKT)for the interventional treatment of coronary bifurcation lesion
224248900|NCT03429634|PROCEDURE|Jailed Wire technique|All patients underwent coronary angiogram that confirmed true bifurcation lesions, and received PCI treatment, Jailed Wire technique(JWT) for the interventional treatment of coronary bifurcation lesion
224248901|NCT05648721|OTHER|Datos mobile health application|The mobile Health application will send women reminders to perform glucose tests and test results will be sent to the clinic personnel for evaluation. The clinic personnel will receive an alert if a woman does not send glucose charts or when there is an abnormality in the test results. In addition, women will be able to communicate with the clinic's personnel via chat, messages, phone calls, and video.
224248902|NCT05648721|OTHER|Regular follow-up|Regular follow-up according to the local clinic protocol
224248903|NCT06225609|PROCEDURE|Ghost ileostomy|Laparoscopic or robotic surgery with ghost ileostomy
223666762|NCT01325337|DRUG|bimatoprost Formulation C|Approximately one mL dose applied evenly onto pre-specified area on scalp, once daily for 6 months.
223666763|NCT01325337|DRUG|bimatoprost vehicle solution|Approximately one mL dose applied evenly onto pre-specified area on scalp, once daily for 6 months.
223666764|NCT01325337|DRUG|minoxidil 5% solution|Approximately one mL dose applied evenly onto pre-specified area on scalp, twice daily for 6 months.
223666765|NCT02230969|DRUG|peginterferon beta-1a|Administered as specified in the treatment arm
223666766|NCT03483922|DIAGNOSTIC_TEST|ctDNA methylation in and it's Correlation wth Development and prediction of HCC|Blood sample from patients with HCC, healthy individuals and individuals with hepatitis B will be collected, and DNA will extracted from PBMC and circulated tumor DNA will be subjected to bisulfite conversion. DNA from PBMC DNA will be analyzed with primers developed for the AHNAK-STAP1 genes. Plasma samples will be subjected to EZ direct DNA extraction and bisulfite conversion kit and will be amplified with primers developed to amplify the target regions. DNA will be used for the subsequent PCR amplification with specific primer to generate PCR amplicon for sequencing using a double PCR procedure. The product of PCR reaction will be subjected to indexed MiSeq Next-Generation sequencing that will allow us quantify DNA methylation level.
224248904|NCT06225609|PROCEDURE|No ileostomy|Laparoscopic or robotic surgery with no ileostomy
223666767|NCT00307320|BEHAVIORAL|Relaxation Training|Relaxation techniques training
223666768|NCT04451213|DIAGNOSTIC_TEST|MRI head|MRI head
223666769|NCT02575547|DRUG|cisplatin and docetaxel|"NC：cisplatin 75 mg/m2 intravenous infusion in day1，docetaxel 75 mg/m2 intravenous infusion in day1，both drugs are given every 3 weeks, two courses.~CCRT: intensity modulation radiation therapy(IMRT) and cisplatin (100mg/m2 on day 1) every three weeks for three\\three cycles during radiation therapy(RT).~Dietary supplement: enteral nutrition and parenteral nutrition"
224248905|NCT06280183|OTHER|Functional Inspiratory Muscle Training|Inspiratory muscle training is a technique that combines aerobic training with inspiratory muscle training. will be applied simultaneously with aerobic exercise. Participants will work with bicycle ergometry and then continue with IMT in the same session for the first three weeks. The intensity of IMT exercise will be set at 40-60% of MIP.
224321852|NCT06139809|PROCEDURE|Intubation|Intubation will take place according to our local standard protocol for nasal intubation using NIPPV delivered through a nasopharyngeal tube. The intubation will be video-recorded to provide a clear view of the procedure and the pulse oximeter displaying the SpO2 and HR.
223770867|NCT01696032|DRUG|Treatment of Choice (topotecan, pegylated liposomal doxorubicin, paclitaxel, or gemcitabine)|Investigator chose to treat with either topotecan, pegylated liposomal doxorubicin, paclitaxel, or gemcitabine
223770868|NCT01696032|DRUG|Carboplatin|
223770869|NCT02188576|DRUG|high dose TXA|
223770870|NCT02188576|DRUG|Low dose TXA|
223770871|NCT05772065|BEHAVIORAL|CDC/NTCA guidelines only|The control group will have a link to US guidelines only.
223770872|NCT05772065|BEHAVIORAL|LTBI ASSIST and CDC/NTCA guidelines only|The intervention group will have a link to both US guidelines, and the LTBI-ASSIST tool.
223770873|NCT01430065|DRUG|ASP015K|oral
223770874|NCT01430065|DRUG|Tacrolimus|oral
223770875|NCT00578565|DRUG|Rituximab|Rituximab 1000 mg. I.V.on each days 1 and 15 with repeat dosing at 6 months.
223770876|NCT06550570|BEHAVIORAL|QEVA questionnaire|QEVA questionnaire administered at 2 days pospartum (in hospital) and 4 weeks postpartum (phone call). (specific for the study)
223770877|NCT06147505|BIOLOGICAL|XS005 Injection|Treatment on this study includes XS005 infusions over an 16 week period. Phase 1： dose escalation (3+3); Phase 2 : dose of recommended phase 2 dose(RP2D).
223666770|NCT00920010|OTHER|biologic sample preservation procedure|
223770878|NCT05645627|DRUG|IBI112|IBI112 by subcutaneous injection through week 16 ,and then will receive Dose 3 IBI112 by subcutaneous injection through week 48
224248906|NCT06280183|OTHER|Aerobic+Resistive Exercise Traning|Aerobic exercise is planned at 60-85% of the Maximum Heart Rate on a cycle ergometer for 30-40 minutes. Resistive exercise will cover all major muscle groups. The upper body (pectoralis, latissimus dorsi, rotator cuff muscles, deltoid, biceps, triceps), abdominal muscles, and lower extremities (quadriceps, hamstring, gastrosoleus) will be exercised to strengthen. For upper body, abdominal, and lower extremity muscles, 1-3 sets of 10-15 repetitions will be planned as 40-70% of 1 maximum repetition (1RM).
224248907|NCT01419093|OTHER|5 A communication intervention|This study will examine the effect of primary care clinicians' communication intervention linked to a community-based exercise program. We will use the 5As in discussion of physical activity in 371 office visits in an ethnically diverse, primarily low income patient population. Secondary and exploratory aims are to provide pilot information on \[feasibility and sustainability of the intervention from the patients' and clinicians' perspective and derive effect sizes on the intervention's effect on objective changes in physical activity in a subset of participants.
223666771|NCT02184455|BIOLOGICAL|DermGEN|DermGEN is a product created by a patented process that decellularizes and sterilizes donated human tissue.
223770879|NCT05645627|DRUG|placebo /IBI112|placebo by subcutaneous injection cross over IBI112 by subcutaneous injection at week 16 through week 48
223770880|NCT05645627|DRUG|IBI112|IBI112 by subcutaneous injection through week 16 ,and then will receive Dose 3 IBI112 by subcutaneous injection through week 48
223770881|NCT01192152|DRUG|saxagliptin|Tablets, Oral, 5 mg, once daily, Single dose
223770882|NCT01192152|DRUG|Glucophage XR|Tablets, Oral, 500 mg, once daily, Single dose
224248908|NCT05417230|DRUG|RC48-ADC|2.5mg/kg, IV, d1, every 2 weeks;
224248909|NCT05417230|DRUG|Envafolimab|200mg, SC, d1, every 2 weeks;
224248910|NCT02061917|OTHER|Tobacco-Heating Cigarette|Smokers switched to a tobacco-heating cigarette for 24 weeks
223666772|NCT00813969|BIOLOGICAL|Autologous mesenchymal stem cell transplantation|A single IV infusion of up to 2 million cells per kg based on the MSC numbers achieved after culture expansion
223666773|NCT01915927|DRUG|MSC-AFP|
223666774|NCT05779384|OTHER|It was an observational study|data collected concerning the incidence of exacerbations
223666775|NCT01347580|DRUG|Ticagrelor|Oral Ticagrelor loading dose (180 mg) followed by matching placebo
223666776|NCT01347580|DRUG|Placebo|Placebo followed by oral Ticagrelor loading dose (180 mg)
223666777|NCT03188172|DRUG|Cyclophosphamide|Chemotherapy
223666778|NCT03188172|DRUG|Bortezomib|Chemotherapy
223666779|NCT03188172|DRUG|Lenalidomide|Chemotherapy
223770883|NCT01192152|DRUG|saxagliptin + metformin XR (FDC tablet)|Tablet, Oral, (saxagliptin 5 mg)(metformin XR 1000 mg), once daily, 4 days
223770884|NCT02657863|PROCEDURE|Urine collection and blood draw|
223770885|NCT02709395|DEVICE|Navina Smart|Transanal irrigation at the same frequency as subject used before enrollment.
223770886|NCT01108575|OTHER|IMST|inspiratory muscle strength training
223770887|NCT01108575|OTHER|Sham IMST|sham inspiratory muscle strength training
223770888|NCT03945877|OTHER|No interventions|No interventions
223770889|NCT05902390|DEVICE|hydrogel spacer|Randomly assigned to either the treatment group, who were injected with hydrogel spacer, or the control group, who were not injected with hydrogel spacer.
223666780|NCT03188172|DRUG|Daratumumab|Chemotherapy
223666781|NCT03188172|DRUG|Dexamethasone|Chemotherapy
223770890|NCT02203591|DRUG|3M CHG/IPA Prep C|Apply topically for 30 seconds to the abdominal region or 2 minutes to the inguinal region, and allow to dry for 3 minutes.
223770891|NCT02203591|DRUG|3M CHG/IPA Prep CH|Apply topically for 30 seconds to the abdominal region or 2 minutes to the inguinal region, and allow to dry for 3 minutes.
223770892|NCT02203591|DRUG|ChloraPrep|Apply topically for 30 seconds to the abdominal region or 2 minutes to the inguinal region, and allow to dry for 3 minutes.
223770893|NCT02203591|DRUG|Normal Saline|Apply topically for 30 seconds to the abdominal region or 2 minutes to the inguinal region, and allow to dry for 3 minutes.
223770894|NCT01142739|OTHER|Clinical variables|Demography, disease duration, treatment duration, current treatment, daily intake of levodopa, Disease stage (Hoehn and Yahr, HY), motor score (UPDRS III) and dyskinesia severity (UPDRS IV). Biological variables.
223770895|NCT01142739|OTHER|Clinical variables|Demography, Biological variables.
223770896|NCT01142739|OTHER|Clinical variables|Eye movement recordings : non-invasive infra-red camera oculometry (EyeBrain) before and after (only parkinson's disease group) levodopa(10 to 15 minute/recording)
223770897|NCT02625493|OTHER|Questionnaire|Questionnaire containing a Best-worst Scaling scenario
224248911|NCT02061917|OTHER|Snus (Smokeless Tobacco)|Smokers switched to snus product for 24 weeks
224248912|NCT02061917|OTHER|Tobacco-Burning Cigarette|Smokers switched to a tobacco-burning cigarette for 24 weeks
224248913|NCT06380023|DEVICE|Enclosure barrier|Surgical mask \& Enclosure tent compared with open suction
223666782|NCT03188172|DRUG|Melphalan|Chemotherapy
223666783|NCT03188172|DRUG|Filgrastim|Haematopoietic agent for the stem cell harvest
223666784|NCT01446783|DRUG|mecasermin|0,1 ml mecasermin (10 mg/ml) is injected intratendinous into the patella tendon with ultrasound guidance.
223666785|NCT01446783|DRUG|Saline|0,1 ml saline is injected intratendinous into the patella tendon with ultrasound guidance.
223666786|NCT04028544|DRUG|Qishenyiqi dropping pills|on the basis of standard treatment, adding QSYQ dropping pills 1 bag each time, 3 times a day
223666787|NCT04028544|DRUG|Placebo|on the basis of standard treatment, adding placebo 1 bag each time, 3 times a day
223666788|NCT03478293|DEVICE|iStent inject surgery|Micro-invasive glaucoma surgery (MIGS) to implant iStent inject
223666789|NCT00000679|DRUG|Zidovudine|
224248914|NCT03430869|DRUG|F-18 AV-45|In the present project, the investigators will recruit 40 patients with lifetime major depressive disorder, and 20 non-depressed cognitively normal comparison subjects. Alzheimer's disease pathology (A) was determined by measuring Aβ deposition by F-18 AV-45 PET.
224248915|NCT03430869|DRUG|F-18-THK-5351|In the present project, the investigators will recruit 40 patients with lifetime major depressive disorder, and 20 non-depressed cognitively normal comparison subjects. All subjects will further undergo F-18-THK-5351 image study to detect underlying tau pathology. By doing this, the investigators will elucidate the neurodegenerative pathophysiology behind the link between depressive disorder and the subsequent development of dementia.
224248916|NCT00651586|DRUG|Gatifloxacin 0.3% ophthalmic solution|Gatifloxacin 0.3% ophthalmic solution. On Day 0, one drop instilled in affected eye every 5 minutes for the first 30 minutes, every 30 minutes while awake, and every 2 hours after retiring; on Day 1, one drop instilled in affected eye every hour while awake and 4 hours after retiring; on Days 2 to 6, one drop instilled in affected eye every 2 hours while awake; on Days 7 to 21, one drop instilled in affected eye 4 times daily while awake. Treatment continued through Day 21 (or Day 28 if ulcer had not healed but was improving); dosing terminated when re-epithelialization was complete or on Day 28, whichever occurred sooner
224248917|NCT00651586|DRUG|Ciprofloxacin 0.3% ophthalmic solution|Ciprofloxacin 0.3% ophthalmic solution. On Day 0, one drop instilled in affected eye every 5 minutes for the first 30 minutes, every 30 minutes while awake, and every 2 hours after retiring; on Day 1, one drop instilled in affected eye every hour while awake and 4 hours after retiring; on Days 2 to 6, one drop instilled in affected eye every 2 hours while awake; on Days 7 to 21, one drop instilled in affected eye 4 times daily while awake. Treatment continued through Day 21 (or Day 28 if ulcer had not healed but was improving); dosing terminated when re-epithelialization was complete or on Day 28, whichever occurred sooner
224248918|NCT03125135|DEVICE|MightySat RX Pulse Oximeter Sensor|Noninvasive pulse oximeter finger sensor.
224248919|NCT02372266|OTHER|Early Maternal-Newborn Infant Discharge|Discharge from the hospital between 12-24 hours of life
224248920|NCT02372266|OTHER|Routine discharge|Discharge of the mother and newborn 2 to 3 days after delivery
224248921|NCT02987439|OTHER|Pulmonary rehabilitation|The intervention is pulmonary rehabilitation
224248922|NCT02393417|BIOLOGICAL|CANDIN|Candida albicans Skin Test Antigen for Cellular Hypersensitivity
224248923|NCT02393417|OTHER|Placebo|0.9% Sodium Chloride Injection USP (non-preserved)
223770898|NCT05013905|DRUG|PRA023 IV|PRA023 administered at timepoints as directed by the protocol
223770899|NCT05013905|DEVICE|Companion diagnostic (CDx)|CDx+ or CDx-
223770900|NCT04942938|DEVICE|Neubie|The Neubie is a direct current neuromuscular electrical stimulation device. This system uses an exponential wave pattern to mimic the natural pattern neurologically to lengthen fibers of the sarcomere and engage force velocity of muscle with minimized protective co-contraction of nearby muscle groups. The golgi tendon and muscle spindles code for joint position and muscle/tendon stretch with 66% of fibers being intrafusal. Impacting these structures has direct impact on reticulospinal tract fibers and proprioceptive central fibers modulation of levels of spasticity. The Neubie direct current is designed to improve positioning of these stretch receptors.
223770901|NCT03178617|OTHER|Educational Intervention|Attend standard of care LIP
224248924|NCT02203058|OTHER|Pursed-lips breathing|Expiration with pursed-lips during functional capacity tests.
223666790|NCT00000679|DRUG|Zalcitabine|
223666791|NCT04708977|PROCEDURE|One-level lateral lumbar interbody fusion with Indirect Decompression|One-level lateral lumbar interbody fusion, with or without percutaneous posterior instrumentation. Thorough discectomy will be performed using lateral access. Fusion will then be performed using lateral access interbody cage and allograft bone graft with or without use of recombinant human bone morphogenic protein 2.
223666792|NCT04708977|PROCEDURE|One-level lateral lumbar interbody fusion with Direct Decompression|"One-level lateral lumbar interbody fusion, with or without percutaneous posterior instrumentation. Thorough discectomy will be performed using lateral access instruments. Fusion will then be performed using lateral access interbody cage and allograft bone graft with or without use of recombinant human bone morphogenic protein 2.~Additionally, direct decompression through midline or parasagittal approach will be utilized. A unilateral laminotomy or complete bilateral laminectomy may be performed."
223770902|NCT03178617|OTHER|Educational Intervention|Attend HIP
223770903|NCT03178617|OTHER|Quality-of-Life Assessment|Ancillary studies
223770904|NCT03178617|OTHER|Questionnaire Administration|Ancillary studies
223666793|NCT01060280|BEHAVIORAL|Education on active management|Routine clinical practice plus education on active management.
223666794|NCT01060280|OTHER|Group GDS physiotherapy|Routine clinical practice (which will be substituted by Group GDS) plus education on active management.
223666795|NCT01060280|OTHER|Individual GDS physiotherapy|Routine clinical practice (except for usual physiotherapy, which is substituted by Group and Individual GDS) plus education on active management.
223770905|NCT05652088|PROCEDURE|Colonoscopy|Colonoscopy is a procedure where an instrument called colonoscope is inserted through the rectum to look at the entire internal surface of the intestine. Participants will be placed on a stretcher on the left side. A colonoscope will be advanced into the colon and into the terminal ileum. The entire procedure should take approximately 40 minutes
224248925|NCT02203058|OTHER|No pursed-lips breathing|To avoid pursed-lips breathing, subjects use a a mouthpiece (2cm diameter X 2cm length) such as the one used in pulmonary functional tests.
224248926|NCT00002062|DRUG|Spiramycin|
224248927|NCT00264394|BEHAVIORAL|Updated CHD risk profiles|Provision of computer generated CHD risk profiles
223770906|NCT00523185|DRUG|Lorazepam|Lorazepam 1 to 2 mg by mouth or intravenously every two hours as needed for alcohol withdrawal symptoms.
223770907|NCT00523185|DRUG|Diazepam|Diazepam 20 mg by mouth every two hours x 3 doses, or for parenteral treatment, diazepam 10 mg intravenously every one hour x 6 doses. Give additional diazepam 10 mg by mouth or intravenously every two hours as needed for alcohol withdrawal symptoms.
224248928|NCT00264394|BEHAVIORAL|Guidelines|provision of guidelines for CHD risk factor management only
224248929|NCT02422264|BIOLOGICAL|Infanrix hexa|• All subjects will receive Infanrix hexa at 2 and 4, at 3 and 5, at 2, 4 and 6 months or at 2, 3 and 4 months, depending on the immunisation schedule of the country. Infanrix hexa is administered intramuscularly to the right thigh.
224248930|NCT02422264|DRUG|Prevnar13|• All subjects will receive Infanrix hexa co-administered with Prevenar13\* at 2 and 4, at 3 and 5, at 2, 4 and 6 months or at 2, 3 and 4 months, depending on the immunisation schedule of the country. \*In some countries/regions with an Infanrix hexa 3-dose vaccination schedule, Prevenar 13 could be administered as 2-doses or 3-doses primary vaccination schedule (according to the routine national immunisation schedule). Prevnar13 is administered intramuscularly to the left thigh.
224248931|NCT05291702|PROCEDURE|PCNL|Percutaneous nephrolithotomy ( Extraction of the renal stones using the nephroscope/ Ureteroscope )
223666796|NCT01337037|DEVICE|VATS lobectomy using modified equipments|"the procedure of this group is the same with standard VATS lobectomy group.the VATS surgical equipments used in the group are designed according to the experience of chinese lobectomy surgery. All the patent applications of the surgical equipments are granted. proprietor of the patents is Jun Wang, head of Department of Thoracic surgery of people's hospital, peking university.~Details of the modified equipments: Lobectomy Equipments Pack (Manufacturer B.J.ZH.F.Panther Medical Equipment Co.,Ltd.) consists of 8 basic surgical equipments, which are crafoord dissecting and ligature forcep, Yankauer suction tube, mixter dissecting and ligature forceps(long),mixter dissecting and ligature forceps(short), atraumatic-grip aorta-aneurysma clamp with toothing De Bakey, De Bakey atraumatic-grip vascular forcep, Bozemann tite grip needle holder, Winter placenta and ovum forcep."
223666797|NCT01337037|PROCEDURE|VATS lobectomy using less staples|VATS lobectomy with at most 4 staples used, aimed at reduced hospital cost.This procedure is similar with the standard VATS lobectomy procedure without staples limits. The lobar vessels and bronchus are stapled. However, the interlobar fissures should be deal with electronic cautery, harmonic scalpel,or suturing.
223666798|NCT01337037|PROCEDURE|Standard VATS lobectomy|VATS lobectomy without new equipments and limitation of staples, same with the current procedure of VATS lobectomy performed in thoracic departments of Peking university people's hospital and the Collaborators. All procedures were conducted under general anesthesia with double lumen intubation. The thoracoscope was introduced through 7th or 8th intercostals space on the mid-axillaries line. The 4 cm long utility incision was made on the 4th or 5th intercostals space anterior axillary's line without rib-spreading. A third retraction incision located on the 7th or 8th intercostals space sub-scapular line. The surgeon stands on the ventral side of patient using an electrocautery hook and a suction device through the utility incision. Anatomic lobectomy was performed with systemic mediastinal lymph node dissection for lung cancer patients.
223666799|NCT01337037|PROCEDURE|Open lobectomy|standard lobectomy procedure by thoracotomy approach
223666800|NCT02129504|DEVICE|root coverage comparing two techniques|The aim of this study was to compare and show the benefits of the extended flap technique (new technique) compared to coronal advanced technique (gold standard technique) both techniques using the porcine collagen matrix for root coverage.
224248932|NCT01503736|DRUG|ferric citrate|0g/day ferric citrate capsule, TID for 56 days
224248933|NCT01503736|DRUG|ferric citrate|4g/day ferric citrate capsule, TID for 56 days
224248934|NCT01503736|DRUG|ferric citrate|6 g/day ferric citrate capsule, TID for 56 days
224248935|NCT00025818|DRUG|Ophthalmic Emulsion|
224248936|NCT01203332|BEHAVIORAL|Effectiveness of different strategies in HIV testing and linkage to care|HIV testing Linkage to Care
223666801|NCT01248104|DRUG|Tranexamic Acid|Infusion during cardiac surgery
223770908|NCT02554110|DEVICE|Stimulator active device|This is a stimulator active device that delivers peripheral nerve stimulation in conjunction with pulse oximetry information.
224248937|NCT06458491|DEVICE|Evolution of urinary symptoms|Evolution of urinary symptoms 3 months after the start of use of the TENSI+ device
224248938|NCT04904120|DRUG|[203Pb]VMT01|Diagnostic imaging radiopharmaceutical; by intravenous infusion
224248939|NCT04904120|DRUG|[68Ga]VMT02|Diagnostic imaging radiopharmaceutical; by intravenous infusion
224248940|NCT00273026|DRUG|salmeterol xinafoate/fluticasone propionate|
224248941|NCT05217524|DEVICE|Galaxy BIA watch|Digital multifunction watch
223666802|NCT01248104|DRUG|Aminocaproic Acid|Infusion during cardiac surgery
223666803|NCT01964755|DRUG|Doxorubicin|Doxorubicin 20 mg/m2 intravenously will be administered on Day 1 in patients with systemic (non-primary CNS) lymphoma as per institutional guidelines
223666804|NCT01964755|DRUG|Methotrexate|Methotrexate administered starting on Day 2, per study protocol.
223666805|NCT01964755|DRUG|Leucovorin|Leucovorin administered first intravenously 24 hours after start of Methotrexate infusion, then orally every 6 hours for at least 10 doses, per study protocol.
223666806|NCT01964755|BIOLOGICAL|Hydroxyurea|Hydroxyurea administered orally twice daily starting on Day 2, and continuing for a total of 10 doses, per study protocol
223666807|NCT01964755|DRUG|Zidovudine|Zidovudine administered first intravenously on Day 2, and then orally twice daily for 10 doses, per study protocol.
223666808|NCT01964755|DRUG|Rituximab|Rituximab is optional and will be administered to study participants, per study protocol.
223770909|NCT02554110|DEVICE|Stimulator sham Device|This is an stimulator sham device that is not providing peripheral nerve stimulation.
224248942|NCT02344732|DRUG|Dexamethasone 0.1%, Neomycin Sulfate and Polymyxin B Sulfate topical eye drops four times daily|
224248943|NCT02344732|DRUG|Homatropine 2% eye drops thrice daily|
224248944|NCT02344732|DRUG|Oxygen gas|
224248945|NCT05951192|DRUG|Daprodustat|Commercially manufactured daprodustat (JESDUVROQ) is provided in tablet strengths of 1, 2, 4, 6 and 8 mg. Tablets will be taken whole and patients will be instructed not to cut, crush, or chew tablets.
224248946|NCT00204074|DRUG|17-beta-estradiol (drug)|
223666809|NCT01502215|OTHER|Red blood cell transfusion|Red blood cell (RBC) transfusion will be given when hemoglobin fall below 9 g/dL since ICU admission until the discharge of intensive care unit. Following administration of the 1 RBC unit, a repeat hemoglobin levels is performed;if a patient's hemoglobin is 9 g/dL or higher, no additional transfusion is necessary.
223666810|NCT01502215|OTHER|Red blood cell transfusion|Red blood cell (RBC) transfusion will be only given when hemoglobin fall below 7 g/dL since ICU admission until the discharge of intensive care unit. Following administration of the 1 RBC unit, a repeat hematocrit is performed;if a patient's hemoglobin 7 g/dL or higher, no additional transfusion is necessary
223666811|NCT05813808|DIAGNOSTIC_TEST|ultra-low-dose computed tomography|7 ultra-low-dose computed tomography imaging
223666812|NCT02894502|BEHAVIORAL|Motivational interviewing|The intervention will consist of a brief session of motivational interviewing (MI) performed by a trained nurse. During MI, the interventionist will address one or two aspects of self-care that the participants want to address. After this first intervention, the same interventionist will contact the participant by telephone to improve the first intervention and provide further support as needed. These telephone contact will be done three times at two week intervals following the first intervention (for a total of two months). Patients and caregivers that receive the intervention also will be given informational material on HF management that is consistent with international guidelines.
223666813|NCT04944108|PROCEDURE|LISA approach|Participants will be randomized to administer surfactant in a preterm manikin by using the LISA approach (thin catheter) or the INSURE approach (tracheal tube)
223666814|NCT04944108|PROCEDURE|Insure approach|Participants will be randomized to administer surfactant in a preterm manikin by using the INSURE approach (tracheal tube)
223666815|NCT01209104|DRUG|GSK1325756|100mg of a single oral dose of GSK1325756 administered as 2 x 50mg tablets
224248947|NCT03205774|BEHAVIORAL|6 hours fasting and free oral intake of water|Ultrasound examination of the gastric antrum are performed in volunteers after prolonged fasting and 10 min after oral intake of water. Volunteer should be lying on his/her back, right lateral decubitus position and left lateral decubitus position with randomization of the order.
224248948|NCT05971420|OTHER|VR activity-based|VR games activities were chosen for simulated cognitive-motor training in the VR group. The VR training modules for this study included fire drill, walking exercise, balancing game activities and community shopping practices. These training modules involved dual task components; the participant was expected to train up his/her physical and cognitive motor performances in an 8-week VR activity-based program. VR group participants received 2-sessions per week, 16 training sessions in total.
224248949|NCT05971420|OTHER|Exercise-based (Baduanjin)|The exercise group used a traditional Chinese Qigong Baduanjin exercise incorporating with a fall prevention education strategy.
223666816|NCT01209104|DRUG|GSK1325756|100mg of a single oral dose of GSK1325756 administered as 2 x 50mg tablets
223666817|NCT03736772|DRUG|LY3090106|Administered SC
223666818|NCT03736772|DRUG|Placebo|Administered SC
223666819|NCT04988191|DRUG|Toripalimab|"Neoadjuvant therapy: Toripalimab is given by intravenous infusion at 3mg/kg d1 every 2 weeks for 3 cycles.~Adjuvant therapy: Toripalimab is given by intravenous infusion at a dose of 240mg every 3 weeks for up to 9 cycles."
223666820|NCT04988191|DRUG|Bevacizumab|Neoadjuvant therapy: Bevacizumab is given by intravenous infusion at 5mg/kg d1 every 2 weeks for 3 cycles.
223666821|NCT04988191|DRUG|Irinotecan|Neoadjuvant therapy: Irinotecan is given by intravenous infusion at 180mg/m2 d1 every 2 weeks for 2 cycles.
224248950|NCT04704531|DRUG|Sodium Hyaluronate Ophthalmic 0.4% BID|Topical ophthalmic administration of one drop of Multidose Lagricel® Ofteno BID.
224248951|NCT04704531|DRUG|Sodium Hyaluronate Ophthalmic 0.4% QID|Topical ophthalmic administration of one drop of Multidose Lagricel® Ofteno QID.
224248952|NCT04704531|DRUG|Sodium Hyaluronate Ophthalmic 0.4% Six times per day|Topical ophthalmic administration of one drop of Multidose Lagricel® Ofteno six times per day.
224248953|NCT02648074|PROCEDURE|Bronchial challenge with allergen|Bronchial challenge is performed with D. pteronyssinus allergen.
224248954|NCT02648074|OTHER|Co-culture formation|Eosinophil and linear bronchial smooth muscle cell co-culture formation. Airway smooth muscle cell proliferation, eosinophil adhesion to the bronchial smooth muscle cells, the role of eosinophil integrins in the airway remodelling process is assessed in individual formed co-culture
224248955|NCT01319162|OTHER|Weight reduction regimen|The dietary intervention begins with a 12-weeks VLCD/LCD period. The diet comprise of 3 to 5 portions liquid diet with a daily energy intake of 450-800 kcal. In addition, patients will be encouraged to drink 1,5-2L daily of non-caloric beverages (\<6 kcal/100 ml). All patients will have scheduled nurse visits at week 0 (baseline), 2, 5, 8, and 12. At these visits general well-being and body weight will be monitored. The patient will also be given support and counselling to enhance compliance to the VLCD/LCD diet.
224248956|NCT00328926|DRUG|Luveris® 75 IU|Recombinant human luteinizing hormone (r-hLH, lutropin alfa, Luveris®), 75 IU will be administered subcutaneously once daily. Duration of treatment cycle will be up to 14 days, or maximum of 21 days (if follicular maturation is imminent, based upon follicular growth and estradiol \[E2\] levels). Total duration will be of 3 treatment cycles.
223666822|NCT05901753|DEVICE|Laryseal pro supra glottic device|The laryseal pro SP will be advanced at a forward angle aiming for the back of the tongue and soft palate. Then the colored connector will be pushed by index finger till feeling resistance . Device insertion will be considered successful by observing bilateral chest wall movement as well as a stable square-wave capnogram trace
223666823|NCT05901753|DEVICE|Laryngeal Mask Airway- Proseal™|The cuff will be inflated with air and the cuff's pressure will be adjusted to 70 mmHg using a cuff pressure manometer. the device will be lubricated well on both sides, head and neck were placed in neutral position, the proximal firmer part of the device will be compressed between the thumb and two fingers and advanced toward hard and soft palate, the tab will be pulled slightly if needed to increase curvature of the device for better fitting, the device will be advanced till resistance felt.
223666824|NCT01198613|BIOLOGICAL|ToleroMune Ragweed|Intradermal injection 1 x8 administrations 2 weeks apart
223666825|NCT01198613|BIOLOGICAL|Placebo|Intradermal injection, 1x8 administrations 2 weeks apart
224248957|NCT00328926|DRUG|Luveris® 25 IU|Recombinant human luteinizing hormone (r-hLH, lutropin alfa, Luveris®), 25 IU will be administered subcutaneously once daily. Duration of treatment cycle will be up to 14 days, or maximum of 21 days (if follicular maturation is imminent, based upon follicular growth and E2 levels). Total duration will be of 3 treatment cycles.
224248958|NCT00328926|DRUG|Placebo|Placebo will be administered subcutaneously once daily. Duration of treatment cycle will be up to 14 days, or maximum of 21 days (if follicular maturation is imminent, based upon follicular growth and E2 levels). Total duration will be of 3 treatment cycles.
223666826|NCT02494063|PROCEDURE|Sentinel lymph node biopsy|Bilateral sentinel lymph node biopsy, pathologic ultrastaging
223666827|NCT02494063|PROCEDURE|At least unilateral systematic pelvic lymph node dissection|
223666828|NCT01008241|BEHAVIORAL|Paper questionnaire|Participants will complete a paper and pencil questionnaire that measures 4 domains of interest (advanced care planning; end of life care; hospice care and death and dying) as well as demographic factors (age, marital status, education etc.)
223666829|NCT02150538|DEVICE|Cardiac resynchronization therapy pacemaker|biventricular stimulation with cardiac resynchronization therapy pacemaker (crt-p)
223666830|NCT02150538|DEVICE|Dual chamber pacemaker|right ventricular stimulation with dual chamber pacemaker
223666831|NCT03289624|BEHAVIORAL|SHARE-CC|"Each of the 6 SHARE-CC sessions are structured similarly, starting with the dyad reviewing goals of the session, the CG \& PWCC meeting jointly or separately with the SHARE-CC Counselor around session-specific material, \& ending with a review of material, addressing questions, \& previewing the next session. Sessions titles are: Communication \& Health Education; Care Values; Care Preferences; Family, Friends, \& Community Resources; Taking care of yourself-taking care of each other; \& Take Action Now.~The SHARE plan will be developed throughout the sessions and reflects the consensus achieved because of participating in SHARE-CC. It is intended to ensure that the PWCC's values \& preferences are supported when decisions have to be in the future."
223666832|NCT00230555|BEHAVIORAL|professional support model|
223666833|NCT02495571|OTHER|Cough Assessment in ALS Patients|"1. Volitional Cough assessment by spirometer:~   a) Peak Cough Espiratory Flow (PCEF)~2. Cough Reflex Test a) Peak Cough Espiratory Flow (PCEF)"
223666834|NCT02845219|DRUG|semaglutide|Oral administration once daily alone or together with oral contraceptive.
224248959|NCT00328926|DRUG|Recombinant human follicle stimulating hormone (r-hFSH)|Fixed dose of recombinant human follicle stimulating hormone (r-hFSH, follitropin alfa) 75 to 150 IU will be administered subcutaneously for 7 days. After 7 days of treatment, if the subject response will suboptimal, based on follicular growth and serum E2 levels, follitropin alfa dose adjusted to maximal dose of 225 IU. Duration of treatment cycle will be up to 14 days, or maximum of 21 days (if follicular maturation is imminent, based upon follicular growth and E2 levels). Total duration will be of 3 treatment cycles.
224248960|NCT00328926|DRUG|Recombinant human chorionic gonadotropin (r-hCG)|When the follicular response will adequate, ovulation will be triggered by a single 250 microgram subcutaneous injection of recombinant human chorionic gonadotropin (r-hCG, choriogonadotropin alfa). Duration of treatment cycle will be up to 14 days, or maximum of 21 days (if follicular maturation is imminent, based upon follicular growth and E2 levels). Total duration will be of 3 treatment cycles.
224248961|NCT02656368|DEVICE|SEBORRHEAMEDIS Face Cream|SEBORRHEAMEDIS Face Cream is a barrier-based, non-steroidal cream. The cream includes plant extracts The cream was designed to manage the symptoms of facial Seborrheic dermatitis symptoms such as erythema, scaling and pruritus.
224248962|NCT03944330|DIETARY_SUPPLEMENT|standard hospital diet|patients were provided standard hospital diet that provided 25-30 kcal/kg/day
224248963|NCT02269657|DEVICE|EOS® imaging system|The EOS® imaging system is a low dose, 3-dimensional imaging system that provides weight bearing images which provide visual information with respect to the interaction between the joints and the rest of the musculoskeletal system, particularly the spine, hips and legs. The imaging system is used for clinical purposes with additional images captured as part of this study to collect data from subjects in two different arm positions during imaging.
224248964|NCT02196766|OTHER|Bioclean First Care EX / comfilcon A|Subjects dispensed Bioclean First Care EX / comfilcon A combination then crossed over to the alternate combination.
224248965|NCT02196766|OTHER|Aosept Clearcare / comfilcon A|Subjects dispensed Aosept Clearcare / comfilcon A combination then crossed over to the alternate combination.
223666835|NCT02845219|DRUG|SNAC|Oral administration once daily together with oral contraceptive.
223666836|NCT02845219|DRUG|Microgynon®|Oral administration once daily alone or together with oral semaglutide or SNAC.
223666837|NCT03599375|BIOLOGICAL|CD19-targeted CART cells|CD19 CAR T cells was transduced with a lentiviral vector to express anti-CD19 scFv.This is a second generation CRAT.
223666838|NCT06131164|OTHER|Diaphragmatic Breathing Exercise Group|The subjects in this group will perform Diaphragmatic Breathing Exercise Group
223666839|NCT06131164|OTHER|Thoracic Extension Exercise Group|The subjects in this group will perform Thoracic Extension Exercise Group
223666840|NCT01873612|PROCEDURE|Hypoxic ventilatory response|
223666841|NCT01873612|PROCEDURE|Hypercapnic ventilatory response|
223666842|NCT02356367|OTHER|telemonitoring|
223666843|NCT01710137|DRUG|Varenicline|
223666844|NCT01710137|DRUG|Placebo|
223666845|NCT01710137|BEHAVIORAL|Smoking Cessation Counseling|
223666846|NCT03007810|DRUG|Hemay005|Subjects will be randomized into 6 cohorts(10mg, 20mg, 40mg, 80mg, 120mg, 180mg) orally single dose
223666847|NCT03007810|DRUG|Placebos|Subjects will be randomized into 5 cohorts(20mg, 40mg, 80mg, 120mg, 180mg) orally single dose
224248966|NCT00186355|PROCEDURE|high dose chemo then auto hematopoietic cell transplant|
224248967|NCT04074655|DEVICE|Driving Simulator in a Virtual Reality Environment|Driving simulator in virtual reality environment is a game with the several level of difficulty and the goal of improving the cognition level of participants in general and their spatial cognition in particular. Moreover this game, will have a positive effect on its users' mood as well.
224248968|NCT03590808|BIOLOGICAL|Influenza vaccination|Purified inactivated influenza virus antigen (Green Cross Corp) 0.5 mL once IM
224248969|NCT01273350|DEVICE|Carotid PTA and stenting|Percutaneous interventional treatment of carotid artery stenosis using XACT carotid artery stent and emboshield protection system with bivalirudin as the procedural anticoagulant
224248970|NCT05115123|DRUG|Duloxetine|60 mg duloxetine
224248971|NCT05115123|DRUG|Placebo|Placebo
224248972|NCT00769964|DRUG|VA111913 TS / placebo|
223770910|NCT01018459|BIOLOGICAL|Ad35.CS.01 Circumsporozoite Malaria Vaccine|Ad35.CS.01 appears clear to slightly opalescent with no visible particles. Each 0.75 mL dose of the assigned dosage will be administered via intramuscular injection into the deltoid muscle. Dosages: 10\^9 viral particles (vp)/mL, 10\^10 vp/mL, 5 x 10\^10 vp/mL, and 10\^11 vp/mL.
223666848|NCT03251131|OTHER|Restrictive fluid management|Daily fluid input is restricted to drugs and nutrition. Fluid boluses and blood products can be given if clinically indicated. Matching fluid output to fluid input whenever possible using diuretics if needed, and additionally, if clinically necessary and plausible, commencing renal replacement therapy. If renal replacement therapy is not deemed clinically desirable, acceptance of a less than targeted fluid balance.
223666849|NCT05045937|DRUG|Ivermectin|Ivermectin treatment of outpatients dosing at 0.4mg/kg until recovered along with supplemental treatment using a multi-modal approach.
223666850|NCT01275807|DEVICE|acupuncture|10 sessions of acupuncture
223666851|NCT01275807|OTHER|self care|physical exercice, diet, self help groups, psychological support
223666852|NCT01810614|OTHER|ADPKD Diet|Diet specifically designed for people with ADPKD
223666853|NCT00601042|OTHER|Swedish snus (smokeless tobacco)|Snus in sachets 1.0 g or 0.5 g, 2 flavors. Usage ad libitum.
223666854|NCT00601042|OTHER|Onico|Tobacco-free, nicotine-free placebo snus, 2 sachet sizes (1.0 g, 0.5 g), 2 flavors (same as in the experimental arm). Usage ad libitum.
223666855|NCT03035487|DEVICE|Ultrasound guided prostate exam using SOC ultrasound system|
223666856|NCT03035487|DEVICE|mpMRI guided prostate examination using PI-RADS v2|mpMRI guided prostate examination using standard of care MRI system
223666857|NCT03035487|DEVICE|High-resolution micro-ultrasound guided prostate biopsy|
223666858|NCT01332799|DRUG|allopurinol or placebo|Daily active drug (allopurinol administered orally) administered orally for 3 years.
223666859|NCT01332799|OTHER|Placebo|Sugar pill administered orally for 3 years.
223666860|NCT00629967|DRUG|pegylated interferon alpha 2a and ribavirin|pegylated interferon alpha 2a 180 mcg/week and ribavirin 1000-1200 mg/day for 48 weeks
223770911|NCT01018459|DRUG|Placebo|Normal saline placebo control delivered via intramuscular injection into the deltoid muscle.
224248973|NCT00045422|BIOLOGICAL|recombinant interferon alfa|
223666861|NCT00629967|DRUG|Pegylated interferon alfa-2a and ribavirin|Pegylated interferon alfa-2a 180 mcg/week and Ribavirin 1000-1200 mg/day for 24 weeks, follow up for 24 weeks
223770912|NCT06055426|OTHER|bed bath application|Patients who agree to participate in the research and are assigned to the experimental group will receive a bed bath. In order to examine the short-term, medium-term and long-term effects of bed bath, it is planned to have the whole body bed bath performed by the researcher nurse xx three times a week, two days apart.
224248974|NCT00045422|DRUG|imatinib mesylate|
224248975|NCT06395194|DRUG|Cardiac outcomes on treatment with valsartan|"Patients who already were on treatment, discontinued their previous antihypertensive medications when randomized to one of the trial's masked study arms (valsartan or amlodipine) without a run-in phase (rolled over). Valsartan treatment started at a dosage of 80 mg daily. If BP did not reach \<140/90 mmHg, the valsartan dose was doubled to 160 mg, and then hydrochlorothiazide (12.5 mg and 25 mg daily) and other antihypertensive drugs were added in sequential steps."
223666862|NCT01198522|DRUG|L19IL2 monoclonal antibody-cytokine fusion protein in combination with gemcitabine|"Part A) Patient cohorts will sequentially be assigned to 800 or 1,000 mg/m2 of gemcitabine. gemcitabine will be given in combination with a fixed dose of L19IL2. Part B) Patient cohorts will sequentially be assigned to 10, 15,22.5,30 or 37,5 MioIU IL2 equivalents of L19IL2. L19IL2 will be given in combination with gemcitabine at the dose recommended from Part A. Should the MTD of L19IL2 not be reached within the planned cohorts listed above, the dose of L19IL2 will be further increased following 7.5 MioIU increasing steps.~Induction treatment: Intravenous (i.v.) infusions of L19IL2 on days 1,3,5,22,24, 26,43,45,47, followed by i.v. infusions of gemcitabine on days 1,8,15,22,29,36,43. Maintenance treatment: Patients with objective tumor responses or stable disease will receive up to 4 cycles of maintenance treatment, starting on day 57: i.v. infusions of L19IL2 on days 1 (day 57), 8,15, followed by an i.v. infusion of gemcitabine. Treatment cycles will be repeated on day 29."
223666863|NCT04347668|OTHER|Virtual Reality|VR requires the user to use a multi-projected in their own room using BroomX to generate realistic images, sounds and other sensations that simulate a user's physical presence in a virtual or imaginary environment
223666864|NCT04347668|OTHER|Usual Care|meals, engagement in scheduled and non-scheduled programs such as exercise, and activities, groups. Residents are supported in their activities of daily living, and social engagement. Specific interventions based on resident needs are supported in a Dementia capable environment.
223666865|NCT00178529|BEHAVIORAL|Psychoeducation, Counseling and Skill Training|
223666866|NCT03532607|OTHER|Music|Patients will listen to soothing music for 30 minutes before their standard of care botox injection
223770913|NCT00028028|DRUG|temsirolimus|Given IV
223770914|NCT00028028|OTHER|pharmacological study|Correlative studies
223666867|NCT06224751|DIAGNOSTIC_TEST|Near logMAR letter acuity|Comparison of gold standard printed tests and computerised versions
223666868|NCT06224751|DIAGNOSTIC_TEST|Near LogMAR word acuity|Comparison of gold standard printed tests and computerised versions
223770915|NCT00028028|OTHER|laboratory biomarker analysis|Correlative studies
223770916|NCT06577298|BIOLOGICAL|Recombinant Trivalent Poliomyelitis Vaccine (Sf-RVN Cell) (VLP-Polio) low adjuvant dose|4 doses of VLP-Polio vaccine (0.5ml) at 2, 3, 4 months and 12-18 months of age for infants
223770917|NCT06577298|BIOLOGICAL|VLP-Polio medium dose|4 doses of VLP-Polio vaccine (0.5ml) at 2, 3, 4 months and 12-18 months of age for infants
223770918|NCT06577298|BIOLOGICAL|VLP-Polio high dose|1 dose of VLP-Polio vaccine (0.5ml) on day 0 for toddlers, 4 doses at 2, 3, 4 months and 12-18 months of age for infants
223770919|NCT06577298|BIOLOGICAL|Vaccine Poliomyelitis Inactivated (IPV)|1 dose of IPV vaccine (0.5ml) on day 0 for toddlers, 4 doses at 2, 3, 4 months and 12-18 months of age for infants
223770920|NCT06384547|DRUG|VRDN-001 10 mg/kg|5 infusions of VRDN-001 10 mg/kg
223770921|NCT06384547|DRUG|VRDN-001 3 mg/kg|5 infusions of VRDN-001 3 mg/kg
224248976|NCT06395194|DRUG|Cardiac outcomes on treatment with amlodipine|"Patients who already were on treatment, discontinued their previous antihypertensive medications when randomized to one of the trial's masked study arms (valsartan or amlodipine) without a run-in phase (rolled over). Amlodipine treatment started at 5 mg daily. If BP did not reach \<140/90 mmHg, the amlodipine dose was doubled to 10 mg, and then hydrochlorothiazide (12.5 mg and 25 mg daily) and other antihypertensive drugs were added in sequential steps."
223666869|NCT06224751|DIAGNOSTIC_TEST|Red Green Stereoacuity|Comparison of gold standard printed tests and computerised versions
223666870|NCT06224751|DIAGNOSTIC_TEST|Auckland Optotype/Auckland Vanishing Optotypes|Comparison of gold standard printed tests and computerised versions
224248977|NCT01880853|OTHER|mammography|participants were screened by mammography alone every year
224248978|NCT01880853|OTHER|ultrasound|participants were screened by ultrasound alone every year
224248979|NCT01880853|OTHER|mammography and ultrasound|Participants were screened by both mammography and ultrasound every year
224248980|NCT01888822|DRUG|Ciprofloxacin|Prophylactic ciprofloxacin infusion before elective laparoscopic cholecystectomy
224248981|NCT01888822|DRUG|Ampicillin-sulbactam|Prophylactic ampicillin-sulbactam infusion before elective laparoscopic cholecystectomy
224248982|NCT01888822|DRUG|Placebo|Prophylactic placebo infusion before elective laparoscopic cholecystectomy
224248983|NCT02527109|DRUG|Nifedipine|
224248984|NCT00309881|BIOLOGICAL|rituximab|
224248985|NCT00309881|DRUG|cyclophosphamide|
224248986|NCT00309881|DRUG|doxorubicin hydrochloride|
223666871|NCT06224751|DIAGNOSTIC_TEST|Vanishing Optotype Sloan Letters|Comparison of gold standard printed tests and computerised versions
223666872|NCT06224751|DIAGNOSTIC_TEST|Letter Contrast Sensitivity|Comparison of gold standard printed tests and computerised versions
223666873|NCT06224751|DIAGNOSTIC_TEST|Low Contrast Letter Acuity|Comparison of gold standard printed tests and computerised versions
223666874|NCT03852680|PROCEDURE|aneurysm clipping|treatment of wide necked intracranial aneurysms using different modalities as open surgery by clipping or endovascular techniques as coiling and flow diversion
223666875|NCT02907840|DEVICE|Swisstom BB2|Electrical impedance tomography lung monitoring uses a dedicated belt placed around patient's thorax to detect change in impedance due to change in aeration within the thorax
223666876|NCT02382484|DEVICE|A dual chamber pacing system (BackBeat Medical)|For each patient, one pacing electrode was placed in the right atrium and the second electrode was placed in the right ventricle. With a dual chamber pacing system (BackBeat Medical) it was possible to pace the heart with a wide variety of pacing settings.
223666877|NCT02908490|DRUG|Sildenafil|Sildenafil 50 mg once daily
223666878|NCT02908490|OTHER|Placebo|Placebo once daily with same size, shape, color, and texture as Sildenafil 50 mg pill
223666879|NCT02926521|DEVICE|2-octyl cyanoacrylate|Addition of 2-octyl cyanoacrylate liquid adhesive to nerve catheter dressing
223666880|NCT02926521|DEVICE|Gum Mastic|Addition of gum mastic liquid adhesive to nerve catheter dressing
223666881|NCT02168387|DEVICE|continuous high frequency oscillator (CHFO)|
223666882|NCT02168387|DRUG|Acetylcysteine|
223666883|NCT02168387|DRUG|dornase alfa|
223666884|NCT06450119|OTHER|walking training|The walking training alone group would receive walking training for 60 minutes twice weekly for twelve weeks.
223666885|NCT06450119|OTHER|cognition training|The cognition training alone group would receive cognition training for 60 minutes twice weekly for twelve weeks.
223666886|NCT03660670|BEHAVIORAL|ONCORAL therapeutic education|Multidisciplinary program that includes informative cessions with a hospital pharmacist about the anticancer drug: information is given to the patients on adverse events and their managements, optimizing drug dosage plans. Moreover, information is shared with town partners: doctor, pharmacists, and nurses.
223666887|NCT03660670|BEHAVIORAL|Standard of care|In the group of standard of care, patients will have interviews with a clinical research associate only dedicated to the record of data for outcomes assessments.
223666888|NCT00002289|DRUG|Thymopentin|
224248987|NCT00309881|DRUG|prednisone|
224248988|NCT00309881|DRUG|vincristine sulfate|
223666889|NCT05342038|DEVICE|T-02|Stent retriever
223666890|NCT01588756|DRUG|AcSDKP-NH2 inuline|Once intravenous administration of 100 µg or less
223666891|NCT01588756|DRUG|AcSDKP-NH2 Cr-EDTA|Once intravenous administration of 100 µg or less
223666892|NCT06079229|OTHER|Phone call|The only follow-up visit provided for in the protocol was a telephone contact 3 to 30 months after the patient's surgery. The rest of the data required for the study were obtained from the patient's medical records, collected in the course of routine practice.
223666893|NCT02211911|DRUG|Bisacodyl|
223666894|NCT02211911|DRUG|Sodium picosulfate|
224248989|NCT06515054|BEHAVIORAL|wall squat|self-learnt wall squat exercise to be conducted for totally 24 weeks
224248990|NCT06515054|BEHAVIORAL|passive stretching|time-matched passive stretching exercise to be conducted for totally 24 weeks
224248991|NCT00851877|BIOLOGICAL|Cetuximab|Cetuximab is an epidermal growth factor receptor (EGFR) inhibitor
224248992|NCT00851877|DRUG|Cisplatin|Cisplatin is an anti-cancer chemotherapy drug
224248993|NCT00851877|DRUG|Nab-Paclitaxel|paclitaxel albumin-stabilized nanoparticle formulation
224248994|NCT00851877|RADIATION|intensity-modulated radiation therapy|intensity-modulated radiation therapy
224248995|NCT04798144|DEVICE|Distilled water irrigation kept at 2.5°C degree|The use of cold distilled water for final irrigation of root canal system during root canal treatment
224248996|NCT04798144|DEVICE|Distilled water irrigation kept at room temperature|The use of distilled water kept at room temperature for final irrigation of root canal system during root canal treatment
224248997|NCT00829673|DRUG|Dexmethylphenidate Hydrochloride|10 mg Tablet
224248998|NCT00829673|DRUG|Dexmethylphenidate Hydrochloride|10 mg Tablet
224248999|NCT05457231|OTHER|specific feedback based on an in-depth assessment tool for communication skills training|In addition to the specific feedback based on an in-depth assessment tool, four strategies modified from common strategies in the previous studies were incorporated into the intervention protocol, including lecture, patient interview, brief feedback, and self-reflection
224249000|NCT00309101|DRUG|tacrolimus|Oral
224249001|NCT05402358|OTHER|Acceptance and Commitment Therapy Group Intervention|The intervention consists of 7, 2-hour weekly sessions. Session 1 focused on introductions, outlining sessions and sharing experiences. Session 2 introduced key techniques used in the psychological approach (ACT) including mindfulness and understanding difficult thoughts and feelings. Session 3 explored ideas of primary and secondary suffering and reviewed the workability of current coping strategies. Session 4 asked participants to clarify their own personal values. Session 5 focused on goal setting and utilising problem solving skills. Session 6 considered barriers to change including assertiveness communication skills. Session 7 reviewed topics covered over the 6 weeks previously and explored pacing and preparing for setbacks. Finally a follow up 8 weeks later brought participants back for a reunion to review progress with goals and offer an opportunity to address any ongoing issues.
223666895|NCT03676101|BIOLOGICAL|9-valent HPV Recombinant Vaccine|Subjects received 3 doses of 9-valent HPV vaccine according to a 0, 2, 6-month schedule.
223666896|NCT03676101|BIOLOGICAL|Placebo|Subjects received 3 doses of Placebo according to a 0, 2, 6-month schedule.
223666897|NCT00732836|DRUG|HAI Abraxane|Escalating doses (beginning dose 180 mg/m\^2) starting Day 1, Cycle 2 and later via hepatic arterial infusion (HAI) following IV Abraxane in Day 1, Cycle 1 for 21 day cycles.
224249002|NCT04093245|BEHAVIORAL|GEM nurse|hospital-based geriatric emergency nurse (GEM nurse) specialist to support patients during the post-discharge transition period
224249003|NCT04093245|BEHAVIORAL|pre- and post-hospitalization medication list reconciliation|pre- and post-hospitalization medication list reconciliation for elderly
224249004|NCT04093245|BEHAVIORAL|systematic discharge summaries|systematic discharge summaries given to patients and/or caregiver, and sent to their family physician
224249005|NCT04093245|BEHAVIORAL|medical follow-up appointment|a planned follow-up appointment with their family physician
224249006|NCT04093245|BEHAVIORAL|follow-up phone call|a systematic follow-up phone call for discharged patients
223770922|NCT06967389|DRUG|Ozempic®|The study medication will be given in accordance with standard of care dosing schedule.
223770923|NCT05914727|DIAGNOSTIC_TEST|eNose|Collection of breath profile with eNose
224249007|NCT04093245|OTHER|Wiki-based Knowledge tools|access to wiki-based patient-oriented KT tools
224249008|NCT04093245|OTHER|Telemonitoring service|access to a community-based telemonitoring service
224249009|NCT02753231|BEHAVIORAL|Low physical activity program|Exercise will be performed at three sessions per week. All sessions will be supervised by a trained health or exercise professional.
224249010|NCT02753231|BEHAVIORAL|High physical activity program|Exercise will be performed at three sessions per week. All sessions will be supervised by a trained health or exercise professional.
224249011|NCT02753231|BEHAVIORAL|Low and High physical activity program|Exercise will be performed at three sessions per week. All sessions will be supervised by a trained health or exercise professional.
224321853|NCT05004116|DRUG|Repotrectinib|TPX-0005 (Repotrectinib) will be taken orally twice daily in 28-day cycles without regard to food and will be administered orally before administration of irinotecan and temozolomide (exception: C1, TPX-0005 (Repotrectinib) will be administered once daily x 14 days, then twice daily D15-D28).
224321854|NCT05004116|DRUG|Irinotecan and temozolomide|Irinotecan and temozolomide will be given as per institutional standard.
224321855|NCT05703425|DRUG|Sulfasalazine|Sulfasalazine will be administered between 24 and 36 weeks of pregnancy
224249012|NCT02753231|BEHAVIORAL|Conventional physical activity program|One Physical Education sessions / week
224321856|NCT03683290|OTHER|Image acquisition and analysis|Oocyte image obtention and analysis prior to intracytoplasmic sperm injection
224321857|NCT05398692|OTHER|On Site Exercise Rehabilitation|The subject will receive on site standard pulmonary and exercise rehabilitation, educational instruction on balance and strength training, stretching, nutrition, hydration, pacing, proper breathing, small or mini-lectures, and information on relaxation techniques.
224321858|NCT01272037|DRUG|Anastrozole|Given PO
224321859|NCT01272037|DRUG|Exemestane|Given PO
224321860|NCT01272037|OTHER|Laboratory Biomarker Analysis|Correlative studies
224321861|NCT01272037|DRUG|Letrozole|Given PO
223666898|NCT00732836|PROCEDURE|Hepatic Artery Catheter|On each day of treatment for Cycles 2-4, hepatic artery catheter placement completed by interventional radiology.
223666899|NCT00732836|DRUG|IV Abraxane|Intravenous (IV) Abraxane only in Cycle 1 (up to Dose Level 4 of 260 mg/m\^2), infused over 60 minutes or 4 hours Day 1 of 21 day cycle.
223666900|NCT02505828|PROCEDURE|Articular punction, salivary samples, blood sample|
223666901|NCT03395119|DRUG|Ozone|After the four-week supplementation period, each subject will be blindly exposed on consecutive days to filtered air for 2 hours and to 0.3 ppm ozone for 2 hours, while undergoing intermittent moderate exercise (minute ventilation of 20 L/min/m²).
223666902|NCT03395119|DIETARY_SUPPLEMENT|Fish Oil|3 (1-gram) soft-gels daily Commercially available, enteric-coated, soft-gels formulated to deliver \>60% eicosapentaenoic/docosahexaenoic acids (EPA/DHA)
223770924|NCT05914727|DIAGNOSTIC_TEST|Volatile exhaled breath sample|Collection of exhaled breath in Tedlar bag
223770925|NCT05914727|DIAGNOSTIC_TEST|Condensate sample|Collection of exhaled breath condensate with EcoScreen
224249013|NCT03450057|DRUG|Daratumumab with dexamethasone|"Daratumumab:~Daratumumab was given at a dose of 16 mg/kg administered as an intravenous (IV) infusion at weekly intervals (QW) for 8 weeks, then every 2 weeks (Q2W) for an additional 16 weeks, then every 4 weeks (Q4W) thereafter. Subjects received pre-infusion medications before infusions to mitigate potential infused-related reactions (IRRs).~Dexamethasone:~Dexamethasone was administered at 40 mg (20 mg for patients \>75 years of age) orally, once daily on Days 1, 8, 15, and 22 of each 28-day treatment cycle."
224249014|NCT00573066|DRUG|Dexmedetomidine|Dosage levels: Dose Level 1: Loading dose 0.35mcg/kg and CIVI 0.25mcg/kg/hr Dose Level 2: Loading Dose of 0.7mcg/kg and CIVI 0.5mcg/kg/hr and Dose Level 3: Loading Dose 1 mcg/kg and CIVI 0.75 mcg/kg/hr.
224321862|NCT01272037|OTHER|Quality-of-Life Assessment|Ancillary studies (closed as of 12/1/12)
224321863|NCT01272037|DRUG|Systemic Chemotherapy|Given IV
224321864|NCT01272037|DRUG|Tamoxifen Citrate|Given PO
224321865|NCT03632915|DRUG|Levetiracetam|Standard of care
224321866|NCT03632915|DRUG|Lacosamide|Standard of care
224321867|NCT03632915|DRUG|Phenytoin|Standard of care
224321868|NCT03632915|DRUG|Phenobarbital|Standard of care
223666903|NCT03395119|DIETARY_SUPPLEMENT|Olive Oil|3 soft-gels daily Commercially available soft-gels containing 1 gram of USDA organic certified, cold pressed, extra virgin, olive oil
223666904|NCT03467152|DRUG|Irsenontrine|Oral hypromellose capsules.
223666905|NCT03467152|DRUG|Placebo|Oral hypromellose capsules.
223666906|NCT01075633|PROCEDURE|Immunochemical fecal occult blood test And colonoscopy if test is positive|Annual (3 rounds), without diet restriction, 1 stool sample. Positive cut-off level: 50 ng/ml.
223666907|NCT01075633|PROCEDURE|Colonoscopy with sedation|Colonoscopy with sedation
223666908|NCT00782470|BEHAVIORAL|Recombinant Factor VIII (Kogenate, BAY 14-2222)|Subjects electing to stay on the prophylactic treatment (prospective)
223666909|NCT00782470|BEHAVIORAL|Recombinant Factor VIII (Kogenate, BAY 14-2222)|Subjects electing to switch to on-demand treatment (prospective)
223666910|NCT00782470|BEHAVIORAL|Recombinant Factor VIII (Kogenate, BAY 14-2222)|Subjects remaining on-demand treatment (retrospective)
223666911|NCT01236547|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
223666912|NCT01236547|DRUG|Paclitaxel|Given IV
223666913|NCT01236547|DRUG|Pazopanib Hydrochloride|Given PO
223666914|NCT01236547|OTHER|Placebo Administration|Given PO
223666915|NCT03466593|OTHER|Prehabilitation|Prehabilitation concerning eating, smoking, drinking and physical activity
223666916|NCT03466593|OTHER|Routine care|Preoperative information
223666917|NCT03466593|OTHER|Extra early mobilization|Mobilization the day of surgery
223666918|NCT03466593|OTHER|Standard mobilization|Mobilization the day after surgery
223666919|NCT00715143|DEVICE|Novation Ceramic|This treatment is the study device (which will be compared to a similar historic control device)
223666920|NCT00000144|PROCEDURE|Argon Laser Treatment|
223666921|NCT00918931|DRUG|Obatoclax Mesylate|30 mg given by vein over 3 hours on Days 1-3 of each 14-day study cycle.
223666922|NCT05099224|BEHAVIORAL|Mindfulness meditation|similar to the information included in arm/group descriptions
223666923|NCT00315757|BIOLOGICAL|Mapatumumab|10 mg/kg IV (in the vein), on day 1 of each 21-day cycle. Number of cycles: Treatment will continue for up to 17 cycles, or until disease progression or unacceptable toxicity.
223666924|NCT00315757|BIOLOGICAL|Mapatumumab|20 mg/kg IV (in the vein), on day 1 of each 21-day cycle. Number of cycles: Treatment will continue for up to 17 cycles, or until disease progression or unacceptable toxicity.
223666925|NCT00315757|DRUG|Bortezomib|1.3 mg/m\^2 IV (in the vein), twice weekly for two weeks (Days 1, 4, 8, and 11) of each 21-day cycle. Number of cycles: Treatment will continue for up to 17 cycles, or until disease progression or unacceptable toxicity.
223666926|NCT05302453|OTHER|Basic Body Awareness Therapy|Basic Body Awareness Therapy (BBAT), which is among the body-mind approaches, is also frequently used in the rehabilitation of patients with psychiatric disorders, pain, and chronic musculoskeletal system problems.
223666927|NCT00659347|DRUG|DOV 21, 947|Capsules, 25 mg, 2 capsules (1 Active/1 Placebo) BID, 2 weeks Capsules, 25 mg, 2 capsules (2 Active) BID, 2 weeks
223666928|NCT00659347|DRUG|Placebo|Capsules,25 mg,BID,6weeks
223666929|NCT00318942|DRUG|Crystalloids|Isotonic or hypertonic saline or Ringer Lactate or any other crystalloids, at the necessary dose to restore hemodynamic for all ICU stay
223666930|NCT00318942|DRUG|Colloids|Gelatines, Albumine, Starch, or any other colloids, at the necessary dose to restore hemodynamic (starch cumulative daily dose should not exceed 35/40 ml/kg), for all ICU stay
223666931|NCT00318942|DRUG|Crystalloids|Any crystalloids given for correction of hypovolemia during all ICU stay
223666932|NCT00318942|DRUG|Colloids|Any colloids given for correction of hypovolemia during all ICU stay
223666933|NCT04453943|DEVICE|Exoskeleton Walking - with or without FES|The study involves validation of computer algorithms to estimate and control walking movements. The Rifton E-Pacer motorized walker, arm crutches, parallel bars, or a conventional walker may be used in order to assist donning and doffing of the exoskeleton system, standing, and walking for all subjects, at any time during experimentation. Walking movements will be elicited by the hybrid walking platform that combines a powered exoskeleton and an FES system. The powered exoskeleton can provide joint actuation at the hip and knee joints of a participant. The FES system can stimulate the quadriceps, hamstrings muscle, glutes, and ankle muscles.
223666934|NCT04453943|DEVICE|Exoskeleton Sitting to Standing - with or without FES|The study involves validation of computer algorithms to estimate and control sitting/standing movements. The Rifton E-Pacer motorized walker, arm crutches, parallel bars, or a conventional walker may be used in order to assist donning and doffing of the exoskeleton system, standing, and walking for all subjects, at any time during experimentation. Sitting/Standing movements will be elicited by the hybrid walking platform that combines a powered exoskeleton and an FES system. The powered exoskeleton can provide joint actuation at the hip and knee joints of a participant. The FES system can stimulate the quadriceps, hamstrings muscle, glutes, and ankle muscles.
223666935|NCT05373888|DEVICE|Flexima®/Softima® stoma bags|"One piece stoma bags for enterostomates available as:~* Closed (flat and convex)~* Drainable with Roll'Up (flat and convex)~* High flow with tape outlet (flat)"
223666936|NCT00910624|DRUG|Boceprevir|Boceprevir, 200-mg capsules, 800 mg three times a day (TID) orally (PO)
223666937|NCT00910624|BIOLOGICAL|Peginterferon alfa-2b (SCH 54031)|Peginterferon alfa-2b 1.5 µg/kg/week subcutaneously (SC)
223666938|NCT00910624|DRUG|Ribavirin (SCH 18908)|Ribavirin weight-based dosing (WBD) 600 mg/day to 1400 mg/day PO divided twice daily (BID).
223666939|NCT02880085|DRUG|Local anesthetic|local injection
223666940|NCT02653703|OTHER|Topical L-menthol 40%|Naturally occurring local anaesthetic, counterirritant and TPRM8-agonist. CAS Number: 2216-51-5
223666941|NCT02653703|OTHER|Vehicle, topical ethanol 96%|Organic solvent CAS Number: 64-17-5
223666942|NCT00755209|DRUG|tranexamic acid|Loading 1 gram (\~20 mg/kg) 100cc solution infuses in 30 minutes Maintenance 1 gram (\~2.5 mg/kg/hr) 1000cc solution infuses in 8 hours
223666943|NCT03775538|DRUG|Cerebral Dopamine Neurotrophic Factor|Repeated intracerebral infusions
223666944|NCT03775538|DEVICE|Renishaw Drug Delivery System|Stereotactically implanted device
223666945|NCT02226133|DEVICE|LAAx, Inc. TigerPaw® System II|Exclusion of Left Atrial Appendage.
223666946|NCT01100957|PROCEDURE|tracheal intubation with a single use flexible videoscope|tracheal intubation with a single use flexible videoscope
223666947|NCT03005873|DRUG|TLC599 LD group|Single dose via intra-articular injection
223666948|NCT03005873|DRUG|Normal Saline|Single dose via intra-articular injection
223666949|NCT03005873|DRUG|TLC599 HD group|Single dose via intra-articular injection
223666950|NCT04622800|OTHER|Exercise, proprioceptive neuromuscular fasilition (PNF) techniques|PNF applications are defined as the autogenous inhibition, reciprocal inhibition, stress relaxation and gate control theory. Anterior elevation / posterior depression will be performed in the form of repetitive contractions using anterior depression / posterior elevation patterns. There will be 10 repetitions, with a 2-minute rest break between each technique. The treatment will continue twice a week for a total of 6 weeks.
223666951|NCT00471809|DRUG|Budesonide + Salmeterol + Azithromycin|
223666952|NCT00471809|DRUG|Budesonide + Salmeterol + Montelukast|
223666953|NCT00471809|DRUG|Budesonide + Salmeterol + Placebo|
223666954|NCT05736029|OTHER|blood, stool and tissue samples collection|blood, stool and tissue samples collection before and during the treatment, as applicable
223666955|NCT00828438|DRUG|Lorcaserin 10mg|
223666956|NCT04645277|DEVICE|Scanning with magnetic resonance imaging|Facial nerves and adjacent blood vessels are scanned using MRI in the patients with hemifacial spasm (HFS). Then multiplanar reconstruction (two dimensional), along with curved planar reconstruction and magnetic resonance virtual endoscopy (three dimensional), will be performed in the different groups of HFS.
223666957|NCT03751254|DEVICE|Stellaris Elite|The Stellaris and the Stellaris Elite platform will be used in myopic patients (axial length \> 25.0 mm) during cataract surgery
223666958|NCT05814302|DRUG|Paracetamol|Emergency physicians were free to administer paracetamol 1000 mg (P), the combination paracetamol 500 mg/ibuprofen 150 mg (PI) or Ibuprofen 600 mg (I)
223666959|NCT03243708|BEHAVIORAL|Risk calculator|Venous thromboembolism (VTE) risk calculator embedded in the admission order set with personalized recommendation for prophylaxis
223666960|NCT06219798|DIAGNOSTIC_TEST|GFR|Exit of the study due to death, dialysis, or transplantation
223666961|NCT04140227|DRUG|NOV03|100% Perfluorohexyloctane
223666962|NCT03613272|PROCEDURE|Subxiphoid approach extended thymectomy by VATS|Extended thymectomy performed through the subxiphoid-right VATS approach with double elevation of the sternum
223666963|NCT03613272|PROCEDURE|Intercostal approach extended thymectomy by VATS|Extended thymectomy performed through the traditional intercostal VATS approach
223666964|NCT00655915|OTHER|Corticosteroid Injection- 1ml of Betamethasone and 1 ml of 1% Lidocaine|Patients will receive a carpal tunnel injection of 1 mg of betamethasone and 1 mL of 1% lidocaine will be infiltrated by small gauge (ie. 25- or 27-gauge) needle via attending surgeon preference. These are routinely performed by injecting 1cm proximal to distal wrist crease just ulnar to palmaris longus tendon although multiple techniques have been described. Elicitation of median nerve symptoms during needle placement requires redirecting needle prior to injection to avoid median nerve infiltration.
223666965|NCT01713933|DEVICE|Ulthera® System|Focused ultrasound energy delivered below the surface of the skin.
223666966|NCT01610375|OTHER|Telephone Follow-up|This is a non-randomised observational study to assess the value of a symptom checklist to detect recurrence in women with endometrial cancer. Women will be telephoned using an evidence-based symptom checklist in parallel to the standard clinic-based follow-up. The researcher will call the participants 2 to 5 days prior to their scheduled clinic review dates to enquire about the presence of symptoms which may be indicative of disease recurrence. In addition, the researcher will also enquire about the participants' wellbeing and provide standard lifestyle resource on physical activity, diet and other lifestyle behaviours and supportive care when needed.
223666967|NCT05748652|DEVICE|digital CBT|An app-based intervention based on principles from cognitive behavioral therapy for anxiety.
223666968|NCT05748652|OTHER|Psychoeducation|Participants will be provided with psychoeducation which will be delivered digitally upon allocation to the psychoeducation arm.
223666969|NCT03573011|DIAGNOSTIC_TEST|[18F]PSMA-11|18F-PET imaging
223666970|NCT01471431|OTHER|spontaneous breathing trial|"The SBT is performed daily on rounds if an infant is on conventional ventilation and meets all predetermined ventilator criteria (set ventilator rate ≤30, peak inspiratory pressure (PIP) delivered on mandatory breaths ≤20 cm H2O, pressure support (PS) ≤8 cm H2O, positive end-expiratory pressure (PEEP) ≤6 cm H2O, inspired fractional oxygen (FiO2) ≤0.40).~During the SBT, the ventilator rate and pressure support are set to zero, and the infant is maintained on continuous positive airway pressure (CPAP) alone via the endotracheal tube. The trial duration is 3 minutes, unless an infant fails before the trial is complete. Failure is defined as bradycardia \<100 for \>15 seconds or oxygen saturation by pulse oximetry \<85% despite a 15% increase in FiO2. If an infant passes the SBT, they are extubated within 3 hours. If an infant fails the SBT, they remain intubated and the daily application of the SBT continues as long as the minimum ventilator criteria are met."
223666971|NCT05171452|BIOLOGICAL|Urine and stoll samples|Urine collection will be proposed to patient during consultations or medical examinations corresponding to routine care of patients with IBD at the time of prescribing a FC test. The urine sample, as for stool samples, will be collected in an ordinary universal container at any time of the day (no dietary restriction is required). Urine and stool samples should be taken during the same period (for example, the same day, or within a maximum of one week if no change in treatment)
223666972|NCT00412373|DRUG|Placebo|for 6 weeks
223666973|NCT00412373|DRUG|Paliperidone ER|(3-12mg/day in 3 mg/day increments for 6 weeks)
223666974|NCT00412373|DRUG|Paliperidone ER|(3-12mg/day in 3 mg/day increments for 6 weeks)
223666975|NCT05594615|DRUG|EDP-235|Subjects will receive EDP-235 once daily on Days 5-15
224321869|NCT03632915|DRUG|Ketamine|Standard of care
224321870|NCT03632915|DRUG|Valproic Acid|Standard of care
223666976|NCT05594615|DRUG|Midazolam|Subjects will receive midazolam once daily on Days 1 and 12
223666977|NCT05594615|DRUG|Rosuvastatin|Subjects will receive rosuvastatin once daily on Days 2 and 13
223666978|NCT05594615|DRUG|Caffeine|Subjects will receive caffeine once daily on Days 1 and 12
223666979|NCT06505720|PROCEDURE|Arthroscopic management of acute pediatric septic hip infecion|Three-portals tractionless hip arthroscopy will be used to treat acute pediatric septic hip infection
223770926|NCT06406738|OTHER|Using High Reality Simulator|Using High Reality Simulator will perform newborn first-care.
224249015|NCT00933530|DRUG|SRT2104|SRT2104 (0.03, 0.1, 0.25, 0.5, 1.0, 2.0, or 3.0 g/day) will be supplied as a powder which will be prepared by the Pharmacist/designee into a liquid suspension. The dosing vehicle is 1% (by weight) hypromellose acetate succinate in water, which is used as a suspension aid and a dispersant for the SRT2104. Test material will be administered orally, in a single dose and subsequently, once daily for seven consecutive days. A trained staff member will prepare individual solutions of test material that the subject will drink once daily in the clinic following a 10-hour (minimum) fast.
224249016|NCT00933530|DRUG|Placebo|Placebo (at the matched dosage as SRT2104) will be supplied as a powder which will be prepared by the Pharmacist/designee into a liquid suspension. Placebo will consist of titanium dioxide USP and prepared for oral administration identically to the SRT2104 investigational product. Test material will be administered orally, in a single dose and subsequently, once daily for seven consecutive days. The subjects enrolled will be blinded to treatment assignment. A trained staff member will prepare individual solutions of test material that the subject will drink once daily in the clinic following a 10-hour (minimum) fast.
224249017|NCT03584919|DRUG|doxycycline|patients received oral doxycycline 100 milgrams bid for 15 days
224249018|NCT03584919|DRUG|Cefuroxime Axetil 500Mg Tab|patients received cefuroxime axetil 500 milgrams bid for 15 days
224249019|NCT03584919|OTHER|control subjects|no intervention
224249020|NCT04574219|OTHER|Use of Facetime with child and parents during induction|Families will be able to use Facetime with their child when the child is taken to the operating room
224249021|NCT01034358|BIOLOGICAL|Human Papillomavirus Vaccine|0.5mL intramuscular for 3 doses at 0, 2, and 6 months
223666980|NCT06505720|PROCEDURE|Open debridement of acute pediatric septic hip|surgical drainage and debridement of acute septic hip in children via classic lateral approach
223666981|NCT04180384|DRUG|Oraxol|"Paclitaxel:~5β,20-Epoxy-1,2α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13- ester with (2R,3S)-N-benzoyl-3-phenylisoserine~HM30181 methanesulfonate monohydrate:~N-(2-(2-(4-(2-(6,7-Dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)ethyl)phenyl)-2H-tetrazol-5-yl)-4,5-dimethoxyphenyl)-4-oxo-4H-chromene-2-carboxamide Methanesulfonate monohydrate"
223666982|NCT00423527|DRUG|levetiracetam|Levetiracetam tablets 500 mg, total daily dose 3000 mg
223666983|NCT06257043|PROCEDURE|Transcatheter aortic valve replacement|A total of 3000 consecutive patients with aortic valve disease undergoing TAVR will be enrolled at 30-50 centers. The devices used will be all post-market transcatheter aortic valves approved for use in China. Clinical follow-up will be conducted in the periprocedural and after aortic valve implantation at 1 month, 6 months, 1 year, 2 years, 3 years, 4 years, 5 years, and 10 years
223666984|NCT00954096|DRUG|transdermal nicotine patch (7mg)|A 7mg transdermal nicotine patch will be applied to the subject's arm for an 8 hour period.
223666985|NCT03458715|DRUG|SGLT2 inhibitor (Empagliflozin 25 MG)|We randomized add SGLT2 inhibitor (Empagliflozin 25 MG) or DPP4 inhibitor (Linagliptin 5 MG) to type 2 diabetes patient poorly controlled with premix insulin therapy.
223666986|NCT03458715|DRUG|DPP4 inhibitor (Linagliptin 5 MG)|We randomized add SGLT2 inhibitor (Empagliflozin 25 MG) or DPP4 inhibitor (Linagliptin 5 MG) to type 2 diabetes patient poorly controlled with premix insulin therapy.
223666987|NCT02113800|DRUG|Everolimus (Afinitor®)|Formulation: 10 mg/day Route: oral (tablet)
223666988|NCT04110652|OTHER|pulmonary rehabilitation program|"The pulmonary rehabilitation program consisting of inspiratory muscle training, manual hyperinflation. chest wall mobilization, rib-cage compression, cough function training, postural drainage and secretion removal will be applied to patient group.~The program will be conducted by physical therapists for 30-45 minutes daily during ICU stay.~The exercise intensity will be increased gradually over the course. Each patient's performance during the exercise sessions will be recorded and reported regularly."
223666989|NCT02871882|RADIATION|Gastric Emptying test|participants eat a standardized meal labeled with radioactive markers (99mTc DTPA \[diethylenetriaminepentaacetic acid\] and In111 Chloride). They have scans taken at specific times after the meal to document the rate of gastric emptying.
224249022|NCT02473718|OTHER|Fluid minimization protocol|Fluid nonresponsive patients will have continuous infusions concentrated, maintenance fluids discontinued, and carrier fluids minimized. Diuretics and/or ultrafiltration will be utilized to maintain an even to negative fluid balance in patients demonstrating fluid non-responsiveness.
224249023|NCT02473718|DEVICE|Ultrasound|
223666990|NCT02871882|OTHER|Mixed Oral Glucose Tolerance test|Participants eat a meal containing 63g glucose in 240mL (milliliters) of skim milk, 2 scrambled eggs, 50g Canadian bacon and one slice of bread. Blood samples are taken prior to and for 6 hours after the meal at specific time points.
224249024|NCT05332002|DRUG|Four week alternating FOLFOX and FOLFIRI (sFOLFOXIRI)|"This is a Single Arm Phase II trial of q4week alternating FOLFOX and FOLFIRI (sFOLFOXIRI), with or without nivolumab, in advanced human epidermal growth factor receptor 2 (HER2) negative gastric and esophageal cancers (GEC).~The study treatment is a chemotherapy combination of either FOLFOX or FOLFIRI as below:~1. mFOLFOX6: (Oxaliplatin 85 mg/m2 IV, leucovorin 400 mg/m2, 5-FU 400 mg/m2 bolus, then 5-FU 2400 mg/m2:~2. FOLFIRI: (Irinotecan 180 mg/m2 IV, leucovorin 400 mg/m2, 5-FU 400 mg/m2 bolus, then 5-FU 2400 mg/m2~3. Nivolumab(Optional) The chemotherapy combination of FOLFOX and FOLFIRI is a FDA approved treatment for advanced bowel and gastric"
224249025|NCT00829790|DRUG|Doxycycline Monohydrate|25 mg 5mL oral dose
224249026|NCT00829790|DRUG|Doxycycline Monohydrate|25 mg 5 mL dose
224249027|NCT04740632|BEHAVIORAL|Personalized Nutritional Counseling by a multidisciplinary team|Active diet therapy, instructions on reading labels, cross-contamination, allergen-free, foods recipes
223666991|NCT02871882|DRUG|Conjugated bile acids sodium|500 mg tablets taken orally twice daily for 28 (+/- 4) days
223666992|NCT02871882|OTHER|Placebo|Placebo tablets taken orally twice daily for 28 (+/- 4) days
223666993|NCT01167387|DIETARY_SUPPLEMENT|PREOP|a carbohydrate beverage (total carbohydrates equal to 12.6g/100 mL: 2.1 g monosaccharide, 10.0 g maltodextrine; 240 mOsm/L) in dose of 800 mL
223666994|NCT01167387|OTHER|water|The control group will receive plain water with the same volume and timing of treatment.
223666995|NCT03349398|PROCEDURE|Uncut Roux-en-Y reconstruction|Uncut Roux-en-Y Reconstruction All surgical procedures will be performed by the single surgery team ,which is leaded by professor Wang Quan. Uncut Roux-en-Y construction will be used in this group.
223770927|NCT02743572|OTHER|iron sucrose-1|iron sucrose-1 group with PN of iron supplementation of 100μg/kg/d
223770928|NCT02743572|OTHER|iron sucrose-2|iron sucrose-2 group with PN of iron supplementation of 200μg/kg/d
223770929|NCT02743572|OTHER|iron sucrose-3|iron sucrose-3 group with PN of iron supplementation of 300μg/kg/d
223770930|NCT02743572|OTHER|iron sucrose-4|iron sucrose-4 group with PN of iron supplementation of 400μg/kg/d
223770931|NCT03022617|DRUG|Apremilast|
223770932|NCT05594342|DRUG|Ivabradine 7.5Mg Tab|Patients will receive ivabradine 7.5 mg twice daily via oral route after dobutamine infusion by 30 minutes.
223770933|NCT05594342|DRUG|DOBUTamine Injectable Solution|Dobutamine infusion by a dose that is titrated according to blood pressure Ranging from 5 to 20 ug/kg/minute
223770934|NCT01624727|DIETARY_SUPPLEMENT|Omega 3 acid ethyl esters|Lovaza 3.6 g daily
223770935|NCT02978690|DRUG|Spesolimab|Solution for infusion
223666996|NCT03349398|PROCEDURE|Roux-en-Y reconstruction|Roux-en-Y Reconstruction All surgical procedures will be performed by the single surgery team ,which is leaded by professor Wang Quan. Roux-en-Y construction will be used in this group.
223666997|NCT03483064|OTHER|Interferential current|interferential currents of 4,000 Hz carrier frequency, 100 Hz of AMF, for 20 minutes and with an amplitude up to the motor threshold
223666998|NCT01009840|DRUG|IV busulfan|PK-directed dosing of IV busulfan for 4 days
223770936|NCT01192594|BEHAVIORAL|Training in all modules including MAPP Recovery Model|50% of the case managers will complete all five modules: Disease state,psychopharmacology,symptom management, motivational interviewing and adherence, and the Milestones of Adjustment Post-Psychosis Recovery Model including the MAPP treatment guide.
223770937|NCT01192594|BEHAVIORAL|Training in all modules except MAPP Recovery Model|50% of the case managers in the study will complete only four training modules: Disease state, psychopharmacology, symptom management, and motivational interviewing and adherence. They will not complete the Milestones of Adjustment Post-Psychosis Recovery Model module.
223770938|NCT05053984|PROCEDURE|Percutaneous Echoguided Neuromodulation|Once the nerve is located, a needle is introduced in the vicinity of the nerve and is stimulated using an electrical current with a frequency of 10 Hz, with a pulse width of 250 µs and a tolerable intensity causing a visible muscle contraction for 1.5 minutes.
223770939|NCT01557075|DRUG|Atorvastatin (High dose statin treatment)|"Patients will be randomly assigned to the type of statins. Randomization of statin therapy will be done 1:1 to one of two different statins on the web-based program~* Atorvastatin 40 mg daily for 12 months after randomization"
223770940|NCT01557075|DRUG|Pravastatin (High dose statin treatment)|"Patients will be randomly assigned to the type of statins. Randomization of statin therapy will be done 1:1 to one of two different statins on the web-based program~Pravastatin 20mg daily for 12 months after randomization"
223770941|NCT03377348|PROCEDURE|intraoperative subconjunctival injection of triamcinolone acetonide and limited peritomy during bare scleral pterygium excision|intraoperative subconjunctival injection of triamcinolone acetonide and limited peritomy during bare scleral pterygium excision
223770942|NCT04666259|DRUG|ABL001|Asciminib will be supplied as 20 mg or 40 mg strength tablets will be administered orally in accordance with the assigned cohort.
223770943|NCT06179082|COMBINATION_PRODUCT|Botox then threads|patients in which Botox injection then threads insertion were used
223770944|NCT06179082|PROCEDURE|threads only|patients in which threads insertion only was used
224249028|NCT05365932|DEVICE|Intra auricular device (IAD)|The Intra Auricular Device (IADs) are a pair of inconspicuous, custom fit auricular prosthetic devices.The ear inserts are manufactured using computer-aided design/computer-aided manufacturing (CAD/CAM) technology and are made from a liquid, photo-reactive acrylate (EShell 300), used in hearing aid shells and otoplastics for the last 10 years. They are designed to be placed into the outer third of the ear canals, and they have a small retraction post used to facilitate removal . A red or blue dot, respectively, indicates the right and the left side. The device do not interfere with hearing or speech
223770945|NCT01211275|BIOLOGICAL|axitinib|axitinib: 5 mg BID, day 2 until day 21 of each cycle; cisplatin: 75 mg/m2 day 1, every 3 weeks; pemetrexed: 500 mg/m2 day 1, every 3 weeks.
223770946|NCT01211275|DRUG|chemotherapy|cisplatin: 75 mg/m2 day 1, every 3 weeks; pemetrexed: 500 mg/m2 day 1, every 3 weeks.
223666999|NCT01009840|DRUG|bortezomib|Single IV bortezomib at a dose of 1.3 mg/m\^2.
223770947|NCT02659332|DEVICE|TURBT|Diode laser (400μm fiber, 6-12W, laser pulse 1ms and intervals of 1 ms)
223770948|NCT04860310|PROCEDURE|Endometrial biopsy|Subjects need to collect 5ml whole blood (EDTA or heparin anticoagulant) once in the morning on an empty stomach. Endometrial tissue samples were taken during a complete 28-day menstrual cycle, a total of 6 times, and blood was taken to measure the level of gonadal hormones before each sampling.
223770949|NCT01565291|DRUG|florbetapir F 18|IV injection, 370MBq (10mCi), single dose
223770950|NCT05066620|DRUG|Chinese herbal medicine FYTF-919|Oral liquid 33ml TID (for patients who are unconscious or dysphagia, a dose of 25ml \* Q6H will be given through nasal feeding)
223667000|NCT01009840|PROCEDURE|Autologous Hematopoietic Stem Cell Transplant (HSCT)|
223667001|NCT04248959|BEHAVIORAL|Multimodal prehabilitation|"Multimodal Prehabilitation~* Aerobic exercise~  * Home-based, high-intensity interval training (HIIT), 2 days/week~ * Home-based, moderate-intensity continuous training (MICT), 2-3 days/week~* Resistance exercise~  * Home-based, moderate-intensity resistance training, 2-3 d/wk, all major muscle groups (working around tumour-related deficits), 8-10 exercises, 12-15 repetitions, resistance bands and body weight based~* Nutrition~  * Protein intake 1.2-1.5 g/kg body weight/day in compliance with European Society for Clinical Nutrition and Metabolism (ESPEN) guidelines~* Stress management~  * Daily mindfulness practice, 20 min/session, guided by audio file created at Mount Sinai Hospital"
223770951|NCT00572507|DEVICE|MonoMax®|Abdominal wall closure with ultra-longterm absorbable monofilament suture after primary median laparotomy
223770952|NCT00515827|DRUG|Raltegravir (MK-0518)|400 mg tablet taken orally twice daily
223770953|NCT00515827|DRUG|Placebo|400 mg placebo tablet taken orally twice daily
224249029|NCT00005785|DRUG|GCSF Mobilized Allogeneic PBSC Cultured w/Cytokines; Transduced w/RV|
224249030|NCT02950805|DRUG|Placebo|Subjects will receive a placebo in either period 1 or period 2 by inhalation.
224249031|NCT02950805|DRUG|AZD5634|Subjects will receive a single tentative dose of 625 μg of AZD5634 in either period 1 or period 2 by inhalation.
224249032|NCT03701594|OTHER|Yoga-based physical therapy group|All yoga-based sessions will be led by the same therapist to maximize between-session consistency. A trained researcher will also be present to provide additional cueing to subjects when required. The basic elements of the postures are similar to that of traditional physical therapy balance exercises. Cues will be provided throughout to pair appropriate breath cycles with appropriate postures consistent with a standard, able-bodied yoga program. The session will close with a 4-5 minute savasana performed in a supine or seated position pending patient physical abilities, which consists of progressive relaxation, guided meditation, and guided motor imagery.
223667002|NCT04097587|BEHAVIORAL|experimental group|This program was carried out for 50 min/week over 8 weeks to empower parents with knowledge and self-efficacy about children's screen use, and motivate them to monitor and change their children's screen behaviors. Teaching strategies included lectures, group discussions, reflection, role playing, and peer sharing (Table 1). Topics included 1) parents' and children's screen use, 2) the relationship between network equipment and children's internet use, 3) the positive and negative effects of excessive screen use on children's physical and psychological development, 4) limiting screen use at mealtimes and bedtime, 5) strategies for screen-related devices, 6) alternative activities to screen use, such as board games and outdoor activities, 7) setting a target of appropriate screen times, and 8) encouraging the signing of a contract between parents and children to limit screen time. We also provided parents with a handbook of the course content.
223667003|NCT04097587|OTHER|control group|received standard school classes and usual activities offered at the kindergarten. Briefly, kindergarten activities included daily learning activities, outdoor activities, breakfast, lunch, snacks, and nap time.
223667004|NCT05778383|DIETARY_SUPPLEMENT|Zinc Acetate|Each participant allocated in the intervention arm will be treated as Standard of Care and will be supplemented with 240mg of Zinc Acetate
223667005|NCT04661761|DIAGNOSTIC_TEST|Paraffin Pellets from Aurosan GmbH|1 to 2 minutes pre-chewing time chewing Paraffin Pellets from Aurosan GmbH, after which the amount of saliva is collected over a period of five minutes. The patient may chew the chewing gum once per second; after each minute the produced amount of saliva is spit in a cup, the whole amount measured after 5 minutes.
223667006|NCT04661761|DIAGNOSTIC_TEST|Chewing wax from the Saliva-Check Buffer from GC Europe|1 to 2 minutes pre-chewing time chewing wax from the Saliva-Check Buffer from GC Europe, after which the amount of saliva is collected over a period of five minutes. The patient may chew the chewing gum once per second; after each minute the produced amount of saliva is spit in a cup, the whole amount measured after 5 minutes.
223667007|NCT04022733|DRUG|Moderate neuromuscular block|maintaining of moderate neuromuscular block (train-of-four count 1-2) during surgery, reversal using neostigmine 50 ug/kg and glycopyrrolate 10 ug/kg
223667008|NCT04022733|DRUG|Deep neuromuscular block|maintaining of deep neuromuscular block (posttetanic count 1-2) during surgery, reversal using sugammadex 4 mg/kg based on actual body weight
223667009|NCT04371874|DRUG|Hydrochlorothiazide, Captopril, Nitrendipine, Aspirin|The participants were grouped into a control group and a TDP group. Hypertension of patients in the control group was managed with the original protocol by doctors in village clinics. Patients in the TDP group were supplied with the TDP treatment, for whom different levels of oral administration plans to patients without drugs treatment in original protocol were: G 0 and G I, nifedipine (20mg, bid) or captopril (25mg, tid), hydrochlorothiazide (12.5mg, bid) for patients who couldn't tolerate previous drugs; G II, nifedipine (20mg, bid) plus hydrochlorothiazide (12.5mg, bid), or captopril (25mg, tid) plus hydrochlorothiazide (12.5mg, bid ), triple therapy for patients whose blood pressure did not reach target BP; G III, three drugs combination. Patients with drugs treatments in the original protocol were changed to be treated with the above antihypertension medications which were uniformly supplied by the government.
223667010|NCT05009433|BEHAVIORAL|High intensity interval training program for pregnant women|"Pregnant women will participate in 8-week HIIT cycles until the day of delivery, 3 times a week, in a volume of each session of 60 minutes. The main part (15-20 min) will be conducted in a form of high intensity intervals, approx. 85-90% of maximum exercise capacity. The intervals will consist of performing exercises for 30-60 seconds, alternating with a 30-60 second rest break, in the ratio of exercise time to rest 1:2, 1:1 or 2:1, according to the individual possibilities of the participant and taking into account the training progression and stage of pregnancy. The exercise intensity will be monitored with the use of heart rate monitors, the Borg Rating of Perceived Exertion (RPE) and the Talk Test.~After birth, women will participate in 3-month HIIT cycles from the moment of achieving postpartum readiness to training until one year postpartum. Classes will be carried out stationary or online, depending on the pandemic situation and the availability of the woman."
223667011|NCT05009433|BEHAVIORAL|Moderate intensity continuous training program for pregnant women|"Pregnant women will participate in 8-week MICT cycles until the day of delivery, 3 times a week, in a volume of each session of 60 minutes. The main part (20-25 min) will be conducted in a form of moderate intensity continuous exercise, of 70-80% of the maximum exercise capacity, e.g. in the form of high- and low-impact aerobics choreography with music. The sessions will also include resistance, neuromotor, body posture and flexibility exercises (25 min), breathing exercises, relaxation and visualization of pregnancy or childbirth (10 min). The exercise intensity will be monitored with the use of heart rate monitors, the Borg Rating of Perceived Exertion (RPE) and the Talk Test.~After birth, women will participate in 3-month MICT cycles from the moment of achieving postpartum readiness to training until one year postpartum. Classes will be carried out stationary or online, depending on the pandemic situation and the availability of the woman."
223770954|NCT02482350|BEHAVIORAL|Reading Training|"Healthy subjects read moving (scrolling) text faster than static text. This type of text, also called Times Square presentation, induces a form of involuntary eye movement called optokinetic nystagmus (OKN) in the reader and, when used as part of a rehabilitation program, has been shown to improve subsequent reading performance of static text."
223770955|NCT01416012|BEHAVIORAL|Physical Therapy (standard)|This group consists of the usual physical therapy rehabilitation with a special emphasis on lower and upper limb and balance reinforcement.
224249033|NCT03701594|OTHER|Seated Rest|Subjects will engage in 1 hour of seated rest in a relaxing environment in a group of approximately 2-5 individuals. This session will occur in the same enclosed, quiet space as condition A to minimize outside noise or distraction and to reproduce environment of condition A. The lights will be dimmed, and the same light, instrumental, calming music will be played throughout to contribute to a relaxing ambiance. Subjects will be instructed to rest quietly.
223667012|NCT05009433|BEHAVIORAL|Standard obstetric care with extended education on healthy lifestyle|Pregnant women will get standard obstetric care according to the national law. They will attend educational sessions on a healthy lifestyle, physical activity in the perinatal period and selected aspects of pregnancy and motherhood. Educational classes will be conducted online in real time, at least once every two weeks, until one year postpartum.
223667013|NCT05009433|BEHAVIORAL|High intensity interval training program for nonpregnant women|"Nonpregnant women will participate in 8-week HIIT cycles for a period of 8 months, 3 times a week, in a volume of each session of 60 minutes. The main part (15-20 min) will be conducted in a form of high intensity intervals, approx. 85-90% of maximum exercise capacity. The intervals will consist of performing exercises for 30-60 seconds, alternating with a 30-60 second rest break, in the ratio of exercise time to rest 1:2, 1:1 or 2:1, according to the individual possibilities of the participant and taking into account the training progression. The exercise intensity will be monitored with the use of heart rate monitors, the Borg Rating of Perceived Exertion (RPE) and the Talk Test.~For the next 12 months of the project, women will participate in 3-month HIIT cycles. Classes will be carried out stationary or online, depending on the pandemic situation and the availability of the woman."
223667014|NCT05009433|BEHAVIORAL|Moderate intensity continuous training program for nonpregnant women|"Nonpregnant women will participate in 8-week MICT cycles for a period of 8 months, 3 times a week, in a volume of each session of 60 minutes. The main part (20-25 min) will be conducted in a form of moderate continuous intensity exercise, of 70-80% of the maximum exercise capacity, e.g. in the form of high- and low-impact aerobics choreography with music. The sessions will also include resistance, neuromotor, body posture and flexibility exercises (25 min), breathing exercises and relaxation (10 min). The exercise intensity will be monitored with the use of heart rate monitors, the Borg Rating of Perceived Exertion (RPE) and the Talk Test.~For the next 12 months of the project, women will participate in 3-month MICT cycles. Classes will be carried out stationary or online, depending on the pandemic situation and the availability of the woman."
223667015|NCT05009433|BEHAVIORAL|Standard health care with extended education on healthy lifestyle|Nonpregnant women will get standard health care according to the national law. They will attend educational sessions on a healthy lifestyle, physical activity and selected aspects of preparation to pregnancy and motherhood. Classes will be conducted online in real time, at least once every two weeks, for a period of 20 months.
223667016|NCT05313776|OTHER|Magnetic Resonance Imaging|IMR is a non-invasive imaging technology that produces three dimensional detailed anatomical images. It is often used for disease detection, diagnosis, and treatment monitoring. It is based on sophisticated technology that excites and detects the change in the direction of the rotational axis of protons found in the water that makes up living tissues.
223667017|NCT04673110|DIAGNOSTIC_TEST|Neutrophil to Lymphocyte Ratio and C-reactive protein|Zahorec et al. identified the neutrophil-lymphocyte ratio (NLR) as an inflammation marker in critical patients, defining as the absolute neutrophil count divided by the absolute lymphocyte count
224249034|NCT03701594|OTHER|Conventional Physical Therapy|"Subjects will engage in 1 hour of a conventional PT session (or treatment as usual) led by a different physical therapist than who is leading the yoga-based session to minimize bias. There will be no restrictions on what can and cannot occur during conventional PT sessions in order to accurately represent and preserve the wide range of treatments that may occur during a physical therapy session in the inpatient setting. Examples of what may occur include, but are not limited to: gait, standing balance, functional mobility, or therapeutic exercise."
224249035|NCT03501147|OTHER|Resistance training|15 minutes of resistance training during work every day
223667018|NCT02878356|BEHAVIORAL|Regular MI-training|Regular training (n= 59) the Motivational Interviewing (MI) -training methods used in the Swedish county councils and municipalities
223667019|NCT02878356|BEHAVIORAL|Regular MI-training + supervision half|Regular MI-training followed by six individual MI-supervision sessions at monthly intervals based on only the behavior counts component of MITI (n= 58)
223667020|NCT02878356|BEHAVIORAL|Regular MI-training + supervision full|Regular MI-training followed by MI-supervision based on both the behavior counts and the five global dimensions of MITI (n= 58)
223667021|NCT06059131|OTHER|KeenMind|320 mg/d (2 capsules/d) during 3 months
223667022|NCT06059131|OTHER|Placebo|320 mg/d (2 capsules/d) during 3 months
223667023|NCT01949701|BIOLOGICAL|HLA-A*0201restricted URLC10 peptides with adjuvant|Open Label, Non-Randomized, Safety/Efficacy study: patients will be vaccinated subcutaneously once a week with HLA-A\*0201restricted URLC10 peptides with adjuvant.
223667024|NCT05290376|PROCEDURE|surgical placement of long dental implants|Two interforaminal implants were placed in the canine region
223667025|NCT05290376|DEVICE|overdenture supported by RTX attachment system|Control group: Implants were loaded after three months by RTX supported overdenture study group: Implants were loaded after four weeks by RTX supported overdenture
223667026|NCT03737227|RADIATION|Cinematographic recording|Cinematographic recording during flexion and extension of the lumbar spine.
223667027|NCT04240678|OTHER|Electronic HBV Alert|Electronic HBV Alert deployed in electronic medical charts of at risk patients
224249036|NCT02246166|DRUG|Test tablet|The active tablet will be administered orally. Product administration will occur within 30mins of the baseline assessment of symptom severity
224249037|NCT02246166|OTHER|Placebo|The placebo tablet will be administered orally. Product administration will occur within 30mins of the baseline assessment of symptom severity
224249038|NCT04455139|DRUG|Topotecan|intravitreal or intra-arterial administration of topotecan
224249039|NCT04455139|DRUG|Melphalan|intravitreal or intra-arterial administration of topotecan
224249040|NCT05278221|DEVICE|Software EstimLT|Healthy volunteers will receive a single per os dose of Lacosamide (200 mg), Brivaracetam (50 mg) or placebo and then the software will be tested
224249041|NCT01526694|DRUG|Bendamustine|Bifunctional alkylating agent consisting of a purine and amino acid antagonist (a benzimidazole ring) and an alkylating nitrogen mustard moiety.
224249042|NCT01526694|DRUG|Thalidomide|Thalidomide can directly inhibit the growth and survival of myeloma cells, by oxidative damage to DNA mediated by free radicals. The drug can induce apoptosis even in drug resistant myeloma cells. Thalidomide modulates cell adhesion molecule expression, so it may interfere with the mutually stimulatory interactions between myeloma cells and the bone marrow microenvironment.
224249043|NCT01526694|DRUG|Dexamethasone|It's a corticosteroid.
224249044|NCT02140580|DEVICE|Minimally invasive surfactant therapy|Active Comparator
224249045|NCT02140580|OTHER|Continuation on CPAP|Sham Comparator
224249046|NCT02069080|DRUG|64-Cu-plerixafor|"Five subjects with CXCR4-positive tumor sample(s) will be administered an initial intravenous (IV) infusion of 64Cu-plerixafor of up to 8+0.8 mCi (0.48+0.048 rem) not to exceed 5 g of 64Cu-plerixafor at Day 0. These subjects will undergo an initial lowdose CT scan followed by 3 consecutive torso PET scans as soon as practical after the infusion, and 2 additional PET/CT scans at 4 hours +/- 1 hour and 24 hours +/- 2 hours post-infusion. Human dosimetry will be calculated based on these results, and a maximum dose will be used, not to exceed the calculated limit of a total effective dose of 5 rem, or the radiation exposure limit for each organ.~The remaining subjects with CXCR4-positive (n=15) and CXCR4-negative (n=5) tumor sample(s) will be administered 64Cu-plerixafor at the same or a newly calculated dose and will undergo 1 PET/CT scan between 1 and 4 hours post-infusion."
224249047|NCT02430272|DRUG|Glycopyrrolate|Intravenously administered 0.005mg/Kg of glycopyrrolate in intervention group
223667028|NCT03844711|OTHER|Transcutaneous electrical diaphragmatic stimulation (TEDS)|"* Stage I: In the first day (group 1) the parameters will be with 30 Hz frequency and the second day (group 2) will be with 80 Hz, with one-day interval between interventions. The TEDS will be applied with symmetrical biphasic pulsed current, pulse width 0.4 ms, rise time of 1 second (s), 1s lift, 2 s descent, maintaining respiratory rate of 15 rpm, intensity required to obtain visible muscle contraction, for 20 minutes or until muscle fatigue.~* Stage II and III:The TEDS will be applied with symmetrical biphasic pulsed current, the parameters will be with 30 Hz frequency, pulse width 0.4 ms, rise time of 1 second (s), 1s lift, 2 s descent, maintaining respiratory rate of 15 rpm, intensity required to obtain visible muscle contraction, for 20 minutes or until muscle fatigue."
223667029|NCT03844711|OTHER|Inspiratory Muscle Training (IMT)|\- Stage II and III: The training will start with a minimum load of 50% and will be progressed until reaching 60% of the PImax. Inspiratory muscle training will start with a minimum load of 50% and progress to 60% of the MIP. The patients will perform daily training, being two sets of 30 breaths, one in the morning and one in the afternoon.
223667030|NCT03844711|OTHER|Conventional physiotherapy|\- Stage III: It consists of ventilatory exercises, bronchial hygiene techniques, passive, active-assisted or active exercises for upper and lower limbs, and resistance exercises.
223667031|NCT03978143|DRUG|Treatment A|Single 250 mg crizotinib dose as coated microsphere 1 (cMS1) formulation will be administered on the morning of Day 1 after an overnight fast of at least 10 hours.
223667032|NCT03978143|DRUG|Treatment B|A single 250 mg crizotinib dose as coated microsphere 2 (cMS2) formulation will be administered on the morning of Day 1 after overnight fast of at least 10 hours.
223667033|NCT03978143|DRUG|Treatment C|A single 250 mg crizotinib dose as FC formulation will be administered on the morning of Day 1 after an overnight fast of at least 10 hours.
223667034|NCT03978143|DRUG|Treatment D|A single 250 mg crizotinib dose as OS will be administered on the morning of Day 1 after an overnight fast of at least 10 hours.
223667035|NCT03978143|DRUG|Treatment E|250 mg crizotinib as cMS1 formulation will be administered with high-fat, high-calorie meal after an overnight fast of at least 10 hours.
223667036|NCT03978143|DRUG|Treatment F|250 mg crizotinib as cMS2 will be administered with a high-fat, high-calorie meal after an overnight fast of at least 10 hours.
224249048|NCT06486623|DRUG|Black chokeberry extract in capsules with 18% standardization of the anthocyanins content|"Supplement group: supplement of diet - black chokeberry extract (capsules) with 18% standardization of the anthocyanins content (one capsule contained 200 mg). Each capsule also contained: chokeberry fiber, E460b magnesium salts of stearic acid (anti-caking agent), E551 silicon dioxide (anti-caking agent), hydrocypropyl methylcellulose (capsule shell) and E171 titanium dioxide (shell colour).~The producer of all capsules is MLD Biotrade in Poznan."
224249049|NCT06486623|DRUG|Chokeberry fiber in capsules|"Placebo group: placebo product - chokeberry fiber (placebo capsules, which were made from chokeberry fiber).~The producer of all capsules is MLD Biotrade in Poznan."
224249050|NCT02603003|DRUG|JinFuKang|po.tid.30ml
224249051|NCT02603003|DRUG|Cisplatin|According to the individual patient's condition
223667037|NCT03978143|DRUG|Treatment G|"40 mg esomeprazole will be administered~1 hour prior to dinner on Day -5 through Day -1. A single 250 mg crizotinib dose as cMS1 formulation will be administered on the morning of Day 1 after an overnight fast of at least 10 hours."
223667038|NCT03978143|DRUG|Treatment H|"40 mg esomeprazole will be administered~1 hour prior to dinner on Day -5 through Day -1. A single 250 mg crizotinib dose as cMS2 formulation will be administered on the morning of Day 1 after an overnight fast of at least 10 hours."
224249052|NCT02603003|DRUG|Pemetrexed|According to the individual patient's condition
224249053|NCT03992118|BEHAVIORAL|Parent coaching|Parents will be coached to implement behavioural strategies to address factors which are contributing to difficult mealtime behaviours and feeding challenges.
224249054|NCT03429959|DEVICE|SOCKNLEG|Donning and doffing success compared with the two study stockings, wearing the assigned study stocking for a day, Patient Quesationnaire on donning and doffing success and wearing comfort of each study stocking
224249055|NCT03429959|DEVICE|SIGVARIS Cotton|SIGVARIS Cotton
223667039|NCT01104376|DRUG|Efavirenz|"In phase 1 day 1 (control phase) a single 100mg dose of efavirenz will be administered.~In phase 2 (voriconazole pretreatment phase), the subject will be pretreated with voriconazole (400mg twice daily on phase 2 day 8 and then 200mg twice daily for the next consecutive 8 days. In phase 3 (efavirenz plus voriconazole phase), the subject will receive on phase 3 day 10 100mg single dose of efavirenz along with 200mg of voriconazole twice daily."
223770956|NCT01416012|BEHAVIORAL|Balance and Gait training in Individualized sessions|The NW group consists of the use of Nintendo Wii games that targeted upper and lower limbs as well as balance reinforcement.
224249056|NCT05194059|BEHAVIORAL|Home-based physical activity|Participants will follow a personalized activity pacing program
224249057|NCT05643911|PROCEDURE|HFNC|In the HFNC group, patients will receive HFNC oxygen therapy for 20 minutes.
224249058|NCT05643911|PROCEDURE|NIV|Patients will receive NIV for 20 minutes delivered with a naso-buccal or face mask according to the patient's tolerance.
224249059|NCT04927091|OTHER|Integration of HIV and PWID services|Co-location of clinical services for HIV and PWID patients
224249060|NCT03190239|DRUG|Apatinib|Apatinib 250mg qd
224249061|NCT03190239|DRUG|Pemetrexed|Pemetrexed 500mg/m2 qm
224249062|NCT04882163|DRUG|CC-220|CC-220
224249063|NCT04882163|DRUG|Polatuzumab vedotin|Polatuzumab vedotin
224249064|NCT04882163|DRUG|Rituximab|Rituximab
224249065|NCT04882163|DRUG|Tafasitamab|Tafasitamab
224249066|NCT04882163|DRUG|Gemcitabine|Gemcitabine
224249067|NCT04882163|DRUG|Cisplatin|Cisplatin
224249068|NCT04882163|DRUG|Dexamethasone|Dexamethasone
224249069|NCT04882163|DRUG|Bendamustine|Bendamustine
224249070|NCT04882163|DRUG|Lenalidomide|Lenalidomide
224249071|NCT00627016|DRUG|Dexlansoprazole|30 mg capsule, orally, once daily for 4 weeks
224249072|NCT00627016|DRUG|Placebo|1 capsule, orally, once daily for 4 weeks
224249073|NCT00974935|DRUG|Aluminum hydroxide|Single dose of recombinant staphylococcal enterotoxin B vaccine (STEBVax) in Alhydrogel adjuvant at 0.01, 0.1, 0.5, 2.5, 10 or 20 mcg intramuscular and 2 doses of 20 mcg intramuscular 21 days apart. STEBVax vaccine will be administered as a single 0.5 mL intramuscular injection into the deltoid muscle of the non-dominant arm; subjects in the 2 dose cohort will have the vaccine administered in the alternate arm.
224249074|NCT00974935|BIOLOGICAL|STEBVax vaccine|Single dose of recombinant staphylococcal enterotoxin B vaccine (STEBVax) in Alhydrogel adjuvant at 0.01, 0.1, 0.5, 2.5, 10 or 20 mcg intramuscular and 2 doses of 20 mcg intramuscular 21 days apart. STEBVax vaccine will be administered as a single 0.5 mL intramuscular injection into the deltoid muscle of the non-dominant arm; subjects in the 2 dose cohort will have the vaccine administered in the alternate arm.
224249075|NCT05443386|PROCEDURE|colorectal surgery|we have included several types of colorectal surgery procedures, in emergency conditions
224249076|NCT01534663|DRUG|Glutamine and Fish Oil Supplementation|This is a prospective, randomized double-blind, placebo-controlled study design. 38 subjects will be randomized to two groups (19 patients in each group), one taking active fish oil and glutamine supplementation and the other taking placebo for 90 days.
224249077|NCT01534663|DRUG|Placebo|This is a prospective, randomized double-blind, placebo-controlled study design. 38 subjects will be randomized to two groups (19 patients in each group), one taking active fish oil and glutamine supplementation and the other taking placebo for 90 days.
224249078|NCT02598063|DRUG|Adefovir dipivoxil|ADV will be administered orally at a dose of 10 mg QD for 72 weeks.
224249079|NCT02598063|DRUG|Lamivudine|Lamivudine tablets will be administered orally at a dose of 10 mg QD for 12 weeks.
224249080|NCT02598063|DRUG|Peginterferon alfa-2a|Peginterferon alfa-2a injection will be administered at a dose of 180 mcg QW for 48 weeks.
224249081|NCT05472350|DRUG|Breztri Aerosphere|Breztri Aerosphere is used to control and prevent symptoms (such as wheezing and shortness of breath) caused by ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema).
224249082|NCT05472350|OTHER|Placebo|placebo is 0.9% normal saline
224249083|NCT02200224|OTHER|Rapid Testing|
224249084|NCT01960920|OTHER|Filtered diesel exhaust|Mask-filtered exposure to diesel exhaust
224249085|NCT01960920|OTHER|Unfiltered diesel exhaust|Diesel Exhaust Inhalation
223667040|NCT01104376|DRUG|voriconazole|"In phase 1 day 1 (control phase) a single 100mg dose of efavirenz will be administered.~In phase 2 (voriconazole pretreatment phase), the subject will be pretreated with voriconazole (400mg twice daily on phase 2 day 8 and then 200mg twice daily for the next consecutive 8 days. In phase 3 (efavirenz plus voriconazole phase), the subject will receive on phase 3 day 10 100mg single dose of efavirenz along with 200mg of voriconazole twice daily."
223667041|NCT01503671|DRUG|Atorvastatin|Atorvastatin 40 mg/day
223667042|NCT00797966|DRUG|OPC-34712|Tablets, Oral, 1 - 4 mg OPC-34712 variable dose once daily, 14 weeks
223667043|NCT00797966|DRUG|Placebo|Tablets, Oral, 1- 4 mg OPC-34712 once daily, 14 weeks
223667044|NCT00797966|DRUG|ADT|Tablets, 10 - 225 mgs, dose once daily, 14 weeks
223667045|NCT02758379|DEVICE|Shockwave Coronary Lithoplasty System|Lithotripsy shockwaves are used to fracture calcified lesions in the coronary arteries
224249086|NCT01960920|OTHER|Clean air|No pollution and no filter mask
224249087|NCT01515592|DRUG|liraglutide|One daily subcutaneous dose for 5 weeks. Dose is weekly incremented with 5 mcg/kg
224249088|NCT01515592|DRUG|liraglutide|One daily subcutaneous dose for 5 weeks. 5 mcg/kg the first week, then 10 mcg the second week followed by 15 mcg the third week, and finally 20 mcg for 2 weeks
224249089|NCT01515592|DRUG|liraglutide|One daily subcutaneous dose for 5 weeks. 5 mcg/kg the first week, then 10 mcg the second week followed by 15 mcg for 3 weeks
224249090|NCT01515592|DRUG|placebo|Liraglutide placebo administered to subjects randomised at each dose level in the ratio of 3:1
224249091|NCT00377260|DRUG|amoxicillin-clavulanate|Augmentin ES-600™: Amoxicillin-clavulanate potassium (600/42.9 mg per 5 mL), administered at a dose of 90/6.4 mg/kg/day in 2 divided doses for 10 days with strawberry cream flavor.
224249092|NCT00377260|DRUG|Placebo|Same base formulation of the licensed product Augmentin ES-600™, with the same strawberry cream flavor.
224249093|NCT02510118|DRUG|mFOLFOX6|mFOLFOX6 regimen is a combination therapy of oxaliplatin (85 mg/m\^2) administered as a 2-hour infusion on Day 1; leucovorin (400 mg/m\^2) administered as a 2-hour infusion on Day 1; followed by a loading dose of 5-fluorouracil (5-FU; 400 mg/m\^2) IV bolus administered over approximately 2 to 4 minutes on Day 1, then 5- FU (2400 mg/m\^2) via ambulatory pump administered for a period of 46 to 48 hours.
224249094|NCT02510118|DRUG|XELOX|XELOX is a combination therapy of Oxaliplatin 130mg/ m\^2 d1 Intravenous infusion, every 3 weeks. and Capecitabine 1000mg/m\^2 bid, days 1-14, every 3 weeks
224249095|NCT02510118|DRUG|Placebo ChangTai Keli|According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of dampness stasis type of spleen deficiency will be given placebo ChangTai Keli, twice daily for 26 weeks for lower dosage.
224249096|NCT02510118|DRUG|ChangTai Keli|According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of dampness stasis type of spleen deficiency will be given placebo ChangTai Keli, twice daily for 26 weeks for lower dosage.
224249097|NCT04354493|DEVICE|Myo-electric Gaming Interface|Non-significant risk, video game controller which maps myo-electric control signals to button presses.
224321871|NCT02091518|BEHAVIORAL|MR Screening Questionnaire|All participants will complete the MR Screening Questionnaire before the MRI exam. During the MRI exam, all participants will be observed through the window from the operator console. Verbal communication will be kept with the participant throughout the exam via a speaker system.
223667046|NCT00732901|DRUG|Escitalopram|Escitalopram: once daily 10 mg on days 1-3, 20 mg on days 4-24 and 10 mg on days 25-28
223667047|NCT00732901|DRUG|Placebo|Once daily days 1-28
223667048|NCT00541190|OTHER|Technetium [Tc-99m] sulfur colloid and Indium [In-111] DTPA|Subjects perform a single nuclear medicine scan after inhaling an aerosol containing Technetium 99m sulfur colloid and Indium 111 DTPA.
223667049|NCT01486043|DRUG|Metformin|All subjects will be started on metformin 500 mg orally twice daily. The dose will be increased by 500 mg weekly as tolerated until subjects' blood glucoses are well controlled or until the patient reaches metformin 1000 mg PO BID.
223667050|NCT02601807|DEVICE|ActiPatch (active)|Active version of the ActiPatch pulsed shortwave therapy device. Emits shortwave radiofrequency pulsed energy.
223667051|NCT02601807|DEVICE|ActiPatch (placebo)|Placebo version of the ActiPatch pulsed shortwave therapy device. Emits no radiofrequency energy but otherwise appears identical to the active device.
223667052|NCT04306991|DEVICE|Auscultation using an electronic stethoscope (EKO CORE 4)|"* Auscultation using an electronic stethoscope (EKO CORE 4). Record of at least 3 cardiac cycles.~* Measurement of cardiac output using echocardiography."
223667053|NCT00972140|DRUG|Formoterol|Formoterol-HFA pMDI 12µg twice daily
223667054|NCT00972140|DRUG|Formoterol|Formoterol-DPI 12 µg twice daily
223667055|NCT03431272|DRUG|Lifitegrast|Eye drop
224249098|NCT06411847|BEHAVIORAL|Virtual appointments|This group will receive the same information as the control group with additional virtual appointments at 1 week, 2 weeks and 6 weeks after fitting a Twin Block appliance. These will be scheduled and held via BlueEye Clinic (RedZinc Services Ltd.), a web-based GDPR compliant platform that allows patients to access a remote video consultation via a link sent to the participant/parent's device. The content of these appointments will follow a template that addresses the patient's experience, difficulties faced and how to overcome these, and would incorporate use of visual aids to highlight expected changes over the duration of wear. The appointments would be held in the late afternoons (after school).
224249099|NCT00959153|DEVICE|LithoSpace Extracorporeal Shockwave Lithotripter|Shockwave therapy to break up kidney stones
224249100|NCT05839613|DIAGNOSTIC_TEST|Therapeutic Drug Monitoring (TDM) and Pharmacogenetics (PG)|Pharmacogenetics (PG) is the study of genetic differences in drug met-abolic pathways Therapeutic Drug Monitoring (TDM) is the quantification and interpre-tation of drug concentration in blood to optimize pharmacotherapy
224249101|NCT01200043|OTHER|fructose restriction diet|fruits and vegetables only
224249102|NCT03804749|DRUG|suramin sodium|The trial will start from the low dose (10mg/kg) group, followed by the middle dose (15mg/kg) and high dose (20mg/kg) groups, only after the safety in the previous dose group has been demonstrated.。
224249103|NCT03804749|OTHER|placebo|Placebo is 0.9% sodium chloride injection.
224249104|NCT01110122|DIETARY_SUPPLEMENT|Whey protein|20g, oral, dissolved in yoghurt-drink, after every training and match for 2 weeks
224249105|NCT04373096|DEVICE|current IPAC-UHN PPE|"* Fit-tested N95 mask~* Open face shield~* Double extended-cuff"
224249106|NCT04373096|DEVICE|modified IPAC-UHN PPE|"* Fit-tested N95 mask~* Hood~* Double extended-cuff gloves"
224249107|NCT01260389|BEHAVIORAL|pharmaceutical care intervention|Pharmaceutical care intervention, focused at improving inhalation technique and drug adherence in patients with Chronic Obstructive Pulmonary Disease (COPD).
224249108|NCT04476511|DRUG|Cholecalciferol|tablet containing 30.000IU cholecalciferol
224249109|NCT04480983|DEVICE|Multidetector Computerized Tomography (MDCT)|To evaluate the role of MDCT in diagnosis of non traumatic causes of acute abdomen in pediatric patients with clinical and surgical correlation.
224249110|NCT05620511|BEHAVIORAL|Mindfulness based stress reduction|Mindfulness based stress reduction v.s.Relaxation
224249111|NCT05999253|PROCEDURE|Modified thoracolumbar plane block (mTLIP)|"Modified thoracolumbar plane block (mTLIP): under ultrasound-guided, the lateral compartment of the longissimus muscle and iliocostal muscle muscles are imagined and the block needle is placed in the interfascial plane of these two muscles and local anesthesic solution is appliced.~* 20 ml of 0.25% bupivacaine will be used on each side (total of 40 ml of 0.25% bupivacaine will be used)~* to be administered only approximately 20-30 minutes before the onset of anaesthesia."
224249112|NCT05999253|PROCEDURE|Erector spinae plane block (ESP)|"Erector spinae plane block (ESP): After determining the vertebral spinal process and trapezius, rhomboid major and erector spinae muscles with ultrasound guidance, the block needle is advanced in the cranio-caudal direction with an in plane approach and local anaesthetic solution is applied to the plane between the erector spinae muscle and the transverse process when the needle rests on the transverse process.~* 20 ml of 0.25% bupivacaine will be used on each side (total of 40 ml of 0.25% bupivacaine will be used)~* to be administered only approximately 20-30 minutes before the onset of anaesthesia"
224249113|NCT00052377|BIOLOGICAL|aldesleukin|Given SC
223667056|NCT05940454|PROCEDURE|Pericapsular nerve group block|"The patient's arm is externally rotated and abducted at 45 degrees. A longitudinal linear ultrasound probe is placed between the coracoid and the humeral head. After defining the humeral head, the tendon of the subscapular muscle and the deltoid muscle on it, a 50 mm needle is inserted with the in-plane technique. When the needle passes through the deltoid muscle and touches the subscapularis tendon, a hard bone-like tissue is felt and the needle is not advanced any further. It is noteworthy that the subscapularis tendon is very rigid and resistant to needle penetration when performing the pericapsular nerve group block. The needle tip is placed between the deltoid muscle and the subscapularis tendon and a local anesthetic drug (20 ml, %0.5 bupivacain hydrochlorur) is injected"
223667057|NCT01596556|DRUG|Nicotine|both groups will be given nicotine lozenges before a VO2 test and a HTT.
224249114|NCT00052377|BIOLOGICAL|recombinant interleukin-12|Given SC
224249115|NCT00052377|OTHER|laboratory biomarker analysis|Correlative studies
224249116|NCT00295477|GENETIC|VRX496|In Step 1 of the protocol, each subject will receive up to 2 cycles of VRX496. Each treatment cycle consists of 3 infusions of VRX496.
224249117|NCT05464394|DRUG|Tranexamic Acid Injection [Cyklokapron]|A set dose of 1500 mg will be used, based on the study population with morbid obesity. It will be administered intravenous dissolved in 100 ml sodium chloride 0.9% in a time frame of 15-30 minutes, with a maximum of 100 mg/min.
224249118|NCT05464394|DRUG|Sodium chloride 0.9%|100 ml sodium chloride 0.9% will be administered in a time frame of 15-30 minutes
224249119|NCT03107091|DRUG|Terlipressin acetate continuous infusion|Low-dose continuous infusion of Terlipressin administered via ambulatory pump over 28 days
224249120|NCT02565160|PROCEDURE|Intra-articular aspiration of Joint|Procedural sampling of the joint for diagnostic purposes
224249121|NCT02565160|PROCEDURE|Joint irrigation washout|Procedural washout for treatment purposes
223667058|NCT01596556|OTHER|cigarette smoking|the smokers will smoke 2 cigarettes before a VO2 exam and a HTT.
223667059|NCT00853268|DRUG|Controlled-Release Oxycodone Hydrochloride 40 mg|Controlled-Release Oxycodone Hydrochloride 40 mg, single dose with food
223667060|NCT00853268|DRUG|OxyContin® 40 mg tablet|OxyContin® 40 mg tablet, single dose with food
223667061|NCT00732043|DIETARY_SUPPLEMENT|pomegranate extract|8 oz per day, 48 months
223667062|NCT00732043|DIETARY_SUPPLEMENT|pomegranate juice|8 oz per day, 48 months
223667063|NCT00732043|DIETARY_SUPPLEMENT|placebo|8 oz per day, 48 months
223667064|NCT00196183|PROCEDURE|trigger-guided catheter-ablation|trigger-guided ablation of paroxysmal atrial fibrillation
223667065|NCT00196183|PROCEDURE|trigger+substrate-guided catheter ablation|trigger-+substrate guided ablation of paroxysmal atrial fibrillation
223667066|NCT00118521|PROCEDURE|Foot Orthotics|
223667067|NCT00118521|PROCEDURE|Physiotherapy|
223667068|NCT02719873|OTHER|The impact of maternal obesity on pregnancy outcomes|observation of maternal obesity effect in foetal and maternal outcome
223667069|NCT02117206|DRUG|L-arginine (L-arginine Veyron)|
223667070|NCT02117206|DRUG|Nacl|
224249122|NCT02565160|PROCEDURE|Total Joint Arthroplasty|
223667071|NCT04967495|PROCEDURE|TACE combined with lenvatinib and iodion-125 seeds brachytherapy|TACE will be performed for the patients after randomization. Lenvatinib (body weight ≥ 60 kg, 12mg P.O. QD; body weight \< 60 kg, 8mg P.O. QD) will be started at 3-7 days after the first TACE and last until disease progresses, intolerable toxicity, withdrawal of informed consent, loss of follow-up, death, or other circumstances that require termination of treatment, whichever occurs first. Iodion-125 seeds will be implanted into the PVTT under CT guidance within 14 days after the first TACE. TACE and iodion-125 seeds implantation can be repeated on demand during follow-up based on the evaluation of laboratory and imaging examination.
223667072|NCT04967495|PROCEDURE|TACE combined with lenvatinib|TACE will be performed for the patients after randomization and it can be repeated on demand during follow-up based on the evaluation of laboratory and imaging examination. Lenvatinib (body weight ≥ 60 kg, 12mg P.O. QD; body weight \< 60 kg, 8mg P.O. QD) will be started at 3-7 days after the first TACE and last until disease progresses, intolerable toxicity, withdrawal of informed consent, loss of follow-up, death, or other circumstances that require termination of treatment, whichever occurs first.
223667073|NCT05202938|DIAGNOSTIC_TEST|ultrasound cardiography|Ultrasound to check heart functions and systolic ejection fraction.
223667074|NCT05202938|DIAGNOSTIC_TEST|FDG PET scan|FDG venous injection and positron emission tomography scan.
223667075|NCT05202938|DIAGNOSTIC_TEST|Palmitate PET scan|C11-Palmitate venous injection and positron emission tomography scan.
223667076|NCT05202938|DIAGNOSTIC_TEST|Acetate PET scan|C11-Acetate venous injection and positron emission tomography scan.
223667077|NCT05202938|DIAGNOSTIC_TEST|Blood sampling|Collecting 20ml of venous blood.
223667078|NCT05441878|DRUG|20% albumin|Albumin arm for resuscitation fluid
223667079|NCT05441878|DRUG|Balanced salt solution|Only Balanced salt solution will be used.
223667080|NCT00076375|DRUG|Nanocrystalline silver cream (NPI)|
223667081|NCT01221454|PROCEDURE|Allogenic bone marrow stem cells transplantation|30ml allogenic bone marrow stem cells were infused to patients using interventional method via portal vein or hepatic artery as well as conserved therapy
223667082|NCT01221454|DRUG|Conserved therapy|Oral or intravenous administration
223667083|NCT04227054|DEVICE|IMPEDE-FX Embolization Plug|Fill an abdominal aortic aneurysm (AAA) sac outside of an endovascular aneurysm repair (EVAR) stent graft
223667084|NCT06257602|PROCEDURE|Tragal graft tympanoplasty|Comparison study between Endoscopic and microscopic tympanoplasty using tragal graft
224249123|NCT02565160|PROCEDURE|Revision Joint Arthroplasty|
224249124|NCT05266313|BEHAVIORAL|Oncosexology program|Thematic workshops throughout the year
224249125|NCT03786341|DEVICE|with auxiliary illuminator|Ambulation training with laser quad-cane for 15 minutes and typical physical therapy with strengthening and balance training for 15 minutes.
223667085|NCT02349308|DEVICE|CentrosFLO Long Term Hemodialysis Catheter|
223667086|NCT02799420|DEVICE|GastroFlex UHD, Cellvizio; Mauna Kea Technologies, Paris, France|The patients who enrolled the pCLE group will undergo endoscopic biopsy using pCLE. The cancerous lesion is observed using probe-based confocal laser endomicroscopy. The biopsy was done at the most suspicious parts of the cancerous lesion.
223667087|NCT02799420|DEVICE|white light endoscopy (WLE)|The patients who enrolled this group will undergo endoscopic biopsy under standard white light endoscopy
223667088|NCT03252340|DRUG|ADSTEM Inj.|"1. ADSTEM Inj. 1.0x10\^8 mesenchymal stem cells as an intravenous infusion once in Phase I clinical trial.~2. ADSTEM Inj. 3.0x10\^8 mesenchymal stem cells as an intravenous infusion once in Phase I clinical trial."
223770957|NCT01416012|BEHAVIORAL|Kinect|The NW group consists of the use of Nintendo Wii games that targeted upper and lower limbs as well as balance reinforcement
224249126|NCT02332863|DEVICE|Back-loaded Needle (Device)|"Fiducial marker placement via a traditional 22G back-loaded needle will be performed with multiple endpoints recorded:~* total length of procedure~* how many markers are successfully deployed~* technical success~Fiducial marker location will be confirmed via fluoroscopy at time of placement and on 4D treatment planning CT ordered by the radiation oncologist for simulation."
224249127|NCT02332863|DEVICE|Preloaded Needle (Device)|"Fiducial marker placement via a novel 22G preloaded needle will be performed with multiple endpoints recorded:~* total length of procedure~* how many markers are successfully deployed~* technical success~Fiducial marker location will be confirmed via fluoroscopy at time of placement and on 4D treatment planning CT ordered by the radiation oncologist for simulation."
224249128|NCT02069535|BIOLOGICAL|AVANZ Cupressus|AVANZ Cupressus
224249129|NCT03049215|DEVICE|Lumen Apposing Metal Stent (LAMS)|The AXIOS Stent and Electrocautery-Enhanced Delivery System is an endoscopic device designed to enable the ultrasound trained interventional endoscopist to deliver a transenteric stent between the gastrointestinal tract and a pancreatic pseudocyst.
223667089|NCT03652623|DRUG|TDF/FTC|In Phase 1, a PK study will be conducted to evaluate the differential PK of TDF/FTC in a cohort of transgender youth on cs-HT by conducting a PK trial of daily TDF/FTC among transgender women taking estradiol and transgender men taking testosterone (ages 15-24 years) using video-based directly observed therapy (DOT) to insure daily TDF/FTC adherence and maximize drug exposure.
223667090|NCT01883453|DEVICE|Glucose oxidase+5%glucose|A hydrogen peroxide producing enzyme
223667091|NCT01883453|DEVICE|Saline+5%glucose|Isotonic saline + 5% glucose in a bag-on-valve nasal spray device
224249130|NCT03049215|DEVICE|LAMS plus double pigtail stent|The AXIOS Stent and Electrocautery-Enhanced Delivery System is an endoscopic device designed to enable the ultrasound trained interventional endoscopist to deliver a transenteric stent between the gastrointestinal tract and a pancreatic pseudocyst. The double pigtail stent is a routinely used plastic biliary stent.
224249131|NCT05507619|OTHER|Acupuncture with Heat Therapy + Standard Care|Biweekly sessions of acupuncture with heat therapy over 6 weeks (total 12 sessions), in addition to standard care (e.g. physiotherapy, dietetics, pain management).
223667092|NCT01217333|BEHAVIORAL|In-person CP|CP is a structured interview in which a lay health worker prompts a patient to articulate questions and concerns about decision issues in preparation for a treatment discussion with a provider. The Consultation Planner (CPer) then completes and prints out a word-processed template, paraphrasing and summarizing the patient's questions and concerns. The patient takes away the printed Consultation Plan to serve as a visual aid and agenda during the meeting with the doctor. CPers are trained to avoid providing medical advice or information. Arrangements will be made for participants who do not have transportation to the CRCMC.
223667093|NCT01217333|BEHAVIORAL|Tele-CP|Participants in the Tele-CP arm will receive CP by telephone. Arrangements will be made for participants who do not have access to a telephone.
223667094|NCT05904418|OTHER|Robot-assisted US Scan of the vertebra L1 to S1|A standardized robot-assisted US-Scan of the vertebra L1 to the S1 is executed. The two probe trajectories are generated automatically by an optical camera or RedGreenBlue-Depth (RGB-D) camera. Then the robot will scan at two mm/s, automatically following the trajectory. A 6 degrees of freedom (DoF) force sensor (Nano25, Ati Industrial Automation Inc.) was assembled at the US probe. During the scanning, it measures the interaction force and torque between the US probe and volunteers' skin to ensure volunteer safety. The US images and corresponding robot poses are recorded for the reconstruction. A previously developed algorithm is used to obtain a preliminary 3D reconstruction that will be used to adapt the scanning pattern in case of incomplete scanning.
223667095|NCT05904418|OTHER|Handheld US scan of the vertebra L1 to S1|A handheld US-Scan of the vertebra L1 to S1 is executed. An optical marker for an Atracsys Camera is mounted to the US probe to track its position. Simultaneously, the optical tracking allows for standardization of the US-Scan through navigation. The acquired US images and corresponding poses are used to reconstruct the lumbar spines and compared to the ground truth (CT scan). Handheld US scanning will be performed at around two mm/s in two scanning trajectories. The US probe orientation will be adjusted during the scanning by comparing the optical marker orientation with the initial probe orientation. This combination leads to different scanning patterns. For each pattern, the scanning procedure will be repeated three times. At least once per volunteer, each handheld scanning pattern will be performed with a higher manual speed to assess the reconstruction quality with faster scanning. A graphical user interface (GUI) will synchronize and store the data during the scanning.
223667096|NCT05904418|RADIATION|ULD CT scan of the vertebra L1 to S1|A ULD CT scan (CT, Siemens Naeotom Alpha: A-207883-62) of the lumbar spine (L1-S1) is performed at the Swiss Center for Musculoskeletal Imaging (SCMI) at Balgrist Campus, Zurich. The total duration estimate for the CT examination is 30 minutes, whereas the scan takes 15 minutes. The volunteers lie on their abdomen during this procedure to simulate the spine's position during the subsequent US examination. The vertebrae (L1-S1) in the CT Scans are manually segmented with global thresholding and the region growing tool in a standard segmentation software (Materialise Mimics, Leuven, Belgium). The 3D surface models are then exported as Standard Triangle Language (STL) files.
223667097|NCT04691414|GENETIC|NGS|next-generation sequencing on preexisting samples
223667098|NCT02299102|DEVICE|Jamshidi Manual Standard Device|Jamshidi Manual Standard Device
223667099|NCT02299102|DEVICE|OnControl Powered Ported Device|OnControl Powered Ported Device
223667100|NCT06157788|DIAGNOSTIC_TEST|functional Magnetic Resonance Imaging and clinical assessment|"* fMRI task: In the active condition, video cues were utilized (lasting 10s) depicting everyday activities that trigger shoulder apprehension. Control videos were created to match the previous content, except for the absence of cues inducing shoulder apprehension. Following each video, a visual analog scale appeared for a duration of 2.5s, and participant were asked to rate the level of perceived apprehension, using an MRI-compatible response box. The rating scale consisted of nine steps, ranging from no apprehension to high apprehension. After providing their rating, participants had a rest period during which a fixation cross was displayed visually for 17.5s. Apprehension and control videos were shown in a pseudo-randomized fashion.~* General Linear Model Analysis of Task-Related Activation~* TICA Analysis of Functional Connectivity~* White Matter TBSS of DTI Data~* Voxel-based morphometry analysis of T1 images"
223667101|NCT03415542|BEHAVIORAL|Exercise Promotion|Evidence-based techniques (goal-setting, reduced barriers) for increasing exercise behavior
223667102|NCT01712724|OTHER|combined resistance and aerobic training|For the group randomized to AT+RT, Patients will gradually be progressed from 1-2 sets and then from 10-15 repetitions and then increase resistance by 1.6-5 kg or increase the exercise band level and then reduced repetitions to 10 and repeated this process.
223667103|NCT03198325|OTHER|Stop of ART|Patients willing to stop antiretroviral therapy will stop ART.The occurrence of two consecutive HIV-1 RNA values \>50 copies/mL or the occurrence of stage B or C AIDS-defining events will be criteria for ART resumption or any serious non-AIDS clinical event at least potentially related to treatment interruption.
223667104|NCT01484886|OTHER|Red blood cell transfusion|10cc/kg weight RBC transfusion as needed according to hemoglobin level
223667105|NCT01484886|OTHER|Red blood cell transfusion|10cc/kg body weight RBC will be transfused for hemoglobin under 9.5 for biventricular repairs and under 12 for single ventricle palliations.
223667106|NCT01707238|DEVICE|etafilcon A|Participants wear a first pair of lenses for two weeks and then crossover and wear an alternate second pair of lenses for two weeks.
223667107|NCT01707238|DEVICE|stenfilcon A|Participants wear a first pair of lenses for two weeks and then crossover and wear an alternate second pair of lenses for two weeks.
223667108|NCT00682578|DRUG|Dihydroartemisinin + Piperaquine (Artekin)|An adult dose consists of four doses of two tablets, given at 0, 8, 24 and 48 h. The approximate total adult dose is 6/48 mg/kg (DHA/PPQ). For children, a dose of 1.6/12.8 mg/kg is given at the same time intervals; this dosage will be obtained by dissolving the tablets in 5 ml of water.
223667109|NCT00682578|DRUG|artesunate-sulphadoxin/pyrimethamine, chloroquine|The standard treatment will be in accordance with that in Afghanistan
223667110|NCT02697149|RADIATION|nonradiation-to-endoscopist endoscopic retrograde cholangiopancreatography|All patients received magnetic resonance cholangiopancreatography before the procedure. Characteristics of lesions (e.g. common bile duct stones, stenosis) in detail was identified. During the procedure, the endoscopist was not exposed to radiation. If fluoroscopy was needed, after contrast injection (sometimes not necessary), the endoscopist went outside of the operation room and observed the X-ray image by remote control of the fluoroscopy machine.
223667111|NCT02697149|RADIATION|standard endoscopic retrograde cholangiopancreatography|Patients received standard endoscopic retrograde cholangiopancreatography. Fluoroscopy was normally used when necessary.
223770958|NCT01416012|BEHAVIORAL|Group Xbox Kinect|The NW group consists of the use of Nintendo Wii games that targeted upper and lower limbs as well as balance reinforcement
223770959|NCT00099775|DRUG|Caspofungin|
223770960|NCT02616003|DRUG|Liraglutide|Initially 1.2 mg Liraglutide as subcutaneous daily injection, boosted to 1.8 mg Liraglutide after 3 days subsequently. 1000 ml infusion of aminosteril hepa 8% from day 1 onwards. Caloric diet with 800 kcal from day 1 onwards till technical operability is achieved (about 21 days)
223770961|NCT02616003|OTHER|Aminosteril hepa 8%|Initially 1.2 mg Liraglutide as subcutaneous daily injection, boosted to 1.8 mg Liraglutide after 3 days subsequently. 1000 ml infusion of aminosteril hepa 8% from day 1 onwards. Caloric diet with 800 kcal from day 1 onwards till technical operability is achieved (about 21 days)
224249132|NCT05507619|OTHER|Standard Care|Treatment as prescribed by orthopaedic surgeon routinely (e.g. physiotherapy, dietetics, pain management)
224249133|NCT02778230|DIETARY_SUPPLEMENT|Pea Fiber|Snacks (2 baked goods) fortified with 5 g pea hull fiber
224249134|NCT02778230|DIETARY_SUPPLEMENT|Control|Snacks (2 baked goods) without fiber fortification.
223667112|NCT01991613|DIETARY_SUPPLEMENT|liquid protein supplement|The liquid protein supplement is already in use. The purpose of this study is to determine whether using the supplement earlier will lead to improved growth.
223667113|NCT01676636|DRUG|Traditional Tablet|The traditional tablets will be swallowed with liquid. Each tablet will contain 500 mg of calcium (as calcium carbonate), thus participants will be asked to take 3 per day.. Participants will be asked to take the tablets with a liquid of their choosing with a meal. Traditional tablets will function as a control in this study, as they represent what is widely available on the market in Bangladesh.
223667114|NCT01676636|DRUG|Chewable tablets|Chewable tablets are chewed in the absence of additional water. Each chewable tablet will contain 300 mg of calcium (as calcium carbonate), thus participants will be asked to take 5 per day. Participants will be asked to consume the chewable tablets with a meal.
223667115|NCT01676636|DRUG|Unflavoured Powder|The unflavoured powder with suspension agent will be tasteless and consumed by either adding it to a semi-solid food or drink of one's choosing. Appropriate foods for mixing with the powder will be at the discretion of the participants. This vehicle was selected on the basis that it would be easy to swallow, given the nausea associated with pregnancy. A similar product is Sprinkles, a multiple micronutrient powder developed at SickKids by Dr. Zlotkin.
223667116|NCT01676636|DRUG|Flavoured Powder|The flavoured powder with suspension agent will be consumed by adding it to clean water with a meal. This vehicle was also selected on the basis that it would be easy to swallow, given the nausea associated with pregnancy. Similar products include oral rehydration salts or artificial juice flavour crystals.
223770962|NCT02616003|DIETARY_SUPPLEMENT|Caloric diet with 1000 kcal|Initially 1.2 mg Liraglutide as subcutaneous daily injection, boosted to 1.8 mg Liraglutide after 3 days subsequently. 1000 ml infusion of aminosteril hepa 8% from day 1 onwards. Caloric diet with 1000 kcal from day 1 onwards till technical operability is achieved (about 21 days)
223770963|NCT06084585|DIETARY_SUPPLEMENT|Study Product A (High-dose 2X)|participants in this arm will consume 1 sachet of this product with 200ml water per time, once a day after meal, for 3 months
223770964|NCT06084585|DIETARY_SUPPLEMENT|Study Product B (Low-dose X)|participants in this arm will consume 1 sachet of this product with 200ml water per time, once a day after meal, for 3 months
223770965|NCT06084585|DIETARY_SUPPLEMENT|Placebo|participants in this arm will consume 1 sachet of this product with 200ml water per time, once a day after meal, for 3 months
223770966|NCT05494788|DRUG|CardiolRx|Pharmaceutically produced Cannabidiol
223770967|NCT05896150|PROCEDURE|Cryoanalgesia AND single-injection paravertebral block|CO2 Cryoanalgesia AND paravertebral block with Bupivacaine 0.5%
224249135|NCT01410630|DIAGNOSTIC_TEST|FLT-PET/CT|Standard of Care
223770968|NCT05896150|PROCEDURE|Single-injection paravertebral block|Paravertebral block with Bupivacaine 0.5%
223770969|NCT06372847|DEVICE|Hypoglossal nerve stimulation implant|The hypoglossal nerve stimulation (HNS) implantation and therapy will be performed according to the standard clinical practice without additional procedures. Information about the surgical procedure will be collected. HNS implant information and settings will be collected throughout the study until the last study measurement (one year follow-up PSG and DISE) for that patient. No additional measures or interventions as part of the research project will be performed during implantation or treatment with HNS.
223770970|NCT06372847|DIAGNOSTIC_TEST|Polysomnography|A PSG at one-year follow-up is part of the standard follow-up pathway in patients receiving HNS therapy. In this study, PSG data will be collected from both baseline and one-year follow-up PSGs to assess treatment effect. Additionally, PSG data will be used for non-invasive prediction of the site and pattern of collapse using a novel, validated tool developed at our research group.
224249136|NCT01410630|DIAGNOSTIC_TEST|FDG-PET/CT|Standard of Care
224249137|NCT01410630|DRUG|FLT|5 mCi IV
224249138|NCT04567186|DEVICE|Investigational senofilcon A C3 Multifocal Lens|TEST
224249139|NCT04567186|DEVICE|delefilcon A Multifocal Lens|Dailies Total 1® Multifocal Contact Lens
224249140|NCT03661047|DRUG|AMR101 (VASCEPA, icosapent ethyl)|Oral administration, 4 grams per day
223770971|NCT06372847|PROCEDURE|Drug-induced sleep endoscopy (DISE)|"Drug-induced sleep endoscopy (DISE) is the clinical standard diagnostic test to assess site, pattern and degree of upper-airway collapse in OSA. Baseline DISE is part of the standard clinical pathway for HNS eligibility.~In this study, DISE data will be collected from routine baseline DISE without any additional procedures for the patient. They will undergo an additional DISE at one-year follow-up to assess the effect of HNS-therapy on site, pattern and degree of collapse. Both DISEs will be performed according to routine clinical practice in the operating theatre. Sleep will be induced using 1.5 mg bolus injection midazolam and target-controlled propofol infusion (2.0 - 3.0 μg). A flexible fiberoptic nasopharyngoscope will be transnasally inserted. Site, pattern and degree of collapse will be assessed using a standardized scoring system. Other maneuvers, including chin-lift, the use of a simulation bite or lateral position of the head will be performed according to clinical practice."
223770972|NCT04569461|DRUG|pembrolizumab|400 mg of pembrolizumab (KEYTRUDA) will be given by IV every 6 weeks for 9 cycles, for approximately one year of study drug administration.
224249141|NCT05479630|OTHER|Transition With a Heart (TWAH)|TWAH is a transition program, especially developed for adolescents with CHD and their parents. TWAH is starting at the age of 12 years and continuing after transfer. The most vital core components include a general and individualized flowchart, adolescent-centred communication, a joined transfer consultation and an appointed transition coordinator. TWAH focuses on promoting disease knowledge, autonomy and skills development of adolescents with CHD. Interventions encompass the use of a communication-paper, autonomously talking to professionals, individualized education and skills development plan. Details can be found in De Hosson et al, 2020 (1).
224249142|NCT05652725|DIETARY_SUPPLEMENT|Clarity Active Study Product 1.1 Usage|Participants will use their Radicle Clarity Active Study Product 1.1 as directed for a period of 6 weeks.
224249143|NCT05652725|DIETARY_SUPPLEMENT|Clarity Active Study Product 2.1 Usage|Participants will use their Radicle Clarity Active Study Product 2.1 as directed for a period of 6 weeks.
223667117|NCT05575050|PROCEDURE|Oral Procedure|Interventions included 2 variants of oral hygienic procedures. One was extended of teeth brushing.
223667118|NCT03156387|PROCEDURE|Diode laser|2.8 W diode laser surgery were applied on high frenulum attachment and follow-up VAS scores were evaluated
223667119|NCT03156387|PROCEDURE|Scalpel|Scalpel surgery were performed after local anesthetic administration and VAS scores were recorded.
223667120|NCT04779788|DEVICE|I-125 seeds loaded stent (self-expanded metal stent with I-125 seeds, Micro-Tech, Nanjing, China)|An I-125 seeds loaded stent consisted of two overlapped parts: an inner normal bare stent and an outer seeds-loaded stent
223667121|NCT04779788|DEVICE|Normal stent (self-expanded metal stent without I-125 seeds, Micro-Tech, Nanjing, China)|Bare self-expanded metal stent
223770973|NCT04569461|RADIATION|Low dose prostate radiation|A single dose of 2 Gy of radiation will be given to the prostate and seminal vesicles on approximately Week 7 for Arm A and approximately 2 weeks prior to the prostatectomy for Arm B.
223770974|NCT04569461|PROCEDURE|Radical Prostatectomy|Robotic assisted laparoscopic prostatectomy (RALP) surgery will be performed at approximately Week 9 for Arm A and approximately 2 weeks after the low dose prostate radiation for Arm B. This surgery is part of the participants routine medical care.
223667122|NCT04121663|DEVICE|Total arthroscopic rotator cuff repair|The equivalence of the two devices was compared by using control and experimental instruments during the operation
223667123|NCT03287518|DIETARY_SUPPLEMENT|WAK2017|WAK2017 is a solution with following active ingredients: Aged Garlic Extract. One (1) ml IP should be taken with breakfast and one (1) ml with supper every day
223667124|NCT03287518|DIETARY_SUPPLEMENT|Placebo|One (1) ml IP should be taken with breakfast and one (1) ml with supper every day
223667125|NCT06193551|DEVICE|Ovitex LPR|Robotic assisted laparoscopic repair of hiatal hernia using permanent sutures with Ovitex mesh as reinforcement.
223667126|NCT02609867|DEVICE|Flowise Cerebral Flow Diverter|Flowise Cerebral Flow Diverter Placement
223667127|NCT05324904|DRUG|Vitamin D|"\- Vitamin D~* The aqueous solution of vitamin D3 (cholecalciferol) will be used ampoule 200,000 IU/2 ML,~* Using a 27-gauge syringe with the bevel facing upward, a maximum of 0.6 ml (60,000 IU) of vitamin D3 solution will be slowly injected into the base of the largest plantar wart (large warts \> 10 mm need multiple injections at different sites)~* Treatment sessions will be performed at 3-week intervals for a maximum of 4 sessions"
223667128|NCT05324904|DRUG|acyclovir|"-Acyclovir~* Acyclovir vial (Zovirax® vial, 250mg, ) will be diluted with 3.5 ml saline to get approximately 70 mg /ml solution.~* After sterilization of the skin, a 27-gauge syringe with the bevel facing upward will be inserted into the base of the largest plantar wart to slowly inject the solution~* Treatment sessions will be performed at 2-week intervals for maximum of 5 sessions"
223667129|NCT03300102|OTHER|Questionnaires, interviews and or tissue donation|Subjects will be asked to complete either structured questionnaires, semi-structured interviews or donate tissue. There will be some overlap, but each subject does not have to do all three interventions.
223667130|NCT00004913|DRUG|cisplatin|
223667131|NCT00004913|DRUG|docetaxel|
223667132|NCT00004913|DRUG|fluorouracil|
223770975|NCT04813770|BEHAVIORAL|Theory-based messages|COVID-19 vaccination information structured to address vaccination necessity and concerns.
223770976|NCT04813770|BEHAVIORAL|General messages|General messages about the COVID-19 virus and the vaccination programme.
223667133|NCT00004913|DRUG|leucovorin calcium|
223667134|NCT01879644|BEHAVIORAL|NF|
223667135|NCT01879644|BEHAVIORAL|SM|
223667136|NCT01879644|BEHAVIORAL|PE|
223667137|NCT01879644|BEHAVIORAL|SU|
223667138|NCT00837317|DIETARY_SUPPLEMENT|Olive Oil, SF, SF+DMP, SF+phenols|All the volunteer subjects will be administered four breakfast meals that have been prepared with four different types of oil, each of which will have been subjected to a standardised frying. The meals will be administered according to a cross-randomized Latin squares design
223667139|NCT00941434|DIETARY_SUPPLEMENT|RUTF|Children with severe malnutrition will be treated with a daily dose of RUTF till their weight for age z scores no longer fall in severe malnutrition group
223667140|NCT02931669|OTHER|Qualitative Descriptive Study|
223667141|NCT01606917|OTHER|Intensive lifestyle counseling|Both dietary advice and individualized advice on increased regular physical activity
223770977|NCT05429268|DRUG|Tafasitamab|Tafasitamab will be administered intravenously in 28-day cycles. During Cycles 1 through 3, tafasitamab will be administered weekly on Days 1, 8, 15, and 22; an additional loading dose will be administered on Cycle 1 Day 4. Starting with Cycle 4, tafasitamab will be administered on Days 1 and 15 of each cycle.
223667142|NCT05829785|DEVICE|Near-infrared spectroscopy monitor|tissue oxygen saturation monitoring combined with vascular occlusion test
223667143|NCT03506230|BEHAVIORAL|Incentives|A bonus to buy their medications if they reduce their HBA1c
223667144|NCT05952128|DRUG|Fluzoparib+ Dalpiciclib|"Drug Fluzoparib 100mg bid PO qd, administered continuously until disease progression, unacceptable toxicity or death. 28 days as a treatment cycle.~Other names: SHR-3162~Drug Dalpiciclib 100mg/125mg/150mg PO qd, administered only from day1 to day 21 every cycle until disease progression, unacceptable toxicity or death. 28 days as a treatment cycle.~Other names: SHR-6390"
223667145|NCT00913458|DRUG|etanercept|
223667146|NCT06530472|OTHER|Monitoring|At baseline, 3, 6 and 12 months, people will undergo to both a psychological and cardiological assessment.
223667147|NCT05439785|DEVICE|Dental floss/Interdental brush|Initially plaque disclosing tablets were used to disclose plaque and plaque and bleeding scores will be recoded. After mechanical plaque debrided, instructions regarding the allocated interdental device given to the patient along with motivation to continue practicing good oral hygiene. After six weeks patients were recalled for reevaluation
223667148|NCT00766753|BIOLOGICAL|Dendritic vaccine pulsed with multiple peptides|Subjects will receive four (4) injections of the vaccine into the lymph nodes. Injection is guided by ultrasonography. Subjects will receive the first cycle of vaccine in the right groin. Two weeks after the first vaccine, subjects receive the same vaccine at the left groin, followed by the 3rd and the 4th vaccines in the left and right armpits, respectively, with two-week intervals. Each injection contains 0.2cc (less than 1/20th of a teaspoon) of a saline solution containing the vaccine cell mixture.
223667149|NCT00766753|BIOLOGICAL|The first booster vaccine phase:|This phase will begin at week 13. These subjects will be treated with additional vaccinations every 4 weeks to a maximum of 5 vaccine injections and, if poly-ICLC is available from the supplier starting on the day of the first additional vaccine and twice/week for 8 injections following each additional vaccine. If poly-ICLC supply is not available from the supplier, DC vaccines only will be given in the booster phases.
223770978|NCT05429268|DRUG|Lenalidomide|Participants will self-administer lenalidomide capsules orally on Days 1-21 of each 28-day cycle, up to 12 cycles.
223770979|NCT04630431|OTHER|Best Practice|Undergo standard of care follow-up
223770980|NCT04630431|OTHER|Educational Intervention|Undergo clinical trial education via a video and educational booklet
223770981|NCT04630431|OTHER|Electronic Health Record Review|Review of medical record
224249144|NCT05652725|DIETARY_SUPPLEMENT|Clarity Active Study Product 3.1 Usage|Participants will use their Radicle Clarity Active Study Product 3.1 as directed for a period of 6 weeks.
224249145|NCT05652725|DIETARY_SUPPLEMENT|Clarity Active Study Product 4.1 Usage|Participants will use their Radicle Clarity Active Study Product 4.1 as directed for a period of 6 weeks.
223667150|NCT00766753|BIOLOGICAL|The second booster vaccine phase:|"At week 33, following the completion of 5 additional vaccines, if participants demonstrate stable disease or positive clinical response, if poly-ICLC supply is still available, participants will be offered additional DC-vaccines and poly-ICLC treatment. The second phase booster vaccines can be continued as long as the patient shows continued positive response or stable disease (both radiological and clinically) with no major adverse events, and as long as funding is available for the study. DC vaccines in this phase will be administered every 6 months+/- 2 weeks.~2). Poly-ICLC at 10µg/kg and up to 1640 µg/injection will be administered intramuscularly (i.m.) on the day of each booster DC vaccine. Poly-ICLC will be administered weekly thereafter for twice (at one week and two weeks after each vaccine) (e.g. if the previous DC vaccine was administered on a Thursday, subsequent poly-ICLC will be administered on the next two Thursdays"
223770982|NCT04630431|BEHAVIORAL|Patient Navigation|Undergo clinical trial navigation
223770983|NCT04630431|OTHER|Questionnaire Administration|Complete questionnaire
223770984|NCT05462145|DEVICE|Globe Pulsed Field System|Ablation and atrial mapping with the Globe Pulsed Field System
223770985|NCT01482260|PROCEDURE|Biopsy|Biopsy
223770986|NCT05894642|BEHAVIORAL|0|It is a case-control study, cross-sectional, so there is no intervention possible.
223770987|NCT02242357|DRUG|Micardis®|
223770988|NCT02242357|DRUG|Micardis® Plus|
223770989|NCT00292357|PROCEDURE|Application of autologous bone marrow|
224249146|NCT05652725|DIETARY_SUPPLEMENT|Clarity Active Study Product 4.2 Usage|Participants will use their Radicle Clarity Active Study Product 4.2 as directed for a period of 6 weeks.
224249147|NCT05652725|DIETARY_SUPPLEMENT|Clarity Active Study Product 4.3 Usage|Participants will use their Radicle Clarity Active Study Product 4.3 as directed for a period of 6 weeks.
224249148|NCT05652725|DIETARY_SUPPLEMENT|Placebo Control Form 1|Participants will use their Placebo Control Form 1 as directed for a period of 6 weeks.
223770990|NCT03884621|OTHER|EHP Group|The Enhanced post-discharge home-based care program (EHP) plus usual care
223770991|NCT01446731|BIOLOGICAL|mRNA transfected dendritic cell|"Autologous monocytes are matured into dendritic cells which are then transfected with mRNA from PSA, PAP, survivin and hTERT.~5x 10e6 DCs are given as intradermal injections in the groin Day 8 and Day 15 in a 3 week period repeated 4 times and thereafter Day 8 in a 3 week period until progression (no maximum duration)."
223770992|NCT01446731|DRUG|Docetaxel|Docetaxel 75 mg/m2 is given as an intravenous injection Day 1 every three weeks in a maximum of 12 cycles (1 cycle = 3 weeks).
223770993|NCT03973346|OTHER|Risk screening tool exposure|Risk screening tool is available to providers
224249149|NCT05652725|DIETARY_SUPPLEMENT|Placebo Control Form 2|Participants will use their Placebo Control Form 2 as directed for a period of 6 weeks.
224249150|NCT05652725|DIETARY_SUPPLEMENT|Placebo Control Form 3|Participants will use their Placebo Control Form 3 as directed for a period of 6 weeks.
224249151|NCT05652725|DIETARY_SUPPLEMENT|Placebo Control Form 4|Participants will use their Placebo Control Form 4 as directed for a period of 6 weeks.
224249152|NCT05652725|DIETARY_SUPPLEMENT|Placebo Control Form 5|Participants will use their Placebo Control Form 5 as directed for a period of 6 weeks.
224249153|NCT05652725|DIETARY_SUPPLEMENT|Clarity Active Study Product 5.1 Usage|Participants will use their Radicle Clarity Active Study Product 5.1 as directed for a period of 6 weeks.
223667151|NCT02045030|DRUG|aflibercept + FOLFIRI|Aflibercept (Sanofi and Regeneron) targets the Vascular endothelial growth factor (VEGF) pathway that is a composite decoy receptor based on VEGFR-1 and VEGFR-2 fused to an Fc segment of IgG1. In pre-clinical assessments, aflibercept results in stronger angiogenesis inhibition than bevacizumab, exhibiting at least 100-1000 times higher affinity to the circulating VEGFs. It is postulated that in vivo, the binding of these ligands to aflibercept results in the blockade of tumor angiogenesis along with pruning of existing tumor vascular elements and reduction of VEGF-driven vascular permeability. The expected outcome is reduced growth of primary and metastatic tumors by impeding the density of tumor vasculature and diminishing the abnormal leakiness of tumor vessels that supply matrix components to the cancer.
223667152|NCT03216434|DIAGNOSTIC_TEST|MRI using DaTscan|"A standard, non-contrast-enhanced structural/anatomic brain MRI will be performed. It will be used to exclude potential subjects and controls with significant and potentially confounding structural/anatomic findings. It will also be used as an anatomic overlay with the functional DaTscan image to aid in anatomic/physiologic correlation. At the same imaging session, a brief functional MRI (not requiring the subject to perform any tasks) will also be performed."
223667153|NCT02998632|PROCEDURE|Mineralized plasmatic matrix for bone augmentation|Vertical bone augmentation of defective posterior mandibular alveolar ridge using MPM (Mineralized Plasmatic Matrix) bone graft.
223667154|NCT02998632|PROCEDURE|Autogenous bone for bone augmentation|Vertical bone augmentation of defective posterior mandibular alveolar ridge using autogenous bone graft (gold standard) covered by titanium membrane.
223667155|NCT05343533|DIETARY_SUPPLEMENT|Probiotic|After baseline or initial testing, participants will be randomly assigned in a double-blind fashion to ingest on a daily basis for 6 weeks either a placebo or a probiotic supplement. Identical follow-up measurements will then occur each visit after taking their assigned supplement. After 6 weeks of administration, the supplementation protocol will stop and a final evaluation will be completed 3 weeks later (9 weeks after initial administration) to assess any residual impact of the assigned supplement after a 3-week washout.
223667156|NCT04109508|DRUG|Oral semaglutide|Oral semaglutide current formulation and oral semaglutide new formulation, each in 3 different strengths, administered once daily during 6 treatment periods, each lasting 12 weeks
223667157|NCT05482750|OTHER|Resistance training in the fasted state|On the first day of evaluations, the subjects will perform the basal metabolic rate (BMR) analysis, as well as familiarization with the neuromuscular tests. After the preliminary tests, the volunteers will perform the pre-intervention procedures. Assessments of body composition, muscle thickness and quality, maximum dynamic strength and maximum power will be performed. In addition, instruments related to dietary control and physical activity level will be applied. Subsequently, in a randomized manner, participants will be allocated to one of two different interventions. During the intervention (8 weeks), the adherence to the standard diet will be verified, as well as body composition, muscle thickness and quality, maximum dynamic strength and maximum power will be reassessed. After the 12 weeks of intervention, the volunteers will perform the evaluations referring to the post-intervention moment, following the same steps of the pre-intervention collections.
223667158|NCT05482750|OTHER|Resistance training in the fed state|On the first day of evaluations, the subjects will perform the basal metabolic rate (BMR) analysis, as well as familiarization with the neuromuscular tests. After the preliminary tests, the volunteers will perform the pre-intervention procedures. Assessments of body composition, muscle thickness and quality, maximum dynamic strength and maximum power will be performed. In addition, instruments related to dietary control and physical activity level will be applied. Subsequently, in a randomized manner, participants will be allocated to one of two different interventions. During the intervention (8 weeks), the adherence to the standard diet will be verified, as well as body composition, muscle thickness and quality, maximum dynamic strength and maximum power will be reassessed. After the 12 weeks of intervention, the volunteers will perform the evaluations referring to the post-intervention moment, following the same steps of the pre-intervention collections.
223667159|NCT04228159|DEVICE|Balance Tutor Biofeedback Rehabilitation System|Balance Tutor system is a unique technology which allows for several postural control ability assessments as well as reactive response training in both standing and walking using controlled perturbation in simple task or multitask performance. Together with proactive training the system allows for optimal rehabilitation outcome and recovery
223667160|NCT04228159|OTHER|Balance and strengthening exercise|exercise training programs for fall prevention including walking and balance exercises, functional tasks, strength, flexibility and endurance
223667161|NCT02720354|OTHER|[11C]-DMDPA|
223667162|NCT06126250|DEVICE|Power sonic toothbrush|Subjects will brush twice daily for 30 seconds using a fluoride toothpaste.
223667163|NCT06126250|DEVICE|Manual toothbrush|Subjects will brush twice daily for 2 minutes using a fluoride toothpaste.
223667164|NCT03554343|DIAGNOSTIC_TEST|test for SMN1 exon 7 deletion|Newborns are screened for SMN1 exon 7 deletion through standard NBS practice Positive case are promptly referred to reference centers
223770994|NCT05402995|DRUG|Irrisept (Irrigation Solution)|Irrisept Antimicrobial Wound Lavage is intended for mechanical cleansing and removal of debris, dirt and foreign materials, including microorganisms from wounds.
223667165|NCT02087267|PROCEDURE|1- or 2-level spinal fusion|1- or 2-level lumbar or lumbar-sacral spinal fusion with the icotec CF/PEEK Pedicle System in combination with the icotec CF/PEEK TLIF Cage ETurn™
223770995|NCT05402995|DRUG|Saline|Saline irrigation
223770996|NCT04413578|DEVICE|Dexcom G6|Continuous Glucose Monitor that, after applied, sends continuous glucose readings to to the patient's smartphone every 5 minutes. This allows the patients to receive more readings over a 24 hour period versus standard of care glucometer finger sticks.
223770997|NCT04413578|DEVICE|Contour NextOne|A Standard of Care Glucometer with Bluetooth capability. The patient inserts a test strip into the device, takes a finger stick and collects a small blood sample on the tip of the strip to initiate the device to detect a glucose reading.
223770998|NCT04385784|OTHER|Balance exercise program.|Multimodal exercise program that combines strength, mobility, elasticity and postural control exercises. It develops once a week for a total of 24 weeks. Each session lasts one hour and is carried out in small groups of 8 to 10 people maximum.
224249154|NCT05652725|DIETARY_SUPPLEMENT|Clarity Active Study Product 5.2 Usage|Participants will use their Radicle Clarity Active Study Product 5.2 as directed for a period of 6 weeks.
224249155|NCT04336930|DIAGNOSTIC_TEST|Pupillary pain index (PPI)|Measurement of PPI with a pupillometer
224249156|NCT00216463|DRUG|ISIS 301012 or Placebo|200 mg subcutaneous injection - 4 loading doses within the first 11 days followed by: 200 mg subcutaneous injection - every other week for 11 weeks
224249157|NCT00216463|DRUG|ISIS 301012 or Placebo|200 mg subcutaneous injection - 4 loading doses within the first 11 days followed by: 100 mg subcutaneous injection - every other week for 11 weeks
224249158|NCT00216463|DRUG|ISIS 301012 or Placebo|300 mg subcutaneous injection - every week for 13 weeks
224249159|NCT00216463|DRUG|ISIS 301012 or Placebo|400 mg subcutaneous injection - every week for 13 weeks
224249160|NCT00216463|DRUG|ISIS 301012 or Placebo|200 mg subcutaneous injection - every week for 13 weeks
224249161|NCT05542108|BEHAVIORAL|Multisensory Stimulation and Family Education Group|Bedside intervention directly with infant with trained healthcare providers and parents. Includes two parts: twice daily multisensory stimulation sessions and separate family education meetings completed with individual infant parent/s and trained operator.
223667166|NCT04617431|BEHAVIORAL|Mobile health application and social media|"The intervention involved reminding the intervention group to upload their dietary diary every day. The researchers were trained by a dietitian and provided suggestions about diet and exercise to the intervention group. LINE  is a mobile app operated by LINE Corporation. All users can use texts, images, video, and audio for contact at any time. A LINE group was created to deliver medical knowledge of diet and exercise. Each of the messages were guided by a diet manual for kidney disease (edited by Department of Dietetics, National Taiwan University Hospital Yunlin Branch). The intervention group also asked questions about CKD management, and a teleconsultation of health information was provided. A daily target of 7,500 steps was set and used to emphasize the correct concepts about exercise. Participants were inspired in the intervention group if someone achieved the target number of steps."
223667167|NCT01585519|DIETARY_SUPPLEMENT|High/ Low Epicatechin Apples/ Apple Extract/ Granules|"(Group 1) Low Apple Diet (i.e. \<1 portion per day) + 2 placebo capsules daily.~(Group 2) 2 x High Epicatechin Apples daily + 2 placebo capsules daily.~(Group 3) 2 x Low Epicatechin Apples daily + 2 placebo capsules daily.~(Group 4) Low apple diet + 2 x 4.4g of apple granules daily + 2 placebo capsules daily.~(Group 5) Low apple diet + 2 x Apple Extract Capsules daily."
223667168|NCT01335022|BEHAVIORAL|lecture|6 lectures on cardiovascular disease covering obesity, diet \& exercise, smoking cessation, coronary artery disease, hypertension, heart failure, diabetes, peripheral vascular disease, and stroke.
223667169|NCT02061319|BEHAVIORAL|Nordic Walking|Participants in the Nordic walking group will be provided with walking poles (GymstickTM Nordic Walking Poles, Gymstick International OY, Lahti, Finland) for the duration of the study. They will attend on-site exercise classes twice weekly for 12 weeks. The on-site exercise training classes will be one hour in length and include the following components: a 15 minute chair warm-up that excludes resistance exercises; 10-15 minutes of walking with Nordic walking poles for the first 3 weeks, progressing to 30 minutes of continuous walking with poles for the remaining 9 weeks; and 15 minutes of cool down exercises. Participants will be instructed to take the walking poles home and perform 200-400 minutes of Nordic walking per week for 12 weeks
223667170|NCT00169858|BIOLOGICAL|Engerix-B|10 mkg per dose; 3 doses according to 0, 1, 6 month schedule; booster doses 5, 10 or 15 years post-primary vaccination.
223667171|NCT02149849|PROCEDURE|Modified lateral positioning.|Right before surgery, the patient are posistioned in lateral position with arm elevated (not more than 90 degree from torso). In the intervention, the arm will be lowered and placed in towards the torso for patients enrolled in the experimantal arm.
223667172|NCT04469829|DRUG|Secukinumab|standard doses of secukinumab for psoriasis
223667173|NCT04469829|DRUG|Methotrexate|Methotrexate 15 mg/week
223667174|NCT01410344|DRUG|Fludarabine and Busulfan|"RIC Regimen (Flu/Bu): Fludarabine total dose: 120-180 mg/m\^2, Busulfan: ≤ 8 mg/kg PO or 6.4 mg/kg IV). Recommended regimen:~* Days -6 to -2: Flu (30 mg/m\^2/day, total dose of 150 mg/m\^2)~* Days -5 to -4: Busulfan (4mg/kg/day PO or 3.2 mg/kg IV, 130 mg/m\^2/day, total dose of 8 mg/kg PO or 6.4 mg/kg IV, or 260 mg/m\^2 IV, respectively)~Patients with a creatinine clearance of 40-70 ml/min (measured or calculated) should have a 20 percent dose reduction in Fludarabine dosage.~Busulfan will be dosed according to the recipient's ideal body weight (IBW), unless the patient weighs more than 125 percent of IBW, in which case the drug will be dosed according to the adjusted IBW."
223667175|NCT01410344|DRUG|Fludarabine and Melphalan|"RIC Regimen (Flu/Mel): Fludarabine total dose: 120-180 mg/m\^2, Melphalan total dose: less than or equal to 150 mg/m\^2. Recommended regimen:~* Days -5 to -2: Flu (30mg/m\^2/day, total dose of 120 mg/m\^2)~* Day -1: Mel (140mg/m\^2)~Patients with a creatinine clearance of 40-70 ml/min (measured or calculated) should have a 20 percent dose reduction in Fludarabine dosage."
223667176|NCT01410344|DRUG|Busulfan and Fludarabine|"MAC Regimen (Bu/Flu): Fludarabine total dose: 120-180mg/m\^2 Busulfan total dose less than or equal to 16mg/kg PO or 12.8 mg/kg IV. Recommended regimen:~* Days -5 to -2: Busulfan (4 mg/kg/day PO with Bu Css 900 plus/equal to 100 ng/mL (or per institutional standard), 3.2 mg/kg/day IV or 130 mg/m\^2/day IV; total dose of 16 mg/kg, 12.8 mg/kg or 520 mg/m\^2, respectively)~* Days -5 to -2: Flu (30 mg/m\^2/day, total dose of 120 mg/m\^2)~Patients with a creatinine clearance of 40-70 ml/min (measured or calculated) should have a 20 percent dose reduction in Fludarabine dosage.~Busulfan will be dosed according to the recipient's ideal body weight (IBW), unless the patient weighs more than 125 percent of IBW, in which case the drug will be dosed according to the adjusted IBW."
223667177|NCT01410344|DRUG|Cyclophosphamide and Total Body Irradiation|"MAC Regimen (Cy/TBI): Cyclophosphamide total dose: 120 mg/kg, Fractionated TBI total dose: 1200-1420 cGy Recommended regimen:~* Days -7 to -4: TBI (total dose of 1200-1420 cGy)~* Days -3 to -2: Cy (60 mg/kg/day, total dose of 120 mg/kg)~Cyclophosphamide will be dosed according to the recipient's ideal body weight (IBW), unless the patient weighs less than IBW, in which case the drug will be dosed according to the actual body weight."
223770999|NCT04385784|OTHER|Home-based exercise program.|Exercises based on the OTAGO program that are carried out at home without supervision. Participants are explained to carry out the program three or four times a week in a safely way.
223771000|NCT03574545|BIOLOGICAL|ianalumab|Human monoclonal antibody (mAb) of type IgG1/κ binding to B-cell activating-receptor (BAFF-R)
223771001|NCT01009099|OTHER|breathing retraining|breathing retraining using a metronome
223771002|NCT01009099|OTHER|exercise training|treadmill exercise training
224249162|NCT05542108|BEHAVIORAL|Family Education Only Group (FEG)|Bedside intervention directly with infant with trained healthcare providers and parents. Includes family education meetings completed with individual infant parent/s and trained operator.
223667178|NCT02872506|DRUG|Anti TNF|Patients are admitted to day hospital with blood test less than 7 days. In the absence of contraindications, hydrocortisone infusion 200 mg will be conducted for 15 minutes followed by anti-TNF treatment infusion over 2 hours for the first three sessions. The following infusions of anti-TNF therapy will be on the same terms without hydrocortisone, every 4 to 8 weeks, in doses of 5-10mg/kg. Adverse effect most frequently reported was URTI. The most serious adverse reactions, were a reactivation of hepatitis B, congestive heart failure, serious infection, serum hypersensitivity reactions, blood diseases, systemic lupus erythematosus / lupus-like syndrome, demyelinating disorders, hepatobiliary metabolism disorders. The QOL will be assessed by IBDQ score at the inclusion visit before the first infusion and at 6 months.
223667179|NCT02872506|PROCEDURE|ileocecal resection|The operation is performed by laparoscopy or laparotomy. Hospital stay is on average 6 days. Preparation for the intervention is sometimes required 3 weeks to 1 month before the procedure to avoid risk situations.The main risk of the intervention is the anastomotic fistula. This risk of anastomotic leakage mainly concerns malnourished patients operated within the context of abdominal sepsis (abscess). An assessment protocol of post-operative pain, every 3 hours, is now well codified in routine surgery. The QOL will be assessed by the IBDQ score before surgery and at 6 months.
223667180|NCT00386542|BIOLOGICAL|Vaxigrip® trivalent inactivated influenza vaccine|See full description elsewhere in this record.
223667181|NCT00386542|DEVICE|Intradermal spacer on Biojector® 2000 jet injector|See elsewhere in this record for full description.
223667182|NCT04649372|PROCEDURE|EndoVE|On the day of the procedure, a review of any changes which occurred since the pre-study visit will be conducted. The patient will be placed under general anaesthesia or sedated before Bleomycin will be delivered intravenously. The patient will then be treated endoscopically with the EndoVE device. The EndoVE procedure should take no longer than 30 minutes.
223667183|NCT04801264|DRUG|68Ga-PSMA|Intravenous injection of one dosage of 74-148 MBq (2-4 mCi) 68Ga-PSMA. Tracer doses of 68Ga-PSMA will be used to image lesions of adenoid cystic carcinoma by PET/CT.
223667184|NCT04801264|DRUG|1.85GBq (50 mCi) of 177Lu-EB-PSMA-617|Patients were intravenous injected with the dose about 1.85GBq (50 mCi) of 177Lu-EB-PSMA-617 every 8 weeks (±1 week) for a maximum of 3 cycles.
223667185|NCT02727543|OTHER|Medisafe|"Medisafe is a smartphone application available to download for free on any iOS or Android device. Medisafe addresses non-adherence by providing alerts to patients when it is time to take their medications. Other features include the ability to allow a Medfriend to check in if a medication is not taken, weekly reports of medication adherence, and monitoring of biometric measurements"
223667186|NCT05908006|DEVICE|Velacur|Imaging Procedures Comparison
223667187|NCT03176017|PROCEDURE|Ejaculatory sparing TUIP|The bladder neck will be incised and vaporized at the 5 or 7-o'clock position. The incision will start near the ureteral orifice and carry downward to about 0.5-1.0 cm proximal to the verumontanum
223667188|NCT03176017|PROCEDURE|Conventional TUIP|the bladder neck will be incised by Collins knife at the 5 or 7-o'clock position till the verumontanum.
223667189|NCT01529775|DEVICE|Osseotite Certain Tapered Prevail|Osseotite implant with platform switching feature
223667190|NCT01529775|DEVICE|Osseotite Certain Tapered|Osseotite implant with non-platform switching feature
223667191|NCT02149771|PROCEDURE|chemoembolization|Conventional chemoembolisation by administering Doxorubicin and Oxaliplatin mix with 5-20 mL iodised oil.Gelatine sponge was used to embolise the feeding artery of the tumour.Repeat if patients with viable lesions demonstrated by CT or MRI.
223667192|NCT02149771|DEVICE|endovascular stents implantation|Bare stents implant within portal vein.
223667193|NCT02149771|PROCEDURE|iodine-125 seed strand implantation|Iodine-125 seed strand implant within portal vein.
223667194|NCT05753579|BEHAVIORAL|Spinal Mobilization|Mobilization applications are passive movements that do not involve pushing or stimuli, applied within the range of motion or up to the physiological range of motion.
223667195|NCT05753579|BEHAVIORAL|Stabilization Exercise|Diyafragmatik solunum ile kombine edilen, pasif-aktif kas iskelet sistemi ve nöral sistemi aktive eden bir yaklaşımdır. Bu yaklaşımda derin çekirdek kaslar olarak transversus abdominis, multifudus kasları aktive edilmektedir
223667196|NCT02958683|OTHER|Chest wall motion analysis|Assessment of chest wall motion using novel technologies including: optoelectronic plethysmography (OEP), structured light plethysmography (SLP), Microsoft Kinnect
223667197|NCT02043600|BEHAVIORAL|Yoga|12-week Hatha Yoga intervention 90 minutes once a week
223667198|NCT02043600|BEHAVIORAL|Self-care|Self-care books are provided for self-directed use
223667199|NCT03096587|DEVICE|XP Endo Finisher|a flexible single use NiTi file with small diameter and no taper, changes from straight M-phase to A-phase in body temperature
223667200|NCT03096587|DEVICE|ultrasonic activated irrigation|by Satelec,Acteon, France
223667201|NCT00357760|BIOLOGICAL|VEGF Trap|Given IV
223667202|NCT01246154|OTHER|EXERCISE TRAINING|EXERCISE TRAINING
223667203|NCT02473692|OTHER|Online Migraine Treatment Optimization|"The educational videos entail a young woman (i.e., an actress) describing her experiences in managing her headaches. The informational content of the videos is organized into 7 content areas that present a wealth of information in an entertaining way:~1. Introduction to the series~2. Getting to know migraine~3. Making the most of your medical care~4. Partnering with your doctor~5. Best use of migraine medication~6. Keeping tabs on your migraine~7. Take home message (summary)"
223667204|NCT00593242|BIOLOGICAL|infusion of autologous cord blood|infants who meet study enrollment criteria for history of moderate to severe hypoxic ischemic encephalopathy in the neonatal period will receive up to 4 infusions of their own volume reduced cord blood cells. The number of doses will be determined by the amount of available cord blood cells. The dose for each infusion is 5x10e7 cells/kg
223667205|NCT00593242|OTHER|Neurodevelopmental outcomes|historical controls, no experimental intervention, standard therapies of hypoxic ischemic encephalopathy in the newborn period with autologous cord blood
224249163|NCT02924883|DRUG|Atezolizumab|Atezolizumab 1200 mg IV infusion
224249164|NCT02924883|DRUG|Trastuzumab emtansine|Trastuzumab emtansine 3.6 mg/kg IV infusion
224249165|NCT02924883|OTHER|Placebo|Placebo matched to atezolizumab
224249166|NCT04386278|DEVICE|Intervention 1|Side one: No treatment Side two: OrthoPulse Gen 2 (2RP) for one minute
224249167|NCT04386278|DEVICE|Intervention 2|Side one: OrthoPulse (approved device) Side two: OrthoPulse Gen 2 (2RP) for one minute
223667206|NCT05377697|OTHER|Dry lavender flower scent|Participants in the experimental group will be informed about the effects of lavender scent on sleep and lavender sachets will be given. They will be informed that they should put these lavender sachets in their pillows every day and sleep with a lavender sachet for the next month, and that they should not make any changes in their rooms or beds other than the lavender sachet.
223667207|NCT02802670|DRUG|[14C]-GDC-0810|Participants will receive a single 300-mg dose of GDC-0810 containing approximately 100 microcuries of \[14C\]-labeled GDC-0810 on Day 1.
223667208|NCT02299401|DRUG|Misoprostol|Women will receive three 800 mcg doses of misoprostol.
223667209|NCT02299401|DEVICE|Semi-quantitative pregnancy test|All women will be given a semi-quantitative pregnancy test (SQPT) for at-home follow-up.
223667210|NCT04136444|DRUG|Padsevonil|Padsevonil will be administered in predefined dosages.
223667211|NCT02238067|DRUG|ESA|Participants will continue to receive their ESA treatment, as per physician's discretion. The study protocol does not specify any particular ESA drug.
223667212|NCT02238067|OTHER|Satisfaction Survey Questionnaire|Each participant will be interviewed to complete treatment satisfaction questionnaire survey at baseline and at 6-month follow-up visit.
223667213|NCT00626470|PROCEDURE|Addition of TSP to DHS|All patients operated with DHS. Of these two groups. One operated with TSP and one without.
223667214|NCT01902771|BIOLOGICAL|Dendritic Cell Vaccine|Post-Leukapheresis. Subjects will receive DC Vaccine administered once weekly, via intradermal injection, for 4 weeks for a total of four vaccinations, per study protocol.
223667215|NCT01902771|BIOLOGICAL|Tumor Lysate|Post-DC Vaccine therapy. Up to 1.5 mg of Lysate of tumor per dose administered via intradermal injection at intervals defined by study protocol.
223667216|NCT01902771|OTHER|Imiquimod|Subjects will self-apply Imiquimod topically to each designated vaccine site before and after scheduled administrations of DC Vaccine or Lysate, per study protocol.
223667217|NCT01902771|PROCEDURE|Leukapheresis|Baseline, post-surgery. Subjects will undergo leukapheresis procedure during baseline, after recovery from surgery to collect peripheral blood mononuclear cells (PBMCs) from which dendritic cells will be obtained, per study protocol.
223667218|NCT01937104|DRUG|Desflurane|"Anesthesia with desflurane in both Group 1 and Group 2~\- adjust MAC to maintain BIS between 40-60"
223667219|NCT01937104|DRUG|Remifentanil|"Adjuvant continuous administration~\- adjust effect site concentration to maintain changes of vital sign below 20%"
223667220|NCT01937104|DEVICE|Ultrasonographic measurement of ONSD|Patients were placed in the supine position with their eyes closed, and a thick gel layer was applied to the closed upper eyelid. The 7.5-MHz linear probe was placed on the gel without excessive pressure and adjusted to the proper angle for displaying the entry of the optic nerve into the globe. The intensity of the ultrasound was adjusted to display optimal contrast between the retrobulbar echogenic fat tissue and the vertical hypoechoic band. An ultrasound beam was focused on the retrobulbar area (4 cm deep) using the lowest possible acoustic power that could measure ONSD. The ONSD was measured 3 mm behind the optic disc. Measurements were performed in the transverse and sagittal planes of both eyes, and the final ONSD value was calculated by averaging 4 measured values.
223667221|NCT01937104|PROCEDURE|Mechanical ventilation|After tracheal intubation, the lungs of the patients were then ventilated with oxygen in air (1:2) using a tidal volume of 8-10 mL/kg and a respiratory rate of 10-12/min, and the ventilation rate was adjusted to maintain the end-tidal carbon dioxide partial pressure between 35 and 40 mmHg and peak inspiratory pressure below 30 cmH2O.
223667222|NCT01937104|PROCEDURE|Trendelenburg position - 30 degree|Trendelenburg position - 30 degree
223667223|NCT01937104|PROCEDURE|Reverse Trendelenburg position - 30 degree|Reverse Trendelenburg position - 30 degree
223667224|NCT04531774|BEHAVIORAL|RECHARGE|"RECHARGE is an abbreviated and adapted version of Problem Management Plus (PM+), an evidence-based intervention that helps to cope with stress in times of crisis. Recharge is specifically developed for HCWs as a brief psychological intervention for adults affected by adversity emerging from stress exposure and teaches people three well-documented strategies to manage acute stress. The strategies are: a) managing stress, b) managing worry, c) meaningful activity. It includes psychoeducation, arousal reduction techniques, managing worries and problem-solving skills, behavioural activation, enhancement of meaningful activities, and relapse prevention, which are all based on the principles of cognitive-behavioural therapy.~RECHARGE is delivered online in a 1 to 1 setting between coach and participant. Trained peers (medical doctors, nurses, psychologists) act as coaches."
223667225|NCT04531774|BEHAVIORAL|Self Study|HCWs are referred to a few recommended webpages that outline well-validated, adaptive coping strategies for managing stress.
223667226|NCT04805879|BIOLOGICAL|FMT oral Capsules|Each dose of FMT capsules consists of 20 capsules. The 20 over encapsulated capsules are derived from 100 grams of stool donated by a healthy indvidual that was screened to have no mental health issues or chronic or contagious doseases. Each capsule will contain 0.67 ml of pelleted intestinal microbes. Therefore it is considered that the 20 capsules are equivalent to 100 grams of stool
223771003|NCT01833403|OTHER|Hyperinsulinemic-euglycemic clamp|"Subject will received 6,6 2H2 Glucose prior and during a 4 hr hyperinsulinemic-euglycemic clamp to characterize hepatic insulin resistance prior to bariatric surgery~\--------------------------------------------------------------------------------"
223771004|NCT04138615|DRUG|Morphine|Subjects will receive Morphine while the effects of this drug on tolerance to a hemorrhagic insult will be assessed.
224249168|NCT04386278|DEVICE|Intervention 3|Side one: OrthoPulse (approved device) Side two: OrthoPulse Gen 2 (2RP) for 5 minutes
224249169|NCT04386278|DEVICE|Intervention 4|Side one: OrthoPulse (approved device) Side two: OrthoPulse Gen 2 (2RCW) for five minutes
223771005|NCT04138615|OTHER|Placebo|Subjects will receive saline while the effects of this drug on tolerance to a hemorrhagic insult will be assessed.
224249170|NCT04386278|DEVICE|Intervention 5|Side one: OrthoPulse (approved device) Side two: OrthoPulse Gen 2 (3RB 2RL) for one minute
224249171|NCT04386278|DEVICE|Intervention 6|Side one: OrthoPulse (approved device) Side two: OrthoPulse Gen 2 (3RB 2RL) for five minutes
224249172|NCT04386278|DEVICE|Intervention 7|Side one: OrthoPulse (approved device) Side two: OrthoPulse Gen 2 (3RB 2RL) for one minute
224249173|NCT04386278|DEVICE|Intervention 8|Side one: OrthoPulse (approved device) Side two: OrthoPulse Gen 2 (3RBP) for five minutes
224249174|NCT05451446|DIETARY_SUPPLEMENT|proprietary water|They are randomized to consume a proprietary water product for five-free living days and to drink on the heat stress chamber day.
223667227|NCT04805879|BIOLOGICAL|Placebo Capsules|Placebo Capsules that will look and weigh the same as the FMT oral capsules.
223667228|NCT05510271|OTHER|White Noise|"Orhan OSMAN's song Don't Let Your Baby Cry-2 from the Kolik album was used."
223667229|NCT05510271|OTHER|Yakson Touch|In order to transfer the Ki energy to the baby, he took a deep breath and gathered the universal energy in his palms, intending the baby's well-being and healing. The researcher applied the Yakson touch by covering the abdomen and chest of the newborn with his right hand (dominant hand) while the newborn was in the supine position, and supported the baby's back and hips with his left hand.
223667230|NCT02866955|DRUG|Estramustine|140mg/4 caps/day
223667231|NCT02866955|DRUG|Tamoxifen|20mg/day
223667232|NCT03751306|PROCEDURE|Transcranial Photobiomodulation|"Photobiomodulation Rehabilitation:~Diode laser, λ infrared = 810 nm, 0.028 cm2 beam area, 100 mW power, 3.5 W / cm2 power density, 3 Joules / dot and Energy Density of 107.1 J / cm2). Each point will be radiated for 30 seconds. The regions of irradiation will be in the middle cerebral arteries (points F7 and F8 will be used as reference point according to the International System 10-20 of the electroencephalogram) and anterior cerebral artery (AFz point according to the International System 10-20 of the electroencephalogram) ."
223667233|NCT03751306|PROCEDURE|Transcranial Photobiomodulation (Placebo)|"Photobiomodulation Placebo Therapy:~The same apparatus of the transcranial group photobiomodulation and the same irradiation points will be used. However, during the procedure, with the laser off."
223667234|NCT03751306|PROCEDURE|Cardiorespiratory Rehabilitation|"Cardiorespiratory Rehabilitation:~Aerobic training on the treadmill will be reliated for 30 minutes using the support of the Rehabilitation and Physical Activity Station BrainMov® (equipment with 4 pillars condition that favors the suspension and stabilization of people with neuromuscular dysfunctions of mild to severe impairment. For monitoring, the training heart rate equation - Karvonen equation, effort perception scale - BORG, systemic arterial pressure, peripheral oxygen saturation, and patient signs and symptoms will be used. Subsequently, respiratory exercises and muscle strengthening of lower limbs, final relaxation and general guidelines will be performed for research volunteer and his / her relatives."
223667235|NCT05275361|BEHAVIORAL|Social Contact Reminder|-The social contact will remind patient about screening mammogram appointment
223667236|NCT02143050|DRUG|Dabrafenib|
223667237|NCT02143050|DRUG|Trametinib|
223667238|NCT02143050|DRUG|Metformin|
223667239|NCT04626141|DRUG|Abaloparatide|Abaloparatide will be dispensed as a 30-day supply of disposable pen injections of the standard, FDA approved dosage (80 mcg abaloparatide).
223667240|NCT04626141|DRUG|Placebo|Placebo will be dispensed as a 30-day supply of disposable pen injections.
223667241|NCT02976220|OTHER|Digital Education|Online videos, illustrations, and text materials designed to improve participants' awareness and understanding of kidney function, kidney disease, kidney failure options, peritoneal dialysis, home hemodialysis, in-center hemodialysis, kidney transplant, medical management, and treatment decision. Also includes online messaging system and discussion board designed to allow participants to message study nurse and peer mentor, as well as to engage in group discussion in an open forum and about specific scenarios.
223667242|NCT01845987|DRUG|Placebo|Placebo, as two 1-ml subcutaneous (SC) injections, at Week 0 and Week 4
223667243|NCT01845987|DRUG|CNTO 1959|CNTO 1959 200 mg, as two 1-ml subcutaneous (SC) injections, at Week 0 and Week 4
223667244|NCT00869778|BIOLOGICAL|εPA-44|subcutaneously injection of εPA-44 at week 0, 4, 8, 12, 20, 28.
223667245|NCT00869778|OTHER|Placebo|subcutaneously injection of Placebo at week 0, 4, 8, 12, 20, 28.
223667246|NCT02856152|DRUG|GDC-0276 capsule|Three 90 milligram \[mg\] capsules of GDC-0276 administered orally.
224249175|NCT05451446|OTHER|Active comparator|They are randomized to consume a carbohydrate drink for five-free living days and to drink on the heat stress chamber day.
223667247|NCT02856152|DRUG|GDC-0276 tablets|Three 90 mg GDC-0276 tablets administered orally.
223667248|NCT03661879|DRUG|NNC9204-1706|Participants will receive NNC9204-1706 subcutaneous (s.c., under the skin) injection(s) once daily (OD) for 10 weeks. They will either receive the same dose throughout the trial, or the dose will be escalated over a period of 1-3 weeks and continued for at least 7 weeks at the same dose.
223667249|NCT03661879|DRUG|Placebo (NNC9204-1706)|Participants will receive matching placebo (NNC9204-1706) s.c., injection(s) OD for 10 weeks.
223667250|NCT03642704|DRUG|Reinforced preventive ARV therapy|"If the mother is HIV-1 or HIV 1/2 infected:~* zidovudine / laminvudine (60/30 mg), ¼ cp morning and evening orally for 12 weeks.~* nevirapine: 15mg/OD if weight ≥ 2500g / 10mg/OD if weight = 2000-2499g / 2mg/kg/OD if weight \< 2000g for 12 weeks in case of HIV-1 infection. After 6 weeks, nevirapine will increase at 20mg/OD~If the mother is HIV-2 infected:~\- zidovudine / laminvudine (60/30 mg), ¼ cp morning and evening orally for 12 weeks."
224249176|NCT05451446|OTHER|Placebo|They are randomized to consume water for five-free living days and to drink on the heat stress chamber day.
224249177|NCT01437501|DRUG|Broccoli Sprout Extract Beverage|Broccoli Sprout Extract Beverage: 600 micromole glucoraphanin and 40 micromole sulforaphane dissolved in 100 mL dilute pineapple and lime juice daily for 84 days.
224249178|NCT01437501|DRUG|placebo beverage|100 mL of dilute pineapple and lime juice daily for 84 days.
223667251|NCT00411580|BIOLOGICAL|CAD106|
223667252|NCT00411580|DRUG|Placebo|
223667253|NCT02725489|BIOLOGICAL|Vigil|Vigil is made up of irradiated autologous tumor cells which have been electroporated ex vivo with the Vigil plasmid designed to suppress expression of both the TGFβ1 and TGFβ2 proteins while simultaneously expressing rhGMCSF protein.
223667254|NCT02725489|DRUG|Durvalumab|A human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody directed against programmed cell death ligand 1 (PD-L1)
223667255|NCT03997045|BEHAVIORAL|Supervised physical exercise program|Supervised physical conditioning program of two 60-minutes sessions per week during pregnancy, developed from gestational week 20 to 38. Each session consists of 25-30 minutes of cardiovascular exercise,15 minutes of strengthening exercises, 5 minutes of coordination and balance exercises and 10 minutes of pelvic floor muscles training.
224249179|NCT05506280|PROCEDURE|blood prolactin levels|The extraction technique was performed by venipuncture in 110 veins located in the antecubital area with a 21G butterfly nut with a Vacutainer Safety 111 Lok@ adapter, a 2.5x45cm latex venous compressor and a tube with separating gel 112 (yellow cap)
224249180|NCT06197529|OTHER|Homeostatic Plasticity|Anodal tDCS S1/M1
224249181|NCT06197529|DRUG|Topical alone (Capsaicin 8% Patch)|4x4 patch
223667256|NCT00574964|OTHER|Gliadel Wafer, Temodar and Radiotherapy|Given concurrently starting 10-30 days after surgery.
223667257|NCT06181045|DRUG|LY3410738|Administered orally.
223667258|NCT06181045|DRUG|Placebo|Administered orally.
223667259|NCT00129298|DRUG|Tiagabine|The tiagabine group will start receiving tiagabine 4mg in the evening of the first day on week 2. The dose will be titrated every third day, until the target dose of 32mg/day is achieved by week 5. The study medication must be titrated to 32 mg/day or to the subject's maximum tolerated dose (MTD).
223667260|NCT00603772|DRUG|Atralin (tretinoin) gel, 0.05%|Assess photoallergic reactions for tretinoin 0.05% and vehicle, measured as skin reactions following induction and challenge.
223771006|NCT04233970|BEHAVIORAL|web-based intervention programme|"The intervention will be designed as an individualized, dialogue-based system that will provide PwMS coordinated, individually tailored information based on the software platform broca®. The intervention programme will consist of three sections:~1. EBPI/decision aid (five modules plus decision aid in case of an acute relapse) provided by the broca® programme. The key element of the EBPI/decision aid is the information on glucocorticosteroids for the treatment of acute relapses.~2. A webinar led via WebEx by a trained MS nurse with questioning/chat session (approx. 60-75min).~3. A supervised chat room provided via the DMSG (https://www.dmsg.de/ms-connect). In addition, email reminders will be used to enhance involvement of participants."
223771007|NCT04233970|BEHAVIORAL|web-based information material offered via the same platform (broca®) in addition to usual care|Participants in the control group will have access to web-based information material offered via the same platform (broca®) in addition to usual care. The control group intervention will be based on material of the German Multiple Sclerosis Society (DMSG) on relapse management. The programme will accompany the participants over a period of 4 weeks and a reminder system with neutral e-mail reminders will be used to promote the use of the programme.
223771008|NCT06178172|OTHER|Remote home monitoring|After at least 48 hours of hospital admission, patients are discharged early with the use of remote home monitoring. At home, patients receive guidance for the management of pain, nutrition and pancreatitis-related complaints by a daily phone call from a nurse from the Virtual Monitoring Centre (VMC). The pancreatitis-related complaints, intake of fluids and food, pain and the use of analgesics are assessed using short questionnaires in a smartphone app. Core temperature is monitored using an ear thermometer and a wearable sensor measures heart rate, respiratory rate, posture and movement every 5 minutes. Remote home monitoring will continue for at least 4 days.
223771009|NCT03461224|RADIATION|accelerated hypofractionated RT|
223771010|NCT03461224|RADIATION|conventional fractionated RT|
223771011|NCT04890392|DRUG|PD-1 inhibitor(Tislelizumab) ,SOX(S-1+ Oxaliplatin)|S-1: 40\~60mg Bid，d1\~14, q3w. Oxaliplatin：130mg/m2，iv drip for 2h，d1, q3w. PD-1（Tislelizumab）:200mg,iv drip for at least 1h,d1,q3w. Stage I: PD1 inhibitor + SOX regimen (q3W) . Stage II: PD1 inhibitor + SOX regimen (q3W) Stage III: PD1 inhibitor + SOX regimen (q3W) . Efficacy evaluation,then followed by surgery.
223771012|NCT03012386|DRUG|Sildenafil Citrate in G allele carrier|chronic use of phosphodiesterase 5 inhibitor in G allele carrier
223771013|NCT03012386|DRUG|Sildenafil Citrate in non G allele carrier|chronic use of phosphodiesterase 5 inhibitor in Non G allele carrier
223771014|NCT03581110|DIAGNOSTIC_TEST|computed tomography|noncontrast-enhanced chest computed tomography
223771015|NCT04952194|DRUG|Stalevo|The dose of Stalevo initially ranges from (Levodopa/Carbidopa/Entacapone) 50/12.5/200 mg 3 times a day to a target dose of 100/25/200 mg 5 times a day, with an interval of 3 hours. No other anti-Parkinson's disease drugs are added.
223771016|NCT04952194|DRUG|Carbidopa and Levodopa Controlled Release Tablets|The dose of Carbidopa and Levodopa Controlled Release Tablets initially ranges from (Levodopa/Carbidopa) 50/12.5mg 3 times a day to a target dose of 100/25 mg 5 times a day, with an interval of 3 hours. No other anti-Parkinson's disease drugs are added.
223771017|NCT00481442|DRUG|Phenylephrine|
223771018|NCT04520945|BIOLOGICAL|Chondrogen|Mesenchymal stem cell-derived from umbilical cord Wharton Jelly and hyaluronic acid
223771019|NCT04520945|BIOLOGICAL|Placebo|Consist of saline and hyaluronic acid
223771020|NCT03099551|DEVICE|Group using manual toothbrush Curaprox 5460 Ultra Soft|Manual toothbrush usage with Bass technique twice a day during 2 minutes
223771021|NCT03099551|DEVICE|Group using sonic toothbrush Edel White|Sonic toothbrush usage twice a day during 2 minutes
223771022|NCT05090020|PROCEDURE|Treatment|Surgery and PAIR
224249182|NCT06197529|OTHER|Placebo Patch|4x4 patch
223667261|NCT06076278|PROCEDURE|resistance exercise|Isometrics contraction of quadriceps Supine straight leg raise Leg lifts in prone position Passive knee flexion Passive knee extension Resistance knee extension Resistance knee flexion Isometric terminal knee extension in lying and mini-squat Concentric and isometric knee extension and flexion in sitting Frequency: A total of 12 sessions, thrice a week, for 4 consecutive weeks. Time Duration: Approx. 25 to 30minutes
223667262|NCT06068920|OTHER|Distress evaluation|To evaluate the effects of psychological distress caused by living with a chronic disease such as rheumatoid arthritis.
223667263|NCT04341428|DRUG|DWP14012 20 mg|DWP14012 20 mg, tablet, orally, once daily for up to 24 weeks
223771023|NCT01841814|RADIATION|Bone densitometry.|
223771024|NCT01032135|BEHAVIORAL|Motivational Interviewing|2 sessions at week 2, potential 2 sessions at week 8 if the participant drops out.
223771025|NCT01032135|BEHAVIORAL|Telephone counseling|one telephone counseling session per week for 10 weeks.
223771026|NCT01032135|BEHAVIORAL|Cognitive Behavioral Therapy (CBT) Counseling|One CBT session per week, for 10 weeks.
223771027|NCT01032135|DRUG|medication management|Prescription for naltrexone
224249183|NCT06197529|OTHER|Homeostatic Plasticity (Sham)|sham Homeostatic Plasticity protocol over S1
224249184|NCT03095846|PROCEDURE|Cooling|Individualized cooling protocol
224249185|NCT01479738|PROCEDURE|Capitate bone grafting|Capitate bone graft transfer for PIP joint reconstruction
224249186|NCT01168557|DEVICE|EIT (Electrical Impedance Tomography)|EIT measurement; concomitant to stress echocardiography (about 45 minutes) EIT measurements (1 minute) are performed at rest, at low dobutamine stress, at peak and at relaxation
224249187|NCT04161365|PROCEDURE|Direct visual urethrotomy|Urethral stricture is treated with urethrotomy under visual control
224249188|NCT04161365|PROCEDURE|Autologous fat grafting|Autologous fat graft is gathered and injected to stricture
224249189|NCT01707420|DRUG|Gabapentin|The active comparator, Gabapentin, is a structural analog of g-aminobutyric acid which has anticonvulsant properties. This study is a prospective randomized double-blinded trial examining the effectiveness of a single dose of liquid Gabapentin given 60 minutes prior to surgery for pain management in pediatric tonsillectomy/adenoidectomy pediatric patients.
224249190|NCT01707420|DRUG|liquid placebo|Subjects randomized to the liquid placebo will receive an identical appearing liquid placebo of 0.4mL/kg.
223667264|NCT04341428|DRUG|DWP14012 20 mg placebo|DWP14012 20 mg placebo-matching tablet, orally, once daily for up to 24 weeks
223667265|NCT04341428|DRUG|Lansoprazole 15 mg|Lansoprazole 15 mg capsule, orally, once daily for up to 24 weeks
223667266|NCT04341428|DRUG|Lansoprazole 15 mg Placebo|Lansoprazole 15 mg Placebo capsule, orally, once daily for up to 24 weeks
223667267|NCT05134532|DRUG|regorafenib|Regorafenib 160 mg orally every day for 3 weeks of every 4-week cycle (i.e. 3 weeks on, 1 week off) plus best supportive care
223667268|NCT03490812|DIAGNOSTIC_TEST|PET scan|Investigational PET scan as add-on to standard-of-care scan
223667269|NCT03490812|OTHER|Retrospective data analysis|Review of pre-existing data from January 1, 2001 through December 5, 2017
223667270|NCT01962038|BEHAVIORAL|Combined Aerobic and Resistance Exercise|Gym and home based aerobic and resistance exercises
223667271|NCT01962038|BEHAVIORAL|Stretching Exercises|Gym and home based stretching exercises
223667272|NCT01962038|BEHAVIORAL|Cognitive Training|Group-based cognitive training
223667273|NCT02766842|PROCEDURE|EUS-FNB with ProCore needle|The use of the standard ProCore needle to acquire diagnostic tissue
223667274|NCT02766842|PROCEDURE|EUS-FNB with SharkCore needle|The use of new SharkCore needle to acquire diagnostic tissue
223667275|NCT02766842|DEVICE|ProCore needle|This is the standard needle used currently to procure tissue from lesions under endoscopic ultrasound guidance
223667276|NCT02766842|DEVICE|SharkCore needle|This is the new FDA approved needle for tissue procurement under endoscopic ultrasound guidance.
223667277|NCT02726308|DRUG|Dexamethasone|5 mg I.V. Dexamethasone just before induction
223667278|NCT02726308|DRUG|10 ml/kg Ringer's lactate|Intra-operative 10 ml/kg Ringer's lactate solution .
223667279|NCT02726308|DRUG|30 ml/kg Ringer's lactate|Intra-operative 30 ml/kg Ringer's lactate solution .
224249191|NCT06189274|OTHER|Anatomy-Based Electrode Array Selection|Use of pre-operative imaging to select the appropriate length electrode vs standard of care
224249192|NCT06189274|OTHER|Standard of Care Electrode Array Selection|Use of standard of care electrode which is the FLEX 28 electrode
223667280|NCT00115323|BEHAVIORAL|Problem Solving|Problem solving intervention
223667281|NCT00115323|BEHAVIORAL|Attention Control|Attention control intervention
223667282|NCT03480724|OTHER|Google Cardboard VRA|Intervention was randomized and shuffled.
223667283|NCT03480724|OTHER|Oculus Rift VRA|Intervention was randomized and shuffled.
223667284|NCT06401187|OTHER|Bar overdenture|use of bar attachments as retentive mean of denture
223667285|NCT06311318|PROCEDURE|lower eyelid massage|The massage technique was executed with the patient in a fully open-eyed state, maintaining an upward gaze. The lateral aspect of the distal phalanx of the index finger was employed, exerting pressure on the lower eyelid to bring its margin into contact with the upper eyelid margin for a duration of 10 seconds per repetition. This procedure comprised 10 repetitions per set, administered once hourly, spanning 10 hours daily. The massage instruction was provided either by the authors or plastic surgery residents.
223667286|NCT02010151|OTHER|NAD-CPR|When Dispatcher detects OHCA, short message service (SMS)about the OHCA event and information about the location of nearest AED is sent to trained laypersons within geographically accessible area.
223667287|NCT01133028|BEHAVIORAL|Behavioral contingency management|Teachers will learn to use reinforcements and response cost procedures to encourage children's display of prosocial behaviors.
223667288|NCT01133028|BEHAVIORAL|Tolerance training|Teachers will be instructed in procedures to encourage the peer group to be accepting of children with ADHD.
223667289|NCT04040491|DRUG|PD-1 blocking antibody, chidamide, lenalidomide and gemcitabine|PD-1 blocking antibody inhibits PD-1. Chidamide is an histone deacetylase inhibitor. Lenalidomide is a potent inhibitor of TNF-α. Gemcitabine is a cytosine nucleoside derivative, its main metabolite incorporates into DNA in cells and mainly acts on G1 / S phase.
223667290|NCT02804841|DIETARY_SUPPLEMENT|Cholecalciferol -Vitamin D3|
223667291|NCT02804841|OTHER|Placebo -gel capsule containing no vitamin D.|
223667292|NCT00451503|DEVICE|Middle Ear Implant|surgery
223667293|NCT03726996|DRUG|Desipramine|Study drug (desipramine) provided in tablet form to be taken daily.
223667294|NCT02411864|OTHER|different low b-values distribution|
223667295|NCT04787081|OTHER|Sleep Care Positioning Training Program GRP1|Video-based tutorial covering six nighttime postural care topic areas which contained narration and closed captioning. This 2-hour online training program was delivered in a University classroom via D2L Brightspace.
223667296|NCT04787081|OTHER|Sleep Care Positioning Training Program GRP2|Web-link based tutorial covering six nighttime postural care topic areas which contained mostly written content. This self-paced online training program was delivered in a University classroom via D2L Brightspace.
223667297|NCT03180619|DRUG|TAF|Tablet administered orally once daily
223667298|NCT00685256|OTHER|counseling intervention|subjects and parents will receive genetic counseling
223667299|NCT00685256|OTHER|educational intervention|subjects and parents will receive education re: genetic testing
223667300|NCT00685256|OTHER|survey administration|surveys will be administered to subjects and parents
224249193|NCT04277026|BEHAVIORAL|Mindful Walking|Eight weekly 60 minute mindful walking sessions involving observations of bodily sensations, experiences, and breath. Discussion of mindful walking experiences and encouragement to meet physical activity goals.
224249194|NCT06349967|DRUG|Nab-paclitaxel Combined With Cadonilimab (AK104)|Nab-paclitaxel 100mg/m2 ivgtt d1, d8, d15, q28d; Cadonilimab (AK104) 6mg/kg ivgtt d1, d15, q28d;
224249195|NCT04966455|DIETARY_SUPPLEMENT|Raisins|Daily supplementation of 50 g of rainsins for 3 months
224249196|NCT01256684|DRUG|Placebo|Placebo vaginal suppository
224249197|NCT01256684|DRUG|DHEA|Vaginal suppository containing 0.25% (3.25 mg) DHEA; daily dosing with one suppository for 12 weeks.
224249198|NCT01256684|DRUG|DHEA|Vaginal suppository containing 0.50% (6.5 mg) DHEA; daily dosing with one suppository for 12 weeks.
223667301|NCT00685256|BEHAVIORAL|psychosocial assessment and care|psychosocial assessment and counseling will be provided
223667302|NCT00685256|BEHAVIORAL|supportive care|parents and children will be provided with supportive care
223667303|NCT02743611|BIOLOGICAL|BPX-701|autologous T cells genetically modified to express the αβ TCR reacting with PRAME peptide/HLA-A2.01 (PRAME TCR) and an inducible safety switch
223667304|NCT02743611|DRUG|Rimiducid|dimerizer infusion to activate the safety switch and induce apoptosis of the BPX-701 T cells in the event of toxicity
223667305|NCT00375401|DRUG|CP-945,598 Treatment A|Arm includes CP-945,598 Treatment A plus Dietary, Physical Activity, and Weight Loss Counseling
223667306|NCT00375401|DRUG|CP-945,598 Treatment B|Arm includes CP-945,598 Treatment B plus Dietary, Physical Activity, and Weight Loss Counseling
223667307|NCT00375401|DRUG|Placebo|Arm includes Placebo plus Dietary, Physical Activity, and Weight Loss Counseling
223667308|NCT04381039|DEVICE|Insole|3D printing insole (Nylon), 3D printing insole (TPU), CNC machine insole (EVA), shoe only
223667309|NCT04520529|OTHER|Biologic Samples|"* An additional punch from lesion skin as part of a skin biopsy performed as part of routine care.~* an additional blood sample will be collected for research during a blood test performed as part of the patient's routine care.~* In patients with clinical superficial lymphadenopathy or detected by imaging, and undergoing a superficial lymph node biopsy as part of the care, a core biopsy will be dedicated to research."
223667310|NCT04732390|PROCEDURE|erector spinae block with bupivacaine|Patient will receive 20 ml 0.25% levobupivacaine into interfascial plane below erector spinae muscle at level of T5
223667311|NCT04732390|PROCEDURE|erector spinae block with bupivacaine and magnesium sulphate|Patient will receive 20ml 0.25% levobupivacaine + 0.7 mg/kg MgSo4 into interfascial plane below erector spinae muscle at level of T5.
223667312|NCT00002280|DRUG|Didanosine|
223667313|NCT02895425|OTHER|Registry (No intervention)|
223667314|NCT04653467|DRUG|GLPG4399 oral suspension|GLPG4399 for oral administration
223667315|NCT04653467|DRUG|GLPG4399 capsules|GLPG4399 for oral administration
223667316|NCT04653467|DRUG|Placebo|Placebo oral suspension
223667317|NCT00206232|DRUG|Spironolactone|Research subjects are randomized to placebo versus spironolactone 25mg daily and followed for 6 months.
223667318|NCT02480725|PROCEDURE|collect CSF (Cerebrospinal fluid) sample|collecting CSF samples for thrombin activity assay
223667319|NCT02673541|DEVICE|AXIOS™ stent|Arm 1 will undergo EUS-guided cystogastrostomy/enterostomy and placement of the AXIOS™ stent 10-15mm (saddled diameter; choice at the discretion of the treating gastroenterologist) though the tract into the collection cavity, and correct positioning of the inner flange confirmed by EUS prior to deploying within the stomach or duodenum.
224249199|NCT02175238|DRUG|BI 691751 fasted|single dose BI 691751 in fasted state
224249200|NCT02175238|DRUG|BI 691751 after high fat breakfast|single dose BI 691751 after a standardised high fat breakfast
223667320|NCT02673541|DEVICE|Double Pigtail Stents|Arm 2 will undergo EUS-guided cystogastrostomy/enterostomy and placement of multiple double pigtail stents (i.e. ≥2) through the tract into the collection cavity.
223667321|NCT02058823|DRUG|Placebo|The subjects receive 1 oral pill of placebo each morning during the second week of the two periods, so 14 pills in all.
223667322|NCT02058823|DRUG|Placebo|The subjects receive 1 oral pill of placebo each morning during the second week of the two periods, so 14 pills in all.
223771028|NCT01032135|BEHAVIORAL|Intensive OutPatient Therapy|Return to IOP, group therapy 3 times weekly for about three hours a day.
223771029|NCT05130203|BEHAVIORAL|MouvMat Exergaming|Sessions engaging with exergaming device.
223771030|NCT05130203|BEHAVIORAL|Standard Recreational Programming|Conducted by recreational therapists.
224249201|NCT04121364|DEVICE|Tetranite|Dental Adhesive for increased implant stability
224249202|NCT03586700|DRUG|Xiao zhong fang granules|Chinese medicine Xiao zhong fang was Professor Sun Chengxiang's experience formula in Massage Department of Dongzhimen Hospital. The function of the formula is to activate blood circulation and dredge collaterals, tonifying kidney and promoting dampness to soothe the liver and nourish tendons.
223667323|NCT02058823|DRUG|Valsartan|The subjects receive 1 oral pill of Valsartan each morning during the second week of the two periods, so 14 pills in all. 1 pill equal 40 mg.
223667324|NCT02058823|DRUG|Amlodipine|The subjects receive 1 oral pill of Amlodipine each morning during the second week of the two periods, so 14 pills in all. 1 pill equal 6,944 mg of amlodipine besilate with 5 mg of amlodipine.
223667325|NCT00436540|DRUG|Clobetasol Propionate 0.05% Spray|Apply to affected areas twice daily
223667326|NCT00436540|DRUG|Clobetasol Propionate 0.05% Foam|Apply to affected areas twice daily
223771031|NCT01346267|PROCEDURE|Real Acupressure Band|Acupressure wristband
223771032|NCT01346267|PROCEDURE|Placebo Acupressure Band|Sham wristband
223771033|NCT02188485|BEHAVIORAL|ENGAGE|Up to 10 sessions delivered in the home.
223771034|NCT00768729|DRUG|Sirolimus|Oral tablets or liquid taken every 12 hours. Dosage adjusted to attain target trough levels of 8-12 ng/mL. Participants who have maintained such levels at study entry on once daily dosage will be permitted to continue on once daily dosing.
223771035|NCT00768729|DRUG|MMF or Azathioprine|600 mg/m2 MMF taken orally daily or Azathioprine orally daily. Dosage of Azathioprine is dependent on weight. MMF or Azathioprine will be reduced by 25% initially and by 25% every 2 months resulting in complete withdrawal by 6 months.
223771036|NCT03367312|DRUG|Hyperpolarized 129Xenon gas|Hyperpolarized 129Xenon gas XeMRI scans will provide 3D images of ventilation and gas exchange pre, post, and 2-4 hours post inhaled prostacyclin treatment. Subjects will inhale HP 129Xe from the dose delivery bags with each scan and then move into the scanner and undergo basic 1H localizer and anatomical scans. Once localization is complete, subjects will undergo several MRI scans after inhalation of HPXe. This will occur as three scans at the three different time points (pre, post, and 2-4 hours post) of inhaled prostacyclin treatment.
224249203|NCT03586700|RADIATION|Short wave infrared radiation|Short waves infrared radiation treatment every other day, ensure 3 times in 7 days, 7 days for a course of treatment, continuously for 4 courses.
224249204|NCT03586700|DRUG|Placebo Xiao zhong fang granules|Made of starch,dextrin and edible pigment from Dongzhimen Hospital of Beijing university of chinese medicine.
224249205|NCT01729377|OTHER|Interview|
224249206|NCT00223197|DRUG|Pregnenolone|
224249207|NCT03169205|OTHER|observation registry|observation registry
223667327|NCT00357591|DEVICE|Continuous Aortic Flow Augmentation|1.0-1.5 lpm augmented blood flow
223667328|NCT00370045|DRUG|Bivalirudin with and without eptifibatide|
223667329|NCT05254977|DRUG|Standard Preparation|Any kind of intervention received to reduce adverse effects
223667330|NCT03683732|BEHAVIORAL|Individual semi-structured interviews|Individual semi-structured interviews were conducted using purposeful sampling of 15- to 18-year-olds, until data saturation, and were transcribed and analysed
223667331|NCT02366884|DRUG|Anti-Bacterial Agents|Doxycycline, Paramomycin, Clarithromycin, Clindamycin, Dapsone, Miltefosine
223667332|NCT02366884|DRUG|Anti-Fungal Agents|Itraconazole, Amphotericin B liposomal, Fluconazole, Terbinafine, Voriconazole
223667333|NCT02366884|DRUG|Anti-Protozoal Agents|Nitazoxanide, Chloroquine, Albendazole, Ivermectin, Mebendazole, Metronidazole, Praziquantel, Levamisole
223667334|NCT06332872|DRUG|Oral Ivermectin|Oral formulation (3mg tablet) Dosage: 2 single doses of 200 mcg/kg given 7 days apart
223667335|NCT06332872|DRUG|4% dimenticone liquid gel|topical formulation (liquid gel) only 1 application
223667336|NCT01612923|OTHER|Midwife|gynecological exam and ultrasound and contraceptive advice provided by midwife
223667337|NCT06113679|DEVICE|RDX-19|RD-X19 device with a 5 minute, 32 J/cm2 dose, 2X/day, 7 days. Each treatment at least 6 hours apart.
223667338|NCT02834754|DRUG|Vedolizumab|Vedolizumab is a monoclonal antibody developed by Millennium Pharmaceuticals, Inc for the treatment of ulcerative colitis and Crohn's disease. It binds to integrin α₄β₇. Blocking the α₄β₇ integrin results in gut-selective anti-inflammatory activity. Vedolizumab was been approved by the Food and Drug Administration (FDA) in 2014 for achieving clinical response, achieving clinical remission, and achieving corticosteroid-free remission in adult patients with moderately to severely active Crohn's disease. We believe that use of vedolizumab constitutes a non-significant risk to the research subject. The dose of vedolizumab administered is 300mg IV
223667339|NCT02834754|DRUG|placebo|Currently there are no clinical guidelines and no standard of care for the maintenance of surgically induced remission. There are no medications that have consistently been proven to be efficacious at preventing recurrent Crohn's disease and as such, no active equivalent arm is being used. Due to the lack of effective prophylactic therapy, many physicians and patients opt not to initiate medical therapy after surgery, rather wait until Crohn's disease recurs, or wait to perform a post-operative colonoscopy within 6-12 months of surgery, and decide on initiating Crohn's disease therapy based on endoscopic Rutgeerts; score. Therefore, acknowledging that many patients are not administered post-operative maintenance medications, we feel the placebo arm is justified.
223667340|NCT02093052|BEHAVIORAL|Attachment and Biobehavioral Catch-up|Enhance nurturance and following the lead among parents. In-home intervention with parents and children present.
223667341|NCT02093052|BEHAVIORAL|Developmental Education for Families|Enhance children's cognitive development. In-home intervention with parents and children present.
223667342|NCT00967980|PROCEDURE|Femoral Nerve Block vs. Psoas Compartment Nerve Block|Patients, undergoing hip arthroplasty or hip resurfacing will be randomized to one of two groups: femoral nerve block or psoas compartment nerve block. Patients randomized to femoral nerve block will receive this block prior to surgery. Patients randomized to psoas compartment nerve block will receive this block prior to surgery. Both patients will receive Mepivicaine via catheter prior to surgery and following surgery, Ropivicaine via pain pump.
223667343|NCT04476004|OTHER|scapular-focused exercise|scapular-focused exercise
223667344|NCT04476004|OTHER|visual feedback|EMG visual feedback
223667345|NCT00886678|DRUG|pemetrexed|500 mg/m2, IV, q 21 days x 2 cycles
223667346|NCT00886678|DRUG|carboplatin|AUC=5,IV,q 21 days x 2 cycles
223667347|NCT00886678|RADIATION|thoracic radiation|66 Gy over 33 fractions
223771037|NCT02788734|OTHER|Web-based survey|This study protocol consists of one anonymous survey. Each participant can complete only one survey. The survey will take approximately 25 minutes to complete. The survey is designed to identify items that best reflect the symptom severity and functional status in patients with CTS and CMT. A unique link to the survey will be included in an email invitation distributed to all adult CMT or HNPP patients self-registered in the RDCRN INC Contact Registry. Upon clicking the link, the participant will be directed to the IRB-approved online consent form. Upon providing consent, the participant will be directed to the online survey.
223771038|NCT05611580|BEHAVIORAL|Chronic Disease Risk Reduction|The intervention involves education information about chronic diseases and way to reduce risk for developing chronic diseases and/or decrease worsening of existing conditions.
223771039|NCT01461304|DRUG|triheptanoin|subjects will receive a modified diet containing triheptanoin (up to 2 grams/kg/24 hours; subjects who experience cardiomyopathy may receive doses up to 4 grams/kg/24 hours), or continued on their previously established triheptanoin dose; not to exceed RDA for fat, substituted for their MCT oil and/or natural fat. Study subjects will continue the triheptanoin-supplemented diet for a period of 12 months and then be able to continue into an indefinite extension phase in this compassionate use study. Laboratory evaluations will take place at two, six, and twelve months as well as every 12 months in the extension phase.
223771040|NCT01596764|DRUG|Loperamide placebo|200 ml apple juice
223771041|NCT01596764|DRUG|Loperamide|20 ml Loperamid-ratiopharm® Lösung (ratiopharm) in 180 ml apple juice containing 4 mg of loperamide hydrochloride (prepared before administration)
224249208|NCT00165594|DRUG|E7070|
224249209|NCT03885362|DEVICE|Dexcom G6 and Abbott Freestyle Libre|Dexcom G6 - continuous glucose monitoring device - blinded. CE mark 2018 Abbott Freestyle Libre - flash glucose monitoring device. CE mark 2014
223667348|NCT03288233|DIAGNOSTIC_TEST|Breath carbon monoxide measurement|Participants will be asked to breath in designed breathing circuits or hold their breath for short period of time and then their breath samples will be collected in special bags and the carbon monoxide and carbon dioxide will be measured with electrochemical techniques.
223667349|NCT00273533|DRUG|Ramipril|
223771042|NCT01596764|DEVICE|Colon Transit|5 capsules containing radio-opaque markers of different shapes, respectively
223667350|NCT03027882|OTHER|No Intervention|This is a reliability/validity study of a functional clinical test. There is no intervention
223771043|NCT01596764|DRUG|Sulfasalazine|Azulfidine® Tabletten 500 mg (Pharmacia/Pfizer) containing 500 mg immediate release sulfasalazine
224249210|NCT00946166|DRUG|simvastatin|40 mg daily in the evening for a maximum of 14 days
224249211|NCT00946166|DRUG|Placebo|Simvastatin-like placebo administered daily in the evening for a maximum of 14 days
224249212|NCT01305226|DRUG|THR-100|THR-100: 15 mg double-bolus (15mg/15ml), separated by 30 minutes (total 30 mg)
224249213|NCT01305226|DRUG|Streptokinase|Streptokinase: Standard regimen (1.5 million IU) is made up in 150 ml of physiological saline or glucose solution and administered intravenously over a period of 60 minutes.
224249214|NCT01386294|DRUG|Tenofovir gel|Tenofovir gel is a clear, transparent, viscous gel at concentrations of 1% formulated in purified water with edentate disodium, citric acid, glycerin, methylparaben, propylparaben, HEC, and pH adjusted to 4-5. Tenofovir gel will be supplies in a 4 ml single use applicator containing approximately 4 grams of gel, equivalent to approximately 40mg of tenofovir.
224249215|NCT01386294|DRUG|Universal placebo gel|The placebo gel is an inert gel containing HEC as the gelling agent, purified water, sodium chloride, sorbic acid and sodium hydroxide. Each applicator contains approximately 4ml of placebo gel
224249216|NCT05486780|BEHAVIORAL|Digital Window|For the digital window, a regal brand, 43R654FC, 43-inch (109 cm) television was used. A three-dimensional frame was built to give the appearance of a window around the television. For the digital window, a regal brand, 43R654FC, 43-inch (109 cm) television was used. A three-dimensional frame was built to give the appearance of a window around the television. Data collection will be completed by the researcher completing the Day and Night Perception Form and the Richards Campbell Sleep Scale (Post-Test) on the 1st, 2nd, and 3rd days of post-op for the patients in the experimental group who are in the field of view of the digital window.
224249217|NCT01185548|DRUG|Tolbutamide|Administered orally
224249218|NCT01185548|DRUG|Tasisulam|Administered intravenously
224249219|NCT02678286|DRUG|N1539|
224249220|NCT02678286|DRUG|Intravenous Placebo|
224249221|NCT00280904|DEVICE|Shunt catheter|standard of care implantation of shunt (any brand). Subjects are followed for 90 days to obtain information about whether or not an infection occurred.
223667351|NCT01374100|BEHAVIORAL|Standard Exercise|The standard exercise therapy program will include 12 treatments of approximately 45 minutes duration, twice a week for a period of six weeks by the same instructor and at the same location as for Qigong therapy. This exercise program is supervised and consists of cardio-vascular and resistance training exercises. Participants are asked to refrain from practicing Qigong during this 6 week period.
223667352|NCT01374100|BEHAVIORAL|Qigong Exercise|Qigong therapy will be led by a trained Qigong instructor and will occur for 45 minutes sessions, twice a week for a period of six weeks. Qigong is a self-directed walking exercise program that involves arm movements that are coordinated with slight movements of the waist, while in a state of deep relaxation or meditation. Patients will be asked to refrain from independent resistance or cardiovascular training during this 6 week period.
223667353|NCT00004845|DRUG|Rofecoxib|
224249222|NCT02330068|DRUG|citalopram|Cases
224249223|NCT04337320|OTHER|newborns from covid 19 positive mothers|Evaluation of apgar, hemogram and developmental status of babies born from covid 19 positive mothers
224249224|NCT01841866|OTHER|LMA removal|
224249225|NCT00378131|DRUG|RC-1291|
224249226|NCT00378131|DRUG|placebo|
224249227|NCT01532674|DEVICE|Antimicrobial photodynamic therapy (Periowave) and scaling and root planing|"ROOT PLANNING PROCEDURE:~The procedure is the same as in the control group~APPLICATION PROCEDURES OF THE PHOTOSENSITIZING AGENT :~The photosensitive agent : Formulation Periowave Treatment Kit-2ml~* Application of the photosensitive using a blunt needle at the bottom of the periodontal pocket with circular movements covering the entire perimeter of the tooth.~* Application of diode laser with a peak of 8.5 cm. long with a curvature of 60 degrees and flexible. Making a move in and out from the apical region to the more coronal region of the periodontal pocket. Each tooth has a working time of 60 seconds.~* All the periodontal pockets will be treated subgingivally~* Elimination of the photosensitive by irrigation"
224249228|NCT01532674|PROCEDURE|scaling and root planing|"ROOT PLANNING PROCEDURE:~An unique operator ( independent from the explorer) will do the root planing for both the test and control group.~Every procedure will be done under local anaesthesia: Ultracain with Epinephrine 40/0,01 mg/ml. NORMON. It will be done a first session of root planning in the first and forth quadrant and in a 48 hours the root planning of the second and the third quadrant will be done. Every session wil be done with this material: Ultrasonic: Satelec suprasson p5 with ultrasonic tip H3, manual scalers: HU-FRIEDY 1/2, 7/8, 11/12, 13/14, 13/14 columbia.~\* The session will finish as soon as the operator have removed all the supragingival and subgingival calculus and plaque."
224249229|NCT05223426|OTHER|Cognitive training|A cognitive training program will be individually developed for each participant based on baseline neuropsychological tests. It will include: Computerized cognitive training: this training include: the Dual-Task, the Stroop and the N-Back task. The tasks are accompanied by feedback based on the participant's responses (e.g., progress graph, feedback, etc.). In order to promote participants' learning, the level of difficulty of the tasks increased as training sessions progressed. Two sets of stimuli will be used to maximize the generalization of learning. Memory training: This training is adapted from the MEMO+ training program (Belleville et al., 2018). These sessions, also home-based, will be done through online video and are covering a variety of topics: memory (normal aging, mnemonic strategies), attention, aging, etc. Each week, participants will be asked to complete the equivalent of 6 training sessions of 15 minutes each, for a total of 1h30 per week.
224249230|NCT05223426|OTHER|Usual Care|Participants will be asked to continue the care and follow-up as usually planned with the attending cardiologist. Apart from weekly follow-ups with the research team member, no changes will be made to the participant's medical care.
224249231|NCT00006226|DRUG|thalidomide|Given PO
224249232|NCT00006226|OTHER|laboratory biomarker analysis|Correlative studies
223667354|NCT00004845|DRUG|Naproxen|
223667355|NCT00496938|DEVICE|XIENCE V®/ XIENCE PRIME™|Coronary artery placement of a XIENCE V®/ XIENCE PRIME™ Everolimus Eluting Stent System
223667356|NCT02453672|BIOLOGICAL|SB8|SB8, proposed bevacizumab biosimilar
223667357|NCT02453672|BIOLOGICAL|EU sourced Avastin®|EU sourced Avastin® (bevacizumab, Roche Registration Ltd.)
223667358|NCT02453672|BIOLOGICAL|US Sourced Avastin®|US Sourced Avastin® (bevacizumab, Roche Registration Ltd.)
223667359|NCT02984930|DRUG|Administration of study drug (esomeprazole, mosapride)|Esomeprazole(Hanxium®) 40 mg once daily and mosapride (Gasmotin®) 5 mg t.i.d for 4 weeks.
223667360|NCT02984930|DRUG|Administration of study drug (esomeprazole, placebo tablet)|Esomeprazole(Hanxium®) 40 mg once daily and placebo tablets that are identical to mosapride tablets t.i.d (3 times a day) for 4 weeks.
223667361|NCT02984930|PROCEDURE|upper endoscopy, scintigraphy|After medication(4weeks), subjects will be undergo upper endoscopy and scintigraphy.
223667362|NCT04838080|BIOLOGICAL|Koçak-19 Inaktif Adjuvanlı COVID-19 Vaccine 4 µg/0.5 ml Vaccine|Two applications on Days 0 and 21
224249233|NCT04622657|OTHER|dubousset functional test|Dubousset Function Test, 3-m backwards walk test, timed up and go test,Tinnetti Balance and Gait Test, Berg BalanceTest, Functional Reach Test
224249234|NCT00381225|PROCEDURE|Ultra-sound guided radio-frequency ablation|
224249235|NCT02134964|DRUG|OLT1177 Capsules|OLT1177 Capsules are an experimental drug.
224249236|NCT02134964|DRUG|Placebo Capsules|Placebo Capsules are identical in all ways to the study drug, but contain no active pharmaceutical ingredient.
224249237|NCT02841033|DRUG|daratumumab|Daratumumab by IV infusion once weekly for two months, then every 2 weeks for four months, then once each month until progression or inability to tolerate.
224249238|NCT05253105|DRUG|TAB006|Recombinant humanized, IgG4κ (immunoglobulin gamma 4, kappa) monoclonal antibody (mAb) that specifically binds to the T cell immunoreceptor with Ig and ITIM domains (TIGIT))
224249239|NCT05253105|DRUG|Toripalimab|a human IgG4k monoclonal antibody that specifically binds to the programmed death 1 (PD-1)
224249240|NCT04459585|DRUG|Dabigatran Etexilate Mesylate|Single oral 150 mg capsule dose
224321872|NCT02091518|DEVICE|Magnetic Resonance Imaging Acquisition and Analysis|MRI Studies: The MRI scans will be performed on a 1.5T or 3T MRI scanner. Conventional MRI studies will be performed using the standard clinical sequences. The new research sequences will be performed.at any point during the clinical exam. Total imaging time for volunteers will be 30-45 minutes.
224321873|NCT04953637|OTHER|Physiotherapy|Participants in the physiotherapy group will receive gait and balance focused physiotherapy at One Step Ahead Mobility physiotherapy clinic for 1-hour per day, 3 times/week for 8 weeks.
224321874|NCT06263452|DRUG|Propranolol|Tablet encapsulated to visually look identical to the placebo.
223667363|NCT04838080|BIOLOGICAL|Koçak-19 Inaktif Adjuvanlı COVID-19 Vaccine 6 µg/0.5 ml Vaccine|Two applications on Days 0 and 21
223667364|NCT04838080|BIOLOGICAL|Placebo|Two applications on Days 0 and 21
223667365|NCT03675009|OTHER|Educational Programming|Green Cleaning educational programming to day care staff.
223667366|NCT05777291|DEVICE|Activity watch monitoring|Patients will be using activity devices during the study period
223667367|NCT05777291|DEVICE|Sleep mattress monitoring|Patients will be using sleep mattress during the study period
223667368|NCT05777291|BEHAVIORAL|Physical activity counseling|Physical activity counseling in accordance to the Swedish model
224321875|NCT06263452|DRUG|Placebo|Encapsulated sugar pill to visually look identical to the experimental condition.
224321876|NCT03321149|OTHER|RiseTx|Participants were given access to the RiseTx application, as well as given a Jawbone, a wrist-worn device that can assess activity patterns throughout the day and provide sensory alerts to stand after prolonged sitting (i.e., ≥30 minutes of sedentary time). The intervention consisted of five phases following initial data collection that comprised of self-regulatory strategies to reduce sitting time and self-monitoring of step counts.
224321877|NCT04756661|DRUG|Carbetocin|100 mcg of Carbetocin intravenous injection
223667369|NCT01094522|DRUG|Methadone|"0.2 mg/kg (IV) for the Initial Loading Dose; followed by PRN (as needed) doses (given by the ICU Nurses) starting at 0.035 mg/kg (IV) every 30 minutes, for postoperative pain. The PRN dose of methadone may be increased by the ICU doctors until the dose is adequate to relieve the patient's pain."
223667370|NCT01094522|DRUG|Morphine|"0.2 mg/kg (IV) for the Initial Loading Dose; followed by PRN (as needed) doses (given by the ICU Nurses) starting at 0.035 mg/kg (IV) every 30 minutes, for postoperative pain. The PRN dose of morphine may be increased by the ICU doctors until the dose is adequate to relieve the patient's pain."
223667371|NCT01687725|DEVICE|Renal denervation using Symplicity Catheter system|percutaneous selective renal sympathetic nerve ablation with the use of the Symplicity Catheter system
223667372|NCT03774719|DEVICE|Hand-carried ultrasound|Hand-carried ultrasound of both kidneys to detect the presence or absence of hydronephrosis. Device used will be the lumify portable ultrasound equipped with the C5-2 curved array transducer (Philips, USA).
223667373|NCT03586570|DRUG|Aprocitentan 25mg|Oral tablets in strength of 25 mg
223667374|NCT03586570|DRUG|Placebo|Oral tablets matching aprocitentan tablets
224249241|NCT04459585|DRUG|Quizartinib|Single oral 60 mg dose of quizartinib administered as two 30 mg tablets (26.5 mg free base per tablet)
224249242|NCT01606540|DRUG|Tablets Ibumetin and placebo|"Group A: Daily tablets Ibumetin, 600 mg x 3, 7 days after reposition.~Group B: Daily tablets Ibumetin, 600 mg x 3, 3 days after reposition. The following days placebo tablets.~Group C: Placebo tablets 1 week after reposition."
224249243|NCT01606540|DRUG|Tablets Ibumetin and placebo|"Group A: Daily tablets Ibumetin, 600 mg x 3, 7 days after surgery.~Group B: Daily tablets Ibumetin, 600 mg x 3, 3 days after surgery. The following days placebo tablets.~Group C: Placebo tablets for 1 week after surgery."
224249244|NCT02098876|DEVICE|Resolute Integrity Zotarolimus eluting stent|PCI with Resolute stent
224249245|NCT02098876|DEVICE|Xience Xpedition everolimus eluting stent|PCI with Xience stent
224321878|NCT04756661|DRUG|Oxytocin|10 IU oxytocin IV drip
224321879|NCT04756661|DRUG|Misoprostol|400 mcg rectal
223771044|NCT01596764|DRUG|Placebo of MNTX and NLX|Placebo capsule (hard gelatine capsule containing multiple sugar spheres)
224249246|NCT02098876|DEVICE|Optical Coherence Tomography (OCT)|Optical coherence tomography (OCT) will be performed at baseline to assess plaque burden prior to and after stent deployment as well as to evaluate stent expansion and stent apposition. OCT will be repeated at one year follow-up to evaluate neo-intimal tissue coverage within the stent and change in plaque area at the stent edges. Offline, manual detection of lumen area and stent area will be performed for each OCT cross-section from baseline and follow up examinations.
224321880|NCT03164876|DRUG|AUT00206|4 capsules of 200mg AUT00206, twice daily, to take orally with food for 4 weeks
224321881|NCT03164876|DRUG|Placebo|4 capsules of placebo, twice daily, to take orally with food for 4 weeks
223771045|NCT01596764|DRUG|Naloxone|Naloxone hydrochloride 20 mg Extended Release Capsule equivalent to 18 mg naloxone (hard gelatine capsule containing a single NLX-ER tablet and multiple sugar spheres)
223771046|NCT01596764|DRUG|Methylnaltrexone|Methylnaltrexone bromide 150 mg extended release capsule equivalent to 122 mg methylnaltrexone (hard gelatine capsule containing multiple MNTX-ER micro tablets)
224249247|NCT02098876|DEVICE|Intravascular Ultrasound (IVUS)|Intravascular ultrasound (IVUS) will be performed at baseline to assess plaque burden prior to and after stent deployment as well as to evaluate stent expansion and stent apposition. IVUS will be repeated at one year follow-up to evaluate neo-intimal tissue coverage within the stent and change in plaque area at the stent edges. Offline, manual detection of lumen area, stent area, vessel area (external elastic membrane) and the media-adventitia interface will be performed for each IVUS cross-section from baseline and follow up examinations.
223667375|NCT00402740|DEVICE|Xact Stent with either Emboshield Pro (Gen 5) or Emboshield (Gen 3)|All subjects will receive the Xact™ Rapid Exchange Carotid Stent System. The first 220 consecutively enrolled subjects will be treated with the investigational filter system, the Emboshield® Pro Rapid Exchange Embolic Protection System (Generation 5). The remaining subjects will be treated with the FDA approved Emboshield® BareWire™ Rapid Exchange Embolic Protection System (Generation 3).
223667376|NCT00147836|DRUG|Human Insulin (Novolin-R, Novo Nordisk)|
223667377|NCT00147836|DEVICE|H-Tron Plus V100; Disetronic Medical System, Burgdorf, Switzerland|
223667378|NCT00147836|OTHER|Pre-meal|
223667379|NCT00147836|DRUG|Novolin-R|
223667380|NCT00147836|DRUG|Human Insulin NPH (Novolin-N, Novo Nordisk)|
223667381|NCT00147836|DRUG|Gliclazide (Diamicron, Servier)|
223667382|NCT00147836|DRUG|Diamicron and Glucophage|
223667383|NCT05338424|OTHER|Sprint Interval Training (SIT)|Active arm-- exercise dictated by protocol
223667384|NCT00504972|DRUG|hLL1|hLL1 administered intravenously once daily Monday through Friday for 2 consecutive weeks (10 total doses) at one of 4 planned dose levels: 1.5, 4, 6 or 8 mg/kg.
223667385|NCT01039103|DRUG|PEG-liposomal prednisolone sodium phosphate|PEG-liposomal prednisolone sodium phosphate 300 mg intravenous (IV), single dose 500 ml infusion over at least 2 hours on day 1
223667386|NCT01039103|DRUG|Methylprednisolone|Methylprednisolone 1 g, IV, infusion over 2 hours on days 1, 2 and 3
223667387|NCT00093249|DRUG|clevidipine|Clevidipine (0.5 mg/mL in 20% lipid emulsion)will be administered intravenously at an initial infusion rate of 0.4 µg/kg/min and will be titrated, as tolerated, at the discretion of the investigator, in doubling increments approximately every 90 seconds up to a maximum of 3.2 µg/kg/min, in order to achieve the desired blood pressure lowering effect. Clevidipine may be titrated upwards or downwards and may be temporarily interrupted and restarted to attain the desired blood pressure effect. The maximum study drug infusion rate of 8.0 µg/kg/min may not be exceeded.
223667388|NCT00093249|DRUG|placebo|Placebo (20% lipid emulsion - vehicle) will be administered intravenously in a fashion identical to clevidipine as described above.
224249248|NCT01159860|PROCEDURE|cryosurgery|freezing of lesion with liquid nitrogen
224249249|NCT01159860|PROCEDURE|Curettage|the lesion will be anesthetized and destroyed with a curette.
224249250|NCT03143920|COMBINATION_PRODUCT|Hyperbaric Oxygen Therapy-|Hyperbaric oxygen therapy provides 100% medical grade oxygen at 2.4 atmospheres of absolute pressure with a Class A multiple person chamber or Class B single person chamber. Hyperbaric chambers are classified as a Class II medical device and have been FDA cleared.
224249251|NCT04202874|PROCEDURE|Surgeon-administered transversus abdominis plane (TAP)|Prior to fascial closure, the rectus muscle is gently elevated superiorly and the surgeon identifies its lateral border; the nerves that supply the anterior abdominal wall travel through the myofascial plane between internal oblique and transversus abdominis muscles, 2 fingerbreadths above the iliac crest. Access to this plane can easily be achieved by inserting a blunted needle through the parietal peritoneum; there is an appreciable loss of resistance ('one pop') and the correct plane is entered. After careful aspiration to ensure no vascular injury has occurred, 20 mL 0.25% bupivacaine or 20 mL of normal saline is injected slowly. The same procedure is repeated on the other side.
224249252|NCT04455230|GENETIC|FLT190|FLT190 is a recombinant adeno-associated viral (AAV) vector (AAVS3) containing the human αGLA gene as a single stranded (ss) deoxyribonucleic acid (DNA).
224249253|NCT05481840|DEVICE|Continence material with sensor|"Healthcare organizations are prepared for the use of smart continence care (for the intervention condition) using specially developed implementation guideline. They receive training, including how to apply continence material (only provided to intervention condition).~Each participating location will use the product for 12 weeks. Correct size and absorption level will be determined for each participant. The optimize the result, this can change. Evaluation meetings with the caregivers, supplier and researcher will be held. Resulting in suggestions for alterations in continence care provided or products used, or giving indications that a team needs support in any way to foster the implementation.~After 12 weeks, the implementation guidance from the research group will be phased out.~The waiting list group will continue their continence care as usual during data collection period. Thereafter they will receive support for implementing smart continence care."
223667389|NCT02385656|DRUG|Modafinil|200mg of modafinil daily for 4 weeks
223667390|NCT03069729|OTHER|no intervention|This study evaluates s system intended to detect bio-markers of DPN. No interventions are involved in this non-invasive study.
223667391|NCT01646333|BEHAVIORAL|Memory and Problem-Solving Intervention|8 weekly 1 hour sessions of memory compensation and problem-solving strategies
224249254|NCT04764214|DRUG|3rd generation EGFR-TKI|Osimertinib will be administered orally at the dose of 80 mg once daily.
223667392|NCT01646333|BEHAVIORAL|Supportive Therapy|8 weekly 1 hour sessions of non-directive supportive therapy.
223667393|NCT03062254|DRUG|radium-223 dichloride|6 doses of Radium-223
223667394|NCT03269929|OTHER|Music therapy|Subjects listened to music for 30 minutes before undergoing brachytherapy with spinal anesthesia
223667395|NCT03269929|DRUG|Midazolam|Subjects received intravenous midazolam 0,02 mg/kgBW injection before undergoing brachytherapy with spinal anesthesia
224249255|NCT04764214|RADIATION|Consolidative SRT|Patients who possess oligoresidual disease after 3rd generation EGFR-TKI therapy will be treated with the intent to ablate all residual disease with consolidative SRT. The choice of dose-fractionation regimen is at the discretion of the treating radiation oncologist. TKI will be continued during and after consolidative SRT until disease progression or intolerable toxicity.
224249256|NCT02809469|DRUG|apixaban dose reduction|Participants taking apixaban 5mg BID will have their dose reduced to 2.5mg BID, and those taking 2.5mg BID will have their dose reduced to 2.5mg once daily (in the morning).
223667396|NCT00470509|DRUG|Adalimumab|2 subcutaneous injections on day 0 and 7
223771047|NCT02489175|DEVICE|Stomaplasty KoringTM|In these patients, the stomaplasty Koring will be implanted at the time of the primary definitive stoma creation. The implantation of the Koring will be performed by experienced surgeons (expertise based, best team approach) who have already implanted the Koring (e.g. participated in the observational study) and/or have reviewed the video documentation. To ensure standardization for all participating centres an operative manual with standardized video sequences is available.
224249257|NCT05237310|DEVICE|Standard Colonoscopy|Standard Colonoscopy using a standard Fujifilm colonoscope
224249258|NCT05237310|DEVICE|G-EYE Colonoscopy|G-EYE Colonoscopy performed using SMART Medical G-EYE Colonoscope
224249259|NCT05237310|DEVICE|CAD-EYE|Colonoscopy performed using with the aid of Fujifilm CAD-EYE artificial intelligence
224249260|NCT01061866|DRUG|3-phthalimidoglutarimide (Thalidomide)|Thalidomide at 200 mg dosage bid was administered during a twelve month period.
224249261|NCT03086473|DRUG|Caffeine Citrate|The intervention in this study is timing of the initial caffeine dose. In the Caffeine arm, participants will receive Caffeine Citrate 20mg/kg IV (volume dose 1ml/kg) within 2 hours of life, and Normal Saline (0.9% NaCl) 1ml/kg IV at 12 hours of life.
224249262|NCT03086473|DRUG|Placebo (Normal Saline)|The intervention in this study is timing of the initial caffeine dose. In the Placebo arm, participants will receive Normal Saline (0.9%NaCl) 1ml/kg IV within 2 hours of life, and Caffeine Citrate 20mg/kg IV (volume dose 1ml/kg) at 12 hours of life.
224321882|NCT02333058|DRUG|Treosulfan|"Treosulfan dose per day is to be calculated by using BSA:~One dose of Treosulfan per day on three consecutive days (day -6, day -5 and day -4) as intravenous (i.v.) infusion, given over 2 hours.~Two background conditioning regimens with Treosulfan are allowed: One regimen consists of a standardised Fludarabine-containing regimen (regimen A) and the other consists of an intensified regimen with Fludarabine and ThioTEPA (regimen B). The investigator decides for each individual patient whether to treat the patient with regimen A or with regimen B.~Treosulfan: i.v., BSA adapted: 10, 12 or 14 g/m²/day within 120 min to be administered prior to Fludarabine; Fludarabine: i.v., 30 mg/m2/day on days from -7 to -3 prior to HSCT; ThioTEPA (Regimen B): i.v., 2 x 5mg/kg/day on day -2."
223667397|NCT00470509|DRUG|Placebos|2 subcutaneous injections on day 0 and 7
224249263|NCT05764980|BEHAVIORAL|visual function evaluation|visual function evaluation
223667398|NCT00225264|DRUG|Pioglitazone|Pioglitazone 15 mg titrated up to 45 mg, tablets, orally, once daily and glimepiride placebo-matching capsules, orally, once daily for up to 72 weeks.
223771048|NCT03580096|OTHER|Core stability|Core stability intervention will be done with different stages and increasing gradually. The training program starts with exercises that isolate specific core muscles but progressing to include complex movements and incorporate core stability in dynamic tasks.
224249264|NCT04270448|BEHAVIORAL|Motor Sequence Task|"Participants will be seated at a laptop with the right hand on a standard joystick. The movement of the joystick will move a cursor on the computer screen. Targets will appear on the laptop screen as a circle in one of twelve spatially distinct locations. The learner must move the joystick cursor to inside the target before the next target will appear."
224249265|NCT04566848|DIAGNOSTIC_TEST|Flow cytometric analysis|Measuring the sCD25 (IL-2Ra), 4-1BB, B7.2 (CD86), Free Active TGF-β1, CTLA-4, PD-L1, PD-1, Tim-3, LAG-3, Galectin-9 levels with flow cytometry
224249266|NCT01185886|GENETIC|gene expression analysis|
224249267|NCT01185886|GENETIC|mutation analysis|
224249268|NCT01185886|GENETIC|polymorphism analysis|
224249269|NCT01185886|OTHER|biologic sample preservation procedure|
224249270|NCT01185886|OTHER|laboratory biomarker analysis|
224249271|NCT01185886|OTHER|pharmacogenomic studies|
223771049|NCT03580096|OTHER|Standard intervention|Standard intervention will include active exercises based on active joint mobilizations, muscle stretching and motor coordination.
223771050|NCT02665975|BEHAVIORAL|CBT-based internet-intervention for tinnitus|Tinnitus e-learning programme
224249272|NCT01216839|DRUG|Everolimus|Everolimus will be administered every day, initial dose 5 mg/m²/day, in 28 days cycle. Maximum dose: 10 mg/day. The cycles will be repeated till progression disease or untolerable toxicity.
224249273|NCT06362486|OTHER|Severity of infection, time of infection.|Severity of infection, time of infection.
224249274|NCT06362486|OTHER|Mental health assessment|Mental health assessment
224249275|NCT06362486|OTHER|biological|Prognostic immunologic factors associated with cognitive impairment in children born of sars-cov-2-infected mothers.
224249276|NCT00637741|DEVICE|Everflex 200|
224249277|NCT00772941|DRUG|Varenicline|"Champix Tablets 0.5mg or Champix Tablets 1mg, depending on the Investigator prescription.~Frequency and duration are according to Package Insert as follows.~The usual adult dosage for oral use is 0.5 mg of varenicline once daily after eating for days 1 to 3, 0.5 mg twice daily after eating in the morning and evening for days 4 to 7, and 1 mg twice daily after eating in the morning and evening on and after day 8. The drug should be administered to patients for 12 weeks."
224249278|NCT06231784|DEVICE|LUMINA IOL|A standard technique of phacoemulsification was performed followed by implantation of the Lumina in the sulcus plane of the eye by using a standard disposable injector system with an adapted, proprietary, AkkoLens butterfly cartridge.
224321883|NCT04070261|OTHER|iOS application usability test|user tasks, questionnaires, semi-structured interviews
223667399|NCT00225264|DRUG|Glimepiride|Pioglitazone placebo-matching tablets, orally, once daily and glimepiride 1 mg titrated up to 4 mg, capsules, orally, once daily for up to 72 weeks.
223667400|NCT02991664|OTHER|Equia Forte|Glass ionomer restorative system
223667401|NCT02991664|OTHER|G-aenial Posterior|Micro hybrid composite resin
223771051|NCT02665975|BEHAVIORAL|Face-to-face clinical tinnitus care|Hospital tinnitus counselling
223771052|NCT04272398|OTHER|dynamic elastomeric fabric orthoses|Wore dynamic elastomeric fabric orthoses with a focus on the lower body and pelvis in addition to the physiotherapy and rehabilitation sessions. The frequency of the use of the orthosis was planned to extend through the week and they had the orthosis during their active hours during the day about 8 hours a day.
223771053|NCT05855863|DRUG|Ginkgo Ketone Ester Tablets|Ginkgo Ketone Ester Tablets taken orally, 3 times a day, 0.5g each time, combined with conventional hypoglycemic treatment for six months
223771054|NCT05855863|DRUG|placebo|placebo, taken orally, 3 times a day, 0.5g each time, combined with conventional hypoglycemic treatment for six months
223771055|NCT02667938|DRUG|HCP1303 capsule 5/0.2mg|
223771056|NCT02667938|DRUG|HCP1303 capsule 5/0.4mg|
223667402|NCT05513118|DIAGNOSTIC_TEST|Periodontal clinical examination and gingival crevicular fluid, saliva, dental plaque, serum sampling|"Probing pocket depth was defined as the distance in millimeters from the gingival margin to the base of the gingival sulcus measured using a manual probe (Michigan 0 probe with Williams Markings) in all the teeth present except for third molars. Similarly, clinical attachment level (CAL) was measured as distance from cementoenamel junction to the base of pocket and recorded manually to the nearest millimeter marking on probe.~1 mililiter of saliva was obtained by each participant. Subgingival dental plaque was collected with sterile endodontic paperpoints from mesial sides of each natural teeth without a prostethic restoration. Gingival crevicular fluid samples were collected with absorbent paper strips. Serum samples were also collected at the time of visit."
223667403|NCT05735210|DEVICE|Polso™ Watch blood pressure measurement compared to a reference blood pressure measurement|The referenced blood pressure measurements are taken by dual auscultators.
223771057|NCT02667938|DRUG|HGP1201|
223771058|NCT02667938|DRUG|HCP1303 capsule 5/0.2mg placebo|
223771059|NCT02667938|DRUG|HCP1303 capsule 5/0.4mg placebo|
223771060|NCT02667938|DRUG|HGP1201 placebo|
223771061|NCT03416400|OTHER|Oocyte vitrification|Immature oocytes were collected from patients (≤37 years old, without endometriosis, Polycystic syndrome or other ovulatory desease) who underwent to ICSI. In addition, immature oocytes collected from patient diagnosed with cancer will be included in this study. Oocytes were matured in vitro with IVM medium and vitrified in closed system (Vitrolife). Kinetic of maturation were analyzed by Primovision (Vitrolife) and actin, and spindle organization were studied by microscopy, immunostaining techniques and quantitive analysis.
223771062|NCT06406127|DRUG|Alpha Lipoic Acid 600 MG Oral Capsule|Single 600 mg daily dose
223771063|NCT02501096|DRUG|Lenvatinib|Lenvatinib will be administered with water orally once a day (with or without food) continuously in 21-day treatment cycle.
223771064|NCT02501096|DRUG|Pembrolizumab|Pembrolizumab will be administered as a dose of 200 mg Q3W, IV in 21-day treatment cycle.
223771065|NCT04106791|DEVICE|closed-loop system for vasopressor administration|The closed-loop system' goal is to keep MAP within 5 mmHg of the predefined target MAP.
223771066|NCT05213858|DIAGNOSTIC_TEST|CAPS questionnaire|PTSD diagnosis and severity will be done using the CAPS-5 questionnaire.
223667404|NCT01920646|OTHER|ALV|Random allocation of children of two rural farm schools per grade to receive either 300 gram cooked ALVs and school meal starch or the normal school meal as daily meal (5 days/weeks) for 3 months.
223667405|NCT03675854|DRUG|Cefazolin|3 weeks
223771067|NCT05213858|DIAGNOSTIC_TEST|Beck Depression Inventory|depression symptoms will be measured by the BDI-II. The BDI-II consists of 21 items and uses a 0 to 3 severity scale. Total scores range from 0 to 63, with higher scores indicating more severe depression.
223771068|NCT05213858|DIAGNOSTIC_TEST|The Fibromyalgia Impact Questionnaire|The FIQ was developed from information gathered from patient reports, functional status instruments and clinical observations. This instrument measures physical functioning, work status (missed days of work and job difficulty), depression, anxiety, morning tiredness, pain, stiffness, fatigue and well-being over the past week.
223771069|NCT05213858|DIAGNOSTIC_TEST|The Pittsburgh Sleep Quality Index|"sleep patterns will be measured using the PSQI. This index assesses the quality and patterns of sleep in adults. It differentiates poor from good sleep quality by measuring seven components: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, the use of sleeping medications and daytime dysfunction over the last month. Items are rated using a 0 to 3 scale. The component scores are summed to produce a global score (range 0 to 21). Higher scores indicate worse sleep quality."
223771070|NCT05213858|DIAGNOSTIC_TEST|Depression, Anxiety and Stress Scale-21 items|The DASS-21 is a three-scale self-report questionnaire designed to measure the emotional state of depression, anxiety and stress. Each scale contains 7 items, divided into subscales with similar content. Scores range between 0 and 21 in each subcategory.
224321884|NCT04459039|DRUG|1000 mL 0.9% sterile saline|Within 12 h of surgery, the experimental group received 1000 mL 0.9% sterile saline intravenously.
224321885|NCT04459039|DRUG|250 mL 0.9% sterile saline|Within 12 h of surgery, the control group received 250 mL 0.9% sterile saline intravenously.
224321886|NCT04328805|DRUG|ibuprofen tablets|oral tablet
224321887|NCT04328805|OTHER|Median nerve neural mobilization|Manual therapy maneuver performed in the upper limb
223771071|NCT05213858|DIAGNOSTIC_TEST|Traumatic Events Questionnaire|"The TEQ examines experiences of traumatic events (e.g. sexual abuse, accidents and crime) that are considered potential triggers of PTSD symptoms. To assess trauma intensity, respondents provide information for each event that was experienced, as well as their age at the time of the event. The items are measured on a 9-point Likert scale from not at all to severely/extremely. The TEQ has previously been used in Israel."
223771072|NCT05213858|DIAGNOSTIC_TEST|Clinician Administered Dissociative States Scale|The CADSS is a 28-item structured clinical interview to assess state dissociation.
223771073|NCT05213858|DIAGNOSTIC_TEST|A diary will be used for seven consecutive nights|"A diary will be used for seven consecutive nights for the evaluation of:~* Mean sleep latency~* The number and duration of awakenings.~* Subjective total sleep time~* Subjective wake after sleep onset~* Sleep efficiency"
223771074|NCT05213858|DIAGNOSTIC_TEST|MRI|Brain imaging will include DTI and resting state for structural and functional MRI scanning. Images will be acquired on MAGNETOM Vida 3T Scanner, configured with 64-channel receiver head coils (Siemens Healthcare, Erlangen, Germany) at the Department of Radiology at Shamir Medical Center.
223771075|NCT05213858|DIAGNOSTIC_TEST|Functional brain imaging|Functional magnetic resonance imaging (fMRI) is widely used to study the operational organization of the human brain. This technology measures brain activity by detecting changes associated with blood oxygenation, using blood-oxygen-level-dependent imaging (BOLD) contrast.
224249279|NCT04786184|BEHAVIORAL|CALM Breathing|CALM Breathing is a mind-body breathing therapy that links CO2 changes to dyspnea and anxiety symptoms and targets breathing efficiency and self-efficacy in COPD. CALM Breathing: Individual interoception- based breathing therapy with capnography (non- exercise training) Home Program: Monitored home- based breathing exercises; RR biofeedback; goal setting; exercise logging. Coaching: Motivational interviewing. Personnel: PT, EP, occupational therapist, or nurse. Frequency: 1-hour sessions, twice per week for 4 weeks. Exercises: • 10 core breathing exercises with ETCO2 biofeedback in recovery postures at rest and with body movement (gentle stretches and brief low-moderate intensity physical activity). • Breathing biofeedback (ETCO2, RR, airflow pattern). Education: Education on anxiety; COPD Patient Guide.
223667406|NCT05991544|BEHAVIORAL|Training and Follow-up According to the Neuman Systems Model|Neuman Systems Model (NSM) it presents a holistic approach to patients by including physiological, spiritual, sociocultural and five major developmental variables
224249280|NCT04786184|BEHAVIORAL|Traditional outpatient PR|"After referral to Columbia's outpatient pulmonary rehabilitation (PR) program, participants randomized to the Wait-List control group will be put on a PR wait list (usual care). In Phase II, all participants will receive PR of 1-hour sessions, twice per week for 10 weeks. Traditional outpatient PR: Group exercise training (ET) combined with pursed lips breathing (PLB) training; 1:2 therapist to patient ratio. Home Program: Unmonitored walking exercise 1-2 days/week; no biofeedback monitoring. Coaching: Traditional monitoring and verbal cueing. Personnel: PT or EP. Frequency:~1-hour sessions, twice per week for 10 weeks. Exercises: • ET of muscles of ambulation with exercise equipment, such as on a treadmill or cycle ergometer (30-min), plus 15-min strengthening and posture exercises; O2 supplementation as needed. No breathing biofeedback. • PLB instruction only during exercise training. Education: Verbal and written information."
223667407|NCT00123253|DRUG|TH9507|
223667408|NCT06173700|BEHAVIORAL|web-based group problem solving and coping training|"The group included one-hour, weekly Zoom sessions, that were facilitated by an occupational therapy doctoral candidate (first author) for 7 consecutive weeks. During the first session, the candidate explained adaptive and maladaptive coping strategies and asked each participant to identify one adaptive coping strategy that they currently use and will continue to use in the future. The candidate then explained the FOCUS problem-solving approach. For each session afterward, the candidate presented a topic-related scenario for parents to identify an effective solution using the FOCUS steps (APA, 2011). Parent-chosen topics included recreation, assistive technology, motivating and advocating, physical activity, skin integrity, and adaptive fashion. The general process of the meetings is presented in Figure 1. After every meeting the candidate sent out a summary of resources that were discussed during the meeting, ultimately putting them all together in an Empowering Caregiver Guide."
223667409|NCT05373056|BEHAVIORAL|Scapular program|the patient will be in prone. With the elbow extended, begin by raising the shoulder above the head, keeping the upper extremity in line with the fibers of the lower trapezius. The participant will then remain pronated with the elbow flexed at 90 degrees and the shoulder abducted and externally rotated. Starting from this position, you should exert the force towards external rotation and then return to internal rotation. For the last exercise, the subject will be placed in a standing position holding the elastic band with one hand while the other end will fix it to the ground, while stepping on it with the foot. You will start the movement with a shoulder elevation in the plane of the scapula above 120 degrees and then perform the eccentric returning to the starting position.
223667410|NCT05373056|BEHAVIORAL|Conventional program|They will be performing a combination of concentric-eccentric type contractions adding an isometric contraction
223667411|NCT03456882|DRUG|RNS60|normal saline plus oxigen in nanobubble
223667412|NCT03225040|DRUG|Pegvisomant|Subjects receiving pegvisomant as part of their clinical care for acromegaly will be studied.
223667413|NCT03154892|PROCEDURE|Intracameral injection|Intracameral Conbercept injection for the treatment of NVG
223667414|NCT03154892|PROCEDURE|Intravitreal injection|Intravitreal Conbercept injection for the treatment of NVG
223667415|NCT02342418|DRUG|Tedizolid phosphate|Each group will receive a single dose of tedizolid phosphate 200 mg through a peripheral intravenous catheter.
223667416|NCT04763681|BEHAVIORAL|Couple HOPES Guided, Internet-Delivered, Self-Help Intervention|Couple HOPES is a guided self-help intervention for individuals with PTSD and their partners based on Cognitive-Behavioral Conjoint Therapy for PTSD (Monson \& Fredman, 2012). This intervention consists of text and video-based content across seven intervention modules and phone and online-based coaching sessions with a paraprofessional. Participants are able to complete these modules in their own home or private location of their choosing. The primary outcomes are PTSD symptoms, relationship satisfaction, and the mental health and wellbeing of partners of those with PTSD.
223667417|NCT00428584|DRUG|New Formulation of rebif - human interferon beta-1a|New Formulation of rebif- 44 mcg, SC (sub-cutaneous) thrice weekly (tiw) injection.
223667418|NCT00428584|DRUG|Interferon beta -1b|Betaseron - 250 mcg, SC (sub-cutaneous) every other day injection.
223667419|NCT01800461|OTHER|OPC-Stroke|Occupational therapy coaching intervention
223667420|NCT01800461|OTHER|Usual care|Usual community care
223667421|NCT03199755|DRUG|ACT|Current approved drug for treating malaria
224249281|NCT03949179|DEVICE|The Low Back Pain and Disability Drivers Management (PDDM) model|The Low Back Pain and Disability Drivers Management (PDDM) model aims to identify the domains influencing pain and disability to guide clinical decisions. The model is composed of five domains upon which the clinician can base his assessment and orientate treatment allocation and includes: 1) nociceptive pain drivers (i.e., somatic, inflammatory or mixed pain), 2) nervous system dysfunction (NSD) drivers (i.e., sensitization of the peripheral and/or central nervous system), 3) comorbidity drivers (i.e., physical and/or mental health comorbidities), 4) cognitive-emotional drivers (i.e., maladaptive cognitions and/or behaviors) and 5) contextual drivers (i.e., occupational-related and social environmental contextual drivers). This profiling will inform and lead the clinician's treatment approach based on the combined contribution of each domain driving the experience of pain and disability.
223667422|NCT03199755|DRUG|DLA1|Experimental drug treatment, single dose.
224249282|NCT00830700|OTHER|CATMH intervention|This intervention is comprised of 6-tandem-sessions of pharmacotherapy and a behavioral intervention conducted over 4-5 months. The telepsychiatrist makes prescribing decisions during the intervention following consensus guidelines for ADHD treatment. The telepsychiatrist also provides education about how neurobiological deficits of ADHD relate to observed behavioral learning and difficulties. After the 6th session, the PCP resumes care of the patient. The behavioral intervention component is delivered by therapists at each participating clinic. The therapists are trained and supervised remotely by a telepsychologist . The 6-session behavioral intervention consists of approaches to managing children's behaviors and coordination with schools and other community agencies to advocate for the child.
224249283|NCT05707507|OTHER|Place of treatment|Patients with an infectious diseases have to be treated with a specify antimicrobial therapy. The differences between the arms is about the possibility to continue with the treatment in or out of the hospital.
223667423|NCT03199755|DRUG|DLA2|Experimental drug treatment, doubled the dose of DLA1.
223667424|NCT05705089|DRUG|Rivaroxaban 15 MG|Rivaroxaban 15 MG once daily orally + Dual anti-platelet therapy (clopidogrel (75 mg daily, orally)+aspirin (80 mg once daily, orally))
223667425|NCT05705089|DRUG|Warfarin|Warfarin (to reach an INR goal of 2-2.5)+ Dual anti-platelet therapy (clopidogrel (75 mg daily, orally)+aspirin (80 mg once daily, orally))
223667426|NCT04320758|OTHER|conventional preparation design|chamfer finish line
223667427|NCT04320758|OTHER|biologically oriented preparation technique|shoulder less preparation design
223667428|NCT06267378|OTHER|Frailty measure|"All participants will be asked to complete baseline assessments and a blood test.~30 participants out of the 100 will be selected to wear a digital motion device before their surgery for seven days. (15 participants will be non-frail and 15 patients will be frail).~Where possible, all baseline assessments will be scheduled to coincide with a routine clinic/hospital visit. The first assessment will complete functional, frailty, nutritional, and quality of life questionnaires. A blood test will be taken for baseline tests and metabolomic assessment. Participants who opt into having a digital motion device will also be shown how to use the device and will wear this for seven days. Written instructions to fit the device will also be given."
223667429|NCT01311167|DRUG|Dexamethasone|Daily administration of 2 mg of dexamethasone for 4 days
223667430|NCT01311167|DRUG|Placebo|Daily administration of 2 mg of placebo for 4 days
223667431|NCT06086197|DRUG|Anlotinib hydrochloride, Rituximab, gemcitabine, oxaliplatin|"Anlotinib: 12mg d1\~14 po qd, Rituximab: 375mg/m2 d1, gemcitabine: 1000mg/m2 d1 and d8, oxaliplatin: 130mg/m2 d1;~For subjects ≥75 years of age, appropriate reduction of chemotherapy drugs (not less than 75% of the standard dose, or withdrawal of day 8 gemcitabine) may be decided by the investigator."
223667432|NCT01348477|PROCEDURE|Elliptical domed mesh technique|A segment of polypropylene mesh of 10 by 15cm enters the inguinal preperitoneal space, where takes the form of a dome and is fixed by four stitches
223667433|NCT00427115|BEHAVIORAL|Multimodal exercise and psychosocial program|
223667434|NCT00985829|RADIATION|photodynamic therapy|treatment of bcc with 5\_ALA cream 20% topical administration once monthly+ photodynamic therapy (red light) 120 j/cm2 once monthly
223667435|NCT01785862|DRUG|Ibuprofen 25 mg|Lozenge, Oromucosal administration
223667436|NCT01785862|DRUG|Placebo|Lozenge matching V0498 lozenge, Oromucosal administration
223667437|NCT04891393|DIETARY_SUPPLEMENT|Coffee|"Starbucks brand Via instant coffee. (Caffeine Content: 3 mg / kg)"
223667438|NCT04891393|DIETARY_SUPPLEMENT|Decaffeinated coffee|"Starbucks brand Via instant decaffeinated coffee. (Caffeine Content: 15 - 25 mg)"
223667439|NCT00635076|OTHER|placebo|Patients continued taking the matching placebo that they were taking when they completed Study A6131002 (oral tablets taken once daily).
224249284|NCT00834756|DRUG|Azithromycin 600 mg Tablet|1 x 600mg, single-dose fasting
224249285|NCT00834756|DRUG|Zithromax® 600 mg Tablet|1 x 600mg, single-dose fasting
223667440|NCT00635076|DRUG|alprazolam XR|Patients continued taking the same dosage of alprazolam that they were taking when they completed Study A6131002 (oral tablets taken once daily (1-6mg)); patients taking less than 6 mg/day who failed to show a satisfactory clinical response since the previous visit, and who were free of dose-limiting adverse events, could have their dosage titrated upward by 1 mg/day; upward daily dosage titration of 1 mg was allowed every 7 days, up to a maximum daily dosage of 6 mg/day; patients who were unable to tolerate the previous dosage level of alprazolam XR could have their daily dosage reduced.
223667441|NCT02550769|PROCEDURE|TRANSANAL TOTAL MESORECTAL EXCISION|The technique begins with the TEO equipment and a purse string 1 cm distal to the tumor. The dissection progresses in the posterior part until the laparoscopic TME field is reached. After the section of the rectum and TME transanal dissection, the anvil of the circular mechanical stapler is introduced through the TEO rectoscope. In the laparoscopic field, the mesosigma is sectioned at the point where the colon section is to be performed. The TEO rectoscope is withdrawn, and the bag containing the specimen is removed through the anus. The stapler is inserted. From the laparoscopic field, the strings of the purse are tightened and the purse is closed around the rectal stump with a clip. Then the stapler are joined to perform the anastomosis and a loop ileostomy is placed in the right flank.
223667442|NCT02550769|PROCEDURE|Laparoscopic-LAR|Standard laparoscopic low anterior resection of the rectum with total mesorectal excision and colorectal anastomosis
223667443|NCT02884713|DRUG|Levofloxacin|The primary objective was to evaluate the efficacy of the 10-day course of levofloxacin, doxycycline and esomeprazole in non-responders to first-line therapies for H. pylori eradication in Saudi Arabia. Secondary objectives included; symptoms response to treatment, factors associated with eradication of H. pylori and adverse events associated with the treatment
223667444|NCT02884713|DRUG|Doxycycline|The primary objective was to evaluate the efficacy of the 10-day course of levofloxacin, doxycycline and esomeprazole in non-responders to first-line therapies for H. pylori eradication in Saudi Arabia. Secondary objectives included; symptoms response to treatment, factors associated with eradication of H. pylori and adverse events associated with the treatment
223667445|NCT02884713|DRUG|Esomeprazole|The primary objective was to evaluate the efficacy of the 10-day course of levofloxacin, doxycycline and esomeprazole in non-responders to first-line therapies for H. pylori eradication in Saudi Arabia. Secondary objectives included; symptoms response to treatment, factors associated with eradication of H. pylori and adverse events associated with the treatment
223667446|NCT04711161|DRUG|GRN-300|A salt-inducible kinase (SIK) inhibitor
223667447|NCT04711161|DRUG|Paclitaxel|Microtubule inhibitor
223667448|NCT01159431|DEVICE|Trigeminal Nerve Stimulation|External stimulation of the supraorbital branch of the Trigeminal Nerve using a digital TENs unit
223667449|NCT01986699|PROCEDURE|Laparoscopic Assisted Polypectomy|
223667450|NCT01550848|DRUG|Abraxane and Gemcitabine|"ABX (Abraxane) 125 mg/m2，intravenous infusion，30min，day 1, 8, 15~GEM (Gemcitabine) 800 mg/m2，intravenous infusion，30min，day 1, 8, 15"
223667451|NCT06226857|DRUG|Cetuximab|FOLFOX+cetuximab/panitumumab q2w until desease progression, deescalation to de Gramont+cetuximab/panitumumab is allowed after 8 cycles
223667452|NCT03858816|OTHER|Mixture probiotics|The mixture probiotics capsule
223667453|NCT03858816|OTHER|Placebo|The placebo contains the same excipient ingredients but without the live bacteria.
224249286|NCT05136183|DEVICE|HA-330 Disposable Hemoperfusion Cartridge (Jafron, China)|"* If no appropriate vascular access available, a double lumen catheter is placed by treating physicians, under ultrasonographic guidance.~* Two sessions of hemoperfusion using HA-330 Disposable Hemoperfusion Cartridge are performed 24 hours apart.~* Hemoperfusion is performed using either hemoperfusion or continuous renal replacement therapy machine. The optimal blood flow rate is 150-200 mL/min. The duration for each session in 2 hours. No systemic anticoagulant is given except for priming of the cartridge according to manufacturer recommendations.~* The first hemoperfusion session is recommended to be initiated within 12 hours after randomization."
223667454|NCT04465838|OTHER|NIS|This is a non-interventional study (NIS).
223667455|NCT05229497|DRUG|AK112|IV infusion,Specified dose on specified days
223667456|NCT05229497|DRUG|AK117|IV infusion,Specified dose on specified days
223771076|NCT05213858|DIAGNOSTIC_TEST|EEG analysis|EEG will be obtained using a point-of care device that consists of an EEG-Sense Headset, EEG-Sense Single-Use brush sensors, a pneumatic sensor positioning mechanism, EEG sampling electronics and software. The EEG-Sense Headset is an EEG electrode positioning system that quickly places electrodes in a uniform and consistent manner, to transfer electrophysiological EEG signals from an individual to a suitable EEG data collection device. The device is nonsterile, non-invasive and non-radiation emitting, and was developed for use in healthcare facilities and hospitals. Typical set-up and procedure time is several minutes. The device does not contain biologics, drugs, coatings or any claim of sterility. The EEG-Sense Single-Use brush sensors are made from well-established medical-grade materials; the Headset is made from Nylon 101. Electronic components and harnesses are embedded between two layers of nylon and are attached to each electrode port.
223771077|NCT05213858|DIAGNOSTIC_TEST|Autonomic nervous system monitors|"Data will be collected using Empatica's E4 wristband. Each of the study participants will wear the wristband for 7 days.~Data collected from the band will include:~ACC - Data from 3-axis accelerometer sensor in the range \[-2g, 2g\]. (sampled at 32 Hz) BVP - Data from photoplethysmography (PPG). (sampled at 64 Hz) EDA - Data from the electrodermal activity sensor in μS. (sampled at 4 Hz) IBI - Inter-beat intervals. (intermittent output with 1/64 second resolution) TEMP - Data from temperature sensors, expressed in degrees on the Celsius (°C) scale. (sampled at 4 Hz)"
224249287|NCT04125576|DIAGNOSTIC_TEST|magnetic resonance imaging(MRI)|magnetic resonance imaging(MRI) will be used to evaluate cerebral blood volume(CBV) of pain network
223667457|NCT05229497|DRUG|Carboplatin|IV infusion,Specified dose on specified days
223667458|NCT05229497|DRUG|Cisplatin|IV infusion,Specified dose on specified days
223667459|NCT05229497|DRUG|5-Fluorouracil|IV infusion,Specified dose on specified days
223667460|NCT00022646|DRUG|gemcitabine hydrochloride|
223667461|NCT00022646|DRUG|pemetrexed disodium|
223667462|NCT04452110|DIAGNOSTIC_TEST|Ultrasonography|Temporomandibular joint diseases of ultrasonography its effectiveness and reliability in diagnosis disadvantages in MR and other imaging methods be ruled out.
223667463|NCT02145650|OTHER|No Intervention|There is no intervention administered in this study.
223667464|NCT04185285|DEVICE|Percutaneous coronary intervention, stents|
223667465|NCT02371915|OTHER|Videoconference follow-up|Rheumatology visits to take place video videoconference with a physiotherapist present
223667466|NCT04367909|DRUG|Nimotuzumab|Nimotuzumab will be administered intravenously at a fixed dose of 200 milligrams (mg) on Day 1 of each 21-day cycle.
223667467|NCT04367909|DRUG|Docetaxel|Docetaxel 75 milligrams per square meter (mg/m\^2) will be administered intravenously on Day 1 of each 21-day cycle.
223771078|NCT02809703|OTHER|Survey Questions|Subjects will receive surveys via direct mail. They will be given the opportunity to opt in to receive a phone call regarding quality of life.
223667468|NCT04367909|DRUG|Carboplatin|Carboplatin AUC 5 will be administered intravenously on Day 1 of each 21-day cycle.
223667469|NCT04326426|DRUG|Tradipitant|Neurokinin-1 antagonist
223667470|NCT04326426|DRUG|Placebo|Matching placebo
223771079|NCT05630027|OTHER|Piroctone Olamine (PO), 2,4 Diaminopyrimidine oxide (2.4 DA) and Vichy mineralizing water|observational, prospective study
224249288|NCT03387176|OTHER|Implementation of a gluten-free diet|Patients will be placed on gluten free diet for 9-12 months.
224249289|NCT00783367|DRUG|Lenalidomide|Lenalidomide: 10mg capsules, orally, once daily for each 28 day cycle for the duration of the study
224249290|NCT00783367|DRUG|Dexamethasone|Dexamethasone: 8mg tablets, orally, once weekly on days 3, 10, 17, 24 of each 28 day cycle for the duration of the study;
224249291|NCT00783367|DRUG|Rituximab|Rituximab: 375mg/m2 IV (in the vein), once weekly on days 1, 8, 15, 22 during month 3 of therapy
224249292|NCT06627725|BEHAVIORAL|Patient-Family Communication|Patient-Family Communication
224249293|NCT05839834|DIAGNOSTIC_TEST|Blood test|RNA sequencing of peripheral blood cells
223667471|NCT03302364|DRUG|Risperidone|patients who have never received risperidone or who have received re-administration of risperidone after discontinuation of risperidone treatment
223667472|NCT00156156|DRUG|Asoprisnil|Asoprisnil 10 mg Tablet, oral Daily for up to 2 years
223667473|NCT00156156|DRUG|Asoprisnil|Asoprisnil 25 mg Tablet, oral Daily for up to 2 years
223667474|NCT03602560|DRUG|seladelpar 5-10 mg|Seladelpar 5 mg for 6 months and then titrating up to 10 mg based on tolerability and response for remainder of double-blind period. After completion of the 1-year double-blind period subjects will be offered the opportunity to enter an open label long term safety study. Subjects will continue the seladelpar dose (5 or 10 mg) received during the double-blinded study
223667475|NCT03602560|DRUG|seladelpar 10 mg|Seladelpar 10 mg for double-blind period. After completion of the 1-year double-blind period subjects will be offered the opportunity to enter an open label safety study. Subjects will continue the seladelpar dose (10 mg) received during the double-blinded study
223667476|NCT03602560|DRUG|Placebo|One capsule daily for double-blind period. After completion of the 1-year double-blind period subjects will be offered the opportunity to enter an open label long term safety study. Subjects on placebo will be re-randomized to initiate seladelpar at 5 or 10 mg once daily
223667477|NCT06294743|PROCEDURE|Posterior tibial nerve neuroprolotherapy|Real-time ultrasound guided needle injecting 10ml of 5% dextrose solution around the posterior tibial nerve to elicit a neurostimulatory response.
223667478|NCT06294743|DRUG|Acetaminophen 500Mg Tab|Oral acetaminophen 500mg tab stat, followed by Q6h if needed.
223771080|NCT00287768|DRUG|docetaxel + S-1|Docetaxel iv on day one and S-1 po days 1 to 14 every 3 weeks
224249294|NCT06317103|DEVICE|WADYMED endo|"Classification of the gastro-endoscopic images as Mucosa or Submucosa by WADYMED endo (Gastric cancer image, computer aided detection/diagnosis software)"
224249295|NCT06317103|OTHER|Control group (the endoscopists)|"Interpretation of the gastro-endoscopic images as Mucosa or Submucosa by the endoscopists"
223667479|NCT05354453|DRUG|BI 1839100|BI 1839100
223667480|NCT05354453|DRUG|Placebo|Placebo
223667481|NCT05354453|DRUG|allyl isothiocyanate (AITC)|allyl isothiocyanate (AITC)
223667482|NCT00222131|DRUG|Esomeprazole|Esomeprazole 40 mg QD
223667483|NCT00222131|OTHER|Placebo|Placebo
223667484|NCT05488821|DRUG|QLH11906|QLH11906 only
223771081|NCT00287768|DRUG|S-1|S-1 po days 1-28 every 6 weeks
223771082|NCT04138407|OTHER|seated Tai Chi|Seated Tai Chi is a redesigned short form of traditional Tai Chi, can be practiced in a chair or wheelchair
224249296|NCT03861845|DEVICE|Standard off-the-shelf pillbox|Then the participant will receive a store bought one-dose per day pillbox.
224249297|NCT03861845|DEVICE|Custom off-the-shelf pillbox|Then the participant will be administered an off-the-shelf pillbox that was purchased specifically for the participant's preferences, routine, medication regimen, and skills/abilities.
223771083|NCT04138407|OTHER|Usual rehabilitation exercise|Regular rehabilitation exercise used in participating hospital
224249298|NCT03861845|DEVICE|Custom designed and manufactured pillbox|Then the participant will describe any design preferences for the pillbox. The researcher will design and manufacture the pillbox using a 3D printer, publically available 3D printing object repository, and computer aided design software.
224249299|NCT03861845|BEHAVIORAL|Education & Training|The participant will receive education and training on how to use the pillbox and how to incorporate the pillbox and taking medications into their daily routine.
224249300|NCT03861845|BEHAVIORAL|Reflection on medication routines|The participant will reflect on his or her daily routine, medication regimen, and use of existing pillboxes. The participant will also engage in a hands-on standardized pillbox task.
223667485|NCT06131528|OTHER|Relaxation Breathing Exercises Group|This group will preform Relaxation Breathing Exercises that includes Slow Deep Breathing, Pursed lip Breathing, Deep Diaphragmatic Breathing and Alternate Nostril Breathing
223667486|NCT06131528|OTHER|Usual Care Group|The control group received lifestyle modifications that are an important part of hypertension management
223667487|NCT03387488|DEVICE|StingrayTM, Medtronic®|Video- assisted pericardioscopic surgery for implanting epimyocardial pacemaker lead model 09090, Medtronic®
223667488|NCT00164476|BEHAVIORAL|Preventive Services Prevention Kit|
223667489|NCT00164476|BEHAVIORAL|peer mentors (control group)|
223771084|NCT03189394|BEHAVIORAL|PRIDE|A couples curriculum that is relationship-focused and in-person, aimed at helping to reduce the odds of a composite HIV risk variable among gay couples.
223667490|NCT00486655|PROCEDURE|NOTES-Assisted Cholecystectomy|
223667491|NCT05157828|OTHER|No intervention|No intervention
223771085|NCT03189394|BEHAVIORAL|ePRIDE|A couples curriculum that is relationship-focused and online, aimed at helping to reduce the odds of a composite HIV risk variable among gay couples.
224249301|NCT02251886|OTHER|Moxibustion in primiparae|Number of primiparae participants with Version of Fetal Breech Position to Cephalic Position up to 4 weeks after treatment
223667492|NCT06021860|DRUG|Spironolactone Oral Suspension|"Spironolactone will be dosed on a mg/kg basis, with actual weight on Day 1 (pre-dose) determining the spironolactone suspension volume administered. Therefore, for a given patient, the dose administered on Day 1, based on the weight measured on Day 1, will be administered throughout their participation in the study.~Spironolactone will be administered as a single dose in the single-dose periods (Group 4, Parts 1 and 2), and as QD dosing in the multiple-dose periods (Groups 1 to 4, Parts 1 and 2).~The low and high doses to be administered during Part 2 of the study will be determined by the Safety Review Committee following their review of Part 1 data."
223667493|NCT01763008|DRUG|No intervention|This is an observational study. Doripenem will be administered as per the recommended dose, ie, 500 mg, intravenously (ie, in the vein), for every 8 hours. Duration of treatment with doripenem: for nosocomial pneumonia including ventilator-associated pneumonia patients: 7 to 14 days; for complicated intra-abdominal infection patients: 5 to 14 days; for complicated urinary tract infection, including pyelonephritis (bacterial infection of the kidneys) patients: 10 days.
223667494|NCT00534599|DRUG|Placebo|oral
223667495|NCT00534599|DRUG|quetiapine fumarate XR|oral
223667496|NCT01625741|DRUG|Rituximab|2000 mg, IV, monthly, for 4 months (= 4 doses)
223771086|NCT03189394|BEHAVIORAL|Men's Health|A men's health curriculum that is individualized and in-person, aimed at helping participants to focus on gay men's health.
223771087|NCT03149237|BEHAVIORAL|Couples-based services|Couples-based services, including treatment, counseling and peer mentoring in the community.
224249302|NCT02251886|OTHER|Moxibustion in multiparae|"Number of multiparae participants with Version of Fetal Breech Position to Cephalic Position up to 4 weeks after treatment"
224249303|NCT00191204|DRUG|Duloxetine|
224249304|NCT06368869|OTHER|Livento press veneers luted with dual cured resin cement|Veneers will be fabricated using Lithium disilicate (Livento® Press) ceramic and luted using Bifix QM dual cured cement
224249305|NCT06368869|OTHER|Livento press veneers luted with light cured resin cement|Veneers will be fabricated using Lithium disilicate (Livento® Press) ceramic and luted using Bisco choice 2 light cured cement
223667497|NCT00625430|BIOLOGICAL|Gene Directed Enzyme Prodrug Therapy, FP253/Fludarabine|"Subjects within a treatment group will be administered a single transrectal intraprostatic injection of FP253.~Group A: 1 x 10Exp9 virus particles (VP); Group B: 3.2 x 10Exp9 VP; Group C: 1 x 10Exp10 VP; Group D: 3.2 x 10Exp10 VP; Group E: 1 x 10Exp11 VP; Group F: 3.2 x 10Exp 11 VP.~If there are no dose-limiting toxicities, three additional patients may be treated at the highest dose.~Twenty four hours following administration of the FP253, subjects will receive a first dose of fludarabine phosphate (20mg/m2 administered as an intravenous bolus). The first dose of fludarabine phosphate will be followed by 4 further doses at 24 hour intervals on treatment Days 3 to 6."
223667498|NCT02439489|DRUG|BKM120-CIS|"BKM120 will be delivered orally once daily on continuous at the dose of 60 mg (dose level 1), 80 mg (dose level 2) and 100 (dose level 3). Cisplatin will be delivered intravenously at the dose of 75 mg/m2 on day 1 every 3 weeks at each dose level of BKM120.~In the absence of BKM120 DLT, each level will be administered to 3 patients A minimum of 2 cycles per each dose level will be administered in the absence of disease progression or toxicity"
223667499|NCT02439489|DRUG|BKM120-CARBO|"BKM120 will be delivered orally once daily on continuous at the dose of 60 mg (dose level 1), 80 mg (dose level 2) and 100 (dose level 3). Carboplatin will be delivered intravenously at AUC 5 on day 1 every 3 weeks at each dose level of BKM120. Should dose level 3 be completed, carboplatin will be given at AUC 6 and BKM120 at 100 mg.~In the absence of BKM120 DLT, each level will be administered to 3 patients A minimum of 2 cycles per each dose level will be administered in the absence of disease progression or toxicity"
223667500|NCT02326480|OTHER|Identification of genetic causes of obesity|A blood test will be performed to the child and his/her parents with the aim of identifying genetic causes of obesity. Different analysis will be as follows: caryotypes, Raindance, whole exome, in order to find potential mutations or new genes associated to this condition
223667501|NCT04847713|OTHER|extraction of blood samples|Two blood samples (3.5 ml each) will be collected directly into purple K2-EDTA tubes and stored at 4°C for up to 24 hours for analysis
223667502|NCT00554710|DRUG|infliximab+azathioprine|infliximab 5 mg/kg at week 0,2 and 6 + azathioprine 2-2.5 mg/kg
223667503|NCT00554710|DRUG|methylprednisolone or budesonide|methylprednisolone 32 mg followed by taper or budesonide 9 mg/day followed by taper
223667504|NCT02082756|DRUG|Bifidobacterium viable pharmaceutics|
223667505|NCT02082756|DRUG|Berberine Hydrochloride|
223667506|NCT03833193|RADIATION|Hypofractionated radiotherapy|Radiation: Hypofractionated radiotherapy at 3Gy/f
223667507|NCT03917407|DRUG|DUR-928 (Moderate AH)|"A total of no more than two doses of DUR-928 will be given, with 72 hrs between each dose. A second dose of the assigned study treatment (test drug) will be repeated 3 days after Dose 1 to patients who are still hospitalized. If a patient meets the discharge criteria prior to Day 4, the patient will receive only one dose of DUR 928.~Patients of Part A (MELD 11-20) will follow the dose escalation procedure based on cohort; each patient will receive an intravenous infusion dose of:~* Cohort 1A: 30 mg of DUR-928in 100 mL 5% dextrose or 0.9% sodium chloride administered over approximately 2 hrs via IV infusion.~* Cohort 2A: 90 mg of DUR 928 in 100 mL5% dextrose or 0.9% sodium chloride administered over approximately 2 hrs via IV infusion.~* Cohort 3A: 150 mg of DUR 928 in 100 mL5% dextrose or 0.9% sodium chloride administered over approximately 2 hrs via IV infusion."
223667508|NCT03917407|DRUG|DUR-928 (Severe AH)|"Dose escalation to the next cohort will be determined after review of safety, tolerability and pharmacokinetic data of the previous cohort. Dose escalation for Part B will follow the same requirements as for Part A. The dose levels for Part B are planned to be the same as Part A.~Patients of Part B (MELD 21-30) will follow the dose escalation procedure based on cohort; each patient will receive an intravenous infusion dose of:~* Cohort 1B: 30 mg of DUR-928 in 100 mL 5% dextrose or 0.9% sodium chloride administered over approximately 2 hrs via IV infusion.~* Cohort 2B: 90 mg of DUR 928 in 100 mL5% dextrose or 0.9% sodium chloride administered over approximately 2 hrs via IV infusion.~* Cohort 3B: 150 mg of DUR 928 in 100 mL5% dextrose or 0.9% sodium chloride administered over approximately 2 hrs via IV infusion More details on preparation and administration of study drug will be provided in the Investigation Product Manual for this study."
223667509|NCT04792242|DEVICE|cv line insertion|Svo2 and central venous pressure measurements
223667510|NCT04792242|DEVICE|Urinary catheter insertion|urine output measurement
223667511|NCT04792242|DEVICE|Arterial line|Arterial blood gases measurment
223667512|NCT04822805|DRUG|Anlotinib hydrochloride|Patients with recurrent high-grade gliomas are being enrolled , treated with anlotinib 12mg once daily for 14 days every 3 weeks until disease progression or unacceptable toxicity.The dose can be adjusted to 10mg or 8mg according to the specific conditions of the patient.
223667513|NCT04686058|DRUG|Propofol 10 MG/ML Injection|
223667514|NCT04686058|DRUG|Midazolam injection|
223667515|NCT04686058|DRUG|Pethidine Hydrochloride 50 Mg/mL Solution for Injection|
223667516|NCT04686058|DEVICE|target controlled infusion pump|
223667517|NCT04686058|DEVICE|patient-controlled sedation pump|
223667518|NCT05918198|DRUG|Ven+CAG|"100 mg on the first day, and then gradually increase to the target dose of 400 mg (100 mg d1, 200 mg d2, 400 mg d3) within 3 days; After that, the drug continued to be administered until the 14th day, 400 mg/day. When combined with CYP3A or P-gp inhibitors (mainly voriconazole in this study), adjust the venetoclax dose to 100 mg/day.~Ara-C 10mg/m2, ih, q12h × 14d； Acla 20mg/d × 4d； G-CSF 5ug/kg × 14d (WBC \> 30 × 10\^9/L pause)"
224249306|NCT06368869|OTHER|Celtra duo veneers luted with dual cured resin cement|Veneers will be fabricated using Zirconia-reinforced lithium silicate (Celtra® Press) ceramic and luted using Bifix QM dual cured cement
224249307|NCT06368869|OTHER|Celtra duo veneers luted with light cured resin cement|Veneers will be fabricated using Zirconia-reinforced lithium silicate (Celtra® Press) ceramic and luted Bisco choice 2 light cured cement
224249308|NCT02819323|DRUG|PEG-ELS|polyethylene glycol based bowel preparation
224249309|NCT02819323|DRUG|BLI800|BLI800 bowel preparation
224249310|NCT06558721|OTHER|Conventional rehabilitation|Lower extremity conventional rehabilitation in stroke patients
223771088|NCT04125316|OTHER|Observation, no intervention|Observational study, no intervnetion
223771089|NCT00000540|DEVICE|defibrillators, implantable|
223667519|NCT03708393|DEVICE|Imagio (IUS+OA)|The Imagio ultrasound and opto-acoustic images to be reviewed as part of the reader study
223667520|NCT03708393|DEVICE|Imagio Ultrasound|Imagio ultrasound images to be reviewed as part of the reader study
223667521|NCT03708393|DEVICE|Mammography|Mammography images as available per standard of care
223667522|NCT04312646|DEVICE|Elastography .|Performance of US, elastography
223667523|NCT03571698|DEVICE|Neuromuscular Electrical Stimulator|The treatment group received exercise programme with simultaneously active contraction with NMES with large or standart electrodes.
223667524|NCT03645434|DRUG|AZD8871|Randomized patients will receive 14 repeated daily doses of AZD8871 600 µg inhalation powder via DPI.
223667525|NCT03645434|DRUG|Anoro® Ellipta®|Randomized patients will receive 14 repeated daily doses of Anoro® Ellipta® (55 µg/22 µg) inhalation powder via DPI.
223667526|NCT02863536|DEVICE|Polybactum®|3 cycles treatment one per month.. Duration of one cycle: 1 week; administration for each cycle: 1 ovule at Day 1, 1 ovule at Day 4; 1 ovule at Day 7.In the two following cycles, the same treatment will be repeated immediately after the end of the first and second menstrual bleeding.
223667527|NCT04796064|OTHER|low-intensity aerobic training|"A low-intensity aerobic training group started with 15 minutes of warm-up, which includes static stretching of the upper and lower limb muscles. then participants were instructed to do 30 minutes of low-intensity aerobic training exercises, which include 20 minutes on the treadmill and 10 minutes of cycle ergometer, followed by 10 minutes of cool down.~\- In high-intensity training (HAT) the same protocol has been followed, but the intensity of exercises was fixed between 60% to 80 % of maximum heart rate. The strength training includes major group muscles such as shoulder flexors, extensors, and abductors, elbow flexors and extensors, hip flexors\& extensors, knee flexors\&extensors, abdominal and back muscles also were trained. Each group of muscles was trained for 10 repetitions for 3 sets with a rest period of 5 minutes."
223667528|NCT00415298|DRUG|DACH polymer platinate AP5346|
223667529|NCT00415298|DRUG|oxaliplatin|
223667530|NCT00415298|GENETIC|gene expression analysis|
223667531|NCT00415298|OTHER|immunohistochemistry staining method|
223667532|NCT00415298|OTHER|pharmacological study|
223771090|NCT01466192|DRUG|MP-424 (generic name:Telaprevir)|750mg q8h for 12 weeks
223771091|NCT01466192|DRUG|Ribavirin|400 - 1000 mg/day based on body weight for 24 weeks
223771092|NCT01466192|DRUG|Peginterferon alfa-2b|1.5mcg/kg/week for 24 weeks
223771093|NCT02211469|DRUG|BMS-986104|
223771094|NCT02211469|DRUG|Placebo|
223667533|NCT00415298|PROCEDURE|biopsy|
223667534|NCT04437121|OTHER|Online Survey about Dietary and Lifestyle Habits|"An online survey was conducted in a random sample of families. Parents self-reported their child's and their own dietary and lifestyle habits, as well as information about their sociodemographic status.~The survey consisted of 70 questions in 3 sections."
223667535|NCT03603678|DRUG|BAY2253651|100 µg (500 µg/ml \* 200 µl) BAY2253651 intranasally
223667536|NCT03603678|DRUG|Placebo|Matching Placebo dosing
223667537|NCT04646564|DRUG|standard of care|patients receive appropriate therapy at the discretion of the treating oncologist, i.e. systemic therapy according to molecular subtypes, including chemotherapy, endocrine therapy, targeted therapy, or immunotherapy.
223771095|NCT01412775|BEHAVIORAL|short-term group intervention program|"The intervention will include three aspects: Psycho-educational intervention: attending a lecture about stress and exhaustion; Techniques for decreasing stress: experiencing relaxation techniques and guided imagery and a BALINT style group:analyzing actual work cases and cognitive-behavioral focusing for reframing thoughts and making them more adaptive, expressing emotions and training for more appropriate behaviors.~The study includes three weekly sessions, Each session will be 90 minutes in duration."
223771096|NCT06078046|BEHAVIORAL|Mind-body interventions|Parallel randomized controlled trial
223771097|NCT01585480|BEHAVIORAL|Weight Gain Prevention Intervention|"1. Behavioral Approaches~   1. Distribution of pedometers~  2. Traffic light labeling in worksite cafeteria and vending machines~2. Informational \& Persuasive Messages~   1. Stair use prompts~  2. Posters, pamphlets, table toppers~  3. Website~3. Social Approaches~   a. Identification and training of influential employees (Peer Helpers) to shape healthy norms~4. Environmental Changes~   1. Traffic light labeling~  2. 1/2 portions at 1/2 price~  3. Walking routes~  4. Introduction of healthier foods~  5. Rearrangement of foods in the cafeteria~  6. Adjusting serving spoon size"
223771098|NCT03033472|DRUG|600 mg Clindamycin orally|600 mg Clindamycin orally 30 minutes before treatment
223771099|NCT03033472|DRUG|Oral Placebo|Oral Placebo 30 minutes before treatment
223771100|NCT04623580|DEVICE|Surgical inguinal or femoral hernia repair|Surgical inguinal or femoral hernia repair (primary or mesh)
223771101|NCT03309280|OTHER|Duration of intubation|Time between intubation in the operating room and exhumation in the Intensive Care Unit.
223771102|NCT03309280|DIAGNOSTIC_TEST|Evolution of the renal function|Evolution of the renal function in the next two days
223771103|NCT02456922|DEVICE|Harmony 1 Sensor|Use of Harmony 1 Sensor over 10 days in arm and abdomen and used with the Guardian Mobile App in subjects aged 2-75 years who have had a diagnosis of type 1 or type 2 diabetes for at least one year.
224249311|NCT06558721|OTHER|Mirror therapy|Mirror therapy of the lower extremity in stroke patients
224249312|NCT06558721|DEVICE|Bicycle ergometer with functional electric stimulation|Bicycle ergometer with functional electric stimulation therapy of the lower extremity in stroke patients
224249313|NCT01691456|DRUG|Montelukast sodium|Montelukast Sodium Oral Granules 4mg
224249314|NCT04992611|BEHAVIORAL|Sleep Extension (Early)|Following a periods of time meant to stabilize their sleep patterns and to induce mild sleep restriction, participants will be randomly assigned to one of two sleep extension conditions, both of which are designed to allow recommended sleep duration. The Early Sleep Extension condition does so by keeping rise time the same as the sleep restriction period, but extending sleep by going to bed earlier. This produces a sleep extension that is aligned for Morning Larks and misaligned for Night Owls.
223771104|NCT04431037|DIETARY_SUPPLEMENT|Early oral feeding/Enhanced recovery after surgery protocols|Early oral feeding refers to NG tube and foley's catheter removed within 12 hours and patients allowed oral sips on day 1 with gradual shift to liquid diet after 12 hrs and semisolid food started after 24 hours later.Patients were given i/v antibiotics,painkillers and i/v PPIs and shifted to oral pain killers on 2nd POD.
224249315|NCT04992611|BEHAVIORAL|Sleep Extension (Late)|Following a periods of time meant to stabilize their sleep patterns and to induce mild sleep restriction, participants will be randomly assigned to one of two sleep extension conditions, both of which are designed to allow recommended sleep duration. The Early Sleep Extension condition does so by keeping bedtime the same as the sleep restriction period, but extending sleep by rising later. This produces a sleep extension that is misaligned for Morning Larks and aligned for Night Owls.
224249316|NCT00006051|DRUG|cisplatin|
224249317|NCT00006051|DRUG|fluorouracil|
224249318|NCT00006051|RADIATION|radiation therapy|
224249319|NCT00962611|DRUG|Copanlisib (Aliqopa, BAY80-6946)|BAY80-6946 given IV over 1 hour every week for three weeks with a one week break until progression or unacceptable toxicities develop.
224249320|NCT03235128|DIAGNOSTIC_TEST|‗Urine analysis ‗Urine protein quantification ‗Serum albumin ‗Lipid profile.Quantitation of miRNA -30a by Real-time polymerase chain reaction (Q-PCR) in peripheral blood.|Specific tests Quantitation of miRNA -30a by Real-time polymerase chain reaction (Q-PCR) in peripheral blood
224249321|NCT02086747|DRUG|Acetaminophen|100 ml iv, 4 times a day for 72 hours
224249322|NCT02086747|DRUG|Isotonic|100 ml iv, 4 times a day for 72 hours
224249323|NCT02895373|DRUG|Alprostadil|5ng/kg/min, continuously, start within 24h of initiation of ECMO therapy and end at the end of ECMO therapy
224249324|NCT02895373|DRUG|0.9% sodium chloride solution|continuously, start within 24h of initiation of ECMO therapy and end at the end of ECMO therapy
224249325|NCT06215976|DRUG|Metformin Hydrochloride 500 MG|Metformin 500mg tablets twice daily
224249326|NCT05350891|PROCEDURE|endoscopic surgery|endoscopic surgery combined with adjuvant immunotherapy with/without chemotherapy
224249327|NCT00004694|DRUG|heparin|
224249328|NCT02527382|PROCEDURE|Closed stump|Before cutting the bowel, a peritoneal sample for bacterial culture is taken from the peritoneal cavity (pelvic pouch). Anastomosis is performed while a bowel clamp is placed on the rectal stump. A second bacterial sample is obtained at the completion of the anastomosis from the same place (pelvic pouch) as the first one.
223667538|NCT04646564|RADIATION|radiotherapy + standard of care|"Patients receive radiotherapy to all known metastases. SBRT technique is preferred, especially for metastases in bone, lung and liver. Conventional RT can be used when SBRT is not appropriate, such as metastasis in mediastinal or contralateral supraclavicular nodal regions. Total doses of 30Gy to 50Gy in 5 fractions for SBRT are recommended depending on the tolerance of adjacent normal tissue. Total dose of 60Gy in 25 fractions is recommended for conventional RT.~Patients can receive systemic therapy concurrently with RT at the discretion of treating radiation oncologist. After completion of SBRT to all sites of known metastatic disease, patients will continue standard of care therapy per the treating oncologist."
223667539|NCT00770380|BEHAVIORAL|behavioral relapse prevention counseling|Behavioral relapse prevention counseling conducted in two one-hour sessions
223667540|NCT00770380|OTHER|hypnosis for relapse prevention|Hypnosis for relapse prevention conducted in two one-hour sessions
223667541|NCT00003496|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Recurrent or Extensive-Stage Small Cell Lung Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
223667542|NCT03805113|DEVICE|Magnetotherapy device|Use of magnetotherapy device 15 consecutive working days in elegible patients with erosive hand osteoarthritis.
223667543|NCT03805113|DEVICE|Placebo|Use of unplugged magnetotherapy device 15 consecutive working days in elegible patients with erosive hand osteoarthritis.
223667544|NCT00833664|DRUG|Terbinafine HCl 250mg tablets|1 x 250 mg
223667545|NCT00833664|DRUG|Lamisil® 250 mg Tablets|1 x 250 mg
223667546|NCT04148144|OTHER|No intervention included|No intervention included
223667547|NCT00600561|BEHAVIORAL|MBSR|Mindfulness-Based Stress Reduction Intervention
223667548|NCT03834636|PROCEDURE|Restorations with nanoparticulated composites and self etch adhesives|The restorations will be placed according to the protocol developed for the care, following the guidelines of the manufacturers, with a self-etching dental adhesive (SingleBond Universal, 3M ESPE), selective enamel etching, and use of a nanoparticulated composite (Z350, 3M ESPE)
223667549|NCT03834636|PROCEDURE|Restorations with nanoparticulated composites and total-etch adhesives|The restorations will be placed according to the protocol developed for the care, following the guidelines of the manufacturers, with a total-etching dental adhesive (SingleBond 2, 3M ESPE), and use of a nanoparticulated composite (Z350, 3M ESPE)
223667550|NCT03834636|PROCEDURE|Restorations with nanohybrid composites and self etch adhesives|The restorations will be placed according to the protocol developed for the care, following the guidelines of the manufacturers, with a self-etching dental adhesive (SingleBond Universal, 3M ESPE), selective enamel etching, and use of a nanohybrid composite (IPS Empress Direct, Ivoclar Vivadent).
224249329|NCT02004535|PROCEDURE|Cochlear Implantation|The standard surgical procedure for a cochlear implant will be used. The asymmetric participant will receive the cochlear implant in the deaf ear.
224249330|NCT02350621|PROCEDURE|ACDF|
224249331|NCT02350621|PROCEDURE|minimal invasive Posterior Cervical Foraminotomy|
224249332|NCT02017223|DEVICE|Knowme Device Wear|
224249333|NCT06022237|DRUG|Ibandronate|Ibandronate 150 mg once monthly.
224249334|NCT06022237|DRUG|Calcium|Calcium 500 mg twice daily
224249335|NCT06022237|DRUG|Vitamin D3|Vitamin D3 - 1000 IU daily
224249336|NCT00717405|DRUG|Standard chemotherapy|As prescribed
224249337|NCT00717405|DRUG|bevacizumab [Avastin]|15mg/kg iv 3 weekly in cycles 1-8
224249338|NCT00717405|DRUG|trastuzumab [Herceptin]|8mg/kg iv loading dose followed by 6mg/kg iv 3 weekly in cycles 5-8.
224249339|NCT02443220|DEVICE|TEAS (transcutaneous electric acupoint stimulation)|"transcutaneous electric acupoint will commence at 30 min on Danzhong and Hegu before anesthesia in distal-proximal group"
223667551|NCT03834636|PROCEDURE|Restorations with nanohybrid composites and total-etch adhesives|The restorations will be placed according to the protocol developed for the care, following the guidelines of the manufacturers, with a total-etching dental adhesive (SingleBond 2, 3M ESPE), and use of a nanohybrid composite (IPS Empress Direct, Ivoclar Vivadent).
223667552|NCT03865316|DEVICE|SedLine Vs Comparator Test Group|Subjects will receive electrodes that compare EEG signals between Masimo's SedLine system and the comparator's system.
223667553|NCT04084561|BEHAVIORAL|HRHA|participants will be asked to consider a hypothetical scenario in which genetic test results reveal that: 1) they carry genotypes that place African American smokers at a particularly high (\~50%-80%) risk for the development of lung cancer, and 2) their genetic profile reflects a particularly high concordance with African heritage (\~90%).
223667554|NCT04084561|BEHAVIORAL|LRLA|participants will be asked to consider a scenario in which genetic test results reveal that: 1) they are at normal (\~7%-10%) risk for the development of lung cancer, and 2) their genetic profile reflects a particularly low concordance with African heritage (\~10%).
223667555|NCT04084561|BEHAVIORAL|HRLA|"participants will receive High Risk, Low Ancestry (HRLA) hypothetical"
223667556|NCT04084561|BEHAVIORAL|LRHA|"participants will receive Low Risk, High Ancestry (HRLA) hypothetical"
223667557|NCT05197569|OTHER|thyme oil|Thyme oil with a carvacrol ratio of at least 74% will be specific to each patient and will be given to the patient in the form of an inhaler stick. According to expert opinion; The patient's own room should be visited every 8 hours and the patient-specific inhaler stick should be sniffed into 8 breathing lungs. Each patient will use an inhaler stick for 5 days. Hemodynamic parameters (ph, CO 2, O 2 ) and Covid-19 symptoms will be measured before the intervention with the patient (pretest) and at the end of the 5th day (posttest). Vital signs will be measured and recorded three times a day in the patient's room at 08:00, 16:00 and 24:00.
223667558|NCT00105768|BEHAVIORAL|Advisor-Teller Money Management-Substance Abuse Counselling|
223667559|NCT01300013|DRUG|Placebo|48-hour infusion of placebo
223667560|NCT01300013|DRUG|Omecamtiv mecarbil|48-hour infusion of omecamtiv mecarbil; dose strength will depend on cohort assignment.
223667561|NCT03395236|COMBINATION_PRODUCT|"StellarexTM 0.014 Over-The-Wire Drug-coated Angioplasty Balloon"|"The Stellarex balloon (0.014) is indicated for the treatment of de-novo or re-stenotic lesions in the lower extremities to establish blood flow and to maintain vessel patency."
223667562|NCT02981459|DRUG|Mirabegron|daily mirabegron 25mg with the option to increase dose based on symptoms to 50mg daily after 4 weeks
223667563|NCT00137878|DRUG|TNFerade™|
223667564|NCT02602756|RADIATION|Protontherapy|Proton-therapy consists in four consecutive sessions. The experimental arm consists in eight sessions. Irradiation is administered over two weeks, delivering a total dose of 60 Cobalt Gris Equivalent (CGE is the physical Gray dose multiplied by a biological factor of relative efficiency of 1.1 for protons compared to photons).
223667565|NCT06320925|DEVICE|Standard of Care Treatment|Subject has undergone joint space repair using one of the study devices and meets eligibility criteria
223667566|NCT04675554|OTHER|Follow up of physical activity|participants will fill in the non-opposition form via the application and will complete, with their smartphone, a series of psychometric questionnaires. Participants will then use the mobile application for a period of 12 weeks during which time, physical activity data provided from participants smartphone will be gathered After 12 weeks, participants will complete again the same series of psychometric questionnaires.
223667567|NCT04816409|OTHER|conventional therapy|"Range of motion and Resistance training Linear actions are used to regularize extensor muscle tone (Neck extensors, back extensors hip extensors, knee extensors).(49) Postural control exercises Bouncing on gym ball in sitting, kneeling, or standing~\- Linear swinging using a platform and swing, glider, hammock, and barrel; swinging in the kneeling, standing, sitting,"
223667568|NCT04816409|OTHER|Neurodevelopmental therapy|"Starting Posture~* Start and evaluate the supreme effective posture to move from(usually straight)~* Reassemble to mid plane (head/trunk)~* Neutral position of body (47) Identify the Missing Components Detect starting posture and compare to normal.(47)~Neurodevelopmental therapy application :~Tonic postural extensor muscle strengthening:~Push-pull scooter board games contrary to resistive tubing strips.(48) 2. Developmental movement patterns training: Obstacle crawl, hold swing's ropes in kneeling and half kneeling position, throw balls to aim kneeling and standing position. Manual Cues .Use hands on key points of control to assist normal posture, movement and prevent abnormal posture and movement. Balance and corrective reactions was established by means of ball and tilt board after the development of the skill of~li"
223667569|NCT03276520|DIAGNOSTIC_TEST|ethyl glucuronide|alcohol urine screening with ethyl glucuronide
223667570|NCT03276520|DIAGNOSTIC_TEST|ethanol|alcohol urine screening with ethanol
223667571|NCT05883384|OTHER|stool analysis , CBC, specific IgE FOR Cow milk protein allergy|apply CoMiSS and food challenge test on patient whom suspected to have cow milk protein allergy.
223667572|NCT05569460|OTHER|No intervention|No intervention
223667573|NCT01103024|BIOLOGICAL|AIN457|
223667574|NCT01103024|BIOLOGICAL|AIN457|
223667575|NCT01103024|BIOLOGICAL|AIN457|
223667576|NCT01103024|BIOLOGICAL|Placebo|
223667577|NCT03137069|DRUG|GDC-0853|GDC-0853 will be administered orally at dosages of 50, 150 and 200mg to participants, as per the dosing schedules described above.
224249340|NCT02443220|DEVICE|TEAS|"transcutaneous electric acupoint will commence at 30 min on Danzhong and Juque before anesthesia in regional group"
224249341|NCT02443220|DEVICE|TEAS|"The device will be connected to Danzhong and Hegu but no stimulation to the acupoints 30 min before anesthesia"
224249342|NCT04826718|OTHER|Questionaire|"A questionnaire will be administered to all participants to evaluate exposures related to infection at the baseline (enrollement) - Baseline questionnaire. A Follow-up questionnaire to all participants will be done after 3 and 6 months.~Capillary blood collection, for diagnosis of anti-SARS-CoV-2 Antibodies by rapid test, will be done at the first interview, for all participants (cases and controls).~Collection of peripheral venous blood, for analysis of the presence and duration of anti-SARS-CoV-2 Antibodies (N and S) will be done at the first interview, and after 6 months for all participants (cases and controls)."
224249343|NCT04535076|PROCEDURE|Transcatheter Aortic Valve Implantation|Transcatheter Aortic Valve Implantation
224249344|NCT04535076|PROCEDURE|Surgical Aortic Valve Replacement|Surgical Aortic Valve Replacement
224249345|NCT02209194|DEVICE|E-liac Stent Graft System|Implantation of the E-liac Stent Graft System in combination with a peripheral covered stent and in case of aortoiliac aneurysm in combination with a AAA Stent Graft
224249346|NCT04035395|OTHER|Peer-led Support Group|The Viviendo Saludable pláticas (or talks) connected Salud y Vida participants living with diabetes together. These talks served as a forum for Salud y Vida participants to share their knowledge and experiences, including some that many health workers, friends, or family do not have. Viviendo Saludable helped participants develop better strategies for managing their diabetes in their daily life. The Viviendo Saludable pláticas complement and enhance the other services by helping participants create a network of emotional, social, and practical support needed to manage diabetes and stay healthy over the long term. Classes met once a week for one hour at locations central to participants' homes.
224249347|NCT04035395|OTHER|Behavioral Health Consult|In a Behavioral Health consult, a participant meets with a counselor for one or more thorough meetings to talk about things that influence their health and well-being. A participant receiving a Behavioral Health consult receives support and is empowered with health coping skills that will allow for improved medication adherence and motivation to control their diabetes.
223667578|NCT03137069|DRUG|Placebo|Matching Placebo will be administered orally, as per the dosing schedules described above.
223667579|NCT03285022|PROCEDURE|Partial caries removel techniques|Removel of all superfacial dentin and leaving the inner affectted dentin
223667580|NCT01454310|DEVICE|Wound coverage by acellular skin substitute|Burn wounds are covered by an acellular skin substitute and remains 10-14 days that peals away in line with re-epithelialisation
223667581|NCT01454310|DEVICE|Autologous skin|Matched burn wound is covered by autologous skin after tangential excision.
223667582|NCT03665025|OTHER|immediate implant using mixed allograft and xenograft|immediate implant using mixed allograft and xenograft in anterior area to fill jumping area
223667583|NCT03453372|DEVICE|MRgFUS Treatment|Treatment of pain caused by knee osteoarthritis with high-intensity focused ultrasound
223667584|NCT03453372|OTHER|Placebo|Procedures in the placebo group will be identical to procedures in the active group, except no sonications (ultrasound emission) will be used.
223667585|NCT01599936|BIOLOGICAL|Anascorp|3 vials of Alacramyn reconstituted in 50 ml of normal saline as an IV infusion over 10 minutes.
223667586|NCT03876392|DIAGNOSTIC_TEST|magnetic resonance imaging|Compare bone marrow biopsy with magnetic resonance imaging to detect bone marrow metastases
223667587|NCT03995251|DRUG|Testosterone Supplementation|Intramuscular Testosterone Undecanoate 1000 Mg (4 ml volume in oily base) will be injected into the upper, outer quadrant of the buttock at 0, 6, 12,16,20, 24 weeks according to manufacturer recommendations
223667588|NCT03995251|DRUG|Standard Medical Treatment|Standard Medical Treatment
223667589|NCT03995251|OTHER|Exercise|Exercise
223667590|NCT00336830|BEHAVIORAL|MD-endorsed Cardiac Rehabilitation referral|Note to patient with general description of the Cardiac Rehabilitation program with signature and strong recommendation from attending physician.
223667591|NCT00336830|BEHAVIORAL|Standard Cardiac Rehabilitation referral|Note to patient with general description of the Cardiac Rehabilitation program without signature or recommendation from attending physician.
223667592|NCT04740645|OTHER|NOCDURNA Cohort|Non intervention
223667593|NCT04740645|OTHER|LUTS Cohort|Non intervention
223667594|NCT01788410|PROCEDURE|Cryoablation under image guidance|Observing efficacy of cryoablation to nerves and facet joints for the treatment of radicular pain and pain resulting from facet joint disease.
223667595|NCT01788410|DEVICE|MRI Seednet Cryotherapy System (Galil Medical)|Observing efficacy of cryoablation to nerves and facet joints for the treatment of radicular pain and pain resulting from facet joint disease.
223667596|NCT00336856|DRUG|Cetuximab|The treatment will include cetuximab 500 mg/m² IV for 120 minutes followed by irinotecan 180 mg/m² or 60 minutes. The starting dose of irinotecan for patients who are 70 years old or greater, or who have had radiation therapy to the abdomen or pelvis, or whose level of functioning is poor (performance status of 2) will have a starting dose of 150 mg/m2 for irinotecan. All subsequent treatments will include cetuximab 500 mg/m² IV over 60 minutes and irinotecan 150 mg/m² or 180 mg/m2 intravenously over 60 minutes every 2 weeks.
223667597|NCT00336856|DRUG|Irinotecan|The treatment will include cetuximab 500 mg/m² IV for 120 minutes followed by irinotecan 180 mg/m² or 60 minutes. The starting dose of irinotecan for patients who are 70 years old or greater, or who have had radiation therapy to the abdomen or pelvis, or whose level of functioning is poor (performance status of 2) will have a starting dose of 150 mg/m2 for irinotecan. All subsequent treatments will include cetuximab 500 mg/m² IV over 60 minutes and irinotecan 150 mg/m² or 180 mg/m2 intravenously over 60 minutes every 2 weeks.
223667598|NCT03633240|OTHER|ER assessment|"To measure the effects of recommendations of ER2, the investigators will use ER users who will have an ER2 assessment without any recommendations as the referent group the older. This choice is possible because ER2 will be integrated into ER care in two steps:~The first step will be limited to its assessment component in order to learn how to use the tool.~The second step will be to follow the recommendations provided after the assessment.~Participants will follow-up during their hospitalization via a review of their chart. They will be censored when they will be discharged from the JGH or when the duration of hospitalization will exceed 31 days."
223667599|NCT05396716|DEVICE|transcutaneous electrical acupoint stimulation|Electrodes are placed at acupoints and connected to the stimulator. Electrical stimulation is given during surgery.
223667600|NCT02720107|DRUG|fingolimod|
223667601|NCT00225810|DRUG|Crohn's Disease|
223771105|NCT00466765|DEVICE|Brava Autologous Fat Transfer System|Number of procedures is based on patient need
223771106|NCT03247439|DEVICE|Cartiva|Synthetic Cartilage Implant
223771107|NCT01812928|DRUG|Diclofenac|
223771108|NCT01227512|DRUG|tolvaptan|15 mg titrated to 30 mg then 60 mg once daily as oral tablet for up to 7 days based on response.
223771109|NCT01227512|OTHER|Fluid Restriction|"Placebo tablet once daily with prescribed daily fluid intake of 1500 mL, then intensifying to 2 lower volumes of fluid intake for up to 7 days based on response.~Since all particpants were blinded to treatment, titration to stricter fluid restriction followed the same algorithm as tolvaptan, increasing both the level of fluid restriction and increasing the placebo dose"
223771110|NCT00003268|DRUG|amifostine trihydrate|
223771111|NCT00003268|DRUG|cytarabine|
223771112|NCT00003268|DRUG|idarubicin|
223771113|NCT04150224|DRUG|PBTZ169 640 mg OD|Two administrations once a day with a wash-out period: food effect
223771114|NCT04150224|DRUG|PBTZ169 640 mg BiD|Twice a day fasted; 1 day of administration
223771115|NCT04150224|DRUG|PBTZ169 960 mg SD|Once a day fasted
223771116|NCT04150224|DRUG|PBTZ169 1280 mg SD|Once a day fasted
223771117|NCT04150224|DRUG|PBTZ169 1280 mg MD|Once a day after meal, 14 doses
223771118|NCT05556122|OTHER|intercostal nerve block|General anesthesia and intercostal nerve block were performed. The drug for intercostal nerve block was 0.33% ropivacaine +2.333mg compound betamethasone (1.667mg betamethasone dipropionate + 0.667mg betamethasone sodium phosphate) to 15ml
223771119|NCT05556122|OTHER|lateral intercostal nerve block|lateral intercostal nerve block
223771120|NCT05556122|DRUG|ropivacaine + compound betamethasone|The drug for intercostal nerve block was 0.33% ropivacaine +2.333mg compound betamethasone (1.667mg betamethasone dipropionate + 0.667mg betamethasone sodium phosphate) to 15ml
223771121|NCT04055116|DRUG|Buffered Lidocaine|Investigator will prepare 1:10 dilution of sodium bicarbonate to 2% lidocaine with 1:100,000 epinephrine on one occasion. 8.4% Sodium Bicarbonate will be used.
223771122|NCT03553316|DRUG|PK101-002|-(Single) PK101-002
223771123|NCT03553316|COMBINATION_PRODUCT|PK101|-(Combination) PK101-001, PK101-002
223667602|NCT02649348|BEHAVIORAL|pre-operative prehabilitation|To climb six flights of stairs (approximately 20 meters in height) at least 6 times as a daily routine and adaptive simulated training of restrictive ventilation dysfunction (increased thoracic and decreased abdominal breathing compliance) following abdominal surgery by using a full elastic breathable abdominal bandage.
223667603|NCT04113369|DEVICE|TENS|30 minutes of conventional antalgic TENS to non-paretic forearm
223667604|NCT04113369|PROCEDURE|Conventional rehabilitation|40 minutes of lower limb training and 20 minutes of upper extremity training for stroke
223667605|NCT04113369|DEVICE|EMS|20 minutes of EMS to non-paretic forearm with 5 minutes of pre and post warm-up
223667606|NCT05049083|DRUG|New Process SHR2554 tablet、Former Process SHR2554 tablet|New Process, 350 mg SHR2554 tablets on study day 1 - Former Process, 350 mg SHR2554 tablets on study day 8
223667607|NCT05049083|DRUG|Former Process SHR2554 tablet、New Process SHR2554 tablet|Former Process, 350 mg SHR2554 tablets on study day 1 - New Process, 350 mg SHR2554 tablets on study day 8
223667608|NCT00842907|DRUG|oral isotretinoin|one 20.0 mg capsule, once a day, every other day, during 24 weeks
223771124|NCT00901875|DRUG|Buprenorphine + naloxone (Suboxone)|Sublingual tablets
223771125|NCT00901875|DRUG|Buprenorphine + naloxone (Suboxone)|
223771126|NCT02774681|PROCEDURE|Cognitive Assessment|Ancillary studies
223771127|NCT02774681|DRUG|Palbociclib|Given PO
223771128|NCT02774681|PROCEDURE|Quality-of-Life Assessment|Ancillary studies
223771129|NCT02774681|BIOLOGICAL|Trastuzumab|Given IV
223667609|NCT00842907|DRUG|Tretinoin|0.05% tretinoin cream applied on face and forearms, once a day, in the night, during 24 weeks
223667610|NCT01452542|DRUG|Eliglustat, common blend proposed commercial formulation|All participants will receive a single oral 150-mg dose of the common blend proposed commercial formulation of eliglustat, administered as one 150-mg strength capsule (Treatment T), on 2 separate dosing occasions.
223771130|NCT03221985|OTHER|questionnaires|questionnaire with application on smartphone
223771131|NCT05430789|BEHAVIORAL|5As brief advice|"Participants will receive brief face-to-face advice following a 5As model at baseline:~1. Ask: Smoking patients will be asked about their smoking status.~2. Advise: Smoking patients will be advised to quit in a clear and personalised manner, with a focus on smoking-related diseases.~3. Assess: Smoking patients will be assessed for their readiness to quit by assessing their self-efficacy and perceived importance.~4. Assist: Those who are ready to quit will be assisted in setting a quit plan.~5. Arrange: Refer to smoking cessation services."
223771132|NCT05430789|BEHAVIORAL|Self-help e-booklet|"A 12-page generic self-help smoking cessation e-booklet via IM apps, including:~1. Highlights of the absolute risk of death due to smoking;~2. Smoking and diseases management;~3. Ten horrible pictorial warnings of health consequences of smoking and second-hand smoking;~4. Benefits of quitting;~5. Methods to quit and handle. withdrawal symptoms."
223771133|NCT05430789|BEHAVIORAL|Nurse-led mHealth intervention|Participants will receive real-time mHealth behaviour and psychosocial support for 12 weeks after baseline through IM apps. mHealth intervention consists of two main parts: regular instant messaging on smoking cessation and personalized real-time mHealth chatting on smoking and disease (including active referral to smoking cessation service)
223771134|NCT05430789|BEHAVIORAL|Regular intervention|Participants will receive text messages using IM app with content on general health and reminding the importance of participating in the follow-up surveys and biochemical validation for quitting.
223771135|NCT04497987|DRUG|Bamlanivimab|Administered IV.
223771136|NCT04497987|DRUG|Placebo|Administered IV.
223771137|NCT04497987|DRUG|Etesevimab|Administered IV.
223771138|NCT01818362|BIOLOGICAL|MVA NP+M1|MVA NP+M1 1.5 x 10⁸pfu intramuscularly.
223771139|NCT01818362|BIOLOGICAL|ChAdOx1 NP+M1|ChAdOx1 NP+M1 2.5 x 10¹⁰vp intramuscularly.
223771140|NCT05443477|DIETARY_SUPPLEMENT|Hericium Erinaceus Mycelium|participants received two oral capsules containing Hericium erinaceus Mycelium every day for the 3 months.
223771141|NCT05443477|DIETARY_SUPPLEMENT|Probiotic|participants received two oral capsules containing Probiotic powder every day for the 3 months.
223667611|NCT01452542|DRUG|Eliglustat, Phase 3 capsule formulation|All participants will receive a single oral 150-mg dose of the Phase 3 capsule formulation of eliglustat, administered as three 50-mg strength capsules (Treatment R), on 2 separate dosing occasions.
224249348|NCT04035395|OTHER|Medication Therapy Management Consult|Medication Therapy Management helps participants and their doctors make sure that their medications are working to improve their health. In a Medication Therapy Management (MTM) consult, a pharmacist gives participants a comprehensive review of all their medications and speaks with them about 1) how well their medications are working, 2) whether their medications have side effects, 3) if there might be interactions between the drugs their taking, 4) whether costs can be lowered and 5) other problems participants are having. The participant will get a written summary of this discussion, including an action plan that recommends what can be done to make the best use of their medications.
224249349|NCT04035395|OTHER|La Cocina Alegre/ The Happy Kitchen|The Happy Kitchen is a program where people come together to learn skills and self-sufficiency in preparing healthy, economical meals, laugh, cook, and enjoy food together. The cooking and nutrition program is an interactive 6-week series of classes, where the essential skills for healthy eating is taught and emphasis is placed on the selection and preparation of fresh, seasonal foods that are nutritious, economical, and delicious. Classes meet once a week for 1 ½ hours to cook, discuss, and learn together. All participants leave each class with recipes and groceries to practice new cooking skills.
224249350|NCT04035395|OTHER|Mind, Exercise, Nutrition, Do it!|MEND is a diet and exercise education program that helps families support their kids, ages 6-13, to reach a healthy weight. The program teaches adults and their children how to maintain energy and confidence throughout the day while learning how to cook healthy meals. Each program lasts 10 weeks and classes are 2 times per week. An adult must attend with the child.
224249351|NCT04263649|DEVICE|Peripherally Inserted Central Catheter|insertion of a Peripherally Inserted Central Catheter (PICC)
224249352|NCT01982318|DRUG|VitroGro® ECM|
224249353|NCT01982318|DRUG|Dulbecco's Phosphate Buffered Saline|
223667612|NCT00949494|DEVICE|Synvisc|intra-articular, 3 weekly injections
223667613|NCT01335802|GENETIC||Genetic counseling
223667614|NCT04415242|OTHER|positioning|different positioning prior surgery
223667615|NCT04048733|DEVICE|patchy-type wireless 12-lead ECG|Perform 12-lead ECG using patchy-type wireless 12-lead ECG. This device automatically record 12-lead ECG in every 15 minutes by its algorithm.
223667616|NCT00362180|DRUG|mipomersen|200 mg subcutaneous injections
223667617|NCT00362180|DRUG|Placebo|subcutaneous injections
223667618|NCT03834649|PROCEDURE|partially de-epithelized connective tissue graft|graft procedures to obtain simultaneous tissue augmentation in the horizontal and vertical dimensions. The donor site was prepared with a full-thickness coronal dissection and a partial-thickness apical dissection.The objectives were to use a single procedure to achieve simultaneously apico-coronal and buccolingual augmentation,to have a smaller open wound in the donor site and less patient discomfort, and to guarantee better revascularization of the onlay section aided by the submerged connective tissue section of the graft.
223667619|NCT03834649|PROCEDURE|Mucograft|"For preprosthetic defects, a standard mucosal augmentation procedure, which is well reported in the literature, was performed. The surgical site produced by the surgery leaves a denuded area supraperiosteally that is addressed by grafting with a xenogeneic collagen membrane (Mucograft).~purpose of the surgery is to improve the quantity of attached mucosa to facilitate the final dental reconstruction"
223667620|NCT03469869|OTHER|balanced and sustainable diet|"the intervention group will get menu recommendation of restriction calorie balanced and sustainable diet for 8weeks. the other group will get menu recommendation of balanced diet for 8 weeks. these menus are given in the apps named EatsUp.~the intervention group will get menu recommendation of restriction calorie balanced and sustainable diet for 8 weeks. the other group will get menu recommendation of balanced diet for 8 weeks. these menus are given in the apps named EatsUp."
223667621|NCT00107484|DRUG|ferumoxtran-10|
223667622|NCT00107484|PROCEDURE|magnetic resonance imaging|
223667623|NCT00107484|PROCEDURE|sentinel lymph node biopsy|
223667624|NCT00481975|DRUG|rimonabant (SR141716)|
223667625|NCT02006095|OTHER|Magnetic resonance imaging|arterial spin labeling, diffusion tensor imaging, and diffusion weighted imaging sequences will be used
223667626|NCT02006095|BEHAVIORAL|Neuropsychological testing|
223667627|NCT04195191|OTHER|ANM|communication intervention
223667628|NCT04195191|OTHER|Placebo|regular assistance in community pharmacies
223667629|NCT03246997|OTHER|Autumn Group|The intervention is participating in a fruit and vegetable farm share for 6 months.
223667630|NCT03246997|OTHER|Spring Group|The intervention is participating in a fruit and vegetable farm share for 6 months.
223667631|NCT01237483|DRUG|Erbitux|To begin 7 days before radiotherapy, loading dose 400 mg / m² in the first week then 250 mg / m² weekly for the duration of radiotherapy (for a total of 7 doses including the loading dose)
223667632|NCT03930264|DRUG|Azathioprine 50Mg Tab|tablet
223667633|NCT03930264|DRUG|Azathioprine 10mg/mL oral suspension|oral suspension
223667634|NCT04441190|BEHAVIORAL|Digital Action Observation Therapy (Digital AOT)|The participants will be asked to observe videos and then practice what the participants observed.
224249354|NCT04671368|DIAGNOSTIC_TEST|Artificial Intelligence|The investigators will use the Artificial Intelligence Diagnostic System to review the H＆E stained slide of each patient and then report the classification of the tumor on a 10-type scale.
223667635|NCT04441190|BEHAVIORAL|Digital Mirror Therapy (Digital MT)|The participants will observe the real-time self-recorded visual illusion, and move their upper limbs as could as possible.
223667636|NCT04441190|BEHAVIORAL|Conventional Occupational Therapy|The participants will receive upper-limb training without providing videos for observing neither providing them mirror illusions of movements.
223667637|NCT04320641|OTHER|ACUPRESSURE|Acupressure points were determined in a certain order considering the direction of the meridian. The order of application was in the form of Spleen 6th point (SP 6) and 4 point of the Large Intestine (Li 4). In total, 4 points in the upper / lower extremities and 6 acupressure points along with parallel points were studied in each attempt.
223771142|NCT05443477|DIETARY_SUPPLEMENT|control|participants received two oral capsules containing control powder every day for the 3 months.
224249355|NCT04671368|DIAGNOSTIC_TEST|Practicing Pathologists|The ordinary pathologist will review the H＆E stained slide of each patient(without additional informations such as: Immunohistochemistry et al.) and then report the classification of the tumor on a 10-type scale only bases on the slide images
223667638|NCT04774211|DIAGNOSTIC_TEST|SOS-PD|Validation of SOS-PD bedside assessments comparing the Danish SOS-PD scale with a Child Psychiatrist using DSM-V as the reference standard
223667639|NCT01737229|DEVICE|Application of Biodentine™ (RD94), dentin substitute|
223667640|NCT05056428|BEHAVIORAL|8-week mindfulness program|The .b Foundations course is an 8-week mindfulness program developed by Mindfulness in Schools Project (MiSP) for school teachers and personnel. It includes a taster session and 8 weekly sessions. Each session lasts for 1.5 hours with a specific theme (e.g. Lesson 1 waking up from autopilot). Formal and informal mindfulness practices (e.g. mindful eating, body scan, mindful walking, habit releaser etc.), psychoeducation, cognitive exercises, inquiry, and home practice are involved.
223667641|NCT05128422|OTHER|Normobaric oxygen therapy|it is simple to administer via oxygen storage facemask at flow rates of 10 L/min for 4 hours.This therapy should begin in the emergency room as early as possible when patients meet the inclusion criteria and are randomized to the experimental group
223667642|NCT01007630|DRUG|Rasagiline|0.5mg for 14 days, then switch to 1mg for remainder of the study (approximately 10 weeks total)
223667643|NCT01007630|DRUG|Placebo|0.5mg for 14 days, then switch to 1mg for remainder of the study (approximately 10 weeks total)
223667644|NCT02434471|DEVICE|Respiratory-triggered T1w DISCO LAVA|"The study will acquire extra image sets using DISCO LAVA with one breath hold during the arterial imaging phase. No additional breath holds will be required.~1. Respiratory-triggered T1w DISCO LAVA precontrast~2. Respiratory-triggered T1w DISCO LAVA in the portal venous phase~3. Respiratory-triggered T1w DISCO LAVA in the equilibrium phase"
223667645|NCT03117439|OTHER|duration of antifungal therapy|Patients in the study group will stop antifungals in presence of a negative result of Beta Glucan Test
223667646|NCT04625296|BEHAVIORAL|Semi-directive interview|Semi-directive interview, lasting a maximum of 45 minutes
223667647|NCT04625296|BEHAVIORAL|Questionnaire : Preparedness for Caregiving Scale|Preparedness for Caregiving Scale - 8 questions
223667648|NCT03667898|PROCEDURE|Lumbar plexus block using NTT|An lumbar plexus block is performed using ultrasound guidance with needle tip tracking.
223667649|NCT03667898|PROCEDURE|Lumbar plexus block without NTT|An lumbar plexus block is performed using ultrasound guidance without needle tip tracking.
223667650|NCT00843778|BIOLOGICAL|Certolizumab Pegol|"200 mg every two weeks~Certolizuimab Pegol 200 mg every two weeks Subjects who flared at Week 48 or Week 52 of feeder study C87076 \[NCT00674362\], will receive respectively once 400 mg Certolizumab Pegol or three times 400 mg Certolizumab Pegol at two weeks interval as part of an induction phase in the C87080 study. Thereafter the subject enters the C87080 study and will be further treated with 200 mg Certolizumab Pegol every two weeks."
223667651|NCT02027129|OTHER|High Frequency Oscillation|Comparison of low frequency HFO/HFO-TGI with cuff leak and high frequency HFO without cuff leak on right ventricular function
223667652|NCT03663556|OTHER|Infant-feeding|Preterm infants hospitalized in the NICU can be feed by three different types of infant feeding, such as breast milk, donor human milk and/or formulas.
223667653|NCT01696162|OTHER|Algorithm based Exercise Videos|The algorithm will adjust the exercises in each session based upon the participant's feedback.
223667654|NCT01696162|OTHER|PDF Exercise Sheets|A sheet of six exercises with descriptions on how to perform them properly
223771143|NCT02489227|DRUG|CHS-1420|
223667655|NCT01696162|OTHER|Limited Exercise Videos|Video of 6 exercises that provide instruction on how to perform the exercises
223667656|NCT00998244|OTHER|Diet - very low carb or low fat|Diet comparison in Gastroesophageal Reflux Disease
223667657|NCT00439049|DRUG|modafinil|400 mg daily
223667658|NCT00439049|DRUG|d-amphetamine|60mg daily
223667659|NCT00439049|DRUG|L-Dopa|800/200mg daily
223771144|NCT02489227|DRUG|Adalimumab|
223771145|NCT00512096|DRUG|Ifosfamide|1200 mg/m\^2 By Vein Over 2 Hours on Days 1-3
223667660|NCT00439049|DRUG|Naltrexone|50mg daily
223667661|NCT02811627|DRUG|Memantine|Namenda (pill and the liquid) will be started at 5 mg/day doses to be titrated up 20 mg/day based on response and tolerability, as per the package insert instructions and based upon clinical titration in other clinical trials for a period of 12 weeks. Namenda XR will be started at 7 mg/day to be titrated up to 28mg/day based on response and tolerability, as per package insert instructions and based upon clinical titration in other clinical trials for a period of 12 weeks.
223667662|NCT02811627|DEVICE|Magnetic Resonance Imaging|The subjects will undergo an MRI assessment after baseline behavioral assessment. The session will involve a structural MRI scan, single voxel spectroscopy scans and resting state functional MRI. The subjects will be started on memantine post the imaging session. The imaging will be carried out on a research dedicated 3 Tesla (3T) Siemens Trio Scanner at the University of Missouri Brain Imaging Center by trained personnel.
224249356|NCT04671368|DIAGNOSTIC_TEST|Gold Standard|Firstly, the two expert pathologist(\>=10 years of experience) will review the H＆E stained slide of each patient on their own (with additional informations such as: Immunohistochemistry et al.) and then report the classification of the tumor on a 10-type scale.If they report the same opinion, that opinion will perform as the ground truth; while if their opinion clash with each other, the expert pathologist(\>=15 years of experience) will get involved and the agreement of three experts will perform as the ground truth
223771146|NCT00512096|DRUG|Paclitaxel (Taxol)|175 mg/m\^2 By Vein Over 3 Hours on Day 1
223771147|NCT00512096|DRUG|Cisplatin|25 mg/m\^2 By Vein Over 2 Hours on Days 1-3
223771148|NCT04652128|DRUG|Zoledronic acid|Subject will receive a single infusion of zoledronic acid 5mg/100mL intravenously.
223771149|NCT04652128|DRUG|Placebo|Subject will receive a single infusion of physiological saline 100mL intravenously.
223771150|NCT03672903|DEVICE|Weight Vest|A vest with added weights up to a maximum of 15 kg.
223771151|NCT01826162|OTHER|acetate or placebo infusion|
223771152|NCT00128258|PROCEDURE|Injection of bone marrow cells in the heart|Biological implant into the heart
223771153|NCT00128258|BIOLOGICAL|Biological bone marrow cell therapy|Biological implant into the heart
223667663|NCT02110602|OTHER|Diet high in amino acid levels|Meals will be prepared in the Clinical Research Center Metabolism \& Nutrition Metabolic Kitchen, and participants will eat only this food during the controlled-diet periods of the study. The diets will contain equivalent calories (matched to the requirements of each participant) and either a low or high percentage of all BCAAs relative to protein content.
223667664|NCT02110602|OTHER|Diet low in amino acid levels|Meals will be prepared in the Clinical Research Center Metabolism \& Nutrition Metabolic Kitchen, and participants will eat only this food during the controlled-diet periods of the study. The diets will contain equivalent calories (matched to the requirements of each participant) and either a low or high percentage of all BCAAs relative to protein content.
223667665|NCT00720447|BIOLOGICAL|alemtuzumab|
223667666|NCT00720447|BIOLOGICAL|donor lymphocytes|
223667667|NCT00720447|DRUG|carmustine|
223667668|NCT00720447|DRUG|cytarabine|
223667669|NCT00720447|DRUG|etoposide|
223771154|NCT04407728|OTHER|early ultrasound screening|"Women whose fetus is at high risk of congenital heart disease at the end of the 1st trimester screening ultrasound (EchoT1), will benefit from an early heart-centered morphological ultrasound (EchoMorpho-T1) by a referring sonographer between 11 and 14 SA +/- an early fetal cardiac ultrasound (EchoCoeur-T1) between 11 and 15 SA by a cardio-paediatrician in case of EchoMorpho-T1 abnormality.~The results of the early morphological and cardiac ultrasounds will be compared with those of the 2nd trimester ultrasound at 18-22SA (EchoMorpho-T2) and +/- of the fetal cardiac ultrasound between 18SA and 24SA (Gold standard) or, failing this, with the anatomopathological examination when it is available if a medical termination of pregnancy took place before the EchoMorpho-T2."
223771155|NCT04139590|DEVICE|Panda|
223771156|NCT04139590|DEVICE|Visual Analogue Scale - Original|
223771157|NCT00003335|BIOLOGICAL|anti-thymocyte globulin|antithymocyte globulin IV for three days on days -3 to -1
223771158|NCT00003335|DRUG|busulfan|If TBI is not tolerated, busulfan is substituted and administered orally every 6 hours for 4 days on days -8 to -5.
224249357|NCT01534520|DRUG|Lidocaine|Intravaginal insertion of 4mL 2% lidocaine gel
224249358|NCT01534520|DRUG|Placebo|KY Jelly
223667670|NCT00720447|DRUG|melphalan|
223667671|NCT00720447|PROCEDURE|allogeneic bone marrow transplantation|
223667672|NCT00720447|PROCEDURE|peripheral blood stem cell transplantation|
223667673|NCT00369629|DRUG|Gemcitabine|Patients will be treated in cohorts of 3-6 per cohort. The starting dose of gemcitabine will be 800 mg/m\^2 given as an intravenous (IV) infusion on days 1 and 15 of each 28-day cycle. The dose will be escalated for each subsequent cohort of patients, up to a maximum of 1200 mg/m\^2.
223667674|NCT00369629|DRUG|Pemetrexed|Patients will be treated in cohorts of 3-6 per cohort. The starting dose of pemetrexed will be 400 mg/m\^2 given as an intravenous (IV) infusion on days 1 and 15 of each 28-day cycle. The dose will be escalated for each subsequent cohort of patients, up to a maximum of 500 mg/m\^2.
223667675|NCT01850576|BEHAVIORAL|Risk Reduction Intervention|STEP is based on social learning theory and provides age-appropriate and culturally acceptable HIV prevention information in a format that encourages information growth and skills enhancement. The program is delivered by 'Instructors,' undergraduate college students aged 18-24, one hour per week for 10 weeks.
223667676|NCT00855270|DRUG|Placebo|IV saline will be used as placebo for control
223771159|NCT00003335|DRUG|cyclosporine|Cyclosporine begin on day -2 and continue for 6 months.
223771160|NCT00003335|DRUG|melphalan|melphalan IV for three days on days -4 to -2
223771161|NCT00003335|DRUG|methylprednisolone|Methylprednisolone IV for three days on days -3 to -1. Methylprednisolone begin on day -2 and continue for 6 months.
223771162|NCT00003335|PROCEDURE|umbilical cord blood transplantation|On day 0, patients receive umbilical cord blood infusion.
223771163|NCT00003335|RADIATION|radiation therapy|9 fractions of total body irradiation (TBI) on days -9 to -5
223771164|NCT01069289|DRUG|Budesonide/formoterol (Symbicort Turbuhaler)|2x160/4.5 microgram, inhalation, twice daily, 12 weeks
223771165|NCT01069289|DRUG|Formoterol (Oxis Turbuhaler)|2 X 4.5 microgram, inhalation, twice daily, 12 weeks
223667677|NCT00855270|DRUG|Hydrocortisone|A single dose 90-150mg of Intra Venous Hydrocortisone. 90mg will be administrated to participants weighing 45-59kg. 100mg will be administrated to participants weighing 60-69kg. 120mg will be administrated to participants weighing 70-89kg. 140mg will be administrated to participants weighing 90-99kg. 150mg will be administrated to participants weighing 100-120kg.
223667678|NCT03386045|RADIATION|Optimal SBRT|Two thirds of the participants in this group will get the SBRT (5 treatments) and one third will get standard treatment (60 Gy in 20 treatments)
223771166|NCT02358824|DRUG|CKD-828|"Telmisartan 80mg /S-Amlodipine 5mg(FDC) Tablet, Oral, Once Daily~(1arm:2period and 4period, 2arm:1period and 3period)"
223771167|NCT02358824|DRUG|Telmisartan|"\- Telmisartan 80mg tablet, Oral, Once Daily (Combination Therapy with S-amlodipine)~(1arm:1period and 3period, 2arm: 2period and 4period)"
224249359|NCT05288881|BIOLOGICAL|ANX105|Participants will receive single-ascending doses of ANX105 administered by IV infusion.
224249360|NCT05288881|DRUG|Placebo|Participants will receive matching placebo administered by IV infusion.
223667679|NCT03386045|RADIATION|Optimal Booster|"Two thirds of the participants in this group will get the two high precision radiotherapy plus 20 doses of standard external beam radiotherapy (ie the Booster approach\|) and one third will get the standard treatment (60 Gy in 20 treatments)"
223667680|NCT02728713|PROCEDURE|Cranial Manipulation|Performed by exaggerating the motion asymmetry with a minimum of pressure (a few ounces) and holding the position until the motion becomes symmetrical.
223667681|NCT02728713|PROCEDURE|Sham/Placebo|A laying on of hands with no actual treatment being performed.
224249361|NCT00439491|BEHAVIORAL|Hypocaloric diet|
224249362|NCT05086562|OTHER|observation study|observation study
223667682|NCT02898285|BEHAVIORAL|Team sports|Participants will choose from a list of team sports and will be signed up with the team.
224249363|NCT02519491|OTHER|Modified Allen Test|The Modified Allen's Test (MAT) will be performed in a well-lit room on both of the participant's hands. This technique will involve compression of both the radial and ulnar arteries by the investigator to assess patency of the contralateral artery. The participant will then be asked to clench and open their hand several times. The participant will then be asked to maintain their hand in an open position. The investigator will then release the compression over the ulnar artery and observe for palmar blush. The length of time to achieve maximal palmar blush will be recorded. This technique will then be repeated by maintaining compression over the ulnar artery and releasing of the compression over the radial artery.
224249364|NCT02519491|OTHER|Iphone artery assessment|The iRADIAL iPhone app (Heart Rate, Azumio software) will be used to assess radial and ulnar artery patency. Briefly, the iPhone camera will be placed over the participant's thumb and patency assessed before and immediately following isolated contralateral artery compression for a maximum of two minutes.
224249365|NCT03423056|OTHER|Preoperative exercise program|Individualized aerobic training program developed by physical therapist using Karvonem's equation . It will programmed in 3 sessions/week (not in row) during 4 weeks. Each 50-minutes session will be organized in three phases: warm up, central and back to calm. The heart rate target will be prescribed between 50 to 70% of the maximum heart rate and will be carried on a treadmill or in a stationary bicycle.
224249366|NCT02147925|DRUG|Liraglutide combined with metformin|Liraglutide, 0.6mg per day for the first week, and will be increased to 1.2mg per day for the second week, and finally 1.8mg per day since the third week
224249367|NCT02147925|DRUG|Insulin glargine combined with metformin|The initial dose will be 0.2 unit/kg/d
224249368|NCT02147925|DRUG|Sitagliptin combined with metformin|The dose throughout the study will be 100mg per day.
224249369|NCT05319990|DRUG|Aminohippurate Sodium Inj 20% Diagnostic aid/agent used to measure effective renal plasma flow (ERPF)|PAH (Basic Pharma, Geleen, Netherlands) has been used to measure ERPF in human research for 7 decades, and is very well tolerated and generally recognized as safe with low toxicity.
224249370|NCT05319990|DRUG|Iohexol Inj 300 MG/ML Diagnostic aid/agent used to measure glomerular filtration rate (GFR)|Iohexol (Omnipaque 300, GE Healthcare, Chicago, IL) is a nonionic, low osmolar contrast agent with a history of extensive use in Radiology practice (for contrast x-rays) that shares many qualities of an ideal GFR marker, like inulin, such as not being absorbed, metabolized, or secreted by the kidney.
224249371|NCT04346927|OTHER|Telerehabilitation|15 volunteers diagnosed with coronavirus will be included in experimental group. An online exercise program has been created for individuals who will participate in the study. This program is planned to continue 3-4 days a week, in a 30-minute session and for 6 weeks. Treatment sessions will include breathing exercises, posture exercises, peripheral muscle exercises and light aerobic exercises. Individuals were asked to participate in the research via telerehabilitation connection system and were told that they would do their exercises with a physiotherapist.
224249372|NCT04346927|OTHER|exercise brochure|15 volunteers diagnosed with coronavirus will be included in control group.The same exercises will be given to the control group as a brochure and they will be asked to do it for 6 weeks.
224249373|NCT01099943|OTHER|Intervention: Education, Decision Support Tools|Clinic sites randomized to the intervention group will participate in an educational intervention comprised of lectures on antimicrobial resistance and implement decision support tools to guide primary care providers in appropriate antibiotic prescribing for common infectious conditions.
224249374|NCT03337997|PROCEDURE|Irreversible Electroporation|Open Irreversible Electroporation by ultrasound guidance for tumors under 3 cm in diameter. Goal is to obtain an Amp rise of 12 or more
223667683|NCT02898285|BEHAVIORAL|Individual sport condition|Participants will choose from a list of individual sports.
223667684|NCT02898285|BEHAVIORAL|Night out|"Participants in this group will be asked to go out to have a weekly night out or personal time of choice, such as dinner or a movie (only restrictions are they cannot go do a sport or physical activity and time must be spent without children)."
223667685|NCT04545970|COMBINATION_PRODUCT|Facial cleanser|Facial cleanser to be used by study participants
223667686|NCT04545970|COMBINATION_PRODUCT|Facial moisturizer|Bland moisturizer to be used by study participants after serum in the evening.
223667687|NCT04545970|COMBINATION_PRODUCT|Sunscreen|Sunscreen to be applied after application of serum in the morning.
223667688|NCT00361413|DRUG|Alefacept (AMEVIVE®)|Alefacept
223667689|NCT00361413|DRUG|control group|these patients will receive the same treatment as group A, without alefacept
223667690|NCT03071757|DRUG|ABBV-368|Intravenous infusion
223771168|NCT02358824|DRUG|S-amlodipine|"\- S-amlodipine 5mg tablet, Oral, Once Daily (combination Therapy with Telmisartan)~(1arm:1period and 3period, 2arm: 2period and 4period)"
223771169|NCT03091803|DEVICE|Dynamic Contrast-Enhanced Magnetic Resonance Imaging|Undergo GOCART DCE MRI
223771170|NCT03091803|DRUG|Gadobenate Dimeglumine|Given IV
223771171|NCT03091803|DRUG|Gadoterate Meglumine|Given IV
223667691|NCT03071757|DRUG|ABBV-181|Intravenous infusion
223667692|NCT03495583|OTHER|Early introduction|Consumption of 2g/week of cow's milk, hen's egg, wheat, peanut, sesame and fish protein from 3 months of age (alongside breastfeeding)
223667693|NCT03069521|DEVICE|EndoArt® Artificial Endothelial Layer|device is intended for use as an endothelial kearatoprosthesis
223667694|NCT01642875|OTHER|Enteral nutrition|Standard enteral diet is administered through a nasojejunal tube. Enteral nutrition is started on the 1st postoperative day and increased daily by 20-40 ml up to the estimated level.
223667695|NCT01642875|OTHER|Oral nutrition|Oral diet is started from the 2nd postoperative day and oral intake is advanced as tolerated
223667696|NCT00391183|PROCEDURE|Biliary stenting|ERCP and stenting
223667697|NCT00724321|DRUG|iloprost|A dose of inhaled iloprost (or placebo) will be given once at baseline and then at altitude. Measurements will be obtained before and after inhalation. Patients will then cross over and be given a dose of placebo (or iloprost)and measurements will be repeated.
223771172|NCT03091803|DEVICE|Magnetic Resonance Imaging|Undergo QSM and T1WI imaging
223771173|NCT05543213|BEHAVIORAL|Action Observation Therapy|A video clip of a series of exercises is shown to the patients, then they practice them according to mirror neurons and observational learning.
224249375|NCT01079988|DRUG|Cyclosporins|Starting dose 4.0 - 5.1 mg/kg/day until clinical improvement. Upon clinical improvement, cyclosporin dose to be tapered by 50% every two weeks.
223667698|NCT02248688|DEVICE|BeadBlock 300 - 500 Micron|Beadblock will be used intraarterially to occlude the left gastric artery and its branches. The left gastric artery supplies the fundus of the stomach, where it is known that the hormone Ghrelin (one of the hormones responsible for appetite) is produced.
223771174|NCT06054048|OTHER|Telemedicine|"Web Real-Time Communication (WebRTC), which enables a peer-to-peer connectivity. Communication platform for all TCs was the software CompuGroup Medical Electronic Visit (CGM ELVI), which provides end-to-end encrypted video conferencing between physicians and their patients."
224249376|NCT01079988|DRUG|Retinoids|Starting dose 25 - 50 mg/day until clinical improvement. Upon clinical improvement, retinoid dose to be reduced by 50%. Thereafter, treatment to be continued for 8 weeks and then stopped.
224249377|NCT01079988|DRUG|Systemic corticosteroids|Starting dose 0.25 - 0.5 mg/kg/day until clinical improvement. Upon clinical improvement, corticosteroid dose to be reduced by 50%. Thereafter, corticosteroids to be weaned by 50% every 2 weeks.
223667699|NCT02248688|PROCEDURE|Left Gastric Artery Embolization|
223667700|NCT00538785|BIOLOGICAL|Motavizumab|15 mg/kg IM administered at monthly intervals
223667701|NCT00538785|BIOLOGICAL|Palivizumab|15 mg/kg IM administered at monthly intervals
223667702|NCT02723045|PROCEDURE|Open Lichtenstein Hernioplasty|
223667703|NCT02723045|PROCEDURE|Laparoscopic TEP Hernioplasty|
223667704|NCT00469170|DEVICE|intravaginal ring|silicone elastomer intravaginal ring containing no drug product
223667705|NCT00641927|DRUG|Venlafaxine|37.5 mg - 375 mg daily, 12 Weeks
223667706|NCT00641927|DRUG|Lithium Carbonate|300 mg - 2100 mg daily, 12 weeks
223667707|NCT02617901|RADIATION|Left hand DXA|"All recruited children will have a left hand DXA scan which will be anonymised and from which 3 observers will independently assess bone age according to Greulich and Pyle and TW3 methods on 2 separate occasions at least 4 weeks apart.~Radiographs and DXA will be read in random and varied order."
223667708|NCT00177047|PROCEDURE|Stem Cell Transplant|As part of the stem cell transplant process, patients receive high doses of chemotherapy and/or radiation to treat their underlying disease, such as cancer. As one of its effects, this treatment also kills the healthy stem cells that are already in the marrow. The transplant provides new stem cells for the patient from a healthy donor; that replace the bone marrow and allow the blood counts to recover.
223667709|NCT00177047|DRUG|Cyclophosphamide + Mesna|Cyclophosphamide: 4mg/m\^2 + Mesna. Mesna is used to reduce the undesired side effects of certain chemotherapy drugs.
223667710|NCT00177047|DRUG|Melphalan|Administered intravenously 200 mg/m\^2
223667711|NCT00177047|BIOLOGICAL|Granulocyte-colony stimulating factor|Administered intravenously 10 ug/kg/day pretransplant then 5 ug/kg/day post-transplant.
223667712|NCT03279627|OTHER|Diabetes Management Questionnaire|Patients will be asked questions regarding their understanding of instructions for home diabetes management within 48 hours of hospital discharge. At 1 and 3 months, participants will be contacted to obtain information regarding ER visits or hospital readmissions.
223667713|NCT02423369|PROCEDURE|Cerebral near infrared spectroscopy|At the start of anesthesia on the patient's forehead two electrodes are attached the for continuous measurement of cerebral near infrared spectroscopy during surgery.
223667714|NCT02423369|OTHER|S-100B protein in serum|0,5-1 ml of blood from periferal site for determination of serum S-100B concentration.
223667715|NCT02423369|OTHER|NSE protein in serum|0,5-1 ml of blood from periferal site for determination of serum NSE concentration.
223667716|NCT05098262|DRUG|DA-5210 10/500mg|single dose administration (one tablet once a day)
223667717|NCT05098262|DRUG|DA-5210-R 10/500mg|single dose administration (one tablet once a day)
223667718|NCT04334395|PROCEDURE|primary tumor resection group|resection of cancer at colon
223667719|NCT02086006|DEVICE|DESolve Novolimus Eluting Bioresorbable Coronary Scaffold|
223667720|NCT00637949|DEVICE|lumiracoxib|400 mg once daily, oral over 6 weeks
224249378|NCT01079988|DRUG|Methotrexate|Starting dose 20 - 25 mg per week until clinical improvement. Upon clinical improvement, dose to be reduced by 25%. Thereafter, methotrexate dose to be reduced by 25% every two weeks.
223667721|NCT00637949|DRUG|rofecoxib|25 mg, oral, daily over 6 weeks
223667722|NCT01160419|DRUG|Docetaxel 50 mg/m2, 1-hour-Infusion, day 1|50 mg/m2, 1-hour-Infusion, day 1
223667723|NCT01160419|DRUG|Oxaliplatin 85 mg/m², 2-hour-Infusion, day 1|85 mg/m², 2-hour-Infusion, day 1
223667724|NCT01160419|DRUG|Folinic acid 200 mg/m², 1-2-hour-Infusion, day 1|200 mg/m², 1-2-hour-Infusion, day 1
223667725|NCT01160419|DRUG|5-FU 2600 mg/m², 24-hour-Infusion, day 1|2600 mg/m², 24-hour-Infusion, day 1
223667726|NCT01478048|BIOLOGICAL|Elotuzumab|Solution; Intravenous (IV); 10 mg/kg; (Cycles 1 \& 2: Days 1, 8 \& 15; Cycles 3-8: Days 1 \& 11; Cycle 9+: Days 1 \& 15); Until subject meets criteria for discontinuation of study drug
223667727|NCT01478048|DRUG|Bortezomib|Solution; IV; 1.3 mg/m2; (Cycles 1 - 8: Days 1, 4, 8, 11; Cycles 9+: Days 1, 8, 15); Until subject meets criteria for discontinuation of study drug
223667728|NCT01478048|DRUG|Dexamethasone|Tablets; Oral; 20 mg; (Cycles 1\& 2: once daily on Days 2, 4, 5, 8, 9, 11; Cycles 3-8: once daily on Days 2, 4, 5, 9, 12; Cycles 9+: once daily on Days 2, 8, 9, 16); Until subject meets criteria for discontinuation of study drug
223667729|NCT01478048|DRUG|Dexamethasone|Tablets; Oral; 8 mg; (Cycles 1\& 2: Days 1, 8, 15; Cycles 3-8: Days 1 \&11; Cycles 9+; Days 1 \& 15); Until subject meets criteria for discontinuation of study drug
223667730|NCT01478048|DRUG|Dexamethasone|Solution; IV; 8 mg; (Cycles 1\& 2: Days 1, 8, 15; Cycles 3-8: Days 1 \&11; Cycles 9+; Days 1 \& 15); Until subject meets criteria for discontinuation of study drug
223667731|NCT01478048|DRUG|Dexamethasone|Tablets; Oral; 20 mg; (Cycles 1-8 once daily on Days 1, 2, 4, 5, 8, 9, 11, 12; Cycles 9+ once daily on Days 1, 2, 8, 9, 15, 16); Until subject meets criteria for discontinuation of study drug
223667732|NCT06069440|OTHER|Swimming Fatigue Task|Swim freestyle at a steady, controlled pace until mechanical failure (i.e., inability to maintain the predetermined speed) is reached.
223667733|NCT03126552|BIOLOGICAL|Necator americanus L3 larvae|50 Necator americanus L3 larvae
223667734|NCT00955201|BEHAVIORAL|Exercise|Structured aerobic exercise (treadmill).
223667735|NCT00955201|BEHAVIORAL|Exercise|Structured isokinetic strength exercise (dynameter).
223667736|NCT02198001|DRUG|tooth extraction with antibiotics (amoxicillin- clavulanate, clindamycine)|"BPs per os\< 3ans: amoxicillin- clavulanate J-1 à J+10~BPs IV ou per os\> 3ans ou per os + comordibities (diabetes, immunosuppression, tobacco):~amoxicillin- clavulanate J-3 à J+10~In case of allergy:~BPs per os: clindamycine J-1 à J+10~BPs IV ou per os\> 3ans ou per os + comordibities (diabetes, immunosuppression, tobacco):~clindamycine J-3 à J+10"
223667737|NCT02198001|PROCEDURE|atraumatic extraction|Atraumatic tooth extraction, alveolar bone reduction, hermetic mucosal closure
223667738|NCT04204551|BEHAVIORAL|high-intensity interval training (HIIT)|Two 12-week HIIT cycles will be divided with 3 months of break. Each HIIT cycle will consist of three 1-hour training sessions weekly. Each 1-hour training session will consist of 10-minutes warm-up (at slow voluntary speed), 40-minutes of interval exercise and 10-minutes cool-down phase. The interval exercise part will consist of 10 sets of 4 minutes interval including 2-minutes cycling at ≥ 60 \[rpm\], but preferably at 80-90 \[rpm\] (fast phase of interval) and 2-minutes cycling at ≤ 60 \[rpm\] (slow phase of interval). The training will be performed on a stationary cycle ergometer (MONARK, Ergomedic 874E, Sweden). The heart rate (HR, \[bpm\]) will be measured by Polar system (Polar, Finland). The patients will pedal on the cycloergometer at 60%-80% of their individualized HRmax.
223667739|NCT04204551|BEHAVIORAL|conventional physical therapy|Conventional physical therapy as prescribed and provided by the National Health Fund of Poland, which includes activities for improving motor control, but without any kind of moderate or high intensity aerobic interval or continuous physical training (example: cycle ergometer, treadmill, or Nordic walking training)
223667740|NCT03406741|BEHAVIORAL|psychometric evaluation|Wechsler type composite scales (WISC)
223667741|NCT03406741|BEHAVIORAL|neuropsychological evaluation|Evaluation of child behavior by the Goodman questionnaire: Strengths and Difficulties Questionnaire
223667742|NCT04343924|OTHER|Scuba diving activities|The subjects of this group daily dive, 5 days per week, for a total of 10 dives at a maximum depth of 6 meters for a maximum duration of 20 minutes in a swimming pool.
223667743|NCT04343924|OTHER|Virtual reality activities|The subjects of this group will follow virtual reality sessions recreating the environment in which the submarine diver of the GP+ group operates
223667744|NCT02867644|OTHER|standard care|Patients coming for preoperative breast assessment will have standard care.
223667745|NCT02867644|OTHER|standard care + conversational hypnosis|Patients coming for preoperative breast assessment will have standard care with conversational hypnosis
223667746|NCT00853216|DRUG|Oxycodone hydrochloride tablet 30 mg|Oxycodone hydrochloride tablet 30 mg, single dose fasting
223667747|NCT00853216|DRUG|Roxicodone™ tablet 30 mg|Roxicodone™ tablet 30 mg, single dose fasting
223667748|NCT04909983|DEVICE|DPLX-PT1|A polymer skin patch for occlusional therapy
223667749|NCT04909983|OTHER|Control arm|Standard of care
223667750|NCT04497038|DRUG|Cabozantinib|Patients will receive therapy with cabozantinib. Dosage in the trial will start at 40 mg PO daily. Each patient will be assessed for the development of toxicity according to the NCI Common Terminology Criteria for Adverse Events, version 5.0. Dose adjustments may be made per the Time-To-Event modification of the Continual Reassessment Method (TITE-CRM). The maximum dosage will be 60 mg PO daily and the minimum will be 20 mg PO daily.
223667751|NCT03298971|OTHER|Questionnaires|Participants were asked to respond to the questionnaires including Hong Kong Chinese Version World Health Organization quality of life measure, abbreviated version (WHOQOL-BREF (HK)), the Chinese version of The Center for Epidemiological Studies - Depression Scale (CES-D), the Chinese version of Rosenberg self-esteem scale, and the Chinese version of the Herth Hope Index (HHI).
223667752|NCT04756336|DRUG|LTX-109 gel, 3% w/w|The drug is applied to affected lesions according to treatment regimen
223667753|NCT02899572|PROCEDURE|Sexology consultation|a sexology consultation is planned in the 15 days after inclusion
223667754|NCT00891540|DRUG|Ropivacaine|Ropivacaine 0.5%
223667755|NCT00891540|DRUG|Ropivacaine|Ropivacaine 0.2%
223667756|NCT00891540|DRUG|placebo|Isotonic NaCl
223667757|NCT05024110|OTHER|High intensity treamill exercise training.|We used the Martti Karvonen formula to calculate the heart rate zone. Firstly, the resting heart rate (rest-HR) was detected for every participant by inviting him to lie in a prone position for 10 minutes while catching a heart rate monitor. After that, the maximum heart rate (max-HR) was calculated by utilizing this formula: maximum heart rate =220- age. Then, we calculated the heart rate reserve (HRR) by using the law: HRR= max-HR - resting HR. Exercise intensity is represented as a percentage of HRR. Finally, the target heart rate (target-HR) was calculated by using the formula: target-HR = HRR x intensity% + rest-HR. Moderate-intensity exercises are defined as the activity which uses 50% to 70% of the HRR, while high-intensity exercises use 70% to 90% of the HRR
223667758|NCT05024110|OTHER|Moderate intensity treamill exercise training.|We used the Martti Karvonen formula to calculate the heart rate zone. Firstly, the resting heart rate (rest-HR) was detected for every participant by inviting him to lie in a prone position for 10 minutes while catching a heart rate monitor. After that, the maximum heart rate (max-HR) was calculated by utilizing this formula: maximum heart rate =220- age. Then, we calculated the heart rate reserve (HRR) by using the law: HRR= max-HR - resting HR. Exercise intensity is represented as a percentage of HRR. Finally, the target heart rate (target-HR) was calculated by using the formula: target-HR = HRR x intensity% + rest-HR. Moderate-intensity exercises are defined as the activity which uses 50% to 70% of the HRR, while high-intensity exercises use 70% to 90% of the HRR
223667759|NCT04958460|DRUG|Placebo|Administrated 1 packet of maltodextrin (as placebo of Bf-688) in the morning and evening
223667760|NCT04958460|OTHER|BF688|Administrated 1 pack each morning and evening (5×109 CFUs per day)
223667761|NCT03642132|DRUG|Chemotherapy + avelumab followed by avelumab + talazoparib|"Chemotherapy Period Paclitaxel Carboplatin Avelumab~Maintenance Period Avelumab Talazoparib"
223667762|NCT03642132|DRUG|Chemotherapy followed by talazoparib maintenance|"Chemotherapy Period Paclitaxel Carboplatin~Maintenance Period Talazoparib"
223667763|NCT03642132|DRUG|Chemotherapy + bevacizumab followed by bevacizumab|"Chemotherapy Period Paclitaxel Carboplatin Bevacizumab~Maintenance Period Bevacizumab"
223771175|NCT03969342|DEVICE|Point of care ultrasound training|Five-day in-person training on point of care ultrasound using portable ultrasound devices followed by remote monitoring of practice scanning
223771176|NCT02134457|BIOLOGICAL|ranibizumab|
223771177|NCT04675320|BIOLOGICAL|blood samples|Blood sampling during PARP inhibitor therapy
223771178|NCT00298038|DRUG|Rifaximin|Oral
223667764|NCT02944006|PROCEDURE|multi-parametric MRI|multiparametric MRI is performed in all patients, and the sequence includes dynamic contrast enhanced (DCE) MRI, diffusion weighted imaging (DWI), tissue maps, and MR cholangiography.
223667765|NCT04414735|OTHER|Extracorporeal Photopheresis|Infusion of autologous cellular products exposed to ultraviolet light (UV), in the presence of a photosensitizer. The cellular product is obtained through leucopheresis and its subsequent exposure to 8-methoxypsoralen (8-MOP) and irradiation with UV-A light.
223667766|NCT03687463|DRUG|Decitabine|Decitabine for injection
223667767|NCT03337490|DRUG|Ivermectin 0.5% Topical Application Lotion|Subjects on Test Product will receive a single dose, 117g, during the study to be applied at baseline.
223667768|NCT03337490|DRUG|Ivermectin 0.5% Topical Application Lotion [SKLICE]|Subjects on Reference Product will receive a single dose, 117g, during the study to be applied at baseline.
223667769|NCT03337490|DRUG|Placebo 0% Lotion|Subjects on Placebo will receive a single dose, 117g, during the study to be applied at baseline.
223667770|NCT03834558|OTHER|Mixed exercise program|"A progressive program of high intensity strength and myofascial conditioning will be carried out in 2 non-consecutive weekly sessions (24 weeks). Each session will include:~A) Warm up on a cycle ergometer~B) Strength circuit: 6 exercises will be included to strengthen different muscle groups (2 in the upper extremities, 2 in the trunk and 2 in the lower extremities). 3 sets of 10-15 repetitions until the failure. The load will be set to 70% of 1 maximal resistance.~C) Self-myofascial conditioning: 10 repetitions, in the direction of the fibres of each muscle group, with different materials. 7 muscle groups will be worked (quadriceps, hamstrings, abductors, gluteus, pectoralis, full back and trapezius).~D) At the end, static stretches will be performed"
223667771|NCT03558880|PROCEDURE|Erector Spinae Plane Block|Erector Spinae Plane Block was performed
223667772|NCT03558880|PROCEDURE|Tumescent Anesthesia|Tumescent Anesthesia was applied
223667773|NCT06277843|DEVICE|Thermal Jacket|In the intervention group, the enrolled preterm or low birthweight eligible neonates gets the intervention (Thermal Jacket) as a supplement of Kangaroo Mother Care (KMC).
223667774|NCT01541397|DRUG|Sapropterin|20 mg/kg, orally, daily, 1 year or patient chooses to discontinue therapy
223667775|NCT02577887|DEVICE|Patients implanted with a St. Jude Medical pacemakers|
223667776|NCT04195971|DIAGNOSTIC_TEST|Liver CT|Liver CT with precontrast, dual arterial phase, portal venous phase, and delayed phase.
223667777|NCT02135003|OTHER|patient-selected care buddy|Patient-selected Care buddy intervention: In addition to standard of care, pre-ART patients randomized to this arm were requested to choose a care buddy who was aware of the patient's HIV infection and resided in the same household or in close proximity. Care buddies attended at least two HIV health education sessions similar to those provided to study participants. Information on HIV, and the importance of adhering to scheduled clinic visits and to prescribed medications will be emphasized. Buddies were requested to remind participants to take their prophylactic treatments, and remind them of clinic appointments
223667778|NCT06146231|DEVICE|Motiva Flora® Tissue Expander|"This hybrid breast reconstruction involves a stage in which the tissue expander (Motiva Flora®) is used as intended for a conventional expansion. After achieving the desired volume, it is deflated in a controlled way to proceed with the execution of serial fat grafting procedures (reverse expansion). This also means the expander is implanted longer than indicated on its current Directions For Use. Once the reverse expansion is complete, the expander is replaced with a long-term breast implant.~Motiva Implants Ergonomix2® Sterile Silicone Breast Implants will be used as per Standard of Care under the CE marked indication.~To obtain the safest, most natural, and aesthetic outcomes, Ergonomix2® breast implants have been selected as the standard silicone breast implants for this study."
223667779|NCT03560518|DRUG|Rapastinel|Rapastinel (prefilled syringe, weekly intravenous IV administration)
223667780|NCT03560518|DRUG|Placebo|Placebo (prefilled syringe, weekly IV administration)
223667781|NCT04727489|GENETIC|DNA from subjects will be stored in the biobank of our study.|Diagnostic Interview-Revised (ADI-R) criteria for autism and Autism Diagnostic Observation Schedule (ADOS-G) criteria for autism or Autism Spectrum Disorders.
223667782|NCT05473650|DIAGNOSTIC_TEST|CBC.with with differential Peripheral smear|determine spectrum of hematological disorders in childern with pancytopenia
223667783|NCT01689532|DRUG|Sirukumab 100 mg|Sirukumab 100 mg subcutaneous (SC) injection, at Weeks 0, 2, and every 2 weeks through Week 52.
223771179|NCT00298038|DRUG|Placebo|Oral
224321888|NCT02847260|DRUG|Remodulin|Treatment will be initiated whilst hospitalized at approximately 2.0 ng/kg/min with dose increments of 1- 2 ng/kg/min approximately every 12 hours according to clinical response and tolerability. Following subject discharge, the dose rate is increased by 1-2 ng/kg/min with dose increments separated by at least 24 hours. When a dose rate of 20 ng/kg/min is achieved dose increments can be increased at a rate of up to 4 ng/kg/min with dose increments separated by at least 24 hours depending on tolerability. The aim is to achieve a dose rate of at least 10, 20 and 30 ng/kg/min by the end of weeks 1, 4 and 12, respectively and a dose rate by the end of week 16 that achieves pre-defined treatment goals subject to clinical response and tolerability.
223667784|NCT01689532|DRUG|Sirukumab 50 mg|Sirukumab 50 mg SC at Weeks 0, 4, and every 4 weeks through Week 52.
223667785|NCT01689532|DRUG|Placebo|Between sirukumab injections, placebo SC at Weeks 2, 6, and every 4 weeks through Week 52.
223771180|NCT04947033|DRUG|TJ210001 Injection|The test drug TJ210001 will be preset with 5 escalation dose levels: 0.3mg/kg, 1mg/kg, 3mg/kg, 10mg/kg and 15mg/kg, administered once a week.
223771181|NCT02490137|BEHAVIORAL|Race Car Video Game|Repeatedly playing a race car video game
223771182|NCT01546948|DRUG|Methadone|Patients in the methadone group will be administered 0.3 mg/kg of methadone intraoperatively: two-thirds of the dose (6 cc or 0.2 mg/kg of methadone) on induction of anesthesia as a bolus. The remainder of the dose (3 cc or 0.1 mg/kg of methadone) will be administered at approximately 1.5-2 hours before the end of the procedure.
223771183|NCT01546948|DRUG|Hydromorphone|Patients in the hydromorphone group will receive 0.03 mg/kg of hydromorphone; two-thirds the dose (6 cc or 0.02 mg/kg) on induction of anesthesia, and the remainder of the hydromorphone (3 cc or 0.01 mg/kg) will be bolused 1.5-2 hours before surgery concludes.
223771184|NCT01500148|DEVICE|PMVr procedure (SJM Percutaneous Mitral Valve Repair (PMVr)|A maximum of ten (10) subjects will receive a percutaneous mitral valve clip procedure.
224321889|NCT04140500|DRUG|RO7247669|Participants will receive intravenous (IV) RO7247669 at different doses either every 2 weeks (Q2W) or every 3 weeks (Q3W)
223667786|NCT04139889|DIAGNOSTIC_TEST|Confocal Laser Endomicroscopy|"Confocal laser microendoscopy (CLE) as a new non-invasive imaging technique can be used for optical biopsy, which can perform real-time microscopic information of tissue in vivo at cellular level with resolutions up to 1μm and magnifications up to 1000 times. CLE is now being increasingly used with very promising results in gastroenterology, especially in the diagnostic investigation of Barret's esophagus, stomach cancer, colorectal cancer and various lesions of the biliary tract. With an intravenous injection of fluorescein, probe-based CLE (pCLE: GastroFlex probe with the Cellvizio laser system, Mauna Technologies, Paris, France) allows us to view the interstitial spaces, cells, and small capillaries in a window of 240 μm and to a depth of 60 μm."
223667787|NCT01363349|DRUG|CYP-1020|CYP-1020 (formerly known as BL-1020) is an orally available new chemical entity.
223667788|NCT01363349|DRUG|Risperidone|
223667789|NCT01958489|DRUG|Evacetrapib|Administered orally
223667790|NCT01958489|DRUG|Pravastatin|Administered orally
223667791|NCT02269085|DRUG|Ibrutinib|"Phase I Starting Dose: 420 mg by mouth daily on Days 1 - 28 of a 28-day cycle.~Phase II Starting Dose: MTD from Phase I."
223667792|NCT02269085|DRUG|Carfilzomib|"Phase I Starting Dose: 20 mg/m2 by vein on Days 1, 2, 8 ,9, 15 and 16 in Cycles 1 - 12, and Days 1,2 and 15,16 of Cycle 13 and beyond.~Phase II Starting Dose: MTD from Phase I."
223667793|NCT02269085|BEHAVIORAL|Phone Calls|Study staff calls participant after end-of-dosing visit every 6 months for 5 years. These calls should take about 2-3 minutes.
223667794|NCT04829084|BEHAVIORAL|Pre-post educational intervention|To Increase the attendance of patients with Diabetes Mellitus, for retinal screening at REMEH by providing health education intervention to selected physicians and establishing a referral pathway
223667795|NCT04226768|OTHER|"Enhanced Haematology Palliative Care (Fast-track) Group"|Early and proactive multidisciplinary care
223667796|NCT04226768|OTHER|Conventional Care|Conventional care and referral as indicated
223667797|NCT03014999|DEVICE|High frequency rTMS (repetitive Transcranial Magnetic Stimulation)|Higher cortical representation area of first right dorsal interosseous muscle will be determined through a figure-eight coil connected to the magnetic stimulator (Rapid2, Magstim, UK) held manually and at 45 degrees from the midline over the right primary motor cortex (C3 - 10/20 System). Then, will be determined the rest motor threshold by finding the lowest stimulator output that elicit motor evoked potential at least 50μV. After determined the RMT, the coil will be positioned over the scalp (Cz - 10/20 System). Thereafter, RMT will be measure. rTMS protocols was based on previous studies. High frequency protocol: 10Hz, 90% RMT, 45 trains, 40 stimuli per train, inter interval of 28s, 1800 stimuli. After each rTMS session, presence of adverse effects will be computed.
223667798|NCT03014999|DEVICE|Low frequency rTMS (repetitive Transcranial Magnetic Stimulation)|Initially, the higher cortical representation area (hotspot) of first right dorsal interosseous (FDI) muscle will be determined through a figure-eight coil connected to the magnetic stimulator (Rapid2, Magstim, UK) held manually and at 45 degrees from the midline, will be placed over the right primary motor cortex (C3 - 10/20 System). Then, will be determined the rest motor threshold (RMT) by finding the lowest stimulator output that elicit motor evoked potential (MEP) at least 50 microvolts (μV). After determined the RMT, the coil will be positioned over the scalp (Cz - 10/20 System). Thereafter, RMT will be measure. Low frequency protocol: 1Hz, 90% RMT, 1500 stimuli (1 train). After each rTMS session, presence of adverse effects will be computed
223667799|NCT03014999|DEVICE|sham rTMS (repetitive Transcranial Magnetic Stimulation)|The hotspot of first right dorsal interosseous (FDI) muscle will be determinate through a figure-eight coil connected to the magnetic stimulator positioned over the motor primary cortex (C3). Then, the motor threshold (RMT) of FDI will be measure. Sham rTMS will be performed with low frequency (1Hz, 90% RMT, 1500 stimuli) protocol using two coils. The first one - connected to the stimulator - will be positioned on a coil support close to the volunteer but not visible. Therefore, characteristic stimulation noises will be audible. The second - disconnected to the stimulator - will be placed over primary motor area Cz. After each rTMS session, presence of adverse effects will be computed.
223667800|NCT00875693|DRUG|CPX-351|CPX-351 is a liposomal formulation of a fixed combination of the antineoplastic drugs cytarabine and daunorubicin. The two drugs are present inside the liposome in a 5:1 molar ratio.
223667801|NCT01697280|BEHAVIORAL|Vaccine promotion messages|"The messages will be low-literacy, of very short duration, and will be delivered with the help of pictorial cards. These educational messages will include the following messages:~1. Vaccines can save a child's life~2. Children who are immunized on time are less likely to become ill~3. Unimmunized children can become disabled for life~4. Photograph of the nearest EPI center where vaccines are offered free of charge, as well as its address and timings."
223667802|NCT01697280|OTHER|Vaccination Verification.|EPI vaccinators/volunteers will identify and record details of un/under-vaccinated children less than 12 months old in households they visit during an NID, and update immunization registries maintained at the local EPI centers so these children can be reached in subsequent outreach activity.
223667803|NCT01697280|OTHER|Distribution of Plastic Pouches to retain vaccination card|At the start of this project, all EPI centers in the study areas will be provided with plastic pouches to be given to parents of all children coming to EPI centers for vaccinations. These pouches will be used to store a child's immunization card.
223667804|NCT01208753|DRUG|GLPG0555|two different aqueous formulations
223667805|NCT01208753|DRUG|GLPG0555 aqueous|multiple dose, aqueous formulation, 13 days, 100 mg/day once daily, maximum dose to be determined
223667806|NCT01208753|DRUG|placebo|multiple dose, aqueous formulation, 13 days days, matching ascending dose schedule
223667807|NCT00710125|DRUG|GPX-150 for Injection|Escalating doses starting at the dose of 14 mg/m2 and increasing to the dose of 265 mg/m2 will be administered IV once every 3 weeks for up to 8 cycles of treatment. Patients who have previously received an anthracycline are limited to 4 cycles of treatment.
223667808|NCT01209182|DEVICE|Testing a new device (LS BioPath TOUCH) on excised tissue|Measurements are obtained with test device on excised tissue.
223771185|NCT04095000|BEHAVIORAL|FACE-TC SP|The current FACE-TC protocol consists of three weekly 60 to 90-minute sessions in a dyadic format facilitated by a trained/certified interviewer. If our community partners recommend otherwise, this structure could change. Each session is followed by a 10-minute assessment, using process measures to assess participants' ratings of the quality of communication and satisfaction.
224321890|NCT04285281|DRUG|Gabapentin oral capsules|Oral capsule pharmaceutical treatment.
223667809|NCT05767567|BEHAVIORAL|Brief Check Your Drinking (CYD)|The CYD is a brief online intervention designed to provide personalized normative feedback aimed at motivating reductions in drinking
223667810|NCT03595618|DRUG|GLPG1972|Film-coated tablets of GLPG1972 for oral use.
223667811|NCT03595618|DRUG|Placebo|Film-coated tablets of matching placebo for oral use.
223667812|NCT01291485|BEHAVIORAL|Life Steps for Medication Adherence|The intervention was adapted into an electronic version of the empirically supported Life Steps intervention for HIV medication adherence. Education about HIV and medication adherence, motivational interviewing, cognitive behavioral techniques, and problem-solving strategies to improve medication adherence and clinical outcomes in people living with HIV were also included in the intervention.
223667813|NCT02338232|DRUG|Telmisartan|
223667814|NCT04277806|BEHAVIORAL|New Oral feeding process|From the beginning of 32 weeks, try oral feeding once a day, suck pacifier for 10 minutes before feeding. When she/he can finish 50% of the amount of one meal in consecutive two days, and there is no adverse events happened, then we will try oral feeding twice a day. In the same way, in the oral feeding she/he can finish 50% of this meal in consecutive two days, there is no adverse events happened, then we will try three oral feedings three times a day. We wil continue the process until the infant can be fully oral fed by herself/himself.
223667815|NCT00027833|BIOLOGICAL|ALVAC-CEA-B7.1 vaccine|
223667816|NCT00027833|BIOLOGICAL|tetanus toxoid|
223667817|NCT00027833|DRUG|FOLFIRI regimen|
223667818|NCT00027833|DRUG|fluorouracil|
223667819|NCT00027833|DRUG|irinotecan hydrochloride|
223667820|NCT00027833|DRUG|leucovorin calcium|
223667821|NCT04595994|DRUG|Selinexor|For both interventional ( Selinexor and Gencitabine) Dose-limiting toxicity (DLT) will be applied only to either of the following toxicities occurring during the first treatment cycle (days 1-21).
223667822|NCT03569345|DRUG|AFXl-assisted ingenol mebutate delivery|"Patients will receive ablative fractional laser (AFXl)-assisted ingenol mebutate (IM) as a treatment for their cutaneous basal cell carcinoma (BCC). Treatment areas consisting of tumors and a 5 mm margin will undergo AFXl exposure (CO2 laser) followed by IM 0.015% or 0.05% under occlusion for 2-3 days. .~local skin reactions are monitored at baseline (day1), day 3/4, day 8, day 15, day 29, day 90, and tumor response monitored at baseline, day 29, and day 90. An additional repeat AFXl-IM treatment on day 29 will be offered if tumors persist, based on clinical evaluation and imaging on day 30."
223667823|NCT02583217|DRUG|Ketamine|To compare ketamine+propofol versus remifentanyl+propofol to maintain good laryngeal mask insertion conditions
223667824|NCT02583217|DRUG|remifentanyl|
223667825|NCT02583217|DRUG|propofol|
223667826|NCT02583217|DEVICE|laryngeal mask|
223667827|NCT02279407|DRUG|placebo|Placebo matching to Omega-3 carboxylic acids (olive oil)
223667828|NCT02279407|DRUG|Omega-3 carboxylic acids|4 g administered as 4 x 1 g capsules
223667829|NCT02279407|DRUG|Dapagliflozin|10 mg administered as 10 mg tablet
223667830|NCT02279407|DRUG|Placebo|Placebo matching to dapagliflozin 10 mg
223667831|NCT00186953|DRUG|Optison|"Intervention description:~Based on recommendation by the FDA, we began with a dose of 0.125ml/m\^2 and escalated at 0.15 ml/m\^2 increments, to 0.275 ml/m\^2 and 0.425ml/m\^2 and 0.500ml/m\^2. We will now continue to escalate the dose of Optison at 0.300ml/m\^2 increments to a maximum single dose of 4ml or a total cumulative dose of 8.7 ml as recommended by the manufacturer."
223667832|NCT04516395|OTHER|Combined antibiotic regimens|Combined antibiotic combinations defined as the optimal antibiotic combination regimens which are created from in vitro study and the application of PK/PD.
223771186|NCT04095000|BEHAVIORAL|Treatment as Usual|Treatment as Usual comparison condition will also be assessed and measures administered at the same time intervals.
223771187|NCT02089750|OTHER|Orthotics|
223771188|NCT02089750|OTHER|Orthotics Plus Chiropractic Care|The six week Chiropractic Care portion of this intervention may include the use of ice packs, hot packs, massage, and chiropractic manipulations to the spine or lower extremities (utilizing High Velocity Low Amplitude and/or Flexion Distraction manipulations).
223771189|NCT02089750|OTHER|Wait List|
223771190|NCT02206516|DEVICE|Transcranial Direct Current Stimulation|
224321891|NCT04285281|OTHER|Median nerve neural mobilization|Manual therapy maneuver performed in the upper limb.
223667833|NCT04516395|OTHER|Standard antibiotic regimens|Standard antibiotic regimens defined as the antibiotic regimens which are generally given to the patients following to the hospital protocol.
223667834|NCT02500056|DEVICE|Optilene LP mesh|Lichtenstein hernioplasty
223667835|NCT02500056|DEVICE|Ultrapro mesh|Lichtenstein hernioplasty
223667836|NCT01191567|PROCEDURE|VAC treatment|wound treatment with VAC-therapy
223667837|NCT01191567|PROCEDURE|Conventional treatment|wound treatment with conventional treatment according to the hospitals local routines
223667838|NCT01671878|OTHER|Reference Glucose|
223667839|NCT01671878|OTHER|Test Food 1 (Cereal)|
223667840|NCT01671878|OTHER|Test Food 2 (Biscuit)|
223667841|NCT04043741|OTHER|Dry Needling|stretching exercises :single knee to chest (15 reps x 3 sets) double knee to chest(15 reps x 3 sets) strengthening exercises: extension exercises (15 reps x 3 sets)
223667842|NCT04043741|OTHER|Sustain Pressure|"Sustain Pressure (Number of repetition and hold according to trigger point chronic level)~\+ Hot pack 10 to 15 minutes + Active muscle stretching exercise (10 repetition twice daily)"
223667843|NCT02760225|DRUG|89Zr-Pembrolizumab|In part A of the imaging trial, a dose finding imaging study will be performed to assess the optimal tracer protein dose of 89Zr-pembrolizumab and the optimal interval between tracer injection and scanning. Approximately 3 cohorts of about 2-3 patients each will undergo 89Zr-pembrolizumab-PET imaging before start of treatment with pembrolizumab. In part B, 12 eligible patients will undergo 89Zr-pembrolizumab-PET imaging at baseline, with the optimal tracer protein dose and scanning schedule as determined in part A.
223667844|NCT02760225|DEVICE|89Zr-Pembrolizumab PET|In part A of the imaging trial, a dose finding imaging study will be performed to assess the optimal tracer protein dose of 89Zr-pembrolizumab and the optimal interval between tracer injection and scanning. Approximately 3 cohorts of about 2-3 patients each will undergo 89Zr-pembrolizumab-PET imaging before start of treatment with pembrolizumab. In part B, 12 eligible patients will undergo 89Zr-pembrolizumab-PET imaging at baseline, with the optimal tracer protein dose and scanning schedule as determined in part A.
224321892|NCT03793166|PROCEDURE|Biospecimen Collection|Undergo blood and urine sample collection
223667845|NCT00864916|DRUG|Combination antiretroviral therapy (cART)|Participants will receive the appropriate cART medications, as prescribed by their primary HIV doctor for 48 weeks. (cART medications may be prescribed beyond the length of this study.)
223667846|NCT00864916|DRUG|Pentoxifylline|Participants will receive 400 mg of pentoxifylline three times per day for 48 weeks.
223667847|NCT00864916|DRUG|Placebo|Participants will receive placebo three times per day for 48 weeks.
223667848|NCT04232332|DRUG|Recombinant human nerve growth factor injection,experimental|Intramuscular injection once on the first day according to dose requirements
223667849|NCT04232332|DRUG|Recombinant human nerve growth factor injection,single dose|Intramuscular injection once on the first day according to dose requirements
223667850|NCT04232332|DRUG|Recombinant human nerve growth factor injection,multiple dose|Intramuscular injection once daily for 7 days according to dose requirements
224249379|NCT01079988|DRUG|Systemic corticosteroids/methotrexate|Upon clinical improvement, corticosteroid dose to be reduced by 50%. Thereafter, to be weaned by 50% every 2 weeks. Methotrexate starting dose 20 - 25 mg per week until clinical improvement. Upon clinical improvement, dose to be reduced by 25%. Thereafter, to be reduced by 25% every two weeks.
223667851|NCT05239429|BEHAVIORAL|Transcendental Meditation Technique|Participants receive one-on-one training on how to use Transcendental Meditation technique which is then practiced twice daily for approximately 20 minutes.
224249380|NCT01324193|DIETARY_SUPPLEMENT|Pomegranate extracts|a 1000mg capsule of a purified pomegranate polyphenol supplement (POMx™, POM Wonderful, Inc. Los Angeles, CA)7 days a week for 12 months.
224249381|NCT01042886|BEHAVIORAL|PILI 'Ohana Lifestyle Program|9-month weight loss and weight loss maintenance intervention focusing on family and community resources/supports.
224249382|NCT01042886|BEHAVIORAL|Standard Behavioral Weight Loss Maintenance Program|9-month weight loss and weight loss maintenance intervention based on empirically-supported behavioral foci and strategies.
224249383|NCT00003186|DRUG|isosulfan blue|
224249384|NCT00003186|PROCEDURE|lymphangiography|
224249385|NCT00003186|PROCEDURE|sentinel lymph node biopsy|
223667852|NCT04369261|DRUG|Synovian®|Synovian® Inj.
224249386|NCT05269901|GENETIC|SLC7A11, GPX4, P53|Obtained patients or healthy controls peripheral blood , used Western blot and Rt-qPCR to investigate the possible difference between two groups
223667853|NCT05414734|DRUG|HHT120|Capsule, oral administration
223667854|NCT05414734|DRUG|Placebo|Capsule, oral administration
223667855|NCT05446337|OTHER|Open-Ended Semi-Structured Interview|Examine the participation and engagement in the Diabetic Foot Care and Limb Preservation Pathway design and implementation; identifying barriers and facilitators of the process
223667856|NCT03996369|DRUG|Etrasimod|Etrasimod 2 mg tablet by mouth, once daily up to 12-Week Induction Treatment Period
223667857|NCT03996369|DRUG|Placebo|Etrasimod matching placebo tablet by mouth, once daily up to 12-Week Induction Treatment Period
223667858|NCT01223443|DEVICE|Paclitaxel eluting stent|Patients are randomized to either stenting the moderate SVG lesion with the paclitaxel stent or standard medical treatment
223667859|NCT00740376|DEVICE|Uniglide Mobile Bearing Unicondylar Knee System|Uniglide Mobile Bearing Knee System includes a femoral component made of cobalt chromium molybdenum (CoCrMo)that articulates with a mobile bearing tibial construct comprised of a cobalt chromium molybdenum (CoCrMo)tibial base plate and ultra high molecular weight polyethylene (UHMWPE) meniscal insert. The femoral component has been cleared as part of the fixed bearing version in K050764. The investigational portion of this device is the mobile bearing tibial construct (tibial tray and meniscal insert).
223667860|NCT00740376|DEVICE|Uniglide Fixed Bearing Unicondylar Knee System|Uniglide Fixed Bearing Knee System includes a femoral component made of cobalt chromium molybdenum (CoCrMo) that articulates with a one piece ultra high molecular weight polyethylene (UHMWPE) tibial bearing (K050764).
224249387|NCT05565053|PROCEDURE|Bilateral thoracal erector spinae plane block|Bilateral upper thoracal erector spinae plane block with ultrasound
224249388|NCT05565053|PROCEDURE|Trapezius muscle trigger point injection|Trapezius muscle trigger point injection
224249389|NCT01540760|DRUG|MCAF5352A|Multiple ascending doses
224321893|NCT03793166|PROCEDURE|Bone Scan|Undergo bone scan
224321894|NCT03793166|DRUG|Cabozantinib|Given PO
223667861|NCT03814421|DRUG|intermittent (40mg as a bolus injection daily for 72hours)|Current guidelines recommend an intravenous bolus dose of a proton pump inhibitor(PPI) followed by continuous PPI infusion after endoscopic therapy in patients with high-risk bleeding peptic ulcers. However, recent many studies suggests intermittent low dose PPI infusion might have equal efficacy at preventing peptic ulcer hemorrhage recurrence. So, the present investigator assumed that intermittent administration of proton pump inhibitor will not be different from administration of continuous proton pump inhibitor for the prevention of rebleeding in patients with peptic ulcer bleeding. Also, intermittent proton pump inhibitor administration in patients with high risk of rebleeding (Rockall score 6 points or more) will not be different from prevention of rebleeding compared with continuous proton pump inhibitor administration.
223667862|NCT06492655|DRUG|CKD-383(Fed)|After maintaining NPO for at least 10 hours before a high-fat meal, take a high-fat meal within 20 minutes on each medication day, and take CKD-383 two tablets orally with 150 mL of water at room temperature.
223667863|NCT06492655|DRUG|CKD-383(Fasted)|After maintaining NPO for at least 10 hours before dosing, and take CKD-383 two tablets orally with 150 mL of room temperature water with 30g of sugar added on each dosing day.
223771191|NCT02696096|OTHER|FMRI|all participants will complete 2 FMRIs
223771192|NCT02696096|DRUG|Suboxone|all participants will be prescribed Suboxone for 4 months during their study participation
224249390|NCT01540760|DRUG|Placebo|Matching MCAF5352A, multiple doses
224249391|NCT02170922|DRUG|BIBR 1048 MS tablet|
224249392|NCT02170922|DRUG|BIBR 1048 MS solution|
224249393|NCT02436447|DRUG|MTP-131|MTP-131 administered as once-daily 1- hour intravenous infusion for 7 consecutive days in subjects with normal renal function.
224321895|NCT03793166|PROCEDURE|Computed Tomography|Undergo CT scan
224321896|NCT03793166|BIOLOGICAL|Ipilimumab|Given IV
224249394|NCT02436447|DRUG|MTP-131|MTP-131 administered as once-daily 1- hour intravenous infusion for 7 consecutive days in subjects with mild renal impairment.
224321897|NCT03793166|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
224321898|NCT03793166|BIOLOGICAL|Nivolumab|Given IV
224249395|NCT02436447|DRUG|MTP-131|MTP-131 administered as once-daily 1- hour intravenous infusion for 7 consecutive days in subjects with moderate renal impairment
224249396|NCT02436447|DRUG|MTP-131|MTP-131 administered as once-daily 1- hour intravenous infusion for 7 consecutive days in subjects with severe renal impairment
224249397|NCT04728763|OTHER|Protein profile|Analysis of the protein content by proteomics of bronchoalveolar lavage
224249398|NCT01044485|DRUG|lapatinib|escalation dose from 1250 to 1500 mg in association with docetaxel
224249399|NCT01044485|DRUG|docetaxel|escalation dose from 75 mg/m2 to 100 mg/m2 in association with lapatinib
223667864|NCT04570059|BEHAVIORAL|Counselling on textured food introduction between 8 and 15 months|"Intervention program : Advice and tips on the why and how introducing textured food during complementary feeding are grouped in a booklet and provided to participants. Monthly counselling via phone call by a dietician (at 9, 10, 11,12, 13, 14 months) and two baskets containing food preparation utensils and commercial textured foods provided at 8 and 12 months.~Usual care : reflects the standard information provided within French national guidelines (PNNS). Two phone calls at 9 and 13 months. If questions are raised by parents, dieticians will restrict their responses based on the food guides of the PNNS. Two gift boxes containing presents for the child of same financial value as those provided to intervention group, provided at 8 and 12 months."
223667865|NCT04440605|PROCEDURE|Preoperative staging--D2 gastrectomy--Postoperative staging|Preoperative TNM staging under CT scan plus endoscopy endoscopic biopsy, and postoperative staging after D2 gastrectomy
223667866|NCT01141062|DEVICE|Philips MR-guided HIFU|HIFU is the use of focused ultrasound energy to penetrate through soft tissue and causes localized high temperatures (55°C to 70°C) for a few seconds within the target producing well defined regions of protein denaturation, irreversible cell damage, and coagulative necrosis.
223667867|NCT00678678|DEVICE|Incentive Spirometry - RESPIRON|Device that stimulates the deep breathing, flow-oriented
223667868|NCT00678678|DEVICE|Kit Epap®:|Device that providing constant positive pressure during expiration, given by spring load (cmH2O), using a face mask as an interface
223667869|NCT02886208|BEHAVIORAL|Measurement|The intervention consists of diabetes prevention education sessions focusing on increasing physical activity and decreasing the intake of sugared drinks while increasing intake of fruits and vegetables. The 2-hr sessions occur weekly for 6 weeks. Height and weight is measured for each consenting participant at baseline and after 6 weeks. Participants are also asked to complete a short questionnaire to collect demographic and knowledge data. Outcome measures include: BMI, knowledge of physical activity and dietary habits conducive to diabetes prevention, and feelings of food insecurity.
223667870|NCT01695876|DRUG|AMG 357|Oral administration available in varying dose strength.
223667871|NCT01695876|DRUG|Placebo|Matching placebo to AMG 357 containing no active drug
223667872|NCT03381534|DEVICE|stenting with EPD|participants will be randomly assigned to control group or experimental group,patients in control group will be undergone stenting of vertebral artery origin without embolic protection device,patient in experimental group will be undergone stenting of vertebral artery origin with embolic protection device
223667873|NCT03381534|DEVICE|stent assisted angioplasty|participants will be randomly assigned to control group or experimental group,patients in control group will be undergone stenting of vertebral artery origin without embolic protection device,patient in experimental group will be undergone stenting of vertebral artery origin with embolic protection device
223667874|NCT03010436|DRUG|Benralizumab|one injection 30 mg under the subjects skin every 4 weeks for 8 weeks and then every 8 weeks for 24 weeks for a total of 5 treatments.
223667875|NCT04134546|PROCEDURE|CBD exoloration|Early versus late intervention after biliary tract injury post cholecystectomy
223667876|NCT05704127|OTHER|Intelligent Moxibustion Robot|The intelligent moxibustion robot holds the thunder fire moxibustion stick and conducts suspension moxibustion treatment on the points BL23, BL25, DU3 and pain points for 10 minutes in each group, a total of 40 minutes. BL23 and BL25 have one acupuncture point on each side of the spine, and the straight line reciprocating moxibustion technique is adopted. DU3, a single point, adopts the whirling moxibustion technique. Pain points,according to the number of pain points, choose straight reciprocating moxibustion or rotary moxibustion.
223667877|NCT05704127|OTHER|Artificial moxibustion|The people hold the thunder fire moxibustion stick and conducts suspension moxibustion treatment on the points BL23, BL25, DU3 and pain points for 10 minutes in each group, a total of 40 minutes. BL23 and BL25 have one acupuncture point on each side of the spine, and the straight line reciprocating moxibustion technique is adopted. DU3, a single point, adopts the whirling moxibustion technique. Pain points,according to the number of pain points, choose straight reciprocating moxibustion or rotary moxibustion.
223667878|NCT03391193|BIOLOGICAL|Multi-dose Quadrivalent Influenza Vaccine|0.5 mL, intramuscular
223667879|NCT03391193|BIOLOGICAL|Single-dose Quadrivalent Influenza Vaccine|0.5 mL, intramuscular
223667880|NCT00734955|DEVICE|49-channel optical spectrometer|
223667881|NCT03740984|OTHER|Interventions are self controlled by the patient via a mp3 player and noise reduction headphones.|During premedication and during chemotherapy the patient is connected to a long term ECG recording and allowed to listen to the mp3 Player via noise reduction headphones.
223667882|NCT01185301|BIOLOGICAL|adalimumab|Pre-filled syringe every other week
223667883|NCT01185301|DRUG|methotrexate|weekly oral capsule dosing
223667884|NCT03597646|DEVICE|Kinesio Tape|
223667885|NCT03597646|DEVICE|Threshold Inspiratory Muscle Trainer|
224249400|NCT01122147|DRUG|chamomilla tincture mouthwash|The patient is directed to mouth wash chamomilla tincture lightly three times a day,ten drops for each time,until ulcers completely heal
224249401|NCT01122147|DRUG|placebo mouthwash|The patient is directed to use placebo mouthwash three times a day, ten drops for each time,until the ulcers completely heal
224249402|NCT04660747|DRUG|Oral anticoagulant|Direct oral anticoagulants or vitamin K antagonists. Please note that the study is fully observational. The choice of anticoagulant type and duration of treatment are left at the discretion of the treating physicians and patients. No treatment, intervention, or examinations are imposed on patients in the context of this study.
224321899|NCT03793166|OTHER|Quality-of-Life Assessment|Ancillary studies
224321900|NCT03793166|OTHER|Questionnaire Administration|Ancillary studies
224321901|NCT03698019|PROCEDURE|Biospecimen Collection|Undergo collection of blood
224321902|NCT03698019|PROCEDURE|Computed Tomography|Undergo CT
223771193|NCT04197635|DIAGNOSTIC_TEST|Maximal functional capacity by cardiopulmonary exercise testing|It will be done with cycle ergometer (CORTEX Metamax3B), starting with 10W of power and increasing 10W every minute. During the test, heart rate, rhythm and blood pressure will be monitored. Gas exchange data shall be evaluated every 10 seconds and the peak oxygen consumption (peak VO2) shall be considered the maximum value obtained during the last 20 seconds of exercise. The main parameters to be determined are: maximum functional capacity, peak VO2, slope of the VE/VCO2 ratio, and chronotropic incompetence variables. It will be performed by a trained cardiologist blind to study treatment at baseline and at 30 and 90 days after treatment initiation.
223771194|NCT04197635|DIAGNOSTIC_TEST|Echocardiography|The following parameters will be evaluated: a)left ventricular volumes; b) left ventricular systolic function; and c)left atrial volume and E/e' ratio. It will be performed by a trained cardiologist blind to study treatment at baseline and at 30 and 90 days after treatment initiation.
223771195|NCT04197635|BEHAVIORAL|Evaluation of health related quality of life|Assessment of the quality of life through the Minnesota Living with Heart Failure Questionnaire (MLHFQ), Spanish version. It will be completed at baseline and at 30 and 90 days after treatment initiation. The score of the questionnaire is 0 to 105 points.
223667886|NCT01319331|DRUG|Alpha 1-Antitrypsin (AAT, Aralast NP)|Eligible subjects will be treated once a week for 8 weeks (8 total treatments).
223771196|NCT04197635|DIAGNOSTIC_TEST|Submáximal functional capacity assesment by 6 minutes walk test|It will be performed in an area equipped for cardiopulmonary resuscitation. Subjects will be asked not to perform a vigorous physical exercise in the previous 2 hours. They will be allowed to have a light meal before the test. Before the test, the vital signs will be determined in a seated position after a rest of 10 minutes. Subjects will be instructed to walk at their own pace to cover as much distance as possible in 6 minutes. It will be performed by a trained nurse blind to study treatment at baseline and at 30 and 90 days after treatment initiation.
223771197|NCT04197635|OTHER|Clinical evaluation|Evaluation of signs and symptoms of heart failure
223771198|NCT01740583|DEVICE|percutaneous annuloplasty|plication of the mitral valve annulus
223771199|NCT00120432|DRUG|1% tropicamide and 10% phenylephrine|single dose vs three doses of 1%tropicamide and 10%phenylephrine
223771200|NCT04751305|BEHAVIORAL|Health Coaching|The weekly health coaching (HC) calls were structured to be participant-centered, built on a coach participant relationship, and include participant-determined goals, a self-discovery process to find solutions, patient accountability, and education. Before each HC call, the participants received a short questionnaire on fatigue, QOL, stress, loneliness, and social support which enabled tailoring the HC call to the individual. Educational topics are discussed in the following order: Goal Setting, Monitoring Behaviour, Barrier Management, Social Support, Stress Management, Adapting the Program, Self-Compassion, Sleep \& Nutrition, Reflection, Health Media, Remote Resources, and Maintaining Motivation. However, the order of the educational topics can be adjusted based on the specific participants' needs each week. At the half-way point of the intervention, the participant provided feedback on the HC calls, ensuring optimization of HC impact.
223771201|NCT04751305|BEHAVIORAL|Online delivered Exercise Classes|The group based remote exercise program was delivered over the Zoom application (2x/wk for first 2 weeks; 1x/wk for the remaining weeks). Classes were one hour long with a ten minute warm up, 40 minute strength and conditioning focused exercise circuits, and a ten minute stretch. Each class was followed by additional time to provide participants with an opportunity to interact with each other, fostering social support.
223771202|NCT02011048|PROCEDURE|Endoscopic components separation|Endoscopic components separation hernia repair
223771203|NCT05408481|DIAGNOSTIC_TEST|Serum cortisol level|Biochemical test
223771204|NCT04035720|OTHER|Quantitative risk|Participants will be able to see a square box that represent the estimated risk of disease progression. They will have to elect making a therapeutic decision based on the description of the case-scenario or based on the estimated prediction as represented in the square box.
223771205|NCT00399334|DRUG|antipsychotic medications|as prescribed
223771206|NCT02121691|BEHAVIORAL|Walk by Faith|The Walk by Faith program is aimed at increasing physical activity and improving healthy eating to reduce or maintain healthy BMI among members of the churches.
223771207|NCT02047604|DRUG|SAN-300 0.5 mg/kg QW|
223771208|NCT02047604|DRUG|SAN-300 1.0 mg/kg QW|
223771209|NCT02047604|DRUG|SAN-300 2.0 mg/kg QOW|
223771210|NCT02047604|DRUG|SAN-300 4.0 mg/kg QOW|
224321903|NCT03698019|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
224321904|NCT03698019|BIOLOGICAL|Pembrolizumab|Given IV
223667887|NCT05214053|DEVICE|Cone Beam CT|Each patient will undergo a Cone Beam CT and a MDCT
223667888|NCT02683746|DRUG|Lyophilized albiglutide DCC pen injector|A fixed-dose, fully disposable pen injector system with a prefilled dual chamber glass cartridge (DCC) containing lyophilized albiglutide (30mg or 50mg) delivering an injection volume of 0.5mL.
223667889|NCT02683746|DRUG|Lyophilized albiglutide DCC pen injector matching placebo|A fixed-dose, fully disposable pen injector system with a prefilled DCC containing matching placebo delivering an injection volume of 0.5mL
223771211|NCT02047604|DRUG|SAN-300 4.0 mg/kg QW|
223771212|NCT02047604|DRUG|Placebo|
223771213|NCT05313516|DEVICE|OKKO Health app|Use of OKKO Health app for home monitoring.
223771214|NCT01945515|DEVICE|tDCS|tDCS will be applied on the primary motor cortex of the lower limb in the impared hemisphere before robotic-assisted gait training. Anodal tDCS will be applied with an intensity of 2mA for 20 min. Sham tDCS will be applied with an intensity of 2mA just for 1 min, after which the current will be slowly tapered down to 0 over a several seconds.
223771215|NCT01945515|DEVICE|Robotic-assisted gait training|Robotic-assisted gait training with an exoskeletal type robot which simulates normal walking on a treadmill for patients with gait impairments
223771216|NCT05928702|PROCEDURE|temperature-elevating armbath|Hydrotherapeutic Approach
223771217|NCT03079336|BEHAVIORAL|Implementation - SOTA|The implementation of an evidence-based treatment is largely principle-based - allowing considerable therapeutic flexibility in determining and timing of different treatment aspects. In this condition progress, subtle changes and sudden gains may be an explicit topic and there is no restraint to avoid such topics. However, the therapists are not obligated to take a systematized focus on potential subtle changes and they may use the timing of the sessions to involve the patients into the other tasks of therapy.
224321905|NCT03698019|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
223771218|NCT03079336|BEHAVIORAL|Implementation - Prolonged focus on changes|Systematized sequence of exploration of subtle changes at a prolonged check-in phase: (1) the precise change situation, (2) related emotional states, (3) related helpful thoughts and self-verbalizations, (4) reinforcement of generalized self-efficacy and treatment motivation, (5) benefit for the upcoming session goals (Flückiger, Grosse Holtforth, et al. 2013, 2014).
223667890|NCT02683746|DRUG|Albiglutide liquid auto-injector|A fixed-dose, single use, disposable auto-injector containing albiglutide liquid (30mg or 50mg) in a prefilled glass syringe. The auto-injector delivers the albiglutide liquid in an injection volume of 0.6 mL for the 30mg dose and 1.0 mL for the 50mg dose.
223667891|NCT02683746|DRUG|Albiglutide liquid auto-injector matching placebo|A fixed-dose, single use, disposable auto-injector containing matching placebo in a prefilled glass syringe. The auto-injector delivers the matching placebo in an injection volume of 0.6 mL for the 30mg dose and 1.0 mL for the 50mg dose.
223771219|NCT03079336|BEHAVIORAL|Mastery your Anxiety and Worry (MAW)|"In the present study, the MAW-packet will be applied within a usual 16-session individual therapy format and up to 3 further booster sessions.~The session format of 50-60 minute usually consists of (a) a check-in phase of 5 to 15 minutes that includes a patients welcoming, reviewing self-help and agenda setting, (b) a working phase around 35-45 minutes that focuses on the previously agreed session goals, (c) a feedback phase of 5 to 10 minutes that summarizes the session and previews the upcoming self-help assignment."
223771220|NCT06467526|DRUG|Hydroxychloroquine|Oral hydroxychloroquine (400mg/day) for 2 months
223771221|NCT06467526|DRUG|Steroid|Oral prednisolone (5 mg) for 2 weeks (1 mg/kg/day for one week with gradually taper for another week with or without intratympanic dexamethasone 5 mg/ml injection for 2-4 times)
224249403|NCT06082258|OTHER|Training in the management of functional disorders|Theoritical and practical training of GP in long COVID and somatic symptom disorders management
223667892|NCT04987944|DRUG|Zavegepant|150 mg BID
223667893|NCT04987944|DRUG|Placebo|Placebo matching active drug
223667894|NCT05306821|OTHER|Comprehensive electronic tool in the electronic medical chart|Use of a comprehensive electronic tool in the electronic medical chart to help the stratification of risk of VTE and the subsequent prescription of an adequate thromboprophylaxis
224249404|NCT06082258|OTHER|Reimbursement of 3 long consultations|3 long consultations (1 hour) reimbursed for each patient
224249405|NCT01234103|BEHAVIORAL|Preventing Helath Damaging Health Behaviors in Male and Female Army Recruits|Groups will be randomly assigned to the sexual/substance use prevention intervention or the comparative/control intervention focused on impro risk Involves 10 hours of didactic presentations, interactive group discussions, skills-building exercises, and topic specific videos to reduce participants' risk for and acquisition of STIs, unintended pregnancies and their associated sexual and substance use behaviors.
224249406|NCT00821834|DRUG|clopidogrel (SR25990)|"Form: tablets~Route: oral"
223667895|NCT05306821|OTHER|Educative sessions|Educative sessions on thromboprophylaxis
223667896|NCT05306821|OTHER|Pocket card|Pocket card (guide for thromboprophylaxis)
223667897|NCT00088556|DRUG|TLK286|Every 3 Weeks with a starting dose of TLK286 @ 400 mg/m²
223667898|NCT00088556|DRUG|carboplatin|AUC 6 mg/mL/min Once every 3 weeks
223667899|NCT00088556|DRUG|paclitaxel|200 mg/m² Once every 3 weeks
223667900|NCT04563832|OTHER|Standardized respiratory management program|Bronchial decluttering education, respiratory physiotherapy, specialized medical follow-up for 2 years
223667901|NCT04563832|OTHER|CoughAssist|self-administered mechanical in-exsufflation - CoughAssist (2 x 15 min per day, 5 days per week for 2 years)
223667902|NCT05277480|DRUG|Apatinib+IE|apatinib po； ifosfamide ivgtt ; etoposide ivgtt .
223667903|NCT05277480|DRUG|IE|ifosfamide ivgtt ; etoposide ivgtt .
223667904|NCT04787523|RADIATION|Radiotherapy|Patients have received neoadjuvant radiotherapy
223667905|NCT04924413|DRUG|Tislelizumab|PD-1 positive lymphocytes are isolated from peripheral blood and amplified for transfusion
223771222|NCT02436512|DRUG|Inhaled Nitric Oxide|"The investigational product is inhaled nitric oxide delivered via nasal cannula or venturi mask with the GeNOsylTM Delivery System or GeNOsylTM Acute DS, during RHC as follows:~* (Dose 1): 5 ppm inhaled nitric oxide for 15 minutes~* (Dose 2): 40 ppm inhaled nitric oxide for 15 minutes"
224249407|NCT00821834|DRUG|ticlopidine|"Form: tablets~Route: oral"
224249408|NCT00821834|DRUG|Placebo|"Form: tablets~Route: oral"
224249409|NCT02563808|OTHER|Standard Decision Aid|Females will receive standard decisions aid for early stage breast cancer.
224249410|NCT02563808|OTHER|Post-surgical Regret Decision Aid|Females will receive anticipated regret-augmented version for early breast cancer.
223667906|NCT05205577|DEVICE|Tens Eco Plus|30min/day of stimulation at 25Hz frequency, 100 microsc pulse with intensity escalation up to 25 mA max
223667907|NCT03693729|DEVICE|HD-tDCS|Participants will complete a metamemory and memory task
224249411|NCT05526118|DRUG|Bictegravir/emtricitabine/tenofovir alafenamide|Patients who are ART-naive adults,18 years of age and older, diagnosed with HIV within 7 days of study entry who have a clinical (diagnosed Opportunistic Infection/AIDS-defining illness) or laboratory (CD4\<200) diagnosis of advanced HIV, who are clinically appropriate for Rapid ART initiation, and are initiated on bic/f/taf per DHHS guidelines at their initial clinic visit will be monitored for time to viral suppression, efficacy and CD4 cell recovery over the course of 48 weeks.
224249412|NCT02329678|PROCEDURE|Peripical surgery|Thirty patients meeting inclusion criteria were selected and allocated randomly into two groups: collagen membrane group and control group. Clinical and radiographic measurements were recorded during follow up at regular intervals of 0, 3, 6, 9, and 12 months after surgery. The criteria for success included the absence of clinical signs and symptoms, and complete or incomplete radiographic healing.
223667908|NCT02983097|DRUG|Rituximab|Rituximab 375 mg/m²
223667909|NCT02983097|DRUG|Cisplatin|Cisplatinum 100 mg / m²
223667910|NCT02983097|DRUG|Carboplatin|Carboplatinum AUC5
223667911|NCT02983097|DRUG|Dexamethasone|Dexamethasone 40 mg
223667912|NCT02983097|DRUG|Cytarabine|Cytarabine 2000 mg/m², administered twice
223667913|NCT02983097|DRUG|Lenalidomide|5-20 mg administered either d1-d7, or d-6-d7
223667914|NCT02983097|DRUG|PegFilgrastim|PegFilgrastim 6 mg
223667915|NCT02983097|PROCEDURE|peripheral stem cell collection|collection of peripheral stem cells for autologous stem cell transplantation
223667916|NCT00006439|BEHAVIORAL|Counseling in the home|
223771223|NCT03289104|DEVICE|Steel Wires|Control: Steel wires (device) are selected for sternal closure after surgery. Currently, most patients who have a sternotomy during cardiac surgery have their sternum closed with steel wires.
223771224|NCT03289104|DEVICE|ZipFix Sternal Closure System|Treatment: ZipFix system (device) are selected for sternal closure after surgery. These plastic cables can also be used to close the sternum during bypass surgery.
223771225|NCT03842475|PROCEDURE|Roux-en-Y gastric bypass (RYGB)|Bariatric surgery
223771226|NCT05379959|DRUG|MDMA|Participants will be given 125 mg of MDMA.
223771227|NCT05379959|DRUG|Methamphetamine|Participants will be given 20 mg of MA.
223771228|NCT05379959|DRUG|placebo oral tablet|Participants will be given a placebo capsule that will only contain lactose.
223771229|NCT00773097|BIOLOGICAL|MUC1 - Poly ICLC|The vaccine will be administered on an outpatient basis in the Digestive Disorders Clinic. The total volume of each dose of vaccine MUC1+ POLY-ICLC will be approximately 250 microliters subcutaneously (SQ) in the upper thigh. The site of injection will remain the same thigh, to enhance the potential immune response.
223771230|NCT01970202|DRUG|40mg Enoxaparin|Patients with obesity undergoing laparoscopic sleeve gastrectomy, will receive 40mg Enoxaparin per day for 3 days after surgery by subcutaneous administration.
223667917|NCT04987788|BEHAVIORAL|Motívate|The Motívate app can be used in English or Spanish and involves four sequential phases. 1) The engaging phase uses videos to welcome participants. 2) Patients willing to discuss the decision to have a screening colonoscopy will answer multiple-choice questions on colorectal cancer prevention - completing the focusing phase. Optional videos will offer additional information. 3) The evoking phase consists of interactive Motivational Interviewing exercises to help participants elicit motivations to get a screening colonoscopy. 4) During the planning phase, participants will view a video that will discuss the steps needed to prepare for the colonoscopy.
223667918|NCT04987788|BEHAVIORAL|Video link|General health information video link
223667919|NCT00790309|PROCEDURE|Weight loss surgery|Weight loss surgery
223667920|NCT00790309|PROCEDURE|Laparoscopic abdominal surgeries|laparoscopic abdominal surgeries
223771231|NCT01970202|DRUG|60mg Enoxaparin|Patients with obesity undergoing laparoscopic sleeve gastrectomy, will receive 60mg Enoxaparin per day for 3 days after surgery by subcutaneous administration.
223771232|NCT01970202|OTHER|Control|no treatment
223771233|NCT05293275|DEVICE|EaseVRx Virtual Reality Headset|Virtual reality device with 360 degree visualization of various scenery and interactive modules
223771234|NCT02707640|DRUG|Matching Placebo|Matching Placebo, oral administration, three times daily for 24 weeks.
223771235|NCT02707640|DRUG|N-acetylcysteine|N-acetylcysteine, 600 mg, oral administration, three times daily for 24 weeks.
223771236|NCT02707640|DRUG|Pirfenidone|Pirfenidone, at least 1602 mg/day, oral administration, for 32 weeks, during the wash-out and screening period and for at least 8 weeks prior to randomization.
224249413|NCT02392000|DEVICE|WatchPAT sleep monitor|Self-management of insomnia using a mobile sleep device
223771237|NCT03732066|BEHAVIORAL|Usual Text Messages|Usual text messages four times a week, including cardiovascular knowledge and follow-up reminders, such as risk factors for CHD and typical symptoms of myocardial infarction.
223771238|NCT03732066|BEHAVIORAL|Personalized Reminders|"1. The mHealth tools will provide special interventions according to the patients' medical history. For example, patients with hypertension will receive daily reminders on blood pressure measurement and medication. They will also receive early warning on hypertension with a systolic blood pressure of \>180 mmHg or \<90 mmHg. Patients who smoke will be required to quit smoking. Every patient will receive a Health Report monthly, which will reflect their drug compliance, blood pressure and so on.~2. Drug Reminders: Patients' medication information will be recorded by obtaining pictures of their medication. Patients will be asked to punch time clocks simply in the mHealth tools. If they forget to punch cards, they can punch cards whenever they think of it. If there is no record of medication for 3 days, SMS alerts will be received, and phone calls will be received over 7 days."
223771239|NCT03732066|BEHAVIORAL|Interactive Responses|"1. Auto-Response: After sending personal or discomfort symptom questions, the patients will be provided with an automatic response pushed by the back-end database by crawling the keywords. It is suggested that the answer is just for reference. In case of urgent questions, they will be advised to consult the clinicians.~2. The researchers will communicate with the patients every month."
223771240|NCT00466960|BIOLOGICAL|sargramostim|Given SC
224249414|NCT02392000|BEHAVIORAL|CBT-i Coach mobile app|Self-management of insomnia using a mobile app based on Cognitive Behavioral Therapy for Insomnia
223667921|NCT05519293|DRUG|H002|Small molecule, Capsule
223667922|NCT02316509|DRUG|GDC-0927|GDC-0927 will be administered as per schedule specified in the respective arm.
223667923|NCT00400296|DRUG|RG547|Administered iv on days 1 and 8 of a 3 week cycle at escalating doses to successive groups of patients until MTD is reached.
223667924|NCT00595374|DRUG|insulin detemir|
223667925|NCT00595374|DRUG|insulin NPH|
223667926|NCT00595374|DRUG|insulin aspart|
223667927|NCT02614469|DRUG|Inosine|Inosine, 1000 mg
223667928|NCT05535010|PROCEDURE|Transforaminal epidural steroid injection(TFESI)|TFESI procedure will be applied again in the 3rd week and 3rd month for the patients whose NRS score decreased by less than 50 percent after the first procedure.
223667929|NCT05094973|DEVICE|Carriere Motion Appliance®|To analyze the distalization or distal tooth displacement and derotation angle produced by Carriere Motion Appliance® in a period of 4 months.
223667930|NCT04272112|COMBINATION_PRODUCT|IPS e.max CAD, Ivoclar Vivadent|Type: monolithic lithium-disilicate glass ceramic
223667931|NCT04272112|COMBINATION_PRODUCT|BruxZir, Glidewell|Type: high translucent zirconia
223667932|NCT04272112|COMBINATION_PRODUCT|BruxZir*, Glidewell|Type: high translucent zirconia with a mini-veneer of porcelain
223667933|NCT00345332|DRUG|Botox|Injected
223771241|NCT00466960|DRUG|paclitaxel albumin-stabilized nanoparticle formulation|Given IV
223771242|NCT00466960|OTHER|laboratory biomarker analysis|Correlative studies
223771243|NCT00466960|OTHER|immunologic technique|Correlative studies
223771244|NCT03087279|BEHAVIORAL|Texas I-CAN!|physically active, academic lessons in the elementary school classroom
223771245|NCT01755416|DRUG|Closed loop with sensor and Insulin|Subject will be on the closed loop device with enlite sensors for about 27 hours. They will not be on any study medication and will be on insulin alone.
223667934|NCT00345332|DRUG|Placebo|Injected
223667935|NCT04869748|OTHER|Perfetti method|"* Participant was blindfolded, while lying flat in a quiet and comfortable room.~* Participants received a 15-minute session of Perfetti method on affected elbow flexor.~* Participants were asked to concentrate on the position of their elbows.~* Protocol has 4 steps of training starting from 2 positions; full flexion and full extension 3 positions; full flexion, elbow flexion 90 degree and full extension 4 positions; full flexion, elbow flexion 110-140 degree, elbow flexion 45-60 degree and full extension 5 positions; full flexion, elbow flexion 110-140 degree, elbow flexion 90 degree, elbow flexion 45-60 degree and full extension of elbow.~* After therapist passively moved elbow joint to a position, participant guessed the position of his/her elbow. If the answers were correct consecutively for 10 times, the therapist increased the number of positions according to the protocol."
223667936|NCT04869748|OTHER|passive stretching|"* Participant was blindfolded, while lying flat in a quiet and comfortable room.~* Each participant received gentle passive stretching of elbow flexor and maintained in full elbow extension position for 15 minutes."
223667937|NCT00406562|BIOLOGICAL|Boostrix|
223667938|NCT06409793|BEHAVIORAL|mHealth|A 3-month structured exercise and PA intervention, supported by an exercise specialist, with a 3-month follow-up
223667939|NCT01426542|DRUG|Topiramate|Topiramate 5 mg/kg by mouth (or by feeding tube) once a day for one week before and one week after heart surgery.
223667940|NCT01426542|OTHER|No medication, but routine heart surgery|No medication, but routine heart surgery
223667941|NCT01610999|DRUG|Plerixafor|Plerixafor will be dosed according to actual body weight. Each dose will be capped at 24 mg (single vial). Plerixafor will be administered subcutaneously according to the assigned cohort starting two hours before the scheduled start of high dose chemotherapy.
223667942|NCT00435253|BIOLOGICAL|BLVR Treatment|BLVR Treatment, 10 mL Hydrogel
223667943|NCT01716962|OTHER|Infusion of 6% tetrastarch for a total of 500 ml|
223667944|NCT04215757|PROCEDURE|peripheral nerve block|peripheral nerve blocks with low dose lignocaine in acute radiculopathy
223667945|NCT06251401|BEHAVIORAL|In-person supervised cardiac rehabilitation|In-person CR consists of weekly group-based supervised exercise training at Women's College Hospital, supplemented with home-based exercise training, with the goal of reaching Canadian Physical Activity Guidelines of 150 minutes a week of moderate-intensity exercise per week. Exercise prescriptions are individualized at baseline by the cardiac rehabilitation team. Both study arms get have the opportunity to attend weekly synchronous virtual group video education sessions for the duration of the 12-week cardiac rehab program with the focus on self-management education and support.
223667946|NCT06251401|BEHAVIORAL|Virtual cardiac rehabilitation|Virtual CR consists of once-weekly telephone or video conferencing-based follow-ups (according to participant preference and access to internet/smart device) by one of the cardiac rehab providers. Similar to the in-person program, the virtual program also encourages participants to set goals to achieve 150 minutes a week of moderate-intensity exercise. The exercise prescription is individualized to each participant's ability and can vary in number of sessions per week and duration of each exercise session, as per the cardiac rehab provider's discretion. Unlike the in-person program, all these sessions are completed at home in an unsupervised manner. Both study arms get have the opportunity to attend weekly synchronous virtual group video education sessions for the duration of the 12-week cardiac rehab program with the focus on self-management education and support.
223667947|NCT03540251|OTHER|Auricular Points Sticking|"Auricular Points Sticking is a kind of acupunture based on Meridians Theory of traditional Chinese Medicine.Sticking and pressing predefined therapeutic auricular points can relieve the frequency and severity of hot flashes and other climacteric symptoms.~Both groups received a booklet with information about self-care indications, auricular points and its management, and patients can record their hot flash score each day for 12 weeks in the booklets.In addition, both group received 8 treatment sessions of sticking and pressing predefined auricular points or placebo auricular points treatments."
223667948|NCT02789319|DEVICE|Blood Glucose Meter Systems|
223667949|NCT04316910|DRUG|General anesthetic|General anesthesia was induced as follows: 0.3 mg kg-1 intravenous (IV) etomidate, 2 mg IV midazolam, 0.4 μg kg-1 IV sufentanil, and 0.2 mg kg-1 IV cisatracurium. Anesthesia was maintained with an end-tidal concentration of 2-3 vol% sevoflurane and 0.2-0.3 μg kg-1h-1 sufentanil to maintain the bispectral index between 40 and 60.
223771246|NCT01755416|DRUG|Closed loop with sensor, Insulin and Liraglutide|In this study visit the subject will be on the closed loop device with enlite sensors for about 27 hours. In addition to being on insulin, they would take a single injection of 1.2 mg of Liraglutide subcutaneously before dinner on Day 1.
223771247|NCT00463359|DRUG|Imiquimod cream|
223667950|NCT04538209|RADIATION|Abdominal computed tomography with angiography.|technique of combing a Computed Tomography scan with the injection of dye to create pictures of the portal circulation and portosystemic collaterals veins.
223667951|NCT01479283|DRUG|24-Hour Prophylactic Cefazolin* Antibiotic Regimen|"Pre-Operative Antibiotic Regimen: Patients will receive 2g (or a weight-based dose based on 100mg/kg/day with a maximum single dose of 2g if \< 18 years old) of IV cefazolin within 60 minutes prior to the procedure. No other pre-operative antibiotics will be administered.~Intra-Operative Antibiotic Regimen: Patients will receive 2g (or a weight-based dose based on 100mg/kg/day with a maximum single dose of 2g if \< 18 years old) of IV cefazolin every 3-4 hours. No other intra-operative antibiotics will be administered.~Post-Operative Antibiotic Regimen: Patients will receive 2g (or a weight-based dose based on 100mg/kg/day with a maximum single dose of 2g if \< 18 years old) of IV cefazolin every 8 hours for 24 hours followed by IV saline for 4 days. No other post-operative antibiotics will be administered."
223667952|NCT01479283|DRUG|5-Days Prophylactic Cefazolin* Antibiotic Regimen|"Pre-Operative Antibiotic Regimen: Patients will receive 2g (or a weight-based dose based on 100mg/kg/day with a maximum single dose of 2g if \< 18 years old) of IV cefazolin within 60 minutes prior to the procedure. No other pre-operative antibiotics will be administered.~Intra-Operative Antibiotic Regimen: Patients will receive 2g (or a weight-based dose based on 100mg/kg/day with a maximum single dose of 2g if \< 18 years old) of IV cefazolin every 3-4 hours. No other intra-operative antibiotics will be administered.~Post-Operative Antibiotic Regimen: Patients will receive 2g (or a weight-based dose based on 100mg/kg/day with a maximum single dose of 2g if \< 18 years old) of IV cefazolin every 8 hours for 5 days. No other post-operative antibiotics will be administered."
223771248|NCT00463359|PROCEDURE|curettage and cautery|
223771249|NCT03842176|PROCEDURE|Neoadjuvant chemotherapy before surgery|The operable breast cancer patients takes neoadjuvant chemotherapy before surgery.
223667953|NCT06192810|PROCEDURE|Laparoscopic/open adrenalectomy|
223667954|NCT03340103|DIETARY_SUPPLEMENT|LUTEIN ofta 0,5 gocce|LUTEIN ofta 0,5 gocce, containing a solution of 5% Lutein and 2,5% Zeaxanthin with excipients (Corn starch, glucose, potassium sorbate, xanthan gum, citric acid)
223667955|NCT03340103|DRUG|Placebo|Placebo solution with unique excipients (Demineralised water, potassium sorbate, xanthan gum, citric acid)
223667956|NCT03077087|DEVICE|thin Integra® (125 cm2)|125 cm2 represents approximately 0.7% of an average sized patient's total body surface area. The remaining injury areas would be covered with standard-thickness Integra® only. The donor graft, a 4 cm x 10 cm sheet of skin, would be meshed in a 3:1 ratio to be expanded to cover the 125 cm2 sheet of thin Integra®. The patient's post-operative care would be largely unchanged, although the patient would have a donor site of 40 cm2 that would be dressed and managed in the usual fashion.
223667957|NCT00918060|DRUG|Camella sinensis gel|clinical effect of locally-delivered gel between Camella sinensis and placebo
223667958|NCT04858971|OTHER|Perception of information source|Participants will see the same health advice, with no source or one of three other sources indicated
223667959|NCT00742664|BEHAVIORAL|Cognitive-behavioral therapy|The manual is informed by behavioral principles and provides a structured, replicable manner of treating OC symptoms in youth with PWS. The treatment is individual in nature, includes a strong family component (i.e., teaching parents to be their child's coach/therapist), and lasts for approximately 12 sessions, held in a twice-weekly format. In addition, the protocol includes several specific components: education about OC symptoms (i.e., etiology, behavioral function, etc.), developing a hierarchy of rituals to target, exposure and response prevention exercises, promoting adaptive familial responses to child behaviors, and relapse prevention and problem solving future situations.
223667960|NCT00742664|BEHAVIORAL|Wait-list control|The subject will not receive active treatment during this interval.
223667961|NCT01989468|BIOLOGICAL|Secukinumab|Secukinumab 150 mg provided in a 1 mL autoinjector (1 autoinjector for 150 mg dose, 2 autoinjectors for 300 mg dose)
223667962|NCT01989468|BIOLOGICAL|Placebo|Secukinumab placebo provided in 1 mL autoinjector
223667963|NCT02817477|DRUG|Ketamine Hydrochloride|Delivered intranasally using an atomizer
223667964|NCT02817477|DRUG|Morphine|Delivered either as an IM injection or a slow IV bolus
223667965|NCT01402336|DRUG|GnRH antagonist (Cetrorelix)|In the first arm, cetrotide will be administrated from the first day during stimulation. In the second arm, cetrotide will be administrated from the sixth day during stimulation
223667966|NCT01402336|DRUG|Conventional GnRH agonist (Triptorelin)|Patients in the agonist group were administered GnRH agonist started 5 days before discontinuation of the oral contraceptive.
223667967|NCT01640327|BIOLOGICAL|Trivalent influenza virus vaccine (TIVf)|A single dose (0.5 mL) of vaccine supplied in prefilled syringes was administered intramuscularly in the deltoid muscle, preferably of the non dominant arm
223667968|NCT01371370|OTHER|Resistance exercise training|The low intensity resistance exercise training intervention consists of lower-body resistance exercise (machines) 3 times per wk for 12 wk. Two sets the first 2 wk and 3 sets the rest of the intervention, at 40% of the estimated 1 repetition maximum, for 17 to 23 repetitions, with 1 minute of rest in between sets.
223667969|NCT01371370|OTHER|Hypocaloric diet|The hypocaloric diet intervention consists of 12 wk of the standard Nutrisystem foods plan complemented by fresh produce and dairy. Subjects consume breakfast, lunch, dinner, and one (women) or two (men) snacks per day.
223667970|NCT01371370|OTHER|Resistance exercise training & diet|Combination of low intensity resistance exercise training and hypocaloric diet
223667971|NCT02864485|PROCEDURE|live donor liver transplantation|live donor liver transplantation
223667972|NCT01797770|DRUG|polyethylene glycol|mechanical bowel preparation with polyethylene glycol one day prior to surgery
223667973|NCT01797770|OTHER|No Preparation|No laxatives or bowel preparation
223667974|NCT03156647|DIAGNOSTIC_TEST|Level of alpha-synuclein|Test of levels of total and ratio total:oligomeric in saliva
223667975|NCT02723487|DRUG|Bupivacaine 0.125%|Patients will receive bilateral Transversus Abdominis Plane Block guided by ultrasound device using bupivacaine (Marcaine, 0.125%), 0.5 ml/kg on each side.
224321906|NCT00588770|BIOLOGICAL|Bevacizumab|Given IV
223667976|NCT02723487|DRUG|Bupivacaine 0.25%|Patients will receive bilateral Transversus Abdominis Plane Block guided by ultrasound device using bupivacaine (Marcaine, 0.25%), 0.5 ml/kg on each side.
223667977|NCT02451371|DEVICE|tDCS|2mA direct current, 20 minutes per session, 2 sessions per day with at least 3hours interval between sessions, a total of 10 tDCS sessions
223667978|NCT01229462|DRUG|brimonidine tartrate/timolol fixed combination ophthalmic solution|One drop of brimonidine tartrate/timolol fixed combination ophthalmic solution (Combigan®) administered to the affected eye(s) twice daily (morning and evening) for four weeks.
223667979|NCT01229462|DRUG|brimonidine tartrate ophthalmic solution|One drop of brimonidine tartrate ophthalmic solution (Alphagan®) administered to the affected eye(s) twice daily (morning and evening) for four weeks.
223667980|NCT01229462|DRUG|timolol ophthalmic solution|One drop of timolol ophthalmic solution administered to the affected eye(s) twice daily (morning and evening) for four weeks.
223667981|NCT01229462|OTHER|fixed combination vehicle|Fixed combination vehicle administered to the affected eye(s) twice daily (morning and evening) for four weeks.
223667982|NCT02830269|DEVICE|Transcranial Doppler ultrasonography measurements|Third ventricle diameter measurements with standard method (CT) and Transcranial Doppler ultrasonography
223667983|NCT03134079|OTHER|apple crisp|Subjects tasted three items (apple crisp, tea and oatmeal) in a randomized sequence schedule to allow for tasting the three recipes (full sugar recipe, reduced sugar recipe and reduced sugar plus spice recipe) over three weeks. Oatmeal and tea were served together as a breakfast meal and tastings of oatmeal and tea were done over 3 weeks and tastings for apple crisp (served alone) were done over 3 different weeks. Subjects tasted one of the three recipes at each weekly seating.
223771250|NCT03842176|PROCEDURE|Surgery followed by adjuvant chemotherapy|The operable breast cancer patients takes surgery followed by adjuvant chemotherapy.
224321907|NCT00588770|DRUG|Carboplatin|Given IV
224321908|NCT00588770|DRUG|Cisplatin|Given IV
224321909|NCT00588770|DRUG|Docetaxel|Given IV
224321910|NCT00588770|DRUG|Fluorouracil|Given IV
224321911|NCT00588770|OTHER|Laboratory Biomarker Analysis|Correlative studies
224321912|NCT03233711|PROCEDURE|Biopsy Procedure|Undergo biopsy
224249415|NCT01051505|DRUG|AZD5069|oral suspension dose of AZD5069. Multiple doses will be given once daily on day 1 and day 8 and twice daily on days 2 to 7
223667984|NCT03134079|OTHER|tea|Subjects tasted three items (apple crisp, tea and oatmeal) in a randomized sequence schedule to allow for tasting the three recipes (full sugar recipe, reduced sugar recipe and reduced sugar plus spice recipe) over three weeks. Oatmeal and tea were served together as a breakfast meal and tastings of oatmeal and tea were done over 3 weeks and tastings for apple crisp (served alone) were done over 3 different weeks. Subjects tasted one of the three recipes at each weekly seating.
223667985|NCT03134079|OTHER|oatmeal|Subjects tasted three items (apple crisp, tea and oatmeal) in a randomized sequence schedule to allow for tasting the three recipes (full sugar recipe, reduced sugar recipe and reduced sugar plus spice recipe) over three weeks. Oatmeal and tea were served together as a breakfast meal and tastings of oatmeal and tea were done over 3 weeks and tastings for apple crisp (served alone) were done over 3 different weeks. Subjects tasted one of the three recipes at each weekly seating.
223667986|NCT01476202|DRUG|nicotine|nicotine in the form of a mouth strip, lozenge and gum
223667987|NCT06046157|OTHER|Breast milk-scented PIOMI|"During PIOMI, the scent of breast milk will be provided through cotton soaked in breast milk placed 1.5 cm away from the babies.~PIOMI: Oral motor intervention for premature infants is a standardized oral motor therapy for preterm infants that has been shown to have strong intervention fidelity and has been tested internationally.~It is a 5-minute, 8-step focused therapy designed to help the premature baby respond functionally to lip, chin and lip movements and pressure, applied for 7 consecutive days using all aseptic precautions with gloved fingers.~Intervention provides assisted movement to activate muscle contraction and movement against resistance to build strength."
223667988|NCT06046157|OTHER|Breast milk-tasting PIOMI|"The finger used during PIOMI application will be performed by dipping it into breast milk. This will ensure that babies taste breast milk.~PIOMI: Oral motor intervention for premature infants is a standardized oral motor therapy for preterm infants that has been shown to have strong intervention fidelity and has been tested internationally.~It is a 5-minute, 8-step focused therapy designed to help the premature baby respond functionally to lip, chin and lip movements and pressure, applied for 7 consecutive days using all aseptic precautions with gloved fingers.~Intervention provides assisted movement to activate muscle contraction and movement against resistance to build strength."
223667989|NCT06405620|OTHER|Assistance robot|the child controls the robot at his parent's home from his room
223667990|NCT02112045|DRUG|Granix|
223667991|NCT02112045|DRUG|High dose melphalan (HDR)|
223667992|NCT02112045|PROCEDURE|Autologous Stem Cell Transplant (ASCT)|
223667993|NCT02771691|OTHER|Mentalization-Based Group Therapy for Adolescents|
223667994|NCT03774498|DRUG|Sensodyne repair and protect|NovaMin \& fluoride toothpaste
223667995|NCT04585971|DIAGNOSTIC_TEST|Signal intensity gradient|"Signal intensity gradient:~In time-of-flight (TOF) MRA, The signal intensities at the iso-point (Φa; signal intensity at position A \[Xa\] along the arterial contour line) and at the inner point (Φb; signal intensity at position B \[Xb\]) were calculated by using a trilinear interpolation algorithm based on the positions and signal intensities in the eight neighboring voxels. The signal intensities of TOF-MRA were normalized to eliminate the offset and scale effects across the MRA datasets of participants. For each iso-point (position A), the SIG was calculated from the difference in signal intensities between points A and B as follows:~Scalar SIG, SI/mm = (Φb - Φa) / │Xb - Xa│ (1)~Vector SIG, SI/mm = (Φb - Φa) n / │Xb - Xa│ (2)"
223667996|NCT05965271|DEVICE|Fabulous Thoracic Aortic Stent System|Endovascular treament in patients with aortic dissection with Fabulous Thoracic Aortic Stent System
223667997|NCT01671943|DEVICE|Ice-Sense3TM|Ice-Sense Cryoprobe
223667998|NCT00002642|DRUG|cisplatin|50 mg/m2, IV Days 1 and 8, two 28 day cycles prior to surgery and two 28 day cycles after surgery
223667999|NCT00002642|DRUG|etoposide|50 mg/m2, IV Days 1-5, two 28 day cycles prior to surgery and two 28 day cycles after surgery
223668000|NCT00002642|PROCEDURE|conventional surgery|surgery some time between weeks 9 and 12
223668001|NCT00002642|RADIATION|low-LET cobalt-60 gamma ray therapy|180 cGy per day, Days 1-5, weekly for 5 weeks
223668002|NCT02614521|OTHER|pulmonary veins ablation's successful outcome|Assessment of predictive factors in patients with successful outcome of pulmonary veins ablations and suffer from paroxysmal atrial fibrillation.
223668003|NCT00000973|DRUG|Pyrimethamine|
223668004|NCT00000973|DRUG|Leucovorin calcium|
223668005|NCT00000973|DRUG|Zidovudine|
223668006|NCT01762020|DEVICE|3M Cavilon No Sting Barrier Film|Half the breast will receive 3M Cavilon No Sting Barrier Film and one half will receive standard skin care
223668007|NCT01762020|DRUG|Standard Preparation|standard creams
223668008|NCT02859584|BIOLOGICAL|Measure OF SERUM TOTAL CORTISOL, SERUM FREE AND SALIVARY CORTISOL|
223668009|NCT00973011|DRUG|FCFD4514S|Intravitreal escalating dose
223668010|NCT00348608|DRUG|iodixanol|
223668011|NCT01819285|PROCEDURE|Immediate Orchiectomy or depot LHRH|
223668012|NCT01819285|PROCEDURE|Delayed Orchiectomy or depot LHRH|
223668013|NCT06264388|DRUG|DB107-RRV|Patients will undergo surgery to remove as much of the high-grade glioma (HHG) tumor as possible and will receive combination intravenous (IV) and adaptive repeat intratumoral delivery of DB107-RRV in the vein (IV) and in the walls of the cavity that remains where tumor is removed.
223668014|NCT06264388|DRUG|DB107-FC|Patients will start taking DB107-FC three times by mouth every day for a period of seven days, which is one cycle of treatment. A cycle of treatment is medication taken on a set schedule with periods of rest in between. Patients will wait five weeks before taking the next seven day course of DB107-FC. The first dose of DB107-FC will be taken at the hospital or clinic; afterward, patients will take the doses of DB107-FC at home. Patients will take DB107-FC for up to 12 months after surgery.
223668015|NCT00977080|DRUG|Paricalcitol|Paricalcitol dosed per label by region (participants were to receive cinacalcet if they developed hypercalcemia)
224249416|NCT01051505|DRUG|Placebo|oral suspension dose of matched placebo. Multiple doses will be given once daily on day 1 and day 8 and twice daily on days 2 to 7
224249417|NCT03180866|DEVICE|Luma Light System|The Luma Light System combines a NBUVB light with an occlusive dressing.
224249418|NCT00062283|DRUG|L-alanosine|
224249419|NCT01459003|OTHER|beauty care|beauty care performed before each chemo cycle
224321913|NCT03233711|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223668016|NCT00977080|DRUG|Cinacalcet|On-label oral cinacalcet by region with low dose vitamin D receptor activator (VDRA) (either doxercalciferol at US sites or alfacalcidol at non-US sites)
223668017|NCT05076721|OTHER|Simulation training|The participants in the simulation group will receive simulation training with high-fidelity manikin to practice and implement one-hour bundle sepsis
223668018|NCT05076721|OTHER|Case-based discussion training|The participants in the conventional group will only do a case-based discussion in implementing one-hour bundle sepsis
223668019|NCT00686114|DRUG|Paclitaxel|135mg/m2, day 1 and day 29 of the radiotherapy.
224249420|NCT04836078|PROCEDURE|open flap subgingival debridement|After the reevaluation phase after that corrective surgical phase started for the three groups. Local infiltration anesthesia administrated then sulcular flaps raised for the purpose of open flap subgingival debridement.Randomization was then performed and concealment from the assessors.
224249421|NCT04836078|PROCEDURE|Subgingival injection of chitosan 2% gel|Group (I); injected subgingivally with chitosan 2% gel containing a microsponges formulated drug weekly
224249422|NCT04836078|PROCEDURE|Subgingival injection of chitosan 2% gel|Group (II); injected subgingivally with chitosan 2% gel containing free drug weekly
224249423|NCT04836078|PROCEDURE|Subgingival injection of chitosan 2% gel|Group (III); injected subgingivally with placebo chitosan 2% gel weekly
224249424|NCT00827853|PROCEDURE|Conventional angioplasty balloon|Post-dilation of clinically indicated nitinol self-expanding stents in the SFA using conventional angioplasty balloon
224249425|NCT00827853|PROCEDURE|cryoplasty balloon|Post-dilation of clinically indicated nitinol self-expanding stents in the SFA using cryoplasty balloon
223668020|NCT00686114|DRUG|Cisplatin|20mg/m2, days 1-3,days 29-31 from the beginning of radiotherapy.
223668021|NCT00686114|DRUG|Tarceva|150mg/day,oral administration, from day 1 to day 42 (at the beginning of therapy)
223668022|NCT00686114|RADIATION|Radiotherapy|Enlarged field radiotherapy
223668023|NCT00686114|RADIATION|Radiotherapy|Conventional field radiotherapy
223668024|NCT06383312|DEVICE|Reflexologic Magnetic Insole Group|Reflexologic magnetic insole will be used for at least 7 hours a day, every day, for 12 weeks in participants diagnosed with primary dysmenorrhea. Then the effectiveness of the insoles will be compared.
223668025|NCT06383312|DEVICE|Orthopedic Insole Group|Orthopedic insole (sham) will be used for at least 7 hours a day, every day, for 12 weeks in participants diagnosed with primary dysmenorrhea. Then the effectiveness of the insoles will be compared.
223668026|NCT05547009|OTHER|Blended-learning group|The BL program included paced, asynchronous online learning modules and scheduled online activities with strategic face-to-face lectures. Resources: 1) Moodle platform: it was used as a virtual communication platform. 2) Online syllabus: an online specific syllabus about cardiac physiotherapy was developed. 3) Online glossary: an online glossary performed by the teacher was available for the students. 4) Online videos: several videos of international and national scientific societies were provided. 5) Websites: several links to websites of international and national scientific societies such as the European Society of Cardiology, the American Heart Association or the World Heart Federation were used. 6) Online activities: five four-question online activities were created. 7) Apps, using the app Ariadna to prevent from cardiovascular risk and look for defibrillators around; 8) Online tutorship, through an online communication platform (Blackboard Collaborate).
223668027|NCT05547009|OTHER|Face-to-face learning group|The FLG included: 1) Face-to-face classes; 2) Hardcopy syllabus; 3) Hardcopy scien-tific societies information; 4) Face-to-face activities: four questions per each theme; 5) Hardcopy glossary; and 6) Face-to-face tutorships. In all cases, the content of the infor-mation provided was the same as the information provided to the BLG, although in a face-to-face design.
223668028|NCT05617456|PROCEDURE|AF ablation|Patients with standard indications to AF ablation
224249426|NCT03133364|OTHER|Sensory optimized meals|19 main meals and 12 between-meals are optimized and composed to a menu for 12 weeks.
224249427|NCT05321446|DEVICE|GoHand(TM)|The GoHand(TM) is a therapeutic wearable that provides positive auditory feedback when the wrist and hand moves optimally during execution of dexterity tests and everyday movements.
224249428|NCT02220166|DIETARY_SUPPLEMENT|Triticum monococcum|
224249429|NCT02266264|DRUG|Hydrocortisone|Subjects will be divided into two groups by randomization. The intervention-group will be received 100 milligrams per day of hydrocortisone and the control-group will be received 200 milligrams per day of hydrocortisone in the first three days after enrollment.
224249430|NCT04840264|DRUG|Docetaxel|25 mg/square metre, D1, D8, D15, repeat every 4 weeks.
224249431|NCT04840264|DRUG|Oxaliplatin|85 mg/msquare metre, D1, D15, repeat every 4 weeks.
224249432|NCT04840264|DRUG|Fluorouracil|1200 mg/square metre, D1, D8, D15, repeat every 4 weeks.
224249433|NCT05723900|DRUG|Castor oil|"Procedure :pulpotomy procedure and histological evaluation. A sample of sixty two primary teeth from thirty healthy cooperative children of both sexes who were between 7-9 years and referred to Pediatric Dentistry Department. Two sound teeth without pulpotomy procedure were extracted and subjected to histological procedures to examine the normal pulp tissue and tissue organization (Negative control). The pulpotomy procedure was performed in sixty primary teeth (by split mouth design).~group I treated with castor oil"
224249434|NCT05723900|DRUG|Formocresol|Group II treated with formocresol
224249435|NCT02527278|PROCEDURE|Laparoscopic tubal ligation|Female permanent birth control method performed via a surgical procedure
224249436|NCT02527278|PROCEDURE|Hysteroscopic sterilization|Female permanent birth control method performed via placement of a device
224249437|NCT06128811|DEVICE|Rubber Dam Isolation|Rubber dam isolation will be placed using a proper size dental clamp on the first permanent molar after topical anesthesia application.
224249438|NCT06128811|DEVICE|DryShieled isolation|For the DryShieled isolation, a pedo-size mouthpiece will be utilized with all the participants.
224249439|NCT06128811|OTHER|fissure sealant|After proper isolation, fissure sealant (Conseal-F TM SDI) will be applied following the manufacturer's instructions, and the quality of the applied fissure sealant will be checked with an explorer. An additional layer will be applied if any deficiency is detected
224249440|NCT01247545|PROCEDURE|Remote ischaemic preconditioning|Blood pressure cuff placed on upper arm and inflated to 200mmHg for 5 minutes then deflated for 5 minutes - this cycle is repeated a total of 4 times.
224321914|NCT03233711|PROCEDURE|Colonoscopy|Undergo colonoscopy
224321915|NCT03233711|PROCEDURE|Computed Tomography|Undergo CT scan
224249441|NCT01247545|PROCEDURE|Control|Control treatment (sham RIC) will consist of four 5-minute simulated inflations of a blood pressure cuff placed on the upper arm. The inflations will be separated by 5-minute periods when the blood pressure cuff will be deflated.
224249442|NCT03546777|DEVICE|magnetic resonance imaging|magnetic resonance imaging of shoulder
224249443|NCT02853162|RADIATION|ARREST-study|Radiotherapy will be delivered in five fractions of 7 Gy every other day. An additional contrast enhanced MRI scan will be performed after the 2nd treatment fraction, and after 6 and 12 months
224249444|NCT02697331|DRUG|Progesterone|"women will receive progesterone vaginal pesarries containing 200mg of progesterone twice daily . it will be used by the patient as one vaginal pessary per vagina twice per day .~women will be showed how to use tablets . medication will be started at 20 -24 weeks and stopped at 36+6 weeks"
224249445|NCT02697331|OTHER|Placebo|women will receive placebo pessary twice a day. women will be showed how to use tablets . medication will be started at 20-24 weeks and stopped at 36+6 weeks
223668029|NCT02992197|BIOLOGICAL|Rotarix, dose 1|Rotarix, dose 1
224249446|NCT04476329|DRUG|Regorafenib 40 MG|Regorafenib (BAY 73-4506) is an oral small molecule tyrosine kinase inhibitor (TKI) that potently blocks multiple protein kinases, including kinases involved in tumor angiogenesis (vascular endothelial growth factor receptor \[VEGFR\] 1, 2, 3, Tyrosine kinase with immunoglobulin-like and epidermal growth factor-like domains 2 \[TIE2\]), stem cell growth factor receptor (KIT, rearranged during transfection \[RET\], p38-alpha, a member of the mitogen activated protein kinase \[MAPK\] family, proto-oncogene c-RAF \[c-RAF\], proto-oncogene BRAF \[BRAF\], BRAFV600E), metastasis (VEGFR3, platelet-derived growth factor receptor \[PDGFR\], fibroblast growth factor receptor1 \[FGFR1\]) and tumor immunity (colony stimulating factor 1 receptor \[CSF1R\]).
224249447|NCT02466594|DEVICE|Hilotherm Clinic®|Controlled Thermoregulation using a water circulation based system (Hilotherm Clinic®). Controlled Thermoregulation with Hilotherm Clinic® - Flap Temperature is altered by passive warming (dressing), active warming (38 C) and active cooling (10 C) each for 60 minutes following free flap transfer in every subject at the day of surgery and the following three days
224249448|NCT05622422|BEHAVIORAL|EMPOWER-BKP|The intervention aims to activate patients' inherent resources and by this, facilitate empowerment, patient activation, and self-care management of their chronic disease. The participants will include people 18 years and older that have been diagnosed with a chronic disease. This pilot study will use a pre-post design. Some of the data will be collected initially at the first session and then again at the seventh session. The intervention will be provided in seven sessions the first three will be face-to-face at a community center and then the last four sessions will be through video conferencing and will be facilitated by three researchers. The participants will be invited to a focus group interview in week nine in order to collect quantitative data. Once the sessions are finished both qualitative and quantitative data will be collected and then analyzed.
223668030|NCT02992197|BIOLOGICAL|Rotarix, dose 2|Rotarix, dose 2
223668031|NCT02992197|DRUG|Placebo (for Rotarix dose 2)|Sterile water to provide volume equivalent as a second dose of Rotarix
223668032|NCT02084290|BEHAVIORAL|Shared Decision Making Program|This study is cluster randomized by study-site, Subjects enrolled at intervention sites will access an educational program and risk prediction tool. Their decisions about treatments will be compared to subjects that did not view the educational program or risk prediction tool.
223668033|NCT02571335|BEHAVIORAL|Intensive Training|"Week 1: Ratio of continuous and interval training of 2:1. Entry point at day one with 20 min of continuous, physiologically defined heart rate controlled cycling at 50-60 rounds per minutes at 75% of HRpeak.~Resistance training is performed with 70% of the subjective-felt 1-round maximum with three sets and 10-12 repetitions and three exercises for the upper and lower extremities.~Week 2 Progression of endurance training: 4x5 minutes with 2 Minutes between each interval performed at 80% of HRmax Progression resistance training: 75% of the subjective-felt 1-round maximum with three sets and 8-10 repetitions and three exercises for the upper and lower extremities.~Week 3 Same as week 2."
224249449|NCT05724810|DEVICE|Active deep transcranial magnetic stimulation (dTMS)|"First, the investigators will find the position of the right abductor pollicis brevis (APB) motor cortex, finding the minimal motor threshold (MT) required for its activation, which determines the strength of the pulses. After determining the MT, dTMS stimulation is applied 6 cm anterior to the motor hot spot, at 120% of the MT. The target threshold is built toward gradually. During the first treatment, participants receive stimulation at 100% of the MT. During the second treatment, stimulation intensity increases to 110% of the MT. Beginning at the third treatment and continuing onward, participants receive treatment at 120% of the MT for the course of the treatment."
223668034|NCT02571335|BEHAVIORAL|Normal Training|The control intervention is the normal rehabilitation program of the Valens clinic.
224249450|NCT05724810|DEVICE|Sham dTMS|Sham group will go through the same procedure. The only difference is that the sham card does not deliver stimulation.
223668035|NCT00441116|DRUG|Dutasteride 0.5mg oral tablets|Dutasteride
223668036|NCT03192358|DIAGNOSTIC_TEST|Videofluoroscopic Swallowing Examination|During the videofluoroscopy, subjects will take up to 21 sips of liquid, ranging in thickness from thin (like water), to extremely-thick (like pudding or custard). The liquids will be mixed with E-Z-Paque barium sulfate, to allow it to be visible on the x-ray.
223668037|NCT03192358|OTHER|Tongue Strength Measurement|"We will measure tongue strength using a tongue pressure measurement system called the Iowa Oral Performance Instrument (IOPI). A small disposable bulb filled with air will be placed in the mouth, just behind the front teeth. Participants will be asked to press their tongue upwards against the bulb as hard as they can, three (3) times at the front of the tongue and three (3) times at the back of the tongue (i.e., total of six (6) maximum isometric tongue presses). Participants will also be asked to swallow their saliva with the bulb placed in their mouth, three (3) times.~Tongue pressure measurement will be completed twice in the data collection session - once at the beginning, and once at the end (following the videofluoroscopy)."
223668038|NCT00578760|DRUG|aspirin|325mg ASA OD for the duration of the cisplatin
223668039|NCT00578760|DRUG|placebo|OD for course of cisplatin chemotherapy
223771251|NCT05069012|DRUG|Morphine Sulfate|Morphine is administered to provide pain relief after cesarean delivery; this is an assessment of the dose-response as measured by the duration of pain relief
223771252|NCT03683381|BEHAVIORAL|Sleep Health|Participants in the intervention group will be provided with an application containing weekly instructions to improve sleep
223668040|NCT06046300|DIAGNOSTIC_TEST|Investigation of the relationship between trunk position sense and muscle activation, balance and quality of life in individuals with transtibial amputation.|It is aimed to investigate whether the trunk position sense, including the trunk right and left sides of the individuals with transtibial amputation, is affected and the relationship between trunk position sense and muscle activation, balance and quality of life.
223668041|NCT03658096|DEVICE|pressure monitor ultrasound system|Patients and healthy volunteers will be tested sitting with the elbow flexed and the forearm pronated. The forearm of the examinee will be secured to the table. The hand will be positioned on an adjustable block such that the forearm will be in a horizontal position. At the distal radioulnar joint level, the transducer will be maintained perpendicular to the longitudinal axis of the ulna. The dorsal surface of the distal radius and the center of the ulnar head will be displayed on a monitor.To determine the same measurement level in each volunteer, the highest aspect of the ulnar head will be taken. The DRUJ motion during cyclic loading toward the palmar direction at the distal ulna will be recorded. The compression-release cycles will be applied with the pressure-monitor ultrasound system. The cycle will be set to 1.5Hz. The pressure in the palmar direction will be applied with different levels of transducer displacements, i.e. 1 mm, 2 mm, and 3 mm.
223668042|NCT01716416|DRUG|Pazopanib|
223668043|NCT01716416|DRUG|Cetuximab|
223668044|NCT00637780|DRUG|Sulfasalazine|Sulfasalazine delayed release tablets 30-60 mg/kg/day (divided into BID doses) for 7 days. Blood sampling for Pharmacokinetic assessment to be performed on Day 7
223668045|NCT05191914|DRUG|Chidamide+ Fulvestrant|"Drug: Chidamide chidamide 30mg orally，Biw~Drug: Fulvestrant Fulvestrant 500mg i.m. injections every 28 days (Cycle n Day 1) with 1 additional dose on Day 15 of Cycle 1"
223668046|NCT02509117|DRUG|PF-06751979 single ascending dose|PF-06751979 administered as a single dose (solution/suspension) in cross-over fashion. Each subject may receive up to 4 study treatments (placebo and up to 3 doses of PF-06751979). The dose levels are 3 mg, 12 mg, 40 mg, 160 mg.
223668047|NCT02509117|DRUG|Placebo single dose|Matched Placebo solution/suspension administered as single dose.
223668048|NCT02509117|DRUG|PF-06751979 multiple ascending dose|PF-06751979 (solution/suspension) administered daily for 14 consecutive days to parallel cohorts. The dose levels are 5 mg, 15 mg, 50 mg.
223668049|NCT02509117|DRUG|Placebo multiple dose|Matched Placebo (solution/suspension)administered daily for 14 consecutive days.
223668050|NCT02509117|DRUG|PF-06751979 multiple dose|PF-06751979 (solution/suspension) administered daily for 14 consecutive days. The dose level is 50 mg.
223668051|NCT02509117|DRUG|PF-06751979 multiple dose|Matched Placebo (suspension/solution) administered daily for 14 consecutive days to parallel cohorts.
223668052|NCT01550653|DRUG|liraglutide|Subcutaneous self-administration of liraglutide(Victoza)by pen. The starting dose is 0.6 mg once daily(day 0 to 7), followed by 1.2 mg once daily (day 8 to 35).
223668053|NCT01550653|DRUG|Placebo|
223668054|NCT02620163|DRUG|telmisartan/amlodipine 40/5mg|
223668055|NCT02620163|DRUG|YH22162 40/5/12.5 mg|
224249451|NCT01743508|PROCEDURE|Misoprostol treatment by midwife|Misoprostol treatment by midwife
224249452|NCT02865356|DRUG|Cyclosporine 5% solution|topical solution
223668056|NCT02620163|DRUG|telmisartan/amlodipine 80/5mg|
223668057|NCT02620163|DRUG|YH22162 80/5/25 mg|
223668058|NCT02620163|DRUG|telmisartan/amlodipine 40/5mg placebo|
223668059|NCT02620163|DRUG|YH22162 40/5/12.5 mg placebo|
223668060|NCT02620163|DRUG|telmisartan/amlodipine 80/5mg placebo|
223668061|NCT02620163|DRUG|YH22162 80/5/25 mg placebo|
223771253|NCT03683381|OTHER|Patient education|Participants in the Patient education group will receive weekly information on insomnia symptoms
224249453|NCT02865356|DRUG|Placebo|topical vehicle solution
224249454|NCT04484493|DRUG|mometasone furoate nasal spray|dose of 2 puff in each nostril (100 µg once daily each nostril).
224249455|NCT03744715|DRUG|Poziotinib|Poziotinib
224249456|NCT03322111|DIAGNOSTIC_TEST|measurement of the cyclofusion|Measurement of the maximal cyclofusion competence with a dynamic 3-D Random-Dot Landolt-C stimulus
224249457|NCT00715377|DRUG|Benztropine|Patients aged ≥ 50 years suffering from a primary psychotic disorder treated with a SGA and benztropine concomittantly at any dose steadily for at least 3 months will be eligible to participate in this study. The dose of benztropine will be reduced by 0.5mg per week. During this 8-week study period, extrapyramidal symptoms will be assessed on a weekly basis. The clinical assessments will be repeated 8 weeks after the initial assessments.
224249458|NCT03109977|DRUG|Zr-DFO-pertuzumab PET/CT|Zr-DFO-pertuzumab studies will be performed as hybrid PET/CT examinations with known HER2-positive malignancy
224249459|NCT03723395|DRUG|tucatinib|300mg dose, orally administered
224249460|NCT03723395|DRUG|itraconazole|200mg dose
223668062|NCT06327724|DRUG|Belimumab|Start of new treatment due to active disease
223668063|NCT01332461|DRUG|fluticasone propionate/salmeterol xinafoate combination|Patients filling a prescription for fluticasone/salmeterol combination as index drug
223668064|NCT01332461|DRUG|Other maintenance Treatments (OMT)|OMT group includes tiotropium, ipratropium alone or in combination with albuterol, inhaled steroids, long acting beta agonists
223668065|NCT00548184|DRUG|Lapatinib|Monoclonal Antibody
223668066|NCT00548184|DRUG|Trastuzumab|Monoclonal Antibody
223668067|NCT00548184|DRUG|Endocrine|Hormonal Therapy
223668068|NCT01251536|DRUG|Dose escalation of cetuximab|"Dose, frequency \& treatment mode: 400 mg/m2 (loading at day 1) followed by 250 mg/m2 weekly (at day 8 and 15)~Arm allocation at day 22:~Patients with skin toxicity grade 0 will follow an increasing dose schedule: on days 22 and 29 they will receive 350 mg/m2 and from day 36 onwards, 500 mg/m2 weekly"
223668069|NCT01251536|DRUG|Standard first line treatment with cetuximab + Folfiri|"Dose, frequency \& treatment mode: 400 mg/m2 (loading at day 1) followed by 250 mg/m2 weekly (at day 8 and 15)~Arm allocation at day 22:~Patients with skin toxicity grade 1-4 or other significant toxicity who are not eligible for dose escalation will continue on the standard dose of cetuximab: 250 mg/m2 weekly."
223668070|NCT01205867|DRUG|AZD8848|Nasal spray solution, intranasal, single ascending doses, 1.4 - 60 μg
224249461|NCT03723395|DRUG|rifampin|600mg dose
224249462|NCT03723395|DRUG|gemfibrozil|600mg tablets
224249463|NCT03723395|DRUG|repaglinide|1mg dose
224249464|NCT03723395|DRUG|tolbutamide|500mg dose
224249465|NCT03723395|DRUG|midazolam|2mg dose
223668071|NCT02601261|OTHER|At the first day of hospitalization the field investigator will submit to pregnant women in a pathological condition five questionnaires|"Some of these questionnaires will have to be completed every day and others every other day:~1. The Internet questionnaire is divided in two parts. The first one investigates the use of internet at home and it will be administered only once, the second part will investigate the internet use at the hospital, in the case the women have a personal smartphone, tablet or personal computer (they are the owners) and it will be administered every other days.~2. The questionnaire is aimed to understand the quality of life (EQ-5D) will be administered only once, at the beginning of the hospitalization.~3. The STAI questionnaire is divided in to parts, the first part aims to determinate the state anxiety and it will be administered every other day, while the second part will discuss the anxiety itself, and has to completed only once.~4. The short questionnaire on critical events occurring during the day,~5. The short questionnaire with obstetric anamnesis."
223668072|NCT00401232|PROCEDURE|Blood Collection|Blood Collection
223668073|NCT00597896|DRUG|pramipexole|po pramipexole versus matching placebo minimum 0.125 mg bid and maximum 0.75 mg bid
223668074|NCT05396599|DEVICE|Model DIU|Subjects will be randomized to a treatment group (masked) in ratio 1:1:1. Surgeons will perform standardized, small-incision, cataract surgery and implant the study lenses using a JJSV-validated insertion system qualified for use with the lens to be implanted.
223668075|NCT05396599|DEVICE|Model DFW|Subjects will be randomized to a treatment group (masked) in ratio 1:1:1. Surgeons will perform standardized, small-incision, cataract surgery and implant the study lenses using a JJSV-validated insertion system qualified for use with the lens to be implanted.
223668076|NCT05396599|DEVICE|Model ZCT|Subjects will be randomized to a treatment group (masked) in ratio 1:1:1. Surgeons will perform standardized, small-incision, cataract surgery and implant the study lenses using a JJSV-validated insertion system qualified for use with the lens to be implanted.
223668077|NCT05790278|OTHER|Survey|Completion of a Purpose in Life Survey
223668078|NCT02920099|OTHER|Nutrition Literacy Assessment Instrument (NLAI)|Assessment tool which combines elements of different nutrition literacy tools.
223668079|NCT03542396|BEHAVIORAL|ImPuls|Participants receive an supervised exercise intervention and behaviour change techniques for 4 weeks and, after that, they are encouraged to engage in physical activity for 8 weeks independently. During this 8-week individual phase, patients have weekly phone contacts with a psychotherapist
223668080|NCT06284824|DEVICE|Stryker Triathlon with MAKO Robotic-Arm|Implant is the Stryker Triathlon total knee arthroplasty and the robotic device is the MAKO robotic-arm
223668081|NCT06284824|DEVICE|DePuy Attune with VELYS Robotic-Assistance|Implant is the DePuy Attune total knee arthroplasty and the robotic device is the VELYS robotic-assistance
223668082|NCT01765218|DRUG|Topiramate|Infants assigned to the topiramate group will receive 5mg/kg of topiramate daily enterally for a total of 5 doses. The first dose will be administered as soon as possible on admission.
223668083|NCT01765218|DRUG|Placebo|A placebo identical in appearance to the active agent (topiramate)
223668084|NCT00946985|DRUG|paliperidone palmitate|50, 75, 100, or 150 mg eq. monthly injection for 2 years
223668085|NCT00946985|DRUG|oral risperidone|2, 4, 6, or 8 mg tabs once daily for two years
223668086|NCT00932061|OTHER|Traditional Acupuncture|"Fibromyalgia subjects will be randomized to receive 9 acupuncture treatments over the course of four weeks.~Subjects enrolled in the study may have 1) only fMRI or 2) fMRI scans and PET scans, depending on their eligibility criteria."
223668087|NCT00932061|OTHER|Sham Treatment|"Fibromyalgia subjects will be randomized to receive 9 sham treatments over the course of four weeks.~Subjects enrolled in the study may have 1) only fMRI or 2) fMRI scans and PET scans, depending on their eligibility criteria."
223668088|NCT06298942|PROCEDURE|natural band|to use the round ligament as a natural band in stead of synesthetic band with sleeve gastrectomy
223668089|NCT06298942|PROCEDURE|silicone band|to use synesthetic band with sleeve gastrectomy
223668090|NCT06460740|OTHER|4-7-8 breathing technique|Treatment will be given 18 exercise sessions per month (four to five times per week). The patient at first will be directed to sit or lie down, in which manner they feel sense of comfort. Then they are asked to exhale completely through mouth emptying their lungs. Then closing their lips and inhaling silently through nose while counting on the count of 4 seconds, holding their breath for a count of 7 seconds and exhale slowly through semi-closed lips making a Whoosh sound for a count of 8 seconds. Inhale, hold breath, and exhale ratio of 4:7:8. In aerobic protocol, F (frequency) subjects will receive training up to 18 exercise sessions per month (four to five times per week). I (intensity) subjects will receive training up to intensity of 70 to 75 %, T \& T (Time and Type) subjects will receive training up to 20 minutes of bicycling.
224321916|NCT03233711|PROCEDURE|Digital Rectal Examination|Undergo digital rectal examination
223668091|NCT06460740|OTHER|Stationary Cycling|In aerobic protocol, F (frequency) subjects will receive training up to 18 exercise sessions per month (four to five times per week). I (intensity) subjects will receive training up to intensity of 70 to 75 %, T \& T (Time and Type) subjects will receive training up to 20 minutes of bicycling
223668092|NCT01316198|DIETARY_SUPPLEMENT|Verum|10 subjects consume for 4 weeks a beverage containing 10 mg lutein and 3 mg zeaxanthin per day
223668093|NCT01316198|DIETARY_SUPPLEMENT|Placebo|10 subjects consume for 4 weeks a placebo beverage without any lutein and zeaxanthin
223668094|NCT06212037|DIAGNOSTIC_TEST|Point of Care Ultrasound|Point of Care Ultrasound will be performed on all subjects and their laryngeal air column width difference will be calculated. The patients will be followed after extubation and the presence/absence of post extubation stridor will be recorded.
223668095|NCT05364333|PROCEDURE|Remote ischemic preconditioning|For each cycle of RIPC, a blood pressure cuff will be inflated to the non-dominant arm at 200mmHg for 5 minutes (or at least 50mmHg above the systolic arterial blood pressure) followed by 5 minutes of reperfusion time
224321917|NCT03233711|PROCEDURE|High Resolution Anoscopy|Undergo anoscopy
224321918|NCT03233711|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
224321919|NCT03233711|BIOLOGICAL|Nivolumab|Given IV
224321920|NCT03233711|OTHER|Patient Observation|Undergo observation
224321921|NCT03233711|PROCEDURE|Proctoscopy|Undergo proctoscopy
224321922|NCT03233711|PROCEDURE|Sigmoidoscopy|Undergo sigmoidoscopy
224321923|NCT03233711|PROCEDURE|X-Ray Imaging|Undergo chest x-ray
224321924|NCT06409000|OTHER|Electronic Health Record Review|Medical records reviewed
223668096|NCT04832269|OTHER|Exposure to methylprednisolone during pregnancy|Exposure to methylprednisolone during pregnancy in the context of an MS relapse therapy
223668097|NCT00523445|DRUG|Varenicline(Chantix)|The dose of antipsychotic drug will remain fixed throughout the study and the titration of varenicline will be as follows: varenicline 0.5 mg/d for days 1 to 3, 0.5 mg twice per day for days 4 to 7, then 1 mg twice per day through week 8.
223668098|NCT00523445|DRUG|Placebo|The dose of antipsychotic and concomitant medications remained fixed throughout the study and the titration of varenicline was as follows: Placebo will be supplied twice daily through week 8.
223668099|NCT02237534|DRUG|Lanthanum carbonate|
223668100|NCT02237534|DRUG|Calcium Carbonate|
223668101|NCT06394934|BEHAVIORAL|Healthscan App|Participants will use the Healthscan mobile application to monitor and record their daily blood pressure at home. The app allows participants to enter their BP measurements, which are then used to calculate blood pressure variability (BPV). The app's use is intended as a non-invasive, practical tool for patient self-management and longitudinal health monitoring in hypertensive individuals.
223668102|NCT03868527|OTHER|Data collection|Data collection for biostatistical analysis about hematological diseases
223668103|NCT03148691|DRUG|A-101|Topical Solution
223668104|NCT05636800|DEVICE|Swift System|"Localized microwave energy applied to the distinct AK lesion. Each subject will receive treatment for a maximum of 2 visits (4-week interval between treatment).~For AK lesions assessed as Thin AK (Olsen Grades 1 and 2): Set at 3W and apply locally for up to a 3 second burst and adjust the dose and duration. Repeat on the same AK lesion as is tolerable for the subject (3 repetitions). There will be approximately 20 seconds between each repeat dose.~For AK lesions assessed as Thick AK (Olsen Grade 3): Set at 4W and apply locally for up to a 3 second burst and adjust the dose and duration. Repeat on the same AK lesion as is tolerable for the subject (3 repetitions).~As the AK lesions may be larger than 3mm in diameter, the dose administered to one AK lesion may require overlapping applications with the applicator tip. Ensure there is approximately 20 seconds between each repeat dose administered"
223668105|NCT02956590|DRUG|Pitavastatin|Statin
223668106|NCT02956590|DRUG|Placebo|Placebo
223668107|NCT00926315|DRUG|calcitriol|Post menopausal patients will receive Calcitriol 0.50 mcg PO per day for 1 month.
223668108|NCT00926315|DRUG|Calcitriol|calcitriol 0.25 mcg PO bid
223668109|NCT03919097|OTHER|Medical Data extraction|Data extraction from the patient's Medical Files
223668110|NCT00171834|DRUG|Patupilone|Patupilone (2.5 mg/mL) was supplied as a clear, colorless concentrate for solution for infusion in glass vials containing 5 mg/2 mL in Phase I and 10 mg/4 mL in Phase II part of the study. Patupilone was administered as a single intravenous (i.v.) infusion over 5 to 10 minutes (Amendment 1) till Amendment 2 and over 10 to 20 minutes (Amendment 2) till the completion of Phase I part of the study. Patupilone was administered as a single i.v. infusion over 20 minutes (Amendment 4), once every 3 weeks in Phase II part of the study.
223668111|NCT02919358|OTHER|Music|
223668112|NCT02919358|OTHER|No music.|This is the control group.
223668113|NCT00554281|DEVICE|Use of glucose sensor (Paradigm Guardian)|Use glucose sensor to prevent episodes of severe hypoglycemia
223668114|NCT02766140|DRUG|SHR1020 plus Docetaxel|SHR1020 20mg qd 2-21days, Docetaxel 60 mg/m\^2 IV Day1/3weeks
224249466|NCT03723395|DRUG|digoxin|0.5 mg dose
224249467|NCT04667091|OTHER|Physiotherapy|"Treatment will be given in 3 sessions per week for 6 weeks with home exercise program and participants will be provided with exercises sheets to remember the exercises.~The selected outcome measure will be taken on baseline (initial visit) and 6th week (post intervention)"
224249468|NCT02218580|OTHER|Massage therapy|
223668115|NCT02766140|DRUG|Placebo plus Docetaxel|Placebo matching SHR1020 qd 2-21days, Docetaxel 60 mg/m\^2 IV Day1/3weeks
223668116|NCT01771341|DEVICE|MAQUET SERVOi ventilator with Edi Catheter|NAVA respiratory modality
223668117|NCT01771341|DEVICE|MAQUET SERVOi ventilator|Pressure Support
223668118|NCT04345367|DRUG|Abrocitinib 200 mg|Abrocitinib 200 mg administered as two 100 mg tablets to be taken orally once daily for 26 weeks. Placebo injections will be administered every other week for 24 weeks.
223668119|NCT04345367|COMBINATION_PRODUCT|Dupilumab 300 mg|Dupilumab 300 mg administered as a single subcutaneous injection every other week for 24 weeks (2 injections on day 1). Placebo tablets will be administered daily.
223668120|NCT04810689|DRUG|Xuanfei Baidu Granules|Xuanfei Baidu granules is a prescription of 13 herbal medicinals made into dissolvable granules for oral intake
223668121|NCT04810689|OTHER|Placebo|Placebo for Xuanfei Baidu granule made into dissolvable granules for oral intake
223668122|NCT05282303|PROCEDURE|CABG operation|Efficacy of regional analgesia techniques in coronary artery bypass operations
223668123|NCT00796523|BEHAVIORAL|Happiest Baby videotape|a videotape demonstrating the Happiest Baby on the Block technique for calming crying infants
223668124|NCT00796523|BEHAVIORAL|control videotape|a videotape with general newborn care instructions
223668125|NCT01429337|DRUG|Midostaurin|Midostaurin 25 mg soft gelatin capsules (2 capsules). The midostaurin capsules will be administered orally with 240 mL of non-carbonated water in the morning (between 8-10 AM), and in the evening (after a 12 hour break) from Day 1 to Day 6. On Day 7, midostaurin will be administered in the morning only (between 8-10 AM).
223668126|NCT01429337|DRUG|Midostaurin|Midostaurin 25 mg soft gelatin capsules (2 capsules). The midostaurin capsules will be administered orally with 240 mL of non-carbonated water in the morning (between 8-10 AM) on Day 1 only.
223668127|NCT01030640|OTHER|placebo|single dose of the drug formulation
224249469|NCT02218580|OTHER|Standard care|
224249470|NCT02331394|DIETARY_SUPPLEMENT|Chinese herbs formula: Shu Yu Wan|The patients will be offered the choice of taking the CH formula in capsules or sachets and given instructions about recommendations to improve palatability. The formula should be taken with meals 3 times a day (each dose is either 1 sachet or 4 capsules) for six-weeks.
224249471|NCT04444557|OTHER|Beck Depression Inventory (BDI)|The Beck Depression Inventory (BDI) is a 21-item, self-report rating inventory that measures characteristic attitudes and symptoms of depression
224249472|NCT02965326|PROCEDURE|Nasal swab; rectal biopsy.|Nasal epithelial cells will be obtained by nasal swabs from patients of the three arms; intestinal epithelial cells will be obtained, by rectal biopsy, only from patients treated by CFTR modulators.
224321925|NCT06409000|PROCEDURE|Three-Dimensional Imaging|Undergo 3D surface scans
223668128|NCT01030640|BIOLOGICAL|tanezumab|single dose of the active drug tanezumab at a dose level of 20 mg
223668129|NCT02252744|OTHER|No intervention|
224249473|NCT05049226|BIOLOGICAL|AstraZeneca ChAdOx1 AZD1222 vaccine (AZ) full dose|"Astrazeneca COVID-19 (ChAdOx1 AZD1222) vaccine:~One dose (0.5 ml) contains: COVID-19 Vaccine (ChAdOx1-S\* recombinant) 5 × 10\^10 viral particles (vp)~\*Recombinant, replication-deficient chimpanzee adenovirus vector encoding the SARS-CoV-2 Spike glycoprotein. Produced in genetically modified human embryonic kidney (HEK) 293 cells.~Administer: Intramuscular (IM) injection in the deltoid muscle"
223668130|NCT05912790|DEVICE|eyeTube|Implantation of a drainage device in the eye, in combination with the eyeWatch implant
223668131|NCT02431260|DRUG|INCB054329 Monotherapy|Initial cohort dose of INCB054329 monotherapy at the protocol-specified starting dose in the treatment group A (TGA), with subsequent cohort escalations in the three treatment groups (TGA, TGB, and TGC) based on protocol-specific criteria
223668132|NCT00168129|PROCEDURE|Helical tomotherapy|
223668133|NCT03267485|DEVICE|real time PCR|Real Time PCR is based on the detection of the fluorescence produced by a reporter molecule which increases, as the reaction proceeds. These fluorescent reporter molecules include dyes that bind to the double-stranded DNA or sequence specific probes . Moreover, there is no need for the post PCR processing which saves the resources and the time. .
223668134|NCT00571168|DRUG|Emend|125 mg/d on day 1; 80 mg/d on day 2-4
223668135|NCT00571168|DRUG|Placebo|Placebo capsules on day 1-4
223668136|NCT05033405|BEHAVIORAL|NEURO-LINGUISTIC PROGRAMMING (NLP)|● One session (20-minute long) of NLP application was performed. The NLP techniques that were employed were representational systems and submodality. In this technique, the sensory, auditory, and kinesthetic feelings of the individual are learned. These emotions are modified by imagining. The NLP application was carried out by a researcher who has a certificate in this field
223668137|NCT00677989|PROCEDURE|Laparoscopic appendectomy|laparoscopic appendectomy:did appendectomy by laparoscopic manipulation
223668138|NCT00677989|PROCEDURE|Open appendectomy|open appendectomy: did appendectomy by laparotomy
223668139|NCT05363306|PROCEDURE|implant insertion|"4% articaine solution, a mid-crestal incision along the center of the edentulous bone ridge was performed. A full-thickness flap was elevated. The sites were prepared to permit insertion of transmucosal, external hex, implants (I-smart, I-RES, Lugano, Switzerland) at three different crestal levels, based upon vertical mucosa thickness measured at implant placement.~Owing to width crest, all implants were 3.75 mm in diameter and operators selected appropriate implant lengths (8, 10 mm) according to available bone crest height. All implants were not submerged and flaps were sutured around the transmucosal component."
223668140|NCT03208985|DRUG|Use Phase (Ulipristal Acetate, 30 mg)|"All subjects enrolled in the use phase of this open-label study will be given the opportunity to purchase and take 30 mg of ulipristal acetate.~Subjects are to use the investigational product based on their understanding of the directions on the outer packaging including Drug Facts Label and inside the product packaging (in the Consumer Information Leaflet)."
223668141|NCT00881543|DRUG|Dipeptidyl Peptidase IV inhibitors|Dosage 100 mg each day, once a day, 2 months
223668142|NCT01064375|BIOLOGICAL|tetwtCEA DNA (wt CEA with tetanus toxoid Th epitope)|Two vaccinations at week 0 and 12. Intradermal administration of 400ug DNA/dose with electroporation
223668143|NCT01064375|DEVICE|Derma Vax (electroporation device)|Electrical pulses applied to vaccination sites in skin using Derma Vax immediately after DNA administration
223668144|NCT01064375|BIOLOGICAL|GM-CSF|GM-CSF will be given for 4 consecutive days starting the day before the vaccination as an intradermal/subcutaneous administration of 150 ug of GM-CSF
223668145|NCT01064375|DRUG|Cyclophosphamide|One intravenous dose of 300 mg/m2 will be given three days before each vaccination with tetwtCEA DNA
223668146|NCT06471387|BEHAVIORAL|Flexiquit Smoking Cessation Intervention|Participants will enter a 6-week (once weekly) self-delivered computerized intervention program called Flexiquit. Developed and validated by Clinical Psychologists of the Department of Psychology at the University of Cyprus, Flexiquit is an avatar-led app designed to support smoking cessation. It aims to assist with abstinence and monitor participants' progress through personalized modules and assessments.
223668147|NCT02968056|PROCEDURE|Radiofrequency ablation|Radiofrequency energy is used for ablation in both arms of this study (Hybrid group and MIS group)
223668148|NCT01644747|DEVICE|transcranial Direct Current Stimulation (tDCS) (Eldith DC NeuroConn Stimulator)|After locating the left DLPFC, ttt with active anodal tDCS with a current of 2 mA or sham over the left DLPFC will be directed by 30-minute session. Treatment will occur 2 sessions per day during 5 days per week. Subjects will be monitored during tDCS for any side effects or adverse events.
223668149|NCT00684541|BEHAVIORAL|Interpretation Modification Program|"The IMP protocol includes twelve 30-min sessions delivered over a 6-week period. Each session will comprise 220 trials. In each trial, participants will first see either a non-threat or a threat (e.g. graceful or clumsy) word on the computer screen. They will then see an ambiguous sentence (e.g. You dance at the party) and will be asked to indicate if the word and sentence were related by pressing a corresponding key. Participants will receive positive feedback (i.e., You are correct!) when they endorse a non-threat interpretation or reject a threat interpretation of an ambiguous sentence. Participants will receive negative feedback (i.e., You are incorrect.) when they endorse a threat interpretation or reject a non-threat interpretation of an ambiguous sentence."
224249474|NCT05049226|BIOLOGICAL|Pfizer/BioNTech BNT162b2 vaccine (PF) full dose|"Pfizer-BioNTech COVID-19 (BNT162b2) vaccine:~Diluent: 0.9% sodium chloride (normal saline, preservative-free)~Administer: Intramuscular (IM) injection in the deltoid muscle"
224249475|NCT05049226|BIOLOGICAL|AstraZeneca ChAdOx1 AZD1222 vaccine (AZ) half dose|"Astrazeneca COVID-19 (ChAdOx1 AZD1222) vaccine:~One dose (0.5 ml) contains: COVID-19 Vaccine (ChAdOx1-S\* recombinant) 5 × 10\^10 viral particles (vp)~\*Recombinant, replication-deficient chimpanzee adenovirus vector encoding the SARS-CoV-2 Spike glycoprotein. Produced in genetically modified human embryonic kidney (HEK) 293 cells.~Administer: Intramuscular (IM) injection in the deltoid muscle"
224321926|NCT01856192|DRUG|Cyclophosphamide|Given IV
224321927|NCT01856192|DRUG|Doxorubicin Hydrochloride|Given IV
224321928|NCT01856192|OTHER|Laboratory Biomarker Analysis|Correlative studies
224321929|NCT01856192|DRUG|Lenalidomide|Given PO
224321930|NCT01856192|DRUG|Prednisone|Given PO
224321931|NCT01856192|BIOLOGICAL|Rituximab|Given IV
224321932|NCT01856192|DRUG|Vincristine Sulfate|Given IV
223668150|NCT00684541|BEHAVIORAL|Interpretation Control Condition|Participants assigned to the PC completed an identical procedure to the IMP procedure except that feedback about participants' performance was not contingent on the type of interpretation (i.e., non-threat or threat) endorsed. Thus, participants in the PC received positive feedback 50% of the time when viewing a threat interpretation and 50% of the time when viewing a non-threat interpretation.
223668151|NCT02890641|GENETIC|Sampling of blood, frozen resected tissues, and cerebrospinal fluid (CSF)|Sampling of blood, frozen resected tissues, and cerebrospinal fluid (CSF)
223668152|NCT04667884|DIETARY_SUPPLEMENT|Prebiotics or Probiotics|All the supplements were provided in solid drinks，and required to drink with plain water 35-40℃, and lifestyle intervention was provided to all the groups by reading materials.
223668153|NCT01621815|BEHAVIORAL|Video Game|Playing various video games: RPG, Race, FPS, Strategy
223668154|NCT00439738|DRUG|HCTZ + Amlodipine|"* 12.5 mg HCTZ capsules~* 25 mg HCTZ capsules~* 5 mg amlodipine capsules~* 10 mg amlodipine capsules"
223668155|NCT00439738|DRUG|Valsartan/HCTZ|"* 160 mg film-coated valsartan tablets~* 320 mg film-coated valsartan tablets~* 12.5 mg HCTZ capsules~* 25 mg HCTZ capsules"
223668156|NCT00170534|BEHAVIORAL|Behavior|
223668157|NCT00978757|DRUG|Ketamine|Ketamine: 0.25 mg/kg, intravenously, one dose.
223668158|NCT00978757|OTHER|Placebo|saline solution
223668159|NCT04034667|OTHER|No intervention|No intervention
223668160|NCT06409416|OTHER|Analysis of diagnostic biomarkers|The investigators will analyze TCP-biomarkers diagnostic by IHC, qRT-PCR and next-generation sequencing, in tumor and plasma samples of lung cancer patients.
223668161|NCT05167006|OTHER|routine physical therapy|Each participant will receive his/her arms training therapy. Only one participant per therapist, with or without caregiver observation. Consisting of many purposeful kinesthetic activities such as Graded pinch exercise, Bimanual placing cone, Arm bicycling, Shoulder curved arch, Double-curved arch, Block-stacking, Skateboard-supported arm sliding exercises on a tabletop, Putty kneading, Pegboard exercise, Picking up a ball and putting it into a basket, Plastic cone stacking. Therapists can offer passive, active-assistive, or active training, as deemed appropriate to the patient's ability
223668162|NCT05167006|OTHER|Perfetti's method|. Only one participant per therapist, with or without caregiver observation. Participant will be blindfolded during the exercises and asked to focus on sensing the position of the limb. The therapist will passively move the shoulder, elbow, wrist, or fing
223668163|NCT00137891|DRUG|Modified Release rhTSH|
223668164|NCT04125953|DEVICE|Andullation|Andullation is a horizontal vibration technique with stochastically modulated vibrations, build-in in a mattress.
223668165|NCT04125953|OTHER|Placebo|Placebo Andullation
223668166|NCT01232036|DRUG|Glucophage 500mg|Single Oral Dose of
223668167|NCT01232036|DRUG|HL-018 500mg|Single Oral Dose of
223668168|NCT01232036|OTHER|No administration of Drug|
223668169|NCT03869463|OTHER|Computerized Cognitive Training|Participants will complete 8 weeks of computerized cognitive training through the Peak platform on mobile devices.
223668170|NCT03869463|OTHER|Control|This group will not receive computerized cognitive training.
223668171|NCT05302336|DRUG|Liposomal doxorubicin + Cyclophosphamide vs Docetaxel + Cyclophosphamide|"All patients who meet the inclusion criteria must first sign the Informed Consent after learning about the details of the trial, and they can be formally enrolled only when they have completed all the pre-enrollment examinations and are qualified. Recruitment will continue until the planned number of cases is completed. The trial was not terminated until each surviving patient was followed for at least 60 months after treatment ended or when all patients had died. The randomization table was generated by the SAS software program, and the patients were randomly divided into the experimental group (AC liposomal doxorubicin + cyclophosphamide) and the control group (docetaxel + cyclophosphamide)."
223668172|NCT02046759|OTHER|Pharmacist- Intervention|Patients received additional education on basic facts about asthma, role of medications, the difference between long-term control medications and quick-relief medications, as well as patient skills in the first visit then reinforcement every two weeks.. The importance of proper inhaler technique, avoidance of asthma triggers and self-monitoring of asthma were also highlighted. Visual aids, physical demonstration as well as written information resources were supplied. Asthma care plans were tailored to patient needs and preferences. Patients were informed how to detect early signs of worsening asthma, when and how to seek medical care as appropriate.
223668173|NCT02046759|OTHER|Routine Care|Patients received usual care delivered by physician without pharmacist intervention. Patients were prescribed asthma medication with summarized basic information on asthma and medication use. Follow-up visits were not planned on consistent basis, but rather individually according to the disease status. No asthma action plans were provided.
223668174|NCT02740803|OTHER|Sodium fluoride toothpaste 1,450 ppmF|
223668175|NCT02740803|OTHER|sodium monofluorophosphate toothpaste 1,450 ppmF|
223668176|NCT02740803|OTHER|stannous fluoride combined with sodium fluoride toothpaste 1,450 ppmF|
223668177|NCT02740803|OTHER|sodium fluoride combined sodium monofluorophosphate toothpaste 1,450 ppmF|
223668178|NCT02740803|OTHER|Amine fluoride toothpaste 1,400 ppmF|
223668179|NCT02740803|OTHER|Non-fluoridated toothpaste 0 ppmF|
223668180|NCT04954651|BIOLOGICAL|Approved vaccines against Sars-Cov2|Subjects who voluntarily are vaccinated against Sars-Cov-2 with any of the approved vaccines by EU
223668181|NCT01629225|DRUG|Candesartan|To investigate the response to candesartan among southwestern Han Chinese with essential hypertrension
223668182|NCT03712085|OTHER|Abdominal acupuncture|Abdominal acupuncture treatment method: 1.Acupoints selection :Zhongwan,Xiawan,Shangqu,Qihai,Guanyuan,Huaroumen,Upper rheumatic and Upper rheumatic external points etc.(Acupoints selection referred to Abdominal Acupuncture Therapy written by Bo Zhiyun ,the founder of Abdominal Acupuncture. 2.Treatment Duration: 30 minutes a session, once a day, 5 times a week for 3 weeks.
224249476|NCT05049226|BIOLOGICAL|Pfizer/BioNTech BNT162b2 vaccine (PF) half dose|"Pfizer-BioNTech COVID-19 (BNT162b2) vaccine:~Diluent: 0.9% sodium chloride (normal saline, preservative-free)~Administer: Intramuscular (IM) injection in the deltoid muscle"
224249477|NCT03446248|DEVICE|Corometrics-146 device|Fetal vibroacoustic stimulation with the Corometrics-146 fetal acoustic stimulator will be performed by placing the device on the maternal skin halfway between the pubic symphysis and the umbilicus and activating the device for 3 seconds.
224249478|NCT03446248|DEVICE|Mobile phone application|Fetal vibroacoustic stimulation with the mobile phone will be performed by placing and iPhone on the maternal skin halfway between the pubic symphysis and umbilicus and using the application to activate for 3 seconds the phone's built in vibration along with a 2,000 Hz tone at a sound level of 74 decibels when measured at 1 meter.
224249479|NCT01313273|DRUG|Lanreotide, non steroidal anti androgens and LHRH-a|"Lanreotide 120 mg. Injection every 28 days, to be administered till progression or for a maximum of 24 months.~Non steroidal anti androgens (e.g. bicalutamide 50 mg/day to be administered till progression) plus LHRH-a (e.g. triptorelin 3.75 mg/month till progression."
224249480|NCT01313273|DRUG|Non steroidal anti androgens and LHRH-a|Non steroidal anti androgens (e.g. bicalutamide 50 mg/day to be administered till progression) plus LHRH-a (e.g. triptorelin 3.75 mg/month till progression
224249481|NCT00344110|DRUG|Aliskiren|
224249482|NCT03687736|BIOLOGICAL|AbobotulinumtoxinA|AbobotulinumtoxinA treatment in the glabellar region at Baseline and Month 6
224249483|NCT01055899|BIOLOGICAL|REGN88|Single SC Dose
223668183|NCT03712085|OTHER|Sham abdominal acupuncture|Sham abdominal acupuncture Abdominal acupuncture treatment method: 1.Acupoints selection and treatment duration are the same as abdominal acupuncture. 3.Method：Using the sham abdominal acupuncture needles were produced by DONGBANG AcuPrime Acupuncture Instrument Co., Ltd. ( U.K.)The tip of the needle was exposed to 1mm of the cannula. The acupoint skin of patients was touched gently by the tip, and the tip of needle was lifted and removed from acupoint skin after 30s. Rest for 30 seconds ,then repeated 6 times, a total time of stimulation is 6min.
223668184|NCT06121245|OTHER|Proton Pump inhibitor|A proton pump inhibitor will be used as a tool to study the effect of pH changes in the stomach lumen on the release of somatostatin (evaluated by measurements of somatostatin and pro-somatostatin 1-64)
223668185|NCT06121245|OTHER|Placebo|Placebo capsule
223668186|NCT03989505|DIAGNOSTIC_TEST|blood-draw for biomarker analyses|Blood will be drawn at three time-points: immediately before catherization, 12-24 hours after catheterization and 4-8 weeks after discharge. Creatinine will be measured for endpoint definition, while the markers urea, CRP (C-reactive protein), NGAL (neutrophil gelatinase-associated lipocalin), KIM-1 (kidney injury marker-1), cystatin C, suPAR (soluble urokinase-type plasminogen activator receptor), and penKid will be measured as biomarkers of interest.
223668187|NCT02559492|DRUG|Itacitinib|Itacitinib (INCB039110) tablets will be administered orally once daily in the morning.
223668188|NCT02559492|DRUG|Epacadostat|Epacadostat tablets will be administered orally, twice daily.
223668189|NCT02559492|DRUG|Itacitinib|Itacitinib (INCB039110) tablets will be administered orally once daily in the morning.
223668190|NCT02559492|DRUG|INCB050465|INCB050465 tablets will be administered orally once daily.
223668191|NCT00577616|PROCEDURE|Endovascular repair|Endovascular repair of the asymptomatic aneurysms of the abdominal aorta
223668192|NCT03291093|DRUG|18F-Flutemetamol PET/MRI|All patients will undergo a PET/MRI of the carotids after 18F-Flutemetamol injection.
223668193|NCT04241900|BEHAVIORAL|Shuttle run test|At the shuttle run test, participants were required to run between two lines 20 meters apart, while keeping pace with audio signals emitted from a pre-recorded CD. The frequency of the sound signals increases in such way that running speed was increased by 0.5 km h-1 each minute from the starting speed 8.5 km h-1.
223668194|NCT05286645|DEVICE|High definition transcranial direct current stimulation|tDCS is described as a non-invasive form of brain stimulation that uses a low-intensity, constant current applied directly to the head through scalp electrodes.
223668195|NCT05286645|DEVICE|sham high definition transcranial direct current stimulation|Sham HD-tDCS was delivered using the same protocol and current intensity, but the period of active stimulation was only during the ramp-up and ramp-down periods of 30 and 30 seconds.
223668196|NCT03754439|BEHAVIORAL|Physiological changes to noise and vibration exposure|Physiological parameters (HR, RR, Sats, NIRS) will be observed during a period of stay on the neonatal unit (Inborn group) or during ambulance transportation (Transported group) whilst simultaneous measurement of noise and vibration exposure. Urine will be collected during the first 24, 48 and 72 hours post exposure for biochemical markers of brain injury (S100B) and stress (Cortisol)
223668197|NCT01700387|DRUG|onabotulinumtoxinA|All subjects will receive a minimum dose of 155 U Botulinum Toxin Type A Purified Neurotoxin Complex administered at 31 fixed-site, fixed-dose injections across seven (7) specific head/neck muscle areas at Visits 2-5.
223668198|NCT01700387|DRUG|Topiramate|"Subjects randomized to the onabotulinumtoxinA + topiramate group will receive:~Week 1: topiramate 25 mg qhs Week 2: topiramate 25 mg bid Week 3: topiramate 25 mg q am + topiramate 50 mg qhs Week 4: topiramate 50 mg bid Only one dosage adjustment (increase or decrease), based on efficacy or tolerability, may be made at the investigator's discretion. Subjects must maintain a dose of at least 50 mg/day to remain in the Treatment Period."
224249484|NCT01055899|BIOLOGICAL|REGN88|Single SC Dose
224249485|NCT01055899|BIOLOGICAL|REGN88|Single SC Dose
224249486|NCT03613337|OTHER|clinical restenosis|The primary endpoints is clinical restenosis, the investigators will compared the incidence of clinical restenosis by different smoking status.
224249487|NCT04163354|PROCEDURE|5% sodium fluoride varnish (NaF)|In the NaF varnish groups, 0.25mL (one drop) of the varnish is placed in a plastic dappen dish. A disposable microbrush is used to apply the varnish onto the second primary molars included in the study and all other teeth. The child is instructed not to eat or drink after the application of varnish for at least half an hour.
224249488|NCT04163354|PROCEDURE|Glass ionomer sealant (GIS)|Glass ionomer sealants (GIS) is applied using the finger pressure technique described in the WHO manual for atraumatic restorative treatment (ART) (Frencken et al.; 1997). The primary second molars are cleaned by applying GC cavity conditioner with micro-applicator for 10-15 seconds, then clean with wet cotton pellets for several times. The surface will be dried with cotton pellets. GIS (GC Fuji VII) is mixed in standardized proportion with an amalgamator, then applied to the occlusal surface and slightly overfilled. A gloved finger with petroleum jelly will be used to push and rub the materials into the pits and fissures, and removing the excess. GIS will be covered and protected by a layer of petroleum jelly (Vaseline ®).
224249489|NCT00010205|DRUG|benzoylphenylurea|Given orally
224249490|NCT00010205|OTHER|pharmacological study|Correlative studies
224249491|NCT01861262|DEVICE|Measurement of StO2|The procedure is a measurement and non-invasive monitoring system of percentage of oxygen saturation of haemoglobin in tissues using infrared technology. The system used in the study is the tissue oxygenation monitor InSpectraTM StO2 Spot Check, Model 300 consisting of a clamp applied to the base of the thumb of the patient.
223668199|NCT01700387|DRUG|Placebo|"Subjects randomized to the onabotulinumtoxinA + placebo group will receive:~Week 1: placebo 25 mg qhs Week 2: placebo 25 mg bid Week 3: placebo 25 mg q am + placebo 50 mg qhs Week 4: placebo 50 mg bid Only one dosage adjustment (increase or decrease), based on efficacy or tolerability, may be made at the investigator's discretion. Subjects must maintain a dose of at least 50 mg/day to remain in the Treatment Period."
223668200|NCT03047824|DEVICE|Intravascular continuous monitoring|Bedside usual insulin therapy guided by continuous glucose monitoring
223668201|NCT03047824|OTHER|Standard of care|Bedside usual insulin therapy guided by intemittent glucose monitoring
223668202|NCT01158001|BEHAVIORAL|Prolonged exposure therapy|Twelve sessions (90 minutes each) of prolonged exposure therapy
223668203|NCT00117052|DRUG|cinacalcet|All eligible subjects were assigned to receive once daily oral doses of cinacalcet, but were randomised in a 1:1 ratio to receive the drug either with the first meal after dialysis or during the dialysis visit on dialysis days.
223668204|NCT01295879|DRUG|Ergocalciferol|Ergocalciferol 50,000 IU's orally per week, for 8 weeks
223668205|NCT02974699|DIETARY_SUPPLEMENT|Potato Starch (Bob's Red Mill)|Subjects will be assigned to Potato Starch (active) following assessment of their gut microbiome.
223668206|NCT02974699|DIETARY_SUPPLEMENT|Pregelatinized Starch (Resource ThickenUp)|Subjects will be assigned to Pregelatinized Starch (placebo) following assessment of their gut microbiome.
223668207|NCT05661084|DEVICE|Transcranial alternating current stimulation (tACS) (active); Transcranial direct current stimulation (tDCS) (active)|Transcranial electrical stimulation (tES), via alternating and direct current, will be administered to the participant in their home by their caregiver administrator to the left angular gyrus and prefrontal cortex.
223668208|NCT05661084|DEVICE|Transcranial alternating current stimulation (tACS) (sham); Transcranial direct current stimulation (tDCS) (sham)|A sham transcranial electrical stimulation (tES) will be administered to the participant in their home by their caregiver administrator to the left angular gyrus and prefrontal cortex. It will physically mimic active stimulation.
223668209|NCT05661084|DEVICE|Transcranial alternating current stimulation (tACS) (active); Transcranial direct current stimulation (tDCS) (sham)|Transcranial electrical stimulation (tES), via alternating and direct current, will be administered to the participant in their home by their caregiver administrator. Active tACS to the left angular gyrus and sham tDCS to the prefrontal cortex.
223668210|NCT05661084|DEVICE|Transcranial alternating current stimulation (tACS) (sham); Transcranial direct current stimulation (tDCS) (active)|Transcranial electrical stimulation (tES), via alternating and direct current, will be administered to the participant in their home by their caregiver administrator. Sham tACS to the left angular gyrus and active tDCS to the prefrontal cortex.
223668211|NCT04986358|OTHER|Follow up at 2 years|The patients will have a follow-up to carry out 2 years after their intervention in addition to their traditional care
223668212|NCT00895102|DRUG|ABT-333 Tablet|See Arm Description for more information.
223668213|NCT00895102|DRUG|Placebo|See Arm Description for more information.
223668214|NCT00895102|DRUG|ABT-333 Capsule|See arm description for more information
223668215|NCT00266786|DRUG|Intranasal Ketorolac Tromethamine|Intranasal at 30mg
223668216|NCT00266786|DRUG|Intranasal Placebo|Intranasal Placebo
223771254|NCT06626490|DEVICE|Prevision Revision hip endoprosthesis stem implantation|"The Prevision hip endoprosthetic stem is a femoral part of a hip joint endoprosthesis. The system provides cementless and cemented variants. Prevision hip stems are modular with a short proximal and longer distal component, or monobloc hip stems. Modular components are coupled via a Prevision specific conical connection with a torque wrench and a tension nut to apply a predefined torsional moment on the connection. The distal component of modular Prevision stems can be combined with locking screws for additional bone fixation.~Both types, the monobloc and the modular, provide a 12/14 taper that serves as a connection for metal or ceramic prosthesis heads. Prevision hip stems are combined at the acetabulum with a cementless or cemented acetabular cup."
224249492|NCT01789294|DRUG|Mesalamine|A standard 50 mg/kg/die daily dose of oral mesalamine was prescribed by Pediatric Gastroenterologists, which informed parents of potential side effects. Whether the drug was not well tolerated, patients were drop out. Treatment was discontinued at time 1 to look for symptom recurrence.
224249493|NCT01789294|BEHAVIORAL|DIET|Dietetic avoidance of cow's milk and egg, plus foods eventually detected by skin tests, was prescribed by Pediatric Allergologists. To ensure the correct adherence to diet with no nutritional impairment, a scheme of admitted foods and an appropriate calcium supplement dose were given to patients.
223668217|NCT02683590|DEVICE|Ceramic Implant|The replacement of the sternum by a ceramic implant
223668218|NCT04580641|OTHER|Questionnaire|A self-administered questionnaire will be completed by each study subject
223668219|NCT01185353|DRUG|LY3009104|Administered orally
223668220|NCT01185353|DRUG|Placebo|Administered orally
223668221|NCT01185353|DRUG|Methotrexate|Administered orally as background therapy
223668222|NCT05742308|BEHAVIORAL|Laughter yoga|Laughter yoga program was composed of four steps. The first step, which took 10 minutes, had warm-up exercises including gentle stretching and hand clapping. The second step, which included deep breathing exercises and hand clapping, took 5 minutes. The third step involved children's games and laughter exercises. The sessions included a combination of different laughter exercises. The last step, which included yoga nidra took 5 minutes.
223668223|NCT02569099|OTHER|Caregiver training|One hour training of family caregivers on the basic function of the brain and the stroke condition and its management in the home.
223668224|NCT05519592|DRUG|Ropivacaine injection|Intramuscular ropivacaine injection (gluteus maximus and rectus femoris)
223668225|NCT05519592|DRUG|Sodium Chloride Injection|Intramuscular sodium chloride injection (gluteus maximus and rectus femoris)
223668226|NCT02551042|DRUG|Fibrogammin®P, coagulation factor XIII concentrate (Human)|IV infusion
223668227|NCT02551042|DRUG|0.9% sodium chloride|IV infusion
224249494|NCT06132074|BEHAVIORAL|School sessions on consent, reciprocity and sexual violence|The intervention consists of a 120-minute workshop led by a representative from Uppsala Tjej- och Transjour and aims to reduce the vulnerability and prevalence of sexual harassment, sexual violence and to counteract men's violence against women and violence in close relationships by raising awareness among pupils, school staff and guardians about sexual health among young people. The workshop covers areas of consent, reciprocity and sexual violence. The participants will do several valuation based and discussion based exercises regarding these topics and discuss issues, legality, and norms during the time.
224249495|NCT05492630|DRUG|HEC73077 tablets|"Single-Dose Study: Each dose of HEC73077 and placebo will be administered with approximately 240 mL of water in the morning after fasting for at least 10 hours overnight.~Multiple-dose study:The study doses, administration method (fasted or fed), dosing frequency, and dosing period are all to be determined based on data from the single-dose study and/or multiple-dose study."
224249496|NCT05492630|DRUG|HEC73077 placebo tablets|"Single-Dose Study: Each dose of HEC73077 and placebo will be administered with approximately 240 mL of water in the morning after fasting for at least 10 hours overnight.~Multiple-dose study:The study doses, administration method (fasted or fed), dosing frequency, and dosing period are all to be determined based on data from the single-dose study and/or multiple-dose study."
224249497|NCT04960163|OTHER|No intervention|No intervention
224249498|NCT01765114|DRUG|PEG-Formulation|
224249499|NCT00940810|PROCEDURE|Plasma Disc Decompression/Nucleoplasty|"Subjects assigned to the PDD Group will be scheduled to receive the plasma disc decompression procedure using the Coblation® method.~Similarly to in Conservative Care group, subjects will be followed-up at 2, 8 weeks, 6 and 12 months (calculated from the date of the PDD procedure). The follow-up visits will consist of a brief physical examination in the clinic and completion of study questionnaires."
224249500|NCT00940810|PROCEDURE|Conservative Care (physiotherapy)|"Subjects assigned to the Conservative Care Group will be scheduled to receive physical therapy according to standard and customary care locally.~Subjects will be followed-up at 2, 8 weeks, 6 and 12 months . (Calculated from the time of first going through the individual training programme).The follow-up visits will consist of a brief physical examination in the clinic and completion of study questionnaires."
224249501|NCT02345395|PROCEDURE|Aneurysm Clipping|All Patients will be submitted to a surgical intervention in order to clip their unruptured brain aneurysm
224249502|NCT02496416|BEHAVIORAL|Aquatic Exercise Program|The aquatic exercise program will consist of 45 minute classes held 3 days/week for 8 weeks (18 hours total). The program is based on guidelines provided by the National Multiple Sclerosis Society (NMSS) and will be led by an aquatic fitness instructor certified to teach individuals with MS at the YMCA in Scotch Plains-Fanwood. The exercises will focus on improving flexibility, balance and strength. Equipment such as water mitts, paddles, noodles and bands will be used to increase the level of difficulty as needed.
224249503|NCT02496416|BEHAVIORAL|Stretching Program|The stretching program will consist of 45 minute classes held 3 days/week for 8 weeks (18 hours total). The program is based on guidelines provided by the National Multiple Sclerosis Society (NMSS) and will be conducted online via a secure video-conferencing website.
224249504|NCT05319938|PROCEDURE|CAF only|After local anesthesia, initially, sulcular incisions were made on the buccal aspect of the teeth and two vertical incisions were made. A trapezoidal flap was elevated with a split-full-split approach in the coronal-apical direction. The anatomic inter-dental papillae adjacent to the involved tooth were de-epithelialized. Plaque, calculus, and soft tooth structures on exposed root surfaces were removed with curettes. No further mechanical or chemical root conditioning materials were performed. The flap was coronally placed over the membranes to completely cover the CEJ and sutured with 6.0 propylene suture.
224249505|NCT05319938|PROCEDURE|CAF+CGF|"After local anesthesia, initially, sulcular incisions were made on the buccal aspect of the teeth and two vertical incisions were made. A trapezoidal flap was elevated with a split-full-split approach in the coronal-apical direction. The anatomic inter-dental papillae adjacent to the involved tooth were de-epithelialized. Plaque, calculus, and soft tooth structures on exposed root surfaces were removed with curettes. No further mechanical or chemical root conditioning materials were performed. The flap was coronally placed over the membranes to completely cover the CEJ and sutured with 6.0 propylene suture.~Blood samples were collected into 10 ml glass-coated plastic tubes without anticoagulant solutions. These tubes were placed into CGF centrifuge machine and centrifuged immediately . CGF membrane were placed over the defect. The flap was coronally placed over the membranes to completely cover the CEJ and sutured with 6.0 propylene suture."
224249506|NCT05319938|PROCEDURE|CAF+A-PRF|"After local anesthesia, initially, sulcular incisions were made on the buccal aspect of the teeth and two vertical incisions were made. A trapezoidal flap was elevated with a split-full-split approach in the coronal-apical direction. The anatomic inter-dental papillae adjacent to the involved tooth were de-epithelialized. Plaque, calculus, and soft tooth structures on exposed root surfaces were removed with curettes. No further mechanical or chemical root conditioning materials were performed. The flap was coronally placed over the membranes to completely cover the CEJ and sutured with 6.0 propylene suture.~Blood samples were collected into 10 ml glass-coated plastic tubes without anticoagulant solutions. These tubes were placed into A-PRF centrifuge machine and centrifuged immediately. A-PRF membrane were placed over the defect. The flap was coronally placed over the membranes to completely cover the CEJ and sutured with 6.0 propylene suture."
224249507|NCT01037023|DRUG|Topotecan|patients administrated Topotecan according to the prescribing information
224249508|NCT03122990|PROCEDURE|FM-SRP|Supra- and sub-gingival mechanical instrumentation of the root surface of the whole dentition within 24 hours.
224321933|NCT05397951|DEVICE|Multi-modality Noninvasive Biosensor|The wearable sensor devices will be placed on the finger, wrist, temple, subclavian, arm, neck, and thigh of the participant and will provide continuous tissue mechanics, heart rate, respiration rate, blood flow, and pulse oxygenation measurements continuously throughout the experimental period.
223668228|NCT00294086|DRUG|valsartan 160 mg|
223668229|NCT00294086|DRUG|valsartan 160 mg BID|
223668230|NCT05921045|OTHER|modification of clinical approach in clinical practice at time 0|evaluation of modification in clinical approach after training
223668231|NCT05921045|OTHER|modification of clinical approach in clinical practice at 6 months|evaluation of modification in clinical approach after retraining
223668232|NCT00638638|DRUG|Abciximab|"* Abciximab: 0.25 mg/Kg bolus~* Abciximab placebo bolus~* Abciximab infusion 10 µg/Kg/min"
223771255|NCT06663943|DRUG|CM313 (SC)|CM313 is an anti-CD38 monoclonal antibody that can help pemphigus patients systematically treat rapid glucocorticoid reduction. It has been proven to have good safety in non-clinical studies and is suitable for human studies
223771256|NCT06663943|DRUG|Glucocorticoids|Patients in the control group receive azathioprine in combination with steroid therapy.
224249509|NCT03122990|PROCEDURE|Q-SRP|"Supra- and sub-gingival mechanical instrumentation of the root surface will be performed in all dentition subdivided in four appointments. Each appointment will be performed in one week interval. In each appointment only a quadrant of the dentition will be instrumented.Performed in 3 weeks time frame."
224249510|NCT01270503|BIOLOGICAL|Menactra®: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
223668233|NCT00638638|DRUG|Abciximab placebo|"* Abciximab placebo Bolus~* Abciximab: 0.25 mg/Kg bolus~* Abciximab infusion 10 µg/Kg/min"
223668234|NCT00685009|DRUG|Estrogen hormone therapy|Estrogen pill daily
223668235|NCT00685009|DRUG|Estrogen plus progesterone hormone therapy|Estrogen plus progesterone hormone therapy pill (Prempro) daily
223668236|NCT00685009|DRUG|Placebo|Placebo pill daily
223668237|NCT05090319|DIAGNOSTIC_TEST|complete blood count|Complete blood count will be performed on the patient. Accuracy of micro-hematology analyzer will be assessed.
223668238|NCT05614856|DEVICE|EVAR off-label use|Normally a femoral access was used, although a brachial approach can be useful for crossing total occlusions. For TASC B and C lesions, predilatation of the iliac lesions is advisable, while for TASC D it is mandatory. In case of total aortic occlusions, the procedure demands that recanalization of the distal aorta occurs as close as possible to the bifurcation.. The key technique is to recanalize from one common iliac artery into the opposing snaring the wire to create a femoral-femoral crossover. The femoral-femoral wire is then replaced with a MPA catheter; the SurePass wire attached to the contralateral limb is then passed through the catheter. The sheath can be placed within 5 cm of the aortic bifurcation, and the AFX can be delivered through the common iliac and aortic occlusion. Predilatation were performed with bilateral 6-8 mm x 150 mm balloons and or progressive dilatators.
223668239|NCT03235232|DRUG|BREMEN eye drops|1 drop in the affected eye(s), twice a day (approximately each 12 hours) for 8 weeks.
223668240|NCT03235232|DRUG|Combigan®|1 drop of Combigan® in the affected eye(s), twice a day (approximately each 12 hours) for 8 weeks.
223668241|NCT00182481|PROCEDURE|Induced sputum cell counts|
223668242|NCT00182481|DRUG|inhaled corticosteroids and other asthma drugs|
223668243|NCT05620121|PROCEDURE|Surgery for Incisional hernias|Laparoscopic and laparoscopic abdominal wall repair for Incisional Hernia with/without prosthetic material in urgent/emergent settings, with/without direct closure of the defect (IPOM and IPOM +).
223668244|NCT01930578|OTHER|Treatment with 0.9% normal saline|"An oral dose of 0.33ml/kg of 10% Sodium Bromide solution at each of 3 study visits. Each dose of Sodium Bromide will be mixed with an equivalent volume; 1:1 of sterile water before oral intake.~An IV infusion of (1) 0.9% saline, (2) 5% Dextrose or (3) 3.3% Dextrose and 0.3% saline will be given at a rate of 1 liter over an hour in a randomized crossover design."
224249511|NCT01270503|BIOLOGICAL|Menactra®: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
224249512|NCT01270503|BIOLOGICAL|Menactra®: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
224249513|NCT03388203|DIAGNOSTIC_TEST|25(OH)D measurement, PTH measurement|25(OH)D analyses by LC-MS/MS were performed as part of our routine clinical work with a commercial kit from Recipe (Munich, Germany) ; PTH was measured in lithium-heparin plasma using the PTH STAT assay from Roche Diagnostics (Mannheim, Germany) on a Cobas 8000 auto-analyzer.
223668245|NCT01930578|OTHER|Treatment with D5+ 0.45 saline|"An oral dose of 0.33ml/kg of 10% Sodium Bromide solution at each of 3 study visits. Each dose of Sodium Bromide will be mixed with an equivalent volume; 1:1 of sterile water before oral intake.~An IV infusion of (1) 0.9% saline, (2) 5% Dextrose or (3) 3.3% Dextrose and 0.3% saline will be given at a rate of 1 liter over an hour in a randomized crossover design."
223668246|NCT01930578|OTHER|Treatment with D5|"An oral dose of 0.33ml/kg of 10% Sodium Bromide solution at each of 3 study visits. Each dose of Sodium Bromide will be mixed with an equivalent volume; 1:1 of sterile water before oral intake.~An IV infusion of (1) 0.9% saline, (2) 5% Dextrose or (3) 3.3% Dextrose and 0.3% saline will be given at a rate of 1 liter over an hour in a randomized crossover design."
223668247|NCT02270944|BIOLOGICAL|GBS Vaccine|Liquid formulation of a vaccine containing polysaccharide capsules from serotypes Ia, Ib, and III of the Group B Streptococcus
223668248|NCT02270944|BIOLOGICAL|GBS Vaccine|Lyophilized formulation of a vaccine containing polysaccharide capsules from serotypes Ia, Ib, and III of the Group B Streptococcus
223668249|NCT04387240|DRUG|Artemisinin / Artesunate|testing the drug capabilities in reducing the shedding and causing the testing for covid 19 to become negative
223668250|NCT04387240|OTHER|placebo|placebo or sham drug will be given to the second arm
223668251|NCT02459288|DRUG|Clopidogrel first|After randomization, 2 weeks Clopidogrel (Plavix) 75 mg QD will be given and then crossover with following 2 weeks Ticagrelor (Brilinta) 90 mg bd
223771257|NCT02869490|OTHER|Data collection|
223771258|NCT06661993|OTHER|Placebo|placebo film-coated tablet orally or via a nasogastric tube for seven days .
223771259|NCT06661993|DIETARY_SUPPLEMENT|Alpha-lipoic acid|Alpha-lipoic acid 1800 mg orally or via a nasogastric tube for seven days .
223771260|NCT05137652|DEVICE|Radiofrequency ablation of medial nerve using single needle approach|The primary outcome is to study the efficacy of the described technique which creates a lesion that we estimate to be 11.0-mm wide and 11.6-mm long along the course of the medial branch adjacent to the SAP ensuring adequate coverage and treatment using VAS score. Responder status was defined as a 30% or greater improvement in VAS pain score from the pre-procedural VAS pain score. Outcomes were summarized by means and standard deviations for continuous outcomes, and frequencies (%) for categorical outcomes.
224249514|NCT02171793|DRUG|BI 1744 CL|
224249515|NCT02171793|DRUG|Placebo|
224249516|NCT00148837|DRUG|Peg-interferon alpha 2b (drug)|
224249517|NCT00148837|DRUG|Ribavirin (drug)|
224249518|NCT00148837|DRUG|Prazosin (drug)|
224249519|NCT06025188|OTHER|training set|LASSO regression analysis, Logistic regression analysis, Nomogram
224249520|NCT02608788|DRUG|S.L.®|"1.5mg/ml Benzydamine hydrochloride, S.L.® spray by mouth . Before intubation, each endotracheal tube cuff was scattered 10 times of spray by physicians that might cover 20 cm long of the cuff."
224249521|NCT02608788|DRUG|Difflam Forte ®|"3.0mg/ml Benzydamine hydrochloride ,  Difflam Forte ® spray by mouth . Before intubation, each endotracheal tube cuff was scattered 10 times of spray by physicians that might cover 20 cm long of the cuff."
224249522|NCT02608788|DRUG|Acular®|"5％ Ketorolac Tromethamine ,  Acular®  spray by mouth . Before intubation, each endotracheal tube cuff was scattered 10 times of spray by physicians that might cover 20 cm long of the cuff."
224249523|NCT02608788|DRUG|placebo|Distilled water spray by mouth. Before intubation, each endotracheal tube cuff was scattered 10 times of spray by physicians that might cover 20 cm long of the cuff.
224249524|NCT04593628|BEHAVIORAL|Connect for Caregivers|The STAR Center developed Connect for Caregivers to help improve connectedness among older caregivers of individuals with Alzheimer's Disease and Related Dementias (ADRD). Connect for Caregivers includes three components: (1) psychoeducational materials on the importance of connectedness for health and well-being; (2) a card sort-based 'discussion prioritization tool' that systematizes and routinizes the process of identifying and prioritizing barriers to connectedness; (3) personalized resources to address the identified barriers/targets. We will tailor Connect for Caregivers for Hispanic/Latino and Spanish-speaking caregivers guided by the Selective and Directed Treatment Adaptation Framework. The intervention is given once during the study.
224249525|NCT03227198|BIOLOGICAL|Intramyocardial injection of stem cell|Autologous bone marrow-derived mononuclear cells are obtained from 100-150ml of bone marrow aspirated under local anaesthesia from the iliac crest. Intramyocardial injection of the cells is performed in patients with Heart failure in open heart surgery (CABG)
224249526|NCT03227198|BIOLOGICAL|Placebo|Injection of Placebo in patients with Heart failure in open heart surgery (CABG)
224249527|NCT00002911|DRUG|marimastat|
224249528|NCT02099747|DRUG|hATG|
224249529|NCT02099747|DRUG|CsA|
224249530|NCT02099747|DRUG|Eltrombopag|
224249531|NCT03128905|DRUG|Colchicine opocalcium 1mg|"International non-proprietary name: Colchicine~Molecule owner: Mayoly-Spindler Laboratory, 1mg scored tablet for oral administration, authorized 03/02/1995.~Composition :~Active principle : Crystallized colchicine Excipients: Erythrosine aluminium lake, lactose, saccharose, magnesium stearate and povidone."
224249532|NCT03128905|DRUG|Prednisone : Cortancyl 20mg|"International non-proprietary name: Prednisone~Molecule owner : SANOFI AVENTIS France 20 mg scored tablet for oral administration, authorized since 02/05/1990, generic drug available.~Composition :~Active principle : Prednisone Excipients: Maize starch, lactose, talc, magnesium stearate."
223668252|NCT02459288|DRUG|Ticagrelor first|After randomization, 2 weeks Ticagrelor (Brilinta) 90 mg bd will be given then crossover with following 2 weeks Clopidogrel (Plavix) 75 mg QD
223668253|NCT02087007|DRUG|Cilostazol|100mg oral tablets bid during 2 weeks after dosing of 50mg oral tablets bid during 2 weeks
223668254|NCT02087007|DRUG|placebo|100mg oral placebo tablets bid during 2 weeks after dosing of 50mg oral placebo tablets bid during 2 weeks
224249533|NCT02459951|OTHER|clenched fist|Observation of performance on a standardized behavioral task pre- and post- administration of Botox A in the context of routine care. Clinical assessment and judgment will be used to determine dosing and which muscles contribute to the hand deformities of a given participant.
223668255|NCT01978938|DRUG|Eravacycline|
223668256|NCT01978938|DRUG|Levofloxacin|
223668257|NCT04455490|OTHER|Self-control|We compared relevant scores of patients before and after surgery
223668258|NCT03618290|DIAGNOSTIC_TEST|Analyze plasma free fatty acid in blood|"This study is prospectively designed with the purpose of investigating potential new lipid targets and the free fatty acids as specific markers of acute brain injury.~Dynamic measurement of lipid profile in 3 consecutive samples at (I) the time intervals of admission, (II) 8 hours and (III) 24 hours after admission will give the opportunity of comparison mass-spectrometric analysis of highly complex plasma samples thus reducing variability between analyzed samples and allowing precise focusing on essential lipid target changes during stroke progression."
224249534|NCT03800251|DIETARY_SUPPLEMENT|Nutricia PreOp - a clear, non-carbonated, lemon flavoured, carbohydrate drink that provides 0.5kcal/ml|Fasting parturients at term, admitted for elective cesarean section and consent to partake in the study, will be given the intervention drink
224249535|NCT02133105|DRUG|Levosimendan|
224249536|NCT02133105|DRUG|Dobutamine|
224249537|NCT00798447|DRUG|MLF 541|22-24 h i.v. infusion, maximum 0.75 ml lipid emulsion per kg BW per hour
224249538|NCT00798447|DRUG|Lipofundin MCT|22-24 h iv.infusion, maximum 0.75 ml lipid emulsion per kg BW per hour
224249539|NCT03959605|GENETIC|blood sample for genetic test|detection of pathogenic variants among the 19 genes known to be involved in albinism
224249540|NCT03959605|DIAGNOSTIC_TEST|Ophtalmological examination|measurement of visual acuity, OCT and OCTA
223668259|NCT05807165|RADIATION|Hypofractionated Stereotactic Radiotherapy (HF-SRT)|The administered dose-fractionation schemes range between 30 and 35 Gy delivered within two weeks with a dose per fractionation ranging from 6 to 7 Gy.
224249541|NCT06132698|DRUG|Tislelizumab, pemetrexed|Drug 1: Tislelizumab 50 mg; Drug 2: pemetrexed 20mg. intrathecal injection therapy
224249542|NCT01278732|OTHER|no intervention performed|no intervention is performed
224249543|NCT03995420|BEHAVIORAL|Virtual Reality Therapy (V-NeST)|V-NeST is a 12-session therapy using psychological intervention principles based on Cognitive Remediation and CBT partly based in Virtual Reality.
224249544|NCT03995420|OTHER|Treatment as Usual|multi-modal treatment consisting of different therapies defined by the treating team. These will include regular contact with a care coordinator and medication management by a psychiatrist.
224249545|NCT04807374|DEVICE|Control IQ|We aim to conduct a non-randomized prospective interrupted time series pilot study to investigate the effect of HCL insulin delivery on glycemic control in underserved adolescents with poorly controlled T1D.
223668260|NCT05807165|RADIATION|Hippocampus-Sparing Whole-Brain Radiotherapy (HS-WBRT) plus memantine|"* The prescribed dose is 30 Gy delivered in 12 fractions for therapeutic or adjuvant WBRT.~* The prescription of memantine for finally twice-daily dosing will be prescribed as follows:~  * During the first 3 weeks concurrent with the delivery of hippocampus-sparing WBRT, 5-mg morning dose will be initially prescribed \[Week 1 -3\]~ * 5-mg twice a day in the following week \[Week 4\]~ * A morning dose of 10 mg and an evening dose of 5 mg in the following week \[Week 5\]~ * 10-mg twice a day for the subsequent weeks up to Week 24 \[Week 6 - 24\]"
224249546|NCT05005494|DRUG|Magnesium sulfate IV|Infusion of magnesium sulphate 50 mg/kg (eq. 0.5ml/kg of magnesium sulphate 100mg/ml)
224249547|NCT05005494|DRUG|Placebo|Infusion of NaCl (sodium chloride) 0.9% (placebo eq. 0.5ml/kg of NaCl 0.9%)
224249548|NCT05566860|PROCEDURE|Positional Therapy|After the a forementioned sleep endoscopy, if the patient has postural sleep apnea, he was treated with positional therapy for three months.
224249549|NCT05566860|PROCEDURE|Intraoral Negative Pressure Therapy|If the patient is effective with intraoral negative pressure therapy (iNAP), this therapy was used for three months.
224249550|NCT05566860|PROCEDURE|Oral Appliances|If the patient is effective with oral appliances use, it was used be for three months.
223668261|NCT06306872|DRUG|Sequence A ABSK-011|Subjects in sequence A will receive 220 mg (100 mg capsule \*2 and 20 mg capsule \*1) Oral administration of ABSK-011 old formulation at the first day of cycle 1 (C1D1), followed by a washout period of at least 4 days.Subjects will receive 200 mg(100 mg capsule \*2) Oral administration of ABSK-011 new formulation at the first day of cycle 2 (C2D1).
224249551|NCT05566860|PROCEDURE|Surgery|If the interventions mentioned above are ineffective, or the patient does not want to try the above treatments, surgery is required. The surgical patients were divided into three groups according to their body weight. One group was overweight patients (BMI\>32) who were treated with upper airway surgery and/or bariatric surgery, and/or postoperative diet education; the other group was overweight people with a BMI between 27 and 32, upper airway surgery and/or bariatric surgery, and/or postoperative diet education will be done; if the weight is normal with the BMI is less than 27, or those patients who are overweight but are not willing receive above mentioned weight loss treatment, upper airway surgery will be done.
224249552|NCT05566860|PROCEDURE|Tongue Muscle Strength Training|If the tongue strength of the aforementioned patient is insufficient, it is recommended that the patient need to do tongue muscle strength training at the same time for three months. If the ambient temperature and humidity have an impact, we will recommend patients to control the ambient temperature and humidity and use the ECG patch to track the changes before and after three months.
224249553|NCT05223894|BIOLOGICAL|hiPSC-CM therapy|Injection of allogenic human pluripotent stem cell-derived cardiomyocytes (hPSC-CMs) during coronary artery bypass grafting surgery. 100 million hPSC-CMs in 2.5-5 mL medium suspension will be injected into the myocardium.
224249554|NCT05223894|OTHER|Control|Coronary artery bypass grafting surgery only.
224249555|NCT01043380|DRUG|Combination therapy with Lipitor [Atorvastatin] and Zetia [Ezetimibe]|Zetia 10 mg/dl + Lipitor. The dosage of Lipitor will be titrated up to a maximum of 20 mg/day with a treatment goal of lowering LDL-C below 70 mg/dl.
224249556|NCT01043380|DRUG|Lipitor (Atorvastatin) monotherapy|The dosage will be titrated up to a maximum of 20 mg/day, which is the highest approved regimen by the Ministry of Health, Labor and Welfare of Japan, with a treatment goal of lowering LDL-C below 70 mg/dl.
224249557|NCT03857295|OTHER|No interventions|No intervention
224249558|NCT02062580|BIOLOGICAL|BCG|
224249559|NCT00481338|PROCEDURE|X-rays|X-rays (hip and knee) every 2 years
224249560|NCT00481338|BIOLOGICAL|biological samples|biological sample (blood and urine) every 2 years
224249561|NCT00481338|OTHER|medical information about osteoarthritis|several questionnaires about pain and function (WOMAC), physical activity (MAQ), quality of life (generic SF-36 and OA specific OAKHQOL/AMIQUAL), comorbidities (FCI), mental status (MMS), heath status (GHQ 28) and health resource consumption
224249562|NCT05267691|PROCEDURE|Excision|Surgical excision of the lesion and histopathology evaluation using Hematoxylin and Eosin stains
224249563|NCT03173391|DRUG|HMS5552|BID Oral administration
224249564|NCT03173391|DRUG|Placebo|BID Oral administration
224249565|NCT03079765|BEHAVIORAL|Behavioral skills training|Participants will receive feedback and error correction on their implementation of the assessment procedures. Feedback will take the form of the experimenter pointing out components of the assessment that are not being conducted accurately and error correction will take the form of the experimenter reviewing the correct way to implement that component of the assessment.
224249566|NCT03079765|BEHAVIORAL|Protocol Only|Participants will be given a written protocol describing how to conduct the target assessment procedure.
224249567|NCT01936194|DIETARY_SUPPLEMENT|DHA+EPA|
224321934|NCT05397951|DEVICE|Oximeter|The oximeter device will be placed on the right middle finger of the participant and will provide continuous pulse oxygenation and heart rate measurements continuously throughout the experimental period.
224321935|NCT05397951|DEVICE|Portable Blood Pressure Monitor|The blood pressure monitor device will be placed on the left arm of the participant and will take a blood pressure measurement every 5 minutes throughout the 15 minute experimental period, and every 15 minutes throughout the 2 hour experimental period.
223668262|NCT06306872|DRUG|Sequence B ABSK-011|Subjects in sequence A will receive 200 mg(100 mg capsule \*2) Oral administration of ABSK-011 old formulation at the first day of cycle 1 (C1D1), followed by a washout period of at least 4 days.Subjects will receive 220 mg (100 mg capsule \*2 and 20 mg capsule \*1) Oral administration of ABSK-011 new formulation at the first day of cycle 2 (C2D1).
223668263|NCT04395950|DRUG|PF-05221304|PF-05221304 10 mg daily (two 5mg tablets daily in the morning for 6 weeks)
223668264|NCT04395950|DRUG|Placebo|Placebo two tablets daily in the morning for 6 weeks
223668265|NCT02121665|DRUG|Probiotic (Inersan)|Each Inersan lozenge contains not less than 1 billion CFU of Lactobacillus brevis CD2
223668266|NCT02121665|DRUG|Placebo|Each placebo lozenge contains all excipients except the active constituent (Lactobacillus brevis CD2)
223668267|NCT05471713|OTHER|Autonomic dysfunction|Autonomic dysfunction
223668268|NCT04669418|DIAGNOSTIC_TEST|RNA expression signature|Whole transcriptome profiling using RNA sequencing
223668269|NCT04453553|DIAGNOSTIC_TEST|Q16 testing|Nasal swab tested on a rapid near patient device
223668270|NCT04453553|DIAGNOSTIC_TEST|Nasopharyngeal swab and main laboratory|Standard of care testing
223668271|NCT00097149|PROCEDURE|Systematic pediatric care|
223668272|NCT03233880|DRUG|Azithromycin 1gm|Azithromicin 1 gm oral single dose
223668273|NCT03233880|OTHER|PLACEBO|placebo
223668274|NCT00095147|DRUG|Abatacept (ABA) + Methotrexate (MTX), double-blind (DB)|Abatacept, intravenous (IV) Solution, Infusion, Depends on participant weight, Monthly, 12 months.
223668275|NCT00095147|DRUG|Infliximab (INF) + MTX, DB|Infliximab, IV Solution, Infusion, Depends on participant weight, Every 2 Months, 12 months.
224249568|NCT01936194|DIETARY_SUPPLEMENT|High Olive Oil|
224249569|NCT01936194|DIETARY_SUPPLEMENT|DHA|
223771261|NCT05137652|DEVICE|Radiofrequency ablation of medial nerve using three needle approach|The primary outcome is to study the efficacy of the described technique by maximizing the lesion size (compared to control group) along the course of the medial branch adjacent to the SAP ensuring adequate coverage and treatment using VAS score.
223771262|NCT07017361|PROCEDURE|Conventional|Pre-operative fasting: NPO for solids and fluids from 00:00. No pre-emptive oral analgesia. Intra-operative: IV dexamethasone 5 mg at anaesthesia induction; IV acetaminophen 1 g about 1 h before wound closure. Post-operative nutrition: Levin tube removed in OR. POD1 morning-sips of water; POD3 morning upright abdominal X-ray; if normal, start soft fluid diet POD3 evening. POD4 pancreatobiliary CT; if normal, start soft bland diet at lunch. Drain management: two drains at hepaticojejunostomy and pancreaticojejunostomy; drain amylase measured POD1, 3 and 5; if POD4 CT normal, drains removable from POD5 per surgeon discretion (output, fever, pain). Analgesia: IV PCA until ≈POD3, then oral acetaminophen 650 mg every 8 h. No carbohydrate loading or NSAID/nefopam adjuncts.
224249570|NCT05038657|DRUG|Atezolizumab|Treatment will consist of atezolizumab, by IV infusion, at a fixed dose of 1680 mg, every 28 days (day 1 of each cycle, +/- 3 days), for up to one year. Each participant will receive up to 13 doses in total.
224249571|NCT05704426|DEVICE|Impulse Dynamics Optimizer Device|The Impulse Dynamics Optimizer is indicated for patients with New York Heart Association (NYHA) class III congestive heart failure (CHF) with left ventricular ejection fraction (LVEF) between 25 and 45% who are not candidates for cardiac resynchronization therapy. The Optimizer device requires a minimally invasive implant by a cardiac electrophysiologist with two transvenous pacemaker wires implanted into the right ventricular septum and attached to a generator in an infraclavicular region, much like a pacemaker. The Optimizer device provides CCM through improved calcium handling and has been shown to reverse the negative remodeling of the left ventricle seen in HFrEF and improve left ventricular contractile strength.
223668276|NCT00095147|DRUG|Placebo (PLA) + MTX, DB|Placebo, IV Solution, Infusion, Depends on participant weight, Monthly, 6 months.
223771263|NCT07017361|PROCEDURE|ERAS|Pre-op fasting: solids NPO from 00:00; clear fluids until 3 h pre-op; 300 mL carbohydrate drink 2-4 h pre-op with oral acetaminophen 650 mg + zaltoprofen 80 mg. Intra-op: IV dexamethasone 8 mg at induction; IV acetaminophen 1 g + ibuprofen 300 mg + nefopam 20 mg 1 h before closure. Post-op nutrition: Levin tube removed in OR. POD1 sips of water; POD2 morning upright abdominal X-ray-if normal, start soft fluid diet POD2 evening. POD3 pancreatobiliary CT-if normal, start soft bland diet at lunch. Drain mgmt: same placement; amylase POD1 \& 3; if POD4 CT normal and amylase ≤ 5 000 U/L trending down, remove drains POD4; otherwise per surgeon. Analgesia: IV PCA until ≈POD3; until POD1 morning, IV acetaminophen 1 g + ibuprofen 300 mg q8h; POD1-5, oral acetaminophen 650 mg + zaltoprofen 80 mg q8h.
224249572|NCT04455126|DRUG|Preservative-free tafluprost eye drops|This was an open-label, non-randomized clinical study that aimed to assess the ocular signs and symptoms in 60 eyes of 30 newly diagnosed Egyptian glaucoma patients receiving preservative-free tafluprost eye drops
224249573|NCT02694731|BEHAVIORAL|Mobile application intervention (Device: Smartphone)|Consists of the app described in the arm description.
224249574|NCT04624620|BEHAVIORAL|Teaching Kitchen Collaborative Curriculum|This is a referral-based teaching kitchen intervention that synergistically provides basic cooking skills, an evidence-based nutrition curriculum, mindfulness skills, activity tracking, and support for behavior change to augment weight management and lifestyle change in the primary care setting.
224249575|NCT02406625|BEHAVIORAL|Behavioral Therapy|16 therapeutic group sessions are delivered to both parents and adolescents; according to the assigned group for each family.
224249576|NCT02481830|DRUG|Nivolumab|
224249577|NCT02481830|DRUG|Topotecan|
224249578|NCT02481830|DRUG|Amrubicin|
224249579|NCT00290030|DRUG|Alfuzosin|
223668277|NCT00095147|DRUG|PLA + MTX switched to ABA+ MTX, DB|Placebo=IV Solution, Infusion, Depends on participant weight, Monthly, 6 months. Abatacept=IV Solution, Infusion, Depends on participant weight, Monthly, 6 months
223668278|NCT00095147|DRUG|ABA, open-label (OL)|Abatacept, IV solution, Infusion. Depends on participant weight, Monthly, 12+ months
223668279|NCT00605956|DRUG|NatrOVA Creme Rinse - 1%|NatrOVA Creme Rinse - 1% spinosad
223668280|NCT00605956|DRUG|NatrOVA Creme Rinse Vehicle Only|NatrOVA Creme Rinse Vehicle - no spinosad
224249580|NCT04997122|OTHER|Olive pomace oil|Volunteers consumed during 4 weeks 45 g/d of olive pomace oil as the only source of dietary fat, used for cooking, salad dressing, toasts, etc.
224249581|NCT04997122|OTHER|High oleic acid sunflower oil|Volunteers consumed during 4 weeks 45 g/d of oleic acid-rich sunflower oil as the only source of dietary fat, used for cooking, salad dressing, toasts, etc.
224249582|NCT03515967|DEVICE|I-PAS Goggles|Portable, head-mounted display goggle system with integrated eye capture technology
224249583|NCT02598882|DEVICE|videogame|Patients will be an assessment of quadriceps muscle strength by surface electromyography, before and after a 30-minute guided activity through an active video game
224249584|NCT02598882|DEVICE|treadmill|Patients will be an assessment of quadriceps muscle strength by surface electromyography, before and after a 30-minute activity in treadmill.
224249585|NCT00102440|DRUG|Febuxostat|Febuxostat 80 mg, orally, once daily for up to 52 weeks.
224249586|NCT00102440|DRUG|Febuxostat|Febuxostat 120 mg, orally, once daily for up to 52 weeks.
224249587|NCT00102440|DRUG|Allopurinol|Allopurinol 300 mg, capsules, orally, once daily for up to 52 weeks.
224249588|NCT03678844|BEHAVIORAL|Taekwondo practice|The Taekwondo intervention program consisted of the technical skill development aspect (e.g., blocking, punching and kicking) of the sport and poomse (forms) for 30-min.
224321936|NCT05397951|DEVICE|Vicorder Pulse Wave Velocity Monitor|The pulse wave velocity monitor device will be placed on the right side of the neck and the right thigh and will provide measurements continuously throughout the experimental period.
224321937|NCT02642042|DRUG|Docetaxel|Given IV
224321938|NCT02642042|OTHER|Laboratory Biomarker Analysis|Correlative studies
224321939|NCT02642042|DRUG|Trametinib|Given PO
224321940|NCT06511882|DRUG|Azacitidine|Standard of Care Intravenous (IV) infusion
223668281|NCT00605956|DRUG|Blank Patch|Blank Patch
223668282|NCT00093665|DRUG|cisplatin|
223668283|NCT00093665|DRUG|fluorouracil|
223668284|NCT00093665|RADIATION|radiation therapy|
223668285|NCT04546828|DRUG|Gemcitabine, Cisplatin, and Nab-Paclitaxe|"* Nab-paclitaxel 100mg/m2 in NS dilute to a total concentration of 5 mg/mL (DO NOT FILTER) over 30 minute IV infusion on days 1 and 8 repeated every 21 days, followed by:~* Cisplatin 25mg/m2 in 500 mL of NS over 60 minute IV infusion on days 1 and 8 repeated every 21 days, followed by:~* Gemcitabine 800 mg/m2 in 500ml over 30 minute IV infusion on days 1 and 8 repeated every 21 days ."
223668286|NCT00936728|OTHER|therapeutic nutritional supplementation|Given orally
223668287|NCT00936728|DIETARY_SUPPLEMENT|white wine|Given orally
223668288|NCT00936728|OTHER|questionnaire administration|Ancillary studies
223668289|NCT05163015|OTHER|Data collection|Description: quality of life assessment
223668290|NCT03540719|PROCEDURE|Osteosynthesis|Osteosynthesis of posterior tibial plateau fracture with a posterior tibial plateau plate
223668291|NCT00200343|DRUG|Ursodeoxycholic acid 150mg / day|Ursodeoxycholic acid, 150mg/ day, three times a day at meals
223668292|NCT00200343|DRUG|Ursodeoxycholic acid 600mg / day|Ursodeoxycholic acid, 600mg/ day, three times a day at meals
223668293|NCT00200343|DRUG|Ursodeoxycholic acid 900mg / day|Ursodeoxycholic acid, 900mg/ day, three times a day at meals
223771264|NCT07023523|BEHAVIORAL|Cognitive Behavioral Therapy|Practicing certain cognitive and behavioral pain self-management strategies such as relaxation and changing negative thoughts about pain.
223771265|NCT07023523|BEHAVIORAL|Disease Education|Providing information about fibromyalgia, including its potential causes and management approaches.
223771266|NCT07024043|DRUG|Dexamethasone versus Dexmedetomidine in IPACK Block to reduce pain post Arthroscopic knee surgeries|Blocks will be carried out with the patient supine with the operative leg externally rotated and slightly flexed at the knee or in prone position.with Ultrasound device with a high-frequency (6-13 MHz) linear probe using in plane lateral to medial approach and this will be done by a senior staff anaesthesia physician skilled in ultrasound guided regional anaesthesia.
224249589|NCT03678844|OTHER|CONTROL|The participants of the control group engaged in physical activities, including athletics, handball and gymnastic, during two sessions of physical education per week at school.
224249590|NCT03337386|DIAGNOSTIC_TEST|inferior vena cava collapsibility|inferior vena cava diameters is obtained in the supine position with a convex probe .The probe is placed in the subxiphoid region or the right anterior midaxillary plane.The sagittal section of IVC is imaged. M-mode probe is used to identify the measurement of minimum and maximum venous dimensions over the respiratory cycle using the 3.5-5 MHz phased array probe. To standardize the measurements, measuring of the IVC diameter is performed at 2 cm caudal of the junction point of the right atrium and IVC. The difference between the maximum (D max) and minimum (D min)diameters of the target vein is normalized according to the standard formula to yield the collapsibility index (CI).
224249591|NCT03337386|DIAGNOSTIC_TEST|subclavian vein collapsibility|Right SCV diameters is checked in the supine position using a high frequency linear array probe (6-13 MHz) and M-mode. To standardize the measurements, the probe is placed beneath the proximal part of the middle part of the clavicle perpendicular to long-axis of the SCV to obtain the best cross-sectional view of the vien. After the target vein is localized , the dynamic diameter change is recorded using M-mode to identify and measure the minimum and maximum venous diameters.To calculate SCV collapsibility index, the standard formula is used.
224249592|NCT03337386|DIAGNOSTIC_TEST|central venous pressure|ultrasound guided 7.5-F central venous catheter is introduced via right internal jugular vein under local analgesia with 2% lidocaine for measuring the CVP.
224249593|NCT01747317|DEVICE|FFR (PressureWire)|Fractional flow reserve measured during cardiac catheterization--A pressure-monitoring guidewire(PressureWire Certus, St. Jude Medical Systems, Uppsala, Sweden;ComboWire, Volcano Corporation, San Diego, California) will be advanced past the stenosis.
224249594|NCT06420986|PROCEDURE|Open Hemorrhoidectomy|Surgical treatment of Hemorrhoids. Removal of hemorrohids leaving the wounds open. Surgical technique described by Milligan Morgan
224249595|NCT06420986|PROCEDURE|Transanal Hemorrhoidal Dearterialization|Surgical treatment of Hemorrhoids. This operation involves no excision. The hemorrhoidal arteries are ligated and the hemorrhoial prolapse is treated by a suture mucopexi. Described by Rato
224249596|NCT05858463|OTHER|Modality of exercise training|muscle adaptations following intermittent high intensity interval exercise training and continuous low intensity exercise training
224249597|NCT01330186|OTHER|FMISO-PET, FDG-PET-CT and Magnetic Resonance Imaging (MRI)|This study involves 6 imaging sessions. One FMISO-PET before radiation therapy, one FDG-PET-CT before radiation therapy and one FDG-PET-CT during radiation therapy and tree Magnetic Resonance imaging (MRI) sessions with one session before radiation therapy, one session during radiation therapy and one sessions post radiation.
224249598|NCT05218486|DRUG|Isotretinoin|Isotretinoin is a vitamin-A derivative for treatment of moderate to severe acne used in a dose from 20-40 mg for 3 months duration
224249599|NCT04597463|PROCEDURE|Endometrial injury|Endometrial injury was performed hysteroscopically after freeze all cycles and during the cycle before the frozen embryo transfer
224321941|NCT06511882|DRUG|Decitabine|Standard of Care Intravenous (IV) infusion
224321942|NCT06511882|DRUG|Venetoclax|Standard of Care PO (By Mouth)
224321943|NCT03694561|OTHER|Observational|This study is a systematic investigation of the natural history of late-onset Pompe disease in infancy and childhood
223668294|NCT03619967|DEVICE|Multispectral imager|"Device: Bio-inspired multispectral imager~-Manufactured at University of Illinois at Urbana Champaign"
223668295|NCT00196846|DRUG|Goserelin|
223668296|NCT01175681|PROCEDURE|remote ischaemic preconditioning|Remote ischaemic preconditioning consisted of three 5-min cycles of right upper arm ischaemia, which was induced by an automated cuff -inflator placed on the right upper arm and inflated to 200 mm Hg, with an intervening 5 min of reperfusion during which the cuff was deflated. There was a 5- to 10-min interval between completion of the remote ischaemic preconditioning protocol and initiation of bypass.Control patients had a deflated cuff placed on the right upper arm for 30 min.
223668297|NCT02973373|DEVICE|MRI with High-frequency non-invasive ventilation|MRI performed under high-frequency non-invasive ventilation
223668298|NCT02973373|OTHER|MRI without High-frequency non-invasive ventilation|MRI performed without High-frequency non-invasive ventilation
223668299|NCT05551247|DRUG|Envafolimab|300mg,sc,d3,Q3W;
223668300|NCT05551247|DRUG|recombinant human endostatin (endostatin)|210mg,civ,d1-3,Q3W
224249600|NCT01464112|DRUG|JNJ-2641585 / VELCADE / Dexamethasone|JNJ-26481585: type=range, unit=mg, number=6 to 12, form=capsules, route=oral use, on Days 1, 3, and 5 of each week. VELCADE: type=exact, unit=mg/m2, number=1.3, form=powder for solution for injection, route=subcutaneous use, on Days 1, 4, 8, and 11 of each 21-day cycle (Cycles 1 to 8) and on Days 1, 8, 15, and 22 of each 35-day cycle (Cycles 9-11). Dexamethasone: type=exact, unit=mg, number=20, form=tablets, route=oral use, on the day of and after VELCADE.
224249601|NCT04627038|DRUG|LY3556050|LY3556050 Given orally
224249602|NCT04627038|DRUG|Placebo|Placebo Given orally
224249603|NCT05607264|OTHER|Kinsiotaping|Patients received the kinesiotaping over supraspinatus muscle and deltoid muscle, tape will be removed every three days and subjects will return back to the clinic to reapplication of tape again. Patients received the same therapeutic treatment 3 times/ week for four weeks. KT is air permeable and water resistant, allowing it to stay in place for three to five days.
224249604|NCT05607264|OTHER|Motion-controlled VR games|Virtual Rehab utilizes the unique characteristics of Microsoft Kinects motion technology to track and capture the movements of the patients so that patients become immersed in a 3D environment where they interact with the game. Subjects will include in a supervised virtual reality exergaming program for shoulder movements for 4 weeks, 3 days per week and 10 minutes for session.
223668301|NCT02753088|DRUG|BCD-063|
223668302|NCT02753088|DRUG|Copaxone-Teva|
223668303|NCT02753088|DRUG|Placebo|
223668304|NCT05933109|BEHAVIORAL|Imagery Rehearsal Therapy and Targeted memory reactivation during REM sleep|Emerging evidence shows that REM sleep plays a causal role in extinction learning, emotion regulation and consolidation of emotionally positive memories. By using targeted memory reactivation (TMR), a known method where a sound S1 is associated with a waking experience (i.e., a positive outcome of imagery rehearsal therapy in this study) and strengthening it during REM sleep, the investigators want to accelerate the remission of traumatic nightmares and PTSD symptomatology.
223668305|NCT05933109|BEHAVIORAL|Imagery Rehearsal Therapy|These patients will receive the classic treatment of Imagery Rehearsal Therapy (IRT) for nightmares without association with the sound S1.
223668306|NCT00533754|PROCEDURE|drawing blood|
224249605|NCT05607264|OTHER|Conventional treatment|patients received conventional treatment for chronic shoulder impingement syndrome only.
224249606|NCT06035107|DIAGNOSTIC_TEST|Radar blood pressure device|The radar blood pressure device will be compared with other traditional blood pressure measurement methods.
224249607|NCT05151588|DRUG|Docetaxel|Docetaxel 75mg/m2 intravenous infusion on day 1 every 3 weeks for 3 cycles as induction therapy
224249608|NCT05151588|DRUG|Cis Platinum|Cisplatin 75mg/m2 intravenous infusion on day 1 every 3 weeks for 3 cycles as induction therapy
224249609|NCT05151588|DRUG|5-FU|5-FU 750mg/m2 intravenous infusion from day 1 to day 5 every 3 weeks for 3 cycles as induction therapy
224249610|NCT05151588|DRUG|Tazemetostat|Tazemetostat 800mg twice per day orally in continuously for 3 cycles as induction therapy and maintenance therapy
224249611|NCT05151588|PROCEDURE|Surgery|Radical surgery
224249612|NCT05151588|OTHER|Chemoradiation|Chemoradiation as either radical treatment or post-operative treatment after surgery
224249613|NCT03254771|OTHER|Decision aid|Decision aids are tools that enables to promote and facilitate patients' involvement in medical decisions concerning their health
224249614|NCT03251911|DRUG|Ivacaftor (VX-770)|of Ivacaftor (VX-770) for the Treatment of Chronic Bronchitis with CFTR Dysfunction
224249615|NCT02255097|BIOLOGICAL|pembrolizumab|
224249616|NCT05340140|DIAGNOSTIC_TEST|deep learning model|deep learning model developed by computer science expert and based on convolution neural network , and trained by our datasets.
223668307|NCT04972643|DIETARY_SUPPLEMENT|EPA|EPA 2000mg Soft capsules
223668308|NCT04972643|DIETARY_SUPPLEMENT|DHA|DHA 2000mg Soft capsules
223668309|NCT04972643|DIETARY_SUPPLEMENT|Placebo|Placebo Soft capsules
223668310|NCT00473980|DRUG|Indomethacin, celecoxib, esomeprazole|
223668311|NCT03678870|OTHER|Opioid Education Handout|a single page handout with information about how to use medications for pain after discharge.
223668312|NCT05712486|OTHER|High force hip Lateral distraction|Hip lateral distraction in adjusted position of maximun flexion and internal rotation, with neutral position of abduction/adduction applying high force of distraction.
223668313|NCT05712486|OTHER|Placebo force hip lateral distraction|Hip lateral distraction in adjusted position of maximun flexion and internal rotation, with neutral position of abduction/adduction applying placebo force of distraction.
223668314|NCT03127098|BIOLOGICAL|ETBX-011|ETBX-011 immunization was administered by subcutaneous (SC) injection.
223668315|NCT03127098|BIOLOGICAL|ALT-803|ALT-803 was administered by SC injection.
223668316|NCT03104816|DRUG|Acetaminophen IV Soln 10 MG/ML|
223668317|NCT03104816|DRUG|Acetaminophen|
223668318|NCT03104816|DRUG|Hydromorphone|
223668319|NCT05783882|DRUG|Prolgolimab|250 mg Q3W
223668320|NCT01997112|DRUG|Paracetamol|
223668321|NCT01997112|DRUG|Placebo oral capsule|
223668322|NCT00150904|PROCEDURE|venous blood puncture|
223668323|NCT02303652|PROCEDURE|Radiofrequency maze procedure|RF energy was used to create continous endocardial and epicardial lesions mimicking most of the left atrial incisions set as described in the Cox Maze III procedure. In all patients a bipolar device was used (Cardioblate BP2 Irrigated RF Surgical Ablation System®, Medtronic Inc, Minneapolis, MN, USA).
223668324|NCT02303652|PROCEDURE|Transthoracic echocardiography|Contemporary to clinical follow up, all patients were evaluated with 2-dimensional transthoracic echocardiography (Philips ultrasound system (iE33®, Andover, MA, USA)) at 3,6,12,24 months in order to specifically monitor the evolution of cardiac chambers dimensions and systolic performance and to record left and right atrial contractility presence.
223668325|NCT04064216|PROCEDURE|Laparoscopic surgery|Patients that will undergo robot assisted laparoscopic surgery and conventional laparoscopic surgery for benign gynecologic disorders will answer 4 questionnaires to assess patient satisfaction, quality of life and cosmesis
223668326|NCT01055067|DRUG|Tivantinib (ARQ 197)|Capsule, 120 mg, BID (360 mg), approximately 112 days
223771267|NCT07024043|PROCEDURE|IPACK and multi-modal analgesic regimen|patients will be put in supine position, the procedure will be performed under complete aseptic precautions and All patients will be divided into three groups:(Group 1) for iPACK block with 0.25% bupivacaine only. (Group 2) for iPACK block with 0.25% bupivacaine and dexamthasone and (Group 3) for iPACK block with 0.25% bupivacaine and dexmedetomidine .
223668327|NCT05881070|BEHAVIORAL|Mobile-health self management|Mobile-health self management
223771268|NCT07025135|BEHAVIORAL|comparison between use of mobile app|Patient-caregiver dyad receive standard care (optimal macrogol treatment) plus a mobile app featuring symptom tracking, medication reminders, dietary tips, and gamification elements.
223771269|NCT07025135|BEHAVIORAL|Patient-caregiver dyad using printed recommendations|Patient-caregiver dyad receives standard care ( optimal macrogol treatment) plus a non-interactive, educational-only printed version of recommendations.
223771270|NCT07023939|DRUG|ART: Atraumatic restorative treatment, SMART: Silver-Modified Atraumatic Restorative Treatment|"ART Group:~Selective caries removal was done using hand instruments-carious dentin was excavated from the axial walls with a spoon excavator, and unsupported enamel was carefully removed using a hatchet. On the pulpal floor, only soft, completely demineralized dentin was removed until firm dentin was reached.~SMART Group:~the surrounding gingival tissues and lips were protected with petroleum jelly to avoid staining and irritation (2) ) one drop of SDF (Advantage Arrest ™, Elevate Oral Care, USA) was placed into a disposable dish, (4) SDF was applied with a bended micro-sponge directly to the affected tooth surfaces for minimum of 60 seconds, (3) excess was blotted with a cotton pellet, (4)and the area was air-dried while maintaining isolation for up to three minutes."
224249617|NCT04512092|BEHAVIORAL|Compassionate Mind Training for Caregivers|CMT-C is a 12-session group program, each lasting about 2,5 hours, which run on a weekly basis. The program is organized across 3 modules: 1) Our mind according to a compassion-based approach (to provide insight into the evolved and socially shaped mind and the affect regulation systems); 2) Compassionate mind training (understanding and cultivating the attributes and competencies of compassion in its three flows, and addressing its fears); and 3) final session (revising key information and practices and its application to the RCH practices/routines). Its sessions have the following structure: 1) Check-in (grounding exercise, reviewing the previous session, sharing the weekly practice); 2) Exploration of the session theme (psychoeducation and experiential practices followed by group opportunities for share experiences and discussion); 3) Check-out (session summary and application to the self, youths and RCH practices, weekly practice challenge, session evaluation, session take-off).
224249618|NCT01533805|OTHER|Pilates exercises with stabilization|This group will focus on exercises with core stabilizing muscles. The frequency will be 16 sessions lasting 1 hour.
224249619|NCT01533805|OTHER|Classic Pilates|This group will make Pilates exercises its focus is on mobilization exercises of the lumbar spine. The frequency will be 16 sessions lasting 1 hour.
224249620|NCT00941174|DRUG|13C5-Calcium-L-Leucovorin|This drug will be used in a clinical trial the objective of which is to determine whether, and to what extent, a physiological concentration of natural folate is absorbed across the large intestine with an intact microflora.
224249621|NCT03918174|DEVICE|Dart splint orthosis|The Dart Splint orthosis was fitted to the subjects in the research group on their first evaluation session. They received oral and written instructions regarding the donning and manner of exercise. Specifically, they were instructed to use the Dart splint orthosis at home. For each 10-minute exercise session, they were asked to perform 5 minutes of radial-extension under resistance and then 5 minutes ulnar-flexion under resistance. In addition, this group was required to fill in a chart at the end of each practice session (morning, noon and evening), throughout the intervention period.
224249622|NCT03918174|OTHER|Conventional treatment|The control group activated the wrist mostly in the sagittal plane. This group was instructed to perform at home active wrist motion similar to that practiced during the supervised therapy sessions. The prescribed instructions were similar to the exercises performed during the sessions. Specifically, they were instructed to exercise at home for 10-minute in each session, three times a day (morning, noon and evening), throughout the intervention period.
224249623|NCT04694391|GENETIC|whole exome sequence|To seek genomic characteristics of relapsed esophageal cancer with whole exome sequence.
224249624|NCT03596944|DRUG|Statin|Prescribed with statins for primary prevention
224249625|NCT03207880|DEVICE|Multi-level pregnancy test|Study participants will be instructed to perform a baseline MLPT immediately prior to administering the first dose of abortion medication and a second MLPT one week later to ascertain the follow-up hCG range. Any woman who obtains a stable or increasing hCG result, when comparing the baseline test result with the follow-up test result, will be instructed to contact safe2choose. Any woman who obtains a decrease in her hCG range, when comparing the baseline test result with the follow-up test result, will be informed that her abortion was a success and she is no longer pregnant.
224249626|NCT02061891|PROCEDURE|Invasive coronary evaluation (Deferred)|Invasive coronary angiography and revascularization (PCI/CABG)
224249627|NCT02061891|PROCEDURE|Invasive coronary evaluation (Acute)|Invasive coronary angiography and revascularization (PCI/CABG)
223668328|NCT02806141|DRUG|Aerosolized plus intravenous colistin|Aerosolized colistin at the dose of 4 mg colistin base activity (CBA)/kg twice daily (8 mg/kg/day) plus intravenous colistin at a dose of 3.5 mg CBA/kg/dose twice daily (7 mg/kg/day)
223668329|NCT02806141|DRUG|Intravenous colistin|Intravenous colistin at a dose of 3.5 mg CBA/kg/dose twice daily (7 mg/kg/day)
223668330|NCT00538083|OTHER|Chocolate|74 grams of single dose solid dark chocolate versus placebo
223668331|NCT00538083|OTHER|Chocolate|22 grams of single dose sugared cocoa, sugar-free cocoa, and placebo
223668332|NCT00538083|OTHER|Chocolate|22 grams of sugared cocoa, sugar-free cocoa, \& placebo given for six weeks
223668333|NCT04349904|DIAGNOSTIC_TEST|Near-Focus Narrow Band Imaging|High Definition White Light Endoscopic Imaging followed by Near-Focus Narrow Band Imaging and target biopsy of 6 areas of the duodenum (2 from the first part and 4 from the second part of the duodenum)
223668334|NCT06044597|DEVICE|SyncAV function on|CRT-D with SyncAV plus activated
223668335|NCT04064125|DRUG|FMX-101|
223668336|NCT04643600|DRUG|L-Arginine, 500 Mg Oral Capsule|The strength test of the the quadriceps muscle, will be measured in all patients on the Biodex isokinetic device. Quadriceps strength testing will be performed on 2 occasions. On one occasion without medication, except those that the patient may take permanently, and on the other 90 minutes after the patient takes 1 tbl of L - Arginine 500 mg on mouth to an empty stomach ,in order to monitor the possible increase in quadriceps strength.
224249628|NCT04525365|PROCEDURE|Pleural aspiration|Pleural aspiration
224249629|NCT00074230|BIOLOGICAL|Autologous Dendritic Cells loaded with MAGE-A3, MelanA and Survivin|Within cohort 1 patients received the vaccine intradermally; in cohort 2 the route of Administration was intravenous Infusion, half of the patients had additional loading with RNA coding for EL-Selektin; in cohort 3 the vaccines was again infused intravenously, the cells were matured not with MCM.mimic as in cohort 1 and 2 but either with TriMix or MCM-mimic plus CD40L-RNA.
224249630|NCT02246322|DEVICE|25G needle|All consecutive patients that will be referred for solid masses to be aspirated will be randomized to be targeted in the 25G needle arm (A), or in the 22G needle arm (B).
223668337|NCT05857280|DEVICE|EXOPULSE Mollii Suit Stimulation|"We designed a randomized crossover, sham-controlled, double-blind trial to demonstrate the improvement of motor functions and MS related symptoms following a single session of active versus sham EXOPULSE Mollii suit stimulation. in phase 1, the patient will receive two stimulations separated by a two-week washout period. The patients will be randomized to receive either active/sham or sham/active and both patients and investigators will be blinded to the order in which the stimulation will be given. A 2-week washout period should be enough to prevent a potential carry over effect. Two weeks after the end of phase 1, a second open label phase (phase 2) of this trial will be proposed to all patients where they will receive active stimulation every other day at home over four weeks (for a total of 14 sessions). This will help understand the long term effects of EXOPULSE Mollii suit stimulation on MS related symptoms."
223668338|NCT01227629|DRUG|dabigatran with ASA|dose comparison in combination
223668339|NCT01227629|DRUG|dabigatran with ASA|dose comparison in combination
223668340|NCT01227629|DRUG|dabigatran with ASA|dose comparison in combination
223668341|NCT01227629|DRUG|dabigatran with ASA|dose comparison in combination
223668342|NCT01227629|DRUG|dabigatran with ASA|dose comparison in combination
223668343|NCT01227629|DRUG|dabigatran with ASA|dose comparison in combination
223668344|NCT01227629|DRUG|warfarin|comparator
223668345|NCT01227629|DRUG|dabigatran without ASA|dose comparison
223668346|NCT01227629|DRUG|dabigatran without ASA|dose comparison
223668347|NCT01227629|DRUG|dabigatran without ASA|dose comparison
223668348|NCT03777462|DRUG|Neoadjuvant gemcitabine plus nab-paclitaxel|Neoadjuvant gemcitabine plus nab-paclitaxel is used in the intervention group for 3 cycles. Standard doses of gemcitabine and nab-paclitaxel are adopted. Surgical resection will be performed after neoadjuvant chemotherapy.
223668349|NCT03777462|DRUG|Neoadjuvant gemcitabine plus nab-paclitaxel with SBRT|Neoadjuvant gemcitabine plus nab-paclitaxel with SBRT is used in the intervention group for 3 cycles. Standard doses of gemcitabine and nab-paclitaxel are adopted. The radiation dose of SBRT is 7.5-8Gy/f for 5 fractions. Surgical resection will be performed 3 weeks after SBRT.
223668350|NCT03777462|DRUG|Neoadjuvant S-1 plus nab-paclitaxel with SBRT|Neoadjuvant S-1 plus nab-paclitaxel with SBRT is used in the intervention group for 3 cycles. Standard doses of gemcitabine and nab-paclitaxel are adopted. The radiation dose of SBRT is 7.5-8Gy/f for 5 fractions. Surgical resection will be performed 3 weeks after SBRT.
223668351|NCT04320030|DRUG|[18F]-DPA-714 PET/CT scan|Pretherapeutic \[18F\]-DPA-714 PET/CT scan
223668352|NCT03470727|DEVICE|Citrate dialysate|Change form acetate to citrate dialysate
223668353|NCT06946199|BIOLOGICAL|cizutamig|Cizutamig will be dosed according to the assigned group.
223668354|NCT00060554|DRUG|fondaparinux sodium|
223668355|NCT00060554|DRUG|heparin|
223668356|NCT00060554|PROCEDURE|percutaneous coronary intervention (PCI)|
223668357|NCT04650880|DIETARY_SUPPLEMENT|Vitamin D|Vitamin D supplementation
223668358|NCT04650880|OTHER|Placebo|Placebo tablets with the same external appearance
223668359|NCT03338959|BIOLOGICAL|Pembrolizumab|Given IV
223668360|NCT03338959|RADIATION|Radiation Therapy|Undergo radiation therapy
224249631|NCT02246322|DEVICE|22G needle|All consecutive patients that will be referred for solid masses to be aspirated will be randomized to be targeted in the 25G needle arm (A), or in the 22G needle arm (B).
224249632|NCT03985267|BEHAVIORAL|Mindfulness based Swinging Effect Intervention|Participants will receive psycho-education about mindfulness and how it operates. That will also assist patients to warm up for the actual intervention. Then the actual swinging effect intervention will commence respectively.
223668361|NCT00125346|DRUG|Tobramycin Inhalation Powder|
223668362|NCT05461378|DRUG|Evusheld|Participants who have received or plan to receive Evusheld.
223668363|NCT05146453|PROCEDURE|Pectointercostal fascia blocks|PIF blocks will be placed at the conclusion of surgery with the surgical drapes in place. The blocks are performed using a high frequency linear transducer with aseptic technique. The ultrasound probe is placed longitudinally 3 cm from the sternum at the level of the 4th-6th intercostal space. Using an in-plane approach, an echogenic needle will be advanced into the fascial plane between pectoralis major and the external intercostal muscles. Peripheral nerve block catheters will then be inserted and secured to the skin surface with tegaderm. For patients weighing over 70 kg, 20 mL of 0.5% ropivacaine will be administered. This will be reduced to 15mL per side for patients weighing less than 70 kg. A CADD™ pump will be connected to each catheter and programmed to deliver 20 mL boluses of ropivacaine 0.2% starting at postoperative hour 2. The boluses will be staggered every 2 hours on alternate sides until hour 24. The catheters will be removed 24 hours post-operatively.
223668364|NCT05146453|OTHER|Placebo|The control group patients will receive the same intraoperative analgesia management. A PIF block will not be performed, instead, a peripheral nerve block catheter will be secured to the skin surface and connected to a CADD™ pump. As the catheter is taped to the skin surface the control group patients will not be exposed to the risks of peripheral nerve block placement.
224249633|NCT03921463|OTHER||This is an observational study
224249634|NCT01773590|OTHER|Rhinovirus Infection|
224249635|NCT02883413|BEHAVIORAL|CRT + Teach the Parent|CRT sessions will occur for 45-60 minutes every day (excluding weekends) for 6-8 days while adolescents are in hospital. Adolescents will be given homework and asked to practice tasks each day.
223668365|NCT02555501|OTHER|PDT + Low level laser|"Two days before the laser treatment, the side of the oral cavity chosen for the experimental treatment was pigmented with aqueous solution of 0.005% methylene blue. A ball of sterile cotton was soaked in the dye solution and placed in the center of the lesion. Photosensitizer remained in the place for 5 minutes (pre-irradiation period). Then, to activate the dye, the lesion was irradiated with red light (InGaAlP / phosphide and Indium, Gallium and potassium).~From the 3rd to the 10th day was carried out only laser therapy. For laser therapy was first used infrared emitter laser unit with active medium AsGaAl (Gallium Arsenide and Aluminium). Then, we used the red emitter, whose active medium was the InGaAlP (phosphide and Indium, Gallium and Potassium)."
223668366|NCT02555501|RADIATION|Low level laser|Two days before the laser treatment, the lesion of the side of the oral cavity chosen for the control treatment was treated with ball of sterile cotton soaked in distilled water and the laser unit placed on the lesion without activation of the light. From the 3rd to the 10th day was carried out laser therapy. For laser therapy was first used infrared emitter laser unit with active medium AsGaAl (Gallium Arsenide and Aluminium). Then, we used the red emitter, whose active medium was the InGaAlP (phosphide and Indium, Gallium and Potassium).
223668367|NCT03626298|DRUG|Adapalene|third-generation topical retinoid primarily used in the treatment of mild-moderate acne. It is effective against acne conditions where comedones are predominant.
223771271|NCT07025525|DEVICE|Ultrasonic activated sodium hypochlorite|Using ultrasonic-activated sodium hypochlorite in the canals of primary molars can significantly enhance root canal disinfection by improving the irrigant's penetration and effectiveness. Primary molars often have complex and irregular canal anatomies, which can limit the reach of traditional irrigation methods. Ultrasonic activation creates acoustic streaming and cavitation effects, allowing sodium hypochlorite to better dissolve organic tissue and disrupt bacterial biofilms, especially in hard-to-reach areas. This leads to more thorough cleaning, reduced microbial load, and potentially better clinical outcomes in pediatric endodontics
223771272|NCT07025525|OTHER|Ultrasonic acivated saline|using ultrasonic-activated saline within the canals of primary teeth lies in its ability to enhance mechanical debridement and improve irrigation effectiveness without the risks associated with stronger chemical agents. Although saline lacks inherent antimicrobial properties, ultrasonic activation generates acoustic streaming and cavitation, which help dislodge debris, disrupt biofilms, and clean intricate canal anatomy more efficiently than passive irrigation. This makes it a safer alternative in pediatric patients, minimizing the risk of cytotoxic effects or damage to developing permanent tooth buds while still improving cleaning outcomes.
223771273|NCT07025525|OTHER|Sodium Hypochlorite Solution|using sodium hypochlorite (NaOCl) within the canals of primary molars is its excellent antimicrobial and tissue-dissolving properties, which are essential for effective root canal disinfection. Primary molars often have complex and irregular canal systems that harbor bacteria and necrotic tissue. Sodium hypochlorite not only helps eliminate a broad spectrum of microorganisms but also dissolves organic debris, improving canal cleanliness and reducing the risk of post-treatment infection. When used in appropriate concentrations, it can significantly enhance the success of pulpectomy procedures in pediatric patients while maintaining safety.
223771274|NCT07025525|OTHER|Saline|Saline is commonly used as an irrigant in the root canal treatment of primary molars due to its excellent biocompatibility and safety profile. It is a non-toxic, isotonic solution that poses no risk to the surrounding periapical tissues, which is particularly important in primary teeth where root resorption and open apices are common. This minimizes the chance of damaging the underlying permanent tooth germ, a critical consideration in pediatric dentistry. Saline is also safe if accidentally extruded beyond the apex or ingested, making it a suitable choice for young children.
223771275|NCT07023406|BEHAVIORAL|Disfrutando|Disfrutando is a six-week, weekly intervention with a booster intervention at week 12. Intervention content includes glucose control with individual goals, glucose monitoring and glucometer practice, healthy eating demonstrations, benefits of physical activity, prevention and management of T2DM. The intervention has a strong focus on mitigating barriers and challenges to diabetes self-care management.
224249636|NCT02883413|BEHAVIORAL|CRT + Contact Control|Adolescents will be asked to spend 3-4 sessions with their parents engaging in fun activities (games, coloring, trivia). Adolescents will be able to choose 2 tasks from a list and be asked to engage in those tasks with their parents.
224249637|NCT00569153|DRUG|TAK-700|"Phase 1 portion of study:~TAK-700 dose escalation. Tablets administered orally, twice daily until disease progression or occurrence of an unacceptable adverse event.~Phase 2 portion of study:~Patients will receive one of 4 treatments:~* TAK-700 at 300 mg twice/day~* TAK-700 at 400 mg and 5 mg prednisone twice/day~* TAK-700 at 600 mg and 5 mg prednisone twice/day~* TAK-700 at 600 mg once/day in the morning"
224249638|NCT02294253|DRUG|Buprenorphine/naloxone|30 day oral Buprenorphine/naloxone
224249639|NCT01010542|DRUG|ILV-095 300 mg in a 4 to 1 ratio|Single dose of ILV-095 300 mg
224249640|NCT01010542|DRUG|ILV-095 300 mg in a 4 to 1 ratio|Single dose of Placebo
224249641|NCT01808794|DEVICE|Mucograft|Mucograft Collagen Matrix
223668368|NCT03626298|DRUG|Nicotinamide, ABA and Zinc PCA|combination of three non-antibiotic active ingredients of nicotinamide, anti-bacterial adhesive agent (ABA) and zinc, or abbreviated as ANAZ to be well-tolerated by patients with acne vulgaris
223668369|NCT03626298|DRUG|Placebos|Placebo cream. to resemble an active medication or therapy so that it functions as a control; this is to prevent the recipient(s) and/or others from knowing (with their consent) whether a treatment is active or inactive, as expectations about efficacy can influence results.
223668370|NCT04044144|DIETARY_SUPPLEMENT|Probiotic Dietary Supplement|Dietary supplement containing a combination of 8 probiotic strains
224249642|NCT01808794|DEVICE|Dynamatrix|Dynamatrix
224249643|NCT05088343|DRUG|Rosuvastatin|Single oral dose of rosuvastatin on Day 1 or co-administered with hetrombopag on Day 11.
224249644|NCT05088343|DRUG|Hetrombopag|7.5 mg hetrombopag was administered on Day 6 to Day 11.
224249645|NCT04920929|DEVICE|Hydrophilic Biomaterial|PICC made out of a Hydrophilic Biomaterial
224249646|NCT04920929|DEVICE|Thermoplastic Polyurethane|PICC made out of a thermoplastic polyurethane material
224249647|NCT03407781|DRUG|68Ga-BBN-IRDye800CW|PET/NIR fluorescent imaging-guided surgery
224249648|NCT01745120|GENETIC|LentiGlobin BB305 Drug Product|Transplant of autologous hematopoietic stem cells transduced with LentiGlobin BB305 lentiviral vector.
224249649|NCT03956862|DRUG|GB001|film-coated oral tablet
223668371|NCT02603796|OTHER|3D Scan of nares|3D scan of subjects nose prior to implementation of ncpap and upon discontinuation of ncpap.
223668372|NCT01604278|DRUG|NVA237 50 µg and indacaterol 150 µg|NVA237 50 µg and indacaterol 150 µg supplied as blistered capsules for inhalation.
223668373|NCT01604278|DRUG|Placebo to NVA237 and indacaterol 150 µg|Placebo to NVA237 and indacaterol 150 µg supplied as blistered capsules for inhalation.
223668374|NCT05167383|DEVICE|VRH (Virtual Reality Hypnosis)|Hypnosis is delivered as a standardized therapeutic intervention through virtual reality, using a digital sedation software (AQUA ®, Onfomfort SA).
223668375|NCT05167383|BEHAVIORAL|Standard care|The standard treatment (ST) for labor pain as used in our hospital contains massage, aquatherapy and postural exercises. This is always available for any woman in labor.
223668376|NCT05832775|BIOLOGICAL|MRx0029|Megasphaera massiliensis MRx0029 (Treatment A) and Placebo
223668377|NCT05832775|BIOLOGICAL|MRx0005|Parabacteroides distasonis MRx0005 (Treatment B) and Placebo
223668378|NCT00815178|BEHAVIORAL|Inspiratory muscle training|For Inspiratory muscle training (IMT)patients carried out the IMT on a daily basis for eight weeks, with duration of 30 minutes and intensity corresponding to 30% of resting PImax, with a linear pressure resistance device (Threshold®). Weekly maximum inspiratory pressure (PImax) evaluations and workload adjustments were performed. Inspiratory load was adjusted on a weekly basis to maintain 30% of the subject's PImax. Training sessions were carried out at home for both groups and supervised once a week at the hospital.
223668379|NCT00815178|BEHAVIORAL|Inpiratory muscle training placebo|Inspiratory muscle training was carried out on the same basis as in the intervention group but with no inspiratory load.
223668380|NCT04911374|OTHER|Gentle Cleansing Lotion, Revision Skincare|Gentle cleansing lotion to be used by study participants
223668381|NCT04911374|OTHER|Aveeno Face Milk SPF 40+|Sunscreen to be applied after application of face moisturizer and eye cream in the morning. Participants were asked to apply the sunscreen if sun exposure was more than 30 minutes per day.
223668382|NCT03515954|PROCEDURE|Treatment of diffuse ocular surface squamous neoplasia|Excision of the conjunctival tumour was done.Amniotic membrane was secured into conjunctival defects. Postoperative topical MMC 0.04% was given. Response to treatment was monitored clinically and by AS-OCT.
223668383|NCT02933671|PROCEDURE|Suprainguinal fascia iliaca (SIFI) block|An ultrasound guided nerve block using a medication that numbs the nerve called ropivacaine.
223668384|NCT02933671|PROCEDURE|Sham block|An ultrasound guided nerve block using a medication that does NOT numb the nerve called saline, or salt water.
224249650|NCT03956862|DRUG|Placebo|film-coated oral tablet
223771276|NCT07025408|DRUG|KJ101|"1. Clean the wound before applying medication.~2. Apply KJ101 (800U/mL) to the wound.~3. Apply a standard wound dressing after treatment.~4. Apply once daily until complete debridement of necrotic tissue has been achieved. After debridement, apply the medication every other day until the wound closes (maximum treatment duration: 28 days)."
224249651|NCT02062489|DRUG|Tamoxifen|20 mg(2#)/day, PO, daily
224249652|NCT02062489|DRUG|Placebo|2#/day, PO, daily
224249653|NCT00852462|BEHAVIORAL|SAMI|Patients and Health care providers use Symptom Assessment and Management Intervention: patient report symptoms by answering validated questionnaires in a secure online program. The system generates a report for providers that displays symptoms and customized suggestions for their clinical management.
224249654|NCT00914420|DEVICE|Intrepide Trapidil eluting stent|"The INTREPIDE coronary stent system consists of a balloon expandable stent coated with two layers of Trapidil and parylene. The Trapidil eluting stent is pre-mounted on a Nimbus PCTA balloon and is intended for use in the treatment of CAD.~The controlled release of Trapidil is achieved through the parylene barrier, locally delivering the drug to the target lesion, inhibiting smooth muscle cell proliferation and hence neointimal hyperplasia."
224249655|NCT00914420|DEVICE|Taxus drug eluting stent|Paclitaxel Drug eluting stent manufactured by Boston Scientific
224249656|NCT02129426|DRUG|Ketamine|Sedation medication
224249657|NCT02129426|DRUG|Midazolam|Sedation medication
224249658|NCT02129426|DRUG|Dexmedetomidine|Sedation medication
223668385|NCT02933671|DRUG|Ropivacaine|Local anesthetic (numbing drug)
223668386|NCT02933671|DRUG|Saline|Salt water placebo
223668387|NCT02955251|DRUG|ABBV-428|ABBV-428 will be administered by intravenous infusion in 28-day dosing cycles on Day 1 and Day 15.
223668388|NCT02955251|DRUG|Nivolumab|Nivolumab will be administered by intravenous infusion according to approved dose and dosing schedules.
223668389|NCT02099071|DRUG|ACT-389949 1 mg|
223668390|NCT02099071|DRUG|ACT-389949 5 mg|
223668391|NCT02099071|DRUG|ACT-389949 20 mg|
223668392|NCT02099071|DRUG|ACT-389949 50 mg|
223668393|NCT02099071|DRUG|ACT-389949 100 mg|
223668394|NCT02099071|DRUG|ACT-389949 200 mg|
223668395|NCT02099071|DRUG|ACT-389949 500 mg|
223668396|NCT02099071|DRUG|ACT-389949 1000 mg|
223668397|NCT02099071|DRUG|Placebo|
223771277|NCT07025408|DRUG|Chymotrypsin|"1. Clean the wound before applying medication.~2. Apply Chymotrypsin (800U/mL) to the wound.~3. Apply a standard wound dressing after treatment.~4. Apply once daily until complete debridement of necrotic tissue has been achieved. After debridement, apply the medication every other day until the wound closes (maximum treatment duration: 28 days)."
224249659|NCT05258474|DRUG|controlled-ileocolonic-release nicotinamide (SAD/MAD/MD)|single- and multiple-ascending dose (SAD/MAD) or multiple dose (MD)
224249660|NCT05258474|DRUG|Immediate-release nicotinamide (SAD)|single-ascending dose (SAD)
224249661|NCT05258474|DRUG|Placebo controlled-ileocolonic-release nicotinamide (SAD/MAD)|single- and multiple-ascending dose (SAD/MAD)
224249662|NCT05258474|DRUG|Placebo Immediate-release nicotinamide (SAD)|single-ascending dose (SAD)
224249663|NCT04784520|DRUG|HA121-28 tablets|HA121-28 600 mg, po, QD×21 days, every 4 weeks (28 days)
224249664|NCT04089592|DRUG|Dexmedetomidine|intravenous dexmedetomidine 0.6mcg/kg in 100ml normal saline 0.9%
224249665|NCT04089592|DRUG|Fentanyl|intravenous fentanyl at 2mcg/kg in 100ml saline
224249666|NCT00040391|DRUG|Investigational drug|
224249667|NCT00040391|DRUG|Irinotecan|
223668398|NCT06210932|BEHAVIORAL|Social, Emotional, and Ethical Development (SEED) curriculum videos|In response to fulfilling children's urgent psychosocial needs, the Bodhi Love Foundation (BLF) adapted the Kindness Curriculum for young children in Hong Kong by translating it from English to Chinese and adapting its length and content for implementation in the local kindergarten context. The adapted Kindness Curriculum, renamed as Social, Emotional, and Ethical Development curriculum (SEED), A series of videos are developed based on the SEED curriculum, with specific themes for children in K2 and K3, each video last for approximately 10-12 minutes. They will watch three videos per week for a total of four weeks. The videos will be designed to promote social, emotional, and ethical development.
223668399|NCT01744145|OTHER|Interventional 40-60|This group will receive the intervention aged 40-60
223668400|NCT01744145|OTHER|Interventional 60 and above|This group will receive the intervention aged 60 and above.
223668401|NCT00828373|DRUG|Placebo|Immediately before induction, patients will receive 0.15 ml kg-1 of the study drug as an intravenous bolus followed, after tracheal intubation, by a continuous intravenous infusion of 0.2 ml kg-1 h-1. In the Placebo group this will be physiologic saline. The infusion will be stopped after complete recovery from the neuromuscular block.
223668402|NCT00828373|DRUG|Lidocaine|Immediately before induction, patients will receive 0.15 ml kg-1 of the study drug as an intravenous bolus followed, after tracheal intubation, by a continuous intravenous infusion of 0.2 ml kg-1 h-1. In the lidocaine Arm this regimen corresponds to 1.5 mg kg-1 lidocaine bolus injection and 2 mg kg-1 h-1 lidocaine continuous infusion. The infusion will be stopped after complete recovery from the neuromuscular block.
223668403|NCT04514783|DEVICE|Debridement with Debritom+ micro water jet device|"Visits to the outpatient wound-care center as directed by a physician. Wound care performed by the study nurse according to the study-protocol. Each necessary wound debridement will be the same and will be as follows:~* Removal of old dressing~* Woundworks® 3D imaging~* Applying analgesic if necessary~* Applying a soaked gaze with Sodium chloride (NaCl) 0.9% solution on the wound (5 minutes)~* Debridement using Debritom+ micro water jet technology~* Wound cleansing with NaCl 0.9% solution~* Woundworks® 3D imaging~* Application of new dressing (according to the wound healing phases, medical prescription)~In the case debridement is no more required, wound dressing change will be performed as follows:~* Removal of old dressing~* Woundworks® 3D imaging~* Wound cleansing with NaCl 0.9% solution~* Application of new dressing (according to the wound healing phases, medical prescription)"
223668404|NCT04514783|OTHER|Debridement with|"Visits to the outpatient wound-care center as directed by a physician. Wound care performed by the respective study nurse according to the study-protocol. Each necessary wound debridement will be the same and will be as follows:~* Removal of old dressing~* Woundworks® 3D imaging~* Applying analgesic if necessary~* Applying a soaked gaze with NaCl 0.9% solution on the wound (5 minutes)~* Debridement using scalpel and curette~* Wound cleansing with NaCl 0.9% solution~* Woundworks® 3D imaging~* Application of new dressing (according to the wound healing phases, medical prescription)~In the case debridement is no more required, wound dressing change will be performed as follows:~* Removal of old dressing~* Woundworks® 3D imaging~* Wound cleansing with NaCl 0.9% solution~* Application of new dressing (according to the wound healing phases, medical prescription)"
223771278|NCT07025408|DRUG|Placebo (Sodium Chloride Injection 0.9%)|"1. Clean the wound before applying medication.~2. Apply Placebo (Sodium Chloride Injection 0.9%) to the wound.~3. Apply a standard wound dressing after treatment.~4. Apply once daily until complete debridement of necrotic tissue has been achieved. After debridement, apply the medication every other day until the wound closes (maximum treatment duration: 28 days)."
224249668|NCT00040391|DRUG|5-fluorouracil|
224249669|NCT00040391|DRUG|Leucovorin|
224249670|NCT05732857|DEVICE|valveless trocar|the valveless trocar will be used instead of the standard trocar - these trocars are used for insufflation of carbon dioxide into the abdomen
223668405|NCT04076553|BEHAVIORAL|CBT|Participants will complete 12 sessions of CBT
223668406|NCT04076553|BEHAVIORAL|ICT|"Participants will complete 4 weeks of daily inhibitory control trainings and booster ICT trainings following CBT treatment in weeks 5-12"
223668407|NCT00693862|DRUG|levodopa, carbidopa, entacapone|
223668408|NCT00693862|DRUG|levodopa, carbidopa|
224249671|NCT05732857|DEVICE|standard trocar|standard trocar, usually camera port for robotic surgery
224249672|NCT05527548|DRUG|Alendronate (ALN)|The oral ALN is the first-line therapy for osteoporosis, and it has been proven that once-weekly ALN 70 mg is an effective and well-tolerated dose for the treatment of postmenopausal osteoporosis. In this study, after receiving the approval of CREC and the Department of Health, we will purchase ALN from drug store. Previous clinical studies have shown that oral administration of ALN at 70mg/week for 1 year and at 5mg/day for 2 years reduced bone loss in postmenopausal women and patients who underwent total hip arthroplasty, respectively. Therefore, in the proposed study, ALN at the dose of 70mg/week will be given to patients post-ACLR for a duration of 8 weeks.
224249673|NCT00509730|PROCEDURE|Urodynamics|
224249674|NCT06123130|DEVICE|Vectorcardiography (VECG)|Patients enrolled will undergo diagnostic ECG recording: three sets of simultaneous 30s recordings with the investigational device AIMIGo and a standard 12L ECG.
223668409|NCT03086564|BIOLOGICAL|ADCC & TACE|Experimental groups will be given TACE as well as Activated-Dendritic Cells(1-2\*10\^8,intravenous drip),simultaneously.Cyclophosphamide(250mg/cm2,intravenous drip) will be used two days before TACE performed.
223668410|NCT03086564|PROCEDURE|TACE|TACE solely in the first day of a clinical course.
224249675|NCT01526330|DRUG|YH14618|A mg/disc
224249676|NCT01526330|DRUG|YH14618|B mg/disc
224249677|NCT01526330|DRUG|YH14618|C mg/disc
224249678|NCT01526330|DRUG|Placebo|0mg/disc
224249679|NCT06225622|DRUG|Irinotecan Liposome|"In dose escalation study, irinotecan liposome injection will be administered by an intravenous infusion at three doses of 60 mg/m2, 70 mg/m2 and 80 mg/m2, d1, 14 days per cycle. In expansion study, irinotecan liposome injection will be administered by an intravenous infusion at the dose of RP2D, d1, 14 days per cycle.~Until the disease progresses or surgery is possible."
224249680|NCT06225622|DRUG|Oxaliplatin|85 mg/m2, intravenously infusion, d1, 14 days per cycle, up to 12 cycles.
224249681|NCT06225622|DRUG|5-FU|2400mg/m2, intravenous infusion, d1-2, 14 days per cycle. Until the disease progresses or surgery is possible.
224249682|NCT06225622|DRUG|LV|400mg/m2, intravenous infusion, d1, 14 days per cycle. Until the disease progresses or surgery is possible.
224249683|NCT06225622|DRUG|Bevacizumab|5mg/kg, intravenous infusion, d1, 14 days per cycle. Until the disease progresses or surgery is possible.It is used to patients in dose escalation phase and with gene mutation in extension phase.
224249684|NCT06225622|DRUG|Cetuximab|500mg/m2, intravenous infusion, d1, 14 days per cycle. Until the disease progresses or surgery is possible.For wild-type patients in extended phase studies.
224249685|NCT02975622|PROCEDURE|Central venous catheterization|Ultrasound guided central venous catheterization
224249686|NCT03961230|DRUG|Jueyin granules|Put each bag of medicine in the same amount into the same container, pour about 50 ml of warm water, stir until the particles are basically dissolved, and then add appropriate amount of boiling water to dilute.
224249687|NCT03961230|DRUG|Jueyin Granules Placebo|Put each bag of medicine in the same amount into the same container, pour about 50 ml of warm water, stir until the particles are basically dissolved, and then add appropriate amount of boiling water to dilute.
223668411|NCT05883826|BEHAVIORAL|sexual health training|The 16-hour sexual health training will be given for 4 weeks. Case discussions using the PLISSIT Model will be held in the training content.
223668412|NCT03328182|DEVICE|New oral endotracheal tube holder|The single arm study product is designed to hold a standard or subglottic ET tube.
223668413|NCT04367571|OTHER|Osteopathic Manipulative treatment (OMT)|"OMT techniques were focused on correcting the dysfunctions found before each OMT session and included myofascial techniques, balanced ligamentous tension, visceral manipulations and osteopathy in the cranial field.~OMT group will receive a total of 4 sessions, one time each week for 4 weeks. Each session will last 40 minutes. It will be required by the patients to modify their bowels habits. The subjects will be evaluated right at baseline (T0), after one month (T1) after four sessions (T2) and after 1 month after the treatment (T3)."
223668414|NCT04367571|OTHER|Manual Placebo (MP)|"The MP treatment consists of passive touch without joint mobilization in a protocolled order. The practictioners will be standing next to the bed, they'll touch lumbar and dorsal spine of the subjects in prone position for 10 minutes, and then in supine position, they'll touch for 10 minutes the shoulders, the hips, then the neck, the sternum and the chest for 5 minutes each.~MP group will receive a total of 4 sessions, one time each week for 4 weeks. Each session will last 40 minutes. It will be required by the patients to modify their bowels habits. The subjects will be evaluated right at baseline (T0), after one month (T1) after four sessions (T2) and after 1 month after the treatment (T3)."
223668415|NCT03938753|DEVICE|Audéo M90-T|Receiver in the canal (RIC) Hearing aid form Phonak which will be fitted to the participants individual Hearing loss.
223668416|NCT00724880|DRUG|Clopidogrel|Clopidogrel is stopped 5 days prior to surgery
223668417|NCT00724880|DRUG|Clopidogrel|Clopidogrel is stopped 3 days prior to surgery
223668418|NCT00724880|DRUG|Clopidogrel|Clopidogrel is stopped 0 days prior to surgery
223668419|NCT03790423|DRUG|Injection of 18F-ASIS|Each patient will receive one injection of 18F-ASIS (approximately 200 Mbq)
223668420|NCT03790423|OTHER|PET/CT scan|Following one injection of 18F-ASIS the patients will be PET/CT scanned at 1 hour, 2 hours and 4 hours post-injection
223668421|NCT00672659|DRUG|Citalopram + Pipamperone|Citalopram, 40 mg daily, 8 weeks Pipamperone, 5 mg twice daily, 8 weeks
223668422|NCT00672659|DRUG|Citalopram|Citalopram, 40 mg daily, 8 weeks Placebo, dummy, twice a day, 8 weeks
223668423|NCT00476671|PROCEDURE|lumbar puncture, MRI, MRS|lumbar puncture, MRI, MRS are only performed in patients with HIV associated dementia
223668424|NCT04601454|DEVICE|Spinal Cord Stimulation System|Rechargeable Implanted neurostimulation system (neurostimulator and leads) with on-label stimulation parameters.
223668425|NCT01670578|BIOLOGICAL|PRP|
223668426|NCT01670578|DEVICE|Hyaluronic acid|
223668427|NCT04307875|DIAGNOSTIC_TEST|Blood pressure measurement (sphygmomanometer)|measuring blood pressure with standard sphygmomanometer
223668428|NCT04307875|DIAGNOSTIC_TEST|Blood glucose measurement|measuring blood glucose using standard measurement devices
223668429|NCT04307875|OTHER|psychometric tests|WHODAS 2.0, PHQ-9, CAPS-5
223668430|NCT00762424|DRUG|Flowmax|0.4 mg once a day until stone passage total = 9 tablets
223668431|NCT00762424|DRUG|placebo|cornstarch
223668432|NCT05010642|DEVICE|Use of Eko DUO electronic Stethoscope|Auscultation of heart sounds using electronic stethoscope
223668433|NCT01926327|BIOLOGICAL|PRP injection|Injection of PRP in patients with knee osteoarthritis.
223668434|NCT01926327|BIOLOGICAL|Placebo|
223668435|NCT00912665|DEVICE|Laser Doppler Flowmetry|blood flow measurements at the temporal neuroretinal rim to assess optic nerve head blood flow
224249688|NCT01537640|BIOLOGICAL|SAR231893 (REGN668) DP1|Pharmaceutical form:solution Route of administration: subcutaneous
224249689|NCT01537640|BIOLOGICAL|SAR231893 (REGN668) DP2|Pharmaceutical form:solution Route of administration: subcutaneous
224249690|NCT04366401|BEHAVIORAL|Conventional Dietary Advice|"The education content in the control group will be centered on the acquisition of knowledge about:~* \- Underlying mental pathology, lifestyles and associated comorbidities~* \- Immediate principles: Carbohydrates, lipids, proteins, fiber, vitamins, and minerals; energy needs; consumption requirements.~* \- Water requirements.~* \- Foodstuffs.~* \- Culinary techniques: conservation of properties of the diet.~* \- Feeding in particular situations."
223668436|NCT00912665|DEVICE|Goldmann applanation tonometer|intraocular pressure measurements
223668437|NCT00912665|OTHER|squatting|Subjects will perform squatting for 6 minutes while either blood flow or intraocular pressure measurements
223668438|NCT00912665|DEVICE|Suction cup|Experimental stepwise increase of intraocular pressure while either optic nerve head blood flow or intraocular pressure measurements
223668439|NCT01650012|DRUG|eplerenone|target 50 mg per day titrated down for hyperkalemia or hypotension
223668440|NCT01650012|DRUG|Placebo|Placebo
223668441|NCT03033498|DRUG|ABBV-951|ABBV-951 administered by subcutaneous infusion.
223668442|NCT00390026|DRUG|Bevacizumab (Avastin)|
223668443|NCT00390026|DRUG|Verteporfin photodynamic therapy (PDT)|
223771279|NCT07025161|BEHAVIORAL|Pain Coping Information|A 4-minute audio recording providing common pain coping techniques (e.g., ice, rest, medication, surgery).
223668444|NCT06251531|OTHER|Goal-Directed Therapist-Guided Play-Based Intervention (GD-TG-PBI)|The GD-TG-PBI used play to improve performance in targeted functional activities. The program was planned by a physiotherapist with 25 years' experience and an occupational therapist with six years' experience in play. The sessions were based on motor-learning principles supporting cortical plasticity. Individual-specific goals were transformed into play activities that increase occupational participation with regard to the child's abilities, needs, and learning potential. A top-down approach based on direct gamification was adapted without dividing it into components, instead of a component-based, bottom-up approach. Thus, a structured play program was created and an individual-specific intervention was applied in line with the occupational goals and detailed motor evaluations. Positive, active experiences facilitated the adaptation of the learned skills to daily life.
223668445|NCT01643031|DRUG|Ticagrelor|Ticagrelor will be given (to patients with low response to clopidogrel randomized to the Ticagrelor group) at a dose of 180 mg given 1-2 hours before the coronary angiography, followed by 90 mg twice a day for 30 days after the PCI. After 30 days the patient's treatment will be switched back to clopidogrel (to complete 1 year of treatment).
223668446|NCT01643031|DRUG|Continued clopidogrel|Patients with low response to clopidogrel randomized to continued clopidogrel treatment will be given an additional 300 mg of clopidogrel loading 1-2 hours before coronary angiography (in addition to the previous 300 mg load or chronic clopidogrel therapy the patient received), followed by 75 mg a day for 1 year after the PCI
223668447|NCT06086262|DEVICE|Hydraulic hand dynamometer (Jamar, Product model J00105, U.S.A)|"The hydraulic hand dynamometer is a reliable and valid an evaluation tool that's used to measure isometric grip force (hand grip strength) .~The hydraulic pinch gauge is a reliable and valid an evaluation tool that's used to measure isometric pinch force."
223668448|NCT04162782|PROCEDURE|obstetric and gynaecological surgeries|surgeries for gynecologic and obstetric diseases
223668449|NCT03134573|DRUG|Interferon beta-1b (Betaferon, BAY86-5046)|Solution for injection
223668450|NCT03134573|DEVICE|Betaconnect auto-injector|Auto-injector for application of Betaferon solution which automatically covers injection related data
223668451|NCT03134573|DEVICE|myBETAapp|Medical device which can be connected with Betaconnect auto-injector and displays injection related data to patients and offers tracking of patient reported data at the wellness- tracker
223668452|NCT04193696|DRUG|Radiation therapy and systemic anti-PD-1 immunotherapy for patients with advanced hepatocellular carcinoma|The treatment will be started within 1 week after being admitted into the trial. IMRT or SBRT are adopted , and dose of radiation: Dt-PGTV=40Gy/10fractions,Dt-PGTV=30Gy/10fractions,Dt-PGTV=20Gy/10fractions ,and so on.200mg/ of Carelizumab for injection will be given intravenously every 3 weeks for 5 times since the first day of radiotherapy until disease progression, or intolerable toxicity.
223668453|NCT01436617|OTHER|blood sample|The IgE anti cetuximab test will then be conducted by an ELISA test
223668454|NCT00603486|DEVICE|GE DINAMAP with SuperSTAT algorithm monitor|Apply cuff on a limb, cuff is inflated and deflated, monitor will displays non-invasive blood pressure values (systolic, diastolic, MAP, and pulse rate)
223668455|NCT01491438|PROCEDURE|PRGF+ Cleaning, debridement of the wound, application of the corresponding dressing and using of antibiotics if necessary|"PRGF once a week (day 1) and conventional treatment twice a week (days 1 and 4)during 12 weeks.~Types of dressing: enzyme cutting dressing (collagenase), hydrogel, polymeric foam, alginate dressing, hydrocolloid hydrofiber dressing, silver dressing, coal and silver dressing, argentum sulfadiazine dressing, polyurethane or caster hydrocolloid dressing"
223668456|NCT01491438|PROCEDURE|Cleaning, debridement of the wound, application of the corresponding dressing and using of antibiotics if necessary|Twice a week (days 1 and 4) during 12 weeks
223668457|NCT00874939|DRUG|MK-0249 7.5 mg|4 tablets (1 x 0.5 mg + 2 x 1 mg + 1 x 5 mg) totaling 7.5 mg, single oral dose during each crossover period
223668458|NCT00874939|DRUG|MK-0249 25 mg|5 x 5 mg tablets totaling 25 mg, single oral dose during each crossover period
223668459|NCT00874939|DRUG|Donepezil 5mg|One 5 mg tablet, single oral dose during each crossover period
223668460|NCT00874939|DRUG|Placebo to MK-0249|Five tablets, single oral dose during each crossover period
223771280|NCT07025161|BEHAVIORAL|Mindful Pain Management|A 4-minute audio recording consisting of a 1-minute introduction to mindfulness followed by a 1-minute and 30-second mindful breathing practice and a 1-minute and 30-second mindfulness of pain practice.
224249691|NCT04366401|BEHAVIORAL|Prebiotic/Probiotic Dietary Modulation|"The education content in the intervention group will be based on general principles of conventional dietary advice in an intensified manner, centered on the acquisition of specific knowledge about:~* \- Underlying mental pathology, lifestyles and associated comorbidities~* \- Immediate principles: Carbohydrates, lipids, proteins, fiber, vitamins, and minerals; energy needs; consumption requirements.~* \- Water requirements.~* \- Foodstuffs.~* \- Description and justification of prescribed prebiotic and probiotic diet.~* \- Culinary techniques: conservation of properties of the prebiotic and probiotic diet.~* \- Optimal distribution and interchange of foods with high prebiotic and probiotic content.~* \- Feeding in particular situations."
224249692|NCT00410774|BIOLOGICAL|bevacizumab|
224249693|NCT00410774|DRUG|gemcitabine hydrochloride|
224249694|NCT00410774|PROCEDURE|adjuvant therapy|
223668461|NCT00874939|DRUG|Placebo to Donepezil|One over-encapsulated capsule, single oral dose during each crossover period
223668462|NCT04028271|DEVICE|Comfort-in injection system|local anesthesia during dental treatment
223771281|NCT07024121|DIAGNOSTIC_TEST|Patient consulting in spine surgery|Self-administered questionnaire quality of life scales
223771282|NCT07023952|PROCEDURE|Laser Treatment|Minimally invasive laser ablation procedure performed under local anesthesia for pilonidal sinus treatment. Laser energy is delivered through a fiber optic probe inserted into the sinus tract to achieve thermal ablation of the sinus cavity.
223771283|NCT07023952|DRUG|Crystallized Phenol|rystallized phenol is applied directly into the pilonidal sinus channels after cleaning and curettage. The phenol remains in contact for a specified duration before being neutralized with normal saline irrigation.
224249695|NCT02059863|BEHAVIORAL|SPRING|SPRING package: Home visits by community based agents carried out from pregnancy to 2 years of age to encourage key behaviours to promote child growth, survival and development together with regular supervision
224249696|NCT04737486|DRUG|AV-001|AV-001 (mpaBr) Cl for Injection 2.5 mg/mL
224249697|NCT04737486|OTHER|Placebo|D-PBS
224249698|NCT02468284|DRUG|degarelix|
224249699|NCT04656223|COMBINATION_PRODUCT|MF/IND/GLY plus sensor system|"There is no treatment allocation. Patients administered MF/IND/GLY plus sensor system by prescription that have started before inclusion of the patient into the study will be enrolled.~Subjects will receive MF/IND/GLY together with the Propeller add-on sensor for the Breezhaler® according to label."
223668463|NCT04028271|OTHER|conventional injection with dental needle|for local anesthesia during dental treatment
223771284|NCT07041021|DIAGNOSTIC_TEST|Respiratory variation of the Internal Jugular Vein (IJV)|In the study group, the fluid therapy will be guided by the respiratory variation (RV) of the Internal Jugular Vein (IJV) throughout surgery. Fluid maintenance will be continued as long as the IJV diameter is less than 2 cm and the IJV RV is more than 18. If the IJV diameter exceeds 2 cm and the IJV RV is less than 18, fluids will be stopped.
224249700|NCT04656223|DRUG|FDC therapy|There is no treatment allocation. Patients administered FDC therapy by prescription that have started before inclusion of the patient into the study will be enrolled.
224249701|NCT02431221|DRUG|Perhexiline|perhexiline maleate, oral, 25mg or 100mg tablets Whenever initiating PHM therapy, subjects will receive a loading regimen of PHM as indicated in in the Heart Metabolics Dose Justification document. Drug levels will be measured first on Day 4 +/- 1 day, with an initial dose adjustment performed on Day 7 +/- 1 day, as needed. The next sampling will occur on Day 21 +/- 1 day for potential dose adjustment, as advised by the DCC, on or about Day 24. Subsequent dosing will be monitored and advised by a Dose Control Center
224249702|NCT02431221|DRUG|Placebo|
224249703|NCT04888819|DRUG|DWP14012|DWP14012 40 mg, orally, once daily just after a meal up to 4 weeks
224249704|NCT04888819|DRUG|DWP14012|DWP14012 40 mg, orally, once daily before a meal up to 4 weeks
224249705|NCT05963321|DEVICE|TDCS|Two tDCS devices will be used simultaneously. The intervention consists of a tDCS session in which the active electrode will be located in the cerebellum and/or in the primary motor cortex (4 stimulation protocols that will be implemented; active cerebellum electrode and active M1 electrode, sham cerebellum electrode and active M1 electrode, active cerebellum and sham M1 electrode, sham cerebellar electrode and sham M1 electrode) and the cathode in the contralateral supraorbital region.
224249706|NCT00904423|DRUG|Vitamin D|up to 2400 mg; oral tablet
224249707|NCT03045250|DEVICE|Corneal confocal microscopy|Confocal miscroscopy will be used to assess corneal nerve changes due to hyperglycemia.
224249708|NCT03045250|PROCEDURE|Skin biopsy|Skin biopsy will be used to assess the appearance of nerve fibers in subjects with type 1 diabetes.
224249709|NCT03045250|PROCEDURE|Nerve conduction study|Nerve conduction studies will be use to assess for neuropathy.
224249710|NCT03045250|OTHER|Blood draw|Subjects will undergo a one time blood draw for biomarkers.
224249711|NCT03974438|PROCEDURE|Superficial dry needling / Acupunture|Se arm-description.
224249712|NCT02038621|DRUG|Paclitaxel|
224249713|NCT02038621|DRUG|Oxaliplatin and Capecitabine|Before randomization,all enrolled patients underwent 3 cycles XELOX chemotheray. After patients' disease achieved CR\\PR\\SD,then randomized into this clinical trial.
224249714|NCT03609866|PROCEDURE|rapid thoracic compression technique|in the expiratory time of the ventilation set, it will be applied a rapid thoracic compression
224249715|NCT03609866|PROCEDURE|inferior limb passive mobilization|it will be performed a passive mobilization technique on the patient
224249716|NCT01331187|PROCEDURE|Pocket-size ultrasonography|Routinely adding a ultrasound examination of the heart, pleura, great abdominal vessels, liver/gall bladder and kidneys at patients admittance to hospital
224249717|NCT01331187|OTHER|Usual care|No intervention, except for usual care (goal-directed diagnostics)
224249718|NCT00505570|DEVICE|AMPLATZER® PFO Occluder Device|PFO device closure
224249719|NCT00861406|DRUG|Pegylated Interferon-Alfa 2b (PEG Intron)|"Group 1:~6 mcg/kg by injection under skin once weekly for 4 weeks, followed by Maintenance Phase of 3 mcg/kg weekly for 20 weeks.~Group 2:~6 mcg/kg by injection under skin once weekly for 8 weeks, followed by Maintenance Phase of 3 mcg/kg weekly for 16 weeks.~Group 3:~6 mcg/kg by injection under skin once weekly for 12 weeks followed by Maintenance Phase of 3 mcg/kg weekly for 12 weeks."
223771285|NCT07051486|DRUG|SHR-A1811 Injection|SHR-A1811 for injection.
224249720|NCT00861406|DRUG|GP-100 Peptide Vaccine|Injection under skin once every 3 weeks (Weeks 1, 4, 7, 10, 13, 16, 19, and 22), for a total of 8 injections.
224249721|NCT00579670|DRUG|Ziprasidone|Ziprasidone 20mg, 40mg, 60mg, 80mg capsules, hard; Ziprasidone 10 mg/ml oral suspension Ziprasidone 20mg/ml powder and solvent for the reconstitution of solution for injection
224249722|NCT00276133|DRUG|Effects of atorvastatin versus probucol on small dense LDL|
224249723|NCT04438707|OTHER|Pilates Method combined with Therapeutic exercice.|Children must perform specific exercices in this combined method with the pilates principes (for back) during 50 min (1 day per week) for 4 weeks.
224249724|NCT04438707|OTHER|Therapeutic exercise|Children must perform specific exercices without the pilates principes (for back) during 50 min (1 day per week) for 4 weeks.
224249725|NCT03414593|DRUG|Ultrasound guided popliteal sciatic nerve block with 0.2% ropivcaine|Ultrasound guided popliteal sciatic nerve block with 0.2% ropivacaine 20ml
224249726|NCT00440453|OTHER|Nutritional therapy|Nutritional therapy by dietician
224249727|NCT04365153|DRUG|Canakinumab Injection 600mg|Subjects will be given one-time intravenous infusion of 600 mg of canakinumab (8 mg/kg for patients \</= 40 kg) in 250 mL of 5% dextrose infused IV over 2 hours
224249728|NCT04365153|DRUG|Canakinumab Injection 300mg|Subjects will be given one-time intravenous infusion of 300 mg of canakinumab (4 mg/kg for patients \</= 40 kg) in 250 mL of 5% dextrose infused IV over 2 hours
224249729|NCT04365153|DRUG|Placebos|250 mL of 5% dextrose infused IV over 2 hours
224249730|NCT03144505|BEHAVIORAL|MCT combined with RT Group|
224249731|NCT03144505|BEHAVIORAL|HIIT combined with RT Group|
224249732|NCT00438945|DRUG|Eprosartan|
224249733|NCT00850174|DRUG|Oxcarbazepine|600 mg Tablet
224249734|NCT00850174|DRUG|Trileptal®|600 mg Tablet
224249735|NCT01158274|DRUG|gamma-secretase/Notch signalling pathway inhibitor RO4929097|Given orally
224249736|NCT01158274|DRUG|capecitabine|Given orally
224249737|NCT01158274|OTHER|laboratory biomarker analysis|Correlative studies
224249738|NCT04492774|COMBINATION_PRODUCT|Goldic serum|epidural injections
224249739|NCT04492774|DRUG|Steroid injections|epidural injections
224249740|NCT04492774|PROCEDURE|Manual therapy|Veno-lymphatic drainage
224249741|NCT01046474|BEHAVIORAL|lifestyle|"Based on beliefs and behaviors of children sections of education will be delivered via classroom activities.~Activities will be facilitated by trained research assistants. Printed instructions and orientations on the facilitation process will support the assistants' efforts. The activities will require 20 to 30 minutes, and teachers will be encouraged to reiterate the message during their lesson. The goal is to promote ten one-hour sessions of activity for each class.~Children will also be stimulated to increase everyday activities such as walking and playing games at home and school. Also, activities with parents and family members such as walking around the neighborhood on weekends will be promoted."
224249742|NCT02413320|DRUG|Paclitaxel|
224249743|NCT02413320|DRUG|Carboplatin|
224249744|NCT02413320|DRUG|Doxorubicin|
224249745|NCT02413320|DRUG|Cyclophosphamide|
224249746|NCT02413320|DRUG|Docetaxel|
224249747|NCT01922180|RADIATION|Chest CT scans|CT examinations were performed with a commercially available 64-detector row scanner. Images were acquired in supine position after full inspiration and full expiration, using the following parameters: slice thickness, 0.6 mm; pitch, 1.4; rotation time, 330 msec; tube voltage, 120 kiloVolts; and tube current-time product, 100 milliAmperes, with automatic exposure control (CareDose 4D, Siemens Healthcare) switched on. From raw data, 1-mm-thick section images were reconstructed at 0.7-mm intervals by using a high spatial algorithm and a soft-tissue algorithm. The inspiratory CT scan at the time of exacerbation was performed with intravenous iodinated contrast material, whereas the control scan was unenhanced.
224249748|NCT01363765|OTHER|Xpert MTB/Rif|Automatized RT-PCR for the detection of Mycobacterium tuberculosis, the agent of TB, in sputum samples
224249749|NCT01363765|OTHER|Smear microscopy|Sputum smears arriving in the laboratory during the observation period will be submitted to the classic routine smear staining. This would be the non-intervention (control) arm.
224249750|NCT04368520|DIETARY_SUPPLEMENT|Vitamin D3|800 IU Fultium-D3, cholecalciferol (Internis), given daily for 3 months
224249751|NCT04368520|DIETARY_SUPPLEMENT|Vitamin D3|3,200 IU Fultium-D3, cholecalciferol (Internis), given daily for 3 months
224249752|NCT04368520|OTHER|Placebo|Hypromellose capsules, given daily for 3 months
224249753|NCT04131374|BEHAVIORAL|Reminiscence Therapy|Virtual reality scenarios will be used to delivered reminiscence therapy with each caregiving dyad (i.e. person living with dementia; family member).
224249754|NCT01900626|DRUG|epidural catheter|epidural catheter with 0.3% ropivacaine
224249755|NCT00635492|DRUG|exenatide|subcutaneous injection, 5mcg or 10mcg, twice a day
224249756|NCT00635492|DRUG|any human insulin or analog insulin(s) given in any regimen by subcutaneous injection|
224249757|NCT03026374|BEHAVIORAL|Be Resilient to Breast Cancer|This is a supportive-expressive group therapy.
224249758|NCT04546074|DRUG|Pembrolizumab and Imatinib mesylate|"In Phase Ib study:~Level 1: Imatinib mesylate 200mg QD + Pembrolizumab 200mg Q3W, Level 2: Imatinib mesylate 400mg QD + Pembrolizumab 200mg Q3W"
224249759|NCT04546074|DRUG|Pembrolizumab and Imatinib mesylate|In Phase II study, eligible patients receive the dose determined in phase Ib cohort.
224249760|NCT02451267|OTHER|physical therapy treatment with aerobic exercise|neck exercise strengthening program with neck massage and aerobic exercise (leg bicycling with relaxed shoulders)
224249761|NCT02451267|OTHER|physical therapy treatment|neck exercise strengthening program with neck massage
224249762|NCT03968601|OTHER|Mitral regurgitation surgery such as mitral valve replacement or repair|Mitral regurgitation surgery such as mitral valve replacement or repair. All kind of mitral regurgitation surgery: replacement or repair, by median sternotomy of minimally invasive surgery, with or without tricuspid plasty
224249763|NCT04549272|OTHER|No interventions|No interventions - observational study
224249764|NCT00485667|DRUG|SKY0402|Subects received either 300mg or 450mg
224249765|NCT00485667|DRUG|Moxifloxacin 400mg|
224249766|NCT00485667|DRUG|Placebo injection|
224249767|NCT00485667|DRUG|Placebo tablet|
224249768|NCT03134586|OTHER|Diagnostic imaging|
224249769|NCT02045563|OTHER|prise de sang|
224249770|NCT02045563|OTHER|magnetic resonance imaging and magnetic resonance spectroscopy|
224249771|NCT04395586|OTHER|Culture|Culture
224249772|NCT00422214|DRUG|Quetiapine fumarate (Seroquel) SR|
224249773|NCT02881255|DEVICE|Implantable Cardioverter Defibrillator|Patients will be randomized to receive either a subcutaneous or transvenous ICD.
224249774|NCT05206318|DRUG|Topical Cysteamine|Topical cysteamine cream applied to the postinflammatory hyperpigmentation dark spots 15 minutes per day, followed by a face wash and moisturizing cream.
224249775|NCT05206318|DRUG|Topical Vehicle Control|Topical vehicle control cream without cysteamine active ingredients applied to the postinflammatory hyperpigmentation dark spots 15 minutes per day, followed by a face wash and moisturizing cream.
224249776|NCT03239990|BEHAVIORAL|Incredible Years, Parent group supported by home visiting|Parents are taught to use positive and consistent strategies in reducing child misbehavior
224249777|NCT02682784|DRUG|Oxytocin|Nasal spray based on naturally occurring hormone, oxytocin.
224249778|NCT02682784|DRUG|Placebo|
224249779|NCT00327379|DRUG|Trasylol (Aprotinin, BAYA0128)|Infusion of aprotinin (loading dose of 2 million KIU (Kallikrein Inhibitor Units) followed by 500,000 KIU/hour until the end of surgery)
224249780|NCT00327379|DRUG|Placebo|Infusion of placebo (loading dose of 2 million KIU (Kallikrein Inhibitor Units) followed by 500,000 KIU/hour until the end of surgery)
224249781|NCT01702987|DIETARY_SUPPLEMENT|ubiquinol|ubiquinol supplementation was given for 1 month to 12 patients
224249782|NCT01702987|DIETARY_SUPPLEMENT|placebo|placebo (identical in appearance to ubiquinol) was given for 1 month to 9 patients
224249783|NCT01702987|DRUG|statin|statin was given for 1 month to 21 patients
224249784|NCT01344707|DRUG|4SC-202|oral administration dose escalation twice daily (bid)or three times a day (tid) continuous dosing for 21 days per cycle
224249785|NCT06013293|PROCEDURE|Zinc oxide eugeonal based sealer|Zinc oxide-eugenol (ZOE)- based preparations, which have been used in root canal obturation (RCO) for over a hundered years and are known for their antimicrobial activities.slight microleakage and zinc oxide-eugenol's superior antibacterial property,slight microleakage and concerning the lower cytotoxicity, the zinc oxide-eugenol (ZOE) sealer can be used for root canal obturation as an endodontic sealer.After root canal prepartion , the root canal will be dried with paper points and obturated using gutta-percha cones and zinc oxide eugenol sealer.
224249786|NCT06013293|PROCEDURE|Resin Based Sealer|resin-based sealer used frequently as a gold standard for endodontic sealers, due to its good physicochemical properties and provide satisfactory adhesion interface with dentin radicular surface.After root canal preparation, the root canal will be dried with paper points and obturated using gutta-percha cones and Resin based sealer
223668464|NCT03690635|PROCEDURE|VISTA (vestibular incision subperiosteal tunnel acess)|"A vertical incision will be made on the mucous membrane and the periosteum with a scalpel. The incision will be 8-10mm long, beginning from the mobile mucosa and reaching the apical end of the keratinized gingiva.~A small subperiosteal elevator will be inserted through the incision and is used to free the subperiosteal tunnel flap. The flap includes the tissues of the mobile and immobile mucosa in the area of the affected teeth and about 1 mm distally and medially from them.~Subperiosteal tunnel will be extended interproximally under each papilla as far as the embrasure space permits, without making any surface incisions through the papilla.~Tunneling instruments will be used through the vertical incision to free the mucosa and the periosteum around the teeth affected by the gingival recession. This is continues at the base of the gingival papillae without affecting their integrity."
223668465|NCT02870933|BIOLOGICAL|Transepicardial with Transseptal CD 133+ Implantation|Transepicardial with Transseptal CD 133+ Implantation
224249787|NCT03247933|DEVICE|Telemedicine: Maintenance Respiratory Rehabilitation|"Telemedicine: Maintenance Respiratory Rehabilitation. Patients will receive a personal program of maintenance respiratory rehabilitation supported by telemedicine (TeleRR).~A personal program of Respiratory rehabilitation consists on: 20-30 minutes of static bicycle exercises + 3 series of ten repetitions from 4 different types of exercises with weights / cufflinks. 3 days a week, every week for a year.~They will be in their homes doing the program of treatment prescribed by the physician. They will be provided with the material that is needed: 1 static bicycle, 2-weights / cufflinks, 3-device mobile (smartphone/PDA) + Pulse Oximeter.~The patient must send the exercises every day that are scheduled training exercises once have been completed."
224249788|NCT06189833|DRUG|Daratumumab|Daratumumab will be administered via a subcutaneous injection (SC)
224249789|NCT06189833|DRUG|Bortezomib|Bortezomib will be administered via a subcutaneous injection (SC)
224249790|NCT06189833|DRUG|Lenalidomide|Lenalidomide will be administered orally
224249791|NCT06189833|DRUG|Dexamethasone|Dexamethasone will be administered orally
224249792|NCT01736878|DRUG|Sorafenib|
224249793|NCT05029297|DRUG|Capsaicin|
224249794|NCT05287061|BEHAVIORAL|Multicomponent Psychological Program (MPP)|"Patients will receive health pills during hospital admission. This intervention will be brief for individual application, but without specific content for each person, protocolized in its content and tools, and with a cognitive-behavioral orientation. Its therapeutic objective is to provide the patient with immediate control strategies for negative emotions and some pattern of active and positive coping. Two months after hospital discharge, the patients will also receive a multicomponent psychological program of a group nature. Based on motivational interviewing and positive psychology, with two blocks: emotions and consolidation of intentions. Two individual sessions will be carried out at the beginning to be able to do individual orientation, plan the intervention protocol, determine the objectives, the group intervention, and the specific action packages that the patient will receive."
224249795|NCT05910853|DIAGNOSTIC_TEST|Specimen Donation|Blood donation
224249796|NCT05209347|DEVICE|Carbon Fiber Custom Dynamic Orthosis (CDO)|The carbon fiber custom dynamic orthosis will consist of a semi-rigid foot plate, a posterior carbon fiber strut, and a proximal cuff below the knee.
224249797|NCT00318045|DEVICE|Eyeglass lenses|
224249798|NCT04353063|BEHAVIORAL|Multidisciplinary care with a personalized care|During the 4-week intervention, participants will be given stickers by the research assistant to increase their motivation to walk. A sticker will be given once a participant reaches a daily walking-time goal. The number of stickers participants receive depends on the number of days they reach their daily goals. The stickers can be redeemed for the participant's choice of gift in the gift shelf of the ward or on a gift card. A final assessment will be conducted at week 4. The participant will be reminded that the ActiGraph and the post-test questionnaires will be picked up at the end of week 4
224249799|NCT00002880|DRUG|Etoposide phosphate|50 mg PO q day for 21 days; repeat every 28 days escalate dose to 100 mg PO q day if ANC remains greater than 1500/microliter during cycle 1: no specified maximum of cycles if PR or CR
224249800|NCT04813692|PROCEDURE|Surgical repair|Surgical repair of post-infarction LVFWR or VSR
224249801|NCT04813692|PROCEDURE|Percutaneous treatment|Percutaneous closure of post-infarction VSR (or treatment for LVFWR)
224249802|NCT04813692|PROCEDURE|Mitral valve surgery|Mitral valve repair or replacement for post-infarction PMR
224249803|NCT06156644|DEVICE|PFA|Ablation to treat trail fibrillation
223668466|NCT01313741|DEVICE|Shoulder arthroplasty with anchor peg glenoid|Shoulder arthroplasty with anchor peg glenoid
224249804|NCT04533594|BEHAVIORAL|NOVELA|The family caregivers that consent to participate will work with the interventionist to use a web-enabled device (computer, smartphone or tablet) to access and view the telenovela video (one of four episodes, each 3-6 mins) over the course of 4 hospice visits (one episode per visit). All four visits will be in person using telehealth via video-conferencing. The number of visits is based on the number of videos which content is prioritized based on previous work. The interventionist will introduce the purpose and topic of the video, facilitate video viewing and then elicit clarifying questions and reinforce main message.
224249805|NCT02938962|DRUG|Tranexamic Acid|
224249806|NCT05305430|DEVICE|Synergy Cervical Disc System|motion preservation disc
224249807|NCT06278844|DEVICE|Conduction system pacing|In the conduction system pacing group, the right ventricular lead will be placed in a septal position to achieve conduction system pacing, either His bundle pacing (HBP) or left bundle branch area (LBBA) pacing. In the usual care group, the right ventricular lead will be placed in the right ventricle apex as usual.
224249808|NCT06278844|DEVICE|Right ventricular apical pacing|This is the usual care group. Patients will receive a pacemaker device with the right ventricular lead inserted in the apex and not in the septal position.
224249809|NCT01650974|DEVICE|HFNOT|high flow nasal oxygen therapy
224249810|NCT00056667|BEHAVIORAL|Relaxation response and cognitive behavioral therapy|The cognitive behavioral therapy program wwill incorporate relaxation training, a modified version of the RA treatment program developed by Bradley et al (1987) and shown to be effective. The cognitive behavioral techniques include problem solving, relabeling, enhanced awareness of pain behaviors, and attention refocusing. The RR component includes instruction in diaphragmatic breathing along with progressive skeletal muscle relaxation. The intervention will be modified from the original program in that neither biofeedback training nor participation of family members will be included. Consequently, the number of weekly group sessions will be reduced from 14 to 12. Homework will be given at the end of each session, to be completed and brought in for review to the next session.
223668467|NCT03560700|DIETARY_SUPPLEMENT|lactobacillus probiotic strain|Approved Dietary supplement
223668468|NCT03560700|OTHER|placebo|placebo comparator
223668469|NCT05371847|OTHER|assessment for upper limb dysfunction|clinical assessments and questionnaires
223668470|NCT05371847|OTHER|retest assessment|For the test-retest reliability testing, participants will be invited to have an additional appointment approximately 1 week after the main assessment.
223668471|NCT03322319|PROCEDURE|Tissue biopsies|"It is commonly accepted that the diagnosis of cardiac amyloidosis may be based on presence of characteristic cardiac abnormalities in echography, associated with the detection of bi-refractive appearance deposits in polarized light after congo red staining of a biopsy fragment.~Usually a biopsy of the abdominal fat or salivary glands can suffice. More rarely, in case of persistent doubt (eg negativity of congo red despite a characteristic appearance, which may occur in 20 to 30% of cases), it will be necessary to perform an endomyocardial biopsy (EMB)."
223771286|NCT06751147|OTHER|Group A|"It consists of 24 patients who were assessed by prone knee bend (PKB) test and knee range of motion was measured by goniometer. In addition to traditional physical therapy and muscle energy procedures, patients in this group received neural mobilization. The patient laid on their side with their knee bent to a 90-degree angle and the affected side looking up while neural mobilization was carried out. The therapist then performed the technique by abducting and extending the patient's hip. Five repetitions of the nerve stretch were performed, each with a 10-second hold and a 5-second rest in between.~METs were implemented in two positions using post-isometric relaxation (PIR): In this initial posture, the patient laid on their back with the affected leg just over the bed's edge. With one hand, the physiotherapist stood facing the affected side and pressed the contralateral ASIS to keep the patient from rolling off the bed. The therapist, however, simultaneously grabbed the femur dist"
223771287|NCT06751147|OTHER|Experimental Group B|It involves 24 patients who had received the neural mobilization described above along with traditional physical therapy that does not involve muscular energy techniques. The treatment took place in the outpatient physical therapy department and lasted around thirty minutes in total
224249811|NCT00056667|BEHAVIORAL|Relaxation response|The relaxation response (RR) consists of a set of integrated physiological changes elicited when a participant engages in the repetitive mental action of focusing on a word, phrase, or image, while passively ignoring distracting thoughts. These changes include decreased oxygen consumption, heart rate, arterial blood pressure, respiratory rate, and arterial blood lactate, along with slight increases in skeletal muscle blood flow. The long-term physiologic changes of participants eliciting the relaxation response are consistent with reduced norepinephrine end organ responsivity. These latter changes provide a plausible psychophysiological mechanism for longer-term actions of the RR.
224249812|NCT00056667|OTHER|RA education|RA education programs have been widely used to supplement routine medical care. They have been found to be of modest benefit, particularly in terms of knowledge about the condition and its treatment. The long-term effects on pain and level of function are less. When used as an attention control, such educational programs have been found to be as credible and as well attended as the active experimental treatment (Professor Francis Keefe, Personal Communication). In this study, patients randomized to the control condition will receive 8 weekly sessions of RA education, in groups of 6-10 patients each, using portions of the Arthritis Self-Management Program and incorporating printed and videotaped materials available from the Arthritis Foundation.
224249813|NCT00622414|BIOLOGICAL|ziv-aflibercept|Given IV
224249814|NCT02307981|OTHER|Training with vision teacher (visual rehabilitation)|Individually adapted training With vision teacher
224249815|NCT03883412|OTHER|Exercise|16 weeks of treatment
224249816|NCT03883412|DRUG|Liraglutide|16 weeks of Liraglutide
224249817|NCT04461379|BIOLOGICAL|BCG vaccine|A single dose BCG vaccine intradermally (deltoid region of the right arm) 0.1 ml, equivalent to 0.075 mg of attenuated Mycobacterium bovis . (Tokio 172 strain)
224249818|NCT04461379|OTHER|Placebo|A single dose intradermally ((deltoid region of the right arm) 0.1 ml of NaCl 0.9% solution
224249819|NCT04146766|COMBINATION_PRODUCT|eHealth|The study was randomized (wait-list-control), and it was estimated that 60 subjects were randomly assigned to the immediate treatment group and the wait-list-control group. The two groups were tested for baseline before intervention in the eHealth. After the first questionnaire evaluation, the experimental group was involved in the eHealth for three months, and after three months, the experimental group and the waiting intervention control group were post-tested. To assess the effectiveness of the two groups before and after the eHealth . Control group that waits for intervention in the fourth month from the beginning of the fourth month to the end of the sixth month
224249820|NCT02288195|DRUG|Oxaliplatin|130 mg/m² iv drip over 2 hours on day 1, repeated every 21 days.
224249821|NCT02288195|DRUG|capecitabine|"825 mg/m² twice daily administered orally and concurrently with radiation therapy for 5 days per week.~1000 mg/m² po twice daily on days 1- 14 repeated every 21 days in Group A and adjuvant chemotherapy in Group B."
223668472|NCT02452788|OTHER|Pharmaceutical care|Pharmacist-provided education on medication adherence in hemodialysis patients.
223668473|NCT01250496|DRUG|Aminophylline|75 mg of intravenous aminophylline
223668474|NCT01250496|DRUG|Placebo|Matching 0.9 Normal Saline (sterile salt water)administered intravenously.
223668475|NCT03554694|DIETARY_SUPPLEMENT|Prebiotics|Galactooligosaccharides (GOS) (prebiotics) will be consumed by the participants for 4-6 weeks
223668476|NCT03554694|DIETARY_SUPPLEMENT|Maltodextrin (placebo)|Maltodextrin (placebo) will be consumed by the participants for 4-6 weeks
223668477|NCT04495205|BIOLOGICAL|PRF under non-eugenol containing periodontal pack|Platelet Rich Fibrin under non-eugenol containing periodontal pack
224249822|NCT02288195|RADIATION|Radiation|The total dosage was 46Gy consisted of 23 fractions of 2 Gy to clinical target volume without a boost dose and with the boost 4 Gy consisted of 2 fractions of 2 Gy to gross tumor volume by IMRT or 3D-CRT.
223668478|NCT04495205|OTHER|Non-eugenol containing periodontal pack|Non-eugenol containing periodontal pack after gingival depigmentation
223668479|NCT03129399|DEVICE|King Vision video laryngoscope|nasal intubation using King Vision video laryngoscope Device after general anesthesia induction
223668480|NCT03129399|DEVICE|McGrath MAC video laryngoscope|nasal intubation with McGrath MAC video laryngoscope Device after general anesthesia induction
223668481|NCT00081094|PROCEDURE|18F-Fluorodeoxyglucose-PET (FDG-PET)|
223668482|NCT00081094|PROCEDURE|11Carbon-Acetate-PET|
223668483|NCT01697410|DRUG|Terlipressin|continuous infusion of terlipressin (0.66ug/min-2.66ug/min) ,dosage modified acorrding to blood pressure
223668484|NCT01697410|DRUG|Norepinephrine|continuous infusion with dose 7.5ug/min-30ug/min,modified acorrding to blood pressure
223668485|NCT03663400|DIAGNOSTIC_TEST|GWAS analysis by Illumina BeadChip|will generate comprehensive genotype data for patients. Samples will be used for transcriptional profiling, microbiota profiling by 16S analysis and immunological profiling by flow cytometry
223668486|NCT06084975|PROCEDURE|Splenic vessels preservation|preservation the splenic vessels
223668487|NCT03706547|BIOLOGICAL|anti-CD19/BCMA CAR-T cells|Retroviral vector-transduced autologous T cells to express anti-CD19 and anti-BCMA CARs
223668488|NCT03706547|DRUG|Fludarabine|30mg/m2/d
223668489|NCT03706547|DRUG|Cyclophosphamide|300mg/m2/d
223668490|NCT03011944|OTHER|Quality Improvement Program|Nutrition screening, Nutrition consult, Oral Nutritional Supplement will be implemented in the Home Health branches as standard of care.
223668491|NCT02775019|DIETARY_SUPPLEMENT|Lactobacillus reuteri|2 x daily repeated consumption of a lozenge containing 10E9 CFU Lactobacillus reuteri for 42 days
223668492|NCT02775019|DIETARY_SUPPLEMENT|Placebo|2 x daily repeated consumption of a lozenge being void of Lactobacillus reuteri for 42 days
223668493|NCT03249662|PROCEDURE|bupivacaine 200 mg|bupivacaine 200 mg ketorolac 30 mg epinephrine 400 mcg add NSS to 80 ml divided to two syringes for bilateral periarticular infiltration
223668494|NCT03249662|DRUG|bupivacaine 100 mg|bupivacaine 100 mg ketorolac 30 mg epinephrine 400 mcg add NSS to 80 ml divided to two syringes for bilateral periarticular infiltration
223668495|NCT03886545|OTHER|Assessment of physical and functional capacities|Comparaison of physical and functional capacities between caregivers with work-related musculoskeletal disorders of the shoulder healthy subjects matched in age and gender;
223668496|NCT01593267|PROCEDURE|coil embolization|Subjects randomized to endovascular therapy will be treated by one of two neurosurgeons expert in such treatment. All endovascular treatments will be accomplished using accepted techniques.
223668497|NCT01593267|PROCEDURE|clip occlusion|Subjects randomized to surgical therapy will receive treatment from one of two neurosurgeons expert in surgery for ruptured aneurysms.
223668498|NCT01131819|DEVICE|Nintendo Wii fit ™ balance board|Nintendo Wii fit ™ balance board will be introduced for a period of at least 20 minutes but not greater than 30 minutes per day to all the subjects for a minimum of 6 times in two weeks and a maximum of 18 times in 6 weeks.
223668499|NCT01491113|DRUG|Levetiracetam 250 mg|Tablet containing Levetiracetam 250 mg
223668500|NCT01491113|DRUG|Levetiracetam 500 mg|Tablet containing Levetiracetam 500 mg
223668501|NCT00950339|DRUG|omeprazole, 20mg twice daily|"Each patient will undergo 3 phases of drug therapy:~A- 4 weeks of PPI treatment (omeprazole, 20mg twice daily)) B- 4 weeks of H2 blocker treatment (famotidine 40mg twice daily) C- 4 weeks of PPI treatment (pantoprazole 40mg once daily).~At the end of each phase- each patient will undergo the following evaluation:~Platelet reactivity"
223668502|NCT00950339|DRUG|famotidine 40mg twice daily|"Each patient will undergo 3 phases of drug therapy:~A- 4 weeks of PPI treatment (omeprazole, 20mg twice daily)) B- 4 weeks of H2 blocker treatment (famotidine 40mg twice daily) C- 4 weeks of PPI treatment (pantoprazole 40mg once daily).~At the end of each phase- each patient will undergo the following evaluation:~Platelet reactivity"
223668503|NCT00950339|DRUG|pantoprazole 40mg once daily|"Each patient will undergo 3 phases of drug therapy:~A- 4 weeks of PPI treatment (omeprazole, 20mg twice daily)) B- 4 weeks of H2 blocker treatment (famotidine 40mg twice daily) C- 4 weeks of PPI treatment (pantoprazole 40mg once daily).~At the end of each phase- each patient will undergo the following evaluation:~Platelet reactivity"
223668504|NCT01425463|DRUG|Ferrous (II) Glycine Sulphate Complex|"Oral dose of 567.7 mg Ferrous (II) Glycine Sulphate Complex three times a day (t.i.d) for 12 weeks (equivalent to 300 mg iron element per day for 12 weeks).~Administered orally with water."
223668505|NCT01425463|DRUG|Polyferose|"Oral dose of 150 mg Polyferose Capsules twice daily (b.i.d) for 12 weeks (equivalent to 300 mg iron element per day for 12 weeks).~Administered orally with water."
223668506|NCT01425463|OTHER|Placebo to Ferrous (II) Glycine Sulphate Complex|Administered orally with water.
223668507|NCT01425463|OTHER|Placebo to Polyferose|Administered orally with water.
223668508|NCT06418139|OTHER|No intervention|No intervention added by the study
223668509|NCT04620213|DRUG|Phentolamine Ophthalmic Solution 0.75%|0.75% phentolamine ophthalmic solution (Nyxol), a non-selective alpha-1 and alpha-2 adrenergic antagonist
223668510|NCT04620213|OTHER|Phentolamine Ophthalmic Solution Vehicle (Placebo)|Topical sterile ophthalmic solution
223668511|NCT01180218|PROCEDURE|complete revascularization|-Complete revascularization : one time primary percutaneous coronary intervention (PCI) of the culprit and nonculprit lesions in patient with ST elevateion myocardial infarction (STEMI) and multivessle disease
223668512|NCT01180218|PROCEDURE|Culprit revasularization|Culprit revascularization : PCI of only the culprit lesion and staged nonculprit PCI at a later date in patients with ST-segment elevation myocardial infarction (STEMI) and multivessel disease.
223771288|NCT07085169|DRUG|Trifluridine/tipiracil (TAS-102) plus bevacizumab|Trifluridine/tipiracil will be given at a 17.5 mg/m2 dose orally twice daily in a 14-day cycle consisting of 10 treatment days/4 rest days. Bevacizumab will be given at a 5mg/kg dose intravenously once at day 1 in a 14-day cycle. This is a single-arm study with all patients receiving these two drugs.
224249823|NCT03892408|DEVICE|Optiflow ™|supply of 100 % of oxygen at 70 L / min through Optiflow ™ (Fisher and Paykel Healthcare Limited, Auckland, New Zealand) plus standard oxygen supply through rigid bronchoscope during apnea period.
223668513|NCT02224196|OTHER|manual ventilation|Anesthesia will be induced by propofol 1mg/kg via intravenous line. Once loss of eyelash reflex occurred, ultrasonography of antral area will be started by same physician. After administration of muscle relaxant (rocuronium 0.2-0.4mg/kg), manual ventilation will be performed with respiratory rate 20 breathes/min, I:E ratio of 1:1 and tidal volume with 9-10mL/kg. The pop-off valve will be set at 15cmH2O at fixed gas flow of 500mL/min of oxygen. Pressure-controlled ventilation will be performed with respiratory rate 20 breaths/min, I:E ratio of 1:1 and peak airway pressure will be set to get a tidal volume of 9-10mL/kg. The peak airway pressure during facemask ventilation will be checked. Another physician will auscultate the epigastric area to detect gastric insufflation during facemask ventilation. Ultrasonography of antral area will be checked once again after 3 minutes of facemask ventilation.
223668514|NCT02224196|OTHER|pressure-controlled ventilation|Anesthesia will be induced by propofol 1mg/kg via intravenous line. Once loss of eyelash reflex occurred, ultrasonography of antral area will be started by same physician. After administration of muscle relaxant (rocuronium 0.2-0.4mg/kg), manual ventilation will be performed with respiratory rate 20 breathes/min, I:E ratio of 1:1 and tidal volume with 9-10mL/kg. The pop-off valve will be set at 15cmH2O at fixed gas flow of 500mL/min of oxygen. Pressure-controlled ventilation will be performed with respiratory rate 20 breaths/min, I:E ratio of 1:1 and peak airway pressure will be set to get a tidal volume of 9-10mL/kg. The peak airway pressure during facemask ventilation will be checked. Another physician will auscultate the epigastric area to detect gastric insufflation during facemask ventilation. Ultrasonography of antral area will be checked once again after 3 minutes of facemask ventilation.
223668515|NCT04176653|DRUG|SLN124 is a GalNAc conjugated double stranded fully modified siRNA. Sodium chloride 0.9% w/v is used as Placebo|IMP will be provided as a solution to be injected by qualified clinical staff in patient's abdomen, upper arms or front of the thighs.
223668516|NCT00205920|BIOLOGICAL|BLVR Hydrogel|10 mL BLVR Hydrogel
223668517|NCT00646854|DRUG|CHOP14 chemotherapy (cyclophosphamide, hydroxydaunorubicin, vincristin, prednison) plus G-CSF, combined with alemtuzumab|Cyclophosphamide 750 mg/m2 i.v. on day 1 Hydroxydaunorubicin 50 mg/m2 i.v. on day 1 Vincristin 1 mg/m2 i.v. day 1 (max. 2mg) Prednisone 50 mg/m2 p.o. day 1 to 5 Alemtuzumab 30 mg s.c.on day 1 of CHOP-14 cycles 1-4
223668518|NCT00646854|DRUG|CHOP14 chemotherapy (see specification under Arm B) plus G-CSF|6 cycles of CHOP every 2 weeks
223668519|NCT00712400|DRUG|Latanoprost 0.005%, Xalatan®|Substance: Latanoprost 0.005%, Xalatan® (Pharmacia Austria Ges.m.b.H. Oberlaaer Straße 251, 1101 Vienna) Dosage form: topical application in one eye Dosage: 1 drop in the evening for 14 days
223668520|NCT00712400|DRUG|Placebo|Substance: Vehicle to latanoprost (eyedrops containing the same stabilizers as latanoprost, but no active drug) Dosage form: topical application in one eye Dosage: 1 drop in the evening for 14 days
223668521|NCT03680235|OTHER|Informational Intervention|Receive standard information about breastfeeding and pregnancy
223668522|NCT03680235|OTHER|Informational Intervention|Receive information about breastfeeding and cancer
223668523|NCT03680235|OTHER|Interview|Participate in focus groups
223668524|NCT03680235|OTHER|Survey Administration|Ancillary studies
223668525|NCT06518590|DEVICE|Cycle|Kettler upright bike Giro P:
223668526|NCT02862756|OTHER|diffusion-weighted MRI and clinical examination|
223668527|NCT02706990|DEVICE|Physica KR|Kinematic retaining total knee implant
223668528|NCT02706990|DEVICE|Physica PS|Posterior stabilized total knee implant
223668529|NCT05014061|DRUG|Adenosine|Adenosine infusion 70 µg/kg/min for 6 hours
223668530|NCT05006300|OTHER|Topialyse Baume Barrière|Evaluation of the efficacy of the cosmetic product SVR TOPIALYSE Baume Barrière on the reduction of topical corticosteroid consumption in children from 3 months to 17 years old presenting mild to moderate atopic dermatitis after 28 and 56 days of use, at one or two apllications /day.
223668531|NCT01656356|BIOLOGICAL|Avian Flu Vaccine|
223668532|NCT01656356|BIOLOGICAL|Placebo|
223668533|NCT00205270|DRUG|Influenza vaccine|influenza vaccine 0.5 ml intramuscularly each season
223668534|NCT02395432|DEVICE|orotracheal intubation|
223668535|NCT04610957|DRUG|Rosafem (FEMININE FORMULA)|Rosafem is the only phytoestrogen product with the convenient dose which provides significant improvement of menopausal related symptoms premenstrual syndrome symptoms
223668536|NCT00575341|DRUG|Dehydroepiandrosterone|25 mg DHEA, oral, once daily
223668537|NCT00575341|DRUG|placebo|placebo, oral, once daily
223668538|NCT03707028|DRUG|Rivoceranib|Film-coated tablet
223771289|NCT06908018|BIOLOGICAL|rDEN2Δ30-7169|rDEN2Δ30-7169 is a recombinat virus that could induce viremia and immunological responses with out serious adverse effect. The virus will be challenged after participants screening and consent for hospitalization. After virus challenge, the virological, immunological and clinical manifestation will be recorded and analyzed for the result from day 0-60 post-virus challenge.
223668539|NCT03707028|DRUG|Paclitaxel|Solution administered intravenously
223668540|NCT02974751|PROCEDURE|Aquablation|Aquablation is a minimally invasive transurethral surgical procedure using the AQUABEAM system, a personalized image-guided waterject resection system that utilizes a high-velocity saline stream to resect and remove prostate tissue.
223668541|NCT01413932|DRUG|HT-2157|QD oral dosing
223668542|NCT01413932|DRUG|Placebo|QD oral dosing
223668543|NCT02396160|DIETARY_SUPPLEMENT|Urox|Active treatment - Proprietary combination of Crateva nurvala, Equisetum arvense and Lindera aggregata herbs
223668544|NCT02396160|OTHER|Placebo|Placebo - Identical vegetarian capsule containing color-matched cellulose to that of the active treatment
223668545|NCT03739229|BIOLOGICAL|Placebo|2 intranasal administrations of lyophilized purified allantoic fluid of chicken embryos with stabilizers
223668546|NCT03739229|BIOLOGICAL|H7N9 LAIV|2 intranasal administrations of H7N9 live influenza vaccine
223771290|NCT06909552|OTHER|Educational Video on Voiding Dysfunction|The educational video is a short 3-minute video which describes the condition in detail, at the level that a parent or child could understand without a medical background.
223771291|NCT06908785|DEVICE|Rotational thromboelastometry|rotem
224249824|NCT04055584|DIAGNOSTIC_TEST|Sputum|DNA extraction and perform a diversity of molecular diagnostic tests
224249825|NCT00051233|PROCEDURE|World Wide Web-Based Psychoeducation|
224249826|NCT05070052|BEHAVIORAL|cognitive behavioral therapy|9 sessions of CBT weekly treatment in group setting
224249827|NCT05070052|BEHAVIORAL|mindfulness-based cognitive therapy|9 sessions of MBCT weekly treatment in group setting
224249828|NCT00000885|DRUG|Indinavir sulfate|
224249829|NCT00000885|DRUG|Abacavir sulfate|
224249830|NCT00000885|DRUG|Nelfinavir mesylate|
223668547|NCT05999162|PROCEDURE|Minimally invasive surgery|Minimally invasive surgery includes laparoscopic surgery or robotic surgery for the treatment of colorectal surgery.
223668548|NCT01037621|DRUG|Valacyclovir|Valacyclovir 500 mg, 2 caplets twice daily for eight weeks
223668549|NCT00918008|GENETIC|Blood draw|The research intervention is the blood sample only collected prior to surgery. Analyses of the data will be made by correlating the gene profile expression with the pathologic finding at surgery and the clinical status of the patients 2 years after surgery.
223668550|NCT05170776|OTHER|Pilates and postural correction exercise|"ten exercises will be performed:~1. Hip Twist Level 1~2. Double leg stretch Level 1~3. Double leg stretch Level 2~4. One leg stretch Level 1~5. Clam Level 1~6. Scissors Level 1~7. Arm openings Level 1~8. Breast stroke prep Level 1t~9. Hip Twist Level 1.~10. Breast stroke prep Level 2 as for level 1 postural correction exercise~1-Strengthening deep cervical flexors 2-Stretching cervical extensors 3- Strengthen shoulder retractors 4-Unilateral and bilateral pectoralis stretch"
223668551|NCT05170776|OTHER|Pilates exercises|"ten exercises will be performed:~1. Hip Twist Level 1~2. Double leg stretch Level 1~3. Double leg stretch Level 2~4. One leg stretch Level 1~5. Clam Level 1~6. Scissors Level 1~7. Arm openings Level 1~8. Breast stroke prep Level 1t~9. Hip Twist Level 1.~10. Breast stroke prep Level 2 as for level 1"
223668552|NCT05170776|OTHER|postural correction exercises|"postural correction exercise in the form of :~1. Strengthening deep cervical flexors through chin tucks,~2. Stretching cervical extensors through a chin drop~3. Strengthen shoulder retractors~4. Unilateral and bilateral pectoralis stretch alternating each two-week period."
223668553|NCT03661476|BEHAVIORAL|Oculo-Motor Exercises (OME)|"Oculomotor Exercises (OME); The saccadic eye movement exercise included moving the eyes horizontally between two stationary targets while keeping the head still.~The smooth pursuit exercise included moving the target horizontally and tracking it with the eyes while keeping the head still.~The adaptation X1 exercise included moving the head horizontally while keeping the stationary target in focus.~The adaptation X2 exercise included moving the head and target in opposite directions horizontally while tracking the target with the eyes."
224249831|NCT00000885|DRUG|Efavirenz|
224249832|NCT00000885|DRUG|Levocarnitine|
224249833|NCT00000885|DRUG|Adefovir dipivoxil|
224249834|NCT00000885|DRUG|Lamivudine|
224249835|NCT00000885|DRUG|Stavudine|
223668554|NCT04592718|BEHAVIORAL|Slow deep breathing plus breath counting|Participants will perform a daily 5-min slow deep breathing exercise for 4 weeks. A breathing rate of 6 breaths per minute will be targeted. In addition, participants will count their breaths during the exercise.
223668555|NCT04592718|BEHAVIORAL|Normal-paced breathing plus breath counting|Participants will perform a daily 5-min normal-paced breathing exercise for 4 weeks. A breathing rate of 15 breaths per minute will be targeted. In addition, participants will count their breaths during the exercise.
223668556|NCT02080702|DEVICE|Monosyn|Monosyn will be used to perform the gastrointestinal anastomoses
223668557|NCT03635580|OTHER|Negative control|Untreated-control group
224249836|NCT00000885|DRUG|Zidovudine|
224249837|NCT00000885|DRUG|Didanosine|
224249838|NCT05506007|DRUG|DA-5216|"During the cross-over \[Part A\], patients will be randomly assigned to receive one of the following treatment sequences:~* Sequence I. Single dose of DA-5216-R(Fasting) on Day 1 followed by a single dose of DA-5216(Fasting) on Day 8.~* Sequence II. Single dose of DA-5216(Fasting) on Day 1 followed by a single dose of DA-5216-R(Fasting) on Day 8."
224249839|NCT05506007|DRUG|DA-5216-R|"During the cross-over \[Part A\], patients will be randomly assigned to receive one of the following treatment sequences:~* Sequence I. Single dose of DA-5216-R(Fasting) on Day 1 followed by a single dose of DA-5216(Fasting) on Day 8.~* Sequence II. Single dose of DA-5216(Fasting) on Day 1 followed by a single dose of DA-5216-R(Fasting) on Day 8."
224249840|NCT05506007|DRUG|DA-5216|"During the cross-over \[Part B\], patients will be randomly assigned to receive one of the following treatment sequences:~* Sequence I. Single dose of DA-5216(Fasting) on Day 1 followed by a single dose of DA-5216(Fed) on Day 8.~* Sequence II. Single dose of DA-5216(Fed) on Day 1 followed by a single dose of DA-5216(Fasting) on Day 8."
224249841|NCT05506007|DRUG|DA-5216|"During the cross-over \[Part B\], patients will be randomly assigned to receive one of the following treatment sequences:~* Sequence I. Single dose of DA-5216(Fasting) on Day 1 followed by a single dose of DA-5216(Fed) on Day 8.~* Sequence II. Single dose of DA-5216(Fed) on Day 1 followed by a single dose of DA-5216(Fasting) on Day 8."
224249842|NCT03666728|DRUG|SHR-1210|SHR-1210 was administered 200 mg iv every 3 weeks
224249843|NCT03666728|DRUG|BP102|BP102 was administered 15 mg/kg iv every 3 weeks
224249844|NCT03727828|DIAGNOSTIC_TEST|Patients with heart failure|Participants will have serial blood collection on medical therapy for heart failure
224249845|NCT05419661|OTHER|Operational Pre-Planning|Using a 3D printer, printing of the patient's aneurysm from the segmented 3D images obtained during the initial assessment and thus allowing a simulation of the embolization procedure. This pre-operative planning (PPO) carried out in real conditions aims to anticipate the possible complications that could be encountered on the same day of treatment.
224249846|NCT04100733|DIAGNOSTIC_TEST|Xpert Bladder Cancer Monitor|Xpert Bladder Cancer Monitor detects mRNA fragments from 5 genes frequently overexpressed in non-muscle invasive bladder cancer.
224249847|NCT04100733|DIAGNOSTIC_TEST|Flexible cystoscopy (WL/NBI) and urinary cytology|Adhering to current danish guidelines for follow-up of non-muscle invasive bladder cancer.
224249848|NCT03738605|DEVICE|Microablative Fractional CO2 Laser Therapy|5 laser therapies intravaginally administered will be applied at monthly intervals.
224249849|NCT04123769|DRUG|Hydronidone|First take Hydronidone capsule, single-dose and then Multiple-dose
224249850|NCT03816072|DRUG|Phenylephrine infusion|Correction of anesthesia induced hypotension with phenylephrine to obtain sCA and dCA measurements at 60, 70, 80, 90 and 100 mmHg mean blood pressure. This is achieved by stepwise increases in phenylephrine infusion dose.
224249851|NCT03816072|OTHER|Mechanical ventilation|Patientes are mechanically ventilated at 6 bpm to obtain low frequency blood pressure oscillations (\~0.1 Hz).
224249852|NCT03816072|DRUG|Propofol|Propofol
224249853|NCT03816072|DRUG|Sevoflurane|Sevoflurane
224249854|NCT02167386|BEHAVIORAL|Enhanced PrEP Adherence|
223668558|NCT01698307|OTHER|Enhanced Treatment Algorithm|The Enhanced algorithm features the early use of combined antimetabolite/adalimumab therapy, and treatment intensification based on ileocolonoscopic findings. Failure to achieve or sustain Deep Remission, which includes sustained normalization of the imaging studies, will result in treatment intensification, according to the steps outlined in the algorithm, irrespective of symptoms.
223668559|NCT01698307|OTHER|Conventional Step-care Algorithm|Step-care algorithm that specifies treatment escalation solely on the basis of symptoms quantified using the Harvey Bradshaw Score.
223668560|NCT01811667|DRUG|Sirolimus|
223668561|NCT05860270|DRUG|Cholecalciferol|Patients in the intervention group will receive oral cholecalciferol 4000U per day.
223668562|NCT05860270|DRUG|Placebo|Patients in the control group will receive placebo 2 capsules per day.
223668563|NCT06089369|DRUG|Sintilimab (9 cycles)|IV infusion of Sintilimab （200mg intravenously every 3 weeks for a total of 9 cycles）
223668564|NCT06089369|DRUG|Sintilimab (18 cycles)|IV infusion of Sintilimab （200mg intravenously every 3 weeks for a total of 18 cycles）
223668565|NCT06089369|OTHER|Active surveillance|Active surveillance
223668566|NCT05532670|DEVICE|Non-Invasive Controlled Hypoxia|Following arterial cannulation, hypoxia is induced by reducing the percent of inspired oxygen the subject breathes while simultaneous measurements are recorded from the test pulse oximeters and arterial blood samples are collected at targeted levels of saturation.
223668567|NCT02965092|GENETIC|Second generation CAR-T cells|
223668568|NCT03813368|PROCEDURE|Whipples pancreatico-duodenectomy|Classic whipples and pylorus preserving
223668569|NCT02085642|OTHER|Acupuncture|Single disposal needle to be used, 0.02 mm x 25 mm in length
223668570|NCT02085642|OTHER|Sham needle|Retractable needle with no skin puncture
223668571|NCT01122264|DRUG|Tadalafil|Administered orally for 24 weeks.
223668572|NCT01122264|DRUG|Sildenafil Citrate|Administered orally for 24 weeks.
223668573|NCT04269382|DEVICE|Combined non-invasive intermittent (oscillometric arm cuff), non-invasive continuous (finger cuff and ClearSight device), and invasive continuous (intra-arterial catheter) BP measurements|Continuous (finger cuff) noninvasive and invasive BP measurements, over a 30-min period. Pairs of noninvasive/invasive BP recorded each minute). In the same time, 3 pairs of oscillometric NIBP (cuff placed around a calf), and invasive BP measurements, at 30-sec intervals. The cuff is then placed around an arm and triplets of BP (arm cuff, finger cuff, intra-arterial catheter) will be taken over a 20-min period, at 3-min intervals and every time the invasive and/or the continuous finger cuff measurements cross the threshold of 65 mmHg for the mean BP. If clinically indicated, a cardiovascular intervention that can be either vascular volume expansion or initiation of vasoactive drug therapy, can be administered during this period. Finally, the cuff placed around the arm will be once again placed around the calf to take 3 pairs of oscillometric NIBP measurement with cuff placed around a calf, and simultaneous invasive BP measurement, at 30-second intervals.
223668574|NCT03209674|PROCEDURE|Cardiothoracic surgery|Cardiac or thoracic procedure
223668575|NCT00657410|DRUG|dexamethasone|
223668576|NCT00657410|DRUG|prednisone|
223668577|NCT00657410|PROCEDURE|quality-of-life assessment|
223668578|NCT00546598|DEVICE|Total hip replacement/arthroplasty|Hip replacement
224249855|NCT02167386|BEHAVIORAL|Standard PrEP Adherence|
223668579|NCT02341937|OTHER|Diagnostic tests for suspected deep vein thrombosis|Pre-test clinical probability (Wells score), D-dimer, compression ultrasonography
223668580|NCT02558829|DRUG|Macimorelin|macimorelin acetate, 0.5 mg/kg body weight, drinking solution, single dose
223668581|NCT02558829|DRUG|Insulin|Insulin, 0.10 U/kg (0.15 U/kg if BMI \> 30 kg/m2), intravenous injection, single dose
223668582|NCT03112954|DRUG|Buccal-relaxant formula|Following physical examinations, 60 patients were randomly allocated to 2 groups of 30 patients each, who had been diagnosed with sleep bruxism. Each patient received a small amber glass bottle containing the floral remedy and was instructed to use four drops sublingually 4 times a day for 22 days. All examiners were different professionals, with no contact among each other, as follows: an examiner who conducted the physical examination, an examiner who randomly divided the patients, and an examiner who prepared the floral and placebo remedies. At the end of the study, each group of 30 patients was re-named: Group F, the group of patients who received the floral remedy.
223668583|NCT03112954|DRUG|Placebo|30 patients diagnosed with sleep bruxism received a small amber glass bottle containing the saline solution and was instructed to use four drops sublingually 4 times a day for 22 days. All examiners were different professionals, with no contact among each other, as follows: an examiner who conducted the physical examination, an examiner who randomly divided the patients, and an examiner who prepared the floral and placebo remedies. At the end of the study, each group of 30 patients was re-named: Group P, the group of patients who received the placebo.
223668584|NCT04585009|DRUG|GSK3923868|GSK3923868 will be available as capsules containing inhalation powder blend to be delivered via Monodose RS01 device.
223668585|NCT04585009|DRUG|Matching placebo|Placebo to match GSK3923868 will be available as capsule containing inhalation powder to be delivered via Monodose RS01 device.
223668586|NCT04585009|DEVICE|Monodose RS01|Participants will receive GSK3923868 and placebo as capsules containing inhalation powder blend to be delivered via Monodose RS01 device.
223668587|NCT00532675|DRUG|LBH589|PAN 5 mg and PAN 20 mg capsules
223668588|NCT00532675|COMBINATION_PRODUCT|Lenalidomide|Lenalidomide 5mg or 25 mg
223668589|NCT05853731|DEVICE|Green light emitting diode|Green light therapy via light emitting diode (LED) in the 520 nanometers (nm) range at 4 lux intensity for up to 5 hours per day, as tolerated.
224249856|NCT05362786|DRUG|Allogeneic adipose-derived mesenchymal stem cells (MSC)|Two intravenous infusions delivered systemically through a peripheral IV(over 30 minutes to 2 hours) of 100x10\^6 cells at day 0 and day 84
224249857|NCT05362786|DRUG|Allogeneic adipose-derived mesenchymal stem cells (MSC)|Single intravenous infusion delivered systemically through a peripheral IV(over 30 minutes to 2 hours) of 200x10\^6 cells at day 0
224249858|NCT03502395|DRUG|Lidocaine|): Patients were received intravenous 1 mg/kg of 2 % lidocaine as a loading dose (just before induction of anesthesia) then received 2mg/kg /h lidocaine as maintenance dose (with maximum of 200 mg/h) till the end of the operation (skin closure).
223771292|NCT04965922|BEHAVIORAL|Multimodal intervention|"The intervention consists of identifying the individual needs of each caregiver and patient and identifying sources of improvement in the management of daily life, including the optimization of social support. This optimization requires the involvement of people in the environment (family, friends, neighbours) who can provide help, support of any kind, recurrent or punctual, minimizing negative family interactions and maximizing positive contributions by each in supporting and supporting the individual.~The intervention is personalized in the sense that the content of each session seeks to adapt itself to the specificities of the couple situation and its surroundings.~interviews/meetings involving a psychologist social worker."
223771293|NCT02543905|PROCEDURE|Prostate MRI and Biopsy|All men will be offered a MRI and prostate biopsy and they can either opt to undergo these procedures at baseline irrespective of PSA level at baseline or they can undergo PSA-only screening until clinically indicated based on an age-defined PSA threshold, at which point, they will undergo prostate MRI and biopsy once their PSA reaches the threshold.
223771294|NCT06938152|DRUG|Romosozumab followed by Denosumab|Romosozumab 210mg/month for 12 months, then Denosumab 60mg/6months for 12 months
223668590|NCT05853731|DEVICE|White light emitting diode|Filtered white light via light emitting diode (LED) displayed for up to 5 hours per day, as tolerated
223771295|NCT06938152|DRUG|Romosozumab and Denosumab Cycle Therapy|Romosozumab 210mg/month for 6 months then followed by Denosumab 60mg/6months once, and then repeat one more time after 6 months
223771296|NCT06243497|PROCEDURE|Ultrasound CycloPlasty|All procedures were performed using the EyeOP1 device . The coupling cone was placed and adjusted on the centre of the patient's eye by visualising an equal white scleral ring surrounding the cornea. The coupling cone was kept in place via vacuum suction activated using a foot pedal and was then filled with a balanced salt solution to allow ultrasound transmission. The transducers were automatically activated at a frequency of 21 MHz and an acoustic power of 2.45 W, with an 8-s duration for each sector and a 20-s pause between each treatment to allow complete evacuation of heat.
223771297|NCT02505126|DEVICE|Active tDCS|One daily session (13:20:13) : active current flows continuously twice for 13 minutes with a rest interval (no stimulation) of 20 min 5 sessions (once a week for 5 consecutive days)
223771298|NCT02505126|DEVICE|Placebo tDCS|One daily session (13:20:13) : inactive current flows continuously twice for 13 with a rest interval (no stimulation) of 20 min 5 sessions (once a week for 5 consecutive days)
223771299|NCT02742103|BIOLOGICAL|CSL_112|CSL112 is a novel formulation of apolipoprotein A-I (apoA-I) purified from human plasma and reconstituted to form high-density lipoprotein (HDL) particles.
224249859|NCT03502395|DRUG|Normal saline|A standardized equal volume of intravenous bolus dose of normal saline was given as loading dose then normal saline was administered on an equal rate of infusion.
224249860|NCT01517321|DRUG|MK-0431/ONO-5435|Double-blind period (12 wk); 50 mg QD. The double-blind period will be followed by a 40 week open label extension period where MK-0431/ONO-5435 could be titrated from 50 mg to 100 mg QD.
223668591|NCT05320744|PROCEDURE|surgical extraction of impacted lower third molar|surgical removal of impacted third molar under local anesthesia.
223668592|NCT01337999|OTHER|blood draws|5 blood draws during ovulatory menstrual cycles in premenopausal women
223668593|NCT00097981|DRUG|Thalidomide|Participants will receive thalidomide orally every night (at bedtime) without food on days 1-28 and dosing will gradually increase during Cycle 1 starting at 50 mg on 1 to 7 days, 100 mg on 8 to 14 days, 150 mg on 15 to 21 days, and 200 mg 22 to 28 days. Thalidomide 200 mg per day will be administered for subsequent cycles. Participants will receive thalidomide for minimum of 4 cycles and a maximum of 12 cycles.
223668594|NCT00097981|DRUG|Dexamethasone|Participants will receive dexamethasone 40 mg orally on Days 1 to 4, 9 to 12 and 17 to 20.
223668595|NCT00097981|DRUG|DOXIL|DOXIL 40 mg/m2 will be administered iintravenously (into a vein) on Day 1.
223668596|NCT04671472|DRUG|NPC-09|The drug will be administered by the oral route with the same manner
223771300|NCT02742103|OTHER|Placebo|0.9% weight/volume sodium chloride solution (ie, normal saline)
223771301|NCT00084695|BIOLOGICAL|anti-thymocyte globulin|Given IV
223771302|NCT00084695|DRUG|busulfan|Given orally
223771303|NCT00084695|DRUG|cyclophosphamide|Given IV
224249861|NCT01517321|DRUG|Placebo, MK-0431/ONO-5435|Double-blind period (12 wks); placebo QD. The double-blind period will be followed by a 40 wk open label extension period where MK-0431/ONO-5435 could be titrated from 50 mg to 100 mg QD.
224249862|NCT04910178|DRUG|Empagliflozin 25 MG|tablets to be taken orally once a day
224249863|NCT04910178|DRUG|Ursodeoxycholic acid|tablets to be taken orally twice a day
223668597|NCT04671472|DRUG|NPC-09 placebo|The drug will be administered by the oral route with the same manner
223668598|NCT00373438|PROCEDURE|Fetoscopic tracheal balloon occlusion|Maternal local anesthesia, percutaneous ultrasound-guided fetal analgo-sedation and relaxation, percutaneous ultrasound-guided access into amniotic cavity with trocar, fetoscopic tracheal ballon occlusion, removal of fetoscope and trocar, maternal abdominal closure, skin-to-skin time 30 minutes
223668599|NCT04549389|DEVICE|Low intensity shockwave therapy|LiST will be applied in the perineum of the patients by using Dornier Aries 2 shockwave machine (5000shockwaves per session, energy level 7)
223668600|NCT05588219|DRUG|Tislelizumab|Tislelizumab injection\[10ml:100mg\] will be used beginning with radiotherapy: 200mg/3W for 1 year or disease progression or intolerable toxicity, whichever occurs first.
223771304|NCT00084695|DRUG|fludarabine phosphate|Given IV
223771305|NCT00084695|DRUG|melphalan|Given IV
223771306|NCT00084695|DRUG|methylprednisolone|Given IV
223771307|NCT00084695|RADIATION|radiation therapy|Patients undergo radiation therapy two times daily on days -7 to -4.
223771308|NCT05190458|OTHER|High Velocity Nasal Insufflation|High velocity nasal insufflation (HVNI), a form of HFNC that utilizes a small bore nasal cannula to generate higher velocities of gas delivery than HFNC which uses large bore cannula, has the ability to accomplish complete purge of extra thoracic dead space at flow rates of 35 litres/min and may be able to provide ventilatory support in patients with respiratory failure in addition to oxygenation support in patients with overlap syndrome.
223771309|NCT05190458|OTHER|Non-invasive mechanical ventilation|Noninvasive ventilation (NIV) refers to the administration of ventilatory support without using an invasive artificial airway (endotracheal tube or tracheostomy tube).
224249864|NCT04910178|DRUG|Pentoxifylline 400 MG|tablets to be taken orally twice a day
224249865|NCT04910178|OTHER|placebo|just starch tablets without any active agents
224249866|NCT04055805|BEHAVIORAL|Observational Analysis|Studying the current state of the clinical approaches to bone diseases in breast cancer patients treated with adjuvant and/or hormone therapy
224249867|NCT02169115|DRUG|Omalizumab|150mg, s.c., every 4 weeks
224249868|NCT02169115|DRUG|Omalizumab|300mg, s.c., every 4 weeks
224249869|NCT02169115|DRUG|Placebo|Placebo, s.c., every 4 weeks
223668601|NCT05588219|DRUG|DDP synchronous with radiotherapy|DDP 40mg/m2/W, synchronous with radiotherapy, complete at least 4 cycles.
223668602|NCT00117884|DRUG|851B|851B 0.15% formulation, gel, topically, twice a week for 2 cycles.
223668603|NCT00117884|DRUG|851B|851B 0.15% formulation, gel, topically, twice a week for 2 cycles.
223668604|NCT00117884|DRUG|851B|851B 0.15% formulation, gel, topically, twice a week for 2 cycles.
223668605|NCT00117884|DRUG|851B|851B 0.15% formulation, gel, topically, twice a week for 2 cycles.
223668606|NCT00117884|DRUG|851B|851B 0.15% formulation, gel, topically, twice a week for 2 cycles.
223668607|NCT00117884|DRUG|851B|851B 0.15% formulation, gel, topically, twice a week for 2 cycles.
223668608|NCT00117884|DRUG|851B|851B 0.15% formulation, gel, topically, twice a week for 2 cycles.
223668609|NCT00117884|DRUG|851B|851B 0.15% formulation, gel, topically, twice a week for 2 cycles.
224249870|NCT03834376|DRUG|Pimodivir|Pimodivir will be administered as tablets taken orally, twice daily (2 tablets of 300 milligram \[mg\]) over a time period of 5 days.
224249871|NCT00233415|DEVICE|Stereotactic Radiosurgery (Cyberknife)|
224249872|NCT00397787|DRUG|sunitinib malate|Given PO
223668610|NCT00117884|DRUG|851B|851B 0.15% formulation, gel, topically, twice a week for 2 cycles.
223668611|NCT00117884|DRUG|851B|851B 0.15% formulation, gel, topically, twice a week for 2 cycles.
223668612|NCT00117884|DRUG|851B|851B 0.15% formulation, gel, topically, twice a week for 2 cycles.
223668613|NCT01518738|BEHAVIORAL|breath attention training|4 week training
223668614|NCT01518738|BEHAVIORAL|working memory attention training|4 week training
223668615|NCT00634738|PROCEDURE|Ischemic Compression (thumb Pressure)|Pressure, one thumb on the other, applied on the trigger points
223668616|NCT00791973|DRUG|fluticasone furoate|2 puffs in each nostril once daily for 1 week
223668617|NCT00791973|DRUG|Placebo|2 puffs in each nostril once daily for 1 week
223668618|NCT03452748|DEVICE|FTIR spectroscopy|FTIR spectroscopy examines collagen fibers in the excised membranes
224249873|NCT03546283|DRUG|Placebos|The patients with hypertensive intracerebral hemorrhage will be randomized into giving placebos, the other treatments in this group follow the guidelines on the treatment of hypertensive intracerebral hemorrhage.
224249874|NCT03546283|DRUG|Cattle Encephalon Glycoside and Ignotin|The patients with hypertensive intracerebral hemorrhage will be randomized into giving CEGI, the other treatments in this group follow the guidelines on the treatment of hypertensive intracerebral hemorrhage.
224249875|NCT01783561|DRUG|Caffeine|Infants will receive a blinded dose of either placebo (IV normal saline) or IV caffeine citrate 20mg/kg infused over 10 minutes within the first 2 hours of life. They will receive a blinded dose of the opposite of what they received in the DR (placebo or caffeine) at 6 hours of life. Therefore, the intervention is timing of initial caffeine dose.
224249876|NCT04503174|DEVICE|t:slim X2 pump with Control-IQ technology|Real-world use
224249877|NCT04836598|OTHER|laparoscopic cholecystectomy|A Prospective randomized controlled trial study was undertaken along 4 years Between November 2016 and October 2020, in two institutions. 400 patients were selected, 200 patients underwent BLLC and 200 patients underwent multiple port laparoscopic cholecystectomy (MPLC).
224249878|NCT03553979|BEHAVIORAL|Stress management program (SM)|Participants follow the SM program.
223668619|NCT05410951|DIAGNOSTIC_TEST|Illumina panel|"Determination of germline mutations using a recent panel including 113 genes from the Illumina protocol"
223668620|NCT01057875|OTHER|caffeine|Starbuck's Grande Pike Roast coffee
223668621|NCT01057875|OTHER|No caffeine|Starbuck's Grande Pike Roast Decaffeinated Coffee
223668622|NCT05008978|OTHER|Test 1|25g of available carbohydrates from White bread with 25g of available carbohydrates from Banana consumed simultaneously at time 0 min
223668623|NCT05008978|OTHER|Test 2|25g of available carbohydrates from Banana consumed at time -15 min and 25g of available carbohydrates from white bread consumed at time 0 min
224249879|NCT03553979|BEHAVIORAL|Stress management + Buddy program (SM-B)|In addition to receiving the SM, participants in the SM-B will also receive one-to-one support through a buddy.
223668624|NCT05008978|OTHER|Test 3|25g of available carbohydrates from White bread consumed at time 0 min and 25g of available carbohydrates from Banana consumed at time 15 min
223668625|NCT05008978|OTHER|Test 4|25g of available carbohydrates from White bread with 25g of available carbohydrates from Papaya consumed simultaneously at time 0 min
223668626|NCT05008978|OTHER|Test 5|25g of available carbohydrates from White bread with 25g of available carbohydrates from Apple consumed simultaneously at time 0 min
224249880|NCT03392454|PROCEDURE|T+LRTI|T+LRTI is the most commonly used procedure, it removes the entire trapezium
224249881|NCT03392454|PROCEDURE|PT+TI|The PT+TI is less invasive than the T+LRTI as only part of the trapezium is removed
224249882|NCT05615454|DEVICE|bio-electromagnetic energy regulation therapy (BEMER) machine model type: B.BOX CLASSIC, model NO: 420100, 12-15 Volt, (BEMER Int.AG, Liechtenstein product).|The experimental group (receive the BEMER therapy) for five sessions/week for three weeks. Plus, pelvic floor exercise.
224249883|NCT05615454|DEVICE|placebo BEMER|Comparison group (receive placebo BEMER therapy) for five sessions/week for three weeks. Plus, pelvic floor exercise.
224249884|NCT03138967|DRUG|Rocuronium|Experimental: Sugammadex Participants to have cystoscopy with bladder tumor resection. Rocuronium used to induce the neuromuscular blockade and given in a rapid sequence for endotracheal intubation at a dose of 0.45 mg/kg of Ideal Body Weight. If maintenance is needed for continued relaxation then a dose of 0.15 mg/kg of Ideal Body Weight repeated as necessary.
224249885|NCT03138967|DRUG|Sugammadex|Sugammadex administered as a single bolus, intravenous injection. The amount used is based on the patient's weight. A dose of 4 mg/kg used if recovery has reached at least 1-2 post-tetanic counts (PTC) following Rocuronium induced blockade.
224249886|NCT03138967|DRUG|Neostigmine|70 mcg/kg by vein to reverse the muscle relaxation.
224249887|NCT03138967|DRUG|Glycopyrrolate|14 mcg/kg by vein to reverse the muscle relaxation.
224249888|NCT02127463|DRUG|MC-1101|Topically, two times a day, morning and bedtime
224249889|NCT02127463|DRUG|MC-1101 Vehicle|Topically, two times a day; morning and bedtime
224249890|NCT05169710|DRUG|SEP-4199 CR 200 mg|SEP-4199 CR 200 mg Tablet (supplied in one 200mg tablet and one placebo tablet)
223668627|NCT04137510|DEVICE|Percutaneous coronary intervention|It's a non-surgical procedure that uses a catheter to place a stent into a coronary blood vessel in order to open up the vessel.
223668628|NCT03549793|BEHAVIORAL|Dance Therapy|the intervention is aimed to ameliorate, through dancing, crucial motor symptoms in PD patients, as walking, balance, postural changes and arm swing
223668629|NCT03549793|BEHAVIORAL|exercises without dance|the intervention consists of exercises aimed at training the walking, the balance, the postural changes and the arm swing
223668630|NCT01812980|BIOLOGICAL|Trivalent Inactivated Influenza Vaccine|"WHO recommendation for influenza vaccines for 2013 for the Southern-hemisphere included the following vaccine strains:~* an A/California/7/2009 (H1N1)pdm09-like virus;~* an A/Victoria/361/2011 (H3N2)-like virus; - a B/Wisconsin/1/2010-like virus."
223668631|NCT05375773|OTHER|PVP-I Nasal Irrigation and gargling|The solution is prepared by the researcher, which contains 0.5% PVP-I and 2.27% hypertonic saline
223668632|NCT04363398|OTHER|Comprehensive Follow-up|Trained research staff members will provide weekly support to coaches on the NMT warm-up.
223668633|NCT04363398|OTHER|Standard Follow-up|Research staff will monitor teams weekly, however no additional support for warm-up will be provided.
223668634|NCT01002820|DRUG|ganaxolone|liquid suspension, 50 mg/mL, up to 500 mg/day TID or 1500 mg/day, up to 1 year
223668635|NCT03611842|OTHER|preservation of mucosal otitis media|Suction of the middle ear fluid and conservation of the fluid to be collected instead of thrown away into children Healthy eardrum and Atrophic eardrum
223668636|NCT04144127|BEHAVIORAL|Soccer|"* Soccer drills and other fitness routines (two 1-hour sessions per week)~* In person education in Life's Simple 7 to help improve life through Lifestyle changes: smoking status, physical activity, weight, diet, blood glucose, cholesterol, and blood pressure."
223668637|NCT01673347|BIOLOGICAL|Meniscal Allograft|Meniscal allograft
223668638|NCT01293578|OTHER|Diabetes Medication Choice Cards|Clinician uses the Diabetes Medication Choice Cards to inform and engage patient in discussing the issues they find relevant in choosing a new diabetes medication.
223668639|NCT00637143|DRUG|Tacrolimus|Oral
223668640|NCT00637143|DRUG|Cyclosporine|Oral
223668641|NCT00631761|OTHER|educational workshop|The intervention group will view a 20 minute video, receive a 30 minute didactic lecture on urethrocystoscopy, and 30 minute coaching/practice performing diagnostic cystoscopy on anatomic replicas.
224249891|NCT05169710|DRUG|SEP-4199 CR 400 mg|SEP-4199 CR 400 mg tablet (supplied in two 200mg tablets)
224249892|NCT05169710|DRUG|Placebo|Placebo tablet (supplied in two tablets)
224249893|NCT04660864|DEVICE|Nasal cavity cooling device.|The RhinoChill® system cools by intranasal evaporation of a liquid coolant sprayed onto the surface of the nasal cavity. The RhinoChill® system is intended for use for the relief of pain and symptoms associated with acute migraine attack.
224249894|NCT05043103|COMBINATION_PRODUCT|Lecigon® based on European Medicines Agency (EMA) SmPC|There might be different brand names in other countries
224249895|NCT06563258|DEVICE|Biodex Balance Training|"Sixty Subjects of both genders aged 40-60 years old with grade 2 knee osteoarthritis years will diagnosed by orthopedists they will assigned randomly into three groups:~* Group A Will receive WBV Training with frequency of 35 Hz, peak-to-peak amplitude of 4- to 6-mm Vertical sinusoidal vibration, and the total exposure time of 30 minutes (vibration 60 seconds, interval rest 60 seconds) in addition to traditional exercises,3 sessions per week for four weeks. , A vibration device (My7™ model Personal Plate, Power Plate, Northbrook, IL, USA) will used in all WBVT sessions.~* Group B will receive Biobex training and traditional exercises Total time of training was 10 minutes each set is 3 minutes with 20-second rest intervals~* Group C Patients will receive only traditional exercises, 3 sessions per week for four weeks. a good general guideline is 2-3 sets of 10-15 repetitions for each exercise."
224249896|NCT06563258|DEVICE|A vibration device|WBV Training with frequency of 35 Hz, peak-to-peak amplitude of 4- to 6-mm Vertical sinusoidal vibration, and the total exposure time of 30 minutes (vibration 60 seconds, interval rest 60 seconds) in addition to traditional exercises,3 sessions per week for four weeks. , A vibration device (My7™ model Personal Plate, Power Plate, Northbrook, IL, USA) will used in all WBVT sessions.
223668642|NCT00631761|OTHER|no intervention (usual resident activities)|usual activities
223668643|NCT05172479|DIAGNOSTIC_TEST|Measurement of qSOFA score|At the patient's arrival to the ED triage, the nurse will enter the patient's vital signs data into electronic data capture (EDC) system that will calculate the patient's qSOFA score.
223668644|NCT05172479|DIAGNOSTIC_TEST|Measurement of SIRS criteria|At the patient's arrival to the ED triage, the nurse will enter the patient's vital signs data into electronic data capture (EDC) system that will calculate the patient's SIRS criteria.
223668645|NCT05172479|DIAGNOSTIC_TEST|Measurement of NEWS|At the patient's arrival to the ED triage, the nurse will enter the patient's vital signs data into electronic data capture (EDC) system that will calculate the patient's NEWS.
223668646|NCT05172479|DIAGNOSTIC_TEST|Measurement of NEWS2|At the patient's arrival to the ED triage, the nurse will enter the patient's vital signs data into electronic data capture (EDC) system that will calculate the patient's NEWS2.
223668647|NCT05172479|DIAGNOSTIC_TEST|Measurement of MEWS|At the patient's arrival to the ED triage, the nurse will enter the patient's vital signs data into electronic data capture (EDC) system that will calculate the patient's MEWS.
223668648|NCT00025727|DRUG|Lopinavir/Ritonavir|
223668649|NCT00025727|DRUG|Ritonavir|
223668650|NCT00025727|DRUG|GW433908|
223668651|NCT04662827|DIETARY_SUPPLEMENT|Palmithylethanolamid|PEA 3x/d
223668652|NCT04662827|OTHER|placebo|placebo 3x/d
223668653|NCT01031420|DRUG|single arm dose dense MVAC|standard doses of methotrexate, vinblastine, adriamycin, and cisplatin given every 14 days.
224249897|NCT06563258|OTHER|traditional exercises|"1. Stretch exercises (flexibility exercise) Rectus femoris, Iliotibial band, Hamstring and self-stretch for calf muscle (3sets, each stretch 30 sec hold, between each set 5sec rests).~2. Strengthen exercises(resistance exercise)~   1. Isometric Exercises for quadriceps (10 rep,3sets)~  2. Hip abductors strengthening 45 degree (10 rep,3sets)~  3. Hip extensor strengthening 15 degree (10 rep,3sets)~  4. Straight leg raising 45-70 degree (10 rep,3sets)~  5. Short arc knee extension (10 rep,3sets)"
223668654|NCT02853799|OTHER|Comparison of the Effects of Intermittent and Continuous Enteral Feeding on Glucose-Insulin Dynamics in Critically Ill Medical Patients|"1. Placement of feeding tube stomach (oral- or naso-gastric tube)~2. Randomized to receive either continuous feeding or intermittent feeding first. Once at goal nutrition for 4 hours, enter first 4-hour data collection interval. Next proceed with cross-over and complete a 4-hour washout period with the feed type. Finally enter second 4-hour data collection period. To enter into the first data collection period, the patient would require an insulin infusion.~3. There will be five blood glucose checks in each data collection period.~4. If two blood glucose concentrations are above 180 mg/dl then a regular insulin infusion will be initiated."
223771310|NCT05299541|DIETARY_SUPPLEMENT|Food dish|"All patients will be assessed for nutritional risk estimates (MUST) as well as a nutritional PANDORA estimate that predicts mortality, the Pandora estimate will be measured even after 3 and 6 months~Group A - will receive a dish of food every evening by a person employed by a rescue organization for 6 months~At the end of the meal once a week~* All dishes will be photographed at the end of the meal by Android camera, iPhone~* A NUTRITION DAY success photo form will be completed and collected ."
223771311|NCT05299541|DIAGNOSTIC_TEST|Indirect calorimetric|• The patient will be measured with an indirect calorimetry device (Fitmate - COSMED Srl. Rome, Italy) to assess the nutritional requirement.
223771312|NCT05299541|DIAGNOSTIC_TEST|Bioimpedance|• The body composition test will be performed by the Bodystat®4000 Bioimpedance Device (BIA 4000, Bodystat, UK). .
223771313|NCT05299541|BEHAVIORAL|Questioners|"At 3 times point , in the recruit + 3 month and 6 month 3 questioners will be given:~HADS, Quality of life 36SF and FIM"
223771314|NCT05299541|DIETARY_SUPPLEMENT|Plated food dish|"All patients will be assessed for nutritional risk estimates (MUST) as well as a nutritional PANDORA estimate that predicts mortality, the Pandora estimate will be measured even after 3 and 6 months Group b - will receive a food dish every evening by a person employed by a rescue organization with improved appearance of a plate for 6 months.~At the end of the meal once a week~* All dishes will be photographed at the end of the meal by Android camera, iPhone~* A NUTRITION DAY success photo form will be completed and collected ."
223771315|NCT05066841|DRUG|CM (Ma-Hsing-Kan-Shih-Tang in combination with Liu-Jun-Zi-Tang)|CM (Ma-Hsing-Kan-Shih-Tang in combination with Liu-Jun-Zi-Tang) for 12 weeks
223771316|NCT05066841|DRUG|10% CM (Ma-Hsing-Kan-Shih-Tang in combination with Liu-Jun-Zi-Tang)|10% CM (Ma-Hsing-Kan-Shih-Tang in combination with Liu-Jun-Zi-Tang) and 90% starch for 12 weeks
223771317|NCT02618330|DEVICE|retainer|24 h wearing whether 0.75-mm-thick or 1.00-mm-thick film retainer
223771318|NCT02127008|PROCEDURE|Resection of epidural fat|During surgical procedure, the epidural fat with pituitary forcep and rongeur was resected.
223771319|NCT02127008|PROCEDURE|No resection of epidural fat|During surgical procedure, the epidural fat with pituitary forcep and rongeur was not resected.
223771320|NCT05832034|DRUG|Immune Globulin Intravenous (Human)|IVIg is 2 g/kg over 2 to 5 days at baseline, followed by 2 g/kg IV in 2 to 5 days after 4 and 8 weeks. The rate of infusion is controlled by means of an infusion pump. The first dosage (30 grams IVIg) will be administered on the neurology ward.
223771321|NCT05832034|DRUG|Placebo|Placebo infusions, containing sodium chloride 0.9%, at baseline and after 4 and 8 weeks.
223771322|NCT04816357|OTHER|Questionaire|only questionaire
223771323|NCT03042312|DRUG|177Lu-PSMA-617|Lutetium (177Lu) -DOTA (1,4,7,10-tetra-azacyclododecane-N,N',N'',N'''-tetraacetic acid )-PSMA has three components: PSMA is the targeting vector , DOTA (1, 4, 7, 10-tetraazacyclododecane-1, 4, 7, 10-tetraacetic acid) is a radiometal chelator and a linking group, and 177Lu is the beta emitter that upon internalization delivers radiation to the nucleus of tumor cells to cause DNA damage. The targeting vector utilizes glu-urea-lys sequence which is an inhibitor capable of binding to the domain of PSMA. These components have been previously used in human subjects and in medical research.
223771324|NCT01099124|DRUG|M2ES|polyethylene glycol rh recombinant endostatin
223771325|NCT01119261|OTHER|Genotype-guided dosing algorithm|Loading and monitoring dose according to genotype-guided dosing algorithm
224249898|NCT00910052|DEVICE|Tisseelä fibrin sealant|Fibrin sealant applied intraoperatively
224249899|NCT05687552|DEVICE|pet -ct|assessment of added value of pet -ct in patients with gastric cancer and how patient get benefit from this finding
224249900|NCT00221299|DRUG|Risedronate|One 35mg tab of risedronate/placebo taken once a week for one year.
224249901|NCT00221299|DRUG|Parathyroid Hormone|This medication comes in a pre packaged 28 day supply pen. Medication is administered once a day by a subcutaneous injection (under the skin) into the thigh or abdomen. For this study, this medication will be taken for one year.
224249902|NCT06421337|DEVICE|BraiN20(R)|"SEP monitoring will be carried out using the BraiN20® medical device and appropriate electrodes. SEP of both median nerves will be recorded, transferred, and stored to the internal card for their evaluation. BraiN20® Medical Device provides an automatic reading of the presence and feature of a N20 response both ipsilateral and contralateral (as control) to the cerebral hemisphere affected by the stroke and do not require specific training. Furthermore, the device provides an outcome prediction (percentage of likelihood of having mRS ≤ 2 day 7 and 90 after stroke onset) based on an internal algorithm.~BraiN20® measures one N20 wave per 33 seconds. Scalp electrodes are easily embedded on a headband and the wrist electrodes on a glove."
224249903|NCT04822259|DEVICE|JOURNEY II BCS Total Knee System|Undergoing Total Knee Replacement(resurfaced patella) with JOURNEY II BCS Total Knee System
224249904|NCT04822259|DEVICE|JOURNEY II CR Total Knee System|Undergoing Total Knee Replacement(resurfaced patella) with JOURNEY II CR Total Knee System
223771326|NCT01119261|OTHER|Non-genotype-guided dosing algorithm|Loading and monitoring dose according to non-genotype-guided dosing algorithm
223771327|NCT06085898|DRUG|Stryphnodendron Adstringens 3% - once daily post bath|Intimate Soap
223668655|NCT02853799|DIETARY_SUPPLEMENT|Osmolite 1.2 cal/ml Enteral Feeds|Osmolite 1.2 cal/ml Enteral Feeds via feeding tube (oral- or naso-gastric tube)
223668656|NCT00560521|BEHAVIORAL|CPAP|Frequency of three times a week, using a positive end expiratory pressure (PEEP) of 10 mmH2O for 30 minutes for four weeks.
223668657|NCT03956797|DEVICE|Recens Cooling Anesthesia Device|Application of cooling anesthesia device prior to intravitreal injection
223668658|NCT05694221|DRUG|Supaglutide injection|Administered subcutaneously in the Supaglutide arms
223668659|NCT05694221|DRUG|Digoxin|Oral Administration
223668660|NCT05694221|DRUG|Metformin|Oral Administration
223668661|NCT05882721|DEVICE|Sofwave|"The Sofwave System, comprised of an applicator and a console, generates high intensity, non-focused ultrasonic energy which can be delivered percutaneously to tissues.~Other Names:~SUPERB"
223668662|NCT02528721|DEVICE|Dual Mode BreathID Hp System|The Dual Mode Breath ID Hp System consists of breath collection bags, a 13C-labelled substrate (urea) and a breath analyzer device
223668663|NCT02368925|DEVICE|Ultherapy™ System|The Investigator will apply to the eligible subject the Study Device Ultherapy™ System with 200\~260 lines of 3.0 and 4.5 probe respectively on the subject's neck.
223668664|NCT00895011|DRUG|Placebo|One dose 30 minutes prior to initiation of sexual activity
223668665|NCT00895011|DRUG|Avanafil|One dose 30 minutes prior to initiation of sexual activity
223668666|NCT00895011|DRUG|Avanafil|One dose 30 minutes prior to initiation of sexual activity
223668667|NCT00376714|DRUG|GSK233705|
223668668|NCT05323162|OTHER|encapsulated autologous fecal microbiota transplantation|Individuals will recieve encapsulated freezedried own fecal microbiota to potentially extingish auto-immunity directed against the residual beta cell fraction
223668669|NCT01934543|OTHER|Polyunsaturated fatty acids diet|During 4 weeks, subjects eat a diet high in polyunsaturated fatty acids (percent of total caloric intake: 15.0% from proteins; 50.0% from carbohydrates; 35.0% from fat: 6.0% from saturated fat; 14.4% from monounsaturated fat; 12.6% from n-6 polyunsaturated fat).
223668670|NCT01934543|OTHER|Saturated fatty acids diet|During 4 weeks, subjects eat a diet high in polyunsaturated fatty acids (percent of total caloric intake: 15.0% from proteins; 50.0% from carbohydrates; 35.0% from fat: 13.4% from saturated fat; 15.3% from monounsaturated fat; 4.0% from n-6 polyunsaturated fat).
223668671|NCT00312754|DRUG|Atazanavir|
223668672|NCT05506605|DRUG|Doravirine 100Mg Tab|Switch from Etravirine to Doravirine
223668673|NCT02661178|DRUG|emodepside (BAY 44-4400)|
223668674|NCT02661178|DRUG|placebo|
223668675|NCT03277820|DIETARY_SUPPLEMENT|Probactiol Mini|6 droplets of Probactiol Mini contain 1 billion bacteria (Lactobacillus rhamnosus GG and Bifidobacterium lactis BB-12)
223668676|NCT03086031|BEHAVIORAL|Program -based vocational rehabilitation intervention|"The VR intervention lasts for a total of 6-9 months with first six different modules (3-month) that are individually planned, and second a work placement program (approximately 3-6 months). Each of the different modules follows a comprehensive standard operating procedures (SOP's). The six modules will be grouped into (a) individual therapies which includes neuropsychological sessions (10-hours), balance between work and everyday life (20-hours), and job matching (10-hours), (b) grouped-based therapies which includes psycho education (18-hours), mindfulness (15-hours), and physiotherapy training (15-hours), (c) an manualized family intervention program (8 sessions of 90 minutes), and an individual caregiver coaching (12-hours), (d) a work placement program including work practice (3-6 month), supported employment by the rehabilitation team (30-hours), and the development of a post rehabilitation plan (4-hours)."
223668677|NCT03086031|BEHAVIORAL|Conventional vocational rehabilitation (controls)|Treatment as usual delivered by the municipalities.
223668678|NCT03810729|DIAGNOSTIC_TEST|Smartphone assessment|The smartphone app will be performed on participants randomly assigned to receive this test.
223668679|NCT03810729|DIAGNOSTIC_TEST|Modified Allen's Test|The modified Allen's test will be will be performed on participants randomly assigned to receive this test.
223668680|NCT02376959|BEHAVIORAL|"Spiritist passe"|"For a period of 5 min per week, the volunteers will remain in the supine position with their eyes closed, in a quiet environment with controlled light and temperature.~The applied intervention will consist of placing both hands in the classic Spiritist passe position for the stipulated 5-min period. Spiritist passe will be applied by volunteers with training and experience of more than two years with the technique."
223668681|NCT02766582|DRUG|Pembrolizumab|IV every 21 days at 200 mg
223668682|NCT02766582|DRUG|Carboplatin|IV every 21 days
223668683|NCT02766582|DRUG|Paclitaxel|IV infusion (80mg/m2) every 7 days for 6 cycles
223668684|NCT04319497|DEVICE|Subjective refraction|Subjective refraction measurements will be performed by two testers for all the patients included
223668685|NCT04319497|DEVICE|Autorefraction|Five autorefraction measurements will be performed for all the patients included
223668686|NCT04319497|DEVICE|Wavefront aberrometry|Five wavefront measurements will be performed for all the patients included
223668687|NCT02776618|PROCEDURE|running subcuticular closure of excisional defect|Excisional defects will be repaired with deep polyglactin 910 sutures, followed by each half of the wound given randomly assigned subcuticular superficial closure as described in the treatment arms.
223668688|NCT04269083|OTHER|BIRC3|BIRC3-expression directed preoperative chemoradiotherapy in patients with resectable adenocarcinoma of the esophagus and EGJ
223668689|NCT00400036|BEHAVIORAL|Cod protein NCEP-diet|
223668690|NCT01369329|DRUG|Group 2 ustekinumab 130 mg|Type=exact, unit=mg, number=130, form=solution for injection, route= intravenous use, in a single dose.
223668691|NCT01369329|DRUG|Group 3: ustekinumab approximately 6 mg/kg|Type=range, unit=mg/kg, number=6, form=solution for injection, route= intravenous use, in a single dose.weight-range based ustekinumab doses approximating ustekinumab 6 mg/kg: 260 mg (weight \<= 55 kg), 390 mg (weight \> 55 kg and \<= 85 kg), and 520 mg (weight \> 85 kg).
223668692|NCT01369329|DRUG|Group 1: Placebo|Form=solution for injection, route=intravenous use, in a single dose.
223668693|NCT02922699|DRUG|OMEZ 40|Omez 40 given to patients for 58days along with Amoxicilin and Clarithromycin
223668694|NCT02922699|DRUG|OMEZ 80|Omez 80 patients for 58days along with Amoxicilin and Clarithromycin
223668695|NCT02861274|DEVICE|pacemaker|
223668696|NCT00773539|PROCEDURE|PVI using an open irrigated tip catheter|transseptal PVI using thermocooled ablation catheter (Biosense) with confirmation of conduction block
224249905|NCT02828033|DRUG|Rilonacept|All patients will receive rilonacept with an initial loading dose of 320 mg delivered as two, 2-mL, subcutaneous injections of 160 mg each given on the same day at two different sites. The initial dose will be administered at the study site by study personnel. Dosing will then be a once-weekly injection of 160 mg administered as a single, 2-mL, subcutaneous injection by the patient at home. Patients will be dosed for 24 weeks.
224249906|NCT01109966|OTHER|Special Medical Food|"Comparison between a standard amino acid based formula and a new amino acid based formula. Subjects with CMA will take their randomised formula for 12 months. Following completion of the intervention (12 months), subjects will transfer to an age appropriate formula and be followed-up at 24 and 36 months.~Infants should typically consume the following amounts of formula during the study \> 500mls/day up to 12 months of age \> 400mls/day between 12 and 18 months of age \> 300mls/day over 18 months of age."
223668697|NCT00773539|PROCEDURE|PVI using a closed irrigated tip catheter|transseptal PVI using the CHILLI II catheter from BOSTON with confirmation of conduction block
223668698|NCT00773539|PROCEDURE|PVI using a cryoballoon|transseptal PVI using the cryoballoon from CRYOCATH
223668699|NCT00148707|DRUG|CT-2103 (Xyotax)|
223668700|NCT01617746|DRUG|Ambrisentan|5mg od two weeks
223668701|NCT01617746|DRUG|Bosentan|62.5mg bd two weeks
223668702|NCT01617746|DRUG|Placebo|bd for two weeks
223668703|NCT01078818|DRUG|IV trivalent saccharose hydroxide ferrous|"Preoperative Period 5-10 days 200 mg Iron iv (Venofer® )in 200cc physiologic solution /24-48h x 3 dosis +1 oral placebo /24h Postoperative Period 1-3weeks 200 mg Iron iv (Venofer® )in 200cc physiologic solution/24-48h x 3 dosis + 1 oral placebo /24h One month Follow-up~1 month 1 oral placebo /24h"
223668704|NCT01078818|DRUG|Oral ferrous fumarate|"200cc physiologic solution iv placebo /24-48h x 3 dosis + 1 oral iron tablet/24h (Ferogradumet®)~Postoperative Period:~200cc physiologic solution iv placebo /24-48h x 3 dosis + 1 oral iron tablet/24h (Ferogradumet®) One month Follow-up: 1 oral iron tablet/24h Ferogradumet"
223668705|NCT01078818|DRUG|Oral and intravenous Placebo|Preoperative Period:1oral placebo/24h Postoperative Period:200cc physiologic solution iv placebo /24-48h x 3 dosis + 1oral placebo/24h One month Follow-up:1 oral placebo/24h
223668706|NCT02852187|DEVICE|SIGNUS MOBIS PEEK Cage|Lumbar Interbody Fusion
223668707|NCT02852187|DEVICE|SIGNUS MOBIS II ST Cage|Lumbar Interbody Fusion
223668708|NCT05468047|DRUG|Ketamine hydrochloride injection|Individuals will be administered a single dose of sub-anesthetic (0.5-0.75 mg/kg; maximum dose of 60 mg regardless of body weight) ketamine hydrochloride injection intramuscularly as part of a ketamine-assisted therapy experience.
223668709|NCT01101308|DRUG|Reformulated OXY (Totowa) (oxycodone HCl)|Reformulated OXY 10-mg tablet (Totowa) x 1 dose taken in the fasted state.
223668710|NCT01101308|DRUG|Reformulated OXY (Wilson) (oxycodone HCl)|Reformulated OXY 10-mg tablet (Wilson) x 1 dose taken in the fasted state.
223668711|NCT01579812|DRUG|Metformin|"Patients receiving primary surgical debulking followed by adjuvant chemotherapy will initiate metformin prior to primary surgery. Following surgery patients will be initiated on metformin prior to the initiation of chemotherapy.~Patients treated with neoadjuvant chemotherapy will be initiated on metformin prior to the initiation of chemotherapy. Following surgery patients will be initiated on metformin prior to the re-initiation of chemotherapy."
223668712|NCT01528540|DRUG|Placebo|This group will include placebo.
223668713|NCT01528540|DRUG|Antioxidant plus Pregabalin|This group will contain combination of antioxidant cocktail and pregabalin
223668714|NCT01873521|PROCEDURE|Non invasive ventilation|
223668715|NCT00061412|BEHAVIORAL|Comprehensive program to improve reading and writing skills|
223668716|NCT04634045|BEHAVIORAL|Web Based Treatment|The literature regarding the efficacy of web-based platforms for behavioral weight management interventions in pediatric populations continues to grow. Considering the continued increase in technology and internet use among youth, web-based interventions have the potential to serve as a more cost-effective and personalized approach to pediatric behavioral weight management. Extant research supports this consideration. More research that compares web-based vs. traditional delivery of acceptance-based pediatric behavioral weight management interventions is necessary to understand the utility of this platform as well as which aspects are most effective.
223668717|NCT04636853|BIOLOGICAL|Subretinal injection of umbilical cord blood platelet-rich plasma (CB-PRP)|"A subretinal injection of umbilical cord blood platelet-rich plasma (CB-PRP) will be performed only in one eye, the other eye will be considered as a control group.~A complete morpho-functional ophthalmological evaluation will be performed in all patient at each control."
223668718|NCT04308031|DRUG|Ivabradine 5 mg [Corlanor]|Starting dose: Ivabradine 2.5mg twice daily (BID) Max Dose: Ivabradine 7.5 mg twice daily (BID)
223771328|NCT05166434|PROCEDURE|trans-crestal sinus lifting|this study will be divided in to three different groups, each group will receive a same technique of Crestal maxillary sinus lifting and implant placement at 2,4,6 mm heights.
223771329|NCT02753647|DRUG|Rituximab|
223668719|NCT04308031|DRUG|Digoxin 0.25 mg|Starting dose: 0.125mg once daily (QD) in estimated Glomerular filtration rate(eGFR)\>60， 0.125mg once every other day (QOD) in estimated Glomerular filtration rate(eGFR)\<60 Max dose: 0.25 once daily (QD)
223668720|NCT00957125|DRUG|Epirubicin|75 mg/m2 i.v. infusion, 30 min, cycle day 1, cycles 1-6.
223668721|NCT00957125|DRUG|Docetaxel|75 mg/m2 i.v. infusion, 60 min, cycles day 1, cycle 1-6.
223668722|NCT00957125|DRUG|Bevacizumab|15 mg/kg, i.v. infusion, 90 min, cycle day 1, cycles 3-6 if PR or SD after cycle 2.
223668723|NCT05168501|OTHER|Rebreathing procedure|Paired Duffin's rebreathing procedures performed two different isoxic end tidal PO2 levels (i.e., hyperoxic and hypoxic conditions) will be performed on Day 1 at 0, 2, 4, 6, and 24 hours.
223771330|NCT02753647|DRUG|Cyclophosphamide|
223771331|NCT02753647|DRUG|Doxorubicin|
223771332|NCT02753647|DRUG|Vincristine|
223771333|NCT02753647|DRUG|Prednisone|
223771334|NCT02753647|DRUG|Chidamide|
223771335|NCT04849949|OTHER|Control|Participants in this group received a traditional muffin with butter as the predominant source of fat.
223771336|NCT04849949|OTHER|Black walnut|Participants in this group received a muffin in which part of the butter was substituted out for black walnuts.
223771337|NCT04849949|OTHER|English walnut|Participants in this group received a muffin in which part of the butter was substituted out for English walnuts.
223771338|NCT02305940|DRUG|Doxycycline|An oral dose of 100 mg of Doxycycline once daily, for a total duration of 52 weeks.
224249907|NCT01109966|OTHER|Special Medical Food|"Comparison between a standard amino acid based formula and a new amino acid based formula. Subjects with CMA will take their randomised formula for 12 months. Following completion of the intervention (12 months), subjects will transfer to an age appropriate formula and be followed-up at 24 and 36 months.~Infants should typically consume the following amounts of formula during the study \> 500mls/day up to 12 months of age \> 400mls/day between 12 and 18 months of age \> 300mls/day over 18 months of age."
224249908|NCT00346385|DRUG|BB-10901|dose escalation study, dose will vary per cohort. patients will receive an IV infusion once every three weeks.
224249909|NCT02729714|DRUG|Suvorexant|10 mg Suvorexant or matching Placebo orally at bedtime with optional up-titration to 15 mg Suvorexant or matching Placebo orally at bedtime after 2 weeks.
224249910|NCT02729714|DRUG|Placebo|10 mg Suvorexant or matching Placebo orally at bedtime with optional up-titration to 15 mg Suvorexant or matching Placebo orally at bedtime after 2 weeks.
223668724|NCT06189235|OTHER|Biofeedback training|The target of additional biofeedback training is to provide hints which are related to the essential aspects during hand therapy such as the stress on the tissue and the distance of tendon gliding.
223668725|NCT01970904|DRUG|Alisporivir|Alisporivir 100 mg or 200 mg soft gel capsules (SGC) in blister packs for oral administration
223668726|NCT01970904|DRUG|Ribavirin|Ribavirin tablets of various strengths for oral administration
223668727|NCT01970904|DRUG|Peg-IFNα2a|Peg-IFNα2a solution for subcutaneous injection
223668728|NCT00353756|DRUG|C326, IL-6 Inhibitory Avimer protein|
223668729|NCT03782831|PROCEDURE|TACE|Hepatic intra-arterial infusion with lipiodol mixed with chemotherapy drugs (EADM, lobaplatin, and MMC), and embolization with polyvinyl alcohol particles (PVA).
223668730|NCT03782831|DRUG|PD-1 antibody|3mg/kg intravenously every 2 weeks
223668731|NCT03782831|DRUG|Placebos|intravenous injection every 2 weeks
223668732|NCT03708562|DEVICE|everlinQ endoAVF System|The everlinQ device is a single-use disposable device. The everlinQ catheter system consists of two flexible, magnetic catheters. Once the catheters are properly inserted and aligned, the magnets contained in each catheter attract to one another, approximating the vessels while simultaneously aligning the electrode with the backstop. Radiofrequency (RF) energy is delivered to the electrode whereby the arterio-venous fistula (AVF) is created.
223668733|NCT04652414|DRUG|Prednisone|Prednisone 50mg will be administered enterally for 7 days.
223668734|NCT04652414|DRUG|Placebo|This is a matching placebo to prednisone.
223668735|NCT02835079|DRUG|Tamoxifen|
223668736|NCT06329128|OTHER|Experimental: Study Group|"A 15-session (5 days a week / 3 weeks) physiotherapy and rehabilitation (electrotherapy and home program) program will be applied to both groups.~Electrotherapy application; It will consist of Hotpack (15 minutes), TENS (20 minutes), Ultrasound (10 minutes) applications. For the home program, a program consisting of isometric and isotonic exercises will be given to the muscles around the knee. The home program will be followed with an exercise diary.~In the manual therapy group, in addition to the above treatment, manual therapy will be given 3 days a week. The content of the manual therapy program is as follows;~* Patellofemoral joint superior-inferior mobilization~* Medial-lateral mobilization with active knee flexion~* Tibiofemoral joint ventral (anterior-posterior) mobilization~* Tibiofemoral traction mobilization"
223668737|NCT06329128|OTHER|Active Comparator: Control Group|"A 15-session (5 days a week / 3 weeks) physiotherapy and rehabilitation (electrotherapy and home program) program will be applied to both groups.~Electrotherapy application; It will consist of Hotpack (15 minutes), TENS (20 minutes), Ultrasound (10 minutes) applications. For the home program, a program consisting of isometric and isotonic exercises will be given to the muscles around the knee. The home program will be followed with an exercise diary."
223668738|NCT04155411|DRUG|Dasatinib|70 mg of Dasatinib orally daily for 12 months
223668739|NCT01133990|DRUG|FOLFIRI|FOLFIRI will be administered as IV infusion on Days 1 and 15 of each cycle, and 5-FU at 400 mg/m\^2 as an IV bolus injection followed by a total of 2400 mg/m2 by CIV infusion over 46 hours over Days 1 and 2 via an ambulatory programmable pump. The 5-FU IV bolus (400 mg/m\^2) and CIV infusion (2400 mg/m\^2) over 46 hours is repeated on Days 15 and 16 of each cycle.
223668740|NCT01133990|DRUG|E7820|E7820 will be administered orally in tablet form once daily, every day of each 28-day treatment cycle.
223668741|NCT01133990|DRUG|Bevacizumab|Bevacizumab will be administered at 5 mg/kg (IV infusion) on Days 1 and 15 of each 28-day treatment cycle.
224249911|NCT06350955|DRUG|Iron isomaltoside|single dose of 500 mg iron isomaltoside
224249912|NCT06350955|DRUG|Iron Carboxymaltose|single dose of 500 mg ferric carboxymaltose
224249913|NCT01633450|OTHER|Zinc biofortified rice|1.12 mg zinc per meal
223668742|NCT04220593|OTHER|tDCS associated with Tcog|2mA-intensity aETCC will be applied to the left dorsolateral prefrontal cortex (CPFDL) region for 20 min, three times a week (every other day) over a one-month period, totaling 12 sessions. In each session activities aimed at stimulating cognition will be applied over the 20 minutes.
223668743|NCT05277337|BIOLOGICAL|Alluzience|Botulinum Toxin Type A (BoNT-A) for treatment of glabellar lines; Mode of administration: intramuscular injection
223668744|NCT05277337|BIOLOGICAL|powder BoNT-A (BOTOX/Vistabel)|Botulinum Toxin Type A (BoNT-A) for treatment of glabellar lines; Mode of administration: intramuscular injection
223771339|NCT02305940|DRUG|Placebo|An oral dose of one capsule of placebo once daily, for a total duration of 52 weeks
224249914|NCT01633450|OTHER|Rice extrinsically fortified with zinc|1.12 mg zinc per meal
224249915|NCT03023150|OTHER|Ischemic Preconditioning|
224249916|NCT03023150|OTHER|Sham|
224249917|NCT05350787|BIOLOGICAL|ThisCART19A|ThisCART19A is a new type CAR-T cells therapy for patients with acute B-cell leukemia
224249918|NCT05250843|PROCEDURE|TACE/HAIC|Within 1-3 days of lenvatinib and sintilimab, start Transarterial chemobolization treatment or FOLFOX-based chemotherapy infusion,after three months,patients who achieved partial response (PR) or minor response (MR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 and were assessed as eligible for R0 resection go on to undergo surgical resection.
224249919|NCT05250843|DRUG|Lenvatinib|Participants received lenvatinib capsules 8mg for patients weight \<60kg, or 12mg for patients weight more than 60Kg.
224249920|NCT05250843|DRUG|Sintilimab|Sintilimab Injection will be administered every three weeks (200mg) until surgery or disease progression.
224249921|NCT05250843|PROCEDURE|liver resection|liver resection is feasible after evaluation by the liver cancer surgery expert group
224249922|NCT00223925|DRUG|Maribavir|
224249923|NCT00223925|DRUG|Placebo|
224249924|NCT02197260|DRUG|3/d 500 mg metronidazole plus 375 mg amoxicillin for 7 days|Systemic antibiotics after sub gingival mechanical debridement
224249925|NCT02184260|DRUG|Metamizole|
224249926|NCT02184260|DRUG|Placebo|
224249927|NCT01305681|DEVICE|LoFric® catheters during clean intermittent catheterization|LoFric® catheters during clean intermittent catheterization
224249928|NCT03018834|DRUG|ANAKINRA 100 mg/daily subcutaneously|ANAKINRA 100 mg/daily subcutaneously once a day until hospital discharge, for a maximum of 14 days, in addition to standard care: ACE and Beta-blocker for 6 months.
223668745|NCT02111278|OTHER|Lumbar Manipulation|The manipulating therapist performs the lumbar manipulation technique. With the patient supine, the therapist stands opposite the side to be manipulated. The patient is passively side-bent away from the therapist. The therapist rotates the thoracic spine and then delivers a quick posterior and inferior thrust through the anterior superior iliac spine. The manipulation is performed on the side the patient reported to be more symptomatic. If the patient is unable to identify a more painful side, the side to be manipulated is left to the manipulating therapist discretion. If a cavitation is experienced, no more manipulations are performed that session. If no cavitation is produced, the patient is repositioned, and the manipulation is attempted again. If no cavitation is experienced again, the therapist attempts to manipulate the opposite side. A maximum of two attempts per side will be attempted.
223668746|NCT02111278|OTHER|Sham Manipulation|The manipulating therapist will perform the sham lumbar manipulation technique with the patient side-lying. The therapist passively flexes both hips until slight lumbar flexion is noted at the patient's most painful vertebral level. The therapist will take time palpating patient's spine taking care to avoid rotating the spine. The therapist will then place both hands on the same lumbar spinous process. An equal and opposite force is then applied to the spinous process with both hands. No physiologic motion is expected with this technique. The patient will then be setup for the same sham technique on the opposite side. The sham manipulation technique will be performed in an attempt to blind the patient to group allocation. This technique is designed to provide similar hands on treatment time as the manipulation intervention.
223668747|NCT02111278|OTHER|Physical Therapy|Patients will receive 4 weeks of physical therapy with 2 visits per week. The treating physical therapist is blinded to group allocation. The treating physical therapist will prescribe exercises based on patient presentation. Therapy visits last approximately 45-60 minutes depending of patient ability to perform exercises. The treating physical therapist will perform no mobilizations or manipulations on the patient.
223668748|NCT02858544|OTHER|The Concussion Identification Index|Patient completion of the Concussion Identification Index, a report of crash characteristics, injuries sustained, and post-accident neurological signs and symptoms
223668749|NCT02858544|OTHER|ImPACT|Patient- completed computerized neurocognitive test battery
223668750|NCT06220890|PROCEDURE|Tooth preparation in Class IV lesions with 2mm bevel|Class IV cavity with 2 mm bevel will be restored with nano-filled composite and clinical performance will be evaluated based on FDI criteria.
223668751|NCT06220890|PROCEDURE|Tooth preparation in Class IV lesions with 2mm stair-step chamfer|Class IV cavity with 2 mm stair step chamfer will be restored with nano-filled composite and clinical performance will be evaluated based on FDI criteria.
223668752|NCT04182464|OTHER|Sucralose|Food additive used to replace sugar providing a sweet taste without calories
223668753|NCT04182464|OTHER|Placebo|Cornstarch without significant physiological effects
223668754|NCT03271983|DRUG|Metronidazole gel 1|RLD gel
223668755|NCT03271983|DRUG|Metronidazole gel 2|generic gel
223668756|NCT03271983|DRUG|Metronidazole cream|generic cream
223668757|NCT00005866|DRUG|busulfan|arm 1: 0.44 mg/kg every 6 hours, IV over 2 hours, day -7 to -4
223668758|NCT00005866|DRUG|cyclophosphamide|arm 2: 60 mg/kg every 24 hrs for 2 doses, IV over 2 hrs, days -5 and -4
223668759|NCT00005866|DRUG|cyclosporine|both arms per published schedule
223668760|NCT00005866|DRUG|methotrexate|GVHD: 15 mg/m2 day 1, 10 mg/m2 day 3, 6 and 11 by IV
223668761|NCT00005866|PROCEDURE|allogeneic bone marrow transplantation|day 0
223668762|NCT00005866|RADIATION|radiation therapy|both arms: 1200 cGy total dose (6 x 200 fractions)
223668763|NCT05555173|DEVICE|Buzzy|Buzzy is a small vibrating bee with ice-pack wings.
223668764|NCT02052765|DEVICE|ECG continuous recording (Analyze ST)|During the ajmaline test, continuous ECG recording was forced to record ST shift
223668765|NCT02173262|DRUG|G-CSF|
223668766|NCT02173262|DRUG|Ciprofloxacin|
223668767|NCT02402738|BEHAVIORAL|Interpersonal and Social Rhythm Therapy|
223668768|NCT02402738|BEHAVIORAL|Enhanced Treatment as Usual|
224249929|NCT03018834|DRUG|Placebo|PLACEBO 100 mg/daily subcutaneously once a day until hospital discharge, for a maximum of 14 days, in addition to standard care: ACE and Beta-blocker for 6 months.
224249930|NCT04107675|DRUG|Liposomal Cyclosporine A|Liposomal Cyclosporine A is administered at different dosages in the first two arms (10 mg bid and 5 mg bid, respectively) with a new technology of nebulizing liquid drugs, creating an aerosol with a low ballistic momentum and a high percentage of droplets in a respirable size range of 3-5 μm
224249931|NCT04107675|DRUG|Liposomal Placebo|Liposomal Placebo is administered with the same new technology of nebulizing liquid drugs used for L-CsA, creating an aerosol with a low ballistic momentum and a high percentage of droplets in a respirable size range of 3-5 μm
224249932|NCT00199277|DRUG|i.v. iron sucrose|
224249933|NCT00199277|DRUG|Oral iron|
224249934|NCT05053763|DRUG|Remimazolam|The study was carried out using a biased coin design up-and-down sequential method, where the dose of remimazolam administered to each patient depended on the response of the previous one with success/failure duodenoscopy insertion during ERCP are required for reliable estimates. The first patient was tested at 0.2mg/kg remimazolam (0.025mg/kg as a step size). Duodenoscopy insertion was conducted when MOAA/S≤1.The response of the patients to the duodenoscopy insertion during ERCP was categorized as either 'success (no movement)' or 'failure (movement). if a patient had a failure duodenoscopy insertion, the dose of remimazolam was increased by 0.025mg/kg in the next subject. If a patient had a successful duodenoscopy insertion the next subject was randomised to receive either a lower dose (with a decrement of 0.025mg/kg), with a probability of b = 0.11, or the same dose, with a probability of 1-b = 0.89.
224249935|NCT03853954|DEVICE|Methoxyflurane|Methoxyflurane (Penthrox) inhaler, 3mL inhalation vapour, liquid
224249936|NCT03713333|DIAGNOSTIC_TEST|Digital Health Device Diagnostics|"Technology-enabled visitations with digital health will include the following devices used at the time of a patient-physician encounter. These findings will be available to the treating physician at the time the visitation and to be used for clinical decisions.~* Handheld imaging - focused echocardiographic examination (Butterfly IQ)~* Smartphone iECG for cardiac rhythm assessments (Alivecor)~* Blood Pressure (CloudDX)~* Oxygen Saturation (CloudDX)~* Weight (CloudDX)~* Point-of-Care Genetic Testing (Phosphorous)"
224249937|NCT00892892|DRUG|Rilmenidine|1 mg Rilmenidine per day versus
224249938|NCT00892892|DRUG|Nitrendipine|20 mg Nitrendipine per day
223668769|NCT00543244|DRUG|Pegylated interferon alfa and ribavirin|"Pegylated interferon alfa-2a 180 ug/week or pegylated interferon alfa-2b 1.5 ug/kg/week Ribavrin 800-1200 mg/day (genotype 1: \< 75 kg 1000 mg/day, \>=75 kg 1200 mg/day; genotype 2: 800 mg/day)~HCV genotype: baseline (Day 0) HCV RNA (real time PCR test): baseline (Day 0), Day 1 (4,8,12 hours after pegylated interferon + ribavirin), Day 2 (24,36 hours), Day 3(48 hours), Day 4 (72 hours), Day 5 (96 hours), Week 2,4,6,8,12,16,20,24, and 28,32,36,40,44,48,72 (for genotype 1 with 48 weeks of treatment), and 48 (for genotype 1 or 2 with 24 weeks of treatment)"
223668770|NCT02282345|OTHER|Laboratory Biomarker Analysis|Correlative studies
223668771|NCT02282345|DRUG|Talazoparib|Given PO
223668772|NCT04564768|BEHAVIORAL|Online Mindfulness-Based Cancer Recovery (MBCR)|Mindfulness-Based Cancer Recovery (MBCR) is a standardized group program which focuses primarily on the challenges faced by people living with cancer. It is an 8-week program consisting of weekly group meetings of 1.5 to 2 hours. Home practice of 45 minutes per day (15 min yoga; 30 min meditation) is prescribed. As the weeks progress, different forms of meditation are introduced, beginning with a body scan sensory awareness experience, progressing to sitting and walking meditations. Gentle Hatha yoga is incorporated throughout, as a form of moving meditation. Didactic instruction as well as group discussion and reflection, problem solving and skillful inquiry are commonly applied teaching tools.
223668773|NCT00729391|BEHAVIORAL|Woman-Focused Intervention (Women's Health CoOp)|Participants in this group will receive VCT and participate in two group sessions of the woman-focused intervention.
223771340|NCT03348267|DIETARY_SUPPLEMENT|Milk protein isolate|Milk protein isolate in a powder form consisted of 80% casein and 20% whey protein. 20g were diluted into 500 ml water
223668774|NCT00729391|BEHAVIORAL|Nutrition (Attention-Control)|Participants in this group will receive VCT and participate in two group sessions of the nutrition intervention.
223668775|NCT00729391|BEHAVIORAL|VCT Only|Participants in this group will receive VCT only.
223668776|NCT01191216|DRUG|1-methyl-d-tryptophan|
223668777|NCT01191216|DRUG|docetaxel|
223668778|NCT01191216|OTHER|diagnostic laboratory biomarker analysis|
223668779|NCT01191216|OTHER|pharmacological study|
223668780|NCT06054204|DEVICE|lateral bony window|bony window will be made on lateral maxillary sinus wall using piezo-electric device after elevation of full thickness mucoperiosteal membrane
223668781|NCT00023699|DRUG|gefitinib|
223668782|NCT00401362|DRUG|SC Methylnaltrexone|Dose 1
223668783|NCT00401362|DRUG|SC Placebo|
223668784|NCT00401362|DRUG|SC Methylnaltrexone|Dose 2
223668785|NCT03203343|PROCEDURE|Operation - PIRS|Operation by its known design for PIRS group
223668786|NCT03203343|PROCEDURE|Operation - MARCY|Operation by its known design for MARCY group
223771341|NCT03348267|DIETARY_SUPPLEMENT|Placebo|500 mL drink that contained water (375 mL), sugar-free cordial (125 mL) and 2 g of low-calorie glucose/dextrose powder.
224249939|NCT03464240|DIETARY_SUPPLEMENT|Glucose|glucose drink
224249940|NCT03464240|DIETARY_SUPPLEMENT|Water|control
224249941|NCT00904553|RADIATION|Novalis Shaped Beam Surgery|Treatment using Novalis SRS
224249942|NCT00693628|DEVICE|compression shrinker|Two levels of compression: 20-30 mmHg or 30-40 mmHg shrinker
224249943|NCT01774435|DRUG|EN3342|
224249944|NCT03579095|DIETARY_SUPPLEMENT|Cereboost|200mg Cereboost and Maltodextrin capsules
224249945|NCT03579095|DIETARY_SUPPLEMENT|Placebo|200mg Maltodextrin capsules
223668787|NCT01565304|BEHAVIORAL|POWER Through Choices|10-session group-based sexual education curriculum
223668788|NCT03844295|DEVICE|Activated Inspire® Upper Airway Stimulation System|At first, INSPIRE® device will be active a month
223668789|NCT03844295|DEVICE|Inactivated Inspire® Upper Airway Stimulation System|"After 15 days wash-out INSPIRE® device will be inactivated for a second period of one month."
223668790|NCT05662709|PROCEDURE|Tooth extraction|Tooth extraction in the most atraumatic way
223668791|NCT05662709|PROCEDURE|Alveolar ridge preservation with L-PRF|Blood will be drawn from the patient, centrifugued and leukocyte and platelet-rich fibrin (L-PRF) will be obtained. L-PRF plugs and membranes will be prepared and placed in the socket after extraction
223668792|NCT01704612|DRUG|ropivacaine|patients received 20 mL ropivacaine 5 mg/mL on subgluteal nerve
223668793|NCT05585281|DRUG|Fluzoparib|Fluzoparib Orally twice daily
224249946|NCT05733884|OTHER|soft contact lens|soft contact lens
223668794|NCT05585281|BIOLOGICAL|QL1101|Maintenance QL1101 7.5 mg/kg will be administered via a 30-minute IV infusion on Day 1 of every 21-day cycle in the absence of progressive disease (PD), unacceptable toxicity, participant withdrawal, Investigator's decision, or death. QL1101 will be administered for up to 10 months during the maintenance phase or up to a total of 15 months inclusive of approximately 5 months of QL1101 received with chemotherapy.
223771342|NCT00646958|DRUG|Radezolid|450mg PO QD
223771343|NCT00646958|DRUG|Radezolid|450mg PO BID
223771344|NCT00646958|DRUG|Linezolid|600mg PO BID
223771345|NCT01480115|OTHER|ultrasound examination for AFC evaluation|Ultrasound examination three times during the menstrual cycle to measure the AFC.
224249947|NCT03999684|DRUG|Tretinoin|ATRA control normal cell growth, cell differentiation (the normal process of making cell different from each other), and cell death during embryonic development and in certain tissues later in life. Retinoids effects on the cells are controlled by receptors on the nucleus of each cell (nuclear receptors)
224249948|NCT05451069|DIAGNOSTIC_TEST|Neurofilament Light Chain ,Chitinase-3 Like-1 Protein Levels and Tolerogenic plasmacytoid Dendritic Cells|"1. Serum and CSF levels assay of NfL and CHI3L1 using the enzyme linked immunosorbent assay kits (ELISA).~2. Peripheral blood mononuclear cells (PBMC) will be obtained by Ficoll-Hypaque gradient. plasmacytoid dendritic cells will be identified in (CSF) and (PBMN) based on their selective expression of surface antigen (cluster of differentiation 303) CD303, named blood dendritic cells antigen 2 (BDCA-2).Antihuman antibodies: BDCA-2, HLA-DR , CD274 , HLA-G and CCR7 for identification of tolerogenic plasmacytoid dendritic cells using flowcytometry."
224249949|NCT05186662|OTHER|patient education|patients in experimental group were asked to join a WeChat group, which was governed by experienced gastroenterologists. Relevant knowledge of H. pylori eradication was released in the group chat irregularly. Patients in WeChat group were allowed to ask questions at any time during the whole treatment process, soon afterwards, suggestions were given.
224249950|NCT05186662|OTHER|patient education|Patients in the control group received verbal education and a specifically designed printout with detailed instructions.
224249951|NCT05479383|OTHER|Not applicable, this is an observational study|Not applicable, this is an observational study
224249952|NCT05655845|OTHER|bowel function score(BFS) questionnaire survey|A cross-sectional bowel function score(BFS) questionnaire survey was conducted in patients with HD who underwent PTs between January 2014 and December 2019 at Children's Hospital of Nanjing Medical University.Patients consented to the survey were asked to complete the questionnaire,and were divided into two groups: dysfunction group(BFS\<17 ); and normal group (BFS\>=17 ). The operative age, birth weight, premature delivery status, operative weight, aganglionic segment, single or stage PT, surgical approach(laparotomy or laparoscopy), post-operative Hirschsprung-associated enterocolitis (HAEC),and immediate complications were recorded and compared between two groups。Both univariate and multivariate regression analysis were used to seek the risk factors of bowel dysfunction after PTs in HD. .
223668795|NCT03409978|DEVICE|in-Motion app|mobile phone application for recording fidgety movements at home
223668796|NCT00520585|DRUG|atorvastatin|atorvastatin 20 mg once vs. atorvastatin 80 mg once vs. placebo
223668797|NCT00499057|RADIATION|interstitial high dose-rate brachytherapy, PBI|Single arm study Treatment schedule is 4 Gy twice a day, with a time relapse of at least 6 hours between each fraction, for four days, for a total dose 32 Gy.
223668798|NCT02085031|PROCEDURE|Intracorporeal Roux-en-Y esophagojejunostomy|During totally laparoscopic total gastrectomy, Roux-en-Y esophagojejunostomy intracorporeally using a transorally inserted anvil (OrVil™) will be performed.
223668799|NCT02085031|PROCEDURE|Extracorporeal Roux-en-Y esophagojejunostomy|During laparoscopic total gastrectomy, Roux-en-Y esophagojejunostomy extracorporeally using a transabdominally inserted anvil will be performed.
223668800|NCT02294760|DEVICE|Subsensory|The stimulation is set to 90% of the sensory threshold.
223668801|NCT02294760|DEVICE|OFF|The stimulation is turned OFF.
223668802|NCT00506532|DRUG|Surfactant (calfactant)|
223668803|NCT03098888|PROCEDURE|bronchoalveolar lavage|bronchoalveolar lavages performed for cytological assessment in critically ill patients with lung diseases, intubated or not
223668804|NCT04837677|DRUG|PRT1419|PRT1419 will be administered by intravenous infusion
223668805|NCT01038869|DRUG|Azelaic acid|Apply sparingly to the face twice a day (morning and night). Massage gently into the skin until vanishing. Approximately 0.5g (2.5cm strip) is sufficient for the entire facial area.
223668806|NCT00001131|DRUG|Aldesleukin|Subcutaneous injection of IL-2 in the amount of 2.0 X 10\^6 mIU per day for the entire duration of therapy
223668807|NCT00001131|DRUG|HAART|Current HAART regimen to be continued for duration of therapy or until certain criteria specified by the study is met
223668808|NCT01606657|PROCEDURE|Irrigation|The patient will receive irrigation as a part of their wound care
223668809|NCT01606657|OTHER|No Irrigation|The patient will not receive irrigation as part of their wound care
223668810|NCT01781091|DEVICE|INTELLIVENT ASV FULLY CLOSED-LOOP VENTILATION|
223668811|NCT01781091|DEVICE|Conventionals Modes|
223668812|NCT04609163|OTHER|data collection|retrospective data collection
223668813|NCT04012489|PROCEDURE|Breath Stacking|Patients were connected to a unidirectional valve coupled to artificial airway (tracheostomy), with bacteriological filter. The ventilator was coupled to the unidirectional valve to measure inspiratory volume mobilized in each cycle and a connection to adapt a manometer. The patient performed successive inspirations for a maximum period of 30 seconds or until unidirectional valve opening or volume increase was observed for 2 consecutive efforts. Ten cycles of the technique were performed, with an interval of 30 seconds.
223668814|NCT04012489|PROCEDURE|Air Stacking|The same system of monitoring and adaptation of the ventilometer and manometer was carried out. A manual resuscitator coupled to a unidirectional valve was used, both connected to the tracheostomy, with a filter interface. Slow and successive inspirations were performed through slow compression of the resuscitator until the maximum inspiratory pressure reached 40 cmH2O. Ten cycles of the technique were performed, with an interval of 30 seconds.
223668815|NCT01329835|BEHAVIORAL|Lifestyle counseling|4 prenatal sessions based on principles of motivational interviewing and positive reinforcement
223668816|NCT01329835|OTHER|brochure|brochure given after randomization
223668817|NCT00105365|DEVICE|Shoe insert|Subjects with knee OA underwent gait analysis and knee pain and function assessment at baseline while wearing walking shoes and after four weeks of wearing walking shoes with lateral-wedged insoles.
223668818|NCT00105365|OTHER|walking shoes|walking shoes
223668819|NCT03138993|BEHAVIORAL|Patient decision aid|Web-based patient decision aid plus a paper workbook.
223668820|NCT03138993|BEHAVIORAL|General sleep education|Web-based information about sleep plus a paper workbook
223668821|NCT00021073|DRUG|alvocidib|Given IV
223668822|NCT00021073|DRUG|leucovorin calcium|Given IV
223668823|NCT00021073|DRUG|fluorouracil|Given IV
223668824|NCT00021073|DRUG|irinotecan hydrochloride|Given IV
223771346|NCT02537080|DRUG|Nimodipine group|the stability of the blood pressure will be managed in interval plus minus 15% of patient's resting blood pressure
224249953|NCT03347435|GENETIC|genetic tests for CYP2C19*2, CYP2C19*17 and ABCB1 3435|The CYP2C19\*2 (10q24.1-q24.3; rs4244285), CYP2C19\*17 (10q24.1-q24.3; rs12248560) and ABCB1 3435 (7q21.1; rs1045642) genetic variants will be genotyped using an ST Q3 system. The conventional genotyping methods so far used for diagnostic purposes will not be used in this study because appropriate labs may not be readily available and the processing time is prohibitive. Q3 is a compact platform enabling the classical laboratory analysis of DNA by means of real-time PCR. The Q3 has been designed as a low entry-cost, portable, point-of-care instrument for foolproof use by unskilled personnel. Antiplatelet therapy will be choose on the basis of clinical and genetic algorithm.
224249954|NCT03347435|OTHER|clinical algorithm|Antiplatelet therapy will be choose on the basis of clinical algorithm alone
224249955|NCT00836056|DRUG|Clindamycin 300 mg capsule|1 x 300 mg
224249956|NCT00836056|DRUG|Cleocin HCl 300 mg capsules|1 x 300 mg
224249957|NCT02569073|DRUG|Dronabinol|Dronabinol 5 mg, every other night, orally
224249958|NCT02569073|DRUG|Placebo|Placebo--no drug
224249959|NCT01851577|BEHAVIORAL|Family Foundations coparenting program|Family Foundations is a coparenting program for new mothers and fathers designed to teach them skills needed to parent together effectively and facilitate healthy child development. Family Foundations will be administered concurrently with home visiting.
224249960|NCT01851577|BEHAVIORAL|Home visiting|Home visiting is a child abuse prevention approach for new mothers designed to strengthen protective factors and mitigate risk factors in order to promote optimal child development.
224249961|NCT01288352|OTHER|early standardised rhythm control|"Patients in the early therapy group will be treated following the same therapeutic recommendations of the ESC guidelines as the usual care group. In addition, rhythm control therapy will be initiated early with the aim of preventing recurrence and delaying or preventing progression of AF.~Early-onset rhythm control therapy can consist of:~1. Optimal antiarrhythmic drug therapy~2. Catheter ablation with the aim of pulmonary vein isolation (PVI),~3. Antiarrhythmic drug therapy and catheter ablation may be combined and supplemented by early cardioversion in patients with persistent AF.~All individual treatment decisions will be taken by the treating study physician considering the labelling of the procedures and drugs and patient preferences."
224321944|NCT04976621|BEHAVIORAL|Behavioral Activation|BA is a brief behavioral treatment that helps people define goals, create and execute plans to attain them, and engage in meaningful activities. BA protocol components include: goal setting (especially for activities that promote social connectedness), creation of a plan (broken down into steps), strategies for implementation of steps, identification of potential barriers, tactics to overcome them, activity monitoring and scheduling, and emotion regulation strategies. The BA intervention will be delivered in 6 sessions over 3 months by Occupational Therapists trained in BA for post-TBI depression. BA sessions will be conducted in person in an office at the VA rehabilitation clinic, virtually by VA Video Connect, or in person in the home, depending on the veteran's preference.
223668825|NCT04959071|PROCEDURE|Vacuum assisted closure VAC vs conventional dressing|"In participants undergoing vacuum assisted closure a drainage tube was placed in the wound followed by dressing with sterile foam sheet and application of occlusive transparent film over the whole assembly. The drainage tube was connected to a suction machine. Intermittent negative pressure of -125mmHg was applied every 15 minutes; the suction was stopped for 10 minutes. The dressing was changed every 48 hours.~In participants with conventional dressings, after wound wash, pyodine soaked gauze pieces were used for initial 48 hours followed by dressings of normal saline soaked gauze pieces, twice daily."
223668826|NCT04906915|DRUG|Ketamine|The efficacy of ketamine was assessed by calculating oxygen supply and consumption
223668827|NCT04121078|DRUG|TAK-906|TAK-906 capsule.
224249962|NCT02640183|DRUG|EMLA|
224249963|NCT02640183|OTHER|Placebo|
224321945|NCT04976621|OTHER|Treatment as Usual|Treatment as Usual refers to usual care provided by the VA medical center.
223668828|NCT04121078|DRUG|Rifampin|Rifampin infusion.
223668829|NCT05577273|DRUG|Cefuroxime axetil (trimethoprim/sulfamethoxazole if penicillin allergy)|single dose of P.O. Cefuroxime Axetil 500 mg. For penicillin allergy patients, single dose of P.O. Trimethoprim/Sulfamethoxazole 160mg/800mg
224249964|NCT04504526|DRUG|68Ga-Pentixafor|Intravenous injection of one dose of 74-148 MBq (2-4 mCi) 68Ga-Pentixafor. Tracer doses of 68Ga- Pentixafor will be used to image lesions by PET/CT.
224249965|NCT03180606|OTHER|Multi-disciplinary and personalized primary care|Team-based primary care where nurse, GP, social-worker, physiotherapist, occupational therapist evaluate and give treatment
224249966|NCT03396523|DRUG|Losartan|administration of losartan (50 mg) (oral)
224249967|NCT03396523|DRUG|Placebo Oral Tablet|administration of placebo (oral)
224249968|NCT06327191|OTHER|No intervention as the study is observational.|No intervention as the study is observational.
224249969|NCT02092805|PROCEDURE|Real rTMS(20 Hz, 10 trains, inter train interval 30 sc with total pulses 2000, intensity 80% of motor threshold) daily for 10 consecutive days (5 days/week)|
224249970|NCT02092805|PROCEDURE|Sham rTMS (same parameters but with coil elevated and angled away from the head) every day for 10 consecutive days (5 days/week).|
224249971|NCT03343795|DRUG|oral progesterone|daily
224249972|NCT03343795|DRUG|intramuscular progesterone|every week
224249973|NCT02812732|BEHAVIORAL|DOSE HPV|"The primary goals of the DOSE HPV intervention are to 1) change clinician HPV vaccine recommendations and responses to hesitant parents, and 2) support systems changes to improve the vaccination process. The first four sessions follow a standardized curriculum, while the last three sessions include development and implementation of tailored activities designed to meet individual practice needs.~Sessions 1 and 2 generate motivation for the project through feedback of vaccination rates (Session 1) and education on HPV disease (Session 2). Brief Negotiated Interview (BNI) skills are taught in Sessions 3\&4. Action Plans are developed in Session 5. Sessions 6\&7, which follow a standard quality improvement format: plan-do-study-act (PDSA) cycles."
224249974|NCT04192006|DEVICE|Total Knee Arthroplasty|Surgical implantation of prosthetic knee using robotic-arm assist
224249975|NCT00846495|DRUG|topiramate|topiramate 25mg 1 tab in PM x 1 week topiramate 25mg 1 tab in AM / 1 tab in PM x 1 week topiramate 25mg 1 tab in AM / 2 tabs in PM x 1 week topiramate 25mg 2 tabs in AM / 2 tabs in PM x 5 weeks
224321946|NCT05992623|DEVICE|Zoll external defibrillator|Patients with AF will be randomized to receive a full output synchronized 200J shock using a RBW waveform from a Zoll defibrillator
224249976|NCT00846495|DRUG|frovatriptan|frovatriptan 5mg tab during premonitory phase of migraine
223668830|NCT05920083|OTHER|CPAP withdrawal|2 weeks of CPAP withdrawal
223668831|NCT00260364|DRUG|Gemcitabine 1000 mg/m2 iv days 1, 8, 15 of a 28 day cycle|
223668832|NCT00260364|DRUG|Capecitabine orally days 1 -21|
223668833|NCT00260364|DRUG|Erlotinib 100 mg orally days 1-28|
223668834|NCT00260364|DRUG|Bevacizumab 5 mg/kg intravenously every 2 weeks|
223668835|NCT03290482|DIAGNOSTIC_TEST|Barium Esophagram|Fast for 4 hours prior to the Esophagram (upper GI x-ray). You will drink a liquid that has barium or another contrast agent in it. The radiologist will use the X-ray machine to look at your upper GI tract while you drink the contrast liquid. The x-ray exam should take between 10-15 minutes.
223668836|NCT03290482|DEVICE|EsophaCap|Subjects will swallow the EsophaCap, which has a string attached, 10 minutes later it has devolved in the stomach. The PI will pull the string to remove the EsophaCap. We will send the sponge for cytology assessing the histologic results of eosinophils per high power field (phf)
223668837|NCT03290482|DIAGNOSTIC_TEST|Physical Examination and Questionnaires|Complete the modified Mayo dysphagia Questionnaire (MDQ) and the Eosinophilic Esophagitis Activity Index (EEsAI) at time of physical exam visit with PI.
223668838|NCT04905498|BEHAVIORAL|Commercial Advertising Literacy Training|"Children were shown food commercials and in between those commercials they saw and heard statements such as These foods won't make you happy and Those foods are so unhealthy."
224249977|NCT01686438|BEHAVIORAL|Cognitive behavioral therapy for insomnia|A behavioral modification program consisting of 6 clinic sessions focused on sleep hygiene, stimulus control, sleep restriction, and cognitive restructuring.
224249978|NCT02192047|OTHER|Palm Olein|8 weeks
224249979|NCT02192047|OTHER|IE Palm olein|8 weeks
224249980|NCT02192047|OTHER|IE soybean oil-based|8 weeks
224249981|NCT05841225|BEHAVIORAL|Food-related inhibitory control training based on computer|Inhibitory control training tasks are performed using E-Prime 3.0 software to present stimuli based on computer. The Go/no-go task is used as the training task, and the stimulus materials are high-calorie and low-calorie food pictures. The training lasted for 5 days, once a day, and the total duration of each training is about 15 minutes.
224249982|NCT05841225|BEHAVIORAL|Non-food-related inhibitory control training based on computer|Inhibitory control training tasks are performed using E-Prime 3.0 software to present stimuli based on computer. The Go/no-go task is used as the training task, and the stimulus materials are non-food pictures. The training lasted for 5 days, once a day, and the total duration of each training is about 15 minutes.
224249983|NCT02816905|DRUG|0.1 % Dexamethasone|20 eyes are randomized to receive topical 0.1% Dexamethasone four times per day for 2 weeks.
224249984|NCT02816905|DRUG|0.1% Fluorometholone|20 eyes are randomized to receive topical 0.1% Fluorometholone four times per day for 2 weeks.
224249985|NCT02816905|DRUG|1% Rimexolone|40 eyes are randomized to receive topical 1% Rimexolone four times per day for 2 weeks. 20 of these eyes were the contralateral eyes of the patients who received 0.1% Dexamethasone in their first eye. The other 20 eyes were the contralateral eyes of the patients who received 0.1% Fluorometholone in their first eye
224249986|NCT01759940|DRUG|ropivacaine 0,375%|
224249987|NCT01759940|DRUG|ropivacaine 0,75%|
224249988|NCT04561622|BEHAVIORAL|Emotional Stroop Task|"Classic Stroop task The subject names one of the 3 colors of the crosses on a sheet.Then, the subject must read the words written on the sheet for 45 seconds.These are the words: RED, BLUE and GREEN, written in black color. The subject must name the color of the word.~Emotional Stroop task This is a computed task in which the patient is asked to answer both as accurately and as quickly as possible.~The target stimulus is an emotional face of joy or anger, surmounted by the word joy or anger.The subject must respond using the arrow corresponding to the face he sees.~A training phase is offered to the subject.~3 / Categorization task For each trial the participant will visualize a short emotional film or not. Then, the participant will have to choose, the emotion corresponding to what he just saw. A training period is offered too."
224249989|NCT03815669|PROCEDURE|Arthroscopic subacromial decompression|Arthroscopic subacromial decompression
224249990|NCT04791150|OTHER|Fill in a form|Patient will have to fill in a form at each perfusion of immunotherapy to tell if they presents rheumatologic clinical signs
224321947|NCT05992623|DEVICE|Lifepak external defibrillator|Patients with AF will be randomized to receive a full output synchronized 360J shock using a BTE waveform from a Lifepak defibrillator
223668839|NCT04905498|BEHAVIORAL|Control|Children were shown food commercials that were the same length as the other group but did not receive any information about whether the content was truthful.
223668840|NCT02282878|DIETARY_SUPPLEMENT|High/Low Sodium Diet|All patients will receive 2 weeks of the high sodium diet followed by a 1 week washout and then 2 weeks of the low sodium diet
223668841|NCT02599051|DEVICE|Mini-arc|We will place a single incision sling at the time of surgery for stress urinary incontinence
223668842|NCT02599051|DEVICE|Monarc|We will place a transobturator sling at the time of surgery for stress urinary incontinence
223668843|NCT00485797|DRUG|Ritalin|The effect of ritalin on postural stability of ADHD childrens will be measured using RCT study design
223668844|NCT03121976|DEVICE|Ultrasound|Femoral catheter inserted using ultrasound only
223668845|NCT03121976|DEVICE|Ultrasound + Nerve Stimulation|Femoral catheter inserted using ultrasound and nerve stimulation
224249991|NCT02967159|DRUG|Abediterol|Treatment A: Abediterol 2.5 μg via DPI
224249992|NCT02967159|DRUG|AZD7594|Treatment B: AZD7594 440 μg via DPI
224249993|NCT02967159|DRUG|AZD7594/abediterol|Treatment C: AZD7594/abediterol 440 μg/2.5 μg FDC via DPI
224249994|NCT02967159|DRUG|AZD7594 and abediterol|Treatment D: AZD7594 440 μg and abediterol 2.5 μg free combination administered via 2 separate DPIs
224249995|NCT06078072|PROCEDURE|Biomaterials augmented with mesenchymal stem/stromal cells|Combined single-step procedure of treating knee articular surface lesions with biomaterials (scaffolds) and mesenchymal stem cells (filtered bone marrow aspirate concentrate)
224249996|NCT05857891|DRUG|Human erythropoietin injection|Each subject in the test group received 40000iu of human erythropoietin intravenously
224249997|NCT05857891|DRUG|0.9%NaCl|Each subject in the control group was injected with an equal volume of 0.9%NaCl
224249998|NCT02308722|RADIATION|5-fraction stereotactic body radiation therapy|"The investigators expect to need a maximum of 3 dose levels investigating dose to the area at risk of involved resection lines and to the tumour bed to assess the tolerability of SBRT in this setting.~Patient entry will commence at level 1. There is the option to de-escalate to Level -1 should 2 or more DLTs be observed at the starting level. SBRT will not be escalated above level 3.~Level -1:~Tumour (PTV) 6Gy/# (total dose 30Gy). Area at risk of R1 (PTV\_R) 8Gy/# (total dose 40Gy)~Level 1:~Tumour (PTV) 6Gy/# (total dose 30Gy). Area at risk of R1 (PTV\_R) 9Gy/# (total dose 45Gy)~Level 2:~Tumour (PTV) 6.5Gy/# (total dose 32.5Gy). Area at risk of R1 (PTV\_R) 9.5Gy/# (total dose 47.5Gy)~Level 3:~Tumour (PTV) 7Gy/# (total dose 35Gy). Area at risk of R1 (PTV\_R) 10Gy/# (total dose 50Gy)"
224249999|NCT00507663|DRUG|Atenolol|Patients with a standing prescription for β-blockers will be continued on that medication. Pts not currently receiving a beta blocker will be given 50mg of atenolol on the morning of surgery, 50-100mg, twice per day, on the first postoperative day until postoperative day 7.
224250000|NCT01938066|DEVICE|Procellera|bioelectric wound dressing
224250001|NCT01938066|DEVICE|negative pressure therapy|
224250002|NCT01209390|DEVICE|Chondromimetic|"The Chondromimetic implant is intended to serve as a scaffold for cellular and tissue ingrowth in osteochrondral defect repair such as bone and/or cartilage.~The plug consists of a chondral layer with collagen and GAG and an osseus layer with collagen, GAG, and calcium phosphate."
224250003|NCT01887145|PROCEDURE|Endoscopic surgery|Surgery dwas done under local anesthesia injected at the portal sites only. Tourniquet was used. Each of the two skin incisions in the endoscopic procedure was 1 cm long. With the endoscope inserted from the distal portal and a hook knife inserted from the proximal portal, the transverse carpal ligament was divided from its distal edge to its proximal edge. Incisions were closed with non-absorbables sutures and a soft dressing was applied. Sutures were removed 10 days postoperatively.
224250004|NCT01887145|PROCEDURE|Open surgery|Open carpal tunnel release using conventional open technique under local anesthesia and tourniquet. The incision in the open procedure extended from about 1 cm proximal to 3 cm distal to the wrist crease. The transverse carpal ligament was divided; no additional procedures were performed. a soft dressing was applied. Dressing and sutures were removed 10 days postoperatively.
224250005|NCT02321566|DEVICE|Epidural Motor Cortex Stimulation|
224250006|NCT02670057|PROCEDURE|Transnasal SPG block|
224250007|NCT04148391|DRUG|Placebo Oral Capsule|Matching placebo capsules.
224250008|NCT04148391|DRUG|NYX-458|NYX-458 is a small molecule that modulates the N-methyl-D-aspartate receptor (NMDAR).
224250009|NCT04228744|DEVICE|DBS system|"The DBS device utilized in the present study includes a dual-channel neurostimulator kit, lead kit, extension kit, clinician-operated wireless programmer, test stimulator, and patient controller. The lead contains four stimulating contacts. The length of each contact is 1.5 mm, and the spacing between contacts is 1.5 mm.~The participants will receive stepwise surgery. The electrodes will be implanted firstly which will be externalized for several days and then the IPG will be implanted. During externalization, the experimenters will record the local field potential and electroencephalography in resting or task-based state with conditions of sham-stimulation or active-stimulation."
223668846|NCT02208687|BEHAVIORAL|Energetic|Physiotherapy and occupational therapy aimed at reconditioning and social participation.
224250010|NCT03295474|OTHER|Rehabilitation using telehealth technology|"Consecutive patients with chronic respiratory disease referred for pulmonary rehabilitation are offered to participate in the protocol.~Patients are taught to use the system during the first session of aerobic training.~During 2 to 5 sessions of aerobic training (depending on the number of sessions needed to be autonomous), they are monitored in the pulmonary rehabilitation center with an oximeter device (Nonin 3150).~At the end of every session, patients are asked to answer to 3 questions on a Likert scale (see outcome session).~The therapist also ascertains wether the telemonitoring gateway successfully provided informations regarding the session.~The study takes off on the session during which the patients are autonomous in using the telehealthcare system.~If patients are not autonomous on the fifth session, the study also takes off."
224250011|NCT01199718|DRUG|CX-4945|CX-4945 capsules, administered orally,as escalating doses. Dose schedule: four times daily for 21 consecutive days every 28 days.
224321955|NCT05819606|OTHER|Immunohistochemistry (IHC) analysis|Setting of the percentage amount of PSMA expression on the primary tumor cell surface on post-surgical samples by the Immunohistochemistry method (IHC)
223668847|NCT02208687|OTHER|Control group|Usual care
223668848|NCT04244305|OTHER|Exercise Therapy|Endurance training in the form of treadmill/cycle-ergometry
224321956|NCT06145178|BIOLOGICAL|SPYVAC01|Novel vaccine SPYVLP01
223668849|NCT02663726|OTHER|Yoga|10 weekly 75-min sessions of specialised yoga
223668850|NCT02663726|BEHAVIORAL|Written advice|Written advice about physical activity
223668851|NCT02532166|OTHER|Esophageal lichen planus|White light endoscopy compared to narrow band imaging and Lugol for detection of esophageal lichen.
223668852|NCT01634425|DEVICE|Alere Triage Meter Pro|Troponin and BNP measured on point of care meter.
223668853|NCT02409108|DEVICE|Exatherm-TBH system|One treatment of Total Body Hyperthermia
223668854|NCT00289055|DEVICE|stent|Cordis SMART™ Nitinol Stent
223668855|NCT00289055|DEVICE|angioplasty|balloon angioplasty
223668856|NCT02907476|BEHAVIORAL|Iyengar Yoga|
223668857|NCT02907476|BEHAVIORAL|Walking|
223668858|NCT03222492|BIOLOGICAL|Brentuximab Vedotin|Ascending dose cohorts. All cohorts will receive intravenous administration of study medication every 3 weeks for 21 weeks, for a total of eight doses.
223668859|NCT03222492|BIOLOGICAL|Placebo|Placebo control for blinding (masking), 0.95% normal saline.
223668860|NCT01143805|DRUG|Tasocitinib 10 mg oral tablet|Treatment A: Single-dose of tasocitinib (CP-690,550) (10 mg) in the form of an oral tablet
224321957|NCT06376682|PROCEDURE|CT-guided bone percutaneous procedure|The EPIONE device is a user controlled, stereotactic accessory intended to assist in the planning and manual advancement of one or more instruments, as well as in verification of instrument position during Computed Tomography (CT) guided percutaneous procedures (thermal ablation, bone consolidation, biopsy procedures).
224321958|NCT04219163|BIOLOGICAL|CLL-1.CAR T cells|"Dose escalation study with 3 dose levels:~DL1: 1x10\^7 cells/m2, DL2: 3x10\^7 cells/m2, DL3: 1x10\^8 cells/m2~If excessive dose limiting toxicity attributed to the product occurs at dose level one, we will request permission from FDA to treat at dose level -1: 5×10\^6 cells/m2"
224321959|NCT01392235|DRUG|Famitinib|25 mg qd p.o. and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
224321960|NCT00612664|DRUG|Anti-CD137 (4-1BB) (BMS-663513)|IV solution, IV, until PD or toxicity
223668861|NCT01143805|DRUG|Tasocitinib 10 mg IV Infusion|Treatment B: Single-dose of tasocitinib (CP-690,550) (10 mg) in the form of a 30 minute intravenous infusion
223668862|NCT05587946|OTHER|Experimental group|In recent years, virtual reality has been widely used as a distraction practice in clinical medical care to relieve pain. Virtual reality is a method of viewing computer images to isolate the individual from real life for a while. Virtual reality glasses, consisting of a head-mounted display and glasses connected to a mobile phone, is a computer technology that creates a 3D environment. The virtual reality application, which was originally designed for entertainment purposes, started to be used in the medical field to reduce pain during invasive procedures in parallel with the developments in computer technologies. It is preferred in clinical practice as an easily accessible, non-invasive and inexpensive method.
223668863|NCT00447200|PROCEDURE|Esophagus Doppler monitoring|
223668864|NCT00447200|PROCEDURE|Fluid optimization|
223668865|NCT01891526|DRUG|9-cis-retinoic acid|Single dose of 9-cis-retinoic acid (Capsule 30 mg) as oral exposure
223668866|NCT06515067|OTHER|back massage|back massage
223668867|NCT06515067|OTHER|no ıntervention|no ıntervention
223668868|NCT03396757|PROCEDURE|Standard strategy|"RRT is initiated within 12 hours after documentation of serum urea concentration \>40 mmol/l and/or an oliguria/anuria for more than 72 hours. The timing of its initiation will be recorded and RRT will continue until criteria for cessation are observed. This arm corresponds to the delayed strategy in the published AKIKI trial (NEJM 2016),"
223668869|NCT03396757|PROCEDURE|Delayed strategy|"RRT will be initiated only if one or more of above-mentioned potentially severe situations occur (identical to those used during the observational study) or if serum urea concentration reaches 50 mmol/L (this level being chosen in order to avoid extreme elevations of serum urea levels as mentioned above). The physician in charge will be allowed to try a medical treatment. Patients will not receive RRT whatever the duration of anuria/oliguria if any above-mentioned indication for RRT is not present. When required, RRT will be performed with the same modalities and stopped according to the same criteria as in the no further delayed RRT strategy, with special care to avoid dialysis disequilibrium syndrome (see below).~The decision to initiate RRT in the delayed strategy arm of the trial will have to be approved by the attending physician(s) involved in patient's care in order to make sure that it corresponds to her/his usual practice."
223668870|NCT01190423|BEHAVIORAL|Family Based Therapy for young adults|Individual and Group Therapy Sessions
223668871|NCT04560244|DRUG|SHR1701|PD-L1 / TGF-β RII double antibody
223668872|NCT03080077|DRUG|Ricrolin+|The IONTOPHOR CXL iontophoresis applicator and the associated blepharostat will be placed onto the cornea to be treated. The applicator will be secured to the cornea and filled with Ricrolin+ which as been aspirated from the bottle using a syringe with a needle. The generator will be switched on and set to 1 mA for 5 minutes. The generator will then be disconnected and the applicator will be removed from the cornea.
223668873|NCT03080077|DRUG|Epi-Off|Using topical anesthesia (proparacaine), the surgeon will create a complete corneal abrasion to facilitate riboflavin diffusion into the cornea. The epithelium will be removed by gently brushing the cornea with a scalpel. A corneal abrasion diameter of \~9mm is recommended, which may be adjusted as needed at the discretion of the investigator to accommodate individual eye geometry. Ultrasound corneal pachymetry should be performed before dis-epithelialization and after dis- epithelialization. Local anesthetics will be administered as needed to maintain patient comfort during the CXL procedure.
223668874|NCT05121571|PROCEDURE|HAIC|administration of Oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries
223668875|NCT05121571|DRUG|Sorafenib|sorafenib 400mg bid
223668876|NCT05313100|DRUG|sugammadex|At the end of the operation, at least 15 minutes after the last dose of rocuronium, sugammadex 2 mg / kg was administered both of groups
223668877|NCT02336126|BEHAVIORAL|Biopsychological intervention|
223668878|NCT01054183|DEVICE|GlideScope Ranger Intubation|Intubation with GlideScope Ranger Video Laryngoscope
223668879|NCT01054183|DEVICE|Direct Laryngoscopy|Intubations will be done with direct laryngoscopy.
223668880|NCT02963844|OTHER|Inspiratory Muscle Training|
223668881|NCT02963844|OTHER|Inspiratory Muscle Training Sham|
223668882|NCT01906879|DRUG|triple, quadruple, non-bismuth quadruple therapy|triple therapy, quadruple therapy, non-bismuth quadruple therapy
223668883|NCT02189954|PROCEDURE|The placement according to the manufacturer's instructions|Before insertion the laryngeal mask used in daily routine (Laryngeal Mask Unique®(LMU)) was lubricated with a water-based gel and the cuff was completely deflated. After induction when BIS values were between 40 and 60 and sufficient chin relaxation was obtained for patients weighing less than 50 kg no. 3 LMU, for those between 50-90 kg no. 4 and for patients above 90 kg no. 5 LMU was inserted by an anesthetist with more than five years experience
224321961|NCT06551779|PROCEDURE|inyección perineural con solución de dextrosa tamponada|Application of perineural injection with buffered dextrose solution, adding 2.5 ml of 7.5% sodium bicarbonate to a 250 ml bottle of glucose solution at 5% concentration, applying 1cc of the solution at different points on the path of the facial nerve.
224321962|NCT03011593|OTHER|Nutrition Support Product|Nutrition support product contains macronutrients, micronutrients, glutamine, and prebiotics. Product is in powder form (41 grams per serving) and is mixed with water or juice before consumption. Taken orally as a nutritional shake twice per day.
224321963|NCT05100160|DRUG|Gabapentin|Given by PO
224321964|NCT05100160|OTHER|Placebo|Given by PO
224250012|NCT00522886|DRUG|Cetuximab|"Eligible patients will be given 2 cycles(of 21 days) of carboplatin (AUC 5) day 1 and gemcitabine (1250 mg/m2) days 1,8. Patients without progressive disease will be entered in the phase I dose-escalation part of the study. Chest radiation will be given concurrently with cetuximab, cisplatin and vinorelbine, which will be escalated in 3 steps until dose-limiting toxicity occurs.~14 days after the last gemcitabine (=day 43), radiotherapy is started : First 3 weeks: 1.5 Gy BID to a dose of 45 Gy in 30 fractions, then 2 Gy QD to a mean lung dose of 19 Gy. Cetuximab: 400 mg/m2 7 days before radiotherapy (= day 36) and during the course of radiotherapy a weekly dose 250 mg/m2. Cetuximab will be delivered at the same days as chemotherapy.~Cisplatin(all steps): 50 mg/m2 days 43, 50; 40 mg/m2 day 64.~Vinorelbine:~Step 1: 10 mg/ m2 days 43, 50; 8 mg/m2 days 66 and 73. Step 2: 20 mg/ m2 days 43, 50; 8 mg/m2 days 66 and 73. Step 3: 20 mg/ m2 days 43, 50; 15 mg/m2 days 66 and 73."
223668884|NCT02189954|PROCEDURE|Cuff inner pressure was held below 44 mmHg|cuff pressure limitation (Group Pressure Limiting (PL), n=45) cuff inner pressure was held below 60 cmH2O (44 mmHg)
223668885|NCT01861951|DRUG|Pazopanib|
223771347|NCT02537080|DRUG|Control group|the stability of the blood pressure will be managed in interval plus minus 15% of patient's resting blood pressure
223771348|NCT05495750|DRUG|Bupivacaine 0.25% Injectable Solution|ultrasound-guided bilateral suprazygomatic maxillary nerve block using 0.15 ml/kg.
223771349|NCT02786615|BEHAVIORAL|Peer Unity|A 4-session, group-delivered intervention focusing on peer/social network-based recruitment and referral program to receive HIV prevention and treatment services in the community.
223668886|NCT01861951|DRUG|Doxorubicin|
223668887|NCT04585061|DRUG|Lidocaine Hydrochloride|1.8ml of 2%Lidocaine HCl to be administered via a 21mm needle
223771350|NCT04318210|DRUG|Tenofovir Disoproxil Fumarate 300 mg + Emtricitabine 200 mg|
223771351|NCT04113252|OTHER|Possible Incentive for Tablet Return|Subjects who return completed diary will have the possibility to receive money for returned opioid tablets.
223771352|NCT04113252|OTHER|Incentive for Completed Diary|Subjects who return completed diary will receive a gift card.
223771353|NCT04113252|BEHAVIORAL|Coaching|Subjects will receive coaching prior to starting pain medication.
223771354|NCT03992105|OTHER|prospective cohort|"topics included openly in the Respite Site, made up of the first 50 subjects followed prospectively"
224250013|NCT06141317|BIOLOGICAL|PASC transplantation (25 million PASCs/patient)|3 doses of 25 million PASCs implantation via peripheral vein (Day 0, 3 months, 6 months)
224250014|NCT06141317|BIOLOGICAL|Control|0.9% saline solution via peripheral vein (Day 0, 3 months, 6 months)
224250015|NCT04987619|DIETARY_SUPPLEMENT|Beetroot juice|Subjects will drink juice 120 minutes before each visit
224250016|NCT04987619|OTHER|Capri-Sun|70 mL of blackcurrant beverage, which is depleted of NO3- will be taken 120 min before each visit.
223771355|NCT03556631|DRUG|live combined Bifidobacterium and Lactobacillus Tablets|take the live combined Bifidobacterium and Lactobacillus Tablets 4# or placebo twice a day
223771356|NCT06219655|PROCEDURE|thoracoscopic sympathectomy|sympathectomy
223771357|NCT02573324|DRUG|Temozolomide|Oral Capsule
224250017|NCT01029340|BIOLOGICAL|Recombinant Factor VIII (BAY81-8973)|Single dose of BAY81-8973 crossed over to single dose of Kogenate FS
224321965|NCT03635892|DRUG|cabozantinib|cabozantinib 40mg, self administered orally once daily on a continuous schedule (days 1-28) Patients will continue to take cabozantinib until disease progression (unless continuing treatment beyond progression), major toxicity, or withdrawal from the study for any reason.
223668888|NCT04585061|DEVICE|Virtual reality device (Harga Miniso Vr Glass 3d terbaru)|"Virtual reality device (Harga Miniso Vr Glass 3d terbaru) is placed on the face of the patient, playing a video of Tom and Jerry cartoon.~Buccal infiltration in posterior maxillary region with traditional technique. A 27 gauge short needle is inserted in the mucobuccal fold above the tooth to be anesthetized"
223668889|NCT04585061|DIETARY_SUPPLEMENT|Xylitol|Buccal infiltration in posterior maxillary region with traditional technique. A 27 gauge short needle is inserted in the mucobuccal fold above the tooth to be anesthetized while xylitol tablet putted under tongue
223668890|NCT00443963|DRUG|Esomeprazole Magnesium|PPI compared to H2RA
223771358|NCT02573324|DRUG|Depatuxizumab mafodotin|Intravenous (IV) Infusion
223771359|NCT02573324|RADIATION|Radiation|
223771360|NCT02573324|DRUG|Placebo for ABT-414|IV Infusion (IV)
223771361|NCT03176810|DEVICE|OCT|OCT is used to guide PCI.
223771362|NCT03176810|DEVICE|Angiography|Angiography is used to guide PCI.
223771363|NCT03713567|BEHAVIORAL|Experimentally induced plaque|Experimentally induced plaque by suspension of oral hygiene only in the tested areas (tooth / implant), protected by a personalized stent made of plastic, according to the experimental gingivitis and mucositis model of 21 days of duration
223771364|NCT03509701|DIAGNOSTIC_TEST|VZV-specific antibody response from blood|Check VZV-specific antibody response, VZV specific T-cell mediated immune response by IFN-γ ELISPOT assay from blood, and real-time PCR results from saliva
223771365|NCT01306552|BEHAVIORAL|Student-Intervention only group|"One visit to the smoking prevention parcours offered by KARUNA e.V. (Rauchst Du noch oder lebst Du schon?) during 7th grade.~The parcours takes approximately 3 hours to complete. The parcours consists of 7 interactive stations where a class of students learns about differences between smokers and non-smokers in terms of health status such as atherosclerosis prevalence, loss of smell or lung capacity and aging. Students also learn about the toxic ingredients in cigarettes. Each station includes a quiz to complete by each group of students. At the end of the parcours, a moderator will announce which group of students accumulated the most points. For more information on the contents of the parcours see http://www.karuna-prevents.de/index.php."
224250018|NCT01029340|BIOLOGICAL|Recombinant Factor VIII (Kogenate FS, BAY14-2222)|Single dose of Kogenate FS crossed over to Single dose of BAY81-8973
224250019|NCT01029340|BIOLOGICAL|Recombinant Factor VIII (BAY81-8973)|Participants received IV injections of BAY81-8973 at 20-50 IU/kg 2-3 times per week with BAY81-8973 measured by Chromogenic Substrate Assay Potency Per European Pharmacopeia (CS/EP) for 6 months and by Chromogenic Substrate Assay/Adjusted to Label Potency (CS/ADJ) for 6 months, sequence according to randomization.
224250020|NCT01029340|BIOLOGICAL|Recombinant Factor VIII (BAY81-8973)|Participants received a loading dose of approximately 50 IU/kg of BAY 81-8973 before the first surgical incision followed by further treatment with BAY 81-8973 according to surgical requirements for up to 3 weeks
224250021|NCT01802086|DRUG|Emla-cream|Topical anaesthetic
224250022|NCT01802086|DRUG|Miniderm cream|Topical
224250023|NCT02648347|DRUG|Vadadustat|Oral dose administered once daily for ≥36 weeks. Dose adjustment based on hemoglobin level as defined in the protocol.
224250024|NCT02648347|DRUG|Darbepoetin alfa|Subcutaneous or intravenous dose administered for ≥36 weeks. Initial dose based on the current package insert for investigational sites in the United States (US), and the Summary of Product Characteristics for all other investigational sites (non-US) for adult participants with chronic kidney disease not on dialysis.
224250025|NCT04025450|DRUG|Chidamide+VRD|Chidamide:30mg d0,d3,d7,d10/Velcade:1.3mg/m2 d1,d4,d8,d11/ Dexamethasone: 10mg BID d1,d2,d4,d5,d8,d9,d10,d11/Lenalidomide: 25mg d1-d14
224250026|NCT04025450|DRUG|VRD|Velcade:1.3mg/m2 d1,d4,d8,d11/ Dexamethasone: 10mg BID d1,d2,d4,d5,d8,d9,d10,d11/Lenalidomide: 25mg d1-d14
224250027|NCT02329197|DRUG|Human Chorionic Gonadotropin (HCG)|intrauterine injection of HCG prior to embryo transfer in an IVF cycle
224250028|NCT05241808|BEHAVIORAL|Girls Can...Move!|Girls Can...Move! is an 8-week intervention designed to increase physical literacy and physical activity among middle school aged girls. One-hour, in-person sessions will be held twice per week for a total of 16 sessions. Each session involves: a brief educational lesson related to physical activity participation, a 30-minute group physical activity session, and a take-home challenge. The physical activities will prioritize enjoyment of physical activity and promote the development of movement competence. These activities may include: yoga; Zumba; Pilates; strength training; kick boxing; circuit training; etc.
224250029|NCT05853666|BEHAVIORAL|CNH+|CNH+ is a bundled intervention targeting all four of Bandura's factors associated with improved self-efficacy (i.e., Mastery \[evidence-based parent targeted education platform\]; Vicarious Experience \[observing other families similar to them succeeding in a task i.e., videos and photos\]; Verbal Persuasion \[in-person/virtual medical rounds and provision of social support\]; and Physiological States \[notifications and encouragement through mHealth text messaging, parent feedback, and tailored clinical care pathway\]).
224250030|NCT04018339|DRUG|Bardoxolone methyl|Bardoxolone methyl 5 mg capsules
223668891|NCT03680118|DEVICE|autogenous rings with GBR and autogenous graft with ti-mesh|"* Autogenous Onlay ring block harvested from either mandibular ramus or chin will be placed over the defected site and fixed using titanium screws (1.6mm diameter) and then GBR using autogenous particulate will be placed around and over the blocks and covered with a resorbable bilayer collagen membrane (Bio-Gide®, Geistlich, USA)~* Autogenous bone graft will be placed on the defected site and covered by a titanium mesh which will be fixed by titanium screws.~* Flap advancement will be acquired by releasing the mylohyoid muscle attachment from the lingual flap and periosteal releasing incision for the buccal flap to provide tension free closure.~* The flap will then be copiously irrigated with saline in preparation for closure.~* The flap will then be closed using horizontal mattress and interrupted 4/0 polypropylene sutures."
223668892|NCT02052713|DRUG|Commercially available combination of dutasteride 0.5 mg and tamsulosin HCL 0.4 mg|Commercially available, orange and brown, hard shell capsule, administered orally as a single dose on Day 1 under fasted condition.
223668893|NCT02052713|DRUG|Second generation dutasteride 0.5 mg and tamsulosin HCL 0.4 mg combination capsule|Orange and brown, hard shell capsule, administered orally, as a single-dose on Day 1 under fasted condition.
223668894|NCT00513825|DRUG|Sodium Bicarbonate|IV solution of NaCl 0.45% (Arm 1) or IV 75 cc of sodium bicarbonate 8.4% solved in 1 liter of NaCl 0.45% (Arm 2) . Each fluid is infused at the rate of 3 ml/kg/ hour one hour before the angiographic procedure, continuing at the rate of 1 ml/kg/ hour for 6 hours after the procedure. Maximum rate of fluid permitted is that for a body weight of 110 Kg.
223668895|NCT01661582|OTHER|CT/PET Myocardial Perfusion Imaging using O-15 water|
223668896|NCT01661582|OTHER|Coronary blood flow measured by doppler echocardiography|
223668897|NCT02524483|BEHAVIORAL|Therapeutic Challenge Program|The Therapeutic Challenge Program will consist of a 5 minute warm-up, 20 minutes of challenging balance training, and 20 minutes of challenging treadmill and overground walking.
224250031|NCT04018339|DRUG|Placebo|Capsules containing an inert placebo
224250032|NCT02449265|RADIATION|Consolidation involved-site radiotherapy (ISRT)|"6 cycles modern CHOP chemotherapy. Involved-site radiotherapy (ISRT) is based on defining the site of gross disease before chemotherapy, the GTV and using a CT-based volume with an expansion to form a CTV in the cranio-caudal direction.~The general dose had been guided that 30-36Gy in 15\~18 fractions of 2 Gy 5 days per week was managed for patients with complete response (CR) after chemotherapy and 40-50Gy in 20\~25 fractions of 2 Gy 5 days per week for partial response (PR)."
223668898|NCT02524483|BEHAVIORAL|Therapeutic Exercise Program|The Therapeutic Exercise Program will consist of 15 minutes of strength training and flexibility exercises, 15 minutes of balance exercises, and 15 minutes of treadmill walking.
223668899|NCT03174002|DRUG|Oxygen|Oxygen administration to achieve a PaO2 of 8 kPa (60 mmHg) from ICU admission to ICU discharge
223668900|NCT03174002|DRUG|Oxygen|Oxygen administration to achieve a PaO2 of 12 kPa (90 mmHg) from ICU admission to ICU discharge
223668901|NCT03515317|BEHAVIORAL|LoRETA Z-score NF|LoRETA Z-score NF will be conducted using a 19-lead cap (Electrocap, Inc), which will be placed on the head according to the standard approach of the international 10-20 system with linked ear and ground reference. After the caps will be less than 5 kΩ. During each session, the participants will sit in front of a computer screen on which predesigned games or animations related to the LoRETA Z-score training are played and instructions regarding the inhibitory and reward aspects of the training are taught.
223668902|NCT03515317|BEHAVIORAL|theta/beta NF|The goal of theta/beta NF is to increase the beta power(13-20 Hz) and simultaneously inhibit the theta power (4-8 Hz) relative to a baseline assessed at the beginning of a training session. The electrodes will be placed on Fz and Cz with a linked ear model(A1). The study will use both visual and auditory feedback. Each participant will sit in front of a computer screen on which predesigned games or animations related to the training criteria are played and instructions regarding the inhibitory and reward aspects of the training are taught. The threshold will be set according to 5-min baseline EEG measurements before each session. The thresholds are the mean amplitude of the beta and the theta in 5-min baseline EEG.
224250033|NCT02449265|RADIATION|Consolidation involved-field radiotherapy (IFRT)|"6 cycles modern CHOP chemotherapy. Radiotherapy field of IFRT defined by CALGB is encompassed the prechemotherapy gross tumor.~The general dose had been guided that 30-36Gy in 15\~18 fractions of 2 Gy 5 days per week was managed for patients with complete response (CR) after chemotherapy and 40-50Gy in 15\~18 fractions of 2 Gy 5 days per week for partial response (PR)."
224250034|NCT02449265|DRUG|cyclophosphamide|Patients in both arms will be given cyclophpsphamide chemotherapy.
224250035|NCT02449265|DRUG|doxorubicin|Patients in both arms will be given doxorubicin chemotherapy.
224250036|NCT02449265|DRUG|vincristine|Patients in both arms will be given vincristine chemotherapy.
223668903|NCT03028454|DIETARY_SUPPLEMENT|Ginger Root|Capsules containing 250 mg of ginger root extract standardized to contain at least 5% gingerol compounds, as well as an additional 225 mg of regular ginger root.
223668904|NCT03028454|DIETARY_SUPPLEMENT|Placebo|Capsules containing rice flour powder.
223668905|NCT00065429|DRUG|BB-10901|"I.V. Infusion - See Arms for dosage - Once/Week for three weeks - Until Progression of disease."
223771366|NCT01306552|BEHAVIORAL|Multi-component Intervention|"One visit to the smoking prevention parcours offered by KARUNA e.V. (Rauchst Du noch oder lebst Du schon?) + one parent night with information about smoking prevention and one informational letter by mail"
224250037|NCT02449265|DRUG|prednisone|Patients in both arms will be given prednisone chemotherapy.
224250038|NCT03548675|DRUG|TCA treatment|All patients fulfilling inclusion criteria will be genotyped for CYP2C19 and CYP2D6 genes. Based on the genetic test results patients will be classified into a metabolisation phenotype (UM, EM, IM or PM).
224250039|NCT01870856|DEVICE|Spectacles|Per participant's habitual prescription
224250040|NCT01870856|DEVICE|Delefilcon A contact lenses|Silicone hydrogel single vision contact lenses
224321966|NCT03635892|DRUG|nivolumab|Patients will receive an intravenous infusion of nivolumab, per institutional standards, at 240 mg on Cycle 1, Day 1 and will return to the center approximately every two weeks (14 ± 3 days) for subsequent infusions until disease progression (unless continuing treatment beyond progression), major toxicity, or withdrawal from the study for any reason.
224321967|NCT04955730|DEVICE|Negative Pressure Wound Therapy|Negative Pressure Wound Therapy is a single use NPWT that produces a negative pressure at -80 mmHg. Participants will have their fascia and skin closed in the same manner as the control arm participants, and will wear the NPWT dressing for 7 days after surgery.
224321968|NCT01474200|DEVICE|Isolated veno-venous ultrafiltration (AQ)|Aquapheresis treatment (isolated veno-venous ultrafiltration) using the Aquadex FlexFlow System during index hospitalization until the patient's signs and symptoms of fluid overload have improved to the satisfaction of the treating physician. Ultrafiltration rates, duration and frequency of treatment are dependent on the amount of patient fluid excess and on the rate of fluid movement from the interstitial spaces into the vascular compartment during Aquapheresis (Plasma Refill Rate, or PRR)
224250041|NCT01870856|DEVICE|Etafilcon A contact lenses|Hydrogel single vision contact lenses
224250042|NCT02848924|OTHER|No intervention|
224250043|NCT03872505|DRUG|Durvalumab|IV administration of 5 treatments;every 2 weeks for 2 treatments and then every 4 weeks for 3 treatments
224250044|NCT03872505|RADIATION|Radiation Therapy|The second dose of durvalumab will be given in conjunction with an RT boost, consisting of 8 Gy in 3 fractions for a total of 24 Gy.
224250045|NCT03872505|DRUG|Carboplatin|IV administration weekly for 12 weeks
224250046|NCT03872505|DRUG|Paclitaxel|IV administration every week for 12 weeks
224250047|NCT02352259|PROCEDURE|Electrochemotherapy|Treatment procedure: anesthesia, positioning of electrodes, intravenous in bolus administration of bleomycin, within 8-30 min after administration of bleomycin application of electric pulses, removal of electrodes.
224250048|NCT02352259|DEVICE|Cliniporator Vitae®|Positioning of electrodes, within 8-30 min after administration of bleomycin application of electric pulses (8 pulses, duration 100 microseconds, frequency 4 Hz with amplitude adequate to cover the whole treated lesion with electric field necessary for reversible plasma membrane permeabilization), removal of electrodes.
224321969|NCT01474200|DRUG|IV Loop Diuretics (LD)|"IV Loop Diuretics treatment using only FDA approved IV loop diuretics indicated for the treatment of patients with fluid overload. This includes furosemide or other IV loop diuretics administered at equivalent doses to furosemide. Patients will receive either a twice daily IV bolus or continuous IV LD infusions according to the high dose protocol of theDiuretic strategies in patients wth acute decompensated heart failure (DOSE) trial."
223668906|NCT03208582|DRUG|Risedronate Sodium|Participants will be initially tested on the response to mechanical stimulation as a baseline and then tested again after 6 weeks treatment with Risedronate
223668907|NCT03208582|DIETARY_SUPPLEMENT|Calcichew tablets|Participants will take calcichew tablets during the 6 week period of risedronate treatment
224250049|NCT02352259|DRUG|Bleomycin PHC 15 e. (United States Pharmacopeia - USP)|Intravenous in bolus administration of bleomycin (15 mg/m2), 8 minutes before application of electric pulses
223668908|NCT02775240|DRUG|Digoxin|0.5 mg (2 x 0.25 mg) Digoxin oral dose
223668909|NCT02775240|DRUG|Maribavir|200mg twice a day for 8 days
223668910|NCT02775240|DRUG|Dextromethorphan|30 mg oral dose
223668911|NCT00355836|BEHAVIORAL|Mental Imagery|
223668912|NCT05577520|PROCEDURE|Sinus floor augmentation|
223668913|NCT05532293|DRUG|MSP008-22|MSP008-22 is a small molecule with demonstrated anticancer activity in-vitro \& in vivo studies. As several anticancer drugs are also good antiviral drugs, it was anticipated that MSP008-22 can also be a promising anti-COVID drug. Accordingly, in vitro assay studies and in an in vivo study in golden Syrian hamster were conducted where MSP008-22 has shown good anti-SARSCoV2 effects.MSP008-22.
223668914|NCT05532293|OTHER|Placebo|Placebo tablets identical in appearance, taste and smell to the tablets of MSP008-22
223668915|NCT03980353|OTHER|Questionnaires|The questionnaires have two parts: a general part and a second part focused on the integration in community of the type 1 diabetes children with specific questions about blood glucose, mealtimes, sporting activities and school trips.
223771367|NCT01306552|BEHAVIORAL|Control Group|"One visit to the Nutrition and Physical Activity Parcours offered by KARUNA e.V. (Kinderleicht gesund zu leben).~(same set up as the smoking prevention parcours with topics around healthy nutrition and promotion of physical activity)"
223771368|NCT01099995|OTHER|Hyperbaric oxygen therapy|one dive at 2 absolute atmosphere (1-hour plateau) with 30 min time for compression and decompression - oxygen was delivered via a full face mask at high concentration to achieve a 100% inspired fraction of oxygen or via mechanical ventilation
224250050|NCT05286203|DEVICE|Metagenomic Deep Sequencing (MDS)|MDS is an RNA-seq based testing of ocular fluid or tissue to identify potential infectious pathogens including bacteria, fungi, parasites, and DNA and RNA viruses.
224250051|NCT05286203|DIAGNOSTIC_TEST|Standard of Care (SOC)|SOC includes any available diagnostic tests, such as Gram stain, cultures, PCRs, that are considered the appropriate testing based on the clinical findings.
224250052|NCT05228626|DRUG|COVIDEX|COVIDEXTm is a prepared plant extract of Zanthoxylum and Warbugia species that is reported to have antiviral agents, one of which berberine with in vitro activity against SARS COV-2, the causative agent for COVID-19 disease. Others constituents in COVIDEX include alkaloids, sponins, reducing sugars and acidic compounds. IT is given either 2 drops nasally plus 6 drops orally or 6 oral drops only of COVIDEXTm three times daily for 7 days.
224250053|NCT02258620|DRUG|dinitrate isosorbide|dinitrate isosorbide (cedocard\*) by continuous intra venous (1 to 5 mg/h) dinitrate isosorbide (cedocard\*) 5 mg by intra arterial direct in the sheat
224250054|NCT02258620|DRUG|nitroglycerine|nitroglycerine dermal patch 15 mg/24h : 67,2 mg/21 cm2
224250055|NCT02731534|DRUG|Z-213|The total iron dosage is calculated based on hemoglobin value and the patients' weight, IV on day 1, 8 and 15 (if needed)
224250056|NCT02731534|DRUG|Saccharated Ferric Oxide|The total iron dosage is calculated based on hemoglobin value and the patients' weight, IV two or three times per week
224250057|NCT05514860|PROCEDURE|Cryoballoon-based PVI|Patients randomized to first-line cryoballoon (CB) ablation will have the pulmonary vein isolation procedure performed according to standard clinical practice using the Arctic Front Cryoballoon ablation catheter. No anti-arrhythmic drugs will be prescribed in this arm.
224250058|NCT05514860|DRUG|Anti-Arrhythmic Drug Therapy|Antiarrhythmic drug therapy (Class I - flecainide, propafenone; Class III - sotalol, dronedarone) will prescribed and monitored based on local clinical practice, and according to guideline-suggested drug management for symptomatic patients with paroxysmal AF.
224250059|NCT01265056|DRUG|Gabapentin|"On Study day 1: 1200mg (single dose).~Study day 2,3: 300mg TID, 900mg daily.~Study day 4-7: 600mg TID 1800mg\* daily.~Study day 8-11: 800mg TID 2400mg\* daily \[Optional increase to 2400 if pain scores are still 4 on NRS\]~Study day 11: 1200mg TID 3600mg\* daily \[Optional increase to 3600 if pain scores are still \>4 on NRS\]~\* May revert back to prior dose if adverse symptoms occur and are thought to be drug related. Up titration then will be preformed in 48 hours following deexcalation."
224250060|NCT01265056|DRUG|Placebo|Sugar Pill is administered similar to the protocol used for the investigational drug.
224250061|NCT01229618|DRUG|Hyperpolarized Pyruvate (13C) injection|single hyperpolarized pyruvate IV (intravenous) injection followed by MR imaging scans (MRI and MRSI)
224250062|NCT01416584|BEHAVIORAL|methadone contingency|Participants had to enroll in methadone treatment and take daily doses of methadone to gain access to the workplace.
224250063|NCT01416584|BEHAVIORAL|Methadone & Abstinence Contingency|Participants had to enroll in methadone treatment and take daily doses of methadone to gain access to the workplace and they had to provide opiate and cocaine negative urine samples to maintain the maximum pay.
224250064|NCT01387633|OTHER|Educational intervention for family members/caregivers of people with diabetes mellitus through telephone contact|For family members/caregivers: telephone contacts will be conducted in day and time which family member/caregiver prefers, and he/she may make collect calls to the researcher always he/she judges it necessary during the period of study. Phone contacts will be recorded to ensure the registration of orientation given, using a digital phone recorder PCTEL. And they will be arranged with the technique of motivational interviewing that includes the skills to ask, listen and inform. For this, protocols based on these skills, which the covered topics will be those worked in group sessions through Diabetes Conversation Maps. Voice quality related to the tone, volume and clarity as well as the skills and strategies to listen to the interviews will be worked under the guidance of an audiologist
224250065|NCT01387633|OTHER|Educational intervention group for people with diabetes through Diabetes Conversation Maps|For people with diabetes mellitus: educational interventions will be conducted in accordance with the assumptions of the Social Cognitive Theory, through Diabetes Conversation Maps , whose use is consistent with this theory (ADA, 2007). Diabetes Conversation Maps are a tool which involves people in the learning process about the disease, to make them able to process information more effectively and use them in making daily decisions in the management of diabetes mellitus (DM). It is recommended that this tool is used in small groups of three to ten people, in order to provide dynamic discussions among the participants (ADA, 2007). Currently, the maps that cover the following learning contexts: How the Body and Diabetes Work, Healthy Eating and Physical Activity, and Medication Treatment and Monitoring of Blood Glucose; Achieving the Goals with the Insulin and Weather Map of Diabetic Foot are available for the Brazilian Portuguese language.
224250066|NCT01732172|OTHER|Sperm sample|Sperm sample
224250067|NCT01123694|OTHER|Survey Study|Survey regarding quality of life
223668916|NCT05568940|DRUG|Tibolone 2.5 Mg Oral Tablet|Tibolone oral therapy for 2-3 months: All participants will take a Tibolone 2.5 mg tablet orally daily, at the same time each day, following a scheduled, luteal-phase injection of leuprolide acetate 11.25mg intramuscular (IM).
223668917|NCT02057328|DRUG|TELMISARTAN|Patients of the group of telmisartan will take 40 mg of telmisartan daily in the morning. At the end of the first month of treatment, patients classified in the normal BP range based on the results of ABPM will continue on the same medication scheme. Patients still classified in the stage I hypertensive range will receive 80 mg of telmisartan daily in the morning. At the end of the 6th month from the beginning of the study patients classified in the normal BP range will continue on the same medication scheme. For patients still classified in the stage I hypertensive range12,5 mg of hydrochlorothiazide will be added. The end of the 12-month period from the beginning of the study indicates the completion of the project.
223771369|NCT01099995|OTHER|hyperbaric oxygen therapy|two dives at 2 absolute atmosphere (1-hour plateau) with 30 min of compression and 30 min of decompression - oxygen being delivered via a full face mask at 100% inspired oxygen fraction or via mechanical ventilation
223771370|NCT01697384|DRUG|histrelin acetate|52 week implant
223771371|NCT03563040|DRUG|Methoxsalen|"Methoxsalen is used in conjunction with the THERAKOS CELLEX Photopheresis System.~During each photopheresis treatment with methoxsalen, the dosage of methoxsalen is calculated according to the treatment volume (which is displayed on the display panel of the instrument) using the formula:~Treatment volume x 0.017 ml of methoxsalen (20 µg/mL) for each treatment For example: Treatment volume = 240 mL x 0.017 = 4.1 mL of methoxsalen (20 µg/mL)"
223771372|NCT03563040|DEVICE|THERAKOS CELLEX Photopheresis System|Methoxsalen is used in conjunction with the THERAKOS CELLEX Photopheresis System.
223771373|NCT01607905|DRUG|Selinexor|Participants in this study will receive selinexor orally at dose levels specified for their respective dose cohorts. Dosing will begin at 3 mg/m\^2 twice a week and will escalate until the MTD or RP2D is determined. Cycles will be repeated in 4-week (28 days for schedule 1 to 7) and 3-week (21 days for schedule 8) intervals until progression of disease, unacceptable toxicity, or another discontinuation criterion is met. In the case of toxicity, dose adjustment will be permitted.
223771374|NCT01607905|DRUG|Acetaminophen|Oral 500 mg (in Cycle 1, Week 1) to 1000 mg (in Cycle 1, Week 2 and onwards) of acetaminophen will be administered 1 hour prior to each selinexor dose up to 8 doses per cycle (28 days per cycle)
223771375|NCT00129519|DRUG|Imiquimod 5% cream|Imiquimod 5% cream applied once daily 5x/week for up to 6 weeks
223771376|NCT02356835|DEVICE|APT001|APT001, is a portable device that uses plasma energy to deliver nitric oxide to the tissues.
223771377|NCT02356835|DEVICE|SHAM|Portable device that uses warmed room air to mimic delivery of the APT001 treatment.
223771378|NCT03614026|BEHAVIORAL|Teachers and Parents as Partners|Family-school partnership intervention
223668918|NCT02057328|DRUG|NEBIVOLOL|Patients will take 5 mg of nebivolol daily in the morning. At the end of the first month of treatment, patients classified in the normal BP range based on the results of ABPM will continue on the same medication scheme. Patients classified in the stage I hypertensive range the nebivolol group will receive 10 mg of nebivolol daily in the morning. At the end of the 6th month from the beginning of the study patients classified in the normal BP range based on the results of ABPM will continue on the same medication scheme. For patients classified in the stage I hypertensive range 12,5 mg of hydrochlorothiazide will be added. The end of the 12-month period from the beginning of the study indicates the completion of the project
223771379|NCT04132349|DRUG|Ulipristal Acetate 5 mg|Ulipristal acetate (from Cenexi manufacturer, France) at daily dose of 5mg in 3 consecutive months course
224250068|NCT03698981|BEHAVIORAL|Mothers Moving towards Empowerment (MME)|"MME integrates 3 components: 1) psychoeducation regarding causes, transmission, and treatment of HIV re how adherence to ART and antenatal care acts to promote health for HIV+ women and PMTCT82,83. We will emphasize ART adherence spanning into PP as a maternal duty to raise a healthy child; 2) challenging stereotypes of HIV+ women, such as promiscuity, that threaten core aspects of being a good woman and hinder treatment adherence; 3) coping skills for HIV-related discrimination, i.e., rejection or abandonment by male partners leading to discontinuing treatment adherence and impacts on raising children."
223668919|NCT02710955|DIETARY_SUPPLEMENT|Thickened infant formula|
223668920|NCT04285840|OTHER|Venous ACT|Matched/paired venous ACT samples will be drawn at the same time as arterial ACT samples to compare the results agreement between venous and arterial ACTs. Subjects undergoing atrial fibrillation ablations will continue to have Heparin dosed on the arterial ACT sample results only per the standard of care. Heparin will not be administered based on venous ACT levels obtained during this study.
224250069|NCT00155545|BEHAVIORAL|Motion analysis of patients|
224250070|NCT03289286|OTHER|Dedicated and coordinated e-follow-up.|"In pre- and post-surgery:~* Completion of questionnaires using an electronic tool,~* Telephone follow-up if necessary between the nurse and the patient."
224250071|NCT05552833|OTHER|High intensity interval training|Participants will undergo 12 weeks of supervised HIIT training (3 times per week). The HIIT protocol will consist of 4x4 min.
224250072|NCT05596279|DIAGNOSTIC_TEST|Intravascular ultrasound|Hybrid IVUS-OCT and control IVUS were performed after stenting
223668921|NCT02883257|BEHAVIORAL|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy will include core mandatory modules of key effective components (e.g., behavioural activation, cognitive restructuring) and optional elements to address individual maintaining factors (e.g., coping and social skills training, perfectionism and self-criticism).
223668922|NCT01352403|PROCEDURE|Roux-en-Y gastric bypass|
223668923|NCT01352403|BEHAVIORAL|Psychotherapy-enhanced lifestyle intervention|
223771380|NCT00134108|BEHAVIORAL|Cognitive Behaviour Therapy|
223771381|NCT01105533|DRUG|PF-00337210|0.67mg Capsule Once Daily (Accelerated Dose Escalation) Continuous
223771382|NCT01105533|DRUG|PF-00337210|1mg Capsule Once Daily (Dose Escalation) Continuous
223771383|NCT01105533|DRUG|PF-00337210|2mg Capsule Once Daily (Dose Escalation) Continuous
223771384|NCT01105533|DRUG|PF-00337210|4mg Capsule Once Daily (Dose Escalation) Continuous
223771385|NCT01105533|DRUG|PF-00337210|6mg Capsule Once Daily (Dose Escalation) Continuous
223771386|NCT01105533|DRUG|PF-00337210|9mg Capsule Once Daily (Dose Escalation) Continuous
224250073|NCT05596279|DIAGNOSTIC_TEST|Optical coherence tomography|Hybrid IVUS-OCT and control OCT were performed after stenting
223771387|NCT01105533|DRUG|PF-00337210|8mg Capsule Once Daily (Dose Escalation) Continuous
223771388|NCT01105533|DRUG|PF-00337210|4mg Capsule Twice Daily (Dose Escalation) Continuous
223771389|NCT01105533|DRUG|PF-00337210|6mg Capsule Twice Daily (Dose Escalation) Continuous
223771390|NCT01105533|DRUG|PF-00337210|6mg Capsule Twice Daily (Dose Expansion) Continuous
223771391|NCT01363323|DRUG|Methylnaltrexone (MNTX)|Dose 1
223771392|NCT01363323|DRUG|Methylnaltrexone (MNTX)|Dose 2
223771393|NCT01363323|DRUG|Methylnaltrexone (MNTX)|Dose 3
223771394|NCT01363323|DRUG|Placebo|
223771395|NCT01363323|DRUG|Moxifloxacin|
223771396|NCT04183400|BEHAVIORAL|Safety Awareness For Empowerment (SAFE)|SAFE is a mindfulness-based cognitive-behavioral intervention that aims to build risk-related attention skills.
223771397|NCT01977911|OTHER|Stem cell based tissue engineered partial laryngeal implants|Stem cells from the patient receiving the implant are removed from the bone marrow, and are then grown on the scaffold in the laboratory. These cells will form the cartilage in the wall of the scaffold. The implant can be considered 'living' due to the cells grown on it, and this type of treatment is referred to as 'tissue engineering' or 'regenerative medicine'. Once these cells have attached and started to grow on the scaffold, it is ready to be implanted into the patient and a two separate operative stages can occur. The final stage of the operation involves removing the narrow section of voicebox or upper windpipe and implanting the scaffold to reconstruct it.
223771398|NCT01917045|DRUG|Sufentanil (R30730, brand name Sufenta)|sufentanil 1ug/ml
223771399|NCT01917045|DRUG|Sufentanil (R30730, brand name Sufenta) + Morphine|sufentanil 0.5ug/ml+morphine 0.25mg/ml
223771400|NCT01917045|DRUG|Morphine|morphine 0. 5mg/ml
223668924|NCT01336400|OTHER|single cell haplotyping|We aim to collect single blastomeres from spare IVF embryos of 30 couples to optimize and test methods for single cell haplotyping. We aim to collect 20 and 10 couples coming to the fertility centre for FISH- or PCR-based PGD respectively. In both groups, at least 5 different indications for PGD will be collected. Per couple, we will perform 10 SNP-arrays: 2 for the couple donating the embryo, 4 for family members (often parents of the couple) and 4 for blastomeres since we aim to pick 2 cells from 2 embryos per couple. For five couples, 2 blastomeres of all available embryos will be aspirated to validate and optimize the phasing methods. Finally, for some embryos, all blastomeres will be picked to be able to prove the reproducibility of single cell haplotyping.
223668925|NCT01494493|DEVICE|rhBMP-2/ACS/allograft bone dowel|The rhBMP-2/ACS used in conjunction with an allograft bone dowel.
223668926|NCT01494493|PROCEDURE|Autogenous bone/allograft bone dowel|An allograft bone dowel containing autogenous bone taken from the patient's iliac crest.
223668927|NCT05622760|OTHER|Audiovisual information|The information provided to this group is in audiovisual format. This information is what has been designed with the aim of reducing the level of anxiety of patients who participate in cervical cancer screening.
223668928|NCT05622760|OTHER|Written information|The information provided to this group is in written format. This information is what is distributed to patients in the midwife's consultation and is available on the website of the health organization (Osakidetza)
223668929|NCT00852839|DRUG|Placebo|Placebo to match oromucosal formulation of 552-02
223668930|NCT00852839|DRUG|552-02|The oromucosal formulation of 552-02 contains 552-02 (25 μg/mL), surfactant, flavoring agents, a humectant, and preservatives.
223668931|NCT00019994|BIOLOGICAL|MART-1 antigen|
223668932|NCT00019994|BIOLOGICAL|aldesleukin|
223668933|NCT00019994|BIOLOGICAL|gp100 antigen|
223668934|NCT00019994|BIOLOGICAL|incomplete Freund's adjuvant|
223668935|NCT02108678|BEHAVIORAL|ACT-ME|1 hour discussion about migraine education (ME) and 5 hours of group therapy based on Acceptance and Commitment Therapy (ACT). Migraine education covers topics including migraine symptoms, triggers for worsening of migraine symptoms, how to use migraine medications, medication overuse headache, etc. The ACT intervention includes: 1) Behavioral Change Training and; 2) Mindfulness and Acceptance Training emphasizing new ways of managing troubling thoughts, feelings, and physical sensations.
223668936|NCT02108678|BEHAVIORAL|Migraine Education Only|6 hour discussion of migraine education only (MEO). This will involve educating participants about migraine, its natural course, its prodromal symptoms and triggers for symptom worsening, risk for migraine chronification, how to use abortive migraine medications, medication overuse headache, medical and psychological treatments of migraine, migraine comorbidity, and menstrual migraine.
223668937|NCT00781885|DRUG|Beraprost sodium modified release|Tablets 60mcg
223668938|NCT04944680|BEHAVIORAL|Transcranial Direct Current Stimulation therapy|Transcranial Direct Current Stimulation with two saline-soaked electrodes (5cm x 7cm) is applied by our occupational therapist. The anode is placed on the ipsilesional primary motor cortex (C3/C4). The cathode is placed on the contralesional shoulder. The current is 1.5 milliampere and lasts 20 minutes.
223668939|NCT04944680|BEHAVIORAL|Motor imagery therapy|Stroke patients are asked to watch a video about the upper extremity movement. The video lasts 20 minutes. The contents are as follows: the patients are asked to relax the muscles for the first 2 minutes; the action refers to shoulder flexion and extension, elbow flexion and extension, forearm pronation and supination, wrist flexion and extension, finger flexion and extension, and corresponding daily functional activities for 16min; the patients are asked to relax their mind and body for the last 2 minutes.
223668940|NCT04944680|BEHAVIORAL|Transcranial Direct Current Stimulation and motor imagery therapy|The treatment parameters are the same as the above. It should be emphasized that the participants sit and perform the motor imagery task while receiving Transcranial Direct Current Stimulation.
223668941|NCT01755026|DRUG|cefazolin|2 gram dose for pre-operative prophylaxis
223668942|NCT01755026|DRUG|cefazolin|4 gram dose for pre-operative prophylaxis
223668943|NCT00115921|BEHAVIORAL|Provision of antimalarial treatment at home|
223668944|NCT06374043|DRUG|Dapagliflozin 10mg Tab|Oral administration
223668945|NCT06374043|DRUG|Placebo|Oral administration
223668946|NCT06374043|DEVICE|Withings BPM Connect|"CE marked and clinically validated blood pressure monitor. Clinical trial results are within the margin of acceptance defined by the internationally recognized evaluation standard of blood pressure monitors ANSI/AAMI/ISO 81060-2:2013, EN ISO 81060-2:2014, developed by the European Society of Hypertension, British Hypertension Society and Association for the Advancement of Medical Instrumentation/American Heart Association.~Blood pressure will be measured by the participants once daily on 28 days. Three consecutive measurements are taken."
223668947|NCT06374043|DEVICE|Withings Body+|"CE marked and clinically validated advanced Wi-Fi smart scale.~Body weight will be measured by the participants once daily on 40 days."
223668948|NCT06374043|DIAGNOSTIC_TEST|Hem-Col Capillary Blood Collection Device|Capillary blood samples will be obtained using a BD Microtainer® Contact-Activated Lancet (Franklin Lakes, New Jersey, USA) once daily on 22 days. These blood samples will be collected into Hem-Col® tubes (Hem-Col, Labonovum, Limmen, the Netherlands), specifically designed for collection of capillary blood acquired through a finger prick. The Hem-Col microtube is equipped with an anticoagulant and a preservation buffer, enhancing the stability of analytes in whole blood. These Hem-Col tubes have the dimensions of standard blood collection tubes and are constructed from polyethylene, featuring a pierceable cap made of thermoplastic elastomers. Each tube incorporates a liquid barrier, with the inner part preventing the loss of Hem-Col preservation fluid and the outer part serving as a scoop for collecting blood from a finger prick. The Hem-Col lithium heparin tubes will be utilized for the analysis of creatinine, CRP, lipid profile, HbA1c, uric acid, glucose and NT-proBNP.
223668949|NCT06374043|DEVICE|MEMS (Medication Electronic Monitoring System) Cap|Medication will be provided in standard medicine bottles with the MEMS® (Medication Electronic Monitoring System) Cap (AARDEX Ltd, Union City, CA, USA), which is a customizable medication package which records and stores up to 4,000 dosing events. The cap fits on standard medicine bottles and with integrated microcircuits, the child-resistant MEMS® Cap records the date and time whenever a patient opens a vial. The stored information can be transferred at any time through the MEMS® Reader to the adherence software for immediate analysis and interpretation.
224250074|NCT01565876|DEVICE|"Minkal- Auxiliary device to alleviate backload"|"The participants will undergo 6 days of study. The first day of the study include medical examination, maximal oxigen consumption day and anthropometric mesurments.~Then The participants will undergo heat tolerance test 5 times (in different days).~first day- without load. second day- with back load of 40% of the body weight. third day- with back load of 40% of the body weight and the Auxilairy Device. fourth day- with back load of 60% of the body weight. fifth day- with back load of 60% of the body weight and the Auxilairy Device. The rectal temperature, skin teperature and heart rate will be mesured each day and compered afterwards."
224250075|NCT02130856|DEVICE|Neonatal kit|"Contents of the neonatal kit:~1. Clean birth kit: sterile blade, a clean plastic square, plastic gloves, hand soap, and cord ties/clamp.~2. 4% Chlorhexidine (CHX) lotion (15 mL) and a bag of cotton balls.~3. Sunflower oil emollient (50 mL)~4. ThermoSpot~5. Mylar infant sleeve~6. Click to heat warmer (http://www.heatinaclick.ca/products/pocket\_size.html) in a fitted cloth pouch.~7. Handheld electric scale with suspended cloth sling. The scale will not be included with the kit but rather one will be issued to each Lady Health Worker."
223668950|NCT06374043|BEHAVIORAL|Questionnaire: participants' perspectives toward remote data collection|Self-made questionnaires consisting of 6 multiple choice questions and 2 open questions will be used to assess patient experience and satisfaction to guide and inform future trials and use in clinical practice.
223668951|NCT05728099|DEVICE|Expiratory muscle strength training + SpiroGym application|Participants will performe an intensive home-based expiratory muscle training programme using an Expiratory Muscle Trainer (EMST150; Aspire Products, LLC, United States), which provide a pressure- threshold range from 30 to 150 cmH20. EMST therapy sessions will be completed at home on 5 days of the patients choosing per week. Participants will be instructed to perform five sets of five forceful expirations coupled with SpiroGym app. per training session for 8 weeks (intensive training period). For another 16 weeks (maintenance period) participants will be instructed to perform, at least twice per week, five sets of five forceful expirations coupled with SpiroGym app. per training session .
223668952|NCT05728099|DEVICE|Expiratory muscle strength training|Participants will performe an intensive home-based expiratory muscle training programme using an Expiratory Muscle Trainer (EMST150; Aspire Products, LLC, United States), which provide a pressure- threshold range from 30 to 150 cmH20. EMST therapy sessions will be completed at home on 5 days of the patients choosing per week. Participants will be instructed to perform five sets of five forceful expirations per training session for 8 weeks (intensive training period). For another 16 weeks (maintenance period) participants will be instructed to perform, at least twice per week, five sets of five forceful expirations per training session. Participants will be given the practice log to track training adherence.
223668953|NCT04231370|DRUG|Sintilimab|Sintilimab, 200mg, iv day1
223668954|NCT04231370|DRUG|Lenalidomide|25mg/d oral d1-14
223668955|NCT05516563|OTHER|EDucation and eXercise intervention|"The exercise programme includes 3 key streams:~1. Low-load isometric abduction~2. Functional loading~3. Abductor loading: Graduated abductor loading, designed to improve load tolerance by applying progressively higher loads across the abductor muscles. Daily exercise will be completed three days a week at a 'hard' to 'very hard' level, alternating with three 'light' days and one rest day. The clinic day will constitute one of the 'hard' days.~Education will be delivered via a 20 minute video which focusses on understanding and managing lateral hip pain ( ie pain associated with gluteal tendinopathy). Education will also be tailored to each patient on attendance with the physiotherapist at the 6 clinic visits"
223668956|NCT01757340|BEHAVIORAL|Weight loss with normal protein and leucine intake|Goal of 8 to 10% weight loss while consuming the recommended daily allowance of protein (i.e, 0.8 grams of protein per kg body weight per day).
223668957|NCT01757340|BEHAVIORAL|Weight loss with protein/leucine supplementation|Goal of 8 to 10% weight loss while consuming 150% of the recommended daily allowance of protein (i.e., 1.2 grams of protein per kg body weight per day) with the additional protein given in the form of whey protein, which has a high leucine content.
223668958|NCT03071250|PROCEDURE|Total knee or Hip Arthroplasty|Patients who received either a total knee or hip arthroplasty will be identified
223668959|NCT04359381|OTHER|kinesiotaping application|kinesiotaping was applied once the menstrual pain begins (one day before menstruation) for periods of 4 to 5 days until the pain disappears and then removed it. Kinesiotaping was used for 3 successive menstruations.
223668960|NCT04359381|OTHER|Pilate exercises program|Each girl in group (B) was engaged in a supervised pilate exercises program for 30 minutes per session for 3 days/week for 12 weeks except days of menstruation. Participants would be oriented to wear comfortable clothes .
223668961|NCT03878641|BEHAVIORAL|Children in Grade 1 to 5 with literacy and language needs|The investigators deliver a telepractice-based intervention targeting: (a) Word reading and phonics instruction, (b) applying a comprehension monitoring strategy to improve text reading accuracy, and (c) complex sentences use in written text. Participants receive 3 online 50-minute tutoring session weekly across 15 weeks.
223668962|NCT02184624|DEVICE|ELLIPTA|Dry powder inhaler (placebo) with two blister strips. One placebo strip containing lactose monohydrate and a second placebo strip containing lactose monohydrate blended with magnesium stearate.
223668963|NCT02184624|DEVICE|DISKUS/ACCUHALER|Placebo inhaler with one blister strip containing lactose monohydrate.
223668964|NCT02184624|DEVICE|MDI|Placebo inhaler containing propellant (1,1,1, 2-Tetrafluoroethane).
223668965|NCT02184624|DEVICE|TURBUHALER|Placebo inhaler containing lactose monohydrate.
223668966|NCT02184624|DEVICE|HANDIHALER|Placebo inhaler containing lactose monohydrate in a capsule.
223668967|NCT02184624|DEVICE|BREEZEHALER|Placebo inhaler containing lactose monohydrate in a capsule.
223668968|NCT03417713|DEVICE|Fluoroscopic imaging with the OEC Elite Device|Vascular, gastrointestinal (GI), urology or pain management procedures for which use of the OEC Elite system in the vascular configuration would be prescribed.
223668969|NCT06194045|DIETARY_SUPPLEMENT|LC-MUFA oil|2 x 1 g capsules containing marine oil from North Atlantic fish
223668970|NCT06194045|DIETARY_SUPPLEMENT|Placebo|2 x 1 g capsules containing corn oil
223771401|NCT02096835|DEVICE|Transcutaneous electrical acupoint stimulation|A surface electrode will be applied to the P6 acupoint on the dominant upper extremity, located approximately 3cm proximal to the distal wrist crease between the tendons of the flexor carpi radialis and the palmaris longus, and a negative surface electrode placed on the opposing dorsum aspect of the forearm.
224250076|NCT00064974|DRUG|CC-5013|CC-5013 10 mg (two 5 mg capsules) daily on days 1-28 every 28 days (28 day cycles)
224250077|NCT02601560|BIOLOGICAL|MEDI6012|Participants received a single IV (24, 80, 240, and 800 mg) and SC (80 and 600 mg) MEDI6012 doses on Day 1.
224250078|NCT02601560|BIOLOGICAL|Placebo SC|Participants received a single SC dose of placebo matched to MEDI6012 on Day 1 of the study.
223668971|NCT00886847|PROCEDURE|Lymph Node Needle Tissue Collections|Total of two lymph nodes sampled per patient. Four biopsies will be taken from each lymph node. Two with suction (FNA) and two without suction (FNC).
223668972|NCT03952949|BEHAVIORAL|Default Option While Online Grocery Shopping|"The default option is a behavioral economics construct that refers to the option a consumer selects if no active choice is made (e.g. opt-out 401K plans, which significantly increase enrollment, compared to active sign up). Participants in the default condition were presented with a prefilled online shopping cart containing groceries that met nutritional requirements based on participants' gender and age."
224250079|NCT02601560|BIOLOGICAL|Placebo IV|Participants received a single IV dose of placebo matched to MEDI6012 on Day 1 of the study.
224250080|NCT03459807|DRUG|Anti-Hypertensive medications|Use of standard Anti-Hypertensive medications
223668973|NCT03952949|BEHAVIORAL|Nutrition Education|"The nutrition education materials were adapted from materials currently utilized by the New York State Office of Temporary and Disability Assistance (Eat Smart New York)."
223668974|NCT00651079|DRUG|GSK1247303|
223668975|NCT05813223|DRUG|Gefapixant|Purinergic (P2X3) Receptor antagonist. Film-coated tablet taken orally.
223668976|NCT02642497|DRUG|intra-wound instillation of ketamine|intra-wound instillation of ketamine (1 mg/ kg) and normal saline in a total volume of 10 ml dispersed evenly throughout the wound; given after hemostasis and before wound closure
223668977|NCT02642497|DRUG|intra-wound instillation of normal saline|intra-wound instillation of normal saline in a total volume of 10 ml dispersed evenly throughout the wound; given after hemostasis and before wound closure
223668978|NCT02642497|DRUG|systemic administration of ketamine|intra-muscular administration of ketamine (1 mg/ kg), given before wound closure.
223668979|NCT02414529|DRUG|Vitamin D2|Ergocalciferol 5000 units capsules given. 300,000 units PO once.
223668980|NCT02414529|DRUG|Placebo|
223668981|NCT04783558|BEHAVIORAL|Mobile-based NAS Caregiving Tool|The information and skills training in the adapted NAS caregiving tool will be largely based on elements of Eat Sleep Console. Therefore, the NAS mobile tool intervention will incorporate non-intrusive caregiving skills and strategies that encompass providing a low stimulating environment (e.g., dimmed light and low noise), swaddling, continuous comfort and contact with caregiver, skin-to-skin contact, frequent breastfeeding/feeding, as well as novel components identified in the key informant interviews (e.g., preparing for stigma during delivery, CPS involvement, etc.).
223668982|NCT04375319|DEVICE|OCT|OCT can provide clear in vivo imaging and evaluate the vascular repair after stent implantation by measuring the optical echo of near-infrared light reflection
224250081|NCT03459807|PROCEDURE|Dry Weight Adjustment|The participant's target post-dialysis dry weight is adjusted
224250082|NCT02431494|DEVICE|Blue light phototherapy|Blue light phototherapy (BLU-U Blue Light Photodynamic Therapy Illuminator manufactured by DUSA Pharmaceutical Inc. Wilmington, MA) At each session, the affected areas of the participant's face will be exposed to a light source using blue light phototherapy machine between 15 to 20 minutes. The duration of each session will be approximately 20 minutes.
224250083|NCT02431494|DEVICE|Microcurrent therapy|Microcurrent therapy (Micro Current Electro-Device w/gloves and carrying case, SKU:DSE-X1008 Classic Spa Collection) The investigators will place one electrode in one of the regional areas of the lymph nodes or affected area (i.e. the forehead) and move the second electrode systematically from the affected area towards the stationary electrode. Once the entire affected area has been covered, the investigators will move the first electrode to another regional area of the lymph nodes or affected area and the process will be repeated. This will continue until all of the affected areas have been treated. The duration of each session will be approximately 45 minutes.
224250084|NCT02431494|DEVICE|Combination of BLP and Microcurrent|Same devices as described above. At each session, participants will receive MCT portion as described in above followed by BLP portion as described above. These visits will last approximately 65 minutes.
224250085|NCT03859102|DIETARY_SUPPLEMENT|Pre-operative Carbohydrate PreLoad drink|Pre-operative Carbohydrate PreLoad drink, 1 sachet given the night before surgery. One sachet given 2-4hours before surgery.
224250086|NCT03859102|DRUG|Oral Gabapentin pre-op|One dose of Gabapentin pre-operatively, 300mg orally.
224250087|NCT03859102|DRUG|Oral Lansoprazole pre-op|One dose of Lansoprazole pre-operatively, 30mg orally.
223668983|NCT00127270|DRUG|Darifenacin|Darifenacin tablets 7,5 mg once daily with the possibility to up-titrate to 15 mg once daily
223668984|NCT00127270|DRUG|Darifenacin|Darifenacin tablets 7,5 mg or 15 mg once daily
223668985|NCT00127270|BEHAVIORAL|Behavioral therapy|Behavioral Modification Programme for symptoms of overactive bladder
224250088|NCT03859102|DRUG|Intravenous Paracetamol intra-operatively|One dose of Paracetamol intra-operatively, 1gram intravenous infusion.
224250089|NCT03859102|DRUG|Intravenous Dexamethasone intra-operatively|One dose of Dexamethasone intra-operatively as an anti-emetic, 8mg intravenous.
224250090|NCT03859102|DRUG|Intravenous Ondansetron intra-operatively|One dose of Ondansetron intra-operatively as an anti-emetic, 4mg intravenous
224250091|NCT03859102|DRUG|Infiltration of surgical wounds with local anaesthetic|Infiltration of surgical wounds with local anaesthetic at the end of surgery, Bupivacaine 1-2mg/kg.
224250092|NCT03859102|DRUG|Intravenous Magnesium intra-operatively|One infusion of intravenous Magnesium Sulphate intra-operatively as an analgesic, 50mg/kg given over 30minutes.
224250093|NCT03859102|DRUG|Post-operative Gabapentin analgesia|Post-operative oral Gabapentin 300mg, three times daily as an analgesic.
224250094|NCT03859102|DRUG|Post-operative oral Paracetamol analgesia|Post-operative Paracetamol as an analgesic. Initially intravenously, then orally. One gram four times daily.
224250095|NCT03859102|DRUG|Post-operative Ondansetron anti-emesis|Intravenous Ondansetron administered post-operatively as prophylactic anti-emesis. 4mg three times daily, for 24 hours. Then as required.
224250096|NCT03859102|PROCEDURE|Early extubation|Removal of the endotracheal tube in the Intensive Care Unit as soon as is safe.
224250097|NCT03859102|PROCEDURE|Early mobilisation/physiotherapy|Mobilisation (active and passive limb movements, deep breathing) with the assistance of nurse/physiotherapist to occur as soon as possible post-operatively.
224250098|NCT03859102|OTHER|Encourage early oral food intake|Patients will be encouraged to start eating as soon as possible post-operatively
224250099|NCT05952986|DRUG|FB825 or Placebo in subcutaneous route|FB825 or placebo solution for SC injection
224250100|NCT05952986|DRUG|FB825 in intravenous route|FB825 solution for IV infusion
224250101|NCT02409979|OTHER|Carbon dioxide method|Insufflation with CO2 during insertion and withdrawal phases of colonoscopy.
224250102|NCT02409979|OTHER|Water Exchange-CO2|Insertion using water exchange, withdrawal using CO2 insufflation.
224250103|NCT02409979|OTHER|Water Exchange-AI|Insertion using water exchange, withdrawal using air insufflation.
224250104|NCT02082392|DRUG|Escitalopram|
224250105|NCT02082392|DRUG|Placebo|A substance or treatment of no intended therapeutic value in a pill form.
224250106|NCT03401086|OTHER|Kinesio Taping|Kinesio Taping
224250107|NCT05643976|BEHAVIORAL|KardioPAC Mobile Application|"Like those in the SOC CR arm, participants assigned to the CR+KardioPAC arm will receive standard of care and attend CR as prescribed by their physician. Additionally, they will receive access to the digital app, KardioPAC, \& a BP device for home use that will record their BP readings in the app.~KardioPAC is a remote patient monitoring system that allows providers to monitor patients and send out daily reminders. It integrates with BP monitors and fitness watches to collect patient health information at home. The information is uploaded to the HIPAA-compliant server and presented on the website for providers to read. Its reminder system can be customized to meet diverse clinical needs.~Lastly, the Kura Care in-house Registered Nurse will provide 20-30 min of health coaching to intervention arm participants on a weekly or bi-weekly basis via the app. The coaching will include greetings, review of medication adherence, encouragement to exercise, and symptom management, if applicable."
224250108|NCT05643976|OTHER|Standard of Care|During the prescribed cardiac rehabilitation, the SOC CR intervention participants will receive standard of care by attending the 36-72 sessions of CR as prescribed by his/her physician and administered by the University of California San Diego Health Cardiac Rehabilitation Center.
223668986|NCT04870697|BEHAVIORAL|ACT intervention|"The components of ACT intervention will include six processes to foster parental PF according to the ACT framework.~Session one - Generate creative hopelessness and build acceptance. The objective is to help parents know about the ACT intervention and realize the experiential avoidance or emotional control strategies do not work, finally turn attention to more useful strategies.~Session two - Create space for your thought. The objective is to help parents create a distance from their thoughts and facilitate parents' ability of not being trapped by thoughts.~Session three - Focus on here and now. The objectives to facilitate parents' experiences of observing self and contact with the present moment but not trapped in the past or future.~Session four - Commit actions in line with the value. The objectives to help parents identify their inner value and take value-based actions even facing the challenges in current difficulties of their children with cancer."
223668987|NCT04870697|OTHER|Usual care|Usual care in this study setting includes providing general information, education, psychological support, and consultation.
223668988|NCT04267900|DRUG|99mTc-HPArk2|99mTc-HPArk2 were injected into the patients before the SPECT/CT scans
223668989|NCT00349115|DRUG|Thalidomide|
223668990|NCT00361933|DRUG|Valganciclovir|valganciclovir open label, two 450mg tablets orally, twice a day
223668991|NCT03523598|OTHER|Placebo gel + Normal Toothpaste|"* 15 days before and during the period of bleaching sessions: Tooth paste used will be normal (Colgate).~* Teeth will be cleaned using rubber cups associated to pumice and water;~* Relative isolation with roller cotton will be done;~* Prior to each bleaching session, the patients will receive the placebo gel application on vestibular surface, for 10 minutes.~* Gingival dam will be performed using a fluid resin.~* A 35% hydrogen peroxide based bleaching agent will applied on the vestibular surface of teeth, remaining for 40 minutes."
223668992|NCT03523598|OTHER|Placebo Gel + Potassium Nitrate Toothpaste|"* 15 days before and during the period of bleaching sessions: Tooth paste used will be normal tooth paste (Colgate).~* Teeth will be cleaned using rubber cups associated to pumice and water;~* Relative isolation with roller cotton will be done;~* Prior to each bleaching session, the patients will receive the 5% Potassium Nitrate gel application on vestibular surface, for 10 minutes.~* Gingival dam will be performed using a fluid resin.~* A 35% hydrogen peroxide based bleaching agent will applied on the vestibular surface of teeth, remaining for 40 minutes."
223668993|NCT03523598|OTHER|Potassium Nitrate Gel + Normal Toothpaste|"* 15 days before and during the period of bleaching sessions: Tooth paste used will be Potassium Nitrate containing (Sensodyne).~* Teeth will be cleaned using rubber cups associated to pumice and water;~* Relative isolation with roller cotton will be done;~* Prior to each bleaching session, the patients will receive the placebo gel application on vestibular surface, for 10 minutes.~* Gingival dam will be performed using a fluid resin.~* A 35% hydrogen peroxide based bleaching agent will applied on the vestibular surface of teeth, remaining for 40 minutes."
223668994|NCT04504409|OTHER|Rehabilitation|Training
223668995|NCT03964558|DRUG|[14C]-acebilustat solution|Acebilustat is a novel synthetic small molecule leukotriene A4 hydrolase (LTA4H) inhibitor.
223668996|NCT06114524|OTHER|binaural music|In the binaural music group, an MP3 player and in-ear stereo headphones were provided. Music therapy was applied for 15 min before the procedure.
224250109|NCT06037772|OTHER|subcutaneous injection administration game|The subcutaneous injection practice game was developed to examine nursing students' injection practice skills and its effect on their satisfaction with learning.
224250110|NCT06037772|OTHER|control group|only
224250111|NCT05344053|OTHER|Community-based precise management|The community-based precise management is a modified management strategy beyond the traditional standard community-based care under the hierarchical medical system of China. In the intervention arm, the community doctors receive training to improve their skills on coronary artery disease management. Patients will be under management for 1 year according to the strategies of community-based precise management and rehabilitation model.
224250112|NCT05344053|OTHER|Standard community-based management|The standard community-based management is the usual community-based care under the hierarchical medical system of China. In this arm, the community doctors will not receive any training on precise management strategies to improve their skills on coronary artery disease management, and patients will be under usual care for 1 year.
224250113|NCT00802763|DEVICE|NORMA-SENSE|Should be used by the clinician. the test usage will take up to 6 hours. The result reading will take few second.
224250114|NCT03119935|DEVICE|Amflow|Amflow deviced was developed for monitoring ventiation rate and ventilation volume. Participants ventilated the simulated patients by Amflow-device assist ambu bag
224250115|NCT03119935|DEVICE|Ambu bag|Participants ventilated the simulated patients by ambu bag
224250116|NCT01356849|DRUG|Atrasentan|Subjects will take two tablets daily of either low dose Atrasentan QD or high dose Atrasentan QD for 12 weeks during the treatment period.
224250117|NCT01356849|DRUG|Placebo|Subjects will take two tablets daily of placebo QD for 12 weeks during the treatment period.
224250118|NCT04444505|OTHER|Prospective study with two measurement points investigating the impact of viral mitigation protocols on mental health|Prospective study with two measurement points investigating the impact of viral mitigation protocols on mental health
224250119|NCT02799108|DEVICE|NIRS|High-resolution EEG-fNIRS recording lasting a maximum of 30 minutes by using expressive and receptive language paradigms
224250120|NCT02799108|DEVICE|fMRI|fMRI acquisition under the same stimulation conditions
224250121|NCT00833937|DRUG|Zolpidem 10 mg tablets|1 x 10 mg
224250122|NCT00833937|DRUG|AMBIEN® 10 mg tablets|1 x 10 mg
223668997|NCT02104037|PROCEDURE|Lumbar puncture|
223668998|NCT00118495|DRUG|Non-prescription Zestra(TM): patented formulation|
223668999|NCT00825253|DRUG|biphasic insulin aspart 30|
223669000|NCT00825253|DRUG|biphasic human insulin 30|
223669001|NCT00795678|DRUG|capecitabine|Capecitabine is an oral prodrug of 5 deoxy-5-fluorouridine (5DFRU) that is converted to 5-fluorouracil (5-FU). 5-FU is metabolized to 5-fluoro-2-deoxyuridine monophosphate (fDUMP) and 5-fluorouridine triphosphage (FUTP) which cause cell injury. Capecitabine is supplied in 150 mg (light peach colored) and 500 mg tablets (film coated)and will be administered pre-operatively.
223669002|NCT00795678|DRUG|cyclophosphamide|Cyclophosphamide is biotransformed principally in the liver to active alkylating metabolites that cross-link tumor cell DNA. Cyclophosphamide is supplied in 100 mg, 200 mg, 500 mg and 1 gram and 2 gram vials as a white powder. The drug should be reconstituted with Sterile Water for Injection, USP, and may be diluted in either normal saline or D5W. Cyclophosphamide will be mixed in 250 mL of D5W and infused over 30 minutes prior to surgery.
223669003|NCT00795678|DRUG|doxorubicin hydrochloride|Doxorubicin is an anthracycline anticancer agent which mediates tumoricidal effects by intercalating into double-stranded DNA and producing structural changes that disrupt DNA and RNA synthesis. Doxorubicin is supplied in 10, 20, and 50 mg single use vials, and 150 mg multidose vials as a red-orange, lyophilized power which has a storage stability of a least two years. The dose will be given 60mg/m2 over 15 minutes of time pre-operatively.
223669004|NCT00795678|DRUG|gemcitabine hydrochloride|Gemcitabine is a fluorinated deoxynucleoside prodrug which disrupts DNA synthesis and induces apoptosis in a broad number of human tumors, including breast cancer. Gemcitabine is supplied as a lyophilized powder in sterile vials containing 200 mg of 1000 mg (1 gram) of gemcitabine as the hydrochloride salt (expressed as the free base) mannitol and sodium acetate. Dosage will be 1250mg/m2, IV pre-operatively over 30 minutes.
223669005|NCT00795678|DRUG|lapatinib ditosylate|: Lapatinib ditosylate monohydrate tablets, 250 mg, are oval, biconvex, orange, film-coated tablets with one side of the tablet plain and other side of the tablet embossed with FG HLS. Lapatinib may also be supplied as oval, biconvex, tan tablets, with no markings. Lapatinib will be administered for at least 3 days pre-operatively at 1250mg.
224250123|NCT03725605|COMBINATION_PRODUCT|LTX-315 and TILs|Intratumoural injection of LTX-315 and infusion of TILs
224250124|NCT02281305|DRUG|Colchicine|
223669006|NCT00795678|DRUG|paclitaxel|Paclitaxel will be given as an intravenous infusion (80mg/m2) the morning of surgery as specified in the protocol, diluted in 0.9% Sodium Chloride Injection, USP, or 5% Dextrose Injection. Paclitaxel will be administered via an infusion control device (pump) using non-PVC tubing and connectors, such as the IV administration sets (polyethylene or polyolefin) which are used to infuse parenteral nitroglycerin.
224250125|NCT05463653|DEVICE|Experimental|A digital pad developed to help, support and monitor the adherence of patients to rehabilitation excercices post surgery
224250126|NCT01944800|DRUG|Ticagrelor|Loading dose of 180 mg, followed by maintenance dose of 180 mg per day
224250127|NCT01944800|DRUG|Prasugrel|Loading dose of 60 mg, followed by maintenance dose of 10 mg/day or 5 mg/day in patients =/\> 75 years or \< 60 kg
224250128|NCT06387771|DRUG|Tolcapone|Tolcapone (Film-coated tablet) 200 mg orally every 8 hours for 7 days
223669007|NCT00795678|DRUG|vinorelbine ditartrate|Vinorelbine (Navelbine®) is a unique semi-synthetic vinca alkaloid 3', 4-didehydro-4' deoxy-C'-norvincaleukoblastine (ditartrate) (IUPAC). The pyogen free, sterile parenteral dosage form is supplied in 10 mg/1 ml ampules/vials and 50 mg/5 ml vials. It will be administered at a dosage of 25mg/m2 IV over 10-30 minutes pre-operatively.
223771402|NCT02096835|DEVICE|Sham transcutaneous electrical acupoint stimulation|The same TEAS protocol will be applied unless silicone covers will be attached to both electrodes. The device will also be turned on during the procedure.
224250129|NCT04544787|BIOLOGICAL|Novel OPV2 candidate 1|"Live-attenuated serotype-2 poliovirus derived from a modified Sabin type-2 infectious cDNA clone and propagated in Vero cells; candidate 1 (S2/cre5/S15domV/rec1/hifi3).~Modifications included the following:~* Changes to the viral nucleotide sequence in part of the 5'-untranslated region to improve the genetic stability of this major attenuating determinant of Sabin type-2 to avoid reversion by single nucleotide changes.~* Two modifications in the polymerase 3D to further improve stability of the attenuation and reduce frequency of recombination events~* Relocation of a key replication element from the 2C coding region to the 5'-untranslated region, to inhibit recombination."
224250130|NCT04544787|BIOLOGICAL|Novel OPV2 candidate 2|"Live-attenuated serotype-2 poliovirus derived from a modified Sabin type-2 infectious cDNA clone and propagated in Vero cells; candidate 2 (S2/S15domV/CpG40).~Modifications included the following:~* Changes to the viral nucleotide sequence in part of the 5'-untranslated region to improve the genetic stability of this major attenuating determinant of Sabin type-2 to avoid reversion by single nucleotide changes.~* silent non-coding modifications engineered within the capsid (VP1-4) designed to reduce replicative fitness and, potentially, to improve stability of the attenuated phenotype while also reducing transmission."
224250131|NCT04544787|BIOLOGICAL|Placebo|sugar syrup, propylene glycol (Sirupus simplex, Propylenglycolum, European Pharmacopoeia)
224250132|NCT03283943|RADIATION|Focal radiotherapy|Focal sensitizing radiotherapy will be given at a starting dose level of 24 Gray (6 Gy X 4 fractions), and may be escalated to 32 Gy (8Gy X4 fractions).
223669008|NCT00795678|DRUG|Trastuzumab|Trastuzumab is a monoclonal immunoglobulin G1 kappa antibody which acts as a mediator of antibody-dependent cellular cytotoxicity (ADCC) agent through its high affinity, high specificity binding to extracellular domain of HER2 Receptor. Trastuzumab is supplied as a lyophilized, sterile powder containing 440 mg trastuzumab per vial under vacuum. Each carton contains one vial of 440 mg trastuzumab and one 30 ml vial of bacteriostatic water for injection, USP, 1.1% benzyl alcohol. This will be given the morning of surgery at 2mg/m2 IV over 90 minutes.
223669009|NCT05382767|DRUG|CKDB-501A|Muscle Spasticity
223669010|NCT05382767|DRUG|Botox®|Muscle Spasticity
223669011|NCT03841747|DRUG|Pembrolizumab|200 mg Pembrolizumab IV Q3W.
223669012|NCT03841747|DRUG|Paclitaxel|80 mg/m2 paclitaxel IV on Days 1,8, and 15 of each 28 day cycle.
223669013|NCT00331110|DEVICE|Laterally-Wedged Insole with Ankle Strapping|
223669014|NCT00331110|DEVICE|Laterally-Weged Insole|
223669015|NCT01806662|DRUG|Ustekinumab|Injection of monoclonal antibody against the p40 subunit of IL-12/23
223669016|NCT01806662|OTHER|Placebo|Injection of placebo
223669017|NCT01696682|PROCEDURE|Narrowed Gastric Conduit|The gastric conduit will be formed much narrower in the intervention arm during minimally invasive esophagectomy
223771403|NCT02096835|DRUG|Tropisetron|will be given at the start of skin closure
224250133|NCT03283943|DRUG|Durvalumab|Durvalumab 1500 mg IV every 28 days
223669018|NCT01696682|PROCEDURE|Widened Gastric Conduit|A widened gastric tube will be formed during the surgery
223669019|NCT00528541|BIOLOGICAL|botulinum toxin type A|200 Units at Visit 1 (Day 1)
223669020|NCT00528541|BIOLOGICAL|botulinum toxin type A|750 Units at Visit 1 (Day 1)
223669021|NCT02967757|DRUG|liraglutide|Patients will be treated according to routine clinical practice at the discretion of the treating physician. The study will gather data over the course of routine treatment for liraglutide 3.0 mg and liraglutide 1.2 mg/1.8 mg treated patients
223669022|NCT05282914|DRUG|administration of UI058|UI058 1Tab/day for 7days
223771404|NCT02096835|DRUG|Dexamethasone|will be given after induction
224250134|NCT03536130|DEVICE|Electronic chest drainage system|Patients in the intervention arm are connected to Drentech Palm Evo with single standard chest tube (28 Ch) immediately after closure of the chest. Patients with digital devices are managed by setting the pump to -20 cmH2O until the morning of postoperative day (POD) 1 and then setting the pump on physiologic mode (0 cmH2O) thereafter. Management of chest tube drainage and decision for chest tube removal will be dictated by clinical signs, symptoms and surgeon preference following standard clinical practice of general thoracic patients
223669023|NCT05282914|DRUG|administration of UIC202004|UIC202004 1Tab/day for 7days
223669024|NCT03259620|DRUG|CLS006|Furosemide Topical Gel
223669025|NCT03259620|DRUG|CLS006 Vehicle|Vehicle Topical Gel
223669026|NCT01151943|OTHER|Transversus Abdominis Plane (TAP) Block|Bilateral injection of levobupivacaine (20 mL, 3.75 mg/mL)
223669027|NCT01151943|OTHER|Incisional Infiltration of Local Anesthetic|continuous administration of levobupivacaine (1,25 mg/mL,5 mL/h) during 48 hours.
223669028|NCT00129662|BEHAVIORAL|Pictorial action plan|
223669029|NCT01252693|DRUG|Ozarelix|Ozarelix Loading dose of 130 mg SC at randomization will be followed by maintenance dosing of 65 mg SC at day 8, 28 and 56.
223669030|NCT01252693|DRUG|Goserelin|Goserelin depot 3.6 mg at randomization will be followed by 3.6 mg SC on days 28 and 56.
223669031|NCT02158429|OTHER|2 dimensional vs. 3 dimensional ultrasound|At the end of a regularly scheduled ultrasound measuring fetal growth an additional 5-10 minute ultrasound will be performed, either in 2-dimensional or 3-dimensional mode
223669032|NCT03002090|DIETARY_SUPPLEMENT|Iron trained|"1. Ferrous sulfate: 100 mg/day of FeSO4 dosed in 2 capsules taken individually by mouth with breakfast and dinner. Capsules were made with FeSO4 and dextrose. Analysis has shown that each capsule contains 11mg of elemental iron, which is expected to be absorbed at roughly 33% bioavailability.~2. Aerobic Training: 25 minutes/day, 5 days/week for 8 weeks working at an intensity between 75-85% of age-predicted maximum heart rate."
223669033|NCT03002090|DIETARY_SUPPLEMENT|Iron Untrained|1\. Ferrous sulfate: 100 mg/day of FeSO4 dosed in 2 capsules taken individually by mouth with breakfast and dinner. Capsules were made with FeSO4 and dextrose. Analysis has shown that each capsule contains 11mg of elemental iron, which is expected to be absorbed at roughly 33% bioavailability.
223669034|NCT03002090|DIETARY_SUPPLEMENT|BZKL Trained|"1. BaZhen KeLi capsules: Traditional Chinese herbal supplement composed of: Radix Paeoniae Alba (White peony root), Rhizoma Atractylodis (Atractylodes), Rhizoma Chuanxiong (Chuanxiong), Radix Angelicae Sinensis (Angelica), Radix Codonopsis Pilosula (Codonopsis), Poria cocos (Poria), licorice, and Rehmannia glutinosa Each pill contained 5g of licorice and 10g of all other ingredients. Dosed in 2 capsules taken individually by mouth with breakfast and dinner. Analysis has shown that each capsule contained 0.5mg of elemental iron.~2. Aerobic Training: 25 minutes/day, 5 days/week for 8 weeks working at an intensity between 75-85% of age-predicted maximum heart rate."
223771405|NCT00467181|DRUG|Fenoldopam|
223771406|NCT02709967|OTHER|Material support|Writing materials
223771407|NCT02709967|OTHER|Economic|Economic support (monthly cash transfer to girls, annual grant to guardians, and payment of school fees in grade 8 and 9)
223771408|NCT02709967|BEHAVIORAL|Community dialogue|Community dialogue (youth club meetings, community and parent meetings)
223771409|NCT04852614|DIAGNOSTIC_TEST|Pharmacokinetic test|Blood samples will be collected 48 hours after the first dose on day 3 of the observed intake of the study medication at the following time points: t=0 (pre-dose), 1, 2, 3, 4, 8 and 12 hours post ingestion (7 samples) (3 mL each), Breast milk samples will be collected by emptying both breasts at 0, 2, 4, 8 and 12 hours (5 samples).
223771410|NCT03892889|COMBINATION_PRODUCT|Abilify MyCite®|Combination product of aripiprazole tablet embedded with sensor and wearable patch.
223771411|NCT03468439|OTHER|Femoral nerve block with phenol|
224250135|NCT05599074|DEVICE|extrusion arch|A stainless steel pre-formed arch wire custom made by placing V-bends 3-5 mm mesial to the molar tubes, placed into the auxiliary molar tubes after leveling phase and tied over the main arch wire distal to the lateral incisors
224250136|NCT02004509|DRUG|Anticoagulant|Anticoagulant treatment will be started in case of subclinical atrial fibrillation (\>5,5 hours per day) be diagnosed by cardiac implantable electronic device at intervention group, or clinical atrial fibrillation in both groups.
224250137|NCT05833594|DIETARY_SUPPLEMENT|Whole-course Immunonutrition Combined With Chemoradiotherapy±ICIs|The Experimental group received a combination of omega-3 fatty acids, and glutamine, whereas the control group received standard formula.
224250138|NCT01467791|OTHER|Observation|Observe patients
224250139|NCT03135834|BIOLOGICAL|MenABCWY|N meningitidis group A, B, C, W, and Y vaccine
224250140|NCT03135834|BIOLOGICAL|Saline|Placebo
224250141|NCT03135834|BIOLOGICAL|rLP2086|Bivalent recombinant lipoprotein 2086 vaccine
224250142|NCT03135834|BIOLOGICAL|MenACWY-CRM|meningococcal group A, C, W-135, and Y conjugate vaccine
224250143|NCT02234661|BEHAVIORAL|CareerAdvance®|CareerAdvance® is a dual-generation program providing education, career coaching, and soft-skills training for parents while their children attend CAP Tulsa's Head Start programs.
224250144|NCT00965185|DRUG|atorvastatin|20 mg PO QD for the first 3 months, followed by 40 mg PO QD for the final 9 months.
224250145|NCT00965185|DRUG|Placebo|Placebo
224250146|NCT00584025|DRUG|levetiracetam|100 - 500mg IV q 15 min
224250147|NCT00584025|DRUG|Placebo|Placebo equivalent of 100 - 500 mg levetiracetam IV q 15 min
224250148|NCT03127826|PROCEDURE|Risk Stratified Care|"Physical therapists providing care will all have attended live training in PIPT principles and be involved in monthly continuing education on these principles. The use of specific principles is guided by the patient's risk stratification (as determined by the STarT Back Tool).~Medium Risk:~\- Reassurance will be provided to address specific concerns related to their LBP and implications on work~High Risk:~\- Physical therapy will be psychologically augmented with the assessment of biopsychosocial risk factors and the adoption of cognitive behavioral principles that explore patient concerns and address unhelpful beliefs and behaviors, including tailored education (e.g., stress management and pain neuroscience), graded exercise, \& graded exposure"
224250149|NCT03127826|PROCEDURE|Usual Care|Usual care at the general practitioner's discretion
223669035|NCT03002090|DIETARY_SUPPLEMENT|BZKL Untrained|1\. BaZhen KeLi capsules: Traditional Chinese herbal supplement composed of: Radix Paeoniae Alba (White peony root), Rhizoma Atractylodis (Atractylodes), Rhizoma Chuanxiong (Chuanxiong), Radix Angelicae Sinensis (Angelica), Radix Codonopsis Pilosula (Codonopsis), Poria cocos (Poria), licorice, and Rehmannia glutinosa Each pill contained 5g of licorice and 10g of all other ingredients. Dosed in 2 capsules taken individually by mouth with breakfast and dinner. Analysis has shown that each capsule contained 0.5mg of elemental iron.
223669036|NCT03002090|DIETARY_SUPPLEMENT|Placebo Trained|1\. Aerobic Training: 25 minutes/day, 5 days/week for 8 weeks working at an intensity between 75-85% of age-predicted maximum heart rate.
223669037|NCT03002090|DIETARY_SUPPLEMENT|Placebo Untrained|No intervention
223669038|NCT04424277|OTHER|diaphragm ultrasound|respiratory loading
223669039|NCT00300430|DRUG|ABT-335 and rosuvastatin calcium|ABT-335 135 mg plus rosuvastatin calcium daily, 52 weeks
224250150|NCT03494894|DIAGNOSTIC_TEST|Middle meatus aspirations and sputum|Bacterial genotype sequencing analysis will be performed in patients with bacteriological concordance between upper and lower airways.
224250151|NCT04714268|PROCEDURE|Aorto-iliac endovascular procedure|Percutaneous procedure with stent placement
224250152|NCT02822248|DRUG|Coppertone (BAY987516)|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation: SR15-64-R84-070)
224250153|NCT02162069|DEVICE|CE certified transcatheter ( aortic valve replacement)|Patients receive a transcatheter aortic valve replacement with CE certified transcatheter aortic valves.
224250154|NCT01376102|DRUG|BONVIVA(ibandronate) injection|Basically there is no treatment allocation. Subjects who would be administered of ibandronate at their physicians' discretion will be enrolled. Dosage regimen will be recommended according to the prescribing information. Subjects will be enrolled consecutively.
224250155|NCT04791670|OTHER|survey study|The surveys will include general data, the type of electronic devices in possession and the purpose of use. eHealth literacy will be assessed with the eHeals questionnaire. Platform's ease of use will be assessed with the System Usability Scale, and participants´ opinion about the digital path utility with six questions. These items will be answered with a Likert-scale. Finally, we added an open question for qualitative analysis.
224250156|NCT02779543|DEVICE|Fitbit|Subjects will be recruited from those patients attending a regularly scheduled overnight PSG sleep study at the Weill Cornell Medical College Center for Sleep Medicine. Willing subjects, after providing informed consent, will be fitted with one of the three aforementioned sleep monitoring devices (randomly assigned) on the wrist of their non-dominant hand when prepared for the sleep study by a technician.
224250157|NCT02779543|DEVICE|Jawbone UP|Subjects will be recruited from those patients attending a regularly scheduled overnight PSG sleep study at the Weill Cornell Medical College Center for Sleep Medicine. Willing subjects, after providing informed consent, will be fitted with one of the three aforementioned sleep monitoring devices (randomly assigned) on the wrist of their non-dominant hand when prepared for the sleep study by a technician.
224250158|NCT02779543|DEVICE|Microsoft Band|Subjects will be recruited from those patients attending a regularly scheduled overnight PSG sleep study at the Weill Cornell Medical College Center for Sleep Medicine. Willing subjects, after providing informed consent, will be fitted with one of the three aforementioned sleep monitoring devices (randomly assigned) on the wrist of their non-dominant hand when prepared for the sleep study by a technician.
224250159|NCT03291925|PROCEDURE|Selective invasive angiography based on CT/CCTA imaging.|
223669040|NCT00300430|DRUG|ABT-335 and atorvastatin calcium|ABT-335 135 mg plus atorvastatin calcium daily, 52 weeks
223669041|NCT00300430|DRUG|ABT-335 and simvastatin|ABT-335 135 mg plus simvastatin daily, 52 weeks
223669042|NCT00000791|DRUG|Glycovir|
223669043|NCT00000791|DRUG|Zidovudine|
223669044|NCT04511377|DEVICE|Rehabilitation using Digital Healthcare System (Uincare Homeplus)|"Uincare Homeplus is a device using infrared, kinect camera and motion capture technology to track 3D motion of the patients' posture and joint articulations. It also has embedded exercise training software dedicated to rotator cuff repair post-op rehabilitation at home.~Home-based self-rehabilitation using brochure for 6 weeks post surgery (same as the active comparator)~Home-based self-rehabilitation using digital healthcare system(Uincare Homeplus) for 6 to 12 weeks post surgery."
224250160|NCT03291925|PROCEDURE|Procedure/Surgery: Invasive angiography|
224250161|NCT03965858|DRUG|Esketamine DPI - low dose|Esketamine DPI is to be administered via dry powder inhaler. Each dose correspond to low Esketamine dose.
224250162|NCT03965858|DRUG|Esketamine DPI - medium dose|Esketamine DPI is to be administered via dry powder inhaler. Each dose correspond to medium Esketamine dose.
224250163|NCT03965858|DRUG|Esketamine DPI - high dose|Esketamine DPI is to be administered via dry powder inhaler. Each dose correspond to high Esketamine dose.
224250164|NCT03965858|DRUG|Placebo DPI|Placebo DPI is to be administered via dry powder inhaler.
223669045|NCT04511377|OTHER|Conventional Rehabilitation|Home-based self-rehabilitation using brochure for 12 weeks post surgery.
224250165|NCT01552447|OTHER|EpiFix|Dehydrated placental tissue
224250166|NCT01552447|OTHER|Compression Therapy|Compression bandaging
224250167|NCT00006194|BEHAVIORAL|Exercise|
224250168|NCT05340010|DRUG|Human Chorionic Gonadotrophin Intramuscular injection 10.000 IU|From the 12th to 13th day of the cycle when endometrium reached the optimal thickness ≥8 mm, group 1 (hCG) will receive 10.000 IU hCG intramuscular injection in the morning then vaginal suppository progesterone 400 mg twice a day will be started in the afternoon
223669046|NCT04926402|OTHER|Kangaroo Care Education Program|It is a special method of caring for a premature infant in which the baby is positioned for at least 1 hour a day in an upright skin-to-skin and chest-to-chest contact with its mother.
223669047|NCT01917656|DRUG|liraglutide|1.8 mg administered subcutaneously (s.c., under the skin) once daily
223669048|NCT01917656|DRUG|metformin|Subjects will continue on their pre-trial metformin tablet treatment, dose unchanged
223669049|NCT01917656|DRUG|sulphonylurea|Subjects will continue on their pre-trial SU tablet treatment, doses unchanged
223669050|NCT02065388|BEHAVIORAL|Standard of care dosing for warfarin|
223669051|NCT02065388|GENETIC|Genotype-guided dosingTaiwan algorithm for warfarin|
223669052|NCT02065388|GENETIC|Genotype-guided dosing IWPC algorithm for warfarin|
223669053|NCT05331417|DIAGNOSTIC_TEST|Patients with herpes-simplex infection requiring bronchoscopy|Due to the observational design of the study, no study-specific interventions are performed. The indication for bronchoscopy is determined by the responsible ICU physicians. Except for the above mentioned laboratory analyses, the treatment of the patients is completely guided by the responsible ICU physicians.
223771412|NCT05760092|COMBINATION_PRODUCT|Institutional standard treatment for xerostomia and Long Covid|(Medical follow-up at the general outpatient clinic for prescription and control of medications, underlying diseases, clinical status and routine short, medium and long-term care follow-up, standard guidelines for the use of aerobic physical activity in those who do not have contraindications, stretching exercises, ergonomics, home adaptation to maximize functionality and energy savings, emotional cognitive support psychotherapy, socio-educational measures, sleep hygiene, Nutritional follow-up and monitoring, dentistry follow-up at the University's odontological team, guidance on proper oral hygiene, use of low-sugar diets, daily topical use of fluoride and antimicrobial mouthwash to prevent dental caries, oral hydration, guidance on avoiding cigarette use or intake of caffeine-containing beverages . When necessary, measures such as oral lubricants, artificial saliva, measures to prevent aspirations, as well as the careful use of liquids during meals, can be instituted ) +
223771413|NCT05760092|RADIATION|Photobiomodulation Therapy|Application of Red LED in the 3 pairs of major salivary glands (parotid, submandibular and sublingual) extraorally, transcutaneously, for 36 seconds, twice a week for 06 weeks.
224250169|NCT00135941|DRUG|insulin glargine|Sequence 1 (Lantus + Apidra first, then Premix): Subjects randomized to this sequence will receive ApidraTM administered three times per day 0-15 minutes before main meals using a fixed bolus regimen following titration based on preprandial blood glucose values; as well as Lantus qd for 12 weeks. After the first 12 weeks, subjects will cross over to the premix insulin for a further treatment of 12 weeks.
224250170|NCT00135941|DRUG|insulin glulisine|Sequence 2 (Premix first, then Lantus + Apidra): Subjects randomized to this sequence will receive premix insulin (either Humalog Mix 75/25 or Novolog Mix 70/30, depending on which insulin they were taking at entry into the study) once or twice per day for 12 weeks. After the first 12 weeks, subjects will cross over to the Lantus plus Apidra sequence for a further treatment of 12 weeks.
224250171|NCT05741437|DRUG|CKD-378, QD, PO Drug: D745, D150, QD, PO|Durg: CKD-378, QD, PO Drug: D745, D150, QD, PO
224250172|NCT03148704|DRUG|palonosetron hydrochloride capsules|Collect all the patients' safty and efficacy data as long as they use palonosetron hydrochloride capsules(Ruo Shan®) .Specific methods of using the drugs are not limited .
224250173|NCT04181905|OTHER|Questionnaire|Firstly, demographic information (name-surname, date of birth, gender, age, height, body weight, dominant hand, family structure, social security, educational status, occupation, smoking, alcohol use, assistive device drug use, resume, surname, complaints). Data collection tools will then be applied to patients by face to face interview technique. Evaluation of kinesiophobia Assessment of quality of life in asthma patients with TAMPA questionnaire Assessment of physical activity level with Asthma Quality of Life Questionnaire (AQLQ) Assessment of physical activity level with International Physical Activity Questionnaire-Short Form (IPAQ) is planned.
224250174|NCT03004820|DEVICE|Remote Ischemic Conditioning|RIC consist of five cycles of 5-min inflation (200 mmHg) and 5-min deflation of cuff on bilateral upper limbs twice a day. Medication strategy is based on physician's best judgement.
224250175|NCT01678066|DEVICE|Bilateral cardiac output|
224250176|NCT03707912|DRUG|Anaferon|Oral administration.
224250177|NCT03707912|DRUG|Placebo|Oral administration.
224250178|NCT00431691|DRUG|vitamin and mineral supplement|"dose: 4 tablets daily for two weeks~vitamin A 7160 IU, vitamin C 113mg, vitamin E 100IU, zinc 17.4mg, copper 0.4mg"
224250179|NCT00431691|DRUG|Escherichia coli Endotoxin (LPS)|dose: 2 ng/kg (corresponding to 20 IU/kg), intravenous bolus over 5 minutes on both study days
223669054|NCT02748382|OTHER|higher chloride crystalloid|Normal saline
223669055|NCT02748382|OTHER|higher chloride albumin|5% Octalbin
223669056|NCT02748382|OTHER|lower chloride crystalloid|Ringers Lactate
223669057|NCT02748382|OTHER|lower chloride albumin|5% Plasbumin
223669058|NCT06333197|PROCEDURE|ORIF through transparotid approach|The Retromandibular Transparotid approach is a surgical method used to access structures in the parotid gland region by making an incision behind the mandible.
223669059|NCT06333197|PROCEDURE|ORIF through retroparotid approach|The Retromandibular Retroparotid approach, also known as the Modified Blair Incision, is a surgical technique used to access structures within the parotid gland region by creating an incision behind the mandible and extending it into the parotid region.
223669060|NCT02081859|DEVICE|Embryoscope|The embryoscope is a microscope that allows for continuous time-lapse monitoring.
224250180|NCT00431691|DRUG|100% O2|breathing for 30 minutes, 2 breathing periods on both study days
223669061|NCT02081859|OTHER|Conventional Criteria|
223669062|NCT02285062|DRUG|lenalidomide|
223669063|NCT02285062|DRUG|Placebo|
223669064|NCT02285062|DRUG|Rituximab|
223669065|NCT02285062|DRUG|Cyclophosphamide|
223669066|NCT02285062|DRUG|Doxorubicin|
223669067|NCT02285062|DRUG|prednisone|
223669068|NCT02285062|DRUG|vincristine|
223669069|NCT03714269|OTHER|measurement evaluated with an isokinetic dynamometer|measurement of the maximum dorsiflexion angle in degrees evaluated on an isokinetic dynamometer
223669070|NCT03714269|OTHER|measurement evaluated with an 2D ultrasound|"* simultaneous recording of force torque, joint angle and myotendinous junction displacement in 2D ultrasound during 5 passive mobilization cycles of ankle flexion-extension at very low speed~* recording of static images in 2D ultrasound representing the proximal insertion of the gastrocnemius muscle in the internal condyle of the femur, the myotendinous junction."
223669071|NCT03714269|OTHER|assessment of the level of discomfort|visual analogue scale (0 = no discomfort and 10 = maximal discomfort)
223669072|NCT05323825|DIETARY_SUPPLEMENT|Probiotic|Fermented milk product containing a probiotic
223669073|NCT05323825|DIETARY_SUPPLEMENT|Placebo|Product with identical characteristics to the experimental product.
223669074|NCT00256971|PROCEDURE|meniscectomy|
223669075|NCT02015221|DEVICE|Dual Action Pneumatic Compression Device|A novel dual action pneumatic compression device that provides both sustained compression while ambulatory, and intermittent pneumatic compression when connected to an AC outlet.
223669076|NCT02015221|DEVICE|Standard Compression Garments|Compression stockings with a 30-40mmHg level of compression.
224250181|NCT00431691|DRUG|nitroglycerin|dose: 0,8 mg sublingual, applied during FMD measurements on both study days
223669077|NCT01770444|OTHER|Low-dose Cardiac CT protocol|"A cardiac CT protocol modified for reduction of radiation exposure~1. Prospective gating~2. Range: dedicated imaging (below carina to heart base)"
223669078|NCT01770444|OTHER|Conventional cardiac CT protocol|"Conventional CCTA protocol~1. Retrospective gating with tube current modulation~2. Range: dedicated imaging (below carina to heart base)"
224250182|NCT00229281|BEHAVIORAL|Group therapy|
224250183|NCT02686333|OTHER|Meditation|10-15 minutes of individually conducted medication practices (silent meditations, guided meditations, body scans, gentle arm movement exercises).
224250184|NCT02745899|DIETARY_SUPPLEMENT|Cow milk|Ingestion of 240 ml cow milk
224250185|NCT02745899|DIETARY_SUPPLEMENT|Soy milk|Ingestion of 240 ml soy milk
224250186|NCT02039908|DRUG|Methylphenidate|Children will receive a double-blind assessment to determine their optimal starting dose of Concerta. Doses will be adjusted over the course of the school year and inceased if tolerance to the medication is detected.
223669079|NCT01612845|PROCEDURE|Arthroscopic repair without platelet rich fibrin|after the tendon is repaired, no additional procedures are performed and no PRF is administered
223669080|NCT01612845|BIOLOGICAL|PRF (vivostat ®) administration after rotator cuff repair|7cc. of autologous PRF are locally administered to the repair site after reconstruction of the rotator cuff
223669081|NCT00322972|DRUG|Mass treatment with oral azithromycin to an entire community|For baseline and follow-up surveys prior to azithromycin distribution, a stratified random sample from two age groups will be chosen: 1) 60 study participants younger than 10 years old and 2) 60 study participants aged 10 years and above. Clinical examination will be performed and conjunctival swabs will be taken from all the study participants. For study arm C and D, nasopharyngeal swabs will be collected from 10 randomly selected children among the 60 participants under 10 who were recruited for conjunctival swabbing. Then a single dose of azithromycin will be distributed according to study design: in tablet form for adults; a weight-adjusted tablet dose for children ages 8-10; and pediatric suspension for children ages 1 - 7.
223669082|NCT01557634|PROCEDURE|Overnight closed-loop insulin delivery|Basal insulin infusion rates on insulin pump will be directed by MPC algorithm using diluted versus non-diluted insulin
223669083|NCT04033588|DEVICE|Freedom® Total Knee System|To evaluate the survivorship, safety and performance of the Freedom® Total Knee System in the treatment of subjects who in the surgeon's opinion require a primary total knee replacement due to severe knee joint pain and loss of mobility due to osteoarthritis, rheumatoid arthritis or post-traumatic arthritis.
223669084|NCT04160975|BEHAVIORAL|Video about safety and effectiveness of adult seasonal flu vaccination|The investigators will show subjects videos of either Black or white male actors providing scripted information on the flu vaccination. The content of the video will be the safety and effectiveness of adult seasonal flu vaccination. The videos contain one of Black or white actors playing the role of either a doctor or a layperson as well as different scripts.
223669085|NCT00766350|DRUG|amitriptyline|initial dose 10 mg/day, target dose: 25 mg/day, maximum dose: 75 mg/day, dosage form: tablets, duration: 16 weeks
223669086|NCT00766350|DRUG|quetiapine|initial dose: 50 mg/day, target dose: 100 mg/day, maximum dose: 300 mg/day, dosage form:extended release tablets , duration: 16 weeks
224250187|NCT03622138|OTHER|Impact|Impact is an easy to use, cost- and time-efficient technology platform that is capable of (a) gathering relevant process and outcomes data in a feasible way within real-world service settings; (b) producing real-time analytics (e.g., graphical displays) and meaningful reports at the provider, service setting, and broader levels (e.g., state-wide); and (c) linking data analytics to continuous quality improvement (CQI) feedback to help providers achieve best practices and targeted youth outcomes.
224250188|NCT07035873|BEHAVIORAL|Remote Programming|Use of the Advanced Bionics Target CI remote programming software to complete behavioral measurements of cochlear implant function and programming via telehealth.
224250189|NCT07035873|DIAGNOSTIC_TEST|Remote Speech Perception|Use of digital audio streaming (DAS) through a proprietary platform to complete remote speech perception testing of performance with cochlear implants via telehealth.
224250190|NCT07035652|OTHER|XH-S004 20 mg, 40 mg or 60 mg|Administered once per day for 140 days.
224250191|NCT07035652|OTHER|Placebo|Administered once per day for 140 days.
224321970|NCT03404739|DRUG|Saline Solution|These patients will be given only one dose of ceftazidime at the start of POEM plus 2 doses of saline solution every 12 hours after the procedure.
223669087|NCT04585503|DEVICE|Electrode implantation|The intervention consist in implanting 6 electrodes in subdural or intra cortical position and monitor the central nervous system activity. This monitoring will be additional to the usual monitoring.
223771414|NCT05760092|RADIATION|Placebo Photobiomodulation Therapy|All parameters as the number of points, dose and place of application of the PBM will be the same as described in the item PBM therapy Intervention Group, however in the placebo PBM equipment will be turned off. The device activation noise will be recorded and used to mimic the irradiation.
223771415|NCT00029835|DRUG|Rimonabant (SR141716)|
223771416|NCT02451345|BEHAVIORAL|Personalized risk model+website+coaching intervention|"A health coach (members of the Patient Support Corps at the University of California San Francisco) will contact each subject individually to discuss his tailored/personalized web-portal report on his risk of aggressive disease and the pro/cons of treatment versus active surveillance.~The contact between subject and the health coaches will be done before subject's visit with his primary urologist. Subjects will be asked to complete different questionnaires on four different occasions: one at first visit to the interactive secure web portal; one before coach's call; one after the coaching (after the urologist visit), and one at 6 months. The questionnaire after subject's visit with the urologist includes discussion about their management choice, decision quality, anxiety and satisfaction with care."
223771417|NCT04260191|DRUG|AMG 910|IV Infusion
223771418|NCT02448303|DRUG|Pembrolizumab|
223669088|NCT06134011|OTHER|Without any intervention|There were no special interventions for the two groups.
223669089|NCT01870076|BEHAVIORAL|Healing Touch|
224250192|NCT07035522|OTHER|Ozone therapy|The study also aims to analyze the efficacy of ozone therapy in participants affected by endometriosis, enriching the knowledge base in the field of women's health/gynecology. The expected results will contribute to improving current therapeutic approaches, informing clinical decisions and encouraging future research. Understanding the technique and its clinical applicability will help health professionals to offer personalized and effective treatments. In addition, the insights obtained can direct new investigations, such as the optimization of protocols or the exploration of innovative therapeutic combinations for even more satisfactory results. Based on the literature review and the biochemical properties of both techniques (ozone therapy and clinical approach), it may be possible that one of the approaches demonstrates a statistically superior advantage over the other. In addition, the research aims to investigate whether the quality of life of these participants will improve and i
224250193|NCT06717750|DRUG|CSCJC3456 tablet|"* Phase Ia: Single and Multiple Dose Escalation.~  1. Dosage form: tablet.~ 2. Dosage: 7 dose groups, 5 mg, 15 mg, 30 mg, 45 mg, 60 mg, 80 mg, 100 mg.~ 3. Frequency: once daily (tentative), or twice daily and other options (adjusted based on the results of the preliminary trials).~ 4. Duration: 5 mg(days 1-28; 28 days per cycle), other groups (days 1-14; 21 days per cycle) .~* Phase Ib: Cohort Expansion. Dosage and dosing regimen: according to the recommended dosage and dosing cycle from the Phase Ia study."
224250194|NCT03309709|DRUG|subcutaneous progesterone|25mg daily for 7 days
223669090|NCT01870076|BEHAVIORAL|Healing Touch, Sham|
223669091|NCT01870076|BEHAVIORAL|Control, Presence|
224250195|NCT06304701|DIAGNOSTIC_TEST|Cognitive and writing tests|"* Wechsler Adult Intelligence Scale - fourth edition (Similarities and Vocabulary subtests)~* MASC (Movie for assessment of social cognition)~* Rey figure~* BHK (Quick Writing Assessment Scale)~* Descriptive text writing~* Persuasive text writing"
223771419|NCT02448303|DRUG|Acalabrutinib|
223771420|NCT04968067|DEVICE|App group|In addition to the usual care, the participant will receive a health talk related to CHD care, a CHD app and a briefing from a trained research nurse (A). The app provides features such as structured e-educational contents and supportive features such as knowledge platform and member area.
223771421|NCT04968067|DEVICE|Nursing telephone advice (NTA) group|All subjects will continue their usual care with prescribed medical treatments and follow-ups if any. By appointment, a trained nurse will provide a health talk related to the CHD care. In addition to the above usual care, three monthly 20-minute telephone follow-ups supplemented by take home leaflet will be provided by a trained research nurse for up to 3 months. Patients can ask about their related health problems, if any. The team has set up a telephone advice guide to support the research nurse in giving phone advice and text messages. .In summary, all two groups will receive from a nurse similar educational content as that related to their CHD and care. The only difference will be the re-enforcement and continual support provided through an app, telephone nursing advice and leaflet.
224250196|NCT06944145|DRUG|raloxifene|Participants in the Finasteride + Raloxifene Combination Therapy Arm will receive both Finasteride and Raloxifene as their intervention.
224321971|NCT03404739|DRUG|Ceftazidime|These patients will be given ceftazidime 2g at the start of POEM plus additional 2 doses given every 12 hours after the procedure.
223771422|NCT03650426|PROCEDURE|Total knee with onlay patellar resurfacing technique|The patellar resurfacing technique that the patellar implant is embedded on the patellar bone.The patellar implant is placed on top of a flat tibial osteotomy or cut-surfaced bone
223669092|NCT05086211|OTHER|proprioceptive neuromuscular facilitation|"Each session including three proprioceptive neuromuscular facilitation techniques:~Balance training exercises,participants will be treated for 20 minutes with PNF techniques that included;Rhythmic initiation, slow reversal techniques practiced with D1 and D2 pattern in lower limb,repeated contraction and Resisted PNF.The Technique will be performed for 3 days per week in same order on all subjects."
223669093|NCT05086211|OTHER|pertubation based balance training|Each session will include a 5-10min warm-up,voluntary tasks intended to induce internal perturbations,voluntary tasks combined with external perturbations and a 5-10mins cool down.The technique will be performed for 2 sets of 10 repetitions on all subjects
223669094|NCT04495608|DRUG|Fluconazole|"Fluconazole 50 mg/capsule or placebo, per os during 18 weeks :~* From W0 to W2 : 1 caps/ day~* From W2 to W4 : 1 or 2 caps/day~* From W4 to W6 : 1, 2 or 3 caps/day~* From W6 to W18 : 1, 2, 3 or 4 caps/day~The number of capsules to take will be determined by 24-hours calciuria results performed every 2 weeks during the titration period (W2, W4 and W6).~During the titration period, if 24-hours calciuria is \> 0.1 mmol/kg/day, fluconazole dose will be increased every 2 weeks to 50 mg per intake, with a maximum dose of 200 mg/day. If 24-hour calciuria is ≤ 0.1mmol/kg/day, fluconazole dose will remain stable.~After W6 and until the end of the study, the treatment dose will remain stable (stable period)."
223669095|NCT04495608|DRUG|Placebo|Placebo (1, 2, 3 or 4 pills to take daily during 18 weeks), same appearance to experimental drug
224250197|NCT06944145|DRUG|Finasteride|"Participants in the Finasteride Monotherapy arm will receive only Finasteride as their standard-of-care intervention.~Participants in the Finasteride + Raloxifene Combination Therapy arm will receive both Finasteride and Raloxifene as the study intervention."
224250198|NCT01802320|DRUG|Akt Inhibitor MK2206|Given PO
224250199|NCT01802320|OTHER|Laboratory Biomarker Analysis|Correlative studies
224250200|NCT01802320|OTHER|Pharmacological Study|Correlative studies
224250201|NCT05790538|PROCEDURE|Assessment of Therapy Complications|Complete clinic assessments
224250202|NCT05790538|OTHER|Electronic Health Record Review|Medical records are reviewed
224250203|NCT05790538|OTHER|Medical Device Usage and Evaluation|Wear SmartSocks
224250204|NCT05790538|OTHER|Medical Device Usage and Evaluation|Wear activity monitor
224250205|NCT05790538|OTHER|Survey Administration|Complete survey
224250206|NCT05974293|DRUG|Nabiximols|Nabiximols is is a yellow-brown oromucosal spray solution containing 27 mg/mL of THC and 25 mg/mL of CBD.
224250207|NCT05974293|DRUG|Placebo|The placebo is a matching oromucosal spray that is identical to the investigational study product in terms of packaging, labelling, schedule of administration, dosing instructions, and appearance.
224250208|NCT00716066|BIOLOGICAL|Anti-Thymocyte Globulin|Given IV
224250209|NCT00716066|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous or syngeneic stem cell transplantation
224250210|NCT00716066|DRUG|Carmustine|Given IV
224250211|NCT00716066|DRUG|Cytarabine|Given IV
224250212|NCT00716066|DRUG|Etoposide|Given IV
224250213|NCT00716066|OTHER|Laboratory Biomarker Analysis|Correlative studies
224250214|NCT00716066|DRUG|Melphalan|Given IV
224250215|NCT00716066|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo autologous or syngeneic stem cell transplantation
224250216|NCT00716066|DRUG|Prednisone|Given PO
224250217|NCT00716066|PROCEDURE|Syngeneic Bone Marrow Transplantation|Undergo syngeneic bone marrow transplantation
224250218|NCT03797872|DRUG|Methotrexate|Methotrexate up to 25mg/week as tolerated po or sc
224250219|NCT03797872|DRUG|Sulfasalazine|Sulfasalazine up to 3g daily po
224250220|NCT03797872|DRUG|Leflunomide|Leflunomide 10-20mg daily po
224250221|NCT03797872|DRUG|Methylprednisolone|For IA or IM injection 20-120mg
224250222|NCT03797872|DRUG|Triamcinolone|For IA or IM injection 20-120mg
224250223|NCT05392621|BEHAVIORAL|Yoga|A single Hatha yoga session designed to support stress management.
224250224|NCT05392621|BEHAVIORAL|Deep Breathing|A single deep breathing exercise session designed to elicit relaxation and to assist in stress management.
224250225|NCT05392621|BEHAVIORAL|Progressive Muscle Relaxation|A single session of progressive muscle relaxation designed to elicit relaxation.
224250226|NCT05392621|BEHAVIORAL|Quiet sitting|A single session of quiet sitting.
224250227|NCT03487224|DEVICE|MRI with fMRI frequency|Functional magnetic resonance imaging or fMRI measures brain activity by detecting changes in blood flow. Participants will do cognitive tasks during fMRI.
224250228|NCT06111963|DIAGNOSTIC_TEST|Serology tests|CD4, CD25, IL17
223669096|NCT05387499|DRUG|NP-011 (Single Ascending Dose Phase)|The participants will receive assigned single dose of NP-011 after a minimum 8 hour fast on Day 1
223669097|NCT05387499|DRUG|NP-011 (Multiple Ascending Dose Phase)|The participants will receive assigned dose of NP-011 after a minimum 8 hour fast once daily for 7 days
223669098|NCT05387499|OTHER|NP-011 (Placebo)|The participants will receive single dose of NP-011 after a minimum 8 hour fast on Day 1 in Single Ascending Dose part and will receive once daily for 7 days after a minimum 8 hour fast in Multiple Ascending dose part of the study
223669099|NCT00492063|BIOLOGICAL|Cell culture-derived trivalent subunit influenza vaccine (cTIV)|One vaccination (0.5 mL) of cell culture-derived influenza vaccine (cTIV) was administered in the deltoid muscle
223669100|NCT00492063|BIOLOGICAL|Egg-derived trivalent subunit influenza vaccine (TIV)|One vaccination (0.5 mL) of egg-derived influenza virus vaccine (TIV) was administered in the deltoid muscle
223669101|NCT05895916|BEHAVIORAL|High-volume road cycling|1,144 km of road cycling performed on seven consecutive days with an increase in energy intake to maintain a stable body weight
223669102|NCT04986956|DIETARY_SUPPLEMENT|Whole coffee cherry extract|200mg WCCE
223669103|NCT04986956|DIETARY_SUPPLEMENT|Placebo|Placebo for comparison to WCCE
223669104|NCT06491901|OTHER|PS was given according to lung ultrasound score|If the lung ultrasound confirms RDS and LUS is more than 8, a full dose of PS will be promptly administered at 200 mg/kg (Poractant Alfa, Curosurf®). If the lung ultrasound does not indicate RDS or if LUS is 8 or less, clinical monitoring will continue. Should the clinical criteria for NRDS be met, a full dose of PS will be administered at 200 mg/kg (Poractant Alfa, Curosurf®). In terms of the administration method, less-invasive surfactant administration (LISA) will be employed for infants in a non-invasive ventilation state, while those in an invasive ventilation state will receive PS via endotracheal tube.
223669105|NCT06491901|OTHER|PS was given according to clinical criteria|In cases where clinical diagnosis confirms NRDS, PS will be administered at a dosage of 200 mg/kg (Poractant Alfa, Curosurf®). LISA will be employed for infants in a non-invasive ventilation state, while those in an invasive ventilation state will receive PS via endotracheal tube. If clinical manifestations do not meet the diagnosis of NRDS, PS will not be administered.
223669106|NCT05973721|BIOLOGICAL|phage|The treatment group was given one phage each time, once a day for two weeks
223669107|NCT03520127|DEVICE|Intact Breast Lesion Excision System (BLES)|Intact BLES is an automated, percutaneous biopsy device capable of delivering a surgical quality specimen for histological review of breast abnormalities. It is uniquely suited to maintain lesion architecture within the biopsy sample, providing an opportunity for pathological assessment and the potential avoidance of an open surgical procedure.
223669108|NCT01975857|BEHAVIORAL|Mind-Body Bridging Program|Bridging aims to reduce the impact of negative thought patterns that contribute to stress in the body.
223669109|NCT01975857|BEHAVIORAL|Supportive Education|This intervention will provide educational lectures on disability, sleep hygiene, and current research on depression and nondirective, supportive discussions about these topics.
223669110|NCT00167856|DRUG|Venalafaxine hydrochloride|Norepinephrine/Serotonin Reuptake Inhibitor (NSRI)
223669111|NCT01467219|PROCEDURE|lymphadenectomy|bilateral pelvic and para-aortic lymph node dissection
224250229|NCT01552499|OTHER|Standard of care|
224250230|NCT01552499|OTHER|Applications of EpiFix|
224250231|NCT00657332|PROCEDURE|blood sample draw|
224250232|NCT00657332|PROCEDURE|urine sample|
223669112|NCT01467219|PROCEDURE|therapeutic conventional therapy|hysterectomy, bilateral salpingo-oophorectomy,bilateral pelvic and para-aortic lymph node dissection +/- omentectomy via laparotomy, laparoscopy or robotic-assisted
223669113|NCT01467219|PROCEDURE|Positron Emission Tomography/ Computed Tomography|Pre-operative PET/CT scan
223669114|NCT01467219|RADIATION|fludeoxyglucose F 18|5 MBq/kg body weight of FDG (up to 550 MBq)
223669115|NCT02434588|DEVICE|Bhattacharjee ring|Insertion of a Bhattacharjee ring to stabilise the pupil during cataract surgery
223669116|NCT02338908|OTHER|exercise program|Patients will be asked to perform an eccentric loading exercise program for the shoulder musculature, particularly the supraspinatus and infraspinatus muscles, to be performed on an individual basis twice every day. The therapeutic protocol will be applied for 5 weeks.
223669117|NCT02338908|OTHER|TrP-DN|In addition, within the second and fourth sessions, they will receive TrP-DN over active TrPs in the shoulder muscles
223669118|NCT00368290|DRUG|Modafinil|300mg a day for 8 weeks
223669119|NCT00368290|DRUG|placebo|placebo pills for 8 weeks
223669120|NCT00368290|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|Weekly cognitive behavioral therapy sessions for a period of 8 weeks.
223669121|NCT03810872|DRUG|Afatinib|Open label
223669122|NCT03810872|DRUG|Paclitaxel|Paclitaxel
223669123|NCT06491966|OTHER|observation|data collected includes demographic information, clinical outcomes (mortality rate, ICU stay length), inflammatory markers (e.g., IL-2, IL-10, TNF-α), and treatment details (mechanical ventilation, CRRT, ECMO, antibiotics). Culture results, NGS findings, and imaging reports were also documented.
223669124|NCT03041129|DIAGNOSTIC_TEST|oral glucose tolerance test|6 hours OGTT
223669125|NCT03041129|DIAGNOSTIC_TEST|MRI of liver|MRI of the liver and use of DIXON method
223669126|NCT03310762|OTHER|Alma Sana Bracelet|Every time a child receives a vaccine, vaccinators will hole punchers to perforate shapes denoting the particular vaccine a child has received.
223669127|NCT03310762|OTHER|Simple Silicon Bracelet|Every time a child receives a vaccine, vaccinators will hole punchers to perforate shapes denoting the particular vaccine a child has received.
223669128|NCT00123890|DRUG|GW873140|
223669129|NCT00510653|DRUG|Imatinib Mesylate|600 mg by mouth daily for 6 Weeks
223669130|NCT00948467|DRUG|TAK-733|"The Initial Escalation Stage will enroll approximately 30 patients with advanced nonhematologic malignancies. TAK-733 will be administered orally in 28-day treatment cycles consisting of intermittent dosing with 21 days of continuous treatment, followed by a rest period of 7 days.~The Expansion Stage will enroll approximately 30 patients with advanced metastatic melanoma. The recommended phase 2 dose determined in the Initial Escalation Stage of TAK-733 will be administered orally in 28-day treatment cycles consisting of intermittent dosing with 21 days of continuous treatment, followed by a rest period of 7 days."
223669131|NCT02990247|DEVICE|anharmonic morphological analysis of the respiratory signals (AMARS)|
223669132|NCT05349201|OTHER|KYMRIAH|Patients (≥18 years of age) with (relapsed/refractory diffuse large B cell lymphoma \[R/R DLBCL\]) or Pediatric and young adult patients (≤25 years of age) with B cell acute lymphoblastic leukemia (ALL) refractory, in relapse post transplant or in second or later relapse
223669133|NCT05349201|OTHER|YESCARTA|Patients (≥18 years of age) with (relapsed/refractory diffuse large B cell lymphoma \[R/R DLBCL\])
223669134|NCT04268602|OTHER|local anesthetic injection|1% lidocaine
223669135|NCT02996058|DRUG|Dexmedetomidine 0.35µg/kg /h|the infants will receive a maintenance dose of 0.35µg/kg /h of Dexmedetomidne without a loading dose and guided by the assessed sedation scale
223669136|NCT02996058|DRUG|Dexmedetomidine 0.5µg/kg /h|the infants will receive a maintenance dose of 0.5µg/kg /h of Dexmedetomidne without a loading dose and guided by the assessed sedation scale
223669137|NCT01947855|DRUG|Placebo|Placebo tablet matching Empagliflozin low dose
224250233|NCT01980823|DRUG|Metformin|"Metformin is an oral diabetes medicine that helps control blood sugar levels.~Dosage/Frequency: 1500 mg per day: divided 500 mg in the morning and 1000 mg in the evening~Metformin is for people with type 2 diabetes. Metformin is sometimes used in combination with insulin or other medications, but it is not for treating type 1 diabetes."
224250234|NCT01980823|DRUG|Atorvastatin|"Atorvastatin is in a group of drugs called statins. Atorvastatin reduces levels of bad cholesterol (low-density lipoprotein, or LDL) and triglycerides in the blood while increasing levels of good cholesterol (high-density lipoprotein, or HDL).~Dosage/Frequency: 80 mg once a day at bedtime~Atorvastatin is used to treat high cholesterol, and to lower the risk of stroke, heart attack, or other heart complications in people with type 2 diabetes, coronary heart disease, or other risk factors."
224250235|NCT01980823|PROCEDURE|Breast surgery|(Non-experimental) Female subjects with histologically-confirmed operable invasive breast cancer or DCIS will undergo core needle biopsy with a plan of surgical excision.
224250236|NCT06009471|OTHER|Routine treatment in Neurology|Routine treatment in Neurology department, including drug treatment,etc.
224250237|NCT06009471|DEVICE|Routine treatment in Neurology and rTMS|Add rTMS to routine treatment. Low frequency rTMS is often used to treat cortical hyperexcitability and high frequency rTMS to treat hypoexcitability
224250238|NCT03829891|DRUG|Beinaglutide|"1. Beinaglutide for 8 weeks,~2. Beinaglutide + glargine for 8 weeks(only the subjects whose blood glucose not reach the standard )"
223669138|NCT01947855|DRUG|Empagliflozin|Empagliflozin low dose
223669139|NCT01947855|DRUG|Placebo|Placebo tablet matching Empagliflozin high dose
223669140|NCT01947855|DRUG|Placebo|Placebo tablet matching Empagliflozin low dose
223669141|NCT01947855|DRUG|Empagliflozin|Empagliflozin high dose tablet once daily
223669142|NCT01947855|DRUG|Placebo|Placebo tablet matching Empagliflozin high dose
224250239|NCT03829891|DRUG|glargine|"1. Glargine for 8 weeks,~2. Glargine+Beinaglutide for 8 weeks(only the subjects whose blood glucose not reach the standard )"
224250240|NCT03483194|DEVICE|Virtual Reality|Bliss is a 3D Interactive application designed to meet the needs of escape and relaxation of people in isolation and / or stress and / or during painful care here osteo-medullary biopsy
224250241|NCT03483194|DRUG|Kalinox|Usually take care of by a gas mixture composed of 50% Nitrous Oxide, 50% Oxygen for the medical procedure (osteo-medullary biopsy)
223669143|NCT02727530|OTHER|VISCERAL MANUAL THERAPY-ADVICES|The subjects of this group will receive an amount of two sessions of visceral manual therapy that will be applied within two weeks. In the first session will be applied procedures in the most superficial body structures. And, in the second session will be applied procedures in the most deep body structures.
224250242|NCT05497362|DEVICE|Real tDCS|2mA of tDCS was delivered to the orofacial area of the primary motor cortex (SM1) for 15 minutes. Speech therapy was delivered simultaneously.
224250243|NCT05497362|DEVICE|Sham tDCS|2mA of tDCS was delivered to the orofacial area of the primary motor cortex (SM1) for 30 sec. Speech therapy was delivered simultaneously.
224250244|NCT00875550|DRUG|Dexmedetomidine|Study drug titrated up or down to maintain target UMSS range.
224250245|NCT00875550|DRUG|Midazolam|Rescue medication for sedation according to UMSS scores
224250246|NCT00875550|DRUG|Fentanyl|Rescue medication for pain based on UMSS scores
224250247|NCT00875550|DRUG|Morphine|Rescue medication for pain based on UMSS scores.
224250248|NCT02053857|DIETARY_SUPPLEMENT|RUTF|
224250249|NCT02053857|DIETARY_SUPPLEMENT|RUTF-P|
223669144|NCT02727530|OTHER|ADVICES|Advices for parents to improve the management of infant colic
223669145|NCT06255678|DIAGNOSTIC_TEST|Angiography-based vessel fractional flow reserve (vFFR) calculation|vFFR is calculated from routinely taken angiography images during PCI using a CAAS workstation (Pie Medical Imaging, Maastricht, the Netherlands)
223669146|NCT02595645|GENETIC|Polypectomy and NGS|NGS of 38 cancer-related genes, systems biological analyses, correlation genetics to pathology and clinical data
223669147|NCT03977311|DEVICE|Sonalleve Magnetic Resonance-guided High Intensity Focused Ultrasound (MR-HIFU)|-To be used in conjunction with radiation therapy in the treatment of locally advanced cervical carcinoma patients
223771423|NCT03650426|PROCEDURE|Total knee with inlay patellar resurfacing technique|The patellar resurfacing technique that the patellar implant is embedded in the patellar bone.The patellar implant is surrounded by a rim of cortical bone and supported by hardened, sclerotic bone
223669148|NCT03977311|RADIATION|Radiation therapy|-Standard of Care
223669149|NCT02777320|DRUG|paracetamol|1000 mg Paracetamol in 150 ml normal saline given as a slow intravenous infusion over 5 minutes (100 ml of saline is removed before the addition of the 100 ml paracetamol to be the same volume)
223669150|NCT02777320|DRUG|Ibuprofen|400 mg Ibuprofen in 150 ml normal saline given as a slow intravenous infusion over 5 minutes
223669151|NCT04796181|DEVICE|Neteera 130H|The Neteera 130H will used to perform measurements in proximity to study participants.
223669152|NCT02885467|PROCEDURE|Total knee arthroplasty with Saphenous nerve burial|
223669153|NCT02885467|PROCEDURE|Standard total knee arthroplasty|
223669154|NCT00003001|DRUG|fluorouracil|
223669155|NCT00003001|DRUG|gemcitabine hydrochloride|
223669156|NCT00003001|DRUG|leucovorin calcium|
223669157|NCT06435559|OTHER|Neurotablet® and Neuropsychological evaluations|The experimental group will carry out cognitive rehabilitation using the Neurotablet device. The cognitive rehabilitation will be performed for 10 consecutive weeks, once a week for 1 hour. Neuropsychological evaluations will be conducted before the start of chemotherapy (T0), 6 months (T1) and 12 months (T2) after the start of chemotherapy. Neuropsychological evaluations will include tests to analyze the main cognitive domains of memory, attention, executive functions and learning.
223771424|NCT00789217|PROCEDURE|Immediate skin test|Intradermal test with immediate reading
223771425|NCT00844454|PROCEDURE|multi-pronged ethanol ablation|Under ultrasound guidance, insert an applicator into the tumor percutaneously and then inject ethanol to destroy the whole tumor tissue.
224250250|NCT02053857|DRUG|Amoxicillin|
224250251|NCT06559566|PROCEDURE|USG|The aim of this study is to measure the intracranial pressure of patients planned for brain tumor surgery by measuring the optic nerve sheath diameter (ONSD) under USG guidance and compare its correlation with the computed brain tomography.
224250252|NCT06559566|PROCEDURE|BCT|The aim of this study is to measure the intracranial pressure of patients planned for brain tumor surgery by measuring the optic nerve sheath diameter (ONSD) under USG guidance and compare its correlation with the computed brain tomography.
224250253|NCT02956460|DEVICE|fanfilcon A|contact lens
224250254|NCT02956460|DEVICE|senofilcon A|contact lens
224250255|NCT01072890|DRUG|Temsirolimus, Pazopanib|Patients will be treated on an outpatient basis with both temsirolimus and pazopanib. All patients will receive temsirolimus intravenously (IV) weekly days 1, 8, 15, and 22. Patients will receive oral pazopanib on a daily basis starting day 1. Treatment will be administered on 28 day cycles. Patients will be in this study for a minimum of 8 weeks or 2 cycles.
224250256|NCT04129346|BEHAVIORAL|Fit2ThriveMB App|The Fit2thriveMB app will encourage participants to increase their physical activity. Participants will be provided with educational information on physical activity and effective behavior change strategies for incorporating more physical activity into their daily lives to increase their step count. Participants will be prompted each morning to report the intensity of their symptom burden (0 to 10). Based on their symptom rating and their previous day's step counts, participants will be provided with three different options or levels of goals for that day to either increase or decrease 10-20% or remain constant.
224250257|NCT04129346|BEHAVIORAL|Fitbit|The Fitbit measures PA intensity, steps, and heart rate and syncs directly with the smartphone and will automatically sync with the Fit2ThriveMB app and provide Fitbit data to the study team in real-time.
224250258|NCT04129346|BEHAVIORAL|Physical Activity Coaching Calls|Participants will receive weekly coaching calls which will: a) provide feedback on the previous week's symptom burden and progress on PA goals; b) review personalized goals and strategies for increasing PA for the next week; c) provide instruction on effective behavioral change techniques
224250259|NCT04129346|BEHAVIORAL|Healthy Living Coaching Calls|Participants will receive weekly calls that will cover health and well-being topics for instance: symptom and stress management, healthy diet, hydration, sun safety, sleep hygiene, and meditation.
224250260|NCT04129346|BEHAVIORAL|Cancer.net app|Cancer.net app content includes information about health and well-being, treatment guidelines specific to cancer type, symptom tracking and medication tracking
224250261|NCT05474365|OTHER|Stepwise training|The protocol of stepwise training is mentioned in Detailed description in Study Description.
224250262|NCT00003484|DRUG|carmustine|
224250263|NCT00003484|DRUG|irinotecan hydrochloride|
224250264|NCT00003484|PROCEDURE|surgical procedure|
223771426|NCT00844454|PROCEDURE|radiofrequency ablation|Under ultrasound guidance, insert an applicator into the tumor percutaneously and then deliver radiofrequency energy to destroy the whole tumor tissue.
223771427|NCT05457270|DRUG|AZD4831|Participants will receive a single oral dose of AZD4831 Formulation A Or a single oral dose of AZD4831 Formulation B on Day 1 Period 1. Depending on what Formulation was received on Day 1 Period 1, participants will receive either a single oral dose of AZD4831 Formulation A Or a single oral dose of AZD4831 Formulation B on Day 1 of Period 2. Each period lasts for 8 days.
223669158|NCT06435559|OTHER|Neuropsychological evaluations|Neuropsychological evaluations will be conducted before the start of chemotherapy (T0), 6 months (T1) and 12 months (T2) after the start of chemotherapy. Neuropsychological evaluations will include tests to analyze the main cognitive domains of memory, attention, executive functions and learning.
223669159|NCT03478436|DRUG|Doxycycline|Doxycycline 40 mg capsules
223669160|NCT04195776|DRUG|Tenofovir Douche|660 mg TFV in 125 mL hypo-osmolar solution
223669161|NCT05828641|PROCEDURE|Supination-flexion maneuver|In the Supination-flexion group, the forearm will be supinated first, followed by full flexion of the elbow joint (Supination-flexion maneuver).
223669162|NCT05828641|PROCEDURE|Hyperpronation maneuver|In the hyperpronation group, the forearm will be pronated with the child's palm facing down (hyperpronation maneuver).
223669163|NCT02102373|DEVICE|polyethylene glycol 3350|Patients received a polyethylene glycol 3350 solution starting at afternoon the day before the colonoscopy at a dose of 1000 ml/15 kg (maximum 4 L). The patients were instructed to drink all solution in about 4-6 hours.
223669164|NCT00763503|DRUG|CD 2027|3µg/g Oily Spray
223669165|NCT06363305|DIETARY_SUPPLEMENT|Dietary capsules|Daily doses of dietary capsaicin or placebo in capsule form
223669166|NCT00821509|BEHAVIORAL|Hand washing|Instructions for proper coughing and sneezing, and for reduced hand shaking, frequent hand washing in office and at home
223669167|NCT00821509|BEHAVIORAL|Disinfectant rubbing|Instructions for proper coughing and sneezing, and for reduced hand shaking; frequent rubbing of hands with alcohol containing disinfectant in office and at home
223669168|NCT03914963|BIOLOGICAL|Fibrin sealant hemipelvis|Following the manufacturer´s instructions, 5 ml of sealant was sprayed evenly across the entire surgical bed in only one hemipelvis (the treated hemipelvis) after pelvis bilateral lymphadenectomy.
223771428|NCT01625052|DEVICE|Placement and use of Baska mask|use of Baska mask as component of standard general anaesthetic
223771429|NCT03757559|DRUG|Cebranopadol 100 micrograms|Tablets were taken under fasted conditions with non-carbonated water.
223771430|NCT03757559|DRUG|Cebranopadol 400 micrograms|Tablets were taken under fasted conditions with non-carbonated water.
223771431|NCT03757559|DRUG|Hydromorphone hydrochloride 4 milligrams|Over-encapsulated immediate-release tablets were taken under fasted conditions with non-carbonated water.
223771432|NCT03757559|DRUG|Placebo matching hydromorphone|Placebo matching over-encapsulated hydromorphone tablets were taken under fasted conditions with non-carbonated water.
223771433|NCT03757559|DRUG|Placebo matching cebranopadol|Placebo matching cebranopadol tablets were taken under fasted conditions with non-carbonated water.
223771434|NCT01973829|OTHER|Checklist for Early Recognition and Treatment of Acute Illness (CERTAIN)|This study is about training and implementation of best critical care practices in the international ICUs with variable resources facilitated by access to a specifically designed electronic checklist
223771435|NCT02229097|DRUG|Normal bolus|"During the normal bolus period, the bolus will be adjusted to the carbohydrate content of each meal and injected immediately. The basal rate will remain at a normal level during the 3 hours postprandial period"
224250265|NCT00003484|RADIATION|iodine I 131 monoclonal antibody 81C6|
224250266|NCT02350231|DRUG|The progesterone vaginal pessary|Those patients will receive progesterone vaginal pessary for prevention of preterm delivery in twins pregnancy
224250267|NCT02350231|DRUG|Tonics group|Those patients will receive only tonics
224250268|NCT05893290|OTHER|Therapeutic Exercise Group|Therapeutic exercise sessions will begin with a short educational talk that provides information on proper body mechanics, and the benefits of exercise, followed by simple warm-ups and three different stretching and five different strengthening exercises that emphasize hip, abdominal, and back muscles. The frequency of repetitions of each stretching and strength exercise will be 10 with a holding time of 10 sec. Each set of strengthening exercises will be followed by a different set of stretching exercises. Sessions will end with a short unguided period of deep slow breathing.
224250269|NCT05893290|OTHER|Therapeutic Exercise+Basic Body Awareness Therapy Group|This group will receive BBAT as well as therapeutic exercises. Therapeutic exercises will include strengthening, stretching, and stabilization exercises. BBAT will include postural alignment, breathing, and cognitive exercises.
224250270|NCT02581553|DRUG|lesinurad/allopurinol 200/300 FDC tablets|
224250271|NCT02581553|DRUG|lesinurad 200 mg|
224250272|NCT02581553|DRUG|allopurinol 300 mg|
224250273|NCT02581553|DRUG|lesinurad/allopurinol 200/200 FDC tablets|
224250274|NCT02581553|DRUG|allopurinol 200 mg|
223669169|NCT03914963|BIOLOGICAL|Control hemipelvis|Contralateral hemipelvis not treated with fibrin sealant
223669170|NCT00057343|DRUG|Zevalin (ibritumomab tiuxetan)|
223669171|NCT00057343|DRUG|Rituxan (rituximab)|
223669172|NCT05827471|DIAGNOSTIC_TEST|Diagnosis of colon cancer|Clinical diagnosis results
223669173|NCT04158193|OTHER|acupuncture|Subjects in acupuncture group will be received acupuncture treatment by inserting LI11, SJ5, SJ9, SJ13, SJ10, HT3, PC2, LI4, and LI15 on the affected limb and RN12, RN9, RN6, RN4, SP9, SP6. Needles will be remained for 30 minutes each time after DeQi sensation, one time a day，three times a week, the treatment will be lasted for 7 weeks.
223771436|NCT02229097|DRUG|Coordinated bolus|The basal rate will be reduced at a rate of 0.1 U/h during the 3 h postprandial period. The insulin subtracted of the basal rate will be added to the normal bolus calculated for the meal and injected immediately.
224250275|NCT04784338|BEHAVIORAL|Virtual shared medical visit|a shared medical visit done by zoom in a group, 1.5 hours
224250276|NCT04784338|BEHAVIORAL|Nutritional classes|A cooking class done by the teaching kitchen demonstrating cooking skills
224321972|NCT01495702|DRUG|NNRTI|NNRTI agents administered according to prescribing information; allowed NNRTIs include efavirenz (EFV), nevirapine, or rilpivirine.
224321973|NCT01495702|DRUG|FTC/TDF|FTC/TDF (200/300 mg) administered according to prescribing information
223669174|NCT04158193|OTHER|sham acupuncture|"Subjects in control group will be treated with non-acupoint shallow needling, points will be selected 1 cm at the radial direction from acupoint LI11, SJ5, SJ9, SJ13, SJ10, LI4, HT3, PC2, LI4, LI15; 2 cm at the left of acupoint RN12, RN9, RN6, RN4; 1 cm at the tibial direction from SP9, SP6.~The needling manipulation is the same as that of the acupuncture group, but only the superficial skin of points are punctured. The depth of needling is less than 0.5 cm, and no manipulation will be performed after puncturing the skin. Needles will be remained for 30 minutes each time,one time a day，three times a week, the treatment will be lasted for 7 weeks."
223669175|NCT01627834|DRUG|Ropinirole|
223669176|NCT05624047|BEHAVIORAL|Breastfeeding education using hybrid simulation method|In addition to the verbal breastfeeding training given to the pregnant women assigned to the experimental group, breastfeeding training will be given using the hybrid simulation method consisting of a wearable breast model and standard patient practice.
223771437|NCT02205619|DEVICE|Air Flow Master Piezon®, EMS SA, Nyon, Swiss|comparison of different instruments on root cementum: Instrumentations with US devices ( Air Flow Master Piezon®, EMS SA, Nyon, Swiss) were performed with medium power settings and with the use of water cooling (as instructed by the manufacturer). One approximal root surface (distal and mesial) of each tooth was randomly subjected to debridement and the other approximal surface was used as control. All the instrumentations of teeth were performed by a single operator. The criteria for adequate treatment were smooth, hard root surfaces, with no remnants of calculus. The cleanliness and smoothness of the root surface were checked using a fine dental explorer. The instrumentations were done under local anesthesia.
223771438|NCT02205619|DEVICE|Gracey curettes, American Eagle, Missoula, MT, USA|comparison of different instruments on root cementum Hand instruments (Gracey curettes 5/6, 11/12, 13/14 American Eagle, Missoula, MT, USA) were used for subgingival root instrumentation. The criteria for adequate treatment were smooth, hard root surfaces, with no remnants of calculus. The cleanliness and smoothness of the root surface were checked using a fine dental explorer. The instrumentations were done under local anesthesia.
223669177|NCT05624047|BEHAVIORAL|Routine verbal breastfeeding education|Women in this group will receive oral breastfeeding training, which is routinely given in the pregnant education class and consists of one session.
224250277|NCT05402137|BEHAVIORAL|Weight stigma intervention|Those undergoing the weight stigma manipulation will be exposed to an interaction partner (a trained confederate) who will endorse anti-fat attitudes. The purpose of this interaction is to examine the causal effects of weight stigma on eating behaviors, physical activity, and sleep.
224250278|NCT00042874|DRUG|alvocidib|Given IV
224250279|NCT00042874|DRUG|irinotecan hydrochloride|Given IV
223669178|NCT04896970|OTHER|Concert|A musical show in a closed hall, lasting for about 2 hours, in respects of safety measure (masks, hydroalcoholic gel, etc…) with approximately 200 participants.
224250280|NCT00042874|DRUG|fluorouracil|Given IV
224250281|NCT00042874|DRUG|leucovorin calcium|Given IV
224250282|NCT00042874|OTHER|laboratory biomarker analysis|Correlative studies
224250283|NCT03512925|OTHER|Standardized debriefing session of coercive measures|Debriefing session following the developed guidelines including setting and themes.
224250284|NCT04767347|OTHER|23.0°C WBGT - Fixed Work Rate|"For four hours, participants will walk on a treadmill to elicit 430 W of metabolic heat production in the following conditions:~23.0°C WBGT (29°C, 46% relative humidity) @ 60 min exercise per hour"
223669179|NCT04718844|DRUG|SLN124|SLN124 for subcutaneous (s.c.) injection
223669180|NCT04718844|DRUG|Placebo|Sodium chloride for s.c. injection
223669181|NCT04548492|OTHER|Survey|to assess and validate how healthcare professionals can trigger or inhibit the use of modern technology applications in home isolation
223669182|NCT01246466|DEVICE|Hybrid: AtriCure Bipolar System & EP ablation procedure|AtriCure Bipolar System plus a catheter ablation
223669183|NCT05334095|DEVICE|Perclose ProGlide|After peripheral vascular diagnostic and interventional procedures, patients are randomized to receive Perclose ProGlide.
223669184|NCT05334095|DEVICE|Angio-seal VIP|After peripheral vascular diagnostic and interventional procedures, patients are randomized to receive Angio-seal VIP
223669185|NCT04612296|GENETIC|Research genetic analysis|Genetic analysis of DNA extracted from saliva. Participants can opt in to receive individual results of research genetic analysis for a predefined panel of clinically actionable cardiomyopathy genes.
223669186|NCT00877773|DRUG|Temsirolimus|25 mg by vein over 60 minutes on Days 1, 8, 15, and 22 of each 4-week study cycle.
224250285|NCT04767347|OTHER|25.5°C WBGT - Fixed Work Rate|"For four hours, participants will walk on a treadmill to elicit 430 W of metabolic heat production in the following conditions:~25.5°C WBGT (31°C, 52% relative humidity) @ 45 min exercise per hour"
224250286|NCT04767347|OTHER|27.5°C WBGT - Fixed Work Rate|"For four hours, participants will walk on a treadmill to elicit 430 W of metabolic heat production in the following conditions:~27.5°C WBGT (33°C, 53% relative humidity) @ 30 min exercise per hour"
224250287|NCT04767347|OTHER|28.5°C WBGT - Fixed Work Rate|"For four hours, participants will walk on a treadmill to elicit 430 W of metabolic heat production in the following conditions:~28.5°C WBGT (34°C, 54% relative humidity) @ 15 min exercise per hour"
224250288|NCT04767347|OTHER|35.5°C WBGT - Fixed Work Rate|"For four hours, participants will walk on a treadmill to elicit 430 W of metabolic heat production in the following conditions:~35.5°C WBGT (40°C, 65% relative humidity) @ 15 min exercise per hour"
224250289|NCT04767347|OTHER|26.0°C WBGT - Fixed work-to-rest ratio|"For four hours, participants will walk on a treadmill at differing levels of metabolic heat production and environmental conditions (noted below), but at a fixed work-rest ratio of 30 minutes per hour.~26.0°C WBGT (31°C, 55% relative humidity) @ 530 W metabolic heat production"
224250290|NCT04767347|OTHER|30.5°C WBGT - Fixed work-to-rest ratio|"For four hours, participants will walk on a treadmill at differing levels of metabolic heat production and environmental conditions (noted below), but at a fixed work-rest ratio of 30 minutes per hour.~30.5°C WBGT (36°C, 55% relative humidity) @ 230 W metabolic heat production"
223669187|NCT00562666|OTHER|T gamma delta lymphocytes|Single hepatic intra arterial administration of increasing doses of T gamma delta lymphocytes
223669188|NCT00140361|DRUG|Sulfadoxine-pyrimethamine|
223669189|NCT00140361|DRUG|sulfadoxine-pyrimethamine plus artesunate|
223669190|NCT00140361|DRUG|lumefantrine plus artemether|
223669191|NCT00140361|BEHAVIORAL|Sleeping under insecticide-treated bednet|
223669192|NCT03218683|DRUG|AZD5991|AZD5991 will be administered intravenously for 9 cycles (each cycle 21 days) or until patient derives treatment benefit or progresses
223669193|NCT03218683|DRUG|AZD5991 + Venetoclax|Ascending oral doses of AZD5991 and/or venetoclax until no longer tolerated or disease progression
223669194|NCT04995289|OTHER|Prone position on ECMO patient|blood gas analysis before and after PP
223669195|NCT00456807|BIOLOGICAL|Placebo|Three doses of vaccine administered intramuscularly according to a 0, 1, 6-month schedule.
223669196|NCT00456807|BIOLOGICAL|Cervarix TM|Three doses of vaccine administered intramuscularly according to a 0, 1, 6-month schedule.
223669197|NCT00706498|DRUG|BI 2536|
223669198|NCT00140543|DRUG|sirolimus versus mycophenolate mofetil|
223669199|NCT00743236|PROCEDURE|cold ischemia procedure|Cold ischemia followed by partial nephrectomy
223669200|NCT00743236|PROCEDURE|warm ischemia procedure|Warm ischemia followed by partial nephrectomy
223669201|NCT06665308|OTHER|No intervention|No intervention will be administered to study participants. Data will be collected using a combination of chart review, clinical outcome assessment administration, and laboratory results through blood tests.
223669202|NCT02673047|BIOLOGICAL|botulinum toxin Type A|Botulinum toxin Type A (Botox®) injection as prescribed as standard of care in clinical practice.
223669203|NCT00716833|DRUG|Etoricoxibe|Preemptive group patients get Etoricoxibe either twice (before and after surgery) or just a single preoperative dose.
223669204|NCT00716833|DRUG|Placebo|Postoperative group patients get placebo before surgery and either a drug application or a placebo again after surgery (so called 2x2 factorial study design).
223669205|NCT02608333|BEHAVIORAL|ESDM-12|"ESDM is a comprehensive relational, developmental and behavioral intervention. It's described in a manual for professional (Rogers et al, 2010).~Children receive ESDM 12H per week by trained therapist. Therapist work in collaboration with parents (at home) and preschool or nursery."
223669206|NCT02608333|BEHAVIORAL|control group|"heteregenous as usual community intervention"
223669207|NCT02984072|DRUG|Menthol|Topical menthol in aqueous cream
223669208|NCT02984072|DRUG|Aqueous Cream|placebo
223669209|NCT04062344|OTHER|Swab|Rectal swab before and after the drug provocation testing
223669210|NCT03841578|DIETARY_SUPPLEMENT|Healthy|25g of dark chocolate (70%) will be provided to participants on Phase 1 (organoleptic assessment). On Phase 2 (gastrointestinal motility assessment), they will ingest a standard liquid meal (NutriDrink, 200ml), consisting of 10g of lactulose and 12g of fat
223669211|NCT00931840|DRUG|EZN-2208, Cetuximab and Irinotecan|"Patients with mutated K RAS tumors will be treated with single-agent EZN-2208 (Arm A). PLEASE NOTE THAT ENROLLMENT IN EXPERIMENTAL ARM (ARM A) IS COMPLETE. NO NEW PATIENT IN THIS ARM IS ALLOWED TO ENROLL.~Patients with wild-type K-RAS tumors will be randomly assigned in a 2:1 ratio to EZN-2208 + cetuximab (Arm B) or the benchmark of irinotecan + cetuximab (Arm C)."
224250291|NCT04767347|OTHER|30.5°C WBGT - Fixed work-to-rest ratio (high intensity)|"For four hours, participants will walk on a treadmill at differing levels of metabolic heat production and environmental conditions (noted below), but at a fixed work-rest ratio of 30 minutes per hour.~30.5°C WBGT (36°C, 55% relative humidity) @ 530 W metabolic heat production"
224250292|NCT03839719|PROCEDURE|Group PI|Before rinsing with the mouthrinse, Ultrasonic scaling was done in the 1st and 4th quadrant without any mouth rinse (placebo mouthrinse) and fall out samples were collected in the blood agar plates kept at a distance of 0.5 m and 1 m from the oral cavity.
224250293|NCT03839719|PROCEDURE|Group OC|After ultrasonic scaling of the 1st and 4th quadrant minimum 30min interval maintained. After interval of 30min rinsing the mouth with the either OC/CHX/Placebo (OC= Ocimum sanctum mouthrinse, CHX=Chlorhexidine Gluconate mouthrinse) mouthrinse) done for 60s, Ultrasonic scaling was again done in the 2nd and 3rd quadrant and fall out samples were collected in the newly placed blood agar plates kept at 0.5 m and 1 m away from the patient.
224250294|NCT03839719|PROCEDURE|Group CHX|After ultrasonic scaling of the 1st and 4th quadrant minimum 30min interval maintained. After interval of 30min rinsing the mouth with the either OC/CHX/Placebo (OC= Ocimum sanctum mouthrinse, CHX=Chlorhexidine Gluconate mouthrinse) mouthrinse) done for 60s, Ultrasonic scaling was again done in the 2nd and 3rd quadrant and fall out samples were collected in the newly placed blood agar plates kept at 0.5 m and 1 m away from the patient.
224250295|NCT05579535|OTHER|gait training exercises|walking exercises in different directions
224250296|NCT00975494|DRUG|Sildenafil|
224250297|NCT00975494|DRUG|Placebo|
223669212|NCT01012219|DRUG|niacin (+) laropiprant|open-label, single dose Tredaptive (1000mg ER niacin/ 20mg laropiprant) 2 oral tablets
223669213|NCT01012219|DRUG|Comparator: aspirin|81 mg oral tablet once daily for 7 days
224321974|NCT01495702|DRUG|Stribild|Stribild® (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate; E/C/F/TDF) (150/150/200/300 mg) STR administered orally once daily with food
223669214|NCT01012219|DRUG|Comparator: clopidogrel|75 mg oral tablet once daily for 7 days
223669215|NCT01012219|DRUG|Comparator: laropiprant|40 mg oral tablet once daily for 7 days
223669216|NCT01012219|DRUG|Comparator: placebo|placebo oral tablet once daily for 7 days
223669217|NCT02941536|DIAGNOSTIC_TEST|Circulating tumor cells evaluation|Sample collection of circulating tumor cells (CTC) before and 4-5 weeks after focal stereotactic radiotherapy in single (SRS) or fractionated (SFRT) dose.
223669218|NCT00674596|DRUG|ramipril|ramipril 10 mg/day during 3 months
223669219|NCT03661567|RADIATION|chest radiation|split-course chest radiation
223669220|NCT03661567|DRUG|concurrent chemotherapy|weekly docetaxel(25mg/㎡) and nedaplatin(25mg/㎡) concurrent with chest radiation
223669221|NCT03661567|DRUG|Methylprednisolone|Methylprednisolone after the first course of radiation, once a day, 32 milligram (mg) for 7 days, 24 mg for the next 7 days, then 16mg for 7 days, and 8 mg for the last 7 days.
223669222|NCT02204124|DEVICE|Thunderbeat|Thunderbeat uses ultrasonic and high frequency bipolar energy simultaneously to seal and cut tissue compared to placebo comparator.
223669223|NCT02204124|DEVICE|Standard of care scissors, ligatures, clips, and sutures|
223669224|NCT02171910|DRUG|Doxapram|
223669225|NCT02171910|DRUG|Placebo|An injection and infusion of normal saline (NaCl 0.9%) as a placebo comparator to doxapram
223669226|NCT00970385|DRUG|CHOP21|"CHOP regimen:~* cyclophosphamide 750 mg/m2 intravenously (IV) day 1~* doxorubicin 50 mg/m2 IV day 1~* vincristine 1,4 mg/m2 (maximum 2 mg) day 1~* prednisone 100 mg/m2/D from D1 to D5."
224250298|NCT01313949|OTHER|Training program|These diabetes patients will undergo a 32-hour 'Train the trainer' program (4 workshops, 8-hours each) led by health care experts in nutrition, physical activity, psychology and neuro-linguistic program \[NLP\] trainer to ensure the adequacy of knowledge and skills of these mentors.
223669227|NCT00970385|DRUG|VIP/ABVD|"VIP regimen:~* etoposide 100 mg/m2/D IV from D1 to D3~* ifosfamide 1000 mg/m2/D from D1 to D5~* cisplatinum 20 mg/m2/D as a continuous infusion from D1 to D5~ABVD regimen:~* doxorubicin50 mg/m2/D on D1 and D14~* bleomycin 10 mg/m2/D~* vinblastine 10 mg/m2/D~* dacarbazine 375 mg/m2/D"
223669228|NCT00970385|RADIATION|Radiotherapy consolidation|The treatment of Ann-Arbor stage I/II and stage III/IV patients with an initial bulky tumor (diameter ≥ 5 cm) was systematically completed by an irradiation plan. Forty grays were delivered (1,8 gray/day) over four weeks on the involved field.
223669229|NCT00003590|DRUG|hydroxyurea|20 mg/kg/day PO
223669230|NCT01542567|DRUG|Abitren|SUPPOSITORIES 50 Mg 2 SUPPOSITORIES A WEEK
223669231|NCT01542567|DRUG|Placebo|Placebo suppositories
223669232|NCT02980809|DRUG|Apatinib|
223669233|NCT02980809|DRUG|Topotecan|
223669234|NCT00511394|DRUG|20% Human Albumin|Infusion of 100 mL of 20% Albumin over 3 hours
223669235|NCT00511394|DRUG|Normal Saline|Infusion of 100 mL of Normal Saline
223669236|NCT05258188|OTHER|Instrument-assisted Soft Tissue Mobilization|Instrument-assisted soft tissue mobilization is used for a mechanical benefit for the therapist providing deeper approach and braces remodeling of connective tissues through dissolution of extravagant fibrosis, while provoking repair and reconstructing forwarded by the recruitment of fibroblast.
223669237|NCT05258188|OTHER|Compressive Myofascial Release Technique|Compressive Myofascial Release Technique is a technique of soft tissue stretching that uses compression and sustained myofascial stretches to create a releasing force in the targeted area
223669238|NCT01956344|BEHAVIORAL|Cognitive Behavioral Therapy|Group cognitive-behavioral therapy for hoarding disorder, 16 weeks
223669239|NCT00883688|DRUG|Bevacizumab|"10 mg/kg given by vein over 90 minutes for first injection (30-60 minutes for subsequent doses) every 2 weeks while on study (2 times during each 4-week study cycle)."
223669240|NCT00883688|DRUG|Lapatinib|Pills of 700 mg/m\^2/dose given orally 2 times each day.
223771439|NCT02205619|DEVICE|Air-flow® Powder Perio, EMS SA, Nyon, Swiss|comparison of different instruments on root cementum: Instrumentations with air polishing (Air-flow® Powder Perio, EMS SA, Nyon, Swiss) were performed with a special nozzle and medium power settings and with the use of water cooling (as instructed by the manufacturer). One approximal root surface (distal and mesial) of each tooth was randomly subjected to debridement and the other approximal surface was used as control. All the measurements and instrumentations of teeth were performed by a single operator. The criteria for adequate treatment were smooth, hard root surfaces, with no remnants of calculus. The cleanliness and smoothness of the root surface were checked using a fine dental explorer. The instrumentations were done under local anesthesia
223771440|NCT03572491|BIOLOGICAL|influenza vaccine|Allantoic split inactivated seasonal influenza vaccine
224250299|NCT03124420|DRUG|Lansoprazole|Group A: lansoprazole 30 mg b.i.d. for 7 days Group B: lansoprazole 30 mg b.i.d. for 14 days
224250300|NCT03124420|DRUG|Amoxicillin|Group A: amoxicillin 1 g b.i.d. for 7 days Group B: amoxicillin 1 g b.i.d. for 14 days
223771441|NCT03223818|OTHER|Fast-track peri-operative program|"Patients who are scheduled for elective liver resection will be screened in clinic or in wards for the eligibility for ERAS program. Patient will then visit a nurse-led clinic for pre-operative assessment of risk adjustment and education. A guided tour on surgical ward and an information booklet about preoperative management will be given.~All patients will receive local infiltration of local anaesthesia (0.25% levobupivacaine) followed by continuous wound instillation using the On-Q PainBuster System balloon pump. Pain control will be supplemented by using opioid-sparing multimodal analgesia."
224250301|NCT03124420|DRUG|Clarithromycin|Group A: clarithromycin 500 mg b.i.d. for 7 days Group B: clarithromycin 500 mg b.i.d. for 14 days
224250302|NCT02293668|DRUG|FSH 225IU and hMG 225IU|
223771442|NCT05123209|BIOLOGICAL|IM83 CAR-T cells|3×10\^9 CAR-T cells
223771443|NCT05123209|COMBINATION_PRODUCT|The second-line treatment of liver cancer|approved by NMPA
224250303|NCT02293668|DRUG|FSH 150IU and hMG 150IU|
224250304|NCT02293668|DRUG|Letrozole 5mg and hMG 150IU|
224250305|NCT06095076|DIAGNOSTIC_TEST|Skin swabbing|Skin swabbing will be performed on CVC insertion site before CVC placement (baseline), and then every 3 days (or when dressing is changed) while CVC is in place, then at ICU discharge. Bacterial metagenomics using bacterial DNA extraction, 16S PCR amplification and Nanopore sequencing will allow for description of cutaneous microbiota and diversity evaluation through Shannon index. Evolution of alpha-diversity will be evaluated through time-series data analysis: comparison of Shannon index at various time points with baseline Shanonn index (before CVC placement). Standard microbiologic culture of skin swabbing will be performed.
224250306|NCT06095076|OTHER|Data collection|General patient characteristics and informations relative to CVC infection and treatment will be collected.
224321975|NCT04152863|BIOLOGICAL|Gebasaxturev IV|Administered as an IV infusion of 1 X 10\^9 TCID50
223669241|NCT05278351|DRUG|Tislelizumab Combined With Cetuximab and Irinotecan|Tislelizumab (an anti-PD-1 monoclonal antibody) Cetuximab (monoclonal antibody against EGFR) Irinotecan
223669242|NCT05278351|DRUG|Third-line regimens|Trifluridinetipiracil or Regorafenib or Fruquintinib
223669243|NCT02051699|PROCEDURE|radiographic of standing knee|the patients stand on their one leg with pillar support and both-leg then shoot the x-ray beam to their knee
223669244|NCT04732013|OTHER|No clinical intervention is planned; study is observational|No intervention
223669245|NCT03908489|PROCEDURE|vital pulpotomy primary molars using garlic oil|vital pulpotomy using garlic oil
223669246|NCT03908489|PROCEDURE|vital pulpotomy using mta|mta vital pulpotomy
223669247|NCT06328387|DRUG|Hydroxychloroquine|The dosage of hydroxychloroquine is determined based on the dose escalation study, and the appropriate administration method will be determined based on this result.
223669248|NCT06328387|DRUG|Sacituzumab Govitecan|Sacituzumab govitecan is a monoclonal antibody, called sacituzumab, linked to a chemotherapy drug, called govitecan. Sacituzumab is a form of targeted therapy because it attaches to specific molecules on the surface of cancer cells, known as Trop-2 receptors, and delivers govitecan to kill them.
224321976|NCT04152863|BIOLOGICAL|Gebasaxturev ITu|Administered as an ITu injection of 3 X 10\^8 TCID50
223771444|NCT00637546|OTHER|Physiotherapy|Gait and Balance training based on recommendations of Robertson et al. and Page et al. (different balance control exercises; progression in consecutive stages: Sensimotor training, a static phase, a dynamic phase combined with functional tasks. The treatment takes place twice a week over 12 weeks. Patients were encouraged to perform specific home exercises.
223669249|NCT06328387|DRUG|Trastuzumab Deruxtecan|Trastuzumab-deruxtecan is a human HER2-directed antibody-drug conjugate (ADC) composed of humanized anti-HER2 immunoglobulin G1 (IgG1) monoclonal antibody (mAb) with the same amino acid sequence as trastuzumab, covalently linked to the membrane-permeable topoisomerase I inhibitor payload, DXd, an exatecan derivative, via a stable tetrapeptide-based linker, selectively cleaved within tumor cells.
223669250|NCT00756912|DRUG|E5564|Three dose levels of Eritoran IV over 14 days for a total of 32, 96, and 224 mg over 14 days.
223771445|NCT02656446|DEVICE|Accuro Handheld Ultrasound|Use of an Accuro Handheld Ultrasound to identify lumbar interspaces, midline, and depth to epidural space
224250307|NCT01167530|DRUG|Everolimus|First phase of the study:RAD001 (everolimus) will be administered per os every Monday, one week before then during the radiotherapy and will be continued for 3.5 weeks after the end of the radiotherapy. Chemotherapy is given 4.5 weeks after the end of radiotherapy. Three patient cohorts are planned, receiving 10, 20 and 50 mg of RAD001 per week.Second phase of the study:RAD001 (everolimus) will be administered per os every day one week before then during the radiotherapy and will be continued for 3.5 weeks after the end of radiotherapy. Chemotherapy is given 4.5 weeks after the end of radiotherapy. Three patient cohorts are planned, receiving 2.5, 5 and 10 mg of RAD001 per day.The two phases of the study may be conducted independently and in parallel.
224250308|NCT06133725|PROCEDURE|erector spinae plane block|The experimental group received ultrasound-guided erector spinae plane block, and bilateral erector spinae plane block was performed at T7 segment with 20ml 0.375% ropivacaine on each side.While the control group received ultrasound-guided transversus abdominis plane block combined with rectus sheath block, which will be performed under the costal margin with 10ml 0.375% ropivacaine for bilateral transversus abdominis plane block and 10ml 0.375% ropivacaine for bilateral rectus sheath block.
223669251|NCT05188157|OTHER|mirror therapy|The patients in IG will receive exercise program before mirror theraphy. The patient will continue to do the exercises in front of the mirror for the remaining 20 minutes of the exercise. While doing the exercise with the healthy side in front of the mirror, the patient will try to do the same movement with the shoulder diagnosed with impingement syndrome on the other side of the mirror. The patient will try to do the movement correctly with the reflection in the mirror.
223771446|NCT02656446|DEVICE|Standard Ultrasound Machine|Use of standard ultrasound as gold standard to identify lumbar interspaces, midline, and depth to epidural space
224250309|NCT05066438|BEHAVIORAL|Antenatal hand expression|Standardized counselling and provision of information/resources on the practice of antenatal hand expression to encourage milk let down and colostrum production/collection.
224250310|NCT01433718|PROCEDURE|Neuromuscular and Resistance Training|1 hour/session, 3 sessions/week, 6 weeks
224250311|NCT02077465|DRUG|Andecaliximab|400 mg andecaliximab administered intravenously
223771447|NCT01629082|DRUG|Clofarabine|
224250312|NCT02077465|DRUG|Placebo to match Andecaliximab|Placebo to match andecaliximab administered intravenously
224250313|NCT00115843|DEVICE|Mobile Cardiac Outpatient Telemetry|
223771448|NCT01629082|DRUG|Lenalidomide|
223771449|NCT02310438|OTHER|Therapeutic Instrumental Music Performance|The same instruments are selected and used with each participant. They are spatially arranged for them to play in their home in a way that addresses the target movement, for example elbow flexion and extension. The music therapist plays specific musical patterns live on a guitar for each exercise whilst the participant plays specific patterns on the instruments.
224250314|NCT02776878|DRUG|dasatinib|
224250315|NCT04400617|BEHAVIORAL|Cross-sectional assessments to examine the relationship among sleep quality, functional/physical capacity, and cognitive performance.|The first visit will consist of screening measurements. Participants will be asked to complete the following questionnaires: InterRAI Self Report Quality of Life Survey for Long Term Care Facilities (interRAI SQoL), Resident Assessment Instrument (RAI)-MDS 2.0, Global Physical Activity Questionnaire (GPAQ), Memory Complaint Questionnaire (MAC-Q), and Pittsburgh Sleep Quality Index (PSQI). At the end of this visit, the participants will be asked to wear the ActiWatch-2 (AW-2) as a wristwatch for 14 days. In the second visit, participants' height and weight will be measured and the participants will perform the following cognitive and functional tests: MoCA, Brief Visuospatial Memory Test-Revised (BVMT-R), Hopkins Verbal Learning Test-Revised (HVLT-R), Time up and Go (TUG), and Cognitive TUG (TUGcog). Finally, visit 3 will consist of on-site PSG recordings.
223771450|NCT02277626|DEVICE|Electro Flo 5000|Airway clearance device
223771451|NCT02277626|DEVICE|Incourage Vest System|Airway Clearance Device
224250316|NCT01853657|OTHER|Virological monitoring|
223669252|NCT05188157|OTHER|conventional physiotherapy|The conventional physiotherapy program included, wand exercises for shoulder abduction, flexion, hyperextension and internal and external rotation, Codman exercises and isometric and resistive exercises of the shoulder girdle. The exercise program is performed under the supervision of an experienced physiotherapist. The isometric exercises will be used during the painful period, and the resistance exercises will be added after the pain began to relieve.under the supervision of a physician in the first 30 minutes of their exercise.
223669253|NCT05334056|DRUG|Cocaine Nasal|2 ml of 4% cocaine given as a nasal spray immediately prior to nasal intubation
223669254|NCT02350751|DRUG|MEDI8852|
223669255|NCT02350751|DRUG|Placebo|
223771452|NCT03897608|BEHAVIORAL|short form 36|"The Short Form (SF)-36 Health Survey was used to measure HRQL. The SF-36 generates a profile of HRQL outcomes by measuring health across eight different dimensions: physical functioning, role limitation because of physical health, social functioning, vitality, bodily pain, mental health, role limitation because of emotional problems and general health. Responses to each question within a dimension are combined to generate a score from 0to100; where100 indicates good health"
223771453|NCT00659646|DRUG|gentamicin-collagen sponge and levofloxacin|Topical Gentamicin Collagen Sponge: 10 × 10 cm in size And 750 mg tablet po every 24 hours or 750 mg IV administered by slow infusion over 90 minutes every 24 hours.
224321977|NCT04152863|DRUG|Pembrolizumab|Administered as an IV infusion of 200 mg
224321978|NCT00742118|PROCEDURE|Colic biopsies|colic biopsies and analysis
223669256|NCT00706576|DRUG|Infusion of opioid growth factor|Volunteers will be treated with an intravenous infusion of opioid growth factor(OGF) starting at 100 µg/kg with a 50 µg/kg dose escalation with each succeeding group. The investigational drug, OGF, will be diluted in sterile saline to its appropriate concentration based upon the body weight of the volunteer and administered in a volume of 60 ml over 45 minutes (rate of 2 ml/min)
223669257|NCT04424329|DIETARY_SUPPLEMENT|Fibers and probiotics|A blend of fibers and seven probiotics
223669258|NCT01964040|DRUG|peri-neural dexmedetomidine as adjuvant to bupivacaine in femoral nerve block|"ultrasound quided femoral nerve block with injection of 15 ml bupivacaine 0.5% perineurally with 0.5 ml dexmedetomidine (50 microgram) either perineurally or subcutaneously.~After adequate assessment of femoral nerve block, patients will be transferred to the operating room to receive a standard general anesthesia"
223669259|NCT04844710|COMBINATION_PRODUCT|acupuncture and standard care|manual acupuncture in acupoint LI4, LI11, ST36 every 2 days for 6 times standard care
223669260|NCT04844710|DRUG|standard care|standard care only
223669261|NCT00522925|DRUG|PS433540|200mg capsule, once daily for 28 days
223669262|NCT00522925|DRUG|placebo|placebo capsule, once daily for 28 days
223669263|NCT00522925|DRUG|PS433540|500mg capsule, once daily for 28 days
224250317|NCT04471272|PROCEDURE|RFA using gradual RF energy delivery mode with Octopus electrodes|RFA therapy is performed on HCC less than 4 cm in size using an octopus electrode, a double-shift unipolar high-frequency transmission mode, and a gradual high-frequency energy loading mode.
224250318|NCT01700244|DEVICE|Pacemaker implant|
223669264|NCT02666157|DRUG|Dabigatran etexilate|this drug is administered twice per day for the entire study period
224250319|NCT04471363|BEHAVIORAL|Cancer-Specific Exercise education|An audio-recorded PowerPoint presentation created by the study team on the benefits of exercise for survivors, caregivers and romantic couples.
224250320|NCT05770063|DIETARY_SUPPLEMENT|amino acid tablet|multiple essential amino acids supplements
224250321|NCT01827163|DRUG|Paclitaxel|
224250322|NCT01827163|DRUG|Trastuzumab|The q 3 week trastuzumab may be started at the last dose of paclitaxel infusion or from 1-3 weeks after the last dose of paclitaxel. Trastuzumab may also be administered at a dose of 6mg/kg during the last dose of paclitaxel in the THL phase.
224250323|NCT01827163|DRUG|Lapatinib|
224250324|NCT01827163|DRUG|Pegfilgrastim|Pegfilgrastim SQ is given on day # 2 of each paclitaxel cycle and may be dropped at the last paclitaxel infusion. Filgrastim may be used in lieu of pegfilgrastim at the physician's discretion.
224250325|NCT03375463|DRUG|Tirzepatide|Administered SC
223669265|NCT02666157|DRUG|Rivaroxaban|this drug is administered once per day for the entire study period
223669266|NCT02666157|DRUG|Apixaban|this drug is administered twice per day for the entire study period
223669267|NCT02437227|DRUG|CCT3833|CCT3833 is a poorly soluble crystalline compound. It is multi-polymorphic and one form, designated Form D, has been purified and typically has a particle size of about 15-20 μm. Form D readily absorbs and desorbs water, but is not a hydrate and has been selected as the form to take forward into clinical development.
224250326|NCT03375463|DRUG|Tirzepatide|Administered IV
224250327|NCT03375463|DRUG|Placebo|Administered SC
224250328|NCT03375463|DRUG|Tirzepatide|Administered IV
224250329|NCT00022386|BIOLOGICAL|epoetin alfa|
224250330|NCT00022386|PROCEDURE|quality-of-life assessment|
224250331|NCT04490941|OTHER|Ophthalmologist-delivered health education|The educational intervention will be conducted on-site by a qualified, experienced ophthalmologist at an ophthalmic center with goals of building awareness on diabetes symptoms, particularly on diabetic retinopathy, and its risk factors with appropriate management.
224250332|NCT04490941|OTHER|Usual care|Usual care follows standard procedure on diabetes management similar to the routine service provision.
224250333|NCT04909190|PROCEDURE|Increased saline flush volume|Additional flushing of the stentgraft delivery system.
224250334|NCT01880814|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|Children will first be randomized into Stage 1 of CBT or Caregiver-Child Treatment. Stage 1 will include six sessions. After Stage 1, child's response to treatment will be evaluated. Responders will be re-randomized into Stage 2 of no treatment or continuation of CBT. If randomized to no treatment, termination session will be completed. If randomized to continuation of CBT, the treatment will include six sessions and a termination session. Insufficient responders will be re-randomized into Stage 2 of continuation of CBT or Caregiver-Child Treatment. Stage 2 will include six sessions and a termination session.
224250335|NCT01880814|BEHAVIORAL|Caregiver-Child Treatment|Children will first be randomized into Stage 1 of CBT or Caregiver-Child Treatment. Stage 1 will include six sessions. After Stage 1, child's response to treatment will be evaluated. Responders will be re-randomized into Stage 2 of no treatment or continuation of Caregiver-Child Treatment. If randomized to no treatment, termination session will be completed. If randomized to continuation of Caregiver-Child Treatment, the treatment will include six sessions and a termination session. Insufficient responders will be re-randomized into Stage 2 of continuation of Caregiver-Child Treatment or CBT. Stage 2 will include six sessions and a termination session.
224250336|NCT01602419|OTHER|Patients using Wilate as standard of care|Patients with von Willebrand Disease using Wilate for a period of 2 years.
224250337|NCT01792635|DRUG|PF-05175157|PF-05175157 will be administered at 200 mg twice a day for 43 days.
224250338|NCT01792635|DRUG|Placebo|Placebo tablets matched to PF-05175157 will be administered twice a day for 43 days.
223680657|NCT02821143|OTHER|Telemedicine consultation|"Establishment of an initial multiprofessional Telemedicine consultation involving a palliative care physician and / or geriatrician, and other physician coordinator of nursing homes, health care team and if possible the patient's treating physician (patient and / or family may participate if they want to).~The aim is to define and formalize:~* Aid to collection and application of advanced directives according to Leonetti Act if the resident is able to do so, or collection of confidence personal choices.~* Definition of the objectives of care and patient's life and therapeutic adaptation with a focus on pain and uncomfortable symptoms.~* Access to a mobile team of palliative care or geriatric hospitalization at home, a hospice network, if the patient's situation requires.~* In case of medical worsening :~Possibility of access to consultations and use of emergency by tele-expertise or decision support within a maximum period of 72 hours, with the same objectives that above."
224250339|NCT04448106|BIOLOGICAL|Celltex- AdMSCs|Autologous adipose-derived stem cells Culture expanded mesenchymal stem cells isolated from a patient's own abdominal fat tissue
224321979|NCT04913142|OTHER|Fecal and oral samples|oral and rectal swab from patients hospitalized at day 1, each 7 days and at the end of their ICU stay
224321980|NCT05284266|PROCEDURE|Liposuction early|Liposuction 6-9 months after inclusion
223669268|NCT05382000|DIAGNOSTIC_TEST|Advanced triage tool for Gynecology and Obstetrics emergencies based on artificial intelligence algorithms.|"After the conventional triage, a second independent doctor will make the suit with the Mediktor Hospital tool.. In less than 3 minutes and with an average of 14 questions, Mediktor performs an interrogation very similar to what an emergency doctor would do. The professional version allows the health professional to modify the course of the questions in the middle of the evaluation, if he considers it necessary to go deeper into some aspect of the anamnesis. The system allows you to see in real time the diseases that Mediktor considers possible during the evaluation.~At the end of the triage process, Mediktor offers the level of urgency and a list of possible diagnoses based on the signs and symptoms answered. The professional can change the level of urgency if he considers it beneficial for the patient.~Once the two triages (Conventional and Mediktor) have been carried out, the patient will be seen according to the care protocols of the center."
223669269|NCT05633030|PROCEDURE|using UAS during flexible ureteroscopy and using PCN during flexible ureteroscopy|under general anesthesia and given appropriate antibiotic cover. a clssic flexible ureteroscopy procedure is done and appropriately sized UAS was then inserted over the wire and positioned just distal to the PUJ or below upper ureteric stone under fluoroscopic guidance. We then perform a flexible ureteroscopy using Olympus URF-V2 (8.5 Fr) flexible ureteroscope to inspect the proximal ureter if there is upper ureteric stone, renal pelvis, and calyces for the presence of stones. Irrigation with 0.9% saline solution via a pressure-infusing system. Next, Holmium laser lithotripsy with a holmium:YAG laser \[20 W; Lumenis (UK) Ltd., Elstree, UK\] using a 272 micron laser fiber (Lumenis, Inc.) is carried out and/or stone extraction with a basket device, in the other group we add inserted trans papillary in the lower calyx of the kidney by an expert intervention radiologist
223669270|NCT01350544|BEHAVIORAL|Treatment Advocacy|Treatment advocacy is a 24-week intervention with booster sessions, including a 4-week intensive intervention followed by a 20-week maintenance period. In the first 4 weeks, all participants receive 4 individual weekly 60-minute sessions and 1 group HIV education session. In the next 20 weeks, all participants receive booster sessions in weeks 12 and 20, and a counselor check-in phone call in week 8 regarding need for new referrals and adherence barriers. Participants who have not demonstrated good adherence (≥90%) during the prior 2 weeks receive ≤4 additional booster sessions at weeks 14, 16, 22, and 24. Clients receive additional linkage with APLA's social service programs, as necessary.
223669271|NCT04825730|DRUG|JOINTSTEM|JOINTSTEM is an OA treatment that uses autologous adipose-derived mesenchymal stem cells. As it does not use allogenic tissues and is incubated without additional genetic modification or mechanical and chemical modification through differentiation, it is classified as 'autologous cell therapy' and is completely free of immunologic rejection.
223669272|NCT01444092|DRUG|Entocort|Entocort capsules, oral
224250340|NCT02120937|BEHAVIORAL|MBCT-C Therapy|Mindfulness Based Cognitive Therapy for Children is a manualized psychotherapeutic intervention that combines mindfulness techniques with certain features of cognitive behavioral therapy. This particular protocol for youth includes weekly group sessions, regular home practice, and the core curriculum of formal mindfulness practices (e.g., body scan, sitting, movement, and walking meditations).
223669273|NCT04290728|DEVICE|Apnea with high-flow nasal cannula|Application of oxygenation with high-flow nasal cannula with a rate of 2L/kg/min
223669274|NCT04290728|OTHER|Apnea|Apnea without any application of oxygenation
223669275|NCT06420258|PROCEDURE|Deeper endotracheal intubation|After general anesthesia, endotracheal intubation was conducted using an ultrafine endoscope (GIF-XP260NS, Olympus Corp., Japan), which allows observation of the exact position and avoids blindness caused by laryngoscopy. To prevent balloon compression of the CE after inflating, the endotracheal intubation tube was inserted above the tracheal carina, roughly the upper thoracic esophagus.
224250341|NCT00800137|DRUG|low molecular weight heparin or unfractionated heparin|"For elective patients with greater than 5 days pre-implant; discontinue oral anti-coagulation (coumadin) 5 days before the procedure. Full therapeutic doses of subcutaneous LMWH 3 days before the procedure.~Patients with less than 5 days to implant can be given vitamin K (up to 2 mg) at the investigator discretion and start full therapeutic doses of either subcutaneous LMWH or IV Unfractionated Heparin (choice is at investigator's discretion) when INR is below the upper limit of the prescribed therapeutic range for the patient (usually greater than or equal to 2; 2.5 for some valve patients) and surgery to proceed when INR is less than 1.6.~Last dose given in the morning(ie. \> 24 hours)of the day prior to the procedure.~Oral anti-coagulation (coumadin) will be resumed on the evening of the procedure.~Full dose LMWH or full dose IV heparin will be restarted 24 hours after surgery."
224250342|NCT00800137|DRUG|Warfarin or coumadin|Continue on oral anti-coagulant (coumadin). INR on the day of surgery will be \< 3.0
224250343|NCT01875952|DRUG|Isoniazid|Isoniazid, 10 mg/Kg/day, no more than 300 mg/day, for six months
224250344|NCT01268085|OTHER|Radiation Alert|A radiation safety pop-up alert with a message about the dangers of cumulative ionizing radiation, the patient's cumulative CAT scan history, and the most recent imaging test from any modality of the same body part
224250345|NCT01268085|OTHER|Control|Control with no inverention
224250346|NCT03974685|DRUG|99mTc niacinamide polyethylene glycol bicyclic RGD peptide (99mTc-3PRGD2)|Single dose
224321981|NCT05284266|PROCEDURE|Liposuction late|Liposuction 18-21 months after inclusion
224321982|NCT05284266|OTHER|Standard conservative treatment|"Standard Conservative treatment consisiting of:~Physical therapy, including compression garment and exercise program, Self-care program"
224321983|NCT05284266|OTHER|Standard conservative treatment with Intermittent Pneumatic Compression (IPC)|Physical therapy, including compression garment and exercise program, Self-care program and Intermittent Pneumatic Compression (IPC)
224321984|NCT00738257|DRUG|Pamidronate|
224321985|NCT02441725|OTHER|1-minute sit-to-stand test|Validation of the 1-minute sit-to-stand test in a COPD patient population
224321986|NCT00195455|DRUG|Trimegestone|
224321987|NCT00195455|DRUG|17b Estradiol|
223669276|NCT01809470|BEHAVIORAL|FIFA2013|Playing FIFA2013 for 1 hour
223669277|NCT01809470|BEHAVIORAL|Call of Duty|Playing Call of Duty for 1 hour
223669278|NCT01809470|BEHAVIORAL|Watching TV|Watching TV for 1 hour
223669279|NCT06066229|OTHER|Questionnaire- Delphi method|Identify important evaluation criteria for lung transplant patients by rating each criterion
223669280|NCT00594425|DRUG|Methyl aminolevulinate (MAL) PDT|Cream application followed by illumination with red light
223669281|NCT03105544|OTHER|simulation-based training|As described under group descriptions
223669282|NCT05368454|BEHAVIORAL|Online Diabetes Self-Management Education and Support (DSMES) Program|An online program for Diabetes Self-Management, Education and Support (DSMES) that includes personal coaching by a certified Diabetes Care and Education Specialist (CDCES), tracking tools, and FreeStyle Libre CGMs, a wearable sensor with data scanning ability accessed through the smartphone app.
223669283|NCT05368454|BEHAVIORAL|Standard of Care|All participants randomized to the standard of care/control arm will be asked to continue with their current care plan and care team for management of their diabetes.
223669284|NCT03211806|BEHAVIORAL|Sedentary Behavior|Messages delivered via smartphone prompting patients to walk after prolonged sedentary behavior bouts are detected via Bluetooth-enabled activity monitor
223669285|NCT03211806|DEVICE|Bluetooth-enabled activity monitor|Monitoring activity using a Bluetooth-enabled activity monitor
223669286|NCT04941443|DRUG|Methadone Pill|All participants will be given a 5mg methadone tablet to be taken immediately following the misoprostol dose.
223669287|NCT04941443|DRUG|Ibuprofen|All participants will be provided additional analgesics (ibuprofen 800mg x4 tabs) available for use as needed every eight hours.
223669288|NCT01768884|DRUG|Nitric Oxide|
223669289|NCT01768884|DRUG|Placebo|
223669290|NCT02270853|DEVICE|sleep apnea screening with ApneaLinkTM|ApneaLink is sleep-screening tool that objectively identifies patients with sleep apnea
223669291|NCT01613846|DRUG|Sorafenib+Pazopanib|Sorafenib (first-line) followed by Pazopanib (second-line)
223669292|NCT01613846|DRUG|Pazopanib+Sorafenib|Pazopanib (first-line) followed by Sorafenib (second-line)
223669293|NCT04848857|DRUG|Colchicine|colchicine is a potent anti-inflammatory drug which is currently recommended for the treatment of pericarditis and acute gout attacks, but also familial Mediterranean fever and Behçet disease. This drug acts on inflammation through inhibition of microtubule polymerization by binding free tubule dimers. Colchicine blunts monocyte and neutrophil invasion at the site of inflammation and reduces intracellular trafficking and thus the release of cytokine and production of reactive oxygen species and a variety of proteolytic enzymes.
223669294|NCT04848857|DRUG|Placebo|the placebo is a drug with no chemical effects but with the same physical characteristics as the experiment drug colchine.
223669295|NCT03085914|DRUG|Epacadostat|Epacadostat oral twice-daily continuous daily dosing at the protocol-defined dose.
223669296|NCT03085914|DRUG|Pembrolizumab|Pembrolizumab
223669297|NCT03085914|DRUG|Oxaliplatin|Oxaliplatin
223669298|NCT03085914|DRUG|Leucovorin|Leucovorin
224250347|NCT06459271|OTHER|Managing Cancer And Living Meaningfully (CALM)|Our team has developed a brief, manualized, individual and couple-based psychotherapeutic intervention for patients living with advanced cancer and their primary caregivers called Managing Cancer and Living Meaningfully (CALM). CALM is a brief supportive-expressive therapy consisting of 3-6 sessions of 30-60 minutes delivered over the course of 3-6 months. This tailored therapy is focused on the most common challenges and concerns facing individuals living with advanced cancer. These four broad content domains are: 1) symptom management and communication with healthcare providers; 2) changes in self and in relationships with close others; 3) sense of meaning and purpose in life; and 4) hopes and fears about the future and mortality. The aim is to offer patients and caregivers reflective space and a supportive environment to reflect on and process the various practical and profound aspects of their life while facing advanced illness.
224250348|NCT03215693|DRUG|X-396 capsule|225mg once daily
224250349|NCT06358053|DRUG|CRTE7A2-01 TCR-T cell therapy|Drug 1: Fludarabine + Cyclophosphamide Drug 2: Interleukin-2 Drug 3: CRTE7A2-01 TCR-T Cell
224250350|NCT02465320|DRUG|COL-1077|single dose of 150mg lidocaine (10%w/w) administered by intravaginal insertion
224250351|NCT02465320|DRUG|Placebo|single dose of bioadhesive gel administered by intravaginal insertion
224250352|NCT04278391|DRUG|DWJ1421|1 tablet administered in fasting condition
223669299|NCT03085914|DRUG|5-Fluorouracil|5-Fluorouracil
223669300|NCT03085914|DRUG|Gemcitabine|Gemcitabine
223669301|NCT03085914|DRUG|nab-Paclitaxel|nab-Paclitaxel
223669302|NCT03085914|DRUG|Carboplatin|Carboplatin
223669303|NCT03085914|DRUG|Paclitaxel|Paclitaxel
223669304|NCT03085914|DRUG|Pemetrexed|Pemetrexed
223669305|NCT03085914|DRUG|Cyclophosphamide|Cyclophosphamide
223669306|NCT03085914|DRUG|Carboplatin|Carboplatin
223669307|NCT03085914|DRUG|Cisplatin|Cisplatin
223669308|NCT03085914|DRUG|5-Fluorouracil|5-FU
223669309|NCT03085914|DRUG|Investigator's choice of platinum agent|Investigator's choice of platinum agent: carboplatin or cisplatin
223669310|NCT01779518|DRUG|Sofosbuvir|
223669311|NCT01779518|DRUG|Ribavirin|
223669312|NCT01779518|DRUG|Pegylated Interferon|
223669313|NCT01242813|DRUG|ACZ885|
223669314|NCT00332735|DRUG|spinal administration of articaine|
223669315|NCT00332735|DRUG|spinal administration of bupivacaine|
223669316|NCT00049985|DRUG|Darbepoetin Alfa|
223669317|NCT02447237|OTHER|dietary counselling|the participants will receive dietary counselling in fulfilling their need of energy and protein according to the group they are randomized to (either solid or liquid food).
223669318|NCT02458937|OTHER|Functional Mobility Assessment|Functional Mobility Assessment (FMA) is a tool that was developed to measure functional mobility in children and adolescents with lower-extremity sarcoma. It is comprised of well-established outcome measures that examine various domains of function. The six categories tested by the FMA include pain, functional mobility, use of assistive devices, satisfaction with quality of gait, participation in the community, and endurance.
223669319|NCT02458937|OTHER|GAITRite® System|Subjects will be required to walk at a self-selected comfortable pace and again at fast speed. Software will then calculate and report the temporo-spatial gait parameters for collection and evaluation by the primary investigator.
224250353|NCT04278391|DRUG|DWC201903|1 tablet administered in fasting condition
224250354|NCT00544180|DRUG|Risedronate|
224250355|NCT03025945|DRUG|Nepafenac 0.3%|
224250356|NCT03025945|DRUG|Saline Solution|
224250357|NCT00704691|DRUG|Lenalidomide|Lenalidomide 25 mg as a daily oral dose days 1-21 followed by a 7 day rest period (28 day cycle) for 1-6 cycles
224250358|NCT01513174|DRUG|Gefitinib|Gefitinib 250 mg once a day, continuously, in 28-day cycles, until progression
224250359|NCT01513174|DRUG|Olaparib|Gefitinib 250 mg once a day, in combination with olaparib (at the recommended dose in the previous Phase Ib study) twice a day, continuously, in 28-day cycles.
224250360|NCT05203562|PROCEDURE|Suction evacuation|both groups underwent complete mole evacuation using suction curettage.
224250361|NCT05203562|DRUG|Letrozole tablets|Group II Patients received 5mg(2tablets 2.5gm) daily letrozole for 10 days after complete mole evacuation
224250362|NCT04195360|OTHER|Standardized mobilization procedure|5 minutes bed rest (h1), followed by 3 minutes passive leg raise (PLR), followed by 5 minutes bed rest (h2), followed by 3 minutes sitting on the egde of the bed (sit), followed by 3 minutes standing/walking on the spot (sta), followed by 5 minutes bedrest (h3)
224250363|NCT03476265|DEVICE|Electrical Stimulation of the Lower Esophageal Sphincter|Laparoscopic implantation of an electrical stimulation device to perform an electrical sphincter augmentation for the treatment of GERD.
224250364|NCT04374448|PROCEDURE|Sinonasal Benign or Malignant Tumor Resection|During sinus tumor resection, margins will initially be estimated with the naked eye. Then the dye, Indocyanine Green (ICG), will be injected through the intravenous line to identify tumor margins and be compared to estimated margins.
224250365|NCT04374448|PROCEDURE|Skull Base Surgery (Assessment of Nasoseptal Flap)|In this surgery, a piece of individuals septum will be used for the reconstruction. The amount of time for the flap to fluoresce Indocyanine Green (ICG) will be measured. It will be ensured that the it is still lighting up at the end of the surgery, indicating it is still receiving a good supply and ensures longevity of the flap.
224250366|NCT04374448|PROCEDURE|Endoscopic Sinus Surgery|During the surgery, the timing of Indocyanine Green (ICG) administration to fluorescence of anterior and posterior ethmoidal artery and of the internal carotid artery will be measured.
224250367|NCT04374448|PROCEDURE|Posterior Epistaxis Management (SPA Ligation)|During surgery timing of Indocyanin Green (ICG) administration to fluorescence of the sphenopalatine artery will be measured.
224250368|NCT02096991|OTHER|Can 1|drink the beverage in a can and a glass bottle
224250369|NCT02096991|OTHER|Can 2|Consume two canned beverage
224250370|NCT02096991|OTHER|Glass|consume two glass bottled beverage
224250371|NCT00335348|DRUG|Bortezomib|Induction- 1.3mg/m2 IV days 1,4,8,11 every 3 weeks up to 8 cycles Consolidation- 1.3mg/m2 IV days 1,8,15,22 every 5 weeks up to 3 cycles Maintenance- 1.3mg/m2 IV days 1,15 every 4 weeks
224250372|NCT00335348|DRUG|Dexamethasone|Induction- 20mg orally days 1,2,4,5,8,9,11,12 every 3 weeks up to 8 cycles Consolidation- 20mg orally days 1,2,8,9,15,16,22,23 every 5 weeks up to 3 cycles Maintenance- 20mg orally days 1,2,15,16 every 4 weeks
224250373|NCT04312165|DEVICE|Duramesh Laparotomy Closure|Closure of midline laparotomy incision with experimental suture
224250374|NCT04312165|DEVICE|Conventional suture closure|Closure of midline laparotomy incision with standard suture
224250375|NCT00190840|DRUG|pemetrexed|
224250376|NCT01844674|DRUG|Tizanidine|Participants will receive tizanidine as single oral doses, 2 milligrams (mg) on Day 1 and repeated on Day 22, each following an overnight fast \>/= 10 hours.
224250377|NCT01844674|DRUG|Vemurafenib|Participants will receive vemurafenib as multiple oral doses, 960 mg twice daily on Days 2 to 22.
224250378|NCT00626184|DRUG|4 dose levels of ALV003|4 dose levels of ALV003 vs placebo
223669320|NCT02458937|OTHER|Range of Motion|Measurements will include hip flexion, hip abduction and adduction, and hip internal and external rotation. Range of motion (ROM) will be attempted on bilateral lower extremities, however if post-operative ROM precautions are implemented, the involved extremity will not be measured. Goniometry is a reliable and valid measure for active and passive ROM when following standardized procedures.
223669321|NCT03816540|DEVICE|HRV and respiratory coherence biofeedback|Biofeedback treatment to support self-regulatory processes on the physiological level: heart rate variability (HRV) and respiratory coherence.
223669322|NCT01910311|DRUG|Baricitinib|Administered orally
223669323|NCT01910311|DRUG|Rifampicin|Administered orally
223669324|NCT01106417|BIOLOGICAL|NeoFuse|Single Dose NeoFuse Surgical Implantation
223669325|NCT01106417|DEVICE|MasterGraft Granules|Single Dose MaterGraft Granules Surgical Implantation
223669326|NCT04232969|DRUG|Exenatide extended release 2mg (Bydureon)|Subcutaneous Injection
223669327|NCT01252667|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic hematopoietic PBSCT
223669328|NCT01252667|DRUG|Clofarabine|Given IV
223669329|NCT01252667|DRUG|Cyclosporine|Given PO
223669330|NCT01252667|OTHER|Laboratory Biomarker Analysis|Correlative studies
223669331|NCT01252667|DRUG|Mycophenolate Mofetil|Given PO
223669332|NCT01252667|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo allogeneic hematopoietic PBSCT
223669333|NCT01252667|OTHER|Pharmacological Study|Optional correlative studies
223669334|NCT01252667|RADIATION|Total-Body Irradiation|Undergo TBI
223669335|NCT00650481|DRUG|Oxybutynin Chloride Extended-release Tablets 5 mg|4x5mg, single dose fasting
223669336|NCT00650481|DRUG|Ditropan XL® Tablets 5 mg|4x5mg, single dose fasting
223669337|NCT04644315|DRUG|Alectinib|Participants will receive 600 mg oral alectinib BID until disease progression, unacceptable toxicity, withdrawal from treatment, or death.
223669338|NCT04403009|OTHER|no intervention|no intervention
223669339|NCT03426982|DRUG|Unfractionated heparin|Infusion dose of unfractionated heparin was adjusted by APTT
223669340|NCT03426982|DRUG|Unfractionated heparin|Infusion dose of unfractionated heparin was adjusted by anti-Xa
223669341|NCT01836276|DRUG|Varenicline|1 mg of varenicline twice daily after titration to full strength in the first week following standard dosing guidelines
223669342|NCT01127789|DEVICE|Transcranial Direct Current Stimulation|Transcranial Direct Current Stimulation
224250379|NCT00900718|DEVICE|Straumann Bone Ceramic|Bone augmentation, after tooth extraction, with Straumann Bone Ceramic (synthetic bone graft material) in combination with resorbable collagen membrane Bio-Gide.
224321988|NCT01207895|DEVICE|PET imaging with [18F]-FLT|Up to three \[18F\]-FLT PET scans; one before beginning treatment, one at week three of treatment, and one at week 11, after completion of treatment but prior to surgery.
224250380|NCT00900718|DEVICE|Bio-Oss|Bone augmentation, after tooth extraction, with Bio-Oss (bovine-derived xenograft)in combination with resorbable collagen membrane Bio-Gide.
224250381|NCT02553564|OTHER|Checklist driven clinical encounter after hospital discharge|"Within 96 hours of hospital discharge an Nurse Practitioner will perform a checklist guided assessment to preventing rehospitalizations. The assessment consists of the following:~1. The participants's hospital course will be reviewed and their clinical recovery and stability assessed.~2. Determination of the participants's estimated dry weight (EDW).~3. The participants's post discharge medications will be checked, compared to the prehospitalization medication, and discrepancies will be reviewed and corrected.~4. Blood tests will be ordered for the participants's first return dialysis treatment if medically appropriate after clinical assessment.~5. Write new dialysis orders.~6. Dialysis Access- review access and determine any changes required in treatment"
223669343|NCT04532580|DEVICE|Diagnosis of fracture on X-Ray Radiographs|Diagnosis of fracture on X-Ray Radiographs with and without the assistance of Boneview Software
223669344|NCT01566812|BEHAVIORAL|Breast feeding optimization|Breast feeding optimization program extends from late pregnancy period to 6 months after birth. Prenatal intervention consists of individual and group counseling/education; perinatal intervention consists of in-hospital lactation support; postnatal intervention consists of home visit, counseling session, reminding telephone call and bulk SMS, special counseling for working mothers, breast pump rental, occupational-related support
223669345|NCT01566812|BEHAVIORAL|Usual care|Usual care applied in the hospital
223669346|NCT01847131|DRUG|oxymetazoline|0.05% Oxymetazoline nasal sprays were commercially available.
223669347|NCT01847131|DRUG|Placebo nasal spray|Placebo nasal spray has made by the local pharmaceutical company in thailand who commercially manufacture and sell 0.05% oxymetazoline nasal spray. The placebo contains the same ingredients as the drug except the active ingredient.
223669348|NCT05247528|DRUG|MANP|Novel designer peptide to represent a pGC-A/cGMP therapeutic
223669349|NCT05247528|DRUG|Placebo|Placebo Comparator
223669350|NCT03014882|DRUG|L-Carnitine and N-acetyl cysteine|
224321989|NCT01207895|DRUG|[18F]-fluorodeoxythymidine|\[18F\]-fluorodeoxythymidine is administered intravenously approximately 60 minutes prior to the start of PET image acquisition.
224250382|NCT05994859|PROCEDURE|SIRT|The patients will receive 1-2 sessions of SIRT. If the patients have invasive tumors, extensive liver involvement or vascular invasion, systematic treatment will be added.
224250383|NCT04146987|PROCEDURE|Rotator cuff repair surgery|Patients will undergo open rotator cuff repair or arthroscopic rotator cuff repair
224250384|NCT05333809|DRUG|Pembrolizumab|an anti-PD-1 monoclonal antibody
224250385|NCT05333809|DRUG|Disitamab vedotin|HER2-ADC
224250386|NCT06151678|OTHER|Pain Education|Pain education was offered to health professionals and the general public using with a focus on pain neuroscience. This was offered with a lecture from pain scientists, personal reflections from individuals with lived experience and health care professionals.
223669351|NCT00331552|DRUG|pegylated liposomal doxorubicin hydrochloride|Given IV
223669352|NCT00331552|DRUG|cyclophosphamide|Given orally
224250387|NCT03671447|OTHER|ICU Usual Care|The control condition delivered at ICU is usual care.
224250388|NCT03671447|BEHAVIORAL|Tele-ICU|The experimental complex intervention ERIC consists of daily tele-medicine based rounds at ICU. Tele-ICU is implemented after a blended learning program for ICU staff which will be completed prior to the site's crossover.
223669353|NCT00331552|BIOLOGICAL|trastuzumab|Given IV
223669354|NCT00443196|PROCEDURE|MiCK Assay|Physician determined treatment
224250389|NCT02078791|DRUG|Botox infiltration|botox cervical infiltration in a group
224321990|NCT02370524|DRUG|[18F]T807|All enrolled subjects will undergo an \[18F\]T807 PET imaging visit. In addition, subjects with AD and aged volunteers will have one PET scan with Amyvid (florbetapir F 18 injection) as part of the screening activities to measure Aβ in the brain.
223669355|NCT00767182|OTHER|blood sample|biological markers evaluated : D-Dimer, sEPCR
223669356|NCT01708096|DIETARY_SUPPLEMENT|Modifast|2 weeks before gastric by-pass patients are treated with VLD, 1000 kcal/day
223669357|NCT01708096|DIETARY_SUPPLEMENT|Normal diet|normal diet 2 weeks before gastric by-pass
223669358|NCT01445548|DRUG|Sirolimus|
223669359|NCT05062993|PROCEDURE|caudal epidural pulse radio frequency|A needle is inserted into the caudal epidural space under ultrasound guidance and pulse radiofrequency is administered at 5 Hz using a 5. ms pulse width for 600 seconds at 55 V.
223669360|NCT00072527|DRUG|carboplatin|IV
223669361|NCT00072527|DRUG|cisplatin|IV
223669362|NCT00072527|DRUG|etoposide|IV
223669363|NCT00072527|DRUG|irinotecan hydrochloride|IV
223669364|NCT00072527|RADIATION|radiation therapy|
223669365|NCT04085939|OTHER|Online survey|Anonymous survey using the online survey tool, JotForm
223669366|NCT00182585|PROCEDURE|computer-based HIV, STD & Hepatitis Education|
223669367|NCT00182585|PROCEDURE|educator-delivered HIV, STD and Hepatitis education|
223669368|NCT01373736|DRUG|123I-meta-iodobenzylguanidine|
223669369|NCT01413633|PROCEDURE|cholecystectomy|single incision laparoscopic cholecystectomy
223669370|NCT01306578|DRUG|IVIG|Intravenous Immune Globulin at a dose 0f 0.4 g/kg/day for 5 consecutive days
223669371|NCT01306578|PROCEDURE|Plasma Exchange|Five sessions of plasma exchange, single plasma volume each, for 5 consecutive days
223680658|NCT02981576|BIOLOGICAL|Autologous Mesenchymal Stem Cells|Autologous Mesenchymal Stem Cells will be collected from patients, prepared in the lab and then injected intrathecally.
223771454|NCT00659646|DRUG|Levofloxacin only|levofloxacin, 750 mg tablet po every 24 hours or 750 mg IV administered by slow infusion over 90 minutes every 24 hours
223771455|NCT04944342|OTHER|No intervention.|No intervention.
224250390|NCT02078791|BEHAVIORAL|Psychology therapy|Psychology problem solving therapy lead by specialized nurses.
224321991|NCT01960335|DIETARY_SUPPLEMENT|Whey Protein|Whey protein provided in 20 gram servings administered three times per day. once in the morning upon waking; a second serving in the mid-afternoon; and a third serving within 2 hours of going to sleep at night.
224250391|NCT02078791|OTHER|Botox infiltration & psychology therapy|Botox infiltration in cervical region and psychology problem solving therapy lead by specialized nurses.
224250392|NCT00467363|DRUG|acetylsalicylic-acid (aspirin)|81mg of low-dose aspirin plus 400micrograms of folic acid.
223669372|NCT03951168|BEHAVIORAL|Routine Management|Routine Management Model of Health Education for diabetes Patient will receive the Routine Management Model of Health Education for Diabetes. After the patient was admitted to hospital, the responsible nurse carried on the diabetes health education for the patient. There are no regulations on the path and time of education. Interspersed with diabetes health education at work. Follow up 2 weeks with phone call after discharge. This is the current clinical model in hospital.
223669373|NCT03951168|BEHAVIORAL|Standardized Management|Standardized Management Model of Health Education for Diabetes The patients were educated by full-time diabetic education nurses according to diabetes education path. Including diabetes diet, exercise, drugs, hypoglycemia, diabetic foot, and so on. Telephone follow-up was performed at 2 weeks and 4 weeks after discharge and 12 and 24 weeks follow-up in diabetes education clinic. Develop telephone follow-up standardized content and implement telephone follow-up according to standardized content.Full-time education nurses carry on education according to diabetes mellitus health education path table.
223669374|NCT05795569|PROCEDURE|Nasogastric Tube removal during extubation|The nurse in charge of the patient and under the cover of a medical prescription, will proceed to the systematic removal of the nasogastric tube during the extubation procedure
224250393|NCT00467363|DIETARY_SUPPLEMENT|Folic acid|400micrograms of folic acid.
224250394|NCT04839276|COMBINATION_PRODUCT|Injection Laryngoplasty with Platelet-rich Fibrin and Autologous Fat|Injection Laryngoplasty with a combination of Platelet-rich Fibrin (PRF) and Autologous Fat. The PRF was made by taking 10 mL of peripheral blood from a healthy donor. Blood is then put inside the tube from the Regen lab kit. The tube was centrifuged with a force of 1,500 g (3000 rpm) for 5 minutes producing platelet-rich plasma (PRP). 4 mL of the aforementioned PRP was transferred to a 10 mL test tube, 1 M CaCl2 was added with a micropipette until final concentration of 25 mM was, reached producing PRF. Autologous fat harvested from the patient's abdomen was then mixed with the PRF solution to create the filler for injection laryngoplasty procedures. The injection procedures are done by placing the patient in a sniffing position followed by intraoral Kleinsasser laryngoscope insertion through the uvula, posterior pharyngeal wall, and epiglottis until the vocal cords are visible. Injection of the filler is then done to the paralyzed vocal cords.
224250395|NCT04839276|PROCEDURE|Injection Laryngoplasty with Autologous Fat|Injection Laryngoplasty with autologous microlobular fat harvested from the patient's abdominal fat. Lidocaine was infiltrated under the umbilicus and then an incision was made in the area followed by fat removal using scissors. The fat was cleaned with 0.9% NaCl solution and then sheared into microlobular form. The injection procedures are done by placing the patient in a sniffing position followed by intraoral Kleinsasser laryngoscope insertion through the uvula, posterior pharyngeal wall, and epiglottis until the vocal cords are visible. Injection of the filler is then done to the paralyzed vocal cords.
224250396|NCT04962594|OTHER|Experimental formulas (EF)|First age formula administered orally ad libitum until 6 months of age, switch to second age formula until 12 months and finally to growing-up milk from 12 to 15 months
224250397|NCT04962594|OTHER|Control formulas (CF)|First age formula administered orally ad libitum until 6 months of age, switch to second age formula until 12 months and finally to growing-up milk from 12 to 15 months
223669375|NCT05795569|DIAGNOSTIC_TEST|Yale Swallow Protocol|"The dysphagia will be evaluated in a systematic way between 1 hour and 6 hours post-extubation with the help of the Yale Swallow Protocol (YSP) by the caregivers trained to the passing of the YSP (nurse or physiotherapist or ICU doctor)."
223669376|NCT05795569|PROCEDURE|Classif Nasogastric Tube Management|The removal of the nasogastric tube will not be performed during the extubation procedure and the time of removal will be left to the discretion of the attending physician (as currently performed in the unit).
223669377|NCT05795569|DIAGNOSTIC_TEST|Classic swallowing test|"Post-extubation dysphagia will be assessed as we do in the unit. Currently, the caregivers in charge of the patient do a gel water test Nutrisens Hydra'Fruit level 4 when the attending physician prescribes it."
223771456|NCT03063229|DEVICE|Accelerometer|Attach a monitor to participants thigh to measure their physical activity for 7 days. The monitor is called the Activpal Micro.
223771457|NCT03063229|OTHER|Anthropomentry|Take skinfold measurements of participants using Harpenden skinfold calipers.
223771458|NCT03063229|PROCEDURE|Blood tests|Taking standard clinical blood tests to measure HbA1c, Glucose, FBC, U\&E's, LFT's, Coagulation Screen, Lipid Profile, Thyroid Function, and Tacrolimus for transplant patients.
223771459|NCT03063229|DEVICE|BODPOD|Measure body composition using a BODPOD machine. This uses Air displacement plethysmography.
223771460|NCT03063229|PROCEDURE|MRI (Magnetic Resonance Imaging)|MRI Scans of abdomen, particularly the livers of islet transplant and insulin pump patients.
223771461|NCT03063229|OTHER|Food Diary|Participants will keep a 7 day weighed food diary.
223771462|NCT03063229|DEVICE|CGMS (Continuous Glucose Monitoring System)|Participants will wear a CGMS for 7 days to measure their glucose control and pattern over a 7 day period.
224250398|NCT04962594|OTHER|Breast feeding (BF)|Exclusive breast feeding up to 4 months
224250399|NCT00609960|BEHAVIORAL|clowns present|clowns present during the proccess of induction of anesthesia
224250400|NCT00609960|DRUG|midazolam|midazolam
224250401|NCT03667183|OTHER|Pilates|Specific postures in movement according to Pilates guidelines.
224250402|NCT04327453|DEVICE|double antibiotic paste with XP-endo Finisher file|XP-endo Finisher files (FKG Dentaire, La Chaux-de-Fonds, Switzerland). file will be used with an endodontic motor X-Smart (Dentsply Sirona, Ballaigues, Switzerland) in removal of double antibiotic paste
224321992|NCT01960335|DIETARY_SUPPLEMENT|Whey Protein and Resistance Exericse|Subjects will receive 20 grams of whey protein three times per day along with 4 days per week of resistance exercise training throughout the 16 week intervention.
224250403|NCT04327453|DEVICE|double antibiotic paste with Irrisafe Ultrasonic tip|passive ultrasonic irrigation (PUI) with an IrriSafe Ultrasonic tips (Acteon,France), which will be driven by an ultrasonic device (Newtron P5, Satelec, Acteongroup, Merignac, France) in removal of double antibiotic paste
224250404|NCT04327453|DEVICE|double antibiotic paste with side vented needle|conventional syringe irrigation with side vented needle (prime Dent, India) in removal of double antibiotic paste
224250405|NCT01223105|PROCEDURE|slow freeze|Eggs will be placed in a cryo-protected solution and frozen slowly in a programable freezer
224250406|NCT01223105|PROCEDURE|Vitrification|Eggs will be placed in a high concentration of cryo-protectant and frozen very quickly by plunging in liquid nitrogen
224250407|NCT02210182|DRUG|Oral Pentamidine|Oral pentamidine given at 300 mg, 600 mg, 900 mg or 1200 mg QD x 3 consecutive days
224321993|NCT01960335|OTHER|Whey Protein and RISE exercise routine|Subjects will consume 20 grams of whey protein three times per day (total of 60 grams) and perform a combination of exercise involving functional resistance exercise (R); sprint intervals (I); stretching/pilates/yoga (S); and endurance exercise (E); RISE four days per week.
224321994|NCT05936515|OTHER|Training of nurses and nursing assistants|Training of nurses and nursing assistants, based on the model of hygiene correspondents, in order to disseminate good geriatric practices
224250408|NCT02210182|OTHER|Placebo|Placebo given at 300 mg, 600 mg, 900 mg or 1200 mg QD x 3 consecutive days
224250409|NCT01111864|DIETARY_SUPPLEMENT|fortification with iron and micronutrients|Iron 0 or 2.5 mg; Copper 0.34 mg; 30 µg Iodine; 7 µg Selenium; 2.5 mg Zinc; 100 µg Vitamin A; Vitamin D 5 µg; 5 mg Tocopherol Equivalent; 30 µg Vitamin K1; 10.5 mg Thiamine; 0.5 mg Riboflavin; 0.5 mg Pyridoxine; 90 µg Folic Acid Anhydrous; 6 mg Niacinamide; 60 mg Vitamin C; 0.9 µg Vitamin B12
224250410|NCT01111864|DIETARY_SUPPLEMENT|Sprinkles|Daily 12.5mg Ferrous fumarate iron with microntrient is compared to no iron with micronutrients. Duration of intervention is 4 months, 80 infants will be inclulded.
224250411|NCT05218772|OTHER|Questionnaires|Each eligible participant will receive a questionnaire to complete concerning: objective health status; perceived health status (QoL assessed by the WHOQOL-Old questionnaire); demographic data; social data; psycho-cognitive data (anxious symptoms, depressive symptoms, use of coping strategies, time perspective)
224250412|NCT00260650|BEHAVIORAL|Heart PACT Program|patient activation intervention
224250413|NCT05253950|OTHER|Questionnaire|answered questions from two standard questionnaires the Internet Addiction Test (IAT) which examines students' dependence on the internet and the Nordic Muscuskeletal Questionnaire (NQS) which examines the onset of symptoms from the musculoskeletal system
224250414|NCT03082872|DEVICE|Cemented K-wire|Fracture of proximal phalanx was treated with Cemented K-wire.
224321995|NCT06454097|DIAGNOSTIC_TEST|Assess the response glioma to radiochemotherapy using radiogenomics-based AI model|Predict the radiochemotherapy sensitivity of patients with glioma using an established radiogenomics-based artificial intellegent mode
224321996|NCT02658942|PROCEDURE|Ureteroscopy|In Group A patients, Karl Storz Flex-X 7.5, FURS with a 365 µm laser fiber.
223669378|NCT03611257|DIAGNOSTIC_TEST|dRAST|Infectious diseases specialists will do active antimicrobial stewardship according to dRAST results in addition to Gram staining results and current standard method.
223669379|NCT03611257|DIAGNOSTIC_TEST|Current standard method|Infectious diseases specialists will do active antimicrobial stewardship according to Gram staining results, and current standard method without dRAST results.
223669380|NCT02204761|RADIATION|Proton Beam Radiation Therapy|Undergo proton beam re-irradiation therapy
223669381|NCT02824406|DRUG|Acetazolamide|Acetazolamide is administered to all participants to induce vasodilation, in order to assess the physiologic response on cerebral blood flow.
223669382|NCT03675906|OTHER|hypoalbuminemia|hypoalbuminemia and acute kidney injury
224250415|NCT03082872|DEVICE|Transfixion Pinning|Fracture of proximal phalanx was treated with transfixion pinning.
223669383|NCT01786070|DRUG|Budesonide|
223669384|NCT01786070|DRUG|placebo|
223669385|NCT01609829|PROCEDURE|SAFE (situation, all together, fly on, evaluate)|Video-assisted, structured debriefing after simulated critical airway-events.
223669386|NCT06370403|OTHER|Cooling of the head and neck|Cooling of the head and neck at 18°C next to the head and neck skin in multiple sclerosis and healthy subjects
223669387|NCT06370403|OTHER|Heating of the head and neck|Heating of the head and neck at 43 ± 1°C next to the head and neck skin in multiple sclerosis
223669388|NCT05839158|OTHER|HFMT cell suspension|Perform FUE autologous hair transplantation on the patient according to the guidelines and standard procedures. During the procedure, a hollow punch is used to individually punch out follicular units from the donor area. The epidermis, some dermis tissue, sebaceous glands, and surrounding tissue of the follicular units are separated and removed before the remaining follicular tissue is implanted into the recipient area. The separated tissue is trimmed with surgical scissors to create a cell suspension. After completion of the procedure, the HFMT cell suspension is evenly applied to the treatment group surface. Double vaseline gauze is used to cover all donor areas and is then wrapped with sterile dry gauze with moderate pressure.
224250416|NCT04325724|OTHER|General evaluation|Demographic characteristic, psoriasis duration, disease duration, treatments
224250417|NCT04325724|OTHER|Dermatological evaluation|treatment and evaluation
224250418|NCT04325724|OTHER|Rheumatological evaluation|joints, enthesis, tendons, and other ultrasound abnormalities
224250419|NCT04325724|OTHER|para clinical data|biological data, medical imaging data
224250420|NCT04325724|OTHER|Patient reported outcomes (PROs)|Psoriatic arthritis impact of disease 12 (PsAID12), hospital anxiety and depression scale (HAD), SF 36
224250421|NCT02135263|DRUG|Methylphenidate|10 mg as a single dose followed by blood samples for the next 33 hours
224250422|NCT02135263|DRUG|Enalapril|10 mg as a single dose followed by blood samples for the next 72 hours
224321997|NCT02658942|PROCEDURE|Shockwave lithotripsy|In Group B patients, a Siemens Lithostar Lithotriptor
224321998|NCT06042582|PROCEDURE|Additional biopsies collection|We will recruit only subjects (UC, CD and NO-UC/CD) scheduled for the endoscopy and biopsies-collection according to the usual clinical practice. During the endoscopy we will collect 6 additional biopsies.
224321999|NCT02436226|DRUG|Clomiphene citrate and Human chorionic gonadotropin (HCG)|Women will receive clomiphene citrate (150 mg/day for 5 consecutive days from day 2 of cycle) and HCG (200 IU/day SC from day 7 of cycle)
224250423|NCT05570981|DIAGNOSTIC_TEST|Laryngeal sensitivity testing|Direct stimulation of the laryngeal adductor reflex, measurement of laryngeal EMG and our capability to assess functional laryngeal response to an inhalational challenge with laryngoscopic techniques.
224250424|NCT00365846|DRUG|Campath-1H|
223669389|NCT05839158|OTHER|Mupirocin ointment|the Minoxidil ointment is evenly applied to the control group surface.
223669390|NCT04119518|DEVICE|CSEM Pulse Watch|Comparison of CSEM Pulse Watch with a gold standard oscillometric device Spacelabs OnTrak Ambulatory Blood Pressure monitor.
223669391|NCT04232618|DIAGNOSTIC_TEST|Multi-biomarker point-of-care test|Lateral flow device containing a combination of markers which have been shown to be associated with active tuberculosis.
223669392|NCT02815722|DRUG|SP2086|The A sequence was that SP2086 was taken at 200mg qd on Days1-Day10; Simvastatin will be administered orally (by mouth) as 40mg on Days 6-Day10.The B sequence was that Simvastatin was taken at 40mg qd dose on Days 6-Day10.
223669393|NCT02815722|DRUG|Simvastatin|The A sequence was that SP2086 was taken at 200mg qd on Days1-Day10; Simvastatin will be administered orally (by mouth) as 40mg on Days 6-Day10.The B sequence was that Simvastatin was taken at 40mg qd dose on Days 6-Day10.
223669394|NCT06519045|DEVICE|Intelligent Fingerprinting Drug Screening System|The Intelligent Fingerprinting Drug Screening System utilizes a single-use, rapid, non-invasive fingerprint sweat drug screening test intended for use with the Intelligent Fingerprinting DSR-Plus fluorescence reader. The Intelligent FingerprintingTM Fingerprint Collection Kit for Laboratory Analysis (i.e. confirmation test) provides a quantitative analytical result via laboratory-based liquid chromatography/tandem mass spectrometry (LC-MS/MS). It is used to collect and measure drug mass in the full set of 10 fingerprints.
223669395|NCT02686008|DRUG|Olaparib|Patients will receive olaparib administered at 300 mg bid x 14 days orally
223669396|NCT02532699|DIETARY_SUPPLEMENT|AC mycelia|An 8 week double-blinded randomized placebo-controlled parallel study with 2 week follow-up period was performed in mild hypertension subjects. Consenting eligible subjects were receive three capsules per day containing either 420 mg of AC mycelia of similar appearance for 8 weeks. The subjects were required to visit at baseline, every two weeks during the intervention period (8 weeks), and at follow-up 2 weeks after treatment had ended. During each study visit, systolic and diastolic BPs were recorded, fasting blood samples were collected and anthropometric measurements were performed. Compliance was evaluated using a food diary and monitored with biweekly telephone calls.
223669397|NCT02532699|DIETARY_SUPPLEMENT|Placebo|An 8 week double-blinded randomized placebo-controlled parallel study with 2 week follow-up period was performed in mild hypertension subjects. Consenting eligible subjects were receive three capsules per day containing 420 mg starch placebo of similar appearance for 8 weeks. The subjects were required to visit at baseline, every two weeks during the intervention period (8 weeks), and at follow-up 2 weeks after treatment had ended. During each study visit, systolic and diastolic BPs were recorded, fasting blood samples were collected and anthropometric measurements were performed. Compliance was evaluated using a food diary and monitored with biweekly telephone calls.
223669398|NCT04009811|DEVICE|Suersen and membraneous obturators evaluation|"The patient will wear one month each obturator prothesis (Suersen and membraneous obturators). The order of evaluation will be randomized in two arms.~Half of patient will first wear one month the membranous obturator then one month the Suersen, the other half of patient will first wear one month the Suersen obturator and one month the membranous obturator."
223669399|NCT01620320|OTHER|Stress echocardiography|Patients able to exercise will have a treadmill test + echography; the others will have a dobutamine echography.
223669400|NCT02204475|DRUG|Grazoprevir/Elbasvir|Participants take a fixed-dose combination of grazoprevir 100 mg and elbasvir 50 mg once daily (QD) by mouth (PO).
223771463|NCT03063229|OTHER|Questionnaire and Hypo Score|Participants with Type 1 Diabetes will fill in 3 short questionnaires about their Diabetes.
223771464|NCT03063229|PROCEDURE|Mixed Meal Tolerance Test (MMTT)|"The patients will under go a test which involves taking 30 minute glucose and C-peptide levels (blood test from a cannula) for 3 hours. They will consume 150ml of a mixed meal supplement drink Fortisip Compact at the start of the 3 hours, after having no morning insulin, breakfast and not eating anything from midnight the night before."
223771465|NCT03063229|PROCEDURE|Indirect Calorimetry|During the Meal Tolerance Test, the patients will be resting on a bed in the research facility and breathing normally into a clear plastic hood. The machine connected to the hood (GEM) will analyse their resting energy expenditure from the gases expired in their breath. They will have the hood on for 2 hours.
224250425|NCT02081612|BEHAVIORAL|Nutrition Education|12 educational weight management group session each addressing a different weight loss topic
224250426|NCT02081612|PROCEDURE|Acupuncture|12 weight loss acupuncture session using both body and auricular points.
224250427|NCT05388266|OTHER|Mask ventilation|Mask ventilation is performed under paratracheal pressure or no pressure in a randomized, crossover manner.
224250428|NCT00503477|DRUG|AZD2171|oral tablet
224250429|NCT03588923|DRUG|SH229|tablet, oral, 400 mg once daily for 3 days
224250430|NCT03588923|DRUG|Placebos|tablet, oral, once daily for 3 days
224250431|NCT03588923|DRUG|SH229|tablet, oral, 600 mg once daily for 3 days
224250432|NCT03588923|DRUG|Placebos|tablet, oral, once daily for 3 days
224250433|NCT03588923|DRUG|SH229|tablet, oral, 800 mg once daily for 3 days
224250434|NCT03588923|DRUG|Placebos|tablet, oral, once daily for 3 days
224250435|NCT06558617|DIAGNOSTIC_TEST|SARC-F Questionnaire|The SARC-F scale consists of five components: strength, walking assistance, rising from a chair, stair climbing, and falls. These elements were selected to reflect changes in health status related to the effects of sarcopenia. Scores on the SARC-F scale range from 0 to 10, composed of five domains, assesses strength, walking assistance, raising from a chair, stair climbing and falls. Each domain score ranges from 0-2. A SARC-F score of ≥4 was considered abnormal. The Thai-version SARC-F questionnaire has been validated in Thai older adults.
224250436|NCT06558617|DIAGNOSTIC_TEST|Calf Circumference Measurement|Calf circumference was measured using a nonelastic tape measure while the participant was standing with relaxed legs. The tape was placed snugly and flat around the widest part of the calf, parallel to the floor. According to the AWGS 2019 criteria, calf circumferences were considered abnormal if they were less than 34 cm for males and less than 33 cm for females.
224322000|NCT02436226|DRUG|Clomiphene citrate|Women will receive clomiphene citrate (150 mg/day for 5 consecutive days from day 2 of cycle)
224250437|NCT06558617|DIAGNOSTIC_TEST|SARC-CalF Questionnaire|This questionnaire integrates the SARC-F and calf circumference as a trigger for case finding. If the calf circumference is below the cut-off value, 10 points are added to the SARC-F score for evaluation. The SARC-CalF score ranges from 0 to 20, with a score of ≥11 considered abnormal for sarcopenia screening.
223669401|NCT02204475|DRUG|Boceprevir|Participants take Boceprevir (BOC) 800 mg three times daily (TID) PO.
223669402|NCT02204475|DRUG|PegIntron|Participants take 1.5 mcg/kg PegIntron (P) once weekly (QW) via subcutaneous injection.
223669403|NCT02204475|DRUG|Ribavarin|Participants take Ribavarin (R) 800-1400 mg (depending on body weight) twice daily (BID) PO.
223669404|NCT01988701|OTHER|Ancillary-Correlative|Blood samples are analyzed for activation status of B lymphocytes, T lymphocytes, and NK lymphocytes via flow cytometry, ELISA, ELISPOT, immunoblot, and microarray assays.
223669405|NCT04938297|DRUG|Rituximab, Lenalidomide, Zanubrutinib|Induction therapy: Rituximab 375 mg / m2, day 1, Zanubrutinib 160 mg bid, orally, Lenalidomide 25mg QD, orally on day 1-21, 28 days as a course of treatment, 8 courses of treatment.
223669406|NCT04938297|DRUG|Lenalidomide, Zanubrutinib|Maintenance therapy: Lenalidomide: 25mg qd (adjusted according to hectogram condition) or Zanubrutinib 160 mg bid. Continuously use for 2 years or until disease progression
223669407|NCT04938297|DRUG|Lenalidomide|Maintenance therapy: Lenalidomide: 25mg qd (adjusted according to hectogram condition) . Continuously use for 2 years or until disease progression
223669408|NCT05260541|DRUG|60 mg PRAX-114 or 40 mg PRAX-114|Once daily oral treatment for 4 weeks
223669409|NCT05260541|DRUG|Placebo|Once daily oral treatment for 4 weeks
223669410|NCT05260541|DRUG|40 mg PRAX-114|Once daily oral treatment for 8 weeks
224322001|NCT00580892|DEVICE|Optical Coherence Tomography imaging|Optical Coherence Tomography imaging
223669411|NCT00147550|DRUG|PD-0325901|Administered orally either once or twice a day; several dosing schedules evaluated; current dosing schedule is 5 days on-drug, 2-days off drug for 3 weeks in a 28-day cycle. Doses evaluated ranged from 1 mg once a day to 30 mg twice daily.
223669412|NCT02561767|OTHER|bone marrow-derived mesenchymal stem cells|BM-MSCs is harvested from third-party health volunteer donors.
223669413|NCT02561767|OTHER|Saline|Saline as placebo of MSCs
223669414|NCT02561767|DRUG|Induction therapy (ATG or Basiliximab)|ATG, antithymocyte globulin; Basiliximab, anti-CD25 mAb. Recipients receive ATG or Basiliximab as induction therapy in both MSCs group and control group.
223669415|NCT02561767|DRUG|Maintenance therapy (Low-dose CNI + MPA + steroids)|Maintenance immunosuppressive therapy consists of low-dose tacrolimus and mycophenolic acid and steroids. Recipients receive the same maintenance therapy in both MSCs group and control group.
223669416|NCT00028145|BEHAVIORAL|Adherence assessment|Adherence will be assessed using questionnaires at all study visits.
223669417|NCT06277453|OTHER|surgery|radical gastric cancer surgery (R0) and D2 lymph node dissection
223669418|NCT04745260|DRUG|Intranasal Fentanyl Spray and Intranasal Midazolam Spray|Intranasal Fentanyl 2mcg/kg and Intranasal Midazolam 0.2mg/kg
224250438|NCT03590795|OTHER|Sleep survey|The Sleep survey was created by the Collaborative Research Center (CRC), a joint effort of the Australian Government, Academia and Industry \[including Philips\]).
223669419|NCT04745260|DRUG|Intranasal Midazolam Spray|Intranasal Midazolam 0.3mg/kg
223669420|NCT02642055|BEHAVIORAL|Neuro+ Attention Training|Attention training program with Neuro+ software
223669421|NCT02642055|OTHER|Treatment as Usual|Continuation of current ADHD treatment
223669422|NCT02322853|DRUG|Tamoxifen|hormonotherapy
223669423|NCT02322853|DRUG|Ralimetinib (LY2228820 dimesylate)|
224250439|NCT04400890|DRUG|Resveratrol|Resveratrol vs placebo given for 15 days.
224250440|NCT04400890|DIETARY_SUPPLEMENT|Vitamin D3|Vitamin D3 100,000 IU given on day one.
224322002|NCT05771948|DEVICE|CCoat|CCoat is a new intra-articular (IA) injectable joint lubricant for patients suffering from joint pain developed by Liposphere LTD. CCoat is a liposomal boundary lubricant which coats the cartilage surface and protects it from further damage and degradation.
224322003|NCT00196326|DRUG|DR-1011|Eighty-four orange, embossed tablets, each containing 100 μg levonorgestrel (LNG) / 20 μg ethinyl estradiol (EE) and 7 yellow, embossed tablets, each containing 10 μg of EE. One combination tablet was to be taken each day for 84 days followed by 7 days of EE tablets in 91-day cycles repeated consecutively for approximately one year (four 91-day cycles).
223669424|NCT04911192|PROCEDURE|mechanical fragmentation|patients who will be treated with catheter-directed mechanical fragmentation under fluoroscopy guidance. This group will include patients with absolute contraindication for fibrinolytic therapy
223669425|NCT04911192|PROCEDURE|In Situ thrombolysis|Group (C) will include the patients who will be treated with bed side administration of low dose of local thrombolytic therapy (In Situ) via a trans-Jugular Swan-Ganz pulmonary artery catheter. with guidance of the pressure waveforms obtained from SGC (Swan-Ganz catheter) and echocardiography guidance for ideal Catheter placement. This group will include the patients with relative contraindications for systemic thrombolysis, contraindications for contrasted administration (patients with renal impairment) and also patients with contraindications for radiation exposure (pregnant women).
223669426|NCT04769180|OTHER|Evaluation of extraintestinal manifestations|The researchers evaluated the prevalence and kind of extraintestinal symptoms in NCWS patients and the possible relationship between the clinical, serological, genetic and histological characteristics of the NCWS patients and the number and kind of extraintestinal manifestations, using, as control groups, CD and IBS patients.
223669427|NCT03081156|DRUG|Glycopyrrolate / Formoterol|Exercise Tolerance
223669428|NCT01765309|PROCEDURE|Bilateral mastectomy with reconstruction|In each patient enrolled in the study, botulinum toxin was injected into one pectoralis muscle while saline placebo was injected on the opposite side in a randomized blinded fashion
223669429|NCT01832584|DIETARY_SUPPLEMENT|RGC|
223669430|NCT01832584|DIETARY_SUPPLEMENT|Placebo|
223669431|NCT03338322|DEVICE|Twisted file adaptive|Endodontic files that are used in preparation of root canals with adaptive motion
223669432|NCT03338322|DEVICE|Reciproc|Endodontic files that are used in root canal preparation with reciprocation motion
223669433|NCT00537615|DRUG|PD 0332334|
224250441|NCT01414933|OTHER|Biopsy|Breast metastases biopsy
224250442|NCT04892823|PROCEDURE|Biospecimen Collection|Undergo collection of blood sample
224322004|NCT06301191|DRUG|Semaglutide, 1.0 mg/mL|Semaglutide, 1.0 mg/mL
224250443|NCT04892823|OTHER|Electronic Health Record Review|Review of medical records
224250444|NCT04892823|OTHER|Questionnaire Administration|Complete questionnaires
224250446|NCT04697368|DEVICE|Exoskeleton-Assisted Upper Limb Rehabilitation|"The patients will be undergone 25+/-3 Armeo-P training sessions, each lasting 40 minutes (i.e. five times a week for five consecutive weeks). During the first session, the device should be adjusted to the patient's arm size and the angle of suspension. The working space and the exercises will be selected once the UL has been fitted with the system. The selection of personalized exercises will be based on the motor skills of each patient and the difficulty can be gradually increased during training. In particular, a course of exercises has been defined in which the difficulty (suspension rate; the level of assistance; the complexity of movement (1D, 2D, 3D)).~The physiotherapist will choose the modality based on the patient's motor skills (standardized personalized training)."
224250447|NCT04697368|OTHER|Traditional Upper Limb Rehabilitation|The control group (CG), in addition to the conventional treatment based on the routine rehabilitation program, will follow 25+/-3 sessions of traditional upper limb rehabilitation (i.e. five times a week for five consecutive weeks). Each session will consist of passive, active-assisted, and active exercises addressed for shoulder, arm and hand motor rehabilitation.
224250448|NCT06261528|DEVICE|Light therapy|Light therapy aimed at alleviating fatigue through circadian rhythm synchronization
224250449|NCT04915248|DRUG|Daratumumab|"Induction phase planning one course (cycle 1) of daratumumab as single agent followed by 8 courses (cycles 2-9) of daratumumab in combination with bortezomib and dexamethasone (DVd regimen).~Patients achieving at least a SD after induction will be addressed to the maintenance phase, planning a maximum of 6 cycles (cycles 10-15) of daratumumab as single agent."
224250450|NCT04915248|DRUG|Bortezomib|"Induction phase planning one course (cycle 1) of daratumumab as single agent followed by 8 courses (cycles 2-9) of daratumumab in combination with bortezomib and dexamethasone (DVd regimen).~Patients achieving at least a SD after induction will be addressed to the maintenance phase, planning a maximum of 6 cycles (cycles 10-15) of daratumumab as single agent."
224250451|NCT04915248|DRUG|Dexamethasone|"Induction phase planning one course (cycle 1) of daratumumab as single agent followed by 8 courses (cycles 2-9) of daratumumab in combination with bortezomib and dexamethasone (DVd regimen).~Patients achieving at least a SD after induction will be addressed to the maintenance phase, planning a maximum of 6 cycles (cycles 10-15) of daratumumab as single agent."
224250452|NCT06851936|BEHAVIORAL|Nicotine cessation program|All participants will complete a nicotine cessation program designed by Area Health Education Center (AHEC). The focus is on known tobacco cessation techniques and motivations to quit with additional focuses on cancer survivors and caregivers. The program consists of 4 sessions (each session is approximately 60 minutes long) that will be delivered by a Tobacco Treatment Specialist by either videoconference or by telephone. Dyad enrollees (i.e., cancer survivors and their caregiver/family member) will complete sessions together. Participants will also be eligible for free nicotine replacement therapy while on study if medically appropriate.
224250453|NCT06173401|RADIATION|Single-fraction spine SRS|Treatment Arm 1: Single-fraction spine SRS (22 Gy x 1)
224250454|NCT06173401|RADIATION|Multi-fraction spine SRS|Treatment Arm 2: Multi-fraction spine SRS (14 Gy x 2)
224322005|NCT06301191|DRUG|Dipeptidyl Peptidase 4 inhibitor|Dipeptidyl Peptidase 4 inhibitor
224322006|NCT05797844|OTHER|Active implementational educational strategy|4 follow-up visits (active implemantation strategy) were carried out for ETT cuff pressure management using the one-on-one demonstration technique every 21 days. These follow-ups included adherence to evidence-based guidelines, nurses' application of endotracheal cuff pressure measurement and solving the problems encountered during its implementation. Uncertainties associated with evidence-based guidance on endotracheal tube cuff pressure control were clarified during these sessions.
224322007|NCT05797844|OTHER|Passive implementational educational strategy|Theoretical training on endotracheal tube cuff pressure management through a 4-hour presentation prepared with evidence-based guide and literature. A PowerPoint presentation including endotracheal tube cuff pressure normal values, complications related to endotracheal tube cuff pressure, management of endotracheal tube cuff pressure, endotracheal tube cuff pressure control methods, methods affecting endotracheal tube cuff pressure, how to measure endotracheal tube cuff pressure was made.
223669434|NCT01336361|OTHER|Survey|A one-time paper survey was mailed to subjects, along with a cover letter, explanation of the research study, and contact and informed consent information. A reminder postcard was sent to subjects approximately one week later, encouraging return of the completed survey.
223669435|NCT01849887|BIOLOGICAL|bone marrow-derived mesenchymal stem cells|bone marrow-derived mesenchymal stem cells
223669436|NCT01849887|DRUG|Placebo|Placebo
223669437|NCT03360864|OTHER|Education program|Patient will participate to a education program.
223669438|NCT04415970|OTHER|Flotation therapy sensory deprivation tank|Participants will float for 60 minutes, 2 times a week for 8 consecutive weeks or alternate with sleep pod every 2 weeks for 8 weeks. All participants will wear a fitness tracker and a sleep monitoring ring worn on the finger for the duration of the study. Each session will be preceded by a short safety questionnaire and an anxiety index. Following each session, the participant will complete the index again. Participants will also complete morning and evening questionnaires and monthly questionnaires on a smartphone.
223771466|NCT03063229|DRUG|Doubly Labelled Water|The Doubly Labelled water will be prescribed for the participants and they will drink their 100ml dose of the stable isotope. Dose depends on the eight of the participant. The participant will then collect urine samples at home on day 5, 10 and 14 after drinking the water. They will store them in the freezer until they can bring them back to us.
223771467|NCT03063229|DRUG|Hepatic Mitochondrial Oxidation breath test|Participants will be given a calculated amount of the stable isotope C-Octanoate, which will be delivered in a water solution. They will then be asked to breath down a small tube into a clear plastic collection bag 10 times over 2 hours.
223771468|NCT05222568|BEHAVIORAL|Lateral positioning|After the DLT intubation, the patient is placed in lateral decubitus position
223771469|NCT05222568|DEVICE|Cuff pressure measurement|The pressure of the bronchial cuff should be measured with cuff-manometer in supine position, and then measurement should be repeated after lateral positioning
224322008|NCT05435846|DRUG|Capmatinib|Given orally
224250455|NCT05630144|BEHAVIORAL|HomeMed|The HomeMed intervention is a multidisciplinary deprescribing intervention including home visits and team-based telehealth communication (optional). The components included in the HomeMed intervention include home medication review, medication education and provision of tools to assist the patients with medication administration, assessment of deprescribing targets by a trained geriatric clinical pharmacist, communication with the patient's treating primary care provider about deprescribing recommendation, deprescribing implementation (optional), and deprescribing monitoring (optional). Depending on the patient's treating primary care provider's decision on deprescribing and monitoring, the number of home visits ranges from a minimum of three to more with the entire duration of the intervention ranging from approximately 1 to 3 months.
224250456|NCT02897414|OTHER|Surveillance of state medical examiner databases|
224250457|NCT06009146|DEVICE|Endovascular treatment|Endovascular treatment for infrapopliteal arterial disease.
224250458|NCT03314870|GENETIC|Genetic signature|To identify molecular signatures of EMT / immune status by using the random forest algorithm. The best signature will be measured by RT-qPCR and/or CATS-RNASeq technics.
224250459|NCT00723710|BIOLOGICAL|Intron A (interferon alfa-2b; SCH 30500)|The recommended regimen includes an induction treatment of 5 consecutive days per week for 4 weeks as a 20-minute intravenous (iv) infusion at a dose of 20 million international units per square meter (MIU/m\^2). The induction treatment should be followed by a maintenance treatment of 3 times per week for 48 weeks as a subcutaneous (sc) injection at a dose of 10 MIU/m\^2. Therapy should be administered for a total of one year unless the disease progresses or the treatment has lead to recurrent unmanageable serious adverse effects.
224250460|NCT03835715|DRUG|Vortioxetine|Flexible doses (10-20 mg) of vortioxetine; 10 mg during the first week which may be increased up to 20 mg week 2-8
224250461|NCT06254781|DRUG|Luspatercept|Erythroid Maturation Agent
224250462|NCT01003054|DRUG|Busulfan|130 mg/m\^2 in normal saline over three (3) hours IV every twenty-four (24) hours for four (4) consecutive days (days -7 to -4)
224250463|NCT01003054|DRUG|Cyclophosphamide|60 mg/kg in 500 ml of normal saline over 4 hours on each of 2 consecutive days (day -3, -2)
224250464|NCT01003054|DRUG|Imatinib Mesylate|Starting dose 100 mg/day (mg/d), escalated to maximal dose of 400 mg/d as tolerated, after day 28 when Absolute neutrophil count (ANC) is \>1500/mcl and platelets \>50,000 /mcl, may be titrated to maintain ANC \>1.0 and platelets \>50,000 /mcl.
224250465|NCT01003054|PROCEDURE|Autologous Stem Cell Transplantation|Stem Cell Infusion: Unpurged hematopoietic stem cells administered intravenously on day 0.
224250466|NCT04405570|DRUG|Molnupiravir 200 mg|Oral capsule of molnupiravir
224250467|NCT04405570|DRUG|Molnupiravir 400 mg|Oral capsule of molnupiravir
224250468|NCT04405570|DRUG|Molnupiravir 800 mg|Oral capsule of molnupiravir
224250469|NCT04405570|DRUG|Placebo (PBO)|placebo oral capsule
223669439|NCT04415970|OTHER|Sleep Pod|Participants will utilize the sleep pod for 60 minutes, 2 times a week for 8 consecutive weeks or alternate with float every 2 weeks for 8 weeks. All participants will wear a fitness tracker and a sleep monitoring ring worn on the finger for the duration of the study. Each session will be preceded by a short anxiety index. Following each session, the participant will complete the index again. Participants will also complete morning and evening questionnaires and monthly questionnaires on a smartphone.
223669440|NCT03163602|DRUG|Control group|Access flap and debridement
224250470|NCT03625661|DRUG|Ferinject|Ferinject 50mg/ml, one injection
223669441|NCT03163602|DEVICE|Test group|Regenerative treatment
223669442|NCT04674540|OTHER|No Intervention|No Intervention
223669443|NCT02185976|OTHER|cartoon|5 different cartoons which will be recorded on a tablet PC.
223669444|NCT01323855|DRUG|Preladenant|After an overnight fast, a single 5 mg dose, (1 x 5 mg tablet) was administered orally
223669445|NCT06455267|DIETARY_SUPPLEMENT|Now Foods L-Ornithine Capsules|L-ornithine is an amino acid that helps the liver clear toxic ammonia and plays an important role in liver protection and treatment of hepatic encephalopathy. Now Foods L-ornithine capsules are an ornithine supplement containing 500mg of L-ornithine per capsule. Patients in the L-ornithine supplementation group take ornithine capsules orally twice a day, three capsules each time, for 8 weeks.
223669446|NCT02024152|DRUG|JDP-205 IV high dose|
223669447|NCT02024152|DRUG|JDP-205 IV low dose|
223669448|NCT02024152|DRUG|JDP-205 IM|
223669449|NCT02024152|DRUG|Control: Zyrtec|
223669450|NCT00885820|DRUG|Tacrolimus|Oral
223669451|NCT00885820|DRUG|MMF|Oral
224250471|NCT03522363|OTHER|Streptococcus dentisani CECT7746|Treatment will be applied topically as an adhesive gel with a dental splint
224250472|NCT05358405|OTHER|Müller maneuver|The Müller maneuver allows maximum inspiratory pressure measurement via a one-way valve connected to the intubation tube and is currently used in routine care for diaphragmatic assessment. Ventilation through the one-way valve results in forced inspiration for about 20 seconds. The endothoracic depression induced by this test is likely increasing venous return and cardiac output in patients with preload reserve, i.e. in preload-dependent patients. The observation of an increase in cardiac output during a Müller maneuver could reflect the existence of a dependent preload state, i.e. with a reserve of preload, and de facto lower risk of pulmonary oedema. This test would be an easy alternative to the passive leg raising test used in current practice to evaluate the preload dependency and the risk of weaning induced pulmonary edema.
224250473|NCT06144918|DRUG|SBI-100 Ophthalmic Emulsion, 0.5%|0.5% (5 mg/mL) SBI-100 Ophthalmic Emulsion eyedrop
224250474|NCT06144918|DRUG|SBI-100 Ophthalmic Emulsion, 1.0%|1.0% (10 mg/mL) SBI-100 Ophthalmic Emulsion eyedrop
224250475|NCT06144918|DRUG|SBI-100 Ophthalmic Emulsion, Placebo|Placebo, SBI-100 Ophthalmic Emulsion eyedrop without the active ingredient (SBI-100)
224250476|NCT04499963|DRUG|Theracurmin HP|The intervention is based on the twice daily dosage of Theracurmin 90 mg capsules used in a trial of patients with mild cognitive impairment
223669452|NCT00885820|DRUG|Corticosteroids (Prednisone)|Oral
223669453|NCT03355482|DRUG|Methylprednisolone|160mg IM at baseline
223669454|NCT03355482|DRUG|Placebos|IM saline injection at baseline
223669455|NCT02122783|DEVICE|ADR™ brace resistance|
223669456|NCT02122783|DEVICE|Conventional brace resistance (using hard stops)|Conventional polypropylene custom molded ankle foot orthosis (MAFO) with Lawrence style double channel adjustable joints containing pins/springs
223669457|NCT06163677|BIOLOGICAL|COVID-19 Vaccine|Receipt of Pfizer BioNTech COVID-19 vaccine
224250477|NCT03144453|DRUG|Sugammadex Injectable Product|Patients receive sugammadex at the end of the surgery
224250478|NCT03144453|DRUG|Neostigmine, Atropine|Patients receive neostigmine+atropine at the end of the surgery
224250479|NCT04000464|BEHAVIORAL|CLIPP|Diabetes Prevention program and Comprehensive Lifestyle Improvement Program consisting of low calorie diet, physical activity, sleep optimization and stress management
224250480|NCT00359905|DRUG|Silodosin|8 mg daily for 12 weeks
224250481|NCT00359905|DRUG|Tamsulosin|0.4 mg daily for 12 weeks
223669458|NCT00924040|DRUG|BL22 (CAT-3888)|30 micrograms/kg intravenous over 30 minutes every other day (QOD) on days 1, 3, 5, of a 4 week cycle (at least 26 days) for a maximum of 16 cycles or until they become ineligible.
224250482|NCT00359905|DRUG|Placebo|once daily for 12 weeks
224250483|NCT05222477|BEHAVIORAL|pelvic floor exercise|pelvic floor exercises(intervention) will be applied for patients with nocturia and type 2 DM for 6 weeks, 3 times/week
224250484|NCT05222477|BEHAVIORAL|Abdominal muscles exercise|abdominal exercises (intervention) will be applied for patients with nocturia and type 2 DM for 6 weeks, 3 times/week
224250485|NCT03503422|PROCEDURE|Real transcranial direct current stimulation + therapeutic exercises for back pain|"Real transcranial direct current stimulation associated with therapeutic exercises for back pain~tDCS: 20 minutes, 2mA, primary motor cortex anode (contralateral to the lesion) and supraorbital cathode (ipsilateral to the lesion).Technique based on the application of weak, direct electrical current to the brain through relatively large electrodes that are placed over the scalp, in which anodal and cathodal stimulation increases and decreases cortical excitability, respectively."
224250486|NCT03503422|PROCEDURE|Sham transcranial direct current stimulation + therapeutic exercises for back pain|"Sham transcranial direct current stimulation associated with therapeutic exercises for back pain.~tDCS: 20 minutes (30 seconds ON), 2mA, primary motor cortex anode (contralateral to the lesion) and supraorbital cathode (ipsilateral to the lesion). Technique based on the application of weak, direct electrical current to the brain through relatively large electrodes that are placed over the scalp, in which anodal and cathodal stimulation increases and decreases cortical excitability, respectively"
224250487|NCT06064799|DIAGNOSTIC_TEST|miRNA-223 & -214 detection|miRNA-223 \& -214 detection in GCF samples by PCR kits
224250488|NCT00407394|DRUG|Amoxycillin|
224250489|NCT05113693|DRUG|CKD-393|QD, PO
224250490|NCT05113693|DRUG|CKD-501, D759, H053|QD, PO
224250491|NCT05854186|BEHAVIORAL|Telehealth solution: video conferencing|Telehealth solution: video conferencing
224250492|NCT01513486|BEHAVIORAL|immobilization|
224250493|NCT02411552|BEHAVIORAL|physical activity|4 strategies are: (1) increased activity time during physical education class, (2) active recess, (3) opportunities for activity before and after school, and (4) active classroom breaks
224250494|NCT04054232|OTHER|High PAD risk Alert|"In this message sent via the electronic health record, a participant's primary care physician will receive a message that details the following:~1. Participant flagged as having a high risk of peripheral artery disease based on their electronic health record data~2. What peripheral artery disease is and why diagnosis may be important~3. Recommendation to refer to a vascular medicine specialist or order ankle brachial index for definitive diagnosis~4. The option to opt out if the potential participant is not deemed a candidate for inclusion in the study with a short explanation of why the potential participant should not be included."
224250495|NCT03444090|PROCEDURE|Colon polypectomy|"For participants assigned into the experimental group, colon lumen is washed and the debris is suctioned as the colonoscopy is slowly inserted from rectum to cecum. Deliberate and systematic inspection of the mucosa is performed with adequate insufflation during both the insertion and withdrawal phases. Colon polyps with size \<10 mm are removed as they are identified on insertion and withdrawal. Polyps with size \>10 mm are removed only during withdrawal.~For participants assigned into the control group, deliberate inspection and polyp removal are performed exclusively on colonoscopy withdrawal.During insertion, minimal mucosal inspection and insufflation are applied to efficiently advance the instrument into cecum."
223669459|NCT04418401|DRUG|Donafenib and anti-PD-1 antibody|Donafenib was taken orally twice daily, and anti-PD-1 antibody was applied biweekly.
223669460|NCT03449784|OTHER|Detection of patients with dyslipidemia|Detection of patients with dyslipidemia
223669461|NCT02783079|BEHAVIORAL|CBT|
223669462|NCT02783079|BEHAVIORAL|MBSR|
223669463|NCT04877509|BIOLOGICAL|Selenium, Zinc and Copper, Vitamin A, D, E plasma concentrations during patient hospitalization|Micronutrient assays on heparinized plasma.
223669464|NCT01890629|DRUG|Gemigliptin + Metformin / Sitagliptin + Metformin / Glimepiride + Metformin|
224250496|NCT03572777|DRUG|Concomitant therapy|Amoxicillin ('Amoksicilin') 1 g bid 14 days.
224250497|NCT03572777|DRUG|Concomitant therapy|Clarithromycin ('Makcin') 500 mg bid for 14 days
224250498|NCT03572777|DRUG|Concomitant therapy|Metronidazole ('Medazol') 500 mg bid for 14 days
224250499|NCT03572777|DRUG|Concomitant therapy|Esomeprazole ('Emanera') 40 mg bid for 14 days
224250500|NCT03572777|DRUG|Hybrid therapy|Amoxicillin ('Amoksicilin') 1 g bid 14 days
224250501|NCT03572777|DRUG|Hybrid therapy|Esomeprazole ('Emanera') 40 mg bid for 14 days
224250502|NCT03572777|DRUG|Hybrid therapy|Clarithromycin ('Makcin') 500 mg bid for the last 7 days
224250503|NCT03572777|DRUG|Hybrid therapy|Metronidazole ('Medazol') 500 mg bid for the last 7 days
224250504|NCT00693290|OTHER|low residue diet|Fleet (usual preparation) plus diet sheet for low residue diet
224250505|NCT00868413|DRUG|ABT-263|ABT-263 is taken orally once daily for 3 days out of each 28 day cycle. This is a dose escalation study, therefore the dose of ABT-263 will change throughout the study.
224250506|NCT00868413|DRUG|FCR|Rituximab will be given by intravenous infusion for 1 day out of each 28 day cycle; Fludarabine will be given by intravenous infusion for 3 days out of each 28 day cycle; and Cyclophosphamide will be given by intravenous infusion for 3 days out of each 28 day cycle
224250507|NCT00868413|DRUG|BR|Rituximab will be given by intravenous infusion for 2 days out of each 28 day cycle and Bendamustine will be given by intravenous infusion for 2 days out of each 28 day cycle
224250508|NCT05048004|PROCEDURE|QMODE intervention|Patients undergoing different forms of pulmonary vein isolation are being monitored for microembolic signals (MES) by transcranial ultrasound. For standard ablation, a Thermocool Smarttouch SF (Biosense Webster) catheter will be used (50 W, target ablation index of 550).
224250509|NCT05048004|PROCEDURE|QMODE+ intervention|Patients undergoing different forms of pulmonary vein isolation are being monitored for microembolic signals (MES) by transcranial ultrasound. For comparison, catheter ablation performed using very high power with a maximum of up tp 90 W (QMODE +) will be used.
223669465|NCT05443139|BEHAVIORAL|Well-being online|Multi component Intervention composed 10 sessions following a structure based on Cognitive Behavioral Therapy (CBT), Acceptance and Commitment Therapy (ACT), Positive Psychology (PP), Mindfulness and Behavioral Activation Therapy (BAT).
223669466|NCT02636140|OTHER|Light|A brief, 1 minute exposure to light of varying color and intensity. The combination of color and intensity will be the same in all participants, but the order in which they are received is randomized.
223669467|NCT00338182|DRUG|AZD1152 part A|48-hour continuous intravenous infusion
223669468|NCT00338182|DRUG|AZD1152 part B|2-hour intravenous infusion
223669469|NCT01138176|PROCEDURE|Cooling|Reduction of rectal temperature to 33.5 C
223669470|NCT04458688|OTHER|Observation of Ocrelizumab as Treatment in RRMS Patients|It is decided by the patient and their physician to begin taking ocrelizumab PRIOR to study enrollment. The study is only observing the effects of ocrelizumab as a pre-decided treatment option for a patient's MS.
223669471|NCT02400164|DEVICE|alfapump system|The Sequana Medical alfapump system is an implanted subcutaneous device with a rechargeable battery that moves ascitic fluid from the peritoneal cavity to the urinary bladder where it is eliminated by spontaneous diuresis.
223669472|NCT02870023|OTHER|Balance training|
223669473|NCT02870023|OTHER|Strength training|
223669474|NCT03356704|OTHER|no intervention|Observational study
224250510|NCT00365534|PROCEDURE|MEI|
224250511|NCT06560814|DRUG|Cabergoline plus timed intercourse|Cabergoline 0.5 mg tab orally twice weekly (fridays and tuesdays) after meal at night for 24 weeks plus intercourse timed with LH kit
224250512|NCT06560814|DRUG|Dydrogesterone plus timed intercourse|Dydrogesterone 10 mg tab orally twice daily from day 5 to day 25 of menstrual cycle for 24 weeks plus intercourse timed with LH kit
224250513|NCT01639092|DRUG|Tenofovir|Tenofovir 300mg Daily Oral
224250514|NCT01639092|DRUG|Tenofovir|Tenofovir 300mg Daily Oral
224250515|NCT01639092|DRUG|Entecavir|Entecavir 1 mg daily Oral
224250516|NCT05593991|OTHER|Elevated heels|"Each subject will undergo the following evaluations:~1. neutral barefoot position;~2. neutral barefoot position (re-test);~3. 3 cm rise of both heels, made with plastic spacer;~4. 7 cm rise of both heels, made with plastic spacer."
224250517|NCT06562699|OTHER|Hot Matcha brew|"* Hot matcha brew will be prepared in usucha (thin consistency) version-2 grams of matcha powder (Dr.Baby) mixed with 30 mL of hot water (75 ̊C). The first step will be to massage the matcha powder with a small amount of water until a smooth paste forms, then additional 50 mL of hot water will be added to dilute down the concentration. The matcha will then be vigorously shaken in a lidded jar.~* After 5 minutes of the acidic attack, participants will be instructed to swish 25 mL of matcha tea 34 times then swallow, and saliva samples will be collected (T2).~* Then saliva will be collected after 10 (T3), 20 (T4), 30 (T5), and 40 (T6) minutes."
224250518|NCT06562699|OTHER|Water|Water (elano) at 13 ̊C swished 34 times then swallowed.
224250519|NCT06562699|OTHER|Cold matcha brew|25 mL of cold matcha brew prepared in usucha (thin consistency) version-2 grams of matcha powder (Dr.Baby) mixed with 80 mL of cold water (13 ̊C) swished 34 times then swallowed.
224250520|NCT06561646|PROCEDURE|single-port robotic-assisted nipple-sparing mastectomy and sentinel lymph node biopsy|the single-port robotic-assisted nipple-sparing mastectomy and sentinel lymph node biopsy in the management of breast cancer
224250521|NCT06561646|PROCEDURE|single-port robotic-assisted nipple-sparing mastectomy and axillary lymph node dissection|the single-port robotic-assisted nipple-sparing mastectomy and axillary lymph node dissection in the management of breast cancer
224250522|NCT02107300|DRUG|NeutraSal|NeutraSal is a powder that when dissolved in water creates a supersaturated calcium phosphate rinse.
224322009|NCT05435846|DRUG|Trametinib|Given orally
223669475|NCT03743077|BEHAVIORAL|Exercise training including inspiratory muscle training|Volunteers will participate in the the spinal mobility fitness training program for a frequency of one to 3 times a week with pre and post tests including four objective measures of function (timed t-shirt test, timed transfer test, four direction reach test and trunk test of strength) and a pre and post subjective interview. In addition to the program consenting volunteers will perform inspiratory muscle training as a home program and submit weekly diaries tracking their training. The inspiratory muscle trainer by Respironics provides specific pressure for inspiratory muscle strength and endurance, regardless of how quickly or slowly patients breathe. It exercises respiratory muscles and improves breathing. It Improves muscle strength and is easy to use.
223669476|NCT05581901|DRUG|Methadone (Dose1)|Dose: 0.10mg/kg
223669477|NCT05581901|DRUG|Methadone (Dose 2)|Dose: 0.15mg/kg
223669478|NCT05581901|DRUG|Methadone (Dose 3)|Dose 0.20mg/kg
223669479|NCT01552798|DRUG|Acetylsalicylic acid (Aspirin, BAY1019036)|2 x 500 mg fast release aspirin tablets (1000 mg) and 2 x placebo acetaminophen caplets
223669480|NCT01552798|DRUG|Acetaminophen|2 x 500 mg acetaminophen caplets (1000 mg) and 2 x placebo fast release aspirin tablets
223669481|NCT01552798|DRUG|Placebo|2 x placebo acetaminophen caplets and 2 x placebo fast release aspirin tablets
223669482|NCT01213576|DRUG|Albendazole 400mg and ivermectin 200mcg/kg|400 mg orally given annually
223669483|NCT01213576|DRUG|Albendazole and ivermectin|albendazole 800 mg and ivermectin 400mg orally given annually
223669484|NCT01213576|DRUG|Albendazole 400mg and ivermectin 200mcg/kg|Albendazole 400mg and ivermectin 200mcg/kg given twice a year
223669485|NCT01213576|DRUG|albendazole 800mg and ivermectin 400mcg/kg bi-annually|albendazole 800mg and ivermectin 400mcg/kg given twice a year
223669486|NCT01663753|DEVICE|18F-FDG-PET|
223669487|NCT02470637|DRUG|SAR439065|"Pharmaceutical form:dry powder insulin~Route of administration: inhalation"
223669488|NCT02470637|DRUG|Insulin lispro|"Pharmaceutical form:solution for injection~Route of administration: subcutaneous"
223669489|NCT02310009|DRUG|Anakinra (AN)|
223669490|NCT02310009|BEHAVIORAL|Exercise (EX)|
223669491|NCT02310009|BEHAVIORAL|Control (CON)|
223669492|NCT04125264|DEVICE|Intense Therapeutic Ultrasound|Application of 1000 pulses, until 5000 joules (5 joules per pulse), during approximately 15 minutes, with the possibility of 5 minutes rest, depending on the tolerance of the patient.
224250523|NCT02107300|DRUG|Placebo Comparator|Placebo is a powder consisting of sodium chloride only; chosen to mimic NeutraSal
224250524|NCT04785456|DEVICE|Active TBS|MagPro X100 device equipped with a Cool-B70 A/P coil and Qooler fluid-cooling device (MagVenture, Farum, Denmark)
224250525|NCT04785456|DEVICE|Sham TBS|MagPro X100 device equipped with a Cool-B70 A/P coil and Qooler fluid-cooling device (MagVenture, Farum, Denmark)
224250526|NCT03513822|DRUG|Ketamine 10 MG/ML|Ketamine infusion 1mg/kg with electric syringe during 2 hours.
224250527|NCT03513822|DRUG|Placebos|Sodium chloride infusion with the same rate, electric syringe during 2 hours.
224250528|NCT03513822|DRUG|Midazolam 1 MG/ML|Bolus of Midazolam 1mg before each perfusion.
224250529|NCT06469671|DEVICE|The system based on real - time artificial intelligence - assisted for colonoscopy|"Russian medical decision support system based on artificial intelligence ArtInCol"
224250530|NCT00134394|DRUG|Etanercept plus tacrolimus|
224250531|NCT06213506|BIOLOGICAL|Measles and Rubella vaccine|Measles and Rubella vaccine is administered to study participants, as part of an Expanded Program on Immunization (EPI) vaccination at the local EPI vaccination centers, and not part of the current clinical trial, as follows: - at 28 days after the first study intervention administration (occurring at Day 1) to infants in the Infants\_9M\_Dose A, Infants\_9M\_Control A, Infants\_9M\_Dose B, Infants\_9M\_Control B, Infants\_9M\_Dose C and Infants\_9M\_Control C groups. - at 28 days after the third study intervention administration (occurring at Day 232) to infants in Infants\_6W\_Dose A, Infants\_6W\_Control A, Infants\_6W\_Dose B, Infants\_6W\_Control B, Infants\_6W\_Dose C and Infants\_6W\_Control C groups. - at Day 232, concomitantly during the last study intervention administration to infants in Infants\_6W\_Dose A\_2, Infants\_6W\_Dose B\_2, Infants\_6W\_Dose C\_2 and Infants\_6W\_Control\_2 groups.
224250532|NCT06213506|BIOLOGICAL|Yellow Fever vaccine|Yellow Fever vaccine is administered to study participants, as part of an Expanded Program on Immunization (EPI) vaccination at the local EPI vaccination centers, and not part of the current clinical trial, as follows: - at 28 days after the first study intervention administration (occurring at Day 1) to infants in the Infants\_9M\_Dose A, Infants\_9M\_Control A, Infants\_9M\_Dose B, Infants\_9M\_Control B, Infants\_9M\_Dose C and Infants\_9M\_Control C groups. - at 28 days after the third study intervention administration (occurring at Day 232) to infants in Infants\_6W\_Dose A, Infants\_6W\_Control A, Infants\_6W\_Dose B, Infants\_6W\_Control B, Infants\_6W\_Dose C and Infants\_6W\_Control C groups. - at Day 232, concomitantly during the last study intervention administration to infants in Infants\_6W\_Dose A\_2, Infants\_6W\_Dose B\_2, Infants\_6W\_Dose C\_2 and Infants\_6W\_Control\_2 groups.
224250533|NCT06213506|BIOLOGICAL|Pentavalent vaccine|Pentavalent vaccine is administered, as part of an Expanded Program on Immunization (EPI) vaccination, at the local EPI vaccination centers, and not part of the current clinical trial, at 6, 10 and 14 weeks of age to infants in Infants\_6W\_Dose A\_2, Infants\_6W\_Dose B\_2, Infants\_6W\_Dose C\_2 and Infants\_6W\_Control\_2 groups.
224250534|NCT06213506|BIOLOGICAL|Pneumococcal vaccine|Pneumococcal vaccine is administered, as part of an Expanded Program on Immunization (EPI) vaccination, at the local EPI vaccination centers, and not part of the current clinical trial, at 6, 10 and 14 weeks of age to infants in Infants\_6W\_Dose A\_2, Infants\_6W\_Dose B\_2, Infants\_6W\_Dose C\_2 and Infants\_6W\_Control\_2 groups.
224250535|NCT06213506|BIOLOGICAL|Inactivated polio vaccine|Inactivated polio vaccine is administered, as part of an Expanded Program on Immunization (EPI) vaccination, at the local EPI vaccination centers, and not part of the current clinical trial, at 6, 10 and 14 weeks of age to infants in Infants\_6W\_Dose A\_2, Infants\_6W\_Dose B\_2, Infants\_6W\_Dose C\_2 and Infants\_6W\_Control\_2 groups.
224250536|NCT06213506|BIOLOGICAL|iNTS-GMMA Dose C|-2 doses of iNTS-GMMA Dose C vaccine administered intramuscularly, at Day 1 and Day 57 to adults and children in the Adults\_Dose C and Children\_Dose C groups; -3 doses of iNTS-GMMA Dose C vaccine administered intramuscularly, at Day 1, Day 85 and Day 169 to infants in the Infants\_9M\_Dose C group, and at Day 1, Day 57 (during the Priming phase) and at Day 232 (during the Booster phase) to infants in the Infants\_6W\_Dose C and Infants\_6W\_Dose C\_2 groups.
224250537|NCT06213506|BIOLOGICAL|iNTS-GMMA Dose B|-2 doses of iNTS-GMMA Dose B vaccine administered intramuscularly, at Day 1 and Day 57 to children in the Children\_Dose B group; -3 doses of iNTS-GMMA Dose B vaccine administered intramuscularly, at Day 1, Day 85 and Day 169 to infants in the Infants\_9M\_Dose B group, and at Day 1, Day 57 (during the Priming phase) and Day at 232 (during the Booster phase) to infants in the Infants\_6W\_Dose B and Infants\_6W\_Dose B\_2 groups.
224250538|NCT06213506|BIOLOGICAL|iNTS-GMMA Dose A|3 doses of iNTS-GMMA Dose A vaccine administered intramuscularly, at Day 1, Day 85 and Day 169 to infants in the Infants\_9M\_Dose A group, and at Day 1, Day 57 (during the Priming phase) and Day at 232 (during the Booster phase) to infants in the Infants\_6W\_Dose A and Infants\_6W\_Dose A\_2 groups.
224250539|NCT06213506|BIOLOGICAL|MenACWY|-1 dose of MenACWY vaccine administered intramuscularly at Day 1 to adults in the Adults\_Control group; -2 doses of MenACWY vaccine administered intramuscularly at Day 1 and Day 57 to children in the Children\_Control B and Children\_Control C groups, and at Day 1 and Day 85 to infants in the Infants\_9M\_Control A, Infants\_9M\_Control B and Infants\_9M\_Control C groups; -3 doses of MenACWY vaccine administered intramuscularly at Day 1, Day 57 (during the Priming phase) and at Day 232 (during the Booster phase) to infants in the Infants\_6W\_Control A, Infants\_6W\_Control B, Infants\_6W\_Control C and Infants\_6W\_Control\_2 groups. A 4th dose of MenACWY vaccine is administered after the trial ends, to infants in the aforementioned study groups, as per the licensed indication and in private vaccination settings.
224250540|NCT06213506|COMBINATION_PRODUCT|DTPa-HBV-IPV+Hib|1 dose of DTPa-HBV-IPV+Hib vaccine administered intramuscularly at Day 169 to infants in the Infants\_9M\_Control A, Infants\_9M\_Control B and Infants\_9M\_Control C groups.
224250541|NCT06213506|DRUG|Placebo|1 dose of Placebo administered intramuscularly at Day 57 to adults in the Adults\_Control group.
224250542|NCT04033471|DRUG|midazolam|epidural needle in the L1-2 or L2-3 space , and using loss of resistance technique udder strict aseptic condition 10 ml of the prepared drug will be given
223669493|NCT00128505|DRUG|Mifepristone|
224250543|NCT04078932|BEHAVIORAL|Violence Prevention Conversation Script to Discuss Safely Navigating Police Encounters|A conversation script to facilitate conversations on safely navigating police encounters as anticipatory guidance and violence prevention strategy. The conversation script will be created using expert recommendations from existing resources and using recommendations (determined from focus groups) from black male youth and their caregivers. The script will be patient-centered.
224322010|NCT01694225|OTHER|bubble packaging for monthly prescription|Monthly bubble packaging among women prescribed anti-estrogens
223669494|NCT01602133|PROCEDURE|peripheral venous puncture|Ultrasound imaging of the arm is performed. If a suitable vein is identified, a percutaneous puncture is performed under ultrasound guidance. Then, an intravenous catheter is inserted according Seldinger method.
223771470|NCT05007457|OTHER|Telerehabilitation|"Patients belonging to the experimental group will receive the brochure and, weekly a telematic comparison will take place lasting about 30 minutes, with a physiotherapist to be asked questions. The physiotherapist will be able to evaluate and modify the training program based on the patient's response.~The tele-rehabilitation sessions will take place: once / week for the first month, once every 2 weeks for the second month and from the third month from the third month the patient can contact the professionals in case of doubts or questions regarding the exercises he is taking place at home."
223771471|NCT00023673|DRUG|carboplatin|
223669495|NCT05610189|DRUG|Tavapadon|Oral tablets
223669496|NCT00689442|DRUG|JTT-705 600 mg and atorvastatin 20 mg|"* JTT-705 300 mg tablets, 600 mg dose, oral, once daily, immediately following breakfast and/or assessment~* Atorvastatin 20 mg tablets, 20 mg dose, oral, once daily, immediately following breakfast and/or assessments"
223669497|NCT00689442|DRUG|Placebo and atorvastatin 20 mg|"* Placebo tablet, 2 tablets, oral, once daily, immediately following breakfast and/or assessments~* Atorvastatin 20 mg tablets, one tablet, oral, once daily, immediately following breakfast and/or assessments"
223669498|NCT04970953|PROCEDURE|Right heart catheterization|Right heart catheterization will be performed via a brachial access under sonographic guidance and hemodynamic measurements will be performed in a semi-supine position.
223771472|NCT00023673|DRUG|paclitaxel|
223771473|NCT00023673|RADIATION|three-dimensional conformal radiation therapy|
223771474|NCT02497326|DRUG|Polyfax & Lignocain gel or silvazine cream|olyfax skin ointment plus Lignocain gel will be applied on superficial PTB area and silver sulphadiazine cream on deep PTB in morning and evening after wound wash.
223771475|NCT02497326|DRUG|Topical Heparin|"Heparin solution (5000 IU/ml) will be sprinkled aseptically on burn surface twice a day for the first 2 days, by #27 needle connected via drip set to the drip containing heparin aqueous saline. The dose will be reduced to 75% of day 1 on day 3 and 4 and to 50% on day 5. Administration of heparin saline solution will be in 3 cycles with 5-10 minutes interval"
223771476|NCT02497326|DRUG|Tramadol|IV Analgesic ( Inj. Tramadol 10mg/dose) will only be given to the patients (in both groups) having pain score \>4, assessed 3 times a day by Numeric Visual Analogue scale (NVAS).
223771477|NCT03921268|DRUG|AZD1402|AZD1402 (PRS-060) is presented as a solution and dry powder for oral inhalation and belongs to a new class of therapeutics, Anticalin® proteins, which are modified lipocalins. AZD1402 is an inhaled IL-4Rα antagonist, which is being developed as controller therapy for asthma.
223771478|NCT02453594|BIOLOGICAL|pembrolizumab|IV infusion
223771479|NCT05239676|BIOLOGICAL|Autologous hematopoietic stem cell transplantation combined with CD19 CAR-T cells|The patient receives ECHOP chemotherapy or other chemotherapy regimens； G-CSF in the low cell stage mobilizes hematopoietic stem cells and freezes them for later use after collection； Autologous hematopoietic stem cells and prepared CD19 CAR-T cells are reinfused into the patient
223771480|NCT06663176|DRUG|RESP302|Nitric Oxide agent
223771481|NCT06663176|DRUG|RESP303|Nitric Oxide agent
223771482|NCT04442594|PROCEDURE|virtual reality session|"The virtual reality sessions will take place in a quiet setting twice a week in the living or hosting residence. The sessions will be hold over a period of time of 6 weeks.~The virtual environment will change every 3 weeks in order to avoid the phenomenon of habituation."
223771483|NCT04849975|OTHER|Pelvimetric measurements|The patients in this group are pregnant women after failure of external manual version (EMV) in case of breech fetal presentation. The participants will successively perform MRI pelvimetry (conventional management) and EOS imaging.
223669499|NCT02353143|DRUG|MEN1112|"Intravenous infusion of MEN1112 pro/Kg body weight dose will be administered for two 21-day cycles; MEN1112 dose is administered as' one shot infusion' (first group of patients) and as a dose to be infused in 3 days for the first two doses in Cycle 1 (second group of patients).~Two treatment cycles will be followed by a 4-week End of Treatment Period and a Follow-up period. The individual treatment/observation period is six months (except for female patients of childbearing potential that will undergo monthly pregnancy test until 6 months from the last study drug administration)."
223669500|NCT01155882|PROCEDURE|Whipple at the Splenic Artery (WATSA)|
223771484|NCT04962269|DIAGNOSTIC_TEST|MRI|monoexponential model, intravoxel incoherent motion (IVIM) model and stretched exponential model
223771485|NCT05059392|BEHAVIORAL|Training for Awareness, Resilience and Action (TARA)|See arm description
223771486|NCT00796029|DRUG|14C-paliperidone|
223771487|NCT02086591|DRUG|Doxycycline|
223771488|NCT04791358|DIAGNOSTIC_TEST|KidneyIntelX|KidneyIntelX is an in-vitro diagnostic that enables accurate risk prediction of progressive decline in kidney function and kidney failure in patients with type 2 diabetes and existing CKD at stages 1-3 (eGFR of 30 to 59 ml/min/1.73m2, or eGFR ≥ 60 ml/min/1.73m2 and uACR ≥ 30 mg/g).
224250544|NCT03170323|DRUG|Mycophenolate Mofetil|steroid 1mg/kg/d and Mycophenolate mofetil 500mg bid
224250545|NCT03170323|DRUG|Cyclosporins|steroid 0.15mg/kg/d and Cyclosporin 3-5mg/kg/d
224250546|NCT03892694|DEVICE|RejuvenAir System|Bronchial metered cryospray using RejuvenAir® System.
224250547|NCT03892694|OTHER|Sham|Sham control procedure
224250548|NCT00501345|DRUG|Aspirin|325 mg by mouth on Day 1 only, followed by 160 mg by mouth daily
224250549|NCT00658762|DRUG|PD 0332334|Capsules, oral, 225 mg BID, 8 weeks, with 2 week taper
224250550|NCT00658762|DRUG|PD 0332334|Capsules, oral, 300 mg BID, 8 weeks, with 2 week taper
224250551|NCT00658762|DRUG|paroxetine|Capsules, oral, 20 mg q am, 8 weeks, with 2 week taper
224250552|NCT00658762|DRUG|Placebo|Capsules, oral, BID, 8 weeks, with 2 week taper
224250553|NCT00362024|DRUG|MK0952|
224250554|NCT00362024|DRUG|Comparator: Placebo|
224322011|NCT03786458|BEHAVIORAL|web-based decision aid|The decision aid is then developed further process of evidence synthesis and multidisciplinary external review.
224322012|NCT02797171|BIOLOGICAL|VRC01|Administered by intravenous (IV) infusion
224322013|NCT02797171|BIOLOGICAL|VRC01LS|Administered by intravenous (IV) infusion
223669501|NCT04272138|BEHAVIORAL|Calm Meditation|"The intervention will run for 4-weeks. Participants will complete the 30 day, How to Meditate meditation series that provides daily 10-minute meditations. Throughout the intervention, participants will be sent reminder emails via REDCap to participate in their assigned practice sessions participants and will complete online weekly participation logs via REDCap. Additionally, they will answer one, multiple-choice ecological momentary assessment question, randomly, 3x per day via test message assessing how one currently feels. Participants will complete baseline and post-intervention measures of the Perceived Stress Scale, Hospital Anxiety and Depression Scale, Mindfulness Attention Awareness Scale, International Physical Activity Questionnaire, Salzberg Stress Eating Scale, Brief Cope, and Brief Resilience Scale. Following these measures, participants will be asked to complete a satisfaction questionnaire (week 5) and have the opportunity to volunteer for a short phone interview."
223669502|NCT04272138|BEHAVIORAL|Educational Podcast Control|The intervention will run for 4-weeks. Control group participants will listen to daily 10-minute health education podcasts. Throughout the intervention, participants will be sent reminder emails via REDCap to participate in their assigned practice sessions and participants will complete online weekly participation logs via REDCap. Additionally, they will answer one, multiple-choice EMA (ecological momentary assessment) question, randomly, 3x per day via test message assessing how one currently feels. Participants will complete baseline and post-intervention measures of the Perceived Stress Scale, Hospital Anxiety and Depression Scale, Mindfulness Attention Awareness Scale, International Physical Activity Questionnaire, Salzberg Stress Eating Scale, Brief Cope, and Brief Resilience Scale. Following these measures, participants will be asked to complete a satisfaction questionnaire (week 5) and have the opportunity to volunteer for a short phone interview.
223669503|NCT05330078|DRUG|Botulinum toxin type A|Participants will receive Botulinum toxin type A 5 units / cm3 with injections of 0.2mL spaced evenly 1cm apart within the treatment area (half of the keloid). Each treatment will consist of a maximum of 2 mL (10 injection sites, 50 unit total) of the study drug. Patients will undergo 3 treatments, 6 weeks apart.
223669504|NCT05330078|DRUG|Vehicle|Participants will receive saline injections of 0.2mL spaced evenly 1cm apart within the placebo area (half of the keloid). Each treatment will consist of a maximum of 2 mL (10 injection sites) of the vehicle control (saline). Patients will undergo 3 treatments, 6 weeks apart.
223669505|NCT03785275|RADIATION|gallium-68-exendin PET/CT|PET/CT scan after injection with gallium-68-exendin
223669506|NCT05627778|DRUG|68Ga-PSMA-11|Intravenous injection of one dosage of 148-185 MBq (4-5 mCi) 68Ga-PSMA-11. Tracer doses of 68Ga- PSMA-11 will be used to image lesions of prostate cancer by PET/CT.
223669507|NCT05627778|DRUG|68Ga-P15-041|Intravenous injection of one dosage of 148-185 MBq (4-5 mCi) 68Ga-P15-041. Tracer doses of 68Ga- 15-041 will be used to image lesions of prostate cancer by PET/CT.
223669508|NCT02664623|PROCEDURE|Individual dietary consultations|Individual dietary consultations with a dietician will be held at inclusion, month 1 and month 3. Consults consist of a personal interview where the dietician delivers comprehensive information to the patient on how to optimize calcium intake and reduce the risk of fractures; the dietician questions the subject on his/her diet and reassesses the quality and quantity of calcium intake during the 3 days preceding the consultation through a survey calculation software based on data from CIQUAL.
223669509|NCT02664623|PROCEDURE|Dietary advice sheet|"At the beginning neurological consult, patients will be delivered a dietary advice sheet called Grio."
223669510|NCT00817128|PROCEDURE|PEPT|Pain Exposure Physical Therapy
223669511|NCT00817128|PROCEDURE|CBO standard|Standard therapy as defined in CBO guideline 2006
223669512|NCT03483129|BEHAVIORAL|Consultation|15 minute, one to one consultation with a trained practice nurse at a GP surgery. Participants will have the opportunity to discuss pre-diabetes, the risks of developing diabetes and the steps that can be taken to improve lifestyle behaviors and reduce the risk of diabetes development.
223669513|NCT01280201|DRUG|Pazopanib|Single arm of pazopanib 800 mg (2x400mg) given once daily as a single agent.
223669514|NCT05240443|PROCEDURE|Bariatric Surgery + Medical Management of CKD.|The intervention group will include medical management and bariatric surgery, which will consist of Roux-en-Y gastric bypass or sleeve gastrectomy performed according to local practice standards. Medical management for CKD will be directed by nephrologists at St. Joseph's Healthcare Hamilton. Comorbidities such as hypertension, dyslipidemia, and type 2 diabetes will be managed at the discretion of individual nephrologists. Generally, this can include anti-hypertensives (angiotensin-converting enzyme inhibitors or angiotensin receptor blockers) for systolic blood pressure control below a target of \<140/90 mmHg (\<130/80 in patients with type 2 diabetes), statins in patients with dyslipidemia to target low-density lipoprotein \<2mmol/L for the treatment of CKD.
223771489|NCT02509689|BEHAVIORAL|Global Z-Score Neurofeedback Training|"The experimental intervention in this study, Global Z-Score Neurofeedback Training, is a non-pharmacological EEG Biofeedback training process using a specific new technology that allows for the training to be semi-automated and to train based on referencing EEG activity in 19 sites on the scalp, whilst comparing in real time to a database of non-clinical normative EEG data. Subjects will be scheduled to receive 20 treatment sessions of GZNT over a six-week period, aiming for four treatment visits per week, but allowing for some missed appointments due to holidays and duty obligations.~Training will be conducted for a continuous time which will begin at 10 minutes in the first session, and progress to a maximum of 30 minutes by the sixth or seventh session, and then remain at 30 minutes of training per session for the remainder of the sessions."
224250555|NCT01650350|DRUG|Naltrexone|"4.1 Low Dose Naltrexone (LDN) LDN, 5 mg/day, at approximately 9pm, on an empty stomach, until disease progression, unacceptable toxicity, need for initiation of narcotic analgesia, or removal from protocol treatment according to section 12.0. (1 cycle = 28 days).~LDN, 5mg/ml, will be prepared by the Lifespan hospital pharmacy for patient use for this study."
224250556|NCT02711852|DRUG|Duvelisib|Administered as oral capsules
224250557|NCT01638741|BEHAVIORAL|Rehabilitation goals of patients with gynaecological cancer.|Conversations with the nurse and supportive phone calls. Conversation are structured and placed 1 and 3 months after surgery. Phone calls are carried out at two and three months after surgery.
224250558|NCT02284490|DRUG|pemetrexed|Administered intravenously at a dose of 900 mg/m2 every 21 days until disease progression.
224250559|NCT05166148|OTHER|Session (a)|Eccentric cycling
224250560|NCT05166148|OTHER|Session (b)|High intensity concentric cycling realized at the same mechanical power output than eccentric cycling
223669515|NCT05240443|OTHER|Medical Management for CKD|Medical management for CKD will be directed by nephrologists at St. Joseph's Healthcare Hamilton. Comorbidities such as hypertension, dyslipidemia, and type 2 diabetes will be managed at the discretion of individual nephrologists. Generally, this can include anti-hypertensives (angiotensin-converting enzyme inhibitors or angiotensin receptor blockers) for systolic blood pressure control below a target of \<140/90 mmHg (\<130/80 in patients with type 2 diabetes), statins in patients with dyslipidemia to target low-density lipoprotein \<2mmol/L for the treatment of CKD.
223669516|NCT04142879|DEVICE|Viz Device Software|Viz uses artificial intelligence to automatically detect, triage and notify stroke specialists of suspected large vessel occlusion (LVOs) and computed tomography angiogram (CTA) imaging. Viz includes functionality to automatically process computed tomography perfusion (CTP) images. Additionally, Viz includes a mobile non-diagnostic image viewer and HIPAA-compliant secure messaging.
223669517|NCT00266669|DRUG|Topical organogel with nitroglycerin|
223669518|NCT05053932|OTHER|blood collection|blood collection
223669519|NCT00002165|DRUG|Nelfinavir mesylate|
223669520|NCT01659801|DEVICE|BunnyLens TR|BunnyLens TR IOL is an Aspheric Toric intraocular lens providing a precise, superior alternative to surgical treatment of pre-existing corneal astigmatism.
223669521|NCT04630574|OTHER|Speech evaluation with the clinical evaluation of dysarthria|A first speech evaluation with the clinical evaluation of dysarthria during 30 minutes is proposed to exclude very severe dysarthria.
223669522|NCT04630574|OTHER|complete assessment of the MonPaGe computerized protocol|The application records directly and anonymously stores speech productions made by the patient.
223669523|NCT03553966|PROCEDURE|Prophylactic|Tooth Brushing HA 3x daily repeated cleaning of all teeth using a standardized electric tooth brush and a non-fluoridated tooth paste containing microcrystalline hydroxylapatite.
223669524|NCT03553966|PROCEDURE|Cleaning teeth|Tooth Brushing F 3x daily repeated cleaning of all teeth using a standardized electric tooth brush and a fluoridated tooth paste.
223669525|NCT03553966|DEVICE|Restorative dentistry|If in a subject a significant increase of carious lesions will be observed, her/his parents are informed about the necessity for further caries preventive measures (e.g. dietary changes, use of fluoride products, reduction of cariogenic microflora with chlorhexidine, xylitol chewing gum, etc.) and caries preventive treatment (removing caries and placing a restoration) by the study centers is offered.
223669526|NCT04038203|DEVICE|Resonance Raman Spectroscopy (RPS)|RRS is a technology that utilizes vibrational spectroscopy, rather than absorbance spectroscopy, to determine the oxyhemoglobin concentration in tissues. Raman measurements for the UAC neonates will be obtained simultaneously on the right AND left lower extremity for 15 minutes daily in the first week of life.
223669527|NCT04422275|DRUG|Budesonide|The drug intervention budesonide (0.5 mg /capsule) will be dissolved in 240 ml nasal saline lavage.
223669528|NCT04422275|BEHAVIORAL|High-Concentration Essential Oil|High-concentration essential oil will include 1 ml of essential oil per jar.
223669529|NCT04422275|DRUG|Placebo|The placebo (lactose monohydrate) drug will be dissolved in 240 ml of nasal saline lavage.
223669530|NCT04422275|BEHAVIORAL|Low-Concentration Essential Oil|Low-concentration essential oil will include 0.1 ml of essential oil per jar.
223669531|NCT01940978|DRUG|Methylphenidate ER|Watson generic, starting dose 18mg QD
223669532|NCT01940978|DRUG|Cyproheptadine|cyproheptadine hydrochloride
223669533|NCT02302430|DRUG|Oxytocin|20 International Units Intranasal Oxytocin
223669534|NCT02302430|OTHER|Placebo comparator|Saline nasal spray
223669535|NCT02480946|DRUG|MBS2320|As described in the arm descriptions
223669536|NCT02480946|DRUG|Placebo|As described in the arm descriptions
223669537|NCT02480946|DRUG|Methotrexate|Background therapy as described in the arm descriptions
223669538|NCT04517279|BEHAVIORAL|Invest in My Recovery Bank|The intervention has not be fully developed. It will be created in partnership with individuals serving in peer provider roles.
223771490|NCT06739915|OTHER|TUTT-PT Intervention|All TUTT-PT arm participants who provide written informed consent will have sputum collected for TB testing (if sputum was not already collected by the clinic staff) and will receive a clinical evaluation for the presence of TB symptoms (cough, fever, weight loss, night sweats) and serious contraindications for TPT initiation (known liver disease, high alcohol intake (men: \>5 drinks/day or \>15 drinks/week; women: \>4 drinks/day or \>8 drinks/week), or strong clinical suspicion of TB disease as evidenced by severity of symptoms, including haemoptysis, or Karnofsky score ≤50. PLHIV for whom the study nurse does not have a strong clinical suspicion of TB nor evidence of serious TPT contraindications will be referred to clinic staff for TPT initiation, irrespective of the presence or absence of TB symptoms.
223771491|NCT04320160|PROCEDURE|Platelet rich plasma|"Eight milliliters of blood sample will be aspirated from the patient's peripheral vein, and the sample will be centrifuged at 1,500 rpm for 5 minutes.~A 30-G needle will be used for superficial intradermal (ID) microinjections (0.1 mL per injection and space about 1 cm apart)"
223771492|NCT04320160|PROCEDURE|Fractional CO2 laser|"Fifteen lesions will be treated by Fr: CO2 laser (10,600 nm; KES Corporation, Beijing, China).~Scanner spot size will be adjusted based on the lesion size. Density selected will be 0.6 in the static mode.~Two passes with minimal overlap will be delivered. The laser will be applied to the vitiligo lesion and over a thin rim of healthy skin"
224250561|NCT05166148|OTHER|Session (c)|Low intensity concentric cycling realized at the same metabolic demand than eccentric cycling
223669539|NCT04517279|BEHAVIORAL|Usual Care Peer Services|Usual peer services involves supporting the process of change for individuals with mental health disorder to improve their health and wellness, live a self-directed life, and strive to reach their full potential.
223669540|NCT01779076|PROCEDURE|30% oxygen|
223669541|NCT01779076|PROCEDURE|100% oxygen|
223669542|NCT00253708|PROCEDURE|management of therapy complications|
223669543|NCT00253708|PROCEDURE|massage therapy|
223669544|NCT00253708|PROCEDURE|pain therapy|
223669545|NCT00253708|PROCEDURE|psychosocial assessment and care|
223669546|NCT00253708|PROCEDURE|quality-of-life assessment|
223669547|NCT05436873|DEVICE|MR-HIFU|MRI guided High Intensity Focused Ultrasound sonication.
223669548|NCT05456282|DEVICE|Automated mechanical peripheral stimulation|Automated mechanical pressure reaching the pain threshold in four specific points at the foots soles
224250562|NCT06425679|BEHAVIORAL|Supervised synchronous online exercise intervention without motivational strategies|Participants will carry out an online synchronic supervised physical exercise intervention through their computer/tablet or mobile phone at home. The exercise professional will supervise the participant's execution online. The training program comprises the same exercise structure and is based on the same muscle groups and movements as the supervised face to face groups. The exercise program will be divided into 3 different levels, progressing the difficulty every 8 weeks.. Each level will contain 3 different sessions including 10 warm-up and joint mobility exercises, 1 balance exercise, 7 strength exercises, 2 aerobic exercises, and 6 flexibility exercises. This multicomponent training will be performed 3 times per week (60 min/session) for 24 weeks
224250563|NCT06425679|BEHAVIORAL|Supervised synchronous online exercise intervention with motivational strategies|Participants will carry out an online synchronic supervised physical exercise intervention through their computer/tablet or mobile phone at home. The exercise professional will supervise the participant's execution online and will also apply motivational strategies based on self-determination theory. The training program comprises the same exercise structure and is based on the same muscle groups and movements as the supervised face to face groups. The exercise program will be divided into 3 different levels, progressing the difficulty every 8 weeks. Each level will contain 3 different sessions including 10 warm-up and joint mobility exercises, 1 balance exercise, 7 strength exercises, 2 aerobic exercises, and 6 flexibility exercises. This multicomponent training will be performed 3 times per week (60 min/session) for 24 weeks.
224322014|NCT02540083|DEVICE|DBT and FFDM|Subjects underwent FFDM breast imaging followed by DBT breast imaging
224322015|NCT05237492|DRUG|Tramadol|Blood samples will be drawn from 15 patients. Tramadol will be added to all this samples in-vitro and its influence on platelets´ function will be measured.
223669549|NCT05456282|DEVICE|SHAM|Automated mechanical pressure reaching the sensory threshold in four specific points at the foots soles
223771493|NCT05424471|BEHAVIORAL|Family Spirit Nurture (FSN)|The FSN intervention lesson is taught to participants previously randomized into the FSN intervention group during the PECO 1 study. Intervention group participants receive 1 Family Spirit Nurture lesson taught by Family Health Coaches. Mothers will receive the 1 - 45 minute lesson within 1-2 weeks of completing the 4-year Follow-up Assessment. The lesson focuses on age-appropriate parental feeding practices, including snack routines, avoidance of SSBs and promotion of water consumption. The lesson is highly visual and interactive, and incorporates cultural teachings related to child feeding and nutrition that support aims. The Family Health Coaches also provide social support and will facilitate referrals to community resources.
223771494|NCT05424471|OTHER|Control Group - Vehicle Safety|The control (vehicle safety) lesson is taught to participants previously randomized into the control group during the PECO 1 study. Control group participants receive 1 - 30 minute lesson with vehicle safety information, taught by Family Health Coaches. Mothers will receive the lesson within 1-2 weeks of completing the 4-year Follow-up Assessment. The Family Health Coaches also provide social support and will facilitate referrals to community resources.
223669550|NCT01981057|OTHER|Numeta|parenteral receipt prescribed with Numeta
223771495|NCT04992949|DRUG|CPX-351|"Induction : patients will receive induction treatment with CPX-351 100 U/m2 on days 1, 3, and 5. Patients who fail to achieve CR/CRi after the induction cycle will be offered a second induction course of CPX-351 100 U/m2 on days 1 and 3, at the investigators' discretion. If CR/CRi is not achieved following the second induction cycle, patients will go off study~Consolidation : patients in CR/CRi after induction cycle will receive up to 2 course of consolidation therapy with CPX-351 65 U/m2 on days 1 and 3. CPX351 doses could be reduced to 65 U/m2 on day 1 in case of unacceptable toxicity following the previous course.~Allo-SCT : patients for whom an allo-SCT is planned will receive a maximum of one consolidation cycle"
223771496|NCT00228891|PROCEDURE|Effect of Pulsatile IV insulin on diabetic neuropathy|Control patients with diagnosed diabetic neuropathy will have objective testing at baseline and every six months to compare and measure results to patients receiving pulsatile intravenous insulin therapy.
223771497|NCT00228891|PROCEDURE|Effect of Pulsatile IV Insulin on diabetic neuropathy|Patients diagnosed with diabetic neuropathy will be treated with pulsatile intravenous insulin on a weekly basis. Patient's Endocrinologist will determine the dosage of intravenous insulin to be given each week based upon the patient's response and insulin resistance.
224322016|NCT04592146|DEVICE|Frailty multicomponent intervention supported by POSITIVE|This technology mainly consists in a home monitoring kit periodically measuring gait speed, involuntary weight loss and power in the lower limb. Furthermore, through a tablet device, other relevant information (e.g. state of mind, activities of daily living-ADLs, etc.) is collected. The same device is used to enhance communication with the clinical team and follow the tailored intervention
223669551|NCT01981057|OTHER|Individual|parenteral receipt prescribed individually
223771498|NCT04973761|OTHER|Zirconium crowns|Prefabricated pirmary anteroir teeth zirconium crowns
223771499|NCT04973761|OTHER|Strip composite crowns|Strip composite crowns
223771500|NCT00064441|DRUG|OPC-6535 Tablets (drug)|
224322017|NCT04592146|OTHER|Frailty multicomponent intervention|This intervention is based on 3 main pillars: medication review (to avoid polypharmacy), tailored nutritional recommendations and a tailored physical activity plan based on the VIVIFRAIL program.
224322018|NCT02407639|OTHER|CO2|gas
223669552|NCT04645485|BIOLOGICAL|Nebulization of autologous non-hematopoietic peripheral blood stem cells (NHPBSC).|Participants received the investigational therapy through compressor (jet) nebulization, in two doses divided on Days 0 and 1. Each dose contains 10 mL of peripheral blood-derived stem cells CD45-/CD90+/CD133+.
223669553|NCT02012868|PROCEDURE|bariatric surgery|
223669554|NCT04644731|DEVICE|Aquadex™ System|Ultrafiltration for fluid removal
223669555|NCT00125398|DRUG|AQUAVAN (fospropofol disodium; GPI 15715 )|
223669556|NCT02776020|DEVICE|CorrecDose Infrared Monitor|The monitor is attached to patient's wrist and ear in order to measure changes in propofol concentrations in blood
223669557|NCT05207189|BIOLOGICAL|UVT|Chemically-treated, viro-inactivated, freeze-dried and irradiated umbilical vein allograft placed in replacement of a failed synthetic sling during a surgical act performed by the investigator.
223669558|NCT03040570|PROCEDURE|Conservative oxygenation target|Participants allocated to the conservative oxygenation target group will receive supplemental oxygen and ventilator settings at the discretion of the treating clinical team with the aim of peripheral oxygen saturations remaining 88-92% (inclusive).
223669559|NCT03040570|PROCEDURE|Liberal oxygenation target|Participants allocated to the liberal oxygenation target group will receive supplemental oxygen and ventilator settings at the discretion of the treating clinical team with the aim of peripheral oxygen saturations remaining \>94%.
224250564|NCT06425679|BEHAVIORAL|Supervised face to face exercise intervention without motivational strategies|Participants will attend the sports facilities and perform the training in small groups, being supervised by an exercise professional. The training program comprises the same exercise structure and is based on the same muscle groups and movements as the online synchronic supervised groups, but is performed in a sports center. The exercise program will be divided into 3 different levels, progressing the difficulty every 8 weeks. Each level will contain 3 different sessions including 10 warm-up and joint mobility exercises, 1 balance exercise, 7 strength exercises, 2 aerobic exercises and 6 flexibility exercises. This multicomponent training will be performed 3 times per week (60 min/session) for 24 weeks.
224322019|NCT02407639|OTHER|air|air
223669560|NCT00430183|DRUG|docetaxel|75 mg/m\^2 will be administered intravenously over one hour on Day 1 of each cycle, every 21 days
223669561|NCT00430183|DRUG|LHRH agonist|Given intramuscularly
223669562|NCT00430183|PROCEDURE|surgery|Patients undergo radical prostatectomy with staging pelvic lymphadenectomy.
223669563|NCT02946931|DRUG|Prizbind®|Prizbind®
223669564|NCT02769897|BEHAVIORAL|Physical exercise|The sessions will last two hours (one hour of physical exercise and the second time divided into nutritional counseling, postural, psychological and oral) with a frequency of three times a week.
223669565|NCT00311298|DIETARY_SUPPLEMENT|Multimicronutrients|Randomised, double-blind trial among pulmonary TB patients, except those who are found to be sputum positive and HIV positive. Both arms received a daily biscuit weighing 30 g (4.5 g protein, 615 kJ). The biscuit given to the No micronutrient-arm contained no additional micronutrients. The biscuit given to the Micronutrient-arm contained the following micronutrients: vitamin A 5000 IU, vitamin B1 20 mg, vitamin B2 20 mg, vitamin B6 25 mg, vitamin B12 50 microg, folic acid 0.8 mg, niacin 40 mg, vitamin C 200 mg, vitamin E 60 mg, vitamin D3 5 µg / 200 IU, selenium 0.2 mg, copper 5 mg, and zinc 30 mg. The intervention was given for 60 days during initial TB treatment.
223669566|NCT00311298|DIETARY_SUPPLEMENT|Energy and proteins|Randomised, single-blind trial among sputum-positive HIV-coinfected pulmonary TB patients. Both arms received a daily for biscuit weighing 30 g (4.5 g protein, 615 kJ), with micronutrients (vitamin A 5000 IU, vitamin B1 20 mg, vitamin B2 20 mg, vitamin B6 25 mg, vitamin B12 50 microg, folic acid 0.8 mg, niacin 40 mg, vitamin C 200 mg, vitamin E 60 mg, vitamin D3 5 µg / 200 IU, selenium 0.2 mg, copper 5 mg, and zinc 30 mg). The experimental arm received an additional 5 biscuits without additional micronutrients. Thus, both arms received the same amount of micronutrients. However, the intervention arm received 3690 kJ and 27 g protein per day, while the control arm received 615 kJ and 4.5 g protein. The intervention was given for 60 days during initial TB treatment.
223669567|NCT00497809|DRUG|AVI-014 versus Filgrastim|3 different dose arms of AVI-014 versus Filgrastim for up to 14 days daily
223669568|NCT02436980|DRUG|Tramadol|GROUP T
223669569|NCT02436980|DRUG|Midazolam|GROUP M
223669570|NCT05628259|BEHAVIORAL|Tele-Nursing based Motivational Interviewing|A motivational interview (MI) program based on the telenursing approach was applied to the individuals in the experimental group. In this study, the MI procedure includes eight sessions in total, with four sessions of motivational interviews by phone in the first month of the intervention and four sessions of motivational interviews by phone in the next two months for each individual. Pre-tests were collected in the first month. Afterwards, MI intervention was applied for three months. This intervention was applied to the experimental group in addition to the routine care provided by the hospital. MI application took an average of 45-60 minutes via phone call.
223771501|NCT04518735|OTHER|Antithrombotic Therapy (anticoagulant and/or antiplatelet) before admission for Covid19|Review of medical records during hospitalization and until day 28 post-entry to compare the clinical outcomes depending on previous antithrombotic therapy
223771502|NCT01534468|BIOLOGICAL|Monovalent Influenza Subvirion Vaccine, H7N7|At study entry, all participants will receive one IM injection of approximately 45 micrograms of inactivated Monovalent Influenza Subvirion Vaccine, H7N7.
223771503|NCT04724239|DRUG|Sintilimab|200mg IV on Day 1 Q3W
223771504|NCT04724239|DRUG|Chidamide|30mg PO BIW each 3-week cycle
223669571|NCT06298344|DRUG|Thiamine|Daily Thiamine 100 mg in 28 days
223669572|NCT04476173|DRUG|Methoxyflurane - Penthrox|ACS patients who received inhaled methoxyflurane as analgesic treatment
223669573|NCT04476173|DRUG|Morphine|ACS patients who received intravenous morphine as analgesic treatment
223669574|NCT03339297|DRUG|Defibrotide|6.25 mg/kg via 2-hour IV infusion every 6 hours
223669575|NCT03339297|DRUG|Standard of Care|Administered according to local institutional guidelines, physician preference, and patient need.
223669576|NCT05015985|OTHER|Music-Care|music relaxation by a specific hardware and software program application (MUSIC-CARE)
223669577|NCT05015985|OTHER|control group|music relaxation using a music playlist supply (control group)
223669578|NCT05705635|DRUG|Docetaxel for injection (Albumin-bound)|Docetaxel for injection (Albumin-bound), by intravenous infusion, every 3 weeks.
223669579|NCT05705635|DRUG|Taxotere|Taxotere, by intravenous infusion, every 3 weeks.
223669580|NCT01274260|DRUG|methylprednisolone|Subjects in this group will receive a loading dose of methylprednisolone 2mg/kg followed by 1mg/kg/day of methylprednisolone infusion from day 1 to day 7; 0.5mg/kg/d from days 8 to 10, 0.25mg/kg/d on days 11 and 12, 0.125mg/kg/d on days 13 and 14. The study drug infusion will be discontinued after 14 days.
223669581|NCT01274260|DRUG|Normal Saline (0.9%)|The placebo will be 0.9% (normal) saline and the active medication will be diluted in 0.9% (normal) saline.
223771505|NCT04724239|DRUG|IBI305|7.5mg/kg IV on Day 1 Q3W
223771506|NCT01782677|PROCEDURE|Bilateral Surgical Resection of Carotid Bodies|
223771507|NCT04693364|OTHER|Decision Aid|Use 3D printed breast model
223771508|NCT04693364|PROCEDURE|Discussion|Participate in consultation
223771509|NCT04693364|OTHER|Questionnaire Administration|Complete questionnaires
223771510|NCT02897739|PROCEDURE|Magnetic resonance imaging|Cardiac MRI and short MRI following USPIO infusion
223771511|NCT02897739|BIOLOGICAL|Acute Inflammatory Activation study|Blood sampling for exploration of type and level of inflammatory response
223771512|NCT02897739|RADIATION|PET CT|PET study for metabolic pathway study
224250565|NCT06425679|BEHAVIORAL|Supervised face to face exercise intervention with motivational strategies|"Participants will attend the sports facilities and perform the training in small groups, being supervised by an exercise professional who will also apply motivational strategies. The training program comprises the same exercise structure and is based on the same muscle groups and movements as the online synchronic supervised groups, but is performed in a sports center.~The exercise program will be divided into 3 different levels, progressing the difficulty every 8 weeks. Each level will contain 3 different sessions including 10 warm-up and joint mobility exercises, 1 balance exercise, 7 strength exercises, 2 aerobic exercises and 6 flexibility exercises. This multicomponent training will be performed 3 times per week (60 min/session) for 24 weeks."
224250566|NCT01547377|DIETARY_SUPPLEMENT|zinc and selenium supplementation|Data from patients were obtained at beginning and after four months of treatment with 10 mg rosuvastatin, concomitantly with zinc (30mg/d) and selenium (150μg/d) supplementation or placebo. The anthropometric and dietary data, zinc and selenium concentrations in plasma and erythrocyte, lipid profile, electronegative LDL (LDL(-)), anti- electronegative LDL, Ac-LDL(-) immune complexes, GPx and SOD activities, IL-6 and hs-CRP were evaluated in all patients
224250567|NCT01547377|OTHER|rosuvastatin + placebo|Data from patients were obtained at beginning and after four months of treatment with 10 mg rosuvastatin, concomitantly with zinc (30mg/d) and selenium (150μg/d) supplementation or placebo. The anthropometric and dietary data, zinc and selenium concentrations in plasma and erythrocyte, lipid profile, electronegative LDL (LDL(-)), anti- electronegative LDL, Ac-LDL(-) immune complexes, GPx and SOD activities, IL-6 and hs-CRP were evaluated in all patients
224250568|NCT01559428|DIETARY_SUPPLEMENT|Plant sterol-enriched margarine|Daily consumption of 20 gram of a plant sterol-enriched margarine (providing daily 3.0 gram of plant sterols), for a period of 4 weeks. At the end of the 4 weeks, subjects will undergo a postprandial test for 8 hours, in which 20 gram of the plant sterol-enriched margarine is consumed together with a high-fat milkshake
224250569|NCT01559428|DIETARY_SUPPLEMENT|Plant stanol-enriched margarine|Daily consumption of 20 gram of a plant stanol-enriched margarine (providing daily 3.0 gram of plant stanols), for a period of 4 weeks. At the end of the 4 weeks, subjects will undergo a postprandial test for 8 hours, in which 20 gram of the plant stanol-enriched margarine is consumed together with a high-fat milkshake
224250570|NCT01559428|DIETARY_SUPPLEMENT|Control margarine|Daily consumption of 20 gram of a control margarine, for a period of 4 weeks. At the end of the 4 weeks, subjects will undergo a postprandial test for 8 hours, in which 20 gram of the control margarine is consumed together with a high-fat milkshake
224250571|NCT04290845|BEHAVIORAL|Relief-Hybrid|A 9-week behavioral intervention for primary care patients designed to reduce depression and pain-related disability.
224250572|NCT04425447|DRUG|Tumescent local anesthesia|"Surgical disinfection of the area will be performed, skin inﬁltration with 2 mL of 1% lidocaine will be done, and wetting fluid will be used (1000 ml normal saline, 20 ml lidocaine 2%, and 1 mg epinephrine).~Infiltration will be initiated with a 25-gauge needle. The 25-gauge needles cause little discomfort and provide enough local anesthesia to allow painless, more complete infiltration using a 20-gauge spinal needle. After the glandular nipple tissue is made somewhat tumescent, a larger (20-gauge) spinal needle can be more easily passed through the otherwise dense and resistant tissue."
224250573|NCT04425447|DRUG|Thoracic paravertebral block|The paravertebral block (PVB) will be performed in the sitting position. Surgical disinfection of the thoracic paravertebral area will be done. A linear high-frequency transducer will be used. The scanning process (longitudinal out-of-plane technique) will be started at 5 to 10 cm lateral to the spinous process to identify the rounded ribs and parietal pleura underneath. The transducer is then moved progressively more medially until transverse processes are identiﬁed as more squared structure and deeper to the ribs. Once the transverse processes will be identiﬁed, skin inﬁltration with 2 mL of 1% lidocaine will be done. A 100-mm, 22 G needle will be inserted out of the plane to contact the transverse process and then walk off the transverse process 1 to 1.5 cm deeper searching for loss of resistance to inject 20 mL (5mL lidocaine 2% and 15 mL bupivacaine 0.25%) at each level of T4.
224250574|NCT04425447|DRUG|Thoracic interfascial plane block|"Total LA injected was 80 mL (10 mL lidocaine 2% and 70 mL bupivacaine 0.25%) The linear probe will be placed below the outer third of the clavicle to detect anatomical landmarks, such as the serratus anterior muscle (SAM), external intercostal muscle (EIM), pectoralis muscles, thoracoacromial artery, and second rib. A test bolus of 1-2 ml of LA will be injected; upon confirmation of diffusion of the test dose between the external intercostal muscles and the SAM, a total of 20 ml of LA will be injected. The needle will be then carefully moved in the direction of the third and fourth ribs while confirming the expansion of the fascial plane.~In the performance of the pecto-intercostal fascial plane block (PIFB), a probe will be placed parallel to the long axis of the sternum at a distance greater than 2 cm from the attachment of the second rib and sternum to identify the pectoralis muscles, EIM, and second rib. A"
224250575|NCT04133623|DRUG|Ketorolac|Administration of ketorolac 0.5 mg/kg up to 10 mg, one single dose at the enrollment. This group will receive also a placebo indistinguishable from the ibuprofen.
224250576|NCT04133623|DRUG|Ibuprofen|Administration of ibuprofen 10 mg/kg up to 600 mg, one single dose at the enrollment. This group will receive also a placebo indistinguishable from the ketorolac.
224250577|NCT03233724|DRUG|Decitabine (DAC)|Administered orally on two consecutive days (preferably Tuesday and Wednesday) for two weeks out of three weeks x 9 weeks
224250578|NCT03233724|DRUG|Tetrahydrouridine (THU)|Administered orally on two consecutive days (preferably Tuesday and Wednesday) for two weeks out of three weeks x 9 weeks
224250579|NCT03233724|DRUG|Pembrolizumab|200 mg intravenous (IV) once a day every Wednesday, Thursday or Friday every 3 weeks.
224250580|NCT00807196|DRUG|Rituximab|250mg/m2 day -21 and day -14 of preparative regimen
224250581|NCT00807196|DRUG|90Y ibritumomab tiuxetan (Zevalin)|0.4 mCi/kg IV on day -14 of preparative regimen
224250582|NCT00807196|DRUG|Cyclophosphamide|300mg/m2 IV daily for 5 days day -8 to day -4 of preparative regimen
224250583|NCT00807196|DRUG|Fludarabine|30mg/m2 IV daily for 5 days day -8 to day -4 of preparative regimen
224250584|NCT00807196|OTHER|Non myeloablative allogeneic stem cell transplantation|Blood stem cell infusion on day 0
224250585|NCT01448902|DRUG|OC000459|OC000459 200mg bid for 8 days
224250586|NCT01448902|DRUG|Placebo|Placebo bid for 8 days
224250587|NCT03509545|DRUG|CHF Patients: ER Torsemide 40 mg|ER Torsemide 40mg given once daily to CHF patients
224250588|NCT03509545|DRUG|CHF Patients: Furosemide 40 mg|Stable CHF patients taking twice-daily 40 mg Furosemide
223669582|NCT05413434|OTHER|exercise|high-intensity interval training will be performed on the treadmill.
224250589|NCT00314990|DRUG|5 mg folic acid, 50 mg pyridoxine and 0.4 mg cyanocobalamin|
224250590|NCT03373162|DRUG|onabotulinumtoxinA|This study is a pre- and post-design. One scan will be collected prior to BOTOX injection and the second will be collected 14-21 days post-injection. BOTOX injections will be limited to 20 units in the glabellar area, as approved by the FDA .
223669583|NCT05413434|DEVICE|inspiratory muscle training|Respiratory muscle strength exercise will be performed with the respiratory muscle strengthening device 'POWERbreathe Classic Light Resistance'.
223669584|NCT02592642|BEHAVIORAL|Self-management Program, Workbook, Video, Pedometer|Participants will attend 12 sessions over a six week period. The following therapies will be provided by licensed chiropractors: instruction on self-management strategies, cognitive behavioural techniques; exercise instruction, manual therapy. An instructional workbook and video will provide education and instruction on how to perform exercises, and reinforce instructions received during the sessions. An exercise diary will outline the frequency and intensity of the exercises. All exercises will be performed twice per day at home with the number, intensity, and frequency increasing weekly. Participants will receive a pedometer and record the maximum number of continuous walking steps and time (minutes) to stop walking due to neurogenic symptoms weekly.
223669585|NCT02592642|BEHAVIORAL|Instructional Workbook, Video, and Pedometer|Participants will attend one session with a chiropractor at the beginning of the six week treatment period. The chiropractor will provide and explain the instructional workbook and video. The workbook and video will provide education and instruction on how to perform exercises all aimed at improving overall fitness in the back and lower extremity and facilitate lumbar flexion. An exercise diary will outline the frequency and intensity of the exercises. All exercises will be performed twice per day at home with the number, intensity, and frequency increasing weekly. Participants will receive a pedometer and record the maximum number of continuous walking steps and time (minutes) to stop walking due to neurogenic symptoms weekly.
223669586|NCT02592642|DEVICE|Para-spinal TENS|Participants randomized to this subgroup will have disposable self-adhesive electrical pads (Blue Sensor P, Ambu A/S, Denmark) applied over the para-spinal musculature from L3 to S1 by a licensed chiropractor. The electrical pad electrodes will be connected to a TENS machine (NeuroTrac TENS from Verity Medical Ltd U.K.) which will be worn by the subject concealed within a waist pouch. The TENS will be programmed for a frequency of 65-100 Hz modulated over 3-second intervals with a pulse width of 100-200 usec, and turned on 2 minutes before the start and during the SPWT. Current intensity will be set to the level of comfort of the patient, approximately 3 milliamps in pilot experiments, and below the level causing muscle twitch.
223669587|NCT02592642|DEVICE|Para-spinal Placebo TENS|Group b: Participants randomized to this subgroup will have disposable self-adhesive electrical pads (Blue Sensor P, Ambu A/S, Denmark) applied over the para-spinal muscular from L3 to S1 by a licensed chiropractor. The electrical pad electrodes will be connected to a TENS machine \[NeuroTrac TENS from Verity Medical Ltd (U.K.)\] which will be worn by the subject concealed within a waist pouch. The TENS will be programmed using a transient placebo frequency and intensity (45) i.e. the unit will be active for the first 30 seconds then ramping down to zero stimulus over 15 seconds and worn from 2 minutes before the start and during the Self-Paced Walk Test (SPWT).
223669588|NCT02592642|DEVICE|Prototype Spinal Stenosis Belt|Participants randomized to this subgroup will be fitted with the prototype spinal stenosis belt by a licensed chiropractor. The belt is designed as garment that will snugly fit over the sacrum and pelvic girdle with a pump that place pressure over the sacrum aimed at reducing lordosis.
223669589|NCT02592642|DEVICE|Sham Spinal Stenosis Belt|Participants randomized to this subgroup will have a standard lumbar support belt (Tensor Adjustable Back Brace from 3M, 207744) fitted around the lumbar spine above the iliac crest comfortably according the manufacturer's instructions for wear. We speculate that the placement of the stenosis belt around the lumbar spine should not have any impact on the lumbar lordosis.
223669590|NCT05953441|OTHER|AI-powered doctor|AI-powered virtual doctor
223669591|NCT05953441|OTHER|Human-controlled doctor avatar|Virtual doctor avatar controlled by the medical student.
223669592|NCT05026814|OTHER|Interview after one year or more from the treatment received|Questionnaires to evaluate the satisfaction with treatment, the motivations and expectations for the treatment, the general well-being, the sexual function and the genital selfimage
224250591|NCT02388191|DRUG|Naproxen sodium|550 mg, oral, on day 1. Number of Cycles: 1
223669593|NCT05726877|OTHER|ventilation strategy|Titrating positive end-expiratory pressure
223771513|NCT02897739|BEHAVIORAL|Psychological assessment|Assessment by a psychologist
224250592|NCT02388191|OTHER|Placebo tablet|
224250593|NCT06144385|BIOLOGICAL|CAR-GPC3 T cells|Subjects will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of JWATM204 . During JWATM204 production, subjects will receive a preconditioning chemotherapy regimen of cyclophosphamide and fludarabine to deplete the lymphocytes. After lymphodepletion, subjects will receive single-dose treatment with JWATM204 by intravenous (IV) injection.
224250594|NCT00057239|DRUG|Radafaxine|
224250595|NCT03301363|DEVICE|CRT|Subjects scheduled to be implanted for CRT by a Quadripolar Pacing System
224250596|NCT03047317|BIOLOGICAL|MABp1|Single dose of intravenous MABp1
224250597|NCT02363634|DIETARY_SUPPLEMENT|magnesium threonate|nutritional product
224250598|NCT02559063|BEHAVIORAL|Vision-based speed of processing training|computerized cognitive tasks addressing vision-based speed of processing
224250599|NCT02559063|BEHAVIORAL|Mental leisure activities|computerized cognitive tasks addressing different aspects of executive function
224250600|NCT02830516|OTHER|Measurement of lung elastance by two methods|Measurement of tidal variations in esophageal pressure followed in the same patient by performing a PEEP-step while simultaneously measuring the change in lung volume
224250601|NCT03805815|DEVICE|tunable crack sensor|blood pressure monitoring via crack sensor
224250602|NCT03686033|DRUG|Placebo|Participants will receive E2082-matched placebo tablets orally.
224250603|NCT03686033|DRUG|E2082|Participants will receive E2082 tablets orally.
224250604|NCT03197883|OTHER|Test Product|Restoring lipid balm
224250605|NCT03197883|OTHER|Cleanser|Moisturizing facial cleanser
223669594|NCT02551796|PROCEDURE|lenticule extraction|Four femtosecond incisions will be created in succession: the posterior surface of the refractive lenticule (spiral in), the lenticule border, the anterior surface of the refractive lenticule (spiral out), and the corneal flap in the superior region. After the suction is released, the flap will be opened using a thin, blunt spatula and the free refractive lenticule will be subsequently grasped with a forceps and extracted, after which the flap will be repositioned carefully.
223669595|NCT02551796|PROCEDURE|laser in situ keratomileusis|During LASIK surgery, the eye will be gently proptosed and a hinged corneal flap will be cut using a microkeratome. The flap will be lifted and the stromal bed will receive a 6 mm diameter and stroma ablation. Finally reposition the flap carefully.
223669596|NCT02551796|PROCEDURE|FS assisted laser in situ keratomileusis|Track distance and spot distance will be 3.0 μm during flap creation and 1.5 μm during flap side-cutting. The flap diameter will be 8.0 mm, and flap thickness will be set to 105 μm. Side-cut angle and hinge angle will be 90°and 50° respectively. The flaps will be created by laser scanning in spirals from the periphery to the center of the pupil. An excimer laser system will be used in the subsequent ablation of thstromal bed with a 6.0 mm optical zone. Once the excimer. ablation is completed, the flap will be repositioned in a similar fashion as in routine LASIK.
224250606|NCT03197883|OTHER|Sunscreen|SPF (Sun Protection Factor) 50 sunscreen
224250607|NCT05114447|OTHER|Routine medical care|"Eligible subjects will be contacted from physicians, by telephone or directly when they attend the clinical centre for control visits. Once the patients have provided their signed informed consent, they will have to fill in the clinical form and to perform routine functional/clinical tests.~Subjects will be investigated at baseline (T0), at 6-month follow-up (T6) and at 12-month follow-up (T12).~All the possible variations that could occur in the patients' disease status and disease management, according to the routine medical care, will be registered and taken into account in the RISER study.~RISER study is not a clinical trial, but it is an observational study without any specific drug administration by the investigators. Participants will receive interventions, which can include medical products, such as drugs or devices, or procedures, as part of their routine medical care but they will not be assigned to specific interventions by the investigator as in a clinical trial."
224250608|NCT05114447|OTHER|Telephone interview|"Eligible subjects will be contacted by telephone from trained personnel of the Research Unit. Once the signed informed consent is obtained by each enrolled subject, they will be invited to answer the phone questionnaire.~Subjects will be investigated at baseline (T0) and at 12-month follow-up (T12). Subjects fitting the epidemiological definition of severe/uncontrolled asthma will be invited at the Pisa clinical centre to have routine clinical/functional tests.~Each subject performing baseline clinical/functional tests at the Pisa clinical centre will be clinically and functionally re-assessed"
223771514|NCT02923375|BIOLOGICAL|Mesenchymoangioblast-derived mesenchymal stem cells|The active agent in CYP-001 is allogeneic mesenchymoangioblast-derived mesenchymal stem cells (MCA-derived MSCs), which are produced using the proprietary Cymerus™ platform technology. Cymerus™ refers to the process of generating cell-based products from intermediate cells, MCAs, which in turn are derived from induced pluripotent stem cells or iPSCs. The iPSCs used in the Cymerus™ process were derived from blood donated by a fully-consented healthy adult donor, and were reprogrammed using a transgene-free, viral-free and feeder-free technique.
223771515|NCT01787513|OTHER|CBM|CBM is an Internet-based intervention comprised of delivery of auditory scenarios taking place over 1 week.
224250609|NCT05878483|DEVICE|Venipuncture Device (VD)|"The Venipuncture Device is a pre-market medical device that fully automates the blood drawing procedure (also called phlebotomy or venipuncture). It automatically detects a vein using near-infrared and ultrasound imaging technology, robotically inserts a needle, automatically connects blood tubes and applies pressure to the puncture site.~During the ADOPT Study, the technology is further improved over time; for example features are released (such as: automated tourniquet). Initially, several manual steps are required to be performed by a device supervisor and operator. At the final stage of the ADOPT Study, Phase C2, the device has full functionality and only limited manual steps are required to be performed by a device supervisor."
224250610|NCT01045161|DRUG|Aclidinium bromide|Aclidinium bromide 200 μg, oral inhalation twice per day 12 weeks of treatment. At week 12, patients who were on Aclidinium bromide 200 μg will receive open label 400µg aclidinium bromide for 40 weeks of treatment.
224250611|NCT01045161|DRUG|Placebo|Dose-matched placebo, oral inhalation twice per day for 12 weeks. At week 12, patients who were on placebo will receive open label 400 µg aclidinium bromide for 40 weeks of treatment
224250612|NCT00807794|DRUG|MEDI-507|0.012 mg/kg dose given twice between 60 to 72 hours apart
224250613|NCT00807794|DRUG|MEDI-507|0.06 mg/kg dose given twice between 60 to 72 hours apart
224250614|NCT00807794|DRUG|MEDI-507|0.12 mg/kg dose given twice between 60 to 72 hours apart
224250615|NCT00807794|DRUG|MEDI-507|0.24 mg/kg dose given twice between 60 to 72 hours apart (supplemental)
224250616|NCT00807794|DRUG|MEDI-507|0.50 mg/kg dose given twice between 60 to 72 hours apart (supplemental)
224250617|NCT02371486|PROCEDURE|hysteroscopic repair of cesarean section defect|Operative hysteroscopy for the repair of cesarean section defect is performed under general anesthesia. the cervix is dilated and the cesarean section defect opened. polypoid tissue is ablated
224250618|NCT02371486|PROCEDURE|Diagnostic Hysteroscopy|Betthochi's method for diagnostic hysteroscopy: No anesthesia will be used. vaginoscopy will be performed, followed by diagnostic hysteroscopy. saline will be used as a distension media. 4.2 mm Storz hysteroscope will be used.
224250619|NCT02371486|PROCEDURE|Ultrasound Scan|"Scanning the uterus with the ultrasound probe . Transvaginal ultrasound usually produces better and clearer images of the female pelvic organs, because the ultrasound probe lies closer to these structures.~The transvaginal ultrasound probe is thin, about 2cm diameter. The probe is covered with a disposable protective sheath. A small amount of ultrasound gel is placed on the end of this probe. The probe is then gently inserted a short distance into the vagina."
224250620|NCT02371486|PROCEDURE|IVF Cycle|Controlled ovarian hyperstimulation, followed by Human chorionic Gonadotropin ( hCG) administration, Ovum Pickup and Embryo transfer
224250621|NCT03677492|OTHER|Medium Supplemented with Cytochalasin D|A medium with in-house supplementation of Cytochalasin D to decrease oocyte degeneration after ICSI and improve the survival rate
224250622|NCT01299363|BEHAVIORAL|Dilator use|Women randomized to vaginal dilators will be given instructions to perform exercises with vaginal dilators from postoperative weeks 4 to 8
223669597|NCT02320201|DEVICE|Transcutaneous Electrical Nerve Stimulator (TENS)|Electrical stimulation will be applied to the foot via skin surface electrodes for a minimum of 2 hours per day for 1 week to 20 subjects.
223669598|NCT01073371|DRUG|Prilocaine|1.8mL infiltration of liposome-encapsulated 3% prilocaine, 3% plain prilocaine or 3% prilocaine with 0,03IU/mL felypressin in the buccal sulcus of the maxillary right canine
224250623|NCT04531605|BEHAVIORAL|YBank program|Adolescents participated in a 12-week peer-led life skills trainings at clinics and received financial incentives via mobile money upon clinic attendance and demonstration of suppressed viral load.
224250624|NCT06561724|DIETARY_SUPPLEMENT|Biscuits maltodextrin|Biscuits includes maltodextrin
224250625|NCT06561724|DIETARY_SUPPLEMENT|Biscuits includes prebiotics tartoufa inulin|Biscuits prebiotics
224250626|NCT06561724|DIETARY_SUPPLEMENT|Biscuits includes prebiotics chicory inulin|Biscuits prebiotics
224250627|NCT06533345|BEHAVIORAL|Behavior Change Coaching|Done by Dr. Hollingsworth or students via consultations with participants. Participant's health behavior aspirations or target outcomes will be clarified, informed by the participant's interactions with other MERCI providers. Behaviors that move the participant towards their aspirations/outcomes will be explored to find target behaviors that the participant is motivated and able to do. Target behaviors and supporting habits will be designed into the participant's existing routine. The Fogg Behavior Model will be used 1) to find the participant's primary motivation for engaging in target behaviors and 2) to make target behaviors easier to do. Implementation intentions - When/then or If/then plans - will be used to form habits and promote behavior engagement. Adopting a growth mindset will also be discussed. Subsequent consultations will focus on troubleshooting, iterative improvements, and incorporation of new aspirations/outcomes, target behaviors, and supporting habits.
224250628|NCT06533345|BEHAVIORAL|Nutrition|Nutrition: The nutrition intervention will be conducted as a 12-week protocol with assessment points at baseline, 1 month, and 3 months. Following consent, eligible participants will work through a self-taught educational module detailing the anti-inflammatory dietary program. Once the module is completed, participants will be scheduled for one-on-one counseling sessions with a Registered Dietitian or a supervised Dietetic Intern or Medical Student on the research team to receive personalized guidance on implementation of the dietary intervention. A dietary recall will be conducted via the automated self-administered dietary assessment tool (ASA24®), which takes about 20 minutes to complete. This survey will be conducted on two non-consecutive days at each timepoint (baseline, 1 month, and 3 months).
224250629|NCT06533345|OTHER|Autonomic Recalibration|Participant will be outfitted with the Empatica wrist sensor. An initial history to rule out pathology and document a chief complaint relevant to pain is conducted. An initial head to toe assessment of withdrawal or startle reflex behavior in response to palpation is performed to identify trigger points and establish patterns of sympathetic dominance. The pattern of sympathetic dominance is addressed during treatment by Primal Reflex Release Technique Protocol to inhibit somatic afferent feedback loops and rebalance the autonomic nervous system towards a state of parasympathetic dominance. Day 2 is the same until the initial history and r/o. Here, the history is from the previous day, asking about perception of pain, sleep, digestion, or other pertinent issues brought up on the first visit. Treatment proceeds same as Day 1. Any emotional tags to trigger points are identified and acknowledged. Subjects may be scheduled for follow-up visits if their pain persists.
224250630|NCT06533345|PROCEDURE|Dry Needling|An initial history to document a chief complaint relevant to pain is conducted and to identify and potential contraindications (infection of overlying skin, patient on anticoagulation drugs, 1st trimester of pregnancy, etc.) A physical exam is performed to identify the trigger points causing pain. The subject is educated about the risks/benefits/indications and alternative treatments. The subject is also educated about dry needling aftercare. The skin over the trigger points is cleaned with 70% isopropyl alcohol. The pertinent trigger points are treated with dry needling (95% of time), direct inhibition (2 - 3% of time) or injection of 1% lidocaine in a fan-like fashion (1 - 2 % of the time). Subject is assessed for any bleeding. An office note, including a procedure note, is documented in the subject's record. Subject is scheduled for additional follow-up meeting.
224250631|NCT06533345|OTHER|Osteopathic Manipulative Treatment|Osteopathic Manipulative Treatment: After inform and consent process, the subject will enter patient room and meet with Dr. Hayes, who will conduct a brief history of patient pain, injuries, and procedures. Subjects will be asked to wear, or change into, athletic shorts or a tank top or loose-fitting T-shirt to facilitate treatment. Subject will undergo a brief somatic dysfunction screen, which involves light tough and manipulation. Once Hayes has diagnosed potential dysfunctions, he will proceed with osteopathic manipulative treatment. Treatment will last anywhere from 15 minutes to 1 hour. At the end of the treatment, subjects will be scheduled for a follow-up visit.
224250632|NCT06533345|BEHAVIORAL|Counseling Psychology|Psychoeducation Workshop and Counseling: The psychoeducational group intervention will be done according to the standardized Empowered Relief (Darnall et al., 2024) protocol. Empowered Relief is a single-session, 2-hour group workshop (online or in person) that teaches participants pain neuroscience education, mindfulness principles, and cognitive-behavioral skills. During the program, participants will complete a personalized plan to work toward pain relief. This program requires a certified instructor; Marilyn Cornish (Co-I), a licensed psychologist, is certified. After completion, participants can attend up to 4 individual counseling sessions with a counseling psychology doctoral student (supervised by Marilyn Cornish). Sessions will be approximately 50-60 minutes and will occur every other week. Specific in-session interventions will be tailored to the participant's unique needs but will focus on participants' pain relief plan and overall psychological wellbeing of participants.
224250633|NCT06533345|OTHER|Multiple Treatments|"Subjects receiving multiple treatment interventions over the same period of time.~Example: A subject joins the Osteopathic Manipulative Treatment group and meets with Dr. Hayes for treatment visits. At the same time, they are meeting with Dr. Kirby in a separate visit (or at the same time, if scheduling allows) to discuss Nutrition. Any subjects who were in multiple/overlapping treatment groups will fit this description."
224250634|NCT03031847|DEVICE|Cardiac Resynchronization Therapy Pacemaker|Patients randomized to the pacemaker arm will receive a CRT-P device.
223669599|NCT05073094|DRUG|Esmolol|Esmolol injected intravenously and added to cardioplegia solution
223669600|NCT05073094|DRUG|Placebo|Equivalent volume of placebo (saline) as a bolus before aortic cross-clamping and in the cardioplegic solution
223669601|NCT00126880|DRUG|AVX754|apricitabine, 600mg BID or 800mg BID
224250635|NCT03031847|DEVICE|Cardiac Resynchronization Therapy Defibrillator|Patients randomized to the defibrillator arm will receive a CRT-D device.
224250636|NCT04841317|COMBINATION_PRODUCT|Mobile technology intervention|Home blood pressure cuff used by patients twice a week, with blood pressures transmitted to providers remotely
224250637|NCT02596100|DRUG|Betrixaban|
224250638|NCT04916548|DRUG|Intravenous Ketamine|Single infusion of intravenous racemic ketamine (0.5mg/kg over 40min)
224250639|NCT00987103|DRUG|Tacrolimus|Oral: 0,1 mg/kg Rectal: 15 mg Sublingual: 0,04 mg/kg
224250640|NCT01353664|DRUG|Romidepsin|The participants will generally continue at the same dose, infusion time and frequency used for the last dose of romidepsin given in the preceding romidepsin study. If the participant entered this rollover study in the middle of a cycle, then the cycle number and cycle day will be carried over from the preceding romidepsin study.
224250641|NCT04294108|OTHER|Prolong in-hospital stay|Patients have a longer length of hospital stay than the common recommendation.
224250642|NCT00688571|DEVICE|Melody Transcatheter Pulmonary Valve|Transcatheter valve implantation into a RV-PA conduit in patients with complex congenital heart defects where the conduit has become dysfunctional and where the patient needs intervention
223669602|NCT00126880|DRUG|3TC|3TC, 150mg BID
224250643|NCT00046527|DRUG|ABI-007|
224250644|NCT04484545|DIAGNOSTIC_TEST|Prognostic score|Validation of scores of systemic inflammatory response
224250645|NCT01964092|BEHAVIORAL|Individual Placement and Support|
224250646|NCT01964092|BEHAVIORAL|Ordinary employment schemes|
223669603|NCT02901327|PROCEDURE|Lumbar Stabilisation Exercise|"McGill protocol starting with:~1. 'cat-camel' exercise exercise 10 repetitions with 7 seconds hold each~2. 'curl-up' exercise 10 repetitions with 7 seconds hold each~3. 'side-bridge' exercise 10 repetitions with 7 seconds hold each~4. 'cat-camel' exercise 10 repetitions with 7 seconds hold each progression was based on subjects' tolerance and endurance."
223669604|NCT02901327|PROCEDURE|treadmill walk exercise|"Bruce protocol~This include:~1. '5 minutes warm up' at zero degree inclination.~2. '20 minutes active exercise with increasing speed and inclination'~3. '5 minutes cool down'"
223669605|NCT03099343|BEHAVIORAL|Location-based Tailored Messaging|The mobile application works by providing tailored messages targeted to participant locations that can help individuals to choose lower sodium foods.
223669606|NCT04951323|DRUG|anti-COVID19 mRNA-based vaccine (BNT162b2, Comirnaty®, commercialized by Pfizer)|Participants will receive the COVID-19 mRNA Vaccine BNT162b2 (Comirnaty®). The vaccine is administered intramuscularly after dilution as a series of two doses at least 21 days apart.
224250647|NCT03549364|BEHAVIORAL|Endurance Race|1 CT and lab tests, 2 CT and lab tests within 24h of a race, 3 follow up investigations 1-2 weeks after the race with CT and lab tests
224250648|NCT01165905|DRUG|ON 01910.Na|The starting dose of ON 01910.Na is 250 mg/m2 as a 24 hour intravenous (i.v.) infusion on days 1, 8 and 15 of a 28-day course. The dose of ON 01910.Na will be escalated in increments in successive cohorts (dose level (DL) 1 = 250 mg/m2, DL 2 = 650 mg/m2, DL 3 = 1050 mg/m2, DL 4= 1350 mg/m2) of new patients. A course is defined as 4 weeks in length.
224250649|NCT01165905|DRUG|Gemcitabine|The dose of gemcitabine will be fixed at 1000 mg/m2 i.v. as a 30 minutes infusion on days 1, 8, and 15 every 28 days.
224250650|NCT04874545|DRUG|Propofol|Total intravenous inhalational anesthesia
224250651|NCT02313064|DRUG|CXA-10|Part A has sequential single ascending doses will be administered in up to 5 cohorts of subjects. Each cohort of subjects will be randomized to receive a single dose of CXA-10 or placebo in, a fasted state. Part B has 2 periods and subjects will receive two doses of the selected dose of CXA-10.
224250652|NCT02313064|DRUG|CXA-10 placebo|
224250653|NCT04236401|PROCEDURE|electrosurgery will be used for abdominal incision|electrosurgery will be used to open anterior abdominal wall and electrosurgery will be used for heamostasis also
224250654|NCT04236401|PROCEDURE|scalpel will be used for abdominal incision|scalpel will be used for abdominal wall incision and thread will be used for haemostsis
224250655|NCT04168346|DRUG|Ferric carboxymaltose|Ferric carboxymaltose iv infusion
224250656|NCT04168346|DRUG|Placebos|NaCl 0.9% infusion
224250657|NCT01592578|PROCEDURE|Ligation and Cyanoacrylate|Patients will be treated with ligation for esophageal varices and cyanoacrylate for gastric varices when necessary.
224250658|NCT01592578|PROCEDURE|Ligation plus Sclerotherapy and Cyanoacrylate Group|Patients will receive sclerotherapy after first ligation for esophageal varices and cyanoacrylate for gastric varices when necessary
224250659|NCT06366477|DEVICE|Vibration stimulation combined with task-oriented training|Participants with chronic stroke underwent 24 sessions of vibration stimulation combined with task-oriented training over 12 weeks, in addition to regular therapy.
224250660|NCT01417390|DRUG|Drug: Gemcitabine and cisplatin|Patients receive Gemcitabine (1000mg/m2 on day 1,8) and cisplatin (20mg/m2 on day 1-4) every three weeks for two cycles before the radiotherapy, then receive radical radiotherapy with IMRT and cisplatin (40mg/m2) every week for six cycles during radiotherapy.
224250661|NCT01417390|DRUG|Cisplatin|Patients receive radical radiotherapy and cisplatin (40mg/m2) every week for six cycles during radiotherapy
224250662|NCT02612337|DRUG|OTO-104|Single intratympanic injection of 12 mg OTO-104
224250663|NCT02612337|DRUG|Placebo|Single intratympanic injection of placebo
224250664|NCT00000194|DRUG|Cycloserine|
224250665|NCT00000697|DRUG|Foscarnet sodium|
224250666|NCT03726151|BEHAVIORAL|Parent Reminders|Automated, system-generated mailed or text message reminders
224250667|NCT03726151|BEHAVIORAL|Multicomponent clinic-system strategies|"1. Workflow modifications to reduce missed opportunities for vaccination~2. Provider- and clinic-level audit and feedback~3. Provider \& staff training on workflow modifications and communication strategies"
224250668|NCT03726151|BEHAVIORAL|Combined Condition|Parent reminders and multicomponent clinic-system strategies
224250669|NCT01714570|DRUG|Piperacillin-tazobactam combination product|4.5g q6h, 5-10 days
224250670|NCT01714570|DRUG|Imipenem|0.5g q6h, 5-10 days
224250671|NCT04473170|BIOLOGICAL|Autologous Non-Hematopoietic Peripheral Blood Stem Cells (NHPBSC)|SENTAD-COVID Study intervention consists of Autologous Non-Hematopoietic Peripheral Blood Stem Cells (NHPBSC) therapy through jet nebulization in addition to standard care. The NHPBSC were characterized as CD90+, CD133+, Oct-4+ (pluripotent markers), and CD45-, CD71-, based on multiparameter flow cytometry.
224250672|NCT04473170|DRUG|COVID-19 standard care|UAE National Guidelines for Clinical Management and Treatment of COVID-19.
224250673|NCT04668105|OTHER|High volume nordic hamstring exercise|To perform Nordic Hamstring Curls, the person will kneel on a pad (for knee comfort) and lower under control, his ankles must be stabilized and kept in a place with the help of a partner, but can also use a moveable object or a loaded barbell can also be used to achieve the stability. The person must then extend his hamstrings in order to lean forward, he should lean forward from the knee and not from the hip. The movement must be kept controlled and slow. The person should go as forward/low as possible but without the help of hands or arms. The only time one can put his hands in front of him is when he can't rely on his legs and then push himself back to starting position and then repeat the procedure again.Group 1 will do the Nordic hamstring exercise with protocol 3 repetitions × 3sets× 3 times for 4 weeks.
224250674|NCT04668105|OTHER|Low volume nordic hamstring exercise|To perform Nordic Hamstring Curls, the person will kneel on a pad (for knee comfort) and lower under control, his ankles must be stabilized and kept in a place with the help of a partner, but can also use a moveable object or a loaded barbell can also be used to achieve the stability. The person must then extend his hamstrings in order to lean forward, he should lean forward from the knee and not from the hip. The movement must be kept controlled and slow. The person should go as forward/low as possible but without the help of hands or arms. The only time one can put his hands in front of him is when he can't rely on his legs and then push himself back to starting position and then repeat the procedure again. Group 2 will do the Nordic hamstring exercise with protocol 3 repetitions × 3 sets × 1 times for 4 weeks.
224250675|NCT00803491|OTHER|Problem based learning|Group sessions under supervision from a nurse. Each group including 8 subjects. 10 occasions during a period of one year.
224250676|NCT00803491|OTHER|Traditional rheumatology care.|Individually base.
224250677|NCT03661593|OTHER|Cataract guideline|The patients gets an IOL according to cataract guideline correcting the ametropia
224250678|NCT05314023|BIOLOGICAL|9vHPV vaccine|A 9-valent HPV vaccine (Types 6, 11, 16, 18, 31, 33, 45, 52, and 58) will be administered as a 0.5 mL IM injection.
224250679|NCT00002047|DRUG|Zidovudine|
224250680|NCT03300934|DEVICE|closed loop glucose control system|Cross over between Closed loop glucose system with DANA pump, Navigator II CGM and Cambridge AP algorithm FD2A, versus usual CSII pump treatment
224250681|NCT00799656|DRUG|ataciguat (HMR1766)|oral administration 200mg once daily for 28 days
224250682|NCT00799656|DRUG|placebo|oral administration once daily for 28 days
224250683|NCT01083277|DEVICE|variable ventilation|In variable ventilation, the tidal volume on the Puritan-Bennett 840 ventilator will be randomly varied by 40% on a breath-by-breath basis around a pre-set mean, using the variable ventilation software developed by Dr. Bela Suki and Dr. Arnab Majumdar. In conventional ventilation, the tidal volume on the Puritan-Bennett 840 ventilator will be set to equal the mean tidal volume used in variable ventilation and does not vary.
223669607|NCT05198544|DEVICE|Hēlaquis Matrix is a hyaluronic acid matrix (HaM)|Hēlaquis Matrix is a hyaluronic acid matrix (HaM) derived from the American Alligator and indicated for the treatment of chronic wounds. Hyaluronic Acid (HA) is a naturally occurring non sulphated glycosaminoglycan consisting of a linear sequence of D-glucuronic and N -acetyl-Dglucosamine. It is present in connective tissue and plays a role in several biological processes including tissue repair.
223669608|NCT02199327|DRUG|Mitomycin C|Patients treated with mitomycin will be handled by cycles until resolution of the lesion, which according to previous studies is expected between 3 and 6 cycles (between half months and 3 months).
224250684|NCT01083277|OTHER|Conventional ventilation|tidal volume will be set as the patient's baseline tidal volume prior to study entry and will not vary.
224250685|NCT02242201|DRUG|PNB Bupivacaine|Infusion
224250686|NCT02242201|DRUG|PAI Ropivacaine|Injection
223669609|NCT02199327|DRUG|Interferon Alfa-2b|Patients managed with interferon will be treated for a period ranging from one month to 12 months according to clinical resolution of the lesion. Both groups will be evaluated by at least one year after the resolution of the lesion to determine the presence of recurrences
224250687|NCT02242201|DRUG|PAI liposomal bupivacaine|Injection
224250688|NCT02242201|DRUG|Epinephrine|Injection, weight-based dosage of 100 mcg - 300 mcg
224250689|NCT02242201|DRUG|Ketorolac|Injection, 30 mg
224250690|NCT03262688|DRUG|Bupivacaine HCl collagen-matrix implant|Placement of the bupivacaine collagen-matrix in the surgical site
224250691|NCT03262688|DRUG|Bupivacaine HCl infiltration|Infiltration of the surgical site
224250692|NCT00011570|DEVICE|Bladder & Bowel Control|
224250693|NCT01802853|DRUG|RO6811135|Single subcutaneous dose
224250694|NCT01802853|DRUG|RO6811135|Single intravenous dose
224250695|NCT00408070|DRUG|Bevacizumab|cycle 2 (6 cycles re-evaluated and follow up)
224250696|NCT00408070|DRUG|Carboplatin|cycle #1 and continuous through entire regimen; treated every 3 weeks
224250697|NCT00408070|DRUG|Paclitaxel|cycle #1 and continuous through entire regimen; treated every 3 weeks
224250698|NCT02356354|PROCEDURE|Skin biopsy|2 biopsies are done on the same patient : 20 cutaneous biopsies from post-burn scar and from healthy skin
224250699|NCT05844553|DEVICE|Measurement of inhaled measuring hydrogen peroxide in exhaled breath|Participant exhales in to device
224250700|NCT05283070|OTHER|Questionnaires, physical tests, and heart rate variability measures|"The 2MWT will be conducted in an unobstructed hallway with patients being asked to walk at moderate intensity (brisk walk) for the duration of the activity (2 minutes). The amount of distance in metres will be recorded.~The EMLi movement consists of pushing a 2kg weighted ball from the chest level forward, and then raising the ball overhead, before returning it to the starting position (Figure 1). The number of repetitions done at moderate intensity will be recorded after 60 seconds.~HRV and questionnaires previously listed"
224250701|NCT03038009|DRUG|Pantoprazole|Pantoprazole (40mg qd) will be concomitant used with DAPT
223669610|NCT04288232|DRUG|Aflibercept Injection [Eylea]|Intravitreal aflibercept Injection 2.0mg/0.05 ml
224250702|NCT03637153|OTHER|Assessment at Low Altitude (470m above sea level)|Assessment at Low Altitude (in Zurich; 470m above sea level) in order to compare this data with High altitude exposure
224250703|NCT03637153|OTHER|Exposure to High Altitude (2500m above sea level)|Exposure to High Altitude (Säntis; 2500m above sea level) for approximately 5 hours
224250704|NCT00590408|DIETARY_SUPPLEMENT|coenzyme Q10|60mg capsule twice daily for 12 weeks
224250705|NCT00590408|DIETARY_SUPPLEMENT|matching placebo|matching placebo capsule twice daily for 12 weeks
223669611|NCT03916107|PROCEDURE|Levator muscle and tarsus resection|Shortening the levator muscle with resection of tarsus to correct severe ptosis
223669612|NCT03916107|PROCEDURE|Frontalis flap|Using frontal muscle flap to correct severe ptosis
223669613|NCT03288792|DEVICE|RI8 device imaging|RI8 Device imaging for adjunctive detection of breast cancer
223669614|NCT02213133|DRUG|Selinexor (KPT-330)|Oral tablet or suspension at 60, 80, 100 or 120 mg per patient-specific body surface area category. Dosing will occur twice weekly in 28-days cycle.
223669615|NCT03196388|DRUG|Enzalutamide|"Radiation: External Beam Radiation Dose will be normalized such that exactly 98% of the PTV (planned target volume) receives the prescription dose and will be scored as per protocol. The maximum allowable dose within the PTV is 107% of the prescribed dose to a volume that is at least 0.03 cc. The minimum allowable dose within the PTV is \>95% of the prescribed dose to a volume that is at least 0.03 cc.~EBRT shall receive prescription doses to the PTV 70 Gy delivered in 2.5 Gy"
223669616|NCT02991989|BEHAVIORAL|Exercise Snacking|"Each bout of exercise snacking consists of 5 exercise. Each exercise is performed for one minute, with aim of completing as many repetitions as possible of that exercise in that minute. One minute of rest is observed between each exercise of the exercise snack. The five exercises are; sit-to-stand from a chair, marching on the spot, seated knee extensions alternating legs, standing knee bends alternating legs, and standing calf raises. The sit-to-stand exercise is always performed first, with the number of repetitions achieved recorded, and subsequent exercises performed in any order without recording of repetitions.~Two exercise snacks are completed each day for 28 days; once in the morning and once in the evening, or at least separated by 2 hours."
224250706|NCT01374750|DRUG|Sirolimus|Sirolimus
224250707|NCT01374750|DRUG|m-TOR inhibitor free|calcineurin inhibitors
224250708|NCT01895205|DRUG|Iron isomaltoside 1000|
224250709|NCT01895205|DRUG|Red blood cell transfusion|
224250710|NCT04023539|DIETARY_SUPPLEMENT|Cinnamomum zeylanicum|Capsules of 2 g cinnamomum zeylanicum orally
224250711|NCT04023539|OTHER|Placebo|Placebo capsules
223669617|NCT02991989|DIETARY_SUPPLEMENT|Yogurt|Participants are asked to consume 150 g of yogurt (Arla, Skyr- natural flavour) with their breakfast meal. Participants may substitute the yogurt for another part of their regular breakfast, or add the yogurt to their regular breakfast, with participants asked to record a log book of daily yogurt consumption and to complete a three day food diary during the last week of the 28 day intervention period.
223669618|NCT06275633|DRUG|Levodopa|Medicine response
223669619|NCT01844479|DEVICE|diabetic foot orthotic|The Dynamic Foot Orthosis (DFO) is designed with a rolling link mechanism at the distal 3rd to reduce sliding friction at the metatarsal heads in addition to decreasing compressive forces. The relative sliding motion of two compliant surfaces over each other allows some deformation horizontally and lowers frictional resistance. The DFO addresses the friction element by accommodating the normal sliding and rolling motion at the distal 3rd of the foot during gait. Additionally, the DFO has a silicone layer at the metatarsal head and the remainder of the anterior section made of 2 separated orthotic layers that slide over each other. This provides an articulating surface to provide a relative motion between the orthotic segments while transmitting load.
223669620|NCT01844479|OTHER|Standard innersole|
223669621|NCT00157287|PROCEDURE|Evidence based weaning protocol|
223669622|NCT02208778|DRUG|Duloxetine|54 participants will be allocated for duloxetine treatment
223669623|NCT02208778|DRUG|Remifentanil|27 participants will be allocated to Remifentanil infusion
223669624|NCT02208778|DRUG|Placebo (for Remifentanil)|Placebo comparator to Remifentanil treatment. 27 participants will be allocated to this arm
223669625|NCT02208778|DRUG|Placebo (for Duloxetine)|Sugar pill manufactured to mimic Duloxetine 30mg. 27 participants will be allocated to this intervention
223669626|NCT02779361|DIETARY_SUPPLEMENT|Green tea|"Lipton pure green tea, 5 teas on the first 6 days, and 9 teas on the day 7. Teas will be ingested at 08:00 am, 10:30 am, 13:00 pm, 15:30 pm, 18:00 pm days 1-6, and 08:00 am (\*), 10:30 am, 13:00 pm (\*), 15:30 pm, 18:00 pm (\*), 20:30 pm on day 7.~One bag of tea will be used to prepare the beverages with exception of some beverages on day 7 that will be prepared with two bags (\*)."
224250712|NCT04048317|DRUG|HepaSphere Microspheres/Doxorubicin Hydrochloride|"evaluation the tumor (size, location and pattern of enhancement) ;and ensure portal vein patency; then evaluation of hepatic arterial anatomy, after that we determine the tumor arterial feeders and the arteries that should be avoided during the maneuver.~Selective celiac and superior mesenteric angiograms were performed using 5 Fr. Catheter then superselective angiogram were used microcatheter. then injection of drug-eluting microsphere (25 mg Hepasphere 50-100 micron) loaded with 50 mg doxorubicin solution for 2 hours."
224250713|NCT04048317|DRUG|Lipiodol|"evaluation the tumor (size, location and pattern of enhancement) ;and ensure portal vein patency; then evaluation of hepatic arterial anatomy, after that we determine the tumor arterial feeders and the arteries that should be avoided during the maneuver.~Selective celiac and superior mesenteric angiograms were performed using 5 Fr. Catheter then superselective angiogram were used microcatheter. then injection of prepared mixture of Lipiodol and (Doxorubicin or 5-FU) vary in dosage depend on operator consideration"
224250714|NCT06176326|OTHER|Ethics Education Program in Nursing|In the 7-session training program, each session, lasting 2 hours, presented to students the topic headings determined through the needs analysis of the program development study. This education program consists of sessions on the Introduction to Ethics-Bioethics, Principles of Beneficence and Non-maleficence, Autonomy and Responsibility, Informed Consent and Those Lacking Capacity for Consent, Respect for Human Vulnerability and Individual Integrity, Respect for Private Life and Ensuring Confidentiality, Discrimination, Stigmatization, and Cultural Diversity.
224250715|NCT03938402|OTHER|Positive end-expiratory pressure|Different levels of positive end-expiratory pressure (i.e., 5, 10 and 15 cm H2O) will be applied to the groups.
224250716|NCT05378360|BIOLOGICAL|DWP708|Placebo Comparator: Placebo of DWP708 / BID / up to 28 days Experimental: DWP708 10 ug/g / BID / up to 28 days Experimental: DWP708 20 ug/g / BID / up to 28 days Experimental: DWP708 40 ug/g / BID / up to 28 days
224250717|NCT02946125|COMBINATION_PRODUCT|MDD-administered EYN-1601|Phenylephrine hydrochloride ophthalmic solution 10% formulated for microdose spray delivery
223669627|NCT03746288|DRUG|CAN008|CAN008 400 mg weekly over no less than 30 minutes via intravenous drip, followed by rRT that same day
223669628|NCT04691947|BIOLOGICAL|ERUCOV-VAC|Vaccination on Day 0 and Day 21
223669629|NCT04691947|OTHER|Placebo Vaccine|Placebo Vaccination on Day 0 and Day 21
223669630|NCT05614167|OTHER|correlation|A total of 97 children with CP between the ages of six and 12 years participated in the study. Muscle strength was measured with a handheld dynamometer. Motor function in children with CP was classified with the Gross Motor Function Classification System (GMFCS), graded with the Gross Motor Function Measure (GMFM)
223669631|NCT02012582|DRUG|VAS203|i.v. infusion
224250718|NCT02946125|DRUG|Phenylephrine 2.5% Eyedrop|Phenylephrine hydrochloride ophthalmic solution 2.5% eyedrop
223669632|NCT02012582|DRUG|Saline|i.v. infusion
223669633|NCT01929941|DRUG|INCB047986|Initial cohort dose of INCB047986 monotherapy at the protocol-specified starting dose, with subsequent cohort escalations based on protocol-specific criteria
223669634|NCT01929941|DRUG|INCB047986|INCB047986 tablets administered orally at the protocol specified dose and frequency
223669635|NCT01929941|DRUG|Gemcitabine|Gemcitabine administered intravenously over 30 minutes at the protocol-specified dose and frequency
223669636|NCT01929941|DRUG|nab-paclitaxel|nab-paclitaxel administered intravenously over 30 minutes at the protocol-specified dose and frequency
223669637|NCT00704275|DRUG|0.05% cyclosporin eye drop|bid dosage for 4 months
223669638|NCT00865423|DRUG|Gabapentin 800 mg Tablets, single dose|A: Experimental Subjects received Purepac formulated products under fasting conditions
223669639|NCT00865423|DRUG|NEURONTIN® 800 mg Tablets, single dose|B: Active comparator Subjects received Parke-Davis formulated products under fasting conditions
223669640|NCT01374035|OTHER|Quality improvement intervention|A complex intervention will be implemented within the group of GPs in the intervention group. It includes participation in defining criteria for good referral letters, information about the correlation between information in the referral letters and outcome, introduction to the guideline, and consecutive feedback on own preformance regarding content of referral letter and outcome for the patient.
223669641|NCT06405945|GENETIC|PCR and sequence|sequence the mutatation SNPs
223669642|NCT01229917|OTHER|Fruit juice with Lactobacillus rhamnosus GG, version 1|
223669643|NCT01229917|OTHER|Fruit juice with Lactobacillus rhamnosus GG, version 2|
223669644|NCT01229917|OTHER|Standard fruit juice|
224250719|NCT02946125|DRUG|Phenylephrine 10% Eyedrop|Phenylephrine hydrochloride ophthalmic solution 10% eyedrop
224250720|NCT03700242|BIOLOGICAL|HDCV|Pharmaceutical form:Solution for injection Route of administration: Intramuscular
224250721|NCT03700242|BIOLOGICAL|HDCV|Pharmaceutical form:Solution for injection Route of administration: Intradermal
224250722|NCT03700242|BIOLOGICAL|PVRV|Pharmaceutical form:Solution for injection Route of administration: Intramuscular
223669645|NCT01277003|DEVICE|Aculife Magnetic Wave Therapist|two therapeutic points, each for 15 minutes
223669646|NCT01277003|DEVICE|TENS|tow therapeutic points, each for 15 minutes
223669647|NCT00802815|DRUG|Etanercept|50 milligrams subcutaneously every week
223669648|NCT06292611|DEVICE|Battery operated toothbrush|Device on extrinsic stain removal efficacy
223669649|NCT06292611|DEVICE|Manual toothbrush|Device on extrinsic stain removal efficacy
223669650|NCT01883856|DEVICE|Silicone plate Ahmed Glaucoma Valve (Model FP7)|This intervention is conducted as a surgical intervention.
223669651|NCT01883856|DEVICE|Porous Plate Ahmed Glaucoma Valve (Model M4)|This intervention is conducted as a surgical intervention.
223669652|NCT05651204|DIAGNOSTIC_TEST|GABA Blood Level|Blood specimens will be collected by a registered phlebotomist according to hospital's specimen collection procedures.
223669653|NCT01794195|BEHAVIORAL|Diffusion tensor imaging and fibres tracking|
223669654|NCT04863183|BIOLOGICAL|CELLISTEM-OA|The intra-articular puncture will be performed by an orthopedic doctor specializing in knee and hip treatments. The procedure will be carried out using sterile technique, after cooling the skin with local ice.
223669655|NCT04863183|DRUG|Triamcinolone acetonide|The intra-articular puncture will be performed by an orthopedic doctor specializing in knee and hip treatments. The procedure will be carried out using sterile technique, after cooling the skin with local ice.
223669656|NCT02846298|BIOLOGICAL|Drug Monitoring|Evaluation of Pharmacokinetic / Pharmacodynamic Data and Interest Individualized Therapeutic Drug Monitoring Glycopeptides and β-lactam-aminoglycoside ICU
223669657|NCT00557817|DRUG|Darbepoetin alpha (Aranesp)|Darbepoetin alpha (Aranesp) will be administered subcutaneously (s.c.) at the dose of 300 µg. The first dose will be given on day 28 and the following doses at 2-week intervals around days 42, 56, 70, 84, 98 and 112 post-transplant. Once the target Hb (13 g/dL) has been attained, the dose of Aranesp will be reduced by half to 150 µg. If the Hb increases to \> 14 g/dL, Aranesp will be withheld and resumed at the dose of 150 µg when the Hb decreases \< 13 g/dL. If the Hb decreases to \< 12 g/dL, the dose of Aranesp will be increased to 300 µg again.
224250723|NCT03700242|BIOLOGICAL|PVRV|Pharmaceutical form:Solution for injection Route of administration: Intradermal
224322020|NCT01709539|PROCEDURE|Diagnostiskt Centrum|Patients who are suspected of having cancer after investigation at the primary care center will be referred to Diagnostiskt Centrum. Each patient who is referred to Diagnostiskt Centrum will undergo the following: (1) clinical chemistry/microbiology tests; (2) medical history; (3) objective clinical examination; and (4) taking of blood samples for analysis of biomarkers. If necessary, patients will also undergo the following: (5) additional laboratory tests; (6) biopsy; (7) X-ray of painful joints; (8) CT scan of the neck, thorax, abdomen, and/or pelvis; (9) mammography and gynecological examination; (10); gastroscopy and/or colonoscopy; and (11) further investigation (e.g., PET-CT scan).
224322021|NCT00199524|DEVICE|Navigator Ureteral Access Sheath|ureteral access sheath
224250724|NCT04913909|DIETARY_SUPPLEMENT|Effects of an oral probiotic or placebo use on oral microbiota and glycemic index in Type 2 diabetic patients|"The participants were randomized to the interventional groups, probiotic or placebo, by the diabetes nurse. During the intervention period of 30 nights, the participants were asked to let one Dentoblis™ or placebo lozenge slowly melt in their mouth for one minute before going to bed and after tooth brushing. Dentoblis™, as a test lozenge, contains 4x109 CFU/g S. salivarius M18 strain isolated from a healthy oral microbiota and has been utilized as oral probiotic inhibiting dental caries-causing pathogens.~The placebo is indistinguishable in form, size, color, and taste from the probiotic lozenge, but contains no bacteria. Placebo and probiotic lozenges were equivalent to 810 mg each and containing same amount of xylitol. Both were provided by the manufacturer, Bluestone Pharma GmbH, Baar, Switzerland, in equal white containers boxes, separated by production code. Neither the investigators nor the subjects were aware of the contents of the lozenges except for the research nurse."
223669658|NCT00557817|DRUG|Iron saccharate (Venofer)|Iron saccharate (Venofer) will be administered intravenously (i.v.) at the dose of 200 mg (2 vials of Venofer) on days 28, 42 and 56 after the transplant. Venofer will be diluted in 250 ml saline and infused over 60 minutes. Iron will be omitted in patients with severe iron overload (serum ferritin \> 2500 µg/L in the absence of inflammation or liver necrosis) or elevated transferrin saturation (TS \> 60%) between days 21 and 56. No iron supplementation will be allowed in arm 1. No iron supplementation will be allowed in arm 2 before day 70 after the transplant. In arms 2 and 3, if patients have evidence of functional iron deficiency (transferrin saturation \< 20%) on day 70 or later, they will receive 300 mg of Venofer over 90 min, for a minimum of 2 doses.
224250725|NCT02541149|PROCEDURE|blood sample|
223669659|NCT05947292|PROCEDURE|Ultrasound-Guided Fascia Iliaca Compartment Nerve Block|Patient's who receive this intervention will have an ultrasound-guided fascia iliaca compartment nerve block performed in the Emergency Department.
223669660|NCT02816567|DRUG|propofol|
223669661|NCT02816567|DRUG|NMBA - cisatracurium|
223669662|NCT02816567|DRUG|placebo - isotonic saline serum|
223669663|NCT02816567|DRUG|sufentanil|
223669664|NCT02816567|PROCEDURE|laparoscopic surgery|
223669665|NCT03257917|OTHER|Understanding value in Metastatic Breast Cancer|The overall objective of this project is to gain knowledge about out-of-pocket (OOP) expenses and lost opportunity costs among metastatic breast cancer (MBC) patients. To achieve this objective, MBC patients will be asked to participate in a short, 37-question survey asking questions about the financial burden, OOP expenses, and opportunity costs related to their cancer care.
223669666|NCT04740905|DRUG|Faricimab|Faricimab will be administered by intravitreal (IVT) injection as specified in each treatment arm.
223669667|NCT04740905|DRUG|Aflibercept|Aflibercept 2 mg will be administered by IVT injection once every 4 weeks (Q4W) from Day 1 through Week 20 (a total of 6 injections).
223669668|NCT04740905|PROCEDURE|Sham Procedure|The sham is a procedure that mimics an intravitreal (IVT) injection, but involves the blunt end of an empty syringe (without a needle) being pressed against the anesthetized eye. It will be administered to participants in both treatments arms at applicable visits to maintain masking.
223669669|NCT02700503|BEHAVIORAL|Encourage 2.0|Participants will be enrolled in the ENCOURAGE 2.0 family-based diabetes prevention intervention that was designed through our work in Aims 1 and 2 of the study. It is this modified population-level ENCOURAGE 2.0 family-based diabetes prevention intervention that will be studied.
223669670|NCT06085976|DRUG|Octreotide|"A loading dose of 100 mcgr of octreotide will be administered in the intervention group, diluted in 100 ml of SSF to be passed in 30 minutes.~Subsequently, it will be administered in continuous perfusion at 25 mcgr/h in the intervention group.~The drug can be administered through a peripheral or central venous line at the choice of the anesthesiologist, since the drug has a density that allows its administration by both routes."
223669671|NCT06085976|OTHER|Placebo|In the case of the control group, 100 ml of SSF will be administered to be passed in half an hour and then an perfusion of SSF.
223669672|NCT05176457|OTHER|communication tool PICT'REA|"The pictograms communication tool PICT'REA will be available to patients with invasive ventilation systems preventing them from speaking"
223669673|NCT01287182|DRUG|Ateronon|Ateronon daily for 3 months
224322022|NCT02641158|OTHER|Control Group|"After screening HCV antibody positive, participants will receive an appointment and reminder card to return for their HCV RNA results. If HCV RNA positive, study staff will attempt to make an appointment for the participant's next step in the HCV continuum. If a participant attends the next step visit, the participant would be subject to whatever is the local standard of care at that clinic/agency from that point forward."
223669674|NCT03051620|DRUG|Discontinue alendronate|136 patients with osteoporosis stopping treatment with alendronate.
223669675|NCT03341780|PROCEDURE|amblyopia therapy|Any of the following amblyopia training activities may be employed during patching: board games, card games, coloring in O's, comic books, craft projects, crossword puzzles, dot-to-dot patterns, drawing, hammering nails, jacks, jigsaw puzzles, lego and other blocks, marbles, mazes, peg-board activities, perceptual materials, pickup sticks, reading, sewing, shooting games, stringing beads, throwing or hitting games, tracing, and video or computer games.
223669676|NCT00305461|DRUG|Ciclesonide|Effect of Ciclesonide on Quality of Life
223669677|NCT05262062|OTHER|Strain Counter Strain Technique|"When general or local pain began to diminish, upper trapezius , levator scapulae and SCM was placed in a position of ease and was held for approximately 20 to 30 seconds.~2\. Moderate digital pressure was applied to the identified MTrP as participants rated their level of pain on a scale ranging from 1 to 10.~3\. Ease was defined as the point at which a reduction in pain of at least 70% was achieved.~4\. Once the position of ease was identified, it was held for 20 to 30 seconds."
223669678|NCT05262062|OTHER|Muscle Energy Technique,|"After the ease position was maintained for 20 to 30sec an isometric contraction focused on the muscle fibers around the MTrP was performed.~2\. Each isometric contraction was held for 7 to 10 sec and was followed by a soft-tissue stretch for 15 seconds and then relax for 30 seconds. Each stretch was held for 30 seconds, and it was repeated 3 times during the treatment session.~3\. Treatment was performed on the 3 most painful areas between the upper border of the upper trapezius muscle, the SCM, the levator scapulae, and the SC muscle."
223771516|NCT01787513|OTHER|iCBT|iCBT is a validated online CBT treatment program for depression delivered in 6 lessons over 10 weeks.
223669679|NCT05262062|OTHER|Integrated Neuromuscular Inhibition Technique|"1. Group c will receive Combination of exercise (strain counter strain , muscle energy \& ischemic compression. In ischemic compression patient will receive compression,~2. After MTrPs identification,~3. Ischemic compression was applied in an intermittent manner for up to 2 minutes for each MTrP.~4. The pincer grasp (for the trapezius muscle and SCM) or direct digital pressure (for the levator scapulae and SC muscle) was used with the patients in either the supine position or sitting upright"
224250726|NCT00591643|PROCEDURE|Imaging, Adrenal acans|The patient will be given 5 drops of saturated solution of potassium iodide daily for 2 days prior to the study and will continue for 5 to 7 days later to minimize the radiation dose to the thyroid gland. One to 2 mCi of I 131 1,6-beta-iodomethyl-19-norcholesterol (NP-59) in 10% ethanol, 0.23% polysorbate 80 and 0.9% NaCl will be given intravenously slowly over 1-5 minutes. Anterior and posterior images of the adrenal area will be obtained 72 and 96 hours later. Additional images will be made if indicated. Each image would require 30 minutes carried out in the nuclear medicine laboratory. To verify the exact location of the adrenal glands, renal scan with 99m Tc DTPA or Mag 3 (routine nuclear medicine radiopharmaceuticals) will also be obtained whenever indicated. In some patients, dexamethasone suppression will be carried out to improve the specificity of NP 59 diagnosis for autonomous hormonal secretions by the adrenal tumors.
224250727|NCT00591643|RADIATION|(NP-59)|One to 2 mCi of I 131 1,6-beta-iodomethyl-19-norcholesterol (NP-59) in 10% ethanol, 0.23% polysorbate 80 and 0.9% NaCl will be given intravenously slowly over 1-5 minutes.
224250728|NCT03648658|DRUG|Paracetamol 120Mg/5mL Oral Suspension|The subjects will be treated with paracetamol in therapeutic doses, 15mg/kg/dose every six hour, with a maximum dosage of 1 g x 4 per day, for three consecutive days.
224250729|NCT00962260|DRUG|Plant cell expressed recombinant glucocerebrosidase (prGCD)|Intravenous infusion every two weeks at the dose level equal to each patient's previous imiglucerase dose before reduction or discontinuation due to shortage
224250730|NCT01050803|BEHAVIORAL|FDSME group|"In the intervention group, diabetes education sessions which are designed based on the Intervention Mapping will be interactive and reflection in between sessions will be encouraged. Group-based problem-solving exercises will be used during the sessions. Participants receive feedback from peers and healthcare professionals at the following sessions."
224250731|NCT01050803|BEHAVIORAL|FDSME|"In the intervention group, sessions which are designed based on the Intervention Mapping will be interactive and reflection in between sessions will be encouraged. Group-based problem-solving exercises will be used during the sessions. Participants receive feedback from peers and healthcare professionals at the following sessions."
223669680|NCT00195208|DRUG|Pantoprazole for approximately 9 weeks|
223669681|NCT01943253|DEVICE|Conventional ESD|Conventional ESD: Conventional ESD technique using IT2-Knife, Dual-Knife, Hook-Knife (Olympus Europe, Hamburg, Germany; Olympus Japan) ERBE VIO 300D (V2.1.4) RF-surgery system (ERBE Elektromedizin GmbH, Tübingen, Germany) Injection of fluid: Syringe
223669682|NCT01943253|DEVICE|Hybridknife ESD|Group 2: Water-jet assisted HybridKnife® ESD technique using HybridKnife® (Erbe Elektromedizin GmbH, Tübingen, Germany) ERBE VIO 300D (V2.1.4) RF-surgery system (ERBE Elektromedizin GmbH, Tübingen, Germany) Injection of fluid: Integrated in HybridKnife® with ERBEJet 2 water-jet surgery system (ERBE Elektromedizin GmbH, Tübingen, Germany)
224250732|NCT02464709|DRUG|Aminolevulinic Acid|A 0,25mm-thick layer of BF-200 ALA (aminolevulinic acid, Ameluz®) light sensitizer gel is applied on one randomized treatment side of face.
223669683|NCT00170690|DRUG|Treosulfan|Treosulfan 600 mg/m² p.o. on daý 1-28, 57-84, etc
223669684|NCT00170690|DRUG|Treosulfan|Treosulfan 7000 mg/m² i.v. on day 1, 29, 57 etc
223669685|NCT04023838|PROCEDURE|artery puncture and coronary angiography|We will perform coronary angiography through a Judkins 5 French diagnostic catheter and will take a basic view. At the end of the examination, the radial sheath is removed and the right conventional radial approach is performed for about 4 hours and the left snuffbox approach for about 2 hours using the compressive bandage method. The hemostatic device will use ez ClotRadial® (SOYEON medical Co., Ltd., Wonju, Korea).
223669686|NCT04811534|BEHAVIORAL|Interview|Mixed exploratory study, mixing a mainly qualitative study (semi-directed interviews) with a descriptive observational study (short self-questionnaire of the interviewees).
223669687|NCT05428878|DIAGNOSTIC_TEST|ANS Watch|"1. ANS Watch will be used to record the pulse waves~2. Constitution questionnaire will be used to measure the constitution type"
224250733|NCT02464709|DRUG|Methyl 5-aminolevulinate|A 0,25mm-thick layer of MAL (methyl 5-aminolevulinate, Metvix®) light sensitizer cream is applied on one randomized treatment side of face.
224250734|NCT04764916|DRUG|Liposomal bupivacaine|Liposomal bupivacaine will be used as adductor canal block
224250735|NCT04764916|DRUG|Bupivacaine Hydrochloride|This is the facility's standard of care medication for this procedure
224250736|NCT03608878|BIOLOGICAL|adagloxad simolenin/OBI-821|"Adagloxad simolenin (OBI-822) is a glyco-conjugated protein comprised of a carbohydrate tumor antigen. Globo H allyl glycoside is covalently linked to a carrier protein KLH, presented in a dominant trimer form with molecular weight between 1200-1395 kDa., to form Adagloxad simolenin (OBI-822) (Globo H-KLH) OBI-821 is a saponin based adjuvant structurally similar to descriptions found in the literature for another adjuvant, QS-21.~Adagloxad simolenin will be mixed with OBI-821 before administration."
224250737|NCT03608878|PROCEDURE|TACE|Transarterial chemoembolization
223669688|NCT00594724|PROCEDURE|MRI|Adaptation Using Functional Magnetic Resonance Imaging and Diffusion Tensor Imaging
223669689|NCT00571402|BEHAVIORAL|Family-focused therapy for adolescents|FFT includes 25 sessions of psychoeducation, communication enhancement training, and problem-solving skills training plus ongoing pharmacological maintenance.
223669690|NCT00571402|BEHAVIORAL|Enhanced care|Enhanced care includes 3 sessions of family psychoeducation plus ongoing pharmacological maintenance.
223669691|NCT00393510|DRUG|TCM|"The Decoction is taken orally, twice a day, treatment period is 24 weeks The herbal formulation or a placebo was given as an adjuvant therapy for the treatment of the unhealing ulcers in these diabetic patients.~The formula consisted of 12 herbs, viz:~Radix astragali, Rhizoma atractylodis marcocephalae, Radix stephaniae tetrandrae, Radix polygoni multiflori, Radix rehmanniae, Radix smilax china, Fructus corni, Rhizoma dioscoreae, Cortex moutan, Rhizoma alismatis, Rhizoma smilacis glabrae, and Fructus schisandrae"
223669692|NCT00393510|DRUG|Placebo|"Placebo taking orally, twice a day, 24 week treatment period The herbal formulation or a placebo was given as an adjuvant therapy for the treatment of the unhealing ulcers in these diabetic patients.~The placebo was made with starch and colouring materials."
223669693|NCT04132804|BEHAVIORAL|Tai Chi|Tai Chi Chuan (taijiquan) or Tai Chi is a mind-body practice borne of Chinese philosophy and martial arts which has been practiced for centuries to promote deep relaxation, strengthened health, and to prevent injuries and illness.
223771517|NCT02660359|BIOLOGICAL|Botulinum toxin type A|600 U intra detrusor injection in two treatment periods (Initial and Retreatment phase) delivered at 30 injection points.
223771518|NCT02660359|BIOLOGICAL|Botulinum toxin type A|800 U intra detrusor injection in two treatment periods (Initial and Retreatment phase) delivered at 30 injection points
223771519|NCT02660359|DRUG|Placebo|AbobotulinumtoxinA Placebo 600 U intra detrusor injection in two treatment periods (Initial and Retreatment phase) delivered at 30 injection points
223771520|NCT02660359|DRUG|Placebo|AbobotulinumtoxinA Placebo 800 U intra detrusor injection in two treatment periods (Initial and Retreatment phase) delivered at 30 injection points
223771521|NCT02414087|DEVICE|ICB Medical insoles|"Study group:~Participants in the study group will be prescribed with customized full-length insoles (ICB Medical) to keep the subtalar joint in neutral position, using self chosen comfortable shoes, for 3 months.~Control group:~Participants in the control group will not be prescribed with customized full-length insoles (ICB Medical) to keep the subtalar joint in neutral position, using self chosen comfortable shoes, for 3 months"
223771522|NCT04498884|DRUG|Rinsulin® mix 30/70|one subcutaneous injection at a dose of 0.4 IU/kg
223771523|NCT04498884|DRUG|Humulin® M3|one subcutaneous injection at a dose of 0.4 IU/kg
223771524|NCT04978857|OTHER|autobiographic movie|viewing an autobiographic film through a virtual reality headset
223669694|NCT01820624|DRUG|tretinoin|Given PO
223669695|NCT01820624|DRUG|lithium carbonate|Given PO
224250738|NCT01424644|BIOLOGICAL|Placebo + Combined Tetanus, Reduced Diphtheria Toxoid, Acellular Pertussis Vaccine + Quadrivalent Human Papillomavirus Vaccine|"All three vaccines were administered concomitantly. Quadrivalent Human Papillomavirus \[Types 6, 11, 16, 18\] Recombinant Vaccine is GARDASIL®.~Reduced Diphtheria Toxoid, Acellular Pertussis Vaccine(Tdap) is Boostrix®."
224250739|NCT01424644|BIOLOGICAL|MenACWY-CRM Conjugate Vaccine + Combined Tetanus, Reduced Diphtheria Toxoid, Acellular Pertussis Vaccine + Quadrivalent Human Papillomavirus Vaccine|"All three vaccines were administered concomitantly. MenACWY-CRM contains diphtheria-like toxoid as carrier for the capsular polysaccharides. Quadrivalent Human Papillomavirus \[Types 6, 11, 16, 18\] Recombinant Vaccine is GARDASIL®.~Reduced Diphtheria Toxoid,Acellular Pertussis Vaccine(Tdap) is Boostrix®."
224250740|NCT01935440|BEHAVIORAL|Prevention & Testing|6 group sessions, 1 individual session, and 1 dyad session
224250741|NCT01935440|BEHAVIORAL|Prevention & Testing Control|7 group sessions
224250742|NCT01350765|BEHAVIORAL|Intervention|The LHWs of the selected intervention areas would receive additional training on ENC for identification, management and referral for birth asphyxia, lbw and neonatal sepsis.
224250743|NCT01350765|BEHAVIORAL|Control|The LHWs in the control areas would perform their routine tasks as assigned to them by their program
224250744|NCT05226169|DRUG|Ferinject|"* Patients will receive an IV FCM (1,000 mg iron) infusion on the first day (visit 1) of chemotherapy. FCM (FerinjectTM; Vifor Pharma, Glattbrugg, Switzerland) will be diluted in 250 ml of sterile 0.9% normal saline by an aseptic technique and infused over 15 min under the supervision of a clinician.~* Patients with a Hb level ≤ 10 g/dL and ID (serum ferritin \< 100 ng/mL or TSAT \< 50% and serum ferritin 100-500 ng/mL) will receive an additional dose of 500 mg of IV FCM at 6, 12, 24, 36, and 48 weeks. FCM will be diluted in 100 ml of sterile 0.9% normal saline by an aseptic technique and infused over 6 min under the supervision of a clinician."
224250745|NCT05226169|OTHER|Conservative management|"* Patients with absolute (must be administered) or functional (according to the physician's choice) IDA in the control arm will be received oral iron, administered as Feroba-You 256mg once or twice a day. Advice will be given regarding ingestion without food and with liquid high in ascorbic acid to maximize enteric absorption.~* If patients in the control arm still meet the absolute or functional IDA at the end of study (at 48 weeks), they can receive IV FCM (1,000 mg) according to the physician's decision."
224322023|NCT02641158|BEHAVIORAL|Care Facilitation Group|"The same will occur for intervention participants, yet an HCV care facilitator will motivate them to return for their HCV RNA results; appointment reminders will be made prior to the next step visit; follow-up contact will be made for missed appointments; and the HCV care facilitator will coordinate and link the participant to available community resources (e.g., mental health, housing agencies) by scheduling appointments, arranging transportation, and helping to complete any clinic registration (or other) paperwork that agencies may require to access services."
224322024|NCT03744624|PROCEDURE|Laparoscopic liver resection|Laparoscopic liver resection for oncological purposes
224322025|NCT03744624|DEVICE|3D printing model|Use of 3D printed liver model in decision-making: preoperative planning and intraoperative guidance.
223669696|NCT01820624|OTHER|laboratory biomarker analysis|Correlative studies
223669697|NCT02700334|DRUG|Dapagliflozin|10 mg, one per day before breakfast during 12 weeks.
223669698|NCT02700334|DRUG|Placebo|one per day before breakfast during 12 weeks.
223669699|NCT06393959|PROCEDURE|Caudal epidural pulsed radiofrequency|The patient lied in prone position. After cutaneous and subcutaneous anesthesia with 3 ml of 2% lidocaine, a 22- gauge 150-mm RF cannula with 20 mm active tip was advanced through the sacrococcygeal ligament into the caudal epidural space under floroscopic guidence. A few milliliters contrast was injected to observe the expansion of the epidural space. After correct needle placement was confirmed, an electrode was connected to the cannula, and stimulation was conducted with impedance measured between 250 and 350 Ohms A different sensation or feeling such as fullness, impression, tingling, pulling or plethora at the rectal and/or coccygeal region was observed by the patients when 50 Hz was applied with 0,4 to 0,7 V sensory stimulation. No leg muscle contraction was observed with 2 Hz motor stimulation at 2 V. PRF was performed for 600 s at 5 Hz using a 5-ms pulse width at 55 V, avoiding electrode tip temperatures above 42 C.
223771525|NCT04410692|OTHER|Prediction Market|"Participants bet on likely future outcomes using a prediction market"
223771526|NCT03266445|DRUG|buprenorphine/naloxone|The intervention will be to either continue taking buprenorphine/naloxone or to have the medication reduced perioperatively.
223669700|NCT06393959|PROCEDURE|Caudal epidural steroid enjection|The patient lied in prone position and aseptic techniques were adopted. After cutaneous and subcutaneous anesthesia with 3 ml of 2% lidocaine, a spinal needle was advanced through the sacrococcygeal ligament into the caudal epidural space under fluoroscopic guidance. The needle tip was confirmed by negative aspiration for blood or cerebrospinal fluid, then a few milliliters of contrast was injected to observe the expansion of the epidural space. After correct needle placement was confirmed, a total of 10 ml mixture of saline and 8 mg dexametzone was administered into the epidural space.
223669701|NCT00002543|DRUG|gallium nitrate|
223669702|NCT01368718|PROCEDURE|Active CPAP is compared with sham CPAP as a control intervention.|Patients are randomized into active or control arm. After the first treatment, a washout period is installed,after which therapy is switched according to the cross-over protocol. A CPAP device consists of a unit that generates airflow, which is directed to the airway via a mask. With active CPAP, the generated airflow creates a positive pressure and prevents upper airway collapse. With sham CPAP, the generated airflow creates a very low pressure.
223669703|NCT02412488|OTHER|Out of cathlab insertion|"Insertion of the Reveal LINQ device in the out-of-cathlab setting (out of the operating room, cardiac catheterization or electrophysiology laboratory)."
223669704|NCT06631053|OTHER|velocity-based FIT (VBFIT)|"Participants will ambulate unilaterally using a shoe modified with a 5cm rocker-style stack and forearm crutches for the duration of the study.~All participants will complete two testing sessions prior to ULLS, one testing session at day 13, and two testing sessions at the end of the study. Those assigned to the exercise group will perform a both high-intensity resistance and aerobic exercise three times per week"
223669705|NCT06631053|OTHER|No Exercise|"Participants will ambulate unilaterally using a shoe modified with a 5cm rocker-style stack and forearm crutches for the duration of the study.~All participants will complete two testing sessions prior to ULLS, one testing session at day 13, and two testing sessions at the end of the study."
224250746|NCT06623643|DIAGNOSTIC_TEST|The investigation of melatonin and cortisol levels in the saliva|In the related study, patient data from individuals who visited the Oral and Maxillofacial Radiology clinic at Van Yüzüncü Yıl University Faculty of Dentistry with complaints of bruxism will be used. The diagnosis of bruxism will be made based on clinical data. Diagnoses will be made by Dr. Sema KAYA using clinical findings such as patient history used for the current diagnosis of bruxism, tooth wear, tooth mobility, pain in the temporomandibular joint (TMJ), headaches, pain in the chewing muscles, hypertrophy, and a feeling of fatigue. Before taking the saliva samples, patients will be asked to rinse their mouths with sterile water, and then they will be asked to spit into sterile plastic containers. After approximately 3 mL of saliva is collected, it will be transferred to appropriate Eppendorf tubes and stored at -80°C. Melatonin and cortisol levels will later be analyzed using the enzyme-linked immunosorbent assay (ELISA) method.
224250747|NCT01629069|BEHAVIORAL|Mindfulness based Resilience Training|6 weekly group sessions
224250748|NCT00662753|DEVICE|Home monitoring|Participants will receive a home blood pressure monitor and be taught how to use it. They will have an education session to review treatment goals, medications, diet and exercise. They will be asked to see their primary care provider at least every 3 months and the research nurse at 3, 6 and 12 months.
224250749|NCT00662753|OTHER|monitor & phone call|Participants will receive all of the same interventions of the home monitoring group plus they will receive scheduled telephone follow up by the research nurse
224250750|NCT03066453|DRUG|Tobi Inhalant Product|inhaled tobramycin 300 mg twice per day
224250751|NCT03066453|DRUG|Nebcin|10 to 12 mg/kg/day in 1 injection for adults and 10 to 15 mg/kg in 1 pediatric injection (combined with another IV antibiotic)
224250752|NCT01061125|OTHER|TTM and Holter monitor|Standard of care visits recordings reviewed during clinical visits
224250753|NCT05396430|DEVICE|Urinary catheter|Duration of planned urinary cathterization following cesarean delivery
224250754|NCT04125706|DRUG|Minocycline Topical|Minocycline will be delivered locally in the periodontal pocket
224250755|NCT04125706|DRUG|Metronidazole Topical Gel|Metronidazole will be delivered locally in the periodontal pocket
224250756|NCT03422770|DIAGNOSTIC_TEST|Echocardiography|Conventional transthoracic echocardiography will be performed, in addition 3D-imaging and acquisitions with high frame rate. The data from these patients will be anonymized and transferred for post-hoc analysis in dedicated computer software (GE Vingmed, EchoPac 2.0) and in validated machine learning algorithms.
224250757|NCT03422770|DIAGNOSTIC_TEST|MRI|Cardiac MRI will be performed. In all patients without contraindications a gadolinium-based contrast agent will be given.
224250758|NCT03422770|DIAGNOSTIC_TEST|Blood test|Conventional brachial venous blood samples will be drawn. Blood samples will be analyzed for markers of myocardial fibrosis at Oslo University Hospital.The findings will be related to imaging findings.
224250759|NCT03422770|DIAGNOSTIC_TEST|ECG and Holter-ECG|ECG/Holter-ECG will be performed, and the findings will be related to the imaging findings.
224250760|NCT03422770|DIAGNOSTIC_TEST|6 min walking test|6 MWT will be performed, and the findings will be related to findings from MRI/echocardiography.
224250761|NCT03550625|DIAGNOSTIC_TEST|Computer program|No study specific intervention. Still images of polyps are collected. Histopathological reports of the resected polyps will be evaluated in order to create a computer program.
224250762|NCT05400148|DRUG|Bupivacaine Hydrochloride|Patients who were administered an analgesic PENG block with a dose of 2.5mg/kg with either lov (\<20ml) or high volume (\>20ml)
224250763|NCT05269381|DRUG|Cyclophosphamide|Given IV
224250764|NCT05269381|BIOLOGICAL|Neoantigen Peptide Vaccine|Receive personalized neoantigen vaccine SC
224250765|NCT05269381|BIOLOGICAL|Pembrolizumab|Given IV
224250766|NCT05269381|BIOLOGICAL|Sargramostim|Given SC
224250767|NCT03585530|DRUG|raltitrexed|Raltitrexed 2.6mg/m2 was administered on d1、d22
224250768|NCT01880593|DRUG|Lithium|Subjects in this arm take 600-1200mg of Lithium pills at night for duration of the study.
224250769|NCT01880593|DRUG|Ketamine|
224250770|NCT01880593|DRUG|Placebo|Subjects in this arm take placebo pills at night for duration of the study.
224250771|NCT02272777|DRUG|Imatinib|Imatinib 400mg QD，300mg QD or 600mg QD
224250772|NCT02272777|DRUG|Nilotinib|Nilotinib 300mg BID or 400mg QD
224250773|NCT04732195|DEVICE|Pilocarpine microneedle patch|Each microneedle (MN) patch contains an array of solid, water-soluble, micron-scale needles that encapsulate the medication (Pilocarpine). The patch form can be placed directly on the skin.
223669706|NCT04590846|BEHAVIORAL|Constipation Health Education Intervention Course|"The 4-weeks health education includes three dimensions. The first is Causes and Hazards of Constipation. The second is Constipation Symptoms and Criteria. The third is Constipation Treatment Strategies and Prevention.~Health education leaflets with 3 to 5 test questions in the weekly are distributed once a week, students will bring them back to parents, and parents need to complete the answers and sign after reading them."
223669707|NCT04590846|BEHAVIORAL|General Health Course|General courses about health issues according to the curriculum of each primary school.
223669708|NCT00756262|BIOLOGICAL|Lactobacillus GG or Culturelle|Drug to be administered orally (capsule form). Dose=2 capsules/day for 14 days. Dosage strength= 1x10\^10 bacteria
223669709|NCT04291404|DEVICE|Virtual Reality Distraction|Distraction therapy using a Virtual Reality (VR) device
223669710|NCT04921813|OTHER|3 dimensional scoliosis exercise|Schroth exercises
223669711|NCT04921813|OTHER|Balance Exercise|Balance-coordination exercises
223669712|NCT04921813|OTHER|Brace treatment|Brace usage
223669713|NCT03817086|BEHAVIORAL|Hand coordination and mental practice|"20 chronic (\>1year) moderate to severe TBI patients, with upper extremity movement deficits, will be randomly and equally assigned to two groups.~In the experimental group, participants undergo 5 weeks (3 hrs/week) of physical practice training combined with mental practice (MP group)."
223669714|NCT03817086|BEHAVIORAL|Hand coordination and action observation|In the control group 2, participants undergo 5 weeks (3 hrs/week) of physical training (PP group).
223669715|NCT01846767|OTHER|Oral glucose breath test|Simultaneous oral glucose tolerance test and exogenous 13C-glucose breath test following a 12hr overnight fast. Fasting samples were obtained for plasma glucose, insulin, c-peptide, leptin, adiponectin, resistin, HbA1c and two breath 13CO2 abundance values (at t = -15 and -5min). At t = 0min, each subject drank a 75g glucose solution (Thornton \& Ross, UK) containing 0.15g of 1-13C glucose. Further breath samples (every 15 min over a 240min interval) and further plasma blood glucose, insulin and c-peptide samples (90,120,180min) were also taken.
223669716|NCT00796991|DRUG|Ipilimumab|Solution, intravenous, 10mg/kg, every 3 weeks in the induction phase, up to 4 doses in the induction phase, 48 weeks
224250774|NCT04732195|DEVICE|Pilocarpine Iontophoresis|Pilocarpine Iontophoresis is a process of transdermal pilocarpine delivery by use of a voltage gradient on the skin. An agar gel disc containing pilocarpine is placed under the electrodes which are connected to the Macroduct 3700 Sweat Inducer device.
224250775|NCT03110003|DRUG|10 mg Bupivacaine|10 mg of preservative-free isobaric bupivacaine with 12.5mcg of fentanyl injected to the epidural space
224250776|NCT03110003|DRUG|5 mg Bupivacaine|5 mg of preservative-free isobaric bupivacaine with 12.5mcg of fentanyl in combination with 10 mL of sterile saline injected into the epidural space.
224250777|NCT02298322|DEVICE|CoolSculpting System|
224250778|NCT00167505|BEHAVIORAL|Risk Avoidance Intervention|The risk avoidance intervention is a Title V compliant curriculum emphasizing abstinence until marriage and strong character development. The curriculum includes 12 classroom and CD-ROM based lessons delivered in the 7th and 8th grade. Lessons include topics such as puberty, reproduction, healthy relationships, consequences of sex, and refusal skills.
224250779|NCT00167505|BEHAVIORAL|Risk Reduction Intervention|The risk reduction intervention is a curriculum providing skills for abstinence and condom and other contraceptive use. The curriculum includes 12 classroom and CD-ROM based lessons delivered in the 7th and 8th grade. Lessons include topics such as puberty, reproduction, healthy relationships, consequences of sex, and refusal skills.
224250780|NCT01852617|BEHAVIORAL|Training in smoking cessation counseling|"Midwife facilitators in the intervention clinics will be identified and trained to deliver the 5 A's to pregnant women and will then disseminate and implement the program. The 5 A's (Ask, Advise, Assess, Assist, Arrange) is a strategy consisting of a brief cessation counseling session of 5-15 minutes delivered by a trained provider, which is considered the standard of care worldwide"
224250781|NCT05275205|DRUG|UBX1325 injection 50 μL|Patients randomized to the UBX1325 arm will receive UBX1325 on Day 1, Weeks 4, 24, and 28
224250782|NCT05275205|DRUG|EYLEA® (aflibercept) Injection 2 mg (0.05mL)|Patients randomized to the active-control aflibercept arm will receive aflibercept per label every 8 weeks starting from day 1 until Week 40. In addition, these patients will receive UBX1325 on Week 24 and Week 32; and a sham procedure at Week 4 and Week 28.
224250783|NCT02947230|OTHER|Tailored Knowledge Translation|Tailored knowledge translation strategies specific to maintaining and increasing physical mobility with age.
224250784|NCT02066922|DEVICE|Delefilcon A contact lens|Commercially available silicone hydrogel contact lens
224250785|NCT02066922|DEVICE|Narafilcon A contact lens|Commercially available silicone hydrogel contact lens
224250786|NCT02066922|DEVICE|Spectacles|Incremental prescription worn over contact lenses if needed to provide acceptable vision
224250787|NCT03338660|BIOLOGICAL|Infusion of Platelets|Platelets will be stored using novel, FDA approved, technique. Subjects will receive infusion of platelets stored by novel technique, routine storage, and placebo (saline).
224250788|NCT03338660|BIOLOGICAL|Infusion of Platelets|Platelets will be stored using the routine platelet storage method. Subjects will receive infusion of platelets stored by routine storage method.
224250789|NCT03338660|BIOLOGICAL|Placebo|Subjects will receive infusion placebo (saline).
224250790|NCT00440297|BIOLOGICAL|Comparator: modified process hepatitis B vaccine|Modified process hepatitis B vaccine 40 ug/1.0 mL injection in a 4 dose regimen at months 0, 1, 6, and 8. Duration of treatment is 9 months.
223669717|NCT00796991|DRUG|Carboplatin|Solution, intravenous, Area Under the Concentration Time Curve=6, every 3 weeks in the induction phase, up to 8 doses in the induction phase, 48 weeks
223669718|NCT00796991|DRUG|Paclitaxel|Solution, intravenous, 175 mg/m2, every 3 weeks in the induction phase, up to 8 doses in the induction phase, 48 weeks
223669719|NCT00796991|DRUG|Dacarbazine|Solution, intravenous, 850 mg/m2, every 3 weeks in the induction phase, up to 8 doses in the induction phase, 48 weeks
223669720|NCT00004042|BIOLOGICAL|monoclonal antibody F19|
223669721|NCT00004042|RADIATION|iodine I 131 monoclonal antibody F19|
223669722|NCT03453788|DEVICE|LETSGO app|LETSGO pilot test Group will test LETSGO app and partially nurseled follow-up
223669723|NCT01411735|DRUG|Enalapril|2.5mg titrated up to 10mg twice daily
223669724|NCT01411735|DRUG|placebo|2.5mg titrated up to 10mg twice daily.
223771527|NCT04402827|DIAGNOSTIC_TEST|Susceptibility to infection|"ACE2 and CD26 receptor study: After genomic DNA extraction and quantification using a NanoDrop-1000, 14 ACE2 SNPs (rs1978124, rs2048683, rs2074192, rs2106809, rs2285666, rs233575, rs4240157, rs4646142, rs4646155, rs4646156, rs4646188, rs4830542, rs6632677, and rs879922) will be studied. In addition, one CD26 (DPP4) SNP (rs7608798) will be analysed (qualitative measure).~SARS-CoV-2 CD4/CD8 T cell response: SARS-CoV-2 peptides (Prot-S, Pros-N and Port-M) will be used to activate CD4 and CD8 T cells. Cytokines released, such as IFNg, TNFa, IL4, IL17A, and IL2, from each cell subset will be measured by flow cytometry (quantitative measure).~KIR characterization: Characterization of the presence of 14 genes plus 2 pseudogenes of KIR gene family (qualitative genotyping) by PCR, mRNA expression profiling (quantitative measures) by RT-PCR, and phenotyping of human NK cells analyzing different KIR receptors (quantitative measure) by flow cytometry, will be analyzed."
223771528|NCT02908997|OTHER|MindMate|A dementia-specific mobile reminding application
223669725|NCT04687514|DRUG|Dulaglutide|Dulaglutide: first week 1x 1.5mg in 0.5 ml, following 3 weeks 2 x 1.5 mg weekly in 0.5ml each, via Pen s.c.
224322026|NCT06035835|COMBINATION_PRODUCT|Lacticaseibacillus rhamnosus|Administration Lacticaseibacillus rhamnosus (L. Rhamnosus) ATCC 53103 (109 UFC/day)
223669726|NCT04687514|DRUG|Placebo|Placebo: first week 1x0.5 ml physiological saline (0.9% sodium chloride) injection s.c. via syringe, following weeks 2x0.5 ml physiological saline (0.9% sodium chloride) injection s.c. via syringe once weekly for 3 further weeks.
223669727|NCT00029146|PROCEDURE|extracranial-intracranial bypass surgery|Surgical anastomosis of a superficial temporal artery branch to a middle cerebral artery branch through a small craniectomy plus best current practice medical therapy
223669728|NCT00029146|DRUG|best medical therapy|best current practice medical therapy
223669729|NCT00005815|DRUG|temozolomide|
223669730|NCT00005815|DRUG|thalidomide|
223669731|NCT04696211|OTHER|Music-with-movement exercise|A music-with-movement exercise programme to reduce chronic pain in older adults.
223669732|NCT05979142|OTHER|community-based primary care program|See group description
223669733|NCT04305067|OTHER|Exercise|Exercise programs will be individually tailored to the capabilities of each participant and gradually progressed accordingly. Each patient will be asked to complete one home-based aerobic exercise sessions each week. At baseline, 16 weeks and 3 month followup patients will complete a physical fitness assessment (30 second sit to stand and six minute walking tests) and a range of quality of life questionnaires. Upon completion of the 16 week exercise intervention, patients will be invited to partake in semi-structured interviews to determine the effectiveness of the program and their experience throughout.
223669734|NCT05783557|DRUG|Clevidipine Butyrate Injectable Emulsion|intravenous injection
223669735|NCT05783557|DRUG|Cleviprex®|intravenous injection
223669736|NCT00313781|DRUG|CP-751,871|CP-750,871 is administered intravenously at a dose of 20 mg/kg on day 1 of each 21-day cycle (for patient convenience and logistical management, the dose of CP-751,871 may be deferred up to 7 days).
223771529|NCT03486041|BEHAVIORAL|Comprehensive Behavior Modification|Behavior therapy approach to BFRBs involving targeted intervention tactics chosen in accordance with the modality of functioning (ex: Sensory, Cognitive.....) seeming to cause the most frequent and problematic urges to engage in the BFRB. Therapist and client work together, using careful assessments including detailed self-monitoring, to determine what behavioral methods will suffice for lasting change.
223771530|NCT03486041|BEHAVIORAL|Attention|Weekly brief calls from therapist to check on safety and clinical status. No focus on TTM.
224322027|NCT06035835|COMBINATION_PRODUCT|Lactobacillus acidophilus + Bifidobacterium bifidum|Administration Lactobacillus acidophilus (L. acidophilus) ATCC 4356 (109 UFC/12 h)+Bifidobacterium bifidum (B. bifidum) ATCC 15696 (109 UFC/12 h)
224323518|NCT04328714|DRUG|Interferon gamma (IFNγ)-primed human bone marrow-derived mesenchymal stromal cells|"To determine the maximal dose, initially adult subjects will receive a single infusion of third party, freshly ex vivo expanded, IFNγ-primed MSCs at a dose of 2 x 106 cells/kg of ideal body weight on Day +1 (the day after infusion of the hematopoietic cell graft). The dose will be escalated to 5 x 106 and then 10 x 106 cells/kg. In absence of any dose limiting toxicity, 10 x 106 cells/kg will be accepted as the maximal dose.~Subsequent participants in the adult and pediatric cohorts will receive the maximal dose as determined by the initial adult participants.~Participants will receive the infusion in an inpatient setting. MSCs will be intravenously infused through a central line or a large bore peripheral IV using standard blood product tubing within 4 hours of release. The product will be infused by IV push or syringe pump over approximately 30-60 minutes or to gravity depending on product volume."
223669737|NCT00313781|DRUG|docetaxel|Docetaxel is administered IV on day 1 of each 21-day cycle, at a dose of 75 mg/m2.
223669738|NCT00313781|DRUG|prednisone|Prednisone is administered at a dose of 5 mg twice daily.
223669739|NCT00313781|DRUG|docetaxel|Docetaxel is administered IV on day 1 of each 21-day cycle, at a dose of 75 mg/m2.
223669740|NCT00313781|DRUG|prednisone|Prednisone is administered at a dose of 5 mg twice daily.
223669741|NCT00272662|DRUG|peginesatide|
223669742|NCT03567343|DIETARY_SUPPLEMENT|Proprietary Spearmint Extract Blend|Water extracted spearmint extract and green tea blend
223669743|NCT03567343|OTHER|Control|Placebo
223771531|NCT01975844|OTHER|Individualized Anemia Mangement Protocol|"Phase 1 (1-3 months): Develop individualized patient models and Anemia Management Protocols (AMP) while patients are receiving standard medical care.~Phase 2 (9 months): Individualized AMP study period. Phase 3 (9 months): Follow up period: return to standard-care AMP ."
223669744|NCT00047645|DRUG|Interferon-gamma 1b|200 mcg, SQ, 3x per week
223669745|NCT01090583|OTHER|Specimen Collection|We will compare mediators from non-invasive samples (blood, urine, saliva, vaginal or cervical secretions) with traditional gold-standard invasive samples (amniotic fluid and placenta samples).
223669746|NCT00518960|DRUG|ProAlgaZyme|
223669747|NCT05515185|DRUG|KT095 CAR-T injection|Clearance of lymphocytes
223669748|NCT00146432|PROCEDURE|Immunoadsorption of LPS, IL-6 and C5a|
223669749|NCT02338570|DRUG|Everolimus|Patients will start study treatment on day 1 and will be treated with daily doses of everolimus (10 mg daily tablets).
223669750|NCT00943449|DRUG|4SC-201|oral administration
223669751|NCT00943449|DRUG|Sorafenib|oral administration
223669752|NCT04123691|DEVICE|pulse oximetry monitoring|pulse oximetry monitoring as per routine clinical practice
223669753|NCT04628455|DEVICE|Inversion and snaring|"Vertical umbilical 5-mm incision was made for 5-mm trocar. Pneumoperitoneum is then established with CO2 flow of 1.5-2.5 L/min keeping intraabdominal pressure between 8-12 mmHg. A two-mm incision was done at a point B \[midway between umbilicus and symphysis pubis\] for 2-mm port passed under direct vision and a tiny 11-blade scalpel puncture is done at the corresponding Mac-Burney's \[Point C\] for SGD.~Both SGDs were used to invert the hernia sac by gradual sustained alternating traction on the round ligament. Each SGD hands to the other one till complete inversion occurs, this is known by the hernial sac hanging from internal ring without retracting-back inside the inguinal canal. Then, the MPS is introduced via 2-mm trocar at point. SGD-C passed inside the loop of MPS and re-catches the hernial sac, which is then twisted around its neck several times. MPS was closed at the neck and diathermy current is applied. Detached sac was then pushed antigradely out through the umbilical port."
223669754|NCT00245167|PROCEDURE|Tracheal Aspirate Fluid|
223669755|NCT00834080|DRUG|Medisorb naltrexone 380 mg|Intramuscular (IM) injection administered once every 4 weeks for up to 2 years
223669756|NCT04887376|DEVICE|Mirror frame|Combined Mirror and NMES therapy
223669757|NCT04887376|DEVICE|Control|Only NMES therapy
223669758|NCT05483829|BEHAVIORAL|Adhera® Fatigue for Long COVID program|"Adhera® for the Long COVID program, which includes an application and a smartwatch, supported by digital health solution based on emotional and behavioral change techniques. Patient Adaptative Self-Management Content (e.g. psycho-educational content, activities for mental wellbeing, personalized motivational messages), and the personalization is based on Adhera® Health Recommender System.~Wearable devices and the mobile app will be used to collect real-time data for 4 weeks to detect biometric and psychometric (patient-reported outcomes) information."
223669759|NCT00027872|DRUG|tipifarnib|Given orally
223669760|NCT00027872|OTHER|laboratory biomarker analysis|Correlative studies
223669761|NCT01416597|BIOLOGICAL|Vaccines|Unadjuvanted, monovalent, and trivalent vaccines, and vaccines delivered intramuscularly, intradermally, or intranasally, depending on what is found in the included studies.
223669762|NCT05424770|OTHER|Education with crossword|Afterwards, crossword activities prepared by the researcher will be implemented and students will be actively involved in the process. The researcher will also include a collaborative learning environment where students can exchange information with each other. After the completion of each puzzle, the researcher will make the necessary checks and corrections.
223669763|NCT05668390|DRUG|STALORAL® Birch 300 IR|2 treatment periods will consist of 2 steps: an escalation phase, where the treatment dose will gradually increase, followed by a maintenance phase.
223669764|NCT04548869|DRUG|CDX-0159|Administered intravenously
223669765|NCT03045224|DEVICE|PTA, balloon angioplasty, stent|
223669766|NCT03986372|BIOLOGICAL|Platlet-rich plasma|Multiple Platlet-rich plasma injection.
223669767|NCT01863654|DRUG|Montelukast 5 mg chewable tablets|Reference product
223669768|NCT01863654|DRUG|Montelukast 5 mg chewable tablets|Test product
223669769|NCT02917057|DRUG|exenatide once weekly|Exenatide treatment in customary clinical care in the USA
223669770|NCT02917057|DRUG|basal insulin|basal insulin tretament in the customary clinical care in USA
223669771|NCT05887778|DRUG|Sodium Chloride 0.9% Inj|administration of 5ml 0,9% sodium chloride - 30 minutes before the supraclavicular brachial plexus block
224250791|NCT00440297|BIOLOGICAL|Comparator: ENGERIX-B™|ENGERIX-B™ two 20 ug/1.0 mL injections in a 4 dose regimen at months 0, 1, 6, and 8. Duration of treatment is 9 months.
224250792|NCT03751605|PROCEDURE|unipulmonary ventilation|observational study based on the computation of respiratory quotient in patient cohort treated by unipulmonary ventilation in routine thoracic surgery
224250793|NCT02024932|DRUG|BVS857|BVS857 lyophilisate in vial; the lyophilisate was reconstituted with sterile water for injection, diluted as appropriate, and administered either i.v. or s.c..
224250794|NCT02024932|DRUG|Placebo|Placebo lyophilisate in vial; the lyophilisate was reconstituted with sterile water for injection, diluted as appropriate, and administered either i.v. or s.c..
224250795|NCT02445339|DRUG|XR-NTX+CM (Extended-Release Naltrexone plus Care Management)|The intervention arm will receive extended-release naltrexone (XR-NTX) 380mg (4 mL) to be administered as an intramuscular gluteal injection every 28 days up to 12 doses total. Expedited referral to alcohol-medical management. Care Management will include coordination of health care and social services for at least 12 months. Harm-reduction counseling and motivational interviewing to identify and work towards goals. The Standard care arm will receive an expedited alcohol-medical management referral.
224250796|NCT00847678|BIOLOGICAL|Efungumab (Mycograb)|
224250797|NCT00847678|BIOLOGICAL|placebo|
224250798|NCT00847678|BIOLOGICAL|Amphotericin B|
224250799|NCT00847678|BIOLOGICAL|5 flucytosine|
224250800|NCT03020641|PROCEDURE|Low pressure pneumoperitoneum|Low pressure pneumoperitoneum
224250801|NCT03020641|PROCEDURE|standard pneumoperitoneum pressure|standard pneumoperitoneum pressure
224250802|NCT05354479|DRUG|Paracetamol|babies will get expressed breast milk along with paracatamol for pain relief
224250803|NCT02058797|BEHAVIORAL|Coherence Therapy|Manualized individual treatment (3 + 1 one-hour sessions)
224250804|NCT02058797|BEHAVIORAL|Cognitive Behavioral Therapy|Manualized individual treatment (3 + 1 one-hour sessions)
224250805|NCT01442857|RADIATION|MRI|High resolution MRI of the brachial plexus
224250806|NCT01397630|DRUG|Oxytocin|Accelerated Oxytocin Titration
224250807|NCT04314505|DRUG|Opioid-Sparing Protocol|After a general anesthesia procedure was performed, an experienced anesthesiologist performed ultrasound guided adductor canal block procedures on both knees. In the opioid-sparing group, a dose of Parecoxib sodium 40 mg was administrated through intravenous route before the incision. After the surgery, Parecoxib sodium 40 mg was given intravenously every 12 hours for 4 more doses. Before the wound closure, the periarticular injection (each side 10 ml of 0.25% Bupivacaine) was done. The total dosage would be recorded in the device. All patients received oral paracetamol 500mg, 4 times a day and oral celecoxib 200mg, 2 times a day after surgery.
224323519|NCT03803943|BEHAVIORAL|Parent-Implemented Communication Intervention (PICT)|Weekly hour long intervention sessions for 6 months
224323520|NCT03803943|OTHER|No Intervention - Business-as-usual control|Does not receive PICT intervention
224323521|NCT05458297|BIOLOGICAL|Zilovertamab vedotin|IV infusion
224323522|NCT05458297|DRUG|Nemtabrutinib|Oral tablet
223669772|NCT05887778|DRUG|0,1mg/kg Dexamethasone|administration of 0,1mg/kg Dexamethasone - 30 minutes before the supraclavicular brachial plexus block
223669773|NCT05887778|DRUG|0,2mg/kg Dexamethasone|administration of 0,2mg/kg Dexamethasone - 30 minutes before the supraclavicular brachial plexus block
223669774|NCT00194649|DRUG|Miglustat (Zavesca)|100 mg Miglustat BID (twice daily) for six weeks
223669775|NCT03011021|DRUG|Liraglutide|Dose escalation of Liraglutide starts from 0.6 mg up to 1.2 mg per day.
223669776|NCT03011021|BIOLOGICAL|UCB-Treg|Receive Treg infusion: 1\~5\*10\^6/kg b.w. in 100ml normal saline
223669777|NCT03011021|DRUG|Insulin|Receive insulin following clinician's instruction.
223669778|NCT04802668|DEVICE|Patients were ventilated with assist-control ventilation（A/C） mode at different tidal volume|Ventilation mode was set to assist-control volume ventilation with different tidal volume, respiratory frequency 15 times/min, PEEP 5 centimeter water column.
223669779|NCT04802668|BEHAVIORAL|spontaneous breathing and no spontaneous breathing|Data were recorded when patients had and did not have spontaneous breathing
223669780|NCT02547961|BIOLOGICAL|HER-2-targeting CAR T Cells infusion|HER-2-targeting CAR t cells infusion in breast cancer
223669781|NCT03653559|BEHAVIORAL|Home meals|"Adult participants with overweight or obesity are asked to consume home meals during 12 weeks."
223669782|NCT03653559|BEHAVIORAL|Healthy meals|"Adult participants with overweight or obesity are asked to consume healthy meals during 12 weeks."
223669783|NCT03031002|BEHAVIORAL|Exposure treatment for spider fear|Two sessions (each session = 60 minutes) of in-vivo exposure treatment (including psychoeducation) with two different spiders. Exposures comprise a hierarchy of 7 steps, to be completed with both spiders.
223669784|NCT03078829|DRUG|Treatment with a GnRh agonists|All patients will be treated with GnRH agonists
224250808|NCT04314505|DRUG|Opioid-Based Patient Controlled Analgesia|After a general anesthesia procedure was performed, an experienced anesthesiologist performed ultrasound guided adductor canal block procedures on both knees. The patient was informed that the intravenous bolus of rescue morphine (4mg) was available every 4 hours if the pain was intolerable. In the PCA group, the device was applied before incision and the initial setting was 0.01mg/kg\*hour, patient-controlled dose 2 mg, lock-out 5 minutes and limited 40mg in each 4 hours. After the surgery, the staff of PCA group would visit the patients and adjusted the dosage. The PCA was removed after 72 hours from the surgery. Before the wound closure, the periarticular injection (each side 10 ml of 0.25% Bupivacaine) was done. The total dosage would be recorded in the device. All patients received oral paracetamol 500mg, 4 times a day and oral celecoxib 200mg, 2 times a day after surgery.
224250809|NCT03041025|DRUG|GSK2330811|GSK2330811 will be provided in vials and packed in 1 vial per carton. Each vial will contain 1.2 mL fill with 1 mL extractable volume at 100 mg/mL.
224250810|NCT03041025|DRUG|Placebo|Normal saline (0.9 percent weight per volume sodium chloride).
224250811|NCT01033305|DRUG|CyCol™|Orally, once per day for 4 weeks
224250812|NCT01033305|DRUG|Placebo|Orally, once per day for 4 weeks
224250813|NCT03388671|PROCEDURE|TAB Block|patients will recieve 0.3ml/kg bupivacaine 0.25% on each side for laparoscopically guided TAB Block
224250814|NCT03388671|PROCEDURE|Psoas Block|patients will recieve 0.3ml/kg bupivacaine 0.25% on each side for laparoscopically guided Psoas Block
224323523|NCT06203054|DEVICE|Penditure™ Left Atrial Appendage (LAA) Exclusion System|Exclusion of the left atrial appendage using the Penditure™ Left Atrial Appendage (LAA) Exclusion System in subjects undergoing concomitant cardiac surgery.
224323524|NCT06312124|BEHAVIORAL|Educational Module|Part 1 consists of an education module with premodule and postmodule assessment questionnaires.
224323525|NCT06312124|PROCEDURE|Salpingectomy|Part 2 consists of incorporating opportunistic salpingectomy /OS into non-gynecologic surgery
224323526|NCT05920356|DRUG|Sotorasib|Oral administration
223669785|NCT00392379|DRUG|Nicotine Lozenges|Nicotine lozenges, 4 mg
223669786|NCT00392379|DRUG|Placebo lozenge|Placebo lozenge
223669787|NCT00167492|DRUG|Myfortic|720 mg by mouth every 12 hours
223669788|NCT05304780|BEHAVIORAL|needs-tailored nurse-led recovery program|The needs-tailored nurse-led recovery program were divided into five major stages of care, which were build partnership, conduct integrated needs assessment, set needs-based recovery goals and provide empowerment-oriented care, conduct continuous monitoring of goals, and conduct effectiveness evaluations.
223669789|NCT05977244|OTHER|HGI+palm olein|A 5-hour postprandial feeding intervention with 1-weeks washout in between. Blood samples will be collected at 0 hour (baseline) and up to 5 hours after consumption of test meal.
223669790|NCT05977244|OTHER|LGI+palm olein|A 5-hour postprandial feeding intervention with 1-weeks washout in between. Blood samples will be collected at 0 hour (baseline) and up to 5 hours after consumption of test meal.
223669791|NCT05977244|OTHER|HGI+soy bean oil|A 5-hour postprandial feeding intervention with 1-weeks washout in between. Blood samples will be collected at 0 hour (baseline) and up to 5 hours after consumption of test meal.
223669792|NCT05977244|OTHER|LGI+soy bean oil|A 5-hour postprandial feeding intervention with 1-weeks washout in between. Blood samples will be collected at 0 hour (baseline) and up to 5 hours after consumption of test meal.
223669793|NCT00006050|DRUG|FOLFOX regimen|
223669794|NCT00006050|DRUG|fluorouracil|
223669795|NCT00006050|DRUG|isolated perfusion|
223669796|NCT00006050|DRUG|leucovorin calcium|
223669797|NCT00006050|DRUG|oxaliplatin|
223669798|NCT01294098|DRUG|Marcaine|0.75 cc/kg of 1/4% Marcaine
223669799|NCT02365233|DRUG|DPP4 inhibitor|Comparison between three common alternative therapeutic strategies to improve glycemic control in patients with type 2 diabetes who are not controlled with metformin alone.
223669800|NCT02365233|DRUG|Pioglitazone|Comparison between three common alternative therapeutic strategies to improve glycemic control in patients with type 2 diabetes who are not controlled with metformin alone.
223669801|NCT02365233|DRUG|Lantus insulin|Comparison between three common alternative therapeutic strategies to improve glycemic control in patients with type 2 diabetes who are not controlled with metformin alone.
223669802|NCT03530709|OTHER|videoconferencing|Parents/caregivers will use smartphones to videoconference in their SCC provider during PCP visits
223669803|NCT00795119|DEVICE|Near Infrared Spectroscopy (NIRS)|NIRS of the head is undertaken at the time of CT or MRI examination
224323527|NCT05920356|DRUG|Pembrolizumab|Intravenous administration
223669804|NCT00827931|DRUG|Tranexamic acid + Standard of Care|Tranexamic acid given slowly intravenously (15 mg/kg body weight) 15 minutes before surgery followed by a second dose at three hour interval from first dose and third dose at three hour interval from the second + standard of care (Standard of care includes the routine surgical and anesthetic techniques being utilized to control blood loss)
223669805|NCT00827931|PROCEDURE|Standard of Care|Standard of care includes the routine surgical and anesthetic techniques being utilized to control blood loss
223669806|NCT04097951|DRUG|Combinations|Montelukast and Bepotastine Combination
223669807|NCT02757417|DRUG|sodium fluorescein|
223669808|NCT02757417|DRUG|phenazopyridine|
223669809|NCT04066712|DRUG|LC350189 200 mg|Study drug in capsule form, take two capsules of LC350189 100mg, by oral, once daily, from Day 1 through 7
223669810|NCT02560506|DEVICE|Elastic assisted treadmill walking|Rubber band pulley system that will assist therapists in advancing limbs while gait training. The device is positioned in front of a treadmill and the stretch of the elastic bands when a legs moves backwards on a treadmill is resists the movement and facilitates limb swing when walking.
223669811|NCT02896322|RADIATION|Partial breast irradiation with cyberknife|
223669812|NCT03158662|OTHER|Survey|Survey Study
223669813|NCT00995566|DRUG|Sitaxentan sodium|Please note that this is a non-interventional study and no drug is actually given as an intervention. Instead, patients prescribed THELIN are being followed under real world circumstances. However at the request of the QA group at CT.gov, we were instructed to add sitaxentan sodium as the intervention type, regardless of the fact that this is a non-interventional study.
223669814|NCT02323100|DRUG|Ravicti low dose|8 am, 4pm and midnight
223669815|NCT02323100|DRUG|Ravicti high dose|8 am, 4pm and midnight
223669816|NCT02323100|DRUG|Placebo|8 am, 4pm and midnight
223669817|NCT00886652|OTHER|Aerobic exercise program|Three weekly sessions, with an interval of one day between each, lasting 60 minutes each, and divided into three separate stages: - A 10-minute warm-up (stretching and low intensity aerobic exercises such as slow, gradual walking); - 40 minutes of aerobic exercise on an electric treadmill, with the work intensity maintained at a 60% to 80% of the maximum heart rate; - 10 minutes of winding down and relaxation (stretching exercises, low energy expenditure aerobics and relaxation techniques).
223669818|NCT04136847|DEVICE|SkinPen Precision|Surgical instrument motors and accessories/attachments/Hydrogel
223669819|NCT02229656|RADIATION|radiotherapy|Primary tumor and lymph nodes will receive 35 fractions of 2 Gy resulting in a total dose of 70 Gy. Elective fields will receive 35 fractions of 1.55 Gy resulting in a total dose of 54.25 Gy in case a SIB technique is used, or 23 fractions of 2 Gy resulting in a total dose of 46 Gy in case a sequential boost technique is used. The higher total prescribed physical dose to the elective fields in a SIB technique based RT plan compensates for the lower dose per fraction and results in an equal biological effective dose when compared with a sequential boost technique.
223669820|NCT02229656|DRUG|Olaparib|The pre-defined dose levels of olaparib are 25mg QD, 25, 50, 100, 200, and 300 mg BID
223669821|NCT00000939|DRUG|Hydroxyurea|
223669822|NCT00000939|DRUG|Efavirenz|
223669823|NCT00000939|DRUG|Stavudine|
223669824|NCT00000939|DRUG|Didanosine|
223669825|NCT02079818|DEVICE|Penumbra Ruby Coil System|The Penumbra Ruby™ Coil is a new generation of detachable coils developed by Penumbra Inc. This coil system is specifically designed for the occlusion of aneurysms and vessels that is equivalent to standard platinum coils. This system consists of: an implantable Coil attached to a Detachment Pusher as well as a Detachment Handle. The Detachment Pusher is comprised of a shaft with a radiopaque positioning marker, a Distal Detachment Tip, and a pull wire. The Detachment Handle is used to detach the Coil Implant from the Detachment Pusher. The Penumbra Ruby Coil is designed for endovascular embolization in the peripheral vasculature. Intended users for this device are physicians who have received appropriate training in interventional radiology and endovascular intervention.
223669826|NCT00608569|DRUG|Lopinavir/ritonavir|Two tablets (200-mg lopinavir and 50 mg ritonavir in each tablet), taken orally twice daily
223669827|NCT00608569|DRUG|Emtricitabine/Tenofovir disoproxil fumarate|200-mg emtricitabine and 300 mg tenofovir disoproxil fumarate in each tablet, taken orally once daily
223669828|NCT00608569|DRUG|Tenofovir disoproxil fumarate|300-mg tablet taken orally once daily
223669829|NCT00608569|DRUG|Zidovudine|300-mg tablet taken orally twice daily
223669830|NCT00608569|DRUG|Emtricitabine|200-mg tablet taken orally once daily
224250815|NCT03388671|DRUG|Bupivacaine|patients will recieve 0.3ml/kg bupivacaine 0.25% on each side for laparoscopically guided Psoas Block or TAB block
224250816|NCT00938171|PROCEDURE|Local anesthesia|All patients will be then given adequate sedation with propofol and local anesthetic given by dermal infiltration in incision site and regional breast and axillary areas. The local anesthetic of choice will be 2 % lidocaine (Xylocaine) and 0.5% Bupivacaine (Marcaine) mixed with 7 % sodium bicarbonate and epinephrine (Bosmine)
224250817|NCT00938171|PROCEDURE|General anesthesia|The method of general anesthesia for the GA group will be induced with fentanyl (1-2 μg/kg) and propofol (2.5 mg/kg). After placement of a laryngeal mask or endotracheal tube airway, anesthesia will be maintained with sevoflurane (end-tidal concentrations 1%-3%) in a 50% oxygen/nitrous oxide mixture.
223669831|NCT03011892|DRUG|Ruxolitinib 0.15% Cream QD|Ruxolitinib 0.15% cream QD
223669832|NCT03011892|DRUG|Ruxolitinib 0.5% Cream QD|Ruxolitinib 0.5% cream QD
223669833|NCT03011892|DRUG|Ruxolitinib 1.5% Cream QD|Ruxolitinib 1.5% cream QD
223669834|NCT03011892|DRUG|Ruxolitinib 1.5% Cream BID|Ruxolitinib 1.5% cream BID
223669835|NCT03011892|DRUG|Triamcinolone 0.1% Cream BID|Triamcinolone 0.1% cream BID
223669836|NCT03011892|DRUG|Vehicle Cream BID|Vehicle cream BID
223669837|NCT01673152|DIETARY_SUPPLEMENT|Oligofructose|Dosing: children aged 7 to 12 years: 8g/day, children aged 12 to18 years: 15g/day Duration: 12 weeks
224250818|NCT01835093|DRUG|Tipepidine Hibenzate|
224250819|NCT02409693|PROCEDURE|Myringotomy with tube insertion|
224250820|NCT02877186|OTHER|commercially-available diet soda|Subjects are asked to consume diet soda three times daily for one week.
224250821|NCT02877186|OTHER|carbonated water (control)|Subjects are asked to consume carbonated water three times daily for one week.
224250822|NCT01670890|DRUG|TMZ|patients were treated with TMZ alone,Oral TMZ 50mg/m2/day,day 1 to 28,for 6 cycles
224323528|NCT06403345|BEHAVIORAL|Green Activity Program|See arm description.
224250823|NCT01670890|DRUG|TMZ plus CDDP|patients were treated with TMZ plus CDDP,CDDP was administered iv from day 1 to 3 with the total dose of 100mg and TMZ was administered orally 50mg/m2/day,day 1 to 28,for 6 cycles
224250824|NCT04953234|DEVICE|NovoTTF-100L|Patients receive continuous TTFields treatment using the NovoTTF-100L device. TTFields treatment will consist of wearing four electrically insulated electrode arrays on the thorax. The treatment enables the patient to maintain regular daily routine.
224250825|NCT05683730|OTHER|Intermittent caloric restriction|"Intermittente caloric restriction:~1. st month: restriction of 50% of the caloric intake previously determined by the dietician 1 day per week~2. nd month: restriction of 50% of the caloric intake 2 days per week~3. rd month: restriction of 60% of the caloric intake 2 days per week~4. th month: restriction of 75% of the caloric intake 2 days per week"
224250826|NCT02533362|DRUG|ANF-Rho|Pegylated version of recombinant human granulocyte-colony stimulating factor (G-CSF)
224250827|NCT00091260|DRUG|dexamethasone|dexamethasone 20 mg daily (10 mg BID) on Days 1-4, 9-12, and 17-20 of every other 28-day cycle.
224250828|NCT00091260|DRUG|lenalidomide|15 mg/day, for 21 days with 7 days rest (28 day cycle) with or without dexamethasone
224250829|NCT04513730|OTHER|Rehabilitation|A device originally designed with the function of keeping the user in a comfortable position of pelvic suspension, in dorsal decubitus, with fixation in the popliteal region and ankles was built to promote lumbar traction. The device is designed in autoCAD software with 2d technical representations and 3d electronic model. It consists of a structure of pipes and fittings and padded material at the support points.
224250830|NCT05900934|OTHER|Myofascial Releasing Group|Using a subjective 7/10 target numeric rating scale rating (0 representing no discomfort and 10 representing maximum discomfort), the intensity of foam roller application can be determined. This intensity defines an application intensity that is mildly painful for the participant and appropriate according to previous literature.
224250831|NCT05900934|OTHER|Sham Myofascial Releasing Group|The severity of the application is not felt at all according to the numerical rating scale of 0/10.
224250832|NCT01713465|OTHER|Computer based Metabolic Syndrome educational program|Individuals in the intervention group will receive metabolic syndrome related education using a touch screen interactive and bilingual multimedia enabled educational program
224250833|NCT02648880|BEHAVIORAL|Exercise program|"Individual exercise sessions in this program implement a whole body approach and consist of a 10-min cardiovascular warm-up and 50 minutes of cardiovascular endurance, resistance, and flexibility exercises. Target intensity of exercise will be based on the American College of Sports Medicine recommendations for cancer survivors. Prior to the start of exercise sessions, participants will be questioned on significant changes in symptoms or the presence of new symptoms (such as nausea or fever), which will used to modify the exercise session for that day to allow maximum symptom-limited participation."
224250834|NCT02648880|OTHER|Standard Care|The services that participants receive as standard care include their medical care, symptom control, social worker support, and nutrition. These services are provided by their oncology team.
224250835|NCT00939003|BIOLOGICAL|Adalimumab|40 mg every other week up to Week 12
224250836|NCT00939003|BIOLOGICAL|Placebo|Placebo every other week up to Week 12
224250837|NCT00939003|BIOLOGICAL|Open-label Adalimumab|40 mg every other week, Week 12 through Week 156
224250838|NCT05539222|OTHER|Food vouchers and education|Intervention and control group individuals received 120 euros/month during 3 months in food vouchers to be spent in supermarkets (60 euros/month if under 12y) plus a 10-week nutrition education for the intervention group. Family food purchases were assessed using electronically recorded supermarket-obtained transactions.
224322028|NCT05919719|PROCEDURE|Non interventional study (study of diagnostic accuracy with an extra echocardiographic assessment).|"Fluid expansion will be delayed while our index test is performed. After fluid expansion, patient will undergo an echocardiographic assessment of response to fluid expansion (gold-standard).~Our index test is the ΔSVi-AC: indexed percentage of stroke volume variation between baseline and during a standardized abdominal compression. Stroke volume will be assessed by transthoracic echocardiography.~Patient will undergo 3 echocardiographic assessment: At baseline, During abdominal compression, After the 10 to 20ml/kg crystalloid fluid expansion Abdominal compression : a sphygmomanometer will be inflated to a pressure of less than 10 mmHg and will be applied to the center of the patient's abdomen. Then, a gentle compression on the sphygmomanometer will be performed, calibrated at 22 - 26 mmHg according to the sphygmomanometer. The echocardiographic assessments will take place between 10 and 60 seconds after the start of the compression, which will therefore last less than a minute."
223669838|NCT01673152|DIETARY_SUPPLEMENT|Maltodextrin|Dosing: children aged 7 to 12 years: 4g/day, children aged 12 to18 years: 6g/day, Duration: 12 weeks
223669839|NCT02577393|DRUG|EGCG|EGCG (purity≥95% by high pressure liquid chromatography; from Ningbo HEP Biotech Co., Ltd) is dissolved in 0.9% saline solution three times a day. A new batch is made up each time. For esophageal application, repeated swallowing of 10 ml of the EGCG solution is indispensable to assure the prolonged presence of drug the esophageal walls. We choose a dose of 440 lmol/L as the recommended concentration for this study by referring to our previous phase I study. Immediately at the beginning of radiotherapy, the EGCG solution is given until two weeks after radiotherapy completed. Steroids, non-steroidal anti-inflammatory drugs, narcotics, local anesthetics, or other antibiotic/antifungal therapy are not given unless esophagitis progressed to grade 4.
224322029|NCT01427608|DRUG|Sertraline + Olanzapine|Olanzapine 15mg/day. Adjustment of dose to 5mg/day to a maximum of 20mg/day will be permitted if necessitated by significant side-effects or clinical worsening
224322030|NCT01427608|DRUG|Sertraline + Placebo|Taper from current dose of olanzapine to placebo over 4 weeks. Continue placebo for remainder of 36 week study.
224322031|NCT03993379|DRUG|CX-072|CX-072 in combination with ipilimumab
224322032|NCT03993379|DRUG|Ipilimumab|CX-072 in combination with ipilimumab
223669840|NCT02577393|DRUG|EGCG|EGCG (purity≥95% by high pressure liquid chromatography; from Ningbo HEP Biotech Co., Ltd) is dissolved in 0.9% saline solution three times a day. A new batch is made up each time. For esophageal application, repeated swallowing of 10 ml of the EGCG solution is indispensable to assure the prolonged presence of drug the esophageal walls. We choose a dose of 440 lmol/L as the recommended concentration for this study by referring to our previous phase I study. Patients begin medications as soon as grade 1 esophagitis occurred during radiation according to the RTOG criterion.
224250839|NCT05675215|DIAGNOSTIC_TEST|Psychopathology screening tests|"The assessment phase includes the SCID-5 (First et al., 2017), the D-PSY questionnaire and standardized questionnaires. The D-PSY questionnaire and the SCID-5 (First et al., 2017) will be counterbalanced in terms of the order of administration, with half of the participants taking the SCID-5 (First et al., 2017) first and then the D-PSY questionnaire and the others standardized; the other half will take the D-PSY first and then the SCID-5 (First et al., 2017) and the other questionnaires.~The other standardised questionnaires will be randomised for order of administration. These standardised questionnaires measure social desirability (Balanced Inventory of Desirable Responding, BIDR, Paulhus, 1985, 1991; in French: Cournoyer \& Sabourin, 1991), dissociation (DIS-Q, Vanderlinden et al., 1993), phobia (the Fear Questionnaire, F.Q., Marks \& Mathews, 1979; in French Cottraux et al., 1987) and autism (AQ, Baron-Cohen et al., 2001; in French, translation by Braun \& Kempenaers, 2007)."
223669841|NCT02577393|DRUG|mLDG|mLDG (lidocaine 0.16mg/mL, dexamethasone 0.02mg/mL, and gentamycin 0.16mg/mL) dissolved in 0.9% saline solution was administered three times a day. Patients were given oral mLDG solution, and began medications as soon as grade 1 esophagitis occurred during radiation according to the RTOG criterion.
223669842|NCT02282293|DRUG|Monthly dihydroartemisinin-piperaquine (DP) + daily trimethoprim/sulfamethoxazole (TS)|
223669843|NCT02282293|DRUG|Monthly placebo + daily trimethoprim/sulfamethoxazole (TS)|
223669844|NCT03829878|DRUG|CP101|Orally administered donor derived full spectrum microbiota
224250840|NCT05128812|DIETARY_SUPPLEMENT|PLX|Intake of natural food supplement of vegetable origin based on lemon verbena extract (Lippia citriodora). To study the anxiolytic effects in subjects with high perceived stress levels and low sleep quality.
224250841|NCT01885455|OTHER|Usual Care|Usual care includes: complete staging work-up (CT/PET scan and possible mediastinoscopy), surgical consultation with a general or cardiothoracic surgeon, cardiac clearance and/or pulmonary function testing (if deemed necessary by the evaluating surgeon), surgical resection (wedge resection, lobectomy, pneumonectomy, or radiosurgery, as indicated by the size and location of the tumor), and adjuvant therapy (radiotherapy and/or chemotherapy, as determined by the intraoperative findings and pathology results).
224250842|NCT01885455|OTHER|Intervention Arm|The proposed Intervention (EPDPN) will be administered by the PNs at the intervention sites on an outpatient basis. Several defining, fundamental characteristics of the PNs will ensure consistency of the intervention delivery across the various study sites.
224250843|NCT01925092|DRUG|mifepristone|tablets
224250844|NCT04607720|PROCEDURE|artificial-EUS-FNA|The ultrasound endoscopists manually determined the region of interest (ROI) according to CH-EUS, and punctured 2 needles in the tumor area with a 22G needle, and each needle moved 15-20 times back and forth in the lesion. After puncture, insert the needle core, rinse the needle with 0.1ml sterile saline, and further apply air flushing to ensure that each tissue is sent to the slide.
224250845|NCT04607720|PROCEDURE|AI-EUS-FNA|In the AI-assisted diagnosis system, the assisted targeting EUS-FNA unit is applied, and the ultrasound endoscopist selects the region of interest (ROI) according to the thermogram to perform targeted EUS-FNA puncture(2 needles in the same way).
224250846|NCT04008498|DIAGNOSTIC_TEST|AEEG brain monitoring|"Babies will be recorded continuously for the entire duration of their time on the intensive care unit.~Once the child is receiving high dependency or special care, we will record aEEG for 4 hours once a week until the baby is discharged home. If a participant is moved back to intensive care, the aEEG will be started again if the aEEG monitor is not being used on another baby."
224250847|NCT01612520|BEHAVIORAL|telecoaching|"The COACH program trains patients to 'drive' the process of achieving and maintaining the target levels for their risk factors while working in association with their GP. The telephone coaching is aimed at improving self-efficacy by adhering to the prescribed therapy and making relevant behavior changes.~The coaching model is a continuous five-stage coaching cycle: Stage 1. Finding out what the patient knows; Stage 2. Telling the patient what they should know; Stage 3. Assertiveness training; Stage 4. Setting an action plan; Stage 5. Reassessment at the next coaching session (monitoring).~The coach monitors and registers: the biomedical risk factors, the lifestyle/behavioral risk factors and use of the recommended medications. Coaching is focused on eliminating the knowledge gap and motivating the patient to apply the appropriate lifestyle and medical therapy."
224250848|NCT01125059|DRUG|Methadone|0.2 mg/kg methadone IV bolus
224250849|NCT01125059|DRUG|Saline|3 mL saline IV bolus
224250850|NCT00226317|DRUG|Aripiprazole|
224250851|NCT02359617|DRUG|insulin delivery|Subcutaneous insulin (100 U/ml, NovoRapid®; Novo Nordisk, Bagsvaerd, Denmark) delivery with an insulin pump (Vibe-TM; Animas Corp., West Chester, PA, USA) and an insulin infusion cannula (SOF-SET MICRO QR 6mm; Medtronic MiniMed, USA) placed at the same site as the continuous glucose sensor.
224250852|NCT02359617|DEVICE|glucose sensing|Glucose sensing with a continuous glucose sensor (Dexcom G4 Platinum Sensor; Dexcom Inc., San Diego, USA) placed at the site of subcutaneous insulin delivery.
224250853|NCT05065229|DEVICE|Oxygen saturation probe Mindray 520 N and Mindray 521 N|"Two oxygen saturation probes will be used in this study:~Mindray 520 N is a disposable oxygen saturation sensor for neonates and adults. It is a disposable, single-use sensor that is wrapped around the infant's arm or foot. Its ends stick together giving a firm, close contact with the skin.~Mindray 521 N is another disposable oxygen saturation sensor for neonates and adults that is used on the neonatal unit in routine practice. As Mindray 520 N and 521 N are CE marked and used within their intended purposes we do not require a letter of no objection from the MHRA for that usage. The Mindray probes will be used without modification and there are no safety issues to the patient. Therefore, a letter of no objection from the MHRA is not required and this is not a medical device study under the Medical Devices Directive."
223669845|NCT03829878|DRUG|Placebo|Placebo for CP101
223669846|NCT02591329|BEHAVIORAL|Mail-out hard copy materials (education plus self-regulatory strategies examples)|
223669847|NCT02591329|BEHAVIORAL|Standard Care|
223669848|NCT00562315|DRUG|FACBC|Anti-3-\[18F\]FACBC is an investigational positron emission tomography (PET) radiotracer being studies given intravenously prior to PET scan
223669849|NCT00562315|OTHER|ProstaScinct|ProstaScint (In-Capromab Pendetide) is used to image the extent of prostate cancer in standard practice. Capromab is a mouse monoclonal antibody which recognizes prostate specific membrane antigen from prostate cancer cells and normal prostate tissue. It is given intravenously prior to undergoing CT imaging.
223669850|NCT04161768|DRUG|Norfloxacin|Norfloxacin 400 mg daily
223669851|NCT04161768|DRUG|Itopride|Itopride 50 mg three times daily
223669852|NCT03190733|DRUG|ATG|ATG will be intravenously infused via a central venous catheter in 4 or 5 days, from day -4 or -3 until day 0. The other conditioning drugs administered before transplantation include fludarabine (Flu), busulfan (Bu),cyclophosphamide (Cy). All transplant recipients will receive cyclosporine A (CsA), mycophenolate mofetil(MMF) for aGVHD prevention.
223669853|NCT03741478|DRUG|OLANZapine 2.5 MG|"Olanzapine capsules (2.5mg) will be administered with the following dosing schedules for each arm:~1. Metabolic arm - 5mg on Day 0, 7.5mg on Day 1, and 10mg on Day 2~2. Cognitive arm - 5mg on Day 0, 10mg on Day 1"
223669854|NCT03741478|DRUG|Placebo|Placebo capsules visually identical to those containing olanzapine will be administered according to the same dosing schedule for each arm.
223669855|NCT03741478|DRUG|Insulin Lispro 100 UNT/ML|"Intranasal insulin spray (or placebo) will be administered on day 2 for each arm.~For the metabolic arm: 40 IU of intranasal insulin lispro will be administered at timepoint 0 during the pancreatic euglycemic clamp procedure.~For the cognitive arm: 160 IU of intranasal insulin lispro will be administered at about 11 am on day 2 prior to the MRI imaging and cognitive testing procedures."
223669856|NCT03741478|OTHER|Saline|Placebo saline spray visually identical to the intranasal insulin spray will be administered on day 2 for each arm according the same dosing schedules.
223669857|NCT02671916|BEHAVIORAL|questionnaire|Investigation on all study patients, no Intervention, no groups
223669858|NCT04976270|DRUG|GLPG3667|GLPG3667 capsules
223669859|NCT04976270|DRUG|Placebo|Matching placebo capsules
223669860|NCT05535205|OTHER|Digital preoperative assessment|a digital preoperative assessment for patient requiring surgery
223669861|NCT05535205|OTHER|Face-to-face preoperative assessment|a face-to-face preoperative assessment for patient requiring surgery
223669862|NCT00908739|GENETIC|gene expression analysis|immunohistochemistry for levels of expression of five different factors related to aggressive tumor behavior (i.e., VEGF expression, E-cadherin regulation, matrix metalloproteinase 2 and 9 activity, and carbonic anhydrase 9 activity)
223669863|NCT00908739|OTHER|immunohistochemistry staining method|immunohistochemistry for levels of expression of five different factors related to aggressive tumor behavior (i.e., VEGF expression, E-cadherin regulation, matrix metalloproteinase 2 and 9 activity, and carbonic anhydrase 9 activity)
223669864|NCT00908739|OTHER|laboratory biomarker analysis|immunohistochemistry for levels of expression of five different factors related to aggressive tumor behavior (i.e., VEGF expression, E-cadherin regulation, matrix metalloproteinase 2 and 9 activity, and carbonic anhydrase 9 activity)
224250854|NCT04320147|DEVICE|Artemia|Before prostate biopsy, all patients be preceded by mpMRI.MR-targeted biopsy using Artemis device fusion of MRI and ultrasound images would be performed. MR targeted biopsy would be performed by radiologist.
223669865|NCT01467778|DEVICE|ELAPR|ELAPR implant product is under development for mid to deep dermal implantation for the treatment of the symptoms of skin aging including the correction of moderate to sever facial wrinkles and folds, such as nasolabial folds and skin abnormalities such as scars.
223669866|NCT01467778|DEVICE|ELAPR|Implant area of the medial aspect of the upper arm along the posterior line of the bicep is to be selected where there are no pigmentations or moles. Injections will be marked with a tattoo and placed at 2 cm intervals. The order is to be from proximal to distal control, ELAPR001, ELAPR002, ELAPR003
223669867|NCT03513341|OTHER|No intervention|No intervention is given to the participants. This is an observational study exploring the students' levels of physical activity and sedentary behaviour in their natural setting.
223669868|NCT00949767|DRUG|BMS-866949|(Panel 1 - 0.5 mg) - Oral Solution, Oral, once, 14 days
223669869|NCT00949767|DRUG|BMS-866949|(Panel 2 - 2.5 mg) - Oral Solution, Oral, once, 14 days
223669870|NCT00949767|DRUG|BMS-866949|(Panel 3 - 10 mg) - Oral Solution, Oral, once, 14 days
223669871|NCT00949767|DRUG|BMS-866949|(Panel 4 - 25 mg) - Oral Solution, Oral, once, 14 days
223669872|NCT00949767|DRUG|BMS-866949|(Panel 5 - 50 mg) - Oral Solution, Oral, once, 14 days
223669873|NCT00949767|DRUG|BMS-866949|(Panel 6 - 100 mg) - Oral Solution, Oral, once, 14 days
223669874|NCT00949767|DRUG|BMS-866949|(Panel 7 - 150 mg) - Oral Solution, Oral, once, 14 days
224250855|NCT02131129|DEVICE|rTMS|"The stimulation sites will be the left and right DLPFC, defined as 5 cm anterior to the scalp positions at which the MTs were determined. Treatments will be delivered within the following stimulation parameters: 110% of MT, 20 Hz, 30 trains, 1.0 second per train, 20 pulses per train, inter-train interval of 30 seconds (600 pulses/hemisphere, for a total of 1200 pulses/session/day).~Ten sessions over a two week duration"
223669875|NCT00949767|DRUG|Placebo|(Matching volume) - Oral Solution, Oral, once 14 days
224322033|NCT04999657|DEVICE|Non-invasive low-frequency tibial nerve stimulator (TNS-01)|The investigational device is a transcutaneous electrical nerve stimulation (TENS) device that is designed to provide stimulation to the nerves at the site of application via surface electrodes temporarily adhered to the skin.
224322034|NCT04486365|PROCEDURE|Bifocal bone transport.|The bifocal approach is a single osteotomy to create one transported bone segment between the osteotomy and the defect.
224322035|NCT04486365|PROCEDURE|Trifocal bone transport|The trifocal approach is two osteotomies creating two separate transported bone segments.
223669876|NCT04105478|PROCEDURE|Shoulder arthroplasty|Patients suffering from severe glenohumeral osteoarthritis are treated surgically by a total shoulder arthroplasty
223669877|NCT05337020|OTHER|Survey|Each patient will be asked to fill in the questionnaire to assess their vision on telemedicine
223669878|NCT03417401|PROCEDURE|Vitrectomy with retinal vein cannulation and intravenous rtPA (Actilyse) infusion up to 1mg.|Standard 3-port pars plana vitrectomy with surgical stabilizer assisted ( surgical robot) retinal vein cannulation with recombinant tissue Plasminogen Activator (Actilyse-0.25mg/ml) infusion with a maximal dose of 1mg..
223669879|NCT03417401|DRUG|Intravenous Infusion|Intravenous infusion in a retinal vein with rtPA (Actilyse 0.25mg/ml).
223669880|NCT01523470|DEVICE|BIPAP Synchrony|BIPAP Synchrony is a machine for non-invasive ventilation for acute hypercapnic respiratory failure in chronic obstructive airway disease exacerbation. It is a temporary measure. It is proven to be effective and reduce mortality and intubation in COAD exacerbation. However, the method of withdrawal of the machine remained controversial.
223669881|NCT02312687|BIOLOGICAL|KRN23|solution for SC injection
223771532|NCT01662869|DRUG|5-Fluoruracil|Participants will receive 5-fluorouracil 400 milligrams per square meter (mg/m\^2) IV bolus and then 2400 mg/m\^2 as a continuous IV infusion over 46-48 hours on Day 1 of every cycle until disease progression or at the maximum of 12 cycles, whichever occurs first.
223771533|NCT01662869|DRUG|Folinic acid|Participants will receive folinic acid 400 mg/m\^2 IV infusion over 2 hours on Day 1 of every cycle until disease progression or at the maximum of 12 cycles, whichever occurs first.
224250856|NCT02131129|DEVICE|Sham Comparator|"The stimulation sites will be the left and right DLPFC, defined as 5 cm anterior to the scalp positions at which the MTs were determined. Treatments will be delivered within the following stimulation parameters: 110% of MT, 20 Hz, 30 trains, 1.0 second per train, 20 pulses per train, inter-train interval of 30 seconds (600 pulses/hemisphere, for a total of 1200 pulses/session/day).~Ten sessions over a two week duration"
224250857|NCT00932880|DRUG|Amlodipine Besylate|10 mg tablets (Torrent Pharmaceuticals, India)
224250858|NCT00932880|DRUG|Norvasc|10 mg dose (Pfizer, USA)
224250859|NCT01848340|DRUG|GSK1265744B (sodium salt) containing 14C-GSK1265744B|A white to slightly colored nonsterile crystalline powder for oral solution
223669882|NCT05632744|DEVICE|CG-100 Intraluminal Bypass Device|Subjects will be treated with the CG-100 Intraluminal Bypass Device
223669883|NCT01699971|PROCEDURE|Hernia repair|Hernia repair admodum Lichtenstein with polypropylene mesh
223669884|NCT01699971|PROCEDURE|Hernia repair|Hernia repair with Ultra Pro Hernia System (UHS)
224250860|NCT01848340|DRUG|150 mg GSK1265744B|This is GSK1265744B (sodium salt of GSK1265744), lactose monohydrate, Microcrystalline cellulose, hypromellose, sodium lauryl sulfate, croscarmellose sodium, magnesium stearate, Opadry film-coating, white OY-S-28876 tablet
224250861|NCT01848340|DRUG|Placebo|Microcrystalline cellulose, Opadry film-coating, white OY-S-28876 tablet
224322036|NCT03685214|DRUG|0.9% saline|we use 0.9% saline in ICU patients with sepsis for resuscitation fluid.
224322037|NCT03685214|DRUG|lactated Ringer's solution|we use balanced balanced crystalloids in ICU patients with sepsis for resuscitation fluid.
223669885|NCT01699971|PROCEDURE|Hernia repair|Hernia repair with Prolene Hernia System(PHS)
223669886|NCT04612023|OTHER|Acellular Amniotic Membrane Derived Allograft Injection (NuDYN)|Injectable acellular amniotic membrane derived allograft tissue (NuDYN) through routine follow-up with physical examination, pain, function and quality of life measurements and compare dose effects (1 mL versus 2 mL of NuDYN injection) to a placebo (sterile saline) in the treatment of knee osteoarthritis. Injection is minimally invasive and is FDA regulated (HCT/P regulation).
223669887|NCT06131671|OTHER|Whole-body electrical stimulation|"The parameters adopted for the treated group will be: symmetrical biphasic current, pulse width of 400 µs, frequency of 80 Hz, contraction time of five seconds and decreasing rest time, varying from 10 to 5 s. The intensity will be individually adjusted to the patient's maximum tolerance limit to produce visible muscle contraction.~The session time will be 15 to 20 minutes and the number of contractions will increase with each week of training.~Concomitant to the electrical stimuli, exercises will be performed for the elbow flexors and extensors, spine flexors and extensors, knee flexors and extensors, hip flexors and extensors and the calf muscles."
223669888|NCT05785481|DIAGNOSTIC_TEST|Clinical and instrumental neurological assessment|"During the neonatal period:~neurological objective exam according to the modified Sarnat score, Thompson score and Hammersmith Neonatal Neurological Examination (HINE) within 6 hours of life, 24 hours of life and before resignation; an AEEG study within 6 hours of life, for 6 hours; cerebral ultrasound within 6 hours of life, in the third and seventh day of life; a brain magnetic resonance imaging study between the seventh and 14th day of life; an EEG evaluation within 7 days.~After resignation, all patients will be included in a minimum duration follow-up program of 12 months, with assessments at 3rd, 6th and 12th month of age:~Hammersmith Neonatal Neurological Examination (HINE) and evaluation of the General Movements; evaluation of psychomotor development through Griffiths/Bayley III scales at the 12th month; EEG evaluation at the 6th and 12th month."
223669889|NCT00735059|DEVICE|treatment with the dialyzer ELISIO 170H|one week of three consecutive dialysis treatments, \> 3 hours
223669890|NCT00735059|DEVICE|treatment with the dialyzer PES-170DS|one week of three consecutive dialysis treatments, \> 3 hours
223669891|NCT00384111|DRUG|Zevalin Therapeutic Regimen|Day 1: 250 mg/m2 Rituxan followed by 5 mCi 111In Zevalin. Day 7: 250 mg/m2 Rituxan followed by 0.4 mCi/kg Zevalin
223669892|NCT00384111|DRUG|R-CVP|Standard R-CVP
223771534|NCT01662869|DRUG|Onartuzumab|Participants will receive onartuzumab 10 mg/kg IV infusion on Day 1 of every cycle (each cycle = 14 days) until disease progression, unacceptable toxicity, or participant or physician decision to discontinue treatment.
223771535|NCT01662869|DRUG|Oxaliplatin|Participants will receive oxaliplatin 85 mg/m\^2 IV infusion over 2 hours on Day 1 of every cycle until disease progression or at the maximum of 12 cycles, whichever occurs first.
223771536|NCT01662869|DRUG|Placebo|Participants will receive onartuzumab matching placebo on Day 1 of every cycle (each cycle = 14 days) until disease progression, unacceptable toxicity, or participant or physician decision to discontinue treatment.
224250862|NCT01467622|PROCEDURE|Chest tube removal|Chest tube removal on the basis of local recommendations for postoperative chest tube management
224250863|NCT04985474|OTHER|questionnaires|
224250864|NCT02865122|DRUG|NTRA-9620|Oral daily dose
224250865|NCT02865122|DRUG|Placebo|Oral daily dose
224250866|NCT00278018|PROCEDURE|Immunotherapy treatment for solid tumors|
224250867|NCT05330754|DIETARY_SUPPLEMENT|Caffeine intake in mg|"Preanesthetic check-up was done. Average daily caffeine consumption in mg was calculated according to caffeine content in consumed drinks as estimated by Food Data Central."
224250868|NCT02388620|DRUG|LEE011|400 mg
224250869|NCT02152683|DEVICE|Renova|Low- Intensity Shockwave
224250870|NCT02934347|PROCEDURE|25 degree back-up position|To test whether a 25 degree back-up position improves laryngeal views and makes intubation easier compared to the standard horizontal position
224250871|NCT04011345|DIETARY_SUPPLEMENT|Folic Acid Supplement|1 milligram folic acid
224322038|NCT04816071|DRUG|Essential amino acids|Dietary Supplement
224322039|NCT04816071|DIETARY_SUPPLEMENT|Maltodextrin|Control
224322040|NCT05476926|DRUG|Faricimab|Faricimab will be administered as per local clinical practice and local labeling.
224323529|NCT05159999|OTHER|Dry weight target adjustment|Target dry weight will be adjusted every 2 weeks to reach the home or pre-dialysis systolic blood pressure target.
224250872|NCT04011345|DIETARY_SUPPLEMENT|Placebo|Placebo
224250873|NCT05984420|DEVICE|LimpiAD 2,5% plus cream|A topical formulation that contains Hyaluronic Acid conjugated with a bacterial wall fragment of Cutibacterium species (HAc-40) and an emollient base. LimpiAD exerts its post-biotic action through the seizure/ trapping and inactivation of catabolites and / or toxins produced by S. aureus as well as protecting the hydrolipidic film, especially in case of dryness, itching, and, in conditions of altered microbiome
224250874|NCT05984420|OTHER|Vehicle|"Vehicle of LimpiAD 2.5 % plus cream which has the qualities of an emollient technically enriched with active ingredients known for their use in AD (plus emollient) - having the same ingredients of LimpiAD 2.5% Plus but without the HAc-40 component."
224250875|NCT05984420|OTHER|Emollient|Standard emollient used as neutral control, having only a moisturizing and skin barrier action, which represents the basic standard treatment (basic therapy) of atopic dermatitis according to the European Guidelines.
224250876|NCT02012920|DRUG|Seviteronel: given orally once daily in 28 day cycles|
224250877|NCT02978586|DEVICE|[Ga-68]PSMA PET/MR|All participants will undergo at least 1 baseline \[Ga-68\]PSMA PET/MR. If participants test positive for \[Ga-68\]PSMA tumor uptake, they will under up to 2 additional scans
224250878|NCT06123533|OTHER|No intervention|There is no intervention.
224250879|NCT00058955|DRUG|sodium oxybate, triazolam and pentobarbital|sodium oxybate, triazolam and pentobarbital
224250880|NCT04480762|DRUG|SHR-1703|SHR-1703
224322041|NCT05476926|COMBINATION_PRODUCT|Port Delivery System with Ranibizumab|The port delivery system with ranibizumab will be administered as per local clinical practice and local labeling.
224250881|NCT04480762|DRUG|Placebo|Placebo of the SHR-1703
224250882|NCT00000661|DRUG|Oxazepam|
224250883|NCT00000661|DRUG|Zidovudine|
224322042|NCT03790657|BEHAVIORAL|practice of a complex walking task|walking over obstacles
223669893|NCT00801307|DEVICE|spirometer|According to the randomisation order, the appropriate medical gas cylinder with the pressure regulator will be connected to a humidifier to avoid the inhalation of very dry gas; the humidifier will be connected to the breathing bag; the flow of the medical gas will be adjusted individually for each subject/patient by the valve of the pressure regulator.
223669894|NCT04733794|PROCEDURE|Stoma reversal|Patients will receive a comprehensive intervention to addresses bowel, sexual, and urinary dysfunction. Patients meeting appropriate inclusion criteria will be approached at a clinic visit with their surgeon. If they agree to participate, they will complete an initial baseline questionnaire. Questionnaires will be distributed on iPads during their clinic visit
223771537|NCT03146702|OTHER|Quality of Life|Patients self administor quality of life questionnaires such as Minnesota Living with Heart Failure Questionnaire and EmPHasis-10 questionnaire
223771538|NCT03859232|OTHER|Delta Dry® Waterproof Pantaloon|Cast with newer waterproof material developed to reduce the skin complications associated with traditional cotton liners.
223771539|NCT03859232|OTHER|Cotton Padding|Cast with traditional cotton liner.
224250884|NCT01816490|DRUG|Intravenous Silibinin (iSIL)|
224250885|NCT03697798|BIOLOGICAL|Boostrix®-IPV combination vaccine|A licensed aP (acellular) booster vaccine developed by GlaxoSmithKline.
224250886|NCT03488186|DRUG|Lansoprazole Capsules|24 healthy volunteers will be recruited and randomized into 2 groups (12 for each). During the study session, subjects will receive T drug in group A or R drug in group B for 7 days in fasted condition.
224250887|NCT00050297|DRUG|YM598|
224250888|NCT01721850|OTHER|control formula|commercial stage 1 infant formula
224250889|NCT01721850|OTHER|intervention formula 1|infant formula with hydrolyzed protein (type I) and pre- and probiotics
224250890|NCT01721850|OTHER|intervention formula 2|infant formula with hydrolyzed protein (type II) and pre- and probiotics
224250891|NCT02404194|BEHAVIORAL|Targeted Cognitive Training|Targeted Cognitive Training is performed on the computer through Posit Science. Games are modern and engaging modifications of classic neuropsychological tests, such as set-shifting games modeled on the Wisconsin Card Sort Test, and cognitive control games modeled on Stroop-like interference tasks. Games will target two sets of skills: Targeted cognitive skills include: processing speed, memory, attention, flexibility/cognitive-control, and problem-solving. After 20 hours of training on these skills, participants will complete 20 hours of training on core social cognitive skills, including facial affect recognition, gaze direction perception, and face identity recognition, and theory of mind.
224250892|NCT02404194|BEHAVIORAL|Computer Games|The comparison intervention consists of 40 hours of commercially available and cognitively non-specific computer games. These computer games - such as checkers, solitaire, crossword puzzles - are entertaining and engaging but do not target specific neurocognitive skills.
224250893|NCT06872034|DRUG|Venostasin (horse chestnut seed extract tablets)|Venostasin (horse chestnut seed extract tablets) ，twice daily, 400 mg per dose, for 14 days
224250894|NCT06872034|OTHER|standard treatment|standard treatment
224250895|NCT02350647|DEVICE|Suture Anchor HEALOCOIL|Rotator cuff tears will be repaired intraoperatively using suture anchors
224250896|NCT02350647|DEVICE|Suture anchor Twinfix Ultra HA|
224250897|NCT01173263|OTHER|BIS 70 maintained|Each patient will receive propofol sedation by continuous infusion titrated to a BIS level of 70.
224250898|NCT01173263|OTHER|BIS level 50|Each patient will receive propofol sedation by continuous infusion titrated to a BIS level of 50.
224250899|NCT01173263|OTHER|BIS 35|Each patient will receive propofol sedation by continuous infusion titrated to a BIS level of 35.
224250900|NCT04739384|DRUG|Ticagrelor 90mg|Ticagrelor 90 mg followed by Ticagrelor 60 mg
224250901|NCT04739384|DRUG|Ticagrelor 60 mg|Ticagrelor 60 mg followed by Ticagrelor 90 mg
224322043|NCT03790657|DEVICE|Active transcranial direct current stimulation (Active tDCS)|mild electrical stimulation delivered to the frontal region of the brain
224322044|NCT03790657|DEVICE|Sham transcranial direct current stimulation (Sham tDCS)|30 seconds of mild electrical stimulation delivered to the frontal region of the brain
224322045|NCT02631889|DEVICE|Transcollation technology|The use transcollation technology for dissection during lung surgery
224322046|NCT02631889|DEVICE|Traditional electrocautery|The use of traditional Electrocautery for dissection during Lung Surgery
224322047|NCT01795950|DRUG|PLX-PAD|intravenous administration of a single dose of PLX-PAD cells
223669895|NCT02643069|OTHER|Intervention Geriatric Program|The investigators will implemented programs to detected and manage care for older patients in four settings: Emergency room, oncology department, surgery departments making major surgery and Cardiology. The core intervention will consist of the following elements: comprehensive geriatric assessment, coordination with primary ans social care, integrated and continued care, access to rehabilitation facilities, management of drug treatment avoiding polypharmacy and stressing adherence.
223669896|NCT00647829|DRUG|valdecoxib|valdecoxib 20 mg tablet by mouth twice daily (BID) for 2 doses over a 24-hour period
223669897|NCT00647829|DRUG|valdecoxib|valdecoxib 40 mg tablet by mouth once daily (QD) for 2 doses over a 24-hour period
223669898|NCT00647829|DRUG|placebo|placebo tablet by mouth for 2 doses over a 24-hour period
223669899|NCT04204070|PROCEDURE|Accuro|A research coordinator recorded the depth of the EDS from skin, the number of attempts to perform the epidural anesthesia, the repositioning of the epidural needle either in the same space or in different space, the time taken for space localisation (it is defined as time taken in seconds from skin puncture until the successful space localisation).the total time of the procedure ( time measured from the patient is fully draped and in the proper sitting position till the end of insertion of the epidural catheter ) Any complications such as paresthesia during catheter insertion, dural puncture, blood in catheter and root irritation will be recorded
223669900|NCT04204070|PROCEDURE|APAD|APAD
223669901|NCT02665403|OTHER|Play intervention|participants received around 30 minutes of hospital play interventions each day, conducted by hospital play specialists. Such interventions consisted of structured and non-structured activities. All these activities were given at the patients' bedside, with or without parental supervision, either once or spreading over an hour, depending on the ward routine.
223669902|NCT02665403|OTHER|control|Children received standard medical and nursing care, such as vital signs observation, pharmacological treatment and wound and pain management as a control treatment
223669903|NCT02880696|BEHAVIORAL|Regular stimulation sequence|Vibrotactile stimulation of the right hand with regular intervals and random omissions
223669904|NCT02880696|BEHAVIORAL|Random stimulation sequence|Vibrotactile stimulation of the right hand with random intervals and random omissions
223669905|NCT02880696|DEVICE|DCS|Near-infrared imaging of the neurovascular response in the left somatosensory cortex
223669906|NCT04628377|DEVICE|Angiography-drived Index of Microcirculatory Resistance|"From coronary angiographic images, angiography-derived IMR will be calculated based on mathematical calculation.~Angiography-derived IMR = (hyperemic Pa x angiography-derived FFR) x (vessel length / {K x V diastole}).~Hyperemic Pa will be estimated from resting Pa according to prespecified equation."
223669907|NCT04049682|BEHAVIORAL|Delayed School Start Time|Francis Parker High School implemented 45-minute later school start time.
223669908|NCT03633877|DEVICE|DuraporeTM and Hy-Tape®|Medical tapes
223669909|NCT06430827|DRUG|irinotecan hydrochloride liposome injection|rinotecan hydrochloride liposome injection (70mg/m\^2) will be administered by intravenous infusion on day 1 in a 2-week treatment cycle.
224250902|NCT01492894|DRUG|Cyclosporins/Tacrolimus|Decrease the dose of calcineurin inhibitor by 1/2 and the drug level will be followed and adjusted to the target level of 50% of the previous levels
224250903|NCT01492894|DRUG|Sirolimus|Change from current calcineurin inhibitor to Sirolumus
224250904|NCT03497247|BEHAVIORAL|Mindfulness-Based Cognitive-Behavioral Therapy|Both arms have the same intervention techniques (relative intervention, stimulus control and others) except relapse prevention sessions. In the experimental arm, these sessions are carried out from Mindfulness, and in the active comparator is the usual relapse prevention.
224250905|NCT01194791|DRUG|Lenalidomide|Lenalidomide 15 mg by mouth for 21 days followed by 7 days rest during 6 cycles
224250906|NCT01194791|DRUG|Cyclophosphamide|Cyclophosphamide 300 mg/m2, on days 1 and 8 every 4 weeks during 6 cycles
224250907|NCT01194791|DRUG|Dexamethasone|Oral dexamethasone 20 mg/day on days 1-4 and 9-12 given at 4-week intervals during 6 cycles
224322048|NCT02691325|DRUG|GSK2269557 ELLIPTA DPI|GSK2269557 ELLIPTA DPI contains GSK2269557 blended with lactose and magnesium stearate. This will be supplied in two strength of 100 mcg per blister.
223669910|NCT06430827|DRUG|Capecitabine|Capecitabine (1000 mg/m\^2) will be administered orally in a 2-week treatment cycle, twice a day from day 1 to day 10 of each cycle
223669911|NCT03612856|DRUG|AB023- Dose 1|Participants will receive a single dose of 0.25 mg/kg AB023.
223669912|NCT03612856|DRUG|AB023-Dose 2|Participants will receive a single dose of 0.5 mg/kg AB023.
224250908|NCT03498391|DRUG|Propofol|Titration of propofol to minimal and moderate sedation as measured by Richmond Agitation-Sedation Scale with behavioral task performance over several hours.
223669913|NCT03612856|DRUG|placebo|Participants will receive a single dose of placebo.
223669914|NCT05630300|DIAGNOSTIC_TEST|PMC Sure Status COVID-19 Antigen Test|COVID-19 professional use kit in out-patient departments
223669915|NCT05630300|DIAGNOSTIC_TEST|Acon Flowflex COVID-19 Antigen Home Test|COVID-19 self-test kits
223669916|NCT01516333|OTHER|High GL 107|Three meals a day
223669917|NCT01516333|OTHER|Medium GL 76|Three meals a day
223669918|NCT01516333|OTHER|Medium GL 68|Three meals a day
223669919|NCT01516333|OTHER|Low GL 48|Three meals a day
224250909|NCT03498391|DRUG|Ketamine Injectable Product|Titration of ketamine to minimal and moderate sedation as measured by Richmond Agitation-Sedation Scale with behavioral task performance over several hours.
224250910|NCT00837486|DEVICE|Reclaim™ DBS System|
224250911|NCT04478786|OTHER|Focus group discussion|There is no intervention. This is a qualitative piece of work only.
224250912|NCT05957003|PROCEDURE|Combined end-expiratory occlusion and end-inspiratory occlusion test|"The EEO test will be performed by interrupting the mechanical ventilation at end-expiration over 15 seconds using the end-expiratory hold button available on the ventilator.~The EIO test will be performed by interrupting the mechanical ventilation at end-inspiration over 15 seconds using the end-inspiratory hold button available on the ventilator."
224250913|NCT05957003|PROCEDURE|Tidal volume challenge test|elevating tidal volume from 6 ml/kg to 8 ml/kg for only 60 seconds
224322049|NCT02691325|DRUG|Placebo ELLIPTA DPI|Placebo ELLIPTA DPI contains lactose.
224322050|NCT02691325|DRUG|Activated charcoal|The activated charcoal will be supplied by the clinical site. Charcoal will be administered as a suspension of 5 gram activated charcoal in 40 mL of water. The suspension will be made to drunk, in its entirety.
223669920|NCT04975529|BEHAVIORAL|Game on Philly: Engaging Underserved Middle School Youth in Out-of- School Time Sports and Nutrition Education|Two-group quasi experimental intervention with schools assigned to intervention or comparison.
223669921|NCT00223236|DRUG|Citicoline|Citicoline or placebo will be given beginning at one table (500mg)/day with an increase to two tablets (1000mg)/day at week 2, three tablets (1500mg)/day at week 4 and four tablets (2000mg)/day at week 6. Patients will remain on 2000mg/day through week 12. Doses will be decreased if needed due to side effects.
223669922|NCT00223236|DRUG|Placebo|Placebo matching active medication in all other aspects.
223669923|NCT03067233|OTHER|Polysomnography|Complete polysomnography with : Electroencephalogry, electro-oculography, surface electromyography (chin muscle, anterior tibial muscles), nasal pressure, respiratory movements (plethysmography of thoracic and abdominal inductance), pulse oximetry and electrocardiography.
223669924|NCT05328349|BEHAVIORAL|Education Program|After the baseline evaluation, all participants will take part in an education intervention, aiming at promoting self-management of shoulder pain, that will include two one-on-one sessions (approximately 30-45 minutes) within 2 weeks with a physiotherapist (1st session right after the baseline evaluation, 2nd session two weeks later). Participants will receive written information regarding shoulder (anatomy and function) and basic pain science and will be directed to watch a series of six educational videos on shoulder pain and function, persistent pain, physical activity, stress, sleep and eating habits. It should be noted that the objective of this study is not to assess the effectiveness of the intervention; the purpose of offering an intervention to participants is to control the intervention that will be received by them.
223669925|NCT01164709|DRUG|bortezomib|Bortezomib i.v., day 8, 11, 15, 18; 1.3 mg/m2
223669926|NCT01164709|DRUG|nelfinavir mesylate|p.o., days 1 to 21; dose level: (625), 1250, 1875, or 2500 mg, 2x/d
223669927|NCT04429477|DEVICE|Cerebral compliance and hemodynamics monitoring|Noninvasive devices are been used to assess cerebral circulation and compliance.
223669928|NCT01763840|DRUG|Contrast enhanced Ultrasound|Ultrasound, then contrast enhanced ultrasound.
223669929|NCT01628185|PROCEDURE|Repositioning|pain assessment at baseline then following routine care repositioning in bed
223669930|NCT04232293|DIAGNOSTIC_TEST|Blood tests|eLift and FibroMeter
223669931|NCT02639416|DIETARY_SUPPLEMENT|Polymeric formula|Polymeric formulae are recommended in the management of inflammatory bowel disease in children
223669932|NCT02639416|DIETARY_SUPPLEMENT|Elemental formula|Elemental formulae are recommended in cow's milk and other food intolerances in children.
223669933|NCT02639416|OTHER|Standard management|Standard management with F-100 and/or RUTF
223669934|NCT02549599|BEHAVIORAL|Chat/Text Program|Participants will receive access to the Chat/Text program on the internet via computer or mobile device. The Chat/Text program involves interactive, immediate, and tailored messages (with pre-determined content) delivered by Chat/Text agents via online chat or mobile phone text. At the conclusion of the session, the participants will receive a combination-baseline and follow-up survey.
223669935|NCT02549599|BEHAVIORAL|Website Content|Participants will be directed to content and information on the Planned Parenthood website. The website contains information on birth control methods, locations of Planned Parenthood health clinics, and on sexual and reproductive health more broadly.
223669936|NCT02549599|OTHER|Delayed Treatment|Participants will receive a baseline survey and be routed to the Planned Parenthood website. No subsequent survey will be administered
223669937|NCT03720652|BEHAVIORAL|8-Week Mindful Self-Compassion (MSC)|"The 8-week MSC is a course of eight 2.5 hour weekly sessions that is based off self-compassion, a construct closely related to mindfulness. Self-compassion (SC) has three main interrelated components: self-kindness, common humanity, and mindfulness. MSC is an 8-session program that integrates SC and mindfulness.~It includes the following components:~* Discovering Mindful Self-Compassion~* Practicing Mindfulness~* Practicing Lovingkindness~* Discovering your Compassionate Voice~* Living Deeply~* Meeting Difficult Emotions~* Exploring Challenging Relationships~* Embracing Your Life"
223669938|NCT03720652|BEHAVIORAL|6-Week Mindful Self-Compassion (MSC)|"The 6-week MSC is a course of six 1 hour weekly sessions that is based off self-compassion, a construct closely related to mindfulness. Self-compassion (SC) has three main interrelated components: self-kindness, common humanity, and mindfulness. MSC is an 6-session program that integrates SC and mindfulness.~It includes the following components:~* What is Self-Compassion~* Practicing Self-Compassion~* Discovering your Compassionate Voice~* Self-Compassion and Resilience~* Self-Compassion and Burnout~* Going Forward This program is a shortened version of the 8-week program, specifically created for the needs of health care staff."
223669939|NCT00548652|BEHAVIORAL|MOVE|is a VA based multidesciplinary weight loss intervention
224250914|NCT01757886|OTHER|Biomarkers to analyze both intracoronary thrombi as blood|
224250915|NCT03024515|DRUG|opioids titration|Standard Practice Arm
224250916|NCT03024515|DRUG|predefined titration steps|comprising of oxycodone immediate release (OXYNORM) and oxycodone sustained release (OXYCONTIN) in pre-defined doses and frequencies
224250917|NCT00361751|DRUG|fenofibrate|
224250918|NCT03568565|BEHAVIORAL|ePREP Program|see arm descriptions
224250919|NCT03568565|BEHAVIORAL|OurRelationship Program|see arm descriptions
224250920|NCT05815056|DEVICE|Sedakit (R) using hypnosis induced by the virtual reality device|we use the virtual reality device and no medication during the surgery
224250921|NCT05815056|DRUG|drug intervention|using sufentanyl 5mg intravenously during the surgery
224250922|NCT03951363|BEHAVIORAL|interactive Obesity Treatment Approach (iOTA)|The investigators will adapt an evidence-based digital health intervention to promote adherence to nationally recommended diet and physical activity guidelines for patients with chronic kidney disease. The intervention includes goal assignment, goal tracking, and skills training messages.
224250923|NCT04729881|OTHER|Conventional Rehabiliation Group|Transcutaneous Electrical Nerve Stimulation, Ultrasound and Exercise
224250924|NCT04729881|OTHER|Spesific Exercise Group|Cervical stretching exercise, Craniocervical flexion exercise, Neck isometric exercises, Cervical retraction exercise, Scapular retraction exercise, Modified push-up plus exercise
224250925|NCT04729881|OTHER|Control group|No intervention will be aplied
224250926|NCT04482465|DIAGNOSTIC_TEST|blood sample|blood sample to determine omega6/omega 3 ratio, EPA, DHA, zinc, cupric oxide, vitamine D
224322051|NCT04958655|BEHAVIORAL|Tetris Task|a visual task where participants are asked to play 'tetris' i.e. attend to and manipulate shapes and positions on screen
223669940|NCT00548652|BEHAVIORAL|medical crisis councelling|group counselling sessions
223669941|NCT00548652|BEHAVIORAL|MOVE|is a VA based multidesciplinary weight loss intervention
223669942|NCT00548652|DRUG|methyphenidate|methyphenidate will be used to treat apathy dose 10mg bid
223669943|NCT00548652|BEHAVIORAL|MOVE|is a VA based multidesciplinary weight loss intervention
223669944|NCT00548652|DRUG|methyphenidate|methyphenidate will be used to treat apathy dose 10mg bid
223669945|NCT00548652|BEHAVIORAL|medical crisis councelling|group counselling sessions
223669946|NCT00548652|BEHAVIORAL|MOVE|is a VA based multidesciplinary weight loss intervention
223669947|NCT02103153|DEVICE|Picosure Laser System|
223669948|NCT01454778|DRUG|Paclitaxel|"Paclitaxel in addition to angioplasty, stenting or atherectomy Dosing will be based on the lesion surface area, and will be calculated using the following formula: dose= 22/7 X diameter (mm) X length (mm) X 3 micrograms/mm\^3~Paclitaxel Dosage:~Superficial Femoral/Common Femoral: 2.4 mg/inflation of balloon\* Popliteal: 1.8 mg/inflation of balloon\* Tibial: 1.4 mg/inflation of balloon\*~* not to exceed 10mg total dose"
223669949|NCT03254511|DRUG|Enoxaparin Sodium 40 MG/0.2 ML Subcutaneous Injectable|Patients are going to receive subcutaneouse Enoxaparin (40 mg daily).
223669950|NCT03254511|RADIATION|Radiotherapy|Patients will be treated with 3D conformal radiotherapy. The median treatment dose will be 50.40 Gy in 25 to 32 fractions.
223669951|NCT03254511|DRUG|Chemotherapeutic Combinations|Patients are going to receive weekly chemotherapy (paclitaxel \[50 mg/m2\] plus carboplatin \[area under the carve=2\]).
223669952|NCT03558568|DEVICE|Deep Brain Stimulation|Deep Brain Stimulation is an established surgical method for Parkinson's Disease.
223669953|NCT00348881|BIOLOGICAL|DTaP-HB-PRP~T combined vaccine|0.5 mL, Intramuscular
223669954|NCT00348881|BIOLOGICAL|Tritanrix-HepB/Hib™ vaccine|0.5 mL, Intramuscular
223669955|NCT00348881|BIOLOGICAL|Oral poliomyelitis vaccine (OPV)|Oral co-administered with study vaccine.
223669956|NCT03428919|PROCEDURE|ICSI|In ICSI group, insemination will be performed by using ICSI, 3 - 4 hours after oocyte retrieval. OCCs will be stripped by using hyaluronidase. Only matured oocytes will be inseminated.
223669957|NCT03428919|PROCEDURE|IVF|In IVF group, insemination will be performed by conventional IVF. Two hours after retrieval, collected OCCs will be inseminated for another 2 hours, at a concentration of 100,000 motile sperm/ml. Inseminated OCCs will be cultured overnight in culture medium.
223669958|NCT00645450|DRUG|Propranolol|Weekly doses of short and long acting propranolol (Inderal, Inderal LA, Hemangeol, Inderal XL) following recollection of traumatic memory
223669959|NCT00645450|DRUG|Placebo|Weekly doses of placebo (inactive pill) following recollection of traumatic memory
223669960|NCT01588470|DRUG|pioglitazone|45 mg per day for 6 months
223669961|NCT00371553|DRUG|SU011248 (Sunitinib)|
223669962|NCT05122598|DRUG|COT|The COT with proprietary odorant molecules is designed to stimulate olfactory neural activity over long periods of time combined with orbitofrontal cortex (OFC) dependent olfactory tasks.
223669963|NCT05122598|DRUG|Sham|Sham COT uses artificially scented compressed room air instead of olfactory stimulants and has control cognitive olfactory tasks.
223669964|NCT03093584|DEVICE|Auricular acupuncture|Auricular acupuncture with indwelling fixed auricular acupuncture needles
223669965|NCT03093584|BEHAVIORAL|Expressive writing|Expressive writing is a standard psychological method in treatment of exam anxiety
223669966|NCT02335671|PROCEDURE|Intra-operative Magnetic Resonance Imaging (MRI)|
223669967|NCT02335671|OTHER|Mass Spectrometer Analysis of Tissue Sample|Analysis of Tissue Sample
223669968|NCT00477841|PROCEDURE|Esophageal stent placement|
223669969|NCT00477841|PROCEDURE|dysphagia scores|
223669970|NCT00477841|PROCEDURE|complications of therapy|
223669971|NCT00477841|PROCEDURE|survival time of therapy|
223669972|NCT04465136|DEVICE|CES, Alpha-Stim stimulator (Electromedical Products International, Inc., Mineral Wells, Texas, USA)|CES is a brain stimulation device with 2 electrodes on the bilateral earlobe. It uses Alternating current to stimulate the brain including thalamus, vagus nerve system and influence EEG and neurotransmitters like gamma-aminobutyrate. Stimulation was applied at a current intensity that can be adjusted continuously to provide between 10 and 600 micro-ampere and frequency of 0.5Hertz for 60 minutes, everyday for 6 weeks, total 42 sessions.
223669973|NCT00434616|PROCEDURE|Autologous bone marrow cell concentrate transplantation|bone marrow aspiration (240 ml), processing and reinjection
223669974|NCT00434616|BIOLOGICAL|saline injection|saline injections
223669975|NCT04842825|DRUG|Er Zhi Wan combined with Si Wu Tang|"The TCM medicines used will be Radix et Rhizoma Ligustrum 15 g, Radix Morindae Sinensis 12 g, Fructus Lycii 15 g, Semen Cuscutae 20 g, Radix Rehmanniae 20 g, Radix Angelicae Sinensis 10 g, Radix Paeoniae Alba 12 g, Radix Yam 20 g. The hospital will be responsible for the decoction of 200 mL per dose, 1 dose per day, divided into 2 doses in the morning and in the evening, for 10-15 days. According to follicular development and endometrial growth monitored by ultrasound, the herbs will be changed to Curculus 10 g, Xianling spleen 15 g, Morinda officinalis 15 g, Cuscutae 20 g, Amethyst 15 g, Rehmannia 20 g, Angelica 15 g, Chuanxiong 10 g，which will be taken for 10-15days.~After ET, the treatment group will continue to take Chinese herbal medicine, changing to Cuscuta 15 g, Sambucus 15 g, Chuan Guan Gong 10 g, Agaricus 9 g, Shu Di 15 g, Angelica 10 g, Bai Shao 12 g for 14 days"
223669976|NCT04842825|DRUG|Recombinant Human Follitropin Alfa 、Fructose 、Tetyacycline Hydrochloride Capsules、Cetrorelix Acetate Powder|The control group will be treated with conventional Western medicine（The specific drug dose is determined according to the individual level of patients）
223669977|NCT00678743|DRUG|Omacor + simvastatin|Omacor 4 grams/day plus simvastatin 80 mg/day. Simvastatin dose adjusted at Investigator discretion after week 6.
223669978|NCT05030948|BEHAVIORAL|Tiempo Juntos Intervention|"If assigned to this group, participants will take part in weekly 1-hour group sessions twice a week for 3 months. The sessions will be with a trained Community Health Worker that will involve group (5-6 participants) moderate-intensity walking. Upon completing the 3 months of physical activity sessions, for the next 3 months, they will receive motivational booster sessions delivered every other week via phone calls/text messaging."
223669979|NCT05872230|DEVICE|Massage Percussion Therapy device|Using massage percussion postoperatively.
223669980|NCT05233397|DRUG|Tocilizumab|For \< 30 kg: 12 mg/kg IV every 2 weeks; For ≥30 kg: 8 mg/kg IV every 2 weeks
223669981|NCT03658876|DRUG|Iron Sucrose Solution for Injection|200mg iron sucrose given on 5 successive haemodialysis sessions
223669982|NCT03658876|DRUG|Epoetin Beta|Uptitration of epoetin beta dose. Scale as follows (in units /session): 0-1000-2000-3000-4000-6000-8000-12000
223669983|NCT00900887|DRUG|Ketorolac|ophthalmic presentation 5 mg/ml dosage one drop (0.25 mg) in the treated eye 3 times a day during one week
223669984|NCT00900887|DRUG|Nepafenac|topic presentation 1 mg/ml dosage one drop (0.05 mg) in the treated eye 3 times a day during one week
223669985|NCT00900887|DRUG|Polietilenglicol 400, propilenglicol|"ocular presentation Polietilenglicol 400 (4 mg), propilenglicol (3 mg), HP guar (1.9 mg)/1 ml~dosage: one drop (0.2 mg polietinglicol 400, 0.15 mg propilenglicol, 0.095 mg HP guar) 3 times a day during one week"
223669986|NCT01330017|DRUG|Phenylephrine HCl|10-mg immediate-release tablets, orally, up to 4 tablets per dose every 4 hours, for 7 days
223669987|NCT01330017|DRUG|Placebo|Placebo tablets, orally, up to five tablets per dose every 4 hours, for 7 days
223669988|NCT01330017|DRUG|Loratadine|10-mg tablets, orally, once per day at a dose not to exceed 10 mg in a 24-hour period.
223669989|NCT06161896|DIAGNOSTIC_TEST|Stool samples|Analysis of microbiome, mutations, alterations in body composition and lifestyle
223669990|NCT04184986|DIAGNOSTIC_TEST|dry blood test|screening test for Fabry disease
223669991|NCT05552144|DEVICE|Hum by Colgate Smart Kids Toothbrush (battery powered) - 490000006871|The first 15 caregivers and their children who meet the inclusion/exclusion characteristics and sign an Informed Consent Form/provide assent will be entered into the study. The caregivers will be asked to supervise the tooth brushing experience of the children with hum Kids toothbrush twice a day for 4 weeks using the associated app. The caregivers will also be asked to fill out questionnaires and participate in interviews regarding the children's brushing habits and experiences.
223669992|NCT05795478|DRUG|Oxycodone and Pregabalin|Oxycodone: 150mg PCIA during 3 days postoperatively Pregabalin: 150mg preoperatvely, 75mg BID for POD1\~7,75mg QD for POD8\~14
223669993|NCT05795478|DRUG|Oxycodone and placebo capsules|Oxycodone: 150mg PCIA for 3 days postoperatively placebo capsules: same numbers as pregabalin at each time point
223669994|NCT05795478|DRUG|Pregabalin and NS|Pregabalin: 150mg preoperatively, 75mg BID for POD1\~7,75mg QD for POD8\~14 NS: Equal volume NS for 3 days postoperatively
223669995|NCT05795478|DRUG|placebo capsules and NS|placebo capsules: same numbers as pregabalin at each time point NS: Equal volume NS for 3 days postoperatively
223669996|NCT04809103|DRUG|cis-diamminedichloroplatinum|Cisplatin delivered bronchoscopically at the time of diagnosis of NSCLC
223669997|NCT01073501|DRUG|Pregabalin|Pregabalin 25 mg (Lyrica; Pfizer, Germany) or placebo will be administered orally daily at the end of hemodialysis sessions in dialysis patients or every evening in non dialysis CKD patients. The dose will be increased up to 50 mg if no improvement of pruritus will be established at the end of first week of the study
223669998|NCT01073501|DRUG|Placebo|Pregabalin 25 mg (Lyrica; Pfizer, Germany) or placebo will be administered orally daily at the end of hemodialysis sessions in dialysis patients or every evening in non dialysis CKD patients. The dose will be increased up to 50 mg if no improvement of pruritus will be established at the end of first week of the study
223669999|NCT02836743|DRUG|Circadin|Slow-release melatonin
223670000|NCT02836743|DRUG|Placebo|
223670001|NCT02739672|DRUG|TAH Tablet (Telmisartan/Amlodipine besylate/Hydrochlorothiazide)|Telmisartan 80.0 mg, Amlodipine besylate 13.87 mg (Amlodipine 10 mg), Hydrochlorothiazide 25 mg combination-drug would be administered orally once
223670002|NCT02739672|DRUG|TWYNSTA(Telmisartan+Amlodipine besylate)|TWYNSTA 2 Tab. 40/5mg(Telmisartan 40 mg, Amlodipine besylate 6.935 mg(Amlodipine 5 mg) would be administered orally once
223670003|NCT02739672|DRUG|Hydrochlorothiazide|Dichlozid 1 Tab.(Hydrochlorothiazide 25.0 mg) would be administered orally once
223670004|NCT04096482|DEVICE|Peregrine Drivable ENT Scope|Peregrine, developed by 3NT Medical, is a single-use disposable handheld endoscope, which is thinner and more flexible than other endoscopes. The endoscope includes a camera at its end and a working channel. The thin endoscope provides a means to visualize the nasal cavity and paranasal sinus space and to deliver irrigation to treat the sinus ostia (drainage openings) and spaces within the paranasal sinus cavities
223670005|NCT04096482|DEVICE|Standard 30° 4mm Endoscope|The Standard 30° 4mm endoscopic sinus evaluation is the standard procedure that would normally be used to evaluate the condition of each participant.
223670006|NCT04863027|RADIATION|Thoracic radiotherapy|Patients will have pre-treatment and post-treatment perfusion DECT for baseline and post-treatment lung function
223670007|NCT00910143|PROCEDURE|conventional rectal surgery|type of rectal surgery before the introduction of TME
223670008|NCT00910143|PROCEDURE|total mesorectal excision|total mesorectal excision
223670009|NCT04090099|OTHER|Erector spina plane block|While the patient is in the sitting position, an area containing 2 cm lateral of the T5 spinous process will be cleaned with povidone iodine. A high frequency ultrasound linear probe covered with a sterile sheath will be placed 2 cm to the side of the T5 spinous process, first to the right or left. After demonstrating the T5 transverse process and the erector spinae muscle on top, the 22-gauge, 80 mm insulated Quincke-type needle will be inserted into the skin at an angle of about 30 degrees from the cranial to the caudal, using an in-plane technique. When the transverse process is touched, the needle is withdrawn and after a negative aspiration test with 0.5 mL of normal saline and after a hypo-echogenic display and hydrodissection, a local anesthetic solution will be applied to the fascia under the erector spinae muscle.
223670010|NCT02616146|DRUG|ENG-E2 125 μg/300 μg vaginal ring|Up to 13 cycles of ENG-E2 125 μg/300 μg administered intravaginally, each cycle consisting of 21 days of vaginal ring use followed by 7 vaginal ring-free days.
223670011|NCT02616146|DRUG|LNG-EE 150 μg/30 μg COC|Up to 13 cycles of LNG-EE 150 μg/30 μg administered orally, each cycle consisting of one tablet per day for 21 days, followed a 7-day tablet-free interval.
223670012|NCT05202158|PROCEDURE|Addition of gentamicin to irrigation fluid during RIRS|During the RIRS, the access sheath is placed first for security. Then, the stone in the kidney is detected with flexible URS and fragmented with a holmium laser. In this group of patients, 80 mg of gentamicin will be added to 3 liters of irrigation fluid while the stone is being fragmented.
223670013|NCT05202158|PROCEDURE|Only irrigation fluid during RIRS|During the RIRS, the access sheath is placed first for security. Then, the stone in the kidney is detected with flexible URS and fragmented with a holmium laser. In this group of patients, only irrigation fluid will be used while the stone is fragmented.
223670014|NCT06191211|BEHAVIORAL|Motivational Interviewing, AIMS|Motivational interviewing (MI). MI is an approach to patient engagement which promotes a collaborative conversation style for strengthening a person's own motivation and commitment to change. With MI, the doctor facilitates patient exploration of potential reasons for behaviour change in the context of what is important to the patient, rather than the physician directly telling the patient what to do. MI has been found more effective than other approaches to patient engagement and health behaviour change and can be effectively taught to primary care providers.
224250927|NCT04906772|DRUG|Dexmedetomidine|participants received loading of ketamine 1 mg/kg and dexmedetomidine 1µg/kg over 10 minutes then continue by a dose of 0.25 mg/kg/hr ketamine and 0.25µg/kg/hr dexmedetomidine throughout the procedure.
224250928|NCT04906772|DRUG|Propofol|participants received loading of ketamine 1 mg/kg and propofol 1mg/kg over 10 minutes then continue by a dose of 0.25 mg/kg/hr propofol and 0.25µg/kg/hr dexmedetomidine throughout the procedure.
224250929|NCT02435823|DEVICE|PulseRider|Adjunctive device for endovascular embolization of intracranial aneurysms
223670015|NCT06191211|BEHAVIORAL|Facility engagement|A letter to the facility from the local health officials; a meeting with the facility manager and health staff to formally announce that we would like providers to encourage COVID-19 vaccinations; deploying a tracking sheet for vaccinations.
223670016|NCT04463511|OTHER|Polyethylene bag before the umbilical cord is clamped|"11 x 16 (279mm x 406mm) sterile resealable PB (Resealable Polybag, Helapet Ltd, Bedfordshire, UK)"
223670017|NCT06230601|OTHER|Cough Trick Method|During the Blood Collection Procedure in School-Age Children, one group will use the Cough Trick Method
223670018|NCT06230601|OTHER|Pinwheel Blowing method|Pinwheel Blowing method
223670019|NCT04444206|PROCEDURE|Transvaginal ultrasound cervical length screening|Cervical lenght and Consistence Cervical Index measurements performed, between 11 and 13 weeks + 6 days, in the , between 19 and 22 weeks and i between 29 and 32 weeks during the ultrasound examinations required by the monitoring routine of pregnancy.
224250930|NCT00831428|OTHER|no intervention|this is a screening study, not an interventional study
224250931|NCT01502254|OTHER|audio recorded information|Access to the audio recorded information about the clinical trial the patient was information about and asked to consider. A copy of the audio recording is given to the patients directly after the clinical visit.
224250932|NCT02105103|DEVICE|Accu-Chek® Insight Insulin Pump|A new insulin pump, the Accu-Chek® Insight insulin pump, will be used by all subjects enrolled in this study. The usability of the Accu-Chek® Insight insulin pump for the intended use has already been investigated in a Human Factor study. The study subjects may encounter the following potential risks of CSII therapy while participating in the study: Possible hypoglycemia; Possible hyperglycemia which might progress to ketosis and DKA; Infusion site reactions (bleeding, bruising, discomfort, pruritus, pain, plaster reactions, inflammation, infection etc.)
223670020|NCT01221272|DRUG|Ranolazine|"* One 500 mg tablet in the evening on Day 1 of the period~* One 500 mg tablet, twice daily on Days 2-3 of the period~* Two 500 mg tablets (1000 mg total), twice daily from Day 4 to the end of the period (Day 15 ± 2 days)"
223670021|NCT01221272|DRUG|Placebo to match ranolazine|Placebo to match ranolazine administered in the same form and frequency as the active drug.
224250933|NCT02187354|DRUG|Blinatumomab|A single cycle of blinatumomab (CIVI) treatment is 6wks, 4wks of treatment followed by a 2wk treatment-free interval. Up to 5 cycles will be administered per subject. In the first cycle, for patients with an M3 bone marrow, the initial dose will be 5μg/m2/day for the first 7days, escalated to 15μg/m2/day on D8-D29. For all subsequent cycles 15μg/m2/day will be the dose for all 4wks of continuous treatment. In case of M2 bone marrow or M1 bone marrow with an MRD relapse at screening, the initial dose will start at 15μg/m2/day for the first 7days of treatment \& no dose step at D8. For all subsequent cycles the dose will remain 15μg/m2/day. A dose of 9μg/day for the initial dose (if applicable) \& 28μg/day for the escalated dose after dose step should not be exceeded.
224250934|NCT02187354|OTHER|Extension of LTFU as per ProtocolAmendment7 7Jun18|LTFU (Long Term Follow-Up) will extend past 18 months for patients already ended the study/still on study or to be enrolled at European sites if they did not receive a transplantation after blinatumomab treatment. For subjects to be included in the additional LTFU, data will be captured until subjects are 18yrs old (every 6 months by phone contact). The following will be captured: relapse (medullary or extra-medullary relapse and its specific location), second tumor (which type), alive/died and cause of death, hospitalization and reason for hospitalization.
224250935|NCT05130554|PROCEDURE|XEN45 gel stent implantation|The XEN45 gel implant is a collagen tube with a length of 6 mm and a diameter of 45 µm, which creates a new channel for drainage of aqueous humor by connecting the anterior chamber and the subconjunctival space. The implant is composed of porcine gelatin cross-linked with glutaraldehyde, and has good biocompatibility and tolerance.This treatment method has excellent safety and effectiveness in reducing the intraocular pressure of patients with open-angle glaucoma. At the same time, the operation is simple and safe.
224250936|NCT04005677|DIAGNOSTIC_TEST|The serum, plasma, urine, faeces, peripheral blood mononuclear cell (PBMC), exhaled breath condensate and the clinical characteristics are collected.|The serum, plasma, urine, faeces, peripheral blood mononuclear cell (PBMC), exhaled breath condensate and the clinical characteristics including age, sex, smoking status, BMI, address, greening environment and the laboratory tests are collected to to analyze the ctDNA, RNA, protein, metabolites, immune status and their relationships with the tumorigenesis and the gene mutation of lung cancer.
223670022|NCT01221272|PROCEDURE|SPECT MPI|Gated single photon emission computed tomography (SPECT) myocardial perfusion imaging (MPI) to confirm the presence of reversible exercise-induced left ventricular perfusion defect size (PDS) performed within 12 weeks prior to baseline or at the baseline visit, and at the end-of-period 1 and end-of-period 2 visits.
223670023|NCT01221272|BEHAVIORAL|Exercise|Treadmill stress test
223670024|NCT04609007|BEHAVIORAL|Cognitive behavioral therapy (CBT)|A brief 4 sessions online CBT program with therapist support.
223670025|NCT04609007|BEHAVIORAL|Regular help-line telephone counselling|A single session of telephone counselling with a help-line counsellor
223670026|NCT04135170|COMBINATION_PRODUCT|ALBC vs plain bone cement|The patients undergoing full-cemented primary total knee arthroplasty are allocated to either ALBC or plain bone cement and compare the effectiveness of ALBC use vs pain bone cement bone cement without antibiotic) with respect to revision due to PJI one year after primary TKA surgery.
223771540|NCT03599427|DRUG|systemic lidocaine|Systemic lidocaine is administrated at induction of anesthesia and at the end of surgery (1.5 mg/kg).
223771541|NCT03599427|DRUG|Placebo|Placebo is administrated at induction of anesthesia and at the end of surgery (0.075 ml/kg)
223771542|NCT06442267|DRUG|Enoxaparin Injectable Solution|Subcutaneous Enoxaparin will be dosed at 0.5 mg/kg twice daily
224250937|NCT01577381|BIOLOGICAL|RN6G|Intravenous, 11 doses, 30 minute infusion, dose ranging from 2.5 mg/kg up to a maximum of 15 mg/kg
224250938|NCT01577381|BIOLOGICAL|Placebo|Intravenous, 11 doses, 30 minute infusion
224250939|NCT03871166|OTHER|Blood transfusion|"Observational post-ad-hoc design to compare patients admitted with an ARDS and separated into different groups according to their mean hemoglobin concentration during their stay on the intensive care unit.~Approximately 1000 adult patients admitted from 2007 to 2018 to the Charite ARDS center will be enrolled in the study. They are followed up until their discharge from the ICU.~\[Time Frame: 01/2007 - 12/2018\]"
224250940|NCT00911781|OTHER|No intervention|We are only asking for photographs from parents.
224250941|NCT06461091|RADIATION|TMI|Observing the efficacy and safety of allogeneic hematopoietic stem cell transplantation in treating adult acute lymphoblastic leukemia with a conditioning regimen including total marrow irradiation (TMI) in individuals aged 16 years and older: Primary Exploratory Endpoint: Event-free survival at 1 year post allogeneic hematopoietic stem cell transplantation (EFS).
224250942|NCT02186821|DRUG|Ceritinib|Ceritinib was dosed on a flat scale of 750 mg (e.g., 5 x 150 mg capsules) orally,once daily, on a continuous dosing cycle. A complete treatment cycle was defined as 28 days. There were no breaks between dosing cycles.
224250943|NCT03989648|OTHER|Esmarch bandages|Esmarch bandage (also known as Esmarch's bandage for surgical haemostasis or Esmarch's tourniquet) in its modern form is a narrow (5 to 10 cm wide) soft rubber bandage that is used to expel venous blood from a limb (exsanguinate) that has had its arterial supply cut off by a tourniquet.
224250944|NCT03989648|OTHER|simple leg elevation|simple leg elevation 45 degree for 2 minutes is used to expel venous blood from a limb
224250945|NCT02587871|DRUG|Cytarabine|Given IV
224250946|NCT02587871|OTHER|Laboratory Biomarker Analysis|Correlative studies
224250947|NCT02587871|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo microtransplant
224250948|NCT02587871|BIOLOGICAL|Therapeutic Allogeneic Lymphocytes|Undergo microtransplant
224250949|NCT02587871|BIOLOGICAL|G-CSF mobilized peripheral blood cells|microtransplantation
223670027|NCT03521102|DRUG|Acetaminophen 1000mg IV|1000mg of IV acetaminophen in 100ml of normal saline, administered as an intravenous drip over 10 minutes + 2ml of normal saline, administered as a slow intravenous push
223670028|NCT03521102|DRUG|Hydromorphone 0.5 mg IV|100ml of normal saline, administered as an intravenous drip over 10 minutes, + 0.5mg of IV hydromorphone in 2ml of normal saline, administered as a slow intravenous push
223670029|NCT00257335|PROCEDURE|IMRT|
223670030|NCT04364438|DEVICE|Electric Muscle Stimulation|EMS is believed to produce some inhibition of the bladder, allowing the bladder to reach a greater volume. This is believed to occur because electrical stimulation also stimulates nerves in the pelvic floor. In most people, bladder voiding is inhibited when the skin of the pelvis is touched or otherwise manipulated. This inhibition is via a reflex in the spinal cord that may have evolved to inhibit voiding during sexual contact. The pelvic floor nerves are responsible for transmitting the sensation of touch from the pelvis to the spinal cord. Electrical stimulation of these nerves thus activates sensory fibers that cause inhibition of bladder voiding via a reflex mechanism in the spinal cord. This may explain EMS is an effective treatment for people with incontinence.
223670031|NCT04364438|DEVICE|Transcutaneous Electric Nerve Stimulation|TENS is based on the gate control theory of abolishing the local micturition reflex arc. It is a non-pharmacological method of inhibiting the presynaptic afferent neurons carrying impulses from bladder by stimulating the nerves of peripheral segmental dermatome (gate control theory of electro modulation by stimulating the peripheral nerves corresponding to the visceral organ). It acts at the level of primitive voiding reflex coordinating the bladder, sphincter and the pelvic floor. Detrusor hyperreflexia can be inhibited by direct inhibition of impulses in the preganglionic afferent neuron or by inhibition of bladder preganglionic neurons of the efferent limb of micturition reflex.
223670032|NCT03678714|BEHAVIORAL|Exercise Intervention|2 sessions of supervised exercise training each week for 8 consecutive weeks and 3 sessions of supervised exercise training each week for the final 4 consecutive weeks, at 57-74% heart-rate max. Each session will last approximately 60 minutes.
223670033|NCT03678714|BEHAVIORAL|Lifestyle Physical Activity|Advice and information on how to increase physical activity will be provided. Participants will be asked to monitor and track their daily physical activity using a smart-phone fitness application. The research team will gain permission to access their recorded activity.
223670034|NCT05001633|BEHAVIORAL|modified media content paradigm|media content
223771543|NCT06442267|DRUG|Argatroban, 1 Mg/mL Intravenous Solution|Intravenous Argatroban will be administered as a continuous infusion of 0.1-1 µg/kg/min with a target modified thrombin time measured using Hemoclot of 0,40 - 0,60 µg/mL.
223771544|NCT06442267|DRUG|Unfractionated heparin|Unfractionated heparin will be administered as a continuous infusion of 7.5-20 units/kg/h with a target Anti FXa calibrated for UFH of 0.3-0.5 u/mL.
223771545|NCT03394300|OTHER|iol power calculation|iol power calculation in high myopia
223771546|NCT03778216|BEHAVIORAL|Family Based Treatment|
223771547|NCT00414752|DRUG|AFQ065|
224250950|NCT03372187|BEHAVIORAL|DIET-MS|Following the completion of testing, all 20 participants will be placed into the DIET-MS group and will follow the prescribed diet plan for 12 weeks. At the end of the 12 weeks, the participants will return to complete follow up testing.
224250951|NCT01789177|DEVICE|Incentive Spirometry|Patients will be provided with plastic, disposable incentive spirometers postoperatively
224250952|NCT01789177|OTHER|Postoperative chest physiotherapy|Patients will be given routine postoperative chest physiotherapy instruction by nursing staff
224250953|NCT01833052|DEVICE|TAVI (Medtronic CoreValve)|
224250954|NCT01833052|DEVICE|Claret-Filter|
224250955|NCT01745783|OTHER|Bone marrow mesenchymal stem cells autologous|Infusion of mesenchymal cells from autologous bone marrow in a dose of 1-2x106 cells / kg
224250956|NCT01745783|OTHER|Placebo comparator|Lactated Ringer's solution, 2.5% glucose and 1% human albumin.
223670035|NCT05001633|BEHAVIORAL|control|media content experience
223670036|NCT00252252|DEVICE|VPAP non-invasive ventilator|
223670037|NCT00252252|DEVICE|AutoVPAP non-invasive ventilator|
223670038|NCT03894722|PROCEDURE|Control|During the third molar extraction the saline solution will be used in the control group.
223670039|NCT03894722|PROCEDURE|0.5% concentration of PVP-I|During the third molar extraction 0.5% concentration of PVP-I solution will be used in the test group.
223670040|NCT03894722|PROCEDURE|1 % concentration of PVP-I|During the third molar extraction 1 % concentration of PVP-I solution will be used in the test group.
223670041|NCT03894722|PROCEDURE|3 % concentration of PVP-I|During the third molar extraction 3 % concentration of PVP-I solution will be used in the test group.
223670042|NCT04316975|OTHER|Study Driven Procurement of Biopsies|Four research biopsies collected at the midpoint of current BE or IMC at Baseline and after reaching CEIM. Biopsies will be used to calculate ML scores both pre and post EET.
223670043|NCT06165458|OTHER|6% hydrogen peroxide gel + violet LED|Tooth whitening with 6% hydrogen peroxide gel (Lase Peroxide Lite, DMC, São Carlos, Brazil) activated by violet LED
223670044|NCT06165458|OTHER|6% hydrogen peroxide gel + blue LED|Tooth whitening with 6% hydrogen peroxide gel (Lase Peroxide Lite, DMC, São Carlos, Brazil) activated by blue LED
223670045|NCT06165458|OTHER|35% hydrogen peroxide gel + violet LED|Tooth whitening with 35% hydrogen peroxide gel (Lase Peroxide Sensy, DMC, São Carlos, Brazil) activated by violet LED
223670046|NCT06165458|OTHER|35% hydrogen peroxide gel + blue LED|Tooth whitening with 35% hydrogen peroxide gel (Lase Peroxide Sensy, DMC, São Carlos, Brazil) activated by blue LED
223670047|NCT01106092|BIOLOGICAL|GSK2036874A vaccine|Intramuscular, single dose
223670048|NCT01106092|BIOLOGICAL|Zilbrix™/Hib vaccine|Intramuscular, single dose
223670049|NCT01106092|BIOLOGICAL|Poliorix™|Intramuscular, single dose
223670050|NCT00320957|DEVICE|OculusGen Biodegradable Collagen Matrix Implant|
223670051|NCT01030081|DRUG|Amlodipine (Norvasc®)|Amlodipine (Norvasc®), tablet, 5 mg
223670052|NCT01030081|DRUG|Nifedipine GITS (Adalat® XL 30|Nifedipine GITS (Adalat® XL 30), controlled released tablet, 30 mg
223670053|NCT02906982|OTHER|Gum health formulation in intra-oral device|The intervention is a gum health formulation for periodontal disease care and teeth whitening to be used within an accelerating intra-oral device.
223670054|NCT02906982|OTHER|Gum health formulation on toothbrush|The intervention is a gum health formulation for periodontal care and teeth whitening to be used on a toothbrush alongside standard toothpaste.
223670055|NCT01371032|DEVICE|VideoMiller|Video-Miller laryngoscope, using the screen (Video laryngoscopy group)
223670056|NCT01371032|DEVICE|Direct Laryngoscopy|Video-Miller laryngoscope, without screen (Direct laryngoscopy group)
224250957|NCT03201523|OTHER|Socio-ecologial, community-based intervention|Intervention components will include a health newsletter, health workshops, community evening/health project registration, lay leader training, neighborhood exercise groups, community walking programs with pedometers, healthy cooking contest, and school health promotion activities.
224250958|NCT04322500|DIETARY_SUPPLEMENT|probiotics|use specific probiotics in addiction to conservative treatment to modify the intestinal microbiome to ameliorate the clinical course of chalaziosis in children by re-establishing intestinal and immune homeostasis
224250959|NCT04322500|OTHER|conservative treatment|lid hygiene, warm compression, and dexamethasone/tobramycin ointment for at least 20 days
224250960|NCT00819741|DRUG|repaglinide|The dose was started from repaglinide 1 mg plus metformin 500 mg once daily. During the dose titration period, the dose could be titrated up to repaglinide 4 mg and metformin 500mg three times daily, according to fasting glucose. the minimal dose was repaglinide 1 mg plus metformin 500 mg three times daily
224322052|NCT04958655|BEHAVIORAL|Mental Imagery for Craving Reduction|a behavioural mental imagery intervention where participants are asked to generate a specific future mental image to reduce cue-induced craving for alcohol
224322053|NCT04931979|DRUG|Pembrolizumab Injection [Keytruda]|Up to 17 cycles of pembrolizumab until disease progression, toxicity, death, or withdrawal of IC (whichever occurs first)
223670057|NCT04427826|DRUG|Morphine hydrochloride|A single open-label injection of morphine (T0) at the dose closest to that defined by the model (estimation by Bayesian method) from among the following 4 doses: 0.02; 0.04; 0.07 and 0.1mg/kg will be adminestred to the patients.
223670058|NCT04124744|OTHER|Health Champions intervention|Health Champions are trained volunteers who will support service users with their physical health goals over 9 months, meeting once a week
223670059|NCT04124744|OTHER|Control group-treatment as usual|Participants will receive treatment as usual from their Community Mental Health Team
223670060|NCT01473368|DIETARY_SUPPLEMENT|Saccharomyces boulardii|500 mg, 2 times daily for 14 days
223670061|NCT01473368|DRUG|Amoxicillin Clavulanate|875/125 mg 2 times daily at least 1 hour before meals for 7 days
223670062|NCT05358340|DIAGNOSTIC_TEST|Dynamic susceptibility contrast magnetic resonance imaging (DSC MRI)|A dye, known as a contrast agent, will be injected through a needle that is inserted into a vein in the arm or hand. Subsequent magnetic resonance imaging will follow.
223670063|NCT05616689|OTHER|Bundled hyperpolypharmacy|Bundled hyperpolypharmacy playbook to be used by pharmacist, with physician approval, in shared decision making with participant,
223670064|NCT00612495|DRUG|oxaliplatin, 5 FU|"Oxaliplatin:130 mg/m² as a 2-hour intravenous (IV) infusion in 500 mL of 5% glucose solution on Day 1 and repeated every 3 weeks.~5-FU: following oxaliplatin administration, 1000 mg/m²/day as a continuous IV infusion from Day 1 to Day 4, repeated every 3 weeks."
223670065|NCT04143308|OTHER|Simultaneous training of walking and cognitive group|"Device:~1. SWATCH system (App \& controller)~2. Wearable technology Fitness wristband \& APP"
223670066|NCT04143308|OTHER|Cognitive training group|"Device:~1. SWATCH system (App)~2. Wearable technology Fitness wristband \& APP"
223670067|NCT04143308|OTHER|Treatment as usual group|Keep treatment as usual
223670068|NCT00003388|BIOLOGICAL|filgrastim|
223670069|NCT00003388|DRUG|cyclophosphamide|
223670070|NCT00003388|DRUG|cytarabine|
223670071|NCT00003388|DRUG|methotrexate|
223670072|NCT00003388|DRUG|pegylated liposomal doxorubicin hydrochloride|
223670073|NCT00003388|DRUG|prednisone|
223670074|NCT00003388|DRUG|vincristine sulfate|
223670075|NCT00003388|RADIATION|radiation therapy|
224250961|NCT00819741|DRUG|metformin|The dose was started from repaglinide 1 mg plus metformin 500 mg once daily. During the dose titration period, the dose could be titrated up to repaglinide 4 mg and metformin 500 mg three times daily, according to fasting glucose. the minimal dose was repaglinide 1 mg plus metformin 500 mg three times daily
223670076|NCT05365854|PROCEDURE|Alveolar Recruitment Maneuver (ARM)|"When patient is under general anesthesia, an arterial catheter is placed for cardiac output and stroke volume (SV) monitoring. To avoid pre-load dependency bias, the blood volume will be optimized. A 250mL fluid-challenge of a balanced crystalloid solution is administered under cover of the SV monitoring. If SV variation is greater than 10%, a new fluid-challenge is performed to obtain a reference SV, corresponding to the patient's optimal blood volume.The patient is then pre-load independent.~Then, patients will be randomized into two groups: a first group will receive a CPAP ARM: 40 cmH2O for 50 seconds, followed by a 10-minute break corresponding to a period of return to basal state; then an extended sigh ARM (e-sigh) also lasting 50seconds (driving pressure: 10cmH2O and successive PEEP levels at 10,15,20,25 and 30cmH2O, a respiratory rate set at 30/min in controlled pressure - 5cycles at each PEEP level); a second group will receive the same two ARM modalities in reverse order."
223670077|NCT04839562|DRUG|Solriamfetol 75 MG|Daily oral consumption
223670078|NCT04839562|DRUG|Solriamfetol 150 MG|Daily oral consumption
223670079|NCT04839562|OTHER|Placebo|Placebo
223670080|NCT05166239|PROCEDURE|HAIC|Hepatic arterial chemotherapy consisted of infusions of oxaliplatin (35 mg/m2 for 2 hours), followed by 5-fluorouracil (600 mg/m2 for 22 hours) on day1-3 every 4 weeks.
223670081|NCT05166239|DRUG|Lenvatinib 1|12/8 mg (weight ≥ 60kg / \< 60 kg) of Lenvatinib once daily after HAIC.
223670082|NCT05166239|DRUG|PD-1 Inhibitors|PD-1 inhibitors injection intravenously or percutaneously before 24h of HAIC every 4 week.
223670083|NCT05166239|DRUG|Lenvatinib 2|12/8 mg (weight ≥ 60kg / \< 60 kg) of Lenvatinib once daily.
223670084|NCT05166239|DRUG|PD-1 inhibitors 2|PD-1 inhibitors injection intravenously or percutaneously every 4 week.
223670085|NCT00730028|DRUG|Trimethoprim-sulfamethoxazole|Trimethoprim-sulfamethoxazole (TMP-SMX) will be administered orally at a dose of 160 mg TMP and 800 mg SMX (as 2 single strength over encapsulated tablets) twice daily (adult or child \> 40 kg dose) or 8-10 mg TMP, 40-50 mg SMX per kg daily, divided into 2 daily doses (child \< 40 kg dose). Study drug will be administered for 10 days.
223670086|NCT00730028|OTHER|Placebo|Placebo capsules will be identical in appearance to the CLINDA and TMP-SMX. Administered 3 times daily for 10 days.
223670087|NCT00730028|DRUG|Clindamycin|CLINDA (adult dose of 300 mg three times daily; pediatric dose of 25-30 mg/kg/day divided three times daily up to a maximum dose of 900 mg/day). Study drug will be administered for 10 days.
223670088|NCT00003472|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|Adults with a recurrent/progressive Oligodendroglioma will receive Antineoplaston therapy (Atengenal + Astugenal).
223670089|NCT03010644|OTHER|n/a - observational study|n/a - observational study
223670090|NCT00528970|DRUG|MOA-728|MOA-728 will be administered per the dose and schedule specified in the arm.
223670091|NCT00528970|DRUG|Placebo|Placebo matching to MOA-728 will be administered per the schedule specified in the arm.
223670092|NCT04321785|OTHER|Placebo|placebo capsule (mannitol)
223670093|NCT04321785|OTHER|Caffeine|caffeine capsule (80 mg of caffeine plus mannitol)
224250962|NCT00819741|DRUG|repaglinide|The dose was started from repaglinide 1 mg three times daily. During the dose titration period, the dose of repaglinide could be titrated up to 4 mg three times daily, according to fasting glucose.
224322054|NCT04931979|RADIATION|Salvage Radiation Therapy (SRT)|SRT according to standard of care (SRT with at least 66 Gy)
223670094|NCT02761837|BEHAVIORAL|IVR call/text|For patients under filling their inhaled corticosteroid or overusing B-agonist, the patient is contacted via IVR call or text
223670095|NCT02761837|BEHAVIORAL|Email|Patients under filling their inhaled corticosteroid or overusing B-agonist, the the patient is contacted via email
223670096|NCT03779243|DIETARY_SUPPLEMENT|Melatonin 5mg and Sleep Education|Melatonin 5mg daily and sleep education for 6 weeks following injury or surgery.
223670097|NCT03779243|OTHER|Placebo|Daily placebo pills for 6 weeks following injury or surgery.
223670098|NCT05930015|BEHAVIORAL|Music intervention only|Music only (120-130 bpm) The effect was achieved by playing music selected by the researchers during originally physical education classes in school; twice a week for eight weeks
223670099|NCT05930015|BEHAVIORAL|Sports games intervention only|Sports games intervention only The effect was achieved by replacing the school's originally physical education classes with sports games of the researchers' choice; twice a week for eight weeks
223670100|NCT05930015|BEHAVIORAL|Music and sports games intervention|Music and sports games intervention, the effect was achieved by replacing the school's physical education classes with sports games of the researchers' choice, and then by playing music of the researchers' choice during class; twice a week for eight weeks
223670101|NCT04446390|OTHER|Himalaya complete care toothpaste|Herbal toothpaste as a part of a caries preventive regimen
223670102|NCT04446390|OTHER|colgate cavity protection|fluoride toothpaste as a part of a caries preventive regimen
223670103|NCT05272436|DEVICE|Virtual Reality Upper Limb Motor Impairment Rehabilitation|Patients wore a VR headset while undergoing their physical rehabilitation at home
223670104|NCT02575066|RADIATION|external beam radiotherapy|external beam radiotherapy 25 x 2 Gy / 18 x 2 Gy
223670105|NCT02575066|DRUG|pazopanib|pazopanib QD 800 mg
223670106|NCT02126748|OTHER|inhalation 4ml hypertonic saline 3% 3x/day|
223670107|NCT02126748|DEVICE|Intrapulmonary Percussive Ventilation|
223670108|NCT02126748|PROCEDURE|Assisted Autogenic Drainage|
223670109|NCT00216164|DRUG|Rituximab|Rituximab 375 mg/m2, day 1 of 21 day cycle
223670110|NCT00216164|DRUG|Gemcitabine|Gemcitabine 1000 mg/m2, days 1 and 8 of 21 day cycle
223670111|NCT01976988|DRUG|Heparin|Subcutaneous Heparin 5000 Units given in the preoperative area one hour prior to surgery and continued every 8 hours for the remainder of the patients hospital course
223670112|NCT01741402|DEVICE|Virtual Reality Training|The participants of the study trained 10 balance games during 14 sessions
223670113|NCT01741402|OTHER|Physical Therapy|Patients of the control group was trained with balance exercises.
224322055|NCT05113784|DRUG|Meplazumab for Injection|humanized antibody target CD147
224322056|NCT05113784|DRUG|Sterile normal saline (0.9%)|Sterile normal saline (0.9%)
223771548|NCT06462807|BEHAVIORAL|ARC|ARC is an evidence-based intervention that uses three strategies (ARC principles, ARC component tools, and ARC mental models) to create organizational social contexts (OSCs) that support the implementation of interventions to improve patient outcomes.
224250963|NCT07037017|BEHAVIORAL|Cognitive-Behavioral Therapy|Manualized 12-week CBT protocol focused on reducing body image disturbance, distorted beliefs about food and appearance, and avoidance behaviors in individuals with anorexia nervosa. The intervention incorporates psychoeducation, cognitive restructuring, emotional regulation, food exposure, and body image work.
224250964|NCT07036185|DRUG|KJ015 Injection (Subcutaneous Injection)|KJ015 is administered via subcutaneous injection, with the dosing frequency set at either Q3W.
224250965|NCT07035977|RADIATION|Participants will receive a 1/6 views undersampling lung CBCT scan.|Participants will receive a 1/6 views undersampling lung CBCT scan. And the CBCT images will be reconstructed by DeepSparseCBCT model for further analysis.
224250966|NCT07036328|DEVICE|repetitive transcranial magnetic stimulation|20 Hz repetitive transcranial magnetic stimulation targeted at the precuneus
224250967|NCT07036328|DEVICE|sham repetitive transcranial magnetic stimulation|20 Hz sham repetitive transcranial magnetic stimulation targeted at the precuneus
224250968|NCT07037511|DRUG|Salbutamol|Meter-dose inhaler of salbutamol performed using large-volume spacer
223670114|NCT00511225|DIETARY_SUPPLEMENT|cholecalciferol|10,000 IU weekly
223670115|NCT00511225|DIETARY_SUPPLEMENT|placebo|placebo capsule
223670116|NCT03153384|PROCEDURE|Blood Culture|For each patient, one single high volume blood culture (3 aerobic and 3 anaerobic of 8 to 10 mL each, numbered), and then 2 samples of 16 to 20 mL (one aerobic bottle and one anaerobic for each sample).
223670117|NCT02567058|DEVICE|Ultrasound exam|"Ultrasound exam with :~* 2 successions of 3 measures repeated for 2 visits (day 0 and day 21) for group I~* 1 succession of 3 measures repeated for 4 visits (day 0, day 14, day 45, day 90)for group II~* 1 succession of 3 measures for group III"
223670118|NCT02567058|BEHAVIORAL|IPAQ questionnaire|IPAQ questionnaire
223670119|NCT00892840|DRUG|BMS-820836|Oral Solution, Oral, 0.1 mg to 4 mg, Once daily, 14 days
223670120|NCT00892840|DRUG|Placebo|Oral Solution, Oral, 0 mg, Once daily, 14 days
223670121|NCT03316911|BEHAVIORAL|MKit|MKit is a web-based application that uses a life-skills approach to address healthy relationships and sexual violence. It includes 14 tiles which incorporate information, goal setting, and resources.
223670122|NCT01119937|DRUG|NVA237|50µg capsules for inhalation, delivered via a single dose dry powder inhaler (Concept 1®)
223670123|NCT01119937|DRUG|Tiotropium|18µg capsules for inhalation, delivered via HandiHaler®
223670124|NCT05916911|DIETARY_SUPPLEMENT|Glizigen|"Treatment initiation: Treatment should be started simultaneously with the appropriate oral and intravaginal formulation after the last menstrual period or immediately in menopausal patients.~A total of 60 single doses of intravaginal use and 60 doses of oral solution should be given to each patient.~The intravaginal gel should be applied every night before going to sleep by inserting the cannula completely into the vagina and pressing the tube until the entire contents of the tube are poured into the vagina, then removing the cannula from the vagina while continuing to press the tube to avoid retrograde aspiration of the product. Application of the intravaginal gel should be discontinued during days of menstrual bleeding.~The oral solution should be administered by drinking 1 vial every morning without interruption for 60 days from the start of treatment. It can be taken either on an empty stomach or with food."
223670125|NCT05916911|OTHER|Placebo|"Treatment initiation: Treatment should be started simultaneously with the appropriate oral and intravaginal formulation after the last menstrual period or immediately in menopausal patients.~A total of 60 placebo single doses of intravaginal use and 60 placebo doses of oral solution should be given to each patient.~The placebo intravaginal gel should be applied every night before going to sleep by inserting the cannula completely into the vagina and pressing the tube until the entire contents of the tube are poured into the vagina, then removing the cannula from the vagina while continuing to press the tube to avoid retrograde aspiration of the product. Application of the intravaginal gel should be discontinued during days of menstrual bleeding.~The placebo oral solution should be administered by drinking 1 vial every morning without interruption for 60 days from the start of treatment. It can be taken either on an empty stomach or with food."
223670126|NCT04235413|BEHAVIORAL|Real-Time Incentives Group|The use of a novel computer program with a mobile phone interface to provide real-time financial incentives at the point of purchase for discounts on fruit and vegetables in low-income families. This intervention will be applied to subjects randomized to the intervention arm. They will receive 50% off eligible fruits and vegetable products at the point of purchase, up to $10 a week for 6 months. Maximum amount they can receive is $260 in discounts over the 6 month period.
223670127|NCT01495312|DEVICE|SLT (selective laser trabeculoplasty ) SENSIMED Triggerfish|SLT (single session; 180 to 360 degrees of angle will be treated)
223670128|NCT05557825|RADIATION|Photobiomodulation Therapy|Focal low-level laser therapy, 1 to 3 Joules per point, depending on the degree of pain, wavelength 633 to 830 nm, transcutaneously on the surface of the tissue injured by radiotherapy, three times a week during radiotherapy treatment and two more applications after the end of radiotherapy
223670129|NCT04677478|OTHER|Impact of respiratory isolation on quality of life|Semi-structured interviews
223670130|NCT03494491|DIETARY_SUPPLEMENT|Chitin-glucan|Second test day (D2), subjects will received 4.5g of chitine-glucan
223670131|NCT03494491|DIETARY_SUPPLEMENT|Maltodextrin|First test day (D0), subjects will received 4.5g of maltodextrin.
223670132|NCT00389402|DRUG|saquinavir/ritonavir|
223670133|NCT00389402|DRUG|atazanavir/ritonavir|
223670134|NCT00853996|DRUG|acolbifene hydrochloride|Given orally
223670135|NCT02965768|DRUG|Naltrexone HCl|4.5 mg Naltrexone HCl, p.o., nocte (standard-dose); 3.0 mg Naltrexone HCl, p.o., nocte (optional-dose);
223670136|NCT03313661|DRUG|Cabergoline|cabergoline 0.5 mg twice weekly within 2 hrs of awakening plus gliclazide
223670137|NCT03313661|DRUG|Gliclazide|gliclazide (60-120 mg)
223670138|NCT03907618|DIAGNOSTIC_TEST|ovarian reserve|To assess ovarian reserve in patients with Type 1 Diabetes Mellitus aged 18-40 years; ultrasonographic and laboratory parameters will be looked at.
223771549|NCT00721526|DRUG|disulfiram plus lorazepam|Disulfiram 500mg three times weekly lorazepam 0.5-2.0 mg three times daily
223771550|NCT05225181|BEHAVIORAL|perform physical exercise|one 60-min session of physical training
223670139|NCT02536404|DRUG|Etrasimod|
223670140|NCT02536404|DRUG|Placebo|
223670141|NCT00770146|DRUG|Mipomersen sodium|200 mg/mL
223670142|NCT00770146|DRUG|Placebo|1 mL matching placebo (i.e., vehicle consisting of 9 mg of sodium chloride, 0.004 mg of riboflavin, filled to 1 mL with water).
223670143|NCT02439333|DEVICE|Nasal high flow cannula (Fisher & Paykel Healthcare, Auckland, New Zealand)|Nasal high flow therapy
223670144|NCT02439333|DEVICE|nasal catheter or Venturi mask|Conventional oxygen therapy
223670145|NCT00003798|DRUG|motexafin gadolinium|
223670146|NCT00003798|RADIATION|radiation therapy|
223670147|NCT01023477|DRUG|Chloroquine Standard Dose (500mg/week)|Patients will receive chloroquine (500 mg/once a week) for 1 month prior to surgical removal of the DCIS lesion.
223670148|NCT01023477|DRUG|Chloroquine Low Dose (250mg/week)|Patients will receive chloroquine (250 mg/once a week) for 1 month prior to surgical removal of the DCIS lesion.
223670149|NCT01023477|PROCEDURE|Breast Biopsy|Patients diagnosed with DCIS will undergo a breast biopsy prior to the start of study treatment. This biopsy is entirely voluntary and is not required to remain in the study. The biopsy will allow researchers to study the tissue for biomarkers and to determine how the DCIS tissue changes during treatment. Additional samples of the DCIS tissue will be collected at the time of surgery.
223670150|NCT00918996|PROCEDURE|Omission of Bladder Flap Creation|Omission of bladder flap creation by making uterine incision 1 cm above the vesico-uterine reflection without incision and dissection of the bladder peritoneum.
223670151|NCT01073046|DEVICE|Naso-Gastric/Jejunal Tube|Silastic Naso-Gastric/Jejunal Tube (Rusch® distributed by Teleflex Medical Srl)
223670152|NCT00277082|DRUG|9-NC in aerosol reservoir|Samples will be minced or centrifuged and L9NC extracted by chromatography. L9NC will be measured by HPLC or mass spectrometry
223670153|NCT02003274|OTHER|Clamp-Mixed Meal|"Standard clinical parameters will be assessed in all patients.~Metabolic tests:~A. Euglycemic insulin clamp. A standard euglycemic insulin clamp will be carried out in type 1 diabetic patients to assess insulin sensitivity, as previously described (1).~B. Mixed meal test. All participants will ingest a standardized mixed meal and will be monitored for 300 minutes thereafter. Right before meal ingestion, a s.c. fast insulin analogue bolus will be administered by the pump~This test will determine the time courses of:~1\. plasma glucose, 2. 13C/12C glucose ratio (hence, meal-derived and endogenous glucose), 3. insulin, 4. free fatty acids, 5. aminoacids, 6. glucagon, 7. incretin hormones 8. glucose control coefficients (CCs) during a mixed meal."
223670154|NCT02003274|OTHER|IVGTT-Mixed Meal Arm|"Standard clinical parameters will be assessed in all subjects.~Metabolic tests:~A. IVGTT. A frequently sampled intravenous glucose tolerance test (IVGTT) in healthy controls will be carried out in study 1 and study 3 to assess insulin sensitivity.~B. Mixed meal test. All participants will ingest a standardized mixed meal and will be monitored for 300 minutes thereafter.~This test will determine the time courses of:~1\. plasma glucose, 2.13C/12C glucose ratio (hence, meal-derived and endogenous glucose), 3. insulin, 4. free fatty acids, 5. aminoacids, 6. glucagon, 7. incretin hormones 8. glucose control coefficients (CCs) during a mixed meal."
223670155|NCT02268929|DEVICE|Accu-Chek Smart Pix Software|Software with adherence evaluation software used according to Integrated Personalized Diabetes Management (PDM)
224250969|NCT07037511|DRUG|Placebo|Meter-dose inhaler of placebo performed using large-volume spacer
223670156|NCT02268929|DEVICE|Accu-Chek Smart Pix readout Device|Smartpix device for data upload out from blood glucose meter devices
223670157|NCT01836874|DRUG|No intervention|This is an observational study. Participants receiving topiramate 25 mg once-a-day for 1 week and later on, receiving increase dose up to 200 mg, twice-a-day, orally will be observed for 3 months.
223670158|NCT00040456|DRUG|Mg Pidolate|Mag 2 will be used (magnesium pidolate, a granular powder, containing 0.184 g of Mg/packet, equal to 7.6 mmol or 15.2 meq Mg), since this preparation has less side effects such as diarrhea than other Mg preparations. The study medication will be a liquid containing 0.6 meq Mg pidolate/kg body weight per day, divided into 2 daily doses. The Mg pidolate (45 g) will be distributed as a pre-mixed powder containing Koolaid Tropical Punch powder (9 gm), and sucrose (67 gm).
223670159|NCT00040456|DRUG|Placebo|The study medication will be a liquid containing an equivalent amount of placebo to the study medication, divided into 2 daily doses.The placebo will have the same amount of sucrose and Tropical Punch powder as the study drug, MG Pidolate, as well as 45 g of lactose. Subjects will continue with the same assignment for 6 months and then switch to the other arm (after a 2-month wash-out period).
223670160|NCT00081510|DRUG|Lonafarnib|
223670161|NCT00081510|DRUG|Placebo|
223670162|NCT00081510|DRUG|anastrozole|
223670163|NCT01569243|OTHER|Text messages|"* Participants will receive diabetic medical care as usual.~* Participants will be given an ActiHealth pedometer to measure daily activity.~* In addition, they will be enrolled to receive the study text messages."
223771551|NCT05225181|BEHAVIORAL|cognitive training|one 60-min session of cognitive training
223771552|NCT05225181|BEHAVIORAL|control group|perform body stretching(15min) and health education courses(90min)
224250970|NCT07037225|OTHER|Fluid challenge during one-lung ventilation (OLV) in the lateral decubitus position|During OLV, a lung recruitment maneuver will be performed, followed by measurements of CPI, CI, SVI, and MAP. A fluid challenge using 250 mL of normal saline (0.9% NaCl) will be administered. Hemodynamic parameters will be recorded at 2 and 5 minutes post-infusion. Patients will be classified as responders (SVI and MAP increase ≥10%) or non-responders. Changes in CPI will also be recorded accordingly.
224250971|NCT07037225|DEVICE|Hemodynamic monitoring|Invasive hemodynamic monitoring will be performed using the HemoSphere device (Edwards Lifesciences).
224250972|NCT07035821|DRUG|Olanzapine Tablets|Oral olanzapine tablets
224250973|NCT07035821|DRUG|Placebo|Oral placebo
224250974|NCT00119015|DRUG|Placebo|
224250975|NCT00119015|DRUG|Montelukast|
224250976|NCT00119015|DRUG|Fluticasone propionate|
224250977|NCT01597245|DRUG|80 mg ixekizumab Dosing Regimen|Administered SC
224250978|NCT01597245|DRUG|50 mg etanercept|Administered SC
224250979|NCT01597245|DRUG|Placebo|Administered SC
224250980|NCT01930227|OTHER|TEAS|Electric stimulation was given through electrode attached to specific acupoints
224250981|NCT01930227|OTHER|Non-acupoint stimulation|Electric stimulation was given through electrode attached to the shoulder
224250982|NCT02989233|OTHER|Non-surgical periodontal treatment|Scaling and oral hygiene instructions with brochure, model or video
224250983|NCT01313780|DRUG|Oxycodone/Naloxone|Dose and administration : Upto 40mg B.I.D per daily.
224250984|NCT01313780|DRUG|Oxycodone(single compound)|Dose and administration : Upto 40mg B.I.D per daily.
224250985|NCT04590443|OTHER|NMP|Participants received the percutaneous electrical stimulation intervention. Specifically, this consisted of the application of a square wave biphasic electrical current, with 3 Hz frequency and a 250µs pulse width, at the maximal tolerable intensity, to cause an tolerable muscle contraction. The application was 10 stimulations of 10 seconds, with 10 seconds at rest between stimulations. A trained physiotherapist performed the PNM intervention.
224250986|NCT00889109|OTHER|Three dimensional unrestricted arm movements|The subjects will carry out three dimensional unrestricted arm movements. The subjects' movements will be recorded by optoelectronic infrared cameras and software. Assessment of smoothness parameters of subjects' movements will allow discriminating between subjects with intact or impaired proprioception.
224250987|NCT03592953|OTHER|Serious game simulation training sessions|"Each participant of the Serious game groups played 3 scenarios of Perinatsims, a screen-based simulation on the management of a post partum hemorrhage. The serious game control group played basic scenarios and the experimental group played specific scenarios."
224250988|NCT01141426|BEHAVIORAL|Intensive Short-term Dynamic Psychotherapy|The ISTDP model is an emotion focused brief format of psychotherapy that helps the patients identify and address emotional factors that culminate into exacerbation of depression and perpetuation of depression. The emphasis is on awareness of emotions and how they affect the person's behavioral patterns and mood. The research protocol calls for the treatment to be delivered according to a 20-session time-limited format. The first session is an extended 2-3 hour appointment (21), then sessions are planned to occur on a weekly basis lasting 60 minutes in duration. Termination in fewer sessions is based upon agreement between therapist and patient.
224250989|NCT01141426|BEHAVIORAL|Secondary Care Treatment as Usual|At the four secondary health care sites, treatment as usual will consist of a multidisciplinary team approach including pharmacotherapy and clinical management, supportive or structured activities focused around symptom management and in some cases, individual or group psychotherapy. Pharmacotherapy treatment strategies will be individualized regimes informed by evidence-based recommendations. TAU will not be regulated in order to get a naturalistic assessment of standard secondary care treatment delivery with the exception that trial participants not be offered a psychodynamic / psychoanalytic based psychotherapy treatment during the course of the trial. Therapeutic interventions are likely to be heterogeneous therefore the trial coordinator will document in detail the dose and approaches delivered to each participant in order to account for this heterogeneity.
224250990|NCT01232426|PROCEDURE|Biodegradable Meniscus Arrow®|Closed reduction of the Mallet fracture and fixation with 1 biodegradable meniscus Arrow®
224250991|NCT01232426|DEVICE|Mallet splint|Conservative treatment of the Mallet fracture with the traditional Mallet splint.
224250992|NCT00000541|BEHAVIORAL|dietary supplements|
223670164|NCT01569243|OTHER|Usual care|"* Participants will receive diabetic medical care as usual.~* In addition, participants in the control group will be given an ActiHealth pedometer to measure daily activity (step counts will be used as a proxy for activity)."
223670165|NCT01649843|PROCEDURE|POEM|Peroral endoscopic myotomy (POEM) has recently been described as a new minimally invasive endoscopic myotomy technique intending a permanent cure from primary achalasia in some centers.
224250993|NCT00000541|DRUG|vitamin C|
223670166|NCT01463137|BEHAVIORAL|Attention bias modification|All arms will consist of 10 minutes of training in front of a computer screen (192 trials) once a day for 14 days.
223771553|NCT01312402|DRUG|topical brinzolamide 1% in 5mL ophthalmic medication|1 drop three times a day in both eyes on days 2,3 and 4
224250994|NCT00000541|DRUG|vitamin E|
224250995|NCT00000541|DRUG|beta-carotene|
224250996|NCT00000541|DRUG|folic acid/Vitamin B6/Vitamin B12|
224322057|NCT01807065|BIOLOGICAL|sipuleucel-T|Given IV
224322058|NCT01807065|RADIATION|external beam radiation therapy|Undergo external beam radiation therapy
224322059|NCT01807065|OTHER|laboratory biomarker analysis|Correlative studies
224322060|NCT03523936|DIETARY_SUPPLEMENT|Prebiotic product|Prebiotic product used during the course of antibiotic treatment
224322061|NCT03523936|DIETARY_SUPPLEMENT|Placebo|Placebo
223670167|NCT03940976|DRUG|Afatinib|Afatinib is orally administered at 40mg Qd of each 28 day cycle.
223670168|NCT01967784|BIOLOGICAL|Quadrivalent Influenza Vaccine (split virion, inactivated)|0.5 mL, Intramuscular
223670169|NCT00816023|DRUG|ecallantide|infusion administered IV over the duration of the surgical procedure
223670170|NCT00816023|DRUG|placebo|solution for IV infusion over the duration of the surgical\>\> procedure
223670171|NCT00748020|PROCEDURE|UVB phototherapy|Group 1: every irradiation an increase of 40%, starting with 70% of the minimal erythema dose
223670172|NCT00748020|PROCEDURE|UVB phototherapy|Group 2: every irradiation an increase of 20%, starting with 30% of the minimal erythema dose
223670173|NCT01525901|DRUG|Insulin-Like Growth Factor-1 (IGF-1)|IGF-1 and placebo will each be administered for 3 months with a four-week washout period in between. IGF-1 will be administered for 3 months subcutaneously.
223670174|NCT01525901|DRUG|Normal saline|Saline solution will be administered for three months subcutaneously.
223771554|NCT01312402|DRUG|Placebo in 5 mL dispenser|Placebo ophthalmic solution in 5 mL dispenser; 1 drop three times a day on days 2,3 and 4
223771555|NCT06432010|OTHER|Group nutrition and physical activity coaching|Group nutrition and physical activity coaching consists of an initial health check-up, followed by nutrition and physical activity coaching sessions over 7 weeks, 2 telephone follow-ups at 3 and 6 months and finally a final health check-up, 12 months after the end of the group nutrition and physical activity coaching sessions.
223771556|NCT06432010|OTHER|Group cognition coaching|Group cognition coaching consists of an initial health check-up, followed by cognition coaching sessions over 7 weeks, 2 telephone follow-ups at 3 and 6 months and finally a final health check-up, 12 months after the end of the cognition coaching sessions.
224250997|NCT04799028|OTHER|Traditional cow's milk|Fortified cow's milk
224250998|NCT04799028|OTHER|Experimental milk|Milk with synbiotics and fat blend
224250999|NCT04799028|OTHER|Habitual diet|Habitual diet
223670175|NCT04739371|DRUG|Insulin, Regular, Human|The spray will last a few seconds and then the participant will be asked to sniff to aid the drug into the nose. The device (i.e. ViaNase) is an atomizer that uses its patented technology that turns the liquid into a fine mist of droplets to facilitate the drug along the nose to brain pathway. Each nostril will receive this administration 2 times for a total of 40 IUs or 0.4 mL of liquid.
223670176|NCT04739371|DRUG|Placebo|The spray will last a few seconds and then the participant will be asked to sniff to aid the saline into the nose. The device (i.e. ViaNase) is an atomizer that uses its patented technology that turns the liquid into a fine mist of droplets to facilitate the drug along the nose to brain pathway. Each nostril will receive this administration 2 times for a total of 40 IUs or 0.4 mL of liquid.
223670177|NCT04746742|PROCEDURE|Tunneled Femoral Catheter (TFC) group|Patients with end-stage chronic kidney disease exhausted upper-extremity and chest-wall vascular accesses will be submitted to creation of a Lower-Extremity Hemodialysis Vascular either through application of tunneled femoral catheter
223670178|NCT04746742|PROCEDURE|Femoro-femoral Arteriovenous graft (FF-AVG) group|Patients with end-stage chronic kidney disease exhausted upper-extremity and chest-wall vascular accesses will be submitted to creation of a Lower-Extremity Hemodialysis Vascular either through application of tunneled femoral catheter
223670179|NCT02737033|DRUG|Rhodiola|Rhodiola rosea 800mg
223670180|NCT02737033|DRUG|Placebo|innocuous pill manufactured to mimic Rhodiola
223670181|NCT04607278|DIETARY_SUPPLEMENT|Probiotic|Oral probiotic supplementation was provided by iHealth; Cromwell, USA. Each sachet included a 1×1010 CFUs dose of four viable microbial cell preparation strains: there are two strains of lactobacillus genus (Lactobacillus acidophillus L1 (2.9×109) and Lactobacillus rhamnosus liobif (2.9×109)), Bifidobacterium longum (2.9×109) and Saccharomyces boulardii (1.3×109). Each participant took a total daily dose of 4×1010 CFUs.
223670182|NCT04607278|DIETARY_SUPPLEMENT|Prebiotic|The prebiotic was made up of inulin from the chicory plant and provided by the Fibrelle (Belgium) company. Five grams packs were given to the participants in boxes. Each participant was requested to take a total daily 10 g dose.
224251000|NCT00731783|DRUG|2% Mupirocin Ointment|Apply ointment to the anterior nares twice daily for 5 days.
224251001|NCT00731783|DRUG|4% Chlorhexidine liquid soap|Bathe with liquid soap daily for 5 days.
224251002|NCT00731783|BEHAVIORAL|Hygiene protocol|"Follow key hygiene tips indefinitely. Tips are:~* Throw out all lotions or creams that you dip your hands into and replace with pumps or pour bottles.~* Use liquid(pour or pump) soaps instead of bar soaps.~* Wash hands frequently or use hand sanitizer(with more than %60 alcohol) such as Germ-X or Purell.~* Do not share personal care items such as razors and brushes.~* Wash all sheets and towels in hot water. Wash sheets every week.~* Use towels and wash cloths only once before washing and do not share."
224251003|NCT06248827|OTHER|Data Collection|Patient data : gender, age, height, weight, daily life (type of job) Diagnostic data : Description of first symptoms/medical history (pain), previous medical history, MRI exams
223670183|NCT04607278|DIETARY_SUPPLEMENT|Placebo|It was composed of maltodextrin, and provided by the manufacturer Fibrelle; (Belgium). The prescription was similar to probiotics or prebiotics groups.
223680659|NCT06433362|DRUG|CMOEP|Drug: Mitoxantrone hydrochloride liposome Mitoxantrone hydrochloride liposome (18 mg/m\^2) on day 1, every 3 weeks; Drug: Cyclophosphamide Cyclophosphamide(750 mg/m\^2) on day 1,every 3 weeks; Drug: Vincristine Vincristine (1.4mg/ m2，Max dose 2mg) will be administered by an intravenous injection on day 1(Or at the discretion of the investigator, use other vinblastine drugs with the same mechanism, such as vindesine 3 mg/m2, the maximum dose of 4mg),every 3 weeks; Drug: Etoposide Etoposide (60 mg/ m2) will be administered by an intravenous infusion on day 1-3,every 3 weeks;
223771557|NCT03621267|OTHER|Interactive Stepping Exercise|Interactive Stepping Exercise will perform on a thin mat, stepping pattern will display through a monitor screen, immediate auditory feedback will give for adjustment
224251004|NCT01591603|PROCEDURE|1 cm|A Tuohy needle will be advanced in-plane with the bevel cephalad to a point that lies between the tibial and common peroneal branches of the sciatic nerve. The catheter will be advanced 1 cm past the tip of the Tuohy
224251005|NCT01591603|PROCEDURE|5 cm|A Tuohy needle will be advanced in-plane with the bevel cephalad to a point that lies between the tibial and common peroneal branches of the sciatic nerve. The catheter will be advanced 5 cm past the tip of the Tuohy
224251006|NCT06945380|OTHER|Best Practice, Comparator Program|Receive access to a comparator program
224251007|NCT06945380|OTHER|Best Practice, Usual Care|Receive usual care
224251008|NCT06945380|OTHER|Internet-Based Intervention|Receive access to the PNR program
224322062|NCT01948115|DRUG|equimolar mixture of oxygen and nitrous oxide or medical air|"We need to include 150 patients for a period of 2 years. Patients will be randomized: 75 patients in each arm: 75 patients in group placebo (medical air), 75 patients in group treatment (equimolar mixture of oxygen and nitrous oxide).~Patients will be single-blind. The ECV be started at least 3 minutes after the start of administration. The maximum time of administration of the gas will be 15 minutes. Just after ECV, we compare success rate of intervention."
224251009|NCT06945380|PROCEDURE|Massage Therapy|Perform the relaxation massage techniques
224251010|NCT06945380|OTHER|Survey Administration|Complete surveys to assess CIPN symptoms, overall well-being and quality of life, and caregiver reaction and attitudes
223680660|NCT04438564|OTHER|Cases for patients diagnosed with breast cancer, colonrectal cancer, ovarian cancer and endometrial cancer|Diagnosis and acceptance of breast cancer, colon rectal cancer, ovarian cancer, and endometrial cancer by the clinical Western medicine team.
223771558|NCT03621267|OTHER|Home exercise program|Home exercise program includes stretching exercise, general strengthening exercise on lower extremity muscles, posture control and balance exercise.
224251011|NCT04439656|DIAGNOSTIC_TEST|Eye movement analysis|Eye movements will be analyzed to identify if seizures are present and compared to the EEG read
224251012|NCT03620175|DRUG|TolaSure Topical Gel|TolaSure topical gel is applied to skin punch biopsies daily over the course of 2 weeks.
224251013|NCT03023956|PROCEDURE|Locking plates were used for proximal humeral fractures.|
224251014|NCT01256892|PROCEDURE|induction of labour|
224251015|NCT05948683|DRUG|MDMA|The stimulant MDMA
224251016|NCT05948683|DRUG|Placebo|Dextrose
224251017|NCT05293145|OTHER|Building Futures Program Primary Services|Primary Services Participants receive 14 hours of Survival Skills for Healthy Families curricula delivered over a series of 7 weekly workshops. Participants also receive support services delivered by Family Coaches and Career Coaches as needed.
224251018|NCT05301361|DRUG|Methylphenidate Oral Solution|The XRMPH or matching placebo will be started at a dose of 0.3 mg/kg/day and individually titrated over two weeks. Phone calls at the end of weeks 1, 2, and 3 will be used to collect adverse event and response data. If there is no evidence of side effects and ongoing symptoms of ADHD, the dose will be increased to 0.5 mg/kg/day at one week and 0.7 mg/kg/day at 2 weeks (maximum dose of 60 mg per day consistent with FDA labeled use in youth).
224251019|NCT05995275|BIOLOGICAL|mRNA-1769|Sterile liquid for injection
223670184|NCT00559182|DRUG|Comparator: MK-8033|"MK-8033 will be administered as an oral formulation in sequentially rising dose levels starting at 50 mg and continuing at 100% dose increments until dose level 4 (800 mg total daily dose). Dose levels 5 to 11 will be escalated at \~40% dose increments until 3000mg (total daily dose). The daily dose of MK-8033 will be divided into two equal doses. MK-8033 will be administered in a first cycle of 14 days (continuous drug administration from Day 1 through Day 14), followed by a 1 week drug holiday (Cycle 1, Day 15 through Day 21). Subsequent cycles of MK-8033 will be administered for 14 days (Cycles 2 to 4) and 28 days (Cycle 5 and beyond).~Enrollment in Parts A and B has been completed."
223670185|NCT00559182|DRUG|Comparator: MK-8033 +/- omeprazole|"Part C will occur at only one of the investigational sites.~In Cycle 1, patients will be randomized to one of two treatment sequences, A/B or B/A, over two treatment periods. Treatment A: 770 mg MK-8033 twice daily with co-administration of 20 mg omeprazole once daily. Treatment B: 770 mg MK-8033 twice daily. After Cycle 1 is complete, patients may continue to receive MK-8033 until disease progression or unacceptable toxicity.~Enrollment for Part C has been suspended."
223670186|NCT00003959|BIOLOGICAL|ras peptide cancer vaccine|
223670187|NCT00003959|BIOLOGICAL|sargramostim|
223670188|NCT00641316|PROCEDURE|AtraumaticTeeth Extraction|Teeth extraction alone, allowed to heal for 2 months followed by implant therapy to the sites
223670189|NCT00641316|PROCEDURE|Atraumatic Teeth Extraction/Grafted Extraction Sockets|Teeth extraction/post-extraction socket grafting with Freeze-Dried Bone Allograft (FDBA) mixed with Tri-Calcium Phosphate(TCP) allowed to heal for 2 months followed by dental implant therapy to the sites
223670190|NCT00641316|PROCEDURE|Atraumatic Teeth Extraction/Grafted Extraction Sockets|Teeth extraction/post-extraction socket grafting with FDBA/TCP enriched with Autologous Platelet-Rich Plasma (PRP) allowed to heal for 2 months followed by dental implant therapy to the sites
223670191|NCT00641316|PROCEDURE|Atraumatic Teeth Extraction/Grafted Extraction Sockets|Teeth extraction/post-extraction socket grafting with FDBA/TCP enriched with Platelet-Derived Growth Factors (PDGF) allowed to heal for 2 months followed by dental implant therapy to the sites
223670192|NCT05027971|DEVICE|Flexiva Pulse High Power Single-Use Laser Fibers|Flexiva Pulse High Power Single-Use Laser Fibers are intended to be used as a device that transmits Ho:YAG laser energy from cleared laser consoles to urological anatomy.
223670193|NCT04506762|PROCEDURE|Regional analgesia|Insertion of bilateral ESP catheters
223670194|NCT06361992|OTHER|Blue Cap Foam|Application regimen: Blue Cap foam 100 ml, Activated Piroctone Olamine (Foam, label 100 ml), Catalysis S.L. Madrid must be applied twice a day on all affected areas. The application is to be continued for 30 days, after which the patients stop using the foam until the final assessment at day 45.
223670195|NCT02486627|DRUG|plazomicin|
223670196|NCT02486627|DRUG|meropenem|
223670197|NCT02486627|DRUG|levofloxacin (oral)|
223670198|NCT00968032|DEVICE|Nit-Occlud® PFO|Transcatheter implantation of a PFO occluder (Nitinol double Umbrella)
223670199|NCT02962375|DIETARY_SUPPLEMENT|Active|100% orange juice with orange pomace fiber
223670200|NCT02962375|DIETARY_SUPPLEMENT|Control|100% orange juice
223670201|NCT04405778|BIOLOGICAL|TAK-102|TAK-102 intravenous infusion
223670202|NCT03325023|DIETARY_SUPPLEMENT|Dietary and life style modification and probiotic Sanprobi Super Formula|Sanprobi Super Formula consisting of: Bifidobacterium lactis, Lactobacillus acidophilus, Lactobacillus paracasei, Lactobacillus plantarum, Lactobacillus salivarius, Lactobacillus lactis, Fructooligosacharide, Inulin.
223670203|NCT03325023|OTHER|Placebo|Placebo
223771559|NCT00192179|BIOLOGICAL|Cold-adapted influenza vaccine trivalent (CAIV-T)|The total volume of 0.2 ml was administered intranasally with a spray applicator (approximately 0.1 ml into each nostril). Each dose of CAIV-T used in this study contained approximately 10\^7+/-0.5 fluorescent focus units (FFU) (equivalent to 10\^7+/-0.5 TCID50) of each of the following three influenza virus strains: Influenza Cold Adapted Virus Type H1N1, strain A/New Caledonia/20/99; Influenza Cold Adapted Virus Type H3N2, strain A/ Panama/2007/99; Influenza Cold Adapted Virus Type B, strain B/Hong Kong/ 330/01.
224251020|NCT05995275|OTHER|Placebo|0.9% sodium chloride injection (normal saline)
224251021|NCT04248543|DEVICE|qMRI with Gadoteridol contrast agent|quantitative MR: MRI uses a magnet and radio waves to make medical images of the body. Gadoteridol is used as a contrast agent. Quantitative MRI involves the use of software to analyze the acquired images.
224251022|NCT04894097|DEVICE|magnetic therapy|High intensity low frequency magnetic therapy
224251023|NCT06134934|OTHER|Telemonitoring 1|This telemonitoring intervention design include self-monitoring of blood glucose (SMBG) together with monitoring of sleep, mental health, blood pressure and activity.
224251024|NCT06134934|OTHER|Telemonitoring 2|This telemonitoring intervention design include self-monitoring of blood glucose (SMBG) together with monitoring of sleep and mental health.
223670204|NCT00401024|DRUG|imatinib mesylate|
223670205|NCT00401024|OTHER|pharmacological study|
223670206|NCT00401024|PROCEDURE|conventional surgery|
223670207|NCT05987592|BEHAVIORAL|Brain Education and WELLness with Migraine Group A|Behavioral intervention that involves 8 weekly group virtual sessions with an instructor that may help improve migraine, plus access to an online platform with additional content and learning
223670208|NCT05987592|BEHAVIORAL|Brain Education and WELLness with Migraine Group B|Behavioral intervention that involves 8 weekly group virtual sessions with an instructor that may help improve migraine, plus access to an online platform with additional content and learning
223670209|NCT01722227|DRUG|Liraglutide|
223670210|NCT01722227|DRUG|Placebo|
223670211|NCT01853488|RADIATION|DXA|Osteodensitometry
223670212|NCT01853488|RADIATION|pQCT|Osteodensitometry
223670213|NCT04083729|PROCEDURE|Percutaneous Mitral Commissurotomy|Percutaneous mitral commissurotomy is performed by experienced interventional cardiologists using the Inoue balloon or multitrack technique. During the procedure, conventional hemodynamic parameters are monitored. A successful immediate result is defined as a mitral valve area \> 1.5 square cm with less than moderate to severe mitral regurgitation.
223670214|NCT05984550|DRUG|NMN|"NMN (Nicotinamide Mononucleotide) is a naturally occurring bioactive nucleotide with the full name of Nicotinamide mononucleotide. Its structure can be divided into α and β Two isomers, of which only β- NMN is a naturally occurring form with biological activity.~In human body, NMN is the precursor of NAD+(Nicotinamide adenine dinucleotide, also known as coenzyme I), and its function is mainly reflected through NAD+."
223670215|NCT05080244|DIETARY_SUPPLEMENT|Probiotics|2 strains 10x10\^9 UFC/capsule
223670216|NCT05080244|DIETARY_SUPPLEMENT|Placebo|Potato starch and magnesium stearate
223670217|NCT05330884|BIOLOGICAL|BCG vaccine|0.1ml BCg vaccine to be given intradermally
223670218|NCT05330884|DRUG|Oral Chemoprophylaxis|Oral chemoprophylaxis will be standard of care - either 6 months of Isoniazid or 3 months of weekly Isoniazid and Rifapentine
223670219|NCT06065111|OTHER|study tendon damage in osteogenesis imperfecta patients|"* To identify and characterize alterations of tendons and ligaments in patients with osteogenesis imperfecta (OI) and to improve clinical management of the disease.~* To analyze interactions of different parameters, such as laxity or administration of bisphosphonates, on the evolution of the disease."
223670220|NCT01597115|PROCEDURE|Duplex ultrasonography|
223670221|NCT01578824|OTHER|Methacholine Challenge Test|Evaluation of airway hyperreactivity as assessed by doubling dose of methacholine with determination of PC20
223670222|NCT01238588|DRUG|Sevelamer Carbonate (Renvela)|Patients' will be given doses of Renvela equivalent to their prior dose of calcium based phosphate binders and the dose will be titrated as necessary to achieve phosphate levels recommended by KDOQI guidelines.
223670223|NCT01126671|DRUG|Supplemental Vitamin D|Subjects were randomized to either take 200 IU of vitamin D or 1000 IU of vitamin D daily for 11 weeks and labs were compared before and after.
223670224|NCT05395091|BIOLOGICAL|AVT03|AVT03 (denosumab) is a recombinant fully human IgG2 monoclonal antibody to RANKL to be administered as a subcutaneous injection. Subjects in this arm received AVT03 60mg administered s.c. on Day 1 and at Month 6. At Month 12, subjects in the AVT03 arm received a third dose of AVT03 60 mg.
223670225|NCT05395091|BIOLOGICAL|Denosumab|"Prolia (denosumab) is a recombinant fully human IgG2 monoclonal antibody to RANKL developed to be administered as a subcutaneous injection.~Subjects in this arm received 60mg of commercially available US-Prolia, administered s.c on Day 1 and at Month 6. At Month 12, subjects in the Prolia treatment group were re-randomized in a 1:1 ratio to receive either:~* AVT03 60 mg administered s.c. on Day365.~* Prolia 60 mg administered s.c. on Day365."
223670226|NCT03534336|BEHAVIORAL|Incentive for Education|"A $150 Incentive for Education is given to the participants for passing at least nine quizzes by the end of the program"
223670227|NCT03534336|BEHAVIORAL|Incentive for Weight Loss|"A $150 Incentive for Weight Loss is given to the participants for losing at least 5% of baseline weight by the end of the program"
223771560|NCT00192179|BIOLOGICAL|Placebo|The placebo consisted of physiologic normal saline.
223771561|NCT02736162|OTHER|No treatment (intervention) was administered|
224251025|NCT05637814|DIAGNOSTIC_TEST|SpO2/PIx Measurement and ML Algorithm|Right upper and any lower extremity oxygen saturation (SpO2) and perfusion index (PIx) will be measured and an online ML inference model will be used to classify a newborn as healthy versus CCHD as new pulse oximetry data is collected.
224251026|NCT05374616|GENETIC|Observation|Retrospective and prospective Natural History Study
224251027|NCT05109975|DRUG|Debio 0123|Debio 0123 orally during 21-day treatment cycles.
224251028|NCT05998369|BEHAVIORAL|Empowered Relief for Youth|The Empowered Relief for Youth is a 90-minute class that provides pain science education, as well as cognitive, emotional, and physiologic self-regulation skills for youth with chronic pain. Youth will also develop a personalized plan to use the acquired skills daily. Participants will receive an audio file (Relaxation Response) post-class. The class provides patients rapid access to actionable skills for symptom management and pain relief.
224251029|NCT05369208|DRUG|Avatrombopag Oral Tablet|Avatrombopag 20 mg given once daily (initial dose). Dosage adjustments were determined by the physician to maintain a platelet count between 50 x 10\^9 to 200 x 10\^9 as defined in the protocol and in accordance with overseas labeling.
224323530|NCT05159999|DRUG|Anti-hypertensive medications|Anti-hypertensive medications will be adjusted every 2 weeks to reach the home or pre-dialysis systolic blood pressure target. Adjustment of currently prescribed anti-hypertensive medications will be prioritized before starting new medications. Only standard anti-hypertensive medications will be used, such as RAAS inhibitors, beta-blockers, calcium channel blockers and diuretics.
224323531|NCT06953661|PROCEDURE|Stellate ganglion block|Patients will receive a SGB
223670228|NCT05019547|BEHAVIORAL|Determining Barriers and Facilitators of Physical Activity|Determining Barriers and Facilitators of Physical Activity
223670229|NCT06171204|PROCEDURE|Injection of SVF in fat pad of the knee|Knee fat pad injection with SVF at orthopaedics/physical medicine outpatient clinic
223670230|NCT03554486|DRUG|Fiasp|Fiasp insulin will be used for 2 weeks with the 670G hybrid closed-loop system
223670231|NCT03554486|DRUG|Novolog|Novolog insulin will be used for 2 weeks with the 670G hybrid closed-loop system
223670232|NCT01509053|DRUG|Aripiprazole (Abilify®) IM Depot Injection|"400 mg IM depot injection every 26-30 days. Dosage may be adjusted at the investigator's discretion to 300 mg.~Number of injections: 6. Participants have the option of entering the extension phase of the study and continuing with injections every 26-30 days until the drug is either commercially available, or December 2014."
223670233|NCT01509053|DRUG|Oral aripiprazole|Oral aripiprazole tablets 10-15 mg/day (up to 30 mg/day).
223771562|NCT04086472|BIOLOGICAL|Clesrovimab|Single dose of clesrovimab administered via IV infusion.
223771563|NCT04086472|OTHER|Placebo|Placebo (0.9% sodium chloride, USP sterile saline) administered via IV infusion.
223771564|NCT04086472|BIOLOGICAL|RSV-A Memphis 37b|Approximately 4Log10 plaque-forming units (PFU)/mL RSV-A virus inoculation strain Memphis 37b administered via intranasal inoculation.
224323532|NCT06953661|PROCEDURE|Sham injection of saline|Patients will receive a subcutaneous sham injection of saline
224251030|NCT05108428|DRUG|Capecitabine|Capecitabine 825 mg/m\^2 twice daily orally 5 days per week on days of planned radiation therapy.
223670234|NCT05078762|OTHER|Immersive Virtual Reality|Training in an iVR environment with Virtual Reality Goggles while using the bronchoscopy simulator, while the control group will train without VR goggles.
224322063|NCT05085262|DIAGNOSTIC_TEST|Bloodwork, Echocardiogram, PET/MRI|The study will use blood samples from COVID biobank at University Health Network. Samples will be collected at time of admission to ER in patients discharged after assessment and at three time points during admission in patients who are admitted for measurement of blood biomarkers. Echocardiography studies will be assessed for structural and functional abnormalities. All included patients will have prospective short-term follow-up (3-6 months) for assessment of clinical events and subclinical cardiovascular disease. 50 patients who had clinical cardiac MRI at our center within 5 years prior to COVID-19 (January 2015-January 2020) and have since tested positive for COVID-19 will be recruited for research cardiac MRI to compare changes between baseline (pre-COVID) and follow-up (post-COVID imaging). A subgroup of 50 patients will undergo cardiac PET/MRI at 1-3 months post COVID-19 diagnosis to evaluate for myocardial inflammation and other imaging markers of cardiac injury.
223670235|NCT01127828|OTHER|Arla Yoghurt with no probiotic|two servings of 200 ml of investigational products per day
223670236|NCT01127828|OTHER|Probiotic yoghurt (Cultura)|200 ml per day
223670237|NCT01500499|GENETIC|gene expression analysis|
223670238|NCT01500499|GENETIC|gene rearrangement analysis|
223670239|NCT01500499|GENETIC|polymerase chain reaction|
223670240|NCT01500499|GENETIC|protein analysis|
223670241|NCT01500499|GENETIC|western blotting|
223670242|NCT01500499|OTHER|laboratory biomarker analysis|
223670243|NCT01500499|OTHER|mass spectrometry|
223670244|NCT01915303|DRUG|Pasireotide with or without cabergoline|The trial consisted of Pasireotide-untreated patients who started pasireotide 0.6mg twice a day for 8 weeks. If biochemical control was not achieved by the end of the 8 weeks, and the 0.6mg dose is well-tolerated, the dose was increased to 0.9mg twice a day for another 8 weeks. If biochemical control is not achieved, cabergoline was added and patients began combination treatment with cabergoline at the starting dose of 0.5mg once a day for 8 weeks. If biochemical control is still not achieved at the end of the third 8 week period, the dose of cabergoline was increased to 1.0mg once a day. Patients could also immediately start the combination treatment by adding cabergoline 0.5mg once a day at study entry to their current maximal tolerated dose of pasireotide. Patients continued with the combination treatment for 8 weeks. If biochemical control was not not achieved by the end of the 8 week period, the dose of cabergoline was increased to 1mg once a day.
223670245|NCT05140824|DRUG|Placebo|0.9% sodium chloride solution
223771565|NCT03348904|DRUG|Nivolumab|Nivolumab administered intravenously at the protocol-defined dose every 3 weeks.
223771566|NCT03348904|DRUG|Epacadostat|Epacadostat administered orally at the protocol-defined dose twice daily.
223771567|NCT03348904|DRUG|Placebo|Matching placebo for epacadostat administered orally twice daily.
223771568|NCT03348904|DRUG|Carboplatin|Carboplatin administered intravenously at the protocol-defined dose every 3 weeks for up to 4 cycles.
223771569|NCT03348904|DRUG|Cisplatin|Cisplatin administered intravenously at the protocol-defined dose every 3 weeks for up to 4 cycles.
223670246|NCT05140824|BIOLOGICAL|TJ202 injection|TJ202 injection
223670247|NCT02925338|OTHER|QOL questionaire|Health assessment questionnaire disability index for rheumatoid polyarthritis questionnaire
223670248|NCT04128813|DEVICE|Vertical whole body vibration|A neuromuscular treatment using two types of whole body vibration platforms, a rotational and a vertical platform.
223670249|NCT00568386|OTHER|Systane Lubricant Eye Drops|Systane Lubricant Eye Drops 1 drop each eye once time
223670250|NCT00568386|OTHER|Optive Lubricant Eye Drops|Optive Lubricant Eye Drops 1 drop each eye one time
223670251|NCT06092268|DRUG|SHR-A2009 for injection ； Almonertinib Mesilate Tablets|"Phase IB: SHR-A2009 will be administered intravenously，Almonertinib Mesilate Tablets will be administered orally. 2 or 3 dose levels are preset in phase IB.~Phase II: 2 dose cohorts will be selected and it's randomization."
223670252|NCT06092268|DRUG|SHR-A2009 for injection；Adebrelimab Injection|"Phase IB: SHR-A2009 and Adebrelimab will be administered intravenously. 2 dose levels are preset in phase IB.~Phase II: RPD2 will be selected to evaluate preliminary efficacy."
223670253|NCT03891797|OTHER|Cognitive Processing Therapy|Group-based psychotherapy.
223670254|NCT01279941|BEHAVIORAL|Behavioral: Team-based intervention|The intervention involves a scripted peer-taught interactive curriculum, which is delivered as twelve, one-hour weekly sessions incorporated into a team's usual work time activities, with four follow-up booster sessions after twelve months.
223670255|NCT03228329|OTHER|fluid boluses|fluid boluses will be given when there will be hypovolemia assessed by presence of pulse pressure variations
223670256|NCT00636363|DEVICE|Bausch & Lomb Multipurpose Solution - Rub Care|Daily care for contact lenses - rub care regimen
223670257|NCT00636363|DEVICE|Bausch & Lomb Multipurpose Solution - No Rub Care|Daily care for contact lenses - no rub care regimen
223670258|NCT00636363|DEVICE|Ciba Vision Aquify Multipurpose Solution|daily care for contact lenses
223670259|NCT05424640|DIETARY_SUPPLEMENT|Dietary fiber 1|Description in the arm description
223670260|NCT05424640|DIETARY_SUPPLEMENT|Dietary fiber 2|Description in the arm description
223670261|NCT05424640|DIETARY_SUPPLEMENT|Dietary fiber 3|Description in the arm description
223670262|NCT05424640|DIETARY_SUPPLEMENT|Dietary fiber 4|Description in the arm description
223771570|NCT03348904|DRUG|Gemcitabine|Gemcitabine administered intravenously at the protocol-defined dose every 3 weeks for up to 4 cycles.
223771571|NCT03348904|DRUG|Paclitaxel|Paclitaxel administered intravenously at the protocol-defined dose every 3 weeks for up to 4 cycles.
224251031|NCT05108428|RADIATION|Radiation Therapy|Participants will receive varying doses of radiotherapy based on MRI guidance, beginning at 28-33 fractions (1.8 Gray units) .
224251032|NCT05108428|DRUG|FOLFOX regimen|Standard of Care FOLFOX regimen consists of 8 cycles (each cycle is 14 days) of 5-fluorouracil, leucovorin, and oxaliplatin. Dosage is as follows: Oxaliplatin 85 mg/m\^2 IV over 2 hours day 1 each cycle. Leucovorin (optional) 400 mg/m\^2 IV over 2 hours day 1 each cycle. 5-fluorouracil bolus\* (optional) 400 mg/m\^2 IV push day 1 of each cycle, and 5-fluorouracil infusion 2400 mg/m\^2 IV continuous infusion over 46 hours day 1 each cycle.
223670263|NCT02422368|DRUG|Methylprednisolone + ASTED|"ASTED tablet: Twice daily for 6 months~Methylprednisolone:~Methylprednisolone tablet of 50 and 5 mg, company….) 1mg/kg for the first 2 weeks, 0.8mg/kg for 2 weeks, 0.7 mg/kg for 2 weeks, and then tapering off the methylprednisolone in 6 weeks (total duration of 12 weeks) by 8-10 mg per week. For example, a patient with 75 kg weight will receive 75 mg for 2 weeks, 60 mg for 2 weeks, 52.5 mg for 2 weeks, and then decreasing by 8-10 mg per week for 6 weeks. The dose regiment will be written and handed to the patient on the first visit and will be monitored during the follow ups."
223670264|NCT02422368|DRUG|Methylprednisolone +Placebo|"Placebo: twice daily~Methylprednisolone:~Methylprednisolone tablet of 50 and 5 mg, company….) 1mg/kg for the first 2 weeks, 0.8mg/kg for 2 weeks, 0.7 mg/kg for 2 weeks, and then tapering off the methylprednisolone in 6 weeks (total duration of 12 weeks) by 8-10 mg per week. For example, a patient with 75 kg weight will receive 75 mg for 2 weeks, 60 mg for 2 weeks, 52.5 mg for 2 weeks, and then decreasing by 8-10 mg per week for 6 weeks. The dose regiment will be written and handed to the patient on the first visit and will be monitored during the follow ups."
223670265|NCT01764919|RADIATION|[124I]FIAU|A single intravenous injection of 5 mCi\[124I\]FIAU in patients with diabetic foot infection who will undergo 2 PET-CT scanning.
224251033|NCT06687616|DEVICE|SynerGI|Standardized 8-week CBT program, used for 20-30 minutes per week
223670266|NCT00280748|DRUG|pemetrexed disodium|500 mg/m2 once every 21 days up to 126 days
223670267|NCT00280748|RADIATION|radiation therapy|Patients will receive cranial irradiation at 2.5 Gy per fraction, 5 days a week, for 3 weeks to a total dose of 37.5 Gy
223670268|NCT01483417|PROCEDURE|Single incision Laparoscopic hysterectomy|SILS port
223670269|NCT01483417|PROCEDURE|Conventional laparoscopic hysterectomy|3-4 conventional ports
223670270|NCT00125606|PROCEDURE|conditioning for allogeneic HSCT|
223670271|NCT01040117|PROCEDURE|Sensory-motor Integration Training|Exercises will be divided into 3 levels. 1 Starting from the patient's most stable and comfortable standing position. 2 Patient will perform a single-step simulation, shifting his/her weight from one foot to the other in a frontal direction. 3 Patient will perform rapid movements, alternating feet in many directions, progressively increasing weight shifting and decreasing the support base amplitude. In the first five sessions exercises will be performed on a stable surface. During the remaining sessions patients will perform exercises on a compliant surface. During the two training periods the patient's visual condition will be progressively changed.
223670272|NCT01040117|PROCEDURE|Conventional neurorehabilitation treatment|"The treatment will be consist in active joint mobilization, muscle stretching and strengthen and motor coordination exercises. In the first part of each session the active joint mobilization will be carried out while the patient was lying on a carpet in supine, prone. The training will continue with muscle stretching and strengthen exercises performed while patient will be in supine, prone (when possible) and standing.~Motor coordination exercises will be carried out in supine position while sitting on a bench and in the standing position with a front support or with against a wall. The patient will be required to performed a total of 10 exercises with the following sequence: 6 exercises in supine position, 2 exercises in sitting position and 2 in standing position."
224251034|NCT06687616|DEVICE|Sham VR|Distraction-based VR program with 2D nature videos to be used for 8 weeks, 2-2 times a week for 10 minutes
224251035|NCT06363929|DEVICE|Dexcom G6 continuous glucose monitor|Dexcom G6 continuous glucose monitor to be placed on neonates with hyperinsulinism for 10 days.
224251036|NCT05775796|DRUG|Serplulimab and Chemotherapy|Serplulimab+Paclitaxel+Cisplatin/Carboplatin Serplulimab+Pemetrexed+Cisplatin/Carboplatin
224251037|NCT03595683|DRUG|Pembrolizumab|200 mg given by intravenous (IV) infusion once every 3 weeks.
224251038|NCT03595683|BIOLOGICAL|EDP1503|Taken by mouth twice daily. Each capsule will contain ≥ 7.5x10\^10 colony-forming units (CFU).
224251039|NCT03410667|BEHAVIORAL|Phase One: Exploration|"Spina Bifida patients from the pediatric urology clinic at Riley Hospital and their caregivers will participate in discussions of UI goals. These patients will self report their experiences and perspectives using a Day in the Life diary tool-kit."
224251040|NCT03410667|BEHAVIORAL|Phase Two: Creation|Patients, caregivers and providers will work to create a goal setting tool to help patients and physicians appropriately address the issue of UI in patients with spina bifida.
224251041|NCT03410667|BEHAVIORAL|Phase Three: Reflection|This is a validation step to test whether the goal-setting tool is widely applicable and functional in a clinic setting. There will be cognitive interviews after the tool is completed to gather patient impressions.
224251042|NCT03410667|BEHAVIORAL|Aim 3|This will be a large scale validation of the app, with assignment to standard care for the first year of enrollment.
224251043|NCT03925025|DRUG|Magnesium Sulfate|Treatment in addition to standard therapy
224251044|NCT03925025|DRUG|Nimodipine|Treatment in addition to standard therapy
224251045|NCT06395129|DEVICE|Low dead-space syringes/needles|LDSS/N are a type of syringe/needle which retains less residual blood following an injecting event when compared to HDSS/N.
224251046|NCT06395129|DEVICE|Hepatitis C Antibody Rapid Diagnostic Test|Administered up to 4 times, at baseline, 6-months, 12-months, and 18-months
224251047|NCT06395129|DEVICE|HIV rapid Diagnostic Test|Administered up to 4 times, at baseline, 6-months, 12-months, and 18-months
224251048|NCT05809752|BIOLOGICAL|Dendritic Cell Vaccine|"Intrathecal (IT) dendritic cell vaccine (DCV) will be administered once every week. As per standard procedures of IT chemotherapy or antibody administration it is administered over 5 -10 minutes or at 1 ml/minute while monitoring the patient under sterile conditions. In general, to assure delivery of the DCVs into the ventricular space and compensate for dead space in the Ommaya, the delivery of IT DCV cells is followed by the administration of 2.5 mls of saline. In general there is a maximum volume of 10 mls of DCVs."
224251049|NCT00732563|DRUG|chemotherapy|Given IV and Orally
224251050|NCT00732563|PROCEDURE|lymphadenectomy|Removal of lymph nodes
224251051|NCT00732563|PROCEDURE|neoadjuvant therapy|Tumor reduction
224323533|NCT06953661|DRUG|Ropivacaine|The SGB group will receive ropivacaine 0.5% 10ml
224251052|NCT00732563|PROCEDURE|quality-of-life assessment|Correlative Study
224251053|NCT00732563|PROCEDURE|therapeutic conventional surgery|Treatment for cancer
224251054|NCT00732563|PROCEDURE|thoracic surgical procedure|removal of tissue
224251055|NCT00732563|RADIATION|fludeoxyglucose F 18|given IV
224251056|NCT00732563|RADIATION|radiation therapy|undergoing radiotherapy
223670273|NCT06266793|DEVICE|Holmium Laser|Assigned to be treated using the Lumenis Pulse 120H Moses 2.0 Holmium Laser.
223670274|NCT06266793|DEVICE|Thulium Laser|Assigned to be treated using the Olympus Soltive Thulium SuperPulsed Fiber Laser
223670275|NCT06393335|DRUG|Metabolically Armed CD19 CAR-T cells|Each subject receive metabolically armed CD19 CAR- T cells by intravenous infusion.
223670276|NCT00920803|DRUG|Placebo|Placebo will be supplied in clinical kits as a powder which will be reconstituted with vehicle and water into a liquid suspension. Placebo must be used immediately following mixing. Placebo will be administered orally, once daily for 14 days.
223670277|NCT00920803|DRUG|SRT501|SRT501 will be supplied in clinical kits as a powder which will be reconstituted with vehicle and water into a liquid suspension. The final drug product must be used immediately following mixing. SRT501 will be administered orally, once daily for 14 days.
223670278|NCT05014737|OTHER|no intervention|this is an abservational study and no intervention will be involved
223670279|NCT05037435|BIOLOGICAL|The pentavalent rotavirus vaccine (live attenuated oral, freeze-dried)|Group 1 (20 participants) - received the pentavalent live vaccine to prevent rotavirus infection Single-use orally 2.5 ml (1 dose).
223670280|NCT05037435|OTHER|Placebo|Group 2 (20 participants ) - received placebo orally once of 2.5 ml (1 dose).
223670281|NCT01433380|DRUG|PF-05175157|One single dose of PF-05175157 will be administered as a powder-in-capsule in the fasting state in the AM.
223670282|NCT01433380|DRUG|Placebo|One single dose of placebo will be administered as a powder-in-capsule in the fasting state in the AM.
223670283|NCT06523829|OTHER|GROUP GIVEN VIDEO TRAINING|Video-based training was given to this group.
223670284|NCT04260139|PROCEDURE|Calculation of metric variables on the colectomy specimens.|"Calculation of metric variables on the colectomy specimens including Lengths as mm~1. Proximal colon,~2. Ileum in cases with right hemicolectomy only,~3. Proximal border,~4. Tumor,~5. Distal border,~6. Total specimen,~7. Vascular pedicle, the longitudinal distance between the nearest bowel wall and the end of ligated major vascular pedicle depending on the tumor's localization, 2. Colonic mesenteric area as mm2."
223670285|NCT02771613|OTHER|Multi professional in situ simulation|After the analysis of adverse effects in Morbidity Mortality reviews, we will create scenarios adapted to these events. Education of the randomized department's arm's staff will be performed by multi professional in situ simulation with these scenarios
223670286|NCT02771613|OTHER|Large diffusion of information|After the analysis of adverse effects in Morbidity Mortality reviews a large scale dissemination activity of information about discussions and decisions towards the staff of the randomized departments' arms will be carried out
223670287|NCT02199717|DEVICE|Accelerometer|
223670288|NCT03034603|DIETARY_SUPPLEMENT|Nutri-jelly with PEITC|Nutri-jelly with PEITC resulted from an addition of tested amount of PEITC, which was shown in animal model to delay cancer growth, into Nutri-jelly.
223670289|NCT03034603|DIETARY_SUPPLEMENT|Nutri-jelly|Nutri-jelly is an edible nutritious gel for patients with chewing and swallowing difficulties. One milligram of Nutri-jelly contains approximately 1 kcal.
223670290|NCT00907452|DRUG|melphalan-prednisone-thalidomide|
223670291|NCT00907452|DRUG|lenalidomide-dexamethasone|
223670292|NCT03354793|OTHER|Survey on first pregnancy after endometriosis diagnosis|Obstetric complications were noted
223670293|NCT03354793|OTHER|Survey on first pregnancy|Obstetric complications were noted
223670294|NCT01074385|BEHAVIORAL|Dignity Therapy|Dignity therapy is a psychotherapeutic intervention developed to address psychosocial and existential distress among terminally ill patients. Basically, it invites patients to discuss topics that matter most or how they want to be remembered. This interview is recorded and then edited and returned to the patient to be used for further reflection or for sharing with loved ones.
223670295|NCT03288051|OTHER|Fluid management|Primary fluid admission: 1 mL/bodyweight kg/ hour crystalloid. If Pulse pressure variation is lower than 10%; 250 mL/15 min of colloid or crystalloid is administered depending on randomization.
224251057|NCT03235739|DRUG|Naloxegol 25 MG|Oral Naloxegol 25 MG
224251058|NCT03235739|DRUG|Placebo|matching oral placebo
224251059|NCT06847087|OTHER|Self-questionnaire|Assessment of the inadequacy between dietary and medicinal calcium intake by the Fardellone self-questionnaire and the patient's clinical record
224251060|NCT00467896|DRUG|Iloprost PD-6|Period I: Patients received iloprost administered using PD-6 for the 37 days prior to the first dosing of iloprost using PD-15. Iloprost inhalation solution was delivered using the I-neb® AAD System. Patients were required to use their own I-neb®.
224251061|NCT00467896|DRUG|Iloprost PD-15|Period II: Iloprost inhalation solution was delivered using the investigational product PD-15 with I-neb® AAD System for 37 days. Patients were required to use their own I-neb®.
223670296|NCT03288051|DRUG|Norepinephrine|Norepinephrine is administered if Mean arterial pressure drops below 65 mmHg. Mean arterial pressure must be maintained above 65 mmHg. Norepinephrine is titrated accordingly.
223670297|NCT03288051|DRUG|Dobutamine|Dobutamine is administered if Cardiac index drops below 2.5 L/min/m2. Cardiac index must be maintained above 2.5 L/min/m2. Dobutamine is titrated accordingly.
223670298|NCT01331252|OTHER|semi-recumbent|Patient rests in a semi-recumbent body position
223670299|NCT01331252|OTHER|supine|Patient rests in a supine position
223670300|NCT02753439|DRUG|Geistlich Bio Oss|Extraction of Impacted 3rd Molars,
223670301|NCT05784285|BEHAVIORAL|Engagement in a 8-week community-based activity program|Participants engage in a 8-week community-based activity program of their choice. In order to engage in the selected activity, an Occupational Therapist (OT) will meet with each youth in their home. Using the PREP 5 steps (Make goals; Map out a plan; Make it happen; Measure the process and outcomes; Move forward) the youth will choose a community program. The OT will then search for the appropriate program, identify and remove potential environmental barriers for participation in that activity (e.g., accessibility, equipment) and educate program instructors regarding the youth's specific needs. This process, which includes up to 12 hours of working with the OT, will set the stage for enrolment of the youth in a community program for a period of 8 weeks - the actual intervention phase.
224251062|NCT00333645|DRUG|Caspofungin|
224251063|NCT04551976|BEHAVIORAL|Mindfulness|Pay attention to the present moment, on purpose, in a nonjudgemental way.
224323534|NCT06953661|DRUG|Normal saline|The control group will receive normal saline in the sham injection.
223670302|NCT06272227|DRUG|alfacalcidol|Subjects assigned to arm 1 take two doses of alfacalcidol once a day for a total of 52 weeks from the day after baseline visit 2 to the day before the end of the test (visit 4).
223670303|NCT06272227|DRUG|placebo|Subjects assigned to arm 2 take two doses of placebo once a day for a total of 52 weeks from the day after baseline visit 2 to the day before the end of the test (visit 4).
223670304|NCT06272227|DRUG|Denosumab|denosumab
223670305|NCT06515795|OTHER|Isometric exercise|In each arm, participants will execute an isometric exercise, in which they will perform 4 repetitions of 2 minutes.
223670306|NCT01433250|DRUG|AIN457|(10mg/kg i.v.).
223670307|NCT01433250|DRUG|AIN457|(10mg/kg i.v.).
223670308|NCT04849702|PROCEDURE|No intervention was compared|No intervention was compared
223670309|NCT00187603|BEHAVIORAL|tobacco cessation program|
223670310|NCT03909594|DRUG|Bupivacaine|Bupivacaine
223670311|NCT03909594|DRUG|Ketamine|Ketamine
223670312|NCT04083625|DRUG|carbetocin 100 mcg|a 10 cm syringe containing 100 mcg carbetocin just before skin incision of myomectomy.
223771572|NCT03348904|DRUG|Pemetrexed|Pemetrexed administered intravenously at the protocol-defined dose every 3 weeks for up to 4 cycles. Optional continuation maintenance every 3 weeks, if eligible.
223771573|NCT05166291|DEVICE|Comfort-in injection system|local anesthesia applyed with comfort-in injection system
223771574|NCT05166291|OTHER|traditional anesthesia|local anesthesia applyed with dental syringe
223771575|NCT01495962|DRUG|Botulinum Toxin Type A|Six 25 cc injection of Botulinum Toxin A
223771576|NCT01495962|DRUG|Placebo|Placebo (Normal Saline)
223771577|NCT01241734|DRUG|Revlimid|"Stage I:~Cohort 1: RICE + Lenalidomide 10mg days 1-7 Cohort 2: RICE + Lenalidomide 15mg days 1-7 Cohort 3: RICE + Lenalidomide 20mg days 1-7 Cohort 4: RICE + Lenalidomide 25mg days 1-7~Stage II:~RICE + Lenalidomide at the MTD days 1-7~Stage III:~Lenalidomide 25mg days 1-21 every 28 days"
224251064|NCT03772522|BEHAVIORAL|dk Leadership|Participants will attend two full-day workshops and four half-day group coaching sessions over the course of six weeks. The workshops and coaching sessions will be supplemented by on-line (e.g., podcasts) and print (e.g., workbooks) material. The full-day workshops will focus on identity-enhancing topics such as self-understanding, creating a life of meaning and purpose, and strategic career development. The half-day group coaching sessions will focus on workshop debriefing and on exploring solutions to transition-related challenges faced by study participants. The program was designed and carried out by dk Leadership - an established leadership and executive coaching centre in Toronto, Canada.
224251065|NCT03734718|DRUG|GIP|Infusion of Glucose-dependent insulinotropic peptide
224251066|NCT06111170|DEVICE|Compression dressing|Application of dressing
224251067|NCT02432976|DRUG|Exenatide|"Exenatide. Exenatide: bolus of 0.05 µg/min infused during the 1st hour of treatment, followed by a continuous infusion of 0.025 µg/min until the end of treatment.~The exenatide therapy will begin as soon as a blood glucose level is above 140 mg/dl will be measured. A of exenatide will be intravenously .~The treatment will be administrated during the first postoperative 48 hours in the intensive care unit or until intensive care unit discharge if this event occurs earlier."
223670313|NCT04083625|DRUG|placebo|a 10 cm syringe normal saline IV given just before skin incision of myomectomy.
223670314|NCT04139993|DRUG|Microbiota-based Formulation RBX7455|Given PO
223670315|NCT02508818|OTHER|Parabolic flight|
223670316|NCT02508818|OTHER|Cardiovascular measurements|
223670317|NCT00453414|DRUG|Iloprost Inhalation Solution (Ventavis)|
223670318|NCT02401425|DRUG|Letrozole|
223670319|NCT02401425|DRUG|Misoprostol|
223670320|NCT02401425|OTHER|Placebo|
223670321|NCT02957214|OTHER|Pain education|The patient education provides a basic set of information that includes the explanation of possible pathophysiological mechanisms involved in the development of chronic pain. The main objective is to reduce pain threatening and alarmist interpretation. The patient must understand that the pain is not necessarily a sign of injury, but the consequence of a maladaptive central sensitization. One element of this therapeutic strategy is to help the patient to perform physical activities that involve a gradual exposition to stimuli associated with their pain and promote physical recovery exposure. Pain education also aims to reduce fear-avoidance behavior and the patient's disability.
223670322|NCT03543072|DRUG|Bisphosphonates|a class of drugs that prevent the loss of bone density, used to treat osteoporosis and similar diseases
223670323|NCT00433602|OTHER|clinical observation|
223670324|NCT00433602|PROCEDURE|management of therapy complications|
223670325|NCT00433602|PROCEDURE|ultrasound imaging|
223670326|NCT03079713|DEVICE|Handheld vibrator triggered during intravitreal injection for wet ARMD|A vibratory device cleaned with alcohol swabs between each use will be attached to the injectors' finger, placed on the lower eyelid of the treatment eye, and triggered during intravitreal injection
223670327|NCT03079713|DEVICE|Normal eye esthesiometry with and without vibration|Healthy patients will undergo corneal and conjunctival esthesiometry with and without triggering of the wearable vibrator placed upon the lower lid of a single eye.
223670328|NCT03079713|DEVICE|Handheld vibrator not triggered during intravitreal injection for wet ARMD|Control group undergoing standard intravitreal injection without triggering of the vibrator.
223670329|NCT05297318|DEVICE|hypotension prediction index guided|patients receiving hypotension prediction index monitoring and let the anesthesiologist' alerted the coming intraoperatiobe hypotension
223670330|NCT05297318|OTHER|without hypotesion prediction index guided|patients receiving usual care without hypotension prediction index monitoring but with usual arterial line care
223670331|NCT02767297|DRUG|FDL169|
223670332|NCT00636350|DIETARY_SUPPLEMENT|Pepper|pepper carotenoids as meals
223670333|NCT02236351|DEVICE|Pinch Patch/ flat Patch|
223670334|NCT03706924|DRUG|VM-1500FDC|A fixed-dose combination of three active substances: tenofovir 300 mg + elsulfavirine 20 mg + emtricitabine 200 mg, film-coated tablets
223670335|NCT03706924|DRUG|Elpida®|Elpida®, capsules, elsulfavirine 20 mg
223670336|NCT03706924|DRUG|Truvada®|Truvada® (tenofovir 300 mg / emtricitabine 200 mg), film-coated tablets
224251068|NCT02432976|DRUG|Insulin|"Insulin: Humalog (insulin lispro human analog). The insulin therapy will begin as soon as a blood glucose level is above 140 mg/dl will be measured.~The dose of insulin intravenously infused will be adapted to blood glucose measurements, following the insulin therapy protocol used in our department.~The insulin therapy protocol used in our department and prescribed as the benchmark treatment in the present study has been validated in a previous study. It has been derived from the protocol validated by Goldberg et al."
224251069|NCT03084250|DRUG|Peginterferon Alfa-2A|180μg/week, 48 weeks; 135μg/week,48weeks
223670337|NCT05089851|PROCEDURE|Onabotulinumtoxin A|Subjects will receive 20 - 24 units to the crows feet (10 - 12 units per side)
223670338|NCT05089851|COMBINATION_PRODUCT|Facial Cleanser|Facial Cleanser to be used by participants twice daily
223670339|NCT05089851|COMBINATION_PRODUCT|Facial Moisturizer|Bland moisturizer to be used by study participants after serum twice daily.
223670340|NCT05089851|COMBINATION_PRODUCT|Sunscreen|Bland Sunscreen to be used by study participants after serum and moisturizer in the morning. Sunscreen to be reapplied if continuous sun exposure occurs.
223670341|NCT01458093|OTHER|colonoscopy|evaluation of surveillance timing adequacy as compared to the guidelines
223670342|NCT05905744|DIAGNOSTIC_TEST|cholangioscopy|cholangioscopy examination and forceps biopsy, followed by brush biopsy from ERCP
223670343|NCT00749047|DRUG|Pioglitazone|15-45 mg/day
223670344|NCT02690571|OTHER|Bronchoscopy|The bronchoscopy procedure was performed six hours after completion of the exposure session, with sampling of endobronchial mucosal biopsies, bronchial wash and bronchoalveolar lavage performed under topical anaesthesia.
223670345|NCT05067218|DEVICE|buzzy device|bee shaped with wings could be frozen.
223670346|NCT05067218|OTHER|Conventinal anasthesia|normal technique of injection
223670347|NCT03841084|DRUG|Oxygen|"Conservative oxygen management strategy- reduces oxygen on the inoblender in the ECMO circuit.~Liberal oxygen management strategy - does not reduce the oxygen on the inoblender via the ECMO circuit"
223670348|NCT03467685|DEVICE|Vibratory Anesthetic Device (VAD)|This is a handheld \~10cm long tool, battery operated, which provides vibration at a rate of \~150 Hz
223670349|NCT03396952|DRUG|Aspirin|Given PO
223670350|NCT03396952|BIOLOGICAL|Ipilimumab|Given IV
223670351|NCT03396952|OTHER|Laboratory Biomarker Analysis|Correlative studies
223670352|NCT03396952|BIOLOGICAL|Pembrolizumab|Given IV
223771578|NCT05882513|DRUG|Serplulimab and neoadjuvant therapy|"Squamous cell carcinoma: Serplulimab: 4.5mg/kg, i.v, day1; albumin paclitaxel 260mg/m2, day1; carboplatin AUC=5, i.v, day1.~Non-squamous cell carcinoma: Serplulimab: 4.5mg/kg, i.v, day1 ; pemetrexed 500mg/m2, day1 ; carboplatin AUC=5, i.v, day1."
223771579|NCT05882513|PROCEDURE|surgical resection of lung cancer|radical resection of lung cancer
223771580|NCT05882513|OTHER|Tumour will be Collected from participant. Fate of sample is Destruction after use|Tumour sample will be collected after surgery
224251070|NCT03084250|DRUG|Adefovir, entecavir,tenofovir, either of them|Adefovir, entecavir,tenofovir, either of them is ok
224251071|NCT03818581|DRUG|Suvorexant|10-mg or 20-mg Suvorexant capsules
224251072|NCT03818581|OTHER|Placebo|Matching placebo capsules
224251073|NCT04722458|OTHER|Lower Urinary Tract Dysfunction Research Network Symptom Index-29 (LURN SI-29)|LURN SI-29
224251074|NCT04722458|OTHER|IPSS|International Prostate Symptom Score
224251075|NCT04722458|OTHER|UDI-6|Urogenital Distress Inventory
224251076|NCT01472848|DRUG|PF 05212389 or placebo|QD SC administration of PF 05212389 (12 subjects) or matching placebo (3 subjects); doses ranging from low to high dose.
224251077|NCT01472848|DRUG|PF 05212389 or placebo|QD SC administration of PF 05212389 (12 subjects) or matching placebo (3 subjects); doses ranging from low to high dose.
223670353|NCT00566202|DRUG|Placebo|Form= capsule, route= oral use. Administration once daily for 8 weeks.
223670354|NCT00566202|DRUG|Escitalopram|Type= range, unit= mg, number= 10 to 20, form= capsule, route= oral use. Administration of 10 mg daily for 1 week, 20 mg daily for 6 weeks, and 10 mg daily for 1 week.
223670355|NCT00566202|DRUG|JNJ-18038683|Type= range, unit= mg, number= 10 to 20, form= capsule, route= oral use. Administration of 10 mg daily for 1 week, 10 or 20 mg daily for 6 weeks, and placebo daily for 1 week.
223670356|NCT03279393|DRUG|fluorodeoxyglucose (FDG)-PET/MRI|Innovative PET combined with magnetic resonance imaging (PET/MRI) to simultaneously study the hematopoietic system, the artery wall, and the brain's fear system, which comprises the amygdala and anterior cingulate cortex (ACC)
223670357|NCT02671513|DRUG|SHR6390|SHR6390 either 50mg,75mg,100mg,125mg,150mg,175mg given orally, QD
223670358|NCT00185198|DRUG|Testogel (Testosterone, BAYV001915)|50mg (5g gel sachet), 75mg (5g+2.5g sachet) or 100mg (2x5g sachet) per day applied to the skin of the shoulders, arms or abdomen for 18 months
223670359|NCT00185198|DRUG|Placebo|5g gel sachet, 5g+2.5g sachet or 2x5g sachets per day applied to the skin of the shoulders, arms or abdomen for 6 months followed by 12 months treatment with testosterone 1% gel as described for arm 1
223670360|NCT04831632|DIAGNOSTIC_TEST|quantitative and qualitative iFOBTs|They will have their qualitative and quantitative iFOBTs done within the week prior to the VCC study completion. The reading of both of them will be done in Hospital El Cruce's laboratory. The result of the qualitative iFOBT will have two valid expressions: positive or negative.The result of the quantitative iFOBT will be expressed as µg from hemoglobin per gram of fecal matter through the use of automatized equipment for laboratory analysis.
223670361|NCT04120311|DRUG|Episcleral Dexamethasone|Sustained Release Episcleral Dexamethasone
223670362|NCT04308200|OTHER|CO-OP approach|"There are 3 stages in the CO-OP approach. Stage I, the Preparation Stage, is primarily concerned with establishing the goal. Before the first interview, the child was contacted, the family and the child were informed, and it was checked whether they met the prerequisites. At this stage, 3 targets were selected and the basic performance level was determined. Stage II, the Acquisition Stage, is essentially the plan and do stage, in which the work of using strategies to acquire skills is done. This stage originally comprised 10 sessions. At this stage, the first session enabling principles were implemented and the global strategy goal-plan-do-check was introduced. The family attended this process with observation. Parents / caregivers were encouraged to make observations to generalize strategies. Stage III, the Verificatíon stage usually consists of only one session in which control is performed; the progress made was revised as learned strategies."
224251078|NCT01472848|DRUG|PF 05212389 or placebo|QD SC administration of PF 05212389 (12 subjects) or matching placebo (3 subjects); doses to be determined from the results of previous cohorts
223670363|NCT04308200|OTHER|NDT|All participations received NDT for 45 minutes once daily, two times a week for period of 6 weeks by the same physiotherapist. The NDT protocol is improving muscular tone and movement patterns. Although the treatment activities varied for each CP participant, the overall goals (improved smoothness and efficiency of movement), which included improved trunk, hip, knee and ankle control, were the same for all CP participants. All sessions incorporated handling techniques that aimed to alter muscle tone during movement and to facilitate anti-gravity, weight-shifting and postural reactions.
223670364|NCT01054547|DRUG|Ropivacaine|100 mg of the following formulations: Liposome-encapsulated 1 and 2% ropivacaine gel, liposome placebo gel and 2.5% lidocaine and 2.5% prilocaine cream were applied once during 5 minutes.
223670365|NCT01054547|DRUG|Ropivacaine|100 mg of the following formulations: Liposome-encapsulated 1 and 2% ropivacaine gel, liposome placebo gel and 20% benzocaine gel were applied once during 30 minutes.
223670366|NCT05605938|DRUG|Tenoten for children|Oral administration
223670367|NCT05605938|DRUG|Placebo|Oral administration
223670368|NCT00795587|DRUG|variation of mannitol dose|in case of intracranial hypertension up to 20 mmHg lasting more than 10 minutes and without nociceptive stimulation or systemic instability: injection of either 0.4 g/ kg or 0.8 g/ kg of mannitol 20% (randomized) on 20 minutes, with monitoring of neurologic, systemic and biologic datas during 120 minutes
223670369|NCT00165802|DRUG|E7974|Maximum Tolerated Dose defined as 0.45 mg/m\^2 administered on Day 1 only of a 21-day cycle; the E7974 compound is administered as a bolus infusion; no placebo is given.
223670370|NCT04204876|DIAGNOSTIC_TEST|Magnet Resonance Imaging (MRI)|MRI with and without Gadolinium contrast agent for the following vessels: thoracic aorta (ascending, arch, descending arch, left and right common carotic, subclavian, and vertebral artery)
223670371|NCT04204876|DIAGNOSTIC_TEST|PET/CT analysis|Standard value uptake measurement (SUV) based on quantitative score normalized to liver (SUV vessel max/liver mean) at the following vessel regions: Carotid artery: common, internal, external; Subclavian artery; Axillary artery; Vertebral artery; Thoracic Aorta; Abdominal Aorta; Common femoral artery; Deep femoral artery; Popliteal artery
223670372|NCT03450330|DRUG|AZD4205|Daily dose of AZD4205, followed by daily dose of AZD4205 and Osimertinib 80 mg. Starting dose of AZD4205 at 75 mg, administered once daily. If tolerated, subsequent cohorts will test increasing doses of AZD4205, and in combination with Osimertinib 80 mg.
223670373|NCT00827138|DRUG|DCC-2036|150 mg BID tablets, continuous dosing of 28 day cycles
223670374|NCT00321646|DRUG|Bevacizumab|Bevacizumab (marketed as Avastin, Genentech) is an antibody to all isoforms of vascular endothelial growth factor and is the first putative anti-angiogenic agent approved by the Food and Drug Administration (FDA) for the treatment of cancer.All subjects will be treated with intravenous docetaxel and bevacizumab for 5 cycles, followed by docetaxel alone for Cycle 6. Bevacizumab will be given first, at a starting dose of 15 mg/kg. Bevacizumab will be given once every 21 days in the infusion center.
223670375|NCT00321646|DRUG|Docetaxel|Docetaxel will be given intravenously once every 21 days in the infusion center. The starting dose is 70mg/square meter.
223670376|NCT03449524|DRUG|75mg CXA-10|CXA-10 (10-nitro-9(E)-octadec-9-enoic acid) is a specific isomer of nitro-oleic acid (OA-NO2)
224251079|NCT01472848|DRUG|PF 05212389 or placebo|QD SC administration of PF 05212389 (12 subjects) or matching placebo (3 subjects); doses to be determined from the results of previous cohorts
224251080|NCT01472848|DRUG|PF 05212389 or placebo|QD SC administration of PF 05212389 (12 subjects) or matching placebo (3 subjects); doses to be determined from the results of previous cohorts
224251081|NCT01472848|DRUG|PF 05212389 or placebo|QD SC administration of PF 05212389 (12 subjects) or matching placebo (3 subjects); doses to be determined from the results of previous cohorts
224251082|NCT02775045|OTHER|Observation Period|8 week observational period
223670377|NCT03449524|DRUG|150mg CXA-10|CXA-10 (10-nitro-9(E)-octadec-9-enoic acid) is a specific isomer of nitro-oleic acid (OA-NO2)
224251083|NCT02299453|BEHAVIORAL|IPT|Nine sessions of telephone-administered interpersonal psychotherapy (IPT)
224251084|NCT04062045|DRUG|Ropivacaine Hcl 0.2% Inj Vil 10Ml|Group A will receive the medicine through the erector spinae catheter.
224251085|NCT04062045|DRUG|Saline 0.9%|Group B will receive Saline 0,9% through the erector spinae catheter.
224251086|NCT00462345|DRUG|rituximab|1000 mg i.v. on Days 1 and 15
223670378|NCT03449524|OTHER|Placebo|Placebo
223670379|NCT00877123|DRUG|Oral vitamin D 100,000 IU|Oral vitamin D 100,000 IU once a month for three consecutive months.
224251087|NCT00462345|DRUG|Methotrexate|10 to 25 mg/week p.o. or parenteral from Day 1 through Week 24
224251088|NCT00462345|DRUG|Corticosteroid or NSAID|≤10 mg/day prednisone p.o., or equivalent corticosteroid, or NSAIDs p.o. from Day 1 through Week 24
224251089|NCT00462345|DIETARY_SUPPLEMENT|Folate|≥5 mg/week, once daily or b.i.d. from Day 1 through Week 24
223670380|NCT00877123|DRUG|Placebo|similar placebo once a month for three consecutive months
223670381|NCT03068351|DRUG|RO6870810|RO6870810 will be administered subcutaneously (SC) at ascending-dose levels (from 0.30 milligrams/kilogram \[mg/kg\] to 0.65 mg/kg). In Cycle 1, RO6870810 will be given on Day 1 (omitted on Day 2) and then every day from Day 3 through to Day 15. Starting at Cycle 2, it will be given every day from Day 1 to Day 14 of each 21-day cycle. In the first combination therapy cohort RO6870810 will be administered at one dose-level below the maximum tolerated dose (MTD).
223670382|NCT03068351|BIOLOGICAL|daratumumab|Daratumumab will be administered intravenously (IV) at a dose of 16 milligrams/kilogram (mg/kg) of body weight weekly for the first 8 weeks, every two weeks for the following 16 weeks, and every four weeks thereafter, until disease progression.
224251090|NCT04904718|DEVICE|DreaMed Advisor Pro|Advisor Pro software is a proprietary algorithm, designed to provide a comprehensive analysis of individual diabetes data consisting of glucose levels, insulin delivery history and meal consumption reported
224251091|NCT04053296|OTHER|Observational study|We follow up the results of patients.
224251092|NCT02018263|DRUG|Cocaine hydrochloride|
224251093|NCT02018263|BEHAVIORAL|Exercise|
224251094|NCT02018263|DRUG|Nicotine|
224251095|NCT04049669|DRUG|Indoximod|Indoximod will be taken by mouth twice daily during radiation and throughout each chemo-immunotherapy treatment cycle.
223670383|NCT04431674|DRUG|Definity Suspension for Injection|MRI-guided ultrasound-stimulated microbubble-treatment
223670384|NCT05113238|PROCEDURE|Assisted gamete activation|compare two different assisted gamete activation protocols to improve ICSI outcome
223670385|NCT00077467|DRUG|bortezomib|Given IV
223670386|NCT00077467|OTHER|pharmacological study|Correlative studies
223670387|NCT00077467|OTHER|laboratory biomarker analysis|Correlative studies
223670388|NCT02605291|OTHER|Diet with a different macronutrient content A|A diet with altered macronutrient content will be provided to participants on days 4-6 of experimental arm 1.
223670389|NCT02605291|OTHER|Diet with a different macronutrient content B|A diet with a different macronutrient content compared to arm 1 will be provided to participants on days 4-6 of experimental arm 2.
223670390|NCT02605291|OTHER|Diet with a different macronutrient content C|A diet with a different macronutrient content compared to arms 1 and 2 will be provided to participants on days 4-6 of experimental arm 3.
223670391|NCT02605291|OTHER|Interval treadmill running exercise|Participants will perform interval treadmill running exercise on days 4 and 5 of all experimental arms.
223670392|NCT02605291|OTHER|Steady state treadmill running exercise|Participants will perform steady state treadmill running exercise on day 7 of all experimental arms.
223670393|NCT03439683|OTHER|Survey about patient-ventilator asynchrony|Participants will fill an online survey that asks multiple-choice questions related to knowledge, attitudes and practice related to patient-ventilator asynchrony and also have images of ventilator waveforms wth asynchrony, where they need to identify the type of asynchrony
223670394|NCT05846607|DIETARY_SUPPLEMENT|Intervention oral supplement|The oral supplement used as intervention for the study will be DongzheSutang(DAISY FSMP,Jiangsu,China). The formula contains only carbohydrate:12.5g in 100ml of product(glucose syrup and maltodextrin)，with a caloric density of 16.32kcal/g.
223670395|NCT00184951|DRUG|Rosuvastatin|
224251096|NCT04049669|RADIATION|Partial Radiation|Palliative low-dose or partial-field radiation plan (low-dose radiation or not all disease sites included).
224251097|NCT04049669|RADIATION|Full-dose Radiation|Palliative full-dose radiation plan to all known sites of disease (\>50 Gy to brain, \>45 Gy to spine).
223670396|NCT02730793|DRUG|Oral Aztreonam|Standard Therapy Comparator (Oral Cayston 75mg three times a day)
223670397|NCT02730793|DRUG|Nasal Aztreonam|Study Therapy (nasal Aztreonam 75mg twice per day)
223670398|NCT02730793|DRUG|Nasal Placebo|Placebo (nasal saline twice per day)
223670399|NCT03618589|DRUG|Pregabalin|Patients in the pregabalin add-on group received 75mg of pregabalin twice a day for the first week (150 mg/day) and 150mg of pregabalin twice a day (300 mg/day) for the second week and 300mg of pregabalin twice a day (600mg/day) for subsequent 6 weeks.
223670400|NCT03618589|DRUG|Opioid|Patients in the opioid group received the only opioid (5mg of oxycodone three times a day) for 8 weeks.
223670401|NCT06294210|DEVICE|Mobile app and wrist-worn monitor|A mobile app was developed based on students feedback about their wellbeing needs gathered in a previous study through focus groups, surveys and design activities. This app includes features for students to track wellbeing habits, enter goals, access evidence-based resources related to their wellbeing topics of interest, and see heart rate variability summary metrics. These metrics will stream via bluetooth from the wrist-worn wearable device that has been developed at the Royal College of Surgeons in Ireland. This device includes a PPG sensor, charging port, and light indicator. There is no screen, so all data will be displayed through the mobile app.
223670402|NCT05117918|OTHER|SUFU Clinical Care Pathway for Overactive Bladder|Treatment of OAB via the SUFU clinical care pathway
223670403|NCT05117918|OTHER|Telemedicine|Delivery of care via telemedicine
223670404|NCT02384642|BEHAVIORAL|COMPASS|COMPASS (Creating Opportunities through Mentoring, Parental involvement and Safe Spaces) is a program for 10-14 year old girls in Eastern DRC. The program is a structured intervention that is intended to engage adolescent girls, through life skills training and establishing or supporting community-supported safe spaces for girls where they can come and gather among themselves and participate in a structured life-skills curriculum.
224251098|NCT04049669|DRUG|Temozolomide|Temozolomide will be taken by mouth once daily, on days 1-5 of each chemo-immunotherapy treatment cycle.
224251099|NCT04049669|DRUG|Cyclophosphamide|Cyclophosphamide will be taken by mouth once daily, on days 1-21 of each chemo-immunotherapy treatment cycle.
224251100|NCT04049669|DRUG|Etoposide|Etoposide will be taken by mouth once daily, on days 1-21 of each chemo-immunotherapy treatment cycle.
224251101|NCT04049669|DRUG|Lomustine|Lomustine will be taken by mouth once daily, on day 1 of each chemo-immunotherapy treatment cycle.
224251102|NCT05558709|OTHER|REALSOCOG|Patients will be asked to perform the REALSoCog serious game-type social cognition assessment task developed by the LMC2 laboratory (UR 7536). Their performance will be compared to those of control individuals recruited in parallel (independant clinical study: CER-U, IRB N°: 00012020-115). Participants will be asked to think about 16 social situations (6 control situations and 10 experimental situations) encountered in a virtual environment representing a city. REALSoCog can be used on a laptop computer, without any additional technical device.
223670405|NCT02384642|BEHAVIORAL|COMPASS plus parenting|The COMPASS plus parenting intervention is the core COMPASS intervention, plus activities for the parents and caregivers of participants.
223670406|NCT02941172|OTHER|Cold exposure|Controlled cold exposure is performed before and during PET scan
223670407|NCT02941172|OTHER|[18F]FMPEP-d2|PET radiotracer used in imaging
223670408|NCT02941172|OTHER|[18F]FDG|PET radiotracer used in imaging
223670409|NCT02051075|BIOLOGICAL|PXN sperm treatment|immotile sperm activation with PXN
223670410|NCT02051075|BIOLOGICAL|Sperm activation with PXN and oocyte activation|
223670411|NCT02920788|BEHAVIORAL|Goal-Oriented Attentional Self-Regulation (GOALS)|GOALS is a manualized, therapist-administered cognitive training program that targets executive control functions of applied mindfulness-based attention regulation and goal management strategies and links them to participant-defined real-life goals. In contrast to training via practice on isolated tasks, this training protocol involves application of attention regulation skills and strategies to participant-defined goals in real life, ecologically valid settings. One of the main training aims is to improve self-regulatory control mechanisms as they contribute to goal attainment.
223771581|NCT01076725|DEVICE|Standard technique group|In the standard technique group (n = 63), the PLMA was inserted by index finger insertion technique.
224251103|NCT05558709|OTHER|BCS|Social-cognitive tasks from the BCS (Ehrlé et al., 2011) will also be offered to patients to test the concurrent validity of REALSoCog. This battery assesses social cognition. It includes paper-and-pencil tasks.
224251104|NCT05558709|OTHER|Hetero-questionnaires|Hetero-questionnaires assessing patients' social behavior will be transmitted to their relative or primary caregiver (Godefroy \& le GREFEX, 2008; Gury and Ehrlé, in progress of validation) in order to verify the concurrent validity of REALSoCog. These hetero-questionnaires aim to identify and quantify the presence of social skills and behaviour disorders.
224251105|NCT04725773|DEVICE|Deep brain stimulation effect on apraxia|We will evaluate the effect of DBS on apraxia
224251106|NCT06427252|DRUG|HIPEC|In the experimental group, HIPEC treatment (paclitaxel, 3000 ml of physiological saline at 43°C for 60 min) was performed on the first day after the first exploratory laparotomy and on the third day after the radical surgery for a total of 2-3 times (total amount of paclitaxel was 175 mg/m2 ), with an interval of not more than 72 h. Intravenous systemic therapy was started 3 weeks after the completion of HIPEC treatment. systemic therapy.
223670412|NCT02920788|OTHER|Brain Health Education (BHE)|BHE group is a formal in-person, active, psycho-educational, control intervention closely matched to GOALS for length, intensity, and contact with a therapist/facilitator. Topics include brain structure, function, sleep, stress, emotion and the brain.
223670413|NCT02920788|DEVICE|fMRI|Functional Magnetic Resonance Imaging of the Brain
223670414|NCT00401687|DRUG|Definity® Vial for (Perflutren Lipid Microsphere) Injectable Suspension|The intervention for this study was that all patients received a slow bolus injection of diluted DEFINITY during the contrast-enhanced imaging study.
223670415|NCT01552421|PROCEDURE|TV NOTES cholecystectomy|Transvaginal NOTES cholecystectomy
223670416|NCT06289205|DRUG|Methotrexate|Methotrexate will be utilised in two different ways to prevent development of proliferative vitreoretinopathy after vitrectomy for rhegmatogenous retinal detachment
223670417|NCT01376518|PROCEDURE|positive end-expiratory pressure|Elevation of positive end-expiratory failure for recruitment
223670418|NCT02603263|OTHER|Social Norms Poster|"A poster containing a social norms message: Most people here choose to eat vegetables with their lunch"
223670419|NCT00832832|OTHER|Eyelid closure|Eyelid will be closed after eye drop instillation
223670420|NCT00832832|OTHER|No intervention will be assigned|No intervention will be assigned to this arm
223670421|NCT04052178|DEVICE|rTMS active and sham|Repetitive transcranial magnetic stimulation of the pharyngeal sensory cortex.
223670422|NCT04052178|DEVICE|PES active and sham|Intrapharyngeal electrical stimulation with a catheter delivering electrical pulses.
223670423|NCT04052178|DIETARY_SUPPLEMENT|Capsaicin active and placebo|Capsaicin solution (TRPV1 agonist) at a concentration of 10-5M or placebo solution.
223670424|NCT03235180|DRUG|Sulfur Hexafluoride|Subjects will receive ultrasound (US) imaging of the terminal ileum without and with sulfur hexafluoride contrast at baseline, 4 week and 6 months. Subjects will receive one to two milliliters of the contrast agent.
223670425|NCT03235180|DEVICE|Ultrasound Elastography|Subjects will receive US Imaging with the GE Logiq E9 Ultrasound Scanner at baseline, 4 week and 6 months without and with contrast.
223670426|NCT03235180|DEVICE|Ultrasound Vascularity|Subjects will receive US Imaging with the Verasonics Ultrasound Scanner at baseline, 4 week and 6 months without and with contrast.
223670427|NCT03235180|DEVICE|Magnetic Resonance Enterography (MRE)|Subjects will receive MRE imaging at baseline and 6 months as part of regular clinical care.
223670428|NCT03131830|OTHER|Online-based questionnaire|Participants receive a web-link to a questionnaire, which is active for 3 months
223670429|NCT00254267|DRUG|AMG 706|AMG 706 125mg, oral, once a day
223670430|NCT04597151|DIETARY_SUPPLEMENT|Dietary Intervention|Attend diet education sessions
223670431|NCT05830110|DEVICE|Active Vibrotactile Coordinated Reset|Gloves providing vibrotactile coordinated reset stimulation
223670432|NCT05830110|DEVICE|Sham vibrotactile coordinated reset|Gloves providing sham vibrotactile coordinated reset stimulation
223670433|NCT03157570|BEHAVIORAL|Exercise|7-min High Intensity Interval Training with 12 different exercises (each exercise 30 seconds continuously with 10 seconds rest interval)
223670434|NCT05139511|DEVICE|Study group|The IPL therapy consists in a polychromatic pulses of light not coherent and not collimated. The therapy leads to a series of processes such as the destruction of superficial blood vessels and thus the reduction of local inflammation, the liquefy of the meibum and an antimicrobial, anti-inflammatory and antioxidant effects. The therapy is performed over the cheeks, nose and upper eyelids.
223670435|NCT05139511|OTHER|Control group|Same procedure but without energy
223670436|NCT05655806|DRUG|Aminophylline bolus then infusion|half an hour before discontinuation of isoflurane
223670437|NCT05655806|DRUG|aminophylline bolus|after discontinuation of isoflurane
223670438|NCT05655806|DRUG|normal saline|given as placebo
223670439|NCT04152993|DEVICE|NeuroPace® RNS® System|In this intervention, patients suffering from PTSD undergo a surgical procedure to implant the responsive neurostimulation device (RNS, NeuroPace). This procedure involves the placement of a depth lead bilaterally in the amygdala and hippocampus following a trans-occipital trajectory. The two leads are then connected to a pulse generator fixated to the skull. RNS is able to detect specific signals from the target and to respond with a programmed electrical stimulation. One month after the implantation of the system, the patients will undergo 3 tasks: a fear conditioning task, the international affective picture system and the subsequent memory recall paradigm. These tasks will yield electrophysiological biomarkers of arousal and re-experiencing. We will then program RNS to detect and respond to those biomarkers. The patients will be followed longitudinally for improvement and evidence of target engagement as seen on cerebral metabolism and global electroencephalography.
223670440|NCT00304213|DRUG|Testosterone|
223771582|NCT01076725|DEVICE|Rotation technique group|The entire cuff of the PLMA was placed in the mouth without finger insertion in a midline approach and was rotated 90 degrees counterclockwise around the tongue. The PLMA was then advanced and rotated back until resistance was felt.
223771583|NCT02210299|OTHER|Exposure study|Sampling of blood, food, water, air and dust and delivery of dietary questionnaire
223670441|NCT05907941|DEVICE|ciNPT|Following closure of the abdominal donor site, the closed incision will be dressed with the ciNPT system \[V.A.C.ULTA™ Negative Pressure Wound Therapy System (KCI, USA)\] applied by the operating surgeon in a sterile fashion (Figure 2). The ciNPT device will be set at -125mmHg of continuous negative pressure for a period of 7 days or until patient discharge from hospital. Removal of the ciNPT dressing will be performed by the surgical team at the time of discharge. Following removal, no additional dressings will be applied to the abdominal incision unless clinically indicated secondary to dehiscence.
224251107|NCT06427252|DRUG|Systemic therapy|"1. Tirilizumab: 200 mg, i.v., D1, Q3W;~2. oxaliplatin: 130mg/m2, i.v., D1, Q3W;~3. Herceptin: a tri-weekly dosing regimen with an initial loading dose of 8 mg/kg followed by 6 mg/kg Q3W.~4. Tegeo: Oral administration: 40 mg per dose for BSA \<1.25, 50 mg per dose for BSA 1.25 to 1.5, and 60 mg per dose for BSA ≥1.5, twice daily for each treatment cycle D1-D14, Q3W;"
224251108|NCT03660020|DRUG|Local anesthetic|ultrasound guided erector spine plane block (ESP) will be done in patients under going mastectomy with local anaesthetics only
223670442|NCT05907941|OTHER|Conventional Tape Dressings|Following closure of the abdominal donor site, the closed abdominal incision will be dressed with 1-inch Micropore™ Surgical Tape (3M, USA) with an alcohol swab applied to the tape for additional adhesion, by the operating surgeon in a sterile fashion. This dressing will remain in-situ for up to 7 days or until patient discharge from hospital. Removal of the traditional tape dressing will be performed by the surgical team at the time of discharge. Following removal, no additional dressings will be applied unless clinically indicated secondary to dehiscence.
223670443|NCT05907941|PROCEDURE|DIEP Breast Reconstruction|All patients enrolled in the study will undergo DIEP breast reconstruction and have their abdominal incision sutured according to routine clinical practice. At the Hamilton sites, we will use 3-0 VICRYL ® suture (Ethicon, USA) for deep fascia closure, 4-0 MONOCRYL® suture (Ethicon, USA) for deep dermal closure, and 5-0 MONOCRYL® suture (Ethicon, USA) for subcuticular closure. At the London sites, we will use 2-0 VICRYL ® suture (Ethicon, USA) for deep fascia closure, 3-0 MONOCRYL® suture (Ethicon, USA) for deep dermal closure, and 4-0 MONOCRYL® suture (Ethicon, USA) for subcuticular closure.
223670444|NCT00680394|DRUG|mifepristone|200 mg mifepristone
223670445|NCT00680394|DRUG|misoprostol|800 buccal misoprostol + matching placebo or 1600 buccal misoprostol
224251109|NCT03660020|DRUG|Hyaluronidase|hyaluronidase will be added to ultrasound guided erector spine plane block (ESP) will be done in patients under going mastectomy
224251110|NCT03638739|OTHER|Twice-weekly exercise|An individualized exercise plan, incorporating aerobic and resistance exercises, following the Physical Activity Guideline recommendations will be provided for each participant.
224251111|NCT05358860|DEVICE|Sofwave|The Sofwave System, comprised of an applicator and a console, generates high intensity, non-focused ultrasonic energy which can be delivered percutaneously to tissues.
224251112|NCT00875030|DRUG|artesunate sachets|single dose 50 mg (2 X 25 mg) artesunate sachets
224251113|NCT00875030|DRUG|Arsuamoon|single dose 50 mg arsuamoon tablet
224251114|NCT01149473|DRUG|Losartan potassium/Hydrochlorothiazide|100/25 mg Tablets
224251115|NCT01149473|DRUG|Losartan potassium/Hydrochlorothiazide|100/25 mg Tablets
224251116|NCT01516996|DRUG|docetaxel and cisplatin|"* The neoadjuvant consists of docetaxel 75mg/m2 day 1 and cisplatin 75mg/m2 days 1 to 3, repeat every 3 weeks, for 2 cycles.~* CCRT: cisplatin 75mg/m2 is administered on day 1 of week 7,10 and 13 on current with RT"
224251117|NCT01516996|RADIATION|IMRT|"IMRT is administered with chemotherapy from week 7 to week 13~* GTV（primary tumor）：68-70Gy/35\~38 F，once a day, 5 times per week~* CTV（Clinical target）：56-66Gy/30\~36f，once a day, 5 times per week~* GTV-ln（positive neck region）：66-70Gy/33\~36 F，once a day, 5 times per week~* CTV-ln（negative neck region）：50-54Gy/28\~30F, once a day, 5 times"
224251118|NCT01516996|BIOLOGICAL|Nimotuzumab|Nimotuzumab was administered 200 mg IV over 1 hour on day 1,once a week, for 13\~14 weeks
224251119|NCT01069536|DRUG|metoclopramide 10 mg|
224251120|NCT04089735|DRUG|APP13007, 0.05%|APP13007 eye drop, 0.05%
224251121|NCT04089735|DRUG|APP13007, 0.1%|APP13007 eye drop, 0.1%
224251122|NCT04089735|DRUG|APP13007 Placebo, 0.05%|APP13007 placebo eyedrop, 0.05%
224251123|NCT04089735|DRUG|APP13007 Placebo, 0.1%|APP13007 placebo eyedrop, 0.1%
224251124|NCT01601145|DIETARY_SUPPLEMENT|consumption of lozenges|Each subject two lozenges a day for 6 weeks
224251125|NCT04295122|DEVICE|Phacoemulsification+ Endoscopic cyclophotocoagulation (ECP) laser|"A clear corneal incision should be used for instrumentation. The choice of viscoelastics to maintain the anterior chamber is left to the surgeon's discretion.~Phacoemulsification energy used during the cataract surgery will be recorded. If the patient has been randomised to ECP laser, the viscoelastic will be washed-out of the capsular bag. Further cohesive viscoelastic material will be injected through the main wound between the anterior capsule and iris, until the iris is close to or touching the cornea. A curved ECP probe will be inserted through the corneal incision wound/wounds and 360° of the anterior section of the ciliary processes will be treated. The power setting will be varied according to tissue response (starting power of 250 mW with continuous setting). 'Pops' should be avoided (but recorded) but no indentation used during treatment. Final power used and duration of surgery will be recorded."
224251126|NCT02974556|PROCEDURE|Standard surgical treatment|Standard surgical treatment (open or laparoscopic techniques) containing at least 12 lymph-nodes for accurate pN staging.
224322064|NCT05085262|DIAGNOSTIC_TEST|Bloodwork, Echocardiogram, MRI|The study will involve use of blood samples from the COVID biobank at UHN (University Health Network) for measurement of blood biomarkers. Echocardiography Studies will be systematically assessed for structural and functional abnormalities. All included patients assessment of clinical events and subclinical cardiovascular disease.
224251127|NCT02974556|PROCEDURE|Proactive management|Colon cancer patients (high-risk T3 and T4) without peritoneal or systemic metastases are resected for cure. Simultaneously patients will undergo infracolic omentectomy, appendectomy, exeresis of the liver round ligament and, in women, a bilateral oophorectomy. After positioning three in- and outflow catheters HIPEC perfusion starts with a minimum of 2 L isotonic dialysis fluid at a flow-rate of 1-2 l min and an inflow temperature of 42-43° C with a total of 30 minutes perfusion time. Before the beginning of HIPEC 5-fluouracil and leucovorin will be administrated intravenously to potentiate oxaliplatin activity.
224322065|NCT01085760|DRUG|Vancomycin|Comparison of different doses of drug
224322066|NCT01085760|DRUG|Vancomycin|Comparison of different doses of drug
224251128|NCT02974556|DRUG|Standard adjuvant systemic chemotherapy|Adjuvant systemic chemotherapy (according CAPOX or FOLFOX regimens for a total of 6 months) will be reserved in patients with pT3 tumors with poor prognostic factors, in patients with pT4 tumors and when lymph-nodes metastases are present. Presence or absence of peritoneal recurrence will be evaluated by MDCT every six months for the first 24 months and later every year for the next three years in both study arms.
224251129|NCT02973685|PROCEDURE|Hepatic arterial infusion chemotherapy|A standard hepatic artery catheter was introduced via the femoral artery percutaneously. Selective catheterization of the proper hepatic artery was performed using standard diagnostic catheters and fluoroscopic guidance. In the event of multiple arterial supply(including superior-mesenteric artery), the proportion of the liver supplied by each artery was estimated by the arteriogram. After optimal positioning of the catheter in dominant supplying artery to ensure minimal reflux, the catheter was fixed and connected with infusion tube. In the condition of multiple tumors on both left and right lobe, the gastroduodenal artery was embolized and the catheter was positioned in the hepatic proper artery for infusion. Folfox Protocol were infused through the fixed catheter sequentially.
224251130|NCT02973685|PROCEDURE|Transarterial chemoembolization|Previous procedure was same with hepatic arterial infusion chemotherapy. After optimal positioning of the catheter, TACE Drug Protocol were injected.
224251131|NCT02973685|DRUG|Folfox Protocol|oxaliplatin,leucovorin and 5-FU
224251132|NCT02973685|DRUG|TACE Drug Protocol|lipiodol mixed with chemotherapy drugs(EADM , lobaplatin, with or without MMC) followed by polyvinyl alcohol particles (PVA)
224251133|NCT00752297|DRUG|Preservative-free Saline|Subjects will receive five 0.1 mL intramuscular injections at the Day 0 Treatment Visit: two in each corrugator and one in the procerus muscle. The total treatment dose (sum of the five injections) to be administered will be 0.5 mL of the placebo (preservative-free saline).
224251134|NCT00752297|DRUG|Mentor Purified Toxin|All subjects will receive five 0.1 mL intramuscular injections (two in each corrugator and one in the procerus muscle) at each Treatment Visit. The total treatment dose (sum of the five injections) to be administered will be 30 U of PurTox. Subjects will have many Treatment Visits throughout the course of the three-year study.
224251135|NCT01305018|DIETARY_SUPPLEMENT|BCAA|7 g of leucine + 3,5 g of isoleucine + 3,5 g of valine per day during 9 days
224251136|NCT01305018|DIETARY_SUPPLEMENT|Leucine|7 g of leucine + 7 g of alanine per day during 9 days
224251137|NCT01305018|DIETARY_SUPPLEMENT|Placebo|14 g of alanine per day during 9 days
224251138|NCT03394235|DEVICE|Long-pulsed, 1064nm Nd-YAG laser|This long-pulsed Nd-YAG laser is commonly used for laser hair removal and vascular lesions, but in this study it is used to reduce the size of the hair shaft at the occipital area.
224251139|NCT06558864|PROCEDURE|Subiculum RF-TC|SEEG implantation after evaluation, record the interictal and ictal EEG, and perform Subiculum RF-TC.
224251140|NCT04444479|OTHER|ECG verification|The correct positioning of the PICC catheter tip will be verified using ECG.
223670446|NCT00680394|DRUG|placebo|800 buccal misoprostol + matching placebo or 1600 buccal misoprostol
223670447|NCT00534313|DRUG|Abatacept|Solution, intravenous, monthly, short-term = 24 weeks (6 months)
223670448|NCT00534313|DRUG|Placebo|Solution, intravenous, placebo (double dummy), monthly, short-term = 24 weeks (6 months)
223670449|NCT02386683|OTHER|lung-protective ventilation|mechanical ventilated with a tidal volume of 6-8ml/kg ideal body weight (IBW) and 6-8 cm H2O PEEP in anesthesia
223670450|NCT01773447|PROCEDURE|Set-back suture|
224251141|NCT04444479|OTHER|X-ray verification|The correct positioning of the PICC catheter tip will be verified using X-ray imaging.
223771584|NCT02565797|DEVICE|DabirAIR alternating pressure overlay|DabirAIR alternating pressure overlay is a dynamic support surface that is placed on top a mattress. The DabirAIR overlay provides periodic pressure relief through the alternate inflation and deflation of air cells.
224251142|NCT03475303|BEHAVIORAL|early hospital discharge|early hospital discharge at 8-12 hours for women undergone elective cesarean section
224251143|NCT01543217|OTHER|RT management|Patients assigned to the RT management arm will receive a 1-hour educational in-service conducted by a respiratory therapist case manager. The patient education session will include general information about COPD, direct observation of inhaler techniques, a review and adjustment of outpatient COPD medications, smoking cessation counseling, recommendations concerning influenza and pneumococcal vaccinations, encouragement of regular exercise, and instruction in hand hygiene.
224251144|NCT01543217|OTHER|Ususal care|Routine respiratory care.
224251145|NCT01439880|BIOLOGICAL|Evolocumab|Administered by subcutaneous injection
224251146|NCT01439880|OTHER|Standard of care|Standard of care therapy as per local practices. This could include prescribed therapies and/or dietary/exercise regimes
224251147|NCT01530880|DRUG|Intravenous Ibuprofen|Ibuprofen 400 mg/100 mL intravenous (IV) over 30 minutes, followed by a continuous infusion of 2000 mg/500 mL at 85 mg/hour (21 mL/hour) for up to post bleed day 14 or discharge from the Neuro ICU, whichever comes first
224251148|NCT01530880|DRUG|Acetaminophen (Standard of Care)|Acetaminophen 650 mg via oral/nasogastric tube every 6 hours as needed for T\>=38.3 C (100.9 F) for up to post bleed day 14 or discharge from the Neuro ICU, whichever comes first.
224251149|NCT05594420|PROCEDURE|Mitral valve replacement|Mitral valve replacement through median sternotomy and minimally invasive approach
224322067|NCT01085760|DRUG|Metronidazole|Comparison of different doses of drug
224322068|NCT01085760|DRUG|Metronidazole|Comparison of different doses of drug
224322069|NCT01085760|DRUG|Vancomycin|Comparison of different drug doses
224322070|NCT02325076|DEVICE|Spirodoc|A device to detect the physical condition of the lungs
224322071|NCT05246670|DRUG|Palmidrol|Given PEA PO
224322072|NCT05246670|DRUG|Placebo Administration|Given PO
224322073|NCT05246670|OTHER|Quality-of-Life Assessment|Ancillary studies
224322074|NCT05305066|DRUG|TNFi|TNFi - any sub-cutaneous (sc) formulation, namely etanercept (receptor fusion protein) 50 mg sc per week, adalimumab (monoclonal antibody) 40 mg sc every 2 weeks, golimumab (monoclonal antibody) 50 mg sc every month, or certolizumab (pegylated fragment of a monoclonal antibody) 400 mg sc at week 0, 2 and 4, and then 200 mg sc every 2 weeks or 400 mg sc every 4 weeks.
223670451|NCT01773447|PROCEDURE|Vertical mattress suture|
223670452|NCT00464880|DRUG|Aliskiren|
223670453|NCT02285036|BIOLOGICAL|vaccination PPV23|All eligible participants were stratified into four age strata namely, 2 to 6 years, 7 to 17 years, 18 to 59 years and more than 60 years. Stratified, block randomization with a size of eight was applied. Vaccination of single dose of either treatment vaccine or control vaccine intramuscularly was performed in a ratio of 1:1. Blood samples were obtained from each subject at baseline, day 30-35 after injection, to evaluate immunogenicity.
224251150|NCT01212848|DEVICE|Transcranial Magnetic Stimulation|Group 1: The treatment group will receive the following dose of repetitive TMS delivered over the left prefrontal cortex: 10 Hz, 120% Motor Threshold, 5 second pulse train, 10 second intertrain (IT) interval, 30 minutes of treatment, 6000 pulses per session; three sessions each day (18,000 stimuli) for three days for a total of 54,000 stimuli.
224251151|NCT01212848|DEVICE|Transcranial Magnetic Stimulation - Sham Comparator|"The control group will receive an identical dosing schedule of sham repetitive TMS over three days."
224251152|NCT00859534|DRUG|afamelanotide|16mg afamelanotide, one dose for the duration of the clincial trial
224251153|NCT02713425|DEVICE|Entertaining Video Game|Children between 7 \& 17 with a social anxiety disorder will be invited to participate in this study. They will attend a single visit. During the visit they will use the therapeutic game. They will be monitored while using the game. After the completion, they will be asked questions regarding their experience with this therapeutic game.
224251154|NCT03874715|DRUG|Insulin Aspart SAR341402|Pharmaceutical form: Solution for injection Route of administration: Subcutaneous
224251155|NCT03874715|DRUG|Insulin Aspart|Pharmaceutical form: Solution for injection Route of administration: Subcutaneous
224251156|NCT03874715|DRUG|Insulin glargine U100|Pharmaceutical form: Solution for injection Route of administration: Subcutaneous
224251157|NCT04229121|OTHER|nonintervention|nonintervention
224251158|NCT03465839|BEHAVIORAL|Education for improving handovers quality|Specific education on the importance of handovers quality will be provided. The educational session will last 4 hours. The program will be divided into the following sections: 1) a structured survey on the perception of the participants on the handovers importance; 2) Key theoretical concepts on the relevance of handovers with case studies of errors related to this critical moment; 3) showing movie clips of nursing handovers to critically interpret the clips by the participants; 4) presentation of the SBAR method recommended by WHO; 5) general presentation of the nursing delivery assessment project of the Valduce Hospital.
224251159|NCT03465839|BEHAVIORAL|Education for improving bedside handovers|In addition to the education for improving handovers quality, the following intervention will be implemented for nurses assigned to the study department. The course will be supplemented by a section of the duration of an hour, containing 1) information on the principles underlying bedside handovers; 2) how to handle information in front of the patient and on his / her direct involvement; 3) role-playing of the bedside handover will be performed, assigning the roles of nurse and patient among the participants to bring out impressions linked to the functions.
224251160|NCT05101564|DRUG|Alpelisib|Alpelisib 300 mg
224251161|NCT05101564|DRUG|Tamoxifen|Tamoxifen 20 mg
224251162|NCT05101564|DRUG|Zotatifin|Zotatifin 0.10mg/kg (by weight)
224251163|NCT05101564|DRUG|Fulvestrant|Fulvestrant 500 mg
224251164|NCT02815527|OTHER|Fresubin intensive|Enteral nutrition containing a high protein concentration
224251165|NCT05382377|BIOLOGICAL|KD-025|Autologous genetically modified anti-NKG2DLs CAR transduced T cells
224251166|NCT03493347|BEHAVIORAL|Equine-assisted Occupational Therapy|Occupational therapy provided in an equine environment that includes activities such as groundwork, grooming, tacking, mounting, and riding horses
224251167|NCT00444847|DEVICE|Hyperbaric chamber|
224251168|NCT05528744|OTHER|Observational Study|No intervention. This is an observational study
224251169|NCT05528744|OTHER|Sample collection only|Collection of blood and/or skin samples.
224251170|NCT00629590|DRUG|AzaSite®|ophthalmic solution; 1 drop in each eye BID for two days, then 1 drop in each eye QD for \~12 days
224322075|NCT05305066|DRUG|Anti-IL6|Anti-IL6 receptor monoclonal antibodies - tocilizumab (if weight \<100 kg: 162 mg SC every other week, followed by an increase to weekly based on clinical response; if weight ≥100 kg: 162 mg SC weekly) or sarilumab (200 mg SC once every 2 weeks)
224322076|NCT05305066|DRUG|JAKi|JAKi - tofacitinib (JAK1/3 inhibitor) 5 mg po bid, baricitinib 2 mg po qd (JAK 1/2 inhibitor) or upadacitinib 15 mg po qd (JAK1 inhibitor)
224251171|NCT05479487|DRUG|Fluzoparib+Apatinib|Fluzoparib 100mg bid+ Apatinib 375mg qd
224251172|NCT05479487|DRUG|Fluzoparib Monotherapy|Fluzoparib 150mg bid
224322077|NCT02836925|DRUG|Ledipasvir+Sofosbuvir|"Patients with genotype 1 or genotype 4 Ledipasvir 90 mg + Sofosbuvir 400 mg~* 12 weeks in previously untreated infected patients~* 24 weeks for previously treated patients with uncertain subsequent retreatment options"
223670454|NCT02285036|BIOLOGICAL|vaccination PNEUMOVAX 23|Vaccination of single dose of either treatment vaccine or control vaccine intramuscularly was performed in a ratio of 1:1.
223771585|NCT02896231|DRUG|PLB1001|PLB1001 is a capsule in the form of 25 mg and 100mg, twice daily.
223771586|NCT00023816|DRUG|carbendazim|
223771587|NCT03614013|OTHER|Immunotherapy responders/non-responders|paraffin samples will be collected retrospectively along with clinical data
224251173|NCT04691895|OTHER|SARS-CoV2 infection|Confirmed COVID19 cases The definitions of COVID19 state are according to the WHO document released in March 2020. A person with laboratory confirmation of COVID-19 infection, irrespective of clinical signs and symptoms.
224251174|NCT02757105|DRUG|BEKINDA|
224251175|NCT02757105|DRUG|Placebo|
224251176|NCT01401647|DRUG|amiodarone|300 mg will be given IV/IO push for reoccurrence of ventricular fibrillation or pulseless ventricular tachycardia after 1 or more shocks. A second dose of 150 mg will be given if VF/pulseless VT reoccurs after initial dose and a subsequent shock. The initial dose for patients estimated to be less than 100 pounds will be 150 mg, followed by a second dose of 150 mg if the VF/pulseless VT persists.
224322078|NCT02836925|DRUG|Sofosbuvir+Velpatasvir|"Patients with genotype 2 or genotype 3 Sofosbuvir 400 mg + Velpatasvir 100 mg~· 12 weeks of treatment"
224322079|NCT03454503|DRUG|Imatinib|Film coated tablet contains 400 mg imatinib (as mesilate)
224322080|NCT01916525|BEHAVIORAL|Exercise based cardiac rehabilitation|The cost-effectiveness between the exercise training vs. control groups
224322081|NCT05298917|DEVICE|silicone hydrogel contact lens|silicone hydrogel contact lens
224251177|NCT01401647|DRUG|Lidocaine|120 mg will be given IV/IO push with reoccurrence of ventricular fibrillation or pulseless ventricular tachycardia after 1 or more shocks. A second dose of 60 mg will be given if VF/pulseless VT reoccurs after initial dose and a subsequent shock. The initial dose for patients estimated to be less than 100 pounds will be 60 mg, followed by a second dose of 60 mg if the VF/pulseless VT persists.
224251178|NCT01401647|OTHER|Normal saline|6 cc of normal saline (NS) will be given IV/IO push for reoccurrence of ventricular fibrillation or pulseless ventricular tachycardia after 1 or more shocks. A second dose of 3 cc will be given if VF/pulseless VT reoccurs after initial dose and a subsequent shock. The initial dose for patients estimated to be less than 100 pounds will be 3 cc, followed by a second dose of 3 cc if the VF/pulseless VT persists.
224251179|NCT00546988|BIOLOGICAL|allogeneic stem cell transplant|
223670455|NCT04089800|OTHER|Mobile phone based multimedia application|The investigators shall develop a multimedia mobile health application using Java programming language, while the database that hosts multimedia messages shall be developed using SQlite. It shall be an offline (stand-alone) application following user-centered design approaches that involve incorporating input from pregnant women as prospective users. Pregnant women shall be provided with solar chargers to supplement electricity charging. The application has three major functionalities, appointment reminder function, calling function and the multimedia (Video and audio) function.
223670456|NCT03665818|DEVICE|oral appliance treatment|mandibular advancement device to enlarge pharyngeal airway space to get rid of apnea and hypopnea events
224251180|NCT01457716|DRUG|Budesonide|Single inhalation
224251181|NCT01457716|DRUG|Formoterol|Single inhalation
224251182|NCT01457716|DEVICE|Easyhaler|Inhaler device
224251183|NCT01457716|DEVICE|Turbohaler Forte|Inhaler device
224251184|NCT03034694|OTHER|teledermatology consult|teledermatology consult
224251185|NCT03034694|OTHER|Routine Care|The patient will undergo imaging but this report will not be put into the chart.
224251186|NCT05428020|DEVICE|Indwelling foley catheter|short-term indwelling catheter inserted in the operating room prior to surgery, removed upon arrival to the floor from post-anesthesia care unit (approx 2-3 hours after surgery).
224251187|NCT05428020|OTHER|No foley catheter|No foley catheter is placed for surgery
224251188|NCT02261857|DEVICE|Personalized continuous positive airway pressure (CPAP) mask|Personalized CPAP mask manufactured for study subjects using a combination of patient-specific computer-aided design and three-dimensional printing
224251189|NCT00473330|DRUG|Ranibizumab|Sterile solution for intravitreal injection.
223670457|NCT01138917|DEVICE|ReCell and Split-thickness skin graft|The surgeon will be required to select two similar non-contiguous injury areas with both areas being at least 100cm2 and second degree depth/severity. One area will be treated using ReCell and the second using Split-thickness Skin Graft.
223670458|NCT02133703|BEHAVIORAL|Enhanced Internet DA|BRCA1/2 carriers randomized to this arm will have access to Internet-based decision support including a preference clarification tool. This intervention is designed to provide education and decision support regarding the available risk management options.
223670459|NCT02133703|BEHAVIORAL|Internet DA|BRCA1/2 carriers randomized to this arm will have access to Internet-based decision support. This intervention is designed to provide education regarding the available risk management options.
223670460|NCT02133703|BEHAVIORAL|Enhanced Print DA|BRCA1/2 carriers randomized to this arm will receive print-based decision support materials which include a preference clarification tool. This intervention is designed to provide education and decision support regarding the available risk management options.
224251190|NCT00473330|DRUG|Sham injection|
224251191|NCT03600480|DRUG|NNC0174-0833|Participants will receive increasing dose levels of 0.16 mg, 0.3 mg, 0.6 mg, 1.2 mg, 2.4 mg or 4.5 mg of NNC0174-0833 (subcutaneous \[s.c.\], in a lifted fold of the abdominal skin) injection once weekly starting with a very low dose and then escalated every 4 weeks to a slightly higher dose each time. Each participant will only be given one dose level.
223670461|NCT02133703|BEHAVIORAL|Print DA|BRCA1/2 carriers randomized to this arm will receive print education materials designed to provide information regarding the available risk management options.
223670462|NCT02133703|BEHAVIORAL|Inconclusive Results DA|Women who receive uninformative BRCA1/2 results randomized to this arm will have access to Internet-based decision support including a preference clarification tool. This intervention is designed to provide education and decision support regarding the available risk management options.
223670463|NCT06431971|DRUG|Talineuren|Talineuren infusion weekly
223670464|NCT06431971|DRUG|Placebo|Placebo infusion weekly
223670465|NCT02358356|DRUG|octreotate|7.8GBq 177Lu Octreotate (Lutate) given intravenously (IV)
223670466|NCT02358356|DRUG|Capecitabine|oral capecitabine 750mg/m2 b.i.d.
224251192|NCT03600480|DRUG|Semaglutide|Participants will receive 2.4 mg of semaglutide (s.c., in a lifted fold of the abdominal skin) injection once weekly starting with a very low dose and then escalated every 4 weeks to a slightly higher dose each time.
224251193|NCT03600480|DRUG|Placebo (NNC0174-0833)|Participants will receive once weekly injections of NNC0174-0833 matched placebo.
223670467|NCT02358356|DRUG|Temozolomide|temozolomide 75mg/m2 b.i.d.
223670468|NCT02521896|DEVICE|Steerable Sheath System|The Vado™ Steerable Sheath consists of a dilator and steerable sheath which are designed to provide intracardiac access and flexible catheter positioning in the cardiac anatomy.
223670469|NCT04168632|OTHER|OPTIMAT|The intervention was to serve a new school lunch menu plan as similar as possible to a baseline menu plan but 40% lower in greenhouse gas emissions, being nutritionally adequate and no more expensive.
224251194|NCT01975948|OTHER|Mental Health Practice Support Program|"1. training and (2) practice support.~   * Three half day workshop sessions over a 24 week period.~  * Practice support:~     3 evidence based Supported Self Management tools (Cognitive Behavioral Interpersonal Skills Manual,Bounceback program, Antidepressant Skills Workbook), and Practice support coordinator provides guidance to incorporate newly acquired tools, skills, and processes"
224251195|NCT01975948|OTHER|Treatment as Usual|Physicians manage patients with depression as usual
224251196|NCT03888430|PROCEDURE|PtcCO2 measure during intubation|Transcutaneous measure during intubation. Non invasive measure without any risk according to the literature
224251197|NCT01675765|BIOLOGICAL|Immunotherapy plus chemotherapy|live attenuated double deleted Lm
224251198|NCT01675765|BIOLOGICAL|Immunotherapy with cyclophosphamide plus chemotherapy|live attenuated double deleted Lm
224251199|NCT04807439|DEVICE|SYNERGY XLV (Megatron) Coronary Stent System|The SYNERGY MEGATRON Everolimus-Eluting Platinum Chromium Coronary Stent System is indicated for improving luminal diameter in patients, including those at high risk for bleeding, with diabetes mellitus, with symptomatic heart disease, stable angina, unstable angina, non-ST elevation MI or documented silent ischemia due to atherosclerotic lesions in native coronary arteries \>3.50 mm to \<5.00 mm in diameter in lesions \<28 mm in length.
224251200|NCT01152840|DRUG|RAD001|"RAD001 10 mg po daily medication~* Treatments will be continued until any of the following events occur:~  * progression of disease,~ * the subject develops unacceptable toxicity,~ * consent to participate in the study is withdrawn."
224251201|NCT00820586|PROCEDURE|Mononuclear bone marrow derived cells|Direct intramyocardial percutaneous delivery of autologous bone marrow-derived total mononuclear cells or selected CD34+ cells
224251202|NCT04303663|PROCEDURE|Fibular Plate|ORIF with Plating
224251203|NCT04303663|PROCEDURE|Fibular Nail|CRIF +/- ORIF with Fibular nail
224251204|NCT02834663|DRUG|Lucentis|Local anesthesia with T-caine with Saline irrigation. Routine eye drap was done by potadine-cotton ball. Lucentis injected to vitreous cavity, finally dressing.
224251205|NCT02986386|PROCEDURE|Dental occlusion restoration|Placement of dental implants by surgical intervention followed, after a healing period of 2 months, by fabrication and installation of implant supported dental prosthesis
224251206|NCT02986386|PROCEDURE|Orthodontic treatment of malocclusion|Orthodontic therapy to treat malocclusion
224251207|NCT03309774|DIAGNOSTIC_TEST|questionnaires|"Children with Complex Regional Pain Syndrome (CRPS) will be filled questionnaires before and after relaxation sessions. These questionnaire evaluate the quality of life and pain of child~There will be:~* Questionnaire KIDSCREEN 52~* Visual Analogue Scale (EVA)~* Neuropathic Pain 4 (DN4)~* Pain of the child Gustave Roussy (DEGR)"
224251208|NCT03309774|DIAGNOSTIC_TEST|holter electrocardiogram|Children with Complex Regional Pain Syndrome (CRPS) will be have holter electrocardiogram before and after relaxation sessions.
224251209|NCT03309774|DIAGNOSTIC_TEST|blood pressure|Blood pressure of Children with Complex Regional Pain Syndrome (CRPS) will be measured by Nexfin monitor before and after relaxation sessions.
224251210|NCT03309774|OTHER|relaxation sessions|"Children with Complex Regional Pain Syndrome (CRPS) will be performed 20 relaxation sessions and 2 per week.~During relaxation sessions children will be recorded by voice recorder. Children should describe his feelings at the preceding session.~After every relaxation sessions children evaluate pain according to Eland Color Scale."
224251211|NCT03965091|DRUG|Fremanezumab|Fremanezumab will be administered per dose and schedule specified in the arm description.
224251212|NCT03965091|DRUG|Placebo|Placebo matching to fremanezumab will be administered per schedule specified in the arm description.
224251213|NCT03680248|DIETARY_SUPPLEMENT|Fat|Subjects will consume dairy cream (150 g of fat) at time 0 hours.
224251214|NCT03680248|DIETARY_SUPPLEMENT|Fasting|Subjects will fast throughout the experiment.
224251215|NCT03680248|DIETARY_SUPPLEMENT|Fat+Glucose|Subjects will consume dairy cream (150 g of fat) at time 0 hours. At the same time and 2 and 4 hours later they will drink herbal tea containing 50 g of glucose.
224251216|NCT03680248|DIETARY_SUPPLEMENT|Glucose|Subjects will drink herbal tea containing 50 g of glucose at times 0, 2 and 4 hours.
224251217|NCT03680248|DIETARY_SUPPLEMENT|Fat+Fructose|Subjects will consume dairy cream (150 g of fat) at time 0 hours. At the same time and 2 and 4 hours later they will drink herbal tea containing 50 g of fructose.
224251218|NCT03680248|DIETARY_SUPPLEMENT|Fructose|Subjects will drink herbal tea containing 50 g of fructose at times 0, 2 and 4 hours.
224251219|NCT03354286|BEHAVIORAL|Developmental & Technological Demands|Education and training related to use of CGM in this age group
224251220|NCT03354286|BEHAVIORAL|Distress Reduction|Education and training on reducing distress
224251221|NCT03354286|BEHAVIORAL|Nutrition, Set Point, & C:I Ratio|Education and training on how to use the HCL system to dose for different kinds of foods to improve glycemic control
223670470|NCT00286598|BEHAVIORAL|Feet First|Phase 1: (enrollment to 3 months) 8 sessions with a physical therapist learning leg strengthening and balance exercises, and initiating a walking program Phase 2: Motivational enhancement calls from a nurse every 2 weeks.
223670471|NCT02859805|OTHER|validation of a diagnostic tool severity of non-motor symptoms in Parkinson patients|
223670472|NCT02890615|BEHAVIORAL|Depression self-care|Toolkit and coaching
224251222|NCT03354286|BEHAVIORAL|Hypoglycemia management|Education and training on reducing worries of hypoglycemia
224251223|NCT03354286|BEHAVIORAL|Minimal Intervention|Minimal intervention to simulate standard care - serves as the control group
224251224|NCT02576938|DRUG|Baricitinib|Administered orally
224251225|NCT02576938|DRUG|Placebo|Administered orally
223670473|NCT04479319|DIAGNOSTIC_TEST|Thorax CT|Subjects in all arms have a Thorax CT and RT-PCR for SARS-CoV-2.
223670474|NCT03707275|DEVICE|Alexa+|Patients will receive the Amazon Echo Dot with Alexa voice technology (Alexa+) and will be asked to interact with the device for 3 months. Alexa+ will ask a series of questions. Based on the answers to these questions, it will either contact a study coordinator or will ask patients to take a specific action (such as weighing themselves). Data from this simple intervention will be merged with data extracted from the patient's health record and analyzed for clinical variables and demographics that are most predictive for success in use of these technologies.
223670475|NCT03707275|OTHER|Standard of Care Arm|This group will receive standard of care (SOC) HF management, which will entail regular follow up from the HF nurse and data from all hospital or clinic visits will be captured from the EHR.
223670476|NCT00927940|DEVICE|MDT-4107 Drug Eluting Stent|Implantation of a MDT-4107 Zotarolimus-Eluting Coronary Stent
223670477|NCT03007888|DRUG|Sinemet|Immediate Release Tablet containing carbidopa-levodopa flexible dosing
223670478|NCT03007888|DRUG|IPX203|Extended Release capsules containing carbidopa-levodopa flexible dosing
223670479|NCT00243646|RADIATION|External beam radiation|All patients will receive a 5-week course of external beam radiation therapy to the pelvis and a Pd-103 brachytherapy implant
223670480|NCT00243646|DRUG|Lupron|9 months of an LHRH agonist and 4 months of an anti-androgen) is optimal for securing long-term biochemical control (a stable, non-rising PSA).
223670481|NCT00243646|DRUG|Casodex|9 months of an LHRH agonist and 4 months of an anti-androgen) is optimal for securing long-term biochemical control (a stable, non-rising PSA).
224251226|NCT02576938|DRUG|Triamcinolone (Optional)|Administered topically
224251227|NCT03500341|DEVICE|INVSENSOR00014|Noninvasive pulse oximeter sensor
224251228|NCT04678141|OTHER|Dyract XP (Dentsply De Trey), Kerr Herculite Classic (Kerr Corporation),R&D Series NOVA(Kuraray Medical Inc) Clearfil TM SE Bond (Kuraray Medical),Hydrocal LC (Medicept Dental)|compomer (Dyract XP,R\&D Series NOVA) , composite (Kerr Herculite Classic),Bonding (Clearfil TM SE Bond), Dycall (Hydrocal LC)
224251229|NCT05802784|PROCEDURE|Hysteroscopic septoplasty with scissors|In hysteroscopic septoplasty with scissors arm, incision of the septum was done by continuous flow hysteroscopy and scissors using saline as distension media.
224251230|NCT05802784|PROCEDURE|Hysteroscopic septoplasty with resectoscope|In hysteroscopic septoplasty with resectoscope arm, incision of the septum was done by 26 Fr monopolar resectoscope with collin's knife using glycine1.5% as distension media.
224251231|NCT01377779|DRUG|Oxiplex/AP gel|Intrauterine application of Intercoat following hysteroscopy
224251232|NCT01377779|DRUG|Normal Saline|No intrauterine application of Intercoat following hysteroscopy
224251233|NCT01010932|DRUG|Dotarem|Each subject will receive one injection of Dotarem 0.2ml/kg
224251234|NCT01010932|OTHER|TOF MRA|Each subject will undergo a Time of Flight Magnetic Resonance Angiography (TOF MRA)
224251235|NCT04481815|DRUG|Rituximab|375mg/m2 intravenous infusion d1, every 3 weeks for 1 cycle, 6 cycles will be prescribed for induction therapy. 375mg/m2 intravenous infusion d1, every 8 weeks for 1 cycle, 4 cycles will be prescribed for maintenance therapy.
224251236|NCT04481815|DRUG|Lenalidomide|25mg orally d1-10 every 3 weeks for 1 cycle, 6 cycles will be prescribed for induction therapy. 25mg orally d1-14,d29-42 every 8 weeks for 1 cycle, 4 cycles will be prescribed for maintenance therapy.
224251237|NCT04481815|DRUG|Methotrexate|3.5g/m2 intravenous infusion for 4 hours in d1, every 21 days for 1 cycle, 6 cycles will be prescribed.
223670482|NCT01479426|DIETARY_SUPPLEMENT|EFLA400|EFLA400(960mg/day)for 12 weeks
223670483|NCT01479426|DIETARY_SUPPLEMENT|Placebo|Placebo(960mg/day) for 12 weeks
224251238|NCT00982397|DEVICE|Protecta VR-ICD|Protecta single-chamber implantable cardioverter defibrillators.
224251239|NCT00982397|DEVICE|Protecta DR-ICD or CRT-D|Protecta dual-chamber implantable cardioverter defibrillators and cardiac resynchronization therapy defibrillators.
223670484|NCT00043550|BEHAVIORAL|Supportive Expressive Therapy|The aim of supportive-expressive psychotherapy is to help patients understand the causes of relationship conflicts in the context of a supportive relationship.
223670485|NCT00043550|DRUG|Sertraline|Participants will receive sertraline.
223670486|NCT00043550|DRUG|Pill Placebo|Participants will receive a pill placebo.
223670487|NCT00043550|DRUG|Venlafaxine|Participants will receive venlafaxine.
223670488|NCT03471624|DRUG|Tenofovir Alafenamide|Tenofovir alafenamide (TAF) is a new formulation of tenofovir with higher intracellular active drug concentration allowing for dosing of only 25 mg once daily and thus can potentially lower the already low risk of renal toxicity and bone loss with tenofovir disoproxil fumarate (TDF).
223670489|NCT04623125|BEHAVIORAL|Spaced Retrieval Practice|Online picture-naming training with 60 words which the participant experiences word-retrieval difficulties. Cards are shuffled arranged by the computerized training program.
223670490|NCT05908643|DRUG|pTTL|pTTL is an autologous cell product for adoptive cancer immunotherapy containing in vitro expanded T cells stimulated with patient-specific tumour neoantigens derived from tumour-draining lymph nodes.
223670491|NCT05212857|DRUG|Leuprolide acetate|Given subcutaneously or as an injection
223670492|NCT05212857|DRUG|Goserelin acetate|Given subcutaneously or as an injection
223670493|NCT05212857|DRUG|Triptorelin acetate|Given subcutaneously or as an injection
223670494|NCT05212857|DRUG|Degarelix acetate|Given subcutaneously or as an injection
224251240|NCT01355133|BIOLOGICAL|Transurethral intrasphincteric autologous myoblast implantation|Patients undergo upper arm muscle biopsy to isolate and cultivate autologous myoblasts. Using the ultrasound-directed transurethral medical device, 15-18 aliquots (50 - 100 µl per depot) of the 2 ml myoblasts/media suspension are directly injected into the urethral rhabdosphincter at two different levels. The procedure is a single-dose injection of a cell count in range of 1x106 -5x107 cells, depending of the size/quality of the biopsy and quality of outgrowing cells in order to identify possible dose related effects. To possibly enhance cell integration following implantation, a course of transvaginal electrical stimulation is undertaken.
224251241|NCT05015114|OTHER|Sarcopenia Assessment|Sarcopenia Assessment
224251242|NCT00303940|DRUG|carboplatin|
224251243|NCT00303940|DRUG|talabostat mesylate|
224251244|NCT00303940|DRUG|temozolomide|
224251245|NCT00303940|OTHER|pharmacological study|
223670495|NCT05212857|DRUG|Abiraterone acetate|Given orally
223670496|NCT05212857|DRUG|Apalutamide|Given orally
223670497|NCT05212857|DRUG|Enzalutamide|Given orally
224251246|NCT01871662|DRUG|Legalon® SIL (Silibinin)|Silibinin 20 mg/Kg/day
224251247|NCT01871662|DRUG|Pegylated interferon alfa2b|1.5 µg/kg once-weekly
224251248|NCT01871662|DRUG|Ribavirin|At weight-based dose 800-1400 mg/day (BID, OS)
224251249|NCT05537129|PROCEDURE|Total Gastrectomy|The laparoscopic or open total gastrectomy with D2 lymphadenectomy was performed according to the Japanese gastric cancer treatment guidelines.
224251250|NCT05862064|DRUG|epirubicin,cyclophosphamide,paclitaxel,Carrelizumab|Conventional chemotherapy in combination with carrelizumab
224251251|NCT05862064|DRUG|epirubicin,cyclophosphamide,paclitaxel|Conventional chemotherapy
224251252|NCT01890057|DRUG|Sugammadex|The dose of sugammadex
224251253|NCT01038817|DRUG|Duraphat|After prophylactic cleaning of the mouth and teeth, application of fluoride varnish according to the manufacturer's recommendations (up to 0.75 ml per application)
224251254|NCT06560775|COMBINATION_PRODUCT|Standard Treatment for SLE|Standard Treatment for SLE
224251255|NCT06558370|OTHER|Empty bladder group|"Patients in the empty bladder group will be instructed to empty the bladder immediately before the procedure. A colleague will perform transabdominal ultrasound to confirm that the bladder is empty.~All the procedures will be performed using the vaginoscopic technique. A rigid 2.9-mm hysteroscope with a 30° lens and a 5-mm outer sheath (Karl Storz GmbH, Tuttlingen, Germany) will be used in all procedures."
224251256|NCT06558370|OTHER|Bladder distension group|"Patients in the bladder distension group will be instructed to drink one liter of water and to avoid urination during a period of 2 h before the scheduled procedure. A colleague will perform transabdominal ultrasound to confirm that the bladder is distended .~All the procedures will be performed using the vaginoscopic technique. A rigid 2.9-mm hysteroscope with a 30° lens and a 5-mm outer sheath (Karl Storz GmbH, Tuttlingen, Germany) will be used in all procedures."
224251257|NCT00793832|BEHAVIORAL|supervised exercise|supervised exercise
224251258|NCT00793832|BEHAVIORAL|Diet advice|Diet Advice
224251259|NCT05967715|BEHAVIORAL|exercise training|high intensity interval training
224251260|NCT05967715|OTHER|Probiotics|VSL#3# Probiotic
223670498|NCT05212857|PROCEDURE|Local treatment for primary lesion|Radical prostatectomy to remove prostate primary lesion
223670499|NCT05212857|RADIATION|Radiotherapy for primary lesion|Radical radiotherapy for primary lesion
223670500|NCT05212857|RADIATION|Radiotherapy for metastatic lesion|Stereotactic body radiation therapy or proton and heavy ion radiation therapy is preferred, which could treat all the lesions at once or treat different lesions in stages.
223670501|NCT01418508|BEHAVIORAL|low protein diet plus α-keto acid|low protein diet plus α-keto acid 0.6g of proteins per kilo of body weight per day, supplemented with α-keto acid tablets
223670502|NCT01418508|BEHAVIORAL|very low protein diet plus α-keto acid|very low protein diet plus α-keto acid 0.3g of proteins per kilo of body weight per day, supplemented with α-keto acid tablets
223670503|NCT00222716|BEHAVIORAL|Problem solving counseling|Telephone nurse counseling behavioral intervention focused on problem solving.
223670504|NCT02762227|DEVICE|Abdominal high resolution CT|CT examinations were performed using a 64-slice CT scanner. Arterial phase scanning was triggered by bolus tracking technique after 100 to 120 mL nonionic contrast material was injected through the antecubital vein. With a delay of 60 and 140 s after the beginning of contrast medium injection, portal venous and equilibrium phase image scanning were followed.
223670505|NCT02762227|DEVICE|Contrast-enhanced ultrasonography (CEUS)|CEUS examinations were performed using a Philips iU 22 scanner with a 1-5 MHz（Mega Hertz, MHz）vector transducer. Traditional transabdominal ultrasound and CEUS were performed by the same investigator, one with more than 3 years experiences in CEUS. Traditional ultrasound was used initially to locate the lesion. The plane with the bottom of the lesion was selected for further examination. When multiple lesions were existed, the largest one was selected to evaluate. The target was placed in the center of the screen and was kept stable. Pulse inversion harmonic imaging with an index of 0.06 was used in CEUS examination. SonoVue, which contained sulfur hexafluoride microbubbles, was used as the contrast agent.
223670506|NCT02762227|PROCEDURE|Cholecystectomy|Cholecystectomy is performed by method of either laparoscopic cholecystectomy or open cholecystectomy.
223670507|NCT03849573|BEHAVIORAL|"OncoTool Intervention (MBSR + HT education)"|OncoTool is a website intended to improve self-management practices for helping cancer patients cope with stress and improve health-related quality of life. OncoTool provides mindfulness-based education and management for dealing with the numerous physical and mental side effects associated with hormone therapy (e.g., muscle and joint pain, vaginal dryness, depressive symptoms). OncoTool is a website designed to improve hormone therapy adherence by improving quality of life, and hormone therapy associated symptom burden. Both intervention and active comparator conditions are administered to participants for 8 weeks.
223670508|NCT03849573|BEHAVIORAL|"Oncotool Control (health +HT education)"|OncoTool is a health promotion website with health education on subjects like nutrition and exercise specific to breast cancer survivors, as well as general advice on lifestyle choices and prevention. The Oncotool control has similar HT education content as the experimental content but without the CBT and MBSR state. Both intervention and active comparator conditions are administered to participants for 8 weeks.
223670509|NCT03035474|OTHER|Digital Engagement|Patient engagement to improve self-management/medication adherence
223670510|NCT03035474|OTHER|Direct Engagement|Health system engagement to improve local QI programs
224251261|NCT05967715|OTHER|Placebo|Probiotic Placebo
223670511|NCT02767362|DRUG|Atorvastatin|Once enrolled on this pre-operative window study, patients with endometrial cancer will be treated with the standard clinical dose of atorvastatin (80 mg once daily orally) for an average of 2-4 weeks prior to surgical staging. Patients will need to be able to undergo atorvastatin treatment for a minimum of 2 weeks but no more than a maximum of 4 weeks prior to surgical staging.
223771588|NCT01584284|BIOLOGICAL|GL-ONC1|A genetically-engineered vaccinia virus administered via intravenous infusion . Cohorts 1, 2, 3: Frequency: 1x in Week 1; Cohort 4: 1x again 1x in Week 2; Cohort 5: 1x Week 1, 1x Week 2, 1x Week 3, 1x Week 4.
224322082|NCT01962818|OTHER|HFOV combined with sigh breaths|"It is planned only to investigate infants already ventilated on the HFOV-modus on high frequency oscillators, where the HFOV modus can be superimposed on conventional modes of ventilation. This gives the opportunity to combine HFOV with intermittent sigh breaths with a pre-set frequency and pre-set peak inspiratory pressure (PIP) and thus comparing HFOV combined with sigh breaths (HFOV-sigh) with conventional HFOV (HFOV-only).~All included participants will be exposed to the two different ventilator strategies tested in this trial, albeit in alternating and different order.~Each patient will serve, as it's own control. The trial will involve four alternating 1-hours periods allowing a sufficient wash-out period, as it has been shown that alveolar recruitment and derecruitment may take up to 25 min after changes to ventilator pressures At study start the patients will randomly be assigned to either starting with HFOV-only or HFOV-sigh"
224322083|NCT00799058|DRUG|dapivirine 4789|dapivirine gel 4789, 0.05%, 2.5g applied once daily
224322084|NCT00799058|DRUG|dapivirine gel 4759|dapivirine gel 4759, 0.05%, 2.5g applied once daily
223670512|NCT05143788|PROCEDURE|Awake craniotomy|The awake neurosurgical procedure performed on the brain is to provide a real-time neurological functions monitoring in order to preserve the functions of brain to the greatest extent.
223771589|NCT01479634|DRUG|Standard ART|Standard Ugandan 3-drug antiretroviral therapy regimen consistent with current practices
224251262|NCT06043037|PROCEDURE|Elamrousy Novel Approach for Immediate Implant Placement Using Socket Shield Technique|The flapless strategy was used. To prepare the SS, tooth decoronation followed by root splitting mesio-distally. The palatally splitted portion of the root is atraumatically extracted while the intact buccal root portion is kept in place with thickness of 1.5mm.(12) The implant fixture is then placed palatally with 2mm gap distance in between. finally, that gap was grafted with ADDG
224251263|NCT06043037|PROCEDURE|Immediate Implant Placement Using Socket Shield Technique alone|The flapless strategy was used. To prepare the SS, tooth decoronation followed by root splitting mesio-distally. The palatally splitted portion of the root is atraumatically extracted while the intact buccal root portion is kept in place with thickness of 1.5mm.(12) The implant fixture is then placed palatally with 2mm gap distance in between. finally, that gap was left without grafts.
224251264|NCT02701556|DEVICE|Complete MPS|a multi-purpose solution for disinfecting, cleaning, conditioning, rinsing, protein removal, and storing soft contact lenses including silicone hydrogel lenses.
224251265|NCT02701556|DEVICE|NNR06|an experimental solution for disinfecting, cleaning, conditioning, rinsing, protein removal, and storing soft contact lenses including silicone hydrogel lenses.
224251266|NCT06466707|OTHER|Collection of microbiome samples|Collection of skin, oral and vaginal (if applicable) microbiome samples by means of a swab and collection of fecal material using Fecotainer collection kit.
224251267|NCT00572637|DRUG|CEP-18770|Administered as intravenous infusion on days 1, 4, 8, and 11 of a 21-day cycle up to 6 cycles. Starting dose 0,1 mg/sqm
224251268|NCT00670761|DRUG|misoprostol|comparison of orally administered 600mcg of misoprostol to either sublingually administered 400mcg or Manual Vacuum Aspiration (MVA)
224251269|NCT00670761|PROCEDURE|MVA|comparison of orally administered 600mcg of misoprostol to either sublingually administered 400mcg or Manual Vacuum Aspiration (MVA)
224251270|NCT06027528|PROCEDURE|dentin graft mixed with autologous fibrin glue|extracted tooth will be grinded into small particles to form dentin graft that will be mixed with autologous fibrin glue to be grafted in the extracted socket using centrifuge
224251271|NCT06027528|PROCEDURE|dentin graft|extracted tooth will be grafted in the socket
223670513|NCT03438721|BEHAVIORAL|Infant obesity prevention|Parents will receive education on infant feeding, sleep, and screen time practices just after well-child visits in the first year of life. The education will be provided by a lay health educator. Parents will also receive text messages to reinforce the intervention content
223670514|NCT03438721|BEHAVIORAL|Financial coaching|Parents randomized to the financial coaching arm will receive basic education on financial topics including budgeting, savings, and managing debt as well as coaching on these topics just after well-child visits in the first year of life. Coaching will be provided by lay health educators trained in financial coaching. Parents will also receive text messages reinforcing the information learned.
223670515|NCT06472986|OTHER|Activity-based therapy and transcutaneous spinal cord stimulation|Activity Based Therapy (ABT) is a method of neuro-rehabilitation that incorporates a high intensity, long duration and effortful engagement from the individual receiving therapy, to garner improvements in sensory and motor function. The ABT constitutes 4 types of exercises including: cardio-fitness, resistance, postural/weightbearing and functional exercises. TransCutaneous Spinal Cord Stimulation (TCSCS) stimulates spinal networks in the cervical region to neuro-modulate the descending motor commands/motor intentions from the brain, which control the muscles. In tCSCS, electrical stimulation is delivered at a frequency of 30-50Hz at 500-1000µs between C3-C7. 12 sessions of ABT (4 weeks), followed by 28 sessions of ABT-TCSCS (7 weeks). Each session will last 1 hour and delivered 3 times per week.
223670516|NCT03444480|DRUG|Remimazolam Tosylate|Initial dose plus supplemental doses
223771590|NCT01479634|DRUG|Study-Provided ART|"Study provided drugs:~1. Truvada® (one tablet PO daily of fixed dose combination consisting of tenofovir disoproxyl fumarate \[TDF\] and emtricitabine \[FTC\]) PLUS~2. Efavirenz \[EFV\]"
224251272|NCT00723047|PROCEDURE|Fibrin glue injection in fistula|
224251273|NCT01928147|DRUG|PPI-383|
224251274|NCT01928147|DRUG|Placebo|
224251275|NCT00240747|DRUG|Synercid|
224251276|NCT04727398|DEVICE|Wide-field optical coherence tomography (Optovue®)|Merged 4 images for wide-filed OCT-based PVD classification, 2 vertical line images and 2 horizontal line images
224251277|NCT01666262|BIOLOGICAL|Vaccine A/17/CA/2009/38 (H1N1)|Pandemic Live Attenuated Influenza Vaccine (PLAIV) Candidate Strain A/17/CA/2009/38 (H1N1)
224251278|NCT01666262|OTHER|Placebo:Stabilizer|5% sucrose
224251279|NCT03375047|DRUG|MRT5005|Nebulization of MRT5005
224251280|NCT03375047|DRUG|Normal saline|Normal Saline for Inhalation
224251281|NCT01837654|BEHAVIORAL|Plantarflexion 2nd wave|At the beginning of the 2nd wave, patients will be asked to perform continuous plantar-flexion by pushing their tiptoes against the floor.
224251282|NCT01837654|BEHAVIORAL|Plantarflexion - 3rd wave|At the beginning of the 3rd wave, patients will be asked to perform continuous plantar-flexion by pushing their tiptoes against the floor.
224251283|NCT04038801|PROCEDURE|Quadrant-wise scaling and root planning (Q-SRP)|Quadrant-wise scaling and root planing were performed by assortment of manuel periodontal curettes over four visits at 1-weekly intervals.
224251284|NCT04038801|PROCEDURE|Full-mouth ultrasonic debridement (FMUD)|Subgingival debridement were performed by a piezoceramic ultrasonic inserts in two visits of the same day.
224251285|NCT04038801|PROCEDURE|Full-mouth disinfection (FMD)|Subgingival debridement were performed by a piezoceramic ultrasonic inserts and an intensive regime of chlorhexidine in two visits of the same day.
224251286|NCT01333332|DRUG|Capecitabine|Capecitabine
224322085|NCT00799058|DRUG|Drug placebo|HEC-based universal placebo gel, 2.5g applied once daily
224251287|NCT01333332|RADIATION|Standard Dose Acclerated Fraction Radiotherapy|Standard dose accelerated fraction radiotherapy
224251288|NCT00906594|DRUG|latanoprost|
224251289|NCT02363803|DRUG|lidocaine|lidocaine is a sodium channel blocker/analgesic. It is approved for intravenous administration for cardiac arrhythmias.
224251290|NCT02363803|DRUG|Placebo|Normal saline, approved for hypovolemia, and homeostasis.
224251291|NCT01912898|DEVICE|No intervention,The group with vitamin D deficient will be treated by the Endocrinology Department by loading of vitamin D|
224251292|NCT02372305|BIOLOGICAL|FlexHD|Patients will be randomized to receive FlexHD.
224322086|NCT00000543|BEHAVIORAL|dietary supplements|
224322087|NCT00000543|DRUG|calcium|
224322088|NCT06299787|DEVICE|intermittent theta burst stimulation|Theta-burst stimulation
223670517|NCT03725462|DEVICE|Cardioskin|Subjects have a monitoring with cardioskin and comparator
223670518|NCT03725462|DEVICE|Neuronaute|Subjects have a monitoring with Neuronaute and comparator
223670519|NCT02444000|DRUG|PCV chemotherapy alone|"PCV cycles are 6 weeks long~PCV chemotherapy is given as:~Day 1: CCNU 110 mg/m2 orally; Days 8 and 29: vincristine 1.4 mg/m2 IV; Days 8 to 21: procarbazine 60 mg/m2 orally"
223670520|NCT02444000|DRUG|Radiotherapy+PCV chemotherapy|Radiotherapy followed by 6 cycles of PCV
223670521|NCT04565808|PROCEDURE|primary percutaneous coronary intervention|Primary Percutaneous Coronary Intervention (PPCI), also known as angioplasty or coronary angioplasty, is a procedure used to diagnose and treat the narrowed coronary arteries of the heart.
223670522|NCT04914260|OTHER|Questionnaire|The participants will have to fill in an on-line questionnaire regarding quality of life, their level of knowledge of the rehabilitation through sport program and their level of satisfaction toward this program.
223670523|NCT05547204|OTHER|Beverage|Free from added carbohydrates (contain 1g CHO only) and electrolytes are absent.
223670524|NCT03894371|DEVICE|Thermage FLX|Thermage FLX system for the correction of mild to moderate laxity of the skin of the face, neck, and eyelids.
223670525|NCT02081066|OTHER|cardiovascular risk factors|
223670526|NCT01845623|DRUG|QAB149 75 mg Concept 1|QAB149 delivered via the concept 1 device.
223670527|NCT01845623|DRUG|QAB149 75 mg Epic Test Fixture|QAB149 delivered via the EPIC test fixture
223670528|NCT01845623|OTHER|Placebo Concept 1|Placebo administered via the Concept 1 device.
224322089|NCT06299787|DEVICE|Sham stimulation|Stimulation with double-sided B70-type coil
223670529|NCT01845623|OTHER|Placebo EPIC Test Fixture|Placebo administered via the EPIC Test Fixture.
223670530|NCT05045989|BEHAVIORAL|Residence-based testing participation pilot (SARS-CoV-2 testing with relaxed social distancing restrictions)|SARS-CoV-2 asymptomatic saliva testing (as available to all students at staff at the participating university) delivered with relaxed social distancing (behavioural element) in two halls of residence.
223670531|NCT03337672|DRUG|Dexmedetomidine|Intravenous dexmedetomidine 0.3mcg/kg is slowly infused at 5 minutes before the end of surgery
223670532|NCT03337672|DRUG|Midazolam|Intravenous dexmedetomidine 0.03mg/kg is slowly infused at 5 minutes before the end of surgery
223670533|NCT05307198|DRUG|Oxaliplatin|"Drug: Oxaliplatin Oxaliplatin 130mg/m2 for inducing chemotherapy in Day 1 every 3 weeks and repeat for two cycles.~The dose of oxaliplatin used for rectal artery infusion was uncertain because there were no previous study. We design this study with Oxaliplatin 85mg/㎡for rectal artery infusion chemotherapy in Day 1 every 3 weeks and repeat for 2 cycles, based on intravenous chemotherapy regimens recommended by NCCN（mFolfox6）.If there were severe side effects caused by oxaliplatin observed within first 5 patients, we would decreasing the dose of oxaliplatin depending on the multidisciplinary discussion of researchers.~We acknowledged that our study did not determine the most appropriate dosage of oxaliplatin used for artery infusion, but rather performed a novel therapeutic method for microsatellite stable locally advanced rectal cancer."
223670534|NCT05307198|PROCEDURE|Rectectomy|Include anterior resection or abdominoperineal resection by open or laparoscopy with Total Mesorectal Excision (TME).
223670535|NCT05307198|DRUG|Capecitabine|Oral Capecitabine 1000 mg/m2 twice daily combined with oxaliplatin chemotherapy in Day 1 to Day 14 every 3 weeks and repeat for 4 cycles.
223670536|NCT05307198|DRUG|Anti-PD-1 monoclonal antibody|Anti-PD1 antibody 200mg/m2 in Day 2 after Rectal Artery Infusion Chemotherapy. Repeat every 3 weeks for 2 cycles.
223670537|NCT05903209|DEVICE|Chang Gung Pneumothorax Detection Software|"The Chang Gung Pneumothorax Detection Software is an independent software as a medical device, which inputs digital Chest X-Ray to automatically detect whether there is a pneumothorax. The inferred results output by this software can assist clinicians or professional medical personnel to identify whether a patient has pneumothorax.~This product is only used to analyze the digitized Chest X-Ray DICOM of patients over 20 years old and under 100 years old."
223670538|NCT02970682|DRUG|SFX-01|Stabilised Sulforaphane
223670539|NCT02970682|DRUG|Fulvestrant|Fulvestrant
223670540|NCT02970682|DRUG|Tamoxifen|Tamoxifen
223670541|NCT02970682|DRUG|Aromatase Inhibitors|
223670542|NCT00181597|DRUG|Trilostane|Taken orally once a day for three days then twice daily thereafter.
223670543|NCT00181597|DRUG|Hydrocortisone|Taken orally with trilostane.
223670544|NCT01150669|OTHER|laboratory biomarker analysis|Samples are analyzed in laboratory studies
223670545|NCT05884801|DRUG|QLS1103|Oral dose
223670546|NCT01143701|OTHER|ADHD Collaborative|The ADHD Collaborative intervention model includes academic detailing, quality improvement methods, and innovative tools (e.g., web portal) designed to promote and support the systematic use of the AAP guidelines.
223670547|NCT00882570|DRUG|Cefdinir 250 mg/5 ml Oral Suspension (Sandoz, Austria)|
223670548|NCT00882570|DRUG|Omnicef 250 mg/5 ml Oral Suspension of Cefdinir (Abbot Laboratories, USA)|
223670549|NCT00930748|DEVICE|MR imaging with endorectal coil|MR imaging with endorectal coil
224322090|NCT03766815|DIETARY_SUPPLEMENT|BCAA 200mg/kg/day|BCAA supplement based on 200mg/kg/day for 18 days.
224322091|NCT03766815|DIETARY_SUPPLEMENT|Placebo|Fiber supplement jelly for 18 days.
224322092|NCT03766815|DIETARY_SUPPLEMENT|BCAA 400mg/kg/day|BCAA supplement based on 400mg/kg/day for 18 days.
224322093|NCT03766815|BEHAVIORAL|Muscle damaging exercise|Participants will be asked to perform muscle damaging elbow eccentric contraction exercise at 120% of 1RM for three sets of 15 repetitions with the dominant arm at maximal effort on a Biodex machine with a 3 minute rest period between each set.
224322094|NCT03639779|DRUG|Sodium Thiosulfate|A volume of 0.1 ml/cm2 of STS will be injected into each lesion.
223670550|NCT00930748|DEVICE|MRI with endo-rectal coil|MRI with endo-rectal coil
223670551|NCT02593071|BIOLOGICAL|RSV-F Vaccine|
223670552|NCT02593071|BIOLOGICAL|Phosphate Buffer Placebo|
223670553|NCT02727231|DEVICE|Florence D2A or similar closed loop glucose control system|Subject's glucose level will be controlled by the Florence D2A or similar automated closed loop glucose control system. The system comprises of FreeStyle Navigator 2 ® Continuous Glucose Monitoring (CGM) System (Abbott Diabetes Care, Alameda, CA, USA), Dana R Diabecare subcutaneous insulin infusion pump (Sooil Corp. Seoul, South Korea)or similar insulin pump, and MPC-based glucose control algorithm running on a smartphone
224251293|NCT02372305|BIOLOGICAL|Alloderm|Patient will be randomized to receive Alloderm.
224251294|NCT03324178|BEHAVIORAL|Neurofeedback training|Sixteen 30-minute sessions of neurofeedback training over four weeks: 7 x 3-minute blocks of training flanked by a 3-minute resting state block with eyes-open.
224251295|NCT03324178|BEHAVIORAL|Video game|Sixteen 30-minute sessions of video game playing over four weeks: 7 x 3-minute blocks flanked by a 3-minute seated relaxation.
224251296|NCT02375386|PROCEDURE|Spinal manipulation|Participants will receive a lumbar SMT technique previously described in the literature and commonly utilized for the treatment of low back pain . The SMT will be performed four times (two times on each side) in a 5-minute period. In addition, the following will be performed: Functional MRI, Behavioral: Pain Sensitivity Testing, Questionnaires,Behavioral: Physical Impairment.
224251297|NCT02375386|PROCEDURE|Therapeutic touch|"Participants in this group will lie prone. The therapist will place both hands in contact with the participants' pelvis across the top of the posterior aspect of the sacrum and ilia and apply a downward force to keep the pelvis in contact with the table. This group accounts for effects of time and personal contact. The amount of hands-on contact will be equivalent between groups. Both groups will be given the same verbal instructions regarding the techniques performed. In addition, the following will be performed: Functional MRI, Behavioral: Pain Sensitivity Testing, Questionnaires,Behavioral: Physical Impairment."
224251298|NCT02375386|PROCEDURE|fMRI|Both groups will receive an fMRI.
224251299|NCT02375386|BEHAVIORAL|Pain Sensitivity Testing|Both groups will receive an Pain Sensitivity Testing
224251300|NCT02375386|OTHER|Questionnaires|Both groups will receive Questionnaires
224251301|NCT02375386|BEHAVIORAL|Physical Impairment|Both groups will receive testing on physical impairment.
224251302|NCT05970653|PROCEDURE|Remote ischemic conditioning|Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 200 mm Hg.
224251303|NCT05970653|PROCEDURE|Sham remote ischemic conditioning|Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 60 mm Hg.
224251304|NCT04509063|BEHAVIORAL|Information about hypothetical mammography screening without benefits|We will present an online questionnaire with two types of information on the harms of screening. Then we will compare the prevalence of irrational decisions in the two arms.
224251305|NCT04293757|PROCEDURE|Rotational angiography|Preprocedural imaging before ablation
224251306|NCT00919230|DRUG|Ferrous sulphate tablets|200mg twice daily for four weeks
224251307|NCT00298350|DRUG|GS-9137 - A Novel HIV-1 Integrase Inhibitor|
224251308|NCT03575650|OTHER|Cardiac imaging modalities|Repeat cardiac echocardiographies, MRI-scans and CT-scans for early subclinical biomarker assessments in breast cancer patients treated with chemotherapy and radiotherapy
224251309|NCT01638520|DRUG|Pascolizumab|0.05mg/kg - 10mg/kg Pascolizumab according to dosing cohort
224251310|NCT01638520|DRUG|Placebo|Saline (volume determined based on weight of patient, and cohort of enrollment)
224251311|NCT00909662|PROCEDURE|assessment of therapy complications|"1. Questionnaires: Brief Fatigue Inventory, Brief Mental Fatigue and BDI FastScreen~2. Cognitive Task (2 timed 2-minute tests) with Concomitant EEG~3. Physical Task (Sustained Elbow Flexion) with Concomitant EEG and EMG plus TMS~4. Borg 15-Category Scale"
224251312|NCT00909662|PROCEDURE|cognitive assessment|Cognitive Task (2 timed 2-minute tests) with Concomitant EEG
224251313|NCT00909662|PROCEDURE|fatigue assessment and management|"1. Questionnaires: Brief Fatigue Inventory, Brief Mental Fatigue and BDI FastScreen~2. Cognitive Task (2 timed 2-minute tests) with Concomitant EEG~3. Physical Task (Sustained Elbow Flexion) with Concomitant EEG and EMG plus TMS~4. Borg 15-Category Scale"
224251314|NCT05494203|DIAGNOSTIC_TEST|questionnaire survey|All patients received lifestyle questionnaire, medical history, physical signs, auxiliary examination and laboratory examination results before treatment.
224251315|NCT03818841|DEVICE|High-flow nasal cannula device|Patients will be randomly allocated to this treatment
224251316|NCT03818841|DEVICE|Non-rebreathing oxygen mask group|Patients will be randomly allocated to this treatment
224251317|NCT00003659|BIOLOGICAL|filgrastim|Filgrastim (300 μg for patients ≤ 70 kg or 480 μg for patients \> 70 kg) will be administered beginning two days after each cyclophosphamide dose and given for a total of eight subcutaneous daily doses.
224251318|NCT00003659|BIOLOGICAL|rituximab|Approximately four weeks after the completion of the last cyclophosphamide dose, patients will receive rituximab 375mg/m2 as an intravenous infusion once weekly for four doses.
224251319|NCT00003659|DRUG|cyclophosphamide|Cyclophosphamide 3000mg/m2 will be given intravenously q 2 - 3 weeks x 3 doses.
224251320|NCT00003659|DRUG|fludarabine phosphate|Fludarabine will be administered intravenously at a dose of 25 mg/m2 per day x 5 days every 4 weeks.
224251321|NCT02842632|OTHER|theoretical test|The theoretical test is a multiple choice test which consists of 50 questions with 1 point per question (max. 50 points). It will be done before the teaching, after the 2 teaching sessions and 3 Months after the study
224251322|NCT02842632|OTHER|practical test|The practical test is an evaluation of 11 basic perioperative TEE examination on the simulator (CAE Vimedix Simulator). Each view is evaluated on a scale of 0 to 10 according to predetermined criteria including image angle, overall clarity and visualization of 3 major anatomic structures pertinent to each view. Each view can receive a maximum score of 10 and each study a maximum of 109 (ME asc. aortic LAX has only 2 main structures). It will be done after the first and second teaching session, and 3 Months after the study.
224251323|NCT05990907|PROCEDURE|Remote ischemic preconditioning|The empty tourniquet (VBM Tourniquet Touch®, Sulz a.N. Germany) is attached to the right upper arm. The measurement starts from this point in time. After lying flat for 10 minutes, the upper arm tourniquet is inflated to 250 mmHg. In all subjects, the ischemia was verified by palpation and Doppler signal of the radial artery. The ischemia phase is carried out for 10 minutes, so the tourniquet is opened and a 10-minute reperfusion phase is started, followed by a total of 3 cycles. After the 3rd ischemia phase, the tilting table test is followed by a 15-minute lying interval.
223670554|NCT02727231|DEVICE|CSII with CGM|Subject glucose level controlled by usual insulin pump therapy in conjunction with continuous glucose monitoring (CGM)
223670555|NCT02030431|DEVICE|Dynaloc|
223670556|NCT02030431|DEVICE|Cancellous screws|
224322095|NCT03639779|OTHER|Saline Solution|A volume of 0.1 ml/cm2 of normal saline will be injected into the control lesion.
223670557|NCT03365388|DRUG|Sodium Hyaluronate|Hyaluronic acid is a component of synovial fluid. N- is glucuronic acid and N-acetylglucosamine repeating disaccharide unit form
223670558|NCT03365388|DRUG|Aerzhi|Sodium Hyaluronate Injection can cover and protect joint tissue, improve lubrication function, and penetrate degenerative cartilage
223670559|NCT00189774|DRUG|nateglinide|
223670560|NCT01150344|DRUG|Malarone (atovaquone + proguanil combination)|4 X (250mg atovaquone + 100 mg proguanil) per os, once a day on 3 days as H0, H24 and H48.
224251324|NCT01625715|DRUG|Ketotifen|titrated dose: 1 mg once a day, then 1 mg twice a day then 2 mg twice a day
224251325|NCT03807037|DIETARY_SUPPLEMENT|Tocotrienols|Mixed tocotrienols (derived from palm oil) to be orally administered at 200mg (1 capsule) twice daily, to achieve dosage of 400mg/day
224251326|NCT03807037|DRUG|Placebo oral capsule|Matching placebo to be administered orally at 1 capsule, twice daily
224251327|NCT04022954|DEVICE|Catheter ablation|Inquiry AFocusII Double Loop and Advisor HD Grid, Sensor Enabled
224251328|NCT06133933|DEVICE|Pain Threshold using algometer/dolorimeter|These patients who consent to participation in the study will receive a preoperative pain threshold measured using a pain algometer/dolorimeter. We will rely on the completion of the questionnaires, opioid consumption journal, and surveys to establish a correlation between pre-operative pain threshold and post-operative outcomes.
224251329|NCT05170607|DIAGNOSTIC_TEST|Proteomic analysis by antibody microarrays|Proteomic analysis by antibody microarrays can be used to identify novel biomarkers and to investigate various signaling pathways including protein phosphorylation and protein-protein interactions. Microchips are manufactured as a matrix of a number of immobilized antibodies covalently bound to the glass, membrane, or gel surfaces. Microchips are used for serum proteomic studies in patients with cardiovascular diseases and cancer
224251330|NCT00925860|PROCEDURE|non positive pressure mechanical ventilatory support|
224251331|NCT03515694|DRUG|Sugammadex Injection [Bridion]|Injection of 10mL of translucide solution
224251332|NCT05324098|OTHER|STAND-T platform|Internet-based intervention comprised of evidence-based, patient materials and resources
224251333|NCT05324098|OTHER|Survey Administration|Satisfaction and follow-up surveys will be administered to participants
224251334|NCT05324098|OTHER|Text Messages|Participants will receive periodic text messages
224251335|NCT02237820|DRUG|Dexamethasone|6 mg/day of Oral Dexamethasone
224251336|NCT02237820|DRUG|Prednisone|40 mg/day of Oral Prednisone
224251337|NCT02177422|DRUG|Telmisartan|telmisartan 80 mg once daily
224251338|NCT02177422|DRUG|Hydrochlorothiazide|12.5 mg or 25 mg Hydrochlorothiazide in addition to telmisartan in case that the goal response (mean sitting diastolic blood pressure \< 90 mmHg) is not met after at least 4 weeks of treatment with telmisartan
224251339|NCT04906148|OTHER|Advertisement content (explicit vs. implicit)|Participants will be randomly assigned to view an advertisement with either implicit or explicit harm messaging content
224251340|NCT04906148|OTHER|Advertisement content (true vs. misleading)|Participants will be randomly assigned to view an advertisement with either true or misleading messaging content
224251341|NCT00987740|DEVICE|Hemolung Respiratory Assist System|Patients meeting the inclusion criteria will be placed on the Hemolung Respiratory Assist System. Patients will be weaned from non-invasive ventilation and then the Hemolung. Hemolung support will be provided for up to 7 days. Follow-up exams will be performed every 15 days until hospital discharge or 30 days from completion of Hemolung therapy, whichever is later.
224251342|NCT05221021|DRUG|Vaginal estrogen|0.01% estradiol cream 1/2 gram applied vaginally once nightly for two weeks then three times per week with once daily placebo oral pill
224251343|NCT05221021|DRUG|Mirabegron 50 MG [Myrbetriq]|50mg oral Mirabegron once daily
224251344|NCT05691322|DIAGNOSTIC_TEST|transvaginal ultrasound|Transvaginal ultrasound for endometriosis diagnosis (UBESS)
223670561|NCT01150344|DRUG|RIAMET (artemether + LUMEFANTRIN combination)|4 X (20mg artemether + 120 mg lumefantrine) per os twice a day on 3 days as H0, H8, H24, H36, H48 and H60
223670562|NCT00536211|BEHAVIORAL|Exercise|Exercise training will consist of walking and/or jogging on a treadmill 5 out of 7 d each week at \~60% of each subject's predetermined VO2max (75% maximal heart rate as monitored by heart rate monitors), 45 min/session, for 12 weeks. The exercise training will follow a three-stage progression: 1. wk 1 = 30 min, 3 d/wk, 60% VO2max; 2. wk 2 = 30 min, 5 d/wk, 60% VO2max; and 3. wk 3-12 = 45 min, 5 d/wk, 60% VO2max.
223670563|NCT00536211|DRUG|Metformin|oral tablet, 1000 mg daily for 17 days
223670564|NCT03829800|DIETARY_SUPPLEMENT|Ensure® Abbott Nutrition|Effect of the intake of Ensure® Abbott Nutrition on the glycemic index, insulin, GLP-1, GIP levels and subjective appetite in subjects with type 2 diabetes
223670565|NCT03829800|DIETARY_SUPPLEMENT|Glucerna® Abbott Nutrition|Effect of the intake of Glucerna® Abbott Nutrition on the glycemic index, insulin, GLP-1, GIP levels and subjective appetite in subjects with type 2 diabetes
223670566|NCT03829800|DIETARY_SUPPLEMENT|Diasip® Nutricia Advanced|Effect of the intake of Diasip® Nutricia Advanced on the glycemic index, insulin, GLP-1, GIP levels and subjective appetite in subjects with type 2 diabetes
223670567|NCT03829800|DIETARY_SUPPLEMENT|Glicolab®|Effect of the intake of Glicolab on the glycemic index, insulin and subjective appetite in subjects with type 2 diabetes
223670568|NCT00436501|DRUG|docetaxel|25 mg/m\^2 given intravenously (IV) over 1 hour (+/- 10 minutes) following VEGF Trap every 3 weeks starting cycle 1 (21 day cycles)
224251345|NCT05691322|DIAGNOSTIC_TEST|MRI|MRI for endometriosis diagnosis (Enzian classification)
224251346|NCT03413839|BEHAVIORAL|Physiotherapeutic Scoliosis Specific Exercises (PSSE)|Exercises with emphasis on trunk extensor strengthening, and teaching patient better postural strategies in supine, sidelying, sitting, standing, and dynamic movements (walking, squatting), led by a PSSE-trained physical therapist.
224322096|NCT06328049|DRUG|Trilaciclib Injection|Patients with lung adenocarcinoma were given Trilaciclib combined with pemetrexed and carboplatin, Q3W; For patients with lung squamous cell carcinoma,Trilaciclib combined with paclitaxel/albumin-bound paclitaxel and carboplatin, Q3W. From cycle 2 onwards, patients chose whether to use trasylol with chemotherapy.
224322097|NCT02088697|DRUG|Placebo|
224322098|NCT02088697|DRUG|ASC-01|
224251347|NCT03413839|BEHAVIORAL|Conventional Physical Therapy (PT)|Conventional PT includes generalized pelvis, and trunk strengthening, lower extremity (LE) stretching, and use of modalities (ice and heat), iontophoresis and E-Stim.
224251348|NCT06015984|BEHAVIORAL|Traning|In order to participate in the training module, a user name and password will be given to the initiative group, the link to be used in the self-managed and asynchronous training platform will be shared, and it will be ensured that it participates in the web-based nurse training, and the training will last for eight weeks.
224251349|NCT06559813|BEHAVIORAL|Step-by-step: A cognitive behavioral parent program with role-plays in virtual reality|A parent training program based on social learning theory and cognitive behavioral therapy (CBT), incorporating virtual reality for training in brief role plays. The program includes similar strategies as other common CBT-parent training programs for parents of children with behavior problems, with the difference that virtual reality is used as an additional way to practice skills.
224251350|NCT02714465|OTHER|hyperbaric oxygen therapy|hyperbaric oxygen therapy
223670569|NCT00436501|BIOLOGICAL|ziv-aflibercept|Starting dose 2 mg/kg given IV Cycle 0. Phase I Group: Every 3 weeks beginning with Cycle 0 (Completed 03/14/2008); Phase II Group: Every 3 weeks starting cycle 1 (Opened 05/09/2008).
223670570|NCT00436501|OTHER|laboratory biomarker analysis|Correlative studies
223670571|NCT00436501|OTHER|pharmacological study|Correlative studies
223670572|NCT00692354|DRUG|CHR-2797 (tosedostat)|Drug was given orally, once daily, ensuring a dosing interval of approximately 24 hours. Dose escalations took place starting at 10mg and escalating (per protocol) as follows: 20, 40, 90, 130, 180, 240 and 320 mg
223670573|NCT03131427|DRUG|Standard of care|Standard of care according to the updated national and/or international guidelines
223670574|NCT02874170|OTHER|Spectroscopy magnetic resonance of phosphorus 31|
223670575|NCT06448416|PROCEDURE|UBE|Patients with HDL were treated with UBE
223670576|NCT04363151|OTHER|No intervention.|
223670577|NCT02613273|BEHAVIORAL|Experimental: Arm 1 (Aerobic Exercise)|This periodized program consists of 3 aerobic exercise sessions per week comprised of two high-intensity interval training workouts and 1 continuous vigorous intensity workout.
223670578|NCT02613273|BEHAVIORAL|Experimental: Arm 2 (Resist. Exercise)|This periodized program consisting of 3 resistance exercise sessions per week comprised of high load/low volume, light load/high volume, and moderate load/moderate volume.
223670579|NCT04641338|DRUG|Fixed dose combination Dipyrone and Codeine|Fixed dose combination: dipyrone 1000 mg + codeine 30 mg every 6 hours if necessary.
223670580|NCT04641338|DRUG|Dipyrone|use of 1000 mg dipyrone every 6 hours if necessary.
223670581|NCT04641338|DRUG|Codeine|30 mg codeine every 6 hours if necessary.
223670582|NCT05424783|OTHER|Genomic Prostate Score assay and Multi-parametric magnetic resonance imaging study of the prostate|The Genomic Prostate Score is a 17 gene relative expression assay used to predict the presence of adverse pathologic findings at radical prostatectomy. This test is used to determine appropriateness for active surveillance. Prostate MRI is a prostate imaging test that has been shown to improve the detection of clinically significant prostate cancer using a PI-RADS scoring system. It relies on T2-weighted imaging, diffusion weighted imaging, dynamic contrast enhancement, and apparent diffusion coefficient to differentiate prostate cancer from normal prostate parenchyma and prostatitis.
223670583|NCT06087419|DRUG|chidamide|30mg twice weekly (BIW) for induction phase (cycle1-2,28 days per cycle)
223670584|NCT06087419|DRUG|Venetoclax Oral Tablet|400mg daily d1-14 induction phase (cycle1-2, 28 days per cycle)
223670585|NCT06087419|DRUG|Inotuzumab Ozogamicin|0.6 mg/m2 on day 1 of cycle 1-2(28 days per cycle)
224251351|NCT00209781|DRUG|Sulfadoxine-Pyrimethamine (Fansidar)|
224251352|NCT00209781|DEVICE|ITNs|
224251353|NCT00709254|DRUG|i.v. fentanyl|single dose, 200 ug
224251354|NCT00709254|DRUG|3 mL AeroLEF (500 µg/1 mL)|A single dose of 3mL (500 µg/1 mL) of AeroLEF (Aerosolized Free and Liposome-Encapsulated Fentanyl)
224251355|NCT00709254|DRUG|3 mL AeroLEF (500 µg/1 mL)|A multiple doses of 3mL (500 µg/1 mL)of AeroLEF (Aerosolized Free and Liposome-Encapsulated Fentanyl)every 12 hours for a total of five doses over a 3 days
224251356|NCT00836849|DRUG|Zoloft® 100 mg Tablets|1 x 100 mg, single-dose fed
224251357|NCT00836849|DRUG|Sertraline hydrochloride 100 mg Tablets|1 x 100 mg, single-dose fed
224251358|NCT01585792|DRUG|TAK-875|
223670586|NCT05982951|PROCEDURE|Shoulder PENG block|Ultrasound guided insertion of a needle between subscapularis tendon and deltoid with injection of 10 mi 0.25% bupivacaine after confirming right plane of injection
223670587|NCT02847572|PROCEDURE|Cataract Surgery|All patients wil be having intraocular lens surgery
223670588|NCT04407572|OTHER|Serum zinc, vitamin d vitamin b12 levels .|Serum zinc, vitamin d vitamin b12 levels of 45 patients will be measured and evaluated together with the information of the patients.
223670589|NCT04722055|DIAGNOSTIC_TEST|Multigene Methylation Detection Kit|Eligible participants are required to take stool samples for multigene methylation detection and gene sequencing, undergo colonoscopy examination, and have a biopsy when necessary (gold standard).
223670590|NCT05143710|DIAGNOSTIC_TEST|PRES in PE or E|patients diagnosed with posterior reversible encephalopathy syndrome with preeclampsia or eclampsia
223670591|NCT01444807|DRUG|sorafenib|sorafenib 400 mg bid
223670592|NCT04157673|BEHAVIORAL|Episodic Future Thinking|This intervention involves participants engaging in episodic future thinking in order to improve their medication adherence and overall prospective thinking ability. This intervention will be introduced following a 6-week, 8-week or 10-week baseline period.
223670593|NCT03206164|OTHER|Asynchronous, eLearning Intervention|20 CBOs with 3-member team (n= 30) will be recruited and placed into either the experimental or the comparison group.
223670594|NCT05471583|OTHER|Main group|no intervention; observational only
223670595|NCT05329038|BIOLOGICAL|Inactivated COVID-19 Vaccine|600SU inactivated virus in 0·5 mL of aluminium hydroxide solution per injection
223670596|NCT05053373|DEVICE|Electroacupuncture group|
223670597|NCT05053373|DEVICE|Sham electroacupuncture group|
224251359|NCT01585792|DRUG|TAK-875|
224251360|NCT01585792|DRUG|Glimepiride|
224251361|NCT01585792|DRUG|Placebo|
224251362|NCT02152332|DRUG|JNJ-54861911-Therapeutic Dose|JNJ-54861911 50 mg once daily for 7 days in all treatment sequence.
224251363|NCT02152332|DRUG|JNJ-54861911 - Supratherapeutic Dose|JNJ-54861911 150 mg once daily for 7 days in all treatment sequence.
224251364|NCT02152332|DRUG|JNJ-54861911-Matched Placebo|JNJ-54861911-matched placebo once daily for 7 days in all treatment sequence.
224251365|NCT02152332|DRUG|Moxifloxacin|Moxifloxacin 400 mg on Day 7 in all treatment sequence.
224251366|NCT02152332|DRUG|Moxifloxacin Matched Placebo|Moxifloxacin matched placebo, 400 mg on Day 7 in all treatment sequence.
224251367|NCT03226522|DRUG|AXS-05|AXS-05
224251368|NCT03226522|DRUG|Bupropion|Bupropion
224251369|NCT03226522|DRUG|Placebo|Placebo
224251370|NCT04988464|BEHAVIORAL|Sleep Scholar|A single-session, internet-based insomnia intervention for college students
224251371|NCT04988464|BEHAVIORAL|Building Healthy Habits|A single-session, self-guided, internet-based intervention focused on healthy eating and exercise
224251372|NCT02972047|BEHAVIORAL|Diaphragmatic Breathing|Subjects in this are practice diaphragmatic breathing for 30 minutes after each meal.
224251373|NCT02972047|BEHAVIORAL|Sham Comparator|Sham therapy (listening to music/watching TV for 30 minutes after each meal
224251374|NCT02319980|PROCEDURE|Extracranial-intracranial bypass surgery|All participants in this group will undergo combined cerebral revascularization surgery,namely superficial temporal to middle cerebral artery bypass (STA-MCA) and encephalo-duro-myo-synangiosis(EDMS)
224251375|NCT00068731|DIETARY_SUPPLEMENT|lycopene|
224251376|NCT04729660|DEVICE|Kinesio Tex Gold|The Kinesio Tex Gold is a kinesio tape that had been certified and patented.
224251377|NCT01336660|BIOLOGICAL|Equine F(ab')2 antivenom|A single dose of 4 vials of Equine F(ab')2 antivenom will be administered intravenously over 10 minute
223670598|NCT05053373|BEHAVIORAL|Pelvic floor muscle training|
223670599|NCT05653531|OTHER|Blood sample|Liver blood tests (AST, ALT, PAL, GGT, bilirubin, PT) will be performed before each ICI injection during the first three injections and again at 6 months.
223670600|NCT04796987|DIAGNOSTIC_TEST|Convolutional Neural Network|Convolutional neural networks, a machine learning technique, have been used in several industrial and research fields increasingly. The development of computational units and the increasing amount of data led to the development of new methods on artificial neural networks. Deep learning (DL) is a multi-layered neural network in which feature extraction is done automatically. It extends traditional neural networks by adding more hidden layers to the network architecture between the input and output layers to model more complex and nonlinear relationships.
224251378|NCT01336660|OTHER|Intensive care support plus placebo|Intensive care support as needed plus placebo
224251379|NCT03113786|OTHER|CLARIX™100|CLARIX™100 is Amniox's processed and cryopreserved human amniotic membrane tissue retrieved from donated placental tissue after elective Cesarean Section delivery. Amniox's Amniotic Membrane is designated by the FDA as a tissue product under PHS 361 HCT/P (human cells, tissues and cellular and tissue-based products).
224251380|NCT03113786|OTHER|CLARIX CORD 1K|CLARIX CORD 1K is made from cryopreserved human umbilical cord, utilizing the patented CRYOTEK™ process. CLARIX CORD 1K is considered a Human Cells, Tissues \& Cellular and Tissue-based product (HCT/P) by U.S. FDA standards.
224322099|NCT02368483|OTHER|Neuromuscular training|Neuromuscular training for the hip and lower limb muscles.The training program is divided into 3 phases, and includes specific exercises for improving the hip range of motion, muscle strength of the hip and lower limb muscles, as well as the trunk stability and coordination. The intervention lasts 12 weeks. Patients will train 2 times/week with a physical therapist and 2 times/weeks alone at home.
224322100|NCT00462904|DRUG|BPI|BPI will be give IV with an initial bolus given over 30 minutes and then a continuous infusion for the next 47.5 hours
224322101|NCT04258592|DRUG|(18F)MFBG|One intravenous injection of 4 MBq/kg (adults) One intravenous injection of 2 MBq/kg (minor participants)
223670601|NCT05138471|DEVICE|transcranial direct current stimulation (tDCS)|tDCS intervention will consist in placing two electrodes, the cathode on the supraorbital surface on the same side as the painful knee, and the anode on the parietal area, corresponding to the area of the primary motor cortex, on the opposite side. The intensity will be 2 milli amperes (mA) and stimulation will be 20 minutes. The placebo will generate an initial sensation, and then descend until the stimulation is turned off.
224251381|NCT00984126|DRUG|turoctocog alfa|The preventative treatment is administered intravenously (i.v.) at specific intervals either every second day or three times a week. Bleeding treatment will be administered if a bleed should occur.
224251382|NCT00984126|DRUG|turoctocog alfa|Treatment is administered intravenously (i.v.) during bleeds and occasionally as a preventative treatment (e.g. before physical activity)
224251383|NCT01001208|DRUG|Methotrexate|Methotrexate tablets over-encapsulated for blinding
224251384|NCT01001208|DRUG|Etanercept|1 mL for subcutaneous injection
224251385|NCT01001208|DRUG|Placebo|Matching placebo to methotrexate capsules
224251386|NCT04591405|BIOLOGICAL|Attenuated Mumps vaccine (KMB-17) in phase II and III|≥4.3logCCID50/ml Attenuated Mumps vaccine (KMB-17)\[≥4.3 logCCID50/ml\] in 360 children (5-11 years old) on 0 day
224251387|NCT04591405|BIOLOGICAL|Placebo in phase II|Freeze-dried stabilizer and diluent without mumps virus antigen in 360 children (5-11 years old) on 0 day
224251388|NCT04591405|BIOLOGICAL|Attenuated Mumps vaccine (KMB-17) in phase III|≥4.3logCCID50/ml Attenuated Mumps vaccine (KMB-17)\[≥4.3 logCCID50/ml\] in 5640 children (5-11 years old) on 0 day
224251389|NCT04591405|BIOLOGICAL|Placebo in phase III|Freeze-dried stabilizer and diluent without mumps virus antigen in 5640 children (5-11 years old) on 0 day
224251390|NCT05084066|OTHER|Repeated remote ischemic preconditioning|"An automated device performs four 5-minute episodes of upper limb ischemia in which the cuff pressure in the experimental group remains at 200 mmHg for 5 minutes, causing and ensuring ischemia. Ischemic episodes alternate with 5-minute reperfusion. The intervention lasts a total of 35 minutes. The participant places the device on his upper arm and presses the Start button, starting the intervention. The intervention takes place at rest in the patient's home environment daily for 28 days. During the first visit to the research center, the research assistant teaches the participant how to use the device. The device measures the patient's blood pressure at the start of the intervention. If the patient's blood pressure is above 200 mmHg, the device will not perform the intervention."
223670602|NCT05138471|DEVICE|TENS|TENS intervention will consist in placing two electrodes on the sides of the patella of the affected knee. The frequency will be 10Herzts and the intensity will remain at a sensitive threshold level, without reaching the motor. The placebo will generate a sensation of current to descend to the minimum value that the equipment allows. Stimulation will last for 20 minutes.
224251391|NCT05084066|OTHER|Simulation of repeated remote ischemic preconditioning (sham)|The automated device simulates the intervention of the experimental group with the difference that the device does not apply pressure to the upper limb and, therefore, no ischemia occurs.
224251392|NCT00306462|DRUG|Magnesium sulfate|Intravenous magnesium sulfate 6g bolus, then increased by 1 g/hour till a maximum of 5g/hour; gradually wean down to 2 g/hour for a total of 48 hours once uterine contractions is \< 6/hour.
224251393|NCT00306462|DRUG|Oral Nifedipine or placebo|Oral nifedipine or placebo at 20 mg every 30 minutes for the first hour, then 20 mg every 3 to 6 hours not to exceed 180 mg in 24 hours, keep maintenance dose at 20 mg every 3 to 6 hours for a total of 48 hours if uterine contractions is \< 6/hour.
224251394|NCT05297630|OTHER|Evaluation of the evolution of biological markers from the biobank.|The evolution of sST2, copeptin, chromogranin, NGAL, suPAR and cystatin will be evaluated between Day 0 and Month 1
224251395|NCT02291263|BIOLOGICAL|bOPV/IPV (6 weeks)|bOPV at 6, 10 and 14 weeks of age IPV at 6 weeks of age
224251396|NCT02291263|BIOLOGICAL|bOPV/IPV (14 weeks)|bOPV at 6, 10 and 14 weeks of age IPV at 14 weeks of age
224251397|NCT02291263|BIOLOGICAL|bOPV/IPV (6 & 14 weeks)|bOPV at 6, 10 and 14 weeks of age IPV at 6 and14 weeks of age
224251398|NCT04068441|OTHER|no intervention|No intervention
224251399|NCT04286802|DEVICE|Salt-meter|Salt-meter, developed by Faculty of Engineering at Mahidol University, is a device to measure sodium chloride content in the food and reflects to user with number and symbols for easy-understanding.
224251400|NCT04286802|BEHAVIORAL|Education|Program dietary education by certified dietician who did not know the patients arm allocation.
224251401|NCT05163132|DEVICE|Shearwave elastography|Shear wave elastography is an ultrasound applied technique used to measure tissue stiffness as a result of a disease. So, it can be used to evaluate liver stiffness as a result of liver cirrhosis
224251402|NCT00818545|DRUG|ER4017 (hydroxypropyltetrahydropyrantriol)|Cream, 10%, each day during 3 months
224251403|NCT00818545|DRUG|placebo|
224251404|NCT04550585|OTHER|Education: Session 1 - Basics of type 1 management|"In a group education session, a diabetes educator provides educational session 1 - Basics of type 1 management.~Accompanying educational guide:~How Can I Manage My Type 1 Diabetes Better?"
224251405|NCT04550585|OTHER|Session 2 - Carbohydrate counting|"In a group education session, a diabetes educator provides educational session 2 - Carbohydrate counting~Accompanying educational guide:~How Can I Manage My Type 1 Diabetes Better?"
224251406|NCT04550585|OTHER|Education: Session 3 - Insulin self- adjustment|"In a group education session, a diabetes educator provides educational session 3 - Insulin self- adjustment~Accompanying educational guide:~How Can I Manage My Type 1 Diabetes Better?"
224251407|NCT04550585|OTHER|Education: Session 4 - Sick day rules and physical activity dose adjustments|"In a group education session, a diabetes educator provides educational session 4 - Sick day rules and physical activity dose adjustments~Accompanying educational guide:~How Can I Manage My Type 1 Diabetes Better?"
224251408|NCT04550585|OTHER|Education: Session 5 - Starting the insulin pen (for pen users) or pump (for pump users)|"In a group education session, a diabetes educator provides educational session 5 - Starting the insulin pen (for pen users) or pump (for pump users)~Accompanying educational guide:~Is the Insulin Pump Right for Me? How Do I Use an Insulin Pump? Is the Insulin Pen Right for Me?"
224251409|NCT04550585|OTHER|Education: Session 6 - Trouble shooting the pump (for pump users)|"In a group education session, a diabetes educator provides educational session 6 - Trouble shooting the pump (for pump users)~Accompanying educational guide:~Is the Insulin Pump Right for Me? How Do I Use an Insulin Pump?"
224251410|NCT01463761|DEVICE|ANS activity|This ANS activity is measured by nocturnal heart rates records with Holter ECG.
224251411|NCT01518439|DEVICE|Alpha 200®|inspiratory capacity is increased with the use of constant pressure device: Alpha 200®
224251412|NCT01518439|DEVICE|Alpha 200® + physiotherapist|inspiratory capacity is increased with the use of constant pressure device (Alpha 200®) combined with the manual pressures techniques to increase cough by the physiotherapist
224251413|NCT01518439|DEVICE|Cough Assist®|increased inspiratory capacity and mechanical exsufflation with the use of insufflation-exsufflation device (Cough Assist®)
224251414|NCT01518439|DEVICE|Cough Assist® + physiotherapist|increased inspiratory capacity and mechanical exsufflation with the use of insufflation-exsufflation device (Cough Assist®) combined with the manual pressures techniques to increase cough by the physiotherapist
223670603|NCT05138471|BEHAVIORAL|Exercise and General Education|The General Education Intervention consisting in an educational program will be applied to all groups using audiovisual material to increase the subject's knowledge about his/her pathology, about chronic pain and recommendations for supervised exercise based on the NEMEX protocol for osteoarthritis (Ageberg et al.)18: the participants will be taught analytical strengthening exercises (quadriceps and hamstrings) and neuromuscular functional exercises (getting up from the chair or going up a step), with their detailed dosage (2 to 3 series with 10 to 15 repetitions) and a home follow-up model where the participant must record compliance with exercise as well as pain during activity.
224251415|NCT01518439|OTHER|physiotherapist|manual pressures techniques to increase cough applied by the physiotherapist
224251416|NCT04593134|BEHAVIORAL|exercise group|"exercise education: A 12-week regimen of homebased walking exercises, include moderate intensity for 40 min, three times a week.~We explained the participants how to perform the exercises, according to an instruction manual for the exercise regimen. Participants were instructed that the exercises would be effective only if they reached 40%-60% of the heart rate reserve, as determined by the Karvonen method, or 13-14 on the RPE.~Exercise education:~Weekly telephone or mobile application LINE consultations concerning exercise.we discussed whether participants' exercise fulfilled the prescribed intensity, duration, frequency and whether the participants experienced any adverse effects."
224251417|NCT01864174|DRUG|Metformin XR|
224251418|NCT01864174|DRUG|Metformin IR|
224251419|NCT01864174|DRUG|Placebo matching with Metformin XR|
224251420|NCT01864174|DRUG|Placebo matching with Metformin IR|
224251421|NCT05585866|DRUG|Anesthesia Agent|The two anesthetic modalities included intravenous propofol anesthesia and sevoflurane gas anesthesia administered according to standard clinical praxis.
224251422|NCT03335761|DEVICE|InterStim Therapy|Device Programming
224251423|NCT03546842|BIOLOGICAL|9vHPV vaccine|9-valent HPV \[Types 6, 11, 16, 18, 31, 33, 45, 52, and 58\] L1 virus-like particle vaccine in a 0.5-mL intramuscular injection
224251424|NCT01639222|DRUG|Calcium 500 mg and Vitamin D3 800 IU|Calcium 500 mg and Vitamin D3 800 IU chewable tablets
224251425|NCT01639222|OTHER|Low calcium meals|A normal Western European diet with reduced calcium content (400 mg per day).
224251426|NCT04772105|DRUG|2.5mg of BAT5906|Specification: 2.5mg of BAT5906
224251427|NCT04772105|DRUG|4.0mg of BAT5906|Specification: 4.0mg of BAT5906
224251428|NCT03555747|OTHER|Canine distalization|GCF was sampled from the mesial (tension) and distal (pressure) sides of maxillary right and left canines immediately before appliance placement (baseline) and after force application (24 hours and 28 days)
224251429|NCT00214097|RADIATION|Radiotherapy|Daily radiation to prescribed dose
224251430|NCT01723397|DRUG|Nasaleze Spray|Subjects are treated with over the counter Nasaleze cellulose powder nasal spray then challenged with allergen
224251431|NCT01723397|OTHER|Placebo spray|Subjects are treated with placebo nasal spray then challenged with allergen
224251432|NCT01723397|BIOLOGICAL|Allergen|Subjects are challenged with grass or ragweed allergen after treatment with Nasaleze or placebo
223670604|NCT02101697|BEHAVIORAL|HIV Stigma Reduction Intervention|"The HIV stigma reduction intervention consists of two computer-administered sessions and one group session.~Session 1. (approx. 60 min). Introduction of the concepts of stigma and discrimination, vulnerable populations and symbolic stigma delivered in an interactive tablet format, using games and videos.~Session 2. (approx. 60 min). Interactive activities to address HIV transmission myths and misconceptions and the importance of universal precautions.~Session 3. (approx 90 min). Patient interaction skills. In person interactive group session co-facilitated by PLHIV and staff focusing on skills building through role-plays and feedback.~Our previous research has found that these modules address factors identified as contributing to health professionals' stigma."
223670605|NCT00878436|DRUG|Panobinostat|
224251433|NCT01884519|BIOLOGICAL|Fluarix/Influsplit SSW® (2013-2014 season)|1 dose administered intramuscularly (or deeply subcutaneously) in the deltoid region of the non-dominant arm
224251434|NCT01268709|DRUG|Doxepin|
224251435|NCT01268709|DRUG|Nortriptyline|
224251436|NCT01268709|DRUG|placebo|
224251437|NCT04977245|OTHER|Mindfulness-Based Stress Reduction|Eight MBSR sessions of 1.5 hours per week
224251438|NCT04977245|OTHER|Self-Guided Mindfulness eCourse|Six weeks of a mindfulness ecourse, and two weeks of coping skills training led by a licensed neuropsychologist
224251439|NCT02078986|OTHER|Whole Body Electromyostimulation|Supervised WB-EMS, 3 sessions in 2 weeks (1,5 sessions/week) for 14 weeks
224251440|NCT02078986|OTHER|High Intensity Resistance Exercise Training|Supervised High Intensity Resistance Exercise Training (HIT) 2-3 sessions/week for 14 weeks
223670606|NCT00878436|DRUG|Bicalutamide|
224251441|NCT00468286|DRUG|Degarelix|"Experimental~Initial dose of 240 mg SC (by injection under the skin) on day 0. Maintenance dose of 360 mg SC (by injection under the skin) given after 1, 4, 7, \& 10 months."
224251442|NCT00468286|DRUG|Degarelix|"Experimental~Initial dose of 240 mg SC (by injection under the skin) on day 0. Maintenance dose of 480 mg SC (by injection under the skin) given after 1, 4, 7, \& 10 months."
224251443|NCT00133822|DRUG|Sertraline and Risperidone|
224251444|NCT03719898|DRUG|Brigatinib|Brigatininb is administered in tablet form. It is to be taken until disease progression, unacceptable toxicity or completion of 24 cycles. patients may continue to take brigatininb beyond 24 cycles if they are benefiting from the drug
224251445|NCT03783793|BEHAVIORAL|Mindfulness Training App|Mindfulness training in the study was performed using a new app called Wildflowers. With this app participants were able to choose and complete a variety of guided meditations over the 3 week training period. Wildflowers includes guided meditations such as breathing, body scans, and open monitoring practices and also provides didactic content in the form of lessons and information about the benefits of mindfulness training.
223670607|NCT04130737|DEVICE|TORUS Stent Graft System|The TORUS Stent Graft is an intravascular prosthesis intended to improve blood flow in the area in which it is implanted and the TORUS Stent Graft Delivery System is a standard pin-and-pull delivery system used to implant the SG in the desired area. Use of the TORUS Stent Graft allows for improving blood flow in the peripheral vasculature.
223670608|NCT03725423|DRUG|Apatinib|250mg, qd once a day, take it half an hour after meal (the time for taking the medicine should be the same as possible), and take it with warm water. 28 days is a drug delivery cycle.
223670609|NCT00535574|DRUG|Bexarotene (Targretin LGD1069)|75 mg per day for 6 weeks
224251446|NCT03783793|BEHAVIORAL|Cognitive Training With 2048|The training app for the control condition was based on an open source code for a popular cognitive training app called 2048 that is marketed as a fun and relaxing puzzle game. Within 2048, participants slide numbered tiles around a grid, matching tiles of the same value. Instead of tiles disappearing, as in Candy Crush or other similar grid-sliding games, matching 2 numbered tiles in 2048 combines them into 1 new tile displaying the sum of the previous 2 numbers. For example, two 2-tiles linked side-by-side become a 4-tile, whereas 2 matched 4-tiles become an 8-tile, and so on. The goal is to match tiles until the sum of 2048 is reached on a single tile. There is no time limit.
224251447|NCT03749512|DIAGNOSTIC_TEST|Complete blood count|During routine preoperative blood test complete blood count is taken.
224251448|NCT03749512|OTHER|Histopathological examination|Routine postoperative histopathological examination of lung tumor.
224251449|NCT05333159|DRUG|SGLT2 inhibitor|dapagliflozin 10mg once daily dose canagliflozin100mg once daily dose empagliflozin 0mg once daily dose
224251450|NCT00798954|DEVICE|Sirolimus-eluting coronary stent (Cypher)|Drug eluting stents: Comparison Sirolimus with Paclitaxel eluting stents for treatment of coronary bifurcation lesions.
224251451|NCT00798954|DEVICE|Paclitaxel-eluting stent (TAXUS)|Drug eluting stents: Comparison Sirolimus with Paclitaxel eluting stents for treatment of coronary bifurcation lesions.
224251452|NCT02158663|DEVICE|Repetitive Transcranial Magnetic Stimulation|TMS Device
224251453|NCT01794715|PROCEDURE|Ultrasound examination by nurses|Ultrasound examination performed by nurses. Focused examination of the pleural space and inferior vena cava.
224251454|NCT04887766|DEVICE|GS300|Gelesis300 hydrogel in gelatin capsules
224251455|NCT04887766|DEVICE|Placebo|Placebo capsules
224251456|NCT01769183|DRUG|Squalamine Lactate ophthalmic solution 0.2%|Patients will start with Squalamine one drop twice daily to the affected eye. If at one week the neovascularization shows no sign of regression, then the dose will be doubled to four times daily with a follow up at one day and one week following the increased dose frequency, then resuming the schedule at four weeks. If neovascularization returns within the study, the dose will be doubled to four times daily. In that case, a one day and one week visit will be added after increasing the dose. Squalamine treatment will discontinue after the week 20 visit.
224251457|NCT00770718|DRUG|Recombinant Activated Factor VII (rFVIIa)|Five patients who meet the selection criteria will be administered an intravenous dose of rFVIIa 1mg upon arrival. INR will be drawn at 20 minutes post-rFVIIa administration. If normalized (≤1.3), then repeat INR with be drawn every 2 hours thereafter for 6 hours total, and again at 24 hours after initial administration. If at any time, the INR is \>1.3, then rFVIIa 1mg will be readministered and the INR will again be checked 20 minutes after administration and every 2 hours for 6 hours total and again at 24 hours post-administration. This may be repeated until a total dose of 80mcg/kg has been given.
224251458|NCT00770718|DRUG|Prothrombin Complex Concentrate|5 patients will receive PCC based on ideal body weight. Each patient will receive 30 i.u./kg ideal body weight as is rounded to the nearest dispensed vial size. Vials are dispensed as 5mL (500 i.u.), 10mL (1000 i.u.), or 10mL (1500i.u.). INR will be drawn at 20 minutes post-administration and, if normalized (≤1.3), 2 hours post-administration and every 2 hours for 6 hours total. The INR will also be checked 24 hours post-administration. If at any time, the INR is \>1.3, then PCC will be readministered at the same dose and the INR will again be checked 20 minutes after administration and every 2 hours for 6 hours total and again at 24 hours post-administration. A maximum total of 60 iu/kg can be administered.
224251459|NCT00770718|BIOLOGICAL|Fresh Frozen Plasma|Five patients will receive transfusions of FFP to normalize INR. If the initial INR is between 2-4, then 2 units of FFP (Round 1) will be administered emergently. If the initial INR is \>4, then 4 units of FFP will be administered (Round 1). The INR will be checked after each round of FFP infusion completed. Once INR ≤1.3, then the INR will be again checked every 2 hours after normalization for 6 hours total and then 24 hours post-initial infusion. If the INR should ever return to \>1.3, then repeat infusions of FFP will begin as outlined above and the INR will be checked serially as defined above.
224251460|NCT02813018|PROCEDURE|0.2 ml/kg of 0.2% ropivacaine|In the preemptive group, 5 minutes before skin incision, the epidural catheter is dosed with 0.2 ml/kg of 0.2% ropivacaine, followed by continuous infusion of 5 minutes before skin incision at 0.2 ml/kg/h.
224251461|NCT02813018|PROCEDURE|0.2mg/kg of Normal Saline|In the saline group, 5 minutes before skin incision, the epidural catheter is dosed with 0.2 ml/kg of normal saline, followed by continuous infusion of 5 minutes before skin incision at 0.2 ml/kg/h.
224251462|NCT01184183|PROCEDURE|Comparing Accuseal Vs. Bovine Pericardial in CEA|"Accuseal patch - The Goretex Company has since designed a new patch, the Accuseal, which is marketed as decreasing the intra-operative time (i.e, having a short hemostasis time) without affecting the perioperative stroke rate.~Bovine Pericardial patch - The Bovine Pericardial patch has been used for nearly two decades, since the late 1990s. However, studies based on retrospective review of data in which patients received the Bovine Pericardial patch, reported the clinical outcomes post-operative stroke, death, time to hemostasis and recurrent restenosis."
224251463|NCT05757765|OTHER|deprescribing pharmacotherapy approach (DPA)|A new way of medication review in patients with sarcopenia. This method is based on previous scientific research and is aimed at minimizing pharmacotherapy. The aim is to combat symptoms and complaints and to stop (preventive) medication as much as possible
224251464|NCT05757765|OTHER|STOPP-START deprescribing approach (SSA)|The usual care in the geriatric medicine in the Netherlands consisting of a medication review based on the STOPP-START criteria. These criteria have been combined in a protocol that describes when certain medication(groups) must be continued or discontinued for specific patient characteristics.
224251465|NCT00251030|DRUG|Nelfinavir and Omeprazole|
224251466|NCT03225456|DRUG|Syntocinon|Intra-nasal oxytocin
224251467|NCT03225456|DRUG|Placebos|Intra-nasal placebo
224251468|NCT03892863|DEVICE|active repetitive transcranial magnetic stimulation|High frequency rTMS to induce the long term potentiation in the left dorsolateral prefrontal cortex
224251469|NCT03892863|DEVICE|sham repetitive transcranial magnetic stimulation|High frequency rTMS to induce the long term potentiation in the left dorsolateral prefrontal cortex
224251470|NCT00007852|BIOLOGICAL|rituximab|Rituximab at 375 mg/m2 administered approximately one week apart prior to collection of the hematopoietic stem cells. Rituxan at a dose of 375 mg/m2 IV will be given either on the days prior to initiation of the BCNU (days -10 to -7) or on the same day that the BCNU is administered for the BEAM chemotherapy regimen (Day -6). A fourth infusion of Rituxan 375 mg/m2 will be given at 30 day (+/- 20 days) post-transplant. At approximately 6 months post-transplant, if the patients have not had progressive lymphoma, they will receive four weekly doses of Rituxan 375 mg/m2 IV.
224251471|NCT00007852|DRUG|carmustine|BCNU 300 mg/M2 IV day -6
224251472|NCT00007852|DRUG|cytarabine|100 mg/m2 on days -5 through -2
224251473|NCT00007852|DRUG|etoposide|100mg/M2 BID on days -5 through -2
224251474|NCT00007852|DRUG|melphalan|140 mg/m2 IV on day -1
224251475|NCT00007852|PROCEDURE|autologous hematopoietic stem cell transplantation|Following the chemotherapy, on day 0 of treatment, the previously stored hematopoietic stem cells will be reinfused via the central venous line
224251476|NCT03216577|OTHER|Phone interview measuring health-related quality of life variables|A phone interview will be conducted by a dedicated nurse who will be blinded to the exposed/non-exposed status of the patient.
224251477|NCT04937101|DRUG|Chlorpheniramine-Codeine|When the filter tester is sensitive, he opened the random letter group envelope to the notification letter manager and jointly confirmed the classification of the message group. The test group used the chlorpheniramine beacon, the physiological surface was used, and the local lesions of fine particles were used in the focus. Injection therapy. No form of anesthesia is used during injection. A total of injection treatment, at intervals, each treatment and the last treatment, treatment and safety after 1 month.
224251478|NCT04309981|BIOLOGICAL|Adult differentiated autologous T-cells with anti-BCMA specificity|After pretreatment, adult differentiated autologous T-cells with a chimeric antigen receptor with anti-BCMA specificity will be transfused.
224251479|NCT00537979|DRUG|Paricalcitol injection|Most recent iPTH level in pg/mL divided by 100 = dose in mcg; dose is rounded down to nearest mcg and administered 3x weekly
224251480|NCT00537979|DRUG|Paricalcitol capsules|Most recent iPTH level in pg/mL divided by 80 = dose in mcg; dose is rounded down to nearest mcg and administered 3x weekly
224251481|NCT05082779|DRUG|CS0159|Tablets administered orally
224251482|NCT04308850|DRUG|Vitamin D drops|Vitamin D-deficient CD patients are divided into two groups, one group is given orally with Vitamin D drops 400IU / d, while the other group do not interfere.
224251483|NCT03525522|DEVICE|Nd:YAG Laser|Three sessions of Nd:YAG treatment every two weeks.
224251484|NCT03525522|DRUG|Topical corticosteroid Diprosone|3 months of topical corticosteroids Diprosone
223670610|NCT00535574|DRUG|bexarotene|75 mg/day 6 weeks
223670611|NCT02884700|BIOLOGICAL|Real-time PCR testing of lower respiratory tract samples|qPCR and high-throughput DNA sequencing testing of lower respiratory tract samples collected routinely in patients with severe legionellosis
223670612|NCT06371820|OTHER|ESPRESSO [The study has no intervention]|This study has no interventions.
223670613|NCT05793229|OTHER|observation|observation
223670614|NCT05503667|DRUG|Furmonertinib|Furmonertinib 80 mg/day for 16 weeks
223670615|NCT05503667|DRUG|Bevacizumab|bevacizumab 400 mg/4 weeks i.v. for 4 times
223670616|NCT00168987|DRUG|oral nutritional supplement rich in eicosapentanoic acid|
223670617|NCT06051708|OTHER|standard AKI care bundle|AKI care bundle include use of iv fluids, diuretics, antihyperkalemic drugs, sodium bicarbonate, antibiotics in septic patients.
223670618|NCT06051708|OTHER|standard care for hospitalized patients|this includes iv fluids, diuretics, antibiotics in septic patients, other measures according to original disease
223670619|NCT02133443|DEVICE|PSV - pressure support ventilation|Gold standard partial ventilator support: Pressure Support Ventilation performed with Servo-i® ventilator (MAQUET,Critical Care, Sweden). Pressure support ventilator assistance to obtain a tidal volume of 6-8 ml/kg of ideal body weight.
223670620|NCT02133443|DEVICE|Neurally Adjusted Ventilatory Assist|"Partial ventilator support partial ventilation mode (NAVA) performed with Servo-i® ventilator (Maquet,Critical Care, Sweden). Different levels of neurally adjusted ventilatory assist are tested. Stepwise implementation of the NAVA level (steps of 25% ), returning to the  optimal  level between each evaluation (PSV 100%, NAVA 100%, 75%, 50%, 125%, 150%)."
223670621|NCT03314246|OTHER|FAST|Fasting Algorithm for Singaporeans with Type 2 Diabetes
223670622|NCT03314246|OTHER|Standard of care|Standard of care
223670623|NCT00716950|DRUG|valsartan/amlodpine|tablets; 160mg/5mg; od; 4 weeks
223670624|NCT00716950|DRUG|losartan/amlodpine|tablets; 100mg/5mg; od; 4 weeks
223670625|NCT01419821|DRUG|Vitamin D|800IU (4gtt/d) once a day for 2 years once a day.
223670626|NCT01419821|OTHER|Placebo (for Vitamin D)|4gtt/d for the placebo for two years.
223670627|NCT01706900|OTHER|Incubator Temp set to 36.5 degree|We will set incubator Temp to 36.5 so we can assess the outcome and compare the results with the placebo group.
223670628|NCT01706900|OTHER|Incubator Temp 37 degree|We will set incubator Temp to 37 degree as the routine embryo culture Temp since 1978 as the placebo arm.
223670629|NCT05711303|DIETARY_SUPPLEMENT|Superba Boost|To assess changes in Trans-epidermal water loss (TEWL), measured at baseline and after 12 weeks of intervention using a TEWAMetre.
223670630|NCT00174772|DRUG|docetaxel and cisplatin followed by concurrent chemoradiotherapy with docetaxel and cisplatin + radiotherapy|docetaxel (75mg/m2, IV, Day 1) and cisplatin (40 mg/m2, IV, Day 1, 2) every 3 weeks for 2 cycles, followed by concurrent chemoradiotherapy with docetaxel (20 mg/m2, IV) and cisplatin (20 mg/m2) weekly for 6 weeks + radiotherapy 2 Gy/day, 5 days per week to a total dose of 66 Gy
223670631|NCT00174772|DRUG|docetaxel and cisplatin + radiotherapy followed by docetaxel and cisplatin|docetaxel (20mg/m2, IV) and cisplatin (20 mg/m2) weekly for 6 weeks + radiotherapy 2 Gy/day, 5 days per week to a total dose of 66 Gy followed by docetaxel and cisplatin (40 mg/m2, IV, Day 1, 2) every 3 weeks for 2 cycles.
223670632|NCT00409305|DRUG|Betahistine|
223670633|NCT00409305|BEHAVIORAL|Dietary counseling|
223670634|NCT02557477|DIETARY_SUPPLEMENT|Omega 3/6 fatty acids|Three Omega 3/6 capsules twice daily
223670635|NCT02557477|DIETARY_SUPPLEMENT|Placebo|Three placebo capsules twice daily
223670636|NCT04516837|DRUG|Eltrombopag|Eltrombopag 25-75 mg oral daily according to platelet response.
223670637|NCT04516837|DRUG|rhTPO|Rh-TPO 300U/kg subcutaneous injection once daily for 7 consecutive days, followed by a tapering dose in maintenance therapy.
223670638|NCT05918081|OTHER|Multi-Stage 20 m Shuttle Run Test|"The aerobic capacities of the participants will be evaluated with the Multi-Stage 20 m Shuttle Run Test, their agility levels with the Pro Agility Test, their core muscle endurance with the McGill Trunk Extensor and Flexor Endurance test and their peripheral muscle strength with the MicroFET® 2 handheld dynamometer."
223670639|NCT02375789|DEVICE|Active RhinoChill|"The device is intended for use for the reduction of temperature via the nasal cavity.~The RhinoChill® System is a British Standards Institution Kite-Marked device that is currently commercially available in Europe. The RhinoChill® device is intended for temperature reduction in patients via the nasal cavity."
223670640|NCT02375789|DEVICE|Placebo RhinoChill|The placebo RhinoChill device looks and functions in an identical way to the active RhinoChill. All components are used, however through some minor changes in the design of the device it now provides a sufficient placebo treatment to the patient.
224251485|NCT00498381|DEVICE|CPAP|
224251486|NCT00741858|PROCEDURE|Duragen duraplasty|Posterior cranial fossa repair and enlargement with application of dural patch (Duragen)
224251487|NCT00741858|PROCEDURE|Duraguard duraplasty|Posterior cranial fossa repair and enlargement with application of dural patch (Duraguard)
224251488|NCT02603055|BIOLOGICAL|30μg/0.5ml Hepatitis E vaccine|three doses, 30μg/0.5ml per dose
224251489|NCT02603055|BIOLOGICAL|30μg/0.5ml Recombinant Hepatitis E vaccine|30μg/0.5ml Hepatitis E vaccine developed by Xiamen innovax biotech Co.,Ltd.,three doses, 30μg/0.5ml per dose
224251490|NCT01852747|PROCEDURE|Multilevel Spinal fusion with Actifuse ABX®|Multilevel spinal fusion as treatment for adult spinal deformity with Actifuse ABX®. Actifuse ABX® is a silicate substituted calcium phosphate bone void filler intended for orthopedic applications such as a filler for gaps and voids that are not intrinsic to the stability of the bony structure.
224251491|NCT02009163|DRUG|Lisdexamfetamine dimesylate|SDP489 30, 50, or 70mg capsule once per day (open-label and double-blind periods)
224251492|NCT02009163|OTHER|Placebo|Placebo capsule once per day (double-blind period)
224251493|NCT03117296|OTHER|Post procedure daily PT and OT|PT evaluation and treatment on post procedure day zero: Nurses mobility patient using egress testing one time
224251494|NCT03117296|OTHER|PT post procedure|post procedure day one: PT and OT assessment, education and intervention.
224251495|NCT03117296|OTHER|OT post procedure|PT and OT Daily until goals met or patient discharge.
224251496|NCT03117296|OTHER|Routine PT or OT|Routine PT or OT consulted by physician when identified discharge disposition of home
224251497|NCT03384602|OTHER|Dalcroze Eurhythmics Program|music-based multi-task exercise in group setting
224251498|NCT03384602|OTHER|home exercise strength program|simple strength exercise program to perform individually at home
224251499|NCT00652288|DRUG|Insulin analogs (Lispro and Aspart)|Insulin bolus given through insulin pump
224251500|NCT00652288|DRUG|Insulin analogs (Aspart and Detemir)|Drugs given separately
224251501|NCT00652288|DRUG|Insulin analogs (Aspart and Detemir)|Drugs given in the same injection
223670641|NCT03070743|PROCEDURE|Posterior Approach Compression Distraction Reduction Surgery|Posterior Approach Compression Distraction Reduction Surgery is performed.All of patients received this procedure routinely in the department of neurosurgery at Xuanwu Hospital.
223670642|NCT06401629|DIAGNOSTIC_TEST|NPRP criteria|Under the NPRP criterion, the plasma glucose level at each time point (TP1, TP2, and TP3) is multiplied by its weight (Doi et al. 2022), and the sum of these products yields the unified Doi's Weighted Average Glucose (dwAG) value for each woman. The dwAG is then categorized into four groups: a dwAG of 6.8 or lower, \>6.8 to ≤7.5, \>7.5 to ≤8.6, and above 8.6 mmol/L, indicating normal gestational glycemia (NGG), impaired gestational glycemia (IGG), gestational diabetes mellitus (GDM), and high-risk gestational diabetes mellitus (hGDM), respectively (Doi et al. 2022).
223670643|NCT06401629|DIAGNOSTIC_TEST|IADPSG criteria|The IADPSG criteria define GDM as any one of the three-time points above specific thresholds: the time point prior to glucose ingestion (TP1) is considered abnormal when the fasting plasma glucose (FPG) value is ≥ 5.1 mmol/L, the 1-hour time-point after glucose ingestion (TP2) is considered abnormal when the value is ≥ 10 mmol/L, and the 2-hour time-point after glucose ingestion (TP3) is considered abnormal when the Post-Load Plasma Glucose levels are ≥ 8.5 mmol/L (Metzger et al. 2010). Put simply, meeting any one of these cut-offs results in a GDM diagnosis, regardless of whether the other time points show normal values or not (Metzger et al. 2010).
223670644|NCT00217464|DRUG|fulvestrant|intramuscularly
223670645|NCT04046588|DIAGNOSTIC_TEST|Infrared thermography|A thermal imager (NEC InfRec R450, Avio Infrared Technologies Co., Ltd., Tokyo) will be used to record thermal images. The temperature of corresponding sites on the Heart and Lung meridians will be analyzed.
223670646|NCT04046588|PROCEDURE|Moxibustion|"Two sessions of moxibustion intervention will be performed in the Heart meridian and Lung meridian, respectivey. During moxibustion, the temperature change of relevant sites in the Heart and Lung meridians will be measured by infrared thermal imaging.~1. Intervention in the Heart meridian: moxibustion will be performed above the acupoint HT3 of the Heart meridian~2. Intervention in the Lung meridian: moxibustion will be performed above the acupoint LU5 of the Lung meridian."
223670647|NCT01089361|DRUG|Ketamine|The treatment group will receive 0.25mg/kg of ketamine over a period of one hour followed by a continuous infusion of ketamine at 0.1 mg/kg/hr for a further 23 hours.
223670648|NCT01089361|DRUG|Normal Saline placebo|The control group will receive 0.25mg/kg of normal saline over a period of one hour followed by a continuous infusion of normal saline at 0.1 mg/kg/hr for a further 23 hours.
223670649|NCT03993093|OTHER|CD4 cell count|CD4 cell count from treatment naive HIV patients
223670650|NCT01576159|OTHER|Running exercise|During this type of exercise intervention, subjects performed weight-bearing exercise. This group participated in sessions of 40-min per day, three days per week, for a period of 12 weeks
224251502|NCT00652288|DRUG|Insulin analogs (Lispro and Glargine)|Drugs given separately
224251503|NCT00652288|DRUG|Insulin analogs (Lispro and Glargine)|Drugs given in single injection
224251504|NCT00725803|DRUG|GS-9450|GS-9450 capsules administered orally once daily
224251505|NCT00725803|DRUG|GS-9450 Placebo|Placebo to match GS-9450 administered orally once daily
224251506|NCT02453386|DRUG|tozadenant|
224251507|NCT02453386|DRUG|placebo|
224251508|NCT01817985|DRUG|GS-5816|
224251509|NCT01517854|DRUG|Sildenafil|20 mg Revatio (sildenafil citrate) three times a day
224251510|NCT01517854|DRUG|Placebo|Placebo identical to Revatio (sildenafil citrate) three times a day
224251511|NCT00833586|DRUG|Terbinafine HCl 250mg tablets|1 x 250 mg
224251512|NCT00833586|DRUG|Lamisil® 250 mg Tablets|1 x 250 mg
224251513|NCT04567082|DIAGNOSTIC_TEST|Examination of saliva|Collection of saliva samples
224251514|NCT03932058|DRUG|Chemotherapy|all osteosarcoma patients will give regular chemotherapy for osteosarcoma, the protocol is the same as Methotrexate+Doxorubicin+Cisplatin.
224251515|NCT06253403|BEHAVIORAL|psychotherapy|psychotherapy related to sexual intervention
224251516|NCT04306068|OTHER|Plyometric protocol|"Each session will last 20 minutes, with 2 sessions a week, over a period of 5 weeks. The intervention will last 20 minutes, which consists of a 4-station circuit.~Exercise 1: jump on the rope, with your feet together at a moderate pace. Exercise 2: In standing with hands on the hip and hip flexion (one foot in front). Knee flexion and dorsal ankle flexion, with straight trunk. Alternate legs.~Exercise 3: box jump (jump on the box with both feet at the same time). Exercise 4: depth jumps from box to antoher box (jump on the box with both feet at the same time and when falling, immediately jump to the other box).~1 minute with 30 seconds between sets."
224251517|NCT02137330|DEVICE|Swallowable Obalon® Gastric Balloon|
224251518|NCT01393054|DRUG|Nigella sativa|Drug name: Nigella sativa seed extract in capsule Dosage 300 mg Frequency: twice daily Duration: 4 weeks
224251519|NCT03069586|PROCEDURE|Pulmonary recruitment|At the end of surgery a manual pulmonary recruitment (5 sec, max 40 cmH2O) is given to the patiënt
224251520|NCT03069586|PROCEDURE|No pulmonary recruitment|At the end of surgery no intervention was completed
224251521|NCT01093963|DRUG|Lisdexamfetamine|oral; 20-70mg/day
224251522|NCT01093963|DRUG|Placebo|oral; 20-70mg/day
224251523|NCT01446445|DRUG|Ganciclovir/ Valganciclovir according to SPC|Doses according to Summaries of Product Characteristics (SPC)
224251524|NCT01446445|DRUG|Ganciclovir/ Valganciclovir according to PK model|Doses according to population pharmacokinetic model
223670651|NCT01576159|OTHER|Cycling exercise|During this type of exercise intervention, subjects performed a partial weight-bearing exercise. This group participated in sessions of 40-min per day, three days per week, for a period of 12 weeks
223670652|NCT01576159|OTHER|Swimming Exercise|During this type of exercise intervention, subjects performed a non-weight bearing exercise. This group participated in sessions of 40-min per day, three days per week, for a period of 12 weeks
223670653|NCT00256477|BEHAVIORAL|Sudarshan KRIYA Breathing Technique|
223670654|NCT00169442|BIOLOGICAL|Tritanrix™-HepB/Hiberix™ Kft.|GlaxoSmithKline (GSK) Biologicals Korlatolt Felelossegu Tarsasag \[Kft\] (Limited Company) combined diphtheria (D), tetanus (T), whole cell Bordetella pertussis (Pw), hepatitis B vaccine with new sources of D, T and Pw antigens mixed with Haemophilus influenzae type b (Hib2.5) vaccine.
223670655|NCT00169442|BIOLOGICAL|Tritanrix™-HepB/Hiberix™|GSK Biologicals' combined diphtheria, tetanus, whole cell Bordetella pertussis, hepatitis B and Haemophilus Influenzae type b vaccine
223771591|NCT04555746|BEHAVIORAL|Physical activity|Four PA experts (researchers (PhD) within the field of PA and health in children, and physical education teachers) in collaboration with two members of the ECEC staff and two members of the municipality health department (paediatric physiotherapists) developed a frame for the intervention based on COP elements to be further developed, concretized and implemented by the staff. The intervention lasted for four months and contained the following components (Table 1): pre-meetings and follow up meetings in each ECEC institution; start up seminar and two follow up courses with all the staff members; ongoing planning and collective reflections practice in the ECEC institutions; Facebook group; and an equipment-package.
223771592|NCT02690285|DRUG|Dichloroacetate (DCA)|Dichloroacetate (DCA) 25 mg/kg oral solution will be administered daily for 5 days.
223771593|NCT02690285|OTHER|GSTZ1 haplotyping|One teaspoon of blood is collected by standard phlebotomy. Cheek cells are collected by standard brushing. Samples will be analyzed at two independent laboratories to validate methods for GSTZ1 haplotype analysis.
223771594|NCT00048724|BIOLOGICAL|peginterferon alfa-2b (SCH 54031)|0.5 µg/kg subcutaneously once weekly for 60 months
223771595|NCT04865835|DRUG|placebo|single dose of placebo
223771596|NCT04865835|DRUG|SEP-363856|single dose of SEP 363856 100 mg
223771597|NCT04865835|DRUG|metformin|metformin-HCl 850 mg
224251525|NCT01681745|DEVICE|Cryo-Touch III|
224251526|NCT02767921|OTHER|Cytology Specimen Collection Procedure|Correlative studies
224251527|NCT02767921|OTHER|Laboratory Biomarker Analysis|Correlative studies
224251528|NCT02767921|PROCEDURE|Radical Cystectomy|Undergo robotic-assisted radical cystectomy
224251529|NCT02767921|BIOLOGICAL|Recombinant EphB4-HSA Fusion Protein|Given IV
224251530|NCT02767921|PROCEDURE|Therapeutic Conventional Surgery|Undergo robotic-assisted radical or partial nephrectomy
224251531|NCT02456714|DRUG|FOLFIRINOX|
224251532|NCT01474551|DRUG|vemurafenib|All patients would be treated with vemurafenib given orally at 960 mg twice a day, which was the phase III dose. One cycle is 4 weeks long.
224251533|NCT00488800|BIOLOGICAL|pneumococcal conjugate vaccine|
224251534|NCT02804945|BIOLOGICAL|Mesenchymal Stem Cells (MSCs)|Participants receive a maximum dose of 3 x 10\^6 cell/Kg by vein one time on Day 1.
224251535|NCT05926479|OTHER|Translating the Questionnaire into Turkish and Related Processes|The first step is the translation from the original language to the other language. The ideal target in the translation phase is to use people who are familiar with the structure of the original language and who are familiar with the language. Two forward translation and one reverse translation methods will be applied after obtaining the written permission of the authors. After the completion of this phase, the terminological differences arising from the translators in the translation process from the original language to Turkish will be collected and discussed on the questions. The cultural adaptation study will be terminated by determining the equivalence between the Turkish version of the index and the English original. The final version of the questionnaire and the necessary changes will be arranged specific to the investigator's society and the authors of the original questionnaire will be consulted and the questionnaire will be finalized.
224251536|NCT05926479|OTHER|Validity|The scale will be applied by face-to-face technique and convergent (moderate-high correlation with optimism measure) and distant (low correlation with depression and anxiety measures) validity will be evaluated.
224251537|NCT05926479|OTHER|Reliability|The reliability of the materials will be tested with Cronbach alpha.
224251538|NCT01351220|BEHAVIORAL|Educational program and FOBT kits|Subjects will participate in a CRC small group educational program and receive FOBT kits from community health advisors who have received a one-time training session.
224251539|NCT01351220|BEHAVIORAL|Educational program and FOBT kits, and technical assistance|In addition to subjects' receipt of a CRC small group educational program and FOBT kits, leadership training and technical support will be provided to the community health advisors and selected leaders and members of the organization.
224251540|NCT02666300|OTHER|TaperGuard ETT|tracheal intubation with TaperGuard ETT
224251541|NCT04092647|DRUG|Ashwagandha|Ashwagandha 350 mg po BID
224251542|NCT04092647|DRUG|Placebo|Placebo 350 mg po BID
224251543|NCT01424293|DEVICE|Indocyanine Green|1ml of intravenous ICG and imaging transanally using the Spyscope system
224251544|NCT01424293|DEVICE|The SPY® Intraoperative Imaging System|
224251545|NCT05454111|PROCEDURE|Multiscale entropy-guided ablation plus PVI|The multiscale entropy is calculated based on intracardiac electrical signals, higher multiscale entropy value indicates closer to the core of rotors which maintains the persistent atrial fibrillation.
224251546|NCT05454111|PROCEDURE|CARTO-Finder-guided ablation plus PVI|CARTO-Finder-guided ablation plus PVI
224251547|NCT05530447|DRUG|Samelisant|Tablet
223670656|NCT00169442|BIOLOGICAL|Hiberix™|GSK Biologicals' Haemophilus influenzae type b vaccine
223670657|NCT00169442|BIOLOGICAL|Polyribosil-Ribitol-Phosphate (PRP) vaccine|plain PRP polysaccharide vaccine
223670658|NCT00169442|BIOLOGICAL|Tritanrix™-HepB Kft|GSK Biologicals Korlatolt Felelossegu Tarsasag \[Kft\] (Limited Company) combined diphtheria, tetanus, whole cell Bordetella pertussis, hepatitis B vaccine with new sources of D, T and Pw antigens produced at GSK Biologicals Kft., Gödöllö, Hungary.
223670659|NCT02900144|BEHAVIORAL|Modified Comprehensive Behavioral Intervention for Tics|In this arm, participants will receive the modified CBIT protocol. In addition to addressing tics, the treatment in this arm will also directly address ADHD symptoms using CBT for ADHD techniques, and quality of life concerns. The treatment itself will be modified to be more accessible to an ADHD population. The treatment will consist of twelve 50-min sessions: ten weekly and then two every other week for relapse prevention.
223670660|NCT02900144|BEHAVIORAL|Comprehensive Behavioral Intervention for Tics|In this arm, participants will receive the standard CBIT intervention (Piacentini et al 2010). The primary components of CBIT are habit reversal training, relaxation training and a functional interventional to assess the environment for situations/factors that exacerbate or sustain tics. The treatment will consist of twelve 50-min sessions: ten weekly and then two every other week for relapse prevention.
223670661|NCT06022484|OTHER|The present study does not contain any intervention|The present study does not contain any intervention
223670662|NCT01426789|DRUG|Placebo|Matching placebo to secukinumab I.V.
223670663|NCT01426789|DRUG|Secukinumab|In part 1 (blinded period), participants randomized to secukinumab received 10 mg/kg I.V.. Participants, enrolled in part 2 (open label), received secukinumab 300 mg subcutaneous.
223670664|NCT03588962|BIOLOGICAL|In-stent restenosis|Patch tests for the metals applicated in each of the patients
224251548|NCT05239819|BEHAVIORAL|Inspiratory muscle training|The initial training intensity of the preoperative threshold IMT trainer (DofinTM, Breathing Strength Builder, Taiwan) was moderate to high intensity (≥50% of MIP), which was according to the patient's baseline level and increased by 5-10% per week. The frequency is 25-30 minutes each time, twice a day and five days per week for at least two weeks. The participants would receive at least 10 times training sessions before surgery
224251549|NCT05239819|BEHAVIORAL|Regulated care and education|Regulated care and education will be applied
224251550|NCT01304641|OTHER|Atorvastatin Initiators|Retrospective database analysis no intervention performed.
224251551|NCT01304641|OTHER|Simvastatin Initiators|Retrospective database analysis no intervention performed.
224251552|NCT02609295|DIETARY_SUPPLEMENT|Placebo|1.2 g (two capsules) of medium-chain triglyceride (MCT) oil
224251553|NCT02609295|DIETARY_SUPPLEMENT|ALA group|1.2 g (two capsules) of perilla oil
224251554|NCT03426241|OTHER|no intervention|this is cross-sectional study
224251555|NCT03211403|DRUG|SHR4640|SHR4640 or placebo once daily for a week
224251556|NCT04813718|DIETARY_SUPPLEMENT|Omni-Biotic Pro Vi 5|Pre- and probiotic
224251557|NCT04813718|DIETARY_SUPPLEMENT|Placebo|Placebo
224251558|NCT04915534|DEVICE|Ambu® AuraGain™ Laryngeal Mask (LM)|Depending on the gender and randomization, the LM is either blocked with 45 cmH2O or with 60 cmH2O cuff pressure. Following general anaesthesia, patients are questioned for postop complications, with focus on postoperative sore throat and hoarseness.
224251559|NCT00913406|OTHER|Lutein fortification|
224251560|NCT00913406|OTHER|Standard formula|
224251561|NCT00465270|DEVICE|AMPLATZER PFO Occluder|patent foramen ovale closure device
224251562|NCT00465270|OTHER|Standard of Care - Medical Management|Medical management - aspirin alone, Coumadin alone, Clopidogrel alone, aspirin combined with dipyridamole
224251563|NCT01514617|PROCEDURE|Diffusion -and perfusion weighted MRI including iv contrast agent injection|"MRI is a technique based on magnetic fields and does not require the use of ionizing radiation. Although there are no known side effects associated with MRI, a few precautions should be taken because of the 3T magnetic field. This implicates that all metal and magnetized objects must be removed from the patients before entering the MRI room. Patients with a pacemaker, a cardiac defibrillator or other implanted conductors/prostheses are for reason not eligible for the study.~During the MRI examination, an intravenous contrast agent will be administered. In most cases, patients do not experience any discomfort and the use of this contrast agent is part of the clinical routine."
224251564|NCT01453465|OTHER|Laboratory Biomarker Analysis|Correlative studies
224251565|NCT04589091|OTHER|Refractive surgery|Refractive surgery for correction of error of refraction
224251566|NCT02155465|DRUG|Ruxolitinib|"Ruxolitinib 10mg PO BID~Ruxolitinib 15mg PO BID~Ruxolitinib 20mg PO BID"
223670665|NCT04253509|DIAGNOSTIC_TEST|Circulating Tumor DNA Methylation Sequencing|Whole blood (21mL) collection through venipuncture. Analysis of tumor markers and ctDNA methylation sequencing.
223670666|NCT01765478|DRUG|HM71224 single ascending dose|
223670667|NCT01765478|DRUG|HM71224 food effect|
223670668|NCT01765478|DRUG|HM71224 Multiple ascending dose|
223670669|NCT01513200|DRUG|Unfractionated heparin (UFH)|UFH solution for infusion Initially 60U/kg bolus followed by intravenous infusion (12U/kg/hr) for approximately 11 hours
223670670|NCT01513200|DRUG|Bendavia|Bendavia for infusion Constant intravenous infusion (Bendavia 0.25mg/kg/hr) for 4 hours
223670671|NCT01513200|DRUG|Saline (0.9%, sterile, for infusion)|Saline (placebo) Constant IV infusion for 4 hours
224251567|NCT02155465|DRUG|Erlotinib|Erlotinib 150mg PO QD
224251568|NCT05437549|PROCEDURE|MRI|MRI prior to PVI, acutely after PVI, and 3 months after PVI
224251569|NCT04967794|OTHER|Teleorientation and Tooth Brushing Orientation|Guide children in toothbrushing with a preventive purpose during the COVID-19 pandemic
224251570|NCT00071591|BEHAVIORAL|Functional Adaptation Skills Training (FAST)|
224251571|NCT04700254|OTHER|DASS questionnaire|The DASS is a 42-item self report instrument designed to measure the three related negative emotional states of depression, anxiety and tension/stress
224251572|NCT04700254|OTHER|EAT-26 questionnaire|The Eating Attitudes Test (EAT-26), is a self-report 26-item questionnaire of symptoms and concerns characteristic of eating disorders.
224251573|NCT00433225|DRUG|Prednisolone Acetate|
224251574|NCT00433225|DRUG|Ketorolac 0.4%|
224251575|NCT00433225|DRUG|Gatifloxacin 0.3%|
224251576|NCT00163514|DRUG|Ciclesonide|
224251577|NCT00858845|DRUG|Clonidine Patch|A clonidine patch (0.1 mg/week) to be worn for a period of 3 months.
224251578|NCT00858845|OTHER|Matching Placebo Patch|A matching placebo patch to be worn for a period of 3 months.
224251579|NCT05259241|DIAGNOSTIC_TEST|activated partial thrombin time|This study aims to find which the point-of-care test (ACT or APTT) has the best correlation with the coagulation status during transcatheter cardiac interventions (either TAVR or PCI)
223771598|NCT03237923|DEVICE|EasySense device|Implementation of EasySense device during hospitalization and daily post-discharge for thirty days.
223771599|NCT02950636|OTHER|Yoga|Restorative Yoga
223771600|NCT05812482|PROCEDURE|Drug balloon dilatation|The Drug balloon is covered with paclitaxel coating that diffuses the drug into the urethral wall when dilated
223771601|NCT05812482|PROCEDURE|Direct vision internal urethrotomy (DVIU)|A control subject will choose DVIU surgery until the desired effect is achieved
224251580|NCT05210062|OTHER|Iterative exposure to suxamethonium during ECT sessions|"The study is divided into 2 phases: phase P and phase E. Phase P: 10 patients to be included in 1 month with a unique dose of suxamethonium during one session of ECT. One blood sample will be taken from patients before their index ECT session. The objective is to evaluate the feasibility of antibody detection relative to the main objective of the study, to ensure the number of patients to include in phase E (analysis in the following month). Depending on the frequency of antibodies detected, particularly IgG4, the number of patients required for phase E will be revised. If no antibodies are detected, the study will be discontinued.~Phase E: 60 patients to be included in 12 months with 5 blood samples: before the first session of ECT (S0), at 2 weeks (S2), at 4 weeks (S4), between 6 - 14 weeks (preferably at S10) and at 6 months (M6). Only first-time patients or those not having been exposed to ECT in the past 10 years will be included in this phase."
224251581|NCT02605928|DEVICE|Injeq Bioimpedance Probe (BIP) Needle|Injeq Bioimpedance Probe (BIP) Needle is an injection needle that has bioimpedance measurement capability. It consists of traditional needle cannulae and removable bioimpedance probe which enables the measurement of bioimpedance. The needle is connected to measurement device and tissue identifying algorithm. Bioimpedance is measured during the operation and the algorithm detects when the needle tip is in contact with synovial fluid.
224251582|NCT05649228|DRUG|Capsaicin 0.1% Cream|A small amount of cream about the size of a U.S. quarter containing 0.10% non-palmitated capsaicin will be applied to participant's forearm using gloved fingers with visible cream left on the surface for one hour.
224251583|NCT05649228|DRUG|Capsaicin Palmitate 0.25% Cream|A small amount of cream about the size of a U.S. quarter containing 0.25% capsaicin palmitate will be applied to participant's forearm using gloved fingers with visible cream left on the surface for one hour.
224251584|NCT05649228|DRUG|Placebo Cream|A small amount of cream about the size of a U.S. quarter will be applied to participant's forearm using gloved fingers with visible cream left on the surface for one hour.
224251585|NCT01889719|BIOLOGICAL|MVA-CMDR|injections of MVA-CMDR vaccine
224251586|NCT01114893|DRUG|Travoprost 0.004%|1 drop in each eye once daily for five days, and 1 drop vehicle in each eye 7 times daily for 5 days
224251587|NCT01114893|DRUG|Travoprost Vehicle|1 drop in each eye 8 times daily for 5 days
224251588|NCT01114893|DRUG|Travoprost (Groups A, B and C)|1 drop in each eye 8 times daily for 5 days
224251589|NCT03233386|BEHAVIORAL|Mantente REAL|substance abuse prevention curriculum for adolescents
224251590|NCT02866422|OTHER|No Intervention|Observational Study: No intervention
224251591|NCT04857008|DEVICE|BNT001|BNT001 is a commercially-available, prescription-only, software / medical device in the form of a digital application (digital app) for use on the participant's mobile device which delivers 10-sessions on cognitive behavioral therapy for cancer patients.
224251592|NCT05212363|DEVICE|Lower extremity compression garments|Compression garments are used to exert external pressure on the lower extremities to reduce vascular wall tension and prevent gravity form pooling blood in the lower extremities which will improve venous return and lymphatic output. Following the resting measurements, subjects will be instructed to wear the garments and moved to the seated gaming position for 2 hours.
224251593|NCT05212363|BEHAVIORAL|Active break|"An active break is currently considered gold standard for increasing blood flow after prolonged sitting. The 6-minute walk will be conducted indoors next to the esport lab in the Wisser library at NYIT, Old Westbury. Participants will be asked to walk for 6 minutes on a flat surface back and forth following one hour of game play."
224251594|NCT01089699|BEHAVIORAL|online support group|online support group
224251595|NCT01089699|BEHAVIORAL|online support group|online support group
224251596|NCT01089699|BEHAVIORAL|home study support materials|self-study materials
224251597|NCT00030446|DRUG|carboplatin|
224251598|NCT00030446|DRUG|erlotinib hydrochloride|
224251599|NCT00556790|PROCEDURE|Standard Care|standard fluid regime, delayed feeding
224251600|NCT00556790|PROCEDURE|Fast Track care|restrictive fluid regime, early oral feeding, enforced mobilisation
224251601|NCT02752126|RADIATION|Conventional radiotherapy|Patients will receive standard palliative radiation in dose of 30Gy in 10 fractions, or 20Gy in 5 fractions.
224251602|NCT02752126|RADIATION|Esophageal-Sparing Intensity-Modulated Radiotherapy|Patients will receive esophageal-sparing intensity-modulated radiotherapy, of 30Gy in 10 fractions or 20Gy in 5 fractions.
224251603|NCT03642548|DRUG|bifico|Patients in BIFICO group receive platinum-based doublet chemotherapy for first-line treatment chemotherapy plus Bifico.
224251604|NCT03642548|DRUG|placebo|Patients in control group receive platinum-based doublet chemotherapy for first-line treatment chemotherapy plus Placebo.
224251605|NCT00465010|BEHAVIORAL|Talking Parents, Healthy Teens|Talking Parents, Healthy Teens is a worksite-based parenting program to help parents of 6th-10th graders learn to promote their adolescents' healthy sexual development. The program is administered in 8 weekly one-hour sessions during the lunch hour to groups of about 15 parents and focuses on parent-adolescent relationships and communication, with an emphasis on promoting sexual health and reducing sexual risk. It is led by a trained facilitator and assistant facilitator.
224251606|NCT03727100|COMBINATION_PRODUCT|Clonidine Micropellets|Injection
224251607|NCT03727100|OTHER|Sham|Injection
223771602|NCT01500824|DRUG|Crizotinib|Crizotinib, 250 mg BID, will be administered orally at approximately the same time each day on a continuous daily dosing schedule
223771603|NCT02755675|OTHER|68Ga-NOTA-AE105 PET/CT|Following injection of 68Ga-NOTA-AE105 the patients will be subjected to PET/CT
223771604|NCT06073327|DIETARY_SUPPLEMENT|dark chocolate|30g of dark or white chocolate was provided by the nutritionist for 30 days
223771605|NCT06073327|DIETARY_SUPPLEMENT|White chocolate|30g of white chocolate was provided by the nutritionist for 30 days
223771606|NCT01867684|OTHER|Psychotherapy|
223771607|NCT01717417|DEVICE|miniscrew|
223771608|NCT01717417|DEVICE|TPA|
224251608|NCT03743753|OTHER|Experimental|The intervention is the educational session, which is a one-on-one session delivered by a research assistant using a visual aide on an iPad (power point presentation). The session is specifically tailored to the method of breast reconstruction (autologous or alloplastic) the patient will undergo and reviews the basics of their reconstruction, explains the normal in-hospital course and post-operative recovery, reviews potential complications and provides advice from previous breast reconstruction patients.
224251609|NCT00830401|PROCEDURE|Treatment of predefined abnormality by hysteroscopic surgery|"* Polyp resection with Hysteroscopic scissors or Versapoint~* Resection of myoma with Resectoscope Storz or Versapoint~* Septum resection with Resectoscope Storz or Versapoint~* Resection of adhesions with Hysteroscopic scissors or Versapoint"
224251610|NCT00830401|DRUG|Ofloxacinum/Doxycycline|Treatment of endometrial inflammation: Ofloxacinum 400mg/day or Doxycyline 2x100mg on day one, followed by 100mg/day during 8 days.
224251611|NCT05372406|OTHER|• no intervention|• no intervention
224251612|NCT05376683|DEVICE|Curate.AI|Personalized, continuous recommendations on anti-hypertensive medication dose titration using an AI-derived platform also known as Curate.AI
224251613|NCT05376683|BEHAVIORAL|Telemonitoring|Patients will report their blood pressure to a telemonitoring health platform
224251614|NCT05383222|BEHAVIORAL|Technical task|Simulated insertion of a central venous catheter
224251615|NCT05383222|BEHAVIORAL|Administrative task|Requesting a battery of investigations on the EPR
224251616|NCT02124122|BIOLOGICAL|Lactobacillus reuteri|Probiotic
224251617|NCT02124122|BIOLOGICAL|Placebo|Placebo
224251618|NCT04004091|BIOLOGICAL|Spermine|Spermine is a polyamine. It is an organic molecule that is involved in cellular metabolism and development.
224251619|NCT01855932|BEHAVIORAL|Technology Supported|All participants will complete 8 weeks of recording of dietary intake, weight, and physical activity on a smartphone application. Time-stamped data from the smartphone will upload automatically to the application server, where it will be visible to the lifestyle coach. The participant's real-time diet, activity and weight data relative to their goals will be visually depicted on the participant's smartphone. The coach will monitor participant adherence and send supportive text messages. Response to the application will be assessed 3 weeks after enrollment into the study; measured by number of food items recorded between weeks 1-3 of the intervention; an indicator of use and adherence. Based on adherence, some participants may receive 4 telephone coaching sessions between weeks 5 and 8. Telephone coaching sessions will include feedback on self-monitoring and goal attainment, problem solving, and motivational interviewing.
224251620|NCT02089997|DRUG|Sodium Risedronate|Sodium risedronate tablets
224251621|NCT01916408|DRUG|Wobenzym plus|3 x 4 tablets of the study medication each day for the one week before and 3 x 2 tablets of the study medication each day for the two weeks after the marathon.
224251622|NCT01916408|DRUG|PL 1|3 x 4 tablets of the study medication each day for the one week before and 3 x 2 tablets of the study medication each day for the two weeks after the marathon.
223771609|NCT04885517|DEVICE|Esophageal catheter|Patients are equipped with an esophageal catheter: positioning is performed after accurate nasopharyngeal anesthesia with lidocaine
224251623|NCT05334173|PROCEDURE|Roux-en-Y Gastric Bypass (RYGB) measuring the lengh of the common limb|The patients are randomized to Type 1 laparoscopic RYGB (150cm alimentary limb and 70cm biliopancreatic limb) or type 2 laparoscopic RYGB (70cm alimentary limb and 150cm biliopancreatic limb). In both groups, the total intestinal length is measured to determine the size of the common limb. We introduce a 10 cm ruler into the abdominal cavity to measure the bowel and then extract it. LRYGB is made with linear stapler anastomosis.
224251624|NCT05704881|DIAGNOSTIC_TEST|End-Tidal CO2 measurement during COPD exacerbation|The EtCO2 will be measured at the emergency reception during assessment of vital signs by the nurse with the help of a mask or oxygen glasses measuring EtCO2. The patient will then be treated conventionally according to current international recommendations. The physician in charge of the patient will be blinded to this measurement. The outcome will be the initiation of invasive or non-invasive ventilation (NIV) within the first 24 hours of admission to the emergency department, as indicated by the physician in charge of the patient.
224251625|NCT01850173|DEVICE|A vertical vibration platform Fitybe|They performed 6 series, and each series consisted of four 30-second repetitions with a frequency of 35 Hz and 2 millimeters of amplitude, with 60 seconds of rest between each series.
224251626|NCT02939729|OTHER|Walking Programme|Walking programme measured by daily step count on pedometer provided to participant. Participants will be advised to increase daily step count from their baseline measure - realistic incremental rise according to individual ability and symptoms. Daily step count will be recorded in a participant study diary.
224251627|NCT02939729|DEVICE|Incentive Spirometer|An incentive spirometer is a device used to measure lung tidal volumes. Participants will be asked to use the incentive spirometer to measure their tidal volume daily. Participants will record daily tidal volume measurement in the participant diary. A physiotherapist will teach participants how to use the incentive spirometer and provide an instruction sheet.
224251628|NCT02939729|OTHER|Deep Breathing Exercises|Participants will be taught deep breathing exercises - these are the same deep breathing exercises shown to all patients after cardiac surgery as part of chest physiotherapy treatment. Participants will be asked to carry out deep breathing exercises at home during the prehabilitation phase. An instruction sheet for the deep breathing exercises will be provided to participants.
224251629|NCT03521856|BEHAVIORAL|shoulder exercise|Exercises performed 3 times a week for 12 weeks
224251630|NCT03521856|BEHAVIORAL|education|
223771610|NCT03227380|OTHER|thoracic densitometry with contrast|injected CT scan at 3 or 6 months after segmentectomy VATS
223771611|NCT00844545|DRUG|Eculizumab|All patients received open-label eculizumab administered intravenously on the following dose schedule: Induction dose - 900 mg per week for four weeks and a dose of 1200 mg one week later; Maintenance dose - 1200 mg every two weeks. Patients who received plasma exchange or infusion during the eculizumab treatment period received a supplemental dose of 600 mg within one hour before plasma infusion or within one hour after the completion of each plasma exchange
223771612|NCT02039427|DRUG|Ketorolac|ketorolac 30 mg mixed with normal saline 1 ml : total volume of 2 ml
224251631|NCT01967485|OTHER|Text- Messaging|Text messages will be sent to the parents of children enrolled in the study.
224251632|NCT01967485|OTHER|Treatment as usual|Children will receive stimulant treatment for ADHD.
224251633|NCT05420805|DIETARY_SUPPLEMENT|ALAC, inulin, FOS, and sodium butyrate|Pre- and post-biotic supplementation will be administered for 3 month period (i.e. 12 weeks) given the filling out of a supplementation diary by parents/caregivers. At the scheduled visits/ phone contacts (i.e., baseline, 4 weeks and 12 weeks), systemic inflammation, intestinal inflammation, and gut microbiome characterization as well as treatment compliance, clinical and dietary intake will be assessed. A seizure diary will be provided to parents/caregivers in order to check the frequency and entity of the critical episodes. An EEG recording will be performed at enrollment (or within 6 months prior to the baseline visit).
224251634|NCT05420805|DIETARY_SUPPLEMENT|Sodium butyrate and zinc oxide|Post-biotic supplementation will be administered for 3 month period (i.e. 12 weeks) given the filling out of a supplementation diary by parents/caregivers. At the scheduled visits/ phone contacts (i.e., baseline, 4 weeks and 12 weeks), systemic inflammation, intestinal inflammation, and gut microbiome characterization, as well as treatment compliance, clinical and dietary intake will be assessed. A seizure diary will be provided to parents/caregivers in order to check the frequency and entity of the critical episodes. An EEG recording will be performed at enrollment (or within 6 months prior to the baseline visit).
224251635|NCT04036422|DEVICE|Rejoyce (Rehabilitation Joystick for Computerized Exercise)|Rejoyce (Rehabilitation Joystick for Computerized Exercise), is a computer game based task specific exercise system developed by Rehabtronics Inc. for use as part of the treatment of stroke and spinal cord injury patients. Rejoyce aims to improve upper extremity and hand function by encouraging neuroplasticity through repeated task specific games.
224251636|NCT04036422|OTHER|Conventional physical therapy|A physical therapy session customised to the patient's needs overseen by a physical medicine and rehabilitation specialist and conducted by a physiotherapist which includes range of motion, neurophysiological and strengthening exercises, balance and coordination training and walking exercises.
224251637|NCT04036422|OTHER|Occupational therapy|Task based exercises overseen by a physical medicine and rehabilitation specialist and conducted by an occupational therapist aimed at improving upper arm dexterity, coordination and strength.
224251638|NCT05801497|PROCEDURE|Balneotherapy|"The patients in the BT group will be treated with 12 daily immersion in a bathtub or in a pool at a 37-38°C or with a combination of bath and mud-packs to carry out in a period of two weeks.~The application of mud-packs will follow the standard procedure with a duration of 15-20 minutes at 40-45°C. After the treatment, patients will have 20-30 minutes of bed rest. To be included in the study, thermal interventions must be carried out with sulfourous, solfate, bicarbonate, saline or sodium chloride and arsenical-ferruginous mineral waters, according to the classification by Marotta and Sica."
224251639|NCT02134834|DRUG|OP0595|Five cohorts of 8 subjects (6 active and 2 placebo) are planned for evaluation
224251640|NCT02134834|DRUG|Placebo|Five cohorts of 8 subjects (6 active and 2 placebo) are planned for evaluation
224251641|NCT02726425|BEHAVIORAL|Diabetes Self Management Medical Group Visits|The Women in Control DSM intervention involves: (1) 8-wk series of interactive, educational medical group visit sessions with groups of 10-12 participants, led by clinicians \& peer leaders lasting \~100'' in length conducted either in Spanish or English and (2) Individual consultation with a clinician lasting 10-15 minutes. Group visits will consist of experiential and discussion based learning of topics including the importance of diet, physical activity, medications, mindfulness and stress reduction to diabetes self management.
224251642|NCT05245357|BEHAVIORAL|Lentil|Participants in the lentil arm of the study will consume a meal containing 140 g of lentils for breakfast one morning.
224251643|NCT05245357|BEHAVIORAL|Control|Participants in the control arm of the study will consume a meal containing 0 g of lentils for breakfast one morning.
224251644|NCT02444715|BEHAVIORAL|Standard care|Participants receive only the usual care including blood analyses, blood pressure controls and individual advice on healthy lifestyle during the outpatient treatment given by the neurologist, by the general practitioner and by other physicians.
224251645|NCT02444715|BEHAVIORAL|CAPSYS|In addition to the usual care, patients are asked to call the CAPSYS system twice a week.
224251646|NCT03863418|DIETARY_SUPPLEMENT|Lactobacillus rhamnosus GG|PROBIOTIC
224251647|NCT03863418|OTHER|placebo|placebo
224251648|NCT01851733|DEVICE|MRI-guided Laser Heat Ablation (MLA)|
224251649|NCT01851733|DRUG|Doxorubicin|
224251650|NCT01851733|OTHER|Blood draw - dendritic cells|"The second 10 patients enrolled to Arm B:~* before MLA (up to 3 days before)~* 2 weeks after MLA~* 4 weeks after MLA~* every 2 weeks thereafter for up to 3 months after biopsy (provided there is no significant chemotherapy induced cytopenia)"
224251651|NCT01851733|DEVICE|Dynamic Susceptibility Contrast Magnetic Resonance Imaging|
224251652|NCT05872178|DIETARY_SUPPLEMENT|Omegia® Softgel -B|How to use: Take once a day for 12 weeks Subject precautions: If the health products and cosmetic care products used contain sea buckthorn ingredients, stop using them.
224251653|NCT05872178|DIETARY_SUPPLEMENT|Omegia® Softgel -A|How to use: Take once a day for 12 weeks Subject precautions: If the health products and cosmetic care products used contain sea buckthorn ingredients, stop using them.
224322102|NCT04258592|DEVICE|PET/CT|Adult patients will undergo a dynamic PET scan for the first 30 minutes, followed by 3 static whole-body PET/CTs at 60 ± 10 min, 120 ± 30 min and 180 ± 30 min post injection. Pediatric patients will undergo, depending on what is feasible for the child, at least 1 and up to 2 static whole-body PET/CTs. In patients 12 years or older, also a dynamic PET scan can be performed.
224322103|NCT04258592|OTHER|Venous blood samples|Blood samples will be obtained for laboratory safety evaluation for initial screening and safety evaluation after injection. Furthermore, in patients undergoing a dynamic PET scan venous blood samples will be obtained for metabolite analysis and activity measurements at various time points post injection (5 ± 2 min, 10 ± 5 min, 20 ± 10 min, 40 ± 20 min, 60 ± 30 min and 120 ± 60 min in adult participants; 5 ± 2 min, 10 ± 5 min, 30 ± 15 min, 50 ± 25 min, 90 ± 30 min in minor participants).
223670672|NCT06012643|OTHER|The purpose of this systematic review of case reports and case series was to evaluate the spectrum of subperiosteal implants for severely atrophied jaws using digital technology.|An electronic and manual search was conducted in the PubMed, Scopus, and Google Scholar databases. Publications of case reports and series written in English without data restrictions
223670673|NCT00265928|DRUG|bortezomib|
223670674|NCT00265928|DRUG|rituximab|
224251654|NCT02766075|BEHAVIORAL|Supervised TAVR Exercise Program|Individualized exercise program designed and implemented by licensed physical therapy clinicians in three 60-minute sessions per week for four weeks. Upon randomization, subjects in the Intervention Group will undergo an initial Dynamic Gait \& Balance Assessment by a licensed physical therapy clinician. The physical therapy clinician will use this assessment to design and implement an individualized STEP in three 60-minute sessions per week for four weeks. Subjects will proceed with their pre-TAVR testing in conjunction with the STEP sessions.
224251655|NCT00098826|DRUG|ispinesib|Given IV
223670675|NCT00265928|PROCEDURE|antibody therapy|
223670676|NCT00265928|PROCEDURE|biological therapy|
223670677|NCT00265928|PROCEDURE|enzyme inhibitor therapy|
223670678|NCT00265928|PROCEDURE|monoclonal antibody therapy|
223670679|NCT06335563|PROCEDURE|AR glasses-assisted pulmonary nodule puncture localization|Combined with placing positioning marks on the patient's body surface and tracing the needle entry point with the assistance of a CT scan gantry laser. Disinfect the area around the puncture needle point, and use 2% lidocaine for local infiltration anesthesia. The doctor wears augmented reality (AR) glasses, completes the connection between the AR glasses and the puncture target, and clicks on the puncture point plane through the puncture target needle tip. Calibrate the puncture position at any two points. After confirming that the patient has held his breath, quickly puncture the needle into the pleura and advance it to the planned puncture position according to the screen prompts. After the second CT scan is performed to confirm that the puncture needle is positioned at a reasonable position, the positioning hook wire is released and the puncture needle sheath is withdrawn.
223670680|NCT06335563|PROCEDURE|CT-guided pulmonary nodule puncture localization|Positioning markers are placed on the patient's surface and the first CT scan is performed. The needle insertion point and needle insertion depth are designed based on the two-dimensional CT scan image and the positioning marks. The location of the needle entry point was traced with the laser assistance of the CT gantry. Disinfect and puncture around the needle point, and use 2% lidocaine for local infiltration anesthesia. According to the designed needle path angle, the needle is first inserted under the skin, and a second CT scan is performed to confirm that the extension line of the puncture needle is within the nodule range. Then the needle is inserted to the target depth, and the third CT scan is performed. After confirming that the puncture needle is positioned at a reasonable position, the positioning hook wire is released and the puncture needle sheath is withdrawn.
223670681|NCT01181986|DRUG|Exenatide SC|Exenatide 5-10 ug sc BID/10 days
223670682|NCT01181986|DRUG|Exenatide IV|50 ng/min intravenously for 45 minutes on 2 out of 3 study visits separated by 5-10 days
223670683|NCT01181986|DRUG|Placebo SC|Placebo sc BID/10days
223670684|NCT01181986|DRUG|Exendin-9|Primed (6,000 pM/kg), continuous (600 pM/kg) intravenous infusion for 75 minutes on 1 out of 3 study visits.
223670685|NCT01181986|DRUG|Placebo IV|Intravenous infusion for 45 minutes on 1 out of 3 visits
223670686|NCT00123643|DRUG|rosiglitazone|
223670687|NCT00123643|DRUG|glyburide|
223670688|NCT02103296|PROCEDURE|Drawing admission labs from cord blood|
223670689|NCT02103296|PROCEDURE|Drawing admission labs from infant blood|
223670690|NCT03583619|RADIATION|APBI|Patients receive radiation to the breast tumor bed to a total dose of 40Gy/10fx/2wks, using intensity-modulated radiation therapy technique.
223670691|NCT03583619|RADIATION|WBI|Patients receive radiation to the whole breast to a total dose of 43.5Gy/15fx/3wks, using intensity-modulated radiation therapy technique.
223670692|NCT02473146|DRUG|Gemtuzumab ozogamicin (GO)|
223670693|NCT02457104|PROCEDURE|Colonoscopy|Patients selected from those undergoing screening colonoscopy. During colonoscopy, stool aspirates and biopsies will be taken from the terminal ileum, cecum, and sigmoid colon.
223670694|NCT02457104|BEHAVIORAL|Weight and diet questionnaire|Brief questionnaire outlining weight history, type and dose of PPI, and diet.
223670695|NCT06110637|OTHER|"hard shoes runners evaluation"|"The hard shoes runners get on the treadmill for 21 km at a speed corresponding to 70 percent (%) of their the maximum aerobic speed (MAV) and are evaluated."
223771613|NCT02039427|OTHER|Dexamethasone|dexamethasone acetate10 mg : total volume of 2 ml
223670696|NCT06110637|OTHER|"Soft shoes runners evaluation"|"The soft shoes runners get on the treadmill for 21 km at a speed corresponding to 70 percent (%) of their the maximum aerobic speed (MAV) and are evaluated."
223670697|NCT01227174|DRUG|Propofol|Procedural sedation will be achieved using propofol
223670698|NCT01267357|OTHER|no intervention|
223670699|NCT00311584|DRUG|irinotecan hydrochloride|Given IV
223670700|NCT00311584|DRUG|temozolomide|Given IV
223670701|NCT02193906|OTHER|Cognitive training|Every patient will have 3 neuropsychological evaluations (with the same battery): baseline, after a 3-month period of training and 6 months after the conclusion of the training. Patients who have computer with internet access at home will perform a minimum of 3 sessions per week of Cogweb® during 3 months. Patients who don't have computer with internet access at home will perform a minimum of 3 sessions per week of Cogweb Monthly Notebooks® during 3 months. Every patient included will have an outpatient appointment in the end of the first and second months of training.
223771614|NCT02039427|DRUG|Placebo|Normal saline 2 ml
223771615|NCT05391217|OTHER|Remote assessment of patient reported outcomes and daily activity|Electronic patient-reported outcomes (NIH PROMIS) will be collected and combined with remotely monitored physical activity, heart rate, and sleep, as measured with a Fitbit (Sense).
223771616|NCT05277467|OTHER|no intervention|no intervention
223771617|NCT01743092|BEHAVIORAL|Webinar|Some clients will receive a webinar as part of their treatment.
223771618|NCT01743092|BEHAVIORAL|Tutuorial workbook|A work book about their addiciton
223771619|NCT01103297|DEVICE|Variable Angle Distal Radius Plate ® (Surgery)|Fracture reduction with distal radius plate
223771620|NCT03925792|BEHAVIORAL|Lifestyle Medicine|diet, sleep, exercise and mindfulness
224251656|NCT00098826|OTHER|laboratory biomarker analysis|Correlative studies
224251657|NCT00098826|OTHER|pharmacological study|Correlative studies
224322104|NCT01221701|BEHAVIORAL|In-Home Cognitive Behavioral Psychology|Adapted form of CBT that is delivered in the home setting, uniquely designed for young, low income new mothers, and is explicitly integrated with home visitation. IH-CBT is delivered by a masters level therapist. It consists of 15 weekly sessions and 1 booster session provided 1 month after the 15th session.
224251658|NCT00017953|BEHAVIORAL|Lifestyle Intervention|The lifestyle intervention is implemented with individual supervision and group sessions and is aimed at achieving and maintaining at least a 7% decrease in weight from baseline and 175 minutes per week in physical activity. It is implemented during a four-year period with the most intensive application during the first year, less frequent attention during the next three years, and a minimum of twice yearly contacts during an extended follow-up period. To help participants achieve and maintain weight loss, a variety of diet strategies (e.g. prepared meals and liquid formula), exercise strategies, and optional weight loss medications are utilized based on a preset algorithm and participant progress.
224251659|NCT00017953|BEHAVIORAL|Diabetes Support and Education|Participants assigned to diabetes support and education are offered three sessions each year in diabetes management and social support.
224251660|NCT00122785|DRUG|dexamethasone|
224251661|NCT02374853|DRUG|Vancomycin|Topical prophylactic antibiotic
224251662|NCT02374853|OTHER|No Vancomycin|Placebo: Sterile water. No Vancomycin.
224251663|NCT00152685|DRUG|human serum albumin|
224251664|NCT03313349|BEHAVIORAL|Psychotherapy: 1. cognitive therapy 2.family intervention|Psychotherapy delivered by trained psychologist for the student and the student´s parents
224251665|NCT02269995|DEVICE|E7040|E7040 of optimal particle size (-300 um, 300-500 um, or 500-700 um to fit in a target vessel, target lesion, or embolized area) as transcatheter study device will be administered .
224251666|NCT00931697|DRUG|AD 452 (+) mefloquine|Single dose delivered as over-encapsulated tablet at ascending doses
224251667|NCT00931697|DRUG|Racemic Mefloquine|Single dose delivered as over-encapsulated tablet at ascending dose
224251668|NCT00931697|DRUG|Placebo|Over-encapsulated placebo to maintain blinding
224251669|NCT02281084|DRUG|Oral Azacitidine|Oral azacitidine (AZA) 100 mg, 150 mg, or 200 mg tablets twice daily (BID) on days 1 to 21 of each 28-day treatment cycle. Participants continued to receive their assigned study treatment unless disease progression, unacceptable toxicity, lost to follow-up or withdrawal by participant occurred.
224251670|NCT02281084|DRUG|Durvalumab|Durvalumab 1500 mg by IV infusion on Day 1 of each 28 day treatment cycle.
224251671|NCT00346814|DRUG|intravitreal injection|
224251672|NCT03902496|OTHER|HIT-6 Questionnaire|Headache Impact Test
224251673|NCT03902496|DEVICE|Avulux Spectacles|Avulux™ Optical Filter in the Form of Spectacle Lenses
224251674|NCT03902496|DEVICE|Sham Spectacles|Sham
224251675|NCT04699149|OTHER|Transcranial magnetic stimulation|Non-invasive brain stimulation
224251676|NCT04699149|OTHER|Sham transcranial magnetic stimulation|Non-invasive brain stimulation
224251677|NCT02351154|OTHER|Cellvizio Viewer software|permets to perform analysis of diameters in micrometers
224251678|NCT04834271|OTHER|Side-lying external rotation exercise with a dumbbell|Side-lying external rotation exercise with a dumbbell (20-30% 1RM). 2 times per week during 4 weeks.
224251679|NCT04834271|OTHER|Side-lying external rotation exercise with a dumbbell with 40% arterial occlusion pressure blood flow restriction|Side-lying external rotation exercise with a dumbbell (20-30% 1RM) with 40% arterial occlusion pressure blood flow restriction. 2 times per week during 4 weeks.
224251680|NCT04834271|OTHER|Side-lying external rotation exercise with a dumbbell with 80% arterial occlusion pressure blood flow restriction|Side-lying external rotation exercise with a dumbbell (20-30% 1RM) with 80% arterial occlusion pressure blood flow restriction. 2 times per week during 4 weeks.
224251681|NCT01613040|DRUG|Moxifloxacin|Single oral dose on Day 1
224251682|NCT01613040|DRUG|Moxifloxacin|Single oral dose on Day 11
224251683|NCT01613040|DRUG|RO4917838|Multiple daily low doses of RO4917838 for 10 days
224251684|NCT01613040|DRUG|RO4917838|Multiple daily oral high doses of RO4917838 for 10 days
223670702|NCT02193906|OTHER|Placebo task|Every patient will have 3 neuropsychological evaluations (with the same battery): baseline, after a 3-month period of training and 6 months after the conclusion of the training. Patients will have to complete a placebo task (send an email with a copy of a journal/magazine heading) a minimum of 3 times a week, for 3 months. Every patient included will have an outpatient appointment in the end of the first and second months of training.
224251685|NCT01613040|DRUG|RO4917838 placebo|Oral daily doses of placebo to RO4917838 for 10 days
224251686|NCT02335658|DRUG|DSP-5423P|40-80mg/day
224251687|NCT01804803|PROCEDURE|Use of software-implemented glucometer for real-time collection and transmission of measured glucose values to remote server.|"Device is a smartphone-connected glucometer. The smartphone will be implemented with a software for real-time collection and transmission of measured glucose values to the remote server. Thus, the glucometer will be made hot for real-time and anywhere data transmission. In addition, at the time of blood glucose measuring, the patient will enter information on whether the measurement is being performed in the pre-prandial, post-prandial or absorptive periods, and will indicate which meals the measurement refers to (i.e., breakfast, lunch, dinner, snack). SMBG results will be immediately transmitted to the remote server, which will perform data collection and analysis, and provide feed-back to the patient and the medical staff according to pre-defined specific algorithms (Decision Supported Software, DSS)."
223670703|NCT04211246|PROCEDURE|Titration of fraction of inspired oxygen (FiO2) guided by SpO2|Titration of fraction of inspired oxygen (FiO2) guided by SpO2
223670704|NCT04211246|PROCEDURE|Titration of fraction of inspired oxygen (FiO2) guided by ORI and SpO2|Titration of fraction of inspired oxygen (FiO2) guided by ORI and SpO2
224251688|NCT01804803|PROCEDURE|Use of regular glucometer|
224251689|NCT02726230|BEHAVIORAL|Ananya|The Ananya program was developed and implemented via a partnership of the Bill and Melinda Gates Foundation and the Government of Bihar as a means of improving reproductive, maternal, newborn and child health (RMNCH) outcomes in the state, in particular focusing on improving health behaviors and service utilization in the final trimester of pregnancy and early postpartum period. Ananya was designed as a series of supply- and demand-side efforts to improve health. Efforts were focused on strengthening outreach services in quantity and quality, improving quality of facility services, and mobilizing communities to improve health behaviors. The Ananya program included training, mobilizing, and monitoring of government frontline health workers (FLWs, including anganwadi workers- AWWS, auxiliary nurse midwives- ANMs, and community health workers-ASHAs) to increase quantity and quality of home visits for RMNH screenings and services, and media messages to increase demand for services.
224251690|NCT00921622|DIETARY_SUPPLEMENT|Vitamin D|1000 IU twice daily for up to 10 days
224251691|NCT00921622|DIETARY_SUPPLEMENT|Vitamin C|500 mg twice daily for up to 10 days
224251692|NCT02957097|DRUG|Gabapentin|Medication used for management of neuropathic pain conditions
224251693|NCT02957097|DRUG|Placebo|Placebo medication. It looks exactly same as the Gabapentin medication in same size, shape, and color.
224251694|NCT00001748|PROCEDURE|Peripheral blood progenitor cell transplant|
224251695|NCT02305758|DRUG|Veliparib|200 mg oral dose beginning 2 days prior to the start of FOLFIRI and continuing twice a day (BID) for a total of 7 consecutive days
224251696|NCT02305758|DRUG|Placebo|200 mg oral dose beginning 2 days prior to the start of FOLFIRI and continuing twice a day (BID) for a total of 7 consecutive days
224251697|NCT02305758|DRUG|Modified FOLFIRI|Irinotecan 180 mg/m\^2 (90-minute infusion ± 30 minutes); leucovorin 400 mg/m\^2 (90-minute infusion ± 30 minutes); and saline bolus (up to 15-minute infusion) on Day 1 of each 14-day cycle
224251698|NCT02305758|DRUG|FOLFIRI|Irinotecan 180 mg/m\^2 (90-minute infusion ± 30 minutes); leucovorin 400 mg/m\^2 (90-minute infusion ± 30 minutes); and fluorouracil bolus 400 mg/m\^2 (up to 15-minute infusion) on Day 1 of each 14-day cycle
224251699|NCT02305758|DRUG|Bevacizumab|At the discretion of the Investigator, 5 mg/kg may be administered intravenously immediately preceding FOLFIRI dosing
224251700|NCT02305758|DRUG|Fluorouracil infusion|2400 mg/m\^2 (46-hour continuous infusion ± 4 hours) starting on Day 1 of each 14-day cycle
224251701|NCT01954680|BEHAVIORAL|COGFLEX-skill building levels|"COGFLEX--in English-- is a computer game designed to build up a specific skill that our work has shown is impaired in children and adolescents with bipolar disorder).~In the R33, children will be randomized to receive either COGFLEX with skill-building levels or COGFLEX-control condition which is just baseline/non-probabilistic trials.~All children will play COGFLEX twice per week for 8-weeks.~This same approach has shown great success in many psychiatric disorders including schizophrenia.~This is the first such study in children/adolescents with bipolar disorder."
223771621|NCT05165121|DEVICE|MDHearing smart hearing aid|air conduction hearing aid with app support
223771622|NCT03125889|DEVICE|AquaBeam System|The AquaBeam system delivers a high-velocity saline stream under precise electromechanical control and live ultrasound guidance to ablate prostatic glandular tissue without the production of heat. The physician uses ultrasound imaging to plan the treatment contour and depth to define the treatment region. The AquaBeam ablates the target tissue, adhering to the pre-defined treatment zone.
223771623|NCT03074721|DEVICE|PCI Suite Software|PCI with PCI Suite Software
223771624|NCT03074721|OTHER|conventional PCI|conventional PCI without PCI Software
224251702|NCT01954680|BEHAVIORAL|COGFLEX-control condition|"In the R33, the control condition will be the same COGFLEX game--but just baseline/non-probabilistic trials. All children will play COGFLEX twice per week for 8-weeks."
224251703|NCT02661529|PROCEDURE|Transesophageal Echocardiogram (TEE)|Transesophageal echocardiography (TEE) is a test that produces pictures of the heart. TEE uses high-frequency sound waves (ultrasound) to make detailed pictures of the heart and the arteries that lead to and from it. Unlike a standard echocardiogram, the echo transducer that produces the sound waves for TEE is attached to a thin tube that passes through the mouth, down the throat and into the esophagus. Because the esophagus is so close to the upper chambers of the heart, very clear images of those heart structures and valves can be obtained.
224251704|NCT02661529|PROCEDURE|Transthoracic Echocardiogram (TTE)|"An echocardiogram is a type of ultrasound test that uses high-pitched sound waves that are sent through a device called a transducer. The device picks up echoes of the sound waves as they bounce off the different parts of the heart. These echoes are turned into moving pictures of the heart that can be seen on a video screen.~Transthoracic echocardiogram (TTE) is the most common type of echocardiogram. Views of the heart are obtained by moving the transducer to different locations on the chest or abdominal wall."
224251705|NCT02661529|OTHER|Saline/Air Mixture|The Saline/Air mixture consists of 10 milliliters of sterile saline and 0.5 milliliters of air agitated together in a syringe prior to injection.
224251706|NCT02661529|OTHER|Saline/Blood Mixture|The Saline/Blood mixture consists of 9 milliliters of sterile saline and 0.5 - 1.0 milliliters of blood agitated together in a syringe prior to injection.
224251707|NCT03732443|DIAGNOSTIC_TEST|FAM-CAM|Family Confusion Assessment Method
224251708|NCT02325271|OTHER|Frequent blood and urine sampling and blood pressure measurement|Blood and urine sampling for the determination of VEGF and biomarkers
224251709|NCT01379664|DRUG|Isoflurane|Isoflurane is administered to patient during surgery as it would normally be administered by the attending anesthesiologist
224251710|NCT01379664|DRUG|Sevoflurane|Sevoflurane is administered to patient during surgery as it would normally be administered by the attending anesthesiologist
224251711|NCT05910632|BEHAVIORAL|Eccentrically strengthened resistance exercise|For each resistance exercise session, 6 to 7 generic exercises will be performed, involving small and large muscle groups (leg extension, leg curl, biceps curl, triceps extension, seated row, shoulder flexion, and shoulder raise). They will perform with 4 sets of 8 repetitions, with a break between exercises of 1 minute and between sets of 2 minutes. They perform those exercises with high intensity (ever 10 on the OMNI-RES Scale).
224251712|NCT05910632|BEHAVIORAL|Traditional resistance training|For each resistance exercise session, 6 to 7 generic exercises will be performed, involving small and large muscle groups (leg extension, leg curl, biceps curl, triceps extension, seated row, shoulder flexion, and shoulder raise). They will perform with 4 sets of 8-12 repetitions, with a break between exercises of 1 minute and between sets of 2 minutes. They perform those exercises with moderate and high intensities (6 to 10 on the OMNI-RES scale).
224251713|NCT02032888|DRUG|Daclatasvir|
224251714|NCT02032888|DRUG|Sofosbuvir|
224251715|NCT01767298|DRUG|Valsartan/Hydrochlorothiazide|Co-administration or fixed dose combination
223771625|NCT04448470|OTHER|Questionnaire for recording daytime sleepiness over the course of the day|Questionnaire for recording daytime sleepiness over the course of the day
223771626|NCT04448470|OTHER|Anamnesis and physicial examination|Anamnesis and physical examination, e.g. medication, comorbidities, complaints
223771627|NCT04448470|OTHER|Questionnaire for quantifying daytime sleepiness|the Epworth Sleepiness Scale (ESS) questionnaire and the STOP BANG Questionnaire
224251716|NCT01767298|DRUG|Valsartan|Valsartan alone
224251717|NCT01767298|DRUG|Hydrochlorothiazide|Hydrochlorothiazide alone
224251718|NCT03502161|DEVICE|QuantiFERON CMV Assay|Assay to measure cell-mediated immune function using QuantiFERON CMV assay.
223670705|NCT03073733|BIOLOGICAL|human retinal progenitor cells|live suspension of 3.0 or 6.0 x 10e6 human retinal progenitor cells (hRPC) suspended in clinical grade medium injected intravitreally under local anesthesia
224251719|NCT01506466|OTHER|blood test/ additional measurement|blood test (hormonal, inflammatory, lipid and growth factors); body composition measurements; energy balance evaluation
224251720|NCT01697696|DRUG|NVA237|NVA237 will be supplied in capsule form in blister packs for use in the Novartis Concept 1 SDDPI
224251721|NCT01697696|DRUG|Long-acting beta 2-agonist (LABA)|QAB149 and matching placebo will be supplied in capsule form in blister packs for use in the Novartis Concept 1 SDDPI
224251722|NCT01697696|DRUG|Placebo|Placebo to match QAB149
224322105|NCT04362228|BEHAVIORAL|Whole-body exercise|10-week one-on-one, virtual, whole-body exercise class, 3x/week, focused on increasing respiratory rate through moderate-intensity aerobic exercises.
223670706|NCT03073733|OTHER|Mock injection|pressing the hub of a syringe with no needle against the eye to mimic intravitreal injection
223670707|NCT06436677|OTHER|molecular subtype based treatment|The immunohistochemistry algorithm established by the previous research group was used to determine the molecular subtype, and the corresponding treatment plan was selected according to the subtype. Such as for TCyEM patients, interferon-based immunomodulatory therapy was selected, and TCM-type patients were treated with retinoids.
223670708|NCT01274689|OTHER|individually tailored lead weight|patients were treated with an individually tailored lead weight to train M. orbicularis oculi during day time
223670709|NCT00835731|DRUG|misoprostol|400mcg misoprostol, buccal administration, 1 time dosing 3-4 hours before abortion by D\&E
223670710|NCT00835731|DEVICE|Dilapan-S, vitamin B-12|One Dilapan-S rod placed in the cervix 3-4 hours before abortion by D\&E. Control: 1000mcg vitamin B-12, buccal administration 3-4 hours before abortion by D\&E
223670711|NCT01407380|DRUG|PWT33597 mesylate|PWT33597 taken orally daily for 28 consecutive days in 28 day cycle
223670712|NCT06329284|DIAGNOSTIC_TEST|ELISA|ELISA estimation of serum Midkine, tumor necrosis factor Alfa, superoxide dismutase, malondialdehyde, placental growth factor and placental soluble fms-like tyrosine kinase 1
224251723|NCT00577668|DRUG|Melphalan, Velcade, Thalidomide, Dexamethasone|To assess, in patients with one or two prior auto transplants, the efficacy of a high-dose combination chemotherapy with MEL 300 (in 3 fractions of 100 mg/m2 on days -7, -4, -1) plus VTD (Velcade = bortezomib 1.3 mg/m2 on days -7, -4, -1; Thalidomide 200 mg/d on days -1 through -7; Dexamethasone 40 mg on days -7, -6, -4, -3, -1, 0) followed by autologous peripheral blood stem cell (PBSC) infusion of a minimum dose of 3 million CD34 cells/kg.
224251724|NCT02852980|OTHER|gestational diabetes women|No intervention.
224251725|NCT02041871|DIETARY_SUPPLEMENT|Oral immunonutrition|Powder 74g within 250ml of water, 3 times per day during 7 days before surgery
224251726|NCT02041871|DIETARY_SUPPLEMENT|Placebo|Powder 74g within 250ml of water, 3 times per day during 7 days before surgery
224251727|NCT05593965|DEVICE|Delta-beta TMS|TMS will be delivered in a delta-beta pattern in which triplets of pulses delivered at 20 Hz (50 milliseconds between each pulse) are sent every 3 Hz (333 milliseconds between the start of each triplet).
224251728|NCT05593965|DEVICE|Theta-gamma TMS|TMS will be delivered in a theta-gamma pattern in which triplets of pulses delivered at 50 Hz (20 milliseconds between each pulse) are sent every 5 Hz (200 milliseconds between the start of each triplet).
224251729|NCT05593965|DEVICE|Arrhythmic TMS|TMS will be delivered in an arrhythmic pattern in which pulses are delivered with a random inter-pulse interval. The number of pulses and duration is matched to that of the Delta-beta TMS and Theta-gamma TMS.
224251730|NCT04494867|DEVICE|Core Warming|Esophageal heat transfer device will be set to 42°C temperature after initial placement, and maintained at 42°C for the duration of treatment.
224322106|NCT00145951|BEHAVIORAL|motivational interviewing, brief advice in primary care|motivational interviewing, brief advice in primary care
224322107|NCT02635412|OTHER|Scheduled timing of delivery|
223670713|NCT06179342|DIAGNOSTIC_TEST|Multiple-Breath-Washout|One additional diagnostic test is performed using the Multiple-Breath-Washout technology
223670714|NCT04953988|PROCEDURE|Robotic TKA|Robotic TKA
223670715|NCT04953988|PROCEDURE|Manual operation|Manual operation
223670716|NCT04918342|OTHER|Multidimensional Exercise Program|The multidirectional exercise program will include cardiovascular training, strengthening, balance training, and flexibility training. This will be delivered 2 times per week for 8 weeks using telehealth and will be delivered by a physical therapist. The exercises will be modified to meet the participants needs. Intensity of exercise interventions will be monitored through patient self report and use of continuous heart rate monitoring.
223670717|NCT02491229|OTHER|Hepafast|Two weeks of Hepafast three times a day and additionally 200 kcal followed by 10 weeks of Hepafast two times a day and a meal according to LOGI diet
223670718|NCT02491229|OTHER|LOGI diet|For twelve weeks, this group eats meals according to the Low Glycemic and Insulinemic Diet (LOGI).
223670719|NCT06276504|DRUG|Pembrolizumab, 25 mg/ml solution for intravenous (IV) injection|Pembrolizumab administration at D0, M1 and M2
223670720|NCT00013702|DRUG|Adefovir|
223670721|NCT02351427|DRUG|Bortezomib|In one group, investigators administer bortezomib and steroid to manage acute cellular rejection in kidney transplantation, and compare the results with another group in which only steroid was administered.
224251731|NCT04494867|OTHER|Standard of Care|Standard temperature management and treatment
223670722|NCT02351427|DRUG|Steroid|Investigators administer steroid in both groups for conventional treatment of acute cellular rejection.
223670723|NCT03596749|DRUG|Sevelamer Carbonate|Sevelamer carbonate 1600mg (p.o. b.i.d) with meals
223670724|NCT03053206|DRUG|ADE Protocol|"ADE chemotherapy~Cytarabine (100mg/m2 d1-d10 BD), Daunorubicin (50mg/m2 d1-d3) and Etoposide (100 mg/m2 d1-5) over a period of 10 days"
223670725|NCT02154828|BEHAVIORAL|Integrative practices|
224251732|NCT03613922|OTHER|Early Manual Therapy|Mulligan's Mobilization with Movement technique for radiocarpal,ulnocarpal, distal radioulnar and proximal radioulnar joints was applied.
223771628|NCT04448470|DIAGNOSTIC_TEST|Pulmonary function test|The measured values of spirometry/body plethysmography, CO diffusion and blood gas analysis are documented, if available.
223771629|NCT04448470|DIAGNOSTIC_TEST|Polygraphy|Polygraphy is a non-invasive portable examination method that the patient uses in the home environment at night to measure possible sleep-related breathing disorders. Typically, the following measurement signals are recorded: nasal airflow, thoracic and abdominal breathing excursions, snoring and breathing sounds via a microphone, pulse, oxygen saturation and position. The evaluation results and the findings are checked by a physician. Essential parameters include the apnoea-hypopnoea index, the number of obstructive, central and mixed apnoea/hypopnoea, the number and duration of desaturation, snoring or the association with a certain position.
223771630|NCT02851576|OTHER|Infusion of ADV specific T cells|Cell engineering
223771631|NCT04337567|PROCEDURE|radiofrequency ablation|ablative treatment as allocated to radiofrequency ablation
223771632|NCT04337567|PROCEDURE|ballon cryoablation|ablative treatment as allocated to ballon cryoablation
223771633|NCT06292143|OTHER|Advance Care Planning Toolkit|Participants or their caregivers will access the digital platform for advance care planning
223771634|NCT02568410|PROCEDURE|coronary artery bypass grafting using cardiopulmonary bypass|no study intervention. Study cohort will undergo coronary artery bypass grafting using cardiopulmonary bypass according to standard practices at DUMC
223771635|NCT01511380|BEHAVIORAL|Risk Reduction Therapy for Adolescents|This project integrates CM and a family systems intervention for sexual risk with evidence-based family engagement strategies, and tests this intervention in a juvenile drug court setting. Due to the individualized nature of the proposed intervention, the specific course of treatment will vary by youth and family. Based on our experience with clinic-based treatment models it is anticipated that most families will remain in active treatment for 4-6 months and that, during this time, they will attend approximately 1-2 sessions per week, for 1-2 hours per session.
223771636|NCT01511380|BEHAVIORAL|Usual services|In addition to the standard juvenile drug court requirements, youth randomly assigned to the usual services condition are also ordered to receive treatment services from the local state or privately-funded alcohol and drug treatment provider agencies. The service delivery model for agencies typically includes intensive outpatient, traditional outpatient, and home-based services, depending upon assessment of youth and family needs. Groups focus on risk reduction, peer influence, conflict resolution, and anger management. Additionally, youth might receive treatment pertaining to drug selling behavior, individual sessions and/or family group therapy. The theoretical orientations of the provider agencies are cognitive-behavioral and systems theory. Interventions are not usually manual driven, and selection of material is typically left to the therapists' discretion.
223771637|NCT02419716|DEVICE|Cologuard|Prescription of Cologuard for at-home stool collection
223771638|NCT05734092|DEVICE|Traditional orthodontic treatment|As for patients in the control group, the strength of the nickel-titanium coil will be adjusted every 4 weeks to the required strength of 40 g on each end until reaching normal coverage.
223771639|NCT05734092|DEVICE|Low-Level Laser|"The laser will be applied to the root of each of the upper incisors in 8 points (4 points from the labial and 4 points from the palatine), and the head of the device will be placed from the labial side of the root in the center of each of the apical and middle thirds and the mesial and distal of the cervical third in contact with Oral mucosa perpendicular to the root axis, with the application of the laser beam for (16) seconds at one point, and the laser will be re-applied in the same way from the palatal side of the root. So that it was the total application time is (128) seconds for one tooth.~The laser will be applied on the day the upper incisor intrusion started (T1), then on days (3, 7, and 14) of the first month, and starting from the second month, the laser will be applied every (15) day, in addition to adjusting the force gauge every 4 weeks until the end of intrusion stage (T2) and reaching normal coverage."
223771640|NCT02509741|BEHAVIORAL|Education|
223771641|NCT02509741|DIETARY_SUPPLEMENT|Food replacement|
223670726|NCT06434987|PROCEDURE|Retrograde Inferior Vena Cava Perfusion|Retrograde inferior vena cava (RIVP) involves perfusing oxygenated blood into the inferior vena cava, which then flows towards the viscera, abdominal organs and lower extremities. By maintaining perfusion to these regions during cardiopulmonary bypass (CPB) and induced hypothermia, Retrograde inferior vena cava (RIVP) helps mitigate the risk of ischemic injury to the abdominal organs. Following the initiation of total cardiopulmonary bypass, the body temperature will be gradually lowered to achieve deep-moderate hypothermia ( 24-38°C). This procedure will involve the combination of selective antegrade cerebral perfusion and retrograde inferior vena cava perfusion. Antegrade perfusion will be maintained at a flow rate of 5-7mL/min/kg, while retrograde perfusion will be regulated to sustain the required pumm pressure and blood flow.
223771642|NCT02509741|BEHAVIORAL|IOT monitoring|
223771643|NCT05572905|OTHER|Exercise|Patients after overnight fast will cycle on ergo-meter for 60 minutes. No per-oral food intake will be allowed during the test. Level of the intensity of exercise will be determined as individual range of heart frequency (HF), oxygen consumption (VO2) and respiratory quotient (RQ) just bellow the aerobic threshold of the given participant (close to anticipated fatmax). These values will be obtained during maximal capacity stress test on cyclo-ergo-meter. This maximum stress test will be performed at least one week prior to the 60 minutes exercise to eliminate potential carry-over effect. Power output will be modulated during the 60 minutes of exercise to ensure keeping participants values of HF, RQ and VO2 in the given range. Blood will be sampled at 5 time points with interval of 30 minutes during the exercise (0, 30, 60, 90, 120) and 24 hours post-exercise.
224251733|NCT03613922|OTHER|Routine Physiotherapy|Routine physiotherapy program consisted of range of motion, flexibility and strengthening exercises, and home exercise program was applied.
224251734|NCT04511507|PROCEDURE|hemoadsorption|three consecutive sessions of hemoadsorption in patients with liver failure
224251735|NCT03437148|DEVICE|Innocor®|Inert gas rebreathing device: Innocor® (Innovision, Odense, Denmark)
224251736|NCT03437148|DEVICE|Physioflow®|Bioimpedance cardiograph: Physioflow® (Manatec, France)
224251737|NCT01077596|DRUG|Regular bupropion use|Regular use of bupropion is defined as use at least 4 times per week for at least 3 continuous months at least 12 months before index date.
224251738|NCT01077596|DRUG|Regular SSRI (Selective serotonin reuptake inhibitors) use|Regular use of SSRI is defined as use at least 4 times per week for at least 3 continuous months at least 12 months before index date.
224251739|NCT01077596|DRUG|Regular TCA (Tricyclic antidepressants) use|Regular use of TCA is defined as use at least 4 times per week for at least 3 continuous months at least 12 months before index date.
224251740|NCT01077596|DRUG|Regular use of any other antidepressant|"Regular use of any other antidepressants is defined as use at least 4 times per week for at least 3 continuous months at least 12 months before index date. An other antidepressant would be any antidepressant other than bupropion, a SSRI or a TCA."
224251741|NCT01091090|BEHAVIORAL|Cognitive behavioral|Cognitive behavioral intervention for smoking cessation
224251742|NCT01091090|BEHAVIORAL|Control|Treatment as usual
224251743|NCT03616106|OTHER|Infographic intervention|All study participants will receive health education using infographics during their regularly scheduled clinic appointments.
224251744|NCT02804204|DRUG|Anti-TNF|
224251745|NCT04191993|DEVICE|Total hip arthroplasty|Surgical intervention designed to replace arthritic joint with artificial implant
224251746|NCT02372630|DRUG|Linagliptin|5 mg daily oral tablets of linagliptin
224251747|NCT02372630|DRUG|Placebo|matching placebo giving orally daily
224251748|NCT02623543|DEVICE|OrthoK|
224251749|NCT00534443|PROCEDURE|Endoscopy of upper GI tract|"Upper GI endoscopy, one time on diagnosis and a second time 15 days after the end of the treatment. Gastric juice will be aspirated immediately after the entrance of the endoscope into the gastric lumen. Four biopsy specimens will be obtained from adjacent areas of the gastric antrum. Each biopsy will be used for in vitro culture. Blood will be sampled from one antecubital vein under aseptic conditions.~Each patient will be given antisecretory treatment and - if necessary- eradication treatment of H. pylori according to international guidelines."
224251750|NCT03619005|DRUG|Placebo Vaginal Insert|Daily administration of a placebo vaginal insert.
224251751|NCT03619005|DRUG|Prasterone 6.5 mg (0.50%) Vaginal Insert|Daily administration of a 6.5 mg (0.50%) prasterone vaginal insert.
224251752|NCT02548897|DEVICE|Deep brain stimulation|The programming of DBS settings in all participants with bilateral DBS implants in the globus pallidus internus (GPi) and pedunculopontine nucleus (PPN) will be performed.
224251753|NCT02548897|OTHER|Electroencephalography|An electroencephalography (EEG) will be performed on all participants to better understand the neurophysiological underpinnings of the symptom.
224251754|NCT02218411|OTHER|Exercise training|Exercises routine based on the Otago exercise programme
224251755|NCT02911597|DRUG|Naltrexone|adding naltrexone (or placebo) to a ketamine infusion to potentially block the effects of ketamine as an anti depressant.
224251756|NCT01690494|BEHAVIORAL|PACT|Couple-based behavioral HIV/STI preventive intervention
224251757|NCT01690494|BEHAVIORAL|TAU|Standard treatment of care services provided to male offenders by the Criminal Court, Community Court or probation sites
224251758|NCT04460105|DRUG|Lanadelumab|Participants will receive 300 mg of lanadelumab IV infusion on Day 1 and Day 4.
224251759|NCT04460105|OTHER|Placebo|Participants will receive placebo matching IV infusion on Day 1 and Day 4.
224251760|NCT00360997|BEHAVIORAL|Conventional UK physical therapy|
224251761|NCT00360997|PROCEDURE|Con UK PT + Mobilisation & tactile stimulation (MTS)|Con UK PT + Mobilisation \& Tactile Stimulation (MTS) which is further randomised to 30, 60 or 120 mins/day
224251762|NCT02750124|DEVICE|Cobas PCR Female swab sample Packet|The cobas® PCR Female Swab Sample Kit is used to collect and transport vaginal swab specimens self-collected.
224322108|NCT06456021|BEHAVIORAL|The Relational Playbook|The Relational Playbook consists of 5 chapters and hosts research-based resources and 50 evidence-based interventions presented in short, digestible content to create supportive learning environments. Implementation is guided by 4-steps: Step 1) Assess the current state: CCL managers assesses the current state of their learning environment through a 13-item Learning Environment Assessment Tool. Results are automatically scored and grouped by Playbook chapters. A summary report is immediately available with guidance on how to interpret results. Step 2) Select areas for improvement: CCL managers determine which Playbook chapters and interventions to adopt. Step 3) Implement/adapt interventions: Over the 6-month intervention period, CCL managers are required to implement interventions from 2-3 Playbook chapters. They may adapt the delivery method/implement additional interventions. Step 4) Evaluate the impact: CCL managers develop feedback loops to monitor intervention performance.
224251763|NCT02750124|OTHER|Routine practice|The standard, annual renewed invitation to cervical screening.
224251764|NCT05986357|DIAGNOSTIC_TEST|maternal serum C reactive protein|maternal serum high sensitivity C reactive protein
224251765|NCT05986357|DIAGNOSTIC_TEST|total leucocytic count levels|total leucocytic count levels
224251766|NCT05986357|DIAGNOSTIC_TEST|differential leucocytic count levels|differential leucocytic count levels
224251767|NCT05076305|OTHER|No specific intervention; cases are retrospective and patients have already been treated.|To assess the geographic variation that exists in the management of locally advanced and recurrent rectal cancers.
224251768|NCT04408144|DRUG|Dydrogesterone 10mg Oral Tablet|oral 10mg dydrogesterone (Duphaston) 2 times daily
224251769|NCT05914857|DRUG|Dapagliflozin 10mg Tab|Dapagliflozin Tablets, Oral, 10mg, Once daily
224251770|NCT05914857|BEHAVIORAL|lifestyle interventions|Consisting of 30 minutes of moderate-intensity exercise every day and a reduction of 300 calories in the total diet
224251771|NCT01454544|BIOLOGICAL|AIT Tablet|1 tablet per day in 12 months
224251772|NCT03206177|DRUG|Galunisertib|Galunisertib 150mg po BID day 4-17
224251773|NCT03206177|DRUG|Paclitaxel|IV Day 1: Paclitaxel 175 mg/m2 over 3 hours
224251774|NCT03206177|DRUG|Carboplatin|IV Day 1: Carboplatin AUC 6\* over 1 hour (or 5\* if prior radiation therapy)
224251775|NCT00383097|GENETIC|LMP1 SPECIFIC CYTOTOXIC T-LYMPHOCYTES|1 injection One of the following 4 dose levels: 2x 10\^7 cells/m2, 1x 10\^8 cells/m2, 3 x 10\^8 cells/m2, 1 x 10\^9 cells/m2
224251776|NCT00383097|GENETIC|LMP2-SPECIFIC CYTOTOXIC T-LYMPHOCYTES|1 injection One of the following 4 dose levels: 2x 10\^7 cells/m2, 1x 10\^8 cells/m2, 3 x 10\^8 cells/m2, 1 x 10\^9 cells/m2
224251777|NCT03365297|DRUG|Apalutamide|240mg (4x60mg) oral tablets daily over a max. of 90 days
224322109|NCT06456021|BEHAVIORAL|Leadership Coaching|Leadership coaching is a novel implementation strategy that enables proactive, knowledgeable, and supportive leadership behaviors. Although coaching has been embraced in the VA, through Whole Health and the VA Leadership Coaching Program, no studies have examined the impact on innovation implementation with clinical managers.
223670727|NCT06434987|PROCEDURE|Antegrade cerebral perfusion|After mild to moderate hypothermia is achieved, a cannula will be inserted into the right axillary artery, brachiocephalic or innominate artery to provide continuous flow to the brain. A flow rate of 5-7mL/min/kg will be maintained.
223670728|NCT00668993|BEHAVIORAL|EFT - the Emotional Freedom technique|"EFT combines cognitive strategies with somatic procedures adapted from acupuncture and related systems for altering the cognitive, behavioural, and neurochemical foundations of psychological problems. It is often referred to as psychological acupuncture. Few adequately controlled studies have been conducted on EFT however acupuncture has been quite extensively studied, with hundreds of research reports published"
223771644|NCT05572905|OTHER|Fasting control|The same participants will be monitored while resting for 120 minutes in calm environment. No peroral food intake will be allowed during the test. Fasting control will take place at least one week apart of the exercise. Blood will be sampled at 5 timepoints with interval of 30 minutes during the exercise (0, 30, 60, 90, 120) and 24 hours post-control.
224251778|NCT05397093|BIOLOGICAL|ITIL-306|ITIL-306 is a cell therapy product derived from a participant's own TILs and contains a unique molecule designed to increase TIL activity when it encounters FOLR1 on the tumor. A portion of the participant's tumor is surgically removed to make a personalized ITIL-306 product. Once ITIL-306 has been made, the participant is treated with 3 days of lymphodepleting chemotherapy including cyclophosphamide and fludarabine, followed by 2 days of rest then a single infusion of ITIL-306.
224251779|NCT03962348|BEHAVIORAL|Specialized Early Engagement Support Service|The Specialized Early Engagement Support Service (SEESS - a Social Worker and Peer Specialist) will link detainees with first-episode psychosis (FEP), using tenets of person-centered treatment and shared decision-making, and the Critical Time Intervention model, to community-based Coordinated Specialty Care (CSC).
224251780|NCT02963259|DEVICE|SJM Infinity™ DBS IPG or SJM Brio™ DBS IPG system|Implanted Medtronic® IPG will be explanted and replaced by a SJM Infinity™ DBS IPG or a SJM Brio™ DBS IPG system
224251781|NCT04236960|BIOLOGICAL|Meningococcal Group ACYW135 Conjugate Vaccine|1 dose in Stage 1 (2\~55 yrs), 2 doses in Stage 2 (7\~23 mos), and 3 doses in Stage 3 (2\&3 mos)
224251782|NCT01472393|DIETARY_SUPPLEMENT|Creatine supplementation|The CR group will receive either 1g or 3g of Cr monohydrate (Creapure®) per day throughout the trial. The dose of creatine will be formulated in a tablet.
224251783|NCT01472393|DIETARY_SUPPLEMENT|dextrose (placebo)|The placebo group will be given the same dose of dextrose formulated in a tablet to be consumed under the same conditions. The two types of tablets will not be distinguishable from each other having the same appearance, taste and smell.
224251784|NCT00731705|PROCEDURE|collection of peripheral blood and apheresis samples|Sixty mL of peripheral blood will be collected from consenting eligible donors. Additionally, after the laboratory techniques have been fully evaluated, leukopheresis samples will also be collected.
224251785|NCT02458586|DIETARY_SUPPLEMENT|Dietary intervention / counseling|dietary counseling and daily intake of 50 g of dietary oil over a period of 8 weeks
224251786|NCT02744820|DRUG|GMC-252-L-Lysine Salt|1 dose by oral route, once a day, 28 days
224251787|NCT02744820|OTHER|Placebo|Matching doses by oral route, once a day, 28 days
224251788|NCT01436422|BIOLOGICAL|TetraVax-DV Vaccine - Admixture TV003|One subcutaneous injection at Day 0 and Day 180 of a live attenuated recombinant TetraVax-DV vaccine, Admixture TV003 (10\^3 PFU of rDEN1Δ30, 10\^3 PFU of rDEN2/4Δ30(ME), 10\^3 PFU of rDEN3Δ30/31-7164, and 10\^3 PFU of rDEN4Δ30)
224251789|NCT01436422|BIOLOGICAL|TetraVax-DV Vaccine - Admixture TV005|One subcutaneous injection at Day 0 and Day 180 of a live attenuated recombinant TetraVax-DV vaccine, Admixture TV005 (10\^3 PFU of rDEN1Δ30, 10\^4 PFU of rDEN2/4Δ30(ME), 10\^3 PFU of rDEN3Δ30/31-7164, and 10\^3 PFU of rDEN4Δ30)
224251790|NCT01436422|BIOLOGICAL|Placebo|One subcutaneous injection at Day 0 and Day 180 of placebo
224251791|NCT01448798|PROCEDURE|Application of a hemostatic gelatin-thrombin matrix|Hemostatic gelatin-thrombin matrix is used for hemostasis during nerve-sparing dissection of the prostate.
224251792|NCT01448798|PROCEDURE|Use of mono- and bipolar electrocautery and surgical clips|Mono- and bipolar electrocautery and surgical clips are used for hemostasis during nerve-sparing dissection of the prostate.
224251793|NCT00191022|DRUG|LY686017|
224251794|NCT00191022|DRUG|paroxetine|
224251795|NCT00191022|DRUG|placebo|
224251796|NCT02828709|DEVICE|Irreversible Electroporation|Guided by CT and accompanied by an external spacer for fixation, needle electrodes will be placed. The amount of probes and probe placement will be attuned for specific tumour size and location, granting 15mm between the electrodes with an active tip length of 15mm. IRE pulses with pulse intensity of 1500 V/cm will be delivered in 90 consecutive pulses of 90µs.
224251797|NCT05087134|DRUG|11C-Choline|11C-Choline were injected into the patients before the PET/CT scans
224251798|NCT00757874|DRUG|Tacrolimus cream|0.5 g per day at bed time for 3 months or less.
224251799|NCT00757874|DRUG|Clobetasol cream|0.5 gram each day at bed time during 3 months or less.
224251800|NCT03919630|OTHER|Thrust Mobilization|Once therapist has assessed subject and has found the patients most comparable sign they will be performing a high velocity thrust at the end of the patients available range, as described by Maitland's Approach. The thrust will be performed only once. The therapist will perform either a localized cervical rotation thrust which primary movement is rotation or a longitudinal cephalad C1 and C2 thrust, both targeting the upper cervical spine
224251801|NCT03919630|OTHER|Non-Thrust Mobilizations|Therapists will perform unilateral posterior to anterior mobilization (UPA) or central posterior to anterior (CPA) mobilizations grades I-IV as described above by Maitland concepts at levels C0-C3 which reproduce the patient's most comparable sign. Therapists will be instructed to perform 3x 30 second bouts of mobilizations at that level.
224251802|NCT03584139|DEVICE|IRIS HOOK|iris hook assisted maneuver in phacoemulsification
224251803|NCT03584139|DEVICE|TRADITION|traditional phacoemulsification or phacoemulsification with 25-gauge vitreous irrigation
224251804|NCT04611789|DRUG|LY3832479|Administered subcutaneously
224251805|NCT04611789|DRUG|Placebo|Administered subcutaneously
224251806|NCT05357417|DRUG|utidelone|30mg/m2 (±10%), day 1-5 every 3-week cycle
224251807|NCT05357417|DRUG|Bevacizumab|15mg/kg, day 1
224251808|NCT02466880|DEVICE|Telemedicine|A diabetes self-management and education program delivered via telemedicine
223771645|NCT02875119|DRUG|Griffithsin Gel|"Griffithsin Gel is a large biologic molecule that is intended for vaginal rather than systemic administration. In addition, Griffithsin Gel is being developed for the prevention of HIV infection and not as a therapeutic agent. The concentration of Griffithsin Gel associated with prevention of HIV in vitro and in vivo has been established in non-clinical studies (see Section 5). Studies have demonstrated that Griffithsin Gel is highly potent for HIV prevention and is effective at very low concentrations.~One 4 mL dose of PC-6500, designed to provide an adequate vaginal concentration of GRFT for the prevention of HIV, based on preclinical data, will be evaluated. Rising dose tolerance is not the goal of this study because GRFT is likely to be minimally absorbed systemically, if at all."
223771646|NCT02875119|DRUG|Placebo Gel|Placebo Gel
223771647|NCT03536728|DRUG|AMXT1501|AMXT 1501 dicaprate is D-lys(palmitoyl)-spermine dicaprate salt in 40 mg or 200 mg (free base content) enterically-coated capsules
223771648|NCT03536728|DRUG|DFMO|DFMO is DL-2-(difluoromethyl) ornithine monohydrochloride monohydrate 250 mg in hard gelatin capsules
223771649|NCT04073316|DRUG|Rivaroxaban 20 MG|Rivaroxaban intake, 20mg/day
223771650|NCT04073316|DRUG|Warfarin|Warfarin intake, with target INR range between 2 and 3
223771651|NCT04592705|DEVICE|Therapeutic plasma exchange|"TPE is the process of plasmapheresis, an invasive procedure separating plasma from red blood cells using centrifuge-based devices.~Filtration involves the insertion of a central venous catheter in the internal jugular, femoral or subclavian vein after which blood is drawn from the patient's circulation and transferred to a filter that separates the plasma from blood cells. Thereafter, the plasma extracted is substituted with human albumin and/or FFP."
223771652|NCT05914467|DRUG|Teicoplanin|Dose will be adjusted in the study arm using MIPD guided TDM- dosing
223670729|NCT04037332|OTHER|Blood sample (combined with malaria RDT) followed by gentoyping analysis|Finger-prick blood samples collected from children with signs of severe febrile illness and a positive mRDT presenting to community-based providers and referral facilities ; analysis for mutations in portions of a P. falciparum gene encoding kelch (K13)-propeller domain
223771653|NCT00040040|DRUG|Bupropion|
223771654|NCT00666367|DRUG|D-cure|4 ml of D-cure (SMB oral intake) in syringe Exacta-Med Oral Dispenser.
223771655|NCT00666367|DRUG|Placebo|4 ml of Arachidis oleum raffinatum Ph. Eur. in syringe Med Oral Dispenser.
223771656|NCT05336500|OTHER|Pilates method exercises|Participants will be randomised into two groups that will be treated with Pilates exercises for 12 weeks (twice a week for 60 minutes). The control group will receive guidance on the specific activation of the center of strength (the powerhouse), while the experimental group will receive guidance to perform the exercises in a relaxed and smooth way.
224251809|NCT02466880|OTHER|Usual care|A 15-30 minute diabetes self-management session. Continued care, as usual, from their primary care provider throughout duration of active 12 month intervention period.
224322110|NCT02832011|DIETARY_SUPPLEMENT|olive oil|The infants fed with olive oil will have received same amount of calorie with infants who will receive eoprotin-fortified breast milk.
223670730|NCT01155167|DRUG|Nitroglycerin and lidocaine|Topical Nitroglycerin and lidocaine
223670731|NCT01155167|OTHER|Placebo|Placebo
223670732|NCT05041608|PROCEDURE|Endoscopic Surgery|These procedures include: POEM (Peroral Endoscopic Myotomy) for Achalasia, G-POEM (Gastric Peroral Endoscopic Myotomy) for gastric outlet obstruction, Z-POEM (Peroral endoscopic myotomy for Zenker's Diverticulum), EMR (Endoscopic Mucosal Resection), ESD (Endoscopic submucosal dissection), STER (Submucosal tunneling endoscopic resection), NOTES (Natural Orifice Translumenal Endoscopic Surgery), TIF (Transoral Incisionless Fundoplication), Endoscopic Fistula Closure, Endoscopic Suturing, Capsule Endoscopy and EFTR (Endoscopic full-thickness resection).
223670733|NCT00286559|DRUG|SonoVue|
223771657|NCT03058796|DEVICE|Contralaterally Controlled Functional Electrical Stimulation (CCFES)|The use of surface electrodes over the paretic finger and thumb extensors to deliver electrical stimulation with an intensity that is proportional to the degree of opening of the contralateral unimpaired hand wearing an instrumented glove. uses surface electrodes over the paretic finger and thumb extensors to deliver stimulation with an intensity that is proportional to the degree of opening of the contralateral unimpaired hand wearing an instrumented glove.
223771658|NCT03058796|DEVICE|Hand Therapy Video Games|The use of video games with CCFES to encourage therapeutic hand movement at home
223771659|NCT04963504|DIAGNOSTIC_TEST|Rest-to-exercise|Pulmonary diffusing capacity is assessed at rest and during exercise (70% of VO2max on a bicycle ergometer)
224322111|NCT02832011|DIETARY_SUPPLEMENT|Eoprotin|Low birth weight infants are premature infants that born with birth weight less than 1500 g. Because these infants have low birth weight, weight gain can be increased by fortifying breast milk after post-natal 7 with eoprotin.
224322112|NCT03232593|DRUG|Atezolizumab|Participants will receive atezolizumab as per the local label and standard of care at physician's discretion.
223670734|NCT00286559|DRUG|Optison|
223771660|NCT04963504|DIAGNOSTIC_TEST|Sitting-to-supine|Pulmonary diffusing capacity is assessed in the sitting and supine position
223771661|NCT04330079|DRUG|Dapagliflozin 10mg|Dapagliflozin 10mg once daily for 6 months.
223771662|NCT04330079|OTHER|Lifestyle modification|lifestyle modification (diet and exercise) for 6 months
223771663|NCT02829359|DRUG|Entecavir therapy|Patients in the antiviral group received entecavir begin in the first 3 days before surgery for at lest 1 month.
223771664|NCT01019681|BIOLOGICAL|Cord blood stem cell injection|"The cord blood stem cells will be simply injected intramuscularly in the leg. 30 minutes prior to stem cell injection the patients will receive Vancomycin 1 gram IVPB x1 as a prophylactic measure. Patients will also receive Ativan 0.5 to 1 mg PO x 1 and Dilaudid 0.5 to 1 mg IV x1 to alleviate the discomfort of the procedure.~Cells will be injected by means of a 22 gauge sterile spinal needle after topical anesthesia of the injection site. The concentration will be at least 2 x 107 total nucleated cells per ml in phosphate buffered saline (PBS) with 5% human serum albumin (Baxter, Deerfield Illinois)."
223771665|NCT00568984|DRUG|repaglinide|
223771666|NCT00568984|DRUG|metformin|
223771667|NCT00568984|DRUG|glicazide|
223771668|NCT05163912|BEHAVIORAL|Virtual home intervention|Group classes with active videogames and discussions
223771669|NCT06572410|DEVICE|EnVisio Navigation System|Patient will be undergoing BCS Breast Conserving Surgery treatment for DCIS or invasive breast cancer with EnVisio Navigation System.
223771670|NCT03586869|DRUG|Aldoxorubicin HCl|Aldoxorubicin Hydrochloride
224251810|NCT01549080|DRUG|Yisuishengxue Granule|Yisui Shengxue Granules，produced by pharmaceutical factory of Guang'anmen Hospital, China Academy of Chinese Medical Sciences, is made from the herbs of Shan Zhu Yu (Fructus Corni), He Shou Wu (Radix Polygoni Multiflori), Shu Di Huang (Radix Rehmanniae Preparata), Huang Qi (Radix Astragali) and etc.Yisui Shengxue Granules：12g/bag， Registration Number：20110602； Yisui Shengxue Granules replacer (placebo)：12g/bag，Registration Number：20110519；Treatment group：Yisui Shengxue Granules，1 bag, tid, po； Control group: Yisui Shengxue Granules replacer (placebo), 1 bag, tid, po; Intervention for 12 weeks. Follow-up 3 months later after stopping the drug intervention.
224251811|NCT00727961|DRUG|Pegylated Liposomal Doxorubicin hydrochloride|Caelyx Intravenous, 50 mg/m\^2 (60 minute infusion) on day 1, every 4 weeks, during 6 cycles
224251812|NCT03338075|RADIATION|fractionated stereotactic radiotherapy|The regular prescription doses were 52 Gy in 13 fractions or 52.5 Gy in 15 fractions.
224251813|NCT03386019|OTHER|Lymphatic massage|One certified physical therapist will perform the massage regimens and techniques adapting from Swedish massage such as effleurage and petrissage that will be used in the massage group. Participants will first lay down in prone position, and the massage leg will be supported on the therapist's leg or on pillows with legs being positioned at approximately 30 degrees of knee flexion. This can promote venous return of the lower legs and also keep the ankle plantar flexors in a relative low muscle tension position. After positioning, long strokes will be applied from the distal to proximal part of gastrocnemius with approximately 20 repetitions and then 20 repetitions of circular strokes would be applied at the popliteal fossa. Finally, therapist will knead around participant's Achilles tendon for 10 repetitions.6 The combination of the techniques mentioned above will repeat 3 times in each subject, and the total duration of massage will be approximately 5 minutes.
224251814|NCT03386019|OTHER|Static stretching|For the static stretching group, participants will perform the standing gastrocnemius stretches. First, participant stands facing a wall and put the stretched leg behind the body. Physical therapist will ask the participant to slightly flex the front leg, and keep back leg extended with heel on the ground. Both toes will be positioned pointing forward. Participant will then be asked to lunge forward slowly until the calf muscles on the back leg feeling stretched. Participant will hold in this position for 60 seconds and repeat 3 times.
224251815|NCT03386019|OTHER|Cold water immersion|In the cold-water immersion group, participant's lower leg will be put in a bucket filled with cold water for 10 minute. The temperature of the water will be kept in 11-15 degrees Celsius.52 The water level should reach participant's fibular head to ensure complete immersion of the lower leg.
224251816|NCT04357639|OTHER|No intervention|No intervention: Usual care for nasopharyngeal sampling and blood sampling for COVID-19 detection
224251817|NCT03880266|DRUG|Glycopyrronium cloth, 2.4%|Pre-saturated 100% polypropylene, nonwoven, fabric cloth with glycopyrronium
224251818|NCT03880266|DRUG|Vehicle|Pre-saturated 100% polypropylene, nonwoven, fabric cloth
224251819|NCT03552250|BEHAVIORAL|Parenting for Lifelong Health for Young Children|In this study, the 12 sessions-PLH version for parents of young children (2-9 years) will be delivered. The PLH (2 - 9) programme is delivered in groups of parents and includes the following general content 1) One-on-one time, 2) Say what you see, 3) Talking about feelings, 4) Praising and rewarding our children, 5) Giving positive, specific, and realistic instructions, 6) Establishing household rules and routines, 7) Redirecting negative behavior, 8) Ignoring negative attention seeking and demanding behavior, 9) Using consequences to support compliance, 10) Using Cool-down as a consequence for aggressive behavior, 11) Avoiding and resolving conflicts, 12) Reflection celebration, and moving on.
223670735|NCT02243423|PROCEDURE|SUPINE|"Patients in the SUPINE group will receive spinal anesthesia for cesarean section in the sitting position, after which they will lay supine horizontal on the surgical table.~A phenylephrine intravenous infusion will be titrated according to a set protocol, to maintain the systolic blood pressure at baseline."
223670736|NCT02243423|PROCEDURE|TILT|"Patients will receive spinal anesthesia for cesarean section in the sitting position, after which they will lay on the surgical table, which will be tilted to the left by 15°.~A phenylephrine intravenous infusion will be titrated according to a set protocol to maintain the systolic blood pressure at baseline."
223670737|NCT00649597|DRUG|Benazepril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg|20/25mg, single dose fasting
223670738|NCT00649597|DRUG|Lotensin HCT® Tablets 20 mg/25 mg|20/25mg, single dose fasting
223771671|NCT03586869|BIOLOGICAL|ALT-803|Recombinant human super agonist interleukin-15 (IL-15) complex
223771672|NCT03586869|BIOLOGICAL|ETBX-011|Ad5 \[E1-, E2b-\]-CEA
223771673|NCT03586869|BIOLOGICAL|ETBX-021|Ad5 \[E1-, E2b-\]-HER2
223771674|NCT03586869|BIOLOGICAL|ETBX-051|Ad5 \[E1-, E2b-\]-Brachyury
224251820|NCT04549883|OTHER|Theoretical practical educational session|1 Theoretical practical educational session of 15 Min about the importance of low back control during hip extension. Includes anatomical issues and one practical exercise in quadruped position
223771675|NCT03586869|BIOLOGICAL|ETBX-061|Ad5 \[E1-, E2b-\]-MUC1
223771676|NCT03586869|BIOLOGICAL|GI-4000|RAS yeast
223771677|NCT03586869|BIOLOGICAL|GI-6207|Carcinoembryonic Antigen (CEA) yeast
223771678|NCT03586869|BIOLOGICAL|GI-6301|Brachyury yeast
223771679|NCT03586869|BIOLOGICAL|haNK for infusion|NK-92 \[CD16.158V, ER IL-2\]
223771680|NCT03586869|BIOLOGICAL|bevacizumab|Recombinant human anti-Vascular Endothelial Growth Factor (VEGF) IgG1 monoclonal
223771681|NCT03586869|DRUG|Capecitabine|5'-deoxy-5-fluoro-N-\[(pentyloxy) carbonyl\]-cytidine
223771682|NCT03586869|DRUG|Cyclophosphamide|2-\[bis(2-chloroethyl)amino\]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
223771683|NCT03586869|DRUG|Fluorouracil|5-fluoro-2,4 (1H,3H)-pyrimidinedione
223771684|NCT03586869|DRUG|Leucovorin|L-Glutamic acid, N-\[4-\[\[(2-amino-5-formyl-1,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)methyl\]amino\]benzoyl\]-, calcium salt
223771685|NCT03586869|DRUG|nab-Paclitaxel|Benzenepropanoic acid, β-(benzoylamino)-α-hydroxy-(2aR, 4S, 4aS, 6R, 9S, 11S, 12S, 12aR, 12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a, 3, 4, 4a, 5, 6, 9, 10, 11, 12, 12a, 12b-dodecahydro-4,11-dihydroxy-4a, 8, 13, 13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca\[3,4\]benz\[1,2-b\]oxet-9-y1ester,(αR,βS)-(9CI) bound to albumin
223771686|NCT03586869|DRUG|Oxaliplatin|cis-\[(1 R,2 R)-1,2-cyclohexanediamine-N,N'\] \[oxalato(2-)- O,O'\] platinum
223771687|NCT03586869|BIOLOGICAL|Avelumab|Recombinant human anti-programmed death-ligand 1 (PD-L1) IgG1 monoclonal antibody
223771688|NCT03586869|PROCEDURE|SBRT|Stereotactic Body Radiation Therapy
223670739|NCT03355547|OTHER|questionnaire about the severity of their symptoms of upper respiratory tract infection|Before the operation, the researcher interviews the parents of the pediatric patients to check whether they have the upper respiratory tract infection and asks them to fill out a questionnaire about the severity of their symptoms. The questionnaire consists of 8 types of symptom about upper respiratory infections and each symptom was checked from 0 to 3 according to severity by their patients.
223670740|NCT00167778|DEVICE|Transverse plane rotation adaptor pylon|Potential future practice
223670741|NCT00167778|DEVICE|Rigid pylon|Current clinical practice
223670742|NCT02654717|DRUG|DFD-07 Cream|
224251821|NCT06041061|BIOLOGICAL|Recombinant 14-Valent Human Papillomavirus Vaccine（Insect Cell）|According to the 0, 2, and 6 months immunization program, intramuscular injection of the upper arm deltoid muscle, 3 doses of the experiment vaccine
224251822|NCT06041061|BIOLOGICAL|placebo|According to the 0, 2, and 6 months immunization program, intramuscular injection of the upper arm deltoid muscle, 3 doses of the placebo
224251823|NCT02492568|DRUG|pembrolizumab|
223670743|NCT02654717|DRUG|Placebo Cream|
223670744|NCT00799175|DRUG|ropivacaine, ketorolac and epinephrine|In Group A, 400 mg ropivicaine, 30 mg ketorolac and 0.5 mg epinephrine (total volume 166 ml) are infiltrated by the surgeon into the soft tissues peri-articularly during the operation in the following way: Before inserting the components, 20-30 ml are injected into the posterior capsule and before closure of the wound the rest is injected into the capsule incision, the synovium, the ligament and the subcutaneous tissue. After 21 postoperative hours in Group A, 200 mg ropivicaine, 30 mg ketorolac and 0.1 mg epinephrine, total volume 22 ml, are injected intraarticularly via the catheter.
223670745|NCT00799175|DRUG|saline|In Group P (placebo) no injections were given intraoperatively. All patients had a tunnelled intra-articular multihole 20-G catheter placed at the end of the operation by the surgeon.After 21 postoperative hours 22 ml of saline was injected intraarticularly via the catheter.
223670746|NCT04187872|COMBINATION_PRODUCT|LITT + Pembrolizumab|Each patient will undergo brain biopsy and laser interstitial thermotherapy (LITT). As soon as possible, no later than two weeks after LITT, pembrolizumab will be administered via infusion and continue q3wks for up to two years.
223670747|NCT02291653|DEVICE|McGrath|video-laryngoscopy
224251824|NCT02492568|RADIATION|Stereotactic Body Radiation Therapy|
224251825|NCT00118547|BEHAVIORAL|In home monitoring with feedback|Behavioral counseling
224251826|NCT03462654|BEHAVIORAL|iLiFE|In the individual LiFE (iLiFE), the program is taught in seven visits in the individuals' homes within eleven weeks. Participants are supervised in a face to face situation by one qualified trainer (physiotherapist or sports scientist). Each home visit takes between 1 and 1.5 hours. A total of five balance exercises, seven strength exercises for the lower extremities, and two exercises to increase physical activity are taught. In addition to the home visits, all participants receive two 'booster telephone calls' within the remaining weeks until the 6-month follow-up assessments.
224251827|NCT03462654|BEHAVIORAL|gLiFE|The group-based LiFE (gLiFE) program consists of seven group sessions (n = 8-12 participants) which are held over the course of eleven weeks, with a maximum duration of 2 hours per session. Each session is led by two qualified trainers (physio therapists or sports scientists), i.e., one main and one co-trainer. In all group sessions, trainers will teach the participants how to perform and integrate the LiFE program, i.e., LiFE balance and strength activities into their daily routines. After the group sessions have ended, participants will receive two 'booster telephone calls' within the remaining weeks until the 6-month follow-up assessments.
224251828|NCT03161405|DRUG|TAK-906 Maleate|TAK-906 capsule
224251829|NCT03161405|DRUG|Itraconazole|Itraconazole solution
224251830|NCT00993122|DRUG|ribavirin pre-treatment|patients receive ribavirin (10,4 mg/kg/day) and pegylated interferon alfa-2b (1,5 mcg/kg/week).Pre-treatment arm will receive a 8-week monotherapy treatment with only ribavirin (same dosage) and the controlled arm will receive 48 week of standard combined therapy (ribavirin plus pegylated interferon)
224251831|NCT04567147|DIETARY_SUPPLEMENT|Probiotic|Patients received the formula probiotic for consecutive 8 weeks ( one sachet per day ).
224322113|NCT05271656|DEVICE|C-Scan System|Subjects will be provided with contrast agent and dietary fiber pills, and instructed to start intake of fiber pills 5 days, and contrast agent 48 hours prior to scheduled C-Scan capsule ingestion. C-Scan system intervention includes ingestion of the C-Scan Cap and attachment of the C-Scan Track to the subject's lower back. The subject is required to keep the C-Scan Track attached to the lower back and to continue intake of contrast agent and dietary fiber pills until the C-Scan Cap's natural excretion. Standard of care optical colonoscopy will be performed within 60 days from the C-Scan Cap ingestion.
223670748|NCT02291653|DEVICE|MIL|direct-laryngoscopy
223670749|NCT02858817|DRUG|atovaquone/proguanil 250mg/100mg (A/P)|Combination drug for chemo-prophylaxis or treatment of malaria
223670750|NCT02858817|BIOLOGICAL|PfSPZ Challenge (NF54)|cryo-preserved Plasmodium falciparum sporozoites injected by venous inoculation
223670751|NCT02858817|OTHER|NaCl 0,9%|0.9% NaCl solution for injection
223670752|NCT01428947|PROCEDURE|Arterial approach|Randomization to right radial or femoral approach
223670753|NCT04408378|OTHER|observation of covid 19 pneumonia|We try to reveal the fact,covid-19 pneumonia prognosis can be estimated by using MPV/PLT ratio
224251832|NCT04567147|DIETARY_SUPPLEMENT|Placebo|Patients received the placebo identical to probiotic for consecutive 8 weeks ( one sachet per day ).
224322114|NCT03815461|DRUG|Nab-paclitaxel and S-1|Nab-paclitaxel was administered at 125mg/m2 intravenously on day 1 and 8, S-1 （80, 100, or 120 mg/d according to body-surface area on days 1 through 14 of a 21-day cycle for 4-6 cycles.
224322115|NCT06511765|DRUG|Ropivacaine and dexamethasone injection solution|Injection of Ropivacaine and dexamethasone
223670754|NCT00118456|DRUG|AEE788|
224251833|NCT03878654|DRUG|Tauroursodeoxycholic Acid|Naturally occurirng bile acid
224251834|NCT07016425|OTHER|Temporal Interference|Researchers apply temporal interference (TI) stimulation to the deep brain nuclei of essential tremor patients.
224251835|NCT02655679|DRUG|VTP-38543|VTP-38543 topical cream
224251836|NCT02655679|OTHER|Vehicle with Transcutol®P|Vehicle matching VTP-38543 cream with Transcutol®P
224251837|NCT02655679|OTHER|Vehicle without Transcutol®P|Vehicle matching VTP-38543 cream without Transcutol®P
224322116|NCT06511765|DRUG|Sodium Chloride 0.9% Injection Solution|Injection of sodium chloride 0.9%
223771689|NCT04578314|BEHAVIORAL|Relating Therapy|Relating Therapy (RT) is a symptom-specific behaviourally oriented intervention that targets interpersonal relating as a key mechanism associated with auditory hallucination distress. The aim is that patients learn to relate more assertively within the difficult relationships they have with both the auditory hallucinations and other people. The RT will follow a treatment manual consisting of three phases: 1. Socialization to relating therapy and its implications; 2. Exploration of themes within the relational history of the participant and their experience of relationships with AH, and interpersonal relating within the family and social environment (identifying any prominent themes, such as abuse, disempowerment, or rivalry); 3. Exploration and development of assertive approaches to relating to AH and other people.
223771690|NCT04578314|OTHER|Treatment as usual|TAU will include medication management, supportive brief counselling sessions and various types of psychosocial (e.g. social work guided support, peer support) and monitoring provided by Mental Health Services, with individual and family psychological therapies offered occasionally. Individual therapies may include CBT or psychodynamic interventions. To amend for the heterogeneity of TAU across centres, the type and extent of any treatment received will be protocolled at T1 and T2.
223771691|NCT01266239|PROCEDURE|kissing balloon inflation|Kissing balloon inflation following the MV stenting
223771692|NCT01266239|DEVICE|EES vs. SES|Rapid endothelialization after EES deployment has been reported compared to that after SES deployment.
224251838|NCT03105453|OTHER|3 Sampling points|When entering the in-vitro fertilization/intracytoplasmatic sperm injection 4 samples will be harvested: a rectal swab, a cervical swab, a vaginal swab and an intra-uterine sample using an empty embryo catheter. After the ovarian stimulation treatment, the same patients will be sampled two more times: once at the moment of oocyte retrieval (rectal, cervical, vaginal and intra-uterine samples) and again just before the embryo transfer (at this stage, the embryo culture medium will be harvested, as well as an intra-uterine sample using the tip of an empty embryo inner catheter before the embryo transfer and a rectal sample)
223670755|NCT02070198|DRUG|Long acting FSH and GnRH antagonist|Woman in long acting FSH and GnRH antagonist arm receive an initial dose of 150 mcg Corifollitropin alfa on second day of the menstrual cycle followed by a fixed daily dose of 0.25 mg of GnRH antagonist on day 7 of the cycle onwards. On the ninth day of the cycle, a daily fixed dose of 300 IU of recombinant FSH will be administered until the day of ovulation triggering.
223670756|NCT02070198|DRUG|Daily FSH and GnRH antagonist|Woman in daily FSH and GnRH antagonist arm receive a fixed dose of 300 IU of recombinantFSH starting 3 day of the menstrual cycle followed by a fixed daily dose of 0.25 mg of GnRH antagonist on day 7 of the cycle onwards until the day of ovulation triggering.
223670757|NCT02070198|DRUG|Triptorelin and recombinant FSH|Women in Triptorelin and recombinant FSH arm receive a fixed dose of 0.05 mg of Triprorelin from the 1 day of the menstrual cycle followed by a fixed dose of 300 IU of recombinant FSH starting 3 day untill the day of HCG administration.
223670758|NCT02230488|OTHER|Intensive Diabetes Case Management|"A diabetes team , led by an endocrinologist and CDE, will manage the patients diabetes while in the hospital and will assist with the patient's discharge Diabetes endocrine consult team will manage the patient's diabetes daily while in the hospital Discharge diabetes medication reconciliation per research team Research team will provide 30 day supply of diabetes medication/supplies at discharge Research Team will provide 30 day supply of glucose test strips at discharge Discharge telecommunication from endocrinologist to primary care provider Patient-centered discharge diabetes education per research CDE Post-discharge 48-72 hours continuity check per phone by a diabetes research team member/CDE~\--------------------------------------------------------------------------------"
223670759|NCT02691585|OTHER|Music Intervention|A raga will be played for 10 minutes \& data collected.
223771693|NCT03037944|DRUG|Yasmin|(ethinyl estradiol 0.03 mg/ drospirenone 3 mg) tablets
224251839|NCT03851250|DRUG|MRx-4DP0004|Participants randomised to receive MRx-4DP0004 will take it in addition to their regular asthma medication.
224251840|NCT03851250|DRUG|Placebo|Participants randomised to receive placebo will take it in addition to their regular asthma medication.
224251841|NCT04270721|BEHAVIORAL|The EAGLE Safe Anastomosis Quality Improvement Intervention|"The intervention is the same in each arm; the EAGLE Safe Anastomosis Quality Improvement Intervention is an educational programme for behavioural change composed of three parts:~1. Introduction of a routine patient risk stratification for anastomotic leak~2. Implementation of the ESCP Safe Anastomosis Checklist~3. Adoption of a harmonised technique for stapled and handsewn anastomosis based on best evidence."
224251842|NCT01421277|DRUG|Statin Therapy|Investigator's choice of any statin.
224251843|NCT00915694|DRUG|nelfinavir mesylate|
224251844|NCT00915694|DRUG|temozolomide|
224251845|NCT00915694|PROCEDURE|adjuvant therapy|
224251846|NCT00915694|RADIATION|radiation therapy|
224251847|NCT00477347|DEVICE|Closed loop administration|intraoperative closed loop administration of propofol and remifentanil
224251848|NCT00477347|DEVICE|Manual administration|intraoperative manual administration of propofol and remifentanil
224251849|NCT00497263|DEVICE|Niti CAR|
224251850|NCT00194454|BEHAVIORAL|Modified cognitive behavioral therapy plus problem-solving|9 sessions with a psychosocial nurse practitioner in which participants learn to use behavioral strategies and specific problem-solving approaches to reduce or prevent behavioral and mood disturbances characteristic of stroke.
224251851|NCT00194454|OTHER|usual care|Usual care with primary provider plus a booklet about mood and behavioral changes following stroke
224251852|NCT00961207|DRUG|Aliskiren|Aliskiren 150mg daily for 2 weeks and increased to 300 mg daily for 4 weeks.
224251853|NCT00961207|DRUG|Aliskiren|Aliskiren 150mg daily for 2 weeks and increased to 300 mg daily for 4 weeks.
224251854|NCT04589910|DIAGNOSTIC_TEST|diaphragm thickness and thickening fraction|Ultrasound measurement of the diaphragm will be performed with the use of a Sono Site SII, portable system in B mode with the child in a 30-degree supine position. The diaphragm thickness will be measured with a high frequency (4-10 MHz) linear array transducer placed in the ninth or tenth intercostal space between the anterior and midaxillary lines in the zone of apposition between lung and liver.
224251855|NCT01549353|BEHAVIORAL|gum chewing|
224251856|NCT04189848|DRUG|Semaglutide|Subjects will receive 1 dose of semaglutide 0.25 mg and 1 dose of dulaglutide 0.75 mg on the same day.
224251857|NCT04189848|DRUG|Dulaglutide|Subjects will receive 1 dose of semaglutide 0.25 mg and 1 dose of dulaglutide 0.75 mg on the same day.
223771694|NCT03037944|DEVICE|Metraplant-E|"Levonorgestrel-releasing Intrauterine System modified levonorgestrel-releasing intrauterine system from the old IUD Metraplant, modified by Azzam 2013"
223771695|NCT05676697|DRUG|Linperlisib|The phosphatidylinositol 3-kinase delta (PI3Kδ) signaling pathway plays a critical role in the activation, proliferation, and tissue homing of self-reactive B cells that contribute to autoimmune diseases. B cells play an essential role in immune system function and dysfunction (e.g., autoimmunity) by producing antibodies and by acting as antigen-presenting cells (APCs) for T cells. Signaling via PI3K controls many essential B cell functions and is therefore a promising target for preventing aberrant B cell activation.
223771696|NCT05446311|DRUG|Dinalbuphine sebacate|After giving the birth, subjects are intramuscularly injected with a single dose of 150 mg of dinalbuphine sebacate (DS). DS is a prodrug of nalbuphine. After injeciton, DS are released to blood stream and hydrolyzed immediately. The onset of action is 12 to 24 hours and the analgesic effect can last about 5 to 7 days.
223771697|NCT01491321|PROCEDURE|Bee Venom Acupuncture Therapy|"Bee Venom 1:20,000 under BVA Increment Protocol~Increment Protocol as~* 1st week : SC 0.2cc/day, 2days/week~* 2nd week : SC 0.4cc/day, 2days/week~* 3rd week : SC 0.8cc/day, 2days/week"
223771698|NCT01491321|DRUG|Loxoprofen|60 mg/Tab, pers os 1Tab tid, for 3 weeks
223771699|NCT01491321|PROCEDURE|Placebo|"Normal Saline (0.9% NaCl) under NS Increment Protocol~Increment Protocol as~* 1st week : SC 0.2cc/day, 2days/week~* 2nd week : SC 0.4cc/day, 2days/week~* 3rd week : SC 0.8cc/day, 2days/week"
223771700|NCT03952884|BEHAVIORAL|Resistance Exercise|Prior to protein consumption participants will perform an acute bout of resistance exercise. They will warm up with two sets of 10 repetitions at 35-75% working load respectively, then perform four working sets of 10-12 repetitions at 65-70% of 1-RM. 1 min, 30 sec rest periods will be implemented between each set.
223771701|NCT03952884|BEHAVIORAL|No Resistance Exercise|Participants allocated to this group will not perform exercise prior to the administration of the nutritional intervention. Participants will remain at rest throughout the trial.
223771702|NCT03952884|DIETARY_SUPPLEMENT|Leucine|Participants will be given 2g of leucine dissolved in 250mL of water. Drink will be consumed immediately after exercise or equivalent time point for non-exercise group.
224251858|NCT05674513|DRUG|Ulipristal acetate|Evaluating the pharmacodynamic and pharmacokinetic outcomes after 1 dose of Ulipristal acetate 30mg in individuals with and without active CYP3A5 alleles
224251859|NCT05349513|OTHER|ESSME questionnaire|The experimental ecological questionnaire ESSME is administered 7 to 14 days after the inclusion visit and 7 to 14 days after the 6 months follow-up visit to the patient at their home.
224251860|NCT03301285|DRUG|Zoledronic Acid|Treatment of osteoporosis
223670760|NCT00970619|DEVICE|Ekos endowave system thrombolysis|Catheter directed thrombolysis will be performed with an Ekos Endowave ® system (EKOS Corporation, Bothell, WA). The system uses a standard guide wire to position the Intelligent Drug Delivery Catheter across the length of the target clot. The guide wire is introduced through the popliteal vein. Along the guide wire the catheter is positioned. The location of the dispersion catheter is controlled and if necessary adjusted by X-ray. The guide wire is then pulled out and replaced with the Microsonic core (a miniscule high frequency (2MHz) ultrasound transducer). The system automatically monitors and controls the microsonic energy delivery. This system does not fragment the thrombus but only gives a structural change by which a better penetration of the thrombolytic agent is achieved.
223670761|NCT03763513|DEVICE|ESWT|Extracorporeal Shock Wave Therapy=ESWT
223670762|NCT03763513|OTHER|Kinesiotaping Application|Kinesiotaping=KT (CT)
223670763|NCT02572739|DEVICE|PICCO|measurements based on thermodilution
223771703|NCT03952884|DIETARY_SUPPLEMENT|Dileucine|Participants will be given 2g of dileucine dissolved in 250mL of water. Drink will be consumed immediately after exercise or equivalent time point for non-exercise group.
223771704|NCT02595684|DRUG|Tadalafil|Tadalafil capsules: 5 mg, one per day, at night, during 28 days.
223771705|NCT02595684|DRUG|Placebo|Calcined magnesia capsules: one per day, at night, during 28 days.
223771706|NCT00403455|DRUG|Paroxetine|SSRI
223771707|NCT05565612|DIETARY_SUPPLEMENT|Normodigest Classic|Symbiotic composed of 15 probiotic strains and fructooligosaccharides as prebiotic
223771708|NCT05565612|DIETARY_SUPPLEMENT|Placebo|Compound based on maltodextrin and other excipients
224251861|NCT03227302|PROCEDURE|attending obstetrician|Attending obstetrician can do the caesarean operation without pregnant complications.
224251862|NCT03227302|PROCEDURE|associate obstetrician|Associate chief Obstetrician can do the caesarean operation without or mild or middle pregnant complications.
223771709|NCT02267655|DRUG|inhaled Nitric Oxide - 30 mcg/kg IBW/hr|inhaled Nitric Oxide in 30 mcg/kg IBW/hr doses Part 1
223771710|NCT02267655|DRUG|inhaled Nitric Oxide 5,10,15 mcg/Kg IBW/hr|inhaled inhaled Nitric Oxide 5,10,15 mcg/Kg IBW/hr dose titration
224251863|NCT03227302|PROCEDURE|chief obstetrician|Chief obstetrician can do all caesarean operation without limitations.
224322117|NCT06583044|OTHER|Questionnaire|It includes 33 questions measuring awareness and knowledge about bruxism.
223670764|NCT02572739|DEVICE|NICCOMO|measurements based on impedance
223771711|NCT02267655|DRUG|inhaled nitric oxide 75 mcg/kg IBW/hr|inhaled nitric oxide 75 mcg/kg IBW/hr -Part 2b
223771712|NCT06572501|PROCEDURE|Robot-assisted laparoscopic partial nephrectomy via extraperitoneal approach in the prone position|This group of patients underwent robotic-assisted laparoscopic partial nephrectomy via extraperitoneal approach in the prone position
223670765|NCT02491359|DRUG|Carfilzomib|Given IV
223670766|NCT02491359|OTHER|Laboratory Biomarker Analysis|Correlative studies
223670767|NCT02491359|OTHER|Quality-of-Life Assessment|Ancillary studies
223670768|NCT02491359|OTHER|Questionnaire Administration|Ancillary studies
223771713|NCT06572501|PROCEDURE|Robot-assisted laparoscopic partial nephrectomy via extraperitoneal approach in the lateral position|This group of patients underwent robotic-assisted laparoscopic partial nephrectomy via extraperitoneal approach in the lateral position
223771714|NCT06574204|DRUG|Erythromycin|The researchers injected 30 units of erythromycin into the inner right wrist of the subjects, which is a liquid dosage form.
223771715|NCT06574204|DRUG|Azithromycin|The researchers injected 30 units of azithromycin into the inner right wrist of the subjects, which is a liquid dosage form.
224251864|NCT06785350|DRUG|0.012%diprospan+0.5%ropivacaine|At the preoperative visit, patients will sign informed consent and learn to use the patient-controlled analgesia (PCA) pump and assess pain with the visual analogue scale (VAS). Standard general anesthesia will be induced and maintained with sufentanil, propofol, cisatracurium or rocuronium, and sevoflurane. Before incision, neurosurgeons will administer the allocated local infiltration solution. 0.5ml of diprospan will be diluted to 30 ml with 15 ml of ropivacaine in 0.9% NaCl to prepare diprospan at concentrations of 0.012%, respectively. The surgeon will use a 22 G straight needle for local infiltration anesthesia near the planned incisions. Postoperatively, patients will receive tropisetron and a PCA pump delivering sufentanil and ondansetron. PCA usage (effective/ineffective presses) and supplemental analgesia with Tylenol or loxoprofen will be monitored for 48 hours and up to 3 months. Dosages and intraoperative parameters will be closely recorded throughout.
224251865|NCT06785350|DRUG|0.009%diprospan+0.5%ropivacaine|At the preoperative visit, patients will sign informed consent and learn to use the patient-controlled analgesia (PCA) pump and assess pain with the visual analogue scale (VAS). Standard general anesthesia will be induced and maintained with sufentanil, propofol, cisatracurium or rocuronium, and sevoflurane. Before incision, neurosurgeons will administer the allocated local infiltration solution. 0.375ml of diprospan will be diluted to 30 ml with 15 ml of ropivacaine in 0.9% NaCl to prepare diprospan at concentrations of 0.009%, respectively. The surgeon will use a 22 G straight needle for local infiltration anesthesia near the planned incisions. Postoperatively, patients will receive tropisetron and a PCA pump delivering sufentanil and ondansetron. PCA usage (effective/ineffective presses) and supplemental analgesia with Tylenol or loxoprofen will be monitored for 48 hours and up to 3 months. Dosages and intraoperative parameters will be closely recorded throughout.
224251866|NCT06785350|DRUG|0.006%diprospan+0.5ropivacaine|At the preoperative visit, patients will sign informed consent and learn to use the patient-controlled analgesia (PCA) pump and assess pain with the visual analogue scale (VAS). Standard general anesthesia will be induced and maintained with sufentanil, propofol, cisatracurium or rocuronium, and sevoflurane. Before incision, neurosurgeons will administer the allocated local infiltration solution. 0.25ml of diprospan will be diluted to 30 ml with 15 ml of ropivacaine in 0.9% NaCl to prepare diprospan at concentrations of 0.006%, respectively. The surgeon will use a 22 G straight needle for local infiltration anesthesia near the planned incisions. Postoperatively, patients will receive tropisetron and a PCA pump delivering sufentanil and ondansetron. PCA usage (effective/ineffective presses) and supplemental analgesia with Tylenol or loxoprofen will be monitored for 48 hours and up to 3 months. Dosages and intraoperative parameters will be closely recorded throughout.
224251867|NCT06785350|DRUG|0.003%diprospan+0.5%ropivacaine|At the preoperative visit, patients will sign informed consent and learn to use the patient-controlled analgesia (PCA) pump and assess pain with the visual analogue scale (VAS). Standard general anesthesia will be induced and maintained with sufentanil, propofol, cisatracurium or rocuronium, and sevoflurane. Before incision, neurosurgeons will administer the allocated local infiltration solution. 0.125ml of diprospan will be diluted to 30 ml with 15 ml of ropivacaine in 0.9% NaCl to prepare diprospan at concentrations of 0.003%, respectively. The surgeon will use a 22 G straight needle for local infiltration anesthesia near the planned incisions. Postoperatively, patients will receive tropisetron and a PCA pump delivering sufentanil and ondansetron. PCA usage (effective/ineffective presses) and supplemental analgesia with Tylenol or loxoprofen will be monitored for 48 hours and up to 3 months. Dosages and intraoperative parameters will be closely recorded throughout.
224251868|NCT06785350|DRUG|0.5%ropivacaine|At the preoperative visit, patients will sign informed consent and learn to use the patient-controlled analgesia (PCA) pump and assess pain with the visual analogue scale (VAS). Standard general anesthesia will be induced and maintained with sufentanil, propofol, cisatracurium or rocuronium, and sevoflurane. Before incision, neurosurgeons will administer the allocated local infiltration solution. 15 ml of ropivacaine will be diluted to 30 ml with in 0.9% NaCl, respectively. The surgeon will use a 22 G straight needle for local infiltration anesthesia near the planned incisions. Postoperatively, patients will receive tropisetron and a PCA pump delivering sufentanil and ondansetron. PCA usage (effective/ineffective presses) and supplemental analgesia with Tylenol or loxoprofen will be monitored for 48 hours and up to 3 months. Dosages and intraoperative parameters will be closely recorded throughout.
224251869|NCT05472038|BIOLOGICAL|BNT162b5 Bivalent (WT/OMI BA.2)|BNT162b5 Wild Type and BNT162b5 OMICRON \[B.1.1.529 sublineage BA.2\]
224251870|NCT05472038|BIOLOGICAL|BNT162b2 Bivalent (WT/OMI BA.1)|BNT162b2 Wild Type and BNT162b2 OMICRON \[B.1.1.529 sublineage BA.1\]
224251871|NCT05472038|BIOLOGICAL|BNT162b2 Bivalent (WT/OMI BA.4/BA.5)|BNT162b2 Wild Type and BNT162b2 OMICRON \[B.1.1.529 sublineage BA.4/BA.5\]
224251872|NCT05472038|BIOLOGICAL|BNT162b5 Bivalent (Original/OMI BA.4/BA.5)|BNT162b5 Wild Type and BNT162b5 OMICRON \[B.1.1.529 sublineage BA.4/BA.5\]
224251873|NCT05472038|BIOLOGICAL|BNT162b6 Bivalent (Original/OMI BA.4/BA.5)|BNT162b6 Wild Type and BNT162b6 OMICRON \[B.1.1.529 sublineage BA.4/BA.5\]
224251874|NCT05472038|BIOLOGICAL|BNT162b7 Bivalent (Original/OMI BA.4/BA.5)|BNT162b7 Wild Type and BNT162b7 OMICRON \[B.1.1.529 sublineage BA.4/BA.5\]
224251875|NCT05472038|BIOLOGICAL|BNT162b7 Monovalent (OMI BA.4/BA.5)|BNT162b7 OMICRON \[B.1.1.529 sublineage BA.4/BA.5\]
224251876|NCT03362060|DRUG|Pembrolizumab|Pembrolizumab is a monoclonal antibody checkpoint inhibitor that blocks a protein in T-cells cells called PD-1, which then allows these cells and other parts of the immune system to attack tumors
224251877|NCT03362060|BIOLOGICAL|PVX-410|PVX-410 is a type of vaccine composed of 4 9-amino acid peptides that may help the immune system stimulate immunity against cancer cells
224251878|NCT05636501|OTHER|Treat-to-target Prednisolone Taper|Systematic prednisolone taper
224251879|NCT05636501|OTHER|Usual care|Prednisolone taper performed by discretion of the patient's general practitioner.
224251880|NCT02792166|PROCEDURE|BPD-DS|Biliopancreatic Diversion with Duodenal Switch
224251881|NCT02792166|PROCEDURE|SADI-S|Single Anastomosis Duodeno-ileal Bypass with Sleeve Gastrectomy
224251882|NCT06213441|OTHER|pecha kucha education|"Pecha kucha training to be given to the experimental arm will be given by the researcher.~The training content will be created in line with the literature and will be given before the patient is discharged."
224251883|NCT05452928|DRUG|Acyclovir 50 MG/ML|Patients are randomised to active treatment with IV acyclovir with the possibility of step-down to valacyclovir. If the treating physician prefers, initial IV treatment can be omitted and the patient can be treated with valacyclovir throughout the study period.
224251884|NCT05452928|DRUG|Placebo|Placebo either in IV formulation or as tablets identical to valacyclovir tablets.
224251885|NCT06176196|DRUG|VX-548|Tablets for oral administration.
224251886|NCT06176196|DRUG|Placebo|Tablets for oral administration.
224251887|NCT06533111|OTHER|Epic Health Record semi-structured handoff cognitive aid|Epic Health Record cognitive aid will be used for intraoperative anesthesia handoff
224251888|NCT06533111|OTHER|Usual care|Epic Health Record cognitive aid will not be used for intraoperative anesthesia handoff
224251889|NCT05240742|OTHER|no intervention, the CORFU study conducts analyses based on data which has been prospectively collected (and aggregated when possible) in 7 existing cohorts|(Clinical) baseline and follow-up data will be collected in the 7 existing cohorts. These data will be aggregated (when possible). The CORFU analyses will be conducted based on the aggregated data.
224251890|NCT05895461|BEHAVIORAL|BWLI-College|"Behavioral modifications are based on empirically-supported principles for weight loss.~Diet recommendations follow a small change approach in which participants will make a series of small, self-selected dietary changes each day (\~100-200 calories) that they build on over the course of the intervention.~Physical activity recommendations are to achieve 150-250 weekly minutes of moderate-to-vigorous physical activity with specific goals and rate of progression that are individualized to each participant."
224251891|NCT05895461|BEHAVIORAL|Control|Psychoeducation around dieting myths, healthy eating, and physical activity
224251892|NCT06230965|PROCEDURE|Lung protective ventilation strategy|They were divided into 2 groups: traditional ventilation strategy group (control group) and lung protective ventilation strategy group (experimental group), with 30 cases in each group. In the conventional ventilation strategy group, the conventional ventilation strategies were followed: tidal volume （VT）=10-12ml/kg, respiratory rate（f） =12 times/minute, PEEP=0 cmH₂O, fraction of inspired oxygen=0.5; Lung protective ventilation strategies were implemented in the Lung protective ventilation strategy group: VT=6-8ml/kg, f=12 times/min, PEEP=6-8 cm H₂O,fraction of inspired oxygen=0.5 Manual lung reexpansion was performed every 30 minutes after mechanical ventilation (continuous positive airway pressure of 30 cm H₂O for 30 seconds).
224251893|NCT06787131|DRUG|ZE50-0134 or placebo|The patients will receive ZE50-0134 or placebo.
224251894|NCT06787131|DRUG|Rabeprazole 20 mg|Rabeprazole 20 mg once daily (QD) on Day 1 and Day 2.
224251895|NCT06787131|DRUG|Itraconazole (200 mg)|Itraconazole 200 mg twice per day.
224251896|NCT03857919|DEVICE|TearCare|The TearCare SmartLids will be applied to the external surface of each eyelid. The TearCare System will be turned on and heat will be delivered to the eyelids for 15 minutes. Immediately following the thermal portion of the procedure, the SmartLids will be removed and the doctor will manually express the meibomian glands.
223670769|NCT05917782|BIOLOGICAL|Test drug (T1): CBP-201 injection (pre-filled syringe, 150 mg/1 mL)|subcutaneous injection of 2 doses on Day 1
224251897|NCT03857919|DEVICE|LipiFlow|The LipiFlow activators will be placed between the inner eyelid and the corneal surface of each eye. The LipiFlow System will be turned on and heat and pressure will be delivered to each eyelid for 12 minutes.
224251898|NCT06956209|DEVICE|Direct Bladder Wall Stimulation|The Akyva System is an implantable device intended to electrically stimulate the bladder muscle that controls bladder emptying or urination
224251899|NCT06783179|OTHER|Non-Interventional Study|Non-interventional study
224251900|NCT05622708|DRUG|Secukinumab|Treatment Period 1: Open-label secukinumab 150 mg PFS s.c. at baseline, Weeks 1, 2, 3 and 4 followed by administration every four weeks up to Week 52.
224251901|NCT05622708|DRUG|Placebo|Treatment Period 2: Double-blind placebo PFS s.c. every 4 weeks from Week 56 to Week 116.
224251902|NCT05622708|DRUG|Secukinumab|"Treatment Period 2: Double-blind secukinumab 150 mg PFS s.c. every 4 weeks from Week 56 to Week 116.~Escape re-treatment (during Treatment Period 2): Open-label secukinumab 150 mg PFS s.c."
224251903|NCT04752592|DIAGNOSTIC_TEST|SeroSelectTB rapid TB test|The SeroSelectTB test is a rapid blood-based immunochemical lateral flow assay for the detection of active tuberculosis.
224251904|NCT06609239|DRUG|Lunsekimig|"* Pharmaceutical form: Solution for injection in vial~* Route of administration: Subcutaneous injection"
224251905|NCT06792552|DRUG|SIM0505 for injection|Every 21 days is one cycle. Multiple dose levels of SIM0505 will be explored in dose escalation, and determine the maximum tolerated dose.
224251906|NCT06792552|DRUG|SIM0505 for injection|Every 21 days is one cycle. 2-3 dose levels of SIM0505 will be explored in dose optimization, and determine the recommended dose (RD) of SIM0505 and evaluate the preliminary anti-tumor activity of SIM0505
224251907|NCT02089217|PROCEDURE|Carotid endarterectomy (CEA)|Carotid endarterectomy
224251908|NCT02089217|DEVICE|Carotid Stenting (CAS)|Carotid stenting
224251909|NCT02089217|OTHER|Intensive Medical Management - no CEA|Intensive Medical Management alone - no CEA
224251910|NCT02089217|OTHER|Intensive Medical Management - no CAS|Intensive Medical Management alone - no CAS
224251911|NCT06832696|DEVICE|RUF-D|"We have developed a simplified fluid removal device (RUF-D) to address the challenges that patients face with being unable to remove the fluid they need with standard dialysis. Participants 01-09 will receive one week of baseline observation (three HD treatments) with two weeks of supervised intervention using RUF-D post HD on Mondays and Wednesdays for up to six hours (total three-week study).~Participants 10-18 will receive one week of baseline observation, two weeks of intervention (identical to cohort one above), with an additional week of intervention (total four weeks) where participants will be fitted with the RUF-D (ensuring functionality) before going home with the device in operation for up to six hours twice weekly."
224251912|NCT05510895|DRUG|Binimetinib|Triplet combination administered neoadjuvant and adjuvant, depending on TRG
224322118|NCT02930044|OTHER|Early administration of subcutaneous insulin glargine dose|DKA patients in the prospective intervention arm will receive subcutaneous glargine within two hours of starting their intravenous insulin infusion. The dose of glargine is 0.3 units/kg with a maximum dose of 30 units.
224322119|NCT02930044|OTHER|IV insulin infusion|All patients will receive the standard of care which is a protocol based continuous insulin infusion
223670770|NCT05917782|BIOLOGICAL|Test drug (T2): CBP-201 injection (pre-filled syringe, 300 mg/2 mL)|subcutaneous injection of 1 dose on Day 1
223670771|NCT05917782|BIOLOGICAL|Reference drug (R): CBP-201 injection (vial, 150 mg/1 mL)|subcutaneous injection of 2 doses on Day 1
223771716|NCT06574204|OTHER|physiological saline|The researchers injected 10-20 μl of physiological saline into the inner left wrist of the subjects, which is a liquid dosage form.
223771717|NCT06573892|DIETARY_SUPPLEMENT|Probiotic|Patients will receive the product twice a day, a single dose of the product is packaged in sachets. The product can be hired in the form of a powder or diluted with a small amount of water. The general course is 90 days.
223771718|NCT06573892|DIETARY_SUPPLEMENT|Placebo|Patients will receive the product twice a day, a single dose of the product is packaged in sachets. The product can be hired in the form of a powder or diluted with a small amount of water. The general course is 90 days.
223771719|NCT04805983|DRUG|BMS-984923|Day 1: Admission, administration of study drug, and 2 night in-patient stay; Day 3: Discharge following the completion of all scheduled procedures.
224251913|NCT02675647|DRUG|Heparin, IV route, based on patients body weights (UI/kg)|
223670772|NCT03703401|DIAGNOSTIC_TEST|Hysterosalpingo-contrast-sonogram|A contrast ultrasound scan to examine fallopian tube pathology and blockage
223771720|NCT06573255|OTHER|Healthy group|Cardiopulmonary exercise test, respiratory function tests, respiratory muscle strength and physical activity assessment will be performed in this group.
223670773|NCT02364401|DEVICE|Ablation|Catheter ablation for atrial fibrillation
223670774|NCT02324127|DEVICE|hsp90|Detect plasma Hsp90α concentration of lung cancer patients
223670775|NCT02880956|DRUG|ABBV-8E12|ABBV-8E12 solution for IV infusion
223670776|NCT02880956|DRUG|placebo for ABBV-8E12|placebo solution for intravenous (IV) infusion
223670777|NCT06988644|DIAGNOSTIC_TEST|exhaled carbon monoxyde measurement|At the initial tobacco consultation: measurement of exhaled carbon monoxyde. At the tobaccology consultation at 12 months, measurement of the cessation rate: no tobacco smoked in the last 7 days (self-reported), confirmed by a measurement of exhaled carbon monoxyde \< 9 ppm.
223670778|NCT06426524|PROCEDURE|IGF-1 Gel|After degranulation of the defect, IGF-1 gel mixed with Hydroxyapatite graft will be placed in the defect.
223670779|NCT06426524|PROCEDURE|Hydroxyapatite|After degranulation of the defect, Hydroxyapatite graft will be placed in the defect.
223670780|NCT01128023|OTHER|Myocardial perfusion imaging using Rb-82 PET or Tc-99m or Tl SPECT|Patients will undergo a clinically indicated PET Rb-82 myocardial perfusion scan for diagnosis or risk stratification of CAD. This cohort will be matched to the SPECT perfusion database.
223670781|NCT05604378|PROCEDURE|Gastrectomy|All patients in our study underwent gastrectomy.
223670782|NCT05129033|DRUG|Prednisone tablet|Basic medication for allergic airway inflammation such as asthma and ABPA, to relieve inflammation. Reduction may failed if disease exacerbate.
223670783|NCT05129033|DRUG|itraconazole|Anti-fungal medication to reduce fugal load.
223670784|NCT05129033|BIOLOGICAL|Omalizumab|Anti-IgE monoclonal antibody, used for high IgE allergic disease.
223670785|NCT00771589|DEVICE|Active Knee Prosthesis|Motorized External Knee Prosthesis for above knee amputees.
223670786|NCT06994052|BIOLOGICAL|Varicella vaccine|lyophilized powder, subcutaneous injection
223670787|NCT06995573|DRUG|NSC001|rigid, orthosteric acetylcholine analog, highly specific for M1 muscarinic receptor
223771721|NCT00087568|DRUG|Ribavirin|1000/1200mg po bid for 36 or 60 weeks
223771722|NCT00087568|DRUG|peginterferon alfa-2a [Pegasys]|180 micrograms weekly for 36 weeks (non-responders) or 60 weeks (non-tolerators)
223771723|NCT02738021|BEHAVIORAL|STRONG|A brief 3-session IPT-based preventive intervention, on maternal and child health outcomes.
223771724|NCT05416619|DEVICE|REMO®|The patients receive daily 1 hour of conventional therapy and 1 hour of treatment of REMO®, that is a wearable composed by 8 bipolar electrodes able to detect the surface electromyography of the forearm muscles. REMO® allows the control of a computer interface using the surface electromyography to execute sEMG-biofeedback exercises for hand rehabilitation. The movements required for hand rehabilitation are the following: thumb abduction, pinch, finger flexion, finger extension, wrist flexion, wrist extension, forearm pronation, forearm supination, radial wrist deviation and ulnar wrist deviation. The treatment consists in 15 sessions, 1hour/day, for 5 days/week, for 3 weeks. The patients are clinically evaluated before and after the REMO® treatment.
224251914|NCT02675647|PROCEDURE|Cardiopulmonary bypass|
223670788|NCT06995573|OTHER|Placebo|matching placebo to NSC001
223771725|NCT03771729|DRUG|LCZ 696|LCZ696 200mg twice daily
223771726|NCT05071755|PROCEDURE|Gastrectomy|Radical Total Gastrectomy, Radical Partial gastrectomy (Proximal / Subtotal)
223771727|NCT00134368|DRUG|Etanercept|
223771728|NCT03009071|PROCEDURE|Doin (conduction exercise)|Doin (conduction exercise) will be combined with acupuncture as active and passive movement to the aim of effective treatment of pain and functional disability. Doin (conduction exercise) sessions will be conducted 2 times a week for 5 weeks.
223771729|NCT03009071|DEVICE|Acupuncture|Acupuncture will be performed with manual stimulation (needle twirling) to evoke de-qi sensation. Acupuncture sessions will be conducted 2 times a week for 5 weeks.
223771730|NCT00426075|DEVICE|Elastic stockings|
223771731|NCT02591693|BEHAVIORAL|Caregiver training|Occupational therapy training focuses on improving confidence to manage practical aspects of care in areas of daily life important to patient and caregiver, in which caregiver reports or anticipates low levels of confidence.
223771732|NCT05658926|BEHAVIORAL|Mindfulness|Patients will learn how to use diaphragmatic breathing with mindfulness
223771733|NCT05658926|OTHER|Education|Patients will be provided with education regarding the Gate Control Theory of Pain.
223771734|NCT04394351|DRUG|Dupilumab|Single-use, prefilled syringe
223771735|NCT04394351|DRUG|Matching Placebo|Matching formulation and regimen (depending on the weight tier) as dupilumab without the active substance
223771736|NCT00268749|DRUG|glycine|0.8 g/kg/day
223771737|NCT05068765|OTHER|Communication skills psychoeducation|Intervention explanations are explained in the groups section.
224251915|NCT02675647|DRUG|Protamin administration|
224251916|NCT06056895|PROCEDURE|Biopsy|Undergo tumor biopsy
224251917|NCT06056895|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
224251918|NCT06056895|PROCEDURE|Computed Tomography|Undergo CT/MRI
224251919|NCT06056895|PROCEDURE|Magnetic Resonance Imaging|Undergo CT/MRI
224251920|NCT06056895|BIOLOGICAL|Retifanlimab|Given IV
224251921|NCT06056895|DRUG|Tuparstobart|Given IV
224251922|NCT06056895|DRUG|Verzistobart|Given IV
223670789|NCT06995066|PROCEDURE|collagenase injection into the epidural space|"The Collagenase injection into the epidural space is a medical procedure for treating cervical disc herniation. Firstly, the patient is positioned, and the specific location of the epidural space at the affected cervical spine segment is accurately identified with the guidance of imaging devices like fluoroscopy or CT. After local anesthesia, a special puncture needle is inserted into the epidural space following the marked path. Once the needle is in the correct position, an appropriate amount of collagenase solution is slowly injected. After the operation, the patient needs to stay in the hospital for observation to monitor vital signs and neurological conditions. The patient should rest in bed for a certain period and then gradually engage in proper activities. Additionally, personalized rehabilitation treatment plans, including physical therapy and exercise, are usually required to help with recovery."
224251923|NCT03993873|DRUG|elzovantinib (TPX-0022)|Oral elzovantinib (TPX-0022) capsules
224251924|NCT03963739|OTHER|Interview|Undergo interview
224251925|NCT03963739|OTHER|Questionnaire Administration|Ancillary studies
224251926|NCT05704829|DRUG|Trastuzumab deruxtecan|T-DXd i.v.
224251927|NCT05704829|DRUG|Standard-of-Care|Chemotherapy+T+P
223670790|NCT01648556|OTHER|Blood tests and bone marrow biopsy repeated|"Blood tests are realized for the dosage of the TPO, the dosage of the antiplatelet antibodies, to measure isotopic lifetime of platelet.~The test in corticoids by the prednisone per os is realized too. The bone marrow biopsy is realized at the inclusion and during follow-ups if the haemogram is abnormal."
224251928|NCT02982694|DRUG|Atezolizumab|Atezolizumab will be administered 1200 mg in 250 ml 0.9% NaCl IV infusion bag, on day 1 of each cycle of 21 days.
224251929|NCT02982694|DRUG|Bevacizumab|Bevacizumab will be administered 7.5 ml/kg (diluted in 0.9% sodium chloride solution) on day 1 of each 21 days cycle.
224251930|NCT05090215|BEHAVIORAL|Aerobic and resistance training 12 week exercise programme|See arm/group description
224251931|NCT05090215|DIAGNOSTIC_TEST|Venous blood sampling|full blood count, urea \& electrolytes, C-reactive protein, coagulation screen, liver function tests, erythrocyte sedimentation rate.
224251932|NCT05090215|DIAGNOSTIC_TEST|Muscle Ultrasound|Ultrasound of vastus lateralis to ascertain muscle structure (thickness, pennation angle and fascicle length)
224251933|NCT05090215|DIAGNOSTIC_TEST|Cardiopulmonary exercise testing (CPET)|The assessment of anaerobic threshold as a measure of changes in aerobic function between the two groups will be assessed using CPET
224251934|NCT05090215|BEHAVIORAL|Quality of life questionnaire completion|The use of validated questionnaires to assess quality of life parameters; Duke Activity Status Index (DASI), EORTC-QLQ C30 (quality of life for cancer patients) and the International Physical Activity Questionnaire (IPAQ).
224251935|NCT04967833|BIOLOGICAL|Tumor Infiltrating Lymphocytes (TIL)|Biological: Tumor Infiltrating Lymphocytes (TIL) Adoptive transfer of 1x10\^9-5x10\^10 autologous TILs to patients i.v. in 30-120 minutes.
224251936|NCT02929303|DRUG|Omegaven IV lipid emulsion|Therapy is started at a dose of 1 gm/kg/day over 12 hrs. Omegaven may be infused via a central or peripheral IV. If additional fat calories are needed they will be provided by the enteral route.
223670791|NCT05520164|OTHER|Listening the maternal heart sound during the invasive interventions|Heart sounds of the newborns' own mothers were recorded on the voice recorder with the help of a hand doppler device. This sound was listened by the newborns in the experimental group during the heel blood procedure.
224251937|NCT04047628|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|"1. PBSC mobilization \& collection regimen per protocol/ institutional standards includes: intravenous cyclophosphamide (Cytoxan®), 4 grams/m\^2); intravenous mesna (Mesnex®),a total delivery of 4 grams/m\^2); oral dexamethasone, 10 mg dose, four times daily); subcutaneous filgrastim,10 mcg/kg/day until leukapheresis goal is completed; and CD34+ peripheral blood stem cells collection by leukapheresis.~2. Conditioning per protocol\& institutional standards:~   * 6-day BEAM (e.g. Carmustine (BCNU), Etoposide (VP-16), Cytarbine (Ara-C), and Melphalan) chemotherapy protocol and,~  * rabbit anti-thymocyte globulin (rATG) 2.5 mg/kg/day x2~3. Autologous cryopreserved graft infusion: The target Cluster of Differentiation (CD)34+ cell dose for infusion is 5 x 10\^6 CD34+ cells/kg (minimum 4 x 10\^6 CD34+ cells/kg; maximum 7.5 x 10\^6 CD34+ cells/kg).~For 1\&2 above: Ideal body weight (IBW) versus Actual Body Weight (ABW) are applicable."
224251938|NCT04047628|BIOLOGICAL|Best Available Therapy (BAT)|"Disease-modifying therapy (DMT) selected by the Site Investigator from the below:~* cladribine~* natalizumab~* alemtuzumab~* ocrelizumab,~* rituximab,~* ofatumumab, or~* ublituximab"
223771738|NCT05068765|OTHER|General psychoeducation|İntervention descriptions are explained in the intervention groups section.
223771739|NCT04257877|PROCEDURE|Blood sampling|Blood samples for proteomic analysis in plasma of both groups
224251939|NCT05022550|DEVICE|DEEP VR|DEEP VR is a virtual reality experience (i.e., video game using a head-mounted display) wherein participants ('players') traverse through a serene underwater adventure for approximately 15 min. Movement through the environment is facilitates through the cued use of regularized, diaphragmatic breathing, captured through a respiratory belt.
224251940|NCT04704661|PROCEDURE|Biopsy Procedure|Undergo tissue biopsy
224251941|NCT04704661|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
224322120|NCT02930044|DRUG|IV fluid repletion|0.9% NaCl or Plasmalyte A will be initiated as a continuous infusion for volume repletion. Fluids will be switched to contain potassium if serum potassium is less than 3.3 mEq/L. Fluids will be switched to contain dextrose if the serum glucose is less than 250 mg/dL.
224322121|NCT04908592|DRUG|Dexamethasone|Patients will receive dexamethasone 8 mg diluted in 100 ml 0.9% normal saline (NS) IVI over 15 min 2 h preoperatively.
224251942|NCT04704661|DRUG|Ceralasertib|Given PO
224251943|NCT04704661|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
224251944|NCT04704661|PROCEDURE|Echocardiography Test|Undergo ECHO
224251945|NCT04704661|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
224251946|NCT04704661|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
224251947|NCT04704661|BIOLOGICAL|Trastuzumab Deruxtecan|Given IV
224251948|NCT05073419|OTHER|Standard of Care|Routine monitoring of post AMI patient with clinic visits
223771740|NCT00541047|DRUG|bicalutamide|
223771741|NCT00541047|DRUG|goserelin acetate|
223771742|NCT00541047|DRUG|leuprolide acetate|
223771743|NCT00541047|PROCEDURE|adjuvant therapy|
223771744|NCT00541047|PROCEDURE|quality-of-life assessment|
224251949|NCT05073419|DEVICE|ICM Implantation|Implantation of ICM through small incision (2 mm) under the skin
224251950|NCT05874479|DEVICE|Active PAC|The active PAC will contain HEPA filters inside the device.
224251951|NCT05874479|DEVICE|Sham PAC|The sham PAC will contain no HEPA filters inside the device.
224251952|NCT05828823|DEVICE|Hemodialysis twice weekly|Frequency and duration of hemodialysis is tailored to the patient. Adjuvant pharmacotherapy is prescribed to maintain volume, electrolyte and acid-base homeostasis ( e.g., diuretics, sodium bicarbonate and potassium binding patiromer)
224251953|NCT05828823|OTHER|Hemodialysis thrice weekly|Conventional hemodialysis regimen
223771745|NCT00541047|RADIATION|radiation therapy|
223771746|NCT00824317|DRUG|methylphenidate|(15 mg daily), medium (25 mg daily) and high (40 mg daily)
223771747|NCT00824317|DRUG|Placebo|
223771748|NCT00058240|DRUG|alvocidib|Given IV
223771749|NCT00985348|DRUG|Levetiracetam (Keppra)|"Test Drug :~Levetiracetam dry syrup~Reference Drug :~500 mg oral tablets of Levetiracetam. Frequency: Single Dose"
223771750|NCT05631639|DEVICE|PillSense System|The PillSense capsule is a diagnostic capsule equipped with a sensor for in vivo detection of liquid blood and a paired PillSense receiver for result display.
224251954|NCT04613440|OTHER|Family Letter (Standard of Care)|The family letter is given to probands in the standard of care arm and provides information on the familial mutation and serves to encourage first degree relatives to complete genetic testing.
224251955|NCT04613440|OTHER|Educational Video|The educational video is provided by the clinical genetic testing laboratory and explains the importance and implications of genetic testing. This educational video is shared with first degree relatives in the intervention arm
224251956|NCT04613440|OTHER|Mailed Saliva Kit for Genetic Testing|The FDR's email will be sent to the genetic testing lab, Invitae, which will allow them to log on to the online portal, create a unique account, and order a genetic testing saliva kit free of charge. The FDR will receive the kit and instructions in the mail. The FDR will collect the saliva sample and send the sample back to the genetic testing laboratory.
224251957|NCT04613440|OTHER|Telephone Counseling|The FDR's will be contacted and receive post genetic testing phone counseling
224251958|NCT06215105|DEVICE|Intracranial Aneurysm Devices|Intracranial Aneurysm occlusion
224251959|NCT05835141|OTHER|OCT Imaging|Each participant will receive imaging of the inferior sectors of the iridocorneal angle at 150°, and 180°, and 210° with the swept-source ANTERION AS-OCT system under standardized light and dark lighting conditions by a trained research technician
224251960|NCT00539071|DRUG|long-acting injectable risperidone|Subjects will be randomized to conventional dose Consta or high dose Consta. All of those who are randomized to the conventional Consta dose will receive it in the form of Consta at a starting dose of 50 mg q 2 weeks. Those who are randomized to high dose Consta will receive a Consta 50 mg injection plus 25 mg injection (total dose 75 mg) q 2 weeks as the starting dose.Oral risperidone will be given up to Week 4 along with the injections for both groups to provide a transition phase.At Week 6, psychopathology will be assessed with a PANSS. If no improvement from baseline is shown, the randomized dose of Consta will be increased to 100 mg q 2 weeks (given as two 50 mg injections ) for those in the high dose Consta group. The dose for those randomized to the conventional dose group will remain the same (50 mg plus placebo).
224251961|NCT00539071|DRUG|long acting injectable risperidone, Conventional Dose Group|Study dose remains 50 mg for the length of the study.
224251962|NCT00539071|DRUG|long acting injectable risperidone, High Dose Group|Beginning dose 75 mg. Can be increased to 100 mg at Week 6.
224251963|NCT06208163|PROCEDURE|Chiropractic|Chiropractic spinal adjustments
224251964|NCT05757414|DEVICE|Tailored Lighting Intervention (LIT)|The lighting intervention will provide high circadian stimulation produced by light sources that provide moderate light levels of spectra that are tuned to the sensitivity of the circadian system.
223771751|NCT02973659|DRUG|Oxybutynin|10% oxybutynin gel (one side) Vs placebo aqueous gel (other side) - 2/d application, 1 month
223771752|NCT02973659|DRUG|Placebos|
223771753|NCT04354831|BIOLOGICAL|anti-SARS-CoV-2 convalescent plasma|"* SARS-CoV-2 convalescent plasma (1-2 units; \~200-400 mL maximum dose as 7 ml/kg adjusted IBW )~* Study drug will be administered as a single intravenous infusion"
224251965|NCT05757414|DEVICE|Actigraph|An actigraph is a wrist worn device that measures rest and activity patterns
224251966|NCT04366791|RADIATION|Low Dose Radiation Therapy|Undergo low-dose radiation therapy
224251967|NCT03674814|DRUG|Enzalutamide|Enzalutamide will be taken by mouth at assigned dose. Enzalutamide will be obtained as standard of care prescription (not provided by study).
224251968|NCT03674814|DRUG|Relacorilant|Relacorilant will be taken by mouth at assigned dose. Relacorilant will be provided by the study.
224251969|NCT05029882|DRUG|ABBV-400|Intravenous (IV) Infusion
224251970|NCT05029882|DRUG|Trifluridine/Tipiracil|Oral Tablet
224251971|NCT05029882|DRUG|Bevacizumab|IV Infusion
224251972|NCT02847650|DRUG|Placebo|
224251973|NCT02847650|DRUG|PF-06649751|
224251974|NCT06045598|OTHER|Semmes Weinstein Monofilament Test|The 10 g Semmes-Weinstein monofilament assessment (SWME) is used to assess sensory loss and screen for diabetic neuropathy. In our study, the evaluation will be made on the plantar surfaces of the 1st fingers, the plantar surfaces of the 1st, 3rd, and 5th metatarsal heads, and the plantar surfaces of the heel in the right and left feet. The first force value felt will be taken as the evaluation data.
224322122|NCT04908592|OTHER|Placebo|Patients will receive 100 ml 0.9% normal saline (NS) IVI over 15 min 2 h preoperatively.
224322123|NCT04355260|PROCEDURE|Echocardiography-guided Radiofrequency ablation for Hypertrophic obstructive Cardiomyopathy (HOCM).|Echocardiography-guided Radiofrequency ablation for Hypertrophic obstructive Cardiomyopathy (HOCM).
224322124|NCT04606160|BEHAVIORAL|Single Session Problem-Solving Intervention|The intervention will be a researcher led 30-45 minute session using the problem-solving module from the Modular Approach to Therapy for Children with Anxiety, Depression, Trauma, or Conduct Issues (MATCH-ADTC protocol.
223771754|NCT03527992|DEVICE|O2 automated|"In the O2 automated group, patients benefit from oxygen therapy via the FreeO2 device. The O2 saturation target is set by the clinician on the device. Saturation is continuously sensed by an oximeter and the oxygen flow is automatically adjusted. The clinician has access to instantaneous values and trends of O2 and SpO2 flow rates."
224322125|NCT04076930|DRUG|angiotensin-converting enzyme inhibitor (ACEI) and angiotensin receptor blocker (ARB)|The use of ACEI/ARB within a 90-day after the date of PD initiation (exposure ascertainment window period).
223670792|NCT04514354|BEHAVIORAL|GEST|On either Visit 3 or 4, subjects performed a maximal cardiopulmonary GEST following the Balke protocol. Immediately prior to the GEST, the study physician or his designee performed a brief physical examination, in which BP was assessed and all relevant medical information (i.e. medical history, medications, family history) were reviewed. The physician who completed the physical examination remained present during the GEST to monitor the subjects' electrocardiogram (ECG) and other physical signs. After the GEST was completed, the study physician reviewed the ECG for signs of ischemia. Breath-by-breath analysis of expired gases (i.e. oxygen and carbon dioxide) (ParvoMedicsTruneOne® 2400 Metabolic Measurement System, ParvoMedics Inc., Sandy, UT) determined maximal oxygen uptake (VO2max). Heart rate was measured continuously with a 12-lead ECG system and BP was measured by auscultation every 3 minutes during the GEST.
223670793|NCT00576420|BIOLOGICAL|FS VH S/D 500 s-apr, 60-seconds polymerization time|FS VH S/D 500 s-apr (FS) is applied to the study suture line. The actual dose of FS VH S/D 500 s-apr depends on the length of the suture line and the intensity of bleeding and is to be decided by the surgeon, but the maximum dose per suture line shall not exceed 4 mL FS VH S/D 500 s apr. After application of FS VH S/D 500 s-apr to the study suture line is completed, the surgeon will wait for 1 minute to allow polymerization of FS VH S/D 500 s-apr.
224322126|NCT02653248|RADIATION|Stereotactic Body Radiation Therapy|Patients will receive 5 fractions of SBRT radiation, treated every other day. No more than three fractions per week. Total dose will depend on cohort. Cohort 1: 40Gy, Cohort 2: 45 Gy, Cohort 3: 50 Gy.
223670794|NCT00576420|BIOLOGICAL|FS VH S/D 500 s-apr, 120-seconds polymerization time|Treatment will be identical to the FS VH S/D 500 s-apr Group, 60 seconds polymerization time, except that the surgeons will wait 2 minutes to allow polymerization and will then open the cross clamps.
223670795|NCT00576420|PROCEDURE|Manual compression with surgical gauze pads|Treatment of the study suture line with manual compression with surgical gauze pads.
223670796|NCT05481541|OTHER|written education|"Other names:~Written/E-Mobile training The study was conducted as a three-group randomized controlled trial to examine the effect of written/mobile education on the quality of life and sleep of patients undergoing transurethral resection of the prostate. Written education was applied to the first group and mobile education was applied to the second group. Group 3 formed the control group."
223670797|NCT04836325|PROCEDURE|transcranial static magnetic field stimulation (tSMS)|The intervention group will receive a treatment of tSMS in the primary motor cortex.
223670798|NCT04836325|PROCEDURE|Sham transcranial static magnetic field stimulation|The placebo group will receive a dummy treatment
223670799|NCT06520475|PROCEDURE|genicular nerve block using bupivacaine and magnesium|The patients will receive 13 ml of 0.5% bupivacaine and 2 ml of 10% magnesium sulfate
223670800|NCT06520475|PROCEDURE|genicular nerve block using bupivacaine and normal saline|The patients will receive 13 ml of 0.5% bupivacaine and 2 ml of normal saline
223670801|NCT00006103|DRUG|fluorouracil|
223670802|NCT00006103|DRUG|irinotecan hydrochloride|
223670803|NCT00006103|DRUG|leucovorin calcium|
223670804|NCT02402959|OTHER|individualized treatment|Individualized treatment includes anything no matter what kind of interventions, like medicine, herbs, acupuncture, massage, behaviour therapy, diet and exercise therapy. The TCM experts should choose the intervention in accordance to the patients' preference, best existed evidence and their empirical knowledge.
223670805|NCT02000154|DRUG|SyB L-1101|SyB L-1101 (rigosertib sodium) will be administered intravenously 72 continuous hours (3 days), followed by 25-day observation period. The treatment period of 28 days (3 days of administration + 25 days of observation) constitutes 1 cycle. The dose at cycle 8 in the study 2011005 will be the dose (if needed, the dose can be reduced) at the first cycle in this study (cycle 9). From cycle 10 on, the dose of SyB L-1101 will be reduced, delayed, or discontinued according to adverse events and results of observation at the previous cycle.
223670806|NCT00000527|DRUG|aspirin|
223670807|NCT00000527|DRUG|dipyridamole|
223670808|NCT01340872|DRUG|ST10-021|30 mg capsules to be taken orally twice a day for 12 weeks
223670809|NCT01340872|DRUG|Placebo Comparator|Matching sugar pill to be taken orally twice a day for 12 weeks
223670810|NCT01502332|OTHER|Intensive Alveolar Recruitment|Recruitment with opening pressures of 45 cmH2O in the airways, followed by ventilation with PEEP = 13 cmH2O, during 4 hours of protective mechanical ventilation with tidal volume (VT) = 6 mL/kg/pbw.
223670811|NCT01502332|OTHER|Moderate Alveolar Recruitment|Recruitment with opening pressures of 20 cmH2O in the airways, followed by ventilation with PEEP = 8 cmH2O, during 4 hours of protective mechanical ventilation with VT = 6 mL/kg/pbw.
223670812|NCT01327183|PROCEDURE|Percutaneous Coronary Intervention (PCI)|at least 1 hour and up to 24 hours after completion of drug infusion
223670813|NCT01327183|DRUG|RO4905417|5 mg/kg iv infusion, completed at least 1 hour and up to 24 hours before PCI
223670814|NCT01327183|DRUG|RO4905417|20 mg/kg iv infusion, completed at least 1 hour and up to 24 hours before PCI
223670815|NCT01327183|DRUG|placebo|iv infusion, completed at least 1 hour and up to 24 hours before PCI
223670816|NCT00483132|DRUG|interferon alpha 2a|
223670817|NCT03004573|OTHER|Neuropsychological detailed tests with focus on social cognition|MATTIS, MOCA, BREF, Light points test, PDQ39
223670818|NCT01771809|DRUG|75mg SHP647 (PF-00547659)|75 mg sterile liquid injected subcutaneously every 4 weeks.
223670819|NCT01771809|DRUG|225mg SHP647 (PF-00547659)|225 mg sterile liquid injected subcutaneously every 4 weeks.
223670820|NCT03802214|DRUG|Vedolizumab|standard vedolizumab induction (300mg IV at week 0, 2, 6)
223670821|NCT00042341|DRUG|clofarabine (IV formulation)|
223670822|NCT02384057|OTHER|Computerized cognitive training program|1000 minutes of computerized cognitive rehabilitation with C8 sciences program
223670823|NCT02384057|OTHER|Conventional cognitive rehabilitation|Same amount of conventional cognitive rehabilitation
223670824|NCT00204945|DRUG|nesiritide|a bolus, then infusion of nesiritide for 10-15 minutes
223771755|NCT03527992|DEVICE|O2 standard|"In the O2 standard group, patients benefit from oxygen therapy with nasal goggles or a high concentration mask. Saturation is continuously captured by an oximeter. The flow rate of oxygen, evaluated in L/min, is adapted according to local protocols (every 8 hours in conventional hospital services, continuous in intensive care"
224251975|NCT06045598|OTHER|Proprioception measurement|"Ankle proprioception will be measured with the participant's knees lying on their back in a semi-flexed position. The test will be performed for 10 degrees of dorsiflexion and 20 degrees of plantar flexion, respectively. Measurements will be made with an electrogoniometer device. The difference between the required degree and the degree in the position brought by the participant will be taken as evaluation data.~Lumbal region proprioception measurement will be made with lumbar flexion and extension movements. The participant will be asked to perform active lumbar flexion. Then, lumbar flexion movement will be performed up to 50% of the measured active flexion angle and it will be requested to stay in this position for 10 seconds. After the participant returns to the upright position, he will be asked to come back to the learned angle and the difference in angle will be taken as evaluation data. The same procedure will be done for the lumbar extension movement."
224322127|NCT05219448|BEHAVIORAL|Education and self-efficacy coaching|"Children and their caregiver(s) in the intervention communities will receive a culturally-adapted, 5-session program consisting of video-based health education and self-efficacy coaching delivered by an indigenous Community Health Worker. Families will be introduced to sugar-free water enhancers that are commercially available and come in the same flavors as regular Tang and Kool-Aid. The sessions will include conversations on related topics, interactive hands-on activities, and homework assignments. Additionally, four brief check-ins will keep families engaged. Local stores in the intervention communities only will carry the sugar-free water enhancers that are highlighted in the health education."
223670825|NCT03594942|DIAGNOSTIC_TEST|procto sigmoidoscopy and biopsy if required|procto sigmoidoscopy of patients presenting with per rectal bleed will be carried out to locate the source of bleeding and biopsy if required.
223670826|NCT04095533|OTHER|Tibialis anterior muscle cross-sectional area assessment by ultrasound|"Assessed using bedside ultrasound with repeat assessments every second day up to 2 weeks of ICU admission, or until discharge from ICU to yield an overall rate of muscle area decline reported as a %/day average muscle atrophy rate.~Tibialis anterior cross-sectional area assessments will be assessed by measurement ultrasound to both legs with portable bedside ultrasound. The cross sectional area will be measured in cm\^2 at 5 cm distal to the lateral eminence of the tibial tuberosity along the muscle belly. Image processing will be performed at the bedside using features available on the ultrasound device. Muscle boundaries will be marked on the device and the cross-sectional area (computed from the perimetral contour of the muscle section) will be determined. This process will be repeated for two times for each leg."
223670827|NCT04095533|OTHER|Muscle strength assessment|Assessed using clinical bedside evaluation every second day with the Medical Research Council Sum Score. This is a clinical assessment of strength of 6 different muscle groups (shoulder abductors, elbow flexors, wrist extensors, hip flexors, knee extensors, and ankle dorsiflexors) on each side of the body and recorded as a score between 0 (flaccid) and 5 (full strength).
223670828|NCT04486274|OTHER|MOSE|After each pass, the stylet will be introduced into the needle, the material will be released onto a smear slide, and a macroscopic on-site quality evaluation (MOSE) of the specimen will be performed by the endoscopist.
223670829|NCT04689412|DRUG|Resveratrol|Nasal administration of resveratrol
223670830|NCT00830791|DRUG|MK-0941 20 mg|Two 10-mg tablets of MK-0941 administered as a single oral dose.
223670831|NCT00830791|DRUG|MK-0941 5 mg|MK-0941 administered as one single 5-mg tablet.
223670832|NCT06246942|DEVICE|Single-pulse transcranial magnetic stimulation (spTMS)|Single-pulse TMS (spTMS) will be delivered with a TMS stimulator (MagPro X100 w/ MagOption, MagVenture, Farum, Denmark) and a figure-of-eight TMS coil. 80 spTMS will be repeated at 0.2 Hz. An MRI-based TMS navigation system will be used to navigate the TMS coil (Localite, Bonn, Germany).
223670833|NCT06246942|DEVICE|Paired associative stimulation (PAS)|Paired associative stimulation (PAS) will be applied with two TMS stimulators (MagPro X100 w/ MagOption, MagVenture, Farum, Denmark) and two TMS coils. The pulses from each stimulator/coil will be repeated at 0.2 Hz, duration of run 15 minutes (180 pulses for each stimulator/coil). In different sessions, we will deliver PAS with different asynchrony values to examine their effects on effective connectivity. Coils will be navigated using an MRI-based TMS navigation system (Localite, Bonn, Germany).
223670834|NCT06246942|DIAGNOSTIC_TEST|Magnetic resonance imaging (MRI)|Structural, diffusion, and functional MRI with a 3-Tesla Siemens scanner
223670835|NCT03206996|BEHAVIORAL|Exposure therapy|"The therapist, child and family collaborate to set short and long term goals, develop the exposure hierarchy and Subjective Units of Distress (SUD) scale and design their challenge activities (i.e., exposures). The exposure hierarchy lists activities in ascending order from minimal exposure/minimally difficult (e.g, toilet is not flushed and bathroom door is closed while child walks by) to maximum exposure/maximally difficult (e.g., toilet is flushed repeatedly while child is inside the stall with the door closed). Treatment begins with exposure to activities on the lower end of the hierarchy, with adjustments as indicated, to present stimuli that provide a just-right level of difficulty as indicated by the participant's SUD level and therapists clinical judgment. Participants communicate the level of difficulty using their individualized SUD scale. Additionally, the child and family complete home exercises with exposures."
223771756|NCT00018109|DRUG|glutamine|
223771757|NCT00018109|DRUG|creatine monohydrate|
223771758|NCT00654849|PROCEDURE|Plasmakinetic bipolar energy forceps|Use of bipolar plasmakinetic vessel sealing during abdominal hysterectomy
223771759|NCT00654849|PROCEDURE|Abdominal Hysterectomy with traditional suture technique|The abdominal hysterectomy was realized using sutures in the haemostasia of pedicles.
223771760|NCT02578485|DEVICE|AVideogame|Participants active video game played by a period of 60 minutes, then remain at rest for the evaluation of post-exercise blood pressure for an additional period of 60 minutes.
223771761|NCT02578485|DEVICE|SVideogame|Participants sedentary video game played by a period of 60 minutes, then remain at rest for the evaluation of post-exercise blood pressure for an additional period of 60 minutes.
223771762|NCT02578485|DEVICE|EMIntensity|Participants performed walking on a treadmill at moderate intensity by a period of 60 minutes, then remain at rest for the evaluation of post-exercise blood pressure for an additional period of 60 minutes.
224251976|NCT06045598|OTHER|Postural control assessment|"Postural control evaluation will be done with the Gyko-Microgate software. Bluetooth data transmission enables real-time measurements to be transferred directly to the computer. After the device was placed on the body of the person thanks to the wearable vest, a connection was established with the software on the computer.~To evaluate postural control, with eyes open, eyes closed and eyes open on a hard surface, accompanied by a cognitive dual task; On soft ground, with eyes open, eyes closed and eyes open, the person is asked to remain in a stable balance for 30 seconds, accompanied by a cognitive dual task. For the cognitive dual task, two countdowns and K-A-S verbal fluency exercises will be performed in each assessment. As a result of each evaluation, data on ellipsoid area, anteroposterior velocity, anteroposterior distance, mediolateral velocity, and mediolateral distance will be obtained."
224251977|NCT06045598|OTHER|Dynamic balance assessment|Dynamic balance evaluation will be done with the Gyko device. To evaluate dynamic balance, walking with eyes open on hard ground, walking with cognitive dual task on hard ground; walking with eyes open on soft ground, and cognitive dual task on soft ground will be evaluated. The walking distance is determined as 6 meters. The first 1 meter and the last 1 meter will not be taken into consideration. The measurement will start at the 1st meter and end at the 5th meter. The measurement will be carried out at a distance of 4 meters. As a cognitive task, the participants will be given the task of counting down by two and K-A-S verbal fluency. As a result of each evaluation, data on the ellipsoid area, anteroposterior velocity, anteroposterior distance, mediolateral velocity, and mediolateral distance will be obtained.
224251978|NCT06045598|OTHER|Timed Up and Go Test|"The Timed Get Up and Walk Test is used to assess balance and fall risk. The participant stands up from the chair, walks 3 meters, turns back, and sits back on the chair. The time elapsed during these phases was recorded.~In our study, the patient will be asked to start the test after the Gyko device is fixed with a wearable vest. During the test, data on the ellipsoid area, anteroposterior velocity, anteroposterior distance, mediolateral velocity, and mediolateral distance will be taken."
224251979|NCT06045598|OTHER|Montreal Cognitive Assessment|MoCA is a 10-minute scale that measures global cognitive skills. It includes items consisting of attention and concentration, executive functions, memory, language, visuospatial skills, abstract thinking, calculation and orientation skills. The lowest score that can be obtained from the scale is 0, and the highest score is 30. Scores of 21 and below indicate the presence of cognitive impairment.
224251980|NCT03616730|DIAGNOSTIC_TEST|NICOM (non-invasive cardiac output monitor)|Transthoracic bio-reactance, or the non-invasive cardiac output measurement \[NICOMTM, Cheetah Medical Inc., Portland, OR\] system, is a new technique that is able to measure multiple hemodynamic parameters with four transdermal electrodes placed on the patients' thorax. It is based on frequency- and phase-modulation of the voltage signal measured in response to an applied transthoracic current. It has shown acceptable accuracy, precision and responsiveness for cardiac output monitoring in patients experiencing a wide-range of hemodynamic situations and is a FDA-approved device.
223670836|NCT03206996|BEHAVIORAL|Psycho-education|Child and caregiver receive education and training will be provided to improve the participant's self-awareness of his/her behavioral and emotional response to auditory stimuli, his/her ability to self-report anxiety/emotional response levels, as well as his/her ability to identify useful arousal level modulation/coping strategies. During this phase, the child, caregiver and therapist will collaborate to identify the participant's Subjective Units of Distress Scale (SUD) from 0-10 with each level defined, particularly for what levels are tolerable or intolerable.
223670837|NCT03206996|BEHAVIORAL|Caregiver education/home program development|Parents will be provided with education on home programs to facilitate treatment gains. Home programs will be designed specifically for each participant. Parent education and home programs are provided either concurrently or after the exposure phase for the family to apply these methods to other settings. Home programs can continue as a maintenance program after treatment has ended. At the end of the treatment phase, the study team will conduct the following assessments for a third time: (1) the Sensory Profile, a clinical tool commonly used in OT to assess parent reports of sensory processing difficulties in children, (2) Parent Stress Index - 4 to evaluate stress related to parent-child interactions, and (3) the Modified Khalfa Hyper-acusis Questionnaire to assess the level of hyper-sensitivity to sound.
223670838|NCT04958512|DRUG|Yangxue Qingnao pill|The treatment group (20 cases) was treated with Yangxue Qingnao pill (2.5g / time, 3 times / day, orally for 6 months
223670839|NCT04958512|DRUG|Hydergotoxine mesylate tablets|The control group (n = 20) was treated with hidezhen 3 mg per day before meals for 6 months
223670840|NCT04958512|OTHER|blank control group|There were 20 cases in the blank control group.Outpatient consultation at any time was prescribed.
223670841|NCT06408155|OTHER|Isometric Task|The task demanded that participants maintain their arm bent at a 90° angle while holding a dumbbell, which weighed 80% of their one-repetition maximum (1RM), in a supine grip on the dominant side of their body for the longest time they could.
223670842|NCT00130312|DRUG|Sulodexide|100 mg gelcap in the morning and evening
223670843|NCT00130312|DRUG|Placebo|1 placebo gelcap in the morning and evening
223670844|NCT03306797|OTHER|STANDARD REHAB|"The rehabilitative standard intervention (Occupational Therapy) consists of 15 minutes of warm-up exercises plus a 20 minutes training with at least 6 exercises selected from:~wrist~* ulnarization radialization~* prono-supination~* horizontal flexion-extension~* vertical flexion-extension hand~* grasping~* pinching~* extensors~* interosseous shoulder-elbow~* vertical flexion-extension~* push forward"
223771763|NCT02578485|DEVICE|EISVideogame|Participants performed walking on a treadmill in intensity similar to the game by a period of 60 minutes, then remain at rest for the evaluation of post-exercise blood pressure for an additional period of 60 minutes.
223771764|NCT02578485|DEVICE|Control|participants remained at rest for a period of 60 minutes, then remain at rest for the evaluation of post-exercise blood pressure for an additional period of 60 minutes.
223771765|NCT02732847|OTHER|A delayed prescription dated 2 days after clinical office visit|
223771766|NCT02732847|DRUG|Usual Dated|
223771767|NCT01942382|DRUG|Paliperidone palmitate|Participants will receive 4 injections of paliperidone palmitate of concentration ranging from 75 to 150 milligram equivalents in deltoid or gluteal muscle as randomized to treatment group A, B, or C on Days 1, 8, 36, and 64.
223771768|NCT01719965|OTHER|Interviews and Focus Group Discussions|
224251981|NCT03825328|DRUG|Albumin-bound paclitaxel|Albumin-bound paclitaxel is paclitaxel formulated as albumin-bound nanoparticles with a mean particle size of approximately 130 nanometers.
223670845|NCT03306797|DEVICE|SONICHAND|"The intervention is similar to the standard protocol (15 minutes of warm-up plus 20 minute of training) but involves the sonification of the exercises selected from the list. The Leap Motion Controller is managed with an ad-hoc developed application that is able to associate the movements with a 4 notes arpeggio or with a modulated texture.~With the first mode the movement produces and modulates an harmonic progression built on the consecutive grades of the major scale played as ascending and descending arpeggio with also a volume crescendo and decrescendo.~With the second mode, the movement modulates the volume and the low-pass cutoff frequency of a synthetic texture."
223670846|NCT06449365|DEVICE|midazolam by nasal atomizer|midazolam
223670847|NCT06449365|DRUG|intravenous midazolam|midazolam
223670848|NCT05470257|OTHER|Cast|Application of fiberglass long arm cast.
223670849|NCT02875574|DRUG|Any treatment regimen|Treatment regimen used to treat patient once isoniazid resistance known (exposure of interest for cohort study)
223670850|NCT02875574|OTHER|Bacterial mutation|Resistance, compensatory or other mutation in the infecting strain of Mycobacterium tuberculosis (exposure of interest for nested case-control study)
223670851|NCT05934188|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|The Magnetic Resonance Imaging protocol will comprise both structural and functional sequences.
223670852|NCT05934188|BEHAVIORAL|Neuropsychological protocol|Neuropsychological tests will be administered to participants to assess general cognitive state and a range of high-level cognitive functions (memory, executive, language). In addition, disease-specific tests will be administered to patients to investigate disease staging and the level of disability and autonomy.
223670853|NCT05934188|BEHAVIORAL|Eating habits|Information on eating habits will be derived from food questionnaires.
223670854|NCT05934188|DIAGNOSTIC_TEST|Microbiome analyses|The Microbiome analyses will be derived from a stool sample (16S rRNA sequencing targeted metagenomic analyses).
223670855|NCT05934188|DIAGNOSTIC_TEST|Inflammatory markers|Inflammatory markers will be evaluated in terms RNA expression level in plasma blood sample.
223670856|NCT05934188|DIAGNOSTIC_TEST|Alzheimer's Disease biomarkers|The Alzheimer's Disease biomarkers will be measured in the plasma of prodromal Alzheimer's Disease patients.
223670857|NCT03409042|BEHAVIORAL|Caloric compensation|The investigators have adapted an established within-subject preload paradigm to assess infant's short term caloric compensation. At each studied age, the measure of caloric compensation required two visits at the laboratory on two non-consecutive days. On the first visit, the infants received a fixed amount of a food preload either low or high in energy density. The order of the two preloads was counterbalanced. After a delay (ranging from several hours in the 3-4 months old infants to 25 min in 10.5- and 14.5-month-old infants), the infants were served an ad libitum meal. Weight intakes (g) were assessed by weighing each bottle/bowl before and after consumption.
223670858|NCT00911443|BIOLOGICAL|Dacarbazine + Interferon alpha + Thymosin-alpha-1 1.6 mg|Dacarbazine 800 mg/m2 IV on day 1;Interferon alpha 3MIU SC on day 11 and 18; Thymosin-alpha-1 1.6 mg SC from day 8 to 11 and from day 15 to 18 of each 28 day cycle up to 6 cycles or until progression or unacceptable toxicity develops.
223670859|NCT00911443|BIOLOGICAL|Dacarbazine + Interferon alpha + Thymosin-alpha-1 3.2 mg|Dacarbazine 800 mg/m2 IV on day 1; Interferon alpha 3MIU SC on day 11 and 18; Thymosin-alpha-1 3.2 mg SC from day 8 to 11 and from day 15 to 18 of each 28 day cycle up to 6 cycles or until progression or unacceptable toxicity develops.
224251982|NCT03825328|DRUG|S-1|a combination preparation of tegafur, gimeracil, and oteracil potassium
223670860|NCT00911443|BIOLOGICAL|Dacarbazine + Interferon alpha + Thymosin-alpha-1 6.4 mg|Dacarbazine 800 mg/m2 IV on day 1; Interferon alpha 3MIU SC on day 11 and 18 Thymosin-alpha-1 6.4 mg SC from day 8 to 11 and from day 15 to 18 of each 28 day cycle up to 6 cycles or until progression or unacceptable toxicity develops.
223670861|NCT00911443|BIOLOGICAL|Dacarbazine + Thymosin-alpha-1 3.2 mg|Dacarbazine 800 mg/m2 IV on day 1; Thymosin-alpha-1 3.2 mg SC from day 8 to 11 and from day 15 to 18 of each 28 day cycle up to 6 cycles or until progression or unacceptable toxicity develops.
223771769|NCT01368458|OTHER|Conversion to Antipsychotic Monotherapy|Patients assigned to the antipsychotic monotherapy group will have the dosage of their secondary (i.e. one due to be reduced) antipsychotic reduced by decreased by approximately 1/3 every 3 weeks. Dosage of the primary antipsychotic will be left unchanged.
223771770|NCT00982189|DRUG|Pravastatin|Participants randomized to take pravastatin (active) or matching placebo pill once daily
224251983|NCT03825328|DRUG|Oxaliplatin|The compound features a square planar platinum(II) center. In contrast to cisplatin and carboplatin, oxaliplatin features the bidentate ligand 1,2-diaminocyclohexane in place of the two monodentate ammine ligands. It also features a bidentate oxalate group.
224251984|NCT03825328|DRUG|Gemcitabine|Gemcitabine is a synthetic pyrimidine nucleoside prodrug-a nucleoside analog in which the hydrogen atoms on the 2' carbon of deoxycytidine are replaced by fluorine atoms.
224251985|NCT02199665|DRUG|selinexor|Given PO
223670862|NCT00911443|DRUG|Dacarbazine + Interferon alpha|Dacarbazine 800 mg/m2 IV on day 1; Interferon alpha 3MIU SC on day 11 and 18 of each 28 day cycle up to 6 cycles or until progression or unacceptable toxicity develops.
223670863|NCT04779749|OTHER|Data extraction from medical files|Data extraction from medical files
223670864|NCT06518850|DRUG|Rifaximin|Both groups were treated with rifaximin for 14 days, during which follow-up records were reported by the subjects in the daily reference case report form. Methane and hydrogen breath tests were repeated 2 weeks after withdrawal.
223670865|NCT00912444|DRUG|Docetaxel, Anthracycline (Doxorubicin or Epirubicin), Cyclophosphamide|Docetaxel 75mg/m2, doxorubicin 50mg/m2 or epirubicin 60mg/m2, cyclophosphamide 500mg/m2 every 3 weeks for six cycles
224251986|NCT02199665|DRUG|carfilzomib|Given IV
224251987|NCT02199665|DRUG|dexamethasone|Given PO or IV
224251988|NCT01383694|DRUG|Piperine|
224251989|NCT06445062|DRUG|RMC-6236|Oral tablet
224251990|NCT06445062|DRUG|mFOLFOX6 regimen|IV infusion
224251991|NCT06445062|DRUG|bevacizumab|IV infusion
224251992|NCT06445062|DRUG|mFOLFIRINOX regimen|IV infusion
224251993|NCT06445062|DRUG|cetuximab|IV infusion
223670866|NCT00912444|DRUG|Docetaxel, cyclophosphamide|Docetaxel 75mg/m2, cyclophosphamide 600mg/m2 every 3 weeks for six cycles
223670867|NCT03821662|BEHAVIORAL|OT Diabetes Self-Management Intervention|Occupational therapy chronic disease self-management intervention.
223670868|NCT02127268|DRUG|Thymosin-α1|with Thymosin-α1 1.6mg twice a week
223670869|NCT00627146|DRUG|ChAgly CD3|6 days treatment 8mg/d intravenous
223670870|NCT00627146|DRUG|Placebo|6 days
223670871|NCT02496572|DRUG|Short course MDR-TB treatment regimen|"Intensive phase:~Pyrazinamide (Z) + Ethambutol (E) + Isoniazid (H) + Moxifloxacin (Mfx) + Capreomycin (Cm) + Prothionamide (Pto) + Clofazimine (Cfz) for at least 4 months and until one negative culture is documented with a maximum of 6 months duration.~Continuation phase:~Continuation phase of Pyrazinamide (Z) + Ethambutol (E) + Moxifloxacin (Mfx) + Prothionamide (Pto) + Clofazimine (Cfz) for fixed 5 months duration."
223670872|NCT01908400|BIOLOGICAL|Intravenous transfer of BMMNC|Intervention therapy , Total 3 doses ,in 30 days ,in 7days interval Intravenous transfer of Autologous Bone Marrow derived Mono Nuclear Stem Cell (BMMNCs)
223771771|NCT00982189|DRUG|Lisinopril|Participants randomized to take lisinopril (active) or matching placebo pill once daily
224251994|NCT06445062|DRUG|gemcitabine|IV infusion
224251995|NCT06445062|DRUG|nab-paclitaxel|IV infusion
224251996|NCT06445062|DRUG|RMC-9805|Oral Tablet
224251997|NCT00500591|BEHAVIORAL|Questionnaire|Questionnaire regarding weight history, gynecologic, and medical history, lasting about 30 minutes.
224251998|NCT03699696|DRUG|Propofol|Induction of anesthesia prior to surgery with propofol
224251999|NCT02935517|BIOLOGICAL|AGTC-402|AGTC-402 is a non-replicating, rep/cap-deleted, recombinant adeno-associated virus vector that expresses the CNGA3 gene.
224252000|NCT04487158|BEHAVIORAL|Small Changes|The Small Changes program is an evidence-based 6-month weight-management program. The program runs weekly for 3 months followed by by-weekly contact for 3-months (1x in-person group and 1x phone call). This program uses behaviour change strategies to help with weight loss. The Small Changes approach is different from traditional dieting programs because it encourages modest changes to diet and physical activity which are not overly taxing to maintain. Participants are asked to reduce their nutritional intake by 200-400 calories per day. You will also be asked to increase their daily step count by 2000-3000 steps. Weekly intervention topics include: Monitoring, Nutrition, Physical Activity, Breaking the Chain, External Cues, Mindful Eating, Body Image, Stress, Sleep, Social Support, Social Eating, and the Stoplight Guide.
224252001|NCT04487158|BEHAVIORAL|INSPIRE|The INSPIRE program is a modification to the Small Changes program. It combines elements of positive psychology and behaviour change to help with weight loss. The first four weeks of the program are oriented towards improving well-being and include topics such as values, self-compassion/mindfulness, character strengths, and gratitude. The remaining 8 weeks mirrors the Small Changes program in making modest changes to diet and physical activity to achieve weight loss. Participants are asked to reduce their nutritional intake by 200-400 calories per day. Participants will also be asked to increase their daily step count by 2000-3000 steps.
224252002|NCT02517294|DEVICE|Parker flex-tip nasotracheal tube|specially designed nasotracheal tube used for nasotracheal intubation assess nasopharynx for severity of bleeding grade adenoid size
224252003|NCT02517294|DEVICE|Standard nasotracheal tube|standard nasotracheal tube for nasotracheal intubation assess nasopharynx for severity of bleeding grade adenoid size
224322128|NCT03038386|OTHER|Dual Energy CT|In this study all patients undergo DECT scan to assess the value of DECT scan in diagnosing acute arthritis caused by gout. If the DECT scan demonstrates MSU depositions and the diagnosis of gout was not ascertained prior to DECT scanning by MSU crystals in the synovial fluid, then additional ultrasound guided aspiration will take place, with knowledge of DECT results, followed by repeat microscopy
223670873|NCT03386877|PROCEDURE|periodontal regeneration|Defects were accessed with the MIST In the test group the obtained micro-grafts enriched in DPSCs were endorsed onto a collagen sponge scaffold (Condress®, Istituto Gentili, Milano, Italy) to form a bio-complex. In the control group the collagen sponge was only hydrated using physiologic sterile solution. The collagen sponge with or without cells was provided to the masked surgeon who filled the intrabony defect. The flaps were repositioned and tension-free primary flap closure was obtained using horizontal internal mattress and interrupted sutures
223670874|NCT00697580|BEHAVIORAL|Nutrition|Nutrition classes for 1 hour \& 30 minutes once a week for 16 weeks + motivational interviewing (4 individual sessions)
224252004|NCT02767791|OTHER|Acupuncture|Acupuncture
224252005|NCT02767791|OTHER|Auriculotherapy|Auriculotherapy
224252006|NCT03777826|OTHER|PKU Synergy|PKU Synergy is a citrus flavored, powdered amino-acid mixture (containing traces of Phe, 4,3mg per portion; and 20 gr. Protein Equivalent (PE)) with a tailored amino acid and micronutrient profile adapted for the special requirements of HPA/PKU (Hyperphenylalaninemia/Phenylketonuria) subjects over 10 years of age with an increased Phenylalanine-(Phe) tolerance/intake.
224252007|NCT06242145|DRUG|Clopidogrel tablet|Efficacy and safety of a 300mg loading dose of ticagrelor administered within 24 hours of first-ever ischemic stroke followed by 75mg daily for 3 months will be assessed through NIHSS, mRS, duration of hospital stay, new ischemic stroke, and possible adverse effects.
224252008|NCT06242145|DRUG|Cilostazol 100 MG|Efficacy and safety of 200 mg clopidogrel followed by 100 mg twice daily for 3 months will be assessed through NIHSS, mRS, duration of hospital stay, new ischemic stroke, and possible adverse effects.
224252009|NCT05370417|OTHER|Use of fluoride toothpaste|The participants received oral hygiene instructions - routine brushing twice per day with toothpaste containing 1000 ppm of fluoride. All participants received a toothbrush and toothpaste to ensure standardization. The aim of this intervention was to assess whether the participants' brushing technique would improve with desensitization.
224322129|NCT01775826|OTHER|Measurement|Measured usual (day-to-day) behavior with body-worn sensors.
224322130|NCT02614924|DEVICE|Flexible fibreoptic scope|Patient intubated using fibreoptic scope
224322131|NCT02614924|DEVICE|Pentax AWS videolaryngoscope|Patient intubated using Pentax AWS videolaryngoscope
224322132|NCT05736835|BIOLOGICAL|CVXGA|CVXGA is a live viral vector, consisting of a recombinant parainfluenza virus type 5 that carries the SARS-CoV-2 S-protein from WA.1 (not enrolling) or XBB1.5 strain.
223771772|NCT04988165|DRUG|Traditional Chinese Medicine|It is a common prescription used in traditional Chinese medicine to treat diarrhea with remarkable efficacy.
223771773|NCT06408467|OTHER|aMMP-8 diagnostic test|40 patients
224252010|NCT05370417|RADIATION|Photobiomodulation|"For laser application, the following dosimetric parameters will be used:~Low level laser diode (infra red) wavelength 808nm with a power of 100mW. Three sessions: initial session, after 48 hours and after one month. LLL was applied to three perpendicular points in contact with the surface on the mesial vestibular and distal cervical faces and in the center of the occlusal face. An energy of 1 J was applied for 10 seconds at each point."
224252011|NCT05370417|PROCEDURE|Simulated Laser Therapy|The same application described in the laser therapy group will be simulated, with the device turned off.
224252012|NCT05370417|PROCEDURE|Sealant application|A glass ionomer sealant will be applied to the occlusal surface of the first permanent molar.
224252013|NCT02408367|BEHAVIORAL|Exercise|30 minutes endurance training at 75% of the Maximum heart rate
224252014|NCT02408367|BEHAVIORAL|Relaxation|30
224252015|NCT04699084|OTHER|Mozart music|A 20-minute piece composed by W.A Mozart ( Sonata K. 448 in D Major for 2 pianos) was applied in music group, directly after the arrival of patients in the Post Anesthesia Care Unit (PACU), while they were receiving usual postoperative care.
223670875|NCT00697580|BEHAVIORAL|Strength Training & Nutrition|Strength Training twice a week for 1 hour a day for 16 weeks + Nutrition once a week for 1 hour \& 30 minutes for 16 weeks + motivational interviewing (4 individual \& 4 group sessions)
223670876|NCT00697580|BEHAVIORAL|Circuit Training & Nutrition|Circuit Training twice a week for 1 hour a day for 16 weeks + Nutrition once a week for 1 hour \& 30 minutes for 16 weeks + motivational interviewing (4 individual \& 4 group sessions)
223670877|NCT01142089|DRUG|Placebo|Placebo (two matching tablets) orally twice daily for 3 days (72 hours).
223670878|NCT01142089|DRUG|Rifamycin SV MMX|Rifamycin SV MMX® 400 mg (two 200 mg tablets) orally twice daily for 3 days (72 hours).
223670879|NCT05011448|OTHER|Music Therapeutic Interaction and Verbal Interaction|"In both sessions (the Verbal Interaction and the Music Therapeutic Interaction) participants will be asked to perform three piano playing exercises in a fixed order: (1) playing a musical scale, (2) playing a short excerpt from a familiar song, and (3) free improvisation. Both sessions will also include a protocol of verbal instructions given by the therapist before each exercise. In session A ('Verbal Interaction') participants will perform these exercises alone while the therapist is only interacting with them verbally (asking them questions, commenting regarding their performance etc.). In session B ('Music Therapeutic Interaction') participants will perform these exercises while the therapist is interacting with them musically, using various music therapy techniques that are matched and attuned to each patient's playing dynamics and style. This is to reflect the dynamics of the music therapeutic interaction as it occurs in the real world of music therapy practice."
223670880|NCT01145638|DRUG|iron isomaltoside 1000|intravenously as bolus or infusion, 500 mg or 1000mg up to full replacement dose
223670881|NCT01145638|DRUG|iron sulphate|oral, 200 mg per day (100 mg bid),12 weeks
223771774|NCT03341130|DEVICE|Mandibular Repositioning Splint|The Morning Repositioner is a hands-free bite deprogrammer designed to help return the patient's jaw back to its pre-treatment centric position.
223771775|NCT03341130|DEVICE|Mandibular Advancement Oral Appliance|Mandibular Advancement Oral Appliances are dental splints used to keep the jaw in an advanced position, opening the upper airway during sleep.
223670882|NCT02592187|BEHAVIORAL|ReMemory-MCI training|
223670883|NCT02592187|BEHAVIORAL|Control intervention|
223670884|NCT05449470|DEVICE|CDSS|A clinical decision support system (CDSS) that provides deprescribing advice and a personalized risk prediction
223670885|NCT05449470|DEVICE|Patient Portal|A Patient Portal that helps patients prepare for their fall clinic visit by giving them information about falls, falls prevention, and medication-related falls. After the fall clinic visit, the Patient Portal also shows the personalized fall-risk and treatment advice.
223670886|NCT00789074|DRUG|Varenicline|Varenicline 1mg twice daily
223670887|NCT00789074|DRUG|Placebo|Placebo 1mg BD
223670888|NCT01490398|DRUG|Rosuvastatin|After baseline assessment, the starting dose of rosuvastatin 10 mg will be given to study patients. If tolerated and LDL-C is \> 100mg/dL after 2-4 weeks, the dose will be increased to 20 mg. Rosuvastatin treatment is scheduled to continue for 1 year without no further dose titration, and each patient will be followed at 2 months, 6 months and 1 year.
223670889|NCT00531687|DRUG|Paclitaxel|"Paclitaxel 175 mg/m2 day 1 (3 hour infusion)~Repeat at 21-day intervals for 4 cycles if toxicity is acceptable. If necessary more than 4 cycles can be administered."
223771776|NCT04953767|DEVICE|Blue light therapy|Blue light therapy has been proved its efficacy and safety is treatment circadian rhythm disorder as well as other diseases.
224252016|NCT05283629|BEHAVIORAL|Neuroplasticity-based Computerized Cognitive Remediation|"Behavioral: Neuroplasticity-based Computerized Cognitive Remediation The nCCR has two major components: Bottom up and Top down training.~* Bottom up training: The training includes selected tasks from Brain HQ, a program designed for older adults, that enhances basic processing of sensory stimuli with the goal to improve fidelity of auditory and visual encoding.~* Top down training: We designed programs to target cognitive control functions associated with poor treatment response, i.e., initiation and use of verbal strategy and susceptibility to interference. These Top Down Programs include a visual attention program, either Catch the Ball or Neurogrow, and a semantic strategy program, Semantic Organization."
224252017|NCT05283629|BEHAVIORAL|Education Control Condition|The education control condition is a learning-based approach that utilizes DVDs on history, art, science, etc. This active condition is comparable to nCCR in length of exposure, audio-visual presentation, computer use and contact with research staff.
224252018|NCT04701983|DRUG|Itepekimab SAR440340|Pharmaceutical form: solution for injection in pre-filled syringe Route of administration: subcutaneous
223670890|NCT00531687|DRUG|Cisplatin|"cisplatin 50 mg/m2 day 1 and 2~Repeat at 21-day intervals for 4 cycles if toxicity is acceptable. If necessary more than 4 cycles can be administered."
223670891|NCT00531687|DRUG|Gemcitabine|"gemcitabine 1000mg/m2 days 1 and 8 (in a 30 minute infusion)~Repeat at 21-day intervals for 4 cycles if toxicity is acceptable. If necessary more than 4 cycles can be administered"
224252019|NCT04701983|DRUG|Placebo|Pharmaceutical form: solution for injection in pre-filled syringe Route of administration: subcutaneous
224252020|NCT03799562|DRUG|Pregnenolone|Pregnenolone 50 mg BID x 14 DAYS, followed by Pregnenolone 150 mg BID x 14 DAYS, followed by Pregnenolone 250 mg BID x thereafter for the remainder of the 8-week trial. Placebo will be identical to the pregnenolone arm, except placebo will be dispensed.
224252021|NCT03799562|DRUG|Placebo|Same as pregnenolone (active study medication), except placebo dispensed.
224252022|NCT06161558|DRUG|Erlotinib|Small-molecule tyrosine kinase inhibitor targeting EGFR
224252023|NCT06161558|DRUG|Lenvatinib|Small-molecule tyrosine kinase inhibitor targeting VEGFR1, VEGFR2, and VEGFR3
224252024|NCT06161558|DRUG|Axitinib|Small-molecule tyrosine kinase inhibitor targeting VEGFR1, VEGFR2, and VEGFR3
223670892|NCT04170478|DEVICE|Echolaser X4 system|Transperineal laser ablation
223670893|NCT01840644|OTHER|Walking on treadmill, different velocities and incline|Walking on treadmill twice, with one week interval in each session the child will walk in different velocities and incline
223670894|NCT02208401|PROCEDURE|conventional cold snare polypectomy|conventional cold snare polypectomy
223670895|NCT02208401|PROCEDURE|Cold snare polypectomy with suction|Cold snare polypectomy with suction
223670896|NCT02907892|PROCEDURE|Glove change|Intra-operative changing of sterile surgical gloves immediately prior to abdominal closure during cesarean section
223670897|NCT02910128|BEHAVIORAL|chiquichefs|A project based learning using healthy trough cooking as the core of the curriculum, so children learn the academic content through cooking workshop of mediterranean diet in their school.
223670898|NCT06522984|DRUG|Tranexamic acid injection|"to evaluate and compare efficacy of:~* Fractional Er: YAG laser combined with topical hydroquinone.~* Intradermal injection of tranexamic acid combined with topical hydroquinone cream.~* Oral administration of tranexamic acid combined with topical hydroquinone cream. In treating refractory melasma."
223670899|NCT01974765|DRUG|Enzalutamide|All enrolled patients will be treated with enzalutamide 160mg by mouth QD. Study drugs will be self-administered by patients. A cycle is 28 days.
223670900|NCT05324865|BEHAVIORAL|Progressive Muscle Relaxation|Progressive Muscle Relaxation PMR is a technique that provides relaxation in the whole body by voluntary and regular relaxation of large muscle groups in the human body, which is included in mind-body applications.
223670901|NCT00864019|DRUG|Sertraline HCl 100 mg tablets, single dose|A: Experimental SSubjects received Purepac formulated products under non-fasting conditions
223670902|NCT00864019|DRUG|Zoloft® 100 mg tablets, single dose|B: Active comparator Subjects received Pfizer formulated products under non-fasting conditions
223670903|NCT02915328|DEVICE|Filterwire EZ™|
223670904|NCT02915328|DEVICE|MO.MA Ultra|
223670905|NCT02915328|DEVICE|Stent Roadsaver®|
223670906|NCT02915328|DEVICE|Carotid Wallstent|
223670907|NCT04043390|DIAGNOSTIC_TEST|CRP and Molbio Truenat MTB|A molecular assay to detect M tuberculosis DNA Truenat is currently undergoing the process of endorsement by the WHO.
223670908|NCT04043390|DIAGNOSTIC_TEST|CRP and Xpert ULTRA MTB/RIF|A molecular assay to detect M tuberculosis DNA ULTRA is already endorsed by the WHO. However the tests are still considered experimental in Nigeria and Ethiopia.
223670909|NCT04043390|DIAGNOSTIC_TEST|standard test Xpert|The investigators will use Xpert to compare its agreement with scheme 1 (CRP plus Truenat MTB) and scheme 2 (CRP plus ULTRA).
223670910|NCT04043390|DIAGNOSTIC_TEST|Culture as reference standard|The investigators will use culture to assess the sensitivity of schemes 1 and 2
223670911|NCT05642962|DRUG|Pertzye|Treatment with standard dose or higher dose Pancrelipase will continue for 20 weeks from enrollment. Participants will consume assigned blinded weight based Pancrelipase dose concurrent with first bite of every meal and snack for the duration of enrollment.
224252025|NCT06508411|OTHER|Pain screening|exploration of the relationship between pain and sexual health
224252026|NCT05095519|DRUG|18F-DCFPyL|18F-DCFPyL will be administered with a single dose of 3.5 MBq per kg (2-4 MBq per kg), maximum 400 MBq), administered as a slow (over 30 seconds) intravenous injection
224252027|NCT01619930|BEHAVIORAL|Physical activity without motivational interviewing|Focus is on physical exercise, motivated by research findings that it has a positive effect on depressive symptoms. An individualized exercise program is constructed, to be followed by the respective participant. A user-friendly pulse watch will be mailed to participants. Exercise is monitored through online self-registration with automated feedback.
224252028|NCT01619930|BEHAVIORAL|Physical exercise with motivational interviewing|Focus is on physical exercise, motivated by research findings that it has a positive effect on depressive symptoms. An individualized exercise program is constructed, to be followed by the respective participant. A user-friendly pulse watch will be mailed to participants. Exercise is monitored through online self-registration with automated feedback. An initial motivational interview (MI) per telephone is also conducted, to explore the intrinsic motivation to change in participants.
224322133|NCT03003195|DRUG|P10s-PADRE|All research participants will receive the Mimotope P10s-PADRE/MONTANIDE ISA 51 VG vaccine via subcutaneous (SC) injection for a total of 4 vaccinations.
224322134|NCT03673917|OTHER|Educational video|The educational video on skin cancer for cosmetologists
224322135|NCT03673917|OTHER|Control video|A publicly accessible healthy lifestyle video on YouTube, which does not contain any information on skin cancer
224322136|NCT06488534|DIETARY_SUPPLEMENT|Fermentable Oligo-, Di- Monosaccharides And Polyols (FODMAPs)|A FODMAP solution of 200 mL will be infused in the colon for over 20 min. via the lumen of the solid-state catheter for high-resolution colonic manometry.
223670912|NCT04666077|BEHAVIORAL|Home-based MT through Supervised, Supported Singing (H3S)|"Daily singing of song of kin. The song of kin will be derived from an assessment session and evaluation inclusive of an interview under the supervision of Dr. Joanne Loewy and her team at the Louis Armstrong Center for Music and Medicine (LACMM). The interview will include the participant and their study partner who will assist in identifying musical preferences and relevant cultural experiences. A recording of prescribed song protocols will be provided. Participants and study partners will be directed to plan a minimum of 1 hour a day in which the participant will sing along with the study partner-administered song of kin. A diary will be provided to the study partner to record the time of day, amount of time spent and comments on the activity. Study staff will contact the members of this group to confirm compliance with the activity."
223670913|NCT04666077|BEHAVIORAL|Individualized Music Therapy (IMT)|The Individualized Music therapy (IMT) conducted by the LACMM staff. It will be administered by a certified music therapist twice weekly for 45 minutes. The sessions will employ extensive clinical improvisation based on the songs of kin utilized in the H3S condition. Compliance will be measured with a weekly log which will record dates and times of each condition.
224252029|NCT01619930|BEHAVIORAL|Behavioral activation with rationale|A behavioral activation program, based on the TRAP-TRAC model according to which suffering individuals are trapped in a vicious circle of avoidance and ever fewer reinforcers, leading to increasing discomfort. To break free of this vicious circle, patients have to replace avoidance patterns with alternative coping strategies. Unlike previous applications of this program done in the U.S., this study will feature an internet-based administration. Approximately 15 minutes of electronic therapist support will be included per week.
224252030|NCT01619930|BEHAVIORAL|Behavioral activation without rationale|"A behavioral activation program without TRAP-TRAC rationale, but with some encouragement provided (Activate yourself and feel better!). Approximately 15 minutes of electronic therapist support will be included per week."
224252031|NCT01202422|DRUG|Pregabalin controlled release, 165 mg|Two tablets of 165 mg controlled release (administered concurrently) once daily for four days.
224252032|NCT01202422|DRUG|Pregabalin controlled release, 330 mg|330 mg controlled release tablet administered once daily for four days.
224252033|NCT01202422|DRUG|Pregabalin immediate release, 150 mg|150 mg immediate release capsules administered every 12 hours for four days
224252034|NCT06031857|OTHER|kinesio tape|kinesio tape was applied over the specific muscle of rotator cuff
224252035|NCT06031857|OTHER|Dry needling|dry needling was applied over the affected muscles
224252036|NCT01982981|OTHER|water provision|perception behavioral change at the beginning and at the end of the intervention
224252037|NCT01982981|OTHER|Water provision|After participants are recruited, drink 2L of water for 8 weeks.
223670914|NCT04666077|OTHER|Attention Control (AtCon)|"The attention control (AtCon) will meet with the LACMM team for an interview in which they will be asked about music preferences and music experiences. They will answer any questions from participant and caregiver about music experiences. Study staff will contact the members of this group at the same schedule as the H3S group to assess music activity engagement. This will measure unplanned exposure and minimize drop-in music activity which could contaminate the control condition."
223670915|NCT01133327|DEVICE|Carotid Artery Stenting|"The Adapt Carotid Stent System is intended to deliver a self-expanding Stent to the extra-cranial carotid arteries via a sheathed percutaneous Monorail delivery system. The Adapt Carotid Stent is a closed cell, self-expanding, rolled nitinol (nickel-titanium alloy) sheet. The stent is thin, flexible and expands to appose the vessel wall.~The FilterWire EZ System is a temporary intravascular guide wire filtration system that is placed in the vessel distal to the lesion to be treated. It consists of either a polyurethane filter bag 1.5 cm in length or a Bionate (polycarbonate urethane) filter bag, 1.0 cm in length attached near the distal end of a 0.014 silicone coated stainless steel guide wire by means of a collapsible, self-conforming, Nitinol filter loop wire."
223670916|NCT05876832|DRUG|XY0206|Dosage form:Tablet;Multiple dose phase:Take the medicine once a day,37.5mg at a time.4 weeks of continuous medication is one course of treatment. After the first course of treatment, the subjects can continue to receive the experimental drug treatment until the subjects meet the withdrawal criteria.
223670917|NCT05876832|DRUG|Salvage Chemotherapy|Low-dose Cytarabine (LoDAC) or azacitidine, fludarabine, cytarabine and granulocyte colony-stimulating factor (FLAG) or mitoxantrone, etoposide, cytarabine (MEC)will be administered by subcutaneous (SC) and/or intravenous (IV) injections.
223670918|NCT04914039|COMBINATION_PRODUCT|Combination Product|Cases of brain death confirmed by the classic brain death confirmation test
223670919|NCT04914039|OTHER|NO CTA examination|NO CTA examination
223670920|NCT01546402|DRUG|Dexamethasone Drug delivery system (Ozurdex)|It is a sustained release intravitreal implant containing 700µg dexamethasone has been approved by the US-FDA (Food and Drug Administration).
223670921|NCT01546402|PROCEDURE|Cataract surgery|Using a clear corneal incision, continuous curvilinear capsulorhexis, hydrodissection, phacoemulsification and irrigation/aspiration of the cortex will be performed. Foldable intraocular lens will be implanted in the capsular bag. All patients will receive standard postoperative topical steroid (betamethasone 0.1%), antibiotic (moxifloxacin 0.5%) and homatropine (2%) therapy.
223670922|NCT04084678|DRUG|Ralinepag|Oral ralinepag
223670923|NCT04084678|DRUG|Placebo|Matching oral tablets
223670924|NCT01669330|PROCEDURE|Nissen fundoplication|Laparoscopic Nissen fundoplication
223670925|NCT01669330|PROCEDURE|Laparoscopic antireflux surgery ad modum Watson|Laparoscopic anterior fundoplication
224252038|NCT02102165|PROCEDURE|metastatic lesion biopsy|a medical test commonly performed by a surgeon or an interventional radiologist in order to collect tissues for examination; in this case from a metastatic lesion
224252039|NCT05378217|DIAGNOSTIC_TEST|AMR LFIA Assay|AMR LFIA will be performed in parallel to routine testing on appropriate sample types retrieved from routine testing : Blood, urine, BronchoAlveolar Lavage (BAL), Tracheal Aspirate (TA), Rectal swab
224252040|NCT04206358|BIOLOGICAL|OrienX010 combination with JS001|"OrienX010 Produced by Oriengene Biotechnology Co., Ltd. Strength: 1.0 mL/vial. Label claim: Titer 8.0 × 10\^7Pfu/mL, NMT 1 × 10 particles11VP/mL.~JS001 Produced by Junshi Biosciences Co., Ltd. Strength: 240 mg/6 mL/vial; Sterile water injection dosage form; Expiry date: 24 months; Date of manufacture: Based on the date of manufacture indicated in the product package."
224252041|NCT00716690|PROCEDURE|Multi donor stem cell transplantation|stem cell transplantation from 2 donors
224252042|NCT00002318|DRUG|Doxorubicin hydrochloride (liposomal)|
223670926|NCT05639244|BEHAVIORAL|Time restricted eating (TRE)|Participants have to consume their regular food intake during a 6 hour period per day for 2 weeks.
223670927|NCT05639244|BEHAVIORAL|Regular diet|Participants have to consume their regular diet within an unrestricted time period for 2 weeks
223670928|NCT01135667|DRUG|clopidogrel|clopidogrel 150 mg once daily for 30 days
223670929|NCT01135667|DRUG|Prasugrel 10 mg|Prasugrel 10 mg once daily for 30 days
223670930|NCT00181636|DRUG|Galantamine-CR|
223670931|NCT06090292|DEVICE|Real TUS|2 channel transducer from Sonic Concepts will be used to deliver 120s train of 20ms ultrasound bursts, repeated every 200ms (Pulse Repetition Frequency (PRF)=5Hz).
224252043|NCT00002318|DRUG|Bleomycin sulfate|
224252044|NCT00002318|DRUG|Vincristine sulfate|
224252045|NCT00002318|DRUG|Doxorubicin hydrochloride|
224252046|NCT05934643|DEVICE|ActivPAL accelerometer|All patient will have an accelerometer (activPAL) applied to characterise the type and quantity of movement during the inpatient postoperative period after undergoing major surgery for colorectal cancer surgery.
224252047|NCT05934643|OTHER|Hospital Anxiety and Depression Scale (HADS) Questionnaire|The use of the HADS questionnaire to ascertain if any correlation between level of activity and and inpatient mood.
224252048|NCT01381848|DRUG|Doripenem|Type=exact number, unit=mg/kg, number=5, form=solution for injection, route=intravenous use, once on Day 1 for patients \<8 weeks CA.
224252049|NCT01381848|DRUG|Doripenem|Type=exact number, unit=mg/kg, number=8, form=solution for injection, route=intravenous use, once on Day 1 for patients \>=8 weeks CA.
224252050|NCT05681130|OTHER|questionaire|two questionaires for each group
224252051|NCT00152646|DRUG|placebo, aspirine, clopidogrel|
224252052|NCT04833504|BIOLOGICAL|CD19 CAR-T Expressing IL7 and CCL19|A fourth generation CD19 targeting CAR-T expressing IL7 and CCL19
224252053|NCT01424124|DRUG|YHD001 dose level 1|Tablet, three times daily / 8 weeks
224252054|NCT01424124|DRUG|YHD001 dose level 2|Tablet, three times daily / 8 weeks
223670932|NCT06090292|DEVICE|Real FES|"Twin Stim Plus EMS stimulator will be used to deliver FES to right and left hand opponens pollicis, first lumbrical and first dorsal interosseous muscles. Parameters of stimulation are 40 Hz frequency, 300 microsecs pulse duration, amplitude as per participant tolerance and total stimulation time 30 mins with ON time of 4 secs and OFF time of 4 secs."
223670933|NCT06090292|DEVICE|Sham TUS|2 channel transducer from Sonic Concepts will be used to deliver 120s train of 20ms ultrasound bursts, repeated every 200ms (Pulse Repetition Frequency (PRF)=5Hz) however the ultrasound head will be flipped so that the active side faces away from the scalp.
223670934|NCT06090292|DEVICE|Sham FES|"Twin Stim Plus EMS stimulator will be used to deliver FES to right and left biceps and long finger flexors. Parameters of stimulation are 40 Hz frequency, 300 microsecs pulse duration, amplitude as per participant tolerance and total stimulation time 30 mins with ON time of 4 secs and OFF time of 4 secs."
223670935|NCT01975324|DRUG|dalfampridine|dalfampridine 10 mgs or placebo twice a day for two weeks, wash out period of two weeks, dalfampridine 10mgs or placebo twice a day for two weeks
223670936|NCT01975324|DRUG|Placebo|placebo (sugar pill) twice a day for two weeks
223670937|NCT03523923|BEHAVIORAL|Collaborative Care|"Up to 12 phone sessions over 16 weeks from Collaborative Care Manager (CCM).~Session 1: Establish rapport, perform structured clinical assessment explain the rationale and parameters of the intervention, provide brief education on pain and together with the participant create an overall treatment plan and detailed follow-up plan.~Sessions 2-12 Components:~* Care Management Weekly monitoring of response to treatment using standardized measures.~* Collaborative Medical Management: Optimized management of problem areas. Medication recommendations will follow evidence-based treatment algorithms with consultation of supervisors.~* Psychosocial Treatment: Evidence based, focus on pain self-management skills/education, initially on foundational skills including: (1) pain education; (2) relaxation skills training; (3) behavioral activation and goal setting; 4) importance of physical activity and (5) motivational interviewing to promote adherence to healthcare and goals."
223670938|NCT01622634|BEHAVIORAL|Sprint Interval Exercise|Participants will undergo sprint interval training on a cycle ergometer 3 times weekly for 6 weeks. Each training session begins with a 5-minute active warm-up. The warm-up is followed by 4-7 bouts of 30 seconds of all-out sprints and 4 minutes of active recovery.
224252055|NCT01424124|DRUG|Singulair|Tablet, one times daily / 8 weeks
224252056|NCT01424124|DRUG|Placebo|Tablet, one times daily / 7 days
223670939|NCT01622634|OTHER|Higher PRO Diet|Participants in the PRO and PRO+EX groups will meet weekly with a diet specialist on staff to monitor their intake and compliance with the high protein diet.
223670940|NCT01622634|OTHER|Higher CARB Diet|Participants in the CHO and CHO+EX groups will meet weekly with a diet specialist on staff to monitor their intake and compliance with the higher carbohydrate diet.
223670941|NCT06081088|OTHER|Graded Motor Imagery (GMI) training|"GMI consists of three basic components:~1. Left / Right Discrimination training (Lateralization training): For lateralization training, patients will be trained by asking them to distinguish between right and left with images taken at various angles and positions in the RecogniseTM (NOI-Australia) applications (shoulder and hand sections) (In weeks 1 and 2).~2. Motor Imagery (Explicit Motor Imagery): At this stage, the participant will be asked to imagine doing various functional activities (brushing teeth, combing hair, etc.) in the position they feel most comfortable in and in a quiet environment (In weeks 2 and 3).~3. Mirror Therapy (providing visual feedback through a mirror): In this phase, active ROM exercises and progressive resistance exercises with simultaneous movement of the affected and unaffected extremities will be applied using a standard size posture mirror (In weeks 3-6).~This program will be applied for 6 weeks (3 sessions per week)."
223771777|NCT04953767|OTHER|White light|White light is used as sham control.
224252057|NCT02816996|PROCEDURE|Hand-holding|Subject will have their hand held.
224252058|NCT02816996|PROCEDURE|Stress Ball|Subject will be given a stress ball to hold.
224252059|NCT03911258|PROCEDURE|nasopharyngeal swab versus nasal wash|The type of procedure will be determine according to patient collaboration
224252060|NCT00047099|DRUG|cyclophosphamide|
224252061|NCT00047099|DRUG|docetaxel|
224252062|NCT00047099|DRUG|epirubicin hydrochloride|
224252063|NCT00047099|DRUG|fluorouracil|
224252064|NCT00047099|DRUG|goserelin acetate|
224252065|NCT00047099|DRUG|tamoxifen citrate|
224252066|NCT00047099|PROCEDURE|adjuvant therapy|
224252067|NCT00047099|RADIATION|radiation therapy|
224252068|NCT00738049|DRUG|darusentan 100 mg|All subjects will receive oral darusentan 100 mg for a total of 2 weeks and placebo for 2 weeks.
224252069|NCT03141671|DRUG|GnRH|-blocks the function of hormones including testosterone which prostate cancer uses to grow and spread
224252070|NCT03141671|DRUG|Bicalutamide|-blocks the function of hormones including testosterone which prostate cancer uses to grow and spread
224252071|NCT03141671|RADIATION|Salvage radiation|Radiation
224252072|NCT03141671|DRUG|Abiraterone|-blocks the function of hormones including testosterone which prostate cancer uses to grow and spread
224252073|NCT03141671|DRUG|Prednisone|Prednisone is a corticosteroid. It prevents the release of substances in the body that cause inflammation. It also suppresses the immune system.
223771778|NCT01430585|DRUG|PF-04691502|PF-04691502 administered as single agent for 2 weeks. After this period, patients in this arm will take PF-04691502 in combination with Letrozole until Week 6. Beyond Week 6, if considered appropriate, patients can be treated with the combination for up to 10 additional weeks until breast surgery.
224252074|NCT03141671|DRUG|Apalutamide|-blocks the function of hormones including testosterone which prostate cancer uses to grow and spread
224252075|NCT01457300|OTHER|Rehabilitation|Model 1: Regular Assessment of Rehabilitation Goal, Rehabilitation Plan, Weekly Multi-Disciplinary Evaluation and Adjustment of Plan, Regular use of Measurement Scales, Regular Dialog between Personnel, Patient and Relatives. Model 2: More Occasional use of the Listed Activities. Model 1 and Model 2: Physical Training and Functional ADL Training, in Groups, One by One or Self-Training.
224252076|NCT05885971|DIAGNOSTIC_TEST|Administration of the SCOFF-F and EDE-Q questionnaires|The participants will answer to the SCOFF-F and EDE-Q questionnaires as well as socio-demographic questions
224252077|NCT03400020|OTHER|Ascorbic acid|Ascorbic acid 500 Mg in normal saline IV two hours before the operation and thereafter 500 mg in normal saline IV daily for three days.
224252078|NCT03400020|OTHER|Normal Saline|Normal saline IV two hours before the operation and thereafter for three days.
224252079|NCT02553044|DIETARY_SUPPLEMENT|Cholecalciferol (Vitamin D3)|Oral vitamin D3 doses made up using 50 000IU ampules of vitamin D3 dissolved in 1ml of olive oil.
224252080|NCT00315562|PROCEDURE|carotid endarterectomy|
224252081|NCT05658341|BEHAVIORAL|ADA|"The 12-weeks program will include one-hour in adapted physical activity (APA), and a discussion on relaxation techniques and the undertaking of deep breathing exercises (making them APA+ sessions). A series of minute for nutrition short information sheets will be distributed at the end of each session.~Two workshops on living better after breast cancer will also be offered: one on general mobility and the other on daily nutrition.~Moreover, women will be asked to set personal challenges as a method of motivational reinforcement, and will also be called for motivational check-ins at least 3 times. Follow-up calls will allow for further individualization, motivation, and the reception of participants' concerns or remarks.~Further, participants in the intervention group will have access to a dedicated internet space containing several documents and videos on topics of concern to patients during the post-treatment phase."
224252082|NCT05658341|BEHAVIORAL|Usual Care|"Participants in the control group will be offered weekly APA sessions for 12 weeks, these sessions are based on current practices within the Siel Bleu organization. Sessions' content is adapted to people who have been treated for (all types) cancer and are based on current recommendations.~These sessions are commonly organized by Siel Bleu in hospitals, community groups or local committees of the national league against cancer organization."
224252083|NCT06801418|DRUG|Adagrasib|Specified dose on specified days
224252084|NCT03167515|DEVICE|074-6751 Lotion|Apply lotion once in the morning and once in the evening daily at approximately the same time every day with 12 hours between doses. Apply the lotion only to the active psoriatic lesions, as instructed by your study doctor.
224252085|NCT05824481|DRUG|Cadonilimab|Injectable solution
224252086|NCT05824481|DRUG|Lenvatinib|Capsule
224252087|NCT03574558|DEVICE|MD-Logic Switch Advisor|Study algorithm will be used in order to determine the initial pump setting/ MDI dosing while switching from from MDI to pump therapy or vice versa
224252088|NCT01646554|DRUG|Modified FOLFOX6|
224252089|NCT01646554|BIOLOGICAL|Aflibercept|Targeted therapy
224252090|NCT01646554|PROCEDURE|Surgery|
224252091|NCT00834249|DRUG|Venlafaxine 25 mg Tablets|1 x 25 mg, single-dose fasting
224252092|NCT00834249|DRUG|Effexor® 25 mg Tablets|1 x 25 mg, single-dose fasting
224252093|NCT00854659|DRUG|ABT-102|BID tablets, 7 days of treatment
224252094|NCT00854659|DRUG|Placebo|BID tablets, 7 days of treatment
224252095|NCT01111461|DRUG|Lenvatinib|Lenvatinib 24 mg administered orally, once daily continuously in 28-day cycles to participants with advanced endometrial cancer and disease progression following first-line chemotherapy. Participants continued to receive study drug until disease progression, development of unacceptable toxicity or withdrawal of consent. 'Treatment interruption and subsequent dose reduction' was allowed for participants who experienced lenvatinib-related toxicity.
224252096|NCT02598089|BIOLOGICAL|Trivalent Seasonal Influenza Vaccine|
223670942|NCT06081088|OTHER|Conventional Physiotherapy|Conventional physiotherapy program includes passive, active-assistive (wand exercises) and active ROM exercises for shoulder joint, passive / active posterior and anterior capsule stretching exercises, superior-inferior, mediolateral and distraction techniques for scapular mobilization exercises, shoulder flexion, abduction, internal and external rotation muscles strengthening exercises, static and dynamic stabilization exercises for proprioception exercises. To reduce the pain that may occur after exercises, cold application and Transcutaneous Electrical Nerve Stimulation (TENS) will be applied to benefit from their analgesic effects. Cold application will be applied around the shoulder using a coldpack (gel pack) cold therapy for 15 minutes. Conventional TENS application around shoulder will be performed using a TENS device and four separate 2 × 2 inch self-adhesive electrodes for 15 minutes.This program will be applied for 6 weeks (3 sessions per week).
223670943|NCT06081088|OTHER|Home Exercise Program|The home exercises program includes shoulder jonit active ROM exercises, active posterior and anterior shoulder capsule stretching exercises, shoulder flexion, abduction, internal and external rotation muscles strengthening exercises, shoulder proprioception exercises, and cold therapy. This program will be applied for 6 weeks (3 sessions per week).
223670944|NCT06112964|PROCEDURE|MRI/ Functional MRI|Participants will undergo an MRI scan lasting approximately 1 hour to examine the structure and function of the brain. During the scan, they will also be asked to perform computer based tasks. This is called functional MRI.
223771779|NCT01430585|DRUG|PF-04691502 in combination with Letrozole|PF-04691502 in combination with Letrozole will be administered for 6 weeks. Beyond Week 6, if considered appropriate, patients can be treated for up to 10 additional weeks until breast surgery.
223771780|NCT01430585|DRUG|Letrozole|Letrozole will be administered for 6 weeks. Beyond Week 6, if considered appropriate, patients can be treated for up to 10 additional weeks until breast surgery.
223771781|NCT06027281|OTHER|Hamilton depression rating scale (HDRS)|Hamilton depression scale (HDRS) is the most commonly used instrument for assessing symptoms of depression.
223771782|NCT06027281|OTHER|Hamilton anxiety rating scale (HARS)|Hamilton anxiety rating scale (HARS) is a 14-item clinician-rated measure of the severity of perceived anxiety symptoms.
224252097|NCT02598089|OTHER|Placebo|0.5 mL of phosphate buffered saline
224252098|NCT00834067|DRUG|Moexipril HCl/hydrochlorothiazide 15/25 mg tablets|1 x 15/25 mg
224252099|NCT00834067|DRUG|UNIRETIC® 15/25 mg tablets|1 x 15/25 mg
224252100|NCT02758496|OTHER|MeRT Efficacy Chart Review|There will be not intervention. This is a chart review.
224252101|NCT06560099|DRUG|Oxytocin|will receive 10 IU oxytocin intravenous bolus over one min and infusion of 10 IU oxytocin in 500 ml of 0.9 saline over four hours.
224252102|NCT04354285|OTHER|Observational|Observational
224252103|NCT03663322|PROCEDURE|OMT Protocol|Selected hands-on OMT techniques intended to improve pancreatic function will be administered during the treatment sessions
223670945|NCT06112964|BEHAVIORAL|Self-reported questionnaires|Participants will complete questionnaires covering subjective measures relating to food attitudes and intake, and report-based measures of relevant psychopathology including depression and anxiety. These will be derived from standardised scales already used clinically, including the setting of eating disorders and normative studies of the neuroscience of appetite.
223670946|NCT06112964|BEHAVIORAL|Computer based tasks|"Participants will complete computer based tasks which are focused specifically on aspects of appetite-related and reward behaviours. Typically, such behaviours are characterised under the following sub-headings:~i) Motivation (the amount of effort, cognitive or physical, that a person is prepared to expend in order to gain access to food), ii) Valuation (the relative rating of foods in comparison to each other and to non-food items), and iii) Hedonic response (the subjective pleasure experienced in consumption) to food intake"
223670947|NCT01373827|DEVICE|VASERShape MC1|Use of the VASERShape MC1 device as part of routine practice
223670948|NCT00146159|DRUG|Mitoxantrone|dosage
223670949|NCT00445016|PROCEDURE|peripheral regional anesthesia|evaluation and description of adverse effects
223670950|NCT02723071|DRUG|Ocrelizumab|Participants will receive a total of 8 intravenous (IV) infusions of ocrelizumab given at intervals of 3 weeks, until disease progression or unacceptable toxicity.
223670951|NCT04280770|PROCEDURE|23 PARS PLANA VITRECTOMY|We performed a three-port vitrectomy: one infusion trocar and two instruments trocars. Non-contact wide-angle viewing systems (Resight- Biom) have a viewing field of 60-130° was used. Put 23 needle attached to the automated pump for silicone oil extraction. Strict examination of the retina to detect new breaks or untreated breaks. Closure of the sclerotomies.
223670952|NCT01378546|DRUG|3,4-diaminopyridine|Treatment will begin with 5mg three times a day or less.
223670953|NCT02310087|DIETARY_SUPPLEMENT|astaxanthin with vitamin E|Four tablets of 4 mg astaxanthin with 10 mg vitamin E daily, taken at once. Daily dose is 16 mg astaxanthin with 40 mg vitamin E. Continuously for three months.
223670954|NCT02310087|OTHER|Placebo|Four tablets of placebo daily, taken at once. Continuously for three months.
223670955|NCT03860935|DRUG|acoramidis|TTR stabilizer administered orally twice daily (BID)
223670956|NCT03860935|DRUG|Placebo Oral Tablet|Non-active control administered orally twice daily (BID)
223670957|NCT05675683|DRUG|Capmatinib|Patients receiving Capmatinib
223670958|NCT02667613|OTHER|HABIT-ILE|Hand and arm bimanual intensive therapy including lower extremities
223670959|NCT02667613|OTHER|Control|Usual customary care
223670960|NCT05527938|OTHER|web-based intervention|"1. Establishing management teams.~2. Establishment of a nursing intervention team.~3. Daily uploading of health intervention records~4. Regularly delivering related health knowledge.~5. Home visiting~6. Psychological guidance. The health teachers in the team should closely understand the psychological trends of the patients during the telephone follow-up and home visits and verbally communicate more with the children to stimulate them to develop good living habits and increase their confidence in healing."
223670961|NCT05060809|DRUG|oral vitamin k1 (phylloquinone)|The enrolled patients received 5 mg of oral vitamin K1 (phylloquinone) three times /week for 6 months at the end of HD session to ensure compliance. We measured the serum dephosphorylated- uncarboxylated matrix Gla protein (dp-ucMGP) before and 6 months after vitamin K1 supplementation. In addition, plain lateral abdominal x-ray was conducted prior to and after 6 months of vitamin K supplementation to assess lumbar aorta calcification. The extent of aortic calcification score (AAC) was assessed by a semi-quantitative grading system developed by Kauppila.
224252104|NCT03663322|PROCEDURE|OMT-Sham Protocol|Selected hands-on Sham-OMT techniques that are not intended to affect pancreatic function will be administered during the treatment sessions
223670962|NCT04034797|OTHER|Photography teletransmission|A photography of the trauma is teletransmitted to SAMU's physician
223670963|NCT04034797|OTHER|No photo|Usual management without photography teletransmission
223771783|NCT06027281|OTHER|Mini international neuropsychiatric interview (MINI)|The Mini International Neuropsychiatric Interview (MINI) was designed as a brief structured diagnostic interview for the major psychiatric disorders in DSM-III-R, DSM-IV and DSM-5 and ICD-10.
223771784|NCT06027281|OTHER|Minnesota Multiphasic personality Inventory (MMPI)|The Minnesota Multiphasic Personality Inventory (MMPI) is used to assess personality traits and psychopathology.
224252105|NCT04362566|DRUG|Bupivacaine|Scalp flap: 2.5cc bupivacaine for 0-10cm2, additional 1cc for each additional 10cm2 up to max 5cc, Ear flap or wedge repair: 2.5cc bupivacaine for 0-10cm2, additional 1cc for each additional 10cm2 up to max 5cc Nose flap, 2.5cc bupivacaine for 0-10cm2, additional 1cc for each additional 10cm2 up to max 5cc. Split volume between nose and donor site for melolabial interpolated flap Paramedian forehead flap: 5cc split between forehead donor site and nasal recipient site: 4cc forehead, 1cc nose Cartilage alar-batten graft (ear donor site) 1cc at auricular donor site in addition to bupivacaine used for nasal reconstruction, if any, that qualifies above Cheek Mustarde flap: 2.5cc bupivacaine for 0-10cm2, additional 1cc for each additional 10cm2 up to max 5cc Lip flap, wedge repair, Abbe flap: 2.5cc bupivacaine for 0-10cm2, additional 1cc for each additional 10cm2 up to max 5cc
224322137|NCT01012336|DRUG|Aprepitant/Ramosetron/Dexamethasone|"Aprepitant: The first day, one 125 mg capsule will be administered per oral, 1 hour before chemotherapy. Thereafter one 80 mg capsule will be repeated daily between 8 to 10 a.m. during days 2 to 3.~Ramosetron: 0.3 mg i.v. a single dose on day 1, administered over 30 seconds, 30 minutes prior to chemotherapy.~Dexamethasone: 20mg diluted in 50ml of 0.9% saline i.v. a single dose on day 1, administered over 30minutes prior to chemotherapy (taxane). Because all patients are premedicated with dexamethasone 20 mg before taxane administration, the dose of dexamethasone can not be reduced to 12 mg."
223670964|NCT02891785|BEHAVIORAL|ANtiPain|After the implementation of ANtiPain, patients will receive cancer pain self-management support by trained staff nurses who follow the ANtiPain protocol. ANtiPain is based on 3 key strategies: Provision of information, skill building and nurse coaching. It consists of an in-hospital one-to-one session before discharge and a telephone follow up according to a clinical algorithm based on pain intensity, patient satisfaction with pain management and patient adherence. Patients will be given a booklet with corresponding info. The implementation process will include training of designated staff nurses, coaching activities based on case discussions on the ward, as well as measures to ensure sustainability of the implementation (e.g., training of ward managers and clinical nurse specialists).
223670965|NCT05905614|DRUG|SPH4336 Tablets|Open-label SPH4336 Tablets ：Administered by oral
223670966|NCT05753397|DRUG|Ropivacaine injection|We are testing if single injection Ropivacaine is non-inferior to multiple-injection Ropivacaine when applied within the intertransverse tissue complex (that is: a paraspinal application mimicking the paravertebral block)
223670967|NCT03046277|OTHER|No intervention|No intervention
223670968|NCT04671953|DRUG|BMS-986165|Specified dose on specified days
223670969|NCT04671953|DRUG|Metformin|Specified dose on specified days
223670970|NCT01844167|PROCEDURE|Noxipoint Therapy (NT)|"• For severe chronic neck pain patients, cervical braces are recommended within the first 2-3 days of each treatment session. The patient has to avoid using the treated tissues/muscles during the Rest Period: Similar to all other cells, the muscle cell healing or regeneration takes time. Patients are instructed not to use the newly recovered muscle/tissue during the Rest Period, which is about three days if they are forty or younger, plus about one extra day for every 10 additional years of age. If the patient has extensive injured muscles, take two more days of rest. Ice packs may be used during or soon after the session to prevent Delayed Onset of Muscle Soreness (DOMS) from the TENS stimulation."
223670971|NCT01844167|PROCEDURE|Physical therapy(PT)|•Placebo effect consideration: TENS is included in both arms to obfuscate the process. Using TENS in the PT arm serves both as a sham-therapy-equivalent to what is used in the NT arm to neutralize placebo bias, and as a meaningful therapeutic remedy. The subject is thus blinded. Placebo effect consideration: TENS is included in both arms to obfuscate the process. Using TENS in the PT arm serves both as a sham-therapy-equivalent to what is used in the NT arm to neutralize placebo bias, and as a meaningful therapeutic remedy. The subject is thus blinded.
223670972|NCT00815854|DIETARY_SUPPLEMENT|Folic Acid|5 mg of folic acid taken daily for 3 months in an open label fashion
223670973|NCT00815854|OTHER|Placebo|Subjects may receive placebo (a sugar pill) for 4 months
223670974|NCT03086967|DEVICE|Double-lumen balloon catheter|introduction of catheter into cervix for ripening prior to induction of labor following standard of care practices
223670975|NCT01426932|OTHER|Video recording of Head Impulse Test|Video recording of Head Impulse Test
223670976|NCT05243173|OTHER|Sequencing|Laboratory analysis of samples
223670977|NCT02623231|DRUG|Escitalopram|Group number 1 will include 50 patients, who will receive Escitalopram at a dose of 10 mg for a week exceeding 20 mg immediately after diagnosis for 3 months
223670978|NCT02623231|DRUG|placebo|group # 2 Will include 50 patients , who will receive placebo at a dose of 10 mg for a week exceeding 20 mg immediately after diagnosis for 3 months
223670979|NCT05059288|DEVICE|Investigational Non Invasive Ventilation Mask|Oronasal non invasive ventilation mask
223670980|NCT02744742|DRUG|Decitabine|Decitabine was administered at 20mg/m2/day on days -14 and -10.
224322138|NCT02517008|OTHER|Mama kit|A low-cost non-monetary incentive (mama kit) was provided to all women who delivered at the facility between June 1, 2013 - Aug 31, 2013. Women were told about the intervention during ANC, and safe motherhood groups in the community promoted the intervention in the catchment areas of the treatment facilities.
224322139|NCT05820464|DIAGNOSTIC_TEST|DDA Doppler|A new Doppler parameter to quantify the amount of vasodilatation in the middle cerebral artery (MCA) and other blood vessels.
223670981|NCT02744742|DRUG|Busulfan (BU)|Busulfan was administered at 3.2 mg/kg/day on days -7 to -4.
223670982|NCT02744742|DRUG|Cyclophosphamide (CY)|Cyclophosphamide was administered at 60 mg/kg/day on days -3 to -2.
223670983|NCT02744742|DRUG|Granulocyte Colony-Stimulating Factor(G-CSF)|G-CSF was administered at 5-10 ug/kg/day on days -17 and -10. When white blood cell is more than 20G/L, stop using G-CSF.
223670984|NCT05099029|BIOLOGICAL|EV71 vaccine|EV71 vaccine (\[1 μg total protein + adjuvant 150 μg AI(OH)3\] per dose) Two vaccinations at 28 days apart
224322140|NCT00911300|DRUG|fondaparinux|Comparison of different drugs
223670985|NCT05099029|BIOLOGICAL|Placebo|Placebo (\[ adjuvant 150 μg AI(OH)3\] per dose) Two vaccinations at 28 days apart
223670986|NCT06372743|OTHER|INTEGREAT-CKD Intervention|"The participant is reviewed once in 12 weeks by a CKD-trained APN, during a 30-minute timeslot, an extended duration compared to the timeslot of 10 to 15 minutes that routinely is designated for a recurrent review of a CKD patient in any restructured hospital in Singapore. The review consists of a 15-minute medical review centred on a discussion of the biochemical reports and clinical data relevant to CKD management, and educating on CKD knowledge and lifestyle modification.~Patients self-report the monitored parameters to a community-based nurse through a telehealth AI-based platform. The APN oversees monitoring the community-based parameters and titration of appropriate medications. The APNs have received a Master's in Nursing, with training that is primarily centred on generalist-led care, with additional clinical training in CKD management. They are supported with protocols to detect anomalies in blood pressure trends, glycemia ranges, and abnormalities in fluid status."
223670987|NCT04396184|PROCEDURE|Aminolevulinic acid photodynamic therapy|Aminolevulinic acid photodynamic therapy
223670988|NCT00813176|DEVICE|Double Lumen Endotracheal Tube|
223670989|NCT00813176|DEVICE|Arndt Bronchial Blocker|
223670990|NCT01430754|DRUG|tasimelteon|20 mg tasimelteon capsules, daily
223670991|NCT01430754|DRUG|Placebo|Placebo capsules, daily
223670992|NCT03656471|DEVICE|clear aligners or fixed appliances|Patients choose clear aligners or fixed appliances to treat their malocclusions
223670993|NCT02073266|PROCEDURE|Macular hole surgery using a 25 G pars plana vitrectomy, ILM peeling, fluid-air exchange followed by air-gas exchange with SF6 or C3F8.|
223670994|NCT01389362|DRUG|Chinese herbal medicine (Radix Rehmanniae and Radix Astragali)|2 sachets to be taken daily
223670995|NCT01389362|DRUG|Placebo comparator|2 sachets to be taken daily
223670996|NCT02713256|DRUG|CFZ533|CFZ533 intravenously over approximately one hour
224252106|NCT04362566|OTHER|Placebo Saline|Scalp flap: 2.5cc salinefor 0-10cm2, additional 1cc for each additional 10cm2 up to max 5cc, Ear flap or wedge repair: 2.5cc saline for 0-10cm2, additional 1cc for each additional 10cm2 up to max 5cc Nose flap, 2.5cc saline for 0-10cm2, additional 1cc for each additional 10cm2 up to max 5cc. Split volume between nose and donor site for melolabial interpolated flap Paramedian forehead flap: 5cc split between forehead donor site and nasal recipient site: 4cc forehead, 1cc nose Cartilage alar-batten graft (ear donor site) 1cc at auricular donor site in addition to saline used for nasal reconstruction, if any, that qualifies above Cheek Mustarde flap: 2.5cc saline for 0-10cm2, additional 1cc for each additional 10cm2 up to max 5cc Lip flap, wedge repair, Abbe flap: 2.5cc saline for 0-10cm2, additional 1cc for each additional 10cm2 up to max 5cc
224252107|NCT01343303|DRUG|Placebo|Placebo tablet/capsule every 12 hours for 21 days
224252108|NCT01343303|DRUG|JNJ-39439335|2 x 25 mg tablets once daily for 21 days
224252109|NCT01343303|DRUG|Naproxen|500 mg capsule every 12 hours for 21 days
224252110|NCT01343303|DRUG|JNJ-39439335|2 x 5 mg tablets once daily for 21 days
224252111|NCT05022381|PROCEDURE|Radiofrequency thermal coagulation of articular branches of femoral and obturator nerves|Patients are operated under sedation in the operating room. C-arm fluoroscopy device is used for imaging purposes for radiofrequency thermocoagulation process. In order to prevent vascular injury, the needle is advanced under the guidance of ultrasonography. There are target points determined in fluoroscopy for the femoral nerve and the obturatory nerve. Before the thermocoagulation procedure, local anesthetic and steroid are injected into each of the target points. Patients who do not have any complications after the procedure and who are mobilized are discharged in the 2nd hour.
224252112|NCT05281341|DRUG|Growth Hormone|In GH groups (Group 4A \& 3A), patients will receive additional treatment with GH (Somatropin, 4 IU/day, subcutaneous injection), daily beginning on the initial day of gonadotropin stimulation until triggering the oocyte maturation by hCG. Control groups (Group 4B \& 3B) will receive only standard COS without GH supplementation
224252113|NCT00111397|PROCEDURE|Cytokine therapy|
223670997|NCT04306185|PROCEDURE|OVARIAN FRAGMENTATION|BILATERAL OVARIAN CORTEX FRAGMENTATION USING LAPAROSCOPIC SCISSORS
223670998|NCT03516474|DEVICE|MIMOSA Diagnostics|"The MIMOSA shines different colours of light on your skin. It will not touch your skin, or change how your wound is healing. The MIMOSA is designed to be used alongside the camera that is built into your cell phone, and we will use a cell phone to take a picture of your skin. This picture will tell us how much oxygen is getting to your wound, which can tell us more about how you are healing. The MIMOSA device is an experimental diagnostic tool, and will not influence how your wound is healing."
223670999|NCT02230527|DRUG|Ticagrelor|90mg twice a day by mouth
223671000|NCT02230527|DRUG|Clopidogrel|75mg once a day by mouth
223671001|NCT04576377|BIOLOGICAL|FluBlok|Recombinant HA quadrivalent influenza vaccine (0.5mL Flublok®, Sanofi Pasteur) containing 180μg antigen, 45μg for each influenza strain included.
223671002|NCT04576377|OTHER|Placebo|0.5mL saline placebo.
223671003|NCT01685645|DEVICE|AlgiScan|The AlgiScan device will be used to monitor analgesia during surgery. The integrated nociceptive stimulator will be used on both legs.
223671004|NCT01010139|DRUG|Codeine Sulfate|15 mg, 30 mg and 60 mg Tablet
223671005|NCT00014755|DRUG|anti-thymocyte globulin|
224252114|NCT00111397|DRUG|Interferon Gamma, GM-CSF|
224252115|NCT01163461|BEHAVIORAL|speech therapy|individuals will receive 60 hours of behavioral speech therapy
224252116|NCT05215483|BEHAVIORAL|Customised testing advice|Customised advice: With Corona related symptoms, get tested at a test facility. If this isn't possible, use a Lateral Flow test.
224252117|NCT05215483|BEHAVIORAL|Regular testing advice|"Government guideline testing advice: With Corona related symptoms, get tested at a test facility."
224252118|NCT05215483|BEHAVIORAL|LFT available|LFT availability: Enough lateral flow tests available at home
224252119|NCT05215483|BEHAVIORAL|No LFT available|LFT availability: No lateral flow tests available at home
224252120|NCT00034905|DRUG|quetiapine fumarate vs risperidone|
224322141|NCT00911300|DRUG|unfractionated heparin|Comparison of different drugs
223671006|NCT00014755|DRUG|cyclophosphamide|
223671007|NCT00014755|DRUG|filgrastim|
223671008|NCT00014755|DRUG|prednisone|
223671009|NCT00014755|PROCEDURE|peripheral blood stem cell transplantation|
223671010|NCT00014755|PROCEDURE|irradiation|
223671011|NCT04834960|OTHER|Minimizing Missed Opportunities for Vaccination (MOV)|This bundle of interventions has four components that include: (1) Disseminate (vaccination awareness among healthcare providers and child caregivers); (2) Document (vaccination status); (3) Deploy (vaccines); and (4) Discharge (provide advice/referrals for catch-up and routine vaccinations).
223671012|NCT05150444|OTHER|Cognitive and physical exercise training|"12 weeks (3 times a week): patients will cycle on an adapted ergometer during their dialysis procedure. The exercise program will be run by kinesiologists. Participants will start with 15 minutes of cycling and then gradually increase the time and intensity. After the physical exercise session, they will continue with cognitive training. This training will be done on a tablet computer on a CogniFit platform (\~30 minutes). The brain games on mentioned platform automatically adapt to individual cognitive abilities."
223671013|NCT01931176|BIOLOGICAL|rDEN2Δ30-7169 vaccine|Administered at a dose of 10\^3 plaque-forming units (PFU); delivered by subcutaneous injection in the deltoid region of the upper arm
223671014|NCT01931176|BIOLOGICAL|Placebo|Delivered by subcutaneous injection in the deltoid region of the upper arm
224252121|NCT03253003|DEVICE|Line extension of the Phonak Audéo B product family|The line extension of Phonak Audéo B product family will be fitted to the participants individual hearing loss.
224252122|NCT05671965|DIETARY_SUPPLEMENT|Xylitol|33.5g xylitol dissolved in 300mL tap water.
224252123|NCT05671965|DIETARY_SUPPLEMENT|Sucrose|33.5g sucrose dissolved in 300mL tap water.
224322142|NCT00911300|DRUG|Vitamin-K-Antagonist|Comparison of different drugs
224322143|NCT05532189|PROCEDURE|ACL reconstruction with BTB autograft with internal brace augmentation (suture tape)|The ACL will be reconstructed using a participant's own patella tendon (BTB autograft), and the graft will be fortified by suture tape during the surgery in order to strengthen it.
223671015|NCT04643301|DRUG|Liraglutide Pen Injector|Daily subcutaneous injection of 3.0mg liraglutide (GLP-1 antagonist) for low-responders 3 months after bariatric surgery.
223671016|NCT02426489|DEVICE|MRI + PEM image|Effect of positron emission mammography on diagnostic accuracy
223671017|NCT04461600|DRUG|AL101|AL101 is an inhibitor of gamma secretase-mediated Notch signaling.
223671018|NCT01020006|DRUG|PCI-27483|"Part A: Closed to enrollment.Part B: Approximately 20 patients will be randomized to the control arm that will receive a standard regimen of gemcitabine and 20 patients will be randomized to the PCI-27483 arm and treated with both gemcitabine and PCI-27483. PCI-27483 will be administered as subcutaneous (SC) injections, nominally at a dosage of 1.2 mg/kg BID. Patients receiving PCI-27483 with a tumor response or stable disease at 12 weeks will have the option to continue PCI-27483 treatment until disease progression or the investigator considers the study treatment no longer tolerable. Treatment with gemcitabine may continue per standard of care.~All evaluable patients will roll over into Part C at week 16 (Day 113±5). If 2 consecutive INRs at 2 hours postdose are \>3.50,a reduced dosage will be calculated."
223671019|NCT01020006|DRUG|Gemcitabine|
223671020|NCT01271582|DRUG|Irinotecan, 5FU, leucovorin|FOLFIRI regimen every 2 weeks \[irinotecan 150mg/m2 or 180mg/m2, leucovorin 20(200)mg/m2, 5FU 400 mg/m2 (bolus) or 2400 mg/m2 (46hour infusion)\]
223671021|NCT01698138|DRUG|Onabotulinumtoxin A|"30 transurethral injections, each of 1 ml solution containing 300 U Onabotulinumtoxin A (Botox ®, Allergan) in 30 ml of NaCl 0.9 %."
223671022|NCT01698138|DRUG|Placebo|30 transurethral injections, each of 1 ml solution containing NaCl.
223671023|NCT05605145|DIAGNOSTIC_TEST|PCR was used to detect pneumocystis in respiratory specimens|Respiratory tract specimens such as alveolar lavage fluid, sputum and throat swabs were collected from all patients who met the enrollment conditions of this study. qPCR and/or mNGS were used to detect pneumocystis in respiratory specimens.
223671024|NCT05767476|DIAGNOSTIC_TEST|Clinical and instrumental neurological assessment|"Participants will be involved in serial assessment:~* Neonatal Cranial Ultrasonography~* Brain magnetic resonance imaging~* Neurological assessment~* Neurodevelopmental and cognitive assessment~* Electroencephalogram (EEG)~* Motor performance assessment"
223671025|NCT01733212|DRUG|Ginger|Ginger is an herb. The rhizome (underground stem) is used as a spice and also as a medicine. It can be used fresh, dried and powdered, or as a juice or oil. Two capsules (1g each) of dry powdered ginger are given, one capsule a half-hour before induction of anesthesia and the second 2h after surgery.
223771785|NCT06027281|OTHER|The Symptom Check-List-90-R (SCL-90-R)|The Symptom Check-List-90-R (SCL-90-R) is a widely used psychological status symptom inventory.
223771786|NCT06027281|OTHER|Socioeconomic scale (A.El Gilany, A.El Wehady and M.El Wasify)|An Arabic version of the socioeconomic scale consisted of four dimensions, namely, level of education, employment, total family monthly income, and lifestyle of the family.
223771787|NCT06027281|OTHER|The female sexual function index (FSFI)|The female sexual function index is a brief multidimensional scale for assessing sexual function in women.
223771788|NCT04163744|DEVICE|Double balloon catheter|Induction of labour with double balloon catheter
223771789|NCT03623737|DRUG|neoadjuvant chemoradiation|"Neoadjuvant chemoradiation:~1. Radiation: 180cGy/fraction, once daily, 5 days a week, to a total of 4,500cGy.~2. Chemotherapy: Arm A or Arm B Surgery: esophagectomy and 3-fields lymph node dissection"
223771790|NCT00951054|DRUG|NK012|30 minute IV infusion once every 28 days. NK012 dose is 28 mg/m\^2 (or 18 mg/m\^2 depending on UGT1A1 polymorphism, with potential to dose escalate). Dose escalation cannot exceed 28 mg/m\^2. Dosing will proceed until progression or unacceptable toxicity develops, or decision by patient or investigator to stop.
224252124|NCT05671965|DIETARY_SUPPLEMENT|Acesulfame Potassium|0.1675g Ace-K dissolved in 300mL tap water.
224252125|NCT05671965|DIETARY_SUPPLEMENT|Water|300mL tap water.
224252126|NCT04738539|DRUG|Contrast Enhanced Voiding Urosonography with Urodynamic Testing|We will be using contrast enhanced voiding urosonography to image urodynamic testing on patients with neurogenic bladder.
224252127|NCT04738539|DIAGNOSTIC_TEST|Urodynamic Testing|We will be using contrast enhanced voiding urosonography to image urodynamic testing on patients with neurogenic bladder.
224252128|NCT03047343|OTHER|Retrospective data extraction in medical files|Retrospective data extraction in medical files
224252129|NCT05044364|DRUG|This is a randomized, single-blind, parallel-controlled clinical study with the original research clevidipine butyrate injection as the positive control drug, which is an equivalence test.|Patients with hypertensive emergency and hypertensive sub-emergency who are clinically diagnosed as unsuitable for oral antihypertensive treatment or oral antihypertensive treatment are ineffective, and require intravenous medication to quickly control their blood pressure. The qualified subjects will be randomly divided into groups according to the test protocol. The method of administration is to infuse clevidipine butyrate injection for emergency blood pressure reduction treatment to achieve rapid, effective and stable lowering of blood pressure to the target blood pressure, and prevent or reduce further damage to the target organ.
224252130|NCT01015703|BIOLOGICAL|CoVaccine HT|intramuscular injection, dose escalation
224252131|NCT01888523|BEHAVIORAL|Expressive writing|log in to an online survey and writing in the survey about your thoughts and feelings about your cancer. This requires 20-30 minutes of writing a day for 4 consecutive days. You will also provide saliva samples.
224252132|NCT01888523|BEHAVIORAL|Everyday experiences writing|log in to an online survey and writing in the survey about your thoughts and feelings about your everyday experiences. This requires 20-30 minutes of writing a day for 4 consecutive days. You will also provide saliva samples.
224322144|NCT05532189|PROCEDURE|ACL reconstruction with BTB autograft without internal brace augmentation (suture tape)|The ACL will be reconstructed using a participant's own patella tendon (BTB autograft). The graft will not be fortified by suture tape in this group. It will be used as is without any modification.
223671026|NCT01733212|DRUG|Placebo Oral Tablet|Two capsules (1g each) of placebo, one capsule a half-hour before induction of anesthesia and the second 2h after surgery.
223671027|NCT00760799|PROCEDURE|Discectomy with anular repair|Comparison of discectomy with and without repair to the anulus fibrosus of the intervertebral disc
223671028|NCT00228176|DRUG|Rimonabant|Tablet, oral administration
223671029|NCT00228176|DRUG|Placebo (for Rimonabant)|Tablet, oral administration
223771791|NCT04122833|OTHER|Next generation sequencing|observational study
223671030|NCT04098055|DEVICE|Custom-Made Foot Orthoses|The foot orthoses were custom made using phenolic foam molds of the feet. They consisted of a polypropylene layer of 2 mm from heel to just proximal to the metatarsal heads, an upper sheet of 30 Shore A polyethylene foam.
223671031|NCT04098055|DEVICE|Placebo|The insole made using phenolic foam molds of the feet. They consisted of an upper sheet of 30 Shore A polyethylene foam.
223671032|NCT04504851|DRUG|Rosuvastatin 10mg|10mg of Rosuvastatin in the Intensive Phase of Therapy (8 weeks)
223671033|NCT04504851|DRUG|Rifampicin|Rifampicin 10mg/kg
223671034|NCT04504851|DRUG|Isoniazid|Isoniazid 5mg/kg
223671035|NCT04504851|DRUG|Pyrazinamide|Pyrazinamide 25mg/kg
223671036|NCT04504851|DRUG|Ethambutol|Ethambutol 15mg/kg
223671037|NCT05955573|DIAGNOSTIC_TEST|xray|radiological description
223671038|NCT03851172|DRUG|Ketorolac Ophthalmic|Preoperative administration of Ketorolac 0.5% eye drops
223671039|NCT03851172|DRUG|Nepafenac Ophthalmic|Preoperative administration of Nepafenac 1 mg eye drops
223671040|NCT03851172|DRUG|Cyclopentolate Ophthalmic|Preoperative administration of Cyclopentolate eye drops
223671041|NCT05307367|BEHAVIORAL|Exercise training|Patients will be enrolled in a 8 week, supervised, single-leg kicking training intervention (1h, or as long as possible, 60-70% peak workload (PWL), 2-5 days a week). Healthy age-, body weight-, gender- and activity level-matched control subjects will undertake the intervention matched to the %PWL obtained by the patients who complete the study.
223671042|NCT06411171|DRUG|Pembrolizumab plus chemotherapy (FLOT)|The experimental group was treated with pembrolizumab combined with FLOT, and the control group was treated with FLOT chemotherapy alone
223671043|NCT03443557|OTHER|oral nutrition supplement|receiving prescription of oral nutrition supplement during hospitalization
223671044|NCT04994470|BEHAVIORAL|Two-week web-based self-help intervention based on principles of positive psychology|"The web-based self-help intervention consists of 14 exercises based on the following positive psychology domains: personal strengths, pleasure, gratitude, engagement (flow, mindfulness) and positive relationships.~The (partly interactive) exercises are created to be implemented by the participants themselves without support of a therapist.~Before starting the intervention, the participants are told that they will receive a daily email with an instruction for a short exercise over the period of two weeks. The participants are instructed to complete the exercises every day and are told that they will be asked to evaluate these exercises at the next appointment (post-test, week 2)."
223671045|NCT04994470|BEHAVIORAL|Two-week web-based text messages containing fun facts|"The web-based sham comparator consists of 14 text messages containing random interesting facts (fun facts).~Before starting the sham comparator, the participants are told that they will receive a daily email with a text message to read every over the period of two weeks. The participants are instructed to read these text messages every day and are told that they will be asked to evaluate these exercises at the next appointment (post-test, week 2)."
223671046|NCT05266573|OTHER|Exercise Group|The exercise program is led by an individual who has a background in exercise physiology and is trained by the Physical Therapist. The task oriented exercise program consists of 45 to 60 minutes of group exercise sessions with the following components: warm-up period (dual task activity and walking progressively), stretching/strengthening/balance (gradual progression of activities and repetitions for 30 minutes), and obstacle course (6 to 15 minutes of obstacle course and challenged walking).
224252133|NCT05859425|DEVICE|Real-time rehabilitative ultrasound imaging (RUSI)|Τhe ultrasound equipment used was B-K Μedical Mini Focus 1402 equipped with high frequency linear probe (8670, 5-12MHz) using standard musculoskeletal settings and the software: V 1.01.01.137. Ultrasound gel (AQUASONIC® 100, Parker Inc., Orange, NJ) was used as coupling agent. TrA imaging was initially performed with participants in crook lying, with the US head positioned along the lateral abdominal wall with reference points at the lower point of the rib cage (last rib) and the anterior superior iliac spine, on the right side of the person, midway between these two points. The US head was moved until tester (investigator) had the best possible visualization of the lateral abdominal muscles (external oblique, internal oblique and TrA). During the execution of the exercises, the participants could watch the ultrasound screen along with the therapist's guidance, thus receiving information (US-visual feedback) of their TrA activation
224252134|NCT05859425|OTHER|Tactile feedback (control intervention)|Palpatory-guided (manual) feedback for TrA activation
224252135|NCT01191996|BIOLOGICAL|MIS416|MIS416 intravenously every week
224322145|NCT05532189|OTHER|Standardized Rehabilitation Protocol|Participants will undergo a standardized rehabilitation protocol with twice weekly physical therapy
223671047|NCT04842032|DRUG|KRN23|KRN23 is a sterile clear colourless and preservative free solution supplied in single use 5 mL vials containing 1 mL of KRN23 at a concentration of 30mg/mL
223671048|NCT05507788|DEVICE|Wheelchair air cushion|Reaching tasks during each of the seating conditions decribed in the Arms section.
223671049|NCT05503901|DRUG|STN1012600 ophthalmic solution 0.002%|1 drop STN1012600 ophthalmic solution 0.002% once daily for 52 weeks
223671050|NCT05503901|DRUG|STN1012600 ophthalmic solution 0.002%|1 drop STN1012600 ophthalmic solution 0.002% once daily for 52 weeks
223671051|NCT05503901|DRUG|STN1012600 ophthalmic solution 0.002% and Timolol ophthalmic solution 0.5%|1 drop STN1012600 ophthalmic solution 0.002% once daily for 52 weeks and 1 drop Timolol ophthalmic solution 0.5% twice daily for 52 weeks
223671052|NCT03999775|DIETARY_SUPPLEMENT|Calcium, vitamin D and bioactive collagen peptides supplement|
223671053|NCT03999775|DIETARY_SUPPLEMENT|Calcium and vitamin D supplement|
223671054|NCT06102018|DIAGNOSTIC_TEST|Collect blood and urine，pathological specimens if necessary|Use EDTA anticoagulant pipe to collect all blood 2ml, and collect 3ml of urine with sterile test tube
223671055|NCT04841473|OTHER|TRAIN Concussion Education|Participants will receive the TRAIN concussion education module.
223671056|NCT04841473|OTHER|Standard Concussion Education|Participants will receive a standard concussion education module.
223671057|NCT00775203|DRUG|Trazodone Hydrochloride (HCl) Extended-Release Tablets|
223671058|NCT00775203|DRUG|Placebo|
224322146|NCT00180999|DRUG|Erythropoiétine|
224322147|NCT01055756|DRUG|Loratadine + Pseudoephedrine sulfate|Loratadine (5 mg) + Pseudoephedrine sulfate (120 mg)
224322148|NCT06531837|DRUG|Esketamine(Continuous infusion)|Continuous intravenous infusion of esketamine at a dose of 0.2 mg/(kg · h). Collect resting-state EEG data and NRS scores 40 minutes after administration.
224252136|NCT03122535|DEVICE|FS-LASIK 70 degree side-cut angle|FS-LASIK surgical procedures will be performed according to the surgeons' standard practices. Patient will be masked as to the treatment they receive in either eye so as not to influence their subjective responses and visual measurements. Patients will be discontinued from the study if, on the day of surgery, both eyes cannot be randomized and operated as per protocol.
223671059|NCT00704522|BIOLOGICAL|Peginterferon alfa-2b (SCH 54031)|Peginterferon alfa-2b and ribavirin will be administered according to the products' labeling.
223671060|NCT00704522|DRUG|Ribavirin (SCH 18908)|Peginterferon alfa-2b and ribavirin will be administered according to the products' labeling.
223671061|NCT00704522|BEHAVIORAL|Patient assistance program|"Assistance programs will be classified as follows:~1. Medications used prophylactically or for treatment(Growth factors: RBC and neutrophil; Psychiatric medications; Other medications)~2. Other interventions (Psychotherapy, Patient Support Groups, Visiting Nurse, Nurse Telephone Calls, Nurse support in office, Other health care professional support, Educational Literature).~In Austria, sites with adherence nurses and side effect handouts will be compared with sites using side effect handouts only."
223671062|NCT00223782|BEHAVIORAL|Gait Training with Feedback|
223671063|NCT00223782|BEHAVIORAL|Gait Training with no feedback|
223671064|NCT04664894|DRUG|Sofosbuvir|the occurrence of AEs (AE) and their severity among chronic HCV patients has assessed in patinets receiving different combinations of DAAs in Pakistani Population
224252137|NCT03122535|DEVICE|FS-LASIK 110 degree side-cut angle|FS-LASIK surgical procedures will be performed according to the surgeons' standard practices. Patient will be masked as to the treatment they receive in either eye so as not to influence their subjective responses and visual measurements. Patients will be discontinued from the study if, on the day of surgery, both eyes cannot be randomized and operated as per protocol.
223671065|NCT05792657|BEHAVIORAL|High dosage in-person exercise coaching|High dosage (one hour each week) of in-person exercise coaching by an exercise professional.
223671066|NCT05792657|BEHAVIORAL|Medium dosage in-person exercise coaching.|Medium dosage (one hour every other week) of in-person exercise coaching by an exercise professional.
223671067|NCT05792657|BEHAVIORAL|Low dosage in-person exercise coaching|Low dosage (one hour every month) of in-person exercise coaching by an exercise professional
223671068|NCT04191083|BEHAVIORAL|Motor imagery|This group will perform motor imagery training on motor learning of different motor tasks
223671069|NCT04191083|BEHAVIORAL|Double time motor imagery|This group will perform motor imagery training by doubling the intervention time to the motor imagery group on motor learning of various motor tasks.
223671070|NCT04191083|BEHAVIORAL|Action observation|This group will perform action observation training on motor learning of various motor tasks.
223671071|NCT04191083|BEHAVIORAL|Placebo intervention|This group will watch a video of a landscape without the presence of people.
223671072|NCT02454361|DRUG|KBP-7072|KBP-7072
223671073|NCT02454361|DRUG|Placebo|Placebo
223671074|NCT04416360|OTHER|Interview by psychologists|"Interviews for children / teenagers and parents :~* The questions encourage a narrative~* Repeated interviews: during confinement, at the end of confinement, and 3 months after the end of confinement~* Interviews carried out by videoconference, by trained psychologists not involved in the care process~Interview for referring caregivers: a single interview of approximately 45 minutes, 3 months post-confinement"
223671075|NCT00701662|BIOLOGICAL|Vivaglobin|
223671076|NCT01414348|BEHAVIORAL|Conventional rehabilitation.|1 hour / 2x / week for up to 15 sessions
223671077|NCT01414348|BEHAVIORAL|Novel rehabilitation approach|1 hr, 2x/week for up to 15 sessions
223671078|NCT02512484|PROCEDURE|venepuncture, sputum collection, xray|venepuncture, sputum collection, xray
223671079|NCT00508781|BEHAVIORAL|Multiphoton laser image in cutaneous pathology|
223671080|NCT00692536|BEHAVIORAL|NNR (Nordic Nutrition Recommendations)|Diet with equal amounts of fat, protein and carbohydrates
223671081|NCT00692536|BEHAVIORAL|MPD (Modified paleolithic diet)|A diet high in protein and fat, but low in carbohydrates
223671082|NCT00635024|BIOLOGICAL|anti-thymocyte globulin|2.5 mg/kg
223671083|NCT00635024|DRUG|melphalan|16 mg/m\^2
224252138|NCT02718326|DRUG|Intravitreal aflibercept injection [IAI]|
223671084|NCT05346822|PROCEDURE|integrated rehabilitation (the collaborative patient education)|Pre-operative education and rehabilitation. During hospitalization: group rehabilitation education program. Discharge: post-operative care navigation for total knee arthroplasty
223671085|NCT00547001|DRUG|Estradiol|1mg during stabilization \& then a taper to 0.75mg, 0.5mg, 0.25mg, 0.125mg.
223671086|NCT02192424|DRUG|Metformin alone|
223671087|NCT02192424|DRUG|Metformin + Intermittent Insulin Therapy|
223671088|NCT05402371|DRUG|Rencofilstat|Rencofilstat soft gel capsule
223671089|NCT05402371|DRUG|Placebo|placebo soft gel capsule
223671090|NCT03371888|BIOLOGICAL|Platelet-Rich Plasma intramuscular injections|A platelet-rich plasma intramuscular injections into the trigger points of painful muscles were performed.
223671091|NCT03371888|BIOLOGICAL|Placebo Comparator: 0,9% NaCl intramuscular injections|A 0,9% NaCl intramuscular injections into the trigger points of painful muscles were performed.
223671092|NCT05339776|BEHAVIORAL|Hand Lateralization Test|Before hand lateralization test, participants will be evaluated. Both groups (Amputees and Control) will complete hand lateralization test for at least 10 days. The test will be sent each day on an online system. Participants' performances will be recorded via online system. After hand lateralization test, participants will be evaluated.
223671093|NCT04717206|OTHER|Plyomtric training to male badmninton players|"Plyometric training has been proven to be effective and effecient in developing strength and speed.~plyometric training includes different types hops,jumping,drills."
223671094|NCT04717206|OTHER|Plyomtric training to female badmninton players|"Plyometric training has been proven to be effective and effecient in developing strength and speed.~plyometric training includes different types hops,jumping,drills."
223771792|NCT03552887|PROCEDURE|Cardiac Surgery|Any type of cardiac surgery
224252139|NCT02718326|DRUG|Sham|
224252140|NCT04559386|OTHER|Survey|Questionnaire
224252141|NCT02896010|OTHER|Sweetch App + DBWS|Usual care for prediabetes management, Sweetch app, weight monitoring via digital body weight scale (DBWS).
224252142|NCT02896010|OTHER|Sweetch App Alone|Usual care for prediabetes management, Sweetch app alone.
224252143|NCT03227835|OTHER|intravascular iodinated contrast material administration|Evaluation of the consequences of the protocol change to not giving prophylaxis to patients with an eGFR \>29mL/min/1.73m2
224252144|NCT01649011|BEHAVIORAL|Application of the initial evaluation|Initial evaluation involves the application of the previously spanish validated Rolland Morris Questionnaire and the new spanish Oswestry Disability Index
224252145|NCT01649011|BEHAVIORAL|Final application of scales|Application of the previously spanish validated version of the RMQ and the new spanish translation of the ODI 2 weeks after initial evaluation
224252146|NCT05025345|DEVICE|Tecnis Eyhance|Investigational intraocular lens replaces the natural lens removed during cataract surgery in both eyes.
224252147|NCT05025345|DEVICE|Tecnis 1 piece IOL|Control intraocular lens replaces the natural lens removed during cataract surgery in both eyes.
224252148|NCT06238791|OTHER|Presence of foot deformity, ankle range of motion, foot posture, local tissue water percentage, and foot pressure distribution will be evaluated in patients with chronic venous disease.|Presence of foot deformity, ankle range of motion, foot posture, local tissue water percentage, and foot pressure distribution will be evaluated in patients with chronic venous disease and lipedema.
224252149|NCT03040362|DRUG|[14C]-lasmiditan|\[14C\]-lasmiditan as a 200 mg (approximately 100 µCi) oral solution
224252150|NCT04383574|BIOLOGICAL|Two doses of medium dosage inactivated SARS-CoV-2 vaccine at the schedule of day 0,28|The inactivated SARS-CoV-2 vaccine was manufactured by Sinovac Research \& Development Co., Ltd..Two doses of medium dosage (600SU/0.5ml) experimental vaccine at the schedule of day 0,28,and one dose of booster immunization(the third dose) with medium dosage (600SU/0.5ml) experimental vaccine 1 year after primary immunization at the schedule of day 0,28 in phaseⅠand 6 months after primary immunization at the schedule of day 0,28 in phase Ⅱ.And the second booster dose (the fourth dose) 1 year after the second dose.
224252151|NCT04383574|BIOLOGICAL|Two doses of high dosage inactivated SARS-CoV-2 vaccine at the schedule of day 0,28|The inactivated SARS-CoV-2 vaccine was manufactured by Sinovac Research \& Development Co., Ltd..Two doses of high dosage (1200SU/0.5ml) experimental vaccine at the schedule of day 0,28,and one dose of booster immunization(the third dose) with medium dosage (1200SU/0.5ml) experimental vaccine 1 year after primary immunization at the schedule of day 0,28 in phaseⅠand 6 months after primary immunization at the schedule of day 0,28 in phase Ⅱ.And the second booster dose (the fourth dose) 1 year after the second dose.
223671095|NCT01105065|DRUG|brimonidine 0.15%|One drop in each eye three times a day for 8 weeks.
223671096|NCT02935426|DEVICE|n-butyl cyanoacrylate and 2-octyl cyanoacrylate|used in cyanoacrylate group
223671097|NCT02935426|DEVICE|5-0 Polytetrafluoroethylene (PTFE) suture|used in suture group
223671098|NCT05714319|OTHER|Data collection|"Variables collected will include:~* demographics (sex, age)~* comorbidities (type 2 diabetes mellitus, familiar history of CAD, smoke habit, dyslipidaemia, hypertension, history of CAD)~* echocardiographic (left ventricle ejection fraction at admission, the presence and grade of diastolic dysfunction, and the presence and grade of any valvulopathies)~* angiographic data (presence of non-obstructive CAD (any coronary lesion \<50% diameter stenosis), the presence of myocardial bridge and, if this latter is present, its localization and length)~* laboratory measurements (hematologic variables (haemoglobin and white blood cells), creatinine, high sensitivity cardiac troponin I (hs-cTnI), and C-reactive protein (CRP) at the time of admission)~* medical therapy at admission~* response to intracoronary provocative test with ACh."
223671099|NCT05714319|OTHER|Clinical follow-up|All patients will undergo a clinical follow-up by telephonic interview and/or clinical visit at 6, 12, 24, 36, 48 and 60 months from hospital discharge, during which the incidence of MACCE in the past months will be investigated and collected.
223671100|NCT04925856|OTHER|blood sample|"•Blood sample:~* 1 heparinized tube (4 mL) for collection of plasma and storage~* 1 heparinized tube (4 mL) for immunophenotyping,~* 4 EDTA tubes (4 x 10 mL) for collecting white blood cells (PBMC) for cryopreservation."
223671101|NCT00303589|DRUG|Standard care|As prescribed
223671102|NCT00303589|DRUG|beta-lactam|750mg iv q8h
223671103|NCT00303589|DRUG|beta-lactam|1500mg iv q8h
223671104|NCT05423860|OTHER|no interventions will be performed (observational)|Not applicable. (no interventions will be performed with this observational study
223671105|NCT04113590|PROCEDURE|Laparoscopic Assisted Transvaginal Cholecystectomy|Perform transvaginal cholecystectomy while obtaining safe access under laparoscopic visualization
223671106|NCT04316702|DEVICE|Hyperbaric oxygen therapy (HBOT) treatment|60 daily hyperbaric oxygen treatment sessions will be administrated 5 days per week. Each session will include exposure of 90 minutes to 100% at 2 ATA, with 5 minutes air breaks every 20 minutes
223671107|NCT04316702|DRUG|Cymbalta / Lyrica - Drug treatment|one of the two medications currently licensed for the treatment of FMS in Israel, i.e. Cymbalta and Lyrica. Two medications currently licensed for the treatment of FM in Israel, i.e. Cymbalta and Lyrica. Treatment with Lyrica will start at a dose of 75 mg twice a day, at morning and at bedtime, while treatment with Cymbalta will start at a dose of 30 mg a day (in the morning).
223671108|NCT00228215|BEHAVIORAL|TIPS Intervention|A behavioral-educational sleep intervention and support from a nurse in the immediate postpartum
223671109|NCT05967039|OTHER|Physiotherapy|Physiotherapy in respiratory rehabilitation
223671110|NCT03160547|OTHER|Usual Protein/Amino Acid Group|Protein targets will be set using pre-ICU dry actual weight. For patients with BMI \>30, ideal body weight based on a BMI of 25 will be used. We will endorse the guidelines for energy targets set forth by ASPEN/SCCM, especially as it pertains to the obese patient.
223671111|NCT03160547|OTHER|Higher Protein/Amino Acid Group|Protein targets will be set using pre-ICU dry actual weight. For patients with BMI \>30, ideal body weight based on a BMI of 25 will be used. We will endorse the guidelines for energy targets set forth by ASPEN/SCCM, especially as it pertains to the obese patient.
223671112|NCT04837326|OTHER|Heel Lance Blood Sampling in Facilitated Tucking Position|
223671113|NCT04837326|OTHER|Heel Lance Blood Sampling When the Infant is Embraced by the Mother|
223671114|NCT04837326|OTHER|Heel Lance Blood Sampling Using White Noise|
224322149|NCT06531837|DRUG|Remifentanil (Target-Controlled Infusion)|The plasma drug concentrations of remifentanil were set at 0.5 ng/ml, 1 ng/ml, and 1.5 ng/ml. After each plasma drug concentration reached a steady state, the NRS scores were assessed, and resting-state EEG was recorded for at least 5 minutes.
223671115|NCT02122913|DRUG|Larotrectinib (Vitrakvi, BAY2757556)|BAY2757556 will be administered orally as capsule or in liquid form over continuous 28-day cycles.
223671116|NCT00062816|DRUG|ISIS 14803, peginterferon alfa, ribavirin|
223671117|NCT05229861|BEHAVIORAL|HIIT|Exercise intensity will be regulated and heart rate controlled based on the achieved maximum heart rate (HRmax) assessed during the initial Cardiopulmonary Exercise Testing. Participants will perform five high-intensity intervals (95% HRpeak) at high pedalling rates of 80-100 rpm for 90 seconds each. Intervals are interspersed by active breaks of unloaded pedalling (20W, 60-70rpm) aimed to return to 60% HRpeak (approximately 1-1.5 min). The duration of a HIIT sessions is approximately 25 minutes.
223671118|NCT05229861|BEHAVIORAL|MCT|Exercise intensity will be regulated and heart rate controlled based on the achieved maximum heart rate (HRmax) assessed during the initial Cardiopulmonary Exercise Testing. Participants perform continuous bicycle ergometry at moderate intensity (60% HRpeak) and 60-70 rpm for the duration of 30 minutes.
223671119|NCT05699473|DIETARY_SUPPLEMENT|5-MTHF glucosamine salt|Active form of folate defined as (6S) 5-methyltetrahydrofolate (5-MTHF) glucosamine salt
223671120|NCT05699473|DIETARY_SUPPLEMENT|5-MTHF calcium salt 1|Active form of folate defined as (6S) 5-methyltetrahydrofolate (5-MTHF) calcium salt, crystal form 1
223671121|NCT05699473|DIETARY_SUPPLEMENT|5-MTHF calcium salt 2|Active form of folate defined as (6S) 5-methyltetrahydrofolate (5-MTHF) calcium salt, crystal form 2
223671122|NCT02984943|DEVICE|Hyperbaric Oxygen|30 treatments of Hyperbaric Oxygen.
223671123|NCT04575792|BEHAVIORAL|Practicing oral habits|children who practice one or more of the specified oral habits ( mouth breathing, object sucking, or tongue thrusting) are considered exposed.
223671124|NCT05608928|DIETARY_SUPPLEMENT|VSL#3|VSL#3 is a commercial probiotic mixture consisting of eight probiotic lactic acid bacteria and Bifidobacteria including Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus casei, Lactobacillus delbrueckii subspecies bulgaricus, Streptococcus salivarius subspecies thermophiles, Bifidobacterium breve, Bifidobacterium longum, and Bifidobacterium infantis. VSL#3 contributes to balancing the gut and vaginal microbiota and is used as a food supplement for management of diseases like irritable bowel syndrome, ulcerative colitis or ileal pouch.
223671125|NCT05608928|DEVICE|Capscan device|"The CapScan device is a short-term single-use class IIa ingestible medical device that collects fluids from the gastrointestinal (GI) tract and is collected in the stool. GI samples are then extracted from the device and analyzed outside the body."
223671126|NCT05608928|COMBINATION_PRODUCT|Placebo|microcrystalline cellulose
223671127|NCT05191056|DIETARY_SUPPLEMENT|Placebo drink|consume 1 bottle per day for 8 weeks
223671128|NCT05191056|DIETARY_SUPPLEMENT|MelaGene drink|consume 1 bottle per day for 8 weeks
223671129|NCT04329689|OTHER|The Septal myectom|"The Septal myectomy is the preferred treatment of most patients with HOCM, and many studies have documented relief of symptoms and satisfactory late patient survival after relief of outflow tract gradients.~valve repair or replacement may be necessary"
223671130|NCT04135105|OTHER|Normal hearing group|Observational
223671131|NCT03229174|DRUG|Droxidopa|Droxidopa initial dose 100mg TID, titrated in increments of 100mg every 24-48 hours to symptomatic response.
223671132|NCT03229174|DRUG|Placebo|Placebo (sugar pill)
223671133|NCT02025153|OTHER|pain testing|physical testing, psychological testing, genetics testing and functional brain imaging
223671134|NCT01414920|DRUG|Placebo|TAK-875 and sitagliptin placebo-matching tablets, orally, once daily for up to 12 weeks.
223671135|NCT01414920|DRUG|TAK-875|TAK-875 25 mg, tablets, orally, once daily for up to 12 weeks.
223671136|NCT01414920|DRUG|TAK-875|TAK-875 50 mg, tablets, orally, once daily for up to 12 weeks.
224252152|NCT04383574|BIOLOGICAL|Two doses of placebo at the schedule of day 0,28|The placebo was manufactured by Sinovac Research \& Development Co., Ltd., Two doses of placebo at the schedule of day 0,28,and one dose of booster immunization with placebo 1 year after primary immunization at the schedule of day 0,28 in phaseⅠand 6 months after primary immunization at the schedule of day 0,28 in phase Ⅱ.
224322150|NCT06531837|DRUG|Flurbiprofen (Single intravenous injection)|Single intravenous injection of Flurbiprofen at a dose of 100 mg. Collect resting-state EEG data and NRS scores 10 minutes after administration.
224322151|NCT06531837|DEVICE|Spinal Cord Stimulation|Collect resting-state EEG data and NRS scores with the spinal cord stimulator both turned off and on.
224322152|NCT06531837|OTHER|No intervention|Collect resting-state EEG data and NRS scores.
223671137|NCT01414920|DRUG|Sitagliptin|Sitagliptin 100 mg, tablets, orally, once daily for up to 12 weeks.
223671138|NCT01414920|DRUG|TAK-875 and Sitagliptin|TAK-875 25 mg, tablets, orally, once daily and sitagliptin 100 mg tablets, orally, once daily for up to 12 weeks.
223671139|NCT01414920|DRUG|TAK-875 and Sitagliptin|TAK-875 50 mg, tablets, orally, once daily and sitagliptin 100 mg tablets, orally, once daily for up to 12 weeks.
223671140|NCT02843997|GENETIC|Endophenotype and sequencing|Draw an endophenotype and genetic study
223671141|NCT00146055|PROCEDURE|Reduced intensity conditioning with allogeneic transplant|
223671142|NCT05282056|DIAGNOSTIC_TEST|CAD analysis|CAD shows the radiologist automatically delineated areas of potential COVID-19 affection, together with an overall lung affection percentage.
224322153|NCT02198937|OTHER|Blood sample|
224322154|NCT00948272|BIOLOGICAL|Purified Vero Rabies Vaccine - Serum Free|0.5 mL, Intramuscular
224322155|NCT00948272|BIOLOGICAL|Purified inactivated rabies vaccine|0.5 mL, Intramuscular
224322156|NCT02287922|BIOLOGICAL|ALX-0061|
223671143|NCT00004082|DRUG|carboplatin|
223671144|NCT00004082|DRUG|docetaxel|
223671145|NCT00004082|DRUG|gemcitabine hydrochloride|
223671146|NCT03276169|PROCEDURE|Left atrial appendage closure|Left atrial appendage closure is performed using a single endocardial plug devices guided by fluoroscopic guidance and transesophageal echocardiography
223671147|NCT03276169|PROCEDURE|Radiofrequency ablation|Each patient with persistent AF receives circumferential pulmonary vein isolation under the 3D electro-anatomical mapping system , and no additional ablation is performed in the extrapulmonary sites unless the patient is diagnosed with atrial flutter before the operation.
224322157|NCT02287922|BIOLOGICAL|Placebo|
224322158|NCT02287922|BIOLOGICAL|Tocilizumab|
224322159|NCT03337061|OTHER|Mindfulness Meditation|Mindfulness Meditation delivered through a mobile application
224322160|NCT01809912|DRUG|Recombinant human apolipoprotein(a) Kringle V|
224252153|NCT04383574|BIOLOGICAL|Two doses of low dosage inactivated SARS-CoV-2 vaccine at the schedule of day 0,28|The inactivated SARS-CoV-2 vaccine was manufactured by Sinovac Research \& Development Co., Ltd..Two doses of low dosage (300SU/0.5ml)experimental vaccine at the schedule of day 0,28,and one dose of booster immunization with low dosage (300SU/0.5ml) experimental vaccine 6 months after primary immunization at the schedule of day 0,28 in phase Ⅱ.
224252154|NCT02226289|DRUG|Bevacizumab|bevacizumab with the latest received cytotoxic regimen
224252155|NCT06559020|BEHAVIORAL|Kangroo mother care|Kangaroo Mother Care (KMC) involves continuous skin-to-skin contact between the mother (or another family member) and the infant, aimed at promoting thermal regulation, breastfeeding, and bonding. In this study, KMC was initiated in the hospital and continued at home for a minimum of 8 hours daily.
223671148|NCT03276169|PROCEDURE|LAAC combined with radiofrequency ablation group|Each patient received the same group of patients with simple radiofrequency ablation radiofrequency ablation treatment at the same time, the transcatheter occlusion of left atrial appendage opening
223671149|NCT00880464|BIOLOGICAL|Autologous, Lethally Irradiated Breast Cancer Cells|Vaccination with autologous tumor cells engineered by adenoviral mediated gene transfer to secrete GM-CS
223671150|NCT01791959|DIETARY_SUPPLEMENT|synbiotic|2 symbiotics capsules per day for 28 weeks
223671151|NCT01791959|OTHER|placebo|2 Maltodexterin capsules as a placebo per day for 28 weeks
223671152|NCT03529071|BEHAVIORAL|CKD-Question Prompt Sheet|The CKD-QPS is a list of 31 questions specific to CKD stage 3 patients about treatment options and self-care management designed to activate patient communication with their providers and question-asking.
223671153|NCT05015413|DEVICE|Shockwave|Shock wave master 500 Germany
223671154|NCT03876301|DRUG|Standard of Care FVIII Replacement therapy|There is no investigational product being administered. Subjects will be administering their own standard of care FVIII replacement therapy.
223671155|NCT02162407|DRUG|insulin detemir|Given as intravenous infusion (i.v.) over a period of 8 hours during euglycaemic clamp
223671156|NCT02162407|DRUG|human soluble insulin|Given as intravenous infusion (i.v.) over a period of 8 hours during euglycaemic clamp
223671157|NCT00606047|RADIATION|Magnetic resonance imaging (MRI)|Participation in this study will involve patients coming to the hospital after regular work hours for an MRI of the hip joints.
223671158|NCT03207373|DIAGNOSTIC_TEST|Stress test (ECG)|Every study participant undergoes a standard diagnostic stress ECG
223671159|NCT03521895|DRUG|Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321)|Patients observed with regular and irregular treatment course
223671160|NCT04575597|DRUG|Molnupiravir|Molnupiravir administered orally in capsule form every 12 hours for 5 days (10 doses total)
223671161|NCT04575597|DRUG|Placebo|Placebo matching molnupiravir administered orally in capsule form every 12 hours for 5 days (10 doses total)
223671162|NCT02553954|PROCEDURE|Collection of healthy skin tissue|Collection of two samples of healthy skin tissue, without disfigurement, during an intervention under general anesthesia for the treatment of a benign or malignant tumor.
223671163|NCT05315869|PROCEDURE|Appendectomy|Surgical procedure for removal of the appendix
223771793|NCT03552887|PROCEDURE|Physiotherapy|Any type of physiotherapy intervention, performed by physiotherapists outside of the protocol
224252156|NCT06133920|OTHER|Early Range of Motion|The early range of motion group will be given a sling for comfort after their surgery. They will be told they can use their arm as tolerated and can remove the sling when comfortable immediately after surgery. They will be allowed to start passive range of motion, active assisted range of motion, and gentle active range of motion with therapy as tolerated with the exception of no internal rotation. They will also not be allowed to strengthen until 12 weeks after surgery. They will get formal physical therapy and be given a home exercise program as well that will be directed by their physical therapist
224252157|NCT06133920|OTHER|Immobilization|"The immobilization group will be placed in a shoulder abduction sling immediately after surgery for four weeks. They will be allowed to start gentle passive range of motion with forward flexion to 120 degrees, abduction to 90 degrees, and external rotation to 30 degrees. They will receive a home exercise program and formal physical therapy with these limits.~When they come out of the sling at four weeks they will start active range of motion and active assisted range of motion. They cannot internally rotate until 10 weeks after surgery. No formal strengthening until 3 months after surgery."
224322161|NCT01690702|DRUG|Epirubicin|
224322162|NCT01690702|DRUG|nab-Paclitaxel|
224322163|NCT01690702|DRUG|Cyclophosphamide|
224322164|NCT01690702|DRUG|Docetaxel|
223671164|NCT06001411|BEHAVIORAL|Prone Position Training|All patients were admitted to our hospital at least 3 days before surgery. Patients in the intervention group (PPT group) received the prone position training daily in the hospital, three times a day, and about 1 hours every times, for at least 3 days before surgery. On the day of admission to the hospital, the patients in the PPT group were instructed to perform prone position training by nurses who were previously trained by prone position training.
223671165|NCT06001411|BEHAVIORAL|control group|Patients in the control group (C group) received standard perioperative care without any prone position training.
223671166|NCT04050020|BIOLOGICAL|Platelet-Rich Plasma (PRP)|All subjects of this group will receive 2 sessions of PRP penile injection with 30 +/- 3 day treatment interval, 10 ml of PRP will be injected at each session.
223671167|NCT04050020|BIOLOGICAL|Normal saline injection|All subjects of this group will receive 2 sessions of normal saline penile injection with 30 +/- 3 day treatment interval for all subjects, 10 ml of normal saline will be injected at each session.
223671168|NCT01578512|BEHAVIORAL|Face-to-Face|Face-to-Face behavioral weight loss
223671169|NCT01578512|BEHAVIORAL|Web-based|Web-based behavioral weight loss
223671170|NCT01578512|BEHAVIORAL|Single session|The core of behavioral weight loss, including calorie and activity prescriptions, are delivered in a single group treatment session.
223671171|NCT01625533|PROCEDURE|Standard Coronary Angiography|Using standard coronary angiography (SA) for the diagnosis of coronary artery disease.
223671172|NCT01625533|PROCEDURE|Dual-axis Rotational Coronary Angiography|Using dual-axis rotational coronary angiography (DARCA) for the diagnosis of coronary artery disease.
223671173|NCT01097083|DRUG|Coriolus Versicolor|
223771794|NCT04437394|DIAGNOSTIC_TEST|flexible endoscopic evaluation of swallowing|The patients were assessment with flexible endoscopic swallowing evaluation was performed with colored pudding.
223671174|NCT02542930|RADIATION|Radiotherapy|Metastatic lesions of Non-small cell lung cancer receiving 3.5Gy per fraction to a total dose of 35Gy/10 fractions over 2 weeks with concurrent thymalfasin.
223671175|NCT02542930|DRUG|Thymalfasin|Metastatic lesions of Non-small cell lung cancer receiving 3.5Gy per fraction to a total dose of 35Gy/10 fractions over 2 weeks with concurrent thymalfasin; Thymalfasin treatment is given twice a week with an interval of 3-4 days each week.
223671176|NCT05264948|DIAGNOSTIC_TEST|Polymerase chain reaction|Covid-19 genetic material detection from mouth and nose swab
223671177|NCT05641389|OTHER|Monitoring|Participants will be monitored for alcohol use.
223671178|NCT04037878|PROCEDURE|Transversus Abdominis Plane Block(TAP Block)|Under ultrasound guidance, a 22 gauge stimuplex needle will be used to approach the transversus abdominis plane and 20ml of 0.25% Bupivicaine will be infiltrated into the TAP space. This procedure will be performed on either sides once anesthesia is induced.
223671179|NCT04037878|PROCEDURE|Intra-peritoneal infiltration|Before skin closure, the surgeon will infiltrate the peritoneal cavity using a mixture of bupivicaine and epinephrine
223671180|NCT04037878|DRUG|PCIA Tramadol|All patients will be given patient controlled intravenous analgesia using Tramadol as the drug
224252158|NCT03562962|BEHAVIORAL|Functional Analytic Psychotherapy|FAP is a therapeutic procedure based on behavior analytic principles. This approach seeks to implement procedures to manipulate the contingencies of reinforcement involved in clients' problem and alternative behaviors within the context of a meaningful therapeutic relationship that is functionally equivalent to other interpersonal contexts outside (Follette, Naugle \& Linnerooth, 2000; Kohlenberg \& Tsai, 1991). FAP therapists modify CRBs by implementing contingent responding (TCRB) within the therapeutic setting. That is, FAP aims to administer differential reinforcement (TCRB1) to reduce CRB1s and to provide positive reinforcement to enhance CRB2s. Based on the changes within the therapeutic setting, clients are prompted to discriminate contexts where those repertoires are likely reinforced and to generalize those responses to such environments (Kohlenberg \& Tsai, 1991).
224252159|NCT05034094|OTHER|VEMP recording|"* Clinical evaluation: All participants will undergo detailed medical and neurological histories and examinations.~* The severity of manifestations of PD will be assessed using the Movement Disorder Society (MDS)-sponsored new version of Unified PD Rating Scale (MDS-UPDRS)."
224252160|NCT04776226|DRUG|Citalopram|Antidepressant use in patients with depression
224252161|NCT00128791|DRUG|Nitroprusside|
224252162|NCT00766701|PROCEDURE|Procedure: Spectroscopy and Digital Imaging|Procedure: Spectroscopy and Digital Imaging
224252163|NCT00850148|PROCEDURE|Anwar|Anwar surgical method
224252164|NCT00850148|PROCEDURE|Melles|Melles surgical method
224252165|NCT04195230|BEHAVIORAL|Multi-tasking Training|Participants will undergo training protocol where they will have, concomitantly, to cook different meals and set the table under different instructions, rules and difficulty level.
224252166|NCT04582019|DEVICE|stent extraction|stent extraction using magnetic retriever or flexible cystoscope
224252167|NCT06015958|OTHER|Streptococcus salivarius M18 toothpaste (1 million cfu)|"Probiotics Streptococcus salivarius M18 toothpaste 1 million cfu/g~In this study, a toothpaste formulation containing S. salivarius M18 will be evaluated for its potential for delivering the probiotic to the oral cavity."
223671181|NCT01768429|BEHAVIORAL|Fatty fish|
223671182|NCT01768429|BEHAVIORAL|Lean Fish|
224252168|NCT06015958|OTHER|Streptococcus salivarius M18 toothpaste (10 million cfu)|"Probiotics Streptococcus salivarius M18 toothpaste 10 million cfu/g~In this study, a toothpaste formulation containing S. salivarius M18 will be evaluated for its potential for delivering the probiotic to the oral cavity."
224252169|NCT05829421|OTHER|Impairment-specific occupational therapy (OT) intervention|"In parallel with standard practice, patients receive an OT intervention adapted to the specific underlying cognitive impairments that are likely to disturb their performance of ADLs.~The intervention is individualised through a 3-step process: a) a list of dysfunctional ADL process skills is forwarded by the OT to the neuropsychologist (NP), b) the NP identifies the cognitive impairments which are most likely to cause the dysfunctional ADL process skills through a cognitive assessment, c) based on the identified cognitive impairments, the NP and the OT select in collaboration the cognitive strategies that are most likely to benefit the individual patient from a pre-prepared intervention manual. Because of the large heterogeneity in how cognitive impairments impact on ADL performance, the exact way of implementing the selected cognitive strategies into the practice of the individual patient is left to the OT´s clinical judgement."
224252170|NCT04854798|DEVICE|Splenic Ultrasound|Daily ultrasound application to the spleen of approximately 18 minutes for up to 7 days, in addition to standard clinical care
224252171|NCT00077077|DRUG|DJ-927|
224252172|NCT00077077|DRUG|capecitabine|
224252173|NCT01964053|BEHAVIORAL|PATCH intervention|The intervention group will receive usual care and the PATCH intervention. The intervention is comprised of two phases in which the in-hospital discharge education session is followed by 12 weeks of post-discharge education sessions delivered by telephone. The focus of this study is to test the mechanism of the proposed patient activation intervention on HF self-management adherence and associated health outcomes.
223671183|NCT01768429|BEHAVIORAL|Alpha-linolenic acid|
223671184|NCT01768429|BEHAVIORAL|Control|
223671185|NCT02128685|DRUG|Dydrogesterone|
223671186|NCT02128685|DRUG|Placebo|
223671187|NCT03207438|DRUG|Quetiapine 50 MG Extended Release Oral Tablet|OD
223671188|NCT03207438|DRUG|Quetiapine Fumarate XR 150-300 mg|Dose ranged from 150 to 300mg, XR preparation, OD
223671189|NCT03207438|DRUG|Placebos|Placebo
223671190|NCT01014923|BEHAVIORAL|Teen driving intervention|Parents of new teen drivers receive guidebook to teach driving skills and safety behaviors; individual instruction on parent-child communication about driving; DVD demonstrating safe driving communication; and, 26-page booklet on driving goals and conversation topics
223771795|NCT04437394|DIAGNOSTIC_TEST|The analysis of voice|Voice recordings were taken from the patients to evaluate the voice disturbance and acoustic evaluation was taken with PRAAT program.
223771796|NCT01280929|PROCEDURE|Panretinal Photocoagulation (PRP)|
223771797|NCT01280929|DRUG|Intravitreous injection of ranibizumab|
223771798|NCT03709550|DRUG|Decitabine|Given IV
223771799|NCT03709550|DRUG|Enzalutamide|Given PO
224252174|NCT01964053|BEHAVIORAL|Usual care|Usual care refers to the standardized discharge written information and scheduled doctor appointments. Standardized discharge instruction, as recommended by CMS and the Joint Commission, includes: activity level, diet, discharge medications, follow-up doctor appointment, weight monitoring, and what to do if symptoms worsen.113 No further follow-ups are routinely done by the hospital and patients are told to see their primary care provider if problems occur.
224252175|NCT00350753|DRUG|Erlotinib and bevacizumab|Erlotonib 150 mg daily bevacizumab 10 mg/kg every 14 days
224252176|NCT04030845|PROCEDURE|breast reconstruction|The breast reconstruction mainly included autologous tissue flaps (latissimus dorsi myocutaneous flaps, pedicled tansverse rectus abdominis myocutaneous flaps, free transverse rectus abdominis musculocutaneous flaps, deep inferior epigastric artery perforator flaps, etc.), implant based breast reconstruction, autologous flaps combined with implant reconstruction, fat graft, etc.
224252177|NCT04030845|PROCEDURE|oncoplastic breast-conserving surgery|The oncoplastic breast-conserving surgery were mainly those surgeries using volume displacement or volume replacement techniques.
224252178|NCT00833209|PROCEDURE|PET (withdrawal)|3 (18F)FDG-PET (before withdrawal, 3 months, 1 year), 2 MRI (before withdrawal, 1 year), will take the Iowa Gambling Task Test(before withdrawal) and will answer questionnaires measuring psychological dimensions (before withdrawal, 3 months, 1 year)
224252179|NCT00833209|PROCEDURE|Imaging|2 MRI (inclusion, 1 year) ; Iowa Gambling Task Test(inclusion) and questionnaires (inclusion)
224252180|NCT00833209|PROCEDURE|Imaging|1 MRI ; Iowa Gambling Task test and questionnaires.
224252181|NCT05347719|BEHAVIORAL|MBCT Intervention|Eight weekly two-hour mindful MBCT intervention sessions involving training in mindfulness meditation and cognitive-behavioral methods. Sessions will be designed to increase participant awareness of internal reactions that trigger relapse in MDD and to provide participants with techniques to detach from dysfunctional cognitive processes and redirect their attention to experiences. Outside of the sessions, participants will be assigned daily homework exercises and provided with handouts and audio recordings of mindfulness exercises to use in their practice.
224252182|NCT03442491|PROCEDURE|Hayman's Haemostatic Suture|After the uterus is exteriorised, bimanual compression is applied to check whether this stopped the bleeding, before the suture is applied. A number 2 polyglactin suture on a straight needle is used to transfix the uterus from front to back, just above the reflection of the bladder, and is then tied above the fundus of the uterus, while an assistant applies bimanual compression.
224252183|NCT01613872|OTHER|Mindfulness Based Stress Reduction|An 8 week protocol of stress reduction sessions using gentle yoga and breath meditation
224252184|NCT04020952|OTHER|"st.st 0.019×0.025 wire"|rectangular stainless steel wire that will be used during canine retraction after first premolars extraction
224252185|NCT04020952|OTHER|"st.st 0.016×0.022 wire"|rectangular stainless steel wire that will be used during canine retraction after first premolars extraction
223671191|NCT05101200|OTHER|High Dose Neural Mobilization Technique|Patients in This Group will receive the high dose neural mobilization along with hot pack, strengthening exercises, Neural mobilization technique (slump, sciatic). Participants in the NMG will be asked to actively perform knee extension, ankle dorsiflexion, and head extension in a slumped posture (body and neck semi flexion) followed by simultaneous ankle plantar flexion together with knee and head flexion, Hot pack for 15 minutes, Strengthening exercises of muscles with 10 /8sets. Strengthening exercises of quadriceps with10 rep/8sets, Static stretching exercise for hamstring muscle with 10 rep/8sets, Group A will be given session of 40 min/day, 2 days/week for 4 weeks.
223671192|NCT05101200|OTHER|Low Dose Neural Mobilization Technique|Patients in this Group will receive the same treatment as group A but with less intensity and low dosage. Hot pack: 15 minutes, Strengthening exercises of muscles with 10 rep/4sets, Static stretching exercise for hamstring muscle with 10 rep/4sets. Group B will be given session of 40min/day, 2 days/week for 4weeks.
223671193|NCT00329056|DRUG|MitoQ|Two doses will be compared to placebo: 40 or 80 mg of MitoQ once daily for a period of 12 months.
223671194|NCT03343353|OTHER|LED (Light Emission Diode)|LED light application in cutaneous lesions from the graft donor area (scalp) in patients who are victims of burns
223671195|NCT01455909|DRUG|ITCA 650 60 mcg/day|exenatide in DUROS
223671196|NCT01455909|DRUG|sitagliptin|sitagliptin oral 100 mg/day
223671197|NCT00220922|PROCEDURE|Alcohol Wipes vs. No Alcohol Wipes|
223671198|NCT01512667|DRUG|MK-0822|A single oral dose (50 mg tablet) of MK-0822 will be administered on Day 1 after an overnight fast.
223671199|NCT05242796|DEVICE|Low frequency magnetic therapy|
223671200|NCT01520428|BEHAVIORAL|Motivational Interviewing, CBT and E-mail support|Motivational Interviewing, elements of Cognitive Behaviour Therapy and E-mail support
223671201|NCT00233831|DEVICE|Generator of electromagnetic millimeter waves|
223671202|NCT04118257|DIETARY_SUPPLEMENT|Sugary beverage: Fruit juice|Participants consumed 100% fruit juice (\~710mL) daily for three weeks, along with their habitual diets.
223671203|NCT04118257|DIETARY_SUPPLEMENT|Sugary beverage: Soda|Participants consumed soda (\~710mL) daily for three weeks, along with their habitual diets.
223671204|NCT04118257|DIETARY_SUPPLEMENT|Control: Water|Participants consumed water (\~710mL) daily for three weeks, along with their habitual diets.
223671205|NCT00473122|PROCEDURE|Delayed-Immediate Breast Reconstruction|Immediate reconstruction surgery if no XRT required; or reconstruction surgery delayed until XRT complete.
223671206|NCT04062903|BEHAVIORAL|Immediate Appointment|The participant will meet with the MIND Cymru link worker and decide upon a course of action requiring the use of local services appropriate for the participant.
223671207|NCT04062903|BEHAVIORAL|Delayed appointment|After a period of delay (Control) The participant will meet with the MIND Cymru link worker and decide upon a course of action requiring the use of local services appropriate for the participant.
223671208|NCT02660008|DRUG|ZP4207|Parallel trial in Group 1 and cross-over trial in Groups 2-4 with single doses of ZP4207 administered s.c. to hypoglycemic Type 1 diabetic patients
223671209|NCT02660008|DRUG|GlucaGen|Parallel trial in Group 1 and cross-over trial in Groups 2-4 with single doses of GlucaGen administered s.c. to hypoglycemic Type 1 diabetic patients
223671210|NCT01280045|PROCEDURE|VAGINAL HYSTERECTOMY|GOSERELINE ACETATE 10.8 MG FOR THREE MONTHS; ANASTROZOL ACETATE FOR THREE MONTHS
223671211|NCT01607203|DRUG|Decapeptyl Daily|Decapeptyl 0.2 mg SC once 1day
223671212|NCT01607203|DRUG|pregnyl|5000 IU SC
224252186|NCT04020952|OTHER|"st.st 0.017×0.025 wire"|rectangular stainless steel wire that will be used during canine retraction after first premolars extraction
224252187|NCT05454683|DIETARY_SUPPLEMENT|melatonin plus zinc|One capsule with melatonin 1mg plus zinc 10 mg o.d. 30 minutes before bedtime, at least 1 hour after dinner during 4 months
224252188|NCT05454683|OTHER|isomaltose and magnesium stearate|One capsule with excipients o.d. 30 minutes before bedtime, at least 1 hour after dinner during 4 months
224252189|NCT00003291|GENETIC|cytogenetic analysis|
224252190|NCT00003291|GENETIC|mutation analysis|
224252191|NCT00003291|OTHER|laboratory biomarker analysis|
224252192|NCT01956591|DRUG|Oxybutynin|All patients are treated with oxybutynin for hyperhidrosis. Usual maintenance dose is 10mg/day, but dose may vary according to weight, efficacy and side effects. Our standard protocol starts with 2.5mg/day in the first 7 days, progresses to 5mg/day for 14 days and then reaches the usual maintenance dose of 10mg/day afterwards.
224252193|NCT03316963|DRUG|Neostigmine Methylsulfate|After the patient demonstrates snoring and obstruction collapse, the patient will receive the study medication (neostigmine methylsulfate 1mg/mL) into the soft palate with co-administration of intravenous glycopyrrolate 0.2mg. At each of 5 injection sites on the soft palate , 0.5 mL (0.5mg) of neostigmine methylsulfate will be administered, yielding a total of 2.5mg (2.5mL) of neostigmine methylsulfate. The medication will be administered using five 1 mL syringes filled with 0.5 mL neostigmine each. Following administration of neostigmine, the patient will be observed for an additional 4 minutes to examine both vibration and sound emanating from the soft palate. The anticipated time under sedation will be 14 minutes.
224252194|NCT04834128|DRUG|TCB008|administration of gamma delta T cells by IV bolus injection
224252195|NCT02322593|DRUG|TAS-118 plus Oxaliplatin|
224252196|NCT02322593|DRUG|S-1 plus Cisplatin|
224252197|NCT00042783|BIOLOGICAL|D1/3-MAGE-3-His fusion protein|
224252198|NCT00042783|BIOLOGICAL|SB-AS02B adjuvant|
224252199|NCT06203951|DIAGNOSTIC_TEST|Xpert® CT/NG and TV testing|Participants randomized to universal STI testing will be offered Xpert® CT/NG and TV testing regardless of symptoms, and they will receive a standard syndromic STI assessment. Participants randomized to the asymptomatic only testing will be offered Xpert® CT/NG and TV testing if no signs or symptoms of CT, NG, or TV are identified during STI assessment. Participants assigned to receive Xpert® testing will be counseled on CT/NG/TV testing, including the benefits of testing even in the absence of symptoms to detect asymptomatic infections (as informed by pilot evaluation). If a client accepts Xpert® testing, she will be instructed by the study nurse on how to self-collect a vaginal swab.
223671213|NCT02489916|DRUG|CM4307|CM4307 300mg bid, each 4 week cycle
223671214|NCT01592656|RADIATION|Functional Respiratory Imaging|CT-scan of thorax. At baseline, after 1 month and after 6 months.
223671215|NCT01592656|OTHER|Lung compliance measurement|At baseline
223671216|NCT01592656|DEVICE|Non-invasive ventilation (Respironics)|Long-term non-invasive ventilation, starting at baseline until 6 months. At baseline the patients should have persisting hypercapnia (pCO2 \> 45 mmHg) under optimal conservative treatment other than NIV. The patients can be hospitalised or being treated at home at inclusion.
223671217|NCT03463876|DRUG|SHR 1210+apatinib|SHR-1210 200mg (3mg/kg for underweight patients) iv every 2 weeks;Apatinib,250 mg/day.
223671218|NCT02373501|PROCEDURE|Intra-abdominal repair|Intra abdominal repair of uterine incision
223671219|NCT02373501|PROCEDURE|Extra-abdominal repair|Extra abdominal repair of uterine incision
223671220|NCT05810818|DIAGNOSTIC_TEST|Dry Needling|Dry needling treatment will be consisting of two treatments per week
223671221|NCT05810818|DIAGNOSTIC_TEST|Self Stretching|Self stretching groups both will receive a TrP manual interventions and stretching protocol
223671222|NCT04637828|DRUG|GNS561|study drug
223671223|NCT01178827|DRUG|trospium chloride|trospium chloride (60mg) once daily for 10 days
223671224|NCT01178827|DRUG|oxybutynin IR|oxybutynin IR (5 mg) three times daily for 2 days
223671225|NCT01178827|DRUG|oxybutynin IR placebo|oxybutynin IR placebo three times daily for 2 days
223671226|NCT00936689|PROCEDURE|Selective TACE via microsphere loaded with Doxorubicin|Chemoembolization with microspheres: doxorubicin (maximum dose of 75 mg x vials of microspheres) loaded with non-reabsorbable microspheres (sulfate hydrospheres) at the dose of 2 ml per vial (definitive embolization).
223671227|NCT00936689|PROCEDURE|Selective traditional TACE|Traditional chemoembolization: epirubicin (maximum dose of 75 mg) conjugated with Lipiodol at the maximum dose of 15 ml + Spongel.
223671228|NCT01204723|DRUG|Placebo Aprepitant|Placebo Aprepitant 0 mg once daily for 5 days
223671229|NCT01204723|DRUG|Active Aprepitant|Active Aprepitant 160 mg once daily for 5 days
223671230|NCT02756988|DRUG|Coppertone (BAY987704)|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation Number: X71-109)
223671231|NCT05051930|DRUG|TQC3721 suspension for inhalation|Participants will receive 0.2 mg/1.0 mg/3.0 mg/6.0 mg/12.0 mg/24.0 mg single dose of TQC3721 suspension for inhalation.
223671232|NCT05051930|DRUG|TQC3721 suspension placebo for inhalation|Participants will receive 0mg single dose of TQC3721 suspension placebo for inhalation .
223671233|NCT05866848|OTHER|Placebo|Flour capsules as a placebo.
223671234|NCT05866848|OTHER|Anhydrous caffeine (45mg)|Capsules dosed with 45mg of anhydrous caffeine.
223671235|NCT05866848|OTHER|Anhydrous caffeine (120mg)|Capsules dosed with 120mg of anhydrous caffeine.
223671236|NCT00445588|DRUG|erlotinib hydrochloride|150mg Given orally once daily
223671237|NCT00445588|DRUG|sorafenib tosylate|400mg Given orally twice daily
223671238|NCT00445588|OTHER|pharmacological study|Correlative studies
223671239|NCT05796206|DRUG|MIL62|An intravenous (IV) infusion of 1000 mg of MIL62 will be administered at W1D1、W3D1、W25D1、W27D1、W53D1、W55D1.
223671240|NCT05796206|DRUG|placebo|An intravenous (IV) infusion of placebo will be administered at W1D1、W3D1、W25D1、W27D1、W53D1、W55D1.
223771800|NCT05709821|DRUG|IMM60|IMM60, every 3 weeks for up to 6 cycles, intravenous (IV) infusion
223771801|NCT05709821|DRUG|Pembrolizumab|Pembrolizumab, 200 mg, every 3 weeks for up to 35 cycles or approximately 2 years, intravenous (IV) infusion
223671241|NCT01182090|PROCEDURE|Colposacropexy|In open approach the anterior vaginal wall is dissected from the bladder to expose a vaginal wall area of at least 3 x 5 cms where the mesh will be attached with four-five Polyglycolic 0 sutures. The procedure is repeated for the posterior vaginal wall, where the mesh will be attached with three-four Polyglycolic 0 sutures. The sacral promontory surface is prepared and 1 or 2 non-reabsorbable 0.0 sutures are placed into the sacral periosteum about 2 cm below the promontory. A sub-peritoneal tunnel is created through which meshes are passed avoiding traction to the sacrum. The peritoneum is closed over the meshes.
223671242|NCT01182090|PROCEDURE|Colposacropexy|In laparoscopic approach the anterior vaginal wall is dissected from the bladder to expose a vaginal wall area of at least 3 x 5 cms where the mesh will be attached with four-five Polyglycolic 0 sutures. The procedure is repeated for the posterior vaginal wall, where the mesh will be attached with three-four Polyglycolic 0 sutures. The sacral promontory surface is prepared and 1 or 2 non-reabsorbable 0.0 sutures are placed into the sacral periosteum about 2 cm below the promontory. A sub-peritoneal tunnel is created through which meshes are passed avoiding traction to the sacrum. The peritoneum is closed over the meshes.
223671243|NCT05161780|DRUG|Lactated Ringer's Irrigation|Lactated Ringers at 40C will be used for the entirety of the surgery including the approach and exposure of the tumor as well as tumor resection, After surgery, two blinded skull base surgeon reviewers will rate the clarity of the endoscopic field of view at the recorded intervals. The surgical field will be graded using a widely accepted numeric integer (Boezaart) scale.
223671244|NCT05161780|DRUG|Normal Saline|Normal Saline at 40C will be used for the entirety of the surgery including the approach and exposure of the tumor as well as tumor resection, After surgery, two blinded skull base surgeon reviewers will rate the clarity of the endoscopic field of view at the recorded intervals. The surgical field will be graded using a widely accepted numeric integer (Boezaart) scale.
223671245|NCT04114617|OTHER|Starch-thickened liquids|Thickener added in amounts required to reach slightly thick, mildly thick, moderately thick and extremely thick consistencies, as defined by the International Dysphagia Diet Standardisation Initiative flow test.
223671246|NCT04114617|OTHER|Xanthan-gum thickened liquids|Thickener added in amounts required to reach slightly thick, mildly thick, moderately thick and extremely thick consistencies, as defined by the International Dysphagia Diet Standardisation Initiative flow test.
223671247|NCT04114617|COMBINATION_PRODUCT|Barium concentration|Commercially available barium products diluted to different concentrations (i.e., 20% w/v, 40% w/v) through the addition of water
223671248|NCT01587898|DRUG|GSK1278863|Tablet
223671249|NCT01587898|OTHER|Placebo|Tablet
223671250|NCT01738477|BIOLOGICAL|Boostrix|Single dose intramuscular administration.
223671251|NCT05570461|OTHER|Modified Constraint-Induced Movement Therapy|Experimental group will receive Modified Constraint-Induced Movement Therapyand traditional physical therapy to the impaired upper limb based on the repetitive training of functional activities and behavioral shaping and a task-oriented approach, while the unaffected arm of subjects in the mCIMT group will be constrained by wearing a mitten during the treatment session and for 3 hours/day outside the therapy hours, 6(six) days/week for two weeks by an experienced Physical therapist.The time duration for Group A will be 40 minutes.
223671252|NCT02871037|DRUG|PF-05221304|Single or repeated, escalating dose of PF-05221304
223671253|NCT02871037|OTHER|Placebo|single or repeated dose of placebo
223671254|NCT01760642|DRUG|Midazolam|Midazolam 3 mg IV
223671255|NCT01760642|DRUG|Ketoconazole|ketoconazole 400 mg PO
223671256|NCT01760642|DRUG|Rifampicin|Rifampicin 600 mg PO
223671257|NCT04096768|DRUG|Dexmedetomidine|Comparing Dexmedetomidine + Ketamine versus Dexmedetomidine + Placebo for sedation in ICU patients
223671258|NCT04096768|DRUG|Ketamine|Comparing Dexmedetomidine + Ketamine versus Dexmedetomidine + Placebo for sedation in ICU patients
223671259|NCT03535246|BIOLOGICAL|Engineered Immune Cells|Engineered immune effector cells (EIE)
223671260|NCT01423188|DRUG|RVX000222|capsule, 200 mg, administer with food, 100 mg twice daily 10-12 hrs apart, 24 weeks
223671261|NCT01423188|DRUG|Placebo RVX000222|capsule, administer with food, twice daily 10-12 hrs apart, 24 weeks
223671262|NCT02136888|DRUG|Ponesimod Placebo|
223671263|NCT02136888|DRUG|Moxifloxacin Placebo|
223671264|NCT02136888|DRUG|Ponesimod 10 mg|
223671265|NCT02136888|DRUG|Ponesimod 20 mg|
223671266|NCT02136888|DRUG|Ponesimod 40 mg|
223671267|NCT02136888|DRUG|Ponesimod 60 mg|
223671268|NCT02136888|DRUG|Ponesimod 80 mg|
223671269|NCT02136888|DRUG|Ponesimod 100 mg|
223671270|NCT02136888|DRUG|Moxifloxacin 400 mg|
223671271|NCT00489125|OTHER|physiologic testing|physical testing of range of motion, grip strength etc.
223671272|NCT01654913|DEVICE|hemoglobin measurement|"Non invasive hemoglobin measurements (Pronto 7 device and NBM-200 device)will be made with :~* at baseline (simultaneous blood sample for a laboratory measurement of hemoglobin),~* with the patient breathing oxygen via a face-mask (FiO2 50 ± 5%),~* with the patient breathing oxygen via a face-mask (FiO2 90 ± 5%) (simultaneous blood sample for a laboratory measurement of hemoglobin)."
223671273|NCT01775397|DRUG|Fidaxomicin|capsule
223671274|NCT01775397|DRUG|Vancomycin|capsule
223671275|NCT01775397|DRUG|Placebo|Capsule
223671276|NCT01096628|OTHER|Chiropractic + Exercise|"Treatment will include eight to 16 treatments provided over the 12-week period. Each treatment visit will last from 10-20 minutes and consist of manual spinal manipulation and mobilization. Light soft tissue techniques (i.e., active and passive muscle stretching, hot and cold packs, and ischemic compression of tender points) will be used as indicated to facilitate the manual therapy.~Patients will attend 8 to 16, one-on-one, 45-minute sessions over the course of 3 months. The sessions will follow a standardized approach but will be individualized to meet the patient's needs specific to their lifestyle, fitness level, and clinical characteristics. The exercise program will be comprised of three parts: 1) education, 2) supervised exercise, and 3) home exercise."
224252200|NCT06342830|DRUG|nanocurcumin gel|firstly patient anesthetized, rubber dam isolation , disinfect the crown with 10%H2O2, saline then sodium hypochlorite solution 2.5% then 5% sodium thiosulphate solution to inhibit the effect of NaOHCl then removal of old coronal restoration, disinfection of pulp chamber by the same previous protocol removal of old root canal filling with gates glidden drills and H files , taken first sample S1 from canal with paper point after using saline wash and scrubbing the canal wall the paper points left for 1 min in the canal then preparation of canal with edge endo files till size 45 taper 0.4 and NaOHCL 2.5% between each file and the next finally 5% sodium thiosulphate to inhibit the antibacterial effect of sodium hypochlorite irrigation then saline irrigation and scrubbing the canal wall and placement of paper points for 1min to taken second sample S2, then dryness of canal and placement of nanocurcumin gel until shown fill the canal under magnification and by using lentulospirals
224252201|NCT06342830|DRUG|Curcumin Gel|firstly patient anesthetized, rubber dam isolation , disinfect the crown with 10%H2O2, saline then sodium hypochlorite solution 2.5% then 5% sodium thiosulphate solution to inhibit the effect of NaOHCl then removal of old coronal restoration, disinfection of pulp chamber by the same previous protocol removal of old root canal filling with gates glidden drills and H files , taken first sample S1 from canal with paper point after using saline wash and scrubbing the canal wall the paper points left for 1 min in the canal then preparation of canal with edge endo files till size 45 taper 0.4 and NaOHCL 2.5% between each file and the next finally 5% sodium thiosulphate to inhibit the antibacterial effect of sodium hypochlorite irrigation then saline irrigation and scrubbing the canal wall and placement of paper points for 1min to taken second sample S2, then dryness of canal and placement of curcumin gel until shown fill the canal under magnification and by using lentulospirals
224252202|NCT06342830|DRUG|Ciprofloxacin 500 mg +ibuprofen 400mg|firstly patient anesthetized, rubber dam isolation , disinfect the crown with 10%H2O2, saline then sodium hypochlorite solution 2.5% then 5% sodium thiosulphate solution to inhibit the effect of NaOHCl then removal of old coronal restoration, disinfection of pulp chamber by the same previous protocol removal of old root canal filling with gates glidden drills and H files , taken first sample S1 from canal with paper point after using saline wash and scrubbing the canal wall the paper points left for 1 min in the canal then preparation of canal with edge endo files till size 45 taper 0.4 and NaOHCL 2.5 % between each file and the next finally 5% sodium thiosulphate to inhibit the antibacterial effect of sodium hypochlorite irrigation then saline irrigation and scrubbing the canal wall and placement of paper points for 1min to taken second sample S2, then dryness of canal and placement of ciprofloxacin + ibuprofen gel until fill the canal under magnification and by using lentulospirals
223671277|NCT01096628|OTHER|Exercise|Patients will attend 8 to 16, one-on-one, 45-minute sessions over the course of 3 months. The sessions will follow a standardized approach but will be individualized to meet the patient's needs specific to their lifestyle, fitness level, and clinical characteristics. The exercise program will be comprised of three parts: 1) education, 2) supervised exercise, and 3) home exercise.
223671278|NCT02835040|OTHER|New model of service delivery|Introduction of a new CAP disease specific clinical team to ensure systematic implementation of standardized treatment protocols (similar to a clinical pathway) for interventions supported by Level-1 evidence.
223671279|NCT02835040|OTHER|Current practice|Interventions as determined by the treating General Medical team consistent with current usual practice.
223671280|NCT00527891|PROCEDURE|Signa Excite 3.0 T MRI Scan|Signa Excite 3.0 T MRI scan within a two week period from the date of receiving standard 1.5 T MR of the liver area.
223671281|NCT02319629|DRUG|URSODIOL|preventive treatment with Ursolit to reduce the incidence of gallstones formation after bariatric surgery
223671282|NCT02319629|DRUG|Placebo|
223671283|NCT02437110|DRUG|Darunavir|Orally-administered medication approved for HIV treatment. MOA is as a protease inhibitor. Dose is 600mg twice daily.
223671284|NCT02437110|DRUG|Ritonavir|Orally-administered, FDA-approved medication for HIV treatment. Used in combination with darunavir. Dose is 100mg twice daily.
223671285|NCT02437110|DRUG|Dolutegravir|Orally-administered, FDA-approved medication to treat HIV. It acts as an integrase inhibitor. Dose is 50mg once daily.
223671286|NCT02437110|DRUG|Tenofovir alafenamide (TAF)|Orally-administered, FDA-approved medication used to treat HIV. It acts as a nucleoside reverse transcriptase inhibitor. Dose is 25mg once daily.
223671287|NCT05893953|DEVICE|immediately feedback device|Sitting in a standard chair with immediate feedback device
223671288|NCT05893953|DEVICE|Unstable chair|sitting in an unstable chair
223671289|NCT05893953|OTHER|Standard chair|Sitting in a standard chair
223671290|NCT04559711|OTHER|Strengthening coverage and quality of nutrition services during ANC|Intervention clusters will receive inputs both at facility level and community level. The supply side inputs will include efforts for improving facility readiness, quality of nutrition services during ANC, multiple micronutrient supplementation(MMS) and strengthening monitoring and supervision for ANC. On the other hand, community mobilization interventions will be carried out for demand creation. All public health facilities providing ANC services in the intervention area will be included; Union Health \& Family Welfare Center, Community Clinic and Satellite Clinic.
223671291|NCT03079544|COMBINATION_PRODUCT|L-Asparaginase or or Pegaspargase containing chemotherapy|Patients receive at least one cycle of combinational chemotherapy containing L-asparaginas or Pegaspargase.
223671292|NCT01037192|DRUG|vancomycin|vancomycin 30 mg/kg intravenous administered once daily
223671293|NCT01037192|DRUG|vancomycin|vancomycin 15 mg/kg intravenous administered twice daily (standard dosing)
223671294|NCT04772677|BEHAVIORAL|BEAM Mental Health and Parenting Program|The BEAM program is a novel mobile app-based therapeutic intervention that incorporates key parenting concepts and Unified Protocol (UP) therapy modules with clinician-facilitated peer social support and connection. The primary aim of the program is to improve symptoms of depression and promote a positive parent-child relationship. There are three main components of the program: 1) the UP content, which will target maternal mental health symptomology, 2) the parenting skills training content, which is designed to correspond to the UP modules and promote maternal responsivity to children's emotions, and 3) a closed online community forum to encourage social support and connection between participants of the program.
224322165|NCT05916430|DIAGNOSTIC_TEST|EarliPoint Investigational Device|Infants will complete eye-tracking data collection at the age of 9 months on the EarliPoint Investigational Device. Eye-tracking video cameras will safely measure the movements of the child's eyes while they watch age-appropriate video scenes of other children playing together. Parents/Caregivers will complete screening forms and questionnaires about their baby's health and development. Parents/caregivers will complete surveys about their child's development. The surveys will be emailed, to be completed when the child is approximately 9, 12, 15, 18, 21, and 24 months old. If the child shows signs of developmental delay, the child will be asked to participate in a comprehensive developmental and diagnostic assessment.
223671295|NCT05176132|OTHER|Life style intervention (dietician+ physiotherapist)|Obese patients with obesity related diseases will be invited to participate in a personalized lifestyle intervention program with dieticians and physiotherapists focusing on health improvement through personal motivation and perceived limitations and body accept.
223671296|NCT05176132|OTHER|Self management|Patients with no obesity related diseases will not be offered lifestyle intervention, but encouraged to physical activity (self management)
223671297|NCT05176132|OTHER|No intervention|Control groups (BMI 20-25 and BMI 25-30)
223671298|NCT00154323|DRUG|Oxcarbazepine|
223671299|NCT05734417|DIETARY_SUPPLEMENT|Probiotic|Oral administration of Bifidobacterium lactis subsp. infantis B8762 at 0.5x10 log colony forming unit (CFU)/day for 4-weeks
223671300|NCT05734417|DIETARY_SUPPLEMENT|Placebo|Intervention consists of daily administration of 2g/sachet of excipient administered daily for 4-weeks
223671301|NCT03853824|OTHER|Increased postoperative surveillance|Increased postoperative surveillance can include either of the following; i) admission to a higher care ward than had been planned at the time of surgery, ii) an increase in the frequency of nursing observations in the postoperative period, iii) ensuring that the patient is placed in view of the nursing station, and not in a remote location in the postoperative ward, or iv) allowing family members to stay with the patient in the ward in the postoperative period.
223671302|NCT03853824|OTHER|Usual postoperative care|Participating sites randomised to the control arm will provide usual postoperative care to patients. The care will be left to the discretion of the healthcare providers.
223671303|NCT03005210|DRUG|Magicbuvir Plus|1 tablet contains 400 mg Sofosbuvir and 90 mg Ledipasvir
223671304|NCT03005210|DRUG|Harvoni (fist dose)|1 tablet contains 400 mg Sofosbuvir and 90 mg Ledipasvir
223671305|NCT03005210|DRUG|Harvoni (second dose)|1 tablet contains 400 mg Sofosbuvir and 90 mg Ledipasvir
223671306|NCT02634190|OTHER|Thinprep® LBC|liquid based cytology
223671307|NCT02634190|OTHER|APTIMA® HPV Assay|in vitro diagnostic test
223671308|NCT02634190|OTHER|HR HC2® HPV DNA|in vitro diagnostic test
223671309|NCT02634190|OTHER|Colposcopy|Colposcopy
223671310|NCT05278598|PROCEDURE|Erector Spinae Plane Block|"After skin sterilization, ESP block will be performed at the level of T9. A curvilinear high-frequency ultrasound transducer will be placed sagittal 3 cm lateral to T9 spinous process where a hyperechoic shadow of the transverse process (TP) and erector spinae will be defined. A 22-gauge spinal needle will be inserted in cranial to caudal direction toward TP in plane to the ultrasound transducer until the needle touches the TP crossing the whole muscles. The location of the needle tip will be confirmed by visible normal saline solution separating erector spinae muscle off the bony shadow of the TP on ultrasound imaging. After confirming the needle site, 30 mL of 0.25% bupivacaine will be injected. Sonographic confirmation of the local anesthetic spread will be seen as an anechoic shadow in the paravertebral spaces from T7 to T12.~This procedure will be done on both sides."
223671311|NCT05278598|PROCEDURE|Thoracic Paravertebral Plane Block|"After skin sterilization, curvilinear high-frequency ultrasound transducer will be used to visualize the T10 paravertebral space in the paramedian sagittal plane. An injection into the paravertebral space will spread to multiple adjacent dermatomes, so exact identification of a specific level will be not necessary. A 22-gauge spinal needle will be inserted in-plane relative to the ultrasound probe and slowly be directed from lateral to medial until its tip was located at the apex of the paravertebral space and the endpoint for successful block will be anterior displacement of the pleura by injected local anesthetic where a single injection of 30 ml of 0.25% bupivacaine will be injected.~This procedure will be done on both sides."
223671312|NCT05278598|PROCEDURE|Quadratus Lumborum Plane Block|"After skin sterilization, curvilinear high-frequency ultrasound transducer will be positioned horizontally in the anterior axillary line halfway between the subcostal margin and iliac crest, to locate the triple abdominal muscle layers, then the probe will be relocated subsequently to the posterior axillary line until the quadratus lumborum muscle could be visualized with its attachment to the lateral edge of the transverse process of the L4 vertebral body. With the psoas major muscle anteriorly, the erector spinae muscle posteriorly and the quadratus lumborum muscle adherent to the apex of the transverse process, this is a well-recognizable pattern of a shamrock with three leaves. A 22-gauge spinal needle will be inserted in-plane relative to the ultrasound probe passing in posterior to anterior direction through the quadratus lumborum to reach the border between it and psoas major, where 30 ml of 0.25% bupivacaine will be injected.~This procedure will be done on both sides."
223671313|NCT04955600|OTHER|Implementation Study|Implementation of digital technology in two different care settings from both patients, informal caregivers, and healthcare professional's perspective.
223671314|NCT03205592|DIAGNOSTIC_TEST|Ultrasound examination of the antrum|Ultrasound assessment of gastric content will be performed : prior to suction of gastric content through a gastric tube (method to assess the residual gastric content volume), after this suctioning of gastric content, then after reinjection of the content suctioned into the stomach (max 250 ml) and 1h30 later
223671315|NCT03601234|PROCEDURE|laparoscopic and endoscopic cooperative surgery|compare to the traditional surgery to resect the tumor,we will add the endoscopy during the operation to improve the safety and effectiveness of surgery
223671316|NCT03601234|PROCEDURE|laparoscopic surgery|the traditional surgery
223671317|NCT00323817|DRUG|Z-338|
223671318|NCT00287417|DEVICE|echography|
223671319|NCT00287417|OTHER|blood sample|
223671320|NCT05766358|BEHAVIORAL|Intensive lifestyle change therapy|Participant of both groups will be followed for 24 months after completing the parent trial intervention, with no intervention during the follow-up
223671321|NCT05766358|DRUG|Tirzepatide|Participant of both groups will be followed for 24 months after completing the parent trial intervention, with no intervention during the follow-up
224252203|NCT06342830|DRUG|Metapaste [calcium hydroxide paste (control group)]|firstly patient anesthetized, rubber dam isolation , disinfect the crown with 10%H2O2, saline then sodium hypochlorite solution 2.5% then 5% sodium thiosulphate solution to inhibit the effect of NaOHCl then removal of old coronal restoration, disinfection of pulp chamber by the same previous protocol removal of old root canal filling with gates glidden drills and H files , taken first sample S1 from canal with paper point after using saline wash and scrubbing the canal wall the paper points left for 1 min in the canal then preparation of canal with edge endo files till size 45 taper 0.4 and NaOHCL 2.5 % between each file and the next finally 5% sodium thiosulphate to inhibit the antibacterial effect of sodium hypochlorite irrigation then saline irrigation and scrubbing the canal wall and placement of paper points for 1min to taken second sample S2, then dryness of canal and placement of calcium hydroxide paste until fill the canal under magnification by using lentulospirals
224322166|NCT01864707|OTHER|Usual care + acupuncture|Patients of this group receive a standardized acupuncture treatment over 12 weeks in addition to usual care
224322167|NCT01864707|OTHER|usual care+mbsr|Patients of this group receive mindfulness based stress reduction in addition to usual care
223671322|NCT02234518|OTHER|High quantity fiber|The intervention type is food product
223671323|NCT02234518|OTHER|Low quantity fiber|The intervention type is food product
223671324|NCT02234518|OTHER|Placebo|
223671325|NCT04326101|OTHER|Transmission of adherence records|Electronic transmission of patient adherence records by pharmacists into medical EHR (Electronic Health Records)
223671326|NCT02113397|DRUG|TOBI™ Podhaler™ 112 mg inhaled twice daily|
223671327|NCT02113397|DRUG|Colistimethate 75 mg inhaled two times daily|
223671328|NCT02856360|OTHER|Moderate Stiffness Footwear|Standard moderately stiff footwear for typical high school football players will be randomly allocated to each group
223671329|NCT02856360|OTHER|High Stiffness Footwear|Standard highly stiff footwear for typical high school football players will be randomly allocated to each group
223671330|NCT05874167|DRUG|DW6013|"Drug: DW6013 Single oral administration of DW6013 after an overnight fast~Drug: Linagliptin and Metformin Single oral administration of Linagliptin and Metformin after an overnight fast"
223671331|NCT03497598|DRUG|Mannose|The powder is dispensed in 2g neutral sticks and ready to be dissolved in 100ml of water for daily oral ingestion.
223671332|NCT03497598|DRUG|Lactose|The powder is dispensed in 2g neutral sticks and ready to be dissolved in 100ml of water for daily oral ingestion.
223671333|NCT02061527|PROCEDURE|Reconstruction with ADM.|If the patient wishes to undergo immediate implant based reconstruction, and meets the selection criteria for entering the study, she is randomly selected to be treated according to Group A or Group B. Group A (no intervention) will be reconstructed with expander or anatomical gel implant without ADM, using complete muscle coverage. Group B (Intervention) will be reconstructed with expander or anatomical gel implant using partial muscle coverage in conjunction with ADM.
223671334|NCT02061527|PROCEDURE|Skin or nipple sparing mastectomy|Mastectomy for invasive or pre-invasive breast cancer
223671335|NCT02061527|PROCEDURE|Reconstruction with implant|Immediate breast reconstruction with implant
223671336|NCT02061527|PROCEDURE|Total submuscular coverage|Implant based breast reconstruction with total submuscular coverage
223671337|NCT02061527|PROCEDURE|Partial submuscular coverage|Implant based breast reconstruction with partial submuscular coverage
223671338|NCT05049317|PROCEDURE|Laparoscopic FTME surgery|Nerve plane was defined as the overlying tiny membranous tissue including the nerves, the adipose tissue and the extremely tiny capillaries around the nerve. Following the TME principles, the surgical procedure of FTME was guided by the nerve plane and dissected between the proper fascia of the rectum and nerve plane (the first gap), which could ensure completeness of the nerve plane and the proper fascia of the rectum.
223671339|NCT00400803|DRUG|Gemcitabine, Carboplatin, Bevacizumab|Patients will be treated with Gemcitabine 2000mg/m\^2 intravenously (IV) over 30 minutes, followed by Carboplatin AUC= 3 IV over 30 minutes and Bevacizumab 10 mg/kg IV over 90 minutes 1st infusion, 60 minutes 2nd infusion and 30 minutes for the following infusions. Cycles will be repeated every 2 weeks for a maximum of 6 cycles of therapy. Bevacizumab will continue to be given until disease progression.
223671340|NCT04458324|DRUG|Buspirone Hydrochloride|Subjects take 30 mg buspirone HCl twice a day for 6 months.
223671341|NCT04458324|DRUG|Buspirone placebo|Subjects take a placebo tablet twice a day for 6 months.
223671342|NCT04458324|DEVICE|Noninvasive Ventilation (NIV)|The ventilator will be set in spontaneous mode with a ramp to reach a minimal pressure of 12 centimeters of water (cmH2O) during inspiration and 3 cmH2O during expiration.
223671343|NCT04458324|DEVICE|Sham Non-invasive ventilation (NIV)|The ventilator will be set in spontaneous mode with a ramp to reach a maximal pressure of 5 centimeters of water (cmH2O) during inspiration and 3 cmH2O during expiration.
223671344|NCT04458324|OTHER|Functional Electrical Stimulation Row Training (FESRT)|Subjects participate in a supervised exercise training program 2-3 times/week for 6 months using an adapted indoor rower and FES.
223671345|NCT01227824|DRUG|GSK1349572 (dolutegravir)|GSK1349572 50 mg taken once daily with or without food
223671346|NCT01227824|DRUG|raltegravir|raltegravir 400mg taken twice daily
223671347|NCT01227824|OTHER|GSK1349572 Placebo|GSK1349572 placebo taken once daily
223671348|NCT01227824|OTHER|ABC/3TC|Abacavir/Lamivudine background therapy once daily
223671349|NCT01227824|OTHER|TDF/FTC|Tenofovir/emtricitabine background therapy once daily
223671350|NCT01227824|OTHER|raltegravir Placebo|raltegravir placebo taken twice daily
223671351|NCT02576145|BIOLOGICAL|DT|Diphtheria and Tetanus Toxoid (DT) will be administered intramuscularly as a 1/3 dilution (0.33 flocculation units). The participants will be rechallenged with DT 6 months after Day 29 if failed to show \>=1.5 fold increase in lymphocyte proliferative response but have a humoral response.
223671352|NCT02576145|DRUG|Daclizumab|The fifth dose (1 milligram per kilogram \[mg/kg\]) of daclizumab will be administered in this study to participants who already received four doses (one dose at 1 mg/kg within 24 hours post-transplant and then every other week for 3 doses).
223671353|NCT02576145|BIOLOGICAL|KLH|KLH will be administered intradermally with a dose of 250 mcg for participants aged 2 to less than 12 years, and 500 mcg for participants aged 12 to 19 years. The participants will be rechallenged with KLH 6 months after Day 29 if failed to show specified increase in lymphocyte proliferative response or humoral response.
224252204|NCT05637125|OTHER|aerobic exercise for upper limb|aerobic exercise for upper limb in the form of arm ergometer 3 session/week for 12 weeks. Patient started with warming up for 5 minutes in form of stretching. Patients used arm ergometer without resistance for upper limb aerobic exercise for 20 minutes and instructed to take rest if they feel tired or fatigue. The intensity was according to rate of perceive exertion, after 20 minutes, patients were asked to cool down for 5 minutes in the form of stretching at the end of an exercise session.
224252205|NCT05637125|OTHER|aerobic exercise for lower limb|received aerobic exercise for lower limb in the form of cycling 3session/week for 12 weeks. Patient started with warming up for 5 minutes. Patients used bicycle for lower limb aerobic exercise for 20 minutes and instructed to take rest if they feel tired or fatigue. The intensity was according to rate of perceive exertion. After 20 minutes, patients were asked to cool down for 5 minutes in the form of stretching at the end of an exercise session.
224252206|NCT06560801|DRUG|Dapagliflozin 10mg Tab|Randomization will take place at visit 1 to either the group receiving standard care and dapagliflozin or standard care only.
223671354|NCT04184388|DIETARY_SUPPLEMENT|Hydrolysed Red Ginseng Extract|once a day for 1 p.o., after breakfast(10 ml/day, Hydrolysed Red Ginseng extract for 1g/day) for 12 week
223671355|NCT04184388|DIETARY_SUPPLEMENT|Placebo|once a day for 1 p.o., after breakfast(10 ml/day, Hydrolysed Red Ginseng extract for 0g/day) for 12 week
223671356|NCT06276738|DIAGNOSTIC_TEST|LINFU® (Low Intensity Non-Focused Ultrasound excitation of the pancreas)|Patients will undergo low intensity non-focused ultrasound excitation of the pancreas for a total of 15 minutes. A contrast agent will be administered IV at five minute intervals. The patient will then receive a dose of secretin and the the patient's pancreatic juice will then be collected for a total of 15 minutes.
223671357|NCT00289029|DRUG|Iopamidol 370 mgI/mL|
223671358|NCT06341790|OTHER|jowar based products|jowar based products like jowar flakes, jowar aata, jowar vermicelli is given to the intervention group
223671359|NCT00798278|DRUG|Urokinase|Chest tube with intrapleural urokinase infusion for 3 days
223671360|NCT00798278|PROCEDURE|Video-Assisted Thoracoscopic|Video-Assisted Thoracoscopic decortication
223671361|NCT02660138|BIOLOGICAL|Botulinum toxin type A|600 U intra detrusor injection in two treatment periods (Initial and Retreatment phase) delivered at 30 injection points
223671362|NCT02660138|BIOLOGICAL|Botulinum toxin type A|800 U intra detrusor injection in two treatment periods (Initial and Retreatment phase) delivered at 30 injection points
223671363|NCT02660138|DRUG|Placebo|AbobotulinumtoxinA Placebo 600 U intra detrusor injection in two treatment periods (Initial and Retreatment phase) delivered at 30 injection points
223671364|NCT02660138|DRUG|Placebo|AbobotulinumtoxinA Placebo 800 U intra detrusor injection in two treatment periods (Initial and Retreatment phase) delivered at 30 injection points
223671365|NCT02889029|DEVICE|new 3D device|dedicated tailored stents wrought by 3D computer-assisted conception
223671366|NCT02971033|DRUG|20mg ezetimibe|Participants assigned to this intervention will receive 20mg per day of ezetimibe for 12 weeks.
223671367|NCT02971033|DRUG|Placebo|Participants assigned to this intervention will receive placebo every day for 12 weeks
223671368|NCT02971033|DRUG|40mg ezetimibe|Participants assigned to this intervention will receive 40mg per day of ezetimibe for 12 weeks.
223671369|NCT03265223|DRUG|0.2% ropivacaine|Intraperitoneal instillation versus intraincisional infiltration
223671370|NCT04108117|PROCEDURE|Robotic nipple sparing mastectomy|Robotic nipple sparing mastectomy means nipple sparing mastectomy performed using robotic surgical systems.
223671371|NCT02123914|OTHER|Aerobic exercise with Vit. C|"walking - running on a treadmill at intensity of 65-70% HRR for 30 minutes per session three times a week combined with taking vitamin C supplemented daily with an oral dose of 2,000 mg 2 times/day for 8 weeks.~Nasal challenge with house dust mites with the evaluation of cytokines in nasal lavage fluid,~Nasal peak flow measurement,~Nasal blood flow measurement,~Exercise training regimen including VO2max measurment at baseline and at the end of the experiment."
223671372|NCT02123914|OTHER|Aerobic exercise|"walking - running on a treadmill at intensity of 65-70% HRR for 30 minutes per session three times a week for 8 weeks.~Nasal challenge with house dust mites with the evaluation of cytokines in nasal lavage fluid,~Nasal peak flow measurement,~Nasal blood flow measurement,~Exercise training regimen including VO2max measurment at baseline and at the end of the experiment."
223671373|NCT02123914|OTHER|No exercise|"Sedentary control.~Nasal challenge with house dust mites with the evaluation of cytokines in nasal lavage fluid,~Nasal peak flow measurement,~Nasal blood flow measurement,~Exercise training regimen including VO2max measurment at baseline and at the end of the experiment."
223671374|NCT02659774|BEHAVIORAL|workshop (Motivational intervention)|Through intensive workshop which includes motivation of quitting enhancement, stress management, smoking triggers, cravings and relapse, to provide smoking cessation intervention
223671375|NCT02659774|BEHAVIORAL|Health talk|Health talk provided information about hazards of tobacco (active smoking, second- and third-hand smoke), benefits of quitting smoking and methods to quit smoking
223671376|NCT02659774|BEHAVIORAL|Face to Face counseling|Use motivational interview strategies through face-to-face counseling to provide smoking cessation intervention
223671377|NCT02659774|BEHAVIORAL|Phone counseling|Use motivational interview strategies through telephone counseling to provide smoking cessation intervention
223671378|NCT02659774|BEHAVIORAL|SMS|Use motivational interview strategies through telephone messages to provide smoking cessation intervention
223671379|NCT02659774|BEHAVIORAL|Booklet|A 26-page booklet included information about smoking and diseases, benefits of quitting smoking, methods to quit smoking, how to handle withdrawal symptoms, stress management, declaration of quitting smoking, decisional balance of smoking or quitting
223671380|NCT00308581|BIOLOGICAL|Certolizumab pegol|400mg Certolizumab Pegol, Q4W, administered 4-weekly
223671381|NCT00308581|BIOLOGICAL|Certolizumab pegol|400mg Certolizumab Pegol, Q2W, administered 2-weekly
223671382|NCT00308581|OTHER|Placebo|placebo administered 4-weekly in Active 1
223671383|NCT01630278|DRUG|Ibuprofen|Very premature infants with a large ductus, selected by an early echocardiogram, will receive ibuprofen before 12 hours of life
223671384|NCT01630278|DRUG|Placebo|Very premature infants with a large ductus, selected by an early echocardiogram, will receive placebo before 12 hours of life
223671385|NCT04753424|PROCEDURE|Surgical technique|Description of novel surgical technique using autologous semitendinosus graft as meniscus transplant.
224252207|NCT06485804|OTHER|Smartphone application guided exercises|"Participants in the intervention group will use a smartphone application to execute a self-rehabilitation program. The app will integrate:~* Basic information about neck pain and ergonomic advice.~* A series of evaluation questions on pain and function.~* Appropriate sets of exercises with videos and instructions.~* Daily reminders.~* Evaluation reports providing feedback and adherence."
224252208|NCT01342939|OTHER|Oral Glucose Tolerance Test (OGTT)|50g waterfree glucose dissolved in 300ml water consumed over 5 min.
224252209|NCT01342939|OTHER|iso glycaemic intravenous (iv) glucose infusion (IIGI)|20% glucose
224252210|NCT01342939|DIETARY_SUPPLEMENT|Meal test|Energy drink, 350ml (525 kcal: 65 g carbohydrates, 20 g fat and 21 g protein)
224252211|NCT01342939|OTHER|Sitagliptin|Healthy control subject are given an acute dosage of 100mg the evening before the experimental day, and the same morning in order to increase levels of endogen incretin hormones
224252212|NCT01342939|OTHER|Incretin effect on sulphonyl urea treatment|Subject with MODY who are treated with sulphonyl urea are investigated without medication break prior to examination.
224252213|NCT00164463|DRUG|Moxifloxacin|400 mg po qd 5/7 days per week
224252214|NCT00164463|DRUG|Isoniazid|isoniazid 300 mg po qd 5/7 days per week
224252215|NCT02331823|DRUG|Isoniazid Aminosalicylate Tablets|a regimen consists of 5 anti-TB drugs (Isoniazid Aminosalicylate Tablets+pyrazinamide tablets+ethambutol tablets+rifabutin capsules+moxifloxacin tablets)to treat retreatment pulmonary tuberculosis patients. The total treatment course is 5 months.
224252216|NCT02331823|DRUG|Streptomycin injectable|standardized regimen 2 months of streptomycin injectable + isoniazid tablets + ethambutol tablets + rifampicin capsules + pyrazinamide tablets and 6 months of isoniazid tablets + ethambutol tablets + rifampicin capsules or 3 months of isoniazid tablets + ethambutol tablets + rifampicin capsules + pyrazinamide tablets and 6 months of isoniazid tablets + ethambutol tablets + rifampicin capsules to treat Arm B patients as a control to arm A.The treatment course is 8-9 months.
224252217|NCT02030223|PROCEDURE|Transversus abdominis plane block|ultrasound guided transversus abdominis plane block
224252218|NCT06040723|DEVICE|EndoMind|The EndoMind system is equipped with an AI model for predicting the Hill grade during gastroscopy.
224252219|NCT06115317|OTHER|Prism|Prism
223671386|NCT00899353|DIETARY_SUPPLEMENT|Omega 3 Fatty Acid|Omega 3 supplementation will be initiated at three 1250 mg capsules daily for the first month. If dose is well tolerated, it will be increased to six 1250 mg capsules daily for 30 days, and finally to nine 1250 mg capsules daily. Treatment period is 12 months.
223671387|NCT03012126|BEHAVIORAL|Healthy Weight Clinic|
223671388|NCT03012126|BEHAVIORAL|Healthy Weight and Your Child|
223671389|NCT02403466|BEHAVIORAL|Resident Handoff Bundle|1\) team training, 2) verbal mnemonics, and 3) standardization of written/computerized handoff tools
223671390|NCT02060916|DRUG|PAZ320|Single-center pilot study, open label dose escalation design
223671391|NCT02438475|DEVICE|Mynx Vascular Closure System|MynxGrip is being used to seal femoral vein access sites while reducing times to hemostasis and ambulation in patients who have undergone diagnostic or interventional endovascular procedures utilizing a 5F, 6F or 7F procedural sheath.
223671392|NCT02438475|OTHER|Manual Compression|manual pressure applied to your groin for approximately 5-10 minutes
223671393|NCT02894697|DEVICE|Angiography-guided PCI with BVS|Everolimus-eluting bioresorbable vascular scaffold (Absorb, Abbott Vascular, Santa Clara, CA, USA) was made from a bioabsorbable polylactic acid backbone which is coated with a more rapidly absorbed polylactic acid layer that contains and controls the release of the antiproliferative drug, everolimus. PCI will be performed with BVS under conventional coronary angiography without any other intravascular imaging modality. After PCI, postprocedural OCT will be evaluated to find OCT-defined suboptimal results requiring additional PCI. If there is OCT-defined suboptimization, additional PCI will be performed including balloon angioplasty or additional stent or BVS implantation for scaffold optimization. Further postprocedural OCT will be also evaluated whether scaffold implantation is fully optimized or not.
223671394|NCT02894697|DEVICE|Optical coherence tomography-guided PCI with BVS|Everolimus-eluting bioresorbable vascular scaffold (Absorb, Abbott Vascular, Santa Clara, CA, USA) was made from a bioabsorbable polylactic acid backbone which is coated with a more rapidly absorbed polylactic acid layer that contains and controls the release of the antiproliferative drug, everolimus. For optimized PCI, both conventional coronary angiography and optical coherence tomography can be used before stent implantation. After PCI, postprocedural OCT will be evaluated to find OCT-defined suboptimal results requiring additional PCI. If there is OCT-defined suboptimization, additional PCI will be performed including balloon angioplasty or additional stent or BVS implantation for scaffold optimization. Further postprocedural OCT will be also evaluated whether scaffold implantation is fully optimized or not.
224252220|NCT06115317|OTHER|Sham|Sham
224252221|NCT01793558|PROCEDURE|Forced-air warming|In the intervention group a forced-air cover (Level 1 Snuggle Warm Upper Body Blanket, Smiths Medicals) will be positioned over the upper body of the patients laying on the operating table just beginning after the spinal block.
224252222|NCT00834418|DRUG|Leflunomide 20 mg Tablets|1 x 20 mg, single-dose fasting
224252223|NCT00834418|DRUG|ARAVA™ 20 mg Tablets|1 x 20 mg, single-dose fasting
224252224|NCT02540603|DEVICE|F&P Jupiter Full Face Mask|Investigative F\&P Jupiter full face mask to be used for OSA therapy
224252225|NCT04277403|RADIATION|Hippocampal Avoiding Whole Brain Radiation Therapy with Simultaneous Integrated Boost|Hippocampal avoiding Whole brain radiation therapy (HA-WBRT) with volumetric modulated arc therapy (VMAT) with a prescribed dose of 30Gy in 12 fractions, 2.5Gy per fraction and a simultaneously integrated boost (SIB) to each brain metastasis of 51Gy to 95% of PTV in 12 Fractions, 4.25Gy per fraction.
224252226|NCT04277403|RADIATION|Single session or hypofractionated stereotactic radiosurgery|Single session or hypofractionated stereotactic radiosurgery (SRS) of multiple brain metastases. Single session SRS will be delivered in 18 to 22Gy to the tumour encompassing 80% Isodose. Hypofractionated stereotactic radiosurgery (HfSRS) will be delivered in 5 sessions of 6Gy each to the tumour encompassing 80% isodose.
224252227|NCT01705574|DRUG|E/C/F/TDF|150/150/200/300 mg FDC tablet administered orally with food once daily
224252228|NCT01705574|DRUG|ATV|300 mg capsule administered orally with food once daily
224252229|NCT01705574|DRUG|RTV|100 mg tablet administered orally with food once daily
224252230|NCT01705574|DRUG|FTC/TDF|200/300 mg tablet administered orally with food once daily
224252231|NCT01705574|DRUG|E/C/F/TDF Placebo|Tablet administered orally with food once daily
224252232|NCT01705574|DRUG|ATV Placebo|Tablet administered orally with food once daily
224252233|NCT01705574|DRUG|RTV Placebo|Capsule administered orally with food once daily
224252234|NCT01705574|DRUG|FTC/TDF Placebo|Tablet administered orally with food once daily
224252235|NCT01705574|DRUG|E/C/F/TAF|150/150/200/10 mg FDC tablet administered orally with food once daily
224252236|NCT00545805|PROCEDURE|Roux-en-Y Gastric Bypass plus total omentectomy|Roux-en-Y Gastric Bypass plus total omentectomy
224252237|NCT00545805|PROCEDURE|Roux-en-Y Gastric Bypass|Roux-en-Y Gastric Bypass without omentectomy
224252238|NCT05257564|DEVICE|Determine the accuracy of quantitative measurements of GLU, HbA1c,CHOL and CRE with POC devices compared to a laboratory reference method (Roche)|Fingerstick capillary blood will be collected according to each manufacturer's Instructions for use. The fingerstick capillary blood samples will be used immediately on the point-of-care assays. The venous blood will be collected in specific tubes for plasma (GLU), for whole blood (HbA1c) and for serum (CREP, CHOL). Plasma will be separated by centrifugation at the PHC facility and health post and aliquots will be prepared. Serum will be left to clot prior to centrifugation and serum aliquots will be prepared at the PHC facility and health post. The samples will be stored until transfer to the BPKIHS reference lab.
223671395|NCT04583059|OTHER|Taping|A hard-preventive Zinc oxide tape was used in this study. Taping procedure consists of three separate steps: First step involved application of the anchor tape, which achieved by applying the tape circumferentially just above the malleolar level at the lo
223671396|NCT04541277|DRUG|Tislelizumab|Tislelizumab combined with DNA demethylation agent +/- CAG regimen
223671397|NCT01247298|COMBINATION_PRODUCT|Stereotactic Body Radiation Therapy (SBRT)|This investigational study will evaluate the combination of TACE along with high dose SBRT. TACE has been used extensively in the palliative treatment of hepatocellular carcinoma (HCC). It will be performed by the Interventional Radiologist prior to radiation therapy.
223671398|NCT03027791|BEHAVIORAL|Virtual Reality|Participation in Virtual Reality experiences focused on a) education about the effects of high sodium foods on coronary arteries, blood pressure, the kidneys, and the cerebral vasculature, and b) stress management.
223671399|NCT03027791|BEHAVIORAL|Group Sessions|12 weekly group sessions that will provide education on topics related to hypertension, dietary sodium, physical activity and stress.
223671400|NCT00878761|BIOLOGICAL|STX-100|SC, single dose followed by multiple dose
223671401|NCT02029378|DRUG|Eculizumab|
223671402|NCT01284491|DEVICE|PEAK PlasmaBlade 4.0|The PEAK PlasmaBlade will be used for the entirety of the operation, including the skin incision.
223671403|NCT01284491|DEVICE|Traditional Electrosurgery with scalpel|Scalpel will be used for the skin incision and traditional electrosurgery for the subcutaneous dissection.
223671404|NCT01375855|PROCEDURE|Percutaneous transluminal Coronary Angioplasty|Coronary artery stent implantation
223671405|NCT04486300|PROCEDURE|Pneumatic reduction and Laparotomy|Pneumatic reduction is the main intervention for suitable cases and If failed a laparotomy exploration and surgical reduction is done to save life
223671406|NCT03005184|DRUG|Valsartan 80 mg bid|oral medication during run-in and washout period
223671407|NCT03005184|DRUG|Enalapril 10 mg bid|oral medication
223671408|NCT03005184|DRUG|Sacubitril-Valsartan 200 mg bid|oral medication
223671409|NCT03005184|DRUG|Icatibant|intravenous medication
223671410|NCT03005184|DRUG|Placebo|intravenous medication
223671411|NCT01033149|DRUG|N-acetylcysteine|N-acetylcysteine, flexible dose 1200-2400mg/day
223671412|NCT01123993|DEVICE|Music CD|During 4-week interventional period of each group, a researcher gives a CD to care giver and advises him/her to open the music for patient for at least 60 minutes daily, after dinner to bedtime. Meanwhile, the care giver notes the exact duration that patient actually listens to it in the calendar provided and returns the CD and document to the researcher at the end of interventional period.
223671413|NCT00852488|PROCEDURE|Placement of transthoracic catheter|Placement of transthoracic catheter into the inferior vena cava
223671414|NCT04503733|DRUG|Q4W GMA301 IV injections (300 mg)|Each cohort will contain 12 subjects, 9 of whom will be administered active GMA301 and 3 of whom will be administrated placebo.
223671415|NCT04503733|DRUG|Q4W GMA301 IV injections (600 mg)|Each cohort will contain 12 subjects, 9 of whom will be administered active GMA301 and 3 of whom will be administrated placebo.
223671416|NCT04503733|DRUG|Q4W GMA301 IV injections (1000 mg)|Each cohort will contain 12 subjects, 9 of whom will be administered active GMA301 and 3 of whom will be administrated placebo.
224252239|NCT00949143|OTHER|rear axle position|Wheelchair axle position located as far towards the rear of the wheelchair as possible.
224252240|NCT00949143|OTHER|forward axle position|Wheelchair will have the axle at least 5cm farther forward than the most rear axle position.
224252241|NCT02006212|PROCEDURE|If any intraoperative EEG abnormality and/or asymmetry is detected a cerebral CT scan will be performed in the immediate postoperative period|
224252242|NCT00777023|DRUG|Gabapentin Extended-Release (G-ER) 1200 mg|G-ER 1200 mg daily dosage given as two 600-mg tablets.
224252243|NCT00777023|DRUG|Gabapentin Extended-Release (G-ER) 1800 mg|G-ER 1800 mg daily dosage given as one 600-mg tablet in the morning and two 600-mg tablets in the evening.
224252244|NCT00777023|DRUG|Placebo|Matching placebo dosages of 1200 mg daily (two 600-mg tablets) and 1800 mg daily (one 600-mg tablet in the morning and two 600-mg tablets in the evening).
224322168|NCT01864707|OTHER|usual care|Patients in this group will follow the same treatment for fatigue they received at study entry
223671417|NCT04503733|DRUG|Q4W GMA301 IV injections (1800 mg)|Each cohort will contain 12 subjects, 9 of whom will be administered active GMA301 and 3 of whom will be administrated placebo.
223671418|NCT04503733|OTHER|Q4W placebo IV injections|Placebo is indistinguishable from GMA301.
223671419|NCT00333944|DRUG|Pralidoxime(drug)|
224252245|NCT06457308|BIOLOGICAL|Physical training of agility|A grouped training for older adults in the community. The training classed lasted for 12 weeks, one session a week for 120 mins, and are under instructed by a trained experienced sport instructor. Use rope ladders and cones to perform multiple tasks of direction changes, acceleration and deceleration of footsteps, hand and foot coordination and spatial orientation training,
224322169|NCT04767399|BEHAVIORAL|protaper next|rotary systems used on patients need root canal treatment
224252246|NCT06457308|BIOLOGICAL|Physical training of resistance|A grouped training for older adults in the community. The training classed lasted for 12 weeks, one session a week for 120 mins, and are under instructed by a trained experienced sport instructor. Resistance training for upper and lower limb muscles and core muscles, including squats, use of elastic bands, and simple bars
224252247|NCT05464836|DRUG|CB-103|Given by PO
224252248|NCT05464836|DRUG|Venetoclax|Given by PO
224252249|NCT00200785|DIETARY_SUPPLEMENT|garlic powder added to ambient water|consumed 2.7 grams of garlic powder added to ambient water (equivalent to 8 grams fresh or raw garlic) in a sandwich, once a day for four weeks
224252250|NCT00200785|DIETARY_SUPPLEMENT|garlic powder added to boiling water|consumed 2.7 grams of garlic powder added to boiling water (equivalent to 8 grams of cooked garlic) in a sandwich, once a day for four weeks
224252251|NCT04919005|OTHER|Virtual Environment|The Virtual Environment was called SorrisoTur and consists of 10 mini-games with difficulty levels in a limited number of cities and mini-games distributed in a thematic scenario of the map of Brazil. The virtual environment consists of the cognitive training mini-games within a theme for all screens, mini-games, and information. The interventions with the Virtual Environment were administered in periods of one hour, twice a week, for a month.
224252252|NCT06407505|OTHER|Acupressure group|LI4 acupressure applied group.
224252253|NCT06407505|OTHER|Placebo group|Group where acupressure was applied to an area 1.5 cm away at the LI4 acupressure point
224252254|NCT02419339|PROCEDURE|Extravesical ureteral reimplantation|Extravesical ureteral reimplantation with or without tapering
224252255|NCT02729090|OTHER|Device: treadmill|Aerobic training on a treadmill continuously with speed and wave periodization. Frequency twice per week ( 2x ) for twelve weeks. Device: treadmill.
224252256|NCT02729090|OTHER|Device: treadmill Train_Comb_aerobic|Device: treadmill Train\_Comb\_aerobic. strength training with free weights, followed by active recovery on a treadmill with fixed intervals of 60 to 120 seconds between each workforce of series. Device: treadmill Train\_Comb\_aerobic
224252257|NCT06628050|DEVICE|ORIGIN® PS Modular devices|Consecutive eligible subjects have been included which have been treated with the ORIGIN® PS Modular devices.
224252258|NCT02659150|DRUG|tocilizumab|subjects will be treated with 162mg of weekly subcutaneous tocilizumab in an open-label manner, this will be done addition to MTX or monotherapy. On subsequent weeks after the first dose of tocilizumab, subjects will be instructed to inject the full amount of syringe according to the directions provided in the Instructions For Use (IFU).
223671420|NCT00709579|DRUG|RV3391A|A standardized quantity of each product will be applied on the evening on anterior side of forearm. The side of application will be randomized.
223671421|NCT00709579|DRUG|Placebo|placebo
223671422|NCT04668261|OTHER|Advanced imaging investigation|MRI imaging
223671423|NCT05761795|DRUG|IVMED 85|Eye drop
223671424|NCT05761795|DRUG|Placebo|Placebo eye drop
223671425|NCT06058208|BEHAVIORAL|Olfactory stimulation|Olfactory stimulation: Mothers will be made to smell their babies' odor.
223671426|NCT06058208|BEHAVIORAL|Visual stimulation|Mothers will be shown video images of their babies.
223671427|NCT03900325|DRUG|Nimacimab|2.5 mg/kg
223671428|NCT03900325|DRUG|Placebo|0.9% sodium chloride
223671429|NCT05384951|DIETARY_SUPPLEMENT|HMB + Vitamin D3|The supplement will be taken orally twice daily. Participants will take 2 blended HMB + Vitamin D3 tablets in the morning and 2 tablets in the evening for 12 weeks.
223671430|NCT00252941|DEVICE|Memokath 028SW Urethral Stent|
223671431|NCT02489422|OTHER|Laboratory Biomarker Analysis|Correlative studies
223671432|NCT02489422|OTHER|Questionnaire Administration|Ancillary studies
223671433|NCT02489422|OTHER|Daily Survey Administration|Ancillary studies
223671434|NCT02489422|BEHAVIORAL|Yoga Skills Training|The YST intervention consists of four 30 minute in-person sessions that instructs skills to enhance mindfulness and promote relaxation. Participants will also be encouraged to practice daily at home.
223671435|NCT02489422|BEHAVIORAL|Attention Control|The AC intervention consists of four 30 minute in-person sessions of supportive conversation. In addition, the interventionist will recommend that the patients write brief diary entries daily at home.
223671436|NCT02489422|OTHER|Actigraphy Assessment|Ancillary studies
224252259|NCT06015035|DRUG|Sintilimab and anlotinib in combination with chemotherapy|Neoadjuvant treatment involved administering anlotinib (10 mg orally, once a day, 2 weeks on and 1 week off) for anti-angiogenesis and sintilimab (200 mg) and chemotherapyfor three cycles. Surgical treatment was performed 4-6 weeks after the last chemotherapy cycle was completed. The primary endpoints assessed were pathological complete response (pCR) rate and safety.
224252260|NCT03939364|DRUG|SBS-101|Isotretinoin Oral-Adhesive Film
224252261|NCT03939364|DRUG|Placebo|Placebo
224252262|NCT05065346|DEVICE|Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT|An intratumoral insertion of a seed(s), loaded with Radium-224, securely fixed in the seeds. The seeds release by recoil into the tumor short-lived alpha-emitting atoms.
224252263|NCT06061146|DRUG|Arm A|anti-PD-1 immunotherapy
224252264|NCT06061146|DRUG|Arm A|chemotherapy
224252265|NCT06061146|RADIATION|Arm A|Radiation Concurrent Radiation, 1.8Gy/f, 28f
224252266|NCT06061146|DRUG|Arm B|chemotherapy
224252267|NCT06061146|RADIATION|Arm B|Radiation Concurrent Radiation, 1.8Gy/f, 28f
224252268|NCT03804762|PROCEDURE|the third space robotic and endoscopic cooperative surgery|This technique combines the endoscopic techniques and the merits of Da Vinci surgical robot, such as flexible and precise instruments, tremors filtering system and a 3-D surgical view, and take full advantage of the methodology of the third space to dissect gastric submucosal tumors.
224252269|NCT03995030|DIAGNOSTIC_TEST|massively paralleled sequencing|Whole genome sequencing libraries will be generated and sequenced in batches on the Illumina MiSeq. FASTQ files will be demultiplexed and then aligned to microbial genomes using Phylosift.
224322170|NCT05488964|BEHAVIORAL|Exercise|Supervised endurance training with moderate-to-high intensity 3-4 times weekly.
224322171|NCT04152291|DIETARY_SUPPLEMENT|Ethyl-Eicosapentaenoic Acid (E-EPA)|3,9 grams of E-EPA (Icosapent ethyl) is added to participants' normal diet.
224322172|NCT03502460|OTHER|Operating Room Fluid Administration Lung Ultrasound|Use of lung ultrasound to limited fluid administration
224322173|NCT05382559|DRUG|ASP3082|Intravenous Infusion
224322174|NCT05382559|DRUG|Cetuximab|Intravenous Infusion
224252270|NCT06324045|OTHER|Deprescribing|"1. The clinical pharmacist will review the patient's medications using validated screening tools, draft a deprescribing plan of the potential problematic medications, consult with the physician (MDT-CKD nephrologist), make the needed amendments, and document in the medical records.~2. The plan will be implemented and monitored during the patient's appointments for 1- 2 weeks at the center by the nephrologist.~3. The medication plan will be reconciled before discharge from dialysis or a planned appointment, and patients will be given a deprescribing card containing medication information. A note will be posted on CERNER as well. The primary care physician might also be contacted by the MDT-CKD team for consultation or any inquiries regarding the patient's condition or medications.~4. The MDT-CKD specialist nurse will conduct 3 post-appointment follow-up phone calls on day 2, day 7, and day 28 to enquire about any withdrawal symptoms or any concerns of the patient."
224252271|NCT02945800|DRUG|nab-Paclitaxel|nab-Paclitaxel: 125 mg/m\^2 intravenously (IV)
224252272|NCT02945800|DRUG|Gemcitabine|Gemcitabine: 1000 mg/m\^2 intravenously (IV)
223671437|NCT04527393|DRUG|Individualized oral morphine|"Analgesic effectiveness is assessed using the Faces Scale by the parents every four hours from postoperative Day 1 to Day 10 (eg: 8:00, 12:00, 16:00, and 20:00, each day).~If the Faces Scale score \> 6, the child receive rescue oral morphine analgesia. Patients with positive results of fentanyl test receive oral morphine 100μg/kg per dose, while patients with negative results receive oral morphine 500μg/kg per dose."
223671438|NCT04527393|DRUG|Conventional oral morphine|"Analgesic effectiveness is assessed using the Faces Scale by the parents every four hours from postoperative Day 1 to Day 10 (eg: 8:00, 12:00, 16:00, and 20:00, each day).~If the Faces Scale score \> 6, the child receive rescue oral morphine analgesia. Patients receive oral morphine 200μg/kg per dose."
223671439|NCT01311284|DEVICE|Macintosh laryngoscope, Airtraq NT, Mcgrath laryngoscope|Each participant will use the Macintosh laryngoscope (blade No. 3), laryngoscope Airtraq NT and Mcgrath Laryngoscope under conditions of normal and difficult airway in different simulated scenarios.
223671440|NCT01311284|DEVICE|Macintosh laryngoscope|intubate with the macintosh laryngoscope
223671441|NCT01311284|DEVICE|McGrath|Intubate with McGrath device
223671442|NCT01311284|DEVICE|Airtraq Nasotracheal|intubate with Airtraq Nasotracheal
223671443|NCT04922047|DRUG|tislelizumab and BCG|Tislelizumab 200 mg administered by intravenous infusion every 3 weeks in first year and continue to second year based on physician choose. BCG 120 mg induction therapy administered via intravesical instillation (once weekly for 6 weeks). BCG induction therapy is followed by maintenance therapy (once weekly for 3 weeks at months 3, 6, 12, 18, 24m).
223671444|NCT04422340|OTHER|Group1|"* Comorbidities (CIRS-G scale),~* Functional status of the patient with~  * Clinical frailty scale (1 month before infection)~ * ADL score (1 month before infection)~* Biological data~  * Blood group~ * TP, D-dimers, CRP, creatinine level at the patient's entry, triglyceridemia, fibrinogen, ferritin~ * Parameters derived from the platelet formula count on D1 of the start of intensive care (lymphocytes, neutrophils, platelets, average platelet volume, red blood cell distribution index), SYSMEX data (IG: Immature granulocytes; HFLC: high fluorescent lymphocyte count)~* Resuscitation outcomes~  * LDH rate at the start of intensive care~ * PaO2 / FiO2 ratio at the start of intensive care~ * IGSII / SASPII score (simplified acute physiology score) on D1 of the start of intensive care~ * SOFA score (sepsis-related organ failure assessment): a posteriori estimate based on IGSII / SASPII~ * Delay between the appearance of the first signs of infection and admission to intensive care"
223671445|NCT03935113|OTHER|Kinesio taping|In KT group, KT was applied using the insertion-origin muscle and space-correction technique of affected upper limb with stroke patients.
223671446|NCT06113380|DEVICE|NTUH-ii, am upper limb rehabilitation robot arm|Rehabilitation programs are planned based on the subject's capabilities, and the differences between assisted rehabilitation with a robot and traditional rehabilitation are compared.
223671447|NCT06113380|OTHER|Traditional upper limb physical therapy|Traditional upper limb physical therapy is performed by the therapist.
223671448|NCT01671527|PROCEDURE|Transcranial magnetic stimulation (TMS)|We will test the sensory system and its interaction with the motor cortex by using TMS. For these tests, you will sit in a chair that looks like one you would find at the dentist's office. A nerve stimulator will be placed on the wrist of your right hand to stimulate the median and ulnar nerves. The intensity of the nerve stimulator will be gradually increased until the right thumb begins to twitch. A magnetic coil will be placed on the scalp on the left side of your head, overlying the brain's motor cortex, to stimulate the brain's output to the muscles in the opposite hand. This procedure will be repeated using the left wrist and the right side of your head.
223671449|NCT05170867|DIETARY_SUPPLEMENT|Hafnia alvei HA4597™|One capsule of probiotic supplement, twice a day, to be taken with water, during each breakfast and lunch (approx. 5 minutes after starting eating), for 90 days. Two capsules of the dietary supplement contain 5x107 CFU of Hafnia alvei HA4597™, 5 mg of zinc and 20 μg of chromium.
223671450|NCT05170867|OTHER|Placebo|One capsule of placebo, twice a day, to be taken with water, during each breakfast and lunch (approx. 5 minutes after starting eating), for 90 days. Two capsules of the placebo contain 5 mg of zinc and 20 μg of chromium.
223671451|NCT05061056|OTHER|Russian current 10%|Russian current with 2500 Hz, modulated in bursts of 50 Hz, 200 µs and 10% duty cycle - 2 ms bursts and 18 ms interbusrts
223671452|NCT05061056|OTHER|Russian current 20%|Russian current with 2500 Hz, modulated in bursts of 50 Hz, 200 µs and 20% duty cycle - 4 ms bursts and 16 ms interbusrts
223671453|NCT05061056|OTHER|Aussie current 10%|Aussie current with 1000 Hz, modulated in bursts of 50 Hz, 500 µs and 10% duty cycle - 2 ms bursts and 18 ms interbusrts
223671454|NCT05061056|OTHER|Aussie current 20%|Aussie current with 1000 Hz, modulated in bursts of 50 Hz, 500 µs and 20% duty cycle - 4 ms bursts and 16 ms interbusrts
223671455|NCT03693560|DRUG|Vildagliptin 50 mg Oral Tablet|Patients who the endocrinologist prescribed them Vildagliptin 50 mg Oral Tablet plus their Metformin 1000 mg Oral Tablet to control their blood sugar level.
223671456|NCT03693560|DRUG|Metformin 1000 mg Oral Tablet|Patients with Coronary artery diseases.and uncontrolled Diabetes Mellitus type 2 who's taking Metformin 1000 mg Oral Tablet only will be enrolled from endocrinology clinic.
224252273|NCT06207123|DRUG|LP-118|LP-118 is an experimental anti-cancer drug that is currently being studied in clinical trials for multiple types of hematological cancers and solid tumors.
224252274|NCT06207123|DRUG|Ponatinib|Ponatinib is used to treat certain types of chronic myeloid leukemia (CML; a type of cancer of the white blood cells).
224252275|NCT06207123|DRUG|Vincristine|Vincristine is a chemotherapy medication used to treat various types of cancer, including leukemia, lymphoma, neuroblastoma, and Wilms tumor. Vincristine belongs to the category of vinca alkaloids, a class of drugs that function by impeding the proper division of cancer cells.
224252276|NCT06207123|DRUG|Dexamethasone|Dexamethasone is used to treat cancer, to decrease inflammation and sometimes used before and after chemotherapy to prevent or treat nausea and/or vomiting. It is given in the vein (IV) or orally (by mouth)
224252277|NCT06207123|DRUG|Methotrexate|Methotrexate is a drug used to treat cancer of the blood, bone, lung, breast, head, and neck. It can also treat rheumatoid arthritis and psoriasis.
224252278|NCT04233320|DEVICE|silicone cream containing Allium Cepa extract|silicone cream containing Allium Cepa extract contains 10% of Allium cepa bulb extract.
224252279|NCT04233320|DEVICE|Commercial scar gel|Commercial scar gel is a topical silicone gel. It contains cyclic and polymeric siloxanes and Vitamin C ester.
224252280|NCT00470769|PROCEDURE|Color-Doppler Ultrasound, 99mTc-DTPA scintigraphy|
224252281|NCT03245086|DEVICE|Transanal hemorrhoid dearterialization|The hemorrhoids are operated in their natural position and not distorted by eversion The proctoscope is fully introduced transanally to reach the lower rectum. Under Doppler guidance, six arterial signals are found circumferentially above the dentate line. The approach to make the 'dearterialization' involves the transfixation of the rectal mucosa and submucosa to entrap the artery using a suture. Mucopexy is performed after the artery ligation with the same suture used for the dearterialization. Finally, the suture is tied to fix the mucopexy.
224252282|NCT03245086|PROCEDURE|Ferguson hemorrhoidectomy|The hemorrhoids are operated in their natural position and not distorted by eversion. A Ferguson-Hill retractor is used to expose the hemorrhoids. Dissection with scissors is directed up to the dentate line where the fibers of the sphincter muscles are exposed and only a mucosal pedicle remains attached. A Buie-Smith crushing clamp is applied to this pedicle and the hemorrhoidal mass is excised at the superior level of the clamp. The pedicle is then ligated and the crushing clamp is removed. After dissection of the intermuscular septum is complete, the margins of the wound are drawn upward into the anal canal with stitches and are secured to the pedicle by the same suture. The remainder of the wound is closed with a stitch tied at the outer extremity of the wound using the same suture.
224252283|NCT00197769|BIOLOGICAL|9 valent pneumococcal con jugate vaccine|
224252284|NCT01798212|PROCEDURE|endoscopic full thickness plication|
224252285|NCT05078944|DEVICE|Active acupuncture|Acupoints: Principal: GV20, EX-HN1, GV24 and bilateral PC6, HT7, ST36, KI3, SP6. Additional: CV6 and bilateral GB39, ST40, SP10 Sterile stainless steel disposable acupuncture needles (size 0.30 × 50 mm, Hwato brand, China) are used. After sterilization, a small plastic ring will be fixed over the acupuncture point with plaster to facilitate maintenance of blinding for the participant, and then the needle will be inserted through the plaster inside the ring. The electric stimulator (SDZ-Ⅲ electroacupuncture apparatus, Hwato brand, China) is applied to GV20, GV24, bilateral PC6 and HT7, dilatational wave, 10/50 Hz and tolerable electric current. Needles placed in other acupoints will be manually stimulated by rotation every 15 minutes. Each session lasts for 45 min.
224252286|NCT05078944|DEVICE|Sham acupuncture|"Sham acupoints: SA1 (5 cun lateral to GV5), SA2 (5 cun lateral to GV4), SA3 (1 cun lateral to BL56).~After sterilization, pragmatic placebo needles with blunt tip (size 0.30 × 50 mm, Hwato brand, China) are used. When their tips are pressed against the skin through plastic rings, participants will feel a pricking sensation. The electric stimulator is applied to bilateral SA1 and SA2 with no current output. The mental wire has been cut off with a same outlook as the electroacupuncture group. Needles placed in SA3 will be manually rotated every 15 minutes. Each session lasts for 45 min."
224252287|NCT05078944|DRUG|Donepezil Hydrochloride|Donepezil hydrochloride (5 mg/capsule, Weicai Pharmaceutical Co., Ltd, China) is to be taken 5 mg daily.
223671457|NCT03693560|DRUG|Glimepiride upto 4 mg Oral Tablet|Patients who the endocrinologist prescribed them Glimepiride 4 mg oral tablet plus their Metformin 1000 mg Oral Tablet
223671458|NCT02412514|BIOLOGICAL|bOPV (three dose)|bOPV administered at 6, 10, and 14 weeks of age.
223671459|NCT02412514|BIOLOGICAL|bOPV (two dose)|bOPV administered at 10 and 14 weeks of age.
223671460|NCT02412514|BIOLOGICAL|IPV|IPV administered at 6 weeks of age
223671461|NCT02694757|DEVICE|Ostom-i device|The Ostom-i alert (OIA) is a discrete novel device which clips onto any ostomy bag from edge to edge and measures the horizontal tension between the edges over time, as a result of stool volume in the ostomy. It is an FDA approved medical device.
223671462|NCT00667173|DRUG|IDP-115|Topical application for 12 weeks
223671463|NCT00667173|DRUG|Vehicle|Topical application for 12 weeks
223671464|NCT00667173|DRUG|Vehicle|Topical application for 12 weeks
223671465|NCT01607827|PROCEDURE|Polyp removal upon insertion and withdrawal|"Endoscopic procedures:~All polypectomies in the study groups were performed using the same techniques as in the standard care of non-study patients, using snare loops, hot biopsy forceps, with and without submucosal injection of saline/epinephrine. Polyps larger than 3 mm were removed by snare, polyps smaller than 4 mm were removed by cold biopsy. There were no differences upon insertion or withdrawal.~The endoscopist removed all visible polyps instantly regardless whether advancing the instrument to the cecum or pulling back."
223671466|NCT01607827|PROCEDURE|Polyp removal upon withdrawal only|"Endoscopic procedures:~All polypectomies in the study groups were performed using the same techniques as in the standard care of non-study patients, using snare loops, hot biopsy forceps, with and without submucosal injection of saline/epinephrine. Polyps larger than 3 mm were removed by snare, polyps smaller than 4 mm were removed by cold biopsy. There were no differences upon insertion or withdrawal.~The endoscopist advanced the endoscope to the cecum without removing polyps. Upon withdrawal, all visible polyps were removed successively by standard techniques."
224252288|NCT04770324|DEVICE|Interposition supraciliary implant|Surgical placement of 2 interposition supraciliary implant in the supraciliary space
224252289|NCT06079736|DRUG|PGN-EDO51|IV infusion
224252290|NCT01115465|DEVICE|Macroplastique|Macroplastique is an injectable soft-tissue bulking agent used to treat stress urinary incontinence (SUI) primarily due to intrinsic sphincter deficiency (ISD).
224252291|NCT00448019|DRUG|Fludarabine|25 mg/m\^2 IV over 30 minutes daily for 3 days
224252292|NCT00448019|DRUG|Cyclophosphamide|250 mg/m\^2 IV over 30 minutes daily for 3 days
224252293|NCT00448019|DRUG|Rituximab|375 mg/m\^2 IV on Day 1 by prolonged infusion. All subsequent doses 500 mg/m\^2 IV 30-minute infusion.
223771802|NCT03920397|BIOLOGICAL|Infusion of adipose tissue-derived stem/stromal cells and oral Cholecalciferol supplementation|The investigators will acess area under the curve of C-peptide after a liquid mixed meal (Glucerna®), considering the time 0 (basal), 30, 60, 90 and 120 minutes in each follow-up outpatient visit (3 \[T3\], 6 \[T6\], 12 \[T12\], 18 \[T18\], and 24 \[T24\] months after the adipose tissue-derived stem/stromal cells infusion). Other Clinical and Pancreatic Function Evaluation that wil be assess are: Weight, height, body mass index (BMI), blood pressure, heart frequency, frequency of hypoglycemia and insulin dose/kg of body weight, blood count, lipids, renal and hepatic function, thyroid stimulating hormone, free tyroxine, antithyroglobulin antibody, calcium, phosphorus and 25-Hydroxy Vitamin D.
223771803|NCT02881814|DIAGNOSTIC_TEST|Lung and diaphragm ultrasound|The ultrasound physiotherapist/operator performs a lung and diaphragm ultrasound. He is blinded to the patient's status and clinical physiotherapist examination. He/she is not involved in patient management or patient clinical decision-making. The ultrasound findings are recorded in the LUS report. The LUS report is reported to the clinical physiotherapist and to the intensivist. The ultrasound diagnosis(es) is recorded.
224252294|NCT00448019|DRUG|Bevacizumab|10 mg/Kg IV on Day 3, course 1 over 30-90 minutes
224252295|NCT02543203|BIOLOGICAL|Reconnect|Topical Essential Oils mixture and aromatic method
224252296|NCT02543203|BIOLOGICAL|Coconut oil Comparator|Topical Essential Oils mixture and aromatic method
224252297|NCT00996788|DRUG|Rebamipide|Rebamipide 100 mg tid for 28 days
224252298|NCT06370507|DEVICE|Electrical impedance tomography assessment of ventilation distribution in course of sedation/general anesthesia for pediatric surgery|Assessment of ventilation distribution through electrical impedance tomography in pediatric patients subjected to sedation or general anesthesia for surgery
224252299|NCT00089661|DRUG|Placebo|60 mg (1.0 mL) administered subcutaneously every six months, beginning on Study Day 1, for a total treatment period of 24 months
224252300|NCT00089661|DRUG|AMG 162 / Denosumab|60 mg (1.0 mL) administered subcutaneously every six months, beginning on Study Day 1, for a total treatment period of 24 months
224252301|NCT00300911|DRUG|Rosiglitazone(drug), cardiac adverse effects|
224252302|NCT00614471|DRUG|Entecavir|0.5mg po daily for 24 weeks
224252303|NCT00614471|DRUG|Entecavir|0.5mg po daily from week 13 to week 36
224252304|NCT00614471|DRUG|peginterferon alfa-2a [Pegasys]|180 micrograms sc/week for 48 weeks
224252305|NCT00614471|DRUG|peginterferon alfa-2a [Pegasys]|180 micrograms sc/week from week 21 to week 68
224252306|NCT04826653|OTHER|Suture removal|Suture removal after coronally advanced flap plus a connective tissue graft
224252307|NCT01602653|DEVICE|Extracorporeal shock wave therapy STORZ MEDICAL Modulith SLK|an energy level of 0.20mJ/mm2, 2400 pulses once a week for 4 weeks.
224252308|NCT01602653|DEVICE|Extracorporeal shock wave therapy STORZ MEDICAL Modulith SLK|an energy level of 0.10mJ/mm2, 2400 pulses once a week for 4 weeks.
224252309|NCT01273805|DRUG|Hydroxychloroquine|
224252310|NCT05044221|OTHER|Former ICU patient and caregiver workshops|In depth interviews and workshops will be conducted with individuals enrolled in the study.
224252311|NCT05044221|OTHER|Health care professional workshops|In depth interviews and workshops will be conducted with individuals enrolled in the study.
224252312|NCT03048812|DEVICE|O'Ring Attachment (A)|Attachment A will be inserted in three months of follow up,followed by treatment B in a random order
224252313|NCT03048812|DEVICE|Equator Attachment (B)|Attachment B will be inserted in three months of follow up,followed by treatment A in a random order
224252314|NCT02647944|DRUG|Liraglutide|Initiate at 0.6mg S.C. daily for 1 week; subjects will return to the Clinical Research Unit (CRU) each week until an increase by 0.6mg/day in weekly intervals to a dose of 3.0 mg/day is achieved (\~4 weeks). Once maintenance dose of 3.0 mg is achieved, subjects will return approximately every 4 weeks to obtain new supply of study medication.
224252315|NCT02647944|DRUG|Placebo|
224252316|NCT04738071|DEVICE|PFO closure|PFO closure after stroke or transient ischemic attack
224252317|NCT05494671|PROCEDURE|conjunctival limbal autologous transplant|"Patients with unilateral chemical ocular injury will be included in the study. All selected patients will receive a thorough explanation of the study design and aims and informed consent will be obtained in all patients. Eyes of all participants will be subjected to: Best corrected visual acuity, Slit lamp examination and ocular ultrasound if no fundus view.~Staging of degree of limbal stem cell deficiency is done by Roper Hall classification and then the patient will have conjunctival limbal autologous transplant (CLAU)"
224252318|NCT03101540|DRUG|Omega-3 PUFA supplementation|Subjects received 2.2g of eicosapentaenoic acid (EPA) and 1.2g of docosahexaenoic acid (DHA) daily for the duration of the study.
224252319|NCT01246076|DRUG|Lenalidomide|
224252320|NCT06263972|DEVICE|Direct Stimulation Prefrontal Cortex|The therapeutic course will include moderate aerobic physical activity (at 60% of the target heart rate adjusted for age) 3 times a week for 4 weeks (a week of adjustment, and 3 weeks of treatment), along with low current electrical stimulation to prefrontal cortex for 3 weeks.
224252321|NCT06263972|DEVICE|Shame cortex stimulation|The therapeutic course will include moderate aerobic physical activity (at 60% of the target heart rate adjusted for age) 3 times a week for 4 weeks (a week of adjustment, and 3 weeks of treatment), along with shame low current electrical stimulation to cortex for 3 weeks.
224252322|NCT06263972|DEVICE|Direct Stimulation to Motor Cortex|The therapeutic course will include moderate aerobic physical activity (at 60% of the target heart rate adjusted for age) 3 times a week for 4 weeks (a week of adjustment, and 3 weeks of treatment), along with low current electrical stimulation to Motor cortex for 3 weeks.
224252323|NCT06263972|BEHAVIORAL|erobic physical activity|Aerobic physical activity (at 60% of the target heart rate adjusted for age) 3 times a week for 4 weeks (a week of adjustment, and 3 weeks of treatment),
224252324|NCT01286922|OTHER|Behavioral: exercise|"Specific Aim: We will identify, recruit, assess, and randomly assign 42 sedentary, overweight-obese individuals who are at risk for pre-diabetes to an AER or INT training group in order to test the hypothesis:~• Individuals randomized to INT will have greater improvements in insulin sensitivity than individuals assigned to traditional AER.~Secondary Aim: We will measure maximal cardiorespiratory fitness (VO2max/peak) in order to test the hypothesis:~• Individuals randomized to the INT group will have a greater improvement in VO2max/peak than individuals in traditional AER group."
224252325|NCT02760368|DRUG|Olokizumab|160 mg/mL sterile solution for SC injection in a 2 mL clear Type I glass vial
223671467|NCT01855373|DIETARY_SUPPLEMENT|PEAK ATP® with GlycoCarn®|PEAK ATP® with GlycoCarn® {Glycine Propionyl-L-Carnitine Hydrochloride, USP (500mg/capsule) and Adenosine 5'-Triphosphate Disodium Salt (100mg/capsule)}: 2 capsules twice daily on an empty stomach
223671468|NCT01855373|DIETARY_SUPPLEMENT|PEAK ATP®|PEAK ATP® (Adenosine 5'-Triphosphate Disodium Salt (100mg/capsule): 2 capsules twice daily on an empty stomach
224252326|NCT02760368|DRUG|Placebo|sodium chloride 0.9% solution supplied in polypropylene plastic ampoules of 10 mL cartons to contain 10 ampoules
224252327|NCT00272597|DRUG|Risperidone|See Detailed Description.
224252328|NCT05033847|BIOLOGICAL|Recombinant COVID-19 Vaccine (CHO cell)|Intramuscular injection of Recombinant COVID-19 Vaccine (CHO cell) in the deltoid muscle of the upper arm
224252329|NCT05033847|BIOLOGICAL|COVID-19 vaccine (Vero cells)|Intramuscular injection of Recombinant COVID-19 vaccine (Vero cells) in the deltoid muscle of the upper arm
224252330|NCT00719745|DRUG|Prograf|oral
223671469|NCT01855373|DIETARY_SUPPLEMENT|GlycoCarn®|GlycoCarn® (Glycine Propionyl-L-Carnitine Hydrochloride, USP (500mg/capsule): 2 capsules twice daily on an empty stomach
223671470|NCT01855373|OTHER|Placebo|Placebo: 2 capsules twice daily on an empty stomach
223671471|NCT02650921|DEVICE|Restylane Lyft with Lidocaine|An injectable gel of Hyaluronic Acid and Lidocaine
223671472|NCT02032043|DRUG|Annual versus Semiannual Albendazole plus Ivermectin MDA|Annual or semiannual Albendazole plus Ivermectin, administered by the Ivorian Ministry of Health.
223671473|NCT00627575|DRUG|lamotrigine|Lamotrigine tablets will be available in 25, 50, 100 and 200 mg dose strength.
223671474|NCT00627575|DRUG|atorvastatin|Atorvastatin will available as 40 mg tablets.
223671475|NCT00627575|DRUG|phenytoin|Phenytoin will available as 100 mg capsules.
223671476|NCT04883723|DEVICE|Shotblocker|Shotblocker is a small, flat, horseshoe-shaped plastic tool that can be used to reduce pain due to intramuscular injection, suitable for all age groups, without drug properties. It is used by keeping it on the skin surface during injection and has no side effects. Shotblocker has short, non-pointed blunt protrusions on one side that connect with the skin, there is a hole in the middle of the vehicle to expose the injection site. The protruding surface of the vehicle is placed in the area to be applied just before injection. The protrusions on the surface of the Shotblocker do not pierce the skin and provide a warning for the Door Control Theory, which is thought to exist regarding pain
223671477|NCT04883723|OTHER|Manual Pressure|The patient was placed in a prone position and the appropriate left or right ventrogluteal region was determined. Pressure was applied to the determined injection area with the thumb of the active hand for 10 seconds. Immediately after the application of pressure was terminated, the injection site was cleaned with an alcohol cotton pad with circular movements of 5 cm diameter from inside to outside, and the alcohol was allowed to dry. With a single movement at a 90 ° angle, the compression area was entered quickly and the injection was performed. Manual pressure reduces pain within the framework of the gate control theory. According to the gate control theory, when pressure is applied to an area, a fiber transmits the feeling of pressure instead of pain and ultimately the pain sensation is alleviated. There are many studies in the literature that prove the effectiveness of this method.
223671478|NCT04276727|DRUG|MINT study IMP|Application of gel for 6 weeks.
223671479|NCT02972385|PROCEDURE|Mouthwash sample|A one time mouthwash sample will be performed.
223671480|NCT02972385|PROCEDURE|Blood Draw|Patients who are receiving a blood draw during their regular clinical appointment will be asked for a blood sample of 15 milliliters. Genomic DNA will be isolated for genotyping and patient plasma samples will also be stored.
223671481|NCT04597242|DRUG|Exebacase|Patients will receive a single IV infusion of exebacase in addition to antistaphylococcal antibiotics prescribed by the treating physician. Patients with normal renal function or mild renal impairment will be administered a dose of 18 mg of exebacase; patients with moderate or severe renal impairment will be administered a dose of 12 mg; patients with end-stage renal disease, including those on hemodialysis, will be administered a dose of 8 mg.
223671482|NCT04604132|DRUG|Derazantinib|Derazantinib was administered orally at a dose of 300 mg once daily as monotherapy in the Substudy 1 (Cohort 1.1).
223671483|NCT04604132|DRUG|Derazantinib-paclitaxel-ramucirumab combination|"Derazantinib was administered orally at a dose of 200 mg once daily in combination with paclitaxel and ramucirumab.~Paclitaxel was administered intravenously at a dose of 80 mg/m² on days 1, 8, and 15 of a 28-day cycle in combination with ramucirumab.~Ramucirumab was administered intravenously at a dose of 8 mg/kg every 2 weeks in combination with paclitaxel."
223671484|NCT04604132|DRUG|Derazantinib-paclitaxel-ramucirumab combination|"Derazantinib was administered orally at a dose of 300 mg once daily in combination with paclitaxel and ramucirumab.~Paclitaxel was administered intravenously at a dose of 80 mg/m² on days 1, 8, and 15 of a 28-day cycle in combination with ramucirumab.~Ramucirumab was administered intravenously at a dose of 8 mg/kg every 2 weeks in combination with paclitaxel."
223671485|NCT04604132|DRUG|Derazantinib|Derazantinib was administered orally at a dose of 200 mg twice daily as monotherapy in the Substudy 1 (Cohort 1.3).
223671486|NCT04604132|DRUG|Derazantinib|Derazantinib was administered orally at a dose of 300 mg once daily as monotherapy in the Substudy 1 (Cohort 1.2).
223671487|NCT00952380|DRUG|dalteparin|dalteparin subcutaneous injection
223671488|NCT03400956|DRUG|Vilaprisan (BAY1002670)|Orally, coated tablet 2 mg, once daily
223671489|NCT03400956|DRUG|Placebo|Orally, coated tablet, once daily
223671490|NCT04821505|BEHAVIORAL|Health Education|didactic classroom instruction on improving ones lifestyle through healthier diet, exercise and control of substance use.
224252331|NCT00719745|DRUG|MR4|oral
224252332|NCT03050944|OTHER|Lifestyle behaviour and dietary habits assessment|Lifestyle behaviour and dietary habits assessment
224252333|NCT04534166|OTHER|Risk Prediction of Fracture in Diabetic Patients with Osteoporosis|Risk Prediction of Fracture in Diabetic Patients with Osteoporosis
224252334|NCT02514330|OTHER|Interval Training at 1% incline|Six stimuli were performed to exhaustion. The vertical drop jump strategy (height and kinematics) served to establish the magnitude of the concurrent effect
224252335|NCT02514330|OTHER|Interval Training at 10% incline|Six stimuli were performed to exhaustion. The vertical drop jump strategy (height and kinematics) served to establish the magnitude of the concurrent effect.
224252336|NCT01661855|DRUG|Riluzole|50mg once daily (QD) for 12 weeks for participants 6-11 years old; 50mg twice daily (BID) for 12 weeks for participants 12-17 years old
224252337|NCT01661855|DRUG|Placebo|Placebo comparator once daily (QD) for 12 weeks for participants 6-11 years old; Placebo comparator twice daily (BID) for 12 weeks for participants 12-17 years old
224252338|NCT02514876|DEVICE|Foresight ICE System|The Foresight ICE System is composed of a sterile, single-use catheter intended to operate with a Foresight ICE PIM and Hummingbird Console.
224252339|NCT02714062|DRUG|Placebo|po once daily
224252340|NCT02714062|DRUG|VI-0521 Mid Dose|po once daily
224252341|NCT02714062|DRUG|VI-0521 Top Dose|po once daily
224252342|NCT03106662|BIOLOGICAL|mesenchymal stem cells|After preferred conditioning regimen for the patient, cyclophosphamide 50 mg/kg/day will be administered at +3 and +4 post transplant day. At +6 post transplant day, 2-8x10\^8 cell/kg mesenchymal stem cells will be infused.
224252343|NCT03106662|DRUG|cyclophosphamide administration|After preferred conditioning regimen for the patient, cyclophosphamide 50 mg/kg/day will be administered at +3 and +4 post transplant day.
224252344|NCT05824325|DRUG|SHR-A1811|HER2 ADC
224252345|NCT05824325|DRUG|TROP2 ADC|TROP2 ADC
224252346|NCT02294604|DEVICE|ethyl alcochol, chlorhexidine and moisturizers|
224252347|NCT02294604|DEVICE|chlorhexidine|
224252348|NCT02294604|DEVICE|povidone-iodine|
224252349|NCT02139839|OTHER|Lactobacillus capsules|L. rhamnosus GR-1 and L. reuteri RC-14 capsules manufactured by Chr. Hansen
224252350|NCT02139839|DRUG|Placebo gelatin pill|Placebo Comparator capsules, identical in appearance to the active product; 98% Gelatin with no L. rhamnosus GR-1 and L. reuteri RC- 14.
223671491|NCT04821505|BEHAVIORAL|Transcendental Meditation|TM is described as simple technique practiced 20 minutes twice a day for deep rest and relaxation.
223671492|NCT04605614|RADIATION|Copper Cu 64-DOTA-pembrolizumab|Given IV
223671493|NCT04605614|BIOLOGICAL|Pembrolizumab|Given IV
223671494|NCT04605614|PROCEDURE|Positron Emission Tomography|Undergo PET
223671495|NCT03364829|DRUG|Indacaterol/Glycopyrronium|
223671496|NCT01409343|DRUG|TrasGEX™|Patients received TrasGEX intravenously every 3 weeks until disease progression in doses of 12-720 mg in a three-plus-three dose escalation design, including an expansion cohort at the highest dose.
223671497|NCT03505398|PROCEDURE|microperimetry|define the retinal fixation point and the differential sensitivity threshold of the retina.
223671498|NCT03505398|PROCEDURE|visual acuity|using ETDRS scales
223671499|NCT03505398|PROCEDURE|automated visual field|recording visual attention based on central or peripheral visual information
223671500|NCT03505398|PROCEDURE|eye movements recording|recording of explicit visual attention based on central or peripheral visual information
223671501|NCT06071728|DIETARY_SUPPLEMENT|Endocalyx Pro (Microvascular Health Solutions, US Patent Number: 9943572)|Subjects will receive Endocalyx Pro (Microvascular Health Solutions, US Patent Number: 9943572) (3,712mg) or placebo for 12 weeks.
223671502|NCT00001012|DRUG|AL 721|
223671503|NCT02917018|DRUG|Dexmedetomidine|Group I will receive 1 ug/kg, group II will receive 0.75 ug/kg and group III will receive 0.5 ug/kg) diluted to 50 ml NaCl 0.9% by syringe pump over 20 minutes before end of surgery.
223671504|NCT00160667|DRUG|Placebo|Daily oral dose of two equal intakes.
223671505|NCT00160667|DRUG|Brivaracetam|Daily oral dose of two equal intakes.
223671506|NCT04810780|DEVICE|DUO Extended Set|to evaluate saftey and efficacy of DUO extended set combined with glucose sensor
223671507|NCT06055335|OTHER|Medium flow anesthesia|Group MeFA; after reaching the MAC 1 value with 4lt/min 50% O2 - 50% air and 8% desflurane with remifentanil infusion, medium flow anesthesia was started with 2 lt/min 50% O2 - 50% air with MAC 1 concentration desflurane. The vaporizer was closed at the end of the last suture, and the flow was increased to 80% oxygen at 6 lt/min.
224252351|NCT03970421|OTHER|Observation|Check clinical status at different time intervals during 3 months
224252352|NCT01860521|PROCEDURE|Programmed Intermittent Epidural Bolus|An initial epidural loading dose consisting of 0.0625% levobupivacaine 20 mL (Chirocaine®, Abbott, Chicago, USA) plus sufentanil 10 µg (Fentatienil®, Angelini, Rome, Italy) was followed by 0.0625% levobupivacaine with sufentanil 0.5 µg/mL, 10 mL every hour, starting 60 minutes after the administration of the initial epidural loading dose until expulsion of the fetus. If the patient still felt pain (VAPS score ≥ 30mm), despite the analgesia, additional manual incremental boluses of 5-mL levobupivacaine 0.125% until the VAPS score was \< 30 mm were administered.
224252353|NCT01860521|PROCEDURE|Continuous Epidural Infusion|An initial epidural loading dose consisting of 0.0625% levobupivacaine 20 mL (Chirocaine®, Abbott, Chicago, USA) plus sufentanil 10 µg (Fentatienil®, Angelini, Rome, Italy) was followed by 0.0625% levobupivacaine with sufentanil 0.5 µg/mL at a rate of 10 mL/h, starting 60 minutes after the administration of the initial epidural loading dose until expulsion of the fetus. If the patient still felt pain (VAPS score ≥ 30mm), despite the analgesia, additional manual incremental boluses of 5-mL levobupivacaine 0.125% until the VAPS score was \< 30 mm were administered.
224252354|NCT01860521|PROCEDURE|Procedure of interruption of pregnancy|Patients were administered 1 mg of gemeprost pessaries (Cervidil®, Merck Serono SPA, Roma, Italy) in the posterior fornix of the vagina every 3 hours up to 5 doses. If the expulsion of the fetus did not occur, the therapeutic regimen was repeated after 24 hours from the initiation of the treatment. Induction-to-abortion time (hours) was considered the period of time comprised between the first gemeprost pessary administration and fetal expulsion. Failure of induction of abortion was defined as women undelivered after two completed cycles (48h).The evacuation of the uterus under general anesthesia was performed if ultrasonography showed retained productions of conception.
224252355|NCT01860521|DRUG|Drug used for analgesia procedures|Levobupivacaine (Chirocaine®, Abbott, Chicago, IL, USA) and sufentanil(Fentatienil®, Angelini, Rome, Italy) were administered in both study groups according to the regimen of each intervention arm (Programmed Intermittent Epidural Bolus Versus Continuous Epidural Infusion).
224252356|NCT01860521|DEVICE|Pump for programmed intermittent bolus.|Pump administering programmed intermittent epidural bolus for the maintenance of analgesia was used.
224252357|NCT01860521|DEVICE|Pump for continuous epidural infusion.|Pump administering continuous epidural infusion for the maintenance of analgesia was used.
224252358|NCT01860521|DRUG|Drug used for termination of pregnancy procedure.|Gemeprost pessaries.
224322175|NCT05382559|DRUG|Leucovorin|Intravenous Infusion
224322176|NCT05382559|DRUG|Oxaplatin|Intravenous Infusion
224322177|NCT05382559|DRUG|Fluorouracil|Intravenous Infusion
223771804|NCT02881814|DIAGNOSTIC_TEST|Lung and diaphragm ultrasound in MV patients|In case of mechanically ventilated patient at St. Vincent Hospital (Sydney, Australia), LUS scan will be performed immediately following intubation. Additionnal LUS scans will be performed 72h after intubation and Immediately prior to or following extubation.
223771805|NCT06573060|DEVICE|Continuous glucose monitoring|Subjects with T2DM and acute coronary syndrome (n=120) were fitted with continuous glucose monitors (CGM) to closely monitor their blood glucose levels continuously for 14 days.
224322178|NCT05382559|DRUG|Irinotecan|Intravenous Infusion
223671508|NCT06055335|OTHER|Minimal flow anesthesia|Group MiFA; after reaching the MAC 1 value with 4 lt/min 50% O2 - 50% air and 8% desflurane with remifentanil infusion, minimal flow anesthesia was started with 0.50 lt/min 50% O2 - 50% air with MAC 1 concentration of desflurane. The vaporizer was closed at the end of the last suture, and the flow was increased to 80% oxygen at 6 lt/min.
223671509|NCT02251964|DRUG|Rituximab|2 times 1000mg dose at 14 days interval treatment
223671510|NCT02251964|RADIATION|Zr-89-rituximab immuno PET/CT|Immuno labeled PET/CT of the lungs
223671511|NCT04605367|DEVICE|Transcranial stimulation|For both tasks, the training modalities are the same. After the pre-test, this group will physically repeat the correct sequence as many times as possible, during 12 blocks of 30s. After this training, they will perform the post-test. And immediately after the post-test, they will receive the real anodal stimulation. The intensity of the current will gradually increase for 30s until it reaches 1mA, will remain constant for 15min, then will gradually decrease for 30s until 0mA is reached. The current density during stimulation will be 0.04 mA/cm². For the manual task the anode will be centered above C4 (according to the international 10-20 EEG system) that is located near the hand area of M1. The cathode will be placed on the supraorbital region ipsilateral to the trained hand (Fp1). For the body task, the anode will be placed in the center of the cortex (Cz) and the cathode will be placed at the medial supraorbital region (Fpz).
223671512|NCT05337397|PROCEDURE|Laser ablation|Laser ablation of non-Muscle invasive bladder tumors in outpatient settings.
223671513|NCT04805489|OTHER|Mask|"The sequence of mask wearing will be done by drawing lots, in double blind. Only the nurse will be informed of the mask sequence. The doctor will take measurements without seeing the type of mask placed between the athlete's face and the VO2 mask.~The patient will not know which mask will be applied. He will have been informed that he will test three masks (a so-called high-tech mask which will in fact be without a mask, a surgical mask and a general public mask). When the mask is put on, the athlete's eyes will be closed, the sequence without a mask, presented to the subject as a high-tech mask, will be done with a mask that will be put on like a surgical mask or a mask for the general public, except that it will be hollowed out in its center.~The effort tests will be done on a carpet with a filter called COVID on the VO2 masks."
223671514|NCT00383474|DRUG|Bortezomib|Given IV
223671515|NCT00383474|OTHER|Laboratory Biomarker Analysis|Correlative studies
223671516|NCT00383474|DRUG|Tipifarnib|Given orally
223771806|NCT03054909|BIOLOGICAL|ALT-803 Subcutaneous|Patient receives ALT-803 10 mcg/kg subcutaneous weekly x 4 followed by 4 weeks of no treatment before continuing with treatment courses 2, 3, and 4. Treatment courses 2, 3, and 4 are identical for all patients - ALT-803 10 mcg/kg subcutaneous weekly x 4 with a 4 week rest (4 weeks on/4 weeks off)
223671517|NCT05315011|OTHER|Whole-body cryotherapy|"The term cryotherapy refers to the process of chilling the body for medicinal purposes. WBC is carried out in a dedicated temperature and humidity controlled cryogenic chamber, which includes a brief exposure to extremely cold air. To avoid frostbite, only a few layers of clothes will be worn during the exposure. To avoid skin burns and necrosis, each participant must first remove their sweat before entering the cryochamber and a surgical mask is also worn to prevent moist air from being exhaled. Subjects will move their fingers and legs in the cryochamber and avoid holding their breath. The exposure time will be 4 minutes and 30 seconds in -85°C."
223671518|NCT05315011|OTHER|Placebo cryotherapy|The patient will be placed in a -85°C chamber for 1 minute as part of the placebo treatment.
223671519|NCT06397521|PROCEDURE|Crown lengthening|Investigation of the three techniques for aesthetic crown lengthening
223671520|NCT02004288|DIETARY_SUPPLEMENT|Lactobacillus reuteri Protectis DSM17938|One chewable tablet with L. reuteri or placebo taken twice a day for 3 months. After the 3 month therapy both groups will be monitored for the next 3 months.
223771807|NCT03054909|BIOLOGICAL|ALT-803 Intraperitoneal|Patient receives ALT-803 10 mcg/kg intraperitoneal weekly x 4 weeks followed by 4 weeks of no treatment before continuing with treatment courses 2, 3, and 4. Treatment courses 2, 3, and 4 are identical for all patients - ALT-803 10 mcg/kg subcutaneous weekly x 4 with a 4 week rest (4 weeks on/4 weeks off).
223771808|NCT00237952|DRUG|EDTA chelating agents|
223771809|NCT06014515|DRUG|18F-FDG|Each subject will undergo a dynamic 18F-FDG PET/CT scan (this drug is FDA approved) and a dynamic 11C-butanol PET/CT scan (this drug is under an IND) on the EXPLORER total-body PET/CT system. The two scans will be performed on the same day or within a period of up to two weeks depending on subject, imaging agent and scanner availability.
223771810|NCT06014515|DRUG|11C-butanol|Each subject will undergo a dynamic 18F-FDG PET/CT scan (this drug is FDA approved) and a dynamic 11C-butanol PET/CT scan (this drug is under an IND) on the EXPLORER total-body PET/CT system. The two scans will be performed on the same day or within a period of up to two weeks depending on subject, imaging agent and scanner availability.
223771811|NCT03324165|OTHER|Proposed Algorithm|Proposed algorithm that uses Alvarado Score to guide CT utilization
223771812|NCT05631080|PROCEDURE|Anatomical Endoscpic enucleation of the Prostate|Transurethral endoscopic enucleation of the prostate adenoma
223771813|NCT01274637|DRUG|Dalteparin Sodium|5,000 IU/0.2ml (anti-Xa) administered once daily in prefilled glass syringes.
223771814|NCT03175042|DEVICE|Masimo spot hemoglobin non-invasive monitor|This non-invasive monitor measures hemoglobin using LED light technology. We will be using it to determine if it is as accurate as routine CBC in anemic obstetric patients.
224322179|NCT05382559|DRUG|Nanoparticle albumin-bound-paclitaxel|Intravenous Infusion
224322180|NCT05382559|DRUG|Gemcitabine|Intravenous Infusion
224322181|NCT05382559|DRUG|Docetaxel|Intravenous Infusion
224322182|NCT05382559|DRUG|Pembrolizumab|Intravenous Infusion
224322183|NCT05382559|DRUG|Cisplatin|Intravenous Infusion
224322184|NCT05382559|DRUG|Carboplatin|Intravenous Infusion
224322185|NCT05382559|DRUG|Pemetrexed|Intravenous Infusion
223771815|NCT01497379|PROCEDURE|surgical implantation of subretinal device|surgical implantation of subretinal device
223771816|NCT01497379|PROCEDURE|surgical implantation of subretinal device|intra-individual implant OFF
223771817|NCT02321982|OTHER|Same-day preoperative consultation|Preoperative consultation occurs on the same day as Mohs surgery
223771818|NCT03952533|DIETARY_SUPPLEMENT|Dav|Daily oral administration of a food supplement constituted by α-lipoic acid, magnesium, vitamin B6 and vitamin D in tablets of 1,2 g (Dav®, Lo.Li. Pharma, Rome, Italy)
223771819|NCT04686097|PROCEDURE|treatment: puncture of coagulation|ultrasound-guided puncture of coagulation
223771820|NCT04686097|PROCEDURE|treatment: sclerosing agent injected|ultrasound-guided sclerosing agent injected
223771821|NCT00902200|DRUG|AR-12286|See arms
223771822|NCT00902200|DRUG|AR-12286 vehicle|See arms
223771823|NCT05294107|PROCEDURE|additional biopsies|"After Verification of eligibility criteria, patient information and consent, digestive biopsies performed for the study are in addition to those performed for the patient's follow-up:~* 6 biopsies are taken on average in clinical routine~* 4 additional biopsies are necessary to obtain a sufficient number of amplifiable stem cells The samples will be sent within one hour to the Biological Resource Center of the University Hospital of Rennes at room temperature in a tube containing isotonic saline. (CRB).~Biopsies will be then prepared by isolating intestinal crypts and cultured on a 3D matrix gel (matrigel) with added growth factors reproducing the niche environment of intestinal stem cells, which favors the development of an intestinal epithelium. After intestinal differentiation, organoids will be used for research such as molecular screening, assessment of the effects of intestinal stress and healing."
223771824|NCT05814562|BEHAVIORAL|Remote Intervention|The study utilizes a tailored telemetric intervention to improve adherence to medications. The telemetric intervention (administered via telephone, or interactive internet chat applications such as Zoom ©, FaceTime ® or Skype ®) will enable experienced therapists to address nonadherence from a remote location, using a structured, tailored approach that accommodates specific patient needs.
223771825|NCT06798012|BIOLOGICAL|TAK-411|TAK-411 IV infusion.
223771826|NCT06461520|OTHER|Maze Balance board|Every child will have their balance evaluated using the SWOC tool, CTSIB, and Pediatric Balance Scale. Patients performed a range of proprioceptive exercises, such as static one-leg standing, board balancing, squatting, and 20 minutes of straight-line walking on a hard surface before moving to a foam surface. For 20 minutes each session, proprioceptive exercises were conducted with open eyes first, followed by closed ones. The training program for the maze balancing board will next take place. There will be seven phases to the maze balance board training; each stage will last for two days and there will be three sessions per day, each lasting an hour.
223771827|NCT06461520|OTHER|Proprioceptive training|This group will get proprioceptive training. For a total of ten weeks, the intervention will be carried out three times a week for forty minutes each. Without maze-balance board training, the training schedule will consist of three sessions each week, lasting ten minutes each for preparatory, twenty minutes for proprioceptive, and ten minutes for restorative activities. Every meeting ended with a 10-minute cool-down and 10-minute warm-up to signify the quality of work.
223771828|NCT06176833|PROCEDURE|Body Weight Supported Treadmill Training|For these training sessions, participants will undergo walking training sessions that consist of wearing a harness for either body weight support or as a safety precaution while walking on a treadmill.
223771829|NCT01112085|DRUG|Ranibizumab 0.05mg|Intravitreal injections of 0.05mg ranibizumab over 6 months then additional treatment with ranibizumab 0.05mg as needed (according to re-treatment criteria)
223771830|NCT01112085|DRUG|Ranibizumab 0.5mg|Intravitreal injections of 0.5mg ranibizumab over 6 months then additional treatment with ranibizumab 0.5mg as needed (according to re-treatment criteria)
223771831|NCT01194297|BIOLOGICAL|Live attenuated influenza vaccine|One dose of live attenuated influenza vaccine, according to routine immunization recommendations
223771832|NCT01194297|BIOLOGICAL|Inactivated influenza vaccine|One dose of inactivated influenza vaccine, according to routine immunization recommendations
223771833|NCT05827302|DEVICE|Health Gauge AI-Based Wearable Device - Model: Phoenix|Wearable device
223771834|NCT03389646|DEVICE|CERAMENT G V|"During the removal of hip and knee prostheses usually bone defects occur at the intramedullary canal of the tibia and or / femur and /or acetabulum. These bone defects are filled with CERAMENTTM\|G or V during the re-implantation of the cementless or hybrid revision THA or TKA. CERAMENTTM\|G or V can be directly injected into the intramedullary canal or bone defect at the acetabulum. Alternatively and preferably, the surface of the prostheses shafts can be used to transfer CERAMENTTM\|G or V into the bone defects. For information of handling and mixing please see the attached instructions for use (IFU)."
223771835|NCT01197469|DRUG|Tadalafil|Tadalafil 10mg once daily for 3 months
224322186|NCT05696626|DRUG|Lasofoxifene in combination with abemaciclib|5 mg/d of oral lasofoxifene plus oral abemaciclib 150 mg twice a day
223771836|NCT01197469|DRUG|Placebo|
223771837|NCT02468466|BEHAVIORAL|Multi-level suicide prevention programs|The intervention included both screening and educational components. The screening component invited residents aged 36-64 years to participate in a two-step screening program. In the initial screening, a self-report questionnaire were mailed to all of those residents in the priority districts with a past high suicide rate. The second stage was conducted for the participants who screened positive though a semi-structural interview. Based on the results, participants who were diagnosed with a major depressive episode were provided with a referral to a psychiatry and support for treatment adherence. Written feedback on the screening results was mailed to all respondents. The educational component was implemented through workshops open to the general public (3 times every year) and local public newsletters (twice every year) designed to improve access and adherence to treatment and to reduce stigma associated with suicide and depression.
223771838|NCT02468466|BEHAVIORAL|Suicide prevention program as usual|Usual mental health program (not including depression screening among middle-aged)
223771839|NCT02357576|DRUG|Intralipid 20% I.V. Fat Emulsion|
223771840|NCT03661515|DRUG|Selinexor|"According to escalation level:~* Level -1: Selinexor 40 mg/day, once weekly~* Level 1: Selinexor 60 mg/day, once weekly~* Level 2: Selinexor 80 mg/day, once weekly~* Level 3: Selinexor 100 mg/day, once weekly"
223771841|NCT03661515|DRUG|fludarabine|fludarabine 30 mg/m2/day intravenously on days 1 to 4
224322187|NCT05696626|DRUG|Fulvestrant in combination with abemaciclib|Fulvestrant 500 mg intramuscular (IM) on Days 1, 15, and 29 and then once monthly thereafter plus oral abemaciclib 150 mg twice a day
224252359|NCT05063903|OTHER|Demographic and clinical characteristics, incremental shuttle walk test, six minute walk test, hand grip strength, M. Quadriceps isometric muscle strength, body composition|"Demographic and clinical characteristics Age and complaints, post-operative follow-up, other problems, medications, ECHO and ECG findings, laboratory tests (complete blood count, liver and kidney function tests, brain natriuretic peptide (BNP) level)~Hand grip strength Right and left hand grip strength the highest of the three measurements~Lower extremity muscle strength Maximum isometric muscle strength of the quadriceps femoris~Body composition Body fat ratio, lean body weight and fat weight by bioelectrical impedance analysis~6 minute walk test The six minute walk test distance recorded in meters~Incremental shuttle walk test The lap number, the number of laps of the last level they can reach, and the walking/running distances recorded in meters"
224252360|NCT00478179|DRUG|Transdermal/Patch (Bupivacaine TTS [Eladur™])|
223671521|NCT06248047|PROCEDURE|uretheroplasty|4\. When the bulb and bulbar urethra are exposed and before further dissection, the bulbar arteries are located using a directional doppler ultrasound stethoscope and a decision is made to sacrifice the artery with the lowest doppler signal to preserve the contralateral best artery. The bulbar urethra is then mobilized, circumferentially dissected and separated distally from the corpus cavernosum up to the penoscrotal angle to gain sufficient length for a tension-free end-to-end anastomosis without detachment of the bulb from the perineal body. If the dissection is not sufficient to bridge the gap,inter-corporal septal separation or even an inferior pubectomy are performed. The scarred tissue is removed completely, the proximal urethral segment is exposed as usual with spatulation of the healthy urethral ends and end-to-end anastomosis of the urethra over a silicon catheter is performed. No dissection is performed contralaterally at the bulb to preserve the artery of that side.
223671522|NCT03893890|BIOLOGICAL|Previously Treated with EN3835|No treatment to be administered - Observational only
223671523|NCT01779219|DEVICE|iMRI-guided brain tumour biopsy|The PoleStar N20 iMRI system (Medtronic Navigation, Louisville, CO, USA) with a 0.15-T constant magnet was used in all procedures.
223671524|NCT01779219|DEVICE|Stereotactic frameless brain tumour biopsy|The entry point, target and optimal biopsy trajectory were defined by the operator before the operation on the basis of the preoperatively obtained high-field MR images with the use of a neuronavigation workstation (Cranial 5, StealthStation Application Software, Medtronic Navigation, Louisville, CO, USA).
223671525|NCT01642628|OTHER|Mirror Education|Patients allocated to the experimental group will be given a small hand-held mirror and structured mirror viewing education verbally. In addition, they will receive a mirror viewing handout. This intervention will be given prior to mastectomy surgery. In addition, participants will receive all other standard care.
223671526|NCT02672020|BIOLOGICAL|omics identity card|
223671527|NCT02728427|DEVICE|Suprapubic catheterization using central venous catheter(CVC-2 7F)|Suprapubic catheterization using central venous catheter(CVC-2 7F) will be performed for patients after laparoscopic surgery for rectal cancer.Suprapubic catheterization is inserted at the end of the procedure. It will be clamped depending on surgeon's specific instruction and removed if the urinary residual is less than 50 cc.
223671528|NCT02728427|DEVICE|Transurethral catheterization using Foley catheter|Traditional transurethral catheterization using Foley catheter will be performed for patients.The catheterization is removed on day 5 in patients without complication.
223671529|NCT04880902|PROCEDURE|sleeve gastrectomy|Laparoscopic sleeve gastrectomy had evident therapeutic effects on preexisting obesity-related comorbidities. All patients were referred for abdominal MSCT with a volumetric assessment of gastric pouch within 1 month of surgery and 1 year postoperatively
223671530|NCT04838808|DRUG|Rivaroxaban 2.5 MG [Xarelto]|Rivaroxaban 2.5mg twice daily for 90-days
223671531|NCT04838808|DRUG|Placebo|Placebo tablet twice daily for 90-days
223671532|NCT05738343|OTHER|dieta mediterranea|nutritional education or Mediterranean food scheme
224322188|NCT06567912|BEHAVIORAL|TEE simulation curriculum|The curriculum comprised of one-hour lecture and 3-hour hands-on training on a simulation model.
224322189|NCT04444921|DRUG|Carboplatin|Given IV
224322190|NCT04444921|BIOLOGICAL|Nivolumab|Given IV
223671533|NCT02369601|OTHER|non- intervention study|Study design is non-interventional. Patient therapy will not be affected by study participation.
223671534|NCT01306929|DRUG|pridopidine|45mg bid
223671535|NCT03717272|DRUG|AEF0117|AEF0117 capsules
223671536|NCT03717272|DRUG|Placebo oral capsule|Corn oil capsule manufactured to mimic AEF0117 capsule
223671537|NCT00928590|DRUG|Travoprost/Timolol Maleate Fixed Combination solution|
223671538|NCT03815578|OTHER|Clinical examination|"* Number of painful joints,~* Number of swollen joints,~* Patient Global assessment VAS (0 - 100)~* and Physician Global assessment VAS (0 - 100)"
223671539|NCT03815578|OTHER|Pain assessment|"* Pressure Pain Thresholds (PPTs),~* Mechanical Temporal Summation (MTS)~* and Diffuse Noxious Inhibitory Control (DNIC)"
223671540|NCT03815578|OTHER|blood sample|18 ml whole blood for ELISA analysis and miRNAs detection
223671541|NCT03815578|OTHER|Patient Reported Outcomes|"* Health Assessment Questionnaire (HAQ),~* Rheumatoid Arthritis Impact of Disease score (RAID),~* Daily joint pain intensity VAS (0-100),~* Hospital Anxiety and Depression scale~* and Coping Strategy Questionnaire."
223671542|NCT04717830|DRUG|Gamezumab|solution for infusion
223671543|NCT05157802|BEHAVIORAL|Physical activity coaching|Physical activity coaching over 5 sessions
223671544|NCT04370340|DEVICE|BabySlide|Application of BabySlide during vacuum-assisted births for perineal protection
223671545|NCT06421129|PROCEDURE|anal fistula surgery|anal fistula surgery consists of;Fistulotomy and Fistulotomy with seton placement
223671546|NCT03709576|DRUG|Pevonedistat|To assess the toxicity and efficacy of a combination of Pevonedistat and Azacitidine as post allogeneic hematopoietic stem cell transplant maintenance therapy for non-remission AML.
223671547|NCT03709576|PROCEDURE|transplant|Although hematopoietic stem cell transplantation (HSCT) is curative for many patients with AML, AML in relapse at the time of transplant is still a major challenge with low rates of leukemia-free survival even with an intensive myeloablative conditioning.
223671548|NCT03709576|DRUG|Azacitidine|To assess the toxicity and efficacy of a combination of Pevonedistat and Azacitidine as post allogeneic hematopoietic stem cell transplant maintenance therapy for non-remission AML.
223671549|NCT00000803|DRUG|Delavirdine mesylate|
223671550|NCT00000803|DRUG|Zidovudine|
224322191|NCT04444921|DRUG|Paclitaxel|Given IV
224252361|NCT01780870|DIETARY_SUPPLEMENT|Weight loss group (Full meal replacement products)|In the intervention arm of this non randomized, open label study to assess the effects of weight loss on insulin sensitivity and leptin tolerance subjects will use full meal replacement products (1280-1320kcal/day). Subjects will be on the full meal replacement products only, for the first 12 weeks, between 13 to 19 weeks they will be transitioned to regular food, from 19 weeks and going forward they will be on chronic maintenance phase
224252362|NCT04396015|DIETARY_SUPPLEMENT|Bulletproof Brain Octane|Medium chain triglyceride oil (MCT)
223671551|NCT00000803|DRUG|Didanosine|
223671552|NCT03430076|PROCEDURE|revascularization|open revascularization for below-knee popliteal in the absence of an suitable autologous vein with PTFE.
223671553|NCT03430076|DEVICE|Propaten®|Propaten®
223671554|NCT03430076|DEVICE|Crude PTFE|Crude PTFE
223671555|NCT00270842|BEHAVIORAL|Tai Chi|This intervention is a 10 week Tai Chi group exercise class designed specifically for persons with Peripheral Neuropathy, having difficulty feeling their feet.
223671556|NCT00270842|BEHAVIORAL|Functional Balance|This intervention is a 10 week Functional Balance group exercise class designed specifically for persons with Peripheral Neuropathy, having difficulty feeling their feet.
223671557|NCT00270842|BEHAVIORAL|Education Control group|This control group participated in 10 weeks of general health education classes.
223671558|NCT05196711|DRUG|MAX-40070|"In the SAD phase, the proposed doses will be increased gradually. Each cohort will consist of 8 subjects, with 6 subjects randomly assigned to MAX-40070.~During the MAD phase, the treatment will be administered once a day for 14 consecutive days."
223671559|NCT05196711|DRUG|Placebo|"In the SAD phase, the proposed doses will be increased gradually. Each cohort will consist of 8 subjects, with 2 subjects randomly assigned to placebo~In the MAD phase, the treatment will be administered once a day for 14 consecutive days. Each cohort will consist of 10 subjects, with 2 subjects randomly assigned to placebo"
223671560|NCT01220544|BIOLOGICAL|Haploidentical transplantation with donor NK cells|Pat received a myeloablative conditioning regimen with 12 Gy total-body irradiation in six single doses from day -11 to day -9, thiotepa (5mg/kg/d) on days -8 and -7, fludarabine (40mg/m2/d) from day -6 to day -3, and OKT-3 (5mg/d) from day -5 to day +3. The stem cell graft was aimed to contain \> 8 x 10e6 CD34+ cells/kg and \< 5 x 10e4 CD3+ cells/kg. A minimum of 1 x 10e7 CD56+CD3- NK cells/kg will be transferred on days +2.
223671561|NCT03581461|BEHAVIORAL|Trauma-Informed Mindfulness-Based Yoga|The TIMBY program will involve twice weekly, 1-hour long sessions that will incorporate the central elements of Hatha Yoga - breathwork (pranayama), physical postures (asana) and meditation.
223671562|NCT02181270|OTHER|high intensity exercise|Subjects will perform 5-10 minute warm-up (50% VO2peak). Subjects will then exercise at an exercise intensity that corresponds to 90% HRmax, for 4 minutes. This will be followed by 3 min of exercise at 55% HRmax. Four of these exercise intervals/recovery periods will be completed. The total exercise commitment will be \~45 minutes
223671563|NCT02181270|OTHER|continuous moderate exercise|Subjects will perform a 5-10 minute warm-up at 50% VO2peak. Thereafter, the intensity of exercise will be increased to 70% VO2peak by increasing the speed and incline of the treadmill. Subjects will exercise at this intensity for 60 minutes.
223671564|NCT01690676|DIETARY_SUPPLEMENT|Epicatechin|
223671565|NCT01690676|DIETARY_SUPPLEMENT|Microcrystalline cellulose|
223671566|NCT02805270|OTHER|medication reconciliation intervention|medication reconciliation intervention comprises medication reconciliation on admission and discharge, bedside medication counseling and take-home medication list
223671567|NCT03608150|DEVICE|Luminopia One|Luminopia One is a virtual-reality based digital therapeutic that applies therapeutic modifications in real-time to cinematic content to rebalance visual input and treat amblyopia.
223671568|NCT03608150|DEVICE|Refractive Correction|Standard of care refractive correction (ex. spectacles)
223671569|NCT02834845|DRUG|Sevoflurane|Sevoflurane %2-3 for general anesthesia maintenance
223671570|NCT02834845|DRUG|Desflurane|Desflurane %6-8 for general anesthesia maintenance
223671571|NCT00403169|DRUG|lenalidomide|drug
223671572|NCT00890045|DEVICE|HeRO Vascular Access Device|HeRO Vascular Access Device
223671573|NCT00890045|DEVICE|Conventional ePTFE hemodialysis graft|Conventional ePTFE hemodialysis graft
223671574|NCT01402427|DRUG|Verapamil|Intraarterial administration of 5 mg verapamil diluted with saline to 10 mL.
223671575|NCT01402427|DRUG|Placebo|Intraarterial administration of 10 mL saline.
223671576|NCT05806827|DIAGNOSTIC_TEST|Virological screening|The preoperative viral screening protocol will start with a self-assessment questionnaire that will be provided to all the enrolled patients, where they will be asked to indicate previously SARS-CoV-2, HPV, EBV, CMV infections. Collection of peripheral blood mononuclear cells (PBMCs) from blood samples and serum specimens for the virological screening (HPV, EBV, CMV, SARS-CoV-2). Preoperative MoCA assessment, follow-up 5 days, 3 months and 6 months after the surgery.
224252363|NCT04396015|DIETARY_SUPPLEMENT|Placebo|Placebo (olive) oil
224252364|NCT04587570|PROCEDURE|Infiltration with PRP|Infiltration with 1.5 ml PRP
224252365|NCT04587570|PROCEDURE|Infiltration with Fat|Infiltration with 1.5 ml Fat
224252366|NCT04587570|PROCEDURE|Infiltration with PRP and Fat|Infiltration with 0.75 ml PRP and 0.75 ml Fat
224252367|NCT04587570|PROCEDURE|Infiltration with NaCl|Infiltration with 1.5 ml NaCl
224252368|NCT05516056|OTHER|ERAS clinical pathway|Prospective evaluation of the clinical results of ERAS implementation in the first 50 patients undergoing ERAS for cholecystectomy in CHUK, Rwanda
224252369|NCT02902211|DEVICE|Ankle foot orthosis|Patients will wear an ankle foot orthosis at all times except when he/she is sleeping or bathing for three months.
223671577|NCT02166177|DRUG|Autologous regulatory T cell product|Autologous regulatory T cell therapy infused intravenously (2 dose groups: low dose and high dose). The patients also receive rabbit Antithymocyte Globulin (rATG), tacrolimus, and sirolimus.
223671578|NCT01136187|PROCEDURE|Access site in primary PCI|
223671579|NCT04355728|BIOLOGICAL|Umbilical Cord Mesenchymal Stem Cells + Heparin along with best supportive care.|UC-MSC will be administered at 100x10\^6 cells/infusion administered intravenously in addition to the standard of care treatment.
223671580|NCT04355728|OTHER|Vehicle + Heparin along with best supportive care|Best supportive care treatment per the treating hospital protocol.
223671581|NCT00243607|OTHER|hydrotherapy according to Kneipp rules|2-5 applications of hydrotherapy according to Kneipp rules (self application) per day
224252370|NCT02902211|OTHER|Control/standard of care|Patients will carry out with typical activities suggested by their physician for three months.
224252371|NCT05075447|BEHAVIORAL|Emotion Control Treatment Program|Intervention programs include Child Training and Training in real scenes
224252372|NCT02498847|BEHAVIORAL|ENGAGE|"Participants are introduced to ENGAGE program by the study OT. The ENGAGE program is located on a website and has several modules. The modules include a video in which a health provider is featured. This health provider gives a short presentation on a topic related to OA, symptom management or lifestyle change. Within each module, there is downloadable homework and additional information which can be printed. The modules are:~* What is Osteoarthritis?~* Information about treatments~* Exercise~* Sleep hygiene~* Relaxation~* Pleasant Activity Scheduling~* Goal setting~* Problem Solving~* Pacing~* Communication"
224252373|NCT00059306|DRUG|aspirin|Participants receive aspirin + placebo, specifically: aspirin (325 mg) with placebo (an inactive substance). Participants will take 1 of each pill a day until the end of the study.
224252374|NCT00059306|DRUG|clopidogrel|Participants will receive aspirin + clopidogrel, specifically: aspirin (325 mg) with clopidogrel (75 mg)-- Participants will take 1 of each pill a day until the end of the study.
223671582|NCT01090895|DRUG|Vitamin C|Intravenous infusion of vitamin C (1 g) 10 minutes before percutaneous coronary intervention.
223671583|NCT01090895|DRUG|Placebo|Intravenous infusion of placebo(saline solution) 10 minutes before percutaneous coronary intervention.
223671584|NCT05725759|BEHAVIORAL|Rehabilitation|Particapants currently receiving tofersen treatment will be referred to outpatient physical and/or occupational therapy.
223671585|NCT02807415|DRUG|Lumacaftor plus Ivacaftor|Oral treatment with lumacaftor/ivacaftor tablets according to the prescribing information
223671586|NCT02073383|PROCEDURE|Axillary brachial plexus block|
223671587|NCT06363188|DEVICE|Radial Extracorporeal shockwave|a device used by physiotherapist to treat various musculoskeletal problems and it was here firstly used to accelerate the bone healing process after bone fracture
223671588|NCT03330392|DIETARY_SUPPLEMENT|AGP|take two tablets per day (500 mg/day) for 8 weeks
223671589|NCT03330392|DIETARY_SUPPLEMENT|Placebo|take two tablets per day (500 mg/day) for 8 weeks
223671590|NCT00385164|PROCEDURE|PET/CT scan for RT planning|
223671591|NCT05024292|PROCEDURE|rapid local ischemic postconditioning (RL-IPostC)|with 5 circules of balloon inflations in the ipsilateral internal carotid artery, each circulation includes inflation lasting 15 seconds followed by 15 seconds of deflation
223671592|NCT00483756|DRUG|Cyclosporine|Standard of care
223671593|NCT00483756|DRUG|CP-690,550|CP-690,550 15 mg BID for Months 1-6, then 10 mg BID for Months 7-12
223671594|NCT00483756|DRUG|CP-690,550|CP-690,550 15 mg BID for Months 1-3, then 10 mg BID for Months 4-12
223671595|NCT05133960|OTHER|Questionnaire assessment|Validity and reliability of the Turkish Version of the Activity Diversity Questionnaire
223671596|NCT01459289|OTHER|leaflet|
223671597|NCT01459289|OTHER|counseling and leaflet|
223671598|NCT04641689|DEVICE|Desk Only|Provision of height-adjustable desk
223671599|NCT04641689|BEHAVIORAL|Program Only|Online modules will promote goal setting, self-monitoring, habit formation, social support, barrier identification, and environmental modifications
223671600|NCT04276909|COMBINATION_PRODUCT|LUM Imaging System|LUM015 will be administered at the beginning of surgery. All subjects will have intraoperative imaging using the LUM imaging device.
223671601|NCT05861622|OTHER|Moisturizer|The test product is a novel moisturizer, that contains active ingredients, including rambutan extract, niacinamide, and glycoin.
223671602|NCT06391528|PROCEDURE|Transversalis Fascia Plane Block|application of local anesthetic between the transversus abdominis muscle and the transversalis fascia surrounding it from the inside, at the level of the posterior axillary line.
223671603|NCT04463069|OTHER|Adapted physical activity|This PA program was modified from an adapted physical activity (APA) program that designed for obesity management among adolescents with intellectual disability (ID). The aim of the APA program was to promote PA and health for people in special needs. In this study, the APA program was carefully designed based on a comprehensive pre-intervention assessment of each adolescent with ID, so that can be able to address their individual needs in learning and adaption. The APA program comprised three stages of APA training at school and each stage consisted of simple and fun endurance and strength-building exercise, at a frequency of two sessions per week, and lasting for about three months.
223671604|NCT06831084|DEVICE|Silver plated technology (SPT) dressing|Silver-plated technology (SPT) dressing technology is a wound dressing that has a permanently plated metallic surface, which provides the antimicrobial benefits of silver in the dressing without staining the skin and without increasing bioburden, reducing the development of acute radiation dermatitis (ARD).
223671605|NCT04663919|PROCEDURE|Bariatric surgery-RYGB|"After the creation of a 15-25-cc gastric pouch from the upper stomach, transection of proximal jejunum 70 cm from Treitz ligament also called alimentary tract and anastomosis of the distal end of jejunum to the gastric pouch, and thereafter, anastomosis of the proximal end of transected jejunum to the distal part of the jejunum at 150 cm below the site of transection (jejunoileal anastomosis)."
223671606|NCT04663919|BEHAVIORAL|Dietary intervention|High-calorie medical nutrition program to ensure weight gain
223671607|NCT00664508|PROCEDURE|Motion analysis|Motion analysis will be administered to each of the three groups: Lateral approach, anterior approach and posterior approach
223671608|NCT05977738|DRUG|Pitavastatin calcium|Daily Pitavastatin administration
223671609|NCT04119375|BEHAVIORAL|Keheala Mobile Health Platform and Behavioral Interventions|"Keheala is a mobile health company that delivers powerful behavior change interventions from the social sciences across basic feature phones or smartphones to address the nonmedical drivers of disease, which exist away from health facilities.~The intervention includes automated reminders, remote self-verification of doses, accessible TB information and individualized follow-up."
223671610|NCT04119375|BEHAVIORAL|Social and Behavior Change Communication (SBCC)|Automated reminders, remote self-verification of doses and accessible TB information. All interactions are behaviorally-informed but do not include regular adherence support/follow-up from study team members as the Keheala intervention does.
223671611|NCT04119375|BEHAVIORAL|SMS Reminder|Patients receive a single daily SMS message to take their medication.
224322192|NCT06965413|DRUG|RO7204239|RO7204239 or matching placebo will be administered as per the schedule specified in the arms.
223671612|NCT04119375|OTHER|Standard of Care|The standard-of-care protocol in Kenya includes diagnosis, the provision of medications - typically administered for a 1-2 week period at which point patients are expected to return to the clinical site - periodic on-the-ground follow-up by community health volunteers (CHVs)(at the discretion of local clinicians and CHVs) and nutritional support, as is sometimes provided.
223671613|NCT04676256|PROCEDURE|Early vitrectomy|Eyes with spontaneous vitreous hemorrhage treated with early vitrectomy (n = 63)
223671614|NCT00831649|DRUG|natalizumab|
223671615|NCT00979797|OTHER|Community-based interventions to promote maternal and child health|Promotion of antenatal and postnatal care and safe delivery Essential Newborn care Community case management, and feeding for children.
223671616|NCT04865874|OTHER|PPV-GDT|fluid-therapy based on PPV monitoring
223671617|NCT04865874|OTHER|Zero-balance|fluid-therapy based on urinary output balance
223671618|NCT01486082|OTHER|OCA 10|A group will be treated with omeprazole (20 mg / 12 h), amoxicillin (1 g/ 12 h)and clarithromycin (500 mg/12 h) for 10 days (as following current guides) without having a previous antibiogram, and the other group will be treated after antibiotic susceptibility.
223671619|NCT04884451|BEHAVIORAL|Lifestyle modification|Diet and physical activity modification and behavioral approach
223671620|NCT04133064|DEVICE|Pivot Breath Sensor|The Pivot Breath Sensor measures the level of carbon monoxide in exhaled breath and displays the carbon monoxide value to the user.
223671621|NCT05236387|DRUG|99m Tc-TM|Each patient will receive a single injection (0.1 ml) of 99mTc-TM (50 mcg) at the upper outer skin of the breast using an intradermal technique confirmed by the presence of a skin wheal.
223671622|NCT01459029|DRUG|D-serine|Adjuvant treatment with D-serine up to 6000 mg/day vs. placebo
223671623|NCT03056599|DRUG|Multiple drug microinjection|This is a feasibility study in patients with localized or metastatic soft tissue sarcoma undergoing surgery to determine how sarcoma in situ responds to injected microdoses of anti-cancer therapeutics.
223671624|NCT03056599|DEVICE|CIVO device|Feasibility of assessing drug response to precise local injection of anti-cancer drugs using Presage's CIVO device in soft tissue sarcoma patients undergoing surgery.
223671625|NCT03603509|DRUG|Fluad Vaccine|FLUAD is an inactivated influenza vaccine indicated for active immunization against influenza. disease caused by influenza virus subtypes A and type B contained in the vaccine. FLUAD is. approved for use in persons 65 years of age and older.
223671626|NCT03603509|DRUG|Fluzone High-Dose|FLUZONE® HIGH-DOSE vaccine is indicated for people 65 years of age and older to help prevent influenza disease caused by influenza A and B strains contained in the vaccine.
223771842|NCT03661515|DRUG|idarubicin|idarubicin 10 mg/m2/day intravenously on days 1 to 3
224252375|NCT00059306|OTHER|Target of Blood Pressure|Participants will be assigned to one of 2 groups of blood pressure control. The difference between the two groups is the target level of systolic blood pressure-either 130-149 mmHg or below 130 mmHg; to do so, the scientists will use medications that are already in the market for blood pressure management.
224252376|NCT00059306|OTHER|placebo|an inactive substance
223671627|NCT05018351|BEHAVIORAL|Integrated Care|Participants receive integrated physical and mental health care from their usual provider.
223671628|NCT05018351|BEHAVIORAL|Peer Navigation|Peer navigators will meet individually and face-to-face with participants to address their health and weight goals (i.e. working on health-related goals, attending health care appointments. and facilitating follow-up activities related to healthcare appointments).
223671629|NCT06516835|OTHER|Enteral fluid|GNAK will be administered to the gastrointestinal tract with EN in the same volume.
223671630|NCT06516835|OTHER|Intravenous fluid|Undiluted EN will be given to the gastrointestinal tract. GNAK, in the same volume, will be administered intravenously.
223671631|NCT00008450|PROCEDURE|Allogeneic Bone Marrow Transplantation|Undergo allogeneic bone marrow transplant
223671632|NCT00008450|DRUG|Cyclosporine|Given PO or IV
223671633|NCT00008450|OTHER|Laboratory Biomarker Analysis|Correlative studies
223671634|NCT00008450|DRUG|Mycophenolate Mofetil|Given PO or IV
223671635|NCT00008450|PROCEDURE|Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation|Undergo nonmyeloablative allogeneic hematopoietic stem cell transplant
223671636|NCT00008450|RADIATION|Total-Body Irradiation|Undergo TBI
223671637|NCT01407653|PROCEDURE|Virtual reality|3 sessions of immersion in a virtual reality 3D environment of 17 minutes per week for 4 consecutive weeks
223671638|NCT01407653|PROCEDURE|Usual care|Classical care
223671639|NCT03167567|BEHAVIORAL|Presence of a medical clown during labor|Presence of a medical clown during labor
223671640|NCT02574572|BIOLOGICAL|Autologous mesenchymal cells transplantation|All patients will undergo laminectomy and autologous mesenchymal cells injection into the lesion area.
223671641|NCT00639652|PROCEDURE|3D-histology|The tumor is marked at the 12 o'clock-position. Excision with a safety margin between 2 and 10 mm, depending on tumor size and location. Plastic reconstruction. Removal of the specimen's margins and base as thin layers, using a scalpel. These primarily three-dimensional layers of the specimen's borders are flattened to one level and microscopically screened for tumor cells. 3D-histology is combined with representative vertical sections for histologic diagnosis. Consecutive excisions are performed topographically at the tumor-positive areas and 3D-histology is repeated until tumor-free margins are obtained.
223671642|NCT00639652|PROCEDURE|Shave excision|Tumor removal by shave excision with a safety margin. Healing by secondary intention. Histologic diagnosis of BCC type (nodular, superficial, morpheaform, micronodular, other type, mixed type) or diagnosis of another tumor than BCC. Comment on complete removal (R0 versus R1).
223771843|NCT03661515|DRUG|cytarabine|cytarabine 2 g/m2/day intravenously on days 1 to 4
223771844|NCT03661515|DRUG|G-CSF|G-CSF 300 mcg/m2/day subcutaneously from days -1 to 5
223771845|NCT00128180|DRUG|Methylprednisolone|Intravenous methylprednisolone 16 mg/kg/day for 3 days as follows: 8 mg/kg (up to 500 mg) given over first hour followed by 8 mg/kg over the next 23 hours; then 16 mg/kg (up to 1000 mg) on days 2 and 3 administered over 24 hours.
223771846|NCT00128180|DRUG|Placebo|Placebo
223771847|NCT01073488|BEHAVIORAL|Community Mobilization, HBLSS and facility improvement|Mobilization of the community, with special emphasis on pregnant women and their families, to identify resources and solutions to improve maternal and neonatal mortality, home-based life savings skills (HBLSS) for community birth attendants and facility improvement activities.
224252377|NCT06056817|DEVICE|Calyan Pacemaker|The Calyan pacemaker is a device designed for implantation in the chest below the xiphoid process, and includes a FlexArm containing stimulation and sensing electrodes. The Calyan pacemaker is implanted using a set of delivery tools and clipped onto the xiphoid process; the FlexArm electrodes are oriented to make contact with the pericardial surface of the heart. Pacing parameters are adjusted wirelessly with a tablet-based programmer that communicates with the Calyan pacemaker via secure Bluetooth.
224252378|NCT03001063|OTHER|Supported Self-Management|This Supported Self-Management intervention consists of bibliotherapy (the Antidepressant Skills Workshop) that is provided to a patient by a health or social worker. The patient is supported in the use of the skills found in the workbook over the course of two months. The skills in the workbook are based on the principles of Cognitive Behavioural Therapy.
224252379|NCT03001063|OTHER|Enhanced treatment as usual|Participants in the control arm will received enhanced treatment as usual in the form of usual care at primary care centres and a leaflet providing information about depression.
224252380|NCT05030363|DRUG|ALDH enzyme supplementation|ALDH enzyme (PICOZYMEQ™)
224252381|NCT00995241|DRUG|Raltegravir|Raltegravir 800 mg / 24 hours.
224252382|NCT04701541|DEVICE|Diaphragmatic Ultrasound|Diaphragmatic ultrasound is non-invasive, portable, quick to perform, with a linear relationship between diaphragmatic movement and inspired volume. In eligible patients, a preoperative baseline ultrasound evaluation of the diaphragm and lungs is accomplished. Evaluation will be performed by a single operator, blinded to the arterial blood gas analysis values. In a semi recumbent position, patients will be asked to rest and breath quietly. An anterior approach will be carried out applying freehand transducer on abdomen at the right midclavicular line immediately below the costal margin with firm pressure, steering in cranial direction. A B-mode transverse scanning will be performed looking across the liver with gallbladder in the middle. Measurements will be recorded by the M-mode frozen images. The M-mode modality will be used to study DIA. The best sinusoidal curve will be considered for measurements.
224252383|NCT02130518|DRUG|Auriclosene Irrigation Solution, 0.2%|
224252384|NCT02130518|DRUG|Auriclosene Vehicle Solution|
224252385|NCT04511910|PROCEDURE|Early Laparoscopic Cholecystectomy|
224252386|NCT00019812|BIOLOGICAL|trastuzumab|
224252387|NCT00019812|DRUG|paclitaxel|
224252388|NCT00451412|DRUG|Certoparin|3000 U anti XA of certoparin in 0.3 ml solution, once daily
224252389|NCT00451412|DRUG|Unfractionated Heparin|solution, 5000 IU of unfractionated heparin in 0.3 ml, 3 times daily
224252390|NCT03617523|BIOLOGICAL|Fluzone Quadrivalent vaccine, 2018-2019 formulation|Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
224252391|NCT03617523|BIOLOGICAL|Flublok Quadrivalent vaccine, 2018-2019 formulation|Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
224252392|NCT03617523|BIOLOGICAL|Fluzone High-Dose vaccine, 2018-2019 formulation|Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
224252393|NCT02408302|DRUG|Midazolam|comparison between 3 routes of administration of the drug Midazolam used for sedation for minor procedures in pediatric population. the routes are oral intranasal and buccal.
224252394|NCT00421850|BEHAVIORAL|UNITED Planned Care|
224252395|NCT05497921|DEVICE|handLITE LED device|handLITETM is a home use wearable LED phototherapy device. The device consists of a flexible silicone glove that contains red and near infrared light emitting diodes (LEDs) and a controller. The LEDs generate the light. The glove is worn on the hand and is held in place by an adjustable Velcro strap.
223671643|NCT02248558|BEHAVIORAL|Conventional Video|Participants will watch a one minute video whose purpose is to increase HIV testing uptake. This video was created by a local CDC via direct CDC funding and internal guidance and development.
223671644|NCT02248558|BEHAVIORAL|Crowdsourced Video|Participants will watch a one minute video whose purpose is to increase HIV testing uptake. This video was the winner in a crowdsourced video contest hosted in China. CBOs all submitted their own independently designed and funded videos.
223671645|NCT00970775|DRUG|AZD2423|oral solution, single dose
223671646|NCT00970775|DRUG|Placebo|oral solution,single dose
223671647|NCT02770209|BIOLOGICAL|biomimetic cartilage matrix + autologous chondrocytes|
223671648|NCT02770209|PROCEDURE|arthroscopic debridement|
223671649|NCT02770209|PROCEDURE|microfracture surgery|
223671650|NCT06147375|DRUG|Tacrolimus or Cyclosporine A|The protocol of IS withdrawal:Week 1-4 take Tacrolimus (Tac) or Cyclosporine A (CsA) once daily for weeks. Week 5-8 medication reduction to taking Tac / CsA 4 times a week . Week 9-12 reduction to taking Tac/ CsA 3 times a week. Week 13-18 reduction to taking Tac / CsA 2 times a week . Week 19-24 reduction to taking Tac/ CsA once per week. Week 25, the recipients will stop taking Tac/ CsA.
224252396|NCT01074203|DRUG|Nitazoxanide|"Drug administration: The drug will be available through the research pharmacy. Patients will receive 1000mg (2 tablets) oral NTZ or an equivalent dose of NTZ suspension 1500mg (75mL) according to the schedule below.~Dose timing Dose Schedule Interval Dose Pre-transplant(on admission) 1000mg oral Once Total 1 dose Pre-transplant (delayed surgery \>12 hours) 1000mg oral Every 12 hrs Variable Post operative dose 1000mg oral/ nasogastric tube Every 12 hrs Total 6 doses~All attempts will be made to administer the tablet form of the medication, given the higher area under the curve that is achieved. If needed, the suspension formulation will be used. Since the suspension form has 70% bioavailability, the suspension dose administered will be 1.5 grams every 12 hours until the tablet form can be given."
224252397|NCT00801164|DRUG|Frio Mouth Rinse Placebo|Prescription Mouth Rinse. Rinse with 15ml twice daily then expectorate.
224252398|NCT00801164|DRUG|Frio Mouth Rinse|Prescription Mouth Rinse. Rinse with 15ml twice daily then expectorate.
224252399|NCT03137251|DEVICE|TENS 1|A portable TENS unit will be used by the principal investigator to apply the experimental intervention. Two pairs of electrodes measuring 5 x 9 cm will be fixed on the paravertebral regions of the participants of the experimental group using hypoallergenic surgical tape. Two paired electrodes will be placed 1 cm laterally on either side of the spine at the T10 to L1 and S2 to S4 levels.
224252400|NCT03137251|DEVICE|TENS 2|An intervention similar to arm 1 will be performed but with different doses.
223671651|NCT02327715|DRUG|Emtricitabine|emtricitabine were given to each patients from week 28 pregnancy to 24 weeks after delivery
223671652|NCT03924557|DIAGNOSTIC_TEST|Genotype-guided Supportive Care|In this arm, supportive care will be administered based on the results of the genotype test.
224252401|NCT03137251|DEVICE|Placebo TENS|An intervention similar to arm 1and 2 will be performed but,in this case, it is a sham device.
224252402|NCT04606628|OTHER|Eggshell membrane (ESM)|The intervention group will consume two capsules containing (in total) 500mg ESM with breakfast every day in 4 weeks.
224252403|NCT04606628|OTHER|Placebo|The placebo group will consume two placebo capsules (Cellulose) with breakfast every day in 4 weeks
223671653|NCT04989452|DIAGNOSTIC_TEST|Recordings of cough sounds from adults|Smartphone recordings of the cough sounds of participants who enrol in the study and obtain a COVID-19 rt-qPCR result.
223671654|NCT02656680|BEHAVIORAL|Continuous Enrollment|Participants will receive a weight loss intervention delivered in an online context. The online coaches will post daily content, respond to questions, address concerns, and encourage engagement. The weight loss intervention is based on the Diabetes Prevention Program (DPP), an evidence-based weight loss program focused on lifestyle changes. The goals for the intervention are 175 minutes of moderate physical activity per week and an overall weight loss of 7%. Each participant will get an individualized calorie goal that would facilitate a 1-2 lbs. weight loss weekly. Participants will also be encouraged to use an app such as MyFitnessPal to track daily diet. For this arm, the study team will keep recruitment open for this condition to allow enrollment of new participants through week 8.
223671655|NCT02656680|BEHAVIORAL|Closed Enrollment|Participants will receive a weight loss intervention delivered in an online context. The online coaches will post daily content, respond to questions, address concerns, and encourage engagement. The weight loss intervention is based on the Diabetes Prevention Program (DPP), an evidence-based weight loss program focused on lifestyle changes. The goals for the intervention are 175 minutes of moderate physical activity per week and an overall weight loss of 7%. Each participant will get an individualized calorie goal that would facilitate a 1-2 lbs. weight loss weekly. Participants will also be encouraged to use an app such as MyFitnessPal to track daily diet.
223671656|NCT02968862|OTHER|observational|The study will involve adult patients undergoing elective thoracolumbar-sacral spine surgery involving 1-5 spine levels, at the Brigham and Women's hospital that have an anticipated post surgical hospital stay of one to three days. These patients will be randomly assigned by the BWH Investigational Drug Service to one of three different groups, each consisting of 33 patients. This is an observational studies with subjects in which biomedical and/or health outcomes are assessed in pre-defined groups of individuals. Subjects in the study may receive a therapeutic intervention, but the investigator does not assign specific interventions to the subjects of the study.
223671657|NCT05541588|PROCEDURE|peripheral nerve block|ultrasound guided nerve block
223671658|NCT05832554|DEVICE|nasal airway|nasopharyngeal airway
223671659|NCT05832554|DEVICE|oral airway|oropharyngeal airway
223671660|NCT01362868|DEVICE|SENSIMED Triggerfish®|Soft contact lens-based device for the continuous monitoring of IOP fluctuations
223671661|NCT02294942|DRUG|RANCAD|Extended-Release RANCAD
223671662|NCT04966910|BEHAVIORAL|Stay Connected|Stay Connected is a menu-driven set of strategies to combat loneliness, anxiety and depression in older adults based on behavioral activation principles.
223671663|NCT04966910|BEHAVIORAL|Treatment as usual|Regular check-ins, resource/referral provision
223671664|NCT02876250|DRUG|Cyclosporine A|a pharmacological postconditioned group with IV administration of 2.5 mg/kg of CsA prior to first graft reperfusion
223671665|NCT02876250|DRUG|Placebo|a control group with IV administration of 2.5 mg/kg of placebo prior to first graft reperfusion
223671666|NCT02930980|DEVICE|Investigational Software loaded on Micra device|Subject will receive an investigational software loaded on subject's Micra device
223671667|NCT03387384|OTHER|Non-interventional study|Non-interventional study
223671668|NCT04810728|DRUG|Extract Psidii guava|2 Capsule Extract Psidii guava, three times daily
223671669|NCT04810728|COMBINATION_PRODUCT|Standard therapy for Covid-19 patient|(Vitamin C, Zinc, medication for clinical symptoms such as: antipyretic agent, decongestan and mucolytic.)
223671670|NCT04892056|OTHER|Friction Mechanics|anterior segment retraction using elastomeric power chains
224322193|NCT06965413|DRUG|RO7204239 Matching Placebo|RO7204239 matching placebo will be administered as per the schedule specified in the arm.
223671671|NCT04892056|OTHER|Frictionless Mechanics|anterior segment retraction using closing loops
223671672|NCT02038374|PROCEDURE|biopsies|
223671673|NCT03475953|DRUG|Phase 1 : Regorafenib|A treatment cycle consists of 4 weeks. Treatment may continue until disease progression or study discontinuation (withdrawal of consent, intercurrent illness, unacceptable adverse event or any other changes unacceptable for further treatment, etc.). Patients will be allocated 3 dose levels of Regorafenib following a 3 + 3 design.
223671674|NCT03475953|DRUG|Phase 1 : Avelumab|A treatment cycle consists of 4 weeks. Treatment may continue until disease progression or study discontinuation (withdrawal of consent, intercurrent illness, unacceptable adverse event or any other changes unacceptable for further treatment, etc.). Avelumab will be administered on cycle 1 Day 15 as a 1-hour intravenous (IV) infusion (10mg/kg), repeated every two weeks thereafter (ie. Day 1 and Day 15 of each subsequent cycle, as a 1-hour intravenous infusion).
223671675|NCT03475953|DRUG|Phase 2 : Regorafenib|Phase 2 : Regorafenib - All patients will be treated at the RP2D of regorafenib defined in the preliminary phase 1 trial with the same schedule as in the phase I.
223671676|NCT03475953|DRUG|Phase 2 : Avelumab|Phase 2 : Avelumab - All patients will be treated with avelumab with the same schedule as in the phase 1 trial.
223671677|NCT03475953|DRUG|Phase 2: low-dose Regorafenib|Phase 2 : Regorafenib - All patients will be treated at a fixed low-dose of regorafenib of 80 mg/day
223671678|NCT03272789|OTHER|Interviews with coach|For Interviews : done at Day 0 and at 1, 2, 3, 6 and 12 months. Questionnaires : given at Day 0, and at 3, 6 and 12 months.
223671679|NCT01266720|BIOLOGICAL|VEGFR1, VEGFR2|One mg of each peptide will be administered subctaneously on days 1, 8, 15 and 22
224252404|NCT04865653|DRUG|Lysergic Acid Diethylamide Base oral drinking solution|A moderate dose of 0.1 mg LSD will be administered.
224252405|NCT04865653|DRUG|Lysergic Acid Diethylamide Base solid orodispersible film|A moderate dose of 0.1 mg LSD will be administered.
224252406|NCT04865653|DRUG|Lysergic Acid Diethylamide Tartrate oral drinking solution|A moderate dose of 0.146 mg LSD tartrate will be administered (equivalent to 0.1 mg LSD base).
224322194|NCT06965413|DRUG|Tirzepatide|Tirzepatide will be administered as per the schedule specified in the arms.
224252407|NCT04865653|DRUG|Lysergic Acid Diethylamide Tartrate intravenous administration|A moderate dose of 0.146 mg LSD tartrate will be administered (equivalent to 0.1 mg LSD base).
224252408|NCT04865653|OTHER|LSD Placebo|Placebo for each formulation containing only the solvent or gel but no LSD.
224252409|NCT03383354|OTHER|Sleep-related disturbances (exposure)|Sleep-related disturbances such as sleep-disordered breathing (e.g. sleep apnea), sleep fragmentation, abnormal sleep architecture, and periodic limb movements (PLMs)
224252410|NCT05408897|DIAGNOSTIC_TEST|liquid biopsy|A test that enables the diagnosis or analysis of tumors using only a blood or fluid sample rather than a solid tissue biopsy.
224252411|NCT01564238|OTHER|Low Na diet (1.3 g/d)|20 day controlled feeding study (live in) providing 1.3 grams per day of sodium.
224252412|NCT01564238|OTHER|High sodium diet (3.8 g/d)|20 day controlled feeding study (live in) providing 3.8 grams per day of sodium.
224252413|NCT00471419|DRUG|Rimexolone|
223671680|NCT01266720|DRUG|Gemcitabine|Gemcitabine will be administered intravenously at a fixed dose of 1000mg/m2 on day 1, 8, 15.
223671681|NCT05252260|PROCEDURE|Diode Laser|Vestibuloplasty surgery was performed via diode laser. Laser irradiation was performed in continuous wave mode, using a 980 nm diode laser with a power of 1.5W, 600 μm optical fiber.
223671682|NCT05252260|PROCEDURE|Conventional Surgery|A local anesthetic was administered bilaterally to the mental area and waited for 5 min for diffusion of the solution. Then, a horizontal incision was prepared at the mucogingival junction with a scalpel blade no. 15c. All the muscle fibers over the periosteum were resected carefully. Following, the mucosal flap was sutured to the depth of the vestibule sulcus with 4-0 polypropylene suture material, once every 4 mm, from a total of 5 regions.
223671683|NCT05252260|OTHER|Low level laser therapy (LLLT)|Vestibuloplasty surgery was performed via diode laser. Following, LLLT was applied in continuous wave mode for 1 minute without contacting the tissue, using a phototherapy probe (power output, 0.5W; total energy of 6 J / cm²) at a distance of 1-2 mm from the tissue. LLLT was repeated immediately after the surgery, on the 1st, 3rd and 7th days
223671684|NCT02361476|DRUG|Clonidine|Injection - during surgery
223671685|NCT02361476|DRUG|Placebo|Injection - during surgery
223671686|NCT04281238|OTHER|Yoga group|Yoga training 3 days a week for 8 weeks. In addition to this, home exercises 5 days a week for 8 weeks
223671687|NCT04281238|OTHER|Control group|Home exercises 5 days a week for 8 weeks
223671688|NCT04617873|PROCEDURE|Bilateral STN-DBS and T10-T12 SCS|simultaneous stimulation of bilaterally-STN-DBS combined with spinal cord stimulation
223671689|NCT03402048|DRUG|Carboplatin|
223671690|NCT03402048|DRUG|Gemcitabine|
223671691|NCT03402048|DRUG|Pemetrexed|
223671692|NCT03402048|DRUG|Docetaxel|
223671693|NCT03402048|DRUG|Vinorelbine|
223671694|NCT00005031|DRUG|irofulven|
223671695|NCT03509415|DIAGNOSTIC_TEST|In-vivo imaging|Skin cancer is imaged using RCM and a diagnosis is recorded before patient is returned to standard of care (biopsy).
223671696|NCT01761071|DRUG|topical ketorolac 0.5% (Acular®, Allergan Inc, Irvine, CA)|On operation day, the patients were randomly assigned to one of the following two groups: group KO,preoperative application of topical ketorolac 0.5% (Acular®, Allergan Inc, Irvine, CA) in one eye and topical ofloxacin 0.3% (Ocuflox®, SamilInc, Seoul, Korea)in the other eye; group DO, topical diclofenac 0.1% (Voltaren®, Novartis, Bern, Switzerland) in one eye and ofloxacin 0.3% in the other eye. Neither the surgeon nor the participants knew which ophthalmic would go to which eye. A randomly assigned ophthalmic was instilled into right eye first three times by 1 minute interval 30 minutes prior to operation and the other ophthalmic was instilled into left eye with the same manner 10 minute later.
223671697|NCT01761071|DRUG|topical diclofenac 0.1% (Voltaren®, Novartis, Bern, Switzerland)|On operation day, the patients were randomly assigned to one of the following two groups: group KO,preoperative application of topical ketorolac 0.5% (Acular®, Allergan Inc, Irvine, CA) in one eye and topical ofloxacin 0.3% (Ocuflox®, SamilInc, Seoul, Korea)in the other eye; group DO, topical diclofenac 0.1% (Voltaren®, Novartis, Bern, Switzerland) in one eye and ofloxacin 0.3% in the other eye. Neither the surgeon nor the participants knew which ophthalmic would go to which eye. A randomly assigned ophthalmic was instilled into right eye first three times by 1 minute interval 30 minutes prior to operation and the other ophthalmic was instilled into left eye with the same manner 10 minute later.
223671698|NCT04139746|PROCEDURE|Scleral Buckling|Limbal 360 degrees peritomy of the conjunctiva was performed and the four recti muscles were isolated with 4 silk threads 4-0. A width-2 mm silicone encircling band was placed and sutured with 5-0 mersilene on the 4 quadrants of the sclera. Anterior chamber paracentesis was performed, draining about 0.3 mL of aqueous humour, and a buckle (220, 501, 506, or 516; Mira, Waltham, MA, USA) was sutured over the break. In all cases, the drainage puncture was executed at a distance of 11 mm from the limbus, in the area of greatest amount of subretinal fluid. Soon after the drainage puncture, a balanced salt solution (BSS) injection was performed in order to compensate the escape of the subretinal fluid.
223671699|NCT04139746|PROCEDURE|Drainage-Injection-Pneumoretinopexy|According to the location of the sub-retinal fluid, a quadrant-flap of conjunctiva was opened. Indirect ophthalmoscopy evaluation was also used intraoperatively to localize the break and the subretinal fluid drainage site: in this area a vicryl 6-0 thread was passed through the sclera, about 9-10 mm posteriorly from the limbus, to facilitate the surgical maneuvers. The drainage puncture was performed 11 mm posteriorly from the limbus, having attention not to perform it directly above the site of the retinal break. In detail, a 2 mm radial sclera incision was created with a 15° disposable knife. The incision was cautiously deepened down to the choroid, which was finally perforated by a lachrymal dilator having a blunt tip. Soon after beginning the subretinal fluid drainage, an injection of BSS was performed in the opposite quadrant of the sclera (4 mm from the limbus) in order to allow an optimal spillage of the subretinal fluid and to flatten the retina.
223671700|NCT05098275|DRUG|DA-5210 10/500mg|single dose administration (one tablet once a day)
223671701|NCT05098275|DRUG|DA-5210-R 10/500mg|single dose administration (one tablet once a day)
223671702|NCT03679442|DRUG|N-acetylcysteine|Non-randomized exposure to N-acetylcysteine (NAC) of healthy individuals corresponding to the clinical treatment guidelines for paracetamol-overdosed patients
223671703|NCT02427178|BIOLOGICAL|Hematopoietic Allogeneic Stem Cells|HLA 10/10 matched allogeneic bone marrow cells will be infused into recipient (patient).
223671704|NCT00297024|PROCEDURE|MRI|Patients will be scanned while breathing in varying amounts of oxygen and carbon dioxide in varying amounts through a breathing device.
223771848|NCT01173562|DRUG|Mebendazole|Type= exact number, unit= mg, number= 500, form= chewable tablet, route= oral use. One mebendazole 500-mg chewable tablet taken on Day 1.
224252414|NCT01599728|DRUG|Urocortin 2, Urocortin 3 and Substance P|"After a 20-min infusion of intra-arterial saline, ascending doses of Urocortin 2 (3.6, 12 and 36 pmol/min \[15, 50 and 150 ng/min\] to achieve estimated end-organ concentrations of 0.6, 2 and 6 µg/L, respectively), Urocortin 3 1200, 3600 and 12000 pmol/min (5, 15 and 50 micrograms/min) \[to achieve estimated end-organ concentrations of 199, 600 and 2000 micrograms/L respectively\] and substance P (a control endothelium-dependent vasodilator that evokes endogenous t-PA release \[2, 4 and 8 pmol/min\]) will be administered intra-arterially.~Baseline blood samples will be taken at the start of the study for full blood count, cholesterol, glucose, renal function Bilateral venous blood samples will be taken at baseline, immediately before the start of Ucn2/Ucn3 infusion and at the end of each dose of Ucn2/Ucn3 for subsequent measurement of plasma Ucn 2 and 3 concentrations and other hormones."
224252415|NCT02554032|PROCEDURE|Axillary artery cannulation|The right axillary artery will be exposed via an infraclavicular incision and a Dacron graft sewn to it in an end to side fashion after 5000 units of IV heparin. Following median sternotomy and full systemic heparinization, CPB will be initiated and the patient cooled. The base of the innominate artery will be clamped, and antegrade cerebral perfusion will be provided via the axillary artery. Following completion of the distal open aortic anastomosis, the clamp on the innominate artery will be removed, CPB via the aorta will be resumed and the patient will be rewarmed. After completion of surgery and weaning from CPB, the axillary artery graft will then be removed, the artery repaired and the skin will be closed.
224252416|NCT02554032|PROCEDURE|Innominate artery cannulation|After median sternotomy, systemic heparinization, cannulation of the ascending aorta and right atrium, CPB and systemic cooling will be initiated. The ascending aorta, proximal arch and the base of the innominate artery will be mobilized. Purse-string sutures are placed on the anterior wall of the proximal innominate artery and a pediatric venous cannula inserted using a J wire and sequential dilatation. Circulatory arrest with ACP is provided by clamping the base of the innominate artery and connecting the afferent limb of the CPB circuit to the innominate cannula. Once the distal aortic anastomosis is completed, ACP is discontinued, and full CPB via the aortic graft is resumed. Rewarming and the remaining surgery are then completed.
224252417|NCT03597243|OTHER|Cash Transfer|Girls enrolled receive a quarterly direct cash transfer of a total of 70,000 Tshs (30 USD) quarterly through mobile phone based cash transfer over a period of two years, for which they will receive mobile phones and SIM cards form the program.
224252418|NCT04156919|BEHAVIORAL|fooya!™|fooya!™ is a science/evidence-based AI-enabled neuromodulation and Cognitive Behavior Therapy (CBT) technology. fooya!™ has been shown to deliver statistically significant outcomes concerning food choices during randomized-controlled clinical trials conducted at the Baylor College of Medicine's Children's Nutrition Research in the United States of America as well as India. In the game, children make several decisions with split-second timing, such as food choices, destroying bad/unhealthy food robots using the bad foods that are thrown at the player, and saving themselves. If the children collect good/healthy foods, they are in fit-zone for a while, which shields them from bad food robots.
224252419|NCT04156919|OTHER|WordSearch|We will have an active control group that will play a WordSearch game. The intention is to have the children play a familiar video game through the same modality (IPAD) that is unrelated to diet or lifestyle choices.
223671705|NCT04199702|OTHER|Same day discharge|Patients will be discharged the same day they undergo catheter ablation of atrial fibrillation.
223671706|NCT03175848|RADIATION|Chemotherapy,radiotherapy|Pelvic,pelvic-inguinal,or extended field radiotherapy：Therapy 45 - 50 Gy in 1.7 - 2.0 Gy daily fractions over 4.5 - 5.5 weeks for PTV Brachytherapy: Therapy 5-6 fractions of 4-6Gy prescribed to the high-risk CTV or A piont.
223671707|NCT04531462|DRUG|Empagliflozin|Empagliflozin
223671708|NCT04531462|DRUG|Placebo|Placebo
223671709|NCT00504582|DRUG|Fibrin Sealant|Tisseel applied externally to the dissected axillary area.
223671710|NCT04197687|BIOLOGICAL|Multi-epitope HER2 Peptide Vaccine TPIV100|Given ID
223671711|NCT04197687|BIOLOGICAL|Pertuzumab|permitted at physician's discretion
223671712|NCT04197687|OTHER|Placebo Administration|Given ID
223671713|NCT04197687|BIOLOGICAL|Sargramostim|Given ID
223671714|NCT04197687|BIOLOGICAL|Trastuzumab|therapy are at the discretion of the treating physicians
223671715|NCT04197687|BIOLOGICAL|Trastuzumab Emtansine|at the discretion of the treating physicians.
223671716|NCT04175509|DRUG|Rectal acetaminophen|Rectal 1300mg
223671717|NCT04175509|DRUG|Intravenous acetaminophen|Intravenous 1000mg
223771849|NCT03363230|BEHAVIORAL|Mindfulness skills training|Mindfulness skills were taught over a 10-week period. Mindfulness skills were delivered in a weekly group-format. Participants were instructed to follow mindfulness practice at home. The treatment was focused on enhancing the patient capacity to defuse from cognitive and emotional content.
223671718|NCT00348933|DRUG|Betaine|100-200 mg per kg per day by mouth with a maximum of 6 grams divided in two daily doses
223671719|NCT00348933|DRUG|Creatine|200 mg per kg per day with a daily maximum of 5 grams divided in two daily doses
223671720|NCT00348933|DRUG|Metafolin|0.5 mg per kg per day by mouth with a maximum of 8 milligrams divided in two daily doses
223671721|NCT00348933|DRUG|Vitamin B12|1 mg by mouth per day for all weights and ages
223671722|NCT01489111|DRUG|turoctocog alfa pegol|Bleeding preventive treatment administered i.v. before, during and after surgery. Individually adjusted doses.
223671723|NCT04698850|DRUG|Aflibercept 40 MG/ML [Eylea]|Patients will be receiving intravitreal aflibercept starting with 3 monthly doses and continuing with treat-and-extend regimen with minimal interval of 8 week and maximum interval of 16 week. Interval can be prolonged or shortened by 2 or 4 weeks based on the disease activity and BCVA..
223671724|NCT04698850|DRUG|Brolucizumab-Dbll 120 MG/ML [Beovu]|Patients will be receiving intravitreal brolucizumab starting with 3 monthly doses followed by the treatment interval of 8 or 12 weeks based on the disease activity and BCVA.
223671725|NCT04698850|DRUG|Ranibizumab 6 MG/ML [Lucentis]|Rescue therapy for patients with study drug related adverse events or with worsening of BCVA and OCT finding even on the shortest treatment interval when resistance to study drug is suspected.
223671726|NCT01018446|DRUG|Busulfan|First dose: busulfan (120 mg/m2 ivs once daily) (if age\<1 yr: 80 mg/ m2) Second to forth dose: according to the daily pharmacokinetic study
224252420|NCT00752973|DRUG|MALG (malathion) Treatment|MALG applied for 30 minutes
224252421|NCT01862627|PROCEDURE|Optical coherence tomography|
224252422|NCT01935076|BEHAVIORAL|Neonatal exposure to maternal obesity|
224252423|NCT03502148|DRUG|PRV111 (Cisplatin Transmucosal System)|Each treatment visit will include one application of a permeation enhancer and then 2, 3 or 5 PRV111 (Cisplatin Transmucosal System) applications depending on the Stage subject is enrolled in.
224252424|NCT04230330|DRUG|IV Nivolumab|240mg every 2 weeks.
224252425|NCT04230330|DRUG|IV Nivolumab|Initial treatment dose is 240mg every 2 weeks for 4 doses. Dose changes to 360mg every 3 weeks when given with GDP/L-aspa. Maintenance treatment dose is 240mg every 2 weeks.
224252426|NCT04230330|DRUG|IV Gemcitabine|800mg/m2 on Days 1 and 8 every 21 days
224252427|NCT04230330|DRUG|IV Cisplatin|20mg/m2 on Day 1 to 4 every 21 days
224252428|NCT04230330|DRUG|IV/PO Dexamethasone|10mg on Days 1 to 4 every 21 days
224252429|NCT04230330|DRUG|IV L-asparaginase|6000 Units/m2 on Days 2 to 8 every 21 days
224252430|NCT04504240|DRUG|Famotidine 20 MG|Famotidine; tablet Famotac 20mg oral form.
224252431|NCT06627140|DIAGNOSTIC_TEST|Diagnostic procedures|Self- and parent-report on behavioral/emotional symptoms and assessment of cognitive functioning
224252432|NCT06029686|DEVICE|Stanford Glove|The vibrotactile device sends weak non-painful pattern type vibratory stimulus to the fingertips and is non-invasive. Some patient may experience dyskinesia which can me medicated with a decrease in Parkinson's medication
224252433|NCT02355886|DRUG|Gabapentin|Given PO
224252434|NCT02355886|OTHER|Placebo|Given PO
224252435|NCT02355886|OTHER|Questionnaire Administration|Ancillary studies
224252436|NCT01200810|OTHER|placebo|Given orally
224252437|NCT01200810|DRUG|gamma-secretase/Notch signalling pathway inhibitor RO4929097|Given orally
224252438|NCT01200810|DRUG|bicalutamide|Given orally
224252439|NCT04215510|PROCEDURE|endonasal endoscopic surgery|143 patients will undergo endonasal endoscopic surgery
224322195|NCT06491680|DRUG|Dapagliflozin 10mg Tab|"Dapagliflozin 10 mg tablet orally, once daily. Started 7 days before the first cycle of anthracyclines till the end of last anthracyclines dose.~taken orally, once daily. Started from 5 to 7 days before the first cycle of anthracyclines till the end of last anthracycline dose."
224252440|NCT04215510|RADIATION|radiation therapy(IMRT)|143 patients will undergo radiation therapy.
224252441|NCT02477202|DEVICE|Mirena® intra-uterine device (IUD)|In this study, a Mirena® IUD will be inserted into volunteers scheduled for a risk-reducing salpingo-oophorectomy (RRSO) or risk-reducing salpingectomy (RRS) at Memorial Sloan Kettering Cancer Center (MSK). Alternatively, women with a Mirena® IUD already in place and who will be scheduled for an RRSO or RRS at MSK can also participate. We are seeking 14 evaluable participants. FTF tissue (and ovarian inclusion cyst tissue, when available) collected at the time of risk-reducing salpingectomy (RRS) will be tested by immunochemistry staining for Ki67 (a protein that is significantly increased when cells are preparing for division).
224322196|NCT00370240|DRUG|Chlorhydrate de Ropivacaine|The Ropivacaïne group received 3mg/kg of 0.375% ropivacaïne(0.75% ropivacaïne, Astra, mixed with saline)
224322197|NCT00370240|OTHER|placebo|The PCB group received saline solution in equal volume.
223671727|NCT01721785|DRUG|GADOFOSVESET TRISODIUM 244 Mg in 1 mL INTRAVENOUS INJECTION, SOLUTION [Ablavar]|Gadofosveset will be used as a lymph-node specific MRI contrast agent and will be administered by manual injection as a single intravenous bolus during MRI.
223671728|NCT01556347|DRUG|Bortezomib, Thymoglobulin, Rituximab, Gamimune N, (IVIG), Plasmapheresis|
223671729|NCT02531971|DRUG|Intravenous fentanyl citrate|100 micrograms (2 millilitres) via intravenous injection
224252442|NCT00614250|DRUG|AVE0657|capsules once a day at bedtime
224252443|NCT00614250|DRUG|placebo|capsules once a day at bedtime
224252444|NCT03976635|DEVICE|Removable Mandibular Retractor|The appliance will be used 18 hours per day. It can only be removed for eating meals.
224252445|NCT03976635|DEVICE|Bone-anchored intermaxillary traction|The patients will be instructed to wear the upper removable appliance for 18 hours per day. The elastics should be extended from the upper appliance towards the lower mini-screws.
224252446|NCT05181566|PROCEDURE|Total hip replacement arthroplasty using modular dual mobility cup|In a total hip replacement (also called total hip arthroplasty), the damaged bone and cartilage is removed and replaced with prosthetic components
224252447|NCT05181566|PROCEDURE|Total hip replacement arthroplasty using conventional acetabular cup|In a total hip replacement (also called total hip arthroplasty), the damaged bone and cartilage is removed and replaced with prosthetic components
224252448|NCT04887818|DRUG|2% Diltiazem ointment with 1.5% lidocaine|3 g of topical 2% diltiazem ointment with 1.5 % lidocaine applied in the perianal region circumferential q12h x 12 weeks
224252449|NCT04887818|DRUG|0.3% Nifedipine ointment with 1.5% lidocaine|3 g of topical 0.3% nifedipine ointment with 1.5 % lidocaine applied in the perianal region circumferential q12h x 12 weeks
224252450|NCT00208819|DRUG|risperidone|
224252451|NCT00208819|DRUG|quetiapine|
224252452|NCT00208819|DRUG|olanzapine|
224252453|NCT00208819|DRUG|divalproex|
224252454|NCT05422521|OTHER|blood samples and 18FDG PET-CT exams|"* 18 FDG PET scanner at inclusion and post CART-cells treatment ( 1, 3, 6, 9 and 12 month)~* blood collection at inclusion and post CART-cells treatment (7 days, 1 month and 3 month)"
224252455|NCT01666899|PROCEDURE|Skin and blood vessel procedures|Biopsies, skin blood flow studies and ultrasound studies will be performed as described.
224252456|NCT04344106|PROCEDURE|Prone positioning|The prone positioning consists of placing the patient on his or her stomach with the head on the side, during sessions lasting several hours a day.
224252457|NCT01181700|DRUG|Treatment A|PF-00241939 300 ug using inhaler A
224252458|NCT01181700|DRUG|Treatment B|PF-00241939 300 ug using inhaler A
224252459|NCT01181700|DRUG|Treatment C|PF-00241939 300 ug using inhaler A
224252460|NCT01181700|DRUG|Treatment D|PF-00241939 300 ug using inhaler B
224252461|NCT01181700|DRUG|Treatment E|PF-00241939 300 ug using inhaler B
224252462|NCT01181700|DRUG|Treatment F|PF-00241939 300 ug using inhaler B
224252463|NCT01181700|DRUG|Treatment G|PF-00241939 300 ug using inhaler B
224252464|NCT00904215|DRUG|telmisartan/telmisartan + HCTZ (Hydrochlorothiazide)|
224252465|NCT01538888|PROCEDURE|WHOLE BODY VIBRATION|03 MONTHS, TWICE PER WEEK
224252466|NCT03890471|BEHAVIORAL|Preoperative telephone call three days before surgery|Patients will receive a provider-initiated telephone call three days before surgery. In order to standardize counseling across providers, each provider will use a telephone script addressing the following components: Purpose of the surgery, alternatives to the surgery, surgical benefits, surgical risk (such as infection, bleeding, injury to other organ systems), potential surgical complications (such as mesh erosion, voiding dysfunction, urinary retention requiring indwelling catheter), bowel complaints (such as nausea, vomiting, constipation, diarrhea), and postoperative expectations (such as Foley management, pain management, activity restrictions, and diet. The following ERAS-specific components will be incorporated into the counseling: management of chronic medical conditions, cessation of alcohol and tobacco, and daily exercise until surgery. Questions from patients and total counseling time will be recorded.
224252467|NCT04596007|DRUG|HEC83518 tablets|Each dose of HEC83518 and placebo will be administered with approximately 240 mL of water in the morning after fasting for at least 10 hours overnight.
223771850|NCT03363230|BEHAVIORAL|Interpersonal Effectiveness skills training|Interpersonal effectiveness skills were taught over a 10-week period. Skills were delivered in a weekly group-format. The treatment was focused on improving interpersonal effectiveness.
223771851|NCT04613609|DEVICE|Electronic Cigarette containing nicotine|Non-smokers used an electronic cigarette containing nicotine
224252468|NCT04596007|DRUG|Placebo|placebo
224252469|NCT01939756|DEVICE|Intravesical baobab oil|Intravesical baobab oil
224252470|NCT01621893|PROCEDURE|Subchondroplasty|
224252471|NCT00501488|DRUG|rosiglitazone|
224252472|NCT01855685|GENETIC|X vivo gene therapy|Transplantation of patient's autologous CD34+ cells transduced with lentiviral vector containing GP91PHOX gene
224252473|NCT01318551|DRUG|BAY85-3934|single dose, 20 mg
224252474|NCT01318551|DRUG|BAY85-3934|single dose, 40 mg (optional)
224252475|NCT01318551|DRUG|BAY85-3934|single dose, 80 mg (optional)
224252476|NCT02020915|PROCEDURE|lateral sphincterotomy|
224252477|NCT02020915|PROCEDURE|ultrasound guided lateral sphincterotomy|
224252478|NCT02356978|DEVICE|Arm1 homemade phototherapy treatment|"session of 10 or 12 hours phototherapy treatment using the homemade device during the first night and then the DRAP device during the next nights."
223671730|NCT02531971|DRUG|Duragesic®|TDDS dosage is 25 micrograms/hour (worn for 72 h)
223671731|NCT02531971|DRUG|Mylan generic fentanyl|TDDS dosage is 25 micrograms/hour (worn for 72 h)
223671732|NCT01153464|BEHAVIORAL|Recovery Support Counseling|Telephone based recovery support provided by paraprofessionals at the City of Philadelphia's Behavioral Health Department. Calls are once weekly for 8 weeks, then step down to every other week for the remainder of the year of study participation. Call frequency can be increased as a result of a rise in risk factor/protective factor ratio.
223671733|NCT00612729|PROCEDURE|Polylens Y30 intraocular lens|cataract surgery
223671734|NCT00612729|PROCEDURE|Orange Series Model PC 440 Y intraocular lens|cataract surgery
223671735|NCT00239369|DRUG|Fixed dose combination telmisartan 80 mg + HCTZ 25 mg|
223671736|NCT00239369|DRUG|Fixed dose combination telmisartan 80 mg + HCTZ 12.5 mg|
223671737|NCT00202527|DEVICE|Nasal continuos positive airway pressure|
223671738|NCT00016900|DRUG|liposomal paclitaxel|
223671739|NCT04164693|DRUG|Low molecular weight heparin|patients began to use low molecular weight heparin or warfarin sodium tablets.
223671740|NCT04164693|OTHER|non anticoagulant therapy group|no anticoagulant was used after operation.
223671741|NCT00618098|BIOLOGICAL|Octaplex (human prothrombin complex concentrate)|INR is determined 15 minutes after the end of each infusion. Each dose (mL/kg body weight) was calculated as = ln(INR/1.4)/0.52. The maximum dose for initial treatment was not to exceed 5500 IU. If the INR is ≥ 1.5 after the initial infusion, additional infusions will be repeated until the INR was \< 1.5. Octaplex (500 units, IU) is supplied in vials and was reconstituted with 20 mL of Water for Injection (Ph.Eur.).
223671742|NCT00618098|BIOLOGICAL|Fresh frozen plasma|INR is determined 15 minutes after the end of each infusion. The initial dose is 10 mL/kg for a participant with an initial INR of \< 3 and 15 mL/kg for a participant with an initial INR of ≥ 3. If the INR is ≥ 1.5 after the initial infusion, additional infusions of 5 mL/kg will be repeated until the INR was \< 1.5. Fresh frozen plasma is supplied by the blood bank at each study site and will be prepared and handled according to the site's standard practice.
223671743|NCT01376440|OTHER|household water treatment|household water treatment with 1.25% sodium hypochlorite
223671744|NCT06299488|OTHER|Sip2Sleep: Montmorency Cherry and Apocynum Venetum|See arm description
223671745|NCT00159497|DEVICE|porous coated Trilogy®|THA
223671746|NCT00159497|DEVICE|Trilogy Calcicoat®|THA
223771852|NCT04613609|DEVICE|Electronic Cigarette without nicotine|Non-smokers used an electronic cigarette without nicotine
224252479|NCT02356978|DEVICE|DRAP|
224252480|NCT02570009|BEHAVIORAL|TEAMS (Talking about Eating, Activity, Mutual Support)|
224252481|NCT02570009|BEHAVIORAL|Need Support Training|
224252482|NCT02322983|BEHAVIORAL|Control of Stress|To control stress were measured (at different times: T1, T2, T3 and T4) Venham's Score, Heart Rate, Respiratory Rate, and the titration of gases.
224252483|NCT05844605|PROCEDURE|Non-invasive neuromodulation (TMS and/or tDCS)|Non-invasive neuromodulation (TMS and/or tDCS) coupled with intensive behavioural training (neurorehabilitation and/or cognitive rehabilitation)
224252484|NCT02008097|DEVICE|GE LOGIQ E9 Ultrasound System|"Subjects will have an ultrasound exam using the GE LOGIQ E9 Ultrasound System which has computer software that combines the color-flow image and B-mode image to produce the new B-Flow method of ultrasound."
224252485|NCT00960297|DRUG|Carboplatin|Carboplatin: AUC=6, given IV on Days 1, 22, 43, and 64
224252486|NCT00960297|DRUG|Paclitaxel|Paclitaxel: 200 mg/m2, given IV on Days 1, 22, 43, and 64
224252487|NCT00960297|DRUG|Bevacizumab|Bevacizumab: 15 mg/kg, given IV on Days 1, 22, and 43 (Note: bevacizumab will not be dosed on Day 64 prior to surgery)
224252488|NCT01033877|BIOLOGICAL|TdaP vaccine SSI|1 vaccine dose of 0.5 mL suspension for injection in a pre-filled syringe: \>= 20 I.U. tetanus toxoid (T), \>=2 I.U. diphtheria toxoid (d), 20 microgram pertussis toxoid (aP)
223771853|NCT03266562|DIAGNOSTIC_TEST|F-18 FES|Evaluate uptake of F-18 FES in breast tissue
223771854|NCT03266562|DIAGNOSTIC_TEST|F-18 FDG|Evaluate uptake of F-18 FDG in breast tissue
223771855|NCT00784446|DRUG|Oxaliplatin, Capecitabine, Bevacizumab, Imatinib|"Dose level I:~Bevacizumab day 1: 7,5 mg/kg body weight Oxaliplatin day 1: 100 mg/m2 Capecitabine days 1-14 bid: 800 mg/m2 Imatinib days 1-21: 300 mg~Repeat on day 22.~Dose level II:~Bevacizumab day 1: 7,5 mg/kg body weight Oxaliplatin day 1: 130 mg/m2 Capecitabine days 1-14 bid: 1000 mg/m2 Imatinib days 1-21: 300 mg~Repeat on day 22."
223771856|NCT03101709|DRUG|Cyclophosphamide|patients will receive a standard pre-conditioning regime with cyclophosphamide 0.8-1.0g/m2/day IV for 2 days(Day-5 to day-4).
223771857|NCT03101709|DRUG|Fludarabine|Fludarabine 25 mg/m2/day IV for 3 days (Day-5 to day-3).
223771858|NCT03101709|BIOLOGICAL|CART-19|CART-19 cells will be administered using a split dose on day0(10%), 1(30%), and 2(60%) after completion of the chemotherapy.
223771859|NCT01455116|PROCEDURE|Mild Induced Hypothermia|Induction of hypothermia to a target temperature of 32 - 34 degrees Celsius (90 - 93 degrees Fahrenheit
223771860|NCT00002335|DRUG|Emtricitabine|
223771861|NCT03296163|DRUG|MB02 (Bevacizumab Biosimilar Drug)|15 mg/kg IV every 3 weeks on Day 1
223771862|NCT03296163|DRUG|EU-approved Avastin®|15 mg/kg IV every 3 weeks on Day 1
223771863|NCT03296163|DRUG|Carboplatin|Carboplatin Area under the curve (AUC) 6 IV every 3 weeks on Day 1 for 6 cycles
223771864|NCT03296163|DRUG|Paclitaxel|Paclitaxel 200 mg/m2 IV every 3 weeks on Day 1 for 6 cycles
223771865|NCT01632800|DEVICE|High pulsed magnetic fields|Magnetic fields will escalate in strength
223771866|NCT00434668|DRUG|cisplatin/docetaxel|
223771867|NCT00434668|DRUG|cisplatin/vinorelbine|
223771868|NCT05647512|DRUG|LM-305|Administered intravenously
223771869|NCT05647512|DRUG|Dexamethasone|Administered orally
223771870|NCT04299711|OTHER|Exposed to the novel coronavirus disease 2019|Exposed to the novel coronavirus disease 2019
223771871|NCT05684679|OTHER|Incentive spirometer plus Chest physiotherapy|Incentive spirometer was given to IS group. However, a conventional chest physiotherapy was given to both groups in the optimal position.
223771872|NCT05684679|OTHER|Diaphragmatic breathing exercise plus Chest physiotherapy|Diaphragmatic breathing exercise was given to DBE group. In addition, a conventional chest physiotherapy was given in the optimal position.
223771873|NCT04900103|OTHER|ITV-Pal|Use of new technologies for volunteering
223771874|NCT05596669|DRUG|Ketamine|to examine the pain-relieving effects of ketamine vs ketamine magnesium infusion, as well as their influence on postoperative morphine consumption following nephrectomy; the secondary goal is to assess hemodynamic effects and pain severity
223771875|NCT03178656|DRUG|Sorafenib|continuous application of the drugs
223771876|NCT03178656|PROCEDURE|surgery|curative resection
223771877|NCT02968199|BEHAVIORAL|A brief intervention|The content of the intervention includes: (1) asking about tobacco use; (2) advising cessation; (3) assessing willingness to quit; (4) assisting in the attempt to quit; and (5) arranging follow-up.
223771878|NCT00782652|DRUG|inhaled nitric oxide|Continuous delivery at either 40 or 80 ppm for a duration of up to 14 days
223771879|NCT00782652|DRUG|nitrogen gas|Continuous delivery at either 40 or 80 ppm for a duration of up to 14 days
223771880|NCT04582422|OTHER|"Touch Therapy"|During the waiting process, first follow the touch flow chart and perform the touch in the waiting area for 10 minutes. When visiting the treatment chair, the companion will be asked to touch the child's unilateral hand for 5 minutes during the consultation process. A small chair is provided to accompany the child for a total of 15 minutes. The two groups will use the chip tool again after the consultation
223771881|NCT00637169|OTHER|Titration of oxygen therapy|Supplemental oxygen to maintain functional arterial oxygen saturations in one of two saturation target ranges.
223771882|NCT02714049|BEHAVIORAL|sex therapy|60 minutes each time, in person or on the telephone
223771883|NCT02714049|DRUG|flibanserin|FDA approved medication for treatment of hypoactive sexual desire disorder in premenopausal women
223771884|NCT00058331|BIOLOGICAL|epoetin alfa|
223771885|NCT06302387|PROCEDURE|Acellular Dermal Matrix|The ADM arm involved vertical soft tissue augmentation using an acellular dermal matrix. This process included the placement of a porcine dermal collagen graft (Mucoderm®, Institut Straumann AG, Switzerland) atop the dental implant site. The graft, measuring 15x20 mm, was hydrated in a 0.5% Metronidazole solution for 20 minutes before application, then trimmed and placed to extend 10 by 5 mm beyond the implant margins in both buccal and lingual directions. The primary wound closure was achieved using double mattress suturing with 6-0 Prolene (Ethicon, USA).
223771886|NCT06302387|PROCEDURE|Soft Tissue Expansion using Tenting Technique|The Tenting Technique arm involved soft tissue expansion using a submerged healing abutment to promote soft tissue growth. After implant placement, 2 mm healing abutments were set on the implants. Flaps were mobilized using vertical releasing incisions, and tension-free wound closure was achieved with horizontal mattress sutures followed by suturing the incision line with interrupted sutures for primary and submerged healing. This method aimed to create a subepithelial healing space for soft tissue expansion and augmentation.
223771887|NCT05458193|DRUG|Daridorexant|Film-coated tablet for oral use
223771888|NCT05458193|DRUG|Placebo|Film-coated tablet for oral use
223771889|NCT05164705|OTHER|Acute Intermittent Hypoxia|Participants will wear a non-rebreathing face mask and alternate between breathing 9% O2 gas mixture for up to 1 minute, or until the target SpO2 of 85 percent is reached, and normal room air (21 percent O2) until 2 minutes are complete. This cycle will be repeated 15 times, resulting in a 30-minute protocol.
223771890|NCT05164705|OTHER|Sham Acute Intermittent Hypoxia|Participants will wear a non-rebreathing face mask and breathe normal air (21 percent O2) for 30-minutes.
223771891|NCT03145727|DEVICE|Placebo Group|In this group, the TENS will be administered by 30 minutes prior to chemotherapy administration with the stander electrodes positions, in the opposite arm of the chemotherapy infusion, but in this group the electrical stimulation will be performed just by 10 seconds and turn off for all reminiscent time of the protocol.
223771892|NCT03145727|DEVICE|Low Frequency Group|In this group the TENS will be administered by 30 minutes prior to chemotherapy administration with the stander electrodes positions, in the arm opposite the chemotherapy infusion. The electrical stimulation will be continued for all time secession. The electrical pulse parameters will be setting according describe early.
224252489|NCT01033877|BIOLOGICAL|Td vaccine SSI|1 vaccine dose of 0.5 mL suspension for injection in a pre-filled syringe: \>= 20 I.U. tetanus toxoid (T), \>=2 I.U. diphtheria toxoid (d)
224252490|NCT05763147|DEVICE|Intravenous Access Device Flushing|locking and flushing the end of catheter line at the intervals of different drug treatment.
224252491|NCT01299454|DRUG|OPC-34712|All groups will receive a single oral 2-mg OPC-34712 dose on Day 1 with 240 mL room temperature still water. Subjects will be administered the OPC-34712 dose in the fasted state (at least 8 hours of fasting) and no food will be allowed for 4 hours postdose. Water will be restricted as part of the dosing procedure from 1 hour prior to dosing and 2 hours post-dose.
224252492|NCT06628102|DIAGNOSTIC_TEST|Chest CT Scan|Chest CT Scan
224252493|NCT03214276|DIETARY_SUPPLEMENT|Vinitrox polyphenols|Vinitrox™ (Nexira - France) is a combination of specific profile polyphenols from grape and apple. The main polyphenol classes are proanthocyanidins (as catechins, B2 dimer), phenolic acids (as chlorogenic acids, gallic acids) and anthocyanins (as malvidin-3-glucoside). It was administrated the night and the morning before the endurance test (oral administration)
224252494|NCT03214276|DIETARY_SUPPLEMENT|Placebo|Made with maltodextrin. It was administrated the night and the morning before the endurance test (oral administration).
224252495|NCT05377931|DIAGNOSTIC_TEST|Changes in heart pulse rate|Measuring heart pulse rate using a wrest smart watch.
224252496|NCT05377931|DIAGNOSTIC_TEST|Changes in eye strain|Changes in Accommodation measured by auto refractometer before and after mobile battle ground gaming.
224252497|NCT03149874|DRUG|Hepatitis B recombinant DNA vaccine|Hepatitis B recombinant DNA vaccine
224252498|NCT03149874|DRUG|Combined hepatitis A and B vaccine|Combined hepatitis A and B vaccine given to the patients
224252499|NCT02305394|DRUG|ketamine and propofol|propofol 1.5 mg/kg and ketamine 0.3 mg/kg will be administered to participants separately by intravenous infusion.
224252500|NCT02305394|DRUG|propofol and normal saline|propofol 1.5 mg/kg and normal saline \[weight(kg)×0.3÷10\]ml will be administered to participants separately by intravenous infusion.
224252501|NCT01208727|PROCEDURE|postconditioning|Direct postconditioning (brief repeated cycle of 4 occlusion and desocclusion of the initially occluded culprit coronary artery) after primary direct stenting.
224252502|NCT01891994|DRUG|Eltrombopag|Oral administration of eltrombopag 150mg/day (75 mg/day for East Asian ancestry) for 6 months
223671747|NCT06482242|BEHAVIORAL|My Best Alaska Life|MBAL's combination of digital innovation, inclusive content, and youth-driven design positions it as a leading-edge intervention in the field of sexual health, with the potential to significantly impact the lives of Y/YA in AK and beyond. The open-access digital website enhances the reach and engagement of MBAL, particularly among adolescents who may prefer to seek information and support online in a private, self-paced setting. By allowing youth to fill out this tool at their own pace and return to their home page as they want to reflect/change answers, they can update it as their lives change. Additionally, MBAL incorporates interactive elements (question types of open response, ranking, scales, drag/drop; journaling prompts \& space) and personalized features (ex. avatars of common AK animals designed by Y/YA), allowing users to tailor their life planning experience according to their individual needs and preferences and return to their answers.
223671748|NCT05088239|DRUG|prophylactic antibiotics duration|Prophylactic cefazolin 1000 mg was given 30 minutes before surgery, every 4 hours in the peri-operative period, and every 6 hours in the post-operative care. Different discontinued duration of antibiotics was divided to 3 groups in one day, 3 days and until to drain removal.
223671749|NCT01830023|DEVICE|cardiac ultrasound examination|cardiac ultrasound examination to examine the vitality
223671750|NCT06099145|DEVICE|Hephaï|Used of the HEPHAI medical device as a tool to improve the delivery of inhaled treatments for asthma and COPD
223671751|NCT02762851|OTHER|Sterile saline|0.5 ml dose injected intramuscularly
223671752|NCT02762851|DRUG|inactivated trivalent influenza vaccine|0.5 ml dose injected intramuscularly
223671753|NCT00711516|DRUG|Armodafinil|Armodafinil once-daily (50 mg/day (1 tablet) on Day 1; increased to 100 mg/day (2 tablets) starting on Day 2; increased to 150 mg/day (3 tablets) starting on Day 5; increased to 200 mg/day (4 tablets) starting on Day 8). Then continue 200 mg/day dosage through Day 14.
223671754|NCT00711516|DRUG|Placebo|Matching Placebo dosed once-daily (50 mg/day (1 tablet) on Day 1; increased to 100 mg/day (2 tablets) starting on Day 2; increased to 150 mg/day (3 tablets) starting on Day 5; increased to 200 mg/day (4 tablets) starting on Day 8). Then continue 200 mg/day dosage through Day 14.
223671755|NCT02921061|DRUG|Cladribine|Given IV
223671756|NCT02921061|DRUG|Cytarabine|Given IV
223671757|NCT02921061|DRUG|Decitabine|Given IV
223671758|NCT02921061|BIOLOGICAL|Filgrastim|Given SC
223671759|NCT02921061|OTHER|Laboratory Biomarker Analysis|Correlative studies
223671760|NCT02921061|DRUG|Mitoxantrone Hydrochloride|Given IV
223671761|NCT01322776|DRUG|Combination of Bortezomib, Fludarabine and Cyclophosphamide|bortezomib 1.3mg/m\^2 i.v. on days 1, 4, 8 and 11 of each 28-day cycle fludarabine 25mg/m\^2 i.v. on days 1\~3 of each 28-day cycle cyclophosphamide i.v. on days 1\~2 of each 28-day cycle
223671762|NCT01455129|DRUG|Tiotropium|18 mcg tiotropium capsule, once daily, inhaled by HandiHaler, for 24 months
223671763|NCT01455129|DRUG|placebo|placebo, once daily, inhaled by HandiHaler
223671764|NCT02254239|DRUG|Brentuximab Vedotin|Given IV
224252503|NCT03559491|DRUG|Intravitreal injection|Long term release steroid injection
224252504|NCT00431730|PROCEDURE|flicker light stimulation|
224252505|NCT00202722|DRUG|Remifentanil|Intravenous patient controlled analgesia (ivpca) during labour
224252506|NCT02516839|BEHAVIORAL|Regulation of Cues (ROC)|Participants are provided information about basic learning theory and how physiological responses to food cues develop and can be managed. Lack of sensitivity to appetite and satiety cues and increased sensitivity to food cues will be discussed. Coping skills are presented to assist in mastery and toleration of food cue sensitivity. Participants will complete experiential learning exercises with food, and taught to monitor their hunger,satiety, and cravings. The physical activity program will focus on increasing both lifestyle activity and structured exercise programs.
224322198|NCT05565482|BEHAVIORAL|Work Chat: An Interactive Virtual Workday|Study participants will receive Standard Transition Services plus Work Chat will be a simulation training using virtual characters to role-play conversations. It will contain conversations with a coworker, a customer, and a supervisor within a workplace setting.
224252507|NCT02516839|BEHAVIORAL|Behavioral Weight Loss (BWL)|All participants will be instructed on how to consume a balanced deficit diet of conventional foods; individual goals for energy intake will be based on initial body weight. Participants will be instructed in measuring portion sizes, counting calories (with a calorie counter provided or on their phone), and self-monitoring food intake. The physical activity program will focus on increasing both lifestyle activity and structured exercise programs. Behavior change recommendations include stimulus control, self-monitoring, goal setting, managing high-risk situations, meal planning, slowing eating, problem solving, social support, cognitive restructuring, lapse and relapse prevention skills, and maintaining weight loss.
223771893|NCT03145727|DEVICE|High Frequency Group|In this group the TENS will be administered by 30 minutes prior to chemotherapy administration with the stander electrodes positions, in the arm opposite the chemotherapy infusion. The electrical stimulation will be continued for all time secession. The electrical pulse parameters will be setting according describe early.
223771894|NCT05155735|PROCEDURE|Replantation|Surgical reattachment of a severed body part
223771895|NCT05155735|PROCEDURE|Primary wound closure|Primary wound closure with removal of exposed bone
223771896|NCT06358079|PROCEDURE|Re-infusion of unwashed shed blood|Use of an isolated cardiotomy circuit for re-infusion of unwashed shed blood during off-pump coronary artery surgery
223771897|NCT00538005|BIOLOGICAL|bevacizumab|
223771898|NCT00538005|DRUG|oxaliplatin|
223771899|NCT00538005|DRUG|sorafenib tosylate|
223771900|NCT01336465|DRUG|placebo|Repeating subcutaneous injection
223771901|NCT01336465|DRUG|rhuMAb Beta7|Repeating subcutaneous injection
223771902|NCT03050086|DRUG|BPX-04 1% minocycline topical gel|once daily administration of topical minocycline gel to face
223771903|NCT03050086|DRUG|BPX-04 2% minocycline topical gel|once daily administration of topical minocycline gel to face
223771904|NCT03050086|DRUG|BPX-04 vehicle topical gel|once daily administration of topical minocycline gel to face
223771905|NCT01994512|PROCEDURE|Decompression without fusion|Decompressive surgery of both central and lateral component of the stenosis.
223771906|NCT01994512|PROCEDURE|Decompression with fusion|Decompressive surgery of both central and lateral component of the stenosis AND concomitant instrumented or uninstrumented posterior fusion of decompressed segments.
223771907|NCT00720876|BIOLOGICAL|rituximab|Rituximab will be administered at a dose of 375 mg/m2 on day 1 of every cycle, every 3 weeks.
223771908|NCT00720876|DRUG|vorinostat|200 mg twice daily, orally for 14 days followed by a seven day break on a 21 day cycle.
223771909|NCT02057107|RADIATION|SBRT|8.8-10 Gy per fraction (total: 44-50 Gy)
223771910|NCT02057107|DRUG|Cetuximab|"Day -7 (One week prior to commencement of stereotactic radiosurgery):~Cetuximab, 400 mg/m2~Days 0 and 8 (The 1st and 2nd week of radiosurgery):~Cetuximab, 250 mg/m2 Cetuximab, 250 mg/m2 will be given weekly ( following radiosurgery)"
223771911|NCT02057107|DRUG|Docetaxel|Days 0 and 8 (The 1st and 2nd week of radiosurgery) Docetaxel, 25 mg/m2 Docetaxel, 25 mg/m2 will be given weekly (following radiosurgery)
223771912|NCT03652324|OTHER|method|to compare the use of general anesthesia and deep sedation
223771913|NCT03666598|DEVICE|Tourniquet|In the patients randomized to the use of tourniquet, the tourniquet time starts before skin incision and terminates when the wound closure starts. The cuff pressure is set at 300mmHg.
224322199|NCT05124691|COMBINATION_PRODUCT|Albendazole and Ivermectin fixed dose coformulation|400 mg Albendazole - 9 mg Ivermectin OR 400 mg Albendazole - 18 mg Ivermectin
224322200|NCT05124691|DRUG|Albendazole|Albendazole 400mg single dose
223771914|NCT01298284|DRUG|propranolol|Starting from 20 mg daily, titrated weekly to decrease heart rate more than 25 % of baseline, administrated during the whole study period
223771915|NCT03198273|OTHER|Clinical pilates exercises|servical, lumbal, pelvic muscles
223771916|NCT03198273|OTHER|physiotherapy program|hot-pack will apply for 20 minutes. Convansionel TENS will apply on the lumbar regions of the cases of the control group paravertebrally with
223771917|NCT00286949|DRUG|Atomoxetine|Open Label uncontrolled active Drug intervention
223771918|NCT00260234|BIOLOGICAL|Allogeneic Cultured Islet Cells (human); Encapsulated|
223771919|NCT06165068|DRUG|Aspirin 81Mg Ec Tab|Patients take aspirin 81 mg per day.
223771920|NCT06165068|DRUG|Clopidogrel|Patients take clopidogrel 75 mg per day.
223771921|NCT06165068|DRUG|N-acetylcysteine|Patients are given N-acetylcysteine 600 mg per day.
223771922|NCT06200805|BEHAVIORAL|tai ji quan|24-Style Taijiquan as an Intervention for College Students with Insomnia
223771923|NCT05731219|BIOLOGICAL|B7-H3 target, CAR gene modified gdT cell injection|After the subjects who signed the informed consent form were screened by the inclusion/exclusion criteria, the qualified subjects will enter 1.0 in order of priority × 108，3.0 × 108 and 6.0 × 108 CAR gdT groups were administered once.
223771924|NCT03767959|PROCEDURE|Chen's U-Suture|Chen's U-Suture is a new technique of the invaginated end-to-end pancreaticojejunostomy with transpancreatic transverse U-sutures
223771925|NCT03767959|PROCEDURE|Classic pancreatic duct to mucosa|A Classical anastomosis technique for Pancreaticojejunostomy
223771926|NCT03495908|DEVICE|VGo|Eligible subjects will be randomized to either stay on RAI delivered by V-Go or randomized to switch to U-100 RHI delivered by V-Go.
223771927|NCT04683055|PROCEDURE|Phacoemulsification combined with trabeculectomy|Patients with chronic angle closure glaucoma assigned to this group will have fornex based trabeculectomy at superior limbus and then phacoemulsification via temporal incision
223771928|NCT04683055|PROCEDURE|Phacoemulsificaiton combined with ab-externo trabeculotomy|Patients with chronic angle closure glaucoma assigned to this group will have Deep Sclerectomy with ab externo trabeculotomy at superior limbus and then phacoemulsification via temporal incision
223771929|NCT02071576|DEVICE|Proscan|One device (500 Hz Excimer Laser - TENEO) with one intervention (Proscan)
223771930|NCT05854693|DEVICE|transCranial direct current stimulation|The intervention consisted of 20 daily 20-min sessions of bilateral prefrontal tDCS
223771931|NCT05854693|DEVICE|sham stimulation|The sham group consisted of 10 daily 20-min sessions of sham stimulation
223771932|NCT00099476|BEHAVIORAL|Effects of dark chocolate|
223771933|NCT06152211|BEHAVIORAL|Choir|A choir for older adults is a musical/singing ensemble composed of individuals aged 65 and above. The choir rehearsals are weekly, 2 hours each and the length of the intervention is 16 weeks total.
224252508|NCT02516839|BEHAVIORAL|BWL + ROC|BWL and ROC will be integrated for this arm, to capitalize on the strengths of both treatments. All participants will be taught to decrease caloric intake and increase physical activity, and to use all of the behavioral skills provided in BWL. However, they will also be taught models of hunger and satiety and about food cue reactivity, and will learn skills to manage these. This arm will include an experiential component, including hunger monitoring during dinner and participating in exposure sessions in the clinic.
224322201|NCT05847582|BEHAVIORAL|Standard inpatient psychiatric care|All participants involved in this study will receive standard of care treatment at Duke University Medical Center's Behavioral Health Inpatient Program.
223671765|NCT02254239|DRUG|Everolimus|Given PO
223671766|NCT02254239|OTHER|Laboratory Biomarker Analysis|Correlative studies
223671767|NCT02254239|OTHER|Pharmacological Study|Correlative studies
223671768|NCT01431209|OTHER|Laboratory Biomarker Analysis|Correlative studies
223671769|NCT01431209|DRUG|Ruxolitinib Phosphate|Given PO
223671770|NCT03758885|DRUG|Nolasiban|Nolasiban single oral administration
223671771|NCT03758885|DRUG|Placebo|Placebo single oral administration
223671772|NCT03315052|DRUG|Budesonide|Oral steroid with high first-pass metabolism in liver
223671773|NCT03315052|DRUG|Tacrolimus（FK506）|Calcineurin immunosuppressant
223671774|NCT03315052|DRUG|Mycophenolate Mofetil|Immunosupressant
223671775|NCT03315052|DRUG|Prednisone|Immunosuppresant
223671776|NCT01711385|BEHAVIORAL|Enhanced intervention|Study patients are notified of their blood test result within 72 hours. Those identified as potentially pre-diabetic or diabetic, and randomized to the enhanced intervention arm, receive a tailored message about their modifiable risks and are advised to see their physician regarding their test results or are provided with a referral to one. They are given a letter to take to their physician that specifies the risk factors identified, the tests carried out for the patient and the exact numeric results. They receive a call at month 2 to see if they have followed up with a physician regarding their test results. If they have not seen a physician regarding their results, they are advised again to do so and reminded of their individual risk factors. At month 4 they are asked again if they have seen a physician regarding their test results. If they still have not seen a physician at this time the message is reinforced. They are contacted again by phone to schedule the 6-month recall visit.
223671777|NCT04482985|DRUG|Meclizine Hydrochloride|Meclzine is given to all study participants to prevent seasickness. Meclizine plasma levels are determined from both the meclizine responders and non responders group.
223671778|NCT03631108|DIAGNOSTIC_TEST|OCTA (ZEISS)|All participants will underwent imaging using the OCTA system (Zeiss) with the anterior segment optical adaptor lens.
223671779|NCT06521879|DIETARY_SUPPLEMENT|Lactobacillus plantarum 299v probiotic support|Addition of Lactobacillus plantarum 299v (L. plantarum 299v) probiotic supplementation to iron replacement therapy.
223671780|NCT01029405|DRUG|AN2728|Ointment B, 2% or 0.5% applied once or twice daily
223671781|NCT01029405|DRUG|Placebo|Ointment B Vehicle applied once or twice daily
223671782|NCT05592873|DRUG|Neoadjuvant chemoradiotherapy (CRT)|Patients with histological diagnosis of locally advanced rectal adenocarcinoma \[clinical T3-T4N0M0 or T(any)N+M0\] were treated with neoadjuvant CRT followed by curative intent elective surgery between January 2014 and December 2019.
223671783|NCT06217185|DRUG|Pyrotinib|Pyrotinib 400mg qd po continuously
223671784|NCT06217185|DRUG|Trastuzumab|For Trastuzumab, the loading dose for the first treatment cycle is 8 mg/kg, and for subsequent cycles, 6 mg/kg. It is to be used once every three weeks
223671785|NCT06217185|DRUG|Taxanes|Taxanes: Usual clinical dose is administered, in a 21-day cycle.
223671786|NCT06217185|DRUG|Capecitabine|Capecitabine: 650mg/m2 each time, given twice daily
223671787|NCT06112873|OTHER|Quality of Life Questionnaire|Patient (or Parent)-Reported Outcomes via specific questionnaires
223671788|NCT02610959|OTHER|Intervention group|The overall aim of the present project is to investigate if intake of cod in pregnancy has impact on infant development up to 12 month.
223671789|NCT02610959|OTHER|Control group|The overall aim of the present project is to investigate if intake of cod in pregnancy has impact on infant development up to 12 month.
223671790|NCT00703703|DRUG|Darifenacin|Darifenacin tablets 15 mg once daily
223671791|NCT00703703|DRUG|Tolterodine|Tolterodine extended release (ER) 4 mg once daily
223671792|NCT00703703|DRUG|Placebo|Placebo tablet once daily
223671793|NCT01435551|OTHER|Hypnotherapy|1 year study,1 hour session per month for 9 months, 3 remaining months evaluation
223671794|NCT01312623|OTHER|Remote ischemic preconditioning|Remote ischemic preconditioning at the left leg.
223671795|NCT01307605|BIOLOGICAL|Rituximab|Rituximab (MabThera®) will be administered for a maximum of 8 infusions at weeks 1, 2, 3, 4 and again at weeks 12, 13, 14, 15 if the first restaging at week 10 (+/- 1 week) shows a partial response with at least more than 25% reduction in sum of product of diameters
223671796|NCT01307605|DRUG|lenalidomide|Lenalidomide will be administered as 15 mg flat dose daily, starting 14 days before first and stopping 14 days after last rituximab administration.
223671797|NCT00004382|DRUG|tin mesoporphyrin|
223671798|NCT00004382|PROCEDURE|Phototherapy|
223671799|NCT05331079|OTHER|Cryotherapy|20 minutes of cryotherapy on the dominant knee with ice bags
223671800|NCT04461041|DRUG|Empagliflozin|Single oral tablet
223671801|NCT04461041|DRUG|Placebo|Placebo tablet manufactured to mimic empagliflozin 10 mg tablet
223671802|NCT05480345|DIAGNOSTIC_TEST|Impedance cardiography|Transthoracic impedance cardiography recorded with ICG monitor (niccomoTM; Medis, Ilmenau, Germany): electrodes attached to both sides of the patient's neck (4 electrodes in total) and along the midaxillary line of the left and right sides of the chest (4 electrodes in total), employing the xyphoid process as a reference line.
223671803|NCT04924439|OTHER|foot reflexology|Foot reflexology was applied to the experimental group for 40 minutes once a week for postpartum 8 weeks. The control group was only watched.
223671804|NCT02483871|DRUG|Rosuvastatin|
223671805|NCT05459090|OTHER|ex-vivo study|ex-vivo experiments in tissue slices obtained from biopsies
224252509|NCT02516839|BEHAVIORAL|Nutrition Education, Stress Management and Social Support|Topics included will be stress management/relaxation, social support, and nutrition education. There will be a strong mindfulness component to this group.
224252510|NCT04215822|DIAGNOSTIC_TEST|Cytogenetic analysis (FISH) for EZH2 gene deletion. -Real time PCR for PHF 19 gene expression.|Cytogenetic analysis (FISH) for EZH2 gene deletion. -Real time PCR for PHF 19 gene expression.
223771934|NCT06152211|BEHAVIORAL|Group Music Listening|A weekly collective music listening, 2 hours each for 16 weeks.
223771935|NCT01351129|DRUG|Formulation 1|150-mg immediate release tablet (single dose)
223771936|NCT01351129|DRUG|Formulation 2|150-mg modified release capsule, short duration (single dose)
223771937|NCT01351129|DRUG|Formulation 3|150-mg modified release capsule, long duration (single dose)
223771938|NCT03246009|DRUG|rHSA/GCSF|single injection-1.8mg
223771939|NCT03246009|DRUG|rHSA/GCSF|single injection-2.1mg
223771940|NCT03246009|DRUG|rHSA/GCSF|single injection-2.4mg
223771941|NCT03246009|DRUG|rHSA/GCSF|multiple injection-1.8mg
223771942|NCT03246009|DRUG|rHSA/GCSF|multiple injection-2.1mg
224252511|NCT03916263|DRUG|Metformin|Traditional care including diet, exercise and metformin
224252512|NCT03916263|OTHER|One-On-One Dietary Instruction|Participant receives one-on-one dietary counseling from study personnel
224252513|NCT03916263|OTHER|Video Dietary Instruction|Participant receives video dietary instruction
223771943|NCT03246009|DRUG|rHSA/GCSF|multiple injection-2.4mg
223771944|NCT05468398|DEVICE|Soothe VR|The Soothe VR system is manufactured by Applied VR. It is a HIPAA-compliant platform and has been validated by randomized control trials. It has not yet been reviewed by the FDA.
223771945|NCT01862172|OTHER|Additional MRI|
223771946|NCT04634071|DRUG|Varenicline|Varenicline therapy will be 12-week course. On days 1-3 participants will receive 0.5mg once daily; days 4-7 receive 0.5mg twice daily and day 8 until the end of treatment receive 1mg twice daily.
223771947|NCT04634071|DRUG|Bupropion|Patients will begin with a dose of 150 mg every morning for 3 days. Then dosage will increase to 150 mg twice daily (morning and evening), for a total daily dose of 300 mg, for 7 to 12 weeks.
223771948|NCT04634071|DRUG|Long-acting nicotine replacement therapy|Nicotine replacement therapy (NRT) patches will be used daily from 1-10 weeks depending on participant's smoking history.
224322202|NCT05847582|BEHAVIORAL|Inpatient Skills Training|Inpatient skills training will be completed while participants are receiving inpatient treatment at BHIP. Skills training includes content designed to improve emotional regulation skills.
224322203|NCT05847582|BEHAVIORAL|mHealth-supported Skills Training for Alcohol-Related Suicidality (mSTARS)|mSTARS includes inpatient skills training and a mobile health (mHealth) telephone app designed to encourage participants to apply skills acquired in inpatient skills training to real-life situations.
223771949|NCT04634071|BEHAVIORAL|Low-intensity counseling|A study coordinator or a member of the treatment team will provide a minimum level of initial counseling, approximately 10-20 minutes in length.
223771950|NCT04634071|BEHAVIORAL|High-intensity counseling|A counselor will provide eight sessions in the first 8 weeks of the study. Up to three follow up sessions over the next 4 months of study will be encouraged, but not required.
223771951|NCT04634071|OTHER|No nicotine replacement therapy|Participants in this group will not receive per required need nicotine replacement therapy.
223771952|NCT04634071|DRUG|Nicotine Replacement Products|Participants in this group will receive per required need nicotine replacement therapy.
223771953|NCT05030142|PROCEDURE|Mechanical Thrombectomy|Mechanical thrombectomy (using a stent retriever among the following:Trevo NXT ProVue Retriever, Catchview mini, pReset Lite, Tigertriever 13) in association with the best medical treatment (usual care)
223771954|NCT05030142|DRUG|Best medical treatment alone|Best medical treatment alone (usual care)
223771955|NCT04616144|DEVICE|Fresh Corneal Lenticule Implantation using Relex-Smile VisuMax Femtosecond Laser|Fresh Corneal Lenticule Implantation using ReLex-Smile
223771956|NCT05065125|DEVICE|digital single-operator cholangioscopy|"1. Duodenoscope passes through esophagus and stomach to the papilla of Vater~2. SpyScope DS Catheter passes through the duodenoscope and into common bile duct~3. After direct visualization of anastomosis site stricture, guidewire is passed through SpyScope DS Catheter above the stricture site."
223771957|NCT01397695|DRUG|Bevacizumab|The bevacizumab will then be sprayed by the treating physician in the clinic, under direct observation. Spray will be achieved by administering the bevacizumab through a mucosal atomization device. 0.1cc will be sprayed into both nares. Patients will then sit for 5 minutes, the application will be repeated for a total of 40 applications, thereby administering 50mgs into each nostril, a total of 100mgs into each patient. The 5 minute spacing has been arbitrarily chosen as sufficient time for 0.1cc of solution to be absorbed by the nasal mucosa. That will complete the treatment.
224252514|NCT01275469|DRUG|GFT505 80mg|Hard gelatin capsules dosed at 20mg, oral administration, 4 capsules per day before breakfast.
224252515|NCT01275469|DRUG|Placebo|Hard gelatin capsules, oral administration, 4 capsules per day before breakfast.
224322204|NCT06252948|OTHER|Non-interventional study (observational)|Participants undergo stool sample collection, complete surveys, and have their medical record reviewed on study.
224322205|NCT05087212|DRUG|plerixafor + G-CSF|subcutaneous (SC) injection
224322206|NCT05635708|DRUG|Tislelizumab|Administered by intravenous infusion
224322207|NCT05635708|DRUG|BGB-A445|Administered by intravenous infusion
223771958|NCT02572050|PROCEDURE|Distal Gastrectomy with D2 LND|Robotic Distal Gastrectomy with D2 lymphadenectomy(#7, #8a, #9, #11p, #12a in Japanese Classification) for patient with stage II or III gastric cancer
223771959|NCT03063827|DRUG|OnabotulinumtoxinA 200 UNT|Patient in the treatment arm received a single injection of onabotulinumtoxinA 200 UNT to the detrusor muscle at 20 sites of the bladder body.
223771960|NCT03063827|DIAGNOSTIC_TEST|Urothelial sensory protein levels|Bladder tissues were investigated for urothelial barrier and inflammation proteins as well as urothelial sensory protein levels by Western blotting, between SCI patients and 10 controls, as well as successful and failed treatment groups.
224252516|NCT02104908|PROCEDURE|paravertebral nerve|a lumbar, sacral plexus and paravertebral nerve block(LSP) group with 20ml 0.5% ropivacaine at lumbar plexus(level L3-4) , 10ml 0.5%ropivacaine at sacral plexus and 10ml 0.5%ropivacaine at paravertebral nerve(level L1).
224322208|NCT05635708|DRUG|LBL-007|Administered by intravenous infusion
224322209|NCT05635708|DRUG|Carboplatin|Investigator's choice; administered by intravenous infusion
224322210|NCT05635708|DRUG|Cisplatin|Investigator's choice; administered by intravenous infusion
224252517|NCT02104908|PROCEDURE|lumbar and sacral plexus block|a lumbar and sacral plexus block(LS) group with 20ml 0.5% ropivacaine at lumbar plexus(level L3-4) and 10ml 0.5%ropivacaine at sacral plexus;
224252518|NCT03545451|DEVICE|Videogames|Videogames
224252519|NCT04435353|DEVICE|VibroLUNG|Lungs intensive therapy
224252520|NCT00838630|DRUG|Cilostazol 100 mg tablets|1 x 100 mg
224252521|NCT00838630|DRUG|Pletal® 100 mg tablets|1 x 100 mg
224252522|NCT01426633|DRUG|Gemcitabine + Trabectedin|Combination therapy of gemcitabine and trabectedin
224252523|NCT01746615|DEVICE|Dynamic Vessel Analyzer|retinal vessel diameter \& oxygen saturation
224252524|NCT01746615|OTHER|Bidirectional Fourier-Domain Optical Coherence Tomography (FDOCT)|retinal blood velocity
223771961|NCT01158625|OTHER|Change of time of administration|Change of time of administration
224252525|NCT01631383|DRUG|l-THP (l-tetrahydropalmatine)|Subjects will arrive the first day (Day 1) for admission and morning l-THP dosing. The l-THP will be dosed as one capsule 30 mg twice daily (matching placebo or l-THP) (total 60 mg daily). Participants will receive 7 total l-THP doses: two doses on Day 1 (morning and evening), two doses on Day 2 (morning and evening), 2 doses on Day 3 (morning and evening) and one dose the morning of Day 4 (cocaine administration day).
224252526|NCT01631383|DRUG|Placebo|Subjects will arrive the first day (Day 1) for admission and morning l-THP dosing. The l-THP will be dosed as one capsule 30 mg twice daily (matching placebo or l-THP) (total 60 mg daily). Participants will receive 7 total l-THP doses: two doses on Day 1 (morning and evening), two doses on Day 2 (morning and evening), 2 doses on Day 3 (morning and evening) and one dose the morning of Day 4 (cocaine administration day).
224252527|NCT05890261|DEVICE|Cold water-perfused cooling garment|Two types of cooling garments will be used. One is a cooling vest and the other includes cooling pants.
224252528|NCT04023461|DEVICE|PVAC GOLD catheter ablation|Isolation of pulmonary veins using PVAC GOLD catheter.
224252529|NCT03113877|OTHER|Autonomic Dysfunction Testing|The participants with CdLS will complete the COMPASS-31 survey and will complete standard clinical testing for autonomic dysfunction including an autonomic reflex screen (tilt table and quantitative sudomotor axon reflex testing) and thermoregulatory sweat test (TST).
224252530|NCT04147845|OTHER|Fractional Carbon Dioxide Laser|"The ablative fractional CO2 laser is delivered to the patients' scalp. The fractional ablative method is applied immediately before the topcial medication.~Laser treatment will be given to the affected area, and immediately after the treatment, the treatment solution will be dropped on the treated area and spread evenly"
224252531|NCT04147845|OTHER|Microneedling using dermapen|"Microneedling is performed using Dermapen. This creates pin point bleeding or mild erythema which will be considered as the end point.~The treatment solution will be applied on each lesion twice, before and after performing microneedling."
224252532|NCT04147845|OTHER|Triamcinolone Acetonide|triamcinolone solution (10 mg/ml) will be dropped on the treated area and spread evenly
224252533|NCT04147845|OTHER|Platelet-rich plasma|The applied PRP will be spread over the whole affected area
224252534|NCT00937898|DIETARY_SUPPLEMENT|BOLD+ Diet|Comparison of lean beef based, high protein diet to DASH diet and Average American diet on cardiovascular disease risk factors
224252535|NCT00937898|DIETARY_SUPPLEMENT|BOLD diet|Comparison of lean beef based diet to DASH diet and Average American diet on risk factors of cardiovascular disease
224252536|NCT01555645|BEHAVIORAL|Stress management, in two steps|All patients start at the first step of the intervention program with a two hours psychoeducation in stress management. Patients, who don't report a decrease in stress related symptoms, after the first step will be offered an intensive stress management, either in individual or group format. Components included in the intervention concern 1) basic knowledge about cancer, treatment, healthy living and stress reactions, 2) self-awareness with help of diary for thoughts, feelings and behavior 3) instruction in various techniques on how to express negative feelings, how to communicate with others more effectively, how to change behaviors related to stress 4) training these techniques in real-life situations 5) cognitive restructuring 6) spirituality, derived from cognitive behavior therapy.
224252537|NCT04167410|OTHER|glycaemic management protocol implemented to clinic|Following the introduction of the glycaemic management protocol to the clinic, data on the patients in the intervention group was collected prospectively between June 2018 and December 2018. Data of the patients in the intervention group was collected after the patient applied to the hospital for surgery or just after the decision on surgery was taken. Patients in the intervention group whose HbA1C values exceeded 7% were referred to endocrinology specialists prior to surgery. Glycaemic management of these patients was evaluated at the department of endocrinology and medications or doses of insulin and oral antidiabetics were changed when necessary. Glycaemic management was conducted by nurses in line with the protocolConsequently, the glycaemic management of patients during the perioperative period was conducted by general surgery nurses according to the protocol.
224252538|NCT01674166|DRUG|prucalopride|single dose 0.03 mg/kg prucalopride open label
224322211|NCT05635708|DRUG|pemetrexed|Investigator's choice; administered by intravenous infusion
224322212|NCT05635708|DRUG|Paclitaxel|Investigator's choice; administered by intravenous infusion
224322213|NCT05635708|DRUG|Nab paclitaxel|Investigator's choice; administered by intravenous infusion
223771962|NCT00203450|DRUG|Zonegran|zonisamide
223771963|NCT00203450|DRUG|Placebo|Placebo pill
223771964|NCT02386943|DRUG|Sitagliptin|100mg po once.
223771965|NCT02386943|DRUG|Saxagliptin|5mg po once.
223771966|NCT02386943|DRUG|Blank control|No medication is taken.
223771967|NCT01769885|DRUG|tivozanib|Given PO
224252539|NCT03410862|DRUG|Elderberry Extract|Thick reddish-brown liquid of Sambucus Nigra (Black Elderberry)
224252540|NCT03410862|DRUG|Placebos|Thick reddish-brown liquid similar in appearance and taste to Elderberry Extract not containing elderberry
224252541|NCT02865005|DRUG|Dapsone 5.0% Gel (SEEGPharm)|Topical Gel
224252542|NCT02865005|OTHER|Placebo|Topical Gel
224252543|NCT02865005|DRUG|Dapsone 5.0% Gel (Allergan)|Topical Gel
224322214|NCT05635708|DRUG|BGB-15025|Administered Orally
223771968|NCT01769885|PROCEDURE|therapeutic conventional surgery|Undergo nephrectomy
224252544|NCT02600403|DIAGNOSTIC_TEST|Optical Coherence Tomography (OCT)|Optical Coherence Tomography (OCT) is a machine that scans eyes and has the capability of measuring thickness of various layers of the retina and nerve fiber layer (NFL).
224252545|NCT02600403|DIAGNOSTIC_TEST|Visual evoked potential (VEP)|Visual Evoked Potential (VEP) is an imaging system that measures electrical activity from the eye to the brain by using electrodes placed on forehead and back of the head similar to electroencephalogram (EEG).
224252546|NCT02600403|DIAGNOSTIC_TEST|Humphrey Visual Field (HVF)|Humphrey Visual Field (HVF) is a test done to evaluate how much peripheral (side) vision has been lost due to glaucoma.
224252547|NCT05183503|DIAGNOSTIC_TEST|DC/TMD examination|Clinical examination by examiners- experienced dentists (minimum 5 years of practice) and trained and calibrated in accordance with the protocol available on the official website of the International Network for Orofacial Pain and Related Disorders Methodology
224252548|NCT01152827|DRUG|RAD001|"RAD001 10 mg daily po medication.~Treatments will be continued until any of the following events occur~* progression of disease~* the subject develops unacceptable toxicity~* consent to participate in the study is withdrawn"
224252549|NCT03140631|DRUG|Protamine Sulfate|Protamine sulfate is a highly basic protein that forms stable compounds with acidic heparin to rapidly neutralize the anticoagulation effects.
224252550|NCT03590782|OTHER|Erector Spinae Block|An ultrasound guided erector spinae block will be performed.
223671806|NCT03513445|DRUG|Morphine|Morphine, epinephrine, and ropivacaine cocktail will be administered peri-incisionally during lumbar spine surgery.
224252551|NCT01477476|DRUG|Anakinra|Anakinra treatment will be given I.V. as a bolus of 2 mg/kg infused intravenously over 30 minutes followed by infusion of 2 mg/kg/hour for 4 hours.
224252552|NCT01477476|OTHER|Placebo Comparator|A placebo will be given to 7 subjects.
223671807|NCT03513445|DRUG|Epinephrine|Morphine, epinephrine, and ropivacaine cocktail will be administered peri-incisionally during lumbar spine surgery.
223671808|NCT03513445|DRUG|naropin|Morphine, epinephrine, and ropivacaine cocktail will be administered peri-incisionally during lumbar spine surgery.
223671809|NCT00654147|DRUG|Raltegravir & Lopinavir/ritonavir|Two drug regimen of an integrase inhibitor and ritonavir boosted protease inhibitor
223671810|NCT00654147|DRUG|Raltegravir and emtricitabine/tenofovir|Three drug regimen of an integrase inhibitor and a fixed dose combination of a non-nucleoside/nucleotide inhibitors
223671811|NCT05440773|OTHER|Artemisia afra tea infusions|A. afra infusions of 5g/1litter of water, 3drinks a day, daily for 1week (7 days) (current recommendation).
223671812|NCT05440773|OTHER|Artemisia afra tea infusions|A. afra infusions of 5g/500ml of water, 2drinks a day, daily for 1week (7 days) (increase concentration and decrease dose frequency).
223671813|NCT05440773|OTHER|Artemisia afra tea infusions|A. afra infusions,5g/1liter of water, 3drinkss a day, weekly for 4weeks (decrease dose frequency and increase length of treatment).
223671814|NCT05440773|OTHER|Artemisia afra tea infusions|A. afra infusions, 5g/1liter of water, 3drinks a day, daily for1week (7 days) (current treatment with improved taste).
223671815|NCT05440773|OTHER|Artemisia afra tea infusions|A. afra infusions, 5g/500ml of water, 2drinks a day, daily for 1 week (7 days) (improved taste, increase concentration and decrease dose frequency).
223671816|NCT05440773|OTHER|Artemisia afra tea infusions|Group of 8 persons receiving flavored A. afra infusions, 5g/1liter of water, 3drinks a day, weekly for 4weeks (improved taste, decrease dose frequency and increase length of treatment).
223671817|NCT05440773|OTHER|Flavored placebo infusions|Flavored placebo infusions, 5g/liter of water, 3drinks a day, daily for 1week (7 days) (improved taste with no active molecule)
223671818|NCT05440773|OTHER|Regular tea placebo|Regular tea placebo taken as desired, daily for 1 week (7 days) (Regular tea with no active molecule).
223771969|NCT00005638|DRUG|cisplatin|
224252553|NCT03774680|DRUG|Cetuximab nanoparticles|The active group will receive cetuximab in nanoparticles as an anti-microbial drug.
223671819|NCT01534182|DRUG|Fingolimod|0.5 mg orally once a day
224252554|NCT03774680|DRUG|Oral approved anticancer drug|The placebo group will receive topical FDA approved anti-microbial jel in different dosage forms as control drug.
224252555|NCT04533295|DEVICE|acupuncture and IVF|Acupuncture was performed three times a week for 30 minutes each time, starting from the 5th day of menstruation and ending within 24 hours after embryo transfer.
224252556|NCT04533295|DEVICE|sham acupuncture and IVF|Sham acupuncture was performed three times a week for 30 minutes each time, starting from the 5th day of menstruation and ending within 24 hours after embryo transfer.
224252557|NCT02159950|OTHER|Laboratory Biomarker Analysis|Correlative studies
224252558|NCT02159950|BIOLOGICAL|Sipuleucel-T|Given IV
223771970|NCT00005638|DRUG|irinotecan hydrochloride|
223771971|NCT00005638|RADIATION|radiation therapy|
224252559|NCT02159950|DRUG|Tasquinimod|Given PO
224252560|NCT03325192|DRUG|Rapid pleurodesis protocol|"* The pleural space will be evacuated completely through the newly placed IPC~* 20mL of 10% iodopovidone and 80mL of normal saline will be instilled into the pleural space~* The patient will be transferred to the recovery unit~* Two hours after instillation the pleural space will be drained~* After recovery from anesthesia and complete drainage of the pleurodesis mix, the subject will be discharged~* Subjects will be asked to drain their effusion on a daily basis for the next 7 days and then on an every other day basis."
224252561|NCT03325192|OTHER|Placebo|"* The pleural space will be evacuated completely through the newly placed IPC~* Only placebo (normal saline) will be instilled into the pleural space~* The patient will be transferred to the recovery unit~* Two hours after instillation the pleural space will be drained~* After recovery from anesthesia and complete drainage of the pleurodesis mix, the subject will be discharged~* Subjects will be asked to drain their effusion on a daily basis for the next 7 days and then on an every other day basis."
224252562|NCT02272556|OTHER|Brain MRS during hyperglycemic clamp|All patients will undergo brain MRS at baseline and following 2 and 4 hours of hyperglycemia using the clamp technique
224252563|NCT02272556|OTHER|Analysis of Metabolites in cerebrospinal fluid|All patients will have the option to undergo a lumbar puncture for analysis of metabolites in cerebrospinal fluid
224252564|NCT02788240|DRUG|Peg GCSF|
224252565|NCT02788240|BIOLOGICAL|20% Albumin|
224252566|NCT02788240|DIETARY_SUPPLEMENT|Nutrition|
223771972|NCT02660918|DRUG|Bupivacaine|Paracervical injection of 20 mL 0.25% Bupivacaine at the completion of the procedure
223771973|NCT02660918|OTHER|Normal Saline|Equal volume injection of normal saline with the same paracervical technique
223771974|NCT05984394|DIAGNOSTIC_TEST|BAL antigen-specific Th1 cells and Th17 cells, ILC and MAIT|BAL antigen-specific Th1 cells and Th17 cells, ILC and MAIT
223771975|NCT05921773|DEVICE|AI-fNIRS neurofeedback device|The device, with AI-fNIRS signals serving as brain monitor to indicate the level of anxiety, provides mindfulness training through visual and auditory cues to help participants modulate their brain activity, and thus alleviates anxious states.
223771976|NCT05921773|DEVICE|AI-fNIRS neurofeedback device with sham signals|The sham control consists of playbacks of someone else's real AI-fNIRS neurofeedback and will be provided 3 times a week, for a total of 4 weeks.
223771977|NCT00403338|DEVICE|CYPHER® Bx Velocity™ stent (sirolimus-eluting)|
223771978|NCT04354922|BEHAVIORAL|Exercise intervention|Subjects in attention control group will receive one session of 75 minutes of stretching exercise weekly. All walking exercise session will be performed on motor-driven treadmill. Subjects in moderate-intensity walking groups will walk at an intensity of 3.25 metabolic equivalents (METs). Subjects in vigorous-intensity walking groups will brisk walk at an intensity of 6.5 metabolic equivalents (METs). Warm-up and cool-down will be provided before and after the training. Participants who failed to achieve 80% attendance will be excluded from the study. All exercise sessions were supervised by qualified athletic coach.
223771979|NCT02066558|OTHER|Carbon monoxide|carbon monoxide, 4.7, Purity 99.997, inhalation of carbon monoxide in a volume corresponding to carboxyhemoglobin 10 and 20%, calculated from baseline Hg and body mass.
223771980|NCT02066558|OTHER|Placebo|
223771981|NCT05683600|BIOLOGICAL|Recombinant SARS-CoV-2 Vaccine (CHO Cell) LYB001|Intramuscular injection of Recombinant SARS-CoV-2 Vaccine (CHO Cell) LYB001 in the deltoid muscle of the upper arm at day 0. The inoculation dose is 0.5 mL.
223771982|NCT05683600|BIOLOGICAL|Placebo|Intramuscular injection of placebo in the deltoid muscle of the upper arm at day 0. The inoculation dose is 0.5 mL.
223671820|NCT01534182|DRUG|Interferon beta - 1a (IFN)|44 mcg subcutaneously three times a week
223671821|NCT01534182|DRUG|Glatiramer acetate (GA)|20 mg subcutaneously once a day
223671822|NCT04293627|BEHAVIORAL|ATTAIN|ATTAIN is an 8-step model to identify co-occurring mental health conditions and facilitate linkage to mental health services for youth with an existing autism spectrum disorder diagnosis.
223671823|NCT01718977|OTHER|Body Weight Supported Treadmill Training|BWSTT protocol will consist of training of individuals with complete SCI on a treadmill with a body weight support system. BWSTT is assisted by three individuals who participate in training. One trainer provides support at the hip, and one trainer at each leg. The participant will be fitted with a harness while seated in their wheelchair and then wheeled up a ramp to the treadmill. Cables attached to the harness will be used to hoist the participant into a standing position. Appropriate body weight support will be set according to the suggested Hocoma locomotor training protocol, in which weight is added until the participant is in dynamic support as indicated by the dynamic gauge on the treadmill. Dynamic support is usually indicated at the weight where participants do not have knee-buckling during a static standing position; however, this may not be observed in all severe, motor-complete SCI participants.
223671824|NCT01718977|OTHER|Arm Cycle Ergometry Training|"Arm Cycle Ergometry Training ACET will be performed on an arm-cycle ergometer against individually determined levels of resistance. Upright hand cuffs will be used so that the hand will be placed with the thumb pointing downward, and the ergometer will be positioned so that the arm never exceeded the height of the shoulder.~The end objective is for the individual to complete 30-minutes of exercise in 2, 15-minute bouts. For safety reasons, stop criteria for individual sessions will be set and participants will have a rest period of 5 minutes and afterwards asked if they want to stop exercise, or resume the session."
223671825|NCT05384704|BEHAVIORAL|Empower@Home|The intervention is a 9-week course of internet-based cognitive behavioral therapy. During the active intervention phase, participants will receive weekly support from a trained research staff.
223671826|NCT00251160|PROCEDURE|Electrothermal arthroscopic capsulorrhaphy (ETAC)|The Oratec Vulcan Generator electro-thermal system (Oratec Interventions Inc., Menlo Park, CA, USA) delivers heat at 75C and 40 watts. An anterior portal is established above the superior border of the subscapularis tendon. For MDI patients, the heat probe is introduced through the posterior portal. The capsule is shrunk using a grid pattern until excess volume is diminished. The extent of the heat probe application is identical to the landmarks used for the open ICS. Care is taken to avoid applying heat to the capsule in the region from 5-7 o'clock within 1cm of the glenoid rim to avoid the axillary nerve. The method of heat application utilizes a grid pattern, which is less likely to cause dissolution of the capsule and subsequent catastrophic capsular loss.
223671827|NCT00251160|PROCEDURE|Open inferior capsular shift (ICS)|MDI: lateral capsule released antero-superiorly from rotator interval to equator, posteriorly on the humeral neck. MDL-AII: release from the rotator interval to 7 o'clock (Right) or 5 o'clock (Left) position on humeral neck, to tighten the 2 bands of the inferior GH ligaments, middle GH ligament and rotator interval. Bone adjacent to the articular surface on the surgical neck of the humerus is roughened to create a bleeding bony bed. With the arm in 0deg flexion, 30deg abduction, 30deg external rotation, the inferior leaflet of the capsule is shifted superiorly and slightly laterally, and sutured to the rim of the capsule using a non-absorbable suture. Superior leaflet is shifted inferiorly and sutured. Subscapularis is repaired at its anatomic length using interrupted sutures.
223771983|NCT03979716|DEVICE|fMRI|fMRI examination
223771984|NCT05815446|DEVICE|CT|NON CONTASR COMPUTED TOMOGRAPHY
223771985|NCT00945516|DEVICE|Bona stent® (Flared end FCSEMS)|Flared end FCSEMS for benign bile duct stricture will be inserted with ERCP.
223771986|NCT00945516|DEVICE|Hanarostent® (Anchoring FCSEMS)|Anchoring FCSEMS for benign bile duct stricture will be inserted with ERCP.
223771987|NCT03511560|DRUG|Tacrolimus Extended Release Oral Tablet|Tacrolimus, extended-release, oral (Envarsus); 0.75 mg, 1 mg, 4 mg tablets will be administered once daily at initial weight-based dose of 0.12 mg/kg.
223771988|NCT03511560|DRUG|Tacrolimus|Tacrolimus immediate-release, oral; 0.5 mg, 1 mg, 5 mg capsules will be administered twice daily per clinical judgment of supervising physician
223771989|NCT03372408|OTHER|Chart review|Retrospective chart review of program participation and socio-demographic \& psychosocial characteristics
224252567|NCT02788240|OTHER|Bowel wash|
224252568|NCT02788240|DRUG|Terlipressin 1- 4mg,if indicated|
224252569|NCT02788240|DRUG|Meropenem or Imepenem, if indicated|
224252570|NCT02788240|DRUG|Placebo|
224252571|NCT04280120|OTHER|Neural Mobilisation|Neural mobilization was applied by gently holding the lower part of the ear between the index finger and thumb. The thumb was placed at the opening of the external auditory meatus and the index finger placed behind the auricle of the ear (Figure 2). The intensity of auricular traction was determined by the patient reporting the level of discomfort. The patient tolerated 3-4 sets of gentle horizontal traction and circular movement 25 times each with 5 seconds rest.
224252572|NCT04280120|OTHER|Massage therapy|Massage therapy consisting of tapping, effleurage and finger and thumb kneading for 15-16 minutes.
224252573|NCT04280120|DIAGNOSTIC_TEST|Faradic electrical stimulation|Faradic electrical stimulation with anode electrode at the back of the neck and cathode over the nerve trunk anterior to the earlobe. The cathodic pen electrode was used to locate the facial nerve trunk for stimulation manually. (Biphasic current, pulse time 300 microseconds, frequency 60 Hz, 20 contractions, Rest 10 seconds). The total treatment time was 15 minutes.
224252574|NCT04280120|OTHER|Exercises|Exercises in front of the mirror like raising the eyebrow, clinching the teeth (patient trying to see his clenched teeth in the mirror), smiling and performing other facial expressions for 12-15 minutes.
224252575|NCT05915091|DIAGNOSTIC_TEST|Dry Needling|Dry needling is a treatment that healthcare providers use for pain and movement issues associated with myofascial trigger points. With this technique, a provider inserts thin needles into or near your trigger points. The needles stimulate your muscles, which causes them to contract or twitch
224252576|NCT05915091|OTHER|Cross Friction Massage|Cross friction massage breaks down scar tissue and remodels the tissue into more flexible, pliable, and functional, healthy soft tissue. Also known as transverse friction massage, this technique is a deep tissue massage technique performed at the site of injury
224252577|NCT06167122|PROCEDURE|Craniofacial reconstruction|"Zone 1 lesions: radical excision and immediate reconstruction with bone grafts for fibrous dysplasia lesions.~Zone 2 lesions: trimming \& recontouring. Zone 3 lesions: observation or conservative recontouring; optic nerve decompression performed when continuous deterioration of vision, and external auditory canal surgery performed when cholesteatoma/near total ear canal stenosis.~Zone 4: observation or conservative recontouring; orthognathic surgery performed when malocclusion or midface retrusion noted."
224252578|NCT03925532|BIOLOGICAL|Denosumab|Given SC
224252579|NCT05661097|PROCEDURE|Suture mode|Patients in the small hernia ring group received continuous suture with barbed wire according to simple random method Closure mode, intermittent full layer suture by hernia hook needle.Patients in the large hernia ring group received continuous suture with barbed wire according to simple random method Closure mode, intermittent full layer suture with hernia hook needle, continuous suture with barbed wire+hernia Intermittent full layer crochet suture.
224252580|NCT04018365|DRUG|Empagliflozin Tablets|The administration is oral administration with water before or after breakfast.
224252581|NCT06561997|DEVICE|Robot-assisted|received percutaneous pedicle screw fixation (PPSF) with robotic assistance
224252582|NCT06561997|DEVICE|Free-hand|received percutaneous pedicle screw fixation (PPSF) without robotic assistance
224252583|NCT04577846|DRUG|Cephalexin 500 MG|Cefalexin 500 mg PO q8 hours will be continued for the duration of the indwelling drains which usually is about 14 days.
223671828|NCT02427269|OTHER|Specimen Collection|"* 1 10mL red tube and 1 8.5mL yellow tube for serum, plasma, and buffy collection~* Up to 10 research-specific biopsies obtained from the esophagus during the routine care EGD.~* Four biopsies will be taken from the midpoint of the current BE (or midpoint of previous BE if the patient has already received ablation for previous BE),~* Two biopsies from normal squamous epithelium, and~* One biopsy from each area of esophageal nodularity seen during the procedure~* Pathology slides from routine care biopsies taken during the enrollment procedure, as well as retrospective pathology slides from routine care biopsies taken prior to enrollment on the study.~* Up to 4 cytology brushes during the procedure."
223671829|NCT02250833|DRUG|CKD-828|Telmisartan 80mg /S-Amlodipine 5mg(FDC) Tablet, Oral, Once Daily
223671830|NCT02250833|DRUG|Telmisartan|\- Telmisartan 80mg tablet, Oral, Once Daily (Combination Therapy with S-amlodipine)
223671831|NCT02250833|DRUG|S-amlodipine|\- S-amlodipine 5mg tablet, Oral, Once Daily (combination Therapy with Telmisartan)
223671832|NCT01687647|OTHER|low-dose CT-scan AND induced sputum sample AND blood test|All subjects will receive a low-dose CT-scan, a blood test (ancillary study) and provide an induced sputum
223671833|NCT00924170|DRUG|LMB-2|Begin with 30 mcg/Kg intravenous (IV) on days 3, 5 and 7. Escalate to 40 mcg/Kg if dose limiting toxicity (DLT) in 0/3 or 1/6 at 30 mcg/Kg. Continue at 40 mcg/Kg if 0-1 of 6 have DLT at 40 mcg/Kg.
223671834|NCT00924170|DRUG|Fludarabine|"Days 1-3:~Patients 1-7, 10-14, and \>18:25mg/m\^2/day Patients 8 - 9:30 mg/m\^2/day Patients 15- 17:20 mg/m\^2/day"
223671835|NCT00924170|DRUG|Cyclophosphamide|"Days 1-3:~Patients 1-7, 10 -14, and \>18:250 mg/m\^2/day Patients 8 - 9:300 mg/m\^2/day Patients 15-17:200 mg/m\^2/day"
223671836|NCT00579436|DRUG|omega-3 fatty acid|4g of omega-3 fatty acid daily by mouth for 12 weeks.
223671837|NCT00579436|DRUG|placebo|4 inert capsules daily by mouth for 12 weeks.
223671838|NCT02312882|DRUG|Tofacitinib|Tofacitinib 5 mg tablet taken by mouth twice a day.
223671839|NCT04449029|DRUG|GSK3228836|GSK3228836 will be available as a clear colorless to slightly yellow solution for injection at a unit dose strength of 150 mg/mL to be administered subcutaneously once weekly.
223671840|NCT04449029|DRUG|Placebo|Placebo will be available as a clear colorless solution for injection to be administered subcutaneously once weekly.
224252584|NCT04577846|DRUG|Placebo|A placebo capsule filled with inert material for the duration of the drains which usually is about 14 days.
223671841|NCT04449029|DRUG|Nucleos(t)ide therapy|Participants receiving nucleos(t)ide therapy upon entry in the study will continue to receive nucleotide therapy for the duration of the study.
223671842|NCT03934697|BEHAVIORAL|imaginal exposure therapy|All participants will complete the same arm, which is ten sessions of imaginal exposure across a ten week time period. Each session is separated by 1 week.
223671843|NCT02025556|DRUG|LBR-101 High Dose|Subcutaneously Administered High Dose LBR-101 Monthly x 3
223671844|NCT02025556|DRUG|LBR-101 Low Dose|Subcutaneously Administered Low Dose LBR-101 Monthly x 3
223671845|NCT02025556|DRUG|Placebo|Subcutaneously Administered Placebo (Vehicle) Monthly x 3
224252585|NCT06403930|DEVICE|Maxillary Obturator|Maxillary obturators are prosthetic devices used to close maxillary defects resulting from surgical removal of part or all of the maxilla bone due to conditions like tumors or congenital anomalies. They separate the oral and nasal cavities, restore speech, swallowing, and mastication functions, provide facial support, and improve aesthetics and quality of life.
224252586|NCT00144014|DRUG|V10153|Single acute intravenous bolus dose up to 10 mg/kg
223671846|NCT03585127|BEHAVIORAL|Cognitive Behavioral Therapy|Participants will be offered 9 individual and weekly sessions of 1 hour, which will be administered in an individual format by a licensed psychologist or psychiatrist trained in Cognitive Behavioral Therapy for psychosis (CBTp). The program is derived and adapted from current evidence-based treatments for hallucinations. The 9 CBTp sessions will consist of a succession of learning modules and suggested task assignments.
223671847|NCT03585127|BEHAVIORAL|Avatar Therapy|Participants will be offered 9 individual and weekly sessions of 1 hour, which will be administered in an individual format by a licensed psychologist or psychiatrist experienced with psychosis patients. The therapy will consist in prompting participants to enter in a dialogue with their persecutor to better regulate their emotional responses. Over the course of the therapy, the avatar's speech and tone will gradually be changed by the therapist to echo participants' improved ability to regulate their emotions. That is, the avatar will progressively change from being abusive to becoming helpful and supportive. By doing so, the therapy will seek to reinforce participants' feeling of empowerment over their voices.
224252587|NCT01208337|DRUG|Alemtuzumab|Alemtuzumab is a monoclonal antibody directed against the CD52 antigen. A single dose of 0.3-0.4 mg/kg is given to enrolled subjects at the time of intestine transplantation, 30 minutes after premedication with acetaminophen, diphenhydramine and methylprednisolone
223671848|NCT02829541|DRUG|BIIB068|Administered as specified in the treatment arm.
223671849|NCT02829541|DRUG|Placebo|Administered as specified in the treatment arm
223671850|NCT00396448|DRUG|CP-945,598 Treatment B|Subjects receive CP-945,598 plus dietary, physical activity, and behavioral counseling.
223671851|NCT00396448|DRUG|CP-945,598 Treatment A|Subjects receive CP-945,598 plus dietary, physical activity, and behavioral counseling.
223671852|NCT00396448|DRUG|Placebo|Subjects receive placebo plus dietary, physical activity, and behavioral counseling.
223671853|NCT00005646|DRUG|paclitaxel|150 mg/sq m IV over 3 hours weekly for 6 weeks per cycle
223671854|NCT02040636|BIOLOGICAL|Tetanus and Diphtheria Toxoids Adsorbed Combined with Component Pertussis Vaccine and IPV|0.5 mL, Intramuscular
223671855|NCT02040636|BIOLOGICAL|Hepatitis B vaccine|0.5 ml, Intramuscular
223671856|NCT00627445|DRUG|biphasic insulin aspart 30|Treat-to-target dose titration scheme (dose adjusted individually), s.c. (under the skin) injection before dinner
223671857|NCT00627445|DRUG|metformin|Tablets, 500 - 2000 mg, once, twice or three times daily
223671858|NCT00627445|DRUG|biphasic insulin aspart 50|Treat-to-target dose titration scheme (dose adjusted individually), s.c. (under the skin) injection before breakfast and lunch
223671859|NCT06472167|BEHAVIORAL|Breathing exercises|Breathing exercises as diaphragmatic breathing exercises and pursued lip breathing and incentive spirometry
223671860|NCT04098224|DEVICE|smART+ System|Utilizing the smART+ System to provide feeding optimization to the patient
223771990|NCT03026673|OTHER|NSAID use|The purpose of the study is to establish that NSAIDS are an appropriate analgesic to be used in the postpartum period, and thus women in the immediate postpartum period are the focus of this study.
224252588|NCT02399917|DRUG|Azacitidine|Given SC or IV
224252589|NCT02399917|BIOLOGICAL|Lirilumab|Given IV
224252590|NCT03663179|DEVICE|Transcranial Magnetic Stimulation (TMS)|A MagPro R30 (Magventure, Inc., Copenhagen, Denmark) device with a Cool-B65 A/P figure 8 coil will be used to deliver TMS. This coil has an active side and a sham side, and can be used to perform double-blinded studies. TMS will be administered at 10 Hertz (Hz) with an intensity of 120% of patient resting motor threshold. Stimulation will be delivered to the left dorsolateral prefrontal cortex using 20 sec cycles (i.e., 5 sec train with 15 sec inter train interval). Subjects will receive 80 trains per session for a total of 4000 pulses per session (\~26 min sessions). Twenty sessions will be completed on sequential weekdays (5 days per week for 4 weeks).
224252591|NCT03663179|DEVICE|Sham Transcranial Magnetic Stimulation (Sham TMS)|A MagPro R30 (Magventure, Inc., Copenhagen, Denmark) device with a Cool-B65 A/P figure 8 coil will be used to deliver TMS. This coil has an active side and a sham side, and can be used to perform double-blinded studies. For sham stimulation, the sham side of the coil is positioned toward the participant's scalp. The sham coil is designed to mimic the appearance and sound of active TMS stimulation, but is equipped with a magnetic shield that reduces the strength of the field by approximately 80%. This reduction in field strength ensures that no neural stimulation occurs. Twenty sessions will be completed on sequential weekdays (5 days per week for 4 weeks).
224252592|NCT05792774|DRUG|Bupivacain|The experimental intervention will consist of ultrasound-guided anesthetic blockade of the phrenic nerve at the laterocervical supraclavicular level with 1 ml of lidocaine without vasoconstrictor 2% to infiltrate the skin and 3ml of bupivacaine without vasoconstrictor 0.25% for neural blockade, making the local anesthetic surround the nerve between the anterior scalene muscle and the sternocleidomastoid muscle.
223671861|NCT06144749|DRUG|HBI-002|Oral liquid carbon monoxide drug product.
223671862|NCT06073223|OTHER|Usual Care|The control group will receive usual care, which involves providing no disease or treatment specific information outside the surgeon visit.
223671863|NCT06073223|OTHER|CQUPLE|"Our research team developed a novel intervention called CQUPLE (pronounced couple), which includes two interventions delivered together: (1) a Chart of side-by-side, evidence-based information comparing all three treatment options for low-risk thyroid cancer, including expected outcomes and (2) a Question Prompt List that contains key questions to consider asking the surgeon. The intervention is grounded in social cognitive theory and aims to increase patient awareness of treatment options and their outcomes, patient activation, and self-efficacy for decision making."
223771991|NCT03487913|DRUG|Lixivaptan|Oral vasopressin V2 receptor antagonist
223771992|NCT02985736|DRUG|Topicort Topical Spray|
223771993|NCT00382733|DRUG|Oral Topotecan|Topotecan will be received in one of the five dose levels:0.25mg/day,0.5mg/day, 0.75mg/day, 1.0mg/day, and 1.25mg/day.
223771994|NCT00433693|DRUG|R744|50μg(i.v.)/2 week until Hb concentration reaches to 11.0g/dL or above, then 25\~300μg(i.v.)/4 week
224252593|NCT05792774|OTHER|Placebo (physiological saline serum infiltration)|The placebo intervention will be similar in relation to 2% lidocaine without vasoconstrictor for the skin, but an ultrasound-guided puncture will be performed at the level of the subcutaneous cellular tissue by injecting 3 ml of physiological saline.
224252594|NCT01615198|DRUG|Olmesartan|10 mg, 20 mg, 40 mg capsules
223671864|NCT05881239|DEVICE|AROMHA Brain Health Test|The AROMHA Brain Health Test is a self-administered, at-home smell test developed as a potential primary screen for identifying individuals at risk for developing Alzheimer's and as a means to follow disease progression in individuals without overt cognitive symptoms. The smell test device consists of five physical smell cards and a paired web-based app that directs participants on how to sample odors and asks them questions regarding what they have smelled. The 45-minute smell test battery includes measures of odor intensity, identification, memory, and discrimination.
223671865|NCT06326476|DRUG|Siplizumab|40 mg doses
223671866|NCT04136119|OTHER|questionnaire|survey exploring practice of vitamin and micronutrient supplementation
223671867|NCT02181517|DRUG|abicipar pegol|Abicipar pegol administered to the study eye by intravitreal injection at day 1, weeks 4 and 8.
223671868|NCT02181517|DRUG|ranibizumab|Ranibizumab (Lucentis®) 0.5 mg administered to the study eye by intravitreal injection every 4 weeks from day 1 through week 16.
223671869|NCT02181517|OTHER|sham procedure|Sham procedure to the study eye at weeks 12 and 16.
223671870|NCT01203852|DRUG|Metoprolol|"Metoprolol 50 mg twice daily titrated to 100 mg twice daily~Note: due to discontinuation of the manufacture of chlorthalidone 15 mg, effective Jan 1, 2013; the starting dose of chlorthalidone will be 25 mg 4 times per week (Mon, Wed, Thur, Sat) with subsequent titration to 25 mg daily."
223671871|NCT01203852|DRUG|Chlorthalidone|Chlorthalidone 25 mg 4 times per week titrated to 25 mg daily
223671872|NCT02811276|OTHER|Diet|The High-Protein Diet Group will receive a eucaloric diet composed of 35% of carbohydrate, 40% of protein, and 25% of lipid constructed around a soy protein-based meal replacement (Almased®) for one and a half day. Participants will consume 1 gram ± 0.1 of Almased® per kg of body weight mixed with linseed oil and skim milk in their breakfast, lunch and dinner. Two snacks (afternoon and evening) composed of 1 gram ± 0.1 of Almased® per kg of body weight mixed with vegetable juice and linseed oil will also be provided.
223671873|NCT01251640|DRUG|BAY86-9766+Gemcitabine|Phase I: 40 mg/day (20 mg twice daily), 60 mg/day (30 mg twice daily, 100 mg/day (50 mg bid) dependent on safety/tolerability Phase II: Recommended Phase II dose (RP2D) dependent on the results of the Phase I part of this study Route of administration: Oral, twice daily (bid) in combination with gemcitabine 1000 mg/m2 Intravenous infusion over 30 minutes weekly for seven out of eight weeks (Cycle 1); followed by 1000 mg/m2 Intravenous infusion over 30 minutes weekly for three out of four weeks (Cycle 2 and subsequent)
223671874|NCT02536183|DEVICE|Magnetic resonance high intensity focused ultrasound|Magnetic resonance (MR)-high intensity focused ultrasound (HIFU) provides precise controlled delivery of heat by focusing ultrasound energy inside a lesion using an external applicator that is completely non-invasive and non-ionizing.
223671875|NCT02536183|DRUG|Lyso-thermosensitive liposomal doxorubicin|A heat-activated formulation of liposomal doxorubicin with unique property of heat-activated release of doxorubicin, an active agent in most pediatric solid tumors.
223671876|NCT02982603|DRUG|Qinggongshoutao Bolus|Qinggongshoutao bolus and placebo identified to Ginkgo Biloba Extract 761
223671877|NCT02982603|DRUG|Ginkgo Biloba Extract 761|Placebo identified to Qinggongshoutao bolus and Ginkgo Biloba Extract 761
223671878|NCT02982603|DRUG|Placebos|Placebo identified to Qinggongshoutao Bolus and placebo identified to Ginkgo biloba
223671879|NCT01544088|BEHAVIORAL|Group Cognitive Behavioral Treatment (GCBT)|GCBT is a 14 week intervention that includes components of exposure (imaginal and in vivo), cognitive restructuring, and relapse prevention.
223671880|NCT01544088|BEHAVIORAL|Present Centered Group Treatment|The active comparison treatment is a 14 week treatment that focuses on here and now problems, especially problem solving skills concerning ongoing stressors.
224252595|NCT01615198|DRUG|Placebo|Matching placebo of LCZ696 tablet, matching placebo of Olmesartan capsule
224252596|NCT01615198|DRUG|LCZ696|100 mg, 200 mg tablets
224252597|NCT02196675|DEVICE|Endocutter|The study utilized Echelon FlexTM Powered ENDOPATH® Stapler (Ethicon, Cincinnati, USA) along with compatible cartridges: Gray (closed staple height, 0.75mm), White (1.0mm), Blue (1.5mm), Gold (1.8mm), Green (2.0mm), and Black (2.3mm).
223671881|NCT00081861|DRUG|Avastin|10 mg/kg given intravenously every 2 weeks for 4 doses.
223671882|NCT00081861|DRUG|Rituximab|375 mg/m\^2 given intravenously weekly for 8 doses, 30 minutes to 1 hour following Bevacizumab.
223671883|NCT00247611|BEHAVIORAL|LifeWindows Intervention Sessions|At each clinical care visit, intervention arm participants use the full LifeWindows program, which includes welcome and assessment surveys and also includes the active intervention modules. ART adherence promotion intervention activities are tailored to the participant's assessment responses. Participants select which activities he or she wishes to use which culminates in an adherence specific goal.
223671884|NCT00247611|OTHER|Control|At each clinical care visit, control arm participants use the portion of the LifeWindows software program that provides a welcome from the avatar and collection of assessment items/surveys.
223771995|NCT02549144|DIETARY_SUPPLEMENT|Low fat/cholesterol diet|The low fat/cholesterol diet had 10% calories from fat and 150-200 mg of cholesterol per day.
223771996|NCT02549144|DIETARY_SUPPLEMENT|High fat/cholesterol diet|The high fat/cholesterol diet had 40% calories from fat and 250-300 mg of cholesterol per day
223771997|NCT06050590|DEVICE|NeuroGlove|Study participant with PTSD will undergo daily at home treatment using the NeuroGlove.
223671888|NCT03182543|DIETARY_SUPPLEMENT|Mango pulp beverage|"The subject consumes mango pulp beverage (200 g mango pulp + 600 mL water). 2 hours later subject performs the exercise test.~Washout: 1 week washout period prior to the administration of this intervention to avoid possible carryover effect."
223671889|NCT03182543|DIETARY_SUPPLEMENT|Mango pulp and peel beverage|"The subject consumes mango pulp and peel beverage (160 g mango pulp + 40 g mango peel + 600 mL water). 2 hours later subject performs the exercise test.~Washout: 1 week washout period prior to the administration of this intervention to avoid possible carryover effect."
223671890|NCT03182543|DIETARY_SUPPLEMENT|Control beverage|"The subject consumes control beverage (600 mL water). 2 hours later subject performs the exercise test.~Washout: 1 week washout period prior to the administration of this intervention to avoid possible carryover effect."
224252598|NCT02414152|DRUG|anakinra|100mg of anakinra adminstered by a subcutaneous injection for a minimum of 28 days, retreatment with additional 28 day cycle based on clinical response
224252599|NCT02105779|OTHER|Targeted Cognitive Training|At present, the TCT exercises consist of three modules: an Auditory Processing Module (40-50 hours of training); a Visual Processing Module (30 hours); a Cognitive Control Module prototype (20 hours). \[Based on the results of our current RCT, Posit Science has revised aspects of the training modules in order to further optimize its effectiveness for treatment of schizophrenia. In this study, we will use updated versions of the training software: an Auditory Module (30 hours), and a Visual Module (30 hours). Features from the Cognitive Control module prototype have been expanded and incorporated into these new modules.
224252600|NCT02105779|OTHER|Social Cognitive Training|We developed a systematic approach to basic training in facial emotion identification and discrimination and simple social perception and theory of mind tasks using components drawn from three commercially available software packages: the MicroExpressions Training Tool and The Subtle Expressions Training Tool (METT and SETT), plus the MindReading program. Training begins with simple emotion identification tasks, and slowly progressed to more difficult tasks that required subjects to discriminate between two subtle emotion expressions, and to correctly interpret the emotional significance of brief social scenes. A total of 10 hours of training occurred over 8 weeks.
224252601|NCT03037697|OTHER|TheraTogs Arm|TheraTogs Arm Received Soft Orthotic undergarments
224252602|NCT03037697|OTHER|Traditional Treatment|"Traditional treatment to Dyskinetic CP~1- Trunk control exercises 2- Core stability training 3- Proximal dynamic stability for the shoulder and pelvic girdles components. 4- Back and abdominal strengthening exercises 5- Standing exercises : - Standing alone gradually increase time. - Stride standing alone. - Step standing alone (other limb supported on wooden step then soft step and finally on small ball). - Standing on balance board"
224252603|NCT01197248|PROCEDURE|Cystocele plication|placement of sutures over the pubocervical fascia during the cystocele repair
224252604|NCT01197248|PROCEDURE|No Plication|Avoid sutures over pubocervical fascia during cystocele plication
224252605|NCT01289262|PROCEDURE|Purse string closure technique|Uterine incision will be closed with purse string closure technique.
224252606|NCT01289262|PROCEDURE|Continuously locked closure technique|Uterine incision will be closed with continuously locked closure technique
224252607|NCT06559748|DEVICE|transcranial magnetic thetaburst stimulation （TBS）|TBS group: iTBS was administered to stimulate RMFC, 80-100% RMT, 10 times a course, twice a day, for a total of 5 days; Conventional drugs group: pantoprazole 40 mg orally once a day; itopride 50 mg orally three times a day; treatment for 4 weeks. （Standard medication regimen）
224252608|NCT02755714|DRUG|Ipratropium bromide spray|The patient will - or will not - receive Ipratropium bromide spray (MDI) 20 μg given through a plastic spacer two puffs 1 hour before a continuous laryngoscopy exercise test (CLE-test)
224252609|NCT00838279|DRUG|Lamotrigine 25 mg Chewable Tablets|2 x 25 mg, single-dose fasting
224252610|NCT00838279|DRUG|Lamictal® 25 mg Chewable Tablets|2 x 25 mg, single-dose fasting
224252611|NCT02175602|DRUG|Escitalopram|10 milligrams administered each morning
224252612|NCT02175602|DRUG|Sertraline|50 milligrams administered each morning
224252613|NCT02175602|DRUG|DCV 3DAA FDC|Fixed dose combination (daclatasvir \[DCV\] 30 milligrams, asunaprevir \[ASV\] 200 milligrams, and BMS-791325 75 milligrams) one tablet administered twice daily
224252614|NCT02175602|DRUG|BMS-791325|75 milligrams single-agent film coated oral tablet administered twice daily
224252615|NCT04882150|DRUG|BMS-986196|Specified dose on specified days
224252616|NCT04882150|OTHER|Placebo|Specified dose on specified days
224252617|NCT06288035|DRUG|Dexamethasone Oral|Patients in the intervention group will receive oral 8 mg dexamethasone at night before surgery. The time of dexamethasone administration will be recorded.
223671891|NCT05468528|PROCEDURE|catheter radiofrequency ablation(individualized stepwise linear without pulmonary vein isolation)|individualized stepwise linear ablation without pulmonary vein isolation
223671892|NCT05468528|PROCEDURE|catheter radiofrequency ablation(PVI)|pulmonary vein isolation
224252618|NCT06288035|DRUG|Dexamethasone|Patients in the control group will receive intravenous 8 mg dexamethasone just before or at the induction of anesthesia. The dexamethasone ampule will be diluted in a 10 ml syringe and given in at least one minute to avoid unpleasant sensations in injection.
224252619|NCT01575457|BEHAVIORAL|Career Counseling and Motivational Interviewing|The Healthy Futures Program is an interactive, multi-session training program. There will be participants in 3 different intervention tracks (College/vocational school, Job, and Career Planning). Activities for all three tracks will occur simultaneously. The intervention group will receive the interactive, multi-session training program including newsletters and workshops. Comparison group participants will receive newsletters and be invited to participate in college and career planning workshops.
224252620|NCT03121716|BIOLOGICAL|SHR-1210|SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody.
224252621|NCT03121716|DRUG|Gemcitabine|gemcitabine
224252622|NCT03121716|DRUG|cis-platinum|cis-platinum
224252623|NCT01116362|PROCEDURE|primary repair|during the first days,the nerve was conducted to repair as end to end (epi-epineurium, epi-epineurium) anastomosis. This was performed following the repair of present tendons and muscle injuries.
224252624|NCT01116362|PROCEDURE|secondary repair|after one week,the nerve was conducted to repair as end to end (epi-epineurium, epi-epineurium) anastomosis. This was performed following the repair of present tendons and muscle injuries.
223671893|NCT04308889|DRUG|Lovaza|Lovaza contains ethyl esters of omega-3 fatty acids (EPA and DHA) obtained from the oil of several fish sources.
223671894|NCT04308889|OTHER|Cantharone|Cantharone is a clinical blistering agent for topical use to remove warts and molluscum contagiosum. We plan to use the drug to elicit a small skin blister and inflammatory response. This is a well described clinical inflammation research experimental model with multiple publications of its safety and utility in tracking the host inflammatory response.
223671895|NCT04308889|OTHER|Phlebotomy|Subjects will have blood drawn from the antecubital vein for not more than 15mL at each visit.
223671896|NCT04161638|BEHAVIORAL|Stigma Video Exposure|The participants watched a 10 minute video on a computer screen that consisted of brief clips from popular television shows that depicted women with overweight and obesity and evoked negative weight-based stereotypes (e.g., clumsy, loud, and lazy). Both the high blood pressure and normal blood pressure arms participated in this intervention.
223771998|NCT02681874|BEHAVIORAL|SSC Program|The Smart and Secure Children (SSC) program is a 10-week manualized intervention that uses a written validated curriculum. The program is group-based and co-led by peer leaders (Parent Leaders). Parent Leaders facilitate conversations on the SSC program content by sharing real life application, experiences, and solutions.
224252625|NCT03623230|PROCEDURE|Ultrasound Guided Femoral Nerve Block|Femoral nerve block will be applied post-operatively with guidance of USG and nerve stimulator
224252626|NCT03623230|OTHER|Dressing|Only dressing will be applied to related area to protect blindness between groups
223671897|NCT04161638|BEHAVIORAL|Neutral video exposure|The participants watched a 10 minute video on a computer screen that consisted of a series of clips depicting neutral scenes (e.g., insurance commercials). Both the high blood pressure and normal blood pressure arms participated in this intervention.
223671898|NCT05182112|RADIATION|Whole liver irradiation (WLI)|Whole liver irradiation (WLI) to a total dose 1800cGy in 10 fractions will be given over 2 weeks with simultaneously integrated boost (SIB) to deliver focal doses of 3600cGy (dose level 1) and 4800cGy (dose level 2) to select gross lesions. SIBl dose assignment will be according to the dose escalation scheme, with all patients in dose level 1 receiving boost of 3600cGy to select lesions and those in dose level 2 receiving boosts of 4800cGy to select lesions. At least one lesion will be selected for dose escalation.
224252627|NCT03623230|DRUG|Bupivacaine 0.25% Injectable Solution|Perineural Injection
223671899|NCT05182112|DRUG|Gemcitabine and Cisplatin|Patients will start cisplatin 10 mg/m2 and gemcitabine 600 mg/m2 intravenously q2 weeks for 1 cycle while undergoing simulation and radiation treatment planning procedures. After completion of CRT, adjuvant cisplatin 25 mg/m2 and gemcitabine 600 mg/m2 q2 weeks will be continued until progression or unacceptable toxicity.
223671900|NCT01964196|DRUG|ASP1517|Oral administration
223671901|NCT01964196|DRUG|Placebo|Oral
223671902|NCT00127465|PROCEDURE|Issue of information booklet|
223671903|NCT02578368|DRUG|5-Fluorouracil|2600 mg/m², d1 i.v., every 2 weeks
223671904|NCT02578368|DRUG|Leucovorin|200 mg/m², d1, i.v., every 2 weeks
223671905|NCT02578368|DRUG|Oxaliplatin|85 mg/m², d1, i.v., every 2 weeks
223771999|NCT02681874|BEHAVIORAL|Written Handouts|The handouts are a part of the SSC program that include didactic curriculum content and instruct parents to write goals and document goal progress.
223772000|NCT05217368|OTHER|mandala painting|In addition to routine antenatal education, pregnant women included in the experimental group will be asked to practice at least 1 mandala per day at least 5 times a week during the 6-week pregnancy education under the supervision of a researcher.
223772001|NCT05217368|OTHER|antenatal education|Routine antenatal education will be given.
223772002|NCT04363281|OTHER|preoperative questionnaire|"1. Three questions to predict acute pain:~   * Verbal numeric score Anxiety 0-10~  * Anticipated postoperative pain level~  * Anticipated analgesic requirements~2. Speilberger STATE-TRATE inventory index~3. Pain Catastrophizing Scale"
223671906|NCT02578368|DRUG|Docetaxel|50mg/m², d1, i.v., every 2 weeks
223671907|NCT02578368|DRUG|Trastuzumab|4 mg/kg BW (6 mg loading dose at 1st administration), i.v. for 1 h, d1, i.v., every two weeks
223671908|NCT02578368|DRUG|sodium folinate|can be used to replace leucovorin (calcium folinate)
223671909|NCT02578368|PROCEDURE|Surgery|Aim of surgical resection is a complete (R0) resection of the primary tumor and the metastases or a complete macroscopic cytoreduction of the metastases.
223671910|NCT06149468|OTHER|inclusion in the register|socio-demographic data collection and proposed therapy
223671911|NCT03087799|BEHAVIORAL|Brief Behavioral Treatment for Sleep|The BBT arm will consist of 2 in-person treatment visits and 2 telephone check-in visits. Treatment will involve psychoeducation about sleep hygiene and stimulus control as well as sleep schedule modification and sleep restriction. The treatment manual is attached for clarification. This manual is used solely to guide clinical decision making and will not be provided to participants.
223671912|NCT02055638|DRUG|SRX246|capsules
223671913|NCT02055638|DRUG|Placebo|
223671914|NCT00346424|DRUG|Alfimeprase|
223671915|NCT06427395|DRUG|Saroglitazar Magnesium 1 mg|Saroglitazar Magnesium 1 mg will be assigned to all participants enrolled in the open label extension program
223671916|NCT04475198|DRUG|ST-2427|Investigational drug
223772003|NCT04363281|OTHER|PACU questionnaire|parturients will be approached and requested to fill out a questionnaire regarding intraoperative pain, medication consumption, anxiety and nausea.
223671917|NCT04475198|DRUG|Placebo|5% Dextrose Injection
223671918|NCT02802917|DRUG|SPF 50 Y49 091 (BAY 987516)|5 μL of the appropriate test or control article were instilled into the lower conjunctival sac of the eye.
223671919|NCT02802917|DRUG|SPF 50 X15 158 (BAY 987516)|5 μL of the appropriate test or control article were instilled into the lower conjunctival sac of the eye.
223671920|NCT02802917|DRUG|SPF 50 X15 160 (BAY 987516)|5 μL of the appropriate test or control article were instilled into the lower conjunctival sac of the eye.
223671921|NCT02802917|DRUG|SPF 50 X57 162 (BAY 987516)|5 μL of the appropriate test or control article were instilled into the lower conjunctival sac of the eye.
224252628|NCT03623230|DRUG|Bupivacaine 0.125% Injectable Solution|Perineural Injection
224252629|NCT00803153|PROCEDURE|Panretinal Photocoagulation [Pattern Scan Laser (PASCAL) system]|
224252630|NCT03359356|DRUG|Dupilumab|A total of 24 doses
224252631|NCT03359356|DRUG|Placebo|A total of 24 doses
224252632|NCT06619041|BEHAVIORAL|HealthyTogether|HealthyTogether is a brief (8-session), virtual, dyadic weight management intervention.
224252633|NCT01218867|BIOLOGICAL|Anti-VEGFR2 CAR CD8 plus PBL|Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of anti-VEGFR CAR CD8+ PBL and high dose (Arms 1-7) or low dose (Arms 8-11) aldesleukin. On day 0, cells will be infused in the Patient Care Unit over 20-30 minutes (Phase 1: 10e6- 3x10e10 cells and Phase 2: maximum tolerated dose of cells from Phase 1)
224252634|NCT01218867|DRUG|Cyclophosphamide|Cyclophosphamide 60 mg/kg/day X 2 days intravenous (IV) in 250 ml dextrose in 5% water (D5W) with mesna 15 mg/kg/day X 2 days over 1 hr
224252635|NCT01218867|BIOLOGICAL|Aldesleukin|Aldesleukin (based on total body weight) will be administered at a dose of 720,000 IU/kg (Arms 1-7) or 72,000 IU/kg (Arms 8-11) as an intravenous bolus over a 15 minute period approximately every eight hours (+/- 1 hour) beginning within 24 hours of the cell infusion and continuing for up to 5 days (maximum 15 doses)
223671922|NCT02802917|OTHER|J & J baby shampoo, X46 046 (control)|5 μL of the appropriate test or control article were instilled into the lower conjunctival sac of the eye.
223772004|NCT04363281|OTHER|Postoperative questionnaire|Parturients will be approached at 24 hours postpartum and questioned regarding anxiety levels and medication consumption and requested to fill out the OBSQOR 11 questionnaire at 24 hours postpartum.
223772005|NCT04363281|OTHER|Postoperative questionnaire- Obstetrician|The attended obstetrician will be questioned regarding the parturient's level of intraoperative pain, postoperative pain levels anxiety medication consumption, uteronic management, surgical technique and management.
223772006|NCT04363281|OTHER|Postoperative questionnaire- anesthesiologist|he attended anesthesiologist will be questioned regarding the parturient's level of intraoperative pain, postoperative pain levels anxiety medication consumption, uteronic management, surgical technique and management.
223772007|NCT06573099|OTHER|No interventions need to be specified for this study|No interventions need to be specified for this study
223772008|NCT01543269|DRUG|ZYT1|Oral dose of ZYT1 in fasting condition with 240±10 ml of water at sitting position in ambient temperature.
223772009|NCT01543269|DRUG|Placebo tablets|Oral dose of Placebo in fasting condition with 240±10 ml of water at sitting position in ambient temperature.
223772010|NCT02170753|PROCEDURE|Regional manual therapy|The experimental group will receive regional thoracic, pelvic, and hip manual therapy and a standard physical therapy approach including motor control exercise and local lumbar spine manual therapy.
223772011|NCT02170753|PROCEDURE|Standard physical therapy|The control group will receive standard physical therapy including motor control exercise and local lumbar spine manual therapy.
223772012|NCT06572527|BEHAVIORAL|Physical Activity Program|"Nurse-Led Coordinated Physical Activity Program for Child Health, developed as part of the Coordinated Approach to Child Health program for preschool children."
223772013|NCT06572488|DEVICE|Non-ablative SMOOTH mode Er:YAG laser|Four intravaginal treatments within four months.
223772014|NCT06573411|DRUG|ACEI/ARB+ finerenone|The intervention group will be administered maximum tolerable dose of ACEI/ARB and finerenone 20 mg QD.
223772015|NCT06573411|DRUG|ACEI/ARB+ Placebo|Control patients will be administered maximum tolerable dose of ACEI/ARB and a placebo.
223772016|NCT04452357|RADIATION|PLDR|"PLDR radiation will be delivered as 10 fractions of 20 cGy, initiated once every 3 minutes. Dose levels will be selected as follows:~Dose level 1: 56 Gy; Dose level 2: 66 Gy Drug: Gemcitabine"
223772017|NCT05769452|DEVICE|closed IV catheter system (BD Nexiva™)|There is a high-pressure extension set and a Q-syte split septum needle-free intervention device at the tip of the catheter. It creates a closed integrated system with this apparatus, reducing the risk of catheter-related bloodstream infection.
223671923|NCT01397734|DRUG|Arsenic trioxide|0.15mg/kg/day Arsenic trioxide given IV on days 1-5 of the cycle.
223772018|NCT05769452|DEVICE|open IV catheter (BD Insyte™ Autoguard™)|BD Instaflash™ needle technology improves initial entry success by confirming vascular access through the needle noch. It has flexible wings for secure cannula fixation.
223772019|NCT06257784|PROCEDURE|Oxygen Therapy|Patients who have SpO2 \< 92% on room air will undergo oxygen therapy (nasal cannula or Venturi-mask).
223772020|NCT06257784|PROCEDURE|Non-Invasive Ventilation (NIV)|Patients with P/F \< 250 or Ph \< 7,35 with PCO2 \> 50 mmHg will undergo Non-Invasive Ventilation (NIV) (high flow nasal cannula or CPAP).
223772021|NCT06257784|PROCEDURE|Invasive Ventilation|Patients with P/F \< 150 associated to dyspnea at rest (moderate to severe, shortness of breath and/ or tachypnea (\>24 breaths/min) despite NIV for at least 2 hours or patients with Ph \< 7,2 with PCO2 \> 60 mmHg despite NIV for at least 2 hours will undergo invasive ventilation (intubation).
223772022|NCT03265028|BEHAVIORAL|TRACE e-learning|The TRACE e-learning (www.acutecough.org) is an educational web-based module including communication training for physicians, and includes patient booklets to be used interactively during the consultation.
223772023|NCT00439140|BIOLOGICAL|botulinum toxin Type A|Botulinum toxin Type A injection into the detrusor.
223772024|NCT00439140|DRUG|Normal Saline (Placebo)|Placebo (Normal Saline) injection into the detrusor.
224252636|NCT01218867|DRUG|Fludarabine|Fludarabine 25 mg/m(2)/day intravenous piggyback (IVPB) daily over 30 minutes for 5 days
223671924|NCT04678687|PROCEDURE|Liver, lung, heart and kidney biopsy|Liver, lung, heart and kidney biopsies will be performed on each case in the COVID-19 group.
223671925|NCT05299853|OTHER|Robot assisted arm training|Patients will receive 30 minutes of robot-assisted arm training and 30 minutes of conventional arm rehabilitation training. Patients will undergo 30 sessions of combined therapy (robotic+conventional) for a total of 6 weeks (5 sessions/week).
223671926|NCT05299853|OTHER|Conventional rehabilitation|Patients will receive 30 sessions of conventional arm training (60 minutes/day) for a total of 6 weeks (5 sessions/week).
223671927|NCT06022471|PROCEDURE|Stapes surgery|Stapedectomy operation
223671928|NCT04865523|OTHER|Manual Lymphatic Drainage|Manual lymphatic drainage is a technique that through gentle passes facilitates the flow of lymph through manual therapy techniques based on Vodder therapy. This technique is being studied to know its effectiveness in pain and for this reason we want to carry out this research.
223671929|NCT00709709|PROCEDURE|multislice coronary scan|multislice coronary scan
223772025|NCT00427804|DRUG|calcitriol|0.25 mcg PO BID for 1 week for low dose then 0.25 mcg PO BID for high dose
223772026|NCT05435573|DRUG|1000 mL of ringer's acetate solution|1000 mL of ringer's acetate solution
223772027|NCT05435573|DRUG|250 mL 6% hydroxyethyl starch (Voluven) then 500 mL of ringer's acetate solution then 250 mL of 6% hydroxyethyl starch (Voluven)|500 mL 6% hydroxyethyl starch 130/0.4 in 0.9% sodium chloride plus 500 mL of ringer's acetate solution
223772028|NCT00762489|OTHER|Temporal artery thermometer temperature|Newborn infants had a temporal artery temperature taken within a few minutes of the axillary and rectal temperatures. The axillary and rectal temperatures are taken via methods which are standard of care.
224252637|NCT01823263|BEHAVIORAL|Portion Size Task|Participants are given a computer program that gives them the opportunity to choose the portions of a variety of food items that they would ideally like to consume
224252638|NCT01823263|PROCEDURE|Blood sample|In the morning following partial sleep deprivation or normal sleep, a blood sample will be taken to assess the level of metabolism-linked and neurodegenerative-linked molecules, as well as to assay blood serum and plasma for the presence of hormones involved in hunger such as ghrelin
224252639|NCT01823263|PROCEDURE|Interference task|30-minute interference task
224252640|NCT01823263|BEHAVIORAL|Memory tasks|Participants will be allowed to learn a procedural memory task before going to bed. Participants will be retested in the morning to assess their change in performance. Other memory tests will also be given to assess the working memory performance in the morning following the intervention.
224252641|NCT01823263|BEHAVIORAL|Intake task|After a normal night of sleep or partial sleep deprivation, participants are presented with an ad libitum meal choice and can select the amount to ingest during a limited time window. Amount and selection will be recorded
224252642|NCT01823263|BEHAVIORAL|Working memory function task|Participants will be evaluated on their working memory performance in the morning following either nighttime intervention (NS or PSD)
224252643|NCT03792477|BIOLOGICAL|Test formulation|A single testosterone cypionate solution for injection (new formulation) 200 mg dose administered IM deep in the gluteal muscle (Test formulation).
223671930|NCT06174168|OTHER|Modified Frailty Index -11|MFI-11: the parameter included in the score is history of congestive heart failure, presence of diabetes mellitus, history of chronic obstructive pulmonary disease or pneumonia, functional health status/dependence, history of hypertension, history of myocardial infarction, cardiac problems, cognitive impairment, history of transient ischemic attack or cerebrovascular accident, history of peripheral vascular disease is questioned. Patients will be monitored according to standard non-operating room anesthesia procedures.
223671931|NCT00067938|DRUG|lamotrigine|Lamotrigine
223671932|NCT01640574|DRUG|Dihydroartemisinin-Piperaquine|Dihydroartemisinin-piperaquine + Primaquine: DHA-P 7mg/kg/day dihydroartemisinin and 55mg/kg/day piperaquine daily for 3 days and Primaquine 1 mg/kg once daily for 7 days
223671933|NCT01640574|DRUG|Dihydroartemisinin-Piperaquine|Dihydroartemisinin-piperaquine + Primaquine: DHA-P 7mg/kg/day dihydroartemisinin and 55mg/kg/day piperaquine daily for 3 days Primaquine 0.5 mg/kg daily for 14 days
223671934|NCT01640574|DRUG|Chloroquine|Chloroquine + Primaquine: Chloroquine 10, 10, 5 and Primaquine 1 mg/kg once daily for 7 days
223671935|NCT01640574|DRUG|Chloroquine|o Chloroquine + Primaquine: Chloroquine 10, 10, 5 and Primaquine 0.5 mg/kg daily for 14 days
223671936|NCT01286961|DRUG|bowel preparation using split dose of polyethylene glycol|polyethylene glycol, split dose(2L/2L), each dose for 1-2hours
223671937|NCT05048550|DEVICE|Near vision spectacles|Near vision spectacles prescribed for full time wear (Add+3.00DS to the full cycloplegic refraction). These glasses will be changed to reflect changes in refractive error or frame fit as appropriate at follow up.
223671938|NCT05870982|BEHAVIORAL|Early TRE|Participants will be instructed to eat only during an 8-hour window starting 1-2 hours after waking.
224252644|NCT03792477|BIOLOGICAL|Reference formulation|A single testosterone cypionate solution for injection (currently marketed formulation) 200 mg dose administered IM deep in the gluteal muscle (Reference formulation).
224252645|NCT02364063|OTHER|urotherapy with or without pharmacotherapy|Individualized
224252646|NCT01557712|DRUG|ketamine venlafaxine|"After a washout period of 7 days of psychotropic medications with the exception of cyamemazine and hydroxyzine:~* Intravenous injection on day 0 to 0.5 mg / kg of ketamine~* D0 to D4: 75 mg of venlafaxine~* D4 to D14: 150 mg per day of venlafaxine~* D14 to D42: 150 mg daily of venlafaxine to 375 mg per day of venlafaxine if patient not responder"
224252647|NCT01557712|DRUG|Venlafaxine|"After a washout period of 7 days of psychotropic medications with the exception of cyamemazine and hydroxyzine:~* Intravenous injection on day 0 to 0.5 mg / kg of placebo (saline serum)~* D0 to D4: 75 mg of venlafaxine~* D4 to D14: 150 mg per day of venlafaxine~* D14 to D42: 150 mg daily of venlafaxine to 375 mg per day of venlafaxine if patient not responder"
224252648|NCT04984473|DEVICE|Inspiratory muscle training|Inspiratory muscle training for 12 weeks at 40% maximal inspiratory pressure
224252649|NCT03655535|DRUG|BTI320|Non-systemic galactomannan complex polysaccharide
224252650|NCT03655535|OTHER|Placebo|Placebo
224252651|NCT02100761|DRUG|Voriconazole|Patients with creatinine clearance at least 50 ml/min will be treated with voriconazole by intravenous drip infusion at the dose of 6 mg/kg twice daily on the first day (Day 1) and 4 mg/kg twice daily from day 2 onward. The IV treatment is at least 7 days. Then switch to 200 mg orally twice daily between meals. The total treatment duration is at least 14 days Patients with creatinine clearance \<50 ml/min will be treated with oral voriconazole (loading dose of 400 mg twice daily followed by maintenance dose of 200 mg twice daily between meals for at least 14.0 days).
224252652|NCT01701492|OTHER|Questionnaire|A one-time assessment using both performance-based measures as well as both self- and parent-report questionnaires.
223671939|NCT05870982|BEHAVIORAL|Late TRE|Participants will be instructed to eat only during an 8-hour window starting 5-6 hours after waking.
223671940|NCT05870982|BEHAVIORAL|DCR|Participants will be instructed to reduce caloric intake by 25%.
223671941|NCT02805504|DRUG|Exparel|This group will receive intraoperative local Liposomal Bupivacaine injection at the surgical site.
223671942|NCT02805504|DRUG|Marcaine|This group will receive intraoperative Bupivacaine HCl injection at the surgical site.
223671943|NCT04645121|DEVICE|Carbon Monoxide-based Rebreathing|6 minutes Carbon Monoxide-based Rebreathing that estimate blood volume, plasma volume and erythrocyte volume.
223671944|NCT04645121|DEVICE|Bioimpedance|Measures total volume, intra and extracellular volume.
223671945|NCT04645121|RADIATION|Radioactive labelling of erythrocytes and albumin|Measure blood volume, plasma volume and erythrocyte volume.
223671946|NCT02395302|DEVICE|Dual Action Pneumatic Compression|Wear in sustained mode for 14 hours and pneumatic compression mode for 3 hours during the 4 week treatment period.
223671947|NCT02630043|DRUG|Tolcapone|Tolcapone is an oral agent that will be administered every day of each 21-day cycle during Cycle 1 and in combination with oxaliplatin during cycles 2-5 given IV on Day 1 of each 21-day cycle.
223671948|NCT02630043|DRUG|Oxaliplatin|Oxaliplatin will be given starting in Cycle 2 at 100 mg/m2 IV on Day 1 of each 21-day cycle
223671949|NCT01812447|DEVICE|Spiration Valve System|Subjects assigned to the treatment group will undergo a bronchoscopic procedure to have valves placed in the most diseased lobe of the lung to occlude all segments of the lobe.
223671950|NCT01812447|OTHER|Medical Management|Stable management is based on the ACP/ACCP/ATS/ERS Guidelines for Management of Stable COPD. Medical management will include management of COPD medications, oxygen use, and pulmonary rehabilitation.
223772029|NCT04424121|DIAGNOSTIC_TEST|CCTA|Coronary Computed Tomography Angiography
223772030|NCT01522859|DEVICE|Telehealth monitoring system (Honni Med)|The system is uploaded with personal information including: monitoring start time; clinical observations (blood pressure, heart rate, oxygen saturations); and questions relating to symptoms. The patient is instructed on use and observed monitoring. The patient is monitored daily for a period of six months. The monitoring session lasts approximately 10 minutes during which the patient attaches a finger probe and blood pressure cuff and responds 'yes' or 'no' to the set questions. Daily data is transmitted via a phone line to a secure server to be downloaded and reviewed by a Telehealth nurse.If one or more of the clinical observations is outside normal limits the appropriate healthcare intervention is utilised.
223772031|NCT03957174|DRUG|Reboxetine|Single dose used to increase central norepinepherine
223772032|NCT03957174|DRUG|Rivastigmine|Single dose to increase central acetylcholine
223772033|NCT03957174|DRUG|Placebo oral tablet|Single dose as control condition
223671951|NCT04577157|BEHAVIORAL|"mHealth usingWhatsApp multifaceted educational and reminder module intervention to improve adherence"|"This multifaceted educational and reminder module is named Health@click. The content of the reminder module has been made based on The Health Belief Model and self-determination theory.~1. Daily notes for medication reminders,~2. Daily a voice message with the same content will be delivered.~3. Daily Graphics-based Reminder (GBR).~4. Twice-weekly Graphics-based Messages (GBM) according to Health believe model and Self-determination theory constituents.~5. Once-weekly lifestyle advice through video~6. Hypertension at a glance, complete information will be provided(Optional)~7. 24/7 help provision service will be given to the participants. A qualified doctor will be there to provide this educational support. Support will be including the dose of medicine, frequency, mode of action, effects of medicine on current illness, side effects, and interaction with different foods (Optional)."
223772034|NCT02697019|BEHAVIORAL|Internet-delivered Emotion Regulation Individual Therapy for Adolescents|
223772035|NCT01798446|DRUG|Axitinib|Axitinib 5mg twice will be orally administered daily with one cycle of 4 weeks. The package of axitinib must be opened right before the administration due to its photosensitivity.
223772036|NCT01193556|DEVICE|PEAK PlasmaBlade TnA|The PEAK PlasmaBlade will be used for the tonsillectomy.
223772037|NCT01193556|DEVICE|Traditional Electrosurgery with scalpel|Traditional electrosurgery for the tonsillectomy.
223772038|NCT03384667|DRUG|Maekmoondong-tang|MMDT is a Herbal medicine consist of six herbs.
223772039|NCT03384667|DRUG|Placebo|The granules do not contain any active ingredients.
224252653|NCT01701492|OTHER|Neurocognitive Evaluation|A one-time neurocognitive evaluation conducted in the Psychology Clinic
224252654|NCT04031001|DEVICE|No-React Non-valved Conduit|Operative replacement of infected graft or implantation in infected area.
224252655|NCT00840411|DRUG|Clarithromycin ER 500 mg tablets|1 x 500 mg
223671952|NCT01087788|BIOLOGICAL|CZP 200 mg Q2W|200 mg subcutaneous (sc) injection of Certolizumab Pegol (CZP) every 2 weeks (Q2W).
223671953|NCT01087788|BIOLOGICAL|CZP 400 mg Q4W|400 mg subcutaneous (sc) injection of Certolizumab Pegol (CZP) every 4 weeks (Q4W).
224252656|NCT00840411|DRUG|BIAXIN® XL 500 mg tablets|1 x 500 mg
224252657|NCT01488630|OTHER|STaRS|The intervention entails testing an automated substance abuse treatment referral system (STaRS) to be implemented in primary care practices through electronic health record systems to improve 1) referral rates to specialty care providers, 2) patient treatment initiation with the specialty care providers, and 3) revenues to the practices.
224252658|NCT00464048|PROCEDURE|controlled physical exercise|
224252659|NCT05813678|DRUG|Pegvaliase|This is an uncontrolled, single-cohort, Phase 4 observational study not falling under the definition of an Applicable Clinical Trial (ACT) (i.e., non-interventional).
224252660|NCT06560580|DRUG|3% Diquafosol Sodium Eye Drops|Each patient was prescribed 3% (5 mL: 150 mg) diquafosol sodium eye drops \[Diquas®, provided by Santen Pharmaceutical (China) Co., Ltd.\], recommended to instill one drop six times daily for 3 months. Follow-up examinations were conducted at baseline, 1 month, and 3 months after treatment initiation.
223772040|NCT03495024|DRUG|Varenicline|Oral medication approved to facilitate smoking cessation
223772041|NCT01149304|DRUG|Pentoxifylline|Pentoxifylline is given for 8 weeks since the evening of the day of intervention with a dose of 400mg applied three times daily (morning, noon, evening).
223772042|NCT01149304|DRUG|Ursodeoxycholic Acid|Ursodeoxycholic acid is administered for 8 weeks since the evening of the day of intervention. Dosage is 250mg given three times daily (morning, noon, evening).
223772043|NCT01149304|DRUG|Enoxaparin|Enoxaparin with a dose of 40mg is injected subcutaneously once a day for 8 weeks since the evening of the day of intervention after the HDR-brachytherapy.
223772044|NCT04260815|DEVICE|Transcranial direct-current stimulation (tDCS)|Transcranial direct-current stimulation is a non-invasive brain stimulation method that can modify spontaneous cortical activity in targeted brain regions. Anodal tDCS delivered through a positively charged electrode has been found to increase cortical excitability in a targeted brain region. Application of tDCS has been found to improve language production in healthy and brain-injured speakers.
223772045|NCT05228782|OTHER|HOW R U? Intervention|HOW RU? intervention uses trained volunteer peers to provide strength-based support sessions weekly for 12 weeks.
223772046|NCT01349283|BIOLOGICAL|HepavaxGene (thiomersal free)|10 µg/0.5 mL, intramuscular injection on Day 1, Month 1, Month 6
223772047|NCT01349283|BIOLOGICAL|Engerix B|10 µg/0.5 mL, intramuscular injection on Day 1, Month 1, Month 6
223772048|NCT00675116|DRUG|GW823296|
223772049|NCT03286140|PROCEDURE|Early endovenous ablation|
223772050|NCT03286140|PROCEDURE|Delayed endovenous intervention|
223772051|NCT01527916|DRUG|placebo|Placebo Comparator
223772052|NCT01527916|DRUG|donepezil|Active Comparator
223772053|NCT01527916|DRUG|ABT-126|low dose, middle dose, high dose
223772054|NCT04584710|DRUG|RTB101|Oral RTB101 10 mg hard gelatin capsule once daily for 2 weeks
224252661|NCT06560086|DRUG|Ketoconazole|A fetal developmental stage is precisely determined. Then, fetal tissues are extracted for in vitro cultivation. Intact aborted fetal testicular tissues are cultured in a medium containing 10-6 mol/L ketoconazole, which is the injectable solution powder. Ketoconazole is administered starting on the first day and then every other day, for a total of 7 times over the 14-day in vitro culture period.
224252662|NCT06560086|DRUG|Luteinizing Hormone|A fetal developmental stage is precisely determined. Then, fetal tissues are extracted for in vitro cultivation. Intact aborted fetal testicular tissues are cultured in a medium containing 1 IU/mL luteinizing hormone, which is the injectable solution powder. Luteinizing hormone is administered starting on the first day and then every other day, for a total of 7 times over the 14-day in vitro culture period.
224252663|NCT00002345|DRUG|Megestrol acetate|
224252664|NCT04699799|OTHER|Present odors to participants while recording brain activity|Present odors to participants while recording brain activity
224252665|NCT04419311|DEVICE|Vanguard® Knee System|Posterior cruciate ligament retention versus sacrificing is one of the main debates in total knee arthroplasty (TKA) and retention or sacrificing depends on the individual preference of the surgeon during the surgery. Whenever the surgeon decides to sacrifice the posterior cruciate ligament (PCL), another controversial question arises regarding the tibial insert type. While the posterior cruciate ligament-stabilized (PS) insert is widely used as the tibial insert in PCL-sacrificing TKA, it has some disadvantages such as increased polyethylene wear, additional bone resection, breakage of the post and patellar clunk syndrome. The ultra-congruent (UC) insert was designed to prevent bone loss in particular, and the other mentioned disadvantages of the conventional PS insert. However, patients with postoperative hyperextension have been seen to be associated with inferior clinical outcomes and knees become gradually more extended until two years after TKA using the UC insert.
224252666|NCT05729061|DEVICE|Assist-Knee|Investigational prosthetic knee-ankle device
224252667|NCT05729061|DEVICE|Prosthetic Knee|Commercially available prosthetic knee devices
223671954|NCT01087788|OTHER|Placebo|Matching Placebo to CZP injection.
223671955|NCT05365945|OTHER|NDT Bobath therapy|Their physiotherapy was based on exercises that heavily employed the core muscles to equalize tension and strength, according to the NDT Bobath concept. The duration of the treatment session for each patient in both groups was 120 minutes.
223671956|NCT05365945|OTHER|The classic exercises.|"They underwent classical neurological rehabilitation. such as passive exercises, but also an approximation. In addition, the patients performed self-assisted exercises on a manual rotor, and in order to relieve the directly affected limb, the patients exercised in a suspension system. As the physiotherapy progressed, the patients performed active exercises, and then active exercises with resistance, e.g. using the Thera Band. Patients also exercised their balance with the use of large gymnastic balls or sensor pads. A large part of the physiotherapy was locomotion training and gait re-education.~The duration of the treatment session for each patient in both groups was 120 minutes."
223671957|NCT06457672|DIAGNOSTIC_TEST|Group I|Complete Crown technique of superimposition
223671958|NCT06457672|DIAGNOSTIC_TEST|Group II|Gold standard technique of superimposition
223671959|NCT02687867|DRUG|Dabigatran (Pradaxa)|As prescribed by treating physicians
223671960|NCT02687867|DRUG|Vitamin K antagonist|As prescribed by treating physicians
223671961|NCT03772288|DRUG|TAK-659|Tablets.
223671962|NCT03772288|DRUG|NKTR-214|Intravenous infusion.
223671963|NCT02589600|DRUG|Zoledronic acid|Annual intravenous 5.0 mg
223671964|NCT02589600|DIETARY_SUPPLEMENT|vitamin D|800 IU daily
223671965|NCT02589600|DIETARY_SUPPLEMENT|calcium|approximately 1200 mg (dietary and supplement)
223671966|NCT02589600|OTHER|Saline|Annual intravenous saline placebo
223671967|NCT02303418|DRUG|Carbetocin|Carbetocin will be given slowly iv after delivery of the baby
224252668|NCT05729061|DEVICE|Prosthetic Ankle|Commercially available prosthetic ankle devices
224252669|NCT05729061|DEVICE|Prosthetic Foot|Commercially available prosthetic foot devices
224252670|NCT05729061|DEVICE|Ankle-Foot Orthosis|Commercially available ankle-foot orthosis devices
224252671|NCT02003547|DRUG|AMA0076|
224252672|NCT02003547|DRUG|Placebo|
224252673|NCT01985308|DEVICE|Magnetic Resonance Therapy (MRT)-Active|
224252674|NCT01985308|DEVICE|Magnetic Resonance Therapy (MRT)-Sham|
224252675|NCT05123495|BEHAVIORAL|Device Briefing Tool|A 4-item supplement to the WHO Surgical Safety Checklist designed to improve teamwork and communication around new/complex surgical devices
224322215|NCT04452825|BEHAVIORAL|Cancer and Aging: Reflections for Elders (CARE) Intervention|For full participants (not training case participants) five sessions (45-60 minutes each) will be delivered over an 8-week period (+4 weeks). Following these sessions, four brief booster sessions (20-30 minutes each) will be delivered at a rate of approximately one per month to extend the interventions to 6 months (+3 months).
223671968|NCT02303418|DRUG|Oxytocin|Oxytocin will be given slowly iv after delivery of the baby
223671969|NCT01615497|BEHAVIORAL|Standard Treatment as Usual (TAU)|Treatment normally offered at this clinic which could include individual or group alcohol and drug counseling sessions one time per week lasting one hour each time.
223671970|NCT01615497|BEHAVIORAL|Web-based CBT4CBT for alcohol plus TAU|Subjects work with a computerized program that teaches skills for stopping alcohol and drug use and increasing coping skills. Computerized sessions are one time per week and last about one hour per session. Plus TAU
223671971|NCT01615497|BEHAVIORAL|Web-based CBT with minimal clinical contact|Subjects work with a computerized program that teaches skills for stopping alcohol and drug use and increasing coping skills. Computerized sessions are one time per week and last about one hour per session. Plus 10 minute check in with clinician.
223671972|NCT02823444|OTHER|Magnetic Resonance Angiography|"Subjects who agree to participate in the study and provide written informed consent will undergo three station (abdomen/pelvis, thighs, and calves/feet) contrast and non-contrast enhanced magnetic resonance angiography of the lower extremities. Study visits may be split into two imaging sessions to decrease the time the participant is in the scanner if necessary. For image quality review, several participant may undergo only abdomen/pelvis imaging.~Performance of the non-contrast magnetic resonance angiography requires placement of magnetic resonance imaging compatible electrocardiography leads on the patient's chest, so that the heart rate can be monitored and images can be obtained timed to each individual patient's heart beat. Electrocardiography monitoring/gating is performed routinely, and is not investigational."
223772055|NCT04584710|DRUG|Placebo|Oral matching placebo once daily for 2 weeks
223772056|NCT00774631|PROCEDURE|Mild induced hypothermia (32-34°C)|"Mild Induced hypothermia:~Investigators are advised to use the cooling techniques as used in patients with cardiac arrest. Thus, the choice of cooling method will be left to investigators. Hypothermia will be induced by cold saline infusion as described in appendix 5 \[6, 48\]. Core temperature will be monitored by oesophageal probe and maintained between 32°C and 34°C during 48 hours and followed by strictly passive rewarming. During this phase of treatment, patients will receive deep sedation associated with neuromuscular blockers. Centers participating to the trial will have expertise in cooling methods."
224252676|NCT05123495|BEHAVIORAL|Surgical Safety Checklist|Reimplementation of the WHO Surgical Safety Checklist to improve adherence and utility of the checklist
224252677|NCT01458808|OTHER|Dietary sodium restriction|Restriction of 2 grams on daily sodium diet intake.
224252678|NCT01458808|OTHER|Dialysate sodium concentration reduction|Reduction of dialysate sodium concentration from 138 to 135 mEq/L
224252679|NCT01306630|DRUG|tivozanib (AV-951) and capecitabine (Xeloda®)|Tivozanib 1.0 mg or 1.5 mg oral once daily for 2 weeks followed by 1 week off. Capecitabine 825 mg/m2, 1000 mg/m2, or 1250 mg/m2, oral twice daily for 2 weeks followed by 1 week off. 1 cycle= 3 weeks. Cycles will be repeated in the absence of disease progression or unacceptable toxicity.
224252680|NCT01939717|OTHER|Dance group|"Participants will attend ten weeks of set dancing classes. Each class will be one and half hours. Family members will be invited to partner each participant with Parkinson's disease during the class. Set dancing steps and sets will be thought and progressed in line with the participants abilities. Frequent rests will be taken during the classes.~Participants will be given a home exercise programme which will involve chair based exercises, mental rehearsal, listening music, watching a dance DVD and practicing dance material thought in class."
224252681|NCT00227136|DRUG|5-Hydroxy-Tryptamine|
224252682|NCT06366009|DEVICE|NaoX in-ear EEG system|EEG recordings will be carried out simultaneously using standard EEG equipment (full set of electrodes according to the 10-20 system extended by additional temporal electrodes T9/T10) and the NAOX in-ear EEG system device.
224252683|NCT04773470|DIAGNOSTIC_TEST|Flexible Endoscopic Evaluation of Swallowing|Endoscopical swallowing study
224252684|NCT00175058|DEVICE|AO Therapy (aqueous oxygen)|90-min adjunctive reperfusion of hyperoxemic blood into target coronary artery, immediately following revascularization by means of PCI with stenting
223772057|NCT00774631|PROCEDURE|local recommendations and guidelines|"Investigational procedure:~This study evaluates the impact of mild induced hypothermia (32-34°C) during 48 hours followed by passive rewarming according to recommendations described in appendix. All treatment will be according to local recommendations and guidelines of medical societies and literature. Physicians are advised to use these recommendations; however, the best treatment option for the individual patient should be used.~Controls will receive standard care and will be also be deeply sedated for 48 hours."
224252685|NCT03696394|DEVICE|BioCartilage® Micronized Cartilage Matrix|BioCartilage® is a scaffold with Collagen Type II and cartilage matrix elements
223671973|NCT02796417|BEHAVIORAL|REHACOP|REHACOP group consists of 90-minute-long sessions 3 days per week. Specifically, REHACOP group remediation consisted of: Attention unit (4 weeks) training sustained, selective, alternant and divided attention; Memory unit (3 weeks) focusing on visual and verbal learning, recall and recognizing memory; Language unit (3 weeks) including grammar, syntax, vocabulary, verbal fluency, verbal comprehension, abstract language; Executive functions unit (2 weeks) training cognitive planning, proverbs, analogies; and Social cognition unit (1 week) exercising theory of mind, social reasoning and moral dilemmas
223671974|NCT02796417|BEHAVIORAL|Occupational activities|Occupational group activities conducted included drawing, gardening, reading the daily news and constructing using different materials (such as paper or wood).
223671975|NCT04008927|DIAGNOSTIC_TEST|HCV screening|All patients will have HCV screening using rapid tests. HIV and HBV testing will also be conducted and patients will be appropriately referred to appropriate health services.
223671976|NCT04008927|DIAGNOSTIC_TEST|Diagnosis of hepatitis C|HCV-RNA assay (GeneXpert, Cepheid) will be performed for all participants with positive HCV serology to determine if patients have chronic hepatitis C (defined by HCV-RNA\>10 UI/mL). In addition a measure of the liver stiffness will be performed.
223671977|NCT04008927|DRUG|HCV treatment|Direct-Acting Antiviral drugs will be prescribed for 8 or 12 weeks according to liver assessment.
223772058|NCT05058313|DEVICE|Photobiomodulation|Six weekly photobiomodulation sessions (PBMT) using the MILTA ™ GYNECO vaginal probe.
223772059|NCT00647621|DRUG|Extended Phenytoin Sodium Capsules 100 mg|3x100mg for 14 days, fasting conditions, continuing 2 days with dosing following high-fat breakfast on Day 16
223772060|NCT00647621|DRUG|Dilantin® Kapseals® 100 mg|3x100mg for 14 days, fasting conditions, continuing 2 days with dosing following high-fat breakfast on Day 16
224252686|NCT04395222|DRUG|Tocilizumab|Tocilizumab 8 mg/kg intravenously administered as a single dose on Day -1 of transplant conditioning regimen
224252687|NCT04395222|DRUG|Fludarabine|Fludarabine 30 mg/m2 intravenously administered on Day -7, Day -6, Day -5, Day -4, Day -3 of transplant conditioning regimen if under the age of 60. If over the age of 60, Fludarabine 30 mg/m2 intravenously administered on Day -5, Day -4 and Day -3 of transplant conditioning regimen.
224252688|NCT04395222|DRUG|Melphalan|Melphalan 140 mg/m2 intravenously administered on Day -2 of transplant conditioning regimen.
224252689|NCT04395222|DRUG|Anti-thymocyte globulin (rabbit)|Anti-thymocyte globulin (ATG) 1.5 mg/kg
224252690|NCT04395222|RADIATION|Total Body Irradiation|Total Body Irradiation (TBI) 2 Gray, administered on Day -4 and Day -3 of transplant conditioning regimen
224252691|NCT04495647|OTHER|Whole-Body Electromyostimulation|"Whole-Body Electromyostimulation (WB-EMS): Simultaneous, individually adjustable stimulation of 12 muscle groups using an interval approach with a duty cycle of 6s impulse/4s rest, bipolar electric current (impulse -frequency 85Hz, -width 350μs, rectangular pattern) will be applied.~After a 4-week conditioning period, 1.5x 20 min/week WB-EMS will be conducted for 4 weeks (total training duration 8 weeks). Easy to perform functional exercises focusing on balance, transfer ability, stepping and lower extremity strength/power will be done during WB-EMS. Exercise intensity will be individually prescribed and adjusted by rate of perceived exertion (RPE-Borg CR10 scale 4 (moderate) to 7 (hard)).~WB-EMS will be fully supervised one on one.~All three arms will receive the same intervention."
224252692|NCT03115242|OTHER|Contrast injection Sonovue®|In addition to standardized assessment routine care, a contrast injection will be performed during the neck vessels doppler ultrasound.
223671978|NCT01905423|DRUG|Albendazole (annual)|Albendazole 400 mg pnce annually
223671979|NCT01905423|DRUG|Diethylcarbamazine (annual)|Diethylcarbamazine 6 mg/kg once annually
223671980|NCT01905423|DRUG|Albendazole (semiannual)|Albendazole 400 mg twice annually
223671981|NCT01905423|DRUG|Diethylcarbamazine (semiannual)|Diethylcarbamazine 6 mg/kg twice annually
223671982|NCT03090048|DRUG|Vitamin A|Vitamin A 2-3 % concentration
223671983|NCT03090048|DRUG|Azithromycin|azithromycin monohydrate
223671984|NCT00726401|DRUG|COLD-fX|200mg BID for 4 weeks
223671985|NCT00726401|DRUG|Placebo|200mg BID for 4 weeks
223671986|NCT03044574|DEVICE|SCD|Intermittent pneumatic compression (IPC) with Kendall SCD™ Sequential Compression System 700 used continuously when the patient is in bed with 6-hours night interval free of compression: from 0 a.m. to 6 a.m. In the ICU SCD used continuously all day, and in surgery department - all time of bed resting. SCD used until discharge.
223671987|NCT03044574|DEVICE|GCS|Thigh-length graduated compression stockings with pressure of 18-21 mm. Hg at the ankle used all the time until discharge plus one month after discharge
223671988|NCT03044574|DRUG|LMWH|LMWH enoxaparin (Clexane) 40 mg once a day subcutaneously started on 1st or 2-5th postoperative day according to the bleeding risk and used until discharge.
223671989|NCT05507359|OTHER|clove gel|4.7% (Pain Out Dental Gel, Colgate Palmolive India Ltd, Solan, India) clove gel
223671990|NCT05507359|OTHER|Benzocaine gel|20% Benzocaine gel (Opahl gel)
223671991|NCT06055738|DRUG|Zimberelimab|240mg,d1,iv,Q21D
223671992|NCT06055738|DRUG|Albumin-bound Paclitaxel|260mg/m2,d1,iv,Q21D
223671993|NCT06055738|DRUG|Cisplatin|75mg/m2,d1,iv,Q21D
223671994|NCT02557074|DRUG|IL2|IL2 1.5MUI/d SC from day 1 to day 5 for the first course of treatment IL2 3MUI/d SC from day 1 to day 5 for the 3 following courses
223671995|NCT02557074|DRUG|placebo|NaCl 9% serum SC from day 1 to day 5 for the four courses of treatment
223671996|NCT00254579|DRUG|CP-675,206|15 mg/kg Q12W dosing regimen
223772061|NCT01950546|DRUG|nanosilver fluoride|The product will be applied in the volunteers in the morning, before the first class, in relative isolation, made with cotton rolls and Vaseline to protect the soft tissue. It will apply 30mg of the product with microbrush, previously standardized in a pilot study on cervical vestibular surfaces of incisors and canines healthy, on a total of 8 teeth, 4 upper and 4 lower. After a period of 7 days,the cervical dental biofilms will be collect, third on the buccal surfaces of incisors and / or canines upper and lower, with the aid of sterile spatulas.
224252693|NCT01642342|OTHER|laboratory biomarker analysis|Correlative studies
223671997|NCT04825197|DRUG|Poractant Alfa Intratracheal Suspension [Curosurf]|up to 4 doses (100 mg Kg) of Poractant alfa every 12 hours; each dose preceded by a recruitment manoeuvre in HFOV.
223671998|NCT00835029|DRUG|Clotrimazole varnish|Each patient will receive 14 syringes (with no needle, equivalent to 50 mg of Clotrimazole in each one) . The varnish will be applied on a dried denture at the inner side by means of a soft brush and left to dry for 60 sec for 14 days.
223671999|NCT00835029|DRUG|Clotrimazole troches|The troche group will be asked to dissolve it in the mouth according to the manufacture instructions five times a day after removal of the denture, for 14 days.
224252694|NCT01642342|OTHER|pharmacological study|Correlative studies
224252695|NCT01642342|BIOLOGICAL|recombinant albumin fusion protein sEphB4-HSA|Given IV
223672000|NCT05694377|BEHAVIORAL|electroencephalography-based neurofeedback (EEG-NFB)|The EEG-NFB training program will involve nine training sessions (three times a week over a 3-week period) each lasting 30 min. EEG-NFB training will be conducted with ProComp Infiniti Encoder and BioGraph Infiniti Software v.5.1.3. The training protocol will be set to decrease the EEG TBR value. For the 12 training sessions, all participants will be subjected the same EEG-NFB protocol at C3 electrode. The EEG-NFB training sessions consists of a 20-s baseline period (i.e., with no feedback), 30-min feedback presentation, and another 20-s baseline period. Subjects will be seated in front of a computer screen and animations will be used as feedback; the animation starts when the subject is sufficiently focused for 20 s. Three 10-min animations (flying duck, roller coaster ride, and moving ball) will be shown to the subject during each EEG-NFB training session. The raw EEG signal, TBR value over time, EEG signal noise, and EEG theta and beta wave amplitudes will be recorded.
223672001|NCT06070220|BEHAVIORAL|traditional occupational therapy intervention and client-centered intervention|"Traditional occupational therapy intervention and client centered intervention were given to the participants.~CC intervention is a dynamic approach that involves a systematic therapy process, that is, in which the participant and the therapist are active in the treatment process. In the current study, a treatment program was designed over a maximum of 5 occupations in which participants evaluated after THA indicated problems in activities of daily living according to COPM. This systematic and dynamic program consists of 4 phases: (1) client-centered goal setting, (2) negotiating an intervention plan, (3) the actual intervention, (4) an evaluation of the outcome and finally reporting to relevant others."
223672002|NCT06070220|BEHAVIORAL|Traditional occupational therapy intervention|"The following training procedure, which included exercise, transfer activities and home arrangements, was followed in common in both groups:~1. st day: After the operation, exercises to strengthen the muscles of the participants (thigh, hip and trunk muscles) were explained verbally and visually. Each exercise consists of 3 sets of 12 repetitions. Exercises were updated in bed, sitting or standing, depending on the participant's functional status, pain and fatigue. Additionally, transfer activities training was provided.~2. nd day: The exercises taught to the participants on the first day were repeated. Following these exercises, participants were given verbal instructions on gait training, and then gait training began. According to the pain and fatigue status of the participants, gait exercises were continued.~3. rd day: The work done on the first and second day was repeated. Pre-discharge home arrangements training was provided."
224252696|NCT02433639|DRUG|TH-302 monotherapy|TH-302 (480 ) mg/m2 D1, D8, D15 Q 4 weeks
224252697|NCT04497181|DEVICE|Coil embolization surgery|Embolization of aneurysms with various coils system
224252698|NCT03680222|PROCEDURE|Reversed Tracking Method|Reversed Tracking Method
224252699|NCT03360305|BEHAVIORAL|GAPcare intervention|Subjects will receive PT and pharmacist evaluation. PT will help determine whether subject may benefit from doing exercises to improve strength or balance. PT may also supply subject with an assist device. A pharmacist will ask patient about any medication they are taking and will make recommendations on how their medication could be changed to prevent falls. Pharmacists will communicate this information to subject's doctors. Subjects will receive a fall calendar for home, where they will record any falls they have after their discharge from the ED. They will receive a phone call at home asking about any recent falls and health care interactions. Study personnel will call subjects every 2 weeks for 6 months. Subjects may receive a referral for outpatient or home-based physical and occupational therapy at the end of the visit.
224252700|NCT02503293|DEVICE|Chrono Super PID then Generic Syringe-Gammanorm|"Each patient will receive the study treatment of Gammanorm using each of the two studied delivery devices according to the sequence randomly assigned based on a cross-over design:~• pump and then syringe~The use of automatic, programmable, compact pumps (such as CRONO SUPER PID) allows patients to remain mobile without interrupting their activities. Patients can infuse several sites simultaneously with infusion rates of up to 40 mL/h at 2 to 4 sites (abdomen, thighs, upper arms, lower back).~Rapid and manual administration of SCIg using a syringe could therefore represent an alternative method by decreasing the duration of administration (around 10 minutes per injection at 1 or 2 sites simultaneously). The injection is self-administered by the patient. The infusion rate usually is 1 to 2 mL/min. The use of low viscosity products could facilitate injection"
224252701|NCT02503293|DEVICE|Generic Syringe then Chrono Super PID-Gammanorm|"Each patient will receive the study treatment using each of the two studied delivery devices according to the sequence randomly assigned based on a cross-over design:~• syringe and then pump.~The use of automatic, programmable, compact pumps (such as CRONO SUPER PID) allows patients to remain mobile without interrupting their activities. Patients can infuse several sites simultaneously with infusion rates of up to 40 mL/h at 2 to 4 sites (abdomen, thighs, upper arms, lower back).~Rapid and manual administration of SCIg using a syringe could therefore represent an alternative method by decreasing the duration of administration (around 10 minutes per injection at 1 or 2 sites simultaneously). The injection is self-administered by the patient. The infusion rate usually is 1 to 2 mL/min. The use of low viscosity products could facilitate injection"
224252702|NCT02305706|PROCEDURE|starting position in colonoscopy|
224252703|NCT05099198|DRUG|Sitagliptin|Sitagliptin dispensing claim is used as the reference
224252704|NCT05099198|DRUG|Glimepiride|Glimepiride dispensing claim is used as the reference
224252705|NCT01921062|BEHAVIORAL|Motor imagery|The kinesthetic motor imagery training consists of the imagination of flexion, extension, abduction, adduction, pronation and supination of their injured wrist.
224252706|NCT00127946|PROCEDURE|AMNIOECHANGE|The AMNIOECHANGE consists of a transabdominal infusion of saline (heated to 37 ° C) with a needle 18 or 20 gauge under ultrasound monitoring while avoiding the placenta. In the case of a normal amniotic fluid, it must be replaced volume per volume of saline (eg depending on the tank where the puncture is made, it can be 300 per 300 ml). The total amount of amniotic fluid exchange is 600-900 ml. In cases of oligohydramnios, the AMNIOECHANGE results in a normalized volume of amniotic fluid.
224252707|NCT03129022|PROCEDURE|epidural anaesthesia|Women requesting epidural analgesia received a bolus of intravenous infusion of lactated Ringer's solution before initiation of the procedure. An 18-gauge Tuohy needle and closed-tip clear catheter with three lateral orifices were used in the sitting or lateral position, with a loss-of-resistance to air technique. Epidural catheters were routinely inserted 5-6 cm inside the epidural space. A test dose of 2 ml of lidocaine 2% was initiated followed by a loading dose of 10 ml of bupivacaine 0.25%. Analgesia is maintained throughout labor using 0.125% bupivacaine with fentanyl 2 μg/ml with patient-controlled epidural analgesia by means of a continuous epidural infusion (8 ml/h basal rate) and patient-controlled boluses (3 ml each) with 20-minlock-out intervals
224252708|NCT00576056|DRUG|Sorafenib|Oral sorafenib (400 mg BID) will start the next day after the first TACE treatment until unacceptable toxicity occurs, or until study termination.
224252709|NCT00576056|DRUG|TACE|TACE will be accomplished with gelatin microspheres (Embospheres) following delivery of 125 mg/m2 of cisplatin.
224252710|NCT01854047|DRUG|Dupilumab|Solution for injection, Subcutaneous injection
223672003|NCT01190735|DRUG|Caffeine alkaloid|"The following intervention will be provided for six consecutive weeks:~Week 1 (100 mg BID), Week 2 (200 mg BID), Week 3 (300 mg BID), Week 4 (400 mg BID), Week 5 and 6(500 mg BID). At the conclusion of the study, patients will decrease their dose by 100 mg BID every other day, until caffeine is stopped. This gradual reduction will be to prevent withdrawal symptoms. If a patient experiences a dose-limiting event, they will be terminated from the study, and will withdraw from the medication in the same manner. If dose-limiting events occur between visits, patients will be encouraged to decrease the caffeine dose back to the previously-tolerated dose until in-person assessment can be performed."
223672004|NCT02518880|OTHER|Parabolic flight|
223772062|NCT04814290|OTHER|health-related quality of life (HRQoL) (36-item short-form health survey, version 1 [SF-36]).|health-related quality of life (HRQoL) (36-item short-form health survey, version 1 \[SF-36\]).
224252711|NCT01854047|DRUG|placebo|Solution for injection, Subcutaneous injection
224252712|NCT01854047|DRUG|ICS/LABA therapy|Oral inhalation, Prior therapy with Mometasone furoate /formoterol, budesonide / formoterol, or fluticasone propionate / salmeterol continued at stable dose
224252713|NCT01854047|DRUG|Salbutamol/albuterol|Oral inhalation as needed
223672005|NCT02518880|OTHER|plasma volume measurements|
223672006|NCT02595632|OTHER|No intervention|
223672007|NCT03971877|DIAGNOSTIC_TEST|Rapid Polymyxin NP test|From rectal swabs of patients admitted in ICU and oncohaematology ward, investigators will use first a new culture medium (SuperPolymyxin) for screening the colistin resistant Gram negative and then a new rapid test (Rapid Polymyxin NP test) to confirm this resistance. These tests will be compared to the reference test of MIC (Minimal Inhibitory Concentration) determined by the broth micro-dilution (BMD) method.
223672008|NCT04762901|DRUG|Niraparib|Oral tablet
223672009|NCT04762901|DRUG|Doxorubicin|IV
223672010|NCT04762901|DRUG|Cyclophosphamide|IV
223672011|NCT04762901|DRUG|Paclitaxel|IV
223672012|NCT04762901|DRUG|Pegfilgrastim|Injection
223672013|NCT04762901|DRUG|Carboplatin|IV
224252714|NCT01854047|DRUG|Levosalbutamol/levalbuterol|Oral inhalation as needed
224252715|NCT01643135|DRUG|tranexamic acid|Transamine acts as antifibrinolysis which looks alike 0.9% NaCl (placebo)
224252716|NCT01643135|DRUG|0.9% NaCl|0.9% NaCL (NSS) is clear fluid which looks alike tranexamic acid
224252717|NCT00304733|DEVICE|cast vs. shoe|
224252718|NCT04086030|OTHER|Blood Flow Restriction Training|Patients will undergo standardized postoperative rehabilitation program including blood flow restriction training. Exercises will be performed with BFR at 80% LOP.
224252719|NCT04086030|OTHER|Sham Blood Flow Restriction Training|Patients will undergo standardized postoperative rehabilitation program where exercises will be performed with sham BFR pressure of 20 mmHG.
223672014|NCT00917293|DRUG|Pyridoxal 5'-Phosphate|Pyridoxal 5'-Phosphate 500mgs po bid for 12 weeks.
223672015|NCT00917293|DRUG|Placebo|Placebo 2 pills, po bid.
223672016|NCT06433856|OTHER|Cold Water Immersion|Cold water immersion consists in 12 min standing in 10 °C water
223672017|NCT06433856|DEVICE|Percussive Massage Therapy|Percussive massage therapy is performed with a massage gun on the thigh muscles for 12 min
223672018|NCT01908946|BEHAVIORAL|SMS reminders|SMS reminders for vaccination visit at 6, 10 and 14 weeks of life.
223672019|NCT00263861|PROCEDURE|management of therapy complications|Patients undergo an interview and clinical evaluation to measure demographic data, cutaneous sensation, gait and balance, vibration, lower extremity muscle strength, orthostatic blood pressure, and glycemic control.
223672020|NCT04240080|DEVICE|Accuvein® Veinfinder|Near-infrared light reflection utilized by healthcare providers to see superficial veins under the skin.
223672021|NCT06261281|BEHAVIORAL|Rehabilitation therapy|Including:Acupuncture: Regular acupuncture treatment that can prevent muscle atrophy, improve circulation, and have a stimulating effect. Exercise therapy: Training that focused on limb movements or joint mobilization to prevent muscle contracture, reduce joint mobility, improve spasms, and promote blood circulation. Others: Regular turning, back patting, and position changes performed by caregivers.
223672022|NCT06261281|DEVICE|Intermittent Oro-esophageal Tube Feeding|Based on this, the patients in the observation group were given nutrition support with Intermittent Oro-esophageal Tube Feeding (Medical Device No. 20010234, developed by the Swallowing Disorders Research Institute of Zhengzhou University). The entire feeding process strictly followed the standard procedure of Intermittent Oro-esophageal Tube Feeding. During the feeding process, patients were maintained in a semi-recumbent position with their head elevated, facilitating the placement of the tube into the oral cavity along one side, with the chin brought close to the manubrium sterni.
223672023|NCT06261281|DEVICE|Nasogastric tube feeding|The patients in the control group were provided nutrition support with Nasogastric tube feeding, while the feeding process strictly followed the relevant guideline. During the treatment, the patients remained in a continuous state of tube indwelling, receiving feeding every 2-3 hours with a maximum feeding volume of 200ml, of which the contents were consistent with the observation group. The entire feeding process was conducted by trained nursing staff. Besides, the tube was replaced by a new one every 5-7 days.
223672024|NCT02700633|DEVICE|Pacemaker|
223672025|NCT04403269|DRUG|IgIV|2 infusion at D1 and D2 (0.8 g / kg by IV infusion)
223772063|NCT02553746|DEVICE|Detection of the puncture site by ultrasound scan of the lumbar spine.|Neuraxial anesthesia will be performed to the patients after detection of the puncture site by ultrasound scan of the spine. The scanning will be performed as described by Arzola et al. The L3-L4 space will be identified by palpation and identification of the landmarks (Tuffier's line). The ultrasound probe will be placed perpendicular to the long axis of the spine. The spinous process will be identified (bright signal followed by dark triangular area). The probe will be moved to cephalad or caudal to identify the intervertebral space and when the best view of the ligamentum flavum is achieved two marks will be drawn on the skin: one at the center of the upper surface of the probe and one at the center of the right lateral vertical side of the probe. The intersection of the two landmarks will be the puncture site. The distance from the skin to the ligamentum flavum will be measured by the ultrasound caliper.
224252720|NCT01085825|PROCEDURE|D & C abortion|Participants will be randomized to receive their abortion using either manual vacuum aspiration or electric vacuum aspiration.
223672026|NCT00710762|DRUG|BIBF1120|
223672027|NCT00710762|DRUG|Placebo|
223672028|NCT00910507|BEHAVIORAL|Exercise counseling|Each participant in the experimental group receives 2 months of exercise counseling from the same physical therapist as described in previous research. In short, during each exercise counseling session, the physical therapist addresses the benefits of exercise for people with type 2 diabetes, advises each participant to adhere to the prescribed exercise program, and assists each participant by reviewing the prescribed exercise program. Exercise counseling is tailored to the stage of exercise behavior as described in previous literature. The experimental group is also provided access to a fitness center.
223672029|NCT00910507|BEHAVIORAL|Supervised exercise training|Participants who are randomly allocated to the comparison group receive a 2-month supervised exercise program. Each participant in the comparison group receives the same prescribed exercise program as the experimental group and is supervised during each exercise training session by a trained co-investigator in a controlled exercise laboratory setting.
223672030|NCT04397770|DRUG|SHR1210|SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody
223672031|NCT04397770|DRUG|apatinib mesylate|apatinib Mesylate is a small molecule tyrosine kinase inhibitor,Through selectively inhibiting the tyrosine kinase activity of the vascular endothelial growth factor receptor 2 (VEGFR-2).
224252721|NCT03922906|DEVICE|Pure-Vu System|Pure-Vu System is intended to connect to standard colonoscopes to help facilitate intra-procedural cleaning of a poorly prepared colon by irrigating and/or cleaning the colon and evacuating the irrigation fluid (saline water), feces and other bodily fluids and matter, e.g. blood.
224252722|NCT03193177|OTHER|the 21-day fasting-like diet|a fasting-like diet with 400 KJ energy intake per day for 21 days
224252723|NCT02160210|DEVICE|Ultrafine Endoscope|Ultrafine endoscope reaching to the cecum within 15mins is thought to be successful.Water colonoscopy with standard colonoscope will be performed in unsuccessful subjects subsequently.
224252724|NCT00314886|DRUG|Diet|
224252725|NCT02441309|DRUG|Mifamurtide|
224252726|NCT02441309|DRUG|Ifosfamide|
224252727|NCT02613000|OTHER|No intervention|
224252728|NCT01944930|DEVICE|Laparoscopic narrow band imaging|
224252729|NCT01944930|DEVICE|Standard white-light laparoscopy|
224252730|NCT02592226|PROCEDURE|Anesthesia: alveolar recruitment maneuver|
224252731|NCT02592226|PROCEDURE|Anesthesia: standardized|
224252732|NCT00901745|DRUG|Angiotensin II|Infusion of up to 30picmol/ml angiotensin II will be infused and respondent vasoconstriction assessed.
223672032|NCT04397770|DRUG|Temozolomide Injection|Temozolomide is an imidazole tetrazine derivative of the alkylating agent dacarbazine.Temozolomide is not directly active but undergoes rapid, spontaneous, non-enzymatic conversion at physiologic pH to the cytotoxic compound, monomethyl triazeno imidazole carboxamide (MTIC).
223672033|NCT01887054|DEVICE|Tower of Hanoi|
223672034|NCT01887054|OTHER|Placebo group - non use of Tower of Hanoi|
223672035|NCT02631473|DRUG|50mg NANO-efavirenz|OD
223672036|NCT02631473|DRUG|400mg NANO-Lopinavir|BID
223672037|NCT02631473|DRUG|200mg NANO-Lopinavir|BID
223672038|NCT02631473|DRUG|100mg Ritonavir|BID
223672039|NCT02631473|DRUG|300mg NANO-Efavirenz|OD
223672040|NCT02631473|DRUG|600mg Sustiva|OD
223672041|NCT02631473|DRUG|200mg NANO-Efavirenz|OD
223672042|NCT02631473|DRUG|Kaletra® (lopinavir 400mg/ritonavir 100mg)|BID
223672043|NCT02631473|DRUG|+/- 200mg NANO-Lopinavir|BID
223672044|NCT02631473|DRUG|+/- 200mg ritonavir NORVIR|BID
223672045|NCT02631473|DRUG|400mg Sustiva|
223672046|NCT05783427|OTHER|liberal hydration|evaluate the effect of 'Sip Til Send' on overall gastric volume pregnant women undergoing elective caesarean delivery
223672047|NCT03838809|DEVICE|surface electromyography-biofeedback|Two electrodes were putted on the motor point of the extensor muscle of the hand and the foot. The positive electrode was placed on the distal zone of the hand or the foot, while the negative electrode was placed on the proximal zone.
223672048|NCT02610101|OTHER|Traditional SCD Diet|Traditional SCD includes removal of all processed foods as well as all grains, sweetners except for honey and all diary except for yogurt fermented for over 24hrs and some hard cheeses
224252733|NCT00901745|DRUG|Noradrenaline infusion|Infusion of up to 480 picomol/ml of noradrenaline will be infused.
223772064|NCT02553746|PROCEDURE|Detection of the puncture site by identification of the landmarks.|Neuraxial anesthesia will be performed to the patients after detection of the puncture site by the identification of the landmarks. The L3-L4 space will be identified by palpation of the posterior iliac crests and the ideal intervertebral space will be selected after palpation of the spinous processes.
224252734|NCT03257956|DEVICE|Investigational Group|The RHEA device and Philips Patient Monitor MX400 are used to monitor the heart rate (HR) and respiratory rate (RR) of participants.
223672049|NCT02610101|OTHER|Modified SCD Diet|Food components of the traditional SCD with the addition of rice and oats.
224252735|NCT03257956|DEVICE|reference group|The reference device Earlysense 2.0 system(vital sign monitoring system) and Philips Patient Monitor MX400 are used to monitor the heart rate (HR) and respiratory rate (RR) of participants.
224252736|NCT04829045|DEVICE|SEIRIN PYONEX Acupuncture Needles|10 press needles (PYONEX ø0.20×1.5mm made by Seirin Corporation) will be placed on abdomen area; 10 sessions over 6 weeks.
224252737|NCT04829045|OTHER|PYONEX Placebo|Subjects are given placebo on abdomen area; 10 sessions over 6 weeks.
224252738|NCT04513379|DRUG|Efavirenz 600mg|EFV 600 mg per day given orally
224252739|NCT04513379|DRUG|Efavirenz 400mg|2 tablets of EFV 200 mg per day given orally
224252740|NCT03651804|PROCEDURE|Radiofrequency ablation of the medial branch nerves|A radiofrequency ablation (RFA) is a procedure in which a heat lesion via a needle is created on the nerve that transmits the pain signal in order to interrupt the brain to interrupt the painful signal to the brain. We will target the medial branch nerves.
224252741|NCT03651804|DRUG|Non-steroidal anti-inflammatory drugs|Some of the most commonly used pain medicines in adults. NSAIDs block proteins, called enzymes, in the body that play a role in pain and inflammation. They include aspirin, ibuprofen (Advil, Motrin), naproxen (Aleve), and many other generic and brand name drugs.
224252742|NCT03651804|DRUG|Bisphosphonates|A class of drugs that prevent the loss of bone density and are used to treat osteoporosis and similar diseases.
223672050|NCT02610101|OTHER|Whole foods diet|A whole foods diet with removal of processed foods. Removal of corn, wheat, sugar and milk are also apart of this dietary regime.
223672051|NCT02346890|DRUG|AZD1722|
223672052|NCT02346890|DRUG|Renvela|
223672053|NCT05736575|GENETIC|BDNF analysis (Elisa KIT)|Analysis of peripheral BDNF will be performed
223672054|NCT02979860|BEHAVIORAL|Sleep duration 90 min|Sleep duration: time in bed increased by 90 minutes
223672055|NCT02979860|BEHAVIORAL|Sleep duration 45 min|Sleep duration: time in bed increased by 45 minutes
223672056|NCT02979860|BEHAVIORAL|Sleep timing|Sleep timing: bed time kept consistent
223672057|NCT03798119|DRUG|Tenofovir Alafenamide|Subjects in this group will switch prior nucleot(s)ide analogs to Tenofovir Alafenamide 25 mg/day for 96 weeks
223672058|NCT01233518|DEVICE|FFR|Fractional flow reserve measured during cardiac catheterization
223672059|NCT02615626|PROCEDURE|Non-surgical Periodontal Treatment.|Non-surgical periodontal therapy is an anti-infective therapy which includes both mechanical and chemotherapeutic approaches to minimize or eliminate microbial biofilm, the primary etiology of gingivitis and periodontitis
223672060|NCT00495040|RADIATION|Proton Radiotherapy|87.5 CGE with 2.5 Gy/fraction for 35 treatments
223672061|NCT03337919|DRUG|Nivolumab|Up to 8 cycles of nivolumab
223672062|NCT05268627|DRUG|Liraglutide|endoscopy
223672063|NCT03231683|DRUG|Esketamine|intravenous S+ketamine 0.25 mg/kg (i.v. bolus) at the beginning and 0.25 mg/kg (i.v. bolus) 20 minutes before extubation along with remifentanil according to Minto model and propofol according to Marsh model
223672064|NCT03231683|DRUG|Saline|intravenous normal saline (as placebo, with similar volume) at the beginning and 20 minutes before extubation along with remifentanil according to Minto model and propofol according to Schnider model
223672065|NCT03231683|DRUG|Remifentanil|Either S+ketamine or saline at the beginning and 20 minutes before extubation along with remifentanil according to Minto model and propofol according to Schnider model
223672066|NCT03231683|DRUG|Propofol|Either S+ketamine or saline at the beginning and 20 minutes before extubation along with remifentanil according to Minto model and propofol according to Schnider model
224252743|NCT03651804|DRUG|Acetaminophen|A medicine used to treat pain and fever. It is typically used for mild to moderate pain relief. Commonly known as Tylenol.
224252744|NCT03651804|BEHAVIORAL|Physical therapy|Physical Therapy.
224252745|NCT03651804|DRUG|Opioids|Opioids are narcotics that act on opioid receptors to produce morphine-like effects and medically they are primarily used for pain relief.
224252746|NCT03399214|DRUG|IOP Injection|T1 and T2
224252747|NCT02175095|DRUG|Regorafenib|Regorafenib will be administered 160 mg/day given orally on day 1 to days 21 following 7 days break, which consists of 4 weeks as 1 cycle. Treatment will be repeated every 4 weeks and continued until disease progression, unacceptable toxicity or the patient's refusal.
223672067|NCT04096378|BEHAVIORAL|EMBRace Intervention Group|The EMBRace intervention will consist of five weekly sessions (weeks 2 - 6) that will be facilitated by EMBRace-trained therapists. Throughout the 8-week intervention, families will be scheduled for 2-hour blocks with sessions being administered to each parent and adolescent for 90 minutes (individually for 30 minutes, 15-minute break, and 45-minutes session with parent and adolescent together). The sessions will cover research-based types of Racial Socialization, including cultural pride, preparation for bias, and attentiveness and balance towards societal racism. Parents and youth will also learn and practice five literacy skills to process and manage the stress of racial encounters including the ability to recognize racial discrimination, accurately appraise the stress of self and others, reduce one's stress, engage instead of avoid, and finally resolve toward healthy outcomes.
223672068|NCT04096378|BEHAVIORAL|EMBRace Waitlist Group|The waitlist group will be asked to complete a pretest and posttest while the treatment group goes through the EMBRace intervention. During this time, the waitlist group will not have any additional requirements and will not be given any form of comparative treatments. Upon the completion of the treatment from the intervention group, the waitlist group will be consented for entry into the intervention arm of the study and will follow the procedures for the intervention group above.
223672069|NCT01724554|DRUG|Intravitreal Aflibercept Injection|Aflibercept administered to the eye intravitreally either every month or every other month.
223672070|NCT01761032|DEVICE|Tanning|Participants will be placed under a tanning canopy for 4-10 minutes.
223672071|NCT05383001|DRUG|combination regimen tremelimumab /durvalumab|"Induction treatment: 2 cyles of Q3W second-line plantium-based chemotherapy according to standard of care: Cisplatin or carboplatin in combination with pemetrexed, paclitaxel, nab-paclitaxel, vinorelbine or gemcitabine~Combination treatment:~Durvalumab 1500 mg fixed dose plus tremelimumab 300 mg fixed bolus dose~Maintenance Therapy:~Durvalumab 1500 mg fixed dose Q4W up to 12 cycles within the study"
223672072|NCT05383001|DRUG|platinum-based chemotherapy (SoC)|"Induction treatment: 2 cyles of Q3W second-line plantium-based chemotherapy according to standard of care: Cisplatin or carboplatin in combination with pemetrexed, paclitaxel, nab-paclitaxel, vinorelbine or gemcitabine~Combination treatment:~Continuation of second-line chemotherapy with 2-4 further cycles (Q3W) platinum-based combination therapy.~Maintenance Therapy:~Optional continued maintenance therapy with pemetrexed according to marketing authorization will be allowed for a maximum of 13 cycles."
224252748|NCT02175095|DIAGNOSTIC_TEST|[18F]FLT-PET|\[18F\]FLT-PET scans before and on 21st day from the administration of regorafenib.
224252749|NCT02175095|DIAGNOSTIC_TEST|[18F]FDG-PET|\[18F\]FDG-PET will be performed before treatment and at 21 days after treatment.
224252750|NCT06206031|DEVICE|Intraosseous ultrasonography at tibia before, during, and after a physiological vascular stimulation (venous occlusions, arterial occlusion, handgrip)|"Timing for sub-protocol 1 (performed twice with 2-to-10-day interval): donning in supine position - rest 5 minutes - venous occlusion to 40 mmHg 3 minutes - rest 10 minutes - arterial occlusion to 200mmHg 2 minutes - post-occlusion period 10 minutes - rest 10 minutes - static handgrip 30% Maximum Voluntary Force 3 minutes - recovery 2 minutes and doffing.~Timing for sub-protocol 2 (performed once). First, two sequences of intraosseous ultrasonography are performed in 45° head-up tilt position, with 10-minutes rest between sequences: donning and rest 5 minutes - occlusion to 80 mmHg 2 minutes - rest 10 minutes - occlusion to 180 mmHg 2 minutes - rest 10 minutes. During the first sequence, ultrasonography probe is positioned between middle and lower third of tibia for cortical bone measurement; during the second - at distal epiphysis of the tibia for trabecular bone measurement. After ultrasonography, subject is sitting down for 10 minutes for computed tomography."
224252751|NCT05052801|DRUG|Bemarituzumab|Intravenous (IV) infusion
224252752|NCT05052801|DRUG|mFOLFOX6|mFOLFOX6 administered as a combination of oxaliplatin and leucovorin as IV infusions. 5-FU administered as bolus followed by additional administration as IV infusion.
224252753|NCT05052801|DRUG|Placebo|IV infusion
224252754|NCT06561074|DRUG|Decitabine|Given by vein
224252755|NCT06561074|DRUG|Venetoclax|Given by mouth
224252756|NCT06561074|DRUG|Calaspargase pegol-mknl|Given by vein
224252757|NCT04914663|BEHAVIORAL|Exercise training|Exercise training performed at home under remote live supervision over 12 weeks while patients undergo chemotherapy for breast cancer.
224252758|NCT02404753|DRUG|Neoadjuvant Chemotherapy|XELOX: Oxaliplatin 130mg/m2,iv.,d1;Capecitabine 1000mg/m2,po.,Bid,d1-14; Repeat every 21 days for 3 courses.
223672073|NCT00272714|DRUG|Afimoxifene (0.057%) in hydroalcoholic gel|
223672074|NCT02719561|BEHAVIORAL|Fatigue Intervention|The Fatigue Intervention will include education, energy conservation and activity promotion
223672075|NCT02867553|DRUG|rituximab|
223672076|NCT02867553|RADIATION|Multi-fields radiotherapy|
223672077|NCT03660137|DEVICE|MOLLI Localization|All patients will also be implanted with an additional MOLLI seed using a specialized introducer needle. A specialized MOLLI probe will be used to find the magnetic seed during the lumpectomy surgery.
224252759|NCT02404753|PROCEDURE|Laparoscopic gastrectomy|Laparoscopic distal gastrectomy with D2 lymph node dissection
224252760|NCT02404753|PROCEDURE|Open gastrectomy|Open distal gastrectomy with D2 lymph node dissection
224252761|NCT02404753|DRUG|Adjuvant Chemotherapy|XELOX: Oxaliplatin 130mg/m2,iv.,d1;Capecitabine 1000mg/m2,po.,Bid,d1-14; Repeat every 21 days for 5 courses.
224252762|NCT03255733|DEVICE|Intense Therapeutic Ultrasound Treatment|
224252763|NCT05309850|BEHAVIORAL|Lifestyle tool|Regular use of the digital Lifestyle tool
224252764|NCT03563248|DRUG|FOLFIRINOX|"FOLFIRINOX is a combination of 4 chemotherapy agents that may help shrink your tumor before surgery~* 5-Fluorouracil (5-FU) - 400 mg/m2 on day one, followed by 1200 mg/m2 by continuous infusion for the subsequent 46-48 hours~* Oxaliplatin - 85 mg/m2 by intravenous infusion over 120 minutes on day 1 of each 14 day cycle~* Irinotecan - administered at a starting dose of 180 mg/m2 by intravenous infusion over 90 minutes on day 1 of each 14 day cycle~* Leucovorin - Administered at a starting dose of 400 mg/m2 over 2 hours on day 1 of each 14 day cycle"
224252765|NCT03563248|DRUG|Losartan|Losartan is a drug that is used to lower blood pressure
224252766|NCT03563248|DRUG|Nivolumab|Nivolumab is an antibody that may cause programmed cell death of cancer cells
224252767|NCT03563248|RADIATION|SBRT|Radiation therapy is believed to increase the likelihood of response of immunotherapy
224252768|NCT03563248|PROCEDURE|Surgery|definitive surgical resection
224252769|NCT00352989|DRUG|Smecta (Diosmectite), duration of treatment - 7 days|
224252770|NCT05284539|DRUG|Pemetrexed, Cisplatin, Bevacizumab Plus Pembrolizumab|Pemetrexed, 500mg/m2, ivgtt, every 21 days. Bevacizumab 15mg/kg, ivgtt, every 21 days. Pembrolizumab, 200mg ivgtt, every 21 days. Atezolizumab, 1200mg, ivgtt, every 21 days.
224252771|NCT06141408|BEHAVIORAL|MPowerment PrEP Promotion Intervention|"In-person events will focus on five specific goals: Fostering a sense of community acceptance and social connection, promoting self-acceptance of sexual identity, teaching skills for navigating healthcare, reducing PrEP stigma, and providing education on HIV risk. In accordance with the MPowerment model, In collaboration with the PI, the core group and volunteers would lead the development, implementation, and evaluation of all intervention events. Both peer leaders and the primary investigator will collaborate to develop specific events (M-Groups), guided by the findings in both the quantitative and qualitative studies. M-Groups will be held once every month. Events will be 2 hour activities focused on the aforementioned goals."
224252772|NCT01344291|DRUG|Curcumin|Curcumin is prescribed to new cases of hyperprolactinoma
224252773|NCT04175613|DRUG|Apremilast|Apremilast dose will be increased from 20 mg BID to 30 mg BID for those subjects that reach a weight of 50 kg or more during the study
224252774|NCT06375460|BEHAVIORAL|Focused App Prompt|Prompts are designed to develop knowledge and self-efficacy in diabetes-related health behaviors (capability). The paired glycemic and behavior data will provide the opportunity to reflect and to plan diet or exercise for the following day (self-reflective motivation).
224252775|NCT06375460|BEHAVIORAL|No App Prompt|No app prompts are designed to assess whether health behaviors are affected without being prompted to reflect and change those behaviors related to glycemic control.
224252776|NCT06375460|BEHAVIORAL|Outreach for Missing Data|For participants randomized to proactive outreach, after 3 or more days of missing CGM data, the study team will reach out to participants by phone and/or text message to troubleshoot and support participants in re-connecting with CGM and apps. For participants randomized to not receive proactive outreach, participants will be instructed to reach out to the study team at their discretion when help is needed related to CGM or app connection.
224252777|NCT00210223|PROCEDURE|ultrasonography (US)-guided percutaneous radiofrequency (RF) ablation with endocrine therapy|ultrasonography (US)-guided percutaneous radiofrequency (RF) ablation with endocrine therapy
223672078|NCT01816451|OTHER|running training|The present study was designed to compare the physiological effects between the two training regimes and the control group.The subjects from interval and continuous group performed others activities as resistance training, swimming or soccer. Those activities wasn't controlled by our study, but the individual didn't do physical activities at least 3 hours before started our running sessions. The control group simply performed their normal physical activities (resistance training, swimming or soccer). But, each 3 weeks we had a contact with control group to check about any injury or illness that could affect the final results. None were found.
223672079|NCT04069364|BEHAVIORAL|TinnitusTipps|Self-helf tips for managing chronic tinnitus will be given via smartphones.
223672080|NCT00002501|BIOLOGICAL|filgrastim|
223672081|NCT00002501|DRUG|cyclophosphamide|
223672082|NCT00592774|DRUG|E2007 (perampanel)|2 mg titrated up to 8 mg maximum; taken once daily.
223672083|NCT00592774|DRUG|Placebo|2 mg titrated up to 8 mg maximum; taken once daily.
223672084|NCT01700439|DEVICE|EDWARDS INTUITY valve|Surgical replacement of the aortic valve with the EDWARDS INTUITY valve.
223672085|NCT01892384|DRUG|Placebo|matching placebo
223672086|NCT01892384|DRUG|BI 409306|BI 409306
223672087|NCT02275884|DIETARY_SUPPLEMENT|Dark chocolate (85% cocoa)|
223672088|NCT02275884|DIETARY_SUPPLEMENT|White chocolate (0% cocoa)|
223672089|NCT03279289|DRUG|Aflibercept|4 mg/kg administered intravenous infusion on day 1
224252778|NCT03653507|DRUG|zolbetuximab|Zolbetuximab were administered as a minimum 2-hour IV infusion.
224252779|NCT03653507|DRUG|oxaliplatin|Oxaliplatin were administered as a 2-hour IV infusion.
224252780|NCT03653507|DRUG|capecitabine|Capecitabine were administered orally twice daily (bid).
224252781|NCT03653507|DRUG|placebo|Placebo were administered as a minimum 2-hour IV infusion.
224252782|NCT05058612|DRUG|Midodrine|10 mg PO/NG q8h
224252783|NCT05058612|DRUG|Placebo|Microcrystalline cellulose PO/NG 18h
224252784|NCT05463666|OTHER|Rheumatoid arthritis|A diagnosis of rheumatoid arthritis.
224252785|NCT03074487|DEVICE|Near-infrared spectroscopy|
224252786|NCT03074487|DEVICE|Long loop reflex measurements|
224252787|NCT06270498|DIETARY_SUPPLEMENT|Sucrosomial iron|"Sucrosomial iron with the addition at a fixed dose of vitamin C to promote iron absorption (SiderAL® Forte) will be administered orally once a day for 24 weeks.~The dose regimen for all participants will be calculated according to the haemoglobin (Hb) levels at baseline evaluation and to patient's body weight as follows:~Hb 14-16 g/dL: 1 tablet once a day, corresponding to 30 mg/daily, for 24 weeks; Hb 10-13.9 g/dL: 2 tablets once a day, corresponding to 60 mg/daily, for 24 weeks"
223672090|NCT03279289|DRUG|Irinotecan|180 mg/m2 intravenous infusion
223672091|NCT03279289|DRUG|folinic acid (dl racemic)|400 mg/m2 intravenous infusion
223672092|NCT03279289|DRUG|5Fluorouracil|400 mg/m2 intravenous bolus
223672093|NCT03279289|DRUG|5-FU|2400 mg/m2 continuous intravenous infusion over 46 hours
223672094|NCT02226744|BEHAVIORAL|Focused Breathing|
223672095|NCT05849961|DEVICE|Exactech Hip Systems|The Exactech Hip System comprises a fixed-bearing hip joint prostheses used in treating human hip joint diseases as part of THA. These prostheses include a combination of the components and are available in a range of sizes to accommodate varying anatomical requirements.
223672096|NCT00714571|BEHAVIORAL|Mnemonic strategy training (MST)|
223672097|NCT00714571|BEHAVIORAL|Repeated exposure (XP)|
224252788|NCT06270498|OTHER|Placebo|"Placebo pills will be identical in shape, form and color of SI tablets; they will contain the same components of SiderAL Forte® except for sucrosomial iron and vitamin C.~Placebo will be administered orally once a day for 3 months according to the same dose scheme in the intervention arm."
224252789|NCT05858320|OTHER|SmartHF application|Adaptive medication recommendations that can be shared with the participants HF provider.
224252790|NCT04408885|OTHER|Rehabilitation|Non-surgical interventions to patients with an Anterior cruciate ligament injury. Rehabilitation regime is the regime provided by the physician at the rehabilitation clinic.
224252791|NCT05365659|DRUG|IKS03|IKS03 is a human monoclonal antibody (Ab) targeting CD19 linked to a pyrrolobenzodiazepine (PBD) pro-drug as the cytotoxic agent.
224252792|NCT06432738|DRUG|ZL-82|This group of subjects take ZL-82
224252793|NCT06432738|DRUG|ZL-82 placebo|This group of subjects take ZL-82 placebo
224252794|NCT04302324|DRUG|Daratumumab SC|Given as 1800mg via injection
224252795|NCT04302324|DRUG|Clarithromycin|Given as 500mg oral capsule
224252796|NCT04302324|DRUG|Pomalidomide|Given as 4mg oral capsule
224252797|NCT04302324|DRUG|Dexamethasone|Given as 20mg IV and 20mg or 40mg oral tablets
224252798|NCT05325866|DRUG|Bemarituzumab|Intravenous (IV) infusion.
224252799|NCT05972967|BIOLOGICAL|OMS906|Biological: OMS906
224252800|NCT05673993|BIOLOGICAL|Telitacicept 80 mg|Telitacicept 80 mg subcutaneously once a week.
224252801|NCT05673993|BIOLOGICAL|Telitacicept 160 mg|Telitacicept 160 mg subcutaneously once a week.
224252802|NCT05673993|DRUG|Placebo|Subjects will be given subcutaneous placebo once a week.
224252803|NCT06343285|DEVICE|Encora Therapeutics Tremor Reduction Device|The proposed therapeutic device uses vibration motors positioned around the wrist that provide on-demand-therapy to suppress resting, postural, or action tremors of the hand.
224252804|NCT06189157|BIOLOGICAL|MB-CART19.1|MB-CART19.1 consists of autologous CD19 Chimeric Antigen Receptor (CAR) transduced CD4/CD8 enriched T cells
224252805|NCT05080946|DRUG|Aspirin 325mg|"Participants will receive a tablet of 325mg aspirin that is taken once daily by mouth. Study treatment begins on first day of neoadjuvant chemotherapy for up to 5 cycles. Participants will be expected to take the study treatment for between 63 and 175 days (3-5 cycles). Participants will stop taking study treatment 7 days prior to participants interval debulking surgery."
224252806|NCT05080946|DRUG|Placebo|"Participants will receive a placebo tablet that is taken once daily by mouth. Study treatment begins on first day of neoadjuvant chemotherapy for up to 5 cycles. Participants will be expected to take the study treatment for between 63 and 175 days (3-5 cycles). Participants will stop taking study treatment 7 days prior to participants interval debulking surgery."
224252807|NCT02770092|OTHER|sip feeding with stable isotope infusion|such as glycerol, D2O, tyrosine, phenylalanine, glucose, arginine, and citrulline
224252808|NCT04756245|BEHAVIORAL|Virtual Reality|Participants in this arm participate in 4 group-based behavioral counseling sessions plus 8 one-on-one coaching session within virtual reality software. Participants aim to engage in approximately 150 minutes per week of moderate-to-vigorous activity, with options including both virtual reality and real-world physical activities.
224252809|NCT04756245|BEHAVIORAL|Video Conference|Participants in this arm participate in 4 group-based behavioral counseling sessions plus 8 one-on-one coaching session within video conference software. Participants aim to engage in approximately 150 minutes per week of moderate-to-vigorous activity, with options including both streaming video and real-world physical activities.
224252810|NCT04280497|DRUG|Administration procedures|"Hydrocortisone hemisuccinate / hydrocortisone placebo will be given as 50 mg intravenous bolus every 6 hours;~9 alpha fludrocortisone / 9 alpha fludrocortisone placebo will be given as a 50 μg tablet via a nasogastric tube once per day in the morning.~Study drugs will be started immediately after randomization (day 0 of the study), until discharge from ICU for a maximal duration of 7 days. Study drugs will be stopped without tapering off."
224252811|NCT04319276|DRUG|Gallium maltolate (500 mg)|This is a 3+3 design. The doses are as follows: level -1: 500 mg every other day; level 0: (starting dose) 500 mg daily; level 1: 1,000 mg daily; level 2: 1,500 mg daily; level 3: 2,000 mg daily; level 4: 2,500 mg daily.
224252812|NCT04319276|DRUG|Gallium maltolate (1,000 mg)|This is a 3+3 design. The doses are as follows: level -1: 500 mg every other day; level 0: (starting dose) 500 mg daily; level 1: 1,000 mg daily; level 2: 1,500 mg daily; level 3: 2,000 mg daily; level 4: 2,500 mg daily.
224252813|NCT04319276|DRUG|Gallium maltolate (1,500 mg)|This is a 3+3 design. The doses are as follows: level -1: 500 mg every other day; level 0: (starting dose) 500 mg daily; level 1: 1,000 mg daily; level 2: 1,500 mg daily; level 3: 2,000 mg daily; level 4: 2,500 mg daily.
224252814|NCT04319276|DRUG|Gallium maltolate (2,000 mg)|This is a 3+3 design. The doses are as follows: level -1: 500 mg every other day; level 0: (starting dose) 500 mg daily; level 1: 1,000 mg daily; level 2: 1,500 mg daily; level 3: 2,000 mg daily; level 4: 2,500 mg daily.
224252815|NCT04319276|DRUG|Gallium maltolate (2,500 mg)|This is a 3+3 design. The doses are as follows: level -1: 500 mg every other day; level 0: (starting dose) 500 mg daily; level 1: 1,000 mg daily; level 2: 1,500 mg daily; level 3: 2,000 mg daily; level 4: 2,500 mg daily.
224252816|NCT04319276|DRUG|Gallium maltolate (recommended phase 2 dose)|The maximum-tolerated dose (recommended phase 2 dose).
224252817|NCT06091254|DRUG|Odronextamab|Administered by intravenous infusion (IV)
224252818|NCT06091254|DRUG|Rituximab|Rituximab will be administered by IV, or subcutaneously (SC)
224252819|NCT06091254|DRUG|Cyclophosphamide|Administered by IV as part of Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (CHOP) chemotherapy, or Cyclophosphamide, Vincristine, Prednisone (CVP) chemotherapy
224252820|NCT06091254|DRUG|Doxorubicin|Administered by IV as part of CHOP chemotherapy
224252821|NCT06091254|DRUG|Vincristine|Administered by IV as part of CHOP, and CVP chemotherapy
224252822|NCT06091254|DRUG|Prednisone/prednisolone|Administered orally (PO) as part of CVP chemotherapy
223672098|NCT00714571|BEHAVIORAL|Subtracting Cues training|
224252823|NCT06091254|DRUG|Bendamustine|Administered by IV as part of chemotherapy (Rituximab-Bendamustine)
224252824|NCT05821660|OTHER|Five-day hypocaloric and ketogenic programme|Dietary intervention
224252825|NCT06405646|DIAGNOSTIC_TEST|Blood CB1, CB2, TRPV-1 concentration measurement|In each of the patients blood CB1, CB2, TRPV-1 concentration will be measure
223772065|NCT03750734|DIAGNOSTIC_TEST|Bronchoscopy|Flexible bronchoscopy will be performed under sedation (typically a sedative such as intravenous midazolam and/or fentanyl) with local anaesthetic to the throat and vocal cords. Bronchial epithelial tissue (via bronchial brushing and biopsy forceps) and bronchial lavage samples will be taken for analysis.
223772066|NCT03750734|DIAGNOSTIC_TEST|Blood test|Peripheral blood will be taken to collect peripheral blood monocytes, which will then allow the production of induced pluripotent stem cell derived bronchial epithelial tissues.
223772067|NCT01994304|BEHAVIORAL|SCC|The intervention involves introducing and orienting health providers on the SCC, facilitating availability of a specific set of commodities and regular targeted supervision. These are expected to improve adherence to life saving interventions immediately before, during and after birth, and reduce intrapartum mortality (still births and very early neonatal deaths).
223772068|NCT02326142|DRUG|OBE001|OBE001 dispersible tablets for a single oral dose a day for up to 7 days.
223772069|NCT02326142|DRUG|Placebo|Placebo dispersible tablets for a single oral dose a day for up to 7 days.
223772070|NCT04196166|OTHER|preoperative blood tests|
223772071|NCT01206985|OTHER|Von Frey electronic|Change in pain threshold testing mechanical stimulation (von Frey electronic)
223772072|NCT02517905|DRUG|Bupivacaine liposome|Local administration
223772073|NCT02517905|DRUG|Placebo|Local administration
223772074|NCT04114058|DRUG|liposomal bupivicaine|local field infiltration
224252826|NCT05726526|DEVICE|VIEWER virtual care platform|VIEWER is a tablet based, CKD specific home telemonitoring platform developed by our team of patients and researchers that integrates data from a wireless blood pressure cuff, weigh scale, transcutaneous O2 sat monitor and wearable motion tracker via a tablet and custom app.
224252827|NCT05802680|DEVICE|Transcranial photobiomodulation|Administration of Sham or 1064 (+/- 50) nanometers tPBM
224252828|NCT05802680|DEVICE|Sham transcranial photobiomodulation|Sham treatment
224252829|NCT05409625|DEVICE|Intraoral Scanner (TRIOS 4, 3Shape TRIOS A/S, Copenhagen, Denmark)|Intraoral scanner which is able to generate a 3D-model of the teeth and is being used for caries detection.
224252830|NCT05409625|DEVICE|Intraoral camera (DIAGNOcam, KaVo, Biberach, Germany, software version 3.0.1/2.9.1)|Intraoral camera used for caries detection in the occlusal and proximal surfaces.
224252831|NCT05409625|DEVICE|X-ray device (X-ray device SOREDEX, MINRAY®; Image plates VistaScan; Image plate scanner VistaScan Mini View, Dürr Dental)|X-ray device used for caries detection. Two radiographs (bitewings) are taken, one in each side.
224252832|NCT05409625|PROCEDURE|Oral cleaning|Removal of tartar and plaque. Tartar removal done at baseline and the fifth visit, but only on selected teeth at the second, third and fourth visit. Regular cleaning with a toothbrush done at all visits.
224252833|NCT03697109|DRUG|Relacorilant|Relacorilant is supplied as 100 mg capsules for oral dosing.
224252834|NCT03697109|OTHER|Placebo|Placebo matched to study drug
223672099|NCT01872325|BEHAVIORAL|Education|An education program will be developed using behaviour change techniques specifically mapped to address modifiable factors identified in a previous study. These techniques will include: information about the significance of agonal breathing, modeling/demonstration of desired behavioural skills, rehearsal of desired skills, and monitoring/reinforcement and feedback.
223672100|NCT01390064|BIOLOGICAL|Vaccination with Mimotope P10s-PADRE/MONTANIDE ISA 51 VG|All research participants will receive the Mimotope P10s-PADRE/MONTANIDE ISA 51 VG vaccine via subcutaneous (SC) injection following the schedule
223672101|NCT03896347|OTHER|ViBone®|Viable bone allograft
223672102|NCT03896347|OTHER|Demineralized Bone Matrix|Demineralized Bone Matrix
223672103|NCT03896347|OTHER|Bone Morphogenetic Protein|Bone Morphogenetic Protein
223672104|NCT00621621|DEVICE|Freezor® Cardiac Cryoablation Catheter CryoConsole System|cryoablation
223672105|NCT01529801|DEVICE|Osseotite Certain Tapered Group A|Osseotite Certain Tapered with different surface roughness
223672106|NCT01529801|DEVICE|Osseotite Certain Tapered Group B|Osseotite Certain Tapered with different surface roughness
223672107|NCT01529801|DEVICE|Osseotite Certain Tapered Group C|Osseotite Certain Tapered with different surface roughness
223672108|NCT05883670|DRUG|Serplulimab|Serplulimab will be administered by intravenous infusion at a dose of 300mg on Day 1 of each 21-day cycle until unacceptable toxicity or loss of clinical benefit as determined by the investigator.
223672109|NCT03865888|DRUG|Cyclosporins|Cyclosporins eye drops to be administered in dry eyes
223672110|NCT03865888|DRUG|Tacrolimus|Tacrolimus eye drops to be administered in dry eyes
223672111|NCT01613976|DRUG|Panobinostat|
223672112|NCT06164821|DRUG|luspatercept|Adult patients with TD thalassemia were given luspatercept subcutaneous injection.
223672113|NCT01829243|DRUG|Milnacipran|
223672114|NCT01829243|DRUG|Placebo|
223672115|NCT05796830|OTHER|Puzzle application|Five expert opinions will be taken for the puzzle application to be applied after the surgery, and the application and difficulty level of the puzzle will be decided.
223772075|NCT04114058|PROCEDURE|Fascia iliaca blockade|fascia iliaca compartment blockade
223772076|NCT03014752|OTHER|Classical ketogenic diet|The classical ketogenic diet with a ratio of 4 to 1 (4:1), each 4 grams of fat to each gram of carbohydrate plus protein, will be introduced gradually.
223772077|NCT03014752|OTHER|Modified Atkins diet|The modified Atkins diet with a ratio of 1 or 2 to 1 (1:1, 2:1), each 1 or 2 grams of fat to each gram of carbohydrate plus protein, will be introduced gradually.
223772078|NCT06348511|DEVICE|XTics|XTics is a gamified protocol of behavioral treatment for tic disorders. The participant's tics are monitored in real-time and they are reflected as achievements in a game that the participant plays at the same time. The rewards aim to counteract processes that consolidate the tic. XTics is compatible with ERP treatment, and it includes an introductory psychoeducation session and three behavioral training sessions.
223772079|NCT00431249|DRUG|Cilostazol|
223772080|NCT05382364|DRUG|Tucatinib|Tucatinib 150 mg and 50 mg tablets taken by mouth at a dose of 300 mg twice daily.
224252835|NCT06849700|OTHER|Active gamification|"The experimental group participated in a physical exercise program for primary school children, with 45-minute sessions three times a week, including warm-up, main activities, and awards. Designed to enhance engagement through game mechanics, the program progressed in three phases: Explorers in Action (Weeks 1-4) focused on coordination, agility, and teamwork with games like Conquering Territories; Movement Heroes (Weeks 5-8) emphasized endurance, collaboration, and strategy through activities like Quest for the Gems; and Health Guardians (Weeks 9-12) incorporated strength, planning, and teamwork challenges, culminating in a final integrated skills circuit. The program promoted continuous improvement in physical and cooperative abilities."
224252836|NCT04935177|DRUG|Imlifidase|Imlifidase is an immunoglobulin G (IgG)-degrading enzyme of Streptococcus pyogenes that is highly selective towards IgG. The cleavage of IgG generates one F(ab')2- and one homodimeric Fc-fragment and efficiently neutralizes Fc-mediated activities of IgG.
224322216|NCT04452825|BEHAVIORAL|Social Work and Supportive Counseling (SWSC) Intervention|The SWSC will include a social work assessment and follow-up augmented with additional components of supportive psychotherapy that have been shown to be an effective form of treatment for patients with cancer. For full participants (not training case participants) five sessions (45-60 minutes each) will be delivered over an 8-week period (+4 weeks). Following these sessions, four brief booster sessions (20-30 minutes each) will be delivered at a rate of approximately one per month to extend the interventions to 6 months (+3 months). Training case participants will follow a slightly condensed schedule.
223672116|NCT00481507|OTHER|Kefir|The intervention was Kefir,a drink that is commercially available in the United States. The following probiotics are present in the Kefir: Lactococcus lactis, Lactococcus plantarum, Lactococcus rhamnosus, Lactococcus casei, Lactococcus lactis subspecies diacetylactis, Leuconostoc cremoris, Bifidobacterium longum, Bifidobacterium breve, Lactobacillus acidophilus, and 1 yeast, Saccharomyces florentinus. Parents were asked to ensure that their enrolled child consumed at least half of the bottle (150mL) everyday.
223672117|NCT00481507|OTHER|Placebo|The intervention was Kefir, a drink that is commercially available in the United States. The following probiotics are present in active Kefir: Lactococcus lactis, Lactococcus plantarum, Lactococcus rhamnosus, Lactococcus casei, Lactococcus lactis subspecies diacetylactis, Leuconostoc cremoris, Bifidobacterium longum, Bifidobacterium breve, Lactobacillus acidophilus, and 1 yeast, Saccharomyces florentinus. The placebo group was heat-treated to kill all cultures. Parents were asked to ensure that their enrolled child consumed at least half of the bottle (150 mL)everyday.
223672118|NCT05721807|OTHER|functional magnetic stimulation|"When applying functional magnetic stimulation, the stress urinary incontinence program P2 stress was chosen. The first 20 min. current frequency was 35 Hz, modulation - rising amplitude (from 0 to maximum per second), total wave duration 12 s. active time 6 s., pause time 6 s. After 20 min. current frequency changed to 5 Hz, modulation and wave remained the same. After 2 min. current frequency changed to 35 Hz, modulation - amplitude, one-sided sinusoidal, wave remained the same. The total duration of the procedure was 30 min. A magnetic spring is installed at the bottom of the chair. During the treatment, each subject was instructed to sit on a chair so that the perineum was centered on the spring and that the subjects felt the contraction of the muscles. The intensity of the magnetic field was adjusted so as to feel comfortable during the study procedure (Vadalà et al., 2017)."
223672119|NCT05721807|OTHER|pelvic floor muscle training program|The program consisted of two parts. From procedures 1 to 6, 6 exercises were performed, after 6 times the exercises were adjusted, and from procedures 7 to 12, another 5 exercises were performed. The program consists of breathing, pelvic floor muscle strength, endurance, speed training exercises and exercises to strengthen the thighs, buttocks, deep back and deep abdominal muscles. Exercises were performed in 2 sets of 10 repetitions at an intensity from various positions: lying on the back, side, sitting, quadruped (Oliveira et al., 2017; Walton et al., 2019).
223672120|NCT02802046|RADIATION|Computed tomographic angiography of coronary artery|
223672121|NCT04850781|BEHAVIORAL|Bi-weekly frozen meal home delivery|All participants randomized to this arm will receive 10 frozen meals that are mailed to their home every two weeks from a MOW vendor, TRIO foods.
223672122|NCT04850781|BEHAVIORAL|Daily home meal delivery|All participants randomized to this arm will receive meals delivered to their home multiple times per week from a MOW program employee/volunteer with a wellness check and socialization.
223672123|NCT02452931|DRUG|Leuprolide Acetate 45 mg|Subcutaneous injection
223672124|NCT05622162|DRUG|Radiopharmaceutical 18F-JK-PSMA-7|"The Investigational product 18F-JK-PSMA-7 is a diagnostic radiopharmaceutical for use with positron emission tomography.~18F-JK-PSMA-7 is administered as direct intravenous injection. One single administration of 2-4 MBq/kg of 18F-JK-PSMA-7 is scheduled in each patient included in this study."
223772081|NCT03069625|BEHAVIORAL|Sit-to-stand test|CF young patients will perform 2 STS tests. Number of repetitions, cardio-respiratory response and physiological adaptations during the second test will be monitored.
223772082|NCT03069625|BEHAVIORAL|6-Minute Walk Test|CF young patients will perform 2 6MWT tests. Number of repetitions, cardio-respiratory response and physiological adaptations during the second test will be monitored.
223772083|NCT06605950|DRUG|KarXT|Specified dose on specified days
223772084|NCT06605950|DRUG|KarX-EC|Specified dose on specified days
223772085|NCT06605950|DRUG|Placebo|Specified dose on specified days
223772086|NCT06605950|DRUG|Omeprazole|Specified dose on specified days
223772087|NCT02680184|DRUG|CMP-001|CMP-001 will be administered as per the dose and schedule specified in the respective arms.
223772088|NCT02680184|DRUG|Pembrolizumab|Pembrolizumab will be administered as per the schedule specified in the respective arms.
224252837|NCT04935177|PROCEDURE|PLEX|PLEX is performed according to the respective site's standard procedure for desensitization.
223672125|NCT05622162|DRUG|Radiopharmaceutical 18F-Fluorocholine|"The active substance of Comparator is 18F-Fluorocholine. The Comparator will be a 18F-Fluorocholine with a Marketing Authorisation in Italy that will be used in compliance with its Summary of Product Characteristics (SmPC).~18F-Fluorocholine is administrated as direct intravenous injection. One single administration of 18F-Fluorocholine is scheduled in each patient included in this study."
223672126|NCT00385476|BEHAVIORAL|PMKT Questionnaire|Patient Medication Knowledge Tool - Questionnaire entailing the medications the patient is currently taking.
223672127|NCT05371873|PROCEDURE|Liver resection method|undergo anatomical or non-anatomical resection of liver cancer
223672128|NCT06286176|BEHAVIORAL|Videos with breastfeeding education material and encouraging messages|Distributed videos aim to increase breastfeeding related knowledge and to receive support
223672129|NCT06286176|BEHAVIORAL|Whatsapp group|The Whatsapp group is used in the intervention as a platform for interpersonal exchange of information and experience, in addition to peer support.
223672130|NCT00515424|DRUG|RKI983|
223672131|NCT03381729|BIOLOGICAL|Onasemnogene Abeparvovec-xioi|Self-complementary AAV9 carrying the SMN gene under the control of a hybrid CMV enhancer/chicken-β-actin promoter
223672132|NCT01059929|DRUG|Dexmedetomidine|continuous IV infusion 0.2 - 1.5 ucg/kg/hour titrated to target RASS
223672133|NCT01059929|DRUG|Propofol|continuous IV infusion (5 - 50 ucg/kg/min) titrated to target RASS
223672134|NCT01059929|DRUG|Fentanyl|25 - 200 mcg IV every hour (as multiple IV pushes) as needed titrated to Non-Verbal Pain Scale
223672135|NCT01059929|DRUG|Midazolam|0.01 - 0.1 mg/kg IV push every 10 minutes as needed for agitation (RASS\>+2)
223672136|NCT01059929|BEHAVIORAL|Physical and Occupational Therapy|Daily therapy sessions targeting range of motion, strength, and mobility
223672137|NCT03445156|BEHAVIORAL|Video game|Participants played either a violent shooting game or nonviolent shooting game in the pilot study, and either either a violent shooting game, nonviolent shooting game, or nonviolent non-shooting game in the experiment proper.
223672138|NCT03445156|BEHAVIORAL|Controller|Participants used either a gun-shaped or regular controller to play the violent and nonviolent shooting video games.
223672139|NCT04456153|DRUG|Experimental Group|Continued standard of care therapy together with an oral dose of 1500 mg atovaquone twice daily (administered with a meal or snack) for up to 10 days
223672140|NCT04456153|DRUG|Placebo Group|Continued standard of care therapy together with matching placebo
223672141|NCT03712709|DIAGNOSTIC_TEST|Truenat MTB|The Truenat MTB (including both MTB and MTB Plus) and the MTB-RIF Dx reflex assays (Molbio Diagnostics; Bangalore, India) utilize chip-based real-time micro-PCR for detection of tuberculosis (TB) and rifampicin (RIF) resistance from DNA extracted (on a separate device) from sputum samples. The Truenat MTB assay targets a single copy gene while the MTB Plus assay combines detection of a single copy and multi-copy gene.
223672142|NCT04879147|DIAGNOSTIC_TEST|Evalution of thyroid function|Determination of TSH, free T4, free T3, SPINA-GT, SPINA-GD and Jostel's TSH index
223672143|NCT00164970|DIETARY_SUPPLEMENT|Vitamin B12|
223672144|NCT00164970|DIETARY_SUPPLEMENT|folate|
223672145|NCT02292901|DEVICE|Macintosh laryngoscope|
223672146|NCT02292901|DEVICE|McGrath Mac videolaryngoscope|
223672147|NCT00189410|DRUG|Pegylated Liposomal Doxorubicin and Carboplatin|
223672148|NCT04064008|DEVICE|PROFEMUR® Z Revision Femoral Stem|Total Hip Total Hip Arthroscopy
223772089|NCT03723694|DIETARY_SUPPLEMENT|650 mg of Cocoapro flavanols|12-week period during which participant will be asked to consume two cocoa-flavanol-containing capsules(650mg) twice a day with meals.
223672149|NCT01210417|OTHER|Non invasive monitoring|Three-lead electrocardiogram (ECG), PPG oxymetry, non-invasive blood pressure (NIBP) are registered
223672150|NCT05208918|PROCEDURE|Epidural steroid|Injection of Depo-Medrol of affected dermatomes
223772090|NCT03723694|DIETARY_SUPPLEMENT|0 mg of Cocoapro flavanols|12-week period during which participant will be asked to consume two cocoa-flavanol-containing capsules(0mg) twice a day with meals.
224252838|NCT04935177|DRUG|IVIg|IVIg prepared from a pool of immunoglobulins from the plasma of thousands of healthy donors is administered in accordance with respective site's standard procedure for desensitization.
224252839|NCT04935177|DRUG|Anti-CD20 antibodies|Rituximab and other anti-CD20 according to the respective site's standard procedure for desensitization.
223672151|NCT05208918|PROCEDURE|PRF plus steroids injection|Pulsed radiofrequency with temperature 42 degrees for 6 minutes to be applied to the dorsal root ganglion plus injection of Depo-Medrol of affected dermatomes
223672152|NCT02787486|OTHER|Blood sampling for Laboratory Developed Test (LDT) analysis|Each enrolled subject, either in the first or second trimester, will donate up to 50 mL (just over 3 tablespoons) of whole blood for development of the LDT
223672153|NCT01587768|DRUG|Antibiotic prescription during the study period between January 1, 2004 and December 31, 2009|Antibiotics will be analysed overall, by class (tetracyclines, penicillins and betalactamics, cephalosporins, macrolides, aminoglycosides, quinolones and other antibiotics (sulphonamides \&amp; others combinations)) and individually. The antibiotics administered to patients include: cefuroxime axetil, cefuroxime sodium, ceftazidime sodium, amoxicillin, amoxicillin/ clavulanate, ampicillin, ampicillin/cloxacillin, flucloxacillin, ticarcillin, and ticarcillin/ clavulanate.
223672154|NCT00668356|DRUG|didanosine|28 days 400 mg/m2/day during the meal 28 days 240 mg/m2/day during fasting
223672155|NCT00668356|DRUG|didanosine|28 days 240 mg/m2/day during fasting 28 days 400 mg/m2/day during the meal
223772091|NCT06662929|RADIATION|Radiation|Radiotherapy for the Head \& Neck Cancer
223772092|NCT06663020|BEHAVIORAL|Smoking Cessation Duration|Participants are categorized based on their smoking status and the duration since they quit smoking prior to lung cancer surgery. This observational study focuses on evaluating the relationship between the duration of smoking cessation (measured in days or weeks) and the incidence of postoperative complications. Smoking cessation duration is recorded for each participant to determine its impact on surgical outcomes.
223772093|NCT06663566|OTHER|Diagnose the patients right heart function as well as right heart fibrosis|Diagnose the patients right heart function as well as right heart fibrosis
224252840|NCT04935177|DRUG|Eculizumab|Eculizumab according to the respective site's standard procedure for desensitization.
224252841|NCT04935177|OTHER|Remain on wait list|Remain on wait list for a more compatible organ offer if desentization with institutional protocol is not appropriate
224252842|NCT05116176|DEVICE|Implantable cardioverter-defibrillators|500 patients age \>65 receiving new primary prevention implantable cardioverter-defibrillators (ICDs).
224322217|NCT05831774|DRUG|Intervention - Intraosseous (IO) administration of vancomycin|"* IV antibiotics (per physician's standard of care): Typically ancef or cefepime is started in pre-op within 1 hour of incision~* IO vancomycin is administered in the OR after sterile prep and draping has occurred (500mg in 100-150mL NS).~* Injection will take place into the proximal humerus"
224252843|NCT06431386|BEHAVIORAL|Behavioural Activation (BA) Therapy|Participants will receive weekly one-hour BA sessions on a day they are not receiving esketamine, delivered virtually or in person as per participant preference. The aim is for participants to learn to observe the relationship between what they did, felt, and thought and what was happening around them, and to identify conditions which maintained, increased, or weakened maladaptive behaviours. Functional behaviour analysis will be used in problem and behaviour evaluation and in planning and reviewing changes introduced by participants between sessions. Other techniques include self-observation and self-report, elaboration of activity hierarchies, behaviour programming, rehearsal and behavioural modelling, and contingency management. Between-session homework will develop relevant and rewarding routines to offer reinforcement in each participant's environment. Participants will be offered 12 BA sessions in total.
224252844|NCT06431386|DRUG|Esketamine|Participants will receive intranasal esketamine twice weekly during the induction phase (first 4 weeks of treatment). Maintenance treatments are administered once per week or once every two weeks at the discretion of the treating physician for 8 additional weeks, totaling 12 weeks of esketamine treatment. Dosing for esketamine usually starts at 56mg on Day 1, followed by 56 or 84mg doses for subsequent treatments.
224252845|NCT06027151|DRUG|1ml of 1% metronidazole gel|Subgingivally at baseline visit
224252846|NCT06027151|DRUG|1ml of 2% minocycline gel|sub gingivally at baseline visit
224252847|NCT06027151|DRUG|1ml of combination of 1% metronidazole gel and 2% minocycline|subgingivally at baseline visit
224252848|NCT06163430|DRUG|TERN-701|TERN-701 orally QD
224252849|NCT02096211|DEVICE|COC 36mm|Total Hip Replacement with COC 36mm Acetabular Cup System
224252850|NCT05665608|DEVICE|Implantable cardioverter-defibrillator (ICD)|"A transvenous ICD consists of an electronic medical device and electrode leads. Besides the possibility to shock during arrhythmias the ICD can potentially terminate ventricular tachycardias by rapid pacing for short periods (small bursts of pacing).~The subcutaneous defibrillator is an established and valid alternative to the transvenous ICD for the prevention of SCD, but in patients without an indication for bradycardia support, cardiac resynchronisation or antitachycardia pacing.~The extravascular implantable cardioverter-defibrillator (EV ICD) system with substernal lead placement is a novel nontransvenous alternative to current available transvenous and subcutaneous ICDs."
224252851|NCT05665608|DRUG|Optimal Medical Therapy (OMT)|"Patients will be treated according to Optimal Medical Therapy defined by the following guidelines:~1. 2019 ESC guidelines for the diagnosis and management of chronic coronary syndromes~2. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure"
223672156|NCT03758755|DEVICE|Blood Flow Restriction Therapy|A wide pressure cuff will be applied to the upper thigh prior to starting strengthening exercises. The cuff is inflated to 80% of resting systolic blood pressure. The cuff remains inflated for the entirety of the exercise (4 sets of a specific movement). Once the exercises are completed, it is deflated for a minimum of one minute before the next type of exercises are started.
223672157|NCT03758755|OTHER|ACL Reconstruction rehabilitation|post-operative rehabilitation according to current standards of care
223672158|NCT05873660|OTHER|No treatment given|No treatment given
223672159|NCT00053898|DRUG|anastrozole|1 mg/day and placebo for 5 years
223672160|NCT00053898|DRUG|tamoxifen citrate|20 mg/day and placebo for 5 years
223672161|NCT00053898|RADIATION|Radiation Therapy|Adjuvant radiation therapy
223672162|NCT05429775|DRUG|Budesonide|single dose of 2 mg oral suspension formulation administered orally under fasting conditions
223672163|NCT04178278|DIAGNOSTIC_TEST|Shuttle walking test|Patients will be required to walk around a 10-m course marked by cones placed 9 m apart, thus allowing 0.5 m for turning at each end. Walking speed will be regulated by prerecorded signals on a compact disc or MP3 file. Patients will increase walking speed at every minute. patients can stop this study, when they can not maintain their speeds due to dyspnea
223672164|NCT04178278|DIAGNOSTIC_TEST|Exercise stress test|Exercise stress test will be performed with cycle. When patients perform this study, they will gradually increase the velocity. Investigators will measure electrocardiography, vital sign, oxygen saturation, oxygen uptake, minute ventilation and fatigue.
223672165|NCT04178278|DIAGNOSTIC_TEST|6 minutes walking test|When participants perform 6 minutes walking test, patients will walk around the tract during 6 minutes. They can their walking speed according to condition and symptom. Investigators records walking distance, pulse rate, oxygen saturation and Borg scale
223672166|NCT02178839|DIETARY_SUPPLEMENT|β- glucan|8.5 g/d of Oat Supplement Containing 3g β- glucan
224252852|NCT05834244|DRUG|Azacitidine|Given by IV (vein)
224252853|NCT05834244|DRUG|Venetoclax|Given by PO
224252854|NCT05834244|DRUG|NK Cells|Given by IV (vein)
224252855|NCT06643884|DRUG|AU-011|AU-011 Via Suprachoroidal Administration with laser treatment
224252856|NCT06643884|DEVICE|SCS Microinjector|Suprachoroidal Injection Device
224252857|NCT06643884|DEVICE|Laser|Laser Administration
224252858|NCT06644625|OTHER|Blood draw for the laboratory assessment|Screening blood sample collection to test for MGUS
224252859|NCT05427370|PROCEDURE|Revascularization by PCI|"Contemporary, State-of-the-art PCI techniques will be encouraged in STICH3C, based on the most recent evidence and clinical practice guidelines recommendations. The best practices to be followed include the use of physiological and intravascular guidance, new-generation drug-eluting stents or scaffolds, rotational or orbital atherectomy for extensive calcifications, recommended bifurcation techniques, chronic total occlusion for viable segments by experienced operators, and trans-radial access.Planned temporary ventricular support is permitted by experienced operators when deemed indicated."
224322218|NCT05831774|DRUG|Control - Standard IV administration of vancomycin|Patients will receive the Houston Methodist Hospital orthopedic surgeon's standard of care pre-operative antibiotic regimen for primary total shoulder arthroplasty patients. This includes IV abx (typically ancef or cefepime and vancomycin) will be started in the pre-operative period approximately 1 hour prior to incision (vancomycin dose weight-based at approximately 15mg/kg \[6,7\] generally 1000-1750mg in 500mL NS).
224322219|NCT06670170|DRUG|PF-07976016 Formulation A|PF-07976016; formulation A - current/reference
224322220|NCT06670170|DRUG|PF-07976016 Formulation B|PF-07976016; Formulation B - new/test
223672167|NCT02178839|DIETARY_SUPPLEMENT|Maltodextrin|8.5 g/d Maltodextrin
223672168|NCT02817399|DEVICE|Functional electrical stimulation|Electrical stimulation that cause muscle contraction while walking
224252860|NCT05427370|PROCEDURE|Revascularization by CABG|The surgical revascularization strategy will be tailored according to the individual patient's coronary anatomy, left ventricular remodeling, aortic atherosclerosis, co-morbidities, local expertise, and surgical judgement. An internal thoracic artery will be used to graft the left anterior descending in all cases. Multi-arterial grafting may be considered in patients without significant co-morbidities and with expected limited vasopressor use, or in patients without saphenous conduits. Choice of on- vs. off-pump surgery is influenced by LV size, associated valvular disease, and aortic atherosclerosis, as well as surgeon experience, but on-pump surgery is recommended routinely. The use of adjunctive intra-aortic balloon support or other cardiac support is not routinely recommended in stable patients; the intra-aortic balloon support is the first line mechanical support.
224252861|NCT05916950|DEVICE|Thor laser atherectomy|Treatment of de novo calcified lesions with laser atherectomy and calcium modification using the Thor system
224252862|NCT01281501|DRUG|Normal saline|10 ml of 0.9% sodium chloride solution
224252863|NCT01281501|DRUG|Pantoprazole|80 mg of intravenous pantoprazole
224252864|NCT01281501|DRUG|Oral antacid|30 ml of oral antacid (1.32 grams of aluminum hydroxide, 0.72 grams of magnesium hydroxide)
224252865|NCT01281501|DRUG|Hyoscine butylbromide|20 mg of intravenous hyoscine butylbromide
224252866|NCT02667405|PROCEDURE|Hot Pack|Patients have a hot pack and 2 layers of towel wrapped around the wrist and forearm for 15 minutes
224252867|NCT02667405|PROCEDURE|Whirlpool|Patients immerse their arm, from elbow to hand, in a whirlpool bath of 104 degrees Fahrenheit for 15 minutes
224252868|NCT01056666|DEVICE|Conveen Optima is a urisheath to be used together with a collecting bag for urine|Conveen optima urisheath is intended to be used together with a collecting bag for urine and to be changed on a daily basis
224252869|NCT01056666|DEVICE|absorbent protection|The patient use his usual absorbent protection (same brand), and change it when needed
224252870|NCT00834522|DRUG|Granisetron hydrochloride 1 mg tablets|2 x 1 mg, single dose non-fasting
224252871|NCT00834522|DRUG|Kytril® 1 mg tablets|2 x 1 mg, single dose non-fasting
224252872|NCT02517684|DRUG|Infliximab|
224252873|NCT02517684|DRUG|Prednisolone|
224252874|NCT02517684|OTHER|Exclusive enteral nutrition|
223672169|NCT02817399|DEVICE|Neuro-muscular electrical stimulation|Electrical stimulation that cause muscle contraction in a stationary position
224252875|NCT02517684|DRUG|Azathioprine|
224252876|NCT04516967|DRUG|Avatrombopag|Oral avatrombopag tablet or sprinkle capsule
224252877|NCT04516967|DRUG|Placebo|Placebo comparator tablet or sprinkle capsule
224252878|NCT03954145|PROCEDURE|Enamel pumicing before bonding the lingual retainer.|"Lingual surfaces of the lower incisors and canines are pumiced before bonding the lingual retainer.~Teeth are being cleaned using a brush loaded with pumice and mounted on a low speed contra-angle. Teeth are then etched and the multi-braided retainer wire is being bonded with composite onto the lingual surfaces of the lower canines and incisors."
224252879|NCT03954145|PROCEDURE|Enamel sandblasting before bonding the lingual retainer.|"Enamel is being initially prepared through sandblasting the lingual surfaces of the mandibular canines and incisors.~Sandblasting is performed with the help of a MicroEtcher IIATM (Danville) which is projecting 50 μm Al2O3 particles onto the enamel surfaces. Teeth are subsequently etched and the retainer is then being bonded with composite onto the lingual surfaces of the mandibular incisors and canines."
223672170|NCT02817399|PROCEDURE|Active exercises|Subjects will receive training exercise according to ACL reconstruction protocol
223672171|NCT01264601|BIOLOGICAL|Trivalent Influenza Vaccine|Age appropriate dose of seasonal Trivalent Influenza Vaccine (TIV), either 0.25mL under age 3 or 0.5mL over the age of 3.
223672172|NCT04531631|DRUG|Dorzagliatin|tablet
223672173|NCT04531631|DRUG|placebo|placebo
223672174|NCT02487342|OTHER|milk|small serving (217 mL) of british semi-skimmed milk
223672175|NCT02487342|OTHER|orange fruit-juice|small serving (217 mL) of orange juice
223772094|NCT06663566|DIAGNOSTIC_TEST|Diagnose the patient&#39;s right heart function as well as right heart fibrosis|Diagnose the patient\&#39;s right heart function as well as right heart fibrosis
223772095|NCT06663566|DIAGNOSTIC_TEST|Diagnose the patient&#39;s right heart function as well as right heart fibrosis|Diagnose the patient\&#39;s right heart function as well as right heart fibrosis
224252880|NCT00283361|DRUG|ZP120|
224252881|NCT00283361|PROCEDURE|I.v. catherization|
224252882|NCT00283361|PROCEDURE|6-minutes walk performance|
224252883|NCT00283361|BEHAVIORAL|Dyspnea severity assessment|
224252884|NCT00283361|PROCEDURE|Blood sampling for laboratory tests|
224252885|NCT00283361|PROCEDURE|ECG|
224252886|NCT00283361|PROCEDURE|Physical examination|
224252887|NCT05246462|OTHER|Logotherapy|In this study, the experimental group received seven-session logotherapy-based interviews on making sense of life, while the control group received only routine nursing care. In this study, Personal Meaning Oriented Psychotherapy (PMOP) was used to structure interviews on making sense of life based on Logotherapy and enhance the sense of meaning in cancer patients, share their concerns, experiences, and feelings about diagnosis-treatment, have their difficulties defined, maintain, and develop their sense of purpose and responsibility.
224252888|NCT05278481|BEHAVIORAL|Reward Message with standard introduction|Each text message will be sent 6 times total over two weeks. Each message type will be combined with a standard introduction.
224252889|NCT05278481|BEHAVIORAL|Reward Message with culturally tailored introduction|Each text message will be sent 6 times total over two weeks. Each message type will be combined with an introduction culturally tailored for Hispanic/Latino participants.
224252890|NCT05278481|BEHAVIORAL|Threat/Self-efficacy with standard introduction|Each text message will be sent 6 times total over two weeks. Each message type will be combined with a standard introduction.
224252891|NCT05278481|BEHAVIORAL|Threat/Self-efficacy with culturally tailored introduction|Each text message will be sent 6 times total over two weeks. Each message type will be combined with an introduction culturally tailored for Hispanic/Latino participants.
224252892|NCT05278481|BEHAVIORAL|Social norms message with standard introduction|Each text message will be sent 6 times total over two weeks. Each message type will be combined with a standard introduction.
224252893|NCT05278481|BEHAVIORAL|Social norms message with culturally tailored introduction|Each text message will be sent 6 times total over two weeks. Each message type will be combined with an introduction culturally tailored for Hispanic/Latino participants.
224252894|NCT06441097|DRUG|Polatuzumab vedotin|Polatuzumab vedotin IV infusion will be administered as per the schedule specified in the respective arm.
223672176|NCT06082973|DEVICE|Automated insulin delivery system algorithm with a dual-hormone configuration (insulin and glucagon) for glucose control|Participants will wear a CSII system with the CGM device. Insulin will be administered through the AID dHmG system, and microdoses of glucagon (GlucaGen®) will be subcutaneously administered based on automatic recommendations for hypoglycemia mitigation. The subcutaneous administration of reconstituted glucagon will be conducted using a 0.5 mL insulin syringe with needle, allowing for precise doses as small as 0.01mg/0.01 mL.
223672177|NCT06082973|DEVICE|Automated insulin delivery system with a single-hormone configuration (insulin) with rescue carbohydrate recommendations for glucose control|Participants will wear a CSII system with the CGM device. Insulin will be administered through the AID sHC system, along with automatic rescue carbohydrate recommendations for hypoglycemia mitigation. As per the carbohydrate recommendation, participants will received the suggested amount of carbohydrates using an oral glucose gel containing 15g of carbohydrates per unit.
223672178|NCT02066987|BEHAVIORAL|Implementation intention|"It may be helpful for you to plan when and where you will brush your teeth each day over the next month. Please write below when, where, and after what activity you will brush your teeth (e.g., at 8.00 a.m. and 9.00 p.m. in the bathroom after eating breakfast/dinner). Because you should brush your teeth twice a day, please make two plans.~If it is \_\_\_\_\_ (WHEN) at or in \_\_\_\_\_\_\_ (WHERE) before/after \_\_\_\_\_\_ (ACTIVITY), then I will brush my teeth! If it is \_\_\_\_\_ (WHEN) at or in \_\_\_\_\_\_\_ (WHERE) before/after \_\_\_\_\_\_ (ACTIVITY), then I will brush my teeth!"
223672179|NCT02066987|BEHAVIORAL|Action planning|"It may be helpful for you to plan when and where you will brush your teeth each day over the next month. Please write below when, where, and after what activity you will brush your teeth (e.g., at 8.00 a.m. and 9.00 p.m. in the bathroom after eating breakfast/dinner). Because you should brush your teeth twice a day, please make two plans.~I will brush my teeth at \_\_\_(WHEN) at or in \_\_\_\_(WHERE) before/after \_\_\_ (ACTIVITY).~I will brush my teeth at \_\_\_(WHEN) at or in \_\_\_\_(WHERE) before/after \_\_\_ (ACTIVITY)."
223672180|NCT02066987|BEHAVIORAL|active control group|Participants in the active control group will receive an educational pamphlet containing what it is dental brushing, why it is done, and how it is done.
223672181|NCT00427401|DRUG|PF-00915275|
223672182|NCT01551940|DRUG|Botox injection|Local ultrasound-guided bilateral injection of botulinum toxin type A in parotid (35 UI/gland) and submandibular (15 UI/gland) glands.
223672183|NCT01551940|DRUG|Placebo injection|A local ultrasound-guided bilateral injection of placebo (NaCl 0.9 %) in parotid (0.7 ml/gland) and submandibular (0.3 ml/gland) glands.
223672184|NCT02630901|DRUG|PRX003|
223672185|NCT02630901|OTHER|Placebo|
223672186|NCT02365142|BIOLOGICAL|100 million Bone marrow mesenchimal stem cells|100 million Bone marrow mesenchimal stem cells with PRGF
223672187|NCT02365142|BIOLOGICAL|Platelet Rich plasma (PRGF)|3 injections of PRGF
223672188|NCT01138878|OTHER|Questionnaire|Administration of written questionnaire to assess attitudes towards the introduction of routine HIV testing programmes to that healthcare setting
223672189|NCT01138878|OTHER|Focus Group Discussion|FGD to explore attitudes within each group towards the introduction of routine HIV screening programmes in each medical setting
223672190|NCT01138878|OTHER|HIV test (serum or salivary)|An HIV test offered to all 16-65 year olds (not known already to be HIV-positive) accessing the healthcare setting during the twelve week pilot period
223672191|NCT01138878|OTHER|Semi-structured telephone interview|Telephone interview administered to patients offered an HIV test during the pilot period
224252895|NCT06441097|DRUG|Rituximab|Rituximab IV infusion will be administered as per the schedule specified in the respective arm.
224252896|NCT06441097|DRUG|Cyclophosphamide|Cyclophosphamide IV infusion will be administered as per the schedule specified in the respective arm.
224252897|NCT06441097|DRUG|Doxorubicin|Doxorubicin IV infusion will be administered as per the schedule specified in the respective arm.
224252898|NCT06441097|DRUG|Prednisone|Prednisone PO will be administered as per the schedule specified in the respective arm.
224252899|NCT06441097|DRUG|Acalabrutinib|Acalabrutinib PO will be administered as per the schedule specified in the respective arm.
224252900|NCT06441097|DRUG|Lenalidomide|Lenalidomide PO will be administered as per the schedule specified in the respective arm.
224252901|NCT06441097|DRUG|Decitabine|Decitabine IV infusion will be administered as per the schedule specified in the respective arm.
224252902|NCT01816997|DRUG|Pravastatin|"The impaired fasting glucose (IFG) subjects with total cholesterol 200-280 mg/dL were randomized into two groups: pravastatin 40 mg or rosuvastatin 10 mg.~IFG subjects with total cholesterol less than 200 mg/dL will be served as controls."
223672192|NCT03441672|BEHAVIORAL|Meaning of Screening|Interactive technology game providing education about prenatal screening and what the results may mean.
223672193|NCT03149367|PROCEDURE|levator muscle resection with fixed sutures technique|The levator muscle is approached through skin incision and the muscle shortened and sutured directly to the tarsus then the skin crease reformed with interrupted sutures which pick up the underlying levator muscle
223672194|NCT03149367|PROCEDURE|Levator muscle resection with adjustable sutures technique|The adjustable sutures technique in which the sutures passes through the levator muscle into the tarsal plate and out through the skin edge .the skin crease is formed separately so that adjusting the suture doesn't open the wound, the suture can be adjusted according to the result up to 4 days post operative.
223672195|NCT05391191|DEVICE|MitrAssist TRISKELE® transcatheter aortic valve system|Patients were treated with MitrAssist TRISKELE® transcatheter aortic valve system
223672196|NCT05054660|OTHER|caring chatbot|The investigators will use the developed caring chatbot to provide care to the cases and to collect case treatment data and interaction data between the case and the caring chatbot.
223672197|NCT02619773|PROCEDURE|mupirocin ointment|Mupirocin ointment will be applied after skin closure. A standard island dressing will be placed over the incision.
223672198|NCT00732004|DEVICE|Silicone Hydrogel Contact Lenses|
223672199|NCT00732004|DEVICE|1x PMBH preserved MPS|
224252903|NCT01816997|DRUG|Rosuvastatin|"The impaired fasting glucose (IFG) subjects with total cholesterol 200-280 mg/dL were randomized into two groups: pravastatin 40 mg or rosuvastatin 10 mg.~IFG subjects with total cholesterol less than 200 mg/dL will be served as controls."
223672200|NCT00732004|DEVICE|1x Polyquad/Aldox MPS|
223672201|NCT00837733|PROCEDURE|Endometrial biopsy|Endometrial biopsy was done at luteal phase on the day 21-26 of spontaneous menstrual cycles, when GnRH agonist uses begun. Endometrial samples were taken by a biopsy catheter
223772096|NCT07021365|DRUG|Phenol Injection|n patients diagnosed with chronic coccydynia, a ganglion impar block is initially performed following conservative treatment. In cases where this intervention provides limited benefit, ganglion impar phenol neurolysis is performed. A short-acting local anesthetic (3-4 mL of 1% prilocaine) will be administered into the skin and subcutaneous tissues. A 90 mm 22-gauge Quincke-tipped spinal needle will be advanced via the trans-coccygeal route under fluoroscopic guidance with intermittent imaging. The needle's position in the area anterior to the coccyx, where the ganglion impar is located, will be confirmed using 1-2 mL of contrast agent (iohexol). If the desired spread of contrast is observed, 5 mL of 7% phenol will be injected.
223672202|NCT00837733|PROCEDURE|Endometrial Biopsy|Biopsy catheter
223672203|NCT04011371|PROCEDURE|Cyanoacrylate closure|Cyanoacrylate glue embolization targeting venous insufficiency
223672204|NCT00832039|DRUG|sodium-selenite|An intravenous bolus of 1000 µg followed by a continuous intravenous infusion of 1000 µg/day until patient is discharged from the ICU but not more than 21 applications à 24 hours.
223672205|NCT00832039|DRUG|Placebo|An intravenous bolus of placebo followed by a continuous intravenous infusion with placebo until patient is discharged from the ICU but not more than 21 applications à 24 hours.
223672206|NCT00832039|PROCEDURE|Procalcitonin guided therapy|"Causal therapy of sepsis is guided by applying the following algorithm:~Day 4: PCT drop from baseline \>=50%: no change in causal therapy; PCT drop from baseline \<50%: change or optimize antimicrobial therapy, new intervention (i.e. surgery, diagnostics) recommended for source control.~Day 7, 10, 14: PCT \<=1.0 ng/ml: finish antimicrobial therapy; PCT \>1.0 ng/ml and PCT drop from last PCT measurement \>=50%: finish antimicrobial therapy; PCT \>1.0 ng/ml and PCT drop from last PCT measurement \<50%: change or optimize antimicrobial therapy, new intervention (i.e. surgery, diagnostics) recommended for source control."
223672207|NCT04801940|DRUG|Apixaban|Apixaban 2.5mg orally twice daily for 14 days.
223672208|NCT04801940|DRUG|Atorvastatin|Atorvastatin 40mg orally once daily for 12 months.
223672209|NCT02644681|PROCEDURE|Aortic Aneurysm, Thoracic surgery|
223672210|NCT05596097|DRUG|Zanubrutinib|Zanubrutinib, 180mg, bid, p.o., d1-28; Treatment cycles every 28 days
223672211|NCT04192227|BEHAVIORAL|EnHAncing BehavIors through wellness TreatmentS (HABITS)|Six 75-minute sessions via live video conference wherein participants will receive training in areas of health, wellness and quality of life. Classes will be supplemented with independent homework assignments and discussion on a closed social media forum with peers and facilitators.
223672212|NCT00497042|DEVICE|Self Adjusting File|
223672213|NCT01491594|DRUG|Eltrombopag|Eltrombopag is taken by mouth daily beginning 5 days before the start of each chemotherapy cycle for 10 days. In the phase 1 part of the study the dose will be 100, 150, 225, or 300 mg.
223672214|NCT00366093|DRUG|Eszopiclone|eszopiclone 3 mg
223672215|NCT00366093|DRUG|Placebo|placebo tablet
223672216|NCT01577290|BEHAVIORAL|Internet-administered Mindfulness Training Program|A 10 week, internet-administered mindfulness training program, featuring no therapist-support. 10 minutes of training, twice per day.
223672217|NCT01577290|BEHAVIORAL|Discussion group|Access to a discussion group with the possibility of sharing experiences, methods of relief, and the like.
223672218|NCT03320551|BEHAVIORAL|Immersion program|Evaluate the impact of an already established one week long lifestyle immersion program sponsored by Whole Foods, Inc for their employees on anthropomorphic, clinical labs such as lipid levels, blood sugar and other markers of nutrition, quality of life and activity levels at baseline, at the end of the program and at 3 and 6 months
223672219|NCT00030004|PROCEDURE|spinal manipulation|
223672220|NCT00030004|DRUG|midazolam|
224252904|NCT01816997|DRUG|Control|placebo
224252905|NCT02494479|DRUG|Prurisol|50mg tablet
223672221|NCT00889616|DRUG|BSAM2/Alhydrogel + CPG 7909|
223672222|NCT01254942|OTHER|B4 Clinic|Fracture Follow-Up Clinic plus Exercise Program
224252906|NCT02494479|DRUG|Placebo|Sugar pill designed to match Purisol tablet
223672223|NCT01254942|OTHER|Usual Care|
223672224|NCT02045953|DEVICE|VENTOLIN Mini-Spacer|VENTOLIN mini-spacer will be used to dispense the SERETIDE Evohaler and FLIXOTIDE Evohaler
223672225|NCT02045953|DEVICE|Aerochamber Plus spacer|Aerochamber Plus spacer will be used to dispense the SERETIDE Evohaler and FLIXOTIDE Evohaler
223672226|NCT05397782|DEVICE|BioNourish, a component of Flourish HEC|BioNourish, one of three parts of the Flourish HEC system, is a vaginal moisturizing gel - a Class II medical device with FDA 510k clearance obtained in 2020.
223672227|NCT03273569|PROCEDURE|PDI-UC protocol|Preplacental delivery intervention for uterine conservation protocol starts after delivery of the fetus during Cesarean delivery and consists of delayed cord clamping, intramyometrial injection of vasopressin, subdecidual injection of saline, ligation of the uterine arteries, multiple 8 compression sutures, followed by delivery of the placenta, application of pressure and interrupted sutures if needed
223672228|NCT01077375|DRUG|Placebo|"* Placebo tablets, oral administration, twice daily for 10 weeks during randomized, double-blind treatment period. Duloxetine capsules, oral administration, 30 mg/day for 1 week after randomization to effect a duloxetine down-taper.~* Placebo tablets, twice daily for 1 week during double-blind down-taper treatment period."
223672229|NCT01077375|DRUG|Milnacipran|"* Milnacipran tablets, 100 to 200 mg/day, oral administration, twice daily in divided doses for 10 weeks during randomized, double-blind treatment period. Placebo capsules, 1 capsule/day administered for 1 week after randomization to maintain double-blind duloxetine down-taper.~* Milnacipran tablets, 100 to 0 mg/day, oral administration, twice daily in divided doses for 1 week during double-blind down-taper treatment period."
224322221|NCT04223752|DRUG|Ceftolozane/Tazobactam|"Participants 12 to \<18 years of age: IV ceftolozane 2 g with tazobactam 1 g infused over a 60-minute period.~Participants \<12 years of age: IV ceftolozane 40 mg/kg with tazobactam 20 mg/kg infused over a 60-minute period (not to exceed a dose of ceftolozane 2g and tazobactam 1 g)."
224252907|NCT05557747|OTHER|cervicothoracic junction mobilization in form of Maitland mobilization|Group A: will receive cervicothoracic junction mobilization mobilization in form of Maitland mobilization to the C7-T1 level, according to their primary movement restriction (for flexion-extension restriction- central PA glide, for rotation restrictions (unilateral PA glide) for 3 sessions/week over 4 weeks periods.
224252908|NCT05557747|OTHER|autogenic muscle Energy Technique|"the technique will applied to neck muscles that are prone to get short including anterior, middle and posterior Scaleni, Sternocleidomastoid, Levator Scapulae and upper fibers of the Trapezius muscle.~The AI MET group will given 3-5 repetitions of post isometric relaxation (PIR) (30-50% isometric contraction of the muscle to be stretched for 7-10 seconds, followed by rest period of 5 seconds and then a stretch of 10-60 seconds hold"
224252909|NCT05557747|OTHER|conventional physical therapy|conventional physical therapy only in form of: (superficial heat using hot pack for 10 minutes , Isometric Neck Exercises and Dynamic Neck Exercises)) for 3 sessions/week over 4 weeks periods
224252910|NCT01807793|BEHAVIORAL|Psychoeducation|
223672230|NCT03088085|PROCEDURE|Self-mobilization|Subjects will mobilize thoracic spine and ribs with a foam roller every night before going to bed.
223672231|NCT03088085|PROCEDURE|Sleep Education|Subjects will be educated on sleep hygiene in order to improve likelihood of having good sleep.
223672232|NCT01847807|DRUG|low dose Astragalus|
223672233|NCT01847807|DRUG|high dose astagalus|
223672234|NCT04204980|DRUG|Daratumumab dose escalation|\- Step I: dose-escalation 3 patients treated weekly during four weeks with 4 mg/kg of daratumumab, then 3 patients treated weekly during four weeks with 8 mg/kg of daratumumab, then 3 patients treated weekly four weeks with 16 mg/kg of daratumumab
223672235|NCT04204980|DRUG|Daratumumab full dose|\- Step II: expansion cohort to 13 patients (with 10 new patients included and the last 3 patients from the step I) with eight weekly doses of 16 mg/kg daratumumab
223672236|NCT02622906|DRUG|Pasireotide|60 mg per month of the Pasireotide during 6 months
223672237|NCT02622906|DRUG|Placebo|Vehicule injection per month during 6 months
223672238|NCT03862508|OTHER|Plyometric exercises|"Jump Drop Jump, dropping the subject from a height of 30cm and then make a vertical jump.~Long jumps asking the athletes to take momentum and make a leap forward trying to reach the greatest possible distance.~Jump Countermovement jump unilaterally, alternating the lower extremities. Jumps 180º with the athletes maintaining a semi-squat position. Jump Countermovement jump repeatedly starting from an upright position and the upper extremities in both hips.~All the exercises will be done through 8 repetitions per session during the first two weeks, increasing two repetitions every two weeks (until reaching 12 repetitions at the end of the intervention).~For the realization of each one of the exercises, the ballasted weight will be used (Powerinstep® model)."
224252911|NCT00941811|DRUG|Imiquimod|Local Imiquimod three times weekly for 16 weeks
224252912|NCT01038661|DRUG|Docetaxel|"Formulation: concentrated solution for intravenous infusion (IV)~Route(s) of administration: 1-hour IV"
224252913|NCT01038661|DRUG|Cisplatin|"Formulation: concentrated solution for intravenous infusion (IV)~Route(s) of administration: 1-3-hour IV"
224252914|NCT01038661|OTHER|Best supportive care (BSC)|Any treatment including palliative radiotherapy for pain relief-but not chemotherapy - that is considered appropriate by the investigator
224252915|NCT05644340|PROCEDURE|Speed 8 (Fast balancing gas flow)|General anesthesia will be induced via intravenous agents, and anesthesia maintenance will be provided via inhalation for all the patients. The maintenance will be provided with sevoflurane using automated gas flow with the selected speed of 8. The anesthesia machine indicates amount of sevoflurane inhaled, inspired and exhaled oxygen, carbon dioxyde, air and sevoflurane concentrations. Accordingly these data and actual flow rate will be recorded every 15 minutes.
223672239|NCT00006212|DRUG|cisplatin|
223672240|NCT00006212|DRUG|vinblastine sulfate|
223672241|NCT00006212|RADIATION|phosphorus P32|
223672242|NCT00006212|RADIATION|radiation therapy|
223672243|NCT06091072|OTHER|Image-guided navigation|A patient-specific 3D model will be created using an available pre-operative SPECT/CT scan. Pre-operatively, three electromagnetic patient trackers will be attached to the patients' skin, close to the pelvis, allowing tracking the patient's position during surgery. After anesthesia and before the skin disinfection procedure, the patient is placed in the final surgical position, where an intra-operative CBCT scan is performed required for the image-guided surgery workflow. During surgery, the preoperative images and 3D model will be visible for the surgeon together with a blunt-tip electromagnetic pointer enabling surgical navigation during robotic surgery. Anatomical structures will be used to validate the accuracy of the navigation. When the target is identified by the surgeon, the pointer is used to store the location digitally. Scheduled standard clinical 99mTc will be used as validation for target(s) identification.
223672244|NCT02000908|DEVICE|photobiomodulation|The photobiomodulation delivered by Realief Therapy involves amplitude wavelength light delivered by a class IV therapeutic laser.
223672245|NCT02000908|OTHER|Sham treatment|All patients in sham treatment arm cross over to laser therapy followed by physiotherapy
223672246|NCT02000908|OTHER|Physiotherapy|Chiropractic massage and lymphedema treatment
224252916|NCT05644340|PROCEDURE|Speed 4 (Medium speed balancing gas flow)|General anesthesia will be induced via intravenous agents, and anesthesia maintenance will be provided via inhalation for all the patients. The maintenance will be provided with sevoflurane using automated gas flow with the selected speed of 4 (Medium speed). The anesthesia machine indicates amount of sevoflurane inhaled, inspired and exhaled oxygen, carbon dioxyde, air and sevoflurane concentrations. Accordingly these data and actual flow rate will be recorded every 15 minutes.
224252917|NCT05385601|OTHER|eVOG (Mobile VideoOculoGraphy)|"* Eyes movements assessed with e-VOG (mobile application developed on an iPad, that uses the face detection features of the front camera to detect and record eye movements).~* Study duration is about 20 minutes, the day the subject performs his standard video-oculography examination in routine care (using Eye-Tracker®T2)"
224252918|NCT03569059|DEVICE|Early Robotic/VR Therapy (EVR)|Subjects will perform state-of-art inpatient usual care therapy. In addition, they will perform an extra 1-hour/day of intensive therapy focusing on the hand in the form of interactive virtual reality games while assisted by robots. This additional treatment will be initiated 5-30 days post stroke.
224322222|NCT04519164|DRUG|Eplerenone|mineralocorticoid receptor antagonist and potassium-sparing diuretic
224322223|NCT04519164|DRUG|Chlorthalidone with potassium chloride|potassium-wasting diuretic with potassium chloride
224252919|NCT03569059|BEHAVIORAL|Dose-Matched Usual Physical Therapy Care|Subjects will perform state-of-art usual physical/occupational care and 10 days of one additional hour of state-of-art usual inpatient and/or outpatient physical therapy/occupational therapy.
224252920|NCT03569059|DEVICE|Delayed Robotic/VR Therapy (DVR)|Subjects will perform state-of-art inpatient usual care therapy. In addition, they will perform an extra 1-hour/day of intensive therapy focusing on the hand in the form of interactive virtual reality games while assisted by robots. This additional treatment will be initiated 31-60 days post stroke.
224252921|NCT03165994|DRUG|APX005M|APX005M IV infusion
224252922|NCT03165994|RADIATION|Radiation Therapy|Radiation therapy, total dose 5040cGy in 180cGy fractions
224252923|NCT03165994|DRUG|Paclitaxel|Paclitaxel IV infusion
224252924|NCT03165994|DRUG|Carboplatin|Carboplatin IV infusion
224252925|NCT03165994|PROCEDURE|Surgical resection of tumor|Surgical removal of the tumor will occur between weeks 10-17
224252926|NCT00519194|DEVICE|Epicor LP Cardiac Ablation System|Surgical ablation of permanent AF during concomitant open chest and/or open heart surgery
224252927|NCT00519194|PROCEDURE|Surgical ablation of permanent AF|Concomitant AF ablation during mitral valve surgery
224252928|NCT02996591|PROCEDURE|25 mL of 0.25% bupivacaine plus 2 mg preservative-free (PF) dexamethasone / 30 ml for popliteal nerve block|
224252929|NCT02996591|PROCEDURE|10 mL of 0.25% bupivacaine plus 2 mg preservative-free (PF) dexamethasone / 30 ml for adductor canal nerve block|
224252930|NCT02996591|DRUG|Midazolam, 2-5 mg IV + Glycopyrrolate, 0.1 mg IV + Ketamine, 10-20 mg + propofol as needed|
224252931|NCT02996591|PROCEDURE|45-60 mg of 1.5% mepivacaine for spinal anesthesia|
224252932|NCT02996591|PROCEDURE|LMA insertion + titrated propofol infusion + sevoflurane + ketamine 10 mg/hr for general anesthesia|
224252933|NCT04564560|PROCEDURE|Endovascular aortic repair with Zenith Alpha Spiral-Z®|The Zenith Alpha Spiral-Z® stent graft may have an increased risk of thrombosis. The intervention in this study is to assess the extent and degree of thrombosis in patients treated with the Zenith Alpha Spiral-Z® during endovascular repair of aortic aneurysm
224252934|NCT02597660|DRUG|Somatropin|Active drug
224252935|NCT02597660|DRUG|Bacteriostatic saline|Placebo, the diluent used to reconstitute somatropin
224252936|NCT02597660|OTHER|Progressive exercise program|Over a 12 week period beginning at the second study visit patients will perform a standard of care eccentric exercise training regime. Each session consists of three bilateral exercises: leg press, back squat, and hack squat. Subjects will complete four sets in each exercise with a 2-3 minute rest between sets. The repetitions/loads are: 15 repetition maximum (RM) week 1, 12RM weeks 2-3, 10RM weeks 4-5, 8RM weeks 6-8 and 6RM weeks 9-12. All exercises are performed from complete 0º to 90º of knee flexion and back again. Each of the eccentric and concentric phases will occur over a period of 3 seconds, respectively for a total of 6 seconds per contraction.
224252937|NCT02597660|PROCEDURE|Patellar tendon biopsy|Bilateral biopsies will be performed on an elective basis, although the investigators will aim to have 8 subjects in each group receive the biopsy. Biopsies will be obtained at the 26 week time point. The data obtained from the biopsy will help address the mechanism behind observed changes in outcome scores, physical measurements or imaging studies. The biopsy will be performed under ultrasound guidance and using sterile technique with a disposable 14G, 2cm biopsy instrument.
224252938|NCT02232776|DRUG|Losartan|Dose of Losartan : 0.7mg/kg once daily.
224252939|NCT00144534|DRUG|MRA (Tocilizumab)|8mg/kg/4 weeks
224252940|NCT04576234|DIETARY_SUPPLEMENT|entral feeding|Intermittent enteral feeding group recieved intermittent feeding as the feed was given over a 24 hour period with intervals of rest (e.g. three hours feeding two hours rest)
224252941|NCT02003833|DEVICE|Poly-L-lactic acid|Sculptra injections
224252942|NCT02003833|DEVICE|Placebo comparator|saline injections
224252943|NCT03565133|DIETARY_SUPPLEMENT|Quinine sham feeding quinine|Oral sham feeding with quinine
223672247|NCT03441217|DRUG|Hyoscine Butylbromide 20Mg/1mL Injection|Nulliparous women with gestations at term receive 20 mg of Hyoscine butylbromide upon arrival in the Labor and Delivery Unit (4-5 cms).
224252944|NCT03565133|DIETARY_SUPPLEMENT|Gastric quinine|A gastric capsule containing quinine
224252945|NCT03565133|DIETARY_SUPPLEMENT|Oral sham feeding placebo|Oral sham feeding with placebo (tap water)
224252946|NCT03565133|DIETARY_SUPPLEMENT|Gastric placebo|A gastric capsule containing placebo (cellulose)
224252947|NCT00665470|DRUG|Aldesleukin|"High-dose aldesleukin intravenous (IV) over 15 minutes every 8 hours beginning within 24 hours after peripheral blood lymphocyte (PBL) infusion and continuing for up to 5 days (maximum of 15 doses).~Receive low-dose aldesleukin subcutaneously (SC) once daily 5 days a week for up to 6 weeks"
224252948|NCT05368870|PROCEDURE|Carlevale implantation|Vitrectomy and Carlevale implantation
224252949|NCT00934050|DRUG|ELND005 (scyllo-inositol)|"Prior to 15Dec2009: ELND005 2000 mg PO BID for 48 weeks~After 15Dec2009: ELND005 250 mg PO BID for 48 weeks"
224252950|NCT00461786|DRUG|pemetrexed|900 mg/m2, intravenous (IV), every 21 days, until disease progression
224252951|NCT02816450|BEHAVIORAL|Water Intake|
224252952|NCT03974035|DRUG|Second infiltration pre-extubation with ropivacaine|The surgeon will proceed firstly with pre-incisional infiltration with lidocaine and adrenaline after intubation, and secondly with pre-extubation infiltration with ropivacaine at the intraoral and intranasal submucosal level in the maxilla and jaw to block the terminal branches of the maxillary and mandibular nerve
224252953|NCT01133470|DRUG|Fexofenadine HCl + Pseudoephedrine HCl|Fexofenadine HCl 180 mg + Pseudoephedrine HCl 240 mg ER Tablets of Dr. Reddy's KLaboratories Limited
224252954|NCT00835991|DRUG|Glyburide/Metformin 5 mg/500 mg Tablets|1 x 5 mg/500 mg, single-dose fed
224252955|NCT00835991|DRUG|Glucovance® 5 mg/500 mg Tablets|1 x 5 mg/500 mg, single-dose fed
224252956|NCT02561520|BIOLOGICAL|PRP eye drops|Eye drops 4x a day, patients will start this eye drop first.
224252957|NCT02561520|BIOLOGICAL|PPP eye drops|Eye drops 4x a day, patients will start this eye drops after PRP.
224252958|NCT05422391|DIETARY_SUPPLEMENT|3 day caloric restriction/metabolic reset|Participants will consume \~500 kcal/day, using commercially available products (Plexus(r)), for 3 days, measuring physiological relevant parameters pre-and post-intervention.
224252959|NCT02149420|DRUG|VAY736|
224252960|NCT02149420|DRUG|Placebo|
224252961|NCT00833157|DRUG|glucosamine sulphate|Subjects are administered glucosamine-sulphate tablets of 500 mg \* 3 daily, while they are performing a strength-training program with both legs (\*3 weekly) for 12 weeks.
224252962|NCT00833157|DRUG|ibuprofen|Subjects are administered 600 mg \* 2 daily, while they are performing a strength-training program with both legs (\*3 weekly) for 12 weeks
224252963|NCT00833157|DRUG|placebo|Subjects are administered placebo tablets, while they are performing a strength-training program (\*3 weekly) with both legs for 12 weeks
224252964|NCT04205123|GENETIC|sickle cell syndrome|"Academic Study prospective multicenter observational factors responsible for nephropathy in patients with sickle cell disease followed by Belgium and the Nord-Pas -De- Calais Region and creating a biobank of blood and urine.~In the population of patients with SCD followed in all participating centres.~Know the prevalence of nephropathy and the relationship between it with their some of their genotypic mutations and clinical phenotype promoting mutated hemoglobin polymerization.~Determine the behaviour of dense cells in the basal state and in a hypeosmolaire environment~Determine the place of the erythrocyte microparticles as a biomarker of sickle cell nephropathy~Studying genes known as risk factor for proteinuria~Create a BioBank of samples of sickle cell patients in clinically stable condition for other research purposes."
224252965|NCT05886660|DRUG|DPI-386 Nasal Gel|Subjects will self-administer DPI-386 Nasal Gel.
224252966|NCT05886660|DRUG|Placebo Nasal Gel|Subjects will self-administer Placebo Nasal Gel.
224252967|NCT05886660|DRUG|DPI-386 Nasal Gel|Subjects will self-administer DPI-386 Nasal Gel. Vibrotactile feedback of tilt direction and magnitude will be provided on a sensory augmentation belt worn by the subject.
224252968|NCT05886660|DRUG|Placebo Nasal Gel|"Subjects will self-administer Placebo Nasal Gel.~Vibrotactile feedback of tilt direction and magnitude will be provided on a sensory augmentation belt worn by the subject."
224252969|NCT03197415|OTHER|Platelet-rich plasma|intradiscal injection of plasma-rich platelet
224252970|NCT01566617|OTHER|Standard care and Pharmaceutical care|Pharmaceutical care is the direct interaction between the pharmacist and the drug's users in order to improve the therapeutic compliance among outpatients and promote adequate pharmacotherapeutic follow-up.
224252971|NCT01566617|OTHER|Standard care|These patients will only receive standard care, with out follow-up by the pharmacist
224252972|NCT06559722|DRUG|Insulin Degludec/liraglutide Injection|Subcutaneously (s.c., under the skin)administration once daily in combination with metformin. Dose was individually adjusted.
224252973|NCT06559722|DRUG|XULTOPHY®|Subcutaneously (s.c., under the skin)administration once daily in combination with metformin. Dose was individually adjusted.
224252974|NCT02023229|DIETARY_SUPPLEMENT|Branched-chain aminoacids|
223672248|NCT03441217|DRUG|Saline Solution|Nulliparous women with gestations at term receive 20 mg of saline solution upon arrival in the Labor and Delivery Unit (4-5 cms).
224252975|NCT02023229|OTHER|High-fiber high protein diet|
224252976|NCT03536091|DIAGNOSTIC_TEST|Magnification endoscopy|All IBD patients will undergo magnification endoscopy with 136-fold optical magnification in conjunction with optical chromoendoscopy
224252977|NCT02378935|DRUG|VOX|100 mg tablet(s) administered orally once daily with food
224252978|NCT02378935|DRUG|SOF/VEL|400/100 mg FDC tablet administered orally once daily with food
223672249|NCT01410851|OTHER|dietary treatment|A within-subject, balanced repeated-measures design was followed where subjects received 4 treatments or control over 5 weeks approximately 1 week apart. The pulse treatments contained: (1) chickpeas (Primo, Toronto, ON), (2) lentils (Primo, Toronto, ON), (3) navy beans (Ferma, Toronto, ON) or (4) yellow peas (Nupak, Toronto, ON).
223672250|NCT04561999|DEVICE|Elastography|Performance of Ultrasound, Elastography
223672251|NCT05999760|DEVICE|evaluation of retention of Versacryle and CAD/CAM partial dentures by force gauge|Evaluation of retention of Versacryle and CAD/CAM partial dentures by force gauge on day one, on first month, and on the second month of prosthesis delivery.
224252979|NCT02378935|DRUG|RBV|Tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
224252980|NCT02649621|BIOLOGICAL|Amniotic Membrane Extract Eye Drop (AMEED)|Use of use Amniotic Membrane Extract Eye Drop (AMEED) on in vivo cultured limbal stem cells in the treatment of unilateral corneal stem cell damage.
224252981|NCT03616535|OTHER|Cognitive training|The investigators will provide participants with tablets to play brain games.
224252982|NCT03616535|OTHER|Exercise training|The investigators will provide participants with foot peddlers.
224252983|NCT03616535|OTHER|Combined cognitive and exercise training|The investigators will provide participants with tablets to play brain games for cognitive training and stationary foot peddlers for exercise training.
224252984|NCT04185493|DIAGNOSTIC_TEST|CCTA|128-multislice CT coronary angiography and complex atherosclerotic plaque analysis with the use of CT imaging post-processing techniques.
224252985|NCT04084197|DRUG|HIP1402|Tamsulosin (HanmiTams Capsule) 0.4mg
224252986|NCT04084197|DRUG|HIP1801|Tamsulosin 0.4mg
224252987|NCT01442753|BEHAVIORAL|Family-Skills Training|Sessions will be divided between self-reflection, didactics, and skill-building exercises all aimed at developing strong parenting practices and facilitating relationship building between parents and youth.
224252988|NCT01375920|DRUG|Metyrapone|500 milligrams to be taken twice a day orally
224252989|NCT01375920|DRUG|placebo|a matched placebo will be administered to patients to take twice a day for 3 weeks
224252990|NCT03199872|BIOLOGICAL|RV001V|Sc injection
224252991|NCT01631331|DRUG|vismodegib|Given PO
224252992|NCT01631331|PROCEDURE|Mohs surgery|Undergo Mohs surgery
224252993|NCT00366925|DEVICE|Adacolumn®|
224252994|NCT04741217|OTHER|Not an interventional study|No interventions are implemented. This is an observational study of respiratory droplet aerosolisation during respiratory procedures.
224252995|NCT02779803|PROCEDURE|EC-IC bypass|To determine if cerebral revascularization via STA to MCA bypass to improve cerebral hemodynamics, cognitive function, and quality of life in a defined subgroup of symptomatic carotid occlusion patients.
224322224|NCT04975555|DRUG|Siltuximab|Siltuximab is administered at the dose of 11mg/kg via intravenous infusion over 1 hour. If no resolution of CRS is achieved then a repeat dose of siltuximab at the dose of 11mg/kg via intravenous infusion over 1 hour will be given.
224252996|NCT03630471|BEHAVIORAL|PRIDE 'Step 1' problem-solving intervention|"The PRIDE problem-solving intervention is one component of the PRIDE stepped care treatment architecture which comprises two sequential treatments of incremental intensity. 'Step 1' is a brief, first-line treatment. It is grounded in stress-coping theory, with a technical focus on practical problem-solving to modify developmentally salient stressors.~Step 1 has been designed as a 'low-intensity' intervention requiring fewer resources than conventional psychological treatments. This is achieved through a relatively brief delivery schedule (up to 5 x 20-30-minute sessions spread over approximately 3 weeks) and limited requirement for specialists. The delivery agents are lay counsellors receiving a combination of specialist and peer supervision. The counsellors offer guidance sessions to support the learning and implementation of problem-solving and complementary coping skills. Illustrated booklets are used to support learning of problem-solving concepts and skills practice at home."
223672252|NCT05999760|DEVICE|chewing efficiency by electromyograph(E.M.G)|Evaluation of chewing efficiency of Versacryle and CAD/CAM partial dentures by force gauge on day one, on first month, and on the second month of prosthesis delivery.
224252997|NCT03630471|BEHAVIORAL|Enhanced usual care|There is no established mental health service provision in the collaborating schools. The control arm participants will receive an enhancement of this 'usual care' (essentially, no care) by having access to the same illustrated booklets used in the Intervention arm, albeit without any counsellor contact.
224252998|NCT04484883|OTHER|Observational|Observational
224252999|NCT02256683|DRUG|Dabigatran etexilate|After inclusion of the patients with LAA thrombus, they are treated according to the randomization either with Pradaxa® (150 mg bid) or Marcumar® (INR 2-3) for at least three weeks. Thrombus resolution will be determined by transesophageal echocardiography (TEE) 3 weeks after start of treatment and subsequently at week 4 and 6 if necessary, i.e. LAA thrombus has not yet resolved. The study is terminated for each patient with the resolution of the LAA thrombus or after 6 weeks of study treatment.
224253000|NCT02256683|DRUG|Phenprocoumon|After inclusion of the patients with LAA thrombus, they are treated according to the randomization either with Pradaxa® (150 mg bid) or Marcumar® (INR 2-3) for at least three weeks. Thrombus resolution will be determined by transesophageal echocardiography (TEE) 3 weeks after start of treatment and subsequently at week 4 and 6 if necessary, i.e. LAA thrombus has not yet resolved. The study is terminated for each patient with the resolution of the LAA thrombus or after 6 weeks of study treatment.
224253001|NCT04414228|DEVICE|M-Entropy guidance of anesthesia depth|In the M-Entropy group, dosage of volatile anesthetics will be adjusted to achieve the response and state entropy values between 40 and 60 from the start of anesthesia to the end of surgery. In the control group, dosage of volatile anesthetics will be titrated according to clinical judgment.
224253002|NCT04414228|DEVICE|ProAQT in guiding goal-directed hemodynamic therapy|If stroke volume variation is ≥ 10%, a bolus of 150 ml of crystalloid fluid will be given until the stroke volume variation is \< 10%. If mean arterial pressure is \< 70 mmHg and/or cardiac index \< 2.5 l·min-1·m-2 despite the stroke volume variation of \< 10% following fluid challenge, single or consecutive boluses of ephedrine 4 mg and/or continuous intravenous infusion of norepinephrine 2-10 μg·min-1 will be administered.
224253003|NCT03289845|DEVICE|BHX implant (Bone anchored hearing system)|Bone anchored hearing system for hearing rehabilitation
224253004|NCT02146105|OTHER|Yoga For Knee Osteoarthritis|Yoga program specifically for women with knee osteoarthritis.
224253005|NCT03647293|PROCEDURE|Ultrasound Guided Central Catheter Insertion|
224253006|NCT03647293|PROCEDURE|Peripherally Inserted Central Catheter|
224253007|NCT05770648|DEVICE|Transcatheter Annuloplasty|Under the guidance of ultrasound, the transcatheter tricuspid ring forming system accurately reaches the designated position of the tricuspid valve region through the jugular vein and superior vena cava approach. The expanded tricuspid ring tissue is clammed together with the clamping parts and anchor parts, and the circumference of the tricuspid ring is reduced, thus reducing the area of the opening of the tricuspid valve that cannot be closed originally, and achieving the purpose of minimally invasive treatment of tricuspid regurgitation.
224253008|NCT05770648|OTHER|The guidelines guide medication|The guidelines guide medication
224253009|NCT05755282|DRUG|Post-market foam alcohol-based hand sanitizer #1|Automated dispenser will dispense 1 mL of hand sanitizer product onto hands.
224253010|NCT05755282|DRUG|Post-market foam alcohol-based hand sanitizer #2|Automated dispenser will dispense 1 mL of hand sanitizer product onto hands.
223672253|NCT05999760|OTHER|masticatory performance(questionnaire)|Evaluation of masticatory performance of Versacryle and CAD/CAM partial dentures by questionnaire on day one, on first month, and on the second month of prosthesis delivery.
223672254|NCT05367375|PROCEDURE|removing osteophyte at patellofemoral joint|to compare anterior knee pain between removing patellofemoral joint osteophytes and non-removing patellofemoral joint osteophytes after medial unicompartmental knee arthroplasty
223672255|NCT05088473|OTHER|Biological collection|Collection of cerebrospinal fluid kappa and lambda free light chains and indexes
223672256|NCT02977182|OTHER|Complete Decongestive Therapy (CDT)|CDT is a multimodal therapy consisting of four components: manual lymph drainage, compression wrapping, exercise, and skin care
223672257|NCT06545162|BIOLOGICAL|CPX101 or placebo 80mg single dose|Subcutaneous injection of CPX101 or placebo
223672258|NCT06545162|BIOLOGICAL|CPX101 or placebo 120mg single dose|Subcutaneous injection of CPX101 or placebo
223672259|NCT06545162|BIOLOGICAL|CPX101 or placebo 160mg single dose|Subcutaneous injection of CPX101 or placebo
223672260|NCT06545162|BIOLOGICAL|CPX101 or placebo 80mg Q2W|Subcutaneous injection of CPX101 or placebo
223672261|NCT06545162|BIOLOGICAL|CPX101 or placebo 120mg Q2W|Subcutaneous injection of CPX101 or placebo
223672262|NCT06545162|BIOLOGICAL|CPX101 or placebo 160mg Q2W|Subcutaneous injection of CPX101 or placebo
223672263|NCT06545162|BIOLOGICAL|CPX101 or placebo 200mg Q2W|Subcutaneous injection of CPX101 or placebo
223672264|NCT06545162|BIOLOGICAL|CPX101 or placebo 200mg single dose|CPX101 or placebo 200mg single dose
223672265|NCT05167552|BIOLOGICAL|Olfactory mucosa-derived mesenchymal stem cells|Olfactory mucosa-derived mesenchymal stem cells
223772097|NCT07021365|DEVICE|Radiofrequency ablation alone|"In patients diagnosed with chronic coccydynia, a ganglion impar block is initially performed following conservative treatment. In cases where this intervention provides limited benefit, ganglion impar radiofrequency (RF) ablation-routinely used in clinical practice-will be performed by an experienced pain specialist (SŞ) with at least 10 years of expertise in this procedure.~Using fluoroscopic guidance and intermittent imaging, a 100 mm RF cannula with an injection tube will be advanced trans-coccygeally. After confirming the needle's position at the site of the ganglion impar in front of the coccyx with 1-2 mL of contrast agent (iohexol), sensory stimulation will be applied via the RF generator to confirm that the needle tip is at the patient's pain site. Motor stimulation will also be performed to ensure there is no muscle contraction. At this stage, 2 mL of lidocaine will be administered before initiating ablation at 80°C for 90 seconds."
223772098|NCT07025213|OTHER|Diet and exercise.|The intervention group will receive recommendations to follow an anti-inflammatory diet. In addition, they will be instructed to increase their level of physical activity and will be asked to attend the institute to carry out a supervised exercise routine.
223772099|NCT07025213|OTHER|Diet.|The comparison group will be instructed to follow the anti-inflammatory diet intervention only.
223772100|NCT07024576|OTHER|Preoperative casting intervention|A serial casting intervention protocol involving the application of heat, stretching, and massage before casting. This is repeated weekly for four weeks, with the cast removed and reapplied each time to promote gradual elongation of restricted tissue.
223772101|NCT07023848|DRUG|89Zr-LNCab104|89Zr-LNCab104 is administered through a superficial dorsal vein, and the patient is given a dose of about 1-3 mCi
223772102|NCT07023848|DRUG|89Zr-LNCab103|89Zr-LNCab103 is administered through a superficial dorsal vein, and the patient is given a dose of about 1-3 mCi
223772103|NCT07023848|DRUG|18F-FDG|18F-FDG is administered through a superficial dorsal vein, and the patient is given a dose of about 0.1-0.15mCi/kg.
223772104|NCT07024602|DRUG|ASC50 tablets or matching placebo|Drug: ASC50 administered orally Drug: Placebo administered orally
223772105|NCT07025109|BEHAVIORAL|Peer support|Peer support counseling will include phone or text communication to assess goal progress, provide motivational counseling as needed, and to provide social support.
223772106|NCT07025109|BEHAVIORAL|Exercise Prescription|Women will be provided with an exercise prescription (Frequency, Intensity, Time, Type) which may be adjusted weekly for 6 weeks to goal of 150min/week of moderate to vigorous physical activity.
224253011|NCT03832530|BEHAVIORAL|Safer conception counseling inclusive of periconception PrEP|Observational evaluation of factors associated with uptake of and adherence to daily, oral TDF/FTC PrEP and other safer conception methods (including: CHCT, ART for the infected partner, and uptake of contraception for those who decide not to conceive during follow-up) over 9 month. Maximum 19 month follow-up period (through pregnancy outcome).
224253012|NCT00844922|DRUG|SCH 900636|"Org 34517 300 mg on Day 1, 600 mg on Day 2, then 900 mg daily starting from Day 3. Subjects in this arm were also to continue the usual treatment for psychotic major depression."
223672266|NCT05167552|OTHER|Standard treatment of type Allergic Rhinitis according to the clinical protocols|Standard treatment of type Allergic Rhinitis according to the clinical protocols
223672267|NCT05167552|OTHER|Standard treatment of type Chronic Polypous Rhinosinusitis according to the clinical protocols|Standard treatment of type Chronic Polypous Rhinosinusitis according to the clinical protocols
223672268|NCT06234332|OTHER|No Interventions|No intervention This is an observational study without any intervention
223672269|NCT05370703|BEHAVIORAL|My A:care|Mobile application with Motivational messages
223672270|NCT05370703|BEHAVIORAL|Smart Coach|Mobile application with Motivational messages
223672271|NCT01924429|DRUG|Lisdexamfetamine|Escalating stepped dose titration: 30, 50 or 70mg
223772107|NCT07025109|BEHAVIORAL|Blood pressure self monitoring|Women will receive a home blood pressure monitor and encourage to record their readings in a log.
223772108|NCT07086846|OTHER|Night splint|All participants will be treated conservatively by wrist splint in a neutral position.
223772109|NCT07086846|OTHER|Myofascial release technique|The participant will receive myofascial release using M2T blade. It will be applied on the carpal tunnel over and above the wrist creases on the ventral aspect of the forearm for 15 minutes, 3 sessions weekly for 6 weeks (total of 18 sessions).
223772110|NCT07086846|OTHER|Acupressure|"It will be applied on the pericardium 6 point (PC-6) for 3 minutes, three times per week for 6 weeks (total of 18 sessions).~It is located on the palm side of the wrist a couple of inches toward the body in between the two tendons (palmaris longus \& flexor carpi radialis) that run approximately down the center of the forearm."
223772111|NCT07086846|OTHER|Home advice|The participants will be asked to follow important advices like supporting the wrists during activity and ensuring proper posture, avoiding wrist flexion and extension, avoiding hard clutches, holding or carrying objects for a long time, catching with fingers, repetitive hand and wrist movement such as knitting or sewing, driving, activities and hobbies such as golf, tennis, table tennis.
223772112|NCT07085104|GENETIC|ALLO-329|An allogeneic CAR T cell therapy targeting CD19 and CD70
223772113|NCT07085104|DRUG|Cyclophophamide|Chemotherapy for lymphodepletion
223772114|NCT07086911|DRUG|Remimazolam|"Remimazolam group (Group R) : After intubation, remimazolam was maintained at a pump rate of 1-2mg/kg/h until ten minutes before the end of the operation.~Group C (remimazolam combined with propofol): After intubation, maintain with 0.3-1 mg/kg/h of remimazolam and 3-6 mg/kg/h of propofol until 10 minutes before the end of surgery."
224253013|NCT00844922|DRUG|Placebo|Placebo
224253014|NCT04089917|DEVICE|Q Aspiration Catheter|The Q Aspiration Catheter is indicated for use in the removal of fresh, soft emboli and thrombi in the neurovascular system.
224253015|NCT05832411|DEVICE|Endoangle|there is additional information presented to endoscopists:（1）the virtual stomach model monitoring；（2）time;（3）scoring.
224253016|NCT03935880|DEVICE|Cartiva Implant|Cartiva hemiarthroplasty: The procedure starts with a small incision over the top of the 1st MTP joint. The joint is exposed. Bone spurs on the metatarsal and proximal phalanx are resected, leaving approximately 2 mm of surrounding bone on the metatarsal head. A guide pin is placed within the metatarsal and a drill is then used to create a site for the implant. The implant is then placed using the implant introducer. The incision is then closed and a sterile dressing is placed.
224253017|NCT03935880|PROCEDURE|Cheilectomy|Cheilectomy: A small incision is made over the top of the 1st MTP joint. The joint is exposed. Bone spurs on the metatarsal and proximal phalanx are resected. The top of the metatarsal head is then cut with a sagittal saw. Additional bone spurs are resected. The incision is closed and a sterile dressing is placed.
224253018|NCT02476994|DRUG|Clinolipid|
224253019|NCT02476994|DRUG|Intralipid|Standard-of-Care Soybean Oil-Based Lipid Emulsion
224253020|NCT01607918|DRUG|D1-D5: (lansoprazole + amoxicillin ) D6-D10: (lansoprazole+clarithromycin +metronidazole)|D1-D5: (lansoprazole 30mg + amoxicillin 1gm) bid D6-D10: (lansoprazole 30mg+clarithromycin 500mg+metronidazole 500mg) bid
223672272|NCT01525992|BEHAVIORAL|Community pharmacist-led diabetes education program|A trained pharmacist will counsel each patient based on his/her individual needs about medications, life style and self-care. The pharmacist will use a checklist to document the type of education delivered to each patient. A glucometer is provided for each patient in this arm to monitor blood glucose daily. Three to six visits to the community pharmacy are set during the 6-months study period. At each visit, medication related problems and self-care issues are discussed with the patient and the glucometer test strips are provided for the following month. A telephone call will be made to each patient between visits to ensure adherence to drug therapy and resolve any problems .
223672273|NCT01525992|OTHER|Usual care|The baseline and 6-month follow-up visits to the community pharmacy will be required. If the physician prefers more visits to his office during the study period, it will be granted. The glucometer and a training session about diabetes self-care will be provide at the end of study for control group patients.
223672274|NCT02680678|OTHER|Colloid Preload|preload infusion
223672275|NCT02680678|OTHER|colloid co-load|co-load infusion
223672276|NCT02680678|OTHER|Crystalloid preload|preload infusion
223672277|NCT02680678|OTHER|Crystalloid Co-load|co-load infusion
223672278|NCT04564131|OTHER|Reflexology|"* Hands are washed.~* The individual is provided to be in a comfortable position to lie down or to be in a semi-sitting position.~* The toes of the patient are crossed and the patient's feet are placed at our chest level when we sit.~* Depending on the size of the foot, a slightly moisturizing amount of non-allergenic petroleum jelly is taken, and it is spread to provide slipperiness.~* Exercises to warm and relax the feet for five minutes.~* General massage is applied to the whole foot for five minutes.~* Reflexology massage is applied to the application areas for neuropathic pain.~* The individual is helped to take a comfortable position.~* Hands are washed."
223672279|NCT04564131|OTHER|Control|No intervention was performed to reduce pain in the control group
223672280|NCT03443947|DEVICE|Tongue depressor group|using a tongue depressor to assess airway score without tongue protrusion
223672281|NCT03443947|PROCEDURE|control group|airway assessment after tongue protrusion
223672282|NCT01943357|BEHAVIORAL|Diabetes Self Management Program|The interventions include modeling and action-planning to enhance self-efficacy.
223672283|NCT01599143|BEHAVIORAL|Teaching Mindfulness-based Stress Reduction strategies|Daily meditation, Hatha yoga,and cognitive restructuring
223672284|NCT04109339|DRUG|Oxytocin|During the laparoscopic hysteromyomectomia operation, different doses of oxytocin was used with different routs.
223672285|NCT01702181|DRUG|OPA-15406|0.3%, 1%, or 3% OPA-15406 topical ointment, applied twice daily for 28 days
224253021|NCT01607918|DRUG|D1-D14: (lansoprazole + clarithromycin + amoxicillin)|D1-D14: (lansoprazole 30mg + clarithromycin 500mg + amoxicillin 1gm) bid
224253022|NCT02563561|DRUG|Apaziquone|One dose of apaziquone administered by intravesical administration
224253023|NCT02563561|OTHER|Placebo|Matching placebo (containing 12 mg FD\&C red #40, 15 mg sodium chloride, and 10 mg mannitol was supplied in identical appearing vials) by intravesical administration.
224253024|NCT03531294|DRUG|Aflibercept Injection|intravitreal 2mg aflibercept injection
224253025|NCT02129894|DEVICE|abdominal Binder|placement of abdominal binder
224253026|NCT06146972|DRUG|Iguratimod|Iguratimod 25mg bid + tofacitinib 5mg bid
224253027|NCT05283850|DRUG|High Calcium, Low Sodium (HCLS) Crystalloid Therapy|Half-normal saline IV drip and 1g IV bolus Calcium Chloride.
224253028|NCT05283850|DRUG|High Calcium, High Sodium (HCHS) Crystalloid Therapy|Normal saline IV drip and 1g IV bolus Calcium Chloride.
224322225|NCT05810870|DRUG|MEN1611|MEN1611 is a potent, orally bioavailable selective inhibitor of the class I phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) with a novel structure which exhibits a strong inhibitory activity especially against the PI3K catalytic subunit alpha (PIK3CA), with potential antineoplastic activity. PI3K alpha inhibitor MEN1611 selectively binds to and inhibits PIK3CA and its mutated forms in the PI3K/Akt (protein kinase B)/mammalian target of rapamycin (mTOR) pathway.
223672286|NCT01702181|DRUG|Tacrolimus|0.1% concentration of tacrolimus.
223672287|NCT01702181|DRUG|Placebo|
223672288|NCT01501084|DRUG|Exenatide|10mcg sc (subcutaneous) injection once at one of the 2 MRI visits
223672289|NCT01501084|DRUG|Normal saline .2cc subcutaneous injection|sterile saline injection
223672290|NCT01715597|DRUG|ascorbic acid|ascorbic acid 2g in normal saline 500ml IV start 30min before the operation and infusion for 2 hour
223672291|NCT01715597|DRUG|Normal saline|normal saline 500ml IV
223672292|NCT02150408|OTHER|PET-CT|
223672293|NCT01779271|DRUG|Pelubiprofen|
223672294|NCT01779271|DRUG|Loxoprofen|
223672295|NCT00146783|DRUG|Sulphadoxine-pyrimethamine|
223672296|NCT00146783|DRUG|Sulphadoxine-pyrimethamine, amodiaquine|
224253029|NCT04347018|DEVICE|BRIUS|This is a device that is designed based on movements planned virtually on a computer program. Then all the planned movements are embedded into the wire causing the wire to have the necessary bends to move every tooth into its pre-planned final position. This causes the pre-activated wire to consistently express a low force over a long period of time onto all the teeth. This allows the teeth to move into the final position and treatment progresses towards completion
224253030|NCT01859858|DIETARY_SUPPLEMENT|curcumin|
224253031|NCT01859858|DRUG|Irinotecan|
224253032|NCT02221921|DEVICE|MicroPort's Transcatheter Aortic Valve and Delivery System|
224253033|NCT02646124|DRUG|Naproxen|Naproxen 500mg by mouth two times a day, #20
224253034|NCT02646124|DRUG|Placebo|28 placebo capsules
224253035|NCT02646124|DRUG|Diazepam|Diazepam 5mg capsules, 1-2 tabs by mouth two times a day, #28
224253036|NCT05624034|DEVICE|Electrogastrography|Electrogastrography is used to study abnormalities in healthy subjects and in patients with Diabetic and Idiopathic Gastroparesis
223672297|NCT03413176|DRUG|Cardiac complication induced by VEGF/VEGFR inhibitor|Case reported in the World Health Organization (WHO) of cardiac complication of patient treated by AAs, with a chronology compatible with the drug toxicity
223672298|NCT05599477|DEVICE|Endoscopic sutured gastroplasty with endomina|"The endomina is is used to perform endoscopic sutured gastroplasty. Two guidewires are introduced via an upper GI endoscopy down to the duodenum. The endomina system is introduced and the endoscope is inserted and fixed to the system. Next a needle preloaded with suture is introduced into the platform. The stomach wall is grasped with a forceps and pulled back. The needle is pushed through the wall, and a first tag is released. The needle is retracted, the first plicature is released and a second plicature is made with the same needle at the opposite wall. Then the pretied knot is grasped and tightened until both plicatures are firmly apposed. The same procedure is repeated along the great curvature from the incisura to the upper body.~The procedure will include the placement of 6-9 sutures. The first suture is done at the level of the incisura, at the lower part of the greater curvature. The following stitches are placed along the body of the stomach"
223672299|NCT04759183|OTHER|Survey Administration|Ancillary studies
223672300|NCT04759183|PROCEDURE|Virtual Reality Game|"Participate in VR Game Angry Birds"
223672301|NCT04759183|PROCEDURE|Virtual Reality Meditation|"Participate in VR Meditation TRIPP"
223672302|NCT00906971|OTHER|diaphragmatic breathing, isometric training of the abdominal muscles and abdominal massage|Exercises will be conducted by one physiotherapist. A one-minute rest period will be observed between each series. Isometric training of the abdominal muscles: This will consist of a contraction of the upper abdomen muscle and diaphragm and the simultaneous relaxation of the lower abdomen. Training will be carried out in two manners: with the patient lying in a left lateral decubitus position with the hip and knee flexed at 90º and sitting. Breathing exercises: With the patient in a seated position, with one hand placed on the abdomen and the other on the thorax, and will be instructed to breath in slowly,. Two series will be completed, with ten repetitions. Abdominal massage: The physiotherapist will perform slow circular clockwise movements, along the line of the colon, with a regular tennis ball, remaining on each point for one minute, beginning with the ascending colon moving in the direction of the sigmoid colon.
223672303|NCT06177275|PROCEDURE|Placement of BLX implants 2 mm sub-crestal i|Placement of BLX implants 2 mm sub-crestal in single missing anterior or premolar teeth in the esthetic zone with immediate provisionalization via a straight emergence profile temporary crown on a temporary abutment.
223672304|NCT06177275|PROCEDURE|Placement of BLX implants equicrestal|Placement of BLX implants equicrestal in single missing anterior or premolar teeth in the esthetic zone with immediate provisionalization via a straight emergence profile temporary crown on a temporary abutment.
223672305|NCT04253886|DEVICE|Ovassapian Fibreoptic Intubating Airway|The fibreoptic bronchoscope remains one of the most important methods of intubating patients particularly when there is difficulty with intubation.Facilitating fiberoptic oropharyngeal intubation procedure, specific airways have been devised to push the tongue anteriorly to clear a passage for the fibrescope into the trachea. Of these airways Ovassapian Fibreoptic Intubating Airway (Kendall, Argyle, New York, New York, USA) and Fekry Oral Intubating Airway (Ameco Tech, Cairo, Egypt).
223672306|NCT01908881|BEHAVIORAL|Group Workshop|The intervention consists in a group workshop (for up to 7 dyads with children aged between 6 and 12 months and two health care professional monitors) of four sessions of two hours each, held weekly. One of the sessions is characterized as including the fathers or other caregivers relevant to the upbringing of the children. Each session is structured around various activities that specifically deal with the skills associated with parental sensitivity and address relevant issues to child rearing, considering the development of the child.
223672307|NCT01908881|BEHAVIORAL|Usual Care|"According to the screening carried out various interventions are offered by Primary Health Care centers (eg. home visits) in the Chile Crece Contigo Program. During pregnancy, if the mother is screened for positive psychosocial risk she would receive different interventions consisting in (usual care at Primary Health Care Centers): home visits, evaluation by social worker and planning interventions according to a multidisciplinary team."
223672308|NCT05355493|BEHAVIORAL|Time to Exhaustion cycling test|After completing the MF/control task. Participants will be asked to take place on the cycle ergometer. Participants will perform a 3-min warm-up at 40% of peak power output followed by a rectangular workload at a power output corresponding to their predetermined respiratory compensation point (±80% PPO). RPM was freely chosen between 60 and 100 RPM and was recorded every minute. TTE was measured from the start until the pedal frequency was less than 60 RPM for more than 5s. This TTE task was chosen, based on a previous study of Marcora et al. (2009), who found that mental fatigue impairs physical performance. A researcher will sit behind the subject to ensure compliance with treatment. Subjects will be equipped with a heart rate monitor to continuously follow up heart rate. Subjective psychological assessment will take place with a M-VAS-scale, the NASA-TLX, the success motivation and intrinsic motivation scales, Karolinska Sleepiness Scale and visual analog scale for boredom.
223772115|NCT07086911|DRUG|Propofol|"Propofol group (Group P) : After intubation, propofol was maintained at a pump rate of 4-10mg/kg/h until surgery ten minutes before the end.~Group C (remimazolam combined with propofol): After intubation, maintain with 0.3-1 mg/kg/h of remimazolam and 3-6 mg/kg/h of propofol until 10 minutes before the end of surgery."
223772116|NCT00750854|DIETARY_SUPPLEMENT|NEM Formulation X|see Treatment Arms
223772117|NCT00750854|DIETARY_SUPPLEMENT|NEM Formulation Y|see Treatment Arms
224253037|NCT06368219|DRUG|ketamine- midazolam versus ketamine- propofol|"* Group A: 25 patients will receive ketamine (0.5 mg/kg) plus midazolam (0.05 mg/kg)~* Group B: 25 patients will receive ketamine (0.5 mg/kg) plus propofol (0.5 mg/kg)"
224322226|NCT05810870|DRUG|Eribulin|Eribulin mesylate (eribulin), a non-taxane inhibitor of microtubule dynamics of the halichondrin class of antineoplastics, suppresses microtubule growth and sequesters tubulin into nonfunctional aggregates, preventing mitotic spindle formation with subsequent G2-M stop and apoptosis.
224322227|NCT03495427|DRUG|F-DCFPyL Injection|F-DCFPyL Injection is a radioactive diagnostic imaging agent indicated for imaging of patients with recurrent prostate cancer.
224322228|NCT03495427|DIAGNOSTIC_TEST|PSMA PET|PSMA PET imaging (for men with high GC \>0.45) will be done after 2 years post-treatment, then yearly up to 5 years.
223672309|NCT05355493|BEHAVIORAL|Go/NoGo task|Participants are to react to different stimuli displayed on a computer screen, preceded by a screen with general instructions. Two different stimuli were present at the same time: a Go or NoGo stimulus, and a left or right stimulus (meaning that four combinations are possible: GoRight, GoLeft, NoGoRight and NoGoLeft). If a Go-stimulus is presented, participants are instructed to react to the left or right stimuli with the corresponding arrows. However, if a NoGo stimulus is presented, participants are instructed to refrain from reacting to the either the left or right stimuli. This proposed paradigm measures attention, response inhibition and working memory. Stimuli will be presented for 500 ms, with a varying interstimulus time between 1100 and 1700 ms. Outcomes for Go trials include reaction time and accuracy while the outcome for NoGo trials is only accuracy.
223672310|NCT00545129|DRUG|Tanezumab 10 mg IV|Single IV infusion of 10 mg tanezumab on Day 1. Maintained on baseline opioid regimen.
223672311|NCT00545129|DRUG|IV Placebo for tanezumab|Single IV infusion of placebo for tanezumab on Day 1. Maintained on baseline opioid regimen.
223672312|NCT05022511|BEHAVIORAL|Screening status|Women are offered check-up on screening status in both CCU and CRC screening. If a woman is not up to date in one or both screening programmes, she will be offered a self-sampling device and/or a FIT kit.
223672313|NCT03504943|OTHER|Early Intradialytic Exercise|Timing of intradialytic exercise first half of HD
223672314|NCT03504943|OTHER|Late Intradialytic Exercise|Timing of intradialytic exercise second half of HD
223672315|NCT00633542|DRUG|thalidomide|100 mg/day orally until progression or severe toxicity
223672316|NCT00633542|DRUG|interferon alpha|3 MU 3 times a week until progression or severe toxicity
223672317|NCT04744376|OTHER|QoR15|Quality of Recovery 15 questionnaire (QoR-15) is a measurement tool that evaluates the recovery quality of patients after surgery and anesthesia by the patient himself.
223672318|NCT04744376|OTHER|ACS risk calculator|American College of Surgeons risk calculator is a risk prediction tool for abdominal surgery. It calculates the risk of possible postoperative complications according to the type of surgery, ASA score, and patients' preoperative co-morbidities.
223672319|NCT04744376|OTHER|Clavien - Dindo classification|It is a classification for postoperative complications.
223672320|NCT00172159|PROCEDURE|Hepatic resection|
223672321|NCT02253927|DRUG|BILR 355 - D1|
223672322|NCT02253927|DRUG|BILR 355 - D2|
223672323|NCT02253927|DRUG|BILR 355 - D3|
223672324|NCT02253927|DRUG|BILR 355 - D4|
223672325|NCT02253927|DRUG|Ritonavir|
223672326|NCT02253927|OTHER|high fat breakfast|
224253038|NCT04343196|RADIATION|Diagnostic Angiography (DSA or DVA based on randomization result)|After radial/brachial/femoral artery puncture using Seldinger technique, the investigators first position a pigtail catheter above the level of the renal arteries. With Siemens Artis Zee Pure DSA machine the examiner will use a postero-anterior X-ray view for the first image, which is an aortography of some part of the iliac system. Then, the catheter will be repositioned to the aortic bifurcation and 15-18 mL contrast media (CM) with 9-10 mL/s flow for the ilio-femoral region will be injected. All of the following image series will be made from this catheter position, with a 9 mL/s flow rate. In cases for when the recorded image series will be inconclusive, image series with left/right oblique position will be recorded. All femoro-popliteal images will be recorded with 10-16 ml CM and crural regions with 12-22mml. DSA images will be calculated from all series on a dedicated Syngo workstation and used for diagnosis. DVA images will be calculated by the Kinepict Medical Imaging Tool
224253039|NCT00840398|DRUG|BUSPAR® 30 mg Tablet|1 x 30 mg, single-dose fed
223672327|NCT01728233|DRUG|Dacomitinib|PF-299804 will be administered orally at a dose of 45 mg/day continuously until surgery, evidence of disease progression or onset of unacceptable toxicity.
223672328|NCT01081548|DRUG|atorvastatin|20 mg
223672329|NCT01081548|DRUG|atorvastatin|20 mg
223672330|NCT04044443|DEVICE|IMPEDE, IMPEDE-FX or IMPEDE-FX RapidFill|Peripheral vascular embolization
223672331|NCT04411381|OTHER|Telemedicine|Telemedicine associated with dried blood spot testing at home for RNA test to sustained virological response determination
223672332|NCT04104269|DIAGNOSTIC_TEST|Heart rupture|Free wall rupture and Ventricular septal rupture
223672333|NCT04474548|OTHER|Ultrasound use|Ultrasound will be used to determine location of IUD after insertion.
223672334|NCT01894568|DRUG|Insulin Peglispro|Administered SC using a prefilled pen.
223672335|NCT01894568|DRUG|Insulin Glargine|Administered SC using a prefilled pen
223772118|NCT02556710|BIOLOGICAL|4 mL injection of AMPION™|4 mL Injection of Ampion
223672336|NCT01894568|DRUG|Oral Antihyperglycemic Medications (OAMs)|Administered orally
223672337|NCT00807573|DRUG|Paclitaxel|Day 1: Paclitaxel (90 mg/m\^2 over 60 minutes) Day 15: Paclitaxel (90 mg/m\^2 over 60 minutes)
223672338|NCT00807573|DRUG|Pemetrexed|Day 1: Pemetrexed (500 mg/m\^2 over 10 minutes) Day 15 Pemetrexed (500 mg/m2 over 10 minutes)
223672339|NCT00807573|DRUG|Bevacizumab|Day 1:Bevacizumab (10 mg/kg over 20 minutes) Day 15: Bevacizumab (10 mg/kg over 20 minutes)
223672340|NCT00198887|PROCEDURE|Operations research|
223672341|NCT00925743|DRUG|cabazitaxel (XRP6258)|"* administered by IV infusion~* in addition to cisplatin treatment"
223672342|NCT02772198|BIOLOGICAL|CD19 CAR T cells|Autologous T cells activated and transduced with a chimeric antigen receptor targeting CD19
223672343|NCT04392700|DRUG|Tenofovir disoproxil fumarate 300mg|Take the medicine once a day ，300mg/d
223672344|NCT04392700|DRUG|Entecavir 0.5 mg|Take the medicine once a day，0.5 mg/d
223672345|NCT00266565|DRUG|Mepolizumab|10mg/kg (max 750 ml) once a month for 3 months
223672346|NCT05580094|OTHER|general anesthesia only.|induction of general anesthesia by propofol and maintenance sevoflurane.
223672347|NCT05580094|OTHER|general anesthesia plus supraclavicular block.|induction of general anesthesia by propofol and maintenance sevoflurane then the patients will receive the supraclavicular block with bupivacaine 0.5 ml per kg.
223672348|NCT04545944|DRUG|Vonoprazan|20 mg tablets administered orally
223672349|NCT04545944|DRUG|Midazolam|2 mg syrup administered orally
223672350|NCT04757454|DIAGNOSTIC_TEST|5-item SARC-F questionnaire|Administration of the 5-item SARC-F questionnaire in patients admitted to an acute care unit
223672351|NCT02994888|DRUG|Cetuximab|All patients will be offered cetuximab 500mg/m2 every 2 weeks, until the time of progression
223772119|NCT02556710|DRUG|4 mL injection of Placebo|4 mL Injection of Placebo
224253040|NCT00840398|DRUG|Buspirone Hydrochloride 30 mg Tablet|1 x 30 mg, single-dose fed
223772120|NCT01592513|DEVICE|BIS monitor|"BIS is a monitor of anesthetic depth approved by the FDA. It incorporates time-domain, frequency-domain and bi-spectral analysis of the EEG. This analysis is displayed as a dimensionless number between zero (deep anesthesia) and 100 (awake).~BIS values between 80-90 represent values corresponding to light/moderate sedation.~BIS is a valuable tool for assessing the depth of sedation and guiding the administration of sedative drugs."
223772121|NCT01184352|DEVICE|TriReme Medical, Inc. Glider(TM) PTCA Balloon Catheter|Percutaneous Coronary Interventions performed with the Glider PTCA Balloon Catheter
223772122|NCT01138748|RADIATION|hypofractionated radiation therapy|hypofractionated radiation therapy
223772123|NCT00014534|BIOLOGICAL|filgrastim|6 mg sub Q
223772124|NCT00014534|DRUG|cisplatin|60 mg/sq m IV
223772125|NCT00014534|DRUG|doxorubicin hydrochloride|50 mg/ sq m IV
223772126|NCT00014534|DRUG|gemcitabine hydrochloride|1000 mg/ sq m IV for Gem + cis arm and 2000 mg/sq m IV for gem + dox + peg arm
223772127|NCT02563340|OTHER|BM-MSCs|BM-MSCs are from third-party healthy donors, and have no HLA alleles similar to renal allograft donors or reacting to positive anti-HLA antibodies in recipients.
223772128|NCT02563340|OTHER|Desensitization therapy (PP, IVIG, rituximab or Bortezomib)|At least one drug or treatment is applied as desensitization therapy to decrease DSA, reduce B cells or inhibit plasma cells, depending on individual condition.
223772129|NCT04772092|BIOLOGICAL|Blood samples|"during the routine blood test, collection of additional blood samples:~* 1 x 5 mL heparinized tube for plasma collection and storage~* 1 heparinized 5 mL tube for immunophenotyping~* 4 x 10 mL EDTA tubes for white blood cell (WBC) collection and cryopreservation"
223772130|NCT04772092|OTHER|Data collection|"* clinical examination data~* test results to measure the degree of geriatric fatigability~* Frailty screening questionnaire for neoplasia patients (G8 score)"
223772131|NCT03082339|OTHER|Cortisone|Observation of QTc-interval
223772132|NCT03634592|PROCEDURE|Catheter ablation|Radiofrequency catheter pulmonary vein isolation
223772133|NCT00263692|BIOLOGICAL|Prophylaxis: Diphtheria, tetanus, pertussis, poliovirus type 1, type 2 and type 3|
223772134|NCT01903694|DRUG|Sorafenib + Pravastatin|
223672352|NCT00599131|DRUG|Cisplatin|1\. Day 1: 100 mg/m2, administered as an i.v. infusion will run over one hour. 2. Day #23: Subjects with a \< 50% response (NR) to induction chemotherapy will undergo salvage laryngectomy followed by RT. Cisplatin will be added to radiation for patients whose surgical pathology reveals high-risk features (i.e. extracapsular spread, \> 2 positive lymph nodes, perineural invasion, or positive margins). Cisplatin will either be dosed a 100 mg/m2 every 21 days or 40 mg/m2 weekly at the discretion of the prescribing physician.
223672353|NCT00599131|DRUG|Cetuximab|1\. Cetuximab will be administered at 400 mg/m2 on Day 20 (2 hour administration). 2. Cetuximab will be administered in combination with radiation therapy to those subjects who had a Partial or Complete response after the first cycle of the chemotherapy regimen is administered. The dosage for these administrations is 250 mg/m2 over sixty minutes and it will be administered for six weeks.
223672354|NCT00599131|DRUG|5-Fluorouracil|5-FU will be administered 750 mg/m2 in 0.9% normal saline as a 24-hour continuous infusion, days #1-4.
223772135|NCT01903694|DRUG|Sorafenib|
223772136|NCT06211582|DEVICE|Cention N (Ivoclar Vivadent, Schaan, Liechtenstein)|The Alkasite-Based Tooth-Colored Material
223672355|NCT00599131|DRUG|Docetaxel|75 mg/m2 by I.V. over one hour on Day # 1 only
223772137|NCT06211582|DEVICE|Equia Forte HT ( GC, Tokyo, Japan)|Glass Hybrid Restorative Material
223772138|NCT06211582|DEVICE|Gradia Direct Posterior ( GC, Tokyo, Japan)|Conventional Composite Resin
223772139|NCT01312909|DRUG|Varenicline 1mg BID|Oral Varenicline 1mg BID, or 1/2 that dose (0.5mg BID) for those subjects that weigh less than or equal to 55kg at baseline, for twelve weeks, follow-up through Week 52
223772140|NCT01312909|DRUG|Varenicline 0.5mg BID|Oral Varenicline 0.5mg BID, or 1/2 that dose (0.5 QD) for those subjects that weigh less than or equal to 55kg at baseline, for twelve weeks, follow-up through Week 52
223772141|NCT01312909|DRUG|Placebo|Oral placebo for twelve weeks,follow-up through Week 52
223772142|NCT04365322|OTHER|Additional biological samples|Peripheral Blood Mononuclear Cell (PBMC) and plasma will be collected.
223772143|NCT00913159|PROCEDURE|Extracorporeal Shock Wave Lithotripsy (ESWL)|Using electric shock wave to treat urolithiasis
223772144|NCT05248893|DRUG|AGN-151586|Intramuscular Injection
224253041|NCT02255292|DRUG|cannabidiol (CBD)|Patients with confirmed solid cancer, after progression of all the available standard therapy or unfit to standard therapy according to oncologist's view, measurable disease as determined by RECIST using CT, life expectancy of at least 6 months, Eastern Cooperative Oncology Group (ECOG) performance status \< or = 2 and aged 18 years old and more will be included in the current study
223772145|NCT05517239|DRUG|Gemcitabine, Oxaliplatin|Gemcitabine 1,000 mg/m2 infusion for 30minutes and followed by oxaliplatin 100mg/m2 infusion for 2hours on day1. All drugs were administered intravenously until progression, intolerance, patient withdrawal, or death.
223772146|NCT04332172|OTHER|General information|General information related to pregnancy is provided electronically.
223772147|NCT04332172|BEHAVIORAL|Baseline brief intervention|Interactive brief motivational intervention is delivered electronically. Provides an introduction, describing the purpose and duration, emphasizing the non-judgmental nature of the brief intervention (BI). Uses a high-quality video featuring gain-framed messaging, quit recommendation, and testimonial from a race-matched woman; tailored on race-ethnicity, efficacy, binge frequency, and level of concern regarding her own alcohol use. The e-BI poses a question regarding the participant's willingness to avoid alcohol throughout her pregnancy. Responses to this question will sort participants into one of three major branches, each using motivational principles to promote alcohol abstinence during pregnancy.
223772148|NCT04332172|BEHAVIORAL|Remote online booster sessions|Two \< 5-minute online e-BI boosters will be sent to participants via text link (one at 6 weeks post-baseline and one at 30 weeks gestation). The boosters will include a brief summary of the prior session in terms of the participant's concerns and goals. It will also include an assessment of her current status regarding (a) use of alcohol, and (b) intentions regarding future use of alcohol. A brief (1-2 minute) video tailored on her current status and prior goal will be provided. Finally, the boosters will contain optional goal-setting regarding reaching or maintaining abstinence.
224253042|NCT00151229|OTHER|target blood pressure|
223772149|NCT04332172|BEHAVIORAL|SMS|Tailored text messages (SMS) will be sent to participants twice a week from baseline throughout her pregnancy (or until she opts out). The messages will be tailored on her quit status, goals, efficacy, level of concern, gestation, and perceived advantages of change. Messages will follow current state of the art regarding messaging preferences, tailoring, and gain-framing. The current list includes messages regarding fetal development, nutrition, exercise, and stress management, as well as alcohol.
223772150|NCT03950024|DIAGNOSTIC_TEST|functional brain MRI|The functional brain MRI realized will be a examination with a resting sequence and a sequence during a movement imagination task. (knee bent)
223772151|NCT04866134|DRUG|ERAS-007|ERAS-007 will be administered orally as specified in Arm description.
223772152|NCT04866134|DRUG|ERAS-601|ERAS-601 will be administered orally as specified in Arm description.
223772153|NCT05737641|OTHER|water ingestion|ingestion of water after an 8h-fasting period
223772154|NCT05737641|DIETARY_SUPPLEMENT|jelly ingestion|ingestion of jelly after an 8h-fasting period
223772155|NCT00218192|BEHAVIORAL|Behavior Therapy|
223772156|NCT03738904|COMBINATION_PRODUCT|ERAS|Gabapentin Acetaminophen Ketoroloac IV (intraop) and PO Dexamethasone (included with benzocaine in local anesthesia) Oxycodone PO Polyethylene glycol
223672356|NCT02700087|DRUG|ranitidine or famotidine|Patients with symptomatic laryngomalacia will receive ranitidine, famotidine, or placebo medications in order to see if these medications help their symptoms to resolve.
223672357|NCT02700087|DRUG|Placebo|Patients with symptomatic laryngomalacia who meet inclusion criteria will be randomized to receive placebo, ranitidine or famotidine, in order to see if these medications help their symptoms to resolve.
223672358|NCT06254196|PROCEDURE|Telenursing interventions for monitoring Supportive Care Needs|"Use of the Intelligence2health platform, data collection forms on Google Forms, and dedicated telephone line for telenursing remote nursing monitoring interventions.~Based on the data, nurses will be able to implement patient education interventions aimed at preventing and monitoring healthcare support needs related to treatment."
223672359|NCT02841878|GENETIC|Analysis on colorectal biopsy|
223672360|NCT06209385|DRUG|YZJ-5053 tablets|YZJ-5053 tablets will be administrated orally QD for 21 days
223672361|NCT05851001|OTHER|Progressive Muscle Relaxation exercise|This intervention consists of two parts. The first part (11 minutes) gives short information about the content and how exercises should be done. It consists of information about deep relaxation. In the second part, there are 27 minutes of relaxation exercises accompanied by command with background music.
223672362|NCT05851001|OTHER|Muscle relaxation exercise|The participant was asked to listen to relaxation music for 30 minutes in a private room.
223672363|NCT02434601|PROCEDURE|Treatment of Dentin Surface|"* Experimental Group 1: Increase the etching time to 30 seconds, performed with phosphoric acid gel at 37%, prior to application of the resin adhesive.~* Experimental Group 2: Prophylaxis cavity probe / blunt tip of ultrasound, applied for 30 seconds on the dentin surface hypermineralized of cervical lesions non-carious.~Both restorative procedures were performed using a conventional adhesive system and composite restorative nanoparticulate."
223672364|NCT02434601|PROCEDURE|Dentin Surface|Treatment of Dentin Surface: Increased etching dentin for 15 seconds to 30 seconds
223672365|NCT02434601|PROCEDURE|Treatment|Treatment of Dentin Surface: Intervention with the cavity prophylaxis probe ultrasound blunt applied for 30 seconds in Surface hypermineralized non-carious dentin cervical lesions. Therefore, the restoration was done following the protocol recommended by the manufacturer of the material.
223672366|NCT00912379|BIOLOGICAL|hemoglobin determination|laboratory and non invasive hemoglobin determinations
223672367|NCT00593580|DRUG|placebo|placebo
223672368|NCT00593580|DRUG|alendronate/cholecalciferol|FOSAVANCE (70 mg/2800 IU of alendronate and cholecalciferol) or placebo will be given weekly for 1 years duration
223772157|NCT03738904|COMBINATION_PRODUCT|Standard of care|Oxcodone PO Ketorolac IV only (intraop)
223672369|NCT01514370|DRUG|IFN beta 1a 44 mcg TIW|Subjects received IFN beta 1a 44 microgram (mcg) subcutaneously TIW for 24 months.
223672370|NCT01514370|DRUG|Curcumin|Subjects received 500 milligram (mg) curcumin orally twice a day for 24 months.
223672371|NCT01514370|DRUG|Placebo|Subjects received placebo matched to curcumin orally twice a day for 24 months.
223672372|NCT05313152|DRUG|TAVO103A|TAVO103A single ascending dose IV infusion.
223672373|NCT05313152|OTHER|Placebo|Placebo single ascending dose IV infusion.
223772158|NCT01383681|OTHER|No treatment|There was no treatment in this study.
223772159|NCT01266772|DRUG|Montelukast sodium.|Children with asthma treated with montelukast and budesonide.
223772160|NCT01266772|DRUG|Placebo tablet and budesonide|Children with asthma treated with placebo tablet and budesonide.
223772161|NCT01323569|DRUG|Sativex|Sativex dose level 1: 10.8 mg THC/10 mg CBD (4 sprays) + 12 placebo sprays + 4 placebo capsules.
223772162|NCT01323569|DRUG|Sativex|Sativex dose level 2: 21.6 mg THC/20 mg CBD (8 sprays) + 8 placebo sprays + 4 placebo capsules
223772163|NCT01323569|DRUG|Sativex|Sativex dose level 3: 43.2 mg THC/40 mg CBD (16 sprays) + 4 placebo capsules
223672374|NCT01551420|DEVICE|Advanced upper limb prosthetic device IMU controlled|Advanced upper limb prosthetic IMU controlled
223672375|NCT01551420|DEVICE|Advanced upper limb prosthetic EMG-PR controlled|Advanced upper limb prosthetic EMG-PR controlled
223672376|NCT03504137|OTHER|mHealth Intervention|The video DOT app will allow transplant recipients to see their medication regimen, record themselves taking every dose, report side effects or symptoms, visualize their treatment progress, access educational content, and track appointments. This information is encrypted and transmitted to a HIPAA-secure web portal for providers to review.
223772164|NCT01323569|DRUG|Placebo|16 placebo sprays and 4 placebo capsules
223772165|NCT01323569|DRUG|Marinol|Marinol dose level 1: 20 mg THC (2 marinol capsules) + 2 placebo capsules + 16 placebo sprays
223772166|NCT01323569|DRUG|Marinol|Marinol dose level 2: 40 mg THC (4 marinol capsules) + 16 placebo sprays
223772167|NCT01837316|DRUG|FF/VI 100/25 mcg|First strip: Fluticasone furoate inhalation powder blended with lactose, 100 mcg per blister
223772168|NCT01837316|DRUG|Placebo|First strip: Inhalation powder of lactose
223772169|NCT04448860|BEHAVIORAL|performance of behavioral locomotion tasks phase 1|The performance of behavioral locomotion tasks is performed on 4 visits on pilot phase (2 in real condition and 2 in virtual reality in D1 and M1)
224253043|NCT00841191|DRUG|CNTO 328; Anti-interleukin-6 monoclonal antibody|Siltuximab 2.8 milligram per kilogram (mg/kg) will be administered as 1-hour intravenous infusion (a fluid or a medicine delivered into a vein by way of a needle) on Day 1, Day 28, Day 42 and Day 56
224253044|NCT00841191|DRUG|CNTO 328; Anti-interleukin-6 monoclonal antibody|Siltuximab 5.5 mg/kg will be administered as 1-hour intravenous infusion on Day 1, Day 28, Day 42 and Day 56
224253045|NCT00841191|DRUG|CNTO 328; Anti-interleukin-6 monoclonal antibody|Siltuximab 11 mg/kg will be administered as 1-hour intravenous infusion on Day 1, Day 28, Day 49 and Day 70
223672377|NCT05604053|BEHAVIORAL|Motivation Manipulation|On some trials, participants have lower motivation and on other trials participants have higher motivation.
223672378|NCT03034668|DIETARY_SUPPLEMENT|CS16-003 Full dose|350 mg 'Rhodiola rosea L. \& Rhaptonticum carthamoides extracts
223672379|NCT03034668|DIETARY_SUPPLEMENT|CS16-003 Half dose|175 mg 'Rhodiola rosea L. \& Rhaptonticum carthamoides extracts + maltodextrin 175 mg
223672380|NCT03034668|DIETARY_SUPPLEMENT|Placebo|Maltodextrin: 350 mg
223672381|NCT04434378|DRUG|Tamsulosin|0.4 mg tamsulosin will be given to a randomized group of patients
223672382|NCT04434378|DRUG|Placebo|placebo will be given to a randomized group of patients
223672383|NCT00986284|DRUG|gefitinib|Patients with EGFR mutation in exon 19 or 21 will be administrated with gefitinib as neoadjuvant therapy. Then evaluated for response and then operation for operable patients.
223672384|NCT00048841|DRUG|alendronate|
223672385|NCT04781777|DRUG|insulin|sonar guided insulin combined with dexamethasone and local anesthetics
223772170|NCT04448860|BEHAVIORAL|performance of behavioral locomotion tasks phase 2|The performance of behavioral locomotion tasks is performed on 6 visits on validation phase (3 in real condition and 2 in virtual reality in D1, M1 and M12)
223772171|NCT02734485|DEVICE|active Deep TMS|"The Brainsway DTMS produces a time-varying magnetic field and, based on Faraday's Law, it can be assumed that a time-varying magnetic field generates an electrical current in a nearby conductive substance. The induced electric current in the cortex travels in an orthogonal path in the direction of the magnetic field with the maximum strength and current located beneath the coil in the helmet placed on the patient's head and transmits magnetic pulses to the patient's brain. The induced current is tangential to the scalp at the cortical surface, and decreases in magnitude with increasing depth.~Patients underwent 12 sessions, 3 times a week, of repetitive DTMS using the novel H2-coil (Brainsway LDT)."
224253046|NCT00841191|DRUG|CNTO 328; Anti-interleukin-6 monoclonal antibody|Siltuximab 15 mg/kg will be administered as 1-hour intravenous infusion on Day 1, Day 28, Day 49 and Day 70
224253047|NCT00841191|DRUG|CNTO 328; Anti-interleukin-6 monoclonal antibody|Siltuximab 15 mg/kg will be administered as 1-hour intravenous infusion once every 21 days for up to a total of 231 days
224253048|NCT00841191|DRUG|CNTO 328; Anti-interleukin-6 monoclonal antibody|Siltuximab 15 mg/kg will be administered as 1-hour intravenous infusion once every 21 days for up to a total of 231 days to participants with ovarian cancer.
224253049|NCT00841191|DRUG|CNTO 328; Anti-interleukin-6 monoclonal antibody|Siltuximab 15 mg/kg will be administered as 1-hour intravenous infusion once every 21 days for up to a total of 231 days to participants with tumors harboring Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations or pancreatic cancer, or non-small cell lung cancer (NSCLC), colorectal cancer (CRC), or head and neck (H\&N) cancer that were refractory or resistant to anti-epidermal growth factor receptor (EGFR) therapy
223672386|NCT02241096|DRUG|Lidocaine|IV lidocaine bolus of 1.5mg/kg over 10 minutes followed by a 1mg/kg/hr IV lidocaine infusion.
223672387|NCT04054947|BEHAVIORAL|Suicide Prevention Program|Structured care management to improve adherence to discharge planning.
223672388|NCT02485678|OTHER|Proactive Telephone Toxicity Management|Centres randomized to this arm will implement a pro-active telephone toxicity management program, for all eligible early stage breast cancer patients beginning neo-adjuvant or adjuvant chemotherapy within the intervention period until the end of their systemic treatment. Patients will receive a phone call from a local nurse who has been trained on the toxicity management toolkit at 24-72 hours and at 8 to 10 days following each chemotherapy administration. The provider conducting the call will be provided with a script and will complete the Telephone Follow-Up Questionnaire which includes questions from the abbreviated NCI PRO-CTCAE tool. The nurse conducting the call will also be provided with the provider version of the symptom management booklet and provide toxicity management counseling. If any toxicity-related problems are identified during the call, a second call will take place 24 hours after the initial call to ensure the problem is resolving or to provide additional support.
223672389|NCT02485678|OTHER|Control Arm|Centres randomized to the control arm will continue to provide routine care for chemotherapy-related toxicities as is the current standard in the centre.
223672390|NCT02485678|OTHER|PRO Sub-Study|A sub-set of approximately 25 patients enrolled at each participating centre will participate in a Patient Reported Outcomes (PRO) sub-study to assess the effect of the intervention on secondary outcomes.
224253050|NCT02703194|DRUG|Prednisone|Prednisone:A starting dose of 0. 5-0. 8mg/(kg\*d) will be given. Following four-week period, the dose will be tapered gradually to 5mg/d until the end of 12 months of follow-up period.
223672391|NCT02284672|DRUG|Dexmedetomidine|
223672392|NCT02284672|DRUG|Normal saline|
223672393|NCT00718562|DRUG|AMN107|
223672394|NCT02012673|DEVICE|Bronchoscopic lung volume reduction|Bronchoscopic lung volume reduction with the RePneu Lung Volume Reduction Coil system. The RePneu LVRC is an implantable device, delivered through a fiber-optic bronchoscope, designed specifically to treat patients suffering from emphysema. The Coil is intended to compress the most damaged parenchyma and tension the surrounding tissue, which increases elastic recoil, reduces hyperinflation and redirects air to healthier portions of the lung for more effective ventilation.
223672395|NCT06185049|BEHAVIORAL|PROCARE+ (Core intervention with add-on modules) and two booster sessions.|The modules will primarily involve therapeutic sessions aimed at equipping adolescents with strategies for addressing risky situations, including enhancing their communication skills and developing coping mechanisms for stress management. The group sessions will also incorporate education on the importance of open discussions about thoughts, emotions, and behavior as integral components of emotional well-being, with a strong focus on offering support tailored to the identified risk factors. It will include two booster sessions at 6 and 12 months into the intervention.
224253051|NCT02703194|DRUG|Leflunomide|Leflunomide:A starting dose of 20 mg/day will be given. This dose may be decreased to 10 mg/day at the discretion of the treating physician if minor adverse effects occur(e.g., liver enzyme elevations).
224253052|NCT02844660|BIOLOGICAL|EpiCord|Weekly application of EpiCord and standard of care (moist wound therapy and offloading)
224253053|NCT02844660|OTHER|Standard of Care|moist wound therapy and offloading
224253054|NCT05790772|BEHAVIORAL|Vigorous Exercise|50 minutes of running on a treadmill
224253055|NCT06008704|DIAGNOSTIC_TEST|Clinical assessment|The clinical assessment consists on behavioural and motor evaluations to determine the characteristics of the population
224253056|NCT06008704|DIAGNOSTIC_TEST|Pain characteristics assessment|The pain characteristics assessment will be made with a variety of scales and questionnaires which allow to identify the extent of central pain and functional impairment
224253057|NCT06008704|DIAGNOSTIC_TEST|MRI|The MRI examination allows anatomical imaging, diffusion imaging and functional imaging to measure specific markers
224253058|NCT06008704|DIAGNOSTIC_TEST|Thermotest|The thermotest is performed to assess the pain perception threshold
224253059|NCT06008704|DIAGNOSTIC_TEST|UPDRS-III Scale|The UPDRS-III scale allows to asses motor functionality of PD patients
223772172|NCT02734485|DEVICE|sham Deep TMS|The Sham DTMS consisted in the same protocol of active treatment with the same preparation of the subject and settings of the instrument but with an INACTIVE DTMS coil.
223772173|NCT01899469|PROCEDURE|Electromagnetic Therapy|20 sessions from Monday to Friday of 20 minutes of Electromagnetic Therapy, using the next parameters: 10 Hz of frequency and 60% of intensity, and 20 sessions from Monday to Friday of 25 minutes of Back School, the exercises were based on the re-education of breathing, self stretching trunk muscles, erector spine reinforcement, abdominal reinforcement and postural exercises. The participants had been performing 8 to 10 repetitions of each exercise and they had been recommended about making a series more at home.
223772174|NCT01899469|PROCEDURE|Transcutaneous Electrical Neurological Stimulation|"Procedure/Surgery: Transcutaneous Electrical Neurological Stimulation (TENS)~20 sessions from Monday to Friday of 20 minutes of TENS Therapy using the next parameters: 100μs of impulse width, 80 Hz of impulse frequency, and 20 sessions from Monday to Friday of 25 minutes of Back School, the exercises were based on the re-education of breathing, self stretching trunk muscles, erector spine reinforcement, abdominal reinforcement and postural exercises. The participants had been performing 8 to 10 repetitions of each exercise and they had been recommended about making a series more at home."
223772175|NCT01899469|PROCEDURE|Back School|25 minutes of Back School, the exercises were based on the re-education of breathing, self stretching trunk muscles, erector spine reinforcement, abdominal reinforcement and postural exercises. The participants had been performing 8 to 10 repetitions of each exercise and they had been recommended about making a series more at home.
224253060|NCT06008704|DIAGNOSTIC_TEST|[18F]-MPPF PET scan|The PET scan after injection of \[18F\]-MPPF at a dose of 200 Megabecquerel/kg +/-10% allows in vivo imaging of 5HT1A receptors
224253061|NCT01851135|OTHER|Neuropsychological examination and quality of life measures|
224253062|NCT03965169|PROCEDURE|Prone spinal surgery|spinal surgery in prone position under general anesthesia
224322229|NCT06622421|DEVICE|Piezoelectric surgery|Patients enrolled and randomized into one of the two groups will all undergo surgery to remove necrotic bone on an outpatient basis by the same operator with a decade of experience in the treatment of MRONJ. As per clinical routine, a marginal bone resection procedure will be performed using rotary instruments or piezoelectric instruments (depending on the assignment to one of the two groups). Both surgical procedures involve complete closure of the wound by primary intention using sutures
223672396|NCT06185049|BEHAVIORAL|PROCARE+ (Core intervention with add-on modules) and one booster session|The modules will primarily involve therapeutic sessions aimed at equipping adolescents with strategies for addressing risky situations, including enhancing their communication skills and developing coping mechanisms for stress management. The group sessions will also incorporate education on the importance of open discussions about thoughts, emotions, and behavior as integral components of emotional well-being, with a strong focus on offering support tailored to the identified risk factors. It will include abooster sessions at 6 months into the intervention.
223672397|NCT06185049|BEHAVIORAL|PROCARE+ (Core intervention with add-on modules) without booster sessions.|The modules will primarily involve therapeutic sessions aimed at equipping adolescents with strategies for addressing risky situations, including enhancing their communication skills and developing coping mechanisms for stress management. The group sessions will also incorporate education on the importance of open discussions about thoughts, emotions, and behavior as integral components of emotional well-being, with a strong focus on offering support tailored to the identified risk factors.
224253063|NCT02525458|DEVICE|QAMS-containing PMMA|Wear retainer with QMAS-containing PMMA on one side of retainer
224253064|NCT02525458|DEVICE|QAMS-free PMMA|Wear retainer with QMAS-free PMMA on other side of retainer
224253065|NCT06302335|DRUG|Povidone-iodine|Application of Povidone-iodine to the surgical wound of patients submitted to colorectal resections.
224253066|NCT06302335|DRUG|Saline solution|Application of saline solution to the surgical wound of patients submitted to colorectal resections.
224253067|NCT03154047|DRUG|NEOD001|humanized monoclonal antibody
224253068|NCT00857454|DRUG|Testosterone MD-Lotion|30 mg to 120 mg administered topically once daily for 60 days
224253069|NCT05831449|DRUG|Local anesthetic injection of CPL-01|Local anesthetic injection (either IP, positive control \[Naropin\], or negative control \[saline placebo\])
224253070|NCT05831449|DRUG|Naropin, 0.5% Injectable Solution|Local anesthetic injection (either IP, positive control \[Naropin\], or negative control \[saline placebo\])
224253071|NCT05831449|DRUG|Placebo|Local anesthetic injection (either IP, positive control \[Naropin\], or negative control \[saline placebo\])
224253072|NCT01997983|DEVICE|TC-3 Gel mixed with Botox (BTX)|TC-3 gel mixed with Botox (BTX). Single intravesical instillations of 40 ml of TC-3 mixed with 200 units of preconstitued BTX, using catheter
224253073|NCT05824897|OTHER|Serum levels of vitamin D|Subjects in this study are grouped according to baseline serum levels of 25(OH)D. The serum level of total 25(OH)D ≥30ng/ml (75nM) is sufficient, 20-30ng/ml (50-75 nm) is insufficient, and less than 20ng/ml (50nM) is deficient.
224253074|NCT04244097|DRUG|Bupivacaine Hydrochloride|after induction of general anesthesia and before the start of surgery, after inflating the pneumoperitoneum and before any surgical manipulation, the surgeon infuse 50 mL of blinded solution (bupivacaine or bupivacaine neostigmine) intraperitoneally to the sub-diaphragmatic space and gall bladder area guided by the camera and the patients are kept in Trendelenburg position for 5-10 minutes. Thereafter all patients will be positioned in the anti-Trendelenburg position to start the surgery and the laparoscopic procedure will be carried out in a standard fashion.
224253075|NCT04244097|DRUG|Neostigmine|after induction of general anesthesia and before the start of surgery, after inflating the pneumoperitoneum and before any surgical manipulation, the surgeon infuse 50 mL of blinded solution (bupivacaine or bupivacaine neostigmine) intraperitoneally to the sub-diaphragmatic space and gall bladder area guided by the camera and the patients are kept in Trendelenburg position for 5-10 minutes. Thereafter all patients will be positioned in the anti-Trendelenburg position to start the surgery and the laparoscopic procedure will be carried out in a standard fashion.
224253076|NCT00992147|DRUG|Adipocell|autologous cultured adipocytes (ANTG-adip)
224253077|NCT05647005|OTHER|Classical music|A total of 15 sessions of music will be applied to this group, two or three days a week, on different days, 3 sessions a day. Sessions will be in the form of listening to classical music for 30 minutes after the babies are fed.
224322230|NCT06622421|PROCEDURE|Conventional surgery|Patients enrolled and randomized into one of the two groups will all undergo surgery to remove necrotic bone on an outpatient basis by the same operator with a decade of experience in the treatment of MRONJ. As per clinical routine, a marginal bone resection procedure will be performed using rotary instruments or piezoelectric instruments (depending on the assignment to one of the two groups). Both surgical procedures involve complete closure of the wound by primary intention using sutures
223672398|NCT02203175|DRUG|saline|Before the anesthesia induction, 5 ml isotonic saline
223672399|NCT02203175|DRUG|fentanyl|before the anesthesia induction 50 mcgr fentanyl
223672400|NCT02203175|DRUG|propofol|during anesthesia 50 mg proposal with 50 mcgr fentanyl
223672401|NCT06367712|DRUG|Letrozole tablets|To determine if the usage of All interventions are effective for simple induction of ovulation in polycystic ovarian syndrome in infertile couples.
223672402|NCT02449343|DRUG|Anlotinib|Anlotinib p.o. qd
223672403|NCT02449343|DRUG|Placebo|Placebo p.o. qd
223672404|NCT04672382|DRUG|Morphine|During the 1st session, each of the middle forearms of the subject will be divided into two squared areas (4x4 cm) located 3 cm apart. Two areas will be treated with an intradermal injection of morphine (0.05 ml, 0.1 mg/ml), and two areas with an intradermal injection of isotonic saline.
223672405|NCT05771883|DRUG|IMM0306|IMM0306 is a fusion protein of CD20 mAb with the CD47 binding domain of SIRPα. The Fc segment of the recombinant protein in IMM0306 is IgG1 and has been modified by ADCC-enhanced genetic engineering.
223672406|NCT05771883|DRUG|Lenalidomide capsule|Chemical name 3-(7-amino-3-oxo-1H-isoindol-2-yl)piperidin-2,6-dione, molecular formula C 13H 13 N 3 O 3, is an anti-tumor drug developed by Celgene Biopharmaceutical Company in the United States, with multiple effects such as anti-tumor, immunomodulatory and anti-angiogenesis
223672407|NCT04806867|OTHER|SePaRIC-Covid19 cohort|All patients with Chronic Inflammatory Rheumatism who were contacted by telephone as part of the innovative organizational strategy and who did not object to the use of their data.
223672408|NCT00575393|DRUG|gold sodium thiomalate|
223672409|NCT00575393|GENETIC|gene expression analysis|
223672410|NCT00575393|OTHER|fluorine F 18 fluorothymidine|
224253078|NCT05647005|OTHER|Harp music|A total of 15 sessions of music will be applied to this group, two or three days a week, on different days, 3 sessions a day. Sessions will be in the form of listening to harp music for 30 minutes after the babies are fed.
224253079|NCT06434753|DRUG|Zinc Acexamate|"The experimental group will receive ACZ at a daily dose of 600 mg, equivalent to 100mg of elemental zinc (one hard gelatin capsule of 300 mg of ACZ twice a day). Treatment will be stopped when the patient presents any of the events that define the main endpoint of the study.~The control group will receive twice a day orally hard gelatin capsules, identical to those of ACZ, in color, weight and nature, but containing an inert preparation (isomaltose)."
223672411|NCT00575393|OTHER|mass spectrometry|
223672412|NCT00575393|OTHER|pharmacological study|
223672413|NCT03594240|DRUG|Vitamin B complex tablets (Neurorubine TM -Forte Lactab TM)|Vitamin B complex tablets (Neurorubine TM -Forte Lactab TM) once daily
223672414|NCT03594240|DIETARY_SUPPLEMENT|Placebo|Patients in placebo group received placebo that were similar in appearance to Vitamin B complex tablets and the administered dose was as the same schedule as Vitamin B complex.
223672415|NCT01900912|OTHER|CLTS|The goal of CLTS is to obtain Open Defecation Free (ODF) villages. CLTS aims to trigger the community's desire for change, propel them into action and encourage innovation, mutual support and appropriate local solutions, in order to foster greater ownership and sustainability. The phases are: pre-triggering (a group of trained-CLTS people visit the community and request a date to discuss sanitation-related issues for the following days), triggering (people are made to express their views on sanitation issues and their needs), monitoring (involves visits of the community twice a week for a period of 1-3 months) and certification (an external committee evaluates the village for certification as an ODF community).
223672416|NCT00074698|DRUG|FG-3019|FG-3019 will be administered per dose and schedule specified in the arm description.
223672417|NCT03870958|PROCEDURE|GIC sealant (GC Fuji TRIAGE®)|Children allocated to this group will receive the same dietary advices and brushing instructions. Additionally, all MIH molars from will receive a GIC sealant (GC Fuji TRIAGE®, GC Europe, Leuven, Belgium).
223672418|NCT03870958|PROCEDURE|Control|Children allocated to this group will receive the same dietary advices and brushing instructions.
223672419|NCT06105671|DRUG|Symbicort|Participants are administered 54 μg Formoterol and 1920 μg Budesonide
224253080|NCT03407677|DEVICE|ROTO track®|An electronic injection form and injection log for keeping track of injection sites in the abdominal region. The device attaches directly to the insulin pen and activates whenever the insulin pen is picked up.
223672420|NCT06105671|DRUG|Formoterol|Participants are administered 54 μg Formoterol from an inhaler device
223672421|NCT06105671|DRUG|Formoterol|Participants are administered 120 μg Formoterol in a capsule, which is taken orally
223672422|NCT06105671|DRUG|Placebo|Participants are administered placebo
223672423|NCT06105671|DRUG|Mannitol|Participants are administered 600 mg Bronchitol
223672424|NCT05287360|DRUG|Rivoceranib|Rivoceranib will be supplied as film-coated tablets for oral administration as 4 different formulations: Formulation 1, 3, and 4 = 250 milligrams; Formulation 2 = 200 milligrams.
223672425|NCT03570164|DRUG|Sevoflurane|End-tidal concentration of sevoflurane is maintained at age-corrected 1.0 minimum alveolar concentration throughout the study period.
223672426|NCT03570164|DRUG|Desflurane|End-tidal concentration of desflurane is maintained at age-corrected 1.0 minimum alveolar concentration throughout the study period.
223672427|NCT01301898|DRUG|GC1111_0.5mg/kg|
223672428|NCT01301898|DRUG|GC1111_1.0mg/kg|
223672429|NCT01301898|DRUG|Elaprase_0.5mg/kg|
223672430|NCT01265264|DRUG|ulodesine|Oral dose administered daily for 84 days.
223672431|NCT01265264|DRUG|Placebo|Oral dose administered daily for 84 days.
223672432|NCT01634191|DRUG|Apremilast|One oral 30 mg dose of apremilast
223672433|NCT00551304|DEVICE|Ardian Catheter|
223672434|NCT02076425|BEHAVIORAL|PCIT-ED|
223672435|NCT00853970|DRUG|Bromfenac Ophthalmic Solution|sterile ophthalmic solution
223672436|NCT00853970|DRUG|Placebo Comparator|sterile ophthalmic solution
223672437|NCT05750199|OTHER|Immunotherapy Special Training Course (ISTC)|16 weeks and includes 8 hours of digital media training and 2 days of workshop training.
223672438|NCT05750199|OTHER|Advanced Oncology Nurse Training Course (AONTC)|4 weeks and includes 8 days of Advanced Oncology Nurse Training Course
223672439|NCT06995001|DRUG|SHR-2173|SHR-2173 injection dose 1；
223672440|NCT06995001|DRUG|SHR-2173 ；Placebo|SHR-2173 injection dose 2 ；Pacebo dose 2
223672441|NCT06995001|DRUG|SHR-2173 ；Placebo|SHR-2173 injection dose 3 ；Pacebo dose 3
223672442|NCT06995001|DRUG|SHR-2173 ；Placebo|SHR-2173 injection dose 4 ；Pacebo dose 4
223672443|NCT06995001|DRUG|SHR-2173 ；Placebo|SHR-2173 injection dose 5 ；Pacebo dose 5
223672444|NCT00417456|OTHER|Evisit|Asynchronous,remote care delivery via a secure web platform
223672445|NCT00417456|OTHER|Office visit|Conventional office-based care
223672446|NCT03538964|PROCEDURE|toric intraocular lens|cataract surgery with implantation of an toric intraocular lens
223672447|NCT03538964|PROCEDURE|non toric intraocular lens|cataract surgery with implantation of a non toric intraocular lens
223672448|NCT02455505|BEHAVIORAL|background questionnaire|
223672449|NCT02455505|BEHAVIORAL|bereavement risk screening tool|
223672450|NCT02055365|BIOLOGICAL|Hepatitis B Vaccine (Recombinant)|All subjects will receive the standard 3-dose course of Recombivax HB (Merck) - Hepatitis B Vaccine (Recombinant).
223672451|NCT02029729|DRUG|omaveloxolone|
223672452|NCT03816670|DRUG|Corifollitropin Alfa|late start (day 4) vs. corifollitropin-alfa standard start (day 2)
223672453|NCT00806871|DRUG|Methylprednisolone 40 mg|"Depo-medrol 40 mg , suspension, injection in the carpal tunnel, one time use~1 ml 40 mg Methylprednisolone + 1 ml 10mg Lidocaine + 1 ml saline"
223672454|NCT00806871|DRUG|Methylprednisolone 80 mg|"Depo-medrol 80 mg , suspension, injection in the carpal tunnel, one time use.~2 ml 80mg Methylprednisolone + 1 ml 10mg Lidocaine"
223672455|NCT00806871|DRUG|Sodium chloride|"Saline solution 0,9%, injection in the carpal tunnel, one time use~1 ml 10 mg Lidocaine + 2 ml saline"
223672456|NCT03828773|DRUG|Posaconazole|Posaconazole is a triazole with broad-spectrum activity, to include Candida species, Aspergillus species, and other fungal pathogens, including the Zygomycetes. Posaconazole is available as slow release tablets (300mg/day) and as intravenous (IV) formulation (300mg/day) and is licensed and approved in Switzerland for the prevention of IFI, including mold and yeast infections, in patients \>18 years who are at high risk of developing these types of infection (patients with long-term neutropenia or HCT recipients). Furthermore, international guidelines recommend posaconazole for primary antifungal prophylaxis in high-risk patients, such as AML patients with prolonged neutropenia. Posaconazole is available in Switzerland under the name of Noxafil® in capsules of 100mg, suspension of 40mg/mL and intravenous formulation of 300mg/16.7 mL.
223672457|NCT03828773|DRUG|Fluconazole|Fluconazole is an antifungal with activity against most Candida species. Fluconazole is licensed and approved in Switzerland for prophylaxis of IC in patients with neutropenia induced by chemotherapy or radiotherapy at a daily dose of 200 to 400 mg once daily. Fluconazole (200 mg or 400 mg once daily) is still currently used as primary antifungal prophylaxis (standard of care) in all 7 centers participating in this trial. Fluconazole is available in Switzerland under the name of Diflucan® in capsules of 50 mg, 150 mg and 200 mg and in powder for preparation of suspension (50 mg/5 ml and 200 mg/5 ml (forte)) or perfusion (2 mg/1 ml). Several generics of Diflucan® are authorized in Switzerland. Prescribing Diflucan® or any of its generics will remain at the discretion of and based on the standard operating procedures (SOP) at each institution.
223672458|NCT03310060|DRUG|Tisseel|Tisseel® (Fibrin Sealant, 4ml, Baxter) was applied on potential bleeding sites: the femoral insertion of the posterior cruciate ligament, the lateral genicular artery after resection of the meniscus, the posterior capsule of the knee joint, the bony surfaces not covered by the implant as well as the pinholes (femur and tibia). The entire content of a 4 mL vial containing the active product was used
223672459|NCT03310060|DRUG|Tranexamic Acid|Drug: Tranexamic acid Intravenous application of tranexamic acid 15mg/kg in 100 ml normal saline before surgical incision and 3 hours after surgery
223672460|NCT04600817|DRUG|TJ107|QW8
223672461|NCT04600817|DRUG|TJ107 placebo|QW8
223672462|NCT03988881|PROCEDURE|Revascularization|PCI or CABG
223672463|NCT03700541|DRUG|Morphine|Morphine intravenous
223672464|NCT03700541|DRUG|Piritramid|Piritramid intravenous
223672465|NCT04296643|DEVICE|Medical Mask|Medical Mask (known also as Surgical Mask)
223672466|NCT04296643|DEVICE|N95 respirator|N95 respirator
223672467|NCT01732094|DRUG|Triptorelin|Triptorelin 0.1 mg/1 ml solution daily from day 21 of the cycle onwards
223672468|NCT01732094|DRUG|Corifollitropin alfa 150μg|Corifollitropin alfa 150μg (single dose) 2 or 3 weeks after initiation of triptorelin
223672469|NCT01732094|DRUG|hpHMG|hpHMG 300IU daily from day 7 following Corifollitropin alfa onwards
224253081|NCT01720147|DRUG|Quercetin (dietary supplement)|"Quercetin will be given orally on a twice a day schedule starting with weight adjusted dose for a maximum total daily dose of 1500 mg/day, for 4 months (16 weeks). Pharmacokinetics (PK) data will be analyzed after each cohort of 3 patients and will be used to optimize the dosing schedule (if required)for subsequent patients.~An expansion cohort has been added to the study protocol. Up to 20 patients may be enrolled. The dose utilized will be the same as the max weight adjusted dose that showed biological activity in our last cohort of patients (subjects #10-12 from above)."
224253082|NCT03166345|OTHER|Treatment of Thin Endometrium|This is a trial to improve endometrial thickness by autologous injection of PRP into the Uterine Cavity compared with CSF or no treatment.
224253083|NCT01777711|BEHAVIORAL|Mental Contrasting- Individual|Investigators will implement the manipulation of mental contrasting/implementation intentions, focusing on the individual. This will entail 3 steps that involve: 1) contrasting of positive future outcomes associated with present conditions that hinder achievement of positive future outcomes (i.e., barriers); 2) strategies to overcome barriers and hence facilitate weight loss; and 3) construction of implementation intentions.
224253084|NCT01777711|BEHAVIORAL|Mental Contrasting- Couple|Investigators will implement the manipulation of mental contrasting/implementation intentions, focusing on the couple. This will entail 3 steps that involve: 1) contrasting of positive future outcomes associated with present conditions that hinder achievement of positive future outcomes (i.e., barriers); 2) strategies to overcome barriers and hence facilitate weight loss; and 3) construction of implementation intentions.
224253085|NCT02258347|DEVICE|Echopulse|
224253086|NCT00742547|OTHER|Telephone counseling|Telephone counseling is provided once a month by the medical secretary of the general practitioner's practices
224253087|NCT00365365|DRUG|Doxorubicin and cyclophosphamide (AC) + bevacizumab|"For every 3-week cycle~* bevacizumab 15 mg/kg infused intravenously (IV) on Day 1 followed by~* doxorubicin 60 mg/m\^2 IV push or infusion followed by cyclophosphamide 600 mg/m\^2 IV push or infusion~* Prophylactic G-CSF was administered within 24 hours following each cycle of chemotherapy but no greater than 72 hours after chemotherapy"
224253088|NCT00365365|DRUG|Docetaxel (T) + bevacizumab|"For every 3-week cycle~* bevacizumab 15 mg/kg infused intravenously (IV) on Day 1 followed by~* docetaxel 100 mg/m\^2 IV~* Prophylactic G-CSF was administered within 24 hours following each cycle of chemotherapy but no greater than 72 hours after chemotherapy~Note: The starting dose of docetaxel was reduced to 75 mg/m\^2 if toxicity occurred that met the criteria for doxorubicin dose reduction"
224253089|NCT00365365|DRUG|Docetaxel, doxorubicin, cyclophosphamide (TAC) + bevacizumab|"For every 3-week cycle~* bevacizumab 15 mg/kg infused intravenously (IV) on Day 1 followed by~* doxorubicin 50 mg/m\^2 IV push or infusion followed by cyclophosphamide 500 mg/m\^2 IV push or infusion followed by docetaxel 75 mg/m\^2~* Prophylactic G-CSF was administered within 24 hours following each cycle of chemotherapy but no greater than 72 hours after chemotherapy"
224253090|NCT00365365|DRUG|Docetaxel, carboplatin, trastuzumab (TCH) + bevacizumab|"For every 3-week cycle~* bevacizumab 15 mg/kg infused intravenously (IV) on Day 1 followed by~* docetaxel in 75 mg/m\^2 IV followed by carboplatin AUC 6 mg/mL/min IV followed by~* trastuzumab 6 mg/kg by IV infusion (For the first cycle 1 only a loading dose of trastuzumab 8 mg/kg IV was infused on Day 2)~* Prophylactic G-CSF was administered within 24 hours following each cycle of chemotherapy but no greater than 72 hours after chemotherapy"
224253091|NCT00365365|DRUG|Bevacizumab and trastuzumab maintenance therapy|"* bevacizumab 15 mg/kg was infused IV followed by~* trastuzumab 6 mg/kg IV~Treatment was every 3 weeks for 52 weeks from the date of the first administration regardless of the number of doses received or missed."
224253092|NCT00365365|DRUG|Bevacizumab maintenance therapy|"\- bevacizumab 15 mg/kg was infused IV~Treatment was every 3 weeks for 52 weeks from the date of the first administration regardless of the number of doses received or missed."
224253093|NCT04736186|DRUG|Loperamide|Loperamide 4 mg， t.i.d.(d 1-7);4 mg, b.i.d.(d 8-21)
224253094|NCT04736186|DRUG|Loperamide and golden bifid|Patients with secondary prevention will be randomly assigned to B：Loperamide 4 mg， t.i.d.(d 1-7);4 mg, b.i.d.(d 8-21)+golden bifid 2 g t.i.d.
223672470|NCT02868814|DRUG|Pregabalin Release Tablets|
223672471|NCT02868814|DRUG|Pregabalin Release Tablets|
223672472|NCT02868814|DRUG|Placebo|
223672473|NCT01258998|DRUG|Akt inhibitor MK2206|Given PO
223672474|NCT01258998|OTHER|laboratory biomarker analysis|Correlative studies
224253095|NCT04736186|DRUG|Loperamide and montmorillonite powder|Patients with secondary prevention will be randomly assigned to D：Loperamide 4 mg， t.i.d.(d 1-7);4 mg, b.i.d.(d 8-21)+montmorillonite powder 3 g t.i.d.
224322231|NCT06972420|BEHAVIORAL|Hypnosis session|Within the two weeks prior to surgery, in addition to the standard preoperative care currently in place, the patient will receive a 30-minute visit from a nurse anesthetist trained in hypnosis. This is an added procedure complementing the anesthesia consultation. The visit is divided into two parts: 10 minutes to review and clarify the explanations given by the anesthesiologist and surgeon, and 20 minutes of a formal hypnosis session. A personalized liaison form will be completed to facilitate communication between the consultation and the operating room.
223672475|NCT01143389|DRUG|Riboflavin|Riboflavin 0.1% eye drops are applied before and during irradiation of the cornea.
224322232|NCT02143466|DRUG|Part A - AZD9291 in combination with AZD6094|Part A - AZD9291 and AZD6094 administered in different doses to investigate the safety and tolerability of this combination and define the combination dose for further clinical evaluation in Part B.
223672476|NCT01143389|DEVICE|UVX light|UVX 365 nm wavelength light source is applied with continued application of riboflavin.
223672477|NCT01215929|DRUG|Dextroamphetamine|Thirty treatment-seeking methamphetamine dependent volunteers will be admitted to a residential facility and be inducted onto d-amphetamine during week 1 of the study. 15 Participants then will be randomized by severity of methamphetamine dependence, sex, amphetamine withdrawal questionnaire score and history of Attention Deficit Hyperactivity Disorder to receive oral d-amphetamine at a dose of 30 mg twice daily for 2 weeks.
223672478|NCT01215929|DRUG|Placebo|Thirty treatment-seeking methamphetamine dependent volunteers will be admitted to a residential facility in this 4-week, double-blind, placebo-controlled, clinical trial and be inducted onto d-amphetamine during week 1 of the study. 15 Participants then will be randomized by severity of methamphetamine dependence, sex, amphetamine withdrawal questionnaire score and history of Attention Deficit Hyperactivity Disorder to receive oral placebo tablets twice daily for 2 week.
224253096|NCT02193763|PROCEDURE|Ultrasound assisted lumbar puncture|An investigator will perform beside ultrasound on the spinal area using a bedside ultrasound device. Attempts will be made to visualize the spinous processes and vertebral bodies in the general lumbarsacral area, as well as the presence of CSF in the thecal space below the conus medullaris, and identify the optimal location to perform the LP. This will be marked with a skin marker (If no CSF or abnormal anatomy is visualized, the LP will be advised to be postponed or cancelled). The treating physician will then proceed with the LP guided by the skin markings.
224253097|NCT00781339|DRUG|sodium 2-(dichloroamino)-2-methylpropane-1-sulfonate monohydrate|0.1% NVC-422 in saline, up to 100 mL, Study Part 1 - once on Day 1 held in the bladder for 1 hour; Study Part 2 (Part 2a - 0.1% NVC-422, Part 2b - 0.2% NVC-422), once daily for 7 days, held in the bladder for 1 hour
223672479|NCT03970356|OTHER|antibiotic stewardship intervention|The intervention is multifaceted, consisting of the implementation of an algorithm for restrictive use of antibiotics as proposed in recent guidelines (Verenso, Dutch guideline), tailored in close collaboration with local stakeholders to the specific implementation setting, by means of a modified participatory-action research (PAR) approach. To support the process of intervention-tailoring and -implementation, a toolbox comprising of materials, aids and actions is developed to be used at the discretion of the local stakeholders to support implementation of the algorithm.The algorithm is congruent with the Swedish and Norwegian guidelines, which also promote more restrictive use of antibiotics in case of non-specific symptoms, even though the algorithm is more detailed.
223672480|NCT00093444|DRUG|lyso-thermosensitive liposomal doxorubicin|
223672481|NCT00093444|PROCEDURE|radiofrequency ablation|
223672482|NCT01238627|DRUG|Nicotine Sublingual Tablet Mint (NSTM)|A single dose of an experimental NSTM, with a 36-hour washout between visits
223672483|NCT01238627|DRUG|Marketed Nicotine Tablet|A single dose of a marketed Nicotine Replacement Therapy (NRT), with a 36-hour washout between visits
223672484|NCT00400478|DRUG|Rituximab|Rituximab 375mg/m2 i every 8 weeks for two years (12 infusions)
223672485|NCT01165762|DRUG|Immune Tolerance|"Immune tolerance Kidney and hematopoietic cell transplantation with a conditioning regimen of total lymphoid irradiation and antithymocyte globulin followed by immunosuppressive drugs for 18 months. Immunosuppressive drugs are stopped if stable chimerism is achieved and there is no rejection of the transplant kidney.~The IDE used in this study is the column used for hematopoietic cell sorting."
223672486|NCT04637009|DRUG|TAS1553|Form: tablet; Route of Administration: oral
223672487|NCT02562469|OTHER|ACTIVATE|A home-based computerized brain training intervention for youth.
223672488|NCT03470532|DRUG|buccal infiltration of 4% Articaine with Epinephrine|Articaine Hydrochloride 4 % / Epinephrine 1:200,000 1.8 ML Cartridge
223672489|NCT03470532|DRUG|buccal infiltration of 2% Mepivacaine with Epinephrine|Mepivacaine Hydrochloride 2% Epinephrine 1:200,000 2.2 Ml Cartridge
223672490|NCT01162798|OTHER|infant formula|test infant formula fed to infants until 6 months corrected gestational age
223672491|NCT01162798|OTHER|control infant formula|commercially available infant formula
223672492|NCT02276027|DRUG|BYL719|BYL719 was dosed as 350 mg once daily. On the first day of each cycle, patient received a prescription of adequate drug supply for self-administration at home. The investigator must emphasized compliance and instructed the patient to take BYL719 exactly as prescribed.
223672493|NCT02276027|DRUG|INC280|INC280 was dosed as 600 mg (tablet) or 400mg(Capsule) twice daily. On the first day of each cycle, patient received a prescription of adequate drug supply for self-administration at home. The investigator must emphasized compliance and instructed the patient to takeINC280 exactly as prescribed.
223672494|NCT02276027|DRUG|LDK378|LDK378 was dosed as 750 mg once daily. On the first day of each cycle, patient received a prescription of adequate drug supply for self-administration at home. The investigator must emphasized compliance and instructed the patient to take LDK378 exactly as prescribed.
223672495|NCT02276027|DRUG|MEK162|MEK162 was dosed as 45 mg twice daily. On the first day of each cycle, patient received a prescription of adequate drug supply for self-administration at home. The investigator must emphasized compliance and instructed the patient to take MEK162 exactly as prescribed.
224253098|NCT00984022|DEVICE|Type of dressing - Iodoform|Dressing for packing a cutaneous abscess
223672496|NCT00316550|DRUG|AV608|
223672497|NCT04300959|DRUG|Anlotinib Hydrochloride in Combination With PD1 With Gemcitabine Plus(+)Cisplatin|"Gemcitabine:1000mg/m2, days 1 and 8; Cisplatin: 25mg/m2, days 1 and 8； Anlotinib : 10mg po qd, days 1-14; Sintilimab: 200mg IV, day 1；~1 cycle = 3 weeks."
223672498|NCT04300959|DRUG|Gemcitabine Plus(+)Cisplatin|"Gemcitabine:1g/m2, days 1 and 8; Cisplatin: 25mg/m2, days 1 and 8；~1 cycle = 3 weeks."
223672499|NCT04450810|OTHER|Observation of serum and salivary NLRP3 levels|Evaluation of serum and salivary NLRP3 levels
223672500|NCT01240265|DIETARY_SUPPLEMENT|Vitamin D3|150,000 IU orally given once
223672501|NCT01240265|DIETARY_SUPPLEMENT|Vitamin D3|5000 IU given orally daily for 28 days
223672502|NCT03923803|DIAGNOSTIC_TEST|C- reactive protein|the measurement will be done by chemileumeniscence
224253099|NCT00984022|DEVICE|Type of dressing - Aquacel|Aquacel dressing
223672503|NCT03923803|DIAGNOSTIC_TEST|Pro calcitonin|the measurement will be done by chemileumeniscence
223672504|NCT01577810|DEVICE|Near Infrared Spectroscopy|Use of Near Infrared Spectroscopy in outpatient setting to determine global cardiac output
223672505|NCT03224598|DRUG|A-101 Topical Solution 40%|A-101 Topical Solution 40%
223672506|NCT03233269|BEHAVIORAL|Music Therapy|During the educational music therapy intervention, member(s) of the Adult Sickle Cell Disease team will share with the patients the medical information pertinent to the appointment via a prerecorded video. The Music Therapist will then engage the patients in a music therapy intervention designed to teach and reinforce the skills and knowledge presented. These music therapy interventions may include but are not limited to original songs/rap/instrumental playing, vocal and/or instrumental improvisation, patient-contributed lyrics, mnemonics, and stress and pain reducing strategies. The music therapy interventions will be tailored to best convey the educational message.
223672507|NCT02259075|DRUG|Botulinum Toxin Type A|
223672508|NCT02183103|DRUG|meloxicam rapid release tablet, 12mg, UH AC62MU|
223672509|NCT00335231|DRUG|gatifloxacin ophthalmic (ZYMAR)|
223672510|NCT06171308|DEVICE|Traditional Chinese moxibustion apparatus|"The study group was treated with traditional Chinese moxibustion and western medicine. The control group was treated with blank moxibustion and western medicine.~1. The study group: Using the moxibustion, select specific 3 groups of acupoints. Select a group of acupuncture points every day, in the moxibustion treatment for 20 minutes, 4 weeks for a course of treatment.~2. The control group: Using the moxibustion with blank patch, select specific 3 groups of acupoints. Select a group of acupuncture points every day, in the moxibustion treatment for 20 minutes, 4 weeks for a course of treatment.~3. The treatment period is 4 weeks, which is a course of treatment, and the observation period is 8 weeks."
223672511|NCT04562753|PROCEDURE|Maïa® TMC Prosthesis (Lépine Groupe)|Patients undergoing thumb basal joint arthroplasty using Maïa® TMC prosthesis as treatment of osteoarthritis.
223672512|NCT04562753|PROCEDURE|APL Suspensionplasty|Patients undergoing thumb basal joint arthroplasty using APL Suspensionplasty as treatment of osteoarthritis.
223672513|NCT02767544|PROCEDURE|Vaginal wound local analgesia after laparoscopic hysterectomy|
223672514|NCT00953459|DRUG|sunitinib malate|
223672515|NCT00953459|OTHER|laboratory biomarker analysis|
223672516|NCT00953459|RADIATION|fludeoxyglucose F 18|
223672517|NCT01000038|OTHER|Wii-Fit intervention|Half hour daily, 5 days a week for 8 weeks
223672518|NCT01000038|OTHER|Walking|Half hour daily, five days a week for 8 weeks
223672519|NCT01653379|DRUG|DP001|DP001 softgel capsules; 55 ng to 550 ng per dose, administered 3 times weekly for 4 weeks
223672520|NCT00007007|PROCEDURE|management of therapy complications|
223672521|NCT00007007|PROCEDURE|quality-of-life assessment|
223672522|NCT04652596|OTHER|Produce prescription program|A monthly $150 stipend will be provided to participants for 6 consecutive months to purchase fresh food items at mobile markets and independent farmers markets across Boston.
223672523|NCT04652596|OTHER|Grocery store gift cards|A monthly value of $150 in grocery store gift cards redeemable at conventional grocery stores will be provided to participants for 6 consecutive months.
223672524|NCT03733431|DEVICE|Gammacore device|Transcutaneous stimulation of vagus nerve with the device positioned below the mandibular angle, medial to the sternocleidomastoid muscle and lateral to the larynx.
223672525|NCT03733431|DEVICE|Gammacore sham device|Sham device which does not deliver electrical stimulation, but instead, produces a buzzing sound will be placed along the lateral border of the sternocleidomastoid muscle in order to avoid mechanical stimulation of the vagus nerve in the carotid triangle.
223672526|NCT04254042|DRUG|Perindopril Arginine|10 mg Perindopril tablet / day will be added to the usual treatment for each patient for a period of 8 weeks.
223672527|NCT04254042|DRUG|Zofenopril, Calcium Salt, (1(R*),2Alpha,4Alpha)-isomer|30 mg Zofenopril tablet / day will be added to the usual treatment for each patient for a period of 8 weeks.
223672528|NCT00729222|DRUG|Comparator: Placebo|rolofylline placebo IV infusion over 4 hours.
223672529|NCT00729222|DRUG|rolofylline|rolofylline 30 mg IV infusion over 4 hours.
224322233|NCT02143466|DRUG|Part A - AZD9291 in combination with continuous selumetinib (Asian subjects)|Part A - AZD9291 and selumetinib (continuous treatment) administered in different doses to investigate the safety and tolerability of this combination in Asian subjects and to define the combination dose for further clinical evaluation in Part B.
224322234|NCT02143466|DRUG|Part A - AZD9291 in combination with continuous selumetinib (non-Asian subjects)|Part A - AZD9291 and selumetinib (continuous treatment) administered in different doses to investigate the safety and tolerability of this combination in non-Asian subjects and to define the combination dose for further clinical evaluation in Part B.
224322235|NCT02143466|DRUG|Part A - AZD9291 in combination with intermittent selumetinib|Part A - AZD9291 and selumetinib (intermittent treatment) administered in different doses to investigate the safety and tolerability of this combination and to define the combination dose for further clinical evaluation in Part B.
223672530|NCT03355443|PROCEDURE|Retroflexion|Retroflexion technique in colonoscopy means turning the colonoscope tip 180 degree in order to look backward in the colon and rectum.
223672531|NCT03355443|PROCEDURE|Re-examination|Re-examination in colonoscopy means examining the cecum and ascending colon twice in the routine fashion.
223672532|NCT04002570|OTHER|blood samples collection|blood samples collection are performed at 4 different timepoints: preop, pre rt, week 6 rt, week 12-14 (fu) for GROUP I and GROUP II; blood samples collection are performed at 3 different timepoints: pre rt, week 6 rt, week 12-14 (fu) for GROUP I bis; blood samples collection are performed just once for control GROUP.
223672533|NCT06200142|DIAGNOSTIC_TEST|Untargeted metabolomics|Untargeted metabolomics in bloodspots and in plasma
223672534|NCT06200142|GENETIC|WES and WGS|WES reanalysis and WGS analysis
223672535|NCT00562900|PROCEDURE|robotic assisted cholecystectomy|robotic assisted cholecystectomy
223772176|NCT04035785|DRUG|Kangfu Anti-inflammatory Suppository|To evaluate the short-term and long-term efficacy of traditional Chinese medicine of Kangfu anti-inflammatory suppository in reducing the use of antibiotics,reducing the risk of clinical use of drugs.
223772177|NCT01774903|DRUG|TTS-fentanyl|TTS-fentanyl patches releasing drug at the rate of 12.5 microgram (µg) per hour for 3 days. The patches will be replaced every 3 days until 30 days.
223772178|NCT05297045|DRUG|RGT001-075|Oral GLP1 Receptor Agonist
223672536|NCT00562900|PROCEDURE|Laparoscopic cholecystectomy|Laparoscopic cholecystectomy
223672537|NCT04048785|OTHER|Behavioral sleep intervention|The intervention consists of an infant behavioral sleep protocol. In the tailored intervention approach, parents are asked to implement the behavioral protocol at bedtime and at subsequent night wakings.
223672538|NCT00103727|DRUG|Talnetant|talnetant
223772179|NCT05297045|OTHER|Placebo|Placebo comparator
223772180|NCT01602315|DRUG|BYL719 as film-coated (FC) whole tablets|Oral alpha-specific PI3K inhibitor
223672539|NCT00103727|OTHER|placebo|Placebo Comparator
223672540|NCT00103727|OTHER|risperidone|Active Comparator
223672541|NCT01527357|BIOLOGICAL|Fibrocaps|Human fibrinogen and thrombin powder, for topical administration.
223672542|NCT01527357|BIOLOGICAL|Gelatin sponge|Absorbable gelatin sponge for topical administration.
223772181|NCT01602315|DRUG|BYL719 as dispersible tablets (DT)|New formulation of the oral alpha-specific PI3K inhibitor
223772182|NCT01602315|BIOLOGICAL|cetuximab|Recombinant chimeric monoclonal antibody driven against EGFR
224253100|NCT01810419|DEVICE|Vscan Ultrasound (GE Healthcare, USA)|Vscan Ultrasound used to determine spleen size and the other qualities described in the arm description.
224253101|NCT01810419|DEVICE|Conventional Ultrasound|Conventional Ultrasound used to determine spleen size and the other qualities described in the arm description.
224253102|NCT03589313|DRUG|GLPG3067 single dose|GLPG3067 film coated tablets provided at Day 1.
224253103|NCT01153503|PROCEDURE|TAP block|"Group Intraoperative (at the end of surgery): Ketorolac 30 mg, IV + TAP block; TAP block~First 24-h Postoperative: Ketorolac 30 mg q 6h + acetaminophen 650 mg q6h + IV-PCA morphine~24-48-h Postoperative: Oral ibuprofen 800 mg q 8 h + hydrocodone/acetaminophen 5mg/500 mg 1-2 tablets q 6h, prn"
224253104|NCT03469843|OTHER|Non intervention|patients without intervention
224253105|NCT04654143|DRUG|BVL-GSK098 capsule, placebo|Oral QD
224253106|NCT00573443|DRUG|dextromethorphan hydrobromide 20 mg and quinidine sulfate 10 mg|Dextromethorphan hydrobromide (DM) and quinidine sulfate (Q) capsules (AVP-923 capsules), containing DM 20 mg/ Q 10 mg, taken once daily for 1 week and then twice daily for 11 consecutive weeks to complete a 12-week period
224322236|NCT02143466|DRUG|Part A - AZD9291 in combination with MEDI4736|"Part A - AZD9291 and MEDI4736 administered in different doses to investigate the safety and tolerability of this combination and to define the combination dose for further clinical evaluation in Part B.~Note: Enrolment into the patient cohort that evaluated AZD9291 treatment in combination with MEDI4736 as 1st line treatment has been terminated due to an increased incidence of ILD-like events (interstitial lung disease/pneumonitis), and is no longer being evaluated in this study."
223672543|NCT02630199|DRUG|AZD6738|The starting dose of 40 mg AZD6738 OD will be escalated to reach a maximum tolerated dose in patients with advanced solid malignancies, as defined by dose-limiting toxicity.
223672544|NCT02630199|DRUG|Paclitaxel|Paclitaxel 80mg/m2 on days 1,8, and 15 every 4 weeks
223672545|NCT04897139|DRUG|Flu-Bu-Mel-E|Fludarabine 150mg/m2, busulfan 6.4mg/kg, melphalan 100mg/m2 and etoposide 600mg/m2
223672546|NCT06129357|BEHAVIORAL|180 individuals who applied to the Periodontology Clinic were included in the study. Individuals were divided into 3 groups as healthy (n=60), gingivitis (n=60) and periodontitis (n=60).|Diagnostic Test: Full periodontal chart A full periodontal chart will be carried out including all biometric periodontal variables: Probing Pocket Depth (PPD), Bleeding on Probing (BoP), presence of Plaque, recession (REC), Full Mouth Plaque Score (FMPS), Full Mouth Bleeding Score (FMBS), presence of furcation and mobility. Periodontal status, as assessed by the periodontal chart, will be evaluated following the New Classification of Periodontal and Peri implant diseases.
223672547|NCT02850081|DRUG|Statin|"Standard of care treatment (one of four):~* Simvastatin (to 40mg without amlodipine)~* Simvastatin (to 20 mg if currently on amlodipine)~* Atorvastatin (to 80mg)~* Rosuvastatin (to 20mg)"
223672548|NCT02850081|DRUG|Atorvastatin|"A lipid-lowering agent and for prevention of events associated with cardiovascular disease.~10 mg or 80 mg capsules"
223672549|NCT02850081|OTHER|Placebo|A placebo pill will be used for patients that are to maintain their current dose of statins prior to their CEA.
223672550|NCT06061614|GENETIC|NGGT002|NGGT002
223672551|NCT02446171|DRUG|Naloxegol 25 mg tablet, crushed, suspended in water, given orally|naloxegol 25 mg (1 tablet) crushed, suspended in water, given orally
223672552|NCT02446171|DRUG|Naloxegol 25mg tablet crushed, suspended in water, given via nasogastric tube|naloxegol 25 mg (1 tablet) crushed, suspended in water, given via nasogastric tube
223672553|NCT02446171|DRUG|Naloxegol 25 mg (10 mL oral solution)|naloxegol 25 mg (10 mL oral solution)
223772183|NCT01602315|DRUG|BYL719 drink suspension|Oral alpha-specific PI3K inhibitor
224253107|NCT00573443|DRUG|dextromethorphan hydrobromide 30 mg and quinidine sulfate 10 mg|Dextromethorphan hydrobromide (DM) and quinidine sulfate (Q) capsules (AVP-923 capsules), containing DM 30 mg/ Q 10 mg taken once daily for 1 week and then twice daily for 11 consecutive weeks to complete a 12-week period
224253108|NCT00573443|DRUG|Placebo|Placebo capsules (identical in appearance to AVP-923 capsules being studied in this trial), taken once daily for 1 week and then twice daily for 11 consecutive weeks to complete a 12-week period
223672554|NCT02446171|DRUG|Naloxegol 25 mg tablet, given orally|naloxegol 25 mg (1 tablet) whole tablet, given orally
223672555|NCT03363022|DRUG|Standard Medical Treatment|Standard Medical Treatment includes antibiotics,CRRT (Continuous Renal replacement Therapy),Liver Dialysis.
223672556|NCT03363022|OTHER|Fecal Microbiota Transplant|"Fecal Microbiota Transplant Stool specimen (preferably Bristol Stool Type 3 or 4) with a weight of ∼50 g will be considered adequate.~250 mL sterile normal saline will be added to the stool sample and homogenized with a blender for 2-4minutes in pulses of 30 seconds with 10 seconds wait in between each pulse.~Enema to be held for 30 minutes."
223672557|NCT03363022|OTHER|Placebo|Placebo will be identical and non medicinal to the Fecal Microbiota Transplant
223672558|NCT00148551|DRUG|Triamcinolone Acetonide|
223672559|NCT04988633|BEHAVIORAL|Intervention CFG App|Online healthy lifestyle education through an App. The intervention will consist of viewing educational videos on diet and exercise through an App. Videos will be uploaded to the app on a weekly basis, lasting 2-3.
223672560|NCT04988633|BEHAVIORAL|Control Group|Standard tips for healthy lifestyles that are carried out in regular Primary Care practice. After day 1, where standard advice is received, follow-up visits are conducted at week 2, week 4, month 3, and month 6.
223672561|NCT05972603|PROCEDURE|1.0 g Vancomycin powder into the wound|0,35% povidone-iodine solution lavage left for 3 minutes following final implantation and additional application 1.0 g Vancomycin powder into the wound
223672562|NCT05972603|PROCEDURE|0,35% povidone-iodine solution lavage|0,35% povidone-iodine solution lavage left for 3 minutes following final implantation
223672563|NCT02065271|DIETARY_SUPPLEMENT|herbal supplement|
223672564|NCT02065271|OTHER|placebo supplement|
223672565|NCT01889095|DRUG|BIAsp 30|patients receiving variable doses of Insulin BIAsp 30.start with 0.2 to 0.6unit per kg
223672566|NCT01889095|DRUG|NPH/Reg|patients receiving Variable doses Of Insulin NPH Start with 0.2 to 0.6 unit per kg
223772184|NCT00741234|DRUG|SB939|SB939 taken orally in a 4-week cycle.
223772185|NCT00741234|DRUG|Azacitidine|Azacitidine taken orally with SB939 in a 4-week cycle
224253109|NCT00905606|DRUG|Topiramate Tablets|
224253110|NCT00905606|DRUG|Topamax® Tablets|
224253111|NCT03975075|BEHAVIORAL|Psychophysiological monitoring|30 minutes of one channel (ECG) physiological monitoring with Mindfield eSense Pulse.
224253112|NCT03975075|BEHAVIORAL|Biofeedback training|Traditional resonance frequency training with the Mindfield eSense Pulse smartphone application. Using visual feedback of real time parameters of HRV and the use of controlled breathing, participants are trained to reach a relaxed state.
224253113|NCT04596670|DRUG|68Ga-ICAM-1pep|68Ga-ICAM-1pep PET/CT: after intravenous injection of 2.96 MBq/kg body weight of quality-controlled 68Ga-ICAM-1pep, a Siemens Biograph PET/CT scan will be applied within 1 h, and the scan range will be from the top of the head to 1/3 of the upper thigh.
224253114|NCT04599998|DIAGNOSTIC_TEST|spirometry, thoracic CT, CPET, 6 minute walking test, SF-36 questionnaire|Participants will perform spirometry, lung diffusion capacity of carbon monoxide, 6-minute walk test (6MWT), Short form-36 (SF-36) questionnaire and cardiopulmonary exercise testing (CPET) after 6-12 months (Visit 1) of COVID-19. Clinical, laboratory and chest image data during the COVID-19 hospitalization will be obtained from medical records.
224253115|NCT00443391|DRUG|ABT-089|Open label study, subjects will take up to 80mg daily for 24 months.
224253116|NCT01293474|DEVICE|Spectralis® SD-OCT, Heidelberg Engineering GmbH, H|Measurement of the choroidal thickness with Spectralis® SD-OCT
224253117|NCT05080894|DEVICE|Virtual reality|Embodiment of a healthy virtual body in virtual reality and action observation/motor imagery of the subject's virtual body performing high-level lower limb exercises.
224253118|NCT00459420|DRUG|Caffeine 100-200 mg BID|Caffeine 100 mg BID for three weeks, then 200 mg BID for three weeks, then 100 mg BID for 1 week, then placebo
224253119|NCT00459420|DRUG|placebo|placebo
224253120|NCT00849576|DRUG|Regular Human Insulin|0.10 U/Kg- 15 minutes before ingestion of a standardized liquid meal.
224253121|NCT00849576|DRUG|Insulin Lispro|90% of Regular Human Insulin dose administer immediately before ingestion of a standardized liquid meal.
223672567|NCT03223636|DEVICE|TMS|We will use TMS with paired-pulse technique to activate corticospinal neurons in the primary motor cortex and motorneurons in the brainstem, respectively (Hallett 2007; Ugawa et al. 1991; Ugawa et al.1994). Two stimulations will be separated with various interstimulus intervals to produce collision on nerve fibers with different conduction velocity in the corticospinal tract. The conduction time on nerve fibers in the corticospinal tract with different conduction velocity will be identified and the distribution of these fibers will be calculated.
223672568|NCT03223636|DEVICE|MRI|MRI exams will consist of several sessions including calibration, anatomic, and diffusion MRI scanning (Avram et al. 2013; Avram et al. 2016; Pierpaoli et al. 1996). Data in each exam will be acquired in the left or right forearm (PNS).
223672569|NCT04444427|DRUG|GLR2007|Administered orally, once daily for 21 days followed by a 7-day treatment holiday.
223672570|NCT00621400|DRUG|Lenalidomide|5 mg/day, orally for 21 days with 7 days rest (28 day cycle) for the first cohort; or 10mg/day, orally for 21 days with 7 days rest (28 day cycle) for the second cohort, 15mg/day, orally for 21 days with 7 days rest (28 day cycle) for the third cohort or 20mg/day, orally for 21 days with 7 days rest (28 day cycle) for the last and fourth cohort
223672571|NCT00621400|DRUG|Melphalan|0,18mg/Kg/day from day 1- 4
223672572|NCT00621400|DRUG|Dexamethasone|40mg/day from day 1- 4.
223672573|NCT02561910|DEVICE|Laparoscopic hernia repair|Preperitoneal mesh implantation because of inguinal hernia disease using the laparoscopic technique
223672574|NCT05143190|DRUG|PTR-01|Intravenous recombinant collagen 7
223672575|NCT00925171|BEHAVIORAL|Pulmonary Intervention|Maintenance programme of 2 hours duration, every 3 months. During the first hour patients will describe the extent to which they have been able to continue with their exercises at home on an individual basis and ways of enhancing adherence to this training will be discussed. Positive re-enforcement will be provided. Patients with suspected depression or social isolation will be referred to their GP for additional management. Patients will be advised on dyspnoea management strategies, especially controlled breathing combined with supervised activity exertion on activities relevant to their daily living. This will be followed by 1 hour of supervised strength and endurance training including walking, cycling, standing from sitting, arm exercises using dumbbells and step-ups. Patients will receive a written report on their progress by their physician and copied to their GP. This will be in addition to the standard advice given to the control group.
223672576|NCT01991639|OTHER|Nutritional and physical activity intervention|Buddies visit malnourished, frail, elderly subjects twice a week for approximately one hour and they perform nutritional and physical activity interventions.
223672577|NCT00583479|OTHER|one injection into the celiac ganglion|one injection into the celiac ganglion of the standard medication for CB for with chronic pancreatitis or pancreatic cancer
223772186|NCT00593372|BEHAVIORAL|Spaced Retrieval Training|Increasing time to remember important information.
224253122|NCT00849576|DRUG|Insulin VIAject™ (75%)|75 % of Regular Human Insulin dose administer immediately before ingestion of a standardized liquid meal
224253123|NCT00849576|DRUG|Insulin VIAject™ (90%)|90 % of Regular Human Insulin dose administer immediately before ingestion of a standardized liquid meal
224253124|NCT05236348|DEVICE|Aktiia.product-us|The study will collect data from subjects by means of the device under test and collect data from subjects by means of double-auscultation, pulse oximetry and volume-clamp BP reading while subjects wear the devices at different body positions and induce BP changes, during eight visits that will be held over the span of seven days, and generate performance reports.
224253125|NCT03591458|DRUG|Amitriptyline|Participants will receive a supply of Amitriptyline capsules for titration, intervention, and taper periods.
224253126|NCT03591458|DRUG|Placebo|Participants will receive a supply of Placebo capsules, matching those of Amitriptyline, for the titration, intervention, and taper periods
224253127|NCT00325663|PROCEDURE|Acupuncture|
224253128|NCT06167694|DRUG|HRS-8080; Dalpiciclib Isethionate Tablets|HRS-8080 combined with Dalpiciclib Isethionate Tablets
224253129|NCT06523842|OTHER|questionnaire|cronell questionnaire for assessment muscloskeletal discomfort in sedentary and standing workers males and females
224253130|NCT05547737|DRUG|Camrelizumab|Cross - line treatment of Camrelizumab in non-small cell lung cancer
224253131|NCT00804856|DRUG|Volasertib|Volasertib administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).
224253132|NCT00804856|DRUG|Cytarabine|Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.
224253133|NCT01796171|DRUG|10 MBq/kg Betalutin|
224253134|NCT01796171|DRUG|15 MBq/kg Betalutin|
224253135|NCT01796171|DRUG|20 MBq/kg Betalutin|
224253136|NCT01796171|DRUG|40 mg lilotomab|
223672578|NCT00583479|OTHER|two injections into the celiac ganglion|two injection into the celiac ganglion of the standard medication for CB for with chronic pancreatitis or pancreatic cancer
223672579|NCT05135312|DRUG|Etanercept|TNF-alpha inhibitors improve nail psoriasis.
224253137|NCT01796171|DRUG|100 mg/m2 lilotomab|
224253138|NCT01796171|DRUG|60 mg/m2 lilotomab|
224253139|NCT01796171|DRUG|Rituximab|
224253140|NCT01796171|DRUG|12.5 mBq/kg Betalutin|
224253141|NCT00418561|BIOLOGICAL|rhASA - Dose Level 1|Intravenous infusion 25 U/kg as a single dose - hereafter 50 U/kg every other week for 26 weeks
224253142|NCT00418561|BIOLOGICAL|rhASA - Dose Level 2|Intravenous infusion 100 U/kg every other week for 26 weeks
224253143|NCT00418561|BIOLOGICAL|rhASA - Dose Level 3|Intravenous infusion 200 U/kg every other week for 26 weeks
224253144|NCT05193461|PROCEDURE|Pulsed mood radiofrequency on dorsal root ganglion|3\) Pulsed radio frequency (PRF): PRF of the dorsal root ganglion (DRG) will be performed to all participants in this study. The procedures will be performed in the operating room under fluoroscopic guidance following radiation safety standards. The dorsal root ganglion of lumbosacral roots will be targeted. The patients will be positioned prone .Lidocaine 1% will be infiltrated at the skin entry site. A 10 cm, 22-gauge radiofrequency needle with a 5 mm curved active tip will be used. A radiculogram will be done to confirm appropriate placement and DRG will be stimulated for confirmation of the appropriate nerve root involved. Proximity of the needle to the DRG will be determined by appropriate sensory stimulation with 50 Hz (0.4-0.6 V), and motor stimulation at 2 Hz will be used to determine a threshold 1.5-2.0 times greater than the sensory threshold to avoid placement near the anterior nerve root. A pulsed lesion will be generated by applying 45 V to the DRG for 6 minutes at 42°C.
224253145|NCT01036009|OTHER|Withdrawal of immunosuppression and donor lymphocyte infusion|Intervention will involve fast withdrawal of immunosuppression and DLI until full donor chimerism is achieved.
224253146|NCT00829309|DRUG|Pravastatin|80 mg Tablet
224253147|NCT00829309|DRUG|Pravastatin|80 mg Tablets
224253148|NCT05569291|DEVICE|Automated Coaching Program (ACP)|A semiautomated tele coaching program (application installed on a smartphone device with real time feedback and motivational messages) and a step counter (Fitbit Charge 4) providing direct feedback on total daily number of steps, walking time, time in at least moderate PA and movement intensity during walking.
224253149|NCT05569291|OTHER|Manual Coaching Program (MCP)|A telecoaching program using a step counter (Fitbit Charge 4) without this custom smartphone application but with the Fitbit application. This intervention will be more focused on weekly personal feedback from a coach by telephone.
224253150|NCT05597982|OTHER|Kidney Transplant Fast Track (KTFT)|Streamlined KT evaluation involving completion of most or all testing on the same day a patient arrives for their first pre-transplant clinic appointment. Or, a transplant clinic scheduler secures testing within a 4 week period.
224253151|NCT05597982|OTHER|Peer Navigation (PN)|Uses trained, previous KT recipients who meet weekly to monthly with patient participants to provide tailored information and assistance in completing the necessary steps to proceed to transplant.
224253152|NCT04999501|OTHER|Prolonged resistance-type exercise training|All volunteers will be subjected to 12 weeks of whole-body resistance-type exercise training (3x/wk).
224253153|NCT01558635|DEVICE|Cardioblate CryoFlex Surgical Ablation|Longstanding persistent AF was treated with the Cox Cryo Maze III procedure During mitral valve surgery a surgical ablation was performed, using the Cardioblate CryoFlex Surgical Ablation System. In addition, the Medtronic Reveal XT Insertable Cardiac Monitor, was implanted.
224253154|NCT01558635|PROCEDURE|Mitral Valve surgery|Classic mitral valve surgery was performed
224253155|NCT01558635|DEVICE|Medtronic Reveal XT Insertable Cardiac Monitor|During the procedure, a Medtronic Reveal XT Insertable Cardiac Monitor was implanted to monitor episodes of AF during follow-up period
224253156|NCT01558635|PROCEDURE|MAZE III|Longstanding persistent AF was treated with the Cox Cryo Maze III procedure
224253157|NCT03651739|DEVICE|Knee Connect|An electronic goniometer with smart phone application
224253158|NCT05911152|PROCEDURE|Intracorporeal anastomosis|Surgeons perform totally laparoscopic intracorporeal digestive reconstruction after specimen resection
224253159|NCT04278261|PROCEDURE|Focal therapy(high-frequency irreversible electroporation)|High-frequency irreversible electroporation will be performed via the perineum with the guidance of ultrasound under general anaesthesia to the patient with localized prostate cancer
223672580|NCT05135312|DEVICE|OCT|Optical Coherence Tomography is a noninvasive imaging device that can be used to monitor nail disease severity.
223672581|NCT00333203|DRUG|Next Generation Ophthalmic Irrigating Solution (NGOIS)|Volume sufficient to irrigate adequately during cataract surgery
223772187|NCT03188965|DRUG|Elimusertib (BAY1895344)|Solution or tablet, oral, to be administered until evidence of tumor progression, unacceptable toxicity, consent withdrawal, or withdrawal from the study at the discretion of the investigator.
223772188|NCT02212730|DRUG|Pembrolizumab Pre-Resection|200 mg administered by IV, once every 3-week cycle for a maximum of 2 cycles
223772189|NCT02212730|PROCEDURE|Surgical Resection|Standard of care surgical resection of RCC tumor
223772190|NCT02212730|DRUG|Pembrolizumab Post-Resection|200 mg administered by IV, once every 3-week cycle for a maximum of 17 cycles
223772191|NCT03730935|DEVICE|Respiratory muscle endurance training|Respiratory muscle endurance training performed over the duration of 4 weeks
224253160|NCT04278261|PROCEDURE|laparoscopic radical prostatectomy|Laparoscopic radical prostatectomy
223672582|NCT00333203|OTHER|BSS Plus|Volume sufficient to irrigate adequately during cataract surgery
224253161|NCT00404183|DRUG|Extended-Release Hydrocodone/Acetaminophen|2 tablets BID
224253162|NCT00404183|DRUG|Placebo|2 tablets BID
224253163|NCT01683045|DEVICE|The Estech COBRA® Surgical System|The Estech COBRA® Surgical System has been designed to create epicardial and endocardial lesions on the heart using temperature controlled radiofrequency (TCRF) ablation with the Estech COBRA surgical probes. Temperature control provides a meaningful endpoint, maintaining tissue at safe yet effective temperatures to produce the desired lesion set. Internal probe cooling and advanced suction helps to ensure reproducible transmural (full-thickness) endocardial or epicardial lesions.
224253164|NCT05149066|BEHAVIORAL|#KindGirlsInACTion|9-session weekly cognitive-behavioural intervention to promote psychological well-being and prevent body image and eating-related disordered behaviours.
224253165|NCT03950362|DRUG|Avelumab|Administration of Avelumab 10mg/kg Infuse IV over 30-minutes: 1 cycle 5 days before External Beam RadioTherapy, then every 21 days x 8 cycles (6 months)
223672583|NCT02641483|OTHER|Electrical Rectal Stimulation|Electrical stimulation of the rectum will be applied to activate sensory afferent neurons of the rectum and evoke a recto-colonic reflex to improve colonic motility. This intervention will compared to individuals' usual mechanical intervention of digital rectal stimulation.
223672584|NCT04216914|DEVICE|Hand outline|A simple outline of a hand, to which the child tried to match their own hand on order to improve positioning.
223672585|NCT04344288|DRUG|Prednisone|The experimental group will receive oral prednisone during 10 days (0.75 mg/kg/day during 5 days then 20 mg/day during 5 more days)
223672586|NCT04344288|OTHER|Control group|The control group will receive standard of care according to the international recommendations and practices of the investigational site. No corticosteroid therapy can be prescribed in this group.
223672587|NCT05588804|DRUG|Broncho-munal®|1 capsule daily in the morning on an empty stomach, 30 minutes before meals, for 10 consecutive days
223672588|NCT05588804|DRUG|Placebo|1 capsule daily in the morning on an empty stomach, 30 minutes before meals, for 10 consecutive days
223672589|NCT05771168|DEVICE|Artificial urinary sphincter|Implantation of peri-urethral artificial urinary sphincter
223672590|NCT05771168|DEVICE|Male sling|Retrourethral implantation of male sling
223672591|NCT04890743|OTHER|Kinesiotherapy combined with electrotherapy (Convenctional TENS method).|One of the four groups created during randomization will undergo a unified program of kinesiotherapy and electrotherapy (Conventional TENS method).
223672592|NCT04890743|OTHER|Kinesiotherapy combined with electrotherapy (Pseudo-acupuncture TENS method).|One of the four groups created during randomization will undergo a unified program of kinesiotherapy and electrotherapy (Pseudo-acupuncture TENS method).
223672593|NCT04890743|OTHER|Kinesiotherapy combined with electrotherapy (Trabert ultrastimulation method)|One of the four groups created during randomization will undergo a unified program of kinesiotherapy and electrotherapy (Trabert ultrastimulation method).
223672594|NCT04890743|OTHER|Kinesiotherapy combined with placebo electrotherapy|One of the four groups created during randomization will undergo a unified program of kinesiotherapy and placebo electrotherapy.
223672595|NCT02651181|DEVICE|HLCL- Hybrid Logic Closed Loop System|All subjects wearing the HLCL System and using it with the closed loop algorithm
223672596|NCT04322201|DEVICE|continuous drainage of ascitic fluid using an intra-abdominal double lumen central venous catheter|Ultrasound-guided placement of an intra-abdominal double lumen central venous catheter, using aseptic Seldinger technique, for continuous drainage of ascitic fluid up to 7 days in Intensive Care
223672597|NCT04322201|PROCEDURE|Ultrasound-guided intermittent large-volume paracentesis|Ultrasound-guided intermittent large-volume paracentesis through 14 Gauge catheter
223772192|NCT05520671|OTHER|Gamified online quizzing platform|"TESLA-G is a novel gamified quizzing platform designed based on Bloom's taxonomy of learning domains. Questions will be created in blocks, where each block will test a specific topic within a specialty (endocrine surgery has been selected for this study). Each block has 5 questions, and each question corresponds to each level of Bloom's taxonomy and each level in game.~For this study, we aim to create 56 blocks of 5 questions, totalling 280 questions. All questions will be created by two board-certified general surgeons and one endocrinologist, and validated by the research team.~The aim of the game is for players to get as many points as they can before the timer runs out. Gamification elements include levels, countdown timer, lives, a point multiplier system, leaderboard rankings and a personalised dashboard.~Participants in the intervention group will be provided with a link to access TESLA-G, sent from an automated Telegram bot; this access will be provided for 14 days."
223672598|NCT02355873|DEVICE|AN69ST hemofilter|
224253166|NCT03950362|DEVICE|Radiotherapy|60-66 Gy in 30-33 Fractions (2 Gy/fractions) given to the whole bladder
224253167|NCT06539273|DRUG|Exosome Complex, RNA|A total of 3 mL of exosomes (2 mL to the frontal and 1 mL to the vertex region) was injected using napage technique (10¹⁰ extracellular vesicles in 1 mL)
224253168|NCT00455312|DRUG|Campath 1H|10, 9, 8, 7, and 6 days before transplant subjects will be given 1 dose of campath 1H given via catheter (0.2 mg/kg over 2 hours).
223672599|NCT02355873|DEVICE|AN69 hemofilter|
223672600|NCT03705624|OTHER|Enhanced Community Case Management (CCM)|Enhanced Community Case Management for malaria (CCM) involving weekly active screening for fever using a research-grade thermometer by a trained health worker. A measured temperature ≥37.5°C or reported fever in the last 24 hours will prompt screening with a conventional rapid diagnostic test (RDT). RDT positive individuals will be treated with AL according to national guidelines
223672601|NCT03705624|OTHER|Monthly Screening and Treatment (MSAT)|Monthly Screening and Treatment (MSAT) regardless of symptoms with a conventional RDT. Screening will be performed by research staff with 25-35 days between screening rounds; RDT positive individuals will be treated with AL according to national guidelines.
223672602|NCT03639532|PROCEDURE|COC THA|standard total hip arthroplasty is done, with ceramic on ceramic for the bearing.
223672603|NCT03639532|PROCEDURE|COP THA|standard total hip arthroplasty is done, with ceramic on highly cross linked polyethylene for the bearing.
223672604|NCT03583203|DEVICE|personalized information about lung damage|Chronic obstructive pulmonary disease (COPD) will be evaluated using spirometry. Based on this value, a motivational message about prevention will be issued for the intervention group, which will be reinforced by individualized text messages over a period of 3 months
223672605|NCT02806193|PROCEDURE|Cardiovascular Magnetic Resonance Imaging|"Cardiac magnetic resonance imaging (CMR) has emerged as both a remarkably powerful diagnostic and prognostic tool for the assessment of cardiovascular disease. The high spatial resolution of CMR and the ability to characterize soft tissue provides the opportunity for unique diagnostic assessment of a myriad of cardiac pathology, including ischemic heart disease (IHD), preoperative assessment, intra- cardiac mass and thrombus, pericardial disease, valvular heart disease, and cardiomyopathy evaluation.~Between individual CMR programs, GCMR will offer information useful in assessing the differences in protocol, performance, and clinical adaptation by varying geographic regions, institutional environments, and expertise. Such an assessment is critical for uncovering possible reasons for disparities in performance and obtaining opportunities for advancement."
223672606|NCT06482918|BEHAVIORAL|Cognitive Remediation|Computer-assisted top-down or bottom-up cognitive remediation using tablets
224253169|NCT00455312|DRUG|Cyclophosphamide|7 days before the transplant, 1 dose of cyclophosphamide is given via catheter (50mg/kg IV over 2 hours).
224253170|NCT00455312|DRUG|Fludarabine|6, 5, 4, 3, and 2 days before the transplant, 1 dose fludarabine is given via catheter (40 mg/kg IV over 1 hour)
224253171|NCT00455312|PROCEDURE|Total Body Irradiation|1 day before the transplant one dose (200 cGy) of total body irradiation is given
224253172|NCT00455312|PROCEDURE|Stem Cell Transplantation|Infusion of stem cells on Day 0.
224253173|NCT00455312|DRUG|antithymocyte globulin|ATG (rabbit) 3 mg/kg for 3 days.
224253174|NCT00455312|DRUG|Methylprednisolone|2mg/kg IV is given before each dose of antithymocyte globulin (ATG).
224253175|NCT05636735|OTHER|data collection|evaluation of self -confidence
224253176|NCT03763435|BEHAVIORAL|Antenatal pregnancy classes|At least three comprehensive full-day educational program covering all the stages of pregnancy.
224253177|NCT06028204|DRUG|Biologic Agent|Biologic group will have biological agent commenced if considered necessary as part of routine care.
223672607|NCT00332371|DEVICE|CPFA (Coupled Plasma Filtration Adsorption)|"CPFA is a specific method for the treatment of sepsis.~It consists of:~1. a plasma-filter (polyethersulfone 0.45 m2 with a cutoff of approx 800 kDa)~2. a hemofilter (polyethersulfone 1,4 m2)~3. a cartridge (contains approximately 140 ml of hydrophobic styrenic resin)~The kit is lodged in the Bellco Lynda machine (Bellco Mirandola, Italy). The treatment consists of the separation of plasma from the whole blood with adsorption of the inflammatory mediators and cytokines from the plasma, and a subsequent purification step by way of a hemofilter."
223672608|NCT02316873|BEHAVIORAL|Music training|This program was based on the Kodaly and Orff pedagogy and adapted to focus on rhythm and temporal processing.
223672609|NCT02316873|BEHAVIORAL|Visual arts|This program emphasized visual-spatial and hand skills as well as creativity.
223672610|NCT01680510|DIETARY_SUPPLEMENT|Alga Dunaliella Bardawil|
223672611|NCT01680510|OTHER|Placebo (starch)|
223672612|NCT05583669|DRUG|DS-2325a|Subcutaneous injection (starting dose 300 mg)
223672613|NCT05583669|DRUG|Placebo|Subcutaneous injection
223672614|NCT02234856|PROCEDURE|Laparoscopic Hysterectomy trainer|In order to increase comfort level amongst Gynecologists, we aim to identify verbal and non-verbal components of teaching TLH through interview and video recordings. Utilizing qualitative analysis of common themes, we will develop an educational video and web-based e-module to be used by Gynecology residents and surgeons. We will also use a combination of quantitative pre- and post-tests and qualitative surveys to assess the effectiveness of such a training tool. Ultimately, the project aims to create a robust tool that can be implemented in Gynecology residencies.
223672615|NCT01887301|DRUG|Sativex|Patients receive four sprays (each 100 uL) of Sativex to the oral mucosa, which contain 10.8 mg THC and 10 mg CBD in total.
223672616|NCT01369654|BEHAVIORAL|Computerized decision aid with 1 type of value clarification|Women will be instructed to view a computerized BSO decision support guide.
223672617|NCT01678937|PROCEDURE|Blood Draw - Rapamycin|Ten calcineurin-inhibitors (CNI) monotherapy or dual therapy (CNI+MMF) patients will have blood taken (40 ml=8 tsp.) 2 wks. prior to conversion, 3-6 months post successful conversion. 1) Regulatory/Suppressor Cells (CD4+CD25+FOXP3+CD127low; and CD8+ CD28-FOXP3+CD127low cells). 2) Dendritic cell assays: myeloid vs. lymphoid (CD11c; CD123); maturation and ability to process antigens (CD83; CD205); markers shown to induce regulatory T cells (ILT3; ILT4), 3) Soluble HLA G, and 4) Liver function/drug levels. If problems develop during conversion (e.g. acute rejection, significant drug side effects) requiring discontinuation of rapamycin, MMF and/or reversion to CNI therapy, assays will not be performed. Monthly liver function/drug levels performed after successful conversion (standard of care).
223672618|NCT01678937|PROCEDURE|Blood Draw from Control Subjects|"Ten healthy individuals will have blood drawn (40 ml = 8 teaspoons (tsps.)).Blood will be drawn at one time point for the following:~* Dendritic cell assays: myeloid vs. lymphoid (CD11c; CD123); maturation and ability to process antigens (CD83; CD205); markers that have been shown to induce regulatory T cells (ILT3; ILT4).~* Regulatory/Suppressor Cells (CD4+CD25+FOXP3+CD127low; and CD8+ CD28- FOXP3+CD127low cells).~* HLA microchimerism \& HLA G"
223672619|NCT01678937|PROCEDURE|Blood Draw - CyA|"Blood drawn from 10 patients on cyclosporine (CyA) (40 ml = 8 tsp.)). Blood will be drawn at one time point for the following:~* Dendritic cell assays: myeloid vs. lymphoid (CD11c; CD123); maturation and ability to process antigens (CD83; CD205); markers that have been shown to induce regulatory T cells (ILT3; ILT4).~* Regulatory/Suppressor Cells (CD4+CD25+FOXP3+CD127low; and CD8+ CD28- FOXP3+CD127low cells).~* HLA microchimerism \& HLA G"
223672620|NCT01678937|PROCEDURE|Blood Draw - Tacrolimus|"Blood drawn from 5 patients on Tacrolimus (40 ml = 8 tsp.) at one time point for the following:~* Dendritic cell assays: myeloid vs. lymphoid (CD11c; CD123); maturation and ability to process antigens (CD83; CD205); markers that have been shown to induce regulatory T cells (ILT3; ILT4).~* Regulatory/Suppressor Cells (CD4+CD25+FOXP3+CD127low; and CD8+ CD28- FOXP3+CD127low cells).~* HLA microchimerism \& HLA G"
223672621|NCT01678937|PROCEDURE|Blood Draw - MMF|"Blood will be drawn from 10 patients on mycophenolate mofetil (MMF) (40 ml or the equivalent of 8 teaspoons). Blood will be drawn at one time point for the following analysis:~* Dendritic cell assays: myeloid vs. lymphoid (CD11c; CD123); maturation and ability to process antigens (CD83; CD205); markers that have been shown to induce regulatory T cells (ILT3; ILT4).~* Regulatory/Suppressor Cells (CD4+CD25+FOXP3+CD127low; and CD8+ CD28- FOXP3+CD127low cells).~* HLA microchimerism \& HLA G"
224253178|NCT02641444|PROCEDURE|Blood plasma collection|Approximately 3mL of blood will be taken from each subject just prior to the colonoscopy.
224253179|NCT02641444|PROCEDURE|Cervical and Vaginal Biopsy|2 biopsies each will be collected from the vaginal wall and the cervix
224253180|NCT02641444|PROCEDURE|Colonoscopy with Ileal and Rectal Biopsy|10 biopsies each will be collected from the rectum and terminal ileum from each subject during the colonoscopy.
224253181|NCT06095401|OTHER|Inelastic adjustable compression garment (INCOM)|Immediately following surgery, participants randomized to INCOM will wear an inelastic adjustable compression garment set to a minimum of 30mm Hg of compression utilizing a standardized garment tensioning tool. Participants will be instructed to wear the compression garment during waking hours with a target wear time of 80% of waking hours. Participants will participate in a standardized rehabilitation program
224322237|NCT02143466|DRUG|Part B - AZD9291 in combination with AZD6094|Part B - AZD9291 and AZD6094 administered in the dose identified in Part A (AZD9291 80mg OD + AZD6094 600mg OD) to further investigate the safety and tolerability of this combination.
223772193|NCT05520671|OTHER|Conventional quizzing platform|"The conventional quizzing platform will be a modified version of TESLA-G with all gamification elements removed. The same set of questions as the gamified version will be used. Upon entering the quiz, a question stem and five choices will be shown. When an option is selected, the right answer along with its explanation will be indicated. The next question will then be sent, and this process repeats until the participant leaves the platform or has answered every question.~Questions will be queued in blocks, with each block corresponding to a particular topic in endocrine surgery. Unlike the gamified version, questions within each block will be randomised, regardless of their level on the Bloom's taxonomy. Participants will also not be informed of the level of Bloom's taxonomy for individual questions. The access link to the platform will be sent to participants from an automated Telegram bot, and this access will last for 14 days."
223772194|NCT03112434|DRUG|Botulinum toxin type A|Botox injection in upper extremity for spasticity in pediatric CP patients
223772195|NCT02880371|DRUG|ARRY-382|ARRAY-382 will be taken by mouth once daily at a fixed dose.
223772196|NCT02880371|DRUG|Pembrolizumab|Pembrolizumab will be administered intravenously over 30 minutes every 3 weeks.
224253182|NCT06095401|OTHER|Elastic compression garment (CONTROL)|Immediately following surgery, participants randomized to CONTROL will wear a thigh-length elastic compression garment (thromboembolism-deterrent \[TED\] hose) for the first 3 weeks after TKA. Participants will be instructed to wear the compression garment during waking hours with a target wear time of 80% of waking hours. Participants will participate in a standardized rehabilitation program
224253183|NCT05187481|DRUG|Jianpi Huatan dispensing granule|once a day in the morning and evening, 30 days as a course of treatment, a total of 3 courses.
224253184|NCT05187481|DRUG|Placebo granule|once a day in the morning and evening, 30 days as a course of treatment, a total of 3 courses.
223672622|NCT01678937|PROCEDURE|Blood Draw - Rapamycin|"Blood drawn from 10 patients on rapamycin (40 ml = 8 tsp.)) at one time point for the following:~* Dendritic cell assays: myeloid vs. lymphoid (CD11c; CD123); maturation and ability to process antigens (CD83; CD205); markers that have been shown to induce regulatory T cells (ILT3; ILT4).~* Regulatory/Suppressor Cells (CD4+CD25+FOXP3+CD127low; and CD8+ CD28- FOXP3+CD127low cells).~* HLA microchimerism \& HLA G"
223672623|NCT05238571|PROCEDURE|Re-surgery|Re-surgery with meshectomy and selective neurectomy
223672624|NCT03293511|DRUG|intranasal oxytocin|24 IU of oxytocin nasal spray will be applied to each subject.
223672625|NCT03293511|DRUG|intranasal placebo|24 IU of of placebo nasal spray will be applied to each subject.
223672626|NCT03117088|OTHER|Checklist ISBAR3|"Checklist ISBAR 3~Use of an online based checklist for handovers with the following items:~Identification Situation Background Assessment Recommendation Read- back Risk~Established Checklist as communication tool"
223672627|NCT03117088|OTHER|Checklist VICUR|"Checklist Vicur~Use of an online based alternative checklist for handovers with the following items:~Vaccination status Insurance status Contact person Utilisation Rehabilitation Organ donor? Patient decree?~alternative checklist missing communication tool"
223672628|NCT02824172|OTHER|cast immobilization group|Patients in this group will have their knee locked with a resin going from the ankle to the top of the thigh for 4 weeks, followed by 4 weeks without cast but with rehabilitation through physiotherapy.
223672629|NCT02824172|OTHER|complete sport rest.|Patients included in this group will follow the current standard procedure for this disease that is to say complete sport rest during 8 weeks including rehabilitation through physiotherapy, following the exact same technic as the experimental group .
223772197|NCT02879097|BIOLOGICAL|CBT124|Induction Phase: CBT124 15 mg/kg IV infusion-Day 1 of each 3-week Cycle for 6 cycles; Carboplatin AUC 6 mgXmin/mL (calculation-Calvert formula recommended) on Day 1 of each 3-week Cycle for 6 cycles; Paclitaxel 200 mg/m2 on Day 1 of each 3-week Cycle for 6 cycles. Maintenance Phase: All the subjects who complete the induction phase and are alive at Week 19 without progression of the disease can be included in the maintenance phase and receive CBT124 (bevacizumab, 15 mg/kg, intravenous infusion on Day 1 of each 3-week Cycle) up to disease progression or unacceptable toxicity (that precludes further treatment with bevacizumab) or death.
223772198|NCT02879097|BIOLOGICAL|EU-sourced Avastin®|Induction Phase: EU-sourced Avastin® 15 mg/kg IV infusion-Day 1 of each 3-week Cycle for 6 cycles; Carboplatin AUC 6 mgXmin/mL (calculation-Calvert formula recommended) on Day 1 of each 3-week Cycle for 6 cycles; Paclitaxel 200 mg/m2 on Day 1 of each 3-week Cycle for 6 cycles. Maintenance Phase: All the subjects who complete the induction phase and are alive at Week 19 without progression of the disease can be included in the maintenance phase and receive CBT124 (bevacizumab, 15 mg/kg, intravenous infusion on Day 1 of each 3-week Cycle) up to disease progression or unacceptable toxicity (that precludes further treatment with bevacizumab) or death.
223772199|NCT02879097|DRUG|Carboplatin|Induction Phase: Carboplatin AUC 6 mgXmin/mL (calculation-Calvert formula recommended) on Day 1 of each 3-week Cycle for 6 cycles.
223772200|NCT02879097|DRUG|Paclitaxel|Induction Phase: Paclitaxel 200 mg/m2 on Day 1 of each 3-week Cycle for 6 cycles.
224253185|NCT06561516|PROCEDURE|Arm I (Red ginseng)|"Step 1. Confrim the inclusion and exclusion criteria to select participants and abtain informed consent before surgery.~Step 2. Before surgery, research nurses randomly assign patients to either the Red ginseng or Control group (single-blind study).~Step 3. Blood tests and stool samples following rectal enema are collected from all patients before surgery.~Step 4. Depending on the type of gastrointestinal cancer (stomach cancer, pancreatobiliary cancer, colorectal cancer), radical resection surgery is performed.~Step 5. From 1 to 4 months after surgery, a three months period is designated for the Red ginseng group to take red ginseng tablets as instructed, with compliance assessements included.~Step 6. Four months after surgery, blood tests and stool samples are collected from all patients.~Step 7. After obtaining samples from the final registered patients, we will commission a contracted institution to conduct microbiome analysis test."
223672630|NCT04653532|BEHAVIORAL|Exercise Programme and Counselling|A 6 month exercise and physical activity programme supported by an exercise specialist
223672631|NCT04653532|DEVICE|Polar Ignite and App|A fitness watch that links to a mobile phone application (App) which enables the exercise specialist to provide greater support and feedback throughout the programme
223772201|NCT00854087|DRUG|Fuzheng Huayu|The subjects will be taking 2 tablets three times a day for 48 weeks.
223772202|NCT00854087|DRUG|Placebo|The subjects will be taking 2 tablets three times a day for 48 weeks.
223672632|NCT06415513|OTHER|ASMR|We used 7 ASMR videos published on the most watched ASMR channel on the YouTube platform, in which applications such as hair combing, brushing, massaging the head are applied sequentially and repeatedly, and there is no speech.
223672633|NCT03109314|DRUG|Donepezil|Donepezil will be administered to subjects three days before each training, and during training, to evaluate if donepezil improves the effectiveness of training.
223672634|NCT03109314|BEHAVIORAL|Single-letter training|Subjects will undergo training to identify single letters (10,000 trials, or 10 blocks per session for 10 sessions).
223672635|NCT03109314|BEHAVIORAL|Uncrowd training|Subjects will undergo training to identify letters closely flanked by other letters (10,000 trials, or 10 blocks per session for 10 sessions).
223672636|NCT05101551|DRUG|Talazoparib|"Talazoparib will be administered in escalating doses based on current dose level.~* Dose Level 1: 400 µg/m2/dose once daily~* Dose Level 2: 600 µg/m2/dose BID on Day 1, then daily on Days 2 to 5~* Dose Level 3: 600 µg/m2/dose BID on Day 1, then daily on Days 2 to 5~* Dose Level 4: 600 µg/m2/dose BID on Day 1, then daily on Days 2 to 5~* Dose Level 5: 600 ug/m2/dose BID on Day 1, then daily on Days 2 to 5 and 15 to19"
223672637|NCT05101551|DRUG|Topotecan|"Administered IV route on Days 1 to 5~* Dose Level -2: 1 mg/m2/dose once daily by IV days 1 to 5~* Dose Level -1: 2 mg/m2/dose once daily by IV days 1 to 5~* Dose Level 1: 2 mg/m2/dose once daily by IV days 1 to 5~* Dose Level 2: 2 mg/m2/dose once daily by IV days 1 to 5~* Dose Level 3: 3 mg/m2/dose once daily by IV days 1 to 5~* Dose Level 4: 4 mg/m2/dose once daily by IV days 1 to 5~* Dose Level 5: 4 mg/m2/dose once daily by IV days 1 to 5"
223672638|NCT05101551|DRUG|Gemcitabine|"Single dose (IV) of gemcitabine on Day 1 of each 28 day cycle for 1 cycle.~* Dose Level -2: 600 mg/m2/dose once daily by IV days 1~* Dose Level -1: 600 mg/m2/dose once daily by IV days 1~* Dose Level 1: 1200 mg/m2/dose once daily by IV days 1~* Dose Level 2: 1200 mg/m2/dose once daily by IV days 1~* Dose Level 3: 1200 mg/m2/dose once daily by IV days 1~* Dose Level 4: 1200 mg/m2/dose once daily by IV days 1~* Dose Level 5: 1200 mg/m2/dose once daily by IV days 1"
223672639|NCT02480036|RADIATION|IORT with Kyphoplasty|IORT with kyphoplasty is give concurrently for the treatment of spinal metastases
223672640|NCT02480036|DEVICE|Intrabeam®|
223672641|NCT04941625|DIAGNOSTIC_TEST|serum cystatin C|blood sampling
223672642|NCT04941625|DIAGNOSTIC_TEST|serum beta-microglubulin|blood sampling
223672643|NCT04941625|DIAGNOSTIC_TEST|urine|neutrophil gelatinase-associated lipocalin
223672644|NCT04892368|OTHER|Home-based supervised exercise program|Combination of aerobic and strength training exercises, in addition to home exercise instructions issued during preoperative physiotherapy education.
223672645|NCT05407740|OTHER|no intervention study|no intervention study
223672646|NCT03811093|DEVICE|Care as Usual Group|"Each participant randomly assigned to the Care As Usual Group will undergo nine therapy sessions over three weeks using a fully functioning invisa-RED Technology Elite device."
223672647|NCT03811093|DEVICE|Sham Group|"Each participant randomly assigned to the Sham Group will undergo nine therapy sessions over three weeks using a non functioning invisa-RED Technology Elite device."
223672648|NCT00476567|OTHER|standard|standard antenatal care
223672649|NCT00476567|BEHAVIORAL|specific training program|a specific training program 12 weeks between pregnancy week 20 and 36. regular exercise 45-60 minutes minimum three times per week.
224253186|NCT06094023|OTHER|Food Frequency Questionnaire|Food frequency questionnaires (FFQs) are a common method for measuring dietary intake in large epidemiological studies, in particular in low literacy settings were diaries and food history would not be viable.
223672650|NCT00464490|DRUG|Dexmedetomidine|Dexmedetomidine .5mcg/kg/hr-.7mcg/kg/hr 1hour prior to extubation. Dexmedetomidine will be titrated according to blood pressure, RASS and heart rate response and the dose will be lowered only after sedation is discontinued or markedly reduced.
223672651|NCT00164697|BEHAVIORAL|Parenting group|Weekly and periodic (10 weeks blocks with 6 week break) parenting group meetings (2.5-3 hr), periodic one-on-one meetings (2 hr), visits to community resources (2-3 hr per event). Legacy intervention activities are designed to enhance sensitive and responsive parenting, parent/child interaction, and promote a sense of community. Other activities include verbal and cognitive stimulation through parent and parent/child group meetings, visits to the home, and participation in community events.
223672652|NCT05537987|DRUG|ICP-723|3+3 dose escalation
223672653|NCT06406153|BIOLOGICAL|Laronidase|Laronidase as Aldurazyme® (the first 12 weeks) or YW17 (the second 12 weeks) is administered.
223672654|NCT06406153|DRUG|Antihistamine|An antihistamine is administered one hour before the infusion.
223672655|NCT06406153|DRUG|Antipyretic|An antipyretic is administered one hour before the infusion.
223672656|NCT00347256|DRUG|cisplatin|
223672657|NCT00347256|PROCEDURE|targeted radiation therapy|
223672658|NCT00347256|PROCEDURE|tumor resection|
223672659|NCT05423223|DEVICE|Paraffin Bath Therapy|Device named 'Fizyowax 1300' (Fizyomed, Turkey).
223672660|NCT05423223|DEVICE|Extracorporeal Shock Wave Therapy|Device named 'Elettronica Pagani,Italy' and will be used with radial probe.
223672661|NCT05344755|OTHER|Plantar Sensorial Training|In addition to the routine treatment, plantar sensorial training will be added.
223672662|NCT05344755|OTHER|Control Group|Routine physiotherapy management of the Hallux valgus
223672663|NCT06339476|DIAGNOSTIC_TEST|Serum ADMA, MDA and M30 levels mesurment|Blood samples collected from patienst, only 7 mL
223672664|NCT03188042|DEVICE|rtACS Stimulation|Electric current stimulation; rtACS is a non-invasive application of electric current to stimulate the retina to induce synaptic efficacy, in particular those cells that have some measure of dysfunction but are not dead, and oscillations of nearby neuronal ensembles.
223672665|NCT03188042|DEVICE|Sham Intervention|A computer-controlled sham stimulation function for masking interventionist to study group. The device will be used to deliver a weak electric current stimulation protocol to participants via electrodes placed transorbitally, with one reference electrode positioned elsewhere.
223672666|NCT02407145|OTHER|24 month follow up of women with validated questionnaire|24 month follow up (clinical and questionnaire based) of women who are already assigned to have a PVDF retropubic midurethral sling (DynaMesh®-SIS soft) as a part of their planned treatment of urodynamic stress incontinence.
224253187|NCT06094023|OTHER|24 Hour food recall|Standardized and validated approach of collecting all foods, beverages, and supplements consumed during the past 24 hours.
224253188|NCT01693523|DRUG|Minocycline|100 mg by mouth two times a day (200 mg/day).
224253189|NCT01693523|OTHER|Placebo|Matching placebo capsules by mouth twice a day.
224253190|NCT01693523|BEHAVIORAL|Questionnaires|Questionnaires completed at baseline, 1 time each week during drug/placebo administration, and at end of study visit.
224253191|NCT02736123|DRUG|Nivolumab - Arm A|Nivolumab will be given during the induction phase of the study for 6 weeks. This is followed by surgery. Then maintenance therapy (after recovery from surgery).
224253192|NCT02736123|DRUG|Nivolumab + Ipilimumab - Arm B|Nivolumab + ipilimumab during the induction phase of the study for 6 weeks. This is followed by surgery (week 6-8+). Then maintenance therapy will be initiated for up to one year from study drug initial administration ((after recovery from surgery).
224253193|NCT02765724|DRUG|Pacritinib|Pacritinib 400 mg (4 capsules of 100 mg each), single dose, oral administration
224253194|NCT03343535|DEVICE|OCS Lung Preservation|OCS Lung Preservation
224253195|NCT05832658|DEVICE|With EMG-Biofeedback|Once a day for a total of 15 sessions, the Mendelsohn maneuver will be performed for 15 minutes and the effortful swallow maneuver will be performed for 15 minutes with game-based emg-biofeedback.
224253196|NCT05832658|BEHAVIORAL|Without EMG-Biofeedback|Once a day for a total of 15 sessions, the Mendelsohn maneuver will be performed for 15 minutes and the effortful swallow maneuver will be performed for 15 minutes with only verbal feedback.
224253197|NCT05832658|BEHAVIORAL|Usual Care|Patient and family education will be provided by the investigator. In addition, each patient will be evaluated and oral motor exercises and thermal tactile stimulation will be given to each patient when necessary.
224253198|NCT04215718|PROCEDURE|fistulotomy and marsupialization|the anal fistula was laid open and the the wound edges was marsupialized using vicryle 3\\0 sutures
224253199|NCT04215718|PROCEDURE|fistulectomy and wound closure|anal fistula was excised with both openings and the wound was closed
224253200|NCT02300935|DRUG|trametinib|
224253201|NCT02300935|DRUG|nab-paclitaxel|
224253202|NCT01045018|DRUG|Placebo|placebo 400 mg
224253203|NCT01045018|DRUG|Mesalamine|
224253204|NCT01045018|DRUG|Mesalamine|
224253205|NCT06440343|DIETARY_SUPPLEMENT|Carbohydrates|60g of maltodextrin + fructose, 2:1 ratio
224253206|NCT06440343|DIETARY_SUPPLEMENT|Placebo|Placebo
224253207|NCT02134379|DEVICE|Medtronic ICDs, CRT-Ds, and CRT-Ps|Any Medtronic implantable cardioverter defibrillator (ICD) or cardiac resynchronization therapy (CRT) device. Device must have capacity to measure thoracic impedance as described in protocol. This includes the majority of FDA-approved Medtronic devices currently in use.
224253208|NCT04303884|DRUG|Pembrolizumab Injection [Keytruda]|Pembrolizumab administration at a fix dose of 200 mg every 3 weeks
224253209|NCT03059979|DRUG|Methylprednisolone|methylprednisolone 1000 mg dissolved in 100 cc of NaCl 0.9%, by intravenous infusion in 30 minutes on three consecutive days Three-day treatment courses are given at week 0, week 4 and week 8.
224253210|NCT03059979|OTHER|sodium chloride|100 cc of NaCl 0,9% , administered by intravenous infusion in 30 minutes on three consecutive days Three-day treatment courses are given at week 0, week 4 and week 8.
223772203|NCT01777997|DRUG|Emtricitabine/rilpivirine/tenofovir disoproxil fumarate|"Step 1: From entry through week 12, the participants received no study treatment. From week 12 through week 60, the participants received one fixed dose combination emtricitabine/rilpivirine/tenofovir disoproxil fumarate (FTC/RPV/TDF) tablet daily.~Step 2 (Optional): From week 60 through week 108, the participants either received one FTC/RPV/TDF tablet daily or no study treatment."
223772204|NCT03341624|PROCEDURE|cataract surgery cataract extraction and intraocular implantation|
223772205|NCT04667819|DRUG|Sodium Hyaluronate|We usage a special type of anterior eye drug delivery system to conduct the transmission of sodium hyaluronate in dry eye patients.
224253211|NCT06561659|BEHAVIORAL|Exercise Condition|Already described in the arm description
224253212|NCT06561659|BEHAVIORAL|Relaxation Control Condition|Already described in the arm description
224253213|NCT03407287|PROCEDURE|Peripheral Intravenous Analysis (PIVA)|Non-invasive measurement of peripheral venous waveform analysis (PIVA) obtained by connecting a standard transducer (AD Instruments, Colorado Springs, Co) to a universal adaptor or stopcock on a peripheral IV
224253214|NCT03407287|PROCEDURE|Standard of care invasive vascular monitoring|Standard of care invasive monitoring in the intensive care settings with central venous catheters, pulmonary artery catheters, or trans-esophageal echocardiography for determining volume status.
224253215|NCT03407287|PROCEDURE|Standard noninvasive vascular monitoring|Standard noninvasive vascular monitoring of blood pressure, pulse rate, pulse oximetry and respiratory rate.
224253216|NCT00041015|DRUG|cisplatin|
224253217|NCT00041015|DRUG|etoposide|
224253218|NCT00041015|DRUG|topotecan hydrochloride|
224253219|NCT00264108|DRUG|Darbepoetin alfa|Either 150 ug once weekly or 500 ug once every 3 wks, variable treatment length.
224253220|NCT00264108|DRUG|Epoetin alfa|40,000 IU once weekly, variable treatment length.
224253221|NCT01315990|DRUG|FOLFIRI + Cetuximab|"1. Cetuximab (Erbitux® )- Cetuximab is a recombinant IgG1 chimeric monoclonal antibody directed against human epidermal growth factor receptor (EGFR).~2. FOLFIRI regimen~Administration Schedule:~Cetuximab at a initial dose 400 mg/sqm (first week), then 250 mg/sqm on day 1 and 8 Background Chemotherapy (every two weeks)~* Irinotecan 180 mg/m² iv , 90 min on day 1~* Folic acid (racemic) 400 mg/m², 120 min on day 1~* 5-FU 400 mg/m² bolus on day 1~* 5-FU 2400 mg/m² iv over 46 h on day 1 to 2"
224253222|NCT00085293|DRUG|Decitabine|Starting dose 6 mg/m\^2 intravenously over 1 hour every day for 5 successive days for 2 weeks (10 doses), with possible second course.
224253223|NCT00085293|RADIATION|Iodine I 131|Undergo thyrotropin-alfa stimulated radioactive iodine scan
224253224|NCT00085293|BIOLOGICAL|Recombinant thyrotropin alfa|Undergo thyrotropin-alfa stimulated radioactive iodine scan
224253225|NCT00085293|RADIATION|Fludeoxyglucose F 18|Optional correlative studies
224253226|NCT00085293|PROCEDURE|Positron emission tomography|Optional correlative studies
224253227|NCT00003766|DRUG|O6-benzylguanine|
224253228|NCT00006218|DRUG|triapine|
224253229|NCT06218524|DRUG|Haloperidol Tablets|Haloperidol tablet 6mg, Oral, Triple/Day
224253230|NCT06218524|DRUG|Temozolomide|Temozolomide, 150mg/kg, Oral, Once/Day, 5/28 days
224253231|NCT05345249|DRUG|Ropivacaine Hydrochloride Injection|Investigating the effectiveness of erector spinae plane block with ropivacaine for lumbar spinal fusion surgery versus placebo.
224253232|NCT05345249|DRUG|Sodium chloride|Placebo comparator
223672667|NCT06078150|BEHAVIORAL|Active video games intervention（1-6weeks）|"Experimental:~Experimental group for weeks 1-3: enter the subject's basic information. The Fitness Ring Adventure requires subjects to be proficient in wearing two Joy-Con devices. Therefore, during the three interventions in the first week, subjects were able to fully understand how the AVG was worn, the game mechanics, and the game modes. Familiarise yourself with the warm-up and stretching patterns in the preparation phase of the game in order to be better prepared for subsequent interventions.~Experimental group for weeks 4-6: to supervise and assist subjects during this intervention phase and to organize a speed passing competition at the end of week 6 to reward the subjects. Variables related to the subjects' activity, mental health, and physical composition were tested and recorded while testing proficiency in the game."
223672668|NCT06078150|BEHAVIORAL|Active video games intervention（7-12weeks）|"Experimental:~Experimental group in weeks 7-9: continue to warm up before each game and then play the game. Passing tasks were set for each subject from week 7 onwards, and they had to pass 2 tasks during each weekly intervention.~Experimental group in weeks 10-12: weekly intervention ensured that subjects were able to complete the pass 2 task, and if they completed the pass within the allotted time they were able to review the previously passed task. A boss fight was held in week 12, with a prize awarded to the person who took the shortest time."
223672669|NCT00521300|DRUG|Octreotide|First week: Octreotide 50 micrograms subcutaneously three times daily. Second week: Octreotide 100 micrograms subcutaneously three times daily. From the third week on: Octreotide LAR 20 mg intramuscularly every 28th day for 6 months
223672670|NCT00521300|PROCEDURE|Direct surgery for acromegaly|Direct transsphenoidal surgery
223672671|NCT02658591|DIETARY_SUPPLEMENT|Crackers/pasta with added faba bean protein concentrate|Protein concentrate treatment
223672672|NCT02658591|DIETARY_SUPPLEMENT|Crackers/pasta with added faba bean protein isolate|Protein isolate treatment
223672673|NCT02658591|DIETARY_SUPPLEMENT|Crackers/pasta with added faba bean starch|Starch treatment
223672674|NCT02658591|DIETARY_SUPPLEMENT|Crackers/pasta with added faba bean flour|Flour treatment
223672675|NCT02658591|DIETARY_SUPPLEMENT|Crackers/pasta with no faba bean fraction|Control treatment
223672676|NCT00427180|DEVICE|Retinal Implant System (IRIS)|AIMD - Active Implantable Medical Device designed for artificial electrical neural stimulation of photoreceptor degenerated retina
223672677|NCT06506695|DEVICE|Craniofacial implant placement|"* Resection of oncologic process or remnants after trauma if necessary~* Placement of craniofacial implants in the nasal floor and/or the temporal bone.~* Placement of split thickness skin graft around the implants~* Placement of nose and/or ear prosthesis within 3 weeks"
223672678|NCT03068832|BIOLOGICAL|Personalized peptide vaccine|-It may take 3-4 months for sequencing, neoantigen prediction, and peptide manufacturing
223672679|NCT03068832|DRUG|Poly ICLC|-Poly-ICLC is supplied by Oncovir in single-dose vials containing 1 mL of 2 mg/mL opalescent white suspension.
223672680|NCT03068832|PROCEDURE|Peripheral blood draw|"* After trial enrollment and up to 7 days after the 1st vaccine dose~* 2 weeks after last dose~* Time of progression or discontinuation"
223672681|NCT00488709|DRUG|Topotecan|
223672682|NCT00488709|DRUG|Fludarabine|
223672683|NCT00488709|DRUG|Cytarabine|
223772206|NCT00767546|DRUG|Botulinum toxin|60- 100 units Local injection to the rash area
223772207|NCT00857194|PROCEDURE|2 hour Oral Glucose Tolerance Test|Fasting baseline blood samples will be drawn for analysis of insulin and glucose. A 75-gram glucose solution will be administered and subjects remain sedentary for 2 hours. After 2 hours, blood is drawn to analyze post-load insulin and glucose levels.
223672684|NCT00948584|OTHER|Insulin dose titration system using a SMS|We applied 'Insulin dose titration system in diabetic patients using a short messaging service automatically produced by a knowledge matrix' for 12 weeks in the intervention group. In the control group, a conventional insulin titration schedule was used. The insulin used in this study was Lantus (insulin glargine).
223672685|NCT05761535|RADIATION|Magnetic Resonance (MR) and positron emission tomograph (PET) imaging analyses|"Regarding the neurological MR protocol, the following may be acquired:~* 3D T1 and T2 high-resolution sequences, acquired in a specific plane and Multiplanar reformation (MPR) reconstructed in the remaining orthogonal planes, for morphological assessment of the different structures under examination;~* diffusion sequences for the evaluation of the connection between different areas within a specific organ;~* perfusion sequences (ASL, arterial spin labeling) for the evaluation of perfusion without ev mdc administration;~* susceptibility sequences for noninvasive assessment of vasculature and deposits of iron."
223772208|NCT00857194|PROCEDURE|Fat Meal Test|A fasting blood draw is performed for analysis of lipids, insulin, and glucose. Subjects ingest a high fat meal (milkshake made from heavy whipping cream and premium ice cream) within 15 minutes. Postprandial blood draws at 2, 4, and 6 hours are made for analysis of lipids, insulin, and glucose.
223772209|NCT06266923|DRUG|SPH6516 tablets|SPH6516 tablets ： Orally, once daily, 25-200mg, 28 days a cycle
223772210|NCT03851653|BEHAVIORAL|Lifestyle Intervention|Cognitive-behavioural intervention for weight loss and lifestyle change
223772211|NCT03675048|DIETARY_SUPPLEMENT|BioGaia Protectis drops|food supplement containing the patented lactic acid bacterium Lactobacillus reuteri Protectis®/™ (L. reuteri DSM 17938).
223772212|NCT03675048|DIETARY_SUPPLEMENT|Placebo|Contains same excipients as study drug, without the active ingredient L. Reuteri.
223772213|NCT04744727|DRUG|paracetamol-pethidine|100 ml containing 1000 mg paracetamol -50 mg pethidine HCL
223772214|NCT01574872|DEVICE|Halotherapy|The treatment consist of 15 session of micronized iodized salt (sodium chloride) skin exposure in a chamber that reproduces the environmental characteristics of a natural salt cave. Each daily session last 30 minutes.
223772215|NCT01574872|DEVICE|Placebo|The treatment consist of 15 sessions in a chamber that emulates the environmental characteristics of a natural salt cave but with no salt emanation. Each daily session last 30 minutes.
223772216|NCT02932891|DRUG|DSXS topical|topical treatment
223772217|NCT03862976|DIAGNOSTIC_TEST|computerized cardiotocography|computerized cardiotocography (C-CTG)
224253233|NCT00134485|DRUG|torcetrapib/atorvastatin|
224253234|NCT00134485|DRUG|atorvastatin|
224253235|NCT05312216|DRUG|Durvalumab plus Lenvatinib|"Durvalumab: 1500mg, iv.drip, Q4w Lenvatinib: 8mg, QD (body weight \< 60kg) or 12mg, QD (body weight ≥ 60kg)~Number of cycle: until subjects withdrawing the informed consent OR progressive disease OR developing unacceptable toxicity events"
224253236|NCT05454943|BEHAVIORAL|Standardized TRE Protocol|A standardized 16:8 TRE protocol with an 11 am to 7 pm eating window.
224253237|NCT05454943|BEHAVIORAL|Personalized TRE Protocol|A personalized TRE protocol following pre-specified rules: 1) 8-10 hour eating window; 2) self-selected eating window start time as long as it ends ≥3h before bedtime; 3) if days off are required, aim to do so after following TRE for ≥5 successive days each week.
224253238|NCT05454943|BEHAVIORAL|External Support for TRE|External support (from study staff) that includes consultation with a registered dietitian and ongoing tailored feedback via support calls at weeks 1, 3, 6, and 12.
224253239|NCT05454943|BEHAVIORAL|Peer Support for TRE|Matched pairs will meet by phone/video at weeks 1, 3, 6, and 12.
224253240|NCT03624751|RADIATION|radioiodine|Patients with thyroid cancer need to choose between Thyrogen® injection and Eltroxin® withdrawal before radioiodine therapy or scan.
224253241|NCT06126666|DRUG|ABL103|ABL103 will be administered biweekly of every 28-day cycle in the dose-escalation. The dosing interval to be used in tumor-expansion part will be evaluated based on the emerging safety and PK data from the dose-escalation part of the study.
224253242|NCT06074588|BIOLOGICAL|Sacituzumab tirumotecan|4 mg/kg of MK-sacituzumab tirumotecan by IV infusion
224253243|NCT06074588|DRUG|Docetaxel|75 mg/m\^2 of docetaxel by IV Infusion
224253244|NCT06074588|DRUG|Pemetrexed|500 mg/m\^2 of pemetrexed by IV infusion
224253245|NCT06230159|BEHAVIORAL|Non-menthol Cigarette Smoking|Smoke a non-menthol cigarette
223672686|NCT05707741|DRUG|dexmetomedine infusion|50 ml mixture of saline 49 ml and dexmedetomidine 100 μg,
223672687|NCT05707741|DRUG|Dexmetomedine infusion|50 ml mixture of saline 48 ml and dexmedetomidine 200 μg
223672688|NCT00603590|DRUG|Polypill|Fixed dose combination therapy - aspirin 81mg, hydrochlorothiazide 12.5mg, enalapril 2.5mg and atorvastatin 20mg Once daily
223672689|NCT00603590|DRUG|Placebo drug|Inactive tablet Once a day Identical in appearance to intervention drug
223672690|NCT02819778|PROCEDURE|usual care|
223672691|NCT02819778|PROCEDURE|S100B|
223672692|NCT03940183|DRUG|Trelagliptin Succinate|the experimental group will use trelagliptin succinate 100 mg for 24weeks
223672693|NCT03940183|DRUG|Placebo Oral Tablet|the placebo Comparator groups use placebo oral tablet for 24weeks
223672694|NCT05765773|BIOLOGICAL|"CoviVac vaccine (inactivated whole-virion concentrated purified) manufactured by FSBSI Chumakov FSC R&D IBP RAS"|200 volunteers who will be vaccinated with the CoviVac vaccine three times with an interval of 21 days intramuscularly at a dose of 0.5 ml.
224253246|NCT06230159|BEHAVIORAL|Menthol Cigarette Smoking|Smoke a menthol cigarette
224253247|NCT06230159|BEHAVIORAL|Synthetic Cooling Agent Cigarette Smoking|Smoke a synthetic cooling agent cigarette
224253248|NCT06230159|BEHAVIORAL|Usual Brand Cigarette Smoking|Smoke usual brand cigarette
224253249|NCT06230159|DIAGNOSTIC_TEST|Spirometry|Pulmonary function test
224253250|NCT06230159|OTHER|Questionnaire Administration|Survey questionnaires
224253251|NCT06230159|DIAGNOSTIC_TEST|Nasal Epithelial Lining Fluid|Nasal strip inserted into the nare to collect nasal epithelial lining fluid.
223672695|NCT04519606|PROCEDURE|Optimal lung compliance during OLV|Stepwise increase of tidal volume from 4 ml/kg PBW to 7 ml/kg PBW during OLV to determine the optimal tidal volume at the level the the pressure-volume loop reaches upper refection point where the peak airway pressure at or just below 30 cmH2O
223672696|NCT03815045|PROCEDURE|Landmark-based lumbar puncture|Traditional landmark based lumbar puncture involves palpating spinous processes on the back and finding the inter-spinous space which is the site of needle entry to gain access to the thecal sac. Finding this space may be difficult by palpation, especially when subjects undergoing the procedure are obese, elderly, have had prior back surgery, or if the patient is positioned incorrectly.
223672697|NCT03815045|PROCEDURE|Ultrasound-guided lumbar puncture|Ultrasound guided lumbar puncture is a novel technique being increasingly utilized by emergency physicians, pediatricians and anesthesiologists. In this technique, an ultrasound probe is used to visualize the inter-spinous space. This space can be marked on the skin as the potential point of entry. This could potentially make it easier when patient factors make it difficult to palpate and find the site of entry.
223672698|NCT04246931|OTHER|No intervention (survey)|No intervention -\> survey at 1 timepoint
223672699|NCT03254303|OTHER|Difficulty of catheterization in group 60 s|
223672700|NCT03254303|OTHER|Difficulty of catheterization in group 90 s|
223672701|NCT03254303|OTHER|Difficulty of catheterization in group 120 s|
223672702|NCT03603067|PROCEDURE|Ocular surgery|Different ocular surgeries (including vitreoretinal surgery, cataract surgery, anti-glaucoma surgery etc) will be performed in one eye of the patient. In monophthalmic patient group the surgery will be performed in eye with better visual acuity.
223672703|NCT01027390|BEHAVIORAL|physical training exercise|physical exercise training at the work site during work time
223672704|NCT05814354|DRUG|SHR-A1811|SHR-A1811 is a lyophilized powder for injection intravenously. Administered according to label, as one option for Physician's Choice.
223672705|NCT05814354|DRUG|Capecitabine/Eribulin/Gemcitabine/Paclitaxel/Nab-paclitaxel|Administered according to label, as one option for Physician's Choice (determined before randomization).
223672706|NCT00366067|DRUG|Phenytoin|
224253252|NCT02669225|OTHER|[18F]florbetaben|PET radiotracer to image Amyloid beta (AB) load in human brain.
224253253|NCT03699020|BEHAVIORAL|Acceptance and Commitment Therapy (ACT)|Empirically based behavioral intervention that encourages acceptance of circumstances with commitment and behavioral change strategies to improve psychological flexibility.
224253254|NCT03699020|OTHER|Chronic Pain Education|Education materials about living with chronic pain developed by Weill Cornell Universitys Translational Research Institute for Pain in Later Life
224253255|NCT04971668|OTHER|Aromatherapy|Three drops of the designated blend aromatherapy (ginger \& lavender) will be placed on a 2-inch by 2-inch impermeable, backed gauze pad and patient will be asked to inhale deeply and simulate like chewing gum for 5 minutes.
224253256|NCT04971668|OTHER|Gum Chewing|Patients will chew gum (sugar free) and inhale deeply with inert gauze for 5 minutes.
224253257|NCT04971668|OTHER|Controlled|Patients will inhale deeply with inert gauze and simulate like chewing gum for 5 minutes.
224253258|NCT04867252|DRUG|Resveratrol (1000mg twice a day), Myoinositol 1000mg (Twice a day)|51 Patients with PCOS receiving Resveratrol and Myoinositol 1000mg and 1000mg BD daily respectively
224253259|NCT04867252|DRUG|Metformin (500 mg Twice a day), Pioglitazone (15 mg Twice a day)|51 Patients with PCOS receiving Metformin and Pioglitazone 500 mg and 15 mg BD daily respectively
224253260|NCT03861065|PROCEDURE|Tertiary Wound Closure|The wound will be closed with what is considered tertiary wound closure. This means, rather than leaving the wound open, the wound will be partially closed after surgery, and then completely closed 4-7 days after surgery.
224253261|NCT03861065|PROCEDURE|Historical Wound Closure|Participants wounds are left partially open to heal.
224253262|NCT02246920|DRUG|Fluticasone propionate|50 mcg/actuation Nasal Spray
224253263|NCT02246920|DRUG|Flonase®|50 mcg/actuation Nasal Spray
224253264|NCT02246920|DRUG|Placebo|Inactive Nasal Spray
224253265|NCT03642769|OTHER|Fluid administration|Fluid administration of bolus and maintenance fluids
224253266|NCT05667246|OTHER|Caffeinated Coffee|"Subjects would be randomized to a group Caffeinated and subjects will be 95 mg of caffeine in caffeinated coffee."
223672707|NCT04352153|DRUG|Febuxostat|Febuxostat is taken at a dose of 20 mg once a day. During the medication period, the urine pH of each subject is monitored and recorded in the morning, noon and night.
223672708|NCT04352153|DRUG|Uralyt-U|Febuxostat is taken at a dose of 20 mg once a day, potassium sodium hydrogen citrate granules 7.5 g / day, 2.5 g / per time, three times a day. During the medication period, the urine pH of each subject is monitored and recorded in the morning, noon and night.
223672709|NCT00649545|BIOLOGICAL|adalimumab|40 mg every other week
223672710|NCT03581890|OTHER|Socioeconomic position|"Socioeconomic position is the exposure in both study 1 and 2. Four different socioeconomic measures will be tested. The primary socioeconomic position measure is highest attained education the year before surgery (short/medium/long). Secondary measures are:~1. age- and sex-adjusted available income the year before surgery~2. Cohabitation status at the year of surgery (living alone/living with a partner) at the year of surgery.~3. Urbanicity (in four officially, predefined categories)."
223672711|NCT06107179|DIAGNOSTIC_TEST|Multispectral Optoacoustic Tomography|In MSOT, laser light is emitted into the target tissue via a handheld probe. Thermoelastic expansion of various molecules in the target area generates ultrasound waves that are detected by the transducer. The detected signals are reconstructed into images using algorithms. Spectral analysis of the optoacoustic signal at different wavelengths in the near-infrared range can detect individual chromophores, such as oxygenated and deoxygenated hemoglobin.
223672712|NCT06374251|PROCEDURE|Discussion|Participate in narrative medicine sessions
223672713|NCT06374251|OTHER|Interview|Ancillary studies
223672714|NCT06374251|OTHER|Survey Administration|Ancillary studies
223672715|NCT03774095|DIETARY_SUPPLEMENT|Hydrolyzed pine nut oil|Given 30 min prior to oral glucose tolerance test
223672716|NCT03774095|DIETARY_SUPPLEMENT|Hydrolyzed pine nut oil and olive oil|Given 30 min prior to oral glucose tolerance test
224253267|NCT05667246|OTHER|Decaffeinated Coffee|"Subjects would be randomized to a group Decaffeinated and subjects will be no caffeine in decaffeinated coffee."
224253268|NCT04860804|DRUG|Aspirin and Ketamine|Drug: Proprietary oral formulation of 0.5mg/kg of ketamine + 324mg of aspirin
224253269|NCT04860804|DRUG|Oral Ketamine|Proprietary oral formulation of 0.5mg/kg of ketamine
224253270|NCT04572386|OTHER|light cure 3m single bond universal bond|light -cure universal bond
224253271|NCT04572386|OTHER|Self-cure universal bond (Palfique, Tokuyama, Japan)|Self-cure universal bond with no light cure
224253272|NCT04294043|DRUG|Gallium nitrate|Study subjects will receive an infusion of gallium nitrate.
224253273|NCT02297932|BEHAVIORAL|Strength training|Participants will engage in a home-based strength training program.
224253274|NCT02297932|BEHAVIORAL|Stretching|Participants will engage in a home-based stretching training program
224253275|NCT06570915|DRUG|Daratumumab Injection|Daratumumab was administered once a week at a dose of 16 mg/kg for a total of 4 times (Day1,8,15,22 ) in one cycle.
223672717|NCT00000187|DRUG|Ritanserin|
223672718|NCT04363229|OTHER|maslach burnout inventory questionnair|The Maslach Burnout Inventory (MBI) is an introspective psychological inventory consisting of 22 items pertaining to occupational burnout
223672719|NCT02764021|DIETARY_SUPPLEMENT|Carbohydrate-Restricted Diet|Macronutritional composition: Carbohydrate 30 E%, Protein 30 E%, Fat 40 E%
223672720|NCT02764021|DIETARY_SUPPLEMENT|Standard Antidiabetic Diet|Macronutritional composition: Carbohydrate 50 E%, Protein 13 E%, Fat 17 E%
223672721|NCT03893344|DIAGNOSTIC_TEST|detection of STAT4 gene|Individuals within both groups will be subjected to STAT4 gene polymorphism typing using both PCR and flow cytometry from a peripheral blood sample
224253276|NCT05971251|DRUG|Loncastuximab Tesirine and Acalabrutinib|Will be given on Day 1 of each cycle with each cycle being 21 days, and is being added to BID Acalabrutinib
223672722|NCT03036475|DEVICE|Sienna+ injection|Subcutaneous injection of Sienna+ in the morning of operation day
224253277|NCT01926912|DRUG|No intervention|This is an observational study. Participants prescribed with paliperidone palmitate by the treating physician as per local labeling information in the hospital setting will be observed and data will be collected.
224253278|NCT04794140|PROCEDURE|different number of passes|Each patient's operation process is the same, that is, after obtaining enough specimens for diagnosis by endoscopic ultrasound-guided fine-needle biopsy (EUS-FNB) wet suction technique, additional three passes are performed. One of which is randomly selected as the one pass group, and the other two passes automatically as the two pass group. Please refer to the literature for EUS-FNB wet technique (Tong T, et al. J Gastroenterol Hepatol. 2020;10.1111/jgh.15371.)
224253279|NCT00191763|DRUG|Gemcitabine|
224253280|NCT00191763|DRUG|cisplatin|
224253281|NCT01037114|PROCEDURE|Blood sampling|Blood sampling at Year 16, 17, 18, 19 and 20 and at the time of challenge dose administration and 14 days and one month after challenge dose administration (if challenge dose needed).
224253282|NCT01037114|BIOLOGICAL|Engerix-B|Engerix-B will be administered to subjects who are not seroprotected against hepatitis B.
224253283|NCT01037114|BIOLOGICAL|Havrix|Havrix will be administered to subjects who are seronegative for anti-HAV antibodies.
224253284|NCT01061021|BEHAVIORAL|In The Mix|Five small group + 2 individual counseling intervention designed to addresses HIV transmission risk behavior and HIV treatment adherence in men and women living with HIV/AIDS.
224253285|NCT01061021|BEHAVIORAL|Information Support Group|Five small group + 2 individual counseling session intervention that serves as an attention control group. Content included stress reduction, nutrition, and exercise for health improvement.
224253286|NCT02193061|BIOLOGICAL|Rotarix|
224253287|NCT02193061|BIOLOGICAL|RotaTeq|
224253288|NCT03075553|OTHER|Laboratory Biomarker Analysis|Correlative studies
224253289|NCT03075553|BIOLOGICAL|Nivolumab|Given IV
224253290|NCT00938951|OTHER|Systane® Ultra|Polyethylene Glycol 400 0.4% / Propylene Glycol 0.3%
224253291|NCT03620747|DRUG|Dupilumab SAR231893 (REGN668)|"Pharmaceutical form: prefilled syringes~Route of administration: subcutaneous"
224253292|NCT05598476|OTHER|5kg bag|a 5 kg bag is applied on the chest for 2 hours
224253293|NCT04314362|DRUG|AZR-MD-001 ointment/semi-solid drug|AZR-MD-001 (1.0%) and suitable excipient
224253294|NCT02959580|DRUG|Hydrocortisone Butyrate|topical use
224253295|NCT02959580|PROCEDURE|extended excision|Lesion extended excision with or without a random breast dermo-glandular flap (BDGF).
224253296|NCT00942318|DRUG|Detemir insulin, Aspart insulin, Metformin|Insulin doses adapted by patients according to self monitoring blood glucose results.
223672723|NCT04665882|PROCEDURE|Axillary surgery based on lymphedema prediction nomogram|Based on the intraoperative lymphedema prediction nomogram, individualized treatment was recommended to breast cancer patients with different level of risk. For patients with low possibility of developing breast cancer related lymphedema, it was not necessary to preserve arm lymphatics. While the breast cancer patients who were performed mastectomy and ALND with 28 kg/m2 prepared to receive taxane-based chemotherapy, supraclavicular and infraclavicular radiotherapy, according to the established intraoperative nomogram, the proportion of the arm lymph flow above the axillary vein needed to exceed 52%. Otherwise, the arm lymphatics should be identified and preserved.
223672724|NCT00559832|OTHER|Hypoxic Exposure|Sleeping in normobaric hypoxia for 14 nights at altitudes from 2500 - 3300 m prior to one night at 4500 m
223672725|NCT06074770|OTHER|no intervention|Natural exposure of iodine
223772218|NCT01766375|DRUG|Cyclosporin A,mycophenolate mofetil,Methotrexate|GVHD is prevented by CSA+MMF+MTX in sibling allogeneic hematopoietic stem cell transplantation (starting from day -1, 3mg/kg of CSA was infused by continuous intravenous drip until gastrointestinal function returned normal when method of administration was changed to oral administration.
223772219|NCT01050595|DRUG|Methylnaltrexone Bromide|The experimental group will receive the recommended dose of MNTX (Relistor) is 8 mg for patients weighing 38 kg to less than 62 kg (84 lbs to less than 136 lbs) or 12 mg for patients weighing 62 kg to 114 kg (136 lbs to 251 lbs). Patients whose weight is below 38 kg or greater than 114 kg, will be dosed at 0.15 mg/kg. If creatinine clearance \<30 will decrease dose by 50%. This will be given after 72 hours of no bowel movement. Bowel management protocol will be instituted four hours afterward with the methylnaltrexone being given every other day.
223672726|NCT02029690|DRUG|ADI-PEG 20|
223672727|NCT02739737|OTHER|Blinded manuscript|Blinded version of sham manuscript
223672728|NCT02739737|OTHER|Unblinded manuscript|Unblinded version of sham manuscript
223672729|NCT03768557|DRUG|Minocycline|Minocycline (200mg)
223672730|NCT03768557|OTHER|placebo|Lactose (400mg)
223672731|NCT04172129|DEVICE|Total Hip Arthroplasty|
223672732|NCT02013141|DRUG|Telavancin|
223672733|NCT04572438|PROCEDURE|Tracheostomy|Tracheostomy is a procedure that creates a surgical airway in the windpipe to improve oxygenation of the lungs.
223672734|NCT01378182|GENETIC|allogeneic mesenchymal stem cell transplantation|1.000.000(one million) cells/kg, IV (1/2 of dose in the Peripheral vein and 1/2 of dose into the right hepatic artery)
223672735|NCT01475071|DRUG|Metvix and natural daylight PDT|Methyl aminolevulinate, cream 160mg/g.One session at baseline and a second session administration at week 12 for lesions showing non-complete response and new lesions on target area.
223672736|NCT01475071|DRUG|Metvix and conventional PDT|Methyl aminolevulinate, cream, 160mg/g. One session at baseline and a second session administration at week 12 for lesions showing non-complete response and new lesions on target area.
223672737|NCT01343823|DRUG|ecallantide 60 mg|Administered as two 3 mL SC injections, each containing 30 mg ecallantide
223672738|NCT01343823|DRUG|ecallantide 30 mg|Administered as one 3 mL SC injection containing 30 mg ecallantide
223772220|NCT01050595|DRUG|Placebo-Normal Saline|Control group will be given an equal amount of normal saline in an identically appearing vial every other day until a bowel movement occurs. A bowel management protocol will also be started.
224253297|NCT03004209|DRUG|Erythropoietin|three times per a week 100IU / k
224253298|NCT04638452|BEHAVIORAL|Video & movements recording|Video recording of face, body movements and physiological parameters (heart rate, conductance using a wireless watch) of the participants during the blood test
224253299|NCT04638452|BEHAVIORAL|Questionnaires|Passing self and hetero questionnaires of emotion felt and perceived.
224253300|NCT05132985|DRUG|Icotinib|125mg 1tt(Take 1 tablet 3 times a day) orally.
224253301|NCT05132985|DRUG|Cisplatin|75 mg/m2 (IV，Q3W)
224253302|NCT05132985|DRUG|Carboplatin|AUC 5 (IV, Q3W)
224253303|NCT05132985|DRUG|Pemetrexed|500 mg/m2 (IV, Q3W)
224253304|NCT03055637|PROCEDURE|Furlow double opposing z-plasty|\* Furlow, (1986) has described a technique for palatoplasty combining the principles of mucosal lengthening with creation of an intact muscular sling in the palate with double opposing Z-plasty. On the soft palate, mirror image Z-plasties are drawn, one for the nasal musoca and the other oral flaps, the nasal flaps are developed and closed first .The oral flaps are then approximated. The defect created usually closes readily. The closure lines of the two soft plate layers do not overlap, minimizing the potential for contracture. Also, this repair permits closure of the hard palate without lateral incisions
224253305|NCT03055637|PROCEDURE|Two flap palatoplasty|design the 2-flap palatoplasty, with a 2-layer closure in the hard palate and 3-layer closure in the soft palate,
224253306|NCT06093932|DRUG|Songling Xuemaikang Capsules|3 capsules at a time, three times a day, duration: 12 weeks
224253307|NCT06093932|BEHAVIORAL|Lifestyle intervention|everyday, duration: 12 weeks
224253308|NCT06093932|DRUG|Placebo|3 capsules at a time, three times a day, duration: 12 weeks
224253309|NCT03650985|PROCEDURE|Fetoscope technique|Intrauterine intervention with fetoscope technique will be applied to treat complex twin diseases with intention to improve the prognosis of patients.
224253310|NCT05970484|BEHAVIORAL|DrinksRation|DrinksRation (www.drinksration.app; formerly called InDEx) app was developed following the Medical Research Council Complex Intervention Guidelines and using a co-design methodology. It was developed by the King's Centre for Military Health Research (King's College London) and Lancaster University, supported by experts in smartphone app development, epidemiology, addiction psychiatry, and military mental health. The app was designed to support veterans drinking at a hazardous or harmful level by providing bespoke advice and support.
224253311|NCT05970484|BEHAVIORAL|BeAlcoholSmart|BeAlcoholSmart is a progressive web app (PWA). The app can take advantage of smartphone features such as push notifications and haptics without requiring the participant to download via an app store. The app will contain a 7-day alcohol unit calculator and generic public health guidance on safe drinking. Participants will also receive reminders via email prompting them to consult the guidance as part of the BeAlcoholSmart. Control participant participants will be invited to complete all questionnaires via Qualtrics, with an email reminder being sent when they are due.
224253312|NCT02580279|DRUG|EGCG|
224253313|NCT02580279|DRUG|placebo|
224253314|NCT00640562|DRUG|Quetiapine Extended Release|Uptitrated starting from 300 mg in the evening on day 0, then increasing to 600 mg and up to 800 mg in the following two evenings. Previous antipsychotic was taken at the full dose on day 0, half dose on day 1 and stopped from day 2. From day 3 onwards it was possible to adjust the Seroquel XR dose, depending on the clinical response and tolerability of the patient, within the range of 400-800 mg per day
224253315|NCT00640562|DRUG|Risperidone|Uptitrated starting from 1 mg bid (morning and evening) on day 0, then increasing to 2 mg bid and up to 3 mg in the following two days. As per the other arm, previous antipsychotic was taken at the full dose on day 0, half dose on day 1 and stopped from day 2. From day 2 onwards, it was allowed to adjust he dose of Risperidone depending on the clinical response and tolerability of the patient.
224253316|NCT02503527|OTHER|Diben 1.5 kcal HP|Continuous (24h) application according to a standardized enteral feeding protocol via nasogastric tube or percutaneous endoscopic gastrostomy (PEG); pump-assisted application (Charriére (CH) \> 8), duration according to patient's tolerance and requirements for a maximum of 5 days. Dosage: 21 - 24 kcal/kg body weight/day (corresponding to 14 to 16 ml/kg body weight/day).
224253317|NCT02503527|OTHER|Fresubin HP Energy Fibre (1.5 kcal)|Continuous (24h) application according to a standardized enteral feeding protocol via nasogastric tube or percutaneous endoscopic gastrostomy (PEG); pump-assisted application (Charriére (CH) \> 8), duration according to patient's tolerance and requirements for a maximum of 5 days. Dosage: 21 - 24 kcal/kg body weight/day (corresponding to 14 to 16 ml/kg body weight/day).
224253318|NCT02937870|DEVICE|Test Product 1|Test adhesive 1 with a thin nozzle
224253319|NCT02937870|DEVICE|Test Product 2|Test adhesive 2 with a thin nozzle
224253320|NCT02937870|DEVICE|Reference Product|Adhesive Cream
223672739|NCT01343823|DRUG|ecallantide 10 mg|Administered as one 3 mL SC injection containing 10 mg ecallantide.
223672740|NCT01343823|DRUG|placebo|Administered as two SC 3 mL injections
223672741|NCT01343823|DRUG|placebo match for 30 mg ecallantide arm|One 3 mL SC injection of matching placebo given to subjects randomized to the 30 mg ecallantide arm.
223672742|NCT01343823|DRUG|placebo match for 10 mg ecallantide arm|One 3 mL SC injection of matching placebo given to subjects randomized to the 10 mg ecallantide arm.
223672743|NCT04733391|OTHER|Quality of life questionnaire|"Quality of life will be evaluated using the child version of the VSP-A questionnaire, for patients aged 8-10 years and the adolescent version for those aged 11-17 years."
223672744|NCT00352716|DRUG|Smecta (Diosmectite), duration of treatment - 7 days|
223672745|NCT05392933|DIAGNOSTIC_TEST|Ultrasound guided piriformis muscle lidocaine injection|Ultrasound guided piriformis muscle (piriformis syndrome) 5 ml %2 lidocaine injection
224253321|NCT02937870|OTHER|Negative Control|No adhesive
224322238|NCT02143466|DRUG|Part B - AZD9291 in combination with selumetinib|Part B - AZD9291 and selumetinib administered in the dose identified in Part A (AZD9291 80mg OD + selumetinib 75 mg BD intermittent \[4 days on/3 days off\]) to further investigate the safety and tolerability of this combination.
223672746|NCT06455618|PROCEDURE|not Indwelling the ureteral stent|"Before the end of surgery, the urologist does not Indwell the ureteral stent in the patient's body. The ureteral stent is usually called Double-J Stent."
223672747|NCT06455618|PROCEDURE|Indwelling the ureteral stent|"Before the end of surgery, the urologist Indwell the ureteral stent in the patient's body. The ureteral stent is usually called Double-J Stent."
223672748|NCT02794610|DRUG|Tacrolimus|Topical tacrolimus 0.05% eye drops will be instilled into the eyes of patients every minute for 5 minutes. After 15 minutes, at the time of cataract surgery, aqueous samples will be collected and will be subjected to detection of presence and level of tacrolimus.
223672749|NCT04537221|BIOLOGICAL|Blood transfusion|Transfusion of red blood cells peri-operatively
223672750|NCT02050971|BIOLOGICAL|Umbilical Cord Blood Infusion|Cord blood collection after delivery of the baby. Preservation of blood in blood bank. Transfusion of autologous cord blood within the first 5 postnatal days.
223672751|NCT02050971|BIOLOGICAL|Intravenous Infusion of Peripheral Blood or its Components|Regular treatment of neonatal anemia with peripheral blood or its components transfusion.
223672752|NCT03505827|DIAGNOSTIC_TEST|24-2 SITA Standard Humphrey Visual Field Test|Patients participate in a 24-2 SITA Standard humphrey visual field test. This includes sitting in a dark room at a visual field machine. Stimulus test points of different intensity and size will be presented to the patient, as per SITA standard protocol. The patient will indicate by pressing a button when they see the visual stimulus.
223672753|NCT00923364|DRUG|Cyclophosphamide (CTX, Cytoxan)|14.5 mg/kg intravenous (IV) (in the vein) infusion over 30 minutes once daily on days -6 and -5 (weight based dosing) or 50 mg/kg IV infusion over 2 hours on day -6 (weight based dosing) or 50/kg IV once daily x 2 doses on days +3 and +4
223672754|NCT00923364|DRUG|Fludarabine(Fludara,Berlex Laboratories)|40 mg/m2 IV (in the vein) over 30 minutes (in the vein) once daily on Days -6, -5, -4, and -3 or 30 mg/m(2) IV over 30 minutes (in the vein) once daily on Days -6, -5, -4, -3, and -2
223672755|NCT00923364|PROCEDURE|Total Body Irradiation (TBI)|200 centigray (cGy) on Day -1 or 300 cGy on Day -1 (for 9/10 URD and Haplo patients)
223672756|NCT00923364|PROCEDURE|Allogeneic Hematopoietic Stem Cell (HSC)|stem cell transplant
224253322|NCT04626167|PROCEDURE|Concomitant Renal and Urinary Bladder Allograft Transplantation|This is a single-center, prospective, single-group unblinded phase I study that will enroll subjects with chronic kidney disease secondary to bladder dysfunction or bladder absence that is refractory to medical treatment and requires surgical intervention to prevent long-term sequelae. Patients will undergo a cadaveric donor bladder transplant in addition to or after their kidney transplant rather than using intestinal segments for bladder reconstruction or contruction.
224253323|NCT04390256|OTHER|Clove water extract|natural product
224253324|NCT04390256|OTHER|Carbopol|Bioadhesive polymer
224253325|NCT04390256|OTHER|Carboxymethyle cellulose|Bioadhesive polymer
224253326|NCT00633451|OTHER|Manual Therapy and Exercise|Manual therapy to the thoracic spine and shoulder, and therapeutic exercise to the shoulder and spine applied in a prescribed progression of therapeutic exercise aimed at improving shoulder function.
224253327|NCT00633451|OTHER|Exercise Only|A prescribed progression of therapeutic exercise for the shoulder and spine aimed at improving shoulder function
224253328|NCT00219154|DRUG|aliskiren|
224253329|NCT00609674|DRUG|Fluticasone furoate nasal spray|Fluticasone furoate nasal spray
224253330|NCT00609674|DRUG|Placebo|Placebo
223672757|NCT00923364|DRUG|Equine Anti-Thymocyte Globulin|30mg/kg IV (in the vein) once daily x 3 days on Days -6, -5, -4 (3 doses total)
224253331|NCT03098394|DEVICE|Cepheid Xpert CT/NG Rapid Turnaround Test|This diagnostic test will be used to help clinicians determine the need for antibiotic prescriptions in patients with a suspected sexually tract infection.
224253332|NCT03098394|DEVICE|Polymerase chain reaction (PCR)|This is the standard of care for diagnosis of a suspected sexually transmitted infection.
224253333|NCT04755387|DRUG|De-escalation strategy|De-escalation strategy indicates conventional DAPT (ticagrelor 90 mg twice daily + aspirin 100 mg once daily) for 1 month, followed by de-escalation DAPT (ticagrelor 60 mg twice daily + aspirin 100 mg once daily) between 1 and 3 months. Between 3 and 12 months, patients will be treated with ticagrelor monotherapy (ticagrelor 60 mg twice daily).
224253334|NCT04755387|DRUG|Conventional strategy|Conventional stratetgy indicates conventional DAPT including ticagrelor 90 mg twice daily and aspirin 100 mg once daily during 12 months.
224253335|NCT02465060|DRUG|Adavosertib|Given PO
224253336|NCT02465060|DRUG|Afatinib|Given PO
224253337|NCT02465060|DRUG|Afatinib Dimaleate|Given PO
223672758|NCT04729478|DEVICE|Drug-induced sleep endoscopy|An intravenous bolus injection of midazolam 1.5 mg will be used to induce sleep. Maintenance of sedated sleep will be obtained by a target-controlled infusion of propofol (2.0-3.0 µg/mL).
223672759|NCT04729478|DEVICE|Natural sleep endoscopy|Endoscopy during natural sleep.
223672760|NCT03045510|DRUG|decitabine|Decitabine 3.5mg/m2，ivdrip，qd x 5d, every four weeks for one cycle. It will be given six cycles.
223672761|NCT00146588|DRUG|Cyclophosphamide|Intravenously on day 1 of each 21-day treatment cycle for 12-18 weeks depending upon response.
223672762|NCT00146588|DRUG|Epirubicin|Intravenously on day 1 of each 21-day treatment cycle for 12-18 weeks depending upon response.
223672763|NCT00146588|DRUG|Capecitabine|Given orally on days 4-17 of each 21-day treatment cycle for 12-18 weeks depending upon response.
223672764|NCT01011478|DRUG|rosuvastatin|
224253338|NCT02465060|DRUG|Binimetinib|Given PO
224253339|NCT02465060|PROCEDURE|Biopsy Procedure|Undergo tumor biopsy
224253340|NCT02465060|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
223672765|NCT01011478|OTHER|placebo|
223672766|NCT03790007|DRUG|Bupivacaine|In our study this local anesthetic agent will be applied for postoperative pain relief
223672767|NCT02403388|OTHER|PRisM|A risk management program for each professional of care in multiprofessional primary care offices in France.
223672768|NCT00827671|DRUG|cetuximab|cetuximab initial dose 400 mg/m2 iv 1 week before start radiotherapy and subsequent weekly doses of 250 mg/m2 iv for the duration of the radiation treatment
223672769|NCT00827671|RADIATION|radiotherapy to oesophageal tumour|45 Gy delivered in 25 fractions of 1.8 Gy 5d/wk
223672770|NCT04508764|OTHER|Families Accelerating Cascade Testing Toolkit|-Online family history assessment, video of Siteman Cancer Center genetic counselors, physicians and patients highlighting the importance of cascade genetic testing, reviewing and receiving a family letter and gene information sheet, reviewing websites/online resources, and offering a family visit with a genetic counselor
223672771|NCT04163731|OTHER|DASI questionnaire|All patients who accept to participate will undergo a self-questionnaire of 10 minutes. Medical data of their cardiac stress test and risk factor will be collected.
223672772|NCT04121351|OTHER|Singing participation|Participants will follow a 15 minute protocol consisting of the components of a Singing for Lung Health class, and a short period walking on a treadmill.
223672773|NCT02924415|BEHAVIORAL|Tele-care support|Psychoeducation treatment based on telemedicine
223672774|NCT02924415|OTHER|Control group|Standard care
223672775|NCT01505504|DRUG|mirtazapine|30 mg at bedtime
224253341|NCT02465060|DRUG|Capivasertib|Given PO
224253342|NCT02465060|PROCEDURE|Computed Tomography|Undergo computed tomography (CT)
224253343|NCT02465060|DRUG|Copanlisib|Given IV
224253344|NCT02465060|DRUG|Copanlisib Hydrochloride|Given IV
224253345|NCT02465060|DRUG|Crizotinib|Given PO
224253346|NCT02465060|OTHER|Cytology Specimen Collection Procedure|Optional correlative studies
224253347|NCT02465060|DRUG|Dabrafenib|Given PO
224253348|NCT02465060|DRUG|Dabrafenib Mesylate|Given PO
224253349|NCT02465060|DRUG|Dasatinib|Given PO
224253350|NCT02465060|DRUG|Defactinib|Given PO
224253351|NCT02465060|DRUG|Defactinib Hydrochloride|Given PO
224253352|NCT02465060|PROCEDURE|Echocardiography Test|Undergo echocardiography (ECHO)
224253353|NCT02465060|DRUG|Erdafitinib|Given PO
224253354|NCT02465060|DRUG|Fexagratinib|Given PO
224253355|NCT02465060|DRUG|Ipatasertib|Given PO
224253356|NCT02465060|OTHER|Laboratory Biomarker Analysis|Undergo molecular analysis
224253357|NCT02465060|DRUG|Larotrectinib|Given PO
224253358|NCT02465060|DRUG|Larotrectinib Sulfate|Given PO
224253359|NCT02465060|PROCEDURE|Magnetic Resonance Imaging|Undergo magnetic resonance imaging (MRI)
224253360|NCT02465060|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
224253361|NCT02465060|BIOLOGICAL|Nivolumab|Given IV
224253362|NCT02465060|DRUG|Osimertinib|Given PO
223672776|NCT04563676|BIOLOGICAL|blood test|covid19 infected patient will have a blood test in order to make an autoimmune assessment (antinuclear antibodies, soluble nuclear anti-antigen, ANCA, antiphospholipid antibodies, FT3, FT4 , TSH, antithyroid antibodies, ACTH cortisol, and creation of a serotheque).
223672777|NCT04306679|OTHER|Animation clips|The first animation clip focuses on the importance of pain assessment introduce three pain scales (categorical, NPS and faces) followed by explanations on their properties and on the appropriate way to use them.The second movie was aimed to provide an opportunity to implement the new knowledge in case studies
223672778|NCT04306679|OTHER|Instructions|Routine preoperative preparations, which included a section on pain assessment instructions.
223672779|NCT02925533|DRUG|B-701|B-701 is a phage-derived, affinity-matured, human monoclonal antibody (mAb) specific for FGFR3. It is based on a human immunoglobulin G1 (IgG1) framework containing heavy chain VHIII and light chain VκI subgroup sequences.
223672780|NCT02925533|DRUG|Pembrolizumab|Pembrolizumab is an mAb that binds to the programmed cell death protein 1 (PD-1) receptor and blocks its interaction with programmed death-ligand 1 (PD-L1) and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response, including the anti-tumor immune response. In syngeneic mouse tumor models, blocking PD-1 activity resulted in decreased tumor growth.
223672781|NCT00794027|BEHAVIORAL|Yoga Classes|8 weeks of yoga training that occurs 2 times per week. The patients will also perform yoga breathing at home 3 times per week.
223672782|NCT00794027|BEHAVIORAL|Yoga classes|Heart failure patients will undergo 8 weeks of yoga training 2 times per week and perform yoga breathing at home 3 times per week
223672783|NCT02597816|RADIATION|Three dimensional ultrasound|
223672784|NCT00564720|DRUG|Gemcitabine|Gemcitabine 1000mg/m2 IV on days 1, 8, and 15 every 28 days for 6 cycles
223672785|NCT00564720|DRUG|Gemcitabine|Gemcitabine 1100 mg/m2 IV on days 1 and 8 every 21 days for 6 cycles
223672786|NCT00564720|DRUG|Erlotinib|Erlotinib 100 mg by mouth (p.o.), daily until disease progression
223672787|NCT00564720|DRUG|Oxaliplatin|Oxaliplatin 130 mg/m2 IV on day 8, every 21 days for 6 cycles
223672788|NCT01919840|PROCEDURE|Group ROTEM|"10 min after administration of protamine, if there is a large diffuse microvascular bleeding or bleed excessively at the exit of surgery then will check an Intem, a Heptem a Extem and Fibtem.~If any of the determinations altered and the patient leaves still bleeding apply the proposed treatment algorithm for Rotem. 10 minutes after each treatment will take the test again indicated that treatment, to ensure that the defect has been corrected."
223672789|NCT01919840|OTHER|Group C|"10 min. after protamine administration, if there is a significant diffuse microvascular bleeding or when the patient departure from surgery if bleeds excessively will be a TCA and routed the following analytical results: prothrombin time, activated partial thromboplastin time, platelet count and fibrinogen.~If any of the determinations altered and the patient still bleeding, apply the standard protocol of the unit. 10 minutes after each treatment was performed new laboratory tests to analyze the result."
223672790|NCT01111409|DEVICE|VFIX Device|Sterile, single-use instrument capable of delivering an absorbable PDS suture anchor
223672791|NCT03042702|DRUG|Kevetrin|Kevetrin dose to associated cohort
223672792|NCT03042702|DRUG|Kevetrin|Kevetrin dose to associated cohort
223672793|NCT05354804|DIAGNOSTIC_TEST|Troponin I (Siemens VTli) 0/1 hour algorithm|Patients will be investigated using the ESC 0/1 hour cTnT algorithm from ESC compared to a 0/1 hour algorithm utilizing the Siemens VTli POC instrument for cTnI.
223672794|NCT05354804|DIAGNOSTIC_TEST|Troponin T (Roche Diagnostics) 0/1 hour ESC algorithm|Patients will be investigated using the ESC 0/1 hour cTnT algorithm from ESC compared to a 0/1 hour algorithm utilizing the Siemens VTli POC instrument for cTnI.
223672795|NCT02573038|DRUG|Aflibercept|The patients are followed on a monthly basis until 52 weeks. Intravitreal injections of aflibercept at a dosage of 2 mg are initiated at inclusion (mandatory injection) followed by mandatory injections at week 4, week 8, week 20, week 32 and week 44. During the other visits, an injection can be performed in case of CNV activity (PRN regimen).Therefore, each patient receives between 6 and 13 injections in the whole study.
223672796|NCT05386628|OTHER|conventional physiotherapy|"A basic physiotherapy program consisting of shoulder exercises will be applied to the participants.~content of the physiotherapy program~* Shoulder passive/active abduction, flexion, internal and external rotation exercises~* Posture exercises~* Neck stretching exercises~* Pectoralis major stretching exercises~* Shoulder capsule stretching exercises~* Scapular Mobilization exercises"
223672797|NCT05386628|OTHER|Manual lymphatic drainage|manual lymph drainage is a manual technique that is applied to the lymphatic system with a pressure of 40-50 mmHg and increases the working speed of lymphatic nodules/collectors. Manual lymph drainage will be made to the anterior axillar-axillar, posterior axillar-axillar and axilla-inguinal anastomosis collectors and the arm region (up to the elbow) lymph collectors.
224253363|NCT02465060|DRUG|Palbociclib|Given PO
224253364|NCT02465060|BIOLOGICAL|Pertuzumab|Given IV
224253365|NCT02465060|DRUG|PI3K-beta Inhibitor GSK2636771|Given PO
224253366|NCT02465060|PROCEDURE|Radiologic Examination|Undergo radiologic evaluation
224253367|NCT02465060|PROCEDURE|Radionuclide Imaging|Undergo nuclear study
224253368|NCT02465060|BIOLOGICAL|Relatlimab|Given IV
224253369|NCT02465060|DRUG|Sapanisertib|Given PO
224253370|NCT02465060|DRUG|Sunitinib Malate|Given PO
224253371|NCT02465060|DRUG|Taselisib|Given PO
224253372|NCT02465060|DRUG|Trametinib|Given PO
224253373|NCT02465060|BIOLOGICAL|Trastuzumab|Given IV
224253374|NCT02465060|BIOLOGICAL|Trastuzumab Emtansine|Given IV
224253375|NCT02465060|DRUG|Ulixertinib|Give PO
224253376|NCT02465060|DRUG|Vismodegib|Given PO
224253377|NCT05886049|PROCEDURE|Biospecimen Collection|Undergo collection of blood
224253378|NCT05886049|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration and biopsy
224253379|NCT05886049|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow aspiration and biopsy
224253380|NCT05886049|DRUG|Cytarabine|Given IV
224253381|NCT05886049|DRUG|Daunorubicin|Given IV
224253382|NCT05886049|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
224253383|NCT05886049|DRUG|Revumenib|Given PO
224253384|NCT05886049|PROCEDURE|Transthoracic Echocardiography Test|Undergo transthoracic ECHO
223772221|NCT00451282|BEHAVIORAL|stepped preventive care|2 targeted assessments (T1: in hospital within a few days of injury; T2: two weeks post-discharge) are administered by nurse or social worker, and determine need for additional assistance modules. Additional modules include case management, care coordination, assistance with child and family coping with injury/distress, and trauma-focused Cognitive Behavior Therapy (CBT) beginning at 4-6 weeks post-injury if needed.
224253385|NCT03985345|DEVICE|intravaginal device (probe) EMY|Free use of EMY and its mobile application for 10 minutes during 5 different days per week.
224253386|NCT00176020|DRUG|nicotinic acid|
224253387|NCT04255420|PROCEDURE|SPG Block|A cotton-tipped applicator soaked in 1% lidocaine will be inserted into the nostril on the side of the headache. If the headache is bilateral, two cotton-tipped applicators will be inserted. The cotton-tipped applicators will be left in place for 15 minutes.
224253388|NCT04255420|DRUG|Standard IV Treatment|Intravenous prochlorperazine 10 mg plus diphenhydramine 50 mg will be administered.
224253389|NCT03340376|DRUG|Atezolizumab|atezolizumab
224253390|NCT03340376|DRUG|Doxorubicin|Doxorubicin
224253391|NCT00204373|DRUG|Lansoprazole (Prevacid)|Lansoprazole 30mg capsules. dose is individualized to each subject based on gastric acid production. The range is 30 mg to 450 mg daily.
224253392|NCT06626776|PROCEDURE|lateral sinus lift with using allograft and collagen membrane|sinus floor elevation with placing allograft and collagen membrane
224253393|NCT06626776|PROCEDURE|lateral sinus lift with using exteneded platelet rich fibrin|sinus floor elevation with placing eprf
224253394|NCT01619891|DIETARY_SUPPLEMENT|Vitamin D|100mcg per day
224253395|NCT01250080|DIETARY_SUPPLEMENT|Total Parenteral Nutrition with Glutamine|daily glutamine supplement of 0.35 g/kg weight as N2-L-Alanyl-L-Glutamine (0.5 g/kg/d - Dipeptiven Fresenius Kabi España) during five days.
224253396|NCT01250080|OTHER|Total Parenteral Nutrition without glutamine|The control group received a supplemental volume of the basic TPN solution to achieve an isocaloric an isonitrogenated formula with the study group.
223672798|NCT05386628|OTHER|Myofascial relasing|it will be done with the thumb or 3rd finger from the acu points of the superficial arm-anterior myofascial chain. 6-8 seconds with thumb to these points. pressure will be applied and vibration will be given clockwise.
223672799|NCT06020729|OTHER|General Exercises without occlusion training|General Exercises as bench press, squats , maximum sprint, leg power without occlusion training
223672800|NCT06020729|OTHER|Occlusion Training|In experimental sessions players will perform with occlusion training which is blood flow resistance training, 4 times a week for 4 weeks with 5 sets of 5 repetitions and then assessed pre-training and post-training values with assessment tools bench press, leg squat, leg power, maximum sprint time.This training will also improve and increase muscular strength as well as speed and physical performance in players.
223672801|NCT04352127|DEVICE|TetraGraph|FDA approved neuromuscular transmission monitor capable of measuring the depth of neuromuscular block in anesthetized patients who received neuromuscular blocking agents. TetraGraph uses EMG to measure the muscle action potentials that are generated in response to electrical neurostimulation via skin electrodes.
223672802|NCT01385332|PROCEDURE|Early luteal phase|We will administer in the tenth day of the cycle 0.25mg/day of ganirelix until the estradiol levels will be less than 60pgr/mL. Then, we'll start a standard protocol of controlled ovarian hyperstimulation beginning with 150 UI/day. At 6th day of stimulation we'll begin with the antagonist.
224253397|NCT00571064|DRUG|Donepezil HCl|One 5 mg tablet per day (for the first 6 weeks) with a full glass of water. For the last 6 weeks, one 10mg tablet per day with a full glass of water.
224253398|NCT00283608|GENETIC|Single nucleotide polymorphism (SNP)|Evaluating SNP association with traits.
224253399|NCT00283608|OTHER|high performance liquid chromatography|analysis of plasma concentrations of drugs
224253400|NCT00283608|OTHER|measurements by DXA|determine bone mineral density (BMD)
224253401|NCT00283608|OTHER|questionnaire administration|determine attitude changes
224253402|NCT00573417|DRUG|modafinil|modafinil 100mg tablets. dose excalation up to 300mg
223672803|NCT01385332|PROCEDURE|Late follicular phase -COH-|We will administer in the 20th day of the cycle 0.25mg/day of ganirelix until the estradiol levels will be less than 60pgr/mL. Then, we'll start a standard protocol of controlled ovarian hyperstimulation beginning with 150 UI/day. At 6th day of stimulation we'll begin with the antagonist.
223672804|NCT00413088|DRUG|bemiparin|
223672805|NCT05438108|COMBINATION_PRODUCT|SBRT Sequential CapeOX Regimen Combined With Bevacizumab and Sintilimab|SBRT Sequential CapeOX Regimen Chemotherapy Combined With Bevacizumab and Sintilimab
223672806|NCT03645018|DIAGNOSTIC_TEST|diagnosis with tomosynthesis|Re-evaluation of lung nodule detection rate at 5 years in patients with early diagnosis of lung cancer
224253403|NCT00573417|DRUG|Placebo|
223672807|NCT05883371|OTHER|Root-cause autoimmune treatment program|The AndHealth autoimmune treatment program combines validated and guideline-driven approaches along with emerging evidence-based modalities. The program includes a comprehensive assessment of disease severity, analysis of root causes and comorbidities, and an evaluation of the patient's readiness for implementing important lifestyle changes. This is followed by the development of an optimized and personalized plan to achieve and sustain clinical remission while monitoring their progress. Each patient participating in the AndHealth program receives a personalized care plan developed by the patient's medical provider in collaboration with a team of healthcare specialists. Helping a patient manage everyday lifestyle decisions can have a profound effect on their ability to achieve and maintain remission. The AndHealth Program has organized these into four basic groups of lifestyle behaviors: 1.) Dietary/Nutrition, 2.) Sleep/Circadian, 3.) Stress/HPA axis, and 4.) Physical Activity.
223672808|NCT02856126|PROCEDURE|Hepatic arterial infusion chemotherapy|
223672809|NCT02856126|PROCEDURE|Transarterial chemoembolization|
224253404|NCT00244764|DRUG|GW786034|All patients receive GW786034. At week 12, some subjects will be randomized based on response (SD) and the others will remain on drug. After the interim analysis, the design was changed to an open label, single arm study with all subjects receiving pazopanib.
224253405|NCT00244764|DRUG|Placebo|All patients receive GW786034. At week 12, some subjects will be randomized based on response (SD) and the others will remain on drug. After the interim analysis, the design was changed to an open label, single arm study with all subjects receiving pazopanib.
224253406|NCT05408884|OTHER|Social Support|"Social support phone buddy program."
224253407|NCT05408884|OTHER|Basic income|$750 per month for 12 months
224253408|NCT00858754|DRUG|methylnaltrexone|
224253409|NCT00858754|DRUG|placebo|
224253410|NCT02472197|PROCEDURE|Hysteroscopic morcellation|The endometrial polyp is resected by a transcervical approach. During the procedure, the polyp is placed by suction against the window of the device, then cut by mechanical energy, in chips which are directly aspirated by the device.
224253411|NCT02472197|PROCEDURE|Standard hysteroscopic resection|The endometrial polyp is resected by a transcervical approach in several chips using a mono or bipolar cove after distension of the uterine cavity under endoscopic control.
224253412|NCT06350591|OTHER|Immobilization|single-leg immobilization
224253413|NCT06350591|OTHER|Resistance training|Leg extension and leg press; 3 sets of 8-12 reps
224253414|NCT01308164|DEVICE|MD Logic Pump Advisor|Insulin pump setting (i.e basal plan, correction factor, carbohydrate ratio and insulin activity time)will be adjusted using the MD-LOgic Pump Advisor
224253415|NCT04530994|DRUG|maralixibat|Maralixibat is an Apical Sodium-dependent Bile acid Transporter (ASBT) inhibitor
223672810|NCT02856126|DRUG|TACE regimen|infusion with lipiodol mixed with chemotherapy drugs (EADM , lobaplatin, and MMC ), and embolization with polyvinyl alcohol particles (PVA)
223672811|NCT02856126|DRUG|HAIC Regimen|Hepatic intra-arterial infusion via the tumor feeding arteries of Oxaliplatin , fluorouracil, and leucovorin
223672812|NCT02856126|DRUG|Oral Sorafenib|Oral Sorafenib, 400mg, Bid
223672813|NCT05737602|BEHAVIORAL|3RP-VHL|An adapted version of the Relaxation Response Resiliency Program (3RP) for individuals with VHL.
223672814|NCT00710437|DRUG|Dexmedetomidine|Steady state infusion 0.007 mcg/kg/min
223772222|NCT02538497|BEHAVIORAL|The Newborn Behavioral Observation (NBO)|"The Newborn Behavioral Observation (NBO) is a flexible parental guidance methodology which takes between 20 and 40 minutes to administer. It consists of 18 neurobehavioral observations which give a profile of the infant´s behavioral repertoire along the dimensions: attentional-interactional, autonomic, motor and state organization.~The intervention group will receive 3 NBO consultations: 1) Routine care plus the NBO at the hospital within two days post-delivery; 2) Routine home visit plus the NBO by a public health nurse when the infant is 7-10 days old; and 3) NBO at the well-baby clinic when the infant is about 4 weeks old."
224253416|NCT00231829|DRUG|Celecoxib|
224253417|NCT06311682|DRUG|Tralokinumab + TCS|The trial medication will be given under the skin (SC). Dose and dosing frequency for each subject will depend on the subject's body weight. Subjects who will receive treatment every two weeks will receive a loading dose corresponding to a double dose at baseline. Subjects who will receive treatment every 4 weeks will receive a staggered loading dose at baseline and Week 2. After the loading dose, they will continue to receive treatment every 4 weeks. The dose and dosing frequency will be adjusted according to the subject's body weight at weeks 16, 32, 52, 64, 88, 112, 136, 160, and 184.
224253418|NCT06311682|DRUG|Placebo + TCS|The trial medication will be given under the skin (SC). Dose and dosing frequency for each subject will depend on the subject's body weight. Subjects who will receive treatment every two weeks will receive a loading dose corresponding to a double dose at baseline. Subjects who will receive treatment every 4 weeks will receive a staggered loading dose at baseline and Week 2. After the loading dose, they will continue to receive treatment every 4 weeks. The dose and dosing frequency will be adjusted according to the subject's body weight at weeks 16, 32, 52, 64, 88, 112, 136, 160, and 184.
223672815|NCT02906228|RADIATION|Exposure within the given regulatory limits for non-ionizing electromagnetic fields according to ICNIRP guidelines and German law|
223672816|NCT05338671|DRUG|Local anesthetic|Patients will receive inferior alveolar nerve block injection following endodontic treatment.
223672817|NCT05946265|DEVICE|Photobiomodulation|120 patients with dentin sensibility after non-surgical scaling and root planning (SRP) will be randomly included in 2 groups: Experimental Group: SRP+ Photobiomodulation (PBM) The dosimetric parameters for the treatment included a wavelength of 660 nm applied in continuous mode with a radiant power of 100 mW (0.1 W). The irradiance ranged from 35.385 mW/cm² to 35 W/cm², with a beam area of 0.002826 cm². Each point received an exposure time of 30 seconds, resulting in a radiant exposure of 1.061 J/cm² and a total radiant energy of 3 J. The procedure involved six irradiated points per tooth, distributed across the vestibular surface (apical, middle, and cervical regions) and the palatal surface. The application technique was performed in contact, maintaining a 90-degree angle to the surface. The treatment consisted of a single session.
224253419|NCT01499147|DRUG|fludarabine/busulfan|All patients below age 55, should receive fludarabine/busulfan, and ATG in case of unrelated or mismatched donor, unless there is significant pulmonary, hepatic or cardiac damage: (E.g FEV1 \<40%, DLCO\<50%, LVEF\<40, Serum bilirubin \>1.5 mg% or serum transaminases \> 2x nl) and/or specific medical conditions such as preventing a standard myeloablative treatment, as per discussion with the PI.
224253420|NCT01499147|DRUG|fludarabine/ melphalan|All patients above age 55 or below age 65, should receive fludarabine/melphalan, and ATG, unless there is significant pulmonary, hepatic or cardiac damage: (E.g FEV1 \<40%, DLCO\<50%, LVEF\<40, Serum bilirubin \>1.5 mg% or serum transaminases \> 2x nl).
224253421|NCT01499147|DRUG|ATG|Patients receiving a transplant from a matched unrelated or mismatched related/unrelated donor would receive ATG in the conditioning regimen.
224253422|NCT00242398|DEVICE|AN69 ST|
224253423|NCT03872128|DRUG|Pregnenolone300|300mg
224253424|NCT03872128|DRUG|Pregnenolone500|500mg
224253425|NCT03872128|DRUG|Placebo|placebo
224253426|NCT05838391|RADIATION|Artificial Intelligence Guided Daily Radiotherapy Treatment Planning and Delivery|Subjects will receive 54 Gy of radiation delivered 5 day a week for 6 weeks, 30 radiation treatments total. Intensity-Modulated photon radiation therapy will be delivered on a Varian Ethos linear accelerator. Daily image-guided radiation therapy (IGRT) is required. All treatments will have artificial-intelligence (AI) daily adaptations of the radiation plan to optimize the radiation dose to the targeted area and minimize radiation dose to the normal surrounding organs such as the bowel.
224253427|NCT05838391|DRUG|Mitomycin-C|As part of the subjects' treatment, 10 mg/meters squared of Mitomycin C will be administered intravenously (IV-into the vein) on Day 1 and Day 29.
224253428|NCT05838391|DRUG|5-Fluorouracil|As part of the subjects' treatment, 1g/meters squared/day for 4 days of 5-Fluorouracil will be administered by continuous infusion on Days 1-4 (for 96 hours) and Days 29-32 (for 96 hours). 5-Fluorouracil or capecitabine will be administered per the physician's discretion.
224253429|NCT05838391|DRUG|Capecitabine|As part of the subjects' treatment, 825 mg/meters squared per day, divided into 2 daily doses, will be taken on days of radiotherapy. Capecitabine or 5-FU will be administered per the physician's discretion.
224253430|NCT01090791|DEVICE|Flotrac/Vigileo third generation software|Measurement of stroke volume according to the arterial pressure waveform
224253431|NCT01090791|DEVICE|Transthoracic echocardiography|Measurement of stroke volume according to the aortic time-velocity integral
224253432|NCT05901272|OTHER|Local clinical champion|A clinical champion is a local provider who serves as a liaison between local clinics and local or regional leadership or national program offices (e.g., HHRC) and advocates for the HITIDES intervention with their local peers. A clinical champion can provide ongoing promotion of and education about HITIDES and remind care providers of its presence and value either formally (e.g., presentations at staff meetings) or informally (e.g., individual conversations about HITIDES benefits). Clinical champions can also engage middle managers or local leadership to buy in to and support intervention uptake. Clinical champions may also work with Veterans in quality improvement efforts to garner their ideas for how to outreach to other Veteran patients, plan quality improvement cycles, or consult in an advisory capacity. Potential champions will be approached about participation after consultation with site HIV care providers and HHRC.
223672818|NCT05946265|DEVICE|simulation of Photobiomodulation|Simulation of the use of FBM will be carried out identically to the Experimental group. The person responsible for applying the FBM will simulate irradiation by positioning the devices in the same locations described for the FBM group, however, the laser pointer will be turned off and the sound of the device will be recorded to mimic the use of the equipment and the participant will not identify the group to be used. who belongs. In this trial, we have no criteria for discontinuing or modifying allocated interventions because no harm is expected with this intervention.
223672819|NCT01924702|BEHAVIORAL|Intensive language therapy|2 weeks of daily computerized naming training, daily, 3 hours
223672820|NCT01924702|DEVICE|transcranial direct current stimulation|1mA anodal over M1 primary motor cortex for 20min with 35cm/2 electrode, Cathode (100cm/2) contralateral
223672821|NCT04456673|DRUG|Dupilumab SAR231893|"Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous"
223672822|NCT04456673|DRUG|Inhaled Corticosteroid|"Pharmaceutical form: Inhaled Powder~Route of administration: Oral inhalation"
223672823|NCT04456673|DRUG|Inhaled Long-Acting Beta Agonist|"Pharmaceutical form: Inhaled Powder~Route of administration: Oral inhalation"
223672824|NCT04456673|DRUG|Inhaled Long-Acting Muscarinic Antagonist|"Pharmaceutical form: Inhaled Powder~Route of administration: Oral inhalation"
223672825|NCT04456673|DRUG|Placebo|"Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous"
223672826|NCT04391049|DRUG|Carboplatin|Intravenously (IV)
223672827|NCT04391049|DRUG|Paclitaxel|Intravenously (IV)
223672828|NCT04391049|RADIATION|Radiation Therapy|Daily fractions
223672829|NCT04391049|BIOLOGICAL|Telomerase-specific Type 5 Adenovirus OBP-301|Intra-tumoral injection
223672830|NCT04974775|DIAGNOSTIC_TEST|Blood collection|Sampling on admission to ICU (all patients)
223672831|NCT04974775|DIAGNOSTIC_TEST|Blood collection, serial sampling|"Additional sampling to admission samples in~1. the Cardiac Arrest group after 12 and 48 hours~2. the Covid-19 group on day 2 and 7 while in the ICU~3. the Covid-19 group after 3 and 12 months."
223672832|NCT03579017|DIAGNOSTIC_TEST|ECAS-N|All participants included will be tested with the ECAS-N
223672833|NCT03579017|DIAGNOSTIC_TEST|MoCA|All included patients With ALS will be tested With the MoCA
223672834|NCT06307418|OTHER|Carer eSupport|Internet-based support
223672835|NCT05804188|OTHER|tracheal intubation|children between 0-16 requiring tracheal intubation
223672836|NCT05189106|DRUG|Baricitinib|Each participant will be treated with open-label baricitinib for 24 weeks. Participants will receive 2 mg baricitinib by mouth daily for the first 8 weeks and 4 mg baricitinib by mouth daily for the remaining 16 weeks.
223672837|NCT05770674|DRUG|1 Month vs. 12 Months DAPT|"Dual antiplatelet therapy with aspirin plus clopidogrel will be given for the following period after PCI according to patient allocation~1. 1 Month following PCI, followed by clopidogrel monotherapy~2. 12 Months following PCI"
223672838|NCT03874429|DEVICE|T2259|Sodium Hyaluronate and Trehalose
223672839|NCT03874429|DEVICE|Vismed multi|HA
223672840|NCT04096183|OTHER|Ventilation of healthy volunteers|Ventilation of healthy volunteers in different clinical situations
223672841|NCT03721445|DEVICE|continuous positive airway pressure|Could the changes of HRV between PSG night and CPAP titration night predict the CPAP adherence?
223672842|NCT04661098|PROCEDURE|(Darwish hymenotomy technique)|Formation of an annular hymen in cases of postpubertal imperforate hymen using a laparoscopic trocar (Darwish hymenotomy technique)
223672843|NCT04008043|DRUG|Vicodin|In addition to taking one tablet of vicodin for pain every 4-6 hours up to 8 tablets, pain scores will be recorded the evening of the surgery, the day after the surgery and one week after the surgery.
223672844|NCT04008043|DRUG|Dexamethasone|In addition to taking one tablet of dexamethasone for pain beginning the day before surgery and on the day of surgery, pain scores will be recorded the evening of the surgery, the day after the surgery and one week after the surgery.
223672845|NCT02515812|DRUG|I-123-MIBG|
223672846|NCT02515812|DEVICE|CZT Camera (D-SPECT)|
223672847|NCT02515812|DEVICE|Anger Camera|
223672848|NCT03351894|PROCEDURE|Femtosecond laser assisted cataract surgery|Ziemer Z8 femtosecond laser assisted cataract surgery
223672849|NCT03351894|PROCEDURE|Conventional phacoemulsification|conventional phacoemulsification with infinity phaco
223672850|NCT05518838|DRUG|OKN-007|OKN-007 is an intravenously administrated drug being developed as a novel anti-cancer therapy against gliomas.
223672851|NCT01953263|OTHER|Autologous Muscle Fiber Fragments|Autologous muscle fiber fragments administered via a single direct injection into the bladder neck sphincter region
223672852|NCT05308719|DEVICE|High Flow Nasal Therapy|High Flow Nasal Oxygen (Airvo2 Device)
223672853|NCT05924295|DIETARY_SUPPLEMENT|Ketone Supplement|Participants will be given 360mg/kg
224253433|NCT05901272|OTHER|Learning collaborative|Learning Collaboratives are groups of providers or provider organizations and foster a collaborative learning environment to improve implementation of the clinical innovation (HITIDES). There are several approaches to this in the literature including peer consultation networks, online communities of practice, quality circles, and learning collaboratives. Groups will meet virtually using a wide variety of media. Participation will be monitored by research staff and recorded by participants in a time-tracking log but not controlled. The learning collaboratives will be comprised of a group of site clinical champions, HIV care providers, and other VHA HIV care representatives, potentially including Veterans who are engaged in implementation activities, to foster a learning environment to improve the implementation of HITIDES through consultation.
224253434|NCT05901272|OTHER|External facilitation|. External facilitation will be provided by a trained external facilitator who is given the HITIDES Operations Guide and Consumer Voice tools for Veteran engagement in quality improvement. Facilitation is a process to enable sites to increase uptake of HITIDES through supportive relationships and strategies to navigate the implementation process. Virtual external facilitation is a recognized modality of facilitation delivery in VHA. The external facilitator will work with the clinical champion, site personnel, and Veterans-not conducting research activities but engaging in quality improvement processes with these individuals. The addition of a facilitator allows problem identification and problem-solving, using processes based on supportive relationships.
224253435|NCT01352091|DRUG|Zoladex+AI|Patients who took tamoxifen or Fareston for 2-3 years were randomized into 2 groups (335 patients for each group). One group would switch to receive Zoladex 3.6mg depot subcutaneously every month and Aromidex 1mg/d po for another 3-2 years
224253436|NCT01352091|DRUG|TAM|Patients who took tamoxifen or Fareston for 2-3 years were randomized into 2 groups (335 patients for each group). One group would receive TAM 20mg/d treated for 3-2 years.
224253437|NCT00007605|DRUG|Amiodarone|Patients assigned will receive 400 mg bid for 14 days, 400 mg QAM and 200 mg QHS for 14 days, 300 mg qd for 48 weeks, then 200 mg qd.
224253438|NCT00007605|DRUG|Sotalol|Patients assigned will receive 80 mg bid for 7 days and 160 mg bid thereafter.
224253439|NCT00550758|DRUG|Methachoine|inhalation of triple-concentration increments (0.06 to13.9mg/ml/methacholine)
224253440|NCT00550758|DEVICE|spirometry|spirometry
224253441|NCT02080663|PROCEDURE|Proximal row carpectomy|
223672854|NCT05924295|BEHAVIORAL|Beverage Tolerability Questionnaire (BTQ) and satiety visual analogue scale|Beverage Tolerability Questionnaire (BTQ) and satiety visual analogue scale will be administered at beginning and end of testing day to tests palatability of supplement
223672855|NCT05924295|BIOLOGICAL|Blood Draw|IV cannula will be inserted at the start of Test Day, and removed at the end of Test Day. Blood samples will be collected at 7 timepoints (possibly 1 more). Cannula will be flushed with a small volume of saline after each sample to maintain patency.
223672856|NCT05924295|OTHER|Urine Analysis|Prior to consumption of the Study Product, participants will be asked to completely void bladder. And hydration status will be determined via urine specific gravity (USG) reporting \<1.025. Urine passed after the ingestion of the study product will be collected in a plastic container; participants will be asked to void their bladder and collect urine at the end of the test day. The volume produced will be recorded at the end of the study and aliquots will be frozen and stored for future analysis
223672857|NCT04741464|DRUG|Tinzaparin|"Tinzaparin 20 000 anti-Xa IU/mL dispensed in graduated syringes of 0.5 mL, 0.7 mL and 0.9 mL at the dose of 175IU/Kg/d.~Strategy: Tinzaparin 175 UI/Kg/d for 21 days After this time the physician will continue the treatment of his choice to treat DVT."
223672858|NCT05303701|DRUG|GV1001 Placebo|0.9% normal saline
224253442|NCT03702608|COMBINATION_PRODUCT|EluNIR Ridaforolimus Eluting Coronary Stent System|"The EluNIR Ridaforolimus Eluting Coronary Stent System is a single use device/drug combination product comprising of:~* Stent - a mounted Cobalt Chromium (CoCr) alloy based stent - 38 mm length and 2.75mm, 3.0 mm, 3.5mm, 4.0mm diameter~* Delivery System - Rapid Exchange (RX) Coronary System~* Polymer matrix coating - (PBMA) and CarboSil®~* Ridaforolimus drug"
224253443|NCT03285594|DRUG|Sotagliflozin|"Pharmaceutical form: Tablet~Route of administration: Oral"
224253444|NCT03285594|DRUG|Insulin glargine (HOE901)|"Pharmaceutical form: Solution~Route of administration: Subcutaneous"
223672859|NCT05303701|DRUG|GV1001 1.12mg|Lyophilized peptide from hTERT
223672860|NCT05601492|DRUG|Otezla - Standard Care|The participant will be given their medication with the electronic adapter cap on it and asked to return for the follow-up visit
223672861|NCT05601492|BEHAVIORAL|Reminder Text Intervention with apremilast|Participants will receive a weekly electronic text/email-based intervention that is designed to promote better adherence to treatment in addition to receiving their medication with the electronic adapter cap on it.
223672862|NCT05601492|BEHAVIORAL|Extended Consultation for apremilast|Participants will be given their medication with the electronic adapter cap on it and will receive an initial patient consult intervention, which will focus on medication education and setting expectations of what to anticipate with usage of the prescribed medication
223672863|NCT06304636|DRUG|Descartes-15|Autogolous T-cells expressing a chimeric antigen receptor directed to BCMA
224253445|NCT03285594|DRUG|Placebo|"Pharmaceutical form: Tablet~Route of administration: Oral"
224253446|NCT03285594|DRUG|Oral Antidiabetes Drugs (OADs)|OADs (including metformin) as prescribed by the investigator as per local labeling.
224253447|NCT04267276|DRUG|Part 1: BI 1265162 - intravenous|Intravenous solution
224253448|NCT04267276|DRUG|Part 2: BI 1265162 - oral|Oral solution
224253449|NCT00492076|BIOLOGICAL|Pangramin Plus D. pteronyssinus 100%|"1. Active. Pangramin Plus D. pteronyssinus 100%~2. Placebo. Pangramin Plus placebo"
224253450|NCT00882505|DIETARY_SUPPLEMENT|vitamin D|Subject will receive vitamin d supplements
224253451|NCT00882505|OTHER|Placebo|Subject will receive a placebo.
224253452|NCT05058508|OTHER|"Just Move Exercise"|"Subjects complete Just Move Exercises Five Times Per Week"
224253453|NCT05058508|OTHER|Standard of Care Exercise|Subjects exercise/move as tolerated
224253454|NCT01312844|DRUG|Scopolamine|Those receiving active drug will receive scopolamine 4mcg/kg IV with each treatment, until completion of ECT
224253455|NCT05645367|OTHER|No intervention|This is a post-hoc analysis of a cross-sectional study.
224253456|NCT02109263|PROCEDURE|saccharose versus breast-feeding|saccharose versus breast-feeding
224253457|NCT05523986|OTHER|Vitamin D|Vitamin D (2000IU/day) for 6 months
224253458|NCT05523986|OTHER|Placebo|Placebo
223672864|NCT00628238|DRUG|Lenalidomide and Rituximab|Lenalidomide starting at a low dose and escalated based on patient tolerability 21 days of every cycle. Rituximab at 375mg/m2 administered following the first 21 days of lenalidomide monotherapy, continued weekly throughout cycle 2, and then every 4 weeks for subsequent cycles. Each patient may receive up to a maximum of 7 cycles of treatment if no progressive disease or significant toxicity.
223672865|NCT00628238|DRUG|Lenalidomide and Rituximab|Lenalidomide starting at a low dose and escalated based on patient tolerability 21 days of every cycle. Rituximab at 375mg/m2 administered following the first 21 days of lenalidomide monotherapy, continued weekly throughout cycle 2, and then every 4 weeks for subsequent cycles. Each patient may receive up to a maximum of 7 cycles of treatment if no progressive disease or significant toxicity.
224253459|NCT01778205|OTHER|Observational|
223672866|NCT05356728|DRUG|Thealoz Duo (combination of trehalose and hyaluronate) eye drop and Hyabak (hyaluronate) eye drop|One of the eyes will be assigned to use Thealoz Duo while the other with Hyabak by using randomisation table
223672867|NCT02679963|DRUG|Olaparib|
223672868|NCT02679963|DRUG|Placebo|
223672869|NCT05688384|DRUG|Propofol + Alfentanil|In addition to LA, patients in the study group are able to self-administer a combination of propofol and alfentanil using a patient-controlled sedation pump. The pump enables the patient via a hand-held button to trigger the release of a single bolus of 0.5ml containing 4.5mg propofol and 25µg alfentanil under an 10second period. This results in a maximal possible amount of 6 bolus doses per minute.
223672870|NCT01203644|DRUG|SKY0402|Single dose of SKY0402 administered locally into the surgical wound.
223672871|NCT01203644|DRUG|Bupivacaine HCl|Single dose of bupivacaine HCl (100 mg) administered locally into the surgical wound.
223672872|NCT00002671|DRUG|aminocamptothecin|
223672873|NCT03183154|OTHER|no intervention|no intervention
223672874|NCT04618627|OTHER|lung ultrasound|Role of lung ultrasonography in prediction of the seveity and the need for surfactant administration in neonates with respiratory distress syndrome.
223672875|NCT00645255|DRUG|placebo|placebo one capsule daily
223672876|NCT00645255|DRUG|sibutramine or placebo|one capsule daily
223672877|NCT05453734|PROCEDURE|Progressive Muscle Relaxation Exercises|Before data collection, one of the researchers received training and certification from a psychotherapist specialist in this field to be able to apply the PMR exercises. The guidelines on the PMR exercises were prepared in line with the literature and training received by the researcher. In the guidelines, the person is asked to be in a comfortable place and position, to reach the face by following the large muscle groups gradually, starting from the feet, to tense the muscles in each step, and then to release them. It is necessary to take a deep breath after each muscle group, to stop for a while, and release it slowly
223672878|NCT04551313|BEHAVIORAL|social skill group|We plan to address basic interactional and conversational skills first, then focus on teaching perspective-taking and theory of mind skills.
223672879|NCT04169971|OTHER|Music|Played through headphones during the operation under spinal anaesthesia
223672880|NCT00884767|DRUG|FOLFOX regimen|
223672881|NCT00884767|DRUG|fluorouracil|
223672882|NCT00884767|DRUG|leucovorin calcium|
223672883|NCT00884767|DRUG|oxaliplatin|
223672884|NCT00884767|GENETIC|gene expression analysis|
224253460|NCT05176600|DEVICE|Robotic rehabilitation using the Arm Light Exoskeleton Rehab Station (ALEx RS) and bimanual serious games|Patients will undergo a bimanual 30-session robotic rehabilitation, using the robot ALEx RS with the bimanual configuration and the related serious games. Each session will last 45 minute. Daily sessions will be provided, five days a week.
224253461|NCT05176600|DEVICE|Robotic rehabilitation using the Arm Light Exoskeleton Rehab Station (ALEx RS) and unimanual serious games|Patients will undergo a unimanual 30-session robotic rehabilitation, using the robot ALEx RS with the unimanual configuration and the related serious games.Daily sessions will be provided, five days a week.
224253462|NCT06628336|DEVICE|HARMONY EVOLUTION|It is planned to include consecutive eligible subjects which will be treated with the HARMONY EVOLUTION devices.
224253463|NCT04877210|DRUG|Topical Insulin|Insulin (Actrapid) diluted in Normal Saline is given to participant 1 drop to both eyes 4 times per days for 4 weeks
224253464|NCT02479633|OTHER|Coronally advanced flap with connective tissue graft|"Two oblique, divergent releasing incisions extending beyond the mucogingival junction were performed. An intra-sulcular incision was performed at the buccal aspect of the involved tooth. Subsequently, a partial-thickness flap was raised beyond the MGJ. The papilla adjacent to the involved tooth were then de-epithelialized.~The CTG was harvested using a single incision approach from the palate. The graft was positioned on the instrumented root surface immediately apical of the CEJ and then stabilized using a sling compressive crossing suture. The flap was coronally displaced 1-2 mm above the CEJ. A sling suture was placed to stabilize the flap in a coronal position, followed by interrupted sutures on the releasing incisions with an apico-coronal direction."
223672885|NCT00884767|GENETIC|protein expression analysis|
223672886|NCT00884767|GENETIC|proteomic profiling|
223672887|NCT00884767|OTHER|laboratory biomarker analysis|
223672888|NCT00884767|OTHER|pharmacogenomic studies|
223672889|NCT00228982|DRUG|Ceftobiprole medocaril|
223672890|NCT00228982|DRUG|Vancomycin|
223672891|NCT02890108|DIETARY_SUPPLEMENT|Sugar sweetened beverages|350 cc (1 can) of sugar sweetened beverage
223672892|NCT02890108|DIETARY_SUPPLEMENT|Artificially sweetened beverages|350 cc (1 can) of artificially sweetened beverage
223672893|NCT00992589|DRUG|Rabeprazole sodium 5 mg|Rabeprazole Sodium 5 mg capsules once daily in the morning.
223672894|NCT00992589|DRUG|Rabeprazole sodium 10 mg|Rabeprazole Sodium 10 mg capsules once daily in the morning.
223672895|NCT00992589|DRUG|Placebo|Matching placebo capsules once daily in the morning.
224253465|NCT01990391|DIETARY_SUPPLEMENT|Brazil nut flour|The Brazil nut group received 13g/day of Brazil nut flour during three months.
224253466|NCT01990391|DIETARY_SUPPLEMENT|Placebo (cassava flavored flour)|The group placebo (cassava flour flavored)received 9g/day of cassava flour flavored during three months
223672896|NCT01215916|DRUG|LY573636|"Individualized dose is dependent on a patient's height, weight, and gender and is adjusted to target a specific exposure range corrected for a patient's laboratory parameters. Intravenous dosing is completed once per cycle (cycle equals either 21 or 28 days).~Patients may continue on study drug until disease progression, unacceptable toxicity, or other withdrawal criteria are met.~Patients are pretreated with folic acid \[350 micrograms (µg) to 1000 µg orally, daily\], Vitamin B12 (1000 µg intramuscular injection every 9 weeks), and dexamethasone \[4 milligrams (mg) orally, twice daily or equivalent\]."
223672897|NCT01215916|DRUG|Pemetrexed|"375 to 500 milligrams per square meter (mg/m\^2), intravenous dosing is completed once per cycle (cycle equals either 21 or 28 days).~Patients may continue on study drug until disease progression, unacceptable toxicity, or other withdrawal criteria are met.~Patients are pretreated with folic acid (350 µg to 1000 µg orally, daily), Vitamin B12 (1000 µg intramuscular injection every 9 weeks), and dexamethasone (4 mg orally, twice daily or equivalent)."
223672898|NCT00045942|DRUG|Itraconazole|Itraconazole was commercially available.
223672899|NCT00045942|DRUG|PKC412|PKC412 was supplied as soft gelatin capsules containing 25 mg PKC412.
223672900|NCT04779736|BEHAVIORAL|A set of implementation strategies to reduce sexual stigma|The set of implementation strategies was finalized based on formative interviews and consultation with an advisory board. This included an in-person workshop for skills development, environmental restructuring through a website of information resources for healthcare consumers and HCWs, and supportive coaching components (i.e., coaching calls, an optional email listserve) and quality improvement meetings with two clinics to encourage and respond to the implementation of recommended practices.
223672901|NCT00643084|PROCEDURE|low residue diet/no standard bowel preparation|low residue diet/no standard bowel preparation
223672902|NCT00643084|PROCEDURE|standard bowel preparation|standard bowel preparation
223672903|NCT02142387|OTHER|BLS CPR program with dispatcher assisted CPR simulation|the training program more focuses on cooperation with a dispatcher, from recognition to perform DA-CPR and hands-on practice.
223672904|NCT05028361|BIOLOGICAL|mRNA COVID-19|ACIP-CDC recommended vaccine
223672905|NCT05028361|BIOLOGICAL|IIV4|ACIP recommended vaccine
223672906|NCT05028361|OTHER|Placebo (saline)|Saline Control
223672907|NCT03526380|BEHAVIORAL|Behavioral: the OPT-IN Intervention|A private one-on-one brief motivational interviewing intervention administered by non-research staff at community organizations. This will take up to 30 minutes to complete. The goal of the intervention is to improve opioid safety and reduce related overdoses among those who has a history of misusing opioids (prescription and illicit). The session will use techniques to change behavior in a respectful, non-confrontational, and non-judgmental manner. This intervention will also seek to empower participants by providing content on bystander response as well as peer outreach, which emphasizes ways to discuss overdose risk with others at risk for overdose.
223672908|NCT01542424|DRUG|biphasic insulin aspart 30|Prescribed at the discretion of the physician
223672909|NCT01542424|DRUG|insulin detemir|Prescribed at the discretion of the physician
223672910|NCT03640780|OTHER|observation|The surgical ages and other information between two groups were compared.
223672911|NCT00465309|PROCEDURE|protective ventilation with CO2 removal technique|In ARDS patients, presenting a Pplat ≥ 26 cmH2O, Vt was lowered (reaching a Pplat \< 26) with CO2-removal veno-venous pump-driven bypass support for 48 consecutive hours with a pH \> 7,30 or at least 72 hours from the beginning of the extracorporeal treatment.
223672912|NCT06449404|OTHER|7T-MRI scaning|7T-MRI scaning
223672913|NCT02513147|DRUG|Dolutegravir|
223672914|NCT02513147|DRUG|PI|(Fosamprenavir, atazanavir, lopinavir or darunavir) boosted with 100 mg of ritonavir, or atazanavir (400 mg / d) not boosted with ritonavir,if the 2 NRTIs are abacavir + Lamivudine
223672915|NCT02513147|DRUG|2 NRTI|
223672916|NCT02513147|DRUG|2 NRTI|
223672917|NCT04727021|DRUG|20 mg tablet rivaroxaban|Single oral dose of a 20 mg tablet rivaroxaban, administered under fed conditions
223672918|NCT04727021|DRUG|20 mg rivaroxaban, granules for oral suspension|Single oral dose of 20 mg rivaroxaban, granules for oral suspension administered under fed conditions.
223672919|NCT03452449|PROCEDURE|planned lumbar spine surgery|planned lumbar spine surgery including decompression, discectomy, foraminotomy, laminectomy
223672920|NCT05095012|OTHER|Pediatric Acute Care Concussion Clinical Pathway|MD assessment will be partially standardized to assess for patients at higher risk of becoming persistently symptomatic. These patients scoring as 'high risk' will be referred to one of three specialty clinics. High risk is defined as scoring 9 or higher out of 12 on the 5P score.
223672921|NCT00912561|BEHAVIORAL|Intense aerobic exercise|3 Units (of at least 30 minutes) of intense aerobic exercise per week for 8 weeks
223672922|NCT01488474|PROCEDURE|peripheral nerve stimulation|defining the minimal current threshold for distal motor response
223672923|NCT00779259|DRUG|Theophylline 300mg|Single doses of theophylline 300 mg as an immediate-release oral solution 80mg/15ml concentration administered alone at 7 am on Day 1 after an overnight fast of at least 10 hours and along with quinine sulfate (2 x 324 mg capsules) at 7am on Day 12 after an overnight fast of at least 10 hours.
223672924|NCT00779259|DRUG|Quinine 648 mg|648 mg quinine sulfate(2 x 324 mg capsules) initiated at 3pm on Day 5 and taken every 8 hours through Day 11 and co-administered with theophylline 300 mg as an immediate-release oral solution 80 mg/15 ml concentration at 7am on Day 12.
223672925|NCT00779259|DRUG|Theophylline 300 mg|Single doses of theophylline 300 mg as an immediate-release oral solution 80mg/15ml concentration administered alone at 7 am on Day 1 after an overnight fast of at least 10 hours and along with quinine sulfate (2 x 324 mg capsules) at 7am on Day 12 after an overnight fast of at least 10 hours.
223672926|NCT00779259|DRUG|Quinine 648 mg|648 mg quinine sulfate(2 x 324 mg capsules) initiated at 3pm on Day 5 and taken every 8 hours through Day 11 and co-administered with theophylline 300 mg as an immediate-release oral solution 80 mg/15 ml concentration at 7am on Day 12.
223772223|NCT02538497|BEHAVIORAL|Routine care|The control group will receive routine care. Between 7 and 10 days after birth a public health nurse routinely visits the family at home. Six weeks after birth, the mother and the infant visit the well-baby clinic
224253467|NCT02291250|DIETARY_SUPPLEMENT|Blackcurrants with polycal OGTT|"Sixteen overweight/obese volunteers from the Aberdeen area will be recruited into a randomised controlled study. Volunteers will be randomised into four groups matched for BMI and age and given 200 grams of blackcurrants (which contain anthocyanins) or greencurrants (which naturally contain no anthocyanins), followed by an OGTT.~The consumption of the currants will be followed by an oral glucose tolerance test (OGTT) with Polycal (complex carbohydrate) or glucose (simple carbohydrate) as the carbohydrate load.~The equivalent carbohydrate load will be standardised across the groups"
224253468|NCT02291250|DIETARY_SUPPLEMENT|Greencurrants with polycal OGTT|"Sixteen overweight/obese volunteers from the Aberdeen area will be recruited into a randomised controlled study. Volunteers will be randomised into four groups matched for BMI and age and given 200 grams of blackcurrants (which contain anthocyanins) or greencurrants (which naturally contain no anthocyanins), followed by an OGTT.~The consumption of the currants will be followed by an oral glucose tolerance test (OGTT) with Polycal (complex carbohydrate) or glucose (simple carbohydrate) as the carbohydrate load.~The equivalent carbohydrate load will be standardised across the groups"
224322239|NCT02143466|DRUG|Part B - AZD9291 in combination with MEDI4736|"Part B - AZD9291 and MEDI4736 administered in the dose identified in Part A to further investigate the safety and tolerability of this combination.~Note: Enrolment into the patient cohort that evaluated AZD9291 treatment in combination with MEDI4736 as 1st line treatment has been terminated due to an increased incidence of ILD-like events (interstitial lung disease/pneumonitis), and is no longer being evaluated in this study."
223672927|NCT05477433|BEHAVIORAL|diabetes mellitus type 1|"Pittsburgh Sleep Quality Index PSQI: It is used to detect sleep disturbance or deficits. The PSQI has a scoring key that can be used to calculate a patient's seven subscores, which range from 0 to 3. The subscores are added together to produce a global score that ranges from 0 to 21. A global score of 5 or higher denotes poor sleep quality, The Strengths and Difﬁculties Questionnaire (SDQ) The SDQ is a well-validated screening tool for children and adolescents aged 4-17 years that can identify behavioural and emotional issues,Emotional Avoidance Strategy Inventory for Adolescents (EASI) is used. The EASI-A is a 17-item assessing the use of emotionally avoidant strategies in adolescents and higher scores means significants use avoidant strategies, The Toronto Alexithymia Scale (TAS-20) is a self-administered 20-item questionnaire which assesses difficulties in identifying and describing emotions. TAS scores were significantly higher in alexithymia"
223672928|NCT04951167|DRUG|Norepinephrine|in the form of infusion
223672929|NCT04951167|DRUG|Norepinephrine|in the form of bolus
223672930|NCT02280122|OTHER|no intervention provided|No Intervention was rendered but the aMMP-8 test was made
223672931|NCT05824143|DRUG|Darigabat|Oral tablet
223672932|NCT05824143|DRUG|Carbamazepine|Oral tablets
223672933|NCT05421884|BEHAVIORAL|5 Love Languages|Emotional support will be given through utilizing the patient/partners specific Love Language (physical touch, words of affirmation, gifts, quality time, and acts of service).
223672934|NCT00854412|OTHER|Weight loss|Very low-calorie diet (VLCD) of 800 kcal/day for 8 weeks
223672935|NCT00879008|DRUG|Moxifloxacin (Avelox, BAY12-8039)|Patients from the normal praxis routine, treated with Moxifloxacin according to the local product information
223672936|NCT02047318|DRUG|LUM001 (Maralixibat)|Dosing of LUM001 also known as Maralixibat (MRX) with the objective of achieving optimal control of pruritus at a dose level that is tolerated by the participant and up to a maximum daily dose of 560 micrograms per kilogram (mcg/kg).
224253469|NCT02291250|DIETARY_SUPPLEMENT|Blackcurrants with glucose OGTT|"Sixteen overweight/obese volunteers from the Aberdeen area will be recruited into a randomised controlled study. Volunteers will be randomised into four groups matched for BMI and age and given 200 grams of blackcurrants (which contain anthocyanins) or greencurrants (which naturally contain no anthocyanins), followed by an OGTT.~The consumption of the currants will be followed by an oral glucose tolerance test (OGTT) with Polycal (complex carbohydrate) or glucose (simple carbohydrate) as the carbohydrate load.~The equivalent carbohydrate load will be standardised across the groups"
224322240|NCT02143466|DRUG|Part C - AZD6094 monotherapy (Japan only)|Part C - AZD6094 monotherapy to assess the safety, tolerability and pharmacokinetics of the monotherapy of AZD6094 in Japanese patients with advanced NSCLC.
223672937|NCT04622228|DRUG|Atezolizumab|Atezolizumab will be administered by intravenous infusion at a fixed dose of 1200 mg on Day 1 of each 21-day cycle until unacceptable toxicity or loss of clinical benefit as determined by the investigator after an integrated assessment of radiographic and biochemical data, and clinical status.
223672938|NCT04622228|DRUG|Cisplatin|Cisplatin will be administered as intravenous infusion at a dose of 75 mg per meter squared (75 mg/m\^2) after completion of atezolizumab on Day 1 of each 21-day cycle during the induction phase (Cycles 1-4).
223672939|NCT04622228|DRUG|Carboplatin|Carboplatin will be administered as intravenous infusion at a dose of area under the concentration-time curve (AUC) of 5 mg/mL/min on Day 1 of each 21-day cycle during the induction phase (Cycles 1-4).
223672940|NCT04622228|DRUG|Etoposide|Etoposide will be administered intravenously at a dose of 100 mg/m\^2 on Days 1, 2 and 3 of each 21-day cycle during the induction phase (Cycles 1-4).
223672941|NCT04622228|RADIATION|Thoracic radiation therapy (TRT)|Participants will receive concurrent thoracic radiation therapy (TRT) treatment, in once daily fractions, 3 Gy per fraction, to a target dose of 15 Gy in 5 fractions from Day 1-Day 5 in the first cycle.
223672942|NCT06504745|OTHER|Peer education|experimental group
223672943|NCT06504745|OTHER|control group|instruction training
223672944|NCT00184769|DRUG|somatropin|
223672945|NCT05946434|OTHER|Kinesio Tape Group|"Physiotherapy Protocol Followed:~* Hot pack and TENS application for 10 minutes.~* Knee isometric exercises by placing roller beneath knee joint and pressing it by keeping leg straight and holding it for 10-15 seconds with 10 repetitions.~* Stretching of hamstrings and gastrocnemius muscles, maintaining stretch for 20 seconds and 7 repetitions should be performed.~* Tibio-femoral glides and patellar mobilizations will be performed.~* At the end kinesio taping will be performed at knee joint for inhibition.~Same procedure will be followed in all follow ups at day 1, day 14 and day 28."
223772224|NCT04354259|DRUG|Peginterferon Lambda-1A|Peginterferon lambda is a covalent conjugate of human recombinant non-pegylated IFN lambda (IFN L) and a 20-kDa linear PEG chain. Peginterferon lambda Injection is a sterile, nonpyrogenic, ready-to-use solution (0.4 mg/mL) that is clear to opalescent, colorless to pale yellow, and essentially free of particles. Lambda Injection is provided in a 1-mL long Type I glass syringe (0.18 mg/syringe) with a staked 29-gauge, 1/2- inch, thin-walled needle. The syringe has a rigid needle shield and is stoppered with a plunger stopper. Syringes are prefilled with a solution of Peginterferon lambda Injection, mannitol, L-histidine, polysorbate 80, hydrochloric acid, and water for injection; they are intended for a single use at adjustable doses. The syringe is marked with dose indicator lines, which are used as a reference point for administering the correct dose.
223772225|NCT04354259|OTHER|placebo|injection of 0.9% sodium chloride (normal saline) solution. A plastic 1 mL syringe will be prefilled by the study pharmacy. Each syringe will contain 0.5 mL (0.45 mL to match the volume of the Interferon plus 0.05 mL overfill) to allow for needle priming by the unblinded study nurse.
223772226|NCT00577122|DRUG|Medroxyprogesterone progesterone acetate (MPA)|1000 mg po daily
223772227|NCT00577122|DRUG|Medroxyprogesterone with Cyclophosphamide + Methotrexate|Medroxyprogesterone Acetate Dose 1000 mg po daily Cyclophosphamide Dose 50 mg po daily Methotrexate Dose 2.5 mg po daily Days 1 and 2 of each week
224253470|NCT02291250|DIETARY_SUPPLEMENT|Sugar matched water with polycal OGTT|"Sixteen overweight/obese volunteers from the Aberdeen area will be recruited into a randomised controlled study. Volunteers will be randomised into four groups matched for BMI and age and given 200 grams of blackcurrants (which contain anthocyanins) or greencurrants (which naturally contain no anthocyanins), followed by an OGTT.~The consumption of the currants will be followed by an oral glucose tolerance test (OGTT) with Polycal (complex carbohydrate) or glucose (simple carbohydrate) as the carbohydrate load.~The equivalent carbohydrate load will be standardised across the groups"
223672946|NCT05946434|OTHER|Rigid Tape Group|"Physiotherapy Protocol Followed:~* Hot pack and TENS application for 10 minutes.~* Knee isometric exercises by placing roller beneath knee joint and pressing it by keeping leg straight and holding it for 10-15 seconds with 10 repetitions.~* Stretching of hamstrings and gastrocnemius muscles, maintaining stretch for 20 seconds and 7 repetitions should be performed.~* Tibio-femoral glides and patellar mobilizations will be performed.~* At the end rigid tape will be applied on knee joint to provide stability.~Same procedure will be followed in all follow ups at day 1, day 14 and day 28"
223672947|NCT02095132|DRUG|Adavosertib|Given PO
223672948|NCT02095132|DRUG|Irinotecan Hydrochloride|Given PO
223672949|NCT04041791|DRUG|Benzyl penicillin|Benzyl penicillin is a penicillin antibiotic.
223672950|NCT04041791|DRUG|Gentamicin Sulfate|Gentamicin is an aminoglycoside antibiotic.
223672951|NCT04041791|DRUG|Ceftriaxone|Ceftriaxone is a third generation cephalosporin antibiotic active against a wide range of gram negative and positive bacteria.
223672952|NCT04041791|DRUG|Amoxicillin Clavulanate|Amoxicillin Clavulanate is a combination of amoxicillin, a β-lactam antibiotic, and potassium clavulanate, a β-lactamase inhibitor.
223672953|NCT04041791|OTHER|Intravenous fluid|Maintenance fluids administered for at least 24 hours.
223672954|NCT04041791|OTHER|Nasogastric feeds|Feeds given via nasogastric tube. Feeds may include cow's milk, breast milk, porridge, formula among others.
223672955|NCT04041791|DRUG|Ampicillin|Ampicillin is a penicillin-type antibiotic.
223672956|NCT00409175|DRUG|Fx-1006A|Fx-1006A 20mg or matched placebo once daily (at the same time each day) for a period of 18 Months
223672957|NCT00409175|DRUG|Placebo|Fx-1006A 20mg or matched placebo once daily (at the same time each day) for a period of 18 Months
223672958|NCT04809077|OTHER|Reverse total shoulder replacement|Long-term radiographic and clinical data of patients who underwent a reverse shoulder replacement
223772228|NCT02977949|DRUG|Raloxifene|
223772229|NCT02514252|DRUG|Fentanyl Sublingual Spray (FSS)|"Stage 1: First Pain Episode - Single dose of breakthrough opioid given from existing PCA pump equivalent to 10% of their MEDD.~Second Pain Episode - Single dose of FSS equivalent to 16-32% of MEDD. If not effective at 30 minutes, participant repeats same dose one more time (with a cap of 1600 mcg total; i.e. dose given 30 minutes ago + dose now = 1600 mcg maximum.~Third Pain Episode (at least 4 hours after second episode) - Participant required 2 breakthrough FSS doses for the last episode of breakthrough pain, or if the effective dose has not been identified, he/she will double the last administered dose. If breakthrough pain not effective at 30 minutes, participant repeats same dose one more time (with a cap of 1600 mcg total; i.e. dose given 30 minutes ago + dose now = 1600 mcg maximum).~Stage 2: If FSS successful in hospital, upon discharge, FSS used as first choice of pain medication instead of oral pain medication for pain for up to 4 weeks."
224253471|NCT03207503|PROCEDURE|fMRI|Patients will undergo fMRI imaging to assess areas of the brain that are active during emotion regulation. No clinical benefit of MRI imaging is anticipated.
224253472|NCT05819918|DRUG|Calcifediol|Subjects hospitalized with COVID-19 treated with calcifediol
223672959|NCT05858840|OTHER|Urinary Artificial Sphincter (UAS) in Children|Patients aged under 18 years old with UAS
223672960|NCT05058495|OTHER|Mobile Lymphedema Self-Care Support Program|The Mobile Lymphedema Self-Care Support Program is composed of three section. First section includes the information about lymphedema and lymphedema self care. Second section includes the exercises videos which women can concurrently exercise with application and an alarm to remind to exercise. Last section is a social network form the women could chat and share anything with eachother. Patients will be told how to use the Mobile Lymphedema Self-Care Support Program and a contact number will be provided to ask questions about the program at any time.
224253473|NCT05819918|DRUG|Best available therapy|Subjects hospitalized with COVID-19 treated with Azithromycin, hydroxychloroquine, corticoids and others authorized treatments.
224253474|NCT04519515|DEVICE|Allergan Vollure|Injection of Allergan Vollure into Atrophic Scars
224253475|NCT06540716|DEVICE|Inspire System|Hypoglossal nerve stimulation therapy will be activated at approximately 1 month post-implant.
224253476|NCT03740295|DIETARY_SUPPLEMENT|Coconut oil and epigallocatechin gallate|600 mg of epigallocatechin gallate (EGCG) and 60 ml of coconut oil (3600 mg of TGCM) per day, divided into two doses (one in the morning and one at noon)
224253477|NCT03740295|OTHER|Placebo|Lactose
224253478|NCT05582915|DIAGNOSTIC_TEST|Blood sampling|4 ml of blood will be collected into EDTA tube for proteomic analysis at visit 0 and visit 1
224253479|NCT03273153|DRUG|Cobimetinib|Cobimetinib 60 mg tablets orally once daily on a 21 days on, 7 days off schedule.
224253480|NCT03273153|DRUG|Atezolizumab|Atezolizumab 840 mg as IV infusion once in every 2 weeks.
224253481|NCT03273153|DRUG|Pembrolizumab|Pembrolizumab 200 mg as IV infusion once in every 3 weeks.
224253482|NCT05456763|DIETARY_SUPPLEMENT|sodium butyrate|add-on therapy irrespective of standard treatment depending on severity (according to the guidelines)
224253483|NCT05456763|OTHER|placebo|placebo
223672961|NCT05058495|OTHER|standart lymphedema education|The control group will receive standard lymphedema education. The standard lymphedema education is an online education composed of information about lymphedema and lymphedema self-care.
223672962|NCT06554483|OTHER|Exercise|supportive reliable exercise programs
223672963|NCT02596750|DEVICE|Microneedle Roller|200 micrometer length microneedles (MR2 roller, Clinical Resolution Laboratories, Inc.) mounted on a disposable roller
223672964|NCT02596750|DEVICE|Sham microneedle Roller|Flat roller without microneedles
223672965|NCT02787239|DRUG|HLX01|
223672966|NCT02787239|DRUG|Rituximab|
223672967|NCT02787239|DRUG|CHOP|
223672968|NCT04501029|DRUG|Gimatecan|Patients will receive gimatecan orally at the recommended dose level on day 1-5 every 4 weeks.
223672969|NCT02108262|BIOLOGICAL|CSL112|CSL112 is a novel formulation of apolipoprotein A-I (apoA-I) purified from human plasma and reconstituted to form high-density lipoprotein (HDL) particles.
223672970|NCT02108262|BIOLOGICAL|Placebo|0.9% weight/volume sodium chloride solution (ie, normal saline)
223672971|NCT02518503|DRUG|Rosuvastatin (≥10 mg)|Current cumulative exposure to high dose rosuvastatin (ATC C10AA07) will be defined as a prescription for ≥10 mg of rosuvastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-\<365 days, or 366-730 days).
223672972|NCT02518503|DRUG|Atorvastatin (≥20 mg)|Current cumulative exposure to high dose atorvastatin (ATC C10AA05) will be defined as a prescription for ≥20 mg of atorvastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-\<365 days, or 366-730 days).
224253484|NCT06452472|DEVICE|I-LIMB|Use of a multi-grip myoelectric hand prosthesis (I-LIMB after using a standard myoelectric prosthesis)
223672973|NCT02518503|DRUG|Simvastatin (≥40 mg)|Current cumulative exposure to high dose simvastatin (ATC C10AA01) will be defined as a prescription for ≥40 mg of simvastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-\<365 days, or 366-730 days).
223672974|NCT02518503|DRUG|Fluvastatin|Current cumulative exposure to fluvastatin (ATC C10AA04) will be defined as a prescription for any dose of fluvastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-\<365 days, or 366-730 days).
223672975|NCT02518503|DRUG|Pravastatin|Current cumulative exposure to pravastatin (ATC C10AA03) will be defined as a prescription for any dose of pravastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-\<365 days, or 366-730 days).
223672976|NCT02518503|DRUG|Lovastatin|Current cumulative exposure to lovastatin (ATC C10AA02) will be defined as a prescription for any dose of lovastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-\<365 days, or 366-730 days).
223672977|NCT02518503|DRUG|Rosuvastatin (<10mg)|Current cumulative exposure to low dose rosuvastatin (ATC C10AA07) will be defined as a prescription for \<10mg of rosuvastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-\<365 days, or 366-730 days).
223672978|NCT02518503|DRUG|Atorvastatin (<20mg)|Current cumulative exposure to low dose atorvastatin (ATC C10AA05) will be defined as a prescription for \<20 mg of atorvastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-\<365 days, or 366-730 days).
224253485|NCT01301794|DIETARY_SUPPLEMENT|Omega 3 fatty acid (Lovaza)|Lovaza is an FDA approved omega 3 fatty acid taken as 4 grams a day (two one gram formulations twice a day).
224253486|NCT01359696|DRUG|GDC-0425|Oral escalating dose
224253487|NCT01359696|DRUG|gemcitabine|Intravenous repeating dose
224253488|NCT02846285|OTHER|No intervention|
224253489|NCT02740647|DRUG|Amoxicillin Clavulanate|getting intra-venous1GR Amoxicillin Clavulanate 3 times a day for 5 days post surgery
224253490|NCT02740647|DRUG|Placebo|50 ml of 0.9% sodium chloride three times a day
224253491|NCT05323396|DRUG|Antiparasitic medication|"Participants in the parasite-positive group (based on positive result of either stool microscopy or stool PCR) will be administered antiparasitic treatment. Antiparasitic medication administered will be targeted to treat the parasite identified. See detailed description of protocol for medication, dose, and frequency that will be given for each parasitic infection identified.~Participants with negative stool microscopy and negative stool PCR will not be administered treatment, thus will serve as controls."
224253492|NCT05675995|BEHAVIORAL|Qigong|6 sessions of combined external and internal qigong delivered in a group-based format once a week.
224253493|NCT05279482|OTHER|observation for outcome of methylprednisolone dose|no intervention as it is retrospective study for outcome
224253494|NCT04852380|PROCEDURE|PRP injections|The 5 mL PRP concentrate was injected every week for three times, starting from recruitment. The patient was placed supine whit a knee flexion of 90°.All the procedures were carried out in an aseptic condition, injected in the knee soft spot through an anterior approach, using a 21-gauge needle.
224253495|NCT03002779|DRUG|JNJ-53718678|Participants will receive a single 500 milligram (mg) dose of 14C-JNJ-53718678 as an oral liquid solution containing 14C-labeled and unlabeled JNJ-53718678 corresponding to a radioactivity dose.
224253496|NCT04562662|DEVICE|mediVR KAGURA|Approximately 20 min mediVR KAGURA-guided rehabilitation
223672979|NCT02518503|DRUG|Simvastatin (<40 mg)|Current cumulative exposure to low dose simvastatin (ATC C10AA01) will be defined as a prescription for \<40 mg simvastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-\<365 days, or 366-730 days).
224253497|NCT00907413|PROCEDURE|ERCP and Photodynamic Therapy|Photodynamic Therapy is a new therapeutic approach that specifically targets neoplastic cells. This therapy has been used in other tumors as a local treatment and involves the intravenous administration of a photosensitizing agent followed by activation of the agent by illumination with non-thermal light of a specific wavelength, resulting in cell death from direct cytotoxicity and ischemic necrosis. Cytotoxicity is directly proportional to tissue oxygenation.
224253498|NCT00907413|PROCEDURE|ERCP only|Endoscopic retrograde cholangiopancreatography and stenting.
224253499|NCT04646213|BEHAVIORAL|Managing Cancer and Living Meaningfully (CALM) Therapy|6 sessions of individualized CALM therapy
223672980|NCT02691598|DRUG|Infusion|Dexmedetomidine Hydrochloride or normal saline 4ug/ml；0.05ml/kg.h infusion for 24hours
223672981|NCT05030961|BEHAVIORAL|Virtual team-based clinic|Virtual team-based clinic will include consultation, counseling, and education from pediatric audiology, psychology, auditory verbal therapy, and education. Each session lasts approximately 30 minutes with a total of 3 sessions within the year.
223672982|NCT05030961|BEHAVIORAL|Remote cochlear implant programming|Remote cochlear implant programming will be provided via Zoom on a study-provided encrypted laptop.
223672983|NCT00203281|DRUG|tacrolimus|
223672984|NCT00203281|DRUG|mycophenolate mofetil|
223772230|NCT02514252|BEHAVIORAL|Questionnaires|Symptom questionnaire completed at baseline and after last dose of FSS while hospitalized. After Day 28, questionnaire completed over the phone about participant's opinion of research study.
223672985|NCT00203281|DRUG|daclizumab|
223672986|NCT00203281|DRUG|intravenous immune globulin|
223672987|NCT00203281|PROCEDURE|plasmapheresis|
223672988|NCT03375073|OTHER|Positive communication during medical transmission|Use of positive communication for medical transmission to the anaesthetic team who takes over the patient.
223672989|NCT01895361|DRUG|SelG1|
223672990|NCT01895361|DRUG|Placebo|
223672991|NCT06311552|OTHER|Participants will undergo a comprehensive CMR scan on either a 1.5- or 3-Tesla scanner|Participants will undergo a comprehensive CMR scan on either a 1.5- or 3-Tesla scanner
223672992|NCT05053542|PROCEDURE|Enema|Patients in the PBP group underwent a cleansing enema procedure with a solution of monosodium phosphate and disodium phosphate (EVAC enema 118 mL/bot, Purzer Pharmaceutical Co., Ltd) before hemorrhoidectomy, whereas patients in the non-PBP group skipped the procedure.
223672993|NCT01498094|PROCEDURE|High Flow Nasal Cannula Oxygen Therapy|Warm humidified oxygen will be delivered at 8 liters/minute via nasal cannulae, at a concentration that maintains saturations greater than 92%.
223672994|NCT01498094|OTHER|Standard low flow oxygen|Standard low flow oxygen will be given to patients to maintain saturations greater than 92%.
223772231|NCT02514252|BEHAVIORAL|Mental Ability Tests|Mental ability tests given while hospitalized 30 minutes after first dose of current pain medication, and 30 minutes after each FSS dose.
223772232|NCT02514252|BEHAVIORAL|Study Diary|Participants given study diary to document pain level, how many times FSS used, and any side effects experienced each day.
224253500|NCT04517019|DEVICE|"Fitness tracker based activity training for Arm A and B. Booklet physical training, exercise and cancer and an introduction about physical activity during cancer therapy for Arm A, B, C"|"Patients receive a fitness tracker, a booklet Physical training, exercise and cancer and an in-person briefing about physical activity during cancer therapy. With offered guidelines for the daily step counts patients should improve their physical activity during radiotherapy of breast cancer. A weekly feedback and a new goal for the next week will be provided until the individual patient reaches a daily activity of 6000 steps. The setting will be to maintain to this daily activity of 6000 steps during radiotherapy."
224253501|NCT05946460|DRUG|Aumolertinib|Aumolertinib treatment (110mg, p.o., QD) for 8 weeks
224253502|NCT01764347|PROCEDURE|therapeutic conventional surgery|Undergo robotic radical prostatectomy
224253503|NCT01764347|PROCEDURE|ultrasound-guided prostate biopsy|Undergo MRI-TRUS fusion image-guided prostate biopsy
223672995|NCT01982968|PROCEDURE|Surgery|Full fundoplication surgery for the treatment of abnormal GER
223672996|NCT00259129|DRUG|Sorafenib (Nexavar, BAY43-9006)|Sorafenib 400 mg twice a day (bid) (2 x 200 mg tablets)
223672997|NCT01198379|DRUG|aspirin|aspirin 100 mg qd for 3 years
223672998|NCT01198379|DRUG|Placebo|
223672999|NCT05988502|OTHER|auricular acupressure|"The well-trained researcher nurse in this study was performed the AA intervention. First of all, the participant was instructed to find a comfortable position. Disinfect the ears using cotton with 75 % alcohol was then provided and followed by placed vaccaria seeds (Beijing, China) with an adhesive patch onto the unilateral each selected auricular acupoint (left ear first) Participants were pressed each acupoint by thumb and index finger for one minute, four times a day, five days a week, remove the taped seeds on the 6th day, and then replaced the opposite ear two days after. They were noted that they experienced various sensations while pressing, including numbness, swelling, mild pain, or warmth. Seeds were taped on the other side of the ear weekly for two weeks.~Two TCM physicians verified the conduct of the AA protocol, which consisted of a selection of acupoints, length of stimulation time, finding location of acupoint, and procedure of practice."
223673000|NCT04249609|OTHER|HCHO meals and exercise|Exercise will be conducted after high carbohydrate dinner and prior to high carbohydrate breakfast
223673001|NCT04249609|OTHER|LCHO meals and exercise|Exercise will be conducted after high fat dinner and prior to high fat breakfast
223673002|NCT05424432|DRUG|Neoadjuvant Chemotherapy|Paclitaxel (135 mg /m2) and carboplatin (AUC=5) every 3 weeks for two cycles (D1,D22)
224253504|NCT01764347|PROCEDURE|magnetic resonance imaging|Undergo MRI-TRUS fusion image-guided prostate biopsy
224253505|NCT02416726|DEVICE|Nextseq500 sequencer|The sequencer will be used to detect the gene mutations of the primary tumor, metastatic LN and peripheral blood samples obtained from patients.
223772233|NCT03821571|DIAGNOSTIC_TEST|Brain MRI|Brain MRI with blood sensitive sequence (SWI) will be performed to all enrolled patients.
223673003|NCT05424432|DRUG|Neoadjuvant Toripalimab|Toripalimab 240mg every 3 weeks for two cycles (D2,D23)
223673004|NCT05424432|RADIATION|Short Course Neoadjuvant Radiotherapy|30 Gy in 12 fractions, 1 fraction per day, 5 days per week, D3-D18
223673005|NCT03723603|DEVICE|Fibrillar collagen powder dressing|A powder-like fibrillar collagen microsponge composed of Type I porcine dermis collagen. The dressing is a currently marketed, cleared device in the United States, indicated for the management of full and partial thickness wounds: pressure ulcers, diabetic ulcers, caused by mixed vascular origin, venous ulcers, and several other wound types.
223673006|NCT02358317|BEHAVIORAL|Video Game Motor Training|
223673007|NCT02358317|BEHAVIORAL|Sedentary Video Game Training|
223673008|NCT05185206|DEVICE|Class 1 cavity preparation using conventional steel bur and restoration with Cention-n(commercially available restorative material).|"Patients aged between 18 and 55 years having class 1 occlusal caries(1.2 according to G. J. Mount classification) on both sides of arch. In order to standardise the cavity preparation depth(approximately 1.5 to 2mm from the roof of the pulp chamber), the distance from occlusal surface to roof of pulp chamber will be used for measuring with the radiograph. This will be followed by caries removal with convention steel bur followed by restoration with Cention-n and checking of postoperative sensitivity using Visual Analog Scale.The Visual Analog Scale consists of a 100-mm line divided into equal intervals of 10 mm, where 0 represents absence of pain and 100 severe pain. The results of Visual Analog Scale will be classified as mild (0-30 mm), moderate (40-70 mm), or severe pain (\> 70 mm)."
223673009|NCT05185206|DEVICE|Class 1 cavity preparation using polymer bur and restoration with Cention-n(commercially available restorative material).|"Patients aged between 18 and 55 years having class 1 occlusal caries(1.2 according to G. J. Mount classification) on both sides of arch. In order to standardise the cavity preparation depth(approximately 1.5 to 2mm from the roof of the pulp chamber), the distance from occlusal surface to roof of pulp chamber will be used for measuring with the radiograph. This will be followed by caries removal with polymer bur followed by restoration with Cention-n and checking of postoperative sensitivity using Visual Analog scale.The Visual Analog Scale consists of a 100-mm line divided into equal intervals of 10 mm, where 0 represents absence of pain and 100 severe pain. The results of Visual Analog Scale will be classified as mild (0-30 mm), moderate (40-70 mm), or severe pain (\> 70 mm)."
223673010|NCT03507114|BEHAVIORAL|Rumination-Focused CBT (RFCBT)|RFCBT consists of six online modules that include psycho-education, mood diaries, on-line experiential exercises using audio-recordings \& vignettes of participants experiences of the therapy.
223673011|NCT00046800|DRUG|OSI-211 (Liposomal Lurtotecan)|
223673012|NCT06328478|DEVICE|Observational prospective study.|Observational prospective study
223673013|NCT02586506|DRUG|Placebo ELLIPTA inhaler|The ELLIPTA Dry Powder Inhaler (DPI) is a molded plastic two-sided inhaler that can hold two individual blister strips. Each strip will contain either lactose or a blend of lactose and magnesium stearate. Subjects will receive 1 inhalation once-daily until visit 2.
223673014|NCT02586506|OTHER|Questionnaire|ELLIPTA Inhaler Ease of Use Questionnaire is a four-point Likert scale. This questionnaire will be filled by investigator (designee) based on responses received from subject. Responses for the questionnaire are Very difficult, Difficult, Easy, Very easy. Subjects will be give either version A or B at Visit 2.
223673015|NCT05297435|DIAGNOSTIC_TEST|Questionnaires|Questionnaire study
223673016|NCT04391985|DRUG|SOF plus (OBV/PTV/r) plus RBV|They were given SOF in a dose of 400 mg/day, and a fixed dose combination of OBV (25 mg), PTV (150 mg), and r (100 mg) taken with food once daily. RBV was supplied in 200 mg capsules, and the recommended dose was 600 mg/ day to reach 1200 mg/day based on patient's body weight and tolerability.
223772234|NCT01177072|OTHER|Cognitive Processing Therapy|12 sessions of cognitive processing therapy. Sessions are expected to be approximately one week apart. Although each counseling session is designed to be carried out one week apart for a total of 12 weeks, there are many reasons why a session will be missed. Our estimation is that a single client will require 4-5 months to complete the therapy.
224253506|NCT00803686|DRUG|Oral rsCT tablet|On Study Day 1, subjects will be given their assigned treatment, based on one of two randomly ordered treatment sequences, at 10 PM (22:00). On Visit 3, subjects will return for administration of the second treatment with a minimum of 7 days washout interval between study drug administrations. On Visit 4, subjects will return for administration of third treatment of rsCT, either oral rsCT tablets or Fortical (rsCT) nasal spray. Interventions are described in Intervention Name, Other Names and in Intervention Description.
224253507|NCT00803686|DRUG|Oral Placebo Tablet|Part 1, Double blind oral placebo tablet given once 4 hours after evening meal.
224253508|NCT00803686|DRUG|Oral rsCT tablet|Part 2, Open-label, oral rsCT tablet given once 2 hours after the evening meal.
224253509|NCT00803686|DRUG|Fortical (rsCT) nasal spray|Intervention: Open label, Fortical nasal spray given once 2 hours after the evening meal.
224253510|NCT01684657|DRUG|Asenapine|This is an atypical antipsychotic that blocks dopamine and increase the serotonin level.
224253511|NCT01950611|DRUG|Bortezomib|Combination of arsenic trioxide with bortezomib in the treatment of relapsed acute promyelocytic leukemia
224253512|NCT00711386|DRUG|GSK706769|50mg, 100mg, 200mg, or 400mg
224253513|NCT00711386|OTHER|Placebo|Placebo
224253514|NCT00415363|DRUG|enzastaurin|1125 mg loading dose then 500 mg, oral, daily, until disease progression
224253515|NCT00415363|DRUG|placebo|oral, daily
224253516|NCT06562738|DRUG|Hetrombopag|Hetrombopag 7.5 mg, once a day, at bedtime for up to 14 days, drug administration was stopped when PLT≥100 ×10\^9/L, and take blood routine examination weekly, drug administration was resumed when PLT \< 100 ×10\^9/L. When PLT ≤30× 10\^9/L or ≥300 ×10\^9/L, take blood routine examination every 3 days.
224253517|NCT02132663|OTHER|Control: Marketed routine infant formula|
224253518|NCT02132663|OTHER|An investigational infant formula containing an alternate source of DHA|
224253519|NCT03382548|DRUG|Reducing Antibiotics treatment duration|Antibiotics should be stopped from day 3 to 7 if respiratory cultures are negative and the patients fulfill a set of stringent clinical criteria signifying cardiopulmonary stability for 48 hours. If the respiratory cultures are positive, patients who fulfill the same set of clinical criteria should have their antibiotics stopped from day 5 to 7.
224253520|NCT03382548|DRUG|Standard Antibiotics treatment duration|Participants in the control (long duration) arm will receive standard care, which is antibiotic treatment for at least 8 days with the exact duration decided by the primary physician.
224253521|NCT02183415|DRUG|BI 1356 BS, low dose|
224253522|NCT02183415|DRUG|BI 1356 BS, medium dose|
224253523|NCT02183415|DRUG|BI 1356 BS, high dose|
224253524|NCT02183415|DRUG|Placebo|
224253525|NCT05106465|DEVICE|Konectom platform|Administered as specified in the treatment arm.
224253526|NCT02216006|PROCEDURE|Control group, conventional ventilatory settings|"Handling of the airway during induction and intubation is performed in a conventional manner.~Initial ventilatory settings are also done in a conventional manner. As soon as correct position of the endotracheal tube is confirmed, controlled ventilation is started with a tidal volume of 7 mL/kg ideal body weight, PEEP 6 or 8 cm H2O (8 if BMI \>25) and a respiratory frequency of 10. The fresh gas flow is set to 1 Liter per minute with an oxygen mixture of 40%, aiming for an inspired FiO2 of 30-35%.~Unless the patient´s SpO2 falls below 90%, the FiO2 remains unchanged throughout the procedure."
224253527|NCT02216006|PROCEDURE|High fresh gas flow, high minute ventilation|"Handling of the airway during induction and intubation is performed in a conventional manner.~Immediately after confirming a successful intubation, the effect of preoxygenation is eliminated with a fresh gas flow of 10 L/min of air, delivered with volume controlled ventilation consisting of tidal volumes of approximately 15 ml/kg ideal body weight, a positive expiratory pressure of 10 cm H20 and a respiratory frequency of 10. As soon as the end tidal O2 reaches 25%, the ventilator settings are adjusted to normal values (same as in the control group), i.e. tidal volume 7 mL/kg ideal body weight, PEEP 6 or 8 cm H2O (8 if BMI \>25). The mixture of oxygen in the fresh gas is increased to 40% and the fresh gas flow is set to 1 Liter per minute, aiming for an inspired FiO2 of 30-35%.~Unless the patient´s SpO2 falls below 90%, the FiO2 remains unchanged throughout the procedure."
224253528|NCT05277779|DIAGNOSTIC_TEST|cardiac magnetic resonance(CMR)|CMR was performed to assess myocardial tissue characteristics in the study population
224253529|NCT00095212|DRUG|1 Transdermal Testosterone (Patch)|300 micrograms twice a week
224253530|NCT00095212|DRUG|2 Placebo Patch|Placebo patch (0 micrograms of testosterone) applied twice a week
224253531|NCT05345665|OTHER|Echography|Neuronal blockade anesthesia for elective surgery of the hand was performed with an only echography.
224253532|NCT05345665|OTHER|Echography and neurostimulation|Neuronal blockade anesthesia for elective surgery of the hand was performed with both echography and neurostimulation.
224253533|NCT05345665|OTHER|Echography, neurostimulation and active mobilization|Neuronal blockade anesthesia for elective surgery of the hand was performed with echography, neurostimulation, and active mobilization.
223673017|NCT01604356|PROCEDURE|Electro-acupuncture|Ten treatment sessions at our center during a two week period (5 sessions per week). Each session will last approximately 30 minutes. The intervention will involve the placement of acupuncture needles in a standard set of points across all patients, located on the head, around the eyes, on the abdomen, on the hands, feet, arms and legs. An electro-acupuncture device \[Transcutaneous electrical nerve stimulator (TENS) unit by Lhasa OMS Inc.; model AWQ-104L\] and will be used on four of the acupuncture points (two per session) located on the forehead, and side of the face/temple.
223673018|NCT06092229|DIAGNOSTIC_TEST|Palpation|identification of the cricothyroid using PALPATION, a procedure used to prepare for front of neck airway access
223673019|NCT06092229|DIAGNOSTIC_TEST|Ultrasonography with TACA approach|identification of the cricothyroid membrane, using ULTRASONOGRAPHY with TACA approach , a procedure used to prepare for front of neck airway access
223673020|NCT02247648|DRUG|tramadol|Patients from tramadol group received tramadol 100 mg day one, 100 mg day 2, and 200 mg day 3
223673021|NCT02247648|DRUG|Placebo|"Patients from control group received a shame tramadol pill on day one, two, and 3"
223673022|NCT01076127|BEHAVIORAL|Ketllebell training|Kettlebell training 3 x 20 min a week for 8 weeks
223673023|NCT01076127|BEHAVIORAL|Control|Receives a health examination before and after the intervention period, and are advised to stay active.
223673024|NCT03796845|OTHER|No limited movement after surgery|Participants should move their arms from the first postoperative day, with unrestricted movement, with an amplitude above 90º for flexion and abduction of shoulder.
223673025|NCT03956719|DRUG|Autologous adipose-derived mesenchymal stem cells|Autologous adipose-derived mesenchymal stem cells is extracted from human abdominal fat, which is crushed, filtered and immediately returned to the articular cavity through a specific device.
224253534|NCT01653353|BEHAVIORAL|peer physician-applied recommendation to the physicians|The peer physician-applied recommendation will include scientific information, practical recommendations to correctly supplement with calcium and vitamin D and a list of individual appraisals of the prescribed supplements among the residents.
224253535|NCT04920877|OTHER|Infection Prevention|Preventing central catheter-related bloodstream infections in intensive care units
224253536|NCT02496546|DRUG|LEO 32731 cream|Applied for 3 weeks
224253537|NCT02496546|DRUG|LEO 32731 cream vehicle|Applied for 3 weeks
224253538|NCT00437853|DRUG|Anastrozole|
223673026|NCT03956719|PROCEDURE|abdominal liposuction|50 ml abdominal fat was extracted by abdominal liposuction to prepare autologous adipose-derived mesenchymal stem cells
224253539|NCT03348553|DIETARY_SUPPLEMENT|control group|no supplements given for 16 weeks, after 4 week washout of all supplements and dietetic products
223673027|NCT06492499|PROCEDURE|Zero-Fluoroscopy Radiofrequency Catheter Ablation|Patients undergo zero-fluoroscopy RFCA for atrioventricular nodal reentrant tachycardia (AVNRT) using the superior vena cava (SVC) or inferior vena cava (IVC) approach. The procedure is performed under conscious sedation and local infiltration anesthesia. A large-tip electrode catheter is used for mapping and ablation, guided by the EnSite NavX system, with ablation parameters set at 40 W power and 50°C temperature.
223673028|NCT04734678|DRUG|Tocilizumab|400 mg IV only once
224253540|NCT03348553|DIETARY_SUPPLEMENT|Omega2|2 capsules of JP+® Omega/d for 16 weeks, after 4 week washout of all supplements and dietetic products
223673029|NCT04734678|DRUG|Infliximab|5 mg/kg/day IV for 2 doses 12-24 hours
223673030|NCT00117533|DRUG|pegylated IFN alfa-2b plus ribavirin|
223673031|NCT00674154|DRUG|Cholecalciferol|2800 IE daily in 52 weeks
224253541|NCT03348553|DIETARY_SUPPLEMENT|Omega4|4 capsules of JP+® Omega/d for 16 weeks, after 4 week washout of all supplements and dietetic products
224253542|NCT03348553|DIETARY_SUPPLEMENT|Omega2+OGV|2 capsules of JP+® Omega/d plus 2 capsules each of an encapsulated fruit, vegetable and berry-juice concentrate (6 capsules) for 16 weeks, after 4 week washout of all supplements and dietetic products
224253543|NCT00175487|PROCEDURE|Hip replacement|This study evaluates femoral head resurfacing versus a large femoral head (Durom®) total hip system. This is a prospective randomized trial.
224322241|NCT02143466|DRUG|Part C - AZD9291 in combination with AZD6094 (Japan only)|Part C combination cohort - AZD9291 80mg OD administered in combination with AZD6094 400mg OD (AZD6094 dose in which DLTs have not been identified in the Japanese monotherapy cohort) in order to confirm the safety, tolerability, pharmacokinetics and preliminary anti-tumor activities of this combination in Japanese subjects. The 400mg OD dosing schedule will be initiated in the first cohort. The dose may be subsequently reduced in further cohorts in response to emerging safety, or PK findings or other reasons identified in the savolitinib programme.
223673032|NCT05093790|DRUG|Ticagrelor|Specified dose on specified days
223772235|NCT01177072|OTHER|Components-Based Intervention|This is a 'components-based' intervention include psychoeducation, relaxation, life-enhancing skills (problems solving and safety planning), exposure, and cognitive processing of life problems and traumatic events. The duration of sessions are approximately one hour), the expected frequency of treatment is weekly, and recommended number of sessions are 12.
223673033|NCT05093790|DRUG|BMS-986141|Specified dose on specified days
223673034|NCT05093790|DRUG|Aspirin|Specified dose on specified days
223673035|NCT03889301|BEHAVIORAL|E-E Video|The E-E video was developed by the research team and chronicles the story of Ana who while enjoying coffee with two family members, shares her challenges with depression and her successful outcome with therapy. The video utilizes the genre of the telenovela which creates an entertaining environment where the audience is captivated by the content and absorbs the messages portrayed.
223673036|NCT03889301|BEHAVIORAL|Discussion|Structured psychoeducation and pamphlet about anxiety and depression.
223673037|NCT04529187|DRUG|Midazolam|To monitor the changes in heart function induced after midazolam sedation using cardiac MRI.
223673038|NCT04529187|DRUG|Dexmedetomidine|To monitor the changes in heart function induced after dexmedetomidine sedation using cardiac MRI.
223673039|NCT01661985|DRUG|Azithromycin|In the randomized arm giver orally 1 g as a single dose. In the non-randomized arm given for 5 days 250mg 2x1 first day and 1x1 following four days.
223673040|NCT01661985|DRUG|Doxycycline|Doxycycline tablets 100 mg 2x1 the first day and 100 mg daily for following eight days (following the Swedish tradition and experience since the 1970s of treating chlamydia)
223673041|NCT01661985|DRUG|lymecycline|Lymecycline 300 mg twice daily for 10 days (Summertime due to less risk of phototoxic reactions)
223673042|NCT03681288|BEHAVIORAL|Mindful Self-Compassion|Mindful Self-Compassion Intervention
223673043|NCT02985424|OTHER|18F-FDG PET/CT|18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography
223673044|NCT04061993|PROCEDURE|Strength and Sensory-Motor Training|Early postoperative strength and sensory-motor training after total hip arthroplasty. Training consists of: hip muscles strengthening (focusing on abductors); hip and pelvic stabilization exercises; ankle and knee muscles strengthening (better dissipation of impact forces and femoral inner rotation control); trunk muscles strengthening (stabilization of pelvis and lumbar spine and reduction of local loading).
223673045|NCT04061993|PROCEDURE|Current Standard Physiotherapy|Mobilisation using a walking aid (usually two crutches, rarely a walker), deep vein thrombosis (DVT) prevention exercises, lower limb range of motion exercises and isometric strengthening program
223673046|NCT03567317|DEVICE|CPAP withdrawal|Patients randomized to withdrawal will stop CPAP use for one week before study evaluations. Patients will also undergo a polysomnography to confirm the presence of severe OSA.
223673047|NCT06349005|OTHER|Tracheal intubation using Storz VL|Video-assisted intubation technique using Storz VL
223673048|NCT06349005|OTHER|Tracheal intubation using Macintosh laryngoscopy|Traditional intubation technique using Macintosh laryngoscopy
223673049|NCT06349005|OTHER|Tracheal intubation using MacGrath VL|Video-assisted intubation technique using MacGrath VL
223673050|NCT06349005|OTHER|Tracheal intubation using EzVision VL|Video-assisted intubation technique using EzVision VL
223673051|NCT05006742|PROCEDURE|CB study arm|Included patients are randomized to receive cryobiopsy
223673052|NCT05006742|PROCEDURE|FB-CB study arm|Included patients are randomized to receive forceps biopsy and cryobiopsy within the same session
223673053|NCT01519193|BEHAVIORAL|Narrative Exposure Therapy for violent offenders (NETvo)|During NETvo the client, with the assistance of the therapist, constructs a chronological narrative of his whole life with a focus on exposure to traumatic stress and also on perpetrated violent acts. Empathic understanding, active listening, congruency and unconditional positive regard are key components of the therapist's behavior who asks in detail for emotions, cognitions, sensory information, and physiological reactions, linking them to an autobiographical context. Positive emotions and cognitions reported for violent acts are linked to the respective past. During four sessions the most important traumatic experiences and perpetrated violent acts are processed. In the fifth session plans and ideas for the future are developed to assist the children to reintegrate themselves into society.
223673054|NCT04334083|BEHAVIORAL|Comparison of biomarkers of stress|Emergency will be followed during a night shift and the rest day et during a day shift and the rest day. They will be observed by a medical externship student. We will assess the role of expertise and habituation to stressful emergency situations.
223673055|NCT05795049|OTHER|Stool and saliva sample collection|Stool and saliva samples collection
223673056|NCT05795049|OTHER|Questionnaire completion|"Questionnaire on;~* demographic, ethnicity, IBS subtype, post-infection onset, previous surgeries~* IBS severity score for adults~* Hospital Anxiety and Depression scores for adults~* Somatization score for adults~* Total glucose and fructose and excess fructose, lactose, sorbitol, mannitol, oligosaccharides (Fructans and GOS) as measured by CNAQ questionnaire for adults and children~* Quality of Life as measured by the PedsQL™ GI Symptoms Module~* GI symptoms as measured by the PedsQL™ GI Symptoms Module~* Anxiety, Depression as measured by the Pediatric PROMIS®"
223772236|NCT03037151|DRUG|Grazaoprevir/Elbasavir|treatment naive
223772237|NCT03037151|DRUG|Grazaoprevir/Elbasavir/RBV|treatment experienced
223673057|NCT03900689|OTHER|Part 1 Survey Group|At the first study visit, participants will answer a series of survey questions about their neighborhoods, educational levels, social activities, access to transportation and food, healthcare management and where participants find social and spiritual support. General information such as age, ethnicity and address will also be collected.
223673058|NCT03900689|OTHER|Part 2 Focus Group|If participants from Part 1 agree to be contacted for Part 2, participants will be included in a focus group to explore unexpected findings and further investigate social determinants identified in Part 1.
223673059|NCT02587182|DEVICE|Deep Dry needling|The muscles were repeatedly perforated by rapidly inserting and partially withdrawing the needle from the myofascial trigger point, eliciting local twitch responses in some insertions
223673060|NCT03124667|BEHAVIORAL|Games|The game training will emphasize general and exercise-specific dual task processing, self-priming and certainty training.
223673061|NCT03124667|BEHAVIORAL|Videos|The video training will emphasize health and educational information.
223673062|NCT02914002|BEHAVIORAL|Psychoeducational intervention|A mobile kitchen visits the 16 selected communities every 2 weeks for a period of 1 year. A 30 minute cooking lesson is given by a trained instructor, the recipes have been designed to be quick and easy to make, use local and inexpensive ingredients, contain mostly vegetables and have a good taste. During the lesson, healthy habit and cooking tips are mentioned as well as the importance of cooking at home and having family meals . A printed version of the recipe is given to every participant. Every session participants are encouraged to prepare the recipe. At the end of the lesson all the participants get to taste the meal and express their opinion.
223673063|NCT05300204|OTHER|Self-help strategies for depression|"Before starting the intervention, the participants are told that they will be shown parts of a website about depression. The participants are instructed to carefully attend to the website (e.g., to read the text precisely, to hear attentively to the podcasts and to view carefully the videos and images on the website). The time window spent for the reception of each part of the website are fixed.~The participants in this intervention group will only be shown parts of the website regarding self-help strategies for depression."
223673064|NCT05300204|OTHER|General information about depression|"Before starting the intervention, the participants are told that they will be shown parts of a website about depression. The participants are instructed to carefully attend to the website (e.g., to read the text precisely, to hear attentively to the podcasts and to view carefully the videos and images on the website). The time window spent for the reception of each part of the website are fixed.~The participants in this intervention group will only be shown parts of the website regarding general information about depression"
223673065|NCT01903252|DRUG|TP05|3.2g/day once daily for 12 weeks (blinded), 1.6g/d - 4.8g/d up to week 38 (open label)
223673066|NCT01903252|DRUG|Asacol 400 mg|3.2g/d twice daily for 12 weeks (blinded), switch to 1.6g/ - 4.8g/d TP05 up to week 38 (open label)
223673067|NCT03598517|RADIATION|high dose chemoradiotherapy|"Radiation therapy: 60 Gy at 2 Gy/Fx/d over 6 weeks, immediately followed by 28.8 Gy in 24 fractions of 1.2 Gy, twice per day,on weeks 6-8 to a total dose of 88.8 Gy.~concurrent chemotherapy: weekly carboplatin area under the curve (AUC) 2 and paclitaxel 45 mg/m2 over the duration (8 weeks) of radiation therapy.~Adjuvant chemotherapy is planned 6 weeks after high dose chemoradiation."
223673068|NCT04270279|DRUG|Xueshuanxinmaining tablet|A kind of Chinese patent medicine
223673069|NCT04270279|DRUG|Xueshuanxinmaining placebo|The simulant of Xueshuanxinmaining tablet
223673070|NCT04270279|DRUG|Nitroglycerin tablets|Be used when angina attack
223673071|NCT01701050|OTHER|Blood collection|Patients will have blood drawn for circulating tumor cell (CTC) endocrine therapy index (CTC-ETI) calculation at baseline (within 30 days prior to the initiation of endocrine therapy) and then subsequently 1, 2, 3 and up 12 months after the initiation of therapy, or at the time of disease progression, whichever occurs first.
223673072|NCT03906916|DIAGNOSTIC_TEST|1,3-β-D-glucan quantification|Patients hospitalised in Internal Medicine with suspicion of invasive candidiasis will be evaluated by 1,3-β-D-glucan test and by means of blood culture to confirm the diagnosis
223673073|NCT03906916|DRUG|Micafungin|Patients hospitalised in Internal Medicine with suspicion of invasive candidiasis will be treated with an echinocandin (micafungin) as timely as possible, and they will continue the antifungal treatment according to international guidelines when diagnosis is confirmed by positive 1,3-β-D-glucan test.
223772238|NCT02379949|BEHAVIORAL|Virtual Reality Exposure Therapy|During virtual reality exposure therapy, a person encounters a feared stimulus (public speaking) in a computer-generated environment.
223772239|NCT02379949|BEHAVIORAL|Exposure Group Therapy|Exposure Group Therapy a behavioral treatment for social phobia. Participants face their fears by giving speeches to other group members.
223772240|NCT04698005|DIETARY_SUPPLEMENT|25g Ketone monoester without added salts|oral supplementation of ketone monoester
223772241|NCT04698005|OTHER|Placebo|The patients will receive a placebo drink (drinking water) of equivalent volume (3x 65ml)
224253544|NCT06402539|BEHAVIORAL|family-centered empowerment program|The intervention will be carried out face to face in the Orthopedics and Traumatology outpatient clinic, and some interviews will be held by phone. The first interview is on the day the patient will be approved in the anesthesia department, the second interview is when the patient is admitted to the ward, the third interview is after the surgery and the fourth interview is in the ward on the day of discharge, the fifth interview is by phone 1 week after discharge, the sixth interview is at the outpatient clinic when the patient comes for a check-up 2 weeks after discharge, and the seventh interview is at the time of discharge. The eighth interview will be held by phone in the 3rd week after discharge, and the eighth interview will be held in the outpatient clinic in the 4th week after discharge.
224253545|NCT04301791|OTHER|nutritional status|impact of nutritional status on clinical outcome of children admitted in PICU
224253546|NCT03133533|PROCEDURE|laparoscopic repair|Surgical inguinal hernia repair using laparoscopic approach.
224253547|NCT03133533|PROCEDURE|robot-assisted repair|Surgical inguinal hernia repair using robot-assisted approach.
224253548|NCT06329947|DRUG|Surufatinib 250mg/d qd once daily|mFOLFOX6( Oxaliplatin + Leucovorin + fluorouracil) Oxaliplatin 85mg/m2 d1+CF 400mg/m2 d1+5-FU 400mg/m2d1 /2400mg/m2 continuous intravenous injection (civ) for 46h, The drug is administered every 14 days for a total of 8-12 cycles.
224253549|NCT05341622|BEHAVIORAL|Differentiated Box|Patients will receive mailed FIT kits in a box with differentiated packaging
224253550|NCT05341622|BEHAVIORAL|Standard Mail|Patients will receive mailed FIT in a standard mailing envelope
224253551|NCT05341622|BEHAVIORAL|Text|Patients will receive a series of up to 3 texts explaining the importance of colon cancer screening and prompts to complete the mailed FIT.
224253552|NCT05341622|BEHAVIORAL|No Text|Patients will not receive text messaging explaining the importance of colon cancer screening or prompts to complete the mailed FIT.
224253553|NCT05341622|BEHAVIORAL|Reminder|Patients will receive a mailed letter reminder to complete their FIT kit if not resulted by 1 month from initial outreach.
223673074|NCT01683097|OTHER|Standardized explanation|Standardized explanation provided on code status, advance directives and end of life care
223673075|NCT01598142|PROCEDURE|Team 1|experienced endoscopist with a experienced assistant
223673076|NCT01598142|PROCEDURE|Team 2|same experienced endoscopist with a new trained assistant
223673077|NCT05834387|PROCEDURE|EICU Transfer Routine Care|EICU Transfer Routine Care
223673078|NCT05834387|PROCEDURE|Implementing interventions based on a 'health care-family-environment' linkage|"Nursing interventions in the experimental group The interventions were based on the health care-family-environment linkage"
223673079|NCT04036123|OTHER|Urodynamic investigation|Simultaneous UDI (same session repeat filling cystometry and pressure flow study) with an air-charged and water-perfused measurement system.
223673080|NCT00131924|BIOLOGICAL|esterified estrogens|
223673081|NCT04303728|DIAGNOSTIC_TEST|Muscle ultrasound|The muscle thickness and muscle quality will be assessed on ultrasound
223673082|NCT01948856|DRUG|J022X ST|"Oral administration - During 6 months and according to the approved summary of product characteristics : 1 sachet per day in the morning on an empty stomach~* First month: 4 consecutive days per week during 3 consecutive weeks~* 5 next months: 4 consecutive days per month at monthly intervals"
223673083|NCT01948856|DRUG|Placebo|"Oral administration - During 6 months : 1 sachet per day in the morning on an empty stomach~* First month: 4 consecutive days per week during 3 consecutive weeks~* 5 next months: 4 consecutive days per month at monthly intervals"
223673084|NCT03946722|DRUG|GnRH analogue downregulation|"Downregulation is the suppression of the ovaries during an IVF cycle in order to perform controlled ovarian stimulation and prevent premature ovulation.~Participants will be exposed to one week of downregulation using a GnRH analogue in the standard downregulation arm and 6 weeks of downregulation using a GnRH analogue in the modified downregulation arm."
223673085|NCT03946722|OTHER|Participant questionnaire|Participant will be offered the opportunity to complete an adenomyosis symptom assessment questionnaire at the start of their treatment, and again two months after completion of treatment.
223772242|NCT03318848|OTHER|Video during simulation|The intervention group simulated the bed bath while watching the video, under the supervision of the tutor
223772243|NCT03962881|BIOLOGICAL|20 µg recombinant hepatitis B vaccine at months 0, 1, and 6|three-dose, 20 µg per dose
223772244|NCT03962881|BIOLOGICAL|20 µg recombinant hepatitis B vaccine at months 0, 1, 2,and 6|four-dose, 20 µg per dose
224253554|NCT05341622|BEHAVIORAL|No Reminder|Patients will not receive any mailed letter reminder to complete their FIT kit.
224253555|NCT00215319|DEVICE|Lumbar I/F with cage and pedicle screws|Surgical Titanium Mesh™ with MOSS-Miami™ Pedicle Screws
224253556|NCT03919058|OTHER|Baseline activity (control regime)|This is a baseline measurement of physical activity during which subjects will be instructed not to change activity patterns during four days and to note all activities they perform.
224253557|NCT03919058|OTHER|Increased sitting time (sit regime)|Participants have to spend 14h of their day sitting, 1h walking and 1h standing, for four consecutive days. According to the compendium of Ainsworth et al. (2011), this corresponds with a daily workload of activities (DWA) of 27 metabolic equivalents (MET's) per day.
224253558|NCT03919058|OTHER|Non-exercise physical activity (sit less regime)|Each day (4 days in total) will consist of 3h walking, 4h standing and 9h sitting. These time frames are chosen to result in a comparable DWA increase as the exercise regime compared to the sit regime (+7 MET's)27. The additional 2h of walking and 3h of standing, compared to the sitting regime, will be done in a minimum of four bouts with a time interval of \> 1h. The subjects will be instructed to walk on a slow pace. i.e. 2-3 km/h (e.g. walking during shopping and work related walking in an office).
224253559|NCT03919058|OTHER|Structured exercise (exercise regime)|One hour of sitting in the sit regime will be replaced with 1 training session (1h) on a cycle ergometer in the research center. The remaining hours of each day (4 days in total) have to be spent as follows: 13h sitting, 1h walking and 1h standing for daily care. The intensity of the training session (50-60% of Wmax) results in a DWA of 34.5 MET's according to the compendium of physical activities. Duration of training sessions will be adapted individually with ActivPAL data of the sit less and sit regime to identically match DWA increase between the sit less and exercise regime, compared to the sitting regime.
224253560|NCT02771353|RADIATION|WT_vDIBH|
224253561|NCT02771353|RADIATION|VMAT_FB|
224253562|NCT01169883|BEHAVIORAL|Coping Peer Support|The Coping Peer Support is delivered at weekly group meetings over the 10 week active treatment phase. The Coping Peer Support consists of: group support, coping peer group problem solving, and development and recording of Coping Peer Asthma Messages. More specifically, a social worker facilitates a peer group discussion of barriers to taking their daily inhaled steroids, and ways to overcome these barriers. The social worker also facilitates peer recording of messages by the participants encouraging each other to take their daily inhaled steroid medication.
223673086|NCT04526821|DRUG|Bovine Lactoferrin|Bovine Lactoferrin 600mg daily for 12 weeks (3 chewable tablets of 100mg , twice a day), for 12 weeks plus personal portection provided from the hospital.
223673087|NCT04526821|DIETARY_SUPPLEMENT|Maltodextrin|Maltodextrin 600mg daily for 12 weeks (3 chewable tablets of 100mg, twice a day), for 12 weeks plus personal portection provided from the hospital.
223673088|NCT01381562|DRUG|Drug: GSK2251052|Reconstituted, added to 250mL 0.9% NaCl solution and administered via IV infusion
223673089|NCT01381562|DRUG|Meropenem|Reconstituted, added to 100mL 0.9% NaCl solution and administered via IV infusion
223673090|NCT01381562|OTHER|Placebo|saline placebo
223772245|NCT03962881|BIOLOGICAL|60 µg recombinant hepatitis B vaccine at months 0, 1, 2,and 6|four-dose, 60 µg per dose
223772246|NCT01268644|DRUG|Leptin|weight based sub-cutaneous injection twice daily of Leptin
224253563|NCT01169883|BEHAVIORAL|Doctor Asthma Messages|The attention control group will receive Doctor Asthma Messages delivered during the 10 week active treatment phase. The content and number of these messages will be equivalent to those received by the intervention group. These messages are developed and recorded by an Allergist/Immunologist. The participants in the attention control group will listen to these Doctor Asthma Messages, between their favorite music tracks on their MP3 player, as they go about their day-to-day activities.
224253564|NCT01169883|BEHAVIORAL|Coping Peer Asthma Messages|The Coping Peer Asthma Messages developed and recorded by study participants for each other at the weekly coping peer group meetings will be placed on intervention group participants' MP3 players. These Coping Peer Asthma Messages will be played on their MP3 players, between their favorite music tracks, during the course of their daily routines. This infuses the coping peer support from the coping peer group meetings into the adolescents' daily routines.
224253565|NCT01169883|BEHAVIORAL|Asthma Supervision|A member of the study team meets individually with each participant at baseline to teach proper use of a peak flow meter and spacer.
224253566|NCT01169883|BEHAVIORAL|Music Tracks|Participants receive an MP3 player (iPod Shuffle) in the baseline period. Participants receives clean, radio-edited music tracks of their choice in the baseline period and 10 week active treatment period.
224253567|NCT02947243|DEVICE|VR distraction via Oculus Rift|In addition to standard pharmacological treatment, Virtual reality distraction through the use of Oculus Rift® will be used as the experimental intervention. The Oculus Rift (Consumer version) is made of two Oled panels with a resolution of 1200p running at 90Hz. It has very effective 360 degree positional tracking and integrated 3D audio. These combine to produce a high level of immersion, with high photorealism while maintaining the low latency necessary to induce presence and prevent cybersickness. The child, depending on the burn site, will have the opportunity to interact with the game. Video games, approved by healthcare professionals with extensive experience in pediatrics, will be adapted for children and tailored to minimize cyber sickness.
224253568|NCT02947243|DRUG|Morphine|As per unit's protocol
223673091|NCT01642732|OTHER|Everolimus, lupron, bicalutamide, and radiation|"Everolimus - there are five dose levels (2.5mg. every 48 hrs.,2.5mg./day, 5mg./day, 7.5mg./day, and 10mg./day) based on the initial expectations of toxicity and the incidence of toxicity of subjects already treated. Subjects will be on one dose level throughout the study. Subjects will receive everolimus starting on study day 1.~Radiation therapy will start on day 60-70 (44 treatments, at 5 treatments a week for a little longer than 8 weeks).~Bicalutamide (50 mg. tablets daily) will begin on study day 10-14, approximately 2 months prior to Radiation Therapy.~Lupron injections will begin on study day 15 to 25, approximately 2 months prior to Radiation Therapy. The typical dose schedule is either one injection (22.5 mg. dose)every 3 months for a total of 8 injections or one injection (30 mg. dose) every 4 months for a total of 6 injections.~Radiation, bicalutamide, and everolimus will end between study day 120-130. Lupron will end at 24 months on study."
223673092|NCT04816968|DRUG|Cefepime|Cefepime from 3 to 6 gr, based on patient's clinical status, reduced dose based on organ function and physician discretion, in 100cc saline solution in elastomer, perfused in 24 hours.
223673093|NCT04816968|DRUG|Piperacillin/tazobactam|Piperacillin/Tazobactam 18 gr, based on patient's clinical status, reduced dose based on organ function and physician discretion, in 100cc saline solution in elastomer, perfused in 24 hours.
223673094|NCT04816968|DRUG|Meropenem|Meropenem 3 gr, based on patient's clinical status, reduced dose based on organ function and physician discretion, in 100cc saline solution in elastomer, perfused in 24 hours.
223673095|NCT04816968|DRUG|Vancomycin|Vancomycin 30 mg/kg, based on patient's clinical status, reduced dose based on organ function and physician discretion, in 100cc saline solution in elastomer, perfused in 24 hours.
223673096|NCT02478567|OTHER|Rotator Cuff Training|four specific band-resisted strength training exercises for scapula
223673097|NCT02478567|OTHER|Scapular Training|four specific band-resisted strength training exercises for rotator cuff
223673098|NCT03538171|DRUG|Entinostat|Entinostat will be repeatedly administered PO on days 1, 8, 15 and 22 of each treatment cycle. Exemestane PO once daily on day 1-28.
223772247|NCT05378386|DEVICE|Edwards Alterra Adaptive Prestent with SAPIEN 3 Transcatheter Pulmonary Valve System|The Edwards Alterra Adaptive Prestent is designed to reduce the diameter of large irregular right ventricular outflow tracts (RVOTs) and provide a circular, semi-rigid landing zone to place an Edwards SAPIEN 3 transcatheter heart valve (THV).
223772248|NCT01416194|DRUG|Bazedoxifene|Patients receiving Bazedoxifene in usual clinical care. In this non-interventional study there is no protocol mandated drug assignment or dosing schedule.
223673099|NCT03538171|DRUG|Placebo|Patients receive Exemestane as in Arm A and placebo PO on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
223673100|NCT03538171|DRUG|Exemestane|Exemestane PO once daily on day 1-28.
223772249|NCT01416194|DRUG|Bisphosphonate|Patients receiving Bisphosphonates in usual clinical care. In this non-interventional study there is no protocol mandated drug assignment or dosing schedule.
223772250|NCT01416194|DRUG|Raloxifene|Patients receiving Raloxifene in usual clinical care. In this non-interventional study there is no protocol mandated drug assignment or dosing schedule.
223772251|NCT04155996|DEVICE|data collection|Patients will receive a full data acquisition set with CGM sensors, an activity tracker and a smartphone application in which they can log daily events.
223772252|NCT01222494|BEHAVIORAL|Behavioral Weight Loss|This intervention is a family-based, behavioral weight loss program that has been employed in studies with overweight and obese children, as well as with children who have diabetes. For the proposed study, the program has been modified to fit the needs of disruptive and behaviorally disturbed youth and their families. The modified program includes 16 weeks of weekly visits with a study interventionist, and supplemental phone contacts as needed. Phone contacts will only replace in-person visits if absolutely necessary to achieve the visit.
224253569|NCT06997523|BEHAVIORAL|Breath Therapy and Benson Relaxation Technique|Relaxing breathing therapy (4-7-8) and Benson relaxation technique will be applied to the intervention group for 6 weeks. No intervention will be made to the control group.
223673101|NCT05532696|DRUG|ABT-101|Patients will receive ABT-101 by oral administration on a 28-day cycle
223673102|NCT04814238|PROCEDURE|Aortic Root Surgery|First time, isolated, minimally invasive (mini-sternotomy, RALT) aortic root or aorta surgery
223673103|NCT00212017|DRUG|voglibose|
223673104|NCT00212017|BEHAVIORAL|diet and exercise therapy|
223673105|NCT03120455|BEHAVIORAL|Almond Group|Obese or overweight female adults will be randomly allocated to have almond as afternoon snacks, while they have a hypoenergetic diet.
223673106|NCT03120455|BEHAVIORAL|Pistachio Group|Obese or overweight female adults will be randomly allocated to have Pistachio as afternoon snacks, while they have a hypoenergetic diet.
223673107|NCT03120455|BEHAVIORAL|Nut free group|Obese or overweight female adults will be asked to avoid nuts, seeds and nut products, while they have a hypoenergetic diet.
223673108|NCT02688322|DRUG|Sulbactam|2 g in 100 ml of normal saline solution and administered via an infusion pump at a constant flow rate 1 h every 12 h. Blood samples (approximately 5 ml) will be obtained by direct venepuncture at the following time: 0, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8 and 12 h after 7th dose of sulbactam
223673109|NCT04140123|DRUG|ZSP1601|ZSP1601 tablets be taken orally for 28 days.
223673110|NCT04140123|DRUG|ZSP1601 Placebo|Subjects will receive matching placebo of ZSP1601
223673111|NCT02370576|OTHER|rating scale application|"Administration of validated PTSD, MDD and anxiety disorders rating scales immediately after birth and 1 month postpartum.~rating scale application"
223673112|NCT03780023|OTHER|Questionnaire|All patients will receive three questionnaires at four different time points during their radiation treatment. The time points are 1) before treatment, 2) during the first week of treatment, 3) at the end of treatment (6-8 weeks after treatment begins), and 4) one year after treatment ends.
223673113|NCT03705273|DRUG|Dexamethasone IV for PO|Common pediatric emergency department practice
223673114|NCT03705273|DRUG|Dexamethasone crushed tablets|Alternative route of administration for patients unable to swallow tablet whole
223673115|NCT05570331|DIAGNOSTIC_TEST|HPV integration test|HPV-positive patients who are eligible for cervical cancer screening will be asked to collect Cervical Exfoliated Cells sample for the HPV integration screening test and for the HPV testing and TCT.
223673116|NCT06226532|DRUG|lidocaine spray|Group SL: Spray 10% lidocaine for 4 puffs at the endotracheal tube cuff, also prepare for spray at the laryngeal inlet for 4 puffs (total approximately 1.5mg/kg)
223673117|NCT06226532|DRUG|Intravenous Lidocaine|2% lidocaine 1.5 mg/kg IV will be given 2 minutes after cisatracurium injection (3 minutes prior intubation).
223673118|NCT04486898|OTHER|Music group|Music group will be given music intervention or listen to music for 30 minutes ,3 times a week for the period of 5 week duration. Music will be selected as per participant's preference
223673119|NCT02339220|BEHAVIORAL|Constraint-Induced Movement Therapy (CIMT)|Constraint-Induced Movement Therapy (CIMT) is a form of physical rehabilitation based on basic research in behavioral psychology and behavioral neuroscience. The therapy will be given on an outpatient basis for 3.5 hours/day for 10 consecutive weekdays. This treatment has four components: 1. intensive training in use of the more-affected arm; 2. organization of this training following shaping principles, which involve frequent positive feedback and progressively increasing the demand of the task in small increments; 3. discouraging use of the less-affected arm by placing the hand in a padded safety mitt, and 4. a set of behavioral procedures, known as the Transfer Package, for transferring gains from the treatment to real-world setting. In this study, two forms of the Transfer Package, standard and enhanced, will be used and form a separate factor (see below).
223673120|NCT02339220|BEHAVIORAL|Lakeshore Enriched Fitness Training (LEFT)|This treatment will given on an outpatient basis for 3.5 hours per day for 10 consecutive weekdays. It will consist of the following components: general fitness exercises (largely lower extremity), sports and recreation (land and water-based); adapted Yoga; breathing exercises and postural control, movement to music, massage therapy, meditation and Progressive Muscle Relaxation (PMR).
223673121|NCT02339220|BEHAVIORAL|standard Transfer Package (sTP)|This intervention will take, on average, 30 minutes out of the 3.5 hour daily planned for treatment. The sTP is a set of behavioral procedures for transferring gains from the treatment setting to real-world. The procedures when the sTP is applied to CIMT include negotiating a behavioral contract with the patient and caregiver, when available, about use of each arm during the treatment period, keeping a daily diary on arm use, completing a structured interview about use of the more-affected arm in daily, problem solving about perceived barriers to use of the more-affected arm outside the treatment setting during treatment, and four weekly follow-up phone calls to assess use of the more-affected arm and problem solve about any remaining barriers perceived to its use. The sTP when applied to the LEFT intervention will have parallel components that target engagement in fitness activities and overcoming perceived barriers to fitness in the home.
223772253|NCT01222494|BEHAVIORAL|Diet and Exercise Education|Participants assigned to this arm will receive monthly medically validated, individualized diet and exercise education by a trained research professional.
224253570|NCT04441216|OTHER|Rhizoma Coptidis, Radix Astragali and Flos Lonicerae|granule
224253571|NCT04441216|OTHER|Rhizoma Coptidis, Radix Astragali and Flos Lonicerae, Ophiopogonis Radix|granule
224253572|NCT00827047|PROCEDURE|Total hemihepatic vascular exclusion|A long vascular clamp is inserted along the midline of the anterior surface of the vena cava,proceed cranially up to the space between the right and the middle hepatic vein trunks. Two tapes are seized with the clamp passing between the anterior surface of the IVC and the liver parenchyma.One tape is use to pass around the hepatic parenchyma for occlusion of the bleeding from the remnant liver;the other is used to loop the right (or left )hepatic vein trunk and short hepatic vein,as well as inferior right hepatic vein,if present. Selectively interrupts the arterial and portal inflow to the part of the liver (right or left hemiliver)ipsilateral to the lesion that requires resection.Thus total hemihepatic vascular exclusion is achieved.
224322242|NCT02143466|DRUG|Part D - AZD9291 in combination with AZD6094|Part D - AZD9291 80mg OD administered in combination with AZD6094 300mg OD to further evaluate the safety, tolerability, pharmacokinetics and antitumor activity in terms of ORR and PFS in patients with locally advanced or metastatic cMET positive EGFRm+ and T790M-negative NSCLC, following progression on EGFR-TKI treatment. The choice of AZD6094 dose of 300 mg is based on results from preclinical and clinical studies. Clinical testing of the 300 mg OD dose will enable better assessment of impact of lower AZD6094 exposure on overall tolerability and hepatotoxicity risk as well as exploration of the efficacy and overall safety profiles with a dose meaningfully lower than the current dose of 600 mg OD.
224322243|NCT06427941|DRUG|BGB-B2033|Administered by intravenous infusion
224322244|NCT06427941|DRUG|Tislelizumab|Administered by intravenous infusion
224253573|NCT00827047|PROCEDURE|Hemihepatic vascular Clamping|Selectively interrupts the arterial and portal inflow to the part of the liver (right or left hemiliver)ipsilateral to the lesion that requires resection. Selective clamping can be achieved after carefully dissecting the right from the left hilar branches or after inserting a clamp between the right and left hilar branches without prior hilar dissection and looping the right or left portal structures with a tape.
224253574|NCT00827047|PROCEDURE|Pringle's Maneuver|Hepatic pedicle clamping is performed by encircling the hepatoduodenal ligament with a tape and then applying a tourniquet or a vascular clamp until the pulse in the hepatic artery disappears distally.
224253575|NCT02658084|DRUG|Vinorelbine|Administered as an intravenous infusion on Day 1 and Day 8 of every 21-day cycle.
224253576|NCT02658084|DRUG|Trastuzumab Emtansine|Administered as an intravenous infusion on Day 1 of every 21-day cycle.
224253577|NCT01173042|DIETARY_SUPPLEMENT|Peanuts|Shake containing 3.0oz of peanuts (including skin) + control (heavy whipping cream, glucose and chocolate syrup)
223673122|NCT02339220|BEHAVIORAL|enhanced Transfer Package (eTP)|This intervention will take, on average, 30 minutes out of the 3.5 hour daily planned for treatment. It is an enhanced form of the sTP. The enhancements include a computerized version of the daily diary, cues to be placed in patients' homes to prompt engagement in desired activities, and additional follow-up phone calls.
224253578|NCT01173042|DIETARY_SUPPLEMENT|Glucose and whipping cream|An oral liquid glucose (75g) and fat (high saturated fat from 60g heavy whipping cream) load. Chocolate syrup is added for flavor.
224253579|NCT01173042|DIETARY_SUPPLEMENT|Oil Blend|Shake containing an oil blend (sunflower, sesame, olive and palm oils) + control (heavy whipping cream, glucose and chocolate syrup). The amount of oil added to the control will provide an equivalent amount of fat to that provided in 3 oz (85g) of peanuts
224253580|NCT02071875|DEVICE|Nautilus NeuroWaveTM recording|Nautilus NeuroWaveTM recording 15 minute recording with Nautilus NeuroWave Neurodiagnostic .
223772254|NCT04485533|DEVICE|VisuXL® Gel|"VisuXL® ophthalmic gel, available in a multidose 10ml bottle without preservatives based on Coenzyme Q10, Vitamin E TPGS and cross-linked sodium carboxymethylcellulose.~Dose/dosage: 1 drop per eye twice a day."
223772255|NCT04485533|DEVICE|HYLO®|"HYLO® ophthalmic solution, a phosphate- and preservative-free sterile eye drops containing 2 mg/ml of hyaluronic acid sodium salt, a citrate buffer, sorbitol and water.~Dose/dosage: 1 drop per eye twice a day"
223772256|NCT05217797|BEHAVIORAL|Wearing glasses (any type)|Participants are asked to wear glasses in public spaces.
223673123|NCT04199598|DRUG|Abediterol (2.4 μg)|2.4 μg (delivered dose) abediterol via PARI LC SPRINT nebuliser
223673124|NCT04199598|DRUG|Abediterol (4.8 μg)|4.8 μg (delivered dose) abediterol via PARI LC SPRINT nebuliser
223673125|NCT04199598|DRUG|Abediterol (2.4 μg)|2.4 μg (delivered dose) abediterol via OMRON NE-C900-E nebuliser
223673126|NCT04199598|DRUG|Abediterol (2.5 μg)|2.5 μg (nominal dose) abediterol via DPI, reference
223673127|NCT03744000|PROCEDURE|Immediate stenting|Abciximab (0.25㎎/㎏) intracoronary injection will be performed to all possible patients after guidewire has passed culprit lesion. Additional manual thrombus aspiration or balloon angioplasty can be performed by operator to achieve TIMI Ⅲ flow. When TIMI Ⅲ flow is achieved after these procedures, patient will be randomized to immediate stenting or deferred stenting group. In immediate stenting group, stenting will be done immediate after achieving TIMI III flow during initial procedure.
223673128|NCT03744000|PROCEDURE|Deferred stenting|Abciximab (0.25㎎/㎏) intracoronary injection will be performed to all possible patients after guidewire has passed culprit lesion. Additional manual thrombus aspiration or balloon angioplasty can be performed by operator to achieve TIMI Ⅲ flow. When TIMI Ⅲ flow is achieved after these procedures, patient will be randomized to immediate stenting or deferred stenting group. In deferred stenting group, second stage procedure (stent implantation) will be done at 3 to 7 days after TIMI Ⅲ flow has achieved.
223673129|NCT05154370|DRUG|Intravenous steroid|This study does not limit treatment methods. Patients commonly use high-dose intravenous steroid therapy (HD-S) during acute stage. Immunomodulatory therapies are necessary for the remission stage. All drugs are used in accordance with relevant guidelines.
223673130|NCT06095622|DIETARY_SUPPLEMENT|Fenugreek Seeds and Indian Rennet|Food herbs like fenugreek Seeds and Indian rennet to formulate rice dish.
223673131|NCT02456480|DRUG|CLS001|topical gel
223673132|NCT02456480|DRUG|Vehicle|topical gel
223673133|NCT05958173|DIETARY_SUPPLEMENT|Capsaicin|Oral stimulation with natural TRPV1 agonist
223673134|NCT05958173|DIETARY_SUPPLEMENT|Piperine|Oral stimulation with natural TRPA1/V1 agonist
223673135|NCT05958173|DIETARY_SUPPLEMENT|Placebo|Oral stimulation with placebo solution
223673136|NCT03582228|BEHAVIORAL|Virtual Envrionment for Social Communication|"Once the Virtual Envrionment for Social Communication intervention begins, participants will meet online from home for one-hour sessions twice a week (twelve sessions over six weeks).~Weekly sessions will follow a standardized format:~* 15 minutes- Social support group (guided discussion of experiences related to weekly topic)~* 20 minutes- Didactic instruction~* 15 minutes- Role playing~* 10 minutes- Debriefing and group feedback"
223673137|NCT01606878|DRUG|Crizotinib|Given PO
223673138|NCT01606878|DRUG|Cyclophosphamide|Given IV
223673139|NCT01606878|DRUG|Dexrazoxane Hydrochloride|Given IV
223673140|NCT01606878|DRUG|Doxorubicin Hydrochloride|Given IV
223673141|NCT01606878|OTHER|Laboratory Biomarker Analysis|Correlative studies
223673142|NCT01606878|OTHER|Pharmacological Study|Correlative studies
223673143|NCT01606878|OTHER|Questionnaire Administration|Ancillary studies
223673144|NCT01606878|DRUG|Topotecan Hydrochloride|Given IV
223772257|NCT03714633|BEHAVIORAL|Stockholm Preterm Interaction-Based Intervention (SPIBI)|Post-discharge intervention to extreme premature infants and their parents
224253581|NCT01678638|PROCEDURE|IH repair before NICU discharge|The IH repair is performed prior to NICU discharge (within 1-2 weeks of enrollment and randomization)
224253582|NCT01678638|PROCEDURE|IH repair at 55-60 weeks post-menstrual age|The IH repair will be performed as an outpatient between approximately 55-60 weeks post-menstrual age.
224253583|NCT01051570|DRUG|carboplatin|AUC = 5 by Calvert's formula, day 1 of each 21 day cycle
223772258|NCT00283725|OTHER|No intervention|Patients will be prescribed either galantamine or no AD treatment (ie, neither an acetylcholinesterase inhibitor \[AChEI\] nor memantine).
223772259|NCT00068055|DRUG|Omr-lgG-am|Omr-IgG-am™ 5% is provided in 100 ml bottles (5.0 grams) as a sterile solution containing 5% protein, 10% maltose and water for injection. This product is licensed in Israel, but not in the US.
223772260|NCT00068055|DRUG|Polygam® S/D|Polygam® S/D is a solvent/detergent treated, sterile, freeze-dried preparation of highly purified immunoglobulin G (IgG) derived from large pools of human plasma. When reconstituted (5%) with the supplied diluent (sterile water for injection, USP) Polygam® S/D contains approximately 50mg of protein per ml (approximately 90% is gamma globulin); 3mg/ml human albumin, 22.5 mg/ml glycine, 20 mg/ml glucose, 2mlg/ml polyethylene glycol (PEG), 1 mcg/ml tri-nbutyl phosphate, 1 mcg/ml octoxynol 9, and 100 mcg/ml polysorbate 80.
223772261|NCT00068055|DRUG|Placebo|Normal Saline.
223772262|NCT05120167|DIAGNOSTIC_TEST|Endocervical liquid-base cytology|Endocervical sample collected by brushing and preserved in a liquid-base.
223772263|NCT05120167|DIAGNOSTIC_TEST|Endocervical cell block|"Endocervical sample collected by endocervical brush and preserved in a buffered formalin base for obtaining a cell block and evaluated as histology."
223772264|NCT05120167|DIAGNOSTIC_TEST|Endocervical curettage|Endocervical sample obtained by curettage, preserved in buffered formalin, and evaluated as histology.
223772265|NCT00749424|DEVICE|SES|CYPHER SELECT™ Sirolimus-eluting Balloon-expandable Coronary Stent
223772266|NCT00749424|DEVICE|SES|CYPHER SELECT™ Sirolimus-eluting Balloon-expandable Coronary Stent
223772267|NCT03606798|OTHER|3 Home visits made by a psychologist|Patient and caregiver interviews with a psychologist at home
223772268|NCT00529386|DRUG|Botox|300 units
223772269|NCT01417832|DRUG|Resin infiltration / adhesive|Treatment at baseline of one caries lesion with a resin infiltration conducted under rubber-dam isolation with the Icon-DMG pre-product; treatment at baseline of another caries lesion with an adhesive under rubber-dam isolation with the Prime Bont NT - Dentsply.
223772270|NCT01417832|DRUG|Placebo|In this split-mouth design study, one of the three randomly selected approximal lesions will be treated with an infiltrant resin, one will be treated with an adhesive resin.
223772271|NCT05613634|DEVICE|Repetitive transcranial magnetic stimulation|A high frequency (10 Hz) rTMs on the dominant dorsolateral prefrontal cortex (DLPFC) was applied with the Magstim Rapid Magnetic Stimulator, Magstim Company. Patients were seated in a chair, arms and legs relaxed, head stable, and no movement was allowed during the procedure. Motor threshold (MT) was determined before each session and was defined as the percent intensity output of the stimulator that generated a 50µV motor evoked response in the abductor pollicis brevis (APB) muscle in five out of 10 trials. The DLPFC of dominant hemisphere was localized on the scalp 5.5 cm anterior to the hot spot for the contralateral APB muscle along the parasagittal plane. The average MT was 50 % (range, 45-55%) of the maximal output of the stimulator. The initial mapping procedure was completed with the coil oriented at 45° lateral diagonal orientation roughly perpendicular to the central sulcus and the center of the coil applied tangentially to the scalp.
223772272|NCT05613634|OTHER|Cawthorne Cooksey exercises|Cawthorne Cooksey exercises were carried in the following sequence: First, bed exercises; eye movements (up and down, side to side, focusing on a finger that is one feet distance); head movements (bending up and down, side to side first with eye opened then closed). Second, sitting exercises involved same eye and head movements, shoulder shrugging, turning head and trunk alternately to the right and left, bending head and trunk forward, and pick an object from the ground. Third, standing exercises involved same eye, head, and shoulder movements, changing position from sitting to standing with eye open then closed, throw a ball from hand to hand above eye level, throw a ball from hand to hand beneath knee, changing position from sitting to standing and turn around in between. Fourth, moving around exercises where the patient revolved around a person sitting in the center who throw him a ball and to whom it was returned.
223772273|NCT04532112|DEVICE|Biocontainment Device For Aerosol Generating Procedures (Biobox)|The intervention consists of a biocontainment and aerosol evacuation device (Biobox) that will be placed around a patient prior to the airway procedure and remain in place throughout the airway procedure. The Biobox device is manufactured by National Flag and consists of a re-useable frame with a disposable, plastic torso drape. This is a new device that has not been used previously in a healthcare setting.
223772274|NCT04532112|DEVICE|Control for aerosol generating procedures|There is no control device for the aerosol containment device. As such, intubation without a device will serve as the control/placebo arm for this trial.
223673145|NCT01606878|DRUG|Vincristine Sulfate|Given IV
223673146|NCT06208930|PROCEDURE|Fecal microbiota transplantation|Fecal microbiota transplantation (FMT) is a method for treating imbalances in the intestinal microbiota. Its basic principle involves extracting a portion of feces from a healthy individual that contains a diverse population of beneficial bacteria, processing it, and transplanting it into the digestive system of the recipient to restore a balanced intestinal microbiota.
223673147|NCT00733447|DEVICE|CardioWest temporary Total Artificial Heart (TAH-t) System|The SynCardia CardioWest temporary Total Artificial Heart (TAH-t) System is a pulsatile biventricular device that replaces a patient's native ventricles and valves, and pumps blood to both pulmonary and systemic circulation. The system consists of the implantable CardioWest TAH-t and an external pneumatic driver connected by drivelines.
224253584|NCT01051570|DRUG|RAD 001|5 mg orally starting on Day 2 then continuous
224253585|NCT01051570|DRUG|prednisone|5 mg orally twice a day starting on Day 1 then continuous
224253586|NCT01051570|OTHER|laboratory biomarker analysis|Samples will be collected from archival tissue.
224253587|NCT01051570|OTHER|pharmacological study|Samples will be collected Cycle 1, day 1, 2 \& 8 and Cycle 2, Day 1 \& 2
223673148|NCT05862662|OTHER|MOVE Program|Mobility Opportunities Via Education functional therapy program.
224253588|NCT00824148|DEVICE|Guardian REAL-Time Continuous Glucose Monitoring System|One group will use the glucose monitoring system for 1 month
224253589|NCT00824148|OTHER|Conventional self-monitoring of plasma glucose|Finger prick blood glucose measurements
224253590|NCT00430196|DRUG|BOTOX®|
224253591|NCT00430196|DRUG|Zanaflex®|
224253592|NCT05693597|DRUG|Imtenan Oil|Cold Press Oil
224253593|NCT05693597|DRUG|Baraka Capsules|Soft Gelatin Capsules
224253594|NCT01875315|OTHER|Diagnostic Cardiac Imaging|
224253595|NCT01069926|DRUG|AZD1656|Single dose oral tablet
224253596|NCT05016063|DRUG|Fludarabine|recommendation: 30mg/m2 (D-5\~D-3),determined by tumor burden at baseline.
224253597|NCT05016063|DRUG|Cytoxan|recommendation: 300-500mg/m2 (D-5\~D-3),determined by tumor burden at baseline.
223673149|NCT05331404|RADIATION|PET examination|PET examinations with auditory stimuli such as human voice and environmental sounds.
224253598|NCT05016063|BIOLOGICAL|Dual CD33-CLL1 CAR-T cells|CD33-CLL1 CAR-T infusion (starting at dose level 1 \[DL1\]: 0.5 x 106 transduced CAR-T cells/kg) on Day 0.
224253599|NCT00055315|BEHAVIORAL|Systems Training for Emotional Predictability and Problem Solving (STEPPS)|STEPPS is a 20-week, manual-based, psychoeducational group treatment that combines skills training with cognitive-behavioral techniques. It includes a systems component to train family members, friends, and significant others.
224253600|NCT00055315|BEHAVIORAL|Treatment As Usual (TAU)|
224253601|NCT03552692|DRUG|Venetoclax|"Venetoclax (ABT-199) will be administered orally (800 mg daily). Patients will receive ABT-199 until disease progression, unacceptable toxicity, withdrawal of consent and/or the investigator determines that further therapy is not in the patient's best interest.~Tumor Lysis Syndrome (TLS) is an important identified risk for Venetoclax in oncology studies. Since there are no available data on the risk of TLS in PTCL, the risk of TLS development should be closely monitored during the study.~to avoid TLS ABT-199 will be administered according the following ramp up: W eek 1 day 1: 20 mg W 1 day 2-3: 50 mg W 1 day 4-7: 100 mg W 2: 200 mg W 3: 400 mg W 4 and following: 800 mg"
224253602|NCT01333150|DRUG|Propranololhydrochlorid|One single dose of Propranolol tablet of 40 mg randomized in one of the two sessions
224253603|NCT01333150|DRUG|Placebo|One single dose of placebo
224253604|NCT00965874|DRUG|Magnesium Sulfate high dose|9 g infusion once during 30 minutes
224253605|NCT00965874|DRUG|Magnesium Sulfate low dose|4.5 g magnesium sulfate infusion
224253606|NCT00965874|DRUG|Placebos|serum salin
224253607|NCT00065312|DRUG|naveglitazar|
224253608|NCT02851992|DEVICE|GTS cementless stem|Total Hip Arthroplasty
224253609|NCT02235662|DRUG|TFV IVR|
224253610|NCT02235662|DRUG|TFV/LNG IVR|
224253611|NCT02235662|OTHER|Placebo IVR|
224253612|NCT05551780|DEVICE|SoundBite Crossing System|Use of the SoundBite Crossing System to cross calcified chronic total occlusions
224253613|NCT03222063|OTHER|Play interventions|The following play were included in play interventions i.e building blocks, paint, puzzles, crayons, doctor set, ludo, snake and ladder. All hospitalized children in experimental group received play interventions at bed side. Taking into consideration the busy clinical setting, each participant received continuously 1 hour of hospital play interventions each day for continuous 5 days. Although the hospitalized children were free to choose according to their choice but still the younger children would be engaged in play such as doctor set, Drawing etc. to obtain more sensory experience and older children were offered play interventions such as puzzle, building blocks, ludo etc.with high cognitive demand.
224253614|NCT02146118|DRUG|Erlotinib|Erlotinib 150 mg/day q 4 weeks
224253615|NCT02146118|DIETARY_SUPPLEMENT|Silybin-phytosome|Silybin-phytosome 1g bid/day q 4 weeks
224253616|NCT04694586|DRUG|rifampicin|rifampicin 35 mg/kg
224253617|NCT04694586|DRUG|pyrazinamide|pyrazinamide 40 mg/kg
224253618|NCT04694586|DRUG|HRZE|isoniazid 75 mg + rifampicin 150 mg + pyrazinamide 400 mg + ethambutol 275 mg combination tablets
224253619|NCT04694586|DRUG|HR|isoniazid 75 mg + rifampicin 150 mg combination tablets
224253620|NCT00873639|DRUG|insulin aspart|Effectiveness and safety data collection in connection with the use of the drug NovoRapid® and Levemir® in routine clinical practice
224253621|NCT00873639|DRUG|insulin detemir|Effectiveness and safety data collection in connection with the use of the drug NovoRapid® and Levemir® in routine clinical practice
224253622|NCT01728181|DRUG|Tivozanib|The phase I study will test two dose levels of tivozanib (dose level 1: 1.0 mg and dose level 2: 1.5 mg) given daily for 3 consecutive weeks followed by one week break. Based on the phase I results, the dose of tivozanib will be chosen for the phase II study.
224253623|NCT01728181|DRUG|Erlotinib|150 mg/day for 28 day cycle. No rest period.
224322245|NCT06004804|BEHAVIORAL|Emotional Awareness and Expression Therapy|Seeks to reduce physical (e.g., pain) and emotional (e.g., depression, anxiety) symptoms by helping individuals become aware of their emotions, express them, and resolve emotional conflicts. It will use techniques such as writing about stress, role playing how to handle difficult relationships, recognizing and expressing anger and other feelings, and being more open with others.
223673150|NCT05331404|OTHER|Quality of life assessment|"quality of life assessment by :~* Speech, Spatial and Qualities of Hearing~* Hearing Handicap Inventory For The Elderly Screening~* Short Form Health Survey"
223673151|NCT06496256|DEVICE|Barrigel|Barrigel is an absorbable gel based on Non-Animal Stabilized Hyaluronic Acid (NASHA™) that is injected into the peri-rectal space
224253624|NCT01728181|OTHER|Standard of Care treatment|This treatment will be determined by the study doctor and is considered standard of care.
224253625|NCT00614952|DEVICE|PSG (polysomnography)|POLYSOMNOGRAPHY
224253626|NCT00614952|OTHER|PR (respiratory polygraphy)|respiratory polygraphy: level III of AASM
224253627|NCT02864615|RADIATION|SBRT|Dose and schedule will be depended on metastases location.
224253628|NCT07194733|OTHER|VET FAM Product Box and Nutrition Education|Food boxes and nutrition education
224253629|NCT07201844|BEHAVIORAL|Metacognitive Internet delivered Cognitive Behavior Therapy|Specialist Guided Internet delivered Cognitive Behavior Therapy based on the metacognitive model of excessive worry
224253630|NCT07201844|BEHAVIORAL|Intolerance of uncertainty based Internet delivered Cognitive Behavior Therapy|Specialist Guided Internet delivered Cognitive Behavior Therapy based on the Intolerance of uncertainty model of excessive worry
224253631|NCT07202351|OTHER|Screening and management of sleep disorders|Patients in the intervention group will undergo a systematic and standardised screening of sleep disorders. If any trouble is identified, a specific treatment plan is offered at the Chronos centre, including for instance, cognitive behavioural therapy for insomnia, or nightmares will be treated with Image Rehearsal Therapy (IRT).
224253632|NCT07200518|DIETARY_SUPPLEMENT|OMNi-BiOTiC® Hetox multistrain probiotic|OMNi-BiOTiC® Hetox multistrain probiotic
224253633|NCT07200518|DIETARY_SUPPLEMENT|Placebo|Placebo
224253634|NCT07200648|OTHER|Unconditional cash transfer|$1,000 unconditional cash transfer per month for 12 months
224253635|NCT07200219|BEHAVIORAL|Psychological Performance Strategies Training|A structured 4-week program of psychological performance strategies training delivered to licensed athletes. The program consisted of 8 sessions (twice per week, 60 minutes each) including modules on goal setting, self-talk, emotional control, imagery, automaticity, action orientation, attention control/negative thinking management, and relaxation techniques. Training was conducted in a supervised group format by qualified instructors.
224253636|NCT07200934|DEVICE|Transcutaneous electrical stimulation (TENS)|"The negative/active pad surface electrode will be applied at the T6 dermatome on the abdomen (is located at the left upper quadrant of the abdomen, 2 cm below the ribcage at the left midclavicular line) for stimulation and the passive/positive electrode will be applied on the left T6 costovertebral junction to complete the circuit.~* The specific parameters of TENS will be burst mode, 2.0 Hz frequency, and 300 micro-seconds width~* The patients will receive 3 times 30 min session each week for a period of consecutive 12 weeks.~* The intensity of TENS will be gradually increased from 0 mA till the subject felt a comfortable tingling sensation beneath the electrode without any muscle contraction and pain."
224253637|NCT07200934|OTHER|Mediterranean Diet|The recommended composition of Mediterranean diet regimen: is characterized by a high intake of plant foods, fruits, vegetables, breads and other cereals (traditionally minimally refined), potatoes, beans, nuts and seeds; minimally processed, fresh fruits as a typical dessert, with sweets containing sugars or honey a few times per week; .a high intake of olive oil (especially virgin and extra-virgin olive oil) as the main source of fat; a moderate intake of dairy products (mostly as cheese and yoghurt); zero to four eggs per week; low to moderate amounts of fish and poultry; low amounts of red meat. The diet plan included generally 50% carbohydrates (from vegetables, fruits, legumes, and whole grains), 35% fats (from healthy oils, nuts, seeds, and fish), and 15% protein (from legumes, fish, nuts, dairy, poultry, and eggs).
224253638|NCT07202195|DEVICE|electro-stimulation suit|"In EXOPULSE Mollii Suit is a multi-channel full-body suit with a low energy electrical stimulation - 20 Volt and 20 Hz. It generates 2 milliamp pulses (into 0-10,000 Ohms) with the following parameters:~* Pulse width: variable between 25 and 170 μs.~* Length of period: 50 ms.~* Maximum amplitude: 20 V. It is composed of a control unit, a jacket and pants, with 58 embed-ded electrodes, in direct contact with the skin, and pre-positioned to stimulate 40 key muscle groups.~The suit comes in different sizes. A trained medical staff pre-programs which nerves/muscles to be stimulated based on a clinical assessment of the user and the outcome is evaluated through standardized methods. The stimulation program is thus specific to each user."
224253639|NCT07202195|OTHER|Usual Care|The rehabilitation therapy that is being offered at the National MS Center Melsbroek, but somewhat reduced/adjusted to make time for initiation and follow-up of using the neuromodulation suit and potentially also during the weeks at home (i.e., rehabilitation being offered by municipalities).
224253640|NCT07201233|BIOLOGICAL|Umbilical cord blood|Umbilical cord blood transfusion should be performed 24 hours to 2 weeks after chemotherapy. One to multiple units of cord blood can be applied, and the minimum interval between two cord blood transfusions should be 2 weeks.
224253641|NCT07202455|DEVICE|Active tDCS|Patients will receive 10 sessions of tDCS stimulation (2mA, 20 minutes with a current on/off ramp of 0.1 mA/s) delivered with a Sooma DUO stimulator. Sooma DUO is a transcranial direct current stimulation (tDCS) device. The device generates a current that modulates brain activity. This current is delivered via electrodes attached to the patient's head.
224253642|NCT07202455|DEVICE|Sham tDCS|Patients will receive 10 sessions of sham tDCS stimulation (2mA, 20 minutes, 0.1mA/s ramp-up, stimulation stopped after the current ramp), delivered with a Sooma DUO stimulator. Sooma DUO is a transcranial direct current stimulation (tDCS) device. The device generates a current that modulates brain activity. This current is delivered via electrodes attached to the patient's head.
224253643|NCT07200206|BIOLOGICAL|Nirsevimab|Route of Administration: Intramuscular Pharmaceutical Form: Solution for injection
224253644|NCT07201870|OTHER|Acces to Precare online platform|Precare is an online educational platform for patients on the waiting list for bariatric surgery. Precare offers personalized educational content as well as a calendar and appointment management system. It has been accredited by the Quebec Ministry of Health and Social Services.
224253645|NCT07201805|OTHER|Early Physiotherapy Program|The physiotherapy program provided upon discharge will consist of family education programs that include parental contact and therapeutic holding, carrying, positioning, and sucking facilitation to stimulate postural responses. The physiotherapist will provide training to integrate these programs into daily routines. The physiotherapy group will receive a routine-based family collaborative early intervention program. This program will consist of family education programs based on a goal-oriented model of active motor learning and sensory strategy development for the baby in an enriched environment, incorporating holding, carrying, and positioning into daily routines. If possible, the entire family will participate in these programs.
224253646|NCT07201805|OTHER|Control group|The control group will be shown one-time positioning and holding and carrying principles in addition to routine developmental NICU care at the time of discharge.
223673152|NCT06496256|DEVICE|Transrectal Ultrasound|All subjects will have a transrectal ultrasound (TRUS) conducted. In the control subjects this will act as a sham procedure. For the investigational subjects, the TRUS will be used to visualize the placement of the needle
223673153|NCT01887093|BEHAVIORAL|walking|Participants in both walking groups were requested to walk at the speed of 2.5 miles/h for 30 min/day or more on at least 5 days/week for a period of 12 weeks.One group was asked to walk in the morning and the other group was asked to walk in the evening.
223673154|NCT02879487|DEVICE|Monopolar needle electrode|Colpotomy during total laparoscopic hysterectomy
223673155|NCT03217253|OTHER|Laboratory Biomarker Analysis|Correlative studies
223673156|NCT03217253|OTHER|Pharmacological Study|Correlative studies
223673157|NCT03217253|DRUG|Tazemetostat|Given PO
223673158|NCT00773045|OTHER|A Pain training program and pain measurement|Comparing patients treated with and without analgesia and sedation protocol
223673159|NCT01765010|DRUG|Calcitriol|
223673160|NCT01765010|DRUG|Alfacalcidol|
223673161|NCT01765010|DRUG|Cholecalciferol|
223673162|NCT01765010|DRUG|Placebo|
223772275|NCT01177033|OTHER|Best endovascular treatment or Best surgical treatment|Intervention type I: Best endovascular treatment (stent-protected angioplasty). Intervention type II: Best surgical treatment (femoro-popliteal bypass above the knee with autologous vein (1° choice) or a prosthetic graft (if vein is not available).
224253647|NCT07200362|DRUG|Compound Nanying zhitong Ointment|Use Compound Nanying Pain Relief Ointment alone, or use it in conjunction with conventional Western medicine treatment, without using any other similar Chinese patent medicines or traditional Chinese medicines.
224253648|NCT07200362|OTHER|Do not use any other similar proprietary medicines or traditional Chinese medicines.|Do not use any other similar proprietary medicines or traditional Chinese medicines.
224253649|NCT07200479|DRUG|CAR T cells chimeric antigen receptor cells|CT1194D cells infusion
224253650|NCT07200843|OTHER|Heel rise test and postural/tibial sway measurement|Participants undergo a heel rise test to assess plantar flexor muscle endurance. Postural and tibial sway are measured during single-leg stance using a wearable sensor under eyes-open and eyes-closed conditions. No therapeutic intervention is applied.
224253651|NCT04743765|OTHER|Accelerated medical clearance and surgery|Rapid medical clearance with targeted arrival to the operating room within 6 hours of eligibility criteria criteria met.
224253652|NCT04706026|OTHER|Open Inguinal Hernia Repair - Local Anesthesia|Patients in the local anesthesia arm will receive an injection of a 50:50 mix of 1% lidocaine with epinephrine and 0.25% Marcaine at the surgical site (in the skin and subcutaneous layers + beneath the external oblique aponeurosis). Patients in the local arm will also receive intravenous sedation (Propofol or Precedex) and pain medication (morphine or fentanyl) at the discretion of the attending anesthesiologist.
224253653|NCT04706026|OTHER|Inguinal Hernia Repair - General Anesthesia|General anesthesia will be administered at the discretion of the anesthesiologist and will involve a combination of inhaled and intravenous anesthesia.
224253654|NCT06422923|BIOLOGICAL|NRTX-1001|Biological: NRTX-1001 is an inhibitory neural cell therapy investigational product. It is derived from a human stem cell line that has been converted into high-purity inhibitory interneurons that produce GABA. NRTX-1001 is intended to persist long-term and not require repeated administration.
224253655|NCT03158454|PROCEDURE|Capsula Closure|The capsular closure is performed with a minimum of two vicryl # 2 resorbable sutures
224253656|NCT03158454|PROCEDURE|Non-Capsula Closure|No capsular closure procedure is performed.
224253657|NCT04811014|DRUG|Buprenorphine, Naloxone Drug Combination|8mg of buprenorphine/2mg of naloxone to initiate MOUD treatment and bridge, if necessary, until referral to MOUD clinic can be made for ongoing treatment
224253658|NCT04811014|BEHAVIORAL|Individual Counseling|One-on-one counseling with a licensed chemical dependency counselor
224253659|NCT04811014|BEHAVIORAL|Peer Recovery Support Services|24/7 support from our team of certified peer recovery support specialists to assist with emotional support and case management
224253660|NCT04811014|BEHAVIORAL|Support Group|Referrals to youth-focused support groups and eventual creation of in-house youth-focused support groups
224253661|NCT04811014|BEHAVIORAL|Referral to Medication Management|Study staff will refer patients to long-term MOUD providers in the community
224253662|NCT04811014|BEHAVIORAL|Assertive Outreach|The investigators will conduct weekly outreach to youths who experienced an opioid overdose and attempt to initiate treatment. Outreach is completed by a paramedic and peer coach.
224253663|NCT06781762|OTHER|N/A (Usual Care)|BC survivors will be using aromatase inhibitors as prescribed in their usual care treatment.
224253664|NCT06835049|DRUG|Doxorubicin|Trial treatment consists of 3 neoadjuvant cycles of doxorubicin with either ifosfamide or dacarbazine (the latter only in case of leiomyosarcoma). Doxorubicin will be given at a dose of 75 mg/m2 Body surface area (BSA) on day 1 of each cycle as a intravenous infusion over 15 minutes.
224253665|NCT06835049|DRUG|Ifosfamide|Trial treatment consists of 3 neoadjuvant cycles of doxorubicin with either ifosfamide or dacarbazine (the latter only in case of leiomyosarcoma). Ifosfamide will be given at a dose of 3 g/m2 BSA on days 1 to 3 of each cycle, for a total dose per cycle of 9 g/m2 BSA, as an intravenous infusion of 3 g/m2 daily over 4 hours.
224253666|NCT06835049|DRUG|Dacarbazine|Trial treatment consists of 3 neoadjuvant cycles of doxorubicin with either ifosfamide or dacarbazine (the latter only in case of leiomyosarcoma). Dacarbazine will be given at a daily dose of 300 mg/m2 BSA on days 1 to 3 of each cycle, for a total dose per cycle of 900 mg/m2 BSA, as an intravenous infusion over 30 minutes.
224253667|NCT06835049|OTHER|Hyperthermia|Hyperthermia (HT) sessions are scheduled on days 1 and 3 of each chemotherapy cycle. The duration of the preheating phase is always 30 minutes. Together with the treatment phase of 60 minutes, the duration of a HT session is uniformly 90 minutes (Total treatment time). On days 2, chemotherapy will be applied without HT.
224253668|NCT06835049|RADIATION|Radiotherapy|"Radiotherapy (RT) treatment should start ideally 19 days after last chemotherapy dose received (range -4 / +7), preferably on a Monday to omit that the last RT fractions will be applied directly after the weekend. Start of RT can be postponed up to 14 days due to medical reasons without violating treatment protocol.~Patients will preferably receive normofractionated RT to a total dose of 50 Gy in 25 fractions of 2 Gy over 5 weeks23.~Alternatively, patients can receive a moderate hypofractionated RT to either a total dose of 42.75 Gy in 15 fractions of 2.85 Gy over 3 weeks or a total dose of 42 Gy in 14 fractions of 3 Gy over 2 weeks and four days41. The respective total treatment time changes respectively.~The RT treatment should be delivered once daily except on weekends."
224253669|NCT06835049|PROCEDURE|Surgery|"Standard of care surgical resection must be done by an experienced sarcoma surgeon. All lesions of the trunk and extremities will be resected after total neoadjuvant treatment with chemotherapy, HT and RT.~Surgery will take place preferentially 6 weeks (+/- 2 weeks) after end of radiation."
224322246|NCT06004804|BEHAVIORAL|Mindfulness Meditation|Seeks to help individuals achieve present moment awareness, self-compassion, and acceptance of chronic pain. It will use techniques such as the body scan, grounding, mindful breathing, mindful walking, loving kindness, and compassionate breathing.
224322247|NCT06004804|BEHAVIORAL|Cognitive Behavioral Therapy|Seeks to help individuals function better and improve symptoms by teaching various cognitive and behavioral skills to manage symptoms. It will use techniques such as relaxation training, engaging in pleasant activities, pacing yourself, and changing unhelpful ways of thinking.
223772276|NCT01537341|BEHAVIORAL|Traditional Treadmill|Participants will complete the intervention in 12-weeks, 3 times per week sessions.
223772277|NCT01537341|BEHAVIORAL|Split-belt|Participants will complete the intervention in 12-weeks, 3 times per week sessions.
223772278|NCT01198184|DRUG|temsirolimus|Given IV or PO
223772279|NCT01198184|DRUG|gamma-secretase/Notch signalling pathway inhibitor RO4929097|Given PO
223673163|NCT06505772|DRUG|Dexmedetomidine|"Infusion syringes are supplied with a concentration of 0.25 mcg / mL (dexmedetomidine ) either 80 mcg / 20 mL, 200 mcg / 50 mL, or 400 mcg / 100 mL.~For example, it begins with an infusion of 4 ml over 10 minutes and then continues the infusion, depending on the weight of the child, at a rate of 1.6 ml/kg/hour.~All injections will be prepared randomly by a doctor who did not participate in the study, and then placed in unmarked infusion pumps, given to an anesthesiologist (more than 10 years experience in pediatric anesthesia) without knowledge of the infusion content. The randomization process is carried out via sealed envelope technique.~The injections in both groups will be stopped before the skin is closed. Both patients and anesthesiologists blinded the study drug (dexmedetomidine or placebo) by infusion of solution (dexmedetomidine or placebo). Depending on the size in ml, to ensure that there is no bias and blindness to the medical team about what the drug is."
223673164|NCT06505772|DRUG|Normal saline|"Normal saline (NS) for intravenous infusion is supplied in pre-filled syringes of 20 ml, 50 ml, and 100 ml. To maintain blinding in this study, NS is handled identically to the study drug, dexmedetomidine. A physician not involved in the study prepares all injections, randomly assigning either NS or dexmedetomidine using a sealed envelope technique. Prepared syringes are then placed in identical, unmarked infusion pumps.~Infusion Protocol:~Anesthesiologists, blinded to the infusion contents, administer the solutions according to the protocol:~For example,Initial Bolus: 4 ml infused over 10 minutes, Maintenance Infusion: Continued at a rate of 1.6 ml/kg/hour, adjusted to the individual patient's weight.~This process ensures both patient and anesthesiologist remain blinded to the treatment arm, minimizing potential bias throughout the study."
223673165|NCT05437302|DEVICE|prism spectacle|a prism is dispensed in prescription glasses
223673166|NCT03570463|BEHAVIORAL|GLA:D Back|The intervention aims at improving the participant's ability to self-manage low back pain (LBP). The content is based on a cognitive behavioural approach aimed at supporting pain self-efficacy. An individual session at the beginning and the end of the group sessions involve goal-setting and physical tests. Key messages of the patient education include that pain is not a sign of danger and back pain is explained using a behavioural model of (im)balance between demands and capacity rather than emphasising tissue damage. The exercises aim at restoring natural variation in movement and provides guidance for patients in exploring movement rather than teaching exercises in only one correct manner.
223673167|NCT02101164|BIOLOGICAL|denosumab|Treatment Group A - 120 mg SC dose every 4 weeks at Day 1 and week 5 Treatment Group B - 120 mg SC dose every 4 weeks at Week 9 and Week 13
223673168|NCT02101164|DRUG|pamidronate|Treatment Group A - 90 mg IV dose every 4 weeks at Week 9 and Week 13 Treatment Group B - 90 mg IV dose every 4 weeks at Day 1 and Week 5
223673169|NCT04564300|PROCEDURE|Training|Both groups will perform a standardized training protocol
223673170|NCT05146102|OTHER|"ethics communication in group, in line with the one to five-step method"|"Healthcare professionals working as ethical representatives at the current ward (n=5) have recently gone through a basic ethics program. They will continue by going through an education program for facilitating ethics communication in group, in line with the one to five-step method~The education program has a theoretical and practical approach, which includes the theoretical base of the ethical communication in groups and practicing the one to five method Thereafter, each ethical representative will facilitate interprofessional sessions at a clinical ward, once a month, for six months at their workplace. Gathering meetings for feedback will be offered for the ethical representatives once a month."
223673171|NCT03086187|DEVICE|Hephaistos unloading orthosis|The Hephaistos unloading orthosis greatly reduces plantarflexor muscle torque and plantarflexor muscle activation during any gait activity.
223673172|NCT05070780|DEVICE|Robot-assisted examination|evaluation of muscle tone with Robot-assisted perturbation
223673173|NCT05631002|DIAGNOSTIC_TEST|Chemical shift encoding-based water-fat MRI|Chemical shift encoding-based water-fat magnetic resonance imaging (MRI): a non-invasive method
223772280|NCT01198184|OTHER|laboratory biomarker analysis|Correlative studies
223772281|NCT01198184|OTHER|pharmacological study|Correlative studies
223772282|NCT01826149|DRUG|Propofol 1.0mcg|Propofol dosage titration to achieve effect site concnetration at 1.0 mcg/ml using target controlled infusion.
224253670|NCT05473143|OTHER|Protocol-based fluid management|"Fluid removal will be prescribed using a standardized template updated at least once per working day, before noon of each day, by the attending care team. This protocolized prescription will contain three components. Fluid removal will be prescribed using a standardized template updated at least once per working day, before noon of each day, by the attending care team. This protocolized prescription will contain three components.~The first component of this prescription will be to define the 24h-fluid balance target either aiming for a negative fluid balance of 2 to 3% body weight (1.4-2.1 liters in a 70 Kg participant) (Option 1) or by aiming to avoid fluid accumulation by targeting a neutral fluid balance within 0.5% of body weight variation (-350 to +350 mL in a 70 Kg participant) (Option 2).~The second component is to pre-specify a prescription for fluid removal using KRT.~The third component is to prompt a daily re-evaluation of fluid intake by the attending care team."
224253671|NCT05473143|OTHER|Usual care|The net fluid removal and the rate of net fluid removal will not be protocolized and will be prescribed and adjusted according to the attending care team without any specific guidance. The use of the documents provided for the intervention group will not be permitted in the control arm.
224253672|NCT06433765|OTHER|No intervention|No intervention
224253673|NCT05997446|DEVICE|Left atrial appendage occlusion (LAAO)|Implantation of an Amplatzer Amulet left atrial appendage occluder
224253674|NCT05665426|OTHER|acupuncture|Patients allocated to the acupuncture group will be punctured at the pre-specified acupoints. According to the theory of traditional Chinese medicine and clinical experience, we will use the Bilateral Weizhong point (BL 40). Because of the similar anatomy, the Chize point (LU 5) was chosen as a control. Sterile disposable stainless steel acupuncture needles (length: 40 mm, diameter: 0.25 mm; Hwato, Suzhou, China) will be used.
224253675|NCT05665426|OTHER|moxibustion|Moxibustion Participants in the moxibustion group will receive moxibustion treatment via portable Moxibustion (Aikeshu, Bozhou, China); the moxibustion is composed of The inner tube (containing the moxa pillar) and the outer tube. To use, pull out the inner tube and light the moxa pillar, then insert the outer tube and fix the moxibustion on the acupuncture points. Two Moxibustion devices will be sequentially applied at two acupoints Weizhong (BL 40) and Chize (LU 5), for 30 minutes.
223673174|NCT04930380|OTHER|phone interview|Cases and controls will receive a phone interview
223673175|NCT05205473|PROCEDURE|Sciatic nerve block under ultrasound control with a electrostimulator peripheral nerves 12.5 ml 1% lidocaine|"Following the ultrasound visualization of the femoral nerve, a insulated injection needle was connected to the nerve stimulator . Under ultrasound visualization guidance, the needle of the electronic nerve stimulator was positioned at the sciatic nerve (in plane) from its lateral side at a slightly superior position . A marker for LA introduction was the visualization of the needle end near the nerve, and a positive muscular response . Subsequently, the introduction of LA solution was initiated (12.5 ml 1% lidocaine).If LA was spreading from the lateral side down to the nerve, then the needle was replaced to the upper point of the nerve and the rest of LA was introduced, and vice versa . The presence of a complete and incomplete spread of LA along the entire circumference of the nerve was assessed. Correspondingly, if the anesthetic was spreading upwardly, the needle would be downwardly replaced.~In addition, a femoral nerve block is performed."
223673176|NCT05205473|PROCEDURE|sciatic nerve blockade under ultrasound control without a peripheral nerve stimulator 12.5 ml 1% lidocaine|"Under ultrasound visualization guidance, the needle owas positioned at the sciatic nerve (in plane) from its lateral side at a slightly superior position . A marker for LA introduction was the visualization of the needle end near the nerve. Subsequently, the introduction of LA solution was initiated. The position of the needle was corrected 1-2 times according to the type of anesthetic spread. If LA was spreading from the lateral side down to the nerve, then the needle was replaced to the upper point of the nerve and the rest of LA was introduced, and vice versa . The presence of a complete and incomplete spread of LA (12.5 ml 1% lidocaine) along the entire circumference of the nerve was assessed. Correspondingly, if the anesthetic was spreading upwardly, the needle would be downwardly replaced.~In addition, a femoral nerve block is performed."
223673177|NCT02257801|DIETARY_SUPPLEMENT|Nutritional beverage fortified with 6mg lutein/day|2 beverages (each containing 3mg lutein) per day (total of 6mg lutein/day) for a total of 4 months
223673178|NCT02257801|DIETARY_SUPPLEMENT|Nutritional beverage fortified with 12mg lutein/day|2 beverages (each containing 6mg lutein) per day (total 12mg lutein/day) for a total of 4 months
223673179|NCT02257801|DIETARY_SUPPLEMENT|Nutritional beverage fortified with 12mg lutein/day|2 beverages (each containing 0mg lutein) per day (total 0mg lutein/day) for a total of 4 months
223673180|NCT06009185|DRUG|Oral zamicastat|Tablets for oral administration under fed conditions containing 100 mg of zamicastat. Zamicastat has to be taken in the morning after breakfast.
223673181|NCT01659879|BEHAVIORAL|Multimedia information|
223673182|NCT01659879|BEHAVIORAL|verbal information|
223673183|NCT00455832|PROCEDURE|peginterferon alpha and ribavirin|sperm collection
223673184|NCT03250364|DEVICE|Multilayer bandage|See arm/group descriptions
223673185|NCT03250364|DEVICE|Double compression bandage|See arm/group descriptions
223673186|NCT03250364|DEVICE|Cohesive bandage|See arm/group descriptions
223673187|NCT03250364|DEVICE|Adhesive compression bandage|See arm/group descriptions
223673188|NCT03250364|DEVICE|Kinesiotaping bandage|See arm/group descriptions
223673189|NCT03250364|OTHER|Manual lymphatic drainage (MLD) + Intermittent Pneumatic Compression|"MLD using a modification of the strokes described by Leduc will be applied to lymphedema resorption. It will be included resorption maneuver in the oedematous areas of the affected limb, in cranial to caudal direction, since the physiotherapist seeing a change in the tissue qualities of the oedema. Then, the subjects will be received thirty minutes of Intermittent Pneumatic Compression (EureducTM) with a pression of 40 mmHg."
223673190|NCT03250364|OTHER|Upper limb exercises|After the bandage will be put, proprioceptive neuromuscular facilitation exercises without resistance in two diagonal in asymmetrical reciprocal patterns with the affected limb will be taught. The first diagonal into flexion from hitch hike to swat fly, and into extension from swat fly to hitch hike, and the second diagonal from hand in opposite pocket to carry tray, and into extension from carry tray to hand in opposite pocket. These exercises must be done at home two times per day, ten repetitions each exercise.
223673191|NCT03250364|BEHAVIORAL|Educational strategy|Instructions about lymphatic system anatomy and pato-physiology, the prevention and identification of possible lymphedema complication or infection, how to use and exercise this arm, avoidance of trauma, injury, an excess of heat and arm constriction.
223673192|NCT05668611|OTHER|Primary Training Phase|A four-day training program taken over the course of two weekends will include materials on RHD and RHD echocardiographic screening using focused artificial intelligence navigational guided echocardiographic acquisition to identify patients who are screen positive or screen negative for RHD. The echo protocol will be limited to the parasternal long axis-view (2D and color Doppler) focusing on mitral and aortic valve morphology and function and a single 2D apical 4 chamber view for auto EF. The curriculum package will include online modules, instructor delivered PowerPoint presentations, and hands on practice on volunteers with and without RHD.
223673193|NCT05668611|OTHER|Primary Assessment Phase|A pre- and post-training test on RHD knowledge and diagnosis will be administered. A rapid competency assessment, including obtaining imaging on volunteers with or without RHD and an online test with pre-recorded cases of RHD, LV dysfunction and Pericardial effusions, will be utilized at the end of the 4-day training sessions. Trainees will be monitored by trained study personnel and at the end of the practicum training, the expert users will blindly review and assess the quality of each study using the standardized scale and competency scorecard provided below. Additionally, they will be asked to pass the knowledge quiz (80% or better). If competency is not achieved, an additional weekend of training can be added.
223673194|NCT05668611|OTHER|Primary Screening Phase|"Following certification, the certified MOH nurses will integrate echocardiographic screening into the routine workflow at the 4 HCIII/IV clinics with each nurse carrying out screening at the assigned HC on patients (aged 5-40) presenting to the health center for routine care.~Screening will be done daily over a period of one month. A minimum total of 400 participants will be screened during this period; each nurse will screen as many patients as they can, with a minimum of 100 participants (at least 5 participants per day). At the end of each screen, the trainees will interpret the screen as screen negative or screen positive. They will go ahead to refer participants identified as screen positives to the district hospital (LRRH) for a confirmatory echo.~At the end of each screening day, all images will be uploaded to a cloud server for a confirmatory review by a cardiology fellow or cardiology attending physician, within in 1 - 2 weeks."
224253676|NCT05902871|DEVICE|External Automatic Glaucoma Laser|Trans-limbal, direct selective laser trabeculoplasty (DSLT) instrument that directs laser energy through the sclera around the limbus overlying the trabecular meshwork and treats 360 degrees of the angle is treated simultaneously
224253677|NCT05902871|PROCEDURE|Direct Selective Laser Trabeculoplasty|Surgical procedure that utilizes a laser to improve fluid drainage in the eye and reduce intraocular pressure
224253678|NCT06561880|DRUG|Gilteritinib|"Induction therapy regimen(2 courses):~triple regimen therapy: Azacitidine 75mg/m2/d d1-7; Venetoclax 100mg d1,200mg d2,400mg d3-28; Gilteritinib (as required at admission: 80 or 120mg) d1-28.~dose-adjusted triple regimen therapy: Azacitidine 75mg/m2/d d1-5; Venetoclax 400mg d1-7; Gilteritinib (as required at admission: 80 or 120mg) d1-28.~Patients with no remission after the first induction course will receive another course with triple regimen therapy; Patients with complete remission after the first induction course will receive another course of dose-adjusted triple regimen therapy."
224253679|NCT06561880|DRUG|Cytarabine|"Consolidation therapy (3 courses):~intermediate-dose cytarabine regimen :2g/m2 q12h d1-3, age \< 60 years;1g/m2 q12h d1-3, age ≥60 years.~If NGS detected FLT3 mutation before consolidation chemotherapy, gilteritinib will be added during the consolidation course at d4-17."
224253680|NCT06561880|DRUG|Gilteritinib|"Maintenance treatment (6 courses):~dose-adjusted triple regimen therapy:Azacitidine 75mg/m2/d d1-5; Venetoclax 400mg d1-7; Gilteritinib (as required at admission: 80 or 120mg) d1-28."
224253681|NCT05610956|DRUG|Empagliflozin|Patients will receive empagliflozin (0.4 - 0.5mg/kg/day) orally (maximum dose 25mg per day)and conventional treatment (corticosteroids +immune suppressive + aminosalicylic acid)for 4 months.
224253682|NCT05610956|DRUG|conventional treatment|conventional treatment (corticosteroids +immune suppressive + aminosalicylic acid)for 4 months
224253683|NCT05257525|OTHER|Esophageal manometry catheter at various PEEP levels and tidal volumes|Participants will undergo placement of an esophageal manometry catheter before planned sternal closure. This catheter will be used to measure esophageal pressure which is a surrogate for pleural (intrathoracic) pressure. Esophageal pressure will then be used to estimate changes in respiratory system mechanics and hemodynamics following sternal closure and across different levels of positive end-expiratory pressure (PEEP) and tidal volumes.
224253684|NCT06542497|DRUG|0.75% phentolamine ophthalmic solution|Once daily dosing
223673195|NCT05668611|OTHER|Secondary Training Phase|Each Primary Trained MOH Nurse will train 3 other nurses from their Health Center using pre-recorded PowerPoints.
223673196|NCT05668611|OTHER|Secondary Assessment Phase|The secondarily trained nurses will be assessed and certified by the nurse trainer.
223673197|NCT05668611|OTHER|Secondary Screening Phase|"Following certification, the certified MOH nurses will integrate echocardiographic screening into the routine workflow at the 4 HCIII/IV clinics with each nurse carrying out screening at the assigned HC on patients (aged 5-40) presenting to the health center for routine care.~Screening will be done daily over a period of two months. A minimum total of 1200 participants will be screened during this period; each nurse will screen as many patients as they can, with a minimum of 100 participants. At the end of each screen, the trainees will interpret the study as screen negative or screen positive. They will go ahead to refer participants identified as screen positives to the district hospital (LRRH) for a confirmatory echo.~At the end of each screening day, all images will be uploaded to a cloud server for a confirmatory review by a cardiology fellow or cardiology attending physician, within in 1 - 2 weeks."
223673198|NCT05606003|BEHAVIORAL|Multi-Level Multi-Component Intervention (MLI)|The strategic components of our multi-level, multi-component intervention (MLI) include: 1. Building testing access for vulnerable populations, 2) Community Health Worker (CHW)-delivered navigation to SARSCoV- 2 testing and access and reinforce risk mitigation recommendations, 3) 2-1-1 helpline-referrals and navigation to FDA approved SARSCoV- 2 testing (and self sampling once approved) and risk mitigation education, and 4) social marketing and small media campaign to provide geo-targeted messages promoting testing and COVID risk mitigation behaviors. We selected these components because of their evidence base, their current use by partners in response to COVID 19, and confidence that they can be adapted through a community engaged process as described.
224253685|NCT06542497|DRUG|Placebo|Once daily dosing
224253686|NCT05998031|DEVICE|Active tDCS|A neuroConn MR-safe 1x1 tDCS stimulator will be used to apply 12 minutes of 2.0 mA electrical current, with 30 seconds ramps up and 30 seconds ramps down. The electrical current will be applied by using two carbon rubber electrodes (one anode, one cathode) with added ten20 conductive paste. The electrode+paste will be affixed on the participant's scalp over the frontal cortices at F3 and F4 location (EEG 10-20 system). Inflow of current (anode) will occur at F4 location, and outflow of current will occur at F3 (cathode).
223673199|NCT05606003|BEHAVIORAL|Community Just-In-Time Adaptive Intervention (Community JITAI)|This intervention includes the same MLI components described above, with an added JITAI approach. Community and stakeholder partners will use real-time data related to testing and other relevant information generated by the Epidemiologic Surveillance and Analysis team (ESA) in Aim 1, as well as other information based on their community and stakeholder experience and tacit knowledge about factors influencing testing determinants, to adapt intervention activities as needed to optimize access to testing.
223673200|NCT05288907|DRUG|Lidocaine Ointment|Composite over-the-counter lidocaine ointment administered twice daily for 2 weeks.
223673201|NCT00306111|DRUG|pegfilgrastim|Single dose (6mg) one day after chemotherapy
223673202|NCT01804829|BIOLOGICAL|Civacir® 10%|The active ingredient is Human Immunoglobulin G (IgG) which is a normal constituent purified from human source plasma containing a diversity of antibodies targeting the Hepatitis C Virus.
223673203|NCT05207800|OTHER|The concentrations of PTX3 and HBP were monitored in maternal blood, placental tissue and amniotic fluid.|The concentrations of PTX3 and HBP were monitored in maternal blood, placental tissue and amniotic fluid.
223673204|NCT01543581|DRUG|Vismodegib|Oral vismodegib, 150mg per day for 12 weeks.
224253687|NCT05998031|DEVICE|Sham tDCS|Sham stimulation will be performed with the same 1x1 device. Participants will receive 2 mA of direct current stimulation for 30 seconds with 30 seconds ramps up and down. This provides the tingling and prickling sensation on the scalp associated with tDCS while prevent delivering sufficient current (12 minutes) to penetrate the skull and stimulate the brain. Prep in sham conditions will be identical to active stimulation conditions. For each stimulation condition (active, sham), each participant will perform three runs of N-back working memory task (baseline/pre-stimulation, during stimulation, and after/post-stimulation) as detailed below. Sham efficacy will be evaluated as a direct comparison in N-back performance and connectivity results in active group versus sham group.
224253688|NCT03729115|PROCEDURE|Magnetic Resonance Imaging (MRI)|Patients will have MRI scans every 6 months.
224253689|NCT04752774|BIOLOGICAL|IPN10200|Powder and solvent for solution for injection
224253690|NCT04752774|DRUG|Placebo|Powder and solvent for solution for injection
224253691|NCT04752774|BIOLOGICAL|Dysport|Powder for solution for injection
224253692|NCT02674152|DRUG|BI 836880|BI 836880
224253693|NCT04934722|BIOLOGICAL|Pembrolizumab|Pembrolizumab is administered as an IV infusion at 200 mg on Day 1 of each 21-day cycle for up to 35 cycles.
224253694|NCT04934722|DRUG|Enzalutamide|Enzalutamide is administered orally as capsules/tablets at a dosage of 160 mg daily. Enzalutamide is administered continuously until criteria for discontinuation are met.
224253695|NCT04934722|DRUG|Androgen Deprivation Therapy (ADT)|Stable regimen of ADT (LHRH agonist or antagonist) at a dose and frequency of administration that is consistent with the local product label.
224253696|NCT04934722|OTHER|Placebo|Placebo infusion solution is administered as an IV infusion on Day 1 of each 21-day cycle for up to 35 cycles.
223673205|NCT01543581|DRUG|Placebo|
223673206|NCT04985344|DRUG|Propranolol Oral Product|Child will receive oral propranolol (syrup). The dose of propranolol will increase gradually over the first 3 treatment sessions in order to assess tolerance.
223673207|NCT04985344|DRUG|Placebo|Child will receive oral placebo (syrup). The dose of placebo will increase gradually over the first 3 treatment sessions in order to match propranolol intervention.
223673208|NCT04985344|OTHER|memory reactivation|90 minutes after the propranolol take, a trained psychologist will ask the child to recount his trauma.
223673209|NCT04357301|DEVICE|Closed-loop vasopressor|The system will adjust the norepineprhine infusion rate based on a target SAP of 130 mmHg in 20 patients
223673210|NCT00627276|DIETARY_SUPPLEMENT|omega-3 fatty acid|Oral, 3 times daily
223673211|NCT00627276|OTHER|placebo|Oral, 3 times daily
223673212|NCT01362010|DRUG|Topical Minocycline Foam FXFM244|Topically applied once a day.
223673213|NCT03736902|OTHER|Qualitative semi structured interview|One-to-one semi structured interviews, guided by the Physical Activity for people with a Disability Framework (van der Ploeg et al, 2004) which is a model for understanding the different factors that influence whether people with a disability engage in physical activity. Participants that agree to take part in the study, will be offered an interview either in a private clinic room at the hospital, at their home (if they live within a 40-mile radius of the hospital) or via a web-based video link. The interviews are expected to last one hour and will be conducted by the primary researcher.
223673214|NCT00839176|DRUG|RX-10100|Extended-release tablet, 5\~15mg, twice day (morning \& evening) at least 30 min before meal, 8 weeks
223673215|NCT02380768|DEVICE|Ambu AuraGain (size 1.5 or size 2.0)|The device will be inserted and timed. A leak pressure test will be performed after successful insertion and after 10 minutes. The larynx will be visualized by placing a fiberoptic bronchoscope through the device. A gastric tube will be inserted through the device and timed.
223673216|NCT02380768|DEVICE|LMA Supreme (size 1.5 or size 2.0)|The device will be inserted and timed. A leak pressure test will be performed after successful insertion and after 10 minutes. The larynx will be visualized by placing a fiberoptic bronchoscope through the device. A gastric tube will be inserted through the device and timed.
223673217|NCT04482023|BEHAVIORAL|Training video on anxiety, fear and loneliness in the COVID-19 environment.|Video with the actions identified as essential to address the diagnosis of anxiety, fear and loneliness in the environment COVID-19 identified by a group of experts.
223673218|NCT00945828|BEHAVIORAL|Annual Intervention Group|Parents/caregivers and the teacher of participants will be asked to evaluate the effectiveness of the child's IEP once per academic calendar year. The evaluation is done through the use of an IEP Questionnaire developed for this study. This questionnaire addresses the child's academic performance, progress, and adherence to the IEP developed.
223673219|NCT00945828|BEHAVIORAL|Quarterly Monitoring of IEP|Parents/caregivers and the teacher of participants will be asked to evaluate the effectiveness of the child's IEP four times per academic calendar year. The evaluation is done through the use of an IEP Questionnaire developed for this study. This questionnaire addresses the child's academic performance, progress, and adherence to the IEP developed.
223673220|NCT03345966|DIAGNOSTIC_TEST|Bmi-1 antibody|B-lymphoma Moloney murine leukemia virus insertion region-1
223673221|NCT03337789|DIETARY_SUPPLEMENT|Polygonatum sibiricum|Polygonatum sibiricum 800mg, 30-60 minutes before sleep, once a day for 4 weeks
223673222|NCT03337789|DIETARY_SUPPLEMENT|Placebo|Placebo 800mg, 30-60 minutes before sleep, once a day for 4 weeks
223673223|NCT04006600|PROCEDURE|Sphincter saving proctectomy|"After rectal resection, when colorectal anastomosis is subperitoneal, it is currently recommended to perform a protective stoma to reduce the potential consequences of a fistula. This stoma, which is intended to be temporary, appears to be permanent in 6 to 32% of cases in the literature.~The objective of the study is therefore to look for a statistical link between the persistence of a permanent stoma and the intraoperative difficulty represented by pelvic anatomical stress."
223673224|NCT04094415|DRUG|Semaglutide|Patients will be treated with commercially available semaglutide in a prefilled pen injector (FlexTouch® variant) according to routine local clinical practice at the discretion of the treating physician. Other anti-hyperglycaemic treatments will be prescribed at the physician's discretion.The decision to initiate treatment with semaglutide is at the treating physician's discretion, and clearly separated from the decision to include the patient in the study.
224253697|NCT04174924|PROCEDURE|Phakic intraocular lens (pIOL) explantation|"Phakic intraocular lens (pIOL) explantation is a surgical procedure to remove the pIOL which needs to be done after cataract formation.~Cataract extraction is a surgical procedure to remove a lens in the eye that has become cloudy over time, affecting vision in that eye."
224253698|NCT04229979|BIOLOGICAL|Galinpepimut-S|Galinpepimut-S admixed with the adjuvant Montanide following specified schedule
224253699|NCT04229979|DRUG|Azacitidine|injection
224253700|NCT04229979|DRUG|Venetoclax|tablet
224253701|NCT04229979|DRUG|Decitabine|injection
224253702|NCT04229979|DRUG|Cytarabine|injection
224253703|NCT04229979|OTHER|Observation|palliative management
224253704|NCT04229979|BIOLOGICAL|GM-CSF|subcutaneous injection
224253705|NCT04229979|OTHER|Montanide|adjuvant
224253706|NCT02720445|DRUG|Nicotine Transdermal Patch|21mg Nicotine transdermal patches worn during waking hours. Active dose will titrate up from 3.5mg to 21mg in the first 6 weeks of treatment, remain at 21mg for 22.5 months, and then taper down in the final month of treatment.
224253707|NCT02720445|DRUG|Placebo Patch|Matching placebo patches worn during waking hours.
224253708|NCT04472949|DRUG|Durvalumab|Durvalumab: 1500 mg iv
224253709|NCT04472949|DRUG|carboplatin|Carboplatin: AUC 5 mg/mL/min iv
224253710|NCT04472949|DRUG|etoposide|Etoposide: 100 mg/m2 iv
224253711|NCT04472949|RADIATION|Thoracic radiotherapy|Thoracic radiotherapy: 39 Gy in 13 fractions, starting 3-8 weeks after day 1 of last cycle of induction treatment, over 2.5 weeks Prophylactic cranial irradiation (PCI) is allowed but optional: according to local practice, starting 3-8 weeks after day 1 of last cycle of induction treatment Follow up phase Patients will be followed up for 24 months, every 8 weeks.
224253712|NCT06785948|DEVICE|active-tDCS|"2mA stimulation (anode on the left dorsolateral prefrontal cortex, cathode on the right fronto-orbital).~10 sessions of 20 minutes each, spread over 2 consecutive weeks (5 days with stimulation, 2 days without stimulation, 5 days with stimulation)."
224253713|NCT06785948|DEVICE|Sham-tDCS|"No intensity applied (anode on the left dorsolateral prefrontal cortex, cathode on the right fronto-orbital).~10 sessions of 20 minutes each, spread over 2 consecutive weeks (5 days with stimulation, 2 days without stimulation, 5 days with stimulation)."
224253714|NCT06321562|DRUG|TimoD implant|Consists of 1 TimoD implant administration in the study eye
224253715|NCT06321562|DEVICE|Injector system|"This is a CE-marked injector intended for intraocular lens (IOL) delivery. In this study, the injector is used as anintraocular implant injection system outside of its scope of intended use."
224253716|NCT03687723|DEVICE|OCS Heart System|The OCS™ Heart System is a portable organ perfusion and monitoring medical device intended to preserve donor hearts in a near physiologic and beating state prior to transplantation.
224253717|NCT04281277|DEVICE|increase of mean arterial pressure at 80-85 mmHg.|increase of mean arterial pressure at 80-85 mmHg (with catecholamines or volemic expansion).
223772283|NCT01826149|DRUG|Propofol 2.0mcg|Propofol dosage titration to achieve effect site concnetration at 2.0 mcg/ml using target controlled infusion.
223772284|NCT01826149|DRUG|Propofol 3.0mcg|Propofol dosage titration to achieve effect site concnetration at 3.0 mcg/ml using target controlled infusion
224253718|NCT04281277|DEVICE|increase of mean arterial pressure at 65-70 mmHg.|increase of mean arterial pressure at 65-70 mmHg (with catecholamines or volemic expansion).
224253719|NCT06154304|DRUG|Albuterol Sulfate Inhalation Aerosol (90 mcg per actuation)|90 mcg
224253720|NCT06154304|DRUG|Ventolin HFA 90Mcg/Actuation Inhalation Aerosol_#1|90 mcg
224253721|NCT06154304|DRUG|Ventolin HFA, 90 Mcg/Inh Inhalation Aerosol_#2|180 mcg
224253722|NCT06154304|DRUG|Placebo|Placebo
224253723|NCT05059210|BEHAVIORAL|Coach McLungs Intervention|Practices have received implementation of Coach McLungs
224253724|NCT05440643|BIOLOGICAL|Peanut SLIT-tablet|Peanut extract
224253725|NCT05440643|OTHER|Placebo|Placebo
224253726|NCT06795412|DRUG|PYX-201|Intravenous (IV) infusion.
224253727|NCT06795412|DRUG|pembrolizumab|IV infusion.
224253728|NCT05265624|BEHAVIORAL|Early disclosure of genetic testing results|Early disclosure group receives results of genetic testing at Month 1
224253729|NCT05265624|BEHAVIORAL|Late disclosure of genetic testing results|Late disclosure group receives results of genetic testing at Month 12
224253730|NCT03995966|BEHAVIORAL|Noncontingent Reinforcement (NCR)|This treatment for ASIB is based on reinforcer competition. Noncontingent Reinforcement (NCR) will consist of first conducting a competing stimulus assessment (CSA) to identify stimuli (toys, massagers, etc.) associated with reductions in ASIB and high levels of engagement. Treatment then involves NCR in which alternative sources of reinforcement are made freely available to compete with reinforcement maintaining ASIB. Providing additional sources of reinforcement is thought to decrease ASIB by producing a shift in the allocation of responding toward accessing the newly available reinforcement. Additional, more restrictive components may be added if the competing stimuli (CS) are ineffective in reducing ASIB. These additional components are applied in accordance to the least-restrictive treatment model and include response blocking, response reduction procedures, protective equipment, or mechanical restraint.
224253731|NCT03995966|BEHAVIORAL|Combination Treatment|Combination Treatment is based on the same principles as NCR, but differs in three ways: 1) It includes three pre-treatment assessments that seek to establish competing stimuli, tasks, and self-control equipment through prompting and reinforcement; ; 2) Intensive training in each of these components is conducted to strengthen skills needed to fully access available reinforcement to compete with ASIB; and 3) Combination treatment is assessed, which includes the noncontingent delivery of competing stimuli and differential reinforcement of alternative behavior to reinforce engagement with competing tasks, and use of alternative self-control equipment. This will increase the amount and vary the sources of alternative reinforcement to more effectively reduce ASIB and self-restraint. Restrictive components may be applied as described for the NCR treatment.
224253732|NCT06794541|DRUG|Eravacycline 2mg/kg|intravenous (IV) infusion
224253733|NCT06794541|DRUG|Eravacycline 1.5mg/kg|intravenous (IV) infusion
224253734|NCT04998604|DRUG|Dupilumab|solution for injection subcutaneous
224253735|NCT04998604|DRUG|Omalizumab|solution for injection subcutaneous
224253736|NCT04998604|DRUG|Placebo|solution for injection subcutaneous
224253737|NCT06834074|DRUG|NVL-655|Drug: NVL-655
224253738|NCT06465368|DRUG|PF-07220060|PF-07220060 given as tablet by mouth twice a day for 14 days.
224253739|NCT06465368|DRUG|letrozole|Letrozole given as tablet by mouth once a day for 14 days
224253740|NCT02219620|BEHAVIORAL|Music, Imagery, Movement|Implementation of music, art and imagery activation, and movement in group modality
223673225|NCT06981429|BEHAVIORAL|Nourish to Flourish: The Power of Positive Food Parenting|This intervention focuses on increasing diet quality and parent use of positive food parenting practices with the goal of promoting healthy child growth). This will be a 12 - week, 12 session study. Sessions 1 and 12 will consist of collection baseline and post-intervention data. Sessions 2 - 11 will be a mix of online - group sessions and individual online or in - person sessions (based on participant preference). The group sessions are focused on principal investigator presentation of the intervention curriculum and group discussion. The individual sessions are focused on goal setting, coping planning, and working through individual situations with a trained coach.
224253741|NCT02219620|BEHAVIORAL|Social Control|social conversational group facilitated by care counselor
224253742|NCT06308055|OTHER|Data Acquisition|Develop algorithms for determining the cardiac output through the synchronous acquisition of hemodynamic data from the pulmonary artery catheter or other pressure sensors and Impella using a network module.
224253743|NCT00859872|DRUG|risperidone oral solution|risperidone oral solution (2-6mg/d) combination clonazepam (4-8mg/d) oral
224253744|NCT00859872|DRUG|haloperidol|haloperidol IM injection (5-20mg/d)
224253745|NCT02895763|OTHER|Form administrations|
223673226|NCT05158400|RADIATION|Ultrasound|Ultrasound examination on the hand
223673227|NCT00156936|DRUG|Medisorb naltrexone 380 mg|Administered via intramuscular (IM) injection once every 4 weeks. Subjects in this dosing group also received this treatment throughout the base study.
223673228|NCT00156936|DRUG|Oral naltrexone to Medisorb naltrexone 380 mg|Subjects in this dosing group received oral naltrexone 50 mg in the base study, but received only Medisorb naltrexone 380 mg in this extension study, administered via IM injection once every 4 weeks.
223673229|NCT05573815|DEVICE|BT-M01|Clinical decision support system for detecting brain metastasis
223673230|NCT03001271|DRUG|Angiotensin 1-7|
223673231|NCT03001271|OTHER|Placebo|
223673232|NCT03754478|OTHER|Physical activity training|subjects will enter a 3-month supervised physical activity program during which they will take part to supervised and unsupervised physical activity sessions. Type of physical activity will be selected among a number of available activities (aquagym, aerobics, resistance training, outdoors activities) based on individual needs and preferences); it will consist in 2 weekly supervised activity sessions during which participants will be instructed by a specialist in adapted physical activity, and 2-3 weekly session of unsupervised physical activity which will be performed according to detailed instructions regarding intensity and duration.
223673233|NCT01962324|RADIATION|SIB Dose-Escalation Radiotherapy|
223673234|NCT00000682|DRUG|Zidovudine|
223673235|NCT00000682|DRUG|Zalcitabine|
223673236|NCT06476054|PROCEDURE|Optimal timing for laparoscopic cholecystectomy|To compare early and late cholecystectomy after cholecystostomy.
223673237|NCT06993805|BEHAVIORAL|OPA|The Our Practice Advisory (OPA) intervention is a behavioral nudge integrated into the electronic health record system. It is designed to prompt providers to reconsider ordering Hemoglobin A1c (A1c) and Thyroid-Stimulating Hormone (TSH) tests if a similar test was performed within the previous 30 days. The OPA aligns with evidence-based guidelines to reduce unnecessary testing, improve resource utilization, and optimize patient care by enhancing clinical decision-making at the point of order entry.
223673238|NCT03881761|BIOLOGICAL|CD19/CD20 bispecific CAR-T cells|collecting blood for CAR-T cells culture three days later, FC regimen (fludarabine 30mg/m2/d x 3, cyclophosphamide 600-800mg/m2/d x 2) another two days later, transfusing CD19/CD20 bispecific CAR-T cell with a dose of 1-3x106/kg
223673239|NCT01688206|BIOLOGICAL|Atezolizumab [TECENTRIQ]|Participants will receive atezolizumab at a fixed dose of 840 mg, intravenously every 2 weeks.
223673240|NCT01688206|BIOLOGICAL|Vanucizumab|Participants will receive escalating doses of vanucizumab (starting dose: 3 milligram \[mg\] per kilogram) and fixed dose of vanucizumab (MTD/RP2D: 30 mg/kg), intravenously every 2 weeks.
223673241|NCT05427617|DRUG|Control group|Physician chosen treatment
223673242|NCT05427617|DRUG|Case group|Druggable ctDNA alterations-guided therapy
223673243|NCT01889745|DRUG|HX-1171|Anti-oxidatant, Anti-inflamation
223673244|NCT02326935|BIOLOGICAL|Autologous adipose derived mesenchymal cells|Autologous adipose derived mesenchymal cells, 150M cells deployed via two (2) treatments via intravenous injection.
223673245|NCT00000158|PROCEDURE|Argon Blue-Green Laser Photocoagulation|
223673246|NCT00129012|PROCEDURE|Tomotherapy|
223673247|NCT04270903|DEVICE|EPR measurement|Subject put in a magnet, magnetic field sweeping around 40 mTesla. Irradiation with a wave with a frequency of 1.1 GHz. A resonator (surface coil) is put at the surface of the skin (arm). The EPR signal is recorded.
224253746|NCT02594358|DRUG|Caffeine|20 MG OR 40 MG ONCE DAILY ALONG WITH PATCHING
224253747|NCT03071575|BIOLOGICAL|Measles-rubella (MR) vaccine at 6 months of age|Infants receive a standard dose according to the vaccine package insert. (Mothers receive no intervention.)
224253748|NCT03071575|BIOLOGICAL|Measles-rubella (MR) vaccine at 9 months of age|Infants receive a standard dose according to the vaccine package insert. (Mothers receive no intervention.)
224253749|NCT04766450|DRUG|Acetyl cysteine|NAC exhibits potent anti-oxidant activity in the cell through augmentation of intracellular GSH, which is a major component of the pathways by which cells are protected from OTS, and its direct scavenging activity of free radicals by providing sulfhydryl groups. Additionally, NAC treatment exhibits anti-inﬂammatory effects via inhibition of NF-κB activation and reducing subsequent cytokine production . Mitochondria-protective mechanisms of NAC may also be related to its anti-oxidant and anti-inﬂammatory properties
224253750|NCT03090568|DRUG|BIA 5-453|BIA 5-453 capsules 50 mg. Route of administration: Oral. In one period subjects received 4 capsules of 50 mg of BIA 5-453 after a fasting of at least 10 hours, and in the other period subjects were dosed with 4 capsules of 50 mg of BIA 5-453 after a standard high-fat and high-calorie meal
223673248|NCT00102492|DRUG|GW679769|
223673249|NCT04249726|PROCEDURE|Direct composite resin restoration|A direct composite resin restoration will be provided intracoronally without cuspal coverage.
223673250|NCT04249726|PROCEDURE|Direct composite resin restoration followed by full coverage metal ceramic crown|A direct composite resin restoration will be provided intracoronally followed by a full cuspal coverage metal ceramic crown.
224253751|NCT03428386|PROCEDURE|Gastric plication ileal bypass|laparoscopic plication of the greater curvature of the stomach then the duodeno-jejunal junction is identified and 300 cm is measured downwards. The selected loop will be ascended without division of the greater omentum, and a stapled isoperistaltic side-to-side to the anterior wall of the antrum of the stomach just 3 cm away from the pylorus with a linear stapler charged with a green cartridge, the diameter of ileal antrum anastomosis is not exceeding 3 cm in diameter. The staple defect is closed with a two-layer running 3/0 polyglactin suture
224253752|NCT00834795|DRUG|Carvedilol 25 mg tablets|1 x 25 mg
224253753|NCT00834795|DRUG|COREG® 25 mg tablets|1 x 25 mg
224253754|NCT02005497|OTHER|HealthLinks|
224253755|NCT06083259|DEVICE|Gelatin sponge stabilization with suture and cyanoacrylate|The donor site will be closed both with gelatin sponge +Cyanoacrylate (Spongostan®, Ethicon, USA)+ supporting sutures (control group)
223772285|NCT02992899|DEVICE|GammaCore/electroCore non-invasive VNS device|Vasal nerve stimulation (VNS) is self-administered using the electroCore non-invasive VNS device. The intensity of the stimulus (the current amplitude) is adjusted by the user, to the maximum tolerable level to ensure VNS without causing excessive pain (typically 10-30 V), the burst frequency to 5 kilohertz (kHz), and the envelope frequency to 25 Hz. These are the standard frequency settings that electroCore has demonstrated to be most effective in capturing the vagus nerve based on evoked potential studies. The duration of delivery is 2 minutes, one minute into which the high-resolution positron emission tomography (HR-PET) scan is conducted; following an additional 8 minutes, a second VNS delivery is administered, after which another scan is obtained.
223772286|NCT02992899|DEVICE|Sham gammaCore/electroCore|Sham vasal nerve stimulation (VNS) is self-administered using the electroCore non-invasive VNS device. The device is programmed such that no actual stimulation is given to the vagus nerve. The duration of delivery is 2 minutes, one minute into which the HR-PET scan is conducted; following an additional 8 minutes, a second sham VNS delivery is administered, after which another scan is obtained.
223772287|NCT02992899|DRUG|O-15 water|Oxygen-15 labelled water is a radioactive variation of regular water, in which the oxygen atom has been replaced by oxygen-15 (15O), a positron-emitting isotope. 15O-water is used as a radioactive tracer for measuring and quantifying blood flow using positron emission tomography (PET) . H2\[15O\] will be prepared on-site in the Emory PET Center cyclotron. During the hours of the test, an intravenous infusion of normal saline will be started to permit the bolus injection of H2\[15O\]. Subjects will receive a 20 mCi intravenous bolus of H2\[15O\] for each of the 14 scans during exposure to neutral and traumatic scripts.
224253756|NCT06083259|PROCEDURE|Gelatin sponge stabilization with cyanoacrylate|Seconder The donor site will be closed both with gelatin sponge +Cyanoacrylate (Spongostan®, USA) (test group)
224253757|NCT00579345|BIOLOGICAL|Cell culture derived seasonal trivalent influenza vaccine (cTIV)|cell cultured trivalent influenza vaccine (cTIV) vaccine administered as 0.5 mL single dose in the deltoid muscle, preferably of the non-dominant arm.
224253758|NCT00579345|BIOLOGICAL|Influenza virus vaccine (egg-derived seasonal trivalent, thiomersal free; eTIV_a).|egg based trivalent influenza vaccine (eTIV\_a) administered as 0.5 mL single dose in the deltoid muscle, preferably of the non-dominant arm.
224253759|NCT00579345|BIOLOGICAL|cTIV or eTIV_a|0.5 mL, Single dose of either cell cultured trivalent influenza vaccine (cTIV) or egg based trivalent influenza vaccine eTIV\_a administered.
224253760|NCT00579345|BIOLOGICAL|cTIV+PV OR eTIV_a+PV|0.5 mL, Single dose of either cell culture derived seasonal trivalent influenza vaccine (cTIV) or influenza virus vaccine (egg-derived seasonal trivalent, thiomersal free; eTIV\_a) administered concomitantly with 23-valent pneumococcal polysaccharide vaccine (PV).
224253761|NCT01921894|DIETARY_SUPPLEMENT|Cholecalciferol|vitamin D supplementation with either 2,000 IU/day or 4,000 IU/day compared to vitamin D3 supplementation with 200 IU/day.
224253762|NCT05240989|PROCEDURE|pulmonary rehabilitation|one-year regular lung rehabilitation treatment and control the intensive monitoring of hemodynamic parameters
223673251|NCT02888418|BIOLOGICAL|Tetravalent recombinant human papilloma virus vaccine (6,11,16,18 type) (Hansenula polymorpha)|Injection vaccine produced by Beijing institute of biological products co., LTD, containing HPV antigen protein, 120μg/0.5ml/bottle
223673252|NCT02888418|BIOLOGICAL|placebo|
223673253|NCT05463094|DRUG|Test Glucophage® XR|Participants will receive single oral dose of Test GXR RM tablet under fasted or fed conditions.
223673254|NCT05463094|DRUG|Reference Glucophage® XR|Participants will receive single oral dose of Reference GXR RM tablet under fasted or fed conditions.
223673255|NCT03039621|DRUG|Ergoferon|For oral use.
223673256|NCT03039621|DRUG|Placebo|For oral use.
223772288|NCT02738775|BIOLOGICAL|Ublituximab|Administered as an IV infusion.
223772289|NCT02738775|DRUG|Placebo|
223772290|NCT03587259|DIAGNOSTIC_TEST|Tomosynthesis|DBT is a x-ray examination that allows to visualize the breast on 3 planes (3D) and therefore to help to see lesions hardly visible to mammography due to the overlap of glandular tissue.
223772291|NCT03587259|DIAGNOSTIC_TEST|2D mammography|2D mammography is a X-ray examinations used to detect breast cancer in the screening programme.
223772292|NCT03018353|DRUG|Patients receiving Sof/Vel (Epclusa) and Navigation services|Implementing HCV treatment in the jails using FDA-approved medications and continuing there treatment in the community if they are released during their treatment regimen.
223772293|NCT04854200|DEVICE|Medtronic HeartWare ™ HVAD™ System|The Medtronic HeartWare™ HVAD™ System includes a ventricular assist device (VAD) that helps the heart pump and increases the amount of blood that flows through the body in patients with advanced heart failure.
223772294|NCT00863538|DRUG|KPS-0373|
224253763|NCT05746104|DRUG|Administration of Indocyanine Green (ICG) and Visualization of Tumor|A single dose of the study drug, ICG, of less than 2 mg/kg will be administered on the day of surgery. The visualization of second window ICG for tumor will be performed approximately one to four hours after administration, depending on how long it takes for the neurosurgeon to get through the skin/skull or lamina/dura to the tumor.
224253764|NCT00193115|DRUG|Docetaxel|
223673257|NCT05722886|DRUG|Alectinib|"Adult patients will be administered alectinib orally at a dose of 600 mg (four 150 mg capsules) twice daily.~Paediatric patients with a body weight ≥40 kg and who are able to swallow the capsules will be administered alectinib orally at a dose of 600 mg (four 150 mg capsules) twice daily.~Each cycle of treatment will consist of 28 days and patients may continue on treatment until disease progression without clinical benefit, unacceptable toxicity or withdrawal of consent."
224253765|NCT00193115|DRUG|Doxorubicin|
224253766|NCT00193115|DRUG|Cyclophosphamide|
224253767|NCT02908776|DIETARY_SUPPLEMENT|Probiotic|Sachets with Streptococcus thermophilus DSM 32245: 70 billion, bifidobacteria (Bifidobacterium lactis DSM 32246, Bifidobacterium lactis DSM 32247) 40 billion, lactobacilli (Lactobacillus acidophilus DSM 32241, Lactobacillus helveticus DSM 29575, Lactobacillus paracasei DSM 32243, Lactobacillus plantarum DSM 32244, Lactobacillus brevis DSM 27961): 90 billion.
224253768|NCT02908776|OTHER|Placebo|Sachets of maltose, flavors and sylicium dioxide, indistinguishable from ecoviesel sachets.
224253769|NCT06558695|DRUG|Sevoflurane|Sevoflurane was managed for maintenance of the general anestesia during spinal surgeries
224253770|NCT06558695|DRUG|TIVA|TIVA was managed for maintenance of the general anesthesia during spinal surgeries
224253771|NCT05643677|DRUG|Fruquintinib|4 mg PO, QD (3 weeks on, 1 week off)
224253772|NCT05643677|DRUG|Irinotecan|participants will receive irinotecan, 100 mg/m2, intravenous drip, day1 and day 14 of every 4 weeks
224253773|NCT00650377|DRUG|Finasteride Tablets 5 mg|5mg, single dose fed
224253774|NCT00650377|DRUG|Proscar® Tablets 5 mg|5mg, single dose fed
224253775|NCT00828815|DRUG|TMC125|
224253776|NCT04388722|DEVICE|Pulse CO-Oximeter Sensor|Investigational Pulse CO-Oximeter sensor will measure hemoglobin (SpHb) and pleth variability index (PVi).
224253777|NCT05761652|OTHER|Observe and record|The general information, environmental indicators, and auxiliary examination indicators of the subjects were observed and recorded, as well as the TCM physical assessment was performed.
224253778|NCT04356508|DRUG|Nivolumab|Single dose at 0.3mg/kg
224253779|NCT06433258|BEHAVIORAL|Enhanced TSSC curriculum|In addition to the original TSSC curriculum participants will also be educated with the enhanced curriculum which includes components related to alcohol and social determinants of health needs) to promote cancer prevention through healthy lifestyles.
224253780|NCT06433258|BEHAVIORAL|Original TSSC curriculum|Participants will be educated with evidence-based modules focused on topics such as introduction to TSSC, physical activity, fruit and vegetable consumption, reduce sugar intake, diabetes, portion control, cancer, and high blood pressure.These modules are provided by community health workers who have been trained in the contents of the modules, as well as motivational interviewing techniques for delivering the modules.
224253781|NCT04629326|OTHER|68Ga-WL12 PET/CT|WL12, labeled with PET radio-nuclide ( Ga-68 )will be used as a molecular imaging tracer for PET/CT scanning
224253782|NCT05411913|DRUG|GoodFOR Pain|GoodFOR Pain is a FDA registered topical analgesic.
224253783|NCT05411913|DRUG|Icy Hot|a FDA OTC registered topical analgesic.
224253784|NCT05411913|DRUG|Tiger Balm|a FDA OTC registered topical analgesic
224253785|NCT05411913|DRUG|Bengay|a FDA OTC registered topical analgesic.
223673258|NCT05722886|DRUG|Atezolizumab|"Adult patients will receive 1200 mg of atezolizumab intravenously every 21 days.~Paediatric patients will receive atezolizumab at a dose of 15 mg/kg (maximum 1200 mg) every 21 days.~Patients may continue on treatment until disease progression without clinical benefit, unacceptable toxicity or withdrawal of consent."
223673259|NCT05722886|DRUG|Entrectinib|"Adult and paediatric patients with body surface area (BSA) ≥1.51 m\^2 will receive entrectinib orally at a dose of 600 mg daily dose (three 200 mg capsules per day).~Paediatric patients with BSA \<1.51 m\^2 will receive a dose adjusted for BSA. Each cycle of treatment will consist of 28 days and patients may continue until disease progression without clinical benefit, unacceptable toxicity or withdrawal of consent."
223673260|NCT05722886|DRUG|Trastuzumab in combination with pertuzumab|"The initial loading dose of trastuzumab is 8 mg/kg body weight followed thereafter by a maintenance dose of 6 mg/kg body weight administered intravenously every 21 days.~The initial loading dose of pertuzumab is 840 mg followed thereafter by a maintenance dose of 420 mg administered intravenously every 21 days. Paediatric patients will receive a dose of pertuzumab adjusted by body weight.~Patients may continue until disease progression without clinical benefit, unacceptable toxicity or withdrawal of consent."
223673261|NCT05722886|DRUG|Vemurafenib in combination with cobimetinib|"Patients will receive vemurafenib at a dose of 960 mg (4 tablets of 240 mg) orally on a twice daily schedule throughout a 28-day cycle.~Patients will receive cobimetinib at a dose of 60 mg (3 tablets of 20 mg) to be taken orally, once daily for 21 consecutive days (days 1 to 21 in each 28-day cycle); followed by a 7-day break.~Patients may continue on treatment until disease progression without clinical benefit, unacceptable toxicity or withdrawal of consent."
223673262|NCT05722886|DRUG|Capmatinib|Patients will be administered capmatinib orally at a daily dose of 800 mg consisting of 400 mg (two 200 mg tablets) twice daily. Each cycle of treatment will consist of 28 days and patients may continue on treatment until disease progression without clinical benefit, unacceptable toxicity or withdrawal of consent.
223673263|NCT05634356|BEHAVIORAL|vocal-social reinforcement|experimental manipulation of social reinforcement in response to vocalizations
223673264|NCT00400608|DRUG|ADVAIR HFA|
223673265|NCT00400608|DRUG|ADVAIR DISKUS|
223673266|NCT04615455|DRUG|ASCs|ASCs expanded from healthy donors. The ASC product contains 22 million ASCs/ml.
223673267|NCT04615455|DRUG|Cryostor CS10|CryoStor® CS10 freeze medium
223673268|NCT00636701|DEVICE|Repetitive Transcranial Magnetic Stimulation|We will position a coil over the motor cortex of the head and give a series of stimulations (called magnetic pulses).
223673269|NCT00002931|BIOLOGICAL|filgrastim|5 ug/kg bid beginning 4 days prior to and continuing through stem cell collection.
223673270|NCT00002931|DRUG|carboplatin|AUC=7, daily X 3
223673271|NCT00002931|DRUG|etoposide|20 mg/kg by 2 hours infusion daily X 3
223673272|NCT00002931|DRUG|ifosfamide|3 gm/m2 IV over 30 minutes X 3 days
223673273|NCT00002931|DRUG|paclitaxel|425 mg/m2 as 24 hour continuous infusion
223673274|NCT00002931|PROCEDURE|autologous bone marrow transplantation|Given in two divided infusions on day -2 and day 0
223673275|NCT00002931|PROCEDURE|bone marrow ablation with stem cell support|Two cycles of high dose chemotherapy followed by stem cell reinfusion
223673276|NCT01535300|PROCEDURE|Ultrasonography of the trachea|Ultrasonographic measurement of the minimal transverse tracheal diameter
223673277|NCT00215670|DRUG|pegaptanib sodium (Macugen)|
223673278|NCT05886985|DRUG|MatriPlax|MatriPlax contains pcMSCs (placenta choriodecidual membrane-derived mesenchymal stem cells) and will be given intravenously on Day 1 and Day 4
223772295|NCT03267238|BIOLOGICAL|Fecal Microbial Transplantation|Fecal Microbial Transplantation via will be offered to eligible Crohn's patient
223772296|NCT02370888|DRUG|Lenalidomide|Subjects will be enrolled in cohorts of three (3). Lenalidomide will be administered for 21 consecutive days in a 28 day cycle X 2 cycles. The starting dose will be 2.5 mg given orally every other day for 21 days.
223772297|NCT01590823|DRUG|Dabigatran Etexilate 110 mg|All participants will receive a single dosage of dabigatran etexilate 110 mg at the start of their 4 hour dialysis session. Blood sampling will be conducted during and up to 48 hours after participant's dialysis session.
223772298|NCT05725603|OTHER|MRI imaging|Shoulder MRI will be performed at least 3 years after shoulder surgery
223772299|NCT05800288|DRUG|Propofol|Patients will be observationally included in the Elveld TCI or Schnider TCI group. The TCI model is choosen at anesthesiologist's discreption, as suggested in literature
223772300|NCT05289102|OTHER|Two postpartum visits.|Group 1 serves as an intervention group (experimental). All enrolled women in the intervention group were in connection with the inclusion given two pre-booked postpartum care visits. One early at 3 weeks and one later at 7 weeks postpartum.
224253786|NCT05411913|DRUG|CBD Clinic Muscle and Joint Pain Relief Ointment|a non FDA registered topical analgesic.
223772301|NCT05289102|OTHER|One postpartum visit.|Group 2 serves as a control group (active comparator). All enrolled women in the control group were in connection with the inclusion given one pre-booked postpartum care visit at 7 weeks postpartum according to the traditional postpartum care.
224253787|NCT05411913|DRUG|CBD FX CBD Muscle and Joint Cream: Cooling Formula|a non FDA registered topical analgesic.
224253788|NCT05411913|DRUG|Essential Wholesale Muscle Gel|a non FDA registered topical analgesic.
223673279|NCT02197455|DRUG|Tofacitinib Administration|5 mg of Tofacitinib will be taken by mouth twice daily for 3 months.
223673280|NCT03127800|DRUG|Morphine sulphate|5mg of intravenous morphine sulphate diluted to 5ml with normal saline (0.9% sodium chloride) will be administered 30 minutes before participant's bed time. The same dose will be administered four hours later. In both instances 4 mg of intravenous ondansetron will be administered after the morphine sulphate dose to prevent sickness.
223673281|NCT03021174|BEHAVIORAL|EXCAP Exercise|12 weeks of at-home walking and resistance exercise
223673282|NCT03021174|BEHAVIORAL|Nutrition Education Control|12 weeks of implementing eating tips
223673283|NCT00936429|BIOLOGICAL|DEN1-80E (HBV-001 D1 + 3.5 mg Alhydrogel)|3 doses of DEN1-80E vaccine administered as 0.5 ml intramuscularly in deltoid.
223673284|NCT00936429|BIOLOGICAL|Placebo for DEN1-80E|3 doses of placebo vaccine administered as 0.5 ml intramuscularly in deltoid.
223673285|NCT01954147|DRUG|GLP-1|GLP-1 therapy
223673286|NCT01954147|BIOLOGICAL|SC|Stem cell infusion
223673287|NCT01954147|OTHER|Standard Medical Treatment|Standard Medical Treatment
223673288|NCT05435040|DEVICE|proprioceptive knee brace|the patient will perform the tests with the knee brace
223673289|NCT05435040|DEVICE|No knee brace|the patient will perform the tests without the knee brace
223673290|NCT04351061|DRUG|Acetazolamide|Acetazolamide 500 mg by mouth twice per day for 7 consecutive days.
223673291|NCT01407003|DRUG|LIK066|Participants will receive a single or multiple doses of LIK066
223673292|NCT01407003|DRUG|Placebo|Participants will receive a single or multiple doses of a matching placebo
223673293|NCT01283854|BEHAVIORAL|Supervised home-based exercise|"Each participant randomised to the exercise group will be required to participate in three 60-minute exercise sessions each week, starting at 14 weeks gestation, for a total of 14 weeks (i.e. to be completed by 28 weeks of gestation). All exercise sessions will be home-based and fully supervised by an experienced exercise physiologist. The exercise program will be implemented in accordance with the American College of Sports Medicine and the American College of Obstetrics and Gynecology guidelines. All sessions will be conducted on a stationary cycle ergometer.~Heart rate will be measured continuously during exercise to ensure that the exercise intensity is maintained as prescribed. In addition, blood pressure and rate of perceived exertion will be monitored at 10-min intervals. Perceived exertion will not be allowed to exceed a rating of 14 (i.e. somewhat hard)."
223673294|NCT06179433|PROCEDURE|Root canal treatment|Two-visit root canal treatment will be performed.
223673295|NCT06179433|PROCEDURE|Regenerative endodontic procedure|Regenerative endodontic procedure with i-PRF and blood clot induction will be performed.
223772302|NCT01578434|DRUG|Vitamin D|Vitamin D: 6 lakh IU single im dose Calcium: 75 mg/kg calcium daily for 3 months vitamin D and Calcium: combination of above two
223772303|NCT01578434|DRUG|Calcium Carbonate|Calcium: 75 mg/kg calcium daily for 3 months
224253789|NCT05411913|DRUG|Extract Labs Muscle Cream|a non FDA registered topical analgesic.
224253790|NCT05758077|DEVICE|Selective Cytopheretic Device|"The Selective Cytopheretic Device (SCD) is comprised of tubing, connectors, and a synthetic hollow fiber membrane cartridge. The device is connected in series to a commercially available CKRT hemofilter. Blood from the CKRT circuit is diverted after the CKRT hemofilter through to the extracapillary space (ECS) of the SCD cartridge. Blood circulates through the SCD ECS and then it is returned to the patient via the venous return line of the CKRT circuit. Regional citrate anticoagulation is used for the entire CKRT and SCD blood circuit.~The SCD cartridge incorporates a synthetic hollow fiber membrane with the ability to bind activated leukocytes to its extracapillary surface; and when used in a CKRT extracorporeal circuit in the presence of regional citrate anticoagulation, the SCD modulates inflammation."
224253791|NCT05758077|OTHER|Standard of Care|Standard of care CKRT for the subject's condition, as appropriate
223673296|NCT04048811|DRUG|HSK3486|The induction dose is 0.4mg/mg. The initial maintenance dose of the first 6 subjects is 1 mg/kg/h. For the subsequent enrolled subjects, the investigator could adjust the subsequent initial maintenance dose according to the dose response of the first 6 subjects, so as to explore the optimal initial maintenance dose. The range of the initial maintenance dose is 1 (± 0.5) mg/kg/h, i.e. the minimum initial maintenance dose should not be less than 0.5 mg/kg/h, and the maximum should not be more than 1.5 mg/kg/h.
223772304|NCT01578434|DRUG|Vitamin D and Calcium|Vitamin D: 6 lakh IU single im dose. along with Calcium: 75 mg/kg calcium daily for 3 months
223772305|NCT00515476|BEHAVIORAL|physical exercise|8 weeks of regular exercise training
224253792|NCT04300335|OTHER|Individual Exercise|Supervised body weight \& resistance band resistance exercises in a one-on-one personal training setting plus home based aerobic exercise
224253793|NCT04300335|OTHER|Group Exercise|Supervised body weight \& resistance band resistance exercises in a Group setting plus home based aerobic exercise
224253794|NCT06799000|DRUG|Remibrutinib Dose A|Remibrutinib Dose A (oral)
223673297|NCT04048811|DRUG|Propofol|The induction dose is 2.0mg/mg. The initial maintenance dose of the first 2 subject is 5 mg/kg/h. For the subsequent enrolled subjects, the investigator could adjust the subsequent initial maintenance dose according to the dose response of the first 2 subjects, so as to explore the optimal initial maintenance dose. The adjustment range of the initial maintenance dose is 5 (± 2.5) mg/kg/h, i.e. the minimum initial maintenance dose should not be less than 2.5 mg/kg/h, and the maximum should not be more than 7.5 mg/kg/h.
223673298|NCT04048811|DRUG|Propofol HSK3486|The induction dose of Propofol is 2.0mg/mgThe initial maintenance dose of HSK3486 is fixed at 1 mg/kg/h, without adjustment.
223673299|NCT06400771|DRUG|DNP007|DNP007 is a therapeutic agent that can replace calcineurin inhibitor (CNI), which is a representative factor that can be used as an adhesive for extrahepatic long-term survival patches such as after liver transplantation in patients with liver disease and hepatocellular carcinoma, adult metabolic status, neoplasms, etc. , an anti-ICAM-1 mouse monoclonal minority, is a humanized Fab region that humanizes MD-3 and the Fc region of human IgG1, separated by translational engineering.
223673300|NCT00894374|DRUG|Artesunate (Test)|Oral tablet, single dose, 1 x 100 mg
223673301|NCT00894374|DRUG|Artesunate (Comparator)|Oral tablet, single dose, 2 x 50 mg
223673302|NCT06520540|DRUG|HDM1002 100 mg QD 12weeks|Participants received maintenance dose of 100 mg HDM1002 administered orally once daily (QD)
223673303|NCT06520540|DRUG|HDM1002 200 mg QD 12weeks|Participants received maintenance dose of 200 mg HDM1002 administered orally once daily (QD)
223673304|NCT06520540|DRUG|HDM1002 400 mg QD 12weeks，Q 2W for titration|Participants received maintenance dose of 400 mg HDM1002 administered orally once daily (QD) Q 2W for titration
223673305|NCT06520540|DRUG|HDM1002 400 mg QD 12weeks，Q 3W for titration|Participants received maintenance dose of 400 mg HDM1002 administered orally once daily (QD) Q 3W for titration
223673306|NCT06520540|DEVICE|Placebo|Placebo
224253795|NCT06799000|DRUG|Remibrutinib Dose B|Remibrutinib Dose B (oral)
224253796|NCT06799000|DRUG|Placebo 1|Placebo matching to remibrutinib Dose A (oral)
224253797|NCT06799000|DRUG|Placebo 2|Placebo matching to remibrutinib Dose B (oral)
224253798|NCT06121219|DEVICE|Training in the Blind Field|A computer software and chin-rest necessary to perform visual training will be loaned to each subject to be used at home. Subjects will perform one to two daily training sessions in their home, consisting of 200-300 trials each. The visual task performed repetitively will involve discriminating the direction of motion, the presence of motion, or the orientation of a visual stimulus (either a small cloud of dots or bars) located at a predetermined location in the blind field. The computer program will automatically create a record of patient performance during each home training session. Subjects will train daily (about 40-60 minutes total), 5 to 7 days per week for at least 3 and up to 12 months at a time.
223673307|NCT01879579|OTHER|Mobile Insulin Titration Intervention|Patients send their fasting blood glucose levels to the clinic diabetes nurses via text message each weekday. The diabetes nurses call each patient once a week to give insulin titration instructions to replace in-person clinic visits for insulin titration.
223673308|NCT00005001|BIOLOGICAL|HIV-1 Immunogen|
223673309|NCT02292784|DRUG|Retosiban|This is a safety follow-up study of infants and children exposed to retosiban during their mother's participation in a Phase III treatment study for SPTL. Infants enrolled in this study will not be administered any investigational product.
223673310|NCT02292784|DRUG|Atosiban|This is a safety follow-up study of infants and children exposed to atosiban comparator during their mother's participation in a Phase III treatment study for SPTL. Infants enrolled in this study will not be administered any investigational product.
223673311|NCT02292784|DRUG|Placebo|This is a safety follow-up study of infants and children exposed to matching placebo for retosiban/ atosiban during their mother's participation in a Phase III treatment study for SPTL. Infants enrolled in this study will not be administered any investigational product
223673312|NCT01264081|DRUG|Lapatinib|500 mg PO (orally) twice a day for 28 days (1 cycle). Up to 27 cycles allowed if response seen.
223673313|NCT00134784|DRUG|[123I]B-CIT SPECT imaging|To assess \[123I\]B-CIT SPECT imaging
223673314|NCT02732197|DRUG|Sedation|Parturients who received IV thiopental 2 mg kg-1 and if necessary additional 50 mg immediately after spinal anesthesia until reaching at least Ramsay sedation score of 3 (1: patient anxious, agitated or restless, 6: patient with no response to light glabella tap or loud auditory stimulus.).
223673315|NCT02732197|DRUG|No sedation|Parturients did not receive any type of sedation after spinal anesthesia.
223673316|NCT02716896|RADIATION|Radiation and chemoradiation|Radiation and chemotherapy will be administered concurrently to those who are randomized to this group.
223673317|NCT02716896|PROCEDURE|Radical cystectomy|Radical cystectomy will be performed on those who are randomized to this group.
223673318|NCT05363943|PROCEDURE|double plating|open reduction and internal fixation by using lateral and medial plates.
223673319|NCT05363943|PROCEDURE|Distal femoral replacement|excision of the distal part of femur and replacement with distal femoral prosthesis
223673320|NCT02086279|DRUG|GnRH analogue|"Patients with uterine myoma, endometriosis, fibromatous uterus, chronic pelvic pain in list for laparoscopic surgery or laparotomy are usually pharmacologically treated by administration of GnRHa, 11.25 mg at 21° day of the menstrual cycle and repeated after 3 months. This treatment is part of our preoperative routine in order to reduce pain symptoms, menstrual blood loss, uterine or fibroids vascularization and size, during the months spent on surgery waiting list.~Patients who will satisfy inclusion and exclusion criteria will be enrolled in this study protocol and will be subjected to valuation of ovarian reserve: specifically, serum levels of AMH and antral follicle count (AFC) between first and fourth days of the menstrual cycle will be measured."
223673321|NCT01284049|DRUG|Intralipid 20%®|Administration of Intralipid 20%® at a dose ranging between 0.5 and 1 g/kg/infusion during 12 weeks.
223772306|NCT03711123|BEHAVIORAL|Group metacognitive therapy|10 weekly Group session of 90 minutes duration
223772307|NCT03711123|BEHAVIORAL|Clinical management|10 weekly individual sessions With clinical management including guided self-help
224253799|NCT06449924|DEVICE|Endotracheal tube|Endotracheal Tube Inserted to the Level of the Hypopharynx
223772308|NCT04468048|OTHER|"Music: Nada Himalaya performed by S. G. Sachchidananda"|"Music: Nada Himalaya performed by S. G. Sachchidananda"
223772309|NCT04574362|DRUG|Rimegepant|One 75mg orally disintegrating tablet
223772310|NCT04574362|DRUG|Placebo|Matching placebo
223772311|NCT05176327|DEVICE|Exoskeleton training with Ekso NR|Walking exercise with Ekso NR
223772312|NCT03228238|DRUG|Vitamin C and Vitamin E|Ascorbic acid Tablet 1g and Tocopherol Capsule 400IU
223772313|NCT03228238|DRUG|Statin|Atorvastatin calcium 10mg
223772314|NCT03228238|DRUG|Standard medication for variant angina|Calcium Channel blocker or NG
223772315|NCT00003341|BIOLOGICAL|epoetin alfa|
223772316|NCT00003341|PROCEDURE|quality-of-life assessment|
223772317|NCT04682600|DEVICE|Liver Incytes System|The Liver Incytes System uses the Shear Wave Absolute Vibro-Elastrography (S-WAVE) method. The imaging procedure of the Liver Incytes system is similar to a traditional ultrasound scanning procedure or FibroScan, in which the patient is asked to lie supine on an examination bed, with the operator seated next to them. A vibration source is placed under the patient, between the patient and the bed to induce shear waves in the liver. Ultrasound imaging through the patient ribs is used to track the displacements of these waves. Through tracking of the displacements, the shear wave velocity and tissue stiffness can be calculated. The use of volumetric multi-frequency imaging increases the amount of liver scanned
223772318|NCT01709058|DRUG|Intramuscular/paravertebral injections of Oxygen-Ozone|"Medical Oxygen will be used as a part of the injected mixture (100% oxygen, 200 bar compressed gas in steel cylinder with valve 14 with an integrated reductive). For the generation of the Oxygen-Ozone mixture a certified equipment OZONOSAN alpha plus will be used according to the D.L. 46/97, EEC Directive 93/42, class 2A with a photometer. The mixture of O2-O3 is produced through a method called silent discharge. Intramuscular/paravertebral injections to 3 cm from the spinal medial line will be performed introducing 5-20 mL of oxygen-ozone to each point, at a concentration of 10-20 micrograms/mL, for a total volume of 40 mL"
223772319|NCT01709058|OTHER|Simulated intramuscular/paravertebral injections|The simulated treatment administration will mimic the treatment in the area to be treated by pricking the skin with the needle without drilling. A light massage will be practice by hand and the application area will be covered with a bandage adhesive leaving the patient in the prone position for 10-15 minutes.
223772320|NCT04013451|BEHAVIORAL|Acts of kindness|Both intervention and control groups will receive an email with access to a relaxation and stress management booklet from Western University's (UWO) Wellness Education Centre (http://studentexperience.uwo.ca/docs/RelaxationAndStressManagement.pdf). In addition, the intervention group will be asked to (1) complete and log/submit a minimum of three deliberate acts of kindness per day for one month, and (2) join the study-dedicated online site to connect with, support, and share experiences and ideas with each other around acts of kindness.
223772321|NCT04420026|RADIATION|Interact Active Tracker|Interact Active Tracker, allowing the automation of the fusion between a CBCT and ultrasound imaging
223772322|NCT00002526|BIOLOGICAL|filgrastim|
223772323|NCT00002526|DRUG|doxorubicin hydrochloride|
223772324|NCT00002526|DRUG|ifosfamide|
223772325|NCT02556008|DRUG|cannabidiol (CBD)|Treatment will begin with 2 mg/kg/day given in two divided doses. The dose will be increased by 3 mg/kg/day after seven days and then by 5 mg/kg/day every seven days up to a maximum dose of 25 mg/kg/day given.
224253800|NCT06396247|BEHAVIORAL|Functional Activity Strength Training|FAST consists of five exercises (stepping on a step, chair stands, push-ups, rows, walking), for 30 seconds each, performed daily, with 30 seconds of rest between.
223772326|NCT05951491|DEVICE|Wearable Shoulder Exoskeleton|The wearable shoulder exoskeleton prototype is under development at the University of Idaho to provide gravity support to the shoulder. Subjects will use the device at home for a period of 5-7 days for at least 2 hours per day.
223772327|NCT05951491|DEVICE|Wearable Hand Exoskeleton|The wearable hand exoskeleton prototype is under development at the University of Idaho to provide hand-opening support. Subjects will use the device at home for a period of 5-7 days for at least 2 hours per day.
223772328|NCT00753324|DRUG|Routine three-drug antiretroviral prophylaxis|Women who are identified as HIV-infected will be offered routine combination antiretroviral prophylaxis starting at 28 weeks gestation (timing consistent with Zambian national guidelines for short-course ZDV). The first-line combination provided to pregnant women will be standardized following consultation with the Ministry of Health, but will likely include ZDV, lamivudine (3TC) and either NVP or lopinavir / ritonavir. In women who with moderate to severe anemia, ZDV is substituted with stavudine (d4T). In accordance with the Zambian national guidelines, any patients who are started on NVP will begin with a once daily dose for two weeks before increasing to the regular twice daily schedule
223772329|NCT06298643|PROCEDURE|Red blood cell transfusion|≥2 units of red blood cell transfusion
224253801|NCT00642980|DRUG|Clindamycin|300 mg capsules (per os) Intervention= 2 capsules/d during 4 days: three times a month apart
224253802|NCT00642980|DRUG|Placebo|Double blinded capsules(per os) Intervention= 2 capsules/d during 4 days: three times a month apart
223673322|NCT01284049|DRUG|OMEGAVEN 10%®|OMEGAVEN 10%® will be used as the sole lipid supplement at a dose of 0.5 to 1.0 g/kg/Infusion with a maximum dose per infusion of 40 grams, in view of formulation constraints during 12 weeks.
223772330|NCT06298643|PROCEDURE|Red blood cell transfusion|0 units or \<2 units of red blood cell transfusion
223772331|NCT02778529|DEVICE|Bilateral assessment robots (BiAS)|The BiAS are two passive desktop robots that will be used in this study to measure right and left arm kinematics for 4 different groups of patients.
224253803|NCT00642980|DRUG|Clindamycin|300 mg capsules (per os) Intervention= 2 capsules/d during 4 days: one time and then, after one month placebo capsules 2 capsules/d during 4 days: two times a month apart
223673323|NCT04767308|BIOLOGICAL|CT125A cells|Subjects will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) to manufacture CT125A cells, during which cyclophosphamide and fludarabine will be administered for the purpose of lymphocytes depletion. After lymphodepletion, subjects will receive one dose treatment with CT125A cells by intravenous (IV) infusion. The initial dose of 1×10\^6 CAR+ T cells/kg will be infused on day 0.
224253804|NCT06513351|BEHAVIORAL|Novel PPH Risk Prediction Model - Comparator Arm B|Patients in this group will receive the standard care risk assessment with the addition of a recently developed, novel PPH risk prediction model, which will automatically calculate a patient's numerical risk of hemorrhage based on 21 risk factors. Elevated risk of hemorrhage (\>=3% predicted risk), as predicted by the model, will be linked to clinical decision support, including a best practice advisory with recommendations presented to providers for consideration when they access the patient's electronic health record.
224253805|NCT04960072|BIOLOGICAL|Tumor Infiltrating Lymphocytes (TIL)|Adoptive transfer of 1x10\^9-5x10\^10 autologous TILs to patients i.v. in 30-120 minutes.
224253806|NCT05692323|OTHER|PREHAB|6-week supervised PREHAB program. Each week of the program consists of 3 x 1 hour supervised training sessions made up of moderate intensity aerobic training and resistance training. In addition to the supervised sessions, patients will be instructed to accumulate a total of 150 minutes per week of moderate aerobic training at home which is measured by a wrist worn FitBit device.
224253807|NCT02709226|RADIATION|Radiation|Radiation therapy will be administered daily Monday-Friday at NCI, ROB unless the treatment schedule requires amendment in the event of inclement weather or federal holidays. Radiation therapy dose will be administered as per on consecutive treatment days, 5 fractions per week via a linear accelerator using 6 MV photons or greater. Dose escalation is as follows: dose level 1 (DL1) 3.5 Gy x 10; dose level 2 (DL2) 3.5 Gy x 12; dose level 3 (DL3) 3.5 Gy x 14. If 2 DLTs are observed in the second dose level a step down dose of 3.0 Gy x 14 fractions will be tested. If 2 DLTs are observed in the third dose level a step down dose of 3.0 Gy x 17 fractions will be tested. The study will have 3 planned re-irradiation dose levels, with 1 to 6 patients per dose level using the 3+3 design to define the MTD. The number of patients may be increased to 9 total patients at the MTD ( provided no DLT) with a maximum of 21 evaluable patients enrolled.
224253808|NCT04870437|OTHER|Extracorporeal phototherapy|The principle of ECP is to collect mononucleated cells from the blood by centrifugation. After purification, the mononucleated cells are incubated ex-vivo with a photo-activatable DNA intercalating agent (8-methoxypsoralen, UVADEX®), then re-injected to the patient.
224253809|NCT06780670|DRUG|Investigators choice of SoC|The control treatment in Phase III is investigator's choice of SoC
224253810|NCT06780670|DRUG|AAA817|The investigational treatment is AAA817
224253811|NCT06780670|DRUG|AAA817|The investigational treatment is AAA817
224253812|NCT06780670|DRUG|AAA817|Investigational treatment is the Dose B of AAA817
223673324|NCT04767308|DRUG|Cyclophosphamide, fludarabine|Subjects will be given IV infusion of cyclophosphamide 500 mg/m2/day and fludarabine 30 mg/m2/day on days -4, -3 and -2
223673325|NCT00919841|OTHER|Ultrasound examination|Sequential three-dimension sonographic examination for the uterine size after vaginal delivery. The examination will be performed once a week, until the completion of 7 weeks after delivery.
223673326|NCT02403687|DRUG|baclofen 2%|compound topical cream
223673327|NCT02403687|DRUG|Bupivacaine hydrochloride 1%|compound topical cream
223673328|NCT02403687|DRUG|Cyclobenzaprine hydrochloride 2%|compound topical cream
223673329|NCT02403687|DRUG|Diclofenac Sodium 3%|compound topical cream
223673330|NCT02403687|DRUG|Flurbiprofen 10%|compound topical cream
223673331|NCT02403687|DRUG|Gabapentin 6%|compound topical cream
223673332|NCT02403687|DRUG|Ketamine 10%|compound topical cream
223673333|NCT02403687|DRUG|Lidocaine 2%|compound topical cream
223673334|NCT02403687|DRUG|Prilocaine 2.5%|compound topical cream
223673335|NCT02403687|DRUG|Meloxicam 0.09%|compound topical cream
223673336|NCT02403687|DRUG|Sumatriptan 5%|compound topical cream
223673337|NCT02403687|DRUG|Tizanidine 0.1%|compound topical cream
223673338|NCT02403687|DRUG|Topiramate 2.5%|compound topical cream
223673339|NCT02403687|DRUG|Capsaicin, USP 0.0375%|compound topical cream
223673340|NCT02403687|DRUG|Menthol, NF 5.00 %|compound topical cream
223673341|NCT04178083|DIAGNOSTIC_TEST|medical examination|medical examination
223673342|NCT01066442|DRUG|BF2.649 (Pitolisant)|1 capsule of BF2.649 (5mg, 10mg , 20 mg) O.D
223673343|NCT05869084|DIAGNOSTIC_TEST|pulmonary function tests|pulmonary function tests
223673344|NCT03762538|DRUG|Propofol|Patients will be induced to unconsciousness using propofol intravenously.
223673345|NCT02599675|DIETARY_SUPPLEMENT|Vitamin D3|Vitamin D3 dissolved in olive oil, encapsuled
223673346|NCT02599675|DIETARY_SUPPLEMENT|Placebo|Olive oil, encapsuled
223673347|NCT05089201|BEHAVIORAL|Animal-assisted interaction|A dog-handler team or a handler alone will visit participants with a dog for approximately 20 minutes on 3 consecutive days during their inpatient hospital stay
223673348|NCT05089201|BEHAVIORAL|Conversational control|A handler alone will visit participants without a dog for approximately 20 minutes on 3 consecutive days during their inpatient hospital stay
223673349|NCT05198778|DRUG|URC102|tablet
223673350|NCT05198778|DRUG|URC102|tablet
223673351|NCT05908318|BEHAVIORAL|olfactory training|In this group, patients were performed 24-48h before surgery used phenylethyl alcohol (rose), phytol (press tree), citronella (lemon), eugenol (clove) 4 kinds of smell，twice a day for three days.
223673352|NCT00479895|DRUG|Hemoglobin Based Oxygen Carrier-201 (HBOC-201, Hemopure)|Pre-oxygenated HBOC-201
223673353|NCT06280846|DEVICE|high-intensity laser acupuncture and Exercise therapy program|"The patients will receive high-intensity lasers and the treatment will be performed at 15 acupuncture points: unilateral GV3, GV4, and GV5, and bilateral BL 20, BL23, BL24, BL25, BL40 and GB30.~Exercise therapy program: The patients will perform an exercise therapy program in the form of:~\- strengthening exercises for abdominal and back muscles, - lumbar stabilization exercises. - stretching exercises"
224253813|NCT05911165|OTHER|No surgical coaching|During the twelve-month study period, all participants will have access to an instructional video related to laparoscopic vaginal cuff suturing and the laparoscopic vaginal cuff trainer in order to practice laparoscopic suturing as desired. All participants will keep a log of voluntary practice time on the vaginal cuff trainer. These resources will constitute the control arm of the study
224253814|NCT05911165|OTHER|Surgical coaching|Surgical coaching sessions will include 30-60 minute meetings in which the coach-coachee pair reviews recorded laparoscopic suturing practice sessions to examine different aspects of surgical performance.
224253815|NCT05574777|DEVICE|Hybrid Argonplasma coagulation (HAPC)|Gastric mucosal ablation is an endoscopic procedure which uses argonplasma coagulation in combination with submucosal injection to achieve selective ablation to the gastric mucosa and preventing thermal damage to the muscle layer.
224253816|NCT06283056|DEVICE|Device treatment|InMode RF system with Morpheus8 Body (up to 7mm depth) Eligible subjects will undergo two treatments with the Morpheus8 device using the 3, 5 7 mm depths or sequential (Burst) mode, based on the treating physician's discretion..each subject is approximately 9 months (including screening, two treatments (2 months apart) and 3 follow-up visits at 1 month, 3 months, and 6 months post treatment.
224253817|NCT05955456|OTHER|No intervention|No intervention is applied to participants. The risk calculator score is not released to the participants or care providers. Participants are followed up for risk calculator accuracy and recalibration.
224253818|NCT05604170|DRUG|Ganaxolone|GNX will be administered.
224253819|NCT06268418|OTHER|Artificial intelligence|Segmentation
224253820|NCT05956626|DRUG|OCU410ST|Subretinal Administration of OCU410ST
224253821|NCT04930094|BIOLOGICAL|Secukinumab 300 mg|Secukinumab 300 mg
224253822|NCT04930094|OTHER|Placebo|Placebo
224253823|NCT04930094|BIOLOGICAL|Secukinumab 150 mg|Secukinumab
224253824|NCT05875168|DRUG|DS-3939a|One IV infusion Q3W on Day 1 of each 21-day cycle
223673354|NCT06280846|DEVICE|low-intensity laser acupuncture and Exercise therapy program|"The patients will receive low-intensity lasers and the treatment will be performed at 15 acupuncture points: unilateral GV3, GV4, and GV5, and bilateral BL 20, BL23, BL24, BL25, BL40 and GB30.~Exercise therapy program: The patients will perform an exercise therapy program in the form of:~\- strengthening exercises for abdominal and back muscles, - lumbar stabilization exercises. - stretching exercises"
223673355|NCT06280846|DEVICE|Sham laser acupuncture|Sham laser acupuncture and exercise therapy program. The patients will receive a sham laser.acupuncture and an exercise therapy program in the form of: - strengthening exercises for abdominal and back muscles, - lumbar stabilization exercises. - stretching exercises
223673356|NCT00398489|BIOLOGICAL|trastuzumab|
223673357|NCT00398489|DRUG|anastrozole|
223673358|NCT00398489|DRUG|cyclophosphamide|
223673359|NCT00398489|DRUG|docetaxel|
223673360|NCT00398489|DRUG|epirubicin hydrochloride|
223673361|NCT00398489|DRUG|goserelin acetate|
223673362|NCT00398489|DRUG|tamoxifen citrate|
223673363|NCT00398489|PROCEDURE|adjuvant therapy|
223673364|NCT00398489|PROCEDURE|conventional surgery|
223673365|NCT00398489|PROCEDURE|neoadjuvant therapy|
223673366|NCT00398489|RADIATION|radiation therapy|
223673367|NCT03998813|DRUG|Ropivacaine|Locoregional analgesia by femoral triangle catheterization
224253825|NCT05798663|DRUG|Atezolizumab|Atezolizumab will be given to participants either intravenously at a dosage of 1200mg or subcutaneously at a dosage of 1875 mg on Day 1 of each 21-day cycle for Arms A, B, and C, and on days 1 and 22 of concurrent chemoradiotherapy for Arm C only.
224253826|NCT05798663|DRUG|Tiragolumab|Tiragolumab will be given to participants intravenously at a dosage of 600 mg on day 1 of each 21-day cycle (Arms B and C), and on days 1 and 22 of concurrent chemoradiotherapy (Arm C only).
224253827|NCT03610113|DEVICE|Reverse shoulder arthroplasty|The implantation of reverse shoulder prosthesis, and reattachment of greater and lesser tuberosities
224253828|NCT03232619|BIOLOGICAL|CD19 CART|Patients will get one course of CART treatment with the dose of 0.5-5\*10\~6/KgBW.
224253829|NCT02209571|OTHER|Venous blood markers|Routine venous blood sampling
224253830|NCT01181622|DRUG|denufosol tetrasodium Inhalation Solution|60 mg by oral inhalation three times daily
224253831|NCT01181622|DRUG|0.9% w/v sodium chloride solution|0.9% w/v sodium chloride solution by oral inhalation three times daily
224253832|NCT03612960|DRUG|Very low nicotine content cigarettes|Very low nicotine content cigarettes
224253833|NCT03612960|DRUG|Normal nicotine content cigarettes|Normal nicotine content cigarettes
224253834|NCT00991965|DEVICE|INFUSE® Bone Graft|Patients will be treated with the commercially available INFUSE® Bone Graft material applied to an ACS in the area of the dental implant on Day 0 (Surgery). A follow-up visit will take place 2 weeks after implant of the INFUSE® Bone Graft material, or as regularly scheduled as per the standard of care (SOC) for the facility. Patients will return to the facility for final End of Study (EOS) assessments 6 months after surgery for placement of the appropriate prosthetic, and assessment of osseointegration and stability. Between the follow-up visit and the EOS visit, patients will be seen as per the SOC schedule for the facility.
224253835|NCT05214924|BIOLOGICAL|Injectable platelet-rich fibrin|Intra-articular injection of injectable platelet-rich fibrin into temporomandibular joint/joints with diagnosed mild to moderate degenerative joint disease.
224253836|NCT05214924|BIOLOGICAL|Platelet-rich plasma|Intra-articular injection of platelet-rich plasma into temporomandibular joint/joints with diagnosed mild to moderate degenerative joint disease.
224253837|NCT05502250|DRUG|gemcitabine, cisplatin and tislelizumab|"All patients will receive 2 cycles of gemcitabine and cisplatin (GP) + tislelizumab. Each cycle lasts 21 days. Treatment is given through an IV line on day 1 and 8.~After 2 cycles a FDG-PET-CT scan will be performed. Patients who respond well will proceed with 2 additional cycles of GP + tislelizumab . Patients with insufficient response will stop with the study treatment and they will continue treatment according to local practice.~After 4 cycles of GP + tislelizumab another FDG-PET-CT scan will be performed. If this scan shows that the disease is under control (metabolic complete remission) patients will proceed with 13 cycles of tislelizumab consolidation treatment (21 day cycles). Treatment is given on day 1 through an IV line."
224253838|NCT06795087|OTHER|Opioid Medication Disposal Education|Education on opioid medication disposal will be provided in the form of a pamphlet created by Atrium Health based on FDA resources and will be given to all participants at discharge (cystectomy, nephrectomy, prostatectomy) beginning in the second year, approximately 13 months from when the first participant is enrolled or until a minimum of 100 evaluable participants are enrolled in the pre-education cohort, whichever occurs last.
224253839|NCT05750394|PROCEDURE|Uterine layers closed|Uterus closed with 1, 2 or 3 layers
224253840|NCT05750394|DEVICE|Suture Type|Barbed or smooth
223673368|NCT03998813|DRUG|Ropivacaine|Tissue infiltration
223673369|NCT00246415|DRUG|Memantine|
224253841|NCT05750394|PROCEDURE|Endometrium|Included or excluded
224253842|NCT00784472|DRUG|oxycodone|intravenous according to patients weight, pn.
224253843|NCT00784472|DRUG|morphine|intravenous administration according to patients weight, pn.
224253844|NCT06119763|DIAGNOSTIC_TEST|anti dfs70 antibodies|blood sample is taken from SLE cases and is tested for antiDFS70 antibodies titre
224253845|NCT03890796|BEHAVIORAL|Activity Scheduling|AS is strategy for behavioral activation that has also been used with success in people with dementia, after the training of their caregivers. A certified occupational therapist will train up the caregivers of dementia in conducting AS activities for participants in experimental group
224253846|NCT03890796|BEHAVIORAL|Educational|A serial of dementia care education program with a weekly theme of topics like: importance of exercise and healthy eating, sleep management, counselling, acceptance therapy, commitment therapy, reminiscence therapy.
224253847|NCT01022463|DRUG|Ivabradine|Ivabradine 5 mg BId for 4 weeks
224253848|NCT01022463|DRUG|Atenolol|50 mg od for 4 weeks
224253849|NCT02227251|DRUG|Selinexor|Dose: 60 mg (BIW); Dosage form: film-coated (20 mg each) immediate release tablets; Route of administration: Oral
224253850|NCT02227251|DRUG|Selinexor|Dose: 40 mg (BIW); Dosage form: film-coated (20 mg each) immediate release tablets; Route of administration: Oral
224253851|NCT02227251|DRUG|Selinexor|Dose: 60 mg (BIW) and 60 mg (QW); Dosage form: film-coated (20 mg each) immediate release tablets; Route of administration: Oral
224253852|NCT05901870|OTHER|Questionnaire administration|All study participants will be surveyed with the questionnaire, which includes such instruments as EQ-5D-3L and WG-SS, to assess their health-related quality of life, health-related behavior, and health care utilization indicators.
224253853|NCT00271752|PROCEDURE|Earlier therapeutic changes regarding infection|For every day Procalcitonin levels increase in the intervention group, antibiotics, surgery, diagnostic imaging and microbiologic testing is intensified
224253854|NCT00272779|DRUG|ATV|300mg Oral capsules for 96 weeks
224253855|NCT00272779|DRUG|RTV|100mg Oral Capsules for 96 weeks
224253856|NCT00272779|DRUG|Tenofovi-Emtricitabine (TDF/FTC) tablet|One tablet with 300 mg - 200 mg once a day for 96 weeks.
224253857|NCT00272779|DRUG|LPV|400 mg (3 133mg capsules) BID for 96 weeks
224253858|NCT01415232|DEVICE|Sonosite S-Nerve® US system (SonoSite, Bothell,WA)|Ultrasound to measure depth to the epidural space in morbidly obese parturients
224253859|NCT00440518|DRUG|Lacosamide|Lacosamide 100mg immediate-release film-coated tablet (white,oval) oral administration twice daily 12 hours apart
224253860|NCT00440518|OTHER|Placebo|Immediate-release film coated tablet (white, oval), oral administration twice daily 12 hours apart
224253861|NCT00440518|DRUG|Lacosamide|Lacosamide 300mg, immediate-release film coated tablet (white,oval), oral administration twice daily 12 hours apart.
224253862|NCT00561015|DRUG|Telaprevir|Telaprevir 750 mg tablet will be administered three times a day orally for 2 weeks.
224253863|NCT00561015|DRUG|Peg-IFN-alfa-2a + Ribavirin (Standard Treatment)|Standard treatment of Peg-IFN-alfa-2a (180 mcg subcutaneous injection, once weekly) and ribavirin (400 mg as oral tablet twice daily) will be administered from Day 15 to Week 24 or 26 in the T2 \& PR24 - genotype 2 and 3 group and from Day 1 to Week 24 or 26 in the T2/PR24 - genotype 2 and 3 group.
223673370|NCT06210126|OTHER|local anesthetic injection|Ultrasound-guided pectointercostal fascial plane block group using 20 mL of 0.25% bupivacaine
224253864|NCT00561015|DRUG|Placebo|Matching placebo tablet to telaprevir will be administered three times a day orally for 2 weeks.
224253865|NCT00003015|DRUG|carboplatin|
224253866|NCT00003015|DRUG|vincristine sulfate|
224253867|NCT00003015|PROCEDURE|conventional surgery|
224253868|NCT00003015|RADIATION|radiation therapy|
224253869|NCT06597370|OTHER|Gene expression mRNA of IgG anti-spike|"b) Peripheral venous blood samples (3 ml per occasion) will be taken from all participants. They will be carried out on days 30,60 and 120 after completion of the COVID-19 vaccination schedule.~c) Sample processing:~* tRNA extraction from all samples.~* cDNA synthesis~* Real time PCR performance."
224253870|NCT04700787|DRUG|Sulopenem|sulopenem intravenous 1000 mg on Day 1 and then sulopenem etzadroxil/probenecid oral 500 mg/500 mg on Day 2
224253871|NCT02440711|DEVICE|Energy storing foot (ESF)|A commercially-available energy storing prosthetic foot
224253872|NCT02440711|DEVICE|Modified running specific foot (mRSF)|A running specific prosthetic foot customized for both running and walking activities
224253873|NCT01980771|BEHAVIORAL|BTWB intervention|Men work in groups to complete a intervention that takes approximately two hours to complete.
224253874|NCT01980771|BEHAVIORAL|Cancer prevention and screening|Men are provided health education about cancer screening and prevention
224253875|NCT02277847|DRUG|Idarubicin(8mg/m2) and cytosine arabinoside|IDA 8mg/M2 per day, D1-3. iv injection in 10 minutes;Ara-C：100-200mg/M2 per day, D1-7. administration advice: at first, 25 mg/M2 of Ara-C is given by fast intravenous injection, then 100 mg/M2 of Ara-C is given by continuous iv drip for 24 hours for successive 7 days.
223673371|NCT06210126|OTHER|Standard perioperative and postoperative analgesia protocol|postoperative IV morphine PCA and paracetamol will be given. If VAS is 3 or above, 75 mg dexketoprofen trometamol will be administered.
224253876|NCT02277847|DRUG|Idarubicin(10mg/m2), cytosine arabinoside|IDA 10mg/M2 per day, D1-3. iv. injection in 10mimutes;Ara-C：100-200mg/M2 per day, D1-7. administration advice: at first, 25 mg/M2 of Ara-C is given by fast intravenous injection, then 100 mg/M2 of Ara-C is given by continuous iv drip for 24 hours for successive 7 days.
224253877|NCT04297891|OTHER|Clinical rating scale to measure Ataxia disease severity and progression|SARA is a clinical scale developed by Schmitz-Hübsch et al which assesses a range of different impairments in cerebellar ataxia. The scale is made up of 8 items related to gait, stance, sitting, speech, finger-chase test, nose-finger test, fast alternating movements and heel-shin test.
224253878|NCT04297891|OTHER|Clinical rating scale to measure spastic paraplegia disease severity and progression|A 13-item scale to rate functional impairment occurring in pure forms of spastic paraplegia (SP). Additional symptoms constituting a complicated form of SP are recorded in an inventory.
224253879|NCT04297891|OTHER|Disease-specific severity index for adults with autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS)|"The DSI-ARSACS is a valid measure of disease severity for the adult ARSACS population that is able to distinguish between patients with different clinical profiles.~It considers the 3 components (pyramidal, cerebellar, neuropathic) of the disease, and documents its content validity, internal consistency, and construct validity."
224253880|NCT04297891|DIAGNOSTIC_TEST|Next-Gen Sequencing (NGS)|Whole Genome Sequencing, Whole Exome Sequencing, Transcriptomics, Proteomics, Metabolomics
224253881|NCT01196572|PROCEDURE|Internal Urethrotomy|surgical incision of urethral stricture using endoscopic cold knife vs. endoscopic laser
224253882|NCT05232786|OTHER|No treatment given|No treatment given
224253883|NCT02311686|DIETARY_SUPPLEMENT|10 g ethanol|Alcohol single oral dose
223673372|NCT04663841|OTHER|transcranial magnetic stimulation|transcranial magnetic stimulation is delivered as part of routine care and is not managed by this observational study
223673373|NCT03034291|DIETARY_SUPPLEMENT|Cacao 70%|Consumption for 8 weeks of 50 grams of chocolate per day with 70% cocoa solids.
223673374|NCT03034291|DIETARY_SUPPLEMENT|White chocolate|
223673375|NCT06458335|BEHAVIORAL|Cognitive-Behavioral Therapy for Perceived Social Isolation|6 sessions focused on addressing thoughts, emotions, and behaviors that maintain feeling alone as a way to reduce loneliness and substance use
223772332|NCT03991195|DIETARY_SUPPLEMENT|Probiotic supplemented intervention|In this project, taking the method of random, double blindness and control, the probiotic supplemented group with aMCI will take Bifidobacterium for three months. After that, cognitive changes will be test to investigate the effectiveness of probiotic supplementation.
224253884|NCT02311686|DIETARY_SUPPLEMENT|20 g ethanol|Alcohol single oral dose
224253885|NCT02311686|DIETARY_SUPPLEMENT|40 g ethanol|Alcohol single oral dose
224253886|NCT02311686|DIETARY_SUPPLEMENT|60 g ethanol|Alcohol single oral dose
224253887|NCT02311686|DIETARY_SUPPLEMENT|80 g ethanol|Alcohol single oral dose
224253888|NCT06185322|OTHER|Physical therapy program with upper cross syndrome specific exercises|Ten physical therapy sessions consisting of electrotherapy and upper cross syndrome -specific exercise program.
224253889|NCT06185322|OTHER|Physical therapy program with conventional neck strengthening exercises|Ten physical therapy sessions consisting of electrotherapy and conventional neck strenthening exercises
224253890|NCT04490005|OTHER|pupillometry|evaluation of pupillary reflex by using the Neuroptics Pupillometer every 4 hours during ICU stay
224253891|NCT04485767|BEHAVIORAL|Progressive Resistance Training Exercise|Progressive Resistance Training Exercise 2x weekly for 6 months.
224253892|NCT04485767|BEHAVIORAL|Flexibility and Balance Exercise|Flexibility and Balance Exercise Training Exercise 2x weekly for 6 months.
224322248|NCT06048822|BEHAVIORAL|Pickleball|Participants will be encouraged to attend ≥2 pickleball sessions per week, with the YMCA offering 5 sessions per week. Sessions will last 2 hours, with participants encouraged to attend ≥1 hour. New players will receive instruction from a YMCA exercise trainer with a USA Pickleball Association Instructor Certification during sessions. At the end of each session, the YMCA trainer will note on attendance sheets whether participants engaged in training/skill development, open play, or both. Participants will be encouraged to engage in 5-10 minutes of structured warm-up exercise (i.e., walking laps around the courts and dynamic and static muscle stretches) prior to playing in each session, and they will be encouraged to perform cool-down stretches after they complete each session.
224322249|NCT06435286|DRUG|Proflavine Hemisulfate|Approximately 5-10 ml of proflavine hemisulfate (0.01%) will be sprayed on the esophageal mucosa.
224322250|NCT06435286|DEVICE|Artificial Intelligence Mobile High-Resolution Microendoscope|The AI-mHRME will be inserted through the endoscope biopsy channel and gently placed against the mucosa where proflavine was sprayed. The probe will transmit images to the computer/laptop for the clinician to observe any abnormal tissues and save photos of these tissues.
224322251|NCT03378752|PROCEDURE|HFJV|On High frequency jet ventilation, Every 15 minutes, after induction of general anaesthesia, a computed tomography of the lower part of the lungs are taken (10 cm volume, with the top of the right diaphragm as the lower border)
223673376|NCT06458335|BEHAVIORAL|Health Education|Health education provides information on the importance and benefits of and guidelines for living a health lifestyle
223673377|NCT06114459|DRUG|Sodium Chloride|Post surgery disinfection
223673378|NCT04360135|DRUG|Acetaminophen|Preemptive acetaminophen the day before surgery
223673379|NCT04360135|DRUG|Placebo|Preemptive placebo the day before surgery
223673380|NCT01732003|DIETARY_SUPPLEMENT|Omega-3 Complete|
223673381|NCT01732003|DIETARY_SUPPLEMENT|Placebo Pill|
223673382|NCT01655966|DRUG|vitamin D +pegylated interferon + ribavirin|Vitamin D: 1mcg once daily 48 weeks Pegylated interferon 160ug once weekly 48 weeks Ribavirin(\> 75kg:1200 mg, \<75kg:1000mg daily)48 weeks
223673383|NCT01655966|DRUG|pegylated interferon + ribavirin|pegylated interferon 160ug once weekly Ribavirin (\> 75kg:1200 mg, \<75kg:1000mg daily)48 weeks
223673384|NCT03873857|DRUG|Venetoclax|tablet;oral
223673385|NCT05206877|DRUG|Insulin, 4 units|Topical insulin 100 U/ml, 1 drop per day
223673386|NCT05206877|DRUG|Insulin, 20 units|Topical insulin 500 U/ml, 1 drop per day
223673387|NCT05206877|DRUG|insulin, 4 units twice daily|1 drop of low dose insulin twice daily.
223673388|NCT05206877|DRUG|insulin, 20 units twice daily|1 drop of high dose insulin twice daily
223673389|NCT05206877|DRUG|insulin, 4 units three times daily|1 drop of low dose insulin three times daily.
223673390|NCT05206877|DRUG|insulin, 20 units three times daily|1 drop of high dose insulin three times daily.
223673391|NCT03550859|DRUG|Telmisartan/Rosuvastatin 40/10mg|Telmisartan/Rosuvastatin 40/10mg qd for 48 weeks
223673392|NCT03550859|DRUG|Telmisartan 40mg|Telmisartan 40mg qd for 48 weeks
223673393|NCT06171932|DRUG|Methylprednisolone,|No intervention required
223772333|NCT03991195|DIETARY_SUPPLEMENT|Placebo|In this project, taking the method of random, double blindness and control, the placebo group with aMCI will take placebo for three months. After that, cognitive changes will be test.
223772334|NCT01060384|DRUG|Lenalidomide|"Dose Cohort -1\^ 10mg daily on Days 1-21 every 28 days~Dose Cohort +1\^\^ 15mg daily on Days 1-21, every 28 days~Dose Cohort +2 20 mg daily on Days 1-21, every 28 days~Dose Cohort #3 25 mg daily on Days 1-21, every 28 days~\^Used only if Dose Cohort +1 requires further reduction~\^\^Starting Dose Cohort in Phase I"
223772335|NCT01060384|DRUG|ofatumumab|8 weekly infusions of ofatumumab 1000mg.
223772336|NCT03147105|BEHAVIORAL|arm ergometry|home based arm ergometry, at least 4-5 sessions/week for 12 weeks
224322252|NCT06124937|DRUG|Empagliflozin 10 MG|The intervention group will receive a 10 mg tablet of empagliflozin once a day from 3 days before surgery until discharge from the hospital.
224253893|NCT04559503|OTHER|Progressive relaxation exercises|Progressive relaxation exercises are those involving the voluntary, regular and consecutive relaxation of the muscles until there is relaxation all over the body. PMR are consisted of taking a deep breath and then tensing and relaxing muscles in both hands and arms, shoulders, chest, abdomen, hips, legs, feet, and face regions. The training was given in line with the CD that was prepared by the Turkish Psychologists Association as three-part relaxation exercises. The first part of the CD contains the definition, purpose and applications to consider when doing the exercises and a definition of 10-minute deep relaxation. In the second 30-minute section, relaxation exercises are explained accompanied by the sound of streams and oral instructions. The last section, which consists of 30 minutes, contains only relaxation music without instructions.
224253894|NCT03532035|DRUG|Brincidofovir|Subjects will receive BCV administered as a continuous IV infusion over 2 hours twice weekly (on Days 1, 4, 8, and 11) for a period of 2 weeks (total of 4 doses).
224253895|NCT03532035|DRUG|Standard of Care|"Subjects randomized to the SoC in each cohort will be managed per local institutional guidelines and investigator judgement. SoC treatment options may include, but are not limited to, taking a watch and-wait approach, with or without decreased immunosuppression (i.e., no active treatment), or treatment with IV CDV, ganciclovir, or ribavirin."
224253896|NCT02651948|PROCEDURE|Transperineal, MRI-guided, prostate biopsy|
224253897|NCT02651948|PROCEDURE|Transrectal prostate biopsy (TRB):|
224253898|NCT00387686|DRUG|rhBMP-2/CPM|
224253899|NCT00387686|DRUG|rhBMP-2/CPM|
224253900|NCT00387686|DRUG|rhBMP-2/CPM|
223673394|NCT04385329|OTHER|Shock wave therapy on plantar fascia extended to the gastrocnemius-soleus trigger points|Enrolled subjects were treated with focused shock wave therapy, once a week for three consecutive weeks, by a specialized physician with more than five years of expertise, using a device powered by a piezoelectric generator (PIEZOSON 100PLUS, Richard Wolf®). At each treatment session, with the patients lying in prone decubitus position, the enthesis of the plantar fascia and the gastrocnemius-soleus trigger points were clinically targeted and treated with a perpendicular technique.
223673395|NCT04385329|OTHER|Shock wave therapy on plantar fascia only|Enrolled subjects were treated with focused shock wave therapy, once a week for three consecutive weeks, by a specialized physician with more than five years of expertise, using a device powered by a piezoelectric generator (PIEZOSON 100PLUS, Richard Wolf®). At each treatment session, with the patients lying in prone decubitus position, the enthesis of the plantar fascia was clinically targeted and treated with a perpendicular technique.
223673396|NCT00821444|DRUG|ziprasidone|40 mg capsule, single dose x 3
223673397|NCT00821444|DRUG|B16 Fasted|40 mg tablet, single dose X 3
223673398|NCT00821444|DRUG|B16 Fed|40 mg tablet, single dose X 3
224253901|NCT00387686|DRUG|rhBMP-2/CPM|
223673399|NCT01467635|DEVICE|Endobronchial ultrasound guided lymph node sampling|Patients with enlarged mediastinal or hilar lymph nodes have these sampled under endobronchial ultrasound guidance using either the EBUS-TBNA needle or the EBUS-TBNB biopsy forceps.
223673400|NCT00925938|DRUG|misoprostol|One vaginal insert containing 100, 200, 400, 800, 1200, 1600 mcg misoprostol administered intravaginally one time and remain in place for 18 - 24 hours prior to the hysteroscopy procedure. An adaptive design will be used to determine whether to escalate or reduce the dose, starting with MVPI 400 mcg.
223673401|NCT00925938|DRUG|placebo|placebo
224253902|NCT05084625|OTHER|Digitized support|Access to information about the disease, treatment, side effects and self-care
224253903|NCT05350917|DRUG|Tislelizumab|"Tislelizumab: 200 mg, d1, intravenous infusion (ivgtt) administration, 21 days as a cycle.~DisitamabVedotin : 2mg/kg, d1, intravenous drip (ivgtt) administration, 21 days as a cycle.~Pyrotinib maleate tablets: 320 mg each time, Qd, orally administered within 30 minutes after breakfast, 21 days as a cycle.~Continuous administration until disease progression, death, toxicity intolerance, withdrawal of informed consent, or other reasons specified in the protocol; for patients who still benefit after comprehensive evaluation after initial disease progression, the investigator may decide whether to continue the treatment with the experimental drug ."
224322253|NCT06124937|DRUG|Placebo|The comparator group will receive a matching placebo from 3 days before surgery until discharge from the hospital.
223673402|NCT05228847|DIETARY_SUPPLEMENT|Human milk-derived HMF|Fortification with human milk-derived product
223673403|NCT05228847|DIETARY_SUPPLEMENT|bovine milk-derived HMF|bovine milk-derived HMF
224253904|NCT05623735|OTHER|Instrument Assisted Soft Tissue Mobilization Group While Lying Prone|"1. Sliding movements in all directions at 30 - 60 degree angles will be made in the form of mobilizations of 45 seconds with instruments.~2. Mobilizations of 45 seconds will be made with instruments along the quarter circle line in all directions at 30 - 60 degree angles.~3. Starting with an angle of 60 degrees on the area to be treated, the movement of shifting towards an angle of 30 degrees will be made in all directions for 30 seconds.~4. The tissue will be mobilized for 30 consecutive seconds, starting from just caudal to your waist and drawing the letter J towards the cranial.~5. Sliding movements in all directions at 30 - 60 degree angles will be made with instruments in the form of mobilizations for 45 seconds.~6. Mobilizations of 45 seconds will be made with instruments along the quarter circle line in all directions at 30 - 60 degree angles.~7. 30 - 60 degree swipe movement shorter brushing style small movements will be done for 30 seconds."
224253905|NCT05623735|OTHER|Instrument Assisted Soft Tissue Mobilization Group Combined with Functional Movement|"1. Sliding movements in all directions at 30 - 60 degree angles will be made in the form of mobilizations of 45 seconds with instruments.~2. Mobilizations of 45 seconds will be made with instruments along the quarter circle line in all directions at 30 - 60 degree angles.~3. Starting with an angle of 60 degrees on the area to be treated, the movement of shifting towards an angle of 30 degrees will be made in all directions for 30 seconds.~4. The tissue will be mobilized for 30 consecutive seconds, starting from just caudal to your waist and drawing the letter J towards the cranial.~5. Sliding movements in all directions at 30 - 60 degree angles will be made with instruments in the form of mobilizations for 45 seconds.~6. Mobilizations of 45 seconds will be made with instruments along the quarter circle line in all directions at 30 - 60 degree angles.~7. 30 - 60 degree swipe movement shorter brushing style small movements will be done for 30 seconds."
224253906|NCT05474079|OTHER|Moderate intensity exercise training|The exercise training program will consist of individually tailored, progressive moderate-intensity aerobic exercise. Exercise training will comprise of a combination of treadmill, cross-trainer and cycle ergometer-based exercise. Exercise will progressively increase in both intensity and duration throughout the course of the intervention. Participants will begin the intervention with 30 minutes of moderate-intensity aerobic exercise at 40% HRR three times per week for the initial 4 weeks. From week 4, exercise intensity will increase to 50% HRR, and at week 6 the duration of each session will increase to 45 minutes. From week 8, participants will exercise at an intensity of 60% HRR for 45 minutes, and from week 10, this will increase to five sessions per week.
224253907|NCT00307996|DRUG|Coenzyme Q10 (drug)|
224253908|NCT00104481|BEHAVIORAL|cognitive behavior therapy|
223673404|NCT03565367|OTHER|Gadolinium|gadolinium enhanced MRI
223673405|NCT03565367|DRUG|Hyperpolarized Carbon C 13 Pyruvate|Given IV
223673406|NCT03565367|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223673407|NCT03565367|PROCEDURE|Magnetic Resonance Spectroscopic Imaging|Undergo MRSI
223673408|NCT00782431|BIOLOGICAL|Vero cell derived, trivalent, seasonal influenza vaccine|Single intramuscular injection
223673409|NCT00782431|BIOLOGICAL|Licensed egg-derived, trivalent seasonal influenza vaccine|Single intramuscular injection
223673410|NCT02410915|DEVICE|Hybrid Assistive Limb (HAL); gait training|Training with HAL is performed in 1 session per day, 4 days per week during 4 weeks. Time for each session is individualised but does not exceed 60 minutes/session (effective time). Training with HAL is performed in combination with body-weight support system and on a treadmill. The training program is performed by 2 physiotherapists, who have been trained in the HAL method.
223673411|NCT02410915|OTHER|Control Group; Conventional gait training|Conventional gait training is individualized and performed according to current practice (approximately 30-60 minutes/session, 5 days a week) and may include standing, weight shifting, stepping, over ground walking with assistance and/or assistant devices as well as the use of a treadmill and body weight support. Conventional gait training is offered to both study groups.
223673412|NCT05061680|DEVICE|endoscopic short duration papillary large balloon dilation|During the large balloon papillary dilation investigators follow the cholangiogram and stop the dilatation as soon as the disappearance of the waist of the papilla is noticed.
223673413|NCT05479669|DIAGNOSTIC_TEST|Echocardiography|Transthoracic echocardiograms will be performed at inclusion. Echocardiographic parameters that will be evaluated are measures of atrial size (including left atrial volume, right atrial dimensions, left ventricular function and dimensions (including left ventricular dimensions, septal wall thickness, posterior wall thickness, systolic function, Simpson biplane left ventricular ejection fraction), parameters of diastolic dysfunction (including E, A, E/A ratio, deceleration time, E' and E/E' ratio) and valve (dys)function.
223673414|NCT05479669|DIAGNOSTIC_TEST|24 hour Holter monitoring|24-hours Holter monitoring will be used to determine markers of increased risk of ventricular arrhythmias, such as non-sustained ventricular tachycardias, and ventricular premature beats and doublets. Also the presence and pattern of AF and runs of supraventricular tachycardias are determined.
223673415|NCT05479669|DIAGNOSTIC_TEST|Cardiac Magnetic Resonance Imaging|Multiple short-axis cine images will be acquired throughout the entire LV with a steady-state free precession sequence. Left ventricular volumes, ejection fraction and myocardial mass will be measured on the short-axis stacks at end diastolic and end systolic frames. Ten to 15 minutes after an intravenous bolus injection of a gadolinium-based contrast agent late gadolinium enhancement will be performed with a segmented inversion recovery gradient-echo sequence, using the same image orientation as in the short-axis stacks. The presence, location and morphology of myocardial fibrosis will be described. The extent of myocardial scar will be quantified using computer-assisted planimetry and expressed as a percentage of left ventricular mass. Pre- and post-contrast T1 measurements will be obtained using a single-shot modified Look Locker inversion recovery sequence. Extracellular volume (a measure of diffuse myocardial fibrosis) will be quantified.
223673416|NCT05479669|DIAGNOSTIC_TEST|99mTc-HDP scan|Patients will receive a 99mTc-HDP scan. 3 hours after the technetium 99m-hydroxymethylene diphosphonate bolus injection, imaging will be performed using a gamma-camera equipped with a collimator which guides individual gamma-rays emitted by the radionuclide. For planar imaging, a collimator will be used to transfer only those gamma-rays which pas in a perpendicular course. Sequentially, a SPECT-CT will be performed in the same session to improve sensitivity. SPECT/CT will be performed on a SPECT/CT dual head gamma camera system. SPECT images will be acquired using a 128 x 128 matrix, 180 degrees of rotation, 64 views, 15s per view. Visual image analysis will be performed by two blinded and experienced nuclear medicine physicians. Data will be scored according to a routine scoring system on a scale from 0 (no cardiac uptake of 99m technetium and normal bone uptake) to 3 (high cardiac uptake, higher than bone uptake).
223673417|NCT05479669|DIAGNOSTIC_TEST|ECG|A 12-lead electrocardiogram will be performed at the 1-year and 2-year follow-up visit to determine the heart rhythm and heart rate.
223673418|NCT01634256|DIETARY_SUPPLEMENT|Placebo|Placebo(3.0g/day)
224253909|NCT05627128|OTHER|DAIN|Participants in the experimental arm will have access to the newly created DAIN curriculum including menus, recipes, and recorded 'how to' recipes. Participants in the experimental arm will also have once-per-week dietary counseling with DAIN-trained nutritionists and monthly cooking classes with a DAIN-trained chef.
224253910|NCT04387552|BEHAVIORAL|Prenatal Safe Sleep Mobile Health (mHealth) Messaging|Participants will receive prenatal Safe Sleep mHealth messaging starting at 34 weeks gestation until birth of their baby.
224253911|NCT04387552|BEHAVIORAL|Prenatal Breastfeeding Mobile Health (mHealth) Messaging|Participants will receive prenatal Breastfeeding mHealth messaging starting at 34 weeks gestation until birth of their baby.
224253912|NCT04387552|BEHAVIORAL|Postnatal Safe Sleep Mobile Health (mHealth) Messaging|Upon birth of baby, participants will begin receiving postnatal Safe Sleep mHealth messaging for a two month period.
224253913|NCT04387552|BEHAVIORAL|Postnatal Breastfeeding Mobile Health (mHealth) Messaging|Upon birth of baby, participants will begin receiving postnatal Breastfeeding mHealth messaging for a two month period.
224253914|NCT01215279|DRUG|AZD2423|100 mg oral treatment once daily for 28 days
224253915|NCT01215279|DRUG|Placebo to AZD2423|Oral treatment once daily for 28 days
224253916|NCT06150807|DEVICE|ultrasound and doppler|Ultrasound examinations of the liver and spleen including color Doppler imaging of the portal veins, hepatic veins, splenic vein, and superior mesenteric vein will done in the Department of Pediatric
224253917|NCT01724515|OTHER|Lipid infusion and muscle biopsies|Subjects will undergo a baseline muscle biopsy, a lipid infusion for 5 hours (60 ml/hr), and a muscle biopsy after the lipid infusion.
224253918|NCT00274781|DRUG|arsenic trioxide|Arsenic trioxide will be administered at a dose of 0.25 mg/kg/day IV over 1-2 hours for 5 consecutive days during the first week. Subsequently, arsenic trioxide will be given at a dose of 0.25mg/kg/day twice a week for 11 additional weeks (weeks 2-12).
224253919|NCT00274781|DRUG|gemtuzumab ozogamicin|Gemtuzumab ozogamicin consists of a 2 hr infusion at a dose of 3mg/m2 on day 8 of each 12-week cycle. Gemtuzumab ozogamicin should be administered at a minimum of one hour after the completion of the arsenic trioxide infusion
224253920|NCT03510923|OTHER|Inspection and palpation of the appendix|The removed appendix will be evaluated for tumours by the operating surgeon by visual inspection and digital palpation of the specimen. The appendix will not be opened. The surgeon will report his or her findings on a predefined scoring form: he or she will report all abnormalities and writes down whether he or she considers there is an indication for histopathological examination. Subsequently, all specimens will be sent for histopathological examination. Histopathological examination will be conducted according to the local protocol. In case of a neoplasm of the appendix, the treatment strategy is discussed and decided by the local multidisciplinary team. If an additional more extensive resection is decided to be appropriate, the specimens of the re-resection will be evaluated for the presence of remaining tumour tissue.
224253921|NCT03510923|OTHER|Inspection and palpation of the gallbladder|The removed gallbladder will be evaluated for tumours by the operating surgeon by visual inspection and digital palpation of the specimen. The gallbladder is opened in its length, without cutting the cystic duct, and is inspected and palpated. The surgeon will report his or her findings on a predefined scoring form: he or she will report all abnormalities and writes down whether he or she considers there is an indication for histopathological examination. Subsequently, all specimens will be sent for histopathological examination. Histopathological examination will be conducted according to the local protocol. In case of a neoplasm of the gallbladder, the treatment strategy is discussed and decided by the local multidisciplinary team. If an additional more extensive resection is decided to be appropriate, the specimens of the re-resection will be evaluated for the presence of remaining tumour tissue.
224253922|NCT03264339|BEHAVIORAL|Small Step Program|The Small Step intervention program has three alternating treatment foci (Hand use, Mobility, Communication) divided into five different steps, each lasting for 6 weeks (in total 30 weeks).
224253923|NCT03641079|DRUG|Brinjal peel extract containing cream|Brinjal peel extract, white wax, white petrolatum, stearyl alcohol
224253924|NCT04638647|BIOLOGICAL|Secukinumab s.c. injection|Secukinumab pre-filled syringes (PFS) for s.c. injection
224253925|NCT05610306|OTHER|Qualitative interview|Qualitative interviews to gain insight into the impact of ichthyosis on the biological, psychological, and social quality of life in adult and elderly patients.
224253926|NCT06449027|DRUG|T Leuprolide Injectable Emulsion|Arm 1 subjects were injected Leuprolide Injectable Emulsion 42mg every 24 weeks for 48 weeks, and taked Tamoxifen Citrate Tablets 10mg bid for 48 weeks.
224253927|NCT06449027|DRUG|Leuprorelin Acetate Microspheres for Injection|Arm 2 subjects were injected Leuprorelin Acetate Microspheres for Injection 11.25mg every 12 weeks for 48 weeks, and taked Tamoxifen Citrate Tablets 10mg bid for 48 weeks.
224253928|NCT06551454|DEVICE|Smart Textile Solution Biofeedback Method|The Smart Textile Solution Biofeedback Method for injury prevention in youth league football players integrates sensors within socks to monitor key biomechanical indicators such as center of pressure and plantar pressure of the foot in real-time. By providing immediate feedback and alerts on potential injury risks, the system helps players adjust their techniques during training sessions and prevent injuries during training and games.
223673419|NCT01634256|DIETARY_SUPPLEMENT|Fermented turmeric|Fermented turmeric(3.0g/day)
223673420|NCT05985564|OTHER|imaging diagnosis|no intervention
223673421|NCT04991818|OTHER|OneBiome microbiome profiling service|participants will be asked to complete the user experience of the OneBiome service
223673422|NCT02057042|BEHAVIORAL|Peer-assisted computerized CBT|Patients in the PS-cCBT intervention will receive usual depression care and will also receive: 1) access to Beating the Blues (BTB), an online cCBT program, 2) support of a peer specialists for 12 weeks, 3) a copy of the Depression Helpbook by Wayne Katon and colleagues
223673423|NCT02057042|BEHAVIORAL|Enhanced usual care|Patients randomized to EUC will receive the following enhancements: 1) patient education regarding the symptoms of depression and evidence-based depression treatments, 2) a copy of the Depression Helpbook by Wayne Katon and colleagues 3) information about how to access local VA mental health depression treatment resources (groups, individual psychotherapy, etc), and 4) bi-weekly study mailings with depression management tips.
223673424|NCT02489929|OTHER|blood samples|This clinical study aims at correlating the values in CDA levels with the risk of drug-related toxicities and to the clinical response to azacytidine treatment for patient suffering of MDS or Myeloid leukemia
223673425|NCT02489929|DRUG|azacytidine|
223673426|NCT04729400|DEVICE|Vacuum Myofascial Therapy device|Therapeutic Percutaneous Electrolysis and Vacuum Myofascial Therapy device once week for four weeks associated with eccentric exercises devices at home.
223673427|NCT04729400|OTHER|physical therapy program|The multimodal physical therapy program includes 10 sessions of ultrasound pulsatil therapy (US) and massage associated with eccentric exercises devices at home.
223673428|NCT04729400|PROCEDURE|Therapeutic Percutaneous Electrolysis|Therapeutic Percutaneous Electrolysis
223673429|NCT04729400|PROCEDURE|ultrasound pulsatil therapy (US) and massage|ultrasound pulsatil therapy (US) and massage
223772337|NCT06571214|DRUG|Recombinant Human Follitropin Alfa Solution for Injection (Gonal-f®)|As a r-hFSH agent, Gonal-f® is used for COS. It is a prefilled ready to use pen device containing follitropin alfa for injection and is designed for subcutaneous self-administration by patients undergoing COS for ART. It is available as dose presentations of 150 IU and 450 IU. The investigators and/or his/her delegate/s will explain the use of Gonal-f® prefilled pen. Gonal-f® will be prescribed by the investigator based on clinical diagnosis and treatment routines, and will not be provided free of charge.
224253929|NCT03181256|PROCEDURE|Biospecimen Collection|Undergo collection of sputum
224253930|NCT03181256|PROCEDURE|Biospecimen collection|Undergo collection of nasal epithelium
224253931|NCT03181256|PROCEDURE|Biospecimen collection|Undergo collection of buccal epithelium
224253932|NCT03181256|PROCEDURE|Biospecimen collection|Undergo collection of blood
224253933|NCT03181256|PROCEDURE|Biospecimen collection|Undergo collection of urine
224253934|NCT03181256|PROCEDURE|Pulmonary Function Test|Undergo pulmonary function test
224253935|NCT03181256|PROCEDURE|Computed Tomography (CT)|Undergo chest CT
224253936|NCT03181256|OTHER|Laboratory Biomarker|Correlative studies
224253937|NCT05106296|DRUG|Ibrutinib|Ibrutinib will be taken by mouth once daily, on days 1-21 of each treatment cycle.
223673430|NCT00874614|RADIATION|Ultratrace® Iobenguane I131|Each subject will be administered 3 mCi to 6 mCi Ultratrace® Iobenguane I 131, referred to as the Imaging Dose, to confirm that subject meets radiological entry criteria and to establish dosimetry. All subjects meeting entry criteria will then receive the investigational product referred to as the Therapeutic Dose (500 mCi or 8 mCi/kg if the subject weighs 62.5 kg or less) of Ultratrace Iobenguane I 131, followed by imaging at 7 days post infusion or upon discharge from isolation. The Therapeutic Doses will be adjusted equally if warranted by results of the dosimetry evaluation. At least 3 months later, subjects will receive the second Therapeutic Dose.
223673431|NCT02523469|BIOLOGICAL|ALT-803|
223673432|NCT02523469|BIOLOGICAL|Nivolumab|
223673433|NCT06213675|BEHAVIORAL|Routine rehabilitation treatment|"Routine rehabilitation treatment Includes oral rehabilitation, rehabilitation training for temporomandibular disorders, orthodontic treatment, and other physical therapy methods.which can alleviate symptoms by adjusting the bite, relaxing muscles, and increasing the range of motion of the temporomandibular joint.~Besides, it also Includes temporomandibular joint exercise training, relaxation training for facial muscles, and functional chewing training aimed at improving temporomandibular joint function and muscle balance."
223673434|NCT06213675|PROCEDURE|Intra-articular Injection|The patient is positioned to maximize mouth opening, and a needle is inserted approximately 10-12 mm in front of the tragus after touching the ankle prominence. An 8# injection needle is chosen and inserted upward and slightly forward into the joint cavity. A total of 2 mL of lidocaine hydrochloride injection solution is injected, repeated once every 5 days for a total of 15 days.
223673435|NCT03699475|BIOLOGICAL|rivogenlecleucel|Biological: T cells transduced with caspase 9 safety switch
223673436|NCT03699475|DRUG|rimiducid|administered to inactivate rivogenlecleucel in the event of GVHD
224253938|NCT05106296|DRUG|Indoximod|Indoximod will be taken by mouth twice daily, throughout each treatment cycle.
224253939|NCT05106296|DRUG|Cyclophosphamide|Cyclophosphamide will be taken by mouth once daily, on days 1-21 of each treatment cycle.
224253940|NCT05106296|DRUG|Etoposide|Etoposide will be taken by mouth once daily, on days 1-21 of each treatment cycle.
224253941|NCT02361983|DEVICE|Double lumen tube|Patients managed with a double lumen tube for one lung ventilation
224253942|NCT02361983|DEVICE|Bronchial blocker|Patients managed with a bronchial blocker for one lung ventilation
224253943|NCT06272487|DRUG|Zilebesiran|Zilebesiran administered by subcutaneous (SC) injection
224253944|NCT06272487|DRUG|Placebo|Placebo administered by SC injection
224253945|NCT03583710|DRUG|Cisplatin|Given IV
223673437|NCT03699475|DRUG|Cyclophosphamide|GVHD prophylaxis
223673438|NCT03699475|PROCEDURE|haplo-HSCT|treatment for disease
223673439|NCT01003314|BIOLOGICAL|AdCh63-MSP1 (lower dose) vaccine and MVA-MSP1 vaccine|Group 1A: single dose of AdCh63-MSP1 vaccine 5 x 10\^9 vp administered IM. Group 1B: single dose of AdCh63-MSP1 vaccine 5 x 10\^9 vp administered IM followed by a single dose of MVA-MSP1 vaccine 5 x 10\^8 vp administered IM 8 weeks later
223772338|NCT06571214|DRUG|Recombinant Human Lutropin alfa for Injection (r-hLH, Luveris®)|This product is a white freeze-dried powder and a colorless and clear injection solvent, and stored away from light under 25℃ in the original packaging. Luveris® will be provided free of charge.
223772339|NCT02002767|DRUG|Velpatasvir|Velpatasvir 100 mg (2 x 50 mg tablets) administered orally
224253946|NCT03583710|DRUG|Etoposide|Given IV
224253947|NCT03583710|DRUG|Mitotane|Given PO
224253948|NCT03583710|OTHER|Quality-of-Life Assessment|Ancillary studies
224253949|NCT06178159|DRUG|Disitamab Vedotin Injection|2.0mg/kg, intravenous infusion，D1, every 2 weeks, Every 6 weeks is a treatment cycle. A total of 3 cycles (18 weeks) of treatment are performed.
224253950|NCT06178159|DRUG|Pertuzumab Injection|Initial dose 840mg, after 2nd dose 420mg intravenous infusion， every 3 weeks
224253951|NCT06178159|DRUG|Toripalimab|3.0 mg/kg, intravenous infusion, D1, every 2 weeks
224253952|NCT05126277|DRUG|ianalumab s.c. q4w|ianalumab s.c. q4w in addition to SoC
224253953|NCT05126277|DRUG|ianalumab s.c. q12w|ianalumab s.c. q12w in addition to SoC
224253954|NCT05126277|DRUG|placebo s.c.|placebo s.c. q4w in addition to SoC
224253955|NCT05707247|DEVICE|software|"The experimental medical device is a prototype software. It is a patient interface.~The device comes in the form of a smartphone with a touch screen"
224253956|NCT06489028|DRUG|allo-APZ2-CVU|Allogeneic dermal ABCB5-positive Mesenchymal Stromal Cells (ABCB5+ MSCs)
224253957|NCT06489028|DRUG|Placebo|Placebo
224253958|NCT01726205|DRUG|Pregabalin and normal saline infusion, PRG|
224253959|NCT01726205|DRUG|Pregabalin and ropivacaine 02% infusion|
224253960|NCT01726205|DRUG|Placebo drug, normal saline infusion|
224253961|NCT03748966|DRUG|Calcitriol|Adults and children (age 3-17) with X-linked hypophosphatemia will be treated with calcitriol therapy without phosphate supplementation. Doses of calcitriol will be escalated and optimized in the first three months of the study. Calcitriol is an oral medication taken once a day.
224253962|NCT05789758|OTHER|No Intervention|Administered as specified in the treatment arm.
224253963|NCT04247282|DRUG|M7824|M7824 (1200 mg) will be administered intravenously on day 1 and 15 to patients enrolled in arm 1-3 (all three arms).
224253964|NCT04247282|DRUG|N803|N-803 (15 mcg/kg, subcutaneously) will be given on day 1 to patients enrolled in arm 3.
224253965|NCT04247282|BIOLOGICAL|TriAd vaccine|TriAd vaccine (5 x 10e(11) viral particles (VP); subcutaneous injection) will be given on day 1 to patients enrolled in arm 2 and arm 3
224253966|NCT00352820|BEHAVIORAL|Interview|Recorded face-to-face session.
224253967|NCT00352820|BEHAVIORAL|Questionnaire|Written survey lasting approximately 30 minutes.
224253968|NCT05478395|OTHER|Questionnaires set|Participants will be asked to respond to the demographic information，the Depression Anxiety Stress Scale（DASS-21）and the Internet Addiction Test（IAT）.
224253969|NCT00485771|DRUG|Olanzapine|
224253970|NCT00485771|DRUG|Fluoxetine|
224253971|NCT00485771|DRUG|Lamotrigine|
224253972|NCT01196260|DRUG|Capecitabine and Oxaliplatin|Capecitabine and Oxaliplatin will be under the NSCLC guideline
224253973|NCT01922765|DRUG|amoxicillin, clarithromycin, metronidazole, rabeprazole|
224253974|NCT00054873|DRUG|tezacitabine|
224253975|NCT00054873|DRUG|5-fluorouracil|
223673440|NCT01003314|BIOLOGICAL|AdCh63-MSP1 vaccine (higher dose) and MVA-MSP1 vaccine followed by challenge|Group 2A: single dose of AdCh63-MSP1 vaccine 5 x 10\^10 vp administered IM. Group 2B: single dose of AdCh63-MSP1 vaccine 5 x 10\^10 vp administered IM followed by a single dose of MVA-MSP1 vaccine 5 x 10\^8 vp administered IM 8 weeks later. Group 2C: single dose of AdCh63-MSP1 vaccine 5 x 10\^10 vp administered IM followed by a single dose of MVA-MSP1 vaccine 5 x 10\^8 vp administered IM 8 weeks later and subsequent sporozoite malaria challenge 12-28 days post second vaccination
223673441|NCT03466515|PROCEDURE|stem cells injection|two surgical interventions as day-surgery, starting with liposuction from the abdomen (about 200-300 ml), and fistula tract debridement and closure of internal opening. The external opening is excised. About 30-40 ml fresh harvested patients own fatty tissue are then injected with large needle around the fistula from internal til external opening.The resting harvested fatty tissue will be sent to stem cells (Adipose Derived Regenrative Cells ADRCs) isolation, using Cytori Celusion system®. When the stem cells isolation is completed, 4ml concentrated stem cells ( contains around 20-40 millions cells ) will be injected around the prepared fistula tract, the same site where the fresh harvested fatty tissue injected before.
223673442|NCT05198375|DIAGNOSTIC_TEST|Lung ultrasound score (LUS)|LU score (LUS) will be performed between 1 and 3 hours of life. LUS will be calculated by performing longitudinal scans of the chest in the anterior (midclavicular line), lateral (anterior axillary line) and posterior (posterior axillary line) area bilaterally using high-frequency linear or micro linear (hockey stick) probe. A score from 0 to 3 will be assigned to each area based on the ultrasound detected pattern.
223673443|NCT00137839|DRUG|Erlotinib|
223673444|NCT02788877|DRUG|aflibercept|Aflibercept 2mg is injected into the vitreous cavity through the pars plana using 30 gauge needle-attached syringe.
223772340|NCT01866436|OTHER|Multimedia group|Participants are provided with unrestricted access to the online multimedia educational tools for self-directed study (during the study period)
223772341|NCT01866436|OTHER|Study Day Group|"Participants in the control arm of the study attend a conventional teaching Study Day involving a series of lectures on Open and Laparoscopic Anterior Resection"
223772342|NCT06094959|OTHER|Suicide Prevention Package|The implementation package consists of co-designed and culturally adapted suicide prevention elements including suicide crisis response planning, contact follow up phone calls, and healthcare provider support mechanisms to optimize implementation.
223772343|NCT00883389|DEVICE|Medical Alert Bracelet|Medical Alert Bracelet alerting health care providers to consider the patient's chronic kidney disease condition when planning care. It also provides a link to a website about safe kidney care (safekidneycare.org)
223772344|NCT00812929|DRUG|Placebo|The current study will include a placebo arm to allow for a valid evaluation of adverse events attributable to GSK2190915 versus those independent of GSK2190915.
224253976|NCT03949153|DRUG|Nivolumab 10 MG/ML Intravenous Solution [OPDIVO]|Single Nivolumab 240 mg infusion at D0
223673445|NCT00539760|DRUG|GSK1827771|GSK1827771 will be administered using injection via subcutaneous (SC) route.
223673446|NCT00539760|DRUG|Placebo|Placebo to GSK1827771 for Injection will be administered via SC route
223772345|NCT00812929|DRUG|GSK2190915|This study will assess FEV1 at various intervals following exercise challenge in subjects who have been administered a single dose of 10 mg, 50 mg, 100 mg, or 200 mg GSK2190915, compared to a placebo control.
223772346|NCT00020410|BIOLOGICAL|filgrastim|
223772347|NCT00020410|PROCEDURE|peripheral blood stem cell transplantation|
224253977|NCT03949153|PROCEDURE|Cryotherapy|Cryotherapy using interventional radiology of metastatic lymphadenopathy at D1
224253978|NCT03949153|DRUG|Ipilimumab Injection|In situ injection with ipilimumab at D2.
224253979|NCT06559423|DEVICE|non-ablative Er:YAG laser and high intensity Tesla magnetic stimulation (HITS)|Patients will initially undergo three monthly intravaginal treatments with the Er:YAG laser. Six weeks after the final laser treatment, patients will receive six sessions of magnetic stimulation. During these sessions, patients will sit on a specialized chair that generates a therapeutic magnetic field.
224253980|NCT01054898|BEHAVIORAL|advocacy intervention|A 12-week telephone social support and empowerment intervention consisting of empowerment training, scheduled weekly telephone calls, and 24-hour access to a hotline for abused women
224253981|NCT01054898|BEHAVIORAL|usual community services|standard care for abused women in the community
224253982|NCT05239832|BIOLOGICAL|Recombinant SARS-CoV-2 Fusion Protein Vaccine|The product should be a milky-white suspension for injection. For prevention of SARS-CoV-2 infection.
224253983|NCT01346007|BIOLOGICAL|7-valent pneumococcal conjugate vaccine|A 0,5 ml dose of 7-valent pneumococcal conjugate vaccine in both arms A 0,5 ml anamnestic dose of 7-valent pneumococcal conjugate vaccine in subjects with idiopathic nephrotic syndrome 12 months after priming
224253984|NCT05431127|DEVICE|IMT therapy using the Pr02 mobile device|Inspiratory Muscle Training using a device used to measure and increase respiratory strength and performance through resisted breathing exercises.
224253985|NCT02256293|BEHAVIORAL|Diabetes self-management group based on Acceptance and Commitment Therapy (ACT).|The group sessions will be lead by a clinician trained in Acceptance and Commitment Therapy and will meet at Duke Medical Center for 1 ½ hours once a week for a total of 8 weeks. During group sessions, participants will identify how avoidance of difficult thoughts and feelings about diabetes has interfered with diabetes management and learn alternative ways of coping with these experiences. The group sessions are intended to supplement regular medical treatment; thus it is important that subjects continue to have diabetes symptoms monitored by their current treatment provider.
224253986|NCT03472105|DIETARY_SUPPLEMENT|New Nordic Renal Diet|One week ingesting a phosphorus reduced diet containing a total of 850 mg of phosphorus/day compared to one week of a habitual diet
224253987|NCT01334632|PROCEDURE|Continuous interscalene block|The continuous interscalene block will be performed with ultrasound 30 minutes before the intervention.
224253988|NCT01334632|PROCEDURE|PCA morphine|Postoperative with iv self-administration of morphine
224253989|NCT04377009|DEVICE|Sleep Healthy Using the Internet (SHUTi)|Cognitive behavioral therapy delivered via internet-guided program customized for military service members
224253990|NCT04377009|OTHER|Education Control Program|Online portal designed to inform participants about healthy lifestyle activities and general insomnia information
224253991|NCT03884088|OTHER|Limits of Stability|Balance analysis is assessment method to estimate fall of risk and deterioration of postural control.
224253992|NCT02214615|DRUG|Carbamazepine|"Day 1: Take 200 mg twice a day. Day 2: Take 200 mg twice a day. Day 3: Take 200 mg twice a day. Day 4: Take 200 mg twice a day. Day 5: Take 400 mg twice a day. Day 6: Take 400 mg twice a day. Day 7: Take 400 mg twice a day. Day 8: Take 400 mg twice a day. Day 9: Take 600 mg twice a day. Day 10: Take 600 mg twice a day. Day 11: Take 600 mg twice a day. Day 12: Take 600 mg twice a day. Day 13: Take 800 mg capsules twice a day. Day 14: Take 800 mg twice a day. Day 15: 800 mg twice a day. Day 16: Take 800 mg twice a day.~Taper Down (After Visit 4 and 7) If maximal dose of 800 mg/day has been achieved, tapering down will take 9 days Taper down for 600 mg/day will take 6 days, and for 400 mg/day will take 3 days."
224253993|NCT02214615|DRUG|Placebo|
224253994|NCT02212847|OTHER|vestibular stimulation|
224253995|NCT04977739|DIAGNOSTIC_TEST|No intervention|No intervention
224253996|NCT06047977|BIOLOGICAL|Tumor Infiltrating Lymphocytes, Fludarabine, Cyclophosphamide, Interleukin-2|Lymphodepleting Chemotherapy with Fludarabine/Cyclophosphamide followed by TIL and Post-TIL Interleukin-2 (IL-2)
224253997|NCT03044587|DRUG|Arm NaI-IRI + 5-FU + Leucovorin (Arm A)|Nal-IRI (80 mg/m2 as a 1.5 hour infusion), 5-FU (2400 mg/m2 as 46 hour infusion) and Leucovorin (400 mg/m2 as 0.5 hour infusion) Cycle q2w
224253998|NCT03044587|DRUG|Arm Cisplatin + Gemcitabine (Arm B)|Cisplatin (25 mg/m2 as 1 hour infusion on D1, D8) and Gemcitabine (1000 mg/m2 as 0.5 hour infusion on D1, D8) Cycle q3w
224253999|NCT01392794|DRUG|YM060|oral, without water
224254000|NCT00476281|PROCEDURE|Urinary collect|
224254001|NCT00476281|PROCEDURE|Continuous Glucose Monitoring System (CGMS)|
224254002|NCT03379467|OTHER|SMS Reminder|A text message sent as a reminder for immunization on the registered phone number
223673447|NCT06506370|OTHER|nonsurgical periodontal treatment|The patients underwent treatment in accordance with the guidelines of the European Federation of Periodontology (EFP). Initially, patients were informed of their condition, educated on oral hygiene practices, and advised to cease detrimental habits such as smoking. Following this, supragingival cleaning was conducted using ultrasound, with manual subgingival instrumentation utilizing a reduced set of Gracey curettes for pockets exceeding 4 mm with persistent bleeding or greater than 6 mm.
223673448|NCT03725254|PROCEDURE|lymphadenectomy|The retroperitoneal lymphadenectomy includes all lymph, fat, and connective tissue in the retroperitoneal space.
224254003|NCT03379467|OTHER|Interactive Reminder|A text message sent as a reminder for immunization on the registered phone number which requires the receiver to respond back
224254004|NCT00382707|DEVICE|cortical magnetic stimulation provided by an eight-shaped coïl placed upon the skull.|
224254005|NCT05162222|DRUG|Danicamtiv|Specified dose on specified days
224254006|NCT05162222|DRUG|Itraconazole|Specified dose on specified days
223673449|NCT03725254|RADIATION|chemoradiotherapy|Radiation therapy is highly appropriate, based on the characteristics of the lesion and the surrounding critical organs, and select IMRT or stereotactic radiotherapy (SBRT).
223673450|NCT06505967|DIETARY_SUPPLEMENT|Qualia NAD+|Qualia NAD+ is a novel dietary supplement, formulated to support the maintenance and enhancement of intracellular NAD levels.
223673451|NCT06505967|OTHER|Placebo|Rice flour
223673452|NCT03920904|OTHER|Collection of blood samples|Nine blood samples will be collected to determine bupivacaine pharmacokinetics at T10min, T20min, T30min, T45min, T60min, T90min, T120min, T180min, and T240min. T0 will be defined as the end of bupivacaine injection.
223673453|NCT01955798|PROCEDURE|Laparoscopic direct entry Trocar|Laparoscopic direct entry with trocar
223673454|NCT01955798|PROCEDURE|Laparoscopic entry Veress needle|Laparoscopic entry with Veress needle
223673455|NCT01955798|DEVICE|Trocar|
223673456|NCT01955798|DEVICE|Veress needle|
223673457|NCT03932006|DRUG|Fengshigutong Capsule plus Imrecoxib|Fengshigutong Capsule 1.2g twice a day,Imrecoxib 0.1g twice a day,orally
223772348|NCT00020410|RADIATION|yttrium Y 90 monoclonal antibody B3|
223772349|NCT02014961|PROCEDURE|Dermal biopsy|Skin biopsy
223772350|NCT02014961|BEHAVIORAL|Gastro-intestinal questionnaire|Pagi-Sym, Bristol Stool Chart, gastrointestinal symptom rating scale (GSRS)
223772351|NCT02014961|GENETIC|Whole-exome sequencing|Whole-exome sequencing (WES)
224254007|NCT05162222|DRUG|Diltiazem|Specified dose on specified days
224254008|NCT04560738|DRUG|[14C]-CC-92480|Oral
224254009|NCT02360761|PROCEDURE|VATS|Patients undergo lobectomy,wedge resection, or anatomical segmentectomy by thoracoscopic surgery or video assisted thoracoscopic surgery.
224254010|NCT02360761|PROCEDURE|Thoracotomy|Patients undergo lobectomy, wedge resection, or anatomic segmentectomy by thoracotomy.
224254011|NCT03174080|RADIATION|FDG (glucose labeled isotope of fluorine)|Patients will receive an intravenous injection of 2-5mCi of 18F-FDG prior to PET MRI
224254012|NCT05881525|BIOLOGICAL|TC-N201 cells|T cells genetically engineered with a TCR targeting NY-ESO-1 (NY-ESO-1 TCR) that displays specific reactivity against HLA-A2+, NY-ESO-1+ target cells.
224254013|NCT05881525|DRUG|IL-2|Following cell infusion, the patient receives intravenous IL-2. IL-2 improves the survival of TC-N201 cells after infusion.
224254014|NCT05881525|DRUG|Fludarabine|Part of the non-myeloablative lymphocyte-depleting preparative regimen.
224254015|NCT05881525|DRUG|Cyclophosphamide|Part of the non-myeloablative lymphocyte-depleting preparative regimen.
224254016|NCT05881525|DRUG|Nab-paclitaxel|Part of the non-myeloablative lymphocyte-depleting preparative regimen.
224254017|NCT03003091|OTHER|Needs-based patient education|
224254018|NCT03003091|OTHER|Traditional patient education|
224254019|NCT03950089|DEVICE|Optical Coherence Tomography Angiography (OCT-A)|Optical Coherence Tomography Angiography (OCT-A) images were acquired using an Spectral Domain Optical Coherence Tomography device (Cirrus High Definition OCT Model 5000 with Angioplex; Carl Zeiss Meditec, Dublin, California, USA). With an acquisition speed of 68,000 A-Scan per second, the OCT Microangiography Complex algorithm provided OCT-A information for three-dimensional (3D) flow reconstruction. At each visit, each subject underwent a 3 x 3 millimeter (mm) macular 3D cube acquisition in both eyes. FastTrac continuous eye tracking technology was employed to control for eye movements and minimize motion artefacts.
224254020|NCT02606825|OTHER|Registry of AML patients > 60 years|
224254021|NCT04138186|DEVICE|2.0g G-PUR®, oral administration|tid for 12 weeks
224254022|NCT04138186|DEVICE|Placebo, oral administration|tid for 12 weeks
224254023|NCT00118235|DRUG|cisplatin|Given IV
224254024|NCT00118235|DRUG|irinotecan hydrochloride|Given IV
224254025|NCT00118235|BIOLOGICAL|bevacizumab|Given IV
224254026|NCT00118235|OTHER|laboratory biomarker analysis|Correlative studies
224254027|NCT02955641|DRUG|Dexamethasone Disodium Phosphate 0.1%|four drops a day for four days after LPI treatment
224254028|NCT02955641|DRUG|Nepafenac 0.1%|four drops a day for four days after LPI treatment
224254029|NCT02955641|DRUG|Hydroxyethylcellulose 0.19%|four drops a day for four days after LPI treatment
223673458|NCT03932006|DRUG|Fengshigutong Capsule|Fengshigutong Capsule 1.2g twice a day,orally
223673459|NCT03932006|DRUG|Imrecoxib|Imrecoxib 0.1g twice a day,orally
224254030|NCT01004341|BEHAVIORAL|Family-based behavioral weight control intervention|Standard behavioral weight control program for children ages 8-12 years old and their parents in a family-based intervention.
224254031|NCT00968812|DRUG|Glimepiride|Glimepiride will be given orally (by mouth), as over-encapsulated tablets, starting at a dose of 1mg once daily and increasing to a maximum of 6 mg or 8 mg once daily for 104 weeks.
224254032|NCT00968812|DRUG|Canagliflozin (JNJ-28431754)|Canagliflozin (JNJ-28431754) will be given orally as over-encapsulated tablets, at a dose of 100 mg or 300 mg once daily for 104 weeks.
223673460|NCT00762593|DEVICE|transvaginal placebo device|Use of a transvaginal placebo home use programmable device used 30 minutes every day during 8 weeks
223673461|NCT00762593|DEVICE|transvaginal electrical stimulation device|Use of a transvaginal electrical stimulation home use programmable device used 30 minutes every day during 8 weeks
223673462|NCT01440543|PROCEDURE|Water immersion insertion AND CO2 insufflation|"* room temperature water infused by water pump into the colon just to facilitate scope insertion~* CO2 insufflation by CO2 insufflation system during colonoscope withdrawal and mucosal inspection"
223673463|NCT01440543|PROCEDURE|Water immersion insertion|"* room temperature water infused by water pump into the colon just to facilitate scope insertion~* standard room air insufflation during colonoscope withdrawal and mucosal inspection"
224254033|NCT00968812|DRUG|Metformin|Metformin will be given orally at the protocol-specified dose for 104 weeks.
224254034|NCT04329728|DRUG|AVM0703|Intravenous infusion over \~1 hours
224254035|NCT04487691|BIOLOGICAL|Nebulized Platelet Lysate|Approximately 520 cc of autologous venous blood (within AABB guideline limits) will be drawn and platelet lysate (PL), maximizing the patients baseline platelet levels (\~2-4x baseline) will be produced in a clean room setting using the Regenexx, LLC proprietary lab protocols (PL-M) utilizing a double lysis technique. From that sample, a high growth factor lysate will be created using a double lysis technique, and a sample will be retained to quantify the protein profile of the PL via ELISA quantitative analysis. The PL will be aliquoted into 56 (n=28x2) 2-ml ampules using sterile technique which will then be frozen at -20°C. The patient will unfreeze each ampule and place it into a handheld ultrasonic nebulizer and inhale the platelet lysate following the nebulizer manufacture's protocol until the treatment is completed. The treatment will be applied once a day for 8-weeks.
224254036|NCT04487691|OTHER|Nebulized Sterile Saline|Approximately 520 cc of autologous venous blood (within AABB guideline limits) will be drawn and donated for research purposes to keep patient blinded to group allocation. Sterile normal saline to mimic the appearance of the platelet lysate will be aliquoted into 56 (n=28x2) 2-ml ampules using sterile technique which will then be frozen at -20°C. The patient will unfreeze each ampule and place it into a handheld ultrasonic nebulizer and inhale the sterile saline following the nebulizer manufacture's protocol until the treatment is completed. The treatment will be applied once a day for 8-weeks.
224254037|NCT00434265|BEHAVIORAL|Physical training|
224254038|NCT02348463|DRUG|Clindamycin-2-phosphate|how many women will deliver before the 37th week of gestation
224254039|NCT01471886|DRUG|Ketorolac Tromethamine|Every 8 hours for 4 days.
224254040|NCT01471886|DRUG|Naproxen|Every 8 hours for 4 days.
224254041|NCT03266263|DEVICE|automatic computer-led feedback|automated feedback software for CPR quality, including compression depth, rate, recoil, hands-off time, and ventilation volume
224254042|NCT03266263|OTHER|instructor-led feedback|feedback for CPR quality by instructors
224254043|NCT00988663|DRUG|memantine|patient will receive 5mg daily for 7day then 10 mgm daily
224254044|NCT00988663|DRUG|Placebo|will give placebo that looks like memantine
224254045|NCT05287763|PROCEDURE|Palatal soft tissue graft harvesting|After local anaesthesia, a horizontal incision 2 mm apically from the gingival margin will be carried out using a #15C blade. The standardized rectangular graft with a thickness of 1.5 mm will be harvested from distal aspect of canine till first molar. The graft will be lifted and separated using tissue forceps and a blade till it is free from all sides.
223673464|NCT01440543|PROCEDURE|CO2 insufflation|\- CO2 insufflation by CO2 insufflation system during both colonoscope insertion and withdrawal
223673465|NCT06370078|DRUG|Albumin Human|To investigate the effect of early administration of albumin in the ICU after onset of septic shock compared to volume replacement therapy without albumin on patient outcome.
223673466|NCT02882152|PROCEDURE|femoral nerve blockade|"femoral nerve blockade followed by a catheter placement for continuous infusion and a single shot block of the sciatic nerve at the end of the surgery"
224254046|NCT02288221|OTHER|Patient's answer with non pharmacological therapeutic|"Installation at patient's home of :~* aromatherapy~* music therapy~* cognitive training in multimedia application offering cognitive games"
224254047|NCT02288221|OTHER|Patient's answer without non pharmacological therapeutic|No installation at patient's home
224254048|NCT04705714|DRUG|Frankincense Extract|The phytochemical composition of the volatile components of the extract was identified by GC-MS analysis, Crystal violet assay to test inhibition of biofilm formation by the tested isolates,Light microscope and scanning electron microscope were used to examine the biofilms and they confirmed the reduction of biofilm formation by frankincense extract
224254049|NCT04645914|BEHAVIORAL|Use of nicotine product (smoking/vaping)|The smokers/vapers are consuming during the study one nicotine product of their own. The dose is the same as each individual is consuming regularly
223673467|NCT02882152|PROCEDURE|morphine|Intrathecal morphine injection
223673468|NCT04405232|OTHER|Non-interventional|Observational study
223673469|NCT05284032|DRUG|isatuximab 10 mg/kg|Given by intravenous infusion
223673470|NCT02133170|BEHAVIORAL|Mindfulness Based Cognitive Therapy (MBCT)|The MBCT program is conducted in HULP (BRV and CBP), which also train therapists from Vitoria, in order to homogenize the intervention. Random sessions are video or audio recorded to be discussed and analyzed by the treatment team. The manualized MBCT therapy consists of 8 weekly sessions of 90 minutes and is applied in groups of approximately 10-15 patients. At least two programs in H. La Paz and two in the hospital de Santiago (Vitoria) will be provided.
223673471|NCT02133170|BEHAVIORAL|Psychoeducation|Psychoeducation program will be held in groups of 10 to 15 patients in 90-minute weekly sessions led by two therapists also outside the research team. The specific program of 8 sessions is focused addressing disease awareness, adherence to treatment and early detection of prodromal symptoms. Homework will also be included. The program is based on the Psychoeducation Manual for Bipolar Disorder . F.Colom , E.Vieta . Ars Medica, 2004. Attendance at least 80 % of the sessions of both interventions will be required to be considered complete.
223673472|NCT02133170|BEHAVIORAL|Standard treatment|Treatment as usual (TAU), including standard psychiatric care with psychopharmacological treatment.
223673473|NCT04507880|DEVICE|Reverse Total Shoulder Arthroplasty|The RTSA (GLOBAL UNITE Reverse Fracture System) from DePuy Synthes.
224254050|NCT03071666|DIETARY_SUPPLEMENT|cobalamin|Vitamin supplment tablet containing 50µg cobalamin
224254051|NCT03071666|DIETARY_SUPPLEMENT|placebo|A tablet identical to the vitamin supplement but containing no vitamin B12
224254052|NCT00275366|DEVICE|Robotic Therapy|
224254053|NCT03100084|OTHER|Blood sampling|Maternal blood sampling
224254054|NCT01149590|PROCEDURE|Computer Tomography Angiography|Computed Tomography Angiography
224254055|NCT05108779|DRUG|QLF32004|In the phase, five dose groups were proposed.The frequency of administration was once a week, and the treatment cycle was 3 weeks.
224254056|NCT00178802|OTHER|thermochemotherapy (with 5-fluorouracil/interferon-a/liposomal doxorubicin)|"5-fluorouracil 400 mg/m2 i.v. over 24 hours for 5 days~Doxil (liposomal doxorubicin) 40 mg/m2 over 1 hour~Fever-range whole-body thermal therapy to 40 oC (104 oF) for 6 hours duration daily~Low-dose interferon-alpha 100,000 i.u. s.c. daily for the duration of the protocol"
224254057|NCT02679703|DEVICE|High voltage|Electrical stimulation treatments will be made in donor areas (scalp and thigh) in patients burns
224254058|NCT02679703|DEVICE|Neuromuscular transcutaneous electrical stimulation (TENS)|Electrical stimulation treatments will be made in donor areas (scalp and thigh) in patients burns.
223673474|NCT04507880|DEVICE|Hemiarthroplasty|The shoulder hemiarthroplasty
223673475|NCT00410709|DRUG|NatrOVA Creme Rinse (1%)|
223673476|NCT00045474|PROCEDURE|adjuvant therapy|
223673477|NCT00045474|RADIATION|iodine I 125|
223673478|NCT00237510|DRUG|terazosin|
223673479|NCT03444532|BEHAVIORAL|12-week aerobic exercise and cognitive-behavioral therapy|12-week intervention of aerobic exercise training and four session of cognitive-behavioral therapy
223673480|NCT05974423|DRUG|Tylenol, Ibuprofen, and Oxycodone|A script for these three medications will be provided
223673481|NCT05974423|DRUG|Tylenol and Ibuprofen only|A script for only these two medications will be provided initially following surgery. Should the patient need stronger medication for adequate pain control, the on-call physician will provide a script for oxycodone
223673482|NCT03190044|DIETARY_SUPPLEMENT|PACR|Daily assumption of PACR for a 3-month period
223673483|NCT03190044|DIETARY_SUPPLEMENT|Placebo|Daily assumption of placebo
223673484|NCT00158821|DRUG|Viread (tenofovir disoproxil fumarate)|Tenofovir DF 300 mg tablets once daily
223673485|NCT00158821|DRUG|Sustiva (Efavirenz)|efavirenz capsules 600 mg once daily
223673486|NCT00158821|DRUG|Epivir (Lamivudine)|lamivudine 150 mg tablets twice daily
223673487|NCT00158821|DRUG|Zerit (Stavudine) Placebo|stavudine placebo capsules twice daily
223673488|NCT03874312|DIAGNOSTIC_TEST|Linear ultrasound (US) assessment of the internal jugular vein|Evaluation of jugular vein distensibility at rest and after Valsalva maneuver by US at the time of the RHC. US-guided IJV is routinely performed at the time of vein cannulation.
223772352|NCT06569342|PROCEDURE|Intradetrusor BoNT-A|For intravesical injections, BoNT-A (Allergan, Irvine, CA, USA) was diluted in 0.9% saline to 10 93 international units/ml. Multiple injections were distributed throughout the detrusor, using a 94 transurethral 23-gauge injection needle under rigid cystoscopic guidance (9.8 Fr paediatric 95 cystoscope) at 10 units/kg to a maximum of 300 units. All injections were performed under general 96 anaesthesia with antibiotic prophylaxis given intra-operative as single dose intravenously.
224254059|NCT02679703|OTHER|Control Group|The control group will not have electrical stimulation however, will be evaluated with digital digital imaging, thermography imaging, skin hardness and subjective pain and healing scales
224254060|NCT02732821|PROCEDURE|Gastric Per Oral Endoscopic Myotomy|Patients will receive Per Oral Endoscopic Gastric Myotomy for Gastroparesis.
223673489|NCT01917877|DRUG|Bevacizumab|Bevacizumab 7mg/kg iv on day1 and 21, followed by Dexamethasone 10mg iv d 1-10, then 5mg iv d11-15, 2.5mg iv d16-20
223673490|NCT01917877|DRUG|Dexamethasone|Dexamethasone 10mg iv d 1-10, then 5mg iv d11-15, 2.5mg iv d16-20
223673491|NCT04693143|OTHER|A randomized controlled open-label clinical trial.|This was a single-center; open-label randomized controlled trial performed at a Pediatric Intensive Care Unit (PICU) in tertiary care hospital
224254061|NCT05907733|DIAGNOSTIC_TEST|Genotyping.|5 ml biood withdrawen by venipuncture in EDTA tube DNA extraction will be done after centrifucation and used for quantatitive Real-time polymerase chain reaction.
224254062|NCT05864807|DEVICE|UCon|The participant self-administer electrical stimulation to the dorsal genital nerve (DGN) for 4 weeks using UCon
223673492|NCT02217774|DEVICE|MGUIDE MORE|MGUIDE MORE System (MGS), consisting of MGUIDE MORE software, MGUIDE MORE surgical kit and MGUIDE MORE template, will be used for planning, drilling and inserting dental implants.
223673493|NCT05720754|DRUG|Diquafosol tetrasodium|3% Diquafosol tetrasodium eye drops will be used to assess its usefulness in dry eye signs and symptoms
223673494|NCT05720754|DEVICE|Heated eye mask|Heated eye mask will be used to assess its usefulness in dry eye signs and symptoms
223673495|NCT04781920|OTHER|datas collection|data collection in history medical : operative report, clinical examination, questionnaires, imaging, isokinetic tests
223673496|NCT00942071|BIOLOGICAL|MVA-NP+M1|1\. Intradermal injection at 5 x 10\^7 pfu at day 0
223673497|NCT00942071|BIOLOGICAL|MVA-NP+M1|2.Intramuscular injection at 5 x 10\^7 pfu/ml at day 0. Intramuscular injection at 2.5 x 10\^8 pfu/ml at day 0
223673498|NCT00942071|BIOLOGICAL|MVA-NP+M1|3.Intramuscular injection at 1.5 x 10\^8 pfu/ml at day 0
223673499|NCT00338897|DRUG|SR123781A|
223673500|NCT05413577|BEHAVIORAL|Mindfulness training|The intervention recordings taught the basic concepts of mindfulness through simple guided meditations with content supported by science. Each recording had the same format that included (1) a daily theme, (2) a meditation exercise echoing the theme, (3) a suggested exercise for practice, and (4) an invitation for participants to give a short response to their meditation experience at the end of the recording.
223673501|NCT01035450|DEVICE|Everolimus-eluting stent|Everolimus-eluting stent
223673502|NCT01035450|DEVICE|Sirolimus-eluting stent|Sirolimus-eluting stent
223673503|NCT06114901|OTHER|SleepFix|SleepFix mobile application uses Sleep Retraining Therapy (SRT) which aims to reduce excess time spent in bed and reset sleep by matching time in bed (minimum of five and a half hours) to total sleep time (TST). There are four stages to the dBTi application and participants will progress based on completion of each stage. At the commencement of SleepFix application, participants enter sleep and bedtime data into the smartphone application for baseline referencing. These data are used to determine the sleep therapy based on a pre-determined algorithm that calculates optimum sleep efficiency.
224254063|NCT02774785|DEVICE|MarginProbe|Surgery to take place as per standard care. When the surgery is nearly concluded, patient to be randomised. If randomised to device arm, the MarginProbe device will be used on the outer edge of the tumour and shavings. If the MarginProbe device indicates that cancer is detected, a further shaving is to be taken. Surgery then to be concluded as per standard care.
224254064|NCT02107456|DEVICE|Dry Needling|Dry needling was performed for one week, three times a week.
224254065|NCT04527107|DRUG|THR-149 dose level 1|3 intravitreal injections of THR-149 dose level 1, 1 month apart
224254066|NCT04527107|DRUG|THR-149 dose level 2|3 intravitreal injections of THR-149 dose level 2, 1 month apart
224254067|NCT04527107|DRUG|THR-149 dose level 3|3 intravitreal injections of THR-149 dose level 3, 1 month apart
224254068|NCT04527107|DRUG|THR-149 0.13mg|3 intravitreal injections of THR-149 0.13mg (selected dose level), 1 month apart, followed after 1 month by a sham (pretend) injection
223673504|NCT06114901|OTHER|Sleep health Education modules|Three Sleep Health education modules that contain information about sleep hygiene and introduces strategies on how to reduce insomnia severity and increase sleep quality.
223673505|NCT02225613|OTHER|Usual protocol|
223673506|NCT02225613|OTHER|Spa protocol|
223673507|NCT00734760|BEHAVIORAL|education|face-to-face education and counseling intervention
223673508|NCT01411553|OTHER|Disposable ECG-LW|Disposable ECG leadwires used in ICU and telemetry monitoring; 5 lead sets for ICU and 6-lead sets for telemetry
223673509|NCT04615169|BEHAVIORAL|Multi-component cognitive intervention with simulated everyday tasks (MCI-SET)|"2 hours per session: consisted primarily of modified everyday cognitive tasks, which were adjusted for individuals and for the group by the group leader to provide an error-reduction learning environment. Each session consisted of: (1) Warm-up: a 15-30 minute dual task of motor-cognitive exercises that increase arousal level and provide cognitive stimulation. For example, at the beginning of the group, the members would sing a song, mimic dance movement of the group leader, and clap hands when specific words occur in the song.~(2) 30-minutes guided and repetitive practices of contextually-relevant simulated everyday cognitive tasks with one 15 to 20- minute break in between; Cognitive tasks addressed complex attention, visual scanning, auditory attention, visual and motor memory, auditory memory, prospective memory, executive functioning, problem solving, etc."
223673510|NCT04490330|OTHER|questionnaire|AUDIT questionnaire (alcohol use disorders identification test)
223673511|NCT05983783|DRUG|Docetaxel|This is Triple drug regimen for mHSPC
223673512|NCT05983783|DRUG|Rezvilutamide|This is doubling drug regimen for mHSPC
223673513|NCT02706223|OTHER|Pharmacist Led|Trial of administering established, licensed treatments by a novel pathway, ie Community Pharmacists, which is hypothesized to improve treatment and retention in treatment of difficult to engage subjects
223673514|NCT02706223|OTHER|Nurse led|Trial of administering established, licensed treatments by the conventional clinical care pathway, ie Specialist nurses
224254069|NCT04527107|DRUG|THR-149 0.13mg + aflibercept 2mg|3 intravitreal injections of THR-149 0.13mg (selected dose level), 1 month apart, followed after 1 month by an intravitreal injection of aflibercept 2mg
224254070|NCT04527107|DRUG|aflibercept 2mg + THR-149 0.13mg|3 intravitreal injections of aflibercept 2mg, 1 month apart, followed after 1 month by an intravitreal injection of THR-149 0.13mg (selected dose level)
224254071|NCT04527107|DRUG|Aflibercept 2mg|3 intravitreal injections of aflibercept 2mg, 1 month apart, followed after 1 month by a sham (pretend) injection
224254072|NCT02900209|OTHER|Influenza Vaccination|
224254073|NCT00448591|DRUG|bevacizumab [Avastin]|10mg/kg iv on day 1 of each 3 week cycle, or 15mg/kg iv on day 1 of each 2 week cycle
224254074|NCT00448591|DRUG|Taxane-based chemotherapy|As prescribed
224254075|NCT00835432|DEVICE|Ossix|Test group
224254076|NCT00835432|DEVICE|Biogide|controls
224254077|NCT03749252|DRUG|P03277|A dose of 0.05 mmol/kg body weight (0.1 mL/kg body weight) of P03277 will be administered to each patient in a single intravenous injection.
224254078|NCT00235352|DRUG|CX516 (Ampakine)|
224254079|NCT05657860|DRUG|Guanfacine Extended Release|Initial dose for all participants will be 1mg per day. If the medication is well tolerated, the dose can be raised to 2 mg until day 28 and increased to 3 mg for the remaining 4 weeks in the trial. The dose schedule will not be fixed., the treating clinician can delay a planned increase or lower the dose to manage adverse effects. At week 8 timepoint, the study will be unblinded.and subjects will continue treatment for 8 weeks.
224254080|NCT05657860|OTHER|Placebo|Placebo will be administered concurrently with GXR during trials.
224254081|NCT06274554|DRUG|Fluconazole|Oral fluconazole capsules.
224254082|NCT06274554|DRUG|Placebo|Oral placebo capsules will be used as a comparator.
224254083|NCT06274554|BIOLOGICAL|IL-23 Therapy|Risankizumab (IL-23), Guselkumab (IL-23), or Ustekinumab (IL-12/23) as standard of care treatment.
224254084|NCT04749888|BEHAVIORAL|Targeted nurse-led home visiting|The KECHI encompasses 25-29 home visits, group activities, and community service linkage by social workers from the prenatal period until the child reaches the age of 2 years; as such, it is a complex intervention involving various domains to address a wide range of outcomes. Pregnant women with two or more risk factors who are deemed to have difficulties in raising children are eligible for the targeted multiple nurse home visits. Each home visit is implemented based on families' needs, and individualized interventions are provided to improve parenting and the home environment in order to promote the child's health and development and maternal health. The program includes educational materials for parents, such as a booklet covering issues on prenatal care, child development, postnatal child care, parent-child attachment, play, communication, safety, and goal-setting.
224254085|NCT01915186|DIETARY_SUPPLEMENT|Dihydroepiandrosterone (DHEA)|DHEA capsules are given at 25mg 3 times a day for 12 weeks
224254086|NCT06027710|PROCEDURE|Extensive alveolar ridge augmentation with allogeneic bone blocks; dental implant insertion in allogeneic bone graft|Alveolar ridge augmentation procedure for extensive bone defect rehabilitation in the upper and/or lower jaw allogeneic bone blocks; dental implant insertion in allogeneic bone graft for oral rehabilitation after 6 month of healing
224254087|NCT04946864|DRUG|APG-2575|APG2575 monotherapy
224254088|NCT04946864|DRUG|Palbociclib|combination APG2575+pablociclib
224254089|NCT04261673|PROCEDURE|Decompressive Craniectomy|A large bone flap must be raised. The evacuation of epidural hematoma is depended on surgeon's preference. The bone flap should not be replaced at the end of the operation. DC has an advantage in controlling brain swelling, but patient is necessary to have another operation of cranioplasty to reconstruct the skull in the future.
223673515|NCT01111929|DRUG|Counseling for LAM+ LNG-EC|"They will be provided by the above proper LAM counseling and contraceptive counseling. Additionally, they will be provided by EC pills and advised to use these pills if one of the prerequisites of LAM expires and sexual relation with their husband had occurred before the initiation of another long term contraceptive. Each women in this group will be supplied with one packet containing two 0.75 mg Levonorgestrel EC pills and advised to swallow the two tablets as soon as possible after having sexual intercourse with their husband after the expiry of LAM. They will be informed that they should not use the method after more than 5 days of having intercourse.~They will be also advised not to use EC pills more than once. All women who have used the EC pills need to visit the clinic within few days of use for contraception advice. All the above information will be additionally given to the patient in a small flyer."
223673516|NCT01047098|DIETARY_SUPPLEMENT|Iron|Iron as iron sulfate
224254090|NCT04261673|PROCEDURE|Craniotomy|A large bone flap must be raised. The evacuation of epidural hematoma is depended on surgeon's preference. However, the bone flap must be replaced and fixed with fixation system (plates and screws). The patient will not need an additional operation to rebuild the skull in the future. But undisciplinable brain swelling and increased intracranial pressure may happen in some patients, and additional decompressive craniectomy is recommended in these cases.
223673517|NCT01047098|DIETARY_SUPPLEMENT|Iron|Iron as iron sulfate
223673518|NCT01047098|DIETARY_SUPPLEMENT|Placebo|Placebo capsule
223673519|NCT05602896|OTHER|Sepsis education|The education program has been reviewed and approved by BJH Center for Practice Excellence
223673520|NCT01514786|BEHAVIORAL|Colorectal Web|The intervention arm will allow participants on Colorectal Web to manipulate their preferences for CRCS
223673521|NCT03213314|DIAGNOSTIC_TEST|Multiparameter magnetic resonance imaging|LiverMultiScan before and after surgery to assess liver health prior to liver resection and in the regenerative phase.
224254091|NCT05943613|DRUG|Clonidine|compare the effect of intrathecal Clonidine and Neostigmine as adjuvants to Bupivacaine in elective cesarean section
224254092|NCT06447805|DEVICE|Double Sequential Defibrillation (DSD)|The second defibrillator will be applyed with electrodes placed in the A-P position
224254093|NCT06447805|DEVICE|Standard defibrillation|Standard defibrillation uning one defibrillator
224254094|NCT02648438|DRUG|AZD7594 Solution for infusion (150 μg intravenous formulation)|Solution for infusion 0.01 mg/ml; AZD7594 150 μg IV
224254095|NCT02648438|DRUG|AZD7594 Oral suspension (1200 μg oral formulation)|0.1 - 10 mg/g oral solution; AZD7594 1200 μg oral
224254096|NCT02648438|DRUG|AZD7594 Inhalation powder (400 μg) by DPI Device 1 (monodose inhaler)|Inhalation powder, hard capsules 400 μg Monodose inhaler; AZD7594 400 μg by dry powder inhaler (DPI) Device 1 (Monodose inhaler)
224254097|NCT02648438|DRUG|AZD7594 Inhalation powder (400 μg) by DPI device 2 (multiple-dose inhaler)|Inhalation powder, multiple-dose dry powder inhaler (DPI) 400 μg; AZD7594 400 μg by DPI Device 2 (multiple-dose DPI)
224254098|NCT02648438|DRUG|AZD7594 Pressurized inhalation suspension (400 μg) by pMDI|Inhalation suspension 200 μg; AZD7594 400 μg by pressurized metered-dose inhaler (pMDI); 2 puffs x 200 μg = 400 μg
223772353|NCT06572007|DIAGNOSTIC_TEST|Ultrasound|To investigate the thickness of the fascia tissue, the subjects will undergo an ultrasound examination using a clinical ultrasound system (S9, SonoScape Corporation, made in China) with a linear 5-14 MHz array of L14-5/38. The transducer with a cross-section of 6.24 cm2 will be aimed at points 2 cm lateral to the midline of the L2 and L3 vertebrae on both sides of the spine.
223772354|NCT02813031|OTHER|Functional meat products|
223772355|NCT02813031|OTHER|Traditional meat products|
224254099|NCT03282344|DRUG|NKTR-214|0.006mg/kg IV on day 1 and every 3 weeks thereafter will be an intravenous (IV) infusion administered over 30 (±5) minutes every 3 weeks.
224254100|NCT03282344|DRUG|Nivolumab|360mg (flat dose) IV infusion administered over 30 (±5) minutes every 3 weeks.
224254101|NCT04132362|BEHAVIORAL|Personalised music listening|People will be sequentially recruited to discover their favourite music playlist, monitor their emotional responses to specific songs and explore the impact of listening to the music, on their behavioural and psychological symptoms. This will be done through a one hour music listening session, to discover the top 10-20 songs they respond to. It will then be followed by multiple shorter music listening sessions, initiated by the dementia resident themselves or their carer, where they listen to their favourite songs during their day, before difficult moments of care or during visits with their families.
224254102|NCT04132362|BEHAVIORAL|Using fMRI to investigate the effect of listening to personalised music evoking positive emotional response on brain activation|12 of the recruited participants, who have symptoms and signs of mild to moderate dementia will be invited to take part in this sub-study. Using an amended version of a previously employed fMRI paradigm, each study participant will be presented inside the MRI scanner with short 30 second epochs of music (identified as evoking a positive or neutral emotional response) in a block design. Each 30 second epoch of music will be followed by a 16 second period when participants will be asked to rate subjective changes in their affective state using a computerised visual analogue scale. Epochs of positive emotional stimuli will alternate with epochs of neutral emotional stimuli in a counterbalanced order of presentation in 2 runs of 10 epochs each (5 positive and 5 neutral in each run).
224254103|NCT04132362|BEHAVIORAL|Personalised music listening in the community|1000 families affected by dementia will be invited to use our WebApp to create a personalised playlist for their loved one with dementia and share their perceptions of how the music has affected the well-being of their loved one.
224254104|NCT04604275|DRUG|Sucrase|1 mL (8,500 I.U.) (one full measuring scoop or 28 drops) per meal or snack for patients up to 15 kg in body weight. 2 mL (17,000 I.U.) for patients over 15kg in body weight. Dosage is 1 or 2 mL (8,500 to 17,000 I.U.) taken orally or by g-tube with each meal or snack diluted in water, milk, or infant formula.
224254105|NCT04604275|OTHER|Placebo|1 mL of placebo per meal or snack for patients up to 15 kg in body weight. 2 mL of placebo per meal of snack for patients above 15kg in body weight. Dosage is 1 or 2 mL of placebo taken orally or by g-tube with each meal or snack diluted in water, milk, or infant formula.
224254106|NCT04572022|OTHER|Step wise post-procedure mobile health shared rehabilitation teaching video instructions modules (as per fracture type)|Intervention group receive proximal humerus fracture standard care with additional mobile health shared step-wise rehabilitation teaching video instructions modules (as per fracture type). Classic Blue tooth technology will be utilized for teaching information sharing from doctor to the patient.
224254107|NCT05296967|BEHAVIORAL|chewing|patients are asked to chew chewing gum X 3/ day
224254108|NCT05615935|OTHER|Experiential HIV Testing|The content of experiential HIV Testing includes HIV testing, counselling, and education and discussion.
224254109|NCT05852262|DRUG|Cephalexin|1000 mg PO QID for 7 days
224254110|NCT05852262|DRUG|Cephalexin|500 mg PO QID plus oral placebo for 7 days
224254111|NCT02162849|DRUG|Varenicline|Varenicline Dosing: 0.5 mg/day by mouth for Days 1-3; 0.5 mg twice a day for Days 4-7, and 1 mg twice a day thereafter.
224254112|NCT02162849|DRUG|Nicotine Patch|Starting on Day 8, and then every day after that, participant applies 1, 21 mg nicotine patch for 11 weeks.
224254113|NCT02162849|DRUG|Placebo Patch|Starting on Day 8, and then every day after that, participant applies 1 placebo patch each day for 11 weeks.
224254114|NCT02162849|DRUG|Placebo Tablet|Participant takes placebo tablet 1-10 days after Visit 1. On Days 1-3, participant takes 1 dose of the placebo each morning. Starting on Day 4, and then every day after that, participant takes 1 dose in the morning and 1 dose in the evening.
224254115|NCT02162849|BEHAVIORAL|Questionnaires|Questionnaire completion 1 to 10 days before first study drug/placebo dose and on Days 8, 17, 24, 31, 38, 52, and 73. Questionnaires should take about 30-45 minutes total to complete. On Days 17, 24, 38, and 73, done over the phone.
224254116|NCT02162849|BEHAVIORAL|Counseling Sessions|Counseling sessions performed on Days 8, 17, 24, 31, 38, 52, and 73. On Days 17, 24, 38, and 73, done over the phone. These sessions take about 15 minutes each time.
224254117|NCT02162849|OTHER|Lab Session|Participant asked to watch slides. During the lab session, brain electrical activity checked with an electroencephalogram (EEG). Participant completes computer tasks, including questionnaires, that will measure emotions and attention level. These tasks should take about 90 minutes to complete. The lab session may last up to 2 hours.
224254118|NCT02162849|OTHER|Saliva Test|Saliva tested to check cotinine level at baseline, on Days 8 and 17, end of treatment visit, and at 3 months and 6 months after quitting smoking.
224254119|NCT05490511|DRUG|Tacrolimus single dose|5 mg once
224254120|NCT05490511|DRUG|Epidiolex single dose|Epidiolex 5 mg/kg
224254121|NCT05490511|DRUG|Epidiolex steady-state and tacrolimus single dose|Epidiolex at up to 5 mg/kg twice daily (for 14 days) and tacrolimus 5 mg once on day 12 of period
224254122|NCT06424015|OTHER|Intralipid and heparin|Intralipid (20%, 0.011ml/kg/min; Baxter, Healthcare, Deerfield, IL) and heparin (200 units prime, 0.2 unit/kg/min continuous) will be infused to induce acute insulin resistance
224254123|NCT06424015|OTHER|Saline|Saline will be infused
224254124|NCT05082584|DRUG|Vadadustat|Vadadustat tablet orally once a day for 52 weeks
224254125|NCT03467399|DEVICE|Nucleus 7 Cochlear Implant System|A new cochlear implant sound processor system.
224254126|NCT06470048|DRUG|Placebo|Ianalumab matching placebo subcutaneous (s.c.) injection as defined in the protocol
224254127|NCT06470048|DRUG|Ianalumab|subcutaneous (s.c.) injection as defined in the protocol
223772356|NCT00211081|DRUG|Spironolactone (drug)|1 mg/kg/day; afer 2 weeks doubled to 2/mg/kg/day. Patient's with endothelium-dependent brachial artery vasodilation and single-ventricle should show improvement within 4-8 weeks. Patients and their labs who are receiving Spironolactone will be followed.
224254128|NCT06502353|DEVICE|BLOOM43|Heat preconditioning
223772357|NCT02560129|OTHER|Questionnaires, Physical and Cognitive Function|ICU survivors will be administered a battery of questionnaires. Measurements of physical and cognitive function will also be performed.
224254129|NCT06119594|DEVICE|Body Comp Pro connected scale (Withings manufacturer)|Patients in the intervention group will use the connected scale at a minimum frequency of once a week from receipt of the scale and throughout their participation in the research (6 months)
223673522|NCT00694538|DEVICE|Interferential Laser therapy|Two GaAlAs laser (810 nm, 100mW)were used. In the interferential laser treatment, two probes were simultaneously applied. In the conventional laser group, only one probe was switched on. Laser was applied at five points over the pain area. The laser emission mode was continuous with an energy dose of 6 joules per point and session, a power density of 1.09 w/cm2 and an irradiation time per point of 60 s. The average output power was 100 mW and the total energy dose delivered in a patient session was 30 J. Every treatment was along 15 sessions. Hence, the accumulated energy delivered on the whole was 450 Joules for the conventional group of patients (using one beam) and 900 Joules for the interferential one (using two beams).
224254130|NCT06439420|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|CBT-I is a non-pharmacological approach to treating sleep disturbance consisting of educational, behavioral, and cognitive intervention components with evidence-based strategies including sleep efficiency, stimulus control, and sleep hygiene modification. CBT-I includes at least 6 group sessions, each approximately 90 minutes in length, delivered over 6 weeks via telehealth.
224254131|NCT04764942|DRUG|Carfilzomib|Given IV
224254132|NCT04764942|DRUG|Dexamethasone|Given PO
223673523|NCT00613067|DRUG|escitalopram|"* Start with escitalopram 10mg~* According to patient's symptoms, stay on 10mg or increase up to 20mg~* Concomitant therapy : up to Xanax 0.5mg, or Ativan 1mg, not allowed above these dosages~* Length of washout period will be at least 2 weeks for any psychotropic drugs"
223673524|NCT05634447|DRUG|Drug: CKD-391, QD, PO|Drug: CKD-331, D337 QD, PO
223673525|NCT04318145|DRUG|PL-3994 Aqueous Intravenous Solution Dose Ascention|Following appropriate dilution, PL-3994 will be injected intravenously by site personnel as a bolus dose followed by continuous infusion
223673526|NCT04318145|DRUG|PL-3994 Aqueous Intravenous Solution Single Dose|Following appropriate dilution, PL-3994 will be injected intravenously by site personnel as a bolus dose followed by continuous infusion
223673527|NCT01143233|OTHER|control formula|infants are fed a commercial hydrolyzed formula
223673528|NCT01143233|OTHER|intervention formula 1|formula has hydrolysed protein and a different protein content
223673529|NCT01143233|OTHER|intervention formula 2|formula has hydrolysed protein, different protein content and pro- and prebiotics
223673530|NCT01143233|OTHER|intervention formula 3|formula has hydrolysed protein, different protein content and pro- and prebiotics
223673531|NCT03049293|DRUG|Midazolam|The impact of Midazolam levels in follicular fluid.
223673532|NCT04935671|DIETARY_SUPPLEMENT|chamomile tea n saffron|20 mg of chamomile and 1 mg saffron in a teabag given twice daily for a month in combination with allopathic treatment for depression.
224254133|NCT04764942|DRUG|Pomalidomide|Given PO
224254134|NCT04764942|OTHER|Quality-of-Life Assessment|Ancillary studies
224254135|NCT04764942|OTHER|Questionnaire Administration|Ancillary studies
223673533|NCT02648828|OTHER|Clinical deterioration|Patients at risk of clinical deterioration
223673534|NCT06050603|DEVICE|TMS|"The target locations of TMS will be cortical regions defined by either anatomical landmarks or functional regions derived from the individual's functional and structural MRI for Aim 1. TMS target locations for Aim 2 and 3 are determined by Aim 1's results. These TMS target regions will be guided by a navigation system.~TMS will be parametrically varied with combinations of pulse strength and frequencies based on experimental conditions. TMS strength will be referred to the resting motor threshold (rMT), which will be determined independently for each participant. TMS pulses will be delivered at fixed time instants for Aim 2 and at time instants based on the phase of oscillatory neural activity for Aim 3."
223673535|NCT02835352|OTHER|Essential oils massages|
223673536|NCT02835352|OTHER|Oil massages|
223673537|NCT04215003|DRUG|A|"Paclitaxel: paclitaxel 80 mg/m2 ivgtt d1, d8, d15, 28 days per cycle. Carboplatin: carboplatin AUC=2 ivgtt d1, d8, d15, 28 days per cycle. Herceptin: 4 mg/kg (loading dose 8mg/kg) ivgtt d1,8,15, 22, 28 days per cycle,6 cycles.~Pertuzumab: 420-mg ( loading dose 840mg) ivgtt d1, 21 days per cycle,6 cycles."
223673538|NCT04215003|DRUG|B|Paclitaxel: paclitaxel 80 mg/m2 ivgtt d1, d8, d15, 28 days per cycle. Carboplatin: carboplatin AUC=2 ivgtt d1, d8, d15, 28 days per cycle.
223673539|NCT04215003|DRUG|CL4|SHR6390（CDK4/6 inhibitor）125 mg qd(three week on one week off); oral letrozole 2.5 mg daily； Adebrelimab was given intravenously, 600mg each time, once every 2 weeks; Premenopause：Goserelin 3.6mg IM IM Q4W.
223673540|NCT01752036|RADIATION|Post-operative, Stereotactic Body Radiation Therapy (SBRT)|All participants received SBRT at 600 cGy x 5 fractions
223673541|NCT04820127|BEHAVIORAL|personalized care preceded by a standardized assessment|"* personalized intervention plan (PIP) proposed to the patient/caregiver dyad to correct potentially reversible causes of psycho-behavioral symptoms. This PIP will be re-evaluated and adapted at each visit by the nurse in close collaboration with the GP;~* PIP implementation will be based on a close follow-up during the 18 months follow-up coordinated by the nurse (3 memory consultation visits, 3 home visits (with the GP) and 6 phone calls). This follow up will be enhanced with the use of a web platform (allowing teleconsultation, tele-expertise and telemonitoring);~* specific training on psycho-behavioral symptoms for caregivers at baseline and during follow-up will be performed. On line training on psycho-behavioral symptoms management for GP will be available;"
223673542|NCT01354054|PROCEDURE|High Frequency TENS|100 usec, 100 Hz, pulse amplitude motor - 10%, 30-40 minutes
223673543|NCT01354054|PROCEDURE|Low frequency TENS|100 usec, 4 Hz, pulse amplitude motor - 10%, 30-40 minutes
224254136|NCT04764942|DRUG|Selinexor|Given PO
224254137|NCT04764942|PROCEDURE|X-Ray Imaging|Undergo x-ray imaging
224254138|NCT04764942|PROCEDURE|Computed Tomography|Undergo PET/CT
224254139|NCT04764942|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
224254140|NCT04764942|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy and aspiration
223673544|NCT01354054|PROCEDURE|Placebo TENS|100 usec, 100 Hz, motor - 10%, pulse amplitude adjusted and maintained for 30 seconds then ramping down to zero in 15 seconds
224254141|NCT04764942|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow biopsy and aspiration
224254142|NCT04764942|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
224254143|NCT05495334|PROCEDURE|Treatment for Knee OA|Pain management treatment for knee OA.
224254144|NCT02414789|PROCEDURE|Skin biopsies|Skin biopsies of patients with Lyme disease (erythema migrans) infected with Borrelia burgdorferi sensu lato will be analyzed by three diagnostic techniques : molecular technique (PCR), biological technique (culture of the bacteria) and proteomics technique (SRM/ MS-MS)
224254145|NCT02258074|DRUG|Nicotinamide|
224254146|NCT02258074|DRUG|Lanthanum Carbonate|
224254147|NCT02258074|DRUG|Placebo (for Nicotinamide)|Sugar pill manufactured to mimic Nicotinamide 750 mg capsule
224254148|NCT02258074|DRUG|Placebo (for lanthanum carbonate)|Sugar pill manufactured to mimic Lanthanum Carbonate 500 mg capsule
224254149|NCT02826434|BIOLOGICAL|PVX-410|This is a Vaccine that will be injected intramuscularly as a mixture with an adjuvant.
224254150|NCT02826434|BIOLOGICAL|Durvalumab|This is an intravenous infusion of a monoclonal antibody.
224254151|NCT02826434|DRUG|Hiltonol|This is an intramuscular injection of an adjuvant to enhance the immune response to vaccine.
224254152|NCT03591510|DRUG|Midostaurin|midostaurin 30mg/m2 bid
224254153|NCT03591510|DRUG|Fludarabine|30mg/m2/day on D1-D5 of Block 2 FLADx
224254154|NCT03591510|DRUG|Cytarabine|"Part 1:~2000mg/m2/day D1 to D5 of Block 2 FLADx 1000mg/m2 every 12 hours D1 to D3 Block 3 HAM 3000mg/m2 every 12 hours D1 to D3 Block 4 HA3E 3000mg/m2 every 12 hours D1 to D3 Block 5 HIDAC~Part 2:~1000mg/m2 every 12 hours D1 to D3 Block 2 HAM 3000mg/m2 every 12 hours D1 to D3 Block 3 HA3E 1000mg/m2 every 12 hours D1 to D3 Block 4 HAM 3000mg/m2 every 12 hours D1 to D3 Block 5 HIDAC"
224254155|NCT03591510|DRUG|Daunorubicin or idarubicin|daunorubicin 60 mg/m2/day OR idarubicin 12mg/m2/day On D2, D4, D6 of Block 2 FLADx
223673545|NCT00704665|DRUG|Relaxin|10 ug/kg/day or 25 ug/kg/day
224254156|NCT03591510|DRUG|Mitoxantrone|10mg/m2/day D3 and D4
224254157|NCT03591510|DRUG|Etoposide|100mg/m2/day D1 to D5
224254158|NCT04000152|DIAGNOSTIC_TEST|niPGT-A|"Two scenarios should be considered according to the results in the SBM analysis:~1. The couple decides to transfer the blastocyst selected according to the SBM result (blastocyst prioritization system).~2. The couple decides to biopsy the blastocysts (if SBM results show low euploidy score). This PGT-A analysis will be offered for free but the outcome of these transfers will be excluded for the analysis per completed protocol. However, all transfers will be included in the intention-to-treat analysis.~In the exceptional case of getting a non-informative result for all the SBM analysed, the niPGT-A could be performed again on new SBM samples collected after an additional culture of the embryos for, at least, 8 hours."
224254159|NCT04000152|OTHER|Morphology criteria|Embryos for transfer will be selected by the only applicable technique, the assessment of morphology according to Gardner´s criteria, which is the most standardized method.
224254160|NCT06319287|BIOLOGICAL|PEP (Purified Exosome Product) / TISSEEL|"PEP Drug Product is a lyophilized powder contained within a 10R glass vial. PEP Drug Product is a lyophilized powder derived from apheresed platelets in plasma. The powder cake weighs approximately 75 mg per vial. This protocol will evaluate 2 vials of PEP Drug Product delivered in 10 mL TISSEEL fibrin sealant (15mg/mL PEP-TISSEEL) for 12 weeks.~TISSEEL is a fibrin sealant indicated as an adjunct to standard surgical techniques (such as suture and ligature) to prevent leakage from colonic anastomoses following the reversal of temporary colostomies"
224254161|NCT05446870|BIOLOGICAL|Pembrolizumab|200 mg by IV infusion on Day 1 of each 21-day cycle
224254162|NCT05446870|DRUG|Paclitaxel|175 mg/m\^2 by IV infusion on Day 1 of each 21-day cycle
224254163|NCT05446870|DRUG|Carboplatin|AUC 5 to 6 by IV infusion on Day 1 of each 21-day cycle
224254164|NCT05446870|BIOLOGICAL|Avastin|According to local practice and at the choice of the investigator.
223673546|NCT00704665|DRUG|Relaxin|Placebo
223673547|NCT01877733|OTHER|Maximal strength training|
224254165|NCT05446870|BIOLOGICAL|MK-4830|800 mg by IV infusion on Day 1 of each 21-day cycle
224254166|NCT05446870|DRUG|Docetaxel|75 mg/m\^2 by IV infusion on Day 1 of each 21-day cycle
224254167|NCT05348785|DRUG|BIIB122|Administered as specified in the treatment arm
224254168|NCT05348785|DRUG|BIIB122-Matching Placebo|Administered as specified in the treatment arm
223673548|NCT01403272|DEVICE|DermaTherapy® Linen and underpads.|"DermaTherapy® Linen is a 100% synthetic silk-like fabric technology designed to provide a cleaner, drier and smoother surface between the skin and support systems for a healthy micro-climate.~Subjects in the DermaTherapy® Linen Group are compared to subjects receiving usual care - bed linen made of cotton-blend fabrics."
223673549|NCT05692973|BEHAVIORAL|Role of Knowledge Retrieval|Students will learn a new knowledge base to perfect mastery. Following the attainment of mastery students will read passages on the topic and answer questions that prompt the literal recall of key facts and the formation of inferences.
223680661|NCT02097927|BEHAVIORAL|Mango-flavour beverage|The study will be a 3-way crossover design: it will assess the impact of a high-energy, sensory-enhanced beverage on energy intake through ad libitum food consumption and subjective feeling of appetite using visual analogue scales (VAS) compared to 2 control beverages following repeated exposures. Each participant will consume each beverage 10 times. This includes 2 satiety-testing sessions on site at Leatherhead Food Research, and 8 occasions consuming the product as a mid-morning snack during the participants' normal routine. Each participant will attend the Nutrition Unit on 6 different occasions before and after repeated exposures to the beverages at home. There will be a two-week washout period in which none of the beverages are consumed between the different beverage manipulations.
224254169|NCT06472817|OTHER|Non-Interventional Study|Non-interventional study
224254170|NCT05244421|OTHER|Primary Services|Primary services: Participants receive 16 hours of 24/7 Dads curricula, 4 hours of Healthy Relationships workshops, and 4 hours of Economic Stability workshops over the course of 8 weeks. Participants also receive ongoing job readiness support and post-employment support.
224254171|NCT05873439|RADIATION|Genomically Guided Radiation Therapy (RT)|Based on the Radiosensitivity Index (RSI) from testing participants tumor sample, participants will receive either standard dose radiation therapy, which is a strength 60Gy or up to 81Gy strength. Radiation treatment is administered 5 days per week for approximately 6 weeks.
224254172|NCT06261463|BEHAVIORAL|CAFES2|The adapted CAFES2 model includes an initial home visit and six multiple family group sessions delivered by peer providers. Families include at least one caregiver and one youth 12 years or older. Key model components include: 1) interfamilial discussion of stressors affecting families and family relationships, 2) psychoeducation on the effects of war and forced displacement on individuals, families and social relationships; 3) emotion regulation and self management strategies; 4) identification and activation of family and social strengths, 5) discussion of family identity and hopes for the future in resettlement and 5) discussion of social and community resources to support health and wellbeing. Each group session incorporates didactic components, family and small group discussion, skill building and separate breakout groups for adolescents and adults.
223673550|NCT05692973|BEHAVIORAL|Inference Intervention|The intervention will pre-teach students a set of 20 essential facts about Egypt. Students will interact with expository and narrative texts. Students will practice using a text clue strategy to activate and integrate prior knowledge, will make in-text connections, connections across the 3 intervention texts, and connections between text and knowledge, and will make inferences about character motives and author intent. The tutor will ask students to justify connections and evaluate how these connections enhance understanding. Students will answer inference questions that require using text and background knowledge. A simple graphic organizer will support and scaffold inferencing. Throughout the intervention, students will practice retrieving the 20 essential facts about Egypt from memory using flash cards, completed in pairs with students providing each other feedback.
223673551|NCT01857557|OTHER|Aerobic exercise|Patients receiving exercise program in addition to usual headache care
223673552|NCT00570479|DRUG|anecortave acetate|Patients will receive the specified dose of anecortave acetate every 4 months in an anterior juxtascleral depot injection
223673553|NCT04805320|PROCEDURE|Dental Extraction|Extraction
223673554|NCT02233764|OTHER|FeZnPM|Iron and zinc biofortified pearl millet will be consumed three times per day, six days per week, for 9 months. Children are anticipated to consume 25-30 grams of the pearl millet at each feeding. The pearl millet will be prepared using a variety of recipes such as porridges, breads, and biscuits.
223673555|NCT02233764|OTHER|CtrlPM|Conventional pearl millet will be consumed three times per day, six days per week, for 9 months. Children are anticipated to consume 25-30 grams of the pearl millet at each feeding. The pearl millet will be prepared using a variety of recipes such as porridges, breads, and biscuits.
223673556|NCT00611910|DEVICE|sirolimus-eluting stent|due to randomization Cypher stent will be implanted
223673557|NCT00611910|DEVICE|paclitaxel-eluting stent|due to randomization Taxus stent will be implanted
223673558|NCT00611910|DEVICE|biodegradable-polymer-based sirolimus-eluting stent|due to randomization a rapamycin-eluting stent with biodegradable polymer will be implanted
223673559|NCT00611910|DEVICE|bare metal stents|Due to randomization one bare-metal stent will be implanted. The decision about the stent type will be up to the interventionalist
223673560|NCT03468543|DRUG|Memantine Hydrochloride MR Prototype Capsule Formulation A|Memantine HCl MR capsule formulation will be administered orally in a single dose
223673561|NCT03468543|DRUG|Memantine Hydrochloride MR Prototype Capsule Formulation B|Memantine HCl MR capsule formulation will be administered orally in a single dose
223673562|NCT03468543|DRUG|Memantine Hydrochloride MR Prototype Capsule Formulation C|Memantine HCl MR capsule formulation will be administered orally in a single dose
223673563|NCT03468543|DRUG|Memantine Hydrochloride MR Prototype Capsule Formulation D|Memantine HCl MR capsule formulation will be administered orally in a single dose
223673564|NCT03468543|DRUG|Memantine Hydrochloride MR Prototype Capsule Formulation E|Memantine HCl MR capsule formulation will be administered orally in a single dose
223673565|NCT03468543|PROCEDURE|Magnetic Resonance Imaging|MRI will be performed on specified days according to protocol
223673566|NCT01188174|DRUG|Clofarabine|The present protocol aims to test the strategy of an early Reduced Intensity Conditioning (RIC) allo-SCT; in combination with a sequential preparative regimen for allo-SCT (Clofarabine, Intermediate dose Ara-C chemotherapy, followed by RIC with Cyclophosphamide, IV Busulfan and ATG; and delayed prophylactic infusion of donor lymphocytes (DLI) will be able to improve the outcome of patients with primary treatment failure AML.
223673567|NCT04834765|OTHER|Mindfulness-based art therapy|The researchers developed a novel MBAT intervention consisting of 10 easily reproducible, clay-based MBAT directives, administered through an online platform delivery strategy. By developing an MBAT intervention that uses an online delivery strategy, the researchers realized it may have the potential of decreasing demands placed on counseling centers.
223673568|NCT04834765|OTHER|Art-only|The AO modules consist of an open-ended art-making exercise, with minimal direction. The AO intervention is designed as an 'art for art's sake' intervention with the focus on the art-making and less on outcome or product. Participants are asked to pull their ball of clay out and spend ten minutes creating a form from the clay to visually express their experience in the present moment.
223673569|NCT04834765|OTHER|Mindfulness-only|The MO modules consist of only the mindfulness practices from the ABM intervention. The participants to follow along with a five-minute light yoga sequence, where asanas (yoga postures) are cued with breath. Yoga, for the purposes of the study, is explicitly defined to participants as the unity of breath with body movement. Poses were chosen based on their accessibility to a variety of body types and abilities, and chosen because they are documented to aid in grounding, increased haptic awareness, lowered levels of stress and anxiety, and restoration.
223673570|NCT04687618|DEVICE|High Flow Nasal Cannula withAutomatic control of FiO2 using OAM|The target oxygen saturation (SpO2) value will to be determined and set by the clinician according to specific patient needs. The target SpO2 in preterm infants is 90-95% with alarm limits at 89-96%. In automatic control of oxygen, the OAM automatically increases or decreases the FiO2 (oxygen delivery) setting on the Vapotherm Precision Flow based on pulse oximetry readings of the OAM. The target saturation will be set at 93% and the FiO2 will be adjusted by OAM to maintain the target saturation. The automated FiO2 setting can be overridden for a clinician pre-set period of time (30-120 sec) by simply manually adjusting the FiO2 on the Precision Flow. Automated control resumes after the clinicians pre-set period of time (30-120 sec) based on the current SpO2 and FiO2. The OAM utilizes a feedback control algorithm that receives a patient's oxygen saturation value from a build in pulse oximetry device (Masimo SET OEM - normal sensitivity, averaging time window set at 8 seconds).
223673571|NCT04687618|DEVICE|High Flow Nasal Cannula with manual control of FiO2|In manual control of oxygen all FiO2 adjustments will be done by the clinical staff to maintain saturations between 90-95%. The alarm limits will be 89-96%.
223673572|NCT00221312|DRUG|Fosamax|
223673573|NCT01437995|DRUG|Fluticasone/Salmeterol Diskus|Continuation of Fluticasone/Salmeterol Diskus 250/50 ug twice daily
224254173|NCT03417921|DRUG|ABTL0812|ABTL0812 in combination with gemcitabine and nab-paclitaxel
224254174|NCT03417921|DRUG|Gemcitabine and nab-paclitaxel|Gemcitabine and nab-paclitaxel as standard pattern
223673574|NCT01437995|DRUG|Fluticasone/Salmeterol Diskus|Reduced dose Fluticasone/Salmeterol Diskus 100/50 ug twice daily
223673575|NCT01437995|DRUG|Fluticasone Diskus|Fluticasone Diskus alone 250 ug twice daily without Salmeterol
223772358|NCT06570967|DRUG|Methimazole(MMI)|The initial dose of methimazole was 0.2-0.8 mg/(kg▪d). This dose was subsequently reduced by 25% to 50% and adjusted to maintain euthyroidism, based on the results of serum thyroid hormone testing during follow-up.
223772359|NCT01983800|DRUG|Isoflurane|
223772360|NCT01983800|DRUG|Propofol/midazolam|
223772361|NCT00917345|DRUG|captopril test|The blood samplings were obtained one hour after the administration of 50 mg of captopril.The testing is performed in the morning on a seated ambulatory patient
223772362|NCT03615651|DIETARY_SUPPLEMENT|Probiotic|The Probiotic Formula is commercially available and contains a combination of 3 probiotic strains in addition to other nutrients. The total daily amount of probiotic strain in the product will be no less than 3 billion colony-forming units (CFU) per 3 g powder sachet.
223772363|NCT03615651|OTHER|Placebo|Placebo intervention.
223772364|NCT04283734|DEVICE|iFR pullback with Syncvision software (Volcano company)|iFR pullback with Syncvision software permit us to analyze the vessel completely and to predict the physiological significance of every lesion and segment, to predict the benefit of the revascularization in terms of iFR improvement, and to predict the minimum stent length necessary to achieve this improvement.
224254175|NCT04904861|BEHAVIORAL|Videoconference intervention group|A short face-to-face dyadic group workshop focused on increasing maternal sensitivity was adapted to be carried out virtually by videoconference. The intervention considers 4 sessions, with a weekly frequency, with a minimum of 3 and a maximum of 6 dyads per group led by a monitor (psychologist). The activities are protocolized in a manual and are designed to be carried out by the mother with the baby under one year of age. .
224254176|NCT04904861|OTHER|Control group|Psycho-educational intervention : They will receive brochures with information on parenting (once a week for 4 weeks) in addition to the usual care in their primary care center
224254177|NCT04765059|DRUG|Osimertinib (AZD9291) pemetrexed cisplatin or carboplatin|Randomized patients will receive oral dose of osimertinib with intravenous (IV) pemetrexed plus either IV cisplatin or IV carboplatin
223673576|NCT03850288|OTHER|Neuropsychological assessment : Stroop task|"Stroop task is an interference task assessing cognitive inhibitory control. This paper-and-pencil task aims to evaluate the inhibition of an automated process such as reading by asking participants to name the color of color names written in a different color ink.~This test is non-invasive."
223673577|NCT03850288|OTHER|Neuropsychological assessment : Go No Go task|"Go No Go task assessing motor inhibitory control. This computer-based task is designed to evaluate motor inhibition by asking participants to respond to a stimulus as quickly as possible by inhibiting another distractor stimulus.~This test is non-invasive."
223673578|NCT02739633|DRUG|Genexol-PM|125 mg/m2 given intravenously over 60 minutes for 3 weeks (days 1, 8 and 15) with 1 week rest. Patients will continue until they experience disease progression or significant toxicity.
224254178|NCT04765059|DRUG|Placebo for osimertinib (AZD9291) pemetrexed cisplatin or carboplatin|Randomized patients will receive oral dose of placebo matching osimertinib with IV pemetrexed plus either IV cisplatin or IV carboplatin
224322254|NCT06581887|BEHAVIORAL|Classical conditioning task|To evaluate the neurophysiological and physiological response to a classical conditioning task, which is comparable to findings that have been made in the mdx dystrophic mouse (deficient in Dp427). The investigators will assess correlations between the specific DMD/BMD genotype and susceptibility to conditioning, as well as the relationship between conditioning and behavioural/emotional characteristics of the syndrome.
224322255|NCT06116630|DIAGNOSTIC_TEST|DCE-MRI|Both groups will undergo DCE-MRIs.
223673579|NCT02739633|DRUG|Gemcitabine|1000 mg/m2 given intravenously for 3 weeks (days 1, 8 and 15) with 1 week rest. Patients will continue until they experience disease progression or significant toxicity.
223673580|NCT03253562|DRUG|Metformin Pill|a biguanide used as an insulin sensitizer for patients suffering from type 2 diabetes mellitus
223673581|NCT03253562|DRUG|Vildagliptin 50 mg|Dpp4i antihyperglycemic drug used for treatment of type 2 diabetes mellitus
223673582|NCT05055401|PROCEDURE|Direct Laryngoscopy|The participant will perform a direct laryngoscopy on a Laerdal SimMan 3G under healthy conditions and under limited cervical range of motion.
223772365|NCT01332305|DRUG|GEn (XP13512/GSK1838262)|Double-Blind Treatment Phase: 600 mg GEn (XP13512) orally, once daily for 3 days followed by 600 or 1200 mg on days 4-6, followed by 600 or 1200 or 1800 mg on days 7-9, followed by 600 or 1200 or 1800 or 2400 mg on days 10-84. Double-Blind Taper Phase: 600 or 1200 or 1800 mg GEn (XP13512) orally, once daily on days 85-86, followed by 600 mg or 1200 mg on days 87-88, followed by 600 mg on days 89-91
223772366|NCT01332305|DRUG|Placebo|Placebo orally once daily
223772367|NCT05501197|OTHER|Exercise Therapy via video conference|"The intervention will include the different levels of the following exercises that are given to the patient considering their functional level:~Straight leg raise (Level 1-2-3) Quadriceps strengthening (Level 1-2-3) Hip abductor/adductor strengthening (Level 1-2-3) Hamstring stretch Gastrocnemius stretch"
223772368|NCT05501197|OTHER|Exercise Therapy via mobile application|"The intervention will include the different levels of the following exercises that are given to the patient considering their functional level:~Straight leg raise (Level 1-2-3) Quadriceps strengthening (Level 1-2-3) Hip abductor/adductor strengthening (Level 1-2-3) Hamstring stretch Gastrocnemius stretch"
223772369|NCT01600040|RADIATION|Proton radiation therapy|5 days per week (Mon-Fri) for 5-6 weeks
223772370|NCT00129415|PROCEDURE|UVA1 Irradiation|The affected areas on the body will be treated with UVA1 (Sellemed UVA1 light source) for up to 5 times per week for 16 weeks. The UVA1 dose will be up to 130 J/cm2.
223772371|NCT00129415|PROCEDURE|UVB Irradiation|The affected areas on the body will be treated with UVB light for up to 5 times per week for 16 weeks. The maximum UVB dose will be 4000 mJ/cm2.
223772372|NCT05040412|DEVICE|difficult laryngoscopy|Patients will be intubated with the direct laryngoscope.
223772373|NCT00734838|DEVICE|High Resolution Microendoscope|Using core biopsy and reduction mammoplasty tissue
223772374|NCT02360917|OTHER|Emerging from the Haze|A 6 week psycho-educational class
223772375|NCT00721994|DEVICE|Cormet Hip Resurfacing System|Cormet Hip Resurfacing System
223772376|NCT04027686|DEVICE|Laser Therapy|Adjunctive application of laser therapy in the periodontal pocket
224254179|NCT06536426|BEHAVIORAL|Knee Isometric Program (KIP)|"The KIP physical therapy protocol follows the schedule outlined below:~* Session 1 (Completed 4-5 days/week including HEP): Double Leg wall sit 3x30 seconds, Double Leg glute bridge hold 3x30 seconds, Single Leg Stance hold 3x1 minutes, Lunge hold 3x1 minutes~* Session 2 (Completed 4-5 days/week including HEP): Single Leg wall sit 3x20 seconds, Single Leg glute bridge hold 3x20 seconds, Single Leg stance hold 2x1.5 minutes, Lunge hold 2x1.5 minutes~* Session 3 (Completed 4-5 days/week including HEP): Single leg wall sit 3x40 seconds, Single leg glute bridge hold 3x40 seconds, Single leg stance hold 2x3 minutes, Lunge hold 2x3 minutes~* Session 4 (Completed 4-5 days/week including HEP): Single leg wall sit 3x40 seconds, Single leg glute bridge hold 3x40 seconds, Single leg stance hold 2x3 minutes, Lunge hold 2x3 minutes"
224254180|NCT02689505|DRUG|BI 836880|Solution for intravenous infusion
224254181|NCT05815160|DRUG|Debio 0123|Administered as capsules.
223673583|NCT05055401|PROCEDURE|Laryngeal Mask Airways|The participant will perform LMA placement on a Laerdal SimMan 3G under healthy conditions and under full tongue edema.
223673584|NCT05055401|PROCEDURE|Video Laryngoscopy|The participant will perform video laryngoscopy on a Laerdal SimMan 3G under healthy conditions and under half tongue edema with pharyngeal obstruction.
223673585|NCT03738748|OTHER|Ultrasound- guided Percutaneous Neuromulation|The experimental group will be treated with percutaneous neuromodulation using a needle with Physio Invasive® device, in its modality of percutaneous electrostimulation for 15 minutes, and guided by ultrasound equipment in the multifidus muscles of L-3, once a week for 4 weeks.
223673586|NCT03738748|OTHER|TENS Therapy|The control group will apply a transcutaneous treatment with surface electrodes with TENS current at 170 Hz for 15 minutes in the L-3 region, once a week for 4 weeks.
223673587|NCT06628765|DEVICE|8.6 Fr single-use fURS (XFGC-FU-660RC)|Comparative device
223673588|NCT06628765|DEVICE|6.3 Fr single-use fURS (Hugemed, HU30S)|Device being tested
223673589|NCT05660421|DRUG|Itacitinib|Given by mouth
223673590|NCT05660421|DRUG|Corticosteroid|Given by mouth or by vein
223673591|NCT05660421|PROCEDURE|Endoscopic Procedure|Undergo endoscopic procedure
223673592|NCT05660421|PROCEDURE|Skin biopsy|Undergo skin biopsy
223673593|NCT05660421|PROCEDURE|Biospecimen Collection|Undergo collection of blood and stool
223673594|NCT01563562|DRUG|Bardoxolone Methyl|Oral, Single dose
223673595|NCT05638789|PROCEDURE|endoscopic sphincterotomy (EST) versus EST plus endoscopic papillary large balloon dilatation (EPLBD)|EST alone vs EST plus EPLBD in removing common bile duct stone
223772377|NCT04027686|PROCEDURE|Non-surgical Scaling and Root Planing|Scaling to remove calculus deposits and root planing to smooth root surfaces
224254182|NCT05815160|DRUG|Etoposide|Administered as IV infusion.
224254183|NCT05815160|DRUG|Carboplatin|Administered as IV infusion.
224254184|NCT05447598|OTHER|Nurse-led remote monitoring program|Symptoms of disease progression, clinical parameters, medication adherence and follow-up needs will be reported by patients or with support from relatives or homecare nurses 2-4 times/months over a three months period using a digital platform. Telephone monitoring is planned for patients who are not able to comply with the digital platform. In addition, an individualized self-treatment plan for diuretics and lifestyle advice will be prepared, preferably together with relatives at the outpatient clinic. Participants will also have access to a website with written information and videos about HF and self-management. Finally, a pillbox will be delivered to facilitate drug adherence.
224254185|NCT05447598|OTHER|Usual care treatment|Usual care treatment and follow-up care at the outpatient clinic and in primary care
224254186|NCT04837209|DRUG|Niraparib|Capsule, taken by mouth
224254187|NCT04837209|DRUG|Dostarlimab|Intravenous infusion
224254188|NCT04837209|RADIATION|Radiation therapy|Radio Therapy
224254189|NCT03526848|DRUG|3BNC117|Intravenous infusion of 3BNC117
224254190|NCT03526848|DRUG|10-1074|Intravenous infusion of 3BNC117
224254191|NCT03526848|OTHER|Analytical treatment interruption|Analytical treatment interruption
223673596|NCT05795998|OTHER|Adaptation of the Sabotage in Romantic Relationships Scale into Turkish and its validity and reliability analyzes|Approval was obtained from the local ethics committee before starting the study. Permission was obtained from Racquel PEEL, who developed the scale. The scale was administered to 495 participants and they were informed about the study by a specialist psychiatrist. Language validity, construct validity and reliability analyzes of the scale were performed. The findings were discussed in the light of the literature.
223673597|NCT04248621|DRUG|Leuprorelin|LHRH agonist
223673598|NCT04248621|DRUG|Goserelin|LHRH agonist
223673599|NCT04248621|DRUG|Triptorelin|LHRH agonist
223673600|NCT04248621|DRUG|Degarelix|LHRH antagonist
223673601|NCT04248621|DRUG|Bicalutamide|Antiandrogen
223673602|NCT04248621|DRUG|Flutamide|Antiandrogen
223673603|NCT04248621|DRUG|Maximum androgen blockade|Combination therapy with LHRH agonist and antiandrogen
223673604|NCT00159822|DRUG|Voriconazole|"Voriconazole oral : loading dose on day 1 : 400mg/12 hours; maintenance dose 200 mg /12 hours for 6 to 12 months depending on clinical response.~Alternatively, patients may start on Voriconazole, IV, for 7 days loading dose, 6mg/Kg/12 hours on day one and maintenance dose 4 mg/Kg/12 hours"
223673605|NCT04211220|OTHER|A decision support software|Insulin pump Continuous glucose monitoring
223673606|NCT05411575|DRUG|Plerixafor 20 MG/ML [Mozobil]|Plerixafor (Mozobil®) continuous intravenous infusion for 7 days
223673607|NCT05411575|OTHER|Placebo|Placebo continuous intravenous infusion for 7 days
223673608|NCT01643785|DRUG|Second-line quadruple therapy with endonase|Compare Second-line quadruple therapy w/o pronase (endonase)
223673609|NCT03541915|DRUG|Mg (magnesium sulfate)|20mg/kg of magnesium sulfate will be infused after induction of anesthesia. And magnesium sulfated will be continuously infused at a rate of 15mg/kg/h during the operation.
223772378|NCT04334603|OTHER|Exercise Training Program|The 12-week exercise-training program will include two sessions of combined exercise training per week, performed at the hospital or at home.
223772379|NCT00966498|PROCEDURE|Peripheral Blood Stem Cell Transplant|Peripheral Blood Stem Cell Transplant
223772380|NCT06107218|OTHER|Bioactive Glass Air Abrasion Particles.|Finishing of cavity walls by AquaCare Air Abrasion Device using Bioactive Glass Air Abrasion Particles.
223772381|NCT06107218|OTHER|Diamond Stone.|Finishing of cavity walls using Diamond Stone.
223772382|NCT02772016|DRUG|Colla corii asini|15 g of Colla corii asini in powder form daily for 4 weeks
224254192|NCT04171635|RADIATION|Quantitative Susceptibility Mapping (QSM) Magnetic Resonance Imaging (MRI)|Investigators will validate hepatic QSM (hQSM) using histological examination and chemical measurement of liver iron concentration (LIC). Patients will undergo clinical MRI in Aim 1. In patients with increased LIC their liver explants will undergo MRI, pathological examination, and chemical determination of the LIC.
224254193|NCT04171635|RADIATION|R2* Magnetic Resonance Imaging (MRI)|Investigators will be able to validate hQSM in measuring liver iron concentration (LIC) by comparing it to this traditional MRI technique
224254194|NCT06969430|DRUG|Debio 1562M|Administered as intravenous (IV) infusion
224254195|NCT02446600|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
224254196|NCT02446600|DRUG|Carboplatin|Given IV
224254197|NCT02446600|DRUG|Cediranib Maleate|Given PO
224254198|NCT02446600|PROCEDURE|Computed Tomography|Undergo CT
224254199|NCT02446600|PROCEDURE|Echocardiography Test|Undergo ECHO
224254200|NCT02446600|DRUG|Gemcitabine|Given IV
223673610|NCT03541915|DRUG|Control (saline)|The same volume of normal saline will be infused after induction of anesthesia and continuously infused at the same rate of magnesium.
223673611|NCT05926375|DIETARY_SUPPLEMENT|HINEX Jelly ( jelly high protein supplement)|In self-controlled phase,which intake 400\~500 kcal breakfast, or in supplement phase consume one servings of jelly high protein supplement (303 kcal, 15 g protein and 2400 mg BCAA per serving) and 100\~200 kcal food at breakfast per day, for 8 weeks.
223673612|NCT04825353|PROCEDURE|Endoscopic compbined guided PCNL|patient undergo stone removal by ECIRS
223673613|NCT04825353|PROCEDURE|Standard PCNL|patient undergo SPCNL
223673614|NCT01149954|DRUG|Ibuprofen|Ibuprofen 200 mg gel capsules of Dr. Reddy's Laboratories Limited
224254201|NCT02446600|DRUG|Gemcitabine Hydrochloride|Given IV
224254202|NCT02446600|OTHER|Laboratory Biomarker Analysis|Correlative studies
224254203|NCT02446600|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
224254204|NCT02446600|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
224254205|NCT02446600|DRUG|Olaparib|Given PO
224254206|NCT02446600|DRUG|Paclitaxel|Given IV
223673615|NCT02307253|DEVICE|Expect™19Flex needle (Boston Scientific Corp.,Natick,MA,USA)|EUS-guided fine needle biopsy performed through the duodenum with the Expect™ 19 Flex needle
223673616|NCT05566483|BEHAVIORAL|Exercise|exercise protocol
223673617|NCT02225054|DRUG|Dexmedetomidine|0.5 u/kg Dexmedetomidine diluted in saline to 1 mL (single interscalene injection) Dexmedetomidine 0.5 u/kg as a single IV bolus over 30 minutes following GA induction
223772383|NCT03023735|OTHER|None. This is an observational study|
223772384|NCT03160430|DRUG|apabetalone|RVX000222 oral (apabetalone), 100 mg capsule
223772385|NCT03160430|DRUG|Placebos|matching placebo capsule
223772386|NCT03617809|PROCEDURE|Preoperative warming|The prewarming time will not be decided by the clinical investigator. Prewarming time will depend on the time the patient has to wait before entering in the operating room.
224254207|NCT02446600|DRUG|Pegylated Liposomal Doxorubicin Hydrochloride|Given IV
224254208|NCT02446600|OTHER|Pharmacological Study|Correlative studies
224254209|NCT02446600|OTHER|Quality-of-Life Assessment|Ancillary studies
224254210|NCT04041778|OTHER|Catheter ablation|Substrate ablation. Pulmonary vein isolation.
224254211|NCT04857684|DRUG|Atezolizumab|Intravenous Infusion
224254212|NCT04857684|DRUG|Bevacizumab|Intravenous Infusion
224254213|NCT04857684|RADIATION|Stereotactic Beam Radiation Therapy (SBRT)|External beam radiation
224254214|NCT03700411|DRUG|Morphine|Morphine intravenous
224254215|NCT03700411|DRUG|Piritramid|Piritramid intravenous
224254216|NCT03700411|DRUG|Epidural|Perioperative epidural analgesia
223673618|NCT02225054|DRUG|Ropivacaine|15 ml 0.5%
223673619|NCT02225054|DRUG|Normal Saline|1 mL 0.9%
223673620|NCT05145738|BEHAVIORAL|C-Raven with avatar|Computer delivered intervention with the investigators' avatar; with linkage to community health worker.
223673621|NCT05145738|BEHAVIORAL|C-Raven without avatar|Computer delivered intervention without the investigators' avatar; with linkage to community health worker.
223673622|NCT01100476|DEVICE|Endovascular Diagnostic Procedures|Patients underwent a percutaneous diagnostic procedure utilizing a 5F procedural sheath in the common femoral artery
223673623|NCT00628043|DRUG|epoetin beta|Subcutaneous administration of epoetin beta 36,000 IU once-weekly for 12 weeks
223673624|NCT00628043|DRUG|placebo|Subcutaneous administration of placebo once-weekly for 12 weeks
223673625|NCT00590928|DRUG|esomeprazole|40mg once daily
224254217|NCT04108858|DRUG|Copanlisib|Given IV
224254218|NCT04108858|BIOLOGICAL|Pertuzumab|Given IV
224254219|NCT04108858|BIOLOGICAL|Trastuzumab|Given IV
224254220|NCT05861973|BEHAVIORAL|Adaptive SMARTer intervention (SMARTer)|Participants will receive calorie, fat, and physical activity goals, a Smartphone application for self-monitoring their diet, activity and weight, online educational readings, and brief bi-weekly remote health sessions with a Health Promotionist. They will also be loaned a Fitbit tracking device and a wireless Bluetooth scale for 12 months.
224254221|NCT05861973|BEHAVIORAL|Diabetes Prevention Program (DPP)|In accordance with the Center for Disease Control curriculum, participants will receive a participant log for tracking physical activity, food intake, and weight, a paper participant guide with worksheets, logs, and psycho-educational materials, and 16 hour long remote sessions with a Health Promotionist.
224254222|NCT05861973|BEHAVIORAL|Self-Guided Treatment (Self-Guided)|Provides paper and internet resources tailored to geographic area, educating on leading a healthier lifestyle, including information on wellness and physical activity. Will have physical measures taken at baseline, 3 months, 6 months, 9 months, and 12 months.
224254223|NCT05236439|DEVICE|Interposition supraciliary implant|Surgical placement of SV22 interposition supraciliary implant in the supraciliary space
224254224|NCT04656054|PROCEDURE|liposuction|liposuction procedure and observation of the hematological changes on the patients
224254225|NCT05996510|DEVICE|ultrasound|Shoulder ultrasound is performed using a linear ultrasound probe. The area under the suprascapular notch and the superior transverse scapular ligament is measured using the cross-sectional area measurement method.
224254226|NCT06346392|DRUG|AZD0901|Participants in the AZD0901 arm 1 will receive dose level 1 AZD0901 IV
224254227|NCT06346392|DRUG|AZD0901|Participants in the AZD0901 arm 2 will receive dose level 2 AZD0901 IV (Enrolment was closed)
224254228|NCT06346392|DRUG|Ramucirumab+ paclitaxel|Ramucirumab 8 mg/kg IV on Days 1 and 15 and paclitaxel 80 mg/m2 IV on Days 1, 8, and 15, Q4W
224254229|NCT06346392|DRUG|Paclitaxel|Paclitaxel 80 mg/m2 IV on Days 1, 8, and 15, Q4W (for participants with contraindication to ramucirumab only)
224254230|NCT06346392|DRUG|Docetaxel|Docetaxel 75-100 mg/m2 IV on Day 1, Q3W (for participants with contraindication to ramucirumab only)
224254231|NCT06346392|DRUG|Irinotecan|Irinotecan 150-180 mg/m2 IV on Days 1 and 15, Q4W
224254232|NCT06346392|DRUG|TAS-102|TAS-102 35 mg/m2 up to a maximum of 80 mg orally twice a day on Days 1 to 5 and Days 8 to 12, Q4W (except China)
224254233|NCT06346392|DRUG|Apatinib|Apatinib 500-850 mg at Investigator's discretion based on participant's condition and tolerability, orally once daily, Q4W (China only)
224254234|NCT04497857|OTHER|Coordinated Specialty Care (CSC)|CSC care is an evidenced-based, comprehensive specialty care programs for young people in the initial phases of psychotic disorders
224254235|NCT02927119|DIETARY_SUPPLEMENT|iodine|≥ 150 µg/day iodine supplementation (iodine containing pregnancy supplement) prior to enrollment
224254236|NCT06580743|OTHER|No intervention|This is an observational study
224254237|NCT04472156|PROCEDURE|Transfer of mosaic embryo|Subjects will transfer a mosaic embryo transferred to their uterus
224254238|NCT04886973|OTHER|Administration of an 8% crystalline L-amino acid solution with high concentrations of branched chain amino acids.|Intravenous administration of 8% crystalline L-amino acids with high concentrations of branched chain amino acids.
224254239|NCT05746442|BEHAVIORAL|Smartphone-delivered Automated Messaging|An interactive smartphone based intervention will provide weekly smoking-related assessments and personalized automated messages designed to increase motivation, self-efficacy, use of coping skills, social support and to reduce nicotine withdrawal symptoms and stress for a 26 week period.
224254240|NCT05746442|DRUG|Nicotine patch|Participants will be provided with a 8 week supply of nicotine patches
224254241|NCT05746442|BEHAVIORAL|Brief Advice to Quit and Smoking Cessation Self Help Materials|Participants will receive self-help materials from Khmer Quit Now, a national smoking cessation campaign in Cambodia
224254242|NCT05746442|BEHAVIORAL|Diet Assessment|Participants will be asked to complete brief weekly smartphone assessments about their diet for a 26-week period
224254243|NCT02739997|DRUG|MK-7625A 1.5 g (ceftolozane 1 g/tazobactam 0.5 g)|MK-7625A 1.5 g (ceftolozane 1 g/tazobactam 0.5 g) administered as an intravenous (IV) infusion
224254244|NCT02739997|DRUG|metronidazole 500 mg|metronidazole 500 mg administered as an IV infusion
223673626|NCT00590928|DRUG|ranitidine|50mg every h hours
223673627|NCT00275821|DRUG|Ranibizumab 0.3 mg - 3 times monthly, then quarterly|Subjects received intravitreal injections (in the study eye) of ranibizumab 0.3 mg over a duration of 12 months. They were treated monthly for 3 consecutive months and then quarterly for the remainder of the study. On those months when ranibizumab was not administered, patients received a sham injection to preserve the masking of the treatment arms.
223680662|NCT01752712|DRUG|CBSST + Oxytocin|The oxytocin dose of 80 IU/day, will be administered in two divided doses: 40 IU in the morning and 40 IU in the evening. Oxytocin will be administered intranasally (10 puffs of the spray, 5 in each nostril at each administration). CBSST groups will occur for an hour twice/week. Nasal spray will be administered an hour prior to the CBSST group.
224254245|NCT04059965|OTHER|Panel Management for Anticoagulation Therapy|Patients in the intervention arm will receive notifications reminding them of upcoming labs and appointments. We hypothesize this will improve adherence and therapeutic control and reduce risk for bleeds and/or strokes
224254246|NCT04059965|OTHER|Usual Care|Patients will receive standard, protocolized care in their respective anticoagulation clinics
224254247|NCT05132933|PROCEDURE|PEEP trial - Electrical Impedance Tomography|Three different levels of PEEP and two different levels of FiO2 will be tested without changing anything else in the baseline patient ventilation
224254248|NCT00731978|PROCEDURE|Restricted intraoperative fluid management|Intraoperative fluid management guided by Sto2.
224254249|NCT02290171|BEHAVIORAL|Activity groups|Children attend to activity groups weekly during the intervention periode.
224254250|NCT02290171|BEHAVIORAL|Group based dietary counselling|Parents attend to four sessions of group based dietary counselling
224254251|NCT02290171|BEHAVIORAL|Individual counselling|Parents attend to individual counselling focusing on parental skills and family structure
224254252|NCT01286090|DRUG|Cisapride|One 10-mg tablet taken orally 4 times a day for up to 8 weeks.
224254253|NCT01286090|DRUG|Placebo|One tablet taken orally 4 times a day for up to 8 weeks.
224254254|NCT04361708|DRUG|Oxaliplatin|Oxaliplatin will be administered on day 1 of each cycle at 85mg/kg. The drugs will be given through the patient's Mediport. It will be given once every 14 days (2 weeks), on days 1 and will be continued for 8 doses (4 months)
224254255|NCT04361708|DRUG|Docetaxel|Docetaxel will be administered on day 1 of each cycle at 25mg at dose level 1; 37.5 at dose level 2. The drugs will be given through the patient's Mediport.It will be given once every 14 days (2 weeks), on days 1 and will be continued for 8 doses (4 months)
224254256|NCT04361708|DRUG|Leucovorin|Leucovorin will be administered on day 1 of each cycle at 400mg/kg. The drugs will be given through the patient's Mediport. It will be given once every 14 days (2 weeks), on days 1 and will be continued for 8 doses (4 months)
224254257|NCT04361708|DRUG|Irinotecan|Irinotecan will be administered on day 1 of each cycle at 120mg/m2 for low risk group, 105mg/m2 for intermediate risk group, 45mg/m2 for high risk group . The drugs will be given through the patient's Mediport. It will be given once every 14 days (2 weeks), on days 1 and will be continued for 8 doses (4 months)
224322256|NCT00346918|DRUG|Sirolimus|Standard plus Sirolimus
224322257|NCT00346918|OTHER|Standard|Standard
224322258|NCT04819893|BIOLOGICAL|Maternal blood sampling|5 mL sample of venous blood on arrival at the maternity ward in accordance with standard protocols
224322259|NCT04819893|BIOLOGICAL|Umbilical cord blood sampling|0.5mL sample from the umbilical cord after childbirth standard protocols
224322260|NCT04819893|BIOLOGICAL|Placenta sampling|Sampling of 3 cotyledons by cutting across the thickness of the placenta
224322261|NCT04819893|OTHER|Data collection|Newborn, Maternal and Premature Retinopathy Screening Data Collection
224254258|NCT04361708|DRUG|5-Fluorouracil|5-FU is given as a continuous intravenous infusion over 2 days. Patient can receive the 2-day infusion as an outpatient. On day 3 of each cycle, the patient will return to the infusion center to have the infusion hook-up disconnected.
224254259|NCT06399705|PROCEDURE|Coronary artery bypass grafting|Coronary artery bypass grafting (CABG), also called heart bypass surgery, is a medical procedure to improve blood flow to the heart.
224254260|NCT06399705|PROCEDURE|Percutaneous coronary intervention|Percutaneous coronary intervention (PCI) is a non-surgical procedure used to treat the blockages in a coronary artery; it opens up narrowed or blocked sections of the artery, restoring blood flow to the heart
224254261|NCT00749177|OTHER|Traditional Healing options|Dream work, energy healing, healing circles, pipe ceremonies, self care, smudging, sweat lodges and traditional learning.
224254262|NCT01305122|BEHAVIORAL|neurocognitive tests|"* inclusion~* 1 year~* 3 years~* 5 years"
224254263|NCT02241434|BIOLOGICAL|Stem Cell|Intrathecal autologous bone marrow mononuclear cell transplantation
224254264|NCT04943029|DRUG|Carrelizumab|Camrelizumab: 200mg, IV, day 1 of each 21-day cycle, neoadjuvant therapy : 3 cycles; Adjuvant therapy: 16cycles.
224254265|NCT04943029|DRUG|Pemetrexed (Nonsquamous NSCLC) or Nab-paclitaxel(Squamous NSCLC)|Nab-paclitaxel: 260mg/m\^2, IV, day 1 of each 21-day cycle, 3 cycles; Pemetrexed: 500 mg/m\^2, IV, day 1 of each 21-day cycle, 3 cycles.
224254266|NCT04943029|DRUG|Carboplatin|Carboplatin was given dosed to an area under the serum concentration-time curve (AUC) of 5 i.v. on day 1 of each 21-day cycle for 3 cycles.
224254267|NCT04943029|PROCEDURE|Surgery|Surgery must be done within the 4th-6th week from day 1 cycle 3 of neoadjuvant treatment (4-6 weeks after day 1 of cycle 3)
224254268|NCT02738086|BEHAVIORAL|Physical Activity Behavior Change (PABC)|Home-based weekly sessions (30 min) using behavior change methods for promoting physical activity. Sessions will occur using home-based computer tablets for real-time video interface between the participant and therapist. Participants will wear wrist-mounted activity sensors with direct physical activity feedback during the intervention period to allow for behavioral feedback and action planning.
224254269|NCT02738086|BEHAVIORAL|Physical Activity Behavior Change (PABC)|Home-based weekly sessions (30 min) using behavior change methods for promoting physical activity. Sessions will occur using home-based computer tablets for real-time video interface between the participant and therapist. Participants will wear wrist-mounted activity sensors with direct physical activity feedback during the intervention period to allow for behavioral feedback and action planning
224254270|NCT03216967|DRUG|everolimus|Patients with viremia above 2.8 log of copies/ml will be randomized (ratio 1:1) into either of 2 groups Group 1 : control group : immunosuppression lowering or Group 2 : experimental group : immunosuppression lowering and replacement of mycophenolate acid by everolimus Evolution of BKV viremia and allograft function will be assessed during 2 years after randomization
224254271|NCT05388305|BIOLOGICAL|CAR--γδT cells|Biological: CAR-γδT; Drug:
224254272|NCT03141047|OTHER|Lifespan Integration|A protocol based psychological treatment method
224254273|NCT02308475|DEVICE|Somatom Force CT Scanner|Dynamic CT perfusion of the heart
224254274|NCT03552393|DRUG|Mircera|The initial dose of Mircera will be one of nine starting doses corresponding to the prefilled syringe strengths based on the total weekly erythropoiesis-stimulating agent (ESA) dose during the screening period.
224254275|NCT04039594|DEVICE|VA ECMO|VA ECMO for cardiopulmonary support
224254276|NCT03328676|DRUG|Cannabis|Patients will receive study medication as drops applied under the tongue 3 times a day - morning, noon and evening, at a minimum of 4hr apart between administrations.
224254277|NCT03328676|DRUG|Placebo oil|Patients will receive study medication as drops applied under the tongue 3 times a day - morning, noon and evening, at a minimum of 4hr apart between administrations.
224254278|NCT03305263|DRUG|Hydroxychloroquine|One tablet a day from inclusion until end of pregnancy or gestational age 28
223772387|NCT01646671|DRUG|LCZ696|LCZ696 200 mg tablet once daily
223772388|NCT01646671|DRUG|LCZ696|2 tablets of LCZ696 200 mg once daily titrated up from 1 tablet of 200 mg once daily
224254279|NCT03305263|DRUG|Hydroxychloroquine placebo|One tablet a day from inclusion until end of pregnancy or gestational age 28
224254280|NCT03488147|DRUG|Esomeprazole|20 mg esomeprazole tablet
224254281|NCT03488147|DRUG|Placebo Oral Tablet|resembling esomeprazole tablet
224254282|NCT04418310|PROCEDURE|Lay open and curettage|Lay open and curettage
224254283|NCT04418310|PROCEDURE|Endoscopic (E.P.Si.T) method|Endoscopic (E.P.Si.T) method
224254284|NCT06456918|PROCEDURE|Quality of Recovery 15 questionnaire|return to daily life after surgery according to the patient's baseline or social norms
224322262|NCT00769587|DRUG|thalidomide|
224322263|NCT05848011|BIOLOGICAL|lorigerlimab|Lorigerlimab is a DART® molecule that binds PD-1 and CTLA-4
223772389|NCT01646671|DRUG|LCZ696|2 tablets of LCZ696 200 mg once daily titrated up from 1 tablet of 200 mg once daily plus other HTN medications
223772390|NCT02074735|DRUG|Placebo|Inactive ingredient matching the active comparator in appearance
224254285|NCT00473863|PROCEDURE|Coronary Computed Tomographic Angiography|CCTA will be performed
224254286|NCT00019591|BIOLOGICAL|aldesleukin|
224254287|NCT00019591|BIOLOGICAL|ras peptide cancer vaccine|
224254288|NCT00019591|PROCEDURE|adjuvant therapy|
224254289|NCT01689311|DRUG|Oxytocin|Oxytocin, 10-10mol/L to 10-5mol/L; solution made in double-distilled autoclaved water and then tested in physiological salt solution.
224254290|NCT01689311|DRUG|Ergonovine|Ergonovine, 10-10mol/L to 10-5mol/L; solution made in double-distilled autoclaved water and then tested in physiological salt solution.
224254291|NCT01689311|DRUG|Prostaglandin F2alpha|Prostaglandin F2alpha, 10-10mol/L to 10-5mol/L; solution made in double-distilled autoclaved water and then tested in physiological salt solution.
224254292|NCT01689311|DRUG|Misoprostol|Misoprostol, 10-10mol/L to 10-5mol/L; solution made in double-distilled autoclaved water and then tested in physiological salt solution.
224254293|NCT06228963|DRUG|Triple therapy for eradication of Helicobacter Pylori and Orelabrutinib|Triple therapy for H. pylori (oral administration for 2 weeks, followed by a 1-week break) plus Orelabrutinib for 8 weeks (or until progression, intolerable toxicity, death, or withdrawal from the study)
224322264|NCT05848011|DRUG|docetaxel|Docetaxel Injection is a cytotoxic anticancer drug approved to treat prostate cancer
224254294|NCT06228963|DRUG|Triple therapy for eradication of Helicobacter Pylori|Triple therapy for H. pylori (oral administration for 2 weeks, followed by a 1-week break)
224254295|NCT02285894|OTHER|Inspiratory hold|Sustainment of the ventilators inspiratory pressure for 10 seconds at a time
224254296|NCT01828528|PROCEDURE|Sleeve gastrectomy|An intra-operative liver biopsy was performed in 20 patients
224254297|NCT02601625|DRUG|Anifrolumab SC injection (300mg)|300 mg of anifrolumab delivered as 2 separate 1 mL SC injections administered serially on Day 1
224254298|NCT02601625|DRUG|Anifrolumab IV infusion (300mg)|300 mg of anifrolumab delivered as an IV infusion over 30 minutes on Day 1
224254299|NCT02601625|DRUG|Anifrolumab SC infusion (600mg)|600 mg of anifrolumab delivered as 4 mL SC by infusion pump on Day 1
224254300|NCT02601625|DRUG|Anifrolumab placebo SC injection (300mg)|300mg of placebo delivered as 2 separate 1 mL SC injections administered serially on Day 1
224254301|NCT02601625|DRUG|Anifrolumab placebo IV infusion (300mg)|600mg of placebo delivered as an IV infusion over 30 minutes on Day 1
224254302|NCT02601625|DRUG|Anifrolumab placebo SC infusion (600mg)|600 mg of placebo delivered as 4 mL SC by infusion pump on Day 1
224254303|NCT05640544|OTHER|Sound and light stimulation in Gamma band|"We expect to screen out the efficacy of Gamma band in the prognosis and treatment of disorders of consciousness by various frequencies of stimulation.~Optical stimulation:~A computer program is used to control the flashing frequency of LED lights for stimulation. The serial port can convert the parallel data characters of the computer CPU into a continuous serial data stream. According to the frequency designed by experiment (10Hz, 20hz, 40hz, 80hz), we modulate the flicker frequency of LED lamp. LED lamp uses T8 lamp, diameter 25.4 mm, length 620 mm, and power 20W.~Acoustic stimulation:~We use Adobe Audition CC 2022 to modulate the tones. The tones modulated to 10Hz, 20Hz, 40Hz and 80Hz are play by noise-canceling headphones to the patients."
224254304|NCT00560443|DRUG|ketorolac|0,5 mg/kg per os one time
224254305|NCT00560443|DRUG|tramadol|2,5 mg/ kg per os in one dose
223673628|NCT00275821|DRUG|Ranibizumab 0.5 mg - 3 times monthly, then quarterly|Subjects received intravitreal injections (in the study eye) of ranibizumab 0.5 mg over a duration of 12 months. They were treated monthly for 3 consecutive months and then quarterly for the remainder of the study. On those months when ranibizumab was not administered, patients received a sham injection to preserve the masking of the treatment arms.
223673629|NCT00275821|DRUG|Ranibizumab 0.3 mg monthly|Subjects received monthly intravitreal injections (in the study eye) of ranibizumab 0.5 mg over a duration of 12 months. On those months when ranibizumab was not administered, patients received a sham injection to preserve the masking of the treatment arms.
223673630|NCT00329901|BIOLOGICAL|Meningococcal ACWY conjugate vaccine (MenACWY-CRM)|
223673631|NCT00329901|BIOLOGICAL|Combined tetanus, reduced diphtheria and acellular pertussis vaccine (Tdap)|
223673632|NCT00329901|BIOLOGICAL|saline placebo|4.5 mg sodium chloride per 0.5 ml dose
224254306|NCT01926821|DRUG|Sonifilan|Sonifilan inj 20mg Intra muscular injection, twice per week for 8 weeks, total 16 times
223673633|NCT03772002|DIAGNOSTIC_TEST|HCV screening|HCV antibody and HCV RNA surveillance, anti-HCV treatment assessment
223673634|NCT06493292|PROCEDURE|Endovascular therapy|Endovascular therapy is a minimally invasive interventional approach that utilizes the vascular system as a pathway to access and treat various pathological conditions within the body. By employing specialized catheters and devices, endovascular techniques enable precise delivery of therapeutic agents or interventional procedures directly to the target site, without the need for conventional open surgery.
223673635|NCT05814276|BEHAVIORAL|Training on non-pharmacological therapies' methodology|"The San Rocco study encompasses a training on the non-pharmacological therapies' methodology. It allows the professional caregiver to methodological definition of the non-pharmacological interventions and a comparison of shared readings of the challenging behaviors by the group of colleagues. Participants will follow:~* Five meetings, lasting 11 hours overall, on the multidimensional assessment, the shared readings of behavioral disorders of each person and identification of the objectives through the discussion of cases, and administration of non-pharmacological therapies within the framework of the personalization of the interventions~* Five meetings, lasting five and a half hours, for the supervision of the staff which implement the non-pharmacological therapies.~As usual control group Participants will continue the usual care activities and non-pharmacological interventions already in use in the Nursing Homes without participating in the training."
224254307|NCT01683474|DEVICE|Venus MedTech Aortic Valve Prosthesis|Percutaneous implantation of aortic valve of Venus-A
224254308|NCT01910688|DEVICE|RFA treatment|If eligible for enrollment, a focal ablation device is selected as an intervention(size according to physician preference) and mounted on the end of the endoscope and introduced via the mouth into the esophagus and gastric pouch. The gastric pouch is treated from the top of the gastric folds to and just through the stomal anastomosis.
224254309|NCT00359281|DRUG|atorvastatin|Atrovastatin 20 mg and AEGR-733 10 mg or 60 mg
224254310|NCT00359281|DRUG|simvastatin|Simvastatin 20 mg and AEGR-733 10 mg or 60 mg
224254311|NCT00359281|DRUG|ezetimibe|Ezetimibe 10 mg and AEGR-733 10 mg
224254312|NCT00359281|DRUG|fenofibrate|Micronized Fenofibrate 145 mg and AEGR-733 10 mg
224254313|NCT00359281|DRUG|dextromethorphan|Dextromethorphan 30 mg and AEGR-733 10 mg
224254314|NCT00359281|DRUG|Extended Release Niacin|1000 mg ER niacin and AEGR-733 10 mg
224254315|NCT02375685|BIOLOGICAL|Gevokizumab|
224254316|NCT05396963|DIETARY_SUPPLEMENT|Egg white|Intake of egg white
224254317|NCT05396963|DIETARY_SUPPLEMENT|Whey protein|Intake of whey protein
224254318|NCT05396963|DIETARY_SUPPLEMENT|Maltodextrin|Intake of maltodextrin
224254319|NCT00448903|DRUG|Bemiparin|Bemiparin sodium
224254320|NCT00448903|DRUG|Placebo|Sodium Chloride 0,9%
224254321|NCT01935934|DRUG|Cabozantinib S-malate|Given PO
224254322|NCT01935934|OTHER|Laboratory Biomarker Analysis|Correlative studies
224254323|NCT01935934|OTHER|Pharmacological Study|Correlative studies
224322265|NCT05848011|DRUG|Prednisone|A corticosteroid drug approved for use with docetaxel in the treatment of prostate cancer
224254324|NCT05672433|DIETARY_SUPPLEMENT|Placebo|Capsule without cafestol twice daily
224254325|NCT05672433|DIETARY_SUPPLEMENT|Cafestol|Capsule with 6 mg cafestol twice daily
224254326|NCT04609917|PROCEDURE|trainee invlovement|Patients underwent selective biliary cannulation with trainee involvement
224254327|NCT00407147|DEVICE|Procalcitonin assay - B.R.A.H.M.S PCT sensitive Kryptor|"antibiotic treatment based on clinical decision making with traditional thought processes used in both groups. In addition the physician will be given access to Procalcitonin values with recommended thresholds for likelihood of infection."
224254328|NCT01111045|DRUG|Bone morphogenetic protein 7|Comparison of different doses of the drug via single intraarticular knee injection
224254329|NCT01111045|DRUG|Placebo|Placebo
224254330|NCT06103058|OTHER|Cross sectional|Cross sectional
224254331|NCT04065867|BEHAVIORAL|ICT activities|Family interventions using ICT to promote family communication, sharing happiness with family members, and well-being in the community.
224254332|NCT06062498|DRUG|elacestrant, palbociclib, abemaciclib, ribociclib|Given orally
224254333|NCT02688023|DRUG|oxaliplatin;irinotecan;leucovorin;5-fluorouracil;capecitabine;S-1|The regimen consisted of irinotecan 150mg/m2 administered as an intravenous infusion on day 1, oxaliplatin 85 mg/m2 administered intravenously on day 2, leucovorin 200 mg intravenously on day 2, 5-fluorouracil 500 mg administered by intravenous bolus,followed by 2400 mg/m2 by 44 h continuous intravenous infusion starting on day 2. S-1 (40-60mg orally twice per day for 10 days) or capecitabine (1000mg/m2 orally twice per day for 10 days) can be substituted for intravenous 5-fluorouracil.14 days as a cycle, up to 4 cycles.
224254334|NCT02045472|DRUG|VIS410|
224254335|NCT02045472|DRUG|Placebo|
224254336|NCT05137184|DRUG|Methoxyflurane|Inhalation of Methoxyflurane
224254337|NCT05137184|DRUG|Fentanyl|Intranasal Fentanyl
224254338|NCT05137184|DRUG|Morphine hydrochloride|Intravenous Morphine
224254339|NCT04887415|BEHAVIORAL|Respiratory Strength Training (RST) Program|Participants will complete RST exercises 5 days per week by performing 5 sets of 5 repetitions of both expiratory and inspiratory muscle strength training (a total of 50 repetitions per day). Trainer devices will be calibrated to 50% of participants' maximum expiratory pressure (MEP) and maximum inspiratory pressure (MIP) as determined via respiratory assessment prior to and during the RST program.
223673636|NCT05855876|PROCEDURE|subanesthetic ketamine infusions and bilateral cervical sympathetic blocks|Combined protocol of subanesthetic ketamine infusions and bilateral cervical sympathetic blocks
223673637|NCT00299468|BEHAVIORAL|Patient Activation Measure Intervention Package|
223673638|NCT03857347|OTHER|Psychoeducation Group for FND|he intervention is a psychoeducation based group.
223673639|NCT05934669|DRUG|Intranasal Midazolam|Using a computer-generated randomization schedule by the research pharmacist, all 90 subjects will be divided into 3 even groups to receive either medication A (intranasal Midazolam), B (intranasal Dexmedetomidine), or C (intranasal Ketamine). Based on the randomization schedule, the pharmacist will dispense medication A, B, or C to the chronological number provided in the order. The total amount of the medication will be based on the patient's charted weight. Small volumes of less than 1ml per nostril are preferred for reliable absorption; therefore, the medication will be dispensed in a 1ml syringe and the barrel of the syringe will be covered by the pharmacist. All the syringes sent from the pharmacy will appear the same, regardless of the volume of the medication.
223673640|NCT05934669|DRUG|Intranasal Dexmedetomidine|See above
223673641|NCT05934669|DRUG|Intranasal Ketamine|See above
223673642|NCT03893253|OTHER|Early Booster Teaching|The early booster group will receive a booster teaching session at 3 weeks post-training followed by feedback.
223673643|NCT03893253|OTHER|Late Booster Teaching|The late booster group will receive a booster teaching session at 2 months post-training followed by feedback
223673644|NCT02296138|DRUG|olodaterol|fixed dose combination
223673645|NCT02296138|DRUG|tiotropium|fixed dose combination
223673646|NCT02296138|DRUG|tiotropium|
223673647|NCT03709732|OTHER|no intervention|observational study
223673648|NCT00224653|PROCEDURE|Mechanical Ventilation|
223673649|NCT00177710|DRUG|Amphotericin B|
223673650|NCT01967368|DRUG|Intanza|Principal Investigator would be responsible for injecting the intradermal vaccine in a sterile technique.
223673651|NCT01967368|DRUG|Vaxigrip|Principal Investigator would be responsible for injecting the intrmuscular vaccine in a sterile technique.
223673652|NCT04847089|DEVICE|Motor imagery BCI training|Motor Imagery (MI)-BCI training, 2-3 hours, 3 times/week for 4 weeks.
223673653|NCT04918056|DIAGNOSTIC_TEST|Hematological Analysis and Genetical Analysis|"Hematological Analysis: Hematological parameters were determined with an automated hematology analyzer (Sysmex, Japan), and hemoglobin analysis was performed with either high-performance liquid chromatography (Bio-Rad, USA) or capillary electrophoresis (Sebia, France and Helena, USA).~Genetical Analysis: Genomic DNA was extracted from peripheral blood (PB) by using a standard phenol/chloroform method. The genotypes of samples are analyzed by NGS assay."
224254340|NCT04224493|DRUG|Tazemetostat|"Stage 1 (Phase 1b):~Tazemetostat was escalated from a starting dose of 400 mg orally twice daily to 600 mg orally twice daily to 800 mg PO twice daily in 28-day cycles as tolerated in a standard 3 + 3 design. Tazemetostat will be administered as monotherapy at an 800 mg twice daily dose for up to 2 years after the initial 12 months of combination therapy."
224254341|NCT04224493|DRUG|Tazemetostat|"Stage 2:~Tazemetostat 800 mg administered orally twice daily in continuous 28-day cycles for 12 cycles. Tazemetostat will be administered as monotherapy at an 800 mg twice daily dose for up to 2 years after the initial 12 months of combination therapy."
224254342|NCT04224493|DRUG|Placebo oral tablet|"Stage 2:~Placebo administered orally twice daily in continuous 28-day cycles. Placebo will be administered as monotherapy twice daily dose for up to 2 years after the initial 12 months of combination therapy."
224254343|NCT04224493|COMBINATION_PRODUCT|Lenalidomide|Lenalidomide 20 mg capsules or 10 mg capsules (if creatinine clearance ≥60 mL/minute or \<60 mL/minute), administered PO QD on days 1 to 21 for 12 cycles.
224254344|NCT04224493|COMBINATION_PRODUCT|Rituximab|Rituximab 375 mg/m2 IV on days 1, 8, 15, and 22 of cycle 1; then on day 1 of cycles 2 to 5.
224322266|NCT04739800|PROCEDURE|Biospecimen Collection|Undergo collection of blood
224322267|NCT04739800|DRUG|Cediranib Maleate|Given PO
224322268|NCT04739800|PROCEDURE|Computed Tomography|Undergo CT
224322269|NCT04739800|PROCEDURE|Computed Tomography with Contrast|Undergo CT with contrast
224322270|NCT04739800|BIOLOGICAL|Durvalumab|Given IV
224322271|NCT04739800|PROCEDURE|Echocardiography Test|Undergo ECHO
223673654|NCT03492840|DRUG|RZL-012|The dosing regimen will be a single dose treatment injection of RZL-012 in multiple sites
224254345|NCT04608188|BEHAVIORAL|Summer Camp|The intervention camps will operate according to routine practice, with no assistance from the investigative team. The camps provide indoor and outdoor opportunities for children to be physically active each day, provide enrichment and academic programming, as well as provide breakfast, lunch, and snacks. All camp meals will adhere to the United States Department of Agriculture Summer Food Service Program nutrition guidelines. The camps employ 1 staff member for every 12 children - which is consistent with childcare regulations in the state of operation and operate daily (Mon-Fri) for 8 weeks during the summer. The camps open at 7am and close 6 pm daily.
224254346|NCT06268665|DRUG|Tart Cherry Juice|Given PO
224254347|NCT03053141|DEVICE|Rhythmia Mapping System|The Rhythmia Mapping System is a 3D electro-anatomical mapping system.
224254348|NCT06665646|BIOLOGICAL|CD40.HIVRI.Env (VRIPRO)|To be administered subcutaneously as 1 mg admixed with Hiltonol, Poly-ICLC as a single dose.
224254349|NCT06665646|BIOLOGICAL|Hiltonol Poly-ICLC-adjuvant|Vaccine adjuvant
224254350|NCT06561867|DRUG|Ticagrelor 90 MG|Efficacy and safety of a 180 mg loading dose of ticagrelor administered within 24 hours of first-ever ischemic stroke followed by 90 mg twice daily for 3 months will be assessed through NIHSS, mRS, duration of hospital stay, new ischemic stroke, and possible adverse effects
224254351|NCT06561867|DRUG|Cilostazol 100 MG|Efficacy and safety of 200 mg clopidogrel followed by 100 mg twice daily for 3 months will be assessed through NIHSS, mRS, duration of hospital stay, new ischemic stroke, and possible adverse effects.
224254352|NCT00838136|DRUG|Lamotrigine 25 mg Chewable Tablets|2 x 25 mg, single-dose fed
224254353|NCT00838136|DRUG|Lamictal® 25 mg Chewable Tablets|2 x 25 mg, single-dose fed
224254354|NCT05363059|DRUG|Hypoglycemic drugs|drug
224254355|NCT05363059|PROCEDURE|Bariatric surgery|surgery
224254356|NCT05895383|DRUG|Nitrous oxide|Nitrous oxide administered at concentrations of minimal sedation (0-50%). Participants will be able to adjust the level of gas throughout the vasectomy using a handheld remote control.
224254357|NCT05606744|DEVICE|Eccentric exercise / Eccentric exercise with blood flow restriction|Individuals will be randomized to receive eccentric exercise only, or eccentric exercise with blood flow restriction.
223673655|NCT04485065|DRUG|IBI188+azacitidine|"Escalating and maintenance dose of IBI188 will be administered 30mg/kg, IV(intravenous infusion),Q4W~Drug:Azacitidine Azacitidine will be administered daily for 7 days, IH, Q4W"
223673656|NCT02643056|DRUG|Panitumumab|IV administration every 2 weeks
223673657|NCT00873470|PROCEDURE|esophagal stimulation|ECG (rest) esophagal stimulation (rest and during effort)
223673658|NCT01887743|DRUG|Pantoprazole|This will be a single dose study where participants will receive 1.2mg/kg or no more than 100mg total one time dose as a liquid containing Carbon 13 labeled Pantoprazole with a final concentration of 4.0mg/mL.
223673659|NCT00539201|DRUG|GSK706769|
224254358|NCT00419640|DEVICE|Pacemaker implantation with RA lead in LAS position|Pacemaker implantation with RA lead placed in low atrial septal position
223673660|NCT02760043|DRUG|Dexamethasone|8mg (2mL) of Dexamethasone added to standard LIA mixture
223673661|NCT02760043|OTHER|0.9% NaCl Placebo|2mL of 0.9% NaCl placebo (saline) added to standard LIA mixture
223673662|NCT02760043|DRUG|LIA Combination Mixture|150mL 2% Ropivacaine, 30mg Ketorolac and 0.6mg of Epinephrine
223673663|NCT05271279|BIOLOGICAL|OVV-01 Injection+IBR900 Cell Injection|"2 dose gradients are used for the OVV-01 injection, and the total infusion dose of IBR900 cell injection is 4.0×10\^9 cells per cycle.~OVV-01 injection will be first administered at W1D1 and then at W4D1 followed by every 2 weeks as a treatment cycle, for a total of 6 doses; after the test in the high-dose group is completed, the investigator and sponsor will determine whether to adjust the dosing frequency of OVV-01 (such as once a week) based on the result evaluations. The IBR900 cell injection will be first administered at W1D3 and W1D5 for 2 infusions, and then at W4D3 and W4D5, followed by every 4 weeks as a cycle, for a total of 4 doses, and cell infusions will be conducted at W1, W4, W8 and W12, respectively."
223673664|NCT02447783|DIETARY_SUPPLEMENT|Control Capsules|Cocoa-based, flavanol-free, control-matched capsules consumed for 12 weeks (Week 1: 2 capsules/day; Week 2: 3 capsules/day; Week 3-12: 4 capsules/day; Week 12-14: no capsule intake).
223673665|NCT02447783|DIETARY_SUPPLEMENT|Mars Cocoa Extract Capsules|Capsules containing Mars Cocoa Extract manufactured by the Cocoapro® process and containing 500 mg of cocoa flavanols per capsule consumed for 12 weeks (Week 1: 2 capsules/day; Week 2: 3 capsules/day; Week 3-12: 4 capsules/day; Week 12-14: no capsule intake).
224254359|NCT00419640|DEVICE|Pacemaker implantation with RA lead in LAS position|Pacemaker implantation with RA lead placed in low atrial septal position
224254360|NCT00419640|DEVICE|Pacemaker implantation with RA lead in RAA position|Pacemaker implantation with RA lead placed in right atrial appendage position
224254361|NCT00419640|DEVICE|Pacemaker implantation with RA lead in RAA position|Pacemaker implantation with RA lead placed in right atrial appendage position
224254362|NCT03380845|DEVICE|Fraxel Restore|Non-ablative Laser. In the study, one side of the face will be treated with Fraxel Restore monthly for three months.
224254363|NCT03380845|DEVICE|Fractora|Fractional Radiofrequency Microneedling Device. In the study, one side of the face will be treated with Fractora monthly for three months.
224254364|NCT01415986|DRUG|Temoporfin|A single dose of 0.15 mg of Temoporfin per kilogram of body weight will be administered by slow intravenous injection into a deep vein (such as the antecubital vein) in not less than 6 minutes.
224254365|NCT01415986|DEVICE|Medical diode laser emitting light at a wavelength of 652 nm. (Ceralas PDT 652, CeramOptec GmbH)|Light dose of 20 J/cm, at a rate of 100 mW/cm, will be delivered to the target tumor and margins, within 200 seconds.
224254366|NCT03118557|OTHER|Pilates pelvic floor strengthening|Pilates pelvic floor strengthening.
224254367|NCT04092023|OTHER|nursing education|Participants will be recruited to attend 2 group sessions; each group will have 10-12 participants and each session will be lasted for 120 minutes. Two subsequent phones follow up to participants will be arranged.
224254368|NCT01434953|BEHAVIORAL|Labeled prehypertension|A study physician informs subjects of their blood pressure level. Subjects are told they have prehypertension and are informed of the associated health risks.
224322272|NCT04739800|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
224322273|NCT04739800|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
224322274|NCT04739800|DRUG|Olaparib|Given PO
224322275|NCT04739800|DRUG|Paclitaxel|Given IV
224254369|NCT01434953|BEHAVIORAL|Unlabeled prehypertension|"A study physician informs subjects of their blood pressure level. The term prehypertension is not used and associated health risks are not discussed."
224254370|NCT01449383|DIETARY_SUPPLEMENT|low meat high fibre|less than 30g red meat and at least 40g dietary fibre per day
224254371|NCT01449383|DIETARY_SUPPLEMENT|high meat low fibre|at least 200g red meat (pork, beef or other mammals) and not more than 20g dietary fibre per day
224254372|NCT01250912|DRUG|123I-metaiodobenzylguanidine|FDA Approved for use in Cancer patients. This use is Off Label. For the imaging study, an activity of 370 MBq (10 mCi) 123I-mIBG (GE Healthcare) will be administered intravenously, and a 10-minute planar image of the anterior thorax (128\_128 matrix) will be acquired beginning 15 minutes after tracer injection.
224254373|NCT03899077|DRUG|Apalutamide|Apalutamide 240mg daily for 6 months (i.e. 6 28-day cycles); oral use
224254374|NCT03899077|DRUG|Leuprorelin Acetate 45Mg Powder for Injection Suspension Vial|Leuprorelin acetate 45mg for 6 months; subcutaneous use
223673666|NCT05898269|DIAGNOSTIC_TEST|Trendelenburg maneuver|Bed tilting from the +13° position to the -13° position for 60 seconds. Evaluator: relative change in continuous cardiac index between baseline, and the highest value observed during the maneuver
223673667|NCT05898269|DIAGNOSTIC_TEST|End-expiratory occlusion test (EE OCC)|"End-expiratory pause performed on the ventilator, and maintained for 15 seconds.~Evaluator: relative change in continuous cardiac index between baseline, and the value observed in the last 5 seconds of the respiratory pause"
223673668|NCT05898269|DIAGNOSTIC_TEST|End-expiratory and end-inspiratory occlusion test (EI OCC)|"End-inspiratory pause performed on the ventilator, and maintained for 15 seconds.~Evaluator: relative change in continuous cardiac index between baseline, and the value observed in the last 5 seconds of the respiratory pause. The evaluator is calculated as the sum of the relative change in cardiac index observed during the end-expiratory pause and that of the end-inspiratory pause. Hence, for this test, the evaluator will be coupled with that of intervention 2 (end-expiratory occlusion test)."
223673669|NCT05898269|DIAGNOSTIC_TEST|Tidal volume challenge|"Increase in tidal volume set on the ventilator from 6 ml.kg-1 of predicted body weight, to 8 ml.kg-1 for 60 seconds.~Evaluator: difference in the pulse pressure variation measured at 6 ml.kg-1 and at 8 ml.kg-1."
223673670|NCT05898269|DIAGNOSTIC_TEST|Fluid bolus (reference diagnostic method)|"After the 4 tests, the patient will receive a 500-ml fluid bolus of crystalloids in less than 15 minutes.~Evaluator (reference method): cardiac index measured by transpulmonary thermodilution before and immediately after the fluid bolus. Patients with a relative change in cardiac index \> 15% will be identified as being fluid responders, and the others as non-responders."
223673671|NCT04644367|OTHER|Tai Chi intervention|TC classes will be 60 minutes long, offered three times per week over a 12-week period. The participants who receive the TC intervention will be encouraged to attend at minimum two of the three sessions offered per week. The TC classes will follow the same order that will begin with a 5 to 10 minutes warm up, 40 minutes of core activities, and 5 minutes of cool-down. The training intensity and difficulty level of the TC program will gradually proceed from low, moderate, to advance. The classes will be offered in a group setting at a convenient location within a community centre or gymnasium. Alternatively, classes will be offered outdoors in the park or by the canal during the spring-summer months. Due to the COVID-19 situation, additional adaptive measures will be taken using online social platforms such as ZOOM or Hangout to deliver the classes.
223673672|NCT04644367|OTHER|Regular Physical Activity (control) group|Regular Physical Activity group who will not be receiving the TC intervention
224254375|NCT03899077|DRUG|Goserelin Acetate 10.8 MG Subcutaneous Implant|Goserelin acetate 10.8mg for 6 months; subcutaneous use
223673673|NCT01209832|DRUG|Tasisulam|Patient specific dose, administered intravenously, on Day 1 of a 28-day cycle. Minimum of one (1) 28-day cycle. Patients may continue to receive tasisulam until disease progression or until discontinuation criteria are met.
223673674|NCT01209832|DRUG|Midazolam|1.2 milligrams (mg), administered orally once prior to the initiation of tasisulam therapy and once on Day 8 after initiation of tasisulam therapy
223673675|NCT01268579|DRUG|ribavirin|The clinical intervention in this study is ribavirin therapy for approximately 14 days. Ribavirin 800 mg/day is administered in divided doses, 400 mg PO qAM and 400 mg PO qPM.
223673676|NCT00197067|BIOLOGICAL|RTS,S/AS02D and RTS,S/AS02A|
224254376|NCT03899077|DRUG|Triptorelin Pamoate|Triptorelin pamoate 22.5mg for 6 months; intramuscular use
224254377|NCT03899077|DRUG|Degarelix acetate|Degarelix acetate 80mg for 6 months; subcutaneous use
224254378|NCT06225921|DRUG|Adebrelimab|Adebrelimab will be given at a dose of 20 mg per kilogram of body weight every three weeks on day 23 of a planned 28-day cycle, and two doses before surgery.
224254379|NCT06225921|DRUG|Dalpiciclib 100mg|Dalpiciclib will be given at a dose of 100 mg every day orally with three weeks on and one week off. Four weeks is a cycle and it will be given for two cycles.
224254380|NCT06225921|DRUG|Dalpiciclib 150mg|Dalpiciclib will be given at a dose of 150 mg every day orally with three weeks on and one week off. Four weeks is a cycle and it will be given for two cycles.
224254381|NCT05822479|PROCEDURE|Bilateral ultrasound guided external oblique intercostal block (EOIB)|"Bilateral ultrasound-guided EOIB (total of 60 ml, %0.25 bupivacaine) will be performed + IV morphine PCA~Multimodal analgesia :~Patients are administered iv tenoxicam 20mg and tramadol 100 mg after induction of general anesthesia, iv paracetamol 1 gr and iv morphine 0.05 mg/kg/ideal body weight (IBW) will be administered. Postoperative analgesia: iv paracetamol 1gr every 8 hours and IV PCA of 0,5mg/ml morphine (the bolus dose is 20 µg/kg, the lock-in time of 10 minutes, the 4-hour limit is adjusted to be 80% of the calculated total amount). Rescue analgesia, when necessary (if the resting NRS score is ≥4 despite PCA demand), 25 mg IV meperidine was administered in the recovery unit, and 50 mg intramuscular (IM) meperidine was administered in the ward."
224254382|NCT05822479|OTHER|Control|"Patients in this group will not be performed interfacial plane blocks.~Multimodal analgesia :~Patients are administered iv tenoxicam 20mg and tramadol 100 mg after induction of general anesthesia, iv paracetamol 1 gr and iv morphine 0.05 mg/kg/ideal body weight (IBW) will be administered. Postoperative analgesia: iv paracetamol 1gr every 8 hours and IV PCA of 0,5mg/ml morphine (the bolus dose is 20 µg/kg, the lock-in time of 10 minutes, the 4-hour limit is adjusted to be 80% of the calculated total amount). Rescue analgesia, when necessary (if the resting NRS score is ≥4 despite PCA demand), 25 mg IV meperidine was administered in the recovery unit, and 50 mg IM meperidine was administered in the ward."
224254383|NCT02877433|DEVICE|Roxolid short implant, 4 mm length (4)|Placement of a combination of four short implants (in positions 35/45, 36/46) as distal support and two implants of conventional length (in positions 33/43) in the interforaminal region, in order to support a cross-arch fixed screw-retained prosthesis.
224254384|NCT02877433|DEVICE|Roxolid short implant, 4 mm length (2)|Placement of a combination of two short implants (in positions 36/46) as distal support and two implants of conventional length (in positions 33/43) in the interforaminal region, in order to support a cross-arch fixed screw-retained prosthesis.
223673677|NCT02753244|OTHER|Motion Based Cognitive Video Games Software|Intendu FBT motion based cognitive video games software
223673678|NCT02753244|OTHER|iPad Apps|Commercially available iPad game applications
223673679|NCT02424214|OTHER|Artificial Oocyte activation|
223673680|NCT02424214|DRUG|Ca Ionophore|
223673681|NCT02424214|DRUG|Strontium Chloride|
223673682|NCT03843710|DRUG|Gold Nanocrystals|CNM-Au8 is a dark red/purple-colored liquid formulation consisting of a stable suspension of faceted clean surfaced elemental gold nanocrystals in buffered deionized water with a concentration of up to 0.5 mg/mL of gold. The formulation is buffered by sodium bicarbonate present at a concentration of 0.546 mg/mL. There are no other excipients. The drug product is formulated to be taken orally and will be provided in single dose HDPE containers. The study doses vary by the concentration of gold nanocrystals per milliliter in a volume of 60 mL.
223673683|NCT00761150|DRUG|ABT-712|ABT-712 extended-release tablet
223673684|NCT00761150|DRUG|Placebo|Placebo tablet
223673685|NCT01267695|DRUG|imatinib mesylate|Patients receive oral imatinib mesylate once daily for 6 months in the absence of disease progression or unacceptable toxicity. Patients with disease progression or unacceptable toxicity are considered for immediate surgical resection. Within 2-6 weeks after completion of imatinib mesylate, patients with responding or stable disease undergo surgical resection. Two to four weeks after surgery, patients receive oral imatinib mesylate once daily for one and a half years.
223673686|NCT01267695|PROCEDURE|conventional surgery|All the patients should receive elective surgery with R0 resection.
223673687|NCT03744143|PROCEDURE|longitudinal suture|Surgical eradication of deep infiltrating endometriosis of the vagina using laparoscopic technique, performing 4 transperitoneal abdominal accesses and trocars from 5 to 12 mm, and closure of the vagina with a longitudinal suture
223673688|NCT03744143|PROCEDURE|transverse suture|Surgical eradication of deep infiltrating endometriosis of the vagina using laparoscopic technique, performing 4 transperitoneal abdominal accesses and trocars from 5 to 12 mm, and closure of the vagina with a transverse suture
223673689|NCT03744143|PROCEDURE|Removal of vaginal endometriotic nodule|Surgical eradication of deep infiltrating endometriosis of the vagina using laparoscopic technique, performing 4 transperitoneal abdominal accesses and trocars from 5 to 12 mm, or vaginal technique, isolating the nodule through the vagina.
223673690|NCT02184351|DRUG|Roxanes's clotrimazole troches|
223673691|NCT02184351|DRUG|Mycelex® troches|
223673692|NCT02692651|DRUG|Fidaxomicin|Eligible patients randomized to receive open-label Fidaxomicin will receive 200 mg twice daily for 10 days or until the end of the duration of concomitant antibiotics exposure, whichever is longer.
223673693|NCT02692651|DRUG|Vancomycin|Eligible patients randomized to Vancomycin will receive 125 mg orally four times daily for 10 days or until the end of the duration of concomitant antibiotics exposure, whichever is longer.
223673694|NCT01245361|DRUG|Infliximab|Infliximab 3 mg/kg wk 0,2,6
223673695|NCT01245361|DRUG|sodium chloride|Group II : Placebo wk 0,2,6
223673696|NCT03002376|DRUG|REGN2810|REGN2810 treatment
223673697|NCT01381146|BEHAVIORAL|Impact of Crime Modules|5 session/1 week modules of a restorative justice inspired victim impact group intervention
223673698|NCT01381146|BEHAVIORAL|TAU|have access to other jail programs and services
223673699|NCT02166372|OTHER|Observation of natural course of Diabetes Mellitus Type 2|
223673700|NCT00907660|BEHAVIORAL|Weight loss counseling|Monitoring of weight; review of food and physical activity records; counseling to reduce calorie intake by 500-1000 calories per day
223673701|NCT00907660|DIETARY_SUPPLEMENT|Portion-Controlled Foods|"Consumption of shakes, meal bars, and prepared entrees for 2 out of 3 meals per day during the 14 weeks of the study. Full dose patients are provided with both meals by the study; half dose patients are provided with one out of two meals by the study."
223673702|NCT01548144|DRUG|Crizotinib (Xalkori)|"Starting dose for Crizotinib - Groups A, B, C: 250 mg by mouth every other day, 1 or 2 times a day on Day 1 of a 21 day cycle. Participant told how often to take this drug.~Expansion Groups Starting Dose: MTD from Phase 1."
223673703|NCT01548144|DRUG|Pazopanib|"Starting Dose for Pazopanib - Groups A, C, D: 200 mg by mouth daily in a 21 day cycle.~Expansion Groups Starting Dose: MTD from Phase 1."
223673704|NCT01548144|DRUG|Pemetrexed|"Starting dose for Pemetrexed - Groups B + C: 200 mg/m2 by vein on Day 1 of a 21 day cycle.~Expansion Groups Starting Dose: MTD from Phase 1.~Starting dose for Pemetrexed Group D: 400 mg/m2 by vein every 3 weeks on Day 1 of a 21 day cycle.~Expansion Group Starting Dose: MTD from Phase 1."
223673705|NCT01192243|DRUG|Gefitinib|250mg qd po d3-16
223673706|NCT01192243|DRUG|Pemetrexed|500mg/m2 venous infusion,D1,q3w
223673707|NCT01192243|DRUG|Cisplatin or carboplatin|Cisplatin:75mg/m2, venous infusion,D1,q3w or Carboplatin: AUC 5, venous infusion, D1,q3w
223673708|NCT02480712|DRUG|SOF/VEL|400/100 mg fixed-dose combination (FDC) tablet administered orally once daily
223673709|NCT00733889|DRUG|cetuximab and chemotherapy (docetaxel, cisplatin, 5-fluorouracil)|"Neoadjuvant chemotherapy plus cetuximab:~3 cycles of chemotherapy (Docetaxel: 75 mg/m2; day1; Cisplatin :75 mg/m2, day 1; 5-FU: 750 mg/m2; 24-hour infusion; day1-5) administered every 3 weeks, plus cetuximab (250 mg/m2; day 1, 8 and 15) Cetuximab will be maintained from the beginning of chemotherapy until the end of radiotherapy.~Radio-chemotherapy plus cetuximab:~The radiotherapy treatment: A dose of 50.4 Gy will be administered in 28 fractions of 1.8 Gy / day, 5 days a week (a total of 5.6 weeks).~Cetuximab:250 mg/m2 and Cisplatin: 40 mg/m2, day 1, 8, 15, 22, 29 and 36"
223673710|NCT00068133|GENETIC|Plasmid based Gene Transfer product-VLTS-589|
223673711|NCT06450951|DIAGNOSTIC_TEST|Urinary EDC metabolite testing|Mail-in urine samples tested for metabolites of bisphenols, phthalates, parabens, and oxybenzone.
223673712|NCT06450951|BEHAVIORAL|Educational curriculum|A self-directed online interactive curriculum of EDC material, with access to live coaches and an online forum.
224254385|NCT03410784|DRUG|Pembrolizumab|Pembrolizumab 200 mg i.v. on Day 1 every 3 weeks up to 22 cycles
224254386|NCT03410784|DRUG|Paclitaxel|Paclitaxel 175 mg/m2 i.v. on Day 1 every 3 weeks up to 6 cycles
224254387|NCT03410784|DRUG|Carboplatin|Carboplatin (AUC 5) i.v. on Day 1 every 3 weeks for up to 6 cycles
224254388|NCT02477787|BIOLOGICAL|allogeneic, donor-derived NK cells|"Patients in the study arm will receive donor NK cell infusion around days 13 and 20. A permissible range of infusion time will be +/- 3 days.~For DNKI to be given on day 13 (DNKI-1), the cell dose is 1-2 x108/kg or about the half of amount generated. For DNKI to be given on day 20 (DNKI-2), the cell dose is up to 5x108/kg.~Avil 1 ampoule will be given intravenously 30 minutes prior to each NK cell infusions."
224254389|NCT03801980|DRUG|SK-1403|Patients receive SK-1403 three times a week administered by intravenous bolus injection at the end of each hemodialysis for the whole treatment periods (24 weeks), with individual dose adjustment.
224254390|NCT03801980|DRUG|Placebo|Patients receive Placebo three times a week administered by intravenous bolus injection at the end of each hemodialysis for the whole treatment periods (24 weeks), with individual dose adjustment.
224254391|NCT04789902|OTHER|SurgeCon|The SurgeCon intervention is a pragmatic ED management platform that includes three distinct intervention components which include 1) Restructuring ED Organization \& Workflow, 2) Establishing a Patient-Centric ED Environment, and 3) E-Health Action-Based ED Management that together act to improve ED efficiency and patient satisfaction and value of care.
224254392|NCT06972355|PROCEDURE|Hiding the eyes|Patients will participate in walking rehabilitation sessions on a treadmill supported by a Lite Gait® harness. All treadmill sessions are consistent with regular rehabilitation sessions. A typical treadmill walking session will take place 3 times a week for 6 weeks, lasting 20 minutes. During the first minute, the speed of the treadmill is gradually increased until a comfortable speed is reached. From then on, the mask will be placed over the patient's eyes for 18 minutes at a constant, i.e. comfortable, speed. The last minute will be devoted to gradually decreasing the treadmill speed until it stops, and will also be performed without the mask.
224254393|NCT05646251|DEVICE|Heart Ultrasound|A wand is placed on the chest to use soundwaves to make a picture of the heart and shows how the muscle and valves work. This helps with device placement.
224254394|NCT02247752|OTHER|inactive carrier|"Yearly demographic, clinic, biologic and ultrasonic data collection realized during usual follow-up as recommended.~Yearly centralisation of a complementary biological analysis in Paul Brousse Hospital laboratory of virology."
224254395|NCT03491579|DRUG|Epacadostat|Epacadostat orally two times daily (BID) for two cycles (28 days each) in combination with standard induction chemotherapy (Cladribine and Cytarabine)
224254396|NCT03491579|DRUG|Cladribine|Standard chemotherapy
224254397|NCT03491579|DRUG|Cytarabine|Standard chemotherapy
224254398|NCT00707408|DRUG|Imatinib|Daily dosing of imatinib 600 mg/day is planned for one month or until progression of disease. Dose increase to 800 mg/ day imatinib is permitted for 2 additional months in the event of response failure. Novartis provided supplies of imatinib for all patients included in the study.
224254399|NCT06043362|OTHER|0 mg nicotine pouch|Oral nicotine pouches that contain 0 mg of nicotine
224254400|NCT06043362|OTHER|3 mg nicotine pouch|Oral nicotine pouches that contain 3 mg of nicotine
224254401|NCT06043362|OTHER|6 mg nicotine pouch|Oral nicotine pouches that contain 6 mg of nicotine
223673713|NCT00885001|PROCEDURE|Short Arc Banding|Lumbar extension on the ATM II from back project. Rehabilitation exercise intervention.
223673714|NCT00353028|DRUG|Fluvoxamine maleate|Test product: Fluvoxamine maleate 25mg tablet. In case that the daily dose is one tablet, the study medication will orally be administered once daily, at bedtime. In case that the daily dose is two tablets or higher (maximam:6 tablets), the study mmedica
223673715|NCT00353028|DRUG|Placebo|Placebo
223673716|NCT03566836|DEVICE|Garmin Smart Watch|Garmin Smart Watch
224254402|NCT06043362|OTHER|Smooth nicotine pouch|Non-flavored nicotine pouches that are characterized as smooth.
224254403|NCT06043362|OTHER|Wintergreen nicotine pouch|Menthol flavored nicotine pouches that are characterized as wintergreen.
224254404|NCT00308048|DRUG|Pegylated Interferon alfa 2b and ribavirin|
223673717|NCT03566836|DEVICE|Garmin Chest Band|Garmin Chest Band
223673718|NCT05018936|DRUG|Hetrombopag|Hetrombopag starting at 5mg/day and increased by 2.5mg/day every 2 weeks if the platelet count remains less than 20×10e9/L and reduced if the platelet count reaches over than 150×10e9/L.
223673719|NCT06322290|DIAGNOSTIC_TEST|assessment of pathogens in blood specimens|Molecular diagnosis of Invasive bacterial diseases due to Streptococcus pneumoniae, Neisseria meningitidis and Haemophilus influenzae
223673720|NCT00475423|DRUG|rituximab [MabThera/Rituxan]|1000mg iv on days 1 and 15
224254405|NCT04808557|OTHER|Biorepair Total Protection|Volunteers will use Biorepair Total Protection for home oral hygiene for the following 30 days from the bonding procedure.
224254406|NCT04808557|OTHER|Sensodyne Repair & Protect|Volunteers will use Sensodyne Repair \& Protect for home oral hygiene for the following 30 days from the bonding procedure.
224254407|NCT05317585|DEVICE|Continuous Glucose Monitor|Continuous Glucose Monitor
224254408|NCT05317585|DEVICE|Routine Capillary Blood Glucose Monitoring (Fingerstick Glucose)|Routine Capillary Blood Glucose Monitoring (Fingerstick Glucose)
224254409|NCT06136884|DRUG|AO-252|AO-252 will be administered oral tablets or capsules daily
224254410|NCT04609826|DRUG|JNJ-74856665|JNJ-74856665 will be administered orally.
224254411|NCT04609826|DRUG|AZA|AZA will be administered IV infusion or SC injection.
224254412|NCT04609826|DRUG|VEN|VEN tablet will be administered orally.
224254413|NCT06545942|DRUG|MOMA-313|MOMA-313 administered orally
224254414|NCT06545942|DRUG|Olaparib|Olaparib administered orally
224322276|NCT04739800|DRUG|Pegylated Liposomal Doxorubicin Hydrochloride|Given IV
223673721|NCT05457894|BIOLOGICAL|Flu-M, Inactivated split influenza vaccine|solution for intramuscular injection, 0.5 ml
223673722|NCT05457894|BIOLOGICAL|Ultrix®, Inactivated Split Influenza Vaccine|solution for intramuscular injection, 0.5 ml
223673723|NCT05463198|DEVICE|CM-1600|Subjects undergoing blood donation will be connected to the CM-1600 device.
223680663|NCT01752712|DRUG|CBSST + Placebo|Matching placebo spray will be administered intranasally (10 puffs of the spray, 5 in each nostril at each administration). CBSST groups will occur for an hour twice/week. Nasal spray will be administered an hour prior to the CBSST group.
224254415|NCT05189093|DRUG|Recombinant humanized anti-CD47/PD-1 bifunctional antibody HX009 injection|There will be a total of 4 cohorts, each cohort will explore 1-2 dose levels, i.e. 10 mg/kg and 15 mg/kg, with an expected enrollment of 40-80 cases. The 10 mg/kg dose level will be enrolled first, the After discussion between the sponsor and the DSC, the 15 mg/kg dose level will be enrolled if necessary. Based on the DMC analysis, the no-trend cohort will be enrolled in a maximum of 10 cases (with the possibility of stopping enrollment halfway through).
223673724|NCT06150144|DRUG|5-Fluorouracil|The invistigators want to assess the safety and efficacy of using intralesional 5-FU for the management of different types of BCC (including all the types EXCEPT the infiltrative one), by estimating different outcomes after the intralesional administration of 5-FU to BCC patient. Patients are randomly selected from the outpatient dermatologic clinic in the Aleppo University Hospital (AUH) over a period of 12 months and then these patients are followed up over another 12 months.
223673725|NCT06150144|OTHER|SURGERY|Total excision of the lesion
224254417|NCT01983761|DRUG|Fludarabine, Clofarabine, Busulfan, ATG, TBI (Myeloablative)|
224254418|NCT01983761|DRUG|Fludarabine, Melphalan, ATG (Reduced Intensity)|
224254419|NCT01372579|DRUG|eribulin mesylate|Given IV
224254420|NCT01372579|DRUG|carboplatin|Given IV
224254421|NCT01372579|PROCEDURE|biopsy|Correlative studies
224254422|NCT06561100|BEHAVIORAL|Sub-symptomatic Adaptable Exercise Treatment (SAET)|Each workout will be structured in a similar format. The first 5 minutes will be devoted to stretching and warm up exercises. Then the next 20 minute segment devoted to light to moderate aerobic exercise. The second 20 minutes of each exercise session will be composed of a series of 5 predetermined exercises that rotate every day. Each workout will have one or two alternatives that the patient can complete either for modification to accommodate a physical limitation or to optimize preference. Resistance training each day will include multi-joint functional movements along with stability work. The last five minutes of the session will include more mobility work, and/or cooling down.
224254423|NCT06561100|BEHAVIORAL|Stretching Control Group (SCG)|Each workout will be 50-60 minutes long and participants are instructed to not do any other type of exercise that may elevate their heart rate. Modifications will be available for stretches that may be too advanced for the individual.
224254424|NCT05239754|OTHER|Primary Services|Primary services: Participants receive 16 hours of 24/7 Dads curricula and at least 2 hours of career readiness workshops over the course of 9 weeks. Participants also receive ongoing job readiness support and post-employment support.
224254425|NCT05782634|DEVICE|immediate satellite implant with immediate loading|"Infiltration anesthesia will be administered using mepivacaine HCl (2%) with levonordefrin 1:20 000 . Injection to control pain and bleeding for hemostasis.~Dental extraction will be done with minimal force to avoid trauma to the bone. Flab will be released, different drilling sizes will be used to attain the final drill size of the planed implant height and width according to Cone Beam CT. Implants were screwed directly into the osteotomy site, a satellite implant device is attached to the implant's abutment placed on the buccal and palatal plates of bone and retention between the abutment and microplate will help in neglecting the lateral destructive forces . sutures will be done . Impression will be taken for immediate loading with the final crown. Cone beam will be done."
224254426|NCT05086783|OTHER|Video-based coaching|The coaching session will follow the Wisconsin Coaching Framework (Greenberg 2015). The surgical coaching session will last at maximum 30 minutes and will occur within 1-2 week following the procedure. The surgical coaching session will occur over Zoom. The second attempt will occur within 1 week following the coaching session.
224254427|NCT05086783|OTHER|Standard surgical teaching (master-apprentice model - (MAM))|Standard surgical teaching that conventionally occurs in the operating room follows a master-apprentice model (MAM).
224254428|NCT06425757|DRUG|ciprofol|Patients who intended to undergo elective surgery under general anesthesia were induced by a single intravenous injection of 0.3mg/kg and ciprofol, and the experimental drug was manually injected by CVC within 30s. 2ml of venous blood was collected before and after administration 0.5min, 1min, 2min, 3min, 5min, 8min, 15min 30min, 1h, 2h and 4h respectively. The concentration of cyclopofol in blood was measured
224254429|NCT01762709|PROCEDURE|The VT 4 ml/kg group|the dependent lung will be ventilated with a TV of 4 mL/kg (predicted body weight), respectively, whereas FiO2, I: E ratio, PEEP, frequency, Ppk, and a FGF will be maintained as during two-lung ventilation (TLV) and the lumen of the nondependent lung will be left open to air. Dependent lung recruitment maneuvers will be repeated at 30-minute intervals by raising the inspiratory pressure up to 35 cmH2O for 10 seconds.
224254430|NCT01762709|PROCEDURE|The VT 6 ml/kg group|the dependent lung will be ventilated with a TV of 6 mL/kg (predicted body weight), respectively, whereas FiO2, I: E ratio, PEEP, frequency, Ppk, and a FGF will be maintained as during two-lung ventilation (TLV) and the lumen of the nondependent lung will be left open to air. Dependent lung recruitment maneuvers will be repeated at 30-minute intervals by raising the inspiratory pressure up to 35 cmH2O for 10 seconds.
223673726|NCT02385227|OTHER|Exclusive blu™ e-cigarette A1|Classic Tobacco rechargeable e cigarette
223673727|NCT02385227|OTHER|Exclusive blu™ e-cigarette A2|Magnificent Menthol rechargeable e cigarette
223673728|NCT02385227|OTHER|Exclusive blu™ e-cigarette A3|Cherry Crush rechargeable e cigarette
223673729|NCT02385227|OTHER|Dual blu™ e-cigarette and usual brand B1|Classic Tobacco rechargeable e cigarette and a usual brand combustible cigarette
223673730|NCT02385227|OTHER|Dual blu™ e-cigarette and usual brand B2|Magnificent Menthol rechargeable e cigarette and a usual brand combustible cigarette
223673731|NCT02385227|OTHER|Dual blu™ e-cigarette and usual brand B3|Cherry Crush rechargeable e cigarette and a usual brand combustible cigarette
223673732|NCT02385227|OTHER|Nicotine product cessation C|Nicotine cessation
223673733|NCT04700033|DEVICE|Somatic IVR (sIVR)|This intervention will consist of an IVR protocol that is focused on somatic interaction that encourages disassociation between pain and visualization and movement of the affected limbs. Subjects in this group will be exposed to an IVR environment that cycles them through a series of stretching and mobility exercises for the affected limbs bilaterally.
223673734|NCT04700033|DEVICE|Distractive IVR (dIVR)|This intervention will consist of an IVR that is focused on distracting the subject from the pain. Subjects in this group will be exposed to a variety of engaging landscape IVR environments, without the ability to visualize their own body.
224254431|NCT01762709|PROCEDURE|The VT 8 ml/kg group|the dependent lung will be ventilated with a TV of 8 mL/kg (predicted body weight), respectively, whereas FiO2, I: E ratio, PEEP, frequency, Ppk, and a FGF will be maintained as during two-lung ventilation (TLV) and the lumen of the nondependent lung will be left open to air. Dependent lung recruitment maneuvers will be repeated at 30-minute intervals by raising the inspiratory pressure up to 35 cmH2O for 10 seconds.
224254432|NCT03122457|DRUG|lidamycin phosphate and benzoyl peroxide 1.2%/3.75% combination|At Day 15, patients will be re-assessed and dispensed the investigational product and instructed on its daily use. Patients will continue to return every 14 days to have their skin assessed until their final visit on day 99, one week after their 3rd menses on treatment (4th menses on study).
224254433|NCT02704286|BEHAVIORAL|Internet-Based Osteoarthritis Risk Calculator|The investigators have developed a personalized risk calculator for knee osteoarthritis. This risk calculator uses the Osteoarthritis Policy Model to estimate an individual's risk of developing knee osteoarthritis within their lifetime based on demographic information and risk factors. It shows this information to the user with interactive graphs and compares their risk to the risk of an average American of the same age.
224254434|NCT02704286|BEHAVIORAL|Generic osteoarthritis information|Subjects viewed generic (i.e. not personalized) information about osteoarthritis risk factors
224254435|NCT03677739|OTHER|Informational Intervention|Receive information focusing on skin cancer
224254436|NCT03677739|OTHER|Informational Intervention|Receive information on healthy lifestyle
224254437|NCT03677739|OTHER|Survey Administration|Ancillary studies
224254438|NCT04501328|BEHAVIORAL|CIC+VA-CRAFT|CIC+VA-CRAFT consists of four 45-min. telephone coaching calls over 8-12 weeks, delivered by a coach following a manual, while participants are completing the VA-CRAFT for PTSD web-based course.
224254439|NCT04501328|BEHAVIORAL|CIC|Coaching Into Care is an existing national VA program that provides telephone consultation and coaching to family members of Veterans with mental health needs who want to help connect them with mental health care by providing referrals, educational information, and a unique coaching service to help callers talk to their Veterans about their decision to seek care.
224254440|NCT05523583|OTHER|questionnaire|A trained interviewer (Clinical Research Associate : CRA) will administer a questionnaire soon after the diagnosis on the phone (within 15 calendar days after diagnosis). The participants are followed up during the first year following the diagnosis through 3 follow-up assessments (at 3, 6, and 12 months after the baseline assessment) and hospital record reviews. At each follow-up, a brief questionnaire will be administered by an interviewer (CRA) via telephone.
224254441|NCT04565795|DEVICE|Uriprene® Degradable Temporary Ureteral Stent|Assess adequate intervention-free drainage during use and the time to complete degradation or the passage of stent fragments/segments from the urinary system by radiological assessment.
224254442|NCT04659603|DRUG|tusamitamab ravtansine|"Pharmaceutical form:Concentrated solution for IV;~Route of administration: IV infusion"
224254443|NCT04659603|DRUG|Gemcitabine|"Pharmaceutical form: Lyophilized powder for reconstitution or as a solution for infusion;~Route of administration: IV infusion"
224254444|NCT01070433|DRUG|MEBO Wound Ointment (MEBO)|Topical application twice a day
224254445|NCT01070433|OTHER|Standard of Care|Topical application twice a day
224254446|NCT03254420|DEVICE|Calypso beacon implant|Calypso beacon implant before radiotherapy
224254447|NCT03254420|RADIATION|moderate hypofractionation Radiotherapy|moderate hypofractionation Radiotherapy
224254448|NCT05743244|DRUG|Abrocitinib 200 MG Oral Tablet|Abrocitinib
224254449|NCT05743244|DRUG|Ritlecitinib|Ritlecitinib
224254450|NCT05743244|DRUG|Placebo|Placebo for Abrocitinib or Ritlecitinib
224254451|NCT05765812|DRUG|Debio 0123|Administered as capsules.
224254452|NCT05765812|DRUG|Temozolomide|Administered as capsules.
224254453|NCT05765812|RADIATION|Radiotherapy|Administered in accordance with the local clinical practice and applicable Radiation Therapy Oncology Group (RTOG) or the European Organization for Research and Treatment of Cancer (EORTC) guidelines.
224254454|NCT03225547|DRUG|Pembrolizumab|Pembrolizumab 200mg will be administered to all patients on day 1 of every 21 day cycle.
224254455|NCT03225547|DRUG|Mifepristone|Mifepristone 300mg will be administered to all patients daily starting the week prior to pembrolizumab.
224254456|NCT04340531|OTHER|Best Practice|Receive usual care
224254457|NCT04340531|OTHER|Survey Administration|Ancillary studies
224254458|NCT04340531|OTHER|Tobacco Cessation Counseling|Receive referred to counseling session
224254459|NCT04340531|OTHER|Tobacco Cessation Counseling|Receive phone counseling
224254460|NCT04340531|OTHER|Training|Undergo training
224254461|NCT01231906|DRUG|Cyclophosphamide|Given IV
224254462|NCT01231906|DRUG|Dexrazoxane|
224322277|NCT04739800|DRUG|Topotecan Hydrochloride|Given IV
224254463|NCT01231906|DRUG|Doxorubicin Hydrochloride|Given IV
224254464|NCT01231906|DRUG|Etoposide|Given IV
224254465|NCT01231906|DRUG|Ifosfamide|Given IV
224254466|NCT01231906|OTHER|Laboratory Biomarker Analysis|Correlative studies
224254467|NCT01231906|DRUG|Topotecan Hydrochloride|Given IV
224254468|NCT01231906|DRUG|Vincristine Sulfate|Given IV
224254469|NCT02747056|OTHER|clinical, psychological and neuropsychological assessment|the subjects will do 3 tests about executive functions, complete 3 questionnaires about autism and 3 questionnaires about the self concept
224254470|NCT02747056|OTHER|Autobiographical memories Assessment|The investigators will ask subjects to tell autobiographical memories freely first and, secondly, to specify participants'characteristics by answering focused questions.
224254471|NCT02747056|OTHER|Autobiographical memories assessment characteristics|During the second time point, the investigators will ask subjects to say the self statements which define them. Then, subjects will have to tell and to specify the characteristics of the autobiographical memories linked to these self statements.
224254472|NCT06777511|DRUG|5-aminolevulinic acid (5-ALA)|All patients who are recruited and enrolled into this study use topical 5- ALA, in combination with the light delivery device as part of their standard stoma management.
224254473|NCT06777511|DEVICE|Photodynamic therapy (PDT)|All patients who are recruited and enrolled into this study use topical 5- ALA, in combination with the light delivery device photodynamic therapy device as part of their standard stoma management.
223673735|NCT04700033|DEVICE|Control IVR (cIVR)|This intervention will consist of an IVR exposure to a black screen for 20 minutes. No light, images or scenery will be present in the IVR and it will serve as a control condition for the trial.
223673736|NCT03304496|DRUG|Nitroglycerin 100 MCG/ML Injectable Solution|Previously described.
223673737|NCT03304496|DRUG|Saline Solution|Previously described.
223673738|NCT05993975|DRUG|Bupivacain 0.5%|Bupivacaine hydrochloride was given without any adjuvant
223673739|NCT05993975|DRUG|Dexmedetomidine Hydrochloride|Use of Dexmedetomidine Hydrochloride 5 micrograms (1 mL) as an adjuvant with bupivacaine hydrochloride
223673740|NCT01348009|DRUG|Tesetaxel-capecitabine-cisplatin|"Phase 1: Tesetaxel orally on Day 1 of each cycle at dose of 18, 21, 24, or 27 mg/m2. If no dose-limiting toxicity, at least 3 subjects will be treated at each dose level until the maximum tolerated dose or the maximum dose of 27 mg/m2 is reached. At each tesetaxel dose level, capecitabine orally at a dose of 2000 mg/m2/day (administered in 2 equally divided doses) on Day 1-Day 14 and cisplatin intravenously at a dose of 60 mg/m2 on Day 1.~Phase 2: Tesetaxel orally on Day 1 of each cycle at dose determined in Phase 1. Capecitabine orally at a dose of 2000 mg/m2/day (administered in 2 equally divided doses) on Day 1-Day 14 and cisplatin intravenously at a dose of 60 mg/m2 on Day 1."
223673741|NCT01856764|DRUG|0.5% Roflumilast Cream|Roflumilast 0.5% cream
223673742|NCT01856764|DRUG|Vehicle Cream|Roflumilast formulation vehicle
223673743|NCT01254955|BIOLOGICAL|H1N1 vaccine Pandemrix|
223673744|NCT05967897|DIETARY_SUPPLEMENT|Blueberries|22 g freeze-dried blueberry powder mixed with water
223673745|NCT05967897|DIETARY_SUPPLEMENT|Blueberries and Whey Protein|22 g freeze-dried blueberry powder mixed with whey protein and water
223673746|NCT05967897|DIETARY_SUPPLEMENT|Blueberries and Pea Protein|22 g freeze-dried blueberry powder mixed with pea protein and water
223673747|NCT05967897|DIETARY_SUPPLEMENT|Blueberries and Hemp Protein|22 g freeze-dried blueberry powder mixed with hemp protein and water
223673748|NCT02239120|DRUG|optional ASA as comedication|optional concomitant treatment which can be used for patients with coronary artery disease. It is not required for these pts.
223673749|NCT02239120|DRUG|placebo to ASA|placebo to comparator drug
223673750|NCT02239120|DRUG|placebo to optional ASA as comedication|optional concomitant treatment which can be used for patients with coronary artery disease. It is not required for these pts.
223673751|NCT02239120|DRUG|placebo to dabigatran etexilate|placebo
223673752|NCT02239120|DRUG|ASA 100 mg|active comparator drug
223673753|NCT02239120|DRUG|dabigatran etexilate|active drug
223673754|NCT03673735|DRUG|Durvalumab|Durvalumab (one dose) before CRT and for 6 months Q4W after CRT
223673755|NCT03673735|RADIATION|radiotherapy|radiotherapy is administered in 33 fractions over 6.5 weeks fro a total of 66 Gy
223673756|NCT03673735|DRUG|Placebo|placebo (one dose) before CRT and for 6 months Q4W after CRT
223673757|NCT03673735|DRUG|Cisplatin|Cisplatin (100mg/m2) is administered at day 1, 22, 43 of radiotherapy
223673758|NCT00184574|DRUG|biphasic insulin aspart|
223673759|NCT00184574|DRUG|metformin|
223673760|NCT00466687|BIOLOGICAL|bevacizumab|10mg/kg, slow IV infusion, Days 1 and 14
223673761|NCT00466687|DRUG|erlotinib hydrochloride|150mg PO qd
223673762|NCT00466687|GENETIC|fluorescence in situ hybridization|Targeting multiple genetic aberrations in isolated tumor cells.
223673763|NCT00466687|GENETIC|gene expression analysis|gene expression analysis
223673764|NCT00466687|OTHER|immunologic technique|immunologic technique
223673765|NCT00466687|OTHER|laboratory biomarker analysis|laboratory biomarker analysis
223673766|NCT00466687|PROCEDURE|biopsy|biopsy
223673767|NCT02963961|BEHAVIORAL|Preoperative Cognitive Training Battery|Patients will engage in a daily preoperative cognitive training battery (BrainHQ, Posit Science) that aims to improve attention, memory, and visuospatial processing.
223673768|NCT01331018|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow harvest
223673769|NCT01331018|BIOLOGICAL|Filgrastim|Given SC
223673770|NCT01331018|BIOLOGICAL|Genetically Engineered Hematopoietic Stem Progenitor Cells|Undergo infusion of genetically modified hematopoietic progenitor cell therapy
223673771|NCT01331018|OTHER|Laboratory Biomarker Analysis|Correlative studies
223673772|NCT01331018|PROCEDURE|Leukapheresis|Undergo leukapheresis
223673773|NCT01331018|DRUG|Methylprednisolone|Given IV
223673774|NCT01331018|DRUG|Plerixafor|Given SC
223673775|NCT01331018|DRUG|Prednisone|Given PO
223673776|NCT01925989|BIOLOGICAL|LY2605541|Administered SQ
223673777|NCT01925989|BIOLOGICAL|Insulin Glargine|Administered SQ
223673778|NCT00167466|DEVICE|Soladey-3 toothbrush|subject to brush with experimental Soladey-3 brush for 4 week
223673779|NCT00167466|DEVICE|Placebo Soladey-3 toothbrush|subjects will brush with placebo Soladey-3 toothbrush for 4 weeks
223673780|NCT00238602|PROCEDURE|Stereotactic radiosurgery|
223673781|NCT03152006|OTHER|ACT|Coordinated, graduated transition which includes an early introduction to the adult clinician during the PAPA pre-transfer period, a peer-facilitated organized support group aimed at improving transition readiness and addressing critical psychosocial skills including self-efficacy and locus of control and a case management team including a patient advocate who coordinates the transfer between pediatric and adult care teams.
223673782|NCT01724619|DRUG|[F-18] fluorinated dihydrotestosterone (FDHT)|
223673783|NCT01489241|PROCEDURE|Telemonitoring|Within 24 hours after patient's discharge, the telemedicine equipment is installed at the patient's home and patients are trained in the use of the equipment. Patients are followed by a dedicated telehealth centre. Patients at home are asked to fill out each morning the CAT questionnaire and to record extra use of COPD relief medications. Patients in stable conditions perform telespirometry and teleoximetry at 4 and 12 weeks. When a clinical worsening is detected (increase in CAT score by 5 points or higher on two consecutive days) the patient is contacted and asked to perform ad hoc telespirometry and teleoximetry and to send the data to the telehealth centre.
223673784|NCT01470443|DRUG|Oxaliplatin|Oxaliplatin 130mg/㎡, day 1, every 3 weeks
223673785|NCT01470443|DRUG|Oxaliplatin|Oxaliplatin 100 mg/㎡, day 1, every 3 weeks
223673786|NCT01535976|DRUG|Placebo|"Placebo Comparator: Placebo~.9 normal saline infusion"
223673787|NCT01535976|DRUG|Ketamine|Ketamine infusion .5mg/kg bolus followed by 1.5 mcg/kg/minute until end of case
223673788|NCT01268371|DEVICE|Promus Element, Boston Scientific Corporation|Everolimus-eluting stent
223673789|NCT01268371|DEVICE|Nobori, Terumo Corporation (Japan)|Biolimus-eluting stent with biodegradable polymer
224254474|NCT04529252|OTHER|Specimen collection|Blood, urine, stool, cerebrospinal fluid, and skin biopsy may be collected
224254475|NCT03503097|PROCEDURE|Biospecimen Collection|Provide saliva samples
224254476|NCT03503097|OTHER|Genetic Counseling|Undergo counseling
224254477|NCT03503097|OTHER|Genetic Testing|Undergo genetic testing
224254478|NCT03503097|OTHER|Laboratory Biomarker Analysis|Correlative studies
224254479|NCT03503097|BEHAVIORAL|Questionnaire|Complete questionnaire
224254480|NCT06389149|OTHER|LEAP therapy|Knee bending from 90°-180° at 1Hz for 1 minute every 10 minutes during 2.5 hours of prolonged sitting
224254481|NCT06389149|OTHER|no LEAP therapy|2.5 hours of uninterrupted prolonged sitting (no movement)
224254482|NCT05568095|DRUG|Domvanalimab|Intravenous (IV) Aqueous Solution
224254483|NCT05568095|DRUG|Zimberelimab|IV Aqueous Solution
224254484|NCT05568095|DRUG|Capecitabine|Oral Tablets
224254485|NCT05568095|DRUG|Fluorouracil|IV Aqueous Solution
224254486|NCT05568095|DRUG|Leucovorin|IV Aqueous Solution
224254487|NCT05568095|DRUG|Oxaliplatin|IV Aqueous Solution
224254488|NCT05568095|DRUG|Nivolumab|IV Aqueous Solution
224254489|NCT07122973|OTHER|Histamine|To deliver histamine, standard allergy skin prick test (SPT) lancets are applied
224254490|NCT07122973|OTHER|Cowhage|The spicules will be manually inserted. Approximately 30-35 spicules are gently rubbed into a 1 cm diameter skin area on the forearm/face
224254491|NCT07122973|OTHER|Capsaicin 8% Patch|Capsaicin patches (dosage form: transdermal patch 8% Qutenza, Astellas) will be applied on 3 squared areas in the face.
223673790|NCT03967691|DRUG|Tocilizumab infusion|Tocilizumab (8mg/kg body weight diluted to 100 ml NaCl 0.9%) will be infused over 1 hour
223673791|NCT03967691|DRUG|Saline 0.9%|100 ml NaCl 0.9% will be infused over 1 hour
224254492|NCT07122973|OTHER|Demo patch|Placebo patch (demo patch, containing the same formulation as the active treatment with the exception of capsaicin) will be applied on 3 squared areas in the face.
224254493|NCT05490433|PROCEDURE|Robot-assisted Nipple-Sparing Mastectomy (RNSM)|"Patients undergoing robot-assisted nipple-sparing mastectomy (RNSM) with immediate breast reconstruction (IBR) will be enrolled in this group. RNSM will be performed using robotic surgical platforms, including the da Vinci S, Si, X, Xi, and SP systems. The procedure will be conducted through an axillary or lateral chest wall incision.~During surgery, posterior areolar tissue sampling for frozen section biopsy will be recommended. If suspicious lesions are detected at the superficial or posterior margins, frozen section biopsy of those lesions will also be performed. When tumor involvement of the nipple-areola complex (NAC), superficial margin, or posterior margin is confirmed by frozen section biopsy, additional resection including the skin and NAC, or postoperative radiotherapy, will be considered."
223673792|NCT06032897|OTHER|Individualized music listening (IML)|The earphones were placed on individuals in the experimental group to listen to individualized music for 20 minutes. The Individualized music listening (IML) were performed twice a week for four weeks, for a total of eight times.
223673793|NCT02034344|PROCEDURE|Skin biopsy|Participants with LE will have 2 adjacent 4 mm punch biopsies collected from involved and uninvolved skin at one timepoint and again from the involved skin site approximately 12 weeks later. Healthy participants will have 2 adjacent 4 mm punch biopsies taken at one timepoint.
223673794|NCT02034344|PROCEDURE|Blood collection|Blood for serum analyses will be taken from all participants. Blood for DNA analysis will only be taken from participants who consent to this separately.
223673795|NCT02034344|PROCEDURE|Urine collection|Urine will be collected from all participants.
224254494|NCT05490433|PROCEDURE|Conventional nipple sparing mastectomy(CNSM)|"Patients who undergo conventional nipple-sparing mastectomy (CNSM) with immediate breast reconstruction (IBR) will be enrolled in this group. CNSM is performed without the use of robotic or endoscopic surgical systems, and all types of skin incisions are permitted.~During surgery, posterior areolar tissue sampling for frozen section biopsy is recommended. If suspicious lesions suggesting tumor involvement are identified at the superficial or posterior margins, frozen section biopsy should also be performed. When frozen section biopsy confirms tumor involvement of the nipple-areola complex (NAC), superficial margin, or posterior margin, additional excision including the skin and NAC, or postoperative radiotherapy, will be considered."
224254495|NCT06842823|DRUG|navenibart|Navenibart will be administered as a subcutaneous injection.
224254496|NCT06842823|DRUG|Placebo|Placebo will be administered as a subcutaneous injection.
224254497|NCT06319248|DRUG|Midodrine|Subjects will receive standard of care for sepsis and 10 mg of Midodrine every 8 hours administered orally or enterally (via nasogastric tube)
224254498|NCT06319248|OTHER|Standard of Care|Subjects will receive standard of care for sepsis treatment.
224254499|NCT06587984|BEHAVIORAL|Text message reminder|One-time text message reminder with information about getting flu vaccine at CHOP
224254500|NCT05639114|DRUG|Ianalumab|ianalumab s.c. monthly or quarterly
224254501|NCT05639114|DRUG|Placebo|placebo s.c. monthly
224254502|NCT06750666|DIAGNOSTIC_TEST|De-implementation of Urinary Dipsticks|In August 2023 / February 2024, urinary dipsticks were de-implemented in hospitals across the North Denmark Region. Using registry-based data, the investigators aim to evaluate the clinical impact of this decision.
224254503|NCT06750666|OTHER|Usual practice with no intervention|In hospitals within the Central Denmark Region and in the primary care sector, urinary dipsticks have not been de-implemented and remain in use. Registry-based data from these settings will serve as a control.
224254504|NCT05727020|DIAGNOSTIC_TEST|Breath test|Patients must be fasted for a minimum of six hours prior to sample collection. For patients undergoing surgery or a procedure (e.g. endoscopy), breath samples must be obtained pre-operatively / prior to the administration of sedation, anaesthetic or other pharmacological agents.
224254505|NCT05727020|DIAGNOSTIC_TEST|Collection of matched samples of breath, biofluids and pancreatic tissue|In accordance with routine clinical practices, patients will be fasted for a minimum of six hours prior to surgery. Exhaled breath, saliva, blood and urine will be collected immediately prior to surgery (before induction of general anaesthesia). Pancreatic tissue samples and duodenal aspirate which will be collected upon resection of the pancreatic specimen.
224254506|NCT06897267|BEHAVIORAL|The Grow to Recovery program-Short Version|"The program is based on Pathways to Recovery:A Strengths Recovery Self-help Workbook. After completing the leader training program, one peer and one professional will conduct a 10-week Grow to Recovery program-Short Version for people with mental illness. This program covers recovery concepts, strengths, and goal setting, which will be helpful for people in recovery."
224254507|NCT06762795|GENETIC|Genome sequencing|Neonates enrolled in this study will undergo genome sequencing with parental controls as applicable.
224254508|NCT07063654|BEHAVIORAL|Heart2Heart|Heart2Heart is a mobile health program for teens with congenital heart disease. It includes information and interactive features to help teens learn about staying healthy with congenital heart disease.
224254509|NCT07065409|BIOLOGICAL|iPSC-EVs|iPSC-EVs，The drug number is NouvSoma002-01. It is from iRegene Therapeutics Co., Ltd.
224254510|NCT05302908|BEHAVIORAL|NuestraSaludSegura|It blends peer navigation and mHealth
224254511|NCT04622150|BEHAVIORAL|Customized Adherence Enhancement (CAE)|CAE is comprised of a series of up to four treatment modules whose inclusion is determined based upon an individuals reasons for nonadherence (adherence barriers).The standardized modules are Psychoeducation, Modified Motivational Interviewing, Communication with Providers, Medication Routines. CAE participants will have a core series of approximately four sessions spaced about one week apart over a period of 4-6 weeks, and one booster in-person session 4 weeks after the completion of the four core sessions (total of approximately 5 sessions). Sessions 2-4 will be delivered remotely by the study interventionist. All participants will have the first session in-person. The final booster session will be conducted at the sites and will review all previously introduced materials. There will be a follow-up phone call with the study interventionist that will occur in the four-week time period between completion of four CAE core sessions and prior to initiation of the booster CAE session.
224254512|NCT04622150|BEHAVIORAL|Enhanced Treatment as Usual (eTAU)|eTAU participants will receive monthly text messages (or phone calls for participants who prefer not to receive texts) to refill medications, fill eCAPs and brief general adherence promotion messages during the follow-up period.
224254513|NCT05644951|DEVICE|Hot AXIOS system used for EPASS|EUS-guided double-balloon-occluded gastrojejunostomy bypass with Hot AXIOS system
224254514|NCT07191821|DRUG|XBD173|Small molecule experimental medication binding to mitochondrial protein TSPO
224254515|NCT07194954|DIETARY_SUPPLEMENT|Combined Dietary Fiber and Probiotics.|The intervention consisted of a daily oral administration of 20g of a mixed dietary fiber powder (FibroBalance®, containing inulin, pectin, and β-glucan) and one multi-strain probiotic capsule (ProbioCare Forte®, delivering 10\^9 CFU of Lactobacillus acidophilus NCFM, Bifidobacterium lactis Bi-07, and Streptococcus thermophilus St-21).
224254516|NCT07194954|OTHER|Standard Nutritional Support|This included dietary counseling from a registered dietitian and, if necessary, a standard oral nutritional supplement (Ensure®) to meet estimated energy and protein requirements.
224254517|NCT07193030|BEHAVIORAL|Peer-led Alcohol Brief Intervention (identification + advice)|"The intervention consists of a peer-led ABI for university students. This intervention aligns with the ABI approach recommended by the WHO as a cost-effective strategy to reduce harmful alcohol use, particularly in primary care and community settings. The brief advice component of the intervention will incorporate Motivational Interviewing (MI) techniques, a client-centred, evidence-based counselling style intervention effective for reducing risky drinking behaviours. The brief advice will be tailored based on behavioural insights identified through formative research, such as individual perceived facilitators and barriers.~The Alcohol Use Disorders Identification Test- Consumption (AUDIT-C) will be used as the screening tool for identification.~A one-on-one Brief Advice sessions of 15-20 minutes will be delivered by trained peer educators, i.e., university students who are not healthcare professionals but have been specifically trained in delivering brief advice."
224254518|NCT07192419|BEHAVIORAL|Promoting Aging and Thriving with HIV (PATH)-Implementation of a Tailored Geriatric Assessment and Management Strategy for HIV Care Settings|"For the intervention arm, participants will be sent geriatric assessment questions through the patient portal in advance of a routine HIV appointment. If the participant is unable to complete the questions in advance, they will be done with the help of a research coordinator to go through on the day of appointment. Every attempt will be made to ensure the assessment can be done in advance of the appointment, however the study team will allow for visits after the regular appointment as in which case the provider will receive results after the patient has left clinic.~The provider will receive the PATH assessment responses and a discussion guide with suggested initial management steps. The provider ultimately determines with the participant when and if they will address concerns identified (that visit or future visit) based on participant priorities. The patient participant will also receive a copy of their screening results."
224254519|NCT07194642|OTHER|Dexcom G7 CGM|The Dexcom G7 is a continuous glucose monitor, FDA 510K cleared (K213919) for people with diabetes. Worn for 10 days at a time, the device monitors the glucose levels of interstitial fluid and, via bluetooth, transmits data every 5 minutes to a receiver.
224254520|NCT07201662|OTHER|Condensed and Revised Multifaceted Empathy Test|Experimental emotional decoding task that measures the cognitive and affective dimensions of empathy based on performance (Edele et al., 2013; Grynberg et al., 2017).Participants view 40 photos of faces expressing either a positive or negative emotion and must identify the emotion (decoding) and then rate on a 1-9 scale the extent to which they share it (emotional sharing). The task lasts approximately 10 minutes on average.
224254521|NCT07201662|OTHER|Hospital Anxiety and Depression Scale|"A self-administered scale with 14 items, divided into two subscales of seven items, used to detect the presence of depression and anxiety. Non-cases or asymptomatic individuals (score ≤ 7); probable or borderline cases (score 8-10); clearly or clinically symptomatic cases (score ≥ 11).~The administration time is approximately 5 minutes."
223673796|NCT04964193|DRUG|Elzsa film-coated tablet|Administered with 240 mL of water
223673797|NCT04964193|DRUG|Diane-35 Sugar-coated tablet|Administered with 240 mL of water
223673798|NCT00456664|GENETIC|IE gene|
224254522|NCT07201662|OTHER|Interpersonal Reactivity Index|The Interpersonal Reactivity Index (Davis, 1980; Guttman \& Laporte, 2002) is a 28-item self-report questionnaire measuring four dimensions of empathy: fantasy, perspective taking, empathic concern, and personal distress. Each item is rated on a 1-to-5 scale and provides a subscore for each dimension, with no overall total score. Administration takes approximately 5 minutes.
224254523|NCT07201662|OTHER|Vicarious Distress Questionnaire|The Vicarious Distress Questionnaire (Grynberg et al., 2012) is an 18-item self-report scale assessing distress experienced in response to others' suffering and its impact on prosocial behaviors. It includes three dimensions-distress, support, and avoidance-each yielding a specific subscore. Administration takes approximately 5 minutes.
224254524|NCT07201662|OTHER|Binge Eating Scale|The Binge Eating Scale (Gormally et al., 1982; Brunault et al., 2016) is a 16-item self-report questionnaire assessing the behavioral, emotional, and cognitive manifestations of binge eating disorder (BED) according to DSM-V criteria. The total score (0-46) reflects symptom severity and can be interpreted dimensionally or categorically (≥ 18 indicating significant symptomatology). Administration takes approximately 5 minutes.
224254525|NCT07200804|DIAGNOSTIC_TEST|Measurement of Serum Vitamin D Level|Vitamin D is made of two types, named ergocalciferol (vitamin D2) and cholecalciferol (vitamin D3). Vitamin D2 is produced by converting ergosterol, a fungi and plants sterol, when it is exposed to light from the sun. Vitamin D3 is made differently, as it is formed in animal skin such as human skin with the help of 7-dehydrocholesterol when the skin is exposed to sunlight (UVB radiation).
224254526|NCT07200804|OTHER|Measurement of Carotid Intima-Media Thickness|Samples were collected by measuring the carotid intima-media thickness (CIMT) with a Mind ray Real time ultrasound scanner DC-6 doppler machine that has a probe at a frequency of 7.5 MHz. The measurement was done from three different sites each 1 cm proximal to the carotid bulb. The average of three values was taken to determine the final value. If CIMT \> 0.8 mm, it was defined as thickened. The measurements adhered to the Mannheim CIMT Consensus (2004-2006)
223772391|NCT02074735|DRUG|Citicoline|Citicoline is an over-the-counter nutritional supplement that is used for neuroprotective effects. It is a naturally occurring neurochemical in the human body.
224254527|NCT07201883|DRUG|Ondansetron (Zofran)|4 mg IV push
224254528|NCT07201883|OTHER|chewing gum|Peppermint sugar free chewing gum
224254529|NCT07201883|COMBINATION_PRODUCT|Ondansetron + Chewing gum|Ondansetron 4 mg IV push Peppermint sugar free chewing gum
224254530|NCT07201493|BEHAVIORAL|color temperature change mode|Subjects are asked to read a terminal display device for 50 minutes, featuring texts with different color temperature mode treatments. Specifically, they will read the same text content for 50 minutes with different color temperature mode. The participants will complete a total of 2 sets of tests in a random order.
224254531|NCT07202234|DRUG|Phage cocktail administered via nebulization|Phage cocktail administered via nebulization，BID
224254532|NCT07202234|DRUG|Nebulized normal saline inhalation therapy|Nebulized normal saline inhalation therapy, BID
224254533|NCT07200336|DRUG|Mepolizumab|Subcutaneous injection of mepolizumab is administered every 4 weeks for a total treatment duration of 24 weeks.
224254534|NCT07200336|PROCEDURE|Simple Polypectomy|Removal of nasal polyps in the middle meatus and superior turbinate region via the middle meatus and olfactory cleft, without opening the involved sinuses and without resection of diseased bone.
224254535|NCT07200336|PROCEDURE|Extended Endoscopic Sinus Surgery|"1. Complete opening of all sinuses~2. Resection of diseased mucosa and hyperplastic bone~3. Ethmoid skeletonization with middle turbinectomy~4. Draf IIb/III frontal dissection when indicated by CT severity."
224254536|NCT07200947|DRUG|QL1706, nab-paclitaxel, carboplatin|Participants will receive QL1706 (5 mg/kg, IV, day 1) in combination with nab-paclitaxel (260 mg/m², IV, day 1) and carboplatin (AUC=4-5, IV, day 1) every 21 days for 4-6 cycles. Dose adjustments may be made based on clinical judgment. Patients who do not experience disease progression or intolerable toxicity will proceed to maintenance therapy with QL1706 (5 mg/kg, IV, day 1) every 21 days. Treatment will continue until disease progression, unacceptable toxicity, consent withdrawal, investigator decision, loss to follow-up, death, or meeting other protocol-defined criteria for discontinuation. The maximum duration of QL1706 treatment is 24 months, after which continuation will be at the investigator's discretion based on individual benefit-risk assessment.
224254537|NCT07200986|BIOLOGICAL|Ixekizumab|80 mg (single dose), SC injection via PFS
224254538|NCT07201558|BIOLOGICAL|Surovatamig|"Surovatamig is a bispecific T-cell engager administered subcutaneously. This is an open-label, dose-escalation study evaluating the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of Surovatamig in adult participants with rheumatoid arthritis (RA) or systemic lupus erythematosus (SLE). The study consists of up to three parts:~Part 1 (SAD): Single ascending dose - participants receive one dose of Surovatamig.~Part 2 (sSUD): Single step-up dosing - participants receive two doses. Part 3 (dSUD): Double step-up dosing - participants receive three doses. Participants are assigned to a study part based on protocol-defined criteria. The study includes follow-up for a minimum of 179 days post-first dose, with extended monitoring up to 12 months for certain participants."
224254539|NCT07201831|OTHER|No treatment given|No treatment given
223673799|NCT00868517|OTHER|True group auricular acupuncture|Received true group auricular acupuncture
223673800|NCT00868517|OTHER|Sham group auricular acupuncture|Received sham auricular acupuncture.
223673801|NCT00868517|OTHER|Wait-List Control Group|Received conventional care only. Eligible to receive true group auricular acupuncture once study period completed.
223673802|NCT06143605|PROCEDURE|salvage treatment|salvage radical surgery or endoscopic resection
223673803|NCT00002988|DRUG|carmustine|
223673804|NCT00002988|DRUG|irinotecan hydrochloride|
223673805|NCT05289401|OTHER|ultrasound guided blocks|Ultrasound Guided Erector Spinae Plane Block Versus Ultrasound Guided Caudal Block in Pediatric
223680664|NCT05200494|PROCEDURE|Recruiting Maneuver|Airway pressure will be increased to 30 cmH2O for 30 seconds at the end of the bronchoscopy
223680665|NCT00375869|DRUG|Darbeopoetin|The treatment group, comprised of ten patients, will receive an intravenous dose of 200 mcg (1 ml) of darbepoetin (Aranesp®). Patients will be randomly assigned to either the treatment group, or the control group in a 2:1 ratio. The treatment group will be given 200 mcg of darbepoetin intravenously. The control group will be given a matching placebo of 1 mL of normal saline.
224254540|NCT07202377|DIAGNOSTIC_TEST|SPECIFIC REVEAL® Rapid AST system|The SPECIFIC REVEAL™ system uses biosensors capable of detecting volatile substances released by microorganisms during their growth. The detection of these volatile compounds by ultra-high-performance biosensors enables very early detection of bacterial growth compared with standard technologies based on visual systems (e.g. diffusion antibiogram or MICs determined by microdilution in liquid media) or optical density measurement systems (e.g. Vitek2)
224254541|NCT07202377|DIAGNOSTIC_TEST|antibiotic susceptibility testing on agar medium|Performance of an antibiotic susceptibility test on agar medium, with results expected between H18 and H24
224254542|NCT06465160|BIOLOGICAL|MNV-201 (Autologous CD34+ Cells Enriched with allogenic Placenta Derived Mitochondria)|"The participant will undergo 5 days of mobilization by G-CSF administration (Neupogen) once a day during 5 days.~On the 5th day, and after receiving the last dose of Neupogen, the participant will undergo Apheresis to collect CD34+ cells.~MNV-201 consists of autologous CD34+ cells enriched with allogeneic placenta derived mitochondria. Autologous CD34+ cells are isolated from the participant's peripheral blood after mobilization by apheresis. Allogeneic mitochondria are isolated under aseptic conditions from healthy donor placenta, cryopreserved and qualified before use.~Each product package will consist of a ready-for-injection sterile infusion bag containing clinical grade MNV-201 product for IV infusion for a single specified (autologous) participant."
224254543|NCT05754216|DEVICE|Nerve stimulation using nerve stimulation device and sterile wire electrode.|A nerve stimulator device will be used in this study as a research tool to investigate whether a future (currently nonexistent) medical device might be able to stimulate desired pharyngeal musculature in a therapeutic manner.
224254544|NCT01701674|DRUG|Ipilimumab|Pre-treatment with ipilimumab (cycle 1): Before the participant's tumor sample is taken to send to the lab for growing the TILs, they will start their first cycle of ipilimumab. This drug is given as an intravenous infusion (through a vein) over a period of about 90 minutes (an hour and a half). Cycle 2 of ipilimumab: About a week after the sample of the participant's tumor was collected for TIL growth (and 3 weeks after their first cycle of ipilimumab), participants will have their second cycle of ipilimumab. This will be another IV infusion, lasting about 90 minutes.
224254545|NCT01701674|PROCEDURE|Tumor Infiltrating Lymphocytes (TIL)|Tumor sample for TIL growth in the lab: About 2 weeks after the participant's first cycle of ipilimumab, a sample of their tumor will be collected and sent to the lab for TIL growth. Growing the TILs takes about 6 weeks. If their sample has grown enough TIL cells, participants will continue with the next part of the study. Depending on how long the TILs take to grow in the lab, they may need to repeat some of their laboratory and imaging tests (blood draws, X-rays, and CT or magnetic resonance imaging \[MRI\] scans). TIL Infusion (inpatient): After completing lymphodepletion, participants will be admitted back into the hospital for IV infusion of the TIL cells.
224254546|NCT01701674|DRUG|Administration of Lymphodepletion|Lymphodepletion (inpatient hospital stay for about 2 days plus outpatient drug dosing for 5 days): About 4 weeks after their second cycle of ipilimumab, participants will be admitted to the hospital for their first two days of receiving the chemotherapy drug, cyclophosphamide. This drug will be given as an intravenous (IV, meaning through the vein) infusion. After 2 days of receiving cyclophosphamide, if their study doctor thinks that they are well enough, you will be discharged from the hospital and will return for the next 5 days in a row for outpatient IV infusions of the second lymphodepletion chemotherapy, fludarabine.
224254547|NCT01701674|DRUG|Cyclophosphamide as Part of Lymphodepletion|
224254548|NCT01701674|DRUG|Fludarabine as Part of Lymphodepletion|
224254549|NCT01701674|DRUG|High Dose IL-2|High dose IL-2 (continued inpatient): Participants will remain in the hospital following TIL infusion for receiving high dose IL-2 and recovery. The IL-2 will be given three times per day for about 3-5 days as an IV bolus (meaning through the vein, more quickly than other infusions - in about 15 minutes each dose). Participants will remain in the hospital for approximately 7-14 days until they have recovered from the IL-2 treatments.
224254550|NCT01701674|BIOLOGICAL|Adoptive Cell Therapy with TIL|
224254551|NCT01199978|RADIATION|Fractionated proton radiation|Given daily for approximately 5.5 weeks
223673806|NCT03513081|BEHAVIORAL|Educative session|The experimental group receive nine educational sessions (one per week) about different vegetables and, at lunch time, they are exposed to a different vegetable. If they try it, they will receive a sticker. In each session, researcher will record their preference for the vegetable and the quantity that they consumed in a scale from one to three (1- the child prooved it; 2 - the child repeated it; 3 - the child ate all the quantity). In the end of 9 sessions, all children (experimental and control group) will receive the same salad that they had eaten at baseline and the procedure will be the same: the salad is weighted before and after the consumption of each child to verify the quantity of each one ate.
223673807|NCT04431089|DRUG|SHC014748M|Each treatment cycle is comprised of 28-day consecutive dosing of SHC014748M, 200mg QD (Days 1 to28). Upon completion of each cycle, patients may continue to receive oral SHC014748M if they can benefit from the treatment and the toxicity is tolerable.
223673808|NCT06228911|DRUG|steroid (triamcinolone)|triamcinolone is a synthetic corticosteroid medication used topically to treat various skin conditions, to relieve the discomfort of mouth sores, and by injection into joints to treat various joint conditions
223673809|NCT05834595|DRUG|CKD-828, D064, D701|QD, PO
223673810|NCT03281993|OTHER|CPAP AT|If the investigators observe rapid desaturation defined as a decline in O2 saturation below 85%; the CPAP apnea test (CPAP-AT) test was aborted.
223673811|NCT05072470|DEVICE|Roger microphone|Commercially available transmitter microphone which sends distant speech signals to a receiver that is attached/embedded into hearing aids.
223673812|NCT05072470|DEVICE|Phonak Audeo hearing aid|Commercially available receiver-in-canal hearing aid
223673813|NCT04378985|DEVICE|Wearing a Wearable device (Fitbit inspire HR)|"'Wearing a wearable device (the smart watch) for 8 weeks~The smart watch to be used in this study is Fitbit Inspire HR. This is a device that has a high worldwide use rate and has active research on its accuracy. It is worn like a normal watch, and it can check heart rate, exercise level, energy consumed, and sleep quality. The values can be checked in real-time on a smartphone application.'"
223680666|NCT00375869|DRUG|Normal Saline (Placebo)|The treatment group, comprised of ten patients, will receive an intravenous dose of 200 mcg (1 ml) of darbepoetin (Aranesp®). Patients will be randomly assigned to either the treatment group, or the control group in a 2:1 ratio. The treatment group will be given 200 mcg of darbepoetin intravenously. The control group will be given a matching placebo of 1 mL of normal saline.
224254552|NCT01199978|DRUG|Losartan|25mg or 50mg daily, oral administration, for approximately 6 months.
224254553|NCT06510556|DEVICE|Ablation Treatment|Subjects scheduled to undergo endocardial mapping and ablation therapy in the treatment of persistent atrial fibrillation or paroxysmal atrial fibrillation. Ablation of the pulmonary veins will be performed; ablation of the left atrial posterior wall, mitral isthmus (MI), LA roof line and/or cavo-tricuspid isthmus (CTI) is at the discretion of the investigator.
224254554|NCT05563844|DRUG|PM 8.4 mg/m^2|The medication is administered once via intravenous infusion on days 1, 4, 8, and 11 of each 21-day treatment cycle. A total of 6 cycles are planned, with tumor response assessments performed every 2 cycles during the treatment period.
224254555|NCT05563844|DRUG|PM 11.2 mg/m^2|The medication is administered once via intravenous infusion on days 1, 4, 8, and 11 of each 21-day treatment cycle. A total of 6 cycles are planned, with tumor response assessments performed every 2 cycles during the treatment period.
224254556|NCT06833008|DRUG|IPN01195|IPN01195 will be administered at assigned dose level.
223673814|NCT00828100|DEVICE|fluID Rapid Influenza Test|The fluID™ Rapid Influenza Test is an in vitro diagnostic assay designed to be used with a reader for the qualitative detection of influenza type A and type B nucleoprotein antigens, and the differentiation of influenza type A subtypes A/H1 and A/H3 antigens associated with the seasonal influenza H1N1 and H3N2, in nasal swabs, nasopharyngeal swabs and nasal wash/aspirate specimens. The test is intended as an aid in the rapid, qualitative diagnosis of influenza type A and type B viral infections in patients symptomatic with influenza-like illness. The fluID™ Rapid Influenza Test is intended for use by a healthcare professional in a laboratory or Point-of-Care (POC) setting.
223673815|NCT00828100|DEVICE|BinaxNOW® Influenza A & B|The BinaxNOW Influenza A \& B Test is an in vitro immunochromatographic assay for the qualitative detection of influenza A and B nucleoprotein antigens in nasopharyngeal (NP) swab and nasal wash/aspirate specimens. It is intended to aid in the rapid differential diagnosis of influenza A and B viral infections. Negative test results should be confirmed by culture.
223673816|NCT05444140|BEHAVIORAL|Health coaching|The health coaching programme includes four monthly health coaching sessions for three months.
223673817|NCT00812643|DRUG|AZD0837|Oral solution, dosing through the Loc-I-Gut catheter, single dose
223673818|NCT04133922|DRUG|GLP-1|glucagon-like peptide 1
223673819|NCT04133922|DRUG|Insulin|we are using to replace basal insulin and to raise insulin concentrations during the insulin clamp
223673820|NCT04133922|DRUG|Dextrose 20 % in Water|We are using Dextrose to maintain Euglycemia during the insulin clamp
223673821|NCT01447667|PROCEDURE|Magnetic resonance elastography|Magnetic resonance elastography before RFA and Liver biopsy of 2 HCC tissue and 2 non tumor liver parenchyma tissue
223673822|NCT00420641|DRUG|GSK372475|GSK372475 1.0-1.5 mg/day
223673823|NCT00420641|DRUG|Paroxetine|Paroxetine 20-30 mg/day
223673824|NCT00420641|OTHER|Placebo|Placebo to Match
223673825|NCT00004071|DRUG|leflunomide|
223673826|NCT00004071|DRUG|mitoxantrone hydrochloride|
223673827|NCT00004071|DRUG|prednisone|
223673828|NCT03920540|COMBINATION_PRODUCT|GC1111|GC1111 is 0.5mg per kg of body weight once weekly to be administered slowly by intravenous infusion.
223673829|NCT03920540|COMBINATION_PRODUCT|Comparator|Comparator is 0.5mg per kg of body weight once weekly to be administered slowly by intravenous infusion.
223673830|NCT05787600|DRUG|Perhyal rinse|Filming mouthwash formulation, enriched with Hydrogen Peroxide and Hyaluronic Acid Subjects will then be given the test intervention, Perhyal rinse, and will be asked to rinse with 10 ml of undiluted mouthwash for 60 s twice per day (30 min after tooth brushing) and will be instructed to refrain from eating and drinking for 30 min after rinsing. participants will be received a toothbrush with medium-hardness bristles and a toothpaste (COLGATE). No modifications to the participants' tooth brushing technique will be permitted. Next, the participants will be re-evaluated after 14 days.
223673831|NCT05787600|DRUG|Chlorhexidine mouthwash|Subjects will then be given Chlorhexidine 0.12%mouthwash, as an active comparator, and will be asked to rinse with 10 ml of undiluted mouthwash for 60 s twice per day (30 min after tooth brushing) and will be instructed to refrain from eating and drinking for 30 min after rinsing. participants will be received a toothbrush with medium-hardness bristles and a toothpaste (COLGATE). No modifications to the participants' tooth brushing technique will be permitted. Next, the participants will be re-evaluated after 14 days.
223673832|NCT05787600|DRUG|Placebo|Subjects will be given the nonactive control, distilled water, and will be asked to rinse with 10 ml of undiluted mouthwash for 60 s twice per day (30 min after tooth brushing) and will be instructed to refrain from eating and drinking for 30 min after rinsing. participants will be received a toothbrush with medium-hardness bristles and a toothpaste (COLGATE). No modifications to the participants' tooth brushing technique will be permitted. Next, the participants will be re-evaluated after 14 days.
223673833|NCT04009083|DEVICE|Standard of Care MRI|Prostate MRI, serum Prostate Specific Antigen (PSA), in field and random systemic prostate biopsies
223673834|NCT04009083|OTHER|Fluciclovine PET scan added to MRI|18F-Fluciclovine (Axumin) is a radioactive diagnostic agent indicated for positron emission tomography (PET) imaging in men with suspected prostate cancer recurrence based on elevated blood prostate specific antigen (PSA) levels following prior treatment
223673835|NCT05165498|PROCEDURE|Real-time ultrasound guidance for thoracic epidural catheter placement.|With an US-guided parasagittal oblique approach, the interlaminar space at the union between laminas and spinous processes at the predefined insertion level will be identified. A skin wheal will be raised with 3 mL of lidocaine 1%. Afterward, an 18-gauge Tuohy epidural block needle will be advanced under direct US vision until the tip is insinuated between the laminas and anchored to the flavum ligament. Then the needle will be attached to a low resistance syringe prefilled with saline solution and advanced until LOR to injection is confirmed. Then a 20-Gauge epidural catheter will be inserted 3-5 cm beyond the needle tip inside the epidural space and the needle removed.
223680667|NCT02440412|OTHER|Massage Therapy|It's a Physical Therapy manual procedure, based in Swedish technique, and applied in a standirzed way for all participants (stroke, kneading, pressure).
224254557|NCT03032172|DRUG|Risdiplam|Risdiplam will be administered orally once daily.
224254558|NCT06104592|RADIATION|Comprehensive Ablative Bridging Irradiation (CABI)|Participants will receive radiation therapy to all pretreatment lesions that are able to be feasibly and safely treated.
224254559|NCT06104592|BIOLOGICAL|Chimeric Antigen Receptor T-Cell Therapy|Yascarta is an autologous anti-CD19 CAR T cell therapy manufactured from the patient's own T cells, which have been extracted and then reprogrammed with CAR molecules to help the T cells recognize cancer cells. The reengineered T cells are infused back into the patient to attack the cancer.
224254560|NCT06430385|DRUG|ION440|ION440 will be administered by intrathecal bolus (ITB) injection.
223673836|NCT03459690|BEHAVIORAL|Meditation|Isha Kriya meditation is simple meditation practice which can be easily learned by employing online guided tools. Isha Kriya meditation requires approximately 12 minutes, twice a day of practice. This regimen was chosen because of its simplicity making it an excellent way to introduce meditation to beginners. Isha Kriya does not incorporate a spiritual or religious focus.
224254561|NCT06430385|PROCEDURE|Sham procedure|An LP will be performed with CSF collection but will not be followed by the administration of study treatment by ITB injection.
224254562|NCT05282199|OTHER|INSPIRATORY MUSCLE TRAINING|In the group of post-COVID-19 patients in which reduced endurance and inspiratory muscle power are identified, inspiratory muscle training (IMT) will be performed with a load equivalent to 50% of MIP (assessed weekly) for eight weeks.
224254563|NCT06361667|OTHER|Arts|Arts (music, cinema, dance).
224254564|NCT06330402|OTHER|Hypertonic saline injection|0.25 mL injection with hypertonic saline (7%) to the infrapatellar fat pad.
224254565|NCT06330402|OTHER|Isotonic saline injection|Control injection with 0.25 mL isotonic saline (0.9%) to the infrapatellar fat pad.
224254566|NCT05111626|DRUG|Bemarituzumab|Bemarituzumab will be administered as intravenous (IV) infusion.
224254567|NCT05111626|DRUG|Nivolumab|Nivolumab will be administered as IV infusion.
224254568|NCT05111626|DRUG|Chemotherapy|"mFOLFOX6: 5-fluorouracil, leucovorin, and oxaliplatin will be administered as IV infusion.~OR CAPOX: oxaliplatin will be administered as IV infusion and capecitabine will be administered orally."
224254569|NCT05111626|OTHER|Placebo|Placebo will be administered as IV infusion.
224254570|NCT04644497|PROCEDURE|ACL-reconstruction|Surgery technique in skeletally immature patients
224254571|NCT04055311|BEHAVIORAL|Cancer Resource Information Support (CRIS)|Intervention support is patient initiated and accessed as needed
223673837|NCT03459690|DEVICE|Enobio 32- EEG machine|This study utilizes the Enobio 32 EEG device made by Neuroelectrics (an FDA-cleared 24-bit EEG data reader which is a wearable wireless device) to analyze EEG changes after subjects have undergone meditation. This study does not evaluate the Enobio device, and the IRB of record approved an Investigational Device Exemption for this study.
223673838|NCT06044766|PROCEDURE|Surgical exatrction of impacted lower third molars|Surgical exatrction of impacted lower third molars to verify the form of the root
223673839|NCT04106024|DRUG|Anlotinib|Anlotinib 12mg.qd ,taken for 2 weeks and discontinued for 1 week, namely 3 weeks (21 days).
223673840|NCT01147133|DRUG|Plavix|1x75 mg
223673841|NCT01147133|DRUG|Kardogrel|1x75 mg
223673842|NCT03333668|DRUG|Lisdexamfetamine dimesylate|Lisdexamfetamine dimesylate (30mg for smaller, 50mg for larger boys) tablet
224254572|NCT04055311|BEHAVIORAL|Usual Care Enhanced|Usual care is enhanced with the addition of the NCI Facing Forward brochure
224254573|NCT02444429|DRUG|Corticosteroid boluses Methylprednisolone|"Intensification of the corticotherapy in accordance with the validated protocol for the treatment of classic and subclinical acute rejections: 3 bolus Methylprednisolone 500 mg IV at D1, D2 and D3 then decreasing during 10-15 days at 1mg/kg/d and down to the maintenance dose.~An anti-pneumocystis and anti-CMV prophylaxis will be systemically introduced for 3 months.~The rest of maintenance immunosuppressive regimen (mycophenolate mofetil and anti-calcineurin) will remain unaltered"
224254574|NCT02444429|OTHER|No therapeutic modification|No therapeutic modification: continuation of the corticotherapy at the maintenance dose and maintaining unaltered the rest of immunosuppressive treatment (mycophenolate mofetil and anti-calcineurin).
224254575|NCT02444429|OTHER|Stop maintenance corticotherapy|Immediate withdrawal of maintenance corticotherapy. Maintaining unaltered the rest of immunosuppressive treatment (mycophenolate mofetil and anti-calcineurin).
224254576|NCT06307821|DIETARY_SUPPLEMENT|Probiotic|The intervention lasts for 12 weeks, with follow-ups conducted at weeks 0, 6, and 12 to assess participants' digestion and absorption rates of dietary protein, as well as to collect fecal samples for analysis of changes in the gut microbiota.
224254577|NCT06307821|DIETARY_SUPPLEMENT|Placebo|The intervention lasts for 12 weeks, with follow-ups conducted at weeks 0, 6, and 12 to assess participants' digestion and absorption rates of dietary protein, as well as to collect fecal samples for analysis of changes in the gut microbiota.
224254578|NCT06848842|DRUG|Ivonescimab plus chemotherapy|Ivonescimab, 20mg/kg, D1, Q3W; Oxaliplatin, 130mg/m2, D1, Q3W; Capecitabine, 1000mg/m2, BID, D1-D14, Q3W
224254579|NCT03427593|GENETIC|FACS analyses|FACS analyses
224254580|NCT03427593|GENETIC|Target Sequencing by NGS ( Next-generation sequencing)|Target Sequencing by NGS ( Next-generation sequencing)
224254581|NCT03427593|GENETIC|Whole Exome Sequencing|Whole Exome Sequencing
224254582|NCT04497584|DRUG|Afatinib + Prednisone|Afatinib (40mg) will be taken by mouth daily starting on Cycle 1, Day -7. Prednisone (40mg) will be taken by mouth daily starting on Cycle 1, Day 1.
224322278|NCT02779855|BIOLOGICAL|Talimogene laherparepvec|Talimogene laherparepvec injection. Phase I: Dose escalation. Phase II: Treatment at Maximum Tolerated Dose (MTD) from Phase I. The MTD dose level is defined as the highest dose level with ≤1 out of 6 patients experiencing a dose limiting toxicity (DLT).
224322279|NCT02779855|DRUG|Paclitaxel|Paclitaxel chemotherapy infusion. The paclitaxel weekly dose is fixed at 80 mg/m\^2.
223673843|NCT03333668|DRUG|Guanfacine Extended Release Oral Tablet|Guanfacine Extended Release (0.05mg/kg) tablet
223673844|NCT03333668|DRUG|Placebo|Vitamin C (10mg) tablet
223673845|NCT02284425|DRUG|REGN1193|
223673846|NCT02284425|DRUG|Placebo|
223673847|NCT04865926|OTHER|Scapular and Neck Proprioceptive Neuromuscular Facilitation exercises|The researcher will perform a total of 12 sessions of scapular and neck pnf exercises for 4 weeks. The participants will apply PNF exercises using rhythmic initiation, rhythmic stabilization and cobination techniques of isotonics. Patterns of anterior elevation, posterior depression, anterior depression, posterior elevation will be used in scapular exercises. Upper cervical flexion, lower cervical flexion, rotation and lateral flexion patterns will be used in neck pnf exercises.
223673848|NCT04865926|OTHER|McKenzie and Kendall exercises|Kendall and Mckenzie exercises will be given to the participants as a home workout. The self-stretch exercise methods are as followed: Placing both hands on the shoulders and pushing out the chest, placing one hand over the shoulder and grasp the elbow of the turned hand, with the other hand over the head and slowly pull it inward, throwback the head until it has reached the fully stretched point, look straight ahead and slowly turn the head horizontally until the maximum value is reached, throwback the head, and turn it until it has reached the fully stretched point, lower the head turn it until it has reached the maximal point. Stretching pectoralis muscle, strengthening shoulder retraction, strengthening the deep cervical flexors, strengthening the deep cervical flexors.
224254583|NCT04453657|DEVICE|FamilyChildCare (provisional name of app)|Parents will provide their child(ren) access to a smartphone, tablet, or computer for approximately 30 minutes, three times per week for 15 weeks with a total dosage of instruction of about 22.5 hours. Parents and providers will receive self-care, parenting, and parent engagement tips and resources through push notifications twice a day. Additionally, daily reminders will be sent to parents through push notification to give their child(ren) access to the learning games. After 15 weeks of app engagement, the providers and parents will be contacted by the PI to notify them of the 15 week time mark and provide the information for post-surveys via Qualtrics.
224254584|NCT05292950|DRUG|ARO-MUC5AC|single or multiple doses of ARO- MUC5AC by inhalation of nebulized solution
224254585|NCT05292950|DRUG|Placebo|calculated volume to match active treatment by inhalation of nebulized solution
224254586|NCT05244447|OTHER|Primary Services|Primary services: Participants receive 12 hours of Relationships Smarts Plus, 3 hours of Mind Matters and 1 hour of Money Habitudes workshops over the course of 6 weeks. Participants also receive life coaching and ongoing job readiness support.
224254587|NCT05710380|OTHER|Risk Map Decision Support System (DSS).|The Risk Map DSS tool is an image analysis software that automatically interprets images of the prostate that were captured using an MR (magnetic resonance) scanner (an imaging technique that uses scanners to take pictures of the body). This tool can potentially identify additional areas of cancer in your prostate that may have otherwise been missed.
224254588|NCT05710380|RADIATION|Magnetic Resonance Imaging (MRI)|A medical imaging test that uses a large machine/scanner to take images of the body and internal organs and structures.
224254589|NCT05710380|PROCEDURE|Magnetic Resonance Imaging (MRI) Guided Biopsy|A removal of tumor tissue from the body based on images of the prostate provided by a previous magnetic resonance imaging (MRI) test. Up to 2 biopsies on trial.
224254590|NCT03946215|OTHER|Each participant will perform:|Part 1: Maximal incremental tests will require running at fixed slopes (+15%, 0% -15%) for stages (2min duration) of increasing velocities (0.5, 1 and 1.5 km/h) Part two: submaximal running tests will require running at constant velocity (80% VO2max uphill; 80%VO2max downhill and downhill at similar velocity as uphill)
224254591|NCT06081114|DIETARY_SUPPLEMENT|Micronutrient Supplement|A packaged food supplement providing calories and protein and fortified with micronutrients provided at an approximate RDA.
224254592|NCT05108870|DRUG|HB-201|A anti-cancer vaccine that treats HPV-related cancers.
224254593|NCT05108870|DRUG|HB-202|A anti-cancer vaccine that treats HPV-related cancers.
224254594|NCT05108870|DRUG|Carboplatin|Chemotherapy drug.
224254595|NCT05108870|DRUG|Paclitaxel|Chemotherapy drug.
224254596|NCT05108870|PROCEDURE|Transoral Robotic Surgery|Transoral robotic surgery is a procedure to remove mouth and throat cancers in which a surgeon uses a sophisticated, computer-enhanced system to guide the surgical tools.
224254597|NCT06399692|PROCEDURE|Coronary artery bypass grafting (CABG)|Coronary artery bypass grafting (CABG), also called heart bypass surgery, is a medical procedure to improve blood flow to the heart.
223673849|NCT04571983|OTHER|Blood Eosinophil counts - comparing historical with stable state|Comparing historical blood eosinophil counts over 24 months to stable state eosinophil count.
223673850|NCT02815280|DRUG|FMX-101, 4% minocycline foam|FMX-101, 4% minocycline foam applied topically once daily for 12 weeks
223673851|NCT02815280|DRUG|Vehicle Foam|Vehicle foam applied topically once daily for 12 weeks
223673852|NCT01367080|DRUG|DWETR10|Amitriptyline hydrochloride 10mg(DWETR10) single dose
223673853|NCT01367080|DRUG|DWETR25|Amitriptyline hydrochloride 25mg(DWETR25) single dose
223673855|NCT02009605|DRUG|Icotinib|125mg, oral administration, three times per day.
223673856|NCT04315584|PROCEDURE|Positron Emission Tomography|Undergo PET/CT Scans
223673857|NCT04315584|PROCEDURE|Computed Tomography|Undergo PET/CT Scans
224254598|NCT06399692|PROCEDURE|Percutaneous coronary intervention (PCI)|Percutaneous coronary intervention (PCI) is a non-surgical procedure used to treat the blockages in a coronary artery; it opens up narrowed or blocked sections of the artery, restoring blood flow to the heart
224254599|NCT05292963|OTHER|Intervention #1: Fatherhood Works Program Delivered to Participants|Participants receive 26 hours of Nurturing Fathers curriculum, delivered in person. Participants also receive employment supports, case management, and financial literacy training.
224254600|NCT04705038|BEHAVIORAL|Patient Education|Brief educational session on surgical castration as an alternative to lifelong ADT for prostate cancer.
224254601|NCT06349759|DRUG|phentolamine ophthalmic solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist|Once daily dosing
224254602|NCT06349759|DRUG|Placebo|Once daily dosing
224254603|NCT02869867|OTHER|refrigerated cushion|refrigerated cushion
224254604|NCT06494488|DRUG|EPA|Fish oil
224254605|NCT06494488|DRUG|DHA|Fish oil
223673858|NCT04315584|PROCEDURE|Multiparametric Magnetic Resonance Imaging Scan|Undergo a multiparametric MRI scan
223673859|NCT04315584|RADIATION|Fludeoxyglucose F-18|IV (intravenous) administration of radiotracer
223673860|NCT04315584|RADIATION|fluorine F 18 fluorodopa|IV (intravenous) administration of radiotracer
223673861|NCT02257762|DIETARY_SUPPLEMENT|LNS|Compact, paste-filled wafer snack containing fish, rice, soy, mungbeans, oil, sugar and multiple micronutrients
223673862|NCT02257762|DIETARY_SUPPLEMENT|Corn-soy blend ++ (CSB++)|Blended flour containing soy, corn, milk powder, oil, sugar and multiple micronutrients.
224254606|NCT06046287|DRUG|Daratumumab and hyaluronidase-fihj|subucatneous, fixed dose 1800mg combination drug product containing rHuPH20 drug substance (2000 U/mL) and daratumumab drug substance (120 mg/mL) will be administered weekly for the first 8 weeks, and then every 2 weeks from week 9 to week 24.
224254607|NCT06556147|BIOLOGICAL|VXB-241 60 mcg (Low Dose)|VXB-241 low dose, single, IM injection.
224254608|NCT06556147|BIOLOGICAL|VXB-241 120 mcg (Medium Dose)|VXB-241 medium dose, single, IM injection.
224254609|NCT06556147|BIOLOGICAL|VXB-241 240 mcg (Medium-high Dose)|VXB-241 medium-high dose, single, IM injection.
224254610|NCT06556147|BIOLOGICAL|VXB-241 480 mcg (High Dose)|VXB-241 high dose, single, IM injection.
224254611|NCT06556147|BIOLOGICAL|VXB-241 240 mcg|VXB-241 240 mcg (RSV preF 120 mcg + hMPV preF 120 mcg) (based on 1 month post 1st IMP injection results) single, IM injection.
224254612|NCT06556147|OTHER|Placebo|Placebo, single, IM injection.
224254613|NCT06556147|BIOLOGICAL|Arexvy 120 mcg|Arexvy 120 mcg, single, IM injection.
224254614|NCT05026645|PROCEDURE|Clinical interventions performed in acute settings (contaminated environment)|Any clinical intervention performed on the patient inflicted by at least one of Chemical, Biological, Radiological, Nuclear, Explosive (CBRNE) weapons in acute settings (from the incident site up to his/her admission to the clean zone of a emergency room or its equivalent (ie.: walking clinic).
224254615|NCT05026645|PROCEDURE|Protection (clinician and patient)|As interrelated competence of the clinical intervention, any protection procedure and capability applied on the patient inflicted by at least one of Chemical, Biological, Radiological, Nuclear, Explosive (CBRNE) weapons in acute settings (from the incident site up to his/her admission to the clean zone of a emergency room or its equivalent (ie.: walking clinic). Concerning the clinician, the protection implied for his/her own safety and for the patient to whom she/he was in closed/contact with.
224254616|NCT05026645|PROCEDURE|Decontamination (clinician and patient)|As interrelated competence of the clinical intervention and protection, any decontamination procedure and capability applied on the patient inflicted by at least one of Chemical, Biological, Radiological, Nuclear, Explosive (CBRNE) weapons in acute settings (from the incident site up to his/her admission to the clean zone of a emergency room or its equivalent (ie.: walking clinic). Concerning the clinician, the protection implied for his/her own safety and for the patient to whom she/he was in closed/contact with. This crucial step is usually expected prior the patient's transfer into a clean zone like the emergency room or its equivalent.
224254617|NCT04260126|COMBINATION_PRODUCT|Pembrolizumab (KEYTRUDA®) and PDS0101|IV infusion of pembrolizumab 200 mg + two 0.5mL sub-cutaneous injections of PDS0101 administered on Cycle 1, 2, 3, 4 and 12. IV infusion of Pembrolizumab 200 mg monotherapy will be administered Cycles 5 - 11 and 13 - 35.
224254618|NCT06577766|DRUG|NNC0638-0355|NNC0638-0355 will be administered as a subcutaneous (s.c. under the skin) injection.
224254619|NCT06577766|DRUG|Placebo (NNC0638-0355)|Placebo matching NNC0638-0355 will be administered as subcutaneous (s.c. under the skin) injection.
224254620|NCT02922777|DRUG|BGB324|75 mg/m2 every 21 days
224254621|NCT02922777|DRUG|Docetaxel|75 mg/m2 given IV every 21 days
224254622|NCT01112254|PROCEDURE|MRI±biopsy|A MRI-guided or CT-guided preoperative biopsy will be performed in case of suspicious enhancement, multiple and large lesions (more than 3 cm for from the initial lesion), which is not viewed on the mammography or breast ultrasound. The surgery type will depends on the MRI +/- ± biopsy results.
224254623|NCT03570749|DRUG|Baricitinib|Administered orally.
223673863|NCT02257762|DIETARY_SUPPLEMENT|Sprinkles|Multiple micronutrient powder packaged in sachet.
223673864|NCT00448396|DRUG|Patupilone|
224254624|NCT03570749|DRUG|Placebo|Administered orally.
224254625|NCT04435197|DRUG|Pembrolizumab Injection|Pre-operative Pembrolizumab+chemoradiotherapy
224254626|NCT02373397|DEVICE|Cacicol20|Investigational device, regenerating agent, single-use doses, topical eye drops. Indicated for corneal wound healing.
223673865|NCT03127982|BEHAVIORAL|Unified Protocol|The Unified Protocol (UP) is a trans-diagnostic cognitive-behavioral therapy (tCBT) for individuals diagnosed with anxiety disorders, depression and related disorders (which we refer to as emotional disorders).
223673866|NCT05466487|DEVICE|Transcranial Alternating Current Stimulation (tACS)|Stimulation frequency and peak-to-peak intensity will be set to 10Hz and 1.5 milliampere (mA), phase offset will be set to 0 and 100 cycles will be used for ramping up. At the start of the neglect training session, the tACS will be started. When the neglect training session is finished, after maximally 40 minutes, the tACS will be switched off.
223673867|NCT05466487|BEHAVIORAL|Visual Scanning Training (VST)|The most common treatment for neglect is VST, which is an intensive compensation training (see Dutch guidelines for rehabilitation of neglect: Ten Brink, Van Kessel, \& Nijboer, 2017). The aim of this training is to improve visual scanning behavior, that is, to encourage neglect patients to actively and consciously pay attention to stimuli on the contralesional side.
223673868|NCT00741429|DRUG|Technosphere Insulin Inhalation Powder|Subjects previously treated with Technosphere Insulin Inhalation Powder
223673869|NCT00741429|DRUG|Comparator|Subjects previously treated with other anti-diabetic medications
223680668|NCT02440412|OTHER|Rest in supine|It's only rest, in a clinic stretcher, with warm ambient temperature, and listening relaxing music with headphones.
223680669|NCT03495544|DIAGNOSTIC_TEST|PD-L1 expression|IHC testing of PD-L1 expression level in tumor tissue samples
223680670|NCT00003854|OTHER|immunohistochemistry staining method|
223680671|NCT00003854|PROCEDURE|lymphangiography|
224254627|NCT02373397|DEVICE|Placebo|Vehicle only in identical packaging, with identical dosage and administration route.
224254628|NCT05155683|DEVICE|Photobiomodulation (PBM) with infrared LED|All participants will receive 30 minutes of PBM (or PBM sham), with an abdominal strap containing 4 LED clusters with 72 devices that emit 830 nm wavelength with 20 nm spectral width, in continuous operating mode, 5 mW average radiant power per LED, 71 mW/cm² power density at aperture, 20.4 cm² of total area irradiated, 71 mW/cm² of irradiance at target, exposure duration of 1800 seconds, 127.8 J/cm² of radiant exposure, 2.6 kJ of radiant energy, per contact application technique, twice a week for a month, totaling 8 sessions.
223680672|NCT00003854|PROCEDURE|sentinel lymph node biopsy|
223673870|NCT03965273|BEHAVIORAL|Full TP|The overall Tipping Point intervention package will span 18 months and will involve: i) Weekly facilitated training sessions with girls' groups and boys' groups; ii) Dialogue sessions jointly with girls' groups and fathers' groups, and girls' groups and boys' groups; iii) Community and Social Norms Change Component; iv) Facilitated sessions with mothers' groups and (separate) fathers' groups; v) 2-days intensive facilitated workshop with selected religious leaders and influential people; vi) Village savings and loans associations (VSLAs) formed by the girls' group members to create opportunities for girls to engage in age-appropriate income generating activities and build their potential as entrepreneurs; vii) Trainings of girls, boys and parents with special interest in activism.
223673871|NCT03965273|BEHAVIORAL|Light TP|The overall Tipping Point intervention package will span 18 months and will involve: i) Weekly facilitated training sessions with girls' groups and boys' groups; ii) Dialogue sessions jointly with girls' groups and fathers' groups, and girls' groups and boys' groups; iii) Facilitated sessions with mothers' groups and (separate) fathers' groups; iv) 2-days intensive facilitated workshop with selected religious leaders and influential people; v) Village savings and loans associations (VSLAs) formed by the girls' group members to create opportunities for girls to engage in age-appropriate income generating activities and build their potential as entrepreneurs; vi) Trainings of girls, boys and parents with special interest in activism.
223673872|NCT00603642|DRUG|Placebo|Subcutaneously administered, once a week, for 12 weeks
223673873|NCT00603642|DRUG|AMG 531|Subcutaneously administered, once a week, for 12 weeks
223673874|NCT02394197|DRUG|Chloroquine phosphate|use at operational doses by age group according to the Mexican guidelines for vector borne diseases
223673875|NCT02394197|DRUG|primaquine|use at operational doses by age group according to the Mexican guidelines for vector borne diseases
223673876|NCT02571738|BIOLOGICAL|CHAM|The treatment indication is for chronic diabetic foot ulcers that can accommodate up to one 5cm x 5cm piece of CHAM
223673877|NCT02571738|OTHER|Control|Standard of Care
223673878|NCT00040846|BIOLOGICAL|alemtuzumab|Given IV
223673879|NCT00040846|DRUG|fludarabine phosphate|Given IV
223673880|NCT00040846|RADIATION|total-body irradiation|Undergo TBI
223673881|NCT00040846|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Undergo allogeneic HSCT
223673882|NCT00040846|PROCEDURE|peripheral blood stem cell transplantation|Undergo allogeneic peripheral blood stem cell transplantation
223673883|NCT00040846|DRUG|mycophenolate mofetil|Given PO
223673884|NCT00040846|DRUG|cyclosporine|Given IV or PO
223673885|NCT01514162|DEVICE|Trifecta valve|surgical replacement of aortic valve
223673886|NCT05036473|DRUG|WD-1603 Carbidopa-Levodopa Extended-Release Tablets|Taking WD-1603 tablets or placebo orally three times a day, in the morning before meals, and the second and third medications will be taken after meals, once every 5 hours (±30 minutes).
223673887|NCT05036473|DRUG|Placebo|placebo tablets-matching the active groups.
223673888|NCT00680719|BEHAVIORAL|IBFT /HIV prevention|Integrated Behavioral and Family Therapy (IBGT) with HIV prevention.
223673889|NCT00680719|BEHAVIORAL|IBFT|Integrated Behavioral and Family Therapy (IBFT).
223673890|NCT02836509|DRUG|Paracetamol|1000 mg Paracetamol in 150 ml normal saline given as a slow intravenous infusion over 5 minutes.
223673891|NCT02836509|DRUG|Ibuprofen|800 mg Ibuprofen in 150 ml normal saline given as a slow intravenous infusion over 5 minutes
223673892|NCT05361902|RADIATION|Adaptive radiotherapy according to UPRATE protocol|According to previously reported STAMPEDE trial (Parker et al.), patients will be treated with 6 weekly fractions of 6 Gy. According to local protocol the target will consist of prostate and entire seminal vesicles. Additional CT-scans will be made prior to and directly following each fraction. For more details, see study description
223673893|NCT00998777|PROCEDURE|Shoulder Strengthening|The intervention program is a 6 week shoulder and scapular stabilizer strengthening program that is performed 3 times per week. The program includes 10 exercises that are performed with Theraband rubber tubing and 2 stretches. The exercises are: shoulder flexion, Ys, Ts, Ws, IR @ 90, ER @ 90, Throwing acceleration, Throwing deceleration, dynamic hug, and low rows. The stretches include the sleeper stretch and the corner stretch.
223673894|NCT01230177|DRUG|etanercept (genetical recombination)|10 to 25 mg of etanercept (genetical recombination) reconstituted in 1 mL of water for injection (JP) administered twice weekly as a subcutaneous injection or 25 to 50 mg of etanercept (genetical recombination) administered once weekly as a subcutaneous injection, are usually the recommended dose for adults.
223673895|NCT02538783|BEHAVIORAL|Escalating Lottery|Participants in the lottery arms will receive financial incentives as part of the intervention. See arm descriptions for more detail.
223673896|NCT02194257|DRUG|[14C]-cyclohexane ambroxol oral solution|
223673897|NCT02194257|DRUG|[14C]-benzyl ambroxol oral solution|
223673898|NCT02194257|DRUG|Ambroxol lozenge|
223673899|NCT04272879|OTHER|Observational Group|Those requiring NIV following an acute exacerbation of COPD
223673900|NCT02647450|OTHER|GIANT Completed patient|Patients identified in the GIANT clinic and who fulfill the inclusion criteria will be sent a 9 page questionnaire. Upon receipt the questionnaire will be sent to the patient's GP for validation.
223673901|NCT05981976|BIOLOGICAL|Abatacept|Specified dose on specified days
223673902|NCT00785616|OTHER|MEMS cap monitoring|Electronic monitoring of medication adherence using MEMS caps
223673903|NCT00785616|OTHER|MEMS cap monitoring|Adherence to antiretroviral medications will be measured using electronic bottle caps (MEMS caps) that record the time signature of each bottle opening.
223673904|NCT00785616|OTHER|MEMS cap monitoring|Adherence to antiretroviral medications will be measured using electronic bottle caps (MEMS caps) that record the time/date signature of each bottle opening.
223673905|NCT05959980|PROCEDURE|Posterior cervical fixation surgery|These patients will undergo posterior cervical fixation in the form of cervical lateral mass screw fixation in extension without decompression under general anesthesia.
223680673|NCT00003854|PROCEDURE|therapeutic conventional surgery|
223680674|NCT00003854|RADIATION|whole breast irradiation|
223680675|NCT02140632|PROCEDURE|Local methylprednisolone acetate and lidnocaine injection|
223680676|NCT02140632|DEVICE|wrist splinting|
223680677|NCT03841838|OTHER|Energy drink|Two 12 oz bottles of commercially available energy drink
223673906|NCT03990350|OTHER|Fecal Sample Collection|With permission from the parent/guardian, stool collected in a sterile container will be brought within 12 hours of defecation from home or the outpatient clinic to a separate clinical laboratory where feces will be collected through use of FLOQswab brush x 3 (Copan Diagnostics, Murrieta, CA) The swabs will be pre-labeled with a de-identified code reflecting patient number, sample number, and date and the sample will be placed into dry ice then transferred to a -80 degrees Celsius freezer until retrieval by the research staff for transfer to CHOP Microbiome Center.
223673907|NCT03990350|OTHER|Physical Activity Questionnaire|At the initial encounter the co-investigator Dr. David Garcia, who is a certified Spanish translator will complete the Physical Activity Questionnaire (Physical Activity Questionnaire for Older Children) with the subject and parent.
223673908|NCT03990350|OTHER|Food Frequency Questionnaire|At the initial encounter the co-investigator Dr. David Garcia, who is a certified Spanish translator will complete the Food Frequency Questionnaire with the subject and parent.
223673909|NCT03990350|OTHER|24-hour dietary recall diary|At the initial encounter the co-investigator Dr. David Garcia, who is a certified Spanish translator will complete the 24-hour dietary recall diary with the subject and parent.
224254629|NCT05155683|DEVICE|Low-frequency ultrasound (LOFU)|Subsequently the demarcation of the target area for LOFU treatment (Thoor DGM Electronica, Santo André, São Paulo, Brazil), the application of the neutral conductive gel will occur for the use of low-frequency ultrasound for 30 minutes, which will occur with 22 cm² effective radiating area (ERA) size, \<8 BNR emission intensity, 40 kHz frequency, continuous mode, 60W, 100 cm² of total treated area, twice a week for a month, totaling 8 sessions.
224254630|NCT05155683|DEVICE|Muscle electrostimulation|The session will end with 20 minutes of Russian Current (Tensor DGM Electronica, Santo André, São Paulo, Brazil), whose carrier frequency occurs in 2500 Hz, which will be adjusted according to the parameters described by Evangelista et al. (2003), which are: pulse frequency of 30 Hz; up/down ramp of 2 seconds each; support/rest time of 13 seconds each. The current intensity used will be the maximum supported by each participant and that is comfortable and sufficient to provide visible contraction. The treatment will consist of eight sessions that will occur twice a week, totaling a month of treatment.
224254631|NCT00163657|DRUG|Daclizumub|anti-rejection drug
224254632|NCT00163657|DRUG|Tacrolimus|anti rejection drug
224254633|NCT00163657|DRUG|Cyclosporine|anti rejection drug
224254634|NCT00163657|DRUG|MMF|anti rejection drug
224254635|NCT05135104|DRUG|Palbociclib|"Palbociclib, an orally active pyridopyrimidine, is a potent and highly selective reversible inhibitor of CDK 4 and CDK6. The compound prevents cellular DNA synthesis by prohibiting progression of the cell cycle from G1 into the S phase. Specifically, Palbociclib inhibits CDK4/6-catalyzed phosphorylation of the retinoblastoma protein (Rb), which is required for cell division.~Palbociclib has selectivity for CDK4/6, with little or no activity against a large panel of 274 other protein kinases including other CDKs and a wide variety of tyrosine and serine/threonine kinases.~Therapeutic indications:~Palbociclib is indicated for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or MBC:~* in combination with an aromatase inhibitor;~* in combination with fulvestrant in women who have received prior endocrine therapy."
223673910|NCT05334810|DRUG|DP303c|DP303c injection, 3.0 mg/kg, every 3 weeks.
224254636|NCT05238168|OTHER|ePIPARI digital follow up tool|A digital platform includes questions to parents about child wellbeing and development and parent wellbeing. A notification by email or app comes two weeks before the follow up time point. The parents respond via a link to a webpage or via an app.They also receive information (text and video) about age-appropriate child development. ePIPARI includes 8 assessment points from term age until 2 years of corrected age.
224254637|NCT00101647|DRUG|Dasatinib|Tablets, Oral, 70 mg, twice daily, until disease progression or intolerable toxicity, switch to the roll-over study or study closure
224254638|NCT02361905|DRUG|ulipristal acetate|5 mg/day will be administered starting from day 1 of the cycle and up to three months later
224254639|NCT02361905|DRUG|Leuprolide acetate|One dose of 11.25 GnRH analogue depot will be administered in the luteal phase of the menstrual cycle (days 21-24)
224254640|NCT04766697|BEHAVIORAL|Risk-Reduction Sessions|The 8-session intervention protocol emphasizes cognitive-behavioral interventions for anger management, conflict resolution, reducing sexual risk behavior, substance use, and enhancement of couple functioning.
224254641|NCT02436005|DEVICE|Phenacite|Subjects will be randomized to wear the Phenacite contact lenses binocularly.
224254642|NCT02436005|DEVICE|comfilcon A|Subjects will be randomized to wear the comfilcon A contact lenses binocularly.
223673911|NCT02433431|BEHAVIORAL|Mindfulness Training|Mindfulness training intervention consisting of 14 x 20-minute audio-guided lessons that participants access on their smartphones during the 14-day intervention period.
223673912|NCT02433431|BEHAVIORAL|Mindful Attention Only Training|Mindful attention training intervention consisting of 14 x 20-minute audio-guided lessons that participants access on their smartphones during the 14-day intervention period.
224254643|NCT00583453|DRUG|Celecoxib|"Celecoxib 200 mg capsule~1. capsule the night before surgery~2. capsules the morning of surgery~1 capsule the night of surgery~1 capsule twice daily for 10 days immediately after the surgery"
224254644|NCT00583453|DRUG|Placebo|"Placebo capsule~1. capsule the night before surgery~2. capsules the morning of surgery~1 capsule the night of surgery~1 capsule twice daily for 10 days immediately after the surgery"
224254645|NCT03076593|OTHER|Exposure: Fall|Participants will be asked about prior falls
224254646|NCT03394547|DEVICE|Allay|pulsed shortwave therapy treatment for painful periods
224254647|NCT03394547|DEVICE|Placebo|A placebo device is given which is identical to the Allay device but emits no pulsed shortwave therapy.
224254648|NCT06570291|DRUG|Mesenchymal Stem Cells|Allogenic adipose tissue-derived mesenchymal stem cells administrated for intra- articular use
224254649|NCT06570291|DRUG|Sodium Hyaluronate Injection|Sodium Hyaluronate administrated for intra-articular use
223673913|NCT02433431|BEHAVIORAL|Analytic Thinking Training|Comparison analytic thinking intervention consisting of 14 x 20-minute audio-guided lessons that participants access on their smartphones during the 14-day intervention period.
223673914|NCT01005121|DRUG|colchicine|2mg, per-os, once daily for six months
223673915|NCT03856268|PROCEDURE|'Surgical Menopause' Group|Women undergoing laparoscopic oophorectomy surgery ('surgical menopause') will be enrolled at Pennington Biomedical.
223673916|NCT03856268|DRUG|'Drug-Induced Menopause' Group|Women undergoing gonadal suppression via leuprolide acetate (Lupron \[AbbVie Inc.\]) will be enrolled at the University of Colorado-Denver.
223673917|NCT04951297|OTHER|None, just observation|None ,just observation test
223673918|NCT02514473|DRUG|VX-809|
224254650|NCT00755313|BIOLOGICAL|trastuzumab|
224254651|NCT00755313|DRUG|aromatase inhibition therapy|
224254652|NCT00755313|DRUG|carboplatin|
224254653|NCT00755313|DRUG|cyclophosphamide|
224254654|NCT00755313|DRUG|docetaxel|
224254655|NCT00755313|DRUG|doxorubicin hydrochloride|
224254656|NCT00755313|OTHER|metabolic assessment|
224254657|NCT00755313|OTHER|questionnaire administration|
224254658|NCT00755313|OTHER|study of socioeconomic and demographic variables|
224254659|NCT00755313|PROCEDURE|cognitive assessment|
224254660|NCT00755313|PROCEDURE|positron emission tomography|
224254661|NCT00755313|RADIATION|fludeoxyglucose F 18|
224254662|NCT06120075|DRUG|AB801|Administered as specified in the treatment arm
224254663|NCT06120075|DRUG|Docetaxel|Administered as specified in the treatment arm
224254664|NCT02651272|DRUG|macitentan|10mg macitentan tablets
224254665|NCT04523168|DEVICE|The Neovasc Reducer™ System|A stainless-steel mesh pre-mounted on a customized hourglass shaped balloon catheter, is designed to create a focal narrowing in the lumen of the CS to generate a pressure gradient across it.
224254666|NCT06561035|DRUG|Opiate Sparing|Subjects will receive medications in the Opiate Sparing arm for pain control.
224254667|NCT06561035|DRUG|Opiate Based|Subjects will receive medications in the Opiate Based arm for pain control.
224254668|NCT06223191|OTHER|Brief Negotiated Interview|"The BNI is a specialized brief intervention for the medical setting, has foundations in motivational interviewing techniques. The BNI helps health care providers explore health behavior change with patients in a respectful, non-judgmental way within a finite time period. The BNI is in the form of an algorithm, or script, that guides providers through the health intervention with carefully phrased key questions and responses, all at the providers' fingertips"
224254669|NCT06223191|OTHER|Narrative Interview|The Narrative Interview is a therapeutic approach that aims to motivate the individual's conscious and transformative knowledge, skills, and capabilities. This interview is based on the technical components of narrative therapy, where the patient narrates their story, using externalizing language and considering social and political aspects related to the issue. It will focus on exploring past and present feelings, thoughts, and actions.
224254670|NCT03831139|BEHAVIORAL|TIM&SARA|
224254671|NCT04938635|DRUG|VIT-2763 60 mg QD|Participants receive one VIT-2763 60 mg capsule plus one Placebo capsule orally in the morning, and 2 Placebo capsules orally in the evening, for 24 weeks.
224254672|NCT04938635|DRUG|VIT-2763 60 mg BID|Participants receive one VIT-2763 60 mg capsule plus one Placebo capsule orally, twice daily for 24 weeks.
224254673|NCT04938635|DRUG|VIT-2763 120 mg BID|Participants receive two VIT-2763 60 mg capsules orally, twice daily for 24 weeks.
224254674|NCT04938635|DRUG|Placebo|Participants receive two Placebo capsules matching VIT-2763 orally, twice daily for 24 weeks.
224254675|NCT02573441|BEHAVIORAL|Jump Math|Jump Math is a workbook based program aimed at improving math skills
224254676|NCT02573441|BEHAVIORAL|Cogmed|Cogmed is an online computer program aimed at improving working memory skills
224254677|NCT02573441|BEHAVIORAL|Liaison Services|Liaison Services will include working closely with schools to help explain the strengths and weaknesses of a child based on cognitive testing and to help with the implementation of recommendations
224254678|NCT01837810|DRUG|Ibuprofen|800mg every 8 hours as needed for pain
223673919|NCT02514473|DRUG|Placebo|
223673920|NCT02514473|DRUG|VX-770|
223673921|NCT02158364|DRUG|Freeze-dried live attenuated measles and rubella combined vaccine (Schwarz FF-8 strain/TO-336 strain)|Freeze-dried live attenuated measles and rubella combined vaccine (Schwarz FF-8 strain/TO-336 strain)
223673922|NCT05520242|OTHER|Use of small animation movies to increase response in a national health survey|Inclusion of animation movies in the invitation cover letter to a national health survey is tested in an embedded randomized controlled trial in the Danish National Health Survey 2021.
223673923|NCT03460743|BIOLOGICAL|Study group - quadrivalent recombinant hemagglutinin influenza vaccine|Eligible subjects will be randomized, 1:1, to receive one or two doses of same vaccine. Subjects will be categorized in two age groups: subjects 9 to 17 years will be allocated in Group A and will receive one dose; Subjects 3 to 8 will be allocated to group B and the ACIP/CDC algorithm will be applied to determine should one or two doses will be applied 28 days apart. Vaccinator will be non blind and will not participate in the clinical evaluation.
223680678|NCT03841838|OTHER|Placebo drink|Two 12 oz bottles placebo drink. Placebo drink will contain carbonated water, lime juice, and cherry flavoring.
224254679|NCT06561672|DRUG|tramadol plus paracetamol|Intravenous infusion of 15mg/kg paracetamol together with 1mg/kg tramadol will be started and to be finished before starting of induction of anesthesia (induction agent will be propofol 2mg/kg and muscle relaxant (cisatracurium) 0.15 mg/kg)
224254680|NCT06561672|DRUG|Fentanyl|Intravenous injection of 1.5 microgram/kg fentanyl will be given to the patient followed by induction agents (propofol 2mg/kg).
224254681|NCT06561672|DRUG|propofol and muscle relaxant (cisatracurium)|propofol 2mg/kg and muscle relaxant (cisatracurium) 0.15 mg/kg)
224254682|NCT06561672|DRUG|Propofol|propofol 2mg/kg
224254683|NCT06086704|DRUG|18F-fluorofuranylnorprogesterone|18F-FFNP will be given by a slow infusion (approximately 2 minutes), and the dose administered will be approximately 7 mCi.
224254684|NCT06086704|DEVICE|Positron Emissions Tomography / Magnetic Resonance Imaging|Breast specific PET/MRI data will be acquired using a 3T simultaneous PET/MRI scanner (Signa PET/MR, GE Healthcare)
224254685|NCT06086704|DRUG|Anastrozole|hormone based chemotherapy that reduces estrogen, 1 mg anastrozole once daily by mouth for a minimum of 14 days
224254686|NCT06086704|OTHER|Blood Sampling|Venous blood samples will be collected at multiple timepoints (e.g., 5, 10, 20, 30, and 45 min after 18F-FFNP injection to determine parent and metabolite fractions
224254687|NCT06086704|DRUG|FDA-approved gadolinium-based intravenous contrast agent|FDA-approved gadolinium-based intravenous contrast agent used for the MRI portion of this study
224254688|NCT03797703|DRUG|Lidocaine Hydrochloride 2% gel enema|Insertion of Lidocaine Hydrochloride 2% gel enema rectally immediately following the procedure.
224254689|NCT03868891|DEVICE|EMST150|The EMST150 consists of a handheld plastic tube with a mouthpiece on one end and an adjustable valve on the other end. Your child will close his/her lips around the mouthpiece and breathe out against resistance. The EMST150 will be adjusted to the point where airflow stops. Each day, your child will blow into the EMST150 5 sets of 5 times with a 10-15 second rest between each use and a 1-2 minute rest between each set of 5. You will adjust the resistance of the device each week, take a picture of the device settings, and document exercise sets performed in an exercise diary. These exercises will be performed twice in each nostril 2 times a day until your child's next visit at the MEPL (at least 8 weeks). Each session should take approximately 10-15 minutes, for a total of 30 minutes per day.
224254690|NCT02115165|DRUG|Cabazitaxel|On Day 1 of each cycle, patients will receive cabazitaxel at a dose of 25 mg/m², administered by IV route in 1 hour
224254691|NCT03835286|DRUG|Vitamin C|6 grams of Vitamin C in 250 ml of 0.9% saline in continuous infusion for 24 hours, 3 doses.
224254692|NCT03835286|DRUG|Placebos|Placebos: 250 ml of 0.9% saline in continuous infusion for 24 hours, 3 doses.
224254693|NCT02984696|DRUG|1 mg of transdermal estradiol daily and 10mg of oral MPA|
224254694|NCT03904381|DRUG|5-fluorouracil|5-fluorouracil subconjunctival injections were a first-choice therapy for bleb failure and were administered according to predetermined criteria.
224254695|NCT03904381|PROCEDURE|Transconjunctival needling|Transconjunctival needling was administered according to predetermined criteria.
224254696|NCT03904381|PROCEDURE|Transconjunctival revision|Transconjunctival revision was administered according to predetermined criteria.
224254697|NCT00681798|DRUG|Vandetanib|100mg/300mg
224254698|NCT06508905|OTHER|Sleep buddy|The toy chosen as a sleep companion was introduced to the children in the experimental group and they were told that it would accompany them for 3 days during their hospitalization. Before giving the sleep companion, parents and children were informed about the sleep companion and their questions about the study were answered. Children who did not have their own sleep companion were included in the sample. The child was encouraged to sleep and spend time with the given sleep buddy and the family was also informed.
223673924|NCT03460743|BIOLOGICAL|Control group - quadrivalent inactivated influenza vaccine|Eligible subjects will be randomized, 1:1, to receive one or two doses of same vaccine. Subjects will be categorized in two age groups: subjects 9 to 17 years will be allocated in Group A and will receive one dose; Subjects 3 to 8 will be allocated to group B and the ACIP/CDC algorithm will be applied to determine should one or two doses will be applied 28 days apart. Vaccinator will be non blind and will not participate in the clinical evaluation.
223673925|NCT01986777|DRUG|lisdexamfetamine|
223673926|NCT01986777|DRUG|Placebo|The placebo capsules will be filled with lactose.
224254699|NCT06560983|OTHER|The investigators are planning to do a observational cohort study, hence won't be doing any intervention.|The investigators won't be doing any intervention since this is an observational study.
223673927|NCT01944839|DRUG|E10030|
223673928|NCT01944839|DRUG|ranibizumab|
224254700|NCT05795504|OTHER|resistive exercise|They will perform combined upper and lower resistive exercises, 30 min, 3 sessions / week for 12 weeks in addition to calcium and vitamin D supplements.
223673929|NCT01944839|DRUG|E10030 sham intravitreal injection|Pressure on the eye with a syringe with no needle
223673930|NCT03425422|DEVICE|VITARIA System|Chronic stimulation of the right cervical vagus nerve
223673931|NCT03332511|DRUG|Nilotinib|Nilotinib 300mg twice-daily
223673932|NCT02837484|OTHER|NuTech Affinity™ Membrane|NuTech Affinity™ Membrane is an aseptically produced hypothermically stored amniotic membrane patch.
223673933|NCT02272387|DIETARY_SUPPLEMENT|Vitamin D3 (Cholecalciferol)|
224254701|NCT05795504|OTHER|high intensity interval training|They will perform HIIT for three sessions/ week for 12 weeks, 30 minutes/ session in addition to calcium and vitamin D supplements.,
224254702|NCT05795504|DIETARY_SUPPLEMENT|calcium and vitamin D|they will receive calcium and vitamin D supplements only.
224254703|NCT06799741|DRUG|AV-1 100 mg|"human monoclonal antibody (mAb) intravenous solution~or"
224254704|NCT06799741|DRUG|AV-1 300 mg|"human monoclonal antibody (mAb) intravenous solution~or"
223673934|NCT02272387|OTHER|Placebo|
223673935|NCT00928122|DEVICE|Intrastromal Correction of Presbyopia|Applying defined, pre-programmed patterns (e.g. rings and/or radial cuts)into the human eye cornea. It is a minimal-invasive procedure which changes the topography of the cornea and by that the refraction ability.
223673936|NCT00928122|DEVICE|Intrastromal correction of Myopia|Applying defined, pre-programmed patterns (e.g. rings and/or radial cuts)into the human eye cornea. It is a minimal-invasive procedure which changes the topography of the cornea and by that the refraction ability.
223673937|NCT00928122|DEVICE|Intrastromal Correction of Hyperopia|Applying defined, pre-programmed patterns (e.g. rings and/or radial cuts)into the human eye cornea. It is a minimal-invasive procedure which changes the topography of the cornea and by that the refraction ability.
224254705|NCT06799741|DRUG|AV-1 900 mg|"human monoclonal antibody (mAb) intravenous solution~or"
224254706|NCT06799741|DRUG|Placebo|(0.9% saline intravenous solution) 12:2
224254707|NCT06212661|DRUG|Ubrogepant|Ubrogepant (Ubrelvy™), oral, dosage at discretion of clinical provider, for treatment of migraine headaches.
224254708|NCT06212661|DRUG|Rimegepant|Rimegepant (Nurtec®), oral, dosage at discretion of clinical provider, for treatment of migraine headaches.
224254709|NCT06212661|DRUG|Atogepant|Atogepant (Qulipta™), oral, dosage at discretion of clinical provider, for treatment of migraine headaches.
224254710|NCT06212661|DRUG|Eptinezumab|Eptinezumab (Vyepti®) injection, dosage at discretion of clinical provider, for treatment of migraine headaches.
224254711|NCT06212661|DRUG|Fremanezumab|Fremanezumab (Ajovy®) injection, dosage at discretion of clinical provider, for treatment of migraine headaches.
224254712|NCT06212661|DRUG|Galcanezumab|Galcanezumab (Emgality®) injection, dosage at discretion of clinical provider, for treatment of migraine headaches.
224254713|NCT06212661|DRUG|Erenumab|Erenumab (Aimovig®) injection, dosage at discretion of clinical provider, for treatment of migraine headaches.
224254714|NCT06212661|DRUG|Botulinum toxin A|Botolinum toxin A (Botox) injections into extracranial muscles, dosage at discretion of clinical provider, for treatment of migraines.
224254715|NCT05244720|DIAGNOSTIC_TEST|Fibroscan|A percutaneous scan, that measures shear wave velocity. It estimates liver stiffness.
224254716|NCT05244720|DIAGNOSTIC_TEST|Blood samples|Blood samples to asses the function of liver, kidney and bone marrow, as well as nutrition/vitamin status.
224254717|NCT00270582|DRUG|Taxotere, Cisplatin, Gemcitabine|
224254718|NCT06631313|DEVICE|PureWick System|The PureWick System consists of the PureWick Urine Collection System used with either the PureWick Male External Catheter or the PureWick Flex Female External Catheter, which are intended for non-invasive urine output management.
224254719|NCT03123094|DRUG|Spesolimab|single dose
224254720|NCT03123094|DRUG|Placebo|single dose
224254721|NCT02739503|DEVICE|Ultrasound|Patients will receive ultrasound in the ultrasound unit at Hillel Yaffe Medical Center within 10 days before onset of induced or spontaneous labors. The ultrasound team has been trained in FHC , Estimated Fetal Weight (EFW) and Biparietal Diameter (BPD) measurement .Optimal ultrasound measurements of FHC and BPD will be obtained. The average of 3 fetal head circumference measurements will be recorded. Investigators consider the FHC and BPD to be optimal when a clear outline of the entire fetal skull is measured, and the landmarks (the thalamus, cavum septum pellucidum and choroid plexus in the atrium of the lateral ventricles) are visualized. Subsequent information of labor outcome as well as normal head circumference ,post-delivery will be obtained from maternal and neonatal medical records.
224322280|NCT06660199|BEHAVIORAL|Text-based intervention|Parents randomized to the texting intervention will receive up to 3 messages each day for 6 weeks: The intervention is comprised of adolescent-centered (A-C) texts focusing on parental adherence to recommended suicide prevention strategies to promote adolescents' safety and parent-centered (P-C) texts focused on improving parents' own well-being.
223673938|NCT00928122|DEVICE|Intrastromal Correction of Myopia incl. Astigmatism|Applying defined, pre-programmed patterns (e.g. rings and/or radial cuts)into the human eye cornea. It is a minimal-invasive procedure which changes the topography of the cornea and by that the refraction ability.
223673939|NCT00928122|DEVICE|Intrastromal Correction of Hyperopia incl. Astigmatism|Applying defined, pre-programmed patterns (e.g. rings and/or radial cuts)into the human eye cornea. It is a minimal-invasive procedure which changes the topography of the cornea and by that the refraction ability.
223673940|NCT02550977|DRUG|Gestodene/EE Patch (BAY86-5016)|7 day patch containing 0.55 mg ethinyl estradiol and 2.1 gestodene in a 21 day regimen.
223673941|NCT04061928|DRUG|PD-1|2 times PD-1 (240mg) combined with preoperative chemoradiotherapy，then another 2 times PD-1 before operation. 4 times PD-1 combined with postoperative chemotherapy.
223673942|NCT05272995|DIAGNOSTIC_TEST|IIEF-5|The participants will be asked to complete a validated IIEF-5 questionnaire, an abridged version of the IIEF. The IIEF is a validated, brief and reliable self-administered questionnaire for assessing erectile function. Moreover, this tool is easily administered in clinical setting and demonstrates adequate sensitivity and specificity for detecting treatment-related changes in erectile function in patients with erectile dysfunction (ED).According to Rosen et al the abridged five-item version of the 15-item IIEF possesses favorable properties for detecting the presence and severity of ED for the preceding 6 months. The IIEF-5 consists of five questions, each of which is scored on a five-point ordinal scale and ED may be classified into five categories based on the calculated scores.
224254722|NCT05624749|DRUG|ianalumab|ianalumab s.c. monthly
224254723|NCT05624749|DRUG|placebo|placebo s.c. monthly
224254724|NCT06599554|OTHER|follow up scores|"The radiological reports will be read, analyzing when the bony consolidation of the fracture is reported in relation to the time elapsed since the operation.~The questionnaires will be submitted to all patients who have completed the course at 1 year.~All patients who sign the informed consent will be asked to complete the questionnaires either at the time of the follow-up visit by common clinical practice or by telephone, in the event that the patients have exceeded the 1-year follow-up"
224254725|NCT05758480|BIOLOGICAL|Blood sample (at inclusion and 6 months later)|(56ml of blood, 8 tubes) 3 heparin, 1 EDTA , 2 SST, 2 CPT
224254726|NCT05758480|OTHER|Patient questionnaires (at inclusion and 6 months later)|(4 questionnaires) Symptoms in the last week, Fatigue Impact Scale (FIS), Short-Form 36 (SF-36) and Nijmegen.
224254727|NCT05353452|BEHAVIORAL|Neurology Based Collaborative Care|Twenty-four week, evidence-based remote collaborative care model initiated around the time of a neurology visit. The collaborative care team roles include the care manager, psychiatrist, and psychologist/social worker who interact with the patient participant and the patient's neurologist.
224254728|NCT05353452|BEHAVIORAL|SOC Neurological care|Usual neurology care means ongoing, epilepsy provider-recommended clinic visits, prescriptions, testing and referrals from their epilepsy provider. Mental health referrals or prescribing of antidepressants may potentially occur in this group; these types of interventions will be tracked at outcome assessments.
224254729|NCT05378464|BIOLOGICAL|Dendritic Cell (DC1) Vaccine|Participants will receive a DC1 vaccine injection at 1.0-2.0 x 10\^7 cells, either to groin lymph notes or to tumor if accessible once a week for 3 weeks on days 1, 8 and 15. Participants will receive DC1 vaccine boosters every 3 weeks x 3.
224254730|NCT05378464|DRUG|Trastuzumab|Participants will receive trastuzumab 8 mg/kg by IV week 1, then 6 mg/kg by IV beginning week 4 and continuing every 3 weeks until disease progression or intolerable toxicity.
224322281|NCT01682395|PROCEDURE|Resection and anastomosis|Resection of sigmoid colon with primary anastomosis
224322282|NCT01682395|PROCEDURE|Resection and colostomy|Resection of sigmoid colon with end colostomy and Hartmann's pouch, followed at a later date by Hartmann's reversal as a second surgical procedure
224322283|NCT01682395|PROCEDURE|Mesosigmoidopexy|Mesosigmoidopexy--the fixation of the sigmoid colon to lateral abdominal wall with concomitant shortening of the mesosigmoid length.
224322284|NCT05880329|DIAGNOSTIC_TEST|Candidate POCTs for detecting UTI|POCT performance will be evaluated in participants who experience possible UTI.
224322285|NCT05734651|DEVICE|PROMIS Stem|Primary Total Hip Arthroplasty with the PROMIS Stem (Fa. Falcon Medical, Mödling, Austria)
224322286|NCT06608745|PROCEDURE|conventional total knee arthroplasty|total knee arthroplasty performed with conventional technique
224322287|NCT06608745|PROCEDURE|computer-assisted total knee arthroplasty|total knee arthroplasty performed with imageless computer-assisted surgery
224322288|NCT06333236|OTHER|Food for Special Medical Purposes: Kron®|Citicoline 40mg/ml + Nicotinamide 15 mg/ml oral solution
223673943|NCT02619539|PROCEDURE|plasma fibrinogen measurement|plasma fibrinogen measurement
223673944|NCT02217527|DRUG|Active JNJ Drug|200 mg/day (100 mg b.i.d.) of Active JNJ Drug will be used for one week while attempting to briefly quit smoking on Mon-Fri of that week.
223673945|NCT02217527|DRUG|Placebo pill|Placebo pill will be taken daily to assess ability to briefly quit smoking on Mon-Fri for one week.
223673946|NCT05478629|OTHER|Survey|Questioning through google forms
223673947|NCT01433276|DRUG|Hyperosmolar sodium lactate|1st loading : Upto 2 liters of Ringer's lactate, followed by Totilac which was given 5 mL/kgBW/15 minutes, followed by maintenance 2 mL/kgBW/hour for 3 hours
223673948|NCT01433276|DRUG|Ringer's lactate|1st loading : Upto 2 litres of Ringer's lactate, followed by 5 mL/kgBW/15 minutes,followed by maintenance : 2 mL/kgBW/hour for 3 hours
223673949|NCT03133065|DRUG|treatment of HCV with oral direct acting antiviral therapy|A total number of 89 patients transplanted for HCV genotype 4 related end stage liver disease Were included in this study 53 PATIENTS were treated after 6 months of transplantation with sofosbuvir 400mg and weight based ribavirin for 24 weeks. 7 patients were treated with sofosbuvir 400mg + simeprevir 150 mg + weight based ribavirin for 12 weeks after 6 months post transplant. In September 2015, we started to adopt early treatment strategy for all recipients after the first 3months post- transplant. 26 recipients were treated with sofosbuvir 400mg+Daclatasvir 60mg ± weight based ribavirin for 12 weeks or 24 weeks. 2 recipient are treated with sofosbuvir 400mg + ledipasvir 90mg for 24 weeks and one recipient is treated with fixed-dose combination of ombitasvir (12.5 mg), paritaprevir (75 mg) and ritonavir (50 mg) + weight based ribavirin due to having persistent renal impairment post transplantation.
223673950|NCT02436369|DIETARY_SUPPLEMENT|low fat yogurt enriched with flaxseed|daily intake of low fat yogurt enriched with flaxseed for 8 weeks
223673951|NCT02436369|DIETARY_SUPPLEMENT|low fat yogurt|daily intake of low fat yogurt for 8 weeks
223673952|NCT04315974|DRUG|Rivaroxaban|Rivaroxaban therapy for at least 4 weeks.
223673953|NCT04315974|PROCEDURE|Catheter ablation|Radiofrequency catheter ablation or cryoballoon ablation.
223673954|NCT02078973|DRUG|15 mg tolvaptan|15 mg pr day for 1 day
223673955|NCT02078973|DRUG|30 mg tolvaptan|30 mg pr day for 1 day
223673956|NCT02078973|DRUG|45 mg tolvaptan|45 mg pr day for 1 day
223673957|NCT02078973|DRUG|Placebo|1 tablet Unikalk pr day for 1 day
223673958|NCT04486209|DEVICE|transcutaneous spinal cord stimulation|electrical stimulation of the lumbosacral spinal cord through surface electrodes
223772392|NCT02810834|BEHAVIORAL|Walking/Running program|"Participants will receive a behavioral intervention that consists of a school-based, walking/running/jogging program. Participants work to accumulate miles towards a goal of at least 100 miles, over the course of the school year. Program will be implemented through a champion in the school and structured/scheduled according to the schools resources (before, during, or after school). Miles are tracked at the school level, and incentives are provided for participants' completion of set milestones (25, 50, 75, and 100 miles).~The intervention will run over two school years (approximately 16 months)"
223673959|NCT00327808|DRUG|TPI-1020|600 mcg BID x 14 days followed by 1200 mcg BID x 7 days
223673960|NCT00327808|DRUG|budesonide|400 mcg BID x 14 days then 800 mcg/day x 7 more days
223673961|NCT04783623|PROCEDURE|Surgical endometrioma excision|We collect medical records of patients who had underwent surgical endometrioma excision at different sites in our hospital and conduct telephone or clinical interview
223673962|NCT05638672|DRUG|Huashi Baidu Granule|Granule is produced by Guangdong Yifang Pharmaceutical Co., Ltd. with a specification of 5g × 12 bags, twice a day, take 2 sachets each time with boiling water.
223673963|NCT05638672|DRUG|Monapiravir|Monapiravir, manufactured by Merck, an American pharmaceutical company, with the specification of 200mg × 40 capsules, 800mg each time, twice a day.
223673964|NCT02548728|DRUG|Intranasal Oxytocin Spray|10 insufflations (40IU of oxytocin total) given three times on day of enrollment and then twice daily for 4 days
223673965|NCT02548728|DRUG|Placebo|10 insufflations (40IU of placebo, same solution as active treatment minus oxytocin) given three times on day of enrollment and then twice daily for 4 day
224254731|NCT05378464|DRUG|Pepinemab|Participants will receive pepinemab 20 mg/kg by IV beginning week 1 and continuing every 3 weeks until disease progression or intolerable toxicity.
224254732|NCT05378464|BIOLOGICAL|T-Cell therapy|Participants will receive IL-15 expanded CD4 T cells infusion by IV Day 1 at week 8, 2 weeks from last DC1 vaccine, and IL-7 expanded CD4 T cells infusion IV at week 8 day 8.
224254733|NCT05645146|BEHAVIORAL|Smoking Cessation treatment delivered by Tobacco Free Florida Quitline|Phone counseling with the state tobacco quitline
223673966|NCT01431300|DRUG|gadofosveset|Intravenous administration of the specified dosage of gadolinium contrast agent
223673967|NCT00031967|DRUG|therapeutic melatonin|
223673968|NCT00031967|RADIATION|radiation therapy|
223673969|NCT00755703|BIOLOGICAL|Pandemic Influenza Vaccine|Undetermined
223673970|NCT00755703|BIOLOGICAL|Placebo|
223673971|NCT02912637|OTHER|Hyperpolarized Xenon MRI|MRI \& MRS of lung using inhaled hyperpolarized Xenon as a contrast agent
223673972|NCT04704687|OTHER|Transcranial Direct Current Stimulation|Children will perform two successive interventions composed each by a set of 15 sessions of effective-tDCS combine with cognitive-training exercises.
223673973|NCT05464888|BEHAVIORAL|+Short AAT|Interaction with therapy dog prior to dental exam, cleaning, and simulated radiographs.
223673974|NCT05464888|BEHAVIORAL|+Long AAT|Interaction with therapy dog throughout dental exam, cleaning, and simulated radiographs.
223673975|NCT05464888|BEHAVIORAL|Active control; NO dog|Color dog picture for 3 minutes prior to dental exam, cleaning, and simulated radiographs.
223673976|NCT06054269|BIOLOGICAL|FLUAD Quadrivalent|0.5 mL intramuscular dose of FLUAD Quadrivalent
223673977|NCT06054269|BIOLOGICAL|FluQuadri|0.5 mL intramuscular dose of FluQuadri
223673978|NCT05788016|BEHAVIORAL|opioid taper|The participant will attempt to taper their opioid dose by \~50% during the 4-6 week preoperative period
223673979|NCT02498171|DRUG|Intrathecal morphine with fentanyl|"Parturients in this arm underwent a single shot spinal following standard procedure. the drug mixture was then introduced into the subarachnoid space following free flow of csf. the parturient was the monitored fo labour progression using the standard partogram, vital signs and the visual analogue scale score for pain recorded every 5 min.~The fetus was monitored with an ultrasonic aided fetal Doppler until delivery"
223673980|NCT02498171|DRUG|Intrathecal morphine with bupivacaine|"Parturients in this arm underwent a single shot spinal following standard procedure. the drug mixture was then introduced into the subarachnoid space following free flow of csf. the parturient was the monitored fo labour progression using the standard partogram, vital signs and the visual analogue scale score for pain recorded every 5 min.~The fetus was monitored with an ultrasonic aided fetal Doppler until delivery"
223673981|NCT00502203|DRUG|Carboplatin|AUC 5 By Vein Over 1 Hour Every 21 Days for 6 Courses
223673982|NCT00502203|DRUG|Paclitaxel|175 mg/m\^2 By Vein Over 3 Hours Every 21 Days for 6 Courses
223673983|NCT00670943|OTHER|Platelet function testing|
224254734|NCT05645146|DRUG|Nicotine patch|Participants will be provided with a 12 week supply of nicotine patches
224254735|NCT05645146|DRUG|Nicotine Lozenge|Participants will be provided with a 12 week supply of nicotine lozenges
224254736|NCT05645146|BEHAVIORAL|Motivation and Problem Solving (MAPS) intervention|MAPS is a phone counseling approach to facilitating smoking cessation among cervical cancer survivors, which uses a combined motivational interviewing and social cognitive theory based approach to smoking cessation. Participants will receive 6 MAPS based counseling calls over 12 months, along with personally-tailored SMS-delivered text based messages delivered to the participants phone over 2 years.
224254737|NCT01846923|BIOLOGICAL|PCV13|
224254738|NCT01109862|PROCEDURE|Total hip arthroplasty|All cemented THA
224254739|NCT01109862|PROCEDURE|Hemiarthroplasty|Cemented bipolar HAP
224254740|NCT06424444|DRUG|Reproxalap ophthalmic solution (0.25%)|Reproxalap ophthalmic solution (0.25%) administered QID for four weeks, followed by BID administration for two weeks
224254741|NCT06424444|DRUG|Vehicle ophthalmic solution|Vehicle ophthalmic solution administered QID for four weeks, followed by BID administration for two weeks
224254742|NCT02533479|OTHER|Caloric restriction|three alternate days weekly along 4 weeks.
224254743|NCT06456658|OTHER|Interruptive Reminder|"The reminder will display at the time the chart is opened for eligible patient visits and alert clinicians that a statin is recommended for the patient and list the reasons the statin is indicated. It will give the clinicians a defaulted option for statin prescription as well as alternatives. If the clinician accepts the alert, an order for a statin will be placed in their shopping cart for convenience, and the order can be signed to prescribe the medication. If the clinician does not wish to prescribe a statin from the reminder, they can choose an acknowledgement reason."
224254744|NCT06456658|OTHER|Non-interruptive Reminder|"The reminder will have the same format as the interruptive reminder group, but it will not be displayed unless providers seek out the education at their own initiative. The reminder will alert clinicians that a statin is recommended for the patient and list the reasons the statin is indicated. It will give the clinicians a defaulted option for statin prescription as well as alternatives. If the clinician accepts the alert, an order for a statin will be placed in their shopping cart for convenience, and the order can be signed to prescribe the medication. If the clinician does not wish to prescribe a statin from the reminder, they can choose an acknowledgement reason."
224254745|NCT06456658|OTHER|No Reminder|No reminder recommending a statin will be displayed/available to the provider.
224254746|NCT00443716|DRUG|estrogen|
223673984|NCT01911910|BEHAVIORAL|Electronic coaching plus standard care|The HAPPY London web-based tool will provide the participant with an individualised score for their lifestyle and 10 year CV risk score, based mainly on the modified Framingham score, and provide tailored advice and education on the suboptimal factors. Ideal targets will be set and the information will be updated at 3 and 6 months allowing the participant to view their progress. Weekly emails with brief health and lifestyle advice will be sent to encourage healthier behaviour based on clinical studies or topical issues in the media. Links to social networks, such as Facebook posting and the ability to allow chosen family and friends to view their progress will aim to further encourage healthier behaviour.
223673985|NCT02653118|BIOLOGICAL|V503|
223673986|NCT02653118|BIOLOGICAL|GARDASIL|
223673987|NCT04898647|OTHER|fundoscopic picture|A central review of numerised fundoscopic picture will be performed.
224254747|NCT02566239|OTHER|Share activity data with care team|Share participant in-home activity data with retirement community care team.
224254748|NCT03326271|PROCEDURE|Exeter stem|Patients treated with an total or hemiarthroplasty using a Exeter stem for a displaced femoral neck fracture
224254749|NCT03326271|PROCEDURE|Lubinus SP2 stem|Patients treated with an total or hemiarthroplasty using a SP2stem for a displaced femoral neck fracture
224254750|NCT05932680|OTHER|Off Drug Surveillance|After stopping teclistamab, participants will be monitored monthly by standard serum paraprotein studies for disease progression. Participants will resume teclistamab at time of disease progression. After Teclistamab therapy re-initiation on-study, monthly response assessments and data for other study endpoints will be obtained. All participants will undergo peripheral blood collection for correlative research studies at baseline and every two months on-study. Participants who enroll on the biomarker sub-study will undergo bone marrow examination and peripheral blood collection for correlative studies at study entry, at time of disease progression and at six months from enrollment.
224254751|NCT05342597|DRUG|MT-1186|A crossover study in which Japanese healthy subjects receive a single dose of MT-1186 under several dosing condition on Day 1, 3, 5, 7 and 24 according to their treatment sequence.
224254752|NCT04711980|DRUG|Mudan granule|"Mudan granule,a traditional Chinese medicine formula,consists of nine Chinese herbs.~Other: Standard medical care.Standard medical care is in accordance with China Guideline for type 2 diabetes (2013)."
224254753|NCT04711980|DRUG|Placebo|"Granule(Placebo) is in accordance with Mudan granule in appearance, colour, taste.~Other: Standard medical care. Standard medical care is in accordance with China Guideline for type 2 diabetes (2013)."
224322289|NCT06653699|DRUG|2 DOSES OF DEXAMETHASONE AND TRANEXAMIC ACID|In group B, 2 doses of 10 mg intravenous dexamethasone and 20mg/kg of intravenous tranexamic acid administered.
224322290|NCT06653699|DRUG|1 DOSE OF DEXAMETHASONE AND TRANEXAMIC ACID|In group A, 1 dose of 10 mg of intravenous dexamethasone and 20mg/kg of intravenous tranexamic acid administered.
224322291|NCT05159765|DEVICE|Single vision contact lenses|Wearing contact lenses during waking hours may alter the progression of myopia
224322292|NCT05159765|DEVICE|Multifocal contact lenses|Wearing contact lenses during waking hours may alter the progression of myopia
224322293|NCT05920837|DEVICE|MyotonPRO|Muscles' viscoelastic properties assess with myotonPRO.
224254754|NCT03210480|DRUG|Lithium sulphate prolonged-release 660 mg|Oral administration of one tablet once or twice daily (one tablet in the morning and one tablet in the evening) or two tablets in a single dose (two tablets in the evening) of Lithium sulphate 660 mg (Lithium sulphate dose will be individualised for each patient according to the relevant SmPC). Treatment duration: 3 months.
224254755|NCT03210480|DRUG|Lithium carbonate immediate-release 150 mg and 300 mg|Oral administration of 300-1800 mg daily divided into 2-6 doses of Lithium carbonate capsules (Lithium carbonate dose will be individualised for each patient according to the relevant SmPC). Treatment duration: 3 months.
224254756|NCT01590485|OTHER|starch|100 mg in each capsule every 6 hours up to 48 hours (400 mg/day)
224254757|NCT01590485|OTHER|saffron|100 mg in each capsule every 6 hours up to 48 hours (400 mg/day)
224254758|NCT06406361|BEHAVIORAL|online stress management program|"-Nurses should have an idea about stress management program Awareness develops about the importance of attending sessions regularly. Nurses have information about the training program. Joint session dates are determined. The educator makes statements about himself and education. The benefits of education for nurses are explained. Nurses are informed about the general rules of education. The importance of regular attendance at sessions is emphasized. Privacy rules and limits are determined. The necessity of completing homework is explained. Nurses are enabled to share their feelings and thoughts. Ensuring that nurses are able to recognize stress and reactions to stress and identify sources of stress in individual and business life.~Being informed about the effects of stress and negative workload perception Being able to recognize the tension created by stress in the body Learning breathing and deep relaxation techniques to reduce or eliminate symptoms of stress"
224254759|NCT05126355|BEHAVIORAL|On the Move group exercise|The OTM exercise program is a group-based program led by a certified OTM instructor. The frequency and duration of OTM is 50 minutes, twice weekly for 12 weeks for a total of 24 classes. The OTM exercise program is based on principles of motor learning that enhance smooth and automatic movement control. The program contains a warm-up (5 minutes), stepping patterns (15 minutes), walking patterns (15 minutes), strengthening exercises (10 minutes), and cool-down exercises (5 minutes). The warm-up and cool down contain gentle range of motion exercises and stretches for the lower extremities and trunk. Considered essential components, the stepping and walking patterns are progressively more difficult, goal-oriented patterns that promote the timing and coordination of stepping integrated with the phases of the gait cycle.
224254760|NCT05342740|OTHER|collect whole blood, urine and stool samples|collect whole blood, urine and stool samples
224254761|NCT03537872|BEHAVIORAL|Miner-Friendly (MF) Service Venues TB/HIV Integration Strategies|"In addition to the control condition strategies (marked PS), the MF intervention includes additional strategies (marked MF):~STRUCTURAL LEVEL Co-location of TB and HIV services (PS); Co-location of clinical and non-clinical services (MF); Demand creation (MF); Weekend service hours (MF) CLINIC LEVEL Intensified TB case finding and IPT (PS); Test and START (PS); Training for healthcare workers (PS); Job aids and mentorship for healthcare workers (MF) INDIVIDUAL/FAMILY LEVEL Health literacy for patients (PS); Family counseling (PS - limited); One-way SMS text messaging and lay counselor support for adherence and retention (MF); A menu of options for medication refills for miners unable to visit the clinic on a monthly basis (MF)"
224254762|NCT03537872|BEHAVIORAL|Public Sector (PS) Health Facilities TB/HIV Integration Strategies|STRUCTURAL LEVEL Co-location of TB and HIV services CLINIC LEVEL Intensified TB case finding and IPT; Test and START; Training for healthcare workers INDIVIDUAL/FAMILY LEVEL Health literacy for patients; Family counseling (limited); Adherence support from nurses and village health workers
224254763|NCT01739101|BEHAVIORAL|Reproductive Life Plan|A structured discussion based on the Reproductive Life plan, including information about reproduction and a brochure with the same information.
224254764|NCT00794963|DRUG|Pravastatin, Fenofibrate, Metformin, Orlistat, irbesartan|The intervention in the 4 patients consisted in dietary recommendations, advice regarding increasing physical activity, and use of Orlistat 60 mg three times daily. No other drugs were prescribed.
224254765|NCT00794963|OTHER|As selected by community physician|As selected by community physician
224254766|NCT02420834|OTHER|Hypromellose 0.15%|Tear supplement to be taken as required to relieve symptoms
224254767|NCT02420834|OTHER|Hypromellose 0.4%|Tear supplement to be taken as required to relieve symptoms
224254768|NCT02420834|OTHER|Carboxymethylcellulose|Tear supplement to be taken as required to relieve symptoms
224254769|NCT02420834|OTHER|Liposomal Spray|Tear supplement o be taken as required to relieve symptoms
224254770|NCT01565902|DRUG|BAF312|Treatment with a single oral dose of 0.25 mg BAF312
224254771|NCT02118532|DEVICE|IN.PACT Admiral Paclitaxel-Eluting Percutaneous Transluminal Angioplasty (PTA) Balloon Catheter|IN.PACT Admiral Paclitaxel-Eluting Percutaneous Transluminal Angioplasty (PTA) Balloon Catheter originally developed, approved and commercialized by Invatec Technology Center GmbH is the investigational medical device used in the study. Medtronic Inc. acquired Invatec on April 21, 2010. Medtronic
224254772|NCT03645785|DIETARY_SUPPLEMENT|Normal fluid intake without true lemon|16.9oz water with True Lemon
224254773|NCT03645785|DIETARY_SUPPLEMENT|Double fluid intake plus 3 bottles of water with True Lemon|No intervention
224254774|NCT02892253|DEVICE|Near Infrared Camera (NIR)|Surgical field is examined with NIR, during a few minutes (\<5') with room lights switched off, to avoid parasite lights, then open thyroidectomy is resumed conventionally. Real-time images, evocative of autofluorescent parathyroids, are checked visually. NIR consists of a 750 nm class 1 laser excitation, with a power \<20mW/cm2 (5 times less than the limit of 100mw/cm2, fixed by the international standard IEC 60601-2-41). It is provided by the Fluobeam® camera, which is inserted into a sterile cover and hold at a 15-20 cm distance from the patient. The system has an FDA 510(k) authorization for clinical use in parathyroid surgery and a European Community certification (Class 2A device).
224322294|NCT05920837|OTHER|Box and Block Test|Upper extremity's functionality assess with Box and Block Test.
224322295|NCT07134153|DRUG|T-DXd|Evaluating safety and efficacy of intrathecal or ommaya reservoir administration of T-DXd in patients with HER2-expressing breast cancer with active leptomeningeal and/or brain metastases based on systemic therapy
224322296|NCT06871020|OTHER|Mandibular removable partial denture retained on OT extracoronal attachment made from fiber-reinforced composite resin|Bilateral OT extracoronal attachments will be milled from fiber-reinforced composite resin after obtaining impressions of the prepared abutments. This will be followed by an overall impression of fabricating a Co-Cr removable partial denture to be retained in the attachments.
223772393|NCT02810834|BEHAVIORAL|Classroom physical activity break program|"Participants will receive a behavioral intervention that consists of a classroom-based, physical activity break program. Classroom teachers, paraprofessionals, and other school staff will lead short (5-15 minute) activity breaks that include both higher intensity (ex. jumping jacks, squats) and low-intensity (ex. stretching, yoga) activities. Classrooms will be encouraged to integrate at least one short break per day. Activities are connected to national Common Core academic standards so that breaks can be integrated with academics.~The intervention will run over two school years (approximately 16 months)"
224254775|NCT06118918|BEHAVIORAL|Phase II comprehensive cardiac rehabilitation program|the program extends over 3 months after cardiac surgery. The program includes exercise, health education, and stress management. all content will be delivered to the participants through the WhatsApp application as instruction videos and short lectures. exercise will be gradually increased in terms of intensity, and duration. health education will cover topics like a healthy diet blood pressure, blood cholesterol control, smoking cessation …etc. stress management will include relaxation therapy, breathing control, behavioral change, and other strategies to control stress. Phone call follow-ups once weekly will be made by one of the research team to evaluate the adherence and answer potential questions All interventions are guided by universal guidelines like the Australian Cardiovascular Health and Rehabilitation Association (ACRA) and American Heart Association (AHA
224254776|NCT01364532|PROCEDURE|Transulnar arterial access|Transulnar arterial access in coronary angiography, ad-hoc or elective PCI
224254777|NCT01364532|PROCEDURE|Transradial arterial access|Transradial arterial access for coronary angiography,ad-hoc or elective PCI
224254778|NCT06312488|DIAGNOSTIC_TEST|Clot Pro|This study enrolls patients admitted to the Adult ICU of Milan Policlinico Hospital with a diagnosis of sepsis or septic shock. A ClotPro® TPA test is performed at admission and on day 1, 2, 3, and 7. Specific markers of coagulation (PAI-1, Plasminogen, Protein C and S) and inflammation (Il-1beta, IL-6, IL-8, TNF-alpha, ADM) are tested at enrollment. Routine laboratory tests are performed daily. Hemorrhagic and thrombotic events are searched. The study ends at 28 days or upon ICU discharge.
224254779|NCT06500624|DRUG|Pizotifen|Each subject will be given 0.5mg pizotifen with 10-20mg escitalopram in patients with depressive disorder
224254780|NCT03544411|BIOLOGICAL|olive oil|the intervention consist of 15 ml / day of olive oil
224254781|NCT03544411|BIOLOGICAL|bran oil|the intervention consist of 15 ml / day of bran oil
224254782|NCT02148497|PROCEDURE|Multi-colored Placido disk imaging|The multi-colored Placido disk instrument records the tear surface using video imaging.
224254783|NCT05804370|DRUG|Gleolan|Gleolan is a prodrug that is metabolized intracellularly to form the fluorescent molecule Protoporphyrin IX (PpIX). The oral provision of Gleolan leads to a highly selective accumulation of PpIX in tumor cells. Following excitation with blue light (BL) (wavelength \[λ\] = 375 - 450 nm), the PpIX, which has accumulated selectively in tumor tissue, emits a red-violet light.
223673988|NCT04898647|BIOLOGICAL|blood sample|"Two 10 ml blood vials will be sampled in addition to standard blood sampling for getting 6 to 7 200 μL aliquot.~One 5 ml EDTA vial for GP1bα expression study, only if this sample can be sent to hemostasis laboratory within the 4 hours after sampling"
223673989|NCT04898647|PROCEDURE|bone marrow sample|Five to 10 ml bone marrow sample will be collected in addition to standard bone marrow sampling for getting molecular characteristics of WM
223673990|NCT02241889|DEVICE|Insulin pump therapy|Subject's own insulin pump will be used to manage blood glucose.
223673991|NCT02241889|DEVICE|Closed-loop Artificial Pancreas Controller|Closed-loop Artificial Pancreas Controller includes insulin and glucagon delivery algorithm implemented on a smart phone, utilizing sensor glucose values from a Dexcom G4 sensor and sending delivery commands to two Tandem t:slim insulin pumps, one filled with insulin and one with glucagon.
223673992|NCT01318005|DRUG|Oral Contraceptive: Ortho-Novum® 1/35|Oral Contraceptive: Ortho-Novum® 1/35, pill, 2-3 mos, daily.
223673993|NCT01318005|DRUG|Oral Contraceptive: Ovcon® 35|Oral Contraceptive: Ovcon® 35, pill, 2-3 mos, daily.
223673994|NCT01318005|DRUG|Oral Contraceptive: Microgestin Fe® 1/20|Oral Contraceptive: Microgestin Fe® 1/20, pill, 2-3 mos, daily.
223673995|NCT03021161|DRUG|Probiotic Formula|The intervention group will receive once daily capsules containing 109 CFU of Lactobacillus rhamnosus HN001, Lactobacillus paracasei Lpc-37 and Bifidobacterium animalis ssp. Lactis HN019
224254784|NCT03181594|DEVICE|ClariFix Device|Cryoablation in the nasal passageway using the ClariFix Device
224254785|NCT03945422|DEVICE|AccuTite/FaceTite|Radiofrequency-assisted lipolysis (RFAL) Morpheus8: Fractional RF
224254786|NCT01499628|BEHAVIORAL|Supervised Reading|Participant attends once a week for three weeks for a 45 minute appointment of supervised reading using appropriate spectacles and/or glasses
224254787|NCT01499628|BEHAVIORAL|EVT at the PRL|Eccentric viewing training at the Preferred Retinal Locus (PRL), using reading/target cards. Three 45 minute sessions completed over three weeks.
223673996|NCT03021161|OTHER|Placebo Oral Capsule|Capsule containing no probiotic
223772394|NCT03754257|PROCEDURE|Experimental Electrical Stimulation|Experimental Electrical Stimulation (100Hz) during 40 minutes
224254788|NCT01499628|BEHAVIORAL|EVT at the TRL|Participant attends once a week for three weeks for a 45 minute appointment of TRL training using the MAIA microperimeter and then further reading using magnifiers and/or spectacles.
224254789|NCT03276247|OTHER|observation|observation
224254790|NCT02787876|DRUG|Pegteograstim|
224254791|NCT03282162|DRUG|intranasal oxytocin|Each subject will be assigned to intranasal administration of oxytocin (24 IU).
223772395|NCT03754257|PROCEDURE|Sham Electrical Stimulation|Sham Electrical Stimulation (5Hz) during 40 minutes
223772396|NCT03754257|OTHER|Conventional Physiotherapy|Active and passive exercises, and walking.
223772397|NCT00471601|BEHAVIORAL|counseling intervention|
223772398|NCT00471601|BEHAVIORAL|questionnaire administration|
223772399|NCT00471601|BEHAVIORAL|psychosocial assessment and care|
224254792|NCT03282162|DRUG|intranasal placebo|An identical amount of intranasal administration of placebo will be assigned to each subject.
224254793|NCT03426722|DRUG|L-carnitine|"* L-carnitine VS Placebo is randomized (1:1)~* L-carnitine 500mg TID(PO),~* First evaluation will be performed at 8 weeks and then unblinding will be done. If symptoms continue after treatment, dose escalation in L-carnitine group by 1000mg TID (PO). If symptoms continue after treatment in Placebo group, L-carnitine 500mg TID(PO) will be given."
224254794|NCT03426722|DRUG|Placebo|Placebo 500mg TID(PO)
224254795|NCT00471523|DRUG|Clomiphene citrate|
224254796|NCT00471523|DRUG|Metformin|
224254797|NCT05442021|DEVICE|Neubie Direct Current Electrical Stimulation Device|Direct Current Electrical Stimulation Device that uses electrodes non-invasively on the skin to stimulate muscle fibers.
224254798|NCT05442021|DEVICE|TENS|Transcutaneous Electrical Nerve Stimulation device - uses alternating current delivered through electrodes on the skin.
224254799|NCT03397056|OTHER|Questionnaire|The Questionnaire is provided in the links at the end of the declaration.
224254800|NCT05244798|DRUG|Sintilimab|Sintilimab: D1 administration) for 2 cycles. Every 3 weeks was a dosing cycle (Q3W)
224254801|NCT05244798|RADIATION|radiotherapy|Radiotherapy: According to IMRT treatment plan, the total dose was 41.4Gy, divided into 23 times, 5 days a week.
224254802|NCT05244798|DRUG|Chemotherapy|Neoadjuvant chemotherapy with TP regimen: albumin-paclitaxel + carboplatin, D1 administration) for 2 cycles. Every 3 weeks was a dosing cycle (Q3W).
224254803|NCT03755947|DRUG|Ibrutinib|Ibrutinib Oral Capsule \[Imbruvica\] Tablets 120 mg. Oral. 420mg/day, day 1 to 28, every 28 days. 3 cycles.
224254804|NCT03755947|DRUG|Obinutuzumab|Obinutuzumab Injection. Intravenous Solution \[Gazyva\] Parenteral. 1000 mg, day 1 of every cycle, every 28 days. 6 cycles.
224254805|NCT03755947|DRUG|Venetoclax|Venetoclax Oral Tablets \[Venclexta\] Tablets 100 mg. Oral. 400 mg/day. Day 1 to 28, every 28 days. 12 cycles.
224254806|NCT01394497|DRUG|N-acetylcystein|15 min systemic NAC infusion of the donor (30 mg/kg, maximum dose 3000 mg) diluted into 500 ml 5 % glucose solution, 30 min before initiating the liver harvesting procedure, and a loco-regional infusion (150 mg/kg of estimated liver weight, maximum dose 300 mg) into the portal vein 5 min before cross-clamping.
224254807|NCT05699551|BEHAVIORAL|Exercise regimen|Exercise will take place Monday, Wednesday, and Friday from 12:00-1:00 pm for 6 weeks. Aerobic exercise will consist of walking, beginning with a 10-minute duration, with gradual progression to 20 minutes. Muscle strength, endurance and range-of-motion exercise will then be performed. Muscle strength and endurance training will begin using no weight and performing one set of 6 repetitions. Progression using added resistance in the form of dumbbell weights (1-6 lbs.) and increased sets and repetitions will be applied as Subjects become increasingly fit. For static range of motion exercise, positions will be held for 10-15 seconds in the beginning and increased over time. Exercise will be kept at a moderate level of intensity. Each session will then end with relaxation training.
224254808|NCT01845376|PROCEDURE|local anesthesia group|Patients will receive local anesthesia similar to that described by Amid et al. except that 1% lidocaine with adrenaline (1:200,000) will be used instead of a mixture of lidocaine and bupivacaine.
224254809|NCT01845376|PROCEDURE|spinal anesthesia group|Patients will be positioned in the lateral position and a Whitacre 25 G needle will be inserted at L3-4 intervertebral space and then heavy bupivacaine 0.5% 15 mg will be injected.
224254810|NCT01845376|PROCEDURE|general anesthesia group|Patients will be induced with propofol 2 mg/kg and fentanyl 1.5 µg /kg. They are then allowed to breathe spontaneously with sevoflurane 2% to 2.5% in a mixture of 60% oxygen through a laryngeal mask. End-tidal concentration of sevoflurane will be adjusted to keep end-tidal sevoflurane 1MAC. Supplemental doses of 25 µg of fentanyl will be administered if intraoperative heart rate and blood pressure are greater than 20% of baseline.
224254811|NCT00732082|DRUG|Gemcitabine|
224254812|NCT00732082|BIOLOGICAL|LAG-3|
224254813|NCT02009462|DRUG|Artefill dermal filler|Four treatment visits will be scheduled at baseline and at weeks 4, 12, and 24. Each treatment session will utilize no more than 8 mL of Artefill and no more than 30 syringes of Artefill.
223673997|NCT05320809|BIOLOGICAL|3D189|"3D189 (200 mcg per peptide x 4 WT1 peptides within the drug product; total weight: 800 mcg) is mixed (1:1 v/v) and emulsified with the adjuvant Montanide, which is then injected subcutaneously to the patient.~A maximum of 15 total injections of 3D189 will be administered as follows:~1. Initial immunization induction phase（the first series of 6 injections of 3D189): every 2 weeks (Weeks 0 - 10) followed by a 4-week period of no treatment.~2. Early immune booster phase（the second series of 6 injections of 3D189): every 4 weeks (between Weeks 14 and 34) followed by a 6-week period of no treatment.~3. Late immune booster phase（the third series of 3 injections of 3D189): every 6 weeks (between Weeks 40 and 52)."
223673998|NCT05596383|DIETARY_SUPPLEMENT|Vitamin D 5000 IU|Intervention vitamin D 5000 IU per day, duration six months, dosage form chewable tablet
223673999|NCT05596383|DIETARY_SUPPLEMENT|Placebo|Placebo
223674000|NCT04478344|OTHER|Ultrasound guided hydrodissection of superior cluneal nerve|Intervention procedure: hydrodissection to the superior cluneal nerve entrapment; Device for guidance of injection: high-resolution ultrasound ; Drug for injection: a mixture of 1 mL of 50% dextrose, 4 mL of 1% lidocaine, and 5 mL of 0.9% normal saline
223674001|NCT03127332|OTHER|Carevive CPS|This intervention will focus on the use of the Carevive CPS at the point of treatment decision making, enabling providers to deliver evidence-based and personalized treatment care plans to their metastatic breast cancer patients on active treatment. The Carevive CPS collects electronic patient reported outcomes (ePROs) and clinical data, reported and generated by clinical staff and/or peer-reviewed evidence, and includes patient education, resources, and referrals developed by cancer clinicians and researchers.
223772400|NCT00471601|BEHAVIORAL|quality-of-life assessment|
224254814|NCT03284476|OTHER|Collection of medical data from ICU patients|Medical data collected on a electronic secured data base
224254815|NCT04819594|OTHER|Elequil aromatabs ®|100% pure essential oils in a unique controlled delivery system for relaxation, comfort, and sleep. Scented tabs on a self-adhesive label will be placed on the nurses's uniform for 4 hours to provide aromatherapy for the clinical setting.
224254816|NCT05646381|DRUG|Pelacarsen (TQJ230) 80mg|Pelacarsen (TQJ230) 80mg
224254817|NCT05646381|DRUG|Matching placebo|Matching placebo
224254818|NCT01177020|OTHER|Biological specimen|Biological specimen taken from placenta
224254819|NCT05381220|OTHER|early mobilization|Patients will receive early mobilization measures within 24 to 48 hours after the onset of stroke.
224254820|NCT01727180|OTHER|Questionnaire based on the McGill Pain Questionnaire|Interview questionnaire based on the short form of the McGill Pain Questionnaire
224254821|NCT00885144|DIETARY_SUPPLEMENT|Nutributter|"Test dose of standard supplementary lipid based nutrient supplement (LNS). 15 grams of Nutributter will be mixed with 30 g of maize porridge and fed to the child over a maximum of 15 minute period, under direct observation."
224254822|NCT00885144|DIETARY_SUPPLEMENT|LNS-20gM|Test dose of modified LNS-20gM supplementary lipid based nutrient supplement (LNS). 15 grams of LNS-20gM will be mixed with 30 g of maize porridge and fed to the child over a maximum of 15 minute period, under direct observation.
224254823|NCT00885144|DIETARY_SUPPLEMENT|LNS-20gNoM|Test dose of modified LNS-20gNoM (milk free) supplementary lipid based nutrient supplement (LNS). 15 grams of LNS-20gNoM will be mixed with 30 g of maize porridge and fed to the child over a maximum of 15 minute period, under direct observation.
224254824|NCT00885144|DIETARY_SUPPLEMENT|LNS-10gM|Test dose of modified LNS-10gM supplementary lipid based nutrient supplement (LNS). 15 grams of LNS-10gM will be mixed with 30 g of maize porridge and fed to the child over a maximum of 15 minute period, under direct observation.
224254825|NCT03247972|DRUG|Evolocumab|Sixty subjects will be treated with high dose statins for 8 weeks followed by 8 weeks of high dose statin + evolocumab (420mg/4 wk) therapy.
224254826|NCT01010555|DEVICE|lotrafilcon B|Commercially marketed, silicone hydrogel, spherical contact lens
223674002|NCT04284462|OTHER|Flavored carbonated soft drink (CSD)|1-2 cans/day (330 ml per can)
224254827|NCT01010555|DEVICE|balafilcon A|Commercially marketed, silicone hydrogel, spherical contact lens
224254828|NCT01010555|DEVICE|senofilcon A|Commercially marketed, silicone hydrogel, spherical contact lens
224254829|NCT01010555|DEVICE|enfilcon A|Commercially marketed, silicone hydrogel, spherical contact lens
224254830|NCT02914990|DRUG|BPI-15086|BPI-15086 is administered once daily with a starting dose of 25 mg in a 21-day cycle. When tolerated, increasing doses of BPI-15086 will be tested in subsequent cohorts, until a maximum tolerated dose is determined.
224254831|NCT01593852|RADIATION|Advanced image processing|Acquisition of x-ray images with reduced X-ray dose and advanced image processing
224254832|NCT01593852|RADIATION|Regular image processing|Acquisition of x-ray images with regular X-ray dose and regular image processing
224254833|NCT04425928|PROCEDURE|occupational therapy based activity training programs|Occupational therapy based activity training programs in which exercises based on physiotherapy are put into the purposeful activities at vestibular rehabilitation.
224254834|NCT04425928|PROCEDURE|Physiotherapy based exercise training programs|Cawthorne-cooksey exercises were performed at vestibular rehabilitation
224254835|NCT06459765|DEVICE|Mi2000 TICI|Cochlear Implantation
224254836|NCT05125406|BEHAVIORAL|Exposure therapy with Virtual Reality.|Experimental arm patients will be offered Exposure therapy with Virtual Reality (ETRV) support with a virtual reality headset. A scenario with progressively increasing stress levels linked to the ICU environment and different situational contexts (alarms, etc.) will be presented to patients. This habituation to the potentially anxiety context of ICU will reduce the occurrence of psycho-cognitive disorders by progressive extinction phenomenon.
224254837|NCT06129539|DRUG|Debio 4326|Administered as an intramuscular (IM) injection
224254838|NCT01154374|DRUG|MEBO Wound Ointment|Topical application twice daily
224254839|NCT01154374|PROCEDURE|Standard of Care (sterile saline moistened gauze)|
224254840|NCT05691244|DRUG|Drug: Normal Saline|Normal saline to be used as vehicle in the phase-III study to assess efficacy of sovateltide in patients with acute cerebral ischemic stroke.
224254841|NCT05691244|DRUG|Sovateltide|Phase-III study to assess efficacy of sovateltide in patients with acute cerebral ischemic stroke.
224254842|NCT05625958|DEVICE|Cilioscleral Interposition Device|Surgical placement of SV22 cilioscleral interposition device in the supraciliary space
224254843|NCT05509608|DEVICE|RM Electrode|The RM Electrode is a corneal ERG electrode. The distinguishing features of the RM electrode are that it is a soft contact lens with a recessed electrode (i.e. no metal electrode makes direct contact with the eye). The RM Electrode also has an integral speculum to hold the wearer's eye lids open. The electrode is designed for superior positional stability on the eye during testing. These features work together to improve ERG signal quality.
224254844|NCT05509608|DEVICE|ERG Jet Electrode|The ERG Jet electrode is an FDA approved, commercially available corneal ERG electrode.
224254845|NCT01005745|PROCEDURE|Surgery|Surgery to remove a tumor for growth of TIL
224254846|NCT01005745|DRUG|Administration of Lymphodepletion|Lymphodepleting chemotherapy with cyclophosphamide and fludarabine to enhance T cell persistence and effectiveness in vivo
224254847|NCT01005745|OTHER|Adoptive Cell Transfer|T-cell infusion
224254848|NCT01005745|DRUG|High Dose IL-2|Beginning approximately 12 - 16 hours after cell infusion.
224254849|NCT06121843|DRUG|BMS-986393|Specified dose on specified days
224254850|NCT06121843|DRUG|Alnuctamab|Specified dose on specified days
224254851|NCT06121843|DRUG|Mezigdomide|Specified dose on specified days
224254852|NCT06121843|DRUG|Iberdomide|Specified dose on specified days
224254853|NCT06121843|DRUG|Elranatamab|Specified dose on specified days
223674003|NCT03836001|DRUG|Serlopitant Tablet|Serlopitant is a small molecule, highly selective NK1-R (neurokinin-1 receptor) antagonist. Two critical mediators of the urge to scratch are Substance P, or SP, and its receptor, NK1-R. SP is a naturally occurring peptide in the tachykinin neuropeptide family. Tachykinins have a broad range of functions in the nervous and immune systems. SP binding of NK1-R has been shown to be a key mediator of sensory nerve signaling, including the itch-scratch reflex and the vomiting reflex.
223674004|NCT03836001|DRUG|Placebo Oral Tablet|The placebo is a tablet that looks like a drug but has no drug or other active ingredient in it.
224254854|NCT05767034|DRUG|Secukinumab 300 mg|Taken subcutaneously every 4 weeks until Week 48 in combination with a 24-week prednisone taper regimen
224254855|NCT05767034|DRUG|Secukinumab 150 mg|Taken subcutaneously every 4 weeks until Week 48 in combination with a 24-week prednisone taper regimen
224254856|NCT05767034|OTHER|Placebo to secukinumab|Taken subcutaneously every 4 weeks until Week 48 in combination with a 24-week prednisone taper regimen
224254857|NCT02468258|PROCEDURE|endometrial flushing|Oocytes were retrieved 34-36 h after hCG administration and aspirated FF was collected and centrifuged at 600 rpm for 10 min and 5-ml sample of supernatant was obtained for ELISA estimation of tumor necrosis factor-α (TNF-α), granulocyte colony-stimulating factor (G-CSF), leptin and anti-Mullerian Hormone (AMH) levels in both groups. The remaining amount was used for endometrial flushing
224254858|NCT02981095|PROCEDURE|Thyroidectomy|Thyroidectomy performed by the same surgical and anesthesia team
224254859|NCT02981095|DRUG|Bupivacaine|bupivacaine 0.5%, 10cc was administered to surgical field after completion of Thyroidectomy and approximately 15-30 minutes before the extubation.
224254860|NCT02981095|DRUG|Saline Solution|%0.9 sodium chloride solution, 10cc was administered to surgical field after completion of Thyroidectomy and approximately 15-30 minutes before the extubation.
224254861|NCT01327222|DRUG|Bevacizumab|1.25 mg intravitreal bevacizumab
224254862|NCT04198844|DRUG|warfarin|warfarin user
224254863|NCT04198844|DRUG|apixaban|apixaban user
224254864|NCT06047834|DRUG|Standard of Care with Lofexidine|Participants will be randomized 3:1 to treatment with standard of care with or without lofexidine. Subjects randomized to standard of care with lofexidine will be sequentially assigned to 1 of 3 dose levels: Dose 1 (32 μg/kg/day, administered as 4 μg/kg/day q3h), Dose 2 (20 μg/kg/day, administered as 5 μg/kg/day q6h), or Dose 3 (16 μg/kg/day to 24 μg/kg/day administered q6h, with the final daily dose level to be decided based on data collected in participants receiving Dose 2).
224254865|NCT06047834|OTHER|Standard of Care without Lofexidine|Participants will be randomized 3:1 to treatment with standard of care with or without lofexidine. Subjects randomized to standard of care without lofexidine wilt receive non-pharmacologic measures and morphine when indicated.
224254866|NCT02727088|PROCEDURE|Pulpotomy|Conservative pulp management (experimental treatment): ablation of the coronal part of the pulp
224254867|NCT02727088|PROCEDURE|Pulpectomy|ablation of the whole dental pulp, preparation and filling of the whole root canal system
224254868|NCT03914183|DEVICE|mCPN Intervention|"Each box of montméd Coloured Pen Needles (mCPN) has the following five features:~i. Distinctively coloured pen needles ii. A user-defined association tool which is intended to help the patient associate each colour to a specific injection zone iii. A concise and intuitive educational message Change color, change site siteTM iv. Unique packaging with educational content v. Four distinctive message-in-a-box educational sound-chips which serve to reinforce the recommended educational message on site rotation at home and come on every tenth time the pen needle box is opened"
224254869|NCT03914183|DEVICE|Control|Use of standard of care insulin pen needle
224254870|NCT03674489|OTHER|Neurodynamic Slider Mobilization|"Subjects will be positioned in supine with the examiner supporting his/her arm and facing caudally. The arm will be taken into the ULNT2a position as described in Butler's text - so as to bias the median nerve. Once passive resistance is felt or a feeling of mild tension is reported in the median nerve field, a series of mobilizations will be performed to slide the nerve proximally and distally in an alternating manner via providing wrist extension with concurrent shoulder girdle elevation and then providing wrist flexion with concurrent shoulder girdle depression. This will be performed for 2 sets of 10 cycles at a rate of 6 seconds per cycle (3 sec in each position) - not moving further into described tension or passive resistance."
224254871|NCT03674489|OTHER|Neurodynamic Tensioner Mobilization|"Subjects will be positioned in supine with the examiner supporting his/her arm and facing caudally. The arm will be taken into the ULND2a position as described in Butler's text - so as to bias the median nerve. Once passive resistance is felt or a feeling of mild tension is reported in the median nerve field, a series of mobilizations will be performed to tension the nerve in an alternating on/off manner via providing wrist extension with concurrent shoulder girdle depression and then providing wrist flexion with concurrent shoulder girdle elevation. This will be performed for 2 sets of 10 cycles at a rate of 6 seconds per cycle (3 sec in each position) - not moving further into described tension or passive resistance."
223674005|NCT00307008|BIOLOGICAL|Pneumovax 23™|Single dose intramuscular injection
223674006|NCT01961583|DRUG|18F-Fluciclatide|"Baseline 18F-Fluciclatide PET imaging will be obtained before starting of Pazopanib therapy(within 7 days).~Subsequent 18F-Fluciclatide PET should be performed on 7 days after Pazopanib therapy"
224254872|NCT03674489|OTHER|Sham Neurodynamic Mobilization|Subjects will be positioned in supine with the examiner supporting his/her arm and facing cranially - in a similar position as the UNLD1 test described previously. From here, the therapist will position the patient's arm in 45 deg. of shoulder abduction without scapular depression, 45 deg. of shoulder external rotation, 45 deg. of elbow flexion, and forearm pronation. From this position, a series of sham mobilizations will be performed by passively alternating flexion and extension of the wrist for 2 sets of 10 cycles at a rate of 6 seconds per cycle (3 sec in each position).
224254873|NCT03944447|DRUG|Cannabis, Medical|Patients will be given medical cannabis recommendations and certifications commensurate with the state law in which the encounter occurs. The variations in mechanisms between the states for recommending, registering, certifying, and developing mandated treatment plans or doses will be adhered to; however, variations in state law and cannabis programs should not cause variation in the study design because the end-result is still the same with patients being treated with medical cannabis.
223674007|NCT00933413|DRUG|LACTIC ACID(ND)|Treatment duration: 21 consecutive days
223674008|NCT04052802|OTHER|Fissure sealing|The materials will be applied to the demineralized fissures as stated in manufacturer's instructions
223674009|NCT00319072|BEHAVIORAL|TalkToYourDoc(sm) hormone therapy module|
224254874|NCT03944447|DEVICE|RYAH-Medtech Inhaler|Our research study will involve incorporation of RYAH-Medtech company's devices into our protocols. They have an inhaler and a transdermal patch for both hemp-derived CBD and cannabis. RYAH has developed an integrated phone app for tracking product use and patient response. They are currently involved in clinical trials in Europe. OMNI Medical will integrate the partner with RYAH device for several reasons. Primary goals will involve using their integrated smart phone app to collect and secure large quantities of data. Secondary goals will include FDA approval as a medical device. The specific cannabis strain will be tracked using scannable QR codes programed into the smart phone app. This will allow us to track patient feedback and capture data on usage. OMNI Medical will have patients use RYAH's products as part of and FDA Investigational Device Exemption, which requires an IRB. Use of the devices would be completely voluntary by study participants.
224254875|NCT04820920|BEHAVIORAL|LTP|LTP is a low-literacy, sustainable programme that will provide depressed mothers with valuable skills on parenting, improve mother-child relation and mental health self-care. This is a research-based activity that enhances postnatal mental health while simultaneously promoting attachment security through building parents' ability to monitor and be sensitive to their children's cues, and thereby, actively involves in their children's mental and physical development.
224254876|NCT04820920|BEHAVIORAL|CaCBT|CaCBT adopts 'here and now' problem-solving approach, which involves collaborating with families, active listening techniques, changing negative thinking, and depressive symptoms associated with postnatal depression and other forms of parenting distress.
224254877|NCT04820920|BEHAVIORAL|Psychoeducation|This is a form of psychoeducation involving basic discussions around mother-child relationships, childcare, child nursing related activities and general maternal discussions.
224254878|NCT03769025|BEHAVIORAL|Suboxone Remote Observed Dosing|The remote observed dosing group will use the provided smartphone to video record themselves taking their Suboxone dose each day
224254879|NCT03769025|OTHER|Suboxone Attention Control|Attention control group will send a text message daily confirming that they have taken their Suboxone dose
224254880|NCT04211779|DEVICE|Real tDCS|Real tDCS (TCT Research Limited, Hong Kong); 3 times a week on alternate days for consecutive 6 weeks. The active session of tDCS will consist in applying anodal stimulation over left M1 (C3 according to the 10-20 international EEG placement) and the cathodal stimulation over right supraorbital area (Fp2 according to the 10-20 international EEG placement), and to inject 2 mA for 20 minutes through sponge electrodes (35 cm²) placed on the scalp.
224254881|NCT04211779|DEVICE|Sham tDCS|Sham current (TCT Research Limited, Hong Kong); 3 times a week on alternate days for consecutive 6 weeks. The sham tDCS will use the same montage and device but direct current will only be injected for 30 seconds, with a ramp-up and ramp-down 15 seconds period, to mimic the somatosensory effects of active tDCS.
224254882|NCT04211779|OTHER|Exercise|The Exercise intervention will include only aerobic exercise 3 times a week on alternate days for consecutive 6 weeks. The program will last 20 minutes.
224254883|NCT05243797|DRUG|Teclistamab|Teclistamab will be administered via a subcutaneous injection (SC)
224254884|NCT05243797|DRUG|Lenalidomide|Lenalidomide will be administered orally
224254885|NCT05653349|BIOLOGICAL|Ianalumab|Intravenous infusion, prepared from concentrate solution
224254886|NCT05653349|DRUG|Placebo|Intravenous infusion, prepared from matching placebo
224322297|NCT06871020|OTHER|Mandibular removable partial denture retained on OT extracoronal attachment made from porcelain-fused to metal|Bilateral OT attachments manufactured from porcelain fused to metal by conventional technique after obtaining impressions of the prepared abutments. This will be followed by an overall impression of fabricating a Co-Cr removable partial denture to be retained in the attachments.
223674010|NCT05235503|DRUG|Medicinal cannabis in combination with oxycodon|The intervention will be administering the combination of medicinal cannabis in combination with oxycodon
223674011|NCT05235503|DRUG|Medicinal cannabis in combination with placebo oxycodon|The intervention will be administering the combination of medicinal cannabis in combination with placebo oxycodon
223674012|NCT01685333|DRUG|Epoetin Alfa|Intravenous single-dose administration of 100 IU/kg of the test drug (Human Recombinant Epoetin) in the first period and intravenous single-dose administration of 100 IU/kg of the comparator drug (Eprex) in the second period, after 23-30 days of washout, or vice-versa.
223674013|NCT03105466|PROCEDURE|Deep anterior lamellar keratoplasty|Deep anterior lamellar keratoplasty using acellular porcine cornea; 0.05%Tacrolimus eye drops, four times a day for at least one year; 0.3% Tobradex eyedrops, four times-one times a day for one year.
224254887|NCT05653349|DRUG|Corticosteroids|Oral or parental (if clinically justified)
223674014|NCT03105466|DEVICE|Acellular Porcine Cornea|
223772401|NCT02418260|PROCEDURE|Bridge Plate osteosynthesis|Trough two anterior skin incisions, the 4.5mm narrow DCP plate will be placed on the anterior surface of the humerus and, after indirect reduction, it will be fixed to the bone with 2 proximal and 2 distal screws.
223772402|NCT02418260|PROCEDURE|Locked intramedullary nail osteosynthesis|Trough an anterolateral approach to the shoulder, the supraspinatus tendon will be longitudinally splited allowing the insertion of the intramedullary nail.
224254888|NCT06256562|DRUG|GZR18|Titrated to dose 1, dose 2, dose 3 or dose 4
224254889|NCT06256562|OTHER|Placebo|Administered the same volume as GZR18
224254890|NCT04349475|DIETARY_SUPPLEMENT|Intervention Omega 3 Supplementation|Participants will supplement 4g of Omega 3 fish oil daily (750DHA/250EPA)
224254891|NCT04349475|DIETARY_SUPPLEMENT|Control Safflower Oil|Participants will consume 2.5g of a Safflower oil supplement daily
224254892|NCT05259410|BEHAVIORAL|TRE|All food eaten within the same self-selected 8 hour eating window daily, water fasting the remaining hours of the day.
224254893|NCT05259410|BEHAVIORAL|MedTRE|A mediterranean style diet will be eaten within the same self-selected 8 hour eating window daily, water fasting the remaining hours of the day.
224254894|NCT01908205|DRUG|Intranasal Oxytocin|
224254895|NCT01908205|DRUG|Placebo|
224254896|NCT06083090|PROCEDURE|Yogatherapy|The experimental arm will benefit from support by a physiotherapist trained in yoga, in a group for ten weeks with two weekly sessions of approximately 1 hour each. A new yoga program adapted for the axSPA will be implemented.
224254897|NCT06083090|PROCEDURE|Physiotherapy|The comparator arm will benefit from support by a physiotherapist, in groups for ten weeks at the rate of two weekly sessions of approximately 1 hour each. An already existing program adapted for the axSPA will be implemented.
224254898|NCT06807983|DIAGNOSTIC_TEST|diagnostic strategy based on lung and cardiac ultrasonography|cardiopulmonary ultrasound performed by the emergency physician, immediately at patient's bed
224254899|NCT04454528|RADIATION|Hypofractionated radiotherapy|Radiation boost (RT) 7 Gy x 1 fraction on Day -14/Day -7 (arm 1) or Day -7/Day -14
224322298|NCT04645862|DIAGNOSTIC_TEST|CT scans|4D CTA imaging
223674015|NCT03105466|DRUG|Tacrolimus eye drops|
223674016|NCT03105466|DRUG|Tobradex eyedrops|
223674017|NCT02819908|DRUG|Imprimis Dropless|Tri-Moxi-Vanc transzonular intravitreal injection
223674018|NCT02819908|DRUG|Imprimis Less Drops|Pred-Moxi-Ketorolac and Pred-Ketorolac topical instillation qd postoperatively
223674019|NCT01863589|DRUG|Adefovir tablets|Administered according to the prescribing information in the locally approved label by the authorities.
224254900|NCT04454528|DRUG|Pembrolizumab infusion|Pembrolizumab infusion flat dosing 200 mg delivered over 30 minutes.
224254901|NCT04454528|PROCEDURE|Blood and tissue sampling|Blood will be collected for laboratory studies and complete correlative studies to examine how the subject's immune system is responding to treatment. On day 0, samples of tumor and any lymph nodes removed from armpit will be analyzed by the UPenn Department of Pathology according to standard practice.
224254902|NCT06650501|DRUG|Dabigatran|Patients will be assigned to change to dabigatran at the monograph approved dose for their indication, bleeding risk, and renal function.
224254903|NCT06650501|DRUG|Apixaban|Patients will continue taking their currently prescribed apixaban, edoxaban, or rivaroxaban
224254904|NCT06650501|DRUG|edoxaban|Patients will continue taking their currently prescribed apixaban, edoxaban, or rivaroxaban
224254905|NCT06650501|DRUG|Rivaroxaban|Patients will continue taking their currently prescribed apixaban, edoxaban, or rivaroxaban
224254906|NCT06730256|DRUG|CAR-T cells Infusion chimeric antigen receptor T cells|CAR-T cells Infusion chimeric antigen receptor T cells
224254907|NCT04001777|DRUG|APG-1252|Multiple dose cohorts, 30 minute IV infusion, weekly for 3 weeks of a cycle with 21days.
224254908|NCT04001777|DRUG|Osimertinib Mesylate Tablets|Osimertinib Mesylate Tablets 40mg/80 mg, one time a day until disease progression
224254909|NCT05170334|DRUG|Binimetinib|Binimetinib will be given at 45 mg orally twice daily during each cycle of 21 days, for up to 16 cycles.
224254910|NCT05170334|DRUG|Belinostat|Belinostat will be administered IV at 1,000 mg/m2 daily on days 1 to 5 every 21 days during each 21 day cycle, for up to 16 cycles
224254911|NCT04343365|OTHER|Evolutionary Tumor Board (ETB)|The ETB consists of evolutionary biologists, mathematicians, research scientists, statisticians,data scientists, radiologists, pathologists, oncologists (surgical, radiation, medical, and pediatric), and clinical trial coordinators.The ETB will generate hypotheses, mathematical models, and experiments from the discussion towards further integration of evolutionary ideas towards therapeutic strategies for participants. The ETB will collect data through a chart review regarding adherence and results of ETB recommendation
224254912|NCT04123080|DEVICE|Endoscopic band ligation assisted polypectomy|A conventional upper endoscope loaded with a band ligator was inserted in the colon and was advanced to the site of the pedunculated polyp. After approaching the lateral side of the stalk and grasping the mid-portion of the stalk using a tripod grasper. Then, the rubber band was released from the cap to ligate the stalk. Thereafter, we performed polypectomy of the remaining stalk just above the ligation by extending the electrosurgical snare.
224254913|NCT03513185|DRUG|Deanxit, SSRI or SRNI|After recruiting participants and collecting the baseline data, the SSS-CN, PHQ-15, PHQ-9 and GAD-7 questionnaires will be carried out. An independent diagnosis will be made by primary care physician using the fifth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) criterion standard. Deanxit, selective serotonin reuptake inhibitors (SSRI) or serotonin-norepinephrine reuptake inhibitors (SNRI) will be selectively prescribed according to the severity category assessed by physician. Two, 6,10 weeks after patients with correspondent medications, a face-to-face interview, telephone interview or mobile-apps survey will be underwent to follow-up using the SSS-CN, PHQ-15, PHQ-9 and GAD-7 checklists.
224254914|NCT00760825|BIOLOGICAL|killed bivalent (O1 and O139)whole cell oral cholera vaccine|1.5 ml given twice orally, 14 days apart
224254915|NCT04046783|DEVICE|patch|an overnight application of a patch containing a standardized quantity of Allium Cepa extract and allantoin on C-section scars over 4 weeks.
224254916|NCT03482882|DRUG|Pimavanserin|Pimavanserin 34 mg total daily dose, tablets, once daily by mouth (provided as two 17 mg NUPLAZID® tablets)
224254917|NCT05860699|DRUG|Placebo|Placebo made by the same manufacturer to look like the active pills
224254918|NCT05860699|DRUG|Half dose CBD|add-on cannabidiol (Echo Pharmaceutical, BV) 450 mg per day for 10 days during their inpatient stay
224254919|NCT05860699|DRUG|Full dose CBD|add-on cannabidiol (Echo Pharmaceutical, BV) 900 mg per day for 10 days during their inpatient stay
224254920|NCT06531876|DEVICE|Dreem 3S recording|Subjects in both Arms A and B will undergo at-home recording with the Dreem 3S EEG Headband to assess sleep. Subjects will undergo in-lab polysomnography and multiple sleep latency testing while also wearing the Dreem 3S EEG headband system. Arm B participants will be asked to withdraw from some or all of their Narcolepsy related medication therapy for roughly 19 days in order to assess the ability of the Dreem Headband System in characterizing sleep disturbances related to Narcolepsy.
224254921|NCT06669533|DRUG|Placebo|Participants will receive placebo (3 tablets) administered vaginally 2-3 hours and 4-6 hours prior to visual inspection with acetic acid (VIA).
224254922|NCT06669533|DRUG|Misoprostol|Participants will receive 600 mcg misoprostol (3 tablets) administered vaginally 2-3 hours and 4-6 hours prior to visual inspection with acetic acid (VIA).
224254923|NCT05691465|PROCEDURE|Biospecimen Collection|Undergo collection of blood
224254924|NCT05691465|PROCEDURE|Computed Tomography|Undergo CT scan
224254925|NCT05691465|RADIATION|Gallium Ga 68-DOTATATE|Given IV
223772403|NCT02418260|PROCEDURE|Open reduction and plate osteosynthesis|Trough an posterior or anterolateral approach, the fracture will be directly reduced and fixed with a broad DCP 4.5mm plate.
224254926|NCT05691465|DRUG|Lutetium Lu 177 Dotatate|Given IV
224254927|NCT05691465|PROCEDURE|Positron Emission Tomography|Undergo PET
223772404|NCT00002912|DRUG|etoposide|
223772405|NCT00002912|DRUG|mitoxantrone hydrochloride|
223772406|NCT00002912|DRUG|valspodar|
224254928|NCT06655896|BIOLOGICAL|rapcabtagene autoleucel|single infusion of rapcabtagene autoleucel
224254929|NCT06655896|BIOLOGICAL|rituximab|rituximab intravenous infusion (i.v.) as per protocol
224254930|NCT05524935|DRUG|Pembrolizumab|Pembrolizumab Day 1 of each 21 day (3 week) cycle
224254931|NCT05524935|DRUG|Olaparib|Olaparib by mouth days 1-21 of each 21 day (3 week) cycle
224254932|NCT06194084|OTHER|Two-sequence of durian pulp doses (100 g and 200 g)|Participants first go through an initial washout maintaining a low-fiber diet for 14 days. After washout, participants will be instructed to consume 100 grams of durian pulp every day following their breakfast or dinner for 1 week. Participants will then continue to consume 200 grams of durian pulp every day during the 2nd week of intervention and then will go through another washout for 2 weeks.
224254933|NCT04234997|DRUG|Suvorexant 20 mg|Participants will be advised to take the medication at 10PM for 7 days.Participants will be instructed to stop smoking by 10 pm the day before, in order to ensure they meet the breath CO criterion (CO ≤ 4 ppm) indicating overnight abstinence.
224254934|NCT04234997|DRUG|Suvorexant 0mg|Participants will be advised to take the medication at 10PM for 7 days.Participants will be instructed to stop smoking by 10 pm the day before, in order to ensure they meet the breath CO criterion (CO ≤ 4 ppm) indicating overnight abstinence.
224254935|NCT06983158|DRUG|gene therapy|Intra-venous gene therapy
224254936|NCT06982521|DRUG|RLY-2608|400 mg orally BID administered daily on a 28-day treatment cycle
224254937|NCT06982521|DRUG|Capivasertib|400mg orally BID administered on an intermittent weekly dosing schedule. Patients will dose on Days 1 through 4 each week of a 28-day treatment cycle
224254938|NCT06982521|DRUG|Fulvestrant|500 mg intramuscularly administered on Cycle 1 Day 1, Day 15, and Day 1 of each subsequent cycle (28-day treatment cycle)
224254939|NCT06605833|DIAGNOSTIC_TEST|12-Lead ECG|"Participants will undergo a standard 12-lead ECG in order to record the electrical activity of the heart. This typically takes a few minutes and the ECG is read by a cardiologist~This is a Standard of Care test being performed at a non Standard of Care timepoint"
224254940|NCT06605833|DIAGNOSTIC_TEST|Transthoracic Echocardiogram|"A transthoracic echocardiogram will be performed in accordance to standard British Society of Echocardiography guidelines. This will involve undertaking an ultrasound scan of the participant's heart with ultrasound jelly to obtain information including left ventricular function and valvular function.~This is a Standard of Care test being performed at a non Standard of Care timepoint"
224254941|NCT06605833|DIAGNOSTIC_TEST|Cardiac MRI|"A cardiac MRI scan will be performed in order to assess the morphology and function of the heart in accordance with international guidelines. Data that will be derived includes biventricular volumes and function and myocardial strain data.~This is a Standard of Care test being performed at a non Standard of Care timepoint"
224254942|NCT06605833|DIAGNOSTIC_TEST|Cardiac Biomarker Screening|"* Cardiac Troponin I,~* NTproBNP\],~* lipid profile,~* HbA1c~* ferritin~These are Standard of Care tests being performed at a non Standard of Care timepoint"
224254943|NCT06605833|OTHER|Basic Observations|"* Heart rate~* Blood pressure~* Oxygen SAT~* Respiratory rate~These are Standard of Care observations being performed at a non Standard of Care timepoint"
224254944|NCT06598150|OTHER|Shoulder Abduction|Individuals will be visually cued to perform short, unilateral, isometric shoulder abduction tasks. A visual display will provide real-time feedback of the shoulder abduction torque, to help the participant target a predetermined torque level.
224254945|NCT06588153|DRUG|Prolia®|Subcutaneous (SC) injection in pre-filled syringe.
224254946|NCT01138436|DRUG|MEBO Wound Ointment (MEBO)|Topical application once a day
224254947|NCT01138436|PROCEDURE|Standard of Care|Application of Profore multilayer compression bandage system
224254948|NCT00649987|DRUG|Albuterol Sulfate Extended-Release Tablets 8 mg|8mg, single dose fed
224254949|NCT00649987|DRUG|VoSpire® ER Tablets 8 mg|8mg, single dose fed
224254950|NCT00652977|PROCEDURE|Ritgens maneuver|Delivery of the fetal head should be managed by Ritgens maneuver, i.e. lifting the fetal chin anteriorly, using the fingers of one hand placed between the anus and the coccyx, and thereby extending the fetal neck, whereas the other hand should be placed on the fetal occiput to control the pace of the expulsion of the fetal head. The maneuver was used during a uterine contraction
224254951|NCT00652977|PROCEDURE|Standard care (Manual support of the perineum)|The protocol entailed our standard care: using one hand to apply pressure against the perineum, and the other hand on the fetal occiput to control the expulsion of the fetal head, and only to use Ritgen´s maneuver in case of labor arrest or abnormal fetal heart rate pattern when the fetal head was at the pelvic floor.
224254952|NCT05632380|PROCEDURE|Autologous hematopoietic stem cell transplantation|Patients receive transplantation conditioning followed by autologous hematopoietic stem cell transplantation after successful stem cell mobilization and collection. If previously collected stem cells are available, no stem cell mobilization or collection is required, and patients will receive conditioning directly.
224254953|NCT05632380|BIOLOGICAL|C-CAR088|C-CAR088 is an BCMA targeted Chimeric Antigen Receptor-T cell product. Patients will receive C-CAR088 single dose infusion 3 days after ASCT. The dose level of C-CAR088 will be determined by the investigator.
224254954|NCT06296056|BIOLOGICAL|Combi|Biological immune cell therapy
224254955|NCT06660355|DRUG|Ruxolitinib|Ruxolitinib is a Janus kinase inhibitor.
224254956|NCT06660355|DRUG|Prednisone|Prednisone is a glucocorticoid.
224254957|NCT06659250|DRUG|PF-06414300|Participants will receive oral ascending doses.
224254958|NCT06659250|DRUG|Placebo|Participants will receive matching placebo.
224254959|NCT06660862|DRUG|Darolutamide|How darolutamide and hormone therapy affects the step count of older men who have prostate cancer
224254960|NCT06660862|DRUG|Physician choice Androgen Deprivation (Hormone) Therapy|How step count/physical activity affects certain quality of life changes these men experience such as differences in pain, mood, function, memory and fatigue
224254961|NCT06824818|BEHAVIORAL|LHRH Agonist Therapy Discontinuation|The intervention involves \*\*discontinuing LHRH agonist therapy\*\* in elderly prostate cancer patients who have been on long-term androgen deprivation therapy. Participants will be monitored for testosterone recovery and PSA levels over a period of up to 3 years.
224254962|NCT00836576|DRUG|Benazepril HCl 40 mg Tablets|1 x 40 mg, single-dose fasting
224254963|NCT00836576|DRUG|Lotensin® 40 mg Tablets|1 x 40 mg, single-dose fasting
224322299|NCT07009704|BEHAVIORAL|Mobile-based social support|Participants will be invited to join an encrypted group chat where they will be encouraged to provide and receive social support related to glucose management during early pregnancy. Other study participants and study team members will be in the group chat.
224322300|NCT07009704|BEHAVIORAL|Real-time continuous glucose monitoring|Participants will receive a real-time continuous glucose monitor that pairs with an existing smartphone app that shows minute-by-minute glucose levels and records glucose levels in 5 minute increments.
224254964|NCT04603014|COMBINATION_PRODUCT|Interdialytic peritoneal ultrafiltration with 10% dextrose solution|Interdialytic peritoneal ultrafiltration with incremental doses of a 10% dextrose solution, after hemodialysis twice weekly for three consecutive weeks
224254965|NCT06985862|OTHER|Voice recording 4 times a day|"* Morning (first recording): Text reading (article 25.1 of the Declaration of Human Rights).~* Noon (second recording): Counting from 1 to 20 at normal speed~* Evening (third recording): Prolonged phonation of the vowel 'a' without catching your breath.~* Bedtime (fourth recording): Free expression describing stressful moments of the day and their impact on diabetes management, for at least 30 seconds."
224254966|NCT06640881|RADIATION|ablative single-dose PBI|ablative single-dose PBI followed by BCS after three weeks At baseline (prior to RT) and prior to BCS, toxicity, PROMS and cosmetic outcome will be assessed. Additionally, a preoperative MRI will be performed three weeks following RT to evaluate the acute tumor response.
224254967|NCT06597396|DRUG|Abrocitinib|50 mg tablets
224254968|NCT06597396|DRUG|Placebo|Tablets
224254969|NCT06840392|DRUG|Remibrutinib Dose A|Remibrutinib Dose A (oral)
224254970|NCT06840392|DRUG|Remibrutinib Dose B|Remibrutinib Dose B (oral)
224254971|NCT06840392|DRUG|Placebo 1|Placebo matching to remibrutinib Dose A (oral)
224254972|NCT06840392|DRUG|Placebo 2|Placebo matching to remibrutinib Dose B (oral)
224254973|NCT01863030|DEVICE|Phasix mesh implant|
224254974|NCT02841748|DRUG|Pembrolizumab|200mg, every three weeks, iv, x 1 year
224254975|NCT02841748|DRUG|Placebo|iv, every three weeks, x 1 year
224254976|NCT05053347|DIETARY_SUPPLEMENT|Flaxseed oil capsule|The participants were asked to take flaxseed oil capsule 4.5 g/d (ALA 2.5g/d). The intervention period is 24 weeks separated by a 12-week washout period. Do not take any other medicine, traditional Chinese medicine, or dietary supplements.
224254977|NCT05053347|DIETARY_SUPPLEMENT|Corn oil capsule|The participants were asked to take corn oil capsule 4.5 g/d. The intervention period is 24 weeks separated by a 12-week washout period. Do not take any other medicine, traditional Chinese medicine, or dietary supplements.
224254978|NCT06858865|DRUG|AD-228A|AD-228A Oral Tablet
224254979|NCT06858865|DRUG|AD-2281 and AD-2282|AD-2281 Oral Tablet + AD-2282 Oral Tablet
224254980|NCT06858579|DRUG|DNTH103|IV Infusion
224254981|NCT06858579|DRUG|DNTH103|SC injection
224254982|NCT06858579|DRUG|Placebo|SC injection
224254983|NCT03238976|OTHER|Nature sounds|Nature sounds will be played for patients in the nature sounds exposure group.
224254984|NCT06989957|DRUG|Psilocybin|Experimental Psilocybin (exact dosages not disclosed)
224254985|NCT06989957|DRUG|Psilocybin|Comparator Psilocybin (exact dosages not disclosed)
224254986|NCT06989957|DRUG|MDMA|Experimental MDMA (exact dosages not disclosed)
224254987|NCT06989957|DRUG|MDMA|Comparator MDMA (exact dosages not disclosed)
224254988|NCT06988527|DRUG|Honey in orabase 1: 1 paste|The experimental drug was manufactured and packed at the Faculty of Pharmacy, Price Sattam University, SA. Production of a mucoadhesive paste involves a step-by-step process. in the final step, honey, comprising 50% of the total composition was thoroughly blended with the prepared base to ensure homogeneity
224254989|NCT03851939|COMBINATION_PRODUCT|Transarterial Chemoinfusion (TAI) Combine Toripalimab|Transarterial Chemoinfusion (TAI) Combine Toripalimab
224254990|NCT06516614|BEHAVIORAL|Sleep Coach|Sleep-promoting intervention consisting of 4 phone sessions to improve sleep duration and consistency.
224254991|NCT06516614|BEHAVIORAL|Diabetes Education|Participants will receive a a binder with educational information about diabetes and educational messages from the study team.
224254992|NCT06665906|BEHAVIORAL|Web-Based Cognitive Behavioral Therapy (PainTrainer)|Self-guided program that contains 8 modules, lasting 30-40 minutes each and can be completed in 8 to 12 weeks. Each module teaches behavioral coping strategies for pain management and recommends practice exercises.
223772407|NCT06535581|PROCEDURE|surgery patient|patients with hypertension (group 2) and without (group 1) hypertension. The predictive ability of postoperative pain as a tool for measuring and assessing pain was examined by analysing the relative change in the Perfuston index.
224254993|NCT06665906|BEHAVIORAL|Social Intervention|At least six phone call visits, plus or minus 4, with patient navigator to coordinate care.
224254994|NCT06995521|DRUG|Vorinostat|"For Matched sibling and matched unrelated donor transplant recipients: Vorinostat will be given orally at a dose of 60 milligrams per square meter two times a day (BID) (120 mg/m2/day) from day -10 to day 30 post-transplant. The maximum dose will be 100 mg BID.~Haploidentical donor transplant recipients:~Vorinostat will be given orally at a dose of 60 mg/m2 BID (120 mg/m2/day) from day +5 (at least 24 hours after completion of the day +4 cyclophosphamide) through day 30 post-transplant. The maximum dose will be 100 mg BID.~Dosing may be rounded by +/- 10%. Patients that are able to take capsules and whose calculated dose is ≥91 mg may take 100 mg capsules."
224254995|NCT06994936|DRUG|Sonelokimab|sonelokimab 120 mg administered subcutaneously via a PFS
224254996|NCT06994936|DRUG|Sonelokimab|sonelokimab 120 mg administered subcutaneously via an AI
224254997|NCT05082571|DRUG|vadadustat|Vadadustat tablet orally once a day for 52 weeks
224254998|NCT06994923|BEHAVIORAL|BWLI-College|Behavioral modifications are based on empirically-supported principles for weight loss. Diet recommendations follow a small change approach in which participants will make a series of small, self-selected dietary changes each day (\~100-200 calories) that they build on over the course of the intervention. Physical activity recommendations are to achieve 150-250 weekly minutes of moderate-to-vigorous physical activity with specific goals and rate of progression that are individualized to each participant.
224254999|NCT06994923|BEHAVIORAL|Control|Psychoeducation around dieting myths, healthy eating, and physical activity
224255000|NCT03153540|DEVICE|Active iTBS|Intermittent theta burst transcranial magnetic stimulation
224255001|NCT03153540|DEVICE|Sham iTBS|Sham intervention
224255002|NCT04751487|DRUG|Itepekimab SAR440340|Pharmaceutical form: solution for injection in pre-filled syringe Route of administration: subcutaneous
224255003|NCT04751487|DRUG|Placebo|Pharmaceutical form: solution for injection in pre-filled syringe Route of administration: subcutaneous
224255004|NCT06182072|DRUG|ProAgio Dose Levels (DL) 1,2,3,4|ProAgio combined with gemcitabine and nab paclitaxel (G-nP) in previously untreated subjects with metastatic PDAC.
224255005|NCT06182072|DRUG|Gemcitabine, nab paclitaxel|ProAgio combined with gemcitabine and nab paclitaxel (G-nP) in previously untreated subjects with metastatic PDAC.
224255006|NCT06822790|DRUG|Plozasiran Injection|ARO-APOC3 injection
224255007|NCT05813327|DRUG|ADI PEG20|ADI-PEG 20 will be given on an outpatient basis at a dose of 36 mg/m\^2 via intramuscular injection into either the deltoid or gluteal muscle.
224255008|NCT05813327|DRUG|Ifosfamide|Ifosfamide will be administered intravenously per package insert and institutional practice on Days 1 through 5 of all 3 cycles.
224255009|NCT05813327|RADIATION|Radiotherapy|Radiotherapy will begin on C2D1 and will continue as per institutional practice.
224255010|NCT05813327|DRUG|Mesna|Mesna will be administered for supportive care either intravenously or by mouth per package insert and institutional practice on Days 1 through 5 of all 3 cycles.
224255011|NCT06746753|DRUG|Angiotensin II|randomized to receive Angiotensin II continuous infusion for up to 48 hours
224255012|NCT06746753|DRUG|Norepinephrine|randomized to receive Norepinephrine continuous infusion for up to 48 hours
224255013|NCT06586905|DEVICE|Medical Device|Multiplo Complete Syphilis (TP/nTP) Antibody Test
224255014|NCT07000591|OTHER|Experimental Group|"Patients will receive a neck massage based on Watson's Human Caring Model in addition to standard medical care. The massage will be performed three times a week for eight weeks, totaling 24 sessions. Sessions will last 30 minutes and follow evidence-based nursing interventions. Care will be individualized and delivered in a calming environment.~Pre- and post-intervention assessments will include the Epilepsy Self-Efficacy Scale and the Epilepsy Symptom Management Scale for patients, and the Zarit Burden Interview for caregivers. Caregivers will also complete an introductory form. All data will be collected at baseline and after eight weeks. The massage's impact on both patient outcomes and caregiver burden will be evaluated."
224255015|NCT06854692|OTHER|Cervical retraction exercise|Participants will perform end-range cervical retraction and cervical retraction with extension, holding the end-range of motion for 3 seconds and performing 10 repetitions of each exercise.
224255016|NCT06864104|DRUG|Tonlamarsen|Tonlamarsen will be administered subcutaneously (SC) every 4 weeks during the randomized part of the study
224255017|NCT06864104|DRUG|Placebo|Placebo will be administered subcutaneously (SC) every 4 weeks during the randomized part of the study
224255018|NCT01594047|DRUG|ketamine infusion|Ketamine infusion scheme: 5mcg/Kg/min from induction od anaesthesia for 10 min, than 2,5mcg/Kg/min for 20 min and than 2 mcg/Kg/min to the end of surgery
224255019|NCT01594047|DRUG|Methadone PCA|Methadone administered by a PCA system (dose 2 mg, lock-out 12min.)
224255022|NCT07005934|DEVICE|Theragun Prime|Percussion massager
224255023|NCT07109414|DRUG|NP-G2-044|NP-G2-044 will be provided as a tablet via oral route of administration in the study.
224255024|NCT07109414|DRUG|PLD|PLD will be provided as an infusion via intravenous route of administration in the study.
224255025|NCT06617962|DIAGNOSTIC_TEST|CBA method of live cells and fixed cells|"1. Study participants with high clinical suspicion of MOGAD: 2mL serum samples were collected for detection. CBA method of live cells and fixed cells was used for all samples. Sensitivity, specificity, positive predictive value and negative predictive value of the two detection methods were calculated according to the detection results and combined with the 2023 MOGAD diagnostic criteria.~2. Control group：2mL serum samples were collected for detection. CBA method of live cells and fixed cells was used for all samples."
224255026|NCT06868212|DRUG|Remibrutinib|Film-coated tablet, oral administration, 25 mg b.i.d.
223772408|NCT05937022|DEVICE|Experimental Transcranial Direct Current Stimulation (tDCS)|This study will deliver tDCS sessions for ten sessions completed within two weeks. Consecutive tDCS sessions are separated by at least 24 hours. Participants assigned to one of the two experimental groups will receive 20 minutes of active stimulation with a 2mA intensity over the corresponding brain regions.
224255027|NCT06868212|DRUG|Remibrutinib matching placebo|Film-coated tablet, oral administration, b.i.d.
224255028|NCT06868212|DRUG|Dupilumab|Solution for injection in pre-filled syringe 600 mg loading dose followed by 300 mg dose every 2 weeks
224255029|NCT06868212|DRUG|Placebo solution for injection|Solution for injection in pre-filled syringe every 2 weeks
223772409|NCT05937022|DEVICE|Sham Transcranial Direct Current Stimulation (tDCS)|This study will deliver tDCS sessions for ten sessions completed within two weeks. Consecutive tDCS sessions are separated by at least 24 hours. Participants assigned to the sham control group will receive 30 seconds of active stimulation over brain regions identical to either the left DLPFC or the right VLPFC experimental tDCS group.
223772410|NCT00529945|DEVICE|PFx Closure System|
223772411|NCT03755765|DRUG|Amoxicillin-Clavulanate 875 Mg-125 Mg Oral Tablet|Amoxicillin-Clavulanate 875 Mg-125 Mg Oral Tablet
223772412|NCT03755765|BIOLOGICAL|BB-12|Bifidobacterium animalis subsp. lactis BB-12-supplemented yogurt
223772413|NCT03755765|OTHER|Control|Yogurt without Bifidobacterium animalis subsp. lactis BB-12 (BB-12)
224255030|NCT02370719|BEHAVIORAL|Mobile application for diabetes self-management|
224255031|NCT07133100|DEVICE|Upper limb rehabilitation wearable device|The intervention consists in using the AuReha system to perform a series of upper limb rehabilitation exercises. No therapeutic or diagnostic interventions will be administered, as this is a non-invasive study focused on system validation and user feedback.
224255032|NCT07129252|DRUG|CRN09682|Study drug CRN09682 intravenously
224255033|NCT02957942|DEVICE|1Hz repetitive transcranial magnetic stimulation (rTMS)|1 session of low-frequency rTMS (1Hz, 1200 pulses, 20 minutes)
224255034|NCT06371807|DRUG|Pembrolizumab injection|(KXCb - PA\[E\]C) vs (KPA\[E\]C - KXCb) Pembrolizumab (K) + paclitaxel (X) + carboplatin (Cb) followed by pembrolizumab + doxorubicin or epirubicin (A or E) + cyclophosphamide (C) followed by pembrolizumab in the adjuvant setting vs Pembrolizumab + doxorubicin or epirubicin (A or E) + cyclophosphamide (C) followed by pembrolizumab (K) + paclitaxel (X) + carboplatin (Cb) followed by pembrolizumab in the adjuvant setting
224255035|NCT05397028|DIETARY_SUPPLEMENT|Meal replacement system|Participants will replace meals with a meal replacement system to assess the efficacy of weight loss leading to remission of diabetes (optimal A1C levels).
224255036|NCT05397028|BEHAVIORAL|Intensive lifestyle Intervention|Participants will sign up with a virtual health program which they will interact with.
224255037|NCT01030848|DEVICE|Total Knee Replacement (LCS rotating platform)|
224255038|NCT06678841|DEVICE|Personalized cardiac pacing|Personalized cardiac pacing treatment based each patient's height and baseline LVEF.
224255039|NCT07010081|PROCEDURE|Surveys|Several questionnaires will be conducted once in-person to each patient after a follow-up consultation in the hospital after their major surgery
224255040|NCT04328597|PROCEDURE|Inguinal hernia repair|Inguinal hernia repair (open, laparo-endoscopic, robotic)
224255041|NCT06865742|BEHAVIORAL|Music intervention|This is the first study to evaluate the effects of music therapy on fatigue, sleep quality and mental well-being of individuals receiving HD treatment.
224255042|NCT05098886|DRUG|DA-5210 10/1000mg|single dose administration (one tablet once a day)
224255043|NCT05098886|DRUG|DA-5210-R 10/1000mg|single dose administration (one tablet once a day)
224255044|NCT01242774|DRUG|Panobinostat|Oral administration of panobinostat given 3 times a week (administered on weeks 2 and 3 of a 4 week cycle) in combination with induction chemotherapy (idarubicin and cytarabine.
223674020|NCT03493932|DRUG|Nivolumab|OPDIVO is a human programmed death receptor-1 (PD-1) blocking antibody indicated for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor.
223772414|NCT00465166|PROCEDURE|Ultrasound|Lumbar ultrasound from L1-S1, carried out using a portable ultrasound system equipped with a 2-5 MHz curved array probe.
223772415|NCT04800185|DRUG|Crisaborole 2% Top Oint|To analyze the skin microbiome of patients with atopic dermatitis before, during, and after treatment with crisaborole 2% ointment
224255045|NCT04383886|OTHER|stress and anxiety questionnaire|Emergency department staff will be asked to fill in questionnaires in order to measure their stress and anxiety level, their propensity to have a burn-out, their consumption of psychoactive substances such as alcohol, tobacco, coffee or anxiolytic, their sleep disorder.
224255046|NCT06275061|PROCEDURE|Metabolic and Bariatric Surgery|Metabolic and bariatric surgery is weight loss surgery that results in weight loss and resolution of metabolic disorders.
224255047|NCT03452319|OTHER|Pretraining|Increased physical activity, and daily strength training and breathing exercises.
224255048|NCT03452319|OTHER|Usual care|Preoperative information
224255049|NCT05401734|DEVICE|Observation and follow up measurement|"The measured variables include:~Questionnaires~* Health related quality of life (Health Related Quality of Life Questionnaire)~* Physical activity level (Physical Activity Scale for Persons with Impairments and Disabilities)~* Walking ability (Walking Index for Spinal Cord Injury)~* Independence in activities of daily living (SCIM III Questionnaire)~* Pain (International SCI Pain Basic Data Set)~* Resilience (Resilience Scale)~* Bowel and bladder function (Neurogenic Bowel Dysfunction score, International Consultation on Incontinence Modular Questionnaire - Lower Urinary Tract Symptoms)~Measurements:~* Muscular strength and joint ROM (Manual Muscle Testing)~* Spasticity (Modified Ashworth Scale)~* Walking parameters (walking time, crutch position, forward and lateral center of gravity shift, step length and height, swing phase, walking speed)~* Cardiovascular response (blood pressure, heart frequency, blood lactate concentration and Borg RPE score)"
224255050|NCT00011960|DRUG|cisplatin|
224255051|NCT00011960|DRUG|paclitaxel|
224255052|NCT00011960|PROCEDURE|adjuvant therapy|
224322301|NCT06873451|PROCEDURE|Surgery First|One month after surgery, patients were called for an appointment and lower and upper brackets were placed. Treatment was completed when right-left Class I canine and molar relationships and ideal overjet and overbite relationships were achieved.
224255053|NCT00011960|RADIATION|radiation therapy|
224255054|NCT03727620|DRUG|amoxicillin plus metronidazole|patients were administered 250 mg of Flagyl and 500 mg of Dyspamox, three times a day for 7 days
224255055|NCT03727620|DRUG|Doxycycline|patients were administered 200 mg of Longamycine the first day and 100 mg per day for 14 days
224255056|NCT01136174|DRUG|Placebo|Placebo BID for cohort 1,2,3
224255057|NCT01136174|DRUG|BIBF 1120|50 mg, 100 mg, 150 mg BID will be used for Cohort 1, 2, and 3 respectively
224255058|NCT01136174|DRUG|BIBF 1120|50 mg, 100 mg, 150 mg BID will be used for Cohort 1, 2, and 3 respectively
224255059|NCT01136174|DRUG|BIBF 1120|50 mg, 100 mg, 150 mg BID will be used for Cohort 1, 2, and 3 respectively
224255060|NCT02939092|DRUG|Pomegranates peel extract|Pomegranate is antimicrobial
223674021|NCT03493932|DRUG|BMS-986016|Anti-Lymphocyte Activation Gene-3 antibody undergoing clinical evaluation by Bristol-Myers Squibb
224255061|NCT02939092|DRUG|Chlorhexidine|Chlorhexidine mouthwash is antiplaque agent
224255062|NCT01074541|RADIATION|UVB|0.375 SED x 4 in a week
224255063|NCT01074541|RADIATION|UVB|0.75 SED x 4 in a week
223674022|NCT01311635|DRUG|AZD1981, current small-particle tablet|3x100 mg per oral, single dose in fasted state
223674023|NCT01311635|DRUG|AZD1981, new small-particle tablet|3x100 mg per oral, single dose
224255064|NCT01074541|RADIATION|UVB|1.5 SED x 4 in a week
224255065|NCT01074541|RADIATION|UVB|3.0 SED x 4 in a week
224322302|NCT06873451|PROCEDURE|Surgery Early|The patients were directed to surgery with the upper and lower bonds applied at their first appointment and the brackets in their mouths. After surgery, treatment continued until the right-left Class I canine and molar relationship and the ideal overjet and overbite relationship were achieved.
223674024|NCT01311635|DRUG|AZD1981, new large-particle table|3x100 mg per oral, single dose in fasted state
223674025|NCT00830076|DRUG|sitagliptin phosphate|Sitagliptin 100 mg tablet on Day 1 and Day 2 in the morning. There will be a 7-day washout between treatment periods.
223674026|NCT00830076|DRUG|metformin hydrochloride|Metformin 500 mg tablet in the morning and evening on Day 1 and two 500 mg tablets of metformin (total dose 1000 mg) on Day 2 in the morning. There will be a 7-day washout between treatment periods.
223674027|NCT00830076|DRUG|Comparator: placebo sitagliptin|Placebo to sitagliptin 100 mg in the morning on Days 1 and 2. There will be a 7-day washout between treatment periods.
224255066|NCT03557762|BEHAVIORAL|Mindfulness|A psychological behavioral intervention that trains participants in mindfulness techniques, which involves achieving a moment-to-moment non-judgmental awareness of their internal psychosocial-emotional state, through meditation and gentle mindful movements.
224255067|NCT03185039|PROCEDURE|Blood and tumor samples|Blood and tumor samples
224255068|NCT02609256|PROCEDURE|Stereotactic infarct tissue aspiration|The patient posed supine position to expose local skin and puncture point was located at 6.5 cm behind the hairline of the lesion side, and 5.0 cm lateral of midline. After routine skin preparation and disinfection, 5% lidocaine 2-5 ml was injected for local anesthesia. The skin was cut to expose periosteum by a scalpel. After skull was vertically drilled through with a 6mm diameter hole, a sterile tube with a needle in tube was put about 8 cm into centrum semiovale. The needle was put out and about 50ml necrosis brain tissue was aspirated by a 20 ml syringe. The tube was fixed into the skin about 2 cm after subcutaneous tunnel, and connected to the drainage bag. Surgical area was sterilized and wrapped by sterile gauze bandage.
224255069|NCT02609256|OTHER|Medical therapy|osmotic therapy with mannitol and glycerol fructose，anti-platelet treatment, statins, and other symptomatic treatments such as controlling blood pressure, blood sugar, and infection, and tracheal intubation or incision, etc
224255070|NCT07010484|DIAGNOSTIC_TEST|PET/MRI|PET/MRI at baseline and week 8
224255071|NCT07010484|DIAGNOSTIC_TEST|PET/CT with 18-FDG|PET/CT in patients not receiving PET/MRI
224255072|NCT02593357|DEVICE|COPD patients|measure of peripheral endothelial function by the reactive hyperemia-peripheral artery tone index with a specific device (EndoPAT®)
224322305|NCT00447993|COMBINATION_PRODUCT|Low Dose NT-501|Low Dose NT-501 Implanted in study eye and fellow eye received sham surgery
224255073|NCT00376285|DRUG|CP-742,033|
224255074|NCT00376285|DRUG|Fenofibrate|
223674028|NCT00830076|DRUG|Comparator: placebo metformin|Placebo to metformin 500 mg tablet in the morning and evening on Day 1 and two placebo to metformin 500 mg tablets (1000 mg total dose) in the morning of Day 2. There will be a 7-day wash out between treatment periods.
223674029|NCT03720392|DRUG|FMT|FMT is a process utilizing microbial components which are the good, healthy bacteria that would otherwise naturally occur in the body.
223674030|NCT03720392|DRUG|Placebo|a harmless pill, medicine, or procedure prescribed more for the psychological benefit to the patient than for any physiological effect.
223772416|NCT04800185|GENETIC|Skin Microbiome Swabs|At the baseline visit the investigator will identify sites for swabbing the skin including one affected distinct crisaborole-treated AD lesion, and one untreated AD lesion. The lesions will both be sampled at baseline, 14 days into treatment, 28 days into treatment, 3 months into treatment, and 4 weeks after treatment completion. Photographs of each lesion will be taken for reference. Skin swabs will be obtained in a sterile fashion using a BD Culture SwabsTM EZ Collection and Transport System (or equivalent) and soaked with sterilized 0.15 M NaCl and 0.1% Tween-20. The samples will be frozen at -80 C, kept at this temperature, and stored until analysis may be completed.
224255075|NCT06399614|OTHER|Occupational Therapy-led Hand Therapy Service|Types of interventions provided by the therapist will include splinting, targeted exercises and activities, occupation-based intervention, edema management, scar management; desensitisation, functional tasks completion, and education. All interventions provided are within occupational therapists' scope of practice and are evidence based. Number of treatment sessions will be individualised to the patient and guided by stages of recovery.
224255076|NCT06399614|OTHER|Care as usual|Care as usual group: Participants attending an emergency department of injury unit, do not have access to occupational therapy services and will undergo 'care as usual' in line with the services\&#39; protocols and procedures. Care as usual involves standard nursing and medical care and may include: wound care, use of 'off the shelf' orthosis, education, and onward referral to other healthcare professionals.
224255077|NCT06202794|DEVICE|Experimental: Experimental group|TENS will be initiated one hour after surgery. A portable device with two channels will be used (Neurodyn Portable TENS, Ibramed, Amparo, São Paulo, Brazil). This device will deliver a biphasic, asymmetrical, balanced current, with a frequency of 100 Hz and pulse duration of 100 μs. Four electrodes (5x5 cm) will be positioned on the left and right sides of the spine according to the indicated instructions. The assessor will increase the intensity to promote a strong tingling sensation, reaching the patient's maximum tolerance level without causing discomfort. Emission will be applied in a single session of one continuous hour and the patients will be informed that the sensation may decrease over time. Every 10 minutes, the assessor will ask the patient if there is habituation to the current and will increase the intensity if necessary. TENS will be administered only once for one hour.
224255078|NCT06202794|DEVICE|Sham Comparator: Control group|Sham TENS will be performed using equipment identical in appearance to active TENS (Neurodyn Portable TENS, Ibramed, Amparo, São Paulo, Brazil) specifically designed for this study. The device will emit an electrical current gradually increased during the first 30 seconds, followed by a gradual decrease over the subsequent 15 seconds reaching an intensity of 0 mA. The device will remain inactive during the rest of the application, but will have a flashing light, giving the patient the appearance that it is active. The assessor will inform the patient that it is possible to feel the sensation of the current or not depending on individual characteristics. This type of equipment is validated and has been used in other studies to facilitate the blinding of participants. Both systems will be calibrated using a digital oscilloscope (DPO 7000, Tektronix Inc., Beaverton, OR, USA).
223772417|NCT02104557|OTHER|Non intervention|Non intervention
223772418|NCT02104557|OTHER|Non intervention|Non intervention
224255079|NCT01280149|BIOLOGICAL|substance P|injections of substance P and low dose allergen or placebo
224255080|NCT01280149|BIOLOGICAL|substance P injections|injections of substance P for 8 weeks
224255081|NCT02417298|DRUG|Normal saline|Normal saline intravenous push (with volume to be administered equivalent to that of ketamine 0.3mg/kg, if the patient was to receive ketamine) followed by a normal saline infusion at the same rate as ketamine arm
224255082|NCT02417298|DRUG|Ketamine|0.3mg/kg IVP ketamine followed by 0.1mg/kg/hr of ketamine infusion for 3 hours
224322306|NCT00447993|COMBINATION_PRODUCT|High Dose NT-501|High Dose NT-501 Implanted in study eye and fellow eye received sham surgery
224322307|NCT02350816|DRUG|HGT-1410|HGT-1410 administered according to Patient Group assignment.
224322308|NCT06619587|DRUG|Phase I Arm A|Dose escalation and expansion arm, with protocol-defined dose(s) of GDC-7035
224322309|NCT06619587|DRUG|Phase I Arm B|Dose escalation and expansion arm, with protocol-defined dose(s) of GDC-7035 in combination with other anti-cancer therapies
224322310|NCT07018050|DRUG|QLS32015|QLS32015 will be administered subcutaneously
224322311|NCT07018050|DRUG|Pomalidomide|Pomalidomide will be self-administered as a single dose orally
224322312|NCT07018050|DRUG|Dexamethasone|Dexamethasone will be administered orally or intravenously
224322313|NCT07018050|DRUG|QL2109 or Daratumumab|QL2109 or Daratumumab will be administered subcutaneously.
224322314|NCT07018050|DRUG|Bortezomib|Bortezomib will be administered subcutaneously
224322315|NCT07018050|DRUG|Lenalidomide|Lenalidomide will be self-administered as a single dose orally
224322316|NCT07018713|DRUG|Xeomin|Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl)
224322317|NCT07018713|DRUG|Placebo|Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl)
223772419|NCT02507102|DEVICE|Voyager|Non-invasive RFE therapy
223772420|NCT05991141|OTHER|Apnea|In both experimental and control groups participants walked on a treadmill at 5.5 km/h with 5º inclination for 6 minutes. The experimental group (EG) added throughout the 6 minutes intervention the following breathing pattern cyclically: 5 seconds breathing normally followed by 10 seconds of low volume apnoea, performing a total of 24 cycles of normal breathing continued by apnoea.
224255083|NCT02167659|DEVICE|23-32 mmHg compression sleeve with gauntlet|A compression intervention consisting of a sleeve and gauntlet with 23-32mm of tension worn for four weeks that is initiated based on a BIS L-Dex change that is ≥6.5 units higher than pre-surgical baseline measure, or a tape measurement guided volume change in the affected arm that is between ≥5% and \<10% above pre-surgical baseline.
224255084|NCT03202459|DRUG|Group A - gabapentin 600 mg|The patient will receive oral 600 mg gabapentin 2 h before surgery
224255085|NCT03202459|DRUG|Group B - pregabalin|The patient will receive oral pregabalin 150 mg 2 h before surgery
224255086|NCT03202459|DRUG|Group C - placebo|The patient will receive oral placebo 2 h before surgery and ondansetron 8mg intravenous at the end of the surgery
224255087|NCT06016894|PROCEDURE|coronally advanced flap|coronally advanced flap operation
224255088|NCT06016894|OTHER|Nanocrystalline hydroxyapatite loaded in PRF|Nanocrystalline hydroxyapatite loaded in PRF
224255089|NCT06016894|OTHER|Nanocrystalline tricalcium phosphate loaded in PRF|Nanocrystalline tricalcium phosphate (NcTCP) loaded in PRF
224255090|NCT04456881|OTHER|Patients with patellar dislocation undergo patellar femoral medial reconstruction|Arthroscopic double-beam anatomical reconstruction of medial patellofemoral ligament
224255091|NCT04313855|DIAGNOSTIC_TEST|SMS in the early detection of postoperative neuropathic pain|"7 days after the intervention, the patient receives a standardized questionnaire by SMS, to determine whether the patient has pain at the operating site and whether this pain has the characteristics of neuropathic pain. After replying to the SMS, the patient will be contacted by phone to assess: the intensity of pain at the operating site using a numerical scale and the existence of neuropathic pain. Depending on the responses received by SMS and/or phone, a consultation appointment with an anesthesiologist specializing in pain may be offered within a maximum of 2 weeks.~Ninety days after your surgery, the patient receives the same standardized questionnaire by SMS. The patient will be contacted by telephone, in order to assess the intensity of pain at the operating site and the existence of neuropathic pain using. If the patient has post-operative pain, a consultation appointment with an anesthesiologist specializing in pain will be offered to him within a maximum of 2 weeks."
224255092|NCT00053287|DRUG|carboplatin|Carboplatin IV over 24 hours on days 1-5
224255093|NCT00053287|DRUG|fludarabine phosphate|Fludarabine IV over 5-10 minutes on days 1-5.
224255094|NCT00053287|DRUG|thalidomide|Oral thalidomide daily beginning within days 1-3 and continuing in the absence of disease progression or unacceptable toxicity.
224255095|NCT00053287|DRUG|topotecan hydrochloride|Topotecan IV continuously over 72 hours.
224255096|NCT01096433|DEVICE|CPAP treatment|maintains upper airway patency and minimizes the obstructive events
224255097|NCT05703438|OTHER|Nutritionally balanced low-calorie diet|Dietary interventions were given with a calorie deficit of 500-600 kcal from the participants' usual daily intake.
224255098|NCT03886935|DIAGNOSTIC_TEST|Metabolomics|
224255099|NCT00128167|DRUG|Liquid CAIV-T|
224255100|NCT06689956|OTHER|Non-Interventional Study|Non-Interventional Study
224255101|NCT07013149|OTHER|Switch from Ambrisentan to Bosentan|This intervention refers to a therapeutic switch from ambrisentan (10 mg once daily) to bosentan (125 mg twice daily) in adult patients with pulmonary arterial hypertension (PAH), performed as part of routine clinical care. The switch was not assigned by the investigators but was made based on clinical indications prior to study enrollment. Patients are followed prospectively for up to 6 months to assess changes in risk stratification, functional status, laboratory parameters, and safety outcomes.
224255102|NCT01754597|OTHER|Dosage of B-type natriuretic peptide (NT-proBNP)|"NT-proBNP concentration assessed at the following time points :~* T0: before induction of general anesthesia, NT-proBNP measurement~* T1: 30 minutes after induction of general anesthesia~* T2: at the end of the procedure~* T3: in the postoperative period, 6 hours after the end of the procedure~* T4: in the postoperative period, 24 hours after the end of the procedure"
223674031|NCT01453387|DRUG|MSC2015103B|Schedule 1: MSC2015103B will be administered orally once weekly on Days 1, 8, and 15 of a 21-day cycle until MTD establishment. Starting dose will be 150 microgram (mcg), which will be escalated to 200 mcg, 300 mcg, 450 mcg, 650 mcg, 1000 mcg and 1500 mcg subsequently.
224255103|NCT07021430|DRUG|Dihydroartemisinin Piperaquine|A single or monthly dose of Dihydroartemisinin Piperaquine based on weight will be taken orally.
224322318|NCT06873867|DEVICE|High Purity Type-I Collagen based Skin Substitute|In this wound care is covering with High Purity Type-I Collagen based Skin Substitute followed by a layer of non-adherent and porous dressing. After 5-7 days, wound examined and procedure is repeated as needed
224255104|NCT03564327|PROCEDURE|External electric cardioversion|Three attempts (200-250 joules)
224255105|NCT06066203|DRUG|GNC-035|GNC-035 was administered by intravenous infusion for 2 h-4 h, once a week ( IV, QW ), 3 weeks as a cycle.
224255106|NCT07029412|DRUG|MBX 1416 (INN imapextide)|A single subcutaneous injection of MBX 1416 at a low dose and a high dose approximately 2 weeks apart.
224255107|NCT07029828|DRUG|Ritlecitinib higher dose|Study intervention will be provided as oral capsules centrally by the sponsor in HDPE bottles.
224255108|NCT07029828|DRUG|Ritlecitinib lower dose|Study intervention will be provided as oral capsules centrally by the sponsor in HDPE bottles.
224255109|NCT06395753|DRUG|Debio 4228|Administered as IM injection.
224255110|NCT06257849|OTHER|BPII 2.0|Banff Patella Instability Instrument 2.0 is a questionnaire developed for measuring outcome in patients with patella instability
224255111|NCT01588236|DRUG|high dose KYG0395|3 KYG0395 capsules tid (morning, midday, and evening)
224255112|NCT01588236|DRUG|lower dose KYG0395|3 KYG0395 capsules 2 times a day (bid) (morning and evening) plus 3 capsules of placebo (midday)
223674032|NCT01453387|DRUG|MSC2015103B|Schedule 2: MSC2015103B will be administered orally thrice weekly on Days 1, 3, 5, 8, 10, 12, 15, 17 and 19 of a 21-day cycle until MTD was established. Starting dose will be 150 mcg, and will be escalated to 200 mcg subsequently.
223674033|NCT01802918|DRUG|GSK2838232|Bottled powder with 5, 10 and 20mg unit dose strength per single dose for re-constituted oral suspension given once daily
223674034|NCT01802918|DRUG|Placebo|Visually matching GSK2838232
224255113|NCT01588236|DRUG|Placebo|3 capsules of placebo tid (morning, midday, and evening)
223674035|NCT01802918|DRUG|Ritonavir|100mg tablets once daily for 12 days
223772421|NCT05991141|OTHER|Control Intervention|In both experimental and control groups participants walked on a treadmill at 5.5 km/h with 5º inclination for 6 minutes. The Control group (CG) performed this protocol breathing normally.
224255114|NCT06876532|OTHER|Additional blood tests (CRP and serum albumin) and data collection.|"These blood tests will be carried out on several occasions (before, during and after treatment with Lu-177 oxodotreotide). No additional blood sampling is required.~In addition, patient clinical data and imaging data (standard examinations: thoraco-abdomino-pelvic CT +/- MRI and Ga-68 DOTA PET-CT) will be specifically collected for study purposes.~For IUCT-O patients only: blood samples may be taken (at cycles 1 and 2, then 12 months after inclusion) for bio-banking purposes."
223674036|NCT02202330|OTHER|Video Arm|"1. 5 minute videos, on various stroke related topics/ themes delivered in one session before discharge from the hospital (list topics on which videos have to made)~2. Discussion and questions and answers after viewing video to ensure that core message has been understood and there are no lacunae in understanding the message of video.~3. Phone card - a memory chip installed in the cell phones of intervention team that ensures that the videos can be replayed at home to refresh memory of some details that may not have been captured in the mandatory viewing sessions."
223674037|NCT01677390|DRUG|SGN-75|1-2 mg/kg IV every 21 days
223674038|NCT01677390|DRUG|everolimus|10 mg PO daily
223674039|NCT04334538|DIETARY_SUPPLEMENT|S-RUTF|Children will receive approximately 175 kcal/kg/d of standard ready-to-use therapeutic food which provides a full daily doses of vitamins and micronutrients. Caregivers will instruct caregivers to feed the supplement only to the enrolled child.
223674040|NCT04334538|DIETARY_SUPPLEMENT|oat RUTF|Children will receive approximately 175 kcal/kg/d of oat ready-to-use therapeutic food which provides a full daily doses of vitamins and micronutrients. Caregivers will instruct caregivers to feed the supplement only to the enrolled child.
223674041|NCT01077752|DRUG|continuous ropivacaine preperitoneal infusion|Bolus of 20 mg after the surgery then 20 mg per hour during 48 hours
223674042|NCT01077752|DRUG|intravenous lidocaine infusion|Bolus of 60 mg after the surgery then 60 mg per hour during 48 hours
224255115|NCT06873945|DRUG|Ritlecitinib 100 mg|100 mg Capsule
224255116|NCT06873945|DRUG|Ritlecitinib 50 mg|50 mg Capsule
224255117|NCT06873945|DRUG|Placebo - 100 mg|Capsule (to match Ritlecitinib 100 mg)
224255118|NCT06873945|DRUG|Placebo - 50 mg|Capsule (to match Ritlecitinib 50 mg)
224255119|NCT06711887|DRUG|Ianalumab|Ianalumab (VAY736) is a human monoclonal antibody (mAb) of the IgG1/κ-class, directed against B cells and binding to BAFF receptor (BAFF-R).
224255120|NCT01494909|DIETARY_SUPPLEMENT|Ensure plus|Ensure plus sip feeds every 20 min during 6 hours. After 2 hour pancreatic enzyme intake in CF
223674043|NCT01077752|DRUG|parenteral analgesia combining acetaminophen and morphine|parenteral analgesia combining acetaminophen and morphine
223674044|NCT01077752|DRUG|NaCl|NaCl
223674045|NCT01574742|DRUG|Minocycline|Minocycline 200 mg/day (2X100 mg) from day 1 to day 3 and Minocycline 400 mg/day (2X200mg) form day 4 until termination visit (day 35)
223674046|NCT00512057|DRUG|allopurinol|allopurinol 300mg twice a day
223674047|NCT00512057|DRUG|placebo|placebo
224255121|NCT02587624|PROCEDURE|catheter ablation|Intervention: All patients undergo magnetically guided pulmonary vein antral isolation and mapping for fibrotic areas. Procedural endpoint: bidirectional PV block. Additional substrate modification on decision of the operator.
224255122|NCT07135986|BIOLOGICAL|MenACYW conjugate vaccine|Pharmaceutical form:Liquid solution-Route of administration:Intramuscular (IM) injection
224255123|NCT07135986|BIOLOGICAL|MenAC conjugate vaccine|Pharmaceutical form:Suspension-Route of administration:IM injection
224255124|NCT07135986|BIOLOGICAL|MenAC conjugate vaccine|Pharmaceutical form:Lyophilized powder-Route of administration:IM injection
224255125|NCT06711588|DEVICE|As-prescribed stiffness|A novel prosthesis that includes a low-profile prosthetic foot whose stiffness category is determined by the person's body weight and activity level (standard clinical practice).
224255126|NCT06711588|DEVICE|Two categories stiffer than the as-prescribed stiffness|A novel prosthesis that includes a low-profile prosthetic foot whose stiffness category is two categories stiffer than the as-prescribed stiffness.
224255127|NCT06711588|DEVICE|Two categories less stiff than the as-prescribed stiffness|A novel prosthesis that includes a low-profile prosthetic foot whose stiffness category is two categories less stiff than the as-prescribed stiffness.
224255128|NCT07120789|OTHER|Application of Patient Knowledge Questionnaire on Pulmonary Hypertension|Participants will complete one version of the DICTA questionnaire, developed to assess patient knowledge about pulmonary arterial hypertension. Depending on the study phase, participants will contribute to content validation (expert judges), semantic validation (patients), or psychometric validation (patients). In the final phase, additional data including risk stratification (COMPERA 2.0), hospitalizations, and quality of life scores (CAMPHOR, SF-36, MBG) will be collected for correlational analysis.
224255129|NCT06876064|BIOLOGICAL|Blood test|A total of 60 ml of blood will be collected while fasting, using the following tubes: one PAXGene Blood RNA Tube, one PAXGene Blood DNA Tube, five 5 mL serum tubes, five 5 mL EDTA tubes and one 2 mL EDTA tube for microbiota DNA analysis.
223674048|NCT00000485|DRUG|diuretics|
223674049|NCT00000485|DRUG|antihypertensive agents|
223674050|NCT03068091|DEVICE|Chest CT|Inspiration and expiration chest CT
223674051|NCT03068091|DIAGNOSTIC_TEST|Pulmonary Function Testing|Measure lung function
223674052|NCT03234140|GENETIC|Genome Wide Association Studies|Using the Genome wide association studies (GWAS) approach on these 1,565 patients, the project plan to identify new prognostic markers. These markers will then be analyzed to decipher the impact of host genetics on somatic alterations and tumor biology, using public or matched patient data.
223674053|NCT03234140|GENETIC|Single-nucleotide polymorphisms's genotyping|Analyze of the influence of single-nucleotide polymorphisms on circulating t(14;18) levels
223674054|NCT05990595|DIETARY_SUPPLEMENT|Adlay with white rice|We will investigate the lipid- and glucose-lowering effects of Adlay rice in comparison to white rice through a randomized cross-over trial.
223674055|NCT05990595|DIETARY_SUPPLEMENT|white rice|white rice
223674056|NCT03050411|DRUG|Apatinib Mesylate Tablets|250mg, 500mg, 750mg, q.d., p.o.
223772422|NCT06300541|PROCEDURE|Colectomy|Observational study.
223772423|NCT01673334|DEVICE|Fine Needle Aspiration (FNA) and Core biopsy (FNB)|
224322319|NCT06873867|DEVICE|Negative Pressure Wound Therapy|In this wound care is by application of Negative Pressure Wound Therapy using a standard polyurethane foam. The NPWT will be removed after 5-7 days, wound examined and procedure is repeated as needed
224255130|NCT06876064|BIOLOGICAL|Urine test|Urine will be collected, while fasting and after the administration of lactulose/ mannitol to assess intestinal permeability.
224255131|NCT06876064|OTHER|stool collection|Stool samples will be collected either at the hospital or at home using a dedicated kit.
224255132|NCT06876064|OTHER|saliva collection|5 ml of saliva will be collected and saliva microbiome DNA will be collected using an OMNIgene Oral kit.
224322320|NCT06692179|DRUG|Orally administered preparation of fecal microbiota (MTP-101P)|As per standard of care, patients will receive MBP and OA the day prior to surgery as well as IV antibiotics at the time of surgery. MTP-101P will be given 48 hours after the administration of the dose of IV antibiotics to avoid the undesired bactericidal effects of antibiotics on the bacterial load from MTP-101P.
223674057|NCT03050411|DRUG|EGFR-TKIs (Erlotinib, Gefitinib and Osimertinib)|EGFR-TKIs include but are not limited erlotinib, gefitinib and osimertinib
224255133|NCT06876064|OTHER|Induced expectoration|inhalation of salbutamol, measurement of peak expiratory flow by screening spirometry (15 min later), inhalation of a hypertonic aerosol for 3 periods of 7 min. At the end of each inhalation period, the induced sputum is collected and the peak expiratory flow is measured to prevent possible bronchospasms
224255134|NCT06876064|OTHER|Hair and nails sampling|Hair and nails samples will be collected.
224255135|NCT06876064|OTHER|Schirmer test|To assess of tear secretion
224255136|NCT06876064|RADIATION|Ultrasound of hands and feet|To assess the risk of RA in high-risk subjects by evaluating for synovitis, tenosynovitis, or intermetatarsal-phalangeal bursitis.
224255137|NCT06876064|RADIATION|MRI Contrast|MRI of the dominant or painful hand will be performed to assess the risk of RA in high-risk subjects.
224255138|NCT06876064|OTHER|Patient questions|Self-questionnaires will assess factors such as ethnic origin, family history of RA, diet, physical activity, exposure to toxic substances, pollution, occupational exposures, psychological and clinical factors.
224255139|NCT06876064|DIAGNOSTIC_TEST|Dental panoramic X-ray|Performed as part of routine care to assess dental health
224255140|NCT06876064|OTHER|Consultation with a psychologist in certain centers|The short-CTQ will be completed during this consultation, only in centers offering consultations with a psychologist.
224255141|NCT06876064|OTHER|Measurement of heart rate variability.|The patient will wear a belt throughout the visit 1. At the end of the day, the heart rate variability data measured by the belt will be recorded in the CRF (RR interval, heart rate variability SDNN, RMSSD, and LF/HF sympathovagal balance).
224255142|NCT06703593|DRUG|Alpha lipoic acid|ALA effectively inhibits nuclear factor-kappa B with subsequent decreasing proinflammatory cytokines production (TNF-α, IL-6) and increasing the release of anti- inflammatory cytokines such as interleukin-10 (Haghighatdoost and Hariri, 2019). Relying on the antioxidant and anti-inflammatory effect of Alpha lipoic acid confirmed by a variety of studies in vitro and in vivo, ALA is selected to be studied in Egyptian breast cancer patients who will be treated with doxorubicin including regimens.
224255143|NCT07038200|DRUG|AOC-1020|Placebo
223674058|NCT05195060|DRUG|casirivimab with imdevimab|Monoclonal antibody
223674059|NCT05195060|DRUG|sotrovimab|Monoclonal antibody
224255144|NCT07038200|DRUG|Placebo|Placebo will be administered by intravenous (IV) infusion.
224255145|NCT06709339|DRUG|Faricimab Injection [Vabysmo]|The investigational medicinal product (IMP) for this study is faricimab (RO6867461), as per clinical practice. No control treatment will be used for this study
224255146|NCT06887088|DRUG|Encorafenib + Binimetinib|Induction treatment with oral encorafenib 450 mg once daily (QD) + binimetinib 45 mg twice daily (BID)(combination: EB) for approximately two months (i.e. 8 weeks)
224255147|NCT06887088|DRUG|cemiplimab+fianlimab|cemiplimab 350 mg + fianlimab 1600 mg combination every 3 weeks (Q3W)(Combination: CF) administered to patients intravenously (IV) for up to two years.
224255148|NCT04321954|DRUG|LENVATINIB|Orally
224255149|NCT07044648|PROCEDURE|Middle Meningeal Artery Embolization|Middle meningeal artery embolization using particles or coils
224255150|NCT06889844|DIAGNOSTIC_TEST|blood sampling|Patients will donate a blood sample for molecular analysis of molecular biomarkers in plasma, which being the only procedure in the study.
224255151|NCT06730919|DIAGNOSTIC_TEST|Estimated Blood Loss after cesarean delivery within 24 h|The total estimated blood loss was calculated by equation: Estimated Blood Loss (EBL) = EBV ×((HCT1 - HCT2)/(HCT mean)), EBV = Estimated Blood volume; whereas EBV = Patient's weight (in kilogram) × 70 mL/kg, HCT1=preoperative hematocrit, HCT2 = postoperative hematocrit, and HCT mean = (HCT1 + HCT2)/2
224255152|NCT06722235|DRUG|Mezagitamab|Mezagitamab injection administered SC.
224255153|NCT06722235|DRUG|Placebo|Mezagitamab placebo-matching injection administered SC.
224322321|NCT04125134|DRUG|Preservative-free Refresh Optive Advanced Lubricant Eye Drops|over the counter artificial tear
224322322|NCT06629493|BEHAVIORAL|Fitbit Versa 3|Fitbit Versa 3 is a commercially available activity tracker
224322323|NCT06629493|BEHAVIORAL|In-patient alcohol use disorder treatment|In-patient alcohol use disorder treatment, including group therapy, counseling, and occupational activities
223674060|NCT05195060|DRUG|molnupiravir|antiviral agent
223674061|NCT01439815|DRUG|Fluticasone Propionate Nasal Spray|two sprays in each nostril once daily
223674062|NCT01439815|DRUG|Saline Nasal Spray|two sprays in each nostril once daily
223674063|NCT04125251|BEHAVIORAL|Life Skills Building Training|The Life Skills Building intervention is a curriculum based on 10-12 sessions. The sessions will include the skills essential for family harmony and improving overall mental health of the participants
223674064|NCT02970240|PROCEDURE|Cardiopulmonary testing|A 2-day consecutive testing on an ergometer cycle
223674065|NCT03353740|DRUG|Ga-68 labeled PSMA-11 PET|Patients will be imaged using Ga-68 labeled PSMA-11 PET to determine if the presence of metastatic disease. Prostate Specific Membrane Antigen (PSMA) is a protein expressed on prostate cancer cells that can be imaged using small molecules that target this protocol.
224255154|NCT04544410|DRUG|Tildacerfont/Placebo|Tablet, administered daily
224255155|NCT05142241|PROCEDURE|Biopsy Procedure|Undergo biopsy
224255156|NCT05142241|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223674066|NCT04803123|DRUG|Copanlisib|Patients must receive at least one dose of copanlisib prior to standard therapy to be evaluable.
223674067|NCT00564538|DRUG|anti-thymocyte globulin (rabbit)|1.5mg/kg per dose with the first dose initiated in the operating room prior to reperfusion of the transplanted liver. It will then be administered again on post operative day #1, 3 and 5 for a total cumulative dose of 6mg/kg.
224255157|NCT05142241|PROCEDURE|Computed Tomography|Undergo CT
224255158|NCT05142241|DRUG|Talazoparib|Given PO
224255159|NCT05142241|DRUG|Temozolomide|Given PO
224255160|NCT06726265|BIOLOGICAL|eftilagimod alfa|30 mg of efti every 2 weeks subcutaneously for the first 6 months, thereafter every 3 weeks for up to 24 months in total
224255161|NCT06726265|DRUG|carboplatin plus paclitaxel|For patients with squamous histology for 4 cycles (1 cycle = 3 weeks) as follows: every 3 weeks: carboplatin area under the curve (AUC) 5 or 6 in combination with paclitaxel 175 mg/m2 or 200 mg/m2
224255162|NCT06726265|DRUG|cisplatin or carboplatin + pemetrexed|For patients with nonsquamous histology for 4 cycles (1 cycle = 3 weeks) as follows: every 3 weeks: cisplatin 75 mg/m2 or carboplatin AUC 5 or 6 in combination with pemetrexed 500 mg/m2. After the initial 4 cycles, pemetrexed 500 mg/m2 maintenance therapy will be administered every 3 weeks
224255163|NCT06726265|BIOLOGICAL|Pembrolizumab (KEYTRUDA®)|200 mg pembrolizumab (KEYTRUDA®) every 3 weeks i.v. for up to approximately 24 months
224255164|NCT06726265|OTHER|Placebo|efti-matching placebo every 2 weeks subcutaneously for the first 6 months, thereafter every 3 weeks for up to 24 months in total
224255165|NCT06732102|BEHAVIORAL|DECIDE|Decision-making Education for Choices In Diabetes Everyday (DECIDE) is a self-management program in which education and problem-solving training are utilized to promote behavior change for optimal clinical outcomes.
224255166|NCT06732102|BEHAVIORAL|Community Health Worker Support|CHWs are expected to actively equip individuals and communities by enhancing health knowledge and promoting self-sufficiency through various activities such as outreach, community education, informal counseling, social support, and advocacy. They act as a crucial link between communities and healthcare providers, helping residents navigate the healthcare system. By offering guidance and social assistance, they improve community members' ability to communicate effectively with healthcare professionals. They also deliver health education that is culturally and linguistically appropriate, advocate for the health of individuals and communities, coordinate care through referrals and follow-up services, and assist eligible individuals in enrolling in federal, state, local, or nonprofit health and human services programs.
224255167|NCT07049172|DRUG|Rituximab|"* Dosage: 375 mg/m²~* Route: Intravenous infusion~* Frequency: Once a week~* Duration: 12 consecutive weeks~* Details: Diluted in 5% glucose solution. Infusion started at 25 ml/h, increased by 25 ml/h every 30 minutes if no adverse reactions, up to 100-150 ml/h."
224255168|NCT07049172|BEHAVIORAL|Targeted Nursing Care|A structured, individualized nursing approach involving joint goal-setting. Included health education, psychological support, relaxation techniques, dietary care, lifestyle guidance, complication management, and medication guidance. Delivered throughout hospital stay and reinforced during monthly follow-ups.
224255169|NCT07049172|DRUG|Baseline Glucocorticoid Therapy|Patients already on maintenance glucocorticoids continued their regimen. For relapse at admission, IV methylprednisolone (2 mg/kg/day), then oral prednisone (2 mg/kg/day, max 60mg/day) tapered according to standard protocols.
224255170|NCT07049172|DRUG|Tacrolimus|"* Dosage: Initial dose 0.05-0.1 mg/kg/day, adjusted to maintain target trough levels of 5-10 ng/mL.~* Route: Oral~* Frequency: Divided into two doses (morning and evening)~* Duration: Throughout the 6-month study period."
224255171|NCT06734039|DEVICE|Programming of cochlear implant audio processor frequency settings|Cochlear implant audio processor frequency settings will be adjusted within the clinical programming software
224255172|NCT07046936|DIAGNOSTIC_TEST|muscle sample|"For participants undergoing standard of care interval cytoreductive surgery via laparotomy, a skeletal muscle biopsy from the rectus abdominis muscle (1 cm x 1 cm x 1 cm, \~300 mg) will be collected.~For participants who undergo standard of care interval cytoreductive surgery with a laparoscopic approach, a skeletal muscle biopsy will be taken from either the rectus abdominis (1 cm x 1 cm x 1 cm, \~300 mg) or the psoas (1 cm x 0.5 cm x 0.5 cm, \~200 mg) muscle."
224255173|NCT07046936|OTHER|blood draw|A total of approximately 60mL or 4 tablespoons of blood will be collected throughout the study
224255174|NCT06745180|BEHAVIORAL|Short Message System (SMS)|The Short Message System (SMS) intervention focuses on personalized, adaptive SMS messages that help the participant maintain physical activity behaviors.
224255175|NCT06745180|BEHAVIORAL|Peer Coach|The peer coach will deliver an intervention that will help participants maintain physical activity.
224255176|NCT06745180|BEHAVIORAL|Usual Care|Participants will be given written materials providing advice on maintaining their physical activity.
223674068|NCT00564538|DRUG|tacrolimus|Tacrolimus will be administered orally on post op day #1 as per standard of care.
223674069|NCT05329571|BEHAVIORAL|Low-FODMAP diet|Participants will be instructed to maintain their usual diet, while eliminating all dietary gluten.
223674070|NCT05329571|BEHAVIORAL|Gluten-free Diet|Participants will be instructed to maintain their usual diet, while eliminating all dietary gluten.
223674071|NCT05329571|BEHAVIORAL|Control group|Patients of this group will have dietary consultation but will not change their regular diet for the period of the study.
223674072|NCT03826784|COMBINATION_PRODUCT|BHA|BHA active ingredients include a blood-derived component and beta-tricalcium phosphate. It is applied directly to the bone fracture and nearby viable bone at the time of wound closure.
224255177|NCT06745180|BEHAVIORAL|Peer Coach and SMS|The Short Message System (SMS) intervention focuses on personalized, adaptive SMS messages that help the participant maintain physical activity behaviors. The peer coach will deliver an intervention that will help participants maintain physical activity.
224255178|NCT02583672|DRUG|N-acetylcysteine|1800mg NAC twice daily (3600mg/day) orally for approximately 90 days.
224255179|NCT06742307|DRUG|Faricimab Injection [Vabysmo]|A planned quarterly (every 12-16 weeks) faricimab injection schedule, following a disease inactivity achieved after initial 2-4 loading doses of faricimab. This intervention schedule is not specifically studied in other literature, although similar schedule exist.
223674073|NCT03297411|PROCEDURE|Brief Temporoparietal ECT|Electroconvulsive Therapy (Brief pulse width, Temporoparietal) The intervention in this study is different combinations of pulse width and ECT electrode placements.
223674074|NCT03297411|PROCEDURE|Ultrabrief Temporoparietal ECT|Electroconvulsive Therapy (Ultrabrief pulse width, Temporoparietal) The intervention in this study is different combinations of pulse width and ECT electrode placements.
223674075|NCT03297411|PROCEDURE|Brief Frontoparietal ECT|Electroconvulsive Therapy (Brief pulse width, Frontoparietal) The intervention in this study is different combinations of pulse width and ECT electrode placements.
223674076|NCT03297411|PROCEDURE|Ultrabrief Frontoparietal ECT|Electroconvulsive Therapy (Ultrabrief pulse width, Frontoparietal) The intervention in this study is different combinations of pulse width and ECT electrode placements.
223674077|NCT05053451|DEVICE|Transcranial Direct Current Stimulation|In tDCS, saline-soaked electrodes are temporarily affixed to the scalp and connected to a battery-powered current generator. A weak (2 mA) constant current is then briefly applied (20 minutes) to stimulate the targeted brain area (e.g. the DLPFC, TPJ, Occipital Cortex) depending on the phase of the study.
223674078|NCT03389048|DEVICE|PMD-200|The PMD-200 system is comprised of a console and designated finger probe with 4 sensors. The Sensors are Photoplethysmography (PPG) Galvanic Skin Response (GSR), Accelerometer (ACC) and Thermistor (TMP)
223674079|NCT03389048|DIAGNOSTIC_TEST|SLR|With the patient lying down on his/her back, the examiner lifts the patient's leg while the knee is straight.
223674080|NCT03133962|OTHER|Adult patients who are candidates for a CAP or long-term central catheter placement|Evaluate the feasibility of finding the correct positioning of the distal end of the PAC or of the long-term catheter by cardiac ultrasound in comparison with the brightness scopy, reference method.
223674081|NCT05420753|PROCEDURE|Transjugular Intrahepatic Portosystemic Shunt (TIPS) creation|During a TIPS procedure, the interventional radiologist, with the help of x-ray and ultrasound guidance, makes a channel through the liver to connect the portal vein (the vein that carries blood from the digestive organs to the liver) to one of the hepatic vein (three veins that carry blood away from the liver back to the heart) using a special type of needle. The interventional radiologist then replaces the needle with a wire and catheter, and a small tubular device called a stent graft is placed in this channel to keep the pathway open between the two blood vessels.
224255180|NCT06894771|BIOLOGICAL|MK-4700|Administered via subcutaneous (SC) injection
224255181|NCT06894771|BIOLOGICAL|Pembrolizumab|Administered via intravenous infusion
224255182|NCT06893471|OTHER|GAS for SAM|"This study adapts Goal Attainment Scaling (GAS) for group-level goal setting within systematic work environment management. Developed collaboratively with organizational stakeholders, the method is:~Tailormade - Allows flexibility in defining and scaling goals. Co-created - Encourages ownership and employee involvement. Standardized - Uses a five-level scale (-2 to +2) for tracking progress and enabling comparisons.~Data-driven - Includes a Progress Graph for systematic follow-up and documentation of goals and initiatives.~Managers in the experiment group will receive training before implementation begins"
224255183|NCT07054411|DEVICE|Radical-7 Pulse CO-Oximeter|Rainbow sensors will be placed on the 4th fingertips of the non-dominant hand of the patients and connected to the Radical-7 Pulse CO-Oximeter device and the initial Hb value will be recorded routinely and recorded hourly during the operation. Hemogram samples will be studied in the laboratory. During the operation, every hour and at the end of the operation, SpHb value, Hb, Hct levels in hemogram will be recorded.
224255184|NCT06702696|DIETARY_SUPPLEMENT|Black chokeberry (Aronia melanocarpa)|The aronia group, who will consume 30 g of freeze-dried aronia powder (n=25)
224255185|NCT06702696|OTHER|Placebo powder|The placebo group, who will consume placebo powder (n=25).
224255186|NCT06805539|OTHER|No treatment given|No treatment given
224255187|NCT06894511|DRUG|AAA617|"Dose formulation: open-label vial~Dose level: 7.4 GBq (200 mCi) ± 10% Once, every 6 weeks for 6 cycles, intravenous administration"
224255188|NCT06894511|DRUG|ARPI: Abiraterone|"Dose formulation: tablet/capsule~Dose level: 160 mg (four 40 mg or two 80 mg soft capsules) as a single daily dose, oral administration"
224255189|NCT06894511|DRUG|ARPI: Enzalutamide|"Dose formulation: tablet~Dose level: 1000 mg daily (two 500 mg tablets or four 250 mg tablets as a single daily dose together with 5 mg oral prednisone 2 times a day, oral administration"
223674082|NCT00911001|BEHAVIORAL|No Drug|Patients in daily life clinical treatment receiving pharmacological agents to prevent VTE.
223674083|NCT06385067|DEVICE|Biolimus Coated Coronary Artery Balloon Dilation Catheter|Patients with Coronary Artery Disease will be treated with Biolimus Coated Coronary Artery Balloon Dilation Catheter
223674084|NCT03195400|DIAGNOSTIC_TEST|Oral Glucose Tolerance Test|The oral glucose tolerance test (OGTT) measures the body's ability to use a type of sugar, called glucose, that is the body's main source of energy. An OGTT can be used to diagnose prediabetes and diabetes.
223674085|NCT03195400|DIAGNOSTIC_TEST|Hyperglycemic Clamp|Test of beta-cell function and insulin secretion. Involves increasing and maintaining blood glucose concentration with IV variable infusion of dextrose.
223674086|NCT03195400|DIAGNOSTIC_TEST|Isoglycemic Intravenous Glucose Test|Test which exposes pancreas to blood glucose levels matched to the ones obtained at the OGTT.
223674087|NCT03195400|DIAGNOSTIC_TEST|Hyperinsulinemic Euglycemic Clamp and 2H20|Test is used to assess insulin effects on hepatic glucose production.
223674088|NCT00171470|DRUG|Tegaserod|
223674089|NCT01071018|DRUG|MK2206 every other day|Dose escalation study: MK2206 will be administered as an oral formulation in rising dose levels of 45 mg and 60 mg, once daily every other day in repeating 4 week cycles.
223674090|NCT01071018|DRUG|MK2206 once weekly|Dose escalation study: MK2206 will be administered as an oral formulation in rising dose levels of 135 mg and 200 mg, once weekly in repeating 4 week cycles.
223674091|NCT03350269|OTHER|Information provision|Kidney transplant recipients are informed that their donors may be eligible for lost wage reimbursement
224255190|NCT04887935|DRUG|Dapagliflozin|-The 10 mg dose is reflective of current clinical practice for diabetes and heart failure
224255191|NCT06739811|DEVICE|Implantable Insulin Pump System|Medtronic Implantable Insulin Pump System (MIIPS 2020)
223674092|NCT06613893|DRUG|TIVA|Anesthesia will be maintained by total intravenous anesthesia with propofol infusion (4 to 12 mcg/kg/min) and fentanyl infusion (1-2mcg /kg/hour) that will be stopped 30 min before the end of the operation ,The heart rate and blood pressure will be maintained within the range of ±20% of the baseline
223674093|NCT06613893|DRUG|Inhalational anesthesia|Anesthesia will be maintained with inhaled isoflurane, Iso-MAC from (0.7 to 1.4%)(Hawkley, Preston, and Maani 2018) and fentanyl infusion (1-2mcg /kg/hour) that will be stopped 30 min before the end of the operation ,The heart rate and blood pressure will be maintained within the range of ±20% of the baseline
223674094|NCT06994351|DEVICE|Electroacupuncture|"The needles will be inserted to 15-40mm in acupoints through adhesive pads. Needles will be lifted, thrusted and twirled gently for 3 times to achieve deqi sensation and manipulated every ten minutes during 10-minute maintenance in prone and supine position respectively.~The electronic acupuncture apparatus will be connected to the bileteral Taiyang, Anmian and Baihui, with a continuous wave of 2 Hertz (Hz) and an electric current of 1-3 milliampere (mA).~Participants receive acupuncture treatment three times a week in the first two weeks and twice a week in the last six weeks."
224255192|NCT06759376|OTHER|Vibration massage|"* Initiation of the stopwatch with the onset of intradialytic muscle cramp,~* Taking a salivary cortisol test,~* Performing vibration massage with a vibration massage device for 10 minutes,~* Visual Analog Scale questioning every 2 minutes during intradialytic muscle cramp,~* Stopping the stopwatch as soon as the patient states that the intradialytic muscle cramp has ended,~* Repeat salivary cortisol test at 20 minutes from the onset of intradialytic muscle cramp."
224255193|NCT06759376|OTHER|Static stretching exercise|"* Initiation of the stopwatch with the onset of intradialytic muscle cramp,~* Taking a salivary cortisol test,~* Perform static stretching exercise for 10 minutes,~* Visual Analog Scale questioning every 2 minutes during intradialytic muscle cramp,~* Stopping the stopwatch as soon as the patient states that the intradialytic muscle cramp has ended,~* Repeat salivary cortisol test at 20 minutes from the onset of intradialytic muscle cramp."
224255194|NCT06759376|OTHER|Usual Care|"* Initiation of the stopwatch with the onset of intradialytic muscle cramp,~* Taking a salivary cortisol test,~* Usual care,~* Visual Analog Scale questioning every 2 minutes during intradialytic muscle cramp,~* Stopping the stopwatch as soon as the patient states that the intradialytic muscle cramp has ended,~* Repeat salivary cortisol test at 20 minutes from the onset of intradialytic muscle cramp."
224255195|NCT07061678|DRUG|perineural dexamethasone|infraclavicular brachial plexus block with 0.2ml/kg 0.2% ropivacaine with 0.1mg/kg perineural dexamethasone
224255196|NCT07061678|DRUG|intravenous dexamethasone|infraclavicular brachial plexus block with 0.2ml/kg 0.2% ropivacaine with 0.1mg/kg intravenous dexamethasone
224255197|NCT07061678|DRUG|control|infraclavicular brachial plexus block with 0.2ml/kg 0.2% ropivacaine
224255198|NCT07054242|DRUG|Sacituzumab Tirumotecan (SKB264) plus Pembrolizumab|SKB264 will be administered intravenously (IV) at a dose of 4 mg/kg every two weeks (Q2W); Pembrolizumab will be administered intravenously at a dose of 200mg every three weeks (Q3W)
224255199|NCT07053111|BEHAVIORAL|Wellness Intervention|Licensed counselors will provide evidence based curricula on the following: work/life balance, resilience building, stress management, self- care practices, imposter syndrome, psychological effects, compassion fatigue, peer support, and mindfulness practices.
224255200|NCT06784726|BIOLOGICAL|Odronextamab|Given IV
224255201|NCT06784726|PROCEDURE|Biospecimen Collection|Undergo collection of blood and oral or rectal swab samples
224255202|NCT06784726|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
224255203|NCT06784726|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
224255204|NCT06784726|BIOLOGICAL|Chimeric Antigen Receptor T-Cell Therapy|Undergo CAR-T cell therapy
224255205|NCT06784726|PROCEDURE|Computed Tomography|Undergo PET/CT
224255206|NCT06784726|PROCEDURE|Leukapheresis|Undergo leukapheresis
224255207|NCT06784726|PROCEDURE|Lumbar Puncture|Undergo lumbar puncture
224255208|NCT06784726|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
224255209|NCT06784726|OTHER|Questionnaire Administration|Ancillary studies
224255210|NCT06784726|PROCEDURE|Biopsy|Undergo tissue biopsy
224255211|NCT07062406|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|8 weekly sessions delivered by federally qualified health center behavioral health provider focusing on stimulus control, sleep restriction, and cognitive therapy
224255212|NCT07062406|OTHER|Usual care for diabetes management|Usual clinical care for management of diabetes (may include pharmacological and non-pharmacological approaches as determined by provider and patient)
224255213|NCT07062406|OTHER|Usual care for treatment of insomnia|Usual clinical care for treatment of insomnia (may include pharmacological and non-pharmacological approaches as determined by provider and patient)
224255214|NCT06789445|BIOLOGICAL|OpCT-001|Cell therapy product composed of photoreceptor precursor cells derived from human induced pluripotent stem cells (iPSCs).
224255215|NCT06789445|BIOLOGICAL|OpCT-001|Cell therapy product composed of photoreceptor precursor cells derived from human iPSCs.
224255216|NCT06769165|OTHER|EMDR therapy|In this study, EMDR therapy will be performed by psychologists of the UMCG who are trained in EMDR therapy and who have experience with patients with somatic diseases. In the EMDR therapy protocol, the patient is guided through eight phases which incorporate dual focus of attention and alternating bilateral visual, auditory, and/or tactile stimulation (see supplement for protocol). The number of sessions varies per patient (1-3 sessions), depending on the desensitization of the conditioned stimuli. The sessions will last 60-90 minutes.
224255217|NCT07068776|DEVICE|Shockwave treatment|The shockwave device will be set to an energy flux density of 0.1 mJ/mm² at 5 Hz, with approximately 25 impulses per centimeter of wound length. This means that one centimeter of the wound will be treated for 5 seconds. The shockwave treatment will then be carried out, with each centimeter of the wound area treated for 5 seconds using gentle circular motions.
224255218|NCT07068776|DEVICE|Sham treatment|The applicator will not be connected to the shockwave device. The applicator treatment will then be carried out, with each centimeter of the wound area treated for 5 seconds using gentle circular motions.
224255219|NCT06899802|BIOLOGICAL|MVA-BN-WEV|MVA-mBN396 (common name MVA-BN-WEV vaccine), is a highly attenuated, live recombinant virus based on the licensed viral vector MVA-BN, provided as a liquid frozen formulation. It is administered as an intramuscular injection.
223674095|NCT06994351|DEVICE|Sham electroacupuncture|"The needle will be inserted to 2-3mm in Bai Hui acupoint. For the remaining acupoints, needles will be inserted into the pad and reaching the skin. Needles will be lifted, thrusted and twirled gently for 3 times to simulate the effect of the needle tip penetrating the skin. The electronic acupuncture apparatus will be connected to the Baihui acupoint, Shang Yin Tang acupoint, and bilateral Anmian acupoints, with a continuous wave of 2 Hertz (Hz) and an electric current of 0.1-0.3 mA. In about 30 seconds, the electric current will be turned down.~Participants receive acupuncture treatment three times a week in the first two weeks and twice a week in the last six weeks."
223674096|NCT06995794|OTHER|kinesio tape|Kinesio tape a therapeutic tape that's applied strategically to the body to provide lessen pain, reduce swelling, improve performance.
223674097|NCT06995794|OTHER|knee strap|knee strap is used to support the tibial tuberosity which lessen the pain and enhance performance of the knee
224255220|NCT06899802|OTHER|Placebo|Tris-Buffered Saline (TBS) (placebo) is a clear liquid, free from visible extraneous particles. TBS is acceptable for use as a diluent and for intramuscular injection.
224255221|NCT05995353|DRUG|Risankizumab|Intravenous (IV) Infusion
224255222|NCT05995353|DRUG|Risankizumab|Subcutaneous (SC) Injection
224255223|NCT03996005|PROCEDURE|Magnetic Resonance Imaging-Guided Transurethral Ultrasound Ablation of Prostate Tissue|Magnetic Resonance Imaging-Guided Transurethral Ultrasound Ablation of Prostate Tissue
224255224|NCT06750289|COMBINATION_PRODUCT|ICS-LABA|ICS-LABA inhalation
224255225|NCT06750289|COMBINATION_PRODUCT|benralizumab|Benralizumab. SC injection.
224255226|NCT06750289|COMBINATION_PRODUCT|Placebo for Benralizumab|"Placebo for Benralizumab (aka, placebo). SC injection."
224255227|NCT04779307|DRUG|Vedolizumab|Vedolizumab IV infusion.
224255228|NCT03761173|DEVICE|FlowTriever System|Thrombectomy
224255229|NCT03761173|DRUG|Anticoagulation Agents|Anticoagulation medication
224255230|NCT07090174|BIOLOGICAL|PDS0101|PDS0101 is an HPV 16-targeted immunotherapy administered as two subcutaneous injections of 0.5 mL each (total 1.0 mL). Each dose contains 3.0 mg of Versamune®, a proprietary cationic lipid nanoparticle adjuvant, and 2.7 mg of HPVmix, a blend of HPV16 E6 and E7 proteins. Versamune® enhances antigen uptake and dendritic cell activation, promoting T-cell priming and memory formation. In preclinical studies, subcutaneous administration resulted in low systemic bioavailability (\<6%) and efficient dendritic cell uptake, consistent with a favorable safety profile. PDS0101 has been studied in a completed Phase I trial in HIV-uninfected women with high-risk HPV and cervical intraepithelial neoplasia (CIN) I. Each participant in this study will receive three doses, spaced 21 days apart (± 7 days) unless there has been Grade 3 or greater toxicity at least possibly related to the study agent.
224255231|NCT06902480|DIETARY_SUPPLEMENT|WPPC|A chocolate-flavored drink with WPPC added
224255232|NCT06902480|DIETARY_SUPPLEMENT|Whole egg powder|A chocolate-flavored drink with whole egg powder added
224255233|NCT06909136|DRUG|Ruxolitinib phosphate tablet（Jakavi,NOVARTIS,9104733)|5-20mg BID (dosage per investigator judgement,JAKi intolerable pts will receive recuded dose of RUX(≥ 5mg BID),and suboptimal JAKi response pts will receive RUX of 15-20 mg BID）
224255234|NCT07096297|DRUG|Luspatercept|Luspatercept will be administered every 3 weeks (21 days) at a starting dose of 1.0 mg/kg (Dose Level 0). Luspatercept will be administered to participants by the study staff at the clinical site and administration will be documented in the participant's source record. Participants must have Hgb, blood pressure and weight assessed (changes of body weight of ≤ ± 5% do not require a dose adjustment) prior to each luspatercept dose administration. Subcutaneous injections will be given in the upper arm, thigh, and/or abdomen. Volume for subcutaneous injection will be per institutional standard/guidelines.
224255235|NCT07096297|DRUG|Darbeopoetin|Darbepoetin alfa will be administered every 3 weeks (21 days), at a starting dose of 300 ug (Dose Level 0). Darbepoetin alfa will be administered to participants by the study staff at the clinical site and administration will be documented in the participant's source record. Darbepoetin alfa will be administered as a subcutaneous injection by the site staff in the upper arm, thigh, and/or abdomen per institutional standard/guidelines.
224255236|NCT06908954|DRUG|Palovarotene|A single dose of maximum 10 mg of palovarotene will be administered orally on Day 1 to healthy control participants with normal hepatic function
224255237|NCT06908954|DRUG|Palovarotene|A single 10 mg dose of palovarotene will be administered orally on Day 1 to Moderate hepatic impaired participants (Child-Pugh class B)
224255238|NCT06908954|DRUG|Palovarotene|A single 10 mg dose of either 5 mg or 10 mg of palovarotene will be administered orally on Day 1 to Severe hepatic impaired participants (Child-Pugh class C).
224255239|NCT07087340|DEVICE|UBLoop System|"Participants (people living with Type-1-Diabetes) will attend a study visit where the UBLoop system will manage insulin delivery via an insulin pump, using blood glucose values from a continuous glucose meter (CGM). Specialized staff and a remote monitoring system, which is integrated into the UBLoop system, will oversee the participants. The investigational product comprises (1) the BernSHELL App, communicating with the CGM and the insulin pump, (2) the UBLoop algorithm receiving CGM data, processing the control algorithm, calculating insulin dosing, checking the safety of the calculated insulin injections, and transmitting instructions to the insulin pump via BernSHELL, (3) the UBLoop Cloud providing secure storage, analytics support, and data backup, (4) DigiCare, monitoring the safety of the study participants and the system's execution flow in real time.~During the intervention, participants will use the Ypsomed myLife YpsoPump (insulin pump) and the Dexcom G6 or G7 CGM."
224322324|NCT07017686|DEVICE|abdominal vagus nerve stimulation (aVNS)|Participants will receive aVNS, delivered by a commercially available stimulator placed under the skin, and a custom-designed electrode array attached to the abdominal vagus nerve. Stimulation will commence 2 weeks after laparoscopic surgical implantation of the device, and occur daily for 22-weeks stimulation in the initial phase of the study.
224322325|NCT06632509|DEVICE|BD SiteRite(TM) 9|Ultrasound-guided vascular access device placement procedure using the BD SiteRite(TM) 9.
224322326|NCT07018700|DRUG|Xeomin|Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl)
223674098|NCT06994273|DRUG|Fentanyl|Patients received fentanyl as a 1 μg/kg bolus over 10 min, followed by a 1-5 μg/kg/hr intravenous infusion after 10-15 minutes.
223674099|NCT06994273|DRUG|Dexmedetomidine|Patients received dexmedetomidine as a 1 μg/kg bolus over 10 min, followed by a 0.2-0.7 μg/kg/hr intravenous infusion after 10-15 minutes.
224255240|NCT04442321|OTHER|PENS plus exercise|"The technique will be performed ultrasound-guided on the radial nerve, the places of the needle's insertions will be the following:~* Needle will be placed at under the lateral intermuscular septum between the triceps brachii and brachialis, approximately 10cm superior to the lateral epicondyle~* Needle will be placed at the upper third of the forearm on the posterior interosseous nerve after passing the arcade of Froshe~The percutaneous electrical stimulation will be realized with a transcutaneous electric nerve stimulation (TENS) current:~* TENS Frequency 2 Hz~* TENS Pulse width - 250 microseconds~* Duration - 30 minutes.~* TENS Intensity - Increased at an intensity of visible motor response of the innervated musculature and maximal tolerable intensity.~* Administration - One per week~Self-management loaded exercises prescribed by a physical therapist, two times per week."
224255241|NCT04442321|OTHER|Sham PENS plus exercise|"The technique will be performed ultrasound-guided on the radial nerve, the places of the needle's insertions will be the following:~* Needle will be placed at under the lateral intermuscular septum between the triceps brachii and brachialis, approximately 10cm superior to the lateral epicondyle~* Needle will be placed at the upper third of the forearm on the posterior interosseous nerve after passing the arcade of Froshe~The electrical current will not be working, and the needles will be placed during 30 minutes:~\- Administration - One per week~Self-management loaded exercises prescribed by a physical therapist, two times per week."
224255242|NCT07099651|OTHER|tests|neuropsychological tests + Neuroimaging
224255243|NCT06752330|DIETARY_SUPPLEMENT|Use of probiotics during oral hygiene at home|The probiotic used in the study is Bifidobacterium Lactis HN019, distributed com-mercially in Italy by Curasept (Curasept Prevent®, Curasept S.p.A., Saronno, VA, Italy), with added Kluyveromyces Marxianus Fragilis B0399, colostrum and biotin. The probiotic was taken by patients following the manufacturer's directions via 2 chewable tablets daily, morning and evening, after normal daily oral hygiene, achieving daily average values of B. Lactis HN019 of 2\*107 CFU and Kluyveromyces marxianus fragilis B0399 of 2\*109 CFU.
224255244|NCT07099430|DRUG|LBL-024 for Injection|LBL-024 , Intravenous infusion.
224255245|NCT07099430|DRUG|LBL-007 Injection|LBL-007 , intravenous infusion.
223674100|NCT04267224|DRUG|Ticagrelor 90mg|Ticagrelor is a direct-acting inhibitor of the platelet P2Y12 receptor with a rapid antiplatelet effect. It has been shown to reduce the rate of major cardiovascular events among patients with acute coronary syndromes, as compared with Clopidogrel, and has the potential to improve coronary reperfusion and the prognosis for patients with STEMI treated with primary PCI.
223674101|NCT03418103|DEVICE|Thermal imaging analysis of participant position in a hospital bed|The SAFE sensor system will use thermal imaging to detect and identify a participant's position relative to the edges of the hospital bed. If a dangerous position is identified, an alarm notification will be sent to the ward staff to allow them to take pre-emptive action to prevent the participant's situation from evolving into a fall event.
223674102|NCT03802058|DRUG|Nab-paclitaxel|Nab-paclitaxel 40mg/m2 for Injection weekly
223674103|NCT03802058|DRUG|Carboplatin|Carboplatin AUC=2 for Injection weekly
223772424|NCT05271929|BIOLOGICAL|Current standard of care and COVID-19 convalescent and vaccinated plasma|ABO compatible convalescent plasma infused intravenously on study day 1 (as soon as possible after randomisation) and the second on day 1 or day 2. Plasma obtained by apheresis from donors who have recovered from COVID-19 infection (at least 14 days after recovery) and have been vaccinated (at least 3 weeks after first dose of vaccine). A combination of both a SARS-CoV-infection and a SARS-CoV-2 vaccination of the donor is required - irrespective of the sequence of infection and vaccination. As far as the availability of CCP units allows, the two plasma units should have been donated by two different convalescents.
224255246|NCT07099430|DRUG|Toripalimab Injection|Toripalimab , intravenous infusion.
224255247|NCT07081555|DRUG|[177Lu]Lu-ABY-271|A single infusion of \[177Lu\]Lu-ABY-271
224255248|NCT07105020|BEHAVIORAL|Interviews|Interviews will be conducted in person, over the phone, or via Zoom.
224255249|NCT05939414|DRUG|AAA617|Stereotactic Body Radiation Therapy (SBRT) followed by AAA617 will be administered once every 6 weeks (1 cycle) for a planned 4 cycles to participants randomized to the Investigational arm
224255253|NCT06455202|BIOLOGICAL|barzolvolimab|Subcutaneous Administration
224255254|NCT06455202|BIOLOGICAL|Matching placebo|Matching placebo Subcutaneous Administration
224255255|NCT07111559|DRUG|rt-PA|Recombinant tissue-plasminogen activator treatment. Low-dose (0.6mg/kg) alteplase will be given because this dosage is the only dosage approved in Japan.
223772425|NCT05271929|OTHER|Current standard of care|"Standard of care therapy may include anti-SARS-CoV-2 specific medication such as, but not limited to:~* Casirivimab~* Casirivimab / Imdevimab (REGN-COV2 or Ronapreve)~* Imdevimab~* Sotrovimab (Xevudy)~* Tixagevimab / Cilgavimab (Evusheld)~* Molnupiravir (MK-4482)~* Nirmatrevlir / Ritonavir (Paxlovid)~* Remdesivir~Centres should ensure that medications used as standard of care are used similarly for patients in both treatment arms."
223772426|NCT00772174|DRUG|Pioglitazone and Metformin|Pioglitazone 15 mg, tablets, orally, two-times daily and metformin stable dose, orally, three-times daily for 4 weeks; then increased to pioglitazone 15 mg, tablets, orally, three-times daily and metformin stable dose, orally, three-times daily for up to 20 weeks.
224255256|NCT07111559|DRUG|DAPT|Dual antiplatelet therapy with aspirin 200mg and clopidogrel 300mg.
224255257|NCT07112651|DIETARY_SUPPLEMENT|CL25216|250mg to take one capsule a day after breakfast for 105 days
223674104|NCT03802058|RADIATION|Thoracic radiation therapy|Thoracic radiation therapy 60-66Gy/30-33 fractions,both three-dimensional conformal and intensity modulated radiation therapy are allowed
224255258|NCT07112651|DIETARY_SUPPLEMENT|Placebo|One capsule a day after breakfast for 105 days
224255259|NCT07109297|BIOLOGICAL|Nirsevimab|Pharmaceutical form:Sterile solution for injection-Route of administration:Intramuscular
224255260|NCT06863974|OTHER|Blood test|Drawing blood to realize biomarkers of disease course of MOGAD-ADEM and pathophysiology of ADEM (and MOGAD) : cellular and molecular signatures, inflammatory signaling.
224255261|NCT07122401|DRUG|MT1013|MT1013 + dummy cinacalcet
224255262|NCT07122401|DRUG|Cinacalcet|Cinacalcet + dummy MT1013
224322327|NCT07018700|DRUG|Placebo|Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl)
224255263|NCT05791994|PROCEDURE|Visual cognitive stimulation exercises|Patients included in Intervention group will receive a 30-minute session of complex visual stimuli on a touch screen (3 10-minute exercises : saccade exercises, then pursuit exercises, then matching exercises) every other day for 30 days, with increasing difficulty of the exercises as the sessions progress.
224255264|NCT05791994|PROCEDURE|Broadcast of a television program|Patients included in Comparator group will watch a 30-minute television program (Allô Docteurs) on a touch screen every other day for 30 days.
224255265|NCT06933524|DRUG|ATB-320|IV infusion
223772427|NCT00772174|DRUG|Metformin|Pioglitazone placebo-matching tablets, orally, two-times daily and metformin stable dose, orally, three-times daily for 4 weeks; then increased to pioglitazone placebo-matching tablets, orally, three-times daily and metformin stable dose, orally, three-times daily for up to 20 weeks.
223772428|NCT04455893|OTHER|Stratified Transplant Survival|The transplant survival rate in the table of outcome statistics is stratified into two groups: (i) patients who received excellent donor organs and (ii) patients who received less than optimal donor organs. Stratified transplant survival is computed from survival rates of transplant patients who received each quality category of organ. excellent transplant survival = \[number of patients surviving after transplant with excellent organ\]/\[number of patients for whom excellent organ was accepted for transplant\] marginal transplant survival = \[number of patients surviving after transplant with marginal organ\]/\[number of patients for whom marginal organ was accepted for transplant\]
224255268|NCT06937931|BIOLOGICAL|IPN10200|Study intervention will be administered in a single treatment cycle after randomisation (Day 1). The administration cycle consists of intramuscular injection.
224255269|NCT06937931|OTHER|Placebo|Excipients without active substance will be administered in a single treatment cycle after randomisation (Day 1). The administration cycle consists of intramuscular injection.
224255270|NCT06945406|DRUG|LY4057996 SC|Administered SC
224255271|NCT06945406|DRUG|LY4057996 IV|Administered IV
224255272|NCT06945406|DRUG|Placebo SC|Administered SC
224255273|NCT06945406|DRUG|Placebo IV|Administered IV
224255274|NCT06945406|DRUG|Degludec SC|Administered SC
224255275|NCT06945406|DRUG|Lispro SC|Administered SC
224255276|NCT06945406|DRUG|Degludec IV|Administered IV
224255277|NCT06945406|DRUG|Pre-study basal insulin SC|Administered SC
224255278|NCT03778307|BEHAVIORAL|Psychophysiological fear conditioning and extinction task|Behavioral task to assess psychophysiological measures of fear
224255279|NCT03778307|BEHAVIORAL|Eyetracking task|Behavioral task to assess dysphoria-relevant attention allocation
224255280|NCT06955741|DRUG|BMS-986446 IV|Specified dose on specified days was administered intravenously (IV).
223772429|NCT06564376|DIAGNOSTIC_TEST|total magnesium|Treatment based on total Magnesium
223772430|NCT06564376|DEVICE|ionized magnesium|Treatment based on ionized magnesium
223772431|NCT05548608|OTHER|Reposition error (RE), pain at target positions of RE and flexibility of the TLF were assesed with iphone tiltmeter app, VAS and goniometric platform, respectively.|Target positions of reposition error were: 30º forward bending and 15º backward bending in sitting and standing.
223772432|NCT02467101|OTHER|Corticosteroid/Saline|"Corticosteroid/Saline~Two groups were defined: group A and group B.~* Group A receives treatment with intralesional triamcinolone acetonide on the right half-head and placebo on the left half-head~* Group B receives administration of intralesional triamcinolone acetonide on left half-head and placebo on the right half-head.~Same patient will be injected with intralesional triamcinolone acetonide and a saline solution.~Each patient will be injected on half-head."
223772433|NCT05508529|DIETARY_SUPPLEMENT|Chaga Mushroom|Effect of chaga on immune/mood support
224255281|NCT06955741|DRUG|BMS-986446 SC|Specified dose on specified days was administered subcutaneously (SC).
224255282|NCT06955741|DRUG|Acetaminophen|Specified dose on specified days
224255283|NCT06955741|DRUG|Loratadine|Specified dose on specified days
224255284|NCT07140783|DRUG|0.75% Phentolamine Ophthalmic Solution|Once daily dosing
224255285|NCT07140783|DRUG|Placebo|Once daily dosing
224255286|NCT07154823|OTHER|None - Observational Study|There are no interventions in this observational study.
224255287|NCT06839079|BEHAVIORAL|A Trauma-informed, Paraprofessional Delivered Virtual Cognitive Rehabilitation Program|The intervention will involve 8 proposed individual sessions conducted virtually by a trained bilingual paraprofessional. The intervention will be provided in English or Spanish depending on the participant's preference. The sessions cover psychoeducation about TBI and related symptoms like depression and anxiety, and cognitive activities to address cognitive symptoms (e.g., relaxation strategies and exercises around improving attention, concentration, learning, and memory). Each session covers the topic, real-life examples and practice, and exercises to do outside of the sessions.
224255288|NCT07162454|DRUG|Group 1. Complete formula|After fulfilling the criteria and agreeing to participate in the study, patients who were included in group 1 after randomisation were evaluated and received a topical cream with cannabidiol, Urea 10%, arnica and menthol as active ingredients. After one month of application of the formula, a second evaluation was carried out.
224255289|NCT07162454|DRUG|Group 2. Cannabidiol and Urea 10% formula.|After meeting the criteria and agreeing to participate in the study, the patients who were included in group 2 after randomisation were evaluated and received a topical cream containing cannabidiol and 10% urea. After one month of application of the formula, a second evaluation was carried out.
224255290|NCT07162454|DRUG|Group 3. Placebo formula.|Participants included in this group after randomisation received a formulation with no active ingredients included in its composition and were assessed at baseline and after one month.
224255291|NCT07166601|BIOLOGICAL|M0324|M0324 will be tested at increasing doses as monotherapy to determine dose-toxicity relationship and MTD (if reached) in order to support selection of recommended dose(s) for expansion (RDE).
224255292|NCT07166601|BIOLOGICAL|M0324|M0324 will be further investigated in part 2 and part 3 of the study as combination regimen, in order to determine dose-toxicity relationship in combination and MTD (if reached) in order to support selection of RDE(s) in combination.
223674105|NCT05406193|OTHER|Patient-centred complex intervention in complicated multimorbidity (CIM2)|CIM2 is the second version of the Patient-centred complex intervention in complicated multimorbidity
223674106|NCT00205907|BIOLOGICAL|BLVR Hydrogel|10 mL BLVR Hydrogel
223674107|NCT01395784|DRUG|pioglitazone|A PPARγ agonist, also marketed as Actos. Participants will be maintained on ascending doses of Placebo, pioglitazone 15 mg and 45 mg, prior to completing a lab session at the end of each dosing period.
223674108|NCT00877097|DRUG|Klodronate and Kliogest|
223674109|NCT00877097|PROCEDURE|Placebo+ Kliogest|
223674110|NCT00877097|DRUG|Bonefos|
223674111|NCT04268823|DRUG|QBW251|Capsule 300mg
223674112|NCT04268823|DRUG|Placebo|Capsule 300mg
223674113|NCT02815826|OTHER|Barefoot training|During 16 weeks, habitual shod runners kept their normal running training routine (wearing shoes), while they were introduced progressively to BF condition. Three training sessions were performed per week. Barefoot training started with 5% and ended with 20% of their WTV being performed without shoes. Soft surfaces (i.e. sand and grass) were adopted in the beginning of training (week 1 to 8). From week 9 to 16, participants mixed soft with harder surfaces, as treadmill and asphalt, to accomplish the training.
223674114|NCT02815826|OTHER|Shod training|Running training planned individually to each runner, according to their physical fitness, and performed with shoes.
223674115|NCT03431103|BEHAVIORAL|Exercise|12 week home exercise program
223674116|NCT05806879|OTHER|Maternity Napkin|"Use of maternity napkin with the following specifications (followed for 4.5 months)~* Length is 230-240mm, to be able to provide adequate coverage.~* Width is 150-155mm with wings.~* Thickness is 3-5mm.~* The maternity napkin is curved to prevent leakage on the sides, has wings for secure attachment to the underwear and able to absorb 30-40 ml per minute."
223674117|NCT03609151|PROCEDURE|laparoscopic hepatectomy (surgery)|Patients receive laparoscopic hepatectomy.
223674118|NCT03609151|RADIATION|stereotactic body radiotherapy|Patients receive stereotactic body radiotherapy(SBRT)
223674119|NCT04211571|DEVICE|Theranova 400 dialyzer|Hemodialysis using Theranova 400 dialyzer
223674120|NCT04211571|DEVICE|High-flux dialyzer|Hemodialysis using high-flux dialyzer
223674121|NCT00993161|DEVICE|Motriplate|Number of contact couples
223674122|NCT00993161|DEVICE|Motriplate|Number of contact couples
223674123|NCT00970866|DIETARY_SUPPLEMENT|Iron and Folic Acid (IFA)|Pregnant women will receive one (1) Iron (60 mg) and Folic Acid (400 mcg) (IFA) tablet daily during pregnancy, and a tablet containing calcium (Ca) only (akin to a placebo) during lactation; there will be no supplementation for infants born to the women. The Fe/FA tablets will be taken each day with water after meals
223674124|NCT00970866|DIETARY_SUPPLEMENT|Multiple Micronutrient (MMN) group|Pregnant women will receive one (1) Multiple Micronutrient tablet daily during pregnancy and the first 6 months of lactation; there will be no supplementation for infants born to the women. The MMN tablets will be taken each day with water after meals
223674125|NCT00970866|DIETARY_SUPPLEMENT|Lipid-based Nutrient Supplements (LNS) group|"Pregnant women will receive 20 g of LNS-P\&L daily during pregnancy and the first 6 months of lactation, whilst infants born to the women will receive 20 g of LNS-20gM daily from 6 to 18 mo of age.~The LNS products (LNS-P\&L and LNS-20gM) will be consumed by being added to prepared food (usually mixed with complementary foods, for the child). Mothers will consume the full sachet of LNS (20 g/day) at one meal each day. Dosage and directions for use of the LNS product for children will be as follows: 20 g (\~4 teaspoons) per day divided into 2 portions and consumed at two different times of the day (2 x 2 teaspoons). Mix the portion of the supplement to be consumed with 2-3 tablespoons of the already prepared food (as done previously in our study in Ghana (1)), and eat the mixture before eating the rest of the food. Do not cook food with the supplement. Store supplement at room temperature. There is no need for refrigeration."
223674126|NCT01949337|DRUG|enzalutamide|Enzalutamide 160 mg daily, orally
223674127|NCT01949337|DRUG|abiraterone|abiraterone 1000 mg daily, orally
223674128|NCT01949337|DRUG|prednisone|prednisone 5 mg twice daily, orally
223674129|NCT02122601|DRUG|LBSA0103 (BDDE cross-linked sodium hyaluronate gel)|
223674130|NCT02519855|BIOLOGICAL|ZOSTAVAX™|A single blinded administration of 0.65 mL subcutaneous injection on Day 1 (concomitant) or at Week 4 (nonconcomitant)
223674131|NCT02519855|BIOLOGICAL|Placebo to ZOSTAVAX™|A single blinded administration of 0.65 mL subcutaneous injection on Day 1 (nonconcomitant) or at Week 4 (concomitant)
223674132|NCT02519855|BIOLOGICAL|Influenza Vaccine|A single open-label administration of 0.5 mL intramuscular injection on Day 1
223674133|NCT00008255|DRUG|INS316|
223674134|NCT00008255|OTHER|sputum cytology|
223674135|NCT05718999|DIAGNOSTIC_TEST|Not intervention|Not having intervention is an observational study
223674136|NCT04378452|BEHAVIORAL|COM-COVID anonimous survey|Anonimous e-survey administered to the general population by sharing it through social and mass media, including questions on sociodemographic data, physical symptoms in the past 14 days compatible with SARS-CoV-2 infection, socio-economic impact of the COVID-19 outbreak and psychological impact of the COVID-19 outbreak and mental health status.
223674137|NCT02037581|BEHAVIORAL|Early detection and Integrated Care|Patients receive integrated care including therapeutic Assertive Community Treatment (TACT)
223674138|NCT02037581|BEHAVIORAL|Standard Care|Standard care as being offered by private psychiatrists
223674139|NCT05577455|DRUG|Medical prescription before ovulation|Medical prescription before ovulation, modified two solstices pill and Si-Wu-Tang: 15g of Nv Zhen Zi (Fructus Ligustri Lucidi), 10g of Mo Han Lian (Yerbadetajo herb), 15g of Gou Qi Zi (Fructus lycii), 20g of Tu Si Zi (Semen cuscutae), 15g of Shu Di (Radix Rehmanniae Preparata), 10g of Dang Gui (Angelica sinensis), 10g of Bai Shao (Paeonia lactiflora Pallas), 20g of Sheng Shan Yao (Rhizoma Dioscoreae), 15g of Fu Pen Zi (Raspberry), and 15g of Shan Yu Rou (Fructus corni). The medical prescription is initiated on the fifth day of menstruation and is taken continuously for 10-15 days.
223772434|NCT05508529|DIETARY_SUPPLEMENT|Algae Extract|Effect of algae extract on immune/mood support
223772435|NCT05508529|DIETARY_SUPPLEMENT|Black Cumin Seed Oil|Effect of black cumin seed oil on immune/mood support
223772436|NCT05508529|DIETARY_SUPPLEMENT|Black Cumin Seed Oil + Astaxanthin|Effect of Black Cumin Seed Oil + Astaxanthin blend on immune/mood support
223772437|NCT05508529|DIETARY_SUPPLEMENT|Black Cumin Seed Oil + Omega 3|Effect of Black Cumin Seed Oil + Omega3 blend on immune/mood support
223772438|NCT05508529|DIETARY_SUPPLEMENT|Placebo|Placebo control
224255293|NCT07166601|BIOLOGICAL|Pembrolizumab|Pembrolizumab will be administered intravenously as per standard of care.
223772439|NCT03081585|BEHAVIORAL|Satiety State|Participants were scanned twice: once after a meal and once after fasting for 24 hours
224255294|NCT07166601|DRUG|mFOLFIRINOX|mFOLFIRINOX will be administered intravenously as per standard of care.
223772440|NCT04173143|DEVICE|Craniocervical flexion training with pressure biofeedback|Total 15 patients participated in this training group. Session was performed thrice in a week. Each session was givenfor approximately 20minutesPatients were asked to lie in supine hook lying position. After that Pressure biofeedback unit's air bag was clipped together and folded in three and positioned behind the neck just below the occiput. Patients were advised to perform Craniocervical flexion and practiced head nodding action to progressively target (reach the incremental targets) and hold the 5 pressure levels for 10 second between 22 mm Hg and 30 mmHg. A 2 minute second rest period was provided between each level. Minimum performance requirement was 26 mm Hg while ideal performance targets are 28 and 30 mm Hg... Patient will be re-assessed for all baseline variables after 4 weeks of training
223772441|NCT04173143|OTHER|Craniocervical flexion training without pressure biofeedback|Total 15 patients participated in this control group.Session was given 3 times in a week. Each session continue forapproximately 20 minutes. The patient lies in supine crook lying position. The patientwas maximally retracted the chin and asked to maintained it while the patient lifts the head and neck until the head is relatively 2 to 5 cm (1 inch) abovethe couch. The examiner places a hand under the head of patient on the table. Patients were instructed to perform10 repetitions for a hold of 20 seconds initially, increasing it by 10 seconds progressively.The entire session had a maximum of 4 sets. Patient will be re-assessed for all baseline variables after 4 weeks of training
224255295|NCT07151573|OTHER|Big Five|"The intervention is self-guided and consists of a brief 14-page psychoeducation module that they are introduced to in the beginning of a 4-week intervention period (day 0). The module starts with a general introduction to mental health and Things you do action and how it promotes mental health. The final section presents the five core actions: 1) healthy thinking, 2) meaningful activities, 3) goals and plans, 4) healthy habits, and 5) social connections. Participants are advised to engage in the five daily actions throughout the intervention period. They are also encouraged to fill out a weekly planner and monitor their progress by keeping an overview of the number of daily activities in My Week.The participants receive the module on a Sunday (Day 0). They receive text reminders Monday to Friday for four weeks, encouraging them to engage in the actions."
224255296|NCT07151573|OTHER|Gratitude|The intervention is self-guided and consists of a brief 14-page psychoeducation module that they are introduced to in the beginning of a 4-week intervention period (day 0). The module starts with a general introduction to mental health and Gratitude and how it promotes mental health, followed by a short summary on the benefits of gratitude. The final section introduces practical strategies for cultivating gratitude by focusing on five key gratitude activities: 1) keeping a gratitude journal, 2) expressing gratitude to others, 3) finding gratitude in misfortune or difficult situations, 4) appreciating good things and 5) another perspective. The participants receive the module on a Sunday (Day 0). They receive text reminders Monday to Friday for four weeks, encouraging them to engage in the actions.
224255297|NCT07161999|DRUG|COYA 302|Administered as specified in the treatment arm.
224255298|NCT07161999|DRUG|Placebo|Administered as specified in the treatment arm.
224255299|NCT07170150|DRUG|Trontinemab|Participants will receive IV trontinemab
224255300|NCT07170150|OTHER|Placebo|Participants will receive IV placebo
224255301|NCT07171970|PROCEDURE|IVM-Fresh (No gonadotropin + Fresh embryo transfer)|Patients randomized to this arm will receive estradiol valerate 8 mg/day. IVM will be performed after ≥10 days of estrogen and ET ≥8 mm. From the day of ICSI, they will continue estradiol and start vaginal progesterone 800 mg/day + dydrogesterone (20mg/day). A fresh embryo transfer will subsequently be performed.
224255302|NCT07171970|PROCEDURE|IVF-FET (GnRH-Antagonist - Agonist Trigger - Frozen embryo transfer)|Patients randomized into this group will receive FSH at a dose of 150 IU/day. Oocyte retrieval will be performed once the criteria for triggering are fulfilled, followed by embryo cryopreservation and frozen embryo transfer in the subsequent cycle. Endometrial preparation for frozen embryo transfer will be conducted using an exogenous steroids regimen. Patients will receive estradiol 8 mg/day starting from cycle days 2-3 for 10 days. When the endometrial thickness reaches ≥8 mm, luteal phase support will be initiated with vaginal progesterone 800 mg/day plus dydrogesterone 20 mg/day.
224322328|NCT03996070|PROCEDURE|Laser therapy|Erbium YAG laser
223772442|NCT00632697|DRUG|pentoxifylline|800 mg daily for six months
223772443|NCT00632697|DRUG|placebo|
223772444|NCT05575648|OTHER|10 meter walk test|To assess the dual task performance of children 10 meter walk test will be used.
223772445|NCT05827497|DRUG|Baricitinib 2 MG|baricitinib 2 mg once daily
223772446|NCT05827497|DRUG|Methotrexate 25mg|25mg daily
223772447|NCT04085822|DEVICE|SMA-001|Intra-dermal injection of SMA-001 and control device.
223772448|NCT02832674|DEVICE|Percutaneous Radiofrequency single treatment|Percutaneous Radiofrequency single treatment' under controlled temperature conditions based on pre-defined amounts of energy as controlled by the device internal algorithm, and investigator expertise. Additionally, Hunsted solution will be infused in the treatment area to eliminate the electrode/fiber to touch inner layers of the skin. External temperatures (skin surface) will be monitored using a temperature reading camera to ensure the external temperature stays within acceptable levels during the procedure Ice packs will also be used as needed to cool the treatment area based on the Thermal Camera Reading where the . heat delivery may be exceeding the threshold.
223772449|NCT00111228|DEVICE|Guardian RT|
223772450|NCT00111228|DEVICE|SMBG only|SMBG only
224322329|NCT05458674|DRUG|Tucatinib|taken orally
224322330|NCT05458674|DRUG|Eribulin|taknen intravenously
224322331|NCT05458674|DRUG|Trastuzumab|taken intravenously
223772451|NCT01325610|DIETARY_SUPPLEMENT|cholecalciferol|a weekly dose of 20,000 IU of vitamin D3 will be given orally for 12 weeks.
223772452|NCT05279521|BEHAVIORAL|pulmonary rehabilitation exercise|The lung rehabilitation exercise is divided into three parts: upper and lower limb muscle strength, endurance training and breathing training skills. It lasts for eight weeks of exercise training, and the exercise frequency is: three times a week.
223772453|NCT00678691|DRUG|armodafinil|50-250mg/d
223772454|NCT00678691|DRUG|placebo|matching placebo
223674140|NCT05577455|DRUG|Medical prescription after ovulation|Medical prescription after ovulation, modified Er Xian decoction for promoting fertilization and Si-Wu-Tang: 10g of Xian Mao (Curculigo orchioides), 15g of Xian Ling Pi (Epimedium Herb), 15g of Ba Ji Tian (Morinda officinalis), 20g of Tu Si Zi (Semen cuscutae), 15g of Nv Zhen Zi (Fructus Ligustri Lucidi), 15g of Zi Shi Ying (Fluoritum), 15g of Shu Di (Radix Rehmanniae Preparata), 10g of Dang Gui (Angelica sinensis), 10g of Bai Shao (Paeonia lactiflora Pallas), and 10g of Chuan Xiong (Szechwan Lovage Rhizome). The medical prescription is administered continuously for 10-15 days after ovulation, based on follicle development and endometrial growth monitored by ultrasound.
223674141|NCT02397499|DRUG|LIPO-202|
223674142|NCT02397499|DRUG|Placebo|
223674143|NCT02027805|BIOLOGICAL|T-Guard|
223772455|NCT04912024|DEVICE|Intermittent Renal Replacement Therapy using the Tablo Hemodialysis System|Intermittent renal replacement therapy using the Tablo Hemodialysis System in the acute setting for participants with AKI or ESKD
223772456|NCT04912024|DEVICE|Intermittent Renal Replacement Therapy using Conventional Hemodialysis Systems|Intermittent renal replacement therapy using Conventional Hemodialysis Systems in the acute setting for participants with AKI or ESKD
223772457|NCT01150838|DRUG|propofol|Initial dose: Propofol 2 mg/kg, then dose changes separately based on the last subject in the same age group and sevo time range
224255303|NCT07179484|DRUG|CT041 autologous CAR T-cell injection|The planned dose of CT041 is 2.5×108 cells. The participants are recommended to receive only a single infusion or multiple infusions (up to 3 infusions) according to the safety and efficacy data of the participants per the investigator. The dose and method of re-infusion are the same as the first infusion. Lymphodepletion pretreatment should be given before re-infusion, and the requirements before lymphodepletion pretreatment and cell infusion should also be met before re-lymphodepletion pretreatment or re-infusion.
224255304|NCT07179016|BEHAVIORAL|Auricular Point Acupressure (APA) - Self Management (SM)|APA is a noninvasive and needle-free pain management therapy based on the principles of acupuncture. The APA-SM intervention program is aimed to manage chronic musculoskeletal pain leveraging a mobile app containing APA videos and remote vs in-person guidance or coaching to practice APA based on APA study assignment.
223674144|NCT03061747|DEVICE|Assesment of outcome of implantable device patients|Evaluation during follow-up of the occurrence of atrial arrhythmias, hospitalizations, and of death.
223674145|NCT03930563|DIETARY_SUPPLEMENT|Pre-beetroot juice supplementation|Before administering beetroot juice to subjects.
223674146|NCT03930563|DIETARY_SUPPLEMENT|Post-beetroot juice supplementation|After administering beetroot juice to subjects.
223772458|NCT00261482|DRUG|norelgestromin + ethinyl estradiol|
224255305|NCT07179016|BEHAVIORAL|Education Control|Education Control group receive an app but the content will be specific to pain and self-management (no APA content) and they practice pain self-management skills (no APA practice).
224255306|NCT07179614|BEHAVIORAL|Overdose Prevention Intervention Package (OPIP)|WJCOIN-II's multi-level 2 X 2 randomized factorial design will examine the effectiveness of OPIP components across four study conditions randomly assigned after baseline data collection (n=75 per condition, 100 per jail site), summarized in Table 7 and described below. In addition to group assignment, outcomes will be assessed as a function of engagement in each intervention component defined as the number of sessions attended (RC and CM conditions) and perceived support, which is a count of the number of types of support provided by the RC and SP (e.g., emotional, financial, etc.).
224255307|NCT07184151|DRUG|well root putty ( premixed bioceramic putty) retrograde filling|well root putty ( premixed bioceramic putty) retrograde filling
224255308|NCT07184151|DRUG|MTA retrograde filling|MTA retrograde filling
224255311|NCT04586660|DRUG|XGEVA®|Participants will receive XGEVA® 120 mg subcutaneously (SC) once every 4 weeks (Q4W) with a loading dose of 120 mg SC on day 8 and day 15.
224255312|NCT07184619|DRUG|Evenamide 15 mg bid|Evenamide capsules 15 mg bid for a total of 12 weeks of add-on treatment
224255313|NCT07184619|DRUG|Placebo|Matching placebo capsules bid for a total of 12 weeks of add-on treatment
224255314|NCT07190625|DRUG|fentanyl intravenous|giving intravenous fentanyl
224255315|NCT07190625|DRUG|Fentanyl intranasal using atomizer|giving intranasal fentanyl using nasal atomizer
224255316|NCT07190625|DRUG|fentanyl intranasal direct|giving intranasal fentanyl directly into nostrils
224255317|NCT07191353|DRUG|Everolimus|Everolimus 5 mg administered once weekly for 24 weeks
224255318|NCT07191353|DRUG|Placebo|Placebo administered once weekly for 24 weeks
223674147|NCT00238940|DRUG|Enteric-Coated Mycophenolate Sodium (EC-MPS)|
223674148|NCT04611672|DIAGNOSTIC_TEST|Assessment of CA|As part of our routine stroke work up, each patient receives an initial CT scan with CT perfusion to indicate thrombolysis therapy (intravenous, mechanical, or both, depending on the time since first stroke symptoms and perfusion-mismatch), an MRI within 2 days, extracranial and transcranial Duplex ultrasound, echocardiography, continuous Monitoring of BP, O2, body temperature, NIHSS and Glagow Coma Scale (GCS) every 6 hours. Assessing CA by continuous recording of blood pressure, cerebral blood flow velocity, end-tidal CO2. Analysis via Transfer function estimates
223674149|NCT04611672|DIAGNOSTIC_TEST|Assesment of CA only|Assessing CA by continuous recording of blood pressure, cerebral blood flow velocity, end-tidal CO2. Analysis via Transfer function estimates
224255319|NCT07191353|OTHER|Resistance training|Resistance training 3 times a week for 24 weeks
224255320|NCT07189416|PROCEDURE|"Laparoscopic One Anastomosis Gastric Bypass by Use the FundoRing method with Enhanced Recovery Protocol and Remote Monitoring in Ambulatory Surgery Center with Integrated Apartments"|"Laparoscopic One Anastomosis Gastric Bypass by Use the FundoRing method with Enhanced Recovery Protocol and Remote Monitoring in Ambulatory Surgery Center with Integrated Apartments"
224255321|NCT07188623|BEHAVIORAL|VR-Enhanced BA|"Participants will choose at least one activity per day to complete in the loaned HTC VIVE Flow Immersive Glasses extended reality over the course of the week. These activities are chosen from the headset and include video 360."
224255322|NCT07194720|DIETARY_SUPPLEMENT|Cornus mas lyophilisate|Participants receiving a Cornus mas (Cornelian cherry) lyophilisate for 4 weeks.
224255323|NCT07194720|DIETARY_SUPPLEMENT|Placebo|Participants receiving a starch- and sugar-based placebo for 4 weeks.
223674150|NCT01481441|DRUG|SonoVue|2.4 ml Bolus Injection by intravenous canule. Multi-repeatable (up to 4 bolus) if necessary.
223674151|NCT02415842|OTHER|Serum samples|The archived sera samples collected in previously completed pandemic influenza vaccine clinical trials (H1N1, H5N1, and H9N2 pandemic vaccines in adult trials and H5N1 pandemic vaccine in a pediatric trial) will be tested in this study.
223674152|NCT06451731|BEHAVIORAL|PHOLEXSEM|Phonological, Lexical, and Semantic training
223674153|NCT06451731|BEHAVIORAL|PACE|See arm description
223674154|NCT06064994|BEHAVIORAL|Mindfulness meditation|"The experimental group received the Smith's version of the mindfulness meditation (Smith, 2005), which is a standardized theory-based intervention found to be effective in improving the different dimensions of health. The Smith's version of the mindfulness meditation (Smith, 2005), includes the following components:~1. Being mindful of breathing (5 minutes).~2. Being mindful of the body (5 minutes).~3. Being mindful of thought (5 minutes).~4. Being mindful of sounds (5 minutes).~5. Being mindful of taste (5 minutes)~6. Full meditation"
223674155|NCT00003830|PROCEDURE|conventional surgery|Sentinel node resection immediately followed by axillary dissection.
223674156|NCT00003830|PROCEDURE|Sentinel node resection followed by node examination|Sentinel node resection followed by node examination then axillary dissection if positive sentinel node. No axillary dissection for negative sentinel node.
223674157|NCT01840059|DEVICE|Renal sympathetic denervation|A fit for purpose radiofrequency catheter is guided to the renal artery using fluoroscopy. This is connected to an external RF generator. RF energy is applied through the catheter to the renal artery wall with the goal of disrupting the sympathetic nerves which run in the adventitia
223674158|NCT06514196|DEVICE|Hintermann Series H3 Total Ankle Replacement System|The H3 includes a metal tibial component, a polyethylene sliding insert (PE inlay), and a metal talar component.
223674159|NCT04179409|DRUG|Amondys 45|This drug is used to target skipping of exon 45 of the dystrophin gene.
223674160|NCT04179409|DRUG|Exondys 51|This drug is used to target skipping of exon 51 of the dystrophin gene.
223674161|NCT04179409|DRUG|Vyondys 53|This drug is used to target skipping of exon 53 of the dystrophin gene.
223674162|NCT03329183|DRUG|Irinotecan|High-dose FOLFIRI regimen (Irinotecan 260mg/m2 2h, leucovorin 400mg/m2, 5- fluorouracil 400mg/m2 , 5- fluorouracil 2400 mg/m2 46h, 14 days per course)
223674163|NCT05595759|OTHER|Violence against women education supported by creative drama|Violence against women supported by creative drama training will be applied to male patients diagnosed with addiction every day for 5 days.
223674164|NCT05595759|OTHER|Routine service operation|No additional training will be applied to the control group and SAMBA trainings in the service operation will be applied.
224255324|NCT07193719|PROCEDURE|End-expiratory lung volume optimization maneuver with PEEP titration|PEEP titration (incremental/decremental) will be performed to optimize lung volume after surgery and find levels of PEEP corresponding to the best lung compliance. Typically PEEP levels between 10-20cmH2O will be applied based on individual response of patients' lung mechanics. Tidal volume will be kept constant at 6ml/kg in both arms. Driving pressures will be limited to 15cmH2O. Balance of CO2 will be guaranteed by adjusting respiratory rate.
224255325|NCT07193719|PROCEDURE|Standard Care (in control arm)|Patients will receive pressure controlled ventilation with target tidal volume of 6ml/kg and PEEP of 5cmH2O. Driving pressures are limited to 15cmH2O.
224255326|NCT07193472|PROCEDURE|serratus intercostal plane block as analgesic technique|the SIPB will be applied after starting surgery and before general anaesthesia
224255327|NCT07193771|OTHER|Geographic Altitude|Participants are grouped according to the altitude of the pediatric intensive care unit (PICU) where they are admitted: low altitude (0-1500 m), intermediate altitude (1501-2500 m), high altitude (2501-3500 m), and very high altitude (\>3500 m). Altitude is treated as the primary exposure variable. No therapeutic intervention is administered as part of this study.
224255328|NCT07201090|BEHAVIORAL|Brief Parent-Child Interaction Therapy with videos and virtual reality (360-degree VR)-films|"10 sessions of PCIT delivered by trained psychologists, supplemented with videos and 360-degree VR-films~Sessions follow the standard PCIT structure, with an initial phase focused on child-directed interaction, followed by a second, modified phase, focused on parent-directed interaction.~To support skill learning, families are provided with digital materials including conventional video modules at home and 360-degree virtual reality (VR) films. The VR films are shown during two sessions at the clinic. Additional videos are available online through a platform for parents to view and practice between sessions. These tools allow parents to rehearse skills flexibly in their home environment and reinforce the in-session training."
224255329|NCT07201415|PROCEDURE|minimally invasive suprachoroidal drainage|minimally invasive suprachoroidal drainage
224255330|NCT07201545|DRUG|Bempedoic acid|"180 mg film coated tablet administered as FDC or co-administered with ezetimibe~Component of FDC"
223674165|NCT05593549|DRUG|Trehalose|Trehalose will be given at a dose of 10g mixed in 500 mL of water to be consumed 1 time per day for 14 days
223674166|NCT05593549|DRUG|Placebo|Microcrystalline cellulose will be given at a dose of 10g mixed in 500 mL of water to be consumed 1 time per day for 14 days
223674167|NCT03416062|DRUG|Remaxol®|Solution for intravenous infusions, containing succinate, methionine, inosine, and nicotinamide in 400 ml glass bottle
224322332|NCT02503787|DEVICE|Spinal Cord Stimulation (SCS)|SCS programming options
223674168|NCT03416062|DRUG|Ringer's Solution|Solution for intravenous infusion, 400 or 800 ml
223674169|NCT05547971|RADIATION|intensity-modulated radiation therapy|The patients got intensity-modulated radiation therapy during observation
223674170|NCT03739242|DIETARY_SUPPLEMENT|Nutraceutical combination|One tablet per os per day to be taken in the evening from randomization (day 0) to the end of the trial (day 56 +/- 3)
223674171|NCT03739242|OTHER|Placebo|One tablet per os per day to be taken in the evening from randomization (day 0) to the end of the trial (day 56 +/- 3)
223674172|NCT04713527|DIAGNOSTIC_TEST|Cultivation and PCR within 24 hours|During operation for appendicitis peritoneal fluid will be extracted. This is sent to cultivation and PCR analysis to determine if there is bacteria within the peritoneal cavity.
223674173|NCT04713527|DRUG|Enteral antibiotics|Patients with complicated appendicitis will receive enteral antibiotics instead of intravenous
223772459|NCT06142812|OTHER|Kahoot!™ Group|The theoretical concepts of each subject were taught over a period of four months, with a total duration of 30 hours. Of the total theoretical concepts of the subject, 50% were randomly selected to receive reinforcement through Kahoot! Each of the theoretical concepts chosen at random was consolidated through a Kahoot! questionnaire. which consisted of 15 questions, with three answer options. This questionnaire was administered at the end of the theoretical explanation of each section, with the objective of strengthening the learning of the contents just presented. After students answered each question in Kahoot!, the teacher clarified any questions related to that question and provided explanations as to why one answer was correct and the other two were incorrect. This process offered immediate feedback to students.
223772460|NCT05315271|DRUG|Bupivacaine-ketamine injection|20 ml volume bupivacaine only (0.5%concentration) (with maximum dose not exceeding 4mg/kg ) plus ketamine (1 mg/kg) with maximum dose 100mg ; the total volume is 30 ml with the infusion of 100 ml normal saline at a rate of 100ml/h.
223674174|NCT01029301|DEVICE|Device: EndyMed Pro System for Skin Tightening|"Based on patient skin type and area of treatment the physician will choose the following parameters (some parameters are fixed):~Pulse energy (J); RF frequency (1MHz); Pulse duration (30 sec); Treatment hand piece (skin tightening);"
223772461|NCT05315271|DRUG|Bupivacaine injection with intravenous ketamine infusion|20 ml volume bupivacaine only (0.5%concentration) (with maximum dose not exceeding 4mg/kg ) plus 10 ml saline ; the total volume is 30 ml with the infusion of ketamine 0.15 mg/kg added to 100 ml normal saline and will be infused at a rate of 100 ml/h, which will be stopped 5 min before the end of surgery.
223772462|NCT05723367|PROCEDURE|lumbar ESPB group where ESPB is performed at L4 with local anesthetics 20ml|ultrasound guided fascial plane injection
223772463|NCT03542643|DIETARY_SUPPLEMENT|n-3 Polyunsaturated fatty acid|1g of Eicosapentaenoic acid (EPA)
223772464|NCT03542643|DIETARY_SUPPLEMENT|Placebo|Olive oil ethyl esters
223772465|NCT05829603|DRUG|Dimethyltryptamin (DMT) & Harmine|Six varying doses of a fixed-combination formulation of Dimethyltryptamin (DMT) and harmine
223772466|NCT00653107|PROCEDURE|Stent insertion|Self-expanding metal stents will be used. These will be of the type which the hospital at any given time uses, at present Ultraflex®.
224255331|NCT07201545|DRUG|Ezetimibe|"10 mg tablet administered as FDC or co-administered with bempedoic acid~Component of FDC"
224255332|NCT07201545|DRUG|Rosuvastatin|"20 mg film coated tablet administered individually or as FDC~Component of FDC"
224255333|NCT07201129|DRUG|Cenerimod|Cenerimod will be supplied as a film-coated tablets at the dose of 4 mg.
223772467|NCT00653107|RADIATION|Brachytherapy|a flexible applicator (with a diameter adapted to the stent's diameter) will be introduced into the oesophagus, so the applicator will be lying in the middle of the lumen of the stent. Thereafter, the flexible applicator is connected to a MicroSelectron afterloading device (Iridium-192), and the treatment is given with a high dose rate (\> 12 Gy/h).
223772468|NCT00653107|RADIATION|Brachytherapy|a flexible applicator will be introduced into the oesophagus. The flexible applicator is connected to a MicroSelectron afterloading device (Iridium-192), and the treatment is given with a high dose rate (\> 12 Gy/h).
223772469|NCT05572242|PROCEDURE|Premolar extraction and socked preservation with L-PRF|"Partially edentulous patients in need of a single-tooth extraction in the premolar region\[ (maxilla or mandible), with two neighboring natural teeth, will be included in the study. The tooth will be luxated first with elevators and then carefully extracted with forceps without raising a flap.~L-PRF group will use 2-5 PRF clots, depending on the size of the socket, which will be inserted and compressed with a large plunger until they reach the alveolar crest. The site will thereafter be covered with L-PRF membranes. Then, crossed horizontal mattress suture will be placed followed by single interrupted sutures for stabilization. No efforts will be undertaken to obtain primary wound closure. The grafted socket will be left to heal for 4 months.~After 4 months of socket preservation, a dental implant will be inserted into the socket. After 4 months of implant healing, a cad cam final restoration will be delivered. The follow-up will be up to 12 months after the final restoration."
223772470|NCT05572242|PROCEDURE|Premolar extraction and socked preservation with Xenogenic bone and collagen membrane.|"Partially edentulous patients in need of a single-tooth extraction in the premolar region (maxilla or mandible), with two neighboring natural teeth, will be included in the study. The tooth will be luxated first with straight and angled elevators and then carefully extracted with forceps without raising a flap.~In the control group, the socket will be grafted with xenogeneic bone substitute material (up to the palatal/lingual bone crest) and covered with a collagen matrix. Single interrupted sutures will be placed to stabilize the collagen matrix. Sutures will be removed at 7-10 days. The grafted socket will then be left to heal for a period of 4 months.~The xenogenic material will be Bio-Oss Collagen® and collagen matrix Bio-Gide® .~After 4 months of socket preservation, a dental implant will be placed. After 4 months of implant healing, a cad cam final restoration will be delivered. The follow-up will be up to 12 months after the final restoration."
224255334|NCT07201129|DRUG|Placebo|Matching placebo will be supplied as identical film-coated tablets formulated with the same excipients but without the active ingredient, cenerimod.
224255335|NCT07200713|OTHER|Treatment as usual (TAU)|Best practice ordinary psychological treatment
224255336|NCT07200713|OTHER|Sensory motor arousal regulation treatment (SMART)|Psychological treatment using SMART room and associated techniques
224255337|NCT07202208|PROCEDURE|"Delirium Zero protocol"|The protocol consists of: i) a patient orientation poster placed in the room in a visible location for the patient, with information updated daily by the family member/caregiver; ii) a clock hung on the wall next to the orientation poster; and iii) a verification sheet of the preventive measures taken by the caregiver/family member, where the caregiver/family member must indicate daily the frequency with which preventive activities have been performed. The caregiver/family member will have this document in the patient's room all day and will need to complete it at the end of the day, when the nurse will collect it for safekeeping. From that day until the patient is discharged, the nurse responsible for the patient's care will be responsible for providing a new verification sheet of the preventive measures taken by the family member/caregiver and collecting it at the end of the day once it has been completed by the family member/caregiver.
224255338|NCT07202208|PROCEDURE|Standard of Care to prevent Delirium.|All participants in the study, regardless of the assigned group, receive information on strategies to prevent delirium, which is provided in the participant information sheet and includes an infographic and a guide for patients and their families. Participants are advised to keep this document accessible throughout their stay for reference.
224255339|NCT07200414|BEHAVIORAL|Integrated Adolescent Health Package|Delivery of an integrated package of adolescent health services through government health facilities. The package includes HPV vaccination, sexual and reproductive health counseling, general health check-ups, nutrition and vision screening, mental health support, deworming, and dental and oral health services. Implemented in intervention LGAs in Lagos and Kebbi States.
224255340|NCT07200414|OTHER|Routine Government Health Services|Routine government health services provided in comparison LGAs. Services may include HPV vaccination as per national immunization schedules and other adolescent health services delivered under existing programs, but without the integrated package.
224255341|NCT07200440|PROCEDURE|Intervention 1|Digital scans using conventional scan bodies scanned with an intra-oral scanner.
224255342|NCT07200440|PROCEDURE|Intervention 2|Digital scans using intra-oral photogrammetry scanned with an intra-oral scanner.
224255343|NCT07200440|PROCEDURE|Intervention 3|Digital scans using calibrated scan flags scanned with an intra-oral scanner.
224255344|NCT07200440|PROCEDURE|Control|Digital scans using conventional scan bodies scanned with a desktop scanner.
224255345|NCT07201727|BIOLOGICAL|CD123+CLL-1 dual-target CAR-T cells sequential infusion CD7 CAR-T cells and bridging to allogeneic|For patients with refractory and relapsed AML, CD123+CLL-1 dual-target CAR-T cells (JY017) are used for treatment. Then, for patients who cannot achieve the minimum residual negative, CD7-targeted CAR-T cells (JY008) are sequentially infused. Finally, allogeneic hematopoietic stem cell transplantation is performed based on patient conditions.
224255346|NCT07200830|DRUG|Lutetium Lu 177 Vipivotide Tetraxetan|Given IV
224255347|NCT07200830|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
224255348|NCT07200830|PROCEDURE|Patient Monitoring|Undergo PSA monitoring
224255349|NCT07200830|PROCEDURE|Computed Tomography|Undergo CT
224255350|NCT07200830|PROCEDURE|Bone Scan|Undergo Bone Scan
224255351|NCT07200830|PROCEDURE|PSMA PET Scan|Undergo PSMA PET Scan
224255352|NCT07200830|PROCEDURE|MRI|Undergo MRI
224255353|NCT07200830|OTHER|Questionnaire Administration|Ancillary studies
224255354|NCT07202533|OTHER|Motor Control Exercises|Participants will perform these exercises under physiotherapist supervision twice per week for 8 weeks. Exercises focus on improving deep trunk muscle coordination and stability.
224255355|NCT07202533|OTHER|Pain Neuroscience Education|A 6-week educational program with weekly sessions using slide presentations and interactive discussions, covering pain neurophysiology, central sensitization, and pain coping strategies, delivered by a certified physiotherapist.
224255356|NCT07202533|OTHER|Motor Control Exercises|Participants will perform these exercises under physiotherapist supervision twice per week for 8 weeks. Exercises focus on improving deep trunk muscle coordination and stability.
224255357|NCT07201766|DRUG|intralesional bleomycin|The role of intralesional bleomycin for the treatment of keloids needs further establishment in terms of effective concentration, number of sessions and post treatment ulceration or/and hypopigmentation. Additionally, its comparison to the commonly used and proven, more effective combination than intralesional steroid alone i-e 5-FU in combination with the intralesional steroid, need also be done so that if found affective will be able to deal with the pathological scar as a 1 st line therapeutic drug. With a strong study design and an adequate sample size, and particularly in a specialized tertiary care clinical setup, Our study, seeks to get over the aforementioned limitations, and will delineates the appropriate guidelines for the management of these pathological scars, and suggest option with the best outcomes, as well as lesser side effects and recurrence rates.
224255358|NCT07201766|DRUG|5-flourouracil and triamcinolone acetonide|The role of intralesional bleomycin for the treatment of keloids needs further establishment in terms of effective concentration, number of sessions and post treatment ulceration or/and hypopigmentation. Additionally, its comparison to the commonly used and proven, more effective combination than intralesional steroid alone i-e 5-FU in combination with the intralesional steroid, need also be done so that if found affective will be able to deal with the pathological scar as a 1 st line therapeutic drug. With a strong study design and an adequate sample size, and particularly in a specialized tertiary care clinical setup, Our study, seeks to get over the aforementioned limitations, and will delineates the appropriate guidelines for the management of these pathological scars, and suggest option with the best outcomes, as well as lesser side effects and recurrence rates.
224255359|NCT07200570|BEHAVIORAL|LLM-Powered HPV Vaccine Chatbot|A vaccine chatbot delivered via WeChat or a web browser, designed to provide information and health education about the HPV vaccine. The chatbot is powered by large language models and is trained on an expert-validated knowledge base derived from authoritative sources such as the WHO and China CDC to ensure accuracy. The knowledge base is validated by experts. The chatbot engages users in interactive, conversational dialogue to answer questions and address concerns regarding HPV and HPV vaccines.
224255360|NCT07201623|BEHAVIORAL|web-based childbirth preparation education|group providing web-based childbirth preparation training
224255361|NCT07202468|DEVICE|Virtual Reality|"1. Aquarium VR Video (3D)~   Children in this group wore a virtual reality headset displaying a 3D Aquarium video. The video included underwater scenes with fish, sharks, and marine mammals. The VR headset was applied 2-3 minutes before the peripheral intravenous catheterization procedure and continued during the procedure to provide distraction.~2. Kaleidoscope VR Video (3D)~   Children in this group wore a virtual reality headset displaying a 3D Kaleidoscope video consisting of colorful, shifting geometric patterns. The VR headset was applied 2-3 minutes before the peripheral intravenous catheterization procedure and continued during the procedure to distract the child and reduce procedural pain and fear.~3. Routine Care (Control Group)~Children in this group received standard peripheral intravenous catheterization procedure in the pediatric surgery unit without any additional distraction intervention."
224255362|NCT07200960|PROCEDURE|ESPB|Patient receiving ESPB for major oncological breast surgery Patient receiving Retrolaminar Block for major oncological breast surgery
224255363|NCT07201636|DIAGNOSTIC_TEST|Motor Function Assessments|The planned functional motor assessments are specific to age and degree of motor impairment. Participants are expected to have varying degrees of motor impairment, for example some will be non-ambulant. There is also a wide range of ages of participants. Therefore, some assessments will not be applicable. Some participants may gain or lose these abilities during the study and the assessments they complete shall be tailored accordingly aiming to reflect their most typical abilities on the day assessed.
224255364|NCT07201636|DEVICE|Syde|Syde is an innovative device intended to be used in a home-based environment. It is composed of two watch-like sensors, each containing a magneto-inertial sensors that record the linear acceleration, the angular velocity, the magnetic field of the movement in all directions.The two watches can be worn as wristwatch or placed near the ankle.
223674175|NCT06280586|OTHER|Multidisciplinary intervention|"* bimonthly personalized follow-up with the appropriate specialists (5 in a year) i~* a program of group activities (6 sessions in a year) with a monitor with the aim of reinforcing adherence to the study intervention and adapting it to the circumstances and the physical, personal and social reality around each participant. The sessions will last approximately one hour and will cover:~  * General dietary and hydration recommendations and dietary recommendations for people at risk of malnutrition~ * Dietary and physical exercise recommendations in obese elderly~ * General physical exercise recommendations in the elderly and physical exercise recommendations in the elderly with sarcopenia~ * Physical exercise recommendations for the elderly at risk of falls.~ * Medication management and social resources for the elderly in Mataró."
224255365|NCT07201636|DIAGNOSTIC_TEST|Respiratory Assessments|The planned respiratory assessments are tailored to the participant's age and respiratory capacity. Participants are expected to have varying degrees of respiratory impairment, and some assessments may not be applicable to all. As participants may gain or lose respiratory function over the course of the study, the assessments completed will be adapted accordingly to reflect their most typical respiratory abilities on the day of assessment.
224255366|NCT07201636|DIAGNOSTIC_TEST|Bulbar Function Questionnaires|The planned bulbar function assessments are age-specific and designed to reflect the participant's typical oral intake abilities. For participants aged 1-17 years, the Children's Eating and Drinking Activity Scale (CEDAS), will be used. For those aged 18 years and older, the Functional Oral Intake Scale (FOIS) will be applied. Both tools are part of a unified 7-item scale validated across paediatric and adult populations, ensuring continuity across age groups.
224255367|NCT07201636|DIAGNOSTIC_TEST|Clinical Global Impression (CGI)|The Clinical Global Impression (CGI) tool will be used to assess overall disease severity and improvement across three functional domains: Physical Motor Function, Respiratory Function, and Bulbar Function. Assessments are based on clinician judgment using all available clinical data and are conducted by clinicians experienced with the disease under study.
224255368|NCT07201636|OTHER|Quality of Life Questionnaires|The planned quality of life and functional status assessments are designed to capture the participant's overall well-being and daily functioning, taking into account the wide range of ages and disease severities in the study population. Validated questionnaires appropriate to age and functional level will be used to evaluate aspects such as health-related quality of life, fatigue, and daily activity limitations.
224255369|NCT07201636|PROCEDURE|Blood Sample Collection|Blood sample collection is usually done annually for NM patients as part of their standard of care. This is usually done by a nurse or a medical doctor according to standard guidelines for blood sampling. During routine blood sampling, additional blood will be collected and up to 20 ml of blood will be taken.
224255370|NCT07201350|OTHER|distraciton technices|UTETC is a distraction method used during ECG procedures.
224255371|NCT07202416|PROCEDURE|Erector spinae plane block|Ultrasound-guided Erector Spinae Plane Block performed at the T9 level with 0,375%, ropivacaine 20 mL administered bilaterally at the end of surgery for postoperative analgesia following cesarean section.
224255372|NCT07202416|PROCEDURE|Intrathecal morphine|Intrathecal administration of 100 mcg of morphine in combination with a local anesthetic was performed at the time of spinal anesthesia for cesarean section.
224255373|NCT07200375|DRUG|Glofitamab|Participants will receive glofitamab as part of a cancer-treatment regimen in a real-world setting. No intervention will be administered by study investigators.
224255374|NCT07201311|DRUG|Combination of activated charcoal with polyethylene glycol for digestive decontamination|"A dose of 25-100g of activated charcoal via the nasogastric tube will be administered, followed by polyethylene glycol1L/15-20 kg ideal body weight at a flow rate of 1L/hour.~polyethylene glycol will be continued until clear stools are obtained, a maximum of 24h of treatment of until the maximum dose of 1L per 15 kg of ideal body weight are administered.~Serial activated charcoal 50g 6 times/day will be administered if prolonged-release forms or drugs with enterohepatic circulation were ingested."
224255375|NCT07201311|DRUG|Standard Treatment (Guideline-Based)|Patients receive activated charcoal according to French guidelines - activated charcoal 25-100g and serial activated charcoal 50g 6 times/day if sustained-release forms or drugs with enterohepatic circulation as routine treatment.
224255376|NCT07200908|DRUG|Brelovitug 300 mg|Route of administration- Subcutaneous Injection
224255377|NCT07200908|DRUG|Bulevirtide 2 mg and Brelovitug - 300 mg|Route of Administration- Subcutaneous Injection
224255378|NCT07201792|OTHER|Early Physiotherapy|The early physiotherapy program will begin when the infant is stable and continue until discharge. Depending on the infant's gestational age and respiratory needs, chest physiotherapy, developmental physiotherapy, or both will be administered, if necessary. The early family collaborative physiotherapy program will begin from the first day the infant is stable and parental contact is established, and will consist of routine-based care and family education programs that include therapeutic holding, carrying, positioning, and sucking facilitation to stimulate postural responses. The physiotherapy group will receive a routine-based family collaborative early intervention program. This program will be based on a model of goal-oriented active motor learning and sensory strategy development in an enriched environment, and will include family education programs that integrate holding, carrying, and positioning training into daily routines. All parents will participate in the training.
224255379|NCT07200596|DRUG|SHR-3045 Injection|SHR-3045 injection.
223772471|NCT02260427|DEVICE|Insertion of the i-gel|After induction of general anesthesia, the i-gel will be inserted according to randomly allocated group.
223772472|NCT02260427|DEVICE|Insertion of the air-Q sp|
223772473|NCT04072484|OTHER|Mild hypoxia|The subject will breathe a gas mixture containing 15% oxygen instead of 21% oxygen.
224255380|NCT07200596|DRUG|SHR-3045 Placebo Injection|SHR-3045 placebo injection.
224255381|NCT07201974|OTHER|Virtual Reality Training|The VR intervention involves the intensive practice of community ambulation skills. The training sessions will be performed in a virtual environment. During the intervention, stroke participants will be invited to practice different dimensions of community ambulation, such as postural transitions, avoiding other pedestrians, dual-task walking, etc.
223674176|NCT02755532|DRUG|Bupivacaine 0,25%|Venous blood samples were collected prior to blocking , every 15 min during the first hour after completion of the blocking and every 30 min during the second hour after completion using an exclusive cannula. Then, 5 ml was drawn off and was stored in two EDTA tubes (BD, Franklin Lakes, NJ, USA). The EDTA tubes were centrifuged at 3,500xg for 10 min to obtain the blood plasma. This plasma was then stored in cryogenic tubes in a freezer at -80 °C until the time of the analysis. A high-performance liquid chromatography apparatus (Shimadzu, Kyoto, Japan) coupled to a Bruker mass spectrometer (MS), model Amazon (USA), with electrospray source ionization and a sequential mass spectrometry system (MS/MS) were used for the analysis. After obtaining the precursor ion, a fragment was obtained via a collision-induced dissociation process. The following molecular ions were selected: 289.0 m/z==\>140.1 m/z. The methodology was validated according to the international FDA recommendations.
223674177|NCT02755532|DRUG|Bupivacaine 0,5%|Venous blood samples were collected prior to blocking , every 15 min during the first hour after completion of the blocking and every 30 min during the second hour after completion using an exclusive cannula. Then, 5 ml was drawn off and was stored in two EDTA tubes (BD, Franklin Lakes, NJ, USA). The EDTA tubes were centrifuged at 3,500xg for 10 min to obtain the blood plasma. This plasma was then stored in cryogenic tubes in a freezer at -80 °C until the time of the analysis. A high-performance liquid chromatography apparatus (Shimadzu, Kyoto, Japan) coupled to a Bruker mass spectrometer (MS), model Amazon (USA), with electrospray source ionization and a sequential mass spectrometry system (MS/MS) were used for the analysis. After obtaining the precursor ion, a fragment was obtained via a collision-induced dissociation process. The following molecular ions were selected: 289.0 m/z==\>140.1 m/z. The methodology was validated according to the international FDA recommendations.
223674178|NCT00966784|OTHER|Dietary Fibers|
223772474|NCT02232659|DEVICE|70cc TAH-t for Destination Therapy|Use of the approved SynCardia 70cc TAH-t for patients who are in biventricular failure (approved use), but who are ineligible for cardiac transplant (experimental use).
223772475|NCT01840670|DRUG|Rapid fluid load test|The test will be performed by infusing 250-300 mL/m2 Body Surface Area of 6% hydroxyethyl starch 6% 130/0.4 (VoluvenR) in 30 minutes
223772476|NCT03765307|DEVICE|SyMap Bronchial Ablation System|The Bronchial Ablation is performed using SyMap Bronchial Ablation System in three sessions at least three weeks apart between each session: Right Lung Lobe, Left Lung Lobe, Right Up Lobe and Left Up Lobe.
224255382|NCT07202338|BEHAVIORAL|CHRONOS therapy|Description: Session 1 : Introduction and awareness of the sleep-wake link Session 2 : Awareness of day/night habits and behaviors Session 3 : Awareness of sleep/wake rhythms and sleepiness signals Session 4 : Awareness of the night/bed/sleep association Session 5 : Awareness of emotions and thoughts related to sleep Session 6 : Awareness of possible alternatives Session 7 : Awareness of one's relationship to sleep Session 8 : Awareness of future benefits
224255383|NCT07202481|DIETARY_SUPPLEMENT|Psyllium powder|Psyllium powder: soluble fiber gel forming, provided at 20 g per day (two doses of 10 g each)
224255384|NCT07202481|DIETARY_SUPPLEMENT|Fructooligosaccharide|Fructooligosaccharide: prebiotic, provided at 20 g per day (two doses of 10 g each)
224255385|NCT07201935|BEHAVIORAL|Cold Water Immersion|Participants will complete 14 daily sessions of cold-water immersion exposure.
224255386|NCT07201935|BEHAVIORAL|High Heat Sauna|Participants will complete 14 evening sessions in the high heat sauna
224255387|NCT07202390|OTHER|20 mg metallic gold microparticles (72.000 particles, 20-40 µm) will be injected into the knee joint using 2 mL hyaluronic acid.|20 mg metallic gold microparticles (72.000 particles, 20-40 µm) will be injected into the knee joint using 2 mL hyaluronic acid.
224255388|NCT07202390|OTHER|Intervention|20 mg metallic gold microparticles (72.000 particles, 20-40 µm) will be injected into the knee joint using 2 mL hyaluronic acid.
224255389|NCT07201012|DIAGNOSTIC_TEST|Sampling of suspected skin lesions (in accordance with good care practices).|Sampling of suspected skin lesions (in accordance with good care practices) and swabbing of skin microbiota.
224255390|NCT07201012|GENETIC|Constitution of a biobank|Collection of previously excised cutaneous and deep tumour lesions kept in a public or private pathological anatomy facility for these patients
224255391|NCT07200856|OTHER|Nocturnal Blood Pressure Dipping|Patients will be classified as dippers (≥10% nocturnal BP fall) or non-dippers (\<10% nocturnal BP fall) based on 24-hour ambulatory blood pressure monitoring.
224255392|NCT07201298|DEVICE|Ray-Tracing Guided LASIK|A form of LASIK where Ray-Tracing technology is used to create the surgical profile for treating the cornea.
224255393|NCT07201298|DEVICE|Keratorefractive Lenticule Extraction (KLEx)|A form of corneal refractive surgery utilizing a femtosecond laser to create a lens shaped lenticule of corneal tissue that is removed through a small corneal incision.
224255394|NCT07201298|DEVICE|WaveFront Optimized LASIK|A form of LASIK where the corneal treatment profile is modified to decrease induced Spherical Aberration.
224255395|NCT07201298|DEVICE|Topography Guided LASIK|A form of LASIK where a corneal topography of the cornea is used to create the surgical profile for treating the cornea.
224255396|NCT04975698|BIOLOGICAL|HST-NEETs|HST-NEETs are manufactured from an autologous peripheral blood or MNCs via apheresis collection and will be administered as a single intravenous (IV) infusion of 2x10\^7/m\^2 cells between 3 Days and 7 Days post-ASCT.
224255397|NCT04975698|BIOLOGICAL|Bone Marrow Transplant|Day 0 is the day of bone marrow transplantation.
223772477|NCT03765307|DEVICE|Boston Scientific Alair System|The Bronchial Thermoplasty is performed using Boston Scientific Alair System in three sessions at least three weeks apart between each session: Right Lung Lobe, Left Lung Lobe, Right Up Lobe and Left Up Lobe.
224255398|NCT07200492|OTHER|Facial serum application|The trained technician will apply the 0.3g-0.4g investigational products on the subject's half face.
224255399|NCT07200492|OTHER|Forearm serum application|The trained technician will apply the (2mg±0.1mg)/cm² investigational products on the subject's forearm.
224322333|NCT06705998|DRUG|BAR502 single dose|"Single oral doses of BAR 502/placebo will be administered as film-coated tablets, in the morning of Day 1, with 150 mL of water, after an overnight fasting of at least 8 hours.~BAR 502 film-coated tablets are available at dose strengths of 3, 10 and 50mg. A maximum of 4 dose levels are pre-planned (3, 10, 30 and 60mg)."
224322334|NCT06705998|DRUG|Placebo single dose|Matching BAR 502 placebo film-coated tablets will be given to 2 out of 8 subjects in each cohort using the same regimen as outlined for the active study treatment
223674179|NCT04139200|BEHAVIORAL|Type 1 physical activity tele coaching intervention|A) Education about the importance of PA. During a one-to-one interview with the coach motivation, self-efficacy, barriers, favorite activities and strategies to become more active are discussed. B) Step counter providing direct feedback. C) A smartphone with a project-tailored application. The application provides automated coaching by displaying an activity goal (number of steps) and feedback on a daily basis. The feedback comes with a graphical presentation. Patients' targets are automatically revised weekly. The aim is to progressively increase the PA during the 12 weeks period and maintain afterwards. D) Telephone contacts triggered in the case of non-compliance with wearing the step counter, failure to transmit data, failure to progress or change in medication. Coaches are alerted by a note at the coaches' backend to take contact with the patient if needed.
223772478|NCT05062668|PROCEDURE|cataract operation and istent|a cataract operation and the placement of one or two iStent inject or inject W at the same time
223772479|NCT05062668|PROCEDURE|cataract operation only|Patients have a classic postoperative treatment after cataract.
223772480|NCT05573516|PROCEDURE|Open reduction and internal fixation|unicortical fully threaded 4mm screws will be used as positional screws after completely reducing the fracture
223772481|NCT05147857|DEVICE|Dilapan s|"is an osmotic hygroscopic dilator produced from a patented Aquacryl® hydrogel that guarantees consistency of action.~It is a rigid gel rod that increases in volume by absorbing fluids from the cervical canal, so it gradually dilates the cervix The thin 4 mm rod can expand up to 15 mm over a 12-24 hours period. This allows it to dilate and soften the cervix gradually."
223772482|NCT05147857|DRUG|Misoprostol|Misoprostol is a synthetic prostaglandin medication used to prevent and treat stomach and duodenal ulcers, induce labor, cause an abortion, and treat postpartum bleeding due to poor contraction of the uterus. Misoprostol is taken by mouth when used to prevent gastric ulcers in persons taking NSAIDs.
223674180|NCT04139200|BEHAVIORAL|Type 2 physical activity tele coaching intervention|A) Education about the importance of PA. During a one-to-one interview with the investigator, patients will receive a personal goal (expressed in steps/day), based on their individual exercise capacity. B) A step counter providing direct feedback. C) A smartphone with a project-tailored application. The application receives the step data of the patient and asks on a weekly basis about the patient's change in medication. The application does provide a graph showing the steps the patient took and presents a general activity plan including their personal goal (which stays the same throughout the entire intervention period). D) Telephone contacts triggered in the case of change in medication. Coaches are alerted by a note at the coaches' backend to take contact with the patient if needed.
223674181|NCT01876433|DRUG|Mirabegron|
223674182|NCT01876433|DRUG|Placebo|
223674183|NCT03848156|OTHER|biopsy|Biopsy of nasal polyp for RNA sequencing
223674184|NCT00786851|DRUG|Lenalidomide and Dexametasone|Lenalidomide will be supplied as 5 mg and 25 mg capsules for oral administration.Dexamethasone (Soldesam 0.2%) will be supplied as 20 mg liquid for oral administration (1 bottle = 20 mg; daily dose = 2 bottles = 40 mg).
223772483|NCT05082194|PROCEDURE|balance with open and closed eyes|"The UNTERBERGER TEST. The subjects performed the test once with their eyes open and then with their eyes closed. The participant's task was to assume a standing position with legs apart at hip-width and then walk in place (50 steps).~Static and dynamic balance testing on the Biodex SD balance platform. Moreover, both during the Unterberger functional test and the tests on the Biodex SD balance platform, the muscle tone was assessed in the subjects using the Luna EMG device. Before starting the tests, surface electrodes were glued to the patient's body (according to the SENIAM procedure). Five surface electrodes were used, consisting of three channels. They were placed on the abdomen of the right sternocleidomastoid muscle, two more were placed on the left longus colli muscle, and one reference electrode on the right shoulder process of the scapula. After each completed test, an ongoing test report was generated."
223772484|NCT02017691|DEVICE|Near Infrared Spectroscopy|If crSO2 is \<10th centile, CPAP via face mask will be started or oxygen support will be increased depending SpO2, on the infants breathing efforts and the heart rate. If crSO2 remains stable \>10th centile, or if crSO2 is \> 90th centile CPAP via face mask will be stopped or FiO2 will be reduced depending on SpO2, the infants breathing efforts and the heart rate.
224255400|NCT07196904|DEVICE|Ultrasonic Device (Piezosurgery)|Mandibular impacted third molar extraction performed with an ultrasonic surgical device. The piezosurgery device was used exclusively for the osteotomy (bone removal) stage, while conventional rotary instruments were still used for tooth sectioning when required. This selective approach aimed to evaluate whether piezosurgery could reduce surgical trauma compared to full rotary techniques.
224255401|NCT07196904|DEVICE|Conventional rotary instruments|Mandibular impacted third molar extraction performed entirely with conventional rotary instruments. Both bone removal and tooth sectioning were conducted using high-speed rotary instruments under continuous irrigation. This served as the control arm to compare with the ultrasonic-assisted technique.
224255402|NCT07200271|PROCEDURE|Arthroscopic reconstruction surgery|Arthroscopic reconstruction with allograft, in which a tendon (generally from a tissue bank) is used to reconstruct the ligaments. This technique is performed through small incisions using arthroscopy.
224255403|NCT07200271|PROCEDURE|Open surgery|Open surgery consists of the modified Broström-Gould technique, which allows for the reconstruction of damaged ligaments using the patient's own tissues through an incision on the lateral side of the fibula. This technique has shown satisfactory functional results.
223772485|NCT02017691|DEVICE|Pulse-oximetry|If SpO2 remains \<10th centile, respiratory support via face mask will be started or FiO2 will be increased depending on the infants breathing efforts and the heart rate. If SpO2 remains stable or if SpO2 is \>90th centile respiratory support via face mask will be stopped or FiO2 will be reduced depending on the infants breathing efforts and the heart rate.
223772486|NCT03242499|DRUG|Lovastatin|Lovastatin 80mg or placebo use for 48 weeks.
223772487|NCT03242499|DRUG|Placebo|placebo for 48 weeks
223772488|NCT00219934|DRUG|Antiretroviral therapy|HAART therapy
223772489|NCT01324375|DEVICE|heat pain test (Modular Sensory Analyzer, Somedic AB, Horby, Sweden).|pain during heat test preoperatively
223772490|NCT00993785|DEVICE|Costar Coronary Stent Delivery System|
224322335|NCT06705998|DRUG|BAR502 multiple doses|The 2 multiple ascending doses selected based on results of study part A will be administered to 2 study cohorts of 10 subjects each. The IMP will be orally administered once a day from Day 1 to Day 14, at 8:00±1 h, for a total of 14 doses.
224322336|NCT05404321|OTHER|Establishment of ex vivo breast cancer organoid models|This study includes 2 steps: The constitution of a collection of tumor and blood samples and the analysis of the ex vivo response of the tumor samples to the treatments for the development of functional tests and the research of predictive biomarkers of this response
223674185|NCT02696187|BEHAVIORAL|KOLwebben|KOL-webben will be introduced to all people with COPD during their ordinary visits to the primary care center during a 3 months period. The introduction to KOL-webben will be tailored to each person's needs and include 1) registration of the patient at KOL-webben 2) showing and discussing specific content on KOL-webben (e.g. movies with exercises if the person needs exercise training) chosen to meet the needs of the individual 3) giving a card (A5 format) with address to KOL-webben, user information and references to chosen content on KOL-webben. All patients will also receive a pedometer.
223674186|NCT03989726|PROCEDURE|AF ablation|AF ablation includes pulmonary vein isolation and/or voltage and fractionation guided ablation
223674187|NCT02274701|OTHER|Holistic Needs Assessment|An assessment completed by the patient in cancer care. It is recommended that this assessment is completed at key points in the care pathway, such as at diagnosis, post treatment and beginning of end of life care. The aim of this assessment is to allow the patient to discuss their most important needs as identified by them. The clinician will take any appropriate action. This may range from listening to the patient to referring to another member of the multi-disciplinary team.
223674188|NCT05299788|OTHER|Active external warming|In this study, methods used routinely in the Intensive Care Unit (ICU) such as cotton blankets and socks were used for the control group. In addition to the cotton blankets and socks, electric blankets were used for the patients in the intervention group. In accordance with the literature, the temperature of the electric blanket was set at 38 °C (Celsius) at the beginning and increased to a maximum of 40-41 °C based on the patient's body temperature .
223674189|NCT05299788|OTHER|Ice application|In the intervention group, an ice pack was applied to the incision site for pain control in addition to active external warming. Ice packs at 0-5 °C with external dimensions of 160 × 91 × 34 mm and a filled weight of 363 g that were kept in the fridge were used for ice application. To prevent direct contact of the ice pack with the patient's skin, the ice pack was wrapped in a thin cotton sheath.
223674190|NCT06000176|DEVICE|Optical coherence tomography angiography|diagnostic test OCTA macula and ONH
223674191|NCT00054171|DRUG|aminolevulinic acid hydrochloride|
223674192|NCT02329366|OTHER|Specimen Collection|. In this study, diabetic patients undergoing DFU debridement under the standard of care will be asked for their permission to collect the debrided tissue for use in scientific research.
223674193|NCT02653885|OTHER|Red red cell distribution width|Results from hemogram
223674194|NCT04810572|DIETARY_SUPPLEMENT|Composition with Silymarin|"Volunteers will receive supplementation for 180 days. They took 4 capsules daily. Two capsules in the morning and two capsules at night.~There will be blood and feces collection at zero time, before supplementation, after 30, 90 and 180 days from the beginning of supplementation."
223674195|NCT04810572|DIETARY_SUPPLEMENT|Low-mineral composition without Silymarin|"Volunteers will receive supplementation for 180 days. They took 4 capsules daily. Two capsules in the morning and two capsules at night.~There will be blood and feces collection at zero time, before supplementation, after 30, 90 and 180 days from the beginning of supplementation."
223674196|NCT02388282|DEVICE|diaphragm ecography|recording of diaphragm ecography
223674197|NCT03574324|DRUG|TPF+CCRT|Patients receive Neoadjuvant Docetaxel (75mg/m2 on day1 03:30-04:30) and cisplatin (75mg/m2 on day 1-5 10:00-22:00) and 5-FU(750mg/m2 on day 1-5 22:00-10:00) every 21days for three cycles followed by concurrent cisplatin (100mg/m2 on day1 10:00-22:00)every 21 days for three cycles during radiotherapy
223674198|NCT03574324|DRUG|CCRT+PF|Patients receive concurrent cisplatin (100mg/m2 on day1 10:00-22:00)every 21 days for three cycles during radiotherapy followed by adjuvant cisplatin (80mg/m2 on day 1-5 10:00-22:00) and 5-FU(800mg/m2 on day 1-5 22:00-10:00) every 21days for three cycles
223674199|NCT01649479|BIOLOGICAL|Antiphospholipid antibody tests|Each patient will be tested for antiphospholipid antibodies.
223674200|NCT01649479|BIOLOGICAL|Thrombophilia bloodwork|"Bloodwork will be drawn up for:~* antithrombin, protein C, protein S~* Factor V Leiden polymorphisms (F5 1691A)~* prothrombin 20210A gene polymorphism (F2 20210A)~* JAK2 617F Mutation~* Homocysteine~* Factor VIII"
223674201|NCT01649479|OTHER|Psychiatric evaluation|During this consultation, the Mini International Neuropsychiatric Interview will be used to screen for psychiatric symptoms. Should the latter be detected, a further consult with a psychiatrist or a psychologist will be organized; this second consult will include the Mood Disorder Questionnaire (MDQ), the Beck Depression Inventory (BDI), the Inventory for Depressive Symptomatology - Clinician (IDS-C) and the Structured Clinical Interview for Disorders (SCID, DSM-IV).
223674202|NCT04862195|DEVICE|Attune™|Software as a medical device
223674203|NCT04862195|DEVICE|Cerena™|Software as a medical device
223674204|NCT05112276|OTHER|Diet|A review has been undertaken to both identify specific bacteria associated with cardiometabolic risk factors and food items that have been shown to affect such bacteria in a beneficial direction. The intervention diet will include a variety of food items e.g. vegetables, fermented vegetables, fermented dairy products and cereal products. The control diet is based on a Swedish Average Diet
223674205|NCT05157919|BEHAVIORAL|ICU-Care|The mobile app intervention, ICU-CARE, will consist of 3 separate education modules, each approximately 5-7 minutes in length: (Module #1) ICU orientation, (Module #2) Symptom Assessment, (Module #3) Symptom Management
223674206|NCT04173364|DRUG|Ropivacaine 0.5% Injectable Solution|Injectable solution of ropivacaine 0.5%
223674207|NCT04173364|DRUG|Ropivacaine 0.1% Injectable Solution|Dilution of ropivacaine to the concentration of 0.1%
223674208|NCT00376818|BEHAVIORAL|exercise intervention|All participants will convene once per week for 8 weeks for a 90-minute session that will be based on yoga principles for a stress reduction.
223674209|NCT00376818|OTHER|educational intervention|A 15-minute educational session on a particular topic (mind-body connection; fight or flight response; relaxation response; the science and philosophy of yoga; the science of meditation; sleeping well; mindfulness; the healer within - how to harness your innate healing potential).
223674210|NCT00376818|OTHER|physiologic testing|Both patients and family caregivers will complete Perceived Stress Scale (PSS) and Beck Anxiety Inventory (BAI) questionnaires.
223674211|NCT00376818|OTHER|management of therapy complications|Brain Cancer module-20 questionnaire to assesses problems specific to brain tumor.
223674212|NCT00376818|BEHAVIORAL|mind-body intervention procedure|"Meditation practice in this study will consist of 15 minutes of body scan to completely relax the body from head to toe and will be followed by 15 minute silence during which the study participants will maintain awareness of their breath, bodily sensations and thoughts as they spontaneously arise. The remainder of the class will be devoted to a group discussion of personal reflections and challenges."
223674213|NCT00376818|PROCEDURE|Measurement of stress-related hormones|Measurements of stress-related hormones: Stress hormones cortisol, dehydroepiandrosterone sulfate (DHEAS) and melatonin will be measured in saliva because their levels in saliva accurately reflect blood levels (Carlson et al, 2004). The non-invasive saliva collection method by cotton swabs (Salivette® by Sardstedt Inc.) will be used in this study.
223674214|NCT01992159|DRUG|Romosozumab|Administered by subcutaneous injection
223674215|NCT01992159|DRUG|Placebo|Administered by subcutaneous injection
223674216|NCT00354185|DRUG|tanespimycin|Given IV
224255404|NCT07201441|BEHAVIORAL|Smart Nursing Based on the Health Cloud Platform|On the day of surgery, ensure that the patient or their family members have followed the hospital's official account and bound the patient's information. Through the intelligent cloud platform on the mobile device, they can query the patient's inpatient information, such as examination reports and details of inpatient expenses, and also consult and communicate about the patient's condition.
224255405|NCT07200531|BEHAVIORAL|Psychotherapy|6-week psychotherapy group intervention
224255406|NCT07202429|DEVICE|MRI|"Multiparametric MRI of adnexal lesions, including conventional sequences, diffusion-weighted imaging (DWI) with apparent diffusion coefficient (ADC) measurement, and dynamic contrast-enhanced (DCE) MRI. Imaging findings were evaluated using the O-RADS MRI scoring system."
224255407|NCT07200310|OTHER|Non-invasive audiologic and vestibular assessments|standardized, single-session test battery performed in a sound-treated clinical laboratory. Procedures include tympanometry, tympanometry with simple maneuvers (Valsalva/Toynbee) for Eustachian tube function, pure-tone audiometry, otoacoustic emission (OAE) testing, acoustic reflex thresholds, and cervical vestibular evoked myogenic potentials (cVEMP) with EMG monitoring for adequate sternocleidomastoid activation. Testing is non-invasive, takes \~60 minutes, and is conducted under routine clinical practice conditions. No investigational drugs, devices, or biospecimens are used.
224255408|NCT07202442|PROCEDURE|Emergency General surgery patients with robotic approach for the surgery|vPrimary Endpoint: The proportion of procedures performed robotically versus laparoscopically or via laparotomy for selected indications. Secondary Endpoints: A 5% change in perioperative morbidity, laparotomy rate, LOS, critical care admission rate, and operative time. Included Pathologies (for patients eligible for laparoscopy) : Acute cholecystitis with predictors of intraoperative difficulty. Bowel obstruction requiring bowel resection (in presence of CT signs of visceral compromise: poor enhancement of bowel loops, pneumoperitoneum). Complicated acute diverticulitis with perforation and peritonitis. Penetrating abdominal trauma with hemodynamic stability requiring surgery (e.g., bowel resection-anastomosis). Right or left colectomy for other etiologies. Splenectomy in hemodynamically stable or embolized patients.
224255409|NCT07202325|BEHAVIORAL|Resilience Training for Veterans (REST-V)|A 6-week self-help intervention tailored for post-9/11 Veterans offering guidance on cognitive-behavioral self-management coping strategies plus when and how to access recovery support services including mental health treatment. Materials are sent once a week for 6 weeks, and participants can opt to receive weekly reminder text messages or up to 3 brief telephone support calls.
224255410|NCT07202325|OTHER|Usual resources|Standard printed resource/treatment information provided in VHA usual care to post-9/11 Veterans. Covers similar domains as the intervention materials and provides information on a variety of VA and community resources for Veterans. Materials are sent once.
224255411|NCT07200258|PROCEDURE|Vestibular Incision Subperiosteal Tunnel Access (VISTA)|"Remote incisions will be performed in the test group. The VISTA technique will be performed as described by Zadeh (Zadeh, 2011).~After administration of local anaesthesia, an access incision will be made in the vestibulum to permit elevation of a broad subperiosteal tunnel. A specialized periosteal elevator will be used to create the tunnel by dissecting beneath the periosteum, extending at least one tooth beyond the recession defects and under each papilla, without surface incisions at the gingival margin. The connective tissue graft will be inserted and positioned beneath the tunnel through the incision. A coronally anchored suturing technique will be used. This technique mean placing a horizontal mattress suture using a 6.0 suture with at approximately 2 to 3 mm apical to the gingival margin of each tooth, covering the width of the tooth. If keratinized gingiva is present, the suture will be placed within the band of keratinized gingiva."
224255412|NCT07200258|PROCEDURE|Modified Coronally Advanced Tunnel (MCAT)|In the MCAT group, the surgical approach will follow the technique described by Aroca et al. (2010). After sulcular incisions made without releasing incisions, a full-thickness muco-periosteal tunnel will be carefully elevated beyond the mucogingival junction and under adjacent papillae using tunneling instruments. The root surfaces will be planed, and a subepithelial connective tissue graft will be harvested from the palatal donor site and inserted into the tunnel. Suspended horizontal mattress sutures will be placed around the contact points to advance and stabilize the flap in a position coronal to the cemento-enamel junction (CEJ) (previous composite at the contact point if necessary). Postoperative care will be identical to that described for the VISTA group.
224255413|NCT07200817|DIAGNOSTIC_TEST|Neutrophils to Lymphocytes and Platelets ratio (N/LP)|The Neutrophils to Lymphocytes and Platelets ratio (N/LP) will be measured
223674217|NCT00354185|DRUG|belinostat|Given IV
223674218|NCT00354185|OTHER|laboratory biomarker analysis|Correlative studies
223674219|NCT00354185|OTHER|pharmacological study|Correlative studies
223674220|NCT03088462|OTHER|Psychiatric management|Routine treatment for bipolar disorder with a psychiatrist including prescription of medications and potentially other treatments such as individual, group or light therapy.
223674221|NCT03088462|BEHAVIORAL|Psychosocial treatment|Any psychosocial treatment participant is involved in such as individual therapy, group therapy, or support groups.
223674222|NCT03088462|BEHAVIORAL|LiveWell Program|Participants work with a health coach to facilitate use of a smartphone application designed for people with bipolar disorder.
223674223|NCT03377088|OTHER|Rose oil|Rose oil will be given as the intervention in this study, an over-the-counter agent that can be commonly found in retail stores. It will be delivered as 2 drops 50% rose oil in water on a cotton ball within 20 cm of the patient's face for 30 minutes.
223772491|NCT05138380|DEVICE|Foot orthoses|"Manufacturer: Foot Science International.~Material: High grade thermoformable closed-cell polyolefin foam (medium density)~Arch support: inbuilt.~Covering: fabric~Provided by: Study Practitioner: Registered physiotherapist \> 2 years musculoskeletal experience will be trained to prescribe the insert according to the prescription algorithm.~Where: Administered via telehealth~When and how much: Week 0 to 1: one telehealth session with study practitioner to fit one pair of pre-fabricated orthoses Week 1 to 2: Follow-up session for questions if required~Tailoring: Orthoses are fit to comfort. Lengths (S, S, M, L, XL, XXL) (dependent on participant's shoe size). Hardness = Medium density. Modifications: can be cut to size to assist in fit using the shoes original sock liner as a guide, by participants using standard scissors. Heat molding: optional.~Adherence: Adherence recorded with diary/ log book (insert wear time)"
223772492|NCT05138380|DEVICE|Flat shoe insert|"Manufacturer: Foot Science International.~Material: High grade thermoformable closed-cell polyolefin foam (medium density)~Arch support: no.~Covering: fabric~Provided by: Study Practitioner: Registered physiotherapist \> 2 years musculoskeletal experience will be trained to prescribe the insert according to the prescription algorithm.~Where: Administered via telehealth~When and how much: Week 0 to 1: one telehealth session with study practitioner to fit one pair of pre-fabricated orthoses Week 1 to 2: Follow-up session for questions if required~Tailoring: Fit to comfort. Lengths (S, S, M, L, XL, XXL) (dependent on participant's shoe size). Hardness = Medium density. Modifications: can be cut to size to assist in fit using the shoes original sock liner as a guide, by participants using standard scissors. Heat molding: optional.~Adherence: Adherence recorded with diary/ log book (insert wear time)"
223772493|NCT00073671|BEHAVIORAL|Cognitive-behavioral prevention program|Cognitive-behavioral prevention program includes 8 weekly and 6 monthly group sessions.
223772494|NCT00073671|OTHER|Usual care|Participants receive usual care
223772495|NCT05329740|DRUG|Methylprednisolone Injection|All eligible patients randomised to the glucocorticoid group will receive intravenous Methylprednisolone for 3 days after surgery. The dosage is 2mg/kg/d on post-operative day 1, 1mg/kg/d on post-operative day 2, and 0.5mg/kg/d on post-operative day 3. The daily dosage will be administered with two injections (12h interval).
223772496|NCT02714452|BEHAVIORAL|Person-centred care|Person-centred and thriving promoting care
223772497|NCT04595487|PROCEDURE|Left ventricular septal pacing|"In the LVSP group, instead of placing the standard RV lead, the commercially available 3830 Select Secure (Medtronic, Minneapolis, USA) lead is introduced via standard transvenous approach and positioned against the right ventricular side of the IVS by using the commercially available non-deflectable septal delivery sheath (C315, Medtronic, Minneapolis, USA) under fluoroscopic guidance. Subsequently this pacing lead is advanced/screwed through the interventricular septum until the left ventricular septum is reached. Accurate lead position at the left ventricular septum will be determined anatomically using fluoroscopy, and electrically by evaluating local electrograms and changes in paced electrocardiogram morphology.~In case of unsuccessful lead positioning in the left ventricular septum, the Select Secure lead may be placed at the His bundle region (natural conduction system of the heart) or in the right ventricle according to the physician's discretion."
223772498|NCT04595487|PROCEDURE|Right ventricular pacing|In the RVP group, the ventricular pacing lead is positioned in the right ventricle.
223772499|NCT00654524|DRUG|gonadotropin-releasing-hormone agonist (GnRHa) - Goserelin|The patient will be managed with GnRH-a injection (Goserelin 3.6mg) every 4 weeks for 6 months plus add-back therapy (Caltrate With Vitamin D 600mg p.o. q.d.\& Livial 1.25-2.5mg p.o. q.d.) if needed.
223772500|NCT01890200|DRUG|Peginterferon alfa-2a|conventional treatment of Hepatitis C
223772501|NCT01890200|DRUG|Ribavirin|conventional treatment of Hepatitis C
223772502|NCT01890200|DRUG|TCM-700C|An add-on drug to conventional treatment of Hepatitis C
223772503|NCT01890200|DRUG|Placebo|Placebo, without acting ingredient.
223772504|NCT00779766|BIOLOGICAL|HPV GSK 580299 vaccine|Subjects were planned to receive three doses of the study vaccine administered intramuscularly according to a 0, 1, 6 month vaccination schedule.
223772505|NCT00779766|BIOLOGICAL|Placebo control|Subjects were planned to receive three doses of the placebo control administered intramuscularly according to a 0, 1, 6 month vaccination schedule.
223674224|NCT03377088|OTHER|Almond Oil|Almond Oil has been shown in limited studies to act as a placebo for pain control when compared to Rose Oil. This subtly sweet oil will be used to ensure the patient always receives a smell, and maintains blinding.
223674225|NCT06260527|DRUG|ARTS-011|Single ascending dose (SAD): 3mg, 10mg, 20mg, 40mg, and 60mg. Multiple ascending dose (MAD): 10mg QD, 20mg QD, and 40mg QD X 7 days. Food effect study: single dose of ARTS-011 under the fasting and high-fat meal.
223674226|NCT06260527|DRUG|Placebo|Multiple ascending dose (MAD): 10mg QD, 20mg QD, and 40mg QD X 7 days. Multiple ascending dose (MAD): 10mg QD, 20mg QD, and 40mg QD X 7 days.
223674227|NCT05809739|DEVICE|STYLAGE Hydro|3 sessions of injections (J0, J14 and J28)
223674228|NCT01849081|DEVICE|CPAP|Subjects in the intervention arm will be treated with continuous positive airway pressure (CPAP) device at night.
223674229|NCT01849081|BEHAVIORAL|LIfestyle|Subjects will undergo 12 weeks of dietary counseling.
223674230|NCT03473028|PROCEDURE|transabdominal ultrasound guided embryo transfer|400 female with body mass index more than 30undergo transabdominal ultrasound guided embryo transfer
223674231|NCT03473028|PROCEDURE|transvaginal ultrasound guided embryo transfer|400 female with body mass index more than 30 undergo transvaginal ultrasound guided embryo transfer
223674232|NCT04440371|COMBINATION_PRODUCT|Tacrolimus 0.1% ointment twice daily plus NBUVB 3 times weekly|Tacrolimus ointment plus phototherapy NBUVB (Tacrolimus arm)
223674233|NCT04440371|COMBINATION_PRODUCT|Calcipotriol/Betamethasone ointment plus NBUVB|Calcipotriol/Betamethasone ointment once daily plus NBUVB 3 times weekly
223674234|NCT01600742|DRUG|Vorinostat|"Run-in phase:~WBRT: 2.5 Gy per fraction per day, day 1 through day 5 every week for 15 days, to a total dose of 37.5Gy.~Vorinostat: 400 mg/day during WBRT, day 1 through day 7 every week till one day after WBRT.~Randomization phase:~WBRT: 2.5 Gy per fraction per day, day 1 through day 5 every week for 15 days, to a total dose of 37.5Gy.~Vorinostat or placebo: 400 or 300 mg/day during radiation therapy (based on the results of run-in phase), day 1 through day 7 every week till one day after WBRT."
223772506|NCT02432794|PROCEDURE|delay phenomenon by arteriographic approach|we improve the microvascularization of the gastric fundus occluding the right and left gastric artery, and splenic artery two weeks before surgery by arteriography
224255414|NCT07201480|BEHAVIORAL|Mortality Salience Prompts|"This intervention implies giving two prompts to participants, in a written format, while asking them to write out answers to the given prompts. The first prompt is: Please briefly describe the emotions that the thought of your death arouses in you. The second prompt is Jot down, as specifically as you can, what you think will happen to you physically as you die and once you are physically dead."
224255415|NCT07201480|BEHAVIORAL|Dental Pain Prompts|"This intervention implies giving two prompts to participants, and requesting that participants write out their answers to these prompts. The first prompt is: Please briefly describe the emotions that the thought of dental pain arouses in you. The second prompt is: Jot down, as specifically as you can, what you think happens to you physically as you experience dental pain and once you have physically experienced dental pain."
223772507|NCT03850886|DIETARY_SUPPLEMENT|Niacinamide Oral Tablet|Nature's Life Niacinamide 1000 mg
223772508|NCT03850886|DRUG|Antidiabetic|Metformin or Sulphonylurea
223772509|NCT02197546|OTHER|Acupuncture & acupressure|Bilateral acupuncture with indwelling fixed needles 1.5 mm length with subsequent acupressure by the parents
224255416|NCT02572713|PROCEDURE|Biofluid samplings|Biofluid samplings (blood, saliva, and cerebrospinal fluid (CSF)
224255417|NCT02572713|PROCEDURE|Tissue samplings|Tissue samplings (skin, colon, submandibular gland)
224255418|NCT02572713|DRUG|DaTSCAN™|
223674235|NCT01600742|DRUG|Placebo|"Randomization phase:~WBRT: 2.5 Gy per fraction per day, day 1 through day 5 every week for 15 days, to a total dose of 37.5Gy.~Vorinostat or placebo: 400 or 300 mg/day during radiation therapy (based on the results of run-in phase), day 1 through day 7 every week till one day after WBRT."
224255419|NCT05813847|DRUG|local anaesthetic injection|Local infiltration of study drug
224255420|NCT05312554|DEVICE|Iris FIT™ PFO closure system|Patients who meet all the inclusion criteria and don't meet the exclusion criteria will be implanted with the Iris Patent foramen ovale occluder according to the INSTRUCTIONS for Use (IFU)
224255421|NCT03708133|DRUG|Nifurtimox (Lampit, BAYA2502)_Test|Orally intake of 1 \*120mg new formulation tablet as test treatment
224255422|NCT03708133|DRUG|Nifurtimox (Lampit, BAYA2502)_Reference|Orally intake of 1 \*120mg current clinical formulation tablet as reference treatment
224255423|NCT06513052|OTHER|Commercial cocoa|daily intake of a beverage made with 8 grams of commercial cocoa low in flavanols, dissolved in 200 mL of low-fat, lactose-free milk
224255424|NCT06513052|OTHER|High flavonols Cocoa|Daily intake of a beverage made with 8 grams of cocoa high in flavanols, dissolved in 200 mL of low-fat, lactose-free milk.
223674236|NCT00434395|DRUG|MOA-728|
223674237|NCT01205581|BIOLOGICAL|Fluzone High Dose Vaccine|Two doses of Fluzone HD will be administered to children with leukemia, solid tumor, or HIV.
223674238|NCT01205581|BIOLOGICAL|Fluzone Standard Dose Vaccine|Two doses of Fluzone Standard Dose Vaccine will be administered to children with leukemia, solid tumor, or HIV.
223772510|NCT03946761|DEVICE|Cancer goggle system|-The cancer goggle system is being used as a non-significant risk device
223772511|NCT02124291|DEVICE|Mechanical Assisted Hatching|The technique of assisted hatching using partial zona pellucida dissection to create an artificial opening of the zona pellucida of early cleaved embryos. While the embryo is stabilized by a holding pipette of micromanipulator, the zona pellucida is pierced with a microneedle that is pushed tangentially through the space between the zona pellucida and blastomeres until it pierces through the zona pellucida again.
223772512|NCT00436306|BEHAVIORAL|Individualized Intervention|Individualized Intervention is a computer-based, stage-matched, tailored intervention to promote the use of dual methods of contraception for STD and unplanned pregnancy prevention.
223772513|NCT00436306|BEHAVIORAL|Computer-based contraceptive information|Contraceptive method information is provided on a computer.
223772514|NCT03063541|DRUG|Acetylsalicylic acid|100 mg daily as one tablet
223772515|NCT03063541|OTHER|intensive blood pressure control|Patients are encouraged to seek any therapy to have a systolic blood pressure of 120 or below. They will be provided with a blood pressure measurement device and are advised to control blood pressure daily.
223772516|NCT02894203|BEHAVIORAL|Mindfulness|
224255425|NCT04647760|BEHAVIORAL|JOIN for ME|JOIN for ME is an empirically tested, effective weight management program for children ages 6-12 years.The curriculum includes 16 weekly in person sessions followed by 4 biweekly and 4 monthly maintenance sessions for a 10-month program. Weekly meetings are attended by the parent/caregiver and child, and occur at a location within their community setting (public housing or patient-centered medical home). Each session is 60 minutes and led by a certified Community Health Worker, with a private weigh-in for each dyad prior to the start of each session. Key behavioral targets include self-monitoring of dietary intake and physical activity, limiting LESS foods, limiting screen time, and weekly attendance. A family-based incentive structure is incorporated into the program such that parents/caregivers reinforce their children for achieving goals. Due to the COVID-19 pandemic, in-person sessions will be conducted virtually until it is safe to resume in-person group sessions.
224255426|NCT04471779|OTHER|Disclosure of APOE genotype|Information about risk of Alzheimer's disease will be given to participants based on their APOE genotypes, in addition to Latino ethnicity and family history.
223772517|NCT02894203|BEHAVIORAL|Yoga|
223772518|NCT01412424|DRUG|Octreotide capsules|Octreotide was provided in hard gelatin capsules.
224255427|NCT05700383|BEHAVIORAL|GetActive-Fitbit|GetActive-Fitbit is an adaptation of the original GetActive-Fitbit program, a mind-body program for the unique needs of individuals with chronic musculoskeletal pain that incorporates activity skills to help individuals improve all aspects of physical function. The GetActive-Fitbit sessions address mind-body skills (e.g., mindfulness, deep breathing, self-compassion), walking skills (e.g., step goals, quota-based pacing), and skills to change thinking (e.g., identify unhelpful thoughts about pain and activity, challenging thoughts). The format is a 10-week program delivered in-person with weekly group sessions and home practice of skills and walking.
224322337|NCT07135349|DRUG|BW-20507 with/without NUC|• BW-20507 with/without NUCs will be administrated for 48 weeks
224322338|NCT07135349|DRUG|BW-20507 with/without NUC, Peg-IFNa|• BW-20507 with/without NUC will be administrated for 48 weeks, Peg-IFNa will be administrated.
224322339|NCT06706817|COMBINATION_PRODUCT|Tezepelumab|IMP. Subcutaneous injection. Unit dose strengths 210 mg.
224255428|NCT05700383|BEHAVIORAL|Healthy Living for Pain|Healthy Living for Pain is an active intervention that will be dose, attention, and time matches to the GetActive-Fitbit program. Healthy Living for Pain is an adaptation of the Health Enhancement Program, developed by Dr. Vranceanu and colleagues from Stony Brook, with adjustments for patients with chronic musculoskeletal pain. The Healthy Living for Pain sessions provide educational information on chronic musculoskeletal pain, the role of sleep and nutrition, physical activity, healthcare management, medication use, and social connection. The format is a 10-week program delivered in-person with weekly group sessions and home practice journaling.
224255429|NCT06837220|BEHAVIORAL|Enhanced Courage to Quit|"Participants will engage in a version of the smoking cessation treatment Courage to Quit that has been optimized for implementation in community behavioral health clinics. The group will run over a period of 3 months, where participants will learn behavioral and cognitive skills for smoking cessation and/or reduction. Special attention will be given to the unique needs of the community, such as technology options or more flexible treatment models. The goal of this intervention is to prove that it is feasible to implement, and can create enhanced engagement and smoking outcomes for adults who smoke (AWS) and have fewer socioeconomic resources."
223674239|NCT05170568|BIOLOGICAL|T cell injection targeting CD7 chimeric antigen receptor|The subjects, who sign the informed consent forms and been screened by inclusion/exclusion criteria, will be assigned into 0.5 × 106, 2.0 × 106 and 4.0 × 106 CAR-T/kg groups in order of sequence. And the subjects will be administered once.
224255430|NCT06217939|DRUG|Early hydrocortisone|"For the Early Hydrocortisone group, 50 mg of hydrocortisone in 10 ml of normal saline will be given as an intravenous bolus, then 200 mg of hydrocortisone in 100 ml of normal saline will be given as continuous intravenous infusion in 24 hours for 2 consecutive days (total 250 mg in day 1 and 200 mg in day 2).~After completion of the study drugs for 2 days, the study drug will be discontinued without tapering."
224255431|NCT06217939|DRUG|Normal saline placebo|"For the Standard Care group, a bolus of 10 ml of normal saline will be given, then 100 ml of normal saline will be given as continuous intravenous infusion in 24 hours for 2 consecutive days as a sham control.~After completion of the study drugs for 2 days, the study drug will be discontinued without tapering."
224255432|NCT06217939|DRUG|Open-label hydrocortisone|An open-label 50 mg of hydrocortisone given as an intravenous bolus followed by intravenous hydrocortisone 200 mg/day given as continuous infusion or divided bolus administration is suggested to be commenced in both study arms if the hemodynamic goal of the patient is not reached despite the dose of norepinephrine or epinephrine ≥ 0.25 mcg/kg/min at least 4 hours after the initiation of the vasopressors as recommended by the guideline. The study drug in each arm will be discontinued once an open-label hydrocortisone is initiated. Capillary or venous blood glucose will be tested at least every 6 hours for 2 days then at least once daily or more as appropriate for the first 7 days as a part of the study protocol.
224255433|NCT06284525|DEVICE|Ankle resistance and biofeedback|An ankle exoskeleton will provide stance phase resistance and a plantar pressure biofeedback system will encourage late stance push-off.
223674240|NCT06515509|PROCEDURE|immediate implant placement with or without loading|immediate implant placement with or without loading
223674241|NCT06181279|PROCEDURE|Individualized PEEP group|Individualized PEEP group: Recruitment Maneuver (RM) is performed first. In pressure control mode, PEEP and airway plateau pressure are increased to 20 cmH2O and 35 cmH2O at a rate of 5 cmH2O every 30s, and driving pressure is maintained at 15 cmH2O throughout. Subsequently, in volume-controlled ventilation mode, PEEP decreases from 20 cmH2O to 4 cmH2O at gradient of 2 cmH2O, and each PEEP level is maintained for 30s. The PEEP corresponding to the lowest driving pressure is the individualized PEEP we need. If multiple PEEP levels showed the same lowest driving pressure, the lowest PEEP value as the individualized PEEP. The above procedures are performed three times during the surgery (5 minutes after intubation,5 minutes after the beginning of pneumoperitoneum, and 5 minutes after the end of pneumoperitoneum).
223674242|NCT06181279|PROCEDURE|Fixed PEEP group|After the same RM, PEEP is fixed at 8 cmH2O.
223674243|NCT02425072|DEVICE|NovoTTF-100A plus chemotherapy|NovoTTF-100A System with Physician's Choice Chemotherapy
223674244|NCT04921098|PROCEDURE|Diode Laser Cyclophotocoagulation|A handpiece (G probe) is used to deliver the diode laser energy with a wavelength of 810 nm.
223674245|NCT01713387|DRUG|Gemcitabine, S-1|Dose of gemcitabine and S-1 and treatment schedule
223674246|NCT04961970|DRUG|oxaliplatin , fluorouracil, and leucovorin|administration of oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries
223674247|NCT04961970|DRUG|gemcitabine and cisplatin|administration of gemcitabine and cisplatin via vein
223674248|NCT00531674|DIETARY_SUPPLEMENT|fortified milk-based beverage|Fortified with multiple vitamins and minerals (1 RDA). Identifical dose and formulation as other supplements for women.
223674249|NCT00531674|DIETARY_SUPPLEMENT|Sprinkles|Powder with multiple vitamins and minerals (1 RDA). Identifical dose and formulation as other supplements for women.
223674250|NCT00531674|DIETARY_SUPPLEMENT|tablets|Multiple vitamins and minerals (1 RDA). Identifical dose and formulation as other supplements for women.
223674251|NCT00531674|DIETARY_SUPPLEMENT|Fortified milk-based pap|Fortified with multiple vitamins and minerals (1 RDA). Identifical dose and formulation as other supplements for children.
223674252|NCT00531674|DIETARY_SUPPLEMENT|Sprinkles|Powder with multiple vitamins and minerals (1 RDA). Identifical dose and formulation as other supplements for women.
223674253|NCT00531674|DIETARY_SUPPLEMENT|Syrup|Multiple vitamins and minerals (1 RDA). Identifical dose and formulation as other supplements for women.
223674254|NCT03663738|BEHAVIORAL|mobile app NOVAME|The training program is divided into 3 periods of 21 days, where each day the patient receives a new formation pill. At the end of one of these periods there will be a week of review in which the patient will receive reminders of the contents that he has already received. These pills will help the patient to acquire healthy lifestyle habits and improve the control of the disease. The length of the program is 84 days, and once completed, the patient can repeat or intensify efforts in the areas he considers and continue to have access to the virtual coach. Patients assigned to the intervention group will receive a brief structured explanation on how to use the application and its contents.
223674255|NCT02812303|OTHER|Centralized support for population health management activities|
223674256|NCT03007108|OTHER|blood withdrawal|
224255434|NCT03844815|DRUG|Decitabine|"Decitabine will be administered intravenously at a dose of 20mg per day for 10 days during Cycle 1 (28 day cycle)~Decitabine will be administered intravenously at a dose of 20mg per day for 10 days of Cycle 2 (28 day cycle).~Decitabine will be administered intravenously at a dose of 20mg per day for 5 days of each 28 day maintenance cycle"
223674257|NCT02840084|DEVICE|Aspen(TM) Ultrasound System|"Two transducers per breast are applied. There will be 10 30 minute sessions, with 2 sessions per week for five weeks. The transducers will be placed on the medial and lateral positions of the affected breast, and then rotated to the superior and inferior aspects, and finally directly over the nipple-areolar complex. Following treatment, the affected breast will be massaged and bandaged per the Aspen Rehabilitation protocol, and the patient will be provided with home exercises as part of the Aspen Rehabilitation Technique.~The treated breast(s) will be examined both prior to and immediately following each treatment session. To evaluate safety, any adverse events such as swelling, redness, or pain will be assessed. To determine efficacy, any change in the Baker Grade level will be assessed by physical examination. The breasts will be photographed prior to treatment at each visit to assist in evaluation of any visible change in the breasts."
223674258|NCT02278471|DRUG|Polypill (atorvastatin, amlodipine, losartan, and hydrochlorothiazide)|
223674259|NCT02669277|DRUG|IVIG prepared by minipool technology|Drug: To demonstrate the efficacy of new product IVIG prepared by minipool technology as assessed by Bleeding Score and platelet count at 3 days, 1 week, 2 weeks and 4 weeks.
223674260|NCT02669277|DRUG|standard IVIG product|to compare efficacy and safety with the minipool IVIG
223674261|NCT02599948|OTHER|no intervention|
223674262|NCT02177487|DRUG|Telmisartan/hydrochlorothiazide|
224255435|NCT03844815|DRUG|Venetoclax|Venetoclax administered orally on days 1-21 of cycle 1, cycle 2 and maintenance (28 day cycles). Dose levels will be assigned at time of enrollment anywhere from 100mg-400mg. Dose escalation will follow the 3+3 study design.
224255436|NCT06228625|BEHAVIORAL|Conventional Exercise Group|"* Wand Exercises (Shoulder flexion, abduction, extension, external, internal rotation \*10 rep.)~* Codmann Exercises (In each direction with front-back, right-left, clockwise and counterclockwise movements \*10 rep.)~* Finger Ladder (flexion and abduction directions \* 10 rep.)~* Strengthening Exercises (Shoulder flexion, abduction, extension, external, internal rotation \*10 rep).~* Posterior, anterior and inferior capsule stretching ,pectoral muscle stretching \* 10 rep."
224255437|NCT06228625|BEHAVIORAL|Body Awareness Training Group|"* Supine: Body scan, contraction-relaxation exercises, strength recovery exercises combined with sound, stretching exercises, cross and star stretching.~* Sitting: Teaching the correct body alignment while sitting, exercise to restore the correct body alignment,~* Standing: Weight bearing exercises within stability limits, midline descent and elevation exercises, midline rotation exercises, wave motion, pushing movement combined with oblique weight bearing."
224255438|NCT06228625|BEHAVIORAL|Rehabilitative Game Exercise Group|"* Cone Knockout: The game requires touching the cones that appear alternately on the right and left within one minute.~* Space Pong: It is required to play by hitting the ball with the right or left hand. It requires only upper extremity use and has seven abductions. Scoring is based on the ball hit.~* Reaction: It is a game that requires touching the green dots that appear on the screen within a certain period. The points received vary depending on the speed of touching the dots. Points are lost when the red dots are touched.~* Whack A Male: The player has 3 rights, and it requires using the upper extremity to hit the moles that come out of 5 holes at different times. A mole with a thorn on its head and a bomb should not be hit. Before the spiny mole emerges, a red light appears in the hole where it will emerge."
224255439|NCT04807426|OTHER|Multi Sensory stimulation exercises|Multi Sensory stimulation exercises:Identification tasks will be given to a blindfolded patient. Which includes recognizing shapes, sizes , textures ,Identifying heights , hardness , weight discrimination .Difficulty will be added by increasing the objects to be identified. Joint angle perception training will be started with one joint perception and will advance to multiple joints position perception. Task Oriented Exercises: Patient will perform upper limb functional activities such as Reaching for objects, putting up and down an object, hand to mouth activity, combing hair, folding piece of cloth grasp and release activity, opening a jar, putting beads in jar and writing letters or draw something will be done. Complexity is added by increasing speed of task performance. Conservative Management:Passive stretching exercises for paretic upper extremity muscles .Stretchings will be applied for 30 sec with 30 sec rest, 10 repetitions for1 set.
224322340|NCT06709469|BIOLOGICAL|Autologous CD19/CD22 CAR T cells|A total of two doses of autologous CD19/CD22 CAR T cells (first dose of up to 0.75x106/kg fresh cells), and a second infusion of unfrozen cells (same dose) if there has been no ≥ grade 1 cytokine-release syndrome (CRS) in the next 72 h; intravenously.
223674263|NCT00640835|DRUG|Buprenorphine/naloxone Film Strip|Buprenorphine/naloxone dosed between 4/1 mg to 32/8 mg once a day for 12 weeks by sublingual route
223674264|NCT00640835|DRUG|Buprenorphine/naloxone Film Strip|Buprenorphine/naloxone dosed between 4/1 mg to 32/8 mg once a day for 12 weeks by buccal route
223674265|NCT00664027|DRUG|RTA 402 (Bardoxolone Methyl)|Stratum 1: 25, 75, 150mg/day, orally, 28 consecutive days Stratum 2: 25 mg/day, orally, 28 consecutive days followed by 75 mg/day, orally, 28 consecutive days
223674266|NCT01191879|OTHER|Blood test|Blood test
223674267|NCT02142010|DRUG|paclitaxel liposome injection plus cisplatin|Paclitaxel liposome injection 80 mg/m2, given on days 1, 8,15 and 22 of a 28-day cycle. Cisplatin 25 mg/m2, given on days 1, 8 and 15 of a 28-day cycle, for 4 cycles(4 months)
223674268|NCT00671359|DRUG|TR-701 600mg|TR-701 600mg
223674269|NCT04934631|OTHER|Recording of CBT-ED session.|Therapists will deliver treatment as usual (CBT-ED) to eating disorder patients. Therapy session will be audio recorded.
223674270|NCT04934631|OTHER|Assessment of CBT-ED clinician competence.|Independent raters will assess CBT-ED competence using the Cognitive-Behavioural Therapy Scale for Eating Disorders (CBTS-ED).
223674271|NCT00677703|OTHER|Daily Text Messages|"Text message reminders to take oral contraception daily:~Each text message will be a short educational message listing the benefits of contraceptive use and providing instructions for avoiding common medication errors."
223674272|NCT01186497|DRUG|Rabeprazole sodium: Treatment E|The contents of 2 rabeprazole sprinkle capsules equivalent to 10 mg rabeprazole sodium mixed with a tablet vehicle suspension (Treatment E) on Day 1.
223674273|NCT01186497|DRUG|Rabeprazole sodium: Treatment C|The contents of 2 rabeprazole sprinkle capsules equivalent to 10 mg rabeprazole sodium sprinkled on 1 tablespoon of applesauce (Treatment C) on Day 1.
223674274|NCT01186497|DRUG|Rabeprazole sodium: Treatment D|The contents of 2 rabeprazole sprinkle capsules containing 10 mg rabeprazole sodium mixed with 5 mL (1 teaspoon) of formula milk (Treatment D) on Day 1.
223674275|NCT01186497|DRUG|Rabeprazole sodium: Treatment A|The contents of 2 rabeprazole sprinkle capsules equivalent to 10 mg rabeprazole sodium mixed with a strawberry-flavored vehicle suspension (Treatment A) on Day 1.
223674276|NCT01186497|DRUG|Rabeprazole sodium: Treatment B|The contents of 2 rabeprazole sodium sprinkle capsules equivalent to 10 mg rabeprazole sodium sprinkled on 1 tablespoon of plain yogurt (Treatment B) on Day 1.
223674277|NCT01453192|DRUG|Raltegravir|Introduction of Raltegravir 2 days after renal transplantation within an antiretroviral regimen without ritonavir boosted antiprotease
223674278|NCT01408329|DEVICE|CVAC Device (Cyclic Variations in Altitude Conditioning)|A hypobaric hypoxia chamber
223674279|NCT01759134|OTHER|Post discharge formula|Babies will be given either materna sensitive or similac neosure
223674280|NCT02632903|DRUG|Zoledronic acid|
223674281|NCT01407731|GENETIC|protein expression analysis|
223674282|NCT01407731|GENETIC|western blotting|
224255440|NCT04807426|OTHER|Task Oriented Exercises|"Task Oriented Exercises: Patient will perform upper limb functional activities such as Reaching for objects, putting up and down an object, hand to mouth activity, combing hair, folding piece of cloth grasp and release activity, opening a jar, putting beads in jar and writing letters or draw something will be done. Complexity will be added by increasing speed of task performance.~Conservative Management:Passive stretching exercises for paretic upper extremity muscles . Stretchings will be applied for 30 sec with 30 sec rest, 10 repetitions for1 set."
224255441|NCT04807426|OTHER|Task-oriented exercises and Multisensory stimulation Exercises|"Multi Sensory stimulation exercises:Identification tasks will be given to a blindfolded patient. Which includes recognizing shapes, sizes , textures ,Identifying heights , hardness , weight discrimination .Difficulty will be added by increasing the objects to be identified. Joint angle perception training will be started with one joint perception and will advance to multiple joints position perception. Task Oriented Exercises: Patient will perform upper limb functional activities such as Reaching for objects, putting up and down an object, hand to mouth activity, combing hair, folding piece of cloth grasp and release activity, opening a jar, putting beads in jar and writing letters or draw something will be done. Complexity will be added by increasing speed of task performance.~Conservative Management:Passive stretching exercises for paretic upper extremity muscles . Stretchings will be applied for 30 sec with 30 sec rest, 10 repetitions for1 set."
224255442|NCT04721834|DEVICE|Low-intensity Extracorporeal Shockwave Therapy|Low intensity shockwave energy would be delivered to stimulate angiogenesis in corporal tissue. Therapy would be delivered through a linear probe in 6 sessions. It would be conducted as a day procedure.
224255443|NCT04721834|DEVICE|Sham Therapy|Same device as the active treatment arm would be used, with the addition of sham probe which block all shockwaves.
224255444|NCT05212350|PROCEDURE|Total pancreatectomy|Patients randomized to receive total pancreatectomy at the time of transection of the pancreas will undergo completion total pancreatectomy according to each Institution's operative standards.
224255445|NCT05212350|PROCEDURE|Pancreatic anastomosis|Patients randomized to receive pancreatic anastomosis at the time of transection of the pancreas will undergo pancreatico-jejunosomy or pancreatico-gastrostomy according to each Institution's operative standards.
224255446|NCT05504902|DEVICE|Vibrotactile coordinated reset|The purpose of this study is to test the efficacy of vibrotactile coordinated reset stimulation on human subject participants with Advanced stage Parkinson's disease
223674283|NCT01407731|OTHER|laboratory biomarker analysis|
223674284|NCT04535167|DRUG|PF-07304814|PF-07304814 is an anti-viral, formulated for intravenous delivery
224255447|NCT00348543|PROCEDURE|laser treatment|
224255448|NCT01539096|PROCEDURE|tDCS: noninvasive brain stimulation|TDCS is a method of noninvasive stimulation of the brain. Using electrodes placed in saline-soaked sponges, low level of direct current (1mA) is delivered over the scalp. This intervention is considered safe and noninvasive because it does not involve implantation or injection or any skin penetration. In the present study, tDCS will be delivered for 1 hr each day for 3 days a week for 5 weeks in conjunction with constraint-induced movement therapy for the affected hand.
223674285|NCT04535167|DRUG|Placebo|Placebo will be formulated for intravenous delivery
223674286|NCT01208831|DRUG|LDE225|
223674287|NCT00978432|DRUG|RAD001|10 mg/day for Part 1 of the trial
223674288|NCT00978432|DRUG|LBH589|40 mg on Monday, Wednesday and Friday weekly for Part 1 of the trial
223674289|NCT00978432|DRUG|Doublet (RAD001 and LBH589)|RAD001 7.5 mg by mouth daily and LBH589 15 mg by mouth on Monday/Wednesday/Friday during Part 2.
223674290|NCT03329781|DIETARY_SUPPLEMENT|BCM-95|Consuming 1 capsule of BCM-95 per day.
223674291|NCT03329781|DIETARY_SUPPLEMENT|Placebo|Consuming 1 placebo capsule per day
223674292|NCT04618770|DEVICE|Triathlon PSR Tibial Insert|The Triathlon PSR Tibial Insert is intended to be used as a component in primary TKA and is designed to reduce rotational constraint at deep flexion.
223674293|NCT02732717|OTHER|ultrasound (observation)|"Important sonographic indices are to be collected from 11-14 weeks, 16-18 weeks, 22-24 weeks, 30-32 weeks and 37-39 weeks,including crown-rump length, nuchal translucency, amniotic fluid, umbilical artery flow, middle cerebral artery flow,ductus venous flow. It is observational.~Conditions as below are thought abnormal: discordance of crown-rump length more than 20%, discordance of nuchal translucency more than 20%, either of twin with abnormal amniotic fluid (polyhydramnios or oligoamnios), either of twin with abnormal umbilical artery flow (elevated resistance index, absent or reverse diastolic flow), either of twin with abnormal middle cerebral artery flow (more than 1.5Mom), either of twin with abnormal ductus venous flow (absent or reverse a-wave)."
223674294|NCT05202132|DIAGNOSTIC_TEST|Questionnaire|A 3 item validated questionnaire assessing masticatory function
223674295|NCT05202132|DIAGNOSTIC_TEST|Chewing gum test|The test is based on the ability of a subject of mixing a two colour chewing gum with 20 masticatory cycles. Mixing of the two colour chewing gum will be assessed as variance of hue in a scanned image of the flattened chewing gum. The method has been validated in independent studies.
223674296|NCT00470665|DRUG|Rapamune|
223674297|NCT03682575|OTHER|Enrollment|All infants whose families consent will be enrolled and will all receive the same treatment which included measurements of work of breathing.
223674298|NCT03458793|BEHAVIORAL|Group walking and group educational workshops|"The experimental group will take part in 12 week intervention consisting of group walking and group educational workshops.~Group walking sessions will run once weekly for up to 45 minutes each in small groups (up to 8-9 people per group) and will be delivered by a trained walk leader once weekly for duration up to 45 minutes per session.~Group educational workshops will be delivered in the form of a group presentation once weekly for up to 45 minutes by the research team (i.e. the PhD student) on a variety of topics focused on the healthy ageing, such as eye hygiene, mental health and well-being, preventing falls, social support, nutritional guides, physical activity recommendations for older adults and other topics"
223674299|NCT05472454|OTHER|Ready-to-eat meals|Participant group to consume ready-to-eat meals in accordance with the DASH diet for a period of 4 weeks.
223772519|NCT06078397|DEVICE|remote programming|Remote programming (RP) is a new type of patient management method after DBS surgery, which allows physicians to understand the patient's movement symptoms and adjust parameters through video conferencing. At the same time, the RP system also includes device checks, medication adjustments, psychological counseling, and other contents. Compared to standard programming that requires going to the hospital, the application of RP can save the burden on patients and their caregivers.
224255449|NCT01539096|BEHAVIORAL|Constraint induced movement therapy (CIMT)|Patients with stroke affecting the hand will receive constraint-induced movement therapy (CIMT) to re-train movements of the affected hand. Training will involve practicing tasks of daily living with qualified personnel. Training will be delivered for 1 hr each day for 3 days a week for 5 weeks. Patients will also be asked to use their affected hand in daily activities at home for 5 hrs a day while wearing a mitt on the unaffected hand.
224255450|NCT01539096|PROCEDURE|Sham tDCS: placebo noninvasive brain stimulation|Placebo set-up for noninvasive brain stimulation will be similar to that for the active tDCS; sponge electrodes would be placed on the scalp and connected to a batter-operated device. Patients will not receive the effective level of direct current as would delivered in active tDCS intervention. But patients will not be able to decipher whether they are receiving active or placebo tDCS.
224255451|NCT01059058|PROCEDURE|MI Paste Plus|A trained staff member from the NW PRECEDENT dental/orthodontic office will give 3 tubes of MI Paste Plus (10% CPP-ACP + 900 ppm Fluoride paste) and instructions to the subject for home use. A pea-sized amount for each arch will be applied 2x/day for 8 weeks. Subjects will apply cream topically to the teeth with their finger or a cotton swab, spread around with their tongue, hold for 1-2 minutes, then expectorate.
224255452|NCT01059058|PROCEDURE|PreviDent Fluoride Varnish|A trained staff member from the NW PRECEDENT dental/orthodontic office will provide a SINGLE application of PreviDent fluoride varnish (22,600 ppm Fluoride) to the subject. The total dosage will be 0.5 mL.
224255453|NCT01059058|PROCEDURE|Normal Home Care|Subjects will receive non-prescription fluoride toothpaste (1100 ppm Fluoride) and oral hygiene instructions. The dosage will be 1/2 inch strip of paste 2x/day for 8 weeks. Subjects will apply paste to a toothbrush and brush teeth thoroughly for at least 1 minute then expectorate.
224255454|NCT01442558|DRUG|Bupivacaine|Bupivacaine 5 mg/cc with adrenaline 5 mcg/cc will be injected with complete spread of the drug around nerves.
224255455|NCT04791813|OTHER|Alginate impressions , Photographic data and panoramic radiographs .|Upper and lower alginate impressions will be poured and dental casts produced and converted to 3D digital cast using a 3D scanner-(3Shape )-the 3D data will be imported to a revers modeling software . Also Photographic data using Canon750 camera and panoramic radiographs to be taken.
224255456|NCT03351296|DRUG|LV5FU2|LV5FU2 (Folinic Acid D, L 400 mg/m² day 1, 5FU 400 mg/m² IV bolus, 5FU 2400 mg/m² 48 hours continuous infusion)
224255457|NCT03351296|DRUG|Streptozocin|streptozotocin 800 mg/m² day 1 every 14 days
224255458|NCT03351296|DRUG|Capecitabine|Capecitabine 750 mg/m² twice daily, days 1-14
224255459|NCT03351296|DRUG|Temozolomide|temozolomide 200 mg/m² once daily, days 10-14, every 28 days
224255460|NCT03351296|DRUG|Bevacizumab|bevacizumab 5 mg/kg every 14 days
224255461|NCT02164435|PROCEDURE|Renal Denervation (EnligHTN™) Renal artery ablation with the EnligHTN™ Renal Denervation System.|
223674300|NCT01171508|DEVICE|Wrist-Actigraph - Octagonal Basic Motionlogger, Ambulatory monitoring Inc, New York, USA|Wrist-Actigraph to be worn on the non-dominant arm on day 0-3-17 of the study.
223772520|NCT06078397|DEVICE|standard programming|Programming refers to a series of methods that set the parameters of the IPG after the implantation of DBS, and adjust the device parameters based on the patient's symptoms during subsequent follow-up to maintain the efficacy of electrical stimulation.
223772521|NCT00367263|DRUG|Alvesco (Ciclesonide) 160 ug/day|
224255462|NCT02577653|OTHER|Posturographic evaluation|Subjects will undergo CDP testing using the modified Clinical Testing of Sensory Integration in Balance (mCTSIB) protocol. Subsequently, subjects will be asked to stand first on the right leg and then on the left leg with eyes open. Finally, subjects will be asked to perform 10 repetition of the squatting movement, with the operator pacing them (telling them when to start and when to stop the movements).
224255463|NCT00611676|DRUG|Venlafaxine|Weeks 0-2: placebo. Weeks 2-3: 75 mg Venlafaxine. Weeks 3-4: 150 mg Venlafaxine. Weeks 4-12: 150-225 mg Venlafaxine.
224255464|NCT01814904|DRUG|colestilan-L|body surface area equivalent (BSAeq) 3 g/day
224255465|NCT01814904|DRUG|colestilan-M|BSAeq 6 g/day
224255466|NCT01814904|DRUG|colestilan-H|BSAeq 9 g/day
224255467|NCT01814904|DRUG|CBPB|
224255468|NCT02017262|BEHAVIORAL|Self-management group|8 weekly sessions of group self-management
224255469|NCT02017262|BEHAVIORAL|Enhanced usual care|Usual care by primary care provider, plus educational pamphlet about depression, list of local mental health resources, and letter for provider advising him/her of depression diagnosis
224255470|NCT01051765|DRUG|irinotecan/cisplatin|irinotecan 130mg/m2 d1 cisplatin 30mg/m2, d1,d2 every 3 weeks
224322341|NCT06709469|BIOLOGICAL|Allogeneic CART-NKG2D cells|A total of up to 3x106/kg allogeneic CART-NKG2D cells divided in three doses of up to 1x106/kg will be infused; intravenously. First infusion of fresh cells, and the 2nd and 3rd infusion of unfrozen cells (same dose) if there has been no ≥ grade 1 CRS (every 48 hours).
224322342|NCT04787627|DEVICE|Power Knee|Powered microprocessor controlled prosthetic knee
223772522|NCT00002312|DRUG|Delavirdine mesylate|
223772523|NCT00002312|DRUG|Zidovudine|
224255471|NCT04599439|DIAGNOSTIC_TEST|Cardiac magnetic resonance imaging|All patients will undergo a cardiac magnetic resonance test to calculate their border zone channel (BZC) mass. This will not be used to decide further interventions, but all the patients will be treated according to standards of care.
224255472|NCT06563024|DEVICE|18F-FET PET/CT|The enrolled patients receive the 18F-FET PET/CT.
224255473|NCT04849650|DRUG|Amisulpride IV|A single 10mg IV dose of Amisulpride given over 1 minute
224255474|NCT04849650|DRUG|Amisulpride Oral Tablet|A single 10mg dose given as an oral tablet
224255475|NCT05840796|DIETARY_SUPPLEMENT|soy protein drink|"The calories oral nutrition supplements were 100 kcal, which included 8.4g of protein and phosphorous was excluded in two oral nutrition supplements formula.~Each participant had two packs of nutrition supplement per day for 4months. The 24-h dietary record, blood pressure, plasma glucose, lipid profile, renal function (estimated glomerular filtration rate, eGFR), inflammatory factor levels were analyzed at the baseline and at the 4th month of the study.~The participants were followed up until the 7th month of the study."
224255476|NCT05840796|DIETARY_SUPPLEMENT|casein protein drink|"The calories oral nutrition supplements were 100 kcal, which included 8.4g of protein and phosphorous was excluded in two oral nutrition supplements formula.~Each participant had two packs of nutrition supplement per day for 4 months. The 24-h dietary record, blood pressure, plasma glucose, lipid profile, renal function (estimated glomerular filtration rate, eGFR), inflammatory factor levels were analyzed at the baseline and at the 4th month of the study.~The participants were followed up until the 7th month of the study."
223674301|NCT01171508|DEVICE|Polysomnograph - Embla A10 (Medcare, Reykjavik, Iceland)|Polysomnography on day 0-3-17 of the study. This is a portable polysomnograph with 16 digital channels for recording of electroencephalogram (EEG), electrooculograph (EOG) and electromyograph (EMG).
223772524|NCT03083496|DRUG|Potassium Oxalate 5%|Prophylaxis, apply uniformly on the teeth, friccion for 10 seconds, wait 10 minutes, remove the gel from the teeth with cotton and abundant water.
224255477|NCT03059186|BEHAVIORAL|Gratitude diary|"The intervention involves keeping a record of three things that the individual feels grateful for during that day.~This can be completed daily, and for the purpose of this study will be completed every evening for the duration of one week."
224255478|NCT00593463|DRUG|Cycloserine|Cycloserine: 500, 675, 750 mg oral capsule may possibly be given
224255479|NCT00593463|DRUG|Diltiazem|Diltiazem: 30, 60, 120 mg oral capsule may possibly be
224255480|NCT00593463|DRUG|Gabapentin|Gabapentin: 100, 200, 400 mg oral capsule may possibly be given
224255481|NCT00593463|DRUG|Isradipine|Isradipine: 5, 10 mg oral capsule may possibly be given
224255482|NCT00593463|DRUG|Naloxone|Naloxone: 0.15 mg/70 kg or 0.2 mg I.M. injection may possibly be given
224255483|NCT00593463|DRUG|Nifedipine|Nifedipine: 5, 10, 20 mg oral capsule may possibly be given
224255484|NCT00593463|DRUG|Placebo|Placebo (sugar pill or microcrystalline cellulose): oral capsule may possibly be given
223772525|NCT03083496|DRUG|Potassium Oxalate 10%|Prophylaxis, apply uniformly on the teeth, friccion for 10 seconds, wait 10 minutes, remove the gel from the teeth with cotton and abundant water.
224255485|NCT00593463|DEVICE|Saline|Saline: I.M. injection may possibly be given
224255486|NCT00593463|DRUG|Verapamil|Verapamil: 30, 60, 120 mg oral capsule may possibly be given
224255487|NCT03682341|GENETIC|endometriosis|patients with or without ovarian endometriosis
224255488|NCT01126203|PROCEDURE|SLT|All eyes will be treated using a commercially available Q-switched Nd:YAG laser (Coherent Selecta 7000, Coherent Inc., Palo Alto , CA, USA) calibrated by the manufacturer. On the day of treatment, IOP will be measured, then one drop of Apraclonidine 1% or Brimonidine 0.2% and pilocarpine 1% or 2% will be instilled. Before the patient is seated at the laser slit-lamp system a proparacaine hydrochloride drop will be instilled in the eye to be treated. A Goldmann goniolens or a Latina SLT or any other goniolens will be placed on the eye to be treated with methyl cellulose 1%. The helium-neon aiming beam is focused onto the pigmented trabecular meshwork. SLT will be performed with approximately 50 applications, a 400um spot size with energies varying from 0.8-1.2 mjoules.
224255489|NCT01126203|PROCEDURE|ALT|All eyes will be treated using Ophthalas 532 Eyelite Laser Photocoagulator (Alcon Surgical, Dallas-Fort Worth, Texas, USA. On the day of treatment, IOP will be measured, then on the day of treatment, IOP will be measured, then one drop of Apraclonidine 1% or Brimonidine 0.2% and pilocarpine 1% will be instilled. Before the patient is seated at the laser slit-lamp system a proparacaine hydrochloride drop will be instilled in the eye to be treated. A Goldmann goniolens will be placed on the eye to be treated with methyl cellulose 1%. The aiming beam is focused onto the anterior portion of the pigmented trabecular meshwork. ALT will be performed to the superior or inferior 180 degrees with \~ 50 applications, a 50um spot size with energies varying from 400-700 mW with 0.1 second duration.
224255490|NCT06553664|DRUG|Treat with Vibrabot capsules for at least 7 weeks|Subjects in the trial group took Vibrabot capsules at least 7 weeks, doses ranging from 2 to 5 capsules orally per week.
224255491|NCT00655590|DRUG|Levitra (Vardenafil, BAY38-9456)|20 mg daily dosing
224255492|NCT00655590|DRUG|Sildenafil|100 mg daily dosing
224255493|NCT00655590|DRUG|Placebo|Matching placebos
224255494|NCT06406608|OTHER|Chemotherapy and targeted-therapy guided by organoid drug sensitivity test|This study conducts drug sensitivity tests on various clinically approved drugs. The most sensitive drug for the patient is selected for treatment. This study aims to evaluate the clinical effectiveness of treatment plans guided by organoid drug sensitivity tests.
224255495|NCT01887652|OTHER|conventional ovarian stimulation|a protocol of ovarian stimulation with recombinant FSH with dose according to age, ovarian size and previous treatment. In patients alder than 35, recombinant LH was added to ovarian stimulation.
224322343|NCT07019064|DRUG|Omaveloxolone|Administered as specified in the treatment arm.
224322344|NCT06718101|DRUG|Lutikizumab|Subcutaneous (SC) Injection
224322345|NCT06718101|DRUG|Placebo|Subcutaneous (SC) Injection
223674302|NCT01171508|DEVICE|Holter monitor - Medilog AR12 (Oxford Instruments, Oxford, England)|Holter monitoring on day 0-3-17 of the study. Measurements are done by superficial skin-electrodes placed after standardised rules from the producer of the device.
223772526|NCT00222287|BEHAVIORAL|Feldenkrais Movement class|
223772527|NCT03161314|PROCEDURE|Strengthening exercises|Conservative physical therapy treatment with home-based strengthening exercises (study 3)
223674303|NCT01171508|PROCEDURE|Urine 6-sulphatoxymelatonin (aMT6s)|Urine sampling for measurement of the primary metabolite of melatonin - 6-sulphatoxymelatonin (aMT6s) will be done on day 0-3-17 of the study. The analysis will be done by a radioimmunoassay.
223674304|NCT01171508|OTHER|Karolinska Sleepiness Scale|Karolinska Sleepiness Scale to measure sleepiness will be filled out twice a day every day of the entire study period of 17 days.
223674305|NCT01171508|OTHER|Visual Analog Scale and 10 point-scales to measure fatigue, general well-being, subjective sleep and pain|Visual Analog Scale and 10 point-scales to measure fatigue, general well-being, subjective sleep and pain will be filled out twice a day everyday of the study period of 17 days.
223674306|NCT01171508|OTHER|Sleep-diary|Sleep-diary to measure subjective sleep quantity will be completed every morning and after every nap in the day.
224255496|NCT01887652|OTHER|individualized ovarian stimulation|After defining cut-off points of anti-mullerian hormone, using a ROC analysis, to discriminate excessive (≥20 oocytes retrieved) and poor response (≤4 oocytes retrieved), a individualized protocol was defined.Mild stimulation using daily doses (112.5 to 150 IU) of recombinant FSH or recombinant FSH combined with recombinant LH supplementation (375 IU total daily dose) were given to patients identified as at risk of excessive and poor response.
223674307|NCT05033002|BEHAVIORAL|Labda Siku Moja stigma reduction intervention|The Labda Siku Moja stigma reduction intervention is a tailored stigma reduction intervention for women living with HIV in Tanzania. It is comprised of five ethnodramas (video stories) culturally and linguistically relevant to the Tanzanian women living with HIV.
223674308|NCT03937544|BIOLOGICAL|CD19 CAR-T CELLS|CD19 CAR-T cells will be administered after completion of the lymphodepletion chemotherapy.
223674309|NCT03937544|DRUG|Cyclophosphamide|Patients will receive lymphodepleting chemotherapy consisting of Cyclophosphamide 250 - 300 mg/m2/day IV(Day -5, Day -4, Day -3 ).
223674310|NCT03937544|DRUG|Fludarabine|Patients will receive lymphodepleting chemotherapy consisting of Fludarabine 25-30 mg/m2/day IV (Day -5, Day -4, Day -3 ).
223674311|NCT06017102|DEVICE|wired magnetic assisted capsule endoscopy|once
223674312|NCT06017102|DEVICE|esophagogastroduodenoscopy|once
223674313|NCT06526975|OTHER|Gamification exercise through a videogame|Different exercises will be performed through a videogame.
223674314|NCT04251676|OTHER|Observational study|Observational study
223674315|NCT03272269|DRUG|IMCY-0098|Small synthetic peptide for SC admin. Solvent: alum hydroxide
223674316|NCT03272269|OTHER|Placebo|Solvent: alum hydroxide
224255497|NCT03827707|BEHAVIORAL|Noise|Noise applied via headphones during 60 min after meal ingestion
224255498|NCT03827707|BEHAVIORAL|Silence|Headphones without sound applied during 60 min after meal ingestion
223674317|NCT05285748|BEHAVIORAL|Self-Paced Intensity Physical Activity|Participants are given a prescription to engage in 150-300 minutes per week of structured exercise with an emphasis on walking. For this study arm, participants are given the explicit recommendation to engage in self-selected intensity PA.
223674318|NCT05285748|BEHAVIORAL|Prescribed Moderate Intensity Physical Activity|Participants are given a prescription to engage in 150-300 minutes per week of structured exercise with an emphasis on walking. For this study arm, participants are given the explicit recommendation to engage in moderate intensity PA consistent with national guidelines.
223674319|NCT06001385|DRUG|Busulfan|Given IV or PO pre-transplant as part of conditioning regimen
223674320|NCT06001385|DRUG|Fludarabine|Given IV pre-transplant as part of conditioning regimen
223674321|NCT06001385|PROCEDURE|PBSC Hematopoietic Stem Cell Transplantation (HSCT)|Peripheral blood stem cell graft is infused from a mismatched unrelated donor on Day 0
223674322|NCT06001385|DRUG|Post-Transplant Cyclophosphamide|"Cyclophosphamide (25mg/kg) is administered on Day 3 and Day 4 post-transplant as an IV infusion over 1-2 hours.~First 20 subjects with a 4-6/8 HLA mismatched unrelated donor will receive an intermediate dose of post-transplant cyclophosphamide of 37.5 mg/kg Day 3 and Day 4 post-transplant."
223674323|NCT06001385|DRUG|Mesna|Mesna is given in divided doses IV 30 min pre- and at 3, 6, and 8 hours post cyclophosphamide.
223674324|NCT06001385|DRUG|Tacrolimus|Tacrolimus is given at a dose of 0.05 mg/kg PO or an IV dose of 0.03 mg/kg of ideal body weight (IBW) starting on Day +5 post-transplant with taper recommended at Day + 90 and finished by Day +180.
223674325|NCT06001385|DRUG|Mycophenolate Mofetil|Mycophenolate mofetil (MMF) is given at a dose of 15 mg/kg three times daily IV or PO from Day +5 to Day +35 post-transplant.
223674326|NCT06001385|OTHER|Patient Reported Outcomes|Survey assessments will be administered to study participants pre transplant, at Day + 100, Day + 180, and Day +365 post transplant.
223674327|NCT06001385|DRUG|Melphalan|Given IV pre transplant as part of conditioning regimen
223674328|NCT06001385|RADIATION|Total-body irradiation|Administered pre-transplant as part of conditioning regimen
223674329|NCT06001385|DRUG|Cyclophosphamide|Given IV pre-transplant as part of conditioning regimen
223674330|NCT06160284|DRUG|Psilocybin|Participants will receive a single dose of psilocybin administered in 20 mg or 25 mg doses depending on the participant's weight: 20 mg (among participants \< 70 kg) or 25 mg (among participants \>70 kg). Participants will be administered psilocybin at CNRU, within 1-2 weeks of the baseline \[11C\]-UCB-J PET.
223674331|NCT06831942|BEHAVIORAL|ASSIP-OA|"ASSIP-OA + TAU~* First session. Narrative interview focusing on the background of the suicidal crisis. The patient receives a psychoeducational text to read and comment on as homework.~* Second session. Video playback. The patient and therapist watch the video recording from session 1 together, periodically pausing the video to comment and add information.~* Third session. Compilation of a written case conceptualization of the individual's vulnerability and triggering events that preceded the suicidal crisis.~* Fourth session. An optional extra session to further train safety strategies.~* Fifth session (optional). Includes one or two close relatives or other support person(s), chosen by the participant. The session focus on how safety measures learned in in ASSIP-OA can be translated into everyday life.~* Standardized letters. therapists will send standardized letters every third month during the first year and biannually during the second year."
223772528|NCT03161314|PROCEDURE|Stretching exercises|Conservative physical therapy treatment with home-based stretching exercises (study 3)
223772529|NCT02722668|DRUG|Fludarabine|Both Arms: 30 mg/m\^2 IV over 1 hour Day -6 to Day -2
223772530|NCT02722668|DRUG|Cyclophosphamide|Arm 1: 50 mg/kg IV over 2 hours Day -6
224255499|NCT03072433|BEHAVIORAL|Counseling Intervention Package|Daily 45 minutes of group teaching for primary caregivers, followed by 45 minutes of supervised play and stimulation with their children for a total of four days. Teaching modules consist of psychosocial stimulation, nutrition and feeding, and water, sanitation and hygiene practices.
224255500|NCT03072433|BEHAVIORAL|Standard of Care|Nutrition and water sanitation and hygiene counseling at any point prior to discharge from hospital as per the local nutrition rehabilitation unit standard of care. In addition, primary caregivers will be stimulated to play with their children in a play area.
224255501|NCT01551498|DIETARY_SUPPLEMENT|Anatabloc Supplement|Product, as mint-flavored lozenges (3 mg anatabine per lozenge), to be taken 3 times each day
224255502|NCT01551498|DIETARY_SUPPLEMENT|Placebo|Placebo, as mint flavored lozenges, to be taken 3 times each day
224255503|NCT06486298|DEVICE|Vacuum Drain and Passive Drain insertion at abdominoplasty surgery|Compare the subcutaneous collection with Vacuum Drain and Passive Drain insertion at abdominoplasty surgery
224255504|NCT01244022|PROCEDURE|colorectal cancer resection|Open radical resection of colorectal cancer, according to oncological principals, depending on the tumor site
224255505|NCT02115347|DRUG|Ertugliflozin 15 mg|Tablet
224255506|NCT01423994|PROCEDURE|pacemaker|"A single or dual chamber pacemaker will be implanted according to the manufacturer's instructions for use with standard techniques.~Either a single or dual chamber pacemaker will be permitted according to local practice unless the patient is in chronic or persistent atrial fibrillation, in which case a single chamber pacemaker will be used. The pacemaker configuration will be at the discretion of the investigator.~Single chamber ventricular pacemakers will be programmed to activity responsiveness off in VVI mode, rates 50-120 bpm.~Dual chamber pacemaker programming will be to DDD mode (50-120) with mode switch on."
224255507|NCT01423994|PROCEDURE|implantable loop recorder|The implantable loop recorder will be programmed for automatic detection using settings of Low Heart Rate \<50 bpm, High Heart Rate \>165 bpm, and Pause \> 3 seconds.
224255508|NCT01776190|DEVICE|UVA1 radiation treatment|
224255509|NCT03600467|DRUG|SEVI-D (Seviteronel in combination with dexamthasone)|"Use of SEVI-D (Serivteronel and dexamethasone) in the treatment of androgen receptor positive solid tumours.~Serivteronel will be administered orally at 450 mg (3 tables) once daily. It will be given in combination with one oral tablet of 0.5 mg tablet of Dexamethosone. SEVI-D will be continuously administered daily while on the study.~Clinical and safety assessments are scheduled every 4 weeks during the study and then every 8 weeks after the end of the safety follow up period of the study."
224255510|NCT05982691|RADIATION|Radiation Therapy|Radiation Therapy(General guideline) Patients will receive radiotherapy after induction chemotherapy or right after diagnosis without diagnosis. The dose and fields of radiation will be according to the histology, presence of dissemination, and response to the induction chemotherapy or radiotherapy. Radiation therapy can be administered using either of photons or protons. When induction chemotherapy is administered, radiotherapy is recommended to be started within 6 weeks from the last chemotherapy.
224255511|NCT03731234|DRUG|Ibrutinib|Ibrutinib in combination to rituximab-CHOP followed by ibrutinib maintenance
224255512|NCT02505347|OTHER|No splint|Can move arm as tolerated with no restrictions on mobility
224255513|NCT02505347|DEVICE|Splint|Wear splint for 6 weeks, only to remove for rehab and personal care
223674332|NCT06831942|OTHER|Treatment as Usual (TAU)|Antidepressant medication, alone or in combination with other types of psychoactive drugs (sedatives/antipsychotics/hypnotics/mood stabilizers) constitute the cornerstone of treatment for suicidal older adults. Persons with serious depression or treatment-resistant depression may be offered electroconvulsive therapy (ECT). Some persons may receive supportive/therapeutic contacts with mental health professionals (nurses/social workers/psychologists) but no psychosocial interventions designed specifically for suicidal older adults are offered as part of ordinary treatment at the participating clinics.
223674333|NCT06369064|OTHER|CVVHD Dialysis parameters|Patients will receive a CVVHD dialysis with a dose of 25ml/kg/h dialysate (100% dialysate), with Fresenius Medical Care multiFiltrate PRO kit and Ultraflux AV1000S filter (polysuflone 1.8m²).Regional anticoagulation with citrate
223674334|NCT06369064|OTHER|CVVHDF Dialysis parameters|Patients will receive a CVVHDF dialysis with a dose of 25ml/kg/h dialysate (50% ultrafiltration, 50% dialysate), with Fresenius Medical Care multiFiltrate PRO kit and Ultraflux AV1000S filter (polysuflone 1.8m²). Systemic anticoagulation with heparine
223772531|NCT02722668|DRUG|MMF|"Both Arms:~Mycophenolate mofetil (MMF) 3 gram/day IV/PO for patients who are ≥ 40 kg divided in 2 or 3 doses. In obese patients (\>125% IBW) 15 mg/kg every 12 hours may be considered. Pediatric patient (\<40 kilograms) will receive MMF at the dose of 15 mg/kg/dose every 8 hours beginning Day -3. MMF dosing will be monitored and altered as clinically appropriate based on institutional guidelines. Patients will be eligible for MMF dosing and pharmacokinetics studies.~Stop MMF at Day +30 or 7 days after engraftment, whichever day is later, if no acute graft versus host disease (GVHD). (Definition of engraftment is 1st day of 3 consecutive days of absolute neutrophil count \[ANC) ≥ 0.5 x 109 /L\]). If no donor engraftment, do not stop MMF."
224255514|NCT00392847|BEHAVIORAL|Promoting Parental Skills and Enhancing Attachment|The first group will receive routine follow-up as currently provided by national community health and social services.
224255515|NCT00392847|BEHAVIORAL|had home visits by community workers during pregnancy|had home visits by community workers during pregnancy to the child's second birthday.
224255516|NCT06087861|RADIATION|External Beam Radiotherapy|Radiation will be delivered by external beam techniques to the tumor and areas of possible microscopic disease at a dose of 30 Gy divided into 5 equal fractions of 6 Gy (administered over a total of 5 to 10 business day
224255517|NCT04702971|DRUG|Flunarizine|The flunarizine will be given per clinical routine
224255518|NCT04702971|OTHER|healthy control|no intervention for healthy control
224255519|NCT00404105|PROCEDURE|PRK|
224255520|NCT00404105|PROCEDURE|LASIK|
224255521|NCT01175018|DRUG|Anakinra|Anakinra 100 mg s.c. daily for 14 days
224255522|NCT01175018|DRUG|Placebo|0.67 ml of NaCl 0.9% solution given subcutaneously daily for 14 days
224322346|NCT03759717|OTHER|Observation|Understanding the biology of skull base tumors will teach the investigators about the genesis and/or mechanisms of treatment resistance. The investigators hope to ultimately identify new targets which will add to the armamentarium by which to treat these tumors.
224322347|NCT05533827|OTHER|Kaleidoscope|Kaleidoscope
224322348|NCT05533827|OTHER|Music|Music
223772532|NCT02722668|DRUG|Sirolimus|"Both Arms:~Adult Dosing: Sirolimus will be administered starting at Day -3 with 8-12 mg oral loading dose followed by single dose 4 mg/day with a target serum concentration of 3 to 12 mg/mL by high-performance liquid chromatography (HPLC) and will be monitored per institutional guidelines. In the absence of acute GVHD sirolimus may be tapered starting at Day +100 and eliminated by Day +180 post-transplantation.~Pediatric Dosing: Sirolimus will be administered starting on Day -3 with an oral loading dose of 10 mg followed by maintenance dosing of 2.5 mg/m\^2/day (Maximum total daily dose of 4mg) as per institutional guidelines. Target serum concentration goals are 3 to 12 mg/mL by high-performance liquid chromatography (HPLC) and will be monitored per institutional guidelines."
224255523|NCT02486900|DEVICE|fMRI-based neurofeedback|During scanning patients will be exposed to picture stimuli (showing alcoholic drinks and life goals) projected on a screen behind the scanner and viewed through a mirror attached on the MRI head coil. In each session patients will be trained to down-regulate/up-regulate activation levels in brain areas that show reliable responses to the alcohol/life goals pictures in a 'localiser' scan. Self-regulation of these brain responses will then be guided by real-time feedback of alcohol/life goals-cue elicited activation, consisting of changes in the visible alcohol/life goals picture (decreasing size = successful down-regulation; increasing size = successful upregulation). Functional MRI data will be acquired in short blocks having a duration of 5-8 minutes.
224255524|NCT04045197|BEHAVIORAL|Relaxation Focused Nursing Care|"Relaxation Focused Nursing Care is composed of HypnoBirthing and Transactional Model. Hypnobirthing Philosophy is based on the laws of mind and aims to create positive thoughts and emotions. The Transactional Model defines stress as a special relationship between the person and the environment. Therefore, Relaxation Focused Nursing Care; positive language, positive environment and reducing stressors."
224255525|NCT00311441|BIOLOGICAL|Tick-Borne Encephalitis vaccine|
224255526|NCT00958334|DRUG|Proellex®|25 mg daily (two 12.5 mg capsules)
224255527|NCT02775812|DRUG|Cisplatin|Given IV
224255528|NCT02775812|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
224255529|NCT02775812|OTHER|Laboratory Biomarker Analysis|Correlative studies
224255530|NCT02775812|BIOLOGICAL|Pembrolizumab|Given IV
224255531|NCT03557541|DIETARY_SUPPLEMENT|Sardine|They received 200gr of canned sardine in olive oil per week (+a common T2D-preventive diet)
224255532|NCT03557541|DIETARY_SUPPLEMENT|Control|They received a common T2D-preventive diet
224255533|NCT06038253|DEVICE|Fibroscan|Fibroscan is device to detect degree of liver fibrosis in NAFLD patients Dexa scan device detect degree of osteoporosis in NAFLD patients
224255534|NCT03442530|BEHAVIORAL|ToPIC|Expanded tobacco cessation counseling for pregnant women.
224255535|NCT03442530|BEHAVIORAL|Tobacco Treatment As Usual (TTAU)|Standard of care tobacco cessation counseling for pregnant women
224255536|NCT04558450|DIAGNOSTIC_TEST|carotid-femoral pulse-wave velocity|early vascular aging tests
224255537|NCT02199873|DRUG|BIIX 1 XX - single rising dose|
223772533|NCT02722668|RADIATION|TBI|Both Arms: 200 cGy on Day -1
223772534|NCT02722668|BIOLOGICAL|Umbilical cord blood cell infusion|Both Arms: Day 0
223772535|NCT02722668|BIOLOGICAL|ATG|Arm 2: 15 mg/kg IV every 12 hours Day -6 to Day -4
224255538|NCT02199873|DRUG|Placebo|
224255539|NCT00028951|DRUG|fibrin sealant|
224255540|NCT00028951|PROCEDURE|surgical wound closure|
224255541|NCT06454864|BEHAVIORAL|Guidelines-based healthy eating|One-on-one phone/virtual counselling from a registered dietitian to change dietary habits to be in line with Canada's Food Guide.
224255542|NCT06454864|BEHAVIORAL|Guidelines-based physical activity|Through a combination of exercise trainer-led in-person and virtual sessions, as well as counselling for independent aerobic exercise, participants will be guided to achieve 150 weekly minutes of moderate-intensity aerobic activity and twice weekly whole-body muscle strengthening.
224255543|NCT06454864|BEHAVIORAL|Stretching exercise|Twice weekly virtual instructor-led whole-body stretching.
224255544|NCT06608537|DRUG|neoadjuvant SCRT followed by Sintilimab plus CAPOX|Patientsreceived neoadjuvant treatment consisting of SCRT (a total of 25 Gy in 5 days) followed by sintilimab (3mg/kg intravenous drip on day 1; every 3-week cycle for two cycles) combined with CAPOX (oxaliplatin 130 mg/m2 intravenous infusion over 2 h on day 1, capecitabine 1000 mg/m2 orally twice daily from day 1-14, in every 3-week cycle for two cycles) 1 week later.
224255545|NCT04731246|OTHER|Video-oculography / Neuropsychological evaluations|Annual evaluation: Medical history; Clinical, Neurological and Neuropsychological evaluations; Video-oculography examination; Inventory of examinations carried out in routine care (brain MRI, cerebral DaTScan, cerebral F-Dopa PET/CT scan, MIBG myocardial scintigraphy, blood test). Follow-up is carried out over 7 years.
224255546|NCT05809973|DIAGNOSTIC_TEST|VISA tool|Validation of VISA
224255547|NCT03590652|DRUG|Ixazomib|4mg PO days 1,8,15 on 28-day cycle
224255548|NCT03590652|DRUG|Pomalidomide|4mg days PO 1-21/28 days
224255549|NCT03590652|DRUG|Dexamethasone|"40mg\*\* PO weekly~\*\* starting dose for age \>75 may be 20mg"
224255550|NCT03590652|DRUG|Daratumumab-Hyaluronidase-Fihj@1,800 Mg-30,000 Unit/15 mL@SUBCUT@VIAL (ML)|1800mg SQ weekly x 8 weeks, biweekly x 8 doses, then monthly
224255551|NCT04762498|BIOLOGICAL|Pegloticase|IV dose of pegloticase q4 weeks co-administered with weekly oral methotrexate
224255552|NCT04762498|DRUG|Methotrexate (MTX)|15 mg oral dose methotrexate administered weekly
224255553|NCT06409455|BEHAVIORAL|Positive Dementia Caregiving in 30 Days|Based on an evidence-based face-to-face Benefit-Finding Intervention, a computer-delivered web-based program supporting 24/7 access without location restriction, is developed. It is a psychoeducation program with an emphasis on strengthening caregivers' coping capacity through skills training and developing a positive way of looking at caregiving challenges. The program consists of reading materials, illustrated texts, caregivers' testimonies, a chatbot, and several interactive apps to facilitate self-learning at the caregiver's own pace.
224255554|NCT06494462|OTHER|virtual reality training|students will watch a video about subcutaneous injection or students will play a about subcutaneous injection by virtual reality glasses
224255555|NCT06148584|BEHAVIORAL|General, status-neutral HIV education|General, status-neutral HIV education
224255556|NCT06148584|DIAGNOSTIC_TEST|HIV self-test kits|HIV self-test kits
224255557|NCT06148584|OTHER|Information about where to receive HIV prevention services|Information about where to receive HIV prevention services
224322349|NCT05533827|OTHER|Virtual reality glasses|Virtual reality glasses
224255558|NCT06148584|BEHAVIORAL|Barber-led peer support group education|Barber-led peer support group education
224255559|NCT06148584|BEHAVIORAL|Facility-based HIV risk reduction counseling|Facility-based HIV risk reduction counseling
223674335|NCT04972630|BEHAVIORAL|Pal-Care|"Pal-Care intervention participants will receive a 6-month intervention based upon the WHO toolkit and it will be delivered by the community health workers (CHWs). The goal of this pragmatic clinical trial is to test and evaluate a home-based palliative care intervention for utilizing community health workers to facilitate the delivery of palliative care to cancer patients in rural India. More details provided in the intervention arms section. After the intervention, clinicians, CHWs and a purposefully selected set of patients/caregivers, who were involved in the Pal-Care will be interviewed to understand their experiences, needs, expectations, barriers, facilitators and strategies."
223674336|NCT04972630|BEHAVIORAL|Control-Usual Care|"The control group will receive usual care palliative services in which the patient or caregiver (by proxy) must visit the Tata Medical Center (TMC) cancer center for care. TMC services include consultation with a multi-disciplinary team (oncologist, nurse, psychologist), a 21-day morphine supply at reduced cost (as morphine is regulated in use),basic training on medication usage, catheter and wound care, other topics as relevant,and psychological counseling. Patients (or their proxy) must return to the cancer center as needed for follow up care and they are provided a 24/7 hotline to call in case of emergency."
223674337|NCT00571584|DRUG|activated recombinant human factor VII|
223674338|NCT02642744|OTHER|Nursing care model|Subjects will be randomized into either the attending nursing model of care vs the standard nursing model
224255560|NCT06148584|DIAGNOSTIC_TEST|Facility-based HIV testing|Facility-based HIV testing
224255561|NCT06148584|OTHER|Information about facility distributed HIV self-test kits|Information about facility distributed HIV self-test kits
224255562|NCT06148584|DIAGNOSTIC_TEST|STI testing|STI testing
224255563|NCT04218331|BEHAVIORAL|JASPER|JASPER is a developmentally anchored behavioral intervention that assumes that communication develops from social interactions in which specific social engagement strategies, symbolic representations, and early communication forms are modeled and naturally reinforced by the adult's responses to the child. The adult referred in this condition is the clinician/therapist.
223674339|NCT02446652|DRUG|Hydralazine/Magnesium|(Hydralazine: 1 oral tablet every 24 hours, 182 mg for rapid acetylators, and 83 mg for low acetylators and Magnesium valproate: orally 30 mg/K weight every 8 hours) starting 1 week prior the first day of the QT
223674340|NCT02446652|DRUG|Placebo|Placebo (orally) starting 1 week before the first day of the QT
223674341|NCT02446652|DRUG|Carboplatin|5 AUC 1 hour/day 1 for every 21 days for 6 cycles
223674342|NCT02446652|DRUG|Paclitaxel|175mg/m2/SC 3hour/day 1 for every 21 days for 6 cycles.
223674343|NCT06131762|OTHER|Active release technique|This include active release technique for 4 weeks
224255564|NCT04218331|BEHAVIORAL|PROMPT|PROMPT is a multidimensional oral-motor approach to speech production disorders.
224255565|NCT02838420|DRUG|Alectinib|Alectinib capsules will be administered orally at a dose of 600 mg BID until disease progression, unacceptable toxicity withdrawal of consent, or death.
224255566|NCT02838420|DRUG|Crizotinib|Crizotinib capsules will be administered orally at a dose of 250 mg BID until disease progression, unacceptable toxicity withdrawal of consent, or death.
224255567|NCT04503278|BIOLOGICAL|CLDN6 CAR-T|administered as an intravenous (i.v.) infusion.
224255568|NCT04503278|BIOLOGICAL|CLDN6 uRNA-LPX/CLDN6 modRNA-LPX|administered as an i.v. injection at protocol-specified intervals.
224255569|NCT06133972|DRUG|Placebo|Placebo s.c. monthly
224255570|NCT06133972|DRUG|Ianalumab|Ianalumab s.c. monthly Ianalumab s.c. quarterly
224255571|NCT06177665|OTHER|Erector Spinae Plane Block|Ultrasound(US)-guided erector spinae plan block(ESP) with 20 ml 0,25% bupivacaine at T4 vertebra level will performe preoperatively to all patients in the ESP group.
224255572|NCT06177665|OTHER|Rhomboid Intercostal Block|Ultrasound(US)-guided rhomboid intercostal block(RIB) with 20 ml 0,25% bupivacaine at T5-T6 vertebra level will performe preoperatively to all patients in the RIB group.
224255573|NCT04773522|DRUG|Talquetamab|Talquetamab will be administered subcutaneously.
224255574|NCT05113641|DIETARY_SUPPLEMENT|Alkalizing Fruit and Vegetables|The weekly deliveries will contain combinations of fresh, frozen, and dried fruits and vegetables, as well as juices and soups which have been selected for their negative potential renal acid load (PRAL) values and shelf-life. All participants will be started at a F+V intake equal to -30 to -40 mEq per day reduction in dietary acid load estimated by the PRAL equation. Participants serum bicarbonate concentration will be measured at 1 month, and at 3 months, those with values \< 22 mEq/L will have their recommended amount of F+V increased to -40 to -50 mEq per day. If a participant's 1- or 3-month serum bicarbonate value exceeds 29 mEq/L, their target dose of F+V in mEq/d will be reduced by 25%.
223674344|NCT06131762|OTHER|Positional release technique|This include positional release technique for 4 weeks
223674345|NCT03452475|DRUG|Arterolane-piperaquine|Arterolane maleate-piperaquine phosphate tablets (37.5 mg/187.5 mg)
223674346|NCT03452475|DRUG|Arterolane-piperaquine+mefloquine|Arterolane maleate-piperaquine phosphate tablets (37.5 mg/187.5 mg) Mefloquine tablets (250 mg)
223674347|NCT03452475|DRUG|Artemether-lumefantrine|Artemether-lumefantrine tablets (20 mg/120 mg)
223674348|NCT02785289|DEVICE|Vaginal swab|Vaginal cell collection will be performed with the two types of indicated swab.
223674349|NCT00075270|DRUG|Paclitaxel|Active Comparator
223674350|NCT00075270|DRUG|GW572016 (Lapatinib)|Oral GW572016 Lapatinib
223674351|NCT02814331|DEVICE|multimodal high-resolution EEG-NIRS|
223674352|NCT03800303|BEHAVIORAL|Family-based treatment|2-week family-based treatment
223674353|NCT02160002|PROCEDURE|Weaning from an incubator at a lower weight (1600 grams)|Infants will be weaned from an incubator at a lower weight (1600 grams)
224255575|NCT05113641|DRUG|Sodium bicarbonate|Study nephrologist will prescribe the oral alkali therapy (sodium bicarbonate) and the medications will be dispensed by the dispensed by the clinic/hospital pharmacies.
224255576|NCT05874375|DEVICE|Urge stimulation|Participants will receive stimulation for 60 seconds, when they feel an urgency.
224255577|NCT05874375|DEVICE|Time limited stimulation|Participant will receive the stimulation as provided in time limited sessions (Range: 15 min - continuous), whenever it suits the participant during the day.
224322350|NCT06882785|DRUG|KarXT|Specified dose on specified days
223674354|NCT02160002|PROCEDURE|Weaning from an incubator at a higher weight (1800 grams)|Infants will be weaned from an incubator at a higher weight (1800 grams)
223674355|NCT04587180|PROCEDURE|Arthroscopic suture-bridge rotator cuff repair|Arthroscopic suture-bridge repair is a widely used and universal surgical method for symptomatic rotator cuff tear patients. It is arthroscopic surgery to reattach ruptured rotator cuff tendons to the original insertion (greater tuberosity) using medial and lateral row anchors.
223674356|NCT01646294|DRUG|YM178 modified release (OCAS)|oral
223674357|NCT01646294|DRUG|YM178 immediate release (IR)|oral
223674358|NCT01070797|BIOLOGICAL|Multi-virus Specific T cells|"Subjects will receive Multivirus specific T cells on one of the following dose levels:~Level One: 5 x 10\^6 rCTLs/m2~Level Two: 1 x 10\^7 rCTLs/m2~Level Three: 2 x 10\^7 rCTLs/m2~Level Four: 5 x 10\^7 rCTLs/m2~If a patient has a partial response (as defined by a 50% fall in viral load) or receives medication (such as steroids) which may affect the persistence or function of the infused CTL they are eligible to receive up to 2 additional doses at the same initial dose. The minimum time between additional doses is 28 days."
223674359|NCT05747547|DIAGNOSTIC_TEST|Central visual acuity|Measurement of central visual acuity using ETDRS (Early Treatment Diabetic Retinopathy Study) optotypes or Snellen optotype chart.
224255578|NCT04617093|DEVICE|PrismaLung+|Overall, up to 60 adult patients will be initiated on ECCO2R using PrismaLung+. A minimum of approximately 15 patients will be treated with ECCO2R using PrismaLung+ as standalone therapy and another minimum of approximately 15 patients will receive ECCO2R using PrismaLung+ in combination with CRRT.
224255579|NCT03744156|BEHAVIORAL|Cognitive Behavioral Treatment-Insomnia|8 session Cognitive Behavioral Therapy for Insomnia. Individualized sessions with a therapist.
224255580|NCT03744156|BEHAVIORAL|Sleep Hygiene Education|8 Session Sleep Hygiene Education. Individualized sessions with a therapist.
224255581|NCT05877963|BIOLOGICAL|Ublituximab|Administered as an intravenous (IV) infusion.
224255582|NCT05877963|DRUG|Placebo|IV infusion
224255583|NCT05574335|DRUG|Siplizumab|Weekly siplizumab doses for a total of 12 weeks
224255584|NCT05153343|DRUG|flonoltinib 25mg|1 case,The starting dose.Take the medicine once on Day1and Day 5-21，and then 14 days per cycle.
224255585|NCT05153343|DRUG|flonoltinib 100mg|Take the medicine once on Day1and Day 5-21，and then 14 days per cycle.
224255586|NCT05153343|DRUG|flonoltinib 150mg|Take the medicine once on Day1and Day 5-21，and then 14 days per cycle.
224255587|NCT05153343|DRUG|flonoltinib 225mg|Take the medicine once on Day1and Day 5-21，and then 14 days per cycle.
224255588|NCT05153343|DRUG|flonoltinib 50mg|Take the medicine once on Day1and Day 5-21，and then 14 days per cycle.
224255589|NCT04007276|DRUG|brimonidine tartrate ophthalmic solution 0.025%|Single dose of brimonidine tartrate ophthalmic solution 0.025% applied as an eye drop to the eye surface.
224255590|NCT04007276|OTHER|sterile balanced saline solution|Single dose of sterile balanced saline solution applied as an eye drop to the eye surface.
224255591|NCT06525649|DRUG|NPT 2042|NPT 2042 is a new drug being developed as an anti-seizure treatment.
224255592|NCT02964039|BEHAVIORAL|Error reduction|During training sessions, a custom-built force-field will exert forces on the legs while participants walk. These forces will push the legs toward mechanically-appropriate mediolateral locations, having the effect of reducing the errors in foot placement that are often present among individuals who have experienced a stroke.
223674360|NCT05747547|DIAGNOSTIC_TEST|Intraocular pressure measurement|Measurement of intraocular pressure using non-contact Canon TX-20P tonometer.
223674361|NCT05747547|DIAGNOSTIC_TEST|Slit lamp examination|Slit lamp examination of the anterior and posterior segment of the eye after pharmacological dilation of the pupil using application of short-time mydriatics (1% tropicamide and 10% phenylephrine).
223674362|NCT05747547|DIAGNOSTIC_TEST|Retinal oximetry|Performing of retinal oximetry with an Oxymap T1 instrument (Oxymap ehf.) paired with a Topcon TRC-50DX retinal camera.
224255593|NCT02964039|BEHAVIORAL|Error augmentation|During training sessions, a custom-built force-field will exert forces on the legs while participants walk. These forces will push the legs away from mechanically-appropriate mediolateral locations, having the effect of amplifying the errors in foot placement that are often present among individuals who have experienced a stroke.
224255594|NCT02964039|BEHAVIORAL|Activity matched control|During training sessions, participants will interface with a custom-built force-field while they walk. The force-field will essentially get out of the way, producing minimal forces on the legs, and having no direct effect on the errors in foot placement that are often present among individuals who have experienced a stroke.
224255595|NCT04530110|DRUG|Fremanezumab|"Participants weighing ≥ threshold will receive Dose A subcutaneously monthly.~Participants weighing \< threshold will receive Dose B subcutaneously monthly.~Subcutaneously monthly, confirmed or adjusted, as appropriate, based on the participant's weight every 3 months."
224255596|NCT05751343|DRUG|TACE-HACI, plus atezolizumab-bevacizumab|transartery chemoembolization and artery infusion of FOLFOX, simultaneously followed by intravenous atezolizumab plus bevacizumab
224255597|NCT04454658|DRUG|ABBV-744|Tablet; Oral
224255598|NCT04454658|DRUG|Navitoclax|Tablet; Oral
224255599|NCT04454658|DRUG|Ruxolitinib|Tablet; Oral
224255600|NCT06382636|BEHAVIORAL|Standard Care|This group will utilize standard care with respect to healthcare provider practices.
224255601|NCT06382636|BEHAVIORAL|Obstetric Prenatal Genetic Testing Engagement Solution (OPUS) AI Chatbot|This group will be exposed to the AI enabled healthcare chatbot.
224255602|NCT05583721|DRUG|[13N]NH3|Ammonia N 13 (a radioactive tracer) will be given per intravenous (IV) injection for diagnostic purposes in conjunction with positron emission tomography (PET) imaging.
224255603|NCT05583721|DRUG|Lexiscan|Given IV prior to PET stress test
224255604|NCT05583721|DIAGNOSTIC_TEST|Positron emission tomography|Participants will complete a onetime PET (stress-rest) myocardial perfusion scan.
224255605|NCT06457906|COMBINATION_PRODUCT|Experimental group (SRS/SRT/Hypo-RT)|The prescription dose of SRS/SRT is 18-22Gy in 1 fraction, 27Gy in 3 fractions and 30Gy in 5 fractions. The prescription dose of Hypo-RT is 40Gy in 8 fraction. The prescription dose could be adjusted if lesions are located in brain stem when treat with SRS/SRT/Hypo-RT.
224255606|NCT06457906|RADIATION|Controled group (HA-WBRT)|The prescription dose of HA-WBRT is 30Gy in 10 fraction.
224322351|NCT06882785|OTHER|Placebo|Specified dose on specified days
223772536|NCT02100007|DRUG|ME-344|"Part 1: ME-344 IV at 10 mg/kg on Days 1, 8, 15, and 22 of each 28-day cycle. Part 2: ME-344 IV at the dose defined in Part 1 on Days 1, 8, 15, and 22 of each 28 day cycle.~Patients will be allowed to continue receiving ME-344 infusions weekly according to the assigned dose level as long as there is clinical benefit to the patient as assessed by the Investigator."
223674363|NCT05747547|DIAGNOSTIC_TEST|Optical coherence tomography and angiography|Performing of optical coherence tomography and angiography with the Spectralis Optical Coherence Tomography Plus (Heidelberg Engineering).
223674364|NCT01549769|DRUG|Bardoxolone Methyl|Oral, once daily
223674365|NCT04896229|OTHER|Talk STEM Familia Treatment Condition|This study has one intervention and two arms: experimental and treatment as usual. Participants randomized to the treatment condition will receive the TSF technology in addition to the vocabulary instruction, monitoring, or resources delivered by English Language Development programs (ELD) and schools. TSF will deliver frequent, brief, dual-language exercises to help families learn, practice and apply SAV words in conversation. Audio-visual lessons will support learning at all literacy levels, regardless of prior familiarity with STEM subjects. The complete TSF tool will contain approximately 72 minutes of video modeling and 12 hours of interactive exercises delivered over 24-weeks in brief, interactive, easy to assimilate lessons.
223674366|NCT05115994|DEVICE|Continous positive airway pressure|
223674367|NCT06191549|COMBINATION_PRODUCT|anodal transcranial direct current stimulation (a-tDCS)|"Stroke participants will be randomly assigned into one of three groups: anodal transcranial direct current stimulation (a-tDCS), sham tDCS (s-tDCS), or control groups (i.e. no brain stimulation). Young and older healthy adults will be randomly assignments into a-tDCS or s-tDCS groups.~Stroke participants in each group will receive a four-week of the assigned brain stimulation combined with visuomotor stepping training and treadmill training"
223674368|NCT02855554|OTHER|Cardiac Magnetic Resonance (CMR) imaging techniques|Evaluation of clinical potential of fast quantitative myocardial tissue characterization using recently emerged CMRI techniques to aid the diagnosis, treatment, and follow up of patients with myocardial diseases.
223674369|NCT03461679|PROCEDURE|Adductor canal block|Single shot block with 0.5% bupivacaine 10mls
223674370|NCT03461679|PROCEDURE|Femoral triangle block|Single shot block with 0.5% bupivacaine 10mls
223772537|NCT02100007|DRUG|Topotecan|Part 1: Topotecan 4 mg/m2 i.v. weekly on Days 1, 8 and 15 of each 28-day cycle. Part 2: Topotecan 4 mg/m2 i.v. weekly on Days 1, 8 and 15 of each 28-day cycle.
224255607|NCT06125678|DIAGNOSTIC_TEST|Small intestinal contrast enhanced ultrasound followed by Computed tomography/Magnetic resonance enterography|First small intestinal contrast enhanced ultrasound shall be done followed by CT enterography or MR enterography
224255608|NCT02418637|OTHER|Worksite screening for DM, HTN and hyperlipidemia|Six monthly visits to worksite to perform screenings
224255609|NCT05538052|DRUG|Tramadol hydrochloride|Supplementary intraligamentary injections deposited in the gingival sulcus of the involved tooth
224255610|NCT05538052|DRUG|Lidocaine Hydrochloride|Supplementary intraligamentary injections deposited in the gingival sulcus of the involved tooth
223674371|NCT03518749|OTHER|1mA tDCS|transcranial direct current stimulation with the intensity of 1mA
223674372|NCT03518749|OTHER|2mA tDCS|transcranial direct current stimulation with the intensity of 2mA
223674373|NCT03518749|BEHAVIORAL|Cognitive control training|cognitive control training with the PASAT
224255611|NCT04337580|DRUG|Omeprazole 80 mg twice daily|Participants will be treated with omeprazole 80 mg twice daily on Day 0. Within 10 days of starting omeprazole, participants will be treated with standard prostate cancer dosing of every three week docetaxel or cabazitaxel based on package insert. Participants that have only had docetaxel will be retreated with docetaxel along with concurrent omeprazole. Patients that have had both docetaxel and cabazitaxel will be retreated with either cabazitaxel or docetaxel (investigators choice) along with concurrent omeprazole. However investigators encourage investigator to choose cabazitaxel in patients previously treated with cabazitaxel.
224255612|NCT05299125|DRUG|Amivantamab|Low fucose, fully human immunoglobulin gamma-1-based bispecific antibody directed against EGFR and MET tyrosine kinase receptors. It shows clinical activity against tumors with the primary activating EGFR mutations Exon 19del or Exon 21 L858R substitution, EGFR Exon 20ins mutations, the EGFR resistance mutations Threonine790Methionine (T790M) or Cysteine797Serine (C797S), and activation of the Mesenchymal Epithelial Transition (MET) pathway.
223674374|NCT04789720|BEHAVIORAL|Symptom Monitoring & Systematic Assessment and Reporting System in Young Survivors (SyMon-SAYS)|Participants will complete a 9-item SyMon-SAYS symptom assessment checklist every week during the intervention phase (Intervention Group: weeks 1-16; Waitlist Control: weeks 9-16) through Epic MyChart via mobile app, computer or tablet. Patients' symptom scores will be monitored and reported to their oncology care providers. When a patient symptom score trigger threshold is met, the system will generate an email alert through Epic (electronic medical record system) messaging to the provider. The provider will take appropriate actions using his/her clinical judgement, including contacting patients and families when needed. Symptom scores overtime will be available in MyChart (patient-facing component of the Epic electronic medical record system) for patients and parents to review and to discuss with the child's provider during clinical visits.
223674375|NCT05562934|BIOLOGICAL|XXB750 drug|SC injection
223674376|NCT05562934|OTHER|Placebo|SC injection
223772538|NCT06167447|OTHER|questionnaire and examination|Demographic data of all participants, height, weight, body mass index, occupation, marriage status, education level, comorbidities, medications used, duration of illness and subtype will be recorded by the researcher. Questionnaires to be filled by patients. On the same day, the musculoskeletal system and neurological examination of the participants will be evaluated by the researcher.
223772539|NCT05573295|OTHER|Diagnostic Test: Willems method|Willems method measures the developmental stages of the seven left permanent mandibular teeth and is frequently used for dental age estimation. The score of each stage is allocated, and the sum of the scores provides an evaluation of the subject's dental maturity.
224255613|NCT05299125|DRUG|Lazertinib|It selectively inhibits both primary activating EGFR mutations (Exon 19del, Exon 21 L858R substitution) and the EGFR T790M resistance mutation, while having less activity versus wild-type EGFR.
224255614|NCT05299125|DRUG|Pemetrexed 500 mg|Inhibits enzymes involved in folate-dependent metabolism, thereby disrupting cellular replication.
224255615|NCT05454956|DRUG|TP-03|TP-03, lotilaner ophthalmic solution, 0.25%, administered twice a day in participants in the BID dosing arm and three times a day in participants in the TID dosing arm
223674377|NCT04418661|DRUG|Vociprotafib|Pharmaceutical form: Varies Route of administration: Varies
223674378|NCT04418661|DRUG|Pembrolizumab|Pharmaceutical form:Sterile Lyophilized powder for reconstitution Route of administration: Infusion
223674379|NCT04418661|DRUG|Adagrasib|Pharmaceutical form:Sterile Tablet Route of administration: Oral
223674380|NCT02666963|DRUG|RTA 901 Capsules, 10 or 40 mg|
223674381|NCT02666963|DRUG|Placebo|
223674382|NCT05219799|DRUG|Propranolol Hydrochloride|Regional forearm blockade of β-adrenergic receptors at 20 mcg/dL/min via brachial artery catheter during normoxia and hypoxia exposures
223674383|NCT05219799|DRUG|Isoproterenol|Dose response (1, 3, 6, and 12 ng/dL/min) regional infusion to assess β-adrenergic receptor responsiveness
223674384|NCT05219799|DRUG|Phentolamine Mesylate|This infusion will be for 10 min before baseline measurement (12 mcg/dL/min) and continue the infusion at a maintenance rate (5 mcg/dL/min).
223674385|NCT05219799|DRUG|Norepinephrine|Regional forearm infusion at 8 ng/dL/min via brachial artery catheter during normoxia and hypoxia exposures
223674386|NCT05564195|DIAGNOSTIC_TEST|Postoperative cognitive function|"Digital cognitive tests - Mindmore-P, will be used to assess neurocognitive capacity and includes tests of verbal episodic memory, executive functions, visuospatial function and attention. The cognitive tests are self-administered on a touch screen tablet (10.1 20-30 min Windows). The Mindmore-P is a web-application running on a full-screen Chrome browser. The test is administered by using a capacitive touchscreen with features that record detailed information such as timing, pauses, and lifting of finger from the touchscreen. Speech recognition is used in the screening of verbal memory and language."
223674387|NCT05898087|DRUG|Marcaine 0.25 % Injectable Solution|Patients in this arm will receive an injection of 20cc of injectable 0.25% bupivacaine solution. It will be injected in a fan-like pattern beneath the pectoralis fascia
223674388|NCT05898087|DRUG|Saline|Patients in this arm will receive an injection of 20cc of injectable saline. It will be injected in a fan-like pattern beneath the pectoralis fascia
223674389|NCT00585598|OTHER|replacing supralaryngeal airway with ET tube|changing tube in trauma bay
223674390|NCT01561196|PROCEDURE|arterial catheterisation|arterial catheterisation in Arterial Radialis
223674391|NCT01886027|BEHAVIORAL|Emotional Awareness and Expression Training|An emotional processing intervention, which aims to reduce stress by helping patients become aware of, and express emotions related to stressful life experiences, as well as teaching patients how to relate to others differently.
224255616|NCT05454956|DRUG|TP-03 Vehicle|Vehicle of TP-03 ophthalmic solution, administered once a day in participants in the BID dosing arm to maintain masking between arms
224255617|NCT06471816|OTHER|Dialogue Based Early Detection|Before the biannual parent-teacher meeting, both the kindergarten teacher and the parents will complete the Early Worry Questionnaire containing 39 items related to development and well-being of the individual child. For each item the respondents are asked to indicate if they during the last three months have been concerned. In the parent-teacher meeting they will discuss their possible concerns and try to reach an agreement on how to evaluate the child. If necessary, possible supportive interventions or further assessments locally in the kindergarten or in the public services will be decided.
224255618|NCT06471816|OTHER|Traditional parent-teacher meeting|This is an annual or biannual meeting that is prepared by the kindergarten teacher where (s)he reports on the child's appearance / behaviour and possible challenges as to development and behaviour from an educationalist's view. There are no common templates for the agenda of such meetings, however, usually the kindergarten teacher's perspective and opinion will dominate.
224255619|NCT05160636|BIOLOGICAL|COVID-19 Vaccine|Receipt of Pfizer BioNTech COVID-19 vaccine
224255620|NCT00302146|DRUG|15-0 H20|
224255621|NCT06192160|DRUG|Isoniazid|INH 300 mg will be administered as one tablet orally once daily.
224255622|NCT06192160|DRUG|Rifampicin|RIF 600 mg will be administered as two 300 mg capsules orally once daily on an empty stomach, 1 hour before or 2 hours after eating a meal.
224255623|NCT06192160|DRUG|Pyrazinamide|PZA will be administered as 500 mg tablets, based on weight, orally once daily.
224255624|NCT06192160|DRUG|Ethambutol|EMB will be administered as 400 mg tablets, based on weight, orally once daily.
224255625|NCT06192160|DRUG|Bedaquiline|BDQ 400 mg will be administered as four 100 mg tablets orally once daily with a meal for the first 2 weeks followed by 200 mg (two 100 mg tablets) orally once daily with a meal for 6 weeks.
224255626|NCT06192160|DRUG|Pretomanid|Pa 200 mg will be administered as one 200 mg tablet orally once daily with a meal.
223674392|NCT01886027|BEHAVIORAL|Relaxation Training|Teaches patients different relaxation training skills to reduce their distress and discomfort (i.e., progressive muscle relaxation, applied relaxation, or guided imagery.
223674393|NCT01848782|BEHAVIORAL|interpretation of the abstract of the systematic review|
223772540|NCT05573295|OTHER|Diagnostic Test: Cameriere method|Cameriere et al. designed a quantitative approach through a formula based on sex and the ratio between length and apex opening measurements of each lower left tooth.
223772541|NCT05573295|OTHER|Diagnostic Test: London Atlas method|The London Atlas requires the user to assess the tooth development and eruption and then match it to one of the 31 pictures of age categories.
223772542|NCT06430541|DRUG|Psilocybin|A tryptamine that produces its behavioral effects primarily by acting as post-synaptic agonists at serotonin 5-HT2A and 5-HT2c receptors.
224255627|NCT06192160|DRUG|Linezolid|LZD 600 mg will be administered as one 600 mg tablet orally once daily.
224255628|NCT06192160|DRUG|TBI-223|TBI-223 2400 mg once daily will be administered as four 600 mg tablets orally once daily with a meal.
224255629|NCT06192160|DRUG|Sutezolid|SZD 1600 mg once daily will be administered as four 400 mg tablets orally once daily with a meal.
223674394|NCT00479921|BIOLOGICAL|Trivalent influenza subunit vaccine|
223772543|NCT03235024|BIOLOGICAL|B244|B244 suspension
223772544|NCT03235024|BIOLOGICAL|Vehicle|Vehicle suspension
223772545|NCT05914584|DRUG|Baricitinib 4 MG|Reference drug
223772546|NCT03413878|OTHER|Breathing in the simulated avalanche snow|Breathing in the simulated wet or dry avalanche snow with a small or large air pocket
224255630|NCT06192160|DRUG|TBI-223|TBI-223 1200 mg once daily will be administered as two 600 mg tablets orally with a meal.
224255631|NCT06192160|DRUG|Sutezolid|SZD 800 mg once daily will be administered as two 400 mg tablets orally once daily with a meal.
224322352|NCT06714955|DRUG|Experimental: 10 mg BGM0504 10 milligrams (mg) BGM0504 administered subcutaneously (SC) once a week.|Drug: BGM0504 Administered SC
224322353|NCT06714955|DRUG|Experimental: 15 mg BGM0504 15 mg BGM0504 administered SC once a week.|Drug: BGM0504 Administered SC
224322354|NCT06714955|DRUG|Placebo Comparator: Placebo Placebo administered subcutaneously (SC) once a week.|Drug: Placebo Administered SC
223674395|NCT00916214|OTHER|Pharmaceutical care program|The pharmaceutical care program consists of 2 elements, that includes individualized medication education and regular follow up
224255632|NCT01481363|BEHAVIORAL|The Talking Sense manual|Talking Sense is a recently written therapy manual for professionals to use with carers of people with dementia. It is intended to be used one to one with carers and is individualisable according to their relatives degree of communication difficulty or the extent to which the carer experiences difficulty with communication. The approach addresses the carers knowledge, skills, thinking and behaviour in a series of interdependent steps. In this study it will be delivered to carers during 3 home visits and up to a total of 4.5 hours.
223674396|NCT04957433|DIAGNOSTIC_TEST|Blood Specimen|Blood and Sputum Specimen Samples
223674397|NCT04309123|DEVICE|TransAeris System|The TransAeris System is a temporary percutaneous intramuscular diaphragm stimulator intended for patients at risk of or on prolonged positive pressure mechanical ventilation. TransAeris is indicated for use in the prevention and treatment of ventilator-induced diaphragm dysfunction (VIDD).
224255633|NCT01481363|BEHAVIORAL|Treatment as usual - communication information and advice|Carers will receive the existing model of support provided by the speech and language therapy service. This is based on a one hour visit during which questions will be answered and specific advice given. No leaflets or manual will be used.
224255634|NCT01417663|DRUG|Alt-711|Alt-711, also known as Alagebrium, an AGE-crosslink breaker, will be given twice daily 100mg
224255635|NCT01417663|BEHAVIORAL|Physical exercise training|Exercise training will be given three times a week for 45 minutes per training session. The heart rate reserve will be slowly increased from 70% to 85%.
224255636|NCT00220415|DRUG|SPM 927|
224255637|NCT02785887|OTHER|Geriatrician review|In addition to routine oncological care, patients will be reviewed by a geriatrician and may receive intervention if CGA deficits are found
224255638|NCT05119725|DEVICE|continous 3 day EKG monitoring with S-Patch Cardio|continous 3 day EKG monitoring with S-Patch Cardio
224255639|NCT04948905|OTHER|Evaluation using the Self-Defining Memory Questionnaire|"This questionnaire consists of 3 pages. Page 1 gives a clear, concise definition of a memory that defines the self. This enlightens the subject on what is expected and helps him/her consider the phenomenological characteristics of the Self-Defining Memory. Page 2 recalls the 6 essential characteristics of the Self-Defining Memory. Page 3 allows the practical application of what has been understood about the questionnaire. At least 3 memories are asked of the participants. Each memory is rated as follows : On a scale of 0 - 6 for each of the following emotions, participants note how they feel when recalling each memory. Happy, Sad, Angry, Fearful, Surprised, Ashamed,Disgusted,Guilty, Interested, Embarrassed, Contemptful, Proud. 0 = not at all, 3 = Moderately and 6 = Extremely.~Participants must then use the same scale to indicate the vividness and importance of the memory.~They must also note the approximate number of years ago the memory took place (to the nearest whole number)."
224255640|NCT00185458|DRUG|LNG IUS|LNG IUS (initial in vitro release 20 µg/24h) intrauterine for minimum of 9 months and maximum of 60 months - 2 phases: a) Contraception Phase b) HRT Phase. For outcome measures (vaginal bleeding variables), five 90-day Reference Periods were defined, which were used for comparison during statistical analysis: Reference Period -1 in Contraception Phase; Reference Periods 1-4 in HRT Phase. 90-day reference periods for analyzing vaginal bleeding data are defined by WHO guideline. Reference Period -1 is the last 90-day reference period that the subject had before starting the HRT. Reference Period 1 covers the first 90-days of the HRT phase, Reference Period 2 covers days 91 to 180, Reference Period 3 days 181 to 270, and Reference Period 4 days 271 to 360 of the HRT phase.
224255641|NCT00251979|DRUG|Esomeprazole|
224255642|NCT02618083|DEVICE|color Doppler ultrasound|pre-operative blood flow velocity measurement with a color Doppler ultrasound device
224255643|NCT01019421|DRUG|Lu AE58054|Add-on treatment to donepezil
224255644|NCT01019421|DRUG|Placebo|Add-on treatment to donepezil
224255645|NCT03567447|DRUG|Droxidopa|starting with 100 mg TID and increasing in 100 mg TID increments, to a maximum of 600mg TID, to identify the highest tolerated dose for each patient.
224322355|NCT05332821|DRUG|PD-1/PD-L1 inhibitors+VEGF-TKI/bevacizumab|PD-1/PD-L1 inhibitors: atezolizumab, sintilimab, pembrolizumab, nivolumab, camrelizumab, tislelizumab, toripalimab, durvalumab, penpulimab, and other ICIs; VEGF-TKI/bevacizumab: sorafenib, lenvatinib, donafenib, apatinib, anlotinib, bevacizumab/ bevacizumab biosimilar, and other anti-angiogenesis drugs; Both PD-1/PD-L1 inhibitors and anti-angiogenesis drugs only include marketed drugs but are not limited to HCC approval.
224322356|NCT05332821|PROCEDURE|TACE|TACE: cTACE (conventional TACE) or dTACE (drug-eluting beads TACE);
224322357|NCT01429116|DRUG|tasimelteon|20 mg tasimelteon capsules, PO daily for 24 months + 12 month optional extension
224322358|NCT04762017|DRUG|OCS-05 +SoC (corticosteroid) IV administration|OCS-05 + SoC (corticosteroid) IV administration for 5 consecutive days
224322359|NCT04762017|OTHER|Placebo + SoC (corticosteroid) IV administration|Placebo + SoC (corticosteroid) IV administration for 5 consecutive days
224322360|NCT00925080|DEVICE|IVBG|Venous blood glucose measurement every 7.5 minutes for 72-hours
224322361|NCT04735861|DRUG|Sintilimab|Sintilimab 200mg iv. q3w, up to 2 years.
224322362|NCT04735861|DRUG|Bevacizumab Biosimilar IBI305|Bevacizumab 15mg/kg iv. q3w, up to 22 cycles
223674398|NCT05841121|DRUG|Dexamethasone|Antenatal dexamethasone will be given a course of four intramuscular injections of dexamethasone 6 mg (1.2 milliliter), 12 hours apart.
223674399|NCT02127060|DRUG|Vitamin C|for 1 month postoperative period, vitamin C was administered orally to the patients.
223674400|NCT02127060|DRUG|Placebo drug|for 1 month postoperative period, placebo medication administered orally to the patients.
223674401|NCT05719727|DIAGNOSTIC_TEST|colonoscopy|lower colonoscopy
223674402|NCT05719987|OTHER|Biodentine|After the endodontic procedure, Biodentine will be placed into the apical portion of the canals. After 12 min, the coronal and middle third of the root canal will be filled with gutta-percha and AH Plus. The coronal restoration will be completed with GIC, composite, and stainless-steel crown.
224255646|NCT03567447|OTHER|Placebo|appearing to be 100 mg TID and increasing in 100 mg TID increments, to a maximum of 600mg TID, to identify the highest tolerated dose for each patient.
224255647|NCT06222645|DEVICE|ICG fluorescence imaging technology|Indocyanine green fluorescence imaging uses fluorescence intensity to assess blood perfusion of gastrointestinal anastomoses during gastrointestinal surgery
224255648|NCT06222645|DEVICE|Imaging photoplethysmography|Imaging photoplethysmography to assess blood perfusion at gastrointestinal anastomoses during gastrointestinal surgery
223772547|NCT00537524|BIOLOGICAL|H5N1 Influenza Vaccine|Two 0.5mL injections of H5N1 influenza vaccine containing 7.5μg of H5N1 antigen (A/Vietnam/1194/2004), administered 3 weeks apart, and one 0.5mL injection of H5N1 vaccine 12 months after the second dose, IM into the deltoid muscle (preferably of the non-dominant arm) or anterolateral thigh (depending on the muscle mass).
223772548|NCT00537524|BIOLOGICAL|H5N1 Influenza Vaccine|Two 0.25mL or 0.5mL injections of H5N1 influenza vaccine, administered 3 weeks apart, IM into the deltoid muscle (preferably of the non-dominant arm) or anterolateral thigh (depending on the muscle mass).
223772549|NCT01642394|BEHAVIORAL|Diabetes Self-Management Program|"The intervention will be performed by patients with type 2 diabetes and health professionals and it will be divided in 6 group sessions for two and a half hours each, on a weekly basis for 6 weeks. The session content includes techniques for dealing with problems in general, promotion of exercise, nutrition concepts, proper use of medication, effective communication and basic knowledge about diabetes and its complications. The sessions are supported with educational material.~Two leaders, previously trained in the DSMP, will lead each group. The leading status (patient or health care professional) is obtained after attending a 6-week structured program of training, a successful completion of 4 days of training sessions, and taking part in a full course for patients with a proven leader."
223772550|NCT04358484|BEHAVIORAL|Incredible Years - ASD and Language Delay®|"The IY - ASLD Program will consist of 22 weekly online group sessions for parents of children between 2-5 years of age with symptoms or a diagnosis of ASD or delayed language acquisition. The program will be conducted by a therapist and a co-therapist, trained in the model.~Fidelity to the intervention will be assessed in accordance with the regulations of the program. All of the therapists and co-therapists will be trained in the intervention by accredited trainers. The three main therapists will be supervised by accredited supervisors of the IY Program, seeking accreditation in the intervention. As the intervention IY - ASLD has not been translated into Spanish, the English materials will be used with simultaneous translation into Spanish language."
223772551|NCT06383039|DEVICE|Transcranial Direct Current Stimulation|"Evaluations will be made in the presence of a physiotherapist. Individuals; For demographic information~• Demographic Information Form~For Static Balance Evaluation:~* Wii-Fit~* Balance Error Scoring System~For Dynamic Balance Assessment:~* Star Balance Test~* Timed Get Up and Go Test"
224255649|NCT00280553|DRUG|bupivicaine|PCA and bupivicaine infusion for up to five days
224255650|NCT00280553|OTHER|Saline infusion|PCA and pump with saline infusion for up to five days
224255651|NCT00909402|DRUG|BMS-833923|Capsule, Oral, Starting dose 30 mg, Once daily, continuous until discontinuation from study
224255652|NCT00909402|DRUG|Cisplatin|Vial, intravenous (IV), 80 mg/m² IV, Once every 21 days, 1 day per cycle until discontinuation from study
224322363|NCT07042776|DEVICE|EMMA (Expert Manipulative Massage Automation)|For the EMMA massage, the subject lies down on the robot platform in a prone position. A therapist sets the robot parameters. The EMMA electronic massager applies massage to the focus points on the back of the participants guided by cameras and computer programs. Treatment lasts approximately 20-30 minutes.
224322364|NCT07042776|OTHER|Therapist-delivered massage|For the therapist-delivered massage treatment, the licensed massage therapist will follow standard of care protocol. Treatment lasts approximately 20-30 minutes.
224255653|NCT00909402|DRUG|Capecitabine|Tablets, Oral, 1000 mg/m², twice a day (BID), 14 days per cycle, until discontinuation from study
224322365|NCT05214105|OTHER|Biospecimen/DNA collection and analysis|Patients will be followed longitudinally with collection of CBC and chemistries as well as research biomarkers (urine, plasma, and genomic materials).
223674403|NCT05719987|OTHER|MTA|After the endodontic procedure, MTA will be placed into the apical portion of the canals. After 12 min, the coronal and middle third of the root canal will be filled with gutta-percha and AH Plus. The coronal restoration will be completed with GIC, composite, and stainless-steel crown.
223674404|NCT00103350|DRUG|TG100-115|
224255654|NCT06131853|OTHER|survey evaluation|assessment of physical activity, fatigue, fear of movement, and quality of life
224255655|NCT05177588|DRUG|Metformin Hydrochloride|Metformin 2000 mg/day
224255656|NCT01460147|OTHER|DXA scan + MRI|This is a non-drug study. Subjects will receive a dual-energy X-ray absorptiometry (DXA) scan (in the main osteoporosis study) and will undergo magnetic resonance imaging (in the MRI substudy).
224255657|NCT03317548|DIAGNOSTIC_TEST|progesterone|according progesterone level to decide fresh or frozen embryo transfer
224255658|NCT03317548|DIAGNOSTIC_TEST|day 3 embryo|according day 3 embryo to decide fresh or frozen embryo transfer
224255659|NCT05800652|BEHAVIORAL|Peer Mentoring Program|Mentoring program created in academic, social, emotional and safety dimensions.In the academic dimension, there is information about the instructors, course selection, preparing a course study program,efficient study methods,information about the education and training program. Social dimension includes interpersonal relations, participation in social life, free time activities, making friends.The emotional dimension includes developing self-confidence,coping with stress,belonging and motivation.In the security dimension, there are student rights,scholarship opportunities, accommodation opportunities, library and internet facilities, use of the health center and clinical practice. In the mentoring program, it was expected that the mentors would make individual meeting(s) with the mentee they were matched with, face to face, online or over the phone, and share information and support every week. The mentoring program continued for 12 weeks.
224255660|NCT05400733|DIETARY_SUPPLEMENT|Total Amino Acids|Histidine, Isoleucine, Leucine, Lysine, Methionine, Phenylalanine, Threonine, Tryptophan, Valine, Alanine, Arginine, Aspartate, Cystine, Glutamine, Glutamate, Glycine, Proline, Serine, Tyrosine. All supplements are commercially available.
224322366|NCT03648853|DEVICE|Tetanic Stimulus|5 second 100 Hz 70 mA tetanic stimulus will be applied to three different locations in a random order
224255661|NCT05400733|DIETARY_SUPPLEMENT|Essential Amino Acids|Histidine, Isoleucine, Leucine, Lysine, Methionine, Phenylalanine, Threonine, Tryptophan, Valine. All supplements are commercially available.
224255662|NCT05400733|DIETARY_SUPPLEMENT|Essential Amino Acids + Hydroxy-methylbutyric acid (HMB)|Histidine, Isoleucine, Leucine, Lysine, Methionine, Phenylalanine, Threonine, Tryptophan, Valine, HMB. All supplements are commercially available.
224255663|NCT05400733|DIETARY_SUPPLEMENT|Essential Amino Acids + Leucine|Histidine, Isoleucine, Leucine, Lysine, Methionine, Phenylalanine, Threonine, Tryptophan, Valine, Extra leucine. All supplements are commercially available.
224255664|NCT05400733|DIETARY_SUPPLEMENT|Essential Amino Acids High|Histidine, Isoleucine, Leucine, Lysine, Methionine, Phenylalanine, Threonine, Tryptophan, Valine. All supplements are commercially available.
223674405|NCT05956184|DEVICE|Intrauterine Device Insertion|All womens will be placed in a gynecological position and underwent a bimanual examination to better determine whether the uterus was in the anteverted or retroverted position. Subsequently, a speculum will be inserted, and the cervix will be disinfected with betadine. In the conventional method: the anterior lip of the cervix is grasped and pulled with Pozzi forceps, and after entering the uterine cavity with a hysterometry the IUD is inserted. In the direct method: the anterior lip of the cervix is grasped and pulled with Pozzi forceps, and without using hysterometry the IUD is directly inserted. The strings will be cut approximately 2-3 cm after the cervix, and the Pozzi forceps and speculum will be removed. The accuracy of the IUD placement will be confirmed using pelvic ultrasound. The process will take about five minutes.
223674406|NCT01235871|DRUG|SB1578|JAK2 Inhibitor
224255665|NCT05400733|DIETARY_SUPPLEMENT|Placebo Water|Water
224255666|NCT00999050|PROCEDURE|Gastric bypass for diabetic patients <35 BMI|The operation is performed under general anesthesia. It is done laparoscopically, meaning that several small openings are made in the abdomen for insertion of long, thin surgical instruments, one with an attached camera. The operation is video monitored. The top of the stomach is divided across, leaving a small pouch for food. The rest of the stomach remains but can receive no food. The gut is divided just past the stomach, and it is attached to the small stomach pouch so that food can get back into the bowel. A second connection is made so that the bile and digestive juices pass into the bowel with the food.
224255667|NCT01303549|DRUG|Anidulafungin|Anidulafungin once a day for 14 days: initial dose 200 mg/day IV administered in 180 minutes. Following doses 100 mg/day IV administered in 90 minutes.
223674407|NCT01235871|DRUG|Placebo|Control arm
223674408|NCT01954420|BEHAVIORAL|Cognitive-Behavioral Intervention|Standard care + Selection of 12 recorded imagery- and non imagery-based cognitive-behavioral coping strategies provided on an MP3 player.
223674409|NCT01954420|OTHER|Attention Control|Standard care + Cancer education
223674410|NCT01271790|DRUG|Tegobuvir (GS-9190)|Tegobuvir (GS-9190) capsule, 30 mg BID
223674411|NCT01271790|DRUG|GS-9451|GS-9451 tablet, 200 mg once daily (QD)
223674412|NCT01271790|BIOLOGICAL|Pegasys®|peginterferon alfa-2a (solution for injection) 180 µg/week
223772552|NCT03162861|DRUG|sevoflurane inhalation for anesthesia|The elderly patients undergoing unilateral total hip arthroplasty will be randomized to assigned to the observation group. In the observation group, tracheal intubation will be conducted for general anesthesia after lumbar plexus-sciatic nerve block, accompanying sevoflurane inhalation for anesthesia maintenance.
223772553|NCT03162861|DRUG|propofol for anesthesia|The elderly patients undergoing unilateral total hip arthroplasty will be randomized to assigned to the control group. In the control group, tracheal intubation will be conducted for general anesthesia, accompanying intravenous administration of propofol for anesthesia maintenance.
223674413|NCT01271790|DRUG|Copegus®|ribavirin tablet (weight based: 1000 mg/day \<75 kg; 1200 mg/day ≥ 75 kg) divided twice daily (BID)
223772554|NCT05040763|DIAGNOSTIC_TEST|Buccal Swabc- Copan flocked swab|All participants will have a buccal swab sampled collected from the inside of the mouth either by themselves or by their caregiver
224255668|NCT01303549|DRUG|Liposomal amphotericin B|Liposomal amphotericin B once a day for 14 days: 3 mg/kg/day. IV administration during 60 minutes.
223674414|NCT01271790|DRUG|GS-9451|GS-9451 tablet, 200 mg QD
223674415|NCT01271790|DRUG|Tegobuvir placebo|placebo matching Tegobuvir (GS-9190) capsule BID
223674416|NCT01271790|BIOLOGICAL|Pegasys®|peginterferon alfa-2a (solution for injection) 180 µg/week
223674417|NCT01271790|DRUG|Copegus®|ribavirin tablet (weight based: 1000 mg/day \<75 kg; 1200 mg/day ≥ 75 kg) divided twice daily (BID)
223674418|NCT01271790|DRUG|Tegobuvir placebo|placebo matching Tegobuvir (GS-9190) capsule BID
223674419|NCT01271790|DRUG|GS-9451 placebo|placebo matching GS-9451 tablet QD
223674420|NCT01271790|BIOLOGICAL|Pegasys®|peginterferon alfa-2a (solution for injection) 180 µg/week
223674421|NCT01271790|DRUG|Copegus®|ribavirin tablet (weight based: 1000 mg/day \<75 kg; 1200 mg/day ≥ 75 kg) divided twice daily (BID); tablet
223674422|NCT00879931|DRUG|Methylprednisolone|Methylprednisolone
223674423|NCT00879931|DRUG|Placebo|Placebo (NaCl 0.9%)
223674424|NCT06135194|DRUG|T-DXd|Efficacy and safety of T-DXd in the treatment of HER2-positive breast cancer with brain metastases after treatment with pyrotinib
223674425|NCT00046891|DRUG|Ginkgo Biloba|Patients will take 120 mg per day (60 mg BID)
223674426|NCT00046891|OTHER|Placebo|Patients will take 1 tablet BID
223674427|NCT04349293|PROCEDURE|Tissue sampling|Collection of a sample of tumor tissue and a sample of adjacent or counter lateral healthy tissue (if possible) from the surgical room
223674428|NCT04349293|PROCEDURE|Blood sampling|Collection of a 30mL peripheral blood sample in heparin at several times: during surgical and medical treatment (before surgery, before the start of mAbs and after mAbs)
224255669|NCT01576042|DRUG|amiodarone|The dosage of antiarrhythmic medications will comply with the ACC/AHA 2006 Guidelines for Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death.
224255670|NCT01576042|DRUG|sotalol|The choice and dosage of antiarrhythmic medications will comply with the ACC/AHA 2006 Guidelines for Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death.
224255671|NCT01576042|DEVICE|Biosense Webster's NAVI-STAR Thermo-Cool|The only ablation catheter that will be allowed in this study will be the Biosense Webster's NAVI-STAR Thermo-Cool catheter as it is the only catheter that has been approved by the FDA for sustained monomorphic VT due to prior myocardial infarction in adults.
224255672|NCT04557449|DRUG|PF-07220060|CDK4 inhibitor
224255673|NCT04557449|COMBINATION_PRODUCT|Letrozole|Endocrine Therapy
224255674|NCT04557449|COMBINATION_PRODUCT|Fulvestrant|Endocrine Therapy
223674429|NCT05473585|OTHER|very low nicotine content cigarettes|Investigational combusted cigarettes with very low nicotine content
223674430|NCT05473585|OTHER|normal nicotine content cigarettes|Investigational combusted cigarettes with normal nicotine content
223674431|NCT05473585|OTHER|Study e-cigarette|E-cigarette provided by study
223674432|NCT03252600|DRUG|Cyclophosphamide|Given IV
223674433|NCT03252600|DRUG|Dexamethasone|Given IV
223674434|NCT03252600|BIOLOGICAL|Elotuzumab|Given IV
223674435|NCT03252600|OTHER|Laboratory Biomarker Analysis|Correlative studies
223674436|NCT03252600|DRUG|Lenalidomide|Given PO
223674437|NCT03252600|OTHER|Pharmacological Study|Correlative studies
223674438|NCT04909476|PROCEDURE|Endotracheal intubation|Airways management in COVID 19 patients pneumonia
223674439|NCT01997385|PROCEDURE|KAPD-C|KAPD-C is a treatment prescribed 2000 mL fill volume per each 4 cycles of dialysis session with an exchange cycle of 90 minutes.
223772555|NCT05040763|DIAGNOSTIC_TEST|Standard of Care COVID-19 swab|All participants will receive a standard of care COVID-19 swab collected by a qualified healthcare professional
223772556|NCT04316624|DRUG|C-CAR066|Autologous 2nd generation CD20-directed CAR-T cells, single infusion intravenously
223772557|NCT04509700|DRUG|Parsaclisib|Participants will continue on the same dose (1,2.5,5 OR 20 mg) and schedule of parsaclisib as that provided in the parent Protocol at the time of the rollover.
223772558|NCT04509700|DRUG|parsaclisib + itacitinib|Participants will continue on the same dose (1,2.5,5 OR 20 mg) and schedule of parsaclisib and 100 mg of itacitinib as that provided in the parent Protocol at the time of the rollover.
224255675|NCT04557449|DRUG|Midazolam|Benzodiazepine used for DDI
223772559|NCT04509700|DRUG|parsaclisib + ruxolitinib|Participants will continue on the same dose (1,2.5,5 OR 20 mg) and schedule of parsaclisib and the same dose of ruxolitinib that was provided in the parent Protocol at the time of the rollover.
224255676|NCT04557449|COMBINATION_PRODUCT|Enzalutamide|Androgen Receptor inhibitor
224255677|NCT03550781|DRUG|Prednisone, cyclophosphamide|Prednisone 0.5mg/(kg•d) and/or cyclophosphamide 2mg/kg
224255678|NCT01311245|BEHAVIORAL|Stage-tailored intervention|Based on the Trans-Theoretical Model of intentional behavior change (TTM). According to their stage of change, participants received two computer generated feedback letters on their risky drinking, stage of change, processes of change, self-efficacy, and decisional balance. The first letter included normative feedback (interpersonal comparison with other individuals in the same stage), and was sent out by mail after baseline. The second letter included normative and ipsative feedback (intrapersonal comparisons: baseline vs. 3 months later), and was sent out by mail three months later.
223674440|NCT01997385|PROCEDURE|KAPD-A|KAPD-A is a treatment initially prescribed 1500 mL fill volume per each 2 cycles of dialysis session with an exchange cycle of 45 minutes and followed by 2 cycles of 2500 mL fill volume with an exchange cycle of 135 minutes.
223674441|NCT04935645|BEHAVIORAL|Progressive Muscle Relaxation|PMR is a technique that provides relaxation in the whole body by voluntary and regular relaxation of large muscle groups in the human body, which is included in mind-body applications.
223674442|NCT02496676|DIETARY_SUPPLEMENT|Magnesium L-threonate|"In Part I, participants will receive 12 weeks of oral magnesium L-threonate; will be dose escalated based on weight.~In Part 2, participants will receive 24 weeks of oral magnesium L-threonate; will be dose escalated based on weight."
223674443|NCT02496676|OTHER|Placebo|In Part I, participants will receive 12 weeks of oral placebo; will be dose escalated based on weight.
223674444|NCT02496676|DRUG|Intravenous (IV) magnesium sulfate (MgSO4)|In Part II, participants will be hospitalized to receive 3 days of IV magnesium sulfate (MgS04).
223674445|NCT02265601|OTHER|computer-based decision aid|Offers tailored education, values clarification exercises, and a sophisticated decision aid that translates an individual's goals and preferences into a specific medical plan that can be implemented by a health care team.
223674446|NCT02265601|OTHER|standard care|paper/pencil living will form
223674447|NCT00006157|DRUG|Desipramine|
223674448|NCT00006157|BEHAVIORAL|Cognitive Behavioral Treatment|
223674449|NCT00756925|DRUG|Acthrel|1 ug/kg, i.v., 1 minute
223674450|NCT06195761|PROCEDURE|computer guided modified ridge splitting technique in horizontal bone deficiency in posterior mandible|treatment plan includes harvesting and fixing the bone graft in posterior mandibular area using a computer-modified surgical guide
223674451|NCT06195761|PROCEDURE|free hand modified ridge splitting technique in horizontal bone deficiency in posterior mandible|treatment plan includes manually harvesting and fixing the bone graft in posterior mandibular area without a surgical guide.
223674452|NCT02666703|DEVICE|CytoSorb|CytoSorb is a first-in-class extracorporeal cytokine adsorber, now approved in the European Union, and broadly indicated for use in any clinical situation where cytokines are elevated.
223674453|NCT02666703|DRUG|Methylprednisolone|
223674454|NCT00100334|DRUG|PPI-1019 (APAN)|
223674455|NCT04725357|DRUG|Meloxicam 15 mg|Participants will receive a prescription of 20 pills of 15 mg Meloxicam after surgery
223674456|NCT04725357|PROCEDURE|Preoperative Interscalene Nerve Block|Preoperatively participants will standardly receive an interscalene nerve block
223674457|NCT04725357|PROCEDURE|arthroscopic labral repair|participant will have their standard surgical procedure done
223674458|NCT00219895|DRUG|Ibuprofen|
223674459|NCT01104532|DRUG|ASP1941|oral tablet
223674460|NCT01104532|DRUG|sitagliptin|oral tablet
223674461|NCT06329089|PROCEDURE|Reoperative Sentinel Lymph Node Biopsy|Reoperative sentinel lymph node biopsy refers to a surgical procedure performed when there is a need to re-examine the sentinel lymph nodes (SLNs) in patients who have previously undergone breast cancer surgery. The sentinel lymph nodes are the first lymph nodes to which cancer cells are likely to spread from the primary tumor. During the procedure, the surgeon locates and removes the previously identified sentinel lymph nodes using techniques such as lymphatic mapping and injection of a radiotracer or dye. The removed lymph nodes are then examined by a pathologist to determine if there is any evidence of cancer spread.
223674462|NCT01117909|OTHER|Mobilization therapy in addition to standard therapy|Subject will receive three 60-second bouts of posterior joint mobilizations applied to the ankle joint during each treatment session. Standard therapy will consist of ankle strengthening exercises with elastic bands, balance, active ROM, and 20 minutes of ice bag application, elevation and compression.
223674463|NCT01117909|OTHER|Sham intervention|Physical therapist will lay hands as if to perform the joint mobilization but no movement will occur.
224255679|NCT01311245|BEHAVIORAL|Non-stage-tailored Intervention|Based on the Theory of Planned Behavior (TPB). Participants received two computer generated feedback letters on their risky drinking, beliefs (behavioral, normative, control), attitude, subjective norm, perceived behavioral control, intention, and they were asked to fill in a where-when-how to change plan. The first letter included normative feedback (interpersonal comparison with other women/ men), and was sent out by mail after baseline. The second letter included normative and ipsative feedback, and was sent out by mail three months later.
223674464|NCT02219802|PROCEDURE|Treatment according arm|
223674465|NCT01653028|DRUG|Alisertib|Given PO
223674466|NCT01653028|OTHER|Laboratory Biomarker Analysis|Correlative studies
223674467|NCT05715671|DRUG|esketamine|The corresponding esketamine dose for each group was used at the end of anesthesia induction, and esketamine was changed to the corresponding maintenance dose for each group prior to surgical skin incision.
223674468|NCT00088036|DRUG|Olanzapine|
223674469|NCT05449015|DRUG|1% atropine|Daily application can be used for mydriasis and refraction examination Weekly long-term application can be used to control myopia
223674470|NCT03639571|DRUG|Ibuprofen 200 mg TEPI Medicated Plaster|Ibuprofen 200 mg TEPI Medicated Plaster, manufactured by AdhexPharma, France on behalf of Medherant Ltd., UK
223674471|NCT03639571|OTHER|Placebo TEPI Plaster|Placebo TEPI Plaster, manufactured by AdhexPharma, France on behalf of Medherant Ltd., UK
223674472|NCT00684047|BIOLOGICAL|FS Grifols|Fibrin Sealant Grifols (FS Grifols). Preliminary Part (I)
223674473|NCT00684047|BIOLOGICAL|FS Grifols|Fibrin Sealant Grifols (FS Grifols). Primary Part (II)
223772560|NCT04509700|DRUG|parsaclisib + ibrutinib|Participants will continue on the same dose (1,2.5,5 OR 20 mg) and schedule of parsaclisib and 140 mg of ibrutinib as that provided in the parent Protocol at the time of the rollover.
224255680|NCT01469026|RADIATION|PET/CT or Conventional diagnostics including CT|"Radiation:~PET/CT. 4 MBq/kg (max. 400 MBq) 18F-flour-deoxyglucosegiven iv. 60 min. before PET/CT scan.~CT. iv.contrast medium (Ultravist 370 mg I/ml)."
223674474|NCT00684047|PROCEDURE|Manual Compression|Manual Compression. Primary Part (II)
223674475|NCT00316108|DEVICE|WALLSTENT® Endoprosthesis™|Carotid Artery Stent
223674476|NCT05244980|DRUG|TDM-105795|TDM-105795 topical solution
223674477|NCT05244980|DRUG|Placebo|Placebo for TDM-105795 topical solution
223674478|NCT05484687|DRUG|Administer 1.5 mg/kg intravenously to the patient before induction of anesthesia, and continue to infuse 1.5 mg/kg/h during the operation until the end of the operation|Administer 1.5 mg/kg lidocaine
223674479|NCT01698710|DRUG|Albumin bound paclitaxel|Albumin bound paclitaxel will be administered into the mucinous cyst of pancreas in endoscopy procedure.
223674480|NCT02830438|DEVICE|Shear wave elastography|Ultrasound technique of the kidneys to assess wave elastography.
223674481|NCT00105053|BIOLOGICAL|HyperAcute-Prostate Cancer Vaccine|Before enrollment in the Phase I and Phase II- Arm A studies, the patient must be determined to have measurable disease with biopsies on first recurrence or bone metastases. In the Phase II- Arm B study, patients will be men with non-measurable progressive disease as evidenced by elevated PSA only. Cells will be injected intradermally every two weeks for 12 cycles on a prime-boost regimen. Dosage will vary from 30 million to 500 million HAP cells.
223674482|NCT04745273|DRUG|Ondansetron 4 MG (Kemoset 4mg)|Ondansetron 4mg (iv) will administer to participants
223674483|NCT04745273|OTHER|Salin solution|Salin solution 2ml (iv) will administer to participants
223674484|NCT01710410|DEVICE|active transcranial Direct Current Stimulation|Brief (20-min) application of weak electric current (e.g., 2 mA) to the scalp.
223674485|NCT01710410|DEVICE|sham transcranial Direct Current Stimulation|Brief (30-sec) application of weak electric current (e.g., 2mA) to the scalp.
223674486|NCT03346707|DEVICE|10.5 Tesla|10.5Tesla MR scan
223674487|NCT04381988|DRUG|Hydroxychloroquine|400mg daily
223674488|NCT04381988|OTHER|Placebo|400mg daily
223674489|NCT04381988|RADIATION|Radiation therapy|Standard radiation therapy will be prescribed and administered as per the patient's radiation oncologist.
224255681|NCT05905575|BEHAVIORAL|Family dyad diabetes intervention|The goals of the intervention are to encourage participants to (1) daily self-manage diabetes and stress; (2) establish a healthy eating pattern; (3) engage in brisk walking of 150 or more minutes a week; and (4) use solution-focused problem-solving strategy and supportive family communication skills.
224255682|NCT02480322|PROCEDURE|bariatric surgery (sleeve resection, proximal RYGB, distal RYGB)|
223674490|NCT03097354|OTHER|no intervention/observational survey study design|no intervention/observational survey study design
223674491|NCT06253221|DRUG|Mavacamten|Specified dose on specified days
223674492|NCT06253221|DRUG|Placebo|Specified dose on specified days
223674493|NCT03976869|DRUG|AZD7594|During treatment period, AZD7594 (360 µg per day) will be administered as oral inhalation via dry powder inhaler or DPI (SD3FL inhaler).
223674494|NCT00575835|DIETARY_SUPPLEMENT|vitamin D twice daily|Kalsipos-D, vitamin D3 400 ID/tbl, 2 tbl/day for one year
223674495|NCT00575835|DIETARY_SUPPLEMENT|Vitamin D3 oil three times in a year|Vigantol oil , D3 20000IU/ml, 4.9 ml every four months for one year
223674496|NCT00782587|DRUG|Chemophase|40 mg mitomycin with 800,000 U rHuPH20 total volume of 40 mL instilled
223674497|NCT01107379|DEVICE|Relieva Balloon Sinuplasty System|Sinuplasty balloon tools for dilation of sinuses in patients with chronic rhinosinusitis
223772561|NCT03840785|OTHER|Argentine tango|"Argentine tango sessions will consist of:~* Body perception and body control: sitting, standing then moving around four axes : space, time, energy, gravity.~* Awareness of oneself, of other and music: listening, communication, touch, empathy, kinesthesia, letting go, feeling"
223772562|NCT02181868|OTHER|Biodegradable and titanium fixation used in mandibular fractures.|
224255683|NCT04568785|BEHAVIORAL|Brief Intervention for Influenza vaccine|Previous to the intervention, patients were asked about the reasons to reject the influenza vaccine. Brief Intervention was performed by the healthcare professional during the consultation. It was given verbally, with written support.
224255684|NCT04568785|BEHAVIORAL|Normal advice|In the CG the influenza vaccine advice was the normal advice that professionals used to give their patients and was not asked for the reasons for the rejection of the vaccine to prevent them from influencing the advice.
224255685|NCT02991378|BEHAVIORAL|Children's emotional and stress coping program|Giving the children lessons about the emotional self-regulation skills and stress coping skills, with the psychoeducation books and lectures for the teachers and parents.
224255686|NCT00182429|DRUG|Metronidazole and Rifampin|
224255687|NCT00280644|DRUG|Leflunomide|
224255688|NCT06065150|PROCEDURE|Standard support|See arm/group descriptions
224255689|NCT06065150|PROCEDURE|Early surgery proposed according to the radiological score|"* If score ≥ 5: the risk of medical treatment failure is multiplied by 2.9 (Feuerstoss F et al, J Gastrointest Surg 2021). Early surgical treatment is proposed; that is, the procedure is performed within 24 hours of admission. The surgery is initiated by laparoscopy and converted to open surgery if necessary.~* If score \< 5: the risk of medical treatment failure is reduced. Initial medical treatment is therefore offered in accordance with standard management."
224255690|NCT00752635|DRUG|Norgestimate-ethinyl estradiol; Cyproterone acetate-ethinyl estradiol|
224255691|NCT06562426|BEHAVIORAL|Descriptive group on vitamin D awareness|300 mothers of under-five children will be recruited in the descriptive study to assess their awareness about vitamin D and observe children for their health status outcome. Three tools will be used which are; sociodemographic characteristics of children and their mothers, Mothers' Awareness of Vitamin D Structured Interview Schedule, and Health Status Outcomes of Under- Five Years Children. Permission to conduct the study will be obtained from the administrative authorities of the settings after an explanation of the aim of the study. Each mother will be interviewed individually to obtain characteristics of mothers and their children, as well as knowledge and performance regarding Vitamin D. Each child will be observed for the manifestation of vitamin D deficiency and to measure their weight and height.
224255692|NCT02544672|DEVICE|Myoelectric Elbow-Wrist-Hand orthosis|An arm orthosis that uses myoelectric signals to control the level of mechanical assistance provided to a user's elbow and hand in order to overcome upper limb weakness or paralysis and achieve functional tasks.
224255693|NCT01904344|DEVICE|Sensor testing and validation|
224255694|NCT02544386|PROCEDURE|MRI and 3D CT scan|Measurement of bone microarchitecture at the legs and wrists by 3D CT Scan and measuring the proportion of fat in the imaging leg bone (MRI)
224255695|NCT04477005|DEVICE|ERCP and insertion ofBio-degradable bile duct stent|ERCP is an accepted mode of treatment and patients rarely need surgery for bile leaks and bile duct stents. Endoscopic management involves sphincterotomy (cutting open the Sphincter of Oddi) and insertion of a plastic or metal stent. Instead of placing a plastic stent bio-degradable stent will be placed. They will be followed up on Day 1, 7,30, 60,90 and 180 days. they will have abdominal x-ray on day 90 and day180.
224255696|NCT03743961|OTHER|geriatric intervention|Geriatric intervention
223674498|NCT01716871|DEVICE|neurocryostimulation with Duo-cryo® device|organized in the morning and in the evening during 3days. The gaz is sprayed with Duo-cryo® device on dry skin over the ankle using a slow, regular, sweeping movement. The tip of the nozzle is kept 15 to 20 cm away from the skin. Neurocryostimulation is applied to patients for a duration of one minute by a trained staff
223674499|NCT01716871|DEVICE|cryotherapy with Cold pack® or ice-cubes pack|"Patients receive 2 controlled applications a day (one in the morning and one in the evening) of cryotherapy with Cold pack® or ice-cubes pack (with average dimensions of 5 cm by 8 cm) to the injury site for a duration of 20 minutes. Furthermore, the patients are instructed to do 2 more applications of the ice-pack during the daytime to follow the usual recommendations.~The first and last sessions of each day must be supervised by the medical care Unit to insure standardized data collection for each group."
223674500|NCT01733797|DEVICE|Wooden spatula|Lollipop sticks placed between incisors
223674501|NCT01733797|DEVICE|Therabite|Hand held device placed in mouth that exercises the jaw
223674502|NCT00609362|DRUG|Rosiglitazone|one tablet of rosiglitazone 8 milligrams per day for 14 weeks
224255697|NCT05752734|DRUG|Group D|"Patients who received 8 mg dexamethasone before bariatric surgery will be included in this group.~Multimodal analgesia protocol is applied to all patients undergoing bariatric surgery in our clinic. According to this protocol, patients are administered iv tenoxicam 20mg, tramadol 100mg after induction of general anesthesia, and iv morphine (0.05mg/kg/IBW) intraoperatively. Postoperative analgesia: iv paracetamol 1gr every 8 hours and iv pca of 0,4mg/ml morphine (the bolus dose is 1mg, the lock-in time of 15 minutes, the 4-hour limit is adjusted to be 40% of the calculated total dose). In cases where rescue analgesia is required (VAS score ≥3) 0.5 mg/kg tramadol is administered to patients. For postoperative nausea and vomiting prophylaxis, patients are routinely administered ondansetron 4 mg IV 20 minutes before extubation."
224322367|NCT04487951|OTHER|Pro BNP , Vitamin D|This study is designed to assess the difference between level of NT-pro-BNP, and Vitamin D in moderate cases who progressed to severe or critically ill category compared to those who did not.
224322368|NCT03553953|DEVICE|BIS device|Recording data from BIS device from patients who undergo elective surgery under general anesthesia
224322369|NCT06719128|DRUG|Olomorasib|Administered orally.
223674503|NCT00609362|DRUG|Placebo pill|One encapsulated placebo pill a day for 14 weeks
223674504|NCT04559529|DRUG|Levetiracetam (LEV) 500 mg|The levetiracetam pill will look just like the placebo pill.
223674505|NCT04559529|DRUG|Placebo|The placebo pill will look just like the levetiracetam pill, but does not contain any levetiracetam.
223674506|NCT02967380|PROCEDURE|Dynamic Contrast-Enhanced Magnetic Resonance Imaging|Undergo DCE-MRI
223674507|NCT02967380|DRUG|Gadobenate Dimeglumine|Given IV
223674508|NCT02967380|DRUG|Gadobutrol|Given IV
223674509|NCT02967380|RADIATION|Gadopentetate Dimeglumine|Given IV
223674510|NCT03553030|DEVICE|coronary artery angiography|In all patients authors performed a coronary artery angiography for detection of coronary artery stenosis.
223674511|NCT01278654|BEHAVIORAL|Incentive to exercise|Participants who attain their walkstation goal will be entered into a draw every two weeks. We are testing the effect of different prizes on walkstation usage.
223674512|NCT01009281|DRUG|AIN457|
223674513|NCT05861180|DEVICE|inclinometer, smart phone goniometer and laser beam|devices to objectively assess proprioception of the neck
223674514|NCT01981369|DRUG|Dexmedetomidine|Intravenous sedation with dexmedetomidine
223674515|NCT01981369|DRUG|Propofol|Intravenous sedation with propofol
223674516|NCT01981369|PROCEDURE|Infraclavicular block|All patients will receive ultrasound guided infraclavicular block with the standard protocol of the Block Room in St. Joseph Hospital.
223674517|NCT05472701|BEHAVIORAL|Diet order: WFPB, PBMA, Animal|Participants followed the WFPB, PBMA, and Animal diets (in this order) for 4 weeks each.
223674518|NCT05472701|BEHAVIORAL|WFPB, Animal, PBMA|Participants followed the WFPB, Animal, and PBMA diets (in this order) for 4 weeks each.
223674519|NCT05472701|BEHAVIORAL|PBMA, WFPB, Animal|Participants followed the PBMA, WFPB, and Animal diets (in this order) for 4 weeks each.
223674520|NCT05472701|BEHAVIORAL|PBMA, Animal, WFPB|Participants followed the PBMA, Animal, and WFPB diets (in this order) for 4 weeks each.
223674521|NCT05472701|BEHAVIORAL|Animal, WFPB, PBMA|Participants followed the Animal, WFPB, and PBMA diets (in this order) for 4 weeks each.
224255698|NCT05752734|DRUG|Group C|"Patients not administered dexamethasone will be included in this group.~Multimodal analgesia protocol is applied to all patients undergoing bariatric surgery in our clinic. According to this protocol, patients are administered iv tenoxicam 20mg, tramadol 100mg after induction of general anesthesia, and iv morphine (0.05mg/kg/IBW) intraoperatively. Postoperative analgesia: iv paracetamol 1gr every 8 hours and iv pca of 0,4mg/ml morphine (the bolus dose is 1mg, the lock-in time of 15 minutes, the 4-hour limit is adjusted to be 40% of the calculated total dose). In cases where rescue analgesia is required (VAS score ≥3) 0.5 mg/kg tramadol is administered to patients. For postoperative nausea and vomiting prophylaxis, patients are routinely administered ondansetron 4 mg IV 20 minutes before extubation."
224255699|NCT05178927|DEVICE|HoloLens v2|The HoloLens v2 will be used to access the participant's hologram \& set the participant up for treatment. Standard of care methods will be utilized to confirm treatment set-up.
224255700|NCT00276926|DRUG|STI571|
224255701|NCT03126747|DRUG|BAY86-5300_YAZ-Flex|Patients with endometriosis-associated pelvic pain and/or dysmenorrhea are enrolled solely after the physician's decision of YazFlex treatment in routine clinical practice.
224255702|NCT00673647|BEHAVIORAL|Cognitive-behavioral treatment|10 sessions of individual psychotherapy including cognitive-behavioral treatment, motivational enhancement and a psychosocial problem training.
223674522|NCT05472701|BEHAVIORAL|Animal, PBMA, WFPB|Participants followed the Animal, PBMA, and WFPB diets (in this order) for 4 weeks each.
223674523|NCT02128360|DRUG|Letrozole, Gonadotropins|
223674524|NCT02128360|DRUG|Gonadotropins|
223674525|NCT01920035|DEVICE|UroCool (Local cooling/hypothermia)|These patients will receive the UroCool device which will be inserted just prior to RARP surgery. The UroCool device will be used to effect localized cooling/hypothermia of the pelvic region prior to and during RARP surgery. It will be removed at the end of surgery.
223674526|NCT01153776|PROCEDURE|64-slice CT angiography|the sensitivity and specificity of 64-slice CT angiography for the detection of lesions at the ostia and proximal segments of the reimplanted coronary arteries
223674527|NCT05049720|DEVICE|Defibrillation using the Extravascular ICD|VT/VF induction attempted for defibrillation testing, as well as requisite electrical testing.
224255703|NCT03670017|DEVICE|OptiScanner® 5000 Glucose Monitoring System|The study population includes surgical critical care patients who require blood glucose monitoring. Subjects must have a vascular access device \[i.e., Central Venous Catheters (CVC), Multi-lumen Access Catheters (MAC) either in place or to be placed with an expected usage of at least 48 hours. During Phase One of the trial, patients will be connected to the OptiScanner for up to 72 hours and the hospital's current standard of care for glucose management will be followed.
224322370|NCT00174954|PROCEDURE|MRI|Subjects underwent MRI to evaluate tophi.
223674528|NCT00548405|BIOLOGICAL|Alemtuzumab 12 mg|Alemtuzumab 12 milligram (mg) per day intravenous (IV) infusion on 5 consecutive days at Month 0, followed by alemtuzumab 12 mg per day IV infusion on 3 consecutive days at Month 12.
223674529|NCT00548405|BIOLOGICAL|Alemtuzumab 24 mg|Alemtuzumab 24 mg per day IV infusion on 5 consecutive days at Month 0, followed by alemtuzumab 24 mg per day IV infusion on 3 consecutive days at Month 12.
223674530|NCT00548405|BIOLOGICAL|Interferon beta-1a|Interferon beta-1a 44 microgram (mcg) subcutaneously 3-times weekly for 24 months. Dose adjustment was done as per Investigator's discretion.
223674531|NCT03102190|DRUG|Verapamil Hydrochloride Intranasal|Verapamil solution for injection, supplied in vials, will be utilized in a Neil Med Sinus Rinse of 240mL buffered normal saline.
223674532|NCT05304091|OTHER|Questionnaire on a smartphone application|Each day, the smartphone application will ask the patient if he or she is having an angioedema attack. It not, the questionnaire will stop. If the patient is having an attack, a series of 5 short questions is asked about the attack characteristics and the events that preceded it.
223674533|NCT05200741|BIOLOGICAL|DelNS1-2019-nCoV-RBD-OPT1|Influenza Virus Vector COVID-19 Vaccine for Intranasal Spray
223674534|NCT05200741|BIOLOGICAL|Matching placebo|Solution for Intranasal Spray
223674535|NCT05664854|DEVICE|Nerve cuff electrodes for spatially selective vagus nerve stimulation and electrical impedance tomography|Vagus nerve electrode cuffs will be placed on the exposed human vagus nerve during routine vagal nerve stimulator implantation surgery. These cuffs will then be used for spatially selective vagus nerve stimulation, with physiological readout, and electrical impedance tomography for the functional imaging of organ-specific regions in the nerve at cervical level.
223674536|NCT00195845|DRUG|Galantamine|
223674537|NCT00195845|DRUG|Placebos|
223674538|NCT02985931|OTHER|Diagnostic imaging scans of SPECT and MRI|
223674539|NCT06094985|GENETIC|DNA exome sequencing of tumor and blood|A piece from tumor and a blood sample will be collected during surgery. DNA will be extracted and presence of tumor specific mutations/aberrations will be analysed with a DNA exome seq panel. Presence of identified markers will be followed in blood samples with the same panel and these blood samples will be collected in routine follow-up during the first two years. Presence of markers over time in blood will be correlated to outcomes 1-5.
224255704|NCT00678717|PROCEDURE|Autonomic Evaluation|Orthostatic vital signs will be determined by measuring heart rate (HR) and brachial blood pressure (BP) during a tilt table test. The degree of vagal mediated sinus arrhythmia will be assessed during controlled breathing (5 seconds inhalation and 5 seconds exhalation during 90 seconds), and the sinus arrhythmia parameters will be calculated as the difference and ratio of the longest to the shortest RR interval. The sympathetic response during breath hold will be measured. Responses of BP, HR, MSNA will be acquired during Valsalva maneuver. The valsalva ratio of heart rate will be calculated from the maximum of heart rate during or shortly after straining and the minimal depressed heart rate in the overshoot phase IV. Blood pressure and MSNA increase during isometric handgrip maintained at 30% of maximal voluntary contraction for five minutes will be determined. The blood pressure and MSNA response will be measured during cold pressor test with the hand in ice water for 1 minute.
224255705|NCT04613258|DIETARY_SUPPLEMENT|SCAR Porridge|The treatment group was given SCAR porridge supplementation in the form of a soft porridge (a mixture of 50 g dry powder porridge added to 200 mL of hot water) along with nutritional counseling. The control group only received nutritional counseling and no SCAR porridge supplementation. A 50 g portion of SCAR porridge was provided once a day for 14 days. The SCAR porridge was monitored and administered by a researcher once a week to inquire about adherence to the supplementation consumption and perceived side effects. All research subjects went through a clearance period of one week and were requested not to consume any supplements.
224255706|NCT04613258|OTHER|Counseling|21 subjects in the control group (C) who only received dietary counseling
224255707|NCT05247463|OTHER|Increase in upper age of eligibility for breast cancer screening from 64 to 70|The upper age limit of eligibility for Breast Cancer Screening increased in England from 64 to 70 as a result of the NHS Cancer Plan, so women were offered an additional 2 rounds of screening.
224255708|NCT05247463|OTHER|Screening round length|The target round length (frequency) of breast cancer screening in England is every 3 years. However in practice there is variability in this due to local centre capacity. The exposures are round lengths of approximately 2 years and approximately 3 years
224255709|NCT05247463|DIAGNOSTIC_TEST|Screening test threshold|Radiologists and equivalent health professionals examine women's screening mammograms for potential signs of cancer, and recall some women for further diagnostic tests. Each has a different test threshold for recall, characterised by the proportion of previous cases that they have recalled.
224255710|NCT06358209|PROCEDURE|Ventricular irrigation|Catheter ventricular irrigation can be employed by various forms. Lavage is performed with with each time at least 200ml of saline. Aside from lavage sessions, the lavage is paused, but continuous CSF drainage remains open.
224255711|NCT04741620|OTHER|Capsaicin 10microM (TRPV1 natural agonist)|10 mL Capsaicin 10microM solution 3 times per day (before each meal) during 14 consecutive days.
223674540|NCT04048161|DRUG|Tacrolimus|"The patients will be divided into two groups randomly. Tacrolimus dose: 0.05-0.10 mg/kg/day, BID. The concentration for tacrolimus is 5-10 ng/ml，then reduce the dosage of drugs to maintian the concentration for tacrolimus is \< 5ng/ml. Total duration : 1 year.~Steroid dose: 1.0-1.5 mg/kg, qod or 0.5-0.75 mg/kg/day, qd， then gradually taper the steroid to 5mg/day."
223674541|NCT04048161|DRUG|Mycophenolate Mofetil|"The patients will be divided into two groups randomly. Mycophenolate Mofetil dose: 20\~30mg/kg/day，BID. The concentration for MPA-AUC is 30\~50 μg.h/ml，then reduce the dosage of drugs to maintian the concentration for MPA-AUC is ≤40 μg.h/ml. Total duration : 1 year.~Steroid dose: 1.0-1.5 mg/kg, qod or 0.5-0.75 mg/kg/day, qd， then gradually taper the steroid to 5mg/day."
223674542|NCT05258669|BIOLOGICAL|BBV152|Each participant will receive 2 doses of the investigational product intramuscular injection of either 6 μg of BBV15 vaccine or placebo.
223674543|NCT01795820|DRUG|loading with Ticagrelor|Patients allocated in the two study arms will receive the same anti platelet treatment, except for the administration of the loading dose, which will be only administered to patients allocated in Group 2
223674544|NCT01795820|DRUG|no loading with Ticagrelor|"Patients allocated in the two study arms will receive the same anti platelet treatment, except for the administration of the loading dose, which will be only administered to patients allocated in Group 2.~In other words, patients randomized to this group (group 1) will not receive a loading dose of ticagrelor during the passage from clopidogrel to ticagrelor."
223674545|NCT04698330|DRUG|Berberine|0.6g (6 pills) of Berberine tablets administered twice a day orally before meal for 3 months
223674546|NCT04698330|DRUG|Inulin|0.6g (6 pills) of Inulin tablets administered twice a day orally before meal for 3 months
223674547|NCT04698330|DRUG|Berberine placebo tablets|0.6g (6 pills) of Berberine placebo tablets administered twice a day orally before meal for 3 months
223674548|NCT04698330|DRUG|Inulin placebo tablets|0.6g (6 pills) of Inulin placebo tablets administered twice a day orally before meal for 3 months
223674549|NCT06570824|DEVICE|active TMS|Transcranial magnetic stimulation using MagVenture XP Orange Stimulator using active side of MagVenture Cool-B70 coil
224255712|NCT04741620|OTHER|Piperine 150microM (TRPV1 & TRPA1 natural agonist)|10 mL Piperine 150microM solution 3 times per day (before each meal) during 14 consecutive days.
224255713|NCT04741620|OTHER|Cinnamaldehyde 756,6microM + zinc 70microM (TRPA1 natural agonist)|10 mL Cinnamaldehyde 756,6microM + zinc 70microM solution 3 times per day (before each meal) during 14 consecutive days.
224255714|NCT04741620|OTHER|Citric acid 457,5microM (pH=3,5) (ASIC3 natural agonist)|10 mL Citric acid 457,5microM (pH=3,5) solution 3 times per day (before each meal) during 14 consecutive days.
223674550|NCT06570824|DEVICE|sham TMS|Sham transcranial magnetic stimulation using MagVenture XP Orange Stimulator, flipping the active side of the MagVenture Cool-B70 coil
223674551|NCT05518877|DRUG|Ketamine|Administration of Ketamine
223674552|NCT06017466|DIAGNOSTIC_TEST|Visual Vertigo Analogue Scale (VVAS)|The Visual Vertigo Analogue Scale (VVAS) was developed by E. Dannenbaum et al in 2011 to diagnose visual vertigo. It is a nine-item analogue scale in which the subjects can rated the intensity of their symptoms. The symptoms can be categorized as None (0), Mild (0.1-40), Moderate (40.01-70) or Severe (70.01-100). The VVAS is already available in English and French but a Dutch version does not yet exist.
223674553|NCT01710371|DRUG|18F-AV-133|296 MBq (8 mCi)
223674554|NCT01710371|DRUG|10% Arginine Hydrochloride-R-Gene 10|
223674555|NCT01946906|DRUG|Rifaximin|
223674556|NCT00119093|PROCEDURE|Laboratory and clinical monitoring regimens|
224255715|NCT04741620|OTHER|Capsaicin 10microM + Citric acid 457,5microM (pH=3,5) (TRPV1 & ASIC3 natural agonists)|10 mL Capsaicin 10microM + Citric acid 457,5microM (pH=3,5) solution 3 times per day (before each meal) during 14 consecutive days.
224255716|NCT04741620|OTHER|Placebo (Methyl benzoate, Propyl benzoate, Propylenglycol)|10 mL placebo solution 3 times per day (before each meal) during 14 consecutive days.
224255717|NCT00835536|DRUG|Ribavirin 200 mg tablets|1 x 200 mg, single-dose non-fasting
224255718|NCT00835536|DRUG|COPEGUS™ 200 mg Tablets|1 x 200 mg, single-dose non-fasting
224255719|NCT06372457|DRUG|Approved Hypertrophic Cardiomyopathy drug treatments|As per product label
224255720|NCT06372457|DRUG|Mavacamten|As per product label
224255721|NCT02502474|OTHER|Staphylococcus aureus carriage|nasal, throat, rectal and groin sampling with swabs. Colonic sampling by colonic biopsy
224255722|NCT00582673|DRUG|AFQ056|
224255723|NCT00582673|DRUG|Placebo|
224255724|NCT01141374|OTHER|auriculotherapy by needles|The chinese auriculotherapy is a intervention used by Chinese Traditional Medicine in order to balance the body energy and to treat several kind of diseases using semi-permanent needles in specific points of the auricular pavilion.
224255725|NCT01141374|OTHER|auriculotherapy by seeds|We used the three points Shenmen, Kidney, and Brain Stem with mustard seeds, 1 time per week for 8 sessions.The subjects were instructed to stimulate the points three times a day.
224255726|NCT03173547|DRUG|146-9251 cream|146-9251 cream contains an active drug and is applied topically.
224255727|NCT03173547|DRUG|Vehicle cream|Vehicle cream does not contain an active drug and is applied topically.
224255728|NCT00657553|DRUG|Bortezomib|Year 1:1.0 mg/m2. IV. Days 1, 4, 8, 11 every 4 weeks Year 2: 1.0 mg/m2. IV. Days 1, 4, 8, 11 every 8 weeks Year 3: 1.0 mg/m2. IV. Days 1, 4, 8, 11 every 12 weeks
223674557|NCT03849391|DIETARY_SUPPLEMENT|Skate group|This group takes 500 mg/day Skate Skin extract for 12 weeks
223674558|NCT03849391|DIETARY_SUPPLEMENT|Placebo group|This group takes 500 mg/day Placebo for 12 weeks
223674559|NCT01967498|DRUG|Montelukast|
223674560|NCT01789918|DEVICE|PARADISE percutaneous renal denervation|Intravascular ultrasound emission
223674561|NCT04221243|DEVICE|3D printed space maintainer by NextDent Ortho Rigid|Biocompatible 3D printing material
223674562|NCT04221243|DEVICE|Conventional Band and Loop|metal space maintainer
223674563|NCT00098982|DRUG|bortezomib|
223674564|NCT00098982|DRUG|fluorouracil|
224255729|NCT05945030|OTHER|Clinical Examination|T2DM patient visiting Fortis CDOC will undergo clinical examination to determine the grade of Xanthelasma.
224255730|NCT00871247|DRUG|Finasteride 5 mg Tablet, single dose|A: Experimental Subjects received Intas Pharmaceuticals Ltd, India formulated products under fed conditions
224255731|NCT00871247|DRUG|Proscar® 5 mg Tablet, single dose|B: Active comparator Subjects received Merck Sharp and Dohme, U.S.A formulated products under fed conditions
224255732|NCT01196000|PROCEDURE|conventional laparoscopic surgery|operation using conventional laparoscopic techniques
224255733|NCT01196000|PROCEDURE|robotic-assisted laparoscopic surgery|operation that involves use of laparoscopic assistance with robotic assistance
223674565|NCT00098982|DRUG|leucovorin calcium|
223674566|NCT00098982|DRUG|oxaliplatin|
223674567|NCT02484625|OTHER|Potato chips|Commercially available potato chips, 180 kcal
223674568|NCT02484625|OTHER|Greek yogurt|Commercially available Greek yogurt, 180 kcal
224255734|NCT01196000|PROCEDURE|quality-of-life assessment|Ancillary studies
224255735|NCT01196000|OTHER|questionnaire administration|Ancillary studies
224255736|NCT00520429|BEHAVIORAL|ACCES - Adjusting to Chronic Conditions with Education and Support|The primary objective of this research is to pilot test a brief mental heath treatment specifically tailored to meet the needs of chronically ill patients with anxiety and/or depression. Using an open-trial format, the proposed study will examine the feasibility of a brief psychosocial intervention. Primary outcomes will assess intervention effects on patient and clinician rated symptoms of anxiety and depression. If proven feasible and effective among this group of participants, the intervention (due to its brief format and focus on medically ill patient needs) will possess unique characteristics that will increase the ability of medical care settings to implement mental health treatments, and will provide valuable pilot data for the development of a larger research project to determine the efficacy of this intervention among a larger group of chronically ill patients relative to usual care.
224255737|NCT03982030|DRUG|Dalbavancin|Dalbavancin 1.5g IV at day 0, day 8-10
224255738|NCT02691130|BIOLOGICAL|Multimeric 001 (M-001)|Multimeric 001 is a recombinant protein comprising 9 conserved peptides from influenza A and B
224255739|NCT02691130|BIOLOGICAL|H5N1 influenza vaccine|Alum adjuvanted whole virion inactivated H5N1 vaccine produced by FluArt (Hungary)
224255740|NCT02691130|BIOLOGICAL|Saline|0.9% NaCl in double distilled water
224255741|NCT00446563|DRUG|Valsartan|160 mg film coated tablets taken orally once daily in the morning.
224255742|NCT00446563|DRUG|Amlodipine|5 mg or 10 mg tablets taken orally once daily in the morning.
224255743|NCT00446563|DRUG|Hydrochlorothiazide|12.5 mg or 25 mg tablets taken orally once daily in the morning.
224255744|NCT00446563|DRUG|Losartan|100 mg tablets taken orally once daily in the morning.
224255745|NCT01202734|DRUG|Methylphenidate HCl|Period 1: One tablet, oral, 36 mg, once daily, single-dose on Day 1
224255746|NCT02403947|DRUG|Mesenchymal stem cells|After the sampling of bone-marrow and culture of MSCs by the French Blood Establishment (Midi-Pyrénées), patients will receive an IV injection of MSCs.
224255747|NCT02403947|DRUG|Suspension media|injection suspension media
224255748|NCT06102213|DRUG|B. infantis (PBCLN-014) and Human Milk Oligosaccharides (HMO) (PBCLN-010)|PBCLN-010: Human Milk Oligosaccharides (HMO). PBCLN-014: B. infantis.
224255749|NCT01169558|DRUG|Bevacizumab|5 mg/kg bevacizumab administered intravenously every 2 weeks or 7.5 mg/kg bevacizumab administered intravenously every 3 weeks according to the standard chemotherapy regimen.
224255750|NCT01169558|DRUG|Fluoropyrimidine-based Chemotherapy|Fluoropyrimidine-based chemotherapy administered according to standard of care.
224255751|NCT03776058|DRUG|Cinacalcet|Tablets for oral administration
224255752|NCT03776058|DRUG|Placebo|Tablets for oral administration
224255753|NCT02184936|OTHER|standard of care|
224255754|NCT04532684|DRUG|Duloxetine|
224255755|NCT04532684|DRUG|Pregabalin|
223772563|NCT05151939|DIAGNOSTIC_TEST|Identification or discharge visualization of mediastinal and abdominal organ/anatomic strictures through Endoscopic ultrasound (EUS) videos by an expert endoscopist|An expert endoscopist will select a dataset of mediastinal and abdominal EUS videos (one per patient). An expert endoscopist will identify or discharge visualization of the following organs correctly: aorta, vertebral spine, aortic arch, trachea, AP window, left kidney, liver, spleen, pancreas body, pancreas tail, coeliac trunk, splenic artery, splenic vein, inferior vena cava, adrenal gland, right kidney, gallbladder, common bile duct, ampulla of Vater, portal vein.
223674569|NCT02484625|OTHER|Cookies|Commercially available cookies, 180 kcal
223674570|NCT02484625|OTHER|Cheese|Commercially available cheese, 180 kcal
223674571|NCT02484625|OTHER|Milk|Commercially available milk, 180 kcal
223674572|NCT05331027|DRUG|Desflurane|After induction of anesthesia maintenance of anesthesia will be performed using goal-directed administration of desflurane with an intraoperative goal of bispectral index (BIS) 50±5.
223772564|NCT05151939|DIAGNOSTIC_TEST|Recognition of mediastinal and abdominal organ/anatomic strictures through Endoscopic ultrasound (EUS) videos using artificial intelligence (AI)|Using the same previous dataset of mediastinal and abdominal EUS videos, the EUS-AI model will recognize the following organs: aorta, vertebral spine, aortic arch, trachea, AP window, left kidney, liver, spleen, pancreas body, pancreas tail, coeliac trunk, splenic artery, splenic vein, inferior vena cava, adrenal gland, right kidney, gallbladder, common bile duct, ampulla of Vater, portal vein. Considering each patient (and not data frame videos) as the study unit, a contingency table per each mediastinal and abdominal organ/anatomic stricture will be designed.
224255756|NCT06321835|PROCEDURE|Endotracheal tube cuff pressure measurement|This is a prospective study conducted on 200 patients undergoing urological procedures in supine, prone, lateral flank and litotomy positions. After intubation (T0), the cuff pressure was checked with a cuff manometer and adjusted at 25 cmH2O as the baseline and continuously monitored. The cuff pressure was checked again before (T1) and after achieving the final position (T2) and then at 5 (T3), 10 (T4), 15 (T5), 30, 45, 60, 90, 120, 150, 180 minutes after the position, at the end of the procedure (T6) and before extubation (T7). At postoperative 2nd and 12th hours, the patients were interviewed for sore throat, hoarseness and cough.
224255757|NCT00910221|DRUG|Atorvastatin|Atorvastatin tablet
224255758|NCT00910221|DRUG|Placebo|Placebo tablet
224255759|NCT02702882|DIETARY_SUPPLEMENT|Fenugreek Seeds Extract|Furosap one caps OD
224255760|NCT06559358|DEVICE|electrical stimulation|A two-channel portable electrical stimulation unit (BTL-4620, Czech Republic).
224255761|NCT02749266|OTHER|Chiropractic adjustment|Participant will receive a chiropractic adjustment utilizing a handheld chiropractic instrument called an Activator.
224255762|NCT02749266|OTHER|Sham chiropractic adjustment|Participants will receive a simulated chiropractic adjustment with a handheld adjusting instrument called an Activator.
224255763|NCT01310257|OTHER|Questionnaires|Patients will be given questionnaires relevant to their condition to complete. In Study 2 and a sub-study of Study 1, patients will be invited to take part in Quantitative Sensory Testing.
223674573|NCT05331027|DRUG|Sevoflurane|After induction of anesthesia maintenance of anesthesia will be performed using goal-directed administration of sevoflurane with an intraoperative goal of bispectral index (BIS) 50±5.
224255764|NCT04215705|PROCEDURE|Quadratus block versus peritubal local infiltration|Quadratus lumborum block III versus peritubal local infiltration in patients undergoing Percutaneous Nephrolithotomy operation
224255765|NCT03251807|DEVICE|Twin-block|Functional treatment will be achieved using the Twinblock appliance
224255766|NCT03251807|OTHER|LIPUS (Low-intensity pulsed ultrasound)|Functional treatment will be combined with LIPUS (Low-intensity pulsed ultrasound )
224255767|NCT03077451|OTHER|Laboratory Biomarker Analysis|Correlative studies
224255768|NCT03077451|DRUG|Nelfinavir Mesylate|Given PO
223674574|NCT06364930|DRUG|Dapagliflozin 10mg Tab|Dapagliflozin 10mg Tab QD for 60 months.
223674575|NCT06364930|DRUG|Placebo 10mg Tab|Placebo 10mg Tab QD for 60 months.
223674576|NCT02582684|DRUG|Dolutegravir|Participants were prescribed 50 mg of DTG orally daily
223674577|NCT02582684|DRUG|Lamivudine|Participants were prescribed 300 mg of 3TC orally daily.
223772565|NCT00414050|BIOLOGICAL|Modified Process Hepatitis B Vaccine (Experimental)|Modified Process Hepatitis B Vaccine given intramuscularly (IM) in 3 injections of 5 ug (micrograms)/0.5 mL each over 4 months (Modified Process Hepatitis B vaccine 5 μg arm). Modified Process Hepatitis B Vaccine given IM in 3 Injections of 10 ug (micrograms)/0.5 mL each over 4 months (Modified Process Hepatitis B vaccine 10 μg arm).
223772566|NCT00414050|BIOLOGICAL|Hepatitis B Vaccine (Recombinant)|RECOMBIVAX HB™ (currently licensed product) given IM in 3 Injections of 5 ug/0.5 mL each over 4 months.
223772567|NCT00414050|BIOLOGICAL|Hepatitis B Vaccine (Recombinant)|ENGERIX-B® (currently licensed product) given IM in 3 Injections of 10 ug/0.5 mL each over 4 months
223772568|NCT01675180|OTHER|Information|Women in the intervention group will recieve information and counseling on oral health care during pregnancy
224255769|NCT04188080|DIETARY_SUPPLEMENT|Jarlsberg Cheese|Oral daily intake of Jarlsberg cheese
224255770|NCT05784428|RADIATION|Single fraction SABR|"Participants randomized to this arm will receive SF SABR~Treatment recommendations are as follows:~Lung: Greater than 2 cm from mediastinum or brachial plexus or if mandatory OAR constraints are met: 30 Gy in 1 fraction~Lung: Within 2 cm of mediastinum or brachial plexus 20 Gy in 1 fraction~Bone, Spine, Adrenal, lymph node/soft tissue: 20 Gy in 1 fraction~Liver: 30 Gy in 1 fraction~Brain: dose as per institutional policy"
223674578|NCT06454188|DRUG|Upadacitinib 15 MG [Rinvoq]|15mg tablet once per day.
223674579|NCT06454188|DRUG|Placebo|15mg tablet once per day.
223674580|NCT06189781|DRUG|Ropivacaine injection|The local anesthetic group will be injected with ropivacaine 2mg/mL (3mg/kg), epinephrine 1mg/mL (0.5mg), and ketorolac 30mg/mL (0.5mg/kg). The maximum dose of ropivacaine regardless of patient weight will be 200mg. This is based on recommended maximum dose protocols from our anesthesia colleagues. If bilateral hips are involved, the total amount will be split evenly between the two sides.
223674581|NCT06189781|DRUG|Bupivacaine, lidocaine, ropivacaine|The lumbar epidural group will receive a combination of either/or bupivacaine, lidocaine, and ropivacaine, which will be monitored by the anesthesia team.
223674582|NCT02391805|DRUG|Entecavir|Entecavir will be administered as per local labeling.
223674583|NCT02391805|DRUG|Placebo|Participants will be administered PO placebo capsules matched to RO6864018, either QOD or QWk for 12 weeks of treatment.
223674584|NCT02391805|DRUG|RO6864018|Participants will be administered RO6864018 as 200-mg PO capsules at a dose of 800 mg or 1200 mg, either QOD or QWk for 12 weeks of treatment.
223772569|NCT01675180|OTHER|Control|No intervention
224255771|NCT05784428|RADIATION|Multiple fraction SABR|"Participants randomized to this arm will receive MF SABR:~Dose/Fractionation are as follows:~Lung: Greater than 2 cm from mediastinum or brachial plexus or if mandatory organ-at-risk (OAR) constraints are met: 48 Gy in 4 fractions (12 Gy/#), 54 Gy in 3 fractions (18 Gy/#), daily or every second day~Lung: Within 2 cm of mediastinum or brachial plexus 60 Gy in 8 fractions (7.5 Gy/#), 50 Gy in 5 fractions (10 Gy/#), daily~Bone: Any bone except spine: 35 Gy in 5 fractions (7 Gy/#), daily~Liver: 54 Gy in 3 fractions (18 Gy/#) or 5 fractions (10.8 Gy/#), daily or every second day~Spine: 24 Gy in 2 fractions (12 Gy/#) or 35 Gy in 5 fractions (7 Gy/#), daily~Adrenal: 40 Gy in 5 fractions (8 Gy/#) or 35 Gy in 5 fractions (7 Gy/#), daily~Lymph node/soft tissue: 40 Gy in 5 fractions (8 Gy/#) or 35 Gy in 5 fractions (7 Gy/#), daily~Brain - dose per institutional policy for stereotactic lesions (no whole brain RT)."
224255772|NCT05784428|OTHER|QoL reporting alone|Participants randomized to this arm will complete the EQ-5D-5L and FACT-G at baseline and each follow-up visit
224255773|NCT05784428|OTHER|QoL reporting, symptom screen and healthcare provider intervention|Participants randomized to this arm will complete the FACT,G, EQ-5D-5L, radiation-symptom screen and receive healthcare provider-guided intervention based on their symptom reports.
224255774|NCT06562517|OTHER|Digital training module|The intervention is a 24/7 accessible educational website for pediatric oncology nurses, based on the EONS Cancer Nursing Education Framework. It features five validated training modules, enhanced with visual and auditory materials such as videos and infographics. Nurses will receive login credentials, allowing them to access the platform and participate in the training. Each module ends with a 20-question test, requiring a score of 60 to advance. A support line enables nurses to ask questions directly to researchers. Successful completion of each module earns a certificate. The website will be piloted with 15 nurses, and feedback will be used to refine its design and content.
224255775|NCT03022786|OTHER|Order set|Inpatient order set and ambulatory care guide offer guidance on initial compression to decrease edema, obtaining gradient compression stockings, how to access evaluation by vascular medicine for pain or dermatology for evaluation of allergic contact dermatitis if itch persists, etc
224255776|NCT03022786|OTHER|Motivational Interviewing training for home health aides|"Home Care aides trained about use of compression stockings and use of motivational interviewing as a tool to help patients make behavior changes to reduce leg swelling. This is part of our 'tool kit'.~There will be a focus group comprised of providers. This focus group will explore the perceptions of the providers and what unmet needs remain for the patients."
224255777|NCT03022786|OTHER|Tools & Education|Engaged physical therapists to evaluate patients for ability to don stockings, to assess need for strengthening exercises or leg exercises to improve venous return. This is part of our 'tool kit'
224255778|NCT04709081|DRUG|ACH-0145228|ACH-0145228 was dosed as 2 x 60 milligram (mg) (Part 1) or 1 x 40 mg (Part 2) powder in capsules.
224255779|NCT04709081|DRUG|Midazolam|Midazolam was dosed at 2 mg (1 milliliter \[mL\] of a 2 mg/mL syrup).
224255780|NCT04709081|DRUG|Digoxin|Digoxin was dosed as Lanoxin (or generic equivalent) at 1 x 0.25 mg tablet.
223772570|NCT00491686|DRUG|AZD6765|intravenous infusion
223772571|NCT02097992|DRUG|Roflumilast Placebo|Placebo pill
223772572|NCT02097992|DRUG|Roflumilast|500 Ug ORAL TABLET
224255781|NCT04709081|DRUG|Itraconazole|Itraconazole was dosed as Sporanox (or generic equivalent) at 200 mg (20 mL of a 10 mg/mL oral solution).
224255782|NCT04489641|BEHAVIORAL|Psychological treatment|Psychological treatment
224255783|NCT04489641|DRUG|Medication|Pharmacological intervention
224255784|NCT06556043|OTHER|cM1 transcranial direct current stimulation|During the 5-day skill acquisition phase, all participants will undertake a 20-minute session of learning a sequential ankle tracking task with their non-dominant (for healthy adults) or affected (for patients with stroke) foot each day, using a custom-built ankle tracking system. The cM1 group will receive AtDCS stimulation at 2 mA during acquisition phase.
224255785|NCT06556043|OTHER|cPPC transcranial direct current stimulation|During the 5-day skill acquisition phase, all participants will undertake a 20-minute session of learning a sequential ankle tracking task with their non-dominant (for healthy adults) or affected (for patients with stroke) foot each day, using a custom-built ankle tracking system. The cPPC group will receive AtDCS stimulation at 2 mA during acquisition phase.
223674585|NCT02391805|DRUG|Tenofovir|Tenofovir will be administered as per local labeling.
223674586|NCT04664738|BIOLOGICAL|10% PEP|PEP is comprised of platelet derived extracellular vesicles enriched in anti-inflammatory and angiogenic growth factors.
223674587|NCT04664738|DRUG|TISSEEL|Fibrin sealant made from pooled human plasma
223674588|NCT04664738|BIOLOGICAL|20% PEP|PEP is comprised of platelet derived extracellular vesicles enriched in anti-inflammatory and angiogenic growth factors.
223674589|NCT05116254|COMBINATION_PRODUCT|AZD1390 + radiotherapy|AZD1390 combined with preoperative radiotherapy
223674590|NCT05116254|COMBINATION_PRODUCT|AZD1390 + durvlaumab + radiotherapy|AZD1390 combined with durvalumab and preoperative radiotherapy
223772573|NCT05369221|DEVICE|ReSpace™|All of the subjects will be injected with ReSpace™ hydrogel.
223772574|NCT03304379|DRUG|Fasinumab|Solution for injection in pre-filled syringe
223772575|NCT03304379|OTHER|Diclofenac|NSAID active comparator (capsule)
223772576|NCT03304379|OTHER|Celecoxib|NSAID active comparator (capsule)
223772577|NCT03304379|DRUG|Matching placebo|Fasinumab-matching placebo (solution for injection in pre-filled syringe); NSAID-matching placebo (capsule)
224255786|NCT06556043|OTHER|iCBM transcranial direct current stimulation|During the 5-day skill acquisition phase, all participants will undertake a 20-minute session of learning a sequential ankle tracking task with their non-dominant (for healthy adults) or affected (for patients with stroke) foot each day, using a custom-built ankle tracking system. The iCBM group will receive AtDCS stimulation at 2 mA during acquisition phase.
224255787|NCT06556043|OTHER|sham transcranial direct current stimulation|For the Sham group, the montages of the paired electrode placements will be randomly selected from the other three pairs using blocks of size 3, so that the three types of montages will have equal opportunities to be used in the Sham group. The intensity will be set at 0 mA for the Sham group. There will be a 30-second ramp-up for the Sham group. Once the current reaches 2 mA in the ramp-up period, it will drop to 0 mA for the entire 20 minutes during learning for the Sham group.
224255788|NCT03916393|DRUG|PF-06651600 20 mg|PF-06651600 in four (4) different oral formulations will be administered in different periods.
224255789|NCT03916393|OTHER|Bitrex solution|Bitrex solution at 0.5 ppm will be included in the treatment sequence together with the four PF-06651600 formulations.
224255790|NCT02193724|OTHER|Skin Biopsy|A very small skin sample will be taken from the participant's arm. This will only be performed while the patient is under sedation for clinical purposes (e.g. exam under anesthesia, MRI, or other procedure requiring sedation).
224255791|NCT02193724|OTHER|Blood Draw|About 1 teaspoon of blood will be drawn from the participant's arm or from a central line catheter if present. Blood collection will be done at the same time the participant has blood drawn for routine clinical care.
224255792|NCT00852696|DRUG|Solifenacin|Solifenacin is used to treat overactive bladder. It works by relaxing the bladder muscles to prevent urgent, frequent, or uncontrolled urination. Take orally once daily for 9 weeks.
224255793|NCT00852696|OTHER|Placebo|Take orally once daily for 9 weeks.
224255794|NCT02512900|DRUG|MEDI9929, 140 mg|On Day 1, two MEDI9929 subcutaneous injection of 70 mg each were given into the anterior aspect of one thigh immediately followed by the second injection into the anterior aspect of the contralateral thigh to make the required dose of 140 mg in participants of 12 to 17 years of age.
224255795|NCT05526313|DRUG|Purinostat Mesylate 1.2mg/m^2|1 case,The starting dose,Take the medicine once on D1, D8, D11, D15.
223674591|NCT06468748|DRUG|Semaglutide|During the first visit, participants will be taught how to self-administer the pen injector by medical staff. Participants will also be provided instructions for self-administering injections and a compliance log to track adherence to the treatment, and additional information about each injection (date, time, injection site)
223674592|NCT06267313|BEHAVIORAL|Attention Bias Modification|Training attention away from threat
223772578|NCT05389592|PROCEDURE|Active tDCS and cognitive training|Electrical stimulation is delivered by the Soterix device, consisting of a one-size-fits-all, transcranial direct current stimulation headset with square electrodes. The anode is positioned over the left prefrontal cortex, and the cathode over the right prefrontal cortex. Current strenght is set at 2mA for 20 minutes, daily for 5 continuous days (with a 2-day pause) for 4 weeks. Cognitive training consists of a series of tasks performed in the BrainHQ app, which aim to stimulate the impaired cognitive domains in people with PASC. The cognitive training sessions are performed concomitantly to the tDCS sessions.
223772579|NCT05389592|PROCEDURE|Sham tDCS and cognitive training|Sham electrical stimulation is delivered by the Soterix device, consisting of a one-size-fits-all, transcranial direct current stimulation headset with square electrodes. The anode is positioned over the left prefrontal cortex, and the cathode over the right prefrontal cortex. The sham protocol consists of a fade-in and fade-out phases of 1mA for 45 seconds, followed by a silent period in between for the remaining session time. Cognitive training consists of a series of tasks performed in the BrainHQ app, which aim to stimulate the impaired cognitive domains in people with PASC. The cognitive training sessions are performed concomitantly to the tDCS sessions.
223772580|NCT03402243|OTHER|Menthol ban on cigarettes|Participants will have menthol and tobacco flavored e-cigarettes available but only non-menthol cigarettes
223772581|NCT03402243|OTHER|Menthol ban on cigarettes and e-cigarettes|Participants will have neither menthol flavored cigarettes or e-cigarettes available
224255796|NCT05526313|DRUG|Purinostat Mesylate 2.4mg/m^2|Take the medicine once on D1, D8, D11, D15.
224255797|NCT05526313|DRUG|Purinostat Mesylate 4.0mg/m^2|Take the medicine once on D1, D8, D11, D15.
224255798|NCT05526313|DRUG|Purinostat Mesylate 6.0mg/m^2|Take the medicine once on D1, D8, D11, D15.
224255799|NCT05526313|DRUG|Purinostat Mesylate 8.4mg/m^2|Take the medicine once on D1, D8, D11, D15.
224255800|NCT05526313|DRUG|Purinostat Mesylate 11.2mg/m^2|Take the medicine once on D1, D8, D11, D15.
224255801|NCT05526313|DRUG|Purinostat Mesylate 15mg/m^2|Take the medicine once on D1, D8, D11, D15.
224255802|NCT06975059|DEVICE|NUSHU shoe|The NUSHU shoe, created by Magnes AG, can measure real-time detection of gait analysis while providing vibrotactile stimulus to the study participant through machine learning sensors. This may provide a feedback mechanism that acts as therapy for gait difficulties.
224255803|NCT02962752|DIETARY_SUPPLEMENT|Blackadder Juice|
224255804|NCT02962752|OTHER|Placebo|
224255805|NCT00031395|DRUG|clonidine|Clonidine is FDA-approved for the treatment of hypertension in adults.
224255806|NCT00031395|DRUG|methylphenidate|MPH is FDA-approved for the treatment of ADHD symptoms in children.
224255807|NCT00031395|OTHER|placebo|an inactive substance
223674593|NCT06267313|BEHAVIORAL|Attention Control Training|Training attention control
223674594|NCT06267313|BEHAVIORAL|Neutral training|Attention training with Neutral stimuli
223674595|NCT03025035|DRUG|Pembrolizumab|Pembrolizumab IV solution administered on Day 1 of each 3-week cycle
223674596|NCT03025035|DRUG|Olaparib|Olaparib administered orally twice a day
223674597|NCT05976828|DRUG|IBRX-042|"* Dose cohort 1: 1e11 virus particles (VP)/dose~* Dose cohort 2: 5e11 VP/dose~* If needed, dose cohort -1 (de-escalation): 5e10 VP/dose"
223674598|NCT00935155|PROCEDURE|Acupuncture|Westerns style acupuncture. Twice a week for 12 weeks
223674599|NCT00935155|PROCEDURE|exercises|Coordination, mobilizing, endurance, strength
224255808|NCT06137833|DIETARY_SUPPLEMENT|APPOPRTAL®|1 sachet of APPORTAL® contains: Vitamin C 37,5 mg; Vitamin E 30 mg; Vitamin PP 18 mg; Vitamin B1 1 mg; Vitamin D 25 μg; Vitamin H 25 μg; L-arginine 1000 mg; L-carnitine 500 mg; Taurine 25 mg; Ginseng e.s. 100 mg; Eleutherococcus e.s. 50 mg; Magnesium 187,5 mg; Iron 14 mg; Zinc 1,5 mg; Iodine 75 μg; Selenium 27,5 μg; Coenzyme Q10 100 mg; Lycopene 3,06 mg; Tocotrienols 2,5 mg; Coenzyme Q10 100 mg; Lycopene 3,06 mg; Tocotrienols 2,5 mg
224255809|NCT06137833|OTHER|Placebo|Ingredients: Maltodextrin, acidifying agent: citric acid, flavours, anticaking agent: tricalcium phosphate, beetroot juice powder; sweetener: sucralose, anti-caking agent: silicon dioxide, colouring agent: beta-carotene
224255810|NCT02510391|BEHAVIORAL|PIPA|Parent-training Intervention for Preschoolers with Anxiety (PIPA) is a behaviorally based modular treatment program for emotional and behavioral problems in young children. 12 sixty minute sessions will be delivered weekly. This intervention employs a modular format following a treatment algorithm in which therapy modules are selected by the therapist and supervisor on a session-by-session basis to address the most pressing clinical needs. Minimum session requirements for parent training/education and fear hierarchy/exposure are set to insure adequate dose of core exposure and response prevention for anxiety across cases.
224255811|NCT02409355|DRUG|Atezolizumab|Atezolizumab will be administered at a dose of 1200 milligrams (mg) by IV infusion on Day 1 of each 21-day cycle until loss of clinical benefit.
224255812|NCT02409355|DRUG|Carboplatin|Carboplatin will be administered at area under the concentration-time curve (AUC) 5 IV infusion once on Day 1 of each 21-day cycle for 4 or 6 cycles.
224255813|NCT02409355|DRUG|Cisplatin|Cisplatin will be administered at 75 milligrams per square meter (mg/m\^2) IV infusion once on Day 1 of each 21-day cycle for 4 or 6 cycles.
224255814|NCT02409355|DRUG|Gemcitabine|Gemcitabine will be administered at 1000 mg/m\^2 (when coadministered with carboplatin) or 1250 mg/m\^2 (when coadministered with cisplatin) IV infusion on Days 1 and 8 of each 21-day cycle for 4 or 6 cycles.
224255815|NCT00838539|DRUG|Neratinib|
224255816|NCT00838539|DRUG|Temsirolimus|
224255817|NCT06563271|DRUG|Dexketoprofen Trometamol 50 Mg/mL Solution for Injection|Dexketoprofen 50 mg administered parenterally (intravenously in 150 cc isotonic saline over 15 minutes infusion).
224255818|NCT06563271|DRUG|Ibuprofen 100 MG/ML Solution for Injection|"Ibuprofen 100 mg/ml administered parenterally (intravenously in 150 cc isotonic saline over 15 minutes infusion).~Group P: Paracetamol 10 mg/ml administered parenterally (intravenously in 150 cc isotonic saline over 15 minutes infusion)."
224255819|NCT06563271|DRUG|Paracetamol 10 Mg/mL Solution for Injection|Paracetamol 10 mg/ml administered parenterally (intravenously in 150 cc isotonic saline over 15 minutes infusion).
224255820|NCT06563271|DRUG|isotonic saline|Ibuprofen and dexketoprofen will be administered intravenously (IV) by mixing them into 150 cc of isotonic saline.
224255821|NCT01255085|DIETARY_SUPPLEMENT|yellow pea protein|Served in a tomato soup
224255822|NCT01255085|DIETARY_SUPPLEMENT|yellow pea fiber|Served in a tomato soup
224255823|NCT01255085|DIETARY_SUPPLEMENT|Control Tomato Soup|Served in a tomato soup
224255824|NCT01704105|BEHAVIORAL|Water Quality|Hardware: Chlorine dispensers provided for free at communal water sources. Promotion: Local promoters will visit study compounds at least monthly during the first year and bi-monthly thereafter to deliver behavior change messages that focus on the treatment of drinking water for all children living in the household.
224255825|NCT01704105|BEHAVIORAL|Sanitation|"Hardware: Free child potties, sani-scoop hoes to remove feces from household environments, and new or upgraded pit latrine for each study compound. Upgrades may include structural improvements, plastic slabs, and superstructure improvements.~Promotion: Local promoters will visit study compounds at least monthly during the first year and bi-monthly thereafter to deliver behavior change messages that focus on the use of latrines for defecation and the removal of human and animal feces from the compound."
224255826|NCT01704105|BEHAVIORAL|Handwashing|"Hardware: Handwashing dual tippy tap stations, including jugs for clean and for soapy water. Handwashing stations will be stocked with soap for the duration of the trial.~Promotion: Local promoters will visit study compounds at least monthly during the first year and bi-monthly thereafter to deliver behavior change messages that focus on handwashing with soap at critical times around food preparation, defecation, and contact with feces."
224255827|NCT01704105|DIETARY_SUPPLEMENT|Nutrition|"Supplement: Lipid-based Nutrient Supplement (LNS) twice daily from ages 6 to 24 months.~Promotion: Local promoters will visit study compounds at least monthly during the first year and bi-monthly thereafter to deliver behavior change messages modeled on those recommended in the Guiding Principles for Complementary Feeding of the Breastfed Child and the recent UNICEF Program Guide for Infant and Young Child Feeding Practices. General messages will include (1) practice exclusive breastfeeding from birth to 6 months of age and introduce complementary foods at 6 months of age while continuing to breastfeed; (2) continue breast feeding as you did before receiving LNS; (3) provide your child micronutrient-rich foods such as meat, fish, eggs, and vitamin A rich fruits and vegetables; and (4) feed your child at least 2-3 times per day when 6-8 months old and 3-4 times per day when 9-24 months old."
224255828|NCT04418349|PROCEDURE|"posterior component separation modified TAR technique Transversus Abdominids Release"|"Evaluation of posterior component separation modified TAR technique Transversus Abdominids Release in the treatment of parastomal hernia"
224322371|NCT01324531|PROCEDURE|Bankart repair and remplissage|Bankart repair may be completed before or after remplissage. While maintaining camera in anterior-superior portal drill guide and anchor cannula is placed through the posterior portal into remplissage site. Anchor cannula with obturator is passed through infraspinatus tendon and posterior capsule via pre-existing portal, and first anchor is placed in inferior aspect of Hill-Sachs lesion.Once anchor is inserted, penetrating grasper is passed through tendon and posterior capsule, 1 cm inferior to the initial portal entry site, to grasp and pull 1 suture limb.Second anchor is placed in superior aspect of Hill-Sachs lesion and grasper penetrator is used in same fashion to pass 1 suture limb 1 cm superior to initial portal entry site. The inferior suture is tied first with knots remaining extraarticular in the subdeltoid space. The superior suture is tied to complete remplissage.
224322372|NCT01324531|PROCEDURE|Bankart repair|Bankart repair based on surgeon's preference
224322373|NCT04943276|DEVICE|Embr Device|The Embr thermal device will be worn at all times from study start to the study endpoint.
224322374|NCT00224380|BEHAVIORAL|Using Medications Effectively|
224322375|NCT01190553|DRUG|Amantadine|Initiation: IV amantadine 200mg/500ml \* 1/d for 3 days Maintenance: IV amantadine 200mg/500ml once per 6 weeks for 6 months
223772582|NCT03402243|OTHER|No menthol ban|Participant will have menthol and tobacco flavored cigarettes and e-cigarettes available
224255829|NCT05528588|COMBINATION_PRODUCT|Furoscix|"Study Drug: Furoscix®, (Furosemide Injection), 80 mg/10 mL is a proprietary furosemide formulation that is buffered to a neutral pH to enable subcutaneous administration and contained in a prefilled Crystal Zenith® (CZ) cartridge.~Study Device: The Infusor is a compact, ethylene oxide (EtO) sterilized, single-use, electro-mechanical (battery powered, micro-processor controlled), on-body subcutaneous delivery system based on the SmartDose® Gen II 10 mL (West Pharmaceutical Services).~The Furoscix Infusor is an investigational drug-device combination product. The Infusor is applied to the abdomen via a medical grade adhesive and delivers a subcutaneous infusion of Furoscix through a pre-programmed, biphasic delivery profile with 30 mg (3.75 mL) administered over the first hour, followed by 12.5 mg (1.56 mL) per hour for the subsequent 4 hours (Total dose is 80 mg (10 mL) over 5 hours)."
224255830|NCT05528588|DRUG|Diuretic Therapy|Patients will receive home dose oral furosemide or oral furosemide per standard of care.
224255831|NCT05347875|OTHER|Walking aid skills app|"The interventional app teaches users how to fit, walk with, and navigate stairs and chairs with a walking aid. It contains instructional videos with key components of these skills highlighted. The user can use their phone's video to record themselves performing the taught skills to enable them to review their usage of the walking aids."
224255832|NCT05347875|OTHER|Breathing skills app|This app has the same interface as the ICanWALK app. Instead, it teaches deep breathing for stress relief and breathing to improve lung function.
224255833|NCT04940312|BEHAVIORAL|App-based physical activity coaching|Individualized app-based coaching via a smartphone
224255834|NCT04940312|BEHAVIORAL|No Intervention: Observational Cohort|no Intervention
224255835|NCT04940312|BEHAVIORAL|Intervention Group 1|pedometer-based tracking of physical activity
224255836|NCT03948503|PROCEDURE|Mulligan concept|Mobilization with movement during an active dorsi-flexion of the ankle
224255837|NCT03948503|PROCEDURE|Placebo|Sham mobilization with movement during an active dorsi-flexion of the ankle
224255838|NCT03182322|DRUG|intranasal insulin|Total of 6 months treatment; daily for the first 7 intervention days and one day per week thereafter (formulation containing rH-insulin, benzalkonium chloride, glycerol and water)
224255839|NCT03182322|OTHER|Placebo|Total of 6 months treatment; daily for the first 7 intervention days and one day per week thereafter placebo (formulation containing benzalkonium chloride, glycerol and water)
224255840|NCT03134222|DRUG|Lanraplenib|30 mg tablets administered orally once daily with or without food
224255841|NCT03134222|DRUG|Filgotinib|200 mg tablets administered orally once daily with or without food
224255842|NCT03134222|DRUG|Lanraplenib placebo|Tablets administered orally once daily with or without food
224255843|NCT03134222|DRUG|Filgotinib placebo|Tablets administered orally once daily with or without food
224255844|NCT00906165|DEVICE|Straumann® Bone Level SLActive Implant (4.1mm diameter)|Straumann® Bone Level Implants will be placed in healed alveolar ridge (at least 8 weeks post extraction). Implants in Arm 1 will be immediately provisionalized. Implants in Arm 2 will not be immediately provisionalized. Implants in both Arms will be loaded at 16 weeks (final prosthetic reconstruction will be performed according to the standard procedure for single crown restoration)
224255845|NCT01220362|DRUG|Bupivacain 0.125%|Bupivacain 0.125%
224255846|NCT01220362|DRUG|Bupivacain 0.125%/Fentanyl 2mcg/ml|Bupivacain 0.125%/Fentanyl 2mcg/ml
224255847|NCT00627419|DRUG|IPI-504|Dose as a 30 to 60 minute IV infusion as part of a 21-day treatment cycle until unacceptable toxicity, disease progression, initiation of alternative anticancer therapy, or other reasons for patient withdrawal. IPI-504 will be administered twice weekly on Study Days 1, 4, 8, and 11 of each 21-day cycle.
223772583|NCT02873104|DEVICE|truSculpt rf device|radiofrequency device
223772584|NCT04480164|DRUG|NDMC|Repeated oral administration of ascending daily doses of NDMC (40mg, 60mg,120mg/day) vs placebo in 3 sequential cohorts
224255848|NCT01270594|BEHAVIORAL|COPD Inhaler Counseling|The counseling will be performed via telephone by a pharmacist at the William S Middleton Memorial Veterans Hospital. The counseling will include education about inhaled COPD medication, inhaler technique review, reminder tools, and motivational interviewing.
224255849|NCT01270594|BEHAVIORAL|Usual Pharmacy Care|The usual care arm will receive standard care from the William S Middleton Memorial Veterans Hospital pharmacists.
224255850|NCT02620891|DEVICE|helium oxygen mixture|
224255851|NCT06249360|OTHER|Veins with reflux|This group included patients who used only recipient veins with reflux
224255852|NCT06249360|OTHER|Reflux-free recipient veins|This group included patients who utilized only reflux-free recipient veins
224255853|NCT02756663|DRUG|panobinostat (capsules)|Panobinostat capsules, oral: 10mg, 15mg, 20mg dosing 3x a week, 1 week on / 1 week off, in a 4 week cycle (28 days). Treatment arm A: only capsules of 10mg will be used Treatment arm B: capsules of 10mg and 15mg are foreseen for dose reduction only.
224255854|NCT02756663|DRUG|carfilzomib (infusion)|Carfilzomib infusion; 20 mg/m2 i.v. on C1D1 and C1D2; 56 mg/m2 i.v. on subsequent dosing days (2x a week; 3 weeks on/1 weeks off ); 4 week cycle (28 days)
224255855|NCT02756663|DRUG|dexamethasone (tablets)|Dexamethasone tablets p.o. 20 mg on days of carfilzomib infusion (2x week) and on D22 and D23 of each 4 week cycle (28 days)
224255856|NCT05410002|DIETARY_SUPPLEMENT|Dietary Supplement: N-111|Dietary supplement N-111
224255857|NCT05410002|OTHER|Placebo|Dietary placebo
224255858|NCT01221129|OTHER|Acclimation|11 mg Zn/day as a controlled intake level
224255859|NCT01221129|OTHER|Dietary zinc depletion|\< 1 mg Zn/day achieved by providing a liquified diet of defined nutrient content
224255860|NCT01221129|OTHER|Dietary zinc repletion|15 mg Zn/day as a daily supplement plus normal habitual diet without restriction
223772585|NCT03753958|PROCEDURE|Conventional treatment|The treatment will consist of oral hygiene orientation, with brushing technique instructions and daily flossing recommendation. All patients will receive a demonstration of oral hygiene techniques. The calculus deposits on the teeth will be removed with an ultrasound equipment and curettes for root scaling and straightening13. In implants, calculus will be removed with specific curettes for use on the implant surface. Treatment will be performed in 2 to 4 sessions under local anesthesia. Other biofilm-retaining factors, such as carious lesions, condemned teeth and maladaptive restorations, will be removed during these periodontal treatment sessions.
224255861|NCT04904705|OTHER|The Cognitive Orientation to Daily Occupational Performance (CO-OP) Approach|"The Cognitive Orientation to Daily Occupational Performance (CO-OP) Approach is a cognitive-based approach. This is a person-oriented, performance-solving problem-solving approach that enables strategy acquisition and guided exploration for the acquisition and learning of new skills.~The main objectives of this approach are; define and transfer domain-specific strategies to other motor-based tasks to gain skills, learn problem-solving strategy (goal, plan, do, check) and adapt to other environments (such as home, school)."
224255862|NCT04904705|OTHER|Home Program|Home Program are activities that a participant can apply at home to improve their skills.
224255863|NCT02411903|DRUG|atorvastatin and clopidogrel|Dose: atorvastatin 40mg/d plus clopidogrel 75mg/d for 9 months.
224255864|NCT02411903|DRUG|rosuvastatin and clopidogrel|Dose: rosuvastatin 20mg/d plus clopidogrel 75mg/d for 9 months.
224255865|NCT01386853|DRUG|Pitavastatin|2 mg QD
224255866|NCT01386853|DRUG|Atorvastatin|10 mg QD
224255867|NCT03432663|DRUG|Intravenous amiodarone(1)|Intravenous amiodarone infusions at doses of 5 mg/Kg for over 30 min, followed by 20 mg/Kg until 24 h was reached
224255868|NCT03432663|DRUG|Intravenous amiodarone(2)|Intravenous amiodarone infusions at doses of 5 mg/Kg for over 30 min, followed by 20 mg/Kg every 24 h for up to 72 h or until sinus rhythm was reached
224255869|NCT02189811|BIOLOGICAL|IPV|IPV at birth, 6, 10, 14 weeks of age and tOPV at 18 and 22 weeks of age
224255870|NCT02189811|BIOLOGICAL|bOPV|bOPV at birth, 6, 10, 14 weeks and tOPV at 18 and 22 weeks of age
224255871|NCT02189811|BIOLOGICAL|bOPV and IPV|bOPV till week 10, bOPV+IPV at 14 and tOPV at 18 and 22 weeks of age
224255872|NCT02189811|BIOLOGICAL|bOPV and IPV and IPV2|bOPV till week 10, bOPV+IPV at 14, tOPV+IPV2 at 18 and tOPV at 22 weeks of age
224255873|NCT02189811|BIOLOGICAL|tOPV|tOPV till 22 weeks of age
224255874|NCT04641702|DRUG|Atropine challenge|Atropine challenge. After baseline FLIP, subjects will be administered 15 mcg/kg of intravenous atropine. Two minutes after administration, FLIP will be repeated.
224255875|NCT04641702|PROCEDURE|Esophageal muscle biopsy|Esophageal muscle biopsy. During standard-of-care Heller myotomy or per-oral endoscopic myotomy, 5mm of lower esophageal sphincter and distal esophageal circular muscle will be collected via biopsy forceps.
224255876|NCT04481451|PROCEDURE|Erector spinae block with ropivacaine 0.2%|Single-shot ultrasound-guided nerve block performed ipsilateral to surgical site.
224255877|NCT04481451|PROCEDURE|Quadratus lumborum block with ropivacaine 0.2%|Single-shot ultrasound-guided nerve block performed ipsilateral to surgical site.
223674600|NCT02720172|BEHAVIORAL|Early Home Exercise Program|The early home exercise program is a 6-week program of home exercises with weekly phone calls to monitor progression and compliance.
223674601|NCT02720172|OTHER|Usual Care|Usual care involves standard postoperative management under the direction of the treating surgeon.
223674602|NCT06140537|DRUG|Dapagliflozin 10mg Tab|Dapagliflozin 10mg orally daily
224255878|NCT04481451|DRUG|Ropivacaine|ropivacaine 0.2% nerve block injection
224255879|NCT00913627|DRUG|ibuprofen|
224255880|NCT00913627|DRUG|ibuprofen|
224255881|NCT00913627|DRUG|naproxen|
224255882|NCT00913627|DRUG|Placebo|
224255883|NCT04604561|DEVICE|EnVisio SmartClip|The Envisio SmartClip is an FDA-cleared (approved) device for localization of in-breast lesions. While using The EnVisio™ Navigation System, the system will detect the presence of the SmartClip™ Soft Tissue Marker(s) and provide real-time three-dimensional navigation during the surgery.
224255884|NCT04604561|DEVICE|EnVisio™ Navigation System|The EnVisio™ Navigation System acquires and analyzes electromagnetic signatures that display the relative distance, depth, and direction from the tip of the electrosurgical tool to the implanted SmartClipTM(s) within the surgeon's field of view during the procedure.
224255885|NCT06627998|DIAGNOSTIC_TEST|Diagnostic (chest x-ray /DXA)and clinical data collected for clinical practice|Biochemical, clinical and radiological data performed for clinical practice will be retrospectively collected. Osteoporosis and vertebral fractures will be diagnosed through DXA scan and vertebral morphometry.
224255886|NCT03887676|DRUG|Arbaclofen|Administered orally as disintegrating tabs, round, white and beveled edges, at the following strengths: 5mg, 10mg, 15mg and 20mg
224255887|NCT03887676|OTHER|Placebo|Administered orally as disintegrating tabs, round, white and beveled edges
224255888|NCT01746238|DRUG|Bevacizumab|Intravenous infusion, every 2 weeks, 3 doses total
224255889|NCT01746238|DRUG|Doxorubicin|Intravenous infusion, bolus infusion followed by 4 day continuous infusion, every week for 5 weeks
224255890|NCT01746238|RADIATION|Radiation Therapy|Daily, Monday-Friday, for 6 weeks
224255891|NCT05847062|PROCEDURE|reverse shoulder arthroplasty|The patient will be admitted to undergo reconstructive surgery of the arthropathy, by means of one of the two mentioned Inverted Arthroplasty implants. The patient will be operated following always the same surgical technique with the same protocol (position, anesthesia, antibiotic prophylaxis...) and by one of the three surgeons of the shoulder unit, being always at least two of them present in each of the interventions. Both the implants used and the complications occurring during surgery or in the immediate postoperative period will be recorded.
224255892|NCT01110005|OTHER|D5 Lactated Ringer's Solution (D5LR)|D5LR IV fluid
224255893|NCT01110005|OTHER|Lactated Ringer's Solution (LR)|LR IV fluid
224255894|NCT05980156|DRUG|Dihydroartemisinin-Piperaquine|Treatment will be with DP (females less than 10 years old and all males) or chloroquine alone (females 10 years old or older).
224255895|NCT05980156|DRUG|Chloroquine|Treatment of females 10 years old and older in Arm 1 and treatment of all participants in Arm 2.
224255896|NCT05980156|DRUG|Sulfadoxine pyrimethamine|Treatment will be with SP and chloroquine (females less than 10 years old and all males) or chloroquine alone (females 10 years old or older).
224322376|NCT02258854|DRUG|Dose 2 gevokizumab|Solution for subcutaneous injection
223674603|NCT06140537|DRUG|Placebo|Placebo one tablet orally daily
223674604|NCT04660838|OTHER|ACB intervention|Stopping and/or switching ACB medication to an alternative
223674605|NCT03034239|DIETARY_SUPPLEMENT|Protein supplementation|\+ insect protein
223674606|NCT03034239|OTHER|Resistance training|Resistance exercise
223674607|NCT02328378|PROCEDURE|Quadratus Lumborum block|Patients will receive a bilateral Quadratus Lumborum block using 0.125% Bupivacaine in a dose of 0.2ml/kg body weight, after the end of surgery.
224255897|NCT00609830|BEHAVIORAL|Tailored Materials|Participants received written educational materials concerning each behavior targeted. The materials were tailored to the participants' stage of change with respect to each behavior.
224255898|NCT00609830|BEHAVIORAL|Tailored Materials Plus Physician Feedback|Participants received written educational materials concerning each behavior targeted. The materials were tailored to the participant's stage of change with respect to each behavior. In additon, the participant's physician received information concerning the participant's status on each behavior targeted.
224255899|NCT00609830|BEHAVIORAL|Generic Materials|Participants received generic written educational materials about osteoporosis prevention.
224255900|NCT00609830|BEHAVIORAL|No Information|Participants received no informational materials.
224255901|NCT02942615|OTHER|limit heart dose|limit heart dose: Dmean≤6Gy,V30≤20%,V10≤50%
224255902|NCT05667272|OTHER|No intervention|No intervention
224255903|NCT01876875|DIETARY_SUPPLEMENT|Energy-restricted, n-3 polysaturated fatty acids-rich diet|The active diet aimed to reduce body weight, to enhance the total intake of n-3 PUFA and to decrease the total intake of n-6 PUFAs. The diet plan was designed to supply an energy intake of 20 kcal/kg/day to maintain an ideal body weight, and followed the guidelines of the American Heart Association (AHA) 'Step-One' Diet: Carbohydrates (mainly complex carbohydrates) and protein constituted of 50-60% and 10-20% of total calories, respectively, and total fat did not exceed 30% of calories. Food values for energy and nutrients were taken from the tables of the Italian National Institute of Nutrition, Souci's Food Composition and Nutrition Tables and the European Institute of Oncology. For long-term and practical daily eating habits, it was important to easily incorporate and consume a variety of selected foods.
224255904|NCT01876875|DIETARY_SUPPLEMENT|Usual diet|The patients of this group were randomized to continue their usual diet
224255905|NCT06347562|GENETIC|Optical Genome Mapping|to evaluate the capability of OGM, its usefulness in clinical diagnosis, and its impact on genetic counseling.
224255906|NCT04843995|PROCEDURE|Mid-urethral sling|Treatment of stress urinary incontinence with retropubic mid-urethral sling
224255907|NCT03391284|DRUG|acetominophen|INTRAVENOUS
224255908|NCT03391284|DRUG|Acetaminophen|ORAL
224255909|NCT01998295|DRUG|Artemether/lumefantrine|Medication was given at 0, 8, 24, 36, 48 and 60 hours. Food was given to all patients prior to medication to ensure proper absorption of the drug.
224255910|NCT01465581|PROCEDURE|Division of the filum terminal|Division of the filum is performed through a 6cm incision over the lumbosacral junction that can be oriented either longitudinally or transversely - to be hidden beneath underclothes or swim wear. A single level laminectomy provides sufficient exposure. The dural opening can be as short as 1cm. Under the microscope the filum is identified visually and separated from lower sacral rootlets with the aid of microelectrode stimulation. When a segment of the filum has been excised and sent for laboratory examination, the dura is closed and reinforced with fibrin glue. The wound is closed in layers, and the patient is kept at bed rest horizontal for 2 nights to discourage CSF fistulization of the wound.
224255911|NCT04542356|DRUG|PEG-rhG-CSF|During the concurrent chemoradiotherapy, a single subcutaneous injection of 6 mg PEG-rhG-CSF was given to the patient 2 hours after radiotherapy on the first day after the end of chemotherapy. Blood tests were performed weekly, if the patient's neutrophils were less than 1.0 × 109 / L during radiotherapy, rhG-CSF was given as a remedial treatment. If fever occurs, antibiotics were given promptly.
223674608|NCT03877640|DEVICE|BTL EMSELLA|High intensity focused electromagnetic (HIFEM) technology induces deep pelvic floor muscle contractions designed to deliver the equivalent of 11,200 Kegel exercises over 28 minutes.
223674609|NCT06172985|OTHER|No intervention|Due to observational study
223674610|NCT00266058|DRUG|Lopinavir/Ritonavir, Efavirenz, Artemether/lumefantrine|participants receive a total of 6 doses of artemether(80mg)/lumefantrine(480mg)for baseline PK evaluation. This is followed by a 26-day course of either efavirenz(600mg) once daily or lopinavir/ritonavir (400mg/100mg) twice daily and additional 6 doses of artemether/lumefantrine to determine the pharmacokinetics of the antimalarial medications in the context of antiretrovirals. The participants undergo at least a 14 day washout period (between the last baseline PK blood draw and the initiation of antiretrovirals)
224255912|NCT04542356|DRUG|rhG-CSF|Blood tests were performed weekly, if the patient's neutrophils were less than 1.0 × 109 / L during radiotherapy, rhG-CSF was given as a remedial treatment. If fever occurs, antibiotics were given promptly.
224255913|NCT02110394|OTHER|bendamustine|Routine practice
224255914|NCT02110394|OTHER|rituximab|Routine practice
224255915|NCT03123471|DRUG|Apremilast|Apremilast 30 mg tablets BID from weeks 0 to 32.
224255916|NCT03123471|OTHER|Placebo|Placebo tablets twice daily (BID) for 16 weeks; placebo participants were switched to apremilast 30 mg at week 16.
224255917|NCT01641380|BEHAVIORAL|Text Messaging Intervention|"1. Online enrollment in the Compliance for Life® (CFL) system through iReminder)~2. Welcome Message 24 hrs after enrollment~3. Appointment Reminder prior to 3 month injection cycles~4. Monthly health reminders i. Condom use ii. Weight control iii. Side Effect Management 5.6-month STD testing reminder~6.Call for missed appointment or no reply to appointment reminder (or other text message)"
224255918|NCT05914454|DRUG|Anakinra 100Mg/0.67Ml Inj Syringe|anakinra 100 mg per day for 14 days
224255919|NCT04184518|DRUG|Cediranib Maleate|Cediranib 20mg, oral, 5 days on and 2 days off until disease progression
224255920|NCT04184518|DRUG|Durvalumab|Durvalumab 1500mg, intravenous, every 4 weeks until disease progression
224255921|NCT03500120|DIAGNOSTIC_TEST|Seated saline infusion test|"Seated saline infusion test: All participants received the infusion of 2 liters of 0.9% saline over 4 h in seated posture.~Fludrocortisone suppression test:Patients received 0.1 mg oral fludrocortisone every 6 h for 4 days, together with slow-release potassium chloride and sodium chloride supplements.~Captopril challenge test:Patients received 50 mg captopril orally at 8-9 a.m. after sitting or standing for at least 1 h. Blood samples were drawn at time zero and 2 h after the challenge."
224255922|NCT04074603|DEVICE|The needle-free jet injector|Continuous insulin therapy for 2 weeks
224255923|NCT04074603|DEVICE|Conventional insulin pen|Continuous insulin therapy for 2 weeks
224255924|NCT04209504|DIAGNOSTIC_TEST|Ultrasound|Ultrasound guided evaluation of diaphragm ipsilateral to the block side.
224255925|NCT04209504|DRUG|Ropivacaine|Local anesthetic (numbing drug)
224255926|NCT04209504|DRUG|Bupivacaine|Local anesthetic (numbing drug)
224255927|NCT04209504|DEVICE|MediPines AGM100 Advanced Respiratory Monitoring System|Non-invasive respiratory monitor to measure oxygenation and ventilation parameters
224255928|NCT04406753|OTHER|Manual therapy techniques in C0-1 and C2-3 with cervical exercise|Manual Therapy + Exercise group will carry out 20-minute session of treatment. The techniques will be applied depending on the clinical findings in each patient and the objective will be to restore the function of C0-1 and C2-3 segments before applying cervical exercises. We will use manipulation (high velocity low amplitude) and/or mobilization (low velocity high amplitude) techniques of C0-1 and C2-3 segments with cervical exercise. Manipulations will be in the direction of traction, with the head in a neutral position. A maximum of two trials at each level on each side will perform (2-6 thrusts). Mobilization will be performed for 5 minutes using repeating cycles of 45 seconds of mobilization and 15 seconds of rest. The cervical exercise will perform by this group will follow the same methodology as the Exercise group.
224255929|NCT04406753|OTHER|Cervical Exercise|"This group will perform the cervical stabilization exercise. They will be teach to perform the contraction of deep neck flexor muscle activity with the help of the Stabilizer Pressure Biofeedback Unit (Chattanooga, USA) in supine. Exercise will be always carry out without pain, because pain can be an inhibitor of muscle contraction.~The Exercise group will carry out one 20-minute session, composed of 2 sets of 10 repetitions, holding each repetition for 10 seconds, a 40-second rest between each repetition and 2 minutes between sets."
223674611|NCT00678756|DRUG|Ketokonazol 2% cream|twice a day at 2 times,2 out of 5 areas have to be treated for 4 weeks/7 days a week
223674612|NCT00678756|RADIATION|UVB-radiation 311nm|3 out of 5 areas are radiated for 4 weeks every MO/DI/DO/FR starting MED orientated, intensified everytime 0,03 J/qcm
223674613|NCT03248349|DRUG|Pharmacokinetics|"* Blood samples are drawn for pharmacokinetic properties of antibiotics during routine care treatment~* Blood samples for relevant covariates of drug disposition (kidney function, liver enzymes, C-reactive protein (CRP), albumin)~* Whole blood is stored for DNA analysis~* Urine is drawn from catheter for more detailed estimation of glomerular filtration rate and drug metabolite analysis"
223674614|NCT00866229|DRUG|Rosuvastatin|10 mg per day for 12 weeks
223674615|NCT00866229|DRUG|Simvastatin|20 mg per day
223674616|NCT06238102|OTHER|pure tone audiometry|measuring hearing impairment to select patients with hearing loss to evaluate who can this hearing impairment affects their quality of life
223674617|NCT02258776|DIETARY_SUPPLEMENT|Pomegranate Extract|Pomegranate extract 1000mg will be taken 1/day for 12 weeks.
223674618|NCT02258776|DIETARY_SUPPLEMENT|Pomegranate Juice|Pomegranate juice 8oz will be consumed 1/day for 12 weeks.
223674619|NCT02258776|DIETARY_SUPPLEMENT|Placebo|Placebo will be taken 1/day for 12 weeks.
223674620|NCT02621840|BEHAVIORAL|Mandatory On-Site Pre-Admission Testing|
223674621|NCT01534858|DEVICE|Prontosan Wound Gel X|Prontasan Wound Gel X will be applied topically as a thin layer to the entire grafted area immediately after transplant and with each dressing change.
223674622|NCT03977740|OTHER|chest PNF|Chest PNF technique includes oblique downward pressure at sternum, diagonal pressure at lower rib cage at supine line, caudal medial pressure at side lying, Caudal pressure at ribcage at prone lying, dorsal and caudal pressure at prone on elbow.
223674623|NCT03977740|OTHER|Conventional|conventional chest physiotherapy treatment, which includes Deep breathing exercise, Diaphragmatic breathing exercise, segmental breathing exercise and purse lip breathing and incentive spirometer
224255930|NCT06559254|DEVICE|transcranial direct current stimulation|Transcranial direct current stimulation (tDCS) is a non-invasive brain stimulation by applying weak current through electrode. It can archive excitation by anode stimulation or inhibition by stimulating cathode. By inducing modification of membrane polarisation, it can modulate cerebral excitability. Literature suggested anode tDCS over the dorsolateral prefrontal cortex (DLPFC) improved cognitive function, in terms of responding faster and more accurate in cognitive tasks. tDCS was well tolerated and accepted by participants.
223674624|NCT00646932|DRUG|paricalcitol|paricalcitol 0.04 mcg/kg three times a week
223674625|NCT00646932|DRUG|paricalcitol|paricalcitol 0.08 mcg/kg three times a week
223674626|NCT00646932|DRUG|paricalcitol|paricalcitol 0.16 mcg/kg three times a week
223674627|NCT00646932|DRUG|paricalcitol|paricalcitol 0.24 mcg/kg three times a week
223674628|NCT00274092|DRUG|tiotropium inhalation capsules (18 mcg once daily)|
223674629|NCT00274092|DRUG|Atrovent MDI (2 puffs of 20 mcg(q.i.d.) in patients|
223674630|NCT00705744|DRUG|Lactic acid (Dermacyd Femina)|
223674631|NCT05631678|DRUG|Rifampicin; ASK120067|Take ASK120067 tablets orally once on the first day at 160mg in fast condition;Take rifampicin capsules orally once on the days 8 to 17 at 600mg in fast condition, and a combination of 160mg ASk120067 and 600mg rifampicin were administrated on the 15th day in fast condition.
223674632|NCT05631678|DRUG|ASK120067;itraconazole|Take ASK120067 tablets orally once on the first day at 80mg in fast condition;Take itraconazole capsules orally twice on the days 8 to 13 at 200mg in fed condition, and a combination of 80mg ASK120067 and 200mg itraconazole were administrated on the 11th day in fast condition.
223674633|NCT02249247|DRUG|Low dose of BIIL 284 BS tablets|
223674634|NCT02249247|DRUG|Medium dose of BIIL 284 BS tablets|
223674635|NCT02249247|DRUG|High dose of BIIL 284 BS tablets|
223674636|NCT02249247|DRUG|Placebo|
223674637|NCT04045509|DEVICE|Liquid Jet Esthesiometer Prototype|Balanced salt solution with a pH value similar to the tear film uesd as a liquid jet stimulus for corneal sensation threshold measurement
223674638|NCT04045509|DEVICE|Tactile Esthesiometer Prototype|A round plastic nozzle (1.8mm diameter) used as a stimulus for corneal sensation threshold measurement
223674639|NCT04045509|DEVICE|Cochet Bonnet esthesiometer|A nylon thread (0.12mm diameter) used as a stimulus for corneal sensation threshold measurement
223674640|NCT02048241|BEHAVIORAL|Parent Management Training|This is a psychological treatment that focuses on decreasing tantrums and outbursts by reducing the ability of the tantrum to coerce parents into giving in to the demand that precipitated the tantrum.
223674641|NCT02048241|OTHER|Placebo|Weekly dispensation of pills matching Intuniv but without the active medication
223674642|NCT02048241|DRUG|Intuniv|Weekly administration of medication in doses as per protocol
224255931|NCT05792397|DEVICE|TwiFlow-Thrombectomy Catheter System|Patients with acute pulmonary embolism and meeting the conditions of this clinical trial will accept the pulmonary embolism removal operation by the novel device named 'TwiFlow-Thrombectomy Catheter System'
224255932|NCT01115647|DIETARY_SUPPLEMENT|Ready-to-Use Therapeutic Food (RUTF)|A Ready-to-Use Therapeutic Food (RUTF), locally produced in Burkina Faso. The RUSF will be nutritionally characterized by chemical analysis (macronutrients, amino acids, vitamins A, C, D, E, B12, thiamin, riboflavin, niacin, calcium, iron, zinc, copper, selenium) and will be analyzed for macronutrients and energy density. All analysis methods are either based on the Official Methods of Analysis of AOAC International or in-house validated analytical methods. The pilot production phase and Hazard Analysis of Critical Control Points (HACCP) risk inventory of the production process will be performed by a food technologist from the Department of Food safety and Food quality, Ghent University.
224255933|NCT01115647|DIETARY_SUPPLEMENT|CBS++|CSB is a low-cost combination of a cereal and a legume sometimes fortified with micronutrients. However, it presents shortcomings such as too many anti-nutrients, suboptimal micronutrient content, high bulk and viscosity. The World Food Program has recently proposed an enhanced CSB, named CSB++, which is prepared from heat treated maize and de-hulled soya beans, sugar, dried skim milk, refined soya bean oil, vitamins and minerals.
223674643|NCT04690439|DEVICE|Photobiomodulation therapy (PBMT)|The MLS M6 laser from ASA will be used to apply the laser therapy.
223674644|NCT04690439|PROCEDURE|Manual Lymphatic drainage|Patients will receive twice weekly MLT executed by trained physiotherapist
223674645|NCT00402233|DRUG|Pramipexole|
223674646|NCT00402233|DRUG|Placebo|
223674647|NCT02483767|DRUG|goserelin|Gonadotropin-Releasing Hormone Agonist
223674648|NCT02483767|DRUG|standard chemotherapy|(Anthracyclines/cyclophosphamide) followed by paclitaxel or doxetaxel; doxetaxel/cyclophosphamide; doxetaxel or paclitaxel/Anthracyclines; fluorouraci/Anthracyclines/cyclophosphamide followed by doxetaxel or paclitaxel; doxetaxel/Anthracyclines/cyclophosphamide; Anthracyclines/cyclophosphamide;
223674649|NCT04658940|DEVICE|AcQBlate® Force Sensing Ablation System|Percutaneous catheter ablation of the cavotricuspid isthmus
223674650|NCT01143740|DRUG|RO5045337|orally day 1-10 each 28-day cycle, 3 cycles
223674651|NCT03579602|DRUG|tozuleristide|Tozuleristide will be administered at least 1 hour and no more than 36 hours prior to planned surgical excision of their tumor.
223674652|NCT03579602|DEVICE|Canvas System|All subjects enrolled in the study will have their tissue imaged with the Canvas System.
223674653|NCT03839043|BEHAVIORAL|Brief behavioral intervention|"Quit for a bit- \*advice to quit from the am. of surgery until one week post-surgery, a special emphasis on morning abstinence\* risks of smoking to perioperative outcomes, includes wound infections, breathing problems, and heart problems\*reduction of these risks if able to quit for a bit\*the fact that most smokers don't experience cravings or increased stress around the time of surgery. Subjects will receive written summarizing instructions and a brief abstinence brochure. Quit for good- 3 out of the 5A's smoking cessation intervention, including Asking, Advising and Assistance will be provided. The advice endorses immediate, sustained quitting (quit for good), accent on the health and economic benefits of long-term abstinence. Assistance includes a method of setting the date of surgery as the quit date, enlisting social support, anticipation of withdrawal symptoms, and the need for complete abstinence. Subjects will receive written summarizing instructions and a 5As brochure."
223674654|NCT03839043|OTHER|SMS Program|"Quit for a bit- Subjects will get SMS messages focused on maintaining abstinence from the morning of surgery until one week after surgery. SMS content focus on the benefits of abstinence to surgical recovery rather than sustained benefits to overall health. Around day 7 postoperatively, messages will encourage subjects to consider extending their abstinence beyond 7 days.Quit for good- Subjects will get SMS messages focused on general advice for maintaining abstinence, focusing on the long-term health benefits rather immediate benefits to recovery from surgery. SMS content focus on the the surgical date as the quit date, general advice and support for quitting based on the standard Truth Initiative (UbiQUITxt) message library and there will be no references to effects of short-term abstinence on surgical outcomes."
223674655|NCT03317301|DRUG|HL151|2 times a day(Day, Night), 2 weeks of treatment / Day: HL151 (1Tab)+Talion Tab (Placebo)(1Tab), Night: HL151 (Placebo)(1Tab)+Talion Tab (Placebo)(1Tab)
223674656|NCT03317301|DRUG|Talion Tab|2 times a day(Day, Night), 2 weeks of treatment / Day: HL151 (Placebo)(1Tab)+Talion Tab (1Tab), Night: HL151 (Placebo)(1Tab)+Talion Tab (1Tab)
223674657|NCT00252044|DRUG|Pergolide|
223674658|NCT01873469|RADIATION|Radiochemotherapy|postoperative radiochemotherapy 60 Gy/ Temozolomide
223674659|NCT02518464|DRUG|Ticagrelor 90 mg twice per day|Patients will be loaded with 180 mg of Ticagrelor during the enrollment office visit and provided with a 28 day supply of Ticagrelor, 90 mg twice per day. P2Y12 reactivity unit (PRU) testing will be conducted at 7-14 days. If the patient has a positive response, they will have the option of continued access of Ticagrelor 180 mg for another 2 months. Participants will be reminded via text message daily to complete a headache survey on line in order to track their headaches.
223674660|NCT04738305|OTHER|Dignity Therapy|"The Italian version Dignity Therapy intervention (Chochinov HM 2015) has been delivered. Intervention questions were not previously delivered to patients.~DT interview was provided to patients by Specifically trained Nurses. Interviews were audio-recorded and transcribed then revised by the patients to develop the final Generativity Document. Generativity Document was delivered to patients that could share it with their loved ones."
223674661|NCT04695613|DRUG|Aminoacid|amino acid infusion 150 ml/kg/hr starting preoperative
223674662|NCT04695613|DRUG|Magnesium sulfate|magnesium sulphate bolus and infusion 60 mg/kg starting preoperative
223674663|NCT01128764|BEHAVIORAL|CBT for depression and healthy lifestyle plus exercise|CBT treatment for depressed teens will be adapted into one integrated protocol that addresses depression using CBT techniques, an exercise component, and advice regarding healthy eating.
223674664|NCT01128764|BEHAVIORAL|CBT for depression|Standard CBT treatment for depressed teens that addresses depression using CBT techniques only
223674665|NCT00045981|DRUG|ALT-711|
223674666|NCT03970408|PROCEDURE|MNT1|"Participants will in supine. Arm will be position in standard MNT1. Shoulder, elbow, wrist and fingers will be maintained in the required position using a costumed splint throughout all testing.~All movements will be limited to the range where pain or other symptoms are not provoked. Passive neck flexion and rotation will be added to MNT1 and will be applied as tensioning movements at level 3. All movements will be repeated three times and an average will be calculated. Myrin goniometer will be used to assess neck flexion and rotation. The movements order will be randomized using excel random generation function. Movements will be done by a single trained therapist. The end position will be held up to 10 seconds until median nerve excursion is recorded by US. For US capturing, the transducer will be positioned perpendicularly and aligned longitudinally with the median nerve at the wrist. Assessor will be blinded to participants grouping."
223674667|NCT04908943|BEHAVIORAL|RENEW|RENEW is a 12-week, peer-led, web-based program to help people with scleroderma learn skills that can be used to manage disease symptoms and improve well-being.
223772586|NCT03753958|RADIATION|aPDT|aPDT will be performed after conventional treatment, in sites with pockets greater than or equal to 5 mm. The PapaMblue® photosensitizer with 100 μM methylene blue will be deposited in the pockets with a syringe, with the bottom of the pouch in the coronal direction, and a pre-irradiation time of 1 min will be adopted, so that the PS may stain the entire bacterial biofilm. Then, the laser emitting an wavelength of 660 nm, with power of 100 mW, will be applied. The laser will be applied to the mucosa on the oral epithelium with an optical fiber (apparatus of DMC Therapy EC, São Carlos, Brazil). Irradiation will be performed until the entire peri-implanted pouch is illuminated for 2 minutes at each point. The 6 points around the implant will be irradiated and each irradiation point will present an area of 0.4 cm2, which will result in radiant exposure of 30 J/cm2 following 2 min of irradiation per point. The irradiation will have a constant power density of 250 mW/cm2.
223772587|NCT03060824|OTHER|Blood sampling|To explore changes in osmolality during coronary artery bypass grafting surgery with the aid of Cardiopulmonary Bypass by repeated measurements of osmolality and concentration shifts of sodium, glucose and urea in plasma.
223772588|NCT00451763|DRUG|Intravitreal Injection of Bevacizumab (1.25 mg/0.05ml)|
223772589|NCT00079547|BEHAVIORAL|Low-calorie diet|low-calorie diet
223772590|NCT00079547|BEHAVIORAL|low-carbohydrate diet|low-carbohydrate diet
223772591|NCT03646422|OTHER|Registry of patients (exposure is Cutaneous Lymphoma)|
224255934|NCT01115647|BEHAVIORAL|CCC|Child-Centred dietary Counselling (CCC). Although educational/behavioral interventions can be effective to improve child growth, there is little evidence of their effectiveness for MAM. Moreover, evidence from Africa is inexistent. Currently, the main management of MAM consists of giving nutritional advice to the caretakers, but mothers of MAM children are given the same general dietary advice as mothers of well-nourished children. A more efficient, child-centred approach is therefore proposed, by adapting the counselling to the needs of the family, developing a more child-centred approach, by providing operational recommendations for MAM children and providing an adequate follow-up post-treatment.
224255935|NCT03681470|DRUG|Aczone Gel|Aczone Gel 7.5%
224255936|NCT01686477|OTHER|Unfortified Human donor Milk used to make up any shortfall in mother's own milk|
223674668|NCT01789931|DEVICE|"Lifebeam"|"The lifebeam sensor will be attached to the participant's skin during the HTT."
223674669|NCT06297252|DIAGNOSTIC_TEST|standardized clinical psychiatric evaluations|"The intervention consists of a psychiatric consultation including :~* assessment of psychiatric disorders using a MINI test~* information gathering (medical, obstetrical and family history, expected term of pregnancy).~* assessment of suicidal behaviour using the Columbia-Suicide Severity Rating Scale (CSSR-S)~* collection of negative life events over the past 12 months, assessed using the Paykel questionnaire"
223674670|NCT06297252|DIAGNOSTIC_TEST|self-administered psychiatric questionnaire assessments|"* EPICES Score: (Evaluation de la Précarité et des Inégalités de santé dans les Centres d'Examens de Santé):~* MIBS: (Mother to Infant Bonding Scale)~* PAI: (Prenatal Attachment Inventory)~* EDEQ: (Eating Disorder Examination Questionnaire)~* PCL-5: (Post-traumatic Stress Disorder Checklist for DSM-V)~* MARS: (Medication Adherence Rating Scale)~* EPDS: (Edinburgh Postnatal Depression Scale)"
223674671|NCT06297252|OTHER|blood sampling|"A blood sample is taken to form an optional biological collection, comprising 3 samples:~* A tube to collect RNA from whole blood.~* A tube to collect serum~* A tube to collect native DNA"
223772592|NCT03284216|PROCEDURE|Steady-state hyperglycemia|"Experimental diabetic like steady-state hyperglycemia will be induced via a continuous-rate intravenous glucose infusion."
223772593|NCT03284216|PROCEDURE|Fluctuating hyperglycemia|"Experimental diabetic like fluctuating hyperglycemia will be induced via repeated intravenous glucose injections."
223772594|NCT03284216|BEHAVIORAL|Exercise|Moderate-intensity exercise bout (45-minutes of cycling at 70% of their heart rate max) at T=4.5 hours
223772595|NCT00684424|OTHER|Non-Interventional Study|Observational Only
223772596|NCT04933851|BEHAVIORAL|ACT1VATE|ACT1VATE, informed by Acceptance and Commitment Therapy (ACT), will consist of five, 90-minute group-based telemedicine therapy sessions delivered by a Behavioral Health Provider.
223772597|NCT04933851|BEHAVIORAL|DSME/S|Diabetes self-management education and support (DSME/S) will be delivered by a Certified Diabetes Care and Education Specialist via one-on-one telemedicine format.
223772598|NCT05669443|DEVICE|conventional PEEP|Maintain positive end expiratory pressure at 5 cmH2O throughout the surgery.
223772599|NCT05669443|DEVICE|optimized PEEP|Immediately after induction of anesthesia, the patient remains unapplied to PEEP. After pneumoperitoneum + Trendelenburg posture, an appropriate PEEP value is derived using electrical impedance tomography (airtom®). And then derived value ( = optimized PEEP value) is applied until the end of the operation.
223772600|NCT00144118|DRUG|sevoflurane or isoflurane|
223772601|NCT03843359|DRUG|GSK3745417|GSK3745417 will be administered.
223772602|NCT03843359|DRUG|Dostarlimab|Dostarlimab will be administered.
223772603|NCT03970135|OTHER|Fasting|Fasting for 24 hours or until hypoglycemia (blood glucose \< 3mmol/L) or symptoms of hypoglycemia
223772604|NCT01044810|DRUG|Efavirenz-based regimens|Efavienz: 600 mg, oral, every 24 hours, continued medication until the end of study.
223772605|NCT06096025|DRUG|pneumoniae bacteremia therapy|To evaluate the effectiveness of short 10 days versus long (≥10 days) duration of therapy associated with S. pneumoniae bacteremia.
224255937|NCT01686477|OTHER|Fortified Human donor Milk used to make up any shortfall in mother's own milk|
224255938|NCT01686477|OTHER|Preterm Formula used when there is a shortfall in mother's own milk|
224255939|NCT02004197|DRUG|Quadruple Allopathic therapy|
224255940|NCT02004197|DRUG|Pylorex plus|
224255941|NCT07007494|OTHER|Nutritional and Inflammatory Marker Evaluation|This is a prospective observational cohort study evaluating whether preoperative immune-nutritional markers-including Prognostic Nutritional Index (PNI), HALP score, Neutrophil-to-Lymphocyte Ratio (NLR), and C-Reactive Protein (CRP)-can predict early postoperative clinical outcomes (complication development, time to oral intake, mobilization, and length of hospital stay) in patients undergoing elective laparoscopic sleeve gastrectomy. No intervention or treatment is administered as part of this study. All data are collected from routine preoperative laboratory tests and standard postoperative clinical follow-up.
223674672|NCT05425316|BEHAVIORAL|Home Recordings|If patients are willing to download the Winterlight application to their personal iOS devices this will be done at study visit 1. The application will send a notification to the patient once per month, requesting that they perform a paragraph reading task, a picture description task, and an animal naming task.
223674673|NCT05425316|BEHAVIORAL|In-patient Recordings|If patients are admitted to UM hospital for suspected or confirmed OHE, with patient assent, physician study staff will assist the patient in recording a paragraph reading task, a picture description task, and an animal naming task.
224255942|NCT04829162|OTHER|Mother with obesity, daughter with obesity|Participants in this group were shown an image of a mother with obesity and a daughter with obesity.
224255943|NCT04829162|OTHER|Mother with obesity, daughter without obesity|Participants in this group were shown an image of a mother with obesity and a daughter without obesity.
224255944|NCT04829162|OTHER|Mother without obesity, daughter with obesity|Participants in this group were shown an image of a mother without obesity and a daughter with obesity.
224255945|NCT04829162|OTHER|Mother without obesity, daughter without obesity|Participants in this group were shown an image of a mother without obesity and a daughter without obesity.
224255946|NCT04829162|OTHER|Mother with obesity, son with obesity|Participants in this group were shown an image of a mother with obesity and a son with obesity.
224255947|NCT04829162|OTHER|Mother with obesity, son without obesity|Participants in this group were shown an image of a mother with obesity and a son without obesity.
224255948|NCT04829162|OTHER|Mother without obesity, son with obesity|Participants in this group were shown an image of a mother without obesity and a son with obesity.
224255949|NCT04829162|OTHER|Mother without obesity, son without obesity|Participants in this group were shown an image of a mother without obesity and a son without obesity.
224255950|NCT04829162|OTHER|Father with obesity, daughter with obesity|Participants in this group were shown an image of a father with obesity and a daughter with obesity.
224255951|NCT04829162|OTHER|Father with obesity, daughter without obesity|Participants in this group were shown an image of a father with obesity and a daughter without obesity.
224255952|NCT04829162|OTHER|Father without obesity, daughter with obesity|Participants in this group were shown an image of a father without obesity and a daughter with obesity.
224255953|NCT04829162|OTHER|Father without obesity, daughter without obesity|Participants in this group were shown an image of a father without obesity and a daughter without obesity.
224255954|NCT04829162|OTHER|Father with obesity, son with obesity|Participants in this group were shown an image of a father with obesity and a son with obesity.
224255955|NCT04829162|OTHER|Father with obesity, son without obesity|Participants in this group were shown an image of a father with obesity and a son without obesity.
224255956|NCT04829162|OTHER|Father without obesity, son with obesity|Participants in this group were shown an image of a father without obesity and a son with obesity.
224255957|NCT04829162|OTHER|Father without obesity, son without obesity|Participants in this group were shown an image of a father without obesity and a son without obesity.
224255958|NCT03290781|DRUG|Ontamalimab|Participants will receive 1 milliliter (mL) of ontamalimab sterile aqueous buffered solution at an appropriate oncentration to provide an intended dose of drug (25 or 75 mg).
224255959|NCT03290781|OTHER|Placebo|Participants will receive 1 mL of sterile aqueous buffered solution.
224255960|NCT01788800|BEHAVIORAL|Cognitive Behavioural Therapy (CBT)|9 sessions of CBT including psychoeducation and interoceptive exposure
224255961|NCT04725708|PROCEDURE|procedure: cerebral oxygenation intervention|During the surgery, cerebral oxygenation will be followed and intervention will be made to pH, PaO2, PaCO2, mean arterial pressure, hematocrit when necessary. In addition perfusion flow was maintained at or close to between 2.2-2.5 L/min/m2 . Perfusion pressure was adjusted using a phenylephrine infusion to maintain a mean arterial pressure of 50 to 70 mm Hg.
224255962|NCT01684241|BIOLOGICAL|RBL001/RBL002|Each participant will receive 8 repeated intranodal administrations of RBL001 and RBL002 during a time frame of 43 to 51 days.
224255963|NCT02000362|BIOLOGICAL|Stem cells|
223674674|NCT05425316|BEHAVIORAL|Same-Day Study Visit - Regular Appointment|Staff will call patients in anticipation of in-person regular visits to set up a same-day study visit. Patients will record the three speech tasks at this time.
224255964|NCT00239863|DRUG|FTY720|
223772606|NCT05015894|DRUG|NNC0480-0389|"A single dose of 18 mg NNC0480 0389 administered subcutaneously (under the skin).~Total duration of study participation for each participant is 38 to 66 days"
224255965|NCT05081466|OTHER|Dietary pattern|(regular meat-eater, occasional meat-eater, fish-eater, vegetarian, and vegan)
224255966|NCT05081466|OTHER|Fruit and vegetable intake|Intake of fruits, vegetables, fruits and vegetables combined from food frequency questionnaire
224255967|NCT05081466|OTHER|Meat intake|Red meat, poultry, processed meat from food frequency questionnaire
224255968|NCT05081466|OTHER|Fish intake|Intake of fish from food frequency questionnaire
224255969|NCT05081466|OTHER|Egg intake|Intake of eggs from food frequency questionnaire
224255970|NCT05081466|OTHER|Dairy intake|Intake of dairy products from food frequency questionnaire
224255971|NCT05081466|OTHER|Tea intake|Intake of tea (drink) from food frequency questionnaire
224255972|NCT05081466|OTHER|Coffee intake|Intake of coffee (caffeinated or decaffeinated) from food frequency questionnaire
224255973|NCT05081466|OTHER|Tea and coffee intake|Combined intake of tea and coffee from food frequency questionnaire
224255974|NCT05081466|OTHER|Protein intake|Estimated intake of protein, derived from food frequency questionnaire
223772607|NCT01887431|OTHER|Telecare|Each patient will transmit glucometer and pump data electronically via a web site (Medtronic Carelink internet site www.carelink.minimed.com) to diabetes team and will receive feedback by telephone. Frequency of data transfer will be directly related to patients' metabolic control. In addition to data transmission Patient of the intervention group will be arriving during the intervention year for 3 clinic visit at the following time point : 0, 6 and 12 month.
223772608|NCT01887431|OTHER|Conventional therapy|3-month routine clinic visits
223772609|NCT04914572|OTHER|Therapeutic rainforest mindful walking|A two-kilometer trail curated by the National Parks Board, Singapore. The walk will be led by Mindfulness Practitioner who volunteered to be guides for this study.
223772610|NCT04914572|OTHER|Therapeutic rainforest walk|A two-kilometer trail curated by the National Parks Board, Singapore. The walk will be led by volunteer guides recruited by the research team.
223772611|NCT04914572|OTHER|Campus Green walk|A two-kilometer trail curated by the Office of Facility Management, NUS. The walk will be led by volunteer guides recruited by the research team.
224255975|NCT05081466|OTHER|Calcium intake|Estimated intake of calcium, derived from food frequency questionnaire
224255976|NCT05081466|OTHER|Vitamin D intake|Estimated intake of vitamin D, derived from food frequency questionnaire and any recorded supplemental intake
224255977|NCT02576730|PROCEDURE|ORIF|surgery for foot and ankle fractures
223674675|NCT05425316|BEHAVIORAL|Same-Day Study Visit - Procedure|Staff will call patients in anticipation of in-person procedure visits to set up a same-day study visit, prior to procedure if sedation is planned. Patients will record the three speech tasks at this time.
223674676|NCT05425316|BEHAVIORAL|Phone Call Follow-up Visits|Non-physician study staff will call the patients every 3 months and, using a phone script, will ask them survey questions about their hepatic health.
223674677|NCT02472509|DRUG|Ursodeoxycholic Acid|"Patients will be commenced on UDCA 15mg/kg/day (maximum dose 900mg/day) in 2-3 divided doses for 12 months.~Patients who are unable to tolerate tablet medication will be started on UDCA syrup at the same dose."
223674678|NCT02905396|DEVICE|Spinal cord stimulation|implantation of spinal cord stimulator
223674679|NCT02642588|DIETARY_SUPPLEMENT|energy gel|energy gel: gelatinous edible containing carbohydrates typically used during endurance races
223674680|NCT05613712|OTHER|Patients|Description by the patients through the questionnaire of the elements limiting the good ambulatory follow-up
223674681|NCT05613712|OTHER|Referring physician|Description by the referring physicians through the questionnaire of the elements limiting the applicability of the recommendations issued by the rheumatology department of the CHU Grenoble Alpes
223674682|NCT01120067|BEHAVIORAL|Intensive Treatment|Participants randomized to the Intensive Treatment condition will attend 6 bi-weekly outpatient therapy sessions conducted in an individual format of 90 minutes in duration.
223674683|NCT01120067|BEHAVIORAL|Treatment as Usual|Treatment as Usual.
223674684|NCT00388427|DRUG|Dasatinib (BMS-354825)|100 mg, 150 mg, or 200 mg per dose escalation schedule; continuous oral dosing on Days 1-21 of each 21-day cycle until progression or unacceptable toxicity develops.
223674685|NCT00388427|DRUG|Cetuximab (Erbitux, C225)|Loading dose of IV 400 mg/m\^2 on Day 1 of Cycle 1; IV 250 mg/m\^2 weekly thereafter each 21-day cycle until progression or unacceptable toxicity develops.
223674686|NCT04465201|DEVICE|Impella CP with Smart Assist (Circulatory Support System)|Subjects will receive the Impella® with the Impella® Hemodynamics Platform prior to High risk percutaneous coronary intervention (HRPCI). Device escalation or early termination of the study will be allowed for subjects as deemed necessary by the treating physician. Subjects will be consented for follow-up through discharge from the index HRPCI admission.
223674687|NCT04610697|BEHAVIORAL|Cognitive Remediation|Cognitive Remediation consists of exercises, preferably supported by coaching, aimed at engaging cognitive skills and, as a result, at improving cognition as well as functional and clinical outcomes.
223674688|NCT04610697|BEHAVIORAL|Active Control|Active control condition for cognitive remediation, matched in terms of session modality, number, duration, frequency, and format.
223674689|NCT05003271|OTHER|Exercise program (virtual/remote)|Intervention (8 weeks): using the participants' initial assessment and personal characteristics, the therapist will provide personalized recommendations (e.g. maximum heart rate, minimum SpO2), explain the educational materials, and instruct patients on safety precautions.
223674690|NCT05579171|DEVICE|Picosecond 755nm Alexandrite Laser|Fractionated picosecond technology has been shown to lead to statistically significant improvement in atrophic, facial acne scars after 4-6 treatment sessions with minimal pain or downtime
223674691|NCT05579171|DEVICE|Picosecond 755nm Alexandrite Laser|Fractionated picosecond technology has been shown to lead to statistically significant improvement in atrophic, facial acne scars after 4-6 treatment sessions with minimal pain or downtime
223674692|NCT03894176|OTHER|Plasma PTX3 concentration|Long pentraxin 3, thrombus burden, final TIMI flow, ST segment resolution, STEMI, primary PCI
223674693|NCT05262348|DEVICE|adaptive DBS delivered through AlphaDBS IPG System|"The AlphaDBS IPG System delivers both conventional DBS and adaptive DBS. Adaptive DBS is a programming mode that provides stimulation in a closed-loop adaptive real-time fashion, using a biosignal recorded from the same macro-electrodes routinely implanted for DBS as an input variable."
223674694|NCT05262348|DEVICE|conventional DBS delivered through AlphaDBS IPG System|The AlphaDBS IPG System delivers both conventional DBS and adaptive DBS. Conventional DBS is programmed by DBS specialists.
223674695|NCT06080724|DRUG|Comparison of intralesional injection of bleomycin alone and combined with injection dexamethasone|already described
223674696|NCT00401388|DRUG|Perifosine|Perifosine is available in 50 mg tablets. Patients will take two perifosine 50 mg tablets orally once a day at bedtime with food.
223674697|NCT00401388|OTHER|Loperamide|All patients should be instructed to take loperamide at the earliest signs of diarrhea and/or abdominal cramping after beginning perifosine.
223674698|NCT00401388|OTHER|Allopurinol|Patients with a known history of hyperuricemia and/or gout should receive prophylactic treatment with allopurinol 300 mg po daily.
224255978|NCT05755763|OTHER|Anal incontinence patients with St. Mark's Incontinence Score|The scale was applied to the patients who applied to our clinic with the diagnosis of anal incontinence.
224255979|NCT01107366|PROCEDURE|lupiae technique|it's a new hybrid technique for the treatment of aortic aneurism and dissection.
224255980|NCT01107366|PROCEDURE|lupiae technique|"LUPIAE technique~Hybrid repair of thoracic or thoraco-abdominal aneurysms of different etiology and type A dissections with a two-stage procedure:~1. surgical arch reconstruction with a Dacron multibranched surgical prothesis~2. endovascular implantation of a thoracic stent graft"
224255981|NCT04256122|OTHER|No intervantion on patients. retrospective study is performed on paraffin embedded tumor tissue specimens routinely collected during TURBT.|evaluate an immunophenotypical profile related to mitochondrial functions in tumors responders vs non-responder to intravescical chemotherapy or immunotherapy. Verify the possible prognostic differences in clinical behavior between the two populations.
223674699|NCT00401388|OTHER|Antiemetics|Antiemetic prophylaxis will be administered at the treating investigator's discretion.
223674700|NCT03936452|DRUG|Sintilimab|Sintilimab 200mg ivdrip D1 Anlotinib 12mg po D1-14 Peg-aspargase 2500U/m2 im D1 combined with radiotherapy
223674701|NCT04857229|DEVICE|Histolog Scanner|Confocal Microscope
223674702|NCT05444998|DRUG|Intuzumab, pyrrolidone, nab-paclitaxel|"Pyrrolidone 400 mg, qd; nab-paclitaxel 125 mg/m2, qw, D1/8/15; inituzumab 6 mg/kg (first dose 8 mg/kg) q3w, D1; 4 cycles in total (q3w as 1 cycle).~The patient's postoperative adjuvant therapy was 4 cycles of epirubicin + cyclophosphamide + physician's choice of anti-HER2 targeted therapy.~Multiple drug interruptions for adverse events were allowed throughout."
223674703|NCT00266877|DRUG|HKI-272|320mg or 240mg daily by mouth. The starting dose was reduced from 320mg to 240mg per amendment #1 to the protocol for subject safety and tolerability.
223772612|NCT05907356|OTHER|sciatic nerve slider technique in slump lying position|The patient will be sitting at the edge of the couch with the posterior aspect of the knee at the edge, the thighs parallel to each other, and flexion at the thoracic and lumbar spines (slouch position). The therapist will be standing at the bedside of the patient with a proximal arm over the patient's shoulder and one hand guiding the neck movements of the patient and the other hand guiding the knee movements, passively performing cervical neck flexion with knee flexion (stretching the nerve proximally and relaxing at the distal end) and then moving into cervical extension with knee extension. Provide five sets in every session: the first: 10 repetitions, the second: 15 repetitions, the third: 20 repetitions, the fourth: 25 repetitions; and the fifth: 30 repetitions. The end position is held for 5 seconds, and the rest between sets is 1-2 minutes
224255982|NCT00115960|BIOLOGICAL|HIV-1 gag DNA|DNA vaccine containing the HIV gene gag
224255983|NCT00115960|BIOLOGICAL|IL-15 DNA adjuvant|Cytokine injection
224255984|NCT00115960|BIOLOGICAL|IL-12 DNA adjuvant|Cytokine injection
224255985|NCT03158675|PROCEDURE|fractional carbon dioxide(CO2) laser|-Fractional CO2 laser: Laser sessions will be performed at half month interval and it will be used with a wave length of 10,600nm.
224255986|NCT03158675|DRUG|Topical corticosteroid|Topical corticosteroid will be applyed twice weekly on both sides for 4 months.
224255987|NCT03158675|RADIATION|Ultraviolet B narrow band|Ultraviolet B narrow band will be performed (wave length ranged from 300 to 320nm).The sessions will be performed twice weekly for 4 months.
224255988|NCT03238781|DRUG|Placebo|Placebo was presented in identical containers, stored/packaged the same as AMG 301. All injections were administered within 30 minutes on treatment days.
224255989|NCT03238781|DRUG|AMG 301|AMG 301 was packaged in 5 mL clear glass vials containing 1 mL of 70 mg/mL of AMG 301. All injections were administered within 30 minutes on treatment days.
224255990|NCT01188850|BIOLOGICAL|VGX-3100|DNA plasmid delivered via IM injection + electroporation using CELLECTRA device
224255991|NCT03331445|DRUG|Nitric Oxide 0.5 % / Nitrogen 99.5 % Gas for Inhalation|Inhaled Nitric Oxide 160ppm balance air
224255992|NCT07011888|DEVICE|SaeboStim GO with Saebo Glove Rehabilitation Program|The intervention consists of a comprehensive rehabilitation program for a chronic stroke patient, utilizing the SaeboStim GO device combined with the Saebo Glove orthosis to facilitate and strengthen hand and upper limb motor function. The program also includes therapeutic ultrasound to support tissue healing, and vestibular rehabilitation therapy (VRT) to enhance motor learning and engagement. This combined approach aims to improve motor skills, balance, gait, daily living activities, and cognitive functions over a treatment period of six months.
224255993|NCT03810118|DIAGNOSTIC_TEST|fluid challenge|4 ml/kg fluid challenge infused over in either 10 or 20 minutes
224255994|NCT05294783|PROCEDURE|ACL reconstruction|ACL reconstruction is a standard surgery for ACL injured patients
224255995|NCT02233985|DRUG|0.9% Sodium Chloride|Salbutamol 100 micrograms / kg / dose administered 0.9% saline solution (4ml) nebulized for 3 initial sessions lasting 20 minutes each and every 4 hours during the entire hospital stay.
224255996|NCT02233985|DRUG|3% Sodium Chloride|Salbutamol 100 micrograms / kg / dose administered 3 % saline solution (4ml) nebulized for 3 initial sessions lasting 20 minutes each and every 4 hours during the entire hospital stay.
224255997|NCT00808418|DRUG|Elesclomol Sodium|Chemotherapy agent
224255998|NCT00808418|DRUG|Docetaxel|Chemotherapy agent
224255999|NCT04931563|BIOLOGICAL|Anifrolumab|Intravenous infusion (IV)
224256000|NCT04931563|DRUG|placebo|Intravenous infusion (IV)
224256001|NCT06033456|PROCEDURE|Radiofrequency stellate ganglion block using ultrasound guidance (SGB)|"Visualization of C6-C7 level will be targeted under fluoroscopic posterior-anterior (PA) guidance. Skin will be infiltrated with 1% lidocaine using a 25-gauge needle. Next, the RF needle will be inserted under a trajectory approach toward the target. Then, with ultrasound guidance, using a superficial linear ultrasound probe to guide further needle penetration so that the needle-tip will lie anterior to the longus colli muscle, the exclusion of vascular structures will be confirmed by duplex(8).~Then, 5 to 1 mL of omnipaque dye (iohexol) will be injected. Subsequently, a 100 mm length Baily RF electrode will be inserted and connected to the generator. The RF needle will be positioned alongside the stellate ganglion in the thermal RF technique. With repeated sensory and motor stimulation before RF lesioning"
224322377|NCT06728683|OTHER|ASSIST-MH|The goal of this SBIR is to create Assist-MH, a new interactive digital support system for SMH providers. Assist-MH will offer an innovative suite of diverse MH strategies to help providers address the clinical needs of youth in distress. In Phase I, the focus will be on depression and anxiety for students ages 12 to 17 years. These MH problems are among the most common for youth, and have shown increasing prevalence in recent years among this age group. Investigators will conduct user-centered testing to determine the set of MH strategies most needed by SMH providers, create a sampling of these resources, and test the usability and promise of the proposed Assist-MH product prior to Phase II full development and pilot testing.
224256002|NCT06033456|PROCEDURE|Radiofrequency thoracic (T2, T3) paravertebral block under fluoroscopic guidance (TPVB)|Radiofrequency sympathectomy will be performed with the patient in the prone position. Under fluoroscopic guidance, the T2, T3 vertebral bodies will be identified in an anteroposterior view. For radiofrequency sympathectomy, 10 cm curved, sharp radiofrequency insulated needle with an active tip of 10 mm, needle entry will be performed, and the final placement of the needle tip will be located at the posterior third of the vertebral body in lateral view and just lateral to the body in the anteroposterior view. Once the correct position is confirmed, 0.5 to 1 ml of Omnipaque will be injected, then a 10 cm electrode will be introduced through the RF needle. Before lesioning, a sensory and motor test stimulation is performed to verify the location.
224256003|NCT06033456|PROCEDURE|Combined radiofrequency of stellate ganglion block plus thoracic T2, T3 paravertebral block|Combination between radiofrequency of stellate ganglion block and thoracic T2, T3 paravertebral block.
224256004|NCT00781794|DRUG|NSA-789 at 2 different doses|
224256005|NCT00351676|BEHAVIORAL|Integration of a team based clinical pharmacist|
224256006|NCT00351676|DRUG|Optimizing therapeutic treatments|
224256007|NCT00351676|BEHAVIORAL|Optimizing processes of care|
224256008|NCT01581658|DRUG|BI10773|BI10773 medium dose tablet single dose
224322378|NCT02016703|OTHER|Erythritol drink|
223674704|NCT02508298|PROCEDURE|HVPG|HVPG will be performed by placing a placing a 7F venous catheter into a supra-hepatic vein and then advancing a 5F balloon-tipped catheter into the right hepatic vein. Wedged hepatic venous pressure (WHVP) and free hepatic venous pressure (FHVP) will be measured by connection to an external transducer and polygraph (PowerLab, ADInstruments Inc., Colorado Springs, CO). After inflating the balloon catheter, adequacy of the occlusion will be established by injection of a small amount of radiologic contrast medium. Hepatic Venous Pressure gradient (HVPG) will be calculated as the difference between WHVP and FHVP.
223674705|NCT02508298|DRUG|Indocyanine Green Retention test|As decribed in arm descriptions
223674706|NCT02508298|DEVICE|Liver stiffness measurement|As decribed in arm descriptions; perfromed by ARFI
223674707|NCT02508298|DEVICE|Spleen stiffness measurement|As decribed in arm descriptions; performed by ARFI
223674708|NCT03848871|DRUG|Enstilar|Enstilar foam applied to affected area once daily
223674709|NCT05945862|BEHAVIORAL|NUTRIGANDO|Program consisting in nutrition education and physical activity training to promote healthy lifestyles
223674710|NCT06103331|OTHER|Invasive Fungal disease surveillance|Management of invasive fungal infection according to pathogen identification and susceptibility report.
223674711|NCT04339842|OTHER|Assessment of Dietary Changes in Adults in the Quarantine|The online survey will help to collect demographic data from the volunteers. Personal information and contact details, such as email, will not be asked. The survey will include questions about any increase or decrease in the consumption of main meals, snacks and fluid intake. If the participants of the study have observed changes in their dietary pattern since the beginning of the quarantine, details of these changes, such as an increase in the amount of main meal consumption, will be questioned.
223674712|NCT01910077|DRUG|Tacrobell capsule 1mg|1 capsule, oral, over the period I\&II(crossover)
223674713|NCT01910077|DRUG|Prograf capsule 1mg|1 capsule, oral, over the period I\&II(crossover)
223674714|NCT02097017|DRUG|Lidocaine|will local application of lidocaine to the cervix alleviate pain of laminaria insertion
223674715|NCT02097017|OTHER|placebo comparator|
223674716|NCT00591110|BEHAVIORAL|Eye care education|Participants will receive an educational intervention communicating practical information about vision, eye conditions and eye care pertinent to the older African American population
223674717|NCT00591110|BEHAVIORAL|Social-contact control|Participants receive an engaging informational session on a non-health related topic
223674718|NCT02299973|PROCEDURE|FMT with donor stool|fecal microbiota transplantation by means of colonoscopy with deliverance of the transplant in the right colon and terminal ileum. Transplants will be collected prior to the start of the study from a healthy pool of donors and will be frozen at -80 degrees celsius after thorough screening for infectious diseases. At the time of transplantation samples will be frozen and administrated to the patients in the treatment group
223674719|NCT02299973|PROCEDURE|FMT with own stool|fecal microbiota transplantation by means of colonoscopy with deliverance of the transplant in the right colon and terminal ileum. Transplants will be collected prior to the start of the study from the patients and will be frozen at -80 degrees celsius after thorough screening for infectious diseases. At the time of transplantation samples will be frozen and administrated to the patients in the control group
223674720|NCT00480948|BEHAVIORAL|Infant formula feeding (InFat™)|Infant formula with InFat™ oil (containing \~49% of C16:0 at sn-2 position), 24 wk
223674721|NCT00480948|DIETARY_SUPPLEMENT|Control|Standard vegetable oil based infant formula
223674722|NCT00184171|DRUG|Budesonide|Budesonide 9 mg
223674723|NCT00184171|DRUG|Bismuth|Bismuth mixture
223674724|NCT00184171|DRUG|Fiber|Fiber for control
223674725|NCT01603524|OTHER|OMSC Group|"The OMSC Group will receive a multi-component intervention which includes:~1. Coaching and Outreach Facilitation Visits: Each practice will receive on-site support to implement the intervention components.~2. Practice tools and real time prompts: Practices will be provided with 4 tools to support the integration of evidence-based cessation practices into brief clinical encounters as part of a practice-level strategy.~3. Provider Training in Smoking Cessation Interventions: All clinic providers will be invited to a 3 hour training workshop on smoking cessation(CME).~4. Telephone follow-up support program: Clinics will be able to refer smokers embarking upon a quit attempt to the smoker's telephone follow-up counseling program."
223674726|NCT01603524|BEHAVIORAL|OMSC + Performance Feedback Group|The OMSC + Performance Feedback Group will receive the same intervention program as the OMSC group. In addition, clinicians will complete a one-hour audit and feedback session prior to the implementation of the OMSC program at their clinic. The goal of the audit and feedback is to increase provider self-efficacy in the delivery of smoking cessation interventions, raise awareness of the current delivery of evidence-based cessation practices, identify areas for improvement, and motivate providers to deliver evidence-based treatments.
223674727|NCT01501045|DEVICE|TMS system MagPro x100, Tonica Elektronik A/S, Denmark|repeated TMS (rTMS)
223674728|NCT01501045|DEVICE|TMS system MagPro x100, Tonica Elektronik A/S, Denmark|repeated TMS
223674729|NCT03985878|DRUG|Eteplirsen|Eteplirsen IV infusion once weekly.
224256009|NCT01581658|DRUG|BI10773|BI10773 medium dose tablet single dose
224256010|NCT01581658|DRUG|BI10773|BI10773 medium dose tablet single dose
224256011|NCT01581658|DRUG|BI10773|BI10773 medium dose tablet single dose
224256012|NCT02304211|DRUG|Insulin|Insulin will be administered either into the radial artery (microdose intervention) or IV (systemic intervention).
224256013|NCT02344381|DIETARY_SUPPLEMENT|Sucrose|
224256014|NCT02344381|DIETARY_SUPPLEMENT|Glucose|
224256015|NCT05335863|DIETARY_SUPPLEMENT|Oral Nutritional Supplement|Participants must consume 416 mL of ONS FontActiv® DiaBest HP / HC vanilla flavor. A maximum time of 10 min will be given to consume the entire product.
224256016|NCT05335863|DIETARY_SUPPLEMENT|Glucose|Participants must consume a 50 g glucose solution in 10 min to obtain the ares under the curve (AUC) data from glucose consumption
224256017|NCT04140877|DEVICE|Visu|An experimental (test) virtual reality display
224256018|NCT04432233|DRUG|Esomeprazole|Proton pump inhibitor
224256019|NCT04432233|DRUG|Metronidazole|antibiotic for H. pylori eradication
224256020|NCT04432233|DRUG|Levofloxacin|antibiotic for H. pylori eradication
224256021|NCT06295211|OTHER|observational|observational
224256022|NCT04044521|OTHER|Systems consultation|"Systems consultation consists of three implementation strategies: academic detailing (AD), practice facilitation (PF), and physician peer consulting (PPC). Clinics will receive a combination of these strategies for 21 months.~AD: Clinicians will attend an educational meeting that will detail the study and Center for Disease Control guidelines for opioid prescribing in primary care. Clinicians will then will get a monthly audit \& feedback report on their prescribing.~PF: clinics will be randomized to receive practice facilitation. Facilitators will meet with each clinic. Facilitators walk through the clinic, identify areas of opioid prescribing workflow improvement, conduct a nominal group technique with the change team, and set a Plan-Do-Study-Act cycle. Clinics will follow-up with the facilitators monthly.~PPC: Clinicians of the clinics will meet quarterly with the physician peer consultant to discuss tough patient cases and panels regarding opioid prescribing."
224256023|NCT02538523|DEVICE|Erchonia FX-635|The Erchonia FX-635 is applied to the lower back and hips area for 20 minutes per treatment administration, 8 times across 4 weeks, 2 times per week.
223674730|NCT01821573|DRUG|botulinum toxin type A|"Experimental arm group:~* 150 Units in rectus femoris ( 3 ml and 3 points)~* 70 units in medial gastrocnemius (1.4 ml and 1 point)~* 70 units in lateral gastrocnemius ( 1.4 ml and 1 point)~* 60 units in soleus ( 1.2 ml and 3 points)"
223674731|NCT01821573|DRUG|injection of NaCl 0.9%|"Placebo comparator group: injection of NaCl 0.9%:~* 3 ml of NaCl 0.9% in rectus femoris in 3 points~* 1.4 ml of NaCl 0.9% in medial gastrocnemius in 1 point~* 1.4 ml of Nacl 0.9% in lateral gastrocnemius in 1 point~* 1.2 ml of NaCl 0.9% in soleus in 3 points"
223674732|NCT02176720|DRUG|FDOPA PET|\[18F\]FDOPA radiopharmaceutical will be intravenousely injected for PET-CT scanning of the brain.
223674733|NCT05843227|OTHER|questionnaire on the organizational management|Data are collected through a questionnaire on the organizational management of the pre-operative / intraoperative / postoperative periods.
224256024|NCT02538523|DEVICE|Placebo Laser|The Placebo Laser is applied to the lower back and hips area for 20 minutes per treatment administration, 8 times across 4 weeks, 2 times per week.
224256025|NCT04444050|DRUG|BMS-986331|Specified dose on specified days
224256026|NCT04444050|OTHER|Placebo, Matching BMS-986331|Specified dose on specified days
224256027|NCT01763177|OTHER|Oxygen|Oxygen mask 40% 8 LPM for 30 minutes
224256028|NCT03396276|DRUG|Suboxone|8mg of buprenorphine/2mg of naloxone
223674734|NCT05301712|DRUG|Naloxone hydrochloride 5.0mg/5ml|"* Initial dose: 4mg, Intravenous injection~* Continuous dose: 8mg(mixed with 1000ml of 5% Dextrose water or saline solution) per day, Intravenous infusion for 7days~* Total dose: 4mg+8mg/day\*7=60mg"
223674735|NCT05301712|DRUG|Sodium Chloride 45mg/5ml|"* Initial dose: 4ml, Intravenous injection~* Continuous dose: 8ml (mixed with 1000ml of 5% Dextrose water or saline solution) per day, Intravenous infusion for 7days~* Total dose: 4ml+8ml/day\*7=60ml"
223674736|NCT00729846|DRUG|Bevacizumab|Patients will receive intravitreal bevacizumab (1.25mg) on same day following photodynamic therapy.
223674737|NCT00729846|DEVICE|verteporfin photodynamic therapy reduced fluence|Patients will receive combination verteporfin photodynamic therapy with stand fluence \[600mW/cm2\].
223674738|NCT00729846|DEVICE|verteporfin photodynamic therapy standardfluence|Patients will receive combination verteporfin with photodynamic therapy at standard fluence \[600mw/cm2\].
223674739|NCT02940002|DRUG|BAY1003803|Simultaneous application of 10μl on psoriasis plaque and on healthy skin for 4 weeks and evaluation of pharmacodynamic effect
223674740|NCT02940002|DRUG|Clobetasol propionate|Simultaneous application of 10μl on psoriasis plaque and on healthy skin for 4 weeks and evaluation of pharmacodynamic effect
224256029|NCT03396276|BEHAVIORAL|Brief counseling in the ED|"Patients will receive brief counseling from ED physician prior to discharge about the options for outpatient treatment, as well as opioid dependency.Consented patients will be provided with a pamphlet from the Substance Abuse and Mental Health Services Administration called Facts About Buprenorphine, as well as an information packet for study contact information for the opioid recovery network providers."
224256030|NCT03396276|BEHAVIORAL|Referral to outpatient treatment|A referral will be made to one of the affiliated MAT clinics.
224256031|NCT03396276|BEHAVIORAL|Follow-up coaching|A designated paramedic with the Houston Fire Department (called the navigator or care coordinator) will work with UTHealth to jointly follow-up on patients both telephonically and in-person. The Houston Fire Department paramedic will provide brief information sharing and assist with coordination in scheduling or registering with MAT clinics or recovery coaching.
224256032|NCT06370377|OTHER|the Egyptian code of ethical practice|Nurses' adherence to the Egyptian code of ethical practice
224256033|NCT03475030|OTHER|pre-filled medication trays|
224256034|NCT03475030|OTHER|automated medication reminders|
224256035|NCT02209428|DRUG|Temozolomide|75 mg/m2/day for 21 days repeated every 4 weeks, 6 cycles.
224322379|NCT02016703|OTHER|Placebo drink|
224322380|NCT05937997|PROCEDURE|high intensity physiotherapy|high intensity exercises for 3 weeks inpatient rehabilitation
224322381|NCT05937997|PROCEDURE|moderate intensity physiotherapy|moderate intensity exercises for 3 weeks inpatient rehabilitation
224322382|NCT05937997|PROCEDURE|low intensity physiotherapy|low intensity exercises for 3 weeks inpatient rehabilitation
223674741|NCT02940002|DRUG|Betamethasone/calcipotriene|Simultaneous application of 10μl on healthy skin for 4 weeks and evaluation of pharmacodynamic effect
223674742|NCT04022161|DRUG|Nitrogen Gas for Inhalation|See arm description
223674743|NCT04022161|OTHER|Blood withdrawal|Blood samples will be collected over four time-points: (I) baseline (before surgery) (II) end of the surgery, (III) end of 24 hours of gas delivery and (IV) 24 hours from the gas suspension.
223674744|NCT04022161|DRUG|Nitric Oxide|See arm description
223674745|NCT06398405|OTHER|Epigallocatechin-3-gallate|Epigallocatechin-3-gallate is administered in a solution with a concentration of 4400 umol/L
223674746|NCT03817450|BEHAVIORAL|Daily Mouth Care|Nursing assistants will be trained to provide daily mouth care to all residents in nursing homes. Mouth care supplies will also be provided to intervention nursing homes.
223674747|NCT05436340|DEVICE|The Effect Of Heel Protector In Intensive Care Units|In the experimental group, foot joint opening and heel pressure sore formation will be observed by using heel protector pad.
223674748|NCT05436340|DEVICE|Control group|Heel pads will not be used in the control group. Routine maintenance will be applied
223674749|NCT03403387|DIETARY_SUPPLEMENT|GlutenShield|combination probiotic, prebiotic, and enzyme supplement
223674750|NCT03403387|OTHER|Placebo|Avicel (cellulose) and bentonite powder
224256036|NCT04975035|DRUG|Zolodine|Collect 200 patients who meet the criteria into the group. After enrollment, according to the principle of cross dressing change, the attending physician can decide the dressing change method according to the patient's condition, individual condition and other factors; within 2-4 weeks, the original antipsychotics should be gradually stopped, and Zoladine capsules will be gradually added to the target The dose is 120-160mg/d, orally 1-2 times a day, with meals.
224256037|NCT03909945|DIETARY_SUPPLEMENT|Annona muricata|Patients with prehypertension or stage 1 hypertension, in dietary measures, will received daily one tablet of 796 mg of aqueous extracts of Annona muricata leaves. During 60 days
224256038|NCT00811655|PROCEDURE|therapeutic conventional surgery|Surgery of a single brain metastasis.
224256039|NCT00811655|RADIATION|stereotactic radiosurgery|Pre-operative single fraction SRS
224256040|NCT02769494|DRUG|Mesalazine Sustained-Release Tablets|Mesalazine sustained-release tablets 500mg and 0.02L glycerol mixed, the preparation of 2.5% the mesalazine glycerol suspension liquid, gently apply to the ulcer surface, 3 times/day. The application time of the drug is 8:00,12:00, 16:00. Daily 20:00 measure the size of the mouth ulcers and record the symptoms in the diary card.
224256041|NCT02769494|DRUG|Riboflavin Sodium Phosphate Injection|gently apply the riboflavin sodium phosphate injection to the ulcer surface, 3 times/day. The application time of the drug is 8:00,12:00, 16:00. Daily 20:00 measure the size of the mouth ulcers and record the symptoms in the diary card.
224256042|NCT00813592|DRUG|SOM230B|SOM230 is an injectable somatostatin analogue. Like natural somatostatin and other somatostatin analogues (SRIFa), SOM230 exerts its pharmacological activity via binding to somatostatin receptors (sst). There are five known somatostatin receptors: sst 1, 2, 3, 4 and 5. Somatostatin receptors are expressed in different tissues under normal physiological conditions. Somatostatin analogues activate these receptors with different potencies (Schmid and Schoeffter 2004) and this activation results in a reduced cellular activity and inhibition of hormone secretion. Somatostatin receptors are strongly expressed in many solid tumors, especially in neuroendocrine tumors where hormones are excessively secreted e.g. acromegaly (Freda 2002), GEP/NET tumors (Oberg, et al 2004) and Cushing's disease.
224256043|NCT03682653|DRUG|Azithromycin|a single dose of Azithromycin will be administered to infants between their 8-27th days of life
224256044|NCT03682653|DRUG|Placebo|a single dose of Placebo will be administered to infants between their 8-27th days of life
224256045|NCT01673685|DEVICE|Portable Oxygen|
223674751|NCT04503915|PROCEDURE|different estrogen supplementation modes|The different estrogen supplementation modes are randomized into two groups.
223674752|NCT05054842|DRUG|Retagliptin phosphate tablets、metformin sustained-release tablets|Retagliptin phosphate tablets 100mg+ metformin sustained-release tablets 1500mg or 2000mg based on prior medication
223674753|NCT05054842|DRUG|Retagliptin phosphate placebo tablets、metformin sustained-release tablets|Retagliptin phosphate 100mg placebo tablets + metformin sustained-release tablets 1500mg or 2000mg based on prior medication
223674754|NCT00655135|DRUG|LDP-02|Each patient in arms 2 \& 3 received a single IV dose of study drug at 0.5 or 2.0 mg/kg LDP-02 on Days 1 and 29.
223674755|NCT00655135|DRUG|Placebo|Each patients in arm 1 received a single IV dose of placebo on Days 1 and 29.
223674756|NCT01251471|DRUG|Escitalopram|10 mg/d; optional 20 mg/d after 2 weeks.
223674757|NCT05002920|PROCEDURE|alveolar bone grafting|the surgery of alveolar bone graft for alveolar defect in cleft patients
223674758|NCT00719433|DEVICE|robot therapy (ARMin)|therapy of the affected arm with a robot for eight weeks, three times weekly for one hour
223674759|NCT00719433|OTHER|conventional therapy|physical and occupational therapy of the affected arm for eight weeks, three times weekly for one hour
223674760|NCT04686045|OTHER|observational study|observational study
224256046|NCT06064331|DRUG|Lignocaine|IV bolus of 1.5 mg/kg of lignocaine 2% diluted in 10 ml syringe over 3 mins followed by infusion at 1 mg/kg/h of lignocaine 2% in 20 ml syringe
224256047|NCT06064331|DRUG|Placebo|IV bolus of 10 ml normal saline over 3 min followed by infusion of equal volume of normal saline in 20 ml syringe
224256048|NCT05255601|DRUG|Relatlimab|Specified Dose on Specified Days
224256049|NCT05255601|DRUG|Nivolumab|Specified Dose on Specified Days
224256050|NCT02820350|DEVICE|SCD-F40|CRRT with SCD
224256051|NCT01519258|OTHER|Pressure Support ventilation|Patients will receive usual care during the period of ventilation on the Pressure Support. The same ventilator, the Servoi (maquet, Sweden) will be used.
224256052|NCT01519258|DEVICE|NAVA|Patients will be ventilated with NAVA for 15 minutes. Back up settings in pressure support mode will be set in case the esophageal catheter is misplaced, and back up settings in pressure control ventilation will be set in case no inspiratory efforts are detected for longer than 15 seconds
224256053|NCT04616287|OTHER|Neuropsychological assessment and Multimodal brain MRI|Neuropsychological assessment and Multimodal brain MRI
223674761|NCT05320497|DEVICE|Transparent cap|Add a self-made transparent cap (made by cutting a silicone drainage tube) to the end of the SpyGlass choledochoscope, and then perform routine choledochoscopy and biopsy operations
223674762|NCT06206070|BEHAVIORAL|The Hong Kong version of Westmead Feeling Program 2|Westmead Feelings Program (WFP) is a manualized emotion-based learning intervention for children on the autism spectrum. WFP teaches autistic children how to understand their own and other's emotions, solve problems, and regulate emotions through the implementation of transactional support. In doing so, parents and teachers are also trained to develop their emotional coaching skills to support children in everyday settings. Its impact on improving emotional competence in primary school-aged children on the autism spectrum has been established in 41 mainstream schools in Australia.
224256054|NCT03968653|DRUG|Debio 0123|Debio 0123 will be given as an oral capsule for 3 days during each 21-day cycle, except Cycle 1 which is of 24 days.
224256055|NCT03968653|DRUG|Carboplatin|Carboplatin will be given as an IV infusion in combination with Debio 0123 on Day 1 from Cycle 2 onwards in Group A.
224256056|NCT03968653|DRUG|Debio 0123|Debio 0123 will be given as an oral capsule for 3 or 6 days during each 21-day cycle.
224256057|NCT03968653|DRUG|Carboplatin|Carboplatin will be given as an IV infusion in combination with Debio 0123 on Day 1 from Cycle 1 onwards.
224256058|NCT06691217|DRUG|CANAKINUMAB (ILARIS®)|Participants with and without TET2 CHIP will receive 150mg of canakinumab every 3 months for 4 doses as part of the randomized clinical trial part of this proposal.
224256059|NCT06691217|DRUG|Saline (NaCl 0,9 %) (placebo)|Participants with and without TET2 CHIP will receive placebo injection every 3 months for 4 doses as part of the randomized clinical trial part of this proposal.
224256060|NCT06698926|DRUG|ABBV-CLS-616|Oral Tablet
224256061|NCT06698926|DRUG|Placebo|Oral Tablet
224256062|NCT06698926|DRUG|Itraconazole|Oral Capsule
224256066|NCT07040397|DEVICE|EMMA massage therapy|Expert Manipulative Massage Automation (EMMA) is equipped with sensors to measure muscle stiffness and uses 3D vision technology to measure muscle stiffness and identify pressure points while delivering a massage to patients. Following that, the electronic massager will determine the best course of action for our patients based on the information stored by our Artificial Intelligence and EMMA's robotic arm will perform the massage. EMMA executes massages through soft treatment modules that are warmed to a temperature of between 38℃ and 40℃ to mimic human touch.
224256067|NCT07040397|OTHER|Clinical massage treatment|The direct person clinical massage treatment will be delivered by a clinical licensed massage therapist. The type of massage will follow the EMMA massage in that it will be a deep tissue massage (to mimic the Tuina massage) and generally will be for about 30 minutes to once again mimic the duration of massage therapy of the EMMA.
224256068|NCT03255421|OTHER|Pressure measurement|Observational study No intervention, only fragmenting the emptying of the bladder
224256069|NCT06930625|DRUG|Debio 4126|IM injection, a 12-week extended-release formulation of octreotide
224256070|NCT06930625|DRUG|Placebo|IM injection of mannitol suspension
224256071|NCT07085767|DRUG|Palazestrant|Participants will be treated with palazestrant 90 mg once daily on a 4-week (28-day) cycle.
224256072|NCT07085767|DRUG|Letrozole-matching placebo|Participants will be treated with letrozole-matching placebo once daily on a 4-week (28 day) cycle
224256073|NCT07085767|DRUG|Ribociclib|Participants will be treated with ribociclib 600 mg once daily on Days 1-21 of a 4-week (28 day) cycle.
224256074|NCT07085767|DRUG|Letrozole|Participants will be treated with letrozole 2.5 mg once daily on a 4-week (28-day) cycle
224256075|NCT07085767|DRUG|Palazestrant matching-placebo|Participants will be treated with palazestrant-matching placebo once daily on a 4-week (28-day) cycle
224256076|NCT07083947|DIETARY_SUPPLEMENT|CL19183|One capsule taken orally each morning after breakfast with water for 16 weeks
224256077|NCT07083947|DIETARY_SUPPLEMENT|CL24212|One capsule taken orally each morning after breakfast with water for 16 weeks
224256078|NCT07083947|OTHER|Placebo|One capsule taken orally each morning after breakfast with water for 16 weeks
224256079|NCT06620380|DEVICE|Pharmacoscopy 1.0|Pharmacoscopy is currently an academically developed platform. The study is designed to investigate the clinical performance of this academic platform. In the interventional arm, the best candidate agent defined by pharmascopy will be considered to guide the therapeutic decision for each patient.
224256080|NCT06620380|OTHER|Control|The next systemic treatment after surgery will be discussed, with the investigator and at the tumor board, considering also standard histopathological and molecular analysis, including next generation sequencing, molecular profiling analysis and previous treatments received
224256081|NCT07088120|DEVICE|Precision-Controlled Ventilation with Real-Time Feedback|Manual ventilation during CPR using a real-time feedback device (EOlife, Archeon Medical) to guide the delivery of tidal volumes (6-8 mL/kg predicted body weight) and ventilation rate (10 breaths per minute). The device measures and displays ventilation parameters in real time, helping providers achieve guideline-recommended targets during resuscitation.
224256082|NCT07088120|OTHER|Standard Manual Ventilation During CPR|Manual ventilation during CPR without real-time feedback, using clinician judgment to guide tidal volume (visible chest rise) and ventilation rate, consistent with American Heart Association guidelines.
224256083|NCT03429712|DEVICE|Dual-source multi-detector computed tomography (DSSE)|Dose split technique in a cohort of pediatric patients to determine, without increase in patient radiation dose, the optimal patient-specific and task-specific radiation dose levels for pediatric cardiothoracic and abdominal CT applications.
224256084|NCT03360890|DRUG|Pembrolizumab|Pembrolizumab will be administered via IV at 200mg every three weeks. Patients will receive pembrolizumab for about 2 years.
224256085|NCT03360890|DRUG|Docetaxel|Docetaxel will be administered via IV at 75mg/m2 every three weeks for 3 to 6 cycles.
224256086|NCT05940493|DRUG|Abemaciclib|Tablet
224256087|NCT05940493|DRUG|Placebo|Tablet
224256088|NCT04709705|BIOLOGICAL|Human platelets|Platelets given to control bleeding
224256089|NCT03222531|DRUG|sofosbuvir/velpatasvir|Drug: sofobuvir/velpatasvir
224256090|NCT05867927|DEVICE|Robotic-assisted surgery (da Vinci)|Robotic-assisted surgery (da Vinci)
224256091|NCT05867927|DEVICE|Non-da Vinci Surgery|Non-da Vinci Surgery
224322383|NCT00839254|BIOLOGICAL|Pneumococcal conjugate vaccine Synflorix (GSK1024850A)|2, 3 or 4 Intramuscular injections, depending on the age at the time of first vaccination
224256092|NCT07092579|DEVICE|Smart Crutch Tips™|Smart Crutch Tips™ are sensor-equipped crutch attachments that measure real-time axial loading during ambulation. The devices connect via Bluetooth to a mobile application and deliver auditory and visual feedback to guide patients toward prescribed weight-bearing levels. The devices continuously record loading and step-count data for clinical monitoring and analysis.
224256093|NCT07092579|PROCEDURE|Finite Element Analysis (FEA)|Finite Element Analysis (FEA) is performed up to four times postoperatively to generate individualized weight-bearing prescriptions during rehabilitation. Simulations are based on CT scans and include segmentation and biomechanical modeling of the bone-fixator system. Assessments occur at: 7 days (baseline), 6 weeks, 12 weeks, and optionally at 16 weeks if healing isn't confirmed. Three regions are segmented: fixation system (screws and nail), bone fragments, and fracture gap. Materials: fixator (Titanium Grade 5), bone (mapped into cortical, trabecular, soft tissue, air), and fracture gap (early connective tissue). FEA calculates personalized safe loading based on: (1) Fixator safety (stress \< 290 MPa), (2) Interfragmentary motion (target: 0.5-2.0 mm), and (3) Strain in the fracture gap (octahedral: 0.001-0.05; hydrostatic: 0.001-0.02), supporting biological healing. Output informs weight-bearing prescriptions and step-count targets, delivered via Smart Crutch Tips™ with real-time fee
224256094|NCT07092579|BEHAVIORAL|Iterative walking|Participants will perform iterative walking sessions as part of their rehabilitation program. These sessions will be repeated throughout the day, with a minimum 2-hour rest interval between sessions. Step count will be progressively increased over time, according to the individualized rehabilitation plan. In the intervention arms, walking sessions will be guided by real-time auditory and visual feedback from Smart Crutch Tips™.
224256095|NCT07092579|PROCEDURE|Lower Limb Rehabilitation Exercise Program|A structured exercise program prescribed postoperatively to promote functional recovery after tibial shaft fracture surgery. Exercises target quadriceps, hamstrings, gluteal muscles, and ankle/foot mobility to maintain muscle tone, prevent stiffness, and improve circulation. The program includes isometric and dynamic exercises such as: static quadriceps and hamstring contractions, straight leg raises, hip abduction, knee extension, hamstring curls, heel slides, ankle dorsiflexion/plantarflexion, ankle inversion/eversion, ankle circles, toe spreading, and passive ankle stretching using a strap or towel. Exercises are performed in pain-free ranges with gradual progression in repetitions and sets according to the rehabilitation plan. Certain ankle and foot mobility exercises (dorsiflexion/plantarflexion) are also performed hourly during the day to prevent swelling and thrombosis.
224256096|NCT07090746|DEVICE|Clear aligner|Clear aligner
224256097|NCT07090746|DEVICE|Fixed orthodontic appliance|Fixed orthodontic appliance
224256098|NCT07091253|OTHER|HIV+|Participants living with HIV will use a triaxial accelerometer for a week in order to measure the physical activity and sedentary behaviors
224256099|NCT06779890|DRUG|Sevoflurane|Sevoflurane will be administered at concentrations maintaining MAC= 0.8 for the first 60 minutes , MAC=1.2 for the next 60 minutes and MAC= 0.8 until surgery completion.
224256100|NCT06779890|DRUG|Desflurane|Desflurane will be administered at concentrations maintaining MAC= 0.8 for the first 60 minutes , MAC=1.2 for the next 60 minutes and MAC= 0.8 until surgery completion.
224256101|NCT06826755|DIETARY_SUPPLEMENT|Terry Naturally® melatonin 5mg SR|Participants will take SR melatonin 5mg (or placebo) orally 1 hour before bed, for approximately 12 weeks. The study is comparing the effects of melatonin supplementation vs. placebo on cardiovascular risk measures in perimenopausal women.
224256102|NCT06826755|DIETARY_SUPPLEMENT|Placebo|Participants will take SR melatonin 5mg (or placebo) orally 1 hour before bed, for approximately 12 weeks. The study is comparing the effects of melatonin supplementation vs. placebo on cardiovascular risk measures in perimenopausal women.
224256103|NCT06603246|DRUG|GDC-6988|GDC-6988 will be administered using a dry powder inhalation
224256104|NCT05792566|OTHER|Atomic app|Using the Atomic app to improve physical activity
224256105|NCT05024175|DIAGNOSTIC_TEST|Disease assessments|CT (Computerized Tomography) scan or PET-CT (Positron Emission Tomography-Computerized Tomography) scans as per protocol
224256106|NCT05024175|PROCEDURE|Tumor Biopsy|Tumor Biopsy per protocol
224256107|NCT05024175|DIAGNOSTIC_TEST|Blood test|Blood Test per protocol
224256108|NCT06914609|DRUG|ION582|ION582 will be administered by IT injection.
224256109|NCT06914609|DRUG|Placebo|ION582 matching placebo will be administered by IT injection.
224256110|NCT07107685|OTHER|Global cohort|All deceased patients admitted to intensive care during the study period and satisfying the eligibility criteria.
224256111|NCT06779773|DRUG|Avacincaptad pegol (ACP)|intravitreal injection
224256112|NCT05125302|DRUG|Ubrogepant|Oral Tablet
224256113|NCT05125302|DRUG|Placebo-Matching Ubrogepant|Oral Tablet
224256114|NCT06814509|BEHAVIORAL|Enhanced Standard of Care (ESoC)|Standard recommended nutrition and gestational weight gain counseling; WIC and SNAP enrollment assistance; emergency food referrals
224256115|NCT06814509|BEHAVIORAL|Delivering HOPE|ESoC plus healthy food provision
224256116|NCT06552754|BEHAVIORAL|Motion Reset|virtual reality-based experiential, sensory intervention
224256117|NCT06552754|BEHAVIORAL|Placebo|virtual reality-based experiential, sensory experience without intervention
224256118|NCT01763385|DRUG|Erlotinib|
224256119|NCT01763385|RADIATION|concurrent brain radiotherapy|
224256120|NCT01763385|RADIATION|secondary brain radiotherapy|
223674763|NCT05353803|OTHER|Digital App and Platform for Supporting Medicines Control and Optimizationin Older Individuals With Heart Failure|Digital App and Platform for Supporting Medicines Control and Optimizationin Older Individuals With Heart Failure
223674764|NCT02699788|DEVICE|Multifunction Cardiogram|
223674765|NCT01070147|OTHER|Computerized Asthma Management System|The intervention group's clinicians will receive prompts via the computerized management system to prompt them for scoring, assessments, and disposition decisions.
223674766|NCT04711746|BIOLOGICAL|blood sample|Blood sample withdrawal in order to perform DNA sequencing
223674767|NCT04667143|DRUG|Retagliptin, Henagliflozein, metformin XR|Retagliptin-DPP4 inhibitor Henagliflozein-SGLT-2 inhibitor Metformin XR
223674768|NCT01850927|PROCEDURE|Remote ischaemic preconditioning|
223674769|NCT01850927|PROCEDURE|Control|
223674770|NCT00214604|DRUG|Rosuvastatin|10mg
224256121|NCT06917781|OTHER|Patients with 18F-PET-PSMA indication|"Blood samples taken on several occasions:~* before the 18F-PSMA PET scan for extension assessment, for all patients.~* at 2nd and 4th treatment cycles (prior to treatment administration), only for patients receiving PLUVICTO® therapy.~During the 1st treatment cycle, samples (optional for the patient) may also be taken at 5 different post-perfusion times.~In addition, all imaging examinations performed during the study (standard 18F-PSMA PET scans) will be collected and centralized by the Sponsor for analysis."
224256122|NCT07113483|DRUG|Midazolam|"Midazolam:~A commonly used benzodiazepine for sedation, administered intravenously at 0.025-0.05 mg/kg with supplemental doses as required. Known for effective anxiolysis and sedation but with a longer recovery profile compared to remimazolam."
224256123|NCT07113483|DRUG|REMIMAZOLAM BESYLATE 2.5 Mg in 1 mL INTRAVENOUS INJECTION, POWDER, LYOPHILIZED, for SOLUTION [BYFAVO]|"Remimazolam:~A novel, ultra-short-acting benzodiazepine used for procedural sedation. Administered intravenously at 5 mg over 1 minute with supplemental dosing as needed. Characterized by rapid onset and quick recovery, with minimal residual sedation."
224256124|NCT03567668|PROCEDURE|mitral valvuloplasty|Commissural plication was the most commonly used technique to repair mitral insufficiency, which was selectively supplemented by a specific combination of one or more of the following procedures: cleft closure, chordal shortening, transposition or replacement, edge-to-edge repair, leaflet augmentation, or division of papillary muscles, depending on the individual etiology and anatomy.
224256125|NCT07110688|BEHAVIORAL|Virtual human social interaction|The participants will perform a social interaction with the virtual human agent platform to assess mental states.
224256126|NCT07110688|BEHAVIORAL|Cold pressor test|Healthy participants will immerse one hand in cold water for less than 3 minutes, while physiological data will be collected by the new wearable sensor from the other hand.
224256127|NCT06907719|OTHER|Primary Services|Participants receive 40 hours of the Blueprint and 24/7 Dad curricula over the course of ten weeks.
224256128|NCT06824103|DRUG|Ruxolitinib|Ruxolitinib is taken orally daily at 10 mg BID, given as two 5 mg tablets.
224256129|NCT07119489|BEHAVIORAL|Dialectical Behavior Therapy -Skill Training brief intervention|A behavioral counseling approach for enhancing skills in emotion regulation, distress tolerance, and mindfulness
224256130|NCT07121478|DRUG|Lurbinectedin 4 MG Injection [Zepzelca]|Lurbinectedin shall be administered intravenously at a dose of 3.2 mg/m2 over 60 minutes every 21 days. The administration of the study drug shall be continued until disease progression or the occurrence of unacceptable toxicity.
224256131|NCT06916143|DRUG|LY4100511|Administered orally.
224256132|NCT06916143|DRUG|Rabeprazole|Administered orally.
224256133|NCT07125378|BEHAVIORAL|Task-oriented resistance exercise|The intervention program includes progressive resistance exercise and daily activity exercise, delivered over a six-week period with an ideal frequency of three sessions per week. Progressive resistance exercise will be provided through a combination of in-person and online sessions, while daily activity exercise will be delivered exclusively in person.
224256134|NCT07127835|DIAGNOSTIC_TEST|Nurse-led penicillin allergy delabelling service|Patients in this group undergo risk assessment and categorization by nurses to identify low-risk individuals for delabeling. For these patients, nurses will collaborate with allergists in the delabeling process.
224256135|NCT07127835|DIAGNOSTIC_TEST|Allergist-led penicillin allergy delabelling service|Patients assigned to this group will undergo risk assessment and delabeling led by allergists for both low-risk and high-risk cases.
224256136|NCT04499729|DEVICE|IntelliCare|IntelliCare provides self management and collects symptom self-report data. Symptom severity scores are displayed to the care manager, allowing them to manage the patient's care. The app also provides a secure messaging service for communication between the care manager and the patient.
224256137|NCT04499729|BEHAVIORAL|Treatment as Usual (TAU)|Treatment as usual in the Rush Collaborative Care service
224256138|NCT05402553|DRUG|Ondansetron|patients will receive, in addition to standard therapy, ondansetron IV bolus 8 mg BID for 3 days
224256139|NCT05402553|DRUG|Placebo|patients will receive, in addition to standard therapy, normal saline IV bolus BID for 3 days
224256140|NCT00032396|DRUG|Retisert Implant|
224256141|NCT05757219|DRUG|Itacitinib|Participants start itacitinib 200 mg PO once daily within 1-4 days after apheresis while awaiting CAR-T-cell manufacturing, which is expected to take approximately from week -4 until day -7. Patients will remain on itacitinib 200 mg PO once daily from initiation until 30 days post-CAR-T-cell therapy (Day 30) including throughout lymphodepleting chemotherapy period (Days -5, -4, -3) and axi-cel infusion (Day 0) for a total of approximately 58 doses.
224256142|NCT05757219|BIOLOGICAL|Chimeric antigen receptor (CAR) T-cell therapy|Yescarta is an autologous anti-CD19 CAR T cell therapy manufactured from the patient's own T cells, which have been extracted and then reprogrammed with CAR molecules to help the T cells recognize cancer cells. The reengineered T cells are infused back into the patient to attack the cancer.
224256143|NCT06942949|DEVICE|ELS (Enhanced Lithotripsy System)|ELS (Enhanced Lithotripsy System) utilizes low pressure ultrasound to actuate proprietary microbubbles administered into the urine to pit and fragment urinary stones.
224256144|NCT06940050|PROCEDURE|Coronally advanced flap with a connective tissue graft|The gum at the recession site is detached and reattached higher (combined with a connective tissue graft).
224256145|NCT06940050|PROCEDURE|Tunneled coronally advanced flap with a connective tissue graft|The gum at the recession site is undermined, only partially detached and reattached higher (combined with a connective tissue graft).
224256146|NCT06257836|OTHER|MPFL-reconstruction|Children with patella dislocations are operated from 2016-2022 with a quadriceps knee cap stabilization technique.
224256147|NCT04037969|DEVICE|Nesofilcon A|Hydrogel contact lens for daily wear
224256148|NCT04037969|DEVICE|Delefilcon A|Silicone hydrogel contact lens for daily wear
224256149|NCT01633645|DRUG|Bortezomib|Velcade
224256150|NCT01633645|DRUG|Gemcitabine|Gemcitabine 1000 mg/m2 on days 1 and 8 of a 21-days treatment cycle for a maximum of 8 cycles
224256151|NCT01633645|DRUG|Cisplatin|Cisplatin 70 mg/m2 on day 1 of a 21-days treatment cycle for a maximum of 8 cycles
223674771|NCT00214604|DRUG|rosuvastatin|20mg
223674772|NCT00214604|DRUG|pravastatin|40mg
223674773|NCT00720018|DRUG|NP101 Sumatriptan Iontophoretic Transdermal Patch|NP101 transdermal patch delivering sumatriptan for 4 hours.
223674774|NCT01739855|DRUG|Calciferol, calcium carbonate|
224256152|NCT00808171|DRUG|Livopan|Inhalation of oxygen and nitrous oxide 50%
223772613|NCT05907356|OTHER|sciatic nerve slider technique in supine position|.The patient will be in a supine position. The therapist will hold the patient's limb passively and then move the hip into flexion with the ankle in plantar flexion and the knee in extension, stretching the nerve at the hip and relaxing at the ankle, Then reversing the movement with the hip into extension, maintaining the knee in extension and the ankle in dorsiflexion, relaxing the nerve at the hip and stretching at the ankle. Provide five sets in every session; the first: 10 repetitions, the second: 15 repetitions, the third: 20 repetitions, the fourth: 25 repetitions, and the fifth: 30 repetitions. The end position is held for 5 seconds, and the rest between sets is 1-2 minutes.
223772614|NCT05907356|OTHER|Conventional physiotherapy|The patient will receive conventional physiotherapy, which includes: a moist hot pack, TENS, and back strengthening exercises (as a home program).
223772615|NCT00727857|DRUG|Pioglitazone and metformin|Pioglitazone 15 mg /metformin 850 mg combination, tablets, orally, twice daily for up to 24 weeks.
223772616|NCT00727857|DRUG|Pioglitazone|Pioglitazone 15 mg, tablets, orally, twice daily for up to 24 weeks.
223772617|NCT00727857|DRUG|Metformin|Metformin 850 mg, tablets, orally, twice daily for up to 24 weeks.
223772618|NCT05937074|OTHER|Weight loss (%)|Change in body weight from cancer diagnosis to study enrollment
223772619|NCT02405416|PROCEDURE|Infrahepatic inferior vena cava clamping|Infrahepatic inferior vena cava is clamped in hepatectomy.
223772620|NCT02405416|PROCEDURE|Selective hepatic vascular exclusion|Selected major hepatic vein is clamped in hepatectomy.
223772621|NCT02405416|PROCEDURE|Portal triad clamping|Portal triad are clamped in hepatectomy.
223674775|NCT04387643|DIETARY_SUPPLEMENT|Ayurvedic Kadha|Kadha (also called Kwath and Kashaya) is a type of ayurvedic formulation prepared by boiling herbs in water. Water and herbs are main ingredients of these preparations. The preparation of Kadha uses dry herbs, which are dried under the sun or in the shade, as directed for the individual herb. Then, the herbs are pounded to form a coarse powder
223674776|NCT03621345|PROCEDURE|Erector spinae plane block|Ultrasound guided bilateral erector spinae plane block will be administered. An intravenous patient control analgesia device with morphine will be given to patients.
223674777|NCT03621345|OTHER|sham block|A sham block will be applied. Skin will be infiltrated with local anesthetics, and 2 mL subcutaneous saline injection will be applied.An intravenous patient control analgesia device with morphine will be given to patients.
223674778|NCT04484168|PROCEDURE|Terminal Interruption of the Reflux Source|Foam Sclerotherapy of veins in the immediate vicinity of the venous ulcer
223772622|NCT03102476|DRUG|Humalog|Subcutaneous injection of Humalog and assessing Pharmacokinetics and Pharmacodynamics properties of Humalog under different environmental conditions
223772623|NCT00890461|RADIATION|CT scan of the chest without contrast|Patients consenting to participate in the study may also undergo a baseline CT scan of the cest without contrast to allow for the geometrical characterization of their intracardiac electrodes from the ICD system in relation to the position of the 12-lead surface ECG electrodes which would be applied to the chest prior to the CT scan. This scan involves a small amount of radiation, a dose of approximately 1 rem. For comparison, radiation workers are permitted, by federal regulation, a maximum annual radiation exposure of 20 rems to the most sensitive organs of their body.
223772624|NCT06349044|RADIATION|Hypofractionated radiotherapy/SBRT（5-10Gy/fx，3-5 fx）|RT: one primary or metastatic focus was selected for hypofractionated radiotherapy/SBRT (5-10 Gy/fx, 3-5 fx) in each round, the target area included only the GTV of the visible tumor lesion, and the GTV was expanded by 5-10 mm to generate the PTV, and the prophylactic lymphatic drainage area could not be irradiated.
223772625|NCT06349044|DRUG|Anti-PD-1 monoclonal antibody|Sintilimab 200mg d1 iv q3w
223772626|NCT06349044|DRUG|Oxaliplatin and Capecitabine|Oxaliplatin130mg/m2 d1 iv；Capecitabine1000mg/m2 d1-d14
223772627|NCT06349044|DRUG|Anti-VEGF 15mg/kg|Bevacizumab 15mg/kg d1 iv q3w
223772628|NCT06349044|DRUG|Anti-VEGF 7.5mg/kg|Bevacizumab 7.5mg/kg d1 iv q3w
223772629|NCT06349044|DRUG|Gemcitabine and Cisplatin|Gemcitabine1000mg/m2 d1 d8 iv；Cisplatin 25mg/m2 d1 d8 iv q3w
223772630|NCT05241886|OTHER|anthoropometric measurement, SARC- F questionnare|SARC-F, CC, MUAC
223772631|NCT02988063|DRUG|Polidocanol Endovenous Microfoam (PEM)|Polidocanol endovenous microfoam (PEM) is a sclerosing agent indicated for the treatment of incompetent great saphenous veins, accessory saphenous veins, and visible varicosities of the great saphenous vein system above and below the knee. PEM improves the symptoms of superficial venous incompetence and the appearance of visible varicosities.
223674779|NCT04484168|PROCEDURE|Axial Ablation|Endovenous ablation of venous reflux in the main superficial veins of the leg
223674780|NCT04932187|DRUG|Capecitabine, Camrelizumab|This is a single-arm study with all patients receiving these two drugs.
223674781|NCT02417948|OTHER|Written Educational Brochure|Receive brochure with skin cancer education and preventative information
223674782|NCT02417948|OTHER|Online educational video|Watch 30-minute online tutorial video about skin cancer, preventive behaviors, and skin self-examinations
223674783|NCT05261776|OTHER|pilates exercise|"Pilates exercise for 40 minutes (5 minutes for warm-up and 30 minutes of pilates and 5 minutes for cool down). These participants will continue their standard care.~Patients in Group-A will get 40 minutes of session, Alternative three days/ week for 12 weeks."
223674784|NCT05261776|OTHER|brisk walk|"Brisk walk on treadmill for 40 minutes (5 minutes for warm-up and 30 minutes of brisk walk on treadmill and 5 minutes for cool down). These participants will continue their standard care.~Patients in Group-B of 40 minutes of session, Alternative three days/ week for 12 weeks."
223674785|NCT00278915|DRUG|Fulvestrant|Participants will receive intramuscular injection of fulvestrant as stated in arm description.
223772632|NCT05116735|PROCEDURE|laparoscopic partial cystectomy with omentoplasty|laparoscopic partial cystectomy with omentoplasty
223772633|NCT06113718|PROCEDURE|Abdominal Exercise (digital rectal stimulation, abdominal massage)|"The recommended bowel exercise program consisted of three steps:~1. Patients will perform a 2-3 minute massage starting from the cecum approximately 20-30 minutes after breakfast, moving along the colon.~2. Patients will assume a suitable position and perform circular massage on the anal walls with their finger for approximately 30 seconds (digital rectal stimulation).~3. Patients will try to defecate while sitting on the toilet."
223772634|NCT04988022|DRUG|Dupilumab|300 mg prefilled syringe
223772635|NCT04988022|DRUG|Placebo|Matching placebo
224256153|NCT00808171|DRUG|Livopan|equimolar mixture of N2O/O2
224256154|NCT00808171|DRUG|EMLA|Lidocaine-prilocain cream
224256155|NCT07070089|DEVICE|BosSTENT implantation|BosSTENT implantation in the transverse venous sinus
224256156|NCT07147348|BIOLOGICAL|BNT3212|Intravenous infusion
224256157|NCT07147348|BIOLOGICAL|BNT327|Intravenous infusion
224256158|NCT07152327|DRUG|Terbinafine Hydrochloride Cream|Topical antifungal treatment. Terbinafine hydrochloride 1% cream will be applied on an ear pack, inserted into the external auditory canal, and changed every 2 days. Treatment continues for 14 days.
224256159|NCT07151248|DEVICE|Cranial electrical/electrotherapy stimulation (CES)|"Cranial electrical/electrotherapy stimulation (CES) is a non-pharmacological, portable, non-invasive intervention.~Active research units will be locked at the specified amplitude and administer that amplitude of stimulation for 60 minutes therapy."
224256160|NCT07151248|DEVICE|Sham Cranial electrical/electrotherapy stimulation (CES)|Sham research units will be locked into active sham mode which provides stimulation designed to provide the sensation of stimulation for only 5 minutes while continuing to count down for the remaining 55 minutes.
224256161|NCT07153341|BEHAVIORAL|STEP Decision Support Toolkit|The STEP toolkit includes (1) an educational booklet provided upon admission and annually, (2) condition-specific decision aids addressing common clinical scenarios, and (3) structured phone scripts for staff. STEP empowers residents and care partners to actively engage in decision-making, promotes care aligned with personal values, and supports staff in facilitating advance care planning to reduce unnecessary or complex transitions.
224256162|NCT07146568|OTHER|Pink and Pearl Campaign|This campaign leverages established infrastructure such as nurse navigation and referral to screening or primary care for further shared decision-making on cancer screening.
224256163|NCT04852978|DRUG|casirivimab+imdevimab|Wave 1 Intravenous (IV) administration Wave 2 Subcutaneous administration
224256164|NCT04852978|BIOLOGICAL|Moderna mRNA-1273 vaccine|Single intramuscular (IM) injection
224256165|NCT07202364|DRUG|YL202|YL202 will be intravenously infused over 60±10 min
224256166|NCT07202299|OTHER|HFOV weaning protocol 1|weaning preterm neonates with RDS from HFOV directly to CPAP
223674786|NCT06236191|DEVICE|transcranial pulsed current stimulation|A form of transcranial electrical stimulation that delivers unidirectional monophasic rectangular pulses of current.
223674787|NCT06236191|DRUG|Melatonin|Melatonin
223674788|NCT04183517|DRUG|PXS-5382A|Orally once daily or twice daily
223674789|NCT03478488|DRUG|KN035 plus Gemcitabine & oxaliplatin|KN035 a programmed death ligand immune check inhibitor Per Investigator decision
223674790|NCT03478488|DRUG|Gemcitabine & oxaliplatin|The standard of care for the patients with unresectable/metastatic biliary tract cancer
223674791|NCT04592952|DRUG|Calcitonin Gene-Related Peptide|Intravenous infusion of 1.5 µg/min of calcitonin-gene related peptide over 20 minutes.
223674792|NCT04592952|DRUG|Erenumab|Erenumab 70 mg or 140 mg packed in a SureClick® Autoinjector Pen (AI)
223674793|NCT00381576|BEHAVIORAL|Resistance training|Intervention group: 12 weeks of resistance training for the lower extremity. Control group: No intervention - 12 weeks of normal daily living
223674794|NCT04900740|DEVICE|Catheter fixation with surgical stitch|The catheter will be fixed using the standard procedure - surgical stitch.
223674795|NCT04900740|DEVICE|Catheter fixation with glue (cyanoacrylate tissue glue Secure PortIV)|The catheter will be fixed using the experimental procedure - novel surgical glue.
223674796|NCT02520089|PROCEDURE|bone autograft of iliac crest|The investigators will take bone autograft of iliac crest of the patient and then apply into the site of pseudoarthrosis, this graft have osteogenic, osteoinductive and osteoconductive properties
223674797|NCT02520089|PROCEDURE|Platelet Rich Plasma plus bone autograft|Sample of 40 mL of peripheric blood and processed to obtain 5 mL of platelet rich plasma, and collocated into pseudoarthrosis
223674798|NCT01337102|PROCEDURE|Physician Receives QoL results|Patient completes the Lung Cancer QoL scale on the Palm held computer device and the Physician receives the print out of the results.
223674799|NCT01337102|PROCEDURE|Physician Does not receive the results|Patient completes the Lung Cancer QoL scale on the Palm held computer device and the Physician does not receive the print out of the results.
223674800|NCT02499445|DRUG|Remifentanil|administering remifentanil for anesthesia maintenance
223674801|NCT02499445|DRUG|sevoflurane 1|administering sevoflurane 1 for anesthesia maintenance
223674802|NCT02499445|DRUG|sevoflurane 2|administering sevoflurane 2 for anesthesia maintenance
223674803|NCT02499445|DRUG|propofol|administering propofol for anesthesia maintenance
223674804|NCT02499445|DRUG|sufentanil|administering sufentanil for anesthesia maintenance
223674805|NCT04242667|BEHAVIORAL|e-Health (web-based) disclosure portal|Patient uses secure web-based portal to access genetic research results
223674806|NCT04242667|BEHAVIORAL|Provider mediated disclosure|Patient has disclosure of genetic research result by a provider (genetic counselor)
223772636|NCT01544244|PROCEDURE|GSC physical therapy|Global Shoulder Concept physical therapy sequence for shoulder tendonitis. The procedures used in this protocol refer to physical therapy sequences, not to devices or drugs.
223772637|NCT01544244|PROCEDURE|Standard physical therapy|Standard physical therapy sequence for shoulder tendonitis. The procedures used in this protocol refer to physical therapy sequences, not to devices or drugs.
224256167|NCT07202299|OTHER|HFOV weaning protocol 2|weaning of preterm neonates with RDS to CMV then to CPAP
224256168|NCT07200232|DEVICE|Phase 1 Test Device Sensor and Adhesive and Reference Device|Test Device Sensor and Adhesive and Reference Device ECG Data Collection for 1 hour
224256169|NCT07200232|DEVICE|Phase 2 Test Device ECG Signal quality over a 10-day simulated use period|Evaluation of the ECG-signal quality of the Test Device sensor and adhesive applied to a single site on a subject's chest to collect ECG readings for a 10-day period.
223674807|NCT02669485|DRUG|indocyanine green|Injection of indocyanine green and using fluorescence imaging to assess perfusion of bowel before bowel transection and anastomosis
223674808|NCT02669485|DEVICE|Fluorescence imaging|
223674809|NCT03931135|DRUG|IV Cyclizine versus IV Dexamethasone for prevention of nausea and vomiting after intrathecal morphine in patients undergoing cesarean section|"The first group (Dexamethasone) will receive 8 mg IV dexamethasone within 1-2 minutes after the umbilical cord is clamped.~The second group (Cyclizine) will receive 50 mg cyclizine within 1-2 minutes after the umbilical cord is clamped"
223674810|NCT02081248|OTHER|Consent Form Specific Format 1|The Consent Form Specific Format 1 is the 'Standard Consent'. The standard consent does not have the format of two-columns with changes in layout readability, organization of content, typography and use of plain language. Standard consents are already used by sites for the BMT CTN 0901, 1101, 1203, and 1301 clinical trials.
223674811|NCT02081248|OTHER|Consent Form Specific Format 2|The Consent Form Specific Format 2 is the 'Easy-to-Read Informed Consent'.The Easy-to-Read Informed Consent is two-columns with changes in layout readability, organization of content, typography and use of plain language.
223674812|NCT05232409|BIOLOGICAL|Zeaxanthin|The doses of zeaxanthin will be based on weight starting with 2 milligrams of zeaxanthin per kilogram of your body weight (mg/kg) followed by 4 mg/kg, 6 mg/kg, and finally 8 mg/kg. If a dose level is found to be unsafe, then a new group of patients will be treated at the midpoint dose between the not tolerated dose and the last tolerated dose. Zeaxanthin is supplied as 50 milligram capsules and a person's dose will be rounded to the nearest 50 milligrams.
223674813|NCT05232409|COMBINATION_PRODUCT|Zeaxanthin Plus Pembrolizumab|"The doses of zeaxanthin will be based on weight starting with 2 milligrams of zeaxanthin per kilogram of your body weight (mg/kg) followed by 4 mg/kg, 6 mg/kg, and finally 8 mg/kg. If a dose level is found to be unsafe, then a new group of patients will be treated at the midpoint dose between the not tolerated dose and the last tolerated dose. Zeaxanthin is supplied as 50 milligram capsules and a person's dose will be rounded to the nearest 50 milligrams.~The dose of pembrolizumab will be administered at a fixed dose of 400 milligrams intravenous every 6 weeks which is an FDA approved dosing schedule to treat cancer patients with pembrolizumab."
223674814|NCT03473548|DEVICE|Portable sleep monitor|Type III at home portable monitor obtaining greater than or equal to 6 hours of data adequate for polysomnography analysis
223674815|NCT03473548|OTHER|In-laboratory Polysomnography|Polysomnography testing will determine the sleep stages, apnea hypopnea index (AHI), blood saturation oxygen nadir (SPO2 nadir), and average blood oxygen saturation. A McGill Oximetry Score will also be calculated for the in-laboratory PSG.
223674816|NCT00726843|OTHER|8 weeks of Iyengar Yoga|Participants will attend 8 weekly, 75 min. yoga sessions, followed by 8 weeks of follow-up (will provide headache frequency/intensity)
223674817|NCT00726843|OTHER|8 weeks of Iyengar Yoga|Participants will provide headache frequency/intensity for 8 weeks, followed by 8 weekly, 75 min. yoga sessions
223674818|NCT03160313|BEHAVIORAL|InFuSE|Each session includes a 45-minute education and group discussion. A 60-minute exercise component then completes the session. Each topic was specifically picked and tailored to benefit Veterans with TBI. The education sessions will be led and moderated by different professionals including physical therapists, recreation therapists, and physicians. Participants will be asked to participate in several learning activities. The activities are included to help improve understanding and promote group discussion. The exercise piece consists of a warm-up, endurance training (20-30 minutes), strengthening (15 minutes), balance/cognitive training (15 minutes), and a cool-down.
223674819|NCT03160313|BEHAVIORAL|Patient Education/Group Discussion|Each week you will participate in a 1 hour health education class with other Veterans. Each topic was specifically picked and tailored for Veterans with TBI. These education sessions will be led and moderated by different professionals including physical therapists, recreation therapists, and physicians. Participants will be asked to participate in several learning activities which are included to help improve understanding and promote group discussion.
223674820|NCT02846220|BEHAVIORAL|Overcoming Immunity to Change health coaching|
223674821|NCT05616481|PROCEDURE|Laparoscopic Burch colposuspension|The original Burch procedure will be performed
223674822|NCT05616481|PROCEDURE|Modefied Burch (TOT - like)|more lateral fixation to avoid post-operative voiding dysfunction
223674823|NCT00553722|DRUG|Eplerenone|Administer Eplerenone, 25 mg,orally twice daily for 4 weeks.
224256170|NCT07200232|DEVICE|Test Device Sensor and Adhesive Variable Placement|Comparison of nine incorrect locations of Test Device Sensor and Adhesive to the ideal location
223674824|NCT00553722|DRUG|Placebo|Administer a placebo tablet orally twice daily for 4 weeks.
223674825|NCT03460509|DRUG|Sugammadex|Dose-response
223674826|NCT02133300|OTHER|electrical stimulation|
223674827|NCT03753581|DEVICE|Care protocol plus microcurrents|"CARE NURSING PROTOCOL: postural treatment every 4 hours more standardized cure according to the guide of recommendations based on evidence in prevention and treatment of pressure ulcers in adults of Osakidetza health service.~MICROCURRENTS: the electrodes will be placed on the edge of the dressing on the sides of the ulcer's longer length during 12 hours a day until the ulcer is completely healed or for a maximum of 25 days.~Characteristics of microcurrents: pulsed monophasic rectangular wave with a pulse of 1.5 s and pause of 300 ms, voltage 21 mV and intensity 42μA with a current density of 4.2 μA."
223674828|NCT03753581|DEVICE|Care protocol plus placebo microcurrents|The same nursing care protocol described for the experimental group will be applied more 12 hours per day of 2 electrodes of microcurrents around the ulcer, which will be previously manipulated and tested with an oscilloscope so that they do not emit electrical currents
223674829|NCT00075192|DRUG|CP-675,206 and leuprolide acetate and bicalutamide|
223674830|NCT00075192|DRUG|leuprolide acetate and bicalutamide|
223674831|NCT01496937|DRUG|GLPG0974|
223674832|NCT01496937|DRUG|GLPG0974|
224256171|NCT07201064|DRUG|SZ1003 injection|once every two weeks at a dose of SZ1003 injection per infusion.
224256172|NCT07202520|DEVICE|IVR : H'Ability Home|H'Ability Home is a Dtx (Digital therapeutics) designed for the neurological rehabilitation of patients who have suffered a stroke, via a wireless virtual reality headset, with a simplified control interface on a tablet or PC
224256173|NCT07202520|DEVICE|Control: paper-based exercise guide|self-rehabilitation booklet used in current practice in centers
224256174|NCT07202143|DRUG|Methylprednisolone sodium succinate|Methylprednisolone sodium succinate Intravenous injection of methylprednisolone sodium succinate (Chongqing Lummy Pharmaceutical Co., Ltd., 40mg/ vial) with a dose of 2mg/kg (maximum dose of 160mg), once daily, for three consecutive days. The initial study drug will be administered as soon as possible after randomization. It is recommended that the initial study drug administrated before arterial access closure, but it should not be delayed more than 2 hours after arterial access closure.
224322384|NCT00839254|BIOLOGICAL|GSK Biologicals' Engerix TM vaccine (Hepatitis B vaccine)|3 or 4 Intramuscular injections, depending on the age at the time of first vaccination only for children \< 12 months of age at the time of first study vaccination.
224256175|NCT07202143|DRUG|Normal Saline|Intravenous injection of placebo (normal saline) (Chongqing Lummy Pharmaceutical Co., Ltd., 40mg/ bottle) with a dose of 2mg/kg (maximum dose of 160mg), once daily, for three consecutive days. The initial study drug will be administered as soon as possible after randomization. It is recommended that the initial study drug administrated before arterial access closure, but it should not be delayed more than 2 hours after arterial access closure.
224256176|NCT05416372|BEHAVIORAL|Religious Engagement in Health Intervention|Religious Engagement in Health Intervention for blood pressure (BP) includes three evidence-based components: (1) educational sessions for Christian and Muslim leaders on religious teachings and medical aspects of BP, (2) equipping religious leaders to provide BP teaching in their communities using knowledge learned from educational sessions and through longitudinal mentorship meetings, and (3) community BP screening organized by religious leaders in partnership with local health care workers, and referrals for clinical care as needed.
224256177|NCT07201155|DEVICE|Continuous Glucose Monitoring Systems|"A trained research member placed the AiDEX® Dynamic Continuous Glucose Monitoring System (Microtech Medical Devices (Hangzhou) Co., Ltd.) on the patient's abdomen, about 3-10 cm to the left or right of the navel, or on the back of the upper arm, according to the instructions. The sensor began to collect data 1-4 hours after successful activation, recording blood glucose values every 5 minutes for 7 consecutive days. For patients who stayed in the ICU for less than 7 days, the continuous glucose monitoring (CGM) was terminated on the day of ICU discharge, and the CGM device was removed.~Patients monitored their blood glucose using fingerstick point-of-care (POC) measurements every 1-6 hours as needed and had routine arterial blood gas analysis 4-6 times a day. After 24 hours of patient wear, the arterial blood gas glucose (aBG) was used to calibrate the CGMS device at least twice a day. Nurses recorded CGMS data paired with POC values and aBG values in a 1:1 format."
224256178|NCT07201155|DEVICE|Continuous Glucose Monitoring|This study is a single-center, prospective, observational study conducted in the Intensive Care Unit (ICU) of Nanfang Hospital, Southern Medical University, from May 2024 to August 2024. Patients with elevated blood glucose levels (BG\>180 mg/dL) undergoing intravenous insulin therapy were included. Simultaneous blood glucose monitoring was performed using fingerstick blood samples and arterial blood gas analysis, along with the installation of CGMS for concurrent monitoring. CGMS data (CGM values) were recorded in a 1:1 paired format with fingerstick point-of-care (POC) values and arterial blood gas (aBG) values. The correlation of paired blood glucose data was examined using Pearson's correlation coefficient. The accuracy of CGMS was assessed using metrics such as Mean Absolute Relative Difference (MARD), ISO 15197-2013, CLSI POCT12-A3, and Clarke Error Grid Analysis, analyzed with R v.4.4.1 software.
224256179|NCT07201155|DEVICE|Continuous Glucose Monitoring|Patients who met the inclusion and exclusion criteria were enrolled in the study after obtaining informed consent from the patient or their legal representative. A trained research member placed the AiDEX® Dynamic Continuous Glucose Monitoring System (Microtech Medical Devices (Hangzhou) Co., Ltd.) on the patient's abdomen, about 3-10 cm to the left or right of the navel, or on the back of the upper arm, according to the instructions. The sensor began to collect data 1-4 hours after successful activation, recording blood glucose values every 5 minutes for 7 consecutive days. For patients who stayed in the ICU for less than 7 days, the continuous glucose monitoring (CGM) was terminated on the day of ICU discharge, and the CGM device was removed.
224256180|NCT07201155|DEVICE|CGMS|Patients who met the inclusion and exclusion criteria were enrolled in the study after obtaining informed consent from the patient or their legal representative. A trained research member placed the AiDEX® Dynamic Continuous Glucose Monitoring System (Microtech Medical Devices (Hangzhou) Co., Ltd.) on the patient's abdomen, about 3-10 cm to the left or right of the navel, or on the back of the upper arm, according to the instructions. The sensor began to collect data 1-4 hours after successful activation, recording blood glucose values every 5 minutes for 7 consecutive days. For patients who stayed in the ICU for less than 7 days, the continuous glucose monitoring (CGM) was terminated on the day of ICU discharge, and the CGM device was removed.
224256181|NCT07200297|OTHER|Active Comparator: Control|Patients who were given only a standard chlorhexidine oral care set
224256182|NCT07200297|OTHER|Experimental: Electric Toothbrush|Patients who were given an electric toothbrush and toothpaste along with a chlorhexidine set
224256183|NCT07200297|OTHER|Experimental: Manual Toothbrush|Patients who were given a manual toothbrush and toothpaste along with a chlorhexidine set.
224256184|NCT07202013|OTHER|Kinesio taping|Kinesio taping was applied in a fan-shaped pattern once weekly for four consecutive weeks. Elastic therapeutic tape was applied with 0-15% tension to the buttocks and thighs at standardized anatomical points, including the gluteus maximus (above the sacroiliac joint), posterior thigh (gluteal fold), and anterior thigh (above the anterior inferior iliac crest). This protocol was designed to promote lymphatic drainage, improve microcirculation, and enhance dermal density and structure in women with stage II cellulite.
223674833|NCT04363190|DIAGNOSTIC_TEST|Cytogenetic analysis|"1. FISH study using the UroVysion kit in interphase peripheral lymphocytes, that allows the study of numerical aberrations for chromosomes 3, 7 and 17 and locus 9p21.~2. G banding study to analyse the whole karyotype study regarding both numerical and structural aberrations during metaphase.~3. Sister chromatid exchanges (SCE) analysis with bromodeoxyuridine (BrdU) staining for the whole karyotype during metaphase: analizing the proportion of SCE per metaphase (NSM)."
224322385|NCT00839254|BIOLOGICAL|GSK Biologicals' Havrix TM vaccine (Hepatitis A vaccine)|2 Intramuscular injections only for children \>= 12 months of age at the time of first study vaccination.
224322386|NCT05855122|DRUG|Tocilizumab|Pateients enrolled in Tocilizumab group will receive tocilizumab(8mg/kg) at day -7 before transfusion of stem cells.
223674834|NCT04939506|BEHAVIORAL|COVID-19 Vaccine Education at the Point of COVID-19 Testing|A rapid vaccination education model to be delivered at the point of COVID-19 testing by pharmacy students, pharmacy technicians, nurse's aides and other health care personnel. The intervention will include: 1) 15 minute vaccine counseling, 2) print material 3) referral to a dedicated vaccine website with feedback forums and 4) opportunity to sign-up for one-on-one vaccine counseling with a clinical pharmacist
223674835|NCT01484288|DEVICE|Barostim Neo System|Baroreflex Activation Therapy using the Barostim Neo System
223674836|NCT00129311|DRUG|Selegiline|5 mg capsules taken by mouth. Participants take 5 mg once a day for the first week of the study, then increase the dose to 5 mg twice a day for 6 weeks, then take 5 mg once a day during the last week of the study. Participants receiving the placebo pill take 1 pill per day for the first week of the study and 1 pill twice a day for the other weeks.
223674837|NCT00129311|DRUG|Placebo|
224256185|NCT07202117|DEVICE|Sculptra Aesthetic|"Sculptra® Aesthetic is manufactured by Galderma Laboratories. It is a sterile, lyophilized preparation of PLLA that is biocompatible and biodegradable. Each vial contains 367.5 mg of freeze-dried powder, including 150 mg of PLLA. Prior to injection, it will be reconstituted with sterile water for injection (SWFI) and lidocaine hydrochloride (2%).~For this study, commercial products will be used. The study products are for single use only."
224256186|NCT07202117|DEVICE|Radiesse|"Radiesse® is manufactured by Merz Aesthetics. It is a sterile, non-pyrogenic, semi-solid injectable implant composed of synthetic CaHA suspended in a gel carrier of sterile water, glycerin, and sodium carboxymethylcellulose. Each pre-filled syringe contains 1.5 mL of product. The product includes 0.3% lidocaine for pain reduction during injection.~For this study, commercial products will be used. The study products are for single use only."
224256187|NCT07201532|OTHER|eDelphi method|A Delphi consensus study will be undertaken to establish a core outcome set for disease modification in type 2 diabetes.
224256188|NCT07201688|DRUG|rhTNK-tPA|Each vial should be dissolved in 3mL of sterile water for injection to prepare a drug solution with a concentration of 5.33mg/mL. Calculate the total drug amount based on the participant's actual body weight, measure the required volume of the drug solution, and ensure the maximum dose does not exceed 25mg. Administer as a single bolus intravenous injection, completing the injection within 5-10 seconds.
224256189|NCT07201688|DRUG|Placebo|One vial is dissolved in 3mL of sterile water for injection. Calculate the total drug amount based on the participant's actual body weight, then measure the required volume of the drug solution. Administer as a single bolus intravenous injection, completing the injection within 5-10 seconds.
224256190|NCT07202312|DEVICE|Ozone-therapy after non-surgical therapy|The test group received ozone therapy immediately after non-surgical treatment, at a fixed concentration of 2100 ppm and 80% oxygen, applied three times at the site. Ozone was delivered into the periodontal pocket using a sterile syringe with a flat tip. Ozone was generated with the Ozone DTA Ozone Generator (Denta Tec Dental AS, Norway), which was operated for 20 seconds in accordance with the manufacturer's instructions.
224256191|NCT07200635|OTHER|HA injection|Using vacuum negative pressure technology, hyaluronic acid and other moisturizing nutrients are directly injected into the deep skin, effectively improving dermal dehydration and dryness from the muscle base, so that the skin can quickly replenish water.
223674838|NCT05673174|DIAGNOSTIC_TEST|Non-Invasive Estimation of Left Ventricular Diastolic Pressure|Modified blood pressure cuff used to detect arterial waveforms used for the estimation of LVDP
224256192|NCT07200635|OTHER|Facial serum application|Dosage on face: About 0.5g/face for serum.
224256193|NCT07200466|DIAGNOSTIC_TEST|ENDORISK personalized risk assesment for lymph node metastases in endometrial cancer.|The intervention group are patients receiving a personalized risk on lymph node metastases as predicted by the ENDORISK model, they also receive a treatment plan (hysterectomy + bilateral salpingo-oophorectomy with or without lymph node surgery) based on this personalized risk.
224256194|NCT07201220|BEHAVIORAL|meditation|The study is planned to include 60 pregnant women (30 in the experimental group and 30 in the control group) in the first stage of labor. After informing the participants about the study and obtaining informed consent, pre-test scales will be administered. Relaxation meditation will be applied during labor for the experimental group, followed by post-test scales.
224256195|NCT07200726|OTHER|Observational study design - no intervention|Observational study design - no intervention
224256196|NCT07200505|OTHER|TR Mixed CORE Exercices|The intervention will last 12 weeks, with five weekly sessions. Prior to starting, all participants will attend three educational sessions and an initial in-person session, during which the physiotherapist will explain and personalise the exercises, ensure proper use of the platform, and provide necessary materials. Participants will then perform the exercises autonomously. he intervention group will receive support through the platform and weekly synchronous supervision, while the control group will only receive basic materials and follow-up phone calls. If needed, family members will be trained to provide occasional assistance with exercise performance.
224256197|NCT07200505|OTHER|TR Asyncronous CORE Exercices|"The intervention will last 12 weeks, with five weekly sessions. Prior to starting, all participants will attend three educational sessions and an initial in-person session, during which the physiotherapist will explain and personalize the exercises, ensure proper use of the platform, and provide necessary materials. Participants will then perform the exercises autonomously.~The intervention group will receive support through the platform and weekly synchronous supervision, while the control group will only receive basic materials and follow-up phone calls. If needed, family members will be trained to provide occasional assistance with exercise performance."
224256198|NCT07200700|DIAGNOSTIC_TEST|Knee laxity arthrometer|Inter-reliability analysis of the GNRB arthrometer between two examinors compared to standard KT 1000 arthrometer
224322387|NCT02028494|DRUG|Capecitabine|Two dosages comparison
224322388|NCT04835623|DRUG|Cyclosporine 0.09% Ophthalmic Solution|one drop each eye twice daily
224322389|NCT00177359|BEHAVIORAL|gait intervention|
224322390|NCT02174289|DEVICE|Targeted left ventricular endocardial lead placement|The left ventricular endocardial lead will be passed through the intra-atrial septum
224322391|NCT05391386|PROCEDURE|modified bonding technique|adding a layer of compomer adhesive at the molar/tube interface.
223674839|NCT02232880|DRUG|Abatacept|All subjects will be treated with chlorthalidone 25 mg/day, lisinopril 20 mg/day \[Patients with a history of adverse reaction to lisinopril will be treated with losartan 50 mg/day\], amlodipine 5 mg/day and spironolactone 25 mg bid as standardized treatment of hypertension prior to randomization and throughout the active treatment phase.
223674840|NCT02232880|DRUG|Placebo|All subjects will be treated with chlorthalidone 25 mg/day, lisinopril 20 mg/day \[Patients with a history of adverse reaction to lisinopril will be treated with losartan 50 mg/day\], amlodipine 5 mg/day and spironolactone 25 mg bid as standardized treatment of hypertension prior to randomization and throughout the active treatment phase.
223674841|NCT03610529|DEVICE|CardioSenseSystem|CardioSensySystem is a novel wireless ECG monitoring system developed by Novosense AB for monitoring of ECG in health care departments.
223674842|NCT03610529|DEVICE|Philips Intellivue|Philips Intellivue in an established ECG monitoring system used at the clinical investigational device.
223674843|NCT02337231|DIETARY_SUPPLEMENT|soybean oil and borage oil|Compare the capacity of humans with GG, GT and TT genotypes at rs174537 taking soybean and borage oils to metabolize medium chain PUFAs.
224256199|NCT07201454|BEHAVIORAL|nursing care|The first stage is the collection of quantitative data. Only quantitative data were collected from patients and caregivers in the experimental and control groups before the implementation of curative care practices based on human caring theory. The second stage includes curative care practices within the scope of the study for the experimental group. Patients and their relatives in the control group will receive routine care services provided at the clinics where the study was conducted, but no interventions will be implemented by the researchers. The third stage is the stage where patient satisfaction, caregiver burden, feelings of entrapment, and satisfaction with caregiving are assessed after the curative care practices. This stage is the final test of quantitative data and the collection of qualitative data. The fourth stage is the evaluation stage. In the final stage, data obtained from all stages will be compared, evaluated, and interpreted.
224256200|NCT07201584|DRUG|Torasemide tablet 10 mg|Tablets by Berlin-Chemie AG (Germany)
224256201|NCT07201584|DRUG|Unat® 10 tablets (Torasemide 10 mg)|Tablets by Viatris Healthcare GmbH (Germany)
224256202|NCT07201194|OTHER|Holistic acupuncture and acupressure|"The intervention consists of one holistic and individualized consultation with an oncologist trained in acupuncture, in connection with outpatient chemotherapy. The consultation follows the principles of Traditional Chinese Medicine (TCM). The theoretical framework applied is Zang-Fu, which describes organ imbalances and aligns closely with Western medical understanding.~Based on individual assessment and anamnesis, the patient receives acupuncture combined with acupressure.~A maximum of 10 needles will be used, regardless of whether a deficiency or excess condition is identified. The acupuncture needles used are CAIR Super Silicon CSC-1, size 0.20 × 25 mm. The needles are inserted perpendicularly, except for Yin Tang, which is inserted transversely. The needles will remain in place for 25 minutes."
224256203|NCT07201194|OTHER|Standard medical treatment|Standard treatment and care includes chemotherapy, supportive antiemetic medication, close monitoring, and management of the patient's symptoms, side effects, and overall health.
224256204|NCT07200622|DRUG|Semaglutide (Rybelsus®)|All subjects will receive oral semaglutide once daily (4-weekly dose escalation from 3 mg to 7 mg and finally 14 mg). This dose escalation schedule is specified in the IMP (Rybelsus) SmPC.
224256205|NCT07200622|DRUG|Placebo|Matched oral Placebo to be taken once daily.
224256206|NCT07202507|OTHER|self-report questionnaires, research interviews|self-report questionnaires and research interviews
224256207|NCT07201376|DRUG|Ameluz 10% Topical Gel|One-time topical application of 10% Ameluz gel for up to 1 hour
223674844|NCT01666847|PROCEDURE|Milking the umbilical cord before cord clamping|The procedure will involve positioning the neonate below the level of the placenta and milking approximately 20cm of umbilical cord three times over 10-20 seconds total from the placental end to the neonate. The cord will then be clamped and the neonate handed to the awaiting medical team for routine care of a premature infant.
224256208|NCT07201376|DEVICE|Protoporphyrin IX|Tissue oxygen imaging using protoporphyrin IX (PIX), a non-significant risk device.
224256209|NCT07201818|DEVICE|Lymphatic Enhancement Technology (LET)|Lymphatic Enhancement Technology (LET) is an FDA-approved electrotherapeutic modality, with indications for addressing local lymphatic and vascular circulation as well as muscle pain and spasm. The Aria LET Elite Instrument (Arcturus Star, Cortez, Colorado) will be utilized for the intervention group.
224256210|NCT07201818|DEVICE|Sham Lymphatic Enhancement Technology (LET)|A separate modified Aria Elite LET Instrument (Arcturus Star, Cortez, Colorado) will be utilized for the sham group. The sham LET device used for the control group will emit a light and sound similar to the true LET device, but will not emit energy waves.
224256211|NCT07202494|OTHER|Imaging Techniques (MRI 3T & 7T, Functional, Structural, and Metabolic Imaging)|Functional MRI (fMRI) Diffusion Tensor Imaging (DTI) Sodium Imaging (23Na-MRI) Phosphorus Imaging (31P-MRI)
224256212|NCT07201337|RADIATION|Radiation Therapy|PTVnx：70Gy/33Fr；PTVnd：70Gy/33Fr；PTV1：60Gy/33Fr；PTV2：42Gy/26Fr.
223674845|NCT06449274|DEVICE|Drug-coated balloon|Non-culprit lesion will be pretreated before DCB treatment. The bail-out stent treatment is permitted if pretreatment failed. Individual will receive guideline-directed medical treatment.
223674846|NCT06449274|DRUG|Guideline-directed medical treatment|All individuals will receive guideline-directed medical treatment.
223674847|NCT04564638|DRUG|Corticosteroid|
223674848|NCT04070976|RADIATION|Hypofractionated therapy|All patients will be treated with an external beam of 37.5 Gray in 15 fractions (2.5 Gray / fraction). They will be treated once a day, 5 days a week. If photon energy 6 MV or 10 MV is used, the patient should be treated with a 4-field technique using the anterior/posterior field and 2 lateral fields. The specification of the dose is in terms of a dose to a point at or near the center of the target volume. For all field dispositions, the dose specification point is the common isocenter of all beams.
223772638|NCT05315388|OTHER|Immersion therapy in nature - Vitamin N|"Usual therapy group The first saliva sample will be taken upon awakening to determine cortisol concentration. At their workplace, they will be asked to remain seated and silent for 3 minutes, the following will be taken: blood pressure, heart rate, psychological instruments (stress-anxiety), blood sample.~Group 2A and Group 2B In the natural environment, a saliva sample will be taken upon awakening to determine cortisol concentration. After arrival at the site, they will be asked to remain seated and silent for 3 minutes, the following will be taken: blood pressure, heart rate, psychological instruments (stress-anxiety), blood sample.~The first phase is a session of observation of the site for 15 minutes. A slow, unhurried walk will be performed for 1 hour and 45 minutes. The order of activities (sitting and walking) will be established to ensure reliability of physiological measurements."
223772639|NCT01752933|DRUG|SGI-110|SGI-110 will be administered by subcutaneously (SC) on Days 1 - 5 every 28 days until disease progression or unacceptable toxicity
223772640|NCT01918475|DRUG|Carbetocin|Carbetocin 0.1 mg single dose is intravenously administered
223772641|NCT01918475|DRUG|Placebo|1ml of NaCl 0.9% is administered intravenously
223772642|NCT02360618|DRUG|Metformin|See Group Description
223772643|NCT02360618|DRUG|Simvastatin|See Group Description
223772644|NCT01665365|PROCEDURE|Remote ischemic perconditioning|Intermittent arm ischemia through four cycles of 5-min inflation and 5-min deflation of a blood-pressure cuff started in the ambulance before admission to primary percutaneous coronary intervention.
224256213|NCT07201337|RADIATION|Radiation Therapy|PTVnx：70Gy/33Fr；PTVnd：70Gy/33Fr；PTV1：60Gy/33Fr；PTV2：54Gy/33Fr.
224256214|NCT07200284|PROCEDURE|Airpolishing device|The authors will assess biochemical and clinical variables
224256215|NCT07200284|PROCEDURE|Manual SRP|Gold standard
224256216|NCT07201909|DIETARY_SUPPLEMENT|Prebiotic fibre blend|A blend of prebiotic fibres in a powdered supplement form.
224256217|NCT07201909|DIETARY_SUPPLEMENT|Maltodextrin powder|Maltodextrin powder
224256218|NCT07200583|PROCEDURE|Protein A immunoadsorption|Extracorporeal therapy performed prior to haploidentical HSCT to remove donor-specific anti-HLA antibodies (DSA)
224256219|NCT07200583|DRUG|Rituximab (optional, in some patients)|Anti-CD20 monoclonal antibody occasionally combined with immunoadsorption as part of desensitization strategy
224256220|NCT07200583|DRUG|Bortezomib (optional, in some patients)|Proteasome inhibitor occasionally used in combination with desensitization therapy.
224256221|NCT07200349|DRUG|Calcitriol Delivery|Local delivery of Calcitriol (active form of vitamin D3) to one side of the maxillary canine area during orthodontic treatment. The aim is to assess its effect on dental and skeletal changes during canine retraction in a split-mouth design.
224256222|NCT07202156|DEVICE|10%TXA+2%Reduced Glutathione applied via ultrasound at 5W/cm² in10min|5w/cm² Ultrasound-assisted topical application of 10% tranexamic acid and 2% reduced glutathione for 10 mins
224256223|NCT07202156|OTHER|10%TXA+2%Reduced Glutathione applied via ultrasound at 0W/cm² 10min|topical application of 10% tranexamic acid and 2% reduced glutathione for 10 mins
224256224|NCT07201077|DEVICE|Articulating lymph-node grasper (SurgeoFlex Grasp)|Arm 1 - SurgeoFlex Grasp A single-use, low-profile articulating grasper with a 5-millimetre (mm) shaft and a 360-degree (360°) steerable distal tip. During uniportal video-assisted thoracoscopic surgery (UVATS), the device is introduced through the same 3-4-centimetre (cm) utility incision used for the camera and stapler. The flexible neck allows the jaws to approach hilar and mediastinal lymph nodes from multiple angles without repositioning the instrument shaft, thereby reducing instrument collision and chest-wall torque.
224256225|NCT07201077|DEVICE|Arm 2 Intervention Name Traditional rigid endograsper|Arm 2 - Traditional Rigid EndoGrasper A reusable, straight-shafted 5 mm grasper with fixed-angle jaws identical to those used in conventional multi-port video-assisted thoracoscopic surgery (VATS). The instrument is passed through the single 3-4 cm incision in the same fashion as the SurgeoFlex Grasp, but its rigid shaft limits the working angle and often requires external repositioning of the entire instrument to reach deep lymph-node stations.
224256226|NCT07201246|OTHER|Necrotizing Pancreatitis patients' organdysfunction progression|Study the dynamic nature of organ dysfunction
224256227|NCT07201324|OTHER|cranial helmet therapy - observational|"This observational study involves children undergoing cranial helmet therapy. The intervention is not assigned by the investigator. Repeated measurements are performed within participants to evaluate therapy effects. Stage 1 assesses head shape changes to analyze therapy effectiveness. Stage 2 examines factors influencing effectiveness, considering age, deformity type, and sex.~Stage 3 measures body surface temperature using thermal imaging before, during, and after helmet use, with participants analyzed in three age groups: 4-6, 7-9, and 10-12 months. Stage 4 evaluates cervical spine rotation before therapy and after completion, with participants analyzed in the same three age groups."
224256228|NCT07201207|DEVICE|Robotic-assisted total knee arthroplasty|In robotic-assisted total knee arthroplasty, the procedure is performed with the guidance of the robot according to CT-based plan.
224256229|NCT07201207|PROCEDURE|Manual total knee arthroplasty|In manual total knee arthroplasty, the procedure is performed with jig guides according to whole leg weight bearing x-ray planning.
224256230|NCT07202104|DEVICE|Eko digital stethoscopes|Use of the Eko CORE 500 digital stethoscope and 3M Littmann CORE Digital Stethoscope to auscultate and record cardiac phonocardiogram and (when available) electrocardiogram waveforms, as well as heart sounds.
223674849|NCT04070976|RADIATION|Standard therapy|All patients will be treated with external beam radiotherapy with 50 Gray in 25 fractions (1.8-2 Gray / fraction). They will be treated once a day, 5 days a week. If photon energy 6 MV or 10 MV is used, the patient should be treated with a 4-field technique using anterior/posterior fields and 2 lateral fields. The specification of the dose is in terms of a dose to a point at or near the center of the target volume. For all field dispositions, the dose specification point is the common isocenter of all beams.
223674850|NCT06133712|DRUG|Dexmedetomidine|Patients will receive injection of 1 microgram/kg dexmedetomidine average (70-100-microgram) (0.7-1ml) plus 4ml lidocaine injection nearby median nerve.
223674851|NCT06133712|DRUG|Ozone|Participants will receive a single local injection of 4 ml ozone (10 micrograms/ml) plus to 1 ml lidocaine (1%) using a 25 G needle.
223674852|NCT06133712|DRUG|Dexamethasone|Patients will receive a single local injection of 5 mL (3 mL lidocaine (1%) and 2 mL \[8 mg\] dexamethasone) via the same technique.
223674853|NCT02405338|BIOLOGICAL|WT1/PRAME vaccination|
223674854|NCT04377347|OTHER|Time|Exposure is the time from patients call the Emergency Medical Coordination Center to they are admitted to a neurosurgiocal department.
223674855|NCT00158132|DRUG|Propranolol|Propranolol 100mg/day in 3 divided doses
223674856|NCT00158132|DRUG|Amantadine|Amantadine 100mg three times daily
223674857|NCT00158132|DRUG|Placebo|Placebo pills
223674858|NCT02212600|OTHER|Observational|observational cohort of proximal humerus fractures
223674859|NCT04203277|OTHER|IVY|a combination of practice education and quality improvement interventions
224256231|NCT07200791|BEHAVIORAL|Mobile Application|Participants in this group will receive routine nursing care and the standard hospital educational booklet. In addition, they will use a mobile application developed to support chemotherapy-related symptom management. The app includes modules for symptom tracking, short educational videos (approx. 2 minutes each), and written/visual brochures. Before use, participants will be trained on installation and navigation. They can also contact a nurse or researcher via the app for questions.
224256232|NCT07200791|BEHAVIORAL|Usual Care Only|Participants in this group will receive routine nursing care and the standard hospital educational booklet. No additional intervention will be provided.
224256233|NCT07201987|DRUG|Vancomycin (local, via calcium sulfate beads)|Patients undergoing spine surgery will receive intraoperative placement of calcium sulfate beads impregnated with vancomycin. The beads are intended to provide local infection prophylaxis.
224322392|NCT02037386|DEVICE|H-side branch stent|Implantation of H-side branch stent at coronary bifurcation stenotic lesion
223674860|NCT02191215|DRUG|Nevirapine (Viramune®)|
223674861|NCT01467687|DRUG|verapamil controlled release|verapamil 300 mg controlled release capsule as a single dose
224256234|NCT07201987|DRUG|Morphine (local, via calcium sulfate beads)|Patients undergoing spine surgery in the experimental arm will receive intraoperative placement of calcium sulfate beads impregnated with morphine. The beads are intended to provide sustained local analgesia.
223674862|NCT01723644|OTHER|the clinical reassessment arm|In the clinical reassessment arm, antibiotherapy is systematically started in the emergency department. The continuation, the discontinuation or the modification of the antibiotherapy initially prescribed in the ED were made at Day 1 and Day 5 based on clinical assessment. On Day 1, the aim of the clinical reassessment is diagnosis reassessment: to confirm or not the diagnosis of community-acquired pneumonia and to confirm or not the antibiotherapy. On Day 5, the aim of the clinical reassessment is to evaluate the possibility to stop the current antibiotherapy based on criteria for clinical stability defined by the Infectious Diseases Society of America
223674863|NCT01723644|OTHER|the procalcitonin arm|In the procalcitonin arm, initiation and discontinuation of the antibiotherapy is based on the antibiotic stewardship based on procalcitonin (PCT) cut-off ranges previously published. Re-evaluation of the clinical status and measurement of serum PCT levels is mandatory after 6-24 h in all persistently sick and hospitalized patients in who antibiotic are withheld. The PCT algorithm can be overruled by pre-specified criteria, e.g. in patients with immediately life-threatening disease. If the algorithm is overruled and antibiotics are given, an early discontinuation of antibiotic therapy after 3, 5 or 7 days is more or less endorsed based on PCT levels. In hospitalized patients with ongoing antibiotic therapy PCT levels are reassessed on days 3, 5 and 7 and antibiotics will be discontinued using the PCT cut-offs defined above.
223674864|NCT03310307|DRUG|Vit D|50,000 IU
223674865|NCT03310307|OTHER|Placebo|
223674866|NCT04592484|BIOLOGICAL|CDK-002|CDK-002 administered intratumorally
223674867|NCT01331421|DRUG|exemestane|25 mg tablet
223674868|NCT02545543|BIOLOGICAL|Seqirus QIV|"Seqirus QIV, inactivated, split-virion, thimerosal-free, quadrivalent influenza vaccine, administered as a 0.5 mL intramuscular dose. The vaccine is presented in a prefilled needleless syringe.~The subject's age and influenza vaccination history determines the dosing regimen (a single vaccination or a 2-vaccination regimen administered 28 days apart) according to the most recent US ACIP guidelines for seasonal influenza vaccination."
223674869|NCT02545543|BIOLOGICAL|Comparator QIV|"The US-licensed Comparator QIV, inactivated, split-virion, thimerosal-free, quadrivalent influenza vaccine, administered as a 0.5 mL intramuscular dose. The vaccine is presented in a prefilled needleless syringe.~The subject's age and influenza vaccination history determines the dosing regimen (a single vaccination or a 2-vaccination regimen administered 28 days apart) according to the most recent US ACIP guidelines for seasonal influenza vaccination."
223674870|NCT02104388|DRUG|SJP-0035 Ophthalmic Solution|
223674871|NCT02104388|DRUG|Vehicle of SJP-0035 Ophthalmic Solution|
224256235|NCT07201987|DRUG|Bupivacaine (local, via calcium sulfate beads)|Patients undergoing spine surgery in the experimental arm will receive intraoperative placement of calcium sulfate beads impregnated with bupivacaine. The beads are intended to provide sustained local analgesia.
224256236|NCT07201259|OTHER|No Intervention: Observational Cohort|No Intervention: Observational Cohort
224256237|NCT07201857|DIETARY_SUPPLEMENT|nutrition education plus active supplement|Nutrition Group (NUT) Participants will receive standard clinical care combined with nutrition education and protein-enriched soy milk supplementation for approximately 2 weeks before surgery and about 3 weeks after hospital discharge.
224256238|NCT07201857|BEHAVIORAL|Exercise|"Exercise and Nutrition~Participants will receive peri-habilitation exercise training together with nutritional intervention, including carbohydrate plus protein-enriched soy milk supplementation twice daily (before and after exercise), for approximately 2 weeks before surgery and about 3 weeks after hospital discharge."
224256239|NCT07202403|DIETARY_SUPPLEMENT|Spermidine|Spermidine is a polyamine that forms naturally in plants, animals, and microorganisms as a byproduct of protein breakdown. While it's found in various foods, the highest concentrations are in wheat germ, soy, and fermented foods like cheese and miso (Madeo et al. 2018). Spermidine is known for its role in promoting autophagy, a cellular process that helps to clear damaged cells and improve overall cellular function (Eisenberg et al. 2009; Gabandé-Rodríguez, Gómez de Las Heras, and Mittelbrunn 2019). As a result, spermidine has recently attracted significant scientific interest for its potential to enhance lifespan and overall health in laboratory studies.
224256240|NCT07200427|BEHAVIORAL|MELIORA Virtual Coach Intervention|Based on baseline assessments, the MELIORA VCI app will prompt intervention group participants to set weekly goals on lifestyle behaviours such as physical activity, diet, alcohol use, and sedentary time, and support daily self-monitoring and step count tracking. Goals will be dynamically adjusted by the virtual coach or the participant to remain realistic and achievable. Τhe app will also offer culturally adapted educational, motivational, and instructional support through mini-courses, tips, recommendations and an embedded library of relevant materials to ensure high adoption rates among women from diverse countries, socioeconomic backgrounds and minority groups. To boost motivation, it will include reminders, gamification features like badges and points, as well as personalized techniques such as action planning, problem solving, social reward, and positive self-talk.
224256241|NCT07200427|OTHER|Control (generic advice)|The control group will receive the standard of care that is generic advice for a healthy lifestyle and BC prevention. A 'light' version of the MELIORA VCI app will be developed to host the control group materials, track participants' step counts, send reminders, and allow scheduling of follow-up visits. No other features will be available in this version of the app.
224256242|NCT07202039|BEHAVIORAL|Brief individual counseling sessions|Five brief, individual counseling sessions will provide education, behavioral support, and motivational strategies to facilitate switching from combustible cigarette use to EC
224256243|NCT07201701|BIOLOGICAL|Supplementary blood samples for PBMC analysis at V2|Supplementary blood (serum and plasma) and urines samples for bio collection at V3
224322393|NCT03703869|DRUG|Insulin glargine (U300)|"Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous injection"
224322394|NCT01522612|DRUG|Cetuximab|500 mg/m2 on day 1, Every 14 days Intravenously
223674872|NCT05787990|DIAGNOSTIC_TEST|Diabetes Microvascular Complication Tests|Continuous glucose monitoring using Freestyle Libre Pro, Foot examination with monofilament and neurothesiometer, HbA1c and Urine Microalbumin Creatinine Ratio, Corneal confocal microscopy, Fundal photography, Optical coherence tomography, Optical cohere
224256244|NCT07201103|BEHAVIORAL|Conventional PSSE-Schroth|Participants performed conventional Physiotherapeutic Scoliosis-Specific Exercises (PSSE-Schroth) for 4 weeks. The program consisted of one 45-minute supervised session per week complemented by home-based exercises. The exercises focused on posture correction, spinal alignment, and corrective breathing techniques according to standard scoliosis rehabilitation protocols.
224256245|NCT07201103|BEHAVIORAL|AR-Assisted PSSE-Schroth|Participants performed Physiotherapeutic Scoliosis-Specific Exercises (PSSE-Schroth) enhanced with augmented reality (AR) support for 4 weeks. The intervention included one 45-minute supervised session per week, plus home-based exercises. The AR system provided real-time visual and kinesthetic feedback during exercise sessions to improve body awareness, trunk appearance perception, and adherence.
224256246|NCT07200401|PROCEDURE|Self-swabbing of surgical wound|Participants will perform self-swabbing of their surgical wound under observation by a research nurse via secure video call.
224256247|NCT07201779|BEHAVIORAL|REDCHiP|REDCHIP comprises 10 telehealth group sessions for parents of young children with T1D, is grounded in Cognitive Behavioral Therapy (CBT) principles, and is designed to address parents FH, and their avoidant coping behaviors related to FH. Sessions also focus on strengthening parents' coping strategies associated with T1D management and helping them to reduce feelings of diabetes distress.
224256248|NCT07201779|OTHER|Treatment As Usual Control Group|Participants will receive their treatment as usual in medical appointments
224256249|NCT07201714|DRUG|Levocarnitine|Oral L-carnitine, 2970mg daily (950mg, to be taken 3 times a day) for 3 months.
224256250|NCT07200869|OTHER|No intervention|retrospective observational study. No intervention will be administered; data will be collected from existing medical records of pediatric sickle cell patients at Assiut University Hospital.
224256251|NCT07201649|OTHER|a blood test and urine sample collection.|The study is offered to all patients who meet the inclusion criteria during their pre-transplant assessment by the principal investigator (during an existing visit). Patients eligible for HT are contacted by a clinical research coordinator, and if they agree, an inclusion visit is arranged.
224256252|NCT07201402|DRUG|Scapular-site insertion of etonogestrel contraceptive implant|Participants will undergo insertion of the etonogestrel contraceptive implant subdermally over the inferior edge of their non-dominant scapula
224256253|NCT07201467|DRUG|KN060|pharmacokinetic and pharmacodynamic characteristics of KN060 in ESRD on Hemodialysis
224256254|NCT07200921|DRUG|Naoxuekang Dropping Pills|A traditional Chinese medicine. Each pill weighs 35mg. Dosage: 20 pills, three times daily, orally for 90 days.
224256255|NCT07200921|DRUG|Naoxuekang Matching Placebo|A placebo pill matched to Naoxuekang Dropping Pills in appearance, taste , size, and packaging. Dosage: 20 pills, three times daily, orally for 90 days.
224256256|NCT07201948|BEHAVIORAL|Lifestyle Immersion Intervention that will address Nutrition, Physical Fitness, and BP Self-Monitoring3 Elements:|"1. : Two distinct groups will be enrolled:~   * Those diagnosed with hypertension: BP \>=140/90, within the last 2 years.~  * Those with BP \>=130/80. Not yet diagnosed with hypertension.~2. . Intervention: Comprehensive and integrated intervention components~   * Implemented by 3 certified experts (Dietician, Fitness Trainer, Cardiologist)~  * Modules: Education, Demonstration, Practical skill development sessions.~3. . Intervention is based on American Hearts Association Life's Simple 7. The nutrition aspect will follow the DASH Diet plan."
224256257|NCT07201389|DEVICE|Scalp Cooling by DigniCap|Scalp cooling with the DigniCap Delta will occur with each chemotherapy dose. The cooling wrap is primed, fitted, and checked for proper contact before a standardized pre-cool phase of 20-30 minutes. Cooling continues during chemotherapy, followed by a post-cool phase of 90-180 minutes based on regimen. The system circulates temperature-controlled coolant through channels in the wrap, with sensors monitoring flow and scalp temperature; a safety sensor ensures scalp temperature never falls below 32°F (0°C). Alerts notify staff of low flow or temperature issues. After cooling, the cap is loosened for 5 minutes to warm before removal, and subjects are given 5 minutes to acclimate before standing.
224256258|NCT07200661|DEVICE|Experimental A tDCS: Transcranial direct current stimulation.|Group 1: Active tDCS combined with dual-task stepping (Experimental A) Participants in this group will receive anodal tDCS applied over the ipsilesional primary motor cortex (M1) at C3 or C4 (based on the 10-20 EEG system), with the reference electrode positioned over the contralesional supraorbital area. Stimulation will be delivered at an intensity of 2 mA for 20 minutes, During the stimulation period, participants will perform dual-task stepping exercises on unstable surfaces. The stepping program stepping on a foam pad (5 cm thick, 20 cm wide, 12 cm long). Each stepping session lasts 10 minutes and is immediately followed by overground walking at a comfortable speed for 10 meters, while simultaneously performing a cognitive task of counting backwards from 99 to 0. Participants are instructed not to pause or stop while performing the dual task. If they stop for more than 5 seconds, it is considered an error, which will be recorded.
223674873|NCT05401396|OTHER|Swimming immediately after eating|After having the last bite of lunch, the participants will swim in the pool with a specific distance.
224256259|NCT07200661|DEVICE|Experimental B tDCS: Transcranial direct current stimulation.|Group 2:This group follows the same stepping and dual-task walking program as Group 1 (stepping on foam pad for 10 minutes, followed by overground walking with backward counting for 10 minutes). However, instead of active stimulation, participants receive sham tDCS.
224322395|NCT01522612|DRUG|5-fluorouracil|Every 2 weeks, 400 mg/m2 on day 1; 2400 mg/m2 from day 1 to day 3, intravenously
223674874|NCT03320525|DIETARY_SUPPLEMENT|T-ChOS|T-ChOS 600 mg (two capsules, each 300 mg) daily in the morning 30 minutes before food.
223674875|NCT00721253|DEVICE|ReSTOR|Implantation of the ReSTOR Aspheric +4 (SN6AD3) multifocal intraocular lens (IOL)
223674876|NCT00721253|DEVICE|Tecnis|Implantation with the Tecnis multifocal (ZM900) intraocular lens (IOL)
223674877|NCT00721253|DEVICE|Acri.LISA|Implantation with the Acri.LISA 366D multifocal intraocular lens (IOL)
223674878|NCT02829944|DRUG|Ropivacaine|
223674879|NCT02829944|DRUG|Ketorolac|
223674880|NCT02829944|DRUG|Placebo|
223674881|NCT06966128|DEVICE|transcranial Direct Current Stimulation|Stimulation intensity: Variable (between 1 mA and 2 mA), Electrode placement: Dorsolateral prefrontal cortex, Duration: 10 minutes
223674882|NCT05397704|DEVICE|brain pulse oximeter|brain oxygen monitoring during hypoxia
223674883|NCT02105753|DEVICE|1210nm Diode Laser treatments|
223772645|NCT03815422|PROCEDURE|Regional anesthesia|Short lasting sciatic nerve block and long lasting plantar block with distal deep peroneal block
224256260|NCT07200661|DEVICE|Experimental C tDCS: Transcranial direct current stimulation.|Group 3:Participants in this group will receive anodal tDCS only, without any dual-task or stepping training.
223674884|NCT00711568|PROCEDURE|Repetitive transcranial magnetic stimulation (rTMS)|20 Hz rTMS delivered for 2 seconds (40 stimuli) every 30 seconds for a total of 2000 stimuli (25 minutes)
223674885|NCT00711568|PROCEDURE|Sham rTMS|20 Hz sham rTMS delivered to L or R frontal region for 2 seconds (40 stimuli) every 30 seconds for a total of 2000 stimuli
223674886|NCT00711568|DEVICE|Repetitive Transcranial Magnetic Stimulator|Repetitive Transcranial Magnetic Stimulator
223674887|NCT06153979|BIOLOGICAL|Verorab|Participants in each group will receive rabies vaccination (standard 3-dose series given as PrEP), with the first dose randomized to either Week 8 or Week 47 after enrollment.
224256261|NCT07201051|DRUG|GSK3862995B|Participants will be administered with dose level 1 of GSK3862995B.
224256262|NCT07201051|DRUG|Placebo|Participants will be administered with matching placebo.
224256263|NCT07202221|OTHER|Participant views Epidural animation before reading gold standard written information|Addition of introductory animation to written OAA epidural information card about labour epidural
224256264|NCT07202221|OTHER|Participant receives current gold standard written information alone|Gold standard OAA (Obstetric Anaesthetists' Association) epidural information card
223772646|NCT05404516|DRUG|Sorafenib|"Induction cycle(s): 400 mg BID on days 8-21.~Consolidation cycles 1-4: 400 mg BID on days 1-21.~Maintenance therapy: 400 mg BID for one year."
223772647|NCT05404516|DRUG|Idarubicin|"Induction cycle(s): 12 mg/m2/day on days 1-3.~Consolidation cycle 1: 8 mg/m2/day administered on days 1-3."
224256265|NCT07200609|OTHER|Virtual Reality Intervention|"The virtual reality training group will have sessions lasting 40 minutes, 3 days a week for 8 weeks.~* A 30-minute VR-based training session using Kinect Xbox (5 min warm-up, 30 min VR, 5 min cool-down)~* The device has an infrared camera sensor (Kinect sensor) that detects the participant's movement in real time~* Even if the user's movement is not performed correctly in the game settings, the user receives visual and auditory sensory feedback about movement errors.~* All games are provided to engage participants' interest in the topics and require the use of the person's lower extremities.~* Each game will be played for 10 minutes during the 30-minute training session. (A total of 3 games will be played)~* Participants in VR programs typically perform active hip flexion, hip abduction, hip external and internal rotation, knee flexion and extension, ankle dorsiflexion, and plantar flexion while standing.~* Game content: Kinect Sports, Kinect Adventures and Kinect Sports Rivals."
223772648|NCT05404516|DRUG|Cytarabine|"Induction cycle(s): 100 mg/m2 by continuous IV infusion for 24 hours on days 1-7.~Consolidation cycles 1-4: 2 g/m2/12h on days 1-3."
224256266|NCT07200609|OTHER|Home-Based Exercise Intervention|"* Home-based exercise training group will also be given online exercises 3 days a week for 8 weeks.~* Active/passive stretching exercises within pain limits~* Patients will perform exercises at home under a supervised exercise program~* They will perform exercises matching the virtual reality group in terms of exercise sequence, intensity, duration, and mode, incorporating open and closed kinetic chain movements~* A 20-second stretch followed by a 20-second relaxation performed five times per session for each muscle~* Light resistance exercises targeting muscle groups in the lower extremities, with a 5-second contraction followed by a 5-second relaxation, performed five times per session~* Bodyweight exercises~* Balance exercises~* Posture exercises"
224256267|NCT07201740|DEVICE|Leap Motion-based Virtual Reality Therapy|"Arm 1 - Experimental (Leap Motion + Routine Hand Rehabilitation)~Intervention Description: Participants will receive standard postoperative hand rehabilitation plus Leap Motion-based virtual reality training. The VR training will be performed for 20 minutes per day, 5 days per week, for 4 weeks, in addition to routine rehabilitation. The Leap Motion Controller tracks hand and finger movements without physical contact and allows participants to practice functional tasks and grasp patterns in a virtual environment.~Arm 2 - Active Comparator (Routine Hand Rehabilitation Only)~Intervention Description: Participants will receive only routine postoperative hand rehabilitation, performed for 1 hour per day, 5 days per week, for 4 weeks, supervised by a therapist."
224256268|NCT07201740|OTHER|Active Comparator - Routine Rehabilitation Only|Participants will receive only routine postoperative hand rehabilitation, performed for 1 hour per day, 5 days per week, for 4 weeks, supervised by a therapist.
224256269|NCT07200453|BEHAVIORAL|intervention group 1.1 - e-learning|"The e-learning environment will include text, images, and short videos created using Articulate Rise 360, an easy-to-use e-learning authoring tool, with the following content to improve the different skills of digital health literacy:~1. Evaluating reliability skills: Participants will get to know criteria and indicators for evaluating the content of the information they find and for assessing the trustworthiness of website providers.~2. Improving information skills: Participants will learn simple rules on how to optimize their Google searches.~3. Improving navigation skills: Participants will learn simple rules for navigation; using the back button; using more than one tab; drop-down lists and anchor links are introduced.~4. Additional goals are to raise awareness about various aspects related to online searches, including the exploration of alternative and complementary therapies, and the importance of data protection."
224256270|NCT07200453|BEHAVIORAL|intervention-group 1.2 - e-learning|Participants are also given access to the e-learning environment. However, they will not be taken step-by-step through the content (tunneling). They can choose the order of the content.
224256271|NCT07200453|BEHAVIORAL|intervention-group 1.3 - e-learning|Participants are also given access to the e-learning environment, but all rehearsal elements such as quizzes will be removed from the e-learning environment.
224256272|NCT07200453|BEHAVIORAL|intervention-group 2 - PDF|Participants in IG2 will receive the same content as participants in the IG1.1, but not within the interactive learning environment, but in a non-interactive PDF format.
224256273|NCT07202000|DRUG|Activin ligand-trap biological therapy|Investigational therapy
224256274|NCT07202000|DRUG|Placebo, Normal Saline|Inactive drug
224256275|NCT07200245|OTHER|adrenalectomy|adrenalectomy for pheochromocytoma and non-secreting tumor (incidentaloma)
224256276|NCT07201675|DRUG|RC48-ADC combined with toripalimab for bladder-sparing therapy|RC48-ADC combined with toripalimab for bladder-sparing therapy
224256277|NCT03688503|DIETARY_SUPPLEMENT|magnesium glycinate supplement|magnesium glycinate (480 mg/day)
224256278|NCT03688503|DIETARY_SUPPLEMENT|placebo|placebo
224322396|NCT01522612|DRUG|leucovorin|Every 2 weeks, Racemic leucovorin 200 mg/m2 or l-leucovorin 100 mg/m2 on day 1, intravenously
223674888|NCT06994689|DIAGNOSTIC_TEST|Perimetry and ShearWave measurement of the quadriceps muscle before and after a pulmonary rehabilitation (PR) programme|"Patients will undergo a pulmonary rehabilitation (PR) programme.~On day 1, perimetry and ShearWave measurements of the quadriceps muscle will be provided. Supplementary assessments of quadriceps thickness, quadriceps strength with a handheld dynamometry, lean body mass (bioelectrical impedance), constant work-rate endurance test and HAD questionnaire will also be provided on day 1.~The same measurements and questionnaire will be provided on the last day of the patient in the PR programme."
223674889|NCT05844709|OTHER|IVH care Bundle|"The experimental group received bundle nursing care within 3 days after birth in addition to routine nursing care after consent was given and the informed consent form was signed.~IVH care Bundle: 1. Maintaining midline head position 2. Avoid prone, place in supine or side-lying position 3. Incubator tilted 15-30 degrees 4. Slow withdrawal and flushing for UAC, UVC, and PAL."
223674890|NCT05841901|DRUG|Huang-long Zhi-xiao Granule|The experimental group was given Huang-long Zhi-xiao Granule.1 dose per day, oral in 2 divided doses, 1 course every 4 weeks, for a total of 8 weeks of treatment.
223772649|NCT03279276|PROCEDURE|Total Hip Arthroplasty|"The usual procedures of the department: Moore incision and insertion of uncemented joints (exceed with vitamin E enriched polyethylene liner and 32 or 36 mm head). Cyclokaprone is administered peroperatively (bleeding-reducing), antibiotics and thrombosis prophylaxis. Follow the usual rehabilitation regimes, fast track, incl. Use of crutches and must support within the pain limit, possibly with crutches the first 4 weeks after surgery, then full load.~By default, postoperative X-ray and RSA recordings will be performed on the 1st or 2nd postoperative day. The surgery will be performed by specialist physicians in orthopedic surgery associated with the hip arthroplasty sector."
223674891|NCT05841901|DRUG|Huang-long Zhi-xiao Granule placebo|The toncral group was given placebo Huang-long Zhi-xiao Granule.The course of treatment was the same as that of the experimental group.
223674892|NCT00336583|DRUG|Oxaliplatin|Oxaliplatin, 130 mg per square meter, on day 1
223674893|NCT05553067|GENETIC|Immunohistochemical staining of normal and neoplastic ovarian tissues by anti human Engrailed-2 antibody.|Immunohistochemical staining of normal and neoplastic ovarian tissues by anti human Engrailed-2 antibody and compare levels of expression in different ovarian specimens to detect its potential role in oncogenesis of ovarian carcinoma.
223772650|NCT03697954|DEVICE|full stage implantation of sacral neuromodulation|full stage implantation of sacral neuromodulation for overactive bladder and urge incontinence
223772651|NCT00098215|BEHAVIORAL|Pediatric residency training on tobacco|
223772652|NCT04629664|DRUG|FX-322|Active Comparator
223772653|NCT04629664|OTHER|Placebo|Placebo
224256279|NCT04299087|DEVICE|repetitive Transcranial Magnetic Stimulation (rTMS)|Repetitive transcranial magnetic stimulation (rTMS) is a form of brain stimulation therapy using a magnet to target and stimulate certain areas of the brain.
224256280|NCT04299087|OTHER|Control group|No application of rTMS
223674894|NCT01908920|OTHER|Osteopathic manipulative treatment|
223674895|NCT01908920|OTHER|SHAM|
223674896|NCT01908920|OTHER|CONTROL|
223674897|NCT05376943|DRUG|Direct Acting Antivirals|Our observational study will assess the exposure to direct acting antivirals - the specific drugs, dose, duration of the therapy and the effect of the treatment.
223674898|NCT05588557|DRUG|Marcaine® 100mg/20mL (0.5%) bupivacaine solution for Injection|"Subjects in this arm will receive a single administration of Marcaine® at the 150 mg.~Marcaine® will be administered under ultrasound guidance with a total volume of 40 mL, of which 20 mL will be used via adductor canal block (ACB) and the other 20 mL will be used as IPACK block (interspace between the popliteal artery and the capsule of the posterior knee)."
223674899|NCT05588557|DRUG|ND-340 (Bupivacaine Microsphere), 300 mg/vial bupivacaine for extended-release injectable suspension|"Subjects in this arm will receive a single administration of ND-340 at the specified dose (90-320 mg).~ND-340 will be administered under ultrasound guidance with a total volume of 40 mL, of which 20 mL will be used via adductor canal block (ACB) and the other 20 mL will be used as IPACK block (interspace between the popliteal artery and the capsule of the posterior knee)."
223674900|NCT06504693|DIAGNOSTIC_TEST|CBC|diagnostic tests for iron status
223674901|NCT02894008|DRUG|ChAd63-KH|ChAd63-KH in adults and adolescents with persistent PKDL.
223674902|NCT05625503|DRUG|Verapamil|All patients routinely receive intra-arterial calcium channel blockers during transradial access for coronary angiography.
223674903|NCT05625503|DRUG|Nicardipine|Calcium channel blocker
223674904|NCT00399672|DRUG|Interferon injections and ribavirin|Weekly pegylated interferon injections will be administered by clinic staff and ribavirin will be dispensed in weekly medication pack.
223772654|NCT00835406|DRUG|Alendronate Sodium Tablets 70mg|1 x 70mg, single dose fasting
223772655|NCT00835406|DRUG|Fosamax® Tablets 70mg|1 x 70 mg, single dose fasting
223772656|NCT01494233|DRUG|250 mg LX1033 tablets|250 mg LX1033 tablets administered orally
223772657|NCT01494233|DRUG|Placebo tablet|Matching placebo tablet administered orally
223772658|NCT05210036|DEVICE|Ultrasound Therapy (US)|"All the patients included in the study received a total of 15 sessions of physical therapy program 5 times a week for 3 weeks.~Physical Therapy Program;~* Hot Pack at 60 degrees Celsius for 20 minutes~* TENS at 80 Hz for 20 minutes~* Therapeutic exercise program (3 sets of 10 reps with 3-minute intervals between the sets) consisting of active-assisted ROM, passive stretching and Codman exercises for their shoulder joint for 30 minutes in accompany with a physiotherapist."
223772659|NCT05210036|DEVICE|High-Intensity Laser Therapy (HILT)|"All the patients included in the study received a total of 15 sessions of physical therapy program 5 times a week for 3 weeks.~Physical Therapy Program;~* Hot Pack at 60 degrees Celsius for 20 minutes~* TENS at 80 Hz for 20 minutes~* Therapeutic exercise program (3 sets of 10 reps with 3-minute intervals between the sets) consisting of active-assisted ROM, passive stretching and Codman exercises for their shoulder joint for 30 minutes in accompany with a physiotherapist."
224256281|NCT04309968|DRUG|Drug: SYHA1801|Drug: SYHA1801 administered orally
224256282|NCT00594035|DEVICE|Spinal Sealant System|
224256283|NCT00594035|DEVICE|Standard of care|Standard of care: devices intended to provide a watertight closure
224256284|NCT00795821|DRUG|LY2216684|Flexible Dosing: 6 mg, 9 mg, 12 mg and 18 mg (3 tablets) administered QD for up to 62 weeks
224256285|NCT00795821|DRUG|Placebo|Dose: 3 tablets QD for 10 weeks
224256286|NCT01285713|DRUG|5% Dextrose (D5) in Normal Saline (NS)|D5NS 10 cubic centimeter (cc)/kilogram (kg) to be followed by 30cc/kg of NS
224256287|NCT01285713|DRUG|Normal Saline (NS)|NS 10 cubic centimeter (cc)/kilogram (kg) to be followed by 30cc/kg NS
224256288|NCT00416780|OTHER|counseling intervention|
224256289|NCT00416780|OTHER|educational intervention|
224256290|NCT00416780|PROCEDURE|psychosocial assessment and care|
224256291|NCT04310345|BEHAVIORAL|Animal-Assisted Interactions|Child and caregivers will spend approximately 10-5 minutes with a registered canine and its owner during potentially anxiety-producing visits to the clinic or hospital.
224256292|NCT01079845|BEHAVIORAL|Nutrition Education, Dietary Counseling, and Cooking|Monthly clinic visits with a dietitian, Monthly telephone calls with a dietitian, Three cooking workshops with a chef
224256293|NCT06239688|BEHAVIORAL|essentiALZ|essentiALZ is a web-based training that contains three hours of self-paced content separated into five modules, plus a final review. Modules include: 1) Alzheimer's disease and dementia; 2) person-centered care; 3) assessment and care planning; 4) activities of daily living; and 5) behaviors and communication. Staff will be encouraged to take the training over the course of four weeks.
224256294|NCT06239688|BEHAVIORAL|Project ECHO|ECHO is a virtual tele-mentoring model grounded in case-based learning. It includes six weekly one-hour sessions of didactic and discussive learning. The first five sessions will reflect the content of the five essentiALZ modules, and the final session will address maintenance. ECHO sessions are group sessions that will be conducted via Zoom.
224256295|NCT06194344|BEHAVIORAL|Individualized imagery|Study personnel will assist participants to create scripts that foster relaxation and safety. Objects, places, and/or scenarios that foster participant relaxation, sense of safety, and/or positive emotions will be identified. Participants will write or type the generated scenario using highly detailed elements (e.g., including visual, olfactory, auditory, tactile, and gustatory sensations, as applicable) associated with the imagery. Study personnel will assist with recording the imagery scripts; audio files will be recorded using an audio recording application. The imagery scripts will be played at night via Bluetooth earbuds connected to the Muse app and script recording while laying down to sleep. The imagery rehearsal prompts will play for approximately 15 minutes, based on 10-20-minute recommendations across imagery rehearsal therapy (IRT) studies
224256296|NCT06194344|BEHAVIORAL|Control|Participants will wear the earbuds, with use of Muse S headband to collect outcome data without the individualized imagery scripts.
224256297|NCT05771558|DEVICE|Tailored Lighting Intervention (TLI)|The lighting intervention will provide high circadian stimulation produced by light sources that provide moderate light levels of spectra that are tuned to the sensitivity of the circadian system.
224256298|NCT05771558|DEVICE|Actigraph|An actigraph is a wrist worn devices that measures rest and activity.
224256299|NCT02816177|OTHER|Telemedicine|
224256300|NCT02816177|OTHER|Usual Care|
224256301|NCT06230588|DRUG|TQH3906 capsule|TQH3906 is a kinase inhibitor.
224256302|NCT06230588|DRUG|TQH3906 placebo|Placebo Comparator
224256303|NCT01555892|BIOLOGICAL|EBV-specific T cells: A|Patients may receive cells with or without lymphodepletion. Dose Level 3: 1 x 10\^8 cells/m2 + 2 x 10\^8 cells/m2
224322397|NCT03709979|DEVICE|C-MAC videolaryngoscope|An intubating device that is used for endotracheal intubation. Endotracheal intubation will be performed by anesthesiologist with C-MAC videolaryngoscope
224322398|NCT03174379|PROCEDURE|Standard of Care with no acupuncture|The control group will lie on a treatment table in the acupuncturist's office for the same amount of time that the treatment group did, but receive no acupuncture
224322399|NCT03174379|PROCEDURE|Acupuncture|The first set consists of core point selection, used in an MS Standard of Care (SOC). The second set of points will be individualized to the patient's needs as determined by the acupuncturist. SOC treatment will be based upon Traditional Chinese Medicine (TCM) interpretation of 4 phases of MS.
224322400|NCT00464438|DRUG|gatifloxacin|Day 1-6 = 1 drop of study medication three times a day
223674905|NCT00399672|DRUG|Interferon injections and ribavirin|Patients will be offered the option of self or nurse administered pegylated interferon injections on an appointment basis. Ribavirin will be dispensed biweekly. The treatment medication cannot be stored at the clinic; it must be the subjects responsibility.
223674906|NCT03564730|PROCEDURE|Simultaneous Knee Arthroplasty (UKA)|Patient will have both knees completed under one anesthetic.
223674907|NCT03564730|PROCEDURE|Staged Knee Arthroplasty (UKA)|Patient will have knees completed under 2 anesthetics.
223674908|NCT02439528|GENETIC|Genetic analysis|"One part of these patients is already included in a cohort: for them the blood sample will be centralized and then analyzed.~The other part of these patients will be recruited during the study: for them intervention will be blood samples for further genetic analysis."
223772660|NCT04865796|OTHER|Lactoferrin products|Patiens will use a toothpaste and 2 tablets per day (between foods) for home oral care.
223772661|NCT04865796|OTHER|Probiotics products|Patiens will use a toothpaste and a chewing-gum (for 10 minutes a day) for home oral care.
223772662|NCT04865796|OTHER|Standard home oral care|Patiens will use a normal toothpaste for home oral care.
223772663|NCT03832959|DEVICE|EnsoETM|The EnsoETM is a device with a esophageal probe that can provide temperature adjustment
224256304|NCT01555892|BIOLOGICAL|EBV-specific T cells: B|Patients may receive cells with or without lymphodepletion. Dose Level 3: 1 x 10\^8 cells/m2 + 2 x 10\^8 cells/m2
224256305|NCT06962865|DRUG|RC108|RC108 in Combination With Furmonertinib
224256306|NCT06962865|DRUG|Furmonertinib Mesilate Tablets Monotherapy|Furmonertinib
224256307|NCT03626662|DRUG|AMG 890|Ascending Single Doses of AMG 890
224256308|NCT03626662|DRUG|Placebo|Calculated volume to match experimental drug.
224256310|NCT05013372|DRUG|CD147- CAR T cells|CAR T cells targeting CD147
224256311|NCT00698256|DIETARY_SUPPLEMENT|vegetable oil-based spread and oat-based drink (no brand name available)|spread and drink (9 g stanols/d)
224256312|NCT00698256|DIETARY_SUPPLEMENT|vegetable oil-based spread and oat-based drink (no brand name available)|Spread and drink (not containing added stanols)
223772664|NCT04273464|PROCEDURE|Brava-group|Breast reconstruction by external tissue expansion and multiple fat transplantations(Brava group); Breast reconstruction with microsurgical DIEP-flap transfer.
223772665|NCT04273464|PROCEDURE|DIEP-group|Microsurgical reconstruction by DIEPO method
223772666|NCT06440772|DRUG|Ringer's Lactate Crystalloid Solutions|7 ml/kg ml of Ringer's Lactate is given in 10 min amongst initially tolerant fluid responders.
223772667|NCT05110001|DRUG|Moxifloxacin Ophthalmic|Topical moxifloxacin 0.5% is a fluoroquinolone antibiotic that is used to treat bacterial infections. This is a standard therapy for bacterial keratitis.
223772668|NCT05110001|DRUG|Chlorhexidine Gluconate|Topical chlorhexidine gluconate 0.02% is an antiseptic agent, with both antibacterial and antifungal properties. This is a standard therapy for Acanthamoeba keratitis.
224256313|NCT02184026|BEHAVIORAL|Exposure, Relaxation, & Rescripting Therapy-Child|Exposure, Relaxation, \& Rescripting Therapy (ERRT) will be conducted once a week for five consecutive weeks for approximately two hours per session. Each treatment session focuses on one of the following topics/skills: psycho-education and investment in treatment, psycho-education, Progressive Muscle Relaxation, diaphragmatic breathing, child-friendly exposure to the trauma-nightmare, and rescription.
224256314|NCT00541788|OTHER|Administration of Common Sage|Administration of Common Sage
224256315|NCT03161158|DEVICE|CHIARA-System|Treatment with veno-venous ultrafiltration (CHIARA-System) complementary to low-dose diuretic therapy according to treatment algorithm. 1-7 Ultrafiltration sessions (6-10h/session, number of sessions depending on clinical assessment) for at least 1-2 consecutive days and a maximum of 7 days.
224256316|NCT03161158|OTHER|Usual care IV diuretics|Guideline-directed therapy including IV loop diuretics (according to treatment algorithm)
224256317|NCT04086108|DIETARY_SUPPLEMENT|Tomato|A maximum of 1 kilo pureed tomatoes, containing 1 gram of GABA.
224256318|NCT04086108|DIETARY_SUPPLEMENT|GABA supplement|1 gram of GABA dissolved in water.
223772669|NCT05110001|DRUG|Natamycin|Natamycin 5% is an antifungal agent used to treat fungi that cause keratitis. This is a standard therapy for fungal keratitis.
224256319|NCT04086108|DIETARY_SUPPLEMENT|Glutamate supplement|A maximum of 8 grams glutamate, adjusted to amount of glutamate given in the tomato arm. Dissolved in water.
224256320|NCT02303405|DRUG|Hydroxychloroquine|Anti-inflammatory and anti-malarial agent
224256321|NCT02303405|DRUG|Pioglitazone|Anti-hyperglycemic agent
224256322|NCT01867164|DRUG|Gynoclin V|One ovule containing 80 milligram (mg) terconazole, 100 mg clindamycin and 0.5 mg fluocinolone acetonide will be administered vaginally, every 24 hours at night, for 3 days.
224256323|NCT01867164|DRUG|Vagitrol V|One ovule containing 500 mg metronidazole, 0.5 mg fluocinolone acetonide and 100,000.00 microgram/milliliter nystatin will be administered vaginally, every 24 hours at night, for 10 days.
224256324|NCT01880632|DRUG|XELOX|"Patients will be given the perioperative chemotherapy as below once recruited:~Capecitabine ：500 mg tablets（Roche） Oxaliplatin：50mg/10ml（according to daily practice in each center）~Schedule of Oxaliplatin plus capecitabine (XELOX) will be as follow:~Capecitabine 1000 mg/m2 ，orally taken 30 minutes after meal, bid ， d 1\~14 every 3 weeks(treatment for 2 weeks and rest 1 week) Oxaliplatin：130mg/m2， iv infusion over 2h，d1,every 3 weeks"
224256325|NCT04030091|DRUG|3 hours humulin R 100 IU/mL PIT|PIT procedure: a venous catheter will be placed into one superficial vein at one arm, which will be connected to the insulin infusion pump and a glucose infusion pump via a three-way connector. Endothelial function will be measured by means of the Vendys 2 device. The blood glucose will be tested by means of a POCT meter and the CGM, and the PIT procedure will be started (10 pulses of 3 U of regular human insulin per hour). Blood glucose will be tested every 5 to 10 min and glucose infusion will be started once a drop in blood glucose is detected. Adjustment of glucose administration will be performed until a stable glucose value between 80 mg/dL to 160 mg/dL is reached. In parallel, endothelial function will be measured every 30 min. At the end of the PIT procedure, the venous catheter will be removed and the patient will be discharged until the next visit.
223772670|NCT05110001|DRUG|Rose Bengal|Study participants receive RB-PDT within 48 hours of randomization. All participants will receive a 30-minute loading dose of topical Rose Bengal (0.1% RB in 0.9% sodium chloride) which will be applied in 5-minute intervals to the de-epithelialized cornea. This will be followed by irradiation with a 6mW/cm2 custom-made green LED source for 15 minutes (5.4J/cm2). Repeat cornea culture will be collected within 24 hours after the procedure.
224256326|NCT04030091|DRUG|2 hours humulin R 100 IU/mL PIT|"As described for the Intervention 3 hours of pulsatile insulin infusion (PIT) with humulin R 100 IU/mL, the treatment duration is just one hour less."
224256327|NCT02744794|DEVICE|Dermal Cooling System|Treatment with cryotherapy.
224256328|NCT02837991|DRUG|CDX-014|
224256329|NCT06272266|DEVICE|Kardiopulmonary exercise test (Quark KPET C12x/T12x device connected to the Omnia version 1.6.8 COSMED system)|"For the cardiopulmonary exercise test, a Quark KPET C12x/T12x device connected to the Omnia version 1.6.8 COSMED system, supported by analyzers that measure oxygen uptake and carbon dioxide output, and a bicycle ergometer connected to the ergoline rehab system 2 Version 1.08 SPI system were used. At the end of the test, the individual's RER , VAT, VO2peak, VO2AT, VE/CO2, HRR, HRR1 values were recorded. These values were estimated by the device based on the wasserman extended protocol on the Quark KPET C12x/T12x device connected to the Omnia version 1.6.8 COSMED system.The test was repeated after 15 sessions of aerobic exercise training in the Covid-19 group.This intervention was applied to 14 people in the COVID-19 group and 15 people in the control group. It was repeated at the end of 15 sessions of aerobic exercise training in the COVID-19 group."
224256330|NCT06272266|DEVICE|Peripheral muscle strength measurement (microFET3 (Hoggan Health Industries, Fabrication Enterprises, lnc) and JAMAR hydraulic hand dynamometer (Sammons Preston, Rolyon, Bolingbrook).|Quadriceps and triceps muscle strength was measured in kilograms using the microFET3 (Hoggan Health Industries, Fabrication Enterprises, lnc) manual muscle strength measurement device in the lower and upper extremity. Hand grip strength was evaluated in the dominant upper extremity using a JAMAR hydraulic hand dynamometer (Sammons Preston, Rolyon, Bolingbrook)This intervention was repeated for individuals in both groups at the beginning and at the end of the 15-session aerobic exercise training planned for the COVID-19 group.
224322401|NCT00464438|DRUG|moxifloxacin 0.5% eye drops|Day 1-6 = 1 drop of study medication three times a day
224256331|NCT06272266|DEVICE|Standard exercise tolerance test (a bicycle ergometer and recorded through the ergoline rehabilitation system 2 Version 1.08 SPI.)|At the beginning of this test, resting pulse and blood pressure were measured and recorded. The test was performed following a bicycle ergometer protocol recommended by the American Cardiovascular and Pulmonary Rehabilitation Society. After a 2-minute warm-up period at 0 load (W), a submaximal exercise test was performed by increasing the load by 25 W in 2-minute periods. At the end of the test, exercise intensity was evaluated with the perceived difficulty level (borg scale), test duration, maximum heart rate, maximum work (W). , metabolic equivalent (MET) values were recorded. VO2peak and VO2peakpredictive levels were calculated. This test was repeated for individuals in both groups at the beginning and at the end of the 15-session aerobic exercise training planned for the COVID-19 group.
224256332|NCT06272266|DEVICE|Aerobic exercise training (a bicycle ergometer and recorded through the ergoline rehabilitation system 2 Version 1.08 SPI.)|Aerobic exercise training was planned for the COVID-19 group with the help of a bicycle ergometer and recorded through the ergoline rehabilitation system 2 Version 1.08 SPI. Aerobic exercise training was applied for a total of 15 sessions, at least 3 days a week, under the supervision of a physician.
224256333|NCT05400694|OTHER|Food|Dairy products with reduced sugar content
224256334|NCT05674734|BEHAVIORAL|4FM Acceptance Training|4FM Acceptance Training, therapeutic intervention in the form of an additional to TAU module - 12 (1,5 hour) group meetings in the form of 4FM Acceptance Training at Day Care Units at IPIN Mental Health Centre for Mokotów and IPiN (1 meeting weekly).
224256335|NCT03083574|DEVICE|Photopheresis Theraflex ECP™|The Macopharma (Theraflex ECP™) approach is based on a multistep procedure involving (1) standard mononuclear cell apheresis, (2) injection of the 8-Mop in the apheresis bag, (3) UVA exposure of the bag in the Macogenic illumination device, and (4) reinfusion of the cells into the patients.
224256336|NCT04116463|BEHAVIORAL|Chronic Disease Self-Management Program (CDSMP)|
224256337|NCT04116463|BEHAVIORAL|Financial Self-Management Program (FSMP)|
224256338|NCT04754035|DRUG|Venetoclax|venetoclax 20 mg, 50 mg, 100 mg
224256339|NCT04754035|DRUG|Imbruvica Oral Product|Imbruvica 140 mg
224256340|NCT03635320|DEVICE|TFNA|intramedullary nail 'Trochanteric Fixation Nail Advanced' to treat proximal femur fracture undergoing internal fixation
224256341|NCT03635320|DEVICE|PFNA-II|intramedullary nail ' Proximal Femoral Nail Antirotation' to treat proximal femur fracture undergoing internal fixation
224256342|NCT05905276|OTHER|ERAS Protocol|The ERAS protocol for ambulatory TURBT has been designed based on patient and provider input, a needs assessment of 150 patients in the hours after TURBT, a review of the literature, and experience with other ambulatory ERAS protocols already implemented at Johns Hopkins Hospital. The ERAS protocol for ambulatory TURBT aims to optimize care delivered in the pre, intra and postoperative settings.
224256343|NCT05905276|OTHER|Standard of Care|Patients in the usual care arm of the EMBRACE trial will experience the present-day care pathway of ambulatory TURBT at Johns Hopkins Hospital.
224256344|NCT04512781|DEVICE|Control Cannula - Prosoft Cannula - Unicorn Cannula|The purpose of this intervention is to evaluate the efficacy of a conventional legacy cannula design to provide targeted relief of dyspnea. The purpose of this intervention is to evaluate the efficacy of a next generation cannula to provide relief of dyspnea.
224256345|NCT04512781|DEVICE|Control Cannula - Unicorn Cannula - Prosoft Cannula|The purpose of this intervention is to evaluate the efficacy of a conventional legacy cannula design to provide targeted relief of dyspnea. The purpose of this intervention is to evaluate the efficacy of a next generation cannula to provide relief of dyspnea.
224256346|NCT06524219|PROCEDURE|unilateral intrafascial resection|Conducting unilateral intrafascial resection in Retzius-sparing robot-assisted radical prostatectomy
224256347|NCT06524219|PROCEDURE|bilateral intrafascial resection|Conducting bilateral intrafascial resection in Retzius-sparing robot-assisted radical prostatectomy
224256348|NCT06524219|PROCEDURE|bilateral extrafascial resection|Conducting bilateral extrafascial resection in Retzius-sparing robot-assisted radical prostatectomy
224256349|NCT06549036|BEHAVIORAL|Veteran Peer Decision Coaching Session for PSA Screening|Veterans in the intervention arm will review the content of the mailed DA, including the values clarification exercise, with the Veteran PDC. Veteran PDC Counseling includes: 1) a structured interview with the patient that focuses on determining his understanding of his prostate cancer risk, his screening options, and his goals and values related to his decision making and 2) role playing exercises to improve SDM skills.
224256352|NCT05162105|OTHER|Short rest (8 hour) between two consecutive shifts.|Participants will have shortened rest opportunity (8 hours) between two consecutive shifts, due to the shift work schedule.
224256353|NCT05162105|OTHER|16 hour rest opportunity between to consecutive shifts.|Participants will have a 16 hour rest opportunity between shifts, due to shift work schedule.
224256354|NCT01354626|OTHER|dietary protein|in the low-protein group 13EN% of protein will be provided in the diet; in the high-protein 25EN% of protein will be provided
224256355|NCT01354626|OTHER|low-protein|The control group will get a diet which is according to healthy eating guidelines.
224256356|NCT02111239|DEVICE|CTA|pelvic/abdominal CTA scan
224256357|NCT02111239|DEVICE|MRA|pelvic/abdominal MRA scan
224256358|NCT04509453|DEVICE|McGRATH laryngoscopy|Patients who underwent general anesthesia with LMA insertion by using McGRATH video layngoscopy
224256359|NCT04509453|DEVICE|Macintosh laryngoscopy|Patients who underwent general anesthesia with LMA insertion by using classic Macintosh video layngoscopy
224256360|NCT03787641|DRUG|Protamine Sulfate|Protamine Sulfate will be administered via an infusion pump to administer a 50 mg test doze, then 100 mg after 5 min waiting period. Following blood samples, additional alliquots of 50 mg will be measured to a maximum of 300 mg.
224256361|NCT03999216|DRUG|Loop Diuretics vs. loop + thiazide diuretics|Participants will receive the diuretic type as determined by the randomized group assignment starting within the first 24 hours of hospital admission and continuing for up to 72 hours. All other treatments are left to the discretion of the treatment team, as this is a pragmatic randomized trial.
224256362|NCT02949739|BEHAVIORAL|Intensive lifestyle modification|The intervention is delivered as 9 face-face and 13 telephone contact sessions over 12 months. Index cases are the focus for the intervention, but lifestyle modification encourages the whole family to adopt healthy living.
224256363|NCT02557035|DRUG|Palonosetron|
224256364|NCT02557035|DRUG|Dexamethasone|
224256365|NCT05472311|OTHER|Thermal Ablation|Thermal ablation is based on local heating (around 100 degrees centigrade), applied for 20 to 60 seconds to destroy abnormal tissue by burning and inducing necrosis of pre-cancer and surrounding tissue. It has been used in by gynecological surgery for over 50 years, proven safe and easy to use by middle level health care providers in primary care settings.
224256366|NCT05457920|BEHAVIORAL|continuous treatment|The treatment period is 12 weeks as a treatment unit, starting from the first day of baseline, subcutaneous injection of Peg-IFN α-2b 180μg once a week, or every 8 weeks of injection, 4 weeks off, periodically, the total treatment course does not exceed 96 weeks.
224256367|NCT05457920|BEHAVIORAL|pulse therapy|pulse therapy
224256368|NCT03921879|DRUG|OT-82 Dose Escalation|The starting OT-82 dose level will be16.5mg/m2 given orally as an oral suspension once daily on Days 1-3, 8-10, and 15-17 of each successive 28-day cycle. Dose escalation will follow a modified 3+3 design. There is no maximum duration of OT-82 treatment; however, treatment will be discontinued if there is unacceptable toxicity, disease progression, withdrawal of consent by the patient, noncompliance with study requirements, intercurrent illness, development of symptoms or conditions listed as exclusion criteria, or closure of the study by the Sponsor.
224256369|NCT03921879|DRUG|OT-82 Dose Expansion|A total of 25 patients evaluable for disease response will be treated with OT-82 on Days 1-3, 8-10, and 15-17 of the 28-day cycle at the MTD or maximum tested dose determined from Stage 1. This may include patients treated at that dose in Stage 1 plus expansion at that dose during Stage 2. Evaluability for disease response requires that patients receive at least one dose of OT-82. There is no maximum duration of OT-82 treatment; however, treatment will be discontinued if there is unacceptable toxicity, disease progression, withdrawal of consent by the patient, noncompliance with study requirements, intercurrent illness, development of symptoms or conditions listed as exclusion criteria, or closure of the study by the Sponsor.
224256370|NCT02995720|DRUG|Fimasartan/Amlodipine combination drug, Rosuvastatin|
224256371|NCT03923192|DEVICE|Vistacam|device for early proximal caries detection
224256372|NCT03923192|RADIATION|Bitewing radiograph|radiograph for proximal caries detection
224256373|NCT00247923|PROCEDURE|Hysteroscopic resection of endometrial polyps. (TCRP)|
224256374|NCT00761813|DEVICE|Open reduction internal fixation (ORIF) with single sliding hip screw|The ORIF will be performed using a single large diameter partially threaded screw that is affixed to the proximal femur with a side plate (with a minimum of two holes and a maximum of four holes) and no supplemental fixations. Surgeons will use any commercially available sliding hip screw implant and will insert implants as per the manufacturers' technical guides. Other surgical factors will be based on surgeon preference and noted.
224256375|NCT00761813|DEVICE|ORIF with multiple cancellous screws|ORIF will be performed using multiple small diameter threaded screws (with a minimum of two screws and a minimum diameter of 6.5 mm). Surgeons will use any threaded screw or hook pin and will follow the manufacturers' technical guides. Other surgical factors will be based on surgeon preference and noted.
224256376|NCT06332170|DRUG|HS-20093|administered as an IV infusion
224256377|NCT06332170|DRUG|Adebrelimab|administered as an IV infusion
224256378|NCT06332170|DRUG|Cisplatin/ Carboplatin|administered as an IV infusion
224256379|NCT06332170|DRUG|Cetuximab|administered as an IV infusion
224256380|NCT06332170|DRUG|Enzalutamide|160mg once daily (QD) orally
224256381|NCT04505085|BEHAVIORAL|Active Dads Healthy Families: Outdoor Education|The intervention will include outdoor education and physical activity opportunities at various outdoor parks. The program will be held one day a week for eight consecutive weeks. Parks and Recreation will facilitate and run the program. Each session will last 60 minutes and include a brief educational discussion and opportunities for various games and activities. Each session will have a special theme relevant to the outdoors. Families will also receive a home toolbox to facilitate activity and learning outside of the program. Feedback on physical activity will be provided at the beginning and the end of the program.
224256382|NCT04505085|BEHAVIORAL|Active Dads Healthy Families: Fitness|The intervention will include physical activity opportunities at a community center. The program will be held one day a week for eight consecutive weeks. Parks and Recreation will facilitate and run the program. Each session will last 60 minutes and include a brief educational discussion and opportunities for various games and activities. Families will also receive a home toolbox to facilitate activity outside of the program. Feedback on physical activity will be provided at the beginning and the end of the program.
224256383|NCT03884894|DIAGNOSTIC_TEST|molecular assay|performed with blood culture simultaneously
224256384|NCT03884894|DIAGNOSTIC_TEST|Blood culture|performed with molecular assay simultaneously
224256385|NCT01899989|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|
224256386|NCT01899989|DRUG|cisplatin or carboplatin-based|Standard chemotherapy with a histology-selected cisplatin or carboplatin-based doublet will be administered intravenously as adjuvant therapy. Gemcitabine will be used for squamous cell carcinomas and pemetrexed will be used for non-squamous non-small cell lung cancer. Cisplatin or carboplatin will be used in combination with the histology-selected agent. The choice of cisplatin or carboplatin will be at the discretion of the treating medical oncologist.
224322402|NCT03536533|OTHER|Exergame|Each of the 8 exercise sessions will last at least 42 minutes, with an actual training duration of 21 minutes. The participants will be accustomed gradually to the game. On one hand this will be achieved by increasing the difficulty in subsequent levels within the exergame.
224256387|NCT02247791|PROCEDURE|Uncemented femoral stem|All patients will be randomized to operation with either an uncemented femoral stem or a cemented femoral stem
224256388|NCT02247791|PROCEDURE|Cemented femoral stem|All patients will be randomized to operation with either an uncemented femoral stem or a cemented femoral stem
224256389|NCT01120340|DRUG|mesalamine|mesalamine: 1.6 g/die for ten days/month until 24 months
224322403|NCT06217211|DIETARY_SUPPLEMENT|Remolacha|BJ or PL will be administered 3 h before the start of the NO2- evaluation test since the peak in blood occurs 2-3 h after ingesting NO3-. Both drinks (BJ and PL) will be provided in an unlabeled 140ml maroon red plastic bottle. Participants will receive a randomly assigned bottle. containing 140 ml (\~ 12.8 mmol, \~ 808 mg NO3-) of BJ Beet-It-Pro Elite Shot concentrate (Beet IT; James White Drinks Ltd., Ipswich, United Kingdom) or PL.
224256390|NCT01120340|OTHER|placebo|2 pills/day for ten days/month until 24 months
224322404|NCT05358509|DRUG|Ferric carboxymaltose|Pregnant participants randomized to intervention arm 1 will receive a single dose of ferric carboxymaltose having 1000mg of iron if they weigh over 50kg. If a participant is under 50kg, they will receive a lower dose as determined by a formula used by the manufacturer (20mg iron/kg body weight). This will be given ideally immediately after randomization, sometime between 14 weeks and 17 weeks of pregnancy.
224256391|NCT03049748|DEVICE|Mobile phone app (VAD Care App)|"VAD Care App is a novel self-management tool being tested for patients with implantable LVADs. The app has daily push notifications (alerts), cues for daily self-management tasks, two-way communication using text messages and videoconferencing (virtual clinic), and links to LVAD self-management skills and videos easily accessible for self-management skill review."
224256392|NCT03049748|OTHER|Usual LVAD Care|Routine clinic follow-up visits over 6 months. Patients and caregivers will both receive self-management education post discharge and as needed throughout the duration of the study.
224256393|NCT01602939|DRUG|Cladribine and pegylated interpheron alpha-2a|"Cladribine (0.07 mg/Kg/day) s.c for 5 consecutive days each month for a total of 6 months.Cladribine daily doses could be increased up to 0.14 mg/Kg in the fourth, fifth and sixth cycles of therapy if no objetive response is achieved after the third cycle.~Pegylated Interpheron alpha-2a (1 mcgr/Kg) s.c weekly for a total of 6 months."
224256394|NCT02266095|DEVICE|Oval-8 Splint|Splinting with Oval-8
224256395|NCT02266095|DEVICE|Tee Pee Splint|Splinting with Tee Pee
223674909|NCT02764424|DEVICE|NIPE (MDoloris®)|Each file consists of a simultaneous recording of an electrocardiogram signal according to usual practice (cardiac monitor PHILIPS), coupled with a concomitant registration of NIPE (Newborn Infant Parasympathetic Evaluation - MDoloris®). The electrocardiogram signal, respiration rate, oxygen saturation (SpO2) and NIPE are recorded simultaneously on a computer with a capture card. The other indices of Heart Rate Variability will be analyzed offline.
224256396|NCT02266095|DEVICE|Forearm Based Splint|Splinting with Forearm based
224256397|NCT03373643|DIAGNOSTIC_TEST|OSA screening|Full night polysomnography
224256398|NCT02263703|BIOLOGICAL|Quadrivalent HPV vaccine|Three 0.5 mL doses will be given at time 0, 2 months after the 1st dose and then 6 months after the initial dose. For kidney transplant recipients the first dose will be at least 6 months post-transplant.
224256399|NCT05367076|BEHAVIORAL|Web-based Aerobic Exercise Program|"Community based FTTs will use a web-based platform to deliver a 12-week exercise training program (120-minute group sessions of aerobic activity 3 times/week). Each session will include:~* Warm-up activities~* Aerobic activities and fitness training in a game-like fashion~* Organized sports/games~* Cool down activity~* Snack/reward time"
224256400|NCT01830335|DRUG|Indomethacin|
224322405|NCT05358509|DRUG|Iron isomaltoside|Pregnant participants randomized to intervention arm 1 will receive a single dose of iron isomaltoside having 1000mg of iron if they weigh over 50kg. If a participant is under 50kg, they will receive a lower dose as determined by a formula used by the manufacturer (20mg iron/kg body weight). This will be given ideally immediately after randomization, sometime between 14 weeks and 17 weeks of pregnancy.
223674910|NCT04883411|DEVICE|CEM-Plate Anterior Cervical Plating System and CEM-Cage Cervical Interbody System|Two-Level ACDF with CEM-Plate Anterior Cervical Plating System and CEM-Cage Cervical Interbody System
223674911|NCT01091727|DRUG|Botulinum toxin A|Comparison of intra-detrusor injection of 300U of Botulinum toxin A versus placebo for effect on neurogenic detrusor overactivity and urinary incontinence.
223674912|NCT02016547|PROCEDURE|abciximab IV and thrombectomy|
224256401|NCT01830335|DRUG|Placebo|
224256402|NCT04855279|OTHER|neutral sodium fluoride|Topically applied
224256403|NCT04855279|OTHER|ACP-CCP gel|Topically applied
224256404|NCT04855279|OTHER|nano-hydroxyapatite solution|Topically applied
224256405|NCT04855279|OTHER|glycerine|Topically applied
224256406|NCT02645500|BEHAVIORAL|Holistic health training and physical exercise messages|The physical activity message arm includes a training workshop in relation to holistic health, and daily physical activity messages.
224256407|NCT02645500|BEHAVIORAL|Holistic Health Training with healthy diet messages|The healthy diet message arm includes a training workshop in relation to holistic health, and daily healthy diet messages.
224256408|NCT03487081|BEHAVIORAL|Social regulation|Participants will be instructed to help another person think about their negative events differently using an emotion regulation strategy called reappraisal.
224256409|NCT03487081|BEHAVIORAL|Self regulation|Participants will be instructed to think about their negative events by reframing the meaning of the event. This is a typical strategy in emotion regulation research known as reappraisal.
223674913|NCT02016547|DRUG|alteplase 0.9mg/kg (10% by IV bolus following by 90% by 1 hour IV drip)|
223674914|NCT05060523|DRUG|Tolvaptan Tablets|• Tolvaptan15 mg once a day for 7 days, stat with 7.5 mg and titrate to 15 mg in 24 hours max30 mg
223674915|NCT05060523|DRUG|Midodrine Oral Tablet|"• Midodrine 5 mg at 0 hours and then 5 mg every 8 hours to maintain Target MAP-80"
223674916|NCT05060523|OTHER|Placebo|Placebo of Midodrine
223674917|NCT05939011|BEHAVIORAL|Well-formulated Ketogenic Diet|1:1 ketogenic diet that is focused on intake of high-quality fats (nuts/seeds, fatty fish, avocado) and reduction in processed food.
223674918|NCT02099669|OTHER|Red Blood Cell Transfusions|
223674919|NCT06354556|DRUG|HRS-1893 tablet|HRS-1893 tablet single dose
223674920|NCT06354556|DRUG|Verapamil tablet|Verapamil tablet 80 mg tid
224256410|NCT04618900|PROCEDURE|Sinus floor elevation with a grafting material|The use of grafting material for sinus floor elevation
224256411|NCT00835484|DRUG|Cefdinir Capsules 300 mg|1 x 300 mg, single-dose fasting
224256412|NCT00835484|DRUG|OMNICEF® 300 mg|1 x 300 mg, single-dose fasting
224256413|NCT01858493|BEHAVIORAL|Continence promotion group education workshop|Interactive group education workshop promoting continence
224256414|NCT01858493|BEHAVIORAL|Sham health lecture|Interactive group education workshop about general health
224256415|NCT03283358|BEHAVIORAL|Person-centered follow up|
224256416|NCT02243982|OTHER|[F18]-FDDNP|radiopharmaceutical tracer, intravenous, single dose, of 360+/- 20 megabecquerel
224256417|NCT01843179|DRUG|Cytarabine|Up to two cycles. Administered via IV infusion on Days 1-5 of each 28 day cycle
224256418|NCT01843179|DRUG|Sulindac|Taken orally twice per day at home for 12 months
223772671|NCT05110001|OTHER|Placebo|Study participants receive sham RB-PDT within 48 hours of randomization. Participants will receive a 30-minute loading dose of topical balanced salt solution which will be applied in 5-minute intervals to the de-epithelialized cornea. A pen light covered with a green filter will be used for 15 minutes. Repeat cornea culture will be collected 30 minutes after the sham procedure.
223772672|NCT04298710|BEHAVIORAL|Arm Cycling|20 minutes of arm cycling exercise at light to moderate intensity.
223772673|NCT04298710|BEHAVIORAL|Leg Cycling|20 minutes of leg cycling exercise at light to moderate intensity.
224256419|NCT03881943|DRUG|Ticagrelor 60 mg|Potent antiplatelet agent, 60mg twice daily for 3 months
224256420|NCT03881943|DRUG|Aspirin 100 MG Oral Tablet, Enteric Coated|antiplatelet agent, 100mg once daily for 3 months
223674921|NCT04864860|DIETARY_SUPPLEMENT|brown seaweed (ecklonia cava)|"The intervention product used in this study is a dietary supplement called Seanol that contain 13% pholoratannic polyphenol per capsule as stated by the manufacture company (Seanol inside, 4215 95th St SW Lakewood, WA 98499 USA). Other ingredients are dextrin, magnesium stearate and silica (in neglected percentage). The intervention supplement is encapsulated in vegetable cellulose that contains 500 Ecklonia cava extract (Seanol). The placebo will be dextrin (BETA CYCLODEXTRIN, NF) ordered from a pharmaceutical company MEDISCA (https://www.medisca.co.uk/). Dextrin was selected to account for the similar complex carbohydrate content of the intervention supplement. Placebo will be encapsulated in vegetable cellulose capsules that is identical in size and coulure to the intervention capsules. The empty capsules will be ordered from MEDISCA and will be encapsulated in by SPIMACO ADDWAIEH (SFDA registered pharmaceutical company) (http://www.spimaco.com.sa/)."
223674922|NCT04438070|DIAGNOSTIC_TEST|COVID-19 Swab|Nasal, Oral-Nasal combined or Nasopharyngeal swab
223674923|NCT04867031|DIETARY_SUPPLEMENT|Milk|One portion of semi-skimmed cow's milk (approx. 450mL), providing \~140µg of iodine.
223674924|NCT04867031|DIETARY_SUPPLEMENT|Fish|One portion of cod (approx. 130g), providing \~140µg of iodine.
223674925|NCT04867031|DIETARY_SUPPLEMENT|Seaweed|One portion of dried seaweed sheets (approx. 6g), providing \~140µg of iodine.
223674926|NCT04412993|OTHER|withdraw blood samples|withdraw blood sample from gorup O donors
223674927|NCT03325660|OTHER|whole body vibration|pelvic floor exercises
223674928|NCT00002779|DRUG|fludarabine phosphate|
223772674|NCT04298710|BEHAVIORAL|Sitting|Remain seated for 20 minutes.
223772675|NCT02550652|DRUG|Mycophenolate Mofetil/Mycophenolic Acid|MMF/MPA will be administered as per schedule specified in the respective arm.
224256421|NCT01312064|DRUG|rituximab and everolimus|rituximab (375mg/m2) induction and subsequently everolimus-based immunosuppressive therapy. Everolimus initial dose: 1 mg bid within 24 hrs after reperfusion, adjusted to a target trough blood level of 6-10 ng/ml for the first 6 months after transplantation.
224256422|NCT01312064|DRUG|thymoglobulin and tacrolimus|thymoglobulin induction and tacrolimus-based immunosuppressive therapy. thymoglobulin dose: 1.0mg/kg/d for 3 days daily dose of tacrolimus: 0.15 mg/kg/d given in two doses starting within 24 hours after transplantation
224256423|NCT03134664|PROCEDURE|Experimental group|Patients with femoral neck fractures are randomly assigned to undergo femoral head replacement via the SuperPATH approach in the experimental group.
224256424|NCT03134664|PROCEDURE|Control group|Patients with femoral neck fractures are randomly assigned to undergo femoral head replacement via the conventional posterior approach in the control group.
224256425|NCT03675633|DIAGNOSTIC_TEST|FEUrea|FEUrea in decompansated liver cirrhosis
224256426|NCT04793971|PROCEDURE|percutaneous paratenon release|percutaneous paratenon release for chronic midportion Achilles tendinopathy
224256427|NCT03721471|OTHER|Scoring of frailty|"1. Patients will be scored by the Clinical frailty Scale~2. Patients' hand-grip-strength will be measured by a dynamometer."
223674929|NCT00002779|DRUG|octreotide acetate|
223674930|NCT05148520|BEHAVIORAL|5A's model|"(1) Ask - ask youth smokers about their smoking habit, (2) Advise - advise youth smokers to quit smoking, (3) Assess - assess youth smokers about their willingness to quit smoking, (4) Assist - assist youth smokers who are willing to make a quit attempt, and (5) Arrange~\- arrange for follow-up."
223674931|NCT02531243|BEHAVIORAL|CALMS|Family Therapy; Multi-user Biofeedback Videogames
223674932|NCT01283243|DEVICE|Acoustic radiation force impulse imaging|Acoustic radiation force impulse (ARFI) imaging were measured 10 times in each patient.The region of interest was chosen in an area where the normal liver parenchyma was at least 6 cm thick and free of large blood vessels was chosen. A measurement depth of 2 cm below the liver capsule was chosen to standardize the examination.
223674933|NCT00910247|DRUG|Eslicarbazepine acetate|800 to 2400 mg once daily (QD)
223674934|NCT06295978|DIAGNOSTIC_TEST|Biochemical marker assays|DOSAGE BIOMARKERS
223674935|NCT01047969|DRUG|Adjuvant Chemotherapy|If after MRI + FDG-PET 8 weeks post CRT the patient shows no visible tumour or further regression adjuvant chemotherapy will be considered.
223674936|NCT01047969|PROCEDURE|Surgery|If after MRI + FDG-PET 8 weeks post CRF no further regression or growth of disease occurs the patient will be referred for surgery.
223674937|NCT00726141|BEHAVIORAL|Brief intervention, Motivational Interviewing, Expert System|Motivational Interviewing, stage-tailored self-help manual, physician letter, expert system feedback letter
223674938|NCT02927067|DRUG|Maribavir|Participants will receive 400 mg of maribavir BID orally.
223674939|NCT02927067|DRUG|Valganciclovir|Participants will receive valganciclovir tablets orally.
223674940|NCT02927067|OTHER|Placebo|Participants will receive placebo tablets matched to either maribavir or valganciclovir.
223674941|NCT01695668|DRUG|Lotemax|Ophthalmic corticosteroid. It decreases inflammation of the eye
223674942|NCT01695668|DRUG|Restasis|Restasis is an immunosuppressive agent. Cyclosporine may reduce inflammation in the eye.
223772676|NCT02550652|DRUG|Obinutuzumab|Obinutuzumab will be administered as per schedule specified in the respective arm.
223772677|NCT02550652|OTHER|Placebo|Placebo matching to obinutuzumab will be administered as per schedule specified in the respective arm.
223772678|NCT02550652|DRUG|Methylprednisolone|Methylprednisolone IV will be administered as per schedule specified in the respective arm.
223772679|NCT02550652|DRUG|Prednisone|Prednisone will be administered as per schedule specified in the respective arm.
223674943|NCT04552262|DRUG|BAY2327949|Single dose of 90 mg BAY2327949
223674944|NCT04552262|DRUG|Placebo|Single dose of placebo to BAY 2327949
224256428|NCT05069688|DRUG|rifampicin|Patients will receive standard TB and HIV treatment, however, for two weeks (study weeks 20-21) the dose of rifampicin will be increased from standard-dose to high-dose to assess pharmacokinetics and safety
224322406|NCT05358509|DRUG|Ferric Sulfate|Pregnant participants randomized to the oral iron arm will be given 200 ferrous sulphate tablets with 60mg elemental iron each, immediately after randomization, and instructed to take two per day (one in the morning and one at night) throughout the remainder of their pregnancy.
223674945|NCT04581447|DRUG|Metformin|Metformin will start at dose of 850 mg once daily and, at one month increased to 850 mg twice daily
223674946|NCT04581447|OTHER|Standard Care|Standard Care
223674947|NCT04581447|DIETARY_SUPPLEMENT|Standardized meal|Measurements of metformin-induced enterohormones secretion will be done after standardized meal test in a subgroup of patients (ancillary study)
223674948|NCT05154968|DRUG|Sodium chloride|Administered SC infusion.
223674949|NCT05154968|DRUG|Citrate buffer|Administered SC infusion.
223674950|NCT05154968|DRUG|Mannitol|Administered SC infusion.
223674951|NCT05154968|DEVICE|Prefilled Autoinjector|Used to administer the drug through SC infusion.
223674952|NCT02853630|DRUG|Metformin|Participant will be instructed to take Metformin tablets as per instructions given by the physician.
223674953|NCT02853630|DRUG|Vildagliptin|Participant will be instructed to take one tablet of Vildagliptin 50mg per day, 30 minutes after breakfast in the morning and second tablet at night, 30 minutes after dinner
223674954|NCT03540498|DIETARY_SUPPLEMENT|AB-DENTALAC [Probiotics (study)]|Treatment for 6 weeks, which will consist of the consumption of a chewing gum AB-DENTALAC with 100mg L.plantarum + L.brevis Probiotics blend (5E+8 CFU each at the end of shelf life), b.i.d (morning and evening).
223674955|NCT03540498|DIETARY_SUPPLEMENT|Placebo (control)|Treatment for 6 weeks, which will consist of the consumption of a chewing gum placebo, without probiotics strains, b.i.d (morning and evening).
223674956|NCT05834855|DRUG|Rituximab|Treatment with rituximab
223674957|NCT02677727|OTHER|EORTC QLQ-CIPN20|EORTC QLQ-CIPN20 is a 20-item chemotherapy-induced peripheral neuropathy-specific questionnaire which includes three scales assessing sensory (9 items: #31-36, 39, 40, 48), motor (8 items: #37, 38, 41-45, 49), and autonomic (3 items: #46, 47, 50) symptoms and functioning with each item measured on a 1-4 scale (1 - not at all; 4 - very much).
223674958|NCT03643614|PROCEDURE|Injection of autologous regenerative cells of adipose tissue|Autologous regenerative cells of adipose tissue obtained by enzymatic digestion of lipoaspirate are injected diffusively in the submucosal plane of the rectum and vagina with a sharp 27G needle. Adipose tissue that has not been subjected to enzymatic processing is injected through the punctures on the skin into the deep layers of the rectovaginal septum by means of cannula of 1.0-1.2 mm in diameter, 70 mm in length, 0.1-0.2 ml in one retrograde pass of the cannula.
223674959|NCT04146298|DRUG|Cyclophosphamide|Cyclophosphamide will be administered prior to cell infusion.
224256429|NCT03502811|DEVICE|MitraClip NTR/XTR System|Percutaneous mitral valve repair using the MitraClip NTR/XTR system.
224322407|NCT04228497|DEVICE|gastric ultrasound|Children in both groups will be scanned in two positions: supine position and right lateral position (RLP) one and two hours following the clear fluid intake and before admission to the operation room in groups 1 and 2 respectively. Gastric antrum will be located in the sagittal plane with simultaneous identification of left lobe of the liver and the descending abdominal aorta or inferior vena cava.
223674960|NCT04146298|DRUG|Fludarabine|Fludarabine will be administered prior to cell infusion.
223674961|NCT04146298|BIOLOGICAL|Mutant KRAS G12V-specific TCR transduced autologous T cells|After preconditioning regimen, T cells will be infused to the patient intravenously in the Patient Care Unit over approximately 30 to 50 minutes.
223674962|NCT04146298|DRUG|Anti-PD-1 monoclonal antibody|During the treatment, anti-PD-1 monoclonal antibody will be administered if needed.
223674963|NCT01593462|PROCEDURE|MRE (magnetic resonance enterography)|The MRE will take approximately 60 minutes to complete. Enrolled subject will have MRE imaging performed at about 4 weeks after treatment for small bowel crohn's disease begins, and when the treatment ends or changes or at 6 months, whichever comes first. The 4 week MRE will be for research purposes only, the treatment end,change or 6 month MRE may or may not be ordered by the treating physician as part of your routine care. If one is not ordered by the treating physician, the subject will have one performed because of the research study.
223674964|NCT01593462|PROCEDURE|The Ultrasound scan, (UEI) Ultrasound Elastography Imaging with ARFI (acoustic radiation force impulse)|The US UEI will take about 60 minutes to perform. This exam will be performed by 2 different radiologists and you will have this completed 5 times over the course of the study. This imaging will be performed with the subject drinking oral contrast material. The US, UEI will be completed at baseline, 2 weeks, 4 weeks, 3 months and at treatment end/change or 6 months, whichever comes first.
223674965|NCT01593462|BEHAVIORAL|Study Questionnaires|"The subject and their parent will be asked to answer questionnaires 2 weeks after the first MRE and US exams and again after the last imaging examinations are performed at treatment end/change or 6 months, whichever comes first.~A Pediatric Crohn Disease Activity Index Assessment will be performed at baseline, 2 weeks, 4 weeks, 3 months, and at treatment end/change or 6 months, whichever comes first. The study questionnaires should take no longer than 10 to 40 minutes to complete."
223674966|NCT01921088|OTHER|real-time functional magnetic resonance imaging neurofeedback (RT-fMRI-NF)|Subjects are provided with RT-fMRI-NF.
223674967|NCT01921088|BEHAVIORAL|Ambulatory Training|Subjects are provided with an ambulatory training.
223674968|NCT01727700|DRUG|Aripiprazole|Once-daily, tablet
223674969|NCT01727700|DRUG|Placebo|
223674970|NCT00320723|DRUG|bupropion, transdermal nicotine patch|
223674971|NCT01780532|PROCEDURE|Photoacoustic Imaging (PAI)|Standard of Care
223674972|NCT01631656|DRUG|Azelaic acid|15% gel on half the face, twice daily, 6 weeks
223674973|NCT01631656|DEVICE|Nd:Yag laser|Treatment with Nd:Yag laser , once at Week 2.
223674974|NCT04551391|OTHER|Blood and urine sampling|Retinal OCT is a novel, non-invasive method for cross-sectionally imaging the eye's retina and choroid
224256430|NCT06331715|DRUG|Palbociclib 125mg|Pharmacokinetic parameters AUC and Cmax will be evaluated to establish bioequivalence betweeen the Test and Reference products
224256431|NCT05144451|DIAGNOSTIC_TEST|Transcranial Doppler|"Transcranial Doppler-derived parameters; pulsatility index (PI), resistance index (RI), mean flow velocity (Vmean) will be recorded before induction of anesthesia (T1).~After induction, TCD parameters, Hemodynamic variables including heart rate (HR), invasive mean arterial blood pressure (MAP), and central venous pressure (CVP) together with Arterial blood gases (ABG analysis with values of PH, PCO2, PO2, blood oxygen saturation SO2 and bicarbonate HCO3), end-tidal carbon dioxide (ETCO2) and body temperature will be recorded too. Just before skin incision (T2), at the end of anhepatic phase 5 minutes before reperfusion (T3), 5 minutes after reperfusion (T4) and at the end of surgery (T5).~Postoperatively at ICU, TCD parameters, Hemodynamic variables, and ABG will be obtained 24 hours postoperative (T6) and at discharge from ICU (T7)."
224256432|NCT04001062|PROCEDURE|Surgical Fixation|For both scissoring and non-scissoring injuries surgical fixation by either pinning, dorsal plate, or lag screws will be considered. This will be determined by surgeon expertise at the time of surgical fixation. Postoperative, a volar short arm splint and immediate AROM at full range with buddy taping to adjacent digit will be indicated. Transition to removable short arm splint at week 2 after suture removal. No strengthening until clinical union.
224256433|NCT04001062|OTHER|Non-Operative Management|"1. For non-scissoring injuries: Placement of short-arm cast; immediate AROM with buddy taping to adjacent digit. Focus on achieving pulp-to palm distance of \<2cm at first visit. Transition to removable short arm splint at week 2 (discontinue at 6 weeks or when non-tender). Strengthening after clinical union.~2. For scissoring injuries: Closed reduction in clinic/ER and placement of short-arm cast; immediate full range AROM with buddy taping to adjacent digit. Focus on achieving pulp-to palm distance of \<2cm at first visit. Transition to removable short arm splint at week 2 (discontinue at 6 weeks or when non-tender). Strengthening after clinical union"
224256434|NCT01735994|BEHAVIORAL|Healthy Weight|Eating Disorder Prevention Program for Athletes
224256435|NCT01735994|OTHER|Brochure|Brochure on the Female athlete triad
224256436|NCT04511039|DRUG|Trifluridine and Tipiracil Hydrochloride|Given PO
224256437|NCT04511039|DRUG|Talazoparib Tosylate|Given PO
224256438|NCT03166267|DEVICE|External fixator|Tibia fracture (AO 41-43) treated with external fracture fixation (large external fixator)
224256439|NCT00736658|DRUG|AZD1386|Oral admin. of doses at 11 days through a 12 days period.
224256440|NCT00736658|DRUG|Placebo|Oral admin. of doses at 11 days through a 12 days period.
224256441|NCT00470691|PROCEDURE|plaster cast|complete circular plaster cast
224256442|NCT00470691|PROCEDURE|dorsal splint|dorsal plaster splint
224322408|NCT04228497|OTHER|the clear fluid intake|the clear fluid intake
224322409|NCT02106897|DRUG|BIIB059 (litifilimab)|See Arm Descriptions
224322410|NCT02106897|DRUG|Placebo|See Arm Descriptions
223674975|NCT00212940|BEHAVIORAL|Supportive Therapy for Adherence to ART (behavior)|
223674976|NCT02404532|DEVICE|MIND1 System|Following placement of the Patch by clinic staff, subjects will ingest one placebo-embedded IEM tablet approximately every other hour, for a total of 4 ingestions. Subjects may eat as they wish over the course of the day. Placebo-embedded IEM tablets are being tested to measure the accuracy of IEM detection by the MIND1 system. Clinic staff will record the time of each ingestion of an IEM. Clinic staff will check the compatible computing device (eg, smartphone) at 30-minute intervals for the presence of a timeline ingestion tile and will record the time it is detected by the MIND1 System compatible computing device (eg, smartphone).
223674977|NCT03923478|DRUG|ABI-M201|Active Treatment
223674978|NCT03923478|DRUG|Placebo|Control Treatment
223674979|NCT01757691|DRUG|Fingolimod 0.5mg/daily|
223674980|NCT01757691|DRUG|Placebo|
223674981|NCT04518202|DRUG|lidocaine patch|5% lidocaine patch applied at 6 hours before the scheduled office hysteroscopy.
223674982|NCT04518202|DRUG|Sham patch|Sham patch containing no study medication applied at 6 hours before the scheduled office hysteroscopy.
223674983|NCT01706679|DRUG|ATX-101 (10 mg/ml)|
223674984|NCT01706679|DRUG|ATX-101 (20 mg/ml)|
224256443|NCT00385320|BIOLOGICAL|HRV vaccine|
224256444|NCT01354886|DRUG|FSH-GEX™|single dose
224256445|NCT01354886|DRUG|Gonal-f|150 IU single dose
224256446|NCT01354886|DRUG|Bravelle|150 IU single dose
224256447|NCT01354886|DRUG|Placebo|single dose
224256448|NCT05653934|BEHAVIORAL|Pre-operative use of virtual reality headset|Patient use the virtual reality headset the day before and / or the day of the surgery
224256449|NCT05653934|PROCEDURE|Standard surgery|Patient are operated as needed for treatment of colorectal cancer (usual care)
224322411|NCT00489827|DRUG|Intravenous infusion of saline|Intravenous infusion of isotonic saline at a rate of 1.65 ml/hour and kg body weight beginning with institution of anesthesia and stopping 2 hours after unclamping of aorta in patients operated for unstable coronary artery disease.
223674985|NCT01706679|DRUG|Moxifloxacin (400 mg)|
223674986|NCT01706679|DRUG|Placebo vehicle (PBS)|
223674987|NCT03603366|DRUG|Acetylsalicylic acid (Aspirin, BAYE4465)|This study does not involve prescription of the drugs. This study is a cross-sectional survey of patients taking low-dose aspirin or patients who are eligible but not taking low-dose aspirin.
223674988|NCT02484859|DRUG|Remifentanil|Remifentanil infusion will be started with a bolus dose of 0.5 µg/kg before the induction, and will be continued throughout the surgery at a dose of 0.25-0.5 µg/kg/min. At the end of the surgery, the rate of infusion will be decreased to 0.05 µg/kg/min, and continued until the patient is extubated.
223674989|NCT02484859|DRUG|Tramadol|1 mg/kg tramadol will be added to 100 ml of isotonic fluid, and will be administered intravenously in exactly 30 minutes via a perfusor. The infusion will be started just before the induction.
223674990|NCT02484859|DRUG|Metoprolol|0.1 mg/kg of metoprolol will be administered intravenously within 5 minutes following the administration of neuromuscular blocking agent.
223674991|NCT04144218|DRUG|Lacosamide|The experimental group will be given oral lacosamide supplementation on the basis of the original antiepileptic drugs.
223674992|NCT04144218|DRUG|Placebo oral tablet|The control group will be given oral placebo supplementation on the basis of the original antiepileptic drugs.
223674993|NCT02054481|DRUG|BI 655066|Medium dose
223674994|NCT02054481|DRUG|BI 655066|High dose
223674995|NCT02054481|DRUG|Ustekinumab|
223674996|NCT02054481|DRUG|BI 655066|Low dose
223674997|NCT01273376|DRUG|RX-10100|Extended-release tablet, taken twice daily for 8 weeks
223674998|NCT05598827|OTHER|Tik Tok|The enrolled patients were encouraged to watch Tik Tok without limit starting 24 days before chemotherapy and continuing until the seventh day after chemotherapy.
223674999|NCT05323565|DRUG|Dexmedetomidine|adjuvants to 0.25 bupivacaine in TAB block.
223675000|NCT04356365|OTHER|Cross-sectional study investigating the association of NPIs with mental health|Cross-sectional study investigating the association of NPIs with mental health
223675001|NCT02933580|DRUG|JNJ-56136379|Participants will receive a single oral dose (tablets) of JNJ-56136379 on Day 1.
223675002|NCT02933580|OTHER|Placebo|Participants will receive matching placebo tablets on Day 1.
223675003|NCT00731432|DRUG|Transmucosal Herbal Periodontal Patch (THPP)|Patch applied to oral gingiva
223675004|NCT00731432|DRUG|Placebo Patch|Identical in shape and texture to treatment patch
223675005|NCT05906238|BEHAVIORAL|STEREOBES Workshops|These workshops are designed to help patients develop appropriate behaviors to deal with stigmatizing situations. They will focus on three main areas: adapted physical activities, nutrition and mental well-being. They will include sessions on developing self-esteem, improving body image and managing emotions. The aim will be to deconstruct the myths and stereotypes surrounding obesity.
223675006|NCT05906238|BEHAVIORAL|Un Poids en moins|"Standard intervention proposed by La Vie la Santé"
223675007|NCT05930704|DRUG|SHR-2017 injection|Randomized participants of multiple dose cohorts will receive a single subcutaneous dose of SHR-2017 injection.
223675008|NCT05930704|DRUG|Placebo|Randomized participants will receive a single SC injection dose of matching placebo.
223675009|NCT04213573|DRUG|silver diamine fluoride|38% silver diamine fluoride liquid will be applied with a brush
223675010|NCT04213573|DRUG|MI Varnish|topical fluoride varnish with calcium and phosphate
223675011|NCT00882973|DRUG|Genexol-PM|Cremophor EL-free polymeric micelle of paclitaxel
223675012|NCT00349427|DRUG|Rosiglitazone 4 mg|
223675013|NCT03351985|DEVICE|quantitative electroencephalogram (qEEG)|the patients receive the quantitative electroencephalogram (qEEG) monitoring within 1 hour when they admitted to ICU
223675014|NCT01612728|OTHER|Women without Arthralgia|For mild arthralgia, women will try the following interventions in the following order: 1) Weight-bearing exercise program, and 2) Glucosamine \& Chondroitin supplements. For women with mild to moderate arthralgia, they will try to the following interventions in this order: 1) Acupuncture, 2) Indomethacin twice daily as needed, 3) Switch to a different aromatase inhibitor, and 4) Switch to tamoxifen.
223675015|NCT01612728|DRUG|Women with Arthralgia|
223675016|NCT03911310|DIAGNOSTIC_TEST|[18F]PSMA-11|\[18F\]PSMA-11 PET/CT
223675017|NCT03911310|DIAGNOSTIC_TEST|[68Ga]PSMA-11|\[68Ga\]PSMA-11 PET/CT
223675018|NCT02320903|DEVICE|VillageWhere App|
223675019|NCT00844168|DRUG|sorafenib tosylate|Given orally
223675020|NCT00844168|OTHER|laboratory biomarker analysis|Correlative studies
223675021|NCT03074942|DRUG|Reslizumab|Reslizumab 3 mg/kg once / every 4 weeks during 24 weeks
223675022|NCT06087003|DRUG|Basiliximab Injection|As an induction treatment for kidney transplantation
223675023|NCT06087003|DRUG|rabbit ATG|As an induction treatment for kidney transplantation
223675024|NCT06309615|OTHER|Standard of Care|To use the patients age, tumor size, grade, and lymph node status and any genomic tests (i.e. OncotypeDx, MammaPrint etc to determine risk of recurrence,
223675025|NCT03548090|OTHER|Skateboard exercise at an incline angle of 0 degrees and 50% body weight|Participants will stand on a specified incline angle (0 degrees) and with a specified body weight (50%) on the paretic LE and will simultaneously move a small skateboard forward with the non-paretic LE.
223675026|NCT03548090|OTHER|Skateboard exercise at an incline angle of 5 degrees and 50% body weight|Participants will stand on a specified incline angle (5 degrees) and with a specified body weight (50%) on the paretic LE and will simultaneously move a small skateboard forward with the non-paretic LE.
223675027|NCT03548090|OTHER|Skateboard exercise at an incline angle determined to be optimal in phase 1 (either 0 or 5 degrees) and 75% body weight|Participants will stand on a specified incline angle (either 0 or 5 degrees, whichever is determined during phase 1 to be optimal) and with a specified body weight (75%) on the paretic LE and will simultaneously move a small skateboard forward with the non-paretic LE.
223675028|NCT03548090|OTHER|Skateboard exercise at an incline angle determined to be optimal in phase 1 (either 0 or 5 degrees) and 90% body weight|Participants will stand on a specified incline angle (either 0 or 5 degrees, whichever is determined during phase 1 to be optimal) and with a specified body weight (90%) on the paretic LE and will simultaneously move a small skateboard forward with the non-paretic LE.
223675029|NCT03548090|OTHER|Control 4-week exercise intervention|This intervention occurs in phase 3. Subjects will participate in 1-hour sessions three times per week for four weeks. The control group will perform three sets of ten repetitions of the following 4 exercises, for a total of 120 repetitions: 1) standing hip abduction against green theraband resistance with upper extremity support, 2) sit to stands from chair with no upper extremity support, 3) bilateral calf raises with upper extremity support, and 4) right and left weight shifting exercises using a wobble board with upper extremity support available if needed.
223675030|NCT03548090|OTHER|Experimental 4-week exercise intervention|This intervention occurs in phase 3. Subjects will participate in 1-hour sessions three times per week for four weeks. The experimental group will perform the skateboard exercise with the optimal parameters established during studies 1 and 2 (that is, an incline angle of either 0 or 5 degrees and a body weight percentage of 50%, 75%, or 90%)--the forward and backward speed of the skateboard will be cued with a metronome that will set at a beats per minute that matches the foot strike cadence of someone walking at 0.7 m/s, and the magnitude of forward excursion of the skateboard will be individualized to the participant based on GAITRite® data (that is, step length of the non-paretic LE).
224256450|NCT05653934|BEHAVIORAL|Post-operative use of virtual reality headset|Patient use the virtual reality headset as many time as they want after the surgery during a maximum of 30 days
224256451|NCT02333123|DRUG|Aspirin|Each 300mg aspirin capsule will contain over-encapsulated 4 x Aspirin 75mg tablets.
224256452|NCT02333123|DRUG|Placebo (for Aspirin)|Each placebo capsule will contain a lactose and magnesium stearate blend, and will appear identical in weight, colour and size to the matched aspirin capsules.
224256453|NCT05726838|OTHER|Inclisiran|There is no treatment allocation. Patients administered inclisiran by prescription will be enrolled. The patients will receive inclisiran therapy as per the approved label and Belgian reimbursement conditions.
224256454|NCT03261323|PROCEDURE|Immediate Breast Reconstruction|Only implant based surgeries will be considered in this study. The patient will be followed for at least 1 year after the last reconstruction surgery. Reconstruction will be attempted immediately after mastectomy.
223675031|NCT03548090|OTHER|Over-ground multi-directional gait training|In the over-ground multi-directional gait protocol, the participant will walk 750 steps forward, 50 steps backward, and 200 side steps over level surfaces. The over ground gait training will focus on equalizing step length while performing multi-directional gait training.
223675032|NCT03548090|OTHER|Home exercise|Home exercise consists of three sets of ten repetitions of the following three exercises to be performed on non-therapy days over the four weeks of phase 3: 1) sit to stands from chair with no upper extremity support, 2) bilateral calf raises with hand support, and 3) resisted side stepping to the non-paretic side using a green theraband with upper extremity support.
223675033|NCT00851760|PROCEDURE|Consecutive surgery|Consecutive surgery for epiretinal macular membrane and cataract extraction
223675034|NCT00851760|PROCEDURE|Combined surgery|Combined surgery for epiretinal macular membrane and cataract extraction
223675035|NCT03386253|DEVICE|active tDCS|two 13 minute tDCS sessions separated by 20 minutes in between
223675036|NCT03386253|DEVICE|sham tDCS|sham tDCS session given for same length of time as active
223675037|NCT00008554|DRUG|Abacavir sulfate|
223675038|NCT00008554|DRUG|Nelfinavir mesylate|
224256455|NCT03261323|PROCEDURE|Delayed Breast Reconstruction|Risk reduction strategies on smoking, weight, and chronic disease control will be offered. The individual risk will be recalculated every three months. Delayed breast reconstruction will be offered when core cancer therapies (mastectomy, chemotherapy and radiation) are complete. Only implant based surgeries will be considered in this study. The patient will be followed for at least 1 year after the last reconstruction surgery.
224322412|NCT00489827|OTHER|Intravenous glutamate infusion|Intravenous infusion of 0.125 M glutamic acid solution at a rate of 1.65 ml/hour and kg body weight beginning with institution of anesthesia and stopping 2 hours after unclamping of aorta in patients operated for unstable coronary artery disease.
224322413|NCT01689727|DRUG|Technetium Tc 99m EC20|
224322414|NCT01977274|OTHER|gynecological cancer|blood and tumor samples
224322415|NCT02132793|BEHAVIORAL|Anger Management Therapy|Anger Management Therapy (AMT) is a 12-session manual-driven cognitive-behavioral intervention found efficacious for anger management treatment.
223675039|NCT00008554|DRUG|Lamivudine|
223675040|NCT00008554|DRUG|GW433908|
223675041|NCT02783846|OTHER|normal saline|receive equal volume of normal saline
223675042|NCT02783846|DRUG|dexmedetomidine 0.5 µg/kg|receive dexmedetomidine 0.5 µg/kg
223675043|NCT02783846|DRUG|dexmedetomidine 1.0 µg/kg|receive dexmedetomidine 1.0 µg/kg
223675044|NCT00637871|DRUG|Casodex|150mg once daily
223675045|NCT00637871|DRUG|Tamoxifen|
223675046|NCT04247685|DEVICE|12-lead ECG monitoring device (MiRTLE Medical)|12-lead ECG monitoring device produced by a Massachusetts-based medical device company MiRTLE Medical is the experimental device;
223675047|NCT04247685|DEVICE|3-lead ECG gating system|3-lead ECG gating system is the placebo/standard of care
223675048|NCT04236388|DIETARY_SUPPLEMENT|Ketone drink|Pre- and post-testing will be completed before and after participants receive 42 doses of ketone supplement drink over a 2-week period (3x/day for 14 days).
223675049|NCT04236388|DIETARY_SUPPLEMENT|Placebo drink|Pre- and post-testing will be completed before and after participants receive 42 doses of placebo supplement drink over a 2-week period (3x/day for 14 days).
223675050|NCT02605044|DRUG|Masitinib (AB1010)|
223675051|NCT02605044|DRUG|FOLFIRI|
223675052|NCT00036374|DRUG|Infliximab|
223675053|NCT00991068|DRUG|Synera (lidocaine 70 mg and tetracaine 70 mg) topical patch|Patients will apply a single Synera patch to the target wrist for 2 hours twice a day (ie, morning and evening applications) for 14 days.
223675054|NCT00790257|DEVICE|"Encapsulated human islets in a Monolayer Cellular Device"|"The product consists of isolated allogeneic human islets of Langerhans formulated in a serum-free transplant media. The islets will be encapsulated in an alginate-based Monolayer Cellular Device.~One device will be transplanted subcutaneously and corresponds to a patch of 1-3cm². One Device per patient. No Retransplantation."
223675055|NCT04350346|DRUG|Motilitone|"1. Ingredients and content: corydalis tuber, pharbitis seed 50% EtOH extracts 30mg~2. Dosage method: Usually, adults take 1 tablet 3 times a day orally before meals.~3. Pharmacological action:~   * It stimulates 5-HT4 receptor as a gastrointestinal motility accelerator to increase acetylcholine secretion and contract smooth muscle.~     * Stimulates stomach smooth muscle contraction by suppressing the effect of dopamine on acetylcholine secretion by inhibiting D2 receptor ③ It shows a pharmacological action that stimulates gastrointestinal movement by acting in combination with 5-HT1A / B receptor."
223675056|NCT04350346|DRUG|Gasmotin|"1. Ingredient and content: mosapride citrate dihydrate 5.29mg (5mg as active ingredient)~2. Dosage method: Usually, an adult is orally administered 1 tablet 3 times a day before meals.~3. Pharmacological action: mosapride is a selective serotonin-4 (5-HT4) receptor agonist with gastrointestinal stimulating activity, contracting smooth muscle"
223675057|NCT04115930|DEVICE|Physical Activity measurement:|7 days measurement with Active style Pro HJA-350IT device
223675058|NCT01094912|DRUG|opioids|
223675059|NCT05527327|DEVICE|traxi® Panniculus Retractor|This is an adhesive medical device designed to retract a pannus during cesarean section. It will be applied to prospective participants according to manufacturer instructions, just prior to the detailed anatomic ultrasound.
223675060|NCT05465473|OTHER|Distalization|Group I: will include 10 patients undergo distalization according to a standardized protocol. Group II: will include 10 patients undergo distalization assisted with low level laser therapy according to a standardized protocol.
223675061|NCT05521880|DRUG|Oritavancin|Sequential therapy with weekly doses of oritavancin 1200 mg in stable, discharge appropriate patients with opioid use related invasive infections collocated in setting of treatment for opioid use disorder
223675062|NCT03140696|DIETARY_SUPPLEMENT|Egg Alone|A chicken egg will be offered for 2 days
223675063|NCT03140696|DIETARY_SUPPLEMENT|Egg and ready to use supplementary food (RUSF)|A chicken egg and ready to use supplementary food (RUSF) will be offered for 2 days
223675064|NCT03140696|DIETARY_SUPPLEMENT|Egg and breast milk|A chicken egg and breast milk will be offered for 2 days
223675065|NCT04599153|OTHER|Ventriculoperitoneal shunt opening pressure setting|The ventriculoperitoneal shunt (Strata®) opening pressure can be changed using a magnetic tool. The possible settings are 0.5, 1.0, 1.5, 2.0, 2.5 with a higher setting number corresponding to a higher opening pressure and less drainage through the shunt. All settings are used in routine clinical practice.
223675066|NCT05344703|DEVICE|Y Balance Plus Visual Perturbations|Stroboscopic glasses will be added to the protocol for the participants to perform the Y-balance lower quarter to examine the differences in Y-balance scores as well as examining the Y-balance's ability to predict injury and concussion with visual perturbations.
223675067|NCT05344703|DIAGNOSTIC_TEST|Y balance|Subjects will perform Y-balance without any interventional strategies.
223675068|NCT03684239|BEHAVIORAL|G-CBT|CBT is based on the model that there is a interaction between cognition, emotion and behavior. The way people think affects the way they feel and the behavior they do. And then the feelings in turn affect how they think,So it is valid for AN patient.
223675069|NCT03684239|OTHER|Conventional treatment|Conventional treatment including nutritional advice, encouragement, and routine treatment by a psychiatrist with work experience with eating disorders.
223675070|NCT02316275|OTHER|No post-operative activity restrictions|Patients are to resume regular activity immediately after mid-urethral sling surgery. The investigators will determine the impact of unrestricted post-operative activity on continence outcomes of mid-urethral sling surgery in women with stress urinary incontinence (SUI). Investigators will measure the effect of unrestricted post-operative activity on early health-related quality of life (HRQOL). A Productivity Loss form for cost-effective analysis will be asked of the patient.
223675071|NCT02316275|OTHER|Standard post-operative activity restriction|
223772680|NCT04466163|BEHAVIORAL|Schema Therapy and the Healthy Adult|The protocol 'Schematherapy and the Healthy Adult' (ST-HA, Broersen \& Claassen, 2019) is a direct intervention meant to strengthen patients' healthy adult functioning by developing compassion and care for well-being in the face of (childhood) adversity.
224256456|NCT03261323|OTHER|Breast-Q questionnaire|Developed out of Memorial Sloan-Kettering Institute for Cancer Research, this questionnaire is designed to create a patient-reported outcome measure to provide quantifiable information about the impact and effectiveness of breast surgery. In this study it will be used for quality of life assessment
224256457|NCT04827368|OTHER|Breath Test|Research Breath sample through disposable mouth filter. Serum sample through routine blood draw. Stool sample through standard collection containers.
224256458|NCT04030429|DRUG|Crizotinib 250 MG|bid orally
224256459|NCT04111965|DRUG|Nanodrop®|minimum to meet 1 drop 4 times a day, both eyes
224256460|NCT04111965|DRUG|Systane Balance|minimum to meet 1 drop 4 times a day, both eyes
223675072|NCT00852332|DIETARY_SUPPLEMENT|Curcumin|
223675073|NCT00852332|DRUG|Taxotere|
223675074|NCT03196700|RADIATION|Short course radiotherapy|An accelerated hypo-fractionation radiotherapy is delivered for palliation in patients with metastatic or locally advanced head and neck cancer.
223675075|NCT06319612|BEHAVIORAL|routine rehabilitation treatment|All participants were given routine rehabilitation treatment by professional rehabilitation therapists, including exercise therapy, guided education, psychological therapy, acupuncture and massage therapy
224256461|NCT06002230|DRUG|Homeopathic medicines|Globules were administered orally..
224256462|NCT01645995|DIETARY_SUPPLEMENT|Reformulated products|Subjects were asked to supplement their habitual diet with reformulated sugar-reduced products for 8 weeks. Subjects were provided with reformulated beverages, sauces, condiments and snacks. They were asked to consume a minimum of 1 drink + 1 food portion intervention supplement daily, in exchange for habitually eaten equivalent foods.
224256463|NCT01645995|DIETARY_SUPPLEMENT|Conventional products|Subjects were asked to supplement their habitual diet with conventional sugar products for 8 weeks. Subjects were provided with conventional beverages, sauces, condiments and snacks. They were asked to consume a minimum of 1 drink + 1 food portion intervention supplement daily, in exchange for habitually eaten equivalent foods.
224256464|NCT00905840|DEVICE|Titanium Zircon implant|"The implant surgery is performed under local anesthesia following standard surgical techniques. The surgeon will be supported by one or two assistants.~The bone will be excavated and prepared for the placement of the implant. After the implant was placed by using a hand ratched or motor drive device, a healing abutment will be inserted to ensure a transmucosal healing."
224256465|NCT00905840|DEVICE|Titanium Grade IV implant|"The implant surgery is performed under local anesthesia following standard surgical techniques. The surgeon will be supported by one or two assistants.~The bone will be excavated and prepared for the placement of the implant. After the implant was placed by using a hand ratched or motor drive device, a healing abutment will be inserted to ensure a transmucosal healing."
224256466|NCT03496623|DRUG|Inhaled treprostinil solution|Treprostinil inhalation solution
224256467|NCT03496623|DRUG|Placebo solution|Placebo solution
223772681|NCT04298528|DRUG|Dronabinol|2.5mg 2 times a day for 30 days after total knee replacement
223772682|NCT04298528|OTHER|Placebo|2 times a day for 30 days after total knee replacement
223772683|NCT04630522|DRUG|Drug: JMT103- 120 mg SC Q4W|JMT103 is administered subcutaneously at a dose of 120 mg on day 1 of each 4-week cycle.
224256468|NCT01334333|DRUG|Tacrolimus - Prograf® twice daily formulation|twice daily, dosage will be as determined by best treatment for each participant, duration of study period will be 4 months for each participant
224256469|NCT01334333|DRUG|Tacrolimus - Advagraf® once daily formulation|once daily, dosage will be as determined by best treatment for each participant, duration of study period will be 4 months for each participant
223675076|NCT06319612|PROCEDURE|Stellate ganglion block|The percutaneous approach via the paratracheal route was used for Stellate ganglion block . The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
223675077|NCT06319612|DRUG|Lidocaine Hydrochloride|The patients were provided with Stellate ganglion block , using 0.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). once a day, 10 days totally.
223675078|NCT06319612|PROCEDURE|Placebo injection|Normal saline is used. The percutaneous approach via the paratracheal route was used for Stellate ganglion block . The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
223675079|NCT00923988|OTHER|secondhand smoke exposure|Participants will be exposed to secondhand smoke for one hour. As a measure of secondhand smoke exposition, room carbon monoxide concentration will be continuously measured using an Ambient Carbon Monoxide Monitor APMA-360 and kept constant between 4.5-6.0 ppm. Levels in this magnitude are typically seen in smoking areas of restaurants and bars.
223675080|NCT03914846|PROCEDURE|Ultrasound|Undergo ultrasound with elastography
223675081|NCT00178503|DRUG|Methylphenidate-extended release|Methylphenidate-extended release was taken in the morning of the MPH treatment trial. Each participant underwent 1 week of the each of the doses as determined by body weight. The lower body weight group (20 to 24 kg/44 to 52.8 lbs) took 10 mg Ritalin LA to 20 mg. The medium body weight group (25 to 33 kg/55 to 72.6 lbs) took from 10 mg Ritalin LA to 30 mg. The higher body weight group (34 to 59 kg/74.8 to 129.8 lbs) took 20 mg Ritalin LA to 40 mg.
223675082|NCT00178503|DRUG|Methylphenidate-immediate release|Methylphenidate-immediate release was taken in the late afternoon. Each participant underwent 1 week at each of the 3 dose levels as determined by body weight. The lower body weight group (20 to 24 kg/44 to 52.8 lbs) took 2.5 mg IR-MPH and 2 weeks of 5 mg. The medium body weight group (25 to 33 kg/55 to 72.6 lbs) took 2 weeks of 5 mg IR-MPH and 1 week of 10 mg. The higher body weight group (34 to 59 kg/74.8 to 129.8 lbs) took 1 week of 5 mg IR-MPH and 2 weeks of 10 mg.
223675083|NCT00178503|OTHER|Placebo|Participants will take a placebo for 1 full week of the randomized drug trial. They will take one capsule in the morning and one capsule in the afternoon.
223675084|NCT02185742|BEHAVIORAL|Strength Based Case Management|
223675085|NCT03584529|DRUG|Vitamin D 3|Non-Vitamin D3 Drops group Patients in this group would take nothing.
223675086|NCT01095094|DRUG|ritonavir|Given orally
223675087|NCT01095094|DRUG|lopinavir|Given orally
223675088|NCT04569071|DEVICE|Sinovation Laser Ablation System|In the present single arm study. All eligible subjects will undergo MgLiTT with the Sinovation Laser Ablation System.
223675089|NCT03860558|OTHER|Lifestyle Intervention|Participants will undergo a 12-week multidisciplinary program for weight control and intensive diabetes management. The program includes adjustments to diabetes medications to enhance weight reduction and improve glycemia, dietary modification, and activity instructions.
223675090|NCT03860558|OTHER|No Intervention|Participants will not undergo an intervention.
223675091|NCT05124301|BEHAVIORAL|Perceptual learning|Reaching task with visual feedback offset from target finger position.
223675092|NCT05124301|BEHAVIORAL|Control|Reaching task with unmanipulated feedback.
223772684|NCT04630522|DRUG|Drug: JMT103- 120 mg SC Q8W|JMT103 is administered subcutaneously at a dose of 120 mg on day 1 of each 8-week cycle.
223772685|NCT04630522|DRUG|Drug: JMT103- 180 mg SC Q8W|JMT103 is administered subcutaneously at a dose of 180 mg on day 1 of each 8-week cycle.
223772686|NCT04630522|DIETARY_SUPPLEMENT|Dietary Supplement: Calcium Dietary Supplement: Vitamin D|Calcium is given orally at a dose of 500 mg at least, once daily. Vitamin D is given orally at a dose of 400 IU at least, once daily.
223772687|NCT05801627|DRUG|SAL067|SAL067 6mg(2 tablet) and Metformin ≥1500mg
224256470|NCT04375384|DRUG|Cetuximab|"A loading dose of Cetuximab will be administered intravenously in the first day of treatment. The dose is 400 mg/m2 and will be infused over 2h followed by 1h observation.~The maintenance dose of Cetuximab is 250 mg/m2 and will be infused over 1h. No further observation time needed.~The maintenance dose of cetuximab will be given every 7 days (+/- 2 days) starting 7 days (+/- 2 days) after the loading dose of cetuximab.~Pre-medicate with 50 mg Diphenhydramine IV before the loading dose of Cetuximab and as per standard of care before the maintenance treatment."
223675093|NCT05347147|DRUG|Presendin|Presendin is supplied as 2 parts, one vial consisting of a drug part (white or greyish white powder in a clear vial) and one pre-filled syringe containing the diluent part (colourless liquid). The drug part is suspended in the diluent part solution and administered SC as a suspension.
223772688|NCT05801627|DRUG|Placebo|Placebo (2 tablet) and Metformin ≥1500mg
223772689|NCT05327790|DRUG|Lyophilized fecal microbiota (LFMT)|vedolizumab or ustekinumab + FMT vs placebo
223772690|NCT05327790|OTHER|Placebo|Placebo
223772691|NCT01706250|OTHER|MAXCLARITY II (2.5% BPO) Foam Cleanser|Available over the counter.
223772692|NCT01706250|OTHER|MAXCLARITY II (2.5% BPO) Foam Treatment|Available over the counter.
223772693|NCT01706250|OTHER|MAXCLARITY II (0.5% Salicylic Acid) Toner Foam|Available over the counter.
223772694|NCT01706250|OTHER|PROACTIV (2.5% BPO) Renewing Cleanser|Available over the counter.
223772695|NCT01706250|OTHER|PROACTIV (2.5% BPO) Repairing Lotion|Available over the counter.
223772696|NCT01706250|OTHER|PROACTIV (2.5% BPO) Revitalizing Toner|Available over the counter.
223772697|NCT05016102|OTHER|Exercise type|Aerobic exercise and Resistance exercise
223772698|NCT02486406|DRUG|Ombitasvir/paritaprevir/ritonavir|Film-coated tablet for oral use
224256471|NCT04375384|OTHER|Questionnaire administration|Ancillary studies
224256472|NCT04375384|OTHER|Quality of life assessment|Ancillary studies
224256473|NCT04552418|DRUG|Potato starch|Starting 5-7 days before treatment with dual-ICI, participant will consume 20g of potato starch (Bob's Red Mill®) once a day for 3 days, then increase to 20g twice a day, continuing throughout dual-ICI treatment (total duration approximately 13 weeks).
224256474|NCT02681263|DRUG|Temocillin|Treatment duration with a minimum of 5 days administration of the study drug: Temocillin (Negaban®) 6g/day (2g/tid) and as monotherapy.
224256475|NCT01932086|DIETARY_SUPPLEMENT|White rice diet|All test foods contained 50 g available carbohydrate from the test food products. A glass of 250 ml water was served together with the clinical trial food, and the participants were instructed to ingest the breakfast with 15 min
224256476|NCT01932086|DIETARY_SUPPLEMENT|Brown rice diet|All test foods contained 50 g available carbohydrate from the test food products. A glass of 250 ml water was served together with the clinical trial food, and the participants were instructed to ingest the breakfast with 15 min
224256477|NCT01932086|DIETARY_SUPPLEMENT|Black rice diet|All test foods contained 50 g available carbohydrate from the test food products. A glass of 250 ml water was served together with the clinical trial food, and the participants were instructed to ingest the breakfast with 15 min
224256478|NCT01932086|DIETARY_SUPPLEMENT|Bread|All test foods contained 50 g available carbohydrate from the test food products. A glass of 250 ml water was served together with the clinical trial food, and the participants were instructed to ingest the breakfast with 15 min
224256479|NCT01932086|OTHER|Glucose solution|All test foods contained 50 g available carbohydrate from the test food products.and the participants were instructed to ingest the breakfast with 10 min.
224256480|NCT01461421|BEHAVIORAL|Nutrition Education|Participants are taught about energy balance, caloric intake, the nutrition content of foods, and diet.
224322416|NCT02132793|BEHAVIORAL|Anger Management Therapy & RELAX app|Anger Management Therapy (AMT) is a 12-session manual-driven cognitive-behavioral intervention found efficacious for anger management treatment. RELAX app (1) enables the practice of anger management strategies remotely through mobile phone interfaces; (2) integrates with evidence-based treatments through implementing an existing CBT anger management course; (3) provides information, direction, and feedback through physiological sensors; and (4) supports communication and direction by the therapist through a web-based therapist interface and a remote and secure patient data server.
224322417|NCT02237703|OTHER|Positron emission tomography (PET) imaging|Positron emission tomography (PET) imaging
223675094|NCT05347147|DRUG|Placebo|Placebo is supplied as 2 parts (visually identical to the Presendin vial and pre-filled diluent syringe). The drug part will exclude the active pharmaceutical ingredient (exenatide acetate) and the diluent part will be the same as the active treatment diluent. The drug part is suspended in the diluent part solution and administered SC as a suspension.
223675095|NCT00280111|BIOLOGICAL|116E AGMK|Single dose of 116E 10\^5 FFu
223675096|NCT00280111|DRUG|I321|Single dose of I321 10\^5 FFu
223675097|NCT00280111|DRUG|Placebo|1 crystal of potassium permanganate dissolved in the bicarbonate buffer to colour match the vaccine
223675098|NCT04628533|BEHAVIORAL|Four Month Duration Online Behavioral Weight Loss Program|"Participants meet weekly on line with other group participants for 16 weeks. The group-based online behavioral weight control program incorporates the elements of current thinking and empirical data on successful weight loss programs, including restricted calorie intake and increased physical activity. Key behavioral strategies to facilitate making sustained changes in dietary habits and activity patterns are introduced, promoted, and reinforced throughout the program. Weekly group meetings in a video chat forum led by an experienced group weight control counselor are the venue for the group process, and extensive web-based resources to support behavior changes are offered. The online groups are closed such that those individuals who start the group remain in that group for the duration of their participation. Weight loss counselor will provide feedback and encouragement to participants after reviewing food diaries via weekly emails."
223772699|NCT02486406|DRUG|Dasabuvir|Film-coated tablet for oral use
223772700|NCT02486406|DRUG|Ribavirin|Film-coated tablet for oral use
223772701|NCT02486406|DRUG|Ombitasvir mini tablet|Film-coated tablet for oral use
223772702|NCT02486406|DRUG|Paritaprevir mini tablet|Film-coated tablet for oral use
223772703|NCT02486406|DRUG|Ritonavir mini tablet|Film-coated tablet for oral use
223772704|NCT02486406|DRUG|Dasabuvir mini tablet|Film-coated tablet for oral use
223772705|NCT02486406|DRUG|Ribavirin solution|Oral solution
223772706|NCT01826825|BEHAVIORAL|Cognitive Screen|Cognitive Screen
223772707|NCT01826825|BEHAVIORAL|Mini-Cog|Cognitive Screen
223772708|NCT01769794|DRUG|Western therapy|Physical cooling paste or warm bathing, vitamin B, vitamin C. On the basis of the attending physician's judgment, participants were allowed to use Ibuprofen suspension if their body temperature was greater than 38.5℃. Likewise, the need for antibiotics was determined by the attending physicians. The use of acetaminophen or antibiotics was recorded on the case record form
223772709|NCT01769794|DRUG|JET|4g/tablet, One tablet each time (Taken after dissolved in 50ml boiled water, 3 times daily if body temperature≥38.5℃)
224256481|NCT01461421|BEHAVIORAL|Behavioral Weight Loss Strategies|Participants are taught self-monitoring and goal setting techniques.
224256482|NCT01461421|BEHAVIORAL|Standard Cognitive Techniques|Participants are taught how to modify, get rid of, or distract from thoughts and also how to regulate emotions.
224256483|NCT01461421|BEHAVIORAL|Acceptance Based Techniques|Participants are taught how to accept and change their perception of their thoughts and emotions.
224256484|NCT05261737|PROCEDURE|Corticosteroid Injection|Steroid injection effectiveness will be determined by relief of pain scored by patient using Visual Analogue Scale (VAS). Data will be collected during clinic visit and contacting patients in a determined protocol for the following 6 weeks after steroid injection.After approval of the study, data will collected from participants over a period of 6 weeks follow up; the whole study will be conducted over a total of 2 years.Since the study will not conduct any further test to participants and follow up regimen will only state pain related to the specific condition (De Quervain tenosynovitis) and quick-DASH score, it will not result in any anticipated/unanticipated incidental findings, therefore participants will not be recontacted.
224256485|NCT00509561|BIOLOGICAL|cetuximab|
224256486|NCT00509561|DRUG|capecitabine|
224256487|NCT00509561|DRUG|cisplatin|
224256488|NCT00509561|RADIATION|radiation therapy|
224256489|NCT05663411|DRUG|SHR6508|SHR6508
224322418|NCT02296931|OTHER|Saline|Standard IV Saline Fluids
224256490|NCT05663411|DRUG|SHR6508|SHR6508
224256491|NCT05663411|DRUG|Cinacalcet|Cinacalcet
224256492|NCT06225076|BEHAVIORAL|Comprehensive rehabilitation|"All the participants are provided with the comprehensive rehabilitation (routine rehabilitation and swallowing function training). The routine rehabilitation included intervention for risk factors (blood pressure, blood lipids, blood glucose, smoking and alcohol restriction, exercise, etc.).~Regrading swallowing function training, both groups are given swallowing function training, including 1) exercises of closure of the vocal folds, pharyngeal, and laryngeal muscles exercises, and respiratory muscle strength training, for 15 min each time and twice per day. 2) isotonic／isometric swallowing exercises, supraglottic swallowing exercises, for 20 min each time and twice per day. 3) effortful swallowing exercises, and cough reflex training, for 10 min each time and twice per day."
224256493|NCT06225076|PROCEDURE|Stellate ganglion block|the patients in the observation group were provided with Stellate ganglion block, using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate ganglion block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
224256494|NCT06225076|DRUG|Lidocaine Hydrochloride|the patients in the observation group were provided with Stellate ganglion block, using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate ganglion block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
224256495|NCT00905931|DRUG|Lycopene|30 mg oral, daily, for 21 days
224256496|NCT00905931|DRUG|placebo|starch
223675099|NCT04628533|BEHAVIORAL|Six Month Duration Online Behavioral Weight Loss Program|"Participants meet weekly on line with other group participants for 24 weeks. The group-based online behavioral weight control program incorporates the elements of current thinking and empirical data on successful weight loss programs, including restricted calorie intake and increased physical activity. Key behavioral strategies to facilitate making sustained changes in dietary habits and activity patterns are introduced, promoted, and reinforced throughout the program. Weekly group meetings in a video chat forum led by an experienced group weight control counselor are the venue for the group process, and extensive web-based resources to support behavior changes are offered. The online groups are closed such that those individuals who start the group remain in that group for the duration of their participation. Weight loss counselor will provide feedback and encouragement to participants after reviewing food diaries via weekly emails."
223675100|NCT04360655|PROCEDURE|bronchoscopic microwave intervention|bronchoscopic microwave intervention
223675101|NCT04360655|DRUG|anti-PD-1 / PD-L1 monoclonal antibody and chemotherapy|anti-PD-1 / PD-L1 monoclonal antibody and chemotherapy
223675102|NCT05326724|DEVICE|Acupuncture|The stainless steel needles are used to insert into the three points of Sishencong and the Baihui, and the Dazhui, once a week, once for 20 minutes, for 12 consecutive weeks.
223675103|NCT04161339|DRUG|Hydroxychloroquine|400mg/daily of hydroxychloroquine for 8 weeks
223675104|NCT04161339|DRUG|Placebo oral tablet|Amido pills/daily for 8 weeks
223772710|NCT01769794|DRUG|Placebo(for JET)|placebos prepared identical in color, taste and consistency to the JET (supplied by Zhongshenghaitian Pharmaceutical, Tianjin, China)
224256497|NCT01450189|BEHAVIORAL|Standard HIV prevention messages|A single session of standard HIV prevention messages during HIV post-test counseling with supplemental information regarding the acute stage of their infection.
224256498|NCT01450189|BEHAVIORAL|BI: Information-Motivation-Behavioral Skills Model|The behavioral intervention consists of five counselor-delivered sessions based on the Information-Motivation-Behavioral Skills (IMB) Model. The sessions are designed to provide participants with the information, motivation, and skills needed to abstain or practice protected sex during the brief acute HIV period, as well as plan for long-term behavioral risk reduction.
224256499|NCT01450189|DRUG|Raltegravir|raltegravir (400 mg) administered orally twice daily for 12 weeks
224256500|NCT01450189|DRUG|emtricitabine/tenofovir disoproxil fumarate|emtricitabine/tenofovir (200/300 mg daily) in a fixed dose combination administered orally for 12 weeks
224256501|NCT01956786|DRUG|Amlodipine-FA tablet,low dose group|5mg amlodipine combined with 0.4mg folic acid,once daily (Low-dose group)
224256502|NCT01956786|DRUG|Amlodipine-FA tablet,high dose group|5mg amlodipine combined with 0.8mg folic acid,once daily (High-dose group)
224256503|NCT01956786|DRUG|Amlodipine|5mg amlodipine,once daily
224256504|NCT01151930|DRUG|SCB01A|This is a companion study to the protocol SCB01A-01 intended to provide long-term continued administration to subjects that completed Protocol SCB01A-01 on a compassionate basis. It is an open-label, single-arm study of SCB01A in subjects who have completed 2 cycles of treatment under the SCB01A-01 protocol.
224256505|NCT02079194|DRUG|P2Y12 antagonist monotherapy|
224256506|NCT02079194|DRUG|aspirin plus P2Y12 antagonist|
224256507|NCT00043394|DRUG|0.04 mg/kg CpG 7909|0.04 mg/kg CpG 7909 by subcutaneous Injection once weekly until progression or 24 weeks
224256508|NCT00043394|DRUG|Herceptin®|Herceptin® (maintenance dose per the manufacturer's directions) followed by a subcutaneous injection of CpG 7909.
224256509|NCT00043394|DRUG|0.08 mg/kg CpG 7909|0.08 mg/kg CpG 7909 by subcutaneous Injection once weekly until progression or 24 weeks
223675105|NCT01510288|DRUG|GVAX and ipilimumab|All patients receive a 500 million cell priming dose of granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells (GVAX) intradermally on day 1 followed by bi-weekly intradermal injections of 300 million cells for a 24 week period. The vaccinations are combined with monthly intravenous administrations of ipilimumab. The dose-escalation part of this study will be performed using the standard 3+3 phase-I trial design. Patients will be enrolled in cohorts of three; each cohort will receive an escalating dose of ipilimumab at 0•3, 1•0, 3•0 or 5•0 mg/kg. Sixteen patients will be treated in an expansion cohort with GVAX and 3•0 mg/kg ipilimumab.
223675106|NCT02858297|DRUG|Glucosamine sulfate|Glucosamine (GlcN) is an N-deacetyl amino sugar derived from the complete hydrolysis of chitosan with recently reported immunoregulatory capacity and anti-inflammatory effect
224256510|NCT00043394|DRUG|Herceptin®|Herceptin® (maintenance dose per the manufacturer's directions) followed by a subcutaneous injection of CpG 7909.
224256511|NCT00043394|DRUG|0.12 mg/kg CpG 7909|0.12 mg/kg CpG 7909 by subcutaneous Injection once weekly until progression or 24 weeks
224256512|NCT00043394|DRUG|Herceptin®|Herceptin® (maintenance dose per the manufacturer's directions) followed by a subcutaneous injection of CpG 7909.
224256513|NCT00043394|DRUG|0.16 mg/kg CpG 7909|0.16 mg/kg CpG 7909 by subcutaneous Injection once weekly until progression or 24 weeks
224256514|NCT00043394|DRUG|Herceptin®|Herceptin® (maintenance dose per the manufacturer's directions) followed by a subcutaneous injection of CpG 7909.
224256515|NCT03552744|OTHER|Mailed training intervention|"PCPs from the intervention group will be mailed an intervention package that includes:~1. 2-page structured evidence summary on CRC screening and information about Colonoscopy \& FIT (Decision box)~2. patient decision aid (20-page booklet) on CRC screening for distribution to patients (Decision Aid)~3. video example for the PCP, which illustrates a participatory approach to discussing CRC screening with a patient~4. 4-page abridged version of the booklet to support PCPs when they discuss CRC screening with patients during a clinical visit (Decision Board)~5. individualized 1-page summary of PCP screening practices comparing their individual prescription patterns to group patterns, based on the data collected in 2017 (Performance card)~6. 2-page document that encourages PCPs still using the inferior guaiac-based FOBT to switch to FIT and includes list of laboratories from which they can order FIT~7. sample FIT for PCPs who may not be familiar with its contents and use"
224256516|NCT04657965|DRUG|LMP1 CAR T-cells|Each subject receive LMP1 CAR T-cells by intravenous infusion
224256517|NCT02365012|DRUG|Midodrine|Crossover intervention comparing midodrine to placebo for subjects with orthostatic intolerance
224256518|NCT02704585|DEVICE|Nellcor|Measurement of pulse oximetry in the delivery room with Nellcor pulse oximeter
224256519|NCT02704585|DEVICE|Masimo|Measurement of pulse oximetry in the delivery room with Masimo pulse oximeter
224256520|NCT04327128|DEVICE|LifePod|The intervention group is testing LifePod on a digital communication platform between patient and healthcare provider
224256521|NCT02334644|DIETARY_SUPPLEMENT|Probiotic Formula (Lactobacillus helveticus R0052 and Bifidobacterium longum R0175)|2 sachets/day x 12 weeks
224256522|NCT02334644|DIETARY_SUPPLEMENT|Placebo|2 sachets/day x 12 weeks
224256523|NCT01135446|DRUG|dapagliflozin|Oral Solution, Oral, 0.001 mg, once on Day 1 only, 2 days
224256524|NCT01135446|DRUG|dapagliflozin|Oral Solution, Oral, 0.01 mg, once on Day 1 only, 2 days
224256525|NCT01135446|DRUG|dapagliflozin|Oral Solution, Oral, 0.1 mg, once on Day 1 only, 2 days
223675107|NCT02858297|DRUG|triamcinolone acetonide|Topical corticosteroid
223675108|NCT05925387|OTHER|CANAP Education|The volunteer group included in the research consists of Yeditepe University Nursing Students. All nursing students over the age of 18, at all levels of the nursing program, will be included in the study based on voluntary participation, in accordance with the sample size. The purpose and design of the research will be explained to the 1st, 2nd, 3rd, and 4th-year nursing students. The announcement of the study will be made through Yeditepe University Nursing's social media accounts, and a consent link provided. Participants who sign the document in the consent link and upload it to the shared Google Drive received the pre-test link. Participants who complete all the procedures are provided with a participant certificate prepared by the researchers as an incentive.
223675109|NCT03249688|OTHER|Regular health advice|Routine healthy lifestyle counseling
223675110|NCT03249688|BEHAVIORAL|Multidomain lifestyle|Nutritional guidance, exercise, cognitive training, vascular risk monitoring
223675111|NCT03249688|DIETARY_SUPPLEMENT|Medical food|Medical food product (Fortasyn Connect)
224256526|NCT01135446|DRUG|dapagliflozin|Tablets, Oral, 0.3 mg, once on Day 1 only, 2 days
224256527|NCT01135446|DRUG|dapagliflozin|Tablets, Oral, 1 mg, once on Day 1 only, 2 days
224256528|NCT01135446|DRUG|dapagliflozin|Tablets, Oral, 2.5 mg, once on Day 1 only, 2 days
224256529|NCT01997372|DRUG|ATG|Drug ATG:2.5mg/kg/d or 3.75mg/kg/d for 5 days; Drug Cyclosporine A (CSA):3-10mg/kg/d ,Adjust the dose to maintain drug levels between 150 and 300ng/ml; Drug prednisone:1mg/kg/d,d1-21 from the first dosage of ATG; Drug Granulocyte Colony-Stimulating Factor(G-CSF):5ug/kg/d until absolute neutrophil count (ANC) \>1×109/L.
224256530|NCT03610035|DRUG|NPT189|IgG1 Fc-GAIM fusion protein, a recombinant fusion protein
224256531|NCT03610035|DRUG|Placebo|Placebo
224256532|NCT01027923|DRUG|Plerixafor|
223675112|NCT04614051|BIOLOGICAL|Cellgram-DC|Patients will receive 3 times every 2 weeks injection of Cellgram-DC(Autologous dendritic cell) subcutaneous injection near the upper arm lymph nodes
224256533|NCT01027923|DRUG|Mitoxantrone|
224256534|NCT01027923|DRUG|Etoposide|
224256535|NCT01027923|DRUG|Cytarabine|
224256536|NCT03837249|DEVICE|Personal Sleep Monitoring|Wearable Sleep Self-Monitoring Device (Actigraphy)
224256537|NCT05901090|OTHER|M-TAPA block|Following sterile conditions for bilateral M-TAPA block application, the transducer was inserted on the chondrium in the sagittal plane at the 9-10th rib level. Subsequently, a deep angle was created with the probe for visualization of the underside of the costochondrium. The sonovisible needle tip was placed just below the chondrium and saline (5 ml) was injected for site confirmation. After the confirmation, 20 ml of 0.25% bupivacaine was administered for each group for a total of 40 ml of local anesthetic. Blocks were applied using an 80 mm sonovisible needle with a 6-10 MHz linear probe under the guidance of a portable ultrasound. M-TAPA block with the same standard technique and drug dose was applied to the contralateral side for each group of M-TAPA patients.
224256538|NCT05901090|OTHER|TAP block|After the necessary sterilization conditions were established, the linear ultrasound probe was sterilely coated and placed in the middle of the iliac crest with the end limit of the ribs. Starting with skin, the layers in descending order, subcutaneous adipose tissue, external oblique muscle, internal oblique muscle, transversus abdominis muscle, and peritoneum were identified. As the tip of the 80 mm sonovisible needle passed through the muscular layers and fascia, a fascial click was felt and the needle was advanced with ultrasound in a controlled manner. After receiving the second click sensation (passage of the fascia of the internal oblique muscle), the location of the needle was fixed and frequently aspirated and applied to the plane so that 20 ml of 0.25% bupivacaine was applied to each side. (40 ml in total)
223675113|NCT02346578|DRUG|Enzalutamide|
223675114|NCT02346578|DRUG|Flutamide|
224256539|NCT01527006|DRUG|perampanel|During the titration period, participants started at a set daily dose of 0.015 mg/kg and had doses up-titrated at 1-week intervals (6 titration steps) to a maximum daily dose of 0.18 mg/kg. During the Maintenance Period, participants continued taking perampanel oral suspension once daily at the dose level they achieved at the end of the Titration Period. During the extension phase, participants continued taking perampanel oral suspension once daily, at the dose level achieved at the end of the treatment phase of the core study to a maximum daily dose of 0.18 mg/kg. The maximum total daily dose a participant was allowed was 12 mg.
224256540|NCT01409278|PROCEDURE|Ropivacaine infiltration and saline infusion.|50ml ropivacaine 0.2% with keterolac 15mg infiltration followed by normal saline infusion at 5ml per hour
223675115|NCT06307860|DEVICE|pulsed field ablation|Selected patients were selected to undergo relevant surgeries, and their preoperative and postoperative baseline data were collected. They were followed up for 6 months after surgery.
223675116|NCT06307860|PROCEDURE|radiofrequency ablation|Selected patients were selected to undergo relevant surgeries, and their preoperative and postoperative baseline data were collected. They were followed up for 6 months after surgery.
223675117|NCT03616223|DRUG|FX-322|Intratympanic injection of FX-322 consists of laduviglusib and sodium valproate
223675118|NCT03616223|DRUG|Placebo|Intratympanic injection
223675119|NCT05849285|OTHER|TLC Clinic|Patients of the TLC clinic - receive coordinated multidisciplinary and specialized care from a team
223675120|NCT02218476|DRUG|CoQ10|
223675121|NCT02218476|DRUG|Placebo|
223675122|NCT01122394|BEHAVIORAL|TI|Tailored intervention based on the transtheoretical model
223675123|NCT01122394|BEHAVIORAL|AP|Attention placebo
223675124|NCT02970370|OTHER|no intervention|
223675125|NCT02446743|BIOLOGICAL|rMenB+OMV NZ (Meningococcal (Group B) multi component recombinant adsorbed vaccine)|One dose of the vaccine administered intramuscularly in the deltoid area of the non-dominant arm.
223675126|NCT03721679|BIOLOGICAL|Poly-ICLC combination treatment with aPD-1 (Nivolumab or Pembrolizumab) or aPD-L1 (Atezolizumab or Durvalumab) over 6 months|Same as above
223675127|NCT03787979|OTHER|Lumbopelvic stiffening technique|"Participants will stretch their hamstrings muscle in standing position with lumbopelvic stiffening technique. Fifteen percent of the body weight will be used to standardize stretching force. During stretching protocol, the participants will be instructed to face the hydraulic table with their hips square, maintain trunk straight up and look straight ahead. Researcher commands during adjusting the bed up, please tense your back rigid. After that, hydraulic bed will be lifted up until force reaches 15 percent of the body weight. Participant will perform 30 seconds/repetition for 4 repetitions with 15 seconds rest between repetitions."
223675128|NCT03787979|OTHER|Lumbopelvic relaxing technique|"Participants will be instructed to face the hydraulic table with their hips square, maintain trunk straight up and look straight ahead. The researcher commands During adjusting the bed up, please relax your back. The hydraulic bed will be lifted up until force reaches 15 percent of the body weight. Participant will perform 30 seconds/repetition for 4 repetitions with 15 seconds rest between repetitions."
223675129|NCT03361176|DRUG|Injectable sodium deoxycholate|Kybella(TM) alone: 2 mg/cm2 of Kybella(TM) with 0.2 mL of 1% lidocaine with no epinephrine plus 0.2cc saline to the non-TMC group to maintain equal concentrations in each injection so that the final Kybella concentration per vial will be 10mg/1.2mls or 1.6mg per 0.2 cc injection point will be delivered in up to 50 injections spaced 1.0 cm apart at 0.2 mL/injection for a total maximal dose of up to 100 mg of SDOC.
223675130|NCT03361176|COMBINATION_PRODUCT|Injectable sodium deoxycholate with Triamcinolone acetate|Kybella(TM)+TMC at 1.0 mg/mL: 2.0 mL of 2 mg/cm2 of Kybella(TM) will be mixed with 0.2 mL of 10 mg/mL of triamcinolone acetate, 0.2 mL of 1% lidocaine with no epinephrine and then delivered in up to 50 injections spaced 1.0 cm apart at 0.2 mL/injection for a total dose of up to 100 mg of SDOC using a 30 gauge (or smaller) 0.5-inch needle. The final Kybella concentration per vial will be 10mg/1.2mls or 1.6mg per 0.2 cc injection point
223675131|NCT03751774|BEHAVIORAL|MAMAACT|Post graduate training and health education materials
223675132|NCT03718299|DRUG|Injections of tildrakizumab|given at Week 0, Week 4, Week 16, Week 28, Week 40 and Week 52
223675133|NCT05347004|DRUG|BI 425809|BI 425809
223675134|NCT00006487|DRUG|cisplatin|"During induction: 50 mg/m2/day, IV on Days 1, 8, 29, 36. 1 hour infusion~During consolidation: 60 mg/m2, IV on Day 1 only at approximately Week 11, Week 14. 1 hour infusion."
223675135|NCT00006487|DRUG|etoposide|"During induction: 50 mg/m2/day, IV on Days 1 - 5, 29 - 33. 1 hour infusion~During consolidation: 120 mg/m2, IV on Days 1, 2 and 3 at approximately Week 11, Week 14. 1 hour infusion."
223675136|NCT00006487|DRUG|tirapazamine|"During induction:~Phase I low dose: 260 mg/m2/day, IV on Days 1, 8, 29, 36. 1 hour infusion~Phase II high dose: 330 mg/m2/day, IV on Days 1, 8, 29, 36 1 hour infusion~During consolidation:~330 mg/ m2, IV Day 1 only at approximately Week 11, Week 14. 1 hour infusion."
223675137|NCT00006487|RADIATION|radiation therapy|Radiotherapy should begin within 1 - 3 hours after completion of TPZ infusion on Day 1 of Cycle 1 of induction chemotherapy as outlined above. Computed tomography based treatment planning is strongly recommended.The primary tumor, adjacent mediastinum and other targeted lymph nodes shall receive 4,500 cGy in 25 fractions, five days/week at 180 cGy daily. A 1,600 cGy boost to areas of gross disease will be delivered through reduced off-spinal cord fields in eight fractions, five days/week at 200 cGy daily.
223675138|NCT04389970|BEHAVIORAL|Time Restricted Feeding|Participants will eat all food within an 8 hour window each day. They will only consume water or black coffee during the remaining 16 hours.
223675139|NCT01787344|DRUG|Botulinum Toxin Type A(Botox®)|Single administration, 4units/kg body weight dose in patients with hemiplegia, 6units/kg body weight dose in patients with diplegia, Maximum dosage 200units
223675140|NCT01787344|DRUG|Botulinum toxin type A(Botulax®)|Single administration, 4units/kg body weight dose in patients with hemiplegia,6units/kg body weight dose in patients with diplegia, Maximum dosage 200units
223675141|NCT03027479|OTHER|Samples|Blood samples, muscle biopsy, adipose tissue samples and ovarian cancer tumor sample
223675142|NCT05171725|DIAGNOSTIC_TEST|EEG,PSG|concurrent overnight sleep study with full electroencephalography (in-lab or at home)
223675143|NCT05171725|DIAGNOSTIC_TEST|biosample collection (blood and CSF)|blood or CSF collection for analyses of neurodegenerative, inflammatory, and, per condition, genetic information
223675144|NCT05171725|DIAGNOSTIC_TEST|neuropsychological testing|paper and pencil, as well as tablet based cognitive testing
223675145|NCT05171725|DIAGNOSTIC_TEST|actigraphy|week long actigraphy assessment with concurrent sleep diary acquisition
224256541|NCT01409278|PROCEDURE|Ropivacaine infiltration and infusion.|50 ml infiltration of ropivacaine 0.2% and ketorolac 15mg admixture followed by ropivacaine 0.2 % at 5ml per hour infusion for 48 hours.
223675146|NCT05171725|DIAGNOSTIC_TEST|clinician assessment|standard clinical assessment by an expert clinician in the respective field of brain disorders
223675147|NCT03818984|BEHAVIORAL|Safer Conception for Men with At Risk Partners|CBT based safer conception counseling with longitudinal follow-up and booster sessions. The primary outcome will be HIV RNA suppression at 6 months. Secondary outcomes include early ART uptake, adherence, serostatus disclosure, couples HIV counseling and testing uptake, and limiting unprotected sex to peak fertility.
223675148|NCT05791370|DIETARY_SUPPLEMENT|A 12-week parallel dietary intervention|Subjects consumed 3 isocaloric meals prepared with the 3 oils for a duration of 12 weeks. The test meals were given for 5-day a week and contained 27-30% energy fat, with 2/3 (20% energy fat) replaced by experimental fat.
223675149|NCT02394145|DRUG|Ticagrelor|Patients with normal kidney function and ESRD on hemodialysis will be treated by ticagrelor 90mg twice a day for 14 days. After then, platelet reactivity will be assessed by light aggregometry and VerifyNow assay.
223675150|NCT02394145|DRUG|Clopidogrel|Patients with normal kidney function and ESRD on hemodialysis will be treated by clopidogrel 75mg or 150mg once a day for 14 days. After then, platelet reactivity will be assessed by light aggregometry and VerifyNow assay.
223675151|NCT00357032|DRUG|belinostat|Given IV
223675152|NCT00357032|OTHER|laboratory biomarker analysis|Correlative studies
223675153|NCT01931670|OTHER|placebo|
223675154|NCT01931670|DRUG|Elagolix|
223675155|NCT06127537|BEHAVIORAL|Therapeutic Intervention Group|"The therapeutic group factors that are worked on in the group session with a psychologist are:~* Altruism.~* Cohesion: feeling of belonging and acceptance in a group.~* Universality: identification with the feelings, ideas or problems of the other group members.~* Interpersonal-internalisation learning: the patient understands himself/herself by sharing his/her experience with the group.~* Interpersonal-externalisation learning: the group offers the patient the possibility to express his own experience and to change his attitudes towards others.~* Counselling.~* Identification: assumption of behavioural patterns of other members as one's own.~* Reactualisation of the family experience.~* Understanding of one's own internal motivations.~* Reciprocal stimulation: the improvement of other members encourages them to solve or approach their problems in a more favourable way.~* Existential factors: empowerment of the individual."
223675156|NCT00278239|PROCEDURE|cognitive assessment|
223675157|NCT00278239|PROCEDURE|psychosocial assessment and care|
223675158|NCT00278239|PROCEDURE|quality-of-life assessment|
223675159|NCT03671473|DEVICE|Extracorporeal shock wave|Shock waves are defined a sequence of acoustic pulse characterized by a high peak pressure (100 MPa), fast pressure rise (\< 10 ns) and short duration (10 μs). Different studies and clinical experiments have demonstrated the efficacy of shock waves in the treatment of musculoskeletal system such as chronic tendinopathies or hypertrophic pseudoarthrosis.
223675160|NCT04863209|OTHER|Upper cervical manipulation|The patient will receive an upper cervical manipulation as described in the Experimental Group 1.
223675161|NCT04863209|OTHER|Sphenopalatine ganglion manipulation|The patient will receive a sphenopalatine ganglion as described in the Experimental Group 2.
223675162|NCT06024733|DRUG|Sevoflurane|patient recieve propofol for induction and sevoflurane for maintenance
223675163|NCT06024733|DRUG|Target Controlled Infusion|target controlled infusion of propofol
223675164|NCT06024733|DRUG|Target Controlled Infusion and lidocaine|patients will receive total intravenous anesthesia with propofol Target Controlled Infusion. At the induction of anesthesia, the patients will receive a bolus of lidocaine 1% 1.5 mg/kg and a continuous infusion of lidocaine 1% 2 mg/kg/h will be associated throughout the procedure.
223675165|NCT06321627|RADIATION|Radiation therapy as curative treatment|Radiation therapy as curative treatment (exclusive, post-operative, with or without chemotherapy) for HPV-related squamous cell carcinomas of the oropharynx, uterine cervix, and anus
223675166|NCT03671278|OTHER|STarT Back Screening Tool Approach|Patients classified as low risk of persistent pain will be educated about their condition and how to manage their back pain by targeting modifiable prognostic factors. Patients classified as medium risk will receive evidence-based physical therapy. Patients classified as high risk will receive evidence-based physical therapy as well as individualized psychological intervention.
223675167|NCT02810678|OTHER|Latent Tuberculosis Infection program evaluation & diagnosis|
223675168|NCT01463332|DRUG|I.V injection of 10 ml normal saline|Patients were randomly assigned in to three groups of 50 each using a computer-generated table of random numbers. Patients Group NS were injected intravenously with 10 ml of normal saline before injection of propofol.
223675169|NCT01463332|DRUG|I.V injection with 0.25mic/kg of dexmedetomidine|Patients were randomly assigned in to three groups of 50 each using a computer-generated table of random numbers. Patients Group D25 were injected intravenously with 0.25mic/kg of dexmedetomidine diluted with normal saline into 10ml before injection of propofol.
223675170|NCT01463332|DRUG|I.V injection of 0.50mic/kg of dexmedetomidine|Patients were randomly assigned in to three groups of 50 each using a computer-generated table of random numbers. Patients Group D50 were injected intravenously with 0.50mic/kg of dexmedetomidine diluted with normal saline into 10ml before injection of propofol.
224256542|NCT01409278|PROCEDURE|Normal Saline|50ml of normal saline infiltration followed by normal saline infusion at 5ml per hour
224256543|NCT00367861|DRUG|interruption of Glivec®|interruption of Glivec®
224256544|NCT02995005|DRUG|Tenofovir Disoproxil Fumarate|300 mg daily
224256545|NCT00447577|DRUG|Loteprednol etabonate and tobramycin ophthalmic suspension|Subjects will self-administer the study drug in the affected eye(s) 4 times a day (QID) for 14 days.
224256546|NCT00447577|DRUG|Tobramycin and dexamethasone ophthalmic suspension|Subjects will self-administer the study drug in the affected eye(s) 4 times a day (QID) for 14 days.
224256547|NCT00296062|BIOLOGICAL|bevacizumab|Phase II: IV over 30-90 minutes on days 1 and 15 of each course.
224322419|NCT02296931|DRUG|Magnesium Sulfate|The standard drug used to prevent and treat convulsions for women with pre-eclampsia and eclampsia is magnesium sulfate (MgSO4)
224322420|NCT00166582|DEVICE|electronic medication monitoring system|
224322421|NCT00166582|BEHAVIORAL|parent-adolescent communication and problem-solving skills|
224256548|NCT00296062|DRUG|capecitabine|Phase I: oral capecitabine twice daily on days 1-7 and 15-21.Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of capecitabine (during both odd- and even-numbered courses) until the maximum tolerated dose (MTD) is determined.Phase II:receive capecitabine (at the MTD determined in phase I(odd-numbered courses)
224256549|NCT00296062|DRUG|irinotecan hydrochloride|Phase I: irinotecan hydrochloride IV over 90 minutes on days 1 and 15 during course 1 and all subsequent odd-numbered courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.Phase II: receive capecitabine (at the MTD determined in phase I) in combination with irinotecan hydrochloride (during odd-numbered courses)
224256550|NCT00296062|DRUG|oxaliplatin|"Phase I: oxaliplatin IV over 2 hours on days 1 and 15 during course 2 and all subsequent even-numbered courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Phase II: oxaliplatin (during even-numbered courses) as in phase I"
224256551|NCT04451837|DRUG|Semaglutide|Ozempic s.c. once weekly for 6 months
224256552|NCT04451837|DRUG|Dapagliflozin|Forxiga 10 mg p.o. once daily for 6 months
224256553|NCT03341182|PROCEDURE|Fluoroscopically Guided Lumbar Transforaminal Epidural Injections|Lay the subject down on the stomach and hold the pillow on the stomach. The skin of the injection area is sterilized by aseptic method and covered with aseptic pouch. After confirming the level of he vertebrae around the C-arm and aligning the anteroposterior view of the endplate of the vertebral body, rotate the C-arm 20\~30 degrees diagonally in the direction to be performed. After confirming the best Scotty dog view, confirm the final target point at 6 o'clock directly below the pedicle. At this position, the skin point is marked on the skin. And then both groups proceed in parallel with the beam direction of the transducer with the tunnel view technique until the needle reaches the back of the vertebral body at the level of the spinal nerve roots. At this time group A uses a mirror and group B dose not. The final reach of the target point (ideal depth) is confirmed through the anterior and posterior views and lateral views.
224322422|NCT01782430|PROCEDURE|- standard oxygenation|
223675171|NCT00518245|DRUG|enoxaparin|Enoxaparin will be given subcutanteously at a dose of 1mg/kg every 12 hours for a minimum of 48 hours (4 doses) and a maximum of 8 days until a diagnostic / therapeutic procedure is performed, or at the discretion of the investigator.
223675172|NCT05249166|OTHER|ALINFA|Comparing the usual recommendations with the healthy diet designed and developed
223675173|NCT05249166|OTHER|Control|control group
223675174|NCT00766441|DRUG|Sitagliptin|tablet, 100mg, once daily, 4 weeks
223675175|NCT00766441|DRUG|sulphonylurea|sulphonylurea, variable, od or bd, during ramadan
223675176|NCT02895997|OTHER|Travel Telehealth Delivery|Clinical Operations Room (COR) staff will travel to Sydney Australia to deliver telehealth to patients in Georgia United States. Upon arrival, participants will have eight nights and seven days free of clinical responsibilities. Thereafter, each participant will work four consecutive days of 12 hour shifts followed by four consecutive days with no clinical assignment. The following week, participants will work three consecutive days of 12 hour shifts followed by four consecutive days with no clinical assignment. Upon return to the USA, participants will have a week free of clinical responsibilities.
223675177|NCT03517488|BIOLOGICAL|XmAb20717|Monoclonal bispecific antibody
223675178|NCT03044639|DRUG|Lipid Emulsions, Intravenous|The every day provision of lipid emulsion as a part of parenteral nutrition along with dextrose, amino acids, electrolytes, trace elements, vitamins and water in the dose of 0.8-1.0 g/kg/day.
223675179|NCT03555838|OTHER|transcranial direct current stimulation|Transcranial direct current stimulation, a form of neuromodulation that uses a low direct current delivered via sponge electrodes on the head.
223675180|NCT03555838|OTHER|sham transcranial direct current stimulation|an inactive or placebo version of transcranial direct current stimulation placed on the head via sponge electrodes.
223675181|NCT02723578|DRUG|Pemetrexed|Pemetrexed 500 mg/m2 IV over 10 minutes on day 1 every 21 days
223675182|NCT02723578|DRUG|Erlotinib|Erlotinib 150 mg PO once daily on days 1-21 every 21 days
223675183|NCT01124630|DRUG|CS-1008|CS-1008 will be administered IV each week. The initial/loading dose (6 mg/kg) will be administered Day 1 of Cycle 1. Maintenance doses of 2 mg/kg will be administered weekly thereafter.
223675184|NCT01124630|DRUG|FOLFIRI|The FOLFIRI regimen will be administered IV at Weeks 1 and 3 of each 4 week cycle, and it will begin at Week 1 of Cycle 1. It will comprise irinotecan, 180 mg/m2 IV infusion over 30 to 120 minutes; leucovorin, 400 mg/m2 IV infusion to match the duration of the irinotecan infusion; and 5-FU, 400 mg/m2 (bolus) followed by 1200 mg/m2/day x 2 days (total 2400 mg/m2 over 46 to 48 hours continuous infusion).
223675185|NCT00976508|DRUG|figitumumab|IGF-1R antibody, 20 mg/kg, IV every 3 weeks for up to 1 year
223675186|NCT00976508|DRUG|pegvisomant|growth hormone antagonist, 10, 20 or 30 mg per day via subcutaneous injection for up to 1 year
223675187|NCT03687905|DRUG|Chloroquine|group1 received chloroquine .
223675188|NCT03687905|DRUG|Hydroxychloroquine|Group 2 received hydroxychloroquine
223675189|NCT01661088|DRUG|FOLFIRINOX|"Starting dose levels as following:~Oxaliplatin 85mg/m2 intravenously over 120 minutes on day 1. Irinotecan 180mg/m2 intravenously over 90 minutes on day 1. NOTE: patients homozygous for the UGT1A1 (TA)7 promoter allele will be treated at an initial lower dose 140mg/m2 (please see Section 6.3.a) Leucovorin 400mg/m2 intravenously over 90 minutes on day 1. 5FU 400mg/m2 as bolus intravenous injection following leucovorin on day 1. 5FU 2,400mg/m2 infused intravenously as a continuous infusion over 46 hours following the bolus 5FU, beginning on day 1."
223675190|NCT01661088|RADIATION|Intensity-modulated radiotherapy (IMRT)|50.0Gy in 2.0Gy per fraction
223675191|NCT01661088|PROCEDURE|Surgical Exploration|Patients without metastatic disease will be offered surgical exploration.
223675192|NCT01198158|BIOLOGICAL|Bevacizumab|Given IV
223675193|NCT01198158|DRUG|Everolimus|Given PO
223675194|NCT01198158|OTHER|Laboratory Biomarker Analysis|Correlative studies
223675195|NCT01198158|OTHER|Pharmacological Study|Correlative studies
223675196|NCT03023046|DRUG|Cyclophosphamide|Given IV
223675197|NCT03023046|DRUG|Dasatinib|Given PO
223675198|NCT03023046|DRUG|Doxorubicin|Given IV
223675199|NCT03023046|DRUG|Etoposide|Given IV
223675200|NCT03023046|DRUG|Imatinib Mesylate|Given PO
223675201|NCT03023046|OTHER|Laboratory Biomarker Analysis|Correlative studies
223675202|NCT03023046|DRUG|Prednisone|Given PO
223675203|NCT03023046|BIOLOGICAL|Rituximab|Given IV
224256554|NCT03341182|PROCEDURE|conventional manner|A portable mirror is located at the side of surgical table and used in this procedure.
224256555|NCT06126263|DRUG|Linezolid|Adjunctive antitoxin therapy
224256556|NCT06126263|DRUG|Clindamycin|Adjunctive antitoxin therapy
224256557|NCT03368287|DEVICE|Fitbit One, the activity tracker|Activity tracker, Fitbit One, will be used for a week to evaluate the steps of daily life before the surgery and at the time of follow up.
224256558|NCT01612091|DEVICE|Monitoring Messenger|Monitoring Messenger prototype device
224256559|NCT01612091|DEVICE|Traditional tools|Paper based records, screenshots of monitors and therapy devices
224256560|NCT04630327|OTHER|Beck Depression Inventory-21 (diagnostic survey)|Kazakh or Russian versions of the Beck Depression Inventory-21will be filled by female cancer patients
224256561|NCT04630327|OTHER|Beck Anxiety Inventory|Kazakh or Russian versions of the Beck Anxiety Inventory will be filled by female cancer patients
224256562|NCT04630327|OTHER|Interview using The International Classification of Diseases in tenth edition (ICD-10) criteria|Interview using The International Classification of Diseases in tenth edition (ICD-10) criteria as a gold standard of diagnosing depression or anxiety
224256563|NCT01526174|DRUG|Golimumab|Intratympanic injection 0.3ml First Arm: 1 injection Second Arm: 4 injections
224256564|NCT05651191|DRUG|Human CD19 Targeted DASH CAR-T Cells Injection|Autologous genetically modified anti-CD19 CAR transduced T cells
224256565|NCT06354894|DEVICE|Proximal humeral fracture fixation|percutaneous pinning VS plate and screws
224256566|NCT05510830|PROCEDURE|diagnostic cervical conization|For the patients who met the inclusion criteria, the gynecologists perform cervical conization and pathological examinations. Then the patients will be followed-up for at least two years with the tests of cervical TCT \& HPV, and colposcopy if necessary. The data will be analyzed and see if the patients with high risk factors benefit from the surgery or not.
224256567|NCT03474757|OTHER|Data Collection|Data will be extracted from July 2009 to the last available database extraction
224256568|NCT02564965|DEVICE|Double Pigtail Plastic Stent|Patients will be stratified into two arms (Greater than 50% necrosis or less than 50% necrosis), then will be randomized to either the double pigtail plastic stent or AXIOS metal stent
224256569|NCT02564965|DEVICE|AXIOS Metal Stent|Patients will be stratified into two arms (Greater than 50% necrosis or less than 50% necrosis), then will be randomized to either the double pigtail plastic stent or AXIOS metal stent
224256570|NCT04009486|DEVICE|Whole Body Vibration|"Subjects will undergo whole body vibration (standing on a power plate device 3 times a week, for 30 minute sessions, for 6 weeks)"
224256571|NCT00123734|DRUG|ThromboView|
224256572|NCT00044135|DRUG|clevudine (drug)|
224256573|NCT03506763|DRUG|Placebo Oral + Placebo Oral|Placebo Oral + Placebo Oral
224256574|NCT03506763|DRUG|Diclofenac oral + Placebo Oral|Diclofenac oral + Placebo Oral
224256575|NCT03506763|DRUG|Diclofenac oral + scopolamina oral|Diclofenac oral + scopolamina oral
224256576|NCT06187363|PROCEDURE|Tubularized incised plate procedure|Tubularized incised plate urethroplasty procedure
223675204|NCT03023046|DRUG|Vincristine Sulfate|Given IV
224256577|NCT06187363|PROCEDURE|Other procedures|Other procedures than tubularized incised plate urethroplasty procedure
224256578|NCT03621163|PROCEDURE|Bleaching agent ( BOOST 40%)|Opalescence Boost 40% is a 40% hydrogen peroxide, medical power bleaching gel. The jet mix syringe ensures freshness for each application and precise dosing of the activator. One barrel contains a unique chemical activation with sodium fluoride and potassium nitrate, which have been demonstrated to reduce caries susceptibility, lower sensitivity, and improve enamel micro-hardness. The other barrel contains the concentrated hydrogen peroxide. When mixed, Opalescence Boost results in a 1.1% fluoride and 3% potassium nitrate concentration.
224256579|NCT03621163|PROCEDURE|laminate veneers(lithium-silicate)|A lithium-silicate glass ceramic is newly introduced to the market. After crystallization, it demonstrates an ideal combination of strength, aesthetics and translucency that mirrors the vitality of natural teeth for fabrication of full anatomic anterior and posterior crowns. It differentiated from other ceramics by its high chipping resistance, due to their monolithic composition and average flexural strength of 385 MPa. Also Milling Block has good wear resistance due to the high content of ultra-fine nano-meter size crystalline structure. Lithium-silicates ceramic blocks are available in the commonly used VITA Classical and Chromascop Bleach shades.
224256580|NCT06400355|DRUG|Mannitol|in which mannitol will be given in doses of 0.5 gm/kg 30 minutes before the end of the surgery
224256581|NCT06400355|DRUG|Ringer's Lactate|similar volume of the infused mannitol but of lactated Ringer will be given 30 minutes before the end of the surgery.
224256582|NCT03161717|DEVICE|Epidural electrical stimulation (EES)|Using loss of resistance technique and electrical stimulation
224256583|NCT03161717|DEVICE|Loss of resistance (LOR)|Using loss of resistance technique only
224256584|NCT01827566|OTHER|gluten|
224256585|NCT01827566|OTHER|gluten free flour|
224256586|NCT04430985|DRUG|Oxaliplatin|Day 1 in cycle 1-4: 100 mg/m2 intrahepatic administration Day 1 in cycle 5-8: oxaliplatin 85 mg/m2 i.v.
224256587|NCT04430985|DRUG|5-Fluorouracil|Day 1 each cycle: 400 mg/m2 i.v. bolus, 2400 mg/m2 i.v.over 46 hrs
224256588|NCT04430985|DRUG|Leucovorin|Day 1 each cycle: 400 mg/m2 i.v.
224256589|NCT04430985|DRUG|Nivolumab|Day 3 in cycle 3 to 8: 3 mg/kg i.v.
224256590|NCT04430985|DEVICE|Ipilimumab|Day 3 in cycle 3 and 6: 1 mg/kg i.v.
224256591|NCT03405688|PROCEDURE|Blood sampling|Extra blood samples taken for laboratory analysis
224256592|NCT02530333|OTHER|Neuromuscular Prevention Program|Participants in the intervention group will complete at 6 week ACL injury prevention program previously described in the literature as being effective at reducing ACL injury risk. The prevention program lasts 20-25 minutes in duration and will take place as a warm-up prior to any practice. The frequency will depend solely on the number of practices each team holds throughout the given 6-week time period.
224256593|NCT03597711|DEVICE|IVcannulation|Peripheral venous cannulation is a common procedure on neonatal NICU, especially in preterm infants
224256594|NCT06381128|RADIATION|Cardiac CT|Computed tomography angiography
224256595|NCT00023361|DRUG|Rifabutin|
224322423|NCT03337269|OTHER|Educational video|Approximately 7 minute video on the HPV vaccine
224322424|NCT03337269|OTHER|Educational handout|One page handout on the HPV vaccine
224256596|NCT02525211|DRUG|Ropivacaine|a bolus of 10 ml of ropivacaine 7,5 mg / l then by a diffuser of local anesthesic (Ropivacaine 2mg / ml in continuous flow 10ml / hour) connected on the catheter the day after the intervention before returning at home
224256597|NCT02525211|DRUG|physiological saline|a bolus of 10 ml of physiological saline in the catheter of multi- drilled cicatricial perfusion
224256598|NCT06041945|DEVICE|Standard, high-definition colonoscopy with the use of CADe assistance|All detected polyps regardless of size and optical diagnosis will be resected and sent to pathology.
224256599|NCT06041945|DEVICE|Standard, high-definition colonoscopy with the use of CADe/CADx assistance, no leave-in-situ|All detected polyps regardless of size and optical diagnosis will be resected and sent to pathology.
224322425|NCT03337269|OTHER|Control|Control
224256600|NCT06041945|DEVICE|Standard, high-definition colonoscopy with the use of CADe/CADx assistance, leave-in-situ|Polyps will be left in situ if diminutive (≤5 mm) in size, located in the rectum or sigma and optically diagnosed by the endoscopist using the system to be hyperplastic with high confidence, otherwise resected and sent to pathology.
224256601|NCT00247247|DRUG|Comtess®|
224256602|NCT04548375|DEVICE|SCS|Conventional SCS implants approved through all payors(government and private) for FDA approved indications
224256603|NCT05074576|OTHER|Mulligan group|"Ultrasound (8minutes, 1.5 w/cm2, pulsed), conventional transcutaneous electrical nerve stimulation (TENS) (20 minutes, 60-120 Hz frequency) and hot pack application (20 minutes) and interferential current (100 rpm) as electrotherapy agents. In addition to the conventional treatments, Sustained Natural Apophysial Gliding (SNAG) a type of Mulligan mobilization technique is applied. Mobilization is performed by giving 15-20 seconds rest between 3 sets of 4-5 repetations.~Patients were treated in a sitting position. SNAG technique was applied by the physiotherapist at each on spinal level. Active movement with using passive manual force in the direction of translation or rotation was applied to the cervical vertebrae. At the end range of the joint, overpressure was applied by the patient himself"
224256604|NCT05074576|OTHER|Control group|Electroterapy agents are applied in the same conditions with Mulligan Group. Active neck, shoulder and thoracic region exercises for correction postural misalignment are performed in both groups. All exercises were done in 3 sets of 10 repetitions. Stretching exercises of upper part of Trapezius, sternocleidomastoideus and pectoral muscles are done with 10 repetitions and for 15-30 seconds.
224256605|NCT00834340|DRUG|Glimepiride 4 mg Tablets|1 x 4 mg, single-dose fasting
224256606|NCT00834340|DRUG|AMARYL® 4 mg Tablets|1 x 4 mg, single-dose fasting
224256607|NCT01480544|OTHER|Experimental: Treatment 1|Physicians will receive financial incentives for improving the quality of obstetric and neonatal care provided to mothers and newborns as reported by mothers during household interviews.
224256608|NCT01480544|OTHER|Experimental: Treatment 2|Physicians will receive financial incentives for improving maternal and neonatal health outcomes as reported by mothers during household interviews.
224256609|NCT03399812|DIETARY_SUPPLEMENT|Animal protein|The animal protein intervention is a smoothie containing 40 grams of whey protein isolate.
224256610|NCT03399812|DIETARY_SUPPLEMENT|Plant protein|The animal protein intervention is a smoothie containing 40 grams of pea protein isolate.
224256611|NCT05956925|BEHAVIORAL|Intervention group was asked to take their BP daily and rate their motivation level and communicate with the research assistant. Their level will trigger the appropriate behavioral change SMS prompt.|The investigators showed participants how to use the Health Mate app, upload Withings BP cuff readings, upload historical data to the cloud, read trend lines in their record, rank their daily motivational level, and answer a brief short message service (SMS) question about whether the participants completed the behavioral change task encouraged by the daily message. A one-page instruction sheet with the research team's contact information was provided. Participants were instructed to take their BP daily, before their first meal and encouraged to avoid prior alcohol and caffeine intake as well as physical activity. The participants were instructed to rate their motivational level as low, moderate, or high via SMS when transmitting their BP value. Their level will trigger the appropriate behavioral change SMS prompt.
224256612|NCT04446676|DEVICE|stabilization with stem|In both groups revision endoprosthesis of knee will be implanted with stem or sleeve stabilization.
224256613|NCT04446676|DEVICE|stabilization with sleeve|In both groups revision endoprosthesis of knee will be implanted with stem or sleeve stabilization.
224256614|NCT02257658|DRUG|Doxycycyline|
223675205|NCT04149392|DEVICE|Continuous Glucose Monitor|Patients with diabetes hospitalized for heart failure or acute myocardial infarction will have a continuous glucose monitor (CGM) placed on the day of discharge. The participants will go home with the device and keep it for 6-14 days until they return to clinic for follow up visit. At this time the device will be removed, the information regarding glucose levels during those days will be downloaded and based on the download, a PharmD will have the option of increasing or decreasing insulin doses by a maximum of 10% to reduce hypoglycemia and/or hyperglycemia. The goal will be to adjust medications, if needed, to target blood sugars between 90-250mg/dl greater than 80% of the time.
223675206|NCT04817527|DRUG|Edaravone Dexborneol|Intravenous injections of edaravone dexborneol (37.5mg in 0·9% NaCl) BID for 7-14days.
224256615|NCT02257658|BEHAVIORAL|Incentive|
224256616|NCT02599558|DEVICE|Cytosponge|A capsule with a string attached with a sponge inside is swallowed. The string is held without any tension to allow the capsule to move into the stomach. The string will be held for five minutes to allow the capsule to dissolve in the stomach; a round mesh sponge about the size of a quarter is released.
224322426|NCT02226601|DRUG|Aprepitant|3 days perioperative Aprepitant once a day
224322427|NCT02226601|DRUG|Placebo|3 days perioperative Placebot once a day
224322428|NCT00394563|DRUG|RN624 (PF-04383119)|10 mcg/kg
224322429|NCT00394563|DRUG|RN624 (PF-04383119)|25 mcg/kg
224322430|NCT00394563|DRUG|RN624 (PF-04383119)|50 mcg/kg
224322431|NCT00394563|DRUG|RN624 (PF-04383119)|100 mcg/kg
224322432|NCT00394563|DRUG|RN624 (PF-04383119)|200 mcg/kg
224322433|NCT00394563|DRUG|placebo|
224322434|NCT06549855|DRUG|Sintilimab or Pembrolizumab and medroxyprogesterone acetate (MPA)/ megestrol acetate (MA)|"1. Sintilimab or Pembrolizumab 200mg intravenous injection, every 3 weeks~2. MA, 320mg/MPA, 500mg, po, once a day"
224322435|NCT05769010|DRUG|SHR-A1811|SHR-A1811: intravenous
224322436|NCT05769010|DRUG|Pyrotinib|Pyrotinib: oral
224322437|NCT05769010|DRUG|Bevacizumab|Bevacizumab: intravenous
224256617|NCT05885594|DRUG|[18F]NOS|\[18F\]-6-(2-fluoro-propyl)-4-methylpyridin-2-amine, also known as \[18F\]NOS, is a positron emitting radiopharmaceutical that has been studied in animals and humans which permits the visualization and measurement by positron emission tomography (PET/CT) imaging of in vivo iNOS expression as a marker of inflammation.
224256618|NCT02846363|OTHER|public awareness campaign|"The public awareness campaign was based on improving knowledge and skills of public to recognize stroke symptoms. The campaign materials were:~* 3 posters presenting the three main symptoms of stroke and the need to call the EMS immediately~* A leaflet on stroke will be created~* 3 participatory movies: These films will be posted on YouTube and broadcast on the website and the Facebook campaign page~* Actions on social networks: A Facebook group will be created (AVC: votre appel peut sauver des vie).~* A website developed with ICAP - UCBL Lyon1 (http://avc.univ-lyon1.fr/)~* On the occasion of World Stroke Day, held annually on 29 October, will be organized an event in Lyon in order to educate and inform the general public about stroke: the main symptoms and reflexes to adopt in case of stroke: call the EMS urgently"
224256619|NCT01885117|BIOLOGICAL|TIVf|Trivalent Influenza Virus Vaccine (purified surface antigen, inactivated, egg-derived)
224256620|NCT06545890|DRUG|Ketamine|continous infusion during surgery
224256621|NCT06545890|DRUG|Dexmedetomidine|continous infusion during surgery
224256622|NCT04238754|DRUG|Epidiolex|Epidiolex 100 mg/mL Oral Solution
224256623|NCT04238754|DRUG|Placebo|Cherry syrup oral solution
224256624|NCT01727947|OTHER|MSOME|A total of 200 spermatozoa of each sample will be analyzed under high magnification (x6600) and the incidence of SLV (sperm cells presenting at least one vacuole that occupied \> 13% of nuclear area) in each sample will be assessed.
224256625|NCT05256147|DRUG|Ibuprofen|Patient will receive ibuprofen 400 mg before the phototherapy session.
224256626|NCT00828698|OTHER|No intervention|
224256627|NCT02926677|BEHAVIORAL|Cue-Centered Treatment (CCT)|Identify stress reactions and develop coping skills to deal with them independently. Helps address ongoing traumatic stressors.
224256628|NCT02926677|BEHAVIORAL|Trauma-Focused CBT (TF-CBT)|Identifies negative cognitive/emotional patterns and helps re-frame them. Uses active support from guardians and focuses on emotional and cognitive conditioning. Focuses on discrete past incidents.
224256629|NCT02926677|BEHAVIORAL|Treatment as Usual|The control group. The standard treatment utilized at Stanford Youth Solutions
224256630|NCT02926677|DEVICE|NIRScout|The device is a portable Functional Near-Infrared Spectroscopy (fNIRS) recording unit. NIRS technology uses specific wavelengths of light, introduced at the scalp to enable the non-invasive measurement of changes in the relative ratios of deoxygenated hemoglobin (deoxy-Hb) and oxygenated hemoglobin (oxy-Hb) in the capillary beds during brain activity.
224256631|NCT00840073|DRUG|Trandolapril 4 mg Tablets|1 x 4 mg, single-dose fed
224256632|NCT00840073|DRUG|Mavik® 4 mg Tablets|1 x 4 mg, single-dose fed
224256633|NCT05107089|DEVICE|Ultrasound|Use of ultrasound at subclavian vein cannulation for visualization
224256634|NCT04814381|DRUG|Ketamine + Magnesium sulfate (drug combination)|A single infusion will be performed over 2 hours with 90 days follow-up.
224256635|NCT06574672|OTHER|Embedded Hospice and Palliative Care Practitioner|The hospice and palliative care practitioner will be embedded in one medical intensive care unit for the first half of the study timeframe, after which the practitioner will expand to both medical intensive care units. While active in a medical intensive care unit, the practitioner will proactively trigger palliative care consultations based on clinical criteria and estimated mortality risk, in addition to providing immediate availability for standard-of-care hospice or palliative care consultations.
224256636|NCT06574672|OTHER|Embedded Hospice and Palliative Care Practitioner (Group Effect)|While the hospice and palliative care practitioner is active in one medical intensive care unit with respect to triggering consultations, the other medical intensive care unit can still utilize the practitioner's services for standard-of-care hospice or palliative care consultations.
224256637|NCT06574672|OTHER|None (Historical)|This control arm includes historical patients admitted to the medical intensive care units prior to the study's enrollment timeframe.
224256638|NCT00424619|DRUG|Vitamin D2|50 000 IU vitamin D2, one time bolus dose
224256639|NCT00424619|DRUG|Vitamin D2|100 000 IU vitamin D2, one time bolus dose
224256640|NCT00424619|DRUG|Placebo|Placebo, 1 time bolus dose
224256641|NCT04325256|PROCEDURE|Manipal ultrasound scoring system|length of the cervix from the internal to external os, presence or absence of funneling and if present width and length of funneling at internal os were measured. Distance between presenting part to external os will be measured and position of the cervix i.e. whether curved or straight will also noted.
224256642|NCT04325256|PROCEDURE|Levine scoring system|maternal height, parity, body-mass index (BMI) at delivery and the results of modified Bishop's score in calculation of probability of CS
224256643|NCT06057753|BEHAVIORAL|MyStroke|Personalized video-based stroke education platform
224256644|NCT01103713|DRUG|Azithromycin plus chloroquine|Study drug is a fixed dose tablet of AZCQ containing 250 mg AZ and 155 mg CQ base. All subjects will be administered a 3 day course of AZCQ IPTp regimen: a single dose of 1000 mg AZ/620 mg CQ base (4 fixed dose combination tablets of AZCQ: 250mg/155mg) administered per os (PO, orally) once daily for 3 days (Days 0, 1, 2).
224256645|NCT05379972|DRUG|Pembrolizumab|Pembrolizumab 200mg IV every 3 weeks starting C2D1
224256646|NCT05379972|DRUG|Olaparib|Olaparib 200mg orally twice daily starting C1D1 concurrently with radiation. Starting C2D1, Olaparib 300mg orally twice with Pembrolizumab
224256647|NCT05379972|RADIATION|Stereotactic Body Radiation Therapy|Stereotactic Body Radiation Therapy Dose 25Gy in 5 fractions daily (M-F) for 5 days starting C1D1 with Olaparib
224256648|NCT04601792|DRUG|Individualized Decoction|Applied in the Tested Drug Observation Period. It is the highly individualized treatment of TCM, the modification of Bronchiectasis Stabilization Decoction (Rhizoma Fagopyri Cymosi 30g, Radix Lithospermi 15g, Radix Ophiopogonis 15g, Poria cocos 15g, Radix Astragali 20g, Rhizoma Bletillae 10g, Platycodon grandiflorum 10g, Semen Coicis 30g) based on syndrome differentiation. For example, for patients with qi and yin deficiency syndrome, the investigators added Adenophora Root, Radix Glehniae and Radix Rehmanniae Recens etc. For patients with phlegm-heat syndrome, the investigators added Radix Scutellariae and Viola Yedoensis etc. Besides, the herbs in a prescription could be changed according to different symptoms of individual patients.
224256649|NCT04601792|DRUG|placebo|Applied in the placebo Observation Period. Placebo is made by dextrin, bitter agent, edible pigment etc. and added 5% test drug. The test drug and control drug have no differences in dosage form, appearance, color, specification, label, and so forth.
224256650|NCT04601792|DRUG|Tested drug minus heat-clearing herbs|It is the decoction of the Syndrome Differentiation Decoction (tested drug) minus heat-clearing herbs. For example, heat-clearing herbs such as Scutellaria Baicalensis, Rhizoma Coptidisor Herba Violae will be removed from the Syndrome Differentiation Decoction.
224256651|NCT05524701|BEHAVIORAL|Sleep Restriction and Normal Sleep|The intervention will consist of either sleep restriction (4 hours per night, 3 am to 7 am) or normal sleep (8 hours per night 11 pm to 7 am) for a duration of two nights.
224256652|NCT02096783|OTHER|informational intervention|Given scripted intervention
224256653|NCT02096783|OTHER|counseling intervention|Given standard counseling
224256654|NCT02096783|OTHER|questionnaire administration|Ancillary studies
224256655|NCT00153530|DRUG|methotrexate|"1. chemotherapy with radiotherapy~2. chemotherapy without radiotherapy"
224256656|NCT00153530|RADIATION|radiotherapy|whole-brain irradiation
224256657|NCT02253420|DRUG|Copanlisib (BAY80-6946)|"Part 1 of Cycle 1 Cycle 1 Day 1: Single i.v. dose 12mg Cycle 1 Day 15: Single i.v. dose 12 mg Part 2 of Cycle 1 Cycle 1 Day 1: Single i.v. dose 60mg (based on Part 1 data) Cycle 1 Day 15: Single i.v. dose 60mg (based on Part 1 data)~Part 1 \& Part 2~Cycle 2 and subsequent cycles:~Day 1: Single i.v. dose of 60mg Day 8: Single i.v. dose of 60mg Day15: Single i.v. dose of 60mg"
224256658|NCT02253420|DRUG|Itraconazole|Cycle 1 Day 12: 2 x 200 mg itraconazole oral (two doses, 12 hours apart) Cycle 1 Days 13-21: 200 mg itraconazole oral, once daily in the morning
224256659|NCT02253420|DRUG|Rifampin|Cycle 1 Days 10 - 21: 600mg Rifampin oral, once daily in the morning
224256660|NCT02253420|DRUG|Copanlisib (BAY80-6946)|"Cycle 1 Day 1: Single i.v. dose 60mg Cycle 1 Day 15: Single i.v. dose 60mg~Cycle 2 and subsequent cycles:~Day 1: Single i.v. dose of 60mg Day 8: Single i.v. dose of 60mg Day15: Single i.v. dose of 60mg"
224256661|NCT01291121|PROCEDURE|Intravitreal expansile gas and ranibizumab injection|Intravitreal expansile gas (0.3 cc C3F8) and 0.5mg ranibizumab at day 0 Additional 3 monthly loading injection of intravitreal ranibizumab Additional injection of ranibizumab as needed
223675207|NCT03299179|DEVICE|MRI scan|Several MRI scan modalities: MPRAGE (structural scan), arterial spin labeling (cerebral perfusion), resting state functional-MRI (fMRI, cerebral activity) and diffusion MRI (white matter diffusion and white matter tracts).
223675208|NCT03299179|DEVICE|Physiological monitoring|During MRI: heart rate, end-tidal carbon dioxide (CO2), respiratory rate and skin conductance
223675209|NCT03299179|BIOLOGICAL|Blood sample|Blood sample after MRI-session: measurement of hematocrit, hemoglobin, estradiol, progesterone, follicle stimulation hormone and luteinizing hormone.
223675210|NCT03299179|DEVICE|Blood pressure measurement|Measuring blood pressure before and after MRI-scan
223675211|NCT03299179|DEVICE|Body temperature|Measuring body temperature before and after MRI-scan
223675212|NCT03299179|OTHER|Questionnaires|Questionnaires at the start of the study on lifestyle. Additionally, a questionnaire before each scan session on the actual state of the volunteer (e.g. mood, caffeine consumption, alcohol, medication, etc.)
224256662|NCT00852020|DIETARY_SUPPLEMENT|oral nutrition supplement, food for special medical purposes|2 servings of 200-300 ml per day, treatment period: 16 weeks
224256663|NCT05769725|DRUG|Serplulimab|Serplulimab, 4.5mg/kg solution intravenously for 30 min in first day every 3 weeks. Repeated every 21 days. 21 days for a cycle.
224256664|NCT05769725|DRUG|Docetaxel|40 mg/m\^2 solution intravenously for 1 hour in first day every 3 weeks. Repeated every 21 days, 21 days for a cycle, from second cycle to seventh cycle.
224256665|NCT05769725|DRUG|S1|Tegafur-gimeracil-oteracil potassium: 50mg bid orally in 14 days, followed by 7 days off. Rrepeated every 21 days. 21 days for a cycle.
224256666|NCT02499718|DEVICE|BiPAP mode|Noninvasive ventilator
224256667|NCT02042781|DRUG|PG545|PG545 will be administered once weekly, as a one hour IV infusion. Patients will be treated until they exhibit disease progression, withdraw due to poor tolerability, or the study reaches its defined end-point. This study is a dose escalation study with doses of 25 mg to 250 mg anticipated.
224256668|NCT02671526|OTHER|Computerized plasticity-based adaptive cognitive training|
224256669|NCT03786822|PROCEDURE|Cryoballoon Pulmonary Vein Isolation - PVI|A 28-mm cryoballoon (Arctic Front Advance™ Cardiac CryoAblation Catheter, Medtronic, Minneapolis, MN) will be employed. The cryoballoon catheter will be introduced into the left atrium, following a single transeptal puncture, through a 12 French steerable sheath (FlexCath, Medtronic), constantly flushed with heparinized saline. A circular mapping catheter (Achieve, Medtronic) will be advanced through the cryoballoon to the PV orifice and positioned as proximally as possible inside the vessel to record the PV potentials at baseline and monitor the isolation procedure in real time.
224256670|NCT01884090|BEHAVIORAL|Youth Empowerment Solutions (YES)|Participants receiving the The 16-week, 30-session YES curriculum YES as a part of the 21st Century after-school program at middle schools that have high economic and academic needs. 21st Century is a U.S. Department of Education program which provides academic enrichment opportunities during non-school hours and during the summer for children who attend low-performing schools in areas with high poverty (U.S. Department of Education, 2009).
223675213|NCT03299179|DIAGNOSTIC_TEST|Pregnancy test|Test for pregnancy using a pregnancy dipstick test
223675214|NCT00082927|DRUG|ibandronate sodium|
223675215|NCT05300373|DIAGNOSTIC_TEST|ADENOSINE DEAMINASE TEST|ADENOSINE DEAMINASE DEFICIENCY TEST
223675216|NCT01479218|DEVICE|Occlutech PDA occluder|Four different sizes of Occluders will be evaluated based on pre-assessment of PDA size.
223772711|NCT01858194|DEVICE|Renal sympathetic denervation|"* The ablation catheter is placed within a long vascular sheath and advanced into the renal artery. The sheath is advanced over the catheter to engage the renal artery ostium and allow for contrast injection and visualization of the vessel during catheter manipulation.~* After completion of the measurement, no more than six radiofrequency ablation lesions separated both longitudinally and rotationally (a spiral pattern, see figure) will be placed per renal artery. The power will be started at 10 W and titrated to a maximum 20 W, as deemed appropriate by the impedance drop (goal 10% drop). Each lesion should be between 30-120 seconds in duration (no more than 120 seconds per lesion)."
223772712|NCT01858194|DEVICE|VT ablation alone|Placebo arm will receive standard VT ablation using current techniques
224256671|NCT01172145|DRUG|Modafinil|100 mg in the morning for the first week and 200 mg in the morning for the remaining seven weeks
224256672|NCT01172145|DRUG|Placebo|100 mg in the morning for the first week and 200 mg in the morning for the remaining seven weeks
224256673|NCT04011917|BEHAVIORAL|Standard care|Treatment by an extended scope physiotherapist following Standard Operating Procedures.
224256674|NCT06462066|PROCEDURE|Experimental medical device|Open the blister and pour the sterile single-dose bottle onto the operating table in a sterile field. Before opening the single-dose bottle verify the state of fluidity of the glue and its transparency. Open the single dose of Gluban Tiss® 2. Insert the transfer tip on the single dose, grabbing it near the neck to apply adequate pressure that allows the insertion of the tip. Gradually fill the cartridge by carefully pressing on the body of the single dose.
224256675|NCT06462066|PROCEDURE|Comparator medical device|Open the blister and pour the sterile single-dose bottle onto the operating table in a sterile field. Before opening the single-dose bottle verify the state of fluidity of the glue and its transparency. Open the single dose of Glubran® 2. Insert the transfer tip on the single dose, grabbing it near the neck to apply adequate pressure that allows the insertion of the tip. Gradually fill the cartridge by carefully pressing on the body of the single dose.
224322438|NCT01590277|DRUG|Active Ethanol|Target BrAC of 0.1% reached over 30 minutes and then clamped to maintain this dose for an additional 60 minutes. This dose is equivalent to consuming approximately 5 drinks. Administered over a total of 90 minutes.
223675217|NCT03641885|BEHAVIORAL|mothers and adolescents|The intervention package will be sent to mothers and adolescents via Telegram social media. It contains behavior change techniques targeting outcome expectancy, self-efficacy, action planning, coping planning, and self-monitoring. There will be 3 assessment points in time, baselines, 1 month and six months after interventions.
223675218|NCT03641885|BEHAVIORAL|adolescents|The intervention package will be sent to only adolescents via Telegram social media. It contains behavior change techniques targeting outcome expectancy, self-efficacy, action planning, coping planning, and self-monitoring. There will be 3 assessment points in time, baselines, 1 month and six months after interventions.
223675219|NCT03641885|BEHAVIORAL|active control|The active control group receives an information sheet regarding recommendations on oral health behavior via telegram. There will be 3 assessment points in time, with 1 month and six months in between.
223675220|NCT03103815|DRUG|Amivita|In each course, Amivita solution (500ml) will be administrated i.v. once daily for 4 weeks. After an interval of 2 weeks, the participants will be treated again. A total of 7 courses will be given,
223675221|NCT05592522|OTHER|External oblique intercostal block|EOI block:Under guidance of the linear high frequency transducer, sagittal plane between anterior axillary line and midclavicular line at the level of the 6th rib, In-plane approach between external oblique and intercostal muscles Hydrodissection with 30 ml of 0.25% bupivacaine hydrochloride .
223675222|NCT05592522|OTHER|Oblique subcostal TAP block|OSTAP block: The needle was inserted in plane through the rectus adjacent to costal margin Once the tip of the needle was visualized in between the rectus muscle and transversus abdominus muscle and negative pressure aspiration was demonstrated, 30 ml bupivacaine 0.25% was deposited within the plane and hydrodissection was noted.
223675223|NCT05592522|OTHER|Posterior Rectus sheath block|Posterior rectus sheath block: Under linear ultrasound probe, the needle was advanced gradually through the rectus muscle posteriorly toward its medial edge, approaching the rectus sheath. After negative aspiration,12.5 mL bupivacaine 0.25% was injected until the rectus muscle was separated from the posterior rectus sheath by hydrodissection.
223675224|NCT00929812|DRUG|Glucagon hydrochloride (GlucaGen®)|1 mg/1 ml of glucagon hydrochloride intramuscularly
223675225|NCT00929812|DRUG|NaCl 0.9%|1 ml NaCl 0.9% intramuscularly
223675226|NCT05105022|DRUG|Propofol|Intravenous induction of general anesthesia in infants 3 months or less.
223772713|NCT04926675|BEHAVIORAL|Psychological Therapy|Participants will be receiving their one-to-one psychological therapy from IAPT as usual. They typically receive between 6 and 12 sessions with a psychological practitioner.
224256676|NCT05608447|BIOLOGICAL|FMT capsules|FMT capsules containing extensively screened donor stool.
224256677|NCT05608447|OTHER|Placebo capsules|Placebo capsules that do not contain donor stool or any active drug.
224256678|NCT04256720|BEHAVIORAL|No intervention|No intervention - questionnaire study
224256679|NCT03084471|BIOLOGICAL|MEDI4736 (Durvalumab)|A human monoclonal antibody (mAb) of the immunoglobulin G (IgG) 1 kappa subclass that blocks the interaction of PD-L1 (but not programmed cell death ligand-2) with PD-1 on T cells and CD80 (B7.1) on immune cells (IC).
224256680|NCT03084471|BIOLOGICAL|MEDI4736 (Durvalumab) + Tremelimumab|"Durvalumab: A human mAb of IgG 1 kappa subclass that blocks the interaction of PD-L1 (but not programmed cell death ligand-2) with PD-1 on T cells and CD80 (B7.1) on IC.~Tremelimumab: A human Ig G2 mAb that completely blocks the interaction of human CTLA-4 (cluster of differentiation \[CD\]152) with CD80 and CD86 and increase release of cytokines (interleukin \[IL\]-2 and interferon \[IFN\]-γ) from human T cells, peripheral blood mononuclear cells and whole blood."
224256681|NCT02354339|DIETARY_SUPPLEMENT|Irvingia gabonensis|Intervention will be administered 30 minutes before meals
224256682|NCT02354339|OTHER|Placebo|Intervention will be administered 30 minutes before meals
224256683|NCT00505622|DRUG|Perampanel|
224256684|NCT02822326|BIOLOGICAL|CD19-CAR-T2 Cells|
224256685|NCT00267592|DRUG|Talampanel|Talampanel administered orally TID beginning the first day and continued until there is talampanel-related toxicity or tumor progression.
224256686|NCT00267592|RADIATION|Radiation Therapy (RT) 5 days a week +|
224322439|NCT01590277|DRUG|Active Iomazenil|Active iomazenil, administered intravenously at a dose of 3.7 ug/kg. Administered over 10 minutes, beginning 10 minutes after the start of the ethanol/placebo clamp.
224322440|NCT01590277|DRUG|Placebo|Control: no alcohol, administered for a total of 90 minutes.
224322441|NCT01590277|DRUG|Placebo|Control: no iomazenil, administered for a total of 10 minutes
224322442|NCT06218576|OTHER|None, purely observational study|None, purely observational study
224322443|NCT01377012|BIOLOGICAL|Secukinumab (AIN457)|AIN457 (Secukinumab) is a human monoclonal antibody. Secukinumab binds and reduces the activity of Interleukin 17 (IL- 17). AIN457 was given as i.v. (10mg/kg) at baseline, week 2 and week 4, and then s.c. (75 or 150mg) every 4 weeks starting at week 8.
224322444|NCT01377012|BIOLOGICAL|Placebo|Placebo was given as i.v. at baseline, week 2 and week 4, and then s.c. every 4 weeks starting at week 8.
224256687|NCT00267592|DRUG|temozolomide(TMZ) 75mg|temozolomide(TMZ) 75mg 3 times daily (TID) for 6 weeks
224256688|NCT00267592|DRUG|adjuvant TMZ 200mg|adjuvant TMZ 200mg TID for 5 consecutive days each month for a total of 6 months.
224256689|NCT05669781|DRUG|Metoclopramide 10mg|Intravenous metoclopramide 10mg 8hourly for the first 72hours post-operatively
224256690|NCT05669781|COMBINATION_PRODUCT|Gum and metoclopramide|Intravenous metoclopramide 10mg 8hourly for the first 72hours post-operatively and one stick of sugar-free gum (over 15minutes) 8 hourly till either the first flatus or feces was passed
224256691|NCT05669781|OTHER|Gum|One stick of sugar-free gum (over 15minutes) 8 hourly till either the first flatus or feces was passed
224256692|NCT05669781|OTHER|Control|10ml of sterile water intravenously 8hourly for the first 72hours post-operatively
224256693|NCT00612287|DRUG|buprenorphine|Sublingual buprenorphine; product name Suboxone® (buprenorphine/naloxone). Dosing is informed by a clinical guideline which permits flexibility dependent up physician's clinical judgment. During the induction period (Day 1, at the physician's office) the first dose is 2 mg and can be brought up to 20 mg depending on patient's response. On Day 2 going forward dose can range from 2 mg q8h to 12 mg q8h. Rescue doses with buprenorphine are also permitted.
223675227|NCT01879527|DRUG|Amiloride hydrochlorothiazide|Blinding will be done by over-encapsulating amiloride HCT tablets and providing corresponding placebo capsules.Patients will be provided with capsules (size 00) containing one tablet of study medication (Amilostad HCT 5/50mg tablet or placebo) and instructed to take these capsules once daily in the morning together with breakfast. Visit 2 will be scheduled one week after baseline and at visit 2 patients will be provided with capsules containing two tablets of study medication. This maintenance dose will not be changed throughout the remaining study period. Placebo will be administered in the exact same manner.
223675228|NCT01879527|DRUG|Sugar pill|containing placebo
223675229|NCT06489379|DEVICE|high flow nasal cannula|humidified and heated oxygen
223675230|NCT06489379|OTHER|standard oxygen|oxygen delivery through Venturi mask
223675231|NCT02187874|PROCEDURE|delayed umbilical cord occlusion|
223675232|NCT02187874|PROCEDURE|early umbilical cord occlusion|
223675233|NCT02187874|DRUG|Oxytocin|
223675234|NCT01063712|DEVICE|Nit-Occlud® PDA-R|"Transcatheter implantation of a PDA Device (Nitinol) The catheterism was done under sedation, using a protocol established by inserting a catheter through a femoral artery and/or vein directed to the heart and great vessels. Invasive measurements are obtained in the descending aorta and pulmonary artery. Once in ductal position, we inject iodinated contrast medium that allows us to observe via X-ray the ductal morphology; obtaining accurate measurements to choose the appropriate device. The device is then inserted via the catheter, closing the ductus.~The catheterism provides measures of aortic and pulmonary pressure, before, during and after the closure."
223675235|NCT04814901|PROCEDURE|Curing small and medium sized oronasal fistula|"* Flap will be marked medial to the duct, which limits posterior extent of flap. Anterior flap marking starts 1cm posterior to oral commissure.~* Width of flap was kept to about 2-2.5cm.~* An initial incision will be made 1cm posterior to oral commissure.~* Incision will be deepened through buccal mucosa, submucosa, \& underlying muscles into layer of buccal fat.~* Flap will be dissected in a retrograde or antegrade manner depending on fistula site, maintaining vessels in a central position in the flap.~* Once completely raised, flap inserted \& sutured in place while donor site be closed primarily with 4-0 polyglactin (Vicryl) interrupted sutures.~* Patient's comparator group will be treated by raising a palatal pedicled flap.~* Flap will be outlined extending from palatal mucosa against permanent 2nd molar till permanent canine anteriorly.~* It is rotated towards oronasal fistula \& secured in place using 4 -0 Vicryl interrupted sutures."
223675236|NCT04733443|DEVICE|Biolimus|140 patients who met the inclusion/exclusion criteria for in-stent restenosis were enrolled and assigned to the Biolimus treatment group
223675237|NCT04733443|DEVICE|SeQuent® Please Neo|140 patients who met the inclusion/exclusion criteria for in-stent restenosis were enrolled and assigned to the SeQuent® Please Neo treatment group
223675238|NCT01596543|OTHER|partial and complete sleep deprivation|The subjects will visit our labs 4 times. The second visit will be used as the experimental control. During the third and fourth visits the subject will go through an exercise heat tolerance test and a measurement of their physiological efficiency after a partial and complete sleep deprivation, respectively.
223675239|NCT05933070|BIOLOGICAL|INKmune|INKmune is a patented biologic delivery system and method for cancer treatment using in vivo priming and activation of natural killer (NK) cells in order to achieve tumor cell lysis. INKmune is a suspension of INB16 cells which have been rendered replication incompetent. INKumne is a replication-incompetent tumor cell line that does not require donor matching.
223675240|NCT00882219|DEVICE|Xience V®|Placement of a Xience V® stent within a restenosed bare metal stent.
223675241|NCT05822531|BEHAVIORAL|Maternal CVH Intervention|All participants will be enrolled into the intervention arm of this pilot study.
223675242|NCT06631937|OTHER|Human Milk Oligosaccharides|Human Milk Oligosaccharides provided in a commercially available infant formula powder, fed daily ad libitum from enrollement to 6 months of age
224256694|NCT04991194|DRUG|BIA 5-1058|Each subject was administered either 1200 mg (Part 1) or 400 mg (Part 2) BIA 5-1058 od for 10 days, in fasting conditions for 8 hours \[Day (D)2 to D9\] or 10 hours (D1 and D13), and remained fasted for 2 hours (D2 to D9) or 4 hours (D1 and D13) post-dose. The formulation was tablets 100 mg and the mode of administration was oral.
224256695|NCT04138368|BEHAVIORAL|dyadic psychotherapeutic intervention|Mothers and infants will be treated with dyadic psychotherapy focused on interactions, emphasizing eye contact, body language, empathy, and social reciprocity, using the principles of Interaction Guidance Therapy (Sameroff et al., 2004). Dyadic psychotherapy will be administered one time a week during the 8-week trial period, at the subject's home. Each session, approximately 90 minutes long, will include videotaping mother-infant interaction, watching the last session's interaction as a part of video-feedback technique, and discussing main issues in the mother-infant relationship. In addition, each session will begin and end with a- 5-minute episode of affectionate touch and gaze synchrony between the mother and her infant.
224256696|NCT04138368|BEHAVIORAL|supportive intervention|Supportive therapy: mothers will receive psychoeducational knowledge regarding the infants' development. The treatment will be administered one time a week during the 8-week trial period, at the subjects' home.
223772714|NCT04926675|BEHAVIORAL|Debt Advice|Participants will receive one-to-one support from a Citizen's Advice (CA) money advisor for as long as needed to resolve any money worries currently affecting their mental health.
223772715|NCT05067075|DEVICE|Blinded CGM|CGM that records blood glucose but is not visible to patient or provider in real-time
224256697|NCT06331247|BEHAVIORAL|General dietary advice|General dietary advice according to the Chinese Dietary Guidelines 2022.
224256698|NCT06331247|BEHAVIORAL|Localized MIND diet intervention|The MIND diet intervention, composed of the consumption of whole grains, dark green leafy vegetables, dark red/yellow vegetables, other vegetables, berries and citrus, poultry, fish and seafoods, beans and legume, nuts, olive and seed oils, and green tea, and restricting red and processed meats, animal fat, fried foods, and sweets and pastries.
224256699|NCT06331247|OTHER|Routine medical care|Routine medical care and follow-ups.
224256700|NCT01451047|BIOLOGICAL|Autologous cultured dermal and epidermal cells|A piece of occipital scalp is taken from the subject. The epidermal and dermal cells from this tissue are expanded in culture. The cells are then harvested and, for certain types of product, combined. These cells are then injected into the balding area of the scalp of the original subject.
224256701|NCT00287963|DRUG|topotecan hydrochloride|
224256702|NCT00287963|DRUG|vinorelbine tartrate|
224256703|NCT05226923|DRUG|KSP-1007|Single and multiple doses, intravenous administration
224256704|NCT05226923|OTHER|Placebo:0.9% sodium chloride|Single and multiple doses, intravenous administration
224256705|NCT05226923|DRUG|Meropenem|Multiple doses, intravenous administration
224256706|NCT04239833|DRUG|SH-1028 tablets|"The initial dose of SH-1028 tablets is 200 mg once daily . A cycle of treatment is defined as 21 days of once daily treatment.~Number of Cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria."
224256707|NCT04239833|DRUG|Placebo SH-1028 tablets|"The initial dose of Placebo SH-1028 tablets is 200 mg once daily . A cycle of treatment is defined as 21 days of once daily treatment.~Number of Cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria."
224256708|NCT04239833|DRUG|Gefitinib|"The initial dose of Gefitinib is 250 mg once daily . A cycle of treatment is defined as 21 days of once daily treatment.~Following objective disease progression according to RECIST 1.1, as per investigator assessment, patients who were randomized to Standard of Care arm may have the option to receive open-label SH-1028 tablets (crossover to active SH-1028 tablets)."
224256709|NCT04239833|DRUG|Placebo Gefitinib|The initial dose of Gefitinib is 250 mg once daily . A cycle of treatment is defined as 21 days of once daily treatment.
224256710|NCT00018733|DRUG|paroxetine|
223675243|NCT06631937|OTHER|Placebo|An identical commercially available infant formula powder without Human Milk Oligosaccharides, fed daily ad libitum from enrollement to 6 months of age
223675244|NCT00246571|DRUG|SU011248|SU011248 capsules administered orally, daily in a continuous regimen, 3-week cycles, starting dose of 37.5 mg daily. 1-week treatment rests and dose reductions allowed for dose-limiting toxicity. Dose escalate SU011248 to 50-mg daily if minimal toxicities . Study will continue until disease progression. Patients randomized to or crossed over to SU011248 may continue beyond the time of Response Evaluation Criterion in Solid Tumors (RECIST) -defined progression at the discretion of the investigator in the case of clinical benefit.
223772716|NCT00517920|DRUG|ABT-869|0.25 mg/kg QD
223772717|NCT05501509|PROCEDURE|Coracoclavicular fixation with acromioclavicular stabilization for the management of an unstable acromiclavicular luxation|Using a 3-hole third plate and high resistance sutures across the acromioclavicular joint to achieve horizontal and vertical stability of the joint
223772718|NCT05501509|PROCEDURE|Coracoclavicular fixation for the management of an unstable acromiclavicular luxation|Isolated coracoclavicular repair using a 3 hole third plate.
223772719|NCT04496609|DEVICE|Stimulation and automated rehabilitation / automated rehabilitation|Stimulation and automated rehabilitation for 40 working days, then washout during 30 days, then automated rehabilitation for 40 working days
224256711|NCT00018733|DRUG|Desipramine|
224256712|NCT00796653|DRUG|Olodaterol (BI 1744)|Comparison of low and high doses on efficacy and safety in COPD patients
224256713|NCT00796653|DRUG|Olodaterol (BI 1744)|Comparison of low and high doses on efficacy and safety in COPD patients
223772720|NCT04496609|DEVICE|Automated rehabilitation / Stimulation and automated rehabilitation|Automated rehabilitation for 40 working days, then washout during 30 days, then automated rehabilitation for 40 working days
223772721|NCT00260052|DRUG|Erythropoietin administration|
223772722|NCT00871559|DRUG|REGN421(SAR153192)|
223772723|NCT03678181|BEHAVIORAL|Information Resources|The investigators will provide a HIV-related content as the attention-control condition.
223772724|NCT03678181|BEHAVIORAL|Social Support|The investigators will provide evidence-based answers to users' health questions, including linkage to care.
223772725|NCT03678181|BEHAVIORAL|HIV Testing|The investigators will provide opportunities for participants to get tested through HIV home test kits.
223772726|NCT05525182|DRUG|ES16001 40 mg|Composition: Elaeocarpus extract 40mg tablet
223772727|NCT05525182|DRUG|ES16001 80 mg|Elaeocarpus extract 80 mg tablet
223772728|NCT05525182|DRUG|ES16001 160 mg|Elaeocarpus extract 160 mg tablet
223772729|NCT05525182|DRUG|Placebo|Placebo Tablet: Tablets for oral use indistinguishable from ES16001 in size, appearance, taste and smell
223772730|NCT02201797|OTHER|DCE MRI|
224256714|NCT00796653|DRUG|Formoterol|Active comparator with Olodaterol (BI 1744) on safety and efficacy in COPD patients
224256715|NCT00796653|DRUG|Placebo|Placebo devices for comparison with Olodaterol (BI 1744) on safety and efficacy in COPD patients
224256716|NCT04405765|DEVICE|NPWT and lyopreserved Stravix|Subjects will be treated with NPWT and lyopreserved Stravix
224256717|NCT04405765|DEVICE|NPWT and cryopreserved Stravix|Subjects will be treated with NPWT and lyopreserved Stravix
224256718|NCT03393208|DRUG|Test GIR|Participants received 500 milligrams (mg) test GIR in fasting or fed state on either Day 1 (Treatment Period 1) or Day 8 (Treatment Period 2).
224256719|NCT03393208|DRUG|Reference GIR|Participants received 500 mg reference GIR in fasting or fed state on either Day 1 (Treatment Period 1) or Day 8 (Treatment Period 2).
223675245|NCT00246571|DRUG|Chemotherapy|"The choice of chemotherapy will be at the discretion of the investigator within the limits outlined below.~1. Capecitabine - 1000-1250 mg/m2 twice daily days 1-14 every 3 weeks~2. Vinorelbine - 25-30 mg/m2 rapid intravenous infusion or 60-80 mg/m2 oral weekly, expressed in 3-week cycles~3. Docetaxel - 75-100 mg/m2 every 3 weeks~4. Paclitaxel - 175-200 mg/m2 every 3 weeks~5. Paclitaxel - 80-90 mg/m2 weekly, in a continuous regimen expressed in 3-week cycles or administration of 3 weeks of treatment followed by 1 week of rest. Use of the 3/1 regimen will require extra care in scheduling disease assessments.~6. Gemcitabine - 800-1250 mg/m2 Days 1 and 8 every 3 weeks Study will continue until disease progression or it is in the best interest of the patient to discontinue based on achievement of maximum benefit or tolerability issues. At the time of progression patients randomized to chemotherapy will be offered crossover to single agent SU011248."
224256720|NCT01459185|DRUG|S-1|Chemotherapy comprised eight courses (4-week administration, 2-week withdrawal; total 1 year) of S-1 at 80-120 mg/body/day according to body surface area (BSA)
224256721|NCT00868374|DRUG|Quetiapine XR|Days 1-14 - 50 mg/day; Days 14-21 - 100mg/day; Day 21-End of Study - 150mg/day
223675246|NCT04221204|DRUG|Highly selective FGFR1-3 inhibitor|All subjects in each cohort will receive a single oral dose of 3D185, followed by a 7-day washout period (i.e. single-dose PK study period). Then, subjects will receive consecutive daily doses (Once daily \[QD\], 28 days/cycle) until disease progression, death, unacceptable toxicity, or withdraw of informed consent, whichever comes first. The dose limiting toxicity (DLT) evaluation period includes the single-dose PK study period and the first treatment cycle (within 35 days after the first dose). The enrolled subjects will be sequentially assigned to the planned dose cohorts according to the protocol and receive 3D185 treatment to observe the occurrence of DLT.
223675247|NCT00300742|DRUG|Topiramate|Topiramate up to 300 mg per day.
223675248|NCT03390842|DRUG|TRC101|Oral suspension
223675249|NCT03390842|DRUG|Placebo|Oral suspension
224256722|NCT00868374|DRUG|Placebo|Days 1-14 - 50 mg/day; Days 14-21 - 100mg/day; Day 21-End of Study - 150mg/day
224256723|NCT05220657|DIAGNOSTIC_TEST|Maximal incremental exercise test|Gas exchanges are measured during all the test on ergocycle until oxygen consumption reach its maximum value
223675250|NCT03947476|DEVICE|thoracic band|Thoracic band fixation
223675251|NCT02192333|PROCEDURE|Management of Therapy Complications|Receive survivorship care
223675252|NCT02192333|OTHER|Quality-of-Life Assessment|Ancillary studies
223675253|NCT02192333|OTHER|Questionnaire Administration|Ancillary studies
223675254|NCT02192333|BEHAVIORAL|Telephone-Based Intervention|Receive phone-based booster intervention
223675255|NCT00983008|BEHAVIORAL|Protected time and Dedicated time|On Sunday through Thursday nights medical intensive care unit interns will have a 5 hour protected period from 2 to 7 am. During this time they will relinquish their pager and cell phone to the Night Float PGY2 or PGY3 who is already responsible for the ICU patients. The four hours between 2 and 6 am are entirely protected. 6 AM to 7 AM is dedicated time during which the interns will be expected to start pre-rounding on the ICU patients and to begin progress notes for the remaining members of the ICU team but still have no pager, cell phone, or cross coverage duties. On Friday and Saturday nights there will be no protected time but these interns will have 42 consecutive hours off following their extended shifts.
223675256|NCT03838094|BIOLOGICAL|Biodentine|it is a dentin substitute, a new biologically active material facilitates its penetration through opened dentinal tubules to crystallize interlocking with dentin and provide mechanical properties.
223675257|NCT03838094|BIOLOGICAL|MTA|MTA is a powder that consists of fine hydrophilic particles that set in the presence of moisture. MTA consists of tricalcium silicate, tricalcium aluminate, tricalcium oxide and silicate oxide. MTA was considered a remarkable biocompatible material with various clinical applications that include surgical and non-surgical applications such as pulp capping
223675258|NCT02935751|OTHER|Lab tests for plasma levels of apixaban and anti-10a factor|All patients will have a blood draw at 48 hours prior to elective surgical procedure and then a second blood draw on the morning of the procedure to test apixaban plasma and anti-Xa levels.
223675259|NCT03702244|DIAGNOSTIC_TEST|cCTA with selective FFRct|PRECISE will evaluate whether a precision evaluation strategy that combines contemporary risk stratification using the PROMISE Risk Tool with functional and anatomic non-invasive evaluation with cCTA with selective FFRct can improve outcomes over usual care in stable chest pain patients while safely deferring further testing in low-risk patients and reducing cost overall
223772731|NCT04401007|OTHER|Erector Spinae Plane Block with 1.5% lidocaine|Erector spinae plane (ESP) block is a new regional nerve block technique that involves a percutaneous injection of local anesthetic as a bolus through a needle or catheter into the fascial plane between the erector spinae muscle and the transverse processes in the upper or mid back.
224256724|NCT05220657|DIAGNOSTIC_TEST|Submaximal exercise test|A 25-min submaximal exercise test on ergocycle under fasting condition. Gas exchanges are measured during all the test.
224256725|NCT02491905|DRUG|HL tablet|
224256726|NCT02491905|DRUG|Placebo|
224256727|NCT01341730|DRUG|Atorvastatin 20mg|20 mg QD for 3 months
224256728|NCT01341730|DRUG|Atorvastatin 20 mg + Pioglitazone 30 mg|atorvastatin 20 mg plus pioglitazone 30 mg QD for 3 months
224256729|NCT01848938|BEHAVIORAL|Smartphone treatment with PFMT|A smartphone application with information on SUI, life style information, different programmes of PFMT with increasing severity, possibility to save statistics on training. The treatment period is three months
224256730|NCT06626867|DIETARY_SUPPLEMENT|Dietary Fiber Supplementation|Each participant ingested either dietary fiber or placebo. The dietary fiber is indi-gestible dextrin (The WiseMan\&#39;s Dining, KING CAR OTSUKA CO., Taipei, Taiwan). The dosage of contents in each package is 6 grams, 3 packs a day, with a total dose of 18 grams.
224256731|NCT06626867|OTHER|Placebo|The placebo was a colored capsule with 5 grams of maltodextrin, which is taken once a day.
224256732|NCT03838276|PROCEDURE|AL 150 BPL100|Roux-en-Y gastric bypass with 150cm of alimentary limb and 100cm of biliopancreatic limb
224256733|NCT03838276|PROCEDURE|AL 100 BPL 150|Roux-en-Y gastric bypass with 100cm of alimentary limb and 150cm of biliopancreatic limb
224256734|NCT01498172|BIOLOGICAL|MAGE-A3 ASCI|5 doses every 3 weeks
224256735|NCT01498172|BIOLOGICAL|BCG|1 intravesical dose /week for 6 weeks
224256736|NCT00879918|DRUG|Deuterated nicotine and cotinine|used as a marker for pharmacokinetic studies
224256737|NCT00066001|DRUG|metronidazole|antibiotic that is particularly effective against Gram negative bacterial species
223675260|NCT01239719|DRUG|Dexamethasone + clemastine|Dexamethasone 0.5 mg clemastine fumarate: 01 tablet every 12 hours.
223675261|NCT01239719|DRUG|Dexamethasone|Dexamethasone 0.5 mg: 01 tablet every 12 hours.
223675262|NCT03348436|PROCEDURE|radiofrequency ablation|
223675263|NCT01394640|BIOLOGICAL|Reassortant vaccine virus NYMC X-179A (New York Medical College, New York) derived form the A/california/7/2009 (H1N1) virus|The vaccine was administered intramuscularly as a single dose of 7.5 ug of hemagglutinin antigen.
223675264|NCT00382642|DRUG|Ondansetron + Cognitive Behavioral Therapy|13 week outpatient trial
223675265|NCT00382642|DRUG|Placebo + Cognitive Behavioral Therapy|13 week outpatient trial
223675266|NCT01115192|PROCEDURE|Group A|Blephacura is a solution with liposomes and used for cleaning of the eye lid to treat blepharitis
224256738|NCT01205425|OTHER|PCI on the basis of coronary angiography|Interventional cardiologist will be blinded to the images obtained by CT. The PCI procedure will be planned and performed solely on the basis of invasive coronary angiography
223675267|NCT01115192|PROCEDURE|Group B|Diluted Baby Shampoo is used for cleaning of the eye lid to treat blepharitis
224256739|NCT01205425|PROCEDURE|CT guided PCI|The results of the CT scan will be analysed by the interventional cardiologist that is to perform angiography and PCI. Based on this analysis preliminary procedural strategy is planned (stent diameters, decision on direct stenting vs. predilatation, decision on postdilation)
224256740|NCT05352789|OTHER|Non validated Survey|Overall inclusion of metabolic and nutritional parameters in prehabilitation practices will be assessed as the proportion of each parameter conducted from the mandatory queries presents as yes/no/unsure responses for each centre. Intervention or process details for included parameters will be described based on the response variable. The survey presents 4 question formats; free text (thematic qualitative analysis), 5 and 6 point likert scales (proportional response), categorical data (proportional response) and yes/no/unsure response sets (Binary response (no and unsure - grouped). All categorical data versions are parameter dependent and response variables can be requested from the research team.
224256741|NCT03186976|BEHAVIORAL|Aggressive Risk Factor Control|"1.) Sleep apnea screening, therapy is recommended if apopnea-hypopnea (AHI) index is greater than 15, with a target index of less than 5.~2\) Counseling regarding alcohol reduction to 2 drinks/day for men, 1 drink/day for women, no binge drinking (\>5 drinks at one setting).~3\) Participation in a 12 week structured, home-based exercise program and nutritional counseling. Weight reduction will be emphasized through modification of diet and exercise.~4\) An OMRON BP monitor will be supplied to each patient. A target SBP of \<140/80 mm/Hg will be targeted.~5\) Smoking cessation - through local resources already established at each site 6) Management of diabetes to achieve HgA1c\<6.5%"
224256742|NCT03186976|OTHER|Standard of Care|Recommendations based on current guidelines
224256743|NCT06324838|PROCEDURE|Standard laparoscopic ileocecal resection|Participants will undergo standard mesocolic sparing resection.
224256744|NCT06324838|PROCEDURE|Extended laparoscopic ileocecal resection|Extended mesocolic resection to assess its impact on reducing recurrence at the anastomotic site.
223675268|NCT05228379|PROCEDURE|Small Bowel Capsule Endosocopy|A wireless capsule is ingested by the patient. It moves passively along with the peristaltic movements to capture images of the small intestine. The images are processed and recorded by data recorder worn on a belt. The recorded images are downloaded and analyzed by the computer software.
223675269|NCT03442868|DEVICE|high frequency rTMS|Participants receive 16 minutes (5Hz, 24 10-second trains with a inter-train interval of 30s) of high frequency rTMS applied to either primary motor cortex (M1), supplementary motor area (SMA) and dorsolateral prefrontal cortex (DLPFC) at different sessions. Walking performance is evaluated before and after the brain stimulation.
223675270|NCT06449937|PROCEDURE|Radical local Surgery|Radical local resection of liver metastases ( hepatectomy, ablation )
223675271|NCT06449937|DRUG|Systemic therapy|Chemotherapy, targeted drug therapy, immunotherapy treatment.
223675272|NCT06449937|OTHER|Interventional therapy|Transcatheter arterial chemoembolization (TACE) Hepatic arterial infusion chemotherapy (HAIC)
223675273|NCT06414785|OTHER|analysis of samples of periprosthetic capsules taken during breast implant change procedure|characteristics of inflammation and the importance of silicone exposure (intact implant, implant rupture in serum or silicone) at the genomic molecular level, by analyzing the level of expression of genes related to the extracellular matrix and inflammation within a periprosthetic capsule fragment
223675274|NCT01261468|DEVICE|Active SCS|SCS IPG activated
223675275|NCT01261468|DEVICE|Deactivated|SCS IPG deactivated
223675276|NCT02228616|DRUG|Prucalopride|During the 12-week treatment phase of the study, the daily dose of 1 tablet of 2-mg prucalopride will be administrated orally before breakfast.
223675277|NCT02228616|DRUG|Polyethylene glycol (PEG)|Optimized dose of PEG will be administrated for 13 weeks (1 week run-in+12 weeks intervention).
223772732|NCT00799617|DRUG|AndroGel® (testosterone gel)|Testosterone levels will be measured at regular intervals in order to achieve a testosterone level in the desired range.
224256745|NCT06131086|OTHER|stabilization exercises|this include stabilization exercise thrice a week for six weeks
224256746|NCT06131086|OTHER|stabilization exercises along with pectoralis minor stretching|this include stabilization exercise with pectoralis minor thrice a week for six weeks
224256747|NCT05277363|OTHER|None (Observational study)|No investigational intervention, marketed product, or placebo will be administered to study participants in this study.
224256748|NCT02132494|BEHAVIORAL|Physical activity|
224256749|NCT01665209|DRUG|Morphine Sulfate|Morphine Sulfate 60mg Extended-release tablets
224256750|NCT03443986|OTHER|Resistance training associated with vibration|The workout will be held three times a week and will last a total of 12 weeks (3 months) for 45 minutes, where there will be 5 minutes of heating, 19 minutes of exercise with load, 16 minutes of vibration and 5 minutes of slowdown.
223675278|NCT02228616|DRUG|Lactulose|Optimized dose of Lactulose will be administrated for 13 weeks (1 week run-in+12 weeks intervention).
223675279|NCT05864456|DEVICE|Prizvalve Pro™ transcatheter aortic valve system|Transcatheter Aortic Valve Replacement
223675280|NCT04173598|BEHAVIORAL|Cognitive Adaptation Training for Caregivers (CAT Famille)|Family CAT manual, with a module each week to be read according to the patient's objectives and a 15-minute webcam feedback by the psychologist.
223675281|NCT04173598|BEHAVIORAL|Usual Care|Psycho-education manual, with a weekly reading module and a 15-minute webcam feedback by the psychology student.
223675282|NCT03254615|BEHAVIORAL|"I Prefer Plain Water"|The students will receive four educational sessions of approximately 1 hour. These sessions will be given every 2 weeks, and some will be supervised by a nutritionist.
223675283|NCT00713310|DRUG|Asacol 400 mg|"High dose:~17-\<33 kg = 3 Asacol 400mg in morning and 2 Asacol 400 in PM, 33-\<54 kg = 5 Asacol 400mg in morning and 4 Asacol 400 in PM, 54-\<90 kg = 6 Asacol 400mg in morning and 6 Asacol 400 in PM"
223675284|NCT00713310|DRUG|Asacol 400 mg|"Low dose:~17-\<33 kg = 2 Asacol 400mg + 1 placebo in morning and 1 Asacol 400 +1 placebo in PM, 33-\<54 kg = 3 Asacol 400mg +2 placebo in morning and 2 Asacol 400 + 2 placebo in PM, 54-\<90 kg = 3 Asacol 400mg + 3 placebo in morning and 3 Asacol 400mg + 3 placebo in PM"
223675285|NCT00875134|OTHER|Verbal prompt|Patient hears a voice recording
223675286|NCT00875134|OTHER|Skin Stimulus|Patient receives either a skin stimulus
224256751|NCT03443986|OTHER|Resistance training associated with vibration sham|"he workout will be held three times a week and will last a total of 12 weeks (3 months) for 45 minutes, where there will be 5 minutes of heating, 19 minutes of exercise with load, 16 minutes of vibration sham and 5 minutes of slowdown."
224256752|NCT06455982|DIETARY_SUPPLEMENT|reduced carbohydrate menu combined with ketogenic supplement|Participants will eat a reduced carb menu for 2 months and they will take 15g of MCT in the morning and the evening for a total of 30g per day.
224256753|NCT03782779|OTHER|Breathing program and regular exercise|This program will be supervised by a physical therapist and will include learning and performing a diaphragmatic-abdominal breathing, and incorporating the new breathing pattern to a upper and lower limbs regular exercises as well as to daily life activities.
224256754|NCT03782779|OTHER|Regular Exercise|Regular upper and lower limbs exercises supervised by a physical therapist
223772733|NCT00799617|DRUG|Placebo|Testosterone levels will be measured at regular intervals.
224256755|NCT02613754|BEHAVIORAL|Contingency Management|See arm description.
224256756|NCT02613754|BEHAVIORAL|Treatment as Usual|See arm description
224256757|NCT00697476|DRUG|topotecan, vorinostat|"Phase I study: vorinostat will be administered daily for a number of days per cycle variable from 7 to 14 according to the level of dose escalation; topotecan will be administered I.V. for 5 consecutive days every 3 weeks.~Phase II study: Patients will receive treatment at the recommended dose established by phase I part of the trial, for a maximum of 6 cycles or until disease progression, unacceptable toxicity or patient's refusal."
224256758|NCT02272647|DRUG|IM Saline Placebo (0.25 ml)|
224256759|NCT02272647|DRUG|IM Estradiol valerate (2.5 mg)|
224256760|NCT02272647|DRUG|IM Saline Placebo (0.5 ml)|
224256761|NCT02272647|DRUG|IM Estradiol valerate (5.0 mg)|
224256762|NCT02272647|DRUG|Oral Micronized Progesterone|
224256763|NCT02272647|DRUG|Oral Placebo|
224322445|NCT02159079|OTHER|Conservative Fluid Management Strategy|For patients in the conservative fluid management arm, beginning 12 hours after admission to study ICU and ending at the first of ICU discharge, death, return to home inspired oxygen, or study day 14, fluid management will be controlled by a study protocol. Patients in shock will receive fluid boluses only as specified by the protocol for oliguria and rapidly increasing vasopressor requirement. Patients not in shock will receive fluid boluses only as specified by the protocol for oliguria. Output will exceed input each day using a diuretic drip if required. Study protocol will be held only for pre-specified Safety Endpoints of persistent oliguria, decompensating shock, diuretic side effect, and intervening acute event.
224322446|NCT01591343|BIOLOGICAL|Depigoid® (500 DPP/ml)|"Depigoid® D. pteronyssinus or Depigoid® 50% D. pteronyssinus / 50% D. farinae (500 DPP/ml).~Dose:~Week 0: 0.2 ml followed by 0.3 ml after 30 min Week 4, 8, 12, and 16: 0.5 ml Mode of administration: subcutaneous injection"
223675287|NCT05973149|DRUG|QLH12016|according to the scheme description
223675288|NCT02266953|BEHAVIORAL|Use of communication tool about diet|The experimental intervention comprise the public health nurse's use of an image based communication tool in her dialogue with the family. This is in order to act in a patient centered way to facilitate participation by the parents and focus on relevant food and feeding practices from the parents' point of view.
223772734|NCT04545515|DRUG|ELX/TEZ/IVA|Fixed dose combination (FDC) tablets for oral administration.
223772735|NCT04545515|DRUG|IVA|Tablet for oral administration.
223772736|NCT04495088|DRUG|mFOLFOX (neoadjuvant)|neoadjuvant application Folinic acid: 400 mg/m2, 2h i.v., on day 1 Oxaliplatin: 85 mg/m2, 2-6h i.v., on day 1 5-FU: 2400 mg/m2, 46-48h i.v., on day 1. Cycles are repeated on day 15. A total of 6 cycles are administered.
223772737|NCT04495088|DRUG|XELOX (neoadjuvant)|neoadjuvant application Capecitabine: 1,000 mg/m2 bid, po, on days 1-14 Oxaliplatin: 130 mg/m2, 2-6h i.v. day 1 Cycles are repeated on day 22. A total of 4 cycles are administered.
223772738|NCT04495088|DRUG|mFOLFOX (adjuvant)|adjuvant application Folinic acid: 400 mg/m2, 2h i.v., on day 1 Oxaliplatin: 85 mg/m2, 2-6h i.v., on day 1 5-FU: 2400 mg/m2, 46-48h i.v., on day 1. Cycles are repeated on day 15. A total of 6 cycles are administered.
224256764|NCT02272647|DRUG|Ghrelin (0.3 ug/kg)|
224256765|NCT02272647|DRUG|Medroxyprogesterone - Acetate|
224256766|NCT02272647|DRUG|Oral Placebo|(in lieu of Medroxyprogesterone)
224256767|NCT05091645|OTHER|GFI|Two trained raters who will be blinded and will have no access to each other's evaluation, will administer the GFI questionnaire within 24 hours of patients' hospital admission.
224256768|NCT00053963|DRUG|romidepsin|Given IV
224256769|NCT01757392|BIOLOGICAL|Candida albicans Skin Test Antigen|0.3 ml injected intralesionally monthly. Number of injections: until wart lesion is resolved or up to 6 injections.
224256770|NCT04808648|DRUG|SH-1028|tablet, oral, 200 mg once daily for day 1 and day 12
224256771|NCT04808648|DRUG|Itraconazole|capsule, oral, 200 mg twice daily for day 8 to day 14
224256772|NCT04808648|DRUG|Rifampicin|capsule, oral, 600 mg once daily for day 8 to day 16
224322447|NCT04539652|DRUG|Experimental|Experimental group are treated with TenofoBell®
224322448|NCT00005000|DRUG|Nelfinavir mesylate|
224322449|NCT00005000|DRUG|Efavirenz|
224322450|NCT00005000|DRUG|Lamivudine|
223675289|NCT02266953|BEHAVIORAL|Treatment as usual|The public health nurses at child health centres in control municipalities are performing consultations at the child health centres as usual and without using the particular communication tool about diet.
224322451|NCT00005000|DRUG|Keyhole-Limpet Hemocyanin|
224322452|NCT00005000|DRUG|Stavudine|
224322453|NCT00005000|DRUG|Zidovudine|
224256773|NCT01218672|DEVICE|Photoselective Vaporization of the Prostate|"GreenLight XPS laser console GreenLight XPS consists of a 532 nm laser console capable of achieving power outputs between 20W and 180W. Laser technology is used to vaporize tissue for debulking prostatic hyperplasia and improvement of lower urinary tract symptoms. The 532 nm wavelength is in the visible spectrum as green light and is strongly absorbed by oxyhemoglobin.~GreenLight XPS will be used in conjunction with the MoXy™ fiber. The fiber features a side firing mechanism delivering up to180W of 532 nm light to vaporize and coagulate the prostate tissue. The fiber is guided to the treatment site by the continuous flow cystoscope, consisting of an inner and outer sheath set, 30ْ forward oblique telescope and visual obturator."
224256774|NCT01218672|DEVICE|Transurethral Resection of the Prostate|Monopolar and bipolar loop TURP Systems The TURP procedure requires the use of a resectoscope, camera system and irrigation fluid. The system consists of a generator unit and a wire loop with an electrical current running through the loop used to cut prostate tissue and cauterize. Prostate tissue is cut away in small pieces and removed at the end of the procedure using irrigation. There are many manufacturers of TURP systems. Any monopolar and bipolar loop system that carry the CE mark may be used for the study.
224256775|NCT03243487|BEHAVIORAL|structured adherence management program|Structured adherence management service (PAMS) program and a web-based information program designed for participants beginning positive airway pressure therapy
224256776|NCT03243487|BEHAVIORAL|Standard of care|Standard care provided at a VA Sleep Center for participants beginning positive airway pressure therapy
224256777|NCT03703791|BIOLOGICAL|AR101|AR101 powder
224256778|NCT05572723|DRUG|Remifentanil 2 MG|Remifentanil is an opioid; it has sedative, analgesic, and sympatholytic properties.
224256779|NCT05572723|DRUG|dexmedetomidine|"Studies show that dexmedetomidine is superior to currently commonly used remifentanil in terms of intraoperative blood pressure control and postoperative pain.~Dexmedetomidine, an alpha-2-adrenoceptor agonist, has sympatholytic, sedative, anesthetic, analgesic, and vasoconstrictor effects. It lowers blood pressure by decreasing plasma norepinephrine and epinephrine levels, thereby reducing intraoperative bleeding. Dexmedetomidine is defined as an analgesic that is now widely used to induce and maintain anesthesia and to control postoperative pain, and is defined as an analgesic that does not cause respiratory depression and neurocognitive impairment. Many studies have shown that the use of perioperative dexmedetomidine reduces the stress response to anesthetic induction and surgery and provides hemodynamic stability."
223675290|NCT04656899|BEHAVIORAL|Reminders messages to improve adherence.|"If the participant does not take their medicine at the correct time, a light on the smart pill cap begins to flash. If the bottle is not opened within 20 minutes, the Pillsy application sends an SMS text reminder to the participant's phone. If the bottle is not opened within 60 minutes, the participant receives an automated phone call. The participant may also receive brief motivational phrases or craving surveys that can be tailored to participant needs and preferences. Also, based on pre-populated and adjustable craving and withdrawal levels, the participants' provider could be contacted automatically based on the thresholds being crossed. Pillsy also includes a Pillsy Helpers feature in which the patient can name friends and family members who will also receive a text message notification one hour after a missed dose."
223675291|NCT00231556|DRUG|topiramate|
223675292|NCT04372056|BEHAVIORAL|Views and experiences of health care professionals working in intensive care units during the COVID-19 pandemic|Health care professionals
223675293|NCT01072565|OTHER|SMBG to guide clinical decisions|The investigator will base clinical decisions on A1c and modal day analysis of SMBG.
223675294|NCT01072565|OTHER|SMBG and CGM|The investigator will base clinical decisions on A1c, modal day analysis of SMBG and CGM data.
223675295|NCT00000477|DRUG|lovastatin|
223675296|NCT02011139|BEHAVIORAL|Cognitive-behavioral group therapy|
224256780|NCT05640531|DRUG|WCK 771 IV Infusion|subjects will receive intravenous infusion of WCK 771
224256781|NCT05640531|OTHER|Placebo IV Infusion|subjects will receive matching placebo intravenous infusion
224256782|NCT01676194|OTHER|Intra-arterial administration of DC BeadsR|
223675297|NCT04145843|PROCEDURE|endoscopic retrograde cholangiopancreatography|ERCP is a procedure that enables the physician to examine the pancreatic and bile ducts and remove gallstones.
223772739|NCT04495088|DRUG|XELOX (adjuvant)|adjuvant application Capecitabine: 1,000 mg/m2 bid, po, on days 1-14 Oxaliplatin: 130 mg/m2, 2-6h i.v. day 1 Cycles are repeated on day 22. A total of 4 cycles are administered.
223675298|NCT00838864|DRUG|ceftrioxone|500 mg iv q12h for 3 days
223675299|NCT00838864|DRUG|ceftrioxone|500 mg q12h for 7 days
223675300|NCT02823639|PROCEDURE|Transcranial direct current stimulation|
223772740|NCT04495088|DRUG|Capecitabine (adjuvant)|adjuvant application Capecitabine: 1,250 mg/m2 bid, po, on days 1-14 Cycles are repeated on day 22. A total of 8 cycles are administered.
223772741|NCT04495088|DRUG|"infusional 5-FU/FA AIO regimen (adjuvant)"|adjuvant application Folinic acid 2h i.v. 500 mg/m² 5-FU 2,600mg/m² (24h infusion) Days 1, 8, 15, 22, 29, 36; cycle is repeated day 57 (representing one cycle); a total of 3 cycles should be administered.
223772742|NCT04495088|DRUG|"infusional 5-FU/FA de Gramont (adjuvant)"|adjuvant application Folinic acid 2h i.v. 200 mg/m² days 1 and 2 5-FU 400mg/m² bolus followed by 600mg/m² 22h infusion days 1 and 2 The cycle is repeated day 15; a total of 12 cycles should be administered.
223772743|NCT02164552|DIETARY_SUPPLEMENT|Vitamin D3 pills|Dietary supplement
223772744|NCT02164552|OTHER|Placebo pills|Placebo pills similar in appearance and shape but without vitamin D
223772745|NCT01848990|DRUG|Commercial Hylenex® recombinant (hyaluronidase human injection)|
223772746|NCT01848990|DRUG|Precommercial Hylenex recombinant (hyaluronidase human injection)|
223772747|NCT01848990|DRUG|Insulin lispro|
224256783|NCT01653951|OTHER|nurse-led care management or peer-led self management|
224256784|NCT03708458|DRUG|indomethacin suppository|the investigators aimed to perform a comparative study, evaluating the efficacy of three prophylactic approaches aiming to reduce the risk of PEP, using indomethacin and/or N-acetylcysteine -NAC, in different regimens
224256785|NCT03708458|DRUG|N-acetylcysteine (NAC)|the investigators aimed to perform a comparative study, evaluating the efficacy of three prophylactic approaches aiming to reduce the risk of PEP, using indomethacin and/or N-acetylcysteine -NAC, in different regimens
224256786|NCT00207090|DRUG|ixabepilone|ixabepilone solution, intravenous, 40 mg/m2, once every 3 weeks until disease progression
224322454|NCT00005000|DRUG|Didanosine|
224256787|NCT00207090|DRUG|Rifampin|rifampin tablets, oral, 600 mg once daily, only on Days 15 to 21 of Cycle 1 and Days 1 to 7 of Cycle 2
224256788|NCT05332535|BEHAVIORAL|serious game based web application education|serious game based web application education for nursing students
223675301|NCT01446614|BIOLOGICAL|bone marrow derived mesenchymal stem cells|Intravenous administration of up to 6x10\^5 MSCs per kg,qw,for 4 weeks
223675302|NCT02828215|DEVICE|Swept-source optical coherence tomography (SS-OCT)|"The SD-OCT provides faster images and the ability to scan more of the central retina (macula). SD-OCT simultaneously measures multiple wavelengths of reflected light across a spectrum generating up to 40,000 A-Scans (axially sample points) per second. This allows the generation of 3 dimensional faster based volumetric images of the retina. The Spectralis OCT utilises real-time hardware eye tracking to resample lines scan enhancing the signal to noise ratio by improving the image quality.~The swept-source OCT (SS-OCT) uses a tuneable laser light source with a longer wavelength of light (typically 1040-1050 nm) that the light source seen in more conventional SD-OCT devices. The tissue penetration and resolution is greater with fast acquisition speeds and longer line scan lengths."
223675303|NCT06024512|DEVICE|Burn|This study is being done to collect pictures of burns using an investigational device called the Spectral MD Deep View Snapshot Handheld (DV-H), similar to a camera. The data collected will be used to assess the performance of the DV-H device, and to determine the device's ability to differentiate healing versus non-healing burn tissue. This device, if approved, is expected to give caregivers a better understanding of what parts of burn wounds will likely not heal on their own and as a tool used by the military in the field. This current study involves the collection of images over the course of your clinical treatment and follow-up according to your routine standard of care. The device will not be used to diagnose or prescribe treatment for your burn.
223675304|NCT03513848|DEVICE|Retimer|The Retimer light device in this study is a commercially-available wearable light device. It permits ambulation while receiving light from LEDs positioned below the eyes. The LEDs emit green light (\~500nm, 230 µW/m2, 500 lux), close to the peak sensitivity of circadian photoreceptors.
223675305|NCT03513848|DEVICE|Retimer placebo|The Retimer device has been dimmed to reduce the light intensity to a level that will not shift circadian timing.
223675306|NCT03691740|DEVICE|Ocular light|A light mask to which small light emitting diode(LED) lights emitting a blue or red color light will be used to deliver ocular light
224256789|NCT05119946|BEHAVIORAL|Suicide prevention video|The video has been developed by the research team as an educational tool to teach patients about suicide, the consequences of such and imparting a message of hope.
224256790|NCT05119946|OTHER|Standard suicide treatment|The standard suicide treatment will be determine by the attending physician and can include medications and/or psychotherapy
224256791|NCT00857103|BEHAVIORAL|CHOICE|Use of Choice support system as preparation for patient consultations
224256792|NCT05458635|PROCEDURE|Right heart catheter|Right heart catheterization was performed for 4 cases with high probability of pulmonary hypertension using multi-lumen swan ganz catheter.
224256793|NCT00191490|DRUG|Gemcitabine|
224256794|NCT00191490|DRUG|docetaxel|
224256795|NCT00191490|DRUG|cisplatin|
224256796|NCT03840291|DRUG|Edoxaban|Edoxaban will be used for resolution of left atrial appendage thrombi
224256797|NCT06559982|DIETARY_SUPPLEMENT|Brown seaweed and tart cherry blend|Blend of brown seaweed and tart cherry blend taken twice daily
224256798|NCT06559982|OTHER|Placebo|Identical in taste and colour to the supplement, but with no brown seaweed or tart cherry.
224256799|NCT01552317|OTHER|OxSalt care bundle|A care bundle consisting of a range of features to help patients to reduce their salt intake such as reminder emails, phone calls and a website.
224256800|NCT06558916|DRUG|Dexketoprofen Trometamol|
223675307|NCT01453582|DRUG|Total Flavonoids of Propolis dropping pill|One pack contains 30 pills, weight 33g. One pack each time, three times a day, 14 days a course.
224256801|NCT06558916|DRUG|Meperidine Injectable Solution|
224256802|NCT06558916|DRUG|Paracetamol|
224256803|NCT06558916|DRUG|Fentanyl|Patients with a VAS score of 40 mm or higher at the 30th minute were given fentanyl (1 mcg/kg, intravenously) as a rescue drug.
224256804|NCT06176534|DRUG|Experimental: chemotheyapy|nab-paclitaxel 130mg/m2，day 1 and day 8 + Capecitabine 2000mg/m2, followed by nab-paclitaxel 130mg/m2，day 1 and day 8 or Capecitabine from day1 to DAY 14 Vinorelbine 25mg/m2，day 1 and day 8 + Capecitabine 2000mg/m2，from day1 to DAY 14
224256805|NCT06176534|DRUG|Active Comparator: endocrine therapy|palbociclib 125mg per day for 21days Dalpiciclib 150mg per day for 21days Letrozole 2.5mg per day Anastrozole 1mg per day fulvestrant 500mg per 28 days
223675308|NCT01453582|DRUG|total Flavonoids of Propolis dropping pill|One pack contains 30 pills, weight 33g. One pack each time, three times a day, 14 days a course.
223772748|NCT01848990|DRUG|Insulin aspart|
223772749|NCT01848990|DRUG|Insulin glulisine|
224256806|NCT06234722|DRUG|Very Low Nicotine Cigarette|Participants will be assigned to one of two investigational cigarette nicotine levels for the duration of the experiment: 0.4mg/g or 15.8mg/g
224256807|NCT06234722|BEHAVIORAL|Reduced nicotine regulatory environment|In this regulatory environment, participants' usual combustible cigarette will not be available in the Experimental Tobacco Marketplace and only the participants' assigned investigational cigarette will be the only available combustible cigarette.
224256808|NCT06234722|BEHAVIORAL|Restriction on characterizing flavors in combustible nicotine products|In this regulatory environment, menthol and other characterizing flavors in combustible nicotine products will not be available in the Experimental Tobacco Marketplace. Only tobacco or no flavored combustible nicotine products will be the only combustible nicotine products available.
224256809|NCT06234722|BEHAVIORAL|Restriction on characterizing flavors in noncombustible nicotine products|In this regulatory environment, menthol and other characterizing flavors in noncombustible nicotine products will not be available in the Experimental Tobacco Marketplace. Only tobacco or no flavored noncombustible nicotine products will be the only noncombustible nicotine products available.
224256810|NCT05613686|DEVICE|repetitive transcranial magnetic stimulation|Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive neuromodulation technology. High and low frequencies of rTMS could modulate the excitability of the cerebral cortex. Theta burst stimulation (TBS) has achieved a similar effect to traditional rTMS mode. Intermittent TBS (iTBS) could upregulate cortical excitability of the primary motor cortex (M1) and continuous TBS (cTBS) with inhibitory effect.
223675309|NCT04095585|GENETIC|chromosomal microarray analysis (CMA) and whole exome sequencing (WES)|"The investigator evaluated the following hypotheses:~i) atypically large 7q11.23 deletions including additional genes; ii) rare pathogenic variants in genes located within the deletion, in particular GTF2I iii) additional pathogenic copy number variants (CNVs) or rare intragenic pathogenic variants located in other chromosomal regions with various inheritance patterns (autosomal recessive, X-linked, de novo autosomal dominant); given the small number of patients recruited, we focused on rare exonic variants considered to be pathogenic according to the criteria of the American College of Medical Genetics and Genomics (ACMG)"
223675310|NCT00686634|DRUG|Sitagliptin|Sitagliptin 100 mg by mouth once daily
223675311|NCT00672113|DRUG|Adalat (Nifedipine, BAYA1040)|Nifedipine GITS 30 mg followed by Coracten 30 mg then back to nifedipine GITS 30 mg
223675312|NCT00672113|DRUG|Coracten|Coracten 30 mg followed by nifedipine GITS 30 mg then back to Coracten 30 mg
223675313|NCT04552678|BEHAVIORAL|Healthy Eating, Active Play, Self-Regulation, Parent Education|In addition to a 27-lesson, core food literacy curriculum that children across all conditions will receive, children in this condition will also be exposed to an 11-lesson Healthy Eating curriculum, an 11-lesson Active Play curriculum, and an 11-lesson Self-Regulation curriculum. Parents will receive access to web-based resources on food literacy, and will be invited to complete 18 web-based education modules on topics including improving household routines, managing children's behaviors and emotions, improving children's sleep patterns, improving access to healthy foods, healthy meal and snack preparation, modeling healthy eating and activity behaviors, and improving family activity patterns.
223675314|NCT04552678|BEHAVIORAL|Healthy Eating, Active Play, Self-Regulation|In addition to a 27-lesson, core food literacy curriculum that children across all conditions will receive, children in this condition will also be exposed to an 11-lesson Healthy Eating curriculum, an 11-lesson Active Play curriculum, and an 11-lesson Self-Regulation curriculum. Parents will receive access to web-based resources on food literacy.
223675315|NCT04552678|BEHAVIORAL|Healthy Eating, Active Play, Parent Education|In addition to a 27-lesson, core food literacy curriculum that children across all conditions will receive, children in this condition will also be exposed to an 11-lesson Healthy Eating curriculum, and an 11-lesson Active Play curriculum. Parents will receive access to web-based resources on food literacy, and will be invited to complete 18 web-based education modules on topics including improving household routines, managing children's behaviors and emotions, improving children's sleep patterns, improving access to healthy foods, healthy meal and snack preparation, modeling healthy eating and activity behaviors, and improving family activity patterns.
223675316|NCT04552678|BEHAVIORAL|Healthy Eating + Active Play|In addition to a 27-lesson, core food literacy curriculum that children across all conditions will receive, children in this condition will also be exposed to an 11-lesson Healthy Eating curriculum, and an 11-lesson Active Play curriculum. Parents will receive access to web-based resources on food literacy.
223675317|NCT04552678|BEHAVIORAL|Healthy Eating, Self-Regulation, Parent Education|In addition to a 27-lesson, core food literacy curriculum that children across all conditions will receive, children in this condition will also be exposed to an 11-lesson Healthy Eating curriculum, and an 11-lesson Self-Regulation curriculum. Parents will receive access to web-based resources on food literacy, and will be invited to complete 18 web-based education modules on topics including improving household routines, managing children's behaviors and emotions, improving children's sleep patterns, improving access to healthy foods, healthy meal and snack preparation, modeling healthy eating and activity behaviors, and improving family activity patterns.
223675318|NCT04552678|BEHAVIORAL|Healthy Eating + Self-Regulation|In addition to a 27-lesson, core food literacy curriculum that children across all conditions will receive, children in this condition will also be exposed to an 11-lesson Healthy Eating curriculum, and an 11-lesson Self-Regulation curriculum. Parents will receive access to web-based resources on food literacy.
223675319|NCT04552678|BEHAVIORAL|Healthy Eating + Parent Education|In addition to a 27-lesson, core food literacy curriculum that children across all conditions will receive, children in this condition will also be exposed to an 11-lesson Healthy Eating curriculum. Parents will receive access to web-based resources on food literacy, and will be invited to complete 18 web-based education modules on topics including improving household routines, managing children's behaviors and emotions, improving children's sleep patterns, improving access to healthy foods, healthy meal and snack preparation, modeling healthy eating and activity behaviors, and improving family activity patterns.
223675320|NCT04552678|BEHAVIORAL|Healthy Eating Only|In addition to a 27-lesson, core food literacy curriculum that children across all conditions will receive, children in this condition will also be exposed to an 11-lesson Healthy Eating curriculum. Parents will receive access to web-based resources on food literacy.
223675321|NCT04552678|BEHAVIORAL|Active Play, Self-Regulation, Parent Education|In addition to a 27-lesson, core food literacy curriculum that children across all conditions will receive, children in this condition will also be exposed to an 11-lesson Active Play curriculum, and an 11-lesson Self-Regulation curriculum. Parents will receive access to web-based resources on food literacy, and will be invited to complete 18 web-based education modules on topics including improving household routines, managing children's behaviors and emotions, improving children's sleep patterns, improving access to healthy foods, healthy meal and snack preparation, modeling healthy eating and activity behaviors, and improving family activity patterns.
223675322|NCT04552678|BEHAVIORAL|Active Play + Self-Regulation|In addition to a 27-lesson, core food literacy curriculum that children across all conditions will receive, children in this condition will also be exposed to an 11-lesson Active Play curriculum, and an 11-lesson Self-Regulation curriculum. Parents will receive access to web-based resources on food literacy.
223772750|NCT01934634|DRUG|LCL161|LCL161 (tablets): 300, 600, 1200, or 1800 mg once a week (Day 1, 8, 15) for 3 weeks, every 28 days
223772751|NCT01934634|DRUG|Gemcitabine|Gemcitabine IV: 1,000 mg/m2 once a week (Day 1, 8, 15) for 3 weeks, every 28 days
223772752|NCT01934634|DRUG|nab-Paclitaxel|nab-paclitaxel IV: 125 mg/m2 once a week (Day 1, 8, 15) for 3 weeks, every 28 days
223772753|NCT00958880|BEHAVIORAL|Group Cognitive Behavioral Therapy|"5 weeks of group CBT for Social Anxiety. The aim of CBT is to help participants become more comfortable with social situations~One arm will receive placebo augmented Group Cognitive Behavioral Therapy and the other will receive yohimbine hydrochloride augmented cognitive behavioral therapy."
223772754|NCT00958880|DRUG|Yohimbine Hydrochloride|Participants in the Yohimbine augmented arm will receive 4 doses of Yohimbine Hydrochloride before 4 of the 5 group cognitive behavioral therapy sessions.
224256811|NCT06498700|DRUG|ketamine|0.5 mg/kg/h ketamine infusion
224256812|NCT06498700|DRUG|dexmedetomidine|0.1 ug/kg/h dexmedetomidine infusion
224256813|NCT06560749|OTHER|Physical Exercise|Measure the impact of physical exercise in the cognition of pacients diagnosed with Bipolar Disorder
224256814|NCT00841698|DRUG|Paroxetine HCl|40 mg Film-Coated Tablet
224256815|NCT00841698|DRUG|Paxil®|40 mg Film-Coated Tablet
224256816|NCT04498806|OTHER|Fitbit|The Fitbit device monitors daily activity as a measure of physical function.
224256817|NCT06561373|BEHAVIORAL|Calm & Alert yoga and mindfulness|The Calm \& Alert protocol is multisensorial, with successive opportunities to practice the explicit concepts taught throughout the lessons using yoga and mindfulness-techniques. Each class has a similar structure of songs, breathing, warm-ups, yoga poses, mindful games, and rest involving meditation with child-friendly language. The study includes the recommended materials of a Hoberman sphere (breathing ball), chime, mind/body/breath icons, two small mason jars (one with mud and one with clear water), yoga mats for students, pictures of feelings (happy, sad, angry, scared, surprised, disgusted), and an on/off switch.
224256818|NCT06555913|OTHER|Maitland Mobilization|"MM applies a passive oscillatory technique, classified from Grade I-IV with respect to intensity, to the shoulder in order to treat pain and stiffness.~Grade I refers to an intensity of small amplitude that is applied at the beginning of the joint ROM, where there is no loading on connective tissue; it is often used in cases of severe pain"
224256819|NCT06555913|OTHER|Scapular Stabilization|"Scapular stabilization exercises are thought to have an important role in improving pain and dysfunction in the shoulder. The concept that an unstable~scapula is associated with pathology and dysfunction of the shoulder is well accepted. The predominant theory emphasizes that for optimal function of the glenohumeral joint, the scapula must provide a stable base upon which upper extremity tasks are completed. Impaired scapular stability increases the risk for pathologies such as impingement or rotator cuff tears"
224256820|NCT06555913|OTHER|Traditional Physical Therapy|ROM exercises, stretching exercises and strengthening exercises for shoulder muscles
224256821|NCT06562049|RADIATION|musculoskeletal ultrasound|musculoskeletal ultrasound on both hands
224256822|NCT00545506|DEVICE|conventional bandage|
223675323|NCT04552678|BEHAVIORAL|Active Play + Parent Education|In addition to a 27-lesson, core food literacy curriculum that children across all conditions will receive, children in this condition will also be exposed to an 11-lesson Active Play curriculum. Parents will receive access to web-based resources on food literacy, and will be invited to complete 18 web-based education modules on topics including improving household routines, managing children's behaviors and emotions, improving children's sleep patterns, improving access to healthy foods, healthy meal and snack preparation, modeling healthy eating and activity behaviors, and improving family activity patterns.
223675324|NCT04552678|BEHAVIORAL|Active Play Only|In addition to a 27-lesson, core food literacy curriculum that children across all conditions will receive, children in this condition will also be exposed to an 11-lesson Active Play curriculum. Parents will receive access to web-based resources on food literacy.
223675325|NCT04552678|BEHAVIORAL|Self-Regulation + Parent Education|In addition to a 27-lesson, core food literacy curriculum that children across all conditions will receive, children in this condition will also be exposed to an 11-lesson Self-Regulation curriculum. Parents will receive access to web-based resources on food literacy, and will be invited to complete 18 web-based education modules on topics including improving household routines, managing children's behaviors and emotions, improving children's sleep patterns, improving access to healthy foods, healthy meal and snack preparation, modeling healthy eating and activity behaviors, and improving family activity patterns.
223675326|NCT04552678|BEHAVIORAL|Self-Regulation Only|In addition to a 27-lesson, core food literacy curriculum that children across all conditions will receive, children in this condition will also be exposed to an 11-lesson Self-Regulation curriculum. Parents will receive access to web-based resources on food literacy.
223675327|NCT04552678|BEHAVIORAL|Food Literacy + Parent Education|Children in this condition will only receive a 27-lesson, core food literacy curriculum (children across all conditions will receive this curriculum). Parents will receive access to web-based resources on food literacy, and will be invited to complete 18 web-based education modules on topics including improving household routines, managing children's behaviors and emotions, improving children's sleep patterns, improving access to healthy foods, healthy meal and snack preparation, modeling healthy eating and activity behaviors, and improving family activity patterns.
223675328|NCT04552678|BEHAVIORAL|Food Literacy Only|Children in this condition will only receive a 27-lesson, core food literacy curriculum (children across all conditions will receive this curriculum). Parents will receive access to web-based resources on food literacy.
223772755|NCT00958880|DRUG|Sugar Pill|Participants in the placebo (sugar pill) augmented arm will receive 4 doses of a sugar pill before 4 of the 5 group cognitive behavioral therapy sessions.
224256823|NCT00545506|DEVICE|warming bandage|
224256824|NCT01501253|DRUG|CKD-828 2.5/40mg|fixed dose combination of S-Amlodipine 2.5mg and Telmisartan 40mg
224256825|NCT01501253|DRUG|CKD-828 2.5/80mg|Fixed dose combination of S-Amlodipine 2.5 and Telmisartan 80mg
224256826|NCT01501253|DRUG|S-Amlodipine 2.5mg|S-Amlodipine 2.5mg monotherapy
224256827|NCT05806957|DEVICE|Fundus Photography|Subjects will undergo Fundus Photography using FDA approved non-mydriatic fundus cameras and mydriatic camera with OCT
224256828|NCT00030186|DRUG|CEP-701 60mg|60mg orally 2 times a day for 28 days
224256829|NCT00030186|DRUG|Cep-701 80mg|80mg 2 times a day, dependent upon response to cycle 1
224256830|NCT00030186|DRUG|Cep-701 40mg|40mg 2 times a day, dependent upon response to cycle 1
224256831|NCT02724605|BIOLOGICAL|Red blood cells unit age 14 days or less|30 Patients who will receive units of packed red blood cells stored stored for 14 days or less
224256832|NCT02724605|BIOLOGICAL|Red blood cells unit age more than 14 days|30 patients who will receive units of packed red blood cells stored for more than 14 days
224256833|NCT06424457|PROCEDURE|video assisted thoracoscopy (VATS)|the investigators compare the outcomes of intervention by VATS and doing complete decortication or open surgery thoracotomy
224256834|NCT06424457|PROCEDURE|open thoracotomy|the investigators assess the outcomes of intervention by doing complete decortication through open surgery thoracotomy
224256835|NCT02571686|DEVICE|Surveyor S4|
224256836|NCT05260697|OTHER|sexual counselling with plissit model|sexual counselling
224256837|NCT05305248|DRUG|Remimazolam|After spinal anesthesia, 5 mg of remimazolam is injected by intravenous route for 1 minute to induce sedation. To maintain sedation, remimazolam is continuously infused at a rate within the range of 0.1 mg/kg/h to 1 mg/kg/h.
224256838|NCT05305248|DRUG|Dexmedetomidine|After performing spinal anesthesia, dexmedetomidine is injected at a loading dose of 1 mcg/kg for 10 minutes to induce sedation. Thereafter, to maintain sedation, Dexmedetomidine is continuously infused at a rate within the range of 0.2 to 0.7 mcg/kg/h.
224256839|NCT06279039|DRUG|Exosome liquid dressing|This study mainly adopted a randomized double-blind self-half face control method. The double-blind method was that the subjects and researchers did not know the experimental group and the control group. 38 sets of matched use sets (left and right, only the manufacturer knew the specific ingredients) were respectively applied to both sides of the cheeks of patients after Q-switched laser. The blind was unblinded after the experiment.
224256840|NCT00239382|DRUG|Meloxicam ampoule|
224256841|NCT00239382|DRUG|Meloxicam tablet|
224256842|NCT00819754|DRUG|IXO regimen + bevacizumab|"Phase I study - identifies the safety of IXO with bevacizumab and recommended phase II dose~Phase II study - assesses efficacy and safety of IXO with bevacizumab"
224256843|NCT00702377|OTHER|SYSTANE Ultra|SYSTANE Ultra Lubricant Eye Drops 1 drop each eye 4 times daily for 42 days
224256844|NCT00702377|OTHER|Optive|Optive Lubricant Eye Drops 1 drop each eye 4 times daily for 42 days
224256845|NCT00304187|DRUG|Erythromycin|Erythromycin, 250 mg or 500 mg, three times a day for 6 weeks
224256846|NCT00304187|DRUG|Placebo|Placebo, 250 mg or 500 mg, three times a day for 6 weeks
224256847|NCT03807180|OTHER|Tai Chi (exercise)|Tai Chi exercise method, which is composed of combination of physical exercise and relaxation techniques for patients with rheumatic diseases.
224256848|NCT03353896|DEVICE|Wear novoTTF-200A|Wear novoTTF-200A device
224256849|NCT03353896|PROCEDURE|Quality-of-Life Assessment|Ancillary studies
224256850|NCT04814160|PROCEDURE|mixture of bioactive glass and autogenous bone graft|bone expansion was performed and autogenous bone mixed with bioactive glass was used to augment the intercortical bone defect after ridge splitting and simultaneous dental implants
224256851|NCT04814160|PROCEDURE|autogenous bone graft|bone expansion was performed and autogenous bone alone was used to augment the intercortical bone defect after ridge splitting and simultaneous dental implants
224256852|NCT05855577|DRUG|Terazosin|Treatment of Terazosine vs placebo and Lisosan-G vs placebo in cross-over double-blind, double-dummy
224256853|NCT03659565|BEHAVIORAL|Enhanced Pre-Visit Consultation|The Intervention Group will be given access to the optimized personal health record and will use Zoom as part of the pre-visit consultation.
223675329|NCT05179551|PROCEDURE|Proximal Medial Gastrocnemius Recession|. A 3-4 cm transverse skin incision is made in the popliteal fossa, the superficial fascia is opened, and the medial gastrocnemius with its tendon (aponeurosis) is located. The tendon is then cut while lifting it with clamps, and care is taken to cut only the white tendon while sparing the underlying muscle. While performing a dorsiflexion movement of the ankle, careful palpation of the muscle is done to ensure that all tendon strands are cut completely. The incision is closed in layers, and only soft dressings applied
223675330|NCT04772742|DRUG|Placebo|Placebo - solution for infusion
223675331|NCT04772742|DRUG|Eptinezumab|Eptinezumab - 100 mg, solution for infusion
223772756|NCT06050408|DEVICE|1hz repetitive transcranial magnetic stimulation|1hz rTMS applied over P3 EEG 10-20 location. Total of 1200 pulses administered. Figure of eight coil used to stimulate, held tangential to the scalp.
223772757|NCT01876264|PROCEDURE|Extended resection|
224256854|NCT03659565|BEHAVIORAL|Usual Care Control|Caregivers and patients will participate in usual pre-visit process.
224256855|NCT00840606|DRUG|BUSPAR® 30 mg Tablet|1 x 30 mg, single-dose fasting
224256856|NCT00840606|DRUG|Buspirone Hydrochloride 30 mg Tablet|1 x 30 mg, single-dose fasting
224256857|NCT04287322|BEHAVIORAL|Tactile-kinesthetic stimulation|"Tactile-kinesthetic stimulation involved three sessions per day; morning, afternoon, and evening for 10 days starting day 3 of life (initial contact). The stimulation included three phases; Phase 1: With neonates in prone position, moderate pressure was used to provide 12 strokes with palms of the hands, each stroke lasting 5 seconds. The strokes were provided in each area as follows: head, neck, shoulders and back.~Phase 2: In supine position, twelve moderate pressure strokes with palms of the hands, 5 seconds each, were provided in each area as follows:forehead,cheeks,chest, abdomen, upper limbs (each separately), lower limbs, palms and soles.~Phase 3: Kinesthetic stimulation was done for 5 minutes. The intervention comprised five passive flexion and extension movements of each large joint."
224256858|NCT04287322|BEHAVIORAL|Recorded maternal voice|Following informed written consent from mothers,maternal voice was recorded (5 minutes talking to her baby and 10 minutes singing) using Philips Electronics, SA2RGA04KS, Netherlands. Recorded voice was played back inside the incubator or cot via micro audio system, which has been validated for safety and feasibility in previous studies (Doheny et al., 2012. Preterm neonate lay in supine/lateral position and recorded maternal voice was played for 15 minutes three times a day (morning, afternoon, evening) starting on day 3 of life up to day 12 of life (10 days).
224256859|NCT03589170|DIAGNOSTIC_TEST|Opportunistic atrial fibrillation screening|Opportunistic pulse palpation and/or ECG at least once a year when they visit doctors or nurse for other reasons.
224256860|NCT06089382|DRUG|Sintilimab|IV infusion of Sintilimab （200mg intravenously every 3 weeks for a total of 18 cycles or tumour recurrence）
223675332|NCT00335270|DRUG|fos-amprenavir calcium, ritonavir|
223675333|NCT00335270|DRUG|abacavir/lamivudine as Epzicom|
223675334|NCT00799773|DRUG|Rituximab|Dose of 375 mg/m2, given intravenously, repeated at 1-week intervals for a total of four doses
223772758|NCT01876264|PROCEDURE|Conventional resection|
223772759|NCT01144156|DRUG|Treatment with Adalimumab|All patients will receive SC adalimumab 160 mg at week 0, 80 mg at week 2 and 40 mg from week 4 every 2 weeks up to 12 weeks
223772760|NCT03359733|DRUG|TAK-659|TAK-659 tablet.
223772761|NCT02657811|DEVICE|Miri, Benchtop Multi-room incubator|Bench Incubation - Morphologic Assessment These embryos will undergo multiple evaluations using light microscopy and traditional morphologic assessment.
224256861|NCT06089382|DRUG|Lenvatinib|8mg orally once a day for 1 year
224256862|NCT06089382|PROCEDURE|Transarterial Chemoembolization (TACE)|One cycle of TACE postoperatively
224256863|NCT00099047|DRUG|celecoxib|Given PO
224256864|NCT00099047|DRUG|placebo|Given PO
224256865|NCT00099047|OTHER|laboratory biomarker analysis|Correlative studies
224256866|NCT02252133|DEVICE|Delefilcon A contact lenses|Silicone hydrogel contact lenses (8.5 and 8.8 base curves) dispensed per manufacturer's guidelines for daily disposable wear
224256867|NCT02252133|DEVICE|Narafilcon A contact lenses|Silicone hydrogel contact lenses (8.5 and 9.0 base curves) dispensed per manufacturer's guidelines for daily disposable wear
224256868|NCT06562868|OTHER|Bulk-fill Composite Resin|The evaluation of the restorative material according to FDI criteria at baseline, 1 year and 2 years after application
224256869|NCT06562868|OTHER|Traditional Posterior Composite Resin|The evaluation of the restorative material according to FDI criteria at baseline, 1 year and 2 years after application
224256870|NCT06562868|OTHER|High-filler Flowable Composite|The evaluation of the restorative material according to FDI criteria at baseline, 1 year and 2 years after application
223675335|NCT00799773|PROCEDURE|Plasma exchange|Target volume of 1.25 plasma volume replacement; fresh frozen plasma (FFP) is the required replacement fluid; provided daily until platelet counts are normal and signs of tissue damage have improved.
223675336|NCT00799773|DRUG|Corticosteroids|1 mg/kg of prednisone (or equivalent) each day until plasma exchange is stopped
223675337|NCT02361580|OTHER|Diary|Subject keeps diary of recovery
224256871|NCT06561789|OTHER|Functionalized Nano ᵦ tricalcium phosphate particles|The intervention is a prepared mouth wash solution for remineralization of demineralized enamel by the investigator at Nano Gate institute (Egypt,cairo,elmokatm)
224256872|NCT06561789|OTHER|Nano ᵦ tricalcium phosphate particles|The intervention is a prepared mouth wash solution for remineralization of demineralized enamel by the investigator at Nano Gate institute (Egypt,cairo,elmokatm)
224256873|NCT06561789|OTHER|sodium fluoride mouth wash|The intervention is mouth wash solution for remineralization of demineralized enamel from Oral-B company
224256874|NCT00005025|BIOLOGICAL|herpes simplex thymidine kinase|
224256875|NCT00005025|DRUG|ganciclovir|
223675338|NCT06003179|DRUG|Cyclophosphamide|Conditioning chemo at different doses
223675339|NCT06003179|RADIATION|TLI|radiation given with conditioning chemo
223675340|NCT06003179|DRUG|Fludarabine|Fludarabine given as part of standard treatment
224256876|NCT00651820|DRUG|Collagenase Santyl|"Dermatome-induced skin wounds treated with drug active.~Each subject serves as his own control receiving both treatments in parallel."
223675341|NCT03303027|DEVICE|6-0 fast absorbing gut suture|Fast absorbing surgical gut suture is a strand of collagenous material, size 6-0
223675342|NCT03303027|DEVICE|5-0 fast absorbing gut suture|Fast absorbing surgical gut suture is a strand of collagenous material, size 5-0
223675343|NCT01439698|DEVICE|Radio Frequency ablation Probe|Any probe that can conduct radiofrequency ablation within biliary ducts.
223675344|NCT00924781|DRUG|MK2578 1mcg for every 600 Units (U) of Epogen® (epoetin alfa) received per week at Baseline|MK2578 was to be administered intravenously (IV). Participants in Cohort 1 were to receive 1 mcg of MK2578 for every 600 U of Epogen (epoetin alfa) received per week at Baseline. Participants were to be randomized to every week (QW) or once every 4 weeks (QM) dosing schedules within each cohort.
223675345|NCT00924781|DRUG|MK2578 1 mcg for every 350 U of Epogen (epoetin alfa) received per week at Baseline|MK2578 was to be administered IV. Participants in Cohort 2 were to receive 1 mcg of MK2578 for every 350 U of Epogen (epoetin alfa) received per week at Baseline. Participants were to be randomized to QW or QM dosing schedules within each cohort.
224256877|NCT00651820|DRUG|Collagenase Santyl Vehicle|Dermatome-induced skin wounds treated with Vehicle alone. Each subject serves as his own control receiving both treatments in parallel.
224256878|NCT00865592|DRUG|dutogliptin|dutogliptin 400 mg, once daily tablet
224256879|NCT01312415|DRUG|Levobupivacaine|Patients will receive peri- and intraarticular surgical site infiltration to the knee during surgery and before wound closure with a solution of levobupivacaine 0.5% 2mg/kg body weight (maximum 200mg levobupivacaine will be used if the patient's weight exceeds 100kg) plus 0.5mg epinephrine made up to 100ml with saline. An intra-articular catheter will be placed by the surgeon before closure under the sterile surgical conditions and this will be left in situ in the wound. The patient will receive one further injection of 15ml of levobupivacaine 0.5% solution at 8am on the morning of the first postoperative day after which the catheter will be removed.
224256880|NCT01312415|DRUG|Intrathecal morphine|Patients will receive spinal anaesthesia with intrathecal bupivacaine 0.5% (17.5 mg if greater than 70 kg and 15 mg if less than 70 kg) and preservative-free morphine (0.3 mg).
223675346|NCT00924781|DRUG|MK2578 1 mcg for every 200 U of Epogen (epoetin alfa) received per week at Baseline|MK2578 was to be administered IV. Participants in Cohort 3 were to receive 1 mcg of MK2578 for every 200 U of Epogen (epoetin alfa) received per week at Baseline. Participants were to be randomized to QW or QM dosing schedules within each cohort.
223675347|NCT03819907|COMBINATION_PRODUCT|Audiovisual Guided Relaxation|Five-minute guided relaxation delivered via a computer screen and speakers
223675348|NCT03819907|COMBINATION_PRODUCT|Virtual Reality Guided Relaxation|Five-minute guided relaxation delivered via a Samsung Galaxy 7s and the Samsung adaptable VR headset.
223675349|NCT02042820|OTHER|In vivo confocal microscopy (IVCM)|IVCM is a sensitive tool for detecting dry eye-associated subclinical inflammation.
224256881|NCT00180986|PROCEDURE|Platelet concentrates|
224256882|NCT01695538|OTHER|Yoga|The subjects will be asked to practice Yoga poses at least 3 times a week at home, although daily Yoga will be encouraged. Participants will be trained in breathing exercises, postures and meditation. Each time they practice yoga will be for 1 hour and include breathing exercises, postures and meditation.
224256883|NCT00925119|DRUG|Atenolol|12.5 mg twice daily of atenolol for 1 week; increased to 25 mg twice daily for a total of 8 weeks, if the medication is well tolerated
224256884|NCT01958450|PROCEDURE|Er:YAG laser|acne scar treatment using Er:YAG laser
224256885|NCT01958450|PROCEDURE|Bipolar radiofrequency with diode laser|acne scar treatment with bipolar radiofrequency combined with diode laser
224256886|NCT04664556|OTHER|observational study|observational study
224256887|NCT01979861|DEVICE|AEGEA Vapor System(TM)|vapor endometrial ablation
224322455|NCT00805961|RADIATION|Radiation therapy|Radiation therapy, 2.0 Gy daily, 5 days per week by single daily dose, to a total of 60 Gy over 6 weeks
224256888|NCT03187158|DIAGNOSTIC_TEST|Forced Oscillation Technique|F.O.T. method can be used to assess obstruction in the large and small peripheral airways , Changes in lung volumes will be measured using a digital spirometer . Every participant will be asked to sit straight, seal the mouthpiece completely with their lips, breathe in fully, blow as hard as possible into the mouthpiece, emptying the lungs completely., Whole blood collected on site (20 mL from every participant, for about 23 metabolites) will be separated into cells and serum. A detailed questionnaire assessing respiratory health, demographic data, habits, and environmental exposure has been developed and validated by Chest Research Foundation.
224256889|NCT01878292|DRUG|Placebo|Dose matched placebo tablets, once per day, oral administration.
224256890|NCT01878292|DRUG|Vilazodone|Vilazodone tablets, 15 mg per day, oral administration
224256891|NCT01878292|DRUG|Vilazodone|Vilazodone tablets, 30 mg once per day, oral administration
224256892|NCT04627467|DRUG|Chloroquine|250mg tablet (150mg base chloroquine)
224256893|NCT00773253|DRUG|Botulinum toxin A|All patients will be treated with Botox using both single-channel and multi-channel EMG mapping.
224256894|NCT06330142|OTHER|Participation in 10 horse-assisted therapy sessions|supporting children and teenagers undergoing radiotherapy with a horse-assisted therapy approach
224256895|NCT02834026|OTHER|Cicloergometry training|
224256896|NCT02834026|OTHER|No Cicloergometry training|
224256897|NCT06380816|DRUG|UCB4594|Participants will receive UCB4594 as an intravenous infusion once every 3 weeks for up to 18 cycles, with each cycle lasting 21 days (\~1 year).
224256898|NCT01527890|DRUG|Fentanyl|intravenous patient-controlled analgesia
224256899|NCT03286439|OTHER|there will be offered a follow up visit|The investigators will offer the patients a follow up visit 3 and 12 months after discharge from the hospital.
224256900|NCT03374176|DRUG|Amoxicillin 500 mg / Metronidazole 250 mg|Subjects were instructed to take a capsule three times a day for 7 days
224256901|NCT03374176|DRUG|Clindamycin 300 mg|Subjects were instructed to take a capsule three times a day for 7 days
224256902|NCT00398983|DRUG|Decitabine|20 mg/m\^2 IV over 1 hour daily for 5 days
224256903|NCT06561568|DIAGNOSTIC_TEST|Conventional physical therapy|Conventional physical therapy protocol for chondromalacia patellae consist of stretches to warm up and cool down Resistance training ,in which patient will perform each exercise for 3 sets of 10 repetitions. Each repetition will be given with a 10 second hold.
224256904|NCT06561568|OTHER|Kinesiotaping|"Kinesio tape will be applied on Vastus medialis Oblique and around the patella.~• Frequency: 3 times a week for 4 weeks."
224256905|NCT05024682|DEVICE|conventional pulsed radiofrequency|After connecting the electrode and the PRF needle, the interventionist determined whether the pudendal nerve innervation produced paresthesia in the sensory stimulation test with a frequency of 50 Hz, pulse width of 1 ms and a voltage of 0.3-0.5 V. Thereafter, the radiofrequency ablation therapy was performed in 42°C, 120 seconds pulse mode which consisted of four cycles (8 minutes)
224256906|NCT05024682|DEVICE|pulse dosed pulsed radiofrequency|After connecting the electrode and the PRF needle, the interventionist determined whether the pudendal nerve innervation produced paresthesia in the sensory stimulation test with a frequency of 50 Hz, pulse width of 1 ms and a voltage of 0.3-0.5 V. Thereafter, the radiofrequency ablation therapy was performed in 42°C, 240 seconds pulse dose mode which consisted of two cycles (8 minutes).
224256907|NCT02102191|DEVICE|e-cigarette|smoking cigarette without tobacco
224256908|NCT02102191|DEVICE|cigarette|smoking cigarette with tobacco
224256909|NCT00699296|DRUG|Panobinostat (LBH589)|20mg/day p.o. on three times-a- week
224256910|NCT06055764|DEVICE|PET/CT|"Patient preparation: Patients will fast for 4 - 6 h before PET scanning to optimize the blood sugar level to 160mg/dl. F-18 FDG dose was 0.14 mCi/kg and injected via intravenous route. During the uptake phase of 18F-FDG patients will be rested in a quite warm room.~Procedure:~All PET-CT studies will be done at the nuclear medicine unit in Assuit University Hospital.~PET-CT images will be interpreted at a workstation equipped with fusion software that offers multi-planar reformatted images and enables display of the PET images, CT images, and fused PET/CT images."
223675350|NCT01385228|DRUG|Pazopanib|"Dose Level Xa - daily administration of pazopanib on days 1 through 21 starting at 400mg with a maximum dose of 1000mg."
223675351|NCT01385228|DRUG|Docetaxel|Docetaxel given IV on Day 1 starting dose 60mg/m2 increase to 75mg/m2
223675352|NCT01385228|DRUG|Pazopanib|"Dose Level Xb - daily administration of pazopanib on days 3 through 19 starting at 400mg with a maximum dose of 1000mg."
224256911|NCT01302548|DEVICE|IRRISEPT|Device containing sterile water and chlorhexidine gluconate (CHG)
223675353|NCT01385228|DRUG|Prednisone|5mg Prednisone given twice daily days 1-21.
223675354|NCT01385228|DRUG|Pegfilgrastim|
224256912|NCT01302548|PROCEDURE|Usual Care|The usual care method will either be the saline irrigation or incision and drainage depending on the physicians discretion.
224256913|NCT00004786|DRUG|iloprost|
224256914|NCT00031434|DRUG|Valganciclovir|Valganciclovir is a mono-valyl ester pro-drug of ganciclovir, which is rapidly converted to ganciclovir on absorption. Valganciclovir oral syrup formulation for administration will be provided as a 15g powder blend containing 3g valganciclovir base, for constitution in 120 mL amber glass bottles. The beginning oral valganciclovir dose under investigation is 14 mg/kg. The dose of oral valganciclovir syrup will be adjusted for the baby's weight and renal function. Weights upon which dosage will be adjustments will be made will be obtained on study days 1, 7, 14, 21, 28, and 35.
224256915|NCT00031434|DRUG|Ganciclovir|Ganciclovir for intravenous infusion will be provided as sterile, lyophilized powder in sealed vials containing 500 mg ganciclovir for re-constitution. The dose of intravenous ganciclovir is 6 mg/kg. Intravenous ganciclovir will be adjusted for the baby's weight and renal function. Weights upon which dosage adjustments will be made will be obtained on study days 1, 7, 14, 21, 28, and 35. Each dose of intravenous ganciclovir should be given over 1 hour using an intravenous pump.
224256916|NCT03537807|DRUG|Riluzole|For adult patients, one 40mg of BHV-0223, administered sublingually, on a twice daily basis (approximately every 12 hours).
223675355|NCT00937885|BEHAVIORAL|Implementation of reminiscence|
223675356|NCT01642810|BEHAVIORAL|Acceptance-based behavioural therapy|Behavioral intervention focusing on acceptance, mindfulness and values-based living instead of focus on symptom control
223675357|NCT01642810|OTHER|Will vary per participant|Participants will continue pre-study treatment under their current licensed practitioners. Intervention may include drug treatment, physical therapy, or other
224256917|NCT03596567|DRUG|Glasdegib single 100 mg dose in normal healthy subjects|A single dose of 100 mg glasdegib tablet will be administered after an overnight fast, followed by serial PK collection, discharge and follow -up.
224256918|NCT03596567|DRUG|Glasdegib single 100 mg dose in moderate renal impairment subjects|A single dose of 100 mg glasdegib tablet will be administered to subjects with moderate renal impairment, after an overnight fast, followed by serial PK collection, discharge and follow -up.
224256919|NCT03596567|DRUG|Glasdegib single 100 mg dose in severe renal impairment subjects|A single dose of 100 mg glasdegib tablet will be administered to subjects with severe renal impairment, after an overnight fast, followed by serial PK collection, discharge and follow -up.
224256920|NCT03741777|OTHER|Clear oral fluid|clear oral fluid including water, pulp-free juice and tea or coffee without milk.
224256921|NCT02116595|OTHER|high or low acid diet|high or low acid diets
224256922|NCT04118335|OTHER|Black Mulberry Syrup|The individuals in the intervention group gargled with 5 ml black mulberry syrup and waited average one minute and then swallow it.
224256923|NCT03905980|PROCEDURE|vaginal delivery|pregnancy ended by vaginal delivery
224256924|NCT03905980|PROCEDURE|Cesarean section|pregnancy ended by cesarean delivery
224256925|NCT05621226|BEHAVIORAL|COVID Booster text messages|Participants will receive text messages per descriptions listed in the arms.
224256926|NCT01471041|DEVICE|Venous Window Needle Guide|Subcutaneous, extravascular needle guide made of medical-grade titanium
224256927|NCT01249651|DRUG|esomeprazole 40 mg|esomeprazole 40 mg once daily, 8 weeks
224256928|NCT01504763|PROCEDURE|Chair massage|Chair massage for 15 minutes once a week for 10 weeks.
224256929|NCT01849003|DRUG|GS-6615|GS-6615 tablet(s) administered orally
224256930|NCT00557752|DEVICE|Non-invasive ventilation|Applied continuously for the first 24 hours, then every 24 hours, trial of discontinuation. Interface specific for the associated injuries.
223675358|NCT06032481|PROCEDURE|surgery|Patients confirmed cervical cancer were undergone radical hysterectomy with pelvic lymphadenectomy
223675359|NCT00708201|DRUG|Alvimopan|
224256931|NCT04029272|DRUG|Metformin|500 mg tid for 12 weeks
224256932|NCT04029272|DRUG|Exenatide 2 MG|Exenatide injection once weekly for 12 weeks
224256933|NCT01140581|DRUG|DRONEDARONE|Pharmaceutical form: tablet Route of administration: oral Dose regimen: 400 mg
224256934|NCT01462279|DRUG|Thiamine|200mg of intravenous thiamine in 50ml of D5W will be infused over 30 minutes once
224256935|NCT01300676|DRUG|Tualang honey|"This was a randomized, prospective, clinical study to evaluate the effect of Tualang honey in comparison with HRT. Subjects will be confined to healthy postmenopausal women who were naturally menopause for more than one year. The study period was four months. A total of 79 patients were recruited.~Group 1: Subjects receiving 20 g/day of Tualang honey. The honey used was from a single batch honey supplied by Federal Agricultural Marketing Authorities (FAMA), Malaysia, evaporated by FAMA to achieve a water content of about 20%, submitted to Sterile Gamma company at Shah Alam, Selangor for sterilization at 25 kGy and packed in 20 g sachet in collaboration with School of Pharmaceutical Sciences laboratory.~Group 2: Subjects receiving hormonal replacement therapy (Femoston®), also known as Femo conti 1/5 (contain 1 mg Estradiol valerate and 5 mg Dydrogesterone) supplied by Solvay Pharma Malaysia."
224256936|NCT02874677|OTHER|Effort reeducation program|personalized reeducation program at a load level preceding hyperventilation
224256937|NCT00494338|DRUG|Docetaxel|
224256938|NCT01724372|DRUG|Antidepressant|
224256939|NCT01724372|DRUG|Antipsychotic|
224256940|NCT01367054|DRUG|Metformin|500 mg tablet
224256941|NCT01367054|DRUG|Glifage|500 mg tablet
223675360|NCT00708201|DRUG|Placebo|
223675361|NCT01653132|DRUG|Incobotulinum Toxin A|Twenty units (0.2 ml) of incobotulinum toxin A were injected into each parotid gland and 30 units (0.3 ml) to each submandibular gland for a total dose of 100 units using anatomical landmarks
223675362|NCT01653132|DRUG|Placebo|Sterile, preservative free 0.9% saline, 1 ml, was used as placebo, and injected into the parotid (0.2 ml each) and submandibular (0.3ml each) glands .
224256942|NCT05044338|DIAGNOSTIC_TEST|imaging|(1) Build the first full information big data cloud platform for diagnosis, treatment and clinical research of senile valvular disease in China (2) To establish a cohort of elderly patients with valvular disease in China and a complete database covering clinical information, functional, imaging evaluation, treatment and follow-up; (3) To analyze the clinical characteristics, functional status and imaging characteristics of senile valvular disease in China, and to understand the current situation of diagnosis and treatment; To establish a whole process standardized comprehensive evaluation system of clinical indicators of senile valvular disease combined with a variety of imaging for Chinese people.
224256943|NCT05434364|OTHER|Facilitated Tucking|giving facilitated tucking before (1st and 3th minutes), during and after (1st and 3th minutes) the procedure
224256944|NCT05434364|OTHER|Swaddling|swaddling before (1st and 3th minutes), during and after (1st and 3th minutes) the procedure
224256945|NCT05434364|OTHER|Prone Position|giving prone position before (1st and 3th minutes), during and after (1st and 3th minutes) the procedure
224256946|NCT00002939|DRUG|irinotecan hydrochloride|
224256947|NCT00002939|DRUG|paclitaxel|
224256948|NCT05369884|DRUG|WPQW granule|WPQW granule, 2 sachets / time, 3 times / day.
224256949|NCT05369884|DRUG|WPQW granule simulant|WPQW granule simulant, 2 sachets / time, 3 times / day.
224256950|NCT00979043|BEHAVIORAL|Dietary Weight-loss|The goal of the dietary weight-loss intervention was to produce and maintain a mean weight-loss of 5% initial body weight during the 18-month intervention, using dietary counseling and behavior modification.
224256951|NCT00979043|BEHAVIORAL|Exercise|Participants participated in resistance training (15 minutes) and aerobic exercise (30 minutes) 3d/week for 18-months. The first 4-months of the exercise training were facility-based. After 4-months, participants were allowed to transition to a home-based intervention if they chose to.
224256952|NCT01391273|DRUG|bimatoprost solution 0.03%|One drop of bimatoprost solution 0.03% applied along each upper eyelid margin once daily in the evening for 4 months.
224256953|NCT01391273|DRUG|bimatoprost vehicle solution|One drop of bimatoprost vehicle solution applied along each upper eyelid margin once daily in the evening for 4 months.
224256954|NCT01277835|DRUG|Lidocaine Infusion|Infusion of lidocaine 3mg/min or 2mg/min during surgery
224256955|NCT01277835|DRUG|Placebo|Saline Infusion at same rate as experimental arm
224256956|NCT00597454|OTHER|Patient Navigation|"we will conduct a detailed analysis of how the patient navigators' time is actually utilized by having them record a detailed log categorizing their activities as it relates to the elimination of recognized barriers to care. Second, we will measure the time interval from receipt of a suspicious mammogram to appropriate diagnostic evaluation and or treatment.~We will measure the number of women who experience diagnostic and or treatment delay and whether the presence of a Patient Navigator enables delivery of coordinated care that avoids delays. Third, we will measure patients' satisfaction with aspects of their care, focusing particularly on care coordination using validated instruments designed for this purpose."
224256957|NCT00164684|BEHAVIORAL|Father Friendly Initiative|
224256958|NCT06873516|DRUG|EVO756|Dose 1
224256959|NCT06873516|DRUG|EVO756|Dose 2
224256960|NCT06873516|DRUG|EVO756|Dose 3
224256961|NCT06873516|DRUG|Placebo control|Placebo control
224256962|NCT01055795|DRUG|Bevacizumab, Everolimus and LBH589|"Dose Escalation Cohort #, Subjects, Bevacizumab, Everolimus, LBH589~1. 3-6, All study drugs administered per dose level~2. 3-6, All study drugs administered per dose level~3. 3-6, All study drugs administered per dose level~Expanded Cohorts Cohort #, Subjects, Bevacizumab, Everolimus, LBH589 A, B \& C; 30, Recommended Phase II Dose for all three compounds"
224256963|NCT01258933|DRUG|Ofatumumab|300 mg Dose 1, then 1,000 mg weekly x 7, (treatment) then 1,000 mg every 2 months beginning on week 12
224256964|NCT02818790|BEHAVIORAL|Intervention 1|Bodyguard + Precious App. Short onsite training session on how to use the system.
224256965|NCT02818790|BEHAVIORAL|Intervention 2|Bodyguard + Precious App + Motivational Interviewing. Face to face counseling session followed by a short onsite training session on how to use the system.
224256966|NCT06406257|DEVICE|3M™ Bair Hugger™ Warming Unit|Utilizing the 3M Temperature Management Unit to ensure intraoperative body temperature of elderly hip surgery patients remains consistent with their preoperative baseline, while patients in Group C receive no intervention.
224256967|NCT03642808|OTHER|rehabilitation program|Availibility of patients to complete a rehabilitation program during 8 weeks and to come back 4 times for a careful medical examination
224256968|NCT01099007|BEHAVIORAL|In Person|Participants in the In Person group have weekly visits for the 12 weeks to the research office. The first visit can last up to one and a half hours and each subsequent visit can last approximately one hour. Group meetings provide appropriate nutrition and physical activity information as well as behavioral change strategies. Sessions also include some light physical activity (equal to brisk walking).
224256969|NCT01099007|BEHAVIORAL|At Home|Participants in the At Home group receive a workbook from the research staff at their baseline visit that outlines an accepted nutrition and physical activity program to complete on their own.
224256970|NCT06874790|BEHAVIORAL|Catalina|"Catalina transmedia web-based app intervention with 10 story-based videos (including bonus story extender videos) totaling 31 minutes plus the blog of the character, Veronica, which has MH resource links including Veronica's recommendations of at least 3 local Latinx-serving clinics in LA and Orange County ZIP Codes that offer low-cost MH Tx."
224256971|NCT06874790|BEHAVIORAL|Control webpage|Links to informational videos (totaling 31 minutes) on depression and anxiety, listing of the same 3 local Latinx-serving clinics in LA and Orange County ZIP codes that offer low-cost MH Tx, and links to nationally available websites that offer resources (including access to service locators).
224256972|NCT03801707|DRUG|Sofosbuvir / Velpatasvir Oral Tablet [Epclusa]|fixed dose combination medication once a day for 12 weeks for the treatment of hepatitis C
223772762|NCT02657811|DEVICE|Miri TL, Time-Lapse incubator|Time Lapse Incubation - Morphologic/Morphokinetic Assessment These embryos will remain in the TLI and undergo both morphologic and morphokinetic evaluation and grading according to a hierarchical multivariable model. They will not be removed from incubation for the duration of culture.
223772763|NCT02657811|DEVICE|Miri TL, Time-Lapse incubator|Time Lapse Incubation - Morphologic Assessment These embryos will remain in the TLI and undergo only traditional morphologic assessment according to accepted criteria with no additional imaging. They will also not be removed from incubation for the duration of culture. The time points and evaluated parameters will be identical to those in arm 1 of the study.
223772764|NCT06031571|PROCEDURE|dry cupping massage|Dry cupping is a form of massage therapy that involves using Hijamat cups without skin injury while applying suction and then performing circular and transverse movements
224256973|NCT03801707|DRUG|Glecaprevir/Pibrentasvir 100 MG-40 MG Oral Tablet [MAVYRET]|Three tablets once a day for 12 weeks for treatment of hepatitis C
224256974|NCT07020221|DRUG|VS-7375|VS-7375 is a highly selective oral, non-covalent, small molecule KRAS G12D (ON/OFF) inhibitor.
224256975|NCT07020221|DRUG|Cetuximab|Cetuximab is a monoclonal antibody targeting the epidermal growth factor receptor (EGFR).
224256976|NCT07020221|DRUG|Carboplatin + Pemetrexed + Pembrolizumab|A combination therapy regimen used as a first-line treatment for advanced non-squamous non-small cell lung cancer.
224256977|NCT07020221|DRUG|Gemcitabine|A chemotherapy used for the treatment of several types of cancer including advanced or metastatic pancreatic ductal adenocarcinoma.
224256978|NCT07020221|DRUG|Gemcitabine + Nab-paclitaxel|A chemotherapy regimen used for the treatment of advanced or metastatic pancreatic ductal adenocarcinoma.
224256979|NCT00208403|DEVICE|Acryloc™ GHV|A high viscosity bone cement for use in total hip replacement
224256980|NCT00208403|DEVICE|Palacos R|A high viscosity bone cement for use in total hip replacement
224256981|NCT03873272|DEVICE|Cryotherapy|Study subjects will wear NatraCure flexible socks on bilateral hands and feet. The sock will act as a mitten and covers the entire hand until past the wrist. There are 2 gel packs inserted into the sock, to provide cooling to the dorsal and frontal aspect of the hand. For the feet, the sock will cover the entire foot until above the ankle. Garments will be refrigerated for at least 3 hours at -25 to -30 Celsius prior to use. With each infusion, patients will wear the frozen garments on their hands and feet for a total of 90-120 minutes, beginning 15 minutes before the start of the infusion and until 15 minutes after the end of the infusion. Two sets of socks will be used during each session for 45-60 minutes each to maintain a consistently low temperatures of the extremities.
223772765|NCT06031571|PROCEDURE|Myofacial release|Myofascial release is a form of manual therapy using hands-on techniques to regain tissue extensibility and elasticity
224256982|NCT03873272|DEVICE|Compression Therapy|Study participants will wear Sigvaris Secure Arm Sleeves and Gloves on bilateral upper extremities. The sleeves and gloves provide 20-30mmHg of compression. Subjects will wear Sigvaris CompreFlex Lite compression garments on the lower extremities which includes a transition liner with a compressive foot, providing 20-30mmHg of compression on the lower leg and 15mmHg on the toes and feet. AccuTabs will be placed along the CompreFlex Lite to easily and accurately set the compression level at 20-30mmHg. With each chemotherapy infusion, patients will wear the sleeves/gloves and socks for a total of 90-120 minutes, beginning 15 minutes before the start of the infusion and until 15 minutes after the end of the infusion.
224256983|NCT03873272|DEVICE|Loose glove/sock|Study participants will wear a non-compressive sleeve and loosely fitting glove on bilateral arms and hands. They will also wear a non-compressive Sigvaris Basic Liner with the CompreFlex Lite loosely applied over it. The investigators will verify that no compression is applied via using an interface pressure sensor (PicoPress). The maximum level of allowed pressure for garments will be 3mmHg. If the pressure reading is greater than 3mmHg, then a larger garment size will be used. Measurements with the pressure sensor will be repeated as needed to ensure a low pressure level of less than 3mmHg. With each chemotherapy infusion, patients will wear the gloves and socks for a total of 90-120 minutes, beginning 15 minutes before the start of the infusion and until 15 minutes after the end of the infusion.
224256984|NCT07033013|DIETARY_SUPPLEMENT|Placebo|Placebo
224256985|NCT07033013|DIETARY_SUPPLEMENT|Dietary Supplement with actives|Dietary supplement containing EstroG-100 and GABA
224256986|NCT04206462|OTHER|Questionnaire of eating habits|frequency and type of aliments
224256987|NCT00787254|DRUG|Lansoprazole|Lansoprazole 15 mg, capsules, orally, once daily and gefarnate placebo-matching capsules, orally, twice daily for up to 6 to 24 months.
223675363|NCT00761748|DEVICE|Convatec Uro 2-piece|"Specific name of the device: 'Combihesive Natura® with a Durahesive Convex-It® base plate, 45 mm coupling, moldable (13-22 and 22-33 mm) hole size with boarder tape'.~The subjects are asked to test each of the two products for 21 days plus/minus 3 days in a randomised order and in accordance with their normal frequency of change and normal use pattern. The duration of the clinical investigation should be enough time to identify any difference in user-preference. If the subject is in the middle of testing an urostomy base plate when the test period is turning into the next period, the urostomy base plate can be worn until it needs to be changed. It is not possible to blind the investigation as the appearance of the test- and refer-ence products are very different in the look."
223772766|NCT00364780|DRUG|XL647|XL647 will be administered orally as a single agent. XL647 will be supplied as 50 mg tablets. Subjects in the Intermittent 5 \& 9 cohort will receive XL647 at a dose of 350 mg on a 5 days on and 9 days off cycle every 2 weeks for 8 weeks. Subjects in the Daily Dosing cohort will receive XL647 administered daily as a single oral dose of 300 mg. In the absence of progressive disease (PD) and unacceptable XL647-related toxicity, subjects may continue to receive XL647 treatment on their assigned dosing schedule for up to 1 year on this study. Subjects who reach 1 year of treatment with no evidence of disease progression may, with the concurrence of the investigator and the sponsor, continue to receive therapy.
223772767|NCT06149637|PROCEDURE|Traditional neck dissection approach|.1. A transverse cervical incision is made with horizontal extension towards the affected side. 2. It is dissected through the subplatysmal plane, the posterior edge of the sternocleidomastoid muscle is dissected along its entire length. 3. Identification and dissection of the spinal nerve at Erb's point. 4. Level V nodes are dissected up to the spinal nerve without identifying or dissecting it 5. The jugular chain nodes are identified and the left level IV nodes are dissected with special attention to ligate the lymphatics of this level 6. Identification and dissection of level III nodes 7. Identification and dissection of level IIA and IIB ganglia with identification and preservation of the accessory nerve.
224256988|NCT00787254|DRUG|Gefarnate|Gefarnate 50 mg, capsules, orally, twice daily and lansoprazole placebo-matching capsules, orally, once daily for up to 6 to 24 months.
224256989|NCT07045467|DRUG|Remimazolam Besylate|"This is the first clinical trial evaluating Remimazolam's pharmacokinetics (PK), pharmacodynamics (PD), and safety in renal transplant recipients-a population with unique physiological alterations due to end-stage renal disease and graft reperfusion. Key differentiators include:~Population-Specific Dosing Protocol:~Induction: 6 mg/kg/h until MOAA/S ≤1 (vs. 5-12 mg/kg/h in general surgery).~Maintenance: Titrated (0.5-2 mg/kg/h) to Narcotrend Index 27-60 (lower than typical BIS 40-60 targets), accounting for altered drug metabolism post-transplant.~Transplant-Specific Context:~Administered alongside standard immunosuppressants (methylprednisolone 750 mg + furosemide 60 mg at reperfusion) but prohibits common sedatives (midazolam/propofol) to isolate Remimazolam's effects.~PK/PD sampling accounts for graft function dynamics (e.g., blood draws during reperfusion and post-op days 1-6).~Exploratory Genetic Analysis:~First study linking VDR/"
224256990|NCT05853328|PROCEDURE|Epley Maneuver|"The patient is sitting with both feet on the table or bed with the head looking forward. Subsequently, they let themselves fall backwards with a pillow under the shoulder and the head is turned 45° to the right. They stay in this position for 30 seconds. Afterwards, they turn the head quickly 90° to the left side followed by a turn of the whole body to the left so that their nose is pointing at the floor. They stay in this position for another 30 seconds.~Subsequently, the patients sit themselves up with the head still turned 45° to the left. They can help themselves by using both arms. After a few seconds, they can turn the head slowly back to the neutral position facing forward."
224256991|NCT05853328|PROCEDURE|SemontPLUS maneuver|The patients first turn head 45° to the left. Then they extend the right arm and subsequently move the whole body by 150°+ to the right side. This position is kept for 60 seconds. Subsequently, patients move their whole body by 240° towards the non-affected side. Finally, after another 60 seconds, the patient sits up for another 60 sec.
224256992|NCT07062419|DEVICE|endoactivator|activation of irrigant during root canal treatment
224256993|NCT07063186|OTHER|Group A - Elastomeric power chain on all bracket wings.|Elastomeric power chain is engaged on all bracket wings
223675364|NCT00761748|DEVICE|SenSura Uro 2-piece|SenSura URO 2-piece Extended Wear, convex light, 50 mm coupling, cuttable (15-33 mm)
223675365|NCT04016740|DRUG|Ropivacaine|Intraoperative bilateral PIFB block with 20 mL of 0.25% Ropivicaine on either side of the sternum after anesthetic induction but before surgical incision
223675366|NCT04016740|DRUG|Ketamine|Intraoperative infusion
224256994|NCT07063186|OTHER|Group B - Stainless steel ligatures with elastomeric power chain placed over all bracket wings.|Stainless steel ligatures are used to tie in the archwire on all bracket wings, with an elastomeric power chain placed over the ligatures
223675367|NCT04016740|DRUG|Remifentanil|Intraoperative infusion
223675368|NCT04016740|DRUG|Dexmedetomidine|Intraoperative infusion
224256995|NCT07063186|OTHER|Group C - Elastomeric modules on mesial wings and power chain on distal wings.|Elastomeric modules are placed on the mesial wings of each bracket, while an elastomeric power chain is engaged on the distal wings
224256996|NCT07068321|COMBINATION_PRODUCT|Control Group (transcutaneous electrical nerve stimulation)|Control Group will consist of 20 sessions of 30 min, applied twice per week over a period of 3 months including transcutaneous electrical nerve stimulation, and standardized exercises for LBP through smart phone application.
224256997|NCT07068321|COMBINATION_PRODUCT|Godelieve Denis-Struf|Experimental Group will receive 20 sessions of 30 min applied twice per week over a period of 3 months of GDS treatment through smart phone application.
224256998|NCT07068321|COMBINATION_PRODUCT|Godelieve Denis-Struf + Cognitive Behavioral Therapy|Experimental Group 2 will receive 20 sessions of 45 min applied twice per week over a period of 3 months of GDS along CBT treatment through smart phone application.
224256999|NCT07068100|BEHAVIORAL|Stage-of-change based physical activity counseling|On the first evaluation day, an individual physical activity program will be created for the participants in the group within the scope of physical activity counseling. A 20-30 minute phone call will be made once a week by a psychologist regarding the stage of change they are in, and a 10-15 minute phone call will be made once a week by a physiotherapist for physical activity counseling.
224257000|NCT07068100|BEHAVIORAL|Giving the group a brochure with recommendations for physical activity and the benefits of physical activity for psychological health|The second group will be given a brochure with recommendations for physical activity and the benefits of physical activity for psychological health.
224257001|NCT07067970|DRUG|serotonin reuptake inhibitor (SSRI)|"Dapoxetine Group~Dosage: 30 mg dapoxetine, taken orally 1-3 hours before anticipated sexual activity, with a maximum of 3 doses per week.~Administration: Provided in blister packs to ensure compliance. Reference: McMahon et al., 2011."
224257002|NCT07067970|DRUG|Placebo|"Dosage: Placebo tablets identical in appearance and taste to dapoxetine, administered on the same schedule (1-3 hours before sexual activity, maximum 3 doses per week).~Administration: Provided in identical blister packs."
224257003|NCT07067970|OTHER|Acupuncture|"Protocol: Two 30-minute acupuncture sessions per week, targeting standardized points (e.g., CV4, SP6, ST36) known to influence sexual function and autonomic nervous system regulation.~Administration: Performed by licensed acupuncturists following a standardized protocol.~Reference: Sunay et al., 2011."
224257004|NCT07067970|OTHER|Sham|"Sham Acupuncture Group:Protocol: Two 30-minute sessions per week using superficial needle insertion at non-active points to minimize therapeutic effects while maintaining the placebo effect.~Administration: Performed by licensed acupuncturists to ensure consistency with the active acupuncture group"
224257005|NCT07067970|BEHAVIORAL|Exercise|"Kegel Exercises Group:Protocol: Participants will perform pelvic floor muscle exercises consisting of three sets of 10-15 contractions daily, each held for 5-10 seconds followed by relaxation.~Training: Participants will receive initial training from a licensed physiotherapist, with weekly follow-up sessions to ensure proper technique and adherence.~Reference: Pastore et al., 2014."
224257006|NCT07068126|BIOLOGICAL|Mini-Pool IVIG|Mini-pool intravenous immunoglobulin (IVIG) is a plasma-derived biologic prepared from small pools of locally donated human plasma using a validated, virus-inactivated, closed-system process. Each participant will receive a loading dose of 1 g/kg infused intravenously over 6-8 hours. Maintenance doses of 0.5 g/kg will be given every 2 to 4 weeks for up to five additional doses, with the dosing schedule adjusted based on platelet count. The preparation contains purified IgG and meets safety standards for sterility and viral inactivation.
224257007|NCT07069257|BEHAVIORAL|Oral Motor Therapy|Structured oral motor exercises will be applied to the lips, tongue, cheeks, and jaw. Facial massage and thermal stimulation (warm and cold) will be performed. Intraoral sensory stimulation will be applied using a brush, lemon juice, and a cold metal probe.
224322456|NCT00805961|DRUG|Temozolomide|Temozolomide 75mg/m2 by mouth daily, beginning day 1 of radiation therapy and continuing through the last day of radiation therapy
224322457|NCT00805961|DRUG|Bevacizumab|Bevacizumab 10mg/kg IV, every 2 weeks, beginning day 1 of radiation therapy
224322458|NCT00805961|DRUG|Bevacizumab|Bevacizumab 10mg/kg IV, every 2 weeks, beginning Week 11
223675369|NCT04016740|DRUG|Rocuronium|Intraoperative intermittent bolus
223675370|NCT04016740|DRUG|Propofol|Intraoperative infusion
223675371|NCT04016740|DRUG|Sevoflurane|Intraoperative inhaled as needed
223675372|NCT04016740|DRUG|Dexmedetomidine|Post-operative infusion
223675373|NCT04016740|DRUG|Propofol|Post-operative infusion
224322459|NCT00805961|DRUG|Everolimus|Everolimus 10mg by mouth daily, beginning Week 11
224322460|NCT04380961|DRUG|Sirukumab|Participants will receive single dose infusion of sirukumab on Day 1.
224322461|NCT04380961|DRUG|Placebo|Participants will receive placebo IV single dose infusion on Day 1.
223675374|NCT04016740|DEVICE|EEG monitoring|Perioperative monitoring
223675375|NCT05704985|BIOLOGICAL|DK210 (EGFR)|Solution for SC administration
223675376|NCT05704985|RADIATION|Radiation therapy|Short regimen radiation therapy (10 fractions or less)
223675377|NCT05704985|BIOLOGICAL|Immune checkpoint blockers|IV administration of approved PD1 blocker
223675378|NCT05704985|DRUG|Chemotherapy|Single agent or combination of not more than two
223675379|NCT05860010|DRUG|Epinephrine injection|patients will be placed on left lateral position and drug will be given the caudal space
223675380|NCT05860010|DRUG|Dexmedetomidine|patients will be placed on left lateral position and drug will be given the caudal space
223675381|NCT05860010|DRUG|Bupivacaine|patients will be placed on left lateral position and drug will be given the caudal space
223675382|NCT03312751|DRUG|Emapalumab|Emapalumab will be administered by intravenous infusion, twice weekly.
223675383|NCT03722290|DRUG|Metformin|Oral administration of metformin 250mg (twice a day) for the 1st week followed by metformin 500mg (twice a day) for the next 8 weeks.
223675384|NCT00241501|DRUG|Esomeprazole (Nexium)|
223675385|NCT03490981|OTHER|Treatment as usual (TAU)|Participants assigned to TAU will receive standard medical care from their primary care provider including pain medications, brief advice (e.g., use of relative rest, application of heat or ice, other self-care strategies), or referral to pain-related adjunctive interventions (e.g., physical therapy), as indicated.
223675386|NCT03490981|BEHAVIORAL|Brief Cognitive Behavioral Therapy for Chronic Pain (Brief CBT-CP)|Brief CBT-CP is a manualized protocol that includes six, 30-minute sessions over the course of 6 weeks. Brief CBT-CP session outlines and patient handouts are included in the appendix. Session one focuses on foundational pain education and the development of treatment goals. Session two emphasizes balanced engagement in physical activity and pleasurable events. Session three emphasizes skills training for easily implemented relaxation techniques. Sessions four and five focus on recognizing and modifying unhelpful thoughts that negatively impact pain. Session six focuses on relapse prevention and independent implementation of CBT-CP skills following treatment.
223675387|NCT04929665|PROCEDURE|Two different block and combination of these two blocks|Thoracic paravertebral block, erector spina block, and a combination of paravertebral block and erector spinae block will be applied to the patients under real-time ultrasound guidance.
223675388|NCT05036811|OTHER|data collection|data collection
223675389|NCT02324543|DRUG|Gemcitabine|IV on days 4 and 11 of a 21 day cycle
223675390|NCT02324543|DRUG|Taxotere|IV on days 4 and 11 of a 21 day cycle
223675391|NCT02324543|DRUG|Xeloda|Twice a day orally on days 1 through 14 of a 21 day cycle
223675392|NCT02324543|DRUG|Cisplatin|IV on days 4 and 11 of a 21 day cycle
223675393|NCT02324543|DRUG|Irinotecan|IV on days 4 and 11 of a 21 day cycle
224257008|NCT07069257|DEVICE|Neuromuscular Electrical Stimulation (NMES)|Active NMES will be applied bilaterally to the masseter muscles and to the orbicularis oris muscle in addition to oral motor therapy sessions, using a Chattanooga NMES device. Each application will be performed in cycles of 5 seconds of stimulation and 10 seconds of rest. The stimulation parameters will be set to a frequency of 10-15 Hz and a pulse width of 300 microseconds. The current intensity will be gradually increased to a level just above the motor threshold, sufficient to elicit a noticeable pulling sensation without causing discomfort, and will be adjusted according to each participant's tolerance. NMES will be delivered for a total duration of 15 minutes per session. For the electrical stimulation of the orbicularis oris muscle, a pen-type electrode will be used. In this procedure, four regions of the orbicularis oris muscle (upper, lower, right, and left) will be stimulated in two cycles of 45 pulses each.
224257009|NCT07069257|DEVICE|Sham Neuromuscular Electrical Stimulation (Sham NMES)|Simulated neuromuscular electrical stimulation will be applied without delivering active electrical current after oral motor therapy sessions to mimic the treatment experience without producing physiological effects.
224257010|NCT05559892|BEHAVIORAL|DM-CCT|Participants randomized to DM-CCT will receive cash transfers of $500 per month for 6 months, but the cash transfers will be conditional on attending a 60-minute diabetes education/skills training (30 minutes) and stress/coping (30 minutes) session delivered by trained nurses every 2 weeks for 6 months (12 sessions).
224257011|NCT05559892|BEHAVIORAL|DM-UCT|Participants randomized to UCT will receive cash transfers of $500 per month for 6 months, but there will be no conditions attached. Therefore, they will receive cash transfer payments every month. However, to control for content and attention, participants will receive mailed version of the diabetes education/skills training materials every two weeks on the same schedule as the DM-CCT telephone sessions.
224257012|NCT05141097|OTHER|Integrative medicine approach|By treated by integrative medicine approaches instead of conventional medicine
224257013|NCT03841188|OTHER|Nutritional orientation|Nutritional orientation with emphasis in rich calcium food
224257014|NCT07072975|OTHER|Normobaric hypoxia|Normobaric hypoxia (inspired oxygen fraction of 12.9%) applied between-sets recovery periods
224257015|NCT07072975|OTHER|normoxic condition|Between-sets recovery periods under normoxic condition
224257016|NCT06025747|DRUG|Abemaciclib|Given PO
224322462|NCT04380961|OTHER|Standard of Care (SOC)|SOC treatment will be determined by the investigator based on local practice and consists of supportive care.
224322463|NCT00562783|DRUG|Vitaliver|
223675394|NCT03108781|DRUG|Lavender Oil|Lavender Oil twice a day; one month on the face and one month on the legs
223675395|NCT03108781|DRUG|sunflower oil|placebo twice a day (sunflower oil); one month on the face and on month on the legs
223675396|NCT00282464|DRUG|Placebo|Subjects will start on placebo and remain on placebo for six weeks. All cards for the Placebo arm will be 0 mg bid.
223675397|NCT00282464|DRUG|Geodon (Ziprasidone)|Ziprasidone flexible dosing treatment arm (20-80 mg bid). For the Ziprasidone arm, the Baseline card will contain 20 mg bid (one 20 mg capsule) for days 1-2 and 40 mg bid (two 20 mg capsules) for days 3-6. Cards A, B, C, and D will contain either 20 mg bid (one 20 mg capsule), 40 mg bid (two 20 mg capsules), 60 mg bid (one 60 mg capsule), or 80 mg bid (one 60 mg capsule and one 20 mg capsule).
224257017|NCT06025747|PROCEDURE|Computed Tomography|Undergo CT
224257018|NCT06025747|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
224257019|NCT06025747|RADIATION|Radiation Therapy|Undergo radiation therapy
224322464|NCT00562783|DRUG|Placebo|
224322465|NCT05093361|PROCEDURE|Total Hip Arthroplasty|Total Hip Arthroplasty for the treatment of hip arthritis.
224322466|NCT05093361|PROCEDURE|Physical Therapy|Self-driven training according to the training plan instructed by physical therapist.
223675398|NCT04822584|DRUG|Baricitinib Oral Product|Baricitinib 4 mg/day orally for 36 weeks
223675399|NCT04822584|DRUG|Placebo|Placebo once a day orally for 36 weeks
223675400|NCT03748043|DRUG|Lactoferrin|lactoferrin 100 mg per day plus ferric hydroxide polymaltose 6 mg /kilogram of Elemental iron
223675401|NCT03748043|DRUG|Ferric Hydroxide Polymaltose|group 2 will receive ferric hydroxide polymaltose 6 mg /kilogram of elemental iron
224322467|NCT00002505|BIOLOGICAL|filgrastim|
224322468|NCT00002505|BIOLOGICAL|recombinant interferon gamma|
224322469|NCT00002505|BIOLOGICAL|tumor cell lysate vaccine therapy|
224322470|NCT06233773|PROCEDURE|Kinesio Taping|Kinesio Taping
224322471|NCT06233773|PROCEDURE|Manual Lymph Drainage|Manual Lymph Drainage Group
224322472|NCT06233773|OTHER|Control Group|Control Group
224322473|NCT01186484|DRUG|JNJ-212082|250 mg, 500 mg or 1000 mg once daily up to discontinuation for any reasons such as progression of the disease or up to the transition to extension study.
224257020|NCT06025747|PROCEDURE|Therapeutic Surgical Procedure|Undergo surgery
224257021|NCT03117257|DRUG|Lobaplatin|Device: Chrono-chemotherapy Drug: induction Chrono-chemotherapy Drug: Lobaplatin chrono-chemotherapy Radiation: intensity-modulated radiation therapy
224257022|NCT03117257|DRUG|Cisplatin|Device: Chrono-chemotherapy Drug: induction Chrono-chemotherapy Drug: cisplatin chrono-chemotherapy Radiation: intensity-modulated radiation therapy
224257023|NCT05849298|DRUG|AAA617|Administration intravenously once every 6 weeks (1 cycle) for 6 cycles
224257024|NCT05849298|DRUG|AAA517|Single intravenous dose of approx. 150 Megabecquerel (MBq) prior PSMA-PET scans
224257025|NCT05849298|DRUG|Piflufolastat F 18|Single intravenous dose of approx. 333 Megabecquerel (MBq) prior PSMA-PET scans
224257026|NCT05849298|DRUG|ARPI|Enzalutamide, Darolutamide, Apalutamide as prescribed by the local investigator
223675402|NCT05578027|PROCEDURE|Mild moxibustion with moxa stick|To conduct this intervention, we used moxa sticks which were 1.5 cm in diameter, 13 cm long, and weighed 12 gram to perform mild moxibustion manipulation at the control acupoint (the left side Pishu acupoint) or Mingmen acupoint in 2 trial phases. The main ingredient of the moxa was dried mugwort leaf, produced in Vietnam. All moxa materials were obtained from the Sai Gon TCS Co., Ho Chi Minh City, Vietnam.
223675403|NCT01695278|BEHAVIORAL|Telephone Counseling|Weekly telephone counseling intervention for 16 weeks, used to identify and overcome barriers to diabetes control and set goals for positive behavioral changes supplemented by monthly group classes on skill development.
223675404|NCT06485115|DEVICE|Digital Telerehabilitation (Euleria Home)|After the in-hospital rehabilitation treatment (1 h/day, 3 days/week), the EG patients will perform the Digital Telerehabilitation program at home. The three weekly sessions will be asynchronous (with the caregiver's supervision if necessary). At each Unit, the physiotherapist will develop the training sessions on the Home- based Digital Telerehabilitation program and monitor the training execution provided by the digital device to adapt the rehabilitation treatment to the patients' improvements/difficulties. The Digital Telerehabilitation device (Euleria Home, Euleria Health) will consist of one wearable sensor and an app on a tablet that guides the patient through the customized exercise-therapy path configured by the professional. The sensor is worn on different body segments to monitor movements and provides real-time feedback on angles, balance, and repetitions.
224257027|NCT05849298|DRUG|ADT|as prescribed by the local investigator
224257028|NCT05849298|OTHER|Best supportive care|as prescribed by the local investigator
224257029|NCT06783647|DRUG|LBL-024 for Injection|intravenous infusion.
224257030|NCT06783647|DRUG|Docetaxel Injection|intravenous infusion.
224257031|NCT06783647|DRUG|Bevacizumab Injection|intravenous infusion.
224257032|NCT06783647|DRUG|Pemetrexed Disodium for Injection|intravenous infusion.
224257033|NCT06783647|DRUG|Paclitaxel Injection|intravenous infusion.
224257034|NCT06783647|DRUG|Carboplatin Injection|intravenous infusion.
223675405|NCT06485115|OTHER|Conventional therapy|After the in-hospital rehabilitation treatment (1 h/day, 3 days/week), the CG patients will be advised to perform the Self-management activities learned during the in-hospital rehabilitation training without home-based Digital Telerehabilitation devices.
224257035|NCT07078604|BIOLOGICAL|CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine|Given ID
224257036|NCT07078604|DRUG|Cisplatin|Given cisplatin
224257037|NCT07078604|PROCEDURE|Computed Tomography|Undergo CT scans
224257038|NCT07078604|PROCEDURE|Computed Tomography Assisted Biopsy|Undergo CT-guided biopsy
224257039|NCT07078604|DRUG|Docetaxel|Given docetaxel
224257040|NCT07078604|DRUG|Doxorubicin|Given doxorubicin
224257041|NCT07078604|DRUG|Eribulin|Given eribulin
224257042|NCT07078604|DRUG|Paclitaxel|Given paclitaxel
224257043|NCT07078604|DRUG|Pegylated Liposomal Doxorubicin Hydrochloride|Given liposomal doxorubicin
224257044|NCT07078604|BIOLOGICAL|Sargramostim|Given ID
224257045|NCT07078604|PROCEDURE|Ultrasound-Guided Biopsy|Undergo ultrasound-guided biopsy
224257046|NCT07078604|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
224257047|NCT07078604|DRUG|Carboplatin|Given carboplatin
224257048|NCT07078604|PROCEDURE|Positron Emission Tomography (PET)|Undergo PET scan
224257049|NCT06834347|DRUG|Itepekimab (SAR440340)|Pharmaceutical form: Solution for injection in prefilled syringe. Route of administration: Subcutaneous
224257050|NCT06834347|DRUG|Placebo|Pharmaceutical form: Solution for injection in prefilled syringe. Route of administration: Subcutaneous
224257051|NCT06834347|DRUG|Mometasone furoate nasal spray (MFNS)|Pharmaceutical form: Solution for administration via spray pump. Route of administration: Intranasal spray
224257052|NCT07080632|DRUG|Calculus bovis sativus (CBS)|Subjects will orally receive 300mg CBS per day from day 1 to day 7
224257053|NCT07080632|DRUG|Natural Calculus Bovis(NCB)|Subjects will orally receive 300mg NCB per day from day 1 to day 7
224257054|NCT05078229|BEHAVIORAL|FOCUS|There will be 6 one on one sessions, either in person or via video conference. The 6 sessions will last between 45-60 minutes. Topics of the sessions will be Mindfulness for the Caregivers, Awareness of Stressors, Skillful Actions, Thoughts, Self-Care and Balance and Planning for the Future. There will be meditation during the sessions and then recommended daily at home mindfulness practice.
224257055|NCT05078229|BEHAVIORAL|Healthy Living|There will be 6 one on one sessions, either in person or via video conference. The 6 sessions will last between 45-60 minutes. Topics of sessions will be Overview of Cancer, Eating Well, Exercise, Cancer Prevention, Sleep and Finances.
224257056|NCT06793358|DRUG|fentanyl and Remimazolam|This is the first dental study that will combine these two sedation drugs
224257057|NCT07084090|BEHAVIORAL|Implementation intention planning|Implementation intention planning to promote patient safety concerns
224257058|NCT07074483|DEVICE|Upper limb rehabilitation wearable device|"The intervention consists in using the AuReha system to perform a series of upper limb rehabilitation exercises.~No therapeutic or diagnostic interventions will be administered, as this is a non-invasive study focused on system validation and user feedback."
224257059|NCT07080866|DIAGNOSTIC_TEST|MRI|Participants will undergo a 60-minute MRI
224257060|NCT07080866|DIAGNOSTIC_TEST|Carotid ultrasound|Participants will undergo an ultrasound
224257061|NCT07086521|BIOLOGICAL|ULSC|Allogeneic umbilical-cord lining stem cells (ULSC) are cryopreserved and supplied in vials to be thawed and prepared for infusion at point of use. Each dose of 1 x 10\^8 ULSC will be added to into 250 sterile saline for infusion (total volume of 260 mL volume).
224257062|NCT07086521|BIOLOGICAL|Placebo|The Placebo will be 250 ml of sterile saline for IV administration.
223675406|NCT02402842|DRUG|Docetaxel, Cisplatin and 5-Fluorouracil|Patients will receive 6 cycles of DCF regimen (docetaxel 75 mg/m2 day, cisplatin 75 mg/m2 and 5 Fluorouracil at 750 mg/m2/day for 5 days) every 3 weeks or 8 cycles of modified-DCF regimen (docetaxel 40 mg/m2 day, cisplatin 40 mg/m2 day and 5-Fluorouracil at 1200 mg/m2/day for 2 days) every 2 weeks, according to their clinical status.
224257063|NCT01548248|DRUG|insulin detemir|Prescribed insulin detemir and insulin aspart based on the clinical judgement of the physician. The insulin preparations were prescribed by the physician solely as a result of a normal clinical evaluation. The physician determined the starting dose and frequency, as well as later changes to either dose or frequency, if any.
224257064|NCT01548248|DRUG|insulin aspart|Prescribed insulin detemir and insulin aspart based on the clinical judgement of the physician. The insulin preparations were prescribed by the physician solely as a result of a normal clinical evaluation. The physician determined the starting dose and frequency, as well as later changes to either dose or frequency, if any.
224257065|NCT03128762|BIOLOGICAL|ILC2 levels in blood|The levels of circulating ILC2 cells relative to other lymphocytes will be determined via flow cytometry
224257066|NCT00295113|PROCEDURE|EFR|
223675407|NCT03500185|OTHER|PFMT in group|Participants randomized to this group will perform the PFMT protocol in a group, with physiotherapeutic supervision, lasting 1 hour, in the Outpatient Clinic of Gynecology of Hospital of Clinics of Porto Alegre (HCPA), for a period of 3 months. You will also be instructed to perform exercises at home. After this period, they will be reassessed and will follow the same protocol for another 3 months now at home. After this period, they will be evaluated again.
223675408|NCT03500185|OTHER|PFMT at home|Randomized participants for this group will receive guidance on the home PFMT protocol on the day of the initial evaluation. They will be instructed to perform the exercises daily for a period of 3 months. After 3 months they will be re-evaluated and will follow the same protocol for another 3 months at home. After this period they will be evaluated again.
223675409|NCT00287170|DRUG|Delayed Release 6MP or Calcitriol vs. Purinethol|
223675410|NCT05111275|OTHER|Cognitive exercises|Exercises that stimulate and train memory, attention, executive functions, language and gnosis.
223675411|NCT04089215|BIOLOGICAL|CD19-targeted Chimeric Antigen Receptor (CAR) T Cells|JWCAR029 be administered at dose level: 1 x 10\^8 CAR+T cells and 1.5 x 10\^8 CAR+T cells
223675412|NCT02724670|RADIATION|IGRT|MR-based IGRT
223675413|NCT03516903|DRUG|Methotrexate|ddMTX-LDE (Methotrexate carried by a lipid nanoemulsion)
223675414|NCT03516903|DRUG|Placebo|Placebo-LDE (Lipid nanoemulsion)
223675415|NCT03516903|DRUG|Folic Acid|Folic acid pill
224257067|NCT06929221|OTHER|use of whiteboard|"Patients will be followed up for 7 days. Routine nursing care will be applied to the control group. The following information will be included on the whiteboard fixed in the patient room for the intervention group.~* Nurse's name~* Doctor's name~* Treatment times during the day~* Nursing interventions and hours for the diagnoses considered for the patient's major problems~* Timing of diagnostic and imaging techniques to be performed on the patient~* Content of appropriate discharge education for the patient~* Points to be considered by the patient before and after treatment~* Dietary considerations for the patient~* Nurse and patient's private note As a result of the data obtained, statistical analyses will be performed and interpreted to determine the effect of whiteboard use on anxiety, depression and satisfaction with nursing care in COPD patients."
224257068|NCT03725436|DRUG|MDM2/MDMX Inhibitor ALRN-6924|Given IV
224257069|NCT03725436|DRUG|Paclitaxel|Given IV
224257070|NCT06888921|DRUG|COM701|COM701 will be administered via intravenous (IV) infusion once every 3 weeks.
224257071|NCT06888921|DRUG|Normal Saline|Saline will be administered via intravenous (IV) infusion once every 3 weeks
224257072|NCT06473597|DRUG|Rimegepant|NURTEC ODT 75 mg orally disintegrating tablets
224257073|NCT06473597|DRUG|Rizatriptan Benzoate|Rizatriptan ODT 10mg orally disintegrating tablets
224257074|NCT06907914|OTHER|Schroth|The Schroth intervention consists of a structured, three-dimensional exercise program based on scoliosis-specific principles. It incorporates corrective postural alignment, rotational breathing techniques, and targeted activation of spinal and scapular stabilizing muscles. The exercises are designed to improve postural control, enhance muscle endurance, and promote neuromuscular re-education for better functional alignment during daily activities.
224257075|NCT05350072|BIOLOGICAL|VAY736|ianalumab s.c.
224257076|NCT05350072|OTHER|Placebo|placebo s.c.
223675416|NCT01376531|PROCEDURE|continuous veno-venous hemodialysis|continuous veno-venous hemodialysis
223675417|NCT01136200|OTHER|Infectious disease specialist advice|Indication, choice, dosing and duration of antimicrobial therapy
224257077|NCT06907901|BEHAVIORAL|PHAS Assessment|Participants will complete the Postural Habits and Awareness Scale (PHAS) to assess postural awareness and habits. The scale will be administered twice, two weeks apart, to evaluate reliability.
224257078|NCT07089043|DRUG|CST-3056|Administered as an oral solution
224257079|NCT07089043|DRUG|Placebo|Administered as an oral solution
223675418|NCT01492543|DRUG|Tegafur Gimeracil Oteracil Potassium Capsule|Aiyi® (Tegafur Gimeracil Oteracil Potassium Capsule; T25mg,G7.25mg,O24.5mg\*42 capsules/box), manufactured by Jiangsu Hengrui Medicine Co., Ltd.,
223675419|NCT05292144|DEVICE|Xperience Pro|Patients in whom treatment with (Xperience Pro) has been attempted
223675420|NCT00088998|BIOLOGICAL|bevacizumab|
223675421|NCT00088998|DRUG|capecitabine|
223675422|NCT00088998|DRUG|docetaxel|
223675423|NCT05438901|BIOLOGICAL|leech therapy|effects of medicinal leeches
223675424|NCT03473418|DRUG|Ketoconazole|Ketoconazole as a topical vaginal gel
223675425|NCT03473418|DRUG|Terconazole|Terconazole 80 mg as a topical vaginal cream
224257080|NCT04986878|PROCEDURE|single-shot adductor canal block|An ultrasound machine (Philips; Model: OTD020, AcBel Polytech Inc., Taiwan) with a 5-10 MHz linear probe was used to perform the adductor canal block immediately postoperatively.
224257081|NCT00305786|DRUG|gemcitabine hydrochloride|
224257082|NCT00305786|DRUG|oxaliplatin|
224257083|NCT00961168|OTHER|Volume Control Ventilation|Mechanical ventilation at a constant tidal volume of 6 mL/kg.
224257084|NCT00961168|OTHER|Pressure Control Ventilation|Mechanical ventilation at a constant airway pressure of 25-30 cm H2O
224257085|NCT05040880|DRUG|Telmione plus 80/12.5mg|Test drug (Fixed-dose combination drug of telmisartan 80mg and hydrochlorothiazide 12.5mg)
223675426|NCT02383225|BEHAVIORAL|Lakota Language enhancement|This intervention component includes more extensive adaptation for Lakota families, focusing on use of Lakota language specifically around relationship/kinship terms. Study arms without this component will include the same adapted intervention but with use of English language rather than Lakota.
223675427|NCT02383225|BEHAVIORAL|Facebook Supplement|This intervention component includes a social media supplement to engage families outside of weekly intervention sessions and will include postings and polls for participating parents/other caregivers to complete between sessions.
223675428|NCT02383225|BEHAVIORAL|Substance Use Resistance Skills|This intervention component consists of the original substance use resistance skills training from the Iowa Strengthening Families Program for Parents and Youth 10-14; arms without this component will include a session on healthy eating and exercise (attention control).
223675429|NCT01594151|RADIATION|Cone Beam Computed Tomography|CBCT scan of upper airway at visit 1
223675430|NCT03831685|OTHER|Blood sample|Patients meeting the inclusion criteria and none of the non-inclusion criteria will benefit from 2 venous blood samples in order to precise the initial blood lactate level, e.g. at the first medical contact, and the final blood lactate level, e.g. at the hospital admission.
223675431|NCT04224545|DRUG|Colchicine Pill|Colchicine at a dose of 1 mg a day before surgery, 2, 3, 4, 5 days after surgery.
223675432|NCT04224545|DRUG|Placebo|Placebo started a day before surgery, 2, 3, 4, 5 days after surgery.
223675433|NCT04025476|DRUG|Steroids|IV and oral steroids
223675434|NCT01992978|PROCEDURE|Radiofrequency-assisted Hepatectomy|Radiofrequency-assisted resection: separating the tumor from liver by using the probe of radiofrequency to block the arterial and vessels before parenchymal transection.
223675435|NCT01992978|PROCEDURE|Conventional Hepatectomy|Hepatectomy was conducted without RF assisted during parenchymal transection. Separating and dissecting the tumor with the routine clamp-crushing technical.
223675436|NCT01680237|BEHAVIORAL|Cognitive behavior therapy|Treatment covers psychoeducation on the nature of anxiety and panic, interoceptive and intensified situational exposure exercises as well as identification and correction of maladaptive thoughts about anxiety and its consequences.
223675437|NCT01680237|BEHAVIORAL|Exposure in-vivo|Treatment covers psychoeducation on the nature of anxiety and panic, interoceptive and intensified situational exposure exercises.
223675438|NCT02842905|OTHER|Fitting Audiologist completion|Phase II of the COSI (Client Oriented Scale of Improvement) questionnaire completed in a scheduled visit with the fitting Audiologist
223675439|NCT02842905|OTHER|Participant's Physician completion|Phase II of the COSI (Client Oriented Scale of Improvement) questionnaire completed in a scheduled visit with the Participant's Physician
223675440|NCT02633852|DRUG|Aflibercept|
223675441|NCT00719797|BIOLOGICAL|bevacizumab|Given IV
223675442|NCT00719797|DRUG|fluorouracil|Given IV
223675443|NCT00719797|DRUG|irinotecan hydrochloride|Given IV
223675444|NCT00719797|DRUG|leucovorin calcium|Given IV
223675445|NCT00719797|DRUG|oxaliplatin|Given IV
224257086|NCT05040880|DRUG|Micardis plus 80/12.5mg|Reference drug (Fixed-dose combination drug of telmisartan 80mg and hydrochlorothiazide 12.5mg)
224257087|NCT03406494|OTHER|Early multicomponent physical therapy program|"1. Positioning (upright bed standing; turning, moving on bed).~2. Peripheral muscle strength training (active or passive full range of motion, lower extremities ergometer cycling).~3. Respiratory muscle training (supine abdominal breathing training).~4. Neuromuscular electrical stimulation (NMES) on target muscles (bilateral bicipital muscles, quadriceps femoris muscles and rectus femoris).~5. Gut rehabilitation (midfrequency NMES; abdominal manual or vibration massage)."
224257088|NCT00059670|PROCEDURE|Shaker Exercise vs. Traditional Dysphagia Therapy Regime|
224257089|NCT07142317|DIETARY_SUPPLEMENT|Cholesterol-poor, plant sterol-poor shake|The first arm is the cholesterol-poor arm, where participants will be given a mixed meal in the form of a cholesterol-poor, plant-sterol-poor shake which provides the lowest cholesterol absorption rate.
223675446|NCT03473080|BEHAVIORAL|Internet CBT|The treatment consists of a standard cognitive behavior therapy for OCD with additional treatment components to make the treatment better suited for children and adolescents with Autism Spectrum Disorder.
223675447|NCT06335147|DRUG|Serplulimab, mFOLFOX6|Serplulimab，200mg，iv，q2w，d1； mFOLFOX6（Oxaliplatin: 85 mg/m2，LV ：400mg/m2，Fluorouracil： 400mg/m2 d1，2400 mg/m2 continuous intravenous drip for 46-48 hours；q2w）
223675448|NCT04332809|PROCEDURE|saline-gentamicin irrigation|Layer-by-layer irrigation of the appendectomy wound will be performed using saline-gentamicin solution
223675449|NCT04332809|PROCEDURE|saline irrigation|Layer-by-layer irrigation of the appendectomy wound will be performed using saline solution
223675450|NCT00421447|DRUG|Anastrozole|Group of women with breast cancer
224257090|NCT07142317|DIETARY_SUPPLEMENT|Cholesterol-rich, plant sterol-poor shake|The second arm is the high-cholesterol arm, where participants will be given a mixed meal in the form of a cholesterol-rich, plant-sterol-poor shake, which provides the highest cholesterol absorption rate.
224257091|NCT07142317|DIETARY_SUPPLEMENT|Cholesterol-rich, plant sterol-rich shake|The third arm is the moderate-cholesterol arm, where participants will be given a mixed meal in the form of a cholesterol-rich, plant-sterol-rich shake, which provides the moderate cholesterol absorption rate.
224322474|NCT06495112|OTHER|Soft contact lens with lathe cut technique Lathe|athe cut technique Lathe cutting involves shaping a solid block of lens material into the desired form using precision machinery. This method allows for customized lens designs but may result in a less smooth surface compared to cast molding. Cast molding, on the other hand, uses a liquid monomer that is cured in a mold to form the lens. This technique typically results in a smoother and more uniform lens surface.
223675451|NCT05652361|OTHER|Additional visualisation of surgical assistance during surgery|Robot-assisted anterior rectal resection using daVinci® system as CE-marked gold standard with additional visualization of surgical assistance functions based on machine learning techniques
223675452|NCT05207137|BEHAVIORAL|Telephone call about vaccination|Participants receive phone call from their family physician, where they are invited to ask questions about the COVID-19 vaccine.
223675453|NCT02702245|DIETARY_SUPPLEMENT|Experimental: Thylakoids 5 g|75 g pure glucose + 5 g chloroplast membranes from spinach leaves in a dried powder.
223675454|NCT02702245|DIETARY_SUPPLEMENT|Experimental: Thylakoids 10 g|75 g pure glucose + 10 g chloroplast membranes from spinach leaves in a dried powder.
223675455|NCT02702245|OTHER|Placebo Comparator: Control|75 g pure glucose.
223675456|NCT04985396|DRUG|Platelet Rich Plasma (PRP) group|Platelet Rich Plasma (PRP) group will be intervened with PRP injection. The collection of 30 ml blood of patients into acid citrate dextrose tube under aseptic condition will be done and subjected for centrifugation at 2000 rpm (soft spin) through digital centrifuge machine speed control (REMI, R-8C PLUS). There will be three layers of blood, among them the supernatant layer and buff coat of plasma will be again subjected to centrifuge at 3000 rpm (hard spin). The upper two thirds of the tube containing platelet poor plasma will be discarded and finally, the lower one third concentrated platelet plasma superficial buffy coat will be injected into medial calcaneal tuberosity at the most tender point.
223675457|NCT00300079|DRUG|brinzolamide 1.0%|
223675458|NCT04024384|DRUG|Daratumumab|Daratumumab, 16 mg/kg, once a week for 8 weeks (cycles 1 and 2); then every 2 weeks for 16 weeks (cycles 3-6), then every 4 weeks thereafter (cycles 7-12).
223675459|NCT05636488|OTHER|No intervention|There is no intervention group in this study
223675460|NCT00644644|OTHER|Rapid Response Team (NTX wireless monitoring system)|If the subject is experiencing a life threatening change in their vital signs, the Rapid Response Team will be initiated per VUMC protocol.
223675461|NCT04417426|OTHER|Survey|A survey was conducted, which was filled voluntarily and completely anonymously; the demographic data asked were: sex, age, religion, and semester. We included questions about their sexual behavior: if they considered having enough knowledge about STDs, sexual intercourse onset, number of sexual partners in the last year, the total number of sexual partners, sexual orientation, the use of condoms and contraceptives, exclusive or non-exclusive sexual intercourses, frequency of STDs screening, and then if they know the location of STD testing centers.
223675462|NCT05421403|PROCEDURE|adenotonsillectomy|all patients with adenoid or tonsillar or adenotonsillar hypertrophy of grade \>2 will undergo adenoidectomy, tonsillectomy or adenotonsillectomy (AT) according to the indication. Overweight or obese patients with mild or moderate OSAS will undergo 6-m trial of lifestyle intervention (LSI) and CPAP if indicated, responders will undergo more follow-up otherwise surgical interference was indicated
223675463|NCT05421403|BEHAVIORAL|Lifestyle intervention|After baseline testing, all subjects began a structured 6-month LSI consisting of dietary modification and exercise. Intensive dietary counseling was provided weekly for the first 4 weeks of the intervention, monthly subsequently until 6 months. A target caloric deficit of \~250.500 cal/d was recommended throughout dietary counseling. Dietary regimen consisted of diets composed of nutrients contributing to total energy as 55% carbohydrate, 15% protein, and 30% fat. Other lifestyle changes included calorie restriction depending on reduction of the frequency of snack consumption, ingestion of low-calorie and low-fat snacks, limiting sugar-based carbonated drinks and the duration of television watching or mobile games. Exercise sessions consisted of both aerobic and strength training three times weekly.
223675464|NCT00625703|DRUG|Linezolid|"Pharmacokinetics~daily dose of linezolid at 15 mg/kg/dose Intravenously (IV) based on subject's weight at study entry, over half an hour period, every 8 hours for a minimum of 7 days to a maximum of 28 days total. The primary doctor may change the route of administration of linezolid from IV to oral (by mouth)after 72 hours on IV formulation and demonstrated clinical improvement based on the clinical evaluation by the primary doctor and comparison of cystic fibrosis exacerbation criteria scores before and after initiating treatment with linezolid."
223675465|NCT01693302|OTHER|Insulin|The timing of insulin delivery varies with each study visit. The dose is given based on carbohydrate content and blood glucose level. The insulin is given either 20 minutes before the meal, immediately before the meal, or 20 minutes after the meal.
223675466|NCT06271174|DRUG|Carbocaine|"After general anesthesia and before incision, patients will receive loco-regional analgesia.~Carbocaïne will be injected around the nerve responsible of the innervation of the operated area by echography guidance."
223675467|NCT06271174|DRUG|Profofol and/or Suxaméthonium and/or Sévoflurane|"General anesthesia~Anesthetic induction is performed on a full stomach using :~* Intravenous hypnotic Propofol 2-5 mg/kg~* A rapid-acting intravenous curare Suxamethonium 1 mg/kg~On an empty stomach :~\- An intravenous hypnotic Propofol 2 to 5 mg/kg or/and an inhalatory hypnotic, Sevoflurane, as anesthetic co-induction by these 2 agents is generally used in pediatrics."
223675468|NCT05817071|PROCEDURE|Arthroscopic massive rotator cuff repair|Arthroscopic massive rotator cuff repair without biceps tendon augmentation either partial or complete repair.
223675469|NCT05817071|PROCEDURE|Arthroscopic massive rotator cuff repair with superior capsular augmentation using the long head of biceps tendon|Arthroscopic massive rotator cuff repair with superior capsular augmentation using the long head of biceps tendon .
223675470|NCT06216470|DRUG|VIR-3434|VIR-3434 is a human monoclonal antibody that binds the antigenic loop present in all forms of the surface envelope protein (small, middle, and large HBsAg).
223675471|NCT00065559|DRUG|celecoxib|
223675472|NCT01071811|BEHAVIORAL|Pedometer-based intervention|The participants were randomly assigned to either a pedometer group or a control group by drawing a sealed envelope with a unique randomizing number. The participants in the pedometer group received a pedometer (Yamax Digi-Walker SW-200), a book with a pedometer program(18), a handout with a summary of the pedometer program, and a calendar for registration of daily steps. During the trial period they were asked to reset the pedometer every morning and to wear it during the entire day. In the evening they should take the pedometer off and register the accumulated steps in the calendar. After three, six, and nine weeks, the participants in the pedometer group got a mail to encourage them to keep using the pedometer and follow the program.
223772768|NCT06149637|PROCEDURE|Anterior neck dissection approach|"1. A transverse cervical incision is made with horizontal extension towards the affected side.~2. It is dissected through the subplatysmal plane, the anterior edge of the sternocleidomastoid muscle is dissected along its entire length.~3. Level V nodes are dissected up to the spinal nerve without identifying or dissecting it~4. The jugular chain nodes are identified and the left level IV nodes are dissected with special attention to ligate the lymphatics of this level~5. Identification and dissection of level III nodes~6. Identification and dissection of level IIA and IIB nodes with identification and preservation of the accessory nerve."
223772769|NCT00360776|DRUG|tipifarnib|Given orally
224257092|NCT07142512|BEHAVIORAL|Step Count tracking and goals|We will provide participants and partners with Fitbits for the duration of the trial. After one week of step counting, the next week target will be to increase by 500 steps/day if baseline \< 5000 steps/day; increase by 750 steps/day if baseline 5000 to 7,500 steps/day; and increase by 1,000 steps/day if baseline \> 7,500 steps/day). Each week thereafter, study staff will pull the step data and apply an algorithm to generate new targets for the next week. In our algorithm, subsequent targets are higher if the participant exceeds prior week targets, and lower/unchanged if below target. This is similar to the algorithm we used in our trial ACTIVE PATIENT GDM (Dasgupta K, Chan D, Bond R, Garfield N, Coolen J, Halperin IJ, Peters TM, et al. Step and weight tracking with targets and coaching interventions in gestational diabetes: A randomized factorial feasibility trial. Diabetes Res Clin Pract. 2025 Jun;224:112241. doi: 10.1016/j.diabres.2025.112241. Epub 2025 May 9. PMID: 40349846.)
224322475|NCT06495112|DIAGNOSTIC_TEST|Soft contact lens with cast molding technique|Participants in this arm would receive Cast molding soft contact lenses and would wear them according to the study protocol, also likely for a specified duration.The cast molding technique for soft contact lenses involves creating lenses by polymerizing a liquid monomer mixture within a mold that forms the desired lens shape. Here's a brief overview of the steps involved in the cast molding process
223675473|NCT03734705|BEHAVIORAL|Imaginal Exposure Writing|Imaginal exposure is a psychotherapy strategy that has been studied and shown to be helpful in the improvement of symptoms (e.g., anxiety, worry) for other psychiatric conditions, including excessive worry and obsessive-compulsive disorder symptoms.
223675474|NCT03734705|OTHER|Neutral Writing|Used in prior research as a control condition for imaginal exposure. Neutral writing will involve writing about what one would do on a day off work or school.
223675475|NCT06284174|DRUG|Povidone-iodine solution; chlorhexidine gluconate|Before wound closure, each group will undergo different irrigation solutions for soaking the wound for three minutes followed by rinsing with copious saline.
223675476|NCT06798675|DRUG|nC-001|solid dosage form single dose
223675477|NCT06798675|DRUG|Placebo|Placebo
223675478|NCT03264079|DRUG|Bardoxolone methyl capsules 10 mg|One 10 mg capsule of bardoxolone methyl administered on Study Day 1 (Period 1) of the trial and one 10 mg capsule of bardoxolone methyl administered on Study Day 18 (Period 2) of the trial
223675479|NCT03264079|DRUG|Itraconazole capsules 100 mg|Two 100 mg capsules of itraconazole administered once daily during Study Days 15 - 27 (Period 2) of the trial
223675480|NCT06158581|BEHAVIORAL|The Emotion Awareness and Skills Enhancement Program|"EASE is a cutting-edge program created by researchers at the University of Alabama and the University of Pittsburgh in collaboration with autistic individuals, caregivers of autistic youth, and therapists. The overarching goal of the program is to support autistic clients who want to work on emotion regulation. EASE is unique because it targets emotional distress in autistic youth and adults, instead of targeting the core symptoms of autism (i.e., it is not a social skills intervention).~The program is a 16-session, mindfulness-based intervention. Each session is 1:1 for 45 minutes to one hour. While the program is designed for individual intervention, caregivers are also invited to play an active role on the care team."
223675481|NCT06158581|BEHAVIORAL|The Unified Protocol|"UP is a thoroughly-studied, manualized intervention created by researchers at the University of Miami in conjunction with researchers at Boston University. The program was designed to be customizable to meet the needs of people with a variety of diagnoses, allowing more individuals to access emotion regulation resources. The protocol also has different modules to accommodate different developmental levels (UP-Children, UP-Adolescent, UP-Adult). The overall goal of UP is to help clients identify emotions and build new strategies to cope with stressful life situations and distressing emotions.~The protocol is flexible, with each session is about 45 to 60 minutes and the number of sessions varying between 12 - 21 sessions. For the current study, the treatment will take place over 16 sessions. The intervention is cognitive behavioral therapy (CBT) based but also includes hints of mindfulness-based intervention strategies."
223772770|NCT00360776|OTHER|laboratory biomarker analysis|Correlative studies
223772771|NCT05262205|OTHER|measuring depth of anesthesia and its relation to the globe|measuring feasibility of BIS monitor in detecting depth of anesthesia in pediatric population and whether it will be beneficial as a tool for helping anesthesiologist in maintaining central globe alignment
223772772|NCT04369248|OTHER|hepassocin|hepassocin levels in polycystic ovary syndrome
223675482|NCT04489901|OTHER|Olive oil|To apply 10 cc (4 tablespoons) of extra virgin olive oil to the entire abdomen by hand without massaging twice a day in the morning and evening.
223675483|NCT01456767|DIETARY_SUPPLEMENT|Probiotics|"Bacterial supplements (Lactobacillus plantarum WCFS1, Lactobacillus plantarum CIP104448, and Lactobacillus plantarum CIP104450) will be prepared in the food-grade pilot plant of NIZO food research. Exactly 1x10\^11 life bacteria are consumed by each participant.~Consumption of this amount of life bacteria is in line with earlier human studies and routinely reached by the consumption of dairy. As a placebo, the same drink will be used without addition of bacterial cells."
223675484|NCT00659477|DRUG|insulin glargine|once daily
223675485|NCT00319319|DRUG|Mecamylamine hydrochloride (Inversine)|
223675486|NCT04672252|DRUG|CBD Oral Disintegrating Tablet (ODT)|Cohort 1: CBD ODTs to be administered with routine post-operative pain management regimen
223675487|NCT04672252|OTHER|Placebo ODT|"Cohort 2 will not receive CBD; but a visually indistinguishable placebo ODT instead.~The resident physician, physician assistant, anesthesiologist, surgeon and study team members will remain blinded. Additionally, all patients will receive a traditional upper extremity interscalene block as per routine."
223772773|NCT00694980|DRUG|placebo|Intravenous and subcutaneous escalating doses
223772774|NCT00694980|DRUG|rhuMAb Beta7|Intravenous and subcutaneous escalating doses
223772775|NCT01122511|DRUG|700 ug dexamethasone|Intravitreal injection of 700 ug dexamethasone into study eye
224257093|NCT07142512|BEHAVIORAL|Dyadic coping intervention|"Couples will participate in 8 one-hour coaching sessions over 12 weeks (virtual, in-person, or a combination, as preferred). The sessions aim to enhance the couple's understanding of how they influence each other. Both couple members will explore their preferences in terms of ways of communicating and supporting one another's goals. We will use changes in steps as a context to explore how partners can effectively support and coach each other without without eliciting behavioural reactance. We will use are goal setting, action planning, self-monitoring, graded tasks, social environment restructuring, and social support. The coaches will be psychology students. They will receive structured training on the coaching strategy from a licensed mental health professional. We will record the sessions for fidelity and quality assurance purposes. All coaches will meet weekly with the supervising licensed mental health professional."
224257094|NCT04295863|DRUG|Nivolumab Standard|For patients on standard schedule dosing of nivolumab, therapy will consist of 240mg IV once every 2 weeks or 480mg IV once every 4 weeks
224257095|NCT04295863|DRUG|Pembrolizumab Standard|For patients on standard schedule dosing of pembrolizumab, therapy will consist of 200mg IV once every 3 weeks or 400mg IV once every 6 weeks
223675488|NCT02927912|RADIATION|Electron Beam Therapy|Undergo IOERT boost
224257096|NCT04295863|DRUG|Nivolumab Extended|For patients on extended interval dosing of nivolumab therapy will consist of 240mg IV once every 4 weeks or 480mg IV once every 8 weeks
224257097|NCT04295863|DRUG|Pembrolizumab Extended|For patients on extended interval dosing of pembrolizumab therapy will consist of 200mg IV once every 6 weeks
224257098|NCT07166861|OTHER|Annual Wellness Visit|Completion of a structured Annual Wellness Visit (AWV) questionnaire administered by an assigned practice staff member for Medicare beneficiaries deemed by study algorithm as high-risk. Those responses will then be used by the primary care team to place any needed referrals and offer any indicated personal health advice and create a care plan for the coming year. Routine usual care from the primary care practice will occur.
224257099|NCT07166861|OTHER|Geriatric Resources and Assessment for the Care of Elders|The practice will initiate the Geriatric Resources and Assessment for the Care of Elders (GRACE) program for Medicare beneficiaries deemed by study algorithm as high-risk and meeting other study criteria (see below). After completion of the in-home structured annual wellness visit (AWV) and GRACE assessment by the NP/SW team, responses will be reviewed and applied to construct an individualized care plan using the GRACE protocols inclusive of advance care planning, health maintenance, medication management, assistance with any difficulty walking, falls, dementia, depression, chronic pain, malnutrition, weight loss, urinary incontinence, visual impairment, hearing impairment, or caregiver burden.
224257100|NCT07164859|DRUG|short dual antiplatelet therapy (DAPT) duration|patients will receive DAPT for 7 days (after randomization) followed by P2Y12 inhibitor alone
224257101|NCT07164859|DRUG|Standard DAPT duration|patients will receive DAPT for at least 3 months after randomization or longer and followed by single antiplatelet therapy
224257102|NCT02478528|DEVICE|Energy-Light lamp|Exposure of the subject, at 5am, to the light source of Energy-Light lamp (Philips)
224257103|NCT02478528|DEVICE|Luminettes lamp|Exposure of the subject, at 5am, to the light source of Luminettes lamp (Lucimed)
224257104|NCT02478528|OTHER|control condition|No exposure of the subject to any light sources (control condition)
224257105|NCT00859430|DRUG|Levetiracetam|1000 mg Tablet
224257106|NCT00859430|DRUG|Keppra®|1000 mg Tablet
224257107|NCT06738160|DRUG|Narlumosbart|Patients who have not received any systemic therapy will receive narlumosbart and bone target lesion SBRT in combination with first-line treatment immunotherapy and chemotherapy after screening eligible subjects. Narlumosbart, 120mg/time, subcutaneous injection, is administered every 4 weeks. For the treatment of SBRT for bone metastases, the dose of 24Gy/3F is used for spinal metastases, and 30Gy/5F or 35Gy/5F is used for non-spinal lesions. Chemotherapy combined with immune checkpoint inhibitor therapy was used in accordance with the guidelines. The primary endpoint is to assess the objective response rate of NSCLC patients with bone metastases from narlumosbart combined with SBRT and first-line chemotherapy and immunotherapy. The secondary endpoints include progression-free survival, overall survival and safety. Sample size calculation used the Simon Two-Stage method. 27 subjects will be enrolled in this project, considering the dropout rate of 10%.
224257108|NCT04115293|DRUG|zilucoplan (RA101495)|Daily subcutaneous (SC) injection
224257109|NCT04115293|DRUG|Placebo|Daily subcutaneous (SC) injection
224257110|NCT06593067|OTHER|Control|Individuals will be exposed to a heated environment (41°C, 15% humidity) for a period of 15 minutes without a cooling modality.
224257111|NCT06593067|OTHER|Fan|Individuals will be exposed to a heated environment (41°C, 15% humidity) for a period of 15 minutes with an electric fan as a cooling modality.
224257112|NCT06593067|OTHER|Fan and Water Spray|Individuals will be exposed to a heated environment (41°C, 15% humidity) for a period of 15 minutes with an electric fan and water spray as cooling modalities.
224257113|NCT06593067|OTHER|Water Spray|Individuals will be exposed to a heated environment (41°C, 15% humidity) for a period of 15 minutes with water spray as a cooling modality.
224257114|NCT03729271|DRUG|Rifaximin|Rifaximin will be given during weeks 2-4
224257115|NCT03729271|DEVICE|Glucose and lactulose hydrogen breath testing|Subjects will undergo glucose and lactulose hydrogen breath tests for Small Intestinal Bacterial Overgrowth (SIBO) on consecutive days using a commercially available home base kits (Glucose Hydrogen Breath Test Collection Kit and Lactulose Hydrogen Breath Test Collection Kit for SIBO from Commonwealth Diagnostic International) prior to Rifaximin treatment and at week 13 of the study.
223675489|NCT02927912|PROCEDURE|Lumpectomy|Undergo lumpectomy
223675490|NCT02927912|OTHER|Quality-of-Life Assessment|Ancillary studies
223675491|NCT02927912|OTHER|Questionnaire Administration|Ancillary studies
224257116|NCT05844462|DRUG|Tadalafil|Oral Tadalafil
224257117|NCT05844462|DRUG|Placebo|Oral Placebo
224257118|NCT06081348|DRUG|Sertraline|Oral capsule (25mg, 50mg, 100mg, 200mg)
224257119|NCT06081348|OTHER|Placebo|Oral placebo capsule
224257120|NCT03523156|DRUG|Azithromycin mass treatment|Standard of care annual community-wide mass drug administration (MDA) will be provided at the normally scheduled time.
224257121|NCT03523156|DRUG|Azithromycin targeted treatment|Two rounds of treatment targeted to all children aged 2 to 9 years old. The first targeted round will be 1-2 weeks after the community-wide MDA and the second round will occur another 1-2 weeks later.
223675492|NCT02927912|RADIATION|Radiation Therapy|Undergo whole breast radiation therapy
223675493|NCT02927912|PROCEDURE|Reconstructive Surgery|Undergo oncoplastic reconstruction
223675494|NCT03751735|BIOLOGICAL|Wharton Jelly Mesenchymal stem cells|Intracavernous injection of Wharton Jelly Mesenchymal stem cells.
223675495|NCT04391569|DRUG|Ganaxolone|Ganaxolone will be administered.
223675496|NCT04391569|DRUG|Placebo|Placebo will be administered.
223675497|NCT05911243|PROCEDURE|Acupressure Therapy|Undergo auricular acupressure
223675498|NCT05911243|OTHER|Best Practice|Receive usual care
223675499|NCT05911243|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
223772776|NCT01122511|BIOLOGICAL|ranibizumab|Intravitreal injection of ranibizumab into study eye
223772777|NCT01122511|OTHER|sham|Sham needle-less injection administered in the study eye
223772778|NCT04888975|DEVICE|Dayspring Active Wearable Compression System|Dayspring Active Wearable Compression System
223772779|NCT06402058|DEVICE|DMSB01|Apply a maximum of 1.0 ml for each side of the Crow's Feet Lines using both the test device (DMSB01) and the control device (Rejuran®).
223772780|NCT06402058|DEVICE|Rejuran®|Apply a maximum of 1.0 ml for each side of the Crow's Feet Lines using both the test device (DMSB01) and the control device (Rejuran®).
224257122|NCT01889498|DRUG|Acetazolamide|"Acetazolamide twice a day, at 12 hour intervals:~* 250 mg Tablets; one tablet to be taken twice daily from three days before the day of surgery~* One tablet to take two hours before surgery~* 500mg Intravenous Acetazolamide; to be administered upon arrival in critical care post-surgery; continuing at 12 hour intervals until last acetazolamide administration at 72 hours."
224257123|NCT05137834|OTHER|Exercise|Post-surgical exercise
224257124|NCT00001703|BIOLOGICAL|incomplete Freund's adjuvant|0.7 ml of ISA-51 (Montanide ISA-51 adjuvant, incomplete Freund's adjuvant) will be mixed with peptide alone and injected subcutaneously every four weeks for a total of four vaccinations.
224257125|NCT00001703|BIOLOGICAL|von Hippel-Lindau peptide vaccine|1000 micrograms administered subcutaneously every four weeks for a total of four vaccinations.
224257126|NCT03242213|BEHAVIORAL|Mobile App|The intervention in this study is a mobile health app, which provides patients with a way to track emotional wellbeing and depression symptoms, set up medication reminders, track adherence to medications, record side effects experienced, and take surveys/tests to assess cognitive symptoms and depression.
224257127|NCT03183986|DEVICE|Phototherapy|Phototherapy for 24 hours.
224257128|NCT01874561|DRUG|Custirsen|Custirsen will be administered iv using an infusion pump over a 2-hour period.
224257129|NCT01874561|DRUG|Placebo|Placebo (commercially available normal saline) will be administered iv using an infusion pump over a 2-hour period.
223772781|NCT01712984|BIOLOGICAL|Influenza Virus Vaccine USP Quadrivalent, (Zonal Purified Subvirion) 2012 2013 Formulation|0.1mL, Intradermal
224257130|NCT01874561|DRUG|Moxifloxacin|Moxifloxacin (400 mg) will be administered orally with 240 mL of room temperature still water.
224257131|NCT02057835|DRUG|Placebo to BI 691751|Placebo to BI 691751
224257132|NCT02057835|DRUG|BI 691751 high dose|BI 691751 high dose
224257133|NCT02057835|DRUG|BI 691751 middle dose|BI 691751 middle dose
224257134|NCT02057835|DRUG|Placebo to BI 691751|Placebo to BI 691751
224257135|NCT02057835|DRUG|BI 691751 low dose 1|BI 691751 low dose 1
224257136|NCT02057835|DRUG|Placebo to BI 691751|Placebo to BI 691751
223675500|NCT05911243|OTHER|Questionnaire Administration|Ancillary studies
223675501|NCT04463797|OTHER|Square-stepping exercise|The square-stepping exercise is a low-cost indoor program to improve lower extremities fitness and cognitive function.
223675502|NCT04463797|OTHER|Stretching and strengthening|whole-body stretching and upper extremity strengthening
223675503|NCT05775367|DEVICE|Cochlear Implant|A cochlear implant is a surgically implanted device that provides access to sound in people cannot get enough access to sound for communication with traditional hearing aids.
223675504|NCT00745355|BEHAVIORAL|Quality Of Life questionnaires|All patients who agree to participate will be interviewed using a baseline idiographic quality of life assessment prior to surgery and at approximately 6, 12, 18 and 24 months postoperatively. All patients will also be asked to respond to a questionnaire including all standard measures (closed-ended, multiple choice items) before surgery and at approximately 3, 6, 12, 18 and 24 months post-surgery.
223675505|NCT05582928|DEVICE|Neurofeedback|Neurofeedback training during which participant will be asked to change the size of a bar using different strategies to vary the parameters of its current brain's states (neurofeedback training) computed on the realtime EEG signals.
223675506|NCT01952808|BEHAVIORAL|Face-to-face family mentoring and education sessions|A total of 13 home visits will be completed over a 6 month period. In addition to an introductory/orientation visit, 12 home visits will consist of family mentoring/educational sessions focused on physical activity and healthy nutrition.
223675507|NCT01952808|BEHAVIORAL|Telephone follow-up|During months 7-12, a total of up to 12 phone calls will be completed. Follow-up calls will consist of a progress report from families on physical activity and healthy diet progress/goals, along with brief content follow-up and re-enforcement points from the 12 intervention sessions.
223675508|NCT04914013|OTHER|no intervention|no intervention
223772782|NCT01712984|BIOLOGICAL|Influenza Virus Vaccine USP Trivalent Types A and B (Zonal Purified Subvirion) Fluzone® Intradermal|0.1mL, Intradermal
224257137|NCT02057835|DRUG|Placebo to BI 691751|Placebo to BI 691751
224257138|NCT02057835|DRUG|BI 691751 low dose 2|BI 691751 low dose 2
224257139|NCT06626698|OTHER|Static stretching|A passive static stretch of the posterior leg muscles will be performed with the subject in a supine position and knees extended, starting with the ankle at 90º and continuing until reaching the maximum tolerated dorsiflexion.
224257140|NCT06626698|DEVICE|Electrical muscle elongation|The intervention will be performed with the subject in a supine position with knees extended. Electrodes will be placed on the gastrocnemius muscles of the leg being assessed. The parameters will be selected. Static stretching will begin until resistance is felt, at which point the intensity of the electrical current will be increased to induce a visible and tolerable contraction. Simultaneously, the subject will be asked to perform an isometric contraction of the antagonist muscles, resisted by the investigator. When the subject feels the stretch again, the intensity of the current will be increased once more until a new movement barrier is reached.
223772783|NCT01712984|BIOLOGICAL|Influenza Virus Vaccine USP Trivalent Types A and B (Zonal Purified Subvirion) Fluzone Intradermal|0.1mL, Intradermal
223772784|NCT01060267|DRUG|Erythromycin|The patients in erythromycin group received intravenous bolus infusion of 125 mg of erythromycin lactobionate in 50 ml of normal saline
223772785|NCT01060267|DRUG|Placebo|patients in placebo group 50ml of normal saline over 10 minutes, 1/2 hour before endoscopy.
223772786|NCT06316739|BEHAVIORAL|Ganchero intervention|"The Ganchero intervention is an HIV, hepatitis C virus (HCV) and overdose prevention intervention for migrant people who inject drugs (PWID) from Puerto Rico who are living in New York City. The intervention has two core components, both centered around the key migrant PWID role of the Ganchero, an individual who provides expert injection services in exchange for money or drugs. First, a sample of Gancheros will be trained in foundational HIV, HCV and overdose risk-reduction knowledge and outreach strategies (over 6 2-hour, in-person, small group sessions facilitated by an Interventionist). Second, during a 4-month outreach period, trained Gancheros will disseminate risk-reduction messages learned in the training, and associated resources (e.g., sterile syringes and other injection equipment, naloxone), to migrant PWID in their neighborhood as they deliver their regular Ganchero services."
223772787|NCT00955266|DRUG|Calcium Chloride|Calcium chloride 10mg/kg in 50cc NS delivered over 5 minutes
223772788|NCT00955266|DRUG|Placebo|Normal saline, 50cc delivered over 5 minutes
223772789|NCT00447928|DRUG|OrthoDerm transdermal nitroglycerin patch|
223772790|NCT04383821|DEVICE|Double-Trunk Mask|The DTM (oxygen delivery system) is worn by the patient for 30 minutes.
223772791|NCT04383821|DEVICE|Non-Rebreather mask|The NRM (standard oxygen delivery system) is worn by the patient for 30 minutes.
223772792|NCT00685932|DEVICE|Mobius Retractor|The Mobius retractor is a dual ring elastic self retaining retractor that is inserted into the abdominal cavity after the peritoneal incision has been established. It is then left in place during the hysterotomy incision, delivery of the fetus, hysterotomy repair, inspection and irrigation.
223772793|NCT02972528|BIOLOGICAL|Platelet Lysate|Direct injection of allogenic Platelet Lysate
223772794|NCT02972528|BIOLOGICAL|Platelet Poor Plasma|Direct injection of allogenic Platelet Poor Plasma
223772795|NCT00355446|DRUG|Bimatoprost 0.03%|
223772796|NCT05449028|DRUG|H. pylori eradication scheme A|Esomeprazole 40mg bid + amoxicillin 1g 12/12h + clarithromycin 500mg 12/12h + metronidazole 500mg 8/8h, for 14 days
224257141|NCT03717805|OTHER|POAM|The new 5 minutes preparatory information movie on oocyte aspiration (POAM) details what couples can expect to happen on the day of oocyte aspiration. More specifically, it describes the patient journey detailing which procedures will happen when and how, in which room, in the presence of their partner or not, and in the presence of which healthcare professionals.
224257142|NCT02984098|DRUG|Dextrose|before heel lance, 2ml oral dextrose gel 25%or 40% was administered, and pain related intensity was evaluated with premature infant pain profile scale
223675509|NCT00899392|OTHER|Emmi Pediatric Upper Endoscopy Patient Education Module|Emmi Pediatric Upper Endoscopy Patient Education Module as designed by EMMI SOLUTIONS, LLC
224257143|NCT00444353|DEVICE|DL6049 (injectable poly-L-lactic acid)|
224257144|NCT00543205|DRUG|Genasense® (G3139, oblimersen sodium)|Genasense 7 mg/kg/day for 5 days
224257145|NCT03089515|OTHER|Cardio-Pulmonary Exercise Testing (CPET)|This test helps determine if the decreased tolerance to exercise or shortness of breath with activity a patient is experiencing is caused by a cardiac disease, versus a pulmonary disease.
224257146|NCT01660243|DRUG|Nalfurafine hydrochloride(MT-9938) 2.5μg|2.5 μg (2capsules) once daily for 8 weeks
224257147|NCT01660243|DRUG|Nalfurafine hydrochloride(MT-9938) 5μg|5 μg (2capsules) once daily for 8 weeks
224257148|NCT01660243|DRUG|Nalfurafine hydrochloride(MT-9938) 10μg|10 μg (2capsules) once daily for 8 weeks
224257149|NCT01660243|DRUG|Placebo|Placebo (2capsules) once daily for 8 weeks
224257150|NCT02873845|OTHER|Preliminary validation of the COBQoL questionnaire|
224257151|NCT03425344|DIAGNOSTIC_TEST|Diagnostic|No traditionally intervention will be given but participants will be exposed to shoulder- MRI, ultrasound and sonoelastography..
224257152|NCT02343926|DRUG|GEMIGLIPTIN LS15-0444|"Pharmaceutical form:tablet~Route of administration: oral"
224257153|NCT02343926|DRUG|vildagliptin|"Pharmaceutical form:tablet~Route of administration: oral"
224257154|NCT02343926|DRUG|metformin|"Pharmaceutical form:tablet~Route of administration: oral"
223675510|NCT02200198|OTHER|Expiratory muscle training|Patient performs training for 30 minutes per day, during 7 consecutive days, using a Threshold with Positive Expiratory Pressure with a load of 30% of maximal expiratory pressure assessed by digital peak respiratory pressure monitor
223675511|NCT02200198|OTHER|Inspiratory muscle training|Patient performs training for 30 minutes per day, during 7 consecutive days, using a Threshold for Inspiratory Muscle Training with a load of 30% of maximal inspiratory pressure assessed by digital peak respiratory pressure monitor
223675512|NCT02200198|OTHER|Sham group|Patient performs training for 30 minutes per day, during 7 consecutive days, using a Threshold without load
223675513|NCT02067975|DRUG|Tryptophan|
223675514|NCT02067975|DRUG|Placebo|
223675515|NCT01431638|DRUG|Canakinumab 150mg in prefilled syringe|Canakinumab 150mg in prefilled syringe will be given in a single dose subcutaneously upon demand for gouty arthritis flares
223675516|NCT04332588|DRUG|[18F]FMISO PET/MRI imaging|\[18F\]FMISO PET/MRI imaging
223675517|NCT01239732|DRUG|Paclitaxel|175 mg/m\^2 on Day 1 every 3 weeks or at a dose of 80 mg/m\^2 every week for a minimum of 4 cycles and not more than 8 cycles or until disease progression or unacceptable toxicity, whichever occurs first
223675518|NCT01239732|DRUG|Bevacizumab|15 mg/kg intravenously on Day 1 of every cycle for up to 36 cycles of 3 weeks each or until disease progression or unacceptable toxicity, whichever occurs first
223772797|NCT05449028|DRUG|H. pylori eradication scheme B|Esomeprazole 40mg bid + amoxicillin 1g 12/12h + clarithromycin 500mg 12/12h + metronidazole 500mg 12/12h, for 14 days
224257155|NCT02697682|BIOLOGICAL|injection with the stromal vascular fraction (SVF) of adipose tissue|Description of the active treatment The active treatment is an intra-articular injection with the stromal vascular fraction (SVF) harvested from the patient's own abdominal subcutaneous fatty tissue. SVF is harvested using the Lipogems system.
224257156|NCT03665194|DRUG|Cortexolone 17α-propionate solution|Single topical application to be applied twice daily (0 hour and 12 hour) on Days 1-3 and Once Daily (0 hour) on Day 4.
223675519|NCT01239732|DRUG|Carboplatin|AUC 5-6 mg/ml/min on Day 1 every 3 weeks for a minimum of 4 cycles and not more than 8 cycles or until disease progression or unacceptable toxicity, whichever occurs first
223675520|NCT04967040|PROCEDURE|medial plantar artery flap|Medial plantar artery flap is a fasciocutaneous island flap raised from the non-weightbearing instep of the plantar foot. The dominant vascular pedicle of the flap consists of the medial plantar artery and venae comitantes
223675521|NCT04967040|PROCEDURE|Distally based sural artery flap|Distally based sural artery flap is a fascio-cutaneous island flap taken from the posterior aspect of the middle third of the leg and fed by the lower peroneal septo-cutaneous perforators in reverse fashion. Its vascular basis is the close association between the median superficial sural artery and peroneal artery perforators
223675522|NCT00002167|DRUG|Tin ethyl etiopurpurin|
223675523|NCT04440423|DRUG|Clotiazepam 5 mg Test Product Coated Tablets|Investigational Medicinal Product
224257157|NCT03665194|DRUG|Placebo|matching placebo
224257158|NCT05488158|OTHER|Osteopathic manipulation|Pain and somatic disfunction were treated with osteopathic manipulations as deemed appropriate by a trained DO.
224322476|NCT05544279|BEHAVIORAL|Education|Education is given about the focused disease and its nursing care management
224257159|NCT05731687|OTHER|Hybrid DEB approach with drug-eluting balloon|If a patient is randomized to the hybrid DEB approach, lesion preparation of the SB with non-compliant balloon (NC) is mandatory before DEB application. The application of DEB can be performed if acceptable result of the lesion preparation is obtained (at least TIMI III flow and no flow limiting dissection). The drug- eluting balloon used in this study is the CE- marked Magic Touch Sirolimus Coated Balloon Catheter (Concept Medical, Gujarat, India). The size of the DEB is measured on a ratio 1:1 on reference diameter of the SB. The DEB balloon is inflated for 60 seconds, or two times more than 30 seconds if long duration inflations are not possible. Finally low pressure kissing inflation with the same DEB in place, and Proximal Optimization Therapy (POT) are performed. In case of SB occlusion, or flow limiting dissections in non-Left Main (LM) bifurcations and \< TIMI 3 flow or 70-99% residual stenosis in LM bifurcations, cross- over to two-stent technique is performed.
224257160|NCT05731687|OTHER|Two-stent strategy|When randomized to the conventional two-stent strategy, TAP/T or Culotte stenting is performed. First lesion preparation of the SB is mandatory. The drug-eluting stent (Supraflex stent) can be placed in the SB if acceptable result of the lesion preparation is obtained and is measured on a 1:1 ratio on reference diameter of the SB. Finally, kissing inflation and POT are mandatory.
224322477|NCT00782405|DRUG|quetiapine|XR, 150-300mg
223675524|NCT04440423|DRUG|Clotiazepam 5 mg Reference Product Coated Tablets|Rize (Trademark)
223675525|NCT03220698|DEVICE|Tracheal ultrasonography|Tracheal ultrasonography
224257161|NCT05794685|PROCEDURE|adductor canal block|patients will receive an injection of 30 ml of .25% of Bupivacaine including 4mg of dexamethasone at a point anterior to the femoral artery, deep to the sartorius muscle (adductor canal block).
224257162|NCT05794685|PROCEDURE|4 in one block|patients will receive an injection of 30 ml of .25% of Bupivacaine including 4mg dexamethasone at the adductor hiatus where the descending genicular artery branches from superficial femoral artery (4 in one block).
224257163|NCT00712959|BIOLOGICAL|Tetanus, Reduced Diphtheria Toxoid and Acellular Pertussis (ADACEL®)|0.5 ml, IM
224257164|NCT00712959|BIOLOGICAL|Tetanus, Reduced Diphtheria Toxoid and Acellular Pertussis (ADACEL®)|0.5 mL, IM
224257165|NCT00508651|BIOLOGICAL|MEDI-560|MEDI-560 vaccine was a frozen preparation of live, attenuated rHPIV3cp45 virus filled into Becton Dickinson\^TM luer slip tip syringes. Each 0.2 mL dose contained 10\^5 TCID50 of MEDI-560 in a sucrose phosphate glutamate buffer.
224257166|NCT00508651|BIOLOGICAL|Placebo|Placebo was a frozen preparation filled into Becton Dickinson\^TM luer slip-tip syringes. Each 0.2 mL dose contained sucrose phosphate buffer.
224257167|NCT03419247|PROCEDURE|Fresh tumor tissue biopsy|A type of surgical procedure that will use a thin needle to remove a sample of tumor tissue.
224257168|NCT03419247|PROCEDURE|Blood draw|Blood will be taken by a needle from a vein.
224257169|NCT03419247|PROCEDURE|Archival tumor tissue collection|A sample of tumor tissue that was taken by biopsy or surgery before agreeing to take part in this study will be collected.
224257170|NCT00012818|BEHAVIORAL|relaxation technique|
224257171|NCT00012818|BEHAVIORAL|educational program|
224257172|NCT03155425|DRUG|SHR-1210|A humanized monoclonal immunoglobulin
224322478|NCT00782405|DRUG|mirtazapine|30-45 mg
223675526|NCT00456144|DRUG|Gonadotropin Releasing Hormone Agonist Therapy|Given either for 24 months and 6 months
223675527|NCT04882969|DEVICE|Fractionated Thulium laser|LaseMD Lutronic Laser is a 1927-nm fractionated thulium laser, which is better absorbed by water than non-ablative 1,540-nm erbium glass laser energy. The laser energy and power can be customized to target a specific penetration depth and achieve selective photothermolysis in skin while mitigating injury to surrounding tissue. The thermal energy generated by the laser has been shown to facilitate the delivery of kerafactor, which contain hair growth factors to stimulate follicular progenitor cell proliferation and differentiation into follicular keratinocytes to promote hair growth.
223772798|NCT05449028|DRUG|H. pylori eradication scheme C|Esomeprazole 40mg bid + bismuth subsalicylate 420mg 6/6h + metronidazole 375mg 6/6h + tetracycline 375mg 6/6h, for 10 days
224257173|NCT01364493|DRUG|Trastuzumab+Capecitabine+Oxaliplatin|"Trastuzumab will be administered at a loading dose of 8 mg/kg (on day 1) followed by 6mg/kg i.v. infusion every 3 weeks.~Capecitabine 2000mg/m2d, d1-14; q3w, Trastuzumab and capecitabine are to be continued until disease progression or intolerable toxicity.~Oxaliplatin 130mg/m2 d1; q3w, 6 cycles"
224257174|NCT05878626|OTHER|Transcranial Direct Current Stimulation|The intensity of TDCS will be 2.5 mA and the duration will be 20 mints. The intervention will be applied twice a day with a time difference of 30 minutes between the two sessions.
224257175|NCT00193245|DRUG|Topotecan|
224257176|NCT00193245|DRUG|Docetaxel|
224257177|NCT03341013|DRUG|MEDI0382 Formulation 2|Sequence 1 Period 1 and Sequence 2 Period 2.
224257178|NCT03341013|DRUG|MEDI0382 Formulation 3|Sequence 1 Period 2 and Sequence 2 Period 1
224322479|NCT06742996|DRUG|Sonrotoclax|Administered orally
224322480|NCT06742996|DRUG|Zanubrutinib|Administered orally
224322481|NCT06742996|DRUG|Placebo|Administered orally
224322482|NCT02506829|BEHAVIORAL|Smoking cessation counseling (Quitline)|
224257179|NCT03595436|DIETARY_SUPPLEMENT|Pea Protein-20g|The study participants will be provided with breakfast preloads to consume. The energy content of the breakfast preload will be standardized to \~325 kcal. This preload will include 20 g pea protein, 5 g mixed protein (from yogurt and peanut-butter), 40 g carbohydrates, and 7 g fat. The preload is a yogurt-based (chocolate-peanut butter flavored) breakfast.
223675528|NCT05270447|OTHER|Massage and patient education|"Connective tissue manipulation: The patients were informed about CTM and its mechanism of action before starting the CTM application. CTM was performed by a trained physiotherapist as the patient was in a sitting position.~Routine care and advising: In-bed activities were taught and recommended to the patients in both groups. In-bed activities; rotation, sitting on the bedside, breathing exercises, range of motion exercises for upper and lower extremities. In addition, hourly walking activities were recommended after the anesthetic effect wore off."
223675529|NCT05270447|BEHAVIORAL|Routine care and advising|Routine care and advising: In-bed activities were taught and recommended to the patients in both groups. In-bed activities; rotation, sitting on the bedside, breathing exercises, range of motion exercises for upper and lower extremities. In addition, hourly walking activities were recommended after the anesthetic effect wore off.
223675530|NCT02591771|DRUG|adrenaline|i.v. adrenaline infusion as an early and fast haemodynamic stabilizer, associated with a tight tissue perfusion monitoring, in the context of a stepwise progression in the treatment of cardiogenic shock, including ventricular mechanical support
223675531|NCT04851093|DRUG|TCM granule plus conventional drug|"All patients will receive conventional drug according to 2020 Global Initiative for Chronic Obstructive Lung Disease (GOLD) and Chinese Medicine Diagnosis Treatment Guidelines.~Yiqiwenfei granule for qi deficiency and internal cold fluid syndrome.~Fuzhengqinghua granule for qi and yin deficiency and unclean phlegm heat syndrome.~Fuzhengzaohua granule for lung and spleen qi deficiency and phlegm-damp amassing in lung syndrome.~TCM granule (Jiangyin Tian Jiang Pharmaceutical Co.,Ltd, 10g/packet) will be administered twice daily for 8 weeks."
223675532|NCT04851093|DRUG|TCM placebo granule plus conventional drug|"All patients will receive conventional drug according to 2020 Global Initiative for Chronic Obstructive Lung Disease (GOLD) and Chinese Medicine Diagnosis Treatment Guidelines.~Placebo Yiqiwenfei granule for qi deficiency and internal cold fluid syndrome.~Placebo Fuzhengqinghua granule for qi and yin deficiency and unclean phlegm heat syndrome.~Placebo Fuzhengzaohua granule for lung and spleen qi deficiency and phlegm-damp amassing in lung syndrome.~TCM placebo granule (Jiangyin Tian Jiang Pharmaceutical Co.,Ltd, 10g/packet) will be administered twice daily for 8 weeks.~The appearance, weight, color and odor of the preparation are the same as those of experimental group.~The placebo granule consists of dextrin, bitter and 5% of the TCM granule."
223675533|NCT03415776|PROCEDURE|Hemodialysis|Renal replacement therapy
223675534|NCT01922401|OTHER|inverse ratio ventilation|change the I: E ratio 1:2-1:1-2:1
223675535|NCT03508791|OTHER|Arterial carbon dioxide monitoring|Arterial carbon dioxide partial pressure is monitored during the laparoscopic surgery undergoing in the Trendelenburg or reverse Trendelenburg positions.
223675536|NCT03508791|OTHER|End-tidal carbon dioxide monitoring|End-tidal carbon dioxide partial pressure is monitored during the laparoscopic surgery undergoing in the Trendelenburg or reverse Trendelenburg positions.
223675537|NCT03508791|OTHER|Transcutaneous carbon dioxide monitoring|Transcutaneous carbon dioxide partial pressure is monitored during the laparoscopic surgery undergoing in the Trendelenburg or reverse Trendelenburg positions.
223675538|NCT03455790|DIAGNOSTIC_TEST|Aerobic Capacity|"Upper limb muscle strength assessments of the athletes will be performed with the ISOMED 2000® isokinetic device and the grip strength with the Jamar® dynamometer. The aerobic capacity values will be measured using the Cosmed K5® instrument and the TS in the Cosmos-Saturn brand running band. Anaerobic capacity will be measured by Wingate anaerobic power test (WanT) for 30 seconds in standard laboratory conditions for TS basketball athletes using Monark 894 E model ergometer developed by Monark for upper extremity anaerobic capacity and power measurement. The sporty performances will be evaluated with the 20 m Sprint test, Slalom Test and Zone Shot tests."
223675539|NCT06129513|BEHAVIORAL|Bilateral resistance exercise|A bout of bilateral resistance exercise consisting of barbell back squat, leg leg press and leg extension
223675540|NCT06129513|DIETARY_SUPPLEMENT|Whey protein|Following execution of bilateral resistance exercise, participants will ingest 32 g protein from whey protein isolate
223675541|NCT06129513|DIETARY_SUPPLEMENT|Plant-blend protein|Following execution of bilateral resistance exercise, participants will ingest 32 g protein from plant-blend protein isolate
223772799|NCT05449028|DRUG|H. pylori eradication scheme D|Esomeprazole 40mg bid + amoxicillin 1g 12/12h for 7 days, followed by esomeprazole 40mg bid + clarithromycin 500mg 12/12h + metronidazole 500mg 12/12h for 7 days
223772800|NCT05449028|DRUG|H. pylori eradication scheme E|Esomeprazole 40mg bid + amoxicillin 1g 12/12h for 7 days, followed by esomeprazole 40mg bid + amoxicillin 1g 12/12h + clarithromycin 500mg 12/12h + metronidazole 500mg 12/12h for 7 days
223772801|NCT03837795|DEVICE|Neurofeedback treatment|A treatment that developed to train adults with sensory modulation disorder by applying EEG (Curry 7 EEG system, Neuroscan-Compumedics). This treatment will aim to normalize the Alpha power (amplitude).
223772802|NCT04294004|COMBINATION_PRODUCT|TGplPTH1-34 in fibrin|TGplPTH1-34 within a fibrin matrix applied within and around a polyetheretherketone (PEEK) intervertebral cage
224257180|NCT03595436|DIETARY_SUPPLEMENT|Pea Protein-30g|The study participants will be provided with breakfast preloads to consume. The energy content of the breakfast preload will be standardized to \~325 kcal. This preload will include 30 g pea protein, 5 g mixed protein (from yogurt and peanut-butter), 32 g carbohydrates, and 7 g fat. The preload is a yogurt-based (chocolate-peanut butter flavored) breakfast.
224257181|NCT03595436|DIETARY_SUPPLEMENT|Pea Protein-40g|The study participants will be provided with breakfast preloads to consume. The energy content of the breakfast preload will be standardized to \~325 kcal. This preload will include 40 g pea protein, 5 g mixed protein (from yogurt and peanut-butter), 24 g carbohydrates, and 7 g fat. The preload is a yogurt-based (chocolate-peanut butter flavored) breakfast.
224257182|NCT03595436|DIETARY_SUPPLEMENT|Whey Protein-20g|The study participants will be provided with breakfast preloads to consume. The energy content of the breakfast preload will be standardized to \~325 kcal. This preload will include 20 g whey protein, 5 g mixed protein (from yogurt and peanut-butter), 40 g carbohydrates, and 7 g fat. The preload is a yogurt-based (chocolate-peanut butter flavored) breakfast.
224322483|NCT02506829|BEHAVIORAL|Smoking cessation pharmacotherapy (e.g, nicotine replacement therapy)|
223675542|NCT00819793|DEVICE|CentriMag Ventricular Assist System|All eligible subjects will receive the CentriMag Ventricular Assist System. The system is comprised of a single-use centrifugal blood pump, a motor, a primary drive console, a back up drive console and cannulae. Blood from the failing heart is directed from the ventricle or the atrium to the inlet of the pump via an inlet cannula. Blood exits through the outlet port of the pump through the outlet cannula ultimately to the pulmonary or systemic circulation. The system can be used in either a right, left or biventricular configuration.
223675543|NCT04232709|OTHER|Shared electronic patient record|MedChart allows access to a shared electronic patient record that contains selected information related to a patient's cancer treatment. If a patient contacts the after-hours telemedicine service, the oncology nurse will have access to this shared record
223675544|NCT01711060|DRUG|oxytocin|
223675545|NCT01711060|PROCEDURE|balloon catheter|
223675546|NCT05451927|DIETARY_SUPPLEMENT|Phaseolus Vulgaris|Weight loss
223675547|NCT05451927|DIETARY_SUPPLEMENT|Placebo|Placebo
223675548|NCT05258370|OTHER|Dosage|Evaluation of circulating C-terminal FGF23 (FGF23Ct) rate, circulating intact FGF23 (FGF23i) rate and Erythropoietin
223675549|NCT05258370|OTHER|Cardiac echography|12 months after patient enrollment
224257183|NCT03595436|DIETARY_SUPPLEMENT|Carbohydrate Control|The study participants will be provided with breakfast preloads to consume. The energy content of the breakfast preload will be standardized to \~325 kcal. This preload will include 5 g mixed protein (from yogurt and peanut-butter), 59 g carbohydrates, and 7 g fat. The preload is a yogurt-based (chocolate-peanut butter flavored) breakfast.
224257184|NCT03209115|DRUG|combination of calcium hydroxide and chlorhexidine|placement of calcium hydroxide and chlorhexidine as intracanal medicament after removal of old filling and mechanical preparation of root canal
224257185|NCT03209115|DRUG|Calcium Hydroxide|placement of calcium hydroxide as intracanal medicament after removal of old filling and mechanical preparation of root canal
224257186|NCT00004985|DRUG|Capravirine|
224257187|NCT00004985|DRUG|Nelfinavir mesylate|
224257188|NCT01278641|BEHAVIORAL|Graded strength resistance training program|Graded strength resistance training, 75 minutes, twice a week for 12 weeks.
224257189|NCT01278641|BEHAVIORAL|Temperate pool exercise program|Temperate pool low intensive exercise, 50 minutes, twice a week for 12 weeks.
223675550|NCT02387476|DEVICE|FRESCA mask first night|FRESCA nasal mask first night
223675551|NCT02387476|DEVICE|CPAP Mask first night|CPAP Nasal Mask first night
223675552|NCT05908058|OTHER|Emotional Changes Investigation|Emotional Changes between Emergency and Intensive care unit and On-site Counter Staffs after COVID-19 Infection and Exploring The Impact of Personnel Emotional Adjustment
223675553|NCT00002975|DRUG|aminolevulinic acid|
223675554|NCT05292300|DIETARY_SUPPLEMENT|Cornelian Cherry (Cornus mas L.)|"Patients in Cornelian Cherry Group and Cornelian Cherry and Diet Group will receive 20 g/day freeze-dried powder Cornelian Cherry supplement."
223675555|NCT05292300|BEHAVIORAL|Diet|"Patient in Diet Group and Cornelian Cherry and Diet Group will be given a personalized diet and be followed up by a dietician."
223675556|NCT01181401|DRUG|TPF induction chemotherapy|Docetaxel 75 mg/m2 d 1 Cis-platinum 75 mg/m2 d 1 5-FU 750 mg/m2/d c.i. d 1-4 Cetuximab loading dose of 400 mg/m2 1 week prior to RTX, and 250 mg/m2 weekly x 6 concurrent to RTX
223675557|NCT01181401|DRUG|TPF experimental|Docetaxel 40 mg/m2 d 1+8 Cis-platinum 40 mg/m2 d 1+8 5-FU 1500 mg/m2/24h c.i. d 1+8 every 21 day for 3 cycles 2. Antibody therapy with: cetuximab loading dose of 400 mg/m2 1 week prior to RTX, and 250 mg/m2 weekly x 6 concurrent to RTX
223675558|NCT01181401|RADIATION|Standard Radiochemotherapy (HART)|Hyperfractionated accelerated radiotherapy with concurrent Cisplatin and 5-Fluorouracil chemotherapy
223675559|NCT03403842|DEVICE|Sublingual sufentanil tablet system|Administration of sublingual sufentanil with a PCA
223675560|NCT03403842|DEVICE|Peridural catheter|Positioning of a peridural catheter with a continuous infusion of ropivacaine 0,2% 99 ml+sufentanil 50 mcg
223675561|NCT03403842|DRUG|PCA Morphine|Administration of endovenous morphine with a PCA
223675562|NCT03603327|DRUG|Direct acting anti-viral agents|Standard of care for Hepatitis C treatment
223675563|NCT05703633|OTHER|uDCD treatment|Thrombolytic treatment/prevention ex-vivo to kidneys procured from patients after circulatory arrest
223675564|NCT00572221|BEHAVIORAL|Continuing Quality Improvement and Quality Assurance system|The main intervention is a facility-wide Continuing Quality Improvement and Quality Assurance system, with problem recognition and ongoing evaluation.
223675565|NCT00572221|BEHAVIORAL|CQI and QA System with Best-Practice Care Protocols|A facility-wide Continuing Quality Improvement and Quality Assurance system, with problem recognition and ongoing evaluation. Research clinical staff will also provide best-practice care protocols designed by our research team to address targeted problem conditions.
223675566|NCT05911282|DRUG|N Acetylcysteine|"The study began at 7 pm, when the volunteers in NAC group drank the contents of a numbered cup with NAC (1.2 g of NAC). At 9 pm, they were given the second cup with 1.2 g of NAC corresponding to their randomized number.~The cups with pure substance NAC were prepared and numbered by the physician not attending the drinking just before the study."
224257190|NCT03199196|DEVICE|Activity Tracker|"Group 1 - Intervention: Participants given an accelerometer at each visit. Participant wears the accelerometer for 7 days.~Group 2 - Newsletters: After completing the 16 week visit, participant given an activity tracker."
224257191|NCT03199196|DEVICE|Smartphone Application|"Group 1 - Intervention: Participant given smartphone application baseline visit to track physical activity, connect with participant's partner to share information about participant's physical activity, and provide support to partner to be more physically active.~Group 2 - Newsletters: After completing the 16 week visit, participant given instruction in the use of a smartphone application."
224257192|NCT03199196|BEHAVIORAL|Questionnaires|Participants complete questionnaires about feelings, moods, motivation for physical activity, any social support received from others, the neighborhood participant lives in, and other physical activity-related topics. Questionnaires completed 1 time at the beginning of the study, 8 weeks after joining the study, and 16 weeks after beginning the study.The questionnaires should take about 45 minutes to complete.
224257193|NCT03199196|BEHAVIORAL|Focus Group|Participants invited to take part in a final focus group. Focus group takes place sometime after the 16-week visit. Focus groups/interviews are audio recorded.
224322484|NCT02506829|BEHAVIORAL|Financial incentives|
223675567|NCT05911282|OTHER|Lemon juice|"The study began at 7 pm, when the volunteers in placebo group drank the contents of a numbered cup with lemon juice. At 9 pm, they were given the second cup with lemon juice corresponding to their randomized number.~The cups with lemon juice were prepared and numbered by the physician not attending the drinking just before the study."
223675568|NCT04334018|DEVICE|conventional CRT|"Conventional CRT or biventricular pacing resynchronizes left ventricular contraction by pacing the right and left ventricles (LV) simultaneously"
223675569|NCT04334018|DEVICE|MPP CRT|CRT with Multipoint pacing (MPP) where pacing can occur from more than one LV site simultaneously
223675570|NCT04058171|DIAGNOSTIC_TEST|Treadmill walking test|Participants will be invited to walk on a treadmill at a speed of 1,2 mph for at most five minutes for both conditions (straight walking posture and inclined walking posture). Each walking posture condition will be followed by a rest time of five minutes in sitting position. Conditions were randomized in each group using a computer-generated sequence.
223675571|NCT02162576|DEVICE|Propeller Health intervention|The Propeller intervention works through the provision of information to patients and their providers. With the Propeller sensor device in place, each actuation of a patient's rescue inhaler is recorded with an automatic time stamp and geographic location. Actuation data are then securely transmitted to Propeller Health where the information is also compiled into individual reports via mobile apps, online dashboards, email reports and text message reminders that are returned to the patient. This communication provides an ongoing assessment of their management based on the national guidelines, together with personalized information to help encourage and support self-management. Each participant was invited to share reports with his or her healthcare provider, but this was not required.
223675572|NCT02593045|BIOLOGICAL|IPH4102|
223675573|NCT01165736|DRUG|PF-05186462|single intravenous infusion of 100 microgram
223675574|NCT01165736|DRUG|PF-05186462|single oral administration of 100 microgram
223675575|NCT01165736|DRUG|PF-05089771|single intravenous infusion of 100 microgram of PF-05089771
223675576|NCT01165736|DRUG|PF-05089771|single oral administration of 100 microgram PF-05089771
223675577|NCT01165736|DRUG|PF-05150122|single intravenous administration of 100 microgram PF-05150122
223675578|NCT01165736|DRUG|PF-05150122|single oral administration of 100 microgram PF-05150122
223675579|NCT01165736|DRUG|PF-05241328|single intravenous infusion of 100 microgram PF-05241328
223675580|NCT01165736|DRUG|PF-05241328|single oral administration 100 microgram PF-05241328
223675581|NCT05683431|BEHAVIORAL|Cognitive Control of Emotion (CCE) Training|Training consists of game-like exercises using a software program developed in collaboration with PositScience Corporation (using BrainHQ platform ) - which has exercises targeting cognition and social cognition. The CCE training program incorporates characteristics that optimize learning-induced neuroplasticity - most importantly, exercises are short \& rewarding, adapt to individual skill-level, and become increasingly difficult as performance improves. There are 5 CCE exercises that are organized in half-hour sessions and proceed in a predetermined sequence.
223675582|NCT04510636|DRUG|Pembrolizumab|Pembrolizumab is a intravenously administered humanized monoclonal antibody that blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2.
223675583|NCT04510636|DRUG|Bendamustine Hydrochloride|Bendamustine is a unique alkylating agent with substantial activity in hematologic malignancies.
223675584|NCT01574001|BEHAVIORAL|Antismoking intervention with no early follow-up|"an anti-smoking intervention in line with the 5A's method without early follow-up; follow-up assessment will be limited to two visits: 3 and 12 months after stroke"
223675585|NCT01574001|BEHAVIORAL|Antismoking intervention with minimal early follow-up|"Anti-smoking intervention in line with the 5A's method (Ask, Advice, Assess, Assist, Arrange follow-up. The intervention will be carried out 5-7 days after stroke, before the planned discharge from the hospital. Seven days after discharge from a stroke unit a brief telephone/personal advice will be given aimed to motivate patients to quit smoking; follow-up assessment will include two visits: 3 and 12 months after stroke"
223675586|NCT01574001|BEHAVIORAL|Antismoking intervention with intensive early follow-up|"an anti-smoking intervention in line with the 5A's method will be given, including four follow-up visits within 6 weeks after discharge from the hospital (week 1, week 2, week 4, week 6 after stroke); follow-up assessment will include two visits: 3 and 12 months after stroke"
223675587|NCT00624702|DRUG|Indacaterol maleate|Four single dose treatments (each dose is 400 µg-for the active salts-via SDDPI), with at least a 7 day inter-dose interval
223675588|NCT00624702|DRUG|Indacaterol maleate|Four single dose treatments (each dose is 400 µg-for the active salts-via SDDPI), with at least a 7 day inter-dose interval
223675589|NCT00624702|DRUG|Indacaterol maleate|Four single dose treatments (each dose is 400 µg-for the active salts-via SDDPI), with at least a 7 day inter-dose interval
223675590|NCT00624702|DRUG|Placebo|
223675591|NCT05767801|PROCEDURE|Evaluation of subclinical inflammation|Minimally invasive synovial tissue biopsy for the semiquantitative and qualitative assessment of synovial immune and stromal cells; Peripheral blood collection for MBDA assessment and phenotyping of immune cells;
223675592|NCT06280014|PROCEDURE|Surgery of impacted mandibular wisdom teeth|All surgical procedures were performed by the same surgeon using the standard surgical technique described below. The anesthetic used was 4% articaine with 1:100,000 adrenaline. In all patients, a sulcus incision was made in the lower second molar and an envelope incision in the third molar region, the mucoperiosteal flap was removed, and extraction was performed with a bone elevator and a third molar elevator. If necessary, the impacted molar was incised with a high-speed dental handpiece and a fissure bur. The wound was irrigated with copious amounts of saline, and the wound edges were carefully sutured with simple 4.0 silk braided non-absorbable sutures. After extraction of impacted wisdom tooth, the patient was given mefenamic acid as a medication.
223675593|NCT06280014|PROCEDURE|Surgery of impacted mandibular wisdom teeth|All surgical procedures were performed by the same surgeon using the standard surgical technique described below. The anesthetic used was 4% articaine with 1:100,000 adrenaline. In all patients, a sulcus incision was made in the lower second molar and an envelope incision in the third molar region, the mucoperiosteal flap was removed, and extraction was performed with a bone elevator and a third molar elevator. If necessary, the impacted molar was incised with a high-speed dental handpiece and a fissure bur. The wound was irrigated with copious amounts of saline, and the wound edges were carefully sutured with simple 4.0 silk braided non-absorbable sutures. After extraction of impacted wisdom tooth, the patient was dexketoprofen as a medication.
223675594|NCT04396054|DEVICE|Lag Screws|Method of internal fixation
223675595|NCT04396054|DEVICE|double Y-shaped plates|Method of internal fixation
223675596|NCT05268211|DIAGNOSTIC_TEST|urinary oxygen partial pressure|measuring urinary oxygen partial pressure and measuring US Doppler renal resistive index
223675597|NCT03472443|OTHER|acupuncture|Subjects will receive Sinew Acupuncture 2-3 times in two weeks, a total of 5 sessions. Needles will be inserted into the Sinew Acupoints on the affected wrist and forearm. Needles will be inserted along the subcutaneous level, nearly parallel to the skin, and the tip of needles pointing towards the painful spot at the radial styloid. 4-6 sinew acupoints will be used.
223675598|NCT04828473|DEVICE|Allay Lamp|"The Allay Lamp is a consumer product currently available and widely used in the US. It emits low intensity (1-10lux)narrow band (20nm) green light (peak wavelength 520nm) that is marketed as non-irritating to users. In that context, it is not a medical device and does not require a 510(k). However, we believe that light likely also has benefits for sleep. To better understand its effects,we are planning to conduct the proposed study. In that context, the Allay Lamp would be considered an investigational medical device because it has not been cleared or approved by FDA for the intended purpose of treating sleep. No FDA submission should be necessary for this study using 21 C.F.R. 812.3, because the Allay Lamp is a non-significant risk (NSR) device:~* It is not an implant~* It is not intended for use in supporting or sustaining human life The Allay Lamp provides a very low risk light-based therapy. The light provides no more risk than any other table lamp available on the market today."
223675599|NCT00260611|DRUG|Oxaliplatin|
223675600|NCT00260611|DRUG|Taxotere|
223675601|NCT05807061|BEHAVIORAL|EmBARK|The narrated training teaches parents about children's biases and introduces multiple strategies for addressing children's biases. Families receive children's books to help practice the strategies.
223675602|NCT05807061|BEHAVIORAL|Popular guidance|The popular press articles teach parents about children's biases and guide parents about how to talk to children about race. Families receive children's books focused on race to help practice talking about race.
223675603|NCT05807061|BEHAVIORAL|Practice first|Animal books are provided to parents to help them practice talking to their children when reading books. Then, families receive a training program about race as well as children's books about race.
223675604|NCT02433158|DRUG|Rivipansel|Rivipansel will be infused intravenously every 12 hours up to a maximum of 15 doses.
224257194|NCT03199196|BEHAVIORAL|Electronic Newsletters|Participant emailed electronic newsletters to read that may help participant be more physically active.
224322485|NCT02687347|DRUG|oral methadone|Oral methadone is the study drug
224257195|NCT03199196|BEHAVIORAL|Telephone Counseling|Research staff provides telephone counseling to participant and partner biweekly during weeks 1-8 (weeks 1, 3, 5, and 7), and monthly during weeks 9-16 (weeks 11 and 15).
224257196|NCT02878018|DRUG|Qi-Ji Shen-Kang formula; Zhu-Bai formula; Yu-Shen formula|Qi-Ji Shen-Kang formula:15g of field thistle,10g of common edelweiss herb,10g of spreading hedyotis herb,10g ofYunnan manyleaf Paris rhizome,10g of hairyvein agrimonia herb,10g of the root bark of the tree peony,15g of root of red rooted salvia, and 15g ofmembranous mikvetch root.Zhu-Bai formula:10g of glabrous greenbrier rhizome,5g of Chinese atractylodes rhizome,10g of amur corktree bark,10g of common edelweiss her),10g of field thistle,10g of lalang grass rhizome,10g of garden burnet root,5g of longbract cattail pollen,5g of rehmanniae radix, and 5g of Chinese angelica root.Yu-Shen formula:15g of membranous mikvetch root,10g of heterophylla falsestarwort root,10g of field thistle,10g of cogongrass rhizome,10g of spreading hedyotis herb,10g of root of red rooted salvia,10g of fresh root of rehmannia,10g of Asian puccoon,10g of wormwoodlike motherwort herb,10g of common cockscomb inflorescence,10g of gordon euyale,10g of root bark of the tree peony, and 5g of licorice root.
224257197|NCT02878018|DRUG|angiotensin-converting enzyme (ACE) inhibitor; adrenergic receptor binder (ARB); adrenal cortical hormone; Tripterygium wilfordii polyglycosidium; immunosuppressant|prednisone at a dose of 1-1.5 mg/(kg·d) and Tripterygium wilfordii polyglycosidium at a dose of 1 mg/(kg·d). For each patient, the specific Western medicines used and their doses may be adjusted at the discretion of his or her physician, but the classes cannot be changed.
224322486|NCT02687347|DRUG|oral morphine|Oral morphine is the active comparator. It is not a placebo intervention
224322487|NCT01296997|DIETARY_SUPPLEMENT|calcium phosphate|the subjects consumed for 3 weeks a bread enriched with 1 g pentacalcium phosphate per day
224322488|NCT01296997|OTHER|placebo|the subjects consumed a bread without pentacalcium phosphate
223675605|NCT03501771|OTHER|Acupuncture|Disposable acupuncture needles will be inserted into acupoints (BL23, BL25, BL40) bilaterally for a depth of 10-30 mm
223675606|NCT00191087|DRUG|Duloxetine|
223675607|NCT04872530|DIETARY_SUPPLEMENT|Pea-protein concentrate|Pea-protein concentrate
223675608|NCT04872530|DIETARY_SUPPLEMENT|Fava-bean protein concentrate|Fava-bean protein concentrate
223675609|NCT04872530|DIETARY_SUPPLEMENT|Chickpea protein concentrate|Chickpea protein concentrate
223675610|NCT04872530|DIETARY_SUPPLEMENT|Red lentil protein concentrate|Red lentil protein concentrate
223675611|NCT04872530|DIETARY_SUPPLEMENT|Non-essential amino acid blend|Non-essential amino acid blend
223675612|NCT04872530|DIETARY_SUPPLEMENT|Whey protein concentrate|Whey protein concentrate
223675613|NCT00204243|DRUG|Naltrexone|surgically implanted naltrexone releasing during 5 to 6 months
223675614|NCT00204243|DRUG|Methadone|Methadone maintenance treatment, flexible high dose (80 to 120 mg / Day)
223675615|NCT05393258|RADIATION|temporally-modulated pulsed radiotherapy (TMPRT)|Intensity modulated RT (IMRT) using single or two arc therapy will be used for RT delivery.
223675616|NCT01273285|DEVICE|Spectralis® SD-OCT, Heidelberg Engineering GmbH, H|
223675617|NCT02026570|BEHAVIORAL|Internal Focus of Attention|Providing instructions for the user to manipulate their residual limb in space during standing and walking tasks.
224322489|NCT03616145|PROCEDURE|Osteopathic Manipulative Treatment (OMT)|Experimental Condition
224322490|NCT03616145|OTHER|Light Touch|Comparator Arm
224322491|NCT00286026|DRUG|Azithromycin|1 gm Azithromycin orally, provided as four 250 mg tablets for adults; pediatric suspension will be provided to children \> 1 year old (20 mg/kg body weight) to a maximal dose of 500 mg. One dose vs 2 doses given 30 days apart.
224322492|NCT03248973|DRUG|Ampicillin Injection|Ampicillin injection 2 g q4h for 3 weeks
224257198|NCT06549998|OTHER|Interprofessional Simulation Experience|"Phase 1 (Pre-Brief): Nursing and physical therapy students will have 10 minutes to gather as a group and prepare for the simulation experience.~The students will work together to review the simulated patient's medical chart, which includes a hand off report, physician orders, patient demographic data, disci-pline-specific progress notes, a physical therapy evaluation, and information from lab results posted on a tri-fold board.~Phase 2 (Simulation): After reviewing the chart and establishing a plan as a group for getting the simulated patient out of bed, the interprofessional team of nursing and physical therapy students will enter the simulated hospital room. The goal for the approximately 20-minute encounter is for the interprofessional group to help the simulated patient to get out of bed while closely monitoring the physiological responses to activity.~Phase 3: The simulation will conclude with a 30-minute faculty guided and structured debriefing session."
223675618|NCT02026570|BEHAVIORAL|External Focus of Attention|Providing instructions for the user to manipulate their prosthetic foot in space during standing and walking tasks.
223675619|NCT03579901|DEVICE|Silicone gel-filled breast implants - Motiva Implants® Investigational breast implants|Breast augmentation
223675620|NCT04817852|OTHER|CBCT data of c-shaped canal in mandibular second molar.|Detection of variation in root canal morphology in mandibular second molar by using CBCT.
223675621|NCT05302661|BEHAVIORAL|re-education|Contact patients by phone or wechat and guide them
223675622|NCT04592263|OTHER|EPD Questionnaire|A 44 items questionnaire (4 point likert scale) was distributed. Included dimensions where: experience with your physician, provision of care, barriers, outcomes of care, symptoms, patient engagement, health literacy and patient empowerment.
224257199|NCT03495011|DIAGNOSTIC_TEST|Breast MRI|Quantitative, multiparametric breast MRI
224257200|NCT03495011|OTHER|Laboratory Biomarker Analysis|Only patients with pure DCIS on surgical excision will have advanced pathologic markers and Oncotype Dx DCIS Score testing.
224257201|NCT01858168|DRUG|Olaparib|Tablets to be taken on an empty stomach twice a day.
224257202|NCT01858168|DRUG|Temozolomide|Tablets to be taken on an empty stomach before bedtime.
224257203|NCT01858168|DRUG|Irinotecan|Administered via IV
224257204|NCT06248528|PROCEDURE|Liver resection|Patients in the intervention group received liver resection and postoperative adjuvant therapy
224257205|NCT06248528|PROCEDURE|Locoregional therapy|Patients in the control group received locoregional therapy and systemic therapy
224257206|NCT04026958|DRUG|Clarithromycin|Clarithromycin will be dosed as 500 mg twice daily, once upon awakening and once with lunch, for 14 days.
224257207|NCT04026958|DRUG|Placebo|A placebo to match clarithromycin will be dosed as 500 mg twice daily, once upon awakening and once with lunch, for 14 days.
224257208|NCT03511534|BEHAVIORAL|Psychotherapy|Evidenced based psychotherapy by a trained psychologist
224257209|NCT03511534|OTHER|Pharmacotherapy|Pharmacotherapy by a psychiatrist
224257210|NCT05521867|DEVICE|Endoscopic balloon dilation|EBD procedures will be performed with wire guided CRE pneumatic balloon (controlled radial expansion balloon, Boston scientific, Marlborough, MA, USA 0of various sizes based on tightness of the stricture (10-12 mm, 12-15 mm, 15-18 mm, 18-20 mm) with graded dilations with inflation pressures varying from 3-8 ATM pressure. Balloon was inflated for at least 2 minutes and slowly deflated. A maximum of two sessions of dilation will be allowed with a minimum interval of 15-30 days between them.
224257211|NCT05521867|DEVICE|Endoscopic stricturotomy with or without stricturoplasty|Endoscopic stricturotomy would be done using either a triple-lumen needle-knife (Boston Scientific, Marlborough, MA) or with a electrosurgical IT knife2 (Olympus Medical Systems, Tokyo, Japan) in the setting of endoscopic retrograde cholangiopancreatography (ERCP) Endocut on Erbe medical device (USA Incorporated Surgical Systems, Marietta, GA) with the following electrocautery settings : Endocut Q (effect 3, cut duration 1, cut interval 3). Strictures will be incised in a circumferential or radial fashion until an adequate passage of the scope. Endoclips may be applied post stricturotomy to act as keep treated stricture open and to prevent delayed bleeding (referred as stricturoplasty). Choice of endoclips and decision to perform stricturoplasty would be at the discretion of endoscopist.
224257212|NCT05660395|DRUG|Loncastuximab Tesirine|Intravenous (IV) Infusion
224257213|NCT05642312|DRUG|Vamikibart|Participants will receive vamikibart IVT injection
224257214|NCT05642312|OTHER|Sham|Participants will receive a sham procedure that mimics an IVT injection.
224257215|NCT03974503|BEHAVIORAL|Exposure, Relaxation, and Rescripting Therapy|ERRT is a weekly 5-session treatment aimed at reducing chronic trauma nightmares and sleep disturbances in trauma-exposed adults.
224257216|NCT03974503|BEHAVIORAL|Sleep and Nightmare Management|This is a manualized protocol developed to be of similar length but exclude the active components of standard ERRT.
223675623|NCT04148872|OTHER|Neuromuscular Retraining Therapy (4 months)|Neuromuscular retraining is an intervention where facial therapists utilize voluntary input to access improved movement patterns in patients with synkinesis.
223675624|NCT04148872|DRUG|Chemodenervation (4 months)|A neurotoxin that temporarily reduces muscle activity and minimizes the effects of uncoordinated muscle.
223772803|NCT04294004|OTHER|Autologous Bone Graft|Local autograft collected from decompression which may be supplemented with iliac crest bone graft (ICBG) if local autograft is insufficient.
224257217|NCT05706870|DRUG|GN-037|GN-037
224257218|NCT05706870|DRUG|Clobetasol 17-propionate|Clobetasol 17-propionate
224257219|NCT05706870|DRUG|Placebo|Placebo
224257220|NCT04318886|BEHAVIORAL|ENABLE Cornerstone|The ENABLE (Educate, Nurture, Advise, Before Life Ends) Cornerstone intervention is led by a specially-trained lay coach who is overseen by an interdisciplinary outpatient palliative care team, who employs health coaching techniques and caregiver distress assessment to behaviorally activate and reinforce psychoeducation on managing stress and coping, getting and asking for help, improving caregiving skills, and decision-making/advance care planning over 6 brief in-person/telephonic sessions plus monthly follow-up from diagnosis through early bereavement.
224257221|NCT04726345|DRUG|Fexofenadine Hcl 180Mg Tab|Fexofenadine 180mg tablet to be taken orally once a day until stent removal.
224257222|NCT04726345|DRUG|Placebo|Placebo tablet to be taken orally once a day until stent removal.
224257223|NCT02772367|PROCEDURE|skin punch biopsy|
224257224|NCT06054412|DEVICE|Neuroptimal (Zengar, Inc.) Neurofeedback|Mothers in the Neurofeedback Training group will complete one training session (lasting approximately 33 minutes) a week for a total of 12 weeks, using the Neuroptimal (Zengar, Inc.) neurofeedback device.
223675625|NCT04148872|OTHER|Neuromuscular Retraining + Chemodenervation|Participants will receive both interventions for the last 4 months of their time on study.
223675626|NCT03849755|DEVICE|PEPPER system|The PEPPER system offers insulin dosing advice that is highly adaptive to the insulin needs of individuals by using Case-Base Reasoning (CBR) approach.
223675627|NCT02069340|DRUG|zoledronic acid|Given IV
223675628|NCT02069340|OTHER|pharmacological study|Correlative studies
223675629|NCT03947554|DIETARY_SUPPLEMENT|HRG80 Panax ginseng|Panax ginseng containing 63.4 mg ginsenosides
223675630|NCT03947554|DIETARY_SUPPLEMENT|Panax ginseng|Panax ginseng containing 19.6 mg ginsenosides
223675631|NCT03947554|DIETARY_SUPPLEMENT|Placebo|800 mg excipient
223675632|NCT04093063|OTHER|Micro-stellated Icosahedron|A portable, inexpensive microsurgery training model that requires the following materials for completion. a stereoscopic dissecting microscope, two jeweler style forceps, a pair of curved-tip micro scissors , 1 meter of monofilament nylon thread, 0.5 meter of polyimide microtubule material , one 15 cm metal ruler, a scalpel blade (#15), and double-sided tape. For a microsurgically-naive subject, a total of 20 hours are required to complete this model.
223675633|NCT04721067|DEVICE|SHUTi|SHUTi is the empirically supported, internet CBT-I that is fully accessible via tablets and smartphones. It uses a self-guided, fully automated, interactive, multimedia format to deliver six 45-minute sessions, the structure and content of which mirror traditional face-to-face CBT-I. Session content includes sleep restriction, stimulus control, sleep hygiene, cognitive restructuring, and relapse prevention. SHUTi is enhanced through a variety of interactive features, including personalized goal setting, graphical feedback based on inputted symptoms, animations and illustrations to enhance comprehension, quizzes to test user knowledge, patient vignettes, and video-based expert explanation. Across sessions, patients also receive tailored sleep recommendations and feedback based on the sleep diary data they enter into the program.
223675634|NCT04721067|BEHAVIORAL|Sleep Education/Hygiene|A research assistant (RA) will deliver the active control procedures. During the first 4 weeks, the RA will have two calls with each control participant - one 45-minute call on insomnia education (including their HIV provider's role in its management) and one 45-minute call on sleep hygiene practices. To end the first call, the RA will email or mail a list of local behavioral health services to patients and will encourage them to follow-up with their HIV provider. We will then notify the HIV provider, which will encourage them to address their patient's insomnia and provide the same list of local services.
223675635|NCT05575921|DIAGNOSTIC_TEST|Polysomnography|Children underwent at-home polysomnography in routine clinical practice. The exam is interpreted in 2 ways by the physician with sleep stages (PSG) and without sleep stages (PG). The data are retrospectively collected from the patient's recording
223675636|NCT04434170|DRUG|Sacubitril-Valsartan|outpatients who start treatment with sacubitril/valsartan according to guidelines will andergo cardiopulmonary exercise testing evaluation
224257225|NCT02925884|DEVICE|Gunnar OTC Glasses|Gunnar Over-the-Counter Computer Glasses have optical power of 0.5 diopters for reducing accommodation demands at a typical computer-viewing distance. The lens also have a partially transmissive yellow tinting and anti-reflective coating for filtering part of the spectral peaks in typical fluorescent or incandescent light. The frame has a wrape-around design meant to reduce air flow in the vicinity of the eyes.
224257226|NCT04691973|BEHAVIORAL|Health and lifestyle tool|Health and lifestyle tool used online
224257227|NCT04691973|OTHER|Usual care|Usual care at ordinary healthcare provider
224257228|NCT00199758|DRUG|cisplatin|
224257229|NCT00199758|DRUG|Gemcitabine|
224257230|NCT00199758|DRUG|Taxol|
224257231|NCT03119025|BIOLOGICAL|Autologous DC-vaccines|"Patients will be vaccinated via intracutaneous injection of autologous DCs (5×106) combined with adjuvant subcutaneous injection of recombinant hIL-2 (250 000 IU).~Initiating course: one vaccination per week, during 1 month. Maintaining course: one vaccination per month, during 6 month. Patients will be monitored in a 2 months (after completing of initiating course), 7 months (after completing of maintaining course) and 13 months (in a 6 months post-vaccination follow-up)."
224257232|NCT05951049|DRUG|AT02|Dosage Form: Solution for injection/infusion Dosage level: Different dose levels of AT02 Route of Administration: Intravenous use
224257233|NCT06234358|DEVICE|osteosynthesis|calcaneus osteosynthesis is a surgical fixation of a displaced fracture of the calcaneous bone. The surgery is performed under general or regional anesthesia. A scar is made on the lateral side of the ankle below the lateral malleolus. The bone fragments are repositioned as anatomically as possible. They are fixed by a percutaneous nailing fastener.
224257234|NCT01421264|DRUG|Gabapentin|300mg capsules by mouth
223675637|NCT04612608|PROCEDURE|upright bed|moving the bed into an upright position
223675638|NCT02233478|DIETARY_SUPPLEMENT|Pomegranate Juice|Pomegranate Juice alone
223675639|NCT02233478|DIETARY_SUPPLEMENT|Soybean Flour Protein|Soybean Flour Protein combined with Pomegranate Juice
223675640|NCT02233478|DIETARY_SUPPLEMENT|Soy Isolate Protein|Soy Isolate Protein combined with Pomegranate Juice
223675641|NCT05959642|DEVICE|dentapen|"Experimental: Controlled Flow Delivery Dentapen according to the manufacturer instructions, It works with standardised 1.8 mL local anaesthetic carpules. The distalingual and mesiolingual line angles are the most effective for multi-rooted upper D teeth.~Articaine hydrochloride 4% with 1:100,000 epinephrine will be injected for each root as shown on a special indicator.The dentist will wait 5 seconds before needle withdrawal. Same steps will be repeated at the mesiolingual line angle"
223675642|NCT05959642|DEVICE|Traditional metal Syringes|"Active Comparator: Conventional Injection of infiltration upper d a standard technique for the Injection of infiltration upper d will be used supplemented with long buccal infiltration for the buccal gingiva.~A 27-gauge disposable dental needle will be used to inject Articaine hydrochloride 4% with 1:100,000 epinephrine. The needle will be directed to primary molars"
224257235|NCT04724187|DRUG|Misoprostol|it is prostaglandin E1 .
224257236|NCT04724187|DRUG|Oxytocin|it stimulates uterine contractions
224257237|NCT02301975|DRUG|Fluticasone Furoate/Vilanterol 100/25 mcg via ELLIPTA inhaler|FF/Vilanterol 100/25 mcg inhalation powders administered once daily via ELLIPTA inhaler. 30 doses per device and 100/25 mcg per actuation.
224257238|NCT02301975|DRUG|Placebo inhalation powders via ELLIPTA inhaler|Placebo inhalation powders administered once daily via ELLIPTA inhaler. 30 doses per device.
223675643|NCT03972891|OTHER|intervention break of 12 weeks|"The intervention of this study is a break of the intervention for 12 weeks under the following conditions:~* no therapeutic intervention during the break~* no language-specific specific exercises~* language-specific strategies in everyday life can be applied, e.g. modeling techniques"
223675644|NCT01346995|OTHER|Experimental knee pain|Injection of 1 ml hypertonic saline (5.8%) into the infrapatellar fat pad
223675645|NCT01346995|OTHER|Non-painful control injections|Injection of isotonic saline into the infrapatellar fat pad
223675646|NCT02622997|OTHER|Cervico-vaginal self-sample taken with first flocked swab|Cervico-vaginal self-sample taken with first flocked swab
223675647|NCT02622997|OTHER|Cervico-vaginal self-sample taken with a second flocked swab|Cervico-vaginal self-sample taken with a second flocked swab
223675648|NCT02622997|OTHER|Cervico-vaginal self-sample taken with a HerSwab device|Cervico-vaginal self-sample taken with a HerSwab device
223675649|NCT03351101|DEVICE|Senofilcon C|Senofilcon C Contact Lens
223675650|NCT03351101|DEVICE|Samfilcon A|Samfilcon A Contact Lens
223675651|NCT00423787|BIOLOGICAL|Ragweed MATA MPL|"4 injections of increasing dose strength:~1. 300 SU/0.5 ml~2. 700 SU/0.5 ml~3. 2000 SU/0.5 ml~4. 6000 SU/0.5 ml"
223675652|NCT02216812|DRUG|500 mg vitamin c, 1 pill per day for 6 weeks|
223675653|NCT02216812|DRUG|1 placebo pill for 6 weeks|
224257239|NCT02301975|DRUG|Fluticasone Propionate/Salmeterol 250/50 mcg via ACCUHALER/DISKUS inhaler|FP/Salmeterol 250/50 mcg inhalation powder administered twice daily via ACCUHALER/DISKUS inhaler. 60 doses per device and 250/50 mcg per actuation.
224257240|NCT02301975|DRUG|Placebo inhalation powder via ACCUHALER/DISKUS inhaler|Placebo inhalation powder administered twice daily via ACCUHALER/DISKUS inhaler. 60 doses per device.
224257241|NCT02301975|DRUG|Fluticasone Propionate 250 mcg via ACCUHALER/DISKUS inhaler|FP 250 mcg inhalation powder administered twice daily via ACCUHALER/DISKUS inhaler. 60 doses per device and 250 mcg per actuation.
224257242|NCT02663960|OTHER|fixed citrate doses protocol|fixed doses of anticoagulant citrate dextrose solution to meet a circuit citrate concentration of 4 mmol/l.
224257243|NCT02663960|OTHER|adjusted citrate doses protocol|the starting infusion rate of anticoagulant citrate dextrose solution be set 2.5 % of blood flow and then be adjusted to obtain postfilter ionized calcium levels of less than 0.40 mmol/l.
224257244|NCT01038960|BEHAVIORAL|Exercise training|3 months supervised interval training
224257245|NCT03809130|OTHER|Internet-Based Intervention|Use Untire application after baseline up to 6 months
224257246|NCT03809130|OTHER|Internet-Based Intervention|Use Untire application after 3 months up to 6 months
224257247|NCT03809130|OTHER|Quality-of-Life Assessment|Ancillary studies
224257248|NCT03809130|OTHER|Questionnaire Administration|Ancillary studies
223675654|NCT00527488|DRUG|Degarelix|Two doses of 16 mg each administered as two administrations (separated by 14 days) will be evaluated for 42 days.
223675655|NCT00527488|DRUG|Degarelix|One dose of 32 mg administered as a single administration will be evaluated for 42 days.
223675656|NCT00527488|DRUG|Degarelix|Two doses of 32 mg each administered as two administrations (separated by 14 days) will be evaluated for 42 days.
223675657|NCT00527488|DRUG|Degarelix|One dose of 64 mg administered as a single administration will be evaluated for 42 days.
223675658|NCT01958827|BIOLOGICAL|Adalimumab|Adalimumab pre-filled syringe, administered by subcutaneous injection.
224257249|NCT01959568|PROCEDURE|Vitrectomy and tamponade|"In the double tamponade arm the result of surgery is vitreous cavity filled in a half with perfluorodecalin and in another half - with silicone oil.~In the silicone oil tamponade arm the result of surgery is vitreous cavity filled with conventional or heavy silicone oil, depending on predominant retinal breaks location."
224257250|NCT04438187|OTHER|antimicrobial initiation|antimicrobial initiation based on protocol assignment.
224257251|NCT01095315|OTHER|lateral positioning|the lateral position was maintained for 6 min after spinal injection before patients were turned to the supine position
224257252|NCT05349435|DRUG|Fezagepras|Investigational drug
224257253|NCT05349435|DRUG|Sodium phenylbutyrate|Investigational drug
223675659|NCT06134531|DRUG|MR001|"Dose Level 1: 0.5 mg/kg Intravenously (IV) Frequency: administered on Day 1 of each cycle (every 3 weeks), 1 cycle~Dose Level 2: 2 mg/kg Intravenously (IV) Frequency: administered on Day 1 of each cycle (every 3 weeks), 4 cycle~Dose Level 3: 6 mg/kg Intravenously (IV) Frequency: administered on Day 1 of each cycle (every 3 weeks), 4 cycle~Dose Level 4: 10 mg/kg Intravenously (IV) Frequency: administered on Day 1 of each cycle (every 3 weeks), 4 cycle~Dose Level 5: 15 mg/kg Intravenously (IV) Frequency: administered on Day 1 of each cycle (every 3 weeks), 4 cycle~Dose Level 6: 20 mg/kg Intravenously (IV) Frequency: administered on Day 1 of each cycle (every 3 weeks), 4 cycle"
224257254|NCT02186691|OTHER|MRI|
224257255|NCT03091335|OTHER|Music-listening|Patients listen to music on headphones
224257256|NCT01931722|DIETARY_SUPPLEMENT|Branched chain amino acid|seven graded intakes of a BCAA (branched chain amino acid) mixture from 50 to 350 mg.kg-1.d-1 will be used to measure BCAA requirement
224257257|NCT01931722|BEHAVIORAL|Strength training|"Strength training will include a split-training program using all major muscle groups of the body on a three day on, one day off protocol. Muscle areas targeted on each training day will be as follows: Day1: chest, shoulder, triceps; Day2: back, biceps; Day3: legs and calfs; Day4: will be a rest day. On Day5: this cycle will begin again. A combination of free weights and machines will be used for each training day. Progressive overload protocol will be applied where the load used by every participant will be adjusted bi-weekly based on their 70% of 1 repetition maximum (maximum weight that can be lifted only one time). Instruction will be provided for all exercises and professional trainers will oversee all training sessions."
224257258|NCT03733730|DEVICE|ACRYSOF IQ RESTOR +3.0 Multifocal Toric IOL|Intraocular lens (IOL) intended for visual correction of aphakia in adult patients with and without presbyopia, who desire near, intermediate and distance vision, reduction of residual cylinder and increased spectacle independence. IOLs are implantable medical devices and are intended for long term use over the lifetime of the cataract subject.
224257259|NCT03733730|DEVICE|ACRYSOF IQ RESTOR +2.5 D Multifocal Toric IOL|Intraocular lens (IOL) intended for visual correction of aphakia in adult patients with and without presbyopia, who desire near, intermediate and distance vision, reduction of residual cylinder and increased spectacle independence. IOLs are implantable medical devices and are intended for long term use over the lifetime of the cataract subject.
224257260|NCT03733730|DEVICE|ACRYSOF IQ RESTOR +2.5 D Multifocal IOL|Intraocular lens (IOL) intended for visual correction of aphakia in adult patients with and without presbyopia, who desire near, intermediate and distance vision with increased spectacle independence. IOLs are implantable medical devices and are intended for long term use over the lifetime of the cataract subject.
224257261|NCT03733730|PROCEDURE|Cataract Surgery|Routine small incision cataract surgery with IOL implantation
224257262|NCT00685607|DRUG|loperamide-simethicone|Four caplets containing 2 mg loperamide HCl and 125 mg of simethicone each, administered orally with 4-8 oz. of water according to the labeled directions of the currently marketed product (i.e., 2 caplets after first loose stool, followed by 1 caplet after each subsequent loose stool, not to exceed 4 caplets in 24 hours). The treatment period will last six hours.
224257263|NCT00685607|DRUG|matching placebo|Four placebo caplets matching the caplets in Arm 1, administered orally with 4-8 oz. of water according to the labeled directions of the currently marketed product (i.e., 2 caplets after first loose stool, followed by 1 caplet after each subsequent loose stool, not to exceed 4 caplets in 24 hours). The treatment period will last six hours.
224257264|NCT03789565|OTHER|Biomarker test|Diagnostic biomarker study
224322493|NCT00970827|PROCEDURE|remote ischemic postconditioning|Three 5- minute cycles of blood pressure cuff inflation according to the assigned group. The cuff is inflated to 200 mm Hg (and at least 20 mmHg above the systolic blood pressure) for 5 minutes followed by a 5-minute deflation (reperfusion).
223675660|NCT01947907|DRUG|ACP-001|Once weekly subcutaneous injection
223675661|NCT01947907|DRUG|Human Growth Hormone|Once daily subcutaneous injection of human Growth Hormone
223675662|NCT00604214|DRUG|Drotrecogin alfa (activated)|24 microgram/kilogram/hour, intravenous, 96 hours (hr)
223675663|NCT00604214|DRUG|Placebo|0.9% sodium chloride, intravenous, 96 hours
223675664|NCT03409887|PROCEDURE|Intraorifice barrier of GIC|After primary root canal treatment, Glass Ionomer Cement (KetacTM Molar, 3M ESPE) applied as intraorifice barrier 3mm inside canal from root canal orifice in first group, as 2mm base on floor of pulp chamber in second group and direct composite restoration in 3rd group without Intraorifice barrier or base.
223675665|NCT03409887|PROCEDURE|Base of GIC|After primary root canal treatment, Glass Ionomer Cement (KetacTM Molar, 3M ESPE) applied as intraorifice barrier 3mm inside canal from root canal orifice in first group, as 2mm base on floor of pulp chamber in second group and direct composite restoration in 3rd group without Intraorifice barrier or base.
223675666|NCT03409887|PROCEDURE|Direct composite restoration|After primary root canal treatment, Glass Ionomer Cement (KetacTM Molar, 3M ESPE) applied as intraorifice barrier 3mm inside canal from root canal orifice in first group, as 2mm base on floor of pulp chamber in second group and direct composite restoration in 3rd group without Intraorifice barrier or base.
223675667|NCT00288743|DRUG|to implement an insulin protocol with target blood glucose levels between 81-110 mg/dL.|
223675668|NCT04355611|OTHER|Evaluation of the epidemiological characteristics of coronavirus infection (SARS-CoV-2)|Epidemiological characteristics of coronavirus infection (SARS-CoV-2) in patients with MS or NMO
223675669|NCT01643980|DRUG|Vaginal micronized progesterone|200 mg vaginal route per day
223675670|NCT01643980|DEVICE|Cervical pessary|Cervical pessary certified by European Conformity (CE0482, MED/CERT ISO 9003/EN 46003;Dr Arabin, lower larger diameter 70 mm, height 30 mm,and upper smaller diameter 32 mm)
223675671|NCT02653261|DRUG|Tranexamic Acid|Tranexamic acid (TXA) is a synthetic analog of serin than reversibly inhibits fibrinolysis by blocking lysine union sites in the plasmin and plasminogen activator molecules. TXA: bolus of 10 mg/kg thirty minutes before resection followed by infusion of 1 mg/kg/h intraoperatively and for 24 h postoperatively
223675672|NCT02653261|DRUG|Placebo|An equal volume of saline
223675673|NCT01066676|DRUG|Dexibuprofen|400mg powder for oral suspension, daily dose 800mg
223675674|NCT01066676|DRUG|Ibuprofen|400mg, powder for oral suspension, daily dose 1600mg
223675675|NCT05780151|OTHER|Methodological intervention|All three arms will receive the same clinical intervention but will differ in their level of decentralisation, the methodological intervention.
224257265|NCT01401803|DRUG|Dysport|Patients entering will be based on gender and assessment of the glabella region (including the corrugators, procerus, and medial frontalis muscles). Muscle mass will be graded separately for males and females as +, ++, or+++ (light/small, moderate/medium, or heavy/large). Male patients will receive 0.3 mL to 0.4 mL (60, 70, or 80 units) in five equally divided doses of Dysport™ and female patients will receive 0.25 mL to 0.35 mL (50, 60 or 70 units) in equally divided doses of Dysport™ at 5 designated injection sites in the glabellar region. On (Day0) patients will be treated with Dysport™ 10 to 20 units bilaterally to the depressor component of the orbicularis. The dosing for patients will be based on assessment of orbicularis muscle mass. Patients will receive .05 mL to 0.1 mL (10 or 20 units) in two equally divided doses of Dysport™. Muscle mass will not be graded based upon gender for this region.
224257266|NCT01531894|DRUG|GSK2110183 (afuresertib)|Afuresertib is an oral, low nanomolar pan-AKT kinase inhibitor immediate release (IR) 50 mg or 75 mg tablets was to be taken orally with at least 200 mL of water, with or without food, in the morning.
224257267|NCT02674880|DRUG|HMW-HA|Aerolized administration b.i.d.
224257268|NCT02674880|OTHER|Placebo|Standard therapy
224257269|NCT06282874|DRUG|Lorlatinib|Lorlatinib 100 mg once daily on days 1 to 28 of each 28-day cycle
224257270|NCT03086460|DRUG|CHF 1531 pMDI|Dose Response: Test one of five different doses of CHF 1531
224257271|NCT03086460|DRUG|Formoterol Inhalation Solution|Active Control
224322494|NCT06894875|DIETARY_SUPPLEMENT|Lentil protein hydrolysate|Plant protein hydrolysate
224322495|NCT06894875|DIETARY_SUPPLEMENT|Placebo MCC micro-crystalline cellulose|Placebo MCC micro-crystalline cellulose
224322496|NCT01700231|PROCEDURE|Liver resection|Liver resection of patient with neoplastic hepatic tumors
223675676|NCT05780151|DRUG|Toujeo|All participants in the study will receive Toujeo® (insulin glargine 300 U/mL). During the treatment period, Toujeo® injection will be administered once daily at the same time as the participant's previous basal insulin was injected, for participant previously treated with once daily injection. In case of previous insulin treatment administered twice a day, the time of injection of Toujeo® will have to be agreed between the physician and the participant before first administration.
224257272|NCT03086460|DRUG|Placebo pMDI|Matched Placebo
224257273|NCT01831362|BEHAVIORAL|Mindfulness-Based Cognitive Therapy|
224257274|NCT01831362|BEHAVIORAL|Focused Attention (FA)|
223675677|NCT03189056|DIAGNOSTIC_TEST|Chagas serology|IFI + ELISA method if no biological confirmation of chagas disease is in our possession
223675678|NCT03189056|BIOLOGICAL|Creatinina|Plasmatic single mesure after consultation 1, to evaluate renal function
223675679|NCT03189056|PROCEDURE|Urodynamic exploration|With a new equipement SmartDyn Albynmedical imported from Spain for the study Single use sterile equipment shipped Control of urine sterility before procedure Informed consent signed If acquired urinary infection after procedure, patient treated free of charge and clinical evolution controlled
223675680|NCT06982495|DEVICE|NCKU-NG system|Nasogastric tube insertion with a novel nasogastric tube assisted placement system (NCKU-NG system)
223675681|NCT06982495|OTHER|Conventional blind insertion|Conventional blind insertion following standard external measurement methods (eg. Nose-Earlobe-Xiphoid + 10 cm)
223675682|NCT06994039|PROCEDURE|EUS-lePPG|EUS-PPG measured in left lateral decubitus position
223675683|NCT04892017|DRUG|Inlexisertib|Oral Tablet Formulation
223675684|NCT04892017|DRUG|Trametinib|Oral Tablet Formulation
223675685|NCT04892017|DRUG|Binimetinib|Oral Tablet Formulation
223675686|NCT04892017|DRUG|Sotorasib|Oral Tablet Formulation
223675694|NCT04317482|BEHAVIORAL|Standard social stress task|Participants will be asked to respond in detail to three scenarios. This is a standard social stressor task. Participants may be prompted by an experimenter. However, the participant will receive no verbal nor nonverbal feedback.
223675695|NCT04317482|BEHAVIORAL|Stressful experience in the ED|Participants will be asked to imagine and then describe both feelings and bodily sensations experienced at their most stressful ED visit, in order to help them more fully re-experience the situation. In this regard, the second condition is more similar to stress imagery employed by Sinha et al, which elevated cortisol to a greater degree than a social stressor task. Participants may be prompted by an experimenter. However, the participant will receive no verbal nor nonverbal feedback.
224257275|NCT01831362|BEHAVIORAL|Open- Monitoring|
224257276|NCT05433857|DRUG|Lacteol forte capsules|probiotic Lacteol Forte® capsules (5 billion heat-killed Lactobacillus LB, corresponding to lactobacillus delbruekii and lactobacillus fermentum) Two capsules are To be taken once daily
224257277|NCT03625063|OTHER|Exercise training group|All exercise program will be applied during supervised session by a physiotherapist. Range of maximal heart rate will be screened by heart rate monitor during supervised session each day at patient's room. Inspiratory muscle training (threshold loading device (Threshold®- Inspiratory Muscle Trainer) at 20-30% of maximal inspiratory pressure (MIP)), upper extremity aerobic exercise training (arm ergometer, at 60-80% of maximum heart rate, dyspnea perception at 3-4 level as well as fatigue perception at 5-6 level according to Modified Borg Scale) and progressive resistance training (shoulder flexors, shoulder abduction and knee extensors at 4-6 level according to modified Borg scale) will be performed in the treatment group during acute hematopoietic stem cell transplantation process.
224322497|NCT03736031|BEHAVIORAL|Intervention (Promotora)|If the patient is in the intervention group, the promotora will call the patient in order to invite them to a meeting. Meetings will be arranged by the promotora and the patients. A total of 2 group meetings will be required by all participants and 1 family meeting.
224322498|NCT00334373|PROCEDURE|Post conditioning|4 cycles of balloon inflation /deflation (post-conditioning) within first minute of opening up artery in primary PCI for STEMI vs usual balloon inflation sequence
224322499|NCT03461601|PROCEDURE|HCG Uterine flushing|HCG Uterine flushing was done one day before IUI with HCG (500 IU) in 10 ml of saline.
223675700|NCT04095234|PROCEDURE|Acupuncture|Acupuncture, a therapy of traditional Chinese medicine (TCM), involves penetrating the skin with thin, solid, metallic needles that are manipulated by hand or electrical stimulation. If the patient has an electronically charged device, they will not receive TENS stimulation.
223675701|NCT04095234|PROCEDURE|Massage|Massage, which involves the manual manipulation of muscles and other soft tissue areas of the body, is one of the earliest known forms of pain relief.
223675702|NCT04543617|DRUG|Tiragolumab|Tiragolumab at a fixed dose of 600 milligrams (mg) administered by intravenous (IV) infusion every 3 weeks (Q3W) on Day 1 of each 21-day cycle.
223675703|NCT04543617|DRUG|Atezolizumab|Atezolizumab at a fixed dose of 1200 mg administered by IV infusion Q3W on Day 1 of each 21-day cycle.
223675704|NCT04543617|DRUG|Tiragolumab Matching Placebo|Tiragolumab matching placebo administered by IV infusion Q3W on Day 1 of each 21-day cycle.
223675705|NCT04543617|DRUG|Atezolizumab Matching Placebo|Atezolizumab matching placebo administered by IV infusion Q3W on Day 1 of each 21-day cycle.
223675706|NCT05957367|DRUG|Inlexisertib|Oral Tablet Formulation
223675707|NCT05957367|DRUG|Ripretinib|Oral Tablet Formulation
224257278|NCT03625063|OTHER|Control training group|All exercise program will be applied during supervised session by a physiotherapist. Range of maximal heart rate will be screened by heart rate monitor during supervised session each day in patient's room.Upper extremity aerobic exercise training (arm ergometer, at 60-80% of maximum heart rate, dyspnea perception at 3-4 level as well as fatigue perception at 5-6 level according to Modified Borg Scale) and progressive resistance training (shoulder flexors, shoulder abduction and knee extensors at 4-6 level according to modified Borg scale) except inspiratory muscle training will be performed in the control group during acute hematopoietic stem cell transplantation process.
224257279|NCT04169633|DIAGNOSTIC_TEST|Cognitive Function Evaluation|Evaluation of cognitive function and evaluation of daily cognition
224257280|NCT05270135|BEHAVIORAL|ASAP|ASAP is an intervention geared toward increasing non-stigmatized syringe sales to people who inject drugs to prevent bloodborne illnesses.
224257281|NCT01747135|DRUG|VTS-270|
224322500|NCT03461601|PROCEDURE|IUI|Intrauterine insemination (IUI)
224322501|NCT03461601|PROCEDURE|Vaginal flushing with 10 ml normal saline|Flushing of the vagina with 10 ml of saline
224257282|NCT00272519|BEHAVIORAL|Life Skills Intervention|Developed to promote life skills among young adolescents perinatally infected with HIV
224257283|NCT02838160|BEHAVIORAL|Routine Care|After baseline measurement, Group 1 did not receive any intervention or education.
224322502|NCT05147012|OTHER|Data collected|"The variable of the characteristic of the patients (i.e.: age, sex, hypertension, diabetes, atrial fibrillation, coronary arteries diseases, body mass index (BMI), surgery, medications) were retrieved from the anesthesia consultation file (Easily, Hospices Civiles de Lyon, France).~We retrieved the mean arterial pressure from our local anesthesia software for each patient ( Diane®, Bow medical, Amiens France). We also performed an automatic extraction of data from our anesthesia software (Diane, Bow Medical, France) with a rate of 1 value / minute for some continuous arterial pressure.~All data was extracted from our institutional database and collected by a physician who was not involved in the care of the study patients."
224257284|NCT02838160|BEHAVIORAL|Routine care Plus the designed booklet|Group 2 received only the designed booklet without any participation in the oral presentation.
224257285|NCT02838160|BEHAVIORAL|Routine care Plus the designed booklet Plus participation in oral presentations|Group 3 participated in oral presentations 14 days after completing self-study booklet. Interactive, standardized and mandatory oral presentations were held five times to ensure maximum attendance of the three nursing shifts.
223675708|NCT06510205|DEVICE|Mentor Breast implants|"Mentor breast implants are circular or waterdrop-shaped devices with shells made of successive cross-linked layers of silicone elastomer. The shell is filled with Mentor's proprietary formulation of silicone gel.~Mentor breast implants are available in smooth and textured shells, both supplied in sterile form."
224257286|NCT02838160|BEHAVIORAL|Routine care Plus the designed booklet Plus participation in oral presentations Plus clinical teaching in bedside|The Group 4 received clinical teaching in bedside after completing self-study booklet and a series of interactive, standardized and mandatory 90-120-minute oral presentations.
224257287|NCT03057730|BIOLOGICAL|Acellular Dermal Matrix|ADM is a human-derived allograft material, treated to remove all cellular components so that only the connective tissue matrix remains.
223675711|NCT04882098|DRUG|Guselkumab|Participants will receive guselkumab as SC injection.
223675712|NCT04882098|DRUG|Placebo|Participants will receive matching placebo as SC injection.
224257288|NCT04364581|DRUG|Letrozole|Women will be treated with letrozole (5 mg daily) for 10 days before hysteroscopic intervention
224257289|NCT04364581|DRUG|Placebo|Women will be treated with placebo for 10 days before hysteroscopic intervention
224257290|NCT00551863|BEHAVIORAL|IVPT|Violence prevention intervention based on Motivational Interviewing and CBT
224257291|NCT03448263|PROCEDURE|Balanced Force technique|Flex-R files sizes 15-45 taper .02 were used according to the technique on each tooth
224257292|NCT03448263|PROCEDURE|WaveOne technique|"WaveOne instrument was used to prepare narrow, straight and curved canals, and file (40.08) was used for large canals.~Three in-and-out motions were used with lengths not beyond 3 mm in the three thirds of the canal until reaching the estimated WL."
224257293|NCT03448263|PROCEDURE|Reciproc technique|Reciproc files were used in wide canals. Three in-and-out motions were used with lengths not beyond 3 mm in the three thirds of the canal until reaching the estimated WL.
224257294|NCT06628063|OTHER|ultrasound evaluation|Ultrasound scan of fetus in second and third trimestrers
224257295|NCT05003232|DEVICE|Near-infrared spectroscopy (NIRS) and ICM+|The intervention group will be given continuous NIRS and invasive blood pressure monitoring at same time. The correlation curve between the brain oxygenation index or the brain hemoglobin index (ORI/THx) and the blood pressure will be obtained through continuous monitoring. According to the correlation curve, the optimal blood pressure will be determined which provides the optimal CPP. Then the goal of blood pressure (within 5 mmHg of CPPopt) will be maintained as the target of blood pressure management for the intervention group during ICU stay.
224322503|NCT00649779|DRUG|albuterol sulfate extended-release 8 mg tablets|8mg, single dose fasting
224322504|NCT00649779|DRUG|VoSpire™ ER 8 mg tablets|8mg, single dose fasting
224322505|NCT04244578|DEVICE|Active tDCS|Active tDCS will be delivered to parieto-occipital areas for five consecutive days. tDCS will be delivered by a battery driven, direct current stimulator through a pair of saline-soaked sponge electrodes kept firm by elastic bands. The electrodes will be placed on the left (anodal) and right (cathodal) parieto-occipital areas, PO7 and PO8 position according to the 10-20 international EEG system for electrode placement. Stimulation intensity will be set at 1 milliampere (mA), the duration of stimulation will be 20 min.
224257296|NCT00202462|DRUG|Testosterone gel|Testosterone gel 7.5 gm qd
224257297|NCT00835575|DRUG|Mirtazapine 15 mg (Orally Disintegrating) Tablets|1 x 15 mg, single-dose fasting
224257298|NCT00835575|DRUG|REMERON SolTab® 15 mg Orally Disintegrating Tablets|1 x 15 mg, single-dose fasting
224257299|NCT05244213|BIOLOGICAL|Sintilimab|200mg Q3W
224257300|NCT05244213|DRUG|Carboplatin|AUC 5, d1 every 3 weeks
224257301|NCT05244213|DRUG|Nab paclitaxel|260 mg/m2, d1 every 3 weeks
223675716|NCT04702425|DRUG|VOB560|Powder for concentrate for solution for infusion
223675717|NCT04702425|DRUG|MIK665|Concentrate for solution for infusion
223675718|NCT04939051|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223675719|NCT04939051|PROCEDURE|Esophageal Biopsy|Undergo esophageal biopsy, brushings and gastric aspirate
223675720|NCT04939051|PROCEDURE|Esophagogastroduodenoscopy|Undergo EGD
223675721|NCT04939051|PROCEDURE|Liver Ultrasonographic Elastography|Undergo liver ultrasound with elastography
223675722|NCT04939051|BIOLOGICAL|Obeticholic Acid|Given PO
223675723|NCT04939051|DRUG|Placebo Administration|Given PO
223675724|NCT04939051|OTHER|Questionnaire Administration|Ancillary study
224257302|NCT01882686|OTHER|Classification Based Cognitive Functional Therapy|A novel multidimensional classification system has been developed incorporating the biopsychosocial model, which subgroups patients based on their presentation. This subclassification is the base for matched interventions directed at the maladaptive cognitive, physical and lifestyle behaviours associated with the disorder. The intervention is called 'cognitive functional therapy' as it directly challenges these behaviours in a functionally specific and graduated manner.
224257303|NCT01440803|DRUG|Teriparatide|Daily injection of 20 mcg teriparatide for the treatment of idiopathic osteoporosis for 24 months.
224257304|NCT01440803|DRUG|Saline Placebo|Daily injection of saline placebo for 6 months, followed by teriparatide treatment for 24 months.
223675736|NCT04452149|DEVICE|Reveal LINQ™ Insertable Cardiac Monitor with investigational ALLEVIATE-HF RAMware download|Reveal LINQ™ Insertable Cardiac Monitor with investigational ALLEVIATE-HF RAMware download.
223675737|NCT04452149|OTHER|Medication intervention|Risk status guided medication intervention.
224257305|NCT04842123|DIAGNOSTIC_TEST|Electrocardiogram|Simultaneous assessment of the heart rhythm determined from a 12-lead ECG and the Garmin ECG software algorithm heart rhythm classification on single-lead ECG data derived from the wearable device. All participants will record three simultaneous 12-lead and single-lead ECGs.
224257306|NCT06626724|PROCEDURE|Liver transplantation|Liver transplantation for patients with hepatocellular carcinoma.
224257307|NCT02742558|BIOLOGICAL|Cholvax|Incepta vaccine Limited, a leading pharmaceutical company in Bangladesh is now producing the OCV, Cholvax with technological support from International Vaccine Institute (IVI), which meets international Good Manufacturing Practice (GMP) standards and WHO production guidelines. Cholvax has the same formulation as ShancholTM in terms of strains and formulation.
224257308|NCT02742558|BIOLOGICAL|Shanchol|The vaccine is manufactured by Shantha Biotechnics, in Hyderabad, India and is prequalified by the WHO. Shanchol™ is available in a single dose vial.This vaccine is used as two dose regimen.
224257309|NCT00004796|DRUG|lactulose|
224257310|NCT03004703|DRUG|Tocilizumab|Active drug: Tocilizumab, 20 mg/ml; 14 ml (280 mg) dissolved in 100 ml NaCl 0.9 % i.v. once.
224257311|NCT03004703|DRUG|Sodium chloride 0.9%|Placebo: Sodium chloride 0.9%; 100 ml i.v. once.
224257312|NCT04676503|DIETARY_SUPPLEMENT|BIOVAGINIL|Biovaginil is a notified food supplement formulated as 480 mg capsules. Each capsule contains Lactobacillus crispatus NTCVAG04 3 billion and Vitamin A 120 μg.
224257313|NCT03607253|OTHER|repetitive heel rise activity|Participants will perform a maximal number of single-legged heel rises on a 10 degrees incline board. Participants will be permitted to apply for fingertip support at shoulder height on a wall in front of them. The test will be terminated when participants could no longer lift their heels from the incline board. The number of correct heel rises will be counted for each leg and will be used as Heel Rise Test score.
224257314|NCT02466451|OTHER|Questionnaires|"For not collaborative patients, under the age of 4 years:~* Standardized questionnaire collecting anamnestic-clinical data~* Stress Parenting Index questionnaire and COPE brief questionnaire(Questionnaire assessing adaptation strategies of parents).~For collaborative patients, over the age of 4 years:~* Standardized questionnaire collecting anamnestic-clinical data~* Fractional exhaled nitric oxide (FeNO) assessment (oral and alveolar )~* Spirometry~* 6-minutes walk test (WT 6')~* Prick tests~* Children Quality of life questionnaire (KINDL questionnaire)~* Psychological test (Raven Matrices)~* Stress Parenting Index questionnaire and COPE brief questionnaire (Questionnaire assessing adaptation strategies of parents)"
224257315|NCT03606174|DRUG|Sitravatinib|Sitravatinib is a small molecule inhibitor of receptor tyrosine kinases
224257316|NCT03606174|DRUG|Nivolumab|Nivolumab is a programmed death receptor-1 (PD-1) blocking antibody
224257317|NCT03606174|DRUG|Pembrolizumab|Pembrolizumab is a programmed death receptor-1 (PD-1) blocking antibody
224257318|NCT03606174|DRUG|Enfortumab vedotin|Enfortumab is a Nectin-4 directed antibody-drug conjugate (ADC) comprised of a monoclonal antibody conjugated to the small molecule microtubule disrupting agent, monomethyl auristatin E (MMAE)
224257319|NCT04968821|BEHAVIORAL|Physical activity intervention|Participants randomized to the physical activity intervention will receive a Fitbit and be enrolled in Fitabase (Fitbit tracking system). Participants will also participate in 8 tele-health sessions with a physical therapist. Sessions will involve setting weekly physical activity goals and reviewing the participant's physical activity on the Fitbit tracking system.
224257320|NCT04968821|OTHER|Usual care|Usual postoperative care includes surgeon-directed lifting restrictions, advice to stay active, and oral analgesics as needed. Physical therapy referral will be at the discretion of the surgeon. However, physical therapy is not typically started until 12 weeks after surgery.
224257321|NCT04762966|DRUG|Metformin|Level of Metformin blood concentration
224257322|NCT04422457|OTHER|68Ga-DX600 PET/CT|DX600, labeled with 68Ga will be used as a molecular imaging tracer for PET/CT scanning
224257323|NCT01609257|BIOLOGICAL|Norovirus Bivalent Vaccine|2 doses IM 28 days apart
224257324|NCT01609257|BIOLOGICAL|Saline Comparator|2 doses IM 28 days apart
224257325|NCT02010918|DRUG|glucosamine sulfate /chondroitin sulfate - capsules|500 mg glucosamine sulfate + 400 mg chondroitin sulfate - capsules; One capsule, three times daily.
224257326|NCT02010918|DRUG|glucosamine sulfate /chondroitin sulfate - sachet|1500 mg glucosamine sulfate / 1200 mg chondroitin sulfate - sachet; One sachet preparation, once daily.
224257327|NCT02010918|DRUG|Cosamin DS®|500 mg glucosamine hydrochloride + 400 mg chondroitin sulfate - Capsules; One capsule, three times daily.
224257328|NCT02125461|DRUG|MEDI4736|MEDI4736 by intravenous infusion. Treatment from Day 1 for a maximum of 12 months or study drug withdrawal if this occurs earlier . The 2:1 ratio (MEDI4736 to placebo).
224257329|NCT02125461|OTHER|PLACEBO|PLACEBO by intravenous infusion. Treatment from Day 1 for a maximum of 12 months or study drug withdrawal if this occurs earlier . The 2:1 ratio (MEDI4736 to placebo).
224257330|NCT04848987|PROCEDURE|Etching|Etching enamel surface using phosphoric acid
224257331|NCT02380976|DRUG|combination drug: DW330SR, DW1030|
224257332|NCT02380976|DRUG|DW340|
224257333|NCT02649335|DRUG|Propranolol|Propranolol will be started at a dose of 40 mg and will be titrated based on pulse rate with target of 55-60 beats per minute or 20-25% reduction in heart rate and maximum tolerated dose.If any patients develop intolerable side effects, they will be withdrawn from the study
224257334|NCT02649335|PROCEDURE|Endoscopic variceal ligation (EVL)|Patients in EVL group will undergo regular sessions of UGIE with EVL till variceal eradication every 2- 4 weekly followed by 3 monthly for initial 6 months and 6 monthly in rest of the study period. If any patient develop acute variceal hemorrhage on follow up , will be treated inpatient with standard medical therapy(SMT) .
224257335|NCT05493735|DRUG|Lidocaine Hcl 2% Jelly|Participants in the experimental arm will undergo pessary removal and reinsertion after the application of lidocaine topical gel.
224257336|NCT05493735|DRUG|Placebo Jelly|Participants in the control arm will undergo pessary removal and reinsertion after the application of lubricating jelly.
223675774|NCT06445543|BEHAVIORAL|MFeast ENHANCED|The intervention group will initially receive 10 weekly prepared heart-healthy meals from MFeast; Lactation nutritional snack bundles to boost milk supply + structural support for breastfeeding/ pumping via lactation consultants and pumping supply subsidization; culturally-adapted seasoning bundles; and dependent meal boxes for children in the household (i.e., will include 10 developmentally appropriate snack and small meal bundles, for up to 24 weeks. At postpartum week 8 participants will be offered a transition from prepared medically tailored meals to Instacart fresh food delivery (medically tailored via study team-crafted virtual grocery store) for 16 more weeks.
223675775|NCT06445543|BEHAVIORAL|MFeast Usual Care|"Those assigned to the MFeast Usual Care group will receive 10 weekly prepared heart-healthy meals from MFeast."
223675778|NCT04569123|DEVICE|real stimulation|Participants will undergo standardized hand task practice therapy (3 sessions/week for 6 weeks) with the watch worn on the paretic wrist. Participants will be randomized into two groups: The device will deliver vibration for the treatment group.
223675779|NCT04569123|DEVICE|No stimulation|Participants will undergo standardized hand task practice therapy (3 sessions/week for 6 weeks) with the watch worn on the paretic wrist. Participants will be randomized into two groups: The device will deliver no vibration for the control group during therapy.
223675780|NCT04068194|DRUG|Avelumab|Given IV
223675781|NCT04068194|PROCEDURE|Biopsy Procedure|Undergo biopsy of tumor
223675782|NCT04068194|PROCEDURE|Biospecimen Collection|Correlative studies
223675783|NCT04068194|PROCEDURE|Computed Tomography|Undergo CT scan
224257337|NCT06093984|PROCEDURE|duostim vs. two antagonist ovarian stimulations|Human menopausal gonadotropin (HMG) 300 IU/day with flexible antagonist protocol is used for ovarian stimulation, except in luteal phase stimulation of the duostim group. In the duostim group, all of the embryos are frozen. Fresh transfers are performed in the control group, frozen embryo transfers are performed in both control and duostim groups.
223675784|NCT04068194|RADIATION|Hypofractionated Radiation Therapy|Undergo hypofractionated RT
223675785|NCT04068194|DRUG|Peposertib|Given PO
224257338|NCT03084263|PROCEDURE|Arthroscopic Assisted Open Reduction Internal Fixation|Surgical fixation of ankle fractures with use of arthroscopy.
224257339|NCT03084263|PROCEDURE|Open Reduction Internal Fixation|Surgical fixation of ankle fractures.
223675786|NCT06948396|BIOLOGICAL|Tezepelumab|Tezepelumab is indicated as an add-on maintenance treatment in adult and adolescent ≥12 years patients with severe uncontrolled asthma despite high-dose inhaled corticosteroids plus long-acting β-agonists
223675789|NCT05133531|DRUG|Ravulizumab|Administered Intravenous (IV) per the protocol
223675790|NCT05133531|DRUG|Pozelimab|Administered IV and subcutaneous (SC) per the protocol
223675791|NCT05133531|DRUG|Cemdisiran|Administered SC per the protocol
223675792|NCT05133531|DRUG|Eculizumab|Administered IV per the protocol
224257340|NCT00714935|BEHAVIORAL|Decision Counseling Program (DCP)|An individual decisional counseling program (DCP) to help them comprehend the information, adjust this information to their personal illness history and elicit their preferences for cardiac risk fctor modification behavior in light of this personalized information
224257341|NCT00714935|BEHAVIORAL|Coronary Artery Disease Decision Aid|"Coronary Artery Disease Decision Aid (CAD-DA) presented as a booklet called: Making Choices: Life Changes to Lower Your Risk of Heart Disease and Stroke~The CAD-DA is developed by the Ottawa Health Research Institute and Division of Clinical Epidemiology at Montreal General Hospital, in CAD patients facing the decision of making lifestyle changes to lower their cardiac risk factors and provides patients with information about what they can you do to prevent the disease from progressing."
224257342|NCT05393050|DRUG|Colquhounia Root Tablet|Colquhounia Root Tablet is a tripterygium preparation
224257343|NCT05393050|DRUG|Methotrexate tablets|Methotrexate is a drug used to treat rheumatoid arthritis
224257344|NCT00994058|DEVICE|Electrical Inhibition (EI) Uterine Pacemaker|"An external powered pulse generator, pacemaker for external stimulation of the uterine muscle through the vaginal canal for the therapeutic use of preventing preterm birth.~Patients with preterm contractions (\< 37 weeks gestation) will be monitored for contraction frequency for 20 minutes before, 20 minutes during use of EI and 20 minutes after EI/uterine inhibitor/pacemaker. Device generates a weak electrical current (0-10mA, 0-50 Hz, 0-50mS)."
224257345|NCT01602575|BEHAVIORAL|Mindfulness based Stress Reduction Training (MBSR)|8 (2 hr) classes weekly of MBSR and required homework of MBSR practice approximately 30 minutes per day.
224257346|NCT01409499|PROCEDURE|hepatic resection|palliative hepatectomy followed by sorafenib
224257347|NCT01409499|PROCEDURE|transcatheter hepatic arterial chemoembolization|TACE followed by sorafenib
224257348|NCT01409499|DRUG|sorafenib|sorafenib monotherapy, 400mg Bid, continuously
224257349|NCT01888276|OTHER|evaluation of word generation and of motivation|"Each subject will realize twice each test during 2 sessions with one hour in between :~During the session 1 :~* The test of words generation, which is to produce action verbs in response to 40 nouns, and noun in response to verbs.~* The test of Stroop that assesses selective attention~During the session 2:~* The test of words generation, which is to produce action verbs in response to 40 nouns, and noun in response to verbs.~* The task of the casino (Iowa Gambling Test)~* The task of landing~* The test of Stroop"
224257350|NCT03747276|OTHER|Clinical Trial Kiosk|Kiosk will consist of a patient facilitator and a computer with access to general information about clinical trials and information specific to active clinical trials at the facility. Patients will be made aware of the kiosk via a large banner visible in the clinic above the kiosk.
224257351|NCT05028855|DIAGNOSTIC_TEST|Cerebral autoregulation assessment|Cerebral autoregulation assessment will be conducted by specialized neurovascular ultrasound doctors during 0-3 and 10-30 days after stroke onset.The recorded data will be stored for further cerebral autoregulation analysis.
224257352|NCT05219864|DRUG|Ruxolitinib cream|Ruxolitinib cream is a topical formulation applied as a thin film to affected areas.
224257353|NCT05219864|DRUG|Vehicle|Vehicle cream is a topical formulation applied as a thin film to affected areas.
224257354|NCT04670107|DRUG|Anlotinib in combination with Immune checkpoint inhibitors|Enrolled patients received anlotinib plus Pembrolizumab treatment (anlotinib, 8-12mg, qd, 2 weeks in a row and 1 week off; anti-PD1 injection or anti-PDL1 injection, Following instructions, iv.)
224257355|NCT04383587|OTHER|Serologic testing|COVID19 IgG antibody testing to be performed
224257356|NCT01916915|DRUG|Tramadol infusion via wound catheter|
223675814|NCT06376994|DEVICE|Air cleaner|The intervention is two active air cleaners with high efficiency particulate air (HEPA) filters which remove PM, as well as activated carbon filters to remove NO2 (and other trace gases). These will be run for a year in a participant's house.
223675815|NCT06376994|DEVICE|Sham air cleaner|The sham intervention is two sham air cleaners that have the internal HEPA and carbon filters removed, but which will run normally, including similar noise, airflow, and overall appearance compared to active air cleaners, thus blinding participants to filter status. These will be run for a year in a participant's house.
224257357|NCT01916915|DRUG|Levobupivacaine|
224257358|NCT04651036|DRUG|QL0605|a pegfilgrastim biosimilar to US Neulasta.
224257359|NCT04651036|DRUG|US Neulasta|US Neulasta
224257360|NCT04635007|DRUG|Tranexamic acid|100 women: will receive preoperative 1 gram of TXA (kapron®, Amoun, Egypt) 10 minutes before skin incision, by slow intravenous injection over 10 minutes (Tranexamic acid injection will be prepared by diluting 1gm (10ml) TXA in 100 ml. of normal saline. TXA will be administrated as an intravenous infusion or slowly injection) and preoperative placebo (4 tablets similar to misoprostol in size and shape as peroxide) will be administrated rectally.
224257361|NCT04635007|DRUG|Misoprostol 200mcg Tab|100 women: will receive preoperative 800 micrograms of misoprostol (4 tablets) rectally after spinal anesthesia and urinary catheterization (as per WHO dose recommendation) (Conde-Agudelo et al., 2013) and preoperative placebo (10 minutes before skin incision, 10 ml of distilled water ampoules by slow intravenous injection over 10 minutes).
224257362|NCT01158118|DRUG|Sargramostim|
224257363|NCT01158118|DRUG|Plerixafor|
224257364|NCT01488435|DIETARY_SUPPLEMENT|Cow's milk|Powdered whole cow's milk
224257365|NCT01488435|DIETARY_SUPPLEMENT|Follow-On Formula|Powdered Follow-On Formula with added long-chain Polyunsaturated fatty acid, prebiotics, and polysaccharide
224257366|NCT04994535|DRUG|OnabotulinumtoxinA|Injection
224257367|NCT04994535|DRUG|Placebo|Saline injection
223675826|NCT04750798|DEVICE|BWI Medical Device|Participants will be treated with commercially approved BWI medical devices following routine clinical practice. No specific intervention will be observed for this study.
224257368|NCT04410653|DRUG|Afatinib 40 MG|single oral dose of afatinib each day starting at a dose of 40 mg on day 1, continuously, until the development of progressive disease or unacceptable adverse events
224257369|NCT01524874|DIETARY_SUPPLEMENT|Vitamin D3|10,000 IU per Day for 12 Weeks
224257370|NCT01524874|DIETARY_SUPPLEMENT|Vitamin D3|10,000 IU per Day for 12 Weeks
224257371|NCT01524874|DIETARY_SUPPLEMENT|Vitamin D3|10,000 IU per Day for 12 Weeks
224257372|NCT05834543|DRUG|TQB2618 injection, Penpulimab injection, Paclitaxel, Cisplatin|"TQB2618 injection：Anti-TIM-3 monoclonal antibody. Penpulimab injection：Humanized Monoclonal Antibody to Programmed Cell Death Protein 1 (PD-1).~Paclitaxel and Cisplatin are chemotherapy."
224257373|NCT05834543|DRUG|Penpulimab injection, Paclitaxel, Cisplatin|"Penpulimab injection：Humanized Monoclonal Antibody to Programmed Cell Death Protein 1 (PD-1).~Paclitaxel and Cisplatin are chemotherapy."
224257374|NCT05834543|DRUG|TQB2618 injection, Penpulimab injection, TQB3617capsules|TQB2618 injection：Anti-TIM-3 monoclonal antibody. Penpulimab injection：Humanized Monoclonal Antibody to Programmed Cell Death Protein 1 (PD-1).
224257375|NCT02726360|BEHAVIORAL|survey|The ILR Scale, a non-English language proficiency self-assessment.
224257376|NCT02726360|BEHAVIORAL|Audio record|Audio record the initial visits between patients and their treating physician
224257377|NCT04197908|DEVICE|EUS-guided gallbladder drainage (EGBD)|As listed in the arms description
224257378|NCT05579262|DIETARY_SUPPLEMENT|Beetroot juice|Single-centre, two-arm study involving 16 weeks of beetroot juice supplementation
224257379|NCT05230758|DRUG|Metformin hydrochloride (HCl) 500mg tablet|"Metformin HCl 500mg tablets contain 500mg of active pharmaceutical ingredient (API) and are white, round, biconvex, film-coated tablets, with a score line on one face and debossed with HMR on the other. Each tablet contains the non-medicinal ingredients magnesium stearate and povidone. Tablet coating is comprised of hydroxypropyl methylcellulose, polyethylene glycol and titanium dioxide."
224257380|NCT05230758|DRUG|Placebo|Matching white round tablet containing excipients only. The placebo tablets will match the active drug as closely as possible in terms of appearance.
224257381|NCT00443274|OTHER|NBIR - US National Breast Implant Registry|NBIR is intended to be a surveillance tool to track patient safety and real-world outcomes associated with breast implants used for aesthetic or reconstructive purposes..
224257382|NCT00443274|DEVICE|410 Arm|Anatomically shaped silicone gel-filled breast implants.
224257383|NCT00443274|DEVICE|BIFs - Breast Implant Follow-Up Study|Round silicone gel-filled breast implants and saline-filled breast implants
223675827|NCT04750798|DEVICE|Varipulse Catheter|Participants treated with Varipulse Catheter in the main study will be part of the VARIPURE sub-study. No specific intervention will be observed for this study.
223675829|NCT06077864|DRUG|survodutide|once weekly subcutaneous injection
223675830|NCT06077864|DRUG|Placebo|once weekly subcutaneous injection
223675835|NCT03595124|DRUG|Axitinib|Given PO
223675836|NCT03595124|BIOLOGICAL|Nivolumab|Given IV
224257384|NCT06248294|DIAGNOSTIC_TEST|CT follow-up|Computed tomography angiography assessment of BAV-related aorthopathy
224257385|NCT01228539|BEHAVIORAL|TARGET (Trauma Affect Regulation)|TARGET teaches a skill sequence for affect regulation and social/interpersonal information processing.
223772804|NCT03413332|OTHER|E-Talkcare|Women in the intervention group will receive the E-Talkcare web address, a user name, and a temporary password. The participant will be able to read or listen (through audio narration) to instructions on how to complete the intervention in order, though she can freely navigate between web modules. Each module will have an ever-present indicator (showing users' progress) and a link to for users to continue navigating through modules.We will ask participants to complete the full intervention within 3 months after intervention delivery and then complete a 3-month post-randomization interview (T1). The website will remain open for six months after intervention delivery to allow participants to use QPL if they wish. A 6-month post-randomization interview (T2) will then be administered.
223772805|NCT03413332|OTHER|Usual Care|Survivors randomized to the usual care group will receive care from their doctors as usual, allowing us to compare the intervention against real-world practice to inform next steps. Since we do not know if the intervention will be efficacious, we decided not to provide a delayed intervention to control participants.
224257386|NCT01228539|BEHAVIORAL|Prolonged Exposure|Cognitive behavior therapy with trauma memory exposure
224257387|NCT05173246|DRUG|JS001|JS001 240mg, ivdrip, d1, Q3w
224257388|NCT05173246|DRUG|nab-paclitaxel|nab-paclitaxel 220 mg/m2,ivdrip, d1,d8,Q3w
224257389|NCT05173246|DRUG|Cisplatin|Cisplatin 75mg/m2, ivdrip,d1,Q3w
224257390|NCT05173246|DRUG|Carboplatin|Carboplatin AUC 5,d1,Q3w
224257391|NCT01493635|OTHER|analgesic ladder|Patients will be managed according to the standard 3 Step approach of the WHO analgesic ladder (Step 1 - Step 2 - Step 3).
224257392|NCT01493635|OTHER|analgesic ladder|Patients managed according to the WHO analgesic ladder bypassing Step 2, i.e. patients will move from Step 1 of the WHO analgesic ladder to Step 3.
224257393|NCT03967223|DRUG|Letetresgene autoleucel (lete-cel, GSK3377794)|letetresgene autoleucel will be administered.
224257394|NCT03967223|DRUG|Fludarabine|Fludarabine will be used as the lymphodepleting chemotherapy
224257395|NCT03967223|DRUG|Cyclophosphamide|Cyclophosphamide will be used as the lymphodepleting chemotherapy.
224257396|NCT05180253|DIAGNOSTIC_TEST|Esophageal studies|Healthy subjects will undergo esophageal and blood testing.
224257397|NCT05381688|PROCEDURE|VIM DBS|Stereotactic deep brain stimulation of ventral intermediate nucleus of thalamus
224257398|NCT00567320|DRUG|Varenicline|Varenicline up to 2 mg a day
224257399|NCT00567320|DRUG|Sugar pill or Placebo|Placebo
224257400|NCT00211263|BEHAVIORAL|Enhanced Clinical Intervention|
224257401|NCT00211263|DRUG|mood stabilizer|
224257402|NCT02297763|DRUG|quetiapine|"patient body weight \<50kg : quetiapine 12.5mg patient body weight \>=50kg : quetiapine 25mg~quetiapine 12.5mg (bwt \<50kg ) or 25mg (bwt\>= 50kg) study medicine is pulverized to power and melted in 10cc tepid water. The study medicine(quetiapine) will be provided as liquid form.~The study medicine(quetiapine) was provided as liquid form (medicine was pulverized and melted in 10cc water)."
224257403|NCT02297763|DRUG|placebo|The placebo is made of 100mg of corn starch which is melted in 10cc water.
224257404|NCT01986491|DRUG|JNJ 39393406 30 mg solid X|Participants will receive JNJ 39393406 30 mg solid X formulation as a tablet orally (by mouth).
224257405|NCT01986491|DRUG|JNJ 39393406 30 mg solid Y|Participants will receive JNJ 39393406 30 mg solid Y formulation as a hard gelatin capsule orally (by mouth).
224257406|NCT01986491|DRUG|JNJ 39393406 120 mg solid X|Participants will receive JNJ 39393406 120 mg solid X formulation as a tablet orally (by mouth).
224257407|NCT01986491|DRUG|JNJ 39393406 120 mg solid Y|Participants will receive JNJ 39393406 120 mg solid Y formulation as a hard gelatin capsule orally (by mouth).
224257408|NCT01986491|DRUG|JNJ 39393406 30 mg solution|Participants will receive JNJ 39393406 30 mg/mL solution orally (by mouth).
224257409|NCT04033276|DRUG|Rituximab|IV rituximab
224257410|NCT04033276|DRUG|intravenous immune globulin|iv intravenous immune globulin
224257411|NCT04561063|DRUG|Nitazoxanide|Nitozoxanide 1 tablet (500 mg) taken 12-hourly with food for the first week, followed by 2 tablets (1000 mg) taken 12-hourly with food thereafter. (Participants that fail to tolerated the 1000 mg 12-hourly dose may revert back to the lower dose.)
224257412|NCT04561063|DRUG|Sofosbuvir/Daclatasvir|Sofosbuvir/daclatasvir 400mg/60 mg sofosbuvir/daclatasvir fixed dose combination 1 tablet daily
223675842|NCT06785012|DRUG|JNJ-89495120|JNJ-89495120 will be administered.
223675843|NCT06785012|DRUG|Placebo|Placebo will be administered.
224257413|NCT00113386|BIOLOGICAL|filgrastim|Consolidation chemotherapy
224257414|NCT00113386|BIOLOGICAL|pegfilgrastim|Consolidation chemotherapy
224257415|NCT00113386|DRUG|cisplatin|
224257416|NCT00113386|DRUG|docetaxel|
224257417|NCT00113386|PROCEDURE|adjuvant therapy|
224257418|NCT00113386|PROCEDURE|conventional surgery|
224257419|NCT00113386|PROCEDURE|neoadjuvant therapy|
224257420|NCT00113386|RADIATION|radiation therapy|
224257421|NCT03620591|DRUG|Lidocaine|Intraoperative administration of lidocaine
224257422|NCT03620591|DRUG|Placebo|Intraoperative administration of normal saline
224257423|NCT03463850|RADIATION|Dual Energy CT (DECT)|Dual Energy CT (DECT)
224257424|NCT03463850|RADIATION|DEXA|Dual-energy x-ray absorptiometry for measurement of bone mineral density
224257425|NCT00392665|DRUG|Bevacizumab|Given intravenously on day one of each 3 week cycle
224257426|NCT00392665|DRUG|erlotinib|Given orally once a day
224257427|NCT00392665|DRUG|Sulindac|Given orally twice a day
224257428|NCT03877692|DRUG|Experimental dosing of labetalol|Subjects with preexisting hypertension who have sustained severe hypertension (SBP≥160 mmHg and/or DBP≥110 mmHg), 15 min apart receive the experimental dosing of labetolol. Subjects in both groups are managed following the standard guidelines established by ACOG (Committee Opinion #623). For each successive episode of hypertension treatment, patients are asked a set of questions to monitor for adverse medication side-effects. The fetus is electronically monitored for four hours after the last IV dose.
224257429|NCT03877692|OTHER|Standard dosing of labetalol|Subjects with preexisting hypertension who have sustained severe hypertension (SBP≥160 mmHg and/or DBP≥110 mmHg), 15 min apart receive either the standard of care dosing of labetolol. Subjects in both groups are managed following the standard guidelines established by ACOG (Committee Opinion #623). For each successive episode of hypertension treatment, patients are asked a set of questions to monitor for adverse medication side-effects. The fetus is electronically monitored for four hours after the last IV dose.
224257430|NCT05374876|OTHER|Hand Therapy Until CIPN|Patient will participate until the time of onset of CIPN of the hands or through 84 days of treatment if no symptoms of CIPN.
224257431|NCT02197481|PROCEDURE|Clamp-Crushing technique|Liver transection during hepatectomy by monopole electronicknife and blood vessel forceps, but without BiClamp forceps
224257432|NCT02197481|DEVICE|BiClamp forceps|liver transection during hepatectomy by BiClamp forceps
224257433|NCT04408794|DRUG|Zavegepant (BHV-3500)|10 mg IN up to 8 times per month, up to 1 year
224257434|NCT01259791|DRUG|Individual-specific statin causing myopathy|Individual-specific statin causing myopathy vs. placebo
224257435|NCT01259791|DRUG|Placebo|Placebo
224257436|NCT00187720|DRUG|Metformin|Subjects will be given a single oral dose of 850 mg of metformin
224257437|NCT00084526|PROCEDURE|computed tomography|
224257438|NCT00084526|PROCEDURE|ultrasound imaging|
224257439|NCT06324825|DRUG|Fuzhegn Nizeng Decoction|Subjects taking prepared Fuzhegn Nizeng granules twice daily for 6 month.
224257440|NCT06324825|DRUG|Moluodan granules|Subjects taking prepared Moluodan granules 9g twice daily for 6 month.
224257441|NCT02458625|DIETARY_SUPPLEMENT|Iron sucrose 500 mg|
224257442|NCT02458625|DIETARY_SUPPLEMENT|Iron bisglycinate 60 mg|
224257443|NCT00252967|DRUG|Atorvastatin|80 mg of Atorvastatin
224257444|NCT00252967|DRUG|Placebo|
224257445|NCT02294786|DRUG|Lapatinib|Lapatinib was supplied as 250mg tablets that are oval, biconvex, and orange film-coated with one side plain and the opposite side debossed, or as 250mg tablets that are oval, biconvex, and yellow film-coated with one side plain and the opposite side debossed. Each tablet contained 405mg of Lapatinib ditosylate monohydrate, equivalent to 250mg Lapatinib free base
224257446|NCT02294786|DRUG|Capecitabine|Capecitabine (Xeloda™) was supplied as a biconvex, oblong, light peach or peach colored film-coated tablet for oral administration. Each light peach colored tablet contained 150mg Capecitabine and each peach colored tablet contained 500mg Capecitabine. Generic versions of capecitabine may have been used within the study if Xeloda cannot be provided. XELODA™ is a trademark of Hoffmann-La Roche AG.
224257447|NCT02294786|DRUG|Octreotide|Octreotide (Sandostatin LAR™) was supplied as sterile 5milliliter (mL) vials delivering 20mg Octreotide as the free peptide. When mixed with diluent (approximately 2mL or 2.5 mL) it becomes a suspension that is given as an intramuscular injection. Two 20mg intramuscular injections were given to deliver a total dose of 40mg. The Octreotide is uniformly distributed within the microspheres which are made of a biodegradable glucose star polymer, D,L-lactic and glycolic acids copolymer. Sterile mannitol was added to the microspheres to improve suspendability
223772806|NCT03992807|OTHER|A patient decision aid|Potential participants receive a printed decision aid booklet with information about cataract surgery choice, and outcome data will be gathered using standardized questions in a structured interview after 2 weeks and 1 year.
223772807|NCT03992807|OTHER|A usual education booklet|Potential participants receive a usual booklet about cataract and cataract surgery, and outcome data will be gathered using standardized questions in a structured interview after 2 weeks and 1 year.
223772808|NCT00803127|DEVICE|vs-sense|detection swab
224257448|NCT02092363|DRUG|OMP-54F28, Paclitaxel and Carboplatin|
224257449|NCT02283463|DEVICE|Intrauterine device (IUD) insertion|
224257450|NCT02283463|PROCEDURE|Endometrial biopsy|
224257451|NCT01778010|DRUG|Modafinil 0 mg|Modafinil (0 mg/day)
224257452|NCT01778010|DRUG|Modafinil 200 mg|Modafinil (200 mg/day)
224257453|NCT01778010|DRUG|Modafinil 400 mg|Modafinil (400 mg/day)
224257454|NCT01778010|DRUG|Cocaine 0 mg|Cocaine (0 mg/day)
224257455|NCT01778010|DRUG|Cocaine 12 mg|Cocaine (12 mg/day)
224257456|NCT01778010|DRUG|Cocaine 25 mg|Cocaine (25 mg/day)
224257457|NCT01778010|DRUG|Cocaine 50 mg|Cocaine (50 mg/day)
224257458|NCT05765708|OTHER|Motor Imagery|Motor imagery is the mental execution of a movement without any overt movement or without any peripheral (muscle) activation. It has been shown that motor imagery leads to the activation of the same brain areas as an actual movement. Therefore, it is used to acquire new motor skills. Action Observation (AO) involves the dynamic process of observing purposeful actions with the intention of imitating and then practicing those actions.
224257459|NCT05765708|DIAGNOSTIC_TEST|Action Observation|Action Observation (AO) involves the dynamic process of observing purposeful actions with the intention of imitating and then practicing those actions.
224257460|NCT05336643|DEVICE|Radiofluorescence|Assessment of pelvic sidewall with Firefly and Sensei
224257461|NCT05168150|BEHAVIORAL|Experimental: Experimental Group - Intelligent Continuous Expertise Monitoring System group|During each of the practice task they will receive real-time auditory feedback instructed by the intelligent system. After each attempt, a student takes a 5-minute break. They will be shown the errors they made during the task regarding five performance metrics. After seeing each error, they will be shown video demonstration to learn how to expertly perform at each performance metrics. On their 6th attempt they will perform on the realistic scenario without any feedback given.
224257462|NCT05168150|BEHAVIORAL|Experimental Group In-person expert-mediated instruction group|During each of the practice task, students will receive verbal feedback from the expert instructor present in the room. After each task, experts will summarize their performance and outline the errors the student made. Based on the student's performance, expert will demonstrate how to expertly perform the task in the simulation, and how to improve their performance in the next attempt. Students will perform the 6th attempt on the realistic scenario without any instruction given.
224257463|NCT04258917|DEVICE|Study withdrawn|Study withdrawn
224322506|NCT04244578|DEVICE|Sham tDCS|Sham tDCS will be delivered to parieto-occipital areas for five consecutive days. tDCS will be delivered by a battery driven, direct current stimulator through a pair of saline-soaked sponge electrodes kept firm by elastic bands. The electrodes will be placed on the left (anodal) and right (cathodal) parieto-occipital areas, PO7 and PO8 position according to the 10-20 international EEG system for electrode placement. Stimulation intensity will be set at 1 milliampere (mA), but the current will be applied for 30 s and will be ramped down without the participants awareness.
224257464|NCT04987411|DIAGNOSTIC_TEST|Measurement of methane concentrations in exhaled breath|To measure methane concentrations, a near-infrared laser technique-based photoacoustic apparatus will be attached to the exhalation outlet of the ventilator upon arrival of severely injured patients. Exhaled methane levels will be monitored continuously during the first 72 in-hospital hours and will be recorded at pre-determined time points (directly upon arrival, 6 hours post-admission, 12 hours post-admission, 24 hours post-admission, 48 hours post-admission and 72 hours post-admission).
224257465|NCT04987411|DIAGNOSTIC_TEST|Videomicroscopy of the sublingual microcirculation|Orthogonal polarization spectral imaging technique (Cytoscan A/R, Cytometrics) will be used to visualize the microcirculation of the sublingual mucosa of the patients. The OPS technique utilizes reflected, polarized light at the wavelength of the isobestic point of oxyhemoglobin and deoxyhemoglobin (548 nm). The diminution of sublingual microcirculation can refer to circulatory redistribution due to hemorrhage. Sublingual microcirculation of the patients will be visualized and evaluated at pre-determined time points (directly upon arrival, 6 hours post-admission, 12 hours post-admission, 24 hours post-admission, 48 hours post-admission and 72 hours post-admission) during the first 72 in-hospital hours.
224257466|NCT04987411|DIAGNOSTIC_TEST|Blood gas and laboratory analysis|Arterial blood gas analysis and laboratory testing of venous blood are routine examinations in clinical practice. Base deficit and lactate are considered as global markers of blood loss and shock, and can be obtained rapidly with blood gas analysis. Hemoglobin and hematocrit values can correspond to the severity of blood loss, and are measured routinely both from arterial and venous blood. Sampling of arterial and venous blood for blood gas and laboratory analyses will be performed at pre-determined time points (directly upon arrival, 24 hours post-admission, 48 hours post-admission and 72 hours post-admission) during the first 72 in-hospital hours.
224257467|NCT04987411|DIAGNOSTIC_TEST|Hemodynamic monitoring|Hemodynamic monitoring is an essential part of emergency trauma care. Non-invasive monitoring of blood pressure, heart rate and respiratory rate of patients will be started immediately upon arrival. After patients are stabilized, invasive arterial blood pressure (IABP) monitoring can be started. IABP is considered as the gold standard of blood pressure measurement in critical care as it reflects the fluctuations of blood pressure in real time. Blood pressure and heart rate values will be recorded at pre-determined time points (directly upon arrival, 6 hours post-admission, 12 hours post-admission, 24 hours post-admission, 48 hours post-admission and 72 hours post-admission) during the first 72 in-hospital hours.
224257468|NCT04050254|DEVICE|Real tDCS|Real tDCS (STARTSTIM® 8 stimulator, Neuroelectric Barcelona, Spain) for five sessions on alternate days.tDCS is a galvanic current applied by a cap for 20 minutes at an intensity of 2 milliamps.
224322507|NCT03672045|DRUG|Carbetocin|carbetocin administered IV, over 1 minute following delivery of the fetal head
224257469|NCT04050254|DEVICE|Sham tDCS|Sham current (STARSTIM® 8 stimulator, Neuroelectric Barcelona, Spain) for five sessions on alternate days. Sham tDCS will be applied for the same time than real tDCS.
223675870|NCT05987241|PROCEDURE|Biospecimen Collection|Undergo collection of tissue and blood
223675871|NCT05987241|OTHER|cfDNA or ctDNA Measurement|Undergo ctDNA surveillance
223675872|NCT05987241|PROCEDURE|Computed Tomography|Undergo CT
223772809|NCT01037478|DRUG|Resminostat (4SC-201)|oral administration
223772810|NCT00678561|DRUG|CP-690,550|Topical treatment once daily for 28 days
224257470|NCT04050254|DEVICE|Therapeutic exercise|The therapeutic exercise program will include aerobic exercise and muscle strengthening for five sessions on alternate days. The program will include exercises and will last 30-45 minutes.
224257471|NCT02362997|DRUG|Pembrolizumab|Anti-PD-1 monoclonal antibody
224257472|NCT02083328|DIETARY_SUPPLEMENT|Caffeine|Caffeine will be filled in gelatine capsules and administrated in a dosage of 6mg per kg body mass
224257473|NCT02083328|DIETARY_SUPPLEMENT|Placebo (Mannitol)|Mannitol filled in gelatine capsules
224257474|NCT05963178|BEHAVIORAL|Pre-operative counselling|"A preoperative speech therapy counseling will be carried out the day before the Total Thyroidectomy with the aim of informing patients about the possible conditions of the immediate post-operative period. Therefore, indications of vocal hygiene and hydration standards will be simultaneously administered, to be implemented from the first post-operative day.~Patients will undergo phoniatric follow-up in the immediate post-operative period, at 7 days, 1 month and 3 months post-operatively.~Patients who, at follow-up checks, should present the symptoms of functional post-thyroidectomy syndrome will undergo a cycle of post-operative speech therapy of 8 sessions."
224257475|NCT05070572|DEVICE|Accuryn Monitoring System|Utilization of the Accuryn Monitoring System to measure intraabdominal pressure and urine output during laparoscopic inguinal hernia repair surgery.
224257476|NCT01518972|DRUG|Prazosin|"Form: Prazosin will be taken orally, in the form of pills.~Dosing: 9 AM, 3 PM, 9 PM~Days 1-2: 0 mg, 0 mg, 1 mg~Days 3-4: 1 mg, 1 mg, 1 mg~Days 5-7: 2 mg, 2 mg, 2 mg~Day 8-10: 2 mg, 2 mg, 6 mg~Day 11-14: 4 mg, 4 mg, 6 mg~Day 15-84: 4 mg, 4 mg, 8 mg"
224257477|NCT01518972|DRUG|Placebo medication|"Form: Placebo will be taken orally, in the form of pills.~Dosing: 9 AM, 3 PM, 9 PM~Days 1-2: 0 mg, 0 mg, 1 mg~Days 3-4: 1 mg, 1 mg, 1 mg~Days 5-7: 2 mg, 2 mg, 2 mg~Day 8-10: 2 mg, 2 mg, 6 mg~Day 11-14: 4 mg, 4 mg, 6 mg~Day 15-84: 4 mg, 4 mg, 8 mg"
224257478|NCT04582318|BIOLOGICAL|NGM621|NGM621 will be administered via IV infusion
223675873|NCT05987241|PROCEDURE|Cystoscopy|Undergo cystoscopy
223675874|NCT05987241|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223675875|NCT05987241|BIOLOGICAL|Nivolumab|Given IV
223675876|NCT05987241|OTHER|Questionnaire Administration|Ancillary studies
223675877|NCT05987241|BIOLOGICAL|Relatlimab|Given IV
223772811|NCT00678561|DRUG|CP-690,550|Topical treatment once daily for 28 days
223772812|NCT00678561|DRUG|CP-690,550|Topical treatment once daily for 28 days
223772813|NCT00678561|DRUG|CP-690,550|Topical treatment twice daily for 28 days
223772814|NCT00678561|DRUG|CP-690,550|Topical treatment twice daily for 28 days
223772815|NCT00678561|DRUG|CP-690,550|Topical treatment twice daily for 28 days
223772816|NCT00678561|DRUG|Placebo Vehicle|Topical treatment once daily for 28 days
223772817|NCT00678561|DRUG|Placebo Vehicle|Topical treatment twice daily for 28 days
224257479|NCT04582318|BIOLOGICAL|Placebo|Placebo will be administered via IV infusion
224257480|NCT05611593|DRUG|FOL100|FOL100 lotion
224257481|NCT05611593|DRUG|Propecia 1Mg Tablet|Oral Finasteride
224257482|NCT00803478|PROCEDURE|LASIK|
224257483|NCT00189293|DRUG|Imiquimod|"Imiquimod 5% cream three times per week for 4 weeks (1 sachet)~1 or 2 sachet(s)"
224257484|NCT00189293|OTHER|vehicle cream|"vehicle cream three times per week for 4 weeks (1 sachet)~1 or 2 sachet(s)"
224257485|NCT02591927|DRUG|Glucose-Insulin-Potassium|Rackley's GIK formula by continuous I.V. infusion at 1.5 ml/Kg/hour for 12 hours (about 100 ml/hour for a 70 kg patient).
224257486|NCT02591927|DRUG|Glucose 5%|Glucose 5% (Placebo) by continuous I.V. infusion at 1.5ml/kg/hour for 12 hours (about 100 ml/hour for 70 Kg patient)
224257487|NCT05552482|OTHER|Identification of predictive factors|Evaluation of the following variables : age, sex, body mass index, Diabetes mellitus, vascular disease, hematologic disease, venous thromboembolic disease, antiplatelet or anticoagulant treatments, haemodialysis Catheter Insertion, number of comorbid conditions, Venous diameter, Arterial diameter, AVF type, AVF limb, Anasthesia group
224257488|NCT05742971|DEVICE|Virtual reality intervention performed through the Oculuc Go VR glasses|The participants randomised into this group are offered a VR intervention during the external version for 5-10 minutes in addition to the standard care of an ECV. The VR is performed through the Oculus Go VR glasses. These women can choose for an immersive guided relaxation VR experience or an interactive VR experience (see descriptions below). The ECV expert executing the ECV will register immediately after the ECV which option the patients has chosen. Immediately after the external version, a pain measurement is taken with regard to the pain during the ECV by means of the NRS score. After the ECV procedure, participants of the VR-group receive a structured questionnaire in which tolerability, feasibility and satisfaction of VR use is evaluated.
224257489|NCT01667679|DRUG|100 mg Sumatriptan Tablet and OPTINOSE Placebo delivered nasally|
223772818|NCT03419091|DEVICE|single-use flexible digital ureteroscope|Device being tested.
223772819|NCT03419091|DEVICE|Reusable Ureteroscope|Comparative device.
223772820|NCT00656253|DRUG|Herbal Medicinal Mixture (Roucongrong, Heshouwu etc.)|12 months period of Herbal Medicinal Mixture per day plus 1 month wash-out period without herbal medicine
223772821|NCT00656253|DRUG|Placebo|12 months period of placebo plus 1 month period without placebo
223772822|NCT03354494|DRUG|Desogestrel (DSG) and Corifolitropin (FSH-CTP) Alfa|
223772823|NCT03580603|OTHER|Visualization tool|Visual representation of past microbiological culture data
223772824|NCT04464642|DRUG|Methotrexate|Methotrexate 25 mg subcutaneous is given in group A
223772825|NCT04464642|DRUG|Tofacitinib|tofacitinib 10 mg given in group B
223772826|NCT01329510|DEVICE|One-night polysomnographic recordings|One-night polysomnographic recordings before and during methylphenidate treatment.
223772827|NCT00437034|BIOLOGICAL|aflibercept|Given IV
223772828|NCT06804603|DRUG|Tradipitant|Oral capsule
223772829|NCT06804603|DRUG|Placebo|Oral capsule
223772830|NCT04118322|OTHER|aromatherapy (peppermint oil)|"The patients in the intervention group received routine medical treatment program and were asked to put one drop of peppermint oil upon lips following chemotherapy administration. Before peppermint oil application; the researcher theoretically and practically provided a training of 8-10 minutes about the use of peppermint oil and the patients were requested to apply this oil three times a day according to Oil Practice Guide (See Fig. 2) in the morning (09:00), at noon (15:00) and in the evening (21:00).~Aromatherapy essential oil used was a mixture of English peppermint (Mentha piperita; 3%) and sweet almond oil (30 ml)"
223772831|NCT04903691|BEHAVIORAL|Cardiac Exercise Program|Participants who enrolled in cardiac exercise program
223772832|NCT01900613|BEHAVIORAL|Ninos Sanos Familia Sana|
223772833|NCT01486017|DRUG|ASP015K|oral
223772834|NCT03273036|DRUG|40 mg Triamcinolone acetate 1 cc|40 mg Triamcinolone acetate 1 cc
223772835|NCT03273036|DRUG|Placebos|no injected agent
223772836|NCT05883605|DEVICE|Measuring blood pressure|Measuring blood pressure using electronic device and using a mercury sphygmomanometer
223772837|NCT04302467|PROCEDURE|fluid therapy during operation|ERAS protocol of lobectomy will implemented to all the participants during perioperation,two groups of participants will be given different intraoperative fluid therapy strategy.
223772838|NCT04612322|DEVICE|Assessment of microvascular function with intracoronary hemodilution|The pressure/temperature wire allows assessing coronary flow reserve, intracoronary pressure, and coronary flow to calculate multiple parameters of coronary macro- and microvascular function.
223772839|NCT03537118|PROCEDURE|Fluoroscopic + Ultrasound Guidance|Fluoroscopic Guidance Alone
223772840|NCT03245021|DRUG|Opdivo|"All patients will receive:~Nivolumab 240mg IV q2-weekly for four cycles~Patients in complete remission (CR):~Nivolumab 240mg IV q2-weekly for four further cycles (8 in total)~Patients with partial response (PR), stable disease (SD), asymptomatic or minor progressive disease (PD) post 4cycles receive:~Nivolumab 240mg IV plus rituximab 375mg/m2 IV q2-weekly for four cycles~Patients in CR:~Nivolumab 240mg IV q2-weekly for four further cycles (8 in total)~Patients with PR, SD, asymptomatic or minor PD post 4 cycles receive:~Nivolumab 240mg IV plus rituximab 375mg/m2 IV q2-weekly for four cycles"
223772841|NCT02827292|OTHER|music|"A standard music with a standard volume as per the protocol will be played with headphones during the entire duration of the surgery starting from the point of induction to the time of extubation.~A proper silent operative room environment will be maintained."
223772842|NCT02827292|OTHER|No music|Silent Headphones (Without music) will be applied to the patient from the point of induction of anaesthesia to the time of extubation.
223772843|NCT02827292|PROCEDURE|Laparoscopic Surgery|Patients will undergo Laparoscopic Surgery as per the set protocol
223772844|NCT01790906|PROCEDURE|RSD|Contrast renal angiography was performed to localize and assess the renal arteries for accessibility and appropriateness for RSD .once the anatomy was deemed acceptable, the internally irrigated radiofrequency ablation catheter(Celsius Thermocool,Biosense Webster,Diamond Bar,California)was introduced into each renal artery.then was maneuvered within the renal artery to allow energy delivery in a circumferential,longitudinally staggered manner to minimize the chance of renal artery stenosis.About six to nine ablation at 10W for 1 min each were performed in both renal arteries.during ablation, the catheter system monitored tip temperature and impedance,altering radiofrequency energy delivery in response to predetermined algorithm.
223675892|NCT06787729|DEVICE|mHealth|The experimental design is composed of three phases: baseline, intervention, and retention. During the first two weeks (baseline), subjects will wear sensors, but no additional features (e.g., feedback, goal-setting, and weekly Zoom calls with clinicians) will be provided. For the next four weeks (intervention), subjects will wear sensors and have access to all intervention features, including weekly Zoom calls and goal-setting with clinicians. They will be encouraged to use the more impaired arm as much as possible. In the final two weeks (retention), the mobile intervention and clinician interactions will be removed, while subjects continue to wear sensors to examine the effects of withdrawing feedback.
223675893|NCT06149559|DRUG|rozanolixizumab|rozanolixizumab solution for injection
224257490|NCT01667679|DRUG|OPTINOSE SUMATRIPTAN delivered nasally and placebo tablet|
224257491|NCT02159183|DEVICE|Standard Plus ESTA STL Roxolid implant|The patient will receive a Straumann Soft Tissue Level Standard Plus Implant Ø 4.1 mm Regular Neck, SLActive® Roxolid, with a modified surface of the neck (ESTA). At 8-12 weeks after insertion, the implant will be loaded.
224257492|NCT02159183|DEVICE|Standard Plus STL implant|The patient will receive a Straumann Soft Tissue Level Standard Plus Implant Ø4.1mm Regular Neck,SLActive® Titanium grade IV, with a machined surface of the neck. At 8-12 weeks after insertion, the implant will be loaded.
224257493|NCT04180280|BEHAVIORAL|Behavioral self-regulation Phone counseling to improve HIV care|Participants receive 5 sessions of behavioral counseling to improve HIV care. Counseling is delivered using phone calls by a trained adherence and care engagement counselor.
224322508|NCT07059325|DEVICE|Transcranial Magnetic Stimulation|Participants will receive 6 to 10 sessions per day (i.e., theta burst; 600 pulses per session; 6000 pulses per day) over 3 to 5 treatment days using a MagVenture MagPro TMS System. Treatment will consist of a total of 30 sessions (18,000 total pulses). A single session is defined as 600 pulses at 50 Hz for 2s (i.e., 5 Hz triplets) and repeated every 10s for a total of 190s per session to l-dlPFC at 120% rMT with 15-minute intersession intervals. TMS will be targeted to Beam F3 for comparison to the bulk of the literature and to most mimic replicable clinical use.
224322509|NCT06749405|BIOLOGICAL|Transfusion algorithm based on Quantra®|"In addition to routine coagulation tests, a Quantra Qstat® analysis will be performed at baseline (before incision), at the end of native liver dissection, and after unclamping of the venous anastomoses. In the event of bleeding, additional Quantra Qstat® analyses may be conducted until bleeding control is achieved.~Transfusion and administration of blood-derived medications will be guided by the results of the Quantra Qstat® analyses."
223772845|NCT01790906|OTHER|Conventional therapy|Optimizing drug therapy,included angiotensin-converting enzyme inhibitors,aldosterone antagonist,beta-receptor blockers,diuretic,digoxin and so on.The patients with chronic heart failure ,whos'condition need for CRT-D(cardiac resynchronization therapy )/ICD(implantable cardioverter-defibrillator),are considered to implant CRT/ICD .CRT is abbreviation for cardiac resynchronization therapy ,ICD is defined for Implantable Cardioverter defibrillator.
223772846|NCT06419049|DEVICE|Altimate Medical EasyStand Bantam|Child will stand in stander 5 days per week for 60 min during each 8 wks intervention
223772847|NCT00690638|DRUG|PHX1149T|200 mg
223772848|NCT00690638|DRUG|PHX1149T|400 mg
224257494|NCT04180280|BEHAVIORAL|Behavioral self-regulation Office counseling to improve HIV care|Participants receive 5 sessions of behavioral counseling to improve HIV care. Counseling is delivered in clinical care offices s by a trained adherence and care
224257495|NCT05329025|DRUG|QL1706|QL1706 will be administered by IV infusion at 5mg/kg on Day 1 of each 21-day cycle until unacceptable toxicity or loss of clinical benefit.
224257496|NCT00109265|DRUG|Erlotinib HCl (OSI-774)|
224257497|NCT03810950|BEHAVIORAL|Trier Social Stress Test|Test to induce high levels of acute social stress, including actors and a faked exam situation
224257498|NCT03810950|BEHAVIORAL|Reading Newspaper|Participants read newspaper
224257499|NCT03810950|BEHAVIORAL|Barlab-Exposure|Participants are exposed to a bar situation with different sorts of alcohol available. They sniff at water and at one alcoholic drink.
224322510|NCT06749405|BIOLOGICAL|Conventional transfusion algorithm|Transfusion and blood-derived medications will be guided by the results of routine coagulation tests.
224257500|NCT06552780|DEVICE|TENs , ultrasound therapy|effect of high intensity laser versus ischemic compression on myofascial trigger points in the upper trapezius
224257501|NCT01203267|DRUG|Paclitaxel, Carboplatin|Paclitaxel 80 mg/m2, carboplatin AUC of 2 mg/min/ml, given on days 1, 8 and 15 of a 28-day cycle.
224257502|NCT04653363|OTHER|assessments|All assesments will be done by the first physiotherapist. But only 3m backward test will be done by the first and second physiotherapist in the first day and second day.
224257503|NCT05187923|DIAGNOSTIC_TEST|Artificial Intelligence Algorithm|Different machine learning and deep learning computer aided strategies for model construction and validation.
224257504|NCT06196281|OTHER|wooble board proprioceptive training|this includes wooble board proprioceptive training twice a day for four weeks
224322511|NCT06736041|BIOLOGICAL|PCV21 vaccine|Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular
224257505|NCT06196281|OTHER|multi-station proprioceptive training|this includes multi-station proprioceptive training twice a day for four weeks
224257506|NCT00057538|BEHAVIORAL|Mantram Repetition|
224257507|NCT05138003|DIAGNOSTIC_TEST|cardiac MRI|"T1 and T2 relaxation times will be evaluated on basal and mid-cavity SA maps; a single ROI measurement in the septum will be manually drawn sufficiently far from tissue interfaces to avoid the impact of susceptibility artifacts from adjacent tissues. The differences in T1 and T2 relaxation times between rest and post-exercise will be analyzed.~Cardiac ventricular volumes, function and LV mass will also be quantified."
224322512|NCT06736041|BIOLOGICAL|Prevnar 20 vaccine|Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular
223772849|NCT00690638|DRUG|Placebo|Placebo
223772850|NCT00002082|DRUG|Azithromycin|
223772851|NCT05451212|BIOLOGICAL|MuSK-CAART|Intravenous infusion of MuSK-CAART at different doses. Subjects may also receive MuSK-CAART following pre-treatment with CY, or CY plus FLU.
223772852|NCT06154434|DRUG|Chlorpromazine HCl 100mg Tablets|single-dose administered after a 10-hour overnight fast.
223772853|NCT01221259|DRUG|E2212|single ascending doses ranging from 10mg to 250mg
223772854|NCT01221259|DRUG|placebo|a single dose of matching placebo
223772855|NCT01578044|BEHAVIORAL|Intervention|"1. Patient education: Patients will receive information on dabigatran, including risks, benefits and potential side effects. This information will be re-enforced during the study on a monthly basis during the IVR calls and during the pharmacy service calls to patients.~2. Tele-monitoring: We will use IVR technology to send patients an automated reminder to refill their dabigatran, rivaroxaban, and apixaban prescriptions. This call will be delivered on day 20 following each dabigatran, rivaroxaban, and apixaban prescriptions.~3. Pharmacists follow-up: If dabigatran, rivaroxaban, and apixaban have not been refilled, the pharmacy staff will contact the patient to assess reasons that the patient has not refilled the medication."
223772856|NCT01578044|OTHER|Control|Usual care
224257508|NCT05138003|DIAGNOSTIC_TEST|Echocardiography|Measurements of mass, volumes and function will be obtained of both the left and right ventricles enabling comparisons with cardiac MRI and traditional echo measures.
223675897|NCT06190951|DRUG|cemiplimab|Administered per the protocol
224257509|NCT05138003|DIAGNOSTIC_TEST|RootiRx for the ECG monitoring during the cycling ride|The final report will include the amount of recorded beats, the average heart rate, the maximum and minimum heart rate, the amount of cardiac pauses defined as an interruption in the ventricular rate \> 2 seconds. Reported atrial events include atrial ectopic beats and supraventricular tachycardia and ventricular events include ventricular ectopic beats, doublets, triplets, bigeminy, trigeminy and ventricular tachycardia.
224257510|NCT05138003|DIAGNOSTIC_TEST|Blood sample|Blood sample will be performed 3 to 6 hours after the stage to analyze high-sensitivity cardiac Troponin T (high-sensitivity) levels, Creatine Phosphokinase (CPK) to eliminate the hypothesis of Troponin elevation induced by rhabdomyolysis and C-reactive Protein to corroborate the inflammatory aspect if there is any.
224257511|NCT00575159|DRUG|GSK189075|investigational drug
224257512|NCT00575159|DRUG|placebo|placebo comparator
224257513|NCT00006256|DRUG|paclitaxel|Patients receive paclitaxel IV over 3 hours every 21 days for 4 courses beginning 3 weeks after completion of the last doxorubicin and cyclophosphamide adjuvant regimen.
224257514|NCT00006256|PROCEDURE|adjuvant therapy|doxorubicin and cyclophosphamide adjuvant regimen
224257515|NCT00006256|RADIATION|radiation therapy|Patients also undergo concurrent radiotherapy 5 days a week for approximately 6-7 weeks.
223675898|NCT06190951|DRUG|Fixed Dose Combination (FDC) cemiplimab+fianlimab|Or coadministration, depending on availability.
223675899|NCT06190951|DRUG|Placebo|Administered per the protocol
224257516|NCT04374487|DRUG|Convalescent Plasma|200 ml of ABO compatible plasma transfusion will be done to the subject randomized for the test arm therapy
224257517|NCT04374487|OTHER|Standard Care Therapy|Subjects randomized to control group will be on standard care treatment according to Institutional Protocols.
224257518|NCT02224742|DEVICE|LeucoPatch|LeucoPatch® is prepared by centrifuging one or more 18mL aliquots of the participant's venous blood in the LeucoPatch device and bench-top centrifuge. The centrifugation yields a tough layer of fibrin, with viable white cells and platelets, and this is applied directly to the wound surface using sterile forceps. The wound is then covered with an inert primary dressing, secondary protective dressing and the ulcerated area protected with appropriate off-loading. The patch is prepared and applied each week for up to 20 weeks or until the wound is judged healed.
223772857|NCT05301933|BEHAVIORAL|Behavioral Parent Training (BPT)|BPT is an evidence-based psychosocial intervention that is directed exclusively to parent of children with ADHD and related disorders. BPT focuses on instructing parents to use approaches to enhance the parent-child relationship (e.g., quality time, praise) and proactive discipline strategies (e.g., time out, reward systems) to reduce challenging child behavior.
223772858|NCT00885872|DRUG|Rosuvastatin (Crestor)|at visit 2 each eligible subject will be allocated to rosuvastatin. study medication wil be taken orally with water once daily, as directed by the study physician. subjects who meet the criteria at visit 3, dosage of rosuvastatin will be titrated.
223772859|NCT01795508|BEHAVIORAL|PMTO|Parent Management Training, Oregon
224257519|NCT02224742|OTHER|Usual care|"Usual wound care provided in a multidisciplinary foot care clinic , in accordance with international guidelines.~Components of usual wound care include:~* Formal assessment of ulcer and surrounding skin~* Provision of any necessary off-loading~* Debridement (i) sharp, (ii) other as appropriate (but excluding the use of larvae)~* Appropriate dressing products~* Appropriate antibiotic therapy~* Nutrition and self care~* Optimal glycaemic control~* Revascularisation if deemed clinically necessary~* Continued close observation"
224257520|NCT05841628|DEVICE|532 nm laser treatment|The port wine birthmark will be treated with the DermaV 532 nm laser.
224257521|NCT04470115|OTHER|General anesthesia|Patients will receive general endotracheal anesthesia with typical drugs used (propofol, fentanyl, sevoflurane). the exact dose of the drug will be on the discretion of anesthesia provider, according to good clinical practice.
224322513|NCT06736041|BIOLOGICAL|M-M-R II vaccine|Pharmaceutical form:Powder, lyophilized, for suspension for reconstitution-Route of administration:Subcutaneous or Intramuscular
223675900|NCT04586426|DRUG|Talquetamab|Talquetamab will be administered by subcutaneous (SC) injection.
223675901|NCT04586426|DRUG|Teclistamab|Teclistamab will be administered by SC injection.
223675902|NCT04586426|DRUG|Daratumumab|Daratumumab will be administered by SC injection.
223675903|NCT05815199|OTHER|E-cigarette (EC)|Fixed dose. Participants are to use the EC as replacement for smoking combustible cigarettes. Participants will vape the EC.
223675904|NCT05815199|OTHER|Nicotine Replacement Therapy (NRT)|Includes nicotine patches and lozenges. NRT use recommendations will follow the guidelines of the product, e.g. one patch per day.
223675905|NCT05815199|BEHAVIORAL|Harm-Reduction Counseling|At baseline, after randomization, participants will receive their first telehealth session (20\~25 minutes) from a counselor trained in motivational interviewing, harm reduction, and smoking cessation. Up to five additional sessions will be delivered, 15\~20 minutes each.
223772860|NCT01795508|BEHAVIORAL|TAU|Other kinds of family training
223772861|NCT00963729|DRUG|cyclophosphamide|Given IV
223772862|NCT00963729|DRUG|docetaxel|Given IV
223772863|NCT00963729|DRUG|epirubicin hydrochloride|Given IV
223772864|NCT00963729|DRUG|fluorouracil|Given IV
223772865|NCT00963729|DRUG|letrozole|Given orally
223772866|NCT01020916|PROCEDURE|Target temperature 36°C|In hospital target temperature management to achieve a core body temperature of 36°C for 24 hours
223772867|NCT01020916|PROCEDURE|Target Temperature 33°C|In hospital target temperature management to achieve a core body temperature of 33°C for 24 hours
224322514|NCT06736041|BIOLOGICAL|RotaTeq|Pharmaceutical form:Solution-Route of administration:Oral
224322515|NCT06736041|BIOLOGICAL|Vaxelis vaccine|Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular
224322516|NCT06736041|BIOLOGICAL|Varivax|Pharmaceutical form:Powder, lyophilized, for suspension for reconstitution-Route of administration:Subcutaneous or Intramuscular
224257522|NCT04470115|OTHER|Regional anesthesia- femoral and lateral femoral cutaneous nerve blocks|The femoral nerve (FN) is identified with ultrasound. The needle is inserted in-plane, from lateral to medial. We administer 15 to 17ml of local anesthetic (0.5 to 0.75% ropivacaine). After good anesthetic spread on FN we identify lateral femoral cutaneous nerve (LFCN) in its expected location 2-3 cm below inguinal ligament, laterally to sartorius muscle and inject usually 4 to 5 ml of local anesthetic. Oxygen 2-3 l/min is given via face mask to maintain Sp02 and the block is followed by sedation. Sedation is achieved with boluses of propofol to enable procedure and maintain patient in comfort. We aim to keep the depth of sedation at Ramsay sedation scale of 4. Whether it is possible we use loud verbal stimulus, if it is not we use gently glabella tap to assess depth of sedation. Patient is breathing spontaneously during the whole surgery. After surgical field is prepared, surgeon infiltrates expected entry points of intramedullary nail system with 0,5% lidocaine.
224257523|NCT01805505|PROCEDURE|Transvaginal ultrasound-guided embryo transfer|Embryo transfer of two day-3 embryos performed with the Kitazato Long ET catheter (Kitazato Medical Co. Ltd., Tokyo, Japan), guided by transvaginal ultrasound
223675906|NCT05815199|BEHAVIORAL|Ecological Momentary Intervention (EMI) Text Messaging|EMI can be defined as delivering tailored interventions via electronic messages (i.e., regular text messages) that include personalized feedback based on real-time assessment responses and other contextual factors. EMI will take place throughout the intervention period.
224257524|NCT01805505|PROCEDURE|Transabdominal ultrasound-guided embryo transfer|Embryo transfer of two day-3 embryos performed with the Cook Soft-Trans ET catheter (Cook Medical Inc., Bloomington, IN, USA), guided by transabdominal ultrasound
224257525|NCT03538327|DRUG|Silybin|After enrollment, all patients were encouraged to make lifestyle changes according with current guidelines, moreover it was also recommended to take silybin coniugated to vitamin E and phosphatidylcholine that shows higher intestinal absorption and bioavailability (Indena, IBI-Lorenzini spa Italy: Realsil®), as granules for oral solution at a dose of 3 g bid. Each subject was re-evaluated monthly performing a clinical examination to consider the opportunity of antihypertensive treatment. Finally, inflammatory, metabolic and hemodynamic parameters were assessed after 6 months of treatment. In particular, at the end of the follow-up period, a new OGTT was performed, to test the effects of silybin on glucose tolerance and IR status.
224257526|NCT00952939|GENETIC|fluorescence in situ hybridization|At time of surgery
223675907|NCT06203002|DRUG|Placebo (blinded)|LX9211 matching placebo tablets
223675908|NCT06203002|DRUG|LX9211 (blinded)|LX9211 (blinded) tablets
223675909|NCT04560660|DRUG|Ketamine|FDA approved anesthetic medication with rapid acting antidepressant effects.
223675910|NCT04560660|DRUG|Midazolam|FDA approved sedative medication with dissociative effects.
224257527|NCT00952939|OTHER|laboratory biomarker analysis|At time of surgery
224257528|NCT00952939|PROCEDURE|fine-needle aspiration|At time of surgery
224257529|NCT00952939|PROCEDURE|therapeutic conventional surgery|At time of surgery
224257530|NCT00952939|OTHER|Questionnaires|The MINI (a structured psychiatric interview) will be administered to all patients that had a pre or post-operative HADS score for suggestive or probable depression or anxiety. A semi-structured interview would be administered to those patients who had some or full decision regret pre-operatively. After completion of the interview, the MINI, a structured psychiatric interview, will be administered.
224257531|NCT03986801|OTHER|pharmaceutical interview|pharmaceutical interview at the end of hospitalization
224257532|NCT06121973|BEHAVIORAL|educational group|Experimental group received online video-supported breastfeeding education in an online classroom for 6-8 people and individual counselling via phone and Whatsapp application when needed for 3 weeks.
224257533|NCT04229225|DRUG|UBX0101|Investigational drug intra-articular (IA) injection
224257534|NCT04229225|OTHER|Placebo|Placebo intra-articular (IA) injection
224257535|NCT03733444|DRUG|GLPG1690|GLPG1690, film-coated tablets for oral use.
223675913|NCT06952660|DRUG|TIVDAK|2 mg/kg once every 3 weeks (Q3W)
224257536|NCT03733444|DRUG|Placebo|Matching placebo, film-coated tablets for oral use.
224322517|NCT06736041|BIOLOGICAL|Hexaxim Vaccine|Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular
224257537|NCT00556322|DRUG|Alimta or Taxotere|500mg/m2 / 3 weeks (Alimta) or 75mg/m2 / 3 weeks (Taxotere)
224257538|NCT00556322|DRUG|erlotinib [Tarceva]|150mg po daily
224257539|NCT00663663|BEHAVIORAL|Telephone-Delivered Intervention 1|Intervention 1 will consist of eight 60-minute sessions conducted by phone over eight weeks. Intervention 1 will include: (1) education about the role of cognitions (particularly catastrophizing) and pain beliefs (including control) in chronic pain and adjustment; (2) instruction in how to identify negative thinking and cognitive distortions about pain; (3) instruction in thought-stopping and cognitive-restructuring techniques, including challenging negative thoughts and core beliefs about pain; (4) instruction in utilization of positive coping self-statements; (5) relaxation techniques; (6) activity pacing and scheduling; (7) coping with pain flare-ups; and (8) relapse prevention/maintenance of gains. Each intervention 1 session will include a brief relaxation exercise practiced over the phone.
224257540|NCT00663663|BEHAVIORAL|Telephone-Delivered Intervention 2|Intervention 2 will consist of eight 60-minute sessions conducted by phone over eight weeks (1 session/week on average), scheduled at times convenient for participants (including evenings and weekends if necessary). The sessions will cover a variety of topics, including the definition of chronic pain, the physiological processes underlying chronic pain, common pain-related conditions such as sleep disturbance, and the effects of chronic pain.
224257541|NCT01756326|DRUG|PREOB® Implantation|
224257542|NCT01756326|PROCEDURE|Bone Autograft|
224257543|NCT05947591|BEHAVIORAL|foot posture index|the tendency to foot pronation in healthy subjects will be compared during one hour of walking versus one hour of running in subjects who usually run.
224257544|NCT01344863|DRUG|trastuzumab [Herceptin]|600 mg subcutaneously using a single-use injection device on Day 1
224257545|NCT01344863|DRUG|trastuzumab [Herceptin]|600 mg subcutaneously using a handheld syringe on Day 1
224257546|NCT01899755|DRUG|GSK2800528, solution for injection|Drug will be administered at 3 different dose levels by subcutaneous injection.
224257547|NCT01899755|DRUG|Placebo (0.9% w/v Sodium Chloride), solution for injection|Subcutaneous injection of. 0.8 mL solution will be administered
224257548|NCT01899755|DRUG|Adalimumab, solution for injection|Subcutaneous injection of 0.8 mL solution will be administered (40mg)
224257549|NCT01788423|DEVICE|hearing aid|All subjects received hearing aids, some selected by audiologist, some selected by consumer, and some programmed as placebo devices.
224257550|NCT03637764|DRUG|Isatuximab SAR650984|"Pharmaceutical form: solution for infusion~Route of administration: intravenous"
224257551|NCT03637764|DRUG|Atezolizumab|"Pharmaceutical form: solution for infusion~Route of administration: intravenous"
224322518|NCT04245839|DRUG|Fludarabine|Fludarabine
224257552|NCT06561763|DRUG|Nimotuzumab,Toripalimab，Cisplatin, albumin paclitaxel, capecitabine|Albumin paclitaxel 200g/m2, intravenous drip administration, d1; Cisplatin 60 mg/m2， Intravenous , d1; Capecitabine, 1000mg/m2, orally administered D1-14； Triprolizumab injection 240mg, intravenous D1; Nivolumab 400mg, intravenous D1; Q3W 1 cycle, 3 cycles Period, 3 weeks in total
224257553|NCT06561763|DRUG|Nimotuzumab,Toripalimab，Cisplatin, Gemcitabine|Cisplatin 80 mg/m2， Intravenous drip administration, d1; Gemcitabine, 1000mg/m2,Intravenous ，D1,D8； Triprolizumab injection 240mg, intravenous ； Nivolumab 400mg, intravenous； Q3W 1 cycle, 3 cycles
224257554|NCT03911037|DRUG|G-CSF|G-CSF will be administered as prefilled syringes at a dosage of 5 μg/Kg subcutaneously every 12 hr for five consecutive days. Four such cycles will be administered at three monthly intervals.
224257555|NCT03911037|DRUG|Placebo|Placebo ( prefilled syringe) filled with normal saline subcutaneously every 12 hr will be administered for five consecutive days. Four such cycles at 3 monthly intervals will be administered.
224257556|NCT06066047|OTHER|TOUCH ATTENTIVE TREATMENT|"15-minute treatment using constant touch (0.20 N, approx. 20 grams) developed after training with visual feedback.~* 5 minutes bilateral touch on external malleolus~* 5 minutes longitudinal occipital front grip for reciprocal tension membrane movement and Sutherland's fulcrum~* 5 minutes bilateral touch on acromion, for midline, centring diaphragms~Throughout the treatment, the practitioner maintained a focused attention on touch by voluntarily and constantly directing attention to the sensation/perception of the hands, perceiving texture, density, temperature, reactivity and motility of the tissue."
224257557|NCT06066047|OTHER|AUDITORY ATTENTIVE TREATMENT|"15-minute treatment using constant touch (0.20 N, approx. 20 grams) developed after training with visual feedback.~* 5 minutes bilateral touch on external malleolus~* 5 minutes longitudinal occipital front grip for reciprocal tension membrane movement and Sutherland's fulcrum~* 5 minutes bilateral touch on acromion, for midline, centring diaphragms~During the treatment, the operator's attention was focused on acoustic signals delivered through earphones. The beeps were delivered at random intervals between 0.5 and 2.0 seconds. The operator had to count the number of acoustic signals produced during the treatment period."
224257558|NCT01660945|DRUG|placebo|
224257559|NCT01660945|DRUG|vytorin|
224322519|NCT04245839|DRUG|Cyclophosphamide|Cyclophosphamide
224322520|NCT04245839|DRUG|JCAR017|JCAR017
224322521|NCT07063511|DEVICE|Restylane Injectables|Participants will receive multilayering treatment (i.e., one product will be placed deep and one in a more superficial plane) in area of primary deficit (i.e., the midface or lower face), in isolation or combination with other treatment areas.
223772868|NCT02513589|DRUG|18F-PBR06|Positron Emission Tomography / Computed Tomography (PET-CT) using 18F-PBR06
224322522|NCT06574607|DEVICE|Interactive Educational Material for Decision-Making|Using severe bleeding from abdominal-pelvic trauma as a scenario case, implementing decision-making teaching strategies to guide learners, and examining the intervention through this research
224257560|NCT06302127|OTHER|Team-based care|The RISIMA model is provided by a family healthcare team composed of one village doctor, one general physician at township health centers and one specialist including cardiologists, neurologists or endocrinologists from county hospital. For villages without village doctor, public health professionals from township health centers would join the service team as the supplement. Within the team, three team members carry the different function. Village doctor is responsible for regular home visits, CVD risk measurement and organizing health education course. GP as the core service provider in the team is responsible for CVD risk monitoring, providing health education course for middle-high risk participants, and generating integrated care plans for each participant. Specialist is responsible for providing guidance particularly for high-risk population management to township and village doctors within the team.
223675921|NCT05787587|DRUG|IDE-161|Oral Medication
223675922|NCT05787587|DRUG|Pembrolizumab|Intravenous Infusion
223675923|NCT04630145|DRUG|Bedaquiline|Participants will receive BDQ tablets only/
223675924|NCT04630145|DRUG|Clarithromycin|Participants will receive CAM 400 or 500 mg twice a day.
223675925|NCT04630145|DRUG|Ethambutol|Participants will receive 500 to 750 mg daily (maximum daily dose of 1.0 gram \[g\]) or 15 mg/kg once a day.
223675926|NCT04630145|DRUG|Rifampicin|Participants will receive daily dose is 450 mg (maximum 600 mg) RFP capsule once a day.
223675927|NCT04630145|DRUG|Rifabutin|Participants will receive daily dose of RBT 300 mg or 150 mg capsules once a day.
223675928|NCT04370301|DRUG|Cyclophosphamide|Given IV
223675929|NCT04370301|DRUG|JAK Inhibitor|Given PO
223675930|NCT04370301|DRUG|Fludarabine|Given IV
223675931|NCT04370301|BIOLOGICAL|Recombinant Granulocyte Colony-Stimulating Factor|Given SC
223675932|NCT04370301|DRUG|Melphalan|Given IV
223675933|NCT04370301|DRUG|Mycophenolate Mofetil|Given PO
223675934|NCT04370301|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Given IV
223675935|NCT04370301|DRUG|Tacrolimus|Given IV and PO
223675936|NCT04370301|RADIATION|Total-Body Irradiation|Undergo TBI
223675937|NCT04370301|PROCEDURE|Computed Tomography|Undergo CT
223675938|NCT04370301|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223675939|NCT04370301|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy and aspiration
223675940|NCT04370301|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow biopsy and aspiration
224322523|NCT06574607|DEVICE|Interactive Educational Material|Teaching with scenario-based interactive materials without incorporating any teaching strategies
224322524|NCT05698914|BEHAVIORAL|Telehealth mindfulness-based intervention (MBI)|The telehealth MBI is adapted from Mindfulness-based cognitive therapy for chronic pain and consists of eight, weekly 75-minute individual sessions (90 minutes allotted for the first session) with a mindfulness interventionist delivering the intervention over telehealth (online with audio and video camera) in addition to the patient receiving their usual postsurgical care. Participants will begin the intervention after completing the 2-week postoperative assessment and within 4 weeks after surgery. Participants will be asked to practice skills between sessions approximately 20-40 minutes per day.
223675941|NCT04370301|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223675942|NCT04370301|PROCEDURE|Echocardiography|Undergo ECHO
223675943|NCT04370301|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
223675946|NCT00580996|OTHER|water high dose|water 16 oz PO x 1
223675947|NCT00580996|OTHER|water tiny dose|water 1 oz PO x 1
224257561|NCT06302127|PROCEDURE|Risk-stratified care pathway|Based on WHO/ISH score, baseline population will be divided into three groups-low risk (10-year CVD risk: \&lt;10%), middle risk (10-year CVD risk: 10%\~20%) and high risk (10-year risk: \&gt;20%). With the support from experts and health care professionals, study had developed a risk-stratified care pathway on the basis of clinical guidance. According to the pathway, participants at different risk tertile are provided with differentiated management plan especially in terms of health education, follow-up frequency and treatment plan.
224257562|NCT06302127|BEHAVIORAL|Strengthened health education|The education comprised 8 monthly sessions developed by GP and village doctors. At the 4th month, individual health counseling by village doctors will be done to encourage the imitation and maintenance of self-management behaviors, and to identify any potential problems in the program. It took half an hour per each participant. At the 8th month, self-management evaluation will be done to assess personal self-management ability. High risk participants are required to take the education course, and middle risk participants are only encouraging to take. All participants would receive the education messages twice a month, which introduce tips about the management of hypertension, diabetes and CVD risk factors.
224257563|NCT06302127|OTHER|Financial incentives for integration of care|Specialists receive reimbursement for case discussion and high risk population management; GP receive reimbursement for providing education program and risk monitoring; Village doctor receive reimbursement for assisting education program, risk measurement and home visits. And overall services quality will be measured, and taken into account for annual performance evaluation.
224257564|NCT06302127|OTHER|Supporting health information system|A dynamic patient risk monitoring information system is established for simplifying the risk data collection and entry for village doctors, meanwhile, GP and specialist can receive the updates of risk scores simultaneously. Apart from the function of risk monitoring, this system also incorporates the e-records of home visits, health education attendance as well as medical records including outpatient visits and hospitalizations. The upgraded information systems not only can support the healthcare professionals with comprehensive and real-time data, but also provide the performance evaluation data for policymakers.
224257565|NCT00224718|PROCEDURE|Endovascular repair (with endograft)|An endovascular stent graft is a tube composed of fabric supported by a metal mesh called a stent. It can be used for a variety of conditions involving the blood vessels, but most commonly to reinforce a weak spot in an artery called an aneurysm. Over time, blood pressure and other factors can cause this weak area to bulge like a balloon and eventually enlarge and rupture. The stent graft seals tightly with your artery above and below the aneurysm. The graft is stronger than the weakened artery and allows blood to pass through it without pushing on the bulge. Physicians typically use endovascular stent grafting to treat abdominal aortic aneurysms (AAAs).
224257566|NCT00224718|PROCEDURE|Open repair|Conventional repair consist in open repair. Different types of surgery can be done : minimal incision aortic surgery (MIAS), transperitoneal approach (TPA), retroperitoneal repair, or conventional median laparotomy.
224257567|NCT03402906|BEHAVIORAL|Family-Clinician Collaboration Program|Family-mediated treatment activities and collaboration between clinician and family members
224257568|NCT05836454|OTHER|Progressive Muscle Relaxation Group:|Progressive muscle relaxation is a relaxation technique that involves regular and sequential contraction and relaxation of muscles until the whole body is relaxed.
224257569|NCT05836454|OTHER|Myofascial Release Technique Group|It is a physiotherapy technique based on soft tissue mobilization. All enveloping fascia sale prices are positive for mobility, a user used for adhesions and pain.
224257570|NCT05814900|DEVICE|Two photon microscopy imaging|Excised tissues will be imaged with two photon microscopy
224257571|NCT04754217|DEVICE|VAVGJ|Replacement of the aortic valve and ascending aorta
224257572|NCT04754217|DEVICE|CAVGJ|Replacement of the aortic valve and ascending aorta
224257573|NCT06615752|DRUG|green tea and quercetin + docetaxel|green tea and quercetin supplements in combination with docetaxel infusion
224257574|NCT06615752|DRUG|Placebo + docetaxel|Placebo will be given along with docetaxel chemotherapy
224257575|NCT04813354|DEVICE|ELLIPTA|"* ELLIPTA followed by BREEZHALER/ Preference Questionnaire version 1~* ELLIPTA followed by BREEZHALER/ Preference Questionnaire version 2~* BREEZHALER followed by ELLIPTA/ Preference Questionnaire version 1~* BREEZHALER followed by ELLIPTA/ Preference Questionnaire version 2"
224257576|NCT04813354|DEVICE|BREEZHALER|"* ELLIPTA followed by BREEZHALER/ Preference Questionnaire version 1~* ELLIPTA followed by BREEZHALER/ Preference Questionnaire version 2~* BREEZHALER followed by ELLIPTA/ Preference Questionnaire version 1~* BREEZHALER followed by ELLIPTA/ Preference Questionnaire version 2"
223675960|NCT05744921|DRUG|Pozelimab|Administered per the protocol
223675961|NCT05744921|DRUG|Cemdisiran|Administered per the protocol
223772869|NCT00184015|DRUG|Bevacizumab and Bortezomib|Bevacizumab 15 mg/kg on day 1 with Bortezomib 1.0 or 1.3 mg/m2 on days 1, 4, 8 and 11 every 21 days
223772870|NCT00184015|DRUG|Bevacizumab and Bortezomib|Bevacizumab 15 mg/kg on day 1 with Bortezomib 1.6 or 1.8 mg/m2 on days 1 and 8 every 21 days
223772871|NCT01844258|PROCEDURE|Modified technique|Peripheral 1-1.5 mm curvilinear capsulorhexis of anterior capsule
223772872|NCT01844258|PROCEDURE|Traditional technique|Central 5-6 mm curvilinear capsulorhexis of anterior capsule
223772873|NCT06663124|DEVICE|EC-DBS ON|The surgical intervention named deep brain stimulation is a well-established neurosurgical treatment for drug-resistant epilepsy.The targets used in this study are extreme capsule.The devices used for intervention have been approved by Chinese National Medical Products Administration (CFDA). The postoperative drug dosage adjustment depends on the efficacy of DBS and the judgment of the epilepsy specialist.
223772874|NCT06664749|OTHER|Three stair position pillow group|Preterm infants were monitored with three stair position pillows.
223772875|NCT06664749|OTHER|Positioning material group|Preterm infants were monitored with positioning material pillows.
224257577|NCT04255147|BIOLOGICAL|Allogeneic Umbilical Cord Tissue-Derived Mesenchymal Stromal Cells|Cryopreserved allogeneic umbilical cord tissue-derived mesenchymal stromal cells are thawed and administered intravenously.
224257578|NCT06343675|OTHER|There is no intervention|There is no intervention
224322525|NCT05698914|BEHAVIORAL|Telehealth Education|Participants will receive a written educational booklet at the time of randomization (within 2-4 weeks after surgery) and 8, weekly telehealth sessions lasting 30 minutes in addition to usual postsurgical care. The educational materials are reviewed individually with the participant during weekly telehealth sessions (online with audio and video camera) by a physical therapist.
224257579|NCT02760927|DEVICE|Endotracheal Tube Fastener|The AnchorFast Guard oral endotracheal tube fastener provides a convenient means to hold an oral endotracheal tube securely in place without the use of adhesive tape. The oral endotracheal tube fastener allows repositioning of the tube in either direction along the track without removal of the device.
223772876|NCT05419947|DRUG|VERDYE powder for solution for injection 25 mg|Verdye 25 mg contains sodium VI powder for solution for injection. VI is a water-soluble agent with a spectral absorption peak of 800 nm. It is a drug approved for diagnostic use only and is indicated for the measurement of the excretory function of the liver.
224257580|NCT06395792|OTHER|No Intervention|As this is an observational study, no intervention will be administered.
224257581|NCT04521426|OTHER|No other than standard care|No other than standard care.
224257582|NCT02105272|DRUG|OPC-1085EL ophthalmic solution|
224257583|NCT02105272|DRUG|Latanoprost ophthalmic solution|
224257584|NCT03684330|DIETARY_SUPPLEMENT|Vitamin D|a dose once a week
224257585|NCT03684330|OTHER|whole body vibration (WBV)|03 months of WBV training three times per week
224257586|NCT02355730|PROCEDURE|Venepuncture|Venepuncture to collect blood samples from Patients undergoing Warfarin Therapy.
224257587|NCT00974558|DEVICE|handheld fan directed to cheeks|Handheld fan directed to cheeks for 5 minutes
224257588|NCT03603990|PROCEDURE|Vitrectomy|"During the first 6 month :Only Panretinal photocoagulation(if high-risk PDR or rubeosis iridis) may be given.~After First Six Months : All therapies for DME may be given at the discretion of the investigator"
224257589|NCT03603990|PROCEDURE|Usual care|"Patients with usual care according to the investigator choice :~During the first 6 month : All therapies for DME may be given at the discretion of the investigator during the study, except a vitrectomy.~After First Six Months : All therapies for DME may be given at the discretion of the investigator, including a vitrectomy."
223675980|NCT05478174|DRUG|HSK3486|HSK3486 for induction of general anesthesia
223675981|NCT05478174|DRUG|Propofol|Propofol for induction of general anesthesia.
223675990|NCT02112188|BEHAVIORAL|In-depth Patient Interviews|
223675991|NCT02112188|BEHAVIORAL|Adaptation of IMCP for Chinese Immigrant Cancer Patients|
223772877|NCT06662773|DRUG|TQB3616 capsule + itraconazole|C2/4/6 inhibitors + CYP3A metabolic enzyme inhibitors
223772878|NCT06662773|DRUG|TQB3616 capsule + rifampicin|C2/4/6 inhibitors + Non-specific cytochrome P450 enzyme inducer
223772879|NCT06663111|OTHER|Blood samples for PK|Blood sampled for pharmacokinetic study
224257590|NCT05363020|DRUG|S-Adenosyl-L-Methionine (Sam-E)|400 mg capsule
224257591|NCT05363020|DRUG|Placebo|400 mg identically appearing placebo
223675992|NCT02112188|BEHAVIORAL|Individual Meaning-Centered Psychotherapy for Chinese (IMCP-Ch) (For Phase 3 and Phase 4)|The six sessions will be delivered every or every other week over a span of 6-16 weeks, depending on participant and interventionist availability. Sessions may also be delivered within 2 weeks to accommodate schedules. Sessions will take place via MSK-approved videoconferencing platforms (e.g. Zoom) or by telephone, depending on participant preference. The IMCP-Ch intervention will be delivered via telehealth in Mandarin Chinese by a bilingual interventionist or in English (for bilingual Chinese and English-speaking patients who prefer English) by an English-speaking therapist or through English-to-Mandarin Remote Simultaneous Medical Interpretation (RSMI), depending on participants' preference. All Phase 4 sessions will be digitally audio-recorded and saved to Zoom cloud. Cloud recording will be deleted from Zoom after the files have been uploaded.
223772880|NCT06663111|OTHER|Blood samples for PK|Blood samples before, shortly after infusion of already assigned/ongoing treatment as well as after 2, 4, 8, 12, 24 weeks for serum conc. measurements.
224257592|NCT05009212|PROCEDURE|Endoscopic stricturotomy|Endoscopic stricturotomy for bowel stricture (\<5 cm)
224257593|NCT05009212|PROCEDURE|Endoscopic balloon dilatation|Endoscopic balloon dilatation for bowel stricture (\<5 cm)
224257594|NCT04480619|DIAGNOSTIC_TEST|Ga-68-IAC|Clinical management and diagnosis of Metastatic Breast Cancer.
224257595|NCT04085887|DRUG|Panitumumab-IRDye800|Panitumumab-IRDye800 is an imaging agent prepared as a drug-dye compound from panitumumab (Vectibix), a fully-humanized IgG2 monoclonal anti-epidermal growth factor receptor (EGFR) antibody, and IRDye800CW dye. Panitumumab-IRDye800 delivered intravenous (IV).
224257596|NCT04085887|DEVICE|Pinpoint-IR9000 endoscopic/handheld device|"Novadaq intraoperative camera capable of exciting and detecting near infrared (NIR) dyes. Imaging will be performed on subjects during both during surgery (in vivo) and/or on the resected tissues while at the back table in the surgery suite (ex-vivo)."
224257597|NCT04085887|DEVICE|Explorer Air camera|"Surgvision intraoperative camera. Imaging will be performed on subjects during both during surgery (in vivo) and/or on the resected tissues while at the back table in the surgery suite (ex-vivo)."
224257598|NCT04085887|DEVICE|PDE-NEO-II|"Hamamatsu Photonics KK intraoperative camera. Imaging will be performed on subjects during both during surgery (in vivo) and/or on the resected tissues while at the back table in the surgery suite (ex-vivo)."
224257599|NCT03418038|DIETARY_SUPPLEMENT|Ascorbic Acid|Given IV
224257600|NCT03418038|DRUG|Carboplatin|Given IV or PO
224257601|NCT03418038|DRUG|Cisplatin|Given IV or PO
224257602|NCT03418038|DRUG|Cytarabine|Given IV or PO
224257603|NCT03418038|DRUG|Dexamethasone|Given IV or PO
224257604|NCT03418038|DRUG|Etoposide|Given IV or PO
224257605|NCT03418038|DRUG|Gemcitabine Hydrochloride|Given IV or PO
224257606|NCT03418038|DRUG|Ifosfamide|Given IV or PO
224257607|NCT03418038|OTHER|Laboratory Biomarker Analysis|Correlative studies
224257608|NCT03418038|DRUG|Oxaliplatin|Given IV or PO
224257609|NCT03418038|OTHER|Placebo Administration|Given normal saline IV
224257610|NCT03418038|OTHER|Questionnaire Administration|Ancillary studies
224257611|NCT03418038|BIOLOGICAL|Rituximab|Given IV
224257612|NCT03418038|DRUG|Decitabine|Given IV
224257613|NCT03418038|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
224257614|NCT03418038|PROCEDURE|Core Biopsy|Undergo core needle biopsy
224257615|NCT03418038|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration and biopsy
224257616|NCT03418038|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow aspiration and biopsy
224257617|NCT03418038|PROCEDURE|Echocardiography|Undergo ECHO
224257618|NCT03418038|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
224257619|NCT03418038|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
224257620|NCT03418038|PROCEDURE|Central Venous Cannula Insertion|Undergo PICC placement
224257621|NCT03418038|PROCEDURE|Portacath Placement|Undergo portacath placement
224257622|NCT03418038|PROCEDURE|Computed Tomography|Undergo PET/CT
224257623|NCT03450850|DEVICE|NOVOTTF-200A|NOVOTTF-200A will be administered under appropriate guidelines. Monthly adherence rate \>= 75% (\>= 18 hours/day) over a 4-week cycle (28 days) will be strongly encouraged.
224257624|NCT03190915|PROCEDURE|Bone Marrow Aspiration and Biopsy|Undergo bone marrow aspiration or biopsy
224257625|NCT03190915|DRUG|Trametinib|Given PO
224257626|NCT04850118|BIOLOGICAL|rAAV2tYF-GRK1-hRPGRco|Adeno-associated virus vector expressing a human RPGR gene
224257627|NCT04850118|DRUG|Control|Untreated Control Group 3
224257628|NCT06516068|DRUG|HRS-1893|HRS-1893
224257629|NCT01903161|PROCEDURE|delayed remote ischemic preconditioning|In the delayed RIPC group, RIPC is performed 24-48 hr before surgery by 5 minutes limb ischemia and reperfusion with pneumatic cuff up to 200 mmHg repeated by four times.
224257630|NCT01903161|PROCEDURE|control|In the control group, all the procedures were the same with delayed RIPC group, except for the fact that the three-way stopcock between the pneumatic cuff and the cuff inflator was opened and therefore the cuff pressure did not increase.
224257631|NCT04624321|BEHAVIORAL|Health and lifestyle tool|Health and lifestyle tool used online
224257632|NCT04624321|OTHER|Usual care|Usual care at ordinary healthcare provider
224257633|NCT00872092|OTHER|Stable-isotope labeled lactose ureide breath test|2 g 13C-labeled lactose ureide orally
224257634|NCT01940341|DRUG|TAF|25 mg tablet administered orally once daily
224257635|NCT01940341|DRUG|TDF|300 mg tablet administered orally once daily
224257636|NCT01940341|DRUG|TAF Placebo|Tablet administered orally once daily
224257637|NCT01940341|DRUG|TDF Placebo|Tablet administered orally once daily
224257638|NCT02741895|BEHAVIORAL|Fitbit monitoring|Patients will be fitted with a Fitbit after surgery, which will monitor steps and active minutes for the duration of hospitalization.
224257639|NCT01885572|DEVICE|TiLOOP Bra|Titaniferously coated polypropylene mesh
224257640|NCT06331910|DRUG|insulin eye drops|Insulin eye drops deliver insulin directly to the cornea, They exploit insulin's ability to stimulate cell growth, potentially reducing healing time with minimal side effects.
224257641|NCT00539110|DRUG|zolipidem|zolpidem dosed at 2200 and 0200 per feeding tube depending on randomization
224257642|NCT00539110|DRUG|ramelteon|ramelteon dosed at 2200 and 0200 per feeding tube depending on randomization
224257643|NCT04673201|PROCEDURE|"Viscotrabeculotomy Versus trabeculectomy with MMC"|Viscotrabeculotomy involved the creation of a partial thickness scleral flap, followed by localization of Schlemm's canal by radial incisions.High viscosity sodium hyaluronate was injected into Schlemm's canal.Trabeculotomy was completed using the standard metal Harm's trabeculotome.The scleral flap was then secured and conjunctival closure ensued.Trabeculectomy technique involved a creation of a limbal-based conjunctival flap, followed by creation of a half-thickness sclera flap. MMC was applied underneath the conjunctival flap.The procedure was completed with both sclera and conjunctiva closed by 10/0 nylon sutures.
224257644|NCT03244553|DRUG|Prucalopride|5 day treatment
223675996|NCT06784193|DRUG|OP-3136|Selective inhibitor of HAT enzymes KAT6A and KAT6B
224257645|NCT05357235|DRUG|PEG-IFN|PEG-IFN 180 or 135 micrograms, subcutaneously injected once a week, with a personalized treatment course of 24 weeks
224257646|NCT02970123|BEHAVIORAL|Sit Less, Interact, Move More (SLIMM)|
224257647|NCT01911676|DRUG|PF-03463275|
224257648|NCT01911676|DRUG|Placebo|
224257649|NCT06563206|PROCEDURE|Exergame|Hand Training assisted with Virtual-Reality
224257650|NCT06563206|PROCEDURE|Robotic|Hand Training assisted with Robotic Syrebo
224257651|NCT06563206|PROCEDURE|Conventional|Hand Training with Physical Therapist
224257652|NCT05391165|BEHAVIORAL|Back school|Intervention was carried out for 8 weeks with a frequency of two sessions per week, with a total of 16 sessions lasting 45 min. Of all the sessions, 14 had a practical focus and the other two had a theoretical focus. In the practical part, strengthening and stretching exercises were performed. In the theoretical part, self-management and pain neuroscience education were performed.
224257653|NCT04519749|BIOLOGICAL|4D-310|4D-310 is a novel adeno-associated virus (AAV) gene therapy comprised of two active components: the capsid (4D-C102) and the transgene cassette, which encodes a codon-optimized full length human GLA transgene driven by the CAG promoter. 4D-310 has been engineered so that it cannot replicate (replication incompetent).
224257654|NCT01960374|DRUG|Selumetinib|1, 2 or 3 x 25 mg selumetinib (AZD6244; ARRY-142886) (Hyd-Sulfate) capsule administered orally as a single dose on Day 1 of the study (total dose 25 mg, 50 mg and 75 mg respectively) with 240 ml of water at room temperature.
224257655|NCT04045925|OTHER|Taïso|Taiso is a physical preparation practice of which the French Judo Federation is a state delegate. It is practiced in most French dojos. During each course, Taiso's practice works the fundamental motor skills (coordination, static and dynamic balance, locomotion and grip), muscle strengthening, target work by simulated attacks-defenses exercises without blows or projections, relaxation and the specific work of knowledge to fall and rise with graduation and progressivity in the intensity and complexity of the exercises as and when practiced.
224257656|NCT06432595|OTHER|Instability resistance training and Traditional resistance training|The 20 intervention actions were divided into three levels (primary, intermediate, and advanced) for instability resistance training and traditional resistance training. Both groups performed training for 60 minutes three times a week. The Swiss ball, BOSU ball, and Wobble boards only provided an unstable surface environment for instability resistance training. The intensity/load was body weight for both training methods.
224257657|NCT00222118|BEHAVIORAL|labor/birth preparation classes|prenatally, peer counselor/advanced practice nurse team, hospital visit, peer counselor telephone support for 4 weeks
224257658|NCT00222118|OTHER|intervention|prenatal classes and phone calls from peer counselor, peer counselor/lactatin consultant, hospital visit, telephone support to 4 weeks postpartum
223675997|NCT06784193|DRUG|Fulvestrant|Selective estrogen receptor degrader (SERD)
223675998|NCT06784193|DRUG|Palazestrant|Complete estrogen receptor antagonist (CERAN)
223675999|NCT06246916|DRUG|fianlimab|Intravenous (IV) administration every 3 weeks (Q3W) in combination with cemiplimab
223676000|NCT06246916|DRUG|cemiplimab|IV administration Q3W in combination with fianlimab
223676001|NCT06246916|DRUG|relatlimab+nivolumab|IV administration every 4 weeks (Q4W)
224257659|NCT00222118|OTHER|usual care|no intervention
224257660|NCT00652418|DRUG|Gadopentetate dimeglumine (Magnevist, BAY86-4882, SH L 451A)|Magnevist at a dose of 0.1 mmol/kg
224257661|NCT00652418|DRUG|Gadopentetate dimeglumine (Magnevist, BAY86-4882, SH L 451A)|Magnevist at a dose of 0.2 mmol/kg
224257662|NCT01093053|BEHAVIORAL|Mind-Body Skills Groups|The mind-body skills group program teaches participants how to do meditation, guided imagery, breathing techniques, and biofeedback. These mind-body techniques are taught and practiced in small groups of 8 to 10 people and also contain an element of social support.
224257663|NCT01093053|OTHER|Standard Treatment|May include individual or group psychotherapy consisting of cognitive behavioral therapy or present-centered (i.e. unrelated to mindfulness) psychotherapy as well as medication management. Medications for depression, anxiety, and sleep disorders are the most commonly used in standard treatment.
224257664|NCT03378492|DEVICE|Ultrasound Guided Epidural|Sterile ultrasound gel will be applied to the patient's back and the sterile device will be used to image the lumbar vertebrae in the area of the palpation-derived location. When the device is placed above the vertebral interspace, the 3D image mode will identify the spine midline and the depth from the skin to the epidural space. A single 3D ultrasound video loop of the vertebral interspace will be saved to confirm correct landmark identification. After identification of the vertebral interspace, the skin will be marked with a marking utensil or physical indentation at the point of needle entry indicated by the device. The epidural needle will then be placed in the same fashion as in the standard procedure group. The depth of the epidural needle placement will be measured and recorded following observation of loss of resistance.
224257665|NCT03378492|PROCEDURE|Standard Epidural|The point of needle entry will be located using the landmarks technique. The specific level of epidural placement will be determined on a per-patient basis at the anesthesiologist's discretion. The spine midline will also be palpated to determine the approximate location of an interlaminar space. The needle will then be inserted at the appropriate location determined by the landmarks technique, and successful epidural placement will be confirmed by observation of loss of resistance and follow-up confirmation of analgesia. The depth of the epidural needle placement will be measured and recorded following observation of loss of resistance. The epidural catheter will be inserted and the procedure will continue according to the standard of care.
224257666|NCT00954590|DRUG|Dimebon (latrepirdine)|20 mg orally three times daily
224257667|NCT00954590|DRUG|Placebo|Placebo orally three times daily
224257668|NCT06130436|DEVICE|Sham-Remote Ischemic Conditioning|Sham-Remote Ischemic Conditioning (at the time points of 30 min before anesthesia, 30 min after surgery, the morning of the postoperative day 1, the afternoon of the postoperative day 1, the morning of the postoperative day 2, the afternoon of the postoperative day 2): Three cycles (30 minutes), each consisting of five minutes of cuff inflation followed by five minutes with a deflated cuff, but the cuff pressure will be 0 mmHg.
224257669|NCT06130436|DEVICE|Remote Ischemic Conditioning Once Daily|"Remote Ischemic Conditioning (at the time points of 30 min before anesthesia, the morning of the postoperative day 1, the morning of the postoperative day 2): Three cycles (30 minutes), each consisting of five minutes of cuff inflation followed by five minutes with a deflated cuff. The cuff pressure will be 200 mmHg.~Sham-Remote Ischemic Conditioning (at the time points of 30 min after surgery, the afternoon of the postoperative day 1, the afternoon of the postoperative day 2): Three cycles (30 minutes), each consisting of five minutes of cuff inflation followed by five minutes with a deflated cuff, but the cuff pressure will be 0 mmHg."
224257670|NCT06130436|DEVICE|Remote Ischemic Conditioning Twice Daily|Remote Ischemic Conditioning (at the time points of 30 min before anesthesia, 30 min after surgery, the morning of the postoperative day 1, the afternoon of the postoperative day 1, the morning of the postoperative day 2, the afternoon of the postoperative day 2): Three cycles (30 minutes), each consisting of five minutes of cuff inflation followed by five minutes with a deflated cuff. The cuff pressure will be 200 mmHg.
224257671|NCT01566721|DRUG|Herceptin|Herceptin will be given as 600 mg SC (into thigh) on Day 1 of each 3-week cycle for up to 18 cycles.
224257672|NCT04024163|DRUG|Benznidazole|Drug: Benznidazole Tablets 100 mg (functionally scored) or Tablets 12.5 mg
224257673|NCT06287281|OTHER|heel hight shoes|stand upright for 2 hours wearing your own shoes with heels at least 7 cm high
224257674|NCT03398486|DIAGNOSTIC_TEST|Kinesiotaping|Dynamic adhesive taping is a method that involves the application of specific tapes to the surface of the patient's skin in order to use the natural self-healing processes of the body. It is often used as an element that sustains the therapeutic effect. Its action is based mainly on the action normalizing muscle tone, supporting the work of joints, improving the function of weakened muscles, increasing microcirculation at the site of application.
224257675|NCT03398486|DIAGNOSTIC_TEST|inactivation of trigger points (TrP)|A procedure for releasing trigger points using physiotherapy using the ischemic compression method, which involves applying pressure to the active trigger point, until it is switched off, i.e. pain ceases.The location of the trigger point is done palpatively, with a pliers grip, covering the strained tissue on the inside and outside of the cheek with the thumb and index finger.
224257676|NCT02951858|BEHAVIORAL|Intervention Group|The medical staffs who received the training will use the manual of brief intervention to deliver BI and other materials about the harm of substance use.
224257677|NCT02951858|BEHAVIORAL|Control Group|The participants only receive the materials about the harm of substance use.
224257678|NCT03480880|DEVICE|Bispectral Index|Thiopentone was administered in 50 mg boluses during induction of anaesthesia, until reduction of Bispectral Index value to less than 50, and total dose of thiopentone recorded.
224257679|NCT01237054|DRUG|18-NaF PET|The patient will receive 5mCi of F-18 NaF IV (intravenous) bolus, followed by a \~20 ml saline (sodium chloride IV infusion 0.9% w/v) flush over a period of \~20 seconds. Serial dynamic imaging (2 minutes/bed position) will be obtained over a 1-hour period. The patient will be permitted an imaging break until a static PET/CT is performed beginning at 2-hours post F-18 NaF injection.
224257680|NCT01237054|OTHER|DCE-MRI|An FDA (Food and Drug Administration) approved gadolinium chelate (e.g. Magnevist, Berlex Laboratories, NJ, USA) will be administered intravenously at 3 cc/sec using an automated pump injector (Medrad, Pittsburgh, PA, USA).
223676015|NCT05049798|DRUG|Guselkumab|Participants will not receive any intervention as a part of this study. Participants who are initiating the treatment with guselkumab, will be observed according to standard clinical practice.
223676016|NCT05049798|DRUG|IL-17i|Participants will not receive any intervention as a part of this study. Participants who are initiating the treatment with IL-17i, will be observed according to standard clinical practice.
223676021|NCT06540560|BEHAVIORAL|My Pelvic Plan website|"Following the baseline interview, participants will receive a link to a web-based self-guided program and have access for two weeks My Pelvic Plan that combines education on several individual conditions that often contribute to CPP, and will include instruction on cognitive and behavioral restructuring, self-administration of acupressure, engaging in physical activity, and a brief introduction to pelvic floor physical therapy techniques. Subsequent to this, participants will then complete another brief questionnaire after a two-week interval. This questionnaire will focus on willingness to consider specific treatment modalities, credibility/expectancy for specific treatment modalities, and a brief measure assessing self-efficacy for managing symptoms."
223676027|NCT01512589|RADIATION|Proton Beam Therapy (PBT)|1.8 Gy (Relative Biologic Equivalence ((RBE)) to be delivered to the periphery of the planning target volume (PTV) 1 time each day, 5 days a week (Monday through Friday) for up to 28 treatments.
223676028|NCT01512589|RADIATION|Intensity Modulated Radiation Therapy (IMRT)|1.8 Gy to be delivered to the periphery of the planning target volume (PTV) 1 time each day, 5 days a week (Monday through Friday) for up to 28 treatments.
223676029|NCT01512589|BEHAVIORAL|Questionnaires|Symptom and Quality of Life questionnaires completed at baseline, every week during radiation therapy, during break after radiation therapy, and during follow up phase.
223772881|NCT05894772|BEHAVIORAL|Power over Pain Portal|Youth from different ages, sexes, gender, sexual orientations, races, dwelling and school/employment status will receive access to the Power over Pain Portal for 4 months. The portal consists of self-assessment tools (bi-weekly check-ins to provide users with feedback on their mood, anxiety, pain, and sleep and guide decision making on choice of interventions), evidence-based virtual educational (pain neuroscience) and cognitive behavioural therapy (CBT) pain interventions that are delivered in a stepped care manner based on participant needs/preference. The overall objective is to determine the implementation (guided by Proctor's implementation conceptual framework) and clinical effectiveness of the PoP Portal in a sample of youth (12-18 years of age) who are on the waitlist for tertiary care consultation at any pediatric CP clinic in Canada.
223772882|NCT06021561|DIAGNOSTIC_TEST|Diagnosis of pain|Pain will be investigated - type, origin, level
223772883|NCT04935021|DRUG|ATTR-CM|Current treatment
224257681|NCT01237054|DRUG|18-FDG PET/CT|The 18F-FDG injection procedure will be injected and be followed by a \~20 ml saline (sodium chloride IV infusion 0.9% w/v) flush over a period of \~20 seconds. The injection site will be evaluated pre- and post administration for any reaction (e.g. bleeding, hematoma, redness, or infection). Whole body (vertex to toes) static PET/CT imaging will be performed beginning at 1-hour, and again at 2-hours post injection.
223772884|NCT00880347|DEVICE|Blood sampling|Venous blood sampling in PaxGene tubes intended to collect blood RNA that will be then analyzed using SpliceArray (tm) technology for transcriptomic profile. sAPPalpha levels will be also dosed. Clinical data to be collected in parallel (medical history, concomitant treatment, MMSE,clinical examination,...)
223772885|NCT03254901|OTHER|Screening test by Oraquick test|The OraQuick assay uses an indirect immunoassay method to detect hepatitis C antibodies in oral fluid or blood
223772886|NCT06996132|DRUG|Glofitamab|Glofitamab is administered as monotherapy or in combination with investigator-selected agents (including but not limited to chemotherapy, ADCs, BTK inhibitors, etc.) for 2 cycles.
223772887|NCT06996132|DRUG|Chimeric Antigen Receptor T Cells (CAR-T)|After two cycles of glofitamab-based salvage therapy, single-target or dual-target CAR-T cells directed against CD19, CD20, and/or CD22 are infused following lymphodepleting (fludarabine + cyclophosphamide) or myeloablative conditioning, at a dose of 2-4 × 10⁶/kg.
224257682|NCT05367986|DEVICE|electro-acupuncture|"Electro-acupuncture was given at the Zusanli (ST36), Guanyuan (CV4), and Qihai (CV6) acupoints, twice a day for 30 minutes, and for 5 days in total.~1. Acupoints were selected as follows. (1) Zusanli (ST36) belongs to zuyangming stomach meridian. It is located on the anterolateral part of the lower leg 3 inches (4 horizontal fingers) below the eye of the external knee between the fibula and the tibia, and a horizontal finger (middle finger) width from the front edge of the tibia. (2) Guan yuan (CV4) is located 3 inches below the umbilicus, on the midline of the abdomen. (3) Qihai (CV6) is located 1.5 inches below the umbilicus on the midline.~2. Acupuncture and electro-acupuncture methods were performed as follows. Participants were in the supine position, and needles was inserted in the skin . After the participant has acid, numbness, swelling, pain or other feelings, the electro-acupuncture device was connect to the acupuncture needle, the frequency was set to continuous wave."
224257683|NCT06503926|OTHER|SARS-COV-2 vaccination|Vaccination
224257684|NCT06527222|DRUG|Ranolazine|500mg twice daily
223676039|NCT05329623|DRUG|JDQ443|All the participants will receive a single oral dose of JDQ443.
223772888|NCT04065347|DEVICE|Digital Pill|Digital Pill over encapsulating tenofovir alafenamide ART
224257685|NCT06527222|DRUG|Ranolazine|1000 mg twice daily
223772889|NCT07019168|BEHAVIORAL|Jump Squat with Blood Flow Restriction (BFR)|This intervention consisted of jump squat exercises performed with blood flow restriction applied using a non-automated, manually adjustable tourniquet placed on the proximal thighs. The restriction was applied during the exercise to partially limit venous return while maintaining arterial flow. The exercise protocol included 3 sets of 10 repetitions, performed 3 times per week for 4 weeks. A standardized warm-up preceded each session.
223772890|NCT07019168|BEHAVIORAL|Jump Squat without Blood Flow Restriction|This intervention consisted of the same jump squat protocol as the experimental group but without the application of blood flow restriction. Participants performed 3 sets of 10 repetitions, 3 times per week for 4 weeks. Each session was preceded by a standardized warm-up routine that included dynamic stretching and general activation exercises.
224257686|NCT06527222|DRUG|Placebo|Ranolazine placebo twice daily
224257687|NCT04815668|OTHER|Acupuncture group|Sterile single-use stainless steel needles (size 0.35 mm × 55 mm) (YiDaiFu brand, Suzhou Tianyi Acupuncture Instrument Co., Ltd., Suzhou, China) will be utilized. Participants in lateral position, the acupoints area will be sterilized with 75% alcohol. To stimulate SPG, the needles will be inserted in the medial superior anterior direction to a depth of approximately 55 mm33 until the participants report a special sensation radiating toward the nose or the upper teeth. After that, the needle will be withdrew slightly. The needles will be retained for 30 minutes after three stimulation. Rescue medication are permitted when participants feel that their symptoms are intolerable.
224257688|NCT04815668|OTHER|Placebo acupuncture group|The acupuncture procedure will be similar to that of the acupuncture group. After sterilizing the skin, the 0.35 × 25 mm disposable needle will be vertically inserted at SPG acupoint about 3-5 mm. No needle manipulation will be conducted to avoid the deqi response. Rescue medication are permitted when participants feel that their symptoms are intolerable.
224257689|NCT04815668|OTHER|Rescue medication group|Participants in the rescue medication group do not receive acupuncture treatment during the study period. They will be only allowed to use rescue medication. They have the option of 4 weeks (up to 8 sessions) of acupuncture free of charge at the end of the follow-up period.
223772891|NCT07084935|DEVICE|Connecting all patients to the nociception level index(NOL) and the surgical pleth index (SPI)|All patients will be connected to the NOL and SPI during surgery after induction of general anesthesia.
223772892|NCT07084935|DEVICE|All patient will receive a tetanic stimuli (60mA, 100hz) of 5 seconds before start of incision|All patient will receive a tetanic stimuli (60mA, 100hz) of 5 seconds before start of incision.
223772893|NCT07087223|DRUG|Vebreltinib combined with Furmonertinib|Vebreltinib 100mg/1500mg/200mg oral twice daily combined with Furmonertinib 80mg oral once daily
224257690|NCT03453476|DEVICE|SRP and Fotosan 630|After isolating the test quadrants with cotton roll, toluidine blue was applied into the deep pockets (PD ≥ 4mm) at the test quadrants for 10 seconds, followed by inserting a perio tip (15 or 21 mm depending on the depth of the pocket) that connected to a LED emitting device, and light was emitted for 20 seconds. Toluidine blue in the deep pocket was removed by injecting normal saline into the pocket.
224257691|NCT04009434|DEVICE|Mitral Valve Clipping|Patients receive treatment for mitral regurgitation with mitral valve clipping including standard drug therapy.
224257692|NCT04009434|DEVICE|TAVI|Transfemoral transcatheter aortic valve implantation plus optimal standard of care therapy.
224257693|NCT03820427|DIAGNOSTIC_TEST|impulse oscillometry|impulse oscillometry
224257694|NCT03820427|DIAGNOSTIC_TEST|multiple breath washout test|multiple breath washout test
224257695|NCT03820427|DIAGNOSTIC_TEST|body plethysmography|body plethysmography
223676047|NCT05076617|DRUG|Staccato alprazolam|"* Pharmaceutical form: Inhalation powder~* Route of administration: Inhalation~Participants will receive Staccato alprazolam during the Treatment Period."
224257696|NCT00001835|DRUG|Oxaliplatin|
224257697|NCT04817904|DRUG|Rosuvastatin 10mg|The statin-treated arm will receive Rosuvastatin tablets 10 mg/day starting from the point of cisplatin initiation through the entire duration of therapy
224257698|NCT05736718|BEHAVIORAL|Champion Announcement Approach Training|AAT is a one-hour communication workshop that trains clinical staff how to recommend HPV vaccine for children ages 9-12. In the champion arm, vaccine champions will deliver the training using slides and a standardized script. They will also conduct outreach and sustainability planning.
224257699|NCT05736718|BEHAVIORAL|Traditional Announcement Approach Training|AAT is a one-hour communication workshop that trains clinical staff how to recommend HPV vaccine for children ages 9-12. In the traditional arm, outside experts will deliver the training using the same slides and script.
224257700|NCT02619682|DRUG|Ixazomib Citrate|Given PO
224257701|NCT02619682|OTHER|Laboratory Biomarker Analysis|Correlative studies
224257702|NCT02619682|DRUG|Lenalidomide|Given PO
224257703|NCT03835689|BEHAVIORAL|Strongest Families Intervention (formerly Family Help)|Distance HEALTH education intervention focused on skill learning for parents
224257704|NCT00002831|BIOLOGICAL|Filgrastim|Subcutaneously (SQ) daily every 12 hours starting 2-4 days prior to the first stem cell collection and before DAC infusion.
224257705|NCT00002831|DRUG|Busulfan|Administered orally every 6 hours on consecutive days -6 through -4.
224257706|NCT00002831|DRUG|Cyclophosphamide|Given intravenously (IV) over 1 hour on consecutive days -3 and -2.
224257707|NCT00002831|DRUG|Cyclosporine|Patients intolerant to tacrolimus receive cyclosporine IV beginning on day -2, then orally following tolerance and engraftment.
224257708|NCT00002831|DRUG|Decitabine (DAC)|IV over 4 hours on days -8 and -7.
224257709|NCT00002831|DRUG|Methotrexate|Given intrathecally or intraventricularly monthly, beginning on the second month through the eighth month of treatment.
224257710|NCT00002831|DRUG|Methylprednisolone|Given according to clinical grade of GVHD procedures.
224257711|NCT00002831|DRUG|Tacrolimus|IV beginning one day before stem cell infusion, then orally following tolerance to tacrolimus.
224257712|NCT00002831|PROCEDURE|Allogeneic Bone Marrow Transplantation|Infusion of stem cells on Day 0.
224257713|NCT00002831|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Stem cell infusion on Day 0.
224257714|NCT00520234|DRUG|Caspofungin|50 mg IV daily
224257715|NCT00520234|DRUG|Normal Saline|100 cc IV daily
224257716|NCT01143311|GENETIC|Arm A|"4 distinct biopsies will be taken~1. in a non UV-exposed area (inner arm)~2. in a UV-exposed area (external surface of the forearm)~3. in a pretumoral region (actinic keratosis)~4. inside the tumor"
224257717|NCT03700723|BIOLOGICAL|Resusix|spray-dried solvent/detergent treated plasma (blood product)
224257718|NCT03700723|BIOLOGICAL|FP24 (Frozen Plasma)|plasma frozen within 24 hours of phlebotomy
224257719|NCT04831307|OTHER|[68Ga]Ga-HTK03149 PET/CT|200 MBq/m2 of body surface area, with a 200 MBq minimum adult administered activity will be injected intravenously prior to perform the PET/CT
224257720|NCT05665205|OTHER|Aerobic plus strength group|A 8 week program of aerobic exercise plus strength exercise of upper and lower limbs in the hospital with a supervised trained physiotherapist
224257721|NCT05665205|OTHER|Aerobic group|This group has a 8 weeks program of only aerobic exercise in the hospital with a supervised trained physiotherapist.
224257722|NCT00268203|BIOLOGICAL|Iodine I 131 Tositumomab Therapeutic Regimen|Patients will receive unlabeled Tositumomab (450 mg) followed by Tositumomab (35 mg) which has been trace-labeled with 5 mCi of Iodine-131 (dosimetric dose). Whole body counts using a gamma camera will be obtained 3 times between Days 0 and 7 following the dosimetric dose to determine a patient-specific mCi dose of Iodine-131 calculated to deliver the desired total body dose of radiation (either 65 cGy or 75 cGy). The therapeutic dose is administered 7-14 days after the dosimetric dose. Patients will receive unlabeled Tositumomab (450 mg) followed by Tositumomab (35 mg) labeled with the patient-specific dose of Iodine-131 (median dose in previous studies was approximately 85 mCi). Patients who are obese will be dosed based upon 137% of their calculated lean body mass. Patients will be treated with thyroid blocking medication at least 24 hours prior to the dosimetric dose and continuing for 14 days following the therapeutic dose.
224257723|NCT06452251|DIAGNOSTIC_TEST|OPG, OC, RANKL, IL-10, IL-1β, Ca, TNF-α and Caspase-1 ELISA|The levels of OPG, OC, RANKL, IL10, IL1β, Ca, TNF-α and Caspase1 in bone and PICF of patients with or without Vitamin D sufficiency were measured by ELISA.
224322526|NCT07077655|OTHER|Marmet Technique|One of the traditional and natural efforts mothers can make to facilitate breast milk production postpartum is the Marmet technique. This technique embraces the principles of massage and stimulation of the milk ejection reflex (Widiastuti et al., 2015; Hairunisyah \& Kusumawaty, 2022). Furthermore, this technique provides a relaxing effect, reactivating the milk ejection reflex, which in turn stimulates spontaneous milk flow (Yuliani et al., 2015). In other words, the Marmet technique is a combination of expressing milk and massaging the breast by emptying the lactiferous sinuses located under the areola. The Marmet technique stimulates prolactin secretion and helps maximize the milk ejection reflex. The more milk that is withdrawn or emptied from the breast, the greater the milk production (Widiastuti et al., 2015).
224322527|NCT07077655|OTHER|Oxytocin Massage|Oxytocin massage is a type of massage performed to increase breast milk production. The massage is applied to the sides of the spine and the fifth to sixth ribs, and it stimulates the prolactin and oxytocin hormones after birth (Kosova et al., 2016). This massage serves to increase the oxytocin hormone, which can calm the mother, leading to an automatic flow of breast milk (Kilci \& Sevil, 2021). Research conducted by Azizah and Ambarika (2022) shows that a combination of the Marmet technique and oxytocin massage can increase breast milk production. Massaging or stimulating the spine sends a message to the hypothalamus in the posterior pituitary by directly stimulating the medulla oblongata via neurotransmitters to release oxytocin, which then causes milk secretion from the breasts (Lestari \& Linar, 2024).
224322528|NCT07077655|OTHER|Plasebo|No intervention will be made to the participants in this group. Superficial touch will be performed on women's wrists, elbows, and shoulders.
224322529|NCT03514017|DRUG|Pembrolizumab|Pembrolizumab will be administered intravenously (IV) at 200 mg every 3 weeks for 1 year and up to 2 years.
224322530|NCT03514017|DRUG|Ibrutinib|Ibrutinib will be administered orally once daily at approximately the same time each day at the dose of 420 mg daily (3 capsules of 140 mg daily).
224322531|NCT06704191|BIOLOGICAL|BCG Solution|Given intravesically
224257724|NCT06452251|DIAGNOSTIC_TEST|Resonance Frequency Analysis|Implant stability was measured by a device (Penguin RFA, Integration Diagnostics, Sweden) based on Resonance Frequency Analysis (RFA) and categorized by Implant Stability Quotient (ISQ) scale.
224322532|NCT06704191|PROCEDURE|Cystoscopy|Undergo cystoscopy
224322533|NCT06704191|DRUG|Docetaxel|Given intravesically
224322534|NCT06704191|DRUG|Gemcitabine|Given intravesically
224322535|NCT06704191|OTHER|Home Health Encounter|Receive access to CCBW home health visits
224322536|NCT06704191|DRUG|Mitomycin|Given intravesically
224322537|NCT06704191|OTHER|Questionnaire Administration|Ancillary studies
223676074|NCT06709521|DRUG|Iohexol|Iohexol,N,N´ -Bis(2,3-dihydroxypropyl)-5-\[N-(2,3-dihydroxypropyl)-acetamido\]-2,4,6-triiodoisophthalamide, is a non-ionic, water-soluble radiographic contrast medium with a molecular weight of 821.14 (iodine content 46.36%)
223676080|NCT06511388|OTHER|Non-Interventional Study|Non-interventional study
223772894|NCT07087223|DRUG|Vebreltinib combined with Furmonertinib|Vebreltinib 100mg/1500mg/200mg oral twice daily combined with Furmonertinib 80mg oral once daily. Based on the safety data from the completed dose cohorts, the investigators will involve the selection of 1-2 dose cohorts for further study. Approximately 10 additional subjects will be enrolled in the selected dose expansion cohort to determine the recommended dose for Phase II clinical trials.
223772895|NCT07087223|DRUG|Vebreltinib combined with Furmonertinib|RP2D of Vebreltinib as determined during Phase Ib oral twice daily combined with Furmonertinib 80mg oral once daily
224257725|NCT06452251|DIAGNOSTIC_TEST|Periodontal clinical examination|Clinical periodontal indices including plaque index (PI) (Silness and Löe 1964), gingival index (GI) (Löe 1967), probing depth (PD), and bleeding on probing (BOP) (Ainamo and Bay 1975) were recorded using a Williams periodontal probe. The BOP percentage (%) was calculated by dividing the number of bleeding sites by the total number of sites examined.
224257726|NCT06452251|PROCEDURE|Dental implant placement and bone sample collection|All patients were received by a single examiner a bone level implant (standard type and Sandblasted, Large-grit, Acid-etched surface) (Implant Swiss, Yverdon, Switzerland).
224257727|NCT06452251|PROCEDURE|Gingival Crevicular Fluid Sampling|One month after the healing caps were inserted, peri-implant crevicular fluid (PISF) samples were collected from 6 different sides of each implant. Before sampling, the area was isolated and dried, and paper strips were gently kept in periimplant sulcus for 30 seconds. Strips with blood or saliva contamination were discarded. PISF volumes of each strip were measured by a device (Periotron 8,010, Oraflow Inc, USA). Strips were then pooled, and inserted into tubes. PISF was recovered from paper strips through agitation in phosphate buffer saline (50 mM Tris-HCl, 5 mM CaCl2, 0.2 M NaCl,pH 7.5). All samples were stored at -80C until the day of analysis.
224257728|NCT01066598|DRUG|Rituximab|Rituximab 375 mg/m2 IV weekly X 4 doses + Prednisone 1 mg/kg/d
224257729|NCT00001035|DRUG|Interferon alfa-2b|
224257730|NCT00001035|DRUG|Zidovudine|
224257731|NCT00001035|DRUG|Zalcitabine|
224257732|NCT00001035|DRUG|Didanosine|
224257733|NCT01247103|DRUG|AZD4316|Single oral doses of AZD4316 suspension in the fasted state. In one group in Part A, subjects will receive a second dose of AZD4316 in the fed state (within 30 min after receiving a high fat breakfast)
224257734|NCT01247103|DRUG|AZD4316|Multiple oral doses of AZD4316 suspension. It's planned that doses will be administered in the fasted state, however, if in Part A it's shown that food increases absorption of AZD4316, then doses will be administered after a meal.
224257735|NCT01247103|OTHER|Placebo|Placebo to match AZD4316
224257736|NCT00639028|OTHER|Ankle echography|Ankle echography
224257737|NCT00639028|OTHER|Ankle echography + stress radiography|Ankle echography + stress radiography
224257738|NCT00639028|OTHER|stress radiography|ankle stress radiography
224257739|NCT05396885|BIOLOGICAL|anitocabtagene-autoleucel|Anitocabtagene-autoleucel-directed CAR T-cell therapy using a novel, synthetic binding domain, called a D-domain
224257740|NCT00001865|DRUG|Daclizumab|
224257741|NCT06413186|DRUG|Uteratonic administration|Administer IV 10 IU oxytocin
224257742|NCT06413186|OTHER|cord clamping|delayed cord clamping
224257743|NCT06413186|OTHER|delivery of the placenta|Applying controlled core traction
224257744|NCT03197207|PROCEDURE|"Dragon and Tiger warring in lifting and thrusting"|"Tight press slow insert in each acupoint through the superficial,intermediate, deep layer, then tight lifting slow withdraw needle through the deep, intermediate, superficial layer . Two acupoints (GB34, GB39) are manipulation in the process three times each during one minute, then let patients lift shoulder up and down for three times, then draw out the needle 20 minutes later."
224257745|NCT03197207|PROCEDURE|"Dragon and Tiger warring in twisting-rotating"|When needle insert in each acupoint through the superficial,intermediate, deep layer, within each layer twisting thumb forward nine times, then twisting backward six times. Two acupoints (GB34, GB39) are manipulation in the process during one minute, then let patients lift shoulder up and down for three times, then draw out the needle 20 minutes later.
224257746|NCT03327545|DEVICE|Neural mobilization|Neural mobilization on the right side of the craniocervical region for a total of 12 minutes.
223676083|NCT04582708|DEVICE|NERv's Inline Device|NERv's Inline Device is comprised of multiple sensors. It attaches in line to existing catheters or peritoneal drains that are currently approved for medical use. This allows the device to measure the pH and electrical conductivity of effluent fluids that are drained through peritoneal drains.
224257747|NCT03327545|DEVICE|Soft tissue techniques and Stretching|Soft tissue techniques and Stretching on the right side of the craniocervical region for a total of 12 minutes
224257748|NCT03327545|DEVICE|Control group|Did not receive any treatment.
224257749|NCT05213156|DRUG|Oxatrex|0.3% ofloxacin eye drops in single doses
224257750|NCT02316015|DIETARY_SUPPLEMENT|Infatrini® or Infatrini Peptisorb®|
224257751|NCT03108911|OTHER|Best Practice|Receive standard diet
224257752|NCT03108911|PROCEDURE|Biospecimen Collection|Provide stool sample
224257753|NCT03108911|OTHER|Dietary Intervention|Receive GFD
224257754|NCT03108911|OTHER|Laboratory Biomarker Analysis|Correlative studies
224257755|NCT03186651|DEVICE|TVS|Efficacy of a novel intra-vaginal device for temporary reduction of urine leakage in women suffering from stress urinary incontinence and to evaluate the safety and ease of use.
224257756|NCT00491192|DRUG|Diclofenac|
224257757|NCT02067611|DRUG|X0002|Parallel Assignment
224257758|NCT02067611|DRUG|Placebo|Parallel Assignment
224257759|NCT01852487|DIETARY_SUPPLEMENT|400mg /day during 6 months|
224257760|NCT04571021|OTHER|I-DEPT|Implementation of the novel triage algorithm
224257761|NCT04571021|OTHER|DEPT|Existing triage algorithm
224257762|NCT05710354|DIETARY_SUPPLEMENT|Nutridrink Compact Protein|Oral Nutritional Supplement, a liquid, ready-to-drink, high protein, high calorie blend. Intended for adult patients (from 18 years of age) with malnutrition or risk of its development. Produced by Nutricia
224257763|NCT02664961|DRUG|TRC105|Subjects will begin by receiving TRC105 weekly. Subjects who achieve a complete response on single agent TRC105 may transition to every two week dosing.
224257764|NCT02664961|DRUG|Bevacizumab|Bevacizumab will be dosed every two weeks.
224257765|NCT00394810|DRUG|Panzem® NCD|suspension, 100 mg/mL, four times daily continuous dosing
224257766|NCT02067624|OTHER|Thai massage|
224257767|NCT05385640|OTHER|NO intervention|NO intervention
223772896|NCT07086573|DIETARY_SUPPLEMENT|Algae oil 1|DHA Origins 550-Y oil (Fermentalg)
224257768|NCT00445445|OTHER|physiologic testing|Urine samples will be assessed for levels of bisphenol-A
223772897|NCT07086573|DIETARY_SUPPLEMENT|Algae oil 2|Oleo H-02 (Microalgas)
223772898|NCT07086573|DIETARY_SUPPLEMENT|Fish oil (control)|Tuna oil
223772899|NCT07084766|PROCEDURE|ultrasonography, pelvic|Ultrasound measurements will be taken before and after bladder emptying. The axes of the uterine body, cervix and vagina will be marked out by tracing the 3 corresponding lines on the image.
224257769|NCT00445445|OTHER|screening questionnaire administration|Patients and healthy participants complete a self-administered questionnaire providing detailed information on breast cancer risk factors, including demographics, behavioral and lifestyle factors, reproductive history, family history of breast cancer, comorbidities, medication and hormone replacement therapy use, and breast cancer screening history. This information is then cross-validated with documented data abstracted from medical records to provide a longitudinal and historical framework for assessing individual risk.
224257770|NCT00445445|PROCEDURE|breast imaging study|Mammographic density (MD) assessment: Patients and healthy participants are evaluated for patterns of longitudinal change in MD and subsequent breast cancer risk by retrospective review of screening mammograms performed prior to breast cancer diagnosis.
224257771|NCT00445445|PROCEDURE|radiomammography|Mammographic density (MD) assessment: Patients and healthy participants are evaluated for patterns of longitudinal change in MD and subsequent breast cancer risk by retrospective review of screening mammograms performed prior to breast cancer diagnosis.
224257772|NCT00445445|PROCEDURE|study of high risk factors|"* Questionnaire: Patients and healthy participants complete a self-administered questionnaire providing detailed information on breast cancer risk factors, including demographics, behavioral and lifestyle factors, reproductive history, family history of breast cancer, comorbidities, medication and hormone replacement therapy use, and breast cancer screening history. This information is then cross-validated with documented data abstracted from medical records to provide a longitudinal and historical framework for assessing individual risk.~* Mammographic density (MD) assessment: Patients and healthy participants are evaluated for patterns of longitudinal change in MD and subsequent breast cancer risk by retrospective review of screening mammograms performed prior to breast cancer diagnosis."
224257773|NCT06368245|PROCEDURE|long-segment posterior TL instrumented fusion|long-segment posterior TL instrumented fusion with either supplementary rod constructs or dual-rod constructs.
224257774|NCT05436860|DEVICE|liver ultrasound|"At the time of access to the emergency room, a cohort of male and female patients aged 18 or over will be consecutively recruited with green or white color coded triage.~patients who agree to participate in the study will undergo liver ultrasound. Patients who test negative on ultrasound evaluation for liver hyperechogenicity will be part of the control group."
224257775|NCT06656416|DRUG|ALTO-100|ALTO-100 40 mg tablet BID
223772900|NCT07085910|DEVICE|Transcranial magnetic stimulation - dual coil|The dual coil stimulation will be applied using two MagPro X100 stimulators connected to two vertically oriented figure-of-eight coils designed for bilateral hemispheric stimulation.
223772901|NCT07085910|DEVICE|Transcranial magnetic stimulation|Single coil TMS will be performed using a TMS stimulator and the same stimulation coil (MC-B65-HO).
223772902|NCT06453941|OTHER|Yizhi Baduanjin (Eight Pieces of Brocades for Mental Health Promotion)|Yizhi Baduanjin (Eight Pieces of Brocades for Mental Health Promotion) is a newly compiled routine developed on the foundation of the traditional Baduanjin (Eight Pieces of Brocades), which is a traditional Chinese medical health exercise consisted of eight movements to be practiced by oneself.
223772903|NCT04839705|DEVICE|WEB|"Device: WEB The WEB is an intra-aneurysmal device intended for use in endovascular embolization of intracranial aneurysms.~Other Names:~• WEB Aneurysm Embolization Device"
223772904|NCT06864819|OTHER|Blood Draw|Patients will have a single blood sample sent for PEth testing, blood draws will happen during standard of care blood draw.
224257776|NCT06656416|DRUG|Placebo|Placebo tablet BID
223676087|NCT06220604|DRUG|JNJ-77242113|JNJ-77242113 will be administered orally.
223676088|NCT06220604|DRUG|JNJ-77242113 Matching Placebo|JNJ-77242113 matching placebo will be administered orally.
223676089|NCT06220604|DRUG|Deucravacitinib|Deucravacitinib will be administered orally.
223676090|NCT06220604|DRUG|Deucravacitinib Matching Placebo|Deucravacitinib matching placebo will be administered orally.
223676091|NCT04829357|DEVICE|Intervention|There is no intervention, beyond necessary clinical care, in this study. The surgical procedures being performed within the study are identical to the surgical procedures the subjects would receive as part of SOC.
223772905|NCT06908148|DEVICE|Electrolysed water|Electrolysed water is a novel antiseptic produced by passing an electric current through a mixture of tap water and salt. Microbiocidal activity is due to the presence of hypochlorous acid at neutral Ph. Irrigation of chronic wounds reduces bacterial load and appears to encourage wound healing. We propose to compare electrolysed water against conventional management.
223772906|NCT06908148|DEVICE|Conventional irrigant|The irrigant (Prontosan™) that is currently 'in-use' in the conventional management of diabetic foot wounds
224257777|NCT06042205|DEVICE|TISSIUM™ Atraumatic Hernia Repair System (TAHRS)|The TAHRS is intended for fixation of prosthetic material to soft tissue
224257778|NCT03527485|DIAGNOSTIC_TEST|11UCB-J PET Scan|11UCB-J PET Scan
224257779|NCT06624267|DIAGNOSTIC_TEST|PET|PET imaging will be performed with a Discovery 710 PET/CT scanner (GE Healthcare, Milwaukee, WI, USA). Two 5-minute PET recordings will be performed of each subject within a single scanning session of 70 min. One 5-minute scan is conducted of the brain in rest. \[15O\]H2O, is produced on-site (GENtrace, GE, Uppsala, Sweden), and 600 MBq \[15O\]H2O is intravenously injected by an automatic Hidex Radiowater Generator (Hidex, Turku, Finland). To induce brain vasodilation, 1 g of acetazolamide is infused over 5 min and 15 min later the brain is scanned. Cerebral perfusion is calculated using PMOD software (PMOD Technologies, Switzerland).
224257780|NCT04930796|DRUG|VER-01|standardised cannabis extract (containing 21 mg THC per gram drug product)
224257781|NCT06149130|DRUG|Adebrelimab|adebrelimab:1200mg intravenously, Q3W.
224257782|NCT06149130|DRUG|dalpiciclib|dalpiciclib:150mg once a day for 3 weeks and stop for 1 week. Q4W.
224257783|NCT03402503|DRUG|Montelukast buccal film|Film with active investigational product (montelukast) inserted and applied on inner cheek
224257784|NCT03402503|OTHER|Placebo buccal film|Film with placebo (no active drug) inserted and applied on inner cheek
224257785|NCT03789019|DRUG|BP-C1|BP-C1, 0.05% solution for injection; doses: 0.035 mg/kg body weight (0.07 mL/kg) intramuscularly once daily for 32 consecutive days
224257786|NCT00613522|OTHER|polygraphic study|"Berlin scale will be measured. A polygraphic study will be performed to subjects with a Berlin scale \> 2.~Patients stroke characteristics will be recorded (initial severity, stroke mechanism) at baseline and stroke outcome will be evaluated at 3 months (stroke recurrence and functional outcome).~Controls will be evaluated at 3 months using a phone interview"
224257787|NCT00730691|DRUG|Placebo|Placebo-matching capsules
224257788|NCT00730691|DRUG|Vortioxetine|Encapsulated vortioxetine immediate release tablets
224257789|NCT00730691|DRUG|Duloxetine|Overencapsulated duloxetine capsules
223676092|NCT05438043|DRUG|Daratumumab|Daratumumab will be administered either intravenously or subcutaneously.
223676093|NCT05438043|DRUG|Carfilzomib|Carfilzomib will be administered intravenously.
223676094|NCT05438043|DRUG|Dexamethasone|Dexamethasone will be administered either orally or intravenously.
223676095|NCT05438043|DRUG|Lenalidomide|Lenalidomide will be administered orally.
223676096|NCT05438043|DRUG|Pomalidomide|Pomalidomide will be administered orally.
223676097|NCT04640623|DRUG|TAR-200|TAR-200 will be administered transuretherally.
223676098|NCT04640623|BIOLOGICAL|Cetrelimab|Cetrelimab will be administered.
224257790|NCT02649647|PROCEDURE|Conventional resection|The conventional technique requests an excision of at least 10 cm of bowel proximal to the tumor, and the sigmoid colon is anastomosed to the rectum or anus. A defunctioning ileostomy is routinely performed.
224257791|NCT02649647|PROCEDURE|Proximally extended resection|The modified technique requests an excision of the whole sigmoid colon and rectum proximal to the tumor, and the descending colon is anastomosed to the rectum or anus. A defunctioning ileostomy is routinely performed.
224257792|NCT02965859|DRUG|Metacavir Enteric-coated Capsules 80mg|Metacavir Enteric-coated Capsules 80mg
224257793|NCT02965859|DRUG|Metacavir Enteric-coated Capsules 160mg|Metacavir Enteric-coated Capsules 160mg
224257794|NCT02965859|DRUG|Metacavir Enteric-coated Capsules 320mg|Metacavir Enteric-coated Capsules 320mg
224257795|NCT02965859|DRUG|Metacavir Enteric-coated Capsules Placebo 240mg|Metacavir Enteric-coated Capsules Placebo 240mg
224257796|NCT02965859|DRUG|Metacavir Enteric-coated Capsules Placebo 160mg|Metacavir Enteric-coated Capsules Placebo 160mg
224257797|NCT02965859|DRUG|Metacavir Enteric-coated Capsules Placebo 320mg|Metacavir Enteric-coated Capsules Placebo 320mg
224257798|NCT02965859|DRUG|Adefovir Dipivoxil Capsule10mg|Adefovir Dipivoxil Capsule10mg
224257799|NCT02965859|DRUG|Adefovir Dipivoxil Capsule Placebo 10mg|Adefovir Dipivoxil Capsule Placebo 10mg
223676102|NCT04542148|DRUG|Sliding Scale Insulin|After antenatal corticosteroid administration, women will continue to receive long- and short-acting subcutaneous insulin injections as prescribed at home. In addition, they will receive supplemental short-acting insulin using a sliding scale based on postprandial glucose values. Capillary blood glucose values will be measured with fingersticks 4 times daily (fasting and 1-hour postprandial).
223676103|NCT04542148|DRUG|Up-Titration of Home Insulin|After antenatal corticosteroid administration, women will receive long- and short-acting subcutaneous insulin injections at increased dosages compared to that prescribed at home. Insulin will be increased by 30% on the day that they receive their 1st dose of antenatal corticosteroids (day 1), 50% on day 2, 50% on day 3, 30% on day 4, and 15% increase on day 5. On day 6 they will return to their home insulin regimen. Capillary blood glucose values will be measured with fingersticks 4 times daily (fasting and 1-hour postprandial).
223676104|NCT04542148|DRUG|Continuous Insulin Infusion|After antenatal corticosteroid administration, women will discontinue their home insulin regimen and be placed on a continuous insulin infusion with insulin boluses and titration of infusion rate per institutional L\&D protocol. Capillary blood glucose values will be measured with fingersticks every hour.
223676105|NCT04542148|DEVICE|Dexcom G6 Professional Continuous Glucose Monitor|Masked Dexcom G6 Pro devices will be worn for 10 days.
223676106|NCT05421663|BIOLOGICAL|JNJ-90014496|JNJ-90014496, an autologous bi-specific chimeric antigen receptor (CAR) - T cell therapy targeting Cluster of differentiation (CD)19 and CD20.
223676107|NCT03145181|DRUG|Teclistamab (IV)|Participants will receive IV infusion of Teclistamab.
223676108|NCT03145181|DRUG|Teclistamab(SC)|Participants will receive SC injection of Teclistamab.
223676111|NCT03404960|DRUG|Niraparib + Nivolumab|Niraparib 200mg PO daily on days 1-28 of each 28-day cycle. Nivolumab 480mg IV day 1 of each cycle.
224257800|NCT05314647|DIETARY_SUPPLEMENT|lutein|daily dose of 5 mg lutein
224257801|NCT05314647|DIETARY_SUPPLEMENT|placebo|daily dose of 0 mg lutein
224257802|NCT00100776|DRUG|Olanzapine|
224257803|NCT00431912|DRUG|APO866|APO866 is administered as 0.126 mg/m²/hr for 4 consecutive days (96 hours), every 3 weeks for a total of 3 cycles
223676112|NCT03404960|DRUG|Niraparib + Ipilimumab|Niraparib 200mg PO daily on days 1-21 of each 21-day cycle. Ipilimumab 3mg/kg IV day 1 of each cycle, for the first 4 cycles only.
223676113|NCT05818683|DRUG|JNJ-78278343|JNJ-78278343 will be administered.
223676114|NCT05818683|DRUG|Cetrelimab|Cetrelimab will be administered by intravenous infusion.
223676115|NCT05818683|DRUG|Cabazitaxel|Cabazitaxel will be administered by intravenous infusion.
223676116|NCT05818683|DRUG|Docetaxel|Docetaxel will be administered by intravenous infusion.
223676117|NCT05818683|DRUG|Apalutamide|Apalutamide will be administered orally.
223676118|NCT05818683|DRUG|Enzalutamide|Enzalutamide will be administered orally.
223676119|NCT05818683|DRUG|Darolutamide|Darolutamide will be administered orally.
223676120|NCT05818683|DRUG|Abiraterone acetate plus prednisone (AAP)|Abiraterone acetate plus prednisone (AAP) will be administered orally.
223676137|NCT06008392|GENETIC|Pan-genomic Testing|Participants will be scheduled to review the study specifics, review consent and gather medical information. Once consented, samples will be collected. When the samples are received by Exact Sciences, DNA and RNA will be extracted, and sequencing will be performed. Following pan-genomic testing, participants will receive the full report with results from their care team and results will also be added to the patient's portal. If a germline finding is identified (positive pathogenic variant) the participant will also be referred for a genetic counselor visit. All results from the germline hereditary test will be reviewed by a certified genetic counselor in addition to a review of their pedigree. To help with review of any genetic research findings, the study team may request to obtain genomic data from previous genetic testing (clinical or research based).
223676141|NCT05670821|DRUG|Spesolimab|Spesolimab
223676142|NCT06182397|DEVICE|MagicTouch PTA Sirolimus drug coated balloon|All patients must first be treated with pre dilatation with a standard balloon angioplasty using any standard balloon catheters at the discretion of the operator. Magic Touch PTA Sirolimus coated balloon catheter is an adjunct treatment that should be used in combination with standard balloon angioplasty. Following successful crossing of wire across the lesion and plain balloon angioplasty of arterial lesion with successful lesion preparation with residual lesion \<30%, subjects will be randomized to receive study device balloon. If patients are assigned to MagicTouch PTA Sirolimus DCB, the Angioplasty of lower limb will be performed with this device in addition to standard balloon angioplasty.
224257804|NCT02554890|DRUG|sacubitril/valsartan (LCZ696)|sacubitril/valsartan (LCZ696) tablet with minimum dose 24/26 mg, maximum dose 97/103 mg twice daily administered orally.
224257805|NCT02554890|DRUG|Enalapril|Enalapril tablet with minimum dose 2.5 mg, maximum dose 10 mg twice daily administered orally.
224257806|NCT02554890|DRUG|sacubitril/valsartan (LCZ696) matching placebo|matching placebo of sacubitril/valsartan (LCZ696) tablet with minimum dose 24/26 mg, maximum dose 97/103 mg twice daily administered orally.
224257807|NCT02554890|DRUG|enalapril matching placebo|enalapril matching placebo tablet with minimum dose 2.5 mg, maximum dose 10 mg twice daily administered orally.
224257808|NCT01845272|DRUG|candesartan cilexetil 32mg, amlodipine 10mg|Treatment A (candesartan 10 days), at least 4 days wash-out, Treatment B (candesartan + amlodipine 10 days, 2-period, 2-treatment crossover
224257809|NCT01845272|DRUG|candesartan cilexetil 32mg, amlodipine 10mg|Treatment A (amlodipine 10 days), at least 4 days wash-out, Treatment B (candesartan + amlodipine 10 days, 2-period, 2-treatment crossover
224257810|NCT01937143|BEHAVIORAL|Low intensity intervention|Pamphlet with information about pain management during infant immunizations at birth of a newborn infant
223676143|NCT06182397|DEVICE|Placebo balloon angioplasty|For participants randomized to a Placebo balloon angioplasty group, a Placebo balloon angioplasty in addition to standard balloon angioplasty will be performed.
223676154|NCT04140487|DRUG|Azacitidine|Given IV
223676155|NCT04140487|DRUG|Gilteritinib|Given PO
223676156|NCT04140487|DRUG|Venetoclax|Given PO
223676162|NCT06312462|BEHAVIORAL|health education|In the intervention group, we provide schistosomiasis health education to students once a month through community health volunteers for a duration of six months. After that, the community health volunteers no longer visit the school for health education until the completion of a one-year follow-up period.
223676174|NCT03016806|RADIATION|Total Body Irradiation 1200 cGy|Total Body Irradiation 1200 cGy in 8 fractions
223676175|NCT03016806|RADIATION|Total Body Irradiation 200 cGy|Total Body Irradiation 200 cGy in one fraction
223676176|NCT03016806|DRUG|Cyclophosphamide|50 mg/kg or 60 mg/kg
223676177|NCT03016806|DRUG|Mesna|50 mg/kg or 60 mg/kg plus 10% loading dose
223676178|NCT03016806|PROCEDURE|Cord Blood Infusion|Intravenous infusion of cord blood stem cells
223676179|NCT03016806|DRUG|Busulfan|0.8 mg/kg x 16 doses
223676180|NCT03016806|DRUG|Fludarabine|30 mg/m2/day x 5 or 40 mg/m2/day x 5
223676181|NCT03016806|DRUG|Melphalan|140 mg/m2
223676183|NCT01534819|DEVICE|EndoAnchor™|Use of the EndoAnchor™ in conjunction with endograft
223676184|NCT01534819|PROCEDURE|endovascular treament|implantation of a device inserted through an artery
223676185|NCT06197672|BIOLOGICAL|CD4CAR|CD4CAR cells transduced with a lentiviral vector to express the single-chain variable fragment (scFv) nucleotide sequence of the anti-CD4 molecule derived from humanized monoclonal ibalizumab and the intracellular domains of CD28 and 4-1BB co-activators fused to the CD3ζ T-cell activation signaling domain administered by IV infusions as a single dose
223676186|NCT06533098|DRUG|Nipocalimab|Nipocalimab will be administered intravenously.
223676187|NCT06533098|DRUG|Intravenous immunoglobulins (IVIG)|IVIG will be administered intravenously.
224257811|NCT01937143|BEHAVIORAL|High intensity intervention|Pamphlet and video with information about pain management during immunizations at birth of a newborn infant
224257812|NCT01937143|BEHAVIORAL|Control|General information about infant immunizations at birth of a newborn infant
224257813|NCT00362596|DRUG|acyclovir|
223676188|NCT06533098|DRUG|Prednisone|Prednisone will be administered orally.
223676189|NCT06254495|DRUG|PF-08046044/SGN-35C|Given into the vein (IV; intravenously)
223772907|NCT06466005|OTHER|UnityPhilly app|UnityPhilly automatically connects bystanders and victims of opioid overdose with nearby community members who can respond immediately with naloxone.
224257814|NCT03336580|DRUG|PRX004|"PRX004 (0.1, 0.3, 1, 3, 10, and 30 mg/kg) IV every 28 days~PRX004 IV every 28 days at RP2D(s)~PRX004 IV every 28 days at RP2D(s)"
224257815|NCT05600699|DEVICE|Cardiac pacemaker and Select Secure lead|model 3830, 69cm, Medtronic, Inc., Minneapolis, MN, USA
223772908|NCT06909097|BEHAVIORAL|Sitting breaks|Participants will take 2 minute physical movement breaks throughout a sedentary work day.
224257816|NCT00216242|BIOLOGICAL|Influenza virus vaccine (Fluviral)|
224257817|NCT00216242|BIOLOGICAL|Saline placebo|
224257818|NCT06627478|DRUG|NKF-INS(G)|Single subcutaneous dose of 0.5 IU/kg administered over three periods
224257819|NCT06627478|DRUG|US-Lantus®|Single subcutaneous dose of 0.5 IU/kg administered over three periods
224257820|NCT06627478|DRUG|EU-Lantus®|Single subcutaneous dose of 0.5 IU/kg administered over three periods
224257821|NCT03073850|DRUG|Antiplatelet|ASA or clopidogrel
224257822|NCT03073850|DRUG|Low dose oral anticoagulant|Edoxaban of 30mg
224257823|NCT03073850|DRUG|Standard dose oral anticoagulant|Edoxaban of 60mg
223676200|NCT05662319|DRUG|Fitusiran|Pharmaceutical form: Solution for injection Route of administration: Subcutaneous (SC)
223676201|NCT05662319|DRUG|Clotting factor concentrates (CFC) or bypassing agents (BPA)|"* Coagulation factor VIII (ATC code: B02BD02)~* Coagulation factor IX (ATC code: B02BD04)~* Coagulation factor VIIa (ATC code: B02BD08)~* Factor VIII inhibitor bypassing activity (ATC code: B02BD03)~Pharmaceutical form: Solution for infusion Route of administration: Intravenous (IV)"
223676202|NCT05662319|DRUG|Antithrombin concentrate (ATIIIC)|Antithrombin III (ATC code: B01AB02) Pharmaceutical form: Solution for infusion Route of administration: Intravenous (IV)
223676203|NCT03821792|DRUG|Abiraterone Acetate|Given PO
223676204|NCT03821792|DRUG|Apalutamide|Given PO
223772909|NCT06908291|DIAGNOSTIC_TEST|Multi-modal photoacoustic/ultrasonic (PA/US) imaging system|The multi-modal PA/US imaging system is equipped with a handheld PA/US probe, and able to provide data of dual-wavelength PA imaging of breat tomor and Ipsilateral axillary lymph nodes, in addition to real-time 2D PA/US imaging.
224257824|NCT06356805|DEVICE|repetitive transcranial magnetic stimulation|Parallel study: Participants are assigned to one of two groups in parallel for 3 months follow up
223676205|NCT03821792|DRUG|Prednisone|Given PO
224257825|NCT02616133|OTHER|chart abstraction|abstraction of breast cancer patients with de-identified data
224257826|NCT03861247|DRUG|Phosphate-binder intervention|Use phosphate-binders according to KDIGO Guidelines, Chinese Guidance for Diagnosis and Treatment of Mineral and Bone Disorder in Chronic Kidney Disease and drug specification .
224257827|NCT03861247|DIETARY_SUPPLEMENT|Phosphorus-restricted dietary intervention|Use low phosphorus diet and prolong the time of hemodialysis according to the phosphorus balance evaluation if necessary
224257828|NCT05087745|BIOLOGICAL|Tumor Infiltrating Lymphocytes|Adoptive transfer of 1x10\^9-5x10\^10 autologous TILs to patients i.v. in 30-120 minutes.
224257829|NCT03730168|OTHER|circuit weight training program|30 male diabetic patients performed circuit weight training for 12 weeks
224257830|NCT04093505|DRUG|Gemtuzumab Ozogamicin 147|Induction therapy: Gemtuzumab Ozogamicin 3mg/m² on days 1,4 and 7
224257831|NCT04093505|DRUG|Gemtuzumab Ozogamicin 1|Induction therapy: Gemtuzumab Ozogamicin 3mg/m² on day 1
224257832|NCT04093505|DRUG|Glasdegib|Consolidation \& Maintenance therapy Glasdegib 100mg on days 4 to 27
224257833|NCT04093505|DRUG|Placebo Oral Tablet|Consolidation \& Maintenance therapy Placebo 100mg on days 4 to 27
223676219|NCT05511363|DRUG|KarXT|KarXT 20 mg/2 mg TID KarXT 30 mg/3 mg TID KarXT 40 mg/4 mg TID KarXT 50 mg/5 mg TID KarXT 66.7/6.67 mg TID
223676220|NCT05511363|DRUG|Placebo|Placebo Capsules
223676221|NCT05757869|DRUG|Milvexian|Milvexian will be administered orally.
223676222|NCT05757869|DRUG|Apixaban|Apixaban will be administered orally.
223676223|NCT05757869|DRUG|Placebo|Milvexian matching milvexian placebo will be administered orally.
223676224|NCT05757869|DRUG|Apixaban Placebo|Apixaban matching apixaban placebo will be administered orally.
223676225|NCT04395001|DRUG|duloxetine|All participants will receive duloxetine 30 mg once daily for one week and 60 mg once daily for 24 weeks.
224257834|NCT04003090|DRUG|Citicoline|After treatment with a solution containing citicoline 1% eye-drops, 0.2% high molecular weight hyaluronic acid and 0.01% benzalkonium chloride patients underwent a 23G standard 3-port pars plana vitrectomy. The vitreous sample was taken at the beginning of the surgery and then analyzed.
224257835|NCT05083221|BEHAVIORAL|Hear-Talk-Activity audiological program|The participants were randomly assigned to either the experimental group or the waiting-list control group, using a computer-generated list of random numbers.
224257836|NCT04572139|DIAGNOSTIC_TEST|Pituitary stimulation test|Pituitary stimulation with 0.1 mg LHRH, 0.2 mg TRH and 0.25 mg ACTH
224257837|NCT05581329|PROCEDURE|Acupuncture|Acupuncture is a method of inserting very thin needles into special points on the body which are called acupoints. To conduct this intervention, we will use disposable acupuncture needles the size of 0.30 x 13 mm to acupuncture the control acupoint (Yuji - LU10) in the first session and the research acupoint (Houxi - SI3) in the second session.
224257838|NCT01161615|DRUG|MRX-7EAT|Application of up to two patches for up to 7 days.
224257839|NCT01161615|DRUG|Placebo|Application of up to two patches for up to 7 days.
224257840|NCT04311320|DEVICE|Low-Resource Oxygen Blender|The device that is being evaluated is a novel low-cost, high access oxygen blender designed to be used in the World Health Organization bCPAP design. It functions by utilizing the Venturi effect, whereby a narrow jet of one fluid (i.e. oxygen) creates a suction effect and entrains surrounding ambient fluid (i.e. room air) into the jet, effectively creating a mixed solution of both fluids. The cost of materials amounts to approximately 1.40 U.S.D. The average time it takes to build a blender and incorporate it into a bCPAP circuit for a new user is approximately 16 minutes. The materials can all be found in a standard hospital, namely 3cc syringes with rubber stops and a 22 gauge hypodermic needle.
224257841|NCT06721455|OTHER|blood sampling|Discarded blood samples will be taken from routine clinical labs drawn during and after heart surgery.
224257842|NCT03649477|DRUG|3.2 mg intranasal carbetocin|three times per day with meals
224257843|NCT03649477|DRUG|9.6 mg intranasal carbetocin|three times per day with meals
224257844|NCT03649477|DRUG|placebo|three times per day with meals
224257845|NCT04142970|DRUG|HSK3486|HSK3486，Initially 0.4 mg/kg was administered as a 1 minute bolus, followed immediately by a constant infusion dose of 0.4 mg/kg/h administered as a 30 minute infusion via infusion pump.
224257846|NCT02608177|DRUG|Linagliptin|Receives 4 weeks of study drug linagliptin
223676226|NCT04395001|BEHAVIORAL|Web-based Cognitive Behavioral Therapy (CBT)|The web-based CBT program is an automated program (i.e., users learn skills with interactive, personalized training without any therapist contact) that includes 8, 35- to 45-minute training sessions, each of which provides an educational rationale and training in cognitive or behavioral pain coping skill drawn from face-to-face CBT.
224257847|NCT02608177|DRUG|Glipizide|Receives 4 weeks of study drug glipizide
224322538|NCT06821815|OTHER|Video Game Based Therapy|Video game based therapy interventions includes active video games for rehabilitation. Leap Motion Controller based rehabilitative games, Xbox Kinect Games and Kinect Based Custom Rehabilitative Games will be applied to the participants
224322539|NCT06821815|OTHER|Bimanual Intensive Therapy|This intervention includes goal directed activity based exercises for upper extremity functions. This intervention also includes exercises for postural control
223676227|NCT04395001|OTHER|Nurse-delivered Motivational Interviewing|Subjects randomized to the duloxetine and web-based Cognitive Behavioral Therapy (CBT) with nurse support will receive 6 phone calls from MI trained nurse at week 3, 6, 10, 14, 18 and 22. Telephone sessions may run for 20 minutes on the average.
224322540|NCT05271409|DRUG|Satralizumab|Study drug will be administered by subcutaneous (SC) injection in the abdominal or femoral region after all other study-related procedures have been performed at a site visit.
223772910|NCT04966000|BEHAVIORAL|Prism Adaptation Therapy|Participants wear goggles with built-in prisms (a 20-diopter lens) that shift the visual scene to the right. While wearing the googles they reach to and cross out 60 lines/circles, requiring them to learn to reach more leftward than the visual targets appear. Participants can only see the end of their movements.
223772911|NCT06428812|OTHER|Experimental: perineal package application group|This group includes those in the 2nd stage of labor upright position spontaneous pushing Hot application will be made
224257848|NCT04187352|DRUG|CS1001+ Fluorouracil+Cisplatin|"CS1001 1200 mg, intravenous infusion on the first day of each cycle (3 weeks) (Q3W).~Fluorouracil: 800 mg/m2/day, continuous intravenous infusion on Day 1 to Day 4 of each cycle Cisplatin: 80 mg/m2, intravenous infusion on the first day of each cycle."
224257849|NCT04187352|DRUG|Placebo+ Fluorouracil+Cisplatin|"Placebo 1200 mg, intravenous infusion on the first day of each cycle (3 weeks) (Q3W).~Fluorouracil: 800 mg/m2/day, continuous intravenous infusion on Day 1 to Day 4 of each cycle Cisplatin: 80 mg/m2, intravenous infusion on the first day of each cycle."
224257850|NCT04755985|DRUG|AD-213-B|1 tablet administered before the breakfast during 5 days
224257851|NCT04755985|DRUG|AD-2132|1 tablet administered before the breakfast during 5 days
224257852|NCT02906293|OTHER|Abdominal acoustic measurement|"On Day 1 participants will record their intestinal rate at baseline fasting, pre-small meal, and upon completion of the meal. On Day 2 participants will record their intestinal rate at baseline fasting, pre-large meal, and upon completion of meal."
224257853|NCT00952406|OTHER|Survey|This is a study to develop a survey for sexual health in women with pelvic floor dysfunction
224257854|NCT04655001|BEHAVIORAL|MORPH|A 12-week movement and caloric restriction intervention meant to reduce pain and body weight.
224257855|NCT02351024|DRUG|OXP005|
224257856|NCT02351024|DRUG|Naprosyn®|
224257857|NCT05519787|DEVICE|Central Veinous access devices' insertion|"Medical doctor should complete a questionnaire with medical history or any important clinical data that could help for the selection of the location of the port and catheter placement. The insertion will be planned only by a surgeon, interventional radiologist, or anaesthesiologist in the surgery block.~For the patient with a medical history of PICC line, PAC implantation, Central venous access device of any kind, or clinical risk of veinous compression (cervical or subclavian adenopathy, pelerine syndrome, mediastinal involvement…). An echo Doppler exam of the veinous cervical system is required before surgery. This exam should identify potential thrombosis that required a special treatment. It is important that the surgeon who will perform the device's insertion is aware of any history or risks of veinous thrombosis, stenosis, or phlebitis for the patient to avoid procedure's failure."
224257858|NCT07056894|BEHAVIORAL|Action-Based Cognitive Remediation|ABCR is a 16 session intervention involving computer-based drills, real-life simulations, and therapist-facilitated discussions intended to promote cognitive strategy monitoring and transfer of cognitive strategies to daily life. The sessions cover the follow key topics: Speed \& Attention, Memory, Executive Functioning, and Social Cognition.
223772912|NCT06907134|BEHAVIORAL|Smartphone delivered internet-based Cognitive Behavioural Therapy|The intervention is 9 week long were partipants use an smartphone app based on CBT-principles with while having access to an internet platform where extra working material and therapist support is available on demand.
224257859|NCT02430480|DRUG|Goserelin|10.8mg administered subcutaneously every 12 weeks (2 doses)
224257860|NCT02430480|DRUG|Enzalutamide|160mg orally, daily for 24 weeks
224257861|NCT02430480|DEVICE|mpMRI|Multiparametric MRI - One at baseline and after 6 months of treatment
224257862|NCT06746181|BEHAVIORAL|Fraction of inspiration O2(FiO2)|After the patient was admitted to the room, anesthesia induction was performed after pre-oxygenation for 3 minutes. Tracheal intubation was carried out once the medication had fully taken effect. After the surgery began, the inspired oxygen concentration was adjusted for each group. The first lung recruitment maneuver was performed 10 minutes later, and subsequent lung recruitment maneuvers were conducted when pulmonary compliance returned to baseline levels. This process was repeated, with all patients undergoing one final lung recruitment maneuver immediately at the end of the surgery.
224257863|NCT02839252|BEHAVIORAL|Iggy and the Inhalers Asthma Education for Kids|It is a comic book, trading cards, and stickers that teach kids about asthma. There is also a 12-minute cartoon video which teaches kids about asthma.
223676244|NCT05316155|DRUG|Erdafitinib Intravesical Delivery System|Erdafitinib intravesical delivery system will be administered.
223676246|NCT06631638|DEVICE|EMPHASYS Cup with VHN|Total Hip Replacement with EMPHASYS Acetabular shell and Non-Invasive Navigation
223772913|NCT02285751|DRUG|acetylsalicylic acid|
223772914|NCT02285751|DRUG|clopidogrel|
223772915|NCT02285751|DRUG|prasugrel|
223772916|NCT02285751|DRUG|ticagrelor|
223772917|NCT01297218|BIOLOGICAL|Human Umbilical Cord Blood Derived-Mesenchymal Stem Cells|DOSE A - 250,000 cells per 5 uL per 1 entry site, 3 million cells per brain DOSE B - 500,000 cells per 5 uL per 1 entry site, 6 million cells per brain
223772918|NCT03116165|BEHAVIORAL|Modified prolonged exposure therapy|Participants will receive three sessions of modified prolonged exposure therapy.
223772919|NCT03116165|BEHAVIORAL|Attention control|Participants will receive three sessions of supportive counselling and psychoeducation
223772920|NCT01156324|BEHAVIORAL|Online Stress Management Group (Upliv)|Personalized online stress management program
223772921|NCT01156324|BEHAVIORAL|Control|Control group receiving routine care along with $50 gift certificate at end of cycle
224257864|NCT06139666|DRUG|Exparel Injectable Solution|"Patients randomized to this arm will receive an interscalene block with Exparel solution, an extended-release formulation of bupivacaine (10cc liposomal bupivacaine + 15cc bupivacaine), approved for use at the study institution. This will be administered preoperatively on the day of surgery. The anesthesiologist administering the injection will be not be blinded to the mixture of injections (the surgeon and the patient will), which will be designated and randomized prior to administration. They will order and draw up the medication as they have been previously with no change in the standard of care.~After surgery, the patient will be asked to keep a daily log of their pain scores, and the amount of narcotics will be counted by the physician at the first postoperative visit. The block would have been offered to the patient even if they are not part of the study. No additional visits are required. The only difference is the journal with pain score surveys and the pill count."
224257865|NCT06139666|DRUG|Bupivacaine Injectable Solution|"Patients randomized to this arm will receive a standard interscalene block consisting of 25 cc of bupivacaine alone. This will be administered preoperatively on the day of surgery.~The anesthesiologist administering the injection will not be blinded to the mixture of injections (the surgeon and the patient will), which will be designated and randomized prior to administration. They will order and draw up the medication as they have been previously with no change in the standard of care.~After surgery, the patient will be asked to keep a daily log of their pain scores, and the amount of narcotics will be counted by the physician at the first postoperative visit. The block would have been offered to the patient even if they are not part of the study. No additional visits are required. The only difference is the journal with pain score surveys and the pill count."
224322541|NCT05271409|OTHER|Placebo|Placebo will be administered by SC injection in the abdominal or femoral region after all other study-related procedures have been performed at a site visit.
223676250|NCT04251156|DRUG|Semaglutide|Semaglutide administered subcutaneously (s.c., under the skin) as well as diet and physical activity counselling for 44 weeks. Doses gradually increased to 2.4 mg
223676251|NCT04251156|DRUG|Placebo (semaglutide)|Semaglutide placebo administered s.c. as an adjunct to a reduced-calorie diet and increased physical activity regimen for 44 weeks
223676252|NCT06144632|DEVICE|THERMOCOOL STSF Bi- Directional Navigation Catheter|THERMOCOOL STSF will be used in conjunction with TRUPULSE Generator to give pulsed field (PF) ablation or radiofrequency (RF) ablation.
223676253|NCT06144632|DEVICE|TRUPULSE Generator|TRUPULSE Generator will be used to deliver PF/RF ablation.
223676257|NCT06455098|DEVICE|OMNYPULSE™ Catheter with the TRUPULSE Generator|OMNYPULSE™ Catheter and TRUPULSE™ Generator will be used for PF ablation.
223676259|NCT05729373|DRUG|SEP-363856|once daily tablet
223676260|NCT05729373|DRUG|Placebo|once daily tablet
223676265|NCT04789018|OTHER|Educational Intervention|Attend virtual genetics board
223676266|NCT04789018|OTHER|Survey Administration|Complete survey
223772922|NCT02258152|DRUG|SYN120|SYN120 Doses to be Administered: 20 mg QD (1 week titration), 50 mg QD (1 week titration), 100 mg QD (14 weeks of maintenance).
223676267|NCT04789018|OTHER|Interview|Complete interview
223676268|NCT06033859|DIAGNOSTIC_TEST|Clinical measurements|With the aid of a periodontal probe, the incidence of BOP, as well as PD, recession and KM will be assessed.
223676269|NCT06033859|DIAGNOSTIC_TEST|Radiographic measurement|A standardized periapical radiograph of the implant will be completed at the beginning and the end of study to determine the marginal bone loss.
223676270|NCT06033859|PROCEDURE|Dental prophylaxis or maintenance|Dental prophylaxis or maintenance will be performed every 3 months.
223772923|NCT02258152|DRUG|Placebo|Placebo QD
223772924|NCT06005259|DRUG|Spironolactone|Spironolactone 25 mg capsule
223772925|NCT06005259|DRUG|Placebo|Placebo capsule
223772926|NCT04258839|DRUG|Brexpiprazole|Oral tablet; taken once daily
223772927|NCT04521010|OTHER|COVID-19 pandemic|The aim of the study was to evaluate the staff absenteeism in the initial period of the COVID-19 pandemic at Wiktor Dega Orthopedic and Rehabilitation Clinical Hospital in Poznań Poznań as well as to assess the level of performance of medical services that were assigned to the Hospital under contract with National Health Fund, the payer of public health services in Poland.
223772928|NCT04498897|DRUG|Vortioxetine|"* Baseline: Vortioxetine 10mg (or placebo) + Acamprosate~* First 2 weeks: Vortioxetine 5-10mg (or placebo) + Acamprosate~* Last 6 weeks: Vortioxetine 5-20mg (or placebo) + Acamprosate"
224257866|NCT07063758|OTHER|Biomarker Analysis|Tumor tissue and serum samples will be collected and analyzed to evaluate the expression of membranous Nectin-4, ADAM10/17, and levels of soluble Nectin-4 (sNectin-4) as predictive biomarkers in patients with advanced urothelial carcinoma receiving standard therapies.
224257867|NCT07063628|DIAGNOSTIC_TEST|TyG-derived index.|"Derived indices included:~* Ty,G×B,M,I = TyG index × body mass index~* TyG×W,C = TyG index × waist circumference~* TyG×WH,tR = TyG index × waist-to-height ratio Quartile-based stratification was applied to each TyG-derived index."
224257868|NCT07063628|DIAGNOSTIC_TEST|Left Ventricular Speckle Tracking|Coronary Angiography and Gensini Scoring: All participants underwent standard diagnostic coronary angiography. CAD was categorized as one-, two-, or three-vessel disease based on the number of vessels with ≥50% stenosis. The severity of CAD was quantified using the Gensini score, which assigns a severity weight to each lesion depending on degree of stenosis and anatomical location. Final scores were calculated by summing weighted values across all coronary segments.
224257869|NCT07068490|DRUG|Routine use of P-CAB on DAPT|This group received P-CAB with DAPT after PCI.
224257870|NCT07068490|DRUG|Guideline Directed Medical Therapy|This group received PPI or not with DAPT after PCI according to GI bleeding risk.
224257871|NCT07067879|OTHER|Lip product|Lip product containing Caulerpa lentillifera extract
224257872|NCT07067255|BIOLOGICAL|GPC3 CD146 CAR-T cells|"The intervention in this clinical trial involves a novel approach using CD146/GPC3 Chimeric Antigen Receptor T (CAR T) cells combined with chemotherapy. The goal is to assess safety and efficacy in patients with specific hematologic malignancies.~Treatment Regimen:~Patients in the trial will undergo the following regimen:~Fludarabine Phosphate (Days -4 to -2): IV administration of fludarabine phosphate over 30 minutes on days -4 to -2. It's part of the preparatory regimen to enhance the body's response to CAR T-cell therapy.~Cyclophosphamide (Day -2): IV cyclophosphamide over 60 minutes on day -2.~GPC3/CD146 Chimeric Antigen Receptor T Cells (Day 0): IV administration of investigational therapy, GPC3/CD146 CAR T cells, over 10-20 minutes on day 0.~Additional Doses: Eligible patients responding well to the initial CD146/GPC3 CAR-T cell infusion without unacceptable side effects and sufficient CAR-T cell availability may receive 2 or 3 additional doses."
224257873|NCT07069114|PROCEDURE|Anterior Cervical Discectomy and Fusion with BAK/C Interbody Fusion|The surgical intervention consisted of anterior cervical discectomy and fusion (ACDF). Patients were placed under general anesthesia in a supine position with slight neck extension. A standard right anterior cervical approach was utilized to expose the affected vertebral levels. Following the removal of the degenerated intervertebral disc and osteophytes, the interbody space was prepared. A Bagby and Kuslich (BAK/C) interbody fusion cage, filled with autogenous bone fragments, was implanted to facilitate fusion. In cases of multi-level surgery, an anterior cervical plate was selectively applied for enhanced stability based on intraoperative assessment. Postoperatively, all patients were required to wear a Philadelphia hard neck brace for a period of 2 months.
224257874|NCT07069075|GENETIC|MMP-2 Gene Polymorphism (rs243865) Analysis|Participants were genotyped for the MMP-2 rs243865 polymorphism. Genomic DNA was extracted from peripheral blood, and the specific genotype (CC, CT, or TT) was determined using Polymerase Chain Reaction-Restriction Fragment Length Polymorphism (PCR-RFLP) analysis. This allowed for the stratification of participants based on their genetic variation at this locus for subsequent association analysis.
224257875|NCT07069075|GENETIC|TIMP-2 Gene Polymorphism (rs8179090) Analysis|Participants were genotyped for the TIMP-2 rs8179090 polymorphism. Genomic DNA was extracted from peripheral blood, and the specific genotype (CC, GC, or GG) was determined using Polymerase Chain Reaction-Restriction Fragment Length Polymorphism (PCR-RFLP) analysis. This allowed for the stratification of participants based on their genetic variation at this locus for subsequent association analysis.
224257876|NCT07068399|PROCEDURE|Extracorporeal shock wave therapy|Extracorporeal shock wave therapy (ESWT) delivers acoustic energy transmitted through liquid medium to internal body tissues. The intervention group will receive a total of 9 ESWT treatment sessions and 200 shocks will be applied to each ischaemic zone of myocardium for 3 times a week on the three weeks that the patients receive ESWT.
224257877|NCT07069556|DEVICE|ColoSense|multi-target stool RNA test
224257878|NCT07067866|OTHER|Titrated weaning of vasopressin.|The titrated group will follow the vasopressin weaning protocol used in the DOVSS study (reduction of 0.01 U/min per hour).
224257879|NCT07067866|OTHER|Abrupt weaning of vasopressin.|The abrupt group will discontinue the vasopressin infusion at the time of randomization, without dose titration.
223676272|NCT06178614|DRUG|JNJ-87890387|JNJ-87890387 will be administered.
223676273|NCT04987229|DRUG|OLZ/SAM|Olanzapine and Samidorphan fixed dose coated tablet taken once daily
224322542|NCT03389347|PROCEDURE|Biospecimen Collection|Undergo collection of bone marrow aspirate and blood
224322543|NCT03389347|DEVICE|High Throughput Screening|Anti-tumor drugs are tested against myeloma cells in the laboratory, in a high-throughput drug sensitivity assay
224322544|NCT03389347|OTHER|Laboratory Biomarker Analysis|Correlative studies
224322545|NCT06818812|DRUG|INCB186748|INCB186748 will be administered at protocol defined dose.
224322546|NCT06818812|DRUG|Cetuximab|Cetuximab will be administered at protocol defined dose.
224322547|NCT06818812|DRUG|GEMNabP|GEMNabP will be administered at protocol defined dose.
224322548|NCT06818812|DRUG|mFOLFIRINOX|mFOLFIRINOX will be administered at protocol defined dose.
223772929|NCT04498897|DRUG|Acamprosate|"* Baseline: Vortioxetine 10mg (or placebo) + Acamprosate~* First 2 weeks: Vortioxetine 5-10mg (or placebo) + Acamprosate~* Last 6 weeks: Vortioxetine 5-20mg (or placebo) + Acamprosate"
223772930|NCT00949013|OTHER|immunohistochemistry staining method|
223772931|NCT00949013|OTHER|laboratory biomarker analysis|
223772932|NCT04292158|DEVICE|SomnoTouch|"The patient will be equipped with the SomnoTouch device. This device is able to record and estimate the following data:~ECG data PPG data Heart rate Respiration rate Blood pressure (mmHg) Oxygen saturation (%).~All patient will be stored for further analysis."
223772933|NCT04292158|DEVICE|MOX|"The patient will be equipped with the MOX device. This device is able to record and estimate the following data:~Accelerometers data Activity Body posture~All patient will be stored for further analysis."
223772934|NCT00944775|BEHAVIORAL|Exercise training|10-month exercise training program during hemodialysis sessions
223772935|NCT01747681|PROCEDURE|Microfracture|
223772936|NCT04741659|DEVICE|Ventimask|The patients will be asked to breathe spontaneously using their actual low oxygen flow
223772937|NCT04741659|DEVICE|High Flow Nasal cannula (HFNC)|The patients will be asked to breathe using high flow nasal cannula (HFNC). Air flow will set up to 60 l/m, temperature according to patient's comfort and FiO2 in order to obtain SpO2 values \>/= 92%
223772938|NCT04741659|DEVICE|Helmet CPAP|The patients will be asked to breathe with Helmet. CPAP will set at 10 cmH2O and FiO2 in order to obtain SpO2 values \>/= 92%
223772939|NCT04741659|DEVICE|Non Invasive Ventilation (NIV)|the patients will be asked to breathe with the support of a ventilator via a oro-nasal interface
223772940|NCT01313234|BEHAVIORAL|Education|Theory based education and systematic daily assessment
223772941|NCT04380584|DIAGNOSTIC_TEST|plasma Apelin level|blood sample for detection of plasma Apelin level
223772942|NCT01123018|BEHAVIORAL|Memtrax Memory screening test|Memory Screening test
223772943|NCT05747846|PROCEDURE|Carpal tunnel release, WALANT technique|Patients will receive 20 ml of 1% lidocaine with 1:100,000 epinephrine (buffered 10:1 with 8.4% sodium bicarbonate). Thirty minutes before carpal tunnel release surgery, 10 mL will be injected subcutaneously, and 10 mL will be injected into the carpal tunnel. Patients will go under open carpal tunnel release without a tourniquet.
223772944|NCT05747846|PROCEDURE|Carpal tunnel release using a tourniquet|Patients will receive 20 ml of 1% lidocaine with 1:100,000 epinephrine (buffered 10:1 with 8.4% sodium bicarbonate). Thirty minutes before carpal tunnel release surgery, 10 mL will be injected subcutaneously, and 10 mL will be injected into the carpal tunnel. Patients will go under open carpal tunnel release using a hemostatic cuff. The hemostatic cuff will be insufflated at the level of the arm at a pressure of 100 mmHg higher than the patient's systolic pressure. The cuff will be removed once wound closure is complete.
223772945|NCT02782819|DRUG|Isotonic crystalloid solution resuscitation|Patient will receive normal saline or Ringer lactate or other balance salt solution during fluid resuscitation for shock reversal.
223772946|NCT02782819|DRUG|Colloid solution resuscitation|Patient will receive 5% albumin or gelatin solution during shock resuscitation
223676280|NCT03399799|DRUG|Talquetamab|Participants will receive IV infusion or SC injection of Talquetamab.
223676281|NCT06563895|DRUG|Acoramidis|TTR stabilizer administered orally twice daily (BID)
223676282|NCT06563895|DRUG|Placebo oral tablet|Non-active control administered orally twice daily (BID)
223772947|NCT05507710|DIAGNOSTIC_TEST|Near-infrared fluorescence imaging of perfusion|Imaging with ICG near-infrared fluorescence is performed besides clinical judgement of the DIEP flap for perfusion evaluation. Based on fluorescence imaging, additional malperfused area(s) are resected.
223772948|NCT02784314|PROCEDURE|Robotic-Assisted Radical Prostatectomy|
223772949|NCT02784314|PROCEDURE|Laparoscopic Radical Prostatectomy|
223772950|NCT05038059|DRUG|ethanolic extract of sapindus mukorossi|ethanolic extract will be used as final endodontic irrigant during root canal procedures in extracted teeth.
223772951|NCT05038059|DRUG|ethylene diamine tetra acetic acid|used as final endodontic irrigant in root canal therapy
223772952|NCT03889717|DIETARY_SUPPLEMENT|vitamin D|vitamin d drops will be given daily to the 2 groups of neonates ( 1st group will be given 400 iu /day and 2nd group will be given 1000 iu per day ) when they reach 100 cc per kg enteral feeding .. until they reach 40 weeks gestational age
223772953|NCT04011475|DRUG|Tiotropium + Olodaterol|Spiolto®
223772954|NCT04011475|DRUG|Other LABA/LAMA|tiotropium/olodaterol, indacaterol/glycopyrronium, vilanterol/umeclidinium
223772955|NCT04011475|DRUG|LAMA|aclidinium bromide, glycopyrronium, tiotropium, umeclidinium
223772956|NCT02595567|DEVICE|Indwelling tunneled pleural catheter (ITPC)|ITPCs have been shown to successfully and safely control dyspnea in patients with malignant pleural effusions. Compared to the large amount of published data regarding the use of indwelling tunneled pleural catheters in malignant effusions, there is a paucity of data regarding the use of ITPC in liver disease for the treatment of hepatic hydrothorax.
223772957|NCT00752505|DRUG|Esreboxetine|Tablet once daily either placebo, 4mg or 8mg per day. Subjects will be on active treatment for 4 weeks out of a total of 11 weeks in a crossover dosing
223772958|NCT00752505|DRUG|Esreboxetine|Tablet once daily either placebo, 4mg or 8mg per day. Subjects will be on active treatment for 4 weeks out of a total of 11 weeks in a crossover dosing
224257880|NCT07067411|BEHAVIORAL|Education Program Using Gamification on GDM|"The five games planned to be used in the study are; What is Gestational Diabetes?, Nutrition Education, Complication Precautions, Medical Treatment Applications and Physical Activity. The creation and implementation of these games will be done through the Genially platform. The Genially platform is an easy-to-use and free web tool used to create interactive visual content. The platform includes features such as sharing or downloading via website, social media or e-mail by adding animations, effects, sounds and interactive elements. In addition, the performances of the people who share the created content can be tracked and feedback can be obtained. At the beginning of the games planned to be used in the study, an informative video of not more than five minutes on the subject created by the researcher will be shared. National and international guidelines will be taken into consideration in the creation of these videos. One day after the informative video is"
224257881|NCT07068828|BEHAVIORAL|Mobilization Encouragement Protocol|This intervention includes a video-based education session delivered before surgery to encourage early mobilization, visual poster reminders in patient rooms on postoperative day 1, and SMS text message reminders sent to patients' phones on postoperative days 1 and 3. Participants will also wear a smart watch starting 8 hours after surgery through postoperative day 3 to monitor physical activity (step count). The goal is to increase physical activity levels, improve recovery quality, and reduce postoperative complications after bariatric surgery.
224257882|NCT07068828|BEHAVIORAL|Smart Watch for Physical Activity Monitoring|Participants in the control group receive standard postoperative care without additional mobilization encouragement. They wear a smart watch starting 8 hours after surgery through postoperative day 3 to monitor physical activity (step count). However, they do not receive video education, posters, or SMS reminders.
224257883|NCT07068971|BEHAVIORAL|Online cognitive behavioural therapy for insomnia, bright light therapy, activity|Multimodal intervention
224257884|NCT07068451|PROCEDURE|Greater Occipital Nerve Block (GONB)|A landmark-guided injection of 1 mL of 2% lidocaine administered at the anatomical location of the greater occipital nerve (GON) to treat cervicogenic headache and occipital neuralgia. Performed without corticosteroids or imaging guidance.
224257885|NCT07068451|PROCEDURE|Combined Greater and Lesser Occipital Nerve Block (GONB + LONB)|Two landmark-guided injections of 1 mL of 2% lidocaine each at the anatomical locations of the greater and lesser occipital nerves. Performed without corticosteroids or imaging, targeting broader nerve involvement in cervicogenic headache and occipital neuralgia.
224257886|NCT07068698|OTHER|Thumb Manipulation|This intervention consists of chiropractic manipulation techniques applied specifically to the thumb joint. The manipulation will be performed by a trained physiotherapist twice weekly for 4 weeks. The procedure aims to improve thumb joint mobility, hand grip strength, sensory function, and overall hand function. Each session includes standardized manual therapy maneuvers targeting the thumb's range of motion and soft tissue mobility without the use of any devices or medications. The intervention differs from other manual therapies by focusing solely on the thumb region.
223676284|NCT05265273|DRUG|Nipocalimab|Nipocalimab will be administered as an IV infusion.
224257887|NCT07068750|PROCEDURE|patients received dental implants using single drilling system in posterior maxilla|All patients will be operated under local anaesthesia Articaine hydrochloride 4% with Epinephrine (1:100,000). Crestal incision will performed and full thickness mucoperiosteal flap will be reflected to access the site. The implant will be prepared using the new specially designed drill. These drills are available with four drilling lengths (7, 9, 11, 13 mm) characterized by different color codes, and three different diameters (4, 4.5, 5 mm). They allow a single drilling procedure before implant placement in bone with all types. Drilling speed of 1500 RPM and profuse normal saline irrigation will be used throughout the drilling procedure. Tapered implants will be inserted in all patients with insertion torque 30-50Ncm. Suturing of the flap with interrupted sutures, using 5/0 polypropylene suturing material (According to the protocol provided by the manufacturer).
223676296|NCT05567185|DRUG|Erdafitinib Intravesical Delivery System|Erdafitinib intravesical delivery system will be administered.
223676297|NCT05379634|DRUG|Nipocalimab|Nipocalimab will be administered intravenously in double-blind period and LTE period.
223676298|NCT05379634|OTHER|Placebo|Nipocalimab matching placebo will be administered intravenously in double-blind period.
223676299|NCT05379634|DRUG|Glucocorticoids|Prednisone or equivalent will be administered orally as Glucocorticoid.
223676303|NCT05179876|DRUG|Macitentan|Adult participants will receive oral dose of macitentan 10 milligrams (mg) tablet once daily. Children greater than or equal to (\>=) 2 year to less than (\<) 18 years will be given an oral macitentan dose tailored to their body weight, ensuring an equivalent level of systemic exposure as in adults.
223772959|NCT04413318|DEVICE|Electronic device (VBM©)|Continuous control of tracheal cuff pressure using an electronic device (VBM©) for 6-hours followed by continuous control using a pneumatic device (Nosten©) for 6-hours.
224257888|NCT07068750|PROCEDURE|patients received dental implants using Densah burs in posterior maxilla|All patients will be operated under local anaesthesia Articaine hydrochloride 4% with Epinephrine (1:100,000). Crestal incision will be performed and full thickness mucoperiosteal flap will be reflected to access the site. Implant sites will be prepared using osseodensification burs (Densah, Versah) at 1200 rpm in the following sequence: (I) pilot (clockwise); (II) WT1828 (counterclockwise), and (III) WT2838 (counterclockwise). These burs have a cutting chisel edge, a tapered shank and non- cutting edges with four or more lands with a negative rake angle. Suturing of the flap with interrupted sutures, using 5/0 polypropylene suturing material (According to the protocol provided by the manufacturer).
224257889|NCT07068750|PROCEDURE|patients received dental implants using conventional drills in posterior maxilla|All patients will be operated under local anaesthesia Articaine hydrochloride 4% with Epinephrine (1:100,000). Crestal incision will be performed and full thickness mucoperiosteal flap will be reflected to access the site. Implant sites will be prepared using conventional surgical drills at 1200 rpm. Suturing of the flap with interrupted sutures, using 5/0 polypropylene suturing material (According to the protocol provided by the manufacturer).
223676304|NCT05179876|DRUG|Selexipag|Adult Participant will receive oral dose of selexipag tablet twice daily at the dose strength corresponding to their maintenance dose at the end of their parent study. Available strengths: 200, 400, 600, 800, 1000, 1200, 1400 and 1600 micrograms (µg). Children with body weight category of \>=50 kg will use the tablets at the required dose strength as described for adults. Children with a body weight \< 50 kg will receive tablets for pediatric use (dose strengths: 100 and 150 mcg), twice daily to enable continuation of individually maximum tolerated dose of selexipag according to their body weight category.
223676305|NCT05179876|DRUG|Macitentan/Tadalafil FDC|Participants will receive oral FDC of macitentan 10 mg and tadalafil 40 mg once daily during the course of the study as already received in the parent studies.
223676306|NCT04459507|OTHER|No intervention|No intervention will be administered as a part of this study. Both retrospective and prospective data will be collected. The retrospective data will be collected through participant charts and prospective data will be collected in accordance with clinical practice at the participant's clinic visits.
224257890|NCT06899971|OTHER|Collecting discarded blood samples|Discarded blood samples will be collected from routine clinical labs collected before and after surgery.
224257891|NCT06129253|OTHER|Urine Sample Collection|When urine is collected as a sample in either CSS or LS, first flow urine samples will be collected
224257892|NCT06129253|OTHER|Self-collected Vaginal Swab|Self-collected Vaginal Swab will be collected by the participant under the supervision of a trained nurse or other health care worker.
224257893|NCT06129253|OTHER|Blood Samples|If funding permits, a blood sample may be collected from participants in LS once during the follow-up period. If blood sample collection was not feasible during a visit, two additional attempts may be made to collect blood samples from LS participants during the subsequent follow-up visits.
224257894|NCT03190005|DRUG|clopidogrel|routine Dual antiplatelet therapy after stent implantation, then check PRU(platelet reactivity unit)
224257895|NCT03190005|DRUG|Placebos|no medication, healthy subjects.
224257896|NCT01692717|DRUG|Atorvastatin|10 mg
224257897|NCT01692717|DRUG|Hydrochlorothiazide + Losartan|12.5 mg + 50 mg
224257898|NCT01692717|DRUG|Hydrochlorothiazide + Losartan + Atorvastatin|12.5 mg + 50 mg + 10 mg
224257899|NCT01097577|DRUG|pregabalin|1 capsule (75 mg) by mouth twice daily starting two hours prior to surgery and continuing 4 days postoperatively.
224257900|NCT01097577|DRUG|Placebo|1 capsule by mouth twice daily starting two hours prior to surgery and continuing 4 days postoperatively.
224257901|NCT02566928|DRUG|2% mupirocin ointment|Index patients and consenting household members will complete a decolonization regimen consisting of twice-daily application of mupirocin ointment to the anterior nares with a sterile cotton applicator for five days.
224257902|NCT02566928|OTHER|Chlorhexidine wash|Index patients and consenting household members will daily daily for five days with chlorhexidine wash.
224257903|NCT02566928|BEHAVIORAL|Hygiene protocol|Index patients and consenting household members will be given educational materials and instructed to in the use of hand-washing, surface disinfection, and laundering.
224257904|NCT03714685|DRUG|Firibastat|Firibastat (QGC001) 500 mg
224257905|NCT01015300|DRUG|Avastin|Patients will receive Bevacizumab (Avastin) 10mg/kg IV every two weeks for 6 months
223772960|NCT04413318|DEVICE|Pneumatic device (Nosten©)|Continuous control using a pneumatic device (Nosten©) for 6-hours followed by 6-hours of continuous control using an electronic device (VBM©).
223772961|NCT02866578|PROCEDURE|Open lung protective ventilation strategy|
224257906|NCT04709926|OTHER|Survey|Paramedics will complete a 5 minute survey that is asking for their opinions on why they did or did not take part in the PRESTO training package and also why they think paramedics might not engage with research training in general.
224257907|NCT04709926|OTHER|Interview (optional)|Paramedics will also be given the option to participate in a 1hr interview to explore the questions asked in the survey in more detail.
224257908|NCT06911203|DRUG|BGM0504|Administered SC
224257909|NCT06911203|DRUG|Tirzepatide|Administered SC
224257910|NCT02616809|OTHER|Maintaining posture and energy expenditure|Participants will sit continuously for 8-hrs during a simulated office environment
223772962|NCT00971971|PROCEDURE|Dialysis|dialysate temperature (DT) reduction with Na and ultrafiltration (UF) profiling
224257911|NCT02616809|OTHER|Increasing energy expenditure|Participants will cycle slowly while seated in prescribed hourly intervals. This condition will increase energy expenditure while keeping a sitting posture
224257912|NCT02616809|OTHER|Changing posture|Participants will transition from sitting to standing in prescribed hourly intervals. This condition will change posture (sit to stand) while maintaining low energy expenditure
224257913|NCT02616809|OTHER|Increasing energy expenditure and changing posture|Participants will transition from sitting to a walking workstation in prescribed hourly intervals. This condition will both increase energy expenditure and change posture.
224257914|NCT01566396|DEVICE|A3F|A3F fractional RF treatments for facial wrinkles
224257915|NCT02894593|OTHER|alcohol free essential oils mouthwash|All subjects were instructed to rinse twice a day, in the morning and in the evening, with 15 ml solution for 60 seconds, after which they expectorated. Subsequent rinsing with water was not allowed.
224257916|NCT02894593|OTHER|alcohol essential oils mouthwash|All subjects were instructed to rinse twice a day, in the morning and in the evening, with 15 ml solution for 60 seconds, after which they expectorated. Subsequent rinsing with water was not allowed.
224257917|NCT02894593|OTHER|0.20% chlorhexidine mouthwash|All subjects were instructed to rinse twice a day, in the morning and in the evening, with 15 ml solution for 60 seconds, after which they expectorated. Subsequent rinsing with water was not allowed.
224257918|NCT02894593|OTHER|Placebo|All subjects were instructed to rinse twice a day, in the morning and in the evening, with 15 ml solution for 60 seconds, after which they expectorated. Subsequent rinsing with water was not allowed.
224257919|NCT06594939|DRUG|Polatuzumab Vedotin|A combination of a monoclonal antibody and a chemotherapy drug.
224257920|NCT06594939|DRUG|Mosunetuzumab|A monoclonal antibody.
224257921|NCT06594939|DRUG|Cyclophosphamide|Chemotherapy drug, alkylating agent.
224257922|NCT06594939|DRUG|Doxorubicin|Chemotherapy drug, anthracycline antibiotic.
224257923|NCT06594939|DRUG|Prednisone|Steroid, anti-inflammatory
224257924|NCT06594939|OTHER|Pegfilgrastim|Granulocyte stimulating factor, biologic response modifier.
224257925|NCT03569761|BEHAVIORAL|Colorectal Cancer Screening Decision Aid|Information previously discussed in arm/group descriptions. There will be baseline, post-encounter, and 5-month follow-up assessments.
224257926|NCT03569761|BEHAVIORAL|Control Group|Information previously discussed in arm/group descriptions. There will be baseline, post-encounter, and 5-month follow-up assessments. Information previously discussed in arm/group descriptions. There will be baseline, post-encounter, and 5-month follow-up assessments.
224257927|NCT03154645|DRUG|Ibuprofen|non-steroidal anti-inflammatory drug
224257928|NCT03154645|DRUG|Acetazolamide|a diuretic
224257929|NCT04086186|PROCEDURE|Liposomal Bupivacaine Peri-articular Injection|A 20mL solution of 266mg of liposomal bupivacaine (Exparel) was mixed with 40mL of normal saline, which was then infiltrated consistently in the posterior capsule, medial and lateral side of the arthrotomy, patella tendon, quadriceps tendon, quadriceps musculature, and subcutaneous soft tissue.
224257930|NCT04086186|PROCEDURE|Adductor canal block|Anesthesiologist performs preoperative adductor canal block using 15mL of 0.5% Bupivacaine HCl
224257931|NCT03052309|DEVICE|Passeo-18 Lux DCB|The decision to treat the patient with Passeo-18 DCB is at the investigator discretion. The endovascular procedure is performed as per standard of care and device Instructions For Use (IFU)
224257932|NCT00316186|DRUG|topotecan|Hycamtin and Carboplatin as first-line treatment of chemonaive subjects with EX-SCLC.
224257933|NCT00316186|DRUG|carboplatin|Hycamtin and Carboplatin as first-line treatment of chemonaive subjects with EX-SCLC.
224257934|NCT05900635|DRUG|Lactoferrin|Effect of adding Lactoferrin to Oral Iron Supplementation for the treatment of Iron Deficiency Anemia in Chronic Kidney Disease Patients
224257935|NCT05900635|DRUG|Ferrous Glycine Sulfate|Effect of adding Lactoferrin to Oral Iron Supplementation for the treatment of Iron Deficiency Anemia in Chronic Kidney Disease Patients
224257936|NCT00748072|DRUG|DDAVP|0.3 mcg/kg subcutaneous
224257937|NCT00748072|DRUG|saline solution|saline solution 1 ml subcutaneous
224257938|NCT06922890|DRUG|STUP-001|in vivo direct cell conversion gene therapy investigational product
224257939|NCT04493684|DRUG|GSK3739937 (PIB)|GSK3739937 will be administered as oral suspension.
224322549|NCT02463708|BEHAVIORAL|BHL COTP|The BHL COTP starts with an initial baseline assessment; following the baseline assessment, it is then divided into several core services. CG receive care management services, which includes contact, support, and active listening, as well as written material regarding caregiving and dementia and referral to appropriate community services. CGs also are offered the Telehealth Education Program (TEP) a manualized program developed to provide both education and psychosocial support for individuals caring for older adults with clinically significant cognitive impairment/dementia.
224257940|NCT04493684|DRUG|Placebo|Placebo will be given orally during each dosing day.
224257941|NCT04493684|DRUG|GSK3739937 (Tablet)|GSK3739937 Tablet will be administered via oral route.
224257942|NCT06933173|OTHER|Dynamic neural retraining system|"Description: The DNRS program includes the following components: 1) cognitive-behavioural therapy; 2) mindfulness-based cognitive restructuring; 3) emotional restructuring therapy; 4) neural linguistic programming; 5) incremental training; and 6) behaviour modification therapy. DNRS offered in this study includes a 14-hour online course followed by a 12-week online LIVING DNRS group support program. The 14-hour online course includes a variety of exercises, instructional videos, and a workbook. Upon completion, participants are offered a 12-week LIVING DNRS Group Support program which provides individuals with support in how to best implement DNRS into their daily lives with the help of a trained facilitator as well as peer support."
224257943|NCT03145493|DEVICE|drainage|Administration of IV tranexamic acid at the moment of anesthetic induction (1g) and at tourniquet release (1g), installing a suction drain
224257944|NCT01963728|DRUG|Insulin, Isophane|daily dosing based on fasting morning glucose levels
224257945|NCT01963728|DRUG|insulin glargine|daily dose based on fasting morning glucose levels
224257946|NCT06929156|DRUG|BGM0504|Receive a single dose of BGM0504 injection
224257947|NCT06929156|DRUG|BGM0504|Receive a single dose of BGM0504 injection
224257948|NCT06929156|DRUG|BGM0504|Receive a single dose of BGM0504 injection
224257949|NCT06929156|DRUG|BGM0504|Receive a single dose of BGM0504 injection
224257950|NCT06944483|PROCEDURE|same-day radioembolization|"On the day of the procedure, angiography is performed, followed by cone-beam CT of the hepatic artery. After injecting 99mTc-MAA into the hepatic artery, the patient is transferred to the nuclear medicine department for a lung shunt scan and lung SPECT/CT. The lung shunt fraction is determined using the planar images.~Using diagnostic CT/MRI and 99mTc-MAA images, the treatment dose is calculated with the multi-compartment MIRD method. The acceptable range for tumor absorbed dose is ≥100 Gy, and the lung dose must be ≤15 Gy. The tumor absorbed dose must be at least 100 Gy and should ideally be within the range of 300 to 600 Gy. There is no upper limit for the tumor absorbed dose."
224257951|NCT06949800|DRUG|EXE-346 Probiotic|Given as a single-dose, powder packet to mix with water
224257952|NCT06949800|DRUG|Placebo|Given as a single-dose, powder packet to mix with water
224257953|NCT06949800|PROCEDURE|Usual Care High Resolution Anoscopy (HRA)|Non-investigational HRA will be performed
224257954|NCT03985865|DRUG|Intragastric quinine hydrochloride|A nasogastric feeding tube was positioned into the stomach, and checked with a pH strip. 10 µmol of quinine hydrochloride per kg body weight was administrated into the stomach.
224257955|NCT03985865|DRUG|Intragastric denatonium benzoate|A nasogastric feeding tube was positioned into the stomach, and checked with a pH strip. 1 µmol of denatonium benzoate per kg body weight was administrated into the stomach.
224257956|NCT03985865|DRUG|Intragastric placebo|A nasogastric feeding tube was positioned into the stomach, and checked with a pH strip. 0.1 ml of water (placebo) per kg body weight was administrated into the stomach.
224257957|NCT03985865|DRUG|Intraduodenal quinine hydrochloride|A nasogastric feeding tube was positioned into the duodenum, and checked with fluoroscopy. 10 µmol of quinine hydrochloride per kg body weight was administrated into the duodenum.
224257958|NCT03985865|DRUG|Intraduodenal denatonium benzoate|A nasogastric feeding tube was positioned into the duodenum, and checked with fluoroscopy. 1 µmol of denatonium benzoate per kg body weight was administrated into the duodenum.
223676308|NCT04372108|DRUG|Ustekinumab|Participants who are new users of ustekunumab will be included in the cohort. No study treatment will be administered as a part of this study.
223676309|NCT04372108|DRUG|Other Biologic Therapies|Participants who are new users of other biologic therapies (for examples for example, infliximab, adalimumab, or vedolizumab administered as per the prescription record) will be included in this cohort. No study treatment will be administered as a part of this study.
223676310|NCT06470438|DRUG|JNJ-88998377|JNJ-88998377 will be administered.
223676311|NCT03811015|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223676312|NCT03811015|DRUG|Cisplatin|Given IV
223676313|NCT03811015|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
223676314|NCT03811015|PROCEDURE|Echocardiography Test|Undergo ECHO
223676315|NCT03811015|OTHER|Fludeoxyglucose F-18|Receive FDG
223676316|NCT03811015|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
223676317|NCT03811015|BIOLOGICAL|Nivolumab|Given IV
223676318|NCT03811015|OTHER|Patient Observation|Undergo observation
223676319|NCT03811015|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
223676322|NCT04557098|DRUG|Teclistamab|Teclistamab will be administered SC.
224257959|NCT03985865|DRUG|Intraduodenal placebo|A nasogastric feeding tube was positioned into the duodenum, and checked with fluoroscopy. 0.1 ml of water (placebo) per kg body weight was administrated into the duodenum.
224257960|NCT04176029|DEVICE|lung ultrasound|Lung ultrasound is performed using an 12-regions technique i.e. six areas on each side of the chest, two ventral, two lateral and two posterior. The lung ultrasound examination is estimated to take around 10 minutes of time.
224257961|NCT00286702|DEVICE|hand splint|
224257962|NCT04870606|DRUG|Proxalutamide (GT0918)|Proxalutamide (GT0918)+Standard of care determined by PI and local regulatory
224257963|NCT04870606|DRUG|Placebo|Placebo+Standard of care determined by PI and local regulatory
223772963|NCT00971971|PROCEDURE|Standard SLED|
223772964|NCT02329405|DRUG|Rifampicin|
223772965|NCT02329405|DRUG|Placebo|
224257964|NCT04845802|OTHER|Inspiratory muscle training(high-IMT group)|A mechanical pressure threshold loading device (POWERbreathe, POWERbreathe International Ltd, UK) will be used for the training. Training intensity will set at 60% of the maximum inspiratory pressure.
224257965|NCT04845802|OTHER|Inspiratory muscle training(low-IMT group)|Dancers will be perform at a load setting of level 1 (corresponding to \~10% baseline MIP), using the same device as the training group.
224257966|NCT01498939|DRUG|insulin detemir|Each subject will be randomly allocated to an insulin detemir dosing sequence. Three doses of insulin detemir (0.2, 0.4 or 0.8 U/kg) will be administered on three inconsecutive days with a wash-out period between each dosing. Injected subcutaneously (s.c., under the skin)
224257967|NCT06438224|OTHER|Extracorporeal shock wave therapy (ESWT)|Those in the ESWT group were asked to select the most hypertrophic and retracting scars for treatment. ESWT was conducted using the Duolith SD-1® device (StorzMedical, Tägerwilen, Switzerland), with an electromagnetic cylindrical coil source used to focus the shock wave. ESWT was performed around the primary treatment site, at an intensity of 100 impulses/cm2, an energy flux density (EFD) of 0.05 to 0.30 mJ/mm2, and frequency of 4 Hz. Regarding the volume of treatment, 1000-3000 impulses were administered per session for 12 sessions held at 1-week intervals.
224257968|NCT06438224|OTHER|sham stimulation|the sham group was treated using an adapter that had the same shape but did not emit any energy
224257969|NCT05152576|DRUG|OnabotulinumtoxinA X|Intramuscular Injection
224257970|NCT05152576|DRUG|Placebo|Intramuscular Injection
224257971|NCT06323239|RADIATION|SBRT|SBRT for metastatic lesions
224257972|NCT06323239|RADIATION|Low-dose Radiotherapy (LDRT)|LDRT for metastatic lesions
224257973|NCT06323239|DRUG|Toripalimab|6 cycles for combined therapy. Toripalimab maintenance for 1 year.
224257974|NCT06323239|DRUG|Gemcitabine|6 cycles for combined therapy.
224257975|NCT06323239|DRUG|Cisplatin|6 cycles for combined therapy.
224257976|NCT06323239|RADIATION|IMRT|IMRT for primary lesion
224257977|NCT06191094|DRUG|Faricimab Injection|Pre-operative injection of bevacizumab appears to have mixed results in lowering post-operative vitreous hemorrhage. One potential reason is due to aspiration and removal of medication in the vitreous humor at the time of pars plana vitrectomy leading to less than anticipated results in controlling neovascularization and vitreous hemorrhage post-operatively. To avoid attenuation of our desired effect we plan to repeat faricimab injection post-operatively around week one.
224257978|NCT06191094|DRUG|sham treatment|Patients will be randomized 2:1 to receive either faricimab (6 mg from 0.05 mL of a 120 mg/mL) or sham injection
224257979|NCT01414153|DRUG|4.0 mg iSONEP|4.0 mg iSONEP given monthly intravitreously for 4 months
223676346|NCT02909036|DEVICE|Melphalan|
223676347|NCT02909036|DRUG|Pegfilgrastim|
223676348|NCT02909036|PROCEDURE|Autologous Hematopoietic Progenitor Cell Transplant|
223676349|NCT05932615|DEVICE|Navitor Transcatheter Aortic Valve Implantation (TAVI) System|TAVI for relief of calcific aortic stenosis in patients with symptomatic heart disease who are at intermediate or low risk for open surgical therapy.
223676350|NCT05932615|DEVICE|Any Commercially Available Transcatheter Aortic Valve (CAV) System|TAVI for relief of calcific aortic stenosis in patients with symptomatic heart disease who are at intermediate or low risk for open surgical therapy.
224257980|NCT01414153|DRUG|0.5 mg iSONEP|0.5 mg iSONEP given monthly intravitreously for 4 months
224257981|NCT01414153|DRUG|0.5 mg Lucentis or 1.25 mg Avastin or 2 mg Eylea|0.5 mg Lucentis or 1.25 mg Avastin or 2 mg Eylea given monthly intravitreously for 4 months
224257982|NCT01414153|DRUG|sham injection|administered monthly for 4 months
224257983|NCT01117220|DRUG|Placebo|Placebo matching the oral ziprasidone capsules of 20,40, 60 and 80 mg in strength. Subjects will be dosed for 4 weeks using a flexible dose design with minimal dose range of 40 mg twice a day (BID) to maximum dose range of 80 mg BID (weight specific- \< 45kg max dose 40 mg BID).
224257984|NCT01117220|DRUG|Ziprasidone Oral Capsules|Oral ziprasidone capsules of 20,40, 60 and 80 mg in strength. Subjects will be dosed for 4 weeks using a flexible dose design with minimal dose range of 40 mg twice a day (BID to maximum dose range of 80 mg BID (weight specific- \< 45kg max dose 40 mg BID).
224257985|NCT06035250|DRUG|Neoadjuvant Chemotherapy|Participants in this group are diagnosed with gastric cancer and are scheduled to undergo neoadjuvant chemotherapy as a part of their treatment regimen. The specific chemotherapy drugs, dosages, and schedules will be determined according to established clinical guidelines and the participant's specific condition.
224257986|NCT01343004|DRUG|Placebo|Placebo 0 mcg subcutaneous daily
224257987|NCT01343004|DRUG|BA058 80 mcg|BA058 80 mcg subcutaneous daily
224257988|NCT01343004|DRUG|teriparatide|teriparatide 20 mcg subcutaneous daily
224257989|NCT03447353|DRUG|Xanax 1Mg Tablet|Single dose on two of four visits, one in conjunction with 1 tab of 10mg/325mg Norco
223676359|NCT05714202|DRUG|TAR-200|TAR-200 will be administered intravesically.
223676360|NCT05714202|BIOLOGICAL|Cetrelimab|Cetrelimab will be administered.
223676361|NCT05714202|BIOLOGICAL|BCG Vesiculture|BCG will be administered intravesically.
223676366|NCT02123758|DRUG|Abiraterone Acetate|Administered orally (by mouth) once daily in morning at a dose of 1000 mg for up to the end of treatment (EoT) visit (ie, for up to approximately 18 months).
223676367|NCT02123758|DRUG|Prednisone|Administered orally twice a day at a dose of 5mg for up to the end of treatment (EoT) visit (ie, for up to approximately 18 months).
223676368|NCT02123758|DRUG|JNJ-56021927|Administered orally once daily in morning at a dose of 240 mg starting on Day 8, Treatment Cycle 1 for up to the end of treatment (EoT) visit (ie, for up to approximately 18 months).
223676371|NCT05217667|DRUG|ARO-ANG 3 Injection|Participants will be randomized to receive ARO-ANG3 SC on Day 1 and Day 84 during the initial 36 Weeks of the study and on Day1 and Months 3, 6, 9, 12, 15, 18, and 21 of the extension period
223676372|NCT04954625|PROCEDURE|Autologous Blood Patch|All patients will be assessed on the morning of postoperative Day 3 and 4 for the presence of an air leak. If an air leak is present, 60-100 ml of autologous blood will be drawn from a peripheral vein and immediately instilled into the chest tube. The individual who draws blood is that the discretion of the site principal investigator. The tubing will be elevated over an IV pole while the patient remains in bed, moving position every 15 minutes for 1 hour to distribute the blood throughout the pleural cavity. The tubing support will then be removed, allowing the chest tube to drain. After ABP intervention, the chest tube will remain to water seal, as long as the patient tolerates it.
223676373|NCT04954625|PROCEDURE|Standard of Care (per Physician)|Patients randomized to Standard of Care will be treated as their surgeon would as routine. This may mean postoperative observation, of another type of intervention.
223676376|NCT05583227|BIOLOGICAL|Tezepelumab|Tezepelumab subcutaneous injection
223676377|NCT05583227|BIOLOGICAL|Tezepelumab|Tezepelumab subcutaneous injection
223676378|NCT05583227|OTHER|Placebo|Placebo subcutaneous injection
223676382|NCT02455557|OTHER|Laboratory Biomarker Analysis|Correlative studies
223676383|NCT02455557|DRUG|Montanide ISA 51 VG|Given SC
223676384|NCT02455557|BIOLOGICAL|Sargramostim|Given SC
223676385|NCT02455557|BIOLOGICAL|SVN53-67/M57-KLH Peptide Vaccine|Given SC
224257990|NCT03447353|DRUG|Norco 10Mg-325Mg Tablet|Single dose on two of the four study visits, one in conjunction with 1mg alprazolam
224257991|NCT03447353|DRUG|Placebo Oral Tablet|Single dose on two of the four study visits, double dose on one of the four study visits
223676386|NCT02455557|DRUG|Temozolomide|Given PO or IV
223676390|NCT00807027|DRUG|Activated T lymphocyte(Immuncell-LC)|"Efficacy/Effects: Removal of minimal residual cancer after removal of brain tumors and relapse prevention~Method of administration and quantity: Test Drug: Per 60kg of average adult body weight, administer 100mg that contains 109\~2x1010 lymphocytes for one hour intravenously. (Duration of administration can be controlled based on patient conditions)"
223676396|NCT06139406|DRUG|JNJ-87801493|JNJ-87801493 will be administered subcutaneously.
223676397|NCT06139406|DRUG|JNJ-80948543|JNJ-80948543 will be administered subcutaneously.
223676398|NCT06139406|DRUG|JNJ-75348780|JNJ-75348780 will be administered subcutaneously.
223676399|NCT01362803|DRUG|AZD6244|AZD6244 orally (at recommended Ph2 dose) every 12 hours on continuous daily schedule for cycles of 28 days until unacceptable toxicity, patient withdrawal or PD
224257992|NCT04259476|DRUG|Ketamine Hydrochloride|low dose perioperative ketamine infusion. and its effects on post-operative pain.
224257993|NCT00313794|DRUG|CP-675,206|15 mg/kg IV q 3 months for 4 cycles in the absence of disease progression or unacceptable toxicity.
224257994|NCT06081569|DIAGNOSTIC_TEST|gait video; speech video; facial expression video;|The videos of participants' gait, facial expression, and speech will be recorded and analyzed further. Other routine diagnostic tests will also be performed such as imaging of MRI, cognitive scales, etc.
224257995|NCT05217472|DRUG|Ravaglimab|Intravenous Injection
224257996|NCT05217472|DRUG|Ravagalimab|Subcutaneous Injection
224257997|NCT05217472|DRUG|Placebo|Intravenous Injection
224257998|NCT05217472|DRUG|Placebo|Subcutaneous Injection
224257999|NCT04504617|BEHAVIORAL|Nutrition education intervention to enhance complementary feeding practices|The intervention consist of a six-week nutrition education intervention developed following the DESIGN procedure and the Socio-Cognitive Theory. The intervention consisted of six three-hour weekly sessions that covered topics such as 1) importance and benefits of exclusive and continuing breastfeeding; 2) nutrition for lactating mothers; 3) importance and benefits of complementary feeding practices; 4) risks for starting complementary feeding too early or too late; 5) complementary feeding practices for each age group (6-8, 9-11, and 12-24); 6) importance and benefits of dietary diversity; 7) importance of animal-source foods; 8) importance and benefits of following water, sanitation, and hygiene practices; 9) food safety practices when preparing meals; and 10) the recommended hand-washing protocol. Each lesson was designed to provide a lecture, a discussion using counseling cards, a cooking demonstration with tasting session, and key messages.
224258000|NCT02399423|BEHAVIORAL|Weight gain|Weight gain of 7% body weight over 4-6 weeks by ingesting an extra 1500-2000 kcal/day
224258001|NCT02399423|BEHAVIORAL|Weight loss|Weight loss of 7-15% body weight over 12 weeks by increased exercise and either an alternate day fasting dietary regime or a weight watchers dietary regime
224322550|NCT05733702|OTHER|All participants will be asked to provide data and samples for collection and analysis.|During the first year from the date of inclusion, data related to demographics, lifestyle, laboratory and physical examinations will be collected at baseline, at 3 months, and at 12 months. Patient-Reported Outcomes (PROs) with voice recordings will be collected at different time points in-between clinical visits using the Colive application. Participants will be asked to provide biological samples (i.e., blood, dried blood spots and stool are mandatory; saliva, urine and hair are optional), tissue samples from endoscopic biopsy and imaging data (if performed as per standard of care) at three timepoints (baseline; 3 months; 12 months). One unscheduled visit may be included in the study in case of occurrence of flare or treatment change.A long-term follow-up (starting from month 12 and up to 4 years after month 12) will include the collection of medical data on a yearly basis, collection of PROs with voice recording every 6 months and continuous collection of data using the smartwatch.
224322551|NCT07124468|DRUG|Meropenem-Pralubactam|The study is designed to enroll approximately 16 healthy participants. The study will evaluate the plasma, epithelial lining fluid, and alveolar macrophage concentrations of Meropenem-Pralubactam
224322552|NCT02369198|DRUG|TargomiRs|"TargomiRs are targeted minicells containing a microRNA mimic. They consist of three components: 1. A miR-16-based microRNA mimic. The miR-16 family has been implicated as a tumour suppressor in a range of cancer types. The mimic is a double-stranded, 23 base pair, synthetic RNA molecule. 2. Drug delivery vehicle - EDVs. EDVs are nonliving bacterial minicells (nanoparticles). They function as leak resistant micro-reservoir carriers that allow efficient packaging of a range of different drugs, proteins or nucleic acids. 3. Targeting moiety. The EDVs are targeted to EGFR-expressing cancer cells with an anti-EGFR bispecific antibody.~TargomiRs are IV injected."
224258002|NCT03306030|DRUG|Split dose of 4L PEG|All patients were given oral instruction for bowel preparation on the day of appointment and re-instruction through phone call on two days before scheduled colonoscopy. They were instructed to have a regular lunch and take only clear liquid or low-residual food for the dinner on the day before colonoscopy. The participants began to drink the first 2 L of PEG at 7:00-9 PM on the day before colonoscopy at a rate of 250 mL every 15 minutes. On the day of the procedure, patients took the remaining 2 L 4-6 hours before colonoscopy.
224258003|NCT03306030|DRUG|Three times dose of 4L PEG|The same as mentioned above. The participants began to drink the first 1.5 L of PEG at 2:00 PM and the second 1.5L of PEG at 8:00PM on the day before colonoscopy at a rate of 250 mL every 15 minutes. On the day of the procedure, patients take the remaining 1.0 L 4-6 hours before colonoscopy.
224258004|NCT06042738|COMBINATION_PRODUCT|proxeed plus|Group 1 was recommended to receive a food supplement containing 2000 mg L-carnitine, 2000 mg fructose, 932 mg acetyl L-carnitine, 225 mg vitamin C, 115 mg citric acid, 50 mg coenzyme Q10, 14 mg zinc, 115 µg selenium, 3750 µg vitamin B12 and 500 µg folic acid as one sachet in the morning and evening
224258005|NCT04740658|OTHER|No intervention|There is no intervention
223676436|NCT05112601|PROCEDURE|Biospecimen Collection|Undergo collection of tissue and/or blood samples
223676437|NCT05112601|PROCEDURE|Computed Tomography|Undergo CT
224258006|NCT05343676|DEVICE|ultrasonography|"* For assessment of LNS ( cervical , axillary and inguinal LNS ), The choice of transducer is an important consideration when evaluating lymph nodes as higher frequencies provide better resolution for superficial structures~* For color Doppler assessment of the lymph nodes, scanning will be done using the slow frame rate, low pulse repetition frequency~* Assessment features including lymph node location, size, shape, border, echogenicity, calcifications, necrosis or cystic change, and adjacent soft tissue edema"
223676438|NCT05112601|BIOLOGICAL|Ipilimumab|Given IV
223676439|NCT05112601|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223676440|NCT05112601|BIOLOGICAL|Nivolumab|Given IV
223676441|NCT06577025|DRUG|Cilta-cel|Cilta-cel infusion will be administered intravenously.
223676442|NCT06577025|DRUG|Talquetamab|Talquetamab will be administered subcutaneously.
223676443|NCT06577025|DRUG|Daratumumab|Daratumumab will be administered subcutaneously as a part of DVRd induction and Tal-D or Tec-D consolidation.
223676444|NCT06577025|DRUG|Teclistamab|Teclistamab will be administered subcutaneously.
223676445|NCT06577025|DRUG|Bortezomib|Bortezomib will be administered subcutaneously as a part of induction.
223676446|NCT06577025|DRUG|Lenalidomide|Lenalidomide will be administered orally as a part of induction.
223676447|NCT06577025|DRUG|Dexamethasone|Dexamethasone will be administered orally as a part of induction.
223676448|NCT06577025|DRUG|Cyclophosphamide|Cyclophosphamide will be administered intravenously as a part of conditioning regimen.
223676449|NCT06577025|DRUG|Fludarabine|Fludarabine will be administered intravenously as a part of conditioning regimen.
223676460|NCT05675410|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223676461|NCT05675410|BIOLOGICAL|Bleomycin Sulfate|Given IV
223676462|NCT05675410|DRUG|Brentuximab Vedotin|Given IV
223676463|NCT05675410|PROCEDURE|Computed Tomography|Undergo CT and/or PET-CT
223676464|NCT05675410|DRUG|Cyclophosphamide|Given IV
223676465|NCT05675410|DRUG|Dacarbazine|Given IV
223676466|NCT05675410|DRUG|Doxorubicin Hydrochloride|Given IV
223676467|NCT05675410|DRUG|Etoposide|Given IV
223676468|NCT05675410|DRUG|Etoposide Phosphate|Given IV
223676469|NCT05675410|OTHER|Fludeoxyglucose F-18|Undergo FDG-PET
223676470|NCT05675410|RADIATION|Involved-site Radiation Therapy|Undergo ISRT
223676471|NCT05675410|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI and/or PET-MRI
223676472|NCT05675410|BIOLOGICAL|Nivolumab|Given IV
223676473|NCT05675410|PROCEDURE|Positron Emission Tomography|Undergo FDG-PET, PET, PET-CT, and/or PET-MRI
223676474|NCT05675410|DRUG|Prednisolone|Given PO
223676475|NCT05675410|DRUG|Prednisone|Given PO
223676476|NCT05675410|DRUG|Procarbazine Hydrochloride|Given PO
223676477|NCT05675410|OTHER|Questionnaire Administration|Ancillary studies
223676478|NCT05675410|DRUG|Vinblastine Sulfate|Given IV
223676479|NCT05675410|DRUG|Vincristine Sulfate|Given IV
223676480|NCT05564390|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Given IV
223676481|NCT05564390|DRUG|Azacitidine|Given IV or SC
223676482|NCT05564390|OTHER|Best Practice|Receive SOC treatment
224258007|NCT04196907|DEVICE|Rad-67 Pulse CO-Oximeter and DCI Mini sensor|Noninvasive Pulse CO-Oximeter device and sensor are used to measure hemoglobin.
224258008|NCT00526188|DRUG|Gadoxetic Acid Disodium (Primovist, BAY86-4873)|Bolus injection of 0.025 mmol/kg body weight (0.1 ml/kg BW) of Gadoxetic Acid Disodium (Primovist, BAY86-4873). Single i.v. injection during MRI procedure, with one contrast-enhanced MRI procedure per patient
224258009|NCT04741893|DEVICE|EndoFLIP|Use of Endoluminal Functional Lumen Imaging Probe to assess anal canal function
224258010|NCT05956561|OTHER|dental implants were placed for all cases while assessing vitamin D levels|vitamin D assessment with measuring implant stability and clinical finding of early failure
224258011|NCT05547711|DIAGNOSTIC_TEST|drawing blood|drawing blood annually measurement of heartrate variability annually determine weight with a bioimpedance scale
224258012|NCT02529709|OTHER|High-Protein Condition|The participants will be fed a high-protein meal
223676483|NCT05564390|PROCEDURE|Biopsy Procedure|Undergo biopsy
223676484|NCT05564390|PROCEDURE|Biospecimen Collection|Undergo collection of blood, urine, and/or buccal swab samples
223676485|NCT05564390|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
223676486|NCT05564390|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
223676487|NCT05564390|DRUG|Busulfan|Given IV
223676488|NCT05564390|PROCEDURE|Chest Radiography|Undergo chest x-ray
223676489|NCT05564390|PROCEDURE|Computed Tomography|Undergo CT
223676490|NCT05564390|DRUG|Cytarabine|Given
223676491|NCT05564390|DRUG|Daunorubicin Hydrochloride|Given IV
223676492|NCT05564390|DRUG|Decitabine and Cedazuridine|Given PO
223676493|NCT05564390|PROCEDURE|Echocardiography Test|Undergo ECHO
223676494|NCT05564390|DRUG|Enasidenib|Given PO
223676495|NCT05564390|DRUG|Fludarabine|Given IV
223676496|NCT05564390|DRUG|Gemtuzumab Ozogamicin|Given IV
223676497|NCT05564390|DRUG|Gilteritinib|Given PO
223676498|NCT05564390|DRUG|Liposome-encapsulated Daunorubicin-Cytarabine|Given IV
223772966|NCT00672880|BEHAVIORAL|Self-System Therapy|12 sessions of structured Self-System Therapy
223772967|NCT00672880|BEHAVIORAL|Education|12 sessions of spine and muscle education including life style changes and medical treatments.
224258013|NCT02529709|OTHER|High-Monounsaturated Fat Condition|The participants will be fed a high-monounsaturated fat meal
224258014|NCT00211653|DRUG|N-Acetylcysteine|
224258015|NCT02642653|DRUG|Lovastatin|Once per day dosing
224258016|NCT02642653|OTHER|Placebo|Once per day dosing
224258017|NCT01424761|DIETARY_SUPPLEMENT|Coenzyme Q10|Coenzyme Q10 300 mg/d (150 mg/bid)
224258018|NCT01424761|OTHER|Placebo|Placebo :starch
224258019|NCT03196258|BEHAVIORAL|Cognitive behavioural therapy|Participants who are randomized to the CBT intervention are required to start CBT within 8 weeks of their fracture surgery. The CBT intervention will consist of 6 weekly one-on-one, 1-hour sessions that will focus on addressing maladaptive beliefs related to pain and recovery as well as teaching skills to enhance coping and management of pain symptoms. The specific focus of CBT sessions will be informed by each individual patient's responses on the SPOC questionnaire. All other aspects of post-operative care will be at the discretion of participant's surgeon
224258020|NCT00378963|DEVICE|ProAdjuster|
224258021|NCT02942563|DRUG|FOLFOXIRI|"Irinotecan\* 165 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5-FU 2800 mg/m² cont. inf. 46h all on day 1 of each 2 weeks cycle for 4-6 cycles,~Chemoradiation for patients who are not suitable to surgery:~Pelvic radiotherapy(45Grey/25Fraction and 5.4Grey/3Fraction boost to the tumor bed) combined with capecitabine(625mg/m², bid po, d1-5, qw), and additional four cycles of modified FOLFOX6 (mFOLFOX6) or Oxaliplatin 135mg/m²plus Capecitabine 1.0/m² bid po(XELOX) of each 3 weeks cycle for 2 cycles chemotherapy before TME.~All patients will receive 6-8 cycles of mFOLFOX6 or 4-5 cycles XELOX as adjuvant chemotherapy after TME."
224258022|NCT00809250|BIOLOGICAL|GM-K562/leukemia cell vaccine|Cultured cell line genetically changed to secrete GM-CSF mixed with irradiated leukemia cells obtained from the participant. A total of 6 vaccine will be given. Vaccines 1-3 will be given once a week. Vaccines 4-6 will be given every other week.
224258023|NCT01344590|OTHER|Normal Saline|Standard saline procedure will be utilized.
224258024|NCT01344590|OTHER|Ethanol 70% pharmaceutical grade|70% pharmaceutical grade ethanol will be instilled in the line in a volume calculated to fill the lumen and the hub.
224258025|NCT00893685|DEVICE|Wireless monitors for disease specific clinical parameters.|Homes of participants will be equipped with wireless monitors for blood pressure, blood oxygen, blood glucose, peak expiratory flow, electrocardiogram, body weight. All vital parameters are monitored on a continuous, at least daily basis and obtained values are transmitted to a monitoring centre. Abnormal values are classified for their health risk and health alarms and/or intervention of health professionals is triggered.
224258026|NCT02267187|PROCEDURE|Fat Grafting|Fat Grafting is a procedure that involves moving a person's own fat from an area of the body where it is less needed to another area of the body to improve its appearance. The fat is usually taken from the thighs or abdomen with a small liposuction tube and then moved to an area that has lost volume or fullness due to aging, trauma, surgery, birth defects, or other causes.
224258027|NCT02267187|DRUG|General Anesthesia|A medicine that will relax and assist the subject in keeping unconscious (in a sleep like state) during the entire procedure.
223676499|NCT05564390|DRUG|Melphalan|Given IV
223676500|NCT05564390|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
223676501|NCT05564390|PROCEDURE|Mutation Carrier Screening|Undergo rapid genetic testing
223676502|NCT05564390|DRUG|Olutasidenib|Given PO
223676503|NCT05564390|DRUG|Placebo Administration|Given PO
223676504|NCT05564390|PROCEDURE|Positron Emission Tomography|Undergo PET
223676505|NCT05564390|RADIATION|Total-Body Irradiation|Undergo total body irradiation
223676506|NCT05564390|DRUG|Venetoclax|Given PO
223772968|NCT00672880|OTHER|Standard Care|Study participants continue with their usual medical care, no changes.
224258028|NCT02267187|DEVICE|Coleman Cannulas|The plastic surgeon, will use small narrow tube-like instruments called cannulas, will remove fat from various places throughout the body (commonly the abdomen and thighs). The plastic surgeon will then use the Coleman cannulas (specialized smaller cannulas with varied shapes and tip sizes specifically made to deliver smaller amounts of fat) to fill the desired area.
224258029|NCT02267187|OTHER|Tefla non-adherent gauze pad|The processing of the fat graft material is done using a Tefla non-adherent gauze pad in a rolling technique that separates the aqueous and oil layers from the injected component.
224258030|NCT06060145|OTHER|Plants placed in an office environment|The intervention group will be provided with an intervention consisting of 34-38 potted plants arranged in an office environment for a duration of 8 hours (09:00-17:00) on weekdays (Monday to Friday) for 4 weeks.
224258031|NCT06060145|OTHER|Devoid of any plant presence in an office environment|Participants assigned to the control group will be exposed to an office environment devoid of any plant presence for a duration of 8 hours (09:00-17:00) on weekdays (Monday to Friday) for 4 weeks.
224258032|NCT04906070|DEVICE|HB-001|An intratumoral insertion of a seed(s), loaded with Radium-224, securely fixed in the seeds. The seeds release by recoil into the tumor short-lived alpha-emitting atoms.
224258033|NCT03579615|DEVICE|FIASP + closed loop device|Participants will be advised to change their usual insulin to the corresponding study visit insulin formulation, 24 hours prior to admission. (For example; if the participant is on insulin aspart, this will be changed to faster-acting aspart 24-hour prior to the admission for closed loop with faster-acting aspart and vice versa).
224258034|NCT03579615|DEVICE|Insulin aspart (standard of care insulin) + closed loop device|Participants will be advised to maintain their usual insulin 24 hours prior to admission.
224258035|NCT04500015|DRUG|INH|3 vaginal tablet of isonicotinic acid hydrazide self-inserted by the patient 12 hours before IUD insertion.
224258036|NCT04500015|DRUG|Placebo Comparator|3 tablet of placebo self-inserted by the patient 12 hours before IUD insertion.
224258037|NCT02427763|DEVICE|hours of use (Essix)|the patient will use de thermoplastic device during the night or during all day
224258038|NCT02427763|OTHER|collect saliva|the patient spit during 30 seconds in a small bottle
224258039|NCT02427763|OTHER|collect biofilm|a sterile swab is rubbed at the buccal surface of the upper teeth
224258040|NCT02427763|OTHER|collect epithelium|a sterile cytobrush is rubbed at the buccal surface of gingiva at the upper arch
224258041|NCT05846022|OTHER|Dry Needling|This dry needling study involves bilaterally insertion of a fine sterile needle into upper trapezius muscle fibers using a clean needling technique.
224258042|NCT05846022|OTHER|Sham Needle|"Shallow penetration of a solid monofilament needle into the skin alone with the in and out plunging movement of the needle simulated with the needle's guide tube."
224258043|NCT03537482|DRUG|APG-2575|APG-2575 will be administered as an oral tablet
224258044|NCT01995227|BIOLOGICAL|AlloVax|Personalized anti-cancer vaccine
224258045|NCT01995227|BIOLOGICAL|CRCL|Personalized anti-cancer vaccine
224258046|NCT01995227|BIOLOGICAL|AlloStim|ID injections IV infusion
224258047|NCT06128967|DRUG|Fluvoxamine Maleate 100 MG|Fluvoxamine Maleate 100 mg each pills
224258048|NCT06128967|DRUG|Placebo|Placebo talc pills of same shape, color, weight if compared with active comparator
224258049|NCT06128967|DRUG|Metformin Extended Release Oral Tablet|Metformin Extended release oral tablets of 750 mg each pill
223676528|NCT06064097|PROCEDURE|Biopsy Procedure|Undergo tissue biopsy
223676529|NCT06064097|PROCEDURE|Biospecimen Collection|Undergo blood and stool sample collection
223676530|NCT06064097|PROCEDURE|Chest Radiography|Undergo chest x-ray
223676531|NCT06064097|DRUG|Cisplatin|Given IV
223676532|NCT06064097|PROCEDURE|Computed Tomography|Undergo CT
223676533|NCT06064097|PROCEDURE|Echocardiography Test|Undergo ECHO
223676534|NCT06064097|OTHER|Electronic Health Record Review|Ancillary studies
223676535|NCT06064097|OTHER|Fluciclovine F18|Given IV
223676536|NCT06064097|DRUG|Gemcitabine|Given IV
223676537|NCT06064097|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223676538|NCT06064097|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
223676539|NCT06064097|BIOLOGICAL|Nivolumab|Given IV
223676540|NCT06064097|PROCEDURE|Positron Emission Tomography|Undergo PET
224258050|NCT02392286|DRUG|Corticosteroid|Subjects will receive prednisone orally; if intravenous corticosteroid required initially they will receive methylprednisolone for the first 3-4 days of therapy.
224258051|NCT06558734|PROCEDURE|Tooth Preperation|After the caries were removed, the teeth were prepared according to the manufacturer's recommendations for Figaro Crowns. Fiberglass crowns (Figaro Crowns Inc., USA) of the most suitable size in terms of the mesio-distal dimension of the tooth were selected. Following the establishment of anesthesia, the teeth were prepared using diamond cutting burs with a high-speed, water-cooled turbine handpiece. In order to achieve adequate interocclusal space, an occlusal reduction of 1-2 mm was executed along with a proximal reduction reaching 1 mm below the gingival margin. A more conservative reduction was applied to the buccal and lingual surfaces. After preparation, any remaining decayed dentin tissue was removed using a steel round bur with a low-speed micromotor. To ensure occlusal harmony, diamond burs were used to perform abrasion on the crown edges, and the trimmed crown edges were polished using rubber aids before cementation.
224258052|NCT06558734|PROCEDURE|Cementation|Figaro crowns were placed on the prepared teeth with finger pressure, following the manufacturer's instructions for the luting cement to be used. For each cement, the recommended setting time was observed, and excess cement residues were removed accordingly.
224258053|NCT04974684|DEVICE|HeartMate 3|Patients implanted with HeartMate 3 will be randomized in 2:1 ratio in interventional and control group. Patients in interventional group will be switched to therapy with apixaban instead of warfarin.
224258054|NCT04974684|DRUG|Apixaban|Patients implanted with HeartMate 3 will be randomized in 2:1 ratio in interventional and control group. Patients in interventional group will be switched to therapy with apixaban instead of warfarin.
224258055|NCT01118598|DRUG|tredaptive (nicotinic acid/ laropiprant)|tablet of nicotinic acid 1000 mg/laropiprant 20 mg one tablet of for 4 weeks followed by two tablets od for 8 weeks
224258056|NCT01118598|DRUG|placebo|placebo tablet one a day for first 4 weeks followed by two a day for 8 weeks
224258057|NCT02222818|DEVICE|Conducted AF Response (CAFR)|The CAFR algorithm is currently available in the Medtronic market-released devices and intended to promote delivery of CRT pacing during conducted AT/AF episodes.
224258058|NCT02222818|DEVICE|Conducted AF Response Plus (CAFRPlus)|The CAFRPlus algorithm is part of the CRTee feature set. This feature set has a diagnostic element that tracks the loss of effective CRT pacing that is occurring over time, both during normal sinus rhythm (NSR) and during AF. It also has an interventional element (i.e. CAFRPlus) that uses this evaluation of effective CRT pacing to adjust the pacing rate during AF to decrease loss of effective CRT pacing.
224258059|NCT00262392|DRUG|Pamidronate (AREDIA)|Pamidronate (AREDIA) vs radiation
224258060|NCT02108535|DRUG|Nanocrystalline silver|Flexible polyester low-grip coated nano-crystalline silver layer. The level of silver is 1.64 mg/ cm². This dressing enables the sustained release of silver in humid conditions dynamically and reached a higher plateau than 60 mg / L in less than 2 hours, and maintains a uniform level by 72 hours.
224258061|NCT02108535|DRUG|Silver Sulfadiazine|This is at Standard treatment. The cream silver sulphadiazine at 1% was applied on the burn aseptically in a thick layer, approximately 3 to 5 mm, ie 5 g per 80 cm2
224258062|NCT06491797|BEHAVIORAL|Immediate reactivation|Our intervention will be booster measure of the existing PTP elements that will be designed for each unit that has been randomized to the immediate intervention group. The booster will consist in a reactivation through audit and feedback of 2-3 elements of the PTP program. The selection of the elements to boost will be done locally in each unit through a coordinated discussion between representants of the PTP organization and representants of the unit's medical and nursing professionals. This will create an adaptable intervention that will feature selected standards among the list of 36 existing standards. The boost will be performed over 3 months
224258063|NCT01743898|DRUG|Rivaroxaban|Patients will continue on their Rivaroxaban dose as previously prescribed by their individual physician. No dose adjustments will be made for the purpose of this study.
224258064|NCT01743898|OTHER|no anticoagulation|
224258065|NCT05106114|OTHER|Intensive gait training rehabilitation protocole|6 weeks of intensive gait training : 4 weeks at the center and 2 weeks of home-based telerehabilitation
223676541|NCT06064097|OTHER|Quality-of-Life Assessment|Ancillary studies
223676542|NCT06064097|OTHER|Questionnaire Administration|Ancillary studies
223676543|NCT06064097|RADIATION|Radiation Therapy|Receive radiation therapy
224258066|NCT03218813|BEHAVIORAL|Intervention cohort ('after' group)|"The intervention will take place during hospitalisation. Patients will complete the BMQ-S and their responses will form the basis of what will be discussed in Session 1. Pharmacists will elicit patients' thoughts and opinions about their medicines and highlight the need to take them. Any erroneous treatment beliefs will be discussed and any concerns will be addressed.~After Session 1, patients will be given a planning sheet and will be asked to think about their usual daily routine and how taking medicines may fit into it. Session 2 will focus on developing specific action plans for taking medication at home. Patients will be asked to formulate an if-then plan ('If it is time X in place Y and I am doing Z, then I will take my pill dose')."
223676544|NCT06064097|PROCEDURE|X-Ray Imaging|Undergo dental x-ray
223676545|NCT06116786|DRUG|JNJ-86974680|JNJ-86974680 will be administered.
223676546|NCT06116786|DRUG|Cetrelimab|Cetrelimab will be administered.
224258067|NCT04405102|DRUG|Ozanimod|The investigational medical product (IMP) for this study is ozanimod. Ozanimod 0.23 mg be administered once daily for 4 days and then ozanimod 0.46 mg will be administered once daily for ten days.
224258068|NCT04405102|OTHER|Standard of care|During hospitalization, patient will be given standard of care (Recommendations for standard of care management of COVID-19 will be provided for anticoagulation, fluid resuscitation, corticoids and other immunomodulators, antipyretics agents, antiviral agents and other treatments. These recommendations are subject to modifications based on the new literature data).
223676547|NCT06116786|RADIATION|Radiation Therapy|Radiation therapy will be administered.
224258069|NCT06563297|DRUG|Alfentanil|We first start with alfentanil 100 ng/ml, and use the up and down method as adjust 25 ng/ml of concentration of alfentanil each time. An SPI higher than 80 and hyperdynamics (the increased HR and MBP up 20% of baseline or HR\>100bpm and ABP\>180/100mmHg) indicates insufficient analgesia, therefore increase it by 25 ng/ml at the next patient; an SPI lower than 80 and stable hemodynamics (the changes of HR and MBP within 20% of baseline or HR\<50bpm and ABP\<90/50mmHg) indicates that analgesia is acceptable, and the next patient will decrease it by 25 ng/ml during skull pin fixation. If the analgesia is inadequate, increase alfentanil concentration will be prescribed. On the other hand, if analgesia is adequate, however hyperdynamics was noted, beta blocker or calcium channel blocker will be prescribed. If hypotension (ABP\<90/50 mmHg) or bradycardia (HR\<50 bpm) occur, we first stop alfentanil infusion and treated with ephedrine or atropine, respectively.
224258070|NCT04204395|DEVICE|Peanut Ball|The participants in the experimental group will use the peanut ball at least every 2 hours, 30-minute usage for each time. More frequency will be available. Then, the participants will stop using the peanut ball when cervical os is dilated and effaced, may be ready to push.
224258071|NCT03025087|DRUG|Hydroxychloroquine|Participants will be getting hydroxychloroquine
224258072|NCT01983501|DRUG|Tucatinib (ONT-380)|Given twice per day, orally
224258073|NCT01983501|DRUG|T-DM1|Given intravenously once every 21 days
224258074|NCT03389113|DEVICE|Whole body vibration|Whole body vibration exercise is a stimulus that uses vibrations generated on a machine with oscillatory movement determined by the amplitude and frequency of the vibration.
224258075|NCT03389113|OTHER|Exersice|Exercise maintain a half-squat position (knee joint angle at 160 degrees) on the tilt table with an incline of 60 degrees.
223676549|NCT03298737|BEHAVIORAL|Covert Spatial Attention|"During behavioral sessions, subjects will sit in a dark room and view a video monitor placed at the minimum of 57 cm distance away from the subject. Staff will be present throughout all the testing to assist the subject and monitor equipment that is used for tracking their eye position. Subjects will be asked to maintain their heads in a stable position of rest in order to insure accurate tracking of their eye position. To stabilize their head, subjects will either use a chin rest in which they position their chin on a soft pad mounted in front of a video screen, or they may use a bite bar."
223676550|NCT04181060|BIOLOGICAL|Bevacizumab|Given IV
224258076|NCT01385930|BEHAVIORAL|Lifestyle counseling|Lifestyle counseling
224258077|NCT02940444|DRUG|Heparin|
224258078|NCT03898804|DEVICE|BCI and FES|The intervention consists of surgical implantation of the device components, BCI and FES that will interface with computers that process and decode neural information, compute stimulation parameters, and control communication between the device components. The device will be tested during research sessions spanning a 13-month period.
224258079|NCT00864396|DRUG|Prevacid|30mg of Lansoprazole twice daily (or placebo)for eight weeks.
224258080|NCT03368443|BEHAVIORAL|treadmill training and overground gait training|The participants will be randomized into two different groups, and they will receive treadmill and overground gait training in one or two rooms.
223676551|NCT04181060|PROCEDURE|Biospecimen Collection|Undergo blood and urine sample collection
223676552|NCT04181060|PROCEDURE|Computed Tomography|Undergo CT
224258081|NCT03423654|OTHER|Spatial Training|Spatial Training using a 5x5 grid
224258082|NCT03423654|OTHER|Letter number matching|Letter number matching
223676553|NCT04181060|PROCEDURE|Echocardiography Test|Undergo ECHO
223676554|NCT04181060|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223676555|NCT04181060|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
223676556|NCT04181060|DRUG|Osimertinib|Given PO
224258083|NCT04210557|DEVICE|Transcranial Magnetic Stimulation (TMS)|Transcranial magnetic stimulation (TMS) is a noninvasive form of brain stimulation in which a changing magnetic field is used to cause electric current at a specific area of the brain through electromagnetic induction. An electric pulse generator, or stimulator, is connected to a magnetic coil, which in turn is connected to the scalp. The stimulator generates a changing electric current within the coil which induces a magnetic field; this field then causes a second inductance of inverted electric charge within the brain itself.
224258084|NCT03711253|DRUG|Bictegravir 50mg+Tenofovir AF 25 mg+emtricitabine 200 mg|antiretroviral therapy
224258085|NCT03821675|DEVICE|Electrical Stimulation - Active|Subjects will receive an active electrical stimulation device to wear for 1 hour daily for 4 weeks.
224258086|NCT03821675|DEVICE|Electrical Stimulation - Sham|Subjects will receive a sham electrical stimulation device to wear for 1 hour daily for 4 weeks.
224258087|NCT03867071|OTHER|recombinant erythropoietin injection|Intravenous injection of 300 international units (IU) per kg (kg) of recombinant erythropoietin with a maximum of 20.000 IU, daily for a maximum of 10 days (D0 to D9).
224258088|NCT03867071|OTHER|placebo injection|Intravenous injection 0,9% saline solution.
224258089|NCT05168787|DRUG|sacubitril/valsartan|Sacubitril belongs to a class of drugs called neprilysin inhibitors and valsartan belongs to a class of drugs called angiotensin receptor blockers (ARBs). They work by relaxing blood vessels so that blood can flow more easily, which makes it easier for your heart to pump blood to your body.
224258090|NCT01957059|DRUG|Regimen Selection Phase Group 2|"All doses of BMN053 will be administered as IV infusions. The proposed doses are as follows:~• 3 mg/kg"
224258091|NCT01957059|DRUG|Regimen Selection Phase Group 3|"All doses of BMN053 will be administered as IV infusions. The proposed doses are as follows:~• 4-6 mg/kg"
224258092|NCT01957059|DRUG|Treatment Phase Group 4|All doses of PRO053 will be administered as IV infusions. The proposed doses will be decided upon completion of the Regimen Selection Phase of Groups 2 and 3
224258093|NCT01957059|DRUG|Regimen Selection Phase Group 1 (COMPLETED)|All doses of BMN053 have been administered as subcutaneous injections.
224258094|NCT01957059|DRUG|Dosing Extension|All doses of PRO053 will be administered as IV infusions. The proposed doses will be decided upon completion of the Regimen Selection Phase of Groups 2 and 3 and the Treatment Phase Group 4.
224258095|NCT05368480|OTHER|Senior Companion Program|Receives a companion to socialize with them, help with daily tasks, etc.
223676558|NCT05856526|DRUG|Spesolimab - solution for infusion|Solution for infusion
223676559|NCT05856526|DRUG|Placebo matching to spesolimab - solution for infusion|Solution for infusion
223676560|NCT05856526|DRUG|Spesolimab - solution for injection|Solution for injection
223676561|NCT05856526|DRUG|Placebo matching to spesolimab - solution for injection|Solution for injection
223676563|NCT04289480|DEVICE|ENTERPRISE 2 device|The ENTERPRISE 2 Vascular Reconstruction Device is intended for use with occlusive devices in the treatment of intracranial aneurysms.
223676564|NCT05455320|DRUG|Talquetamab|Talquetamab will be administered subcutaneously.
223676565|NCT05455320|DRUG|Daratumumab|Daratumumab will be administered subcutaneously.
224258096|NCT04307680|DEVICE|Peritron perineometer|Perineometry will be used to assess quality of each observed treatment modality.
224258097|NCT05693623|OTHER|cold application|cold application
224258098|NCT02589093|DEVICE|Stimulation|
223676566|NCT05455320|DRUG|Pomalidomide|Pomalidomide will be administered orally.
223676567|NCT05455320|DRUG|Dexamethasone|Dexamethasone will be administered orally or intravenously.
223676568|NCT05172245|PROCEDURE|Biopsy Procedure|Undergo tumor biopsy
223676569|NCT05172245|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223676570|NCT05172245|DRUG|Cisplatin|Given IV
223676571|NCT05172245|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
223676572|NCT05172245|DRUG|Ipatasertib|Given PO
223676573|NCT05172245|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
224258099|NCT03841266|DIAGNOSTIC_TEST|recurrence risk evaluation|Recurrence score were obtained by 21-gene detection kits from different biological companies. The expression of ER, PR, and Her-2 were also detected by IHC.
224258100|NCT01310647|DRUG|Testosterone|Transdermal testosterone (20µg/kg/day)from day 24 of the previous cycle to day 2 of the ICSI cycle
224258101|NCT01310647|DRUG|Estradiol|Transdermal estradiol (200µg/day)from day 20 of the previous cycle to day 3 of the ICSI cycle
224258102|NCT01310647|DRUG|CombEq|"(150µg Desogestrel + 30µg Ethinylestradiol)/day during the luteal phase of the two cycles prior to the ICSI.~Valerate estradiol 4mg/day during 10 days, starting the second day of the cycle prios to the ICSI cycle."
223676574|NCT05172245|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
223676575|NCT05172245|RADIATION|Radiation Therapy|Undergo radiation therapy
223676576|NCT06692907|OTHER|B7A (ETEC challenge strain)|A pathogenic strain of ETEC that can cause illness ranging from mild watery diarrhea to severe symptoms. The primary complication associated with an infection from this strain is dehydration.
223676577|NCT06692907|BIOLOGICAL|CssBA|A CS6 based vaccine against ETEC (Enterotoxigenic Escherichia coli) in preventing moderate-severe diarrhea obtained via purification from a host E. coli expression strain, BL21(DE3), harboring a pET24a (+) plasmid containing the CssBA gene expressing the his-tagged CssBA protein.
223676578|NCT06692907|BIOLOGICAL|dmLT|An E. coli double mutant heat labile toxin. This genetically attenuated strain is expressed from a plasmid (pLC403) in the E. coli expression strain JM83.
223676579|NCT06692907|OTHER|Placebo|Placebo
223676580|NCT06095089|DRUG|JNJ-78278343|JNJ-78278343 will be administered.
223676581|NCT06095089|DRUG|JNJ-87189401|JNJ-87189401 will be administered.
223676588|NCT04530565|PROCEDURE|Biospecimen Collection|Correlative studies
223676589|NCT04530565|BIOLOGICAL|Blinatumomab|Given IV
223676590|NCT04530565|PROCEDURE|Bone Marrow Aspiration and Biopsy|Undergo bone marrow aspiration and biopsy
223676591|NCT04530565|DRUG|Cyclophosphamide|Given IV
223676592|NCT04530565|DRUG|Cytarabine|Given IV or IT
223676593|NCT04530565|DRUG|Dasatinib|Given PO
223676594|NCT04530565|DRUG|Dexamethasone|Given PO or IV
223676595|NCT04530565|DRUG|Doxorubicin Hydrochloride|Given IV
223676596|NCT04530565|PROCEDURE|Echocardiography Test|Undergo ECHO
223676597|NCT04530565|PROCEDURE|Electrocardiography|Undergo ECG
224258103|NCT04718025|DRUG|Ticagrelor 90mg|Up to day 30 after ACS, all enrolled patients will receive standard-dose ticagrelor 2x90mg as a part of dual antiplatelet therapy. Participants in SDTA arm will continue treatment with ticagrelor 2x90mg until 12 months post-ACS, while patients in LDTA and LDTP will be switched to low-dose ticagrelor 2x60 mg starting on day 31.
224258104|NCT04718025|DRUG|Ticagrelor 60mg|Starting from day 31, LDTA and LDTP patients will receive low-dose ticagrelor 2x60mg until 12 months post-ACS.
224258105|NCT04718025|DRUG|Aspirin|Up to day 90 after ACS, all enrolled patients will receive aspirin 1x100mg as a part of dual antiplatelet therapy. Starting from day 91, LDTP patients will discontinue aspirin and proceed with low-dose ticagrelor monotherapy until 12 months post-ACS, while patients in LDTA and SDTA will continue aspirin 1x100 mg until 12 months post-ACS.
224322553|NCT07113678|BEHAVIORAL|Body confidence podcast episode and supplementary exercises in a journal|"The 52-minute long podcast episode is hosted on the How to Fail podcast featuring a conversation between its host, Elizabeth Day, and the guest, actor and activist, Pamela Anderson (It wasn't about being pretty, it was about being brave).~The podcast episode is accompanied by supplementary exercises in a journal to reinforce the body confidence messages shared during the episode. The 8-page journal (Beauty on Your Own Terms) consists of two primary activities. The first activity (A vision for your future) involves 3 questions, a 3-minute visualisation exercise, and a prompt for written reflection all intended to facilitate accepting your body as it is, rejecting societal and media pressures that define beauty narrowly, and defining beauty on your own terms. The second activity (Beauty-on-your-own-terms challenge) involves 4 exercises intended to help women reflect on what they can change about your routine and habits to start defining beauty on your own terms."
223676598|NCT04530565|PROCEDURE|Lumbar Puncture|Undergo lumbar puncture
224258106|NCT03968172|BEHAVIORAL|EBBC programme|"Web-based behavioural lifestyle intervention that provides patients with coordinated information based on their existing health beliefs, interests, etc. In the programme, techniques and exercises will be taught in sequentially active interactive learning units (simulated dialogues) and followed-up with email and SMS reminders in the second study year. The following topics will be focused on:~1. Diagnosis and disease progression~2. Support in disease processing~3. Techniques for coping with stress and depressive symptoms as well as developing positive emotions~4. Optimisation of dietary behaviour~5. Optimisation of physical activity behaviour~6. Sleep hygiene and methods for dealing with insomnia.~The programme will accompany each patient with information material and e-mail reminders over a period of 12 months with initial 2-3 weekly tasks, later only weekly reminders and inputs every 2 weeks. All in all, the intervention programme will consist of 16 modules."
224258107|NCT03968172|BEHAVIORAL|Control group programme|"Web-based information platform with optimized standard care compiled from information material of the German Multiple Sclerosis Society (DMSG). Information will be provided in sequentially activated modules over a period of 12 months, covering the following topics:~1. Disease progression~2. Invisible symptoms of multiple sclerosis~3. Symptomatic therapy~4. Immunotherapy decision support~5. Coping strategies~6. Autonomy~7. Fatigue~8. Quality of life~9. Physical activity~10. Nutritional behaviour~In addition, a reminder system with neutral e-mail reminders will be used to promote the use of the programme."
224258108|NCT04949334|DEVICE|Dofin Breathing Strength Builder|"If the patient's condition is stable, respiratory muscle training will be performed under Dofin Breathing Strength Builder 7 days after stroke. The patient will receive respiratory muscle training by repetition of 30 times, two courses per day, x 7 days, for three weeks.~The initial load was set at 30% of the participants' maximal baseline strength and increased weekly at intervals of 2 cmH2O."
224258109|NCT04546334|DRUG|Medical treatment|routine medical treatment of post herpetic neuralgia as controls (Pregabalin, acyclovir, and paracetamol)
224258110|NCT04546334|PROCEDURE|Real Erector Spinae block|Ultrasound guided Erector spinae plane block with injection of local anesthetic bupivacaine (2 - 2.5 mg/kg, with a maximum of 175 mg/dose)
223676599|NCT04530565|DRUG|Mesna|Given IV
223676600|NCT04530565|DRUG|Methotrexate|Given IV or IT
223676601|NCT04530565|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
223676602|NCT04530565|DRUG|Ponatinib Hydrochloride|Given PO
223676603|NCT04530565|DRUG|Prednisone|Given PO
223676604|NCT04530565|DRUG|Vincristine Sulfate|Given IV
223676605|NCT06745921|BIOLOGICAL|HydroVax-001B WNV|A vaccine to West Nile Virus (WNV) that is prepared by propagating naturally attenuated Kunjin strain of WNV on well characterized low-passage Vero cells. The vaccine contains 10 mcg of inactivated purified whole virion WNV formulated in a volume of 0.5 mL/dose with 0.10% aluminum hydroxide, 10% D-sorbitol, 0.001% Polysorbate 80 (Tween80) in 10 mM phosphate-buffer with 350 mM NaCl.
224258111|NCT04546334|PROCEDURE|Real Erector Spinae block with magnesium sulphate|Ultrasound guided Erector spinae plane block with injection of local anesthetic bupivacaine (2 - 2.5 mg/kg, with a maximum of 175 mg/dose with the addition of MgSO4 (equivalent to 100 mg))
224258112|NCT04546334|PROCEDURE|Sham Erector Spinae block|Ultrasound guided Erector spinae plane block with injection ofnormal saline
224258113|NCT00828295|DRUG|palonosetron|palonosetron IV 1 mcg/kg
224258114|NCT00828295|DRUG|palonosetron|palonosetron 3mcg/kg IV
224258115|NCT01601158|BIOLOGICAL|Umbilical Cord Blood administration|The subjects will be undertaken allogeneic umbilical cord blood infusion intravenously or intraarterially under non-myeloablative immunosuppression.
224258116|NCT01601158|OTHER|Active Rehabilitation|All subjects should participate in active rehabilitation. They will receive two physical and occupational therapy sessions per day. Post discharge, each participant should continue to receive rehabilitation therapy at least 3 days per week until the study completion.
223676606|NCT06745921|OTHER|Placebo|Placebo
223676607|NCT06745921|OTHER|Sodium Chloride, 0.9%|0.9% Sodium Chloride Injection
223676609|NCT04606381|DRUG|Ami-LC-MD|Participants will receive amivantamab admixed with rHuPH20 SC infusion.
223676610|NCT04606381|DRUG|Ami-LC|Participants will receive amivantamab SC infusion.
223676611|NCT04606381|DRUG|Ami-HC|Participants will receive amivantamab SC infusion.
223676612|NCT04606381|DRUG|Ami-HC-CF|Participants will receive amivantamab co-formulated with rHuPH20 as SC infusion.
223676613|NCT04606381|DRUG|Lazertinib|Participants will receive lazertinib orally as a film-coated tablet.
223676614|NCT02839850|DEVICE|Cementless Total Knee Arthroplasty|Patients will undergo a primary total knee replacement using one of the two configurations of the ATTUNE Cementless knee (CR RP or PS RP)
223676616|NCT06441968|BIOLOGICAL|MPV/S-2P|A live murine pneumonia virus (MPV) vector expressing an additional SARS-CoV-2 S-protein, stabilized in its prefusion form, is being tested for its efficacy in protecting against the SARS-CoV-2 virus. It is speculated to be a next-generation vaccine for COVID-19.
224258117|NCT02762422|OTHER|Phlebotomy|Removal of 500 cc of blood via forearm vein
224258118|NCT01665690|OTHER|Patient delivered partner therapy|The study will provide communities with access to free PDPT for heterosexuals with gonorrhea or chlamydial infection. PDPT will be packaged to meet the requirements of the WA State Board of Pharmacy and will include 1gram of azithromycin, information about STD, condoms, and information about enclosed medication in English and Spanish. PDPT packs for gonorrhea will also include 400mg of cefixime.
223772969|NCT06463847|DRUG|UC-MSCs|"In this study, three dose groups are preset, which are low-dose group: 5×10\^6 cells/2.5mL; medium-dose group: 1×10\^7 cells/2.5mL; high-dose group: 2×10\^7cells/2.5mL, 9 to 18 subjects will be recruited, and will be sequential from the low-dose group to the high-dose group according to the 3+3 dose escalation principle. At least 3 subjects are enrolled in each group for the safety and tolerability test of single administration. After the last subject in each dose group completes the DLT observation period, the sponsor and the researcher jointly confirm the safety tolerance of the subjects in the previous dose group, and only after the safe tolerance is determined can the subjects enter the next dose group, so as to evaluate the safety and tolerance of human umbilical cord mesenchymal stem cell injection in the treatment of knee osteoarthritis. Recommend appropriate cell therapy dose (RP2D) for Phase II clinical trials."
223772970|NCT05167838|PROCEDURE|fresh embryo transfer|55 patients undergoing fresh embryo transfer after ovarian stimulation followed by luteal phase support
224322554|NCT07113678|BEHAVIORAL|Body confidence podcast episode|"The podcast episode is hosted on the How to Fail podcast featuring a conversation between its host, Elizabeth Day, and the guest, actor and activist, Pamela Anderson (It wasn't about being pretty, it was about being brave)."
224258119|NCT01665690|BEHAVIORAL|Targeted public health partner services|During intervention periods, communities will receive public health partner services (PS) provided by Disease Intervention Specialists (DIS). Diagnosing clinicians will triage their patients to receive PS based on defined criteria associated with not ensuring partners' treatment. PS will include an offer to notify partners for each index case. When DIS notify partners they will offer them the opportunity to obtain free medication at a local pharmacy, at a clinic (as available) or through the mail. DIS will also offer to refer partners for complete evaluations insofar as such care is available in local communities.
224258120|NCT02561845|DRUG|rosuvastatin|5mg, 10mg, 20mg
224322555|NCT07113678|BEHAVIORAL|Non-body image-related podcast episode|"A podcast episode from the same podcast series as the intervention, How to Fail, which contains no body image content and is matched on length and guest similarities. The episode features host Elizabeth Day in conversation with actor and activist Cynthia Nixon (Being brave is feeling scared and doing it anyway), which is 47 minutes in length."
224322556|NCT07133308|DRUG|Deuruxolitinib|Deuruxolitinib will be dosed orally as tablets at a dose of 8 mg
223676624|NCT06668181|DRUG|Bimekizumab|Bimekizumab will be administered at pre-specified timepoints.
223772971|NCT05167838|PROCEDURE|Frozen embryo transfer|55 patients undergoing frozen embryo transfer after ovarian stimulation followed by cryopreservation of all embryos and transfer in another cycle.
223772972|NCT00310687|PROCEDURE|BLOOD DRAW|
223772973|NCT03531593|DIAGNOSTIC_TEST|Ultrasound Elastography|Ultrasound elastography is a new, noninvasive technique that can assess the stiffness of the liver by the evaluation of how sound waves propagate through the liver parenchyma.
223772974|NCT02602288|BEHAVIORAL|Ask, Advise, Refer|WIC clinic staff ask about children's secondhand smoke exposure (SHSe), advise about harms of SHSe, and refer to smoking cessation resources
223772975|NCT02602288|BEHAVIORAL|Telebased tobacco counseling|Telephone counseling to promote parent's smoking cessation and behaviors to protect children from secondhand tobacco smoke
223772976|NCT02602288|BEHAVIORAL|Telebased nutrition counseling|Telephone counseling to promote nutritious eating practices in the family.
223772977|NCT02602288|DEVICE|Mobile phone smoking cessation application|Smartphone based application to support smoking cessation efforts
223772978|NCT02602288|DEVICE|Mobile phone nutrition application|Smartphone based application to support healthy eating habits
223676640|NCT06559306|DRUG|Seltorexant|Seltorexant will be administered orally.
223676641|NCT06559306|DRUG|Placebo|Matching Placebo tablets will be administered orally.
223676642|NCT06559306|DRUG|Selective Serotonin Reuptake Inhibitor (SSRI)/Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)|SSRI/SNRI will be administered orally.
224258121|NCT05954598|DIETARY_SUPPLEMENT|probiotic|This study was designed as a randomized double-blind controlled study. The enrolled subjects were randomized into two groups: intervention group and waiting intervention group. The intervention group received 12 weeks of probiotic intervention from the start of the study, and the waiting group received 12 weeks of placebo intervention from the start of the study. At the start of the study, both groups received 12 weeks of probiotic intervention.
224258122|NCT03757195|PROCEDURE|Augmentation|combination product
224322557|NCT07133308|DRUG|Placebo|Deuruxolitinib matching placebo will be dosed orally as tablets
224322558|NCT07133360|PROCEDURE|Third molar extraction|Surgical third molar extraction with conventional medication
224322559|NCT07158151|DRUG|RSS0393 ointment|RSS0393 ointment 0.05%
224322560|NCT07158151|DRUG|RSS0393 ointment|RSS0393 ointment 0.01%
223676658|NCT02494986|DRUG|Rilpivirine|Participants will continue to receive oral tablets of rilpivirine (RPV) 25 milligram once daily (mg qd) or a weight-adjusted dose, in combination with an investigator selected background regimen consisting of other ARVs.
223676660|NCT05508074|DRUG|IFB-088 50mg/day|Tested product
223676661|NCT05508074|DRUG|Placebo|Placebo
223676662|NCT05508074|DRUG|Riluzole 100mg/day|Standard of care treatment, co-administered with tested product (IFB-088 50mg/day) or placebo
223772979|NCT02602288|DRUG|Nicotine polacrilex|Over the counter nicotine replacement therapy in gum or lozenge form.
223772980|NCT01310413|BIOLOGICAL|Influenza A (H5N1) Virus monovalent vaccine|All subjects will receive 2 doses administered as an intramuscular (IM) injection.
223772981|NCT01310413|BIOLOGICAL|Saline placebo|All subjects will receive 2 doses administered as an intramuscular (IM) injection.
223772982|NCT04870567|RADIATION|Stereotactic ablative radiotherapy|Patients were randomly assigned (1:1) to conventionally high dose rate brachytherapy or stereotactic body radiotherapy. Randomisation was done Chief researcher blinded to patient data by telephone stratification by risk group (low or intermediate).
223772983|NCT04870567|RADIATION|High dose rate brachytherapy|Patients were randomly assigned (1:1) to conventionally high dose rate brachytherapy or stereotactic body radiotherapy. Randomisation was done Chief researcher blinded to patient data by telephone stratification by risk group (low or intermediate).
224258123|NCT02267408|OTHER|Warfarin adjustment using the Fearon algorithm|All available historical data will be used to calculate with the Fearon algorithm the individual sensitivity to warfarin and to dose changes as well as lag time until a dose adjustment reaches full effect. Based on this a personal dosing nomogram will be developed and provided to the investigator and to the patients. This nomogram will be used during 6 month but override is possible if the investigator feels that the suggestion from the nomogram is unsafe.
224258124|NCT02267408|OTHER|Warfarin adjustment using standard dosing|Patients will receive warfarin dosing instructions from a trained nurse using fixed nomograms and computer-based dosing suggestion.
224258125|NCT01402050|DRUG|CERVIDIL (Dinoprostone)|INDUCTION OF LABOR
224258126|NCT01402050|DEVICE|FOLEY BALLOON|INDUCTION OF LABOR
224322561|NCT07158151|DRUG|RSS0393 ointment|RSS0393 ointment 0.03%
224322562|NCT07158151|DRUG|RSS0393 ointment|RSS0393 ointment placebo
223676665|NCT05264779|OTHER|Periviable GOALS DST|An iPad application that contains outcomes information, values clarification and embedded short documentary style videos. The tool was designed with low-literacy and low-numeracy populations in mind, and utilizes graphics and video content to enhance meaning-making of complex medical information and jargon. The GOALS DST refers patients back to their physicians to discuss specific treatment options, local outcomes, and management strategies available to them. The DST's content focuses largely on helping patients better understand the choice they have between comfort care and life-sustaining efforts in the context of periviable delivery.
223772984|NCT01183091|PROCEDURE|Ablation of atrial fibrillation|Ablation of atrial fibrillation
223772985|NCT04502160|PROCEDURE|Vascular Access Creation|arteriovenous fistula creation
223676671|NCT06449651|DRUG|Nipocalimab|Nipocalimab will be administered intravenously.
224258127|NCT03581097|OTHER|Video Group|Patients in the film group watched the film using a laptop computer equipped with headphones, and Visual Analog Pain Scale (VAS) was repeated after the movie. Video was recorded by the Anaesthesiology department team, in order to explain and show in a detailed way on a model, the sequence of events, which occurs between the arrival of patients in the operating room and the performance of Intra-Venous Regional Anesthesia (IVRA)
224258128|NCT03330990|DRUG|Entrectinib|600 mg oral capsule (fasted and fed)
224258129|NCT03330990|DRUG|Midazolam Hydrochloride|2 mg oral syrup (fasted)
224258130|NCT06012006|OTHER|constant work-rate cycling exercise test|Description: at the end of pulmonary rehabilitation, a constant work-rate second cycling exercise test will be performed with the same duration as the cycling exercise test at inclusion
224258131|NCT04860349|OTHER|High Intensity Interval Training|4-weeks of high intensity interval training, 3 sessions/week on alternate days. each session for 20 minutes, excluding the warm-up and cool-down.
224258132|NCT06627946|PROCEDURE|TAP group|Local anesthesia 0.25% bupivacine was administered in the TAP plane
224258133|NCT06374134|BEHAVIORAL|Community Engagement Practice|Community engagement includes pre- and post-approval clinical trials that partnered and engaged with diverse public and patient communities; trusted community leaders; local advocacy groups; faith-based and civic organizations; community influencers; community health and government health communities.
224258134|NCT06374134|BEHAVIORAL|Patient-Centric Protocol Element|Patient-centric clinical trial designs include those that solicited patient, investigative site and community input into protocol design and clinical trial feasibility; offered solutions that improved patient participation convenience and access; and that more fully and effectively communicated clinical trial knowledge to diverse public and patient communities, health care providers and community influencers.
224258135|NCT00721435|PROCEDURE|3D Tomosynthesis and ultrasound imaging|3D tomosynthesis \& ultrasound imaging for scanning masses or healthy breast tissue
224258136|NCT04857138|DRUG|RO7300490|Participants will receive RO7300490, as described in the Arm Descriptions.
224258137|NCT04857138|DRUG|Atezolizumab|Participants will receive Atezolizumab, as described in the Arm Descriptions.
223676672|NCT06449651|DRUG|Placebo|Placebo will be administered intravenously.
224258138|NCT02375477|OTHER|Educational Intervention|Given educational presentation
223676673|NCT05565560|DRUG|Apremilast|Oral tablets
223676674|NCT05948826|DRUG|TORL-3-600|antibody drug conjugate
223676675|NCT04696809|DRUG|Teclistamab|Teclistamab will be administered subcutaneously.
223676678|NCT03778957|DRUG|Durvalumab|Durvalumab IV (intravenous)
223676679|NCT03778957|DRUG|Bevacizumab|Bevacizumab IV (intravenous)
223676680|NCT03778957|OTHER|Placebo|Saline solution for Durvalumab and/or Bevacizumab masking (IV intravenous)
223676681|NCT03778957|PROCEDURE|Transarterial Chemoembolization (TACE)|TACE (chemo and embolic agent injection into the hepatic artery)
223676682|NCT06095102|DRUG|JNJ-77242113|JNJ-77242113 will be administered orally.
223676683|NCT06095102|DRUG|Placebo|Placebo will be administered orally.
223676685|NCT02609776|DRUG|Amivantamab|The first cohort of participants will receive IV infusions of Amivantamab 140 mg as monotherapy. Each subsequent cohort will receive IV infusions of Amivantamab at increased dose level until maximum tolerated dose is reached or all planned doses are administered. Participants will receive lazertinib and Amivantamab at predefined dose levels, based upon observed safety and protocol defined criteria. The duration of each treatment cycle is 28 days. In Chemotherapy Combination Cohort, participants will receive Amivantamab, administered on a 21-day cycle, in combination with the administration of standard of care carboplatin and pemetrexed.
223676686|NCT02609776|DRUG|Amivantamab|Participants will receive IV infusion of Amivantamab as monotherapy at RP2D regimen or in combination lazertinib at RP2CD regimen as determined in Part 1.
223772986|NCT02376426|BIOLOGICAL|MVA-BN-Filo|One 0.5 milliliter (ml) intramuscular (IM) injection of 1\*10\^8, (50%Tissue Culture Infectious Dose \[TCID50\]) on Day 1, 29, 57.
224258139|NCT05777005|BEHAVIORAL|5A's/5R's advice|5A's (Ask, Advise, Assess, Assist, Arrange) for smokers who are ready to quit, and 5R's (relevance, risks, rewards, roadblocks, and repetition) for smokers who are not ready to quit.
224258140|NCT05777005|OTHER|Brief leaflet on health warning and smoking cessation|The contents of the leaflet include the absolute risk of smoking, diseases caused by active and second-hand smoking, horrible pictorial warnings of the health consequences of active and second-hand smoking, and the benefits of quitting.
223676687|NCT02609776|DRUG|Lazertinib|Lazertinib will be administered in combination with Amivantamab at predefined dose levels, based upon observed safety and protocol defined criteria. Lazertinib will be administered daily on the 28-day Amivantamab treatment cycle.
223676688|NCT02609776|DRUG|Carboplatin|Participants will receive carboplatin in combination with pemetrexed and Amivantamab as an IV infusion on 21-day treatment cycle in Part 1 Chemotherapy Combination Cohort only.
223676689|NCT02609776|DRUG|Pemetrexed|Participants will receive pemetrexed in combination with carboplatin and Amivantamab as an IV infusion on 21-day treatment cycle in Part 1 Chemotherapy Combination Cohort only.
223676690|NCT06299540|BEHAVIORAL|Individual Physical Activity Intervention (IPAI)|No drug will be administered as a part of this study. The intervention will consist in an IPAI provided to participants for 6 months to practice physical activity in addition to their medical treatment in routine clinical practice settings. IPAI will be an adaptive program and will comprise two periods, the first period consisting in a supervised 4-month program and the second one in an unsupervised 2-month program to achieve greater autonomy.
223676691|NCT06299540|DRUG|Ibrutinib|No drug will be administered as a part of this study. Participants received ibrutinib as per their routine clinical practice settings.
224258141|NCT05777005|OTHER|Self-help smoking cessation booklet|The contents include information about the benefits of quitting, methods to quit, how to handle withdrawal symptoms, misperceptions of quitting, etc.
224258142|NCT05777005|BEHAVIORAL|Counselor-led individual support|Participants will receive three months of counselor-led individual support via WeChat. The regular messages and instant messaging on psychosocial support aim to provide cessation advice, increase self-efficacy and confidence, and social support and behavioral capacity of quitting.
224258143|NCT05777005|BEHAVIORAL|Chatbot-led group support|Participants will receive three months of chatbot-led group support via WeChat.
224258144|NCT04695041|DRUG|PBI-4050/ Placebo|Participants receive either 800mg PBI-4050 capsules or placebo, twice a day for 14 days
223676692|NCT05083182|DRUG|Ustekinumab|Ustekinumab will be administered as subcutaneous injection.
223676693|NCT05083182|DRUG|Guselkumab|Guselkumab will be administered as subcutaneous injection.
224258145|NCT04695041|DRUG|PBI-4050/ Placebo|Participants receive either 1200mg PBI-4050 capsules or placebo, once a day for 14 days
224258146|NCT04695041|DRUG|PBI-4050/ Placebo|Participants receive either 1000 mg PBI-4050 capsules or placebo, twice a day for 14 days
224258147|NCT04695041|DRUG|PBI-4050/ Placebo|Participants receive either 1200 mg PBI-4050 capsules or placebo, twice a day for 14 days
224258148|NCT04695041|DRUG|PBI-4050/ Placebo|Participants receive either 800 mg PBI-4050 capsules or placebo, three times a day for 14 days
224258149|NCT03220958|DRUG|Metoclopramide|Metoclopramide 20mg
224258150|NCT03220958|DRUG|Diphenhydramine|Diphenhydramine 25mg
224258151|NCT03220958|DRUG|Normal saline|100ml normal saline
224258152|NCT06625021|PROCEDURE|Chiropractic manipulation|"Chiropractic manipulation: Lower cervical chiropractic manipulation is a technique used to increase mobility and relieve pain in the lower vertebrae of the neck. However, such procedures should only be performed by trained chiropractors; if done incorrectly, they can lead to serious problems. The patient should be placed in a comfortable position. The supine or side-lying position is usually preferred. Contact is established with the transverse processes of the lower cervical vertebrae. High-velocity, Low-amplitude thrust is applied within anatomical limits.~As a graduate of Bahcesehir University Chiropractic Masters Degree, I applied chiropractic twice a week for 3 weeks."
223676699|NCT06550895|DRUG|Cilta-cel|Cilta-cel infusion will be administered intravenously.
223676700|NCT06550895|DRUG|Talquetamab|Talquetamab will be administered subcutaneously.
223772987|NCT02376426|BIOLOGICAL|Ad26.ZEBOV|One 0.5 mL IM injection of 5\*10\^10 viral particles (vp) on Day 1, 29, 57.
223676707|NCT05957276|OTHER|Standard of Care|Participants will not receive any intervention in this study. Participants will receive standard of care therapy.
223676708|NCT04898634|DRUG|JNJ-78278343|JNJ-78278343 will be administered.
224258153|NCT06625021|PROCEDURE|Exercises to be done for neck pain of mechanical origin|Conservative treatment, which is frequently used in the treatment of mechanical neck pain, was planned. A warm-up period was defined with stretching exercises in all areas of neck movement. Again, isometric exercise should be 10 seconds in all directions. In addition to neck and shoulder mobility exercises, neck region posture exercises were included. It was planned to do these exercises for 4 weeks, 5 days a week, in all 4 groups.
224322563|NCT07162857|DEVICE|non-invasive cardiac output monitoring|Monitoring commenced immediately after enrollment, with baseline parameters recorded after signal stabilization (≤5 minutes), including cardiac output (CO), stroke volume (SV), stroke volume variation (SVV), and systemic vascular resistance (SVR). The system automatically updated these parameters every 30 seconds and displayed them in real-time on the monitor screen. Fluid resuscitation was dynamically adjusted according to these continuous measurements until achieving the predefined therapeutic targets.
224258154|NCT06625021|PROCEDURE|Classic Hand-Wrist Exercises|The participants of this group will be subjected to wrist range of motion (ROM), stretching and strengthening exercises. Measurements will be made in all axes of motion of the wrist, which are extension, flexion, ulnar and radial deviation. ROM exercises and stretching exercises were applied passively to all axes of motion within anatomical limits. At the last angles of the movement, the individual was forced and stretched without causing discomfort and waited at the last angles for a short time. Stretching exercises were performed five times for each movement. Strengthening exercises for all axes of movement of the wrist will be performed using dumbbells weighing 1 and 2 kilograms and an exercise band suitable for the persons endurance and strength. In exercises performed with dumbbells, all movements of the wrist will be performed against gravity. All applications were applied to the classical hand-wrist exercise group for at least half an hour every day for 4 weeks.
224322564|NCT07162857|DEVICE|Ultrasonic technology|In the critical care ultrasound group, patients underwent immediate bedside This protocol ensured real-time, comprehensive evaluation of both cardiac function and fluid status to guide resuscitation.Ultrasound reassessment was performed every 1-2 hours to dynamically adjust both the volume and rate of fluid administration until predefined resuscitation targets were achieved.
224322565|NCT07168018|BIOLOGICAL|Coadministration of ChAdOx2 RabG and licensed inactivated rabies vaccine (IRV)|A single visit of coadministration of 5×10\^10 vp ChAdOx2 RabG (2 site IM) and licensed IRV (2 site IM).
223676715|NCT05923073|DRUG|Guselkumab|Guselkumab will be administered subcutaneously.
223676716|NCT05923073|DRUG|Guselkumab|Guselkumab will be administered intravenously.
223676717|NCT03767244|DRUG|Apalutamide|Participants will receive apalutamide 240 mg (4 tablets of 60 mg each) orally once daily.
223676718|NCT03767244|DRUG|Androgen Deprivation Therapy (ADT)|Participants will receive a stable regimen of ADT - gonadotropin-releasing hormone analog (agonist or antagonist) (GnRHa). ADT is a kind of hormone therapy for prostate cancer. GnRHa will be administrated to achieve and maintain sub-castrate concentrations of testosterone (50 nanogram per deciliter \[ng/dL\]).
223676719|NCT03767244|DRUG|Placebo|Participants will receive matching placebo oral tablets daily.
223676720|NCT04829058|DEVICE|Intervention|There is no intervention, beyond necessary clinical care, in this study. The surgical procedures that were performed in subjects within this study are identical to the surgical procedures the subjects would have received as part of SOC.
223676722|NCT05137054|DRUG|Linvoseltamab|Linvoseltamab is administered by intravenous (IV) infusion
223772988|NCT02376426|BIOLOGICAL|Placebo|One 0.5 mL IM injection of 0.9% saline on Day 1 and 29 or on Day 1 and 57.
223676723|NCT05137054|DRUG|Daratumumab|Daratumumab is administered by IV infusion and/or subcutaneous (SC) injection; SC injection may be used after a minimum of 2 cycles of IV administration at the investigator's discretion.
223676724|NCT05137054|DRUG|Carfilzomib|Carfilzomib is administered by IV infusion
223676725|NCT05137054|DRUG|Lenalidomide|Lenalidomide is administered by mouth (PO) as a capsule
223676726|NCT05137054|DRUG|Bortezomib|Bortezomib is administered by IV infusion or SC injection
223676727|NCT05137054|DRUG|Pomalidomide|Pomalidomide is administered by mouth (PO) as a capsule
223676728|NCT05137054|DRUG|Isatuximab|Isatuximab is administered by IV infusion
223676729|NCT05137054|DRUG|Fianlimab|Fianlimab is administered by IV infusion
223676730|NCT05137054|DRUG|Cemiplimab|Cemiplimab is administered by IV infusion
223676731|NCT05137054|DRUG|Nirogacestat|Nirogacestat is administered by mouth (PO) as a tablet
223772989|NCT00815126|PROCEDURE|Lysine-ASA Nasal ProvocationTest|Lysine-ASA 80 µl (16 mg of aspirin) will be installed in both nostrils with pipette
223772990|NCT00905333|DRUG|Candesartan (test)|16 mg oral tablet, single dose
223772991|NCT00905333|DRUG|Felodipine (test)|5 mg oral extended release tablet, single dose
223772992|NCT00905333|DRUG|Candesartan Cilexetil|16 mg oral tablet, single dose
223772993|NCT00905333|DRUG|Felodipine|5 mg oral extended release tablet, single dose
223772994|NCT00927446|PROCEDURE|Endoscopy screening with narrow band imaging|Narrow Band Imaging (NBI) system, an optical technology that enhances the visualization of superficial vascular network, may be superior to the conventional white light endoscopy for the detection of neoplastic lesions.
223772995|NCT00612066|DRUG|rosiglitazone maleate|
224322566|NCT07168018|BIOLOGICAL|Inactivated Rabies Vaccine (IRV)|A World Health Organization (WHO) prequalified IRV at two anatomical sites (2 site ID) on days 0, 3 and 7.
223676732|NCT05137054|DRUG|Cevostamab|Cevostamab is administered by IV infusion
223676733|NCT03586609|DRUG|Azacitidine|Given SC or IV
223676734|NCT03586609|DRUG|Cladribine|Given IV
223676735|NCT03586609|DRUG|Cytarabine|Given SC
223676736|NCT03586609|DRUG|Venetoclax|Given PO
223676743|NCT05083169|DRUG|Daratumumab|Daratumumab will be administered SC injection.
223676744|NCT05083169|DRUG|Pomalidomide|Pomalidomide will be administered orally.
223676745|NCT05083169|DRUG|Dexamethasone|Dexamethasone will be administered orally or intravenously.
223676746|NCT05083169|DRUG|Bortezomib|Bortezomib will be administered SC injection.
223676747|NCT05083169|DRUG|Teclistamab|Teclistamab will be administered SC injection.
224258155|NCT06625021|PROCEDURE|Proprioceptive exercise group|Similar to the classical wrist exercise group, the participants in this group were applied joint range of motion, stretching and strengthening exercises as well as proprioceptive exercises such as joint approximation, traction and mobilization. In addition to all axes of motion of the wrist, active and passive stretching exercises were applied to the forearm flexor and extensor muscles five times each. The resistance and repetition number were gradually increased according to the wrist strength and endurance of the individuals to at least 10 repetitions. Repetitive contraction and rhythmic stabilization techniques were used from proprioceptive neuromuscular facilitation methods. Joint approximation technique and taping of forearm flexor and extensor muscles were used to increase the level of contraction and stimulation of joint receptors. External stabilization and perturbation exercises were performed with an exercise ball against the wall at different angles of the upper extremity.
224258156|NCT01930903|DEVICE|Pantera Lux Drug Eluting Balloon|All patients are treated with the PRO-Kinetic Energy Stent and Pantera Lux drug eluting balloon for the last post dilatation.
224258157|NCT02977221|PROCEDURE|Piezosurgery|The device tip will be used to to create small vertical incisions into the cortex of the dento-alveolar process of the lower anterior teeth.
224258158|NCT02393014|PROCEDURE|Simple physical exercises|"1. The participant must stay out of the bed 3 hours. This pre-required level prevents the occurrence of acute postural mismatch which can occur when elderly patients are bedridden and too long increases the risk of falling.~2. The participant stands standing in static equilibrium to a chair holding the back of it for 2 minutes. Depending on the patient's abilities, the exercise will be done on both feet or one foot.~3. The participant performs a transfer activity of sitting to standing repeated 5 times (FTSS test). According to the patient's abilities, the exercise will be done with physical assistance or not."
223676750|NCT06544616|DRUG|JNJ-64042056|JNJ-64042056 will be administered intramuscularly.
223676751|NCT06544616|DRUG|Placebo|Placebo will be administered intramuscularly.
223676757|NCT06181240|DEVICE|Intravascular lithotripsy|Lithotripsy-enhanced percutaneous coronary intervention of de novo, calcified, stenotic coronary artery lesions prior to stenting.
223676760|NCT00606346|BIOLOGICAL|Anti TNF therapy including infliximab|Treatments will be prescribed according to investigator judgement.
223676761|NCT00606346|DRUG|No Biologics|Treatments will be prescribed according to investigator judgement.
224258159|NCT00816413|DRUG|cyclosporine|2 mg/kg IV over 2 hours every 12 hours starting at 0700 on days -1, 0, and +1 (total of six doses).
224258160|NCT00816413|DRUG|mycophenolate mofetil|15 mg/kg orally twice a day starting day 0 until day +27 then stopped without tapering in the absence of aGVHD then tapered over two months in the absence of aGVHD. Doses will be rounded to the nearest 250 mg.
223772996|NCT00855829|DEVICE|Miniature Actilady device active|"Devices: Targeted pressure waves are created by two kind of methods ActiLady).~1. The effect of the waves used will be examined by the use of a silicon tube or polyvinyl chloride (PVC) tube which is inserted into the vaginal cavity. The other end of the tube will be connected to an off the shelf pressure waves generator and controller.~2. Self manufactured device inserted into the vaginal cavity and creating subsound pressure waves."
224258161|NCT00816413|DRUG|pentostatin|4 mg/m2/d IV over 30 minutes daily x 3 days, (days -10, -9, -8)to begin ten days prior to stem cell infusion (Day 0).
224258162|NCT00816413|GENETIC|cytogenetic analysis|At days +28 and +70 post-transplant, patients' blood will be evaluated for CD3 and overall WBC chimerism.
224258163|NCT00816413|GENETIC|fluorescence in situ hybridization|Mixed chimerism is defined as the detection of 95% or less donor T cells (CD3+), expressed as a proportion of the total T cell and WBC population as measured by DNA.
224258164|NCT00816413|GENETIC|protein analysis|Blood samples will be at baseline(day -11 or before) , days -8 and -1, prior to transplant on day 0, then weekly (days +7, +14, +21 and +28) post-transplant through day +28. Five ml's of blood will be drawn at each collection through a central line using heparinized vaccutainers. Samples will be spun down at 1200 g and plasma aspirated and stored in -80 oC until analyzed for the ELISA Assays being done for research purposes in this protocol.
224258165|NCT00816413|OTHER|flow cytometry|Peripheral blood Peripheral blood flow cytometry for immunophenotyping including Th/c1 and Th/c2 subsets, mitogens (PHA, PWM), NK and LAK function studies, DCs, apoptosis assay of tumor cells, and lymphocyte subsets (CD4, CD8, CD19, CD56
224258166|NCT00816413|OTHER|immunoenzyme technique|Peripheral blood for immunophenotyping including Th/c1 and Th/c2 subsets, mitogens (PHA, PWM), NK and LAK function studies, DCs, apoptosis assay of tumor cells, and lymphocyte subsets (CD4, CD8, CD19, CD56
224258167|NCT00816413|OTHER|laboratory biomarker analysis|Donor mononuclear cells from the stem cell product (SCP) obtained with apheresis will be analyzed for surface markers, including CD3, CD4, CD8, CD19, CD14, CD56, TCR+CD8+ cells, Th/c1 and Th/c2, Fas and FasL, and DCs, as well as for apoptosis
224258168|NCT00816413|OTHER|reduced-intensity transplant conditioning procedure|"Allopurinol 300 mg orally once daily x 10 days, to begin one day prior to treatment with Pentostatin (day -11 to day -2) .~Pentostatin 4 mg/m2/d IV over 30 minutes daily x 3 days, (days -10, -9, -8)to begin ten days prior to stem cell infusion (Day 0) .~Pre and Post Pentostatin Hydration: 1000ml Normal Saline IV over 2 hours pre each dose of Pentostatin and 1000ml Normal Saline IV over 4 hours post each dose of Pentostatin on days -10, -9, -8.~Pre Pentostatin Recommended Antiemetics: Ondansetron 32 mg IV over 30 minutes to be given 30 min. before each dose of Pentostatin on days -10, -9, -8. Alternative ondansetron equivalent or other ancillary antiemetics may be used at the discretion of the treating physician.~Pred Forte Eye Drops: two drops in each eye every 4 hours while awake x 7 days after starting Pentostatin (day -10 to day -4)."
224258169|NCT00816413|PROCEDURE|nonmyeloablative allogeneic hematopoietic stem cell transplantation|Each patient will receive up to four IV infusions administered over 30 minutes of donor T cells at increasing cell doses given at intervals.
224258170|NCT00816413|PROCEDURE|peripheral blood stem cell transplantation (PBSC)|PBSC are infused intravenously either by infusion or IV push on day 0 through a secure intravenous access (i.e. the double-lumen central catheter place pre transplant) according to institutional guidelines.
224258171|NCT00816413|RADIATION|total-body irradiation|2.0 GY will be administered on day -1. Total-body irradiation (TBI) will consist of 2.0 GY at 8-12cGy/min via 6MV photons delivered AP/PA fields, without lung blocks or via lateral fields with lucite compensator along the head and neck region. TLD (thermal luminescent dosimetry) will be used to verify dose uniformity. It is anticipated that TBI will be given on day -1; however, the timing of TBI administration may be altered by factors beyond the control of the Principal Investigator because of the delivery of unrelated donor stem cells.
224322567|NCT07167732|DIAGNOSTIC_TEST|A General Medical and Neurological Assessment|Clinical assessments will consist of gathering demographic data, detailed relevant medical history, and parents' perspectives on treatment priorities, clinical trial interest, and acceptability of risk in future clinical trials. A general medical and neurological examination will be performed by a trained and skilled physician with a valid Good Clinical Practice Certification.
223772997|NCT00855829|DEVICE|Miniature Actilady device not active|"Devices: Targeted pressure waves are created by two kind of methods ActiLady).~The effect of the waves used will be examined by the use of a silicon tube or polyvinyl chloride (PVC) tube which is inserted into the vaginal cavity. The other end of the tube will be connected to an off the shelf pressure waves generator and controller.~Self manufactured device inserted into the vaginal cavity and creating subsound pressure waves."
224258172|NCT00364559|DRUG|Rosuvastatin|20 mg 10 days daily
224258173|NCT01376037|DEVICE|Erchonia(r) ML Scanner (MLS)|The Erchonia ML Scanner (MLS) low level laser light therapy device is administered to both arms for 20 minutes each, 6 times across 2 weeks.
224258174|NCT01376037|DEVICE|inactive placebo laser device|non-therapeutic light application
224258175|NCT05710588|OTHER|motor-motor dual-task training|The intervention compromises balance-related tasks which are selected among the tasks often used in balance rehabilitation and motor secondary tasks might be required hand dexterity like popping a fidget toy or reaching ability like touching wall. All sessions will be individual. The initial training session will be undertaken in University of Plymouth. This will be followed by a recorded training video programme which can be accessible through Panopto- a University-led, web-based platform- undertaken in the participants' home for 30 minute sessions, three times a week over 6 weeks.
224258176|NCT05710588|OTHER|motor-cognitive dual-task training|The intervention compromises (1) balance-related tasks which are selected among the tasks often used in balance rehabilitation and (2) cognitive secondary tasks might required to activate sensory and cognitive systems like listening podcast and memorizing the details about it or reading a tongue twister and repeating. intervention delivery will be the same with M-DTT group.
224258177|NCT04200833|DRUG|Golimumab|subcutaneous injection
224322568|NCT07167732|DIAGNOSTIC_TEST|World Health Organisation (WHO) Motor Milestones|Ages of six WHO Motor milestones achievements - sitting without support, hands and knees crawling, standing with support, walking with support, standing independently, and walking independently - will be assessed. The age of milestone achievement will be compared to normative variations in age as recommended by the WHO (WHO, 2006).
223772998|NCT00630877|DRUG|Niacin extended-release (NER)|Tablets administered once daily for 6 weeks; titrated to a maximum dose of 2000 mg
223676777|NCT06112093|DEVICE|Repetitive Transcranial Magnetic Stimulation|rTMS will be used to regulate the motor cortex to reduce headaches and post-concussion symptoms.
223676778|NCT06112093|DEVICE|Sham Repetitive Transcranial Magnetic Stimulation|Sham rTMS will be delivered by a sham coil as a comparator to the (active) rTMS. Sham rTMS will not change the brain function of the control group.
223676779|NCT05945485|BIOLOGICAL|DCVC H1 HA mRNA vaccine|A modified nucleoside messenger RNA (mRNA) vaccine encoding the full length HA of influenza A/California/07/2009 (H1N1) encapsulated in lipid nanoparticle (LNP) composed of ionizable lipid, DSPC, cholesterol, and PEG lipid for delivery
223676780|NCT05945485|BIOLOGICAL|Quadrivalent Recombinant Seasonal Influenza Vaccine|The vaccine contains recombinant hemagglutinin (HA) proteins from four influenza viruses, expressed using a baculovirus vector. These HA proteins are produced in a continuous insect cell line.
223676781|NCT05945485|OTHER|Sodium Chloride, 0.9%|0.9% Sodium Chloride Injection
223676782|NCT04779918|DEVICE|OviTex Reinforced Tissue Matrix|All study subjects will receive OviTex. All OviTex Reinforced Tissue Matrices are intended for use as a surgical mesh to reinforce or repair soft tissue where weakness exists.
223676783|NCT04580771|DRUG|Cisplatin|Given IV
223676784|NCT04580771|BIOLOGICAL|Liposomal HPV-16 E6/E7 Multipeptide Vaccine PDS0101|Given SC
223676785|NCT04580771|RADIATION|Radiation Therapy|Undergo radiation therapy
223676786|NCT01804686|DRUG|Ibrutinib|Ibrutinib will be given orally as capsules, once daily continuously, according to the current dosing regimen established in the parent ibrutinib clinical study (560 mg, 420 mg, 280 mg, or 140 mg), at approximately the same time each day.
223676799|NCT06049017|DRUG|JNJ-77242113|JNJ-77242113 tablet will be administered orally.
223676800|NCT06049017|DRUG|Placebo|Placebo tablet will be administered orally.
223676802|NCT05076175|DRUG|Ozanimod|Specified dose on specified days
223676804|NCT05272631|DEVICE|Retrograde Femoral Nail Advanced|No drug will be given as part of this study. Participant will undergo surgery with RFNA based on the surgeon's decision and the site's SOC.
223676805|NCT05272631|DEVICE|Tibial Nail Advanced|No drug will be given as part of this study. Participant will undergo surgery with TNA based on the surgeon's decision and the site's SOC.
223676806|NCT05702034|DRUG|Milvexian|Milvexian will be administered orally.
223676807|NCT05702034|DRUG|Placebo|Placebo will be administered orally
223772999|NCT00630877|DRUG|Niacin extended-release (NER) placebo|Tablets administered once daily for 6 weeks
224258178|NCT06054984|DRUG|TCR-T Cells Injection（GB3010 Cells Injection）|The TCRT cells used in this clinical trial were derived from the patient's autologous peripheral-blood T cells and were genetically transduced to express a T-cell Receptor that recognizes the RAS/TP53.Patients were sequentially enrolled into 3 dose escalation groups(dose level 1-3) :5×10\^8±20%,5×10\^9±20%,5×10\^10±20%.
224258179|NCT05795140|DRUG|Iptcaopan 200 mg|Open label, participant specific kits, hard gelatin capsules to be taken twice a day
224322569|NCT07167732|DIAGNOSTIC_TEST|Burke-Fahn-Marsden Dystonia Rating Scale|The Burke-Fahn-Marsden Dystonia Rating Scale (BFMDRS; Burke, Fahn, Marsden et. al, 1985) is a universally applied biomarker for the severity of dystonia in children and adults. The scale consists of a movement and disability subscale (Burke-Fahn-Marsden Movement Scale \[BFMMS\] and Burke-Fahn-Marsden Disability Scale \[BFMDS\], respectively. Only the BFMMS will be assessed. The BFMMS measures dystonia in nine body regions (including the eyes, mouth, speech and swallowing, neck, trunk, arms, and legs) with scores ranging from 0 (minimum) to 120 (maximum).
223676812|NCT06408935|DRUG|Guselkumab|Guselkumab will be administered IV and SC.
223676813|NCT06260163|DRUG|Guselkumab Subcutaneous|Guselkumab will be administered subcutaneously.
223676814|NCT06260163|DRUG|Guselkumab Intravenous|Guselkumab will be administered intravenously.
223676817|NCT02531516|DRUG|Apalutamide|
223676818|NCT02531516|DRUG|Bicalutamide|
223676819|NCT02531516|DRUG|Bicalutamide Placebo|
223676820|NCT02531516|DRUG|Apalutamide Placebo|
223676821|NCT02531516|DRUG|GnRH (agonist)|
223676822|NCT02531516|RADIATION|74-80 Grays (units of radiation)|
223676823|NCT03702322|BEHAVIORAL|Voice therapy: respiratory|Abdominal voice onset
223676824|NCT03702322|BEHAVIORAL|Voice therapy: glottal closure|Pulling/pushing task
223676825|NCT03702322|BEHAVIORAL|Voice therapy: loud|Assertive task
223676826|NCT03702322|BEHAVIORAL|Voice therapy: Semiocclusion|Semi-occluded vocal tract
223773000|NCT00630877|DRUG|Aspirin (ASA)|Tablets (325 mg) administered once daily for 6 weeks
224258180|NCT02328040|DRUG|Placebo and Insulin monotherapy via CL|In the control arm patient receives a placebo pill with the closed loop with insulin/novolog (placebo and insulin/novolog via CL)
224258181|NCT02328040|DRUG|Sitagliptin and insulin/novolog via CL|In the treatment arm the participant receives a single dose of sitagliptin with closed loop with insulin/novolog (Sitagliptin and insulin/novolog via CL), Part B
224322570|NCT07167732|DIAGNOSTIC_TEST|Spastic Paraplegia Rating Scale|The Spastic Paraplegia Rating Scale (SPRS; Schüle et al., 2006) is a 13-item scale used to measure disease severity in spastic paraplegia. The items include walking distance without pause, gait quality, maximum gait speed, climbing stars, arising from chair, spasticity of hip adductor and knee flexion muscles, weakness of hip abduction and foot dorsiflexion, contracture of lower limbs, pain related to spasticity, and bladder and bowel function. Each item has a score ranging from 0 to 4, where 0 represents no dysfunction and 4 represents most severe dysfunction. The score result is calculated by adding single scores of each of the 13 items. The total score varies between 0 (no dysfunction) and 52 (most severe dysfunction).
223773001|NCT00630877|DRUG|Aspirin (ASA) placebo|Tablets administered once daily for 6 weeks
223773002|NCT04681521|OTHER|Hot and Cold compress, nursing interventions|using thermal compress at 38-39 °C (hot) and 15-16 °C (cold) on the distal regions of both lower extremities of the patients
223773003|NCT02657850|OTHER|non- head and neck self reporting|non- head and neck patient self reports dysphagia symptoms
223676836|NCT06799169|DRUG|Nortriptyline|Nortriptyline (7.5 mg) plus Topiramate (10 mg) taken by mouth daily with appropriate dosage increase as necessary
223676837|NCT06799169|DRUG|Topiramate|Nortriptyline (7.5 mg) plus Topiramate (10 mg) taken by mouth daily with appropriate dosage increase as necessary
223676838|NCT06799169|DRUG|Paroxetine|Verapamil (30 mg) plus Paroxetine (4 mg) taken by mouth daily with appropriate dosage increase as necessary
223676839|NCT06799169|DRUG|Verapamil|Verapamil (30 mg) plus Paroxetine (4 mg) taken by mouth daily with appropriate dosage increase as necessary
223676840|NCT03208868|DIETARY_SUPPLEMENT|Leucine enriched essential amino acid (EEA/LEU)|Patient with cirrhosis will be randomized to either take a Leucine enriched essential amino acid or a balanced amino acid supplement.
223773004|NCT02657850|OTHER|head neck self reporting|head and neck patient self reports dysphagia symptoms
223773005|NCT02657850|OTHER|provider reporting|provider reports on head and neck cancer patients' dysphagia symptoms
223773006|NCT04542993|DIETARY_SUPPLEMENT|Zinc Picolinate|Zinc Picolinate (50 mg PO TID x 5 days)
223773007|NCT04542993|DIETARY_SUPPLEMENT|Resveratrol|Resveratrol 2 grams po BID x 5 days
224258182|NCT06556602|OTHER|MPACT|Four components are part of this intervention: 1) accredited training about patient centered, trauma-informed care and the standard of care under the current federal regulation (42CFRpart8), 2) education about trauma and trauma symptoms including vicarious (work related) trauma and navigation to symptoms screening and resources including treatment, 3) reflective supervision for counseling, case management and peer staff, and 4) clinic self assessment for trauma-informed and patient centered care
224258183|NCT01257984|DRUG|BAY86-5300|0.02 mg EE as ß-CDC / 3 mg DRSP in a tablet form (1 tablet/day) for up to 120 days, followed by a 4-day tablet-free interval, administered with a dispenser supported by a reminder function
224258184|NCT01257984|DRUG|BAY86-5300|0.02 mg EE as ß-CDC / 3 mg DRSP in a tablet form (1 tablet/day) for up to 120 days, followed by a 4-day tablet-free interval, administered with a dispenser without reminder support
224258185|NCT03567551|OTHER|Women w/ Preeclampsia w/o Visual Disturbances or Headache|Up to three maternal blood samples collected from each participant, cerebrospinal fluid collected from each participant during spinal or combined spinal/epidural anesthesia, one umbilical cord blood sample obtained from each participant, four placenta samples obtained from each placenta from each participant
224322571|NCT07167732|DIAGNOSTIC_TEST|5. CTNNB1-Related Neurodevelopmental Disorder (NEDSDV) Cardiac Health Questionnaire|In a recent study (Sinibaldi et al., 2023), several patients with NEDSDV showed heart abnormalities. To expand on that, investigators developed a parent report questionnaire on the presence of potential heart defects.
223676841|NCT03208868|DIETARY_SUPPLEMENT|Balanced amino acid supplement (BAA)|Patient with cirrhosis will be randomized to either take a Leucine enriched essential amino acid or a balanced amino acid supplement.
223676845|NCT04204408|DRUG|NNC0365-3769 (Mim8)|Mim8 administered subcutaneously (s.c., under the skin). The treatment period will consist of 12 once-weekly doses or 3 once-monthly doses
223676846|NCT04204408|DRUG|Placebo (Mim8)|Mim8 placebo administered subcutaneously (s.c., under the skin)
223676850|NCT05040971|DRUG|Semaglutide 2.4 mg|Administered subcutaneously (s.c., under the skin) once weekly as well as reduced-calorie diet and increased physical activity for 52 weeks. Doses gradually increased to 2.4 mg
223676851|NCT05040971|DRUG|Placebo|Administered subcutaneously once weekly (s.c., under the skin) as well as reduced-calorie diet and increased physical activity for 52 week
224258186|NCT03567551|OTHER|Women w/ Preeclampsia w/ Visual Disturbances or Headaches|Up to three maternal blood samples collected from each participant, cerebrospinal fluid collected from each participant during spinal or combined spinal/epidural anesthesia, one umbilical cord blood sample obtained from each participant, four placenta samples obtained from each placenta from each participant
224322572|NCT07167732|DIAGNOSTIC_TEST|10m Walk-Run Test|The 10m Walk-Run Test is is a performance measure used to assess walking or gait speed in meters per second over a short distance. It involves measuring the time it takes for a person to walk the distance, with results reported in meters/second (m/s). The patient's ability to walk at both comfortable and fast speeds can be measured, and assistive devices can be used. The test will be performed in ambulant children by an experienced physiotherapist.
224258187|NCT03567551|OTHER|Women w/o Preeclampsia|Up to three maternal blood samples collected from each participant, cerebrospinal fluid collected from each participant during spinal or combined spinal/epidural anesthesia, one umbilical cord blood sample obtained from each participant, four placenta samples obtained from each placenta from each participant
224258188|NCT04643691|DRUG|Losartan 50 mg and Spironolactone 25 mg pillules oral use|Losartan 50 mg and Spironolactone 25 mg pillules oral use during 10 days
224258189|NCT00022555|DRUG|bryostatin 1|Given IV
224258190|NCT00022555|DRUG|vincristine sulfate|Given IV
224258191|NCT03135847|DEVICE|Tactor|The tactor is a small robot providing touch and vibration.
224258192|NCT03996837|OTHER|Intra uterine infusion of platelet rich plasma|Platelet Rich Plasma (PRP) is a blood product with a high platelet and a normal plasma fibrinogen level. Given the effective factors of RPR in repairing damaged tissues, its application in the field of regenerative medicine has widely been interested over the last three decades. According to the literature, PRP is an effective and safe treatment in the fields of orthopaedics, dermatology, ophthalmology, and repair of neurological, vascular, and connective tissue damage, but its application in the field of infertility is limited to a few pilot studies in which the effects of PRP on endometrium and recurrent implantation failure (RIF) were investigated.
224258193|NCT05679921|DRUG|pembrolizumab, pazopanib|Pembrolizumab will be given for a maximum of 2 years i.e. a total of 35 cycles of pembrolizumab with the q3 week dosing. Participants who complete study intervention after 2 years of pembrolizumab can be treated with pazopanib monotherapy based on physician's judgement. The duration of optional pembrolizumab crossover treatment will be maximum of 2 years i.e. a total of 35 cycles of pembrolizumab for patients progressing on pazopanib.
224258194|NCT03047746|DEVICE|CliniMACs|Peripheral blood stem cells from closely matched unrelated or partially matched related donors will be processed using the CliniMACS device to remove TCRalpha/beta T cells and B cells, in accordance with the Investigator Brochure and Technical Manual following the laboratory standard operating procedures (SOPs) and using aseptic technique
224258195|NCT04588922|DRUG|SLS009|Solution for injection
224258196|NCT04588922|DRUG|venetoclax|Tablets
224258197|NCT04588922|DRUG|azacitidine|Solution for injection
224258198|NCT04516434|DEVICE|Neurometer Neurotron CPT|All participants will undergo CPT testing. A Neurotron catheter (12-French) with electrode will be inserted through the urethra into the bladder. The catheter balloon will be inflated and positioned at the urethrovesical junction to stimulate the urethra 10-14 mm from the bladder neck. For bladder stimulation, the catheter balloon will be deflated and the catheter will be advanced into the bladder. The device will deliver sine wave stimulus pulses at 5, 250, and 2,000 Hz. CPT will be established using an automated forced choice paradigm by the method of levels. Testing order of the bladder and urethra will be randomized between participants.
224258199|NCT04516434|PROCEDURE|Cystometry|After bladder stimulation or during intraurethral stimulation, cystometry will be performed to assess bladder sensation and storage. A dual-chamber 8-French catheter will be passed through the urethra into the bladder for retrograde filling. A second 8-French catheter will be placed in the vagina to measure intra-abdominal pressure. A stimulation electrode catheter will only be inserted in the intraurethral stimulation arm. EMG pads will then be placed at 3 and 9 o'clock on each side of the perineum. The bladder will then be filled with room-temperature sterile saline solution in a retrograde fashion using a pump. Bladder sensation and urgency will be assessed while filling.
224258200|NCT04516434|PROCEDURE|Pressure-flow study|A pressure flow study will be performed to evaluate voiding function after stimulation. The transurethral and intra-vaginal catheters are left in place after cystometry and the participant will be asked to void around them, into a commode. Bladder and abdominal pressures will be recorded, as well as urine flow over time.
224258201|NCT02473341|DRUG|Bovine Colostrum|"Protein 1.5 gm/kg/day, energy (kcal) 30-40/day, B complex vitamins daily. Pasteurized Bovine colostrum as a freeze dried powder (20 gm thrice a day) for 4 weeks.~\+ Antibiotics + Diuretics +Terlipressin for HRS + acid suppression for prophylaxis against gastrointestinal hemorrhage + EVL for variceal bleed +drugs for HE if indicated"
223676891|NCT06636097|DEVICE|Full arch|design
224258202|NCT02473341|DRUG|Placebo|"Protein 1.5 gm/kg/day, energy (kcal) 30-40/day, B complex vitamins daily. Placebo (Pasteurised Milk Powder) 20 gms thrice a day for 4 weeks~\+ Antibiotics + Diuretics + drugs for HE + Terlipressin for HRS + acid suppression for prophylaxis against gastrointestinal hemorrhage + EVL for variceal bleed + if indicated."
224258203|NCT03121586|DRUG|Pimavanserin|Pimavanserin 10 mg, tablet, taken as one 10 mg tablets, once daily by mouth, OR Pimavanserin 20 mg, tablet, taken as two 10 mg tablets, once daily by mouth, OR Pimavanserin 34 mg, tablet, taken as two 17 mg tablets, once daily by mouth
224258204|NCT06381102|DEVICE|transcutaneous auricular vagus nerve stimulation 30/30|Transauricular vagus nerve stimulation (taVNS) is a simple technique in which small surface electrodes are placed over the skin of the ear that are thought to be innervated by the auricular branch of the vagus nerve (ABVN). Participants in this group will first receive taVNS with a 30 second on and 30 second off, for 1 hour, in-person.
224258205|NCT06381102|DEVICE|transcutaneous auricular vagus nerve stimulation 10/10|Transauricular vagus nerve stimulation (taVNS) is a simple technique in which small surface electrodes are placed over the skin of the ear that are thought to be innervated by the auricular branch of the vagus nerve (ABVN). Participants in this group will first receive taVNS with a 10 second on and 10 second off, for 1 hour, in-person.
224258206|NCT06326437|OTHER|6-week dyadic intervention|Comprising 6 weekly 60-90min internet-based sessions.
224258207|NCT04120935|OTHER|Observation|Prospective Observation of standard clinical practice.
224258208|NCT05840900|BEHAVIORAL|Digital Mindfulness Training|Once daily, 5-10 minute mindfulness exercises for 8 week intervention period using the existing perinatal mindfulness application Expectful
223773008|NCT04542993|DIETARY_SUPPLEMENT|Zinc Picolinate Placebo|Zinc Picolinate Matched Placebo PO TID x 5 days
223773009|NCT04542993|DIETARY_SUPPLEMENT|Resveratrol Placebo|Resveratrol Matched Placebo PO BID x 5 days
224322573|NCT07167732|DIAGNOSTIC_TEST|The Nine Hole Peg Test|The Nine-Hole Peg Test (9-HPT; Kellor et al., 1971) is a standardized, quantitative assessment used to measure finger dexterity. It is administered by asking the client to take the pegs from a container, one by one, and place them into holes on the board as quickly as possible. The 9-HPT has been validated for children above the age of 4 years (Poole et al., 2006). The test will be performed in children over 4 years old by a trained investigator.
223676900|NCT06075147|DRUG|Aflibercept 8 mg (VEGF Trap-Eye, BAY86-5321)|Following the manner of observational study, no intervention will be provided in the study. Any treatment decision, including the decision for aflibercept 8 mg treatment, is at the discretion of the attending physician, made in accordance with his/her experience and follows approved clinical guidelines.
223773010|NCT05990049|DRUG|Hyadent BG|Hyadent BG is a cross-linked hyaluronic acid. 1,6% cross-linked hyaluronic acid (xHA), 0,2% native hyaluronic acid (HA)
224258209|NCT03456063|DRUG|Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody|"Atezolizumab will be administered as intravenous (IV) infusion at a dose of 1200 milligrams (mg) on Day 1 of each 21-day cycle (every 3 weeks) for 4 cycles during the neoadjuvant treatment phase~Atezolizumab will be administered as IV infusion at a dose of 1200 milligrams (mg) every 3 weeks for 16 cycles during the post-operative adjuvant phase"
224258210|NCT03456063|DRUG|Placebo Comparator|Placebo will be administered as IV infusion at a dose of 1200 milligrams (mg) on Day 1 of each 21-day cycle for 4 cycles during the neoadjuvant treatment phase
224258211|NCT03456063|DRUG|Nab-paclitaxel|Nab-paclitaxel 100 mg/m\^2 will be administered intravenously on Days 1, 8, and 15 of each 21 day cycle for 4 cycles during the neoadjuvant treatment phase
224258212|NCT03456063|DRUG|Pemetrexed|Pemetrexed 500 mg/m\^2 will be administered intravenously on Day 1 of each 21-day cycle for 4 cycles during the neoadjuvant treatment phase
224258213|NCT03456063|DRUG|Carboplatin|Carboplatin initial target AUC of 6 mg/mL/min will be administered intravenously on Day 1 of each 21-day cycle for 4 cycles during the neoadjuvant treatment phase
224258214|NCT03456063|DRUG|Cisplatin|Cisplatin 75 mg/m\^2 will be administered intravenously on Day 1 of each 21-day cycle for 4 cycles during the neoadjuvant treatment phase
224258215|NCT03456063|DRUG|Gemcitabine|Gemcitabine 1250 mg/m\^2 will be administered intravenously on Day 1 and 8 of each 21-day cycle for 4 cycles during the neoadjuvant treatment phase
224258216|NCT01098786|BIOLOGICAL|Cell-derived A/H1N1 influenza HA vaccine|Single group vaccinated
224258217|NCT05655494|BEHAVIORAL|Stand-alone Research Portal|The standard of care condition will include a portal that provides patients with access to existing online cancer clinical trial resources in one location. This includes links to pages with basic information about cancer clinical trials, ongoing studies, enrollment opportunities for existing institutional research registries, and contact information for study coordinators.
223773011|NCT02661906|OTHER|SKY|Sudarshan Kriya Yoga is a rhythmic breathing exercise with slow and fast breath at a particular pace.It is recommended for stress management as yoga is a mind body control tool. SKY is having effect on multiple organ thus causing the positive effect.
223773012|NCT00938925|PROCEDURE|Nail lacquer plus aggressive debridement|Nail lacquer plus aggressive debridement: Will be applied abrasion ungual aggressive, this abrasion will be applied in the beginning of the study, week 0 (baseline), the week 12 and the week 24 and he will follow standard treatment with nail lacquer (Odenil 5%) with 2 weekly applications during 36 weeks.
223773013|NCT00938925|PROCEDURE|Nail lacquer alone|Nail lacquer alone: Will be applied exclusively standard treatment with nail lacquer during 36 weeks, according to the usual care
224258218|NCT05655494|BEHAVIORAL|Portal with Virtual Community Health Educator (vCHE)|The virtual community health educator condition will provide all information in standard of care with the addition of a virtual community health educator. Patients will have the opportunity to choose which virtual community health educator will provide digital navigation. The choices will include at least four English-speaking and four Spanish-speaking virtual community health educators representing different genders and racial/ethnic backgrounds.
224258219|NCT05596435|OTHER|No intervention|No intervention
224258220|NCT03100422|DEVICE|ARMin|arm therapy robot
224258221|NCT03100422|OTHER|Occupational Therapy|bilateral arm training
224258222|NCT05519150|DIAGNOSTIC_TEST|low dose radiation abdomen/pelvis CT scan (stone protocol)|Kidney donors who consent will undergo a low dose radiation abdominal CT scan to identify new kidney stones in the remaining kidney. The will come to an IU Health Hospital for a low dose radiation abdomen/pelvis CT scan (stone protocol).
224258223|NCT05519150|PROCEDURE|Blood draw|To compare the changes changes in eGFR in evaluated kidney donors Blood will be draw by a trained phlebotomist.
224258224|NCT05519150|OTHER|24 hour urine collection|To compare the changes in metabolic kidney stone risk parameters in 24-hour urine assessments to pre-donation urine studies in evaluated kidney donors.
224258225|NCT05838703|DRUG|tiotropium bromide inhalation powder (Spiriva HandiHaler)|Spiriva HandiHaler is a COPD medication that is available for use.
224258226|NCT05838703|DRUG|tiotropium bromide (Spiriva Respimat)|Spiriva Respimat is a COPD medication that is available for use.
224258227|NCT05838703|DRUG|Hyperpolarized 129XeMRI|Xe129 hyperpolarized with use of MRI for evaluation of lung ventilation has recently been FDA approved
224258228|NCT06192303|DIAGNOSTIC_TEST|Bronchoalveolar lavage and pathogen metagenomic sequencing|After the patient is enrolled, traditional pathogen testing will be improved, and the clinical physician will make a preliminary diagnosis based on routine pathogen testing, clinical manifestations, infection indicators, and imaging. Within 24 hours of initial diagnosis, bronchoalveolar lavage and pathogen metagenomic sequencing were performed, and BALF mNGS results were fed back to clinical physicians (without interfering with clinical decision-making). Clinical treatment data of patients were collected at 72 hours, 7 days, 14 days, and 28 days after the start of treatment, and follow-up and efficacy evaluation were conducted. Finally, a review committee consisting of two senior respiratory physicians and one imaging physician conducted a systematic review of cases to make the final diagnosis of enrolled patients (as the gold standard), analyzing the accuracy, sensitivity, specificity, positive predictive value, and negative predictive value of BALF mNGS in diagnosing CIP.
223676908|NCT05622604|BEHAVIORAL|pray.com app (autonomous use)|Participants will be given a free subscription to the Pray.com app and will be directed to use the app five days per week.
223676909|NCT05622604|BEHAVIORAL|pray.com app (meditative prayer condition)|Participants will be given a free subscription to the Pray.com app and will be directed to listen to a meditation prayer five days per week.
223773014|NCT03886038|BIOLOGICAL|Shingrix|immunization with 2 doses of a subunit vaccine against herpes-zoster (Shingrix) administrated with at least 2 months apart
223773015|NCT05595798|DIAGNOSTIC_TEST|Airmod breathing sound monitoring|Respiratory monitoring and sedation depth monitoring will be applied during procedural sedation.
224258229|NCT04207203|COMBINATION_PRODUCT|sodium zirconium cyclosilicate and healthy diet|During 3 weeks, SZC will be prescribed to normalize plasma potassium to 3.5 to 5.0 mml/L, and a diet with energy 25-35 kcal/kg/day and protein 0.6 to 0.8 g/kg/day and with low K content will be prescribed. At the end of the first 3 weeks, the patients will initiate a healthy diet containing 3700 to 4000 mg/potassium for 3 weeks (healthy diet phase). A food basket containing fruits, vegetables, whole grains, nuts, white meat, fish and eggs in amounts adequate for the patient will be provided. Serum K will be monitored to promote serum K between 3.5 to 5.0 mmol/L and adjustments in the dose of SZC will be performed according to the drug label. During stabilization and healthy diet phases, serum K will be measured every 72 hours until serum K is normalized and after that, once per week.
224258230|NCT04972864|OTHER|Exercise training group|A regular advanced exercise program was given and followed.
224258231|NCT04972864|OTHER|Control training group|Basic exercises was given at the beginning and did the same exercises
223773016|NCT01519518|DRUG|unfractionated heparin|70 units/kg body weight intravenous
223773017|NCT01519518|DRUG|Bivalirudin|intravenous bolus of 0.75 mg/kg followed by infusion of 1.75 mg/kg per hour
223773018|NCT02033889|DRUG|Ertugliflozin 5 mg|Ertugliflozin 5 mg orally (1 ertugliflozin 5 mg tablet and 1 placebo ertugliflozin 10 mg tablet), once daily from Day 1 to Week 104.
223773019|NCT02033889|DRUG|Ertugliflozin 15 mg|Ertugliflozin 15 mg orally (1 ertugliflozin 5 mg tablet and 1 ertugliflozin 10 mg tablet), once daily from Day 1 to Week 104.
223773020|NCT02033889|DRUG|Placebo to Ertugliflozin|Placebo to ertuglioflozin (1 placebo ertugliflozin 5 mg tablet and/or 1 placebo ertugliflozin 10 mg tablet), orally once daily from Day 1 to Week 104.
223676929|NCT05910749|DEVICE|QEEG-Guided sLoreta Neurofeedback Training|The team will produce a neurofeedback (NFB) protocol based on QEEG sLORETA Brodmann Voxel evaluation of brain deviated/dysregulated areas. Subsequent 12 to15 sessions of individualized NFB protocol will be conducted using BrainAvatar software to normalize these regions. The NFB session will display the cortical surface and subsurface networks being trained in a live fashion. Patients will be seated on a comfortable chair in a dimly lit room and, wearing a 19-channel EEG-cap connected to an EEG amplifier, they will receive auditory and visual feedback when they meet Brodmann Voxels Z-Scores inside of +/-1.5 standard deviations (SD) on each electrode training site. Thresholds for the feedback will be first set a +/-2 SD and brought down to +/-1.5 SD throughout the sessions (subject performance dependent). Patients are encouraged to relax, hear the sounds, and watch a feedback game.
224258232|NCT06560242|OTHER|Speech discrimination|Two different speech sounds are played at the same sound intensity.
224258233|NCT01835860|PROCEDURE|Prostate artery embolization|
224258234|NCT01978730|DRUG|high dose group of SaiLuoTong capsule|high dose group of SaiLuoTong capsule: take three pills (180 mg) of SaiLuoTong capsule each time, twice a day, 0.5 hours after breakfast and dinner, taking with lukewarm water.
224258235|NCT01978730|DRUG|low dose group of SaiLuoTong|low dose group of SaiLuoTong capsule: take two pills (120 mg) of SaiLuoTong capsule plus one pill of placebo (analog SaiLuoTong capsule) each time, twice a day, 0.5 hours after breakfast and dinner, taking with lukewarm water.
224258236|NCT01978730|DRUG|the control group|The control group is randomly divided into two groups by 1:1. During the first 26 weeks, all subjects will take three pills of placebo each time, twice a day. During the last 26 weeks, the subjects in the placebo group will take two pills of SaiLuoTong plus one pill of placebo or three pills of SaiLuoTong each time, twice a day.
224258237|NCT04910425|DRUG|Fluorine F 18 DCFPyL|Given IV
224258238|NCT04910425|DRUG|Gadobenate Dimeglumine|Given IV
224258239|NCT04910425|DRUG|Gadobutrol|Given IV
224258240|NCT04910425|PROCEDURE|Magnetic Resonance Imaging|Undergo PET/MRI
224258241|NCT04910425|PROCEDURE|Multiparametric Magnetic Resonance Imaging|Undergo mpMRI
224258242|NCT04910425|PROCEDURE|Positron Emission Tomography|Undergo PET/MRI
224258243|NCT04910425|PROCEDURE|Transrectal Ultrasonography Guided Biopsy|Undergo TRUS-guided biopsy
224258244|NCT02173834|OTHER|18F- fluorodeoxyglucose-positron emission tomography Computed Tomography scan and 123I-metaiodobenzylguanidine-single-photon emission computed tomography scan|
224258245|NCT02009774|PROCEDURE|NBI Function|
224258246|NCT03079466|OTHER|CPAP|This is a randomized study where patients are included consecutively under a randomization order that will be given to the investigators. Patients will continue to be treated with CPAP and other treatment with no CPAP for a duration of 3 months and with intention-to-treat analysis And by protocol.
224258247|NCT06135857|DEVICE|Protocol ECOEMS|Use electo estimulation therapy. The 4-channel stimulator will be used. The 6 electrodes will be located on the biceps, triceps and deltoids. Two daily sessions will be distributed, five days a week, lasting 20 minutes, the vascular program designed by the electro stimulation team itself will be applied.
224258248|NCT01379222|DEVICE|Endurant Stent Graft System|The Endurant Stent Graft System is designed to treat infrarenal abdominal aortic aneurysms using an endovascular approach. When placed within the aneurysm, the Endurant Stent Graft is designed to provide a permanent, alternative conduit for blood flow within the patient's vasculature by excluding the aneurysmal sac from blood flow and pressure.
223773021|NCT02033889|OTHER|Glimepiride|Open-label Glimepiride will be used for glycemic rescue therapy (up to a maximum of 6 or 8 mg per day, based on the local label of glimepiride) in the 26-week initial period. Blinded Glimepiride (up to a maximum of 6 or 8 mg per day, based on the local label of glimepiride will be used in the 78-week extension period in participants who were not rescued with open-label glimepiride during the 26-week initial period.
224258249|NCT05278507|DEVICE|Arrowga+rd Blue Advance Protection PICC Placement|The PICC will be placed by a qualified healthcare professional, in accordance with institutional policies and procedures and the device's IFU.
224258250|NCT05278507|DEVICE|Sham Comparator PICC placement|The sham comparator PICC will be placed by a qualified healthcare professional, in accordance with institutional policies and procedures and the device's IFU.
224258251|NCT04278560|DEVICE|Transcranial direct current stimulation (tDCS)|tDCS will be delivered via six gel electrodes with placement and current parameters optimized based on a standard brain to maximize the average normal component of the generated electric field over the left dlPFC. Current delivered by anyone electrode will never exceed 2.0 mA; the total amount of current from all electrodes will not exceed 4 mA. Each 20-minute session will begin and end with a 60-second ramp up/down of current amplitude to maximize comfort.
224258252|NCT04278560|DEVICE|Sham stimulation|An 'active' sham will be used in which very low-level currents are transferred between the same electrodes used in the active condition throughout the 20-minute session. However, currents will be designed to mimic the cutaneous sensations induced by tDCS yet not significantly influence cortical tissue.
224258253|NCT04278560|BEHAVIORAL|Behavioral intervention to increase physical activity|Study staff will complete face-to-face and telephone counseling sessions with each participant, tailored to their state of readiness to increase physical activity levels. The participant will be provided with a goal to increase their average daily step count by 20% from baseline. The staff member will review the participant's stated barriers to exercise and provide them with a list of strategies they may use to augment their step counts throughout each day. Bi-weekly face-to-face counseling sessions will then be completed to review and discuss activity performance and answer any questions the participant may have regarding their efforts to increase physical activity.
223676930|NCT04077463|DRUG|Lazertinib|Lazertinib will be administered orally.
223676931|NCT04077463|DRUG|Amivantamab|Amivantamab will be administered as an intravenous (IV) infusion.
223676932|NCT04077463|DRUG|Carboplatin|Carboplatin will be administered as IV infusion.
223676933|NCT04077463|DRUG|Pemetrexed|Pemetrexed will be administered as IV infusion.
224258254|NCT00702091|DRUG|Ramipril|10 mg capsule
224258255|NCT02832063|BIOLOGICAL|B244|4 pumps of spray to saturate the entire face applied BID. Applications should occur in the morning and at night for 12 weeks.
224258256|NCT02832063|BIOLOGICAL|Placebo|4 pumps of spray to saturate the entire face applied BID. Applications should occur in the morning and at night for 12 weeks.
224258257|NCT05445739|BEHAVIORAL|The effect of an online exercise course on the increase of elders' regular exercise intention|The intervention of an online exercise course which 2 days a week for 4 weeks to increase the elders' regular exercise intention.
224258258|NCT01934816|OTHER|Intradermal injections of GLP-1 and its analogues|native GLP-1,Exenatide (Byetta)and Liraglutide (Victoza) will be microinjected at the same visit in no particular order in all study arms
224258259|NCT04425941|OTHER|artificial intelligence diagnosis|artificial intelligence prediction of colorectal polyp histology
224258260|NCT00604162|DEVICE|PillCam COLON|The PillCam COLON capsule is an ingestible capsule equipped with an endoscope that has two imagers, enabling it to acquire video images from both ends. the device measures 31 by 11 mm and acquires images at a rate of 4 frames per second. Recording and downloading of data are similar those of the data for small-bowel capsule endoscopy.
224258261|NCT00604162|PROCEDURE|Standard colonoscopy|Standard colonoscopy was the standard against which capsule endoscopy was compared,and it was performed after capsule endoscopy (after capsule excretion or at least 10 hours after capsule ingestion, whichever came first), on either the same day as ingestion or the next morning.
224258262|NCT02241551|DRUG|gemcitabine/nab-paclitaxel|three cycles of treatment in the gemcitabine/nab-paclitaxel
224322574|NCT07167732|DIAGNOSTIC_TEST|The Gross Motor Function Classification System|The Gross Motor Function Classification System (GMFCS; Palisano, Rosenbaum, Bartlett, Livingston, 2007) is a 5-level classification system that describes the gross motor function of children and youth with cerebral palsy on the basis of their self-initiated movement with particular emphasis on sitting, walking, and wheeled mobility. Distinctions between levels are based on functional abilities, the need for assistive technology, including hand-held mobility devices (walkers, crutches, or canes) or wheeled mobility, and to a much lesser extent, quality of movement. The questionnaire is available for four age groups of children and youth: 2 to \< 4 years, 4 to \< 6 years, 6 to \< 12 years, and 12 to 18 years.
224258263|NCT02241551|DRUG|mFOLFIRINOX|6 cycles in the mFOLFIRINOX
224258264|NCT01015287|DRUG|Placebo|Administered once orally
224258265|NCT01015287|DRUG|Prasugrel|Administered orally
223676934|NCT04120493|GENETIC|intra-striatal rAAV5-miHTT|One time MRI-guided stereotaxic infusion of rAAV5-miHTT into the brain
223676935|NCT04120493|OTHER|Imitation (sham) surgery|Simulated surgical procedure with skin incisions only; no intrastriatal injections and no burr holes through the skull
223676938|NCT04253392|DEVICE|LINX Reflux Management System|"The LINX Reflux Management System consists of a series of titanium beads each with a magnetic core connected with independent titanium wires to form an annular shape when implanted. The attractive force of the magnetic beads is designed to provide additional strength to keep a weak lower esophageal sphincter (LES) closed. During swallowing, the magnetic beads slide away from each other on the independent titanium wire links to allow esophageal distention as the bolus passes by."
223676940|NCT06807424|DRUG|Icotrokinra|Icotrokinra will be administered.
223676941|NCT06807424|DRUG|Placebo|Placebo will be administered.
224258266|NCT06443385|BEHAVIORAL|PDMP Legal Mandate E-mail|E-mails highlighting the state's legal requirements to use the PDMP. There will be one initial email and one follow-up email one month later.
224258267|NCT06443385|BEHAVIORAL|PDMP Clinical Benefit E-mail|E-mails highlighting the clinical benefits of having access to the PDMP and checking the PDMP before prescribing opioids. There will be one initial email and one follow-up email one month later.
224258268|NCT04196062|DEVICE|EndoMASTER EASE Robotic system for ESD|EndoMaster EASE System, is a robotic-assisted endoscopy system indicated for endoscopic visualization and therapeutic access to the adult gastrointestinal (GI) tract for endoscopic surgery
224258269|NCT00062296|BIOLOGICAL|rituximab|
224258270|NCT00062296|DRUG|epirubicin hydrochloride|
224258271|NCT00440063|DRUG|epoetin beta [NeoRecormon]|
224258272|NCT00429221|BEHAVIORAL|Tailored Medication Messages for Parents|
224258273|NCT00253838|PROCEDURE|Restoration HA stem|The Restoration hip stem, is made from titanium alloy, a different type of metal that has a roughened surfacing and allows for a hydroxylapatite (HA) coating to be applied to the entire length of the stem.
224258274|NCT00253838|PROCEDURE|Solution stem|The Solution stem is made from Cobalt Chrome, a type of metal, and does not have a hydroxylapatite (HA) coating.
224258275|NCT00469898|DRUG|Carboplatin|"Carboplatin dosage calculation to be given on day 1, every 21 days:~Carboplatin (mg) = (AUC of 5) x (GFR + 25)~\*up to 6 cycles at physician's discretion"
223773022|NCT02033889|DRUG|Placebo to Glimepiride|Placebo to glimepiride will be used in the 78-week extension period in participants who were not rescued with open-label glimepiride during the 26-week initial period. Dosing and titration of placebo to glimepiride is at the discretion of the investigator.
223676951|NCT04133636|DRUG|JNJ-68284528|Participants in Cohorts A,B,C, D, E, F, G, and H will receive JNJ-68284528 intravenously.
223676952|NCT04133636|DRUG|Lenalidomide|Some participants in Cohort D and all participants in Cohorts E, G, and H will also receive lenalidomide capsules orally.
223773023|NCT02033889|BIOLOGICAL|Basal Insulin|Basal insulin will be administered in the initial 26-week period for participants with glucose values exceeding protocol-specified values and for participants requiring rescue therapy in the 78-week extension period. Dosing and titration of basal insulin is at the discretion of the Investigator.
223773024|NCT02033889|DRUG|Metformin|Metformin \>=1500 mg/day, orally, once a day
223773025|NCT03391843|DRUG|FOLFOXIRI+Cetuximab regimen|FOLFOXIRI+Cetuximab Irinotecan 165 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5-FU 2800 mg/m² cont. inf. 46h +Cetuximab 500mg/m²,all on day 1 of each 2 weeks cycle
223773026|NCT02517580|DIETARY_SUPPLEMENT|Vitamin K2 (MK7)|
223773027|NCT00030797|DRUG|Irinotecan 70 mg/m2|Irinotecan i.v. 70 mg/m2, day 1, 8, 15, 22, 29
223773028|NCT00030797|DRUG|Irinotecan 240 mg/m2|Irinotecan i.v. 240 mg/m2 day 1 and day 22
223773029|NCT02599792|DRUG|CTP-656|
223773030|NCT02599792|DRUG|Placebo for CTP-656|
223773031|NCT02599792|DRUG|Kalydeco|
223773032|NCT03655158|DEVICE|ozone device ( Ozonytron XL )|The adjustment of the ozone generator was %75 power for 30 seconds (75 ug/ml) based on manufacturer's instructions
223773033|NCT04623294|PROCEDURE|Oxygen supply of high-low-high procedure|"The protocol consisted of 1-hour resting, 3-minute baseline measurement, half-hour measurement at 60% FIO2(phase I, high oxygen), half-hour measurement at 40% FIO2 (phase II, low oxygen) and half-hour measurement at 60% FIO2 (phase III, high oxygen).~Device: Optical monitor for hemodynamic parameter. Near infrared spectroscopy instrument was attached on the subjects' forehead to detect the changes of hemodynamic parameters."
223773034|NCT04623294|PROCEDURE|Oxygen supply of low-high-low procedure|"The protocol consisted of 1- hour resting, 3-minute baseline measurement, half-hour measurement at 40% FIO2 (phase I, low oxygen), half-hour measurement at 60% FIO2 (phase II, high oxygen) and half-hour measurement at 40% FIO2 (phase III, low oxygen).~Device: Optical monitor for hemodynamic parameter. Near infrared spectroscopy instrument was attached on the subjects' forehead to detect the changes of hemodynamic parameters."
223676953|NCT04133636|DRUG|Daratumumab|Participants in Cohorts E, G, and H will also receive daratumumab subcutaneous (SC) injection.
223676954|NCT04133636|DRUG|Bortezomib|Participants in Cohorts E and H will also receive bortezomib subcutaneously.
223676955|NCT04133636|DRUG|Dexamethasone|Participants in Cohorts E, G, and H will also receive dexamethasone orally or intravenously.
224258276|NCT00469898|DRUG|irinotecan hydrochloride|"50 mg/m2 IV on days 1 and 8 every 21 days~Should be infused IV over 30- 90 minutes."
224258277|NCT02739724|PROCEDURE|Adnexal surgery|
223676957|NCT05755386|DRUG|Placebo|Placebo to iptacopan 200mg b.i.d. (Adults 200mg b.i.d; Adolescents 2x 100mg b.i.d)
223676958|NCT05755386|DRUG|iptacopan|iptacopan 200 mg b.i.d. (Adults 200mg b.i.d; Adolescents 2x 100mg b.i.d)
223676959|NCT06599502|DRUG|AZD0022|AZD0022 is an oral KRASG12D inhibitor that blocks KRASG12D function in patients with this type of mutation.
223773035|NCT03300388|DIETARY_SUPPLEMENT|Omega-3 (DHA-rich dietary supplement)|Double-blind randomized placebo-controlled intervention with DHA-rich dietary supplement with or without resistance training program for 16 weeks.
223773036|NCT03300388|DIETARY_SUPPLEMENT|Placebo (olive oil)|Double-blind randomized placebo-controlled intervention with DHA-rich dietary supplement with or without resistance training program for 16 weeks.
223773037|NCT03300388|OTHER|Resistance training|Double-blind randomized placebo-controlled intervention with DHA-rich dietary supplement with or without resistance training program for 16 weeks.
223773038|NCT05058274|DEVICE|Implant of the AT-TORBI 709 lens|Implant of the AT-TORBI 709 lens
223773039|NCT01031823|BEHAVIORAL|Multi-Media Social Skills Training Program|All individuals will participate in a twelve week social skills training program designed to enhance the social skills of adolescents with Asperger's Disorder or high-functioning autism. The intervention is comprised of both group therapy and peer generalization.
223676960|NCT06599502|DRUG|Cetuximab|Cetuximab (Erbitux®) is a recombinant chimeric human/mouse Immunoglobulin G monoclonal antibody which binds to EGFR and competitively inhibits the binding of EGFR and other ligands
223773040|NCT01679119|DRUG|Cyclophosphamide|Cyclophosphamide 750mg/m2 IV, given day 1
223773041|NCT01679119|DRUG|Vincristine|Vincristine 1.4mg/m2(max 2mg)IV given day 1
223773042|NCT01679119|DRUG|Prednisolone|Prednisolone 100mg OD Oral given days 1-5
223773043|NCT01679119|DRUG|Rituximab|Rituximab 375mg/m2 IV given day 1
223773044|NCT01679119|DRUG|Inotuzumab Ozogamicin|Inotuzumab Ozogamicin 0.8mg/m2 IV given on day 2
224258278|NCT03497858|OTHER|Coconut Water|participants will consume coconut water and complete a simulated basketball game
224258279|NCT03497858|OTHER|Placebo - water|participants will consume Placebo - water and complete a simulated basketball game
224258280|NCT03497858|OTHER|Sports drink|participants will consume a sports drink and complete a simulated basketball game
224258281|NCT05438433|DEVICE|St.Jude bi leaflet prosthetic mitral valve to replace the diseased valve with preservation of both leaflets|St.Jude prosthetic(FDA approved) mitral valve replacement with or without coronary artery bypass grafts
224258282|NCT00785135|DEVICE|Lenses containing prismatic correction|The patient will receive lenses containing prismatic correction for heterophoria, as well as correction for hyperopia, myopia and astigmatism as indicated during initial examination.
223676961|NCT01754363|DEVICE|Attune Primary Total Knee Replacement|Patients will undergo a primary total knee replacement using one of the four configurations of the Attune knee (CR FB, CR RP, PS FB, PS RP).
223676962|NCT06454721|DRUG|[89Zr]Zr-DFO-BIIB080|Administered as specified in the treatment arm.
223676963|NCT06454721|DRUG|BIIB080|Administered as specified in the treatment arm.
223676964|NCT05997693|DRUG|Ticagrelor 90 MG|Ticagrelor 90 mg twice daily taken orally for one month
223676965|NCT05997693|DRUG|Low-dose aspirin|75-150 mg once daily taken orally
223676966|NCT05478681|DEVICE|active tDCS|All participants will receive active tDCS with a constant current intensity of 2mA. Anodal tDCS will be applied to the left dorsolateral prefrontal cortex, while cathodal electrode will be positioned on the right dorsolateral prefrontal cortex. Caregivers will help setting up and administering tDCS for participants with AD at home. tDCS will be applied for 30min at an intensity of 2mA, with 30 s ramping up and down.
223676967|NCT04721106|DRUG|Vizimpro|treatment group
223676975|NCT05155709|DRUG|siremadlin|Siremadlin is a capsule taken orally once a day (QD) and comes in 10 mg, 20 mg and 30 mg strengths
223676976|NCT05155709|DRUG|venetoclax|Venetoclax is a tablet taken orally once a day (QD) and comes in 10 mg, 50 mg and 100 mg strengths.
223676977|NCT05155709|DRUG|azacitidine|Azacitidine is a powder for suspension for injection or powder for solution for infusion taken intravenously or subcutaneously according to standard local clinical practice
223773045|NCT01679119|DRUG|Gemcitabine|Gemcitabine up to 1g/m2 IV given day 1 and day 8 (Patients with ECOG PS 0-1: starting dose: 875mg/m2 (1st cycle). If tolerated can be escalated to 1g/m2 in cycle 2 and subsequent cycles. Patients with ECOG PS 2: starting dose 750mg/m2 (1st cycle). If tolerated can be escalated to 875mg/m2 in cycle 2 and then escalated to 1g/m2 in cycle 3 and subsequent cycles.)
223773046|NCT02174536|BIOLOGICAL|Decidual stromal cells|Decidual stromal cells (approximately 1x10\^6 cells/kg) will be infused intravenously.
223773047|NCT02174536|BIOLOGICAL|Placebo|
223773048|NCT00753441|PROCEDURE|Surgical bypass|Surgical bypass (choledochojejunostomy, in combination with gastroenterostomy if necessary)
223773049|NCT00753441|PROCEDURE|Endoscopic stenting|Placement of a biliary metal stent (in combination with a duodenal metal stent in case of gastric outlet obstruction if necessary)
224258283|NCT00785135|DEVICE|Lenses not containing prismatic correction|The patient will receive lenses containing correction for hyperopia, myopia and astigmatism as indicated during initial examination. The patient will not receive prismatic correction in these lenses.
224258284|NCT05634941|DEVICE|Active ON-tDCS|DC was transmitted via a saline-soaked pair of surface sponges and delivered by specially developed, battery-driven, constant current stimulator with a maximum output of 2 mA. For each participant receiving ON-tDCS, the anodal electrode placed over the left C2 nerve dermatome, and cathodal electrode placed over the right C2 dermatome. A constant current of 1.5 mA was applied for 20 min.
224258285|NCT05634941|DEVICE|Sham ON-tDCS|For sham group, placement of the electrodes was identical to that of active ON-tDCS. ON-tDCS was first switched on in a ramp-up fashion over 5 s. Current intensity (ramp down) was gradually reduced (over 5 s) as soon as ON-tDCS reached a current flow of 1.5 mA. Hence, sham ON-tDCS only lasted 10 s (as opposed to 20 min in the active group).
224258286|NCT01452035|OTHER|Exercise|single session of exercise
224258287|NCT04877093|DRUG|Clonidine Pill|The study will use a flexible-dose adjustment schedule to identify the minimum dose needed to alleviate symptoms while also ensuring acceptable adverse effects. In other words, all subjects will start at the minimum dose (0.1 mg/night). Near the end of every week, each subject will be assessed for symptom alleviation and adverse events by asking the patient two questions from the CAPS-5 (questions B2 and E6. At baseline, each patient will have scored a ≥3 on each of these questions. If one or both scores remain at ≥3 and if any reported adverse events are marked acceptable by both the clinician and subject, then the dosage for the following week will be increased one level according to the titration chart. However, if both scores for these questions are ≤2 and any current adverse events are acceptable, then the dosage will remain the same. Finally, if any adverse events are deemed unacceptable, the clonidine dosage will be reduced to the lowest acceptable daily dosage.
224258288|NCT04877093|OTHER|Placebo|Blinded placebo capsules will be provided to participants.
224258289|NCT06219980|COMBINATION_PRODUCT|SBRT+chemoimmunotherapy|All eligible patients will receive SBRT (6Gy\*3 fractions, qod) to the primary site and metastatic lymph nodes. One week later, neoadjuvant chemoimmunotherapy of Sindilizumab (200mg) plus docetaxel (75mg/m2) and cisplatin (75mg/m2) will be administered every three weeks for three cycles. Then radical surgical resection will be performed and postoperative radiotherapy with or without chemotherapy will be supplemented according to the initial tumor staging and postoperative pathologic characteristics.
224258290|NCT01561807|DRUG|VX-787|
224258291|NCT01561807|DRUG|Placebo|
224258292|NCT03239314|DRUG|Saline Solution|Injected in the adductor canal
224258293|NCT03239314|DRUG|Dexamethasone|Injected in the adductor canal
224258294|NCT02504138|DRUG|Desflurane balanced anesthesia|Desflurane balanced anesthesia induced with thiopental sodium, remifentanil and atracurium and maintained with remifentanil target controlled infusion and desflurane inhalation
224258295|NCT02504138|DRUG|Propofol total intravenous anesthesia|Propofol total intravenous anesthesia induced with propofol, remifentanil and atracurium and maintained with remifentanil and propofol target controlled infusion
224258296|NCT02442063|DRUG|Radium Ra 223 dichloride (Xofigo, BAY88-8223)|50 kBq/kg intravenous injection once every 4 weeks, will be administrated from cycle 2 up to 6 cycles
224258297|NCT02442063|DRUG|paclitaxel|90 mg/m2 intravenous injection per week in a 3-week-on / 1-week-off regimen, will be administered as per local standard of care, starting in cycle 1
224258298|NCT03904563|DRUG|Bevacizumab|Patients are treated with Bevacizumab 1-2 months after the chemoradiotherapy.The recommended dose for intravenous infusion is 15mg/kg body weight, which is given every 3 weeks for up to 1 year.
224258299|NCT03904563|RADIATION|chest radiation|split-course chest radiation
224258300|NCT03904563|DRUG|concurrent chemotherapy|weekly docetaxel(25mg/㎡) and nedaplatin(25mg/㎡) concurrent with chest radiation
224258301|NCT04665063|BIOLOGICAL|Auto CAR-T|Biological: Auto CAR-T
224258302|NCT04665063|DRUG|Cyclophosphamide,Fludarabine|Drug: Cyclophosphamide,Fludarabine
224258303|NCT04665063|PROCEDURE|Leukapheresis|Leukapheresis
224258304|NCT01370317|DRUG|MK-1029|Five (5) X 100 mg capsules, orally, once daily for 28 days
224258305|NCT01370317|DRUG|Placebo for MK-1029|Five (5) X 100 mg capsules, orally, once daily for 28 days
224258306|NCT01688609|DRUG|lapatinib ditosylate|Given PO
224258307|NCT01688609|DRUG|paclitaxel|Given IV
223676984|NCT06803329|BEHAVIORAL|Qnnections|A novel group-based suicide prevention intervention that augments standard VA mental health services for LGBTQ+ Veterans with current suicidal thoughts or recent suicidal behavior. Informed by the empirically-supported theoretical framework of the interpersonal theory of suicide and prior work tailoring interventions for minority stress, Qnnections is a structured 10-week group that uses a cognitive behavioral framework to target perceived burdensomeness and thwarted belongingness. Veterans will also receive safety planning and referrals.
223676985|NCT06803329|BEHAVIORAL|Enhanced Usual Care|The active control condition includes: 1) VA Safety Planning Intervention and 2) referrals to VA and non-VA services relevant to the individual. The safety plan will be conducted by Dr. Chang, a licensed psychologist. Therefore, EUC only differs from the Qnnections condition as it does not have the 10-session Qnnections intervention. EUC is intended to include elements of VA suicide prevention standard practice. The control condition is considered enhanced as all participants will receive these elements, whereas Veterans are not guaranteed to receive all of these services if not enrolled in this study.
224258308|NCT01688609|BIOLOGICAL|trastuzumab|Given IV
224258309|NCT01688609|PROCEDURE|therapeutic conventional surgery|Undergo lumpectomy or mastectomy
224258310|NCT01688609|OTHER|pharmacological study|Correlative studies
224258311|NCT01688609|OTHER|laboratory biomarker analysis|Correlative studies
224258312|NCT03283345|PROCEDURE|modified radical mastectomy|systemic responses to trauma are compared with evaluating inflammatory cytokine levels between premenopausal and postmenopausal patient groups with different estrogen levels who underwent modified radical mastectomy.
224258313|NCT04665375|DRUG|DOR/3TC/TDF|switch antiretroviral regimen to doravirine/lamivudine/tenofovir disoproxil fumarate once daily for 1 year
224258314|NCT03681080|PROCEDURE|leg crossing|As Counter maneuvre legs will be crossed and cognitive tests will be performed.
224258315|NCT00854711|PROCEDURE|inhaled nitric oxide|80 PPM
224258316|NCT02728674|OTHER|Person in the case is a male.|Person in the case is a male.
224258317|NCT02728674|OTHER|Person in the case is a female.|Person in the case is a female.
224258318|NCT02728674|OTHER|Symptom in the case is breathlessness.|Symptom in the case is breathlessness.
224258319|NCT02728674|OTHER|Symptom in the case is pain.|Symptom in the case is pain.
224258320|NCT02717260|DEVICE|transcranial random noise stimulation (tRNS) (Starstim)|subjects are stimulated 3 times in a day by transcranial random noise stimulation (tRNS) (Starstim). each 20 minutes stimulation are separated by a period of at least 30 minutes. before and after each stimulation, inhibition is evaluated by cognitive tests: go nogo test, stroop test, Hayling test and by the BIS 10 scale. During the stimulation, subjects compleat the STAXI and STAI scales. Cognitive tests are repeated 24 hours and 8 days after the stimulation to evaluate duration of the effect. Possible side effects will be notified throughout the protocol.
224258321|NCT03133637|DRUG|ceftriaxone|Eligible infants will receive ceftriaxone as standard of care for sepsis
224258322|NCT03829397|DIAGNOSTIC_TEST|Questionnaire|Questionnaire
224258323|NCT06082154|DEVICE|ultrasound|Patient will undergo multiorgan ultrasonography
224258324|NCT05205876|BEHAVIORAL|Eddii mobile application|Participants will use the Eddii mobile application in the intervention arm.
224258325|NCT02957994|DRUG|Tenofovir alafenamide fumarate|Patients on TDF will be switched to TAF
224258326|NCT01269086|BEHAVIORAL|Family Preventive Visit|Systematic assessment of health diseases or risk factors in the spouse and adolescent child.
224258327|NCT06223763|PROCEDURE|Cytoreductive surgery|Cytoreductive surgery is a surgical procedure performed with the goal of reducing the tumor burden in the body. This type of surgery is commonly used in the treatment of certain types of cancers, especially in the context of peritoneal carcinomatosis. During cytoreductive surgery, the surgeon attempts to remove as much visible tumor as possible. This may involve the removal of tumors from specific organs and the elimination of tumor lesions on the surface of intra-abdominal organs.
224258328|NCT06223763|DRUG|Neoadjuvant chemotherapy|Neoadjuvant chemotherapy refers to chemotherapy administered before the primary treatment in cancer management. The goals include reducing tumor size, treating micrometastases, assessing treatment response, converting inoperable tumors to operable ones, and preserving organs or tissues.
224258329|NCT06223763|DRUG|Adjuvant chemotherapy|Adjuvant chemotherapy is chemotherapy given after the primary treatment, such as surgery or radiation therapy, with the aim of eliminating any remaining cancer cells and reducing the risk of recurrence. It is administered to patients who have undergone the initial treatment to enhance the overall effectiveness of the therapy.
224258330|NCT01342263|BEHAVIORAL|iCDM|The iCDM intervention will be managed by a nurse with experience in chronic disease management who will review patient data, communicate with the patients, implement the Treatment Algorithms and interact with the patients' PCP. Patients will also be able to interact with a dietitian and exercise specialist to support them in their disease management. These personnel will have formal training in principles of the Transtheoretical Model of Change and Social Cognitive Theory.
224258331|NCT03931460|DRUG|Medical Abortion|Medical Abortion
224258332|NCT04717960|PROCEDURE|nasal submucosal injection of platelet rich plasma|"* The selected region will be inﬁltrated with a cold saline solution with addition of 1 mL of adrenaline and 25 mL of 2% lignocaine per 500 mL saline.~* Platelet-rich plasma is prepared by drawing 10 mL of blood sample from the patient.~* The blood will be centrifuged at 1530 g for 10 min to obtain platelet-poor plasma.~* This will again centrifuged at 2720 g for 10 min to get platelet-rich plasma.~* Approximately 1 mL of platelet-rich plasma will be obtained from 10 mL blood. Usually amount of about 3ml is needed to be injected in each nostril at the affected sites of inferior and middle turbinates, septum and floor of the nose. Platelet rich plasma injected into the affected area after degranulating the platelet by adding 0.5 mL of calcium chloride.~  * Injection interval of 2 weeks (up to total 3 consecutive injections).~ * Follow-up duration: 4 months"
224258333|NCT04782765|DRUG|Camrelizumab+Chemotherapy+Chemoradiotherapy|Patients received neoadjuvant Camrelizumab 200mg combined with chemotherapy (Cisplatin 20mg/m2, Day 1-3, Docetaxel 75mg/m2, Day 1) for 2 cycles every 21 days, followed by concurrent chemoradiotherapy with Camrelizumab monotherapy maintenance
224258334|NCT00161850|BIOLOGICAL|Tick-Borne Encephalitis (TBE) Vaccine (Inactivated)|
224258335|NCT02849457|DRUG|Early Vigabatrin|Subjects randomized to vigabatrin will be treated with vigabatrin 100mg/kg/day until 24 months of age or until they show evidence of clinical seizures or electrographic seizures on video EEG. If electrographic or clinical seizures occur while on study drug, they will transition into the Open label phase of the study and continue to be followed until 36 months of age.
224258336|NCT02849457|DRUG|Delayed Vigabatrin (Placebo)|Subjects randomized to placebo will be treated with matching placebo at 100mg/kg/day until 24 months of age or until they show evidence of clinical seizures or electrographic seizures on video EEG. If electrographic or clinical seizures occur while on study drug, they will transition into the Open label phase of the study and continue to be followed until 36 months of age.
224258337|NCT01844050|DRUG|Chinese herbal medicine|According to the traditional Chinese medicine syndrome of subject to make up a prescription within the 35 kinds of chosen Chinese herbal medicine, and the dosage without limitation.
224322575|NCT07167732|DIAGNOSTIC_TEST|Bayley Scales of Infant and Toddler Development-4: Fine Motor, Gross Motor, Language, and Cognitive Scales|Bayley Scales of Infant and Toddler Development-4 (BSID-4; Bayley et al., 2019) is an extensive formal developmental assessment tool for diagnosing developmental delays in early childhood. It consists of 419 items across 5 scales, each of which can be administered separately - Cognitive Scale (81 items), Language Scale (79 items), Motor Scale (104 items), Social-Emotional Scale (35 items), and Adaptive Behavior Scale (120 items). In our study, Motor, Language and Cognitive scales will be performed by a trained psychologist - if possible, at the patient's home country and in their native language.
224258338|NCT01844050|DRUG|Placebo|
224258339|NCT01857167|DIETARY_SUPPLEMENT|Fish Oil Supplementation|
224258340|NCT01857167|DIETARY_SUPPLEMENT|Flaxseed Oil Supplementation|
224258341|NCT01857167|DIETARY_SUPPLEMENT|placebo|
224258342|NCT00589186|BIOLOGICAL|Ad5F35-LMP1/LMP2-transduced autologous dendritic cells|
224322576|NCT07167732|DIAGNOSTIC_TEST|Wechsler Non-Verbal Scale of Ability|Wechsler Nonverbal Scale of Ability (WNV, Wechsler et al., 2006) is a standardized, individually administered test designed to assess general cognitive ability in individuals aged 4 to 21 years, particularly those who may have language, cultural, or communication challenges that make traditional verbal IQ tests less appropriate. It consists of six different subtests that are utilized based on the participant's age. In our study, the test will be performed in children above the age of 4 years by a trained psychologist - if possible, at the patient's home country and in their native language.
224258343|NCT00589186|DRUG|celecoxib|
224258344|NCT00589186|OTHER|flow cytometry|
224258345|NCT00589186|OTHER|immunoenzyme technique|
224258346|NCT00589186|OTHER|laboratory biomarker analysis|
224258347|NCT05318690|DEVICE|PlayGait|PlayGait is a dynamic energy storing and returning lower-limb exoskeleton.
224258348|NCT05318690|OTHER|Baseline|Baseline condition with no prescribed or intervention lower-limb devices.
224258349|NCT05323916|BEHAVIORAL|"Neuroproprioceptive facilitation, inhibition"|"Participants will undergo a standard comprehensive intensive rehabilitation program three hours a day for three weeks and moreover one hour a day of neuroproprioceptive facilitation, inhibition physical therapy."
224258350|NCT05323916|BEHAVIORAL|Technology based physical therapy|Participants will undergo a standard comprehensive intensive rehabilitation program three hours a day for three weeks and moreover one hour a day of technology based physical therapy.
224322577|NCT07167732|DIAGNOSTIC_TEST|The Vineland Adaptive Behaviour Scales - 3|The Vineland Adaptive Behaviour Scales (VABS-3; Sparrow et al., 2018) is a standardized assessment tool that utilizes semi-structured interview to measure adaptive behaviour and support the diagnosis of intellectual and developmental disabilities, autism, and developmental delays. It is validated for children of all ages and consists of five primary domains (Communication, Daily Living Skills, Socialization, Motor Skills, and Adaptive Behavior Composit).
224322578|NCT07167732|DIAGNOSTIC_TEST|Aberrant Behaviour Checklist -Community|"The Aberrant Behaviour Checklist-Community (ABC-C) is a parent report behavioural rating scale designed to assess problem behaviours in individuals with developmental disabilities. It consists of 58 likert-type items across five domains (Irritability, Social Withdrawal, Stereotypic Behaviour, Hyperactivity, and Inappropriate Speech) with responses ranging from not at all a problem to the problem is severe in degree."
224322579|NCT07167732|DIAGNOSTIC_TEST|The Modified Checklist for Autism in Toddlers|The Modified Checklist for Autism in Toddlers (M-CHAT; Robins, Fein, \& Barton, 2009) is a 2-stage parent report screening tool to assess risk for autism spectrum disorder (ASD). It is validated for children 16-30 months old.
224258351|NCT05323916|BEHAVIORAL|Effectively managed rehabilitation implementing the recommendations of the World Health Organization|Participants will undergo a four hour a day for three weeks of effectively managed comprehensive intensive rehabilitation implementing the recommendations of the World Health Organization.
224258352|NCT05323916|BEHAVIORAL|Standard care|Participants will undergo standardly provided care including face to face physiotherapy (bed mobility, transfers, gait, therapeutic exercises, positioning, education).
223677000|NCT04577833|DRUG|Niraparib|Niraparib will be administered orally.
223677001|NCT04577833|DRUG|Abiraterone Acetate (AA)|Abiraterone Acetate will be administered orally.
223677002|NCT04577833|DRUG|Prednisone|Prednisone will be administered orally.
223773050|NCT03865277|RADIATION|dose-escalated radiochemotherapy|"Patients will receive simultaneous radiochemotherapy, however the simultaneous chemotherapy is standard and not part of the evaluation in this trial. Present standard chemotherapy is cisplatinum 40 mg/m²/week (chemotherapy over the whole course of radiotherapy).~Radiotherapy is applied to doses of 54 Gy(RBE)/ 1.8 Gy(RBE) per fraction to the adjuvant region, 70 Gy(RBE)/ 2 Gy(RBE) per fraction to the tumor and involved lymphonodes and, if hypoxic and randomized to the intervention arm, 77 Gy(RBE)/ 2.2 Gy(RBE) per fraction to the primary tumor and lymphonode metastases \> 2 cm.~Radiotherapy is always applied with 5 fractions per week."
224258353|NCT04677075|PROCEDURE|mastectomy|mastectomy either simple or modified radical
224322580|NCT07167732|DIAGNOSTIC_TEST|The Autism Spectrum Quotient Questionnaire -Children's Version|"The Autism Spectrum Quotient-Children's Version (AQ-Child; Auyeung, Baron-Cohen, Wheelwright \& Allison, 2008) is a parent report questionnaire that aims to quantify autistic traits in children 4 - 11 years old. It contains 50 likert-type items with responses ranging from definitely agree to definitely disagree."
224258354|NCT03673670|DRUG|RPL554 Suspension|A PDE3/4 inhibitor
224258355|NCT03673670|DRUG|Placebo|A placebo solution
224258356|NCT03673670|DRUG|Tiotropium/olodaterol (Respimat)|An anticholinergic/β-agonist combination medication
224258357|NCT00308152|DRUG|Infusion of 1 litre of normal saline before colonoscopy|Prehydration with normal saline
224258358|NCT03238183|DRUG|dextrose|compare the therapeutic effects of hyaluronic acid combined dextrose injections with hyaluronic acid injections only to patients with knee osteoarthritis
224258359|NCT03238183|DEVICE|hyaluronic acid|compare the therapeutic effects of hyaluronic acid combined dextrose injections with hyaluronic acid injections only to patients with knee osteoarthritis
224258360|NCT04742686|OTHER|Aerobic exercise training|5-day, power-assisted, low- to moderate-intensity, aerobic exercise training programme. Exercise duration to progress from 10 minutes on day 1, to 30 minutes on day 5. Exercise equipment: Letto-2 (Motomed, Germany).
224258361|NCT04553146|PROCEDURE|Immediate implantation in posterior region with alveolar ridge preservation combined with sealing socket abutment|Twenty BLXⓇ Straumann immediate implants were placed flapless. The gap around the implant was filled with xenogeneic biomaterial. An intra-oral scanner was performed and sent to the dental laboratory to digitally design a customized healing abutment. The abutment was then milled from a block of PEEK and placed a couple of hours later in the clinic. Three months after implantation, the abutment was removed and the final monolithic crown based on the initial IOS was placed. The transmucosal design from the SSA was replicated on the final crown.
224258362|NCT04588311|DRUG|Epoetin Alfa 40000 UNT/ML|Epoetin alfa 40,000IU 1mL pre-filled syringe given as subcutaneous injection.
224322581|NCT07167732|DIAGNOSTIC_TEST|The Autism-Spectrum Quotient (AQ)-Adolescent Version|"The Autism Spectrum Quotient-Children's Version (AQ-Child; Auyeung, Baron-Cohen, Wheelwright \& Allison, 2008) is a parent report questionnaire that aims to quantify autistic traits in children 12 - 15 years old. It contains 50 likert-type items with responses ranging from definitely agree to definitely disagree."
224322582|NCT07167732|DIAGNOSTIC_TEST|Continuous Movement Monitoring (Actimyo/Syde)|Continuous movement data will be collected using the ActiMyo/Syde® device (Servais et al., 2022), which is attached to the ankles and uses magneto-inertial sensors to quantify movement. At the first study visit, 20 ambulant patients older than 2 years old will be fitted with a Syde device to each ankle and their carers will be provided with training on use and care of the device. It will be worn for 30 days and then repeated in one year.
224258363|NCT04588311|DRUG|Sodium Chloride 0.9%|Sodium Chloride 0.9% 1mL in volume given as subcutaneous injection.
224322583|NCT07167732|DIAGNOSTIC_TEST|Sleep Disturbance Scale for Children|"The Sleep Disturbance Scale for Children (SDSC; Bruni et al., 1996) is a parent report questionnaire used to identify sleep disorders in children. It contains 26 likert-type items with responses ranging from never to always (daily). The items are divided in six categories - disorders of initiating and maintaining sleep, sleep breathing disorders, disorders of arousal/nightmares, sleep-wake transition disorders, disorders of excessive somnolence, and sleep hyperhidrosis (nighttime sweating)."
224322584|NCT07167732|DIAGNOSTIC_TEST|Seizure Diary|A 28-day seizure diary is a self-reported tool used to record seizure activity to obtain insight into the patient's seizure triggers and severity, monitor medication side effects, and promote medication adherence. Patients are asked to record their seizure occurrence, duration, and type of seizures.
224322585|NCT07167732|DIAGNOSTIC_TEST|30min EEG Recording|Recording will take place in the hospital's EEG department in a quiet room with low-light levels. If children will be unable to lay still, melatonin or dexmedetomidine may be used, as per standard department protocol. An EEG cap with international system 10-20 electrodes, ECG and respiratory electrodes will be placed on the head and chest respectively. Data will be recorded for at least 30 minutes, and an attempt will be made to capture both wakefulness and sleep. Intermittent photic stimulation will be performed as per standard protocol.
224322586|NCT07167732|DIAGNOSTIC_TEST|PedsQL Family Impact Module|"The PedsQL Family Impact Module is a parent report standardized questionnaire designed to measure the impact of paediatric chronic health conditions on the health-related quality of life (HRQOL) of parents and the functioning of the family as a whole. It consists of 36 likert-like items over 8 domains (Physical Functioning, Emotional Functioning, Social Functioning, Cognitive Functioning, Communication, Worry, Daily Activities, Family Relationships). The items are scored with responses ranging from never a problem to always a problem."
224322587|NCT07167732|DIAGNOSTIC_TEST|PedsQL Core Module|"The PedsQL™ (Pediatric Quality of Life Inventory) Core Module is a health-related quality of life (HRQOL) questionnaire designed for children and adolescents. It assesses physical, emotional, social, and school functioning by using 23 likert-like items across 4 subscales (Physical Functioning, Emotional Functioning, Social Functioning, School Functioning). The items are scored with responses ranging from never a problem to always a problem. Items differ across age groups - toddlers (2-4 years), young children (5-7 years), children (8-12 years), teens (13-18 years), and young adults (18-25 years). In toddlers, the parents serve as proxy, and in young children, a three-point scale with faces is used instead of likert-type responses."
224258364|NCT01528462|OTHER|Expedited Treatment of Sleep Disorders|Patients in this arm will undergo an expedited polysomnogram (if clinically necessary) and early treatment of any sleep disorders. Sleep-related disorders will be managed with the currently recommended therapies; patients with obstructive sleep apnea will be treated with positional therapy, continuous positive airway pressure (CPAP), etc., and those with restless legs syndrome will be treated with standard treatments such as iron, or dopaminergic agonists. Patients will also be counselled on improving their sleep hygiene and adjusting the timing of their medication administration to optimize efficacy. Furthermore, patients will receive information handouts.
224258365|NCT03570905|OTHER|Sugar Tong Splint|A splint made of 8-10 layers of plaster rolled into a single long sheet which begins at the distal volar crease of the hand and traverses around the elbow and stops at the dorsal metacarpal heads. The skin is protected with cotton cast padding (webril) and the splint is held in place with ace bandages
224258366|NCT03570905|OTHER|Clam Shell Splint|A 2-part splint made of 8-10 layers of plaster. The piece traverses from the distal volar crease of the hand to the volar aspect of the proximal forearm. The second piece runs along the dorsal aspect of forearm from metacarpal heads to proximal forearm. The elbow is left free. In the same fashion as the sugar tong splint, the skin is protected with cotton cast padding (webril) and held in place with ace wrap
224258367|NCT05514392|DEVICE|HP Cosmos Torqoalizer|Participants will sign a consent form approved by the ethics committee. Height, weight, thigh length, leg length, foot length and kinematic foot length will be recorded before data collection. Ergometer positions will be adjusted according to participant preference. Participants will be invited to the Health Sciences University Physiotherapy and Rehabilitation Hall once. Before starting the exercise of the participants, muscle activity, balance assessment, leg fatigue will be evaluated. Participants will be made an exercise protocol. At the end of the exercise, necessary evaluations will be made again, and then the person will rest for 1 hour. After 1 hour, the exercise groups will change; Persons receiving single foot bicycle ergometer training will receive double foot bicycle ergometer training, and the group receiving double foot bicycle ergometer training will receive single foot bicycle ergometer training. Necessary evaluations will be repeated at the end of the training.
224258368|NCT02777580|DRUG|Tenecteplase|Half dose Tenecteplase
223677011|NCT06218589|DIAGNOSTIC_TEST|Velacur|Velacur is a liver ultrasound that measures hepatic fat and fibrosis through the propagation of a continuously, externally conducted shear wave. An enrolled participant may choose to do the ultrasound at the time of a clinic visit, or research visit or a scheduled radiology visit according to manufacturer's instructions by trained study staff. Fibrosis and steatosis measures will be collected from all scans.
223677012|NCT06218589|DIAGNOSTIC_TEST|MRI|Participants who have not had an MRI within the past two years will be offered a research MRI (no contrast or sedation will be used) to measure hepatic fat and hepatic stiffness (if required). Participants who have had an MRI or liver biopsy in the past two years will use historical data comparison data. MRI data will include the PDFF hepatic fat, any assessment of fibrosis and notes of other abnormalities.
223677013|NCT06218589|DIAGNOSTIC_TEST|Blood sample collection for biomarkers|Biomarkers are metabolic thumbprints of how the body is behaving to different health or disease processes, some of the biomarkers can be studied from plasma or serum combined with other demographics. A lipid profile and comprehensive metabolic panel (CMP), if not obtained clinically within 4 weeks, will be collected as a standard of care.
223677014|NCT06218589|DIAGNOSTIC_TEST|Liver biopsy|Liver biopsy data will be collected only if liver biopsy is done clinically when available and scored using the Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN) approach.
223677018|NCT04825223|DRUG|Multicomponent Meningococcal B Vaccine|Pharmaceutical form:Liquid suspension for injection in a single vial Four liquid suspensions and one diluent (only for Stage 1) Route of administration: Intramuscular
223677019|NCT04825223|DRUG|Meningococcal Group B Vaccine MenB|Pharmaceutical form:Liquid suspension for injection in a pre-filled syringe Route of administration: Intramuscular
223677020|NCT04825223|DRUG|Meningococcal Group B Vaccine (recombinant deoxyribonucleic acid [rDNA], component, adsorbed)|Pharmaceutical form:Liquid suspension for injection in a pre-filled syringe Route of administration: Intramuscular
223677021|NCT04825223|DRUG|Placebo|Pharmaceutical form:Liquid solution for injection in a vial Route of administration: Intramuscular
223677022|NCT04825223|DRUG|Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine MenACYW conjugate vaccine|Pharmaceutical form:Liquid solution for injection in a vial Route of administration: Intramuscular
223677028|NCT05918185|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223677029|NCT05918185|OTHER|Comprehensive Geriatric Assessment|Undergo cGA
223677030|NCT05918185|OTHER|Electronic Health Record Review|Medical records are reviewed
223677031|NCT05918185|OTHER|Survey Administration|Complete surveys
223677035|NCT06553027|DRUG|CVN424 75 mg|Participants will receive 75 mg CVN424 tablet once daily.
223677036|NCT06553027|DRUG|CVN424 150 mg|Participants will receive 150 mg CVN424 tablet once daily.
223677037|NCT06553027|DRUG|Placebo|Participants will receive matching placebo tablet once daily.
224258369|NCT02777580|DRUG|Clopidogrel|300 mg p.o. initial loading dose. Maintenance dose of 75 mg p.o. once daily. The maintenance dose of Clopidogrel (75 mg p.o. per day) should be continued for 1 year.
224258370|NCT02777580|PROCEDURE|Coronary angiography|Coronary angiography followed by PCI or CABG if required, rescue PCI if required
224258371|NCT02777580|PROCEDURE|Primary PCI|Primary PCI accoring to local standards
224258372|NCT00952250|BEHAVIORAL|Targeted Feedback Reports|Sites randomized to this arm will receive specialized feedback summarizing their adherence to the guidelines and suggestions on ways to improve performance.
224258373|NCT00952250|BEHAVIORAL|Targeted Feedback Report|Report designed to target areas for local hospital-specific improvement
224258374|NCT02856386|DIETARY_SUPPLEMENT|polyphenol supplement|8 mL once daily
224258375|NCT00029263|DRUG|herbals|
224258376|NCT01294917|DEVICE|Multi-purpose disinfecting solution|For the cleaning, rinsing, and storage of soft contact lenses.
224258377|NCT01294917|DEVICE|Clear Care|Peroxide-based regimen for cleaning and disinfecting soft contact lenses.
224258378|NCT01294917|DEVICE|Opti-Free RepleniSH|Multi-purpose disinfecting solution for the cleaning, rinsing and storing of soft contact lenses.
223677042|NCT05492188|BEHAVIORAL|Operant Conditioning of Cutaneous Reflexes|This is a training intervention in which people with a spinal cord injury are trained to change (increase or decrease) the activity of a certain spinal reflex. By changing this reflex, it is hypothesized that individuals can reduce pain due to spinal cord injury.
223677043|NCT02275533|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
223677044|NCT02275533|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
223677045|NCT02275533|OTHER|Clinical Observation|Undergo standard of care clinical observation
223677046|NCT02275533|PROCEDURE|Echocardiography Test|Undergo ECHO
223677047|NCT02275533|BIOLOGICAL|Nivolumab|Given IV
223677049|NCT05347212|DRUG|Nivolumab|Given by IV
223677050|NCT05347212|DRUG|Relatlimab|Given by IV
223677052|NCT02891603|DRUG|Pacritinib|Pacritinib Dose and Schedule: 200 mg twice a day (BID) orally from day 0 until day +100. PAC will be tapered to 50% of the total dose at day +70, then 25% of total dose at day +84, then stop at day +100 (+/- 7 days).
224258379|NCT04726163|DEVICE|Continuous blind glucose measurement device (Free style Pro)|A continuous blind glucose measurement device (Free style Pro) will be set up on the first day and throughout the entire hospital stay
224258380|NCT00611364|OTHER|Physical Therapy and education meetings|Physical therapy was realized three two times per week and education meeting every fifteen days
224258381|NCT00611364|OTHER|education meetings|This group only participed of education meeting (every fifteen days)
224258382|NCT05039112|DEVICE|Verofilcon A toric contact lenses|Soft contact lenses for optical correction of astigmatism, used as indicated
224258383|NCT05039112|DEVICE|Stenfilcon A toric contact lenses|Soft contact lenses for optical correction of astigmatism, used as indicated
224258384|NCT01193712|PROCEDURE|temporary left ventricular endocardial pacing|a temporary pacemaker lead will be introduced through the aortic valve to evaluate the effect of left ventricular endocardial pacing. Four different pacing sites (basal and apical septal, basal and apical lateral) will be investigated with measurement of LV dP/dtmax. Afterwards, the endocardial pacing lead will be removed.
224258385|NCT04306107|DEVICE|Prone position during non-invasive respiratory support|HFNC and NIV application with patient on prone position
224258386|NCT06562764|OTHER|Counselling by the Trained Pharmacist|The intervention group 1 is verbally counselled about the proper use of their inhaler devices.
224258387|NCT06562764|OTHER|Pictograms Cards and Counselling by the Trained Pharmacist|The investigator developed pictogram cards for the use of inhalers (MDI and DPI) and pictogram cards are attached to the inhalers of patients in the intervention group with counselling by the trained pharmacist.
223677053|NCT02891603|DRUG|Sirolimus|Sirolimus (SIR) will be administered and dosed according to Moffitt Cancer Center, Department of Blood and Marrow Transplantation standard practice. Attending physician discretion is permitted with regard to timing, rapidity, and completion of SIR taper. SIR levels will be monitored according to program standard operating procedures. Dose modifications of SIR for concurrent use of CYP3A4 inhibitors or inducers will be based on program standard operating procedures.
223677054|NCT02891603|DRUG|Tacrolimus|Tacrolimus (TAC) will be administered and dosed according to Moffitt Cancer Center, Department of Blood and Marrow Transplantation standard practice. Attending physician discretion is permitted with regard to timing, rapidity, and completion of TAC taper. TAC levels will be monitored according to program standard operating procedures. Dose modifications of TAC for concurrent use of CYP3A4 inhibitors or inducers will be based on program standard operating procedures.
223677055|NCT02891603|PROCEDURE|Allogenic hematopoietic cell transplant (alloHCT)|Patients will undergo allogenic hematopoietic cell transplant (alloHCT) as a part of their standard of care treatment.
224258388|NCT02778321|DEVICE|Uses of SpiderFlash monitor|"Investigators will use the SpiderFlash®, Holter monitor (technology Secure Data) to have a storage capacity enabling a registration up to 30 days with sufficient autonomy.~The data collected :~* Demographic data: age, sex, vascular risk factors, antithrombotic therapy at the entrance, history of Transient Ischemic Accident (TIA) or Cerebral infarct (CI)~* Data on the CI:~* Monitoring Results scope ICU Neurovascular.~* Presence palpitations~* Treatment influencing the rate (beta-blockers or antiarrhythmic)~* Data on cardiac monitoring:~A questionnaire evaluating the safety of SpiderFlash® will be given to the patient and the results of Holter will be communicated at the end of the recording to the blinded rhythm specialist"
223677066|NCT06077838|BEHAVIORAL|RELAXaHEAD Smartphone App Version 1|RELAXaHEAD is a smartphone application that allows users to track headache frequency and severity, sleep, medication, medication side effects, and menstrual cycle, and create personal notes daily. The RELAXaHEAD app has an option for users to view their data reports and charts.
223677067|NCT06077838|BEHAVIORAL|RELAXaHEAD Smartphone App Version 2|RELAXaHEAD is a smartphone application that allows users to track headache frequency and severity, sleep, medication, medication side effects, and menstrual cycle, and create personal notes daily. The RELAXaHEAD app has an option for users to view their data reports and charts. This version also contains audio materials.
223677076|NCT04712721|DRUG|68Ga-FF58|Single intravenous radiolabeled gallium FF58 injection determined by body weight (3 Megabecquerel (MBq)/Kg (+/- 10%)). Administered dose must not be lower than 150 MBq or higher than 250 MBq.
223677077|NCT04923893|DRUG|Bortezomib|Bortezomib will be administered SC.
223677078|NCT04923893|DRUG|Dexamethasone|Dexamethasone will be administered orally.
223677079|NCT04923893|DRUG|Lenalidomide|Lenalidomide will be administered orally.
223677080|NCT04923893|DRUG|Cilta-cel|Cilta-cel infusion will be administered.
223677081|NCT04923893|DRUG|Cyclophosphamide|Cyclophosphamide will be administered intravenously.
223677082|NCT04923893|DRUG|Fludarabine|Fludarabine will be administered intravenously.
224258389|NCT01444378|DEVICE|Stenting using Absolute Pro® and Pro LL® Peripheral Stent Systems|Stenting of the Superficial Femoral Artery (SFA) and/or proximal popliteal artery using either of these devices.
224258390|NCT00164307|BEHAVIORAL|Parent assisted social skills training|
224258391|NCT01569269|BEHAVIORAL|Yoga Intervention|"The yoga intervention will take place for one hour per week for six weeks. All sessions will be guided by a Registered Yoga Teacher (RYT) who is also a Licensed Clinical Social Worker (LCSW).~Each yoga session will follow a similar protocol. The introductory period (10 minutes) will focus participants on increasing interoceptive and proprioceptive capacity. The main segment is comprised of a series of yoga postures that progress from lying or seated postures that provide gentle muscle stretching to standing stretches that increase balance and flexibility. The postures will be introduced, practiced, and combined with breathing exercises for forty minutes.~The conclusion of the session will be comprised of 10 minutes of relaxation."
224258392|NCT01569269|BEHAVIORAL|Meditation Intervention|The meditation intervention will be conducted weekly for weeks. Each class will follow a similar protocol: During the one-hour meeting, participants will focus on developing attention to the breath. In a supine or seated position and with eyes closed, participants will be guided to attend solely to their breathing. As physical sensations, thoughts, and emotions begin to arise, participants will be taught to recognize, acknowledge, and accept the presence of the sensations or emotions and then to step back, release the thought or sensation, and refocus attention toward the breath At the conclusion of each meeting, the meditation instructor will encourage participants to voluntarily engage in daily meditation practices.
224258393|NCT01569269|BEHAVIORAL|Reiki|The Reiki intervention will be conducted for one hour per week for 6 weeks. Protocol for each session: Briefly meet with the Reiki practitioner to review experiences with symptoms of CIPN. Then, the participant will be directed to lie supine and fully clothed on a massage table. Beginning at the top of the head, the practitioner will move inferiorly and pause while holding their hands above, but facing the participant at each energy point until reaching the feet. Upon reaching the participant's feet, the participant will roll from the supine position to a prone position and the process repeated. After being guided to a seated position on the massage table, the practitioner will spend a few moments in conversation with the participation before ending the session.
224258394|NCT01569269|OTHER|Holistic Education|The psychoeducational intervention will be presented in a traditional classroom format with weekly one hour meetings taking place during the six week study period. Each class meeting will address specific aspects of CIPN. Participants will be presented with content related to basic neuroanatomy, physiology, the effects of chemotherapy on peripheral nervous system, how available allopathic treatments (pharmacological/psychopharmacological) can be helpful, and psychosocial issues related to CIPN. The final week of the psychoeducational group will include the identification of complementary interventions that may be of help to people living with CIPN.
224258395|NCT00927069|DRUG|Adalimumab every other week|Adalimumab 40mg injection every other week for 24 weeks
224258396|NCT00927069|DRUG|Adalimumab Every Week|Adalimumab 40mg injection every week for the last 12 weeks of study.
224258397|NCT03946891|DRUG|Inhaled Furosemide|Subjects in the A arm will receive 1 mg/kg of inhaled furosemide Q 24 hours for 3 days. This will be followed by a washout period of a day followed by 1 mg/kg of intravenous furosemide Q 24 hours for 3 days.
224258398|NCT03946891|DRUG|Intravenous Furosemide|Subjects in the B arm will receive 1 mg/kg of intravenous furosemide Q 24 hours for 3 days followed by a washout period, which is then followed by 1 mg/kg of inhaled furosemide Q 24 hours for 3 days.
224258399|NCT02911792|DRUG|Dapagliflozin|SGLT2 inhibitor
224258400|NCT02911792|DRUG|Metformin|Oral diabetes medicine that helps control blood sugar levels.
224258401|NCT02911792|DRUG|Glipizide 5 MG|Oral diabetes medicine that helps control blood sugar levels.
223677095|NCT04829175|DEVICE|Intervention|There is no intervention, beyond necessary clinical care, in this registry. The surgical procedures being performed within the registry are identical to the surgical procedures patients would receive as part of SOC.
223677097|NCT01495676|OTHER|Radiation + cisplatin|"RT will encompass bilateral internal and external iliac lymph nodes at a dose of 45 Gy and the bladder up to 63 Gy. Fractionation will be 1.8 Gy per fraction.~Cisplatin: 20 mg/m2/day through continuous iv perfusion for 4 consecutive days, from D2 to D5 and from D23 to D26 for the first part of the treatment, then from D2 to D5 if an additional treatment is decided.~A cystoscopy with a transurethral resection will be performed 3 weeks after the last day of the first part of radio-chemotherapy.~* In the absence of tumor cells, the 2nd part will start on the 4th week or at latest on the 5th week after the last day of the 1st part of radio-chemotherapy.~* In case of a microscopic tumor residue or of a local tumor progression, operability will be re-evaluated in view of a radical cystectomy and the patient will exit the study."
223677098|NCT01495676|OTHER|Radiation + cisplatin + gemcitabine|"Radiotherapy will encompass bilateral internal and external iliac lymph nodes at a dose of 45 Gy and the bladder up to 63 Gy. Fractionation will be 1.8 Gy per fraction.~Cisplatin: 20 mg/m2/day through continuous iv perfusion for 4 consecutive days, from D2 to D5 and from D23 to D26 for the first part of the treatment, then from D2 to D5 for the second part of the treatment if an additional treatment is decided.~Gemcitabine: iv injection for 30 minutes, twice a week at a dose of 25 mg/m2 on days 2, 5, 9, 12, 16, 19, 23, 26, 30, and 33 for the 1st part of treatment, then on days 2, 5, 9, and 12 for the 2nd part of treatment if an additional treatment is decided (cystoscopy with a transurethral resection). RT will be delivered between 2 and 6 hours after completion of the gemcitabine injection."
224258402|NCT04414891|DEVICE|Non invasive ventilation|"Non invasive ventilation will be delivered using an oro-facial interface in both arms. NIV NAVA will be administered using Servo-i ventilator (Maquet, Getinge Group, Sweden) with software to compensate for air leaks.~ASV arm will receive NIV using a Galileo GOLD ventilator (Hamilton Medical, AG, Switzerland)."
224258403|NCT01124305|DEVICE|Customized Patient Instrumentation|Custom cutting guides based on computed tomography (CT) images of the patient's leg are used to make the bone cuts and select the implant size.
224258404|NCT01124305|DEVICE|Traditional Instrumentation|Traditional surgical instruments will be used to make bone cuts and size the components in this control group.
224258405|NCT02022254|DRUG|semaglutide|Subjects will initiate treatment with 0.25 mg for the first four weeks followed by dose doubling every four weeks up to a dose of 1.0 mg.
224258406|NCT02022254|DRUG|placebo|Semaglutide placebo will be administered s.c.
223677101|NCT05554406|DRUG|Azacitidine|Given SC or IV
224258407|NCT02022254|DRUG|metformin|For oral administration twice daily, in two periods, each of 3.5 days duration. The first period is initiated before semaglutide treatment and the second period is initiated at the end of semaglutide treatment.
224258408|NCT02022254|DRUG|warfarin|For oral administration, given as a single dose. The first dose is given before semaglutide treatment and the second dose is given at the end of semaglutide treatment.
224258409|NCT01868945|DIETARY_SUPPLEMENT|5 µg/day Hy.D Calcifediol|5 µg/day Hy.D Calcifediol taken together with breakfast for a total period of 24 weeks
224258410|NCT01868945|DIETARY_SUPPLEMENT|10 µg/day Hy.D Calcifediol|10 µg/day Hy.D Calcifediol taken together with breakfast for a total period of 24 weeks
224258411|NCT01868945|DIETARY_SUPPLEMENT|15 µg/day Hy.D Calcifediol|15 µg/day Hy.D Calcifediol taken together with breakfast for a total period of 24 weeks
224258412|NCT01868945|DIETARY_SUPPLEMENT|20 µg/day vitamin D3|20 µg/day vitamin D3 taken together with breakfast for a total period of 24 weeks
224258413|NCT04244877|DRUG|Rifaximin|Drug: Rifaximin tablet
224258414|NCT02622737|OTHER|Functional training|Three times per week, with 50 minutes per session, during 8 weeks of training activities involving 10 minutes of muscle stretching, 5 minutes of warm-up exercise, 30 minutes of a functional training and 5 minutes of respiratory exercises.
224258415|NCT02622737|DEVICE|Stationary bike|Three times per week, with 50 minutes per session, during 8 weeks of training activities involving 10 minutes of muscle stretching, 5 minutes of warm-up exercise, 30 minutes of a Stationary Bike exercise and 5 minutes of respiratory exercises.
224258416|NCT02622737|DEVICE|Exergaming|Three times per week, with 50 minutes per session, during 8 weeks of training activities involving 10 minutes of muscle stretching, 5 minutes of warm-up exercise, 30 minutes of a Virtual Reality exercise (performed by Xbox360 with KinectTM sensor) and 5 minutes of respiratory exercises.
223677102|NCT05554406|PROCEDURE|Biospecimen Collection|Undergo collection of blood
223677103|NCT05554406|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
223677104|NCT05554406|DRUG|Cytarabine|Given IV
223677105|NCT05554406|DRUG|Daunorubicin Hydrochloride|Given IV
223677106|NCT05554406|PROCEDURE|Echocardiography Test|Undergo ECHO
223773051|NCT03865277|RADIATION|dose-escalated radiochemotherapy with carbon ion boost|"Patients will receive simultaneous radiochemotherapy, however the simultaneous chemotherapy is standard and not part of the evaluation in this trial.~Radiotherapy is applied to doses of 54 Gy(RBE)/ 1.8 Gy(RBE) per fraction to the adjuvant region, 70 Gy(RBE)/ 2 Gy(RBE) per fraction to the tumor and involved lymphonodes and, if hypoxic and treated in the study site Heidelberg, 77 Gy(RBE)/ 2.2 Gy(RBE) per fraction to the primary tumor and lymphonode metastases \> 2 cm using a carbon ion boost.~Radiotherapy is always applied with 5 fractions per week."
224258417|NCT02952456|OTHER|interview with a psychologist|interview with a psychologist in Bereaved families, Patients with épilepsy and relatives of patients with epilepsy Relatives (Parents / spouse/ Husband) of patients with epilepsy
224258418|NCT03315247|BEHAVIORAL|Telephone-Based CBT|The Tele-CBT sessions focus on introducing the cognitive behavioural model of overeating and obesity, scheduling healthy meals and snacks at regular time intervals and recording consumption using food records, scheduling pleasurable alternative activities to overeating, identifying and planning for difficult eating scenarios, and reducing vulnerability to overeating by solving problems and challenging negative thoughts. Participants are expected to complete CBT homework between sessions, such as completing food records, engaging in pleasurable and self-care activities, and completing a variety of worksheets.
224322588|NCT07167732|DIAGNOSTIC_TEST|Blood Sample Collection|"Venepuncture will be performed by a qualified member of the research team on all participants at each visit and 2x 5ml of blood will be collected (\< 0.8 ml/kg) for analysis of DNA methylation and RNA expression, and analysis of serum for neurofilaments, b-catenin, and zinc. All blood samples will be labelled with the study ID and visit number and processed at the laboratory of the UMCL following the protocol CTNNB1."
223677107|NCT05554406|DRUG|Liposome-encapsulated Daunorubicin-Cytarabine|Given IV
223677108|NCT05554406|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
223677109|NCT05554406|DRUG|Venetoclax|Given PO
224258419|NCT01877317|DEVICE|SelfFit adjusted hearing device|Comparison of threshold measurements through in-situ audiometry with full diagnostic audiometry; Comparison of First-Fit based on SelfFit-formula with conventional fitting formula NAL-NL1 (IG-measurements; Speech intelligibility with First fit of SelfFit; Speech intelligibility with Final fit of SelfFit; Comparison of fine tuning through SelfFit (Final fit) with First fit; Comparison of Final fit with Traditional fit (conventional fitted hearing aid of the test person)
223677116|NCT04634552|DRUG|Talquetamab|Talquetamab will be administered SC until disease progression.
223677117|NCT02710968|DEVICE|11540KE and Balt Goldbal 2 balloon|Fetoscopic tracheal occlusion will be performed using above devices and reversed after 4-5 weeks.
223677118|NCT04619420|DRUG|JNJ-63733657|JNJ-63733657 low or high dose will be administered by IV infusion.
223677119|NCT04619420|DRUG|Placebo|Placebo matching to JNJ-63733657 will be administered by IV infusion.
223677126|NCT05888233|DRUG|Allopurinol|Single arm of Allopurinol treatment for 300mg/daily for 4 weeks then may be increased to 600mg/daily for an additional 4 weeks.
223677130|NCT06058663|PROCEDURE|Angiography|Undergo mapping angiography
223677131|NCT06058663|PROCEDURE|Biopsy|Undergo biopsy
223677132|NCT06058663|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223677133|NCT06058663|PROCEDURE|Computed Tomography|Undergo CT
223677134|NCT06058663|BIOLOGICAL|Durvalumab|Given IV
223677135|NCT06058663|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223677136|NCT06058663|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
223677137|NCT06058663|BIOLOGICAL|Tremelimumab|Given IV
223677138|NCT06058663|PROCEDURE|Yttrium-90 Microsphere Radioembolization|Receive transarterial Y90 radioembolization
223677139|NCT02720094|DRUG|Cabotegravir Oral Tablet|30 mg tablet
223677140|NCT02720094|DRUG|TDF/FTC tablets|300 mg/200 mg fixed-dose combination tablets
223677141|NCT02720094|DRUG|Placebo for TDF/FTC tablets|
223677142|NCT02720094|DRUG|Placebo for cabotegravir oral tablet|
223677143|NCT02720094|DRUG|CAB LA|Administered as one 3 mL (600 mg) IM injection in the gluteal muscle at two time points 4 weeks apart and every 8 weeks thereafter
223677144|NCT02720094|DRUG|Placebo for CAB LA|Administered as one 3 mL IM injection in the gluteal muscle at two time points 4 weeks apart and every 8 weeks thereafter
223677145|NCT05922904|DRUG|Brentuximab vedotin|Given by IV (vein)
223677146|NCT05922904|DRUG|Doxorubicin Hydrochloride|Given by IV (vein)
223677147|NCT05922904|DRUG|Pembrolizumab|Given by IV (vein)
223677148|NCT05922904|DRUG|Dacarbazine|Given by IV (vein)
223677152|NCT01302834|BIOLOGICAL|cetuximab|400 mg/m2 IV 5-7 days before IMRT then 250 mg/m2 IV weekly for 7 weeks
223677153|NCT01302834|DRUG|cisplatin|100 mg/m2 IV on days 1 and 22 of IMRT
223677154|NCT01302834|RADIATION|IMRT|35 fractions over 6 weeks, 6 fractions per week, 2 Gray per fraction to total dose of 70 Gy.
223677157|NCT05947760|DRUG|IV Magnesium Sulfate|Participants will receive IV Magnesium Sulfate intraoperatively.
224258420|NCT04459260|BEHAVIORAL|Cognitive Behavior Therapy|"A standardized evidence-based treatment manual based on cognitive behavior therapy, developed specifically for targeting perfectionism (Egan et al., 2016). Includes the following components: 1) providing psychoeducation about perfectionism and creating an individualized conceptualization 2) broadening the domains for self-evaluation 3) testing out beliefs and predictions, and 4) addressing personal standards and self-criticism.~Week 1: Understanding your perfectionism.~Week 2: Your own model, values, and motivation.~Week 3: Surveys and experiments.~Week 4: Dealing with perfectionistic behaviors.~Week 5: New ways of thinking.~Week 6: Self-criticism and self-compassion.~Week 7: Self-worth.~Week 8: Maintain and continue positive change."
224258421|NCT04459260|BEHAVIORAL|Unified Protocol|"A standardized evidence-based treatment manual based on cognitive behavior therapy, developed to target the shared emotional factors in depression and anxiety disorders (Ellard et al., 2010). Fundamental to this approach is to register and become more aware of the emotions, cognitions, and physical sensations that occur in difficult situation, and to try out more adaptive ways of coping in these instances.~Week 1: Emotional symptoms.~Week 2: Understanding your emotions.~Week 3: Emotional awareness.~Week 4: Thoughts.~Week 5: Behaviors.~Week 6: Emotional exposure.~Week 7: Continued emotional exposure.~Week 8: Planning ahead."
224258422|NCT04289532|DRUG|99mTc-RWY|99mTc-RWY were injected into volunteers and patients before the SPECT/CT scans .
224258423|NCT01244620|DRUG|sitaxentan|sitaxsentan 100 mg QD for 6 days
224258424|NCT01244620|DRUG|tadalafil|tadalafil 40 mg QD for 6 days
224258425|NCT01244620|DRUG|sitaxsentan|sitaxsentan 100 mg QD for 6 days
224258426|NCT01244620|DRUG|tadalafil|tadalafil 40 mg QD for 6 days
224258427|NCT01244620|DRUG|sitaxsentan|sitaxentan 100 mg QD for 6 days
224322589|NCT07167732|DIAGNOSTIC_TEST|Optical Coherence Tomography|To test for FEVR, the participants will be asked to perform Optical Coherence Tomography in their home countries at baseline and before or after every subsequent visit. OCT will only be performed in patients who will be able to cooperate - focus gaze for about 5 seconds.
224322590|NCT07167732|DIAGNOSTIC_TEST|Brain MRI|If a participant has had a brain MRI performed prior to enrolling in our study, pictorial data will be analysed. If the participant will plan to have an MRI performed as a standard procedure in their native country, they will be asked to follow the CTNNB1 MRI protocol: T1 MPRAGE sequence, 3D FLAIR sequence, T2 axial planeartane, SWI, DWI, and DTI with at least 64, but preferably 90 diffusion directions. MRI will not be performed on site.
224322591|NCT07166549|DRUG|Experimental Intervention|"The study intervention includes:~* Lymphapheresis~* Lymphodepleting chemotherapy~* CAR-T infusion~Lymphocytes will be collected from the patients by lymphapheresis to produce a personalized IMP, bispecific anti-CD19, anti-CD20 CAR T cells, which will be manufactured at the GMP facility of the University Hospital Basel.~Patients receive a preparative lymphodepleting chemotherapy of intravenous cyclophosphamide and fludarabine from day -5 until day -3 (or Bendamustine on day -3 and day -2), before anti-CD19/20 CAR T cells are infused (day 0 = day of infusion).~Participants will undergo lymphapheresis 2-8 weeks prior to CAR T cell infusion."
224322592|NCT07167758|DRUG|TRIV-509|TRIV-509 (Subcutaneous injection)
223677158|NCT02354014|DRUG|Bedaquiline (TMC207)|Bedaquiline (TMC207) oral tablet adult formulation (containing 100 mg bedaquiline (TMC207) per tablet) administered as 400 milligram (mg), once daily, for the first 2 weeks, followed by bedaquiline 200 mg 3 times per week with intakes at least 2 days (48 hours) apart for 22 weeks in cohort 1. Cohort 2, 3 and 4 will receive an age appropriate oral tablet formulation containing 20mg bedaquiline . Bedaquiline tablet administered orally as 200 mg, once daily, for the first 2 weeks, followed by bedaquiline 100 mg 3 times per week with intakes at least 2 days (48 hours) apart for 22 weeks in cohort 2. In Cohort 3, dose of bedaquiline 8 mg/kg qd for the first 2 weeks, followed by bedaquiline 4 mg/kg times weekly (TIW) with intakes at least 2 days (48 hours) apart for 22 weeks will be administered. In cohort 4, bedaquiline (TMC207) qd for the first 2 weeks, followed by bedaquiline TIW with intakes at least 2 days (48 hours) apart for 22 weeks.
223677159|NCT02354014|DRUG|Background Regimen (BR)|Background Regimen (BR) of Multidrug Resistant Tuberculosis (MDR-TB) medications will be dosed according to World Health Organization (WHO) guidelines, National Tuberculosis Program (NTP) guidelines and current standard of care at the site.
223677160|NCT05347095|DRUG|Guselkumab|Guselkumab will be administered subcutaneously/IV infusion.
223677161|NCT05347095|DRUG|Placebo|Matching placebo will be administered subcutaneously/IV infusion.
224258428|NCT01244620|DRUG|sildenafil|sildenafil 20 mg TID for 6 days
224258429|NCT02450682|DRUG|Apixaban|Anticoagulant agent for Atrial Fibrillation and undergo CIED generator change
224258430|NCT02450682|DRUG|Warfarin|Anticoagulant agent for Atrial Fibrillation and undergo CIED generator change
224258431|NCT00620711|DEVICE|Olympic Cool Cap|Olympic Cool Cap will be applied to infants 32-35 weeks gestation who meet criteria for HIE.
224258432|NCT05379647|DRUG|QN-019a|Experimental Interventional Therapy
224258433|NCT05379647|DRUG|Rituximab|Monoclonal Antibody
224258434|NCT05379647|DRUG|Cyclophosphamid|Lympho-conditioning Agent
224258435|NCT05379647|DRUG|Fludarabine|Lympho-conditioning Agent
224258436|NCT05379647|DRUG|VP-16|Lympho-conditioning Agent
224258437|NCT00897377|RADIATION|Radiation therapy|
224258438|NCT00897377|DRUG|Temozolomide|
223677176|NCT03735238|OTHER|SMILE Computerized Decision-Aid|SMILE is a computerized decision-aid designed to give lupus patients information about lupus, treatments for lupus available to them, as well as side effects. This will be administered at every lupus clinic session. Every patient will see the SMILE Computerized Decision-Aid at their index baseline clinic visit.
223677178|NCT06548100|DRUG|mibavademab|Administered by intravenous (IV) infusion followed by subcutaneous (SC) injection
224258439|NCT00131391|DRUG|Comparator: taranabant|taranabant 2 mg capsule, 4 mg capsule, 6 mg capsule. 52 week treatment period.
223677181|NCT05523700|OTHER|Mobile Application|Intervention is a mobile application than combines patient data via EMR with PROMIS outcome measures.
223677182|NCT05700903|DRUG|Gonadotropin Releasing Hormone Agonists (GNRH)|8 weeks of GnRH agonist
223677183|NCT05700903|DRUG|Androgen receptor (AR) inhibitor|2 weeks of AR Inhibitor
223677184|NCT05700903|DRUG|Placebo|Placebo tablet and injection
223677190|NCT03153449|DEVICE|ATTUNE Revision Knee System in Total Knee Arthroplasty|Implants from the ATTUNE Revision Knee System will be used to treat subjects whose surgeons have determined their anatomy is such that the use of revision components are required to perform primary total knee arthroplasty
224258440|NCT00131391|DRUG|Comparator: placebo|Placebo capsule once daily . 52 week treatment period.
224258441|NCT05430776|RADIATION|Photobimodulation|laser therapy application
223677195|NCT05111574|PROCEDURE|Biospecimen Collection|Undergo blood and tissue sample collection
223677196|NCT05111574|PROCEDURE|Bone Scan|Undergo bone scan
223677197|NCT05111574|DRUG|Cabozantinib S-malate|Given PO
223677198|NCT05111574|PROCEDURE|Computed Tomography|Undergo CT
223677199|NCT05111574|PROCEDURE|Echocardiography Test|Undergo ECHO
223677200|NCT05111574|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223677201|NCT05111574|BIOLOGICAL|Nivolumab|Given IV
223677202|NCT05111574|DRUG|Placebo Administration|Given PO
224258442|NCT02493283|DRUG|Dapsone single dose|Administration of two tablets Dapson-Fatol 50 mg Tabletten (= 100 mg dapsone) and sampling of blood (before and 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16, 24, 36, 48, 72 and 96 h after single-dose administration), urine (0-24 h, 24-48 h, 48-72 h, 72-96 h, 96 -120 h) and feces (on treatment days 1-5)
224258443|NCT02493283|DRUG|Dapsone multiple dose|Administration of two tablets Dapson-Fatol 50 mg Tabletten (= 100 mg dapsone) s.i.d. for 7 days and sampling of blood (before and 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16, 24, 36, 48, 72 and 96 h after last repeated-dose administration), urine (last treatment day 0-24 h) and feces (on treatment days 12-15)
224258444|NCT02493283|BIOLOGICAL|leucocytes|sampling for leucocytes collection: study days -1, 1, 14 and 15
224258445|NCT02493283|BIOLOGICAL|Met-Hb|sampling before and 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16, 24, 36, 48, 72 and 96 h after single-dose administration, before and 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16, 24, 36, 48, 72 and 96 h after last repeated-dose administration and sampling for additional safety analyses (Met-Hb): study days 10, 12, 14 and hematology on study day 12
224322593|NCT07167758|DRUG|Placebo|Drug: Placebo (Matching Placebo subcutaneous injection)
224258446|NCT01663233|DRUG|LCZ696|LCZ696 will use tablets available at a strength of 200mg. Patients will be instructed to take the prescribed medication once a day.
224258447|NCT01663233|DRUG|Amlodipine|Amlodipine will use tablets available at a strength of 5 mg. Patients will be instructed to take the prescribed medication once a day.
224258448|NCT01663233|DRUG|Placebo|Matching placebo to LCZ696
224322594|NCT07178535|DEVICE|Feasibility of Two Types of Real-Time Visual Feedback in an Augmented Reality|"Participants will walk in a corridor (45 m), equipped with Xsens inertial sensors recording their kinematics and an HTC Vive Elite-XR AR headset superimposing virtual feedback onto the real world. Three real-time feedback conditions (3 trials/condition) will be evaluated randomly: (1) an avatar reflecting the participant's movements; (2) visual bars indicating step lengths; (3) control condition without feedback. Participants take part in an evaluation/intervention session."
223677203|NCT05111574|PROCEDURE|Positron Emission Tomography|Undergo PET
223677204|NCT05022849|DRUG|JNJ-75229414|JNJ-75229414 infusion will be administered intravenously.
223677205|NCT05022849|DRUG|Bridging Therapy|Bridging therapy including Anti-AR agents (example, abiraterone, enzalutamide) will be administered orally and radiotherapy, or chemotherapy (example, docetaxel) will be administered intravenously.
223677206|NCT05784441|DRUG|JNJ-90009530|JNJ-90009530, an autologous Chimeric Antigen Receptor (CAR) - T therapy targeting CD20
223677213|NCT03761108|DRUG|Linvoseltamab|Administered per the protocol
223677214|NCT05963074|DRUG|Ibrutinib|Ibrutinib capsules will be administered orally.
223677215|NCT05963074|DRUG|Venetoclax|Venetoclax tablets will be administered orally.
223677228|NCT04002947|DRUG|DA-EPOCH|Vincristine 1.4 mg/m2 (2 mg cap) IV on Day 1, Doxorubicin 10 mg/m2/day CIVI on Days 1-4, Etoposide 50 mg/m2/day CIVI on Days 1-4, Cyclophosphamide 750 mg/m2 IV on Day 5. Prednisone 60 mg/m2 PO BID is administered daily on Days 1-5 of each cycle. Each cycle is 21 days and drugs will be given for 6 cycles.
223677229|NCT04002947|BIOLOGICAL|Rituximab|Rituximab 375 mg/m2 IV on Day 1 of each 21-day cycle for 6 cycles.
223677230|NCT04002947|DRUG|CHOP|Cyclophosphamide 750 mg/m2 IV, Doxorubicin 50 mg/m2 IV, Vincristine 1.4 mg/m2 (2 mg cap) IV are administered on Day 1 of each 21-day cycle for 6 cycles. Prednisone 40 mg/m2 PO is administered daily on Days 1-5 of each cycle.
223677231|NCT04002947|DRUG|Acalabrutinib|Acalabrutinib is administered orally at 100 mg twice a day for 14 days during the window period. During combination therapy, acalabrutinib is administered 100 mg twice daily for the first 10 days for 6 cycles.
223677232|NCT05317000|DRUG|Combination 5-azacytidine and nivolumab|The primary objective of the study is to determine whether exposure to the demethylating agent 5-azacytidine will sensitize HPV-associated oropharynx cancer to nivolumab by induction of interferon response, neoantigen expression, and augmentation of lymphocyte infiltration of the tumor microenvironment.
224258449|NCT02321098|DRUG|Loceryl NL + Cosmetic varnish|Loceryl NL + Cosmetic varnish once/week for 12 weeks
224258450|NCT02321098|DRUG|Loceryl NL 12 weeks|Loceryl NL once/week for 12 weeks
224258451|NCT02321098|DRUG|Loceryl NL 15 months|Loceryl once/week for additional 15 months
224258452|NCT01610245|DRUG|Nitazoxanide|
224258453|NCT01610245|DRUG|Oseltamivir|
224258454|NCT01610245|DRUG|Placebo Oral Tablet|
224258455|NCT01610245|DRUG|Placebo Oral Capsule|
224258456|NCT03998605|BEHAVIORAL|Abuse Prevention Program|The abuse prevention program will be comprised of nine shared learning modules for the individual with Intellectual Disabilities (ID) and a care provider. Each shared module will contain an action step in the Individual Response Plan and will include video, guided practice and workbook activities to equip persons with ID with a range of judgment, decision-making skills and the efficacy needed for identifying, rejecting, and reporting abuse.
224258457|NCT03998605|BEHAVIORAL|Control Condition|The control group will receive worksheets from the ESCAPE-NOW curriculum.
224258458|NCT05947734|DEVICE|"VTS surgical robotic system"|"TheVTS surgical robotic system can accurately match the preoperative and intraoperative image data with the patient's anatomical structure on the operating table, track and locate the surgical instruments during the operation. With the help of the robotic arm, the surgeon can make the operation procedure more accurate and safer."
224258459|NCT02558491|DEVICE|Decision Support System|"The purpose of this study is to demonstrate the safety and feasibility of a Decision Support System aimed at reducing glucose variability in T1DM patient using an insulin pump or MDI. The system will be deployed on our portable medical application platform (DiAs) and will include the following elements:~1. An insulin pump treatment parameters optimization routine, using a month of collected CGM/insulin/meal data~2. An exercise risk warning system, capable of predicting hypoglycemia at the onset of physical activity and advising on mitigating alteration of treatment.~3. A smart bolus calculator based on CGM glucose measurements and insulin sensitivity estimation."
224258460|NCT02558491|OTHER|Usual Care|During the Control study admission, DiAs will be programmed with the home insulin dosing parameters. The study subject will use the home basal/bolus MDI or continuous subcutaneous insulin infusion (CSII) insulin regimen via the home insulin pens or pump and determine the amount of insulin to give for the entire admission per the subject's home carb counting parameters and as calculated by the DiAs meal screen.
224258461|NCT01197391|BIOLOGICAL|REGN728|2 Subcutaneous Cohorts (dose 1, 2)
224258462|NCT00878020|DRUG|BMS-830216|Capsules, Oral, Single Dose, 1 day
224258463|NCT00878020|DRUG|Placebo|Capsules, Oral, 0mg, Single Dose, 1 day
223677233|NCT05317000|DRUG|5-azacytidine|Chemotherapy is the use of drugs to destroy cancer cells. It usually works by keeping the cancer cells from growing, dividing, and making more cells. Because cancer cells usually grow and divide faster than normal cells, chemotherapy has more of an effect on cancer cells. 5-azacytidine works by slowing down the growth of cancer cells. 5-azacytidine has been demonstrated to improve the cell's ability to make some proteins which signal to the immune system.
224258464|NCT00878020|DRUG|BMS-830216|Capsules, Oral, Single Dose on Day 1, Period 1 and Day 1, Period 2, 2 days
224258465|NCT00878020|DRUG|Placebo|Capsules, Oral, 0mg, Single Dose, on Day 1, Period 1 and Day 1, Period 2, 2 days
224258466|NCT00746395|DRUG|Lubiprostone|24 mcg oral administration
223677234|NCT05317000|DRUG|Nivolumab|"Immunotherapy is a type of treatment that uses your body's own immune system to help fight cancer. Specifically, Nivolumab belongs to a class of anti-cancer drugs known as immune checkpoint inhibitors. Cancer cells are able to turn off the immune system by increasing the production of a protein called PD-1. Nivolumab can block PD-1 and may be able to re-activate the immune response to kill head and neck cancer cells."
224258467|NCT00746395|DRUG|Placebo|Oral administration
224258468|NCT00834431|DRUG|Famciclovir 500 mg Tablets|1 x 500 mg, single-dose fasting
224258469|NCT00834431|DRUG|Famvir® 500 mg Tablets|1 x 500 mg, single-dose fasting
224258470|NCT06627673|DEVICE|Total Knee Arthroplasty|Primary Total Knee Arthroplasty with a PEEK femoral component
224258471|NCT06124638|DIAGNOSTIC_TEST|Panbio™ COVID-19/Flu A&B Panel|The Panbio™ COVID-19/Flu A\&B Rapid Panel Self-Test device is a visual lateral flow assay, for rapid immunochromatographic qualitative detection of COVID-19 antigen, Influenza A antigen and Influenza B antigen in self-collected mid-turbinate nasal swabs. The test is designed to be used by lay users.
224258472|NCT05192720|DIETARY_SUPPLEMENT|Andosan|See also detailed study design, Mushroom juice based on Agaricus Blazei and two other types of mushroom.
224258473|NCT05192720|DIETARY_SUPPLEMENT|Placebo|drinking water with food colour
223677235|NCT05487846|BEHAVIORAL|Patient Navigation|Receive peer navigation services
223677236|NCT05487846|OTHER|Genetic Counseling|Receive genetic counseling
223677237|NCT05487846|OTHER|Survey Administration|Ancillary studies
223677238|NCT05487846|OTHER|Best Practice|Receive standard care
223677239|NCT05487846|OTHER|Genetic Counseling|Receive genetic counseling
224258474|NCT06429540|BIOLOGICAL|Partially Demineralized Dentin Block|"The extracted tooth will be dried using air, then ground and partially demineralized with the Tooth Transformer device following the manufacturer's protocol. Dentin particles will be obtained with dimensions of 400-800 μm. The partially demineralized dentin will then be prepared by cutting the Leukocyte-Platelet Rich Fibrin (L-PRF) membranes into small pieces and mixing them with the dentin particles. Liquid fibrinogen will be added to the homogeneous mixture. Within a few minutes, the fibrinogen will convert into fibrin primarily from the activated blood platelets in the chopped L-PRF membranes. This process will effectively trap the biomaterial and the L-PRF pieces, forming the dentin block. After that, the sockets will be carefully packed with the dentin block and it will be covered with L-PRF membrane. To ensure stability and prevent displacement, the wounds will be secured using non-resorbable sutures."
224322595|NCT07173543|OTHER|Intermittent Hypoxia 1 (IH1)|Intermittent Hypoxia 1 (IH1): 5 cycles of normoxia (4 minutes)/hypoxia (6 minutes) per session. 3 sessions per week for 8 weeks
224322596|NCT07173543|OTHER|Intermittent Hypoxia 2 (IH2)|Intermittent Hypoxia 1 (IH2): 5 cycles of normoxia (4 minutes)/hypoxia (6 minutes) per session. 3 sessions per week for 4 weeks
224322597|NCT07173543|OTHER|SHAM - normoxia|Participants will receive normoxia (no hypoxia) over 50 minutes.
223677240|NCT05487846|OTHER|Survey Administration|Ancillary studies
223773052|NCT03865277|RADIATION|standard radiochemotherapy|"Patients will receive simultaneous radiochemotherapy, however the simultaneous chemotherapy is standard and not part of the evaluation in this trial. Present standard chemotherapy is cisplatinum 40 mg/m²/week (chemotherapy over the whole course of radiotherapy).~Radiotherapy is applied to doses of 54 Gy(RBE)/ 1.8 Gy(RBE) per fraction to the adjuvant region and 70 Gy(RBE)/ 2 Gy(RBE) per fraction to the tumor and involved lymphonodes.~Radiotherapy is always applied with 5 fractions per week."
223773053|NCT03961594|OTHER|expansion volémique|cardiac output, VVP, VVE, blood pressure, Eadyn, EtCO2 will be measured before and after ELJP. In the event of an increase of more than 10% in cardiac output during the ELJP, patients will receive a volume expansion of 500ml of balanced crystalloids. The same measurements will be repeated immediately at the end of the volume expansion and 20 minutes after the end of the infusion. Patients with a 15% increase in cardiac output at the end of volume expansion will be classified as responders.
223773054|NCT00820768|DRUG|ABI-010|17-AAG and ABI-007
223773055|NCT03293823|BEHAVIORAL|VSOP training|a computerized cognitive training of attention and processing speed
224258475|NCT06429540|BIOLOGICAL|Xenograft|In the control group using the Xenograft, the same extraction and socket debridement procedure will be performed. Following that, the extraction socket will be thoroughly filled with deproteinized bovine bone mineral, and a collagen membrane will be employed to cover the socket. The membrane will be shaped to extend 2-3 mm beyond the margins of the extraction socket and positioned just beneath the marginal mucosa. To ensure its stability, a cross-suture will be performed, securing the membrane in place.
224258476|NCT05080322|DRUG|Fluticasone Nasal 50 Mcg/Inh Nasal Spray, Azelastine Nasal 140 Mcg/Inh Nasal Spray|on-demand INS (Fluticasone) combined with nasal spray AH1(Azelastine)
224258477|NCT05080322|DRUG|Fluticasone Nasal 50 Mcg/Inh Nasal Spray|on-demand or maintenance
224258478|NCT04979663|COMBINATION_PRODUCT|Combination of Gemcitabine, Oxaliplatin, Donafenib and Tislelizumab|Combination of Gemcitabine, Oxaliplatin, Donafenib and Tislelizumab every 3 weeks
224258479|NCT06293586|PROCEDURE|peribulbar block|"Peribulbar block using a two-injection technique was performed by a second anesthetist under sterile conditions and before the application of surgical drapes. LAM was injected both infratemporal and superonasally using a 26-G needle, in contrast to the single infratemporal injection approach.~Gentle digital oculopression was performed for 5 minutes"
223773056|NCT03293823|BEHAVIORAL|MLA control|a computerized cognitive intervention of multiple mental leisure activities
224258480|NCT06293586|PROCEDURE|sub-tenon block|Children in the sub-Tenon group received a sub-Tenon block. Sub-Tenon's anesthesia was performed with 0.5% bupivacaine (0.08 ml/kg), bearing in mind not to exceed the maximum dose. Under sterile conditions, a 19- gauge curved blunt metallic cannula (25 mm) was inserted into sub-Tenon's space and the local anesthetic was injected by the ophthalmologist after the application of surgical drapes.
224258481|NCT06293586|DRUG|Paracetamol|Children in the control group received IV paracetamol (15 mg/kg) after induction of anesthesia before any surgical intervention.
224258482|NCT04825314|DEVICE|Urethral catheter|All Patients will have urethral catheterization with either Noble Metal Alloy coated catheter or Silicon Foley catheter.
224258483|NCT03081481|DRUG|PRX302|Single prostate cancer lesion injected with PRX302
223773057|NCT02873923|DRUG|undefined|Chemotherapy drug (meta-analyses of randomized trials)
223773058|NCT00001663|DEVICE|Magstim Super Rapid Stimulator|
223773059|NCT04092426|OTHER|opthalmologic examination|opthalmologic examination : Refraction Best corrected visual acuity Intraocular pressure Slit lamp examination
223773060|NCT04488731|BEHAVIORAL|Normal BMI and moderate coffee consumption|Normal BMI and moderate coffee consumption
223773061|NCT04488731|BEHAVIORAL|Normal BMI and heavy coffee consumption|Normal BMI and heavy coffee consumption
223773062|NCT04488731|BEHAVIORAL|overweight and moderate coffee consumption|overweight and moderate coffee consumption
224258484|NCT05878964|OTHER|EQ-5D-5L questionnaire|Quality of life evaluation questionnaire
224258485|NCT05878964|OTHER|FACT-G (Functional Assessment of Cancer Therapy - General)|Quality of life evaluation questionnaire
224258486|NCT05878964|OTHER|FACT-EGFRI-18 (Functional Assessment of Cancer Therapy - Epidermal Growth Factor Inhibitors 18 Item)|Self reported evaluation of cutaneous toxicity questionnaire.
224258487|NCT02220647|DRUG|Linagliptin/Metformin FDC|
224258488|NCT02220647|DRUG|Linagliptin|
223773063|NCT04488731|BEHAVIORAL|overweight and heavy coffee consumption|overweight and heavy coffee consumption
224258489|NCT02220647|DRUG|Metformin|
224258490|NCT00859105|DRUG|Imiquimod 5%: manufactured by Apotex|Treatment applied as a thin layer to target area once a day, 2 days each week, 16 weeks
224258491|NCT00859105|DRUG|Adara 5% Cream US|Treatment applied as a thin layer to target area once a day, 2 days each week, for 16 weeks
224258492|NCT00859105|DRUG|Adara 5% Cream Canada|Treatment applied as a thin layer to target area once a day, 2 days each week, for 16 weeks.
224258493|NCT00859105|DRUG|Imiquimod Vehicle|Treatment applied as a thin layer to target area once a day, 2 days each week, for 16 weeks
224258494|NCT02448862|DEVICE|Fentanyl based IV-PCA|We have used a disposable PCA pump (Ambix Anaplus®; E-Wha Fresenius Kabi, Korea or accufuser plus®; Woo Young Medical, Korea) and fentanyl was diluted in 100 mL with saline for 48 hrs PCA infusion. The pump was set as follows: infusion rate as 2 ml/hr, bolus dose as 0.5 ml or 1 ml, lockout time as 15 min. It was decided at the anesthesiologist's option whether the additional analgesic drug (ketorolac or nefopam) and the antiemetic drug (ondansetron, ramosetron or palonosetron) would be added in PCA or not. The anesthesiologist who performed the anesthesia decided the amount of chosen drugs.
224258495|NCT06603532|OTHER|low-load blood flow restriction (BFR) training|The training program lasted four weeks with three training sessions per week, for a total of 12 training sessions. Participants in the BFR group exercised with blood flow restriction caused by an inflatable cuff placed on the proximal part of the thigh and inflated to 120-140 mmHg. Subjects trained against the maximum mechanical resistance they could overcome thirty times (30 repetitions maximum; 30 RM). All training sessions were performed under the supervision of a physiotherapist and included leg press and knee extension exercises.
224258496|NCT06603532|OTHER|low-load resistance training|The training program lasted four weeks with three training sessions per week, for a total of 12 training sessions. Participants in SHAM-BFR group performed an identical exercise protocol as experimental (BFR) group, while having thigh cuff inflated to only 20 mmHg, which did not affect normal muscle blood flow. Subjects trained against the maximum mechanical resistance they could overcome thirty times (30 repetitions maximum; 30 RM). All training sessions were performed under the supervision of a physiotherapist and included leg press and knee extension exercises.
224258497|NCT02349763|DRUG|Intravenous Dexamethasone|Lactose (Placebo) 5 tablets given orally at 12 and 6 hours before paclitaxel infusion and dexamethasone 20 mg (5mg/ml) given intravenously at 30 minutes before paclitaxel infusion
223677267|NCT04711837|DRUG|HSK3486|HSK3486 for induction of general anesthesia.
223677268|NCT04711837|DRUG|Propofol|Propofol for induction of general anesthesia.
224258498|NCT02349763|DRUG|Oral Dexamethasone|Dexamethasone 20 mg (4 mg/tablet) or 5 tablets given orally at 12 and 6 hours before paclitaxel infusion and 0.9% NaCL (Placebo) 4 ml given intravenously at 30 minutes before paclitaxel infusion
224258499|NCT03359863|DRUG|Pirfenidone|Subjects will receive pirfenidone for 52 weeks, titrated to 2403 mg/day (3 capsules, 3× daily) after a 4-week titration period (1 capsule, 3x daily for 2 weeks, 2 capsules, 3x daily for 2 weeks) for a total of 56 weeks of pirfenidone. Eligible participants will continue pirfenidone beyond 56 weeks.
224258500|NCT06364267|DRUG|Tamoxifen 10 MG|Blinded tamoxifen 10 mg every other day
224258501|NCT06364267|DRUG|Exemestane 25 MG|Blinded exemestane 25 mg every other day
224258502|NCT01747174|DRUG|IC Adenosine|IC Adenosine 1mg injected distally via micro-catheter in to IRA following thrombus aspiration with further dose (1mg if IRA is RCA otherwise 2mg) via guide catheter following coronary stent deployment.
224258503|NCT01747174|DRUG|IC Sodium nitroprusside (SNP)|IC SNP 250mcg injected distally via micro-catheter distally in to IRA following thrombus aspiration with further 250 mcg dose delivered via guide catheter following coronary stent deployment.
224258504|NCT01747174|PROCEDURE|Standard PCI|PCI procedure with thrombectomy (via aspiration catheter) and bivalirudin given as standard.
224258505|NCT04075578|DRUG|OnabotulinumtoxinA / Botox®, Allergan Ltd, Irvine, CA, United-States|Botox® intradetrusor injections, with a rigid cystoscope, under local anaesthesia performed by Lidocaïne 2% diluted in 30ml of bicarbonate 14‰. 20 injections of 0,5ml each will be heterogeneously administrated into the bladder wall, sparing the trigone
224258506|NCT04881240|BIOLOGICAL|CD19-CAR(Mem) T-cells|Allogeneic CD19-CAR.CD45RA-negative T-cells Intravenous infusion
224258507|NCT04881240|DRUG|Cyclophosphamide|Cyclophosphamide is a nitrogen mustard derivative. It acts as an alkylating agent that causes cross-linking of DNA strands by binding with nucleic acids and other intracellular structures, thus interfering with the normal function of DNA.
223677274|NCT03231150|PROCEDURE|Local Steroid Injection into the plantar heel|Injections consisting of 0.5 ml 0.25% bupivacaine plain, 0.5 ml dexamethasone phosphate, and 0.5 ml triamcinolone acetonide 40 mg/ml.
223677275|NCT03231150|PROCEDURE|Ultrasound Guided Injection|Execution of the USGI will employ an actual diagnostic US machine (Voluson E8 Expert, General Electric Company, Boston, MA) and a plantarmedial approach
223773064|NCT03414138|BEHAVIORAL|Mindfulness Training|A well-validated brief mindfulness-based mental training regimen \[four sessions; 20 min/session\] will be used to teach patients to independently practice mindfulness meditation.
223773065|NCT03414138|BEHAVIORAL|Book Listening Control|Study volunteers will listen to four 20 minute blocks of The Natural History and Antiquities of Selborne throughout their interventions.
223773066|NCT02687152|OTHER|N-hydroxy-nor-L-arginine|
223773067|NCT05083767|OTHER|Experimental|The study protocol of WBV includes twelve weeks of whole-body vibration training provided to the Type 2 diabetic patients. It was recommended to all participants that they follow their regular diet and medication during the training. Two sets of six 1-minute vibration squats were designed with 20 seconds of rest, 3 times weekly for a duration 12 weeks (total workout time 36 minutes a week), using a vertical vibration machine. The six static positions consisted of (a) a deep squat position (knee angle 900) (b) an elevated squat position (knee angle 1250) (c) an elevated squat position (with elevated heels) (d) a slight knee flexion1 (hand straps with shoulder bending) (e) a slight knee flexion (hand straps with shoulder abduction) and (f) a slight knee flexion 3 (hand straps with elbow flexion). The training load steadily increased from the initial vibration of 30 Hz and the platform amplitude was raised from 2 mm at week 1 to 40 Hz and from 4 mm at week 5 to the completion of training.
223773068|NCT05083767|OTHER|Control|The control group was advised to their normal physical activity level, diet, and medication.
223773069|NCT01610700|DRUG|GW-1000-02|Containing THC (27 mg/ml):CBD (25 mg/ml), in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring. The maximum permitted dose of study medication was eight actuations (22 mg THC and 20 mg CBD) in any three hour period, and 48 actuations (130 mg THC and 120 mg CBD) in any 24 hour period.
223773070|NCT01610700|DRUG|Placebo|Each actuation of placebo delivered the excipients only.
223773071|NCT03137862|OTHER|Gluten free bread|patients will receive bread containing 3 g of cornstarch daily for 12 weeks; these patients will serve as controls
223773072|NCT03137862|DIETARY_SUPPLEMENT|Gluten friendly bread 3g/day|"patients will have to continue the GFD supplemented with 3 gr of gluten friendly bread daily for 12 weeks"
223773073|NCT03137862|DIETARY_SUPPLEMENT|Gluten friendly bread 6g/day|"patients will have to continue the GFD supplemented with 6 gr of gluten friendly bread daily for 12 weeks"
223773074|NCT06131918|DRUG|Resveratrol, Alpha lipoic acid, Super oxide dismutase|Tab Resveratrol 1500 mg BD Tab Alpha lipoic Acid 600 mg BD Tab Superoxide dismutase 250 mg BD
224258508|NCT04881240|DRUG|Fludarabine|Fludarabine phosphate is a synthetic purine nucleoside analog. It acts by inhibiting DNA polymerase, ribonucleotide reductase and DNA primase by competing with the physiologic substrate, deoxyadenosine triphosphate, resulting in inhibition of DNA synthesis.
224258509|NCT04881240|DRUG|Mesna|Mesna is a synthetic sulfhydryl (thiol) compound. Mesna contains free sulfhydryl groups that interact chemically with urotoxic metabolites of oxaza-phosphorine derivatives such as cyclophosphamide and ifosfamide.
224322598|NCT07179874|PROCEDURE|Remote Ischemic Preconditioning|"This intervention involves a non-invasive, mechanical stimulus applied to an upper limb with the goal of activating systemic protective pathways against contrast-induced nephropathy in diabetic patients. Unlike pharmacologic or device-based interventions, RIPC:~* Does not involve any drugs, biologics, or implants~* Is performed using a standard blood pressure cuff, inflated to 50 mmHg above systolic pressure, specifically designed to induce repetitive transient limb ischemia~* Consists of four alternating cycles of 5 minutes inflation followed by 5 minutes reperfusion~* Is applied 45 minutes before coronary catheterization, timed to optimize systemic renal protection prior to exposure to contrast media~* Targets activation of the heme oxygenase-1 (HO-1) enzymatic pathway, linking limb ischemia with antioxidant renal defense mechanisms Unlike interventions that rely solely on hydration or pharmacological antioxidants, this approach seeks to prime endogenous protective systems through is"
223773075|NCT06131918|DRUG|Resveratrol|Tab Resveratrol 1500 mg BD Tab Placebo 600mg BD Cap Placebo 250mg BD
223773076|NCT06131918|DRUG|Alpha lipoic acid|Tab Alpha lipoic acid 600 mg BD Tab Placebo 600mg BD Cap Placebo 250mg BD
223773077|NCT06131918|DRUG|Super Oxide Dismutase|Tab Super oxide dismutase 250 mg BD Tab Placebo 600mg BD Cap Placebo 250mg BD
224258510|NCT04881240|DEVICE|CliniMACS|A CliniMACS device is used to select donor T-cells for manufacturing of the memory CAR T-cell product.
223677276|NCT03231150|PROCEDURE|Anatomical Guided injection|Execution of the ATGI will employ a sham diagnostic US machine and a plantarmedial approach.
223677277|NCT06659029|DRUG|Anifrolumab|Anifrolumab is a human monoclonal antibody that binds to subunit 1 of the type 1 interferon receptor, which was developed based on the evidence supporting the role of type 1 interferon pathway in SLE. Clinical trial evidence from TULIP 1 and TULIP 2 have showed that monthly intravenous administration of anifrolumab led to a higher percentage of patients with a response, assessed with the British Isles Lupus Assessment Group-based Composite Lupus Assessment, compared with patients receiving placebo. Moreover, the phase II MUSE study showed that administration of anifrolumab resulted in substantially reduce disease activity, as measured by the SLE Responder Index, compared to patients receiving placebo. Anifrolumab was approved by the FDA and EMA in July 2021 and February 2022, respectively, for the treatment of adult patients with moderate to severe SLE who are receiving standard therapy.
223773078|NCT01899924|BEHAVIORAL|Event Related Potentials recording|
223773079|NCT03866993|BIOLOGICAL|AK105|IV infusion
223773080|NCT03866993|DRUG|Paclitaxel|IV infusion
223773081|NCT03866993|DRUG|Carboplatin|IV infusion
223773082|NCT03866993|DRUG|Placebo|IV infusion
224258511|NCT04881240|PROCEDURE|Leukapheresis|Leukapheresis is performed to collect the T cells that are needed to generate the CD19-CAR.CD45RA-negative T-cells product for the clinic study.
224258512|NCT06132841|DRUG|AZD6234|Participants will receive repeated doses of AZD6234 as a solution via SC
224258513|NCT06132841|DRUG|Placebo|Participants will receive matching volumes of the placebo as a solution via SC
224258514|NCT00393276|BIOLOGICAL|Twinrix|Combined hepatitis A and hepatitis B immunization
224258515|NCT00393276|BIOLOGICAL|Decavac|Diphtheria and tetanus toxoid vaccine
224258516|NCT06444178|DRUG|Aspirin|Oral administration
224258517|NCT06444178|DRUG|REGN9933|Administered intravenous (IV)
224258518|NCT06444178|DRUG|REGN7508|Administered IV
224258519|NCT06444178|DRUG|Rivaroxaban|Oral administration
224258520|NCT05628233|DRUG|SENS-401 (R-Azasetron Besylate)|Patients will receive SENS-401 ((R)-azasetron besylate) B.I.D. up to 23 weeks: 1 week prior to the initiation of the cisplatin treatment, during the whole duration of the chemotherapy treatment (estimated to last up to 18 weeks) and 4 weeks after stopping chemotherapy.
224258521|NCT06092801|OTHER|No intervention|No intervention
224258522|NCT06696118|DEVICE|Electromagnetic Transduction Therapy (EMTT)|Subjects will be treated with Electromagnetic Transduction Therapy (EMTT) using the Curamedix MAGNETOLITH device. Treatments will be administered twice per week, for four weeks. Each treatment will have the following settings: level 8, 8Hz, and 10,000 pulses andwill take about 15 to 20 minutes. Treatments will be spaced 2-3 days apart.
224258523|NCT05630885|DRUG|CVC 150 mg|Administered as one 150-mg tablet by mouth once a day with food.
224258524|NCT05630885|DRUG|CVC 300 mg|Administered as two 150-mg tablets by mouth once a day with food.
224258525|NCT05630885|OTHER|Placebo for CVC 150 mg|Administered as one 150-mg matching placebo tablets by mouth once a day with food.
224258526|NCT05630885|OTHER|Placebo for CVC 300 mg|Administered as two 150-mg matching placebo tablets by mouth once a day with food.
224258527|NCT05922683|DRUG|Vivomixx|"Vivomixx (a mixture of Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus casei, Lactobacillus delbrueckii subspecies bulgaricus, Streptococcus salivarius subspecies thermophiles, Bifidobacterium breve, Bifidobacterium longum, and Bifidobacterium infantis), as VivomixxAll consenting participants will be randomized into the treatment to control arm, receiving either Vivomixx or a placebo for 8 weeks.~During the study, women will visit the healthcare center or vice-versa on a bi-weekly basis to receive sachets of Vivomixx or a placebo according to their trial arm."
224258528|NCT05922683|DEVICE|CapScan®|"The only non-standard sample collection instrument is the CapScan device. The CapScan Collection Capsule (Capsule) is a non-invasive device that collects gastrointestinal samples along the GI tract that are then analyzed outside the body. Samples collected by the Capsule will be expressed, then undergo DNA sequencing and mass spectrometric analysis to determine the identity and function of the bacterial and host cells in the different regions of the GI tract and compared to similar analyses conducted on concomitantly collected stool samples."
224258529|NCT06283615|DRUG|Vitamin D|Vitamin D2 injection
224258530|NCT06852651|PROCEDURE|Superficial Cervical Block (SCB) Group|"Patients in this group will receive a bilateral superficial cervical block under ultrasound guidance after anesthesia induction but before the surgical procedure begins.~The block will be performed using 0.1 mL/kg of 0.25% bupivacaine per side, targeting the superficial branches of the cervical plexus.~The primary goal is to assess its efficacy in postoperative pain management and its impact on recovery parameters."
224258531|NCT01262001|DRUG|FG-3019|Cohort 1 and Cohort 1-EX: 15 mg/kg by infusion every 3 weeks for 45 weeks in the target population (first treatment year and first extended treatment year and every 3 weeks thereafter for three additional extended treatment years).
224258532|NCT01262001|DRUG|FG-3019|Cohort 2 and Cohort 2-EX: 30 mg/kg by infusion every 3 weeks for 45 weeks in the target population (first treatment year and first extended treatment year and every 3 weeks thereafter for three additional extended treatment years).
224258533|NCT04813081|PROCEDURE|Free Gingival Graft|In the recipient area, a half-thickness flap with two vertical incision widths was removed with a horizontal incision with 15C blades from the mucogingival junction. The recipient site was determined such that one or two teeth or one tooth extends into the mesial and distal regions of the tooth. Muscle attachments were dissected and FGG was placed on recipient bed and non-resorbable monofilament sutures were used for fixing the four corners of the graft.
224258534|NCT02866357|OTHER|No intervention|Just collection of nasopharyngeal aspirate for assessment
223677280|NCT06362252|DRUG|Ifinatamab deruxtecan|Intravenous administration
223677281|NCT06362252|DRUG|Atezolizumab|Intravenous administration
223677282|NCT06362252|DRUG|Carboplatin|Intravenous administration
224258535|NCT05745363|DRUG|AL2846 capsule|AL2846 is a multi-target tyrosine kinase inhibitor
224258536|NCT01909024|PROCEDURE|Coil embolisation|transjugular coil embolisation of pelvic veins
224258537|NCT01909024|PROCEDURE|endovenous treatment of leg recurrent varicose veins|endovenous treatment of leg recurrent varicose veins
224258538|NCT04050943|OTHER|observational cohort|Recording the clinical, pathophysiology, and psychological parameters, to observe and predict the clinical outcomes of these patients.
224322599|NCT07181122|DRUG|Androgen Receptor Pathway Inhibitors (ARPIs)|Men with metastatic hormone-sensitive prostate cancer will receive androgen receptor pathway inhibitors (abiraterone acetate, apalutamide, enzalutamide, or darolutamide) in addition to standard androgen deprivation therapy. The choice of ARPI will be determined by routine clinical practice. The study does not assign treatments; it observes patient outcomes under real-world conditions.
224258539|NCT03510208|PROCEDURE|Near-Infrared Fluorescence Imaging|Undergo NIR imaging
224322600|NCT02690441|BEHAVIORAL|Cognitive Behavioural Therapy|Cognitive behavioural therapy conducted individually. 10 weekly sessions, first session lasts 90 minutes, the remaining sessions last 45 minutes.
224258540|NCT03510208|BIOLOGICAL|Panitumumab|Given IV
223773083|NCT02818205|OTHER|Sensory Challenge Protocol|Measurement of electrodermal activity in response to sensation
223773084|NCT01471535|DRUG|Pegylated interferon alfa-2a|patients were given peginterferon alfa-2a (40KD) (Pegasys®; Roche, Basel, Switzerland)180 µg by subcutaneous injection once weekly for 120 weeks
223773085|NCT04414670|PROCEDURE|C/S|laparoscopic or robotic metroplasty
223773086|NCT05186324|OTHER|Interview|"During each interview, patients will be asked questions to collect demographic and clinical information, and asked a set of open-ended questions with probes to describe their experiences with Fabry disease (symptomology and impacts on patient's lives \[i.e., activities of daily living, school/work, ability to take holidays/vacation\]), and pegunigalsidase alfa treatment (experience of infusions and schedule) and their experience of change in symptoms and impacts over the BRIGHT-F51 clinical study.~A semi-structured discussion guide will be used to conduct the approximately 60-minute interviews. The use of open-ended questions avoids bias and questions will not be read verbatim to allow for a free-flowing discussion."
223773087|NCT00001022|DRUG|Zidovudine|
223773088|NCT00001022|DRUG|Zalcitabine|
224258541|NCT03510208|DRUG|Panitumumab-IRDye800|Given IV
224258542|NCT03510208|DEVICE|POINPOINT-IR9000|"Intraoperative camera capable of exciting and detecting near infrared (NIR) dyes. Imaging will be performed on subjects during surgery and/or on ex-vivo resected tissues in the surgery suite (back table)."
224258543|NCT05242705|DIAGNOSTIC_TEST|Serum Cysteine Rich Protein 61|collection of serum samples for chemical analysis
224258544|NCT06539676|DEVICE|Nighttime Aligners|Nighttime aligners worn 10-12 hours per day or night during 2-8 months
224258545|NCT06539676|DEVICE|Daytime Aligners|Daytime aligners worn 20-22 hours per day or night during 2-8 months
224258546|NCT03202238|OTHER|Conventional|Conventional venepuncture without use of any venepuncture assistive device.
223773089|NCT00001022|DRUG|Didanosine|
223773090|NCT06529367|OTHER|Snellen chart|"Patients will be asked to use the 5 feet distance for standardization, which allows for visual acuity assessment from 20/16 to 20/200.~Patients will be asked to wear their current corrective lens for distance, to take the test at home in a place with good lighting and to test each eye separately.~Office-based vision testing will be performed by a trained ophthalmic technician in a dimmed room with the Snellen chart illuminated on a screen. Patients will be asked to wear their current corrective lens for distance and an eye occluder will be used to test each eye separately."
223773091|NCT01971398|BEHAVIORAL|Positive FASD education brochure|Exposure to a positive FASD education brochure
223773092|NCT01971398|BEHAVIORAL|Negative FASD education brochure|Exposure to a negative FASD education brochure
223773093|NCT01971398|BEHAVIORAL|Active comparator (a general women's health brochure)|Exposure to a general women's health brochure
223773094|NCT00302224|DRUG|2S, 4R Ketoconazole (DIO-902)|
224258547|NCT03202238|DEVICE|Veinlite|Commercial transilluminator device that allows veins to show up as a silhouette among surrounding soft tissue
224258548|NCT03202238|DEVICE|TenTaTorch|Transilluminator device that allows veins to show up as a silhouette among surrounding soft tissue
224258549|NCT00222625|DRUG|rFVIIa + (vit K in AO patients)|
224258550|NCT00222625|DRUG|FFP or aPCC+ vit K in AO treated patients|
224258551|NCT05201833|BEHAVIORAL|Telephone Outcome Assessment|Assessments will be administered over the telephone to evaluate participant outcome status
224258552|NCT05201833|BEHAVIORAL|In-Person Outcome Assessment|Assessments will be administered to evaluate participant outcome status
224258553|NCT05201833|PROCEDURE|3T Magnetic Resonance Imaging (MRI)|Participants will be asked to complete a 3T MRI
224258554|NCT05201833|PROCEDURE|Blood Draw|Blood Draw for Plasma, DNA, Serum, RNA
224258555|NCT02181647|BEHAVIORAL|Safe Touches: Personal Safety Training for Children|The intervention includes a 50-minute interactive training and an age-appropriate activity book on personal body safety to take home and complete with caregivers. Using culturally appropriate puppets, workshop facilitators use role-play to model scenarios to help children: a) recognize safe and not-safe touches, b) understand body safety, c) practice assertiveness skills, and d) help children identify whom they can go to for help.
224258556|NCT05615909|RADIATION|Online MR-guided radiotherapy|Online adaptive MR-guided radiotherapy in the Unity MR-linac for localized intermediate risk prostate cancer (60 Gy/20 fx) or low-volume metastatic prostate cancer (36 Gy/6 fx).
224258557|NCT05615909|RADIATION|CT-guided radiotherapy|CT-guided radiotherapy in linear accelerators for patients with high-risk prostate cancer (78 Gy/39 fx), intermediate risk prostata cancer (60 Gy/20 Fx) or having salvage radiotherapy (70 Gy/35 fx)
224258558|NCT06443151|PROCEDURE|Brachial intra-arterial infusion of vasoactive and antioxidant drugs (acetylcholine, nitroprusside, ascorbic acid)|The brachial artery in the non-dominant arm will be catheterized to infuse endothelium-dependent vasodilator acetylcholine, endothelium-independent vasodilator nitroprusside, and antioxidant ascorbic acid at concentrations to have isolated effect in the forearm.
224258559|NCT06443151|PROCEDURE|venous occlusion plethysmography|Whole forearm blood flow will be measured by mercury-strain gauge while venous occlusion is applied to the forearm and hand by rapid-cuff inflation to sub-arterial pressures. Changes in whole forearm blood flow with be measured at baseline, endothelial agonists, and removal of oxidative stress via acorbic acid.
224258560|NCT06443151|DRUG|Acetylcholine|Endothelium-dependent vasodilation will then be assessed by changes in FBF in response to intra-arterial infusions of the endothelial agonist acetylcholine infused at rates of 4.0, 8.0, 16.0 μg/100 mL of forearm tissue/min to generate a dose-response curve.
224258561|NCT06443151|DRUG|Sodium Nitroprusside|Endothelium-independent vasodilation will be assessed by changes in forearm blood flow in response to intra-arterial infusions of sodium nitroprusside at 1.0, 2.0, 4.0 μg/100 mL forearm tissue/min.
224258562|NCT06443151|DRUG|Ascorbic acid|Ascorbic acid will be infused at a constant rate (12 mg/100 mL tissue/min) and maintained at the same rate while the acetylcholine and sodium nitroprusside dose-response curves are repeated.
224258563|NCT06443151|PROCEDURE|venous phlebotomy|Venous blood samples will be collected to measure baseline cardiometabolic characteristics and isolate endothelial cell microvesicles for characterizations and in vitro experiments.
224258564|NCT04311164|OTHER|Questionnaire-based survey|The online questionnaire-based survey is composed of multiple items including pre-coded (multiple choice) questions, dichotomous (yes/no) questions, rating scales and validated questionnaire scales to measure general and diabetes/insulin pump-specific behavior, psychological concepts and preferences.
224258565|NCT04311164|OTHER|No intervention given.|No intervention was given.
224258566|NCT04849390|DRUG|ESO-101|Daily administration in the evening at bedtime for 28 days
224258567|NCT04849390|DRUG|Placebo|Daily administration in the evening at bedtime for 28 days
224258568|NCT03872596|DRUG|Seroquel IR 300mg|Administered during Part A, administered orally BID with water, over 5 days.
224258569|NCT03872596|DRUG|Seroquel IR 25mg|Administered during Part B, as a single, 25mg dose taken with water.
224258570|NCT03872596|DRUG|Quetiapine Formulation A 300mg|Administered during Part A, administered orally BID with water, over 5 days.
224258571|NCT03872596|DRUG|Quetiapine Formulation B 300mg|Administered during Part A, administered orally BID with water, over 5 days.
224258572|NCT03872596|DRUG|Quetiapine Formulation 25mg|Administered during Part B, as a single, 25mg dose taken with water.
224258573|NCT03616405|DRUG|rabeprazole, amoxicillin, tetracycline, furazolidone (only for the first 7 days), colloidal bismuth pectin (for the second 7 days)|Patients will go through a gastroscopy and antimicrobial susceptibility test. Liver and kidney function will be monitored by blood test before and after the treatment. Then, patients will receive a 14-day modified sequential therapy for the Helicobacter pylori eradication. The regimen contains rabeprazole, amoxicillin, tetracycline and furazolidone for the first 7 days, followed by rabeprazole，amoxicillin, tetracycline and colloidal bismuth pectin for the second 7 days.
224258574|NCT04515095|OTHER|Water-only Fasting|Participants consume only water for at least 7 days in an in-patient, residential setting with 24 hour medical supervision.
224258575|NCT01953185|OTHER|Sham manual diaphragm release technique|For this group, light touch at the same anatomical points was done without exerting pressure or traction. Positioning and duration were identical to the IG to perform the sham protocol (Licciardone \& Russo, 2006).
223677302|NCT04662580|DRUG|ARX517|ARX517 is an ADC consisting of a humanized anti-PSMA monoclonal antibody (mAb) (IgG1κ) covalently conjugated to two (2) proprietary microtubule-disrupting toxins referred to as AS269.
223677303|NCT04662580|DRUG|Apalutamide|Oral tablet and will be given once daily by mouth.
223677304|NCT04662580|DRUG|Abiraterone acetate|Oral tablet and will be given once daily by mouth.
223677305|NCT04662580|DRUG|Prednisone|Oral tablet and will be given once daily in metastatic castration-sensitive prostate cancer( mCSPC) and twice daily in metastatic castration-resistant prostate cancer (mCRPC) cohort by mouth.
223677306|NCT03891160|OTHER|3D model of heart|To assess if a 3D printed cardiac model improves visualization of VAD and cannula placement sites in CHD-HF patients as compared to 2D imaging. The investigators will prospectively enroll CHD-HF patients at multiple centers and randomize to group A (3D printed models will be used for pre-VAD planning) or Group B (controls).
223677308|NCT06208150|DRUG|Talquetamab|Talquetamab will be administered as a SC injection.
223773095|NCT06044298|OTHER|procedural sedation|"Participants, adverse events during and after gastrointestinal procedures with sedation administered were observed and recorded. No intervention was performed."
224322601|NCT02690441|BEHAVIORAL|Physical Exercise|Manualised exercise. 15 weekly sessions with instructor, and two weekly unsupervised sessions performed individually.
224322602|NCT02690441|BEHAVIORAL|Placebo control|One follow-up telephone call à 15 minutes each week for 15 weeks. Aims to control for therapist contact in physical exercise condition and total duration of treatment.
223677309|NCT06208150|DRUG|Pomalidomide|Pomalidomide will be administered orally.
223677310|NCT06208150|DRUG|Teclistamab|Teclistamab will be administered as a SC injection.
223677311|NCT06208150|DRUG|Elotuzumab|Elotuzumab will be administered intravenously.
223677312|NCT06208150|DRUG|Dexamethasone|Dexamethasone will be administered either orally or intravenously.
223677313|NCT06208150|DRUG|Bortezomib|Bortezomib will be administered as a SC injection.
224258576|NCT01953185|OTHER|The manual diaphragm release technique|To perform the technique the volunteer was placed in supine position with limbs relaxed. Positioned behind the head of the volunteer, the therapist performed manual contact (pisiform, ulnar edge and the last three fingers) with the underside of the costal cartilage of the 7th, 8th, 9th and 10th rib, and guiding forearms toward the shoulders of the corresponding side. In the inspiratory phase, the therapist gently pulled the points of contact with both hands, in the direction of the head, yet slightly lateral, accompanying the elevation movement of the ribs. During exhalation, the therapist deepened contact toward the inner costal, maintaining resistance throughout the inspiratory phase. In the breaths following, the therapist sought to gain traction and smooth increase in the deepening of contacts. This maneuver was performed in two sets of ten deep breaths, with a one minute interval between them.
224258577|NCT01861535|DRUG|Imiquimod|
223677314|NCT04856410|OTHER|Spaceflight|Exposure to the spaceflight environment on the International Space Station for 2, 6, or 12 months.
223677315|NCT04856410|OTHER|Controls|No intervention
223677316|NCT04557059|RADIATION|Radiotherapy|Participants will receive radiotherapy (RT) with or without optional stereotactic body radiation therapy (SBRT), which will start within 4 weeks after randomization.
223677317|NCT04557059|DRUG|LHRHa|Participants will be administered with LHRHa (example, leuprolide, goserelin, triptorelin acetate) as a 3-monthly depot preparation within 3 days after randomization and the end of Week 12 or as a 6-monthly depot preparation within 3 days after randomization.
223677318|NCT04557059|DRUG|Apalutamide|Participants will receive therapeutic dose of apalutamide 240 mg once daily for 180 Days.
223677319|NCT02876107|DRUG|Carboplatin|Given IV
223677320|NCT02876107|OTHER|Laboratory Biomarker Analysis|Correlative studies
223677321|NCT02876107|DRUG|Paclitaxel|Given IV
223677322|NCT02876107|BIOLOGICAL|Panitumumab|Given IV
223677323|NCT05907954|DRUG|Darovasertib|Oral, potent, selective inhibitor of Protein Kinase C
223677325|NCT05214573|DRUG|Glucagon like peptide 1 receptor agonist|Patients in the data who filled a glucagon-like peptide-1 receptor agonist medication
223677326|NCT05214573|DRUG|Sodium-glucose cotransporter 2 inhibitor|Patients in the data who filled a sodium-glucose cotransporter 2 inhibitor
223677327|NCT05214573|DRUG|Dipeptidyl Peptidase 4 Inhibitor|Patients in the data who filled a dipeptidyl peptidase-4 inhibitor
224258578|NCT01861535|PROCEDURE|Surgery|
224258579|NCT02441621|OTHER|passive leg raising|The passive leg raising maneuver (PLR) involves a leg elevation up to 45° with the trunk in a horizontal position and is performed to induce hemodynamic effects by a volume challenge, turning unstressed blood volume to stressed volume proportional to body size.
224258580|NCT02441621|OTHER|premedication|patients receive premedication with midazolam 7.5 mg p.o.
223677328|NCT05214573|DRUG|Sulfonylurea|Patients in the data who filled a sulfonylurea
223677329|NCT06285318|OTHER|Teclistamab|No Intervention will be administered during the study. Retrospective data analysis using participants medical records collected within this study will be entered into CRF.
223677330|NCT06285318|OTHER|Talquetamab|No Intervention will be administered during the study. Retrospective data analysis using participants medical records collected within this study will be entered into CRF.
223677331|NCT05757973|DRUG|Talquetamab|Talquetamab will be administered subcutaneously.
223677340|NCT00575718|BEHAVIORAL|Hospital Counseling + Nicotine Replacement Therapy. questionaires|"brief face-to-face or telephone tobacco cessation counseling provided by a tobacco cessation specialist prior to admission and during hospitalization (15-20 minutes per encounter)provision of multi-media self-help materials (e.g., Smoking Cessation Guide for Cancer Patients and Their Families) tailored to address cancer-specific issues such as the benefits and barriers of quitting for cancer patients; 3) tobacco cessation pharmacotherapy, unless medically contraindicated (for this study we will standardize the pharmacotherapy as transdermal nicotine patch), and; 4) two brief telephone counseling (15 minutes) sessions completed as seen clinically appropriate by the tobacco cessation specialists. The content of these counseling sessions is based on the patient's smoking status."
223773096|NCT04317300|DRUG|Varenicline|Dosage of 0.5 mg once daily for 3 days, increasing to 0.5 mg twice daily for days 4 to 7, and then to the maintenance dose of 1 mg twice daily for the remaining 11 weeks of treatment.
223773097|NCT04317300|OTHER|brief behavioral therapy|brief behavioral therapy
223773098|NCT04841343|DRUG|Triamcinolone|Triamcinolone in sinus
223677341|NCT00575718|BEHAVIORAL|Hospital Counseling + Nicotine Replacement + Presurgical Scheduled Reduced Smoking, questionaires|Same components of HC+NRT as well as the PS/SRS enhancement.The research team will provide education about scheduled reduced smoking either in person or over the phone. Purpose of the training session, will be audio taped, to prepare participants for daily PDA use over the dur of the scheduled-reduced smoking intervention. Training will demonstrate use of PDA and simulate common technical and procedural issues that might arise during the intervention (e.g., forgetting to record a cigarette or wake time; repeating a day's schedule if needed, prior to the quit date). The simulation will reflect anticipated problems and those identified by users of the PDA. A study helpline number and instructional manual will be provided. A member of the research staff will contact the study participants, once the reduced smoking schedule has begun, to check that the patient understands the schedule and that the PDA is working properly. Estimate patient training with the PDA will require 30 minutes.
223773099|NCT01199081|DRUG|Dronedarone|"Pharmaceutical form: tablet~Route of administration: oral (together with meal)~Dose regimen: 400 mg twice daily"
223773100|NCT04297046|DEVICE|PCA (patient controlled analgesia)|Intravenous Patient-Controlled Analgesia was used for postoperative pain control with a bolus dose of 25 mg Tramadol and a lockout interval of 20 min. The pain was evaluated at different times after the operation, both at rest and movement (Dynamic VAS) at the 0., 2., 6., 12. hours and 24h later. All patients received 1 g iv paracetamol 8 hourly intervals regularly. 75 mg im diclofenac sodium was given as rescue analgesic.
223773101|NCT03383432|DEVICE|Intrauterine device|Copper T 380 A
223773102|NCT03383432|RADIATION|Ultrasound|Transabdominal ultrasound
224258581|NCT02441621|OTHER|intubation and mechanical ventilation|After induction of anesthesia with sufentanil (0.5 µg/kg) and propofol (1.5 mg/kg), orotracheal intubation is facilitated with rocuronium (0.6 mg/kg). Anesthesia is maintained with sufentanil (1 µg/kg/h) and propofol (3 mg/kg/h) and patients are ventilated with an oxygen/air mixture in volume-controlled mode, using a tidal volume of 8 ml/kg related to the ideal body weight. Positive end-expiratory pressure is set at 5 cmH2O.
224258582|NCT02441621|OTHER|central venous catheter|a central venous catheter in the right or left internal jugular vein.
224258583|NCT02441621|OTHER|arterial catheter|Continuous monitoring is performed including electrocardiogram, radial arterial pressure catheter
224258584|NCT02441621|OTHER|transesophageal echocardiography|Before placement of a transpulmonary thermodilution catheter a transesophageal echocardiography (TOE) is performed. TOE is used to detect diastolic dysfunction of the left ventricle and to exclude right ventricular dysfunction.
224258585|NCT02441621|OTHER|transpulmonary thermodilution catheter|In presence of left ventricular dysfunction a transpulmonary thermodilution catheter is placed in the femoral artery and connected to a PiCCO2 monitor (PiCCO2, Pulsion Medical Systems, Munich, Germany).
224258586|NCT03122015|OTHER|Therapeutic clown distraction|The presence of the therapeutic clown, which can adapt his interventions of distraction to the state of health of the patient and the culture of the child, is a multimodal and multi sensorial distraction intervention and can have an impact on health status, procedures, family and multidisciplinary team members. The results of five studies evaluated the effects of distraction by the clown therapy demonstrate a decrease in pain and anxiety in children aged 2 to 17 years, as well as parental anxiety in painful procedures involving needles such as venipuncture.
224258587|NCT04345107|DRUG|SY-009|The subjects were admitted to the clinical trial center two days before the administration period (D-2), fasted for 10 hours overnight on the day before the Administration (D-1), and banned water for 1 hour before the administration. Take sy-009 test drug or placebo immediately before meal (QD is before breakfast, bid is before breakfast and dinner) in the morning of the first day of administration, and deliver it with not more than 200ml warm boiled water. From the day 2 (D2) to the day 7 (D7) before dinner, the oral cavity of the subjects was checked for residual drugs after each administration.
224258588|NCT04345107|DRUG|SY-009 matching placebo|SY-009 matching placebo
224258589|NCT02645409|DRUG|OTL38|OTL38 is a folate analog conjugated with a fluorescent dye that emits light in the near infrared spectrum. This longer wavelength allows for deeper penetration of the fluorescent light through tissues with the potential to better image tumors beneath adipose tissue or deeper into organ parenchyma.
223773103|NCT03383432|PROCEDURE|uterine sounding sparing technique|we will insert intrauterine device without using the uterine sound and we will replace this step by ultrasound before insertion
223773104|NCT03548844|PROCEDURE|local excision|Pathologically verified ypT0-1cN0 rectal cancer patients after local excision are randomized to observation (local excision group) .
224258590|NCT02645409|DEVICE|Intraoperative fluorescence imaging system|
223773105|NCT03548844|PROCEDURE|total mesorectal excision|Pathologically verified ypT0-1cN0 rectal cancer patients after local excision are randomized to complementary rectal excision (total mesorectal excision group).
224258591|NCT06561607|DRUG|TQB2102 for Injection|TQB2102 is a next-generation HER2 Antibody-Drug Conjugate (ADC) drug proposed for patients with HER2 low-expressing breast cancer.
224322603|NCT07176299|PROCEDURE|Unilateral laparoscopic TAP block (0.25% bupivacaine)|Injection of 20 mL 0.25% bupivacaine into the transversus abdominis plane under direct laparoscopic vision.
224322604|NCT07176299|PROCEDURE|Local anesthetic infiltration (0.25% bupivacaine)|Injection of 20 mL 0.25% bupivacaine distributed across trocar insertion sites under laparoscopic guidance.
224322605|NCT07176299|PROCEDURE|Combined TAP block and local anesthetic infiltration (0.25% bupivacaine)|10 mL of 0.25% bupivacaine given as a TAP block and 10 mL administered as local infiltration at trocar sites.
223773106|NCT06263777|OTHER|Nurses training program on early detection of disability|It included four main elements, which are: a booklet defining different disabilities, a list of the guidelines for early detection, a guide for family guidance for families of children with disabilities, a monitoring and follow-up form for 8 cases of children with disabilities). The program consisted of twelve training sessions with a total of 48 hours (4 hours per session) and was based on the techniques of lecture, dialogue, working groups, cooperative learning techniques and participatory learning
223677352|NCT06532032|DRUG|Amivantamab|Amivantamab will be administered as IV infusion.
223677353|NCT06532032|DRUG|Docetaxel|Docetaxel will be administered as IV infusion.
223677357|NCT05488314|DRUG|Capmatinib|Capmatinib will be administered orally.
223677358|NCT05488314|DRUG|Amivantamab|Amivantamab will be administered as IV infusion.
223677360|NCT05912517|DRUG|Nipocalimab|Nipocalimab will be administered as an intravenous infusion.
223677361|NCT05912517|DRUG|Placebo|Placebo will be administered as an intravenous infusion.
223677366|NCT06250322|DEVICE|Intervention|No study treatments will be administered during this study. However, data will be collected from medical records of patients who have been treated with the subject device of this study.
223677368|NCT03829787|DEVICE|Eye tracking|Subjects will be assessed for attentional biases, reward sensitivity, and cognitive control using eye tracking technology
223677369|NCT02486718|DRUG|Atezolizumab|Participants will receive atezolizumab (1200 mg IV) Q3W for 16 cycles (cycle length=21 days).
223677370|NCT02486718|DRUG|Cisplatin|Participants will receive cisplatin 75 milligrams per square meter (mg/m\^2) IV on Day 1 of up to four 21-day cycles.
223677371|NCT02486718|DRUG|Vinorelbine|Participants will receive vinorelbine 30 mg/m\^2 IV on Days 1 and 8 of each of the four 21-day cycles.
223773107|NCT06367374|DRUG|Sonrotoclax|"Participants receive zanubrutinib orally 160mg bid from start of Cycle 1, and in combination with sonrotoclax (SZ) from Cycle 4 onwards at increasing doses until 320mg daily target dose is reached and continuing for at least 12 cycles (each cycle is 28 days).~Participants with uMRD and PR/CR by the end of Cycle 15 will stop SZ treatment, others will continue to receive SZ for another 12 cycles and stop SZ if uMRD and PR/CR.~Participants will receive sonrotoclax up to 2 years, and receive zanubrutinib for those with MRD-positive by then."
223773108|NCT06367374|DRUG|Zanubrutinib|"Participants receive zanubrutinib orally 160mg bid from start of Cycle 1,Participants with uMRD and PR/CR by the end of Cycle 15 will stop SZ treatment, others will continue to receive SZ for another 12 cycles and stop SZ if uMRD and PR/CR.~Participants will receive sonrotoclax up to 2 years, and receive zanubrutinib for those with MRD-positive by then."
223773109|NCT03527108|DRUG|Nivolumab|The treatment will be given on a 28-day cycle, with doses of nivolumab and ramucirumab given on days 1 and 15. The dose of nivolumab will be fixed at 240 mg. Nivolumab should be administered first, followed by premedication, and then ramucirumab. Ramucirumab should be administered approximately 30 minutes after premedication
223677372|NCT02486718|DRUG|Docetaxel|Participants will receive docetaxel 75 mg/m\^2 IV on Day 1 of each of the four 21-day cycles.
223677373|NCT02486718|DRUG|Gemcitabine|Participants will receive gemcitabine 1250 mg/m\^2 IV on Days 1 and 8 of each of the four 21-day cycles.
223677374|NCT02486718|DRUG|Pemetrexed|Participants will receive pemetrexed 500 mg/m\^2 IV on Day 1 of each of the four 21-day cycles. Pemetrexed will be administered only in participants with non-squamous cell NSCLC.
223677375|NCT04722146|DRUG|Teclistamab|Participants will receive teclistamab.
223677376|NCT04722146|DRUG|Daratumumab|Participants will receive daratumumab.
223677377|NCT04722146|DRUG|Pomalidomide|Participants will receive pomalidomide.
223677378|NCT04722146|DRUG|Lenalidomide|Participants will receive lenalidomide.
223677379|NCT04722146|DRUG|Bortezomib|Participants will receive bortezomib.
223677380|NCT04722146|DRUG|Nirogacestat|Participants will receive nirogacestat.
223677381|NCT05908734|DRUG|Cetrelimab|Cetrelimab will be administered as IV infusion.
223677382|NCT05908734|DRUG|Amivantamab|Amivantamab will be administered as IV infusion.
223677383|NCT05945927|DRUG|Trastuzumab emtansine|Trastuzumab emtansine will be administered as per local clinical practice and local labeling.
223677384|NCT05652335|DRUG|JNJ-79635322|JNJ-79635322 will be administered as SC injection.
224322606|NCT07177131|BEHAVIORAL|Relative Dehydration Protocol|Participants will abstain from water intake for 12 hours prior to the study visit. Food is allowed, but fluid intake is limited to a maximum of 250 ml until 20:00 h on the previous evening. Eye measurements will be performed in the morning (8-10 h).
223677389|NCT06145581|BEHAVIORAL|Supportive Care (home-based physical activity)|Receive health coaching
223677390|NCT06145581|OTHER|Exercise Intervention|Participate in home-based physical activity
223677391|NCT06145581|OTHER|telephone interview|Participate in a telephone interview
223677392|NCT06145581|OTHER|Remote Monitoring|Undergo remote monitoring
223677393|NCT06145581|PROCEDURE|Patient Monitoring|Monitor physical activity
223677394|NCT06145581|OTHER|Questionnaire Administration|Ancillary studies
223677395|NCT06145581|OTHER|Electronic Health Record Review|Ancillary studies
223677400|NCT04119050|DRUG|M281|M281 injection administered as intravenous infusion
223677401|NCT04119050|DRUG|Placebo|Placebo administered as intravenous infusion
223677402|NCT03523442|DRUG|Apalutamide|The participants will receive apalutamide 240 mg once daily orally.
223773110|NCT03527108|DRUG|Ramucirumab|The treatment will be given on a 28-day cycle, with doses of nivolumab and ramucirumab given on days 1 and 15. The dose of ramucirumab will depend upon the patient weight as noted below. Nivolumab should be administered first, followed by premedication, and then ramucirumab. Ramucirumab should be administered approximately 30 minutes after premedication
223773111|NCT01256775|DRUG|NCX-4016|NCX4016 800 mg b.i.d. for 6 months on top of aspirin 100 mg o.d.
223773112|NCT01256775|DRUG|NCX4016 placebo|NCX4016 placebo b.i.d. for 6 months
223773113|NCT05105269|OTHER|Treatment from a physiotherapist|Any treatment provided by a physiotherapist e.g. exercise, advice and massage
224258592|NCT06561607|DRUG|Chemotherapy drug (Capecitabine/Paclitaxel/Albumin Paclitaxel)|"Based on each patient's condition and previous treatment history, the investigator will select one of the chemotherapy drugs for treatment.~* Capecitabine: 1000-1250 mg/m2 twice daily, administered consecutively on day 1-14, 21 days as a treatment cycle.~* Paclitaxel: 175 mg/m2, IV infusion, administered Day1 per cycle, 21 days as a treatment cycle. OR 80 mg/m2 by IV infusion administered weekly.~* Albumin Paclitaxel: 260 mg/m2, IV infusion, administered every cycle of Day1 for 21 days as a treatment cycle. 100 mg/m2 or 125 mg/m2, IV infusion, administered every cycle of Day 1 and Day 8 for 21 days as a treatment cycle; or Day 1, Day 8, and Day 15 administered every cycle for 28 days as a treatment cycle."
224258593|NCT05747807|DEVICE|Percutaneous intradiscal radiofrequency treatment|using heat created by radiofrequency electrode to destroy the nociceptive pain fibres and enhance the structural integrity of the disc
224258594|NCT00886522|PROCEDURE|Intrabone cord blood infusion|"Myeloablative conditioning regimen (MAC):~i.v. Busulfan 12.8 mg/kg, Cyclophosphamide 120 mg/kg, ATG-Fresenius 30 mg/kg~Reduced intensity conditioning regimen (RIC):~Tiothepa 10 mg/kg, Fludarabine 100 mg/kg, Cyclophosphamide 100 mg/kg, ATG-Fresenius 30 mg/kg~GVHD prophylaxis:~Cyclosporine 1 mg/kg since day -7 to +120, Mycophenolate 15 mg kg x 2 since day +1 to +27"
224258595|NCT04440436|DRUG|IM19 CAR-T Cells|"IM19 CAR-T cells~Drug: Fludarabine~Two days before cell infusion, all patients will be treated with fludarabine for 3 days~Drug: Cyclophosphamide~Two days before cell infusion, all patients will be treated with Cyclophosphamide for 3 days"
224322607|NCT07177131|BEHAVIORAL|Hyperhydration Protocol|Participants will consume 2 liters of water within 4 hours prior to the study visit. Eye measurements will be performed in the morning (8-10 h).
224258596|NCT03419403|DRUG|Steroid eye drops|Solution, eye drop
224258597|NCT03419403|DRUG|Vasoconstrictor eye drops|Solution, eye drop
224258598|NCT03419403|OTHER|Cold compress|Cold compress
224258599|NCT03419403|DRUG|Ophthalmic steroid ointment|Ointment
224258600|NCT03419403|DRUG|Depatuxizumab mafodotin|During the Chemoradiation Phase, participants were to receive depatuxizumab mafodotin at 2.0 mg/kg IV infusion over 30 - 40 minutes once every 2 weeks (Day 1 of Weeks 1, 3, and 5 of the 6-week regimen). During the Adjuvant Therapy Phase, participants were to receive depatuxizumab mafodotin at 1.25 mg/kg on Day 1 (± 2 days) and Day 15 (± 2 days) of each 28-day cycle as a 30 - 40 minute infusion for 12 cycles.
223677405|NCT04936308|DRUG|Guselkumab|Participants will receive guselkumab as SC injection.
223677406|NCT04936308|DRUG|Placebo|Participants will receive matching placebo as SC injection.
223677416|NCT06465485|DRUG|Benralizumab|Severe eosinophilic asthma taking medium-high dose ICS/LABA with/without LTRAs, LAMAs will be enrolled into this single arm treatment.
223677417|NCT05901649|DRUG|Apalutamide|No interventions will be administered as a part of this study. Participants will receive apalutamide as per their routine clinical practice.
224258601|NCT03419403|DRUG|Temozolomide|Temozolomide was to be administered according to the local standard of care. Duration of treatment was to be 6 - 12 cycles in the adjuvant phase and at the discretion of the investigator as supported by local standard of care.
224258602|NCT03419403|RADIATION|Radiation|Radiation therapy treatment planning and administration was to be performed as per local institutional guidelines.
224258603|NCT04179058|OTHER|Follow-up|Clinical data, radiological data and laboratory tests follow-up
223677418|NCT05901649|DRUG|Enzalutamide|No interventions will be administered as a part of this study. Participants will receive enzalutamide as per their routine clinical practice.
223677419|NCT03661307|DRUG|Decitabine|Given IV
223677420|NCT03661307|DRUG|Quizartinib|Given PO
223677421|NCT03661307|DRUG|Venetoclax|Given PO
224258604|NCT04407403|BEHAVIORAL|Tai Chi tailored for lowering blood pressure (PRESSURE)|PRESSURE Tai Chi routine consisted of eight forms following Yang style. PRESSURE was tailored for the targeted health outcome of BP in consultation with the professional, certified Tai Chi instructor and an experienced physical therapist. Specifically, investigators tailored PRESSURE to emphasize slow, deep breathing and relaxation by utilizing Tai Chi movements that: 1) were slow and smooth; 2) without break or pause; and 3) had minimal muscular force and exertion. Investigators included the following eight forms in PRESSURE: 1) Begin Tai Ji Quan; 2) Part the Horse's Mane; 3) Brush Knee and Push; 4) Cloud Hands; 5) Open and Close; 6) Part the Grass; 7) Single Whip; and 8) Finish Tai Ji Quan.
224322608|NCT07160205|BIOLOGICAL|ULSC (1.5 x 10^8 cells/dose)|Allogeneic umbilical-cord lining stem cells (ULSC) are cryopreserved and supplied in vials to be thawed and prepared for infusion at point of use. Each dose of 1.5 x 10\^8 ULSC will be added into 250 sterile saline IV bag for infusion (total volume of 260 mL volume).
224322609|NCT07160205|BIOLOGICAL|Placebo (no cells)|The Placebo will be 250 ml sterile saline with vehicle (total volume of 260 mL) IV bag for infusion.
224322610|NCT07177846|BEHAVIORAL|LiveWell: An Adapted Dialectical Behavioral Therapy Skills Training Program|LiveWell: Adapted DBT Skills Training for Patients with Metastatic Lung Cancer
223773114|NCT05487924|OTHER|SVV-GDHT|GDHT guided by SVV using Flotra/Vigileo monitor
223773115|NCT05487924|OTHER|O2ER-GDHT|GDHT guided by O2ER
223773116|NCT05487924|OTHER|conventional care|conventional fluid therapy without GDHT
223773117|NCT04896957|BEHAVIORAL|Interview|Face to face semi-directed interviews about perceptions, representations and experiences of Covid-19 vaccination, including six opened-questions
224258605|NCT04407403|BEHAVIORAL|Tai Chi tailored for improving balance (BALANCE)|BALANCE Tai Chi routine consisted of eight forms following Yang style. BALANCE was tailored for the targeted health outcome of balance in consultation with the professional, certified Tai Chi instructor and an experienced physical therapist. Specifically, investigators tailored BALANCE to provide moderate to high levels of challenge to balance control by emphasizing movement principles (e.g., consciously control weight shifting during multi-directional stepping), and integrating Tai Chi movements that: 1) reduced the base of support; 2) moved the center of gravity; and 3) improved lower-extremity strength. Investigators included the following eight forms in BALANCE: 1) Begin Tai Ji Quan; 2) Roll the Ball; 3) Kick with Heel; 4) Repulse the Monkey; 5) Gather the Earth's Qi; 6) White Crane Spread Wing; 7) Fairy Weaves the Shuttle; and 8) Finish Tai Ji Quan.
224258606|NCT04290858|DRUG|Nitric Oxide|Nitric Oxide (NO) will be delivered together with the standard of care for a period of 20-30 minutes 2 times per day for 14 consecutive days from time of enrollment. Targeted concentration will have a tidal oscillation between 100 and 300 ppm, in order to maintain an average inhaled concentration from 140 to 180 ppm. The gas will be delivered through a CPAP circuit ensuring an end-expiratory pressure between 2 and 10 cmH2O or trough a non-rebreathing mask without positive end expiratory pressure, depending on the clinical needs of the patient.
224258607|NCT04825847|DEVICE|BIS monitor|Information provided by the BIS (Medtronic, Canada) monitor will guide the volatile anesthetic administration in the EEG-guided group to maintain a BIS value between 40 and 60, a Suppression Ratio (SR; % of time with suppressed brain electrical activity) at 0% or the closest, a direct EEG display without any suppression time and a spectrogram (DSA or density spectral array) with most of the EEG wave frequency within the Alpha (8-12Hz), Theta (4-8Hz) and Delta (0.5-4Hz) frequencies.
224258608|NCT04825847|OTHER|Control group|In the standard care group, the age-adjusted Minimum Alveolar Concentration (MAC-age) of sevoflurane will be kept at \[0.8-1.2\] MAC.
224258609|NCT02525445|PROCEDURE|acupuncture|acupuncture was administered (sharp needles diameter 0.25 x length 40 mm) bilaterally to the acupuncture point pericardium six (PC6) between the tendons of palmaris longus and flexor carpii radialis at two body-inches (one body-inch approximately 1.5 cm) proximal to the wrist at 0.5 body-inch depth. The therapists manually manipulated the needles three times per treatment by rotating, thrusting or lifting the needles. When the participant reported a sense of numbness or soreness and the therapist noted a minimal muscular contraction around the needle.
224258610|NCT02525445|PROCEDURE|sham acupuncture|"sham acupuncture was administrated (blunt needles diameter 0.25 x length 40 mm) bilaterally to a non-acupuncture point four body-inch proximal and one body-inch radial from the PC6 point, with the telescopic non-penetrating Park´s sham needle \[20\]. Park's credible needle looks identical to a real needle but glides upward into its handle, giving an illusion of penetration. A marking tube, identical for both acupuncture types, held the sham needle in place. The therapists manipulated the needles a few seconds three times per session until the needles touched the skin, but no needle sensation occurred, and then lifted the needles up from the skin."
224258611|NCT02525445|PROCEDURE|positive communication|"During the acupuncture treatment the therapist conveyed, at least three out of several positive statements, such as: Many acupuncture studies have shown excellent results concerning relaxation effects, Brain imaging studies show that acupuncture treatments affect areas that affect pulse, blood-pressure and muscle tension."
224258612|NCT02525445|PROCEDURE|neutral communication|"During the acupuncture treatment the therapists conveyed, at least three out of several neutral statements, such as: During treatment you will just lie down and rest and I will not talk so much to you, We don´t really know if acupuncture is a good method for relaxation effects; thus we need to perform this study,"
224258613|NCT02828449|BEHAVIORAL|therapeutic education program|
224258614|NCT03468764|PROCEDURE|Vigileo monitoring during lung recruitment maneuver|"Standard monitoring parameters, invasive blood pressure and hemodynamic values (SVV and CO, through Vigileo device) will be monitored. With the patient in a supine position and as SVV reaches a value of 12-15%, a LRM is performed, consisting in the application of 30 cm H2O continuous positive airway pressure for 30 seconds.~The alterations in the above mentioned parameters will be registered before and after the maneuver.~The same procedure will be performed after a 8 ml/kg crystalloids fluid challenge, as soon as SVV reaches the value of 10%."
224258615|NCT03429725|OTHER|Online prime (statements writing)|Participants to write statements describing themselves or their similarities to their community.
224258616|NCT03429725|OTHER|Online prime (circling)|Participants to circle either pronouns denoting themselves or pronouns denoting others.
223677422|NCT05823142|BEHAVIORAL|CB Sleep|The CB-sleep intervention is a cognitive behavioral intervention guided by principles and practices from motivational interviewing and the psychology of behavior change, primarily drawing on self-efficacy and action planning theory. The goals of CB-sleep are for participants to achieve adequate sleep duration (7-9 hours per night), adequate sleep efficiency (≥ 85%), and regular sleep timing (\<60-minute differences in bed and wake times). The intervention components include improving sleep knowledge (hygiene), developing a nightly routine, addressing competing activities, modifying environmental conditions, lifestyle (avoiding caffeine and vigorous exercise before bed), technology (limiting or avoiding screens for at least one hour before bed), basic stress-management (progressive muscle relaxation and guided imagery), and self- monitoring.
223677423|NCT05327114|DRUG|Nipocalimab|Nipocalimab will be administered intravenously.
223677424|NCT05327114|DRUG|Placebo|Placebo will be administered intravenously.
223677425|NCT04273945|DRUG|Macitentan 10 mg|Participants will receive macitentan 10 mg film-coated tablets orally.
223677426|NCT04273945|DRUG|Macitentan 37.5 mg|Participants will receive macitentan 37.5 mg film-coated tablets orally.
223677427|NCT04273945|DRUG|Macitentan 75 mg|Participants will receive macitentan 75 mg film-coated tablets orally.
223677428|NCT04273945|DRUG|Placebo|Participants will receive matching placebo film-coated tablets orally.
223677429|NCT03642639|DEVICE|MICRUSFRAME and GALAXY coils|MICRUSFRAME and GALAXY Coils
223677430|NCT04883619|OTHER|Placebo|Placebo will be administered intravenously.
224258617|NCT03429725|OTHER|Online prime (Sumarian Warrior)|Participants read a passage which described the factors that led to his success in a war.
224258618|NCT03429725|OTHER|Online prime (all)|Participants wrote statements, circled pronouns, as well as read the Sumarian Warrior passage.
224258619|NCT03466866|BEHAVIORAL|PREVENT|Community Health Workers (CHWs), who are race-concordant with participants, will: 1) deliver in-home DM education to increase participants' knowledge and skills; 2) use DM-specific Behavioral Activation to improve DM self-care; and 3) facilitate telehealth visits with the participant's primary care physician (PCP) and a DM nurse educator to increase access to care.
224322611|NCT07177573|OTHER|Virtual Reality|The demographic information of the participants will be collected through face-to-face interviews. Pain and comfort levels will be assessed using the Visual Analog Scale (VAS) prior to the intervention. Additionally, anxiety levels will be measured with the Spielberger State-Trait Anxiety Inventory, and vital signs will be recorded. Patients included in the study will be informed about the use of virtual reality (VR) goggles and introduced to the videos that will be viewed. During the Continuous Passive Motion (CPM) application, patients will be positioned in a semi-Fowler's position with a pillow placed under the head for support. Through virtual reality, patients will watch the video Forest Walk along the Middle Fork Snoqualmie River Trail with Relaxing Sounds and the accompanying sounds will be delivered through headphones integrated into the goggles.
223677431|NCT04883619|DRUG|Nipocalimab|Nipocalimab dose 1 and dose 2 will be administered intravenously.
223677432|NCT04883619|DRUG|Standard-of-care treatment|Standard-of-care treatment including MMF or MPA and glucocorticoids will be administered intravenously through Week 52.
223773118|NCT06168643|OTHER|Core stability|Physical therapy interventions will include core stability exercises which will be demonstrated and will be checked if they are being performed correctly. The exercises guided shall be performed 3 times daily and logbook will be provided to keep the record of exercise program.
223773119|NCT06168643|OTHER|Core stability with pregnancy support belt|Participants will receive same information and exercises as those in Group A. they will also receive pregnancy support belt. The logbook will be provided to keep the record of hours the belt has been worn along with exercise record.
223773120|NCT00337649|DRUG|Epothilone D|≤100 mg/m\^2 intravenously (iv) on days 1, 8 and 15 once every 4 weeks
223773121|NCT00337649|DRUG|Herceptin|4mg/kg iv loading dose, followed by 2mg/kg iv weekly
223773122|NCT01312116|BEHAVIORAL|iCBT|Internet-delivered cognitive behavior therapy, 8 weeks
223773123|NCT01312116|BEHAVIORAL|iPDT|Internet-delivered psychodynamic therapy, 8 weeks
223773124|NCT00938431|DRUG|Lacosamide|Lacosamide oral solution (syrup) 10 mg/mL or 15 mg/mL
223773125|NCT03444857|DEVICE|Continuous positive airway pressure|The optimal continuous positive airway pressure (CPAP, AutoSet S9, ResMed, Sydney, Australia) settings will be determined during 1-2 nights within 7 days after pPCI.
223773126|NCT05031624|DRUG|CDX-0159|Single subcutaneous dose of one of four dosages of CDX-0159
223773127|NCT05031624|DRUG|Normal saline|Single subcutaneous dose of normal saline
223773128|NCT03309436|DRUG|Clomiphene Citrate protocol|Take CC 100mg/d at the same time with Gn until hCG injection.
224258620|NCT03466866|BEHAVIORAL|EUC (Enhanced Usual Care)|In-home diabetes education with no goal setting or telehealth visits
224258621|NCT00060697|BEHAVIORAL|Adolescent sexual activity education for mothers|
224258622|NCT04926480|PROCEDURE|low and high flow Anesthesia|comparison of hemodynamic changes in low and high flow anesthesia groups
224258623|NCT02068820|DEVICE|ISB dye and standard white light imaging|Sentinel lymph node mapping utilizing the da Vinci surgical system and ISB dye with standard white light imaging.
224258624|NCT02068820|DEVICE|ICG dye and FireFly fluorescence imaging|Sentinel lymph node mapping utilizing the da Vinci surgical system with ICG dye and FireFly fluorescence imaging.
224258625|NCT02089685|BIOLOGICAL|Pembrolizumab|IV infusion
224258626|NCT02089685|BIOLOGICAL|PegIFN-2b|Subcutaneous infusion
224258627|NCT02089685|BIOLOGICAL|Ipilimumab|IV infusion
224322612|NCT07178353|OTHER|Bedrest|5 days of strict bedrest. Participants are allowed to sit up in bed, but will perform any bathing or bathroom activities in a wheelchair.
224258628|NCT03965377|BEHAVIORAL|Home Safety Hero Computer Game|Home Safety Hero computer game presents players with virtual rooms in a home where vilians have planted safety risks. It involves the player taking the role of a body guard for a child. It has three phases: 1. Identifying risks in a set of rooms (e.g., burn, falling, suffocation, poisoning); 2. Identifying risks and then selecting a resolution to reduce the risk or eliminate it entirely; and 3. Identifying risk when faced with distractions typical to home environments (e.g., phone ringing, fire engine siren sounds, a moving child).
224258629|NCT00318461|DRUG|liraglutide|0.6 mg for s.c. (under the skin) injection.
224258630|NCT00318461|DRUG|metformin|1.5-2.0 g tablets
224258631|NCT00318461|DRUG|glimepiride|4 mg tablets
224258632|NCT00318461|DRUG|placebo|Glimepiride placebo 1 mg and 2 mg tablets
224258633|NCT00318461|DRUG|placebo|Liraglutide placebo 1-3 mL for s.c. (under the skin) injection
224258634|NCT00318461|DRUG|liraglutide|1.2 mg for s.c. (under the skin) injection
224258635|NCT00318461|DRUG|liraglutide|1.8 mg for s.c. (under the skin) injection
224258636|NCT00863083|BEHAVIORAL|Multifamily weight management intervention|8 week multifamily group weight management intervention incorporating behavioral health, nutrition, and activity disciplines.
224258637|NCT03372876|DIETARY_SUPPLEMENT|Protein and carbohydrate supplementation|Participants were randomly assigned to protein-carbohydrate group (PC) (n=17), that ingested 30 g of whey protein immediately after exercise and 30 g of maltodextrin in the afternoon; and to carbohydrate-protein group (CP) (n=17), that ingested 30 g of maltodextrin immediately after exercise and 30 g of whey protein in the afternoon. Both groups performed the same resistance training protocol in the morning, 3 times a week, at 70% of 1-maximum repetition (1-RM) during 8 weeks.
224258638|NCT05134220|DIAGNOSTIC_TEST|Serum Calcium|"* Serum calcium level.~* Serum phosphorus level. will be measured to all study population"
223677445|NCT06848491|BEHAVIORAL|AYA WELL Intervention|Behavioral weight management intervention for adolescent and young adult cancer survivors with digital tools, smartphone web app behavioral program, text messages, and expert-guided closed social networking group for peer support.
224258639|NCT00171886|DRUG|Octreotide|
224258640|NCT04940494|OTHER|collection of data|collection of data for all Obstetrical Anal Sphincter Injury women (score of quality of life, experimenting anal incontinence...)
224258641|NCT00111098|DRUG|Darbepoetin Alfa|QM administration for 28 weeks, adjusted as necessary to maintain Hb between 11.0 - 13.0 g/dL PFS concentrations: 20, 30, 40, 50, 60, 80, 100, 150, 200 and 300 mcg.
224258642|NCT01372345|DRUG|CIPRO®XR|Ciprofloxacin 1000 mg Tablets Dr. Reddy's Laboratories Limited
224258643|NCT02338583|DEVICE|Echelon Flex™ 45 and 60 Powered ENDOPATH® Stapler Articulating Endoscopic Linear Cutter|
224258644|NCT04134091|DRUG|LPCN 1144 Formulation A|Oral LPCN 1144 Formulation A capsule, total daily dose of 450 mg testosterone undecanoate administered as 225 mg testosterone undecanoate twice daily (BID).
224258645|NCT04134091|DRUG|LPCN 1144 Formulation B|Oral LPCN 1144 + d-alpha tocopherol total daily dose of 450 mg testosterone undecanoate + 476 mg d-alpha tocopherol administered as 225 mg testosterone undecanoate + 238 mg d-alpha tocopherol BID
224258646|NCT04134091|DRUG|Placebo|Oral matching placebo capsule administered as BID
224258647|NCT04673721|DIETARY_SUPPLEMENT|Fortified eggs|Average 12 eggs consumed per week
224258648|NCT04673721|BEHAVIORAL|Intermittent fasting|16-hour fast and then an 8-hour nutritional window with aim for energy needs to be consumed during an 8 hour eating window (e.g., 11 am - 7 pm) with fasting for 16 hours (e.g., 7 pm - 11 am the next day).
224258649|NCT04673721|DIETARY_SUPPLEMENT|Non-egg supplemented|2 or less eggs consumed per week
224258650|NCT04673721|BEHAVIORAL|Usual care diet|Consistency with current diet without consideration of intermittent fasting
224258651|NCT03206008|DRUG|Magnesium Sulfate|
224258652|NCT03206008|DRUG|Normal saline|Placebo
223677446|NCT06848491|BEHAVIORAL|Self-Guided|Self-guided intervention with digital tools, periodic informational support, and moderated social networking group for peer support.
223677450|NCT06852222|DRUG|Bleximenib|Bleximenib will be administered orally.
223677451|NCT06852222|DRUG|Venetoclax (VEN)|VEN will be administered orally.
223677452|NCT06852222|DRUG|Azacitidine (AZA)|AZA will be administered intravenously or subcutaneously.
223677453|NCT06852222|DRUG|Placebo|Placebo will be administered orally.
223677457|NCT00572481|PROCEDURE|Axillary Reverse Mapping|During surgery, the technetium-99m sulfur colloid will be injected into the breast and the blue dye injected (if the patient is not allergic and it is not required to locate the SLN) in the patient's ipsilateral upper arm. The lymph node biopsy and/or dissection will be performed by the surgeon, according to standard practice.
223677459|NCT04803214|DEVICE|ReActiv8|Market-approved ReActiv8 device implanted
223677460|NCT05695846|DEVICE|externally applied cricoid cartilage pressure|
223677462|NCT06120491|DRUG|Saruparib|Oral
223677463|NCT06120491|DRUG|Placebo|Oral
223677464|NCT06120491|DRUG|Abiraterone Acetate|Oral
223677465|NCT06120491|DRUG|Darolutamide|Oral
223677466|NCT06120491|DRUG|Enzalutamide|Oral
223773129|NCT03309436|PROCEDURE|Procedure|When a dominant follicle diameter over 14mm or serum E2 over 350pg/ml, use GnRH-ant 0.25mg/d, until hCG injection.
223773130|NCT01146938|DRUG|fimasartan|single administration of fimasartan 120mg
223773131|NCT01146938|DRUG|fimasartan|single administration of fimasartan 120mg
223773132|NCT06247163|RADIATION|PET based Raditherapy boost|An Interim PET CT will be performed. If there is residual vital tumor, a higher radiation dose will be applied.
223773133|NCT04390750|BEHAVIORAL|Care Partner-Assisted Intervention|Tailored teaching and coaching
223773134|NCT01529645|BIOLOGICAL|Acellular pertussis vaccine|Acellular pertussis (aP) vaccine was administered with different antigen doses intramuscularly in the upper deltoid region of the subject's non-dominant arm.
223773135|NCT01529645|BIOLOGICAL|Tetanus, reduced diphtheria, and acellular pertussis vaccine (adsorbed)|Tetanus, reduced diphtheria, and acellular pertussis (TdaP) vaccine was administered with different antigen doses intramuscularly in the upper deltoid region of the subject's non-dominant arm.
223773136|NCT01529645|BIOLOGICAL|Licensed TdaP booster vaccine|Licenced TdaP booster vaccine was administered intramuscularly in the upper deltoid region of the subject's non-dominant arm.
223773137|NCT01529645|BIOLOGICAL|Diphtheria and tetanus vaccine (adsorbed, reduced antigen content, Germany)|To ensure all subjects receive a tetanus and diphtheria booster vaccination, an injection was administered on Study Day 30, one month after the administration of the investigational vaccine.
223773138|NCT01529645|OTHER|Saline solution|Subjects received one injection of saline solution at one month after vaccination.
223773139|NCT03913143|DRUG|sepofarsen|RNA antisense oligonucleotide for intravitreal injection
223773140|NCT03913143|OTHER|Sham|Sham-Procedure (no experimental drug administered)
223773141|NCT03882619|BEHAVIORAL|Calligraphy|Participants will (1) detect the emotion him or herself; (2) do the calligraphy activity by writing positive terms (e.g., peace, life); (3) detect emotion again; (4) share the experience with group members.
223773142|NCT03411226|PROCEDURE|re-TREPP|repeated hernia repair via the TREPP technique
223773143|NCT01491477|DEVICE|INFUSE™ Bone Graft/CORNERSTONE-SR™ /ATLANTIS™|Cornerstone-SR™ allograft bone containing recombinant human Bone Morphogenetic Protein (rhBMP-2) soaked into an absorbable collagen sponge (ACS) used in conjunction with ATLANTIS™ anterior cervical plate system.
223773144|NCT01491477|DEVICE|Autogenous bone/CORNERSTONE-SR™ /ATLANTIS™|Cornerstone-SR™ allograft bone packed with autogenous iliac crest bone graft used in conjunction with ATLANTIS™ anterior cervical plate system.
224258653|NCT06177418|PROCEDURE|Transumbilical laparoscopic appendectomy + Glove finger technique|Ssince the appendix becomes infected when it is removed from the umbilicus, the infected appendix contacts the edge of the incision during release, thus contaminating the incision and causing postoperative wound infection. Additionally, in the experimental, to prevent this wound infection, after the appendix is taken out through the umbilical incision, the appendix is placed inside the glove finger, thus preventing the appendix from touching the wound during its release. This reduces wound infection in the postoperative period.
224258654|NCT06177418|PROCEDURE|Standard transumbilical laparoscopic appendectomy|Standart transumbilical laparoscopic appendectomy
223773145|NCT03855215|DIAGNOSTIC_TEST|ACTIM CRP Rapid Test (Medix, Biochemica)|The implementation of CRP point of care tests will be conducted at commune health centres (CHCs), the primary access point for public health services in Vietnam. In the intervention CHCs, healthcare workers will be trained on the use and interpretation of CRP testing in ARI. healthcare workers can decide to follow the test results or not.
223773146|NCT02782650|OTHER|survey and interview|"all participants: survey on prenatal counseling and treatment decisions at the limits of viability.~a selection of participants: focus group interviews to further perform in-depth exploration of prenatal counseling preferences"
223773147|NCT05491707|OTHER|Music|Patients will choose a genre of music from the following list; pop, gospel, classical, jazz, and soul, at the preoperative visit. This will be played on disposable ear phones at a self-selected volume for the duration of the surgical procedure.
223773148|NCT03394014|PROCEDURE|sciatic nerve block|blocking sciatic nerve either at the subgluteal area or the popliteal region for effective anesthesia and analgesia during below knee amputation
223773149|NCT01842009|DEVICE|High Definition transcranial Direct Current Stimulation|
223773150|NCT01807130|OTHER|Automated HF/EP Referral|Patients in the intervention arm without compelling contraindications to HF therapies will be referred automatically to specialists in HF or electrophysiology (EP) with recommendations to consider those therapies that are not in compliance with guidelines.
224258655|NCT06560853|OTHER|Comprehensive School Health Programme|"Combination intervention which consists of:~* Upgrading sanitation facilities and constructing a 'health room' in the school~* Health teacher training: 5-10 teachers per school are recruited and trained for two weeks to become School Health Workers (SHWs) by Healthy Learners~* The SHWs: (1) deliver education on health and good sanitation and hygiene (2) coordinate with local clinics to deliver preventive care (e.g. school deworming and vitamin A supplementation); (3) assess sick students in the health room with a tablet-based clinical decision support system (CDSS); (4) treat sick students in the health room for some conditions (malaria, diarrhoea, schistosomiasis, pneumonia, conjunctivitis) or (5) refer to the health facility for treatment; (6) monitor absence of learners~* Referral: learners referred by SHWs are given a referral form by the SHW, which contains information about symptoms and suggested diagnosis by the CDSS. The learners are prioritised in the local clinic."
224258656|NCT06560853|OTHER|Deworming and vitamin A supplementation delivery|Schools implement the government policy of distributing deworming drugs and vitamin A supplementation to learners twice a year. Additional support from Healthy Learners ensures reliable delivery.
224258657|NCT01908556|DRUG|Letrozole|
224258658|NCT01924377|PROCEDURE|standard circumferential pulmonary vein isolation by radiofrequency ablation catheter|To perform circumferential pulmonary vein isolation left and right circumferential lines will be created with contiguous focal radiofrequency lesions at a distance \>5 mm from the pulmonary vein ostia. Two additional ablation lines will be performed in the posterior left atrium (LA), and an ablation line will be placed in the mitral isthmus to prevent postablation LA flutter. Patients with a history of typical atrial flutter will also undergo cavotricuspid isthmus ablation.
224322613|NCT07185581|DIAGNOSTIC_TEST|Impulse Oscillometry|Impulse Oscillometry (IOS) is a simple, non-invasive, effort-independent method that uses sound waves to detect airway changes quickly. It only requires the patient to breathe normally to assess lung function by measuring both resistance and reactance of the airways. 6,7 These features of IOS suggest it may be a useful test for assessing patient respiratory function during exacerbation periods when airway resistance, airflow limitation, and respiratory muscle weakness further impair breathing.
223773151|NCT01807130|OTHER|Placebo (Registry Arm)|Patients assigned to the registry will receive referral to specialists in HF or EP as deemed necessary by the patients physicians.
223677498|NCT06425991|DRUG|Teclistamab|Teclistamab will be administered subcutaneously.
223677499|NCT06150157|DRUG|JNJ-88549968|JNJ-88549968 will be administered.
223773152|NCT03165201|DEVICE|LiverMultiScan|We will study participants who are due to be evaluated for possible liver transplant rejection. There will be no change to usual care as part of the study, but patients will get an additional MRI scan, so that the results can be compared to the biopsy results. Each centre has a consultant radiologist specialising in liver imaging with experience in post-transplant review; the radiologist will review the MRI scans and inform the patient's doctor if any structural liver abnormalities are found (e.g. abnormal vessels, haemangiomas, tumours or cysts) as this may have implications for the patient's planned biopsy.
223773153|NCT01546415|DRUG|Desferasirox|Initial Dose: 20 mg/kg/d. Dose modification according to protocol.
223773154|NCT00253526|DRUG|bevacizumab|
223773155|NCT00253526|DRUG|gemcitabine hydrochloride|
223773156|NCT00253526|PROCEDURE|adjuvant therapy|
223773157|NCT00253526|PROCEDURE|anti-cytokine therapy|
223773158|NCT00253526|PROCEDURE|antiangiogenesis therapy|
223773159|NCT00253526|PROCEDURE|antibody therapy|
223773160|NCT00253526|PROCEDURE|biological therapy|
223773161|NCT00253526|PROCEDURE|chemotherapy|
224258659|NCT01924377|PROCEDURE|CPVI + rotors' identification and ablation|In CPVI + Rotor arm, two LA sequential maps will be collected before and after CPVI, respectively. During each map creation, rotor electrograms will be identified by the physician. Rotors will be ablated after collecting the second LA sequential map.
223677501|NCT05424822|DRUG|JNJ-80948543|JNJ-80948543 will be administered as SC or IV injection.
224258660|NCT05790824|OTHER|Spa therapy|"The RH2 rheumatology treatment protocol will propose treatments that can be carried out with water from the SL5 borehole and will be composed of:~* 54 treatments among the following treatments:~  * Swimming pool, 15 minutes (code 201)~ * Bath with aerobath, 10 minutes (code 205)~ * Bath with immersion shower, 10 minutes (code 206)~ * Cataplasm in multiple local application, 10 minutes (code 408)~* 18 sessions of mobilization pool, 15 minutes (code 601)"
224258661|NCT04137575|BEHAVIORAL|ConquerFear-Group|The intervention consist of one 1½-hour individual session in which a psychologist will conduct an oral psychological assessment, and five 2-hour group sessions. The key goals of the intervention are to: a) teach strategies for controlling worry and excessive threat monitoring; b) modify underlying unhelpful beliefs about worry; c) develop appropriate monitoring and screening behaviors; d) educate about follow-up care and empirically-supported behavioral change (e.g., weight loss, exercise, etc.) to improve overall survival; e) address existential changes brought about by a cancer diagnosis; f) promote goal-setting. Each session is accompanied by home-based practice of skills learned in session and home reading to consolidate skill acquisition. Four trained psychologists (MSc) will perform the therapy. The intervention will be delivered on Zoom, a secure online platform.
223773162|NCT00253526|PROCEDURE|conventional surgery|
224258662|NCT04137575|BEHAVIORAL|Relaxation Training|The control group will receive one 1½-hour individual session and participate in five 2-hour group sessions. Patients will receive guided progressive muscle relaxation training. The intervention will be delivered on Zoom, a secure online platform.
224258663|NCT01655654|BEHAVIORAL|Physical activity|This intervention includes cardiorespiratory exercise, resistance exercise, flexibility exercise and neuromotor exercise.
223677502|NCT03370276|DRUG|Nivolumab|Nivolumab intravenously (IV) at 240 mg as outlined in the treatment arms.
223677503|NCT03370276|DRUG|Cetuximab|Cetuximab intravenously (IV) at 500 mg/m\^2 or 250 mg/m\^2 as outlined in the treatment arms.
223773163|NCT00253526|PROCEDURE|growth factor antagonist therapy|
223773164|NCT00253526|PROCEDURE|monoclonal antibody therapy|
223773165|NCT00253526|PROCEDURE|surgery|
223773166|NCT05453305|PROCEDURE|Control group: Traditional venipuncture, on the stretcher.|The companion will be given the State/Trait Anxiety Questionnaire(STAI) for the initial assessment of the companion's anxiety and will be asked to recall their perceived emotions during the venipuncture. The observer will assess child pain and stress using FLACC and Groningen scale and will record it. Next, the companion will place the child on the stretcher in supine position with the limb to be punctured in decline. During the technique, the companion will be present, being able to participate by establishing links of consolation or distraction, as is usually done in the hospital. Simultaneously, a professional from the service will be in charge of holding the chosen extremity, as well as the opposite one. The responsible nurse will perform the venipuncture and/or collecting samples. The observer will assess child's pain and stress and caregiver's STAI during the intervention with the same scales.
223773167|NCT05453305|PROCEDURE|Intervention group: DAK method venipuncture, simulating a hug|The companion will be given the State/Trait Anxiety Questionnaire(STAI) for the initial evaluation of the companion's anxiety and will be asked to recall their perceived emotions during the venipuncture. The observer will assess child's pain and stress using the FLACC and Groningen scale and record it. Subsequently, the caregiver will sit in a chair placing the child on top in front of him, with one leg on each side and the arms resting on the shoulders of the companion. The patient's head will rest on the adult's shoulder, contralateral to the limb to be punctured. Simultaneously, the responsible adult patient will hold the simulating a hug. A professional will take care of immobilizing the chosen limb. The responsible nurse performed the venipuncture and collecting samples. The observer will assess the child's pain and stress during the intervention, and will deliver the STAI to the caregiver, to be completed with their perceived sensations during the technique.
223773168|NCT03840161|DEVICE|non-invasive tissue glucose prediction|Generation of non-invasive and invasive glucose readings for comparison with a standard laboratory reference glucose determination method (YSI glucose analyzer)
223773169|NCT00907894|DRUG|LDT600 (Telbivudine)|LDT600 (Telbivudine)
224258664|NCT01655654|BEHAVIORAL|Dietary|Make at least one positive dietary change including or similar to a DASH diet snack substitution.
224258665|NCT01655654|OTHER|Primary care provider visit|Subjects with hypertension will be asked to visit their primary care provider seeking treatment options. If a subject does not have a primary care provider then they will be encouraged to obtain one and seek medical treatment.
224258666|NCT00426621|DRUG|Diclofenac Sodium Gel|4 grams per knee, 4 times per day, for 12 weeks
224258667|NCT00426621|DRUG|Placebo|4 grams per knee, 4 times per day, for 12 weeks
224258668|NCT06524921|PROCEDURE|dental pulpectomy using metapex|Metapex: A dental pulpectomy treats tooth with irreversible pulpitis in primary and teeth by removing infected pulp tissue using files and irrigation in the radicular part. The procedure involves anesthesia, decay removal, pulp chamber access, filing and irrigation till we reach cleaned dried canals and applying a medicament like Metapex . The tooth is then restored with a filling, often a stainless steel crown. The loss of pulp tissue weakens the tooth's structure and increases the risk of fracture and infection.
224258669|NCT06524921|PROCEDURE|dental pulpectomy using biodentine|Biodentine: A dental pulpotomy treats tooth decay or trauma in primary and young permanent teeth by removing infected pulp tissue in the crown while preserving healthy root pulp. The procedure involves anesthesia, decay removal, pulp chamber access, hemostasis, and applying a medicament like MTA or Biodentine. The tooth is then restored with a filling, often a stainless steel crown. Pulpotomies preserve tooth structure, relieve pain, and are less invasive than full root canals, but require regular follow-up.
224258670|NCT03612440|DRUG|dexmedetomidine|receive a loading infusion of dexmedetomidine (1ug/kg)for 20min follow by a maintenance infusion (0.4ug/kg/h) continued until the end of the surgery
224258671|NCT03612440|OTHER|normal saline|receive matching placebo (equal volum of normal saline)
224258672|NCT03904329|DRUG|Oral Anticoagulant|Oral tablets of anti coagulations either warfare or NOACs
224258673|NCT06970028|OTHER|Quantitative Sensory Testing|We will perform QST on the dominant hand and lower back.
224258674|NCT06970028|OTHER|Questionnaires regarding pain and quality of life|Questionnaires will be filled out by patients with ADPKD to evaluate pain and quality of life.
224258675|NCT03435835|DEVICE|Control/Sham Treatment|Water at 33ºC was circulated through water-circulating trousers.
224258676|NCT03435835|DEVICE|Heat Therapy (HT)|Water at 42-43ºC was circulated through the water-circulating trousers.
224258677|NCT00179231|DRUG|olanzapine vs. clozapine|
224258678|NCT04793607|OTHER|Pleural procedures|Any pleural procedure that removes fluid
224258679|NCT02278757|OTHER|High protein diet|Group received a diet with higher protein content (1.34gr/kg body weight). Meal replacements (drinks and bars) and individualized menus, controlling the content of calories, protein, carbohydrates, and fat, had more control over the total amount of protein consumed daily. Participants consumed two, protein-enriched drinks, contributing to the daily protein intake along with conventional foods and two low-fat bars. For both groups (intervention and control), the calorie density had a restriction of 500kcal/day calories less than the resting metabolic rate (RMR) and were equivalent in the type of carbohydrate. Recommendations for exercise (e.g., walking, biking or jogging at least 30 minutes/day, 5 days per week).
224258680|NCT02278757|OTHER|Low protein diet|Control group received a diet with a lower protein content (0.8gr/kg body weight). Conventional foods (such as fish, meet, vegetables, fruits, nutrs, beans, etc) were prescribed. Individualized menus, controlling the content of calories, protein, carbohydrates, and fat, had more control over the total amount of protein consumed daily. The calorie density had a restriction of 500kcal/day. Recommendations for exercise (e.g., walking, biking or jogging at least 30 minutes/day, 5 days per week)
224258681|NCT05912127|DEVICE|implant supported fixed full arch prosthesis|the patients will receive screw-retained cast metal-ceramic fixed prostheses that replace lost gingival tissues with pink porcelain.
224258682|NCT02314403|DRUG|Belatacept|A selective T-cell (lymphocyte) costimulation blocker
224258683|NCT02314403|DRUG|ATG|A T-Cell Depleting Agent
224258684|NCT02314403|DRUG|Rituximab|B-Cell Depleting Agent
224258685|NCT02314403|RADIATION|Total Body Irradiation|
224258686|NCT02314403|RADIATION|Thymic Irradiation|
224258687|NCT02314403|PROCEDURE|Combined Bone Marrow/Kidney Transplantation|
224258688|NCT01929863|DRUG|GSK2330672|GSK2330672 will be supplied as oral solution, and will be administered BID \[45 mg (2 days repeat dose) and 90 mg (5 days repeat dose) in each period\]
224258689|NCT01929863|DRUG|Placebo|GSK2330672 matching placebo will be supplied as oral solution, and will be administered BID (7 days of dosing in each period)
224258690|NCT01929863|DRUG|Metformin|Metformin 850 mg will be administered BID from Run-in period till Day 7 of period 2
224258691|NCT05644743|DEVICE|gemcitabine + cisplatin|Gemcitabine intravenous drip, day 1, 8； Cisplatin intravenous drip, day 1； 3 weeks is a cycle, and 6 cycles are used continuously.
224258692|NCT00532090|DRUG|RG4733|Administered orally daily at ascending doses to successive cohorts of patients
224258693|NCT00532090|DRUG|RG4733|Administered orally at ascending doses to successive cohorts of patients, on a 3 days on/ 4 days off schedule
224258694|NCT00532090|DRUG|RG4733|Administered orally at ascending doses to successive cohorts of patients, on days 1-7 of each 21 day cycle
224258695|NCT06559514|BEHAVIORAL|Group-based multi-component psychoeducational inventions (GMC-PEIs)|The participants were randomly assigned to either the experimental group, using a computer-generated list of random numbers.
224258696|NCT01734265|DRUG|Depigoid 50% Grasses/50% Olea europaea (2000DPP/ml)|
223677534|NCT04794101|BIOLOGICAL|Genetic: AAV5-hRKp.RPGR Intermediate Dose|Bilateral, subretinal administration of AAV5-hRKp.RPGR - deferred treatment group
223677535|NCT04794101|BIOLOGICAL|Genetic: AAV5-hRKp.RPGR Low Dose|Bilateral, subretinal administration of AAV5-hRKp.RPGR - deferred treatment group
223677536|NCT06272981|DEVICE|Pulsed Field (PF) /Radiofrequency (RF) Catheter ablation|THERMOCOOL STSF catheter will be used in conjunction with TRUPULSE Generator to give PF ablation or RF ablation.
223677537|NCT05754957|DRUG|Milvexian|Milvexian will be administered orally.
223677538|NCT05754957|OTHER|Placebo|Placebo will be administered orally.
224258697|NCT01734265|DRUG|Depigoid 50% Grasses/50% Parietaria judaica (2000DPP/ml)|
224258698|NCT05545826|DEVICE|Vibrotactile coordinated reset|The purpose of this study is to test the efficacy of vibrotactile coordinated reset stimulation on human subject participants with early stage Parkinson's disease
224258699|NCT06451783|OTHER|Traditional Chinese medicine combined with manipulation treatment|"The specific procedure involves administering the Shengyu Decoction, which consists of the following herbs:~* Shu Di Huang 20 grams~* Bai Shao 15 grams~* Dang Gui 15 grams~* Chuan Xiong 8 grams~* Ren Shen 20 grams~* Huang Qi 18 grams One dose is taken per day, and a course of treatment consists of five weeks. Add manipulation of massage：~  * Press and grasp the affected limb three times；~    * Five-finger five-acupoint pressing method；~      * Point pressing on Zusanli (ST36) and Sanyinjiao (SP6)；~        * grasp the interior method to treat the calf three times；~          ⑤ Apply rolling technique around the knee joint；~          ⑥ Knead and straighten the standing tendon (the lateral muscle of the calf)；~          ⑦ Six-finger six-acupoint pressing method；~          ⑧ Push and pull the patella to flex and extend the knee joint；~          ⑨ Knee joint reunion and smooth dispersion method."
223677552|NCT04108195|DRUG|Daratumumab|Participants will receive daratumumab.
223677553|NCT04108195|DRUG|Talquetamab|Participants will receive talquetamab.
223677554|NCT04108195|DRUG|Teclistamab|Participants will receive teclistamab.
223677555|NCT04108195|DRUG|Pomalidomide|Participants will receive pomalidomide.
223677556|NCT04540796|DRUG|JNJ-75348780|Participants will receive JNJ-75348780 by subcutaneous (SC) administration.
223677582|NCT06112418|DEVICE|The Cleerly CAD Staging System|The Cleerly CAD Staging System is software that utilizes a proprietary algorithm to identify CAD, stage the severity of CAD when present, and generate a prognostic risk score to inform treatment decisions that support CV disease prevention.
223773170|NCT04375423|BEHAVIORAL|Ecological momentary assessment and intervention: Behaviorally-dependent messaging|In response to behavioral data submitted intervention arm participants receive messages on their phones reinforcing healthy behaviors or encouraging alternative behaviors to limit risks
223773171|NCT04375423|BEHAVIORAL|Ecological momentary assessment only|Participants will receive twice daily and weekly prompts to submit behavioral report data and self-initiate event-contingent behavioral report data submissions
224258700|NCT06451783|DRUG|Celecoxib capsule|Oral Celecoxib Capsules, 200mg per dose, once daily after lunch.
224258701|NCT02692547|DEVICE|Hybrid-logic closed loop system|All patients get to wear the pump
224258702|NCT00772161|DRUG|Methylphenidate|Comparison of two extended-release formulations of 20mg Methylphenidate in a cross-over design.
224258703|NCT02120547|DRUG|Cenicriviroc in mild liver impaired|Subjects with mild hepatic impairment will receive CVC, 1 tablet once daily, for 14 days. Matching healthy subjects will receive CVC, 1 tablet once daily, for 14 days.
224258704|NCT02120547|DRUG|Cenicriviroc in moderate liver impaired|Subjects with moderate hepatic impairment will receive CVC, 1 tablet once daily, for 14 days. Matching healthy subjects will receive CVC, 1 tablet once daily, for 14 days.
224258705|NCT02882945|OTHER|Group A|150 healthy blood donors without a family history of diabetes mellitus were enrolled in the study.
224258706|NCT02882945|OTHER|Group B|200 cases of type 2 DM without complications were enrolled in the study.
223677584|NCT04919512|DRUG|TAR-200|TAR-200 will be administered.
224258707|NCT02882945|OTHER|Group C|120 cases of type 2 DM with macroangiopathy complication were enrolled in the study.. Among the group C subjects, 65 individuals had CHD; 55 patients had cerebrovascular disease (CVD); and 30 subjects had a combination of peripheral vascular diseases (PVD) and CHD.
223677585|NCT04919512|BIOLOGICAL|Cetrelimab|Cetrelimab will be administered.
223677586|NCT06406114|DRUG|Beta-lactam antibiotic (cefazolin, cefuroxime, cefotaxime, ceftazidime, ceftriaxone, cefepime, pre-pen, penicillin G, ampicillin, and histamine) double-blind skin testing|Percutaneous and intradermal skin testing will be performed in all participants. Concentrations for percutaneous testing; cefazolin (330 mg/ml), cefuroxime (90 mg/ml), ceftazidime (100 mg/ml), ceftriaxone (100 mg/ml), cefepime (200 mg/ml), pre-pen (undiluted), penicillin G (10,000 U/ml), ampicillin (20 mg/ml) and histamine (6 mg/ml). Concentrations for the first intradermal testing; cefazolin (3.3mg/ml), cefuroxime (1 mg/ml), ceftazidime (1 mg/ml), ceftriaxone (1 mg/ml), cefepime (2 mg/ml), Pre-PEN (undiluted), penicillin G (1000 U/ml), ampicillin (20 mg/ml), and histamine (0.1 mg/ml). Concentrations for the second intradermal testing; cefazolin (33mg/ml), cefuroxime (10 mg/ml), ceftazidime (10 mg/ml), ceftriaxone (10 mg/ml), cefepime (20 mg/ml), Pre-PEN (undiluted), penicillin G (10,000 U/ml), ampicillin (20 mg/ml) and histamine (0.1 mg/ml). Histamine and saline will be used as positive and negative controls.
223677587|NCT06406114|DRUG|Culprit cephalosporin (cefazolin, ceftazidime, ceftriaxone, cefepime, cephalexin, cefaclor, cefadroxil, cefuroxime, cefpodoxime, cefdinir, or cefixime) double-blind placebo-controlled drug challenge|After double-blind skin testing, participants will undergo a 3-step double-blind placebo-controlled drug challenge to their culprit cephalosporin (the cephalosporin they are suspected to be allergic to, either cefazolin, ceftazidime, ceftriaxone, cefepime, cephalexin, cefaclor, cefadroxil, cefuroxime, cefpodoxime, cefdinir, or cefixime). The challenges are 1:1 randomized to the order of active drug versus placebo. In Step 1, participants will receive 1:1000 of a full dose of either the culprit drug or placebo, followed by a 30-minute observation period. In Step 2, participants will receive 1:50 of a full dose of either, followed by another 30-minute observation period. In Step 3, participants are administered the full dose of either agent, followed by a 60-minute observation period. The same testing process is repeated for the second challenge.
223773172|NCT00127790|BEHAVIORAL|CBT for Insomnia (CBT-I)|
223773173|NCT00127790|BEHAVIORAL|CBT for Pain (CBT-P)|
224258708|NCT02604420|DRUG|eculizumab|
224258709|NCT02907047|OTHER|tourniquet inflated|
224258710|NCT02907047|OTHER|tourniquet not inflated|
223773174|NCT04734353|DRUG|Prasugrel 5mg|Prasugrel 20 mg loading, followed by prasugrel 5 mg/day for 12 months
223773175|NCT04734353|DRUG|Ticagrelor 60mg|Ticagrelor 120 mg loading, followed by ticagrelor 60 mg bid for 12 months
223773176|NCT04751253|DEVICE|High Intensity Laser Therapy|different doses of energies of high-intensity LASER on pain and functional activity in patients with chronic knee OA.
224258711|NCT00096291|OTHER|Doxorubicin followed by Paclitaxel|"Patients will be randomized into 2 groups based on sequence of neoadjuvant chemotherapy:~Doxorubicin followed by Paclitaxel Paclitaxel followed by Doxorubicin"
224258712|NCT00096291|OTHER|Paclitaxel followed by Doxorubicin|"Patients will be randomized into 2 groups based on sequence of neoadjuvant chemotherapy:~Doxorubicin followed by Paclitaxel versus Paclitaxel followed by Doxorubicin"
224258713|NCT03820310|BIOLOGICAL|autologous Tcm cellular immunotherapy|autologous cellular immunotherapy plus traditional therapy. • cells will be infused in 3-5×109 cells/100 ml 1 month after radical resection, then cells will be infused as the same dose followed by a 1 month rest period, Each subject in experimental group will receive a total of 5 cell infusions.
224258714|NCT04131842|OTHER|External focus of attention visual feedback|Patients will receive external focus of attention visual feedback during the impairment-based rehabilitation program.
224258715|NCT04131842|OTHER|External focus of attention auditory feedback|Patients will receive external focus of attention auditory feedback during the impairment-based rehabilitation program.
224258716|NCT04131842|OTHER|Internal focus of attention video feedback|Patients will receive internal focus of attention visual feedback during the impairment-based rehabilitation program.
224258717|NCT04131842|OTHER|No feedback|Patients will receive no feedback during the impairment-based rehabilitation program.
223677588|NCT06406114|DRUG|Similar cephalosporin (cefepime, ceftriaxone, cefaclor, cephalexin, cefixime, or cefdinir) antibiotic double-blind placebo-controlled drug challenge|Participants will undergo a 3-step double-blind placebo-controlled drug challenge to a cephalosporin antibiotic that shares a similar side chain with their culprit. This will be cefepime for those allergic to ceftriaxone, cefaclor for those allergic to cephalexin, cefixime for those allergic to cefdinir, cefdinir for those allergic to cefixime, cephalexin for those allergic to cefaclor or cephadroxil, and ceftriaxone for those allergic to cefepime, cefuroxime, or cefpodoxime. The challenges are 1:1 randomized to the order of active drug versus placebo. In Step 1, participants will receive 1:1000 of a full dose of either the culprit drug or placebo, followed by a 30-minute observation period. In Step 2, participants will receive 1:50 of a full dose of either, followed by another 30-minute observation period. In Step 3, participants are administered the full dose of either agent, followed by a 60-minute observation period. The same testing process is repeated for the second challenge.
223677589|NCT06406114|DRUG|Dissimilar cephalosporin (ceftriaxone or cefazolin) antibiotic double-blind placebo-controlled drug challenge|Participants will undergo a 3-step double-blind placebo-controlled drug challenge to a cephalosporin antibiotic that has a dissimilar side chain to their culprit. This will be ceftriaxone for those allergic to cefazolin, and cefazolin for those allergic to any other cephalosporin. The challenges are 1:1 randomized to the order of active drug versus placebo. In Step 1, participants will receive 1:1000 of a full dose of either the culprit drug or placebo, followed by a 30-minute observation period. In Step 2, participants will receive 1:50 of a full dose of either, followed by another 30-minute observation period. In Step 3, participants are administered the full dose of either agent, followed by a 60-minute observation period. The same testing process is repeated for the second challenge.
223677590|NCT06406114|DRUG|Amoxicillin double-blind placebo-controlled drug challenge|Participants will optionally undergo a 3-step double-blind placebo-controlled drug challenge to Amoxicillin. The challenges are 1:1 randomized to the order of active drug versus placebo. In Step 1, participants will receive 1:1000 of a full dose of either the culprit drug or placebo, followed by a 30-minute observation period. In Step 2, participants will receive 1:50 of a full dose of either, followed by another 30-minute observation period. In Step 3, participants are administered the full dose of either agent, followed by a 60-minute observation period. The same testing process is repeated for the second challenge. The order of challenge to similar vs. dissimilar cephalosporin will be randomized as well.
223677598|NCT06151964|DRUG|AZD9550|Part A: A constant dose Part B: Doses of AZD9550 that increase each week Part C: Doses of AZD9550 that increase every 2 weeks, then every 4 weeks Part D: Doses of AZD9550 that increase every 2 weeks, then every 4 weeks
223677599|NCT06151964|DRUG|Placebo|Matching administration volumes for SC injection
223677603|NCT06295692|DRUG|JNJ-77242113|JNJ-77242113 tablet will be administered orally.
223773177|NCT05880953|BEHAVIORAL|Parent-to-parent coaching|Parents and parent coaches will meet as needed via the family's preferred method. Engagement may include text messaging, phone conferencing, Zoom conferencing, or occasional in-home or hospital visiting as preferred. Coaching sessions will vary based on family desired frequency and location, but may include: on-site in the family home or hospital room, telephone or video conferencing, or asynchronous contacts via email or text messaging. The template for the intervention includes an initial introductory session which is intended to build rapport and orient the parent to our program. Subsequent session topics may include: addressing specific needs including topics of interviewing and selecting home health agencies, expectation setting for home based nursing care, recruiting for home health team from inpatient settings, and recruiting for home health team from professional and personal networks.
223773178|NCT01340989|PROCEDURE|alteration of the insufflation gas|addition of 4% oxygen
224258718|NCT05978726|DRUG|Dual antiplatelet therapy with aspirin and either ticagrelor or clopidogrel|Patients with acute myocardial infarction randomly received dual antiplatelet therapy with with aspirin 100mg daily and either ticagrelor 90mg twice daily or clopidogrel 75mg once daily for at least 9 months after PCI as needed.
224258719|NCT03887910|OTHER|Enhanced Intervention|Participants randomized to the Enhanced Intervention group will receive the Family Connects program, an evidence- based structure that begins at the birthing hospital stay, followed by 1 to 3 nurse home visits between 4 to 12 weeks of infant age, a follow-up contact one month later and a discharge home visit six months later and a final follow-up contact one month after that. During the home visits, the nurse engages with the mother and completes a holistic health and psychosocial assessment, during which the unique risks and family needs across 12 family domains are evaluated and addressed with either referrals with matched community resources or thorough education. In addition, they will be given a set of six developmental toys.
224258720|NCT03887910|OTHER|Intervention|Participants randomized to the Intervention group will receive the Family Connects program, an evidence- based structure that begins at the birthing hospital stay, followed by 1 to 3 nurse home visits between 4 to 12 weeks of infant age, a follow-up contact one month later and a discharge home visit six months later and a final follow-up contact one month after that. During the home visits, the nurse engages with the mother and completes a holistic health and psychosocial assessment, during which the unique risks and family needs across 12 family domains are evaluated. For each screened domain, the nurse is able to systematically address them, which may result in an immediate intervention; either referrals with matched community resources or thorough education.
224258721|NCT04410263|DIAGNOSTIC_TEST|Sampling (EDTA blood, pharyngeal and nose swabs, bronchoalveolar lavage ,urine)|"Most data and part of the biological material required for addressing the research questions in this project are generated in the treatment of the patients. The following data and samples are collected specifically for this project according to the study schedule (i.e. extra sampling or additional questioning):~* blood samples (day 0= 40 ml EDTA, day 2= 20 ml EDTA, day 3= 30 ml EDTA, day 5=10 ml EDTA, every 5 days = 20 ml EDTA)~* Swabs (oral +/- nasal +/- nasopharyngeal)~* Sublingual microscopy"
224258722|NCT06562114|DRUG|TML-6 Granules|Administered orally
224258723|NCT06562114|DRUG|Placebo|Administered orally
224258724|NCT01094457|DRUG|aspirin, clopidogrel|patients in the standard group received standard dual antiplatelet therapy: aspirin 300mg/d for 30 days followed by 100mg/d indefinitely, clopidogrel 75mg/d for at least 1 year
223677629|NCT03126916|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous HSCT
223677630|NCT03126916|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223677631|NCT03126916|PROCEDURE|Bone Marrow Aspiration and Biopsy|Undergo bone marrow aspiration and biopsy
223677632|NCT03126916|DRUG|Busulfan|Given IV
223677633|NCT03126916|DRUG|Carboplatin|Given IV
223677634|NCT03126916|DRUG|Cisplatin|Given IV
223677635|NCT03126916|PROCEDURE|Computed Tomography|Undergo CT scan
223677636|NCT03126916|DRUG|Cyclophosphamide|Given IV
223677637|NCT03126916|DRUG|Dexrazoxane Hydrochloride|Given IV
223677638|NCT03126916|BIOLOGICAL|Dinutuximab|Given IV
223677639|NCT03126916|DRUG|Doxorubicin Hydrochloride|Given IV
223677640|NCT03126916|PROCEDURE|Echocardiography Test|Undergo echocardiography
223677641|NCT03126916|DRUG|Etoposide Phosphate|Given IV
223677642|NCT03126916|RADIATION|External Beam Radiation Therapy|Undergo EBRT
223677643|NCT03126916|RADIATION|Iobenguane I-123|Given 123 I-MIBG
223677644|NCT03126916|RADIATION|Iobenguane I-131|Given IV
223677645|NCT03126916|DRUG|Isotretinoin|Given PO
223677646|NCT03126916|DRUG|Lorlatinib|Given PO
223677647|NCT03126916|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223677648|NCT03126916|DRUG|Melphalan Hydrochloride|Given IV
223677649|NCT03126916|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA scan
223677650|NCT03126916|PROCEDURE|Positron Emission Tomography|Undergo PET scan
223677651|NCT03126916|BIOLOGICAL|Sargramostim|Given SC
223677652|NCT03126916|PROCEDURE|Therapeutic Conventional Surgery|Undergo standard of care surgery
223677653|NCT03126916|DRUG|Thiotepa|Given IV
223677654|NCT03126916|DRUG|Topotecan Hydrochloride|Given IV
223677655|NCT03126916|DRUG|Vincristine Sulfate|Given IV
223677657|NCT06371768|BEHAVIORAL|AYA Educational Information|AYA-specific educational information is delivered using video conferencing by a clinical psychologist over six sessions. Participants will receive a written manual providing tips for engaging with educational content as well as access to a website specific to the control arm, which will provide written, video, and pictorial information.
223773179|NCT01340989|PROCEDURE|full conditioning|"addition of 4% oxygen + 10% nitrous oxide to the peritoneum~* humidification~* set temperature of 32°C"
223677658|NCT06371768|BEHAVIORAL|AYA STEPS|The intervention provides cognitive-behavioral and patient activation theory-based skills designed to enhance AYA survivors' abilities to manage their high symptom burden and engage in follow-up health care. Sessions with the psychologist will focus on enhancing participants' abilities to apply intervention skills and engage in the AYA STEPS digital health intervention using motivational interviewing, goal setting, and problem-solving techniques. Participants will complete the six sessions over the 12 weeks of the AYA STEPS intervention.
223677659|NCT05101148|DRUG|Selumetinib|The dosing regimen for selumetinib (25 mg/m2 bid) will be based on BSA, during T1 and T2 the dose will be 25mg/m2, consistent with the approved prescribing information in the US. If T3 is required, appropriate dose of selumetinib will be defined by Data Review Committee for T3.
223677660|NCT05059236|DRUG|Darolutamide (BAY1841788, Nubeqa)|300 mg per tablet, oral administration with food
223677661|NCT05059236|OTHER|ADT|LHRH agonist/antagonist or orchiectomy
223677665|NCT06566664|DEVICE|B Braun HNS 12 nerve stimulator|Nerve stimulator that is traditionally used for nerve localization during block placements.
223677666|NCT06566664|DEVICE|B Braun HNS 12 nerve stimulator sham control|Stimulator will be placed and turned on, but the grounding electrode will not be connected to prevent nerve stimulation.
223677669|NCT05303064|DRUG|OLZ/SAM|OLZ/SAM refers to the fixed dose combination of olanzapine and samidorphan. The starting dose of olanzapine will be 2.5 mg/day or 5 mg/day at the discretion of the Investigator with a maximum daily dose of 20mg/day. The starting dose of samidorphan will be 5 or 10 mg.
223677670|NCT05303064|DRUG|Olanzapine|The starting dose of olanzapine will be 2.5 mg/day or 5 mg/day at the discretion of the Investigator with a maximum daily dose of 20mg/day
223773180|NCT01340989|PROCEDURE|standard pneumoperitoneum|no intervention besides the use of CO2
223773181|NCT06630637|BEHAVIORAL|Glucose-Ketone Index (GKI) monitoring|Ketone and blood glucose monitoring with Abbott Optium Neo up to 10 times per day to observe GKI dynamics for gamification of adherence.
224258725|NCT01094457|DRUG|aspirin, clopidogrel, cilostazol|Firstly,all patients in this group were received aspirin 300mg/d and clopidogrel 150mg/d for 3 days. Then a platelet aggregation function test was performed. The regimen will lasted for another 27 days if patients were judged as responsive to current clopidogrel dose. Patients still with clopidogrel resistance were then randomly assigned to receive clopidogrel 75mg/d plus cilostazol 100mg, twice per day or clopidogrel 150mg/d plus cilostazol 50mg, twice per day for 27 days. At 30-day, a repeat platelet aggregation function test wil performed for all patients. Then a standard dual antiplatelet regimen with aspirin 100mg/d indefinitely and clopidogrel 75mg/d for at least 1 year will be prescribed for all patients.
224258726|NCT02911701|DRUG|Acetaminophen|
224258727|NCT02911701|DRUG|Ibuprofen|
224258728|NCT06328829|BEHAVIORAL|Conventional Care|"Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training.~Pulmonary function training, including standing training, cough training, and diaphragm muscle training."
223773182|NCT06630637|BEHAVIORAL|Continuous Glucose Monitoring (CGM)|Monitoring with an Abbott Freestyle Libre to observe glucose dynamics for gamification of adherence.
223773183|NCT06630637|OTHER|Digital dynamometer|Grip strength measurements, right and left hand, up to 20 readings per day per hand.
223773184|NCT06630637|DEVICE|Wearables|All Apple Watch 9 and Whoop data daily \[heart rate variability (HRV), resting heart rate, cardio recovery, sleep duration, composition (stages of sleep) and analogous scores, potential maximum rate of oxygen consumption attainable during physical exertion (VO2 max), basal metabolic rate and potential respiratory rate\].
223773185|NCT06630637|DIAGNOSTIC_TEST|Blood tests|Pre- and Post-fast (48h) testing of lipid panel, ApoB, ApoA1, CRP, interleukin panel, omega 3:6 ratio, and autophagy analysis. Potential CBC, renal and liver panels to be taken where appropriate.
223773186|NCT06630637|DIAGNOSTIC_TEST|Stool tests|"15 g of stool will be collected from the subject pre- and post-fast for microbiome assessment and pre- and post- the first week (the three meal phase). After the first week, the maximum number of tests is four per month (maximum of two fasts, with a pre- and post-fast test for each fast)."
223677677|NCT06317649|DRUG|Azacitidine|Given IV or SC
223677678|NCT06317649|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223677679|NCT06317649|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow biopsy and aspiration
223677680|NCT06317649|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy and aspiration
223677681|NCT06317649|DRUG|Gilteritinib|Given PO
223677682|NCT06317649|DRUG|Venetoclax|Given PO
223773187|NCT06630637|DIAGNOSTIC_TEST|Saliva tests|Saliva samples will be collected from the subject pre- and post-fast for microbiome assessment. Maximum number of tests is four per month (maximum of two fasts, with a pre- and post-fast test for each fast).
224258729|NCT06328829|DEVICE|Intermittent Oral-esophageal Tube Feeding|Before each feeding, inside and outside of the tube was cleaned with water. During feeding, the patient should maintain a semi-reclining or sitting position with mouth opened, and the tube was inserted slowly and smoothly into the upper part of the esophagus by medical staffs while the appropriate depth of intubation was checked with the calibration markings on the tube wall. The distance from the incisors to the head part of the tube should be between 22-25 cm. However, the specific depth should be evaluated based on patients' feedback and adjusted accordingly. After insertion, the tail part of the tube should be put into a container full of water and the absence of continuous bubbles indicated a successful intubation. Then, the feeding was to be conducted three times per day with 50 ml per minute and 400-600ml for each feeding.
224258730|NCT06328829|DEVICE|Nasogastric tube|Within 4 hours after admission, the placement of the feeding tube was conducted by professional medical staffs and after intubation, the tube was secured to the patient's cheek with medical tape. The feeding was conducted once every 3-4 hours, with 200-300ml each time. The total feeding volume was determined based on daily requirements. The feeding content was formulated by the nutritionists based on the patient's condition and relevant guidelines to reach the energy demand as 20-25 kcal/kg/day and protein supplementation of 1.2-2.0 g/kg/day for both two groups. For patients with limited tube feeding compliance, we made appropriate adjustments to ensure that they were not at risk of severe malnutrition as much as possible.
224258731|NCT00830024|DRUG|Alprazolam Extended-Release 3 mg Tablets|1 x 3 mg, single dose non-fasting
224258732|NCT00830024|DRUG|Alprazolam Extended-Release 3 mg Tablets|1 x 3 mg, single dose non-fasting
224258733|NCT00429416|DRUG|L-leucyl-L-leucine Methyl Ester (LLME)|Infusion of L-leucyl-L-leucine methyl ester (LLME) treated donor white blood cells
224258734|NCT00429416|DRUG|Fludarabine|Fludarabine 30 mg/m2 prior to HSCT infusion
224258735|NCT00429416|DRUG|Cytarabine|Cytarabine 2gm/m2 prior to HSCT infusion
224258736|NCT00429416|DRUG|Cyclophosphamide|Cyclophosphamide 1gm/m2 prior to HSCT infusion
224258737|NCT00429416|DRUG|Tacrolimus|Tacrolimus given before and after HSCT infusion
223677690|NCT05540392|PROCEDURE|Acupuncture|10 treatments of acupuncture over the course of 10 weeks
223677691|NCT05540392|OTHER|Waitlist Control|The waitlist control group will not receive any acupuncture treatments during the 14-week waiting period. Patients in waitlist control group will have the option to receive up to 10 acupuncture treatments after a 14-week waiting period.
223677692|NCT05540392|OTHER|Questionnaires|Patients will complete Patient Reported Outcomes (PRO)
223773188|NCT06630637|BEHAVIORAL|Fitness intervention|90 minutes of strength and/or cardiovascular training for a minimum of 5 days per week.
223773189|NCT06630637|BEHAVIORAL|Cold & heat intervention|"Cold plunge: at least 3 days per week, 2 sessions of maximum 5 minutes each (minimum 2 minutes between sessions) at a minimum of 6 degrees Celsius. Potential inclusion of GKI measurements before and after plunge.~Heat Therapy: maximum of 2 sessions of 20 minutes each of dry sauna blanket (minimum 5 minutes break between sessions) following the cold plunge intervention."
223773190|NCT06630637|DEVICE|Airofit|"Airofit is a smart breathing training device designed to improve respiratory strength and efficiency. It is used for enhancing sport performance, well-being, and overall health. The device works by providing adjustable resistance to breathing muscles.~5-10 minutes of daily use."
223773191|NCT06630637|BEHAVIORAL|18h fasting|Minimum of 18 hours fasting per day, with feeding window to occur between 5pm-8pm or 12pm-3pm. The fasting procedures will occur only after the Three Meal Phase.
224258738|NCT00429416|DRUG|Mesna|Mesna 1gm/m2/day given prior to HSCT infusion.
223677697|NCT06026410|DRUG|Darlifarnib|Oral administration
223677698|NCT06026410|DRUG|Cabozantinib|Oral administration
223677699|NCT06026410|DRUG|Adagrasib|Oral administration
224258739|NCT00429416|BIOLOGICAL|Granulocyte Macrophage Colony-Stimulating Factor (GM-CSF)|GM-CSF given post HSCT infusion
224258740|NCT00429416|PROCEDURE|Hematopoietic stem cell transplantation (HSCT)|CD34 selected allogeneic stem cell infusion with 5x104/kg untreated T cells
224258741|NCT03347487|PROCEDURE|Deep brain stimuation system implantation|All subjects will receive bilateral surgical implantation of DBS system.The Medtronic DBS 3389 electrode is utilized in this study. The DBS system includes a dual-channel neurostimulator kit, lead kit, extension kit, clinician-operated wireless programmer, test stimulator, and patient controller.
224258742|NCT05852392|OTHER|Adapted PARENT Model|PARENT is a team-based approach to care that utilizes a clinic-based community health worker as part of the WCC team to provide comprehensive and family-centered preventive care services.
224258743|NCT01499602|DRUG|LNG-IUS; Mirena; Bayer Schering Pharma Oy, Finland|Initial release rate of 20µg Levonorgestrel per day for one year follow up.
224258744|NCT01499602|DRUG|Norethisterone Acetate tablets|Norethisterone Acetate tablets at a dose of 5 mg three times daily (15mg/day) for 3 weeks over three months.With persistence of endometrial hyperplasia, the treatment is repeated for another 3 months
224258745|NCT01983969|DRUG|Azacitidine|Starting dose 15 mg/ m2 by vein on Day -11.
224258746|NCT01983969|DRUG|Vorinostat|1000 mg by vein on Day -11 through Day -2.
224258747|NCT01983969|DRUG|Gemcitabine|Loading dose 75 mg/m2 by vein followed by 22775 mg/m2 by vein on Day -8.
224258748|NCT01983969|DRUG|Busulfan|Busulfan test dose 32 mg/m2 by vein either as outpatient before Day -12 or as inpatient on Day -11. Busulfan pharmacokinetics performed with test dose and first dose on Day -8. Doses on Days -6 and -5 adjusted to target an AUC of 4,000 microMol.min-1.
223677712|NCT05135559|DRUG|Concizumab|"Participants in Arm 1 will be assigned to concizumab prophylaxis starting with a loading dose on treatment day 0 followed by daily injections of an individual maintenance dose.~Participants in Arm 2 will be assigned to concizumab prophylaxis with daily injections of an individual maintenance dose."
223773192|NCT06630637|BEHAVIORAL|48h fasting|48h fasting maximum twice monthly, at least one week apart. Multivitamin and electrolytes with water, and black coffee or tea (0-calorie drinks) will be consumed.The fasting procedures will occur the Three Meal Phase.
224258749|NCT01983969|DRUG|Melphalan|60 mg/m2 by vein on Days -3 and -2.
224258750|NCT01983969|DRUG|Dexamethasone|8 mg by vein twice a day from Day -11 AM to Day -2 PM.
224258751|NCT01983969|OTHER|Caphosol|Caphosol oral rinses 30 mL four times a day used from Day -9.
224258752|NCT01983969|DRUG|Glutamine|Oral glutamine, 15 g four times a day, swished, gargled and swallowed from Day -9.
224258753|NCT01983969|DRUG|Pyridoxine|100 mg by vein or mouth three times a day from Day -1.
223677713|NCT06372782|DEVICE|Restylane Skinboosters Vital Lidocaine|Each subject will receive treatment on Day 1 with Restylane Skinboosters Vital Lidocaine in one hand and Restylane Vital in the opposite hand, as randomly assigned.
223677714|NCT06372782|DEVICE|Restylane Vital|Each subject will receive treatment on Day 1 with Restylane Vital in one hand and the experimental device in the opposite hand, as randomly assigned
223677715|NCT05388669|DRUG|Lazertinib|Lazertinib tablets will be administered orally.
223677716|NCT05388669|DRUG|Amivantamab Subcutaneous and Co-Formulated with Recombinant Human Hyaluronidase (SC CF)|Amivantamab injection will be administered subcutaneously by manual injection.
224258754|NCT01983969|DRUG|Rituximab|375 mg/m2 by vein on Days -9.
224258755|NCT03141840|DEVICE|ABL01|Experimental medical device
223677717|NCT05388669|DRUG|Amivantamab Intravenous|Amivantamab will be administered by IV infusion.
224258756|NCT03141840|DEVICE|Placebo|ABL01 lacking active component
224258757|NCT00436163|DRUG|Peginterferon alfa-2a|180 mcg subcutaneously once per week for 48 weeks.
224258758|NCT05615324|BEHAVIORAL|Family Talk Preventive Intervention|This is a clinician facilitated, psychoeducational preventive intervention that includes on average 8 sessions designed to improve family communication and understanding of parental mental illness, improve interpersonal relationships, and promote child resilience and utilization of social support. An important tool throughout the intervention is the logbook which the clinician uses for taking notes with each family. The logbook prescribes the planned topics to be covered in each session and the contents of the sessions are noted in the logbook by the clinicians.
223677727|NCT04240704|DRUG|JBH492|Anti-CCR7 antibody-drug conjugate (ADC)
224258759|NCT01203215|BEHAVIORAL|2 print based physical activity interventions|physical activity promotion
224258760|NCT01349218|OTHER|Blood sample drawn from a vein|0.5 ml will be drawn from a vein when an IV is started for the surgery or from an IV already in place. The blood will be placed into a heparinized, 1 ml syringe for venous blood gas analysis.
224258761|NCT01349218|OTHER|Blood sample drawn from a heel stick|A second blood sample, 0.3 ml will be drawn into a capillary pipette from a heel stick for capillary blood gas analysis.
224258762|NCT05961501|DRUG|An aqueous solution containing CBD and CBN|An aqueous solution containing CBD and CBN, to drink at home in the dose determined by the attending physician
224258763|NCT05961501|OTHER|The aqueous solution of placebo|An aqueous solution of placebo, to drink at home in the dose determined by the attending physician
224258764|NCT06466213|OTHER|single exercise bout about one-leg exercise|cycle exercise includes single leg
224322614|NCT07186231|DEVICE|Low-load resistance training with Blood flow Restriction|Each session began with a warm-up including mobility and stretching exercises for the shoulders and upper limbs. During the first session, the one-repetition maximum (1RM) for each participant and exercise was determined using a failure-to-repetition method with applied coefficients. Training was performed at 30 percent 1RM, following a standardized sequence of three shoulder-targeted exercises (shoulder abduction, external rotation, Dumbbell Overhead Press), totaling 75 repetition per session (30/15/15/15), 30-second rest intervals per sets. Movements were executed at a controlled 4-sec. tempo (2 seconds concentric, 2 seconds eccentric). BFR was applied using pneumatic cuffs, maintained during each exercise, released for 60 seconds between exercises, and reapplied for the next. Participants rated exercise difficulty, including pain, tension, and numbness, using a 0-10 numeric scale, with protocol adjustments or session cancellation if symptoms exceeded 7/10.
224322615|NCT07186231|OTHER|High-load resistance training.|Each session began with a warm-up including mobility and stretching exercises for the shoulders and upper limbs. During the first session, the 1RM for each participant and exercise was determined using a failure-to-repetition method with applied coefficients. Training was performed at 70 percent following a standardized sequence of three shoulder-targeted exercises (shoulder abduction and external rotation, and Dumbbell Overhead Press). Four sets of 8 to 10 repetitions were completed for each exercise, with 2-minutes rest between sets and exercises. Movement speed was moderate (1-second concentric, 2-second eccentric).
224322616|NCT07176455|BEHAVIORAL|Anti-frailty dietary behavior intervention|Design intervention measures based on the mechanism of dietary behavior changes related to frailty
224322617|NCT07186361|DEVICE|Symptom Assessment and Management Program (SAM-CKD) which is delivered via Smart Kidney mobile app|An intervention program delivered through a mobile app to support symptom assessment and management for adults with CKD. The SAM-CKD program has three components - introduction, symptom tracker and symptom management. A list of 17 common symptoms will be assessed. Users can self-assess symptoms and rate these according to the severity level (overwhelmingly, severely, moderately, slightly, and not at all). The SAM-CKD program will provide symptom management strategies based on symptoms reported by patients. The intervention's duration is 6 weeks.
224258765|NCT03169985|DRUG|Rosuvastatin 10 mg plus ezetimibe 10 mg orally once a day|After the initial 12 months, randomized intervention will be stopped and then this arm will be received either usual dose rosuvastatin plus ezetimibe or high-dose rosuvastatin during the next 24 months by clinical judgement.
224258766|NCT03169985|DRUG|Rosuvastatin 20 mg orally once a day|After the initial 12 months, randomized intervention will be stopped and then this arm will be received either usual dose rosuvastatin plus ezetimibe or high-dose rosuvastatin during the next 24 months based by clinical judgement.
224258767|NCT06001762|DRUG|Abemaciclib|CDK4 and CDK6 inhibitor, tablet taken orally
224258768|NCT06001762|DRUG|Tamoxifen|Selective estrogen receptor modulator, taken orally per institutional standard of care
224258769|NCT06001762|DRUG|Anastrozole|Non-steroidal aromatase inhibitor, taken orally per institutional standard of care
224258770|NCT06001762|DRUG|Letrozole|Non-steroidal aromatase inhibitor, taken orally per institutional standard of care
224258771|NCT06001762|DRUG|Exemestane|Steroidal aromatase inhibitor, taken orally per institutional standard of care
224258772|NCT06001762|DRUG|LHRH Agonist|Luteinizing hormone-releasing hormone agonist), taken orally per institutional standard of care
224258773|NCT02530905|DRUG|SRP-4045|SRP-4045 solution for IV infusion.
224322618|NCT07184632|DRUG|NNC0662-0419|NNC0662-0419 will be administered subcutaneously.
224322619|NCT07184632|DRUG|Placebo|Placebo matched to NNC0662-0419 will be administered subcutaneously.
223677741|NCT05718570|DRUG|Somapacitan|Sogroya therapy in participants with AGHD.
223773193|NCT06630637|BEHAVIORAL|Three meal phase|During the first week of the study, the participant will follow a regime of three meals per day.
224258774|NCT02530905|DRUG|Placebo|SRP-4045 placebo-matching solution for IV infusion.
223677744|NCT03940352|DRUG|HDM201|Capsule
223677745|NCT03940352|BIOLOGICAL|MBG453|LIVI (Liquid in vial) Concentrate for Solution for infusion
223677746|NCT03940352|DRUG|Venetoclax|Tablet
223677747|NCT06058013|DRUG|NMRA-335140|Participants will receive NMRA-335140 at a dose of 80 mg QD, orally
223677748|NCT06058013|DRUG|Placebo|Placebo will be administered orally
223677750|NCT06063876|PROCEDURE|Induction of experimental peri-implant mucositis|Patients will refrain from oral hygiene measures at the implant sites for 3 weeks to induce peri-implant mucositis, by using a stent in the included implant during oral hygiene.
223677751|NCT06063876|PROCEDURE|Resolution of experimental peri-implant mucositis|Patients will reinstitute oral hygiene measures, receive an oral prophylaxis and oral hygiene instructions and will be evaluated during 3 weeks.
224258775|NCT02478047|DRUG|only antiemetic (Ramosetron, Tropisetron and dexamethasone)|The control group will receive standard antiemetic alone. Standard antiemetic for all groups is based on American Society of Clinical Oncology clinical practice guideline. 5-hydroxytryptamine-3 (5-HT3) antagonist (Ramosetron, Tropisetron) and dexamethasone are supplied from the first day of chemotherapy, and lasting for 3-5 days.And plus antiemetic drug as the comparator group.
223773194|NCT06630637|BEHAVIORAL|Mediterranean-inspired diet|"Regimen of Mediterranean-inspired nutrition comprised of Olive Oil, Olives, Leafy Green Vegetables, Lean Protein (Beef, Chicken, Lamb, Pork, Duck, Salmon, Tuna), Chia Seeds, Pecans, Macadamia, Pumpkin Seeds, Walnuts, Greek Yogurt, Salt, Pepper, Paprika, Cumin, Garlic powder, onion powder; Fruit: Blueberry, Grapefruit; Carbohydrates: Rolled Oats; Hydration: Water, Black Coffee, Black Tea, Coke Zero and 100 Zero sparingly, Ultima electrolytes.~Photographs of meals will be taken to create a visual record of the diet followed. Photographs of the devices will be taken to create a visual record of the blood glucose and ketone concentration results."
223773195|NCT06630637|DIETARY_SUPPLEMENT|Supplements|Multivitamin (Centrum), Vitamin D (Up to 2000 IU per day), Creatine (Up to 2000mg), Fisetin (1 pill), Omega-3 (1 tablet), Turmeric, Pre-Probiotic, Blueberry Extract, Holy Basil Extract.
224258776|NCT02478047|OTHER|Matching points ST36+CV12 plus antiemetic drug|"Choose both Zusanli(ST36) and Zhongwan point(CV12). Manipulating until achieving a de Qi sensation, then the needles are connected through a electro-acupuncture apparatus, the positive poles are linked to the needle, and the reference poles are located near the acupoint about 1cm with a paster. Frequency 10Hz,the intensity of stimulation is adjusted according to the patient's tolerance, and the electric current is less than 10mA. The operation lasts for 30 min. The treatment is scheduled to occur within 30min-60min before chemotherapy infusion for 4 days.And plus antiemetic drug as the comparator group."
223773196|NCT06630637|BEHAVIORAL|Generative AI|Feeding ketone data, glucose data (from finger prick and/or CGM), any/all Apple Watch Data, and dietary images into a generative AI platform to convert data into images using any selected prompts, with the intent of the images serving as immediate, visual readouts as a function of activity and/or inactivity.
224322620|NCT07186894|DRUG|Antistaphylococcal penicillins|It in not an interventional study. This project is a phase IV, retrospective, descriptive, and multicentric study.
223677763|NCT04809064|PROCEDURE|Arthroscopic Bankart repair procedure|Bankart repair with remplissage consists of arthroscopic anterior inferior capsulolabral repair with arthroscopic infraspinatus tenodesis to the posterior humeral head.
223677764|NCT04809064|PROCEDURE|Open Bankart|Open Bankart repair consists of anterior capsulorrhaphy with labral repair.
223677765|NCT04809064|PROCEDURE|Latarjet|Latarjet consists of open transfer of the coracoid to the anterior glenoid bone deficiency.
223677766|NCT04809064|OTHER|Post-Operative Rehabilitation|Post-operative rehabilitation will be conducted following surgical procedure-specific rehabilitation guidelines and will be progressed based on individual needs.
223677767|NCT03978442|BEHAVIORAL|Smoking Cessation Cognitive Behavioral Therapy (CBT)|12 sessions of cognitive behavioral therapy for smoking cessation, designed to help participants prepare for quitting smoking, make a quit attempt, and stay quit from smoking.
223677768|NCT03978442|DRUG|Bupropion|All medically eligible participants will be prescribed bupropion to begin 7 days before the quit date and continued through 12 weeks post-quit. Participants will be scheduled to begin at 150mg/day of bupropion for at least 3 days before titrating up to 300mg/day dose of bupropion.
224258777|NCT02478047|OTHER|Matching points PC6+CV12 plus antiemetic drug|"Choose both Neiguan(PC6) and Zhongwan point(CV12). Manipulating until achieving a de Qi sensation, then the needles are connected through a electro-acupuncture apparatus, the positive poles are linked to the needle, and the reference poles are located near the acupoint about 1cm with a paster. Frequency 10Hz,the intensity of stimulation is adjusted according to the patient's tolerance, and the electric current is less than 10mA. The operation lasts for 30 min. The treatment is scheduled to occur within 30min-60min before chemotherapy infusion for 4 days.And plus antiemetic drug as the comparator group."
224258778|NCT02478047|OTHER|Matching points CV13+CV12 plus antiemetic drug|"Choose both Shangwan(CV13) and Zhongwan point(CV12). Manipulating until achieving a de Qi sensation, then the needles are connected through a electro-acupuncture apparatus, the positive poles are linked to the needle, and the reference poles are located near the acupoint about 1cm with a paster. Frequency 10Hz,the intensity of stimulation is adjusted according to the patient's tolerance, and the electric current is less than 10mA. The operation lasts for 30 min. The treatment is scheduled to occur within 30min-60min before chemotherapy infusion for 4 days.And plus antiemetic drug as the comparator group."
224258779|NCT04360161|DEVICE|swept-source optical coherence tomography|Aswe pt-source OCT (CASIA SS-1000; Tomey Corporation, Nagoya, Japan), which is specifically designed for anterior segment imaging using a 1310 nm wavelength with a scan speed of 30,000 A-scans per second and an axial resolution of \<10 μm.
224258780|NCT01083784|DRUG|Use of prophylactic anticonvulsants (valproate, clonazepam)|start at hypothermia induction valproate : 30mg/kg iv loading - 8hr after - 6mg/kg q 8hr iv till 72hr clonazepam : 1mg po bit via L-tube till 72 hr
224322621|NCT07186894|DRUG|Cefazolin|It in not an interventional study. This project is a phase IV, retrospective, descriptive, and multicentric study.
224258781|NCT01083784|DRUG|Control group|Control group
224258782|NCT05860686|OTHER|Monoject syringe|monoject syringe is used to clean the wound
224258783|NCT02208128|DRUG|Sunitinib, Pazopanib, Bevacizumab, Everolimus...|Clinical standard
224258784|NCT04266405|DIETARY_SUPPLEMENT|Placebo drink|consume 1 bottle (50 mL) per day for 28 days
223677769|NCT03978442|BEHAVIORAL|Cognitive Processing Therapy|12 sessions of CPT, which is a well-established trauma-focused psychotherapy for PTSD that has demonstrated efficacy and effectiveness in Veterans.
224258785|NCT04266405|DIETARY_SUPPLEMENT|Collagen Cubilose Drink|consume 1 bottle (50 mL) per day for 28 days
224258786|NCT01055041|DRUG|inhaled budesonide and formeterol plus oral montelukast|1st two weeks -run in period all the participants prescribed Metered dose inhaler (budesonide 200 mcg/puff + formeterol 6 mcg/puff) two times a day Next 8 weeks- Metered dose inhaler (budesonide 200 mcg/puff + formeterol 6 mcg/puff) two times a day plus tablet montelukast (10 mg/day)orally in the evening
224258787|NCT01055041|DRUG|inhaled budesonide and formeterol plus oral doxophylline|1st two weeks -run in period, all participants prescribed Metered dose inhaler (budesonide 200 mcg/puff + formeterol 6 mcg/puff) two times a day Next 8 weeks- Metered dose inhaler (budesonide 200 mcg/puff + formeterol 6 mcg/puff) two times a day plus tablet doxophylline sustained release(400 mg/day)orally in the morning
224258788|NCT01055041|DRUG|Doubling the dose of inhaled budesonide and formeterol|1st two weeks -run in period, all groups participants prescribed Metered dose inhaler (budesonide 200 mcg/puff + formeterol 6 mcg/puff) two times a day Next 8 weeks- Metered dose inhaler (budesonide 200 mcg /puff + formeterol 6 mcg/puff) two times a day plus metered dose inhaler of budesonide (200 mcg/puff) two times a day
224258789|NCT00322439|DRUG|Etanercept|Observational study - no drug administered
223677770|NCT03978442|BEHAVIORAL|Smoking Abstinence Reinforcement Therapy|Monetary reinforcement for smoking abstinence that is bioverified by breath carbon monoxide and saliva samples.
224258790|NCT05423197|DRUG|89Zr-panitumumab IV|Subjects will be given a bolus of 1.0 mCi (range 0.8 - 1.2 mCi) of 89Zr-panitumumab before undergoing further standard of care diagnostic evaluation of the lesions
224322622|NCT07186127|DRUG|Drug: Methotrexate (MTX) Patients received methotrexate treatment according to institutional protocols. Dosage and administration routes were recorded retrospectively. For patients who did not respond|MTX medical treatment Laparoscopic salpingectomy Laparoscopic salpingostomy
224322623|NCT07184918|DRUG|Continuing Ramipril|Participants in this group will continue taking Ramipril at their usual dose before, during, and after the coronary angiography. The objective is to evaluate the renal effects of uninterrupted ACE inhibitor therapy during contrast exposure.
223677771|NCT03978442|BEHAVIORAL|Yoked Contingency Management|Participants in the yoked control will receive the monetary reinforcement of their yoked participant regardless of smoking abstinence or session attendance.
223677772|NCT05165810|BEHAVIORAL|Same-day ART initiation [experimental]|Participants assigned to same-day ART initiation will be offered standard, first-line ART on the day of trial enrollment. Participants, will be provided with focused counseling and instructions on where to follow-up for ongoing HIV care (either community-based HIV care or government-based HIV care, depending on randomization).
224258791|NCT05423197|DRUG|Panitumumab|Panitumumab 30mg will be given orally
224258792|NCT02280733|OTHER|Usual care|advanced dressings, off-loading, venous ulcer compression, arterial screening
224258793|NCT05929222|RADIATION|Radiotherapy|Involved-Site Radiation Therapy 24Gy
224258794|NCT05929222|OTHER|Radiotherapy plus Obinutuzumab|Involved-Site Radiation Therapy 24Gy followed by Obinutuzumab 1000mg flat dose 4 doses weekly plus addition 4 doses every 3 weeks
224258795|NCT04279353|OTHER|Mindfulness Based Intervention|this intervention is a 4 weeks program with logbook and follow up during intervention
224258796|NCT03769922|PROCEDURE|Extensive mesenteric resection|The mesentery is resected avoiding the root region.
224258797|NCT03769922|PROCEDURE|Limited mesenteric excision|The mesentery is retained.
224258798|NCT00660426|DRUG|Oxaliplatin|
224258799|NCT00660426|DRUG|Gemcitabine|
224258800|NCT00660426|DRUG|Capecitabine|
224258801|NCT00950989|DRUG|Brodalumab|3 single subcutaneous (SC) injections at day 1 and weeks 1, 2, 4, 6, 8, and 10
224258802|NCT00950989|DRUG|Placebo|3 single SC injections at day 1 and weeks 1, 2, 4, 6, 8, and 10
224258803|NCT00950989|DRUG|Methotrexate|Two methotrexate dose adjustments were allowed in the event of methotrexate toxicity, however, doses \< 7.5 mg/week necessitated discontinuation from study.
224258804|NCT00950989|DIETARY_SUPPLEMENT|folic acid|at least 5 mg per week
224258805|NCT03230630|DIAGNOSTIC_TEST|plasma melatonin levels|
224258806|NCT03936556|DRUG|Marketed toothpaste|Marketed stannous fluoride (0.454%) toothpaste
224258807|NCT03936556|DRUG|Marketed Cavity Protection Toothpaste|Marketed sodium monofluorophosphate (0.76 %) toothpaste
223677773|NCT05165810|BEHAVIORAL|Standard ART initiation [usual care]|Participants randomized to standard ART initiation will not initiate ART on the day of trial enrollment, but only after linking to their assigned source of HIV care (either community-based HIV care or government-based HIV care, depending on randomization). In standard ART initiation, patients typically, complete an intake visit at the HIV clinic, with baseline laboratory testing, and return to the clinic approximately 2 weeks later to begin ART.
223677774|NCT05165810|OTHER|Community-based HIV care [experimental]|Participants randomized to community-based HIV care will be referred to PWID-focused integrated care centers (ICCs) for ongoing HIV clinical management - a prototype of decentralized HIV care in India. ICCs will provide free HIV care that will adhere closely to Indian HIV treatment guidelines and, when relevant, to local HIV treatment standards.
223677775|NCT05165810|OTHER|Government-based HIV care [usual care]|Participants randomized to government-based HIV care will be referred to government-based HIV clinics for ongoing HIV clinical management. Government-based clinics provide free HIV care that adheres closely to Indian HIV treatment guidelines
223677776|NCT05165810|BEHAVIORAL|Enhanced adherence support [experimental]|Participants who i) experience virologic failure after 6 months in the study and ii) are randomized to enhanced adherence support will receive an intensive, tailored adherence intervention lasting a maximum of 6 months, with two components: 1) tracking and outreach, and 2) psychosocial support and navigation. These will aim to equip PWID with skills to independently manage their ART using motivational interviewing and strengths-based case management.
223773197|NCT06630637|OTHER|Interviews|Three interviews, of 30-60 minutes each one, at baseline, end of three meal phase and end of study, to gain insights into the participant's experience. Exploration of daily routines including diet, exercise and the use of technology and aspects of a healthy lifestyle.
223773198|NCT03292757|DRUG|Indocyanine Green|Fluorescent dye - indocyanine green
223773199|NCT02908568|DEVICE|Spring device|Brisk dilatation of fhe mouth.
223773200|NCT02908568|DEVICE|Mandible stimulator|Stimulation of fhe mouth.
224258808|NCT01841554|DEVICE|Cardioband|
224258809|NCT01039961|DRUG|losmapimod 1 mg|IV infusion
224258810|NCT01039961|DRUG|losmapimod|IV infusion (dose to be determined based on PK from first dose)
224258811|NCT01039961|DRUG|losmapimod 15 mg|oral, two 7.5 mg tablets
224258812|NCT02992366|PROCEDURE|implant placement|implant placement
224258813|NCT03554577|DEVICE|Hearing Aid without NR|"Each participant will be fitted with the 4 different Noise Reduction (Sound Changing) principles on the same hearing aid, saved to 4 manual programs.~Noise Reduction principle is a sound processing algorithm to remove noise from a speech signal to improve the speech intelligibility and comfort. The experimental conditions vary in their parametrization to result in different degrees of noise suppression and good speech quality."
224258814|NCT03554577|DEVICE|Hearing Aid with NR_A|"Each participant will be fitted with the 4 different Noise Reduction (Sound Changing) principles on the same hearing aid, saved to 4 manual programs.~Noise Reduction principle is a sound processing algorithm to remove noise from a speech signal to improve the speech intelligibility and comfort. The experimental conditions vary in their parametrization to result in different degrees of noise suppression and good speech quality."
224258815|NCT03554577|DEVICE|Hearing Aid with NR_B|"Each participant will be fitted with the 4 different Noise Reduction (Sound Changing) principles on the same hearing aid, saved to 4 manual programs.~Noise Reduction principle is a sound processing algorithm to remove noise from a speech signal to improve the speech intelligibility and comfort. The experimental conditions vary in their parametrization to result in different degrees of noise suppression and good speech quality."
224258816|NCT03554577|DEVICE|Hearing Aid with NR_C|"Each participant will be fitted with the 4 different Noise Reduction (Sound Changing) principles on the same hearing aid, saved to 4 manual programs.~Noise Reduction principle is a sound processing algorithm to remove noise from a speech signal to improve the speech intelligibility and comfort. The experimental conditions vary in their parametrization to result in different degrees of noise suppression and good speech quality."
224258817|NCT05718284|DEVICE|AIRVO2|APPLICATION OF HIGH FLOW NASAL CANNULA OXYGEN FOR 48 HOURS AFTER ESOPHAGECTOMY
224258818|NCT05718284|OTHER|STANDARD CARE|APPLICATION OF OXYGEN THROUGH STANDARD CARE FOR 48 HOURS AFTER ESOPHAGECTOMY
224258819|NCT01767103|DRUG|Ferriprox®|
224258820|NCT00665145|DRUG|SB-509|Active drug
224258821|NCT00665145|DRUG|SB-509|Active drug
224258822|NCT00665145|DRUG|Placebo|Placebo
224258823|NCT00665145|DRUG|SB-509|Active drug
224258824|NCT03423485|DEVICE|CG-100 Intraluminal Bypass Device|Intended to reduce contact of fecal content with an anastomotic site , following colorectal surgery.
224258825|NCT04486339|RADIATION|Stereotactic Radiotherapy|Stereotactic radiotherapy targets on the pulmonary vein ostium aiming to achieve pulmonary vein electrial isolation
224258826|NCT03804983|DEVICE|Hybrid Closed Loop (HCL)|Participants will use Control-IQ with Hybrid Closed Loop (HCL) with their own insulin parameters during the entire two-week study, including the 72-hour ski admission and the at-home study collection times. Parameters will be reduced 20% during the ski admission to adjust for the increased activity.
224258827|NCT03804983|DEVICE|Control-IQ with MyTDI|Participants will use their own insulin parameters during the first 5 days of the study. After randomization at the ski admission, the participants insulin parameters will be modified using the MyTDI calculations. Additionally, parameters will be reduced 20% during the ski admission to adjust for the increased activity.
224258828|NCT03644888|OTHER|Cycle ergometer training|Already in arm/group descriptions
224258829|NCT03644888|OTHER|Airway clearance program|Already in arm/group descriptions
224258830|NCT03644888|DEVICE|Vibration therapy|Already in arm/group descriptions
224258831|NCT03644888|DEVICE|Sham vibration therapy|Already in arm/group descriptions
224258832|NCT03600376|DRUG|Ryanodex and Standard of Care|Ryanodex to be administered as a rapid IV push
223677777|NCT05165810|BEHAVIORAL|Routine adherence support [usual care]|Participants who i) experience virologic failure after 6 months in the study and ii) are randomized to routine adherence support will receive a guideline-based, HIV clinic-based adherence counselling intervention lasting a maximum of 6 months
224258833|NCT03600376|OTHER|Standard of Care|Body cooling measures and supportive measures
224258834|NCT06248879|DEVICE|Intermittent Oral-esophageal Tube Feeding|The specific procedure was as follows: the infant was placed in a semi-recumbent or sitting position with the head fixed. Before each feeding, the infant's oral and nasal secretions were to be cleared. An intermittent oro-esophageal tube was appropriately lubricated with water on the head part. The professional medical staff held the tube and slowly inserted it through one side of the mouth into the upper part of the esophagus. The depth of insertion depended on the patient's age and height. After each feeding, the tube was immediately removed, and the patient was held upright for at least 30 minutes in case of reflux.
224258835|NCT06248879|DEVICE|Nasogastric Tube Feeding|Nasogastric Tube Feeding were used for feeding to provide nutritional support. Each feeding was administered by a nurse using the infant's mother's breast milk through the tube. The amount of each feeding varied from 20 to 100 ml depending on the age of the infant, with feedings given every 2 to 3 hours, approximately 10 times per day. The duration of each feeding procedure ranged from 10 to 20 minutes. The total daily intake ranged from 200 to 1000 ml. Each tube was kept indwelling for 5 to 7 days. When the tube needed to be replaced, it was removed after the last feeding of a day and a new tube was to be inserted through the other nostril on the following morning to continue the nutritional support.
224258836|NCT06248879|BEHAVIORAL|comprehensive rehabilitation therapy|Both groups were given comprehensive rehabilitation therapy. The main intervention measures included: 1) non-invasive ventilator treatment, generally at least once every night and typically not exceeding continuous daily usage.; 2) attention to feeding and sleeping positions, with a recommended sleeping position of lateral recumbent and the head of the bed raised by 20-30°; 3) swallowing function training, such as tongue muscle stretching training, assisted anterior jaw protrusion training, lemon ice stimulation to the soft palate, pharyngeal wall, etc., generally 5 days per week, twice per day, 5-20 minutes each time; 4) pulmonary ultrashort wave therapy, generally at least 2-3 times a week, and not more than once a day; 5) physical therapy, such as intensive training for gross motor functions including lifting the head, turning over, sitting, crawling, standing, etc., generally 3-5 days per week, 1-2 times per day, 5-20 min each time.
224258837|NCT00139113|BIOLOGICAL|hepatitis A vaccine|2 doses of inactivated hepatitis A vaccine manufactured by GSK in licensed pediatric formulation of 720 EL. U. per dose given on 3 different schedules: aged 6 and 12 months, 12 and 18 months, and 15 and 21 months. Within each group, subjects were randomized to achieve a relatively equal number of children born to anti-HAV positive and anti-HAV negative mothers.
224258838|NCT02152163|DRUG|IV Ibuprofen|
224258839|NCT02152163|DRUG|placebo|
224322624|NCT07184918|DRUG|Withholding Ramipril|Participants in this group will stop taking Ramipril 48 hours before the angiography procedure and resume it 72 hours after. This intervention is used to evaluate whether temporarily withholding ACE inhibitors reduces the risk of contrast-induced nephropathy.
223773201|NCT03488381|DEVICE|Soccer Heading|"Soccer Heading: Subjects stood approximately 40 feet away from a JUGS soccer ball launcher and participated in 10 consecutive soccer headings, separated by one minute intervals.~Soccer Kicking: Subjects stood approximately 40 feet away from a JUGS soccer ball launcher and participated in 10 consecutive soccer kicks, separated by one minute intervals."
223773202|NCT00388518|DRUG|Actos|45mg po daily
223773203|NCT00388518|DRUG|Placebo|po daily
223773204|NCT00388518|DRUG|aleglitazar|Administered po daily, at ascending doses with a starting dose (arm 1) of 0.05mg.
224258840|NCT05191550|BEHAVIORAL|Virtual reality brain tumor simulation|"Task: Complete removal of a simulated tumour - distinguishable by colour and haptic properties - with minimal bleeding and damage to surrounding healthy brain using two surgical instruments (Cavitron Ultrasonic Aspirator and Bipolar pincers) of the NeuroVR (CAE Healthcare) surgical simulator.~Intervention: A single 28-minute simulation session, including six virtual subpial tumour resection attempts. Five simple practice scenarios (3 minutes per task) and one complex realistic scenario (13 minutes). Pre- and post-questionnaires to obtain participant demographics and assess face and content validity of the simulated tasks."
224258841|NCT03480321|DRUG|Cilostazol 100 mg|One immediately-release tablet (Cilostazol 100 mg) at 08:00 and another at 20:00, twice daily oral dose (total daily dose of 200 mg)
224258842|NCT03480321|DRUG|PMR 150 mg|Two extended-release tablets (PMR 150 mg) at 08:00, single oral dose (total daily dose of 300 mg)
224258843|NCT03480321|DRUG|PMR 200 mg|Two extended-release tablets (PMR 200 mg/tablet) at 08:00, single oral dose (total daily dose of 400 mg)
224258844|NCT00796562|DRUG|Busulfan|Participant will receive Busulfan injections, 4 times a day for 4 days with dilantin prophylaxis (in patients 10 years of age or older). Busulfan levels in the blood will be measured and dose adjusted, if needed.
224258845|NCT00796562|DRUG|Cyclophosphamide|Patient will receive Cy by IV once a day for 2 days.
224258846|NCT00796562|RADIATION|Total body irradiation|Patients will receive TBI once a day for 4 days.
224258847|NCT01799798|DRUG|Denosumab|Denosumab will be given subcutaneously in a dosage of 1mg/kg body weight every 12 weeks. 4 interventions are planned until trial week 36. There is no control group planned.
224258848|NCT00424047|DRUG|CC-5013 plus dexamethasone|25 mg daily for 21 days every 28 days.
224258849|NCT00424047|DRUG|Dexamethasone plus Placebo|Oral pulse dexamethasone is administered at a dose of 40mg daily on Days 1-4, 9-12, and 17-20 of each 28 day cycle for Cycles 1 through 4. Beginning with Cycle 5, the oral dexamethasone dosing schedule will be reduced to 40mg daily for Days 1-4 every 28 days. In addition, oral placebo capsules will be administered for 28 days of every cycle.
224258850|NCT05957263|OTHER|Biofeedback training and Osteopathy procedure|the biofeedback training lasts 10 weeks and involves 3 sessions per week, with each session lasting for 15 minutes. the child was asked to contract the pelvic floor muscles as if stopping peeing, after which the biofeedback device helps them understand how to better control their muscle. muscle inhibition for the psoas muscle, deep massages in the obturator foramen, stretching for the greater omentum, and abdominal maneuvers. a high velocity, low amplitude manipulation performed for the sacroiliac joint and T10-L2 region. The treatments were implemented in phases, with multiple sessions for each phase over a 10-week period. Each osteopathy session typically lasted 30 minutes, with the myofascial, visceral, and articular techniques performed twice a week for 15 minutes each session for 10 weeks, and the high velocity, l
224258851|NCT05957263|OTHER|Biofeedback training|the biofeedback training lasts 10 weeks and involves 3 sessions per week, with each session lasting for 15 minutes. During biofeedback-assisted pelvic floor muscle exercises, the child was asked to contract the pelvic floor muscles as if stopping peeing, after which the biofeedback device helps them understand how to better control their muscles.
224258852|NCT05957263|OTHER|Osteopathy procedure|specific techniques included muscle inhibition for the psoas muscle, deep massages in the obturator foramen, stretching for the greater omentum, and abdominal maneuvers. In addition, there was a high velocity, low amplitude manipulation performed for the sacroiliac joint and T10-L2 region. The treatments were implemented in phases, with multiple sessions for each phase over a 10-week period. Each osteopathy session typically lasted 30 minutes, with the myofascial, visceral, and articular techniques performed twice a week for 15 minutes each session for 10 weeks, and the high velocity, low amplitude manipulation performed three times a week for 15 minutes each session for 10 weeks.
224258853|NCT06322420|BEHAVIORAL|Behavioural Activation (BA)|"Behavioural activation treatment delivered in this single arm study. Individual treatment given to all participants in 12 sessions over 11 weeks. All treatment components have been introduced by session 8 that defines minimum amount of treatment in the trial (i.e. 8 session completed).~Behavioral Activation is a psychological treatment for depression focused on gradually re-engaging people with sources of reinforcement and reward in their environment by re-establish healthy patterns of activity, and replace avoidance behaviours with more adaptive behaviours."
224258854|NCT03603808|DEVICE|Electroporation|Undergo electroporation
224258855|NCT03603808|BIOLOGICAL|HPV DNA Plasmids Therapeutic Vaccine VGX-3100|Given IM
224258856|NCT03603808|OTHER|Laboratory Biomarker Analysis|Correlative studies
224258857|NCT06649370|DRUG|Hypotensive Drugs and/or Vasoactive Drugs|If the patients' mean arterial pressure falls below 60 mmHg or 20% below the preoperative value, ephedrine will be administered.
224258859|NCT05292339|DRUG|Triamcinolone injection to the shoulder, elbow, wrist, or hand|Triamcinolone is a corticosteroid that decreases the inflammatory process by inhibiting the release of arachidonic acid from phospholipids.
224258860|NCT05292339|DRUG|Ketorolac injection to the shoulder, elbow, wrist, or hand|Ketorolac is a non-steroidal anti-inflammatory drug (NSAID) that reduces inflammation by inhibiting Cyclo-oxygenase (COX)-2 dependent prostaglandin release via the cyclooxygenase pathway.
224258861|NCT06834607|DEVICE|Physician Modified Aortic Endograft repair for complex aortic aneurysm|To assess the use of the Physician-Modified Endovascular Grafts to repair juxtarenal aneurysms in high-risk subjects considered to be unsuitable candidates for open surgical repair, have limited or no other options for treatment, and having appropriate anatomy.
224258862|NCT05355883|BEHAVIORAL|Remote Ischemic Conditioning (RIC)|See descriptions under arm/group descriptions. RIC is delivered for 5 intervention visits. Visits 1 is the pre-training assessment visit, visits 2-6 are RIC plus training visits, visit 7 is a post-training assessment visit.
224258863|NCT05355883|BEHAVIORAL|Sham conditioning|See descriptions under arm/group descriptions. Sham conditioning is delivered for 5 intervention visits. Visits 1 is the pre-training assessment visit, visits 2-6 are RIC plus training visits, visit 7 is a post-training assessment visit.
223677790|NCT06013969|DRUG|Spesolimab|Spesolimab intravenous (i.v.) infusion
223677791|NCT05624450|DRUG|Tozorakimab|Single IV dose of tozorakimab on Day 1.
223677792|NCT05624450|DRUG|Placebo|Single IV dose of matching placebo on Day 1.
224258864|NCT05355883|BEHAVIORAL|Hand Arm Bimanual Intensive Therapy (HABIT)|HABIT is a child-friendly, intensive intervention directed at improving bimanual coordination and function of the affected arm. The intervention employed in this study includes various age-appropriate fine and gross motor bimanual activities that will be delivered in a play context. Children practice bimanual activities for 6 hours per day, 5 days per week, for 1 week.
224258865|NCT05355883|BEHAVIORAL|Bimanual Cup Stacking Training|Children practices bimanual cup stacking, 15 trials/day for 5 consecutive day.
224258866|NCT05355883|BEHAVIORAL|Balance training|All children undergo training on a balance board, learning to hold the board level with equal weight on each leg and using various bilateral upper extremity strategies. Participants perform the balance task for 15, 30-second trials per day at visits 2-6.
224258867|NCT02571907|DEVICE|Zenith® Branch Endovascular Graft-Iliac Bifurcation,|Implantation of the Zenith® Branch Endovascular Graft-Iliac Bifurcation.
224258868|NCT02571907|DEVICE|Atrium iCAST™|Implantation of Atrium iCAST
224258869|NCT02571907|DEVICE|Zenith® Flex AAA Endovascular Graft|Implantation of the Zenith Flex Endovascular Graft
224258870|NCT05607420|BIOLOGICAL|UCART20x22|Allogeneic engineered T-cells expressing anti-CD20 and anti-CD22 Chimeric Antigen Receptors given following a lymphodepletion regimen
224258871|NCT05607420|BIOLOGICAL|CLLS52|A monoclonal antibody that recognizes a CD52 antigen
224258872|NCT05633394|DEVICE|AtaCor StealthTrac Lead|Subjects will receive the AtaCor StealthTrac Lead being evaluated in the study.
224258873|NCT01512823|BEHAVIORAL|Education|"Interactive educational intervention:~* 4 hour education session (with notes and 'evidence packs'); presentations, small group discussion tasks and practice of particular skills - 2 hour session (1 week later)~* Emailed notes from second session~* Telephonic/email follow-up (reminders)~Didactic educational intervention:~\- 4 hour education session (with notes and 'evidence packs'; questions answered but no discussion or application of skills"
224258874|NCT06649110|DRUG|LTP|LTP001
224258875|NCT06649110|DRUG|Placebo|Placebo
224258876|NCT03666026|BEHAVIORAL|1 MyChart R/R|Up to 1 flu vaccine reminder recall notice sent via MyChart to patients who are due for the flu vaccine, per the EMR records of the health system.
224258877|NCT03666026|BEHAVIORAL|2 MyChart R/R|Up to 2 flu vaccine reminder recall notices sent every 3-4 weeks via MyChart to patients who are due for the flu vaccine, per the EMR records of the health system.
224258878|NCT03666026|BEHAVIORAL|3 MyChart R/R|Up to 3 flu vaccine reminder recall notices sent every 3-4 weeks via MyChart to patients who are due for the flu vaccine, per the EMR records of the health system.
224258879|NCT02286739|DEVICE|"TKA with Verasense"|VERASENSE replaces the standard tibial trial inserts and is embedded with microelectronics and sensors to provide surgeons with real-time knee kinetic data. The data is wirelessly transmitted to a graphic display (VERASENSE Knee Application), allowing surgeons to quantify and assess soft tissue intercompartmental loads throughout the range of motion. The VERASENSE sensor is not an investigational device. OrthoSensor, Inc., received FDA pre-market submission (510K) clearance in 2009. The indication for use is a tool for adjustment of the femoral knee implant to reduce instability from flexion gap asymmetry. The VERASENSE sensor is sterile and single patient use.
224258880|NCT02286739|PROCEDURE|"TKA without Verasense"|TKA will be performed manually without the use of Verasense
224322625|NCT07184528|DEVICE|Endobronchial Blood Patch|This component of the procedure involves sealing persistent air leak (PAL) defects using autologous blood delivered via a balloon catheter. After identifying the target segment, carefully noting the airway angle and distal carina, a sizing balloon is deployed and inflated to ensure a tight seal. Under anesthesia, 30 mL of fresh blood is prepared and infused into the target airway until either visible extravasation occurs or the full volume is delivered. Following this, up to 10 mL of tranexamic acid (TXA) may be administered, again until extravasation occurs or the volume is fully instilled. The balloon remains inflated for 3-5 minutes after the instillation to allow clot formation and sealing of the defect.
223677793|NCT06168942|DEVICE|Experimental: Laminar Left Atrial Appendage Closure System|Treatment with the Laminar Left Atrial Appendage Closure System.
223677794|NCT06168942|DEVICE|Active Comparator: WATCHMAN / Amulet|Treatment with a WATCHMAN left atrial appendage closure device / Amulet left atrial appendage occluder.
223677795|NCT05574959|DEVICE|investigational IOL Model DEN00V|Eligible subjects will be randomized in a 1:1 ratio to receive the investigational IOL Model DEN00V in both eyes for the duration of the study.
224258881|NCT05572281|DRUG|Tasimelteon Oral Capsule|No additional information
224258882|NCT05572281|DRUG|Tasimelteon Oral Suspension|No additional information
224258883|NCT04071652|DEVICE|Mistral implantation|Mistral implant is implanted in the Tricuspid valve
224258884|NCT03913676|BEHAVIORAL|Velibra|"Velibra is grounded in a cognitive-behavioral theoretical orientation and consists of six treatment modules representing different skills and therapeutic techniques. Each of the first five modules is followed by a training session, and contains activities related to training attention biases (CBM-I). All sessions plus trainings are designed to be completed in 1 - 2 hours, depending on the user's reading speed, interest, motivation, and individual path through the program. The modules cover a variety of therapeutic content that is broadly consistent with a cognitive-behavioral perspective. The modules' content draws from therapeutic strategies: (1) Cognitive Modification, (2) Mindfulness, Acceptance, and Relaxation techniques (4) Exposure, (5) Interpersonal Skills, (6) Psychoeducation and Relapse Prevention."
224258885|NCT01660789|BEHAVIORAL|Physical activity, dietary counseling, coaching|Physical activity, dietary counseling, coaching
224258886|NCT03859089|OTHER|Medical Cannabis|N/A - Observational Cohort Study
224322626|NCT07184528|DEVICE|Spiration Valve System (SVS) Placement|Once the blood patch component is complete and the balloon is deflated, a Spiration Valve System (SVS) is placed proximally in the airway. The valve acts as a one-way device that decompresses the targeted lung segment while stabilizing the clot created by the blood patch. This supports durable resolution of the air leak, particularly in cases where collateral ventilation might otherwise reduce the efficacy of valve therapy alone.
223677796|NCT05574959|DEVICE|control IOL Model ZCB00/DCB00|Eligible subjects will be randomized in a 1:1 ratio to receive the control IOL Model ZCB00/DCB00 in both eyes for the duration of the study.
224258887|NCT05635448|BEHAVIORAL|Better Together Physician Coaching Program|thought-based coaching. This type of coaching focuses on thoughts and beliefs. It combines a cognitive behavioral therapy (CBT) model with mindfulness-based awareness and integrates theories of acceptance and commitment therapy (ACT), nonattachment, and radical questioning from Socratic and Greek philosophies. BT delivers a robust coaching experience via a 4-month web-based, group-coaching model. This novel program allows residents to participate as actively as they are inclined and able, offering flexibility via multiple modalities of coaching: twice weekly group coaching calls, unlimited anonymous written coaching, and weekly self-study modules that are housed on a secure members-only website.
224258888|NCT05635448|BEHAVIORAL|No intervention - waitlist control|No intervention - waitlist control
224258889|NCT03110848|DRUG|Atorvastatin|Atorvastatin 20 mg daily
224258890|NCT03110848|DRUG|Methylprednisolone|500 mg of methylprednisolone weekly for 6 weeks, followed by 250 mg weekly for another 6 weeks, for a total dose of 4.5 mg.
224258891|NCT03374605|DEVICE|active tDCS|15 minutes of active (2mA) high definition tDCS will be applied to the participant's skull. The anodal electrode will be placed over 10-20 EEG coordinate AF7 and cathodal electrode over coordinate Fz.
224258892|NCT03374605|DEVICE|sham tDCS|15 minutes of sham high definition tDCS will be applied to the participant's skull. The anodal electrode will be placed over 10-20 EEG coordinate AF7 and cathodal electrode over coordinate Fz.
224258893|NCT05468879|DRUG|Glimepiride|Glimepiride is a sulfonylurea, indicated as an adjunct to proper dietary management, exercise and weight reduction to lower the blood glucose in patients with type 2 diabetes whose hyperglycemia cannot be controlled by diet and exercise alone.
224258894|NCT05468879|DRUG|Amaryl®|Amaryl®
224258895|NCT01373593|DRUG|lidocaine|
224322627|NCT07187141|DRUG|Protollin|For the 0.1, 0.5, and 1.0 mg dose groups, Protollin (450 μL per vial) in an aqueous buffer will be administered in two, 0.1 μL sprays, one per nostril. For the 1.5 mg dose group, Protollin (450 muL per vial) in an aqueous buffer will be administered in three, 0.1 μL sprays, two in one nostril and one in the other nostril.
224322628|NCT07187167|DRUG|Lenalidomide|The combination therapy period consists of 12 cycles: Lenalidomide: 25mg, orally, D1-21, every 28 days per cycle. Combined with Dexamethasone: 40mg, orally, D1, 8, 15, 22, every 28 days per cycle. The single-agent maintenance period consists of 12 cycles: Lenalidomide: 25mg, orally, D1-21, every 28 days per cycle. The total treatment duration is 24 cycles or until disease progression, death, or the occurrence of intolerable toxicity.
224322629|NCT07187167|DRUG|Dexamethasone|The combination therapy period consists of 12 cycles: Lenalidomide: 25mg, orally, D1-21, every 28 days per cycle. Combined with Dexamethasone: 40mg, orally, D1, 8, 15, 22, every 28 days per cycle. The single-agent maintenance period consists of 12 cycles: Lenalidomide: 25mg, orally, D1-21, every 28 days per cycle. The total treatment duration is 24 cycles or until disease progression, death, or the occurrence of intolerable toxicity.
224322630|NCT07184762|PROCEDURE|open reduction and internal fixation with bone plate|mandibular fracture were reduced and fixed with bone plates.
224322631|NCT07184762|PROCEDURE|z-plates.|mandibular fracture were reduced and fixed with z-plate miniplates.
224322632|NCT07184762|PROCEDURE|conventional miniplates.|mandibular fracture were reduced and fixed with conventional two miniplates.
224258896|NCT01373593|DRUG|Placebo|
224258897|NCT04102085|OTHER|no intervention|no intervention
224258898|NCT02570477|PROCEDURE|Fecal Microbiota Transplantation|Healthy donor is screened and donates feces. It will then be diluted with sterile saline, blended and filtered. Supernatant will be infused to recipient.
224258899|NCT02570477|DRUG|Vancomycin|125mg Vancomycin four times per day
224258900|NCT00834717|DRUG|Granisetron hydrochloride 1 mg tablets|2 x 1 mg, single dose fasting
224258901|NCT00834717|DRUG|Kytril® 1 mg tablets|2 x 1 mg, single dose fasting
224258902|NCT05936645|PROCEDURE|A temporary sub-placental Uterine Tourniquet in management of Placenta Accreta Spectrum disorder by a retrograde cesarean hysterectomy (Bladder Last)|Comparing the use of a temporary sub-placental uterine tourniquet versus no tourniquet in reducing blood loss in patients with Placenta Accreta Spectrum disorder undergoing cesarean hysterectomy.
224258903|NCT05936645|PROCEDURE|Retrograde cesarean hysterectomy (Bladder Last) for management of Placenta Accreta Spectrum disorder|Comparing the use of a temporary sub-placental uterine tourniquet versus no tourniquet in reducing blood loss in patients with Placenta Accreta Spectrum disorder undergoing cesarean hysterectomy.
224258904|NCT00217503|BIOLOGICAL|bevacizumab|
224258905|NCT00217503|BIOLOGICAL|filgrastim|
224258906|NCT00217503|BIOLOGICAL|pegfilgrastim|
224258907|NCT00217503|DRUG|bortezomib|
224258908|NCT00217503|DRUG|cyclophosphamide|
224258909|NCT00217503|DRUG|doxorubicin hydrochloride|
224258910|NCT00217503|DRUG|etoposide|
224258911|NCT00217503|DRUG|ganciclovir|
224258912|NCT00217503|DRUG|valganciclovir|
224258913|NCT00217503|DRUG|zidovudine|
224322633|NCT07185360|OTHER|blood sampling for volunteers|A 38.5 ml blood sample will be taken to test for research taken to test for research
224322634|NCT07185360|OTHER|blood sampling for diabetics patients with F3/F4 fibrosis|32.5 ml will be sampled at inclusion, at one year visit and two year visit
223677811|NCT02196376|OTHER|History|the physician / PI will conduct a history that may include: demographics Framingham risk factors metabolic diseases inflammatory diseases autoimmune disorders review of medications date of last menstrual period (females) family history of autonomic disorders Onset of postural orthostatic tachycardia syndrome
223677812|NCT02196376|OTHER|Physical|"the physical exam will include: height weight orthostatic vitals (heart rate and blood pressure), supine and standing for up to 10 minutes.~Beighton Criteria for Join Hypermobility Syndrome Dependent acrocyanosis"
223677813|NCT02196376|OTHER|blood draw|"blood will be drawn for: antibodies regulating cardiovascular function inflammatory markers~no more than 15 ml (1 TBSP) will be drawn."
223677814|NCT02196376|BEHAVIORAL|Questionnaires|"The questionnaires will be completed directly online (web-based interface) using a personalized link that will be provided to the subjects after they give their informed consent. These will be created in a REDCap-Survey environment, with the data collected and stored on a password-protected, HIPAA-compliant, secure computer server.~The following questionnaires will be conducted:~RAND-36 Health Thermometer Chalder Fatigue Scale Daily diary of Fatigue Symptoms - Fibromyalgia Pain Detect Questionnaire Orthostatic Grading Scale COMPASS-31"
223677815|NCT04899336|BIOLOGICAL|ExPEC9V|ExPEC9V will be administered as an IM injection.
223677816|NCT04899336|OTHER|Placebo|Matching placebo will be administered as an IM injection.
223677819|NCT04519619|DRUG|Aflibercept (Eylea, BAY86-5321)|Administration by intravitreal injection
223677820|NCT05705258|DRUG|Aflibercept (Eylea, BAY86-5321)|Treatment with Intravitreal (IVT)-AFL must be made by the treating ophthalmologist
223677824|NCT06561230|OTHER|Chart review|Patients eligible for prescreening will be identified using structured criteria (e.g., anyone with an appointment in the upcoming 2 months with a relevant provider). All individual charts will be de-identified. De-identified EHRs will then be transferred to Mendel's secure data abstraction platform, where trial eligibility criteria will be abstracted. Patients will be rank-ordered by number of eligibility criteria met, with patients meeting the most eligibility criteria at the top of the queue. The study team will then review eligibility criteria and flag eligible patients.
224322635|NCT07185360|OTHER|blood sampling for patients with liver disease|A blood sample of 35.5 mL maximum will be taken for research purposes at the inclusion visit, M1 visit and M3 visit.
224322636|NCT07187258|DRUG|tranexamic acid (1 g diluted in 100 mL of 0.9% saline|The pharmacist also prepared indistinguishable infusion bags containing tranexamic acid (1 g diluted in 100 mL of 0.9% saline) . The infusion was administered intravenously over 10-15 minutes immediately after induction of anesthesia and before skin incision, at a maximum rate of 100 mg per minute
224258914|NCT05826119|DRUG|magnesium sulfate group|Anesthesia induction was provided with propofol (2mg/kg), fentanyl (2mcg/kg). Intubation was performed after administration of 0.6 mg/kg rocuronium with an appropriate endotracheal tube. Anesthesia was maintained using AIR/O2 (50%/50%), 1 minimum alveolar concentration (MAC) sevoflurane, 0.1-0.25 mcg/kg/min remifentanil infusion. The target BIS value was kept between 40 and 50. Systolic blood pressure (SBP) \<90mmHg or \<20% of baseline was considered hypotension; remifentanil infusion was reduced. If no response was obtained, 5-10 mg of IV ephedrine was administered. HR \< 45 beats/min was evaluated as bradycardia; IV atropine 0.5 mg was planned The magnesium group received a bolus of 20 mg/kg of magnesium sulfate in 100 mL of saline for 15 minutes prior to induction, followed by a continuous infusion of 20 mg/kg/hr until skin closure.
224258915|NCT05826119|DRUG|Placebo|Anesthesia induction was provided with propofol (2mg/kg), fentanyl (2mcg/kg). Intubation was performed after administration of 0.6 mg/kg rocuronium with an appropriate endotracheal tube. Anesthesia was maintained using AIR/O2 (50%/50%), 1 minimum alveolar concentration (MAC) sevoflurane, 0.1-0.25 mcg/kg/min remifentanil infusion. The target BIS value was kept between 40 and 50. Systolic blood pressure (SBP) \<90mmHg or \<20% of baseline was considered hypotension; remifentanil infusion was reduced. If no response was obtained, 5-10 mg of IV ephedrine was administered. HR \< 45 beats/min was evaluated as bradycardia; IV atropine 0.5 mg was planned The same volume of isotonic saline for the control group was administered as indicated in the magnesium group.
224258916|NCT01669980|DRUG|Ceftaroline fosamil|"* Subjects ≥ 6 months: IV ceftaroline fosamil 15 mg/kg (or 600 mg if \> 40 kg) infused over 120 (± 10) minutes q8h (± 1 hour)~* Subjects \< 6 months: IV ceftaroline fosamil 10 mg/kg infused over 120 (± 10) minutes q8h (± 1 hour)~Optional Oral Switch:~* PO amoxicillin clavulanate 45 to 90 mg/kg/day divided q12h~* PO clindamycin 13 mg/kg/dose~* PO linezolid 600 mg q12h (Cohort 1) or 10 mg/kg q8h"
224258917|NCT01669980|DRUG|IV Ceftriaxone and Vancomycin|"* IV ceftriaxone 75 mg/kg/day (up to 4 g/day) divided equally every 12 hours (q12h) (± 2 hours) infused over 30 (± 10) minutes AND~* IV vancomycin 15 mg/kg every 6 hours (q6h) (± 1 hour) infused over at least 60 minutes.~Optional Oral Switch:~* PO amoxicillin clavulanate 45 to 90 mg/kg/day divided q12h~* PO clindamycin 13 mg/kg/dose~* PO linezolid 600 mg q12h (Cohort 1) or 10 mg/kg q8h"
224258918|NCT02028221|DRUG|Metformin|metformin 850 mg 1 tablet taken by mouth daily X 4 weeks, then metformin 850 mg 1 tablet taken twice daily for the duration of he intervention period.
224258919|NCT02028221|DRUG|Placebo|1 tablet daily by mouth X 4 weeks, then 1 tablet twice daily by mouth for the remaining duration of the trial (12 months)
224258920|NCT01092455|DRUG|Heparin N reduction|Dialysis with Citrasate, acid concentrate plus 100% of patient's standard heparin N dose; Dialysis with Citrasate acid concentrate plus 80% of patient's standard heparin N dose; Dialysis with Citrasate acid concentrate plus 66.7% of patient's standard heparin N dose.
224258921|NCT05850676|DIAGNOSTIC_TEST|Sleep study|Participants will spend two nights in the Penn Sleep Center
224258922|NCT04604262|DEVICE|Waterpik|Waterpik dental water jet
224258923|NCT01559727|DRUG|prednisone|The patients with symptomatic heart failure are treated with prednisone at dose of 15 mg/day.
224258924|NCT01559727|DRUG|prednisone|The patients with symptomatic heart failure are treated with prednisone at dose of 30 mg/day
224258925|NCT01559727|DRUG|prednisone|The patients with symptomatic heart failure are treated with prednisone at dose of 60 mg/day
224258926|NCT05735145|DRUG|paclitaxel combined with platinum|Adjuvant chemotherapy with paclitaxel combined with platinum
224258927|NCT06563115|DRUG|(PEG)-BHD1028 Single Ascending Dose|4, 8, 16, 32, and 64 μg/Kg
223677848|NCT04312672|BIOLOGICAL|AAV5-hRKp.RPGR|Participants will not receive any intervention in this study. Participants from the retrospective (MGT009-NCT03252847) study will be follow-up.
224258928|NCT06563115|DRUG|(PEG)-BHD1028 Multiple Ascending Dose|8, 16, and 32 μg/Kg
224258929|NCT06563115|OTHER|Placebo|Diluent
224258930|NCT05644184|BIOLOGICAL|Novel Live Attenuated Type 1 Oral Poliomyelitis Vaccine (nOPV1)|Drop counts of nOPV vaccine will be varied to achieve approximately 10\^5.5, 10\^6.0, 10\^6.5 CCID50 or 10\^7.0, 10\^7.5 dose levels.
223677860|NCT04929210|DRUG|Guselkumab|Guselkumab will be administered as subcutaneous injection.
223677861|NCT04929210|DRUG|Placebo|Matching placebo will be administered as subcutaneous injection.
224258931|NCT05644184|BIOLOGICAL|Sabin Monovalent Oral Poliomyelitis Vaccine Type 1 (mOPV1)|The Sabin Monovalent Oral Poliomyelitis Vaccine Type 1 control and challenge vaccine (mOPV1) contains ≥ 10\^6.0 CCID50 per 0.1 mL (2 drops) dose.
224258932|NCT00744679|DRUG|Natalizumab|Participants continue to receive regularly-scheduled doses of Tysabri (300 mg infusion every 28±7 days) through the Tysabri Outreach: United Commitment to Health Prescribing Program (TOUCH) throughout the screening and assessment periods. Participants must continue to be dosed every 28±7 days in order to maintain steady-state pharmacokinetics.
224258933|NCT05276635|BEHAVIORAL|The Sleep Hygiene Education (SHE)|Patients were randomized into two equal groups of 30 participants each. One group received a Sleep Hygiene Education (SHE) intervention
224258934|NCT05276635|BEHAVIORAL|Emotional Freedom Techniques (EFT)|30 participants had a form of Emotional Freedom Techniques (EFT) adapted for use with insomnia (EFT-I).
224258935|NCT04137835|DEVICE|Showmotion|Each healthy volunteers will wear sensors at the interested joint and do the measurement.
224258936|NCT02255149|DEVICE|Bone/Mesh|A titanium mesh (Ti-Mesh) that is more porous than other materials will be placed in order to hold a spot for the bone particles to grow.
224258937|NCT05438550|DRUG|14-day high-dose Tegoprazan Dual Therapy (HDDT)|14-day Tegoprazan high-dose dual therapy (HDDT) Tegoprazan（Luo Xin Pharmaceutical Group Co. LTD）50mg bid Amoxicillin (Amoxicillin, United Laboratories Co. LTD) 750mg qid To investigate the efficacy of high-dose dual therapy of Tegoprazan, a novel p-CAB acid suppressant, combined with amoxicillin for the eradication of Helicobacter pylori
224258938|NCT00308906|DRUG|aminoglycoside|Aminoglycosides will be administered and monitored as part of the routine standard of care for the subject.
224322637|NCT07187258|DRUG|placebo (100 mL of 0.9% saline).|The pharmacist also prepared indistinguishable infusion bags containing placebo (100 mL of 0.9% saline). The infusion was administered intravenously over 10-15 minutes immediately after induction of anesthesia and before skin incision, at a maximum rate of 100 mg per minute
224322638|NCT07187011|DRUG|PT150|Glucorticoid antagonist 900 mg
224258939|NCT00506376|BEHAVIORAL|Interview|Interview that will take about 20 minutes to complete.
224258940|NCT03098485|DRUG|Levofloxacin|5 days of levofloxacin administration
224258941|NCT03098485|DRUG|Azithromycin|5 days of azithromycin administration
223677862|NCT00870129|PROCEDURE|MRI and advanced MRI sequences|This is a nonrandomized study in which each patient will receive the standard clinical care (in the form of surgery, radiation therapy and/or chemotherapy), as per the treating physician. Surgical resection will be performed at the discretion of the treating Neurooncologist and/or Neurooncology Tumor Board. Advanced brain MRIs with the 2 (or, in some cases, 3) special sequences will be obtained at the time of the clinically scheduled contrast MRIs, which are usually obtained immediately prior to and 1 months±3 weeks after radiation therapy if the patient requires radiation therapy for his/her tumor. The advanced brain MRI may also be obtained before surgery for suspected or confirmed gliomas, as per the standard of care, in some patients who may or may not require radiation therapy.
224258942|NCT03098485|DRUG|Cefpodoxime|5 days of cefpodoxime administration
224258943|NCT02508870|DRUG|Atezolizumab|Participants will receive atezolizumab as per the schedule described in individual cohort.
224258944|NCT02508870|DRUG|Azacitidine|Participants will receive azacitidine as per the schedule described in individual cohort.
224258945|NCT03866265|DIETARY_SUPPLEMENT|Food Grade Extract of Salmon Polar Lipids (FGE-Salmon-PLs)|Each participant will be administered per day a capsule of the FGE-Salmon-PLs food supplement (containing 0.125 g of FGE-Salmon-PLs) for a period of 28 days in a double blind randomized, crossover and placebo-controlled design.
224322639|NCT07187011|DRUG|Placebo|900 mg
224322640|NCT07185672|RADIATION|Peptide Receptor Radionuclide Therapy with Lu177 DOTATATE|Radionuclide Therapy
224322641|NCT07185672|DRUG|Capecitabine plus temozolamide|Chemotherapy
224322642|NCT04859946|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo stem cell transplant
223677863|NCT05092269|DRUG|Ustekinumab|Ustekinumab will be administered as a SC injection.
224258946|NCT03866265|OTHER|Placebo|Each participant will be administered per day a placebo capsule (containing 0.125 g of glycerin) for a period of 28 days in a double blind randomized, crossover design.
224258947|NCT00238615|DRUG|Docetaxel|20 mg/m2, 75 mg/m2 infusion
224322643|NCT04859946|DRUG|Busulfan|Given IV
224322644|NCT04859946|DRUG|Cyclophosphamide|Given IV
224322645|NCT04859946|DRUG|Fludarabine|Given IV
224322646|NCT04859946|DRUG|Itacitinib|Given PO
224258948|NCT00238615|DRUG|Carboplatin|AUC of 2 and 6 infusion
224258949|NCT00238615|PROCEDURE|Radiation therapy|NEOADJUVANT RADIOTHERAPY Radiation therapy will be concurrent with the chemotherapy. Radiation therapy will begin within 24 hours of chemotherapy. CONSOLIDATION RADIOTHERAPY Patients with positive surgical margins or incomplete resection (tumor shaved from spine or great vessels) will receive an additional boost of radiotherapy 3 to 6 weeks after surgery. This will be a 16 Gy boost given with concurrent weekly chemotherapy as during the neoadjuvant period.
224258950|NCT00238615|PROCEDURE|Surgical resection|All patients will be taken to surgical excision, unless they have developed a condition other than progressive disease, which would make surgery unsafe.
224322647|NCT04859946|DRUG|Tacrolimus|Given IV or PO
224322648|NCT04859946|DRUG|Thiotepa|Given IV
224322649|NCT05502341|DRUG|Bictegravir|Tablets administered orally without regard to food
224322650|NCT05502341|DRUG|Lenacapavir|Tablets administered orally without regard to food
224322651|NCT05502341|DRUG|BIC/LEN FDC|Tablets administered orally without regard to food
224322652|NCT05502341|DRUG|Stable Baseline Regimen|"SBR will include a combination of antiretroviral (ARV) regimen. ARV regimen may include the following, except for participants taking a single tablet regimen or taking a complete parenteral regimen (Cabenuva).~* Nucleos(t)ide Reverse Transcriptase Inhibitors:~  * Abacavir~ * Emtricitabine~ * Lamivudine~ * Tenofovir alafenamide~ * Tenofovir disoproxil fumarate~ * Zidovudine~* Non-Nucleosite Reverse Transcriptase Inhibitors:~  * Delavirdine~ * Efavirenz~ * Nevirapine~ * Rilpivirine~ * Doravirine~* Integrase Inhibitors:~  * Bictegravir~ * Cabotegravir~ * Dolutegravir~ * Elvitegravir~ * Raltegravir~* Protease Inhibitors:~  * Atazanavir~ * Darunavir~ * Fosamprenavir~ * Indinavir~ * Lopinavir~ * Nelfinavir~ * Saquinavir~ * Tipranavir~* Chemokine Co-receptor 5 (CCR5) Antagonist:~  * Maraviroc~* Fusion Inhibitors:~  * Enfuvirtide~* gp120 Attachment Inhibitor:~  * Fostemsavir~* Anti-CD4 Monoclonal Antibodies:~  * Ibalizumab-uiyk"
224258951|NCT03914105|PROCEDURE|Without music|"The starting condition will be without music: the subjects, after a rest period of 10 minutes, will perform a test of induced pain for 6 minutes. There will be no music for the duration."
224258952|NCT03914105|PROCEDURE|With music|"The starting condition will be with music: the subjects, after a rest period of 10 minutes, will perform a test of induced pain for 6 minutes. There will be music for the duration."
224258953|NCT00106223|BEHAVIORAL|Cognitive behavioral therapy (CBT)|Participants will receive a total of 22 sessions of individual, manual-based CBT. The CBT sessions will occur weekly during the course of the study. During the sessions, participants will receive education about BDD and CBT, engage in activities that help them confront their BDD, learn new ways of thinking about body image, and learn relapse prevention techniques.
224258954|NCT00503919|PROCEDURE|Multi-spectral Digital Colposcopy (MDC)|Use of a digital camera and a special light to take pictures of the cervix and vagina.
224258955|NCT05710718|DEVICE|PureWick™ System|The PureWick™ FEC is intended for non-invasive urine output management in female patients. The PureWick™ FEC is a flexible, contoured external catheter that is positioned against the area where urine exits the female body. The PureWick™ FEC is connected to the PureWick™ Urine Collection System (PUCS) via connector tubing. The PUCS uses suction (not felt by the user) to pull voided urine through the device, regardless of the urine flow rate. Urine continues through vinyl tubing until it reaches a collection canister, away from the body.
224258956|NCT05710718|DEVICE|Hollister® Female Urinary Pouch External Collection Device|The Hollister Female Urinary Pouch External Collection Device is intended to collect and contain urine for individuals with urinary incontinence. It is designed to be emptied and should be attached to a drainage bag. The FUP is made with hydrocolloid skin adhesive and polymer/copolymer plastics.
224258957|NCT04808947|PROCEDURE|Local infiltration analgesia|Procedure: Local infiltration analgesia performed by surgeons.
224258958|NCT04808947|PROCEDURE|Ultrasound-guided adductor canal block|Procedure: Ultrasound-guided adductor canal and iPACK blocks performed by anesthesiologists preoperatively.
224258959|NCT06169605|PROCEDURE|removal of primary tumor, neck dissection|removal of the primary tumor with safety margins and removal of the neck lymph node levels I, II, III and IV. histological assessment of tumor thickness and whether it is associated with positive nodes in level IV or not.
224258960|NCT04712045|OTHER|New PPE|The use of a new protocol of level 2 PPE which involves wearing a short-sleeve gown and a single pair of gloves
224258961|NCT04712045|OTHER|Old PPE|The use of a standard protocol of level 2 PPE which involves wearing a long-sleeve gown and double pairs of gloves
224258962|NCT00186251|PROCEDURE|high dose chemo then auto hematopoietic cell transplant|
223677864|NCT06804811|DRUG|Ruxolitinib Cream|Ruxolitinib cream applied topically to the affected area as a thin film twice daily.
223677865|NCT06804811|DRUG|Vehicle Cream|Matching vehicle cream applied topically to the affected area as a thin film twice daily.
224258963|NCT01521481|OTHER|Triple inguinal nerve block.|Ultrasound-guided genitofemoral, iliohypogastric and ilioinguinal nerve block with ropivacaine 5 mg/ml, 150 mg.
224258964|NCT01521481|OTHER|Unilateral subarachnoid anesthesia|Subarachnoid anesthesia with hyperbaric bupivacaine 10 mg/ml, 12 mg, homolateral to inguinal hernia.
224258965|NCT01319383|DRUG|Vorinostat|Vorinostat (VOR) 400mg will be given as single doses by mouth. Participants eligible to advance in study will have opportunity to receive more than one dose of VOR. Each participant will only take one dose of VOR in a 24 hour period. Repeat doses will be administered at least 24 hours apart, with option for dosing at intervals up to 96 hour
224258966|NCT01972386|DEVICE|Spectrum Image Analysis using a Linear Array Ultrasound Bronchoscope|
224258967|NCT02124135|BEHAVIORAL|Diet/Nutrition Education|"As described elsewhere, all participants will receive 1 phone call and 3 in person sessions with the registered dietitian.~Participants in the clinic arm will receive the education intervention in the clinic.~Participants in the restaurant arm will receive the education intervention while dining in a restaurant."
224322653|NCT06176365|DRUG|Survodutide|once weekly subcutaneous injection
224322654|NCT06176365|DRUG|Placebo matching survodutide|once weekly subcutaneous injection
224322655|NCT03939689|DRUG|I-131-1095|Participants received up to 4 (8-week) cycles of I-131-1095: 100 mCi for the first dose. Subsequent dose(s) were reduced to 75 mCi for participants experiencing any dose-limiting toxicities. The third and fourth therapeutic doses could be reduced to 75 mCi on the basis of dosimetry assessment after administration of 10 mCi of I-131-1095 prior to the third dosing cycle. Participants also received the label dosage of enzalutamide once daily for up to 53 weeks.
224322656|NCT03939689|DRUG|Enzalutamide|Participants received the label dosage of enzalutamide once daily for up to 53 weeks.
223677868|NCT05316311|DEVICE|CERENOVUS ENTERPRISE 2 Intracranial Stent|CERENOVUS ENTERPRISE 2 Intracranial Stent will be used to treat severe symptomatic intracranial artery stenosis.
224322657|NCT05665595|BIOLOGICAL|Pembrolizumab/Vibostolimab|Co-formulation of pembrolizumab 200 mg/20 mL vial and vibostolimab 200 mg administered as IV infusion for up to 17 administrations
224322658|NCT05665595|BIOLOGICAL|Pembrolizumab|Pembrolizumab 25 mg/mL administered as IV infusion for up to 17 administrations
224322659|NCT04169763|DRUG|Cisplatin|Given IV
224322660|NCT04169763|RADIATION|External Beam Radiation Therapy|Undergo EBRT
224322661|NCT04169763|DRUG|Nelfinavir|Given PO
224322662|NCT05758246|DRUG|Fisetin-dose 1|20mg/kg once a day for one day.
223677875|NCT06649019|DEVICE|ACUVUE OASYS 1-Day for Astigmatism (AO1DfA)|Test Lens
223677876|NCT06649019|DEVICE|Dailies Total 1 for Astigmatism (DT1fA)|Control Lens
223677878|NCT02960555|BIOLOGICAL|Isatuximab|Given IV
223677879|NCT02960555|OTHER|Laboratory Biomarker Analysis|Correlative studies
223677880|NCT02420860|BIOLOGICAL|Elotuzumab|Given IV
223677881|NCT02420860|DRUG|Lenalidomide|Given PO
223677882|NCT02420860|OTHER|Questionnaire Administration|Ancillary studies
223773205|NCT06337929|OTHER|CAPOEIRA TRAINING|The protocol of the capoeira training program and the movements (blows, dodges and flourishes) will be based on the Capoeira Abadá method.
224322663|NCT05758246|DRUG|Fisetin-dose 2|20mg/kg once a day for two days
223773206|NCT06337929|OTHER|CONTROL GROUP|The protocol of the control group will be based on an intervention with capoeira movements, however, without important cardiovascular, neuromuscular and metabolic demands, being an activity with stretching movements from positions of the capoeira modality itself.
223677906|NCT04968912|OTHER|Placebo|Placebo infusion will be administered intravenously.
223677907|NCT04968912|DRUG|Nipocalimab|Nipocalimab dose 1 and dose 2 infusions will be administered intravenously.
223677908|NCT04968912|DRUG|Standard of Care Treatment|Standard of care treatment including ophthalmic drops, artificial tears and saliva, punctum plugs, and secretagogues, and/or one immunomodulator with or without low-dose glucocorticosteroids will be administered topically/orally.
223677909|NCT04887870|DRUG|Sitravatinib|Sitravatinib is a small molecule inhibitor of receptor tyrosine kinases.
223773207|NCT02464501|OTHER|Paclitaxel administration using the OPC|
223773208|NCT05718622|DEVICE|real EECP|Real EECP treatment is delivered 45min per day for 14 sessions continuously. The treatment pressure sets at 150 millimeters of mercury.
223773209|NCT05718622|DEVICE|sham EECP|Sham EECP treatment is delivered 45min per day for 14 sessions continuously. The treatment pressure sets at 75 millimeters of mercury.
223773210|NCT04244474|DRUG|A single one ml injection|All children were treated with antibiotics according to WHO classification and treatment of childhood pneumonia at health facilities 2012 \[18\], at enrollment after obtaining consent from parents and completing the baseline assessment, children were given a single injection of one ml of 100.000 IU of vitamin D3 (Cholecalciferol), vitamin D3 obtained from 2 ml vials containing 200,000 IU each (Devarol- S- 200.000 I.U. produced by Memphis for Pharmaceutical and Chemical Industries) and stored in manufacturer's recommended conditions in a dry, cool environment for 1-16 weeks (depending on the date of recruitment) or placebo which is 1 ml saline injection. Syringes were labeled with a unique ID number and given by the blinded doctors choosing the next syringe with a randomization code. (only office secretary aware of randomization codes).
224322664|NCT05758246|DRUG|Placebo|Placebo treatment
223677910|NCT04887870|DRUG|Nivolumab|Nivolumab is a programmed death receptor-1 (PD-1) blocking antibody
223677911|NCT04887870|DRUG|Pembrolizumab|Pembrolizumab is a programmed death receptor-1 (PD-1) blocking antibody
223677912|NCT04887870|DRUG|Enfortumab Vedotin-Ejfv|Enfortumab is a Nectin-4 directed antibody-drug conjugate (ADC) comprised of a monoclonal antibody conjugated to the small molecule microtubule disrupting agent, monomethyl auristatin E (MMAE)
223677913|NCT04887870|DRUG|Ipilimumab|Ipilimumab is a CTLA-4 (cytotoxic T-lymphocyte-associated protein 4) blocking antibody
223677914|NCT05987449|DRUG|NXT007|Participants will receive NXT007 administered subcutaneously (SC), 2 loading doses once every two weeks (Q2W) followed by once every 4 weeks (Q4W) maintenance doses based on the schedule.
223677915|NCT04675151|DRUG|Phentolamine Ophthalmic Solution 0.75%|0.75% phentolamine ophthalmic solution (Nyxol), a non-selective alpha-1 and alpha-2 adrenergic antagonist
223677916|NCT04675151|DRUG|Pilocarpine|Pilocarpine ophthalmic solution
223677917|NCT04675151|OTHER|Placebo|Topical sterile ophthalmic solution
223677920|NCT04035486|DRUG|Osimertinib|"Drug: Osimertinib (Oral)~Other Names:~AZD9291"
224322665|NCT05771428|DRUG|ABBV-552|Oral Capsule
224322666|NCT05771428|DRUG|Placebo for ABBV-552|Oral Capsule
224322667|NCT04800159|DRUG|THC Cannabis|Vaporization of cannabis
224322668|NCT04800159|DRUG|CBD Cannabis|Vaporization of cannabis
224322669|NCT04800159|DRUG|Placebo|Vaporization of placebo
223677921|NCT04035486|DRUG|Pemetrexed/Carboplatin|Drug: Pemetrexed (500 mg/m2) plus carboplatin (AUC5) on Day 1 of 21day cycles (every 3 weeks) for 4 cycles, followed by Osimertinib daily with pemetrexed maintenance (500 mg/m2) every 3 weeks.
223677922|NCT04035486|DRUG|Pemetrexed/Cisplatin|Drug: Pemetrexed (500 mg/m2) plus cisplatin (75 mg/m2) on Day 1 of 21day cycles (every 3 weeks) for 4 cycles, followed by Osimertinib daily with pemetrexed maintenance (500 mg/m2) every 3 weeks.
223677926|NCT03519945|DRUG|Mirikizumab|Administered SC.
223677927|NCT01730937|DRUG|Sorafenib|By mouth (PO)
223677928|NCT01730937|RADIATION|stereotactic body radiation therapy|Intensity-modulated radiation therapy (IMRT), stereotactic body radiation therapy (SBRT), and proton therapy are allowed.
223677930|NCT04486768|OTHER|Survey Instrument|This registry contains several surveys that will be released for patient/caregiver completion at enrollment and at time points following enrollment. These surveys can be completed on any computer that is connected to the internet.
223773211|NCT01319734|DIETARY_SUPPLEMENT|Vitamin C|Vitamin C supplementation 500mg
224258968|NCT05820360|BEHAVIORAL|CoMBI-SMI|The first step is analysis of the behavioral problem because the core need is insufficiently compensated by the current environment or counteracted by the behavior of people within that environment. Step 2 is to choose the right core need based on this analysis. CoMBI-SMI describes the patient's self-image, the image of others, the triggering events and the problematic behavior of the patient based on personality disorders as classified by the Diagnostical and Statistical Manual of Mental Disorders. Step 3 is to choose the nursing intervention that is easily deployable so that Healthcare providers can identify the underlying core need and reduce the behavioral problems and burden on the healthcare providers. The fourth and final step is to draw up a CoMBI plan. The CoMBI-SMI is a cyclical process where it is important that the entire team is aligned with the patient's behavioral approach. Interventions are carried out by the entire team and evaluated after an agreed period of time.
224258969|NCT00522262|BEHAVIORAL|Aerobic exercise intervention|Women in the exercise arm underwent a year-long exercise intervention of five days per week of 45 minutes/session of moderate-vigorous intensity aerobic exercise.
224258970|NCT01031394|OTHER|Frequency of Aerobic/Resistance Training - 3 to 3|comparing group results based upon frequency of exercise
224258971|NCT04988594|DIETARY_SUPPLEMENT|Lactobacillus acidophilus 207, Bifidobacterium lactis B420/205|Cultures containing 3.7 × 10 \^ 9 CFU/mg
224258972|NCT04988594|DIETARY_SUPPLEMENT|Lactobacillus bulgaricus and Streptococcus thermophillus|Cultures containing 3.7 × 10 \^ 6 CFU/mg
224258973|NCT04988594|DIETARY_SUPPLEMENT|No culture|No probiotic cultures
224258974|NCT01137591|DRUG|APAP and NAC combination|APAP 650mg and NAC 600mg combination oral tablet administered once
224258975|NCT01137591|DRUG|APAP and Placebo|APAP 650mg and Placebo combination oral tablet administered once
224258976|NCT00601120|PROCEDURE|Radiofrequency Ablation|Needles are inserted into the tumor(s) under guidance by a CT scan or ultrasound. The electrodes in the needles will be heated up to 202 degrees Fahrenheit and will remain heated for up to 12 minutes.
224258977|NCT05827991|DEVICE|1565nm Non-ablative Fractional Laser|1565nm Non-ablative Fractional Laser is used for treatment once every 2 weeks, a total of 10 times. 1565nm Non-ablative Fractional Laser uses square and rectangular light spots, and the size is adjusted according to the treatment area, which is about 8-16mm, 250-300spot, 10J/cm2.
224258978|NCT05827991|DRUG|5% minoxidil external use|The method of use of 5% minoxidil tincture is for topical use on the scalp, 1 ml per time, 2 times per day.
224322670|NCT06215118|DRUG|Elranatamab|BCMA-CD3 bispecific antibody
223677931|NCT05112614|PROCEDURE|Biospecimen Collection|Undergo collection of blood and stool samples
223677932|NCT05112614|OTHER|Electronic Health Record Review|Review of medical records
223677934|NCT04408638|DRUG|Obinutuzumab|Participants will receive a single dose of intravenous (IV) obinutuzumab pre-treatment 7 days prior to the first dose of glofitamab.
223677935|NCT04408638|DRUG|Glofitamab|Participants will receive IV glofitamab for up to 12 cycles.
223677936|NCT04408638|DRUG|Rituxumab|Participants will receive IV rituxumab on Day 1 of each cycle for up to 8 cycles.
223677937|NCT04408638|DRUG|Tocilizumab|Participants will receive IV tocilizumab as needed for treatment of cytokine-release syndrome (CRS).
223677938|NCT04408638|DRUG|Gemcitabine|Participants will receive IV gemcitabine prior to oxaliplatin administration for up to 8 cycles.
223677939|NCT04408638|DRUG|Oxaliplatin|Participants will receive IV oxaliplatin after gemcitabine administration for up to 8 cycles.
223677941|NCT04829994|DEVICE|Intervention|There is no intervention, beyond necessary clinical care, in this study. The surgical procedures being performed within the study are identical to the surgical procedures subjects would receive as part of SOC.
223677944|NCT00734110|DEVICE|P.F.C. Sigma Total Knee System|An orthopaedic implant for total knee replacement
224258979|NCT05827991|DEVICE|1565nm Non-ablative Fractional Laser combined with 5% minoxidil|The two treatment mentioned above
224258980|NCT01314391|GENETIC|mutation analysis|
224258981|NCT01314391|GENETIC|polymerase chain reaction|
224258982|NCT01314391|OTHER|laboratory biomarker analysis|
224258983|NCT01987765|DRUG|Relestat Ophthalmic Solution 0.05%|Relestat Ophthalmic Solution 0.05% prescribed as local standard of care in clinical practice.
224258984|NCT02404701|DIETARY_SUPPLEMENT|Aloe vera with cactus|Eligible participants who provide consent/authorization will report for an orientation visit (1 of 3 visits), during which participants will: provide a medical history and a 24-hour diet recall, have height and weight measured, learn how to collect 24-hour urine, receive instructions on following a standardized diet for 7 days, learn to use a food scale and provide diet records, and receive a 4-day supply of the supplement they were allocated to take along with instructions. After 3 days on the diet (no supplement), participants will return their first (of 2) diet record and 24-hour urine collection. After 4 days on the diet while taking the supplement, participants will return their second (and final) completed diet record and their second (and final) 24-hour urine collection.
224258985|NCT02404701|DIETARY_SUPPLEMENT|Cranberry|Eligible participants who provide consent/authorization will report for an orientation visit (1 of 3 visits), during which participants will: provide a medical history and a 24-hour diet recall, have height and weight measured, learn how to collect 24-hour urine, receive instructions on following a standardized diet for 7 days, learn to use a food scale and provide diet records, and receive a 4-day supply of the supplement they were allocated to take along with instructions. After 3 days on the diet (no supplement), participants will return their first (of 2) diet record and 24-hour urine collection. After 4 days on the diet while taking the supplement, participants will return their second (and final) completed diet record and their second (and final) 24-hour urine collection.
224258986|NCT02404701|DIETARY_SUPPLEMENT|Green tea extract|Eligible participants who provide consent/authorization will report for an orientation visit (1 of 3 visits), during which participants will: provide a medical history and a 24-hour diet recall, have height and weight measured, learn how to collect 24-hour urine, receive instructions on following a standardized diet for 7 days, learn to use a food scale and provide diet records, and receive a 4-day supply of the supplement they were allocated to take along with instructions. After 3 days on the diet (no supplement), participants will return their first (of 2) diet record and 24-hour urine collection. After 4 days on the diet while taking the supplement, participants will return their second (and final) completed diet record and their second (and final) 24-hour urine collection.
224322671|NCT06215118|DRUG|Iberdomide|cereblon-modulating agent
224322672|NCT04025229|BEHAVIORAL|HIIT exercise|High intensity interval training (4 to 6 sessions) prior to surgery
224322673|NCT06329531|OTHER|Screen of Cancer Survivorship - Occupational Therapy Services (SOCS-OTS)|Given by Questionnaire
224322674|NCT03059940|BEHAVIORAL|Questionnaires|Questionnaires completed at baseline and at 6 weeks, 12 weeks, and 6 months after the CT scan.
224322675|NCT03059940|PROCEDURE|Low Dose Computed Tomography Scan|Participants have a CT scan of chest to look for signs of lung cancer.
223677952|NCT05486416|DRUG|HSK3486|HSK3486 for induction of general anesthesia
223677953|NCT05486416|DRUG|Propofol|Propofol for induction of general anesthesia
223677959|NCT06044935|OTHER|Standard Diet|Consisting of 15% protein, 35% fat, and 50% carbohydrate, matching the macronutrient composition of a typical American diet
223677960|NCT06044935|OTHER|Ketogenic Diet|Consisting of a macronutrient composition of 15% protein, 80% fat, and 5% carbohydrate
223677961|NCT06044935|DIETARY_SUPPLEMENT|Placebo|Subjects without MODY2 will take either placebo or NR (1 g BID, 2 g per day total) supplements for 7 days during this Run-in phase
223677962|NCT06044935|DIETARY_SUPPLEMENT|Nicotinamide Riboside|Subjects without MODY2 will take either placebo or NR (1 g BID, 2 g per day total) supplements for 7 days during this Run-in phase
223677972|NCT06143878|DRUG|JNJ-77242113|JNJ-77242113 will be administered orally.
223677973|NCT06143878|DRUG|JNJ-77242113 Matching Placebo|JNJ-77242113 matching placebo will be administered orally.
223677974|NCT06143878|DRUG|Deucravacitinib|Deucravacitinib will be administered orally.
223677975|NCT06143878|DRUG|Deucravacitinib Matching Placebo|Deucravacitinib matching placebo will be administered orally.
223677976|NCT03301220|DRUG|Daratumumab SC: daratumumab + rHuPH20|Participants will receive daratumumab SC injection (daratumumab 1800 mg + rHuPH20 \[2000 U/mL\]) once weekly for Cycles 1 and 2 (Days 1, 8, 15, and 22 of each week), every 2 weeks for Cycle 3 to Cycle 6 (Days 1 and 15), and thereafter every 4 weeks (Day 1) until 39 cycles or up to 36 months or until confirmed disease progression, unacceptable toxicity or withdrawal from the study treatment, study termination or study completion. Each cycle is 28 days in duration.
223677977|NCT02919592|DEVICE|MemoryShape® Breast Implants|MENTOR® MemoryShape™ Breast Implants are devices with shells constructed from medical grade silicone elastomer. The shell is filled with Mentor's proprietary formulation of medical grade silicone gel. The textured shell is constructed of successive crosslinked layers of silicone elastomer, and includes raised orientation marks on the anterior and posterior of the implant intended to help the physician orient the implant and ensure proper placement during implantation. Each MENTOR® MemoryShape™ Breast Implant is provided sterile. MemoryShape Breast Implants are available in sizes ranging from 120 cc-775 cc and 5 styles with various projection and height options.
223677978|NCT02919592|DEVICE|MemoryGel® Breast Implants|MENTOR® MemoryGel™ Breast Implants are round devices with shells constructed from medical grade silicone elastomer. The shell is filled with MemoryGel™, Mentor's proprietary formulation of medical grade silicone gel, and is constructed of successive cross-linked layers of silicone elastomer. There are two styles of shell: smooth and textured. Each MENTOR® MemoryGel™ Breast Implant is provided sterile. MemoryGel Breast Implants are available in sizes ranging from 100 cc-800 cc and 4 styles with various projection and height options.
223677979|NCT02919592|PROCEDURE|Other Aesthetic Surgery|Other aesthetic surgery procedures (for example, liposuction, rhinoplasty, brow lift, rhytidectomy, mentoplasty/genioplasty, otoplasty, or blepharoplasty; may not include silicone implants)
223677980|NCT05242484|BIOLOGICAL|Guselkumab|Guselkumab will be administered as subcutaneous injection.
223773212|NCT01319734|DRUG|glyburide|this group receiving glyburide 5 mg alone
223773213|NCT05746338|DEVICE|Ring-type wearable device|The ring-type wearable device is a slim, lightweight smart ring that continuously tracks blood oxygen saturation and heart rate throughout the day.
224258987|NCT02404701|DIETARY_SUPPLEMENT|Bilberry|Eligible participants who provide consent/authorization will report for an orientation visit (1 of 3 visits), during which participants will: provide a medical history and a 24-hour diet recall, have height and weight measured, learn how to collect 24-hour urine, receive instructions on following a standardized diet for 7 days, learn to use a food scale and provide diet records, and receive a 4-day supply of the supplement they were allocated to take along with instructions. After 3 days on the diet (no supplement), participants will return their first (of 2) diet record and 24-hour urine collection. After 4 days on the diet while taking the supplement, participants will return their second (and final) completed diet record and their second (and final) 24-hour urine collection.
224322676|NCT03059940|OTHER|Shared Decision Making + Video|Participants given shared decision making and discussion about screening with the LDCT provider. Participants watch a short video about lung cancer, CT scans, and smoking cessation.
223677981|NCT05242484|BIOLOGICAL|Golimumab|Golimumab will be administered as subcutaneous injection.
223677982|NCT05242484|BIOLOGICAL|JNJ-78934804|JNJ-78934804 will be administered subcutaneously as per defined regimen.
224322677|NCT03059940|BEHAVIORAL|Cessation Counseling|Brief cessation counseling given by LDCT provider.
223677983|NCT05242484|DRUG|Placebo|Placebo will be administered as subcutaneous injection.
223773214|NCT05746338|DEVICE|Overnight polysomnography|Overnight polysomnography is the gold standard for diagnosing OSAS.
223773215|NCT01478698|DRUG|Tissue Plasminogen Activator (tPA)|tPA 10mg per dose intraperitoneal
223773216|NCT01478698|DRUG|recombinant deoxyribonuclease (DNase)|DNase 5mg per dose given intraperitoneally.
223773217|NCT01984723|DRUG|Experimental: EVP-6124|
223773218|NCT00006508|PROCEDURE|Controlled hypoglycemia using insulin|
223773219|NCT00006508|PROCEDURE|formula meal|
224322678|NCT03059940|BEHAVIORAL|Quitline|Participants referred to the Quitline for counseling. Participants have 5 smoking cessation counseling sessions over the next 12 weeks.
223773220|NCT05309512|BIOLOGICAL|KN052|0.01mg/kg, 0.1mg/kg, 0.3mg/kg, 1mg/kg, 2mg/kg, 4mg/kg, 6mg/kg, 9mg/kg, RP2D once every two or three weeks intravenously
224258988|NCT02404701|DIETARY_SUPPLEMENT|Cinnamon|Eligible participants who provide consent/authorization will report for an orientation visit (1 of 3 visits), during which participants will: provide a medical history and a 24-hour diet recall, have height and weight measured, learn how to collect 24-hour urine, receive instructions on following a standardized diet for 7 days, learn to use a food scale and provide diet records, and receive a 4-day supply of the supplement they were allocated to take along with instructions. After 3 days on the diet (no supplement), participants will return their first (of 2) diet record and 24-hour urine collection. After 4 days on the diet while taking the supplement, participants will return their second (and final) completed diet record and their second (and final) 24-hour urine collection.
224258989|NCT02404701|DIETARY_SUPPLEMENT|Milk thistle|Eligible participants who provide consent/authorization will report for an orientation visit (1 of 3 visits), during which participants will: provide a medical history and a 24-hour diet recall, have height and weight measured, learn how to collect 24-hour urine, receive instructions on following a standardized diet for 7 days, learn to use a food scale and provide diet records, and receive a 4-day supply of the supplement they were allocated to take along with instructions. After 3 days on the diet (no supplement), participants will return their first (of 2) diet record and 24-hour urine collection. After 4 days on the diet while taking the supplement, participants will return their second (and final) completed diet record and their second (and final) 24-hour urine collection.
224258990|NCT02404701|DIETARY_SUPPLEMENT|Turmeric|Eligible participants who provide consent/authorization will report for an orientation visit (1 of 3 visits), during which participants will: provide a medical history and a 24-hour diet recall, have height and weight measured, learn how to collect 24-hour urine, receive instructions on following a standardized diet for 7 days, learn to use a food scale and provide diet records, and receive a 4-day supply of the supplement they were allocated to take along with instructions. After 3 days on the diet (no supplement), participants will return their first (of 2) diet record and 24-hour urine collection. After 4 days on the diet while taking the supplement, participants will return their second (and final) completed diet record and their second (and final) 24-hour urine collection.
224258991|NCT02404701|DIETARY_SUPPLEMENT|Aloe vera|Eligible participants who provide consent/authorization will report for an orientation visit (1 of 3 visits), during which participants will: provide a medical history and a 24-hour diet recall, have height and weight measured, learn how to collect 24-hour urine, receive instructions on following a standardized diet for 7 days, learn to use a food scale and provide diet records, and receive a 4-day supply of the supplement they were allocated to take along with instructions. After 3 days on the diet (no supplement), participants will return their first (of 2) diet record and 24-hour urine collection. After 4 days on the diet while taking the supplement, participants will return their second (and final) completed diet record and their second (and final) 24-hour urine collection.
224258992|NCT05315557|DRUG|Terlipressin|1mg/24 hour and titrate according to MAP
224258993|NCT05315557|DRUG|vasopressin|0.03 U/hour and titrate according to MAP
224258994|NCT02310386|DEVICE|BEMER electromagnetic field therapy|To study the effects of three months electromagnetic field therapy on pain in women with fibromyalgia.
224258995|NCT01499186|OTHER|Local Vibration|The subjects of the vibration group will be subjected to local vibration training by the use of custom-made cylindrical vibrators which will be placed on the hip and thigh. The subjects will apply the vibrations by themselves and they will learn how to follow the pre-programmed training program. Training sessions take place 5 times a week, during one year. The physiotherapist and the research assistant will attend the training session 1x/week. Training parameters will vary during the year to create a variable stimulus (frequency 40-80Hz and G-force 0.5-5g). The intervention group will perform all measurements.
224258996|NCT05294471|DEVICE|Non-contrast MRI with novel MRI software|The investigational software being used in automatic prescription of the imaging is an application of an AI algorithm. This software prescribes where the MRI system will take images by finding the liver within a set of localizer scans. The software gives coordinates to the scanner.
224258997|NCT01083264|DRUG|Gestodene/EE Patch (BAY86-5016)|Transdermal Patch, 0.55mg Ethinylestradiol + 2.1mg Gestodene, 4x7 days patch wearing period, patch-free interval of 7 days, application site: buttocks
224258998|NCT01083264|DRUG|Gestodene/EE Patch (BAY86-5016)|Transdermal Patch, 0.55mg Ethinylestradiol + 2.1mg Gestodene, 4x7 days patch wearing period, patch-free interval of 7 days, application site: arm
224258999|NCT01083264|DRUG|Gestodene/EE Patch (BAY86-5016)|Transdermal Patch, 0.55mg Ethinylestradiol + 2.1mg Gestodene, 4x7 days patch wearing period, patch-free interval of 7 days, application site: abdomen
224259000|NCT00996684|DRUG|Microplasmin|Microplasmin, 1.875 mg, will be given by intravitreal injection,on Day 0.
224259001|NCT00996684|DRUG|Placebo control|The placebo control will be the microplasmin vehicle without the microplasmin.
224259002|NCT03266393|DRUG|Envarsus XR|Once daily sustained-release tacrolimus
224259003|NCT03266393|DRUG|Tacrolimus|Twice daily immediate-release tacrolimus
224259004|NCT04757298|BEHAVIORAL|Navigation Services|Navigation services include assessment and support with service referrals. Each participant will meet with a peer navigator in person or on Zoom Conferencing for 30 minutes to go over results from their social and health needs assessment that is retrieved from the baseline assessment. The navigator shares information about COVID-19, answers questions about testing, and makes referrals to other needed services
223677989|NCT03153475|DEVICE|ATTUNE Revision Knee System in Revision Total Knee Arthroplasty|Implants from the ATTUNE Revision Knee System will be used to treat subjects whose surgeons have determined their existing implants need to be removed and replaced.
223677993|NCT03652064|DRUG|Daratumumab|Daratumumab (1800 mg) will be administered by SC injection once every week for Cycles 1 to 2, then every 3 weeks for Cycles 3-8. For Cycle 9 and beyond, participants will receive daratumumab 1800 mg SC once every 4 weeks until documented disease progression or unacceptable toxicity.
223677994|NCT03652064|DRUG|Bortezomib|Bortezomib 1.3 mg/m\^2 will be administered by SC injection twice weekly on Days 1, 4, 8, and 11 of each 21-day cycle for Cycles 1-8.
224259005|NCT04757298|BEHAVIORAL|Critical Dialogue|Critical Dialogue includes three one-hour-long, open-group-sessions facilitated in person or online by a trained licensed facilitator. Group critical dialogue is prompted by thematic images developed by the NCCB to foster a deeper understanding of how systematic stigma, feelings of rage as victims of discrimination, and/or apathy may impact participants' beliefs and behaviors related to COVID-19 and empower participants to make critical choices to protect their health and the health of their communities.
224259006|NCT04757298|BEHAVIORAL|Brief Counseling|Brief Counseling is a 15-minute post-COVID-19 test session delivered by a trained licensed clinician in person or via Zoom Conferencing. In the session, the clinician shares the test results and offers recommendations and information about COVID-19 treatment and prevention.
224259007|NCT04757298|BEHAVIORAL|Referral and Digital Brochure|Referral will consist of a five-minute phone call where an outreach worker offers participants information about COVID-19 testing and encourages them to get tested within one week. A digital brochure containing NJ recommendations is e-mailed or texted to participants.
224259008|NCT01639911|DRUG|Alisertib|Alisertib at the assigned dose by mouth (PO) twice a day for 7 days beginning on day 1 of a 21 day cycle.
224259009|NCT01639911|DRUG|Pazopanib|Pazopanib at the assigned dose once a day continuously for the duration of treatment.
224259010|NCT00938509|DRUG|ibuprofen suppositories|5-10 mg/kg/day-suppositories
223677995|NCT03652064|DRUG|Lenalidomide|Lenalidomide will be self-administered at a dose of 25 mg orally on Day 1 to Day 14 for Cycles 1 through 8 and on Days 1 to 21 for Cycle 9 and beyond until disease progression or unacceptable toxicity whichever occurs first.
223677996|NCT03652064|DRUG|Dexamethasone|Dexamethasone will be self-administered orally, 20 mg on Days 1, 2, 4, 5, 8, 9, 11, 12 of each 21-day cycle for Cycles 1-8. During Cycle 9 and beyond dexamethasone, will be self-administered orally at a total dose of 40 mg on Days 1, 8, 15, 22 of each 28-day cycle.
224259011|NCT02489461|DRUG|VM-1500|VM-1500 up to 96 weeks
224259012|NCT02489461|DRUG|Efavirenz|Efavirenz up to 48 weeks
224259013|NCT02489461|DRUG|Antiretroviral therapy (ART)|Antiretroviral therapy up to 96 weeks
224259014|NCT00006468|DRUG|FOLFOX regimen|
224259015|NCT00006468|DRUG|fluorouracil|
224259016|NCT00006468|DRUG|leucovorin calcium|
224259017|NCT00006468|DRUG|oxaliplatin|
223678007|NCT05789082|DRUG|Divarasib|Participants will receive one of two doses of divarasib orally (PO), QD on days 1-21 of each 21-day cycle.
223678008|NCT05789082|DRUG|Pembrolizumab|Participants will receive a 200 mg IV infusion of pembrolizumab Q3W on Day 1 of each 21-day cycle.
223678009|NCT05789082|DRUG|Carboplatin|Participants will receive IV carboplatin Q3W for four 21-day cycles.
223678010|NCT05789082|DRUG|Cisplatin|Participants will receive IV cisplatin Q3W for four 21-day cycles.
223678011|NCT05789082|DRUG|Pemetrexed|Participants will receive IV pemetrexed Q3W.
224259018|NCT04252001|DEVICE|YESS! game|"The YESS! game is a real-life game for smartphone or tablet in which the player has to solve a mystery. The adolescent plays an active role in the course of the story. This results in an interactive experience. During the game, the adolescent is challenged with regard to self-management and responsible behaviour in general life, with parallels to medical selfmanagement and responsible behaviour.~The adolescent has to decide at several different moments whether to take action or not, whether to accept help or not and whether to share (fictive) confidential information or not. Other aspects that are covered are 'taking responsibility' and 'being on time'. The choices the adolescent makes throughout the game are registered in a coded manner, for later analysis. The game is available in Dutch, English and Spanish."
224259019|NCT04252001|DEVICE|Snake '97|Snake '97 is a game for smartphone or tablet which is free and can be downloaded in the App Store. The game is a remake of the original snake on the mobile phone in 1997 in which the player moves the snake around and makes the snake 'consume food' (little dots) which causes the snake to grow longer. The goal is to make the snake as large as possible. The game has 12 difficulty levels.
224259020|NCT04252001|OTHER|Transition-toolkit|The transition toolkit consists of paper cards with assignments, ideas and tips regarding medical self-management.
224259021|NCT04048096|DIETARY_SUPPLEMENT|Krill Oil|Aker Biomarine Superba Krill Oil
224259022|NCT04048096|DIETARY_SUPPLEMENT|Placebo|Mixed vegetable oil
224259023|NCT03548363|DIETARY_SUPPLEMENT|Gingest powdered extract obtained from Ginger rhizomes|"Description: Powdered extract obtained from Ginger rhizomes. Botanical name: Zingiber officinale Roscoe Plant part used: Dried rhyzome Extraction solvent: CO2 Extract Ratio 45-60 / 1 100mg of extract are equivalent to an average of 4400 mg of dry ginger rhizomes~Composition: Natural extract, Calcium Hydroxide, Polysorbate 80, De-oiled soya lecithin, Calcium silicate"
223678024|NCT06308263|DRUG|Tuvusertib [14C]Tuvusertib microtracer|Participants will receive single oral dose of Tuvusertib containing a \[14C\] Tuvusertib microtracer solution on Day 1 of period 1 under fasted conditions.
223678025|NCT06308263|DRUG|Tuvusertib|Participants will also receive a single oral dose of Tuvusertib on Day 1 of Period 1 or Period 1a, and daily single oral dose of Tuvusertib for 2 weeks in 21 days cycle of Period 2.
223678026|NCT06308263|DRUG|Tuvusertib + [14C]Tuvusertib microdose bolus injection|In Period 1a, participants will receive on Day 1 of Period 1 a single oral dose of tuvusertib and an intravenous (IV) (14C) tuvusertib microdose as bolus injection.
223678032|NCT06500702|DRUG|frexalimab|frexalimab treatment
223678033|NCT06500702|DRUG|SAR442970|SAR442970 treatment
223678034|NCT06500702|DRUG|rilzabrutinib|rilzabrutinib treatment
223678035|NCT06500702|DRUG|placebo|placebo treatment
224259024|NCT03548363|DIETARY_SUPPLEMENT|Placebo|200 mg/d maltodextrin
223678043|NCT05352919|DRUG|Litifilimab|Administered as specified in the treatment arm.
223678044|NCT05352919|DRUG|Litifilimab-matching placebo|Administered as specified in the treatment arm.
224259025|NCT01528696|DEVICE|Silverlon|"Patients will be randomized to either receive a silver dressing. Patients who receive a silver dressing will have that dressing replaced on postoperative day number 2. This will be left in place until the patient is seen for follow up by the visiting nurse.~All patient will be evaluated by the visiting nurse on postoperative day 4 or 5 and have their wounds photographed. All patients will be contacted for a brief survey 6 weeks postpartum."
224259026|NCT01528696|DEVICE|Standard Dressing|Standard island dressing. Patients who receive a standard dressing will have that dressing removed on postoperative day 2. This will be left in place until the patient is seen for follow up by the visiting nurse.
224259027|NCT06448221|BEHAVIORAL|a web-based Relationship Teaching(RT)/communication education programs|receives the RT program and uses 3 months' smartphone-based videoconferencing without the HEA system.
223678063|NCT03977233|DRUG|Oxaliplatin|85 mg/m2 in 250 cc Dextrose solution given by IV on Day 1 of each 14-day cycle
223678064|NCT03977233|DRUG|Leucovorin|400 mg/m2 in 100 cc dextrose solution given with irinotecan by IV on Day 1 of each 14-day cycle
223678065|NCT03977233|DRUG|Irinotecan Hydrochloride|180 mg/m2 in 500cc dextrose solution given with leucovorin by IV on Day 1 of each 14-day cycle
223678066|NCT03977233|DRUG|5-FU|400 mg/m2 bolus and then 2400 mg/m2 via continuous infusion on Day 1 of each 14-day cycle
223678072|NCT05050097|DRUG|Talquetamab|Talquetamab will be administered subcutaneously.
223678073|NCT05050097|DRUG|Carfilzomib|Carfilzomib will be administered as an IV infusion.
224259028|NCT06448221|BEHAVIORAL|Helper of Emotional Assessment Relationship Teaching (HEART) program|receives the RT program and uses 3 months smartphone-based videoconferencing along with the HEA system
224259029|NCT02143245|DIAGNOSTIC_TEST|Synovial Biopsy|Synovial biopsy is a procedure using a guided needle, where 6 to 8 small tissue samples with be extracted from the shoulder using an x-ray guided needle.
223678074|NCT05050097|DRUG|Daratumumab SC|Daratumumab will be administered subcutaneously.
223678075|NCT05050097|DRUG|Lenalidomide|Lenalidomide will be self-administered orally.
223678076|NCT05050097|DRUG|Pomalidomide|Pomalidomide will be self-administered orally.
223678077|NCT06810180|BEHAVIORAL|Go/No-Go Task|A computerized test in which participants are presented with red and green spaceship stimuli. They are told to press the spacebar in response to green spaceships (80% of trials) and withhold their response to red spaceships (20% of trials).
223678078|NCT06810180|BEHAVIORAL|Delay discounting task|Participants make decisions between smaller, immediate rewards and larger, delayed rewards. The amount of the immediate reward and delay time are manipulated to identify individual delay discounting curves, or how the reward value decreases as a function of delay.
224259030|NCT02143245|DIAGNOSTIC_TEST|Open Tissue Biopsy|During the standard of care revision surgery, 6 to 8 small tissue samples will be taken in order to test for infection. This is standard of care treatment. As part of this study, an additional 1 to 2 samples of tissue would be taken in order to develop a test to determine more precisely what type of infection there may be.
224259031|NCT03600805|DRUG|Sarilumab SAR153191|Pharmaceutical form: solution for injection Route of administration: subcutaneous
224259032|NCT03600805|DRUG|Sarilumab matching placebo|Pharmaceutical form: solution for injection Route of administration: subcutaneous
224259033|NCT03600805|DRUG|Prednisone|Pharmaceutical form: tablets or capsules Route of administration: oral administration
224259034|NCT03600805|DRUG|Prednisone matching placebo|Pharmaceutical form: capsules Route of administration: oral administration
224259035|NCT01948167|BEHAVIORAL|Interpersonal Psychotherapy- Adolescent Skills Training|A group prevention program that includes a 60-minute pre-group session, 8 weekly 90-minute group sessions, a 60-minute mid-group session, and 3 60-minute booster sessions. IPT-AST focuses on psychoeducation and interpersonal skill-building to decrease interpersonal conflict and increase interpersonal support and competence.
223678079|NCT06810180|BEHAVIORAL|Mirror Tracing Persistence Task|A computerized test in which participants trace a star line drawing with a computer cursor using a trackpad with reversed directional controls. There are increasing levels of difficulty with participants being told they could quit the task during the very hard third star that they try to trace.
223678080|NCT06810180|BEHAVIORAL|Spatial Span|Participants are instructed to attend to a computer screen to keep track of the order in which a happy face stimuli appears in a sequence of boxes positioned on the screen. They are presented with 2 trials at each level of difficulty, increasing from 2 stimuli by 1 additional stimuli per trial until they respond incorrectly for both trials within a level. There are two task conditions, forward and backward span, with the participant responding in the reverse order that the stimuli were presented for backward span.
224259036|NCT01948167|BEHAVIORAL|Coping with Stress|A group prevention program that consists of 8 acute 90-minute group sessions, 2 parent group sessions, and 3 continuation sessions lasting 60 minutes each. Participants are taught to apply cognitive techniques to their personal thoughts, with the goal of generating effective counterarguments to unrealistic negative beliefs.
223678081|NCT06810180|BEHAVIORAL|Stop Signal Task|A computerized test in which participants are presented with a right or left facing arrow and are instructed to press a response button indicating the direction of the arrow. On 25% of the trials, an auditory beep is presented (i.e., stop signal) following the onset of the arrow (i.e., go signal) and participants are instructed to withhold their response when they hear the stop signal.
223678082|NCT06810180|BEHAVIORAL|Flanker task|A computerized test in which a group of arrows are presented on the screen with the central arrow (target) pointing in the same/opposite direction as the 4 surrounding arrows (flankers). Participants are instructed to respond as quickly and accurately as possible to the central target arrow.
223678083|NCT06808880|DEVICE|Single-gene Noninvasive Prenatal Testing (sgNIPT)|Natera sgNIPT is intended for use in pregnant people whose 'fetus/ fetuses are identified as at increased risk for a single gene disorder when there is no reproductive partner (paternal) screening available or when there is positive reproductive partner screening, but prenatal diagnostic testing is not an option or when there is concern for a single-gene disorder in the fetus/ fetuses irrespective of carrier status (e.g., based on fetal ultrasound findings).
223678084|NCT04840602|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223678085|NCT04840602|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow biopsy and aspiration
223678086|NCT04840602|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy and aspiration
223678087|NCT04840602|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
223678088|NCT04840602|DRUG|Ibrutinib|Given PO
223678089|NCT04840602|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
224259037|NCT00256230|DRUG|Disulfiram (DSF)|DSF pills at 250 mg will be given orally, two times a day. If this dose is tolerated, the dose will be escalated until the maximum tolerated dose is reached. Treatment will continue every day for 3 months or longer unless the disease gets worse, the side effects are too dangerous for the subject, or the subject decides to discontinue treatment.
224259038|NCT01767363|OTHER|5-alpha reductase inhibitors|Use of 5-alpha reductase inhibitors over the course of the study period.
224259039|NCT01767363|OTHER|Alpha-blockers|Use of alpha-blockers over the study period.
224259040|NCT01138163|DRUG|Docetaxel plus bavituximab or placebo|Patients will be randomized to receive docetaxel plus placebo, docetaxel plus 1 mg/kg bavituximab, or docetaxel plus 3 mg/kg bavituximab in the Combination Therapy Period. The Combination Treatment Period for each patient will begin on Study Day 1. Docetaxel, 75 mg/m2, will be given on Day 1 of each 21 day cycle for up to 6 cycles, and placebo or the assigned dose of bavituximab will be given weekly. Docetaxel administration will occur every 21 days. All patients who complete the Combination Therapy Period (or discontinue for any reason other than disease progression or toxicity) will be eligible to enter the Monotherapy Period. Patients will continue to receive assigned blinded treatment (placebo or 1 or 3 mg/kg bavituximab) weekly until progression or toxicity.
224259041|NCT00320034|DRUG|R-albuterol, S-albuterol|
224322679|NCT03059940|BEHAVIORAL|Pharmacotherapy Discussion|Participant informed of the risk, benefits and relative efficacy of cessation medications and to assess their medication preferences, expectations and medical suitability for either option. At the conclusion of this conversation the patient is provided with an initial supply of the medication jointly decided between provider and patient.
224322680|NCT03059940|DRUG|Nicotine Patch|Nicotine patch dispensed. Dosing at physician's discretion.
224322681|NCT03059940|DRUG|Anti-Smoking Drug|Varenicline or Buproprion prescribed by study doctor with directions of when and how much of anti-smoking drug that should be taken each time.
223678090|NCT04840602|BIOLOGICAL|Rituximab|Given IV
223678091|NCT04840602|DRUG|Venetoclax|Given PO
223678094|NCT07120763|DRUG|Ketamine + Lidocaine|Including comparisons between patients randomized for treatment with full ketamine sedation in setting of distal radius fracture reduction, hematoma block/minimal ketamine pain control (. 0.25mg/kg) for distal radius fracture reduction, or intranasal fentanyl and hematoma block, utilized in the setting of distal radius fractures in pediatric patients requiring reduction
223678095|NCT07120763|DRUG|Ketamine group|Including comparisons between patients randomized for treatment with full ketamine sedation in setting of distal radius fracture reduction, hematoma block/minimal ketamine pain control (. 0.25mg/kg) for distal radius fracture reduction, or intranasal fentanyl and hematoma block, utilized in the setting of distal radius fractures in pediatric patients requiring reduction
223678096|NCT07120763|DRUG|Fentanyl (Nasalfent, Fentanyl Citrate Nasal Spray)|Including comparisons between patients randomized for treatment with full ketamine sedation in setting of distal radius fracture reduction, hematoma block/minimal ketamine pain control (. 0.25mg/kg) for distal radius fracture reduction, or intranasal fentanyl and hematoma block, utilized in the setting of distal radius fractures in pediatric patients requiring reduction
223678097|NCT02908906|DRUG|JNJ-63723283|JNJ-63723283 will be administered by IV infusion or SC injection or infusion.
223678098|NCT06319820|COMBINATION_PRODUCT|TAR-210|TAR-210 will be administered intravesically.
223678099|NCT06319820|DRUG|Gemcitabine|Gemcitabine will be administered intravesically.
223678100|NCT06319820|DRUG|MMC|MMC will be administered intravesically.
223678103|NCT04107285|BEHAVIORAL|neurocognitive evaluations|The test battery consists of validated and reliable measures of attention, executive functions and memory.
223678104|NCT04107285|DIAGNOSTIC_TEST|brain MRIs|Patients will undergo baseline and follow-up research MRIs in the same scanner at MSKCC (3 Tesla scanner (GE, Discovery 750W, USA) with a GEM HNU 24-channel head coil) (total scan duration=15 minutes).
223678105|NCT04107285|OTHER|Blood samples|Blood samples will be collected at each time point (Day -1, day 0, day 1, day 3, day 5, day 7, day 10, day of neurotoxicity onset, and 3-4 months post- CART).
223678106|NCT03875235|DRUG|Durvalumab|IV infusion every 3 weeks with gemcitabine plus cisplatin up to 8 cycles followed by monotherapy every 4 weeks until disease progression or other discontinuation criteria.
223678107|NCT03875235|DRUG|Placebo|IV infusion every 3 weeks with gemcitabine plus cisplatin up to 8 cycles followed by monotherapy every 4 weeks until disease progression or other discontinuation criteria.
223678111|NCT04901195|DRUG|Bimekizumab|Subjects will receive bimekizumab at pre-specified time-points.
223678112|NCT05567796|DRUG|Cagrilintide|Cagrilintide will be administered subcutaneously.
223678113|NCT05567796|DRUG|Semaglutide|Participants will recieve semaglutide subcutaneously.
223678114|NCT05567796|DRUG|Placebo cagrilintide|Participants will receive placebo matched to cagrilintide.
223678115|NCT05567796|DRUG|Placebo semaglutide|Participants will receive placebo matched to semaglutide.
223678116|NCT06260891|DRUG|25 mg/day zinc|25 mg of zinc as zinc gluconate taken orally once a day
223678117|NCT06260891|DRUG|40 mg/day zinc|40 mg of zinc as zinc gluconate taken orally once a day
223678120|NCT06655649|DIETARY_SUPPLEMENT|Ketone-IQ (1,3 Butanediol)|Ketone-IQ (1,3 Butanediol) 20 or 40 g will be ingested (open-label) before bedtime.
224322682|NCT03059940|BEHAVIORAL|Tobacco Treatment Program|Participant referred to Tobacco Treatment Program (TTP). TTP provides 4-8 counseling sessions and pharmacotherapy over a 10-12 week period,
224322683|NCT03059940|OTHER|Carbon Monoxide (CO) Level Test|Participant asked to blow air through a CO-measuring device.
224322684|NCT03218761|DIAGNOSTIC_TEST|NET mRNA level|quantification of mRNA to the Norepinephrine Transporter (NET)
224322685|NCT03218761|DIAGNOSTIC_TEST|Plasma catechols|plasma for assay of norepinephrine (NE), DHPG (intraneuronal metabolite of NE), and other catechols
223678135|NCT06814977|PROCEDURE|Acupuncture|Acupuncture is a non-pharmacological intervention that does not involve the use of any therapeutic agents or devices. Participants will receive 10 weekly treatments over 10 weeks.
224259042|NCT06313034|BEHAVIORAL|Breastfeeding education based on motivational interviewing technique|"Breastfeeding education based on motivational interviewing technique; Breast milk properties, benefits to mother and baby, breastfeeding positions, the relationship between breastfeeding and attachment, signs of hunger in the newborn, Breastfeeding frequency, duration and termination, Breast milk expressing methods, Expressions showing that the newborn has enough milk, Breast milk storage will cover the topics. These topics will be given based on motivational interviewing technique.~According to the motivational interviewing technique, the mother's intention, importance and confidence-sufficiency regarding breastfeeding will be determined and firstly, an agenda will be created on issues related to breastfeeding with the mother. Each session will be conducted by following the open-ended questioning, verification, reflective listening and summarizing approaches of the motivational interviewing technique."
223678143|NCT04015180|DRUG|Eylea (Aflibercept, BAY86-5321)|Treatment administered in 20090. Solution in a sterile glass vial, Dose A, IVT injection.
223678144|NCT04015180|PROCEDURE|Laser photocoagulation|Treatment administered in 20090. Transpupillary conventional laser ablative therapy
223678145|NCT06159673|DRUG|ACP-204|ACP-204 is a potent and selective antagonist/inverse agonist of 5-hydroxytryptamine (serotonin) receptor subtype 2A.
223678146|NCT06159673|DRUG|Placebo|ACP-204 matching placebo
224259043|NCT01855035|OTHER|prolonged ECG monitoring|10-day Holter ECG measurement
224259044|NCT01855035|OTHER|standard care|Usual care according to current guidelines (minimum of 24 hours of cardiac monitoring).
224259045|NCT04985019|PROCEDURE|Arm I (Prepectoral)|Participants followed the Self-Guided Virtual Reality-based Cognitive Behavioral Therapy for 4 weeks.
224259046|NCT04985019|OTHER|Arm II (Subpectoral)|Participants followed the Self-Guided Virtual Reality-based Cognitive Behavioral Therapy for 4 weeks.
224259047|NCT04478435|OTHER|glucose loaded clear fluid|Ultrasound assessment of gastric antrum is done at different time interval following glucose loaded clear fluid ingestion
224259048|NCT06195579|BEHAVIORAL|Transforming the Intense Child Workbook (Glasser, 2016)|The NHA was delivered in a guided self-help format, using the Transforming the Intense Child workbook (Glasser, 2016) and weekly phone calls.
224259049|NCT00378547|DRUG|paracetamol + placebo + placebo|Comparing the analgesic effect of combinations of paracetamol + placebo + placebo
224259050|NCT00378547|DRUG|paracetamol + pregabalin + placebo|Comparing the analgesic effect of combinations of paracetamol + pregabalin 300 mg + placebo
223678158|NCT06095115|DRUG|JNJ-77242113|JNJ-77242113 will be administered orally.
223678159|NCT06095115|DRUG|Placebo|Placebo will be administered orally
223678173|NCT03772834|BEHAVIORAL|Exercise Intervention|Undergo resistance training and walking
223678174|NCT03772834|DRUG|Methylphenidate|Given PO
223678175|NCT03772834|OTHER|Placebo|Given PO
223678176|NCT03772834|OTHER|Quality-of-Life Assessment|Ancillary studies
223678177|NCT03772834|OTHER|Questionnaire Administration|Ancillary studies
224259051|NCT00378547|DRUG|paracetamol + pregabalin + dexamethasone|Comparing the analgesic effect of combinations of paracetamol + pregabalin 300 mg + dexamethasone 8 mg
224259052|NCT04875117|DEVICE|Hearing aid|One or two behind the ear hearing aids provided by the UK National Health Service.
224259053|NCT01452802|DEVICE|HM II (HeartMate II LVAD)|The HM II pump contains a single moving component, the rotor. The pump is implanted just below the left hemidiaphragm with the inflow attached to the apex of the left ventricle and the outflow graft anastomosed to the ascending aorta. Blood is pumped continuously throughout the cardiac cycle from the left ventricle to the aorta.
224259054|NCT01452802|DRUG|OMM (Optimal Medical Management)|Optimal medical management per established heart failure guidelines for this subject population including ACE inhibitors, beta blockers and aldosterone antagonists 45 out of the last 60 days or an inability to tolerate neurohormonal antagonists.
224259055|NCT04535388|DEVICE|LK scleral lens|LK scleral lens fitting and application were done for 12 weeks.
224259056|NCT00127153|BIOLOGICAL|V110, pneumococcal vaccine polyvalent|
224259057|NCT02545283|DRUG|Cytarabine|Participants will receive cytarabine 1 gram per square meter (g/m\^2) intravenous (IV) infusion for 5 days of every treatment cycle.
224259058|NCT02545283|DRUG|Idasanutlin|Participants will receive idasanutlin 300 mg per oral (PO) twice daily (BID) (in Cycle 1) or once daily (QD) (in Cycles 2 and 3) for 5 days of every treatment cycle.
224259059|NCT02545283|OTHER|Placebo|Participants will receive idasanutlin matching placebo PO BID or QD for 5 days of every treatment cycle.
224259060|NCT03609203|OTHER|10 Weeks of Strength Trailing|"Week 1 (pre training session): self efficacy survey; 5-point frailty assessment\*; diet survey; metabolic assessment; Functional status and body composition; blood and stool sample~Week 5: self efficacy survey; Functional status and body composition~Week 10: self efficacy survey; 5-point frailty assessment\*; diet survey; metabolic assessment; Functional status and body composition; blood and stool samples"
223678178|NCT03772834|OTHER|Stretching|Undergo stretching
223678179|NCT06651229|DRUG|JNJ-90189892|JNJ-90189892 will be administered.
224259061|NCT03609203|OTHER|Group Nutrition Discussion: week 1, week 5 and week 10|"Week 1 (pre training session): self efficacy survey; 5-point frailty assessment\*; diet survey; metabolic assessment; Functional status and body composition; blood and stool sample~Week 5: self efficacy survey; Functional status and body composition~Week 10: self efficacy survey; 5-point frailty assessment\*; diet survey; metabolic assessment; Functional status and body composition; blood and stool samples"
224259062|NCT05570487|DIAGNOSTIC_TEST|Since the data were collected retrospectively, there were no interventions|Since the data were collected retrospectively, there were no interventions
224259063|NCT00650871|DRUG|GW679769|
223773221|NCT05660616|DRUG|Gemcitabine|"The study includes patients with unresectable malignant pleural mesothelioma who received at least 4 cycles of first line platinum (Cisplatin or Carboplatin) and pemetrexed combination chemotherapy~* Response after first line treatment will be assessed by the modified Response Evaluation Criteria in Solid Tumors (mRECIST) version 1.1 for pleural mesothelioma.~* Patients will be randomized according to a (1:1) ratio to either Arm 1: Administration of maintenance gemcitabine (1000 mg/m²) on days 1 and day 8, in cycles of 21 days plus supportive care Arm 2 (control arm): best supportive care alone.~* Cases will be evaluated every cycle clinically and every three cycles radiologically with CTs."
224259064|NCT00650871|DRUG|Placebo|
223773222|NCT05660616|OTHER|supportive care|supportive care
224259065|NCT00088192|DRUG|pegaptanib sodium|
224259066|NCT01443195|DRUG|Iron preparation|"Iron supplementation with IPC in a dose of 4 mg/kg/day of elemental iron started not before 4 weeks of age and as soon as 120 ml/kg/day of enteral feedings is tolerated given together with the first morning meal. Serum samples will be obtained at 3 different times:~1. Before starting iron supplementation (maximum one week before).~2. At the beginning of iron supplementation in order to assess early signs of erythropoiesis, iron overload or free iron (day 4 - 7 days of supplementation).~3. Before discharge from hospitalization in order to asses the iron metabolism and sings of iron deficiency (At least more than 2 weeks of supplementation)."
224259067|NCT01673672|BIOLOGICAL|CYT003|7 subcutaneous injections, weekly/biweekly within 10 weeks
224259068|NCT01673672|BIOLOGICAL|Placebo|7 subcutaneous injections, weekly/biweekly within 10 weeks
224259069|NCT06626581|DIETARY_SUPPLEMENT|Iodine excess|Iodine excess areas: water iodine ≥100μg/L; or urinary iodine concentration(median urinary iodine levels in children aged 8-10 years old) ≥300μg/L
224259070|NCT06626581|DIETARY_SUPPLEMENT|Iodine suitable|Iodine suitable areas: water iodine ≥40μg/L and ≤100μg/L; or urinary iodine concentration(median urinary iodine levels in children aged 8-10 years old) 100-199μg/L.
224259071|NCT05913128|PROCEDURE|Glandular Urethral Disassembly technique|For Primary Distal Hypospadius Repair
224259072|NCT02826694|GENETIC|Well infant, whole exome sequencing|Whole exome sequencing will be performed in children with diagnosed conditions. Investigators will analyze results that are associated with their condition.
223678192|NCT06819891|DRUG|Afimkibart|Afimkibart will be administered as IV infusion. Afimkibart will be administered as SC injection.
223678193|NCT06819891|DRUG|Placebo|Placebo matching IV afimkibart.
224259073|NCT02826694|GENETIC|Diagnosed, whole exome sequencing|In addition to returning results of conditions associated with a child's phenotype, investigators will also analyze genes that are associated with conditions that have childhood onset and are medically actionable.
224259074|NCT03886129|DIAGNOSTIC_TEST|Transcranial Doppler Ultrasound (TCD)|Participants will undergo an assessment of brain blood flow using TCD, with two small ultrasound probes held in place on the temples with a customised headframe. During the assessment, heart rate, breathing and blood pressure will also be monitored using a 3 lead ECG, nasal capnography and Finometer® respectively. The assessment will comprise three recordings. Firstly, participants will sit quietly for 5 minutes. Next, they will be asked to sit quietly for one minute before standing and remaining standing for 5 minutes. Lastly, they will be asked to stand and then complete a squat-stand manoeuvre in time with a computer sequence. A tilt sensor attached to the thigh will measure the efficiency and angle of the squatting motion. The squat-stand manoeuvre will consist of 15 squats and participants will be informed that they should try and complete all 15 squats if possible.
224322686|NCT03218761|DIAGNOSTIC_TEST|Urine Catechols|urine for assay of norepinephrine (NE), DHPG (intraneuronal metabolite of NE), and other catechols
224259075|NCT01619904|PROCEDURE|Goal-Directed Therapy|Peri-operative optimisation of fluid status, based on Oxygen Delivery
224259076|NCT01619904|PROCEDURE|Standard Therapy|Following standard protocol during peri-operative period
224259077|NCT04581304|DEVICE|Geistlich Bio-Oss® Collagen|Geistlich Bio-Oss® Collagen is intended to be used for filling bone defects and for bone augmentation.
224259078|NCT04581304|DEVICE|Geistlich Bio-Oss® Granules|Geistlich Bio-Oss® Granules is intended to be used for filling bone defects and for bone augmentation.
224259079|NCT00852163|DRUG|Clofarabine with Busulfan|Clofarabine 40 mg/m2 IV QD × 5 days Busulfan (Busulfex™) 3.2 mg/kg IV QD × 2 days
224259080|NCT04715295|DRUG|Doxycycline Tablets|Doxycycline 200 mg daily for 7 days
224259081|NCT04715295|DRUG|Rivaroxaban 15Mg Tab|Rivaroxaban 15 mg tablets daily from day 1 to day 10
224259082|NCT04715295|COMBINATION_PRODUCT|Hydroxychloroquine and Azithromycin|Hydroxychloroquine 400mg daily from day 1 to day 5 in combination with Azithromycin 500mg on day 1 and 250 mg daily from day 2 to day 5
224259083|NCT05305690|OTHER|No intervention|This study did is a retrospective case series and does not involve an intervention. Investigators will compare patients managed operatively vs nonoperatively, focused on nonoperative therapy.
224259084|NCT05150041|DEVICE|Guardian connect|"* Treatment group 1 will go through target lifestyle coaching including diet and exercise and will have 1 session of RT-CGM after which they will undergo 24 weeks of follow-up period.~* Treatment group 2 will go through target life coaching including diet and exercise and will have 2 sessions(CGM 1week, 12week after measuring HbA1c) of RT-CGM after which they will undergo 24 weeks of follow-up period."
224259085|NCT05150041|DEVICE|iPro2|"* Treatment group 1 will go through target lifestyle coaching including diet and exercise and will have 1 session of RT-CGM after which they will undergo 24 weeks of follow-up period.~* Treatment group 2 will go through target life coaching including diet and exercise and will have 2 sessions(CGM 1week, 12week after measuring HbA1c) of RT-CGM after which they will undergo 24 weeks of follow-up period."
224259086|NCT00951457|DRUG|Bendamustine|
224259087|NCT00951457|DRUG|Alemtuzumab|
224322687|NCT06779851|DRUG|BPT567|Immunocytokine infusion
224322688|NCT04269902|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
224322689|NCT04269902|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
224322690|NCT04269902|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
224322691|NCT04269902|PROCEDURE|Computed Tomography|Undergo CT
224322692|NCT04269902|BIOLOGICAL|Obinutuzumab|Given IV
224322693|NCT04269902|OTHER|Questionnaire Administration|Ancillary studies
224322694|NCT04269902|DRUG|Venetoclax|Given PO
224322695|NCT06041503|DRUG|Pembrolizumab|Pembrolizumab is administered IV at 200 mg on day 1 of each 21-day cycle.
224322696|NCT06041503|DRUG|Enfortumab vedotin|EV is administered IV at 1.25 mg/kg on days 1, 8, and 15 of each 28-day cycle (Arm 1) and on days 1 and 8 of each 21-day cycle (Arm 2).
224259088|NCT00447941|DRUG|SCA-136|
224259089|NCT00932841|OTHER|Placebo|One packet PO daily x 8 weeks.
224259090|NCT00932841|DRUG|VSL#3 900 billion bacteria|One packet PO daily, x 8 weeks
224259091|NCT00932841|DRUG|VSL#3 90 billion bacteria|One packet PO daily, x 8 weeks.
224259092|NCT04057287|OTHER|No intervention|No intervention
224259093|NCT02342535|BEHAVIORAL|Physical Activity|Culturally tailored physical activity intervention for South Asian women and their children.
224259094|NCT01834183|DRUG|Tivozanib|
224259095|NCT01834183|DRUG|Gemcitabine|
224259096|NCT03170219|COMBINATION_PRODUCT|subcutaneous furosemide and sc2wear device|subcutaneous furosemide administered via sc2wear device vs. standard of care
224322697|NCT06335303|DRUG|BI 1819479|BI 1819479
224322698|NCT06335303|DRUG|Placebo matching BI 1819479|Placebo matching BI 1819479
224322699|NCT06828588|DRUG|ABY-025 Loading Dose|Subjects will receive a loading dose (400 micrograms) of ABY-025 prior to the \[68Ga\]Ga-ABY-025 infusion.
224322700|NCT06828588|DRUG|[68Ga]Ga-ABY-025|Subjects receive a tracer dose of \[68Ga\]Ga-ABY-025 and will receive a PET/CT scan a few hours after the injection.
224322701|NCT03500328|OTHER|Natalizumab/natalizumab-sztn, Alemtuzumab, Ocrelizumab, Rituximab/rituximab-arrx/rituximab-abbs/rituximab-pvvr, Cladribine, Ofatumumab, Ublituximab-xiiy, Ocrelizumab and hyaluronidase-ocsq|Early Aggressive Therapy
224322702|NCT03500328|OTHER|Glatiramer acetate, Interferons (intramuscular, subcutaneous, pegylated) Teriflunomide, Fumarates (dimethyl, diroximel, monomethyl) Fingolimod, Siponimod, Ozanimod, Ponesimod|Traditional Therapy
223678210|NCT05552976|DRUG|Mezigdomide|Specified dose on specified days
223678211|NCT05552976|DRUG|Carfilzomib|Specified dose on specified days
223678212|NCT05552976|DRUG|Dexamethasone|Specified dose on specified days
223678214|NCT06855771|DRUG|BMS-986504|Specified dose on specified days
223678217|NCT06663332|DRUG|Guselkumab|Guselkumab will be administered as subcutaneous injection.
223678218|NCT06662786|BIOLOGICAL|Amivantamab|Amivantamab will be administered.
223678219|NCT06662786|BIOLOGICAL|Cetuximab|Cetuximab will be administered.
223678220|NCT06662786|DRUG|5-fluorouracil|5-fluorouracil will be administered as chemotherapy regimen.
223678221|NCT06662786|DRUG|Leucovorin calcium/Levoleucovorin|Leucovorin calcium/Levoleucovorin will be administered as chemotherapy regimen.
223678222|NCT06662786|DRUG|Oxaliplatin|Oxaliplatin will be administered as chemotherapy regimen.
223678223|NCT06662786|DRUG|Irinotecan Hydrochloride|Irinotecan hydrochloride will be administered as chemotherapy regimen.
223678226|NCT06660563|DRUG|JNJ-80948543|JNJ-80948543 will be administered as subcutaneous (SC) or intravenous (IV) injection.
223678227|NCT06660563|DRUG|JNJ-75348780|JNJ-75348780 will be administered as SC injection.
223678233|NCT06819878|DRUG|Afimkibart|Afimkibart will be administered as IV infusion. Afimkibart will be administered as SC injection.
223678234|NCT06819878|DRUG|Placebo|Placebo matching IV afimkibart. Placebo matching SC afimkibart.
223678237|NCT06988319|DRUG|Psilocybin (Usona Institute)|Single dose of pharmaceutical grade psilocybin (25 mg) combined with psychotherapy sessions
223678238|NCT03604991|PROCEDURE|Biospecimen Collection|Undergo collection of blood sample
223678239|NCT03604991|DRUG|Carboplatin|Given IV
223678240|NCT03604991|PROCEDURE|Computed Tomography|Undergo CT scan
223678241|NCT03604991|BIOLOGICAL|Ipilimumab|Given IV
223678242|NCT03604991|BIOLOGICAL|Nivolumab|Given IV
223678243|NCT03604991|DRUG|Paclitaxel|Given IV
223678244|NCT03604991|PROCEDURE|Positron Emission Tomography|Undergo PET scan
223678245|NCT03604991|RADIATION|Radiation Therapy|Undergo radiation therapy
223773223|NCT01600300|DEVICE|Tesmac|Subjects were treated twice daily for five consecutive days, followed by two days untreated, and then treated twice daily for five more consecutive days.
224259097|NCT03979664|DEVICE|Activapatch intellidose 2.5 using active Iontophoresis|Iontophoresis is a drug delivery system that uses electromigration and electro-osmosis to move charged molecules. Electromigration is the movement of ions across the skin by an electrical field. Positive ions move away from a cathode (positive charge) and towards an anode (negative charge). Negative ions move away from an anode and towards a cathode. Electro-osmosis is the volume movement of positive ions away from the opposite charge. Since skin is negatively charge, positively charged ions penetrate deep in the tissue from the negatively charged skin. 4 The use of iontophoresis was incorporated into medicine in efforts to increase the penetration of medications and avoid injection procedures. Dexamethasone sodium phosphate 4 mg/mL vial will be used in the study. Using a syringe, 2 cc of dexamethasone will be drawn and poured onto the designated medication site on the iontophoresis patch. Once the medication is poured, the patch will be applied on the skin and turned on.
224259098|NCT03979664|DEVICE|Activapatch intellidose 2.5 using inactive Iontophoresis|Iontophoresis is a drug delivery system that uses electromigration and electro-osmosis to move charged molecules. Electromigration is the movement of ions across the skin by an electrical field. Positive ions move away from a cathode (positive charge) and towards an anode (negative charge). Negative ions move away from an anode and towards a cathode. Electro-osmosis is the volume movement of positive ions away from the opposite charge. Since skin is negatively charge, positively charged ions penetrate deep in the tissue from the negatively charged skin. 4 The use of iontophoresis was incorporated into medicine in efforts to increase the penetration of medications and avoid injection procedures. Inactive medication will be used in the study. Using a syringe, 2 cc of inactive medication will be drawn and poured onto the designated medication site on the iontophoresis patch. Once the medication is poured, the patch will be applied on the skin and turned on.
223678272|NCT02290951|DRUG|Odronextamab multiple dose levels|Administered by intravenous (IV) infusion
223678273|NCT02290951|DRUG|Odronextamab multiple dose levels|Administered by subcutaneous (SC) injection
223773224|NCT01600300|DEVICE|Sham Tesmac device|Treatment with inactivated Tesmac device on the same schedule as the group treated with the active Tesmac device.
224259099|NCT03979664|DRUG|Dexamethasone|Dexamethasone sodium phosphate 4 mg/mL vial will be used in the study. Using a syringe, 2 cc of dexamethasone will be drawn and poured onto the designated medication site on the iontophoresis patch. Once the medication is poured, the patch will be applied on the skin and turned on.
224259100|NCT03570060|BIOLOGICAL|Blood sample|2 ml of blood for testing for serum biomarkers (IL-6, GDF-15, soluble ST-2 soluble, osteoprotegerin, galectin 3)
224259101|NCT03570060|PROCEDURE|Long term ECG monitor|Fitting and removal of a long term ECG monitor (SpiderFlash, LivaNova)
224259102|NCT03570060|PROCEDURE|Monitoring ECG|Recording of automatic ECG monitor results (CSM Philips IntelliVue MP50 system)
224259103|NCT01411462|DEVICE|VIBE + drug-eluting balloon|VIBE before and after durg-eluting balloon angioplasty
224259104|NCT03256396|PROCEDURE|PEEP setting based on esophageal pressure measured|PEEP is set on the basis of esophageal pressure measurement with the aim to maintain transpulmonary pressure during expiration between 0 and 5 cmH2O
224259105|NCT03264092|PROCEDURE|Endoscopic ultrasound guided fine needle biopsy|Using the echoendoscope the lesion is identified and the needle is inserted in it to obtain a biopsy also under sonographic guidance
224259106|NCT04162899|DRUG|Drug: SHR0302|The study drug, SHR0302, is designed to block the activity of an enzyme protein called JAK-1(known as a JAK-1 inhibitor).
224259107|NCT01205035|DRUG|ranibizumab 2.0mg|Baseline monthly intravitreal injection of ranibizumab 2.0mg for 3 months followed by possible monthly injections up to 9 additional injections
224259108|NCT06627023|DEVICE|Implant Placement with Conical or Butt-Joint Connection|Thirty eight patients were enrolled in the study and received randomly allocated implants with conical and butt-joint implant-abutment connection type. A standard healing abutment was placed after 6 months for two weeks. The definitive screw retained crowns were manufactured in a digital workflow. The soft tissue profile was digitized using IOS on following stages: pre-op, post-op: immediately, two, 7 and 14 days, pre-exposure, immediately after exposure, two weeks after exposure (pre-delivery), immediately after crown delivery, 6 and 12 months post-op.
224259109|NCT04982523|BEHAVIORAL|Online Mental Health Program|The proposed program consisted of eight sessions conducted twice per week, consisting of 5 minutes of introductory material, 12-15 minutes of main content, and 5 minutes of concluding content. The main content intended to improve the control processes and each of the four adaptive modes of the RAM. The eight sessions were uploaded on the web. Links and passwords for each session were provided to the participants through SNS. The program was accessible from any electronic device with Internet access
224322703|NCT06174805|DEVICE|AXIOS(TM) Stent and Electrocautery Enhanced Delivery System|Patients who meet all the inclusion criteria and none of the exclusion criteria will have a EUS-guided gastroenterostomy (EUS-GE) using the AXIOS(TM) lumen-apposing Metal Stent for the management of symptoms associated with gastric outlet obstruction from malignant unresectable neoplasm
224259110|NCT01774058|DRUG|Ilomedin|3000ng ilomedin in 15ml salt water will be injected intraarterial into the common femoral artery over 2 minutes for one time,then the investigators will measure the blood flow volume after 5 and then after 10 minutes on the common femoral artery. The patients will be observed by the anaesthesiologist. The patient will get ilomedin one day before the surgery and then for 6 day after surgery into the vein. (10microgramm/o,5ml in 250ml salt water)
224322704|NCT04930653|PROCEDURE|Extracorporeal Photopheresis|Undergo ECP
224322705|NCT04930653|BIOLOGICAL|Mogamulizumab|Given IV
224322706|NCT04930653|OTHER|Quality-of-Life Assessment|Ancillary studies
224322707|NCT04930653|OTHER|Questionnaire Administration|Ancillary studies
224322708|NCT06694454|DRUG|azacytidine|"Aerosolized azacytidine (AZA) via nebulizer on 3 consecutive days during the first week of every cycle (1 cycle=21 days), for a maximum (total) of 3 cycles.~Azacytidine will be given at escalating doses in phase 1, and at the established RP2D in phase 2."
224322709|NCT06694454|DRUG|carboplatin|Carboplatin (intravenous/IV), area under the serum drug concentration-time curve (AUC)=5-6 mg/mL/min based on cancer histology administered on day 4 of every cycle (1 cycle=21 days), for a maximum (total) of 3 cycles.
224322710|NCT06694454|DRUG|paclitaxel|Paclitaxel (IV), 200 mg/m\^2, is administered on day 4 of every cycle (1 cycle=21 days), for a maximum (total) of 3 cycles.
224322711|NCT06694454|DRUG|durvalumab|Durvalumab (IV) administered as a flat dose of 1500 mg on day 4 of every cycle (1 cycle=21 days), for a maximum (total) of 3 cycles.
223678288|NCT06988488|DRUG|Elranatamab|Specified dose on specified days
223678289|NCT06988488|DRUG|Mezigdomide|Specified dose on specified days
223678290|NCT06988488|DRUG|Dexamethasone|Specified dose on specified days
224322712|NCT06694454|DRUG|cisplatin|Cisplatin (IV), 75 mg/m\^2, administered on day 4 of every cycle (1 cycle=21 days), for a maximum (total) of 3 cycles.
224322713|NCT06694454|DRUG|gemcitabine|Gemcitabine (IV), 1,250 mg/m\^2, administered on day 4 of every cycle (1 cycle=21 days), for a maximum (total) of 3 cycles.
224322714|NCT06694454|DRUG|pemetrexed|Pemetrexed (IV), 500 mg/m\^2, administered on day 4 of every cycle (1 cycle=21 days), for a maximum (total) of 3 cycles.
224259111|NCT04492696|OTHER|Education|Education
224259112|NCT02663349|BEHAVIORAL|Social Cognition and Intervention Training|A manualized group therapy that teaches social cognitive skills.
223678296|NCT04526665|DRUG|Elafibranor 80mg|Elafibranor 80mg daily
223678297|NCT04526665|DRUG|Placebo|Placebo daily
223678298|NCT06612268|DRUG|Etavopivat|Etavopivat will be administered orally.
223678299|NCT06612268|DRUG|Placebo|Placebo matching Etavopivat will be administered orally.
223773225|NCT00297817|BIOLOGICAL|serogroup B meningococcal vaccine|0.5mL doses in pre-filled syringes. All subjects will receive the study vaccine following a 0,2,6 vaccination schedule.
224259113|NCT04865471|PROCEDURE|Liver transplantation|Auxiliary liver transplantation and staged hepatectomy
223773226|NCT00297817|BIOLOGICAL|serogroup B meningococcal vaccine|0.5mL doses in pre-filled syringes. All subjects will receive the study vaccine following a 0,2,6 vaccination schedule.
223773227|NCT00297817|BIOLOGICAL|serogroup B meningococcal vaccine|0.5mL doses in pre-filled syringes. All subjects will receive the placebo following a 0,2,6 vaccination schedule.
223773228|NCT00284531|DRUG|Daclizumab|
223773229|NCT01878604|GENETIC|Gene analysis|Gene analysis
223773230|NCT01878604|OTHER|Historical data of lipid-lowering drug administration|Collecting historical data of lipid-lowering drug administration
223773231|NCT01878604|OTHER|Historical data of plasma lipids, xanthoma changes|Collecting historical data of plasma lipids and xanthoma changes
224322715|NCT04798768|DEVICE|mCRM Therapy System|Communication testing between S-ICD and LCP in 4 body postures as well as required electrical testing.
224322716|NCT04167969|DRUG|(64Cu)-NOTA-PSMAi-PEG-Cy5.5-C' dot tracer, or (89Zr)-DFO-PSMAi-PEG-Cy5.5-C' dots|Patients will be injected with approximately 6-7 mCi (+/- 10%) of 64Cu-NOTA-PSMAi-PEG-Cy5.5-C' dots or 89Zr-DFO-PSMAi-PEG-Cy5.5-C' dots, up to 48 hours before surgery.
224322717|NCT04167969|DIAGNOSTIC_TEST|PET/MRI/fluorescence imaging|Imaging will be performed using the GE Signa PET/MRI.
224322718|NCT04167969|OTHER|Blood and urine sampling|Staff will perform the IV blood draws and collect urine samples
224259114|NCT06802471|DEVICE|electroacupuncture|"The supine position, the local skin of the acupoints was routinely sterilized, and the selected acupoints were pasted with Acupuncture auxiliary device.~The main acupuncture points are DU20, bilateral EX-HN5, ST8, GB20, GB20, LI4, LR3, ST40.~Select compatible acupoints based on the patient's accompanying symptoms: 1.Discomfort in the neck: EX-B2 of Cervical 3-4; 2.Emotional anxiety, depression or sleep disorders: GV29, HT7; 3.Stomach or abdominal discomfort: CV12, ST25 and CV6.~The disposable acupuncture needles and the electronic acupuncture treatment instrument SDZ-V nerve and muscle intimulator both manufactured by Suzhou Medical Appliance Factory Co., Ltd., China.The specifications of acupuncture needles are Φ0.30×25mm, Φ0.30×40mm, Φ0.30×50mm. The needles will be inserted into the skin of acupuncture points and manipulated manually by using the techniques such as lifting, thrusting, and twirling, until the internal compound sensation known as deqi."
224259115|NCT06802471|DEVICE|Sham electroacupuncture|"The SEA group will use Hua Tuo brand disposable non-insertive sham control needles (Φ0.3mm×40mm) and the electronic acupuncture treatment instrument SDZ-V nerve and muscle intimulator both manufactured by Suzhou Medical Appliance Factory Co., Ltd., China. Sham points 1-2, 3-4, 5-6, and 7-8 are bilaterally located at the midpoints between the following pairs of acupoints: SP19 and EX-UE12, SP6 and LR5, EX-UE1 and HT1, and HT7 and SI8. sham LI4: Bilateral of midpoint between acupoint LI4 and LU9; sham LR3: Bilateral of midpoint between acupoint LR3 and ST44; sham ST40: Bilateral of midpoint between acupoint ST40 and GB35. Compatible acupoints: EX-B2 of Cervical 3-4 horizontal side by 0.5 cun; sham GV29: midpoint between acupoint GV29 and BL2. sham CV12: midpoint between acupoint CV12 and ST21; sham ST25: Bilateral of midpoint between acupoint ST25 and SP15; sham CV6: 3 cun lateral to the level of the CV6; The width of the interphalangeal joint of the patient's thumb was 1 cun."
224259116|NCT01690780|DRUG|Oral morphine|oral morphine 0.5 mg/kg (max 10 mg) every 6 hours as needed for 24 hours
224259117|NCT01690780|DRUG|Ibuprofen|Ibuprofen 10 mg/kg (max 600 mg) every 6 hours as needed for pain (maximum 4 doses) for 24 hours following discharge from the emergency department
224259118|NCT03382925|PROCEDURE|cervical interlaminar with lidocaine|Interlaminar cervical epidural steroid injection at the C7-T1 level with triamcinolone 80 mg (40 mg/mL) + 2 mL 1% lidocaine.
224259119|NCT03382925|PROCEDURE|cervical interlaminar with normal saline|Interlaminar cervical epidural steroid injection at the C7-T1 level with triamcinolone 80 mg (40 mg/mL) + 2 mL preservative saline
224259120|NCT03382925|DRUG|Lidocaine|2 mL lidocaine to be used as steroid diluent in group #1 cervical interlaminar procedure.
224259121|NCT03382925|DRUG|Triamcinolone Acetonide|2 mL of 40 mg/mL will be used as the steroid in group #1 and group #2 cervical interlaminar procedures.
224259122|NCT03382925|DRUG|Normal saline|2 mL of normal saline to be used as steroid diluent in group #2 cervical interlaminar procedure.
224259123|NCT03128723|DEVICE|Acne Mask|The light therapy acne mask contains a combination of red and blue light-emitting diodes. The device is applied once daily, in the evening for a duration of 10 minutes.
224259124|NCT00075478|PROCEDURE|Total-Body Irradiation|Undergo TBI
224259125|NCT00075478|DRUG|Fludarabine Phosphate|Given IV
224259126|NCT00075478|DRUG|Mycophenolate Mofetil|Given PO
224259127|NCT00075478|DRUG|Cyclosporine|Given PO
224259128|NCT00075478|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo transplantation
224322719|NCT04167969|PROCEDURE|laparoscopic radical prostatectomy and bilateral pelvic LN dissection or a salvage lymph node dissection|Surgery will be performed within 24 h of the third PET/MRI scan.
224322720|NCT06083883|DRUG|Fludarabine phosphate|Given by IV (vein)
223773232|NCT06580821|PROCEDURE|mucogingigval surgery|Is a form of mucogingival surgery that attempts to improve the height of the keratinized tissue (KT), as well as augment the thickness of the gingival phenotype to facilitate meticulous oral hygiene.
224259129|NCT03949426|DRUG|KPG-818|KPG-818 Capsules (1 mg, 5 mg and 20 mg) for oral administration is the drug substance powder filled in capsule (PIC) dosage form. KPG-818 Capsules and placebo capsules are packaged in HDPE bottle capped with HDPE cap.
224259130|NCT05836545|DRUG|Remimazolam|The patient with remimazolam
224259131|NCT05836545|DRUG|Midazolam|The patient with midazolam
224259132|NCT04030286|OTHER|Observation|Evaluation of Malondialdehyde level and correlation of Malondialdehyde level with periodontal and cardiovascular disease
224322721|NCT06083883|DRUG|NY-ESO-1 TCR/IL-15 NK|Given by IV (vein)
223773233|NCT01550939|DEVICE|Ophthalmic Biometer|One complete biometry examination
224259133|NCT00673660|BEHAVIORAL|Patient Compliance|Compliance of patients to statin treatment and reasons of compliance or non compliance will be obtained by Patient Reported Outcomes (PROs) every 3 months.
224322722|NCT06083883|DRUG|Cyclophosphamide|Given by IV (vein)
224322723|NCT04798274|DEVICE|Continuous Theta Burst Stimulation|Continuous theta burst stimulation (cTBS) will be applied using a MagPro X100 (MagVenture, Inc. Alpharetta, GA). The cTBS protocol consists of bursts of three pulses of 50 Hz stimulation repeated at 200 ms intervals (5 times per second) for 40 seconds (for a total of 600 pulses). Stimulation will be applied at an intensity of 80% of active motor threshold (AMT). Brainsight (Rogue Research) frameless neuronavigation system will be used to target the specific structural MRI-defined region of stimulation.
223773234|NCT03231904|DIAGNOSTIC_TEST|Blood test|blood samples will be taken for maternal and fetal levels of ACTH and LIF
223773235|NCT01086553|DRUG|budesonide|9mg budesonide OD
223773236|NCT01086553|DRUG|budesonide|3mg budesonide TID
223773237|NCT03541733|OTHER|mid-gut tubing|mid-gut tubing at different time
223773238|NCT03511521|DRUG|NPH Insulin|Intermediate acting insulin
223773239|NCT03511521|DRUG|glargine|basal insulin
223773240|NCT03511521|DRUG|Insulin Aspart|prandial insulin
223773241|NCT00439400|DRUG|doxycycline|
224259134|NCT02861560|OTHER|dHACM|Dehydrated human amnion/chorion membrane (dHACM) product and is regulated as a Human Cells, Tissues and Cellular and Tissue Based Product (HCT/P) under Section 361 of the Public Health Service Act by the Food and Drug Administration (FDA)
224259135|NCT00245063|DRUG|cediranib maleate|Given PO
224259136|NCT00245063|OTHER|laboratory biomarker analysis|Correlative studies
224259137|NCT00245063|OTHER|pharmacogenomic studies|Optional correlative studies
224259138|NCT02471820|DRUG|Lenalidomide|Lenalidomide 25 mg by mouth for the first 21 days of a 28-day-cycle for 4 cycles
224259139|NCT02471820|DRUG|Adriamycin|Adriamycin as intravenous bolus infusion at a dose of 9 mg/m2, on days 1-4 of a 28-day cycle for 4 cycles
224322724|NCT05310201|BEHAVIORAL|Be Well Care Well|Be Well Care Well addresses teacher well-being through activities implemented in the classroom aimed at reducing teacher stress and improving physical activity. A subset of teachers involved in the program will complete classroom observations and cortisol testing to examine additional measures of stress.
223678328|NCT06667076|DRUG|Amivantamab|Amivantamab will be administered.
223678329|NCT06667076|DRUG|Lazertinib|Lazertinib tablet will be administered.
223678330|NCT06667076|DRUG|Chemotherapy: Pemetrexed|Pemetrexed will be administered.
223678331|NCT06667076|DRUG|Chemotherapy: Carboplatin|Carboplatin will be administered.
223678332|NCT02724371|DEVICE|Mentor Larger Size MemoryGel Ultra High Profile Breast Implant|The Mentor smooth and Siltex® larger size MemoryGel® Ultra High Profile (UHP-L) breast implants are large round silicone gel-filled breast implants. The devices are made with cross linked layers of silicone to provide the prosthesis with elasticity and integrity.
223678333|NCT06672146|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223678334|NCT06672146|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
223678335|NCT06672146|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
223678336|NCT06672146|DRUG|Decitabine and Cedazuridine|Given PO
223678337|NCT06672146|DRUG|Enasidenib|Given PO
223678338|NCT06672146|DRUG|Venetoclax|Given PO
223678346|NCT06991556|DRUG|JSB462|JSB462 is administered orally, daily and continuously (100 mg or 300 mg QD) until disease progression per PCWG3-modified RECIST 1.1 as assessed by the investigator, the occurrence of unacceptable toxicities, death, participant decision or investigator decision.
223678347|NCT06991556|DRUG|Abiraterone|Abiraterone 1000 mg is administered orally, daily and continuously until disease progression per PCWG3-modified RECIST 1.1 as assessed by the investigator, the occurrence of unacceptable toxicities, death, participant decision or investigator decision.
224259140|NCT02471820|DRUG|Dexamethasone|Dexamethasone by mouth at a dose of 40 mg, on days 1, 8, 15, and 22 of a 28-day cycle for 4 cycles
224259141|NCT05099380|DEVICE|senofilcon A C3|TEST Lens
224259142|NCT05099380|DEVICE|senofilcon A|CONTROL Lens
224259143|NCT05170594|DRUG|Bevacizumab|Bevacizumab will be administered at 15mg/kg IV, every 3 weeks
224259144|NCT05170594|DRUG|chemotherapy|The non-platinum chemotherapy regimen will be determined by the investigator.
224259145|NCT05170594|DRUG|Fluzoparib|Fluzoparib will be administered orally continuously at 150mg bid until disease progression and toxicity becomes intolerable
224259146|NCT05569629|PROCEDURE|Bronchial washing before endobronchial biopsy and brushing|Bronchial washing: adding bronchial washing once to the standard endoscopic sampling sequence (endobronchial biopsy and brushing first, followed by bronchial washing once) in the experimental arm
224259147|NCT03092466|PROCEDURE|femoral nerve catheter|femoral block with Ropivacaine 0.75% (15 ml) in femoral catheter
224259148|NCT03092466|DRUG|femoral group|femoral block with Ropivacaine 0.75% (15 ml) in femoral catheter
224259149|NCT03092466|DRUG|control group|infusion of saline solution (15ml) in femoral catheter
224259150|NCT02831920|OTHER|CEUS and targeted biopsies|
224259151|NCT02831920|OTHER|MRI and targeted biopsies|
224322725|NCT04161066|DRUG|Psilocybin with facilitated counseling|open-label pilot study
224322726|NCT06485141|BEHAVIORAL|Safe Storage Intervention|Firearm storage information and secure storage device.
223678348|NCT06991556|DRUG|Enzalutamide|Enzalutamide 160 mg is administered orally, daily and continuously until disease progression per PCWG3-modified RECIST 1.1 as assessed by the investigator, the occurrence of unacceptable toxicities, death, participant decision or investigator decision.
223773242|NCT00439400|DRUG|placebo|
223773243|NCT04546204|OTHER|vaginal delivery|normal vaginal spontaneous delivery
224259152|NCT05408169|BEHAVIORAL|Suggested deadline for return of screening test|"A screening invitation letter modified to state, highlighted in yellow: Please return your kit within \[X\] weeks (by \[DD.MM.YYYY\]) or as soon as possible."
223773244|NCT03446703|BEHAVIORAL|SCIT|SCIT is a 18 weekly sessions lasting 45-60 minutes per session. The group will include 8-12 patients, with 2 therapists. The content of the sessions is based on the Spanish translation of the original SCIT (Social Cognition and Interaction Training) instruction manual (Combs, Adams, et al., 2007); (G. Lahera et al., 2013). The manual of the program developed for the improvement of emotional perception skills, attributional style and theory of mind in people with schizophrenia.
223773245|NCT03446703|BEHAVIORAL|TAR|TAR is a 12-session training on facial affect recognition over a period of 6 weeks. Treatment includes one therapist (psychiatrist or clinical psychologist) and 2 patients. It involves neuropsychological strategies, such as restitution and compensation, as well as principles of errorless learning, direct positive reinforcement, verbalization and self-instruction (Frommann et al., 2003; Wölwer et al., 2005).
224259153|NCT05408169|BEHAVIORAL|Planning sheet|A planning tool presented on a separate single sheet of paper inserted into the screening invitation envelope. The colour illustrated tool prompts participants to identify concerns they have with using the bowel screening kit and to link them to a tip to help them overcome this concern.
224259154|NCT00564408|DRUG|Carbachol|3 microgram per kg bodyweight infused intravenously
224259155|NCT01400984|DEVICE|easypod™|Saizen (Somatotropin) as per Summary of Product Characteristics (SmPC) administered by easypod™
224322727|NCT06485141|BEHAVIORAL|Safe Kids Medication|The Control participants will view a brief medication storage safety video produced by Safe Kids. A Frequently Asked Questions handout on medication safety created by Safe Kids will be available for parents as well.
224322728|NCT02315157|DRUG|Bendamustine|Given IV
224322729|NCT05303519|DRUG|safusidenib|safusidenib administered continuously as dosed single agent orally on Days 1 to 28 of a 28-day cycle. Subjects may continue treatment with agent safusidenib until disease progression or development of other unacceptable toxicity.
223773246|NCT02112786|DEVICE|Intermittent or Continuous Setting RestorePrime Implanted Impulse Generator|This is a routine procedure already performed, we are simply changing a post surgical setting to observe for improvement.
224322730|NCT05303519|DRUG|Placebo|Placebo administered continuously as dosed single agent orally on Days 1 to 28 of a 28-day cycle. Subjects may continue treatment with placebo until disease progression or another reason for discontinuation occurs.
223773247|NCT02442921|DRUG|Colchicine|up to 2mg of Colchicine daily
223773248|NCT02442921|DRUG|Placebo|Daily placebo
224259156|NCT05248711|BEHAVIORAL|Calm Daily Move|The Daily Move is a series of short, 5-min videos outlining mindful movement exercises. The Daily Move is part of the Calm app's library of content.
224259157|NCT04380181|DRUG|dobu|Use of dobutamine versus milrinone and epinephrine for separation from cardiopulmonary bypass
224259158|NCT03716466|OTHER|Endotracheal intubation|Subjects will receive prophylactic endotracheal intubation for upper gastrointestinal endoscopy procedure
224259159|NCT03716466|OTHER|No airway intervention|Subjects without prophylactic endotracheal intubation during upper gastrointestinal endoscopy procedure
224259160|NCT01891461|DRUG|Floseal|Floseal (5 milliliters) will be applied to the exposed bone in the following order: around the margins of the tibia, the femur (anterior surface, intercondylar notch, exposed medial and lateral condyles) and around the un resurfaced portion of the patella. The other syringes (each of 5 milliliters) will then be applied to the supra-patellar synovium and into the medial and lateral gutters of the knee. No Floseal will be applied outside the knee joint capsule.
224259161|NCT04776798|OTHER|Taping|Tape applications will repeat twice per week, for 4 weeks.
223773249|NCT00011804|DRUG|Topiramate|
223773250|NCT04660123|DRUG|Bismuth Colloidal Pectin Granules Quadruple Therapy for H. Pylori Eradication|"Standard dose of proton pump inhibitor, bismuth , and 2 antibiotics, 14 days course.~Standard doses of proton pump inhibitors are esomeprazole 20mg, rabeprazole 10mg (or 20mg).~Omeprazole 20mg, lansoprazole 30mg, pantoprazole 40mg, alprazole 5mg, any one of these.~Bismuth is colloidal bismuth pellets, 150mg, 2 times/d.~Antibiotic Program:~Scheme 1 Amoxicillin 1000 mg, 2 times/d; Clarithromycin 500mg, 2 times per day Scheme 2 Amoxicillin 1000 mg, 2 times/d; Levofloxacin 5001 times/2 times Scheme 3 Amoxicillin 1000 mg, 2 times/d; Furazolidone 100mg, 2 times/d. Scheme 4 Amoxicillin 1000 mg, 2 times/d; Metronidazole 400mg, 3 times/d or 4 times/d Scheme 5 Amoxicillin 1000 mg, 2 times/d; Tetracycline 500mg, 3 times/d or 4 times/d Scheme 6 Tetracycline 500mg, 3 times/d or 4 times/d; Metronidazole 400mg, 3 times/d or 4 times/d Scheme 7 Tetracycline 500mg, 3 times/d or 4 times/d; Furazolidone 100mg, 2 times/d."
223773251|NCT04746937|DRUG|Nitazoxanide|nitazoxanide adjuvant to standard therapy
223773252|NCT04746937|DRUG|Norfloxacin|Standard therapy
223773253|NCT05130775|OTHER|Transesophageal echocardiograpgy|3D acquisition of the right ventricle regurgitation volume
223773254|NCT03689127|DEVICE|Heated breathing circuit on|Heated breathing circuit will be turned on.
223773255|NCT03689127|DEVICE|Heated breathing circuit off|Heated breathing circuit will be turned off.
224259162|NCT02412085|DRUG|Golimumab|"Subcutaneous golimumab. Induction regimen: 200 mg (week 0), 100 mg (week 2)~Maintenance regimen:~* body weight \< 80kg: 50 mg every 4 weeks~* body weight ≥ 80 kg: 100 mg every 4 weeks"
224322731|NCT05731856|DEVICE|Apollo Wearable|Participants will be provided with the Apollo wearable device and asked to install the study mobile application on their mobile phones. Participants will use the Apollo for at least 30 minutes after waking up and at least 30 minutes before bed on the corresponding settings for those times of the day. They will be given the Apollo Device TVS (10-200 Hz) to borrow, which they will be instructed to wear daily. They will be asked to wear the device until all study data is collected.
224322732|NCT06274047|DRUG|Apalutamide|Given by PO
224322733|NCT06274047|DRUG|Androgen Deprivation Therapy|Given by PO
224322734|NCT03606967|PROCEDURE|Biopsy Procedure|Undergo tumor biopsy
224322735|NCT03606967|PROCEDURE|Biospecimen Collection|Undergo blood and urine sample collection
224322736|NCT03606967|DRUG|Carboplatin|Given IV
224322737|NCT03606967|PROCEDURE|Computed Tomography|Undergo CT scan
224322738|NCT03606967|BIOLOGICAL|Durvalumab|Given IV
224322739|NCT03606967|DRUG|Gemcitabine Hydrochloride|Given IV
223773256|NCT00440271|DRUG|tipranavir|
223773257|NCT00440271|DRUG|ritonavir|
224322740|NCT03606967|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
224322741|NCT03606967|DRUG|Nab-paclitaxel|Given IV
224322742|NCT03606967|BIOLOGICAL|Personalized Synthetic Long Peptide Vaccine|Given SC
224322743|NCT03606967|DRUG|Poly ICLC|Given SC
224322744|NCT03606967|BIOLOGICAL|Sacituzumab Govitecan|Given IV
224259163|NCT06485908|DRUG|administration of axitinib in combination with etoposide|"1. st stage:~   * Axitinib (Inlyta®) PO, in the morning and in the evening every day~  * Level -1 : Dose 1.2 mg/m²~  * Level 1: Dose 1.6 mg/m²~  * Level 2: Dose 2.0 mg/m²~  * Level 3: Dose 2.4 mg /m² (equivalent to 4 mg in adults)~  * Etoposide (50 mg capsules or in the form of etoposide phosphate if required): 25 mg/m²/day in the evening orally every day fasting (capped to a maximum of 50 mg/day) First patient will be enrolled at dose level 1~2. nd stage:~   * Axitinib (Inlyta®) dosing as selected at the 1st stage~  * Etoposide (50 mg capsules or in the form of etoposide phosphate if required): 25 mg/m2/ day in the evening orally every day fasting(capped to a maximum of 50 mg/day)"
224322745|NCT03606967|BIOLOGICAL|Tremelimumab|Given IV
224322746|NCT03456843|DRUG|Antiandrogen Therapy|To demonstrate at least 30% improvement in FFS at 2 years after randomization with the power of 90% and error of 5% on a one-sided exponential MLE test.
224322747|NCT03456843|DRUG|Docetaxel|To demonstrate at least 30% improvement in FFS at 2 years after randomization with the power of 90% and error of 5% on a one-sided exponential MLE test.
224259164|NCT02825160|DRUG|Ventavis (Iloprost, BAYQ6256)|The treatment of Ventavis should comply with the local product information
224259165|NCT06560060|OTHER|No intervention|There are no interventions. The only medical procedure is a blood draw
223678381|NCT06619561|DRUG|Vimseltinib|Administered orally
223678386|NCT07007793|DRUG|Baxdrostat|Baxdrostat tablet administered orally, once daily (QD).
223678387|NCT07007793|DRUG|Placebo|Placebo tablet matching baxdrostat, administered orally, once daily (QD).
223678389|NCT06646289|BIOLOGICAL|AAV5-hRKp.RPGR|AAV5-hRKp.RPGR will be administered sub-retinally.
223678390|NCT06646289|OTHER|No intervention (Follow-Up assessment)|Participants will not receive any intervention and will undergo follow-up assessment.
223678391|NCT06624085|DRUG|Glofitamab|Participants will receive IV glofitamab for up to 12 cycles (cycle length = 21 days)
224259166|NCT03151876|DRUG|Chidamide|30 mg oral twice weekly for 2 weeks
224259167|NCT03151876|DRUG|Cladribine|6 mg/m2 intravenously daily for 5 days
223678392|NCT06624085|DRUG|Tocilizumab|Participants will receive IV tocilizumab as needed to manage cytokine release syndrome (CRS)
223678393|NCT06624085|DRUG|Obinutuzumab|Participants will receive IV obinutuzumab pretreatment
223678394|NCT06624085|DRUG|Gemcitabine|Participants will receive IV gemcitabine for up to 8 cycles (cycle length = 21 days)
223678395|NCT06624085|DRUG|Oxaliplatin|Participants will receive IV oxaliplatin for up to 8 cycles (cycle length = 21 days)
224259168|NCT03151876|DRUG|gemcitabine|2500 mg/m2 intravenously twice weekly for 1 week
224259169|NCT03151876|DRUG|Busulfan|3.2 mg/kg intravenously daily for 4 days
224259170|NCT03151876|PROCEDURE|Autologous hematopoietic stem cell transplantation|autologous hematopoietic stem cells infusion after ChiCGB chemotherapy
224259171|NCT03428880|DRUG|Morphine|spinal morphine is done before cesarean section
224259172|NCT03428880|DRUG|Quadratus lumborum block|a US Block QLB is done after surgery
224259173|NCT05694676|OTHER|Assessment of the quality of Genaral Movements (GMs)|The variation, complexity and fluency of movements over a video recording is done and the quality of GMs is classified as normal-optimal, normal-suboptimal, mildly abnormal, and definitely abnormal movements.
224322748|NCT03456843|OTHER|Laboratory Biomarker Analysis|Correlative studies
223773258|NCT00440271|DRUG|Optimized Background Regimen (OBR)|Patients received between two and four active anti-retroviral medications based on resistance testing results, as background treatment, and remained on these for the duration of the trial.
224322749|NCT03456843|PROCEDURE|Quality-of-Life Assessment|Ancillary studies
224322750|NCT03456843|OTHER|Questionnaire Administration|Ancillary studies
224322751|NCT03456843|PROCEDURE|Radical Prostatectomy|Undergo cytoreductive radical prostatectomy
224259174|NCT05694676|OTHER|State-Trait Anxiety Inventory-Trait, (STAI-T)|The scale consists of 20 items in total and provides a four-point Likert type measurement (1- anxiety symptom is not present, 4- the symptom lasts all the time). Scores range from 20 (low anxiety) to 80 (high anxiety).
224259175|NCT05694676|OTHER|Beck Depression Inventory, (BDI)|BDI contains 21 items and rates the depressive symptoms for the last week. Each item has four options and is scored between 0 and 3. The total score ranges from 0 to 63. Higher scores indicate more severe depression
224259176|NCT01020474|DRUG|placebo|matching placebo capsules twice daily.
224259177|NCT01020474|DRUG|pregabalin (Lyrica)|75-450mg/day pregabalin dose optimised at start of study
224259178|NCT00350389|BEHAVIORAL|Outdoor use of plain distance glasses with counselling|Provision of single lens glasses, glasses aids, counselling, updated multifocal glasses if required
224259179|NCT04964440|DEVICE|Pure-EP|Advanced Signal Acquisition and Processing
224259180|NCT04853563|OTHER|PEEP|High PEEP targeted to 10 cmH2O to be maintained during the period of mechanical ventilation compared with low PEEP maintaining 3-5 cmH2O
224259181|NCT06319495|BEHAVIORAL|Rehabilitation therapy|"During the treatment, All the participants were provided with the rehabilitation therapy, which included routine rehabilitation, cognitive training, swallowing function training and nutrition support.~Particularly, due to dysphagia, the patients enrolled might face difficulty in eating. For patients who were able to finish intake via mouth by compensatory means, the consistency, type, and size of food bolus was arranged. For those who cannot acquire sufficient nutrition through oral intake, the nasogastric tube feeding was provided."
224322752|NCT05633017|COMBINATION_PRODUCT|CereVu Objective Dyspnea Score|Small forehead wearable and mobile app
223678401|NCT06679400|BEHAVIORAL|Massage|"Participants will have one massage that will last 30 minutes and focus on the chest and shoulder of the side that received the cancer treatment. There will be certain techniques applied during the intervention (per protocol). The timing and order of each element will be varied based on tissue response and patient feedback.~All participants will have ultrasounds and complete surveys prior and after the massage."
223678402|NCT07011004|BIOLOGICAL|Cytokine Induced Memory-Like Natural Killer Cells|Subjects will receive subcutaneous recombinant human IL-2 (rh-IL2) every other day x 6 doses beginning on day 0 via subcutaneous injection.
223678403|NCT07011004|BIOLOGICAL|Atezolizumb|Single dose of Atezolizumab IV over 60 minutes IV.
223773259|NCT01980849|DRUG|Nadroparin, long term|
223773260|NCT01980849|DRUG|Nadroparin: short-term|
224259182|NCT06319495|PROCEDURE|Stellate ganglion block|Based on the invention above, the patients in the observation group were provided with Stellate ganglion block, using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate ganglion block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
224259183|NCT06319495|DRUG|Lidocaine Hydrochloride|Based on the invention above, the patients in the observation group were provided with Stellate ganglion block, using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate ganglion block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
223678404|NCT07011004|BIOLOGICAL|CIML-NK cell therapy|CIML-NK cell therapy as an intravenous (IV) infusion
224259184|NCT06319495|BEHAVIORAL|placebo injection|1 milliliter of normal saline will be used for injection. The percutaneous approach via the paratracheal route was used for Stellate ganglion block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
224259185|NCT00663481|DRUG|CoFactor|
224259186|NCT00663481|DRUG|Leucovorin|
224259187|NCT03004118|DIETARY_SUPPLEMENT|Nutridrink|Liquid meal of 200ml
224259188|NCT03004118|DEVICE|High resolution manometry probe|Catheter inserted via the nose into the stomach to measure intragastric pressure.
224322753|NCT02964013|BIOLOGICAL|vibostolimab|Administered as an intravenous (IV) infusion on Day 1 of 21-day infusion Cycles 1-35
224322754|NCT02964013|BIOLOGICAL|pembrolizumab|Administered as an IV infusion on Day 1 of 21-day infusion Cycles 1-35
223773261|NCT00838305|DRUG|MDMA and citalopram|MDMA 1.5 mg/kg and citalopram 20 mg
223773262|NCT00838305|DRUG|Placebo|drug: placebo subjects also get citalopram and placebo in a 2x2 crossover design
223773263|NCT03126981|OTHER|1.5 oz of whole, natural almonds|1.5 oz of whole, natural almonds
223773264|NCT03126981|OTHER|Low-fat, high refined starches/sugars|Low-fat foods, high in refined starches and added sugars
223773265|NCT00723801|DRUG|Atenolol|Atenolol 50mg PO QD
223773266|NCT00723801|DRUG|Losartan|Losartan 100mg PO QD
223773267|NCT03358576|DRUG|Ertapenem|Antibiotic for complicated intra-abdominal infection
223773268|NCT03358576|DRUG|Sulopenem-Etzadroxil/Probenecid|Antibiotic for complicated intra-abdominal infection
223773269|NCT03358576|DRUG|Ciprofloxacin|Antibiotic for complicated intra-abdominal infection
224259189|NCT03004118|DEVICE|perfusion catheter|Catheter inserted via the nose into the stomach to perfuse the nutridrink intragastricly.
223773270|NCT03358576|DRUG|Metronidazole|Antibiotic for complicated intra-abdominal infection
223773271|NCT03358576|DRUG|Amoxicillin-Clavulanate|Antibiotic for complicated intra-abdominal infection
224259190|NCT03004118|DRUG|Placebo Oral Tablet|4 week oral intake (daily)
224259191|NCT03004118|DRUG|Ursochol oral tablet|4 week oral intake (daily) (dose of 10.5mg/kg/day)
224259192|NCT03004118|DEVICE|Duodenal fluid aspiration catheter|Catheter inserted via the nose into the duodenum to aspirate duodenal fluids for 2.5 hours.
224259193|NCT03004118|PROCEDURE|Duodenogastroscopy|Catheter inserted via the mounth into the duodenum to take duodenal biopsies.
224259194|NCT03004118|PROCEDURE|Blood sample|Blood sample will be taken to measure liver enzyme serum levels and marker for bile acid synthesis.
224259195|NCT04374864|DRUG|Trelagliptin|Anti diabetic
223773272|NCT03358576|DRUG|Sulopenem|Antibiotic for complicated intra-abdominal infection
224259196|NCT05637333|DIAGNOSTIC_TEST|Contrast Stress Echocardiography|Dipyridamole will be infused at 0.56mg/kg of body weight over 4mins. After 2 minutes, if the patient has tolerated the infusion well, a further 0.28mg/kg will be infused over 2 minutes. Tolerance will be determined by the absence of 1) myocardial ischaemia (significant chest pain with ECG ST depression or T wave inversion or wall motion abnormality on ECHO) 2) a significant drop in blood pressure 3) significant arrhythmia and 4) intolerable symptoms. One minute after completion of Dipyridamole infusion Sonazoid will be infused at the same rate as was used during acquisition of the rest images. After 45 seconds when steady state is reached, the ultrasound images will be acquired as stated below in contrast imaging. If the Dipyridamole is not well tolerated by one minute after the 0.56mg/kg infusion, we will move straight to the infusion of Sonazoid with no extra 0.28mg/kg infusion.
224259197|NCT03851354|OTHER|Ultrasound meal acommodation test|to observe their tolerance a 500 ml of solution with glutamine, or Caseinate and the protocol will be carried out will be given. Ultrasound measures will be performed and observing changes in Cross Sectional Area of the gastric antrum of the first measurement at the time after administration. Gastric residue will be measured.
224259198|NCT00466167|DRUG|Pramipexol Extended Release|
224259199|NCT00466167|DRUG|Pramipexol Immediate Release|
224259200|NCT00466167|DRUG|Placebo|
224259201|NCT01470976|OTHER|Goal-directed Resuscitation Therapy (GDT)|"* A target value of a cardiac index (CI) greater than 3.0 L/min/m2 will be sought.~* The first step will be fluid resuscitation with 250ml aliquots of Lactated Ringer's solution whenever the CI is lower than 3,0 L/min/m2 and systolic volume index (SVI) is lower than 35ml/m2. The fluid challenge will be stopped if the CVP rises by more than 4 mmHg during the infusion period.~* When the CI is lower than or equal to 3,0L/min/m2 and SVI higher than or equal to 35 ml/m2, dobutamine will be initiated with increasing doses up to 20mcg/kg/min.~* The final step will be red blood transfusion to reach a hematocrit higher than 28%."
224259202|NCT01470976|OTHER|Standard protocol|The control group will be managed by the anesthetic team in the operative room and by the surgical ICU staff in the postoperative period according to institutional protocol of hemodynamic monitoring.
224259203|NCT02784262|DRUG|botox injection Multiguide|botox injection under CT/MR navigation and with the navigation tool MultiGuide
224259204|NCT02611440|BEHAVIORAL|Pharmaceutical care|"Initial interview with pharmacist (at the hospital discharge): Evaluation aimed to identify barriers to adherence to drug treatment followed by an information session on the disease, the benefit of drugs and the importance of diet and lifestyle habits. Pharmacist advices focused on how to take medication and how to manage adverse events will be provided.~Telephone interviews with hospital clinical pharmacist - patient (at M3 M6 and M9): The objective is to review with the patient its medication-taking routine and its potential difficulties, to motivate adherence to treatment and lifestyle/dietary rules, to give advices about therapeutics and how to take medication.~HCP contacts CP to determine the prescription refill. Final interview with HCP pharmacist (at M12): The objective is to take stock with the patient about its taking drug load."
223773273|NCT05649605|DRUG|Testosterone treatment|Cross-sex hormone therapy consisting of intramuscular injection of testosterone undecanoate 250mg/ml. 4ml (total dosage of 1000mg) administered by trained nurse in the gluteal region at visit 1.
224259205|NCT04354363|OTHER|Platelet rich plasma|Giving women PRP before ICSI
224259206|NCT00684697|DIETARY_SUPPLEMENT|iron|High, intermediate and low iron dosage orally for 2 months
223773274|NCT05649605|OTHER|Placebo treatment|Saline solution. Intramuscular injection of physiological saline solution. 4ml administered by trained nurse in the gluteal region at visit 1.
223773275|NCT03424538|OTHER|Neurorehabilitation|5-week-long intervention, administered daily, targeted postural instability, balance and mobility using at-limit intensity sensorimotor and visuomotor agility training
224322755|NCT02964013|DRUG|pemetrexed|Administered as an IV infusion on Day 1 of 21-day infusion Cycles 1-35
224322756|NCT02964013|DRUG|carboplatin|Administered as an IV infusion on Day 1 of 21-day infusion Cycles 1-4
224322757|NCT02964013|BIOLOGICAL|pembrolizumab/vibostolimab coformulation|Administered as an IV infusion on Day 1 of 21-day infusion Cycles 1-35
224322758|NCT02964013|DRUG|cisplatin|Administered as an IV infusion on Day 1 of 21-day infusion Cycles 1-4
223678417|NCT06871579|DIAGNOSTIC_TEST|EnteroTracker(R) EST|The device consists of a gelatin-coated capsule with a collection string wrapped inside.
223678425|NCT06062420|DRUG|Dostarlimab|Dostarlimab will be administered.
224259207|NCT01039363|DRUG|Salvage reinduction chemotherapy including Gemtuzumab ozogamicin, Idarubicin and Cytarabine and Vorinostat|"Salvage reinduction therapy:~Vorinostat 200mg BID po (D1-14) Gemtuzumab ozogamicin 3 mg/m2 once (D1) Idarubicin 12mg/m2 for 2 days (D2-3) Cytarabine 500mg/m2 bid IV for 5 days (D2-6)~Maintenance:~Once achieved CR, then Vorinostat 200mg BID po for 2 weeks, then 1 week's rest (1 cycle) for 11 cycles~* Vorinostat should be stopped at least 2 weeks ahead of starting of consolidation therapy.~* Gemtuzumab will be omitted in a consolidation schedule.~* Allogeneic hematopoietic stem cell transplantation (HSCT) can be performed if HLA-matched sibling or unrelated donor is available. Vorinostat will be stopped 2 weeks prior to starting of conditioning regimen for allogeneic HSCT."
224259208|NCT00161785|BIOLOGICAL|FSME-IMMUN 0.5ml|
224259209|NCT02278809|BEHAVIORAL|Movie Models|"The intervention group got acces to a private website for 4 weeks on which the online videos were placed (Week 1: fruit + water, week 2: vegetables + breakfast + supermarket, week 3: PA, week 4: SB)~After each week, parents received a link for an online process evaluation questionnaire in which we asked how many times they watched each video, if they discussed the videos with other people, if they found them interesting, boring…"
224259210|NCT03669861|DRUG|Abatacept|Subjects will receive weekly subcutaneous doses of abatacept (125mg) for 24 doses (24 weeks)
224259211|NCT05799677|OTHER|Reflexology|Additive reflexology treatment
224259212|NCT02189226|DEVICE|Endoscopic submucosal dissection (ESD) with or without probe-based confocal laser endomicroscopy (pCLE)|Before ESD, the lesion will be observed either by pCLE or by CE to determine proximal and distal margin of the lesion. In the pCLE group, after injection of intravenous fluorescein, the lesion will be observed using a flexible confocal miniprobe. In the CE group, the lesion will be observed conventionally under white light after spraying indigocarmine directly via the forceps channel. Marking dots will be placed on both margins using needle knife. Then several dots will be marked on the surrounding normal mucosa 5 mm from the tumor with Argon plasma coagulation. After injection of saline solution with epinephrine into the submucosa, an initial cut will be made with needle knife outside the line of surrounding marks. An insulation-tipped (IT) knife will be inserted into initial cut, and electrosurgical current will be applied to complete the incision around the tumor. After the circumferential cut, the submucosa will be dissected with the IT knife.
224259213|NCT00900094|GENETIC|fluorescence in situ hybridization|
224259214|NCT00900094|GENETIC|polymerase chain reaction|
224259215|NCT00900094|GENETIC|protein expression analysis|
224259216|NCT00900094|OTHER|immunohistochemistry staining method|
224259217|NCT00900094|OTHER|laboratory biomarker analysis|
224259218|NCT00900094|OTHER|mass spectrometry|
224259219|NCT00599820|DRUG|Intravitreal Bevacizumab|
223678426|NCT06062420|DRUG|Belrestotug|Belrestotug will be administered.
224259220|NCT02465125|BIOLOGICAL|red blood cell transfusion|
224259221|NCT04775004|OTHER|Bone marrow venting procedure (BMVP)|The BMVP involves creating small holes in a non-weight bearing area of the bone that does not have any important structures; the holes act as channels, which allow for flow of the participants own biologic products and stem cells from within the bone marrow.
224259222|NCT04775004|OTHER|Platelet Rich Plasma (PRP)|The PRP group will have 40cc to 60cc (about 3 tablespoons) of blood drawn at the time of surgery. The blood sample will then be prepared in a centrifuge machine to collect a component of the blood called platelet rich plasma. Once appropriate concentrations of the PRP are confirmed, the PRP will be injected into the subject's knee prior to wound closure.
224259223|NCT06208358|DEVICE|tACS|We aim to use tACS devices to improve the disrupted interpersonal interaction among gaming disorder individuals.
224259224|NCT01002963|DRUG|PF-04418948|solution, 30 mg, single
224259225|NCT01002963|DRUG|PF-04418948|solution, 100 mg, single
224259226|NCT01002963|DRUG|PF-04418948|solution, 300 mg, single
223678427|NCT06062420|DRUG|Nelistotug|Nelistotug will be administered.
223678428|NCT06062420|DRUG|Remzistotug|Remzistotug will be administered.
223773276|NCT03424538|OTHER|Physiotherapy|5-week-long intervention, physiotherapy, stretching, walking preparation, strengthening
224259227|NCT01002963|DRUG|PF-04418948|solution, 1000 mg, single
224259228|NCT01002963|DRUG|PF-04418948|solution, 3000 mg, single
224259229|NCT01002963|DRUG|PF-04418948|solution, 4500 mg, single
224259230|NCT01002963|DRUG|PF-04418948|solution, 6000 mg, single
224259231|NCT03516539|DEVICE|Group ML|Mcgrath videolaryngoscope
224259232|NCT03516539|DEVICE|Group DL|Macintosh laryngoscope
224322759|NCT02964013|DRUG|etoposide|Administered as an IV infusion on Days 1-3 of 21-day infusion Cycles 1-4
224259233|NCT04987216|DEVICE|IOL implantation experimental|Mono- or bilateral implantation of toric intraocular lenses PODEYE TORIC. If only one eye qualifies for toric lens implantation due to small amount of pre-existing corneal astigmatism, one eye will be implanted with PODEYE TORIC and the contralateral eye will be receive an implantation with the monofocal parent lens PODEYE (PhysIOL sa/nv, Liège, Belgium).
224259234|NCT00818558|BIOLOGICAL|ISET Methode|Sampling of blood - ISET Methode
224259235|NCT04342663|DRUG|Fluvoxamine|Randomized to either fluvoxamine or placebo for approximately 15 days. Will take up to 300mg per day (3 capsules per day) as tolerated.
224259236|NCT04342663|DRUG|Placebo|Randomized to either fluvoxamine or placebo for approximately 15 days. Will take up to 3 capsules per day as tolerated.
224259237|NCT00404963|DRUG|placebo|
224259238|NCT00404963|DRUG|GSK376501|
224259239|NCT03643250|OTHER|Smaller Portion Size and Standard Appeal (non-divided plate)|Food with Smaller Portion Size and Standard Appeal on a non-divided plate
224259240|NCT03643250|OTHER|Smaller Portion Size and Enhanced Appeal (divided plate)|Food with Smaller Portion Size and Enhanced Appeal on a divided plate
224322760|NCT04104126|OTHER|Standard of Care Physical Therapy|Will receive standard of care physical therapy
224259241|NCT03643250|OTHER|Larger Portion Size and Standard Appeal (non-divided plate)|Food with Larger Portion Size and Standard Appeal on a non-divided plate
224259242|NCT03643250|OTHER|Larger Portion Size and Enhanced Appeal (divided plate)|Food with Larger Portion Size and Enhanced Appeal on a divided plate
224259243|NCT03643250|OTHER|Smaller Portion Size and Standard Appeal (divided plate)|Food with Smaller Portion Size and Standard Appeal on a divided plate
224259244|NCT05248308|DEVICE|Embozene Microspheres|"Embozene Microspheres are manufactured by Varian Medical Systems (Palo Alto, CA). These microspheres are non-resorbable hydrogel microspheres coated with polyzene-F. Embozene microspheres are approved for use in treating arteriovenous malformations, hypervascular tumors such as uterine fibroids and hepatomas, and prostatic arteries in patients with benign prostatic hyperplasia.~One of the causes of chronic pain in the setting of a knee arthroplasty may be increased blood flow to the specific area(s) of pain. The purpose of this procedure is to reduce blood flow (embolize) to specific parts of the knee which are contributing to your pain.~This procedure is performed by infusing the Embozene particles into specific knee arteries (genicular arteries) in the region of knee pain."
224322761|NCT04104126|OTHER|Blood flow restriction|Blood flow restriction therapy is a blood pressure cuff placed around the desired limb with a handheld device that controls the pressure exerted by the cuff. The cuff is placed around the desired limb before a specific exercise, the physical therapist determines the appropriate pressure and time, and the patient completes the exercise as they normally would. The monitor determines the limb occlusion pressure and has an automatic timer that will deflate after the specified time has elapsed.
223678440|NCT07015190|DRUG|Darovasertib|Dosed orally, twice daily (28-day/ cycle
223678441|NCT07015190|PROCEDURE|Primary Local Therapy|Plaque Brachytherapy or Enucleation
224259245|NCT00064038|DRUG|dexamethasone|Given orally
224259246|NCT00064038|DRUG|lenalidomide|Given orally
224259247|NCT00064038|OTHER|placebo|Given orally
224322762|NCT04785534|OTHER|Clinical Evaluation|Undergo clinical evaluation
223678445|NCT07015398|DRUG|NAL ER|Oral tablets
223678446|NCT07015398|DRUG|Pirfenidone|Oral tablets
223678447|NCT07015398|DRUG|Nintedanib|Oral capsules
223678448|NCT03289195|PROCEDURE|MRI Biopsy|Patient will undergo percutaneous MR guided biopsy by study Breast Radiologist within 0-60 days of completing NAC.
223678449|NCT06626516|DRUG|Tebentafusp-Tebn|Dosing: All patients enrolled in this study will receive treatment with tebentafusp-tebn based on the approved step-up dosing regimen of 20 mcg on C1D1, 30 mcg on C1D8, then 68 mcg weekly beginning on C1D15 and thereafter. This escalated dose administered at C1D15 will be the dose used for the remainder of the treatment period unless dose reduction is implemented for toxicity. Beginning with C1D8, tebentafusp-tebn will be administered on the scheduled day (± 2 days), and consecutive infusions of tebentafusp-tebn must be administered at least 5 days apart.
223678450|NCT06626516|DRUG|GM-CSF (Sargramostim)|Recombinant human GM-CSF (Sargramostim, Leukine®, Sanofi US) 1,500mg will be mixed with ethiodized oil (Ethiodol®). The GM-CSF/ethiodized oil mixture will be injected selectively into one of the hepatic lobes, followed by infusion of gelatin sponge particles to achieve the stasis of blood flow. This will repeat every 4 weeks.
223678451|NCT06626516|DRUG|BCNU|Patients will be treated with hepatic artery infusion of 300mg BCNU (1,3-bis \[2-chloroethyl\]-1-nitrosourea, Carmustine) dissolved in ethiodized oil followed by embolization with gelatin sponge particles \[TACE with BCNU 300mg\]; every 4 weeks +/- 7 days in the case of either bilobar or unilobar metastasis
223773277|NCT02848118|DEVICE|A nasal-oral cannula of capnography|After propofol infusion, the complete induction is defined when capnography shows hypoventilation and bronchoscope is then introduced to patients.
224322763|NCT04785534|OTHER|Laboratory Biomarker Analysis|Correlative studies
224322764|NCT04785534|PROCEDURE|Liver Ultrasonographic Elastography|Undergo fibroscan
224322765|NCT04785534|OTHER|Survey Administration|Complete survey
223678452|NCT06618001|DRUG|JNJ-89853413|JNJ-89853413 will be administered.
224259248|NCT01826838|DRUG|Dasatinib|"1.1 Primary Objective 1.1.1 To evaluate the maximum tolerated dose and dose limiting toxicities of dasatinib, up to a dose of 100mg/day, with concurrent standard radiation and hormone therapy for patients with intermediate and high risk prostate cancer.~1.2 Secondary Objective: 1.2.1 To determine the time to progression and overall survival for patients who are diagnosed with Intermediate and High Risk Prostate Cancer and were treated with dasatinib."
224259249|NCT01448096|DRUG|Rituximab|R-CHOP21 consist of rituximab (375 mg/m2), cyclophosphamide (750 mg/m2), doxorubicin (50 mg/m2), and vincristine (1.4 mg/m2, a maximum of 2mg), administered intravenously on day 1 and 100 mg oral prednisone on days 1 through 5.
224259250|NCT01448096|PROCEDURE|Prophylactic intrathecal chemotherapy|Prophylactic intrathecal chemotherapy using methotrexate (12mg total dose) will be performed
224259251|NCT01736007|DEVICE|308-nm excimer laser to alopecia patch|MED dosing as per protocol with beginning at 50 mJ/cm2 below MED with increases by 50mJ/cm2 every 2 treatments as tolerated. Maximum dosing would be 850mJ.Treatments given twice a week for 12 weeks.
224259252|NCT01736007|DEVICE|Liquid light guide tip on laser|Sham treatment involves placement of liquid light guide tip developed by the laser company which attaches to the end of the hand wand and blocks the laser light from passing to the target. Patients are treated twice a week for 12 weeks.
224259253|NCT04185857|DRUG|canrenone 50-100 mg orally once a day|After two biochemical and clinical evaluations under baseline conditions and after pharmacological washout from diuretics, betablockers, ARBs or ACEI (about 4 weeks) and MRAs (abut 6 weeks), PA patients will be treated with canrenone 50-100 mg orally once a day. After 1 or 2 weeks the dose will be doubled if necessary to control BP and serum potassium.
224259254|NCT04185857|DRUG|olmesartan 10-20 mg orally once a day|"After one month of treatment with canrenone the patients will undergo a clinical and biochemical evaluation (FW1) in a manner identical to the two basal evaluations. After, they will continue with a combination therapy with canrenone, at the dose reached, plus olmesartan starting with 10 mg a day for oral administration, a dose that could be doubled, if necessary, to achieve normotension.~At the end of the second month of the double therapy, patients will undergo a biochemical re-evaluation at the Center of Hypertension (FW2) with methods identical to those performed in the two baseline evaluations and after one month of canrenone."
224259255|NCT01608360|DRUG|Intravenous lidocaine injection|Patients in Group I (intravenous lidocaine injection group) received an intravenous bolus injection of 1.5 mg/kg lidocaine followed by a continuous lidocaine infusion of 2 mg/kg/hr.
224259256|NCT01608360|DRUG|Intravenous normal saline injection|The patients in Group C (placebo control group) received normal saline intravenous injection
224259257|NCT04661007|DRUG|tafasitamab|tafasitamab will be administered at protocol defined timepoints based on the groups participants are assigned.
224259258|NCT04661007|DRUG|lenalidomide|lenalidomide will be administered orally at protocol defined timepoints based on the groups participants are assigned.
224259259|NCT04661007|DRUG|parsaclisib|parsaclisib will be administered at protocol defined timepoints based on the groups participants are assigned.
224259260|NCT04661007|DRUG|R-CHOP|R-CHOP is a combination regimen consisting of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone. R-CHOP will be administered at protocol defined timepoints based on the groups participants are assigned.
224259261|NCT04041713|DRUG|Rett-T|antioxidant cocktail
224259262|NCT04041713|OTHER|Placebo|Placebo
223678475|NCT06687655|DIETARY_SUPPLEMENT|Ketone-IQ|This is a crossover study where participants will ingest either Ketone-IQ for 2 nights, or placebo for 2 nights before sleep. This is the Ketone-IQ (1,3 Butanediol) intervention.
223678476|NCT06687655|DIETARY_SUPPLEMENT|Placebo|This is a crossover study where participants will ingest either Ketone-IQ for 2 nights, or placebo for 2 nights before sleep. This is the Placebo intervention.
224259263|NCT06822374|DRUG|Normosol-R|Standard of care isotonic fluid.
224259264|NCT06822374|DRUG|buffered 2% hypertonic saline|"A solution containing 2% sodium chloride (NaCl) that is buffered by the addition of another salt like sodium acetate."
224259265|NCT01875562|DRUG|Qishe Pill|Pill, 3.75 g, twice per day, four weeks
224259266|NCT03986294|DRUG|S1 + Nal-IRI|S-1 will be given for 14 consecutive days, twice daily, followed by 2 weeks rest. Nal-IRI will be administered as an intravenous infusion on day 1 and 15. Courses of treatment will be repeated every 4 weeks.
224259267|NCT03986294|DRUG|Nal-IRI+Leucovorin+5-FU|Nal-IRI 80 mg/m2 will be administered first, followed by LV 400 mg/m2, followed by 5-FU 2400 mg/m2 as an IV infusion over 46-hours on days 1-3. Each cycle consists of 14 days. Courses of treatment will be repeated every 2 weeks.
224259268|NCT02825680|OTHER|Enhanced NCP Support|NCP is a central policy office that provides support to MOVE! program teams through monthly phone calls and technical assistance. Facilities will also have access to the audit and feedback process and barrier buster tool
224259269|NCT02825680|OTHER|LEAP|The Learn. Engage. Act. Process (LEAP) intervention relies on virtual (phone and online) coaching based on the IHI Model for Improvement, an online learning platform for clinician teams to share ideas and progress, an audit and feedback process, and a barrier buster tool.
224259270|NCT06219317|DRUG|Cemiplimab|Cemiplimab is provided in a 10 ml glass vial
223678483|NCT07019883|BIOLOGICAL|H5 AC-Anhui RNA Vaccine|A nucleoside-modified mRNA vaccine encoding a stabilized, antigenically central hemagglutinin (HA) from influenza A(H5), based on A/Anhui/1/2005 (clade 2.3.4) with substitutions 222QL, 224GS, 156TA, and 134TA. The 2119-nt mRNA is encapsulated in lipid nanoparticles (LNPs) for intramuscular delivery.
223678484|NCT07019883|BIOLOGICAL|H5 Astrakhan RNA Vaccine|The vaccine product consists of a monovalent nucleoside-modified mRNA that encodes a traditionally selected avian influenza HA. The H5 Astrakhan RNA encodes the HA from the clade 2.3.4.4b A/Astrakhan/3212/2020 virus.
223678485|NCT07019883|OTHER|Sodium Chloride, 0.9%|0.9% Sodium Chloride Injection
223678493|NCT07023627|DRUG|INCB123667|Administered orally twice daily (BID).
223678496|NCT05931393|DRUG|Cabozantinib 80 MG|cabozantinib 80mg daily
223678497|NCT07025564|PROCEDURE|Biospecimen Collection|Undergo bone marrow and blood sample collection
223678498|NCT07025564|PROCEDURE|Echocardiography Test|Undergo ECHO
223678499|NCT07025564|DRUG|miR-126 Inhibitor miRisten|Given IV
223678500|NCT07023835|DRUG|50 mg Usnoflast|50 mg Usnoflast (50 mg Usnoflast capsules and matching placebo of 25 mg capsule)
223678501|NCT07023835|DRUG|75 mg Usnoflast|75 mg Usnoflast (25 mg + 50 mg Usnoflast capsules)
223678502|NCT07023835|DRUG|Placebo|Matching placebo of 25 mg and 50 mg
223678504|NCT05379595|BIOLOGICAL|Amivantamab IV|Amivantamab will be administered as intravenous infusion.
223773278|NCT02848118|OTHER|Observer Assessment of Alertness and Sedation scale|After propofol infusion, the complete induction is defined when OAAS is 3 to 2 (conscious sedation) and bronchoscope is then introduced to patients.
223773279|NCT02189187|BEHAVIORAL|Mindfulness|
224259271|NCT06219317|DRUG|Placebo|standard saline solution
224259272|NCT04258735|DIAGNOSTIC_TEST|Genomic analysis|WES, RNASeq, ctDNA, Exosome
224259273|NCT02805166|DRUG|PEG-rhG-CSF|
224259274|NCT00284791|DRUG|Lamotrigine (drug)|
224259275|NCT00284791|DRUG|Fluoxetine (drug)|
224322766|NCT05384587|DRUG|asciminib|Supplied in 40 mg and 100 mg tablets for oral use to be taken daily. Dose may be increased at 6 and 12 months based on molecular response with BCR-ABL1 Polymerase Chain Reaction testing.
224322767|NCT05000294|DRUG|Atezolizumab|Subjects on both the phase Ib and phase II portions of this study will receive 1680 mg intravenously of atezolizumab on Day 1 of each 28 day cycle.
223678505|NCT05379595|BIOLOGICAL|Fluorouracil|Fluorouracil will be administered as intravenous infusion.
223678506|NCT05379595|BIOLOGICAL|Leucovorin|Leucovorin will be administered as intravenous infusion.
223678507|NCT05379595|BIOLOGICAL|Oxaliplatin|Oxaliplatin will be administered as intravenous infusion.
223678508|NCT05379595|BIOLOGICAL|Irinotecan|Irinotecan will be administered as intravenous infusion.
223678509|NCT05379595|BIOLOGICAL|Amivantamab|Amivantamab will be administered.
223678510|NCT06628167|BEHAVIORAL|Transportation|Participants with ordered low dose CT and participants with scheduled low dose CT are offered free transportation to and from appointment. Participants with ordered low dose CT are also offered assistance in connecting with scheduling staff.
223678511|NCT06628167|BEHAVIORAL|Scheduling|Participants with ordered low dose CT are offered assistance in connecting with scheduling staff.
223773280|NCT02189187|BEHAVIORAL|Psychoeducation|
223773281|NCT02691767|DRUG|pazopanib|
224259276|NCT00284791|DRUG|sertraline (drug)|
224259277|NCT06106958|BEHAVIORAL|Home Exercise Program|"Participants will receive a home exercise program that consists of 2 exercises and 3 stretches. The exercises include:~* Massage on the bottom of the foot with a ball~* Calf-raises~* Lunge calf-stretch with the knee straight~* Calf-stretch with the knee bent~* Stretch for the bottom of the foot~These exercises are intended to be performed daily."
224259278|NCT06106958|BEHAVIORAL|Minimalist Shoes|"Participants will receive a pair of minimalist shoes. They will wear them for an allotted amount of time per day each week, in order to allow for a slow adjustment into the shoes. The protocol is as follows:~* Week 1: 1 hour per day~* Week 2: 2 hours per day~* Week 3: 4 hours per day~* Week 4: 6 hours per day~* Week 5: 8 hours per day~* Week 6: 8 hours per day~* Week 7: 8 hours per day~* Week 8: 8 hours per day"
224259279|NCT01978925|OTHER|Pharmaceutical care|"The clinical pharmacist will provide a structured 30-minute intervention for enhancing their medication adherence.~The recommendations include: discussion on hypertension and/or diabetes, risk of complications, prescribed drug therapy, correct use of medications and proper dosage, possible adverse effects, route of administration, schedule of administration and correct storage. The pharmacist will also emphasize the importance of lifestyle modifications. Printed educational material, with information on hypertension and/ or diabetes medications, including suggested lifestyle interventions was prepared to assist in the intervention and will be handed to patients in the end of the session."
224259280|NCT02917525|DIETARY_SUPPLEMENT|Vitamin K2|
224259281|NCT02917525|OTHER|Placebo|
224259282|NCT05479058|DRUG|Filgotinib|Administered orally once daily
224259283|NCT05479058|DRUG|Placebo|Administered orally once daily
224259284|NCT05309876|BEHAVIORAL|Lifestyle tool|Regular use of the digital Lifestyle tool
224259285|NCT03302039|DRUG|Single shot phenylephrine|A single shot of phenylephrine (1.5 mcg/Kg) will be administrated intravenously.
224259286|NCT03302039|DRUG|Fixed infusion phenylephrine.|Fixed infusion of phenylephrine will be administrated at a rate of 0.75 mcg/Kg/min
224259287|NCT03302039|DRUG|Variable infusion phenylephrine.|Variable infusion of phenylephrine will be administrated at a starting rate of 0.75 mcg/Kg/min.
224259288|NCT03302039|DRUG|Bupivacaine|Bupivacaine will be administrated in the subarachnoid space for spinal anesthesia.
224259289|NCT05972174|BIOLOGICAL|mRNA-1018 for H5N8|Sterile liquid for injection
224259290|NCT05972174|BIOLOGICAL|mRNA-1018 for H7N9|Sterile liquid for injection
224259291|NCT05972174|BIOLOGICAL|mRNA-1018 for H5 Only|Sterile liquid for injection
224259292|NCT05972174|BIOLOGICAL|mRNA-1018 for H7 Only|Sterile liquid for injection
224259293|NCT05972174|BIOLOGICAL|mRNA-1018 for H5 Only-CG|Sterile liquid for injection
224259294|NCT01370733|DEVICE|NEST-1 (NeoSync EEG Synchronized TMS)|The NeoSync EEG Synchronized TMS (NEST) is an electromechanical medical device that produces and delivers a sinusoidal magnetic field to areas of the brain in the treatment of Major Depressive Disorder.
224259295|NCT01370733|DEVICE|SHAM|The sham device is configured to simulate the actual NEST-1 device without sTMS therapy being actively delivered.
224259296|NCT03279250|DRUG|Abiraterone Acetate|Given PO
224259297|NCT03279250|DRUG|Apalutamide|Given PO
224259298|NCT03279250|BIOLOGICAL|Gonadotropin-releasing Hormone Analog|Given IM
223678521|NCT06691984|DRUG|Xaluritamig|Short-term IV infusion
223678522|NCT06691984|DRUG|Abiraterone|Oral tablets
223678523|NCT06691984|DRUG|Enzalutamide|Oral tablets
223773282|NCT01174030|DRUG|CD07805/47 Gel|CD07805/47 Gel 0.5% QD
224259299|NCT03279250|DRUG|Prednisone|Given PO
224259300|NCT03279250|PROCEDURE|Radical Prostatectomy|Undergo radical prostatectomy
224259301|NCT01157130|OTHER|Exercise Regimen|Exercise instruction
223678524|NCT06691984|DRUG|Cabazitaxel|IV infusion
224259302|NCT05301218|PROCEDURE|angioplasty|Coronary angioplasty, also called percutaneous coronary intervention, is a procedure used to open clogged heart arteries. Angioplasty uses a tiny balloon catheter that is inserted in a blocked blood vessel to help widen it and improve blood flow to the heart
224259303|NCT04153877|OTHER|Kinesiotape|Kinesio-tape® is an elastic, hypoallergenic, cotton-fiber tape with acrylic heat-activated backing and is widely used within sports.
224259304|NCT06353139|DEVICE|Modified olfactory training device|Conduct olfactory training in patients with olfactory disorders
224259305|NCT05457452|DEVICE|Knee Brace|Installation of an angle-adjustable knee brace, used after ACL reconstruction performed by an orthopedic specialist or orthopedic PPDS with the first week the angle locked at 00, in the second week the angle 0-900, in the third week the angle 0-1200, and the fourth week the angle of flexion full. Braces are used except for physical therapy according to the rehabilitation protocol in the first week.
224259306|NCT04803487|OTHER|robot-assisted cholecystectomy|cholecystectomy was performed for patients using the Chinese Micro Hand S surgical robot.
224259307|NCT04803487|OTHER|robot-assisted cholecystectomy|cholecystectomy was performed for patients using the da Vinci surgical robot.
224259308|NCT00563264|BEHAVIORAL|KAN-DO|"The 10 month KAN-DO intervention includes eight mailed interactive activity modules involving both the preschooler and mother that include relevant printed materials emphasizing parenting skills, healthy eating habits and increased physical activity. Mailed kits will each be followed by a supportive telephone counseling session based on motivational interviewing techniques. Mailed modules and telephone calls will be supplemented with two in-person motivational and informational sessions (at the beginning and in the middle of the intervention period).~The Active Comparator group will receive monthly newsletters over the 10 month period related to boosting reading skills in their preschool children."
224259309|NCT06030583|OTHER|Scales and Forms|This study does not involve any interventions. Information will be collected from the study group and the control group through scales and forms.
224259310|NCT05799313|OTHER|At home removal|Removal of PNE lead at home
224259311|NCT05799313|OTHER|In office removal|Removal of PNE lead in the office
224259312|NCT02256943|DRUG|Amitriptyline|100 mg single dose
224259313|NCT02256943|DRUG|Tolterodine|Placebo 1 mg single dose
223678531|NCT07030517|DRUG|Teclistamab|Teclistamab will be administered subcutaneously.
223678534|NCT06695845|DRUG|Zanidatamab|Administered by intravenous (IV) infusion
223773283|NCT01174030|DRUG|Vehicle Gel|Vehicle Gel QD
223773284|NCT01174030|DRUG|CD07805/47 Gel|CD07805/47 Gel 0.18% QD
224259314|NCT06352138|BIOLOGICAL|Experimental: Epoetin alfa Megalabs® Erythropoietin injectable in intravenous administration.|comparison vs the reference product to demonstrate biological similarity
224259315|NCT06352138|BIOLOGICAL|Active comparator: European Union licenced epoetin alfa|comparison vs. the test product to demonstrate biological similarity
224259316|NCT02317263|DRUG|testosterone|
224259317|NCT02317263|DRUG|placebo gel|
224259318|NCT03910231|DRUG|Tolvaptan Oral Tablet|Tolvaptan, to block V2R
224259319|NCT00604474|DEVICE|HiResolution Bionic Ear System (Cochlear Implant)|Subjects are required to have bilateral implantation of the Advanced Bionics HiResolution Bionic Ear System (Cochlear Implant)
224259320|NCT00000915|BEHAVIORAL|Vaccine preparedness|
224259321|NCT01090687|RADIATION|computed tomography (CT scan)|Subjects will undergo cone beam breast CT scan
224259322|NCT01090687|DEVICE|computed tomography (CT scan)|Subjects will undergo cone beam breast CT scan
224259323|NCT00463684|BIOLOGICAL|Live, Attenuated Japanese Encephalitis SA 14-14-2 Vaccine|Manufactured by Chengdu Institute of Biological Products (CDIBP), Chengdu, China; batch 200611A078-1. Administered subcutaneously in the right brachium.
224259324|NCT00463684|BIOLOGICAL|Live, attenuated measles vaccine|Manufactured by Serum Institute of India, Ltd, Pune, India; batch EU3244. Administered subcutaneously in the left brachium.
224259325|NCT04952857|DRUG|cholecalciferol 6 lakh IU|vitamin D levels and serum calcium will be assessed at day 3,7, 14.
223678542|NCT06880692|OTHER|Educational Materials delivered via the Tick App|Education about tick bite prevention
223678547|NCT06718582|DEVICE|Delfi Training Device|Delfi (Vancouver, Canada) training devices will be used for exercise and testing sessions. Cuffs will be placed around the right and left proximal thigh. The LOP will be set at 60% immediately before exercise and will be applied during the entire exercise set (approximately 30-60 seconds in duration) following manufacturer specifications. In the supine LOP session, the BFR cuffs will be pressurized to 60% of the supine LOP. In the seated LOP session, the BFR cuffs will be pressurized to 60% of the seated LOP. And, in the standing LOP session, the BFR cuffs will be pressurized to 60% of the standing LOP. The cuffs will maintain pressure during training and rest periods. The LOP will be reduced to 0% immediately after completing the last set.
223678549|NCT06881251|DRUG|Dupilumab|Dupilumab will be administered subcutaneously.
223678550|NCT06881251|DRUG|JNJ-95475939|JNJ-95475939 will be administered subcutaneously.
223678551|NCT06881251|DRUG|Placebo|Placebo will be administered subcutaneously.
223678553|NCT07032727|DRUG|Olutasidenib|Given by po
223678554|NCT07032727|DRUG|Cladribine (CLAD)|Given by IV
223678555|NCT07032727|DRUG|Venetoclax|Given by po
223678556|NCT07032727|DRUG|Gilteritinib|Given by po
223678557|NCT07032727|DRUG|Ruxolitinib|Given by po
223678558|NCT07032727|DRUG|Cytarabine|Given SQ
223678561|NCT06293482|DEVICE|Cochlear™ Nucleus® System|The Cochlear™ Nucleus ® System is a commercially available system intended for restoration of hearing sensation through electrical stimulation of the auditory nerve in adult patients with bilateral symmetrical sensorineural hearing loss.
223678562|NCT07037771|DRUG|zodasiran Injection|ARO-ANG3 Injection
223678563|NCT07037771|DRUG|Placebo|sterile normal saline (0.9% NaCl)
223678569|NCT06886737|OTHER|Virtual-reality convergence training game|The participant plays a custom virtual-reality game that is designed to train convergence.
223678570|NCT06447688|DRUG|Verapamil|Prevent
223678580|NCT07046494|DRUG|RAP-219|RAP-219 tablets administered orally, once daily for 21 days
223773285|NCT01174030|DRUG|CD07805/47 Gel|CD07805/47 Gel 0.18% BID
223773286|NCT01174030|DRUG|Vehicle Gel|Vehicle Gel BID
224259326|NCT00990535|DRUG|Octreotide-LAR|Octreotide-LAR 30 mg administered every 21 days until progression
223678581|NCT07046494|OTHER|Placebo|Matching placebo tablets administered orally, once daily for 21 days
224259327|NCT04948619|BIOLOGICAL|Vaccine|Patients will have lab evaluations for immune function at baseline, 3, 6, 9 and 24 months post completion of treatment. At 3 months off therapy, patients with abnormal vaccine antibody titers will be randomized to receive either single booster vaccines or to begin a full revaccination series that models post-hematopoietic stem cell transplant vaccination strategies.
224259328|NCT03072030|BIOLOGICAL|GamEvac-Combi (vaccine)|vaccination
224259329|NCT03072030|BIOLOGICAL|Placebo|vaccination
224259330|NCT00191815|DRUG|Gemcitabine|Gemcitabine (30 min intravenous infusion) dose of 1000mg/m2 on Day 1 and Day 8 (21 day cycle).
224259331|NCT00191815|DRUG|cisplatin|Cisplatin (30-120 min intravenous infusion) dose of 35 mg/m2 on Day 1 and Day 8 (21 day cycle).
224259332|NCT01349257|DRUG|BDP/Formoterol|One single day treatment of CHF 1535 100/6 NEXT DPI®: CHF 1535 dry powder for inhalation (fixed combination of beclomethasone dipropionate 100 µg plus formoterol fumarate 6 µg per actuation) administered via the NEXT DPI® dry powder inhaler with charcoal block.
223773287|NCT00628550|DRUG|Vasopressin|One dose of vasopressin (0.8 units/kg) intravenously rescue as the second vasopressor medication.
223678586|NCT06310031|DEVICE|BrioVAD System|Implantation of the BrioVAD System to evaluate the safety and efficacy of the BrioVAD System by demonstrating non-inferiority to the HeartMate 3 LVAS when used for the treatment of advanced, refractory, left ventricular heart failure.
223678587|NCT06310031|DEVICE|HeartMate 3|Implantation of the commercially approved HeartMate 3 LVAS, which is the standard treatment for advanced heart failure.
223773288|NCT00628550|DRUG|Epinephrine|One standard dose epinephrine (0.01 mg/kg) intravenously rescue as the second vasopressor medication.
223773289|NCT01064921|DRUG|vorinostat|The first vorinostat dose level is 100mg, and the second dose will be 200mg, third dose will be 300mg. If the first vorinostat dose level is found to be excessively toxic, the patient will be reduced to -1 dosing level then if still too toxic reduced again to dose level -2. Dose escalation of vorinostat will continue in increments of 100 mg (i.e., 200 mg on dosing days, 300 mg on dosing days). Vorinostat will be given 3 consecutive days per week (e.g. Monday, Tuesday, Wednesday).
223773290|NCT01064921|DRUG|cisplatin|Given IV
224259333|NCT01776138|OTHER|Collect Blood and Survey Instruments|
224259334|NCT06571734|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
224259335|NCT06571734|PROCEDURE|Computed Tomography|Undergo CT
224259336|NCT06571734|PROCEDURE|Echocardiography|Undergo ECHO
223773291|NCT01064921|RADIATION|radiation therapy|Standard chemoradiation therapy X 7 weeks (Days 7-56), concurrent with oral Vorinostat given three days per week (Mon, Tues, Wed)
223773292|NCT01064921|PROCEDURE|Correlative Studies|Day 35, 2 weeks post radiation therapy completion optional tumor/normal muscosal biopsy and blood draw for correlative studies. At day 153 an optional tumor/normal tissue biopsy and blood draw for correlative studies.
223773293|NCT01565993|DEVICE|Hemoclip|"A rotatable clip-fixing device Quickclip 2 standard was used (Olympus Medical Systems Corp. Hachioji-shi, Tokyo, Japan), with an opening diameter of 135º and a maximum insertion portion diameter of 2.6 mm"
223773294|NCT01565993|DEVICE|Conventional Polipectomy|Disposable electrosurgical snares (Olympus Medical Systems Corp. Hachioji-shi, Tokyo, Japan) and an electrosurgery unit ERBE (ERBE Elektromedizin GmbH, Germany) were used for polyp resection
223773295|NCT06018961|OTHER|Post-operative ileus surgery|Collection of ileus events, items of IFEED score and surgical complications
223773296|NCT02804165|GENETIC|Enterovirus vaccination|Enterovirus vaccination in genetically predisposed subjects having a high risk to develop type 1 diabetes.
223773297|NCT01960231|OTHER|OGTT|
223773298|NCT03745703|BEHAVIORAL|MOCHA|(see above)
223773299|NCT03995004|DRUG|Melatonin|Melatonin (N-acetyl-5-methoxytryptamine) is a neurohormone that is endogenously produced and secreted by the pineal gland in the brain following a circadian rhythm, with a plasma concentration highest at night and lowest during the day.
224259337|NCT06571734|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
224259338|NCT06571734|DRUG|Zanzalintinib|Given PO
224259339|NCT03808376|DEVICE|Continuous Glucose Monitoring System|The Eversense® 180 CGM System
224259340|NCT06302114|OTHER|Assessment of overhead athletes|Assessment of medicine ball forward throw, Y balance test, Range of motion of the shoulder (internal and external rotation), strength of internal and external rotator muscles.
224259341|NCT03644550|DRUG|LMB-100|Given intravenous (IV) at recommended phase 2 dose (RP2D) on days 1, 3 and 5 of two (2) 21 day cycles.
224259342|NCT03644550|BIOLOGICAL|Pembrolizumab|Given intravenous (IV) at approved dose on day 1 of each 21 day cycle, starting with cycle 3, for up to 2 years with the option of a second course for patients meeting criteria.
224259343|NCT04215328|DIETARY_SUPPLEMENT|Mixed-Meal|Per 250ml bottle: 220 calories, protein 9g, carbohydrate 33g (15g sugar), fat 6g, sodium 190mg, potassium 390mg; 500mLs by tube daily in 4 doses
224259344|NCT04215328|DIETARY_SUPPLEMENT|Electrolyte Solution|Electrolyte Solution 500mLs by tube daily in 4 doses
224259345|NCT01208935|DRUG|Nicotine Patch|
224259346|NCT01208935|DRUG|Nicotine Gum|
224259347|NCT02552758|BIOLOGICAL|omega-3 fatty acid|omega-3 fatty acid
224259348|NCT02552758|BIOLOGICAL|placebo|placebo
224259349|NCT02552758|DEVICE|positron emission tomography (PET)|
224259350|NCT03563872|OTHER|Intervention|Enhancements to team-based care include clinical decision support and improved protocols for telehealth prescribing.
224259351|NCT03563872|OTHER|Active Comparator|Usual, team-based care
224259352|NCT00831103|DRUG|EPB-348|Treated over seven days
224259353|NCT00831103|DRUG|Valacyclovir|Treated over seven days
224259354|NCT04454229|OTHER|Direct oral penicillin challenge|The patient will receive a single dose of oral penicillin, following baseline vital signs.
224259355|NCT04454229|OTHER|Standard of care|Routine management as per the treating clinicians that include skin prick and intradermal beta-lactam testing, followed by oral penicillin challenge in the setting of negative skin testing.
224259356|NCT01501448|DRUG|Levonorgestrel and ethinylestradiol|30 microgram of ethinylestradiol plus levonorgestrel daily for 12 to 16 days
224259357|NCT01501448|DRUG|Estradiol valerate|4mg estradiol valerate from cycle day 20 till the day before the initiation of the cycle
224322768|NCT05000294|DRUG|Tivozanib|Subjects in both the phase Ib and phase II portions of the study will take tivozanib orally once daily on Days 1-21 of each 28 day cycle. Subjects on the phase Ib will be assigned to receive either 1.34 mg/day (Dose level 0) or 0.89 mg/day (Dose level -1). Subjects in the phase II portion of the study will receive 0.89 mg/day.
224322769|NCT06361342|BEHAVIORAL|General decrease in smartphone use|Subjects will decrease their time on smartphone in general.
224322770|NCT06361342|BEHAVIORAL|Avoiding Social Media Apps|Subjects will avoid use of social media apps on the smartphone which includes Twitter, Facebook, Tik Tok, Instagram, and Pinterest.
224322771|NCT02790853|PROCEDURE|Biopsy|Undergo brush biopsy and incisional biopsy
223773300|NCT03995004|DRUG|Dexamethasone Sodium Sulphate 4mg/1mL|Dexamethasone is a glucocorticoid commonly used in orthognathic surgery to reduce postoperative facial edema by its potent anti-inflammatory effect
223773301|NCT01824303|DRUG|LiRIS 400 mg|LiRIS 400 mg contains lidocaine which is gradually released into the bladder over 14 days.
223773302|NCT01824303|OTHER|LiRIS Placebo|LiRIS Placebo contains lactose, inactive substance.
223773303|NCT03144570|OTHER|None, non-interventional study|Not applicable, non-interventional study
224259358|NCT03011294|DEVICE|Continuous positive airway pressure (CPAP)|Standard treatment for sleep apnea
224259359|NCT03011294|DEVICE|Nasal strip|Placebo
224259360|NCT06290284|PROCEDURE|Long Peripheral Catheter|PowerGlide Pro™ Midline Catheter
224259361|NCT06290284|PROCEDURE|Peripheral Intra-Venous Catheter|Venflon™ Pro Safety Needle Protected IntraVenous Cannula
224259362|NCT00323882|DRUG|MDX-010|selected dose administered IV every 3 weeks
223773304|NCT02624102|BEHAVIORAL|Trial based cognitive therapy|Patients with MDD, in use of antidepressants plus Trial Based Cognitive Therapy
223773305|NCT02624102|BEHAVIORAL|Behavioral Activation|Patients with MDD, in use of antidepressants plus Behavioral Activation
223773306|NCT02624102|DRUG|Antidepressants|Patients with MDD, in use of antidepressants (fluoxetine, citalopram, escitalopram, bupropion, etc.) without psychotherapy.
223773307|NCT04273100|COMBINATION_PRODUCT|PD-1 mAb combined with TACE and lenvatinib|the combination of immunotherapy (PD-1 monoclonal antibody), local therapy (TACE) and anti-angiogenic therapy (lenvatinib)
224259363|NCT01469351|DRUG|Liraglutide|"Liraglutide (Victoza ®), human GLP-1 analog produced using recombinant DNA technology in saccharomyces cerevisiae. Victoza ® is registered and approved for the treatment of type 2 diabetes.~Victoza ® stimulates glucose-dependent insulin secretion from β-cells and inhibits glucagon secretion, slows ventricle emptying and reduces body weight and body fat mass by affecting appetite regulation.~Form of administration: Liraglutide is a clear injection fluid, which comes in a prefilled disposable pen.~1 ml contains 6 mg of liraglutide in sterile water. There is added disodium phosphate and propylene glycol and the preservative phenol. A filled pen contains 18mg liraglutide in 3ml. NovoFine® needles are used."
224322772|NCT02790853|PROCEDURE|Fluorescence Imaging|Undergo PS2.1/PS3 imaging
224322773|NCT02790853|PROCEDURE|High-Resolution Microendoscopy|Undergo HRME imaging
224322774|NCT02790853|DRUG|Proflavine Hemisulfate|Applied on mucosa
223773308|NCT02872415|BIOLOGICAL|Blood puncture site|Blood puncture site
223773309|NCT05809895|DRUG|Ociperlimab|900 mg intravenously (IV) every 3 weeks (Q3W)
223773310|NCT05809895|DRUG|Tislelizumab|200 mg intravenously (IV) Q3W
223773311|NCT05809895|DRUG|Paclitaxel|90 mg/m2 intravenously (IV) on Days 1, 8 and 15 every 28 days
223773312|NCT05809895|DRUG|Nab-paclitaxel|100 mg/m2 intravenously (IV) on Days 1, 8 and 15 every 28 days
223773313|NCT05809895|DRUG|Carboplatin|AUC 2 intravenously (IV) on Days 1 and 8 every 21 days
223773314|NCT05809895|DRUG|Placebo|normal saline intravenously (IV) Q3W
223773315|NCT05809895|DRUG|Pembrolizumab|200 mg intravenously (IV) Q3W
223773316|NCT05809895|DRUG|Gemcitabine|1000 mg/m2 intravenously (IV) on Days 1 and 8 every 21 days
224259364|NCT01469351|DRUG|non-active study drug|placebo
224259365|NCT00165685|DRUG|Sibutramine Hydrochloride Monohydrate|
224259366|NCT03323008|OTHER|Prototype|Usability testing and System Usability Scale
224322775|NCT04821622|DRUG|talazoparib plus enzalutamide|experimental arm
224322776|NCT04821622|DRUG|Placebo plus enzalutamide|Active comparator arm
224259367|NCT04521218|OTHER|Thrust Joint Manipulation|"Experimental group included TJM, Cervical hot pack, strengthening exercises and home plan; 3 sessions of manipulation per week and total of 4 weeks. Measurement will be taken at base level and after the last session, i.e. Pain intensity, pain pressure threshold, ROM, and disability.~These exercises included. Cervical Flexion, Extension Rotation, lateral flexion and back strengthening exercises. These all exercises were performed 3 x 15 Repetitions with 10 sec hold. This protocol was for 4 weeks and 3 sessions per week.~Home plan exercises includes Craniocervical Flexion, Craniocervical Extension, Rotation Exercise, Lateral Flexion Exercise, Chin Tuck in and Shoulder blade exercise were advised to perform 3 x 10 Repetition with 10 - 30 sec hold."
224259368|NCT04521218|OTHER|Reverse Sustained Natural apophyseal glides|"Control group included Moist Hot Pack (Cervical contour- 8.25 x 10 x 2) for 10 Mins, Reverse SNAGS (10 Repetitions holding for 10 sec in each glide with a rest time of 30 seconds in between), Strengthening exercise and home plan. 3 sessions of mobilization per week and total of 4 weeks. Measurement will be taken at base level and after the last session, i.e. Pain intensity, pain pressure threshold, ROM, and disability.~These exercises included. Cervical Flexion, Extension Rotation, lateral flexion and back strengthening exercises. These all exercises were performed 3 x 15 Repetitions with 10 sec hold. This protocol was for 4 weeks and 3 sessions per week.~Home plan exercises includes Craniocervical Flexion, Craniocervical Extension, Rotation Exercise, Lateral Flexion Exercise, Chin Tuck in and Shoulder blade exercise were advised to perform 3 x 10 Repetition with 10 - 30 sec hold"
223678600|NCT06778057|DEVICE|Test Lens 1|Acuvue® Oasys MAX 1-Day daily disposable contact lenses
223678601|NCT06778057|DEVICE|Test Lens 2|Dailies Total 1 daily disposable contact lenses
223678602|NCT06778057|DEVICE|Test Lens 3|Clariti 1-Day daily disposable contact lenses
223678603|NCT04102189|DRUG|Semaglutide|Participants will receive semaglutide s.c. once weekly for a dose escalation period of 16 weeks and a maintenance period of 52 weeks
223773317|NCT02809976|DRUG|Ruxolitinib 1.5% Phosphate Cream|twice daily topical application of Ruxolitinib 1.5% Phosphate Cream beginning at baseline and ending at week 20
224259369|NCT00210587|DRUG|epoetin alfa|
224259370|NCT05922696|DRUG|Cholecalciferol|50.000IU weekly in Group A , or 200.000IU monthly in Group B
224259371|NCT04371133|DIAGNOSTIC_TEST|Adropin (ng/L)|Thawed samples were measured on a Molecular Devices SpectraMax i3 Multi-Mode, Microplate Reader (batch number: SER 35 370-1448, made in Austria) using enzyme linked immunosorbent assay (ELISA).
224259372|NCT05131113|OTHER|Physical exercise|Physical exercise
224259373|NCT00471133|BIOLOGICAL|Xenogeneic Tyrosinase DNA Vaccine|
224259374|NCT00471133|DEVICE|TriGrid Delivery System for Intramuscular Electroporation|
224259375|NCT00067535|DRUG|Cocaine-Related Disorders|
224259376|NCT02969616|BIOLOGICAL|Trinity Elite|cell based allograft
224259377|NCT01794845|DRUG|Erbitux|Erbitux: 400 mg/m2 as a loading dose one week prior to radiation and taxotere, and then at 250 mg/m2 given weekly on Day 1 of treatment week following Taxotere.
224259378|NCT01794845|DRUG|Taxotere|Taxotere : 20 mg/m2 IV once a week on Day 1 during treatment weeks 2 to 7.
223678604|NCT04102189|OTHER|Placebo|Participants will receive semaglutide placebo s.c. once weekly for a total of 68 weeks
223678607|NCT06712810|DRUG|Axl/Mer/CSF1R Inhibitor Q702|Given PO
223678608|NCT06712810|PROCEDURE|Biospecimen Collection|Undergo blood and urine sample collection
223678609|NCT06712810|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow biopsy and aspiration
223678610|NCT06712810|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy and aspiration
223773318|NCT05322603|DRUG|Analgesics Non Opioid (Neodolpasse manufactured by Fresenius Kabi)|A decrease in the pain severity (VAS);opioid-sparing effect
223773319|NCT05322603|DRUG|Analgesics|A decrease in the pain severity (VAS)
223773320|NCT00965900|PROCEDURE|Endoscopic band ligation|"* Perform EBL within 7 days after randomization~* Apply 1-2 band/column/session to varices in the distal 5-7 cm of the esophagus till they are eradicated (disappearance or too small to apply band) with interval of 4 weeks (at 4,8,12 weeks after initial treatment)~* Acid suppression using proton pump inhibitor until eradicated.~* After eradication, then follow-up endoscopy according to a preset schedule (at 1, 2, 3 months after initial treatment, then every 3-6 months until 36 months)."
224259379|NCT01794845|RADIATION|Low Dose Fractionated Radiation Therapy|Low-dose fractionated Radiation (LDFRT): 0.5 Gy per fraction twice-a-day (BID) at least 6 to 8 hours apart on Days 2 and 3 of treatment weeks 2 to 7 for a total dose of 12 Gy.
224259380|NCT03332485|DRUG|ECP Colon Prep Kit|ECP Colon Prep Kit
224259381|NCT03332485|DRUG|MoviPrep®|MoviPrep®
224259382|NCT00966589|PROCEDURE|laparoscopic hernioplasty (TEP)|Insertion of polypropylene mesh behind pubic bone
224322777|NCT05581511|OTHER|Evaluation of the natural history of cutaneous neurofibromas|Cutaneous neurofibromas (cNFs) are the most common tumors in people with neurofibromatosis type 1 (NF1). Despite their benign histology, they can significantly impact patients' quality of life (QoL). In this project, the natural history of cNFs will be prospectively and systematically studied. To accomplish this, the reproducibility and efficiency of using 3D whole-body photography was evaluated in a small cohort of patients. The study is enrolling patients of all ages with cNFs into groups by epochs of life to characterize the baseline tumor burden and the change in number and morphology of cNFs over five years. In addition, the study will perform next generation sequencing to describe the genetic variations in the NF1 gene and evaluate potential relations between genotype and phenotype. Lastly, the study will validate clinician- and patient-reported severity scales of cNFs developed for this patient population.
224322778|NCT06336018|DRUG|Etavopivat|Participants will receive a single dose of etavopivat orally.
224322779|NCT03160274|GENETIC|Genetic screening|Germline and/or tumor samples will be screened for mutations
224322780|NCT01872260|DRUG|LEE011|LEE011 - 28 day cycles (21 days followed by a 7 day break) for Arms 1, 3. LEE011 28 days cycles (continuous) Arm 4.
223678611|NCT06712810|PROCEDURE|Computed Tomography|Undergo CT scan
223678612|NCT06712810|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223678613|NCT06712810|PROCEDURE|Positron Emission Tomography|Undergo PET scan
223678614|NCT06712810|OTHER|Survey Administration|Ancillary study
223678615|NCT06733441|DRUG|TLN-254|TLN-254 will be administered orally at a specified dose on specified days depending on treatment allocation.
223678616|NCT06733441|DRUG|TLN-254|TLN-254 will be administered orally at a specified dose on specified days.
223678625|NCT06614712|OTHER|Pre-pricing & reimbursement, incident renal disease cohort (study observation period 2020- 2024)|"Incident renal disease patients in this cohort are defined as those that newly met the renal function measurement definition stated above, with first-ever registered laboratory UACR and/or eGFR measurements or CKD diagnosis on or after the start date of this cohort study period, the 1st August 2020 and until the 1 st February 2023 (DAPA\_CKD P\&R date in Spain). The first of the dates fulfilling any of the criteria defined above for the renal function measurement or CKD diagnosis, is defined as the patient index date-1 of this study cohort.~At the index date-1, the renal disease will be staged based on eGFR (and/or UACR measurements in addition, if available) as specified in the KDIGO guidelines.~Patients will be followed up from the index date-1 until the end of continuous enrolment, last date of available data or date of death, until the end of the overall observation period."
224259383|NCT03184389|BEHAVIORAL|Prompt to use smartphone apps for stress management|Study smartphone and software will be used to deliver intervention prompts to use stress management applications on the study smartphone at various times throughout the day, during at least 10 days of study participation. The delivery of prompts will be micro randomized to occur when participants are classified as stressed, and when participants are not classified as stressed. Headspace, a commercial stress management application, will be installed on the study smartphones. Thought Shakeup and Mood Surfing, stress management applications that are not commercially available, also will be installed on the study smartphones. These smartphone applications guide participants through stress management exercises that draw upon techniques from mindfulness, cognitive behavioral therapy, and acceptance and commitment therapy.
224259384|NCT01445691|DRUG|5-ALA (Gliolan)|20 mg/kg administered once 3-5 hours prior to surgery
224259385|NCT00621491|DRUG|Warfarin|Single daily dose of Warfarin (5 mg/orally), adjusted to achieve an International Normalized Ratio (INR) between 2 to 3.5 times the normal value during six months
224322781|NCT01872260|DRUG|Letrozole|Letrozole 2.5 mg/day
224322782|NCT01872260|DRUG|BYL719|BYL719 - 28 days cycle (continuous) for Arm 2; 3 and 4
224322783|NCT06040918|DRUG|N-803|fixed dose of 1 mg by subcutaneous (SC) injection
224322784|NCT06621251|DRUG|TRL1068 (calpurbatug), a human monoclonal antibody|A human IgG1κ (G1m1,17 (z,a); Km3 allotype) monoclonal antibody
224322785|NCT06621251|PROCEDURE|DAIR|DAIR procedure will be performed between days 15-22
224322786|NCT06406465|DRUG|Belinostat|400mg/m\^2/24h or 600 mg/m\^2/24h IV over (48h continuous infusion) on days 1, 2 and 3 based on UGT1A1 status
223678626|NCT06614712|OTHER|Post-pricing & reimbursement, incident renal disease cohort (study observation period 2023-2024)|We define the post-P\&R cohort including all incident renal disease patients observed in the dapagliflozin-CKD post-pricing and reimbursement period. Patients in this cohort newly met the renal function measurement definition stated above, with first-ever registered laboratory UACR and/or eGFR measurements or CKD diagnosis on or after the 1 st February 2023 (DAPA\_CKD P\&R date in Spain) and until the end of the study observation period. The first of the dates fulfilling any of the criteria defined above for the renal function measurement or CKD diagnosis, is defined as the patient index date-2 of this study cohort. At the index date-2, the renal disease will be staged based on eGFR (and/or UACR measurements in addition, if available) as specified in the KDIGO guidelines. Patients will be followed up from the index date-2 until the end of continuous enrolment, last date of available data or date of death, until the end of the overall study period
224259386|NCT04584294|BEHAVIORAL|MyPath Web-Based Informational and Decision Support Tool|"The MyPath Decision Support Tool includes the following sections and features:~* Questions to capture reproductive goals and orientations towards a potential pregnancy~* Education modules about the menstrual cycle, fertility, and prepregnancy health with the opportunity to flag topics that are relevant and of interest to the patient~* A contraceptive decision module that provides education, elicits patient preferences about different aspects of contraception, and suggests methods most appropriate based on the patient's preferences~* A feature for adding free-text questions that patients may have for their provider~* An email with a summary page that the patient can bring to a visit to guide discussions with primary care providers about reproductive needs"
224259387|NCT03507491|DRUG|Gemcitabine|Gemcitabine will be administered intravenously once weekly over 60 minutes every 3 out of four weeks. The dose of gemcitabine will start at 675 mg/m2/dose. If the MTD has been exceeded at the Dose Level 1, then the subsequent cohort of participants will be treated with gemcitabine at a dose of 500 mg/m2/dose (Dose Level 0).
224259388|NCT03507491|DRUG|Nab-paclitaxel|Nab-Paclitaxel will be administered intravenously over 30 minutes once weekly every 3 out of 4 weeks. Nab-paclitaxel will be administered prior to administration of gemcitabine. The starting dose of nab-paclitaxel will be 180 mg/m2/dose (dose level 1). Dose levels for subsequent groups of subjects are 210 mg/m2/dose (for dose level 2) and 240 mg/m2/dose (for dose level 3).
224259389|NCT05728541|DRUG|SYH2043|Patients will receive SYH2043 once everyday on day 1-21 of each 28-day cycle
224322787|NCT06406465|DRUG|Cisplatin|60 mg/m\^2 IV over 60 minutes on day 2
224322788|NCT06406465|DRUG|Etoposide|80 mg/m\^2 IV over 60 minutes on day 2 after infusion of cisplatin and again on days 3 and 4
224322789|NCT02626312|OTHER|Laboratory Biomarker Analysis|Correlative studies
224322790|NCT02626312|PROCEDURE|Magnetic Resonance Imaging|Correlative studies
223773321|NCT00965900|DRUG|Propranolol|"* start with 20 mg of propranolol b.i.d~* Adjust by 20-40 mg/day reaching reduction by 25 percent in HR or HR less than 55/min~* After reaching target HR, then FU according to a preset schedule (at 1, 2, 3 months after initial treatment, then every 3 months until 36 months)"
223773322|NCT00965900|PROCEDURE|EBL+Propranolol|"1. EBL~   * Perform EBL within 7 days after randomization~  * Apply 1-2 band/column/session to varices in the distal 5-7 cm of the esophagus till they are eradicated (disappearance or too small to apply band) with interval of 4 weeks (at 4,8,12 weeks after initial treatment)~  * Acid suppression using proton pump inhibitor until eradicated.~  * After eradication, then follow-up endoscopy according to a preset schedule (at 1, 2, 3 months after initial treatment, then every 3-6 months until 36 months).~2. Propranolol~   * start with 20 mg b.i.d~  * Adjust by 20-40 mg/day reaching reduction by 25 percent in HR or HR less than 55/min~  * After reaching target HR, then FU according to a preset schedule (at 1, 2, 3 months after initial treatment, then every 3 months until 36 months)"
223773323|NCT02505516|OTHER|metformin|
223773324|NCT01152723|DRUG|Nicotine|2 mg, Single Dose
223773325|NCT01070927|DRUG|RO4929097|80mg po daily, 3 days on 4 days off schedule
223773326|NCT01070927|DRUG|RO4929097|recommended phaseII dose, orally once daily, 3 days on 4 days off schedule
223773327|NCT05663489|BEHAVIORAL|Bergen 4-Day Treatment (B4DT)|A concentrated and exposure-based psychological treatment over four consecutive days
223773328|NCT01163734|DRUG|Ranolazine|Intravenous treatment followed oral treatment for 13 days.
223773329|NCT01163734|OTHER|Saline 0.9% and placebo tablet|Intravenous treatment followed by oral treatment for 13 days
223773330|NCT03888313|OTHER|Pretreatment group consultation|A consultation in group with several patients and one surgeon
223773331|NCT01083550|OTHER|Decision aid exposure|Exposure to a computerized decision aid on adjuvant radioactive iodine treatment decision-making. The exposure is during one visit.
224322791|NCT02626312|RADIATION|Radiation Therapy|Undergo radiation therapy
223678637|NCT06743776|DRUG|MN-166|MN-166 will be taken orally at a dose of 10 mg in the morning and 20 mg in the evening for the first 2 weeks, whereafter dose of 30 mg BID will be taken.
223773332|NCT00727389|BEHAVIORAL|Physiotherapy|Exercise two days a week for six month
223773333|NCT03294369|OTHER|Observational|This is an observational study. No specific diagnostic or therapeutic procedure will be performed due to the study.
223773334|NCT06358924|OTHER|Potassium nitrate with fluoride|Bleaching of teeth using in-Office chemically-activated bleaching agent (Power Whitening YF) was performed followed by the application of the desensitizing agent recommended by the manufacturer (After Whitening Mousse), once for 10 minutes.
223773335|NCT06358924|OTHER|Casein phosphopeptide-amorphous calcium phosphate with fluoride|Bleaching of teeth using in-Office chemically-activated bleaching agent (Power Whitening YF) was performed followed by the application of Mi Paste Plus once for 3 minutes.
223773336|NCT06358924|OTHER|Hydroxyapatite with fluoride|Bleaching of teeth using in-Office chemically-activated bleaching agent (Power Whitening YF) was performed followed by the application of Hydroxyapatite and Fluoride (ReminPro) once for 3 minutes.
224322792|NCT02626312|OTHER|Survey Administration|Ancillary studies
223678638|NCT02407405|DRUG|Selumetinib|orally 50 mg/dose, every 12 hours every day continuously (1 cycle = 28 days)
223678639|NCT07052760|DRUG|111In-ABD147|Given intravenously (IV) prior to imaging
223678640|NCT07052760|PROCEDURE|Single-photon emission computed tomography (SPECT)/Computerized tomography (CT)|Undergo imaging
223678641|NCT07053345|DRUG|Esketamine 56 mg|Participants will self-administer 56 mg of esketamine as intranasal spray into each nostril.
223678642|NCT07053345|DRUG|Esketamine 84 mg|Participants will self-administer 84 mg of esketamine as intranasal spray into each nostril.
224259390|NCT05235581|OTHER|Intervention A : virtual environment with avatar|30-second right and left unipodal static and dynamic balance test with avatar only
224259391|NCT05235581|OTHER|Intervention B : virtual environment with reinforced visual signal|30-second right and left unipodal static and dynamic balance test with reinforced visual signal only
224259392|NCT05235581|OTHER|Intervention C : virtual environment with avatar and reinforced visual signal|30-second right and left unipodal static and dynamic balance test with avatar and reinforced visual signal
224259393|NCT05235581|OTHER|Intervention D : real environment|30-second right and left unipodal static and dynamic balance test in real environment
224259394|NCT01747694|BEHAVIORAL|Multi-respiratory muscle training|Patients will be taught the diaphragmatic breathing technique at the same time also will be instructed a four-item (including upper-arm weighted exercise, body side-bends, modified sit-ups, body crunching) multi-respiratory muscle training motions. To practice three times/day, three days a week lasting 12 weeks at home.
224259395|NCT01745679|DRUG|Ceftriaxone treatment|ceftriaxone will be administered à high dose : \> or equal to 75mg/kg/day or 4 gr/day
224259396|NCT01633281|PROCEDURE|acupuncture|Ten sessions of acupuncture at 2x per week over 5 weeks will be given to patients. The acupuncture points include a standard set of obligatory points and additional points based on symptoms.
224259397|NCT01456221|DIETARY_SUPPLEMENT|Omega3 and an hypocaloric diet.|Thirty caps with the supplement will be provided every mo during three mo. Supplement will be administered as gel caps containing 1.1 g of DHA and EPA (®MaxEpa, Merck Laboratory) Hypocaloric diet will start at admission and will continue during the six months of follow-up. It will consist in providing a personalized diet including: a) reduction of 700 Kcal from the usual diet considering lipids and carbohydrates, b) increasing fruits and vegetables intake up to six portions daily each, and c) incrementing the intake of fiber to 30 g a day through the inclusion of whole grains.
224259398|NCT01456221|DIETARY_SUPPLEMENT|Sunflower oil with an hypocaloric diet.|Thirty caps with the placebo will be provided every mo during three mo. Placebo will be administered as gel caps containing 1g of sunflower oil, which is omega-3 free, and is not expected to produce anti-inflammatory or insulin sensitivity effects. Hypocaloric diet will start at admission and will continue during the six months of follow-up. It will consist in providing a personalized diet including: a) reduction of 700 Kcal from the usual diet considering lipids and carbohydrates, b) increasing fruits and vegetables intake up to six portions daily each, and c) incrementing the intake of fiber to 30 g a day through the inclusion of whole grains.
224259399|NCT02197741|DRUG|opiate with bolus|
224322793|NCT06956352|BEHAVIORAL|Usual Care|Usual, referral-based, care.
224322794|NCT06956352|BEHAVIORAL|Adapted Collaborative Care Model (CCM)|Person-centered, recovery supports.
224322795|NCT05918211|DRUG|Udenafil|Active drug
223678653|NCT05811351|DRUG|JNJ-81201887|JNJ-81201887 will be administered as intravitreal injection.
223678654|NCT05811351|DRUG|Prednisone|Prednisone will be administered as oral capsule.
223678655|NCT05811351|OTHER|Placebo|Prednisone matching placebo will be administered as oral capsule.
223678656|NCT05811351|DRUG|Triamcinolone|Triamcinolone (corticosteroid injection) periocular injection will be administered as per local practice.
223678657|NCT05811351|OTHER|Sham Procedure|Sham injections matching to single JNJ-81201887 injection and matching to corticosteroid (triamcinolone) periocular injection will be administered.
223678660|NCT06749496|DEVICE|Test Lens|ACUVUE® OASYS MAX 1-Day for ASTIGMATISM (AOM1DfA).
223678661|NCT06749496|DEVICE|Control Lens|Alcon DAILIES TOTAL1® for Astigmatism Contact Lenses (DT1fA).
224259400|NCT04416386|OTHER|Vitamin C|Pre and post-operative blood plasma levels of vitamin C will be investigated
224259401|NCT06561191|OTHER|Hemodialysis mode, dialyzer type|Change of hemodialysis mode and dialyzer type
224259402|NCT00130377|BIOLOGICAL|cell therapy|autologous or allogeneic cells
224259403|NCT06538181|DRUG|Pacritinib|Starting dose is 200 mg twice per day by mouth. Dose level -1 is 100 mg twice per day by mouth.
224259404|NCT05271383|DEVICE|Orthognathic surgery using Global D's implants.|Major or minor participants who will be treated by an orthognathic surgery with ORTRAUTEK® or MINITEK® implant(s).
224322796|NCT05918211|DRUG|Placebo|Matching Placebo
224322797|NCT06465329|DRUG|Cemiplimab|Intravenous (IV) infusion administration
223678677|NCT06664788|DEVICE|ETHIZIA|ETHIZIA patch will be applied to bleeding site intraoperatively.
223678678|NCT06664788|DEVICE|SURGICEL Original|SURGICEL Original will be applied to bleeding site intraoperatively.
223678681|NCT07054190|DRUG|Inavolisib|Inavolisib will be administered as per the schedule specified in the arms
223678682|NCT07054190|DRUG|Ribociclib|Ribociclib will be administered as per the schedule specified in the arms
223678683|NCT07054190|DRUG|Letrozole|Letrozole will be administered as per the schedule specified in the arms
223678684|NCT07059364|BEHAVIORAL|CAST Treatment|Activity completion will be evaluated based the number of consecutive and total activities completed, duration of sustained activity engagement, prompts or redirection, and adult proximity at baseline and post-trial.
223678686|NCT06124157|PROCEDURE|Biospecimen Collection|Undergo blood and CSF sample collection
223678687|NCT06124157|BIOLOGICAL|Blinatumomab|Receive IV
223678688|NCT06124157|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
224322798|NCT06465329|DRUG|Platinum-based chemotherapy|IV infusion
223678689|NCT06124157|DRUG|Calaspargase Pegol|Receive IV
223678690|NCT06124157|DRUG|Cyclophosphamide|Receive IV
223678691|NCT06124157|DRUG|Cytarabine|Receive IV or subcutaneously
223678692|NCT06124157|DRUG|Dasatinib|Receive PO
223678693|NCT06124157|DRUG|Daunorubicin|Receive IV
223678694|NCT06124157|DRUG|Doxorubicin|Receive IV
223678695|NCT06124157|PROCEDURE|Echocardiography Test|Undergo ECHO
223678696|NCT06124157|DRUG|Imatinib|Given PO
223678697|NCT06124157|DRUG|Leucovorin|Receive PO or IV
223678698|NCT06124157|DRUG|Mercaptopurine|Receive PO
223678699|NCT06124157|DRUG|Methotrexate|Receive IT or IV or PO
223678700|NCT06124157|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
223678701|NCT06124157|DRUG|Pegaspargase|Receive IV or intramuscularly
223678702|NCT06124157|DRUG|Prednisolone|Receive PO
223678703|NCT06124157|DRUG|Prednisone|Receive PO
223678704|NCT06124157|RADIATION|Radiation Therapy|Undergo radiation therapy
223678705|NCT06124157|DRUG|Thioguanine|Receive PO
223678706|NCT06124157|DRUG|Vincristine|Receive IV
224322799|NCT06465329|DRUG|REGN7075|IV infusion
224322800|NCT06551324|DRUG|PF-06821497|875 mg BID (2 times a day)
224322801|NCT06551324|DRUG|Docetaxel|75 mg/m2 IV (every 21 days)
224322802|NCT06551324|DRUG|Enzalutamide|160 mg QD
224322803|NCT05554380|PROCEDURE|Biopsy Procedure|Undergo tumor biopsy
223773337|NCT06358924|OTHER|PAMAM-carboxylic acid dendrimer|Bleaching of teeth using in-Office chemically-activated bleaching agent (Power Whitening YF) was performed followed by the application of PAMAM once for 30 minutes.
223773338|NCT02097875|DRUG|BLZ-100|
223773339|NCT02205892|DRUG|Lupeol|Patients are supposed to apply 2% lupeol cream to one side of their face two times per day for 4 weeks. Application side is randomly determined.
223773340|NCT02205892|DRUG|Placebo vehicle|Patients are supposed to apply their control vehicle cream two times per day to the other side of their face for 4 weeks. Application side is randomly determined.
224259405|NCT06647173|BEHAVIORAL|Blued+ Service Platform|During the intervention period, participants received the enhanced version of the Blued app. The free HIV prevention services were integrated into the Blued app: health messaging, in-home HIV testing, linkage to care for those testing HIV positive, condoms, lubricants, in-app screening, and provision to PrEP.
224322804|NCT05554380|PROCEDURE|Biospecimen Collection|Undergo blood collection
224322805|NCT05554380|PROCEDURE|Computed Tomography|Undergo CT scan
224259406|NCT06415045|DRUG|BI 1015550|BI 1015550
224259407|NCT06738966|DRUG|BL0175|"BL0175 is a nano-medicine for cancer therapy. Nano-medicine means the tiny size of this study drug allows it to enter and concentrate into the tumor tissue. This is a new way of delivering an active drug (an estrogen receptor down regulator) for the treatment of tumor directly into tumor tissue."
224259408|NCT05206344|OTHER|clowns|presence or absence of clowns during the performance of a painful act, on pain
224322806|NCT05554380|DRUG|Ipatasertib|Given PO
224322807|NCT05554380|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
224322808|NCT05554380|DRUG|Paclitaxel|Given IV
223773341|NCT02929810|BEHAVIORAL|sleep extension|
223773342|NCT02929810|BEHAVIORAL|sleep maintenance|
223773343|NCT00113516|DRUG|carboplatin|AUC of 6 mg\*min/mL via IV infusion every 21 days for 4 cycles as per institutional practices.
223773344|NCT00113516|DRUG|paclitaxel|175-225 mg/m2 via IV infusion every 21 days for 4 cycles as per institutional practices.
223773345|NCT00113516|DRUG|sunitinib|50 mg orally daily for 4 weeks followed by 2 weeks off treatment up to 1 year (after completing 1 year of treatment, pts deriving clinical benefit may continue to receive sunitinib in a separate continuation protocol).
223773346|NCT00393445|DRUG|GLP-1 control|intravenous infusion of GLP-1
223773347|NCT00393445|DRUG|GLP-1 and Exendin(9-39) 300|intravenous infusion of exendin(9-39) at 300 pmol/kg/min during GLP-1 at 0.3 and 0.9 pmol/kg/min
223773348|NCT00393445|DRUG|saline control|intravenous infusion of saline
224322809|NCT02150889|BEHAVIORAL|Running Program|16 week supervised running program
224322810|NCT02150889|BEHAVIORAL|Yoga Program|once weekly supervised yoga
223773349|NCT00393445|DRUG|GLP-1 and Exendin(9-39) 600|intravenous infusion of exendin(9-39) at 600 pmol/kg/min during GLP-1 at 0.3 and 0.9 pmol/kg/min
223773350|NCT00393445|DRUG|GLP-1 and Exendin(9-39) 900|intravenous infusion of exendin(9-39) at 900 pmol/kg/min during GLP-1 at 0.3 and 0.9 pmol/kg/min
224259409|NCT05497804|PROCEDURE|Bone Marrow Aspiration and Biopsy|Undergo bone marrow aspiration and biopsy
224259410|NCT05497804|DRUG|Carfilzomib|Given IV
224259411|NCT05497804|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
224259412|NCT05497804|BIOLOGICAL|Daratumumab|Given SC
224259413|NCT05497804|DRUG|Dexamethasone|Given IV/PO
224259414|NCT05497804|DRUG|Lenalidomide|Given PO
224259415|NCT05497804|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
224322811|NCT06055920|DEVICE|FlowTriever System|Mechanical Thrombectomy for pulmonary embolism
224322812|NCT06055920|DRUG|Anticoagulation Agents|"Commercially available/market approved anticoagulation medication including but not limited to: Heparin Sodium, Coumadin, Rivaroxaban, Apixaban, etc.~Anticoagulants are a group of medications that decrease your blood's ability to clot."
224322813|NCT05473429|DEVICE|TSA2 Thermosensory Stimulator|TSA thermal analyzer uses the thresholds for four sub-modalities to measure thermal sensory threshold. This device is capable of heating or cooling the skin as needed to detect heat and cold tolerance and to deliver thermal stimuli.
224259416|NCT05497804|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
224259417|NCT05497804|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA scan
224259418|NCT05497804|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
224259419|NCT05497804|PROCEDURE|Echocardiography|Undergo ECHO
224259420|NCT05497804|PROCEDURE|Chest Radiography|Undergo chest x-ray
223773351|NCT00393445|DRUG|GLP-1 and Exendin(9-39) 1200|intravenous infusion of exendin(9-39) at 1200 pmol/kg/min during GLP-1 at 0.3 and 0.9 pmol/kg/min
224259421|NCT01019889|DRUG|SCRT|4 capsules,three times daily, for 7days or within symptom disappearance
224259422|NCT01019889|DRUG|YPS|4 capsules, three times daily, for 7days or within symptom disappearance
224259423|NCT01019889|DRUG|Placebo|4 capsules, three times daily, for 7days or within symptom disappearance
224259424|NCT02485847|PROCEDURE|Ophthalmology|A registry of ophthalmic ambulatory encounters which captures essential data elements for continuous quality improvement efforts, enhanced patient care outcomes, and pay for performance programs.
224259425|NCT04891744|DRUG|Selinexor|Selinexor (ATG-010# is a first-in-class, oral selective exportin 1 (XPO1) inhibitor (1,2). Selinexor functions by binding with and inhibiting the nuclear export protein XPO1 (also called CRM1), leading to the accumulation of tumor suppressor proteins in the cell nucleus along with inhibition of translation of oncoprotein mRNAs.
223678768|NCT06752681|DRUG|DAY301|DAY301 will be administered as IV infusion
224259426|NCT04891744|DRUG|Thalidomide|100mg/d, Po. on day1-28
224259427|NCT04891744|DRUG|Dexamethasone|20 mg/d Po. on day 1, 2,8,9,15,16,22,23
224259428|NCT01278953|DEVICE|Catheter ablation to treat paroxysmal atrial fibrillation|A pulmonary vein isolation procedure will be performed using radiofrequency ablation.
223678789|NCT06767319|OTHER|No intervention|The difference in diopters of depth of focus range achieving a threshold of 0.20 logMAR between Trial lens vs. Chart testing method per pre-study IOL group.
223678790|NCT07068477|BEHAVIORAL|Values Assessment Tool|The Values Assessment Tool was provided to the participants at baseline and every clinic visit for 3 months
223678792|NCT06768476|BIOLOGICAL|CART123 Cells|1.3x10\^8 CART123 cells
223678793|NCT06768476|DRUG|Ruxolitinib 10 MG|Twice Daily
223678794|NCT06768476|DRUG|Ruxolitinib 5 MG|Twice Daily
223678795|NCT06667908|DRUG|JNJ-90301900|JNJ-90301900 will be injected intratumorally and/or intranodally.
223678796|NCT06667908|BIOLOGICAL|Durvalumab|Durvalumab will be administered as intravenous (IV) infusion as cIT.
223678797|NCT06667908|RADIATION|Concurrent Chemo/Radiation Therapy (cCRT)|Radiation by intensity modulated radiation therapy (IMRT) will be administered.
223678798|NCT06667908|DRUG|Concurrent Chemo/Radiation Therapy (cCRT): Carboplatin|Carboplatin will be administered as IV infusion as platinum-based doublet chemotherapy.
223678799|NCT06667908|DRUG|Concurrent Chemo/Radiation Therapy (cCRT): Paclitaxel|Paclitaxel will be administered as IV infusion as platinum-based doublet chemotherapy.
223678801|NCT06788509|DRUG|JNJ-75348780|Participants from the parent study (75348780LYM1001 \[NCT04540796\]) who are deriving benefit from study treatment will continue to receive subcutaneous JNJ-75348780.
223678802|NCT06788509|DRUG|JNJ-67856633|Participants from the parent studies (64264681LYM1002 \[NCT04657224\], 67856633LYM1002 \[NCT04876092\] and 67856633LYM1001 \[NCT03900598\]) who are deriving benefit from study treatment will continue to receive JNJ-67856633 orally.
223678803|NCT06788509|DRUG|JNJ-54179060|Participants from the parent study (67856633LYM1002 \[NCT04876092\]) who are deriving benefit from study treatment will continue to receive JNJ-54179060 orally.
223678804|NCT06788509|DRUG|JNJ-64264681|Participants from the parent studies (64264681LYM1001 \[NCT04210219\], 64264681LYM1002 \[NCT04657224\]) who are deriving benefit from study treatment will continue to receive JNJ-64264681 orally.
224259429|NCT00312897|DRUG|Omega-3 Fatty Acids|10 wk treatment period
223678805|NCT06788509|DRUG|JNJ-74856665|Participants from the parent study (74856665AML1001 \[NCT04609826\]) who are deriving benefit from study treatment will continue to receive JNJ-74856665 orally.
223678806|NCT06788509|DRUG|JNJ-70218902|Participants from the parent study (70218902EDI1001 \[NCT04397276\]) who are deriving benefit from study treatment will continue to receive JNJ-70218902 orally.
223678807|NCT06788509|DRUG|JNJ-64619178|Participants from the parent study (64619178EDI1001 \[NCT03573310\]) who are deriving benefit from study treatment will continue to receive JNJ-64619178 orally.
223678814|NCT06214507|OTHER|No intervention|No intervention
224259430|NCT00312897|DRUG|corn oil|placebo comparator
224259431|NCT05778110|OTHER|Type of disease|Different types of pathogen: brain injury by trauma or intracranial hemorrhage due to hypertension.
224259432|NCT04097483|BEHAVIORAL|Telephone Intervention Group|Nurse-led, telephone-based, and psychoeducational intervention centered on motivational interviewing and cognitive behavioral therapy for adherence and depression.
224259433|NCT03100344|DRUG|Nemolizumab|Injection every 4 weeks during 24 weeks (last injection at week 20)
224259434|NCT03100344|DRUG|Placebo|Injection every 4 weeks during 24 weeks (last injection at week 20)
224259435|NCT02414711|OTHER|HSCL25 scale|The patient must answer to 25 questions of the HSCL25 scale. In function of the results, the patients was diagnosed depressed (≥1.75) or not depressed (\<1.75)
224259436|NCT02414711|OTHER|PSE9 questionary|On the 900 patients recruited, 50 patients who was diagnosed depressed or no depressed have to have a psychological interview with the PSE9 questionary to validate the first diagnosis done by the HSCL25 scale
224259437|NCT03967938|DRUG|Olaparib Oral Capsule|Olaparib tablets 300mg twice daily
224259438|NCT01327391|PROCEDURE|On line Hemodiafiltration|3 sessions/week; 3-4 hours per session
224259439|NCT01327391|PROCEDURE|Hemodialysis|3 sessions/week; 3-4 hours per session; high flux dialyzers
224259440|NCT01966484|DRUG|Succinylcholine|Anaesthesia was induced and maintained with propofol(1-2mg/kg and 5mg/kg/h) and remifentanil (1µg/kg and 0,2µ/kg/min). The study arm is immobilized and a dual electrode for peripheral nerve stimulation is placed over the ulnar nerve near the wrist. Neuromuscular monitoring is performed with accelerometry. the patients receive the muscle relaxant according to the study group.
224322814|NCT05509582|DRUG|fostamatinib|Subjects will receive fostamatinib at the same dose as the dose they receive at the time of rollover. The dose could be reduced to 100mg daily, 150 mg daily, 100 mg twice a day if a dose-limiting adverse event occurred. After the initial 12 weeks on the extended access (total of 24 weeks of treatment), subjects will have the option to start tapering fostamatinib if they are maintaining hematologic recovery. Subjects with persistent (=2 readings, 2 weeks apart) loss of hematologic response, defined as Hb\<9g/dL and/or PLT\< 30 X 10\^9/L can increase their dose to next higher dose. Once count stabilization again occurs, a slow dose reduction to next lowest dose (100mg or 150mg) can be performed to identify the lowest dose necessary to keep counts over these thresholds.
223773352|NCT00642304|DRUG|methoxy polyethylene glycol-epoetin beta [C.E.R.A.]|Methoxy polyethylene glycol-epoetin beta is administered SC every four week up to Week 20.The starting dose is 120, 200 or 300 mcg based on the dose of darbepoetin alfa or epoetin beta participants shall be receiving in the week preceding the study start. Further dose adjustment during the study depending on the hemoglobin (Hb) values.
223773353|NCT05932316|DIAGNOSTIC_TEST|spirometry|participants will undertake spirometry testing before and after bronchodilators and placebo
223773354|NCT05932316|DRUG|Salbutamol|Salbutamol inhalation to determine bronchodilator response
223773355|NCT05932316|DRUG|placebo|placebo inhalation prior to repeating spirometry
223773356|NCT04475445|OTHER|Ultrasound-guided transforaminal epidural steroid injection|Ultrasound identification of the nerve root, fluoroscopic control of the position and injection of a mixture of 10 mg of dexamethasone and 20 mg of lidocaine.
223773357|NCT04475445|OTHER|Interlaminar epidural steroid injection|Fluoroscopic location of the epidural space C5C6 or C6C7, injection of a mixture of 10 mg of dexamethasone and 20 mg of lidocaine.
224259441|NCT01966484|DRUG|Mivacurium|Anaesthesia was induced and maintained with propofol(1-2mg/kg and 5mg/kg/h) and remifentanil (1µg/kg and 0,2µ/kg/min). The study arm is immobilized and a dual electrode for peripheral nerve stimulation is placed over the ulnar nerve near the wrist. Neuromuscular monitoring is performed with accelerometry. the patients receive the muscle relaxant according to the study group.
224259442|NCT04829981|DEVICE|SAFEWATER systems for drinking water disinfection|A domestic water purification technology, consisting of a raw water storage tank, a pump, a filtration unit (2 cartridge filters), a UVC disinfection unit (UV lamp), a storage tank for drinking water (treated and safe water), and a distribution network inside the house for drinking water.
224259443|NCT04829981|BEHAVIORAL|Behaviour change interventions|Targeting behaviors around the use of the technology and water more generally. Behavioral interventions will be data-driven (i.e., dependent on the problems that arise) but are likely to include household and community-level activities.
224259444|NCT06275321|OTHER|Synchronous-supervised online home-based group|An online exercise program combining endurance and strength training
224259445|NCT06275321|OTHER|Exercise recommendation group|General recommendation about physical exercise. No supervised
223678820|NCT06772025|OTHER|No investigational study intervention|No investigational study interventions will be administered in this study. Participants will undergo therapeutic and diagnostic procedures as per local standard medical care and as deemed appropriate by the treating physicians. Collection of blood (not exceeding 200 mL) and urine samples and of available clinical data are the only activities performed in addition.
223678821|NCT07070115|DEVICE|OviTex Reinforced Tissue Matrix|All study subjects will receive OviTex. All OviTex Reinforced Tissue Matrices are intended for use as a surgical mesh to reinforce or repair soft tissue where weakness exists.
223773358|NCT00812812|DRUG|paroxetine 10mg tablet|1 or 2 tablet(s) once a day
223773359|NCT00812812|DRUG|paroxetine 20mg tablet|1 tablet once a day
223773360|NCT00812812|DRUG|matched placebo to paroxetine 10mg|2 tablets once a day
224259446|NCT02885909|DEVICE|CONTINUE GLUCOSE MONITOR|Continue glucose monitor
224259447|NCT02885909|PROCEDURE|Insulin protocal|Using insulin protocal based on glucose monitor
224259448|NCT06269952|OTHER|No intervention|No intervention. The participants are asked questions from and questionnaire and later also interviewed guide by an interview-guide
224259449|NCT04633564|BIOLOGICAL|Bevacizumab as MYL-1402O|Bevacizumab as MYL-1402O 15 mg/kg IV + Carboplatin AUC 6 IV+ Paclitaxel 200 or 175 mg/m2 IV
224259450|NCT04633564|BIOLOGICAL|Bevacizumab as Avastin|Bevacizumab as Avastin 15 mg/kg IV + Carboplatin AUC 6 IV+ Paclitaxel 200 or 175 mg/m2 IV
224259451|NCT04984902|DEVICE|Extracorporal therapy|Extracorporal therapy
224259452|NCT01083719|PROCEDURE|FDG-PET|Fluoro-deoxy gluocose-Positron emission tomography for delineating volumes in Glioblastoma
224259453|NCT01010503|DRUG|tocilizumab [RoActemra/Actemra]|tocilizumab 8 mg/kg intravenous infusion once in 4 weeks
223678834|NCT05557162|OTHER|AI ECG Amyloid algorithm|Artificial intelligence enabled electrocardiogram screening tool used to identify the predictive model that best differentiates those at greatest risk for an amyloidosis diagnosis
223773361|NCT00812812|DRUG|matched placebo to paroxetine 20mg|1 tablet once a day
223773362|NCT02721589|BIOLOGICAL|SHR-1210|A fully human monoclonal immunoglobulin (IgG4 subtype)
223773363|NCT01646034|DRUG|carboplatin, thiotepa, and cyclophosphamide|tandem intermediate-dose alkylating therapy: carboplatin 800 mg/m2, thiotepa 240 mg/m2, and cyclophosphamide 3000 mg/m2) with PBPC-reinfusion.
223678837|NCT06663319|DRUG|JNJ-89402638|JNJ-89402638 will be administered.
223678845|NCT06356129|DRUG|Golcadomide|Specified dose on specified days
223678846|NCT06356129|DRUG|Placebo|Specified dose on specified days
223678847|NCT06356129|DRUG|Rituximab|Specified dose on specified days
223678848|NCT06356129|DRUG|Cyclophosphamide|Specified dose on specified days
223678849|NCT06356129|DRUG|Doxorubicin|Specified dose on specified days
223678850|NCT06356129|DRUG|Vincristine|Specified dose on specified days
223678851|NCT06356129|DRUG|Prednisone|Specified dose on specified days
223678852|NCT04665739|PROCEDURE|Biospecimen Collection|Undergo blood and tissue sample collection
223678853|NCT04665739|PROCEDURE|Computed Tomography|Undergo CT
223678854|NCT04665739|DRUG|Everolimus|Given PO
223678855|NCT04665739|OTHER|Fludeoxyglucose F-18|Given FDG
223678856|NCT04665739|DRUG|Lutetium Lu 177 Dotatate|Given IV
223678857|NCT04665739|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223678858|NCT04665739|PROCEDURE|Positron Emission Tomography|Undergo PET
223678859|NCT04665739|PROCEDURE|Single Photon Emission Computed Tomography|Undergo SPECT
223678860|NCT04665739|OTHER|Survey Administration|Ancillary studies
223678861|NCT06029439|DRUG|NMRA-335140|Participants will receive NMRA-335140 at a dose of 80 mg once daily (QD), orally during a 52-week treatment period.
223773364|NCT01646034|DRUG|chemotherapy (docetaxel, doxorubicin, cyclofosfamide, carboplatin, paclitaxel, gemcitabine)|"* chemotherapy naïve;three cycles of docetaxel, doxorubicin, and cyclofosfamide~* chemotherapy naïve;1 cycle of dose-dense Adriamycin and cyclophosphamide followed by 4 cycles of carboplatin and paclitaxel~* previously received anthracyclines without taxanes;three cycles of carboplatin and paclitaxel~* previously received anthracyclines and taxanes;three cycles of carboplatin and gemcitabine"
223773365|NCT00351780|DEVICE|FFR measurement, side branch angioplasty|
223773366|NCT06136520|BEHAVIORAL|Baby massage|"After the first measurements are made and the groups are determined; Personal Information Form, Perinatal Attachment Inventory and Beck Depression Inventory will be applied to the experimental and control groups. Pregnant women in the experimental group were 32-40 weeks of pregnancy.~After baby massage training is given, 30-42 weeks after birth. between days and 60-72. Maternal Attachment Scale and Edinburgh Postpartum Depression Scale will be applied to the experimental and control groups on the following days. The control group will receive standard care while the experimental group receives training. After the second postpartum data of the pregnant women in the control group are collected, a 30-minute baby massage training will be given by the researcher."
223773367|NCT02503280|DRUG|Autologous hMSCs|Autologous hMSCs: 40 million cells/ml delivered in 0.5 ml injection volumes times 10 injections for a total of 2 x 10\^8 (200 million) hMSCs.
223773368|NCT02503280|DRUG|Autologous Human C-Kit CSCs II|Autologous hMSCs PLUS autologous C-Kit hCSCs: Mixture of 39.8 million hMSCs and 0.2 million C-Kit hCSCs/ml delivered in 0.5 ml injection volumes times 10 injections for a total of 1.99 x 10\^8 (199 million) hMSCs and 1 million C-Kit hCSCs.
223773369|NCT02503280|DRUG|Placebo|Placebo (ten 0.5 ml injections of phosphate-buffered saline \[PBS\] and 1% human serum albumin \[HSA\]).
223773370|NCT02503280|DEVICE|Biosense Webster MyoStar NOGA Injection Catheter System|Biosense Webster MyoStar NOGA Injection Catheter System will be used to administer the study drug
223773371|NCT04536844|DEVICE|Mobile application MyDignio (follow disease activity by assigning questionnaires to participants)|An electronic application available both on Apple store and Android play which the patients can download for free will be used to collect data from the Telehealth follow up group. This group will be compared to conventional outpatient clinic follow-up group.
223773372|NCT04536844|OTHER|Conventional prescheduled follow-up|Patients will be followed in the outpatient clinic by prescheduled follow-up
223773373|NCT05437146|BEHAVIORAL|puppet|pain and fear during blood collection
223773374|NCT03091751|DRUG|BeneFIX|BeneFIX is a recombinant FIX that contains nonacog alfa, reconstituted in solvent and administered as a single dose of 65-75 IU/kg.
223773375|NCT05115383|OTHER|VO2 Max test|The participant will be equipped with a vo2 mask or mouthpiece. They will get on the bike and begin with a 5 minute warmup ranging from 30-100 watts. After the warm up there will be a 15-30 watt increase every minute in the cadence that the participant is required to maintain. Once the participant has decided to stop pedalling, the participants mask will be removed to ensure they are feeling well. They will allowed to continue pedaling at their own pace for a cool down for up to two minutes.
224259454|NCT00570609|OTHER|CPR Anytime education|After consent, participants will be asked to complete the 22 minute DVD CPR Anytime program with their parent(s)/legal guardian(s) and encouraged to include other friends and family members in the program
224259455|NCT00669721|DRUG|law molecular weigth heparin|administration of LMWH as anticoagulation for hemodialysis circuit;nadroparin is administred ad the dosage of 65 IU/kg on starting dialysis and in the arterial hemodialytic line after a washing phase with 2 litres of a heparin-free saline solution 0.9%.
223678874|NCT06551506|BIOLOGICAL|Abrysvo|A maternal RSV vaccine based on the prefusion F protein administered during pregnancy
223678875|NCT06551506|BIOLOGICAL|Beyfortus|A passive, long-acting monoclonal antibody to Respiratory syncytial virus (RSV) administered to infants
223678876|NCT06585787|DRUG|KarXT|Specified dose on specified days
223678877|NCT06585787|DRUG|Placebo|Specified dose on specified days
223678878|NCT05840159|DRUG|Doxycycline|Doxycycline is a synthetic tetracycline derivative with similar antimicrobial activity.
223678879|NCT05840159|OTHER|Placebo|Placebo
223678884|NCT06120140|DRUG|Amivantamab IV|Amivantamab will be administered.
223678885|NCT06120140|DRUG|Amivantamab SC|Amivantamab will be administered as SC injection.
223678886|NCT06120140|DRUG|Lazertinib|Lazertinib tablet will be administered orally.
223678887|NCT06120140|DRUG|Doxycycline|Doxycycline tablet will be administered orally.
223678888|NCT06120140|DRUG|Minocycline|Minocycline capsule will be administered orally.
223678889|NCT06120140|DRUG|Clindamycin|Clindamycin lotion will be used as topical application on the scalp.
223678890|NCT06120140|DRUG|Chlorhexidine|Chlorhexidine solution will be used as topical application on hands and feet.
223678891|NCT06120140|OTHER|Noncomedogenic skin moisturizer|Noncomedogenic skin moisturizer will be used as topical application.
223678892|NCT06120140|OTHER|Ruxolitinib|Ruxolitinib will be used to the affected skin area.
223678893|NCT06120140|OTHER|Tacrolimus|Tacrolimus will be used as topical application to the affected skin area.
223678894|NCT06120140|DRUG|Zinc gluconate|Zinc gluconate tablet will be administered.
223678895|NCT06120140|DRUG|Propranolol|Propranolol tablet will be administered.
223678896|NCT06120140|DRUG|Timolol|Timolol will be used to the affected skin area.
223678897|NCT06120140|DRUG|Clobetasol|Clobetasol shampoo will be used on the scalp.
223773376|NCT01161329|OTHER|High-Intensity Functional Exercise Programmes (HIFE)|Hife include functional exercises consisting of everyday tasks challenging leg strength, postural stability, and gait ability. All exercise shall be performed in weight-bearing positions, eg squats and walking over obstacles. HIFE are performed twice a week during 1 h. for three months in a group with 6-7 seven patients with stroke. Two physiotherapists lead the group and one physiotherapist select exercises for each participant according to their functional deficits. The exercises will be progressively increased in load and difficulty.
223773377|NCT02215590|DEVICE|Re-Step|"Research Group:~Each session begins with a warm-up exercise, muscle stretching, and strengthening exercises: duration 10 minutes.~Afterwards, walking exercises for 40 minutes with Re-Step according to a program individually tailored and progressing with the training. Progress is shown by an increased range of tilting of the shoe and speed of changes, according to the individual ability of each patient.~At the end of the session 10 min of cool-down exercises~22 training sessions of 60 minutes each, twice a week."
223773378|NCT01529528|DRUG|Anagliptin|Anagliptin 100mg, tablet, BID
223773379|NCT01529528|DRUG|Anagliptin|Anagliptin 100mg, tablet, BID
224259456|NCT00669721|DRUG|unfractioned heparin|administration of UFH as anticoagulation of hemodialysis circuit; standard heparin ( Sodic Heparin, Vister by Parke-Davis) 1500 IU on starting dialysis and 1500 ± 500 IU in continues intradialytic infusion per dialysis session
224259457|NCT03173872|PROCEDURE|Reiki Protocol Hand Placement Procedures|Ten Reiki hand placement procedures will last 3 minutes each for a total Reiki session lasting 30 minutes long.
224259458|NCT05662163|PROCEDURE|TIVA|Anesthesia will be maintained with propofol (6-10 mg/kg/hour) and remifentanil (0.1-0.3 μg/kg/min).
224259459|NCT05662163|PROCEDURE|GENERAL ANESTHESIA|Anesthesia will be maintained with sevoflurane (2 ml/min) 50% oxygen and remifentanil (0.1-0.3 μg/kg/min).
224259460|NCT05821647|OTHER|HPI guided treatment advice|Administer hemodynamic altering intervention aimed at either a preload, contractility, or afterload problem to prevent impending hypotension. Treatment options include: administering either fluids, inotropes, vasopressors, positional changes, or a combination.
224259461|NCT06819787|OTHER|Electronic Heath Record Platform to Support Pharmacists in Delivering Contraceptive Services|An electronic health record (EHR) platform specifically designed to support community pharmacists in delivering contraceptive services. The platform streamlines clinical workflows, provides clinical decision support, and promotes adherence to the US Medical Eligibility Criteria (USMEC) guidelines and state regulatory requirements.
224259462|NCT01923753|DEVICE|Aerosure at 15 Hz|Active Aerosure HFAO device operating at lower frequency
224259463|NCT01923753|DEVICE|Aerosure at 25 Hz|Active Aerosure HFAO device operating at higher frequency
224259464|NCT01923753|DEVICE|Sham Aerosure|Deactivated but identical Aerosure HFAO device
224259465|NCT05487547|DEVICE|IPL_RF_MGX|intense pulsed light followed by Radiofrequency followed by meibomian gland expression
223678904|NCT07132918|RADIATION|MRgART|Magnetic Resonance-guided Adaptive Radiation Therapy (MRgART) is a form of MRgRT that incorporates daily adaptive planning, or making a new treatment plan each treatment, and real-time imaging during treatment delivery.
223773380|NCT01529528|DRUG|Placebo of Anagliptin|Placebo of Anagliptin 100mg, tablet, BID
223773381|NCT01689896|DRUG|Testosterone Gel|
223773382|NCT01689896|DRUG|Placebo Gel|
223773383|NCT05232448|BEHAVIORAL|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy focuses on challenging and changing cognitive distortions and behaviors, improving emotional regulation and the development of personal coping strategies that target solving current problems.
223773384|NCT02863354|DRUG|Aflibercept|Intravitreal injection
223773385|NCT04986618|OTHER|One-way Nordic Exercise|Participants in this group will be given the standard Nordic Hamstring exercise.
224259466|NCT01322321|DRUG|ACZ885|
224259467|NCT01322321|DRUG|Placebo|
224259468|NCT03887884|DRUG|CVT-301|Levodopa Inhalation Powder
224259469|NCT03887884|DRUG|Sinemet|Single oral dose of Carbidopa/Levodopa 25 mg/100 mg
224259470|NCT06986421|OTHER|completion of a structured questionnaire|completion of a structured questionnaire
224259471|NCT01935674|DRUG|Switch ritonavir-boosted PI|Switch their existing ritonavir-boosted PI to another potent ART drug with lesser effects on serum cholesterol selected by the investigator.
224259472|NCT01935674|DRUG|Continue Ritonavir-boosted PI+Rosuvastatin|Continue ritonavir-boosted PI-based ART and commence rosuvastatin 10 mg daily (5 mg daily in Asian participants).
224259473|NCT06610227|BIOLOGICAL|SapRNA™-MICA/B Tumor Vaccine|patients will receive the monotherapy with SapRNA™-MICA/B Tumor Vaccine, which will be administered by intramuscular injection on Day 1, Day 14, and Day 28 respectively
224259474|NCT04684706|DEVICE|intermittent Theta Burst Stimulation|The present study will utilize TMS dosage of iTBS of 18 000 pulses a day for 5 consecutive days.
224259475|NCT01472263|DRUG|Pentoxifylline|Pentoxifylline 400mg 3 times a day on a total dose o 1200mg, oral capsules
224259476|NCT01472263|DRUG|Placebo|Placebo capsules 3 times a day. The capsules have the same shape, color and form as the treatment group, and are identified by envelope numbers.
224259477|NCT02576522|RADIATION|brain metastatic patients|Surgery followed by hypofractionated intensity modulated radiation therapy (IMRT) using VMAT approach
224259478|NCT02684747|OTHER|Autologous Transfusion|Participants will receive autologous transfusion on Day 21
224322815|NCT05904886|DRUG|Atezolizumab|Atezolizumab will be administered by intravenous (IV) infusion at a fixed dose of 1200 milligrams (mg) on Day 1 of each 21-day cycle.
224259479|NCT02684747|OTHER|Control - Normal Saline (Placebo)|Participants will receive saline on Day 21
224259480|NCT03633214|OTHER|Online training module|Responses of GPs in the intervention group will then be compared before and immediately after the online training video and also 3-months later; as well as to the control group.
224259481|NCT06861790|BEHAVIORAL|tVNS|Though we will be utilizing a tVNS (Transcutaneous Vegus Nerve Stimulation) device this study is not a device study. The device being used is being done so under its approved usage. The intervention utilizes a non-invasive process to stimulate the Vagus nerve using very small electrical currents. This intervention is completed daily for one month.
224259482|NCT06861790|PROCEDURE|Complete Vagotomy|Participants will not be receiving bariatric surgery as an intervention of this study. Instead, the study will enroll patients already planning on undergoing the surgery. The surgeon will utilize one of two surgical approaches which will be observed in this study.
224322816|NCT05904886|DRUG|Bevacizumab|Bevacizumab will be administered by IV infusion at a dose of 15 milligrams per kilogram (mg/kg) on Day 1 of each 21-day cycle.
224322817|NCT05904886|DRUG|Tiragolumab|Tiragolumab will be administered by IV infusion at a fixed dose of 600 mg on Day 1 of each 21-day cycle.
224322818|NCT05904886|OTHER|Placebo|Placebo matching tiragolumab will be administered by IV infusion on Day 1 of each 21-day cycle.
224322819|NCT06536283|OTHER|13-item Barriers Questionnaire (BQ-13)|Given by questionnaire
224322820|NCT06536283|OTHER|Four-item Medication Adherence Questionnaire|Given by questionnaire
224322821|NCT06536283|OTHER|14-item Hospital Anxiety and Depression Scale (HADS)|Given by questionnaire
224322822|NCT06052267|DRUG|TEV-56248|Fluticasone Propionate/Salbutamol Sulfate. Oral inhalation powder.
223678905|NCT07132918|RADIATION|LINAC|Daily 3D x-ray scans will be obtained for radiation delivery to confirm tumor and organ at risk placement.
223678909|NCT02390297|GENETIC|Blood tests|Collection of blood samples for general health (complete blood count) and Cal-1 specific analyses
223678910|NCT03596645|DRUG|Golimumab|Participants receive subcutaneous (SC) golimumab through Week 50, where doses will be based on body surface area. After the Week 54 evaluations, at the discretion of investigator, participants benefiting from continued SC golimumab will continue to receive SC golimumab in the extension until end of study.
223678911|NCT03596645|DRUG|Infliximab|Participants will receive infliximab intravenous (IV) through Week 46. Doses will be based on body weight. After the Week 54 evaluations, participants receiving infliximab will be withdrawn from study participation and transition to local standard of care which may include continued commercially available infliximab at the discretion of their physician.
223678913|NCT06635148|DRUG|JNJ-81201887|No study intervention will be administered as part of this LTE study.
223678914|NCT06635148|OTHER|Sham Procedure|No study intervention will be administered as part of this LTE study.
223678915|NCT06741969|DRUG|Nipocalimab|Nipocalimab SC.
223678916|NCT06741969|DRUG|Placebo|Placebo SC.
224322823|NCT06052267|DRUG|Albuterol sulfate|Oral inhalation powder
224322824|NCT06149104|DRUG|sacubitril/valsartan|sacubiril/valsartan
224322825|NCT06790693|DRUG|Inavolisib|Participants will receive oral inavolisib once daily (QD).
224322826|NCT06790693|DRUG|Placebo|Participants will receive oral placebo QD.
224322827|NCT06790693|DRUG|CDK4/6i|Participants will receive oral palbociclib on Days 1-21 of each 28-day cycle.
224322828|NCT06790693|DRUG|Letrozole|Participants will receive oral letrozole QD.
224322829|NCT06422806|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
224322830|NCT06422806|PROCEDURE|Diagnostic Imaging Testing|Undergo standard imaging scans
224322831|NCT06422806|DRUG|Doxorubicin|Given IV
224322832|NCT06422806|PROCEDURE|Echocardiography Test|Undergo ECHO
224322833|NCT06422806|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA scan
224322834|NCT06422806|BIOLOGICAL|Pembrolizumab|Given IV
224322835|NCT06011954|DRUG|Enfortumab Vedotin|Intravenous
224322836|NCT05621317|BIOLOGICAL|PVX-108|PVX108 comprises a mixture of peptides that represent sequences from peanut allergens
223678917|NCT06741969|DRUG|Standard of care treatment|Protocol-defined topical and systemic standard of care background treatments.
223773386|NCT04986618|OTHER|Two-way Nordic Exercise|In addition to the standard Nordic Hamstring exercise, participants in this group will do the same exercise backwards for the quadriceps.
224259483|NCT06861790|PROCEDURE|Anterior Vagotomy|Participants will not be receiving bariatric surgery as an intervention of this study. Instead, the study will enroll patients already planning on undergoing the surgery. The surgeon will utilize one of two surgical approaches which will be observed in this study.
224259484|NCT05865769|OTHER|Balance|measuring pulmonary and vestibular functions in all subjects
224259485|NCT06559410|OTHER|Electroencephalogram (EEG), CT Brain, Echocardiogram|analyze the etiology, electroencephalographic (EEG) findings, neuroimaging, and neurological sequalae of newborns with congenital heart disease who were presented with seizures
224259486|NCT05103514|OTHER|Online Survey|There are no interventions planned for this study. This is an observational study only.
224259487|NCT06999265|DEVICE|Transcutaneous electrical nerve stimulation - Tibial Nerve|"Standard Transcutaneous electrical nerve stimulation (TENS) device (Empi Select 199584, Medi-Stim Inc.)~Electrical stimulation applied to target the tibial nerve on one leg, with electrodes above the malleolus and on the bottom of the foot"
224259488|NCT06999265|DEVICE|Transcutaneous electrical nerve stimulation - Genital Nerve|"Standard Transcutaneous electrical nerve stimulation (TENS) device (Empi Select 199584, Medi-Stim Inc.)~Electrical stimulation applied to target the genital nerve, with electrodes on either side of the clitoris."
224259489|NCT06999265|BEHAVIORAL|Neutral and Erotic Film Clip Alternation|During the testing period, participants will first view a 5-minute neutral film depicting nature scenes to allow blood flow levels to stabilize. This will be followed by a 10-minute period while the subject watches an erotic film clip for assessment of arousal responses without electrical stimulation. A 10-minute clip of the same neutral film will follow, to allow blood flow levels to return to baseline. Five minutes into this film, electrical stimulation will be resumed at the previously determined amplitude. Finally, the subject will view another 10-minute erotic film clip depicting similar sexually explicit material as the first while electrical stimulation remains on as the last sequence in the testing. Physiological arousal will be assessed with a vaginal photoplethysmography probe, yielding vaginal pulse amplitude (VPA) for analysis. Subjective arousal will be assessed with a subjective arousal questionnaire.
224322837|NCT05621317|BIOLOGICAL|Placebo|Matching placebo comprises the formulation vehicle without peptides
224322838|NCT05134480|PROCEDURE|Descemet membrane endothelial keratoplasty|cornea transplant procedure to replace dysfunctional endothelial cell layer
224322839|NCT06436274|BIOLOGICAL|GARDASIL®9|GARDASIL®9 or equivalent vaccines will be used for this study. These are FDA-approved vaccines.
224259490|NCT05133817|DRUG|Normal saline|Simultaneous with spinal anesthesia, 500 mL 6% Hydroxyethyl starch (130/0.4) coload was given and a maintenance dose of normal saline by IV infusion.
224322840|NCT06436274|BIOLOGICAL|Menveo®/Menactra®|Menveo®/Menactra® or equivalent vaccines will be used for this study. These are FDA-approved vaccines.
224322841|NCT03874988|BEHAVIORAL|Portion-Controlled Meals|Participants will receive portion-controlled meals with the aim of encouraging weight loss and healthier eating.
223773387|NCT01281488|PROCEDURE|fluorescence imaging|Undergo NIR fluorescence imaging with ICG on the da Vinci surgical system
223773388|NCT01281488|PROCEDURE|laparoscopic surgery|Undergo standard approach robot-assisted laparoscopic partial nephrectomy
223773389|NCT01281488|DRUG|indocyanine green|Given IV
223773390|NCT03746821|DIETARY_SUPPLEMENT|Biotin|Biotin supplements (2) to be taken daily
224322842|NCT03874988|BEHAVIORAL|Enhanced Self-Monitoring|Participants will be encouraged to track their physical activity, food intake, and weight using technology that will be provided as part of the study.
224322843|NCT03874988|BEHAVIORAL|GLB-SCI|Participants will take part in a lifestyle intervention program (tailored for spinal cord injury needs) that encourages steady weight loss through increased physical activity and healthier diet patterns.
224322844|NCT03874988|BEHAVIORAL|GLB-SCI+|Participants will receive a combination of the prior interventions studied, with the goal of showing that a multi-component intervention will be the most effective in encouraging weight loss among participants with a spinal cord injury.
224322845|NCT04989803|DRUG|Cyclophosphamide|Lymphodepleting chemotherapy administered intravenously
224322846|NCT04989803|DRUG|Fludarabine|Lymphodepleting chemotherapy administered intravenously
224322847|NCT04989803|BIOLOGICAL|KITE-363|A single infusion of CAR-transduced autologous T cells administered intravenously
223678935|NCT06806163|BEHAVIORAL|EHR-Embedded Elevated-Risk Flag|Clinicians seeing patients at elevated predicted risk will see a flag on the EHR 'storyboard' during in person or telephone encounters indicating the patient is at elevated predicted risk of opioid overdose. The clinician will have the option of including this information into their decision-making process when providing care. There will be no best practice alerts/behavioral nudges in this arm.
223678936|NCT06806163|BEHAVIORAL|EHR-Embedded Elevated-Risk Flag with Behavioral Nudges|"Clinicians seeing patients at elevated predicted risk for opioid overdose will see a flag on the EHR storyboard indicating that the patient is at elevated predicted risk.~Clinicians will also receive up to 4 best practice alerts/behavioral nudges during an in-person or telephone primary care encounter with elevated risk patients when certain requirements are met: 1) if the patient does not have an active naloxone prescription on their medication list, the clinicians will receive an active choice alert during any medication ordering to encourage naloxone prescription; 2) if the patient's opioid dosage is \>50 MME, OR they are ordered a new opioid prescription, OR they have an overlapping opioid and benzodiazepine prescription order, the clinicians will receive an accountable justification alert when the relevant order is entered."
223678937|NCT06806163|BEHAVIORAL|Usual Care|Patients in the practices randomized to the Usual Care arm will receive standard care practice without change.
223773391|NCT00705575|DRUG|Aliskiren/hydrochlorothiazide (HCTZ) (300/25 mg)|During the titration period, patients received aliskiren/hydrochlorothiazide (HCTZ) 150/12.5 mg for 1 week.
223773392|NCT00705575|DRUG|Aliskiren (300 mg)|During the titration period, patients received aliskiren 150 mg for one week. Subsequently, patients were up-titrated and received aliskiren 300 mg.
223773393|NCT00934271|RADIATION|fractionated stereotactic radiotherapy|Audit of outcome
223773394|NCT04614766|DRUG|Lutathera|intravenous administration
223773395|NCT04614766|DRUG|Azedra|intravenous administration
224259491|NCT05133817|DRUG|Norepinephrine (0.025 μg/kg/min)|Simultaneous with spinal anesthesia, 500 mL 6% Hydroxyethyl starch (130/0.4) coload was given and a different maintenance dose of norepinephrine by IV infusion.
223678942|NCT07082803|DRUG|TLN-121|Specified dose on specified days.
223678943|NCT07082803|DRUG|TLN-254|Specified dose on specified days.
223678944|NCT07082803|DRUG|TLN-121|Specified dose on specified days.
223773396|NCT00726115|DRUG|SAM-531|
223773397|NCT00726115|DRUG|placebo|
223773398|NCT01623440|COMBINATION_PRODUCT|Placebo and fMRI|Pill form, participant dosed one time an hour before fMRI.
223773399|NCT01623440|COMBINATION_PRODUCT|Naltrexone and fMRI|50 mg pill given one time, one hour before fMRI
223773400|NCT03767491|DEVICE|Smartphone-delivered CBT for OCD|12-week Smartphone-delivered CBT for OCD. In-person cognitive-behavioral therapy (CBT) is an empirically supported treatment for OCD. The app-delivered CBT in this project includes modules such as cognitive skills (e.g., cognitive restructuring, core belief work), behavioral skills (e.g., exposure with ritual prevention), and perceptual retraining/mindfulness skills.
223773401|NCT03097068|DRUG|Lucentis|0.3mg Lucentis
223773402|NCT01136824|OTHER|Questionnaires|"Subjects will be given a series of questionnaires to assess the effect of AI chemotherapy, and the possible role of tumor load, on the amount of symptoms. The extent of nausea, vomiting, fatigue, anxiety, sleep disturbance, and cognitive changes will be measured. In adjuvant chemotherapy patients, we will also assess the relationship between tumor size and amount of chemotherapy-induced symptoms. These questionnaires will involve the following assessments:~Demographic \& health Trait anxiety Quality of life Nausea Expectations Anxiety \& total mood disturbance Nausea \& vomiting Multiple symptoms"
223773403|NCT01298063|DRUG|Afatinib|1 tablet, once qd in the morning
223773404|NCT01298063|DRUG|Afatinib|1 tablet, once qd in the morning
223773405|NCT01298063|DRUG|Afatinib|1 tablet, once qd in the morning
224259492|NCT05133817|DRUG|Norepinephrine (0.05 μg/kg/min)|Simultaneous with spinal anesthesia, 500 mL 6% Hydroxyethyl starch (130/0.4) coload was given and a different maintenance dose of norepinephrine by IV infusion.
224259493|NCT05133817|DRUG|Norepinephrine (0.075 μg/kg/min)|Simultaneous with spinal anesthesia, 500 mL 6% Hydroxyethyl starch (130/0.4) coload was given and a different maintenance dose of norepinephrine by IV infusion.
224259494|NCT05133817|DRUG|Norepinephrine (0.1 μg/kg/min)|Simultaneous with spinal anesthesia, 500 mL 6% Hydroxyethyl starch (130/0.4) coload was given and a different maintenance dose of norepinephrine by IV infusion.
224259495|NCT03612232|DRUG|Cabozantinib-s-malate|oral cabozantinib-S-malate 60 mg as a daily single oral dose continuously
224259496|NCT01261039|RADIATION|UV radiation|Subjects in both groups will be exposed to light in a solar bed for approximately 10 minutes (depending on Fitzpatrick skin type test) on the first day, but only one of the solar beds wields ultraviolet rays. The other has a filter, which filters out the ultraviolet rays.
224259497|NCT01955200|DRUG|Clopidogrel|(ASA 100mg daily + Clopidogrel 150mg daily) x 1 month; (ASA 100mg daily + Clopidogrel 75mg daily) x 11 month.
224259498|NCT01955200|DRUG|Cilostazol|(ASA 100mg daily + Clopidogrel 75mg daily + Cilostazol 150mg Bid) x 1 month; (ASA 100mg daily + Clopidogrel 75mg daily) x 11 month.
224259499|NCT01955200|DRUG|Ticagrelor|(ASA 100mg daily + Ticagrelor 90mg Bid) x 1 month; (ASA 100mg daily + Clopidogrel 75mg daily) x 11 month.
224259500|NCT01955200|DRUG|Clopidogrel|(ASA 100mg daily + Clopidogrel 75mg daily) x 12 month.
224259501|NCT01955200|DRUG|Clopidogrel|(ASA 100mg daily + Clopidogrel 75mg daily) x 12 month.
224259502|NCT06868056|BEHAVIORAL|Suite of healthy food policies|an online application with a suite of healthy food policies ultra-processed food and beverage taxes, front-of-pack nutrition labeling, and healthy check out regulations that restrict the promotion of ultra-processed products on the checkout page
224322848|NCT04989803|BIOLOGICAL|KITE-753|A single infusion of CAR-transduced autologous T cells administered intravenously
224259503|NCT06321653|RADIATION|Hypofractionated radiotherapy scheme|Hypofractionated radiotherapy scheme with 2.67Gy/fraction for 15 fractions. WBRT with simultaneous integrated boost to the tumor bed
223678946|NCT07076160|DEVICE|INFUSE® One Day Multifocal|Test Lens
223678947|NCT07076160|DEVICE|ACUVUE® OASYS MAX 1-Day Multifocal Contact Lens|Control Lens
223678950|NCT07082920|DRUG|JNJ-78278343|JNJ-78278343 will be administered intravenously.
223678951|NCT07082920|DRUG|JNJ-95298177|JNJ-95298177 will be administered intravenously.
223678952|NCT07084363|DEVICE|Quantitative monitoring|The TetraGraph TOF monitor will be used to quantitatively assess the TOF-ratio. Quantitative monitoring includes objective measurement of the TOF-ratio, as defined by the ratio between the first and the fourth muscular responses and is quantified by acceleromyography. A TOF twitch response ratio equal or greater to 95% (TOF0.95) will be targeted prior to extubation. If TOF0.95 is not reached within 10 min of administering the initial dose of the respective reversal agent, redosing is recommended.
223678953|NCT07084363|OTHER|Qualitative monitoring|Clinicians will assess the TOF-ratio. Qualitative monitoring includes subjective assessment of the count and the amplitude of the muscular responses related to neuromuscular block depth. A TOF twitch response count of 4 similarly strong twitches will be targeted prior to extubation. If 4 similarly strong TOF twitch responses are not reached within 10 min of administering the initial dose of the respective reversal agent, redosing is recommended.
223678954|NCT07122193|DRUG|NT 201|Clostridium Botulinum neurotoxin A (150 kiloDalton \[kD\], free of complexing proteins), powder for solution for injection.
223678955|NCT07122193|DRUG|NT 201 Placebo|NT 201 matching-placebo
223678956|NCT02910700|DRUG|Binimetinib|Given PO
224259504|NCT02665715|OTHER|Low carbohydrate meals|Meal macronutritional energy composition: Carbohydrate 30% Protein 30% Fat 40%
224259505|NCT02665715|OTHER|Standard carbohydrate meals|Meal macronutritional energy composition: Carbohydrate 55% Protein 15% Fat 30%
224259506|NCT00641134|OTHER|A: Home-Based exercise after Cardiac Rehabilitation|Home-Based exercise program,after CR, with reinforcement sessions
224259507|NCT05854602|BEHAVIORAL|Component A|"All components consist of one online therapist-led session, and 14 daily assignments. In the online session, parents watch an animation clip explaining the technique, and parents perform an exercise guided by the therapist. In the daily assignments, parents reflect on situations in which their child was anxious during the day in which they (could have) applied the technique. If the child was not anxious that day, parents are asked to think about a future or past situation and fill in similar questions.~Component A focusses on making parents aware of the process of avoidance in children with anxiety, and helps them to identify situations in which they accommodate to the anxiety of their children. Subsequently, a first step that parents can take to reduce accommodation is discussed."
224322849|NCT06442488|DEVICE|Respiratory Monitoring System|Comparing the SNR and accuracy of measurement (RR, TV, MV, apnea duration) in a noisy external environment when the RMS has adaptive filtering and active noise cancellation turned on versus turned off.
224322850|NCT05276297|DRUG|GSK3228836|2 doses of GSK3228836 study intervention administered subcutaneously once per week for 12 weeks (Day 1 up to Day 78) to participants in ASO12-TI and ASO12 groups, or for 24 weeks (Day 1 up to Day 162) to participants in ASO24-TI and ASO24 groups, plus loading doses administered at Day 4 and Day 11 (2 doses each day) to participants in all groups during Treatment 1 period.
223678957|NCT02910700|DRUG|Dabrafenib|Given PO
223678958|NCT02910700|DRUG|Encorafenib|Given PO
223678959|NCT02910700|OTHER|Laboratory Biomarker Analysis|Correlative studies
223678960|NCT02910700|BIOLOGICAL|Nivolumab|Given IV
223678961|NCT02910700|OTHER|Pharmacological Study|Correlative studies
223678962|NCT02910700|DRUG|Trametinib|Given PO
223678963|NCT07085039|DRUG|Ruxolitinib|Participants will take the study drug in a tablet form, by mouth, every day for the next year, as long as it is helping with their disease and not causing unacceptable side effects.
223678964|NCT06903065|DRUG|RO7790121|Participants will be administered RO7790121 via IV infusion on Day 1, and Weeks 2, 6 and 10. Participants will then be administered RO7790121 SC injections every four weeks (Q4W) from week 14 up to and including Week 50.
223678968|NCT06058039|DRUG|NMRA-335140|Participants will receive NMRA-335140 at a dose of 80 mg QD, orally
223678969|NCT06058039|DRUG|Placebo|Placebo will be administered orally
223678970|NCT04644770|DRUG|JNJ-69086420|Participants will receive JNJ-69086420.
223678971|NCT04644770|DRUG|JNJ-78278343|Participants will receive JNJ-78278343.
223678972|NCT04644770|RADIATION|Stereotactic body radiation therapy|Participants will receive stereotactic body radiaition therapy.
223678973|NCT02625389|DRUG|Lipiodol Ultra Fluid with surgical glues|Lipiodol Ultra Fluid and surgical glue mixture administered via selective arterial catheterization.
223678974|NCT06929260|DRUG|Ceralasertib|Participants will receive repeated dosing of ceralasertib from Day 1 to Day 7 until steady state.
223678975|NCT06929260|DRUG|Drug X|Participants will receive a single dose of Drug X on Day 5 and Day 22.
223678976|NCT06929260|DRUG|Drug Y|Participants will receive a single dose of Drug Y on Day 7 and Day 28.
223678977|NCT06929260|DRUG|Drug Z|Participants will receive a single dose of Drug Z on Day 7 and Day 28.
224259508|NCT05854602|BEHAVIORAL|Component B|"All components consist of one online therapist-led session, and 14 daily assignments. In the online session, parents watch an animation clip explaining the technique, and parents perform an exercise guided by the therapist. In the daily assignments, parents reflect on situations in which their child was anxious during the day in which they (could have) applied the technique. If the child was not anxious that day, parents are asked to think about a future or past situation and fill in similar questions.~Component B tries to increase parents empathetic reactions to their anxious child. This is done by teaching parents to label the emotion of their children, empathize with the emotion, and communicate confidence in the abilities of their child to face the situation."
224259509|NCT05854602|BEHAVIORAL|Component C|"All components consist of one online therapist-led session, and 14 daily assignments. In the online session, parents watch an animation clip explaining the technique, and parents perform an exercise guided by the therapist. In the daily assignments, parents reflect on situations in which their child was anxious during the day in which they (could have) applied the technique. If the child was not anxious that day, parents are asked to think about a future or past situation and fill in similar questions.~Component C consists of cognitive restructuring of parental maladaptive cognitions concerning their child's anxiety. Parents are taught to recognize their own cognitions about the anxiety of their child, challenge this thought and come up with an alternative, helpful thought."
224259510|NCT01771939|PROCEDURE|25-G vitrectomy and phacoemulsification|25-G vitrectomy with Internal Limiting Membrane peeling and phacoemulsification (cataract intervention)
224259511|NCT01771939|PROCEDURE|phacoemulsification (cataract surgery)|lens extraction after phacoemulsification and intra-ocular artificial lens implantation
224259512|NCT03923660|OTHER|Incremental Concentric-eccentric exercise test|Patients will perform incremental exercise test on semi recumbent eccentric ergometer
224259513|NCT03923660|OTHER|Incremental Eccentric-concentric exercise test|Patients will perform incremental exercise test on semi recumbent concentric ergometer
224259514|NCT05048017|DRUG|Regorafenib|Regorafenib, 120 mg, once a day, 3 weeks on/1 week off
224259515|NCT05048017|DRUG|PD-1 inhibitor|"Camrelizumab: 200mg (BW ≥ 50 kg) or 3 mg/kg (BW \< 50 kg) Toripalimab: 240mg is given through intravenous drip every 3 weeks on Day 1 of each course of treatment.~Pembrolizumab: 200mg is given through intravenous drip every 3 weeks."
224259516|NCT05672030|OTHER|Non-Interventional|No intervention.
224259517|NCT04018482|OTHER|Povidone Iodine|FDA-approved disinfectant for intravitreal injections
224259518|NCT04018482|OTHER|Hypochlorous Acid|FDA-approved disinfectant for intravitreal injections
224322851|NCT05276297|BIOLOGICAL|GSK3528869A|"The GSK3528869A chronic Hepatitis B targeted immunotherapy (CHB-TI) consisting of 4 doses administered intramuscularly as follows:~* 1 dose of the Chimpanzee adenovectored HBV vaccine (ChAd155-hIi-HBV) at Day 1 of Treatment 2 period.~* 1 dose of the Modified Vaccinia Virus Ankara HBV vaccine (MVA-HBV) at Day 57 of Treatment 2 period.~* 2 subsequent doses of the AS01B-4-adjuvanted HBc-HBs proteins (HBc-HBs/AS01B-4) administered at Day 113 and Day 169 of Treatment 2 period."
224322852|NCT05276297|DRUG|Control|4 doses of non-active control administered intramuscularly in the deltoid region of the non-dominant arm at Days 1, 57, 113 and 169 to participants in ASO24 and ASO12 control groups during Treatment 2 period.
223678979|NCT06930651|DRUG|Dexamethasone|Given Orally
223678980|NCT06930651|DRUG|Cyclophosphamide|Given by IV
223678981|NCT06930651|DRUG|Fludarabine|Given by IV
223678982|NCT06930651|DRUG|Decitabine|Given by IV
223678983|NCT06930651|BIOLOGICAL|TGFBR2 KO CAR27/IL-15 NK cells|Given by Infusion
223678984|NCT06930755|DRUG|NMS-03305293|Route of administration: Oral
224259519|NCT02827266|DRUG|Epoetin beta|Participants will receive epoetin beta as a weekly subcutaneous (SC) injection over an 8-week correction phase with 60 international units per kilograms (IU/kg) as starting dose. Baseline weight will be used to determine the dose and adjustments in the dose will be implemented based on the participant's blood hemoglobin levels. Participants with a response to correction treatment will then enter a 4-week extension phase to receive the SC injection every 2 weeks, and those without response will continue at the same weekly dose for a 4-week continuation phase.
223678985|NCT06930755|DRUG|Topotecan|Route of administration: Intravenous
224322853|NCT06958211|DRUG|Ruxolitinib Cream|Ruxolitinib cream applied topically to the affected area as a thin film twice daily.
224322854|NCT06958211|DRUG|Vehicle Cream|Matching vehicle cream applied topically to the affected area as a thin film twice daily.
223678987|NCT06675175|DRUG|AZD4144|Oral solution of AZD4144 will be given to randomised participants as per the arm they have been assigned.
223678988|NCT06675175|OTHER|Placebo|Placebo will be given orally to randomized participants as per the arm they are assigned.
223678989|NCT06769880|OTHER|Ultrasound and Educational Intervention|This will include the educational intervention combined with a point-of-care ultrasound
223678990|NCT06769880|OTHER|Educational Intervention Alone|This will include only the educational intervention (without ultrasound)
223678991|NCT03971253|DRUG|Peficitinib|Oral
223678992|NCT06311578|DRUG|JNJ-87704916|JNJ-87704916 will be administered as an intratumoral injection.
223678993|NCT06311578|DRUG|Cetrelimab|Cetrelimab will be administered.
223678997|NCT06433661|DRUG|Etavopivat|Participants will receive single dose of oral Etavopivat in each treatment period.
223678998|NCT06549595|DRUG|AZD0486|a fully human bispecific monoclonal IgG4 antibody
223678999|NCT06549595|DRUG|R-CHOP|Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone
223679000|NCT06549595|DRUG|R-CVP|Rituximab, Cyclophosphamide, Vincristine and Prednisone
223679001|NCT06549595|DRUG|BR|Bendamustine, Rituximab
224259520|NCT02892747|BEHAVIORAL|Educational Program|
224259521|NCT02097550|OTHER|eHealth Intervention|Patients randomized to this arm will receive eHealth materials every 2-4 weeks over the 12-month intervention. However, the exact nature of timing, dose, and delivery channel will be informed by the formative research.
224259522|NCT06016361|OTHER|VS-200Cr|Topical cream with moisturizing factors.
224259523|NCT06016361|OTHER|Standard of care|AAD recommended course of care.
224259524|NCT05814926|DRUG|GP681|GP681, tablet, oral
224259525|NCT01292590|OTHER|High fat meal|40 grams saturated fat
224259526|NCT01845298|DRUG|Rifampicin 600 mg|The investigators will administer a single dose of rifampicin 600 mg to study subjects in order to conduct a pharmacokinetic study of rifampicin absorption.
224259527|NCT03427944|DRUG|Calcium Dobesilate group|Calcium dobesilate was used to treat patients with chronic renal failure on the basis of conventional treatment.
224259528|NCT03427944|DRUG|Conventional Treatment group|Conventional treatment were used to treat patients with chronic renal failure.
224259529|NCT01521780|PROCEDURE|MRI|Participants undergo volumetric \& diffusion weighted (DW) MRI. Participants are scanned twice, with an intervening fifteen minute walk between the scans.
224322855|NCT06962995|PROCEDURE|Blood Draw|Up to 60 mL (about 4-5 Tbsp) of blood will be collected for an initial blood draw and up to 30 mL (about 2-3 Tbsp) may be collected for a second blood draw, 25-45 days after first blood draw. The research blood will be collected at the time of a clinical blood draw, if possible.
224322856|NCT06962995|OTHER|Surveys|Participants will complete surveys related to attitudes and beliefs around Multi-Cancer Detection testing.
224322857|NCT06956235|DRUG|Tulisokibart|Solution in autoinjector for subcutaneous (SC) injection
224322858|NCT06956235|DRUG|Placebo|Solution in autoinjector for SC injection
224322859|NCT06710964|OTHER|The Ten Item Personality Inventory|"The Ten Item Personality Inventory (TIPI) is a brief self-report measure of the Big Five personality dimensions, which will provide the mock basis for the self-dehumanization induction. Participants will indicate responses on 7-point Likert scale ranging from 1 (disagree strongly) to 7 (agree strongly).~Building off previously validated tasks participants will be told that the TIPI measure provided certain information about their personalities (and therefore expectations for their future). To establish credibility, participants will receive accurate feedback surrounding their reported levels of extraversion (high, medium, low). Participants will be randomly assigned to receive one of the following pre-written, feedback scripts as additional implications about their extraversion scores in relationship to future social expectations."
223679004|NCT06547424|DRUG|Chondroitin sulfate|Neonates with Bell's Stage 2 NEC will be given chondroitin sulfate (20mg/kg/day) mixed with 1-2 ml of milk or formula for 2 days
223679007|NCT05411081|BIOLOGICAL|Atezolizumab|Given IV
224259530|NCT01521780|PROCEDURE|Pathology|Participants who are undergoing surgical resection of HCC per their standard of care treatment, will submit tumor samples for biomarker analysis.
224259531|NCT01521780|PROCEDURE|Blood Samples|Blood is collected from participants during screening Visit 1 - 24.5 ml. During Visit 3, blood samples totaling 22 ml, are collected at least 6-18 hours post-resection, and every other day up to a week until discharge. At follow up Visit 4, 5.5 ml of blood is collected.
224259532|NCT01521780|PROCEDURE|Blood Samples|Blood is collected from participants during screening Visit 1 - 24.5 ml, and follow up Visit 4 - 5.5 ml.
224259533|NCT02259972|DRUG|BI 113823 solution|
224259534|NCT02259972|DRUG|BI 113823 tablet|
223679008|NCT05411081|PROCEDURE|Biospecimen Collection|Undergo collection of blood and urine samples
223679009|NCT05411081|PROCEDURE|Bone Scan|Undergo bone scans
224259535|NCT02259972|DRUG|Placebo|
224259536|NCT02259972|OTHER|High fat, high calorie breakfast|only for dose group 5
224259537|NCT01554410|RADIATION|Intensity Modulated Radiation Therapy (IMRT)|45 Gy in 25 daily fractions (1.8 Gy per fraction)
224259538|NCT01554410|DRUG|Cisplatin|Weekly infusion of 40 mg/m2 x 5 weeks (70 mg maximum)
224259539|NCT01554410|DRUG|Gemcitabine|Weekly infusion x 5 weeks at escalating dose levels (50mg/m2, 75mg/m2, 100mg/m2, and 125mg/m2)
224259540|NCT02220049|DRUG|Bortezomib|
224259541|NCT01788072|DRUG|Intranasal Oxytocin|24 IU taken twice daily (BID), in the morning and at noon/early afternoon
224259542|NCT01788072|DRUG|Placebo|24 IU taken twice daily (BID), in the morning and at noon/early afternoon
224259543|NCT00048334|DRUG|Depsipeptide, FR901228, FK228|
224259544|NCT04241757|DIAGNOSTIC_TEST|ElectroCardioGram (ECG)|Collection of results ElectroCardioGram (ECG).
224259545|NCT06059625|PROCEDURE|rotatori cuff repair|rotatori cuff repair
224259546|NCT03978780|PROCEDURE|Erector spinae plane block|80mm 22G block needle will be inserted using an in-plane cranial to caudad approach, the needle will be advanced to target the interfascial plane deep to the erector spinae muscle at the T2 transverse process. Once the needle tip is in the correct position, 20 ml of the local anaesthetic (ropivacaine 0.5% with 1:400,000 epinephrine) will be administered slowly in 5 ml aliquots under frequent aspiration and correct spread in the interfascial plane will be observed.
224322860|NCT06710964|OTHER|Mechanistic Self-Dehumanization Condition|"Future Mechanistic Self-Dehumanization Script: Based on your responses, you're the type who will feel at times that you're just a number in the system. The day-to-day pattern of going to work and fulfilling responsibilities will seem repetitive, like you are a mechanical device just going through the motions. You might find that relationships feel distant or lack the warmth you seek, making it challenging to form deeper connections. Over time, each day will blend into the next, which will likely lead to you operating on autopilot, existing among humans."
224259547|NCT03978780|PROCEDURE|Placebo Block|Patients randomised to the Control group will then receive a sham subcutaneous injection of 0.5ml normal saline injected at the same site as the ESP block under ultrasound guidance to stimulate a real block procedure.
223679010|NCT05411081|DRUG|Cabozantinib S-malate|Given PO
223679011|NCT05411081|PROCEDURE|Computed Tomography|Undergo CT scans
223679012|NCT05411081|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223679025|NCT05564650|BIOLOGICAL|Navitoclax|Given PO
223679026|NCT05564650|DRUG|Venetoclax|Given PO
223679027|NCT05564650|DRUG|Decitabine|Given IV
223679028|NCT05564650|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
223679029|NCT05564650|PROCEDURE|Biospecimen Collection|Undergo collection of blood
223679030|NCT05564650|OTHER|Laboratory Biomarker Analysis|Correlative studies
223679031|NCT05564650|OTHER|Quality-of-Life Assessment|Ancillary studies
223679034|NCT05242471|BIOLOGICAL|Guselkumab|Guselkumab will be administered as subcutaneous injection.
223679035|NCT05242471|BIOLOGICAL|Golimumab|Golimumab will be administered as subcutaneous injection.
223679036|NCT05242471|BIOLOGICAL|JNJ-78934804|JNJ-78934804 will be administered subcutaneously as per defined regimen.
223679037|NCT05242471|DRUG|Placebo|Placebo will be administered as subcutaneous injection.
224259548|NCT05444296|OTHER|Superficial Dry Needling|"1/2 needles will placed into defined innervation fields of the trigeminal nerve and rotated. Total time will be 5-7 minutes."
223679043|NCT06673043|DRUG|Anifrolumab|Anifrolumab 300 mg concentrate for solution for infusion
223679046|NCT06877676|DRUG|TAR-200|Participants will undergo insertion of TAR-200 transurethrally into the bladder via catherization using the co-packed urinary placement catheter only in accordance with the Instructions for Use (IFU).
223679048|NCT05704049|DRUG|Isatuximab|Investigational medicinal product; Pharmaceutical form: Solution for Subcutaneous administration; Route of administration: Subcutaneous
223679049|NCT05704049|DRUG|Carfilzomib|Investigational medicinal product; Pharmaceutical form: Powder for solution for infusion; Route of administration: Intravenous
223679050|NCT05704049|DRUG|Dexamethasone|Investigational medicinal product/background treatment; ATC code: H02AB02; Pharmaceutical form: Tablet; Route of administration: Oral
223679051|NCT05704049|DRUG|Dexamethasone IV|Investigational medicinal product/background treatment; ATC code: H02AB02; Pharmaceutical form: Powder for solution for infusion; Route of administration: Intravenous
223679052|NCT05704049|DRUG|Montelukast|Background Treatment; ATC code: R03DC03; Pharmaceutical form: As per local commercial product; Route of administration: Oral
223679053|NCT05704049|DRUG|Acetaminophen|Background Treatment; ATC code: N02BE01; Pharmaceutical form: As per local commercial product; Route of administration: Oral or intravenous (IV)
223679054|NCT05704049|DRUG|Diphenhydramine|Background Treatment; ATC code: R06AA02; Pharmaceutical form: As per local commercial product; Route of administration: Oral or IV
224259549|NCT05444296|OTHER|Non-thrust Mobilizations only|Non-thrust mobilizations to be applied to the most symptomatic level of the upper cervical spine as determined by a treating physical therapist. The mobilization technique will be applied for 3 bouts of 30 seconds.
224259550|NCT00131417|DRUG|ready-to-use therapeutic food|
224259551|NCT05863962|OTHER|walking and Stretching|Stretching exercise will be given for 6 weeks (3 sessions per week). 15 minutes of moderate walking with stretching exercises 5 times a week with Warm up and Cool down. Videos will be provided to participants to follow at home. Participants will be provided forms for home to fill after every session completed and frequency of each exercise
223679055|NCT05704049|DRUG|Methylprednisolone|Background Treatment/Rescue medication; ATC code: H02AB04; Pharmaceutical form: As per local commercial product; Route of administration: IV
223679056|NCT07095231|BIOLOGICAL|STX-S|A proprietary vaccine developed internally by Capricor utilizing exosomes that were engineered to express spike proteins on the surface
223679063|NCT06910813|GENETIC|DFT383|DFT383 is an autologous hematopoietic stem cell (HSC) gene therapy.
223679068|NCT07098364|BIOLOGICAL|Vevoctadekin|Given SC
223773406|NCT01714700|BEHAVIORAL|High protein diet, Resistance exercise|The progressive supervised resistance exercise training program was performed by all participants under supervision. They participated in an onsite supervised protocol for 12 weeks (six days per week); weeks 1-4 (Monday - pectorialis major, Tuesday - latissimus dorsi, Wednesday - femoral, Thursday - deltoid, Friday - biceps brachii, Saturday - triceps brachii muscle), weeks 5-8 (Monday and Friday- pectorialis major and triceps brachii, Tuesday and Saturday - latissimus dorsi and biceps brachii, Wednesday and Monday - femoral, Thursday and Tuesday - deltoid muscle), weeks 9-12 (Monday and Thursday - pectorialis major and latissimus dorsi, Tuesday and Friday - femoral and deltoid, Wednesday and Saturday - triceps brachii and biceps brachii muscle).
224259552|NCT05863962|OTHER|walking and Jacobsons relaxation technique|Jacobson's Relaxation Technique will be given for 6 weeks. 15 minutes of moderate walking with Jacobson's Relaxation Technique. Videos will be provided to participants to follow at home. Participants will be provided forms for home to fill after every session completed. Participants will also bring their Pedometer
224259553|NCT02814877|OTHER|promotion of appropriate use of antibiotics in hospital|promotion of appropriate use of antibiotics in hospital by visiting physicians
224259554|NCT03973658|DEVICE|Hearing aids|Fitting of hearing aids (for the first time)
224259555|NCT03043872|DRUG|Durvalumab|IV infusions every 3 weeks for 12 weeks (4 cycles) and every 4 weeks thereafter until PD or other discontinuation criteria.
223679069|NCT07098364|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
223679070|NCT07098364|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
223679071|NCT07098364|PROCEDURE|Computed Tomography|Undergo CT
223679072|NCT07098364|PROCEDURE|Echocardiography Test|Undergo ECHO
224259556|NCT03043872|DRUG|Tremelimumab|IV infusions every 3 weeks for 12 weeks(4 cycles). An additional dose of tremelimumab will be administered in the week 16.
224259557|NCT03043872|DRUG|Carboplatin|up to 4 cycles every 3 weeks in Arm 1 and 2, up to 6 cycles every 3 weeks in Arm 3
224259558|NCT03043872|DRUG|Cisplatin|up to 4 cycles every 3 weeks in Arm 1 and 2, up to 6 cycles every 3 weeks in Arm 3
224259559|NCT03043872|DRUG|Etoposide|up to 4 cycles every 3 weeks in Arm 1 and 2, up to 6 cycles every 3 weeks in Arm 3
223679073|NCT07098364|PROCEDURE|Leukapheresis|Undergo leukapheresis
223679074|NCT07098364|BIOLOGICAL|Lisocabtagene Maraleucel|Given IV
223679075|NCT07098364|PROCEDURE|Lumbar Puncture|Undergo lumbar puncture
223679076|NCT07098364|PROCEDURE|Lymphodepletion Therapy|Undergo lymphodepletion chemotherapy
223679077|NCT07098364|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
223679078|NCT07098364|PROCEDURE|Positron Emission Tomography|Undergo PET scan
223679079|NCT07098364|PROCEDURE|X-Ray Imaging|Undergo x-ray
223679080|NCT07098364|PROCEDURE|Biospecimen Collection|Undergo blood and CSF sample collection
224259560|NCT03411148|BEHAVIORAL|Weekly exercise sessions with physical therapist and psychologist|Eight weekly sessions integrating techniques from physical therapy and cognitive behavioral therapy. At the start of each session participants play virtual reality games that target balance and functional gait and then discuss their balance confidence and activity avoidance behaviors with a behavioural counselor. Weekly homework assignments ask participants to report on thoughts causing them to avoid activities and to slowly engage in activities that present increasing levels of fear.
224259561|NCT03411148|BEHAVIORAL|Home-based exercises|Stretching and other exercises are safely taught by physical therapist and then practiced at home following a provided schedule. Participants receive periodic calls to discuss progress.
224259562|NCT04862572|OTHER|MRI scanning|"In the audiological assessment, participants will undergo various audiometric test, such as pure tone audiometry with extended high-frequency range, speech audiometry, tympanometry, and auditory reflex threshold. These tests are all noninvasive and aim to assess participants hearing threshold, speech-in-noise difficulty, whether or not they have conductive hearing loss, and test efferent auditory function. The appointment will take around 60-90 minutes. An experienced audiologist on-site will be in charge of this procedure.~In the MRI appointment, participant will undergo MRI scanning. Before the MRI scan, a researcher with experienced radiographer will re-check that the participant is safe to be scanned, with the standard University of Nottingham safety questionnaire. This rechecking step is necessary to make sure that participants are still eligible for the scanning. An experience radiographer will be in charge of this procedure."
224259563|NCT05902702|OTHER|Nebulized isotonic saline|The intervention will constitute nebulized isotonic saline.
224259564|NCT05902702|OTHER|Nasal irrigation with isotonic saline|The intervention will constitute isotonic saline administered as nasal drops.
224259565|NCT05261945|OTHER|Routine Physical Therapy|Routine Physical Therapy treatment with hot pack, TENS, and ultrasound helps in improving and relaxing the muscle spasm and soft tissue elasticity along pain reduction.
224259566|NCT05261945|OTHER|Manual Therapy And Routine Physical Therapy|Mulligan is consider one of the most effective technique of mobilization.it is also important treatment for neck pain so that many physiotherapist used mulligan by including several methods such as Natural Apophyseal Glides or Sustained Natural Apophyseal Glides.
224259567|NCT05261945|OTHER|Stretching Exercises And Routine Physical Therapy|Regular stretching helps increase your range of motion in the joints, improves blood circulation and posture and alleviates muscular tension throughout the body.
224259568|NCT07035119|OTHER|Transcranial magnetic stimulation|Resting motor threshold will be established by first finding the area of the motor cortex associated with visible twitch of the right abductor pollicis brevis (APB). Parameter Estimation by Sequential Testing (PEST) will be conducted to quantify resting motor threshold using visible APB twitch. The left dorsolateral prefrontal cortex (DLPFC) will be located using the Beam F3 method and marked with a felt-tipped marker on the scalp. TMS will be delivered over left DLPFC at 110% of resting motor threshold at 10Hz (5-seconds-on; 10-seconds-off) for 15 minutes per session (3000 pulses), 3 sessions each day (30-minute rest in-between sessions), for 3 days (within 5 consecutive days; a total of 27,000 pulses).
224259569|NCT04235595|OTHER|Connective Tissue Manipulation|The application was delivered with the participant in a sitting position, with the entire back and sacral regions left exposed. The treatment was administered to the sacral, lower thoracic and pelvic regions.
224259570|NCT04235595|OTHER|Transcutaneous Electrical Nerve Stimulation|TENS was administered with the participant lying face down with a flat cushion underneath the abdomen. TENS was administered via 2 channels of electrodes placed with the sacral region in the middle. The intensity of the current was increased until the participant felt it.
224259571|NCT03614845|PROCEDURE|VCV|after induction for anesthesia patients will be supported by mechanical ventilation on volume controlled ventilation mode
224259572|NCT03614845|PROCEDURE|PCV-VG|after induction for anesthesia patients will be supported by mechanical ventilation on pressure controlled and volume guaranteed ventilation mode
224259573|NCT03614845|DIAGNOSTIC_TEST|lung ultrasonography|all patients will be performed lung ultrasonography pre and postoperatively
224259574|NCT05699005|DRUG|Packed Red Blood Cells (PRBCs)|"Patient will recieve PRBCs transfusion only in case of ScVO2 level\<65% after assessment of patient for optimisation of SaO2 targeting 100%, volume status, ECMO flow (increase to 20% in relevant), pain, anxiety and fever (body temperature \>38°3).~In both groups transfusion may be performed in case massive bleeding according to local protocols, STEMI, Hyperlactatemia \>4 that can be related to oxygen demand and supply DO2/VO2 ratio impairement, in all groups, transfusion should be performed in case of hemolobin level \<7g/dL or worsening of neurological condition (Increase in Neurological SOFA component of 1 and more) related to DO2/VO2 impairement."
224259575|NCT06719726|PROCEDURE|PECS I Block|The PECS I block is a regional anesthesia technique performed preoperatively under ultrasound guidance. It involves the injection of 10 mL of 0.5% bupivacaine between the pectoralis major and pectoralis minor muscles to block the medial and lateral pectoral nerves. This procedure targets the right breast in the study to reduce postoperative pain and is compared to local anesthetic infiltration.
223679090|NCT06878404|DRUG|Icotrokinra|Icotrokinra will be administered.
223679091|NCT06878404|DRUG|Placebo|Placebo will be administered.
223679092|NCT06878404|DRUG|Active reference comparator|Active reference drug will be administered.
224259576|NCT06719726|PROCEDURE|Local Anesthetic Infiltration|Local anesthetic infiltration involves the intraoperative administration of 10 mL of 0.5% bupivacaine under direct visualization into the pectoralis major muscle prior to muscle transection. This procedure targets the left breast in the study for pain management and is compared to the PECS I block.
224259577|NCT04647266|PROCEDURE|endoscopic submucosal dissection|endoscopic submucosal dissection
224259578|NCT05573620|BEHAVIORAL|ACT|"Acceptance and Commitment Therapy methods were focused on promoting Values clarification, Acceptance, Cognitive defusion, Committed action and Flexible attention to the present moment, and included 'The dreamed professional exercise' -variation on 'imagine your funeral exercise'-, Ship's captain metaphor, Imaginal exposure, Physicalizing exercise, and Watching thoughts as graffiti."
224259579|NCT05573620|BEHAVIORAL|In vivo exposure:|The audience was made up of university students. Every session included a 12 minute oral presentation. Participants were asked to improvise a talk about a new topic (e.g. violence against women, education system in Spain…). Participants had 3 minutes to prepare their speech. Difficulty increased based on each participant's pre assessment (topics and distractors as ringtones, audience whispering...)
224259580|NCT05573620|BEHAVIORAL|Virtual Reality|"Virtual reality was delivered through Psious platform distributed in Spain by TEA and through a Virtual Reality equipment that included a Samsung S7 mobile and Samsung Gear VR glasses.~Every session included a 12 minute oral presentation. Participants were asked to improvise a talk about a new topic (e.g. violence against women, education system in Spain…). Participants had 3 minutes to prepare their speech. Difficulty increased based on each participant's pre assessment (topics and distractors as ringtones, audience whispering...)"
224259581|NCT05612204|PROCEDURE|Biopsy under MRI|Biopsy under MRI
224259582|NCT06747117|DEVICE|Indigo Aspiration System|Mechanical aspiration thrombectomy with the Indigo Aspiration System.
224259583|NCT07060742|DEVICE|Dividat Senso|Participants in the intervention group will receive cognitive-motor training using the Dividat Senso exergame platform, which records body movements and adapts game difficulty in real time. The training targets cognitive and physical functions through interactive games involving steps and weight shifts. It follows a progressive structure, with difficulty increasing over time, and can be personalized by investigators using the Dividat Manager.
224259584|NCT07060742|OTHER|OTAGO Falls-prevention program|The OTAGO Falls Prevention Program is an evidence-based exercise program designed to reduce falls in older adults. It includes strength and balance training exercises performed at home under the guidance of a physiotherapist. The program aims to improve muscle strength, balance, and mobility, helping to prevent falls and maintain independence.
224259585|NCT07060690|BEHAVIORAL|iCBT with human interaction|The 3D programme is a 10-week online intervention based on Cognitive Behavioural Therapy (CBT), designed to support women's mental health. Participants will use the 3D website to complete 10 weekly self-guided modules that include videos, written materials, and interactive activities. Topics address depression and issues commonly experienced by women, such as hormonal changes, caregiving, body image, and sexism. All content is available in both video and text formats. Participants will also have six one-to-one video sessions with a trained health/clinical psychologist, who will tailor the programme by recommending specific modules or tasks. All therapists will complete training on the 3D programme and online therapy. Participants will receive guidance on how to use the 3D website before starting.
224259586|NCT07060690|BEHAVIORAL|Psychoeducational videos|This control arm provides psychoeducational content without therapist support or homework assignments, serving as an adjunct to standard care. This distinguishes it from the experimental arm, which includes therapist-guided interventions and active homework components.
223679094|NCT07105228|DRUG|aflibercept 2mg|No study-specific interventions administered in this observational study
223679095|NCT07100990|DRUG|High-dose corticosteroids (HDCS)|"Subjects will receive initial treatment with high-dose corticosteroids (HDCS) in the form of methylprednisolone (1,000mg daily) administered intravenously for 5 days or a bioequivalent dose of oral corticosteroids (e.g., 1,250mg prednisone daily or 176mg dexamethasone daily).~Subjects will be escalated to PLEX if there is an insufficient response to HDCS (decision point at 14±2 days for the ON sub-trial and 7±2 days for the TM sub-trial) PLEX will be performed as 5 sessions over 5-10 days, with 1-1.5 plasma volumes exchanged per session."
223679096|NCT07100990|DRUG|High-dose corticosteroids (HDCS) and PLEX|"Subjects will receive treatment with high-dose corticosteroids (HDCS) and PLEX initiated concurrently.~HDCS will be administered in the form of methylprednisolone (1,000mg daily) administered intravenously for 5 days or a bioequivalent dose of oral corticosteroids (e.g., 1,250mg prednisone daily or 176mg dexamethasone daily).~PLEX will be performed as 5 sessions over 5-10 days, with 1-1.5 plasma volumes exchanged per session."
223679097|NCT03576274|BEHAVIORAL|Technology Enhanced Home Exercise (TEHE)|A 12 week program including one 60-minute goal setting and exercise training program and follow up phone calls.
223679098|NCT03576274|BEHAVIORAL|Auricular Point Acupressure (APA)|A non invasive complementary method to provide pressure on the ear points.
223679099|NCT03576274|BEHAVIORAL|Mindfulness body scan (MBI)|The open, nonjudgmental attention to move one's attention calmly to the different part of the body
223679100|NCT03072927|DEVICE|MILD|MILD is performed under fluoroscopic image guidance through an ipsilateral interlaminar dorsal approach to the spine. Following epidurography, partial decompression is performed through the removal of tissue and bone at the symptomatic level confirmed with correlated MRI and clinical findings.
223679101|NCT03072927|DEVICE|Interspinous Process Decompression|Interspinous Process Decompression
223679102|NCT07107230|DRUG|JNJ-95437446|JNJ-95437446 will be administered.
223679103|NCT05363865|BEHAVIORAL|Virtual Community Intervention|Modules of community building, HIV/HCV prevention, drug and service stigma, identification of mental health problems
223679104|NCT05363865|BEHAVIORAL|Standard of Care|health websites and county information provided to participants
223679107|NCT06546995|DRUG|NMRA-323511|Participants will receive NMRA-323511 orally.
223679108|NCT06546995|DRUG|Placebo|Participants will receive matching placebo tablets orally.
223679109|NCT03899155|DRUG|Nivolumab|Specified dose on specified days
223679110|NCT03899155|DRUG|Ipilimumab|Specified dose on specified days
223679111|NCT03899155|DRUG|Cabozantinib|Specified dose on specified days
224322861|NCT06710964|OTHER|Debrief|Debrief: Those in the self-dehumanized condition will receive a brief rehumanization intervention to undo the effects of the self-dehumanized condition. This intervention will involve a reminder that the condition was fabricated and will involve reading quotes involving general themes of humanness. The participants will then share with the experimenter how they connect to their humanness. The experimenter will document responses and encourage engagement in humanizing activities following the study visit. Findings from these qualitative responses will inform a rehumanization intervention in another study.
224259587|NCT01154231|DRUG|Nonacog Alfa (Genetical Recombination)|"Patients with hemophilia B (congenital blood coagulation factor IX deficiency) who are administered this drug.~Patients with hemophilia B are either patients for whom treatment was already started with a blood coagulation factor IX product (Previously treated patients: hereinafter, PTPs) or patients who have no history of treatment with a blood coagulation factor IX product in the past and for whom treatment will be started with this drug for the first time (Previously untreated patients: hereinafter, PUPs).~The definition of PUPs in this survey is Patients in whom the total number of days of administration of a blood coagulation factor IX product other than this drug before administration of this drug was 3 exposure days (actual number of days of administration: hereinafter, EDs) or less."
223679112|NCT03899155|DRUG|Trametinib|Specified dose on specified days
224259588|NCT07059104|PROCEDURE|Breast augmentation|Breast augmentation with an implant
224259589|NCT07059104|PROCEDURE|Breast reconstruction after mastectomy|Breast reconstruction after mastectomy
224259590|NCT01938339|DEVICE|PET/MR|Multi-radiotracer PET/MR will be performed in patients with primary and recurrent prostate cancer
224259591|NCT07061327|BEHAVIORAL|Online fever management|Online training application will be carried out via Whatsapp
224259592|NCT07060677|PROCEDURE|Inmersive Virtual Reality|Participants will receive a intervention of immersive virtual reality using Meta Quest 3 and the Kinesix XR platform. Sessions will take place twice per week for 8 weeks. The IVR component will focus on balance and mobility through interactive, immersive environments designed to enhance engagement, adherence, and functional outcomes. This multimodal approach aims to reduce fall risk and frailty while improving motivation and quality of life in older adults.
224259593|NCT07060677|PROCEDURE|Conventional occupational therapy sessions|Participants will receive conventional occupational therapy only, with sessions conducted twice per week for 8 weeks. The intervention will focus on cognitive stimulation, manipulative skill training, and psychomotor exercises, all adapted to the functional level of each participant. Activities aim to maintain or improve autonomy, balance, and coordination, following established occupational therapy guidelines for older adults. No immersive virtual reality or digital technology will be included in this group. This control condition allows for comparison with the experimental group to evaluate the added value of immersive virtual reality in fall risk and frailty reduction.
224259594|NCT01165385|DRUG|cisplatin|60, 75 or 100 mg/m2 , day 1 - 3 weekly
224259595|NCT01165385|DRUG|Pazopanib|400 mg, 600 mg or 800 mg/day, daily
224259596|NCT07061054|DEVICE|Netrod™ six-electrode radiofrequency renal denervation system|Netrod™ renal denervation (RDN) system, which is indicated for the treatment of uncontrolled hypertension. It consists of the following two components: Netrod™ Six-Electrode Basket Radiofrequency Renal Denervation Catheter and Netrod™ Renal Denervation Radiofrequency Generator. The catheter's electrodes deploy into a self adaptive basket structure, optimizing contact with the vessel wall for effective ablation.
223679113|NCT03899155|DRUG|Relatlimab|Specified dose on specified days
223679114|NCT03899155|DRUG|Nivolumab + Relatlimab|Specified dose on specified days
223679115|NCT03899155|DRUG|Capecitabine|Specified dose on specified days
223679116|NCT03899155|DRUG|Bevacizumab|Specified dose on specified days
223679117|NCT03899155|DRUG|Temozolomide|Specified dose on specified days
223679118|NCT03899155|DRUG|Rucaparib|Specified dose on specified days
223679119|NCT03899155|DRUG|Daratumumab|Specified dose on specified days
224322862|NCT06710964|OTHER|Control Condition|"Future Control Script: Based on your responses, you're the type who will have a very normal life. You will wake up, go to your job during the weekdays, and complete all necessary tasks. On the weekends you will spend time doing fulfilling activities. Relationships will have natural ups and down, but overall, you will feel satisfied by your connectedness to others. Though some days may feel monotonous, you will feel relaxed knowing you belong."
223679120|NCT03899155|DRUG|Regorafinib|Specified dose on specified days
223679121|NCT03899155|DRUG|Leucovorin|Specified dose on specified days
223679122|NCT03899155|DRUG|Fluorouracil|Specified dose on specified days
223679123|NCT03899155|DRUG|Oxaliplatin|Specified dose on specified days
223679124|NCT03899155|DRUG|Enzalutamide|Specified dose on specified days
223679125|NCT03899155|DRUG|Sunitinib|Specified dose on specified days
223679126|NCT03899155|DRUG|Pemetrexed|Specified dose on specified days
223679127|NCT03899155|DRUG|Pembrolizumab|Specified dose on specified days
223679134|NCT05859334|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
223679135|NCT05859334|DRUG|Erdafitinib|Given PO
223679136|NCT05859334|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223679137|NCT05859334|PROCEDURE|Optical Coherence Tomography|Undergo OCT
224259597|NCT01305161|OTHER|Blood simple|Single Blood simple at Day 1
224259598|NCT07063485|BEHAVIORAL|Resilience Theory and Satir Model Nursing Skills Training|A structured psychological and nursing intervention program based on resilience theory and the Satir model. It consists of 15 two-hour group sessions during hospitalization, focusing on enhancing resilience, communication, and self-efficacy through themed activities, interactive learning, relaxation techniques, and guided training. The intervention is led by psychologists and psychiatric nurses and includes post-discharge follow-up.
224259599|NCT07063485|BEHAVIORAL|Routine Nursing Intervention|Standard nursing care for patients with depression, including illness monitoring, daily life guidance, psychological support, and health education on disease management, emotion regulation, and medication.
223679141|NCT04071223|PROCEDURE|Biospecimen Collection|Undergo blood and urine sample collection
223679142|NCT04071223|PROCEDURE|Bone Scan|Undergo bone scan
223679143|NCT04071223|DRUG|Cabozantinib S-malate|Given PO
223679144|NCT04071223|PROCEDURE|Computed Tomography|Undergo CT
223679145|NCT04071223|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223679146|NCT04071223|PROCEDURE|Positron Emission Tomography|Undergo FDG-PET or NaF-PET
223679147|NCT04071223|OTHER|Questionnaire Administration|Ancillary studies
223679148|NCT04071223|RADIATION|Radium Ra 223 Dichloride|Given IV
223679155|NCT05429502|DRUG|Topotecan|Starting out dose of topotecan administered at standard dose given to neuroblastoma patients (0.75 mg/m2/day).
223679156|NCT05429502|DRUG|Temozolomide|Starting out dose of temozolomide for cohort A1 and A2 for Phase 1-Part A: 150mg/m2/day. Starting out dose for subsequent cohorts, Cohort A3 and onwards, in Phase 1-Part A will initiate at 100mg/m2/day.
223679157|NCT05429502|DRUG|Ribociclib|Starting out dose of ribociclib for cohort A1 Phase 1-Part A: 200mg/m2/day. Starting out dose for Cohort A2 and A3 was 100mg/m2/day.
223679158|NCT06500884|DRUG|Talquetamab|Talquetamab will be administered subcutaneously.
223679159|NCT06500884|DRUG|Prophylaxis A|Prophylaxis A will be administered orally.
223679160|NCT06500884|DRUG|Prophylaxis B|Prophylaxis B will be administered orally.
223679161|NCT06500884|DRUG|Prophylaxis C|Prophylaxis C will be administered orally.
223679165|NCT06236815|DRUG|Delta-9-THC|Healthy volunteers will attend three test sessions, at least 14 days apart, in which cognition and driving performance will be assessed following vaporization of (1) Δ9-THC, (2) Δ8-THC, or (3) a placebo. The order of these conditions will be counterbalanced across participants. Serial blood samples will be drawn during each dosing visit and compared with concurrent dried blood spots from a finger stick.
223679166|NCT06236815|DRUG|Delta-8-THC|Healthy volunteers will attend three test sessions, at least 14 days apart, in which cognition and driving performance will be assessed following vaporization of (1) Δ9-THC, (2) Δ8-THC, or (3) a placebo. The order of these conditions will be counterbalanced across participants. Serial blood samples will be drawn during each dosing visit and compared with concurrent dried blood spots from a finger stick.
223679167|NCT06236815|DRUG|Placebo|Healthy volunteers will attend three test sessions, at least 14 days apart, in which cognition and driving performance will be assessed following vaporization of (1) Δ9-THC, (2) Δ8-THC, or (3) a placebo. The order of these conditions will be counterbalanced across participants. Serial blood samples will be drawn during each dosing visit and compared with concurrent dried blood spots from a finger stick.
224259600|NCT07068373|DIAGNOSTIC_TEST|Mixed method (Exploratory Sequential)|4-6 Expert SLPs working with Cochlear Implant, A cohort of 100 Urdu speaking children who received cochlear implants
223773407|NCT01714700|BEHAVIORAL|Standard diet, Resistance exercise|The progressive supervised resistance exercise training program was performed by all participants under supervision. They participated in an onsite supervised protocol for 12 weeks (six days per week); weeks 1-4 (Monday - pectorialis major, Tuesday - latissimus dorsi, Wednesday - femoral, Thursday - deltoid, Friday - biceps brachii, Saturday - triceps brachii muscle), weeks 5-8 (Monday and Friday- pectorialis major and triceps brachii, Tuesday and Saturday - latissimus dorsi and biceps brachii, Wednesday and Monday - femoral, Thursday and Tuesday - deltoid muscle), weeks 9-12 (Monday and Thursday - pectorialis major and latissimus dorsi, Tuesday and Friday - femoral and deltoid, Wednesday and Saturday - triceps brachii and biceps brachii muscle)
223773408|NCT03223389|DIETARY_SUPPLEMENT|C-8 dietary oil|Ingestion of 13.15 g C-8 dietary oil providing 0.0216 mol of triglycerides.
223773409|NCT03223389|DIETARY_SUPPLEMENT|Tricaprylin|Ingestion of 10.17 g tricaprylin providing 0.0216 mol of triglycerides.
223773410|NCT03223389|DIETARY_SUPPLEMENT|Olive oil|Ingestion of 19 g olive oil providing 0.0216 mol of triglycerides.
223773411|NCT05718908|DIETARY_SUPPLEMENT|Food supplement|FibrofixPlus® is an authorized food supplement.
223773412|NCT03691038|DRUG|Pregabalin 75mg bid|Through the study period, Incremental protocol follows the conventional dose regimen starting pregabaline 75mg bid.
223773413|NCT03691038|DRUG|Pregabalin 25mg, 50mg|Through the study period, Incremental protocol follows the new dose regimen starting pregabalin 25mg, 50mg
223773414|NCT04120389|DEVICE|bandage contact lenses(PureVision; Bausch & Lomb Inc., Rochester, NY)|wear an bandage contact lenses for a week after Complicated and Combined cataract surgery.
223773415|NCT04120389|PROCEDURE|phacoemulsification|underwent standard phacoemulsification through a 2.8-mm clear corneal temporal incision and intraocular lens
223773416|NCT00062244|BIOLOGICAL|oblimersen sodium|Given IV
223773417|NCT05303805|DRUG|Sevoflurane|Topical application of 1 mL sevoflurane per 1 cm2 ulcer area once or two times daily.
223679180|NCT07110532|BIOLOGICAL|A/Arkansas/08/2020 (pH1N1)|GMP-grade, cell-based influenza A (pH1N1) virus (Lot #24-005), derived via reverse genetics for use in controlled human infection studies.
223679181|NCT07110532|OTHER|Sham/Diluent (1X SPG+Arg+Gel)|Sterile diluent containing 1X Sucrose Phosphate Glutamate (SPG), 1% arginine, and 1% hydrolyzed gelatin, used as a sham comparator in the human challenge trial.
223679182|NCT06412198|DRUG|Cetuximab|Given by IV
223679183|NCT06412198|DRUG|Cemiplimab|Given by IV
223679184|NCT06412198|DRUG|Adagrasib|Given by PO
223679198|NCT05788536|GENETIC|DB-OTO|"DB-OTO will be administered as a single intracochlear injection into one ear (Part A).~* LD Cohort (lower dose)~* HD Cohort (high dose) - not implemented"
223679199|NCT05788536|GENETIC|DB-OTO|DB-OTO will be administered as a single intracochlear injection into both ears (Part B). For bilateral injections (Part B), patients will receive DB-OTO in 1 surgical session.
223773418|NCT05303805|COMBINATION_PRODUCT|Cyteal|Rinsing and cleaning of ulcer.
223773419|NCT05168007|DRUG|WID-RGC20(Cariprazine) 3mg/day|The initial dose is WID-RGC20(Cariprazine) 1.5mg/day, followed by an up-titration of 1.5mg/day until the target dose(3mg/day) is achieved. The investigational product is administered during the double-blind treatment period(6 weeks).
223773420|NCT05168007|DRUG|WID-RGC20(Cariprazine) 6mg/day|The initial dose is WID-RGC20(Cariprazine) 1.5mg/day, followed by an up-titration of 1.5mg/day until the target dose(6mg/day) is achieved. The investigational product is administered during the double-blind treatment period(6 weeks).
223773421|NCT05168007|DRUG|Placebo for WID-RGC20(Cariprazine) 3mg/day or 6mg/day|The placebo comparator is administered during the double-blind treatment period(6 weeks).
223773422|NCT00431457|DEVICE|Implantation of an intracranial electrode|Implantation of an intracranial electrode will be followed.
223773423|NCT00431457|PROCEDURE|amygddohyppocampertomy|Resective surgery
223773424|NCT04563312|PROCEDURE|Exercise|Nine different clubs and sport centers were screened and 18- to 35-year-old individuals regularly engaged in MT or BB for the last 6 months were invited to join the study.
223773425|NCT02054364|BEHAVIORAL|FBT and CRT|
223773426|NCT02054364|BEHAVIORAL|FBT and art therapy|
223773427|NCT02410811|OTHER|Cardiac magnetic resonance imaging (CMR)|CMR is obtained on all participants in all arms/groups
223773428|NCT02371499|DIETARY_SUPPLEMENT|Lactobacillus casei DG|the patients will receive 1 capsule of Lactobacillus casei DG (Enterolactis plus®) twice daily for 4 weeks
223773429|NCT02371499|DIETARY_SUPPLEMENT|Placebo|the patients will receive 1 capsule of product without bacteria (Enterolactis placebo) twice daily for 4 weeks
223679201|NCT06919666|DRUG|NT219|NT219 is a first-in-class small molecule targeting IRS 1/2 and STAT3. Preclinical studies in melanoma have shown NT219 induces PD-L1 expression in vitro and in vivo, resulting in increased efficacy of PD-1 inhibition via synergistic antitumor effect in PD-1 sensitive models and restoration of sensitivity in resistant models. NT219 also synergized with cetuximab in vitro and reversed cetuximab resistance in a head and neck cancer xenograft platform.
223679202|NCT06919965|DRUG|TAR-210|TAR-210 will be administered intravesically.
223679203|NCT06919965|DRUG|Mitomycin C|MMC will be administered intravesically.
223679204|NCT06919965|DRUG|Gemcitabine|Gemcitabine will be administered intravesically.
223679205|NCT06912763|DRUG|Pravastatin (drug)|Given PO
224259601|NCT07067476|OTHER|Instant Anti-Redness Emulsion (FLA#2039188 43)|A topical emulsion not yet marketed, developed to relieve skin redness. It contains panthenol and is applied once to the test side of the face after heat-induced redness.
224259602|NCT07067476|OTHER|Purified Water (Control)|0.3g of water is applied to the control side of the face. Used as placebo comparator to evaluate the redness-relieving efficacy of the test emulsion.
224259603|NCT07068360|COMBINATION_PRODUCT|Strength Training +Postural Correction Exercises + Balance Training +Flexibility Exercises|"Interventions details (Group A) Strength Training Postural Correction Exercises Balance Training Exercises~Flexibility Exercises:"
223679206|NCT06912763|DRUG|Pentoxifylline|Given PO
223773430|NCT03747029|OTHER|No intervention is provided|No intervention is provided
223773431|NCT04701268|OTHER|Device: Hemiverse|Implantation of the hemiverse shoulder prothesis
223773432|NCT03178071|DRUG|Lorlatinib|oral tablets, administered daily, continuously
224259604|NCT07068360|DIAGNOSTIC_TEST|Standard Intervention (Control Group)|"The control group will receive standard physiotherapy for postural hyperkyphosis.~The standard intervention will consist of:~Postural education: Educating participants on proper posture, body mechanics, and ergonomics in daily activities.~Basic stretching exercises targeting the thoracic spine and back muscles. Recommendations for low-impact aerobics activities (e.g., walking or cycling) to promote overall healthThe standard intervention will be delivered over the same 12-week period, with two sessions per week. This group will not receive the integrated multimodal framework with strength training, postural correction, balance training, and flexibility exercises that the experimental group receives. Duration and Frequency"
224259605|NCT07069062|DRUG|Test product HY0001a for injection|HY0010a for injection should be administered at the recommended dosage
224259606|NCT07068412|COMBINATION_PRODUCT|3D-printed Orthognathic Surgical Simulation|Two standardized 3D-printed anatomical models were created-one representing skeletal Class II and the other skeletal Class III. Simulated osteotomies, including Le Fort I and Bilateral Sagittal Split Osteotomies, were performed on the models to demonstrate surgical movements. These models are used to help patients visualize the procedures planned for their specific cases.
224259607|NCT07068412|COMBINATION_PRODUCT|2D Visual Representations of Skeletal Movements in Orthognathic Surgery|Two-dimensional images generated from virtual surgical planning-one depicting a Class II skeletal deformity and the other a Class III malocclusion-are used to illustrate the patient's condition and demonstrate the anticipated surgical movements.
224322863|NCT06710964|DIAGNOSTIC_TEST|Clinical Interview|Clinical Interview. Self-Injurious Thoughts and Behaviors Interview-Short Form (SITBI-SF). Participants will complete an in-person interview featuring 72-items about their history of self-injury and suicidal behaviors. This interview includes 6 yes/no style questions about suicidal thoughts, suicidal plans, suicidal gestures, suicidal attempts, nonsuicidal self-injury thoughts, and nonsuicidal self-injury. Each category that is endorsed, across the lifetime, has follow up questions surrounding times, duration, intensity, severity, type, and if medical attention was sought. This interview has sound psychometric properties.
223679207|NCT06912763|DRUG|ketoprofen|Given PO
223679208|NCT06912763|DRUG|Pirfenidoneone|Given PO
223679209|NCT06912763|OTHER|Standard of Care (SOC)|SOC
223679210|NCT06912763|DRUG|tocopherol|Given PO
223679211|NCT04497844|DRUG|Niraparib|Participants will receive Niraparib 200 mg once daily.
223679212|NCT04497844|DRUG|Abiraterone acetate (AA)|Participants will receive AA 1000 mg once daily.
223679213|NCT04497844|DRUG|Prednisone|Participants will receive prednisone 5 mg once daily.
223679214|NCT04497844|DRUG|Placebo for Niraparib|Participants will receive matching placebo for Niraparib once daily.
223679215|NCT06922617|BEHAVIORAL|Switching to E-Cigarette|Participants will receive twelve weeks of e-cigarette products with instructions to switch completely at switch date
223679216|NCT06922617|DRUG|Quitting using Medication|Participants will receive twelve weeks of FDA approved medication, combination NRT, with instructions to quit smoking cigarettes at quit date
223679217|NCT06922617|BEHAVIORAL|Counseling|Participants will recieve brief weekly counseling to support their quit or switch attempt from cigarettes.
223679220|NCT07116057|BIOLOGICAL|MOv19-BBz CAR T cells|Autologous T cells engineered to express an extracellular single chain variable fragment (scFv) with FRa specificity.
223773433|NCT04378933|DEVICE|Amber Glasses|Half of the participants will be wearing the amber glasses to see if they can help with sleep onset.
223773434|NCT04378933|DEVICE|Clear Lens Glasses|Half of the participants will be wearing the clear glasses to see if the glasses help with sleep onset.
223773435|NCT03464344|OTHER|neurological, neuropsychological and MRI evaluation|neurological, neuropsychological and MRI evaluation
223679221|NCT07116057|DRUG|Cyclophosphamide/Fludarabine|Cytotoxic chemotherapy agents used for lymphodepletion prior to MOv19-BBz CAR T cell administration.
223679222|NCT07116057|DEVICE|FRa Expression Testing|Laboratory Developed Test used to determine subject eligibility
223679229|NCT06921850|DRUG|Bimekizumab|Bimekizumab will be administered at pre-specified timepoints.
223679230|NCT07119125|DRUG|MRT-8102|Oral capsules
223679231|NCT07119125|DRUG|Placebo|Oral capsules
223679238|NCT04810611|DRUG|MBG453|Anti-TIM3 monoclonal antibody
223679239|NCT04810611|DRUG|NIS793|Anti-TGF-β monoclonal antibody
223679240|NCT04810611|DRUG|canakinumab|Anti-IL-1β monoclonal antibody
223679241|NCT04597125|DRUG|Radium-223 dichloride (Xofigo, BAY88-8223)|Participants will receive Radium-223 (BAY88-8223) every 4 weeks for a total of 6 administrations via intravenous (IV) injection
223679242|NCT04597125|DRUG|NAH therapy|Participants will receive continuous NAH (either Abiraterone acetate plus prednisone/prednisolone \[AAP\] or enzalutamide) by mouth (per os) daily
223679246|NCT07121192|BIOLOGICAL|Flu mRNA (Formulation A)|One dose of Flu mRNA (Formulation A) received intramuscularly.
223679247|NCT07121192|BIOLOGICAL|Flu mRNA (Formulation B)|One dose of Flu mRNA (Formulation B) received intramuscularly.
223679248|NCT07121192|COMBINATION_PRODUCT|Comparator 1|One dose of Comparator 1 received intramuscularly.
223679249|NCT07121192|COMBINATION_PRODUCT|Comparator 2|One dose of Comparator 2 received intramuscularly.
223679250|NCT07121192|COMBINATION_PRODUCT|Comparator 3|One dose of Comparator 3 received intramuscularly.
223679254|NCT06934226|DRUG|JNJ-77242113|JNJ-77242113 will be administered orally.
223679255|NCT06934226|DRUG|Matching Placebo to JNJ-77242113|Matching placebo will be administered orally.
223773436|NCT05821101|DEVICE|Clareon Vivity and Clareon Vivity Toric IOLs targeted for mini-monovision with dominant eye set at emmetropia and non-dominant eye at -0.50.|Bilateral implantation of IOLs such that dominant eye is corrected for distance vision while the non-dominant eye is corrected with a small amount of nearsightedness (-0.5 diopters).
223679256|NCT06934226|DRUG|Ustekinumab|Ustekinumab will be administered subcutaneously.
223679257|NCT06934226|DRUG|Matching Placebo to Ustekinumab|Matching placebo will be administered subcutaneously.
223679259|NCT06926868|DRUG|Iza-bren|Specified dose on specified days
223679260|NCT06926868|DRUG|Nab-paclitaxel|Specified dose on specified days
223679261|NCT06926868|DRUG|Paclitaxel|Specified dose on specified days
223679262|NCT06926868|DRUG|Capecitabine|Specified dose on specified days
223679263|NCT06926868|DRUG|Carboplatin|Specified dose on specified days
223679264|NCT06926868|DRUG|Gemcitabine|Specified dose on specified days
223679265|NCT06925542|BIOLOGICAL|CTX112|CTX112 (CD19-directed T-cell immunotherapy comprised of allogeneic T cells genetically modified ex vivo using CRISPR-Cas9 gene editing components)
224322864|NCT06710964|OTHER|Self-Report Measures|Depressive Symptom Index - Suicidality Subscale (DSI-SS). Patient Health Questionnaire-8 (PHQ-8). Interpersonal Needs Questionnaire (INQ). Self-Dehumanization Scale (SDS).
224259608|NCT07068269|OTHER|Self-Management Program|"Week 1: Learn about COPD, practice pursed-lip and diaphragmatic breathing (2-3 sets, 10-15 reps, 2-3x/day), start 5-10 min light walking, conserve energy with frequent rests.~Week 2: Understand benefits of activity and oxygen use, add seated marches/leg raises, walk 10-15 min, pace activities with rest breaks.~Week 3: Begin strength exercises (sit-to-stand, wall push-ups, 2 sets of 10), increase walking to 15-20 min, practice relaxation for anxiety.~Week 4: Focus on nutrition, walk 20-25 min, continue strength work, recognize flare-up signs, create action plan.~Week 5: Seek social support, walk 25-30 min, add stretching (2-3x/week), track activity daily.~Week 6: Set SMART goals, maintain daily walking 30 min, review coping strategies, add new activities if desired."
224259609|NCT07068269|OTHER|Routine Physical Therapy Exercises|"Week 1: Practice pursed-lip and diaphragmatic breathing (2-3 sets, 10-15 breaths, 2-3x/day), start walking 5-10 min (3-5x/week), add gentle upper body stretches (20-30 sec holds, 2-3 reps).~Week 2: Continue breathing exercises, increase walking slightly each session, maintain stretches 3-5x/week for flexibility.~Week 3: Keep breathing routines, walk or cycle 15-20 min (4-5x/week), start sit-to-stand strength exercises (2-3 sets of 10-15 reps, 2-3x/week), keep stretching routine.~Week 4: Maintain breathing drills, increase walking/cycling intensity if tolerated, continue strength work and flexibility exercises.~Week 5: Keep up breathing exercises, walk/cycle 20-30 min (5x/week), do sit-to-stand exercises (3 sets of 10-15 reps, 3x/week), maintain upper body stretching.~Week 6: Sustain daily breathing practice, aim for 30 min walking/cycling daily, continue strength and stretch exercises, adjust intensity as needed for long-term progress."
224259610|NCT07068464|PROCEDURE|delayed cytoreduction surgery|Delayed cytoreduction surgery is defined as cytoreduction surgery after six cycles of carboplatin and paclitaxel neoadjuvant chemotherapy.
224259611|NCT07068464|PROCEDURE|interval cytoreduction surgery|Interval cytoreduction surgery is defined as cytoreduction surgery after three cycles of carboplatin-paclitaxel neoadjuvant chemotherapy.
223679270|NCT07135596|DEVICE|OviTex PRS|A multi-layer construct of extracellular matrix (ECM) derived from ovine forestomach and embroidered with polymer filament.
223679271|NCT07137598|DRUG|Afimkibart|Afimkibart will be administered as SC injection.
223679272|NCT07137598|DRUG|Placebo|Placebo will be administered as SC injection.
223679276|NCT07141329|DRUG|SPN-817|SPN-817 starting at 0.25 mg bid up to 4.00 mg bid
223679283|NCT06939348|DEVICE|The Brainsonix BX Pulsar 1002 was designed to deliver low-intensity focused ultrasound pulsations (LIFUP) to the human brain.|The BX Pulsar 1002 consists of two main elements: the transducer and the ultrasound console. The transducer itself and the housing for it went through several iterations in order to be compatible with an MRI environment. Currently, the transducer and its housing are deemed MR-conditional at 3T with SAR ≤ 2W/kg. The design includes a solid acoustic coupling gel pad attached to the front of the transducer to provide good acoustic transmission into the scalp. An outer housing was designed to attach the transducer firmly to the head above the temporal window, and to allow it to be moved side to side to accurately target intended structures.
224259612|NCT07068061|DEVICE|PDO suture|A biodegradable polymer used in dissolvable sutures and lifting threads, stimulating collagen production as it degrades.
224259613|NCT07067515|COMBINATION_PRODUCT|non surgical with PUFA injection|The hyperpigmented gingiva in the canine/1st premolar region to the contralateral comparable tooth region in the maxillary aesthetic areas will be the target area for this procedure. A local anesthesia will be used to numb the area. Using an insulin and plastic syringe (needle: 30-gauge, 8 mm length), 1-2 gram /0.1-0.2 ml of Omega-3 (PUFAs) will be injected into the gingiva at approximately the epithelial connective tissue interface until the tissue blanche, 2-3 mm apart. The insulin syringe, bevel facing upward, will be inserted into the corresponding gingival tissues. For four weeks, this dosage of omega-3 (PUFAs) will be administered once a week. Furthermore, patients will take 2 capsules. Each capsule contains 1 gram of Omega3(PUFAs) as an additional food supplement (up to 3 gram daily for the period of injection except the day of injection. the patients will receive a packet containing required number of capsules have to be taken every week.
224259614|NCT07067515|PROCEDURE|surgical treatment|Patients with gingival hyperpigmentation of oral mucosa. For the scalpel technique, following the administration of a local anesthetic solution, a partial split thickness flap was raised with the help of blade no. 15 with the Bard Parker handle to scrape the epithelium in maxillary anterior area from canine to canine in the other side; will be surgical removal of pigmentation using the scalpel in 45 degrees to remove the superficial layer. Bleeding Will be controlled using a pressure pack with sterile gauze. Care was taken that excessive tissue was not removed thereby avoiding any bone exposure. This will be followed by careful examination of the exposed connective tissue surface, and the wound will be irrigated with saline. Bleeding will be controlled using a pressure pack, and once hemostasis is achieved, the site will be covered by a periodontal dressing for a period of one week. patients will be advised to stop eating hard, acidic, spicy, and colored foods before surgery. All patie
224259615|NCT07069582|DRUG|Standard dose rifampicin|Single-dose rifampicin at 10 mg/kg body weight
224259616|NCT07069582|DRUG|High dose rifampicin|Single-dose rifampicin at 20 mg/kg body weight
224259617|NCT07069582|DRUG|Standard dose isoniazid|Single-dose isoniazid at 5 mg/kg body weight
224259618|NCT07069582|DRUG|Standard dose levofloxacin|Single-dose levofloxacin at 10-15 mg/kg body weight
224259619|NCT07069582|DRUG|Standard dose rifapentine|Single-dose rifapentine at 10 mg/kg body weight
224259620|NCT07069582|DRUG|Standard dose bedaquiline|Single-dose bedaquiline at 400 mg
224259621|NCT06701240|BEHAVIORAL|ParentChild+|92-session early literacy focused intervention
224259622|NCT06701240|BEHAVIORAL|FamilyNutrition+|92-session active control focused on child nutrition
224259623|NCT06899022|OTHER|Normal therapeutic DBS|Participants will receive deep brain stimulation delivered at the clinically determined therapeutic frequency and current over approximately 20 min.
224259624|NCT06899022|OTHER|Reduced current DBS|Participants will receive deep brain stimulation delivered at the clinically determined therapeutic frequency and reduced (50%) current over approximately 20 minutes.
224259625|NCT06899022|OTHER|Reduced frequency DBS|Participants will receive deep brain stimulation delivered at the clinically determined therapeutic current and reduced (4 Hz) frequency over approximately 20 min.
224259626|NCT04786353|OTHER|LongCOVIDkidsDK|Exposure: To be identified as an exposure for the current study, children from 0-18 years with at least one positive SARS-CoV-2 test will be identified from COVID-19 data from January 2020 until the last updated version. To be able to identify the parents who will receive the questionnaires we will also need CPR-data on the children's parents.
224259627|NCT07067853|DEVICE|Lidocaine 2 % Pharmacopuncture|Injection of 0.5mL Lidocaine 2% solution into GB20 acupuncture point, both sides every week for 4 week
223679297|NCT03976323|BIOLOGICAL|Pembrolizumab|IV infusion
223679298|NCT03976323|DRUG|Pemetrexed|IV infusion
223679299|NCT03976323|DRUG|Carboplatin|IV infusion
224259628|NCT07067853|DRUG|propranolol 20mg|Propranolol 20mg, twice daily for 28 day / 4 week
224259629|NCT07067957|OTHER|Arabic Dysfunctional Voiding Symptom Score Questionnaire (DVSS)|A validated Arabic version of the Dysfunctional Voiding Symptom Score Questionnaire (DVSS) questionnaire will be used to screen children for symptoms of lower urinary tract dysfunction. It includes 10 items assessing urinary and bowel habits.
224259630|NCT07067177|DRUG|Paracetamol (drug)|IV prophylactic paracetamol will be given prior to detection of PDA starting from 6 hours of age. It will be used to measure wethere this intervention reduces the risk of having persistant PDA, HsPDA, or any of their complications.
223679300|NCT03976323|DRUG|Cisplatin|IV infusion
223679301|NCT03976323|DRUG|Olaparib|Oral Tablet
223679314|NCT06948747|DRUG|AZD5004|"Participants will receive oral tablets of AZD5004 as single dose on the following days, (i) Day 7, Day 14, Day 21, Day 28, Day 35, Day 42 and Day 55 in Part A. (ii) Day 9 to Day15, Day 16, Day 17 to Day 23, Day 24 to Day 30, Day 31 to Day 37, Day 38 to Day 41 and Day 42 in Part B.~(iii) Day 3 to Day 9, Day 10 to Day 25, Day 26 to Day 33, and Day 34 in Part C."
224259631|NCT07068035|BEHAVIORAL|Temporary abstinence and expressive writing|This brief, self-administered intervention combined both temporary gaming abstinence and gaming-focused expressive writing to mitigate gaming problems
223679315|NCT06948747|DRUG|Rosuvastatin|Participants will receive single oral tablets of rosuvastatin 10mg on Days 1, 7, 14, 21, 28, and 35.
223679316|NCT06948747|DRUG|Erythromycin|Participants will receive oral doses of erythromycin 500 mg, twice a day from Day 49 to Day 54; and a single dose of 500 mg on Day 55.
223679317|NCT06948747|DRUG|Atorvastatin|Participants will receive single oral doses of 40 mg atorvastatin on Days 4, 8, 16, 38, and 42.
223679318|NCT06948747|DRUG|Simvastatin|Participants will receive single oral doses of 20 mg simvastatin on Days 1 and 31.
223679319|NCT06948747|DRUG|Repaglinide|Participants will receive single oral doses of 0.5 mg repaglinide on Days 1, 10, 26, and 34.
223679320|NCT06947993|DRUG|GHZ339|GHZ339 administered at dose A, B, C and D
223679321|NCT06947993|DRUG|Placebo|Matching placebo
223773437|NCT05056168|OTHER|Dermatology-Specific Treatment Satisfaction Instrument|Study subjects will also be administered a dermatology-specific treatment satisfaction questionnaire, as well as other questionnaires including the generic validated Treatment Satisfaction Questionnaire for Medication (TSQM-9) and the validated Dermatology Life Quality Index (DLQI). Study participants will also self-report their disease severity using PGA. Depending on patients' preferred method of interacting with the study team, the investigators will collect their responses to these questionnaires either in-person, over the phone, or electronically via secure research platforms.
223773438|NCT05661292|DIAGNOSTIC_TEST|Fecal inmunochemical test|A fecal inmunochemical test will be performed prior to colonoscopy.
223773439|NCT05661292|DIAGNOSTIC_TEST|Colonoscopy|A colonoscopy will be performed. Any polyp identified will be resected (polypectomy) and analyzed histologically. NOTE: The subject and colonoscopist will be blinded to FIT test results and risk category.
223773440|NCT05661292|BIOLOGICAL|Optional collection of tissue, blood and urine for future biomedical research|Subjects may optionally participate in the collection of tissue, blood, and urine samples for future biomedical research. This procedure consists of taking a 15 ml sample of venous blood and 20 ml of urine. The tissue samples to be used will be those that have been taken for diagnostic purposes during the colonoscopy. Additional biopsies not required for medical care will not be taken. These samples will be used as long as they are no longer required to establish a diagnosis.
224259632|NCT07068035|BEHAVIORAL|Gaming as per usual and control writing|Participants continued with their usual gaming routine and engaged in control writing exercises for 15 minutes every other day for a total of 4 sessions
223679329|NCT07141004|DRUG|Guselkumab|Guselkumab will be administered as subcutaneous injection.
224259633|NCT04368624|OTHER|Skin Tape|Skin sample collection: samples of human stratum corneum will be obtained with squame adhesive tape disks typically at the time of their clinic appointment. The tape will be placed on the inside of the forearm and the procedure will be repeated up to five times per patient to have sufficient corneocytes for analysis. This type of sampling is non-invasive.
224259634|NCT04368624|DIAGNOSTIC_TEST|Blood Draw|Blood specimens: blood will be obtained for serum amino acids/phenylalanine levels. This sample is obtained for disease monitoring as part of routine standard of care. Results from up to three clinic visits will be correlated with the tape sample obtained on the same day.
224259635|NCT06664931|OTHER|Group (A) Muscle Energy Technique (MET)|"MET will be applied to three key muscles commonly associated with neck pain:~upper trapezius, levator scapulae, and anterior scalenus."
224259636|NCT06664931|OTHER|Group (B) Mulligan Mobilizations Techniques (MMT).|Participants in Group (B) will receive MMT alongside the traditional treatment. MMT utilizes a specific technique called Sustained Natural Apophyseal Glides (SNAGs) to improve joint mobilization.
223679337|NCT06950008|OTHER|Educational Intervention|Receive links to informational websites
223679338|NCT06950008|BEHAVIORAL|Patient Navigation|Receive patient navigator phone calls
223679339|NCT06950008|OTHER|Survey Administration|Ancillary studies
223679340|NCT06950008|BEHAVIORAL|Telephone-Based Intervention|Receive patient navigator phone calls
224259637|NCT03886961|DEVICE|Reflux Band|The Reflux Band is to be worn when sleeping by lung transplant patients for 4 weeks starting 8 weeks after transplant.
223679346|NCT04914247|DRUG|Selexipag|
223679347|NCT07149857|DRUG|Cilta-cel|Cilta-cel will be administered as intravenous infusion.
223679348|NCT07149857|DRUG|Cyclophosphamide|Cyclophosphamide will be administered as intravenous infusion.
223773441|NCT01482104|DRUG|MAL-PDT re-treatment|a schedule of 1 single treatment of Metvix(R)-Photodynamic therapy with re-treatment of non-complete responders by 3 months
224259638|NCT02761512|DRUG|CJ-12420 50 mg QD|CJ-12420 50 mg tablets will be orally administered, once daily, for up to 8 weeks. For subjects whose gastric ulcer is not endoscopically healed(S1 or S2 stage) at Week 4, subjects will receive additional 4 weeks treatment of CJ-12420 50 mg.
223679349|NCT07149857|DRUG|Induction therapy|Induction therapy consist of bortezomib, lenalidomide, and dexamethasone (VRd) or daratumumab, lenalidomide, and dexamethasone (DRd) or daratumumab, bortezomib, lenalidomide, and dexamethasone (DVRd), will will be administered.
224259639|NCT02761512|DRUG|CJ-12420 100 mg QD|CJ-12420 100 mg tablets will be orally administered, once daily, for up to 8 weeks. For subjects whose gastric ulcer is not endoscopically healed(S1 or S2 stage) at Week 4, subjects will receive additional 4 weeks treatment of CJ-12420 100 mg.
224259640|NCT02761512|DRUG|Lansoprazole 30 mg QD|Lansoprazole 30 mg capsule will be orally administered, once daily, for up to 8 weeks. For subjects whose gastric ulcer is not endoscopically healed(S1 or S2 stage) at Week 4, subjects will receive additional 4 weeks treatment of Lansoprazole 30 mg.
224259641|NCT05061108|BEHAVIORAL|PAL2|Community health worked based intervention to mitigate psychosocial and life circumstance barriers to optimize health promotion coupled with high blood pressure and lifestyle disease state education
224259642|NCT05625022|DRUG|Lianhua Qingke tablets|Lianhua Qingke tablets: 4 tablets once, three times daily
224259643|NCT02202486|OTHER|Brain MRI|Brain MRI with gadolinium contrast
224259644|NCT02433977|DIETARY_SUPPLEMENT|Conjugated Linolenic Acid|CLA is a polyunsaturated fatty acid Subjects will receive capsules for daily oral administration at the dose of 3 g/day
224259645|NCT02433977|DRUG|Sodium Nitrite|Subjects will receive capsules for daily oral administration at the dose of 20 mg (2 x 10 mg)
223679350|NCT07149857|DRUG|Fludarabine|Fludarabine will be administered as intravenous infusion.
224259646|NCT02433977|DRUG|Sodium Nitrate|Subjects will receive capsules for daily oral administration at the dose of 1g (2 x 500 mg)
223773442|NCT01482104|DRUG|usual MAL-PDT|schedule of 2 standard Metvix(R)- Photodynamic therapy treatment sessions 1 week apart.
223773443|NCT06230887|BEHAVIORAL|Building Spiritual Strength|Spiritually Integrated group intervention for moral injury
223773444|NCT06230887|BEHAVIORAL|Present Centered Group Therapy|Active control, manualized evidence-based coping skills intervention for PTSD
224259647|NCT04887480|DEVICE|Abthera™ Open Abdomen Negative Pressure Therapy Device System|Suction set at -125mmHg
224259648|NCT04887480|DRUG|Dianeal PD-2 with 2.5% Dextrose|800mL to 1000mL of Dianeal PD-2 into Abthera™ and dwell for 1 hour.
224259649|NCT03331289|DRUG|Placebo|Placebo will be administered to 20 subjects after a 3 hour tracer equilibration period
224259650|NCT03331289|DRUG|Exenatide|Exenatide will be administered to 20 subjects after a 3 hour tracer equilibration period
223679351|NCT07141394|DRUG|Medication for Addiction Treatment (MAT)|MAT includes medications for alcohol use disorder (MAUD) and medications for opioid use disorder (MAUD). It reduces substance use, increases SUD treatment engagement, enhances quality of life, and reduces overdoses.
223679352|NCT07141394|BEHAVIORAL|Cognitive Behavioral Therapy for Substance Use Disorders (CBT-SUD)|An evidence-based psychotherapy that uses cognitive behavioral therapy to further recovery goals across SUD diagnoses.
223679353|NCT07154901|DRUG|Opemalirsen (AZD2373)|Single, subcutaneous injection of AZD2373
223679356|NCT06092333|DRUG|VIR-2218 and peginterferon alfa-2a|(VIR-2218) administered as a lead-in followed by combination with peginterferon alfa-2a
224259651|NCT03331289|DRUG|Dapagliflozin|Dapagliflozin will be administered to 20 subjects after a 3 hour tracer equilibration period
224259652|NCT03331289|DRUG|Exenatide and Dapagliflozin|Exenatide and Dapagliflozin will be administered to 20 subjects after a 3 hour tracer equilibration period
223679364|NCT07162363|PROCEDURE|Minimally Invasive surgery (MIS)|Lobar (superficial) hematomas will be evacuated via a minimally invasive trans-sulcal parafascicular approach, whereas deep hematomas will be removed through a minimally invasive burr-hole approach with catheter placement to allow controlled clot dissolution using alteplase.
223679365|NCT07162363|DRUG|Deferoxamine|Deferoxamine will be administered as a continuous intravenous infusion at a dose of 32 mg/kg/day over 24 hours for a total of 3 consecutive days.
223679366|NCT07162363|OTHER|Standard Medical Care (SMD)|We will follow the American Heart Association and European Stroke Organization guidelines for the management of non-traumatic spontaneous intracerebral hemorrhage, ensuring a standardized approach to monitoring patients' airways, ventilation, intracranial pressure, sedation, and pharmacologic management of intracranial mass effect.
223679376|NCT07164989|BEHAVIORAL|Motivational Interviewing-Based Counseling|Motivational interviewing (MI) is a structured, patient-centered counseling technique that helps individuals explore and resolve ambivalence toward behavior change. In this study, MI sessions will be delivered by trained pediatric dental professionals during routine orthodontic visits. Each session will last approximately 10-15 minutes and will be guided by a standardized MI protocol, focusing on improving oral hygiene behavior and increasing personal motivation and responsibility for oral care among adolescent participants. Sessions will be conducted at multiple time points during the course of treatment.
223679377|NCT07164989|BEHAVIORAL|Standard Oral Health Education|Participants in this group will receive the conventional oral hygiene education typically provided in orthodontic clinics. This includes verbal instructions and printed educational materials on topics such as toothbrushing technique, flossing with braces, and the importance of maintaining oral hygiene during orthodontic treatment. Education will be delivered by pediatric dental staff during scheduled orthodontic appointments at the same time points as the intervention group (baseline, 1-month, and 6-month visits). No motivational interviewing techniques will be used. This approach reflects routine care and serves as the comparator for evaluating the added value of MI.
223679378|NCT07169318|OTHER|Placebo for VNT-101|Capsules will be size 00 and filled with microcrystalline cellulose
223679379|NCT07169318|DRUG|VNT-101|VNT-101 is an orally bioavailable, direct-acting antiviral with a novel mechanism of action - inhibiting oligomerization of the influenza nucleoprotein (NP) and thereby inhibiting viral ribonucleic acid (RNA) synthesis.
223679382|NCT07164443|BIOLOGICAL|Pasritamig|Pasritamig will be administrated through IV infusion.
223679383|NCT07164443|OTHER|Placebo|Placebo will be administrated through IV infusion.
223679384|NCT07164443|DRUG|Best Supportive Care (BSC)|BSC will be administered as per physician.
223773445|NCT06094348|PROCEDURE|Endonasal osteotomy|Patients will undergo median-oblique and lateral osteotomy, with conventional 2 mm guarded, straight osteotome.
224259653|NCT05307432|BEHAVIORAL|SPI+ Delivered by ED Staff|ED staff will deliver SPI+ (Safety Planning Intervention plus follow-up phone calls) to patients at risk for suicide in the ED who are not admitted to an inpatient unit.
224259654|NCT05307432|BEHAVIORAL|SPI+ Delivered by SPCC Clinicians|The Suicide Prevention Consultation Center (SPCC) will be located external to the Emergency Department (ED). ED staff will be able to refer patients at risk for suicide to the SPCC. Licensed and credentialed mental health clinicians will deliver SPI+ (Safety Planning Intervention plus follow-up phone calls) via telehealth to patients at risk for suicide in the ED who are not admitted to an inpatient unit.
224259655|NCT06943924|PROCEDURE|Frailty assessment|This study aims to investigate the accuracy and clinical utility of these scoring systems in predicting mortality in individuals aged 65 and older undergoing emergency surgery.
224259656|NCT03011476|DRUG|Donepezil|"1. Start with 5 mg/day for 4 weeks~2. Increased to 10 mg/day for 8 weeks"
224259657|NCT03011476|DRUG|Placebos|"1. Start with 5 mg/day for 4 weeks~2. Increased to 10 mg/day for 8 weeks"
224259658|NCT06939803|OTHER|Risk model-driven CDS|"The CDS intervention will use an automated risk model called VTE-AI to add EHR-based prompts in the form of alerts targeting those encounters on which 1) VTE-AI risk is above 5% predicted risk (found to be high risk in prior analyses), 2) no active DVT prophylaxis pharmacologic order is present, 3) no contraindication has been documented in the current admission"
224259659|NCT00712777|DRUG|Brimonidine 0.2 %|Brimonidine 0.2 % (Alphagan, Irvine, CA, USA), dose: 1 drop per eye
223679396|NCT07174310|DRUG|Prasinezumab|Participants will receive Prasinezumab as an IV Infusion as per the schedule mentioned in the protocol.
223679397|NCT07174310|DRUG|Placebo|Participants will receive Placebo as an IV Infusion per the schedule mentioned in the protocol
223679398|NCT07169578|DRUG|Trontinemab|Participants will receive IV trontinemab.
223679399|NCT07169578|OTHER|Placebo|Participants will receive IV placebo.
223679400|NCT07174596|DEVICE|B+L Infuse spherical soft contact lenses|Test lens
223679401|NCT07174596|DEVICE|J&J ACUVUE OASYS 1-Day spherical soft contact lenses|Control lens
223679409|NCT07182591|DRUG|DS5361b|"Dose Escalation Part: DS5361b will be administered at escalating doses to determine the RDE.~Dose Expansion Part: DS5361b will be administered at RDE."
223679410|NCT07182591|DRUG|Pembrolizumab|"Dose Escalation Part: Pembrolizumab will be administered at a standard dose.~Dose Expansion Part: Pembrolizumab will be administered at a standard dose."
223679411|NCT07183709|BIOLOGICAL|PepGNP-COVID19|A synthetic T cell priming setpoint-modifying SARS-CoV-2 vaccine composed of ultrasmall carbohydrate-coated gold nanoparticles carrying covalently bound MHC class I-binding SARS-CoV-2 peptides.
223679412|NCT07183709|OTHER|Sterile Water for Injection|A sterile, nonpyrogenic preparation of water for injection which contains no bacteriostat, antimicrobial agent or added buffer and is supplied only in single-dose containers to dilute or dissolve drugs for injection
223679413|NCT07185425|DEVICE|NeuroCuple|Device around the abdomen over c-section bandages in the PACU
223679414|NCT07185425|DEVICE|Sham|Device around the abdomen over c-section bandages in the PACU
223679415|NCT07185945|DRUG|Zanzalintinib|60 mg orally once daily
224259660|NCT06948773|DEVICE|Helix Surgical System|A handheld device to viscodilate up to 360 degrees of Schlemm's canal and collector channels that also enables intracanalicular scaffolding procedure to restore the aqueous outflow system of a glaucomatous eye.
224259661|NCT06954870|OTHER|Ozone therapy|As detailed in the research arms, major ozone application and local ozone application will be performed.
224259662|NCT06517056|DEVICE|Emovi Knee Kinesiography|All participants will receive a KneeKG exam. This device will capture three-dimensional knee kinematics for a participant's knee, using the KneeKG system. Therapists will use these reports and suggested exercises to guide their care for participants in the Intervention group.
224259663|NCT05261802|OTHER|Descriptive Intervention|A trained facilitator, supported by Career and Family Coaches, leads every HMRE parenting workshop for adults via multiple delivery models: in recurring weekly workshops (2 hours each workshop for 7 weeks) and intensive weekend retreats (totaling 16 hours). Additionally, AVANCE offers the weekly workshops either virtually via Zoom or in-person. All workshop models were offered to program participants who were able to choose whether the weekly (either in-person or virtually) or the weekend (in-person only) format worked best for them. Curriculum content is consistent across all delivery methods and target hours for all participants is 14 hours.
223679416|NCT03218488|DRUG|Ustekinumab|Participants will not receive any intervention as part of this study. Participants with moderate to severe plaque psoriasis who are initiating treatment with ustekinumab in clinical practice (patients should either start therapy with ustekinumab within 2 months after the first assessment in the study or have started therapy with ustekinumab in the 12-week period before the first assessment in the study for the treatment of psoriasis) will be observed for the long-term safety of ustekinumab and the long-term effects of ustekinumab on growth and development.
224259664|NCT03114891|DEVICE|Transcranial Magnetic Stimulation (TMS)|Transcranial Magnetic Stimulation (TMS) is a non-invasive form of brain stimulation. TMS can influence activity in various brain regions, and it allows researchers to test or modify brain circuit communication. In this study, we used administered theta burst TMS stimulation.
224259665|NCT03114891|BEHAVIORAL|Task|Subject completes a working memory task (Letter Nback) between the two rounds of theta burst stimulation.
224259666|NCT03114891|PROCEDURE|fMRI-guided TMS target|Administration of TMS to individualized targeting from the participant's fMRI scans. Our preliminary data suggest this target region is particularly effective at influencing the sgACC.
224259667|NCT05117489|DRUG|Miricorilant 150 mg|Miricorilant 150 mg for oral dosing
224259668|NCT05117489|DRUG|Miricorilant 100 mg|Miricorilant 100 mg for oral dosing
224259669|NCT05117489|DRUG|Miricorilant 50 mg|Miricorilant 50 mg for oral dosing
224259670|NCT05117489|DRUG|Miricorilant 10 mg|Miricorilant 10 mg for oral dosing.
224259671|NCT01199562|PROCEDURE|infection prophylaxis and management|Undergo infection prophylaxis and management
224259672|NCT01199562|OTHER|laboratory biomarker analysis|Correlative studies
224259673|NCT01199562|OTHER|flow cytometry|Correlative studies
224259674|NCT01199562|GENETIC|DNA analysis|Correlative studies
224259675|NCT01199562|GENETIC|RNA analysis|Correlative studies
224259676|NCT01199562|PROCEDURE|management of therapy complications|undergo infection prophylaxis and management
224259677|NCT01199562|DRUG|ganciclovir|Given IV
224259678|NCT01199562|DRUG|valganciclovir|Given orally
224259679|NCT01199562|DRUG|foscarnet sodium|Given orally
224259680|NCT01199562|PROCEDURE|antiviral therapy|undergo infection prophylaxis and management
223679420|NCT07190794|DEVICE|OverStitch™ or OverStitch NXT™|The OverStitch™ or OverStitch NXT™ Endoscopic Suturing System was used as part of each patient's ESG procedure within the routine clinical practice.
223679421|NCT07190794|BEHAVIORAL|Lifestyle Modification|Patients participated in a lifestyle modification program for weight loss management.
223679424|NCT07191548|DEVICE|Irreversible Electroporation|"Irreversible electroporation (IRE) is a procedure which involves the passage of short intense electrical pulses between probes to destabilize cell membranes by creating nanopores which leads to cell destabilisation and cell death.~IRE can be used to selectively damage cancerous cells whilst sparing adjacent supporting connective tissue in vessels and bile ducts allowing a more targeted treatment compared to other types of ablation. IRE also avoids the heat-sink phenomenon which compromises the effectiveness of thermal ablation and possibly reduces the risks of biliary injury."
223679425|NCT07194070|OTHER|Standard of Care|No study treatment will be administered as part of this study. Participants will receive standard of care therapy as per local clinical practice.
224259681|NCT01199562|GENETIC|polymerase chain reaction|Correlative studies
224259682|NCT01199562|GENETIC|protein expression analysis|Correlative studies
224259683|NCT05432466|DRUG|ACER-002 (celiprolol) 200 mg BID|ACER-002 (celiprolol) 200 mg BID
224259684|NCT05432466|DRUG|Placebo BID|placebo for ACER-002
224259685|NCT06703840|DRUG|LIB-01|LIB-01 oral suspension
224259686|NCT06703840|DRUG|LIB-01 Placebo|LIB-01 Placebo oral suspension
224259687|NCT06437119|DIETARY_SUPPLEMENT|Compound plant nutrients|The compound plant nutrients include extracts of licorice, sophora, wild cherry berry, dendrobium officinale, and pomegranate.
224259688|NCT06437119|DIETARY_SUPPLEMENT|placebo|A placebo with an indistinguishable appearance and color.
224259689|NCT02881541|PROCEDURE|Enhanced support|
224259690|NCT02881541|PROCEDURE|Usual care|
224259691|NCT05665361|DRUG|Sasanlimab|Sasanlimab will be given (SC on day 1 of every cycle, starting on day 1 (+/- 5 days) of cycle 2).
224259692|NCT05665361|DRUG|Palbocicilib|Palbociclib will be given PO for 21 days of every 28-day cycle, starting on day 1 of cycle 1.
224259693|NCT04480086|DRUG|Mivebresib|Tablet: Oral
224259694|NCT04480086|DRUG|Navitoclax|Tablet; Oral
224259695|NCT04480086|DRUG|Ruxolitinib|Tablet; Oral
224259696|NCT00772603|DRUG|Placebo|Non-active tablet identical to study drug tablets
224259697|NCT00772603|DRUG|2400mg SPN-804|tablets containing 600mg OXC XR, identical to non-active tablets
224259698|NCT00772603|DRUG|1200mg SPN-804|two active tablets and two non-active tablets, all identical
224259699|NCT05452785|DRUG|DFD-29 (Minocycline) Fasting|In each study period, a single 40 mg dose of DFD-29 Capsules will be administered orally with approximately 240 mL of water, in the morning, following a 10-hour overnight fast.
224259700|NCT05452785|DRUG|DFD-29 (Minocycline) Fed|In each study period, a single 40 mg dose of DFD-29 Capsules will be administered orally with approximately 240 mL of water, in the morning, following a 10-hour overnight fast and 30 minutes after the start of a high-fat, high-calorie breakfast.
224259701|NCT05452785|DRUG|Solodyn (Minocycline) Fasting|In each study period, a single 105 mg dose of SOLODYN® Tablets will be administered orally with approximately 240 mL of water, in the morning, following a 10-hour overnight fast.
224259702|NCT02882776|DIETARY_SUPPLEMENT|Ginger drink|Ginger powder dissolved in water
224259703|NCT06073691|BEHAVIORAL|Exercise intervention|Practice systematic and regular aerobic physical exercise (walking and running).
224259704|NCT06073691|OTHER|Placebo|Placebo
224259705|NCT00836004|DRUG|Clindamycin 300 mg capsule|1 x 300 mg
224259706|NCT00836004|DRUG|Cleocin HCl 300 mg capsules|1 x 300 mg
223679428|NCT07192731|DEVICE|Irreversible Electroporation|"Irreversible electroporation (IRE) is a procedure which involves the passage of short intense electrical pulses between probes to destabilize cell membranes by creating nanopores which leads to cell destabilisation and cell death.~IRE can be used to selectively damage cancerous cells whilst sparing adjacent supporting connective tissue in vessels and bile ducts allowing a more targeted treatment compared to other types of ablation. IRE also avoids the heat-sink phenomenon which compromises the effectiveness of thermal ablation and possibly reduces the risks of biliary injury."
224259707|NCT04548635|DEVICE|VR-PAT|Smartphone-based Virtual Reality Pain Alleviation Tool (VR-PAT) via a lightweight, mobile VR headset
224259708|NCT02138539|OTHER|Herbal depigmenting agent (Epionce)|A two product herbal pigmentation reducing regimen is applied twice a day to either the left or right side of the face for a duration of 4 months.
223679431|NCT07192432|GENETIC|Dose Level 1, VNX-202|Adeno-associated viral vector encoding the CD3/HER2 Bi-Specific T-Cell Engager (AAV.CD3/HER2), Single IV Infusion
223679432|NCT07192432|GENETIC|Dose Level 2, VNX-202|Adeno-associated viral vector encoding the CD3/HER2 Bi-Specific T-Cell Engager (AAV.CD3/HER2), Single IV Infusion
223773446|NCT06094348|DEVICE|Piezo assisted osteotomy|Piezo is a system for cutting bone with micrometric ultrasonic piezoelectric vibrations, with varying frequency and cutting energy. The device consists of a platform with a powerful piezoelectric hand piece and employs a functional frequency between 25-29 kHz. The device is fitted with a cooling irrigation system with a 0-60 cc/min variable sterile solution flow. Specific inserts and scalpels act in a linear vibration pattern, with a spatial range between 60 and 210 microns, moved by an ultrasonic power that exceeds 5 watts, reaching up to 16 watts.
224259709|NCT02138539|DRUG|Hydroquinone|Hydroquinone 4% is applied twice a day to either the left or right side of the face for a duration of 4 months.
223679433|NCT07192432|GENETIC|Dose Level 3, VNX-202|Adeno-associated viral vector encoding the CD3/HER2 Bi-Specific T-Cell Engager (AAV.CD3/HER2), Single IV Infusion
223679434|NCT07192432|GENETIC|Dose Level 4, VNX-202|Adeno-associated viral vector encoding the CD3/HER2 Bi-Specific T-Cell Engager (AAV.CD3/HER2), Single IV Infusion
224259710|NCT01004562|OTHER|informational intervention|
224259711|NCT01056484|BEHAVIORAL|Mindfulness Based Relapse Prevention for Alcohol Dependence|"All subjects receive outpatient standard of care (SOC) therapy for alcohol dependence. Experimental subjects also receive the Mindfulness Meditation Relapse Prevention ('meditation') intervention. The intervention is an extension of existing meditation-based therapies for stress, relapse prevention in addictive disorders, and depression. It has been patterned after Mindfulness Based Relapse Prevention and tailored to the specific needs of alcoholics. Its curriculum includes both meditation and traditional cognitive therapy relapse prevention components. The intervention consists of an 8-week, manualized meditation course (2 hours/week group sessions) guided by trained instructors. In addition, experimental subjects are asked to meditate at-home (30 min/day, 6 days/week) during the study."
224259712|NCT01056484|OTHER|"Wait-list control"|'Standard of care' (SOC) outpatient therapy for alcohol dependence is provided to all subjects through their outpatient treatment centers and as recommended by their regular providers. Subjects in the control group receive SOC only. Subjects in the experimental arm will receive the study meditation intervention in addition to SOC.
224259713|NCT02435160|BIOLOGICAL|Fecal Microbiota Transplantation|
224259714|NCT00033917|DRUG|indomethacin|an anti-inflammatory drug
224259715|NCT00033917|DRUG|placebo|saline
224259716|NCT04870320|BEHAVIORAL|Endeavor: Computer-Based Cognitive Stimulation Intervention|Endeavor application will be utilized by participant on iPad
224259717|NCT04870320|BEHAVIORAL|Words!: Computer-Based Cognitive Stimulation Intervention|Words! application will be utilized by participant on iPad
224322865|NCT06710964|OTHER|Blood Draw|Five milliliters of blood will be drawn before and after study interventions for the quantification of plasma oxytocin concentrations by certified phlebotomists. Samples will be collected into chilled Ethylenediaminetetraacetic Acid (EDTA) tubes, inverted ten times to mix with anticoagulants, and centrifuged at 1600g for 15 minutes at 4˚C. Cleared plasma will be aliquoted into cryotubes and stored at -80˚C. Consistent with expert recommendations, oxytocin levels will be obtained from the samples diluted 1:4 (i.e., oxytocin can be discarded through plasma proteins when incorporating an extraction step before conducting the enzyme-linked immunosorbent assay \[ELISA\]). Second, to buffer against contrasting concerns, an aliquot of each sample will be analyzed for test-retest purposes. Oxytocin concentrations will be measured using a validated commercially available and sensitive ELISA neurophysin kit (Abcam).
223679438|NCT07196072|BEHAVIORAL|MiPAL|MiPAL participants meet with a coach to co-develop a self-directed yoga practice based on individual preferences and limitations.
224259718|NCT04870320|OTHER|Quality of Life (QOL) Questionnaires|Standardized QOL questionnaire will be administered at each study visit
224259719|NCT02185144|BEHAVIORAL|PATH For Triples|In addition to providing weekly home-health nursing focused psycho-education aimed at insuring adherence to drug treatment regimen, the nurse health navigator model provided in PFT combines continuous and integrated care across mental health, substance abuse, and infectious disease provides. The nurses will accompany the patient to appointments, or make collateral contacts with other care providers. Often the nurses serve as intermediaries and ensure accurate and timely information exchange. Their specialized training also allows them to monitor side effects of medications and advocate for the patients with their various specialty providers. A treatment cascade approach is utilized when the patient is non-adherent to treatment allowing for increased patient monitoring.
224259720|NCT02185144|BEHAVIORAL|Treatment as Usual|Control subjects receive enhanced TAU care which will consist of the opportunity to complete the full complement of baseline instruments that will then be shared with their outpatient mental health case manager to facilitate linkage with needed MH, SA, and ID care
223679439|NCT07196722|DRUG|Icotrokinra|Icotrokinra will be administered orally, daily.
223679440|NCT07196722|DRUG|Placebo|Matching placebo will be administered orally, daily.
223773447|NCT06445842|OTHER|Exercise|The protocol involves a 10-minute warm-up and cool-down session, followed by two sets of high-intensity circuit training exercises (bench press, squats, overhead press, calf raising, barbell row, deadlifts) that last 12 minutes each (6 stations×2sets). There will be a 3-minute break between the exercise sets. The heart rate required during the exercise will be between 70-90% of their maximum capacity and a pre-scale rate of 7.5. The intensity of the exercise will be progressive each two weeks, commencing at 50% of their one rep max and increasing to 80% in their last week. During the initial phase, participants will be required to complete eight reps for each exercise. We will encourage them to increase their intensity level every two weeks.
224259721|NCT01421901|DRUG|Ertapenem|Ertapenem i.v,m 1g, once a day, 3 days
224259722|NCT01421901|PROCEDURE|appendectomy|
224259723|NCT04403672|DEVICE|performance evaluation study of RealDetect RT-PCR Kit for COVID-19 detection|"IEDCR uses many different kits for COVID-19 detection. These kits include, (1) A\*Star Fortitute Kit 2 for COVID-19 detection (Singapure), (2) Sansure Biotec Limited (China), (3) ModularDx Kit (TIB Molecular Biology, Germany, and (4) DaAn Kit (China). Among these 2 kits, A\*Star Fortitude Kit 2 has been known as the best kit in IEDCR depending on its performance because it rarely generates false positive or false negative results.~A\*Star Fortitude Kit 2 is used for confirmation of any discordant results for other kits in IEDCR. That is, IEDCR uses A\*Star Fortitude Kit for COVID detection as the Gold Standard. In our case, this is the main reason for the selection of this kit in order to compare the performances of RealDetect™ COVID-19 RT-PCR kit."
224322866|NCT06168799|DRUG|Ilofotase alfa|After dilution of the concentrate, the investigational medicinal product will be administered by intravenous infusion for 1 hour at the same day before and after the surgery (Day 1)
223679467|NCT07196748|DRUG|Icotrokinra|Icotrokinra tablet will be administered orally.
224259724|NCT04018404|OTHER|FRI CLINICAL PROGRAM|University Le Bonheur Pediatric Specialists and Le Bonheur Community Health and Well-Being, Maternal Child Department, have started the Family Resilience Initiative (FRI) in the ULPS General Pediatrics Clinic. This clinical program screens children 9 months to less than five years of age for ACES and SDH at the time of presentation for well child checks. There are two outreach coordinators who screen and enroll children attending clinic for a well-child check during morning clinics 3 to 4 days per week. Children with positive screens for ACES and/or SDH, and their adult caregivers, receive community resource referrals with warm handoffs to vetted organizations. In addition, if indicated, psychological services are offered for children based upon the presence of one or more of ACEs and current health and behavioral problems.
224259725|NCT01686386|DRUG|Bendamustine|Phase I: dose escalation of Bendamustine Phase II: Dexamethasone will be given in combination with the MTD of Bendamustine and Lenalidomide in cycles lasting 28 days.
224259726|NCT01686386|DRUG|Lenalidomide|Phase I: dose escalation of Lenalidomide Phase II: Dexamethasone will be given in combination with the Maximum Tolerated Dose (MTD) of Bendamustine and Lenalidomide in cycles lasting 28 days.
224322867|NCT06168799|DRUG|Placebo|After dilution of the concentrate, the investigational medicinal product will be administered by intravenous infusion for 1 hour at the same day before and after the surgery (Day 1)
224322868|NCT05039801|BIOLOGICAL|Bevacizumab|Given IV
223679468|NCT07196748|DRUG|Placebo|Placebo tablet will be administered orally.
224322869|NCT05039801|DRUG|Glutaminase-1 Inhibitor IACS-6274|Given by PO
224322870|NCT05039801|DRUG|Paclitaxel|Given by IV (vein)
224322871|NCT05039801|DRUG|Capivasertib|Given by PO
224322872|NCT04139902|DRUG|Dostarlimab (TSR-042) (singly)|"If patients are randomized to Dostarlimab (TSR-042) alone, during the Pre-operative Phase, 500mg will be administered through an IV over 30 minutes, on Cycle 1 Day 1, and then again on Cycle 2 Day 1.~Surgery will occur 1-4 weeks after completion of the pre-operative phase.~During the Post-operative phase, Dostarlimab (TSR-042) 500mg will be administered through an IV over 30 minutes for 4 cycles every 3 weeks (Cycles 3-4), and then 1000mg will be administered through an IV over 30 minutes every 6 weeks (Cycles 5-10) for approximately 48 weeks."
223679471|NCT07201519|DEVICE|Hepatic Artery Infusion Pump (HAIP)|HAIP will be filled with mixture of FUDR + Dexamethasone, Heparin \& Saline for a 14 day infusion of drugs, followed by a 14 day infusion of Heparin+Saline.
223679472|NCT07201519|PROCEDURE|Standard Treatment|systemic therapy per standard-of-care and institutional standards; visits every two weeks and standard manual HAI dose calculation
223679473|NCT07201519|PROCEDURE|Community Treatment|systemic therapy fill by home infusion based on TO orders. In person visit with CO for systemic chemotherapy with dose recommendations from TO. Locally obtained testing with telehealth visits with TO team.
223679474|NCT07201519|DRUG|Systemic Chemotherapy Standard of Care|"Dosing of systemic therapy will be according to established routine practice guidelines. Patients with colon cancer will receive systemic chemotherapy that will consist of either FOLFIRI, FOLFOX, or Irinotecan/oxaliplatin at the discretion of the oncologist.~Patients with intrahepatic cholangiocarcinoma will receive Gemcitabine/Oxaliplatin or Gemcitabine alone, at the discretion of the oncologist."
223679475|NCT07201519|DRUG|Standard Of Care targeting driver mutations|Per current SOC guidelines, EGFR inhibitors targeting driver mutations (e.g., RAS wild-type) will be administered as appropriate (FDA-approved agents such as Panitumumab for EGFR)
223679478|NCT07197892|OTHER|CIRCA Texting Platform|Two-way texting platform that uses artificial intelligence to match patient texts to clinician-vetted responses and send educational content
223679482|NCT07207564|OTHER|Non-Interventional Study|Non-interventional study
223773448|NCT06445842|OTHER|No exercise|This group will need to maintain their sedentary lifestyle without changing their activity levels or diet
224322873|NCT04139902|DRUG|Dostarlimab (TSR-042) and TSR-022 (combination)|"If patients are randomized to the combination, Dostarlimab (TSR-042) and TSR-022, during the Pre-operative Phase, Dostarlimab (TSR-042) 500mg and TSR-022 300mg will be administered through an IV over 30 minutes on Cycle 1 Day 1 and then again on Cycle 2 Day 1.~Surgery will occur 1-4 weeks after completion of the pre-operative phase.~During the Post-operative Phase, Dostarlimab (TSR-042) 500mg will be administered through an IV over 30 minutes for 4 cycles every 3 weeks (Cycles 3-4) and then 1000mg will be administered through an IV over 30 minutes every 6 weeks for 6 doses (Cycles 5-10) for approximately 48 weeks."
224322874|NCT04206553|DRUG|dupilumab|Loading dose administered subcutaneous (SC), followed by SC once every 2 weeks (Q2W) dosing.
224322875|NCT04206553|DRUG|Matching Placebo|Matching dupilumab without active substance
224322876|NCT04206553|DRUG|Oral corticosteroids (OCS)|Prednisone or prednisolone per standard of care to obtain control of disease activity.
224322877|NCT02685605|PROCEDURE|Standard surgery|
224322878|NCT02685605|RADIATION|Intraoperative radiotherapy|Dose to applicator surface: 20-30 Gy; Carl Zeiss INTRABEAM System. IORT with a surface dose of 30 Gy is recommended.Should the proximity to any risk structure not allow to apply 30 Gy, a dose reduction by up to 10 Gy (resulting in a surface dose of 20 Gy) is allowed.
224322879|NCT02685605|RADIATION|Radiochemotherapy|EBRT to 60 Gy plus 75 mg/m2/d temozolomide
224322880|NCT02685605|DRUG|Temozolomide|Adjuvant chemotherapy with 150-200 mg/m2/d temozolomide per cycle (5/28 days).
224322881|NCT06173115|DEVICE|Perclose Proglide system|"Preclosure technique has emerged as a common vascular closure approach using a Perclose Proglide system (Abbott Vascular), in which sutures are deployed before dilating the arterial access site."
224322882|NCT00588068|OTHER|Tumor and Marrow Markers|Tumor and Marrow Markers
224322883|NCT06182124|BIOLOGICAL|Multivalent Pneumococcal Vaccine - Formulation 1|Multivalent pneumococcal conjugate vaccine. This is a possible candidate for continuation in Phase 2 (Stages 2, 3, and 4).
224322884|NCT06182124|BIOLOGICAL|Multivalent Pneumococcal Vaccine - Formulation 2|Multivalent pneumococcal conjugate vaccine. This is a possible candidate for continuation in Phase 2 (Stages 2, 3, and 4).
223679486|NCT07210619|DRUG|d-MAPPS|Ophthalmic Solution for oGVHD
223679489|NCT07209436|PROCEDURE|Paravertebral block (single injection)|Paravertebral block at preop
223679490|NCT07209436|PROCEDURE|Pectoral block|Pectoral block at preop
223679491|NCT07210255|DEVICE|SAINT Neuromodulation System|SAINT will be delivered via a MagPro X100 edition (MagVenture, Skovlunde, Denmark) TMS device equipped with a Cool-B65 A/P coil. The stimulation paradigm consists of 10 daily sessions (50 total sessions over 5 days) of SAINT stimulation (3-pulse 50-Hz bursts at 5-Hz for 2-second trains, with trains every 10 seconds), delivered with 50-minute inter-session intervals (10-minute sessions, 50-minutes in between sessions). Stimulation will be administered at 90% of the participant's resting motor threshold, with depth correction applied to adjust for the measured distance between the scalp and cortical surface. The stimulation target, the L-DLPFC, will be identified and localized by the study investigator using the Localite neuronavigation system.
224322885|NCT06182124|BIOLOGICAL|20-valent pneumococcal conjugate vaccine (20vPnC)|20-valent pneumococcal conjugate vaccine (20vPnC)
224322886|NCT06182124|BIOLOGICAL|Licensed pneumococcal comparator vaccine|A licensed pneumococcal comparator vaccine
224322887|NCT06182124|BIOLOGICAL|Multivalent Pneumococcal Vaccine - Formulation 3|Multivalent pneumococcal conjugate vaccine
224322888|NCT06182124|BIOLOGICAL|Multivalent Pneumococcal Vaccine - Formulation 4|Multivalent pneumococcal conjugate vaccine
223679492|NCT07210255|DEVICE|Sham SAINT Stimulation|Sham stimulation will be delivered using the MagVenture MagPro X100 TMS system with the Cool-B65 A/P coil and targeted to the L-DLPFC. The stimulation paradigm will be identical to the active SAINT stimulation with the exception that active stimulation will not be delivered.
223679493|NCT07212465|DEVICE|Active Brainsway H7-Coil Deep TMS System|Deep Transcranial Magnetic Stimulation (dTMS) is a new form of TMS which allows direct stimulation of deeper neuronal pathways than the standard TMS. The H-coil is a novel dTMS coil designed to allow deeper brain stimulation without a significant increase of electric fields induced in superficial cortical regions. dTMS will be administered 6-8 times a day for 5 consecutive days.
223679494|NCT07212465|DEVICE|Sham Brainsway H1-Coil Deep TMS System|In addition to the active H7-coil, a sham coil is included in the H1-coil helmet. The sham treatment will be administered 6-8 times a day for 5 consecutive days.
223773449|NCT05811247|DRUG|AD109|Oral administration at bedtime.
223773450|NCT05811247|DRUG|Placebo|Oral administration at bedtime.
223773451|NCT03983473|OTHER|Microbiota Sequencing|virome, bacteriome, fungome NGS sequencing
224322889|NCT03394066|DEVICE|TMS (MagVenture MagPro 100 with MagOption)|TMS will be applied using the MagVenture MagPro 100 with MagOption (MagVenture Inc, Alpharetta, GA) stimulator with a figure-of-eight TMS coil. An MRI compatible version of the figure-of-eight coil will be used inside the MRI scanner with an appropriate TMS coil holder.
224322890|NCT02180711|DRUG|acalabrutinib|
224322891|NCT02180711|DRUG|rituximab (IV)|
224322892|NCT02180711|DRUG|Lenalidomide|
224322893|NCT06347796|PROCEDURE|Conventional Surgery|Conventional surgery is surgical drainage through burr holes or craniotomy.
224322894|NCT06347796|DEVICE|Middle Meningeal Artery Embolization (MMAE)|Particle embolization of the middle meningeal artery with micron variants of the Embosphere Microspheres or CONTOUR Embolization Particles device.
224322895|NCT05388006|DRUG|Acalabrutinib|Given PO
224322896|NCT05388006|BIOLOGICAL|Durvalumab|Given IV
224322897|NCT05388006|DRUG|Venetoclax|Given PO
224259727|NCT01686386|DRUG|Dexamethasone|Phase I and Phase II Dexamethasone fixed dose 40 mg/die
224322898|NCT05388006|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
224322899|NCT05388006|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
224322900|NCT05388006|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
224259728|NCT00656786|DRUG|Menadione Topical Lotion|Menadione Lotion will be applied topically twice a day; beginning when the rash appears during EGFRi therapy.
224259729|NCT00656786|DRUG|Menadione Topical Lotion|Menadione Lotion will be applied topically twice a day, starting 1 day before EGFRi therapy.
224259730|NCT00598052|DRUG|Escitalopram|10mg/day
224322901|NCT05388006|PROCEDURE|Positron Emission Tomography (PET)|Undergo PET/CT
224259731|NCT04066088|OTHER|Placebo|Placebo will be administered same times as GXR
224259732|NCT04066088|DRUG|Guanfacine extended release (GXR)|The starting dose for all subjects will be 1 mg per day. If the medication is well-tolerated, the dose can be raised to 2 mg until day 28 and increased to 3mg for the remaining 4 weeks in the trial. The dose schedule will not be fixed; the treating clinician can delay a planned increase or lower the dose to manage adverse effects. At week 8, the study will be unblinded and subjects will continue treatment for 8 more weeks.
224259733|NCT06366815|OTHER|Different Phenotypes of non ambulant patients with Duchenne Muscular Dystrophy|clinical and functional data collection of non ambulant patients with Duchenne muscular dystrophy
224259734|NCT00310271|BIOLOGICAL|pPJV7630 with pPJV2012 administered by PMED|
224322902|NCT05388006|PROCEDURE|Computed Tomography|Undergo PET/CT or CT
224259735|NCT01441297|DRUG|BIBF 1120|BIBF 1120 200mg bid, PO, daily until PD
224322903|NCT05866679|DRUG|Hyperpolarized 13-C-pyruvate|Given by PO
224322904|NCT01374919|DRUG|ferumoxytol|IV administration of 1020 mg of ferumoxytol in 15 minutes
224322905|NCT05405712|BEHAVIORAL|Mobile Phone App|App-based peer support program, used in conjunction with standard outpatient treatment
224322906|NCT06195072|DRUG|Amlitelimab|"IP will be administered subcutaneously by the Investigator or designee as follows:~* Amlitelimab or~* Matching placebo"
223679495|NCT07212504|DEVICE|Active Brainsway H7-Coil Deep TMS System|Deep Transcranial Magnetic Stimulation (dTMS) is a new form of TMS which allows direct stimulation of deeper neuronal pathways than the standard TMS. The H-coil is a novel dTMS coil designed to allow deeper brain stimulation without a significant increase of electric fields induced in superficial cortical regions. dTMS will be administered 6-8 times a day for 2-5 consecutive days.
223679496|NCT07212504|DEVICE|Sham Brainsway H1-Coil Deep TMS System|In addition to the active H7-coil, a sham coil is included in the H1-coil helmet.The sham treatment will be administered using the H1-coil helmet 6-8 times a day for 2-5 consecutive days.
223773452|NCT04874506|DRUG|MBM-02|Study drug will be administered orally using the capsule formulation (200 mg). The study drug will be administered 7 days a week for the entire treatment period.
223773453|NCT00898976|OTHER|immunohistochemistry staining method|
224322907|NCT06195072|DRUG|BI 1015550 (Nerandomilast)|Study participants will take the active investigational product BI 1015550 (Nerandomilast) or matching placebo provided as film-coated tablets, administered orally BID.
224322908|NCT06195072|DRUG|Placebo|see Experimental Arm intervention description
224322909|NCT03612531|PROCEDURE|Manual Therapy|Receive manual therapy
224322910|NCT06206408|DRUG|Fezolinetant|oral
223773454|NCT00898976|OTHER|laboratory biomarker analysis|
223773455|NCT00653354|DRUG|valdecoxib|valdecoxib 40 mg tablet by mouth within 6 hours of surgery followed by valdecoxib 20 mg tablet by mouth 1 to 12 hours after the first dose
223773456|NCT00653354|DRUG|valdecoxib/placebo|valdecoxib 40 mg tablet by mouth within 6 hours of surgery followed by placebo 1 to 12 hours after the first dose
223773457|NCT00653354|DRUG|placebo|placebo within 6 hours of surgery followed by placebo 1 to 12 hours after the first dose
224259736|NCT03720691|DEVICE|Real rTMS Supplementary motor area|There will be a series of four rTMS blocks separated by 10 minutes. Each block will consist of 15 to 25 pulse trains of 1-second duration at 25 Hz, with an intertrain interval of 10 seconds.
224259737|NCT03720691|DEVICE|Sham rTMS Supplementary motor area|There will be no real brain stimulation in Sham rTMS, and participant will be blinded.
224259738|NCT00446966|DRUG|Omega Three Polyunsaturated fatty acids|2 grams orally twice daily pre-operatively and 2 grams orally daily after until primary endpoint or 14 days.
224259739|NCT06501222|DEVICE|Remote ischemic conditioning|RIC is a non-invasive therapy that performed by an electric auto-control device with cuff placed on arm. RIC procedure during which bilateral arm cuffs are inflated to a pressure of 200mmHg for five cycles of 5 min followed by 5 min of relaxation of the cuffs.
224259740|NCT00376493|DRUG|metronidazole and doxycycline|use of metronidazole 500mg/day and doxycycline 200mg/day up to 10 days
224322911|NCT06206408|DRUG|Placebo|oral
224322912|NCT04144790|DIETARY_SUPPLEMENT|ferrous sulfate|Although established guidelines do not currently exist for iron supplementation for children, studies have demonstrated effectiveness of a 3-month treatment regimen of 5mg/kg per day of orally-administered ferrous sulfate in reducing PLMS and subjective RLS symptoms and in increasing serum ferritin levels. Ferrous sulfate 80 mg/day resulted in improvement of ADHD symptoms in iron-deficient children.
224322913|NCT05920161|BEHAVIORAL|Socially Evaluated Cold Pressor Test|The SECPT is a brief validated laboratory-based stress induction containing both physical and social elements
224322914|NCT05920161|BEHAVIORAL|Control|This is matched to the SECPT but with warm instead of cold water
224322915|NCT05456243|BIOLOGICAL|Low dose adipose tissue derived mesenchymal stromal cells (A-MSC)|Single intra-arterial infusion of 1 x 10\^5 cells/kg
224322916|NCT05456243|BIOLOGICAL|High dose adipose tissue derived mesenchymal stromal cells (A-MSC)|Single intra-arterial infusion of 5 x 10\^5 cells/kg infused over 5 minutes
224322917|NCT06093490|DEVICE|Eysz Hyperventilation Recorder|App used to guide and record hyperventilation
224322918|NCT06148272|DRUG|LY3971297|Administered SC
224322919|NCT06148272|DRUG|Placebo|Administered SC
224322920|NCT06148272|DRUG|LY3971297 IV|Administered IV
224322921|NCT04079868|BEHAVIORAL|Bone Health Service Model|Patients in PACTs randomized to the BHS model will have osteoporosis screening, education, and follow-up handled centrally by the bone health team.
223679497|NCT07214610|BEHAVIORAL|Structured behavioral intervention|All participants will be prospectively assigned to a structured behavioral intervention embedded within the research process. The goal of the intervention is to improve communication with healthcare providers and enhance self-advocacy during breast cancer care. Components include reflective behavioral self-assessments, symptom reporting tools, regular interaction with nurses and lay health educators, access to webinars and newsletters, patient-centered educational materials, and the return of study results to participants through a report-back process. The behavioral engagement components are standardized and delivered over the first 12 months post-enrollment.
223679498|NCT07215637|DRUG|CKD-512|Orally administered BID
224259741|NCT02975765|PROCEDURE|Piezosurgery|The surgical tip is going to be used to make small cuts into the cortex of the alveolar bone between the crowded teeth.
224259742|NCT06235723|DEVICE|Virtual Reality|Virtual Reality was used before and during punctures. For every observation patients underwent either port puncture or peripheral venous puncture. One examination was carried out according to the Standard-of-Care. The other one was carried out with the additional use of VR. Participants watched a passive distraction video.
224259743|NCT05646823|DIETARY_SUPPLEMENT|Probiotic blend|Bifidobacterium longum CCT 1934; Bifidobacterium lactis CCT 7858; Lactobacillus rhamnosus CCT 7863; Streptococcus thermophilus ATCC 19258) Final concentration: 1 x 10e10 CFU/ day
224259744|NCT05646823|DIETARY_SUPPLEMENT|Placebo|vehicle only - Maltodextrin gluten free
224259745|NCT00100464|DRUG|Paroxetine|
224259746|NCT00100464|DRUG|5HTP|
224259747|NCT01261663|OTHER|oral nutritional energy and protein enriched supplement (NOS)|
224259748|NCT01564394|BEHAVIORAL|Qigong|Classes will be 60 minutes in duration, held two times a week, supplemented with home-based sessions over 12 weeks. The classes will be led by a trained Qigong instructor and consist of postures, movements, deep breathing techniques and meditation. It will include eccentrically-biased Qigong movements with an emphasis on weight shifting and posture control. The continuous body movements coupled with progressively diminishing base of support, dynamic challenge to balance, and concentration on body positions requiring eccentric muscle activity should improve the levels of fatigue and quality of life in older prostate cancer survivors.
224259749|NCT01564394|BEHAVIORAL|Non-aerobic stretching|The non-aerobic stretching classes will serve as an attention control. They will be 60 minutes in duration, held two times a week, supplemented with home-based sessions over 12 weeks. They will be led by an Huntsman Cancer Institute (HCI) fitness specialist and will consist of light stretching exercises; while avoiding a focus on meditation.
224259750|NCT02855853|OTHER|serious game et virtual reality|
224259751|NCT02855853|OTHER|Nintendo Wii|
224259752|NCT00443651|DRUG|Rituximab|Rituximab was supplied as a concentrate for IV administration at a concentration of 10 mg/mL in 500 mg (50 mL) single-use vials.
224259753|NCT00443651|DRUG|Anti-inflammatory drugs|Each rituximab infusion was preceded by methylprednisolone 100 mg IV. Use of stable doses of oral corticosteroids was permitted (≤ 10 mg of prednisone or equivalent per day) as were stable doses of nonsteroidal anti-inflammatory drugs (NSAIDs).
224259754|NCT01988376|DEVICE|Surepath|A liquid-base method of Pap smear for screening the recurrence of cervical cancer
224259755|NCT01988376|DEVICE|Conventional Pap smear|Conventional Pap smear
224259756|NCT06619184|PROCEDURE|NCEHFORSCS transplantation|One vitiligo lesion of participans treated with NCEHFORSCS transplantation including follicle unit extraction (FUE) procedure from the occipital area, laboratory procedure for preparation of cell suspension, and transplantation of NCEHFORSCS.
224259757|NCT06619184|PROCEDURE|MPG procedure|"Another vitiligo lesion treated with MPG procedure~Follow up The dressing was removed by the researcher on day 8 The participants were asked to attend for follow-up at the clinic on week 2, 4, 8, 12, and 16 after the two procedure were done.~At 2, 4, 8, 12 and 16 weeks of follow-up visits, any possible complications were evaluated and digital photographs of the lesions were taken for evaluating the two procedure efficacy using its parameter: appearance of repigmentation (AOR), total number of repigmentation NSV lesions, extent area of repigmentation, and color match"
224259758|NCT02663921|OTHER|Part A: Baseline-Week 2|"The study doctor will shine 2 different light bulbs (one a regular or incandescent bulb and the other an LED light bulb) on 12 different areas of patients skin approximately 6 square centimeters in size (less than 1 square inch or the size of your thumb nail). Each light bulb will be exposed to your skin for approximately 20 - 35 minutes. After exposure, the study doctor will perform skin assessments at 3 time points:~1. Immediately after the light exposure;~2. 30 minutes after light exposure; and~3. 1 hour after light exposure."
224259759|NCT02663921|OTHER|Part B: Week 4-Week 12|"The study doctor will perform the same 4 skin assessments used in Part A at each visit to assess potential changes in your skin: Digital Photography~1. Visual Clinical Assessment~2. Spectroscopy~3. Colorimetry"
223679499|NCT07215637|COMBINATION_PRODUCT|Pembrolizumab|Intravenous (IV) Infusion
223679500|NCT07215520|BIOLOGICAL|NDV-HXP-S-KP.2|Nasal Administration of a COVID-19 vaccine to compare against a commercially available mRNA vaccine
223679501|NCT07215520|BIOLOGICAL|COVID-19 mRNA Vaccine|Used as a comparator to study vaccine
223679502|NCT07215585|DRUG|AZD0486|Bispecific monoclonal IgG4 antibody
223679503|NCT07215585|DRUG|R-mini-CHOP|Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone
224259760|NCT02275143|RADIATION|CT TAP Scan|Modification of chest CT protocol in the routine CT TAP: The Research CT of Thorax will be acquired as per the routinely performed CTCA with inclusion of the lung apices. Therefore the study will be acquired axially with prospective gating.
224259761|NCT00859521|DRUG|Levetiracetam|1000 mg Tablet
224259762|NCT00859521|DRUG|Keppra®|1000 mg Tablet
224259763|NCT04273971|OTHER|Plyometric exercises|Plyometric exercises will be composed of vertical jumps, box jumps, half squat jumps, high straight jumps, bounding jumps, drop jumps and 10-m sprint.
223679506|NCT07215481|DEVICE|Shame Control (Baseline)|Participant's device (Boston Scientific Vercise Genus neurostimulator) is turned off for 45 minutes.
223773458|NCT03887039|OTHER|clinical examination|clinical examination for all the oral findings
224259764|NCT04367766|PROCEDURE|Prosthetically driven implant placement|Insertion of an osseointegrated implant into the bone of anterior maxilla/mandible, following the right prosthetic plan
224259765|NCT03168126|DEVICE|Pro-AQT|Use of the device for advanced hemodynamic monitoring
224259766|NCT04606550|DEVICE|Microablative Fractional CO2 Laser Therapy|Microablative Fractional CO2 Vaginal Laser Therapy
224259767|NCT03934281|DEVICE|Honey dressing Melectis G|"The protocol includes rinsing the wound with the saline, gently drying the edge of the wound, applying a thin Mélectis®G film to the entire wound surface and covering with a secondary dressing.~Dressings will be rehabilitated based on the evolution of the wound and clinical judgement of the investigator or nurse at home as recommended."
223679507|NCT07215481|DEVICE|Standard of Care Deep Brain Stimulation|Participant's device (Boston Scientific Vercise Genus neurostimulator) is turned 'ON' for 45 minutes using a configuration and amplitude determined as standard of care by the clinician.
223679508|NCT07215481|DEVICE|Illumina 3D Deep Brain Stimulation|Participant's device (Boston Scientific Vercise Genus neurostimulator) is turned 'ON' for 45 minutes using a configuration and amplitude determined by the automated Illumina 3D algorithm.
224259768|NCT03934281|DEVICE|HAS recommendation dressing|"Patients included in the standard arm will receive the best available dressing according to the HAS recommendations.~Dressings will be rehabilitated based on the evolution of the wound and clinical judgement of the investigator or nurse at home as recommended."
224259769|NCT02888756|BIOLOGICAL|iHIVARNA-01|Therapeutic vaccination, followed by treatment interruption
223679509|NCT07215481|DEVICE|Illumina 3D Deep Brain Stimulation Reduced Amplitude|Participant's device (Boston Scientific Vercise Genus neurostimulator) is turned 'ON' for 45 minutes using a configuration and amplitude determined by the automated Illumina 3D algorithm but at a reduced stimulation amplitude.
223679510|NCT07215481|DEVICE|Illumina 3D Deep Brain Stimulation Higher Amplitude|Participant's device (Boston Scientific Vercise Genus neurostimulator) is turned 'ON' for 45 minutes using a configuration and amplitude determined by the automated Illumina 3D algorithm but at a higher stimulation amplitude.
223679511|NCT07215663|DRUG|Cizutamig|Cizutamig will be dosed according to the protocol
223679512|NCT07215039|OTHER|Survey|Non-interventional study
223679513|NCT07215078|DRUG|atirmociclib (PF-07220060)|Open-label, two-period, cross-over study to evaluate dose proportionality of atirmociclib (PF-07220060) pharmacokinetics when administered under fed condition to healthy participants
223679516|NCT07215221|BEHAVIORAL|TBI-RECOVER|The TBI-RECOVER intervention model consists of three components: 1) a web-based brain injury and cognitive impairment screener using the Online Brain Injury Screening and Support System (OBISSS) of the National Association of State Head Injury Administrators, 2) brief education and information on traumatic brain injury and substance use disorders, and 3) neurocognitive accommodations, or compensatory strategies, for neurological impairment.
223679517|NCT07215221|BEHAVIORAL|Control|The control condition includes a brief information and educational sheet on traumatic brain injury and substance use disorder, how these two conditions are connected with each other, and a list of suggested accommodations they can use in treatment.
223679520|NCT07214896|BIOLOGICAL|Skin Cell Dip|Lab-grown keratinocyte dip applied to humanoid units to improve tactile sensitivity and surface regeneration.
223679521|NCT07214896|BIOLOGICAL|Stem Cell Dip|iPSC-derived neuroblast dip applied to humanoid units to enhance neural responsiveness and adaptive learning.
223679522|NCT07214896|OTHER|Wage Token Distribution|HumanoidWage (HMW) tokens minted and distributed based on biometric audit scores and ESG task completion.
223679523|NCT07214896|BEHAVIORAL|ESG Compliance Monitoring, Operational protocol|Real-time tracking of energy usage, sanitation cycles, and carbon offset metrics via coalition dashboard.
223679524|NCT07214805|BEHAVIORAL|Ultra-Processed, Red, Icon-plus-text Labels|Participants will view a fast-food restaurant menu excerpt. Each menu item will be displayed with an image of the item, name, price, and total calories. The Ultra-Processed, Red, Icon-plus-text labels will be displayed next to items that are ultra-processed. Participants will view the menu and then the label in isolation and then be asked about a hypothetical intention to purchase a menu item with the label.
223679525|NCT07214805|BEHAVIORAL|Contains Food Additives, Red, Icon-plus-text Labels|Participants will view a fast-food restaurant menu excerpt. Each menu item will be displayed with an image of the item, name, price, and total calories. The Contains Food Additives, Red, Icon-plus-text labels will be displayed next to items that are ultra-processed. Participants will view the menu and then the label in isolation and then be asked about a hypothetical intention to purchase a menu item with the label.
223773459|NCT03734471|DEVICE|Reactor Device|The Reactor is a Class II FDA medical device to facilitate the insertion of chest tubes into the thoracic cavity.
223773460|NCT03734471|PROCEDURE|Tube thoracostomy|Traditional chest tube placement
224259770|NCT02888756|BIOLOGICAL|TriMix|Therapeutic vaccination, followed by treatment interruption
224259771|NCT02888756|BIOLOGICAL|Placebo|Therapeutic vaccination, followed by treatment interruption
224259772|NCT06118697|PROCEDURE|Esophageal stimulation with high resolution esophageal manometry and nutritive oral feeding therapy|Subjects will be given weekly pharyngo-esophageal stimulation guided by high resolution impedance manometry for 4 weeks. During this time of study intervention, every feed will start with nutritive oral stimulation with at least 5 mL of the infant's prescribed diet.
224259773|NCT02305732|BIOLOGICAL|INTERCEPT Platelets|INTERCEPT platelet components (PC). Leukocyte reduced apheresis platelet components collected in Platelet Additive Solution (PAS) or 100% plasma without gamma irradiation, bacterial detection, and Cytomegalovirus (CMV) serology testing.
224322922|NCT05064813|BEHAVIORAL|Mindfulness Based Stress Reduction MBSR Intervention|MBSR is an 8-week group-based course developed by Jon Kabat-Zinn (1990) and colleagues at the University of Massachusetts' Center for Mindfulness. Weekly 2.5 hour long classes are given once a week, as well as one day-long weekend class. The classes instruct participants in the theory and practice of several forms of mindfulness meditation, breathing awareness, and mindfulness stretching exercises. Teaching of the theory of mindfulness and experiential practice are both utilized during weekly classes and at-home CD-guided practice sessions.
224259774|NCT03631628|DEVICE|Bilateral Transcutaneous electrical nerve stimulation (Bi-TENS)|The stimulator is a 120z Dual-Channel TENS Unit (ITO Physiotherapy \& Rehabilittaion, Co, Ltd, Tokyo, Japan). The TENS stimulation will be at 100 Hz, with 0.2 ms square pulses at an intensity of twice the sensory threshold (defined as the minimum intensity at which subject reported feeling a tingling sensation and below the motor threshold as indicated by the absence of muscle twitching, to provide sensory stimulation to both paretic and intact arms. Two pairs of disposable surface electrodes will be applied over the median nerve from the carpal tunnel to the flexor digitorum superficialis and the superficial radial nerve from the extensor pollicis longus to the extensor digitorum communis, with the cathode on the proximal site, and the anode on the distal site.
224259775|NCT03631628|BEHAVIORAL|Mirror Therapy (MT)|"A customised angle-adjustable frame with a mirror board will be used. All subjects are instructed to perform~1. Elbow flexion and extension exercise~2. Forearm pronation and supination exercise~3. Wrist flexion and extension exercise~4. Wrist radial and ulnar deviation exercise~5. Fingers opposition exercise~6. Gripping exercise~The subject will complete bilaterally upper limb exercises during the 30 minutes period.~Intact arm will be placed in front of mirror, and paretic arm will be placed behind the mirror.~Joints involved will be flexed and extended in full available range in sitting positon, in order to improve the active control of elbow joint, wrist joint and all fingers joint respectively.~Participants will be encouraged to focus on the image of intact arm when performing upper limb exercises bilaterally."
224259776|NCT03631628|BEHAVIORAL|sham-Mirror Therapy (sham-MT)|"A customised angle-adjustable frame with a mirror board will be used while the reflecting surface of the mirror was covered with paper. All subjects are instructed to perform~1. Elbow flexion and extension exercise~2. Forearm pronation and supination exercise~3. Wrist flexion and extension exercise~4. Wrist radial and ulnar deviation exercise~5. Fingers opposition exercise~6. Gripping exercise~The subject will complete bilaterally upper limb exercises during the 30 minutes period.~Intact arm will be placed in front of covered mirror, and paretic arm will be placed behind the covered mirror.~Joints involved will be flexed and extended in full available range in sitting positon, in order to improve the active control of elbow joint, wrist joint and all fingers joint respectively."
224259777|NCT03631628|BEHAVIORAL|Conventional Rehabilitation Program|Standardized upper limb training
224259778|NCT00834132|DRUG|Azithromycin 600 mg Tablet|1 x 600mg, single-dose fed
224259779|NCT00834132|DRUG|Zithromax® 600 mg Tablet|1 x 600mg, single-dose fed
224322923|NCT05064813|BEHAVIORAL|Stress Education Control Condition (SE)|Stress Education (SE) was designed to provide an active comparator condition that does not include overlapping active components of mindfulness meditation with MBSR. It will also be delivered over 8-weekly, in-person, 2.5 hour group sessions of the same size (n=4 to 6). In SE, participants receive extensive information about stress and health, but will not receive any MBSR or other mind-body training. Instead, stress relevant psycho-educational information will be taught.
224259780|NCT01515891|DRUG|BIA 9-1067|90 µCi (3.33 MBq) \[14C\]-labeled of 100 mg BIA 9-1067 (single-dose).
224259781|NCT06447948|BEHAVIORAL|Keep Exercising and Stay Steady|"Digital Health, home exercise intervention containing a digital NHS approved falls prevention exercise App (Keep On Keep Up), fitness watches, telephone and/or social media communication, and behavior change techniques.~Currently (date, 13 May 2024) the intervention has not been developed with the community of practice group. Further details of the phase 1 and phase 2 interventions will be provided after the community of practice events."
224259782|NCT02380794|DRUG|Danshen Gegen Capsule|"Danshen can dilate blood vessels, reduce the number of angina attacks and significantly improve endothelial function in patients with Coronary Angina Pectoris.~Gegen is also effective in dilating cardiovascular and cerebrovascular of the brain, and improving blood circulation. The main active ingredient of Gegen isoflavones is effective in dilating the coronary arteries, improving metabolism in normal and ischemic myocardium and reducing blood pressure, heart rate and myocardial oxygen consumption."
224322924|NCT06472089|BEHAVIORAL|BMT-CARE|Therapist-delivered psychosocial intervention comprised of 6 sessions
224322925|NCT06472089|BEHAVIORAL|Usual Care|Meeting a transplant social worker prior to HCT and as needed for extra visits
224322926|NCT05099172|DRUG|BAY2927088_formulation A|Oral administration
224322927|NCT05099172|DRUG|BAY2927088_formulation B_1|Oral administration
224259783|NCT02380794|DRUG|Placebo|
224322928|NCT05099172|DRUG|BAY2927088_formulation B_2|Oral administration
224322929|NCT05722743|BEHAVIORAL|Harmony at HOME|The Harmony at HOME (Help Online Modifying the Environment) intervention builds on prior successful foundations of dementia care interventions with a novel approach combining remote implementation, antecedent education, and home environment intervention. The intervention will teach caregivers how to 1) assess the home environment as an antecedent to behavior for the person with ADRD, and 2) design and implement individualized environmental modification through an environmental cueing approach to address the needs of the person with ADRD in a supportive environment.
224322930|NCT05722743|BEHAVIORAL|National Institute on Aging Program|"Standard of care will address behaviors and psychiatric symptoms of dementia (BPSD) for persons with ADRD, as recommended by their medical provider. Caregivers will receive training regarding home safety via a home safety handout based on National Institutes on Aging Home Safety and Alzheimer's Disease webpage."
224322931|NCT01841736|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
224322932|NCT01841736|PROCEDURE|Computed Tomography|Undergo CT
224322933|NCT01841736|PROCEDURE|Echocardiography Test|Undergo ECHO
224322934|NCT01841736|OTHER|Laboratory Biomarker Analysis|Correlative studies
223773461|NCT03181542|DEVICE|Infrared illumination|Infrared illumination of veins using the FDA approved AccuVein (AccuVein, Inc., Huntington, NY) device.
224322935|NCT01841736|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
224322936|NCT01841736|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
224322937|NCT01841736|DRUG|Pazopanib Hydrochloride|Given PO
224259784|NCT05470153|DEVICE|Continuous Positive Airway Pressure|For each patient with Obstructive Sleep Apnea, titration of Continuous Positive Airway Pressure (CPAP) pressure will be performed by conventional polysomnography or using auto-CPAP equipment using a validated protocol. The CPAP device should have an hour meter recording system, so that machine-on time hours could be checked at each clinical visit.
224259785|NCT05058430|DEVICE|Electrical salivary stimulator system assigned to subjects with xerostomia|SaliPen is an electrical salivary stimulator system, intended to electrically stimulate a relative increase in saliva production. It is an intraoral device indicated for use in patients with xerostomia (dry mouth).
224259786|NCT05058430|DEVICE|No Electrical salivary stimulator system assigned to subjects without xerostomia|SaliPen is an electrical salivary stimulator system, intended to electrically stimulate a relative increase in saliva production. It is an intraoral device indicated for use in patients with xerostomia (dry mouth).
224259787|NCT03683667|DRUG|Azithromycin Oral Product|Azithromycin oral suspension (10 mg/kg; 3 days) administered by study personnel at 6 and 9 months of age
224259788|NCT03683667|DRUG|Placebos|Contain inert excipients only
224322938|NCT01841736|OTHER|Placebo Administration|Given PO
224322939|NCT01841736|OTHER|Quality-of-Life Assessment|Ancillary studies
224322940|NCT01841736|PROCEDURE|X-Ray Imaging|Undergo chest x-ray
224322941|NCT05439772|DRUG|Ondansetron|Patient will take one dissolvable tablet of ondansetron prior to initiating PEG consumption.
224322942|NCT06283953|BEHAVIORAL|Trach Plus|The Trach Plus program includes education, social support, and outreach to outpatient care team.
224322943|NCT06283953|BEHAVIORAL|Trach Me Home|The Trach Me Home discharge program includes caregiver education, skills training and case management.
224322944|NCT03412916|BEHAVIORAL|GetActive|GetActive is a comprehensive, multimodal treatment that was designed to increase quality of life, resiliency and ability to cope with medical symptoms and stress. This program is rooted in the elicitation of the relaxation response, a non-judgmental state of focused attention and increased awareness.
224322945|NCT03412916|BEHAVIORAL|Get Active with Fitbit|The GetActive Program for Pain with a Digital Monitoring Device (GetActive Fitbit) is identical to the GetActive with the addition of a FitBit for recording of physical activity.
223679526|NCT07214805|BEHAVIORAL|Warning Ultra-Processed, Red, Icon-plus-text Labels|Participants will view a fast-food restaurant menu excerpt. Each menu item will be displayed with an image of the item, name, price, and total calories. The Warning Ultra-Processed, Red, Icon-plus-text labels will be displayed next to items that are ultra-processed. Participants will view the menu and then the label in isolation and then be asked about a hypothetical intention to purchase a menu item with the label.
223679527|NCT07214805|BEHAVIORAL|Warning UPF, Red, Icon-plus-text Labels|Participants will view a fast-food restaurant menu excerpt. Each menu item will be displayed with an image of the item, name, price, and total calories. The Warning UPF, Red, Icon-plus-text labels will be displayed next to items that are ultra-processed. Participants will view the menu and then the label in isolation and then be asked about a hypothetical intention to purchase a menu item with the label.
223679528|NCT07214805|BEHAVIORAL|Ultra-Processed, Yellow, Icon-plus-text Labels|Participants will view a fast-food restaurant menu excerpt. Each menu item will be displayed with an image of the item, name, price, and total calories. The Ultra-Processed, Yellow, Icon-plus-text labels will be displayed next to items that are ultra-processed. Participants will view the menu and then the label in isolation and then be asked about a hypothetical intention to purchase a menu item with the label.
223679529|NCT07214805|BEHAVIORAL|Contains Food Additives, Yellow, Icon-plus-text Labels|Participants will view a fast-food restaurant menu excerpt. Each menu item will be displayed with an image of the item, name, price, and total calories. The Contains Food Additives, Yellow, Icon-plus-text labels will be displayed next to items that are ultra-processed. Participants will view the menu and then the label in isolation and then be asked about a hypothetical intention to purchase a menu item with the label.
223679530|NCT07214805|BEHAVIORAL|Warning Ultra-Processed, Yellow, Icon-plus-text Labels|Participants will view a fast-food restaurant menu excerpt. Each menu item will be displayed with an image of the item, name, price, and total calories. The Warning Ultra-Processed, Yellow, Icon-plus-text labels will be displayed next to items that are ultra-processed. Participants will view the menu and then the label in isolation and then be asked about a hypothetical intention to purchase a menu item with the label.
224259789|NCT03683667|DIETARY_SUPPLEMENT|Protein Supplement|Blended food providing 125 kcal and 10 g protein as egg white powder prepared as porridge and fed daily to infants from 6-12 months of age
224259790|NCT03683667|DIETARY_SUPPLEMENT|Isocaloric Supplement|Blended food providing 125 kcal and 1 g protein as rice powder prepared as porridge and fed daily to infants from 6-12 months of age
224259791|NCT03683667|DIETARY_SUPPLEMENT|Egg|Egg provided daily to infants from 6-12 months of age
224259792|NCT03683667|BEHAVIORAL|Nutrition Education|Monthly messaging on infant and young child feeding
224259793|NCT04456972|DIAGNOSTIC_TEST|One arm only|Samples of plasma to analyze ctDNA
224259794|NCT02768701|DRUG|Pembrolizumab|Subjects will be treated every 3 weeks with 200 mg of pembrolizumab via a 30 minute infusion.
224259795|NCT02768701|DRUG|Cyclophosphamide|A single 300 mg/m2 dose of cyclophosphamide IV over 30-60 minutes will be administered on Day 1 of this study.
224259796|NCT00014768|DRUG|glucose|
224322946|NCT05914116|DRUG|DB-1311|Administered I.V.(intravenous infusion)
224259797|NCT00014768|DRUG|insulin|
224322947|NCT05914116|DRUG|Lopinavir and Ritonavir Tablets|Lopinavir and Ritonavir Tablets
224322948|NCT05914116|DRUG|itraconazole|itraconazole
224322949|NCT05947955|DRUG|Rhu-pGSN|Intravenous administration based on actual body weight
224259798|NCT00014768|DRUG|leucine|
224322950|NCT05947955|DRUG|normal saline|intravenous administration in the same volume as the active therapy
224322951|NCT05620108|PROCEDURE|Endotracheal Intubation at TOFC=1|Intubation using a video laryngoscopy will be performed after train-of-four (TOFC) stimulation indicates neuromuscular blockade
224322952|NCT05620108|PROCEDURE|Endotracheal Intubation 2 minutes after rocuronium administration|Intubation using a video laryngoscopy will be performed 2 minutes after administration of rocuronium at 0.6 mg/kg (usual current clinical routine)
224322953|NCT03734393|OTHER|HIVD+/R+|Liver from an HIV-infected deceased donor
224322954|NCT06530849|DRUG|GC012F Injection|GC012F Injection is an autologous chimeric antigen receptor T cell therapy targeting both BCMA and CD19
224322955|NCT03032783|RADIATION|Total-Body Irradiation|Undergo Total Body Irradiation
224322956|NCT03032783|PROCEDURE|Donor Lymphocyte Infusion|Undergo Donor Lymphocyte Infusion
224322957|NCT03032783|DRUG|Cyclophosphamide|Given IV
224322958|NCT03032783|DRUG|Tacrolimus|Given IV
224322959|NCT03032783|DRUG|Mycophenolate Mofetil|Given IV
224322960|NCT03032783|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo Hematopoietic Stem Cell Transplantation
224322961|NCT06563804|DRUG|S227928|For administration via intravenous (IV) infusion
224259799|NCT02718963|DEVICE|Synchronized Electrical Stimulation Device|electrical stimulation at muscles which related with deglutition
224322962|NCT06563804|DRUG|Venetoclax|For oral administration
224322963|NCT06624072|DRUG|Nerandomilast, Formulation 1|Reference treatment (R)
224322964|NCT06624072|DRUG|Nerandomilast, Formulation 2|when taken without food: Test Treatment 1 (T1) when taken with food: Test Treatment 2 (T2)
224322965|NCT04500574|DRUG|Latanoprost eluting contact lens|The latanoprost-contact lens will be worn in one eye for one week.
224322966|NCT04500574|DRUG|Topical Latanoprost|A commercial contact lens with no drug will be worn in one eye for one week.
224259800|NCT01847495|DRUG|Irinotecan|40mg/m2 x 3-5 days
224322967|NCT06264843|DEVICE|MiraQ with Transit-Time Flow Measurement (TTFM) and L15 High Frequency Ultrasound (HFUS) probes|Identify and validate intraoperative TTFM and HFUS findings (e.g. threshold values of Mean Graft Flow (MGF), MGF capacity, flow curve pattern, morphological issues)
224322968|NCT06959225|DRUG|Ruxolitinib Cream|Ruxolitinib cream applied topically to the affected area as a thin film twice daily.
224322969|NCT06959225|DRUG|Vehicle Cream|Matching vehicle cream applied topically to the affected area as a thin film twice daily.
224322970|NCT06831162|OTHER|Multi-level HRSN initiative|The multi-level health-related social needs (HRSN) initiative includes multiple components aimed at assessing and addressing HRSN in clinical practice: HRSN screening, EHR tools for clinical decision support, training and tools for health care providers to address HRSN, care coordinator support for patient outreach, and community resources for referral and support.
224322971|NCT05648968|BIOLOGICAL|Ianalumab|i.v. infusion, prepared from concentrate solution
224259801|NCT01847495|RADIATION|CyberKnife|45-60 Gy for 3-5 days CyberKnife SBRT to liver metastasis within 10 elapsed days. Irinotecan will be administered on the same day, prior to SBRT.
224259802|NCT01350986|BEHAVIORAL|Cognitive-Behavioral Self-help Workbook + Counseling Telephone Calls|"In intervention period of 5 months parents work through 8 cognitive-behavioral self-help booklets (FLOH) and additionally receive 10 counseling telephone calls. Primary purpose of telephone calls is to clarify content of the booklets and support parents in managing their homework assignments accompanied with each booklet. 3 and 6 months after intervention period has ended, two additional booster telephone calls are provided. The booklets are based on the therapy manual Treatment program for children with hyperactive and oppositional problem behavior (THOP) (Döpfner, Schürmann, \& Frölich, 2007) and the parent self-help book Wackelpeter and Trotzkopf: Help for parents of children with hyperkinetic and oppositional behavior (Döpfner, Schürmann, \& Lehmkuhl, 2006)."
224322972|NCT05648968|DRUG|Placebo|i.v. infusion, prepared from matching placebo
224322973|NCT06200012|BEHAVIORAL|Multi-level stigma reduction intervention: educational training plus controlled substance agreement policy change|Pairing a professional training targeting known attitudinal and knowledge drivers of substance use stigma with a policy altering potentially stigmatizing features of controlled substance agreements.
224322974|NCT06200012|BEHAVIORAL|Single-level stigma reduction intervention: educational training|A professional training targeting known attitudinal and knowledge drivers of substance use stigma
224322975|NCT06679140|DRUG|ibuzatrelvir|ibuzatrelvir tablets
224322976|NCT06679140|DRUG|placebo|placebo tablets
224322977|NCT06273163|OTHER|Medically tailored meals|Medically tailored meals are nutritious meals formulated for weight wellness.
224322978|NCT06273163|BEHAVIORAL|Noom®|Noom® is a subscription-based mobile application used to support healthy eating and exercise behavior change.
224322979|NCT06273163|OTHER|Usual care|Care is provided at the discretion of the individual provider (e.g., usual care).
224322980|NCT05652504|BIOLOGICAL|PfSPZ Vaccine|PfSPZ Vaccine contains aseptic, purified, vialed, cryopreserved, radiation attenuated NF54 Pf sporozoites (PfSPZ) produced by Sanaria Inc. PfSPZ Vaccine is manufactured in compliance with Good Manufacturing Practice (GMP) regulations (21 Code of Federal Regulations \[CFR\] 21), that is described in detail in Investigational New Drug (IND) 13969. Manufacture of PfSPZ Vaccine is performed in Sanaria s Clinical Manufacturing Facility (CMF) in Rockville, Maryland, USA.
224322981|NCT05652504|OTHER|PfSPZ Diluent|The diluent for PfSPZ Vaccine is composed of phosphate-buffered saline (PBS) and human serum albumin (HSA) and is termed PfSPZ Diluent (or Diluent). The PfSPZ Diluent was manufactured in compliance with GMP by Sanaria, Inc. (9800 Medical Center Dr., Rockville, MD, USA), or Sanaria s contractor Emergent Biosolutions (https://www.emergentcdmo.com/). Each lot of PfSPZ Diluent is issued a Certificate of Analysis (CoA) and is also placed on a stability program. HSA used in PfSPZ Diluent is a licensed product which is approved for parenteral, IV administration to humans and is purchased by Sanaria, Inc. from CSL Behring, Bern, Switzerland.
224322982|NCT05652504|DRUG|Normal Saline|Sterile isotonic (0.9%) normal saline will be procured in the US and shipped to Mali at ambient temperature. Like the study product, normal saline is a clear liquid, making it indistinguishable from the study product when drawn up into a syringe. Normal saline will be used as a placebo, rather than a comparator vaccine being used, as currently there are no licensed vaccines available as IV formulations. The NS to be used in this trial will be an FDA-licensed product which is commercially available (sodium chloride for injection 10 mL by Pfizer). NS will be purchased by Sanaria and supplied to the clinical site.
224322983|NCT06628908|DRUG|Suzetrigine|Tablets for oral administration.
224322984|NCT06628908|DRUG|Placebo (matched to SUZ)|Placebo matched to SUZ for oral administration.
224322985|NCT06628908|DRUG|Pregabalin|Capsules for oral administration.
224322986|NCT06628908|DRUG|Placebo (matched to Pregabalin)|Placebo matched to Pregabalin for oral administration.
224322987|NCT06654050|DRUG|alrizomadlin|Alrizomadlin (APG-115) oral tablets (150 mg) taken every other day on Days 1, 3, 5, 7, 9, 11, and 13 of every cycle (1 cycle=21 days) for 8 cycles (i.e., Course 1). Individuals with stable or responding disease may receive an additional 8 cycles (i.e., Course 2). Maximum (total) of 2 treatment courses.
223773462|NCT04425330|OTHER|physiotherapy exercises|The evidence on the effectiveness of physical therapy in children with myelomeningocele is limited. The International Classification of Functionality, Disability and Health for Children and Youth is a useful tool to assist therapists in analyzing problems about the focus of the intervention. The evidence in physical therapy practice for individuals of all ages with neurological disorders, focuses on 5 Ps: prevention, prediction, participation, personalized and plasticity. Thus, neurological physiotherapists must perform the care with a focus on preventing the patient's disabilities, predicting the ideal response of an intervention, through measures of results of the movement system. In addition, it is of paramount importance that the goal of rehabilitation is that people with neurological disabilities are fully included and participate in life activities that are important to them and that their care is personalized. All of these measures facilitate the process of positive plasticity.
223773463|NCT04425330|OTHER|PBM|Photobiomodulation occurs from the application of low intensity light such as low intensity laser and light emitting diode (LED). The therapeutic effectiveness of phototherapy is based on the absorption of photons by photoreceptors or chromophores. Studies on the experimental model of spinal cord injury have shown that both wavelengths have the potential to be an effective and non-invasive means of therapy, promoting axonal appearance, increased concentration of glial cells and nerve connections, in addition to functional and sensitive. The findings of a clinical trial involving individuals diagnosed with spinal cord injury demonstrate that PBM exerted positive effects on motor function, especially during isotonic contraction of stimulated muscles assessed by electromyography, and there was a recovery in sensory perception and muscle strength.
223773464|NCT04425330|OTHER|SHAM PBM|SHAM PBM
223773465|NCT03970473|OTHER|Pulmonary recruitment maneuver (PRM)- 30 cm H2O|Pulmonary recruitment maneuver (PRM) consists of five manual pulmonary inflations where each positive pressure inflation will be performed for 5 s at a maximum pressure of 30 cm H2O in the semi-fowler position (30° head-of-bed elevation ). PRM is performed after LS when the main umbilical port is remaining and aims to remove the remaining gas following LS.
223773466|NCT03970473|OTHER|Pulmonary recruitment maneuver (PRM)- 15 cm H2O|Pulmonary recruitment maneuver (PRM) consists of five manual pulmonary inflations where each positive pressure inflation will be performed for 5 s at a maximum pressure of 15 cm H2O in the semi-fowler position (30° head-of-bed elevation ). PRM is performed after LS when the main umbilical port is remaining and aims to remove the remaining gas following LS.
223773467|NCT03658083|PROCEDURE|Thoracotomy|Open surgery
223773468|NCT03658083|PROCEDURE|Robotic-assisted thoracic surgery|Minimally invasive surgery
223773469|NCT05940974|OTHER|Questionnaire administration|All study participants will be surveyed with the EQ-5D-5L questionnaire to measure their quality of life indicators before the surgery and after the surgery (on 4 dates over a 1-year period); the DASH and ASES questionnaires to measure their functional outcomes before the surgery and after the surgery (on 4 dates over a 1-year period); the costs questionnaire to measure direct and indirect costs borne by patients because of their condition before the surgery and after the surgery (on 4 dates over a 1-year period).
223773470|NCT05626946|OTHER|Observation|Observation
223773471|NCT05902208|DRUG|Antiviral treatment with conventional non-surgical treatment|Valaciclovir, a antiviral treatment will be added to the conventional non-surgical treatment of generalized periodontitis. One gram per day will be administered during 28 days.
223773472|NCT05902208|DRUG|Placebo with conventional non-surgical treatment|Placebo of valaciclovir (same composition, without active substance) will be added to the conventional non-surgical treatment of generalized periodontitis. One gram a day will be administered during 28 days.
223773473|NCT00113256|DRUG|Rubitecan|
223773474|NCT00180856|PROCEDURE|Radiofrequency ablation|
223773475|NCT02419846|OTHER|Educational Intervention|Attend 10-20 minute PowerPoint presentation that will discuss prostate cancer facts, screening guidelines, risks, benefits, and consequences
223773476|NCT02419846|PROCEDURE|digital rectal examination|Undergo digital rectal exam by a licensed healthcare professional. The results of this exam will be subjective as per clinician; however, will be coded as normal or abnormal. This is considered standard of care for prostate cancer screening
223773477|NCT02419846|OTHER|Pre-test administration|15 questions which test participants' knowledge of prostate cancer according to ACS guidelines. Questions will be multiple choices and true/false/unsure answers
223773478|NCT02419846|OTHER|Survey Administration|Survey will be administered at the end of the program for participants to assess their experience
223773479|NCT02419846|OTHER|Prostate-specific antigen measurement|PSA levels will be drawn and run as per institutional Laboratory standards. Criteria for referral and follow up will be assessed as per National Comprehensive Cancer Network (NCCN) guidelines
223773480|NCT02419846|OTHER|Post test administration|Post test will include the same 15 questions as on the pretest to assess for improvement in knowledge and understanding
223773481|NCT03994770|DIAGNOSTIC_TEST|Balanced Reach Assessment and Training Protocol|Three one-hour training sessions for one week in the Balanced Reach Training Protocol
223773482|NCT00113737|DRUG|fluoxetine|
224259803|NCT01350986|BEHAVIORAL|Non-Directive Self-Help Workbook + Counseling Telephone Calls|"In intervention period of 5 months parents are provided 8 non-directive self-help booklets and additionally receive 10 non-directive counseling telephone calls. If the telephone calls are used to clarify content of the booklets or to discuss other child and parenting related topics is at the parents' discretion. Main focus for counselor is to be congruent, empathic and to have unconditional positive regard toward the parents. 3 and 6 months after intervention period has ended, two additional booster telephone calls are provided. The booklets are based on Parent effectiveness training (Gordon, 1970) and Teaching children self-discipline at home and at school (Gordon, 1989)."
223773483|NCT00113737|BEHAVIORAL|cognitive behavioral therapy|
223773484|NCT02865031|DRUG|Decorin|Intravitreal Injection following ocular trauma to prevent scar tissue formation.
224322988|NCT05267626|DRUG|AU-007|Monoclonal Antibody Targeting IL-2
224322989|NCT05267626|DRUG|Aldesleukin|IL-2
224322990|NCT05267626|DRUG|Avelumab|Monoclonal Antibody Targeting PD-L1
224322991|NCT05267626|DRUG|Nivolumab|Monoclonal Antibody Targeting PD-1
224322992|NCT02831335|OTHER|MRI|Perform MRI studies
224322993|NCT02831335|OTHER|MRI|Perform MRI studies
224322994|NCT02831335|OTHER|MRI|Perform MRI studies
224322995|NCT02831335|OTHER|Group 4|Perform MRI studies
224322996|NCT06203600|PROCEDURE|Biospecimen Collection|Undergo optional blood sample collection
224322997|NCT06203600|PROCEDURE|Computed Tomography|Undergo CT scan
224322998|NCT06203600|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
224322999|NCT06203600|BIOLOGICAL|Nivolumab|Given IV
224323000|NCT06203600|DRUG|Paclitaxel|Given IV
224323001|NCT06203600|OTHER|Questionnaire Administration|Ancillary studies
224323002|NCT06203600|BIOLOGICAL|Ramucirumab|Given IV
224323003|NCT06130254|DRUG|Adagrasib|Given by PO BID
224323004|NCT06130254|DRUG|Olaparib|Given by PO BID
224323005|NCT05087888|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
224323006|NCT05087888|PROCEDURE|Magnetic Resonance Imaging|Undergo functional MRI
224323007|NCT05087888|PROCEDURE|Multiparametric Magnetic Resonance Imaging|Undergo multiparametric MRI
224323008|NCT05087888|OTHER|Questionnaire Administration|Complete questionnaires
224323009|NCT06476548|DEVICE|EMI|Participants will complete 3 counseling sessions (30 minutes), download and use a smartphone app for 4 weeks, complete 2 online surveys, and a brief phone call at the end of the study to provide feedback. In the first 3 weeks, participants will use the prototype app every day to complete ecological momentary assessments (EMAs), receive brief mindful skills, and practice formal mindfulness meditations (5-20 minutes). In the final week, participants will continue completing EMAs. Participants will also be provided with nicotine patches.
224323010|NCT06516965|DRUG|Povorcitinib|Oral Tablet
223773485|NCT01492634|OTHER|Prescription of post-dialytic weight based on BCM device|"Prescription of post-dialytic weight target: On a weekly base, the patients are pre-dialytically measured by BCM (body composition monitor).~The time average fluid overload (TAFO) determines the target range. TAFO is defined as the mean value of pre- and post-dialytic overhydration (TAFO = (OHpre+OHpost)/2). The target range is set asymmetrically around a TAFO of 0.8, from -1.0 L to +0.5, i.e. the TAFO target range will be from -0.2 L to 1.3 L.~Prescription steps will be calculated weekly for all study patients. TAFO \< -0.2 L: Increase post-dialytic weight by Cw x 0.5 kg/week, TAFO between -0.2 to 1.3 L: No action, TAFO between 1.3 to 2.8 L Decrease post-dialytic weight by Cw x 0.5 kg/week, TAFO \> 2.8 L: Decrease post-dialytic weight by Cw x 1.0 kg/week."
223773486|NCT05209685|OTHER|Resistance exercise on the lower extremities|Resistance exercise mainly on the lower extremities will be executed by carrying weight according to each participant's tolerance while performing certain movements, such as side step-up, sit-to-stand, and tip-toe-standing.
224323011|NCT06516965|DRUG|Placebo|Oral Tablet
224323012|NCT06010719|DRUG|Azithromycin|oral azithromycin (20 mg/kg, single directly observed dose, oral suspension),
224323013|NCT06010719|DRUG|Amoxicillin|Standard of Care. A 7-day, twice-daily course of amoxicillin will be offered as a syrup to children (80 mg/kg divided into twice-daily doses, estimated with weight-based dosing).
224323014|NCT06010719|OTHER|Placebo|A 7-day, twice-daily course of placebo will be offered as a syrup to children (80 mg/kg divided into twice-daily doses, estimated with weight-based dosing).
224323015|NCT06832618|DRUG|Ruxolitinib|The study cream will be applied topically as defined in the protocol for each period.
224323016|NCT06832618|DRUG|Vehicle Cream|Matching vehicle cream will be applied topically as defined in the protocol for each period.
224323017|NCT06735209|BIOLOGICAL|PfSPZ Vaccine|PfSPZ is a candidate vaccine, it consists of a suspension of purified, live-attenuated cryopreserved Pf sporozoites in a cryoprotectant.
224323018|NCT06735209|BIOLOGICAL|PfSPZ (7G8) Challenge|PfSPZ (7G8) Challenge consists of cryopreserved Plasmodium falciparum (Pf) sporozoites (SPZ) that have been developed to be used to infect volunteers in controlled human malaria infection (CHMI) to assess the efficacy of antimalarial drugs and vaccines. The PfSPZ Challenge (7G8) contains a laboratory malaria clone derived from Brazil.
224323019|NCT06735209|OTHER|Sodium Chloride, 0.9%|0.9% Sodium Chloride Injection
224323020|NCT06789913|DRUG|RLY-2608|RLY-2608 is a mutant-selective, oral PI3Kα inhibitor.
224323021|NCT06789913|DRUG|Placebo|RLY-2608 matched-placebo
224323022|NCT06793371|DRUG|CK-4021586 (150 mg, 300 mg, 450 mg, and 600 mg)|CK-4021586 administered orally
224323023|NCT06793371|DRUG|Placebo to match CK-4021586|Placebo administered orally
224323024|NCT06630338|OTHER|Non-Interventional Study|Non-interventional study
224323025|NCT04922281|DEVICE|Insertable Cardiac Monitor or external non-invasive LT-ECG patch|"Implantable device that provides accurate daily transmission. Patients without an existing CIED who prefer to use noninvasive LT-ECG monitoring will be offered to use the Carnation Ambulatory Monitor (CAM™; Bardy Diagnostics) the CAM™ patch approved for LT-ECG monitoring applied to the skin over the chest for a time-period of 7-days every 2 months for cardiac electrical data for arrhythmia detection."
224323026|NCT06315556|DRUG|Aflibercept (Eylea)|Eylea 40 mg/mL solution for injection in pre-filled syringe.
224323027|NCT05293496|BIOLOGICAL|vobramitamab duocarmazine|Vobramitamab duocarmazine is an antibody drug conjugate (ADC) targeted against B7-H3.
224323028|NCT05293496|BIOLOGICAL|lorigerlimab|Lorigerlimab is a bispecific DART® molecule that binds PD-1 and CTLA-4.
224323029|NCT06398847|DEVICE|Virtual Reality headset|Self-hypnosis software in a Virtual Reality headset. This is the development of software that provides a self-hypnosis experience that can be inserted into any virtual reality device.
224323030|NCT03887455|DRUG|Lecanemab IV|Administered as IV infusion.
224323031|NCT03887455|DRUG|Placebo|Biweekly (once every 2 weeks) administered as intravenous infusion.
224323032|NCT03887455|DRUG|Lecanemab SC|Administered weekly as a subcutaneous injection.
224323033|NCT03068273|DEVICE|Real-time CGM data|
224323034|NCT04073420|DEVICE|Surgical Heart Valve Repair Products|Surgical heart valve repair products.
224323035|NCT04073420|DEVICE|Surgical Heart Valve Replacement Products|Surgical heart valve replacement products.
224323036|NCT03569293|DRUG|Placebo for Upadacitinib|Tablets taken orally once a day
224323037|NCT03569293|DRUG|Upadacitinib|Tablets taken orally once a day
224323038|NCT01171898|DRUG|ARN-509 (Phase 1)|ARN-509 will be administered at a starting dose of 30 milligram per day (mg/day), with escalations to 60 mg, 90 mg, 120 mg, 180 mg, 240 mg, 300 mg, 390 mg, and 480 mg daily.
224323039|NCT01171898|DRUG|ARN-509 (Phase 2)|ARN-509 will be administered at Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RP2D), determined in Phase 1.
224323040|NCT06845774|BEHAVIORAL|CDC PrEP with active referral|The single session SOC utilizes structured risk assessments and educational materials recommended by the CDC, based on the CDC PrEP 101 information, and delivered one-on-one by trained study staff in about 15 minutes. This will be followed by active referral to a local provider; local providers have been identified to receive study referrals in each community. This session will occur the same day or within one week of study enrollment.
224323041|NCT06845774|BEHAVIORAL|TelePrEP|The TelePrEP intervention includes an initial one-on-one in person intervention session with trained study staff that: 1) engages in provides basic education on PrEP care tailored for PWID; 2) encourages participation in a telehealth clinical evaluation for PrEP; and, 3) offers the opportunity to participate in point of care baseline testing for PrEP. At the conclusion of session 1, for those who express readiness to link with PrEP care, study staff will immediately facilitate access to the telehealth platform onsite. Four telehealth visits will be offered to access initial and follow-up clinical care for PrEP.
223679531|NCT07214805|BEHAVIORAL|Warning UPF, Yellow, Icon-plus-text Labels|Participants will view a fast-food restaurant menu excerpt. Each menu item will be displayed with an image of the item, name, price, and total calories. The Warning UPF, Yellow, Icon-plus-text labels will be displayed next to items that are ultra-processed. Participants will view the menu and then the label in isolation and then be asked about a hypothetical intention to purchase a menu item with the label.
223679532|NCT07214805|BEHAVIORAL|Ultra-Processed, Red, Text-only Labels|Participants will view a fast-food restaurant menu excerpt. Each menu item will be displayed with an image of the item, name, price, and total calories. The Ultra-Processed, Red, Text-only labels will be displayed next to items that are ultra-processed. Participants will view the menu and then the label in isolation and then be asked about a hypothetical intention to purchase a menu item with the label.
223679533|NCT07214805|BEHAVIORAL|Contains Food Additives, Red, Text-only Labels|Participants will view a fast-food restaurant menu excerpt. Each menu item will be displayed with an image of the item, name, price, and total calories. The Contains Food Additives, Red, Text-only labels will be displayed next to items that are ultra-processed. Participants will view the menu and then the label in isolation and then be asked about a hypothetical intention to purchase a menu item with the label.
223679534|NCT07214805|BEHAVIORAL|Warning Ultra-Processed, Red, Text-only Labels|Participants will view a fast-food restaurant menu excerpt. Each menu item will be displayed with an image of the item, name, price, and total calories. The Warning Ultra-Processed, Red, Text-only labels will be displayed next to items that are ultra-processed. Participants will view the menu and then the label in isolation and then be asked about a hypothetical intention to purchase a menu item with the label.
223679535|NCT07214805|BEHAVIORAL|Warning UPF, Red, Text-only Labels|Participants will view a fast-food restaurant menu excerpt. Each menu item will be displayed with an image of the item, name, price, and total calories. The Warning UPF, Red, Text-only labels will be displayed next to items that are ultra-processed. Participants will view the menu and then the label in isolation and then be asked about a hypothetical intention to purchase a menu item with the label.
223679536|NCT07214805|BEHAVIORAL|Ultra-Processed, Yellow, Text-only Labels|Participants will view a fast-food restaurant menu excerpt. Each menu item will be displayed with an image of the item, name, price, and total calories. The Ultra-Processed, Yellow, Text-only labels will be displayed next to items that are ultra-processed. Participants will view the menu and then the label in isolation and then be asked about a hypothetical intention to purchase a menu item with the label.
223679537|NCT07214805|BEHAVIORAL|Contains Food Additives, Yellow, Text-only Labels|Participants will view a fast-food restaurant menu excerpt. Each menu item will be displayed with an image of the item, name, price, and total calories. The Contains Food Additives, Yellow, Text-only labels will be displayed next to items that are ultra-processed. Participants will view the menu and then the label in isolation and then be asked about a hypothetical intention to purchase a menu item with the label.
223679538|NCT07214805|BEHAVIORAL|Warning Ultra-Processed, Yellow, Text-only Labels|Participants will view a fast-food restaurant menu excerpt. Each menu item will be displayed with an image of the item, name, price, and total calories. The Warning Ultra-Processed, Yellow, Text-only labels will be displayed next to items that are ultra-processed. Participants will view the menu and then the label in isolation and then be asked about a hypothetical intention to purchase a menu item with the label.
223679539|NCT07214805|BEHAVIORAL|Warning UPF, Yellow, Text-only Labels|Participants will view a fast-food restaurant menu excerpt. Each menu item will be displayed with an image of the item, name, price, and total calories. The Warning UPF, Yellow, Text-only labels will be displayed next to items that are ultra-processed. Participants will view the menu and then the label in isolation and then be asked about a hypothetical intention to purchase a menu item with the label.
223679541|NCT07215416|DRUG|Antisense oligonucleotide targeting the ATM gene|Atipeksen is a fully modified PS-2'MOE splice-switching antisense oligonucleotide that is designed to restore normal splicing patterns in patients with the ATM c.7865C\>T mutation.
223679542|NCT07215468|DRUG|TMB-365|A monoclonal antibody acts as a HIV post-attachment inhibitor to be given intravenously
223679543|NCT07215468|DRUG|TMB-380|A broadly neutralizing antibody (bNAb) against HIV to be given intravenously
223679544|NCT07215468|DRUG|Baseline ART|Baseline ART to be taken daily and orally
223773487|NCT05209685|OTHER|Resistance exercise on the lower extremities with blood flow restriction|Blood flow restriction on the thigh of the dominant leg will be used in combination with resistance exercise.
223773488|NCT04185168|DIETARY_SUPPLEMENT|soy isoflavone|100 mg soy isoflavone (as 2 tablets)
223773489|NCT04185168|OTHER|control|2 tablets of placebo
223773490|NCT02751177|GENETIC|KRAS, NRAS et BRAF mutation analysis from circulating plasma DNA|Mutation in plasma DNA vs tumor tissue
223773491|NCT01071512|DRUG|Tysabri|Infuse TYSABRI® 300 mg in 100 mL 0.9% Sodium Chloride Injection, USP over approximately one hour. After the infusion is complete, flush with 0.9% Sodium Chloride Injection, USP. Tysabri will be infused every four weeks.
223773492|NCT03212625|DRUG|Urea Cream 20%|Sorafenib 400mg (twice daily), Spread urea cream (urea 20%)
223773493|NCT03212625|DRUG|Placebos|Sorafenib 400mg (twice daily), Spread placebo cream (urea 0%)
223679545|NCT07215208|OTHER|CAD/CAM metallic partial denture frameworks|The CAD/CAM workflow starts with scanning of the physical model (master cast) to create a 3D virtual representation. Dental professionals then digitally analyze this virtual model and design the metallic partial denture frameworks using specialized computer software. Once the design is finalized, a wax pattern of the framework is either milled or 3D printed. Then proceeding with this wax pattern to fabricate the final metal partial denture framework, either by conventional casting process, or milling of the metallic framework
223679546|NCT07215208|OTHER|Conventional metallic partial denture frameworks|The metallic partial denture frameworks have proven to be affordable and convenient treatment option for partially dentate patients for it is rigidity and durability. It can be used in thin sections and provide high strength and stiffness. However, metallic partial denture frameworks also come with several drawbacks. A significant concern for some patients is the metallic display, which can lead to poor esthetics. Other disadvantages include increased prosthesis weight, a potential metallic taste, and a tendency for plaque accumulation. Additionally, they can induce stresses on the abutment teeth
223773494|NCT00075829|PROCEDURE|One Autologous Transplant|Melphalan will be administered at a dose of 200 mg/m2. Melphalan will be given in one dose infused on Day -2. Melphalan dose is based on ideal body weight (IBW) for patients who weigh 100-120% of their IBW. All patients will receive an autologous graft with a minimum cell dose of 2.0 x 106 CD34+ cells/kg patient weight. Patients will receive \~5 ug/kg/day of Granulocyte-Colony Stimulating Factor (G-CSF) subcutaneously from Day 5 post-transplant until absolute neutrophil count (ANC) \> 500/mm3 for two days.
223773495|NCT00075829|PROCEDURE|Non-Myeloablative Allogeneic Transplant|Upon recovery and at least Day 60 post-autograft, patients with an available 6/6 HLA matched sibling will receive an allograft after non-myeloablative conditioning. Day 0 patients will receive Total Body Irradiation (TBI) 2.0 Gy from a linear accelerator ≤ 20 cGy/min, followed by allogeneic peripheral blood stem cell (PBSC) infusion. Commence cyclosporine (CSA) on Day -3 at 5 mg/kg bid PO for a daily dose of 10 mg/kg/day through Day +84 based on actual body weight. Starting on Day 84, patients in partial or complete response with the absence of graph versus host disease (GVHD) will have CSA tapered so the patient will be off CSA by Day 180. Oral administration of Mycophenolate Mofetil will be at a daily dose of 30 mg/kg/day from the evening of Day 0 until Day 27 post-transplant.
223773496|NCT00075829|PROCEDURE|Second Autologous Transplant|Upon recovery from the first autograft, but at least 60 days (preferably between 60-120 days) after the first autograft, patients without an HLA-matched sibling donor will receive a second autograft, also conditioned with melphalan 200 mg/m2.
223773497|NCT00075829|DRUG|Thalidomide|Patients will be initiated on a starting dose of 50 mg/day. The dose will be increased weekly by 50 mg as tolerated to achieve a target dose of 200 mg/day. Patients will be treated for 12 months with thalidomide.
223773498|NCT00075829|DRUG|Dexamethasone|Patients will receive dexamethasone at a dose of 40 mg per day during Days 1-4 of each month for 12 months. The first dose of dexamethasone to be given the same day the patient starts thalidomide.
223773499|NCT00075829|BEHAVIORAL|Observation|One year of observation post-transplants.
223773500|NCT04089267|DRUG|TPO|
223773501|NCT01387204|DRUG|GSK1120212|The 2 mg dose is based on clinical data from the ongoing FTIH study in which subjects have been dosed daily for greater than 21 days, as well as preclinical toxicity data.
223773502|NCT03126799|DRUG|Erlotinib plus Bevacizumab|Erlotinib 150mg, po, daily, q 3weeks plus Bevacizumab 15mg/kg, IV, on D1 Q 3 weeks
224323042|NCT03417388|DRUG|High dose potent statin|The IMT-assigned women will receive high-dose, potent statin (atorvastatin 40-80 mg/d or rosuvastatin 20-40mg) class of lipid-lowering medications.
224323043|NCT03417388|DRUG|ACE-I (lisinopril) or ARB (losartan)|Angiotensin converting enzyme inhibitors (ACE inhibitors) and angiotensin receptor blockers (ARBs) are widely prescribed for primary hypertension.
224323044|NCT03417388|DRUG|Aspirin 81 enteric coated tablet daily|Will be recommended to IMT women without contraindications or bleeding risk.
223679547|NCT07215455|DIETARY_SUPPLEMENT|Ashwagandha 300 mg standardized root extract|Participants in this group will receive KSM-66 Ashwagandha, a standardized root extract of Withania somnifera, 300 mg once daily in capsule form. KSM-66 is a high-concentration, full-spectrum extract of Ashwagandha root, designed to provide adaptogenic effects for stress reduction and support weight management. Participants will be instructed to take the capsule with water, preferably at the same time each day, for the duration of the 8-week study. Adherence will be monitored via pill counts and participant diaries.
223773503|NCT03126799|DRUG|Erlotinib|Erlotinib 150mg, po, daily, Q weeks
223773504|NCT05068973|DEVICE|NOVATECH® LUCIOLA™ EB - (Fiducial Marker)|Bronchoscopic implantation in the lung of the NOVATECH® LUCIOLA™ EB fiducial marker
223773505|NCT02794272|DEVICE|tDCS|
223773506|NCT02794272|DEVICE|sham-tDCS|
223773507|NCT01122966|DRUG|intraocular injections of bevacizumab|intracameral and subconjunctival injections
223773508|NCT05267171|OTHER|Web access|The intervention group will have access to the website where the information is provided. The control group will not have this access.
223773509|NCT04341974|DIAGNOSTIC_TEST|Serum creatinine|Will be described: 1) the number of patients actually screened with postoperative serum creatinine and 2) the number of patients actually screened with the same parameter at the long-term after surgery
223773510|NCT00499135|OTHER|Computed Tomography|Correlative studies
223773511|NCT00499135|OTHER|Fluorothymidine F-18|Correlative studies
224323045|NCT03417388|BEHAVIORAL|Lifestyle Counseling|The PACE Lifestyle Assessment Intervention which is a program to assist with smoking cessation, weight loss, and exercise.
224323046|NCT03417388|BEHAVIORAL|Quality of Life Questionnaires|Quality of Life Questionnaires will be obtained.
224323047|NCT04820933|DRUG|Doravirine 100 Mg|Doravirine 100 Mg orally dail
224323048|NCT06847724|BIOLOGICAL|CYB704|Intravenous Infusion
224323049|NCT06847724|BIOLOGICAL|Ocrevus-EU|Intravenous Infusion
224323050|NCT06847724|BIOLOGICAL|Ocrevus-US|Intravenous Infusion
224323051|NCT06843902|OTHER|Health Education|Health Education
224323052|NCT06843902|OTHER|Subspecialty clinic referral|This intervention will entail referred to establish clinical care in either the MGH Lipid and Metabolism Clinic or the MGH Renal Clinic for consideration of SGLT2 inhibitor therapy. SGLT2 inhibitor therapy (e.g. empagliflozin 10 mg by mouth daily or dapagliflozin 10 mg by mouth daily) may or may not be prescribed by the subspecialty clinician as part of routine clinical care, according to the clinician's clinical judgement.
224323053|NCT06843590|DRUG|ALKS 2680|Oral tablet containing ALKS 2680 for once daily administration
224323054|NCT06843590|DRUG|Placebo|Oral placebo tablet for once daily administration
224323055|NCT05037097|BIOLOGICAL|ARCT-165|Dose 3
224323056|NCT05037097|BIOLOGICAL|ARCT-154|Dose 2
224323057|NCT05037097|BIOLOGICAL|ARCT-021|Dose 1
224323058|NCT04244604|OTHER|Low Sodium Meal (140 mg sodium chloride)|Varied amounts of salt (sodium chloride) will be added to a very low sodium soup to determine the effects of a single high sodium meal on measures of vascular function and autonomic regulation of blood pressure. The Low Sodium soup will serve as the control condition.
224323059|NCT04244604|OTHER|High Sodium Meal (2500 mg sodium chloride)|Varied amounts of salt (sodium chloride) will be added to a very low sodium soup to determine the effects of a single high sodium meal on measures of vascular function and autonomic regulation of blood pressure. The Low Sodium soup will serve as the control condition.
224323060|NCT05329649|BIOLOGICAL|CTX001|Administered by intravenous infusion following myeloablative conditioning with busulfan.
224323061|NCT03143374|DRUG|18F-AV-1451|"The experimental tracer used for this study is called 18F-AV-1451 is a specialized radioactive PET tracer used to detect the presence of tau proteins in the brain.~Participants will undergo a baseline 18F-AV-1451 brain scan. If funding is available, participants will be asked to return for one or more longitudinal visits, including a 18F-AV-1451 brain scan, every 9 to 18 months after the prior visit.~The 18F-AV-1451 PET/CT scan will require up to 3 hours of time, including preparation. The scan will take place using PET/CT scanners in the Perelman Center for Advanced Medicine or the Hospital of the University of Pennsylvania."
224323062|NCT05361551|PROCEDURE|Liver ablation|Ablation needle placement An image-guidance device be used for planning of the procedure and for placement of the ablation needle
224323063|NCT05557695|DRUG|Acalabrutinib|Acalabrutinib
224323064|NCT03430583|DRUG|Udenafil|Open-label extension with Udenafil 87.5 mg BID treatment for 52 weeks.
224323065|NCT01852370|BIOLOGICAL|CD3/CD19 negative allogeneic hematopoietic stem cells|Negative selection for CD3/CD19 will be performed on a CliniMACS® depletion device within 36 hours of collection and given at time no less than 8 weeks post lung transplant.
224323066|NCT06039566|DRUG|IV N-acetylcysteine|N-acetylcysteine (NAC) 150 mg/kg (Max dose 15,000 mg) through an IV that will run for 60 minutes at the start of the procedure
224323067|NCT06039566|DRUG|IV Placebo|Placebo 0 mg/kg (placebo: 0.45% NaCl or D5W) through an IV that will run for 60 minutes at the start of the procedure.
224323068|NCT04201288|BEHAVIORAL|Acceptance-Based Behavior Therapy (ABBT)|Acceptance-Based Behavior Therapy (ABBT) In the first session, the interventionist will introduce the concept of acceptance and its possible benefits in the context of life values and participant-identified barriers to retention in care. Interventionists will help participants identify potential challenges to acceptance, including disclosure concerns. At the second session, participants will practice acceptance-based coping skills and a behavioral plan will be developed to target barriers identified in the first session. These discussions will help the participant clarify how best to align their values with decisions on how to manage their HIV.
224323069|NCT04201288|BEHAVIORAL|Enhanced-Treatment-as-Usual (ETAU)|ETAU will consist of two brief sessions lead by study interventionists, performed at the same times and by same methods as ABBT. Topics of education include safe sex practices, review of treatment options, and review of HIV-related indices of health.
224323070|NCT03983837|OTHER|Neocate Splash|Neocate Splash is a hypoallergenic, amino acid based elemental liquid diet that is taken orally.
224323071|NCT03732898|DEVICE|Novel Programming (nDBS)|The commercial CP installed with the investigational DBS programming software will be used to set up Novel Programming (nDBS) therapy on the IPG.
224323072|NCT03732898|DEVICE|Conventional Programming (cDBS)|The commercial CP installed with commercial software will be used to set up standard cDBS therapy on the IPG.
224259804|NCT01547286|BIOLOGICAL|Standardized Cat Allergen Extract and Standardized Dust Mite Allergen|The route of administration will be topical application of the titrated allergen via nebulized droplets to the lungs. The starting dose of allergen will be 3 dose dilutions below the estimated provocative concentration of allergen that causes a 20% fall in Forced Expired Volume in 1 second delivered for 5 minutes at tidal breathing, followed by Forced Expired Volume in 1 second at 10-minute intervals until the lowest Forced Expired Volume in 1 second is established. If the percent of Forced Expired Volume in 1 second fall is \< 20%, the next concentration is given, until the Forced Expired Volume in 1 second falls ≥ 20 percent. When this happens the Forced Expired Volume in 1 second will be followed at 10, 20, 30, 45, and 60 minutes, then hourly for 7 hours. The early asthmatic response is the maximum percent of Forced Expired Volume in 1 second fall between 0 and 3 hours and the late asthmatic response between 3 and 7 hours post allergen challenge.
224259805|NCT01547286|RADIATION|Computed Tomography imaging, functional Positron Emission Tomography imaging|Physiology study using Computed Tomography and Positron Emission Tomography imaging with Nitrogen-13 saline as radiotracer; images obtained during the early and late phases after allergen challenge
224323073|NCT05582993|BIOLOGICAL|Vonicog Alfa|Vonicog Alfa administered by intravenous injection.
224259806|NCT01547286|DRUG|Nebulized methacholine inhalation|Standard methacholine challenge performed once to determine the subject's dose that causes a 20% fall in Forced Expired Volume in 1 second from baseline.
224323074|NCT05582993|BIOLOGICAL|ADVATE|ADVATE administered by intravenous injection.
224323075|NCT05489575|DEVICE|Active CPAP|Continuous positive airway pressure (CPAP) is applied at 8, 10, or 12 cm H20. The active CPAP level will be determined during a CPAP titration trial
224323076|NCT05489575|DEVICE|Sham CPAP|Sham continuous positive airway pressure applied at \<4 cm H2O
224323077|NCT05489575|OTHER|Sleeping in a head-up tilt (HUT) position|Sleeping with the whole bed tilted head-up by 10 degrees or with the head elevated by 13-14 inches.
224323078|NCT06392789|BEHAVIORAL|Cognitive Behavior Therapy for Insomnia|Receive sleep education
224323079|NCT06392789|OTHER|Internet-Based Intervention|Receive access to website content modules
224323080|NCT06392789|OTHER|Medical Device Usage and Evaluation|Wear activity tracker
224323081|NCT06392789|OTHER|Questionnaire Administration|Ancillary studies
224323082|NCT06392789|OTHER|Text Message-Based Navigation Intervention|Receive sleep compression SMS conversations
223773512|NCT00499135|OTHER|Laboratory Biomarker Analysis|Correlative studies
223773513|NCT00499135|OTHER|Pharmacological Study|Correlative studies
224259807|NCT03254225|BEHAVIORAL|Resistance training|Resistance training performed three times at week for 16 weeks, in 8 exercises for the main muscles, the protocol of 3 sets of 10 repetitions with intensity of 50% of 1 maximum repetition (MR).
224259808|NCT02188563|OTHER|Comprehensive smoking cessation intervention|
224259809|NCT02188563|BEHAVIORAL|Enhanced usual care|
224259810|NCT00540995|DRUG|busulfan|Given IV
224323083|NCT04778371|OTHER|Almonds|64 g total dry roasted, unsalted almonds per day for a total of 12 weeks
224323084|NCT04778371|OTHER|Placebo|200 g total calorie matched granola bar per day for total of 12 weeks
224323085|NCT02038842|BIOLOGICAL|LIPO-5|LIPO-5: 1mL IntraMuscular, 2 shots;
224323086|NCT02038842|BIOLOGICAL|MVA HIV-B (MVATG17401)|MVA HIV-B (MVATG17401): 0.5mL IntraMuscular, 2 shots;
223679548|NCT07215455|OTHER|Identical placebo capsule.|Participants in this group will receive an identical placebo capsule that matches the appearance, size, color, and taste of the KSM-66 Ashwagandha capsule but contains inactive ingredients. The placebo is administered once daily for 8 weeks. Participants will be instructed to take the capsule with water, preferably at the same time each day. Adherence will be monitored via pill counts and participant diaries. The use of a placebo allows comparison with the Ashwagandha group to evaluate efficacy and safety outcomes while maintaining blinding for participants and study staff.
224259811|NCT00540995|DRUG|etoposide|Given IV
224259812|NCT00540995|RADIATION|intensity-modulated radiation therapy|Initially 150 cGy X 8 doses with gradual dose escalation to 200 cGy X 10 doses
224259813|NCT00540995|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Stem cell transplantation occurs on Day 0 after High Dose Therapy
224259814|NCT00540995|PROCEDURE|allogeneic bone marrow transplantation|Stem cell transplantation occurs on Day 0 after High Dose Therapy
224259815|NCT00540995|PROCEDURE|peripheral blood stem cell transplantation|Stem cell transplantation occurs on Day 0 after High Dose Therapy
224259816|NCT00540995|RADIATION|tomotherapy|Initially 150 cGy X 8 doses with gradual dose escalation to 200 cGy X 10 doses
224259817|NCT01464450|DRUG|Rivaroxaban|Single 20 mg-dose
224259818|NCT02376114|DRUG|Ginkgo biloba|The Ginkgo biloba extract that was used contained 24% ginkgo flavone glycosides and 6% terpene lactones (Vitamin Research Products, Carson City, Nevada). Patients took 60 mg of Ginkgo or a placebo twice daily by mouth for two weeks. The placebo consisted of 40 mg of corn starch. Ginkgo and the placebo were encapsulated to ensure identical appearance.
224259819|NCT02376114|DRUG|Placebo to Ginkgo biloba|
224323087|NCT02038842|BIOLOGICAL|GTU®-MultiHIV B: 0.5 mL IM via Biojector® 2000 and 0.5mL IntraDermic, 3 shots|GTU®-MultiHIV B: 0.5 mL IM via Biojector® 2000 and 0.5mL IntraDermic, 3 shots
223679551|NCT07215130|DEVICE|Cavitron Ultrasonic Surgical Aspirator (CUSA) Clarity|Ex vivo application of the Cavitron Ultrasonic Surgical Aspirator (CUSA) Clarity device to ovarian endometrioma cyst wall specimens. Tissue Select settings from 0 to 4 are used to evaluate tissue selectivity, specifically removal of endometriotic epithelium while preserving normal ovarian stroma. Samples are subsequently analyzed histopathologically.
224323088|NCT05443126|DRUG|EP0031|EP0031 is a potent next-generation selective RET-inhibitor (SRI)
223773514|NCT00499135|OTHER|Positron Emission Tomography|Correlative studies
223773515|NCT00499135|DRUG|Sunitinib Malate|Given PO
224259820|NCT03541538|DEVICE|Global manipulation|The therapist positioned himself at the head of the stretcher and with one hand supported the side of the participant's face. With the other hand supported the opposite face of the same and then performed contralateral rotation of the cervical and a slight traction to the tissue barrier to perform the manipulation impulse of high speed and short amplitude in rotation. The procedure was carried out bilaterally.
224259821|NCT03541538|DEVICE|Especific manipulation|The therapist positioned himself at the head of the stretcher and with one hand kept the middle phalange of the second finger laterally on the articular processes of the C6-7 vertebrae. With the contralateral hand he supported the opposing face of the participant by performing a tilt up to the C6-7 segment and contralateral rotation up to the tissue barrier to carry out the impulse quickly and short. The procedure was carried out bilaterally.
224259822|NCT05453422|OTHER|Self-Acupressure|Acupressure is a therapy method performed with an instrument or hand, fingertip, palm, elbow, knee, thumb relaxation and wrist bands on various points representing the waist organs in order to ensure the continuation and balance of the energy in our body.
224259823|NCT03006835|DRUG|Clopidogrel|
224259824|NCT05931458|PROCEDURE|Appendectomy|Laparoscopic appendectomy is a relatively simple surgical procedure that can be performedby most surgeons, either on an outpatient basis or with a single-night hospital stay. The laparoscopic approach is now the recommended option due to faster recovery times and fewer wound complications.
224259825|NCT05931458|DRUG|Infliximab|Administration of Infliximab (Anti-TNF-a biologic drug)
224259826|NCT04176835|DRUG|Oxytocin nasal spray|Single-dose oxytocin will be administered intranasally
224259827|NCT04176835|DRUG|Placebo|
224259828|NCT06152458|DRUG|Vitamin C|Patients in the intervention group (G1) (n=23) received the combined vitamin therapy: IV vitamin C (1.5 g every 6 hours administered as an infusion over 30 to 60 minutes and mixed in a 100- mL solution of normal saline), hydrocortisone (100 mg in bolus-100 mg in perfusor up to 60 min (200mg 24h),), and thiamine (200 mg every 12 hours administered as an infusion over 30 to 60 minutes and mixed in a 100-mL solution of normal saline) for 3 days.
224259829|NCT00258024|DRUG|IPT-sulphadoxinepyrimethamine|
223773516|NCT02076412|DRUG|Fostamatinib Disodium|Fostamatinib Disodium tablet 100 mg or 150 mg PO bid (morning and evening) over the course of 24 weeks.
223773517|NCT02076412|DRUG|Placebo|Placebo tablet PO bid (morning and evening)
223773518|NCT01760148|DRUG|interferon alpha 2b|"Interferon:dosage,5 million units/person;frequency,every other day (qod);duration,48 weeks;Subcutaneous injection.~Ribavirin: dosage,15mg/kg/day;frequency,three times a day (t.i.d);duration,48 weeks;take orally."
224259830|NCT03257735|DIAGNOSTIC_TEST|next-generation sequencing|"1. Patients' cerebrospinal fluid, blood and tumor tissue were collected within 3 days before treatment at diagnosis.~2. Patients' cerebrospinal fluid and blood were extracted at the time of first evaluation of efficacy after treatment (TKI began after 1 month or chemotherapy after 2 cycles).~3. Patients' cerebrospinal fluid and blood were extracted at first time of tumor progression，and re-biopsy of tumor tissue was done as much as possible.~All the samples were tested by next-generation sequencing."
224259831|NCT01804608|OTHER|Strength|
224259832|NCT01804608|OTHER|Sensorimotor|
224259833|NCT05651243|DIETARY_SUPPLEMENT|Ketone Ester Supplement|Oral ingestion of a ketone supplement combined with a flavoring agent and diluted in water
224323089|NCT05530772|DEVICE|Endoscopic necrosectomy|Initially, a tract is created between the stomach or duodenum with the walled-off pancreatic necrotic collection through placement of a stent. Then, the endosocpe is entered the necrotic cavity with CO2 insufflation, and the necrotic materials are removed with snare, grasper, or suctioning.
224323090|NCT05055843|PROCEDURE|Magnetic Resonance Imaging|Undergo 3D MRI
224323091|NCT05908240|OTHER|Care Coordinator Model|A centralized care coordinator at the National Psoriasis Foundation will provide evidence-based education regarding a heart healthy lifestyle (i.e., diet, exercise, smoking cessation) and guidance from the American Heart Association/American College of Cardiology regarding management of dyslipidemia and hypertension. This information will be conveyed to a primary care provider of the patient's preference.
224323092|NCT05285982|DRUG|Nintedanib (Ofev®)|Nintedanib (Ofev®) soft capsules
224323093|NCT04520451|DRUG|rilzabrutinib|oral tablet
223679552|NCT07215533|BEHAVIORAL|High-intensity interval training|The 4-week HIIT intervention will use a stationary bicycle performed 3 times/week (a total of 12 sessions over the 4-week), performing at the CRL. All participants will perform a 20-minute HIIT protocol (20 repetitions of 10-seconds work time followed by 50-seconds resting/active recovery for the first two weeks, and 10 repetitions of 20-seconds work time followed by 100-seonds resting/active recovery for the rest of two weeks; targeted 90% HRmax) after 5-minute warm-up (10% HRmax). The supervisor (PI: Joon Young Kim and/or Graduate researcher: Wonhee Cho) will provide encouragement and supervision for exercise adherence. Heart rate (Polar, Polar Electro Oy, Kempele, Finland) and rating of perceived exertion (RPE; detail described in the questionnaire section) will be recorded.
223773519|NCT00799149|DRUG|Gabapentin, Etoricoxib, Sugar pill|Control (Sugar pill) or gabapentin (1200 mg) or etoricoxib (120 mg) administered 30-90 min before the patient entered the operating room with a sip of water. Subsequent doses of the oral study drugs were administered on the mornings (08H00) of the first, second, and third postoperative days. .
223773520|NCT06135662|PROCEDURE|CAF + CTG|Surgical techniques for mandibular gingival recession: coronally advanced flap + connective tissue graft. Participants undergo initial evaluations, including periodontal exams and digital imaging, followed by standardized pre-operative preparations. Post-surgery, uniform care includes pain management and oral hygiene instructions, with follow-ups to monitor healing and assess outcomes. Primary and secondary outcomes, like root coverage and patient-reported satisfaction, are consistently measured across groups. Standardized data collection and analysis procedures ensure reliable, comparable results, facilitating an effective comparison of the surgical methods' efficacy.
224259834|NCT05651243|OTHER|Placebo|Oral ingestion of cellulose combined with a flavoring agent and diluted in water
224259835|NCT04754984|BEHAVIORAL|Pelvic floor workshop|Physiotherapist-led workshop on managing pelvic floor symptoms
224259836|NCT03415308|OTHER|Focus Groups|Investigators will use qualitative methods to gather data on the elements associated with the patient perception of implicit bias (e.g. communication, respect, patient-centeredness) to ensure that our selected outcomes reflect the breadth of patients' concerns.
224323094|NCT04520451|DRUG|Glucocorticoids|oral tablet or capsule
224323095|NCT03412773|DRUG|Tislelizumab|Tislelizumab 200 mg intravenously (IV) once every three weeks (Q3W)
224323096|NCT03412773|DRUG|Sorafenib|Sorafenib 400 mg orally (PO) twice daily (BID)
224323097|NCT06280391|DRUG|Itepekimab (SAR440340)|Pharmaceutical form: solution for injection in pre-filled syringe. Route of administration: subcutaneous
224323098|NCT06280391|DRUG|Placebo|Pharmaceutical form: solution for injection in pre-filled syringe. Route of administration: subcutaneous
224323099|NCT04718389|BIOLOGICAL|GSK3511294 (Depemokimab)|GSK3511294 (Depemokimab) will be provided in a single-use prefilled syringe (PFS).
224323100|NCT04718389|BIOLOGICAL|Mepolizumab|Mepolizumab will be provided in a single-use PFS.
224323101|NCT04718389|BIOLOGICAL|Benralizumab|Benralizumab will be provided in a single-use PFS.
224259837|NCT03415308|OTHER|Cognitive Interviews|To gather insights from stakeholders regarding how to best refine the design of our existing implicit bias intervention to ensure that we have addressed potential facilitators and barriers to uptake, use, and sustainability
224259838|NCT03415308|OTHER|Pilot Testing of Implicit Bias Training|Determine the feasibility of delivering the refined implicit bias reduction intervention and assessing patient centered outcomes by giving providers a refined implicit bias training.
224259839|NCT05946486|DRUG|immunomodulatory treatment by rituximab|1g for adults or 375 mg/m2 for children, renewed at 14 days (+/- 3 days)
224323102|NCT04718389|BIOLOGICAL|Placebo|Placebo will be a sterile liquid formulation.
224323103|NCT04718389|DRUG|Standard of care (SoC)|Non-biologic SoC will include inhaled corticosteroid (ICS) plus at least one other controller, long-acting beta-2-agonist (LABA), long-acting muscarinic antagonist (LAMA), with or without maintenance oral corticosteroids (OCS).
224323104|NCT04718389|DEVICE|Pre-filled Syringes (PFS)|PFS will include glass barrel with pre-staked needle and plunger.
223679553|NCT07215533|BEHAVIORAL|Time-restricted eating|"Participants randomized into the TRE group will be instructed to consume all their calories within a 10-hour period. We will instruct participants that they can choose their time-window (early TRE \[7am - 5pm\] or late TRE \[1pm - 11pm\]), but it must remain constant for the duration of the study. Further, we will give no restrictions on the type of foods and/or the quantities individuals can consume. We will ask individuals to maintain their diet for the duration of the study. Participants will be given clear instructions on their diet and how to use the MyFitnessPal application. Participants will have their total daily energy requirement calculated using the following formula (Basal metabolic rate \[BMR\] x activity level) and will be told to eat that amount within their allotted time window. BMR will be calculated when participants have their body composition taken by the InBody. Participants will be told to start their 4-week diet the following day after visit."
223679556|NCT07215598|DEVICE|Composite Aligner Attachment|Composite aligner attachments are small, tooth-colored resin bumps bonded to specific teeth during Invisalign treatment to enhance aligner retention and force application. These attachments are digitally planned in ClinCheck software and fabricated using manufacturer-provided templates. In this study, two designs: optimized and conventional, will be compared for their accuracy and durability using 3D digital scans at multiple time points.
223679557|NCT07215572|OTHER|Implementation Strategy: Foundational Support|Foundational Support uses the Replicating Effective Program (REP) implementation strategy and includes 5 elements that were developed and tested in our prior Function QUERI work: shareholder engagement, Group PT toolkit, Online shared resources (SharePoint) access for clinical program training materials, data reports to assist sites with tracking their data, and Diffusion Networks to promote peer-to-peer sharing and implementation support.
223679558|NCT07215572|OTHER|Implementation Strategy: Reach+Equity Bundle|The Reach+Equity bundle will include the same activities as foundational support plus the Reach+Equity bundle activities which include: 1) external facilitation (provide an outside perspective to help sites identify barriers, develop effective strategies, and navigate complex change processes particularly through the lens of achieving equitable reach); 2) equity in implementation toolkit (guide that supports awareness and consideration of health equity during the implementation process); and 3) equity-focused data-driven monitoring (inform progress regarding equitable reach-related goals).
224259840|NCT02601963|DRUG|FMX-103 1.5%|The investigational product is FMX-103 minocycline foam. Two concentrations of the investigational product, 1.5% and 3%, will be studied compared to vehicle in patients with moderate-to-severe papulopustular rosacea. The foam will be applied once daily to the face for the 12-week treatment duration of the study.
224259841|NCT02601963|DRUG|FMX-103 3%|The investigational product is FMX-103 minocycline foam. Two concentrations of the investigational product, 1.5% and 3%, will be studied compared to vehicle in patients with moderate-to-severe papulopustular rosacea. The foam will be applied once daily to the face for the 12-week treatment duration of the study.
224259842|NCT02601963|DRUG|Vehicle foam (0%)|The investigational product is FMX-103 minocycline foam. Two concentrations of the investigational product, 1.5% and 3%, will be studied compared to vehicle in patients with moderate-to-severe papulopustular rosacea. The foam will be applied once daily to the face for the 12-week treatment duration of the study.
224259843|NCT05608642|OTHER|Intravenous hydration|500 cc intravenous serum for 1 hour in the first group service consists of patients who have been given.
224259844|NCT05608642|OTHER|Intravenous prednisolone|The second group consisted of patients who were given 80 mg intravenous prednisolone for the first 4 days and then gradually reduced doses of prednisolone in the following days.
224259845|NCT05608642|OTHER|Intravenous lidocaine|The third group includes patients in whom 2 mg/kg of intravenous lidocaine is given by 1-hour infusion.
224259846|NCT03563833|OTHER|Minimal Flow Anesthesia|Minimal Flow Anesthesia with 0,4 L min-1
224259847|NCT03563833|OTHER|High Flow Anesthesia|High Flow Anesthesia with 2 L min-1
224259848|NCT02036788|OTHER|Occlusion test|Occlusion test to assess the correct positioning of esophageal balloon catheter when the patient is breathing spontaneously.
224259849|NCT02036788|OTHER|Thoraco-abdominal compressions|Thoraco-abdominal compressions to assess the correct positioning of esophageal balloon catheter when the patient is sedated and paralyzed.
224259850|NCT05911711|OTHER|Prognostic factor|normal person (no sepsis group)
224259851|NCT00620893|DRUG|PEG- 400 based artificial tear|Baseline: Instill one drop in the randomized eye four times daily starting the day after surgery can be used more frequently if needed Month 3: Instill one drop in the randomized eye twice daily
224259852|NCT00620893|DRUG|Systane|Baseline: Instill one drop in the randomized eye four times daily starting the day after surgery can be used more frequently if needed Month 3: Instill one drop in the randomized eye twice daily
224259853|NCT03911583|BEHAVIORAL|Control Group (CG)|The control group does not receive these notifications (PUSH)
224259854|NCT03911583|BEHAVIORAL|Moderate physical activity group (MPA)|The women of the experimental group receive PUSH notifications remembering the objective set in consultation and encouraging them to achieve it.
224259855|NCT03911583|BEHAVIORAL|Intense physical activity group (IPA)|The women of the experimental group receive PUSH notifications remembering the objective set in consultation and encouraging them to achieve it.
224259856|NCT02225405|DRUG|Cisplatin|Given IV
224259857|NCT02225405|DRUG|Docetaxel|Given IV
224259858|NCT02225405|OTHER|Laboratory Biomarker Analysis|Correlative studies
224259859|NCT02225405|DRUG|Nintedanib|Given PO
224259860|NCT01471353|DRUG|Sorafenib Plus Capecitabine (SorCape)|Sorafenib 200-400 mg PO twice daily on days 1-21 (dose escalation schema) plus Capecitabine 1000 mg/m2 PO twice daily on days 1-14 repeated every 21 days
224259861|NCT00787553|DRUG|cefazolin|2.0 g, IV, 2 hours before surgery
224259862|NCT00787553|DRUG|tinidazole|2.0 g orally, 12 hours before surgery
224259863|NCT00787553|DRUG|cefazolin plus tinidazole|cefazolin, 2.0 g IV 2 hours before surgery plus tinidazole 2.0 g orally 12 hours before surgery
223773521|NCT06135662|PROCEDURE|Tunnel Technique + CTG|Surgical techniques for mandibular gingival recession: tunnel technique + connective tissue graft. Participants undergo initial evaluations, including periodontal exams and digital imaging, followed by standardized pre-operative preparations. Post-surgery, uniform care includes pain management and oral hygiene instructions, with follow-ups to monitor healing and assess outcomes. Primary and secondary outcomes, like root coverage and patient-reported satisfaction, are consistently measured across groups. Standardized data collection and analysis procedures ensure reliable, comparable results, facilitating an effective comparison of the surgical methods' efficacy.
223679561|NCT07215104|DEVICE|MuscleSCS|"The population for this study will include two specific groups of the same pain population. Group one is the Pre-existing SCS Group, these are pain patients with chronic back pain, and who have been implanted with an SCS system with a percutaneous lead or a paddle lead and BurstDRTM IPG for more than 6 month and having success with their BurstSCS stimulation (\>50% pain relief).~Group two is the Trial SCS Group, these are pain patients with chronic back pain, and who have been determined to be candidates for trial and potential permanent SCS with a percutaneous lead or a paddle lead and BurstDRTM IPG."
223679562|NCT07215728|OTHER|No intervention studied|No intervention studied
223679563|NCT07215364|BEHAVIORAL|Training program|Training program consist on physical activity sessions (combined resistance plus aerobic exercises) that will be performed 3 times per week every-other-day.
223679564|NCT07215169|OTHER|HIT|Manual Lymph Drainage 20 completions, first over the neck, then the face, and finally the neck again. This is repeated every second hour during the daytime.
223679565|NCT07215169|OTHER|LIT|Manual Lymph Drainage 20 completions, first over the neck, then the face, and finally the neck again once a day.
223679566|NCT07215676|DIETARY_SUPPLEMENT|AV1PD1A|Saccharomyces cerevisiae fermentate, N-acetyl-glucosamine, Saccharomyces boulardii, heat-killed Lactobacillus rhamnosus, methylcobalamin, berberine, ginger extract
223679567|NCT07215273|DRUG|EL219|EL219 is specifically being developed for early antifungal therapy (EAT), when infection is suspected due to highly suggestive signs and symptoms of disease; in high-risk people, antifungals are recommended even before confirmation of the microbial cause of infection, because delayed therapy is associated with poor outcomes in those who lack adequate immune responses. EL219 may provide a once-weekly alternative to LAmB and other polyenes that could also reduce the toxicities that often limit the frequency and duration of administration for these highly efficacious antifungals.
223679568|NCT07215273|DRUG|Antifungal Comparator|Placebo IV infusions (inf.) on Days 2-7, 9-14 to match LAmB dosing. Thereafter, twice daily oral or IV placebo equal to voriconazole dosing until Day 42/EOT. Active Comparator/SoC will receive LAmB 3 mg/kg IV inf. for at least 14 days \& up to 42 days. Voriconazole daily dosing loading 6 mg/kg via IV inf. every 12hrs for first 24hrs. Post-load: 4 mg/kg oral every 12hrs (50 mg tablets) or 4 mg/kg via IV inf. every 12hrs. Oral therapy will be admin., placebo IV inf. to match EL219 on Days 15, 22, 29 \& 36. May switch from LAmB to voriconazole (oral or IV) if any of these occur: diagnosis of proven or probable IA per EORTC/MSG criteria, other proven or probable susceptible mould infection, possible IMI requiring continued antifungal therapy. Toxicity: acute renal injury, hypokalemia or hypomagnesemia not controlled by IV supplementation, increase ALT 3×baseline and/or total serum bilirubin 3×baseline, intractable IRR. Need to switch to oral therapy for imminent hospital discharge.
223679569|NCT07215013|DEVICE|Personalized ART|ART personalized to the patient's exact cranio-facial dimensions. Once dimensions are calculated, ART frequency is calculated by an algorithm that is then transmitted to a headband worn by the patient three times a day.
223679570|NCT07215013|DEVICE|Non-personalized ART|ART frequency randomly transmitted to a headband worn by the patient three times a day.
223679571|NCT07215182|DRUG|[68Ga]Ga-FAPI-46|Patients undergo two PET/CTs with the experimental tracer \[68Ga\]Ga-FAPI-46 (drug).
223679572|NCT07215403|PROCEDURE|Prescriptive Infusion Algorithm|The study intervention is comprised of the neurosurgical procedure and the bilateral intraputaminal delivery of AB-1005.
223679573|NCT07215403|DRUG|AB-1005|bilateral intraputaminal delivery of AB-1005
223679574|NCT07215338|DEVICE|Palmar Temperature Control Device|The intervention will be placing the palms of the hands on a water perfused pad.
223679575|NCT07215299|DEVICE|Temporal Interference (TI) Electrical Stimulation - NAcc TI Active|"Non-invasive electrical brain stimulation delivered through two sets of scalp electrodes using alternating current frequencies (e.g., 2000 Hz and 2020 Hz) at up to 2 mA per electrode. This stimulation creates a beat frequency interference pattern (e.g., 20 Hz) that focally stimulates deep brain regions without activating overlying cortex.~For the NAcc TI Active condition, 2000Hz will be administered in one channel and 2020Hz in the other. These frequencies will be administered in 2 minutes on/2 minutes off cycles with a 30 second ramp up and ramp down beginning at the start of each 2 minute period."
223679576|NCT07215299|DEVICE|Temporal Interference (TI) Electrical Stimulation - NAcc TI Sham|"Non-invasive electrical brain stimulation delivered through two sets of scalp electrodes using alternating current frequencies (e.g., 2000 Hz and 2020 Hz) at up to 2 mA per electrode. This stimulation creates a beat frequency interference pattern (e.g., 20 Hz) that focally stimulates deep brain regions without activating overlying cortex.~For the NAcc TI Sham condition, 2000Hz will be administered in one channel and 2020Hz in the other. These frequencies will be administered in 2 minutes on/2 minutes off cycles, however, instead of the 30 second ramp up and ramp down at the beginning of each 2 minute period (as seen in the Active TI condition), the stimulation in the NAcc TI Sham condition will immediately ramp down as soon as it reaches 2mA after ramp up."
223679577|NCT07215299|DEVICE|Temporal Interference (TI) Electrical Stimulation - NAcc No-TI Active|"Non-invasive electrical brain stimulation delivered through two sets of scalp electrodes using the same current frequencies at up to 2 mA per electrode.~For the NAcc No-TI Active condition, 2000Hz will be administered in both channels. These frequencies will be administered in 2 minutes on/2 minutes off cycles with a 30 second ramp up and ramp down beginning at the start of each 2 minute period."
223773522|NCT00412165|BEHAVIORAL|Cell Phone|The cell phone arm receives access to the website with weekly health ed materials and weekly case management via phone, mail, e-mail
224323105|NCT01697930|DRUG|[18F] 4-L-Fluoroglutamine (2S,4R)|Thirty cancer patients will receive an injection of a 0.5 to 7.5mCi of \[18F\] 4-LFluoroglutamine (2S,4R) , followed by serial PET/CT scanning and blood draws, (at the direction of the investigator) over a period of 3.5 hours, on a single day. Each patient will be offered the opportunity to repeat the \[18F\] 4-L-Fluoroglutamine (2S,4R) injection and subsequent set of post-injection PET-CT scans, once, on a separate date. At the discretion of the investigator, scan 3 can be waived. Immediately prior to injection of the radiotracer, a blood sample will be obtained for measurement of serum glutamine level. The serum glutamine level will be assayed, if necessary, as part of an amino acid screen assay.
223679578|NCT07215299|DEVICE|Temporal Interference (TI) Electrical Stimulation - NAcc No-TI Sham|"Non-invasive electrical brain stimulation delivered through two sets of scalp electrodes using the same current frequencies at up to 2 mA per electrode.~For the NAcc No-TI Sham condition, 2000Hz will be administered in both channels. These frequencies will be administered in 2 minutes on/2 minutes off cycles, however, instead of the 30 second ramp up and ramp down at the beginning of each 2 minute period (as seen in the NAcc No-TI Active condition), the stimulation in the NAcc No-TI Sham condition will immediately ramp down as soon as it reaches 2mA after ramp up."
223679579|NCT07215117|BEHAVIORAL|Inpatient Whole Health Bundle|Hospitalized patients on the intervention units will be offered participation in the Inpatient Whole Health Bundle, which is comprised of a variety of offerings aimed at improving the wellbeing of the patient. They can choose to use any or none of the bundle elements.
223679580|NCT07215650|DRUG|Cizutamig|Cizutamig will be dosed according to the protocol
223679581|NCT07213947|OTHER|Nicotine Pouch Dosage|All participants will be experimentally manipulated by having nicotine dosage in hypothetical purchase tasks/ experimental marketplaces altered between market groups.
223679582|NCT07214792|BEHAVIORAL|Control (QR) Labels|Participants will view a fast-food restaurant menu with main entrée items. Each menu item will be displayed with an image of the item, name, price, and total calories. Control (QR) labels will be displayed beneath each item. Participants will view the menu and then the label in isolation and then be asked about a hypothetical intention to purchase a menu item with the label.
223773523|NCT00412165|BEHAVIORAL|Weekly access to interactive web site|This group receives access to the website with weekly health ed materials and weekly case management via phone, mail, e-mail
223773524|NCT00412165|BEHAVIORAL|Group|The Group arm receives monthly face to face group sessions plus access to the website with weekly health ed materials and weekly case management via phone, mail, e-mail
223773525|NCT03072173|DRUG|Xylometazoline|Patient will be given a nasal decongestant (Xylometazoline) prior to their 2nd or 3rd night of PSG.
223773526|NCT03072173|DRUG|placebo (saline)|Patient will be given a placebo nasal spray (saline) prior to their 2nd or 3rd night of PSG.
224323106|NCT05181683|DRUG|Casirivimab+Imdevimab|Randomized 1:1 for intravenous (IV) or subcutaneous (SC) administration
224323107|NCT06230224|DRUG|Odronextamab|Administered by intravenous (IV) infusion
224323108|NCT06230224|DRUG|Ifosfamide|Administered by IV infusion, as part of the ICE ± R salvage therapy
224323109|NCT06230224|DRUG|Carboplatin|Administered by IV infusion, as part of the ICE ± R salvage therapy
223679583|NCT07214792|BEHAVIORAL|Low Sustainability Labels|Participants will view a fast-food restaurant menu with main entrée items. Each menu item will be displayed with an image of the item, name, price, and total calories. Low Sustainability labels will be displayed beneath select items. Participants will view the menu and then the label in isolation and then be asked about a hypothetical intention to purchase a menu item with the label.
223773527|NCT04430426|OTHER|Controlled Diet|Participants will consume a controlled low oxalate diet for five days.
223773528|NCT04430426|OTHER|Glycolate Administration|Participants will come to the UAB Clinical Research Unit (CRU) and be administered a glycolate load via intravenous (IV) catheter.
223773529|NCT00029731|DRUG|Arginine hydrochloride|
223773530|NCT03778970|OTHER|Pain Neuroscience Education|Pain neuroscience education (2 sessions during 40 minutes) administered by an interactive workshop
223773531|NCT03778970|OTHER|Self-Management Education|A self-management education (2 sessions during 40 minutes) administered by an interactive workshop
223773532|NCT03778970|OTHER|Movement Control Exercises|Eight sessions of movement control exercises (30 minutes each) + advice to perform the exercises at home twice a week.
224323110|NCT06230224|DRUG|Etoposide|Administered by IV infusion, as part of the ICE ± R salvage therapy
224323111|NCT06230224|DRUG|Rituximab|Administered by IV infusion, as part of the ICE ± R, or DHAP ± R, or GDP ± R salvage therapy.
224323112|NCT06230224|DRUG|Dexamethasone|Administered by IV, or orally (PO) as part of the DHAP ± R, or GDP ± R salvage therapy.
223773533|NCT01221974|DEVICE|Essure Micro Insert|
223773534|NCT01910064|DRUG|GK530G|
223773535|NCT03072212|OTHER|Observational study|No intervention
223773536|NCT00851175|DRUG|rosuvastatin|7 day treatment with rosuvastatin 1dd 20mg
223773537|NCT00851175|DRUG|caffeine|intra-arterial (brachial artery of non dominant arm) administration of caffeine(90 ug/min/100ml forearm volume)for approximately 60 minutes
224323113|NCT06230224|DRUG|Cisplatin|Administered by IV infusion, as part of the DHAP ± R or GDP +/-R salvage therapy.
224323114|NCT06230224|DRUG|Cytarabine|Administered by IV infusion, as part of the DHAP ± R salvage therapy.
224323115|NCT06230224|DRUG|Gemcitabine|Administered by IV infusion, as part of the GDP ± R salvage therapy.
224323116|NCT06632457|DRUG|Survodutide|Subcutaneous injection
224323117|NCT06632457|DRUG|Placebo matching survodutide|Subcutaneous injection
224323118|NCT06000475|BEHAVIORAL|Cognitive Processing Therapy|CPT as described in the treatment manual
224323119|NCT06000475|BEHAVIORAL|Cognitive Processing Therapy (CPT) + Memory Support|CPT+Memory support will also incorporate frequent and intentional use of strategies to enhance learning and memory of this content.
224323120|NCT05056818|OTHER|Electronic Health Record Review|Review of medical records and past imaging examinations
224323121|NCT05650710|DEVICE|Nerve stimulation using nerve stimulation device and sterile wire electrode.|A nerve stimulator device will be used in this study as a research tool to investigate whether a future (currently nonexistent) medical device might be able to stimulate desired infrahyoid musculature in a therapeutic manner.
224323122|NCT06564844|DRUG|Datopotamab Deruxtecan|Datopotamab Deruxtecan IV (intravenous)
224323123|NCT06564844|DRUG|Rilvegostomig|Rilvegostomig IV (intravenous)
224323124|NCT06564844|DRUG|Carboplatin|Carboplatin IV (intravenous), Active Comparator
224259864|NCT06627712|DRUG|SBRT+PD-1 Inhibitor + Chemotherapy|"Radiotherapy: 24Gy/3f, once every other day; Chemotherapy: Cycles 1-4: Albumin-bound paclitaxel: 260 mg/m², IV, administered on day 1 of each cycle; Carboplatin AUC=5, IV, administered on day 1 of each cycle.~Cycles 5-8: Epirubicin: 90-100 mg/m², IV, administered on day 1 of each cycle; Cyclophosphamide: 600 mg/m², IV, administered on day 1 of each cycle; Immunotherapy: PD-1 inhibitor, once every three weeks"
224259865|NCT06627712|DRUG|PD-1 Inhibitor + Chemotherapy|"Chemotherapy: Cycles 1-4: Albumin-bound paclitaxel: 260 mg/m², IV, administered on day 1 of each cycle; Carboplatin AUC=5, IV, administered on day 1 of each cycle.~Cycles 5-8: Epirubicin: 90-100 mg/m², IV, administered on day 1 of each cycle; Cyclophosphamide: 600 mg/m², IV, administered on day 1 of each cycle; Immunotherapy: PD-1 inhibitor, once every three weeks"
224323125|NCT06564844|DRUG|Cisplatin|Cisplatin IV (intravenous), Active Comparator
224323126|NCT06564844|DRUG|Etoposide|Etoposide IV (intravenous), Active Comparator
224323127|NCT06564844|DRUG|Pemetrexed|Pemetrexed IV (intravenous), Active Comparator
224259866|NCT03187925|PROCEDURE|open, transcervical versus rigid endoscopic treatment|The goal of the project is to perform the first prospective, multi-institutional long-term (5 year) study comparing the outcomes of open, transcervical versus rigid endoscopic treatment of cervical esophageal diverticulum and cricopharyngeal dysfunction in resolving associated symptoms, complications, and recurrence rates of dysphagia surgery. This study will also include cricopharyngeal bar as it pertains to an early Zenker's diverticulum.
224259867|NCT00836472|DRUG|Glyburide/Metformin 5 mg/500 mg Tablets|1 x 5 mg/500 mg, single-dose fasting
223679584|NCT07214792|BEHAVIORAL|Unsustainable Labels|Participants will view a fast-food restaurant menu with main entrée items. Each menu item will be displayed with an image of the item, name, price, and total calories. Unsustainable labels will be displayed beneath select items. Participants will view the menu and then the label in isolation and then be asked about a hypothetical intention to purchase a menu item with the label.
223679585|NCT07214792|BEHAVIORAL|Environmental Harm Labels|Participants will view a fast-food restaurant menu with main entrée items. Each menu item will be displayed with an image of the item, name, price, and total calories. Environmental Harm labels will be displayed beneath select items. Participants will view the menu and then the label in isolation and then be asked about a hypothetical intention to purchase a menu item with the label.
224259868|NCT00836472|DRUG|Glucovance® 5 mg/500 mg Tablets|1 x 5 mg/500 mg, single-dose fasting
224259869|NCT03519139|OTHER|individual dietary counselling|individual dietary counsellings with the aim to ensure sufficient coverage of energy and protein needs of the test subjects
224259870|NCT02804724|OTHER|No intervention|
223679586|NCT07214792|BEHAVIORAL|High Environmental Harm Labels|Participants will view a fast-food restaurant menu with main entrée items. Each menu item will be displayed with an image of the item, name, price, and total calories. High Environmental Harm labels will be displayed beneath select items. Participants will view the menu and then the label in isolation and then be asked about a hypothetical intention to purchase a menu item with the label.
224259871|NCT00486187|DRUG|rosiglitazone|
224259872|NCT00486187|DRUG|metformin or sulfonylurea|
224259873|NCT00907387|DRUG|RT001|Dose A RT001
224259874|NCT00907387|DRUG|RT001|Dose B RT001
224259875|NCT00907387|OTHER|Placebo|Dose C Placebo
223679587|NCT07214792|BEHAVIORAL|High Environmental Cost Labels|Participants will view a fast-food restaurant menu with main entrée items. Each menu item will be displayed with an image of the item, name, price, and total calories. High Environmental Cost labels will be displayed beneath select items. Participants will view the menu and then the label in isolation and then be asked about a hypothetical intention to purchase a menu item with the label.
223679588|NCT07214792|BEHAVIORAL|Numeric Environmental Cost Labels|Participants will view a fast-food restaurant menu with main entrée items. Each menu item will be displayed with an image of the item, name, price, and total calories. Numeric environmental cost labels will be displayed beneath each item. Participants will view the menu and then the label in isolation and then be asked about a hypothetical intention to purchase a menu item with the label.
223679589|NCT07215429|DEVICE|No intervention|No intervention
223679590|NCT07215611|OTHER|data collection|data collection from electronic health records
224259876|NCT02013882|PROCEDURE|1-1-12 wash-in|wash-in phase during start of low flow anesthesia
224259877|NCT04858126|DEVICE|ECOM cardiac output|Measure cardiac output during perioperative period and compare to pulmonary artery catheter thermal dilution cardiac output measurement.
224259878|NCT04998526|OTHER|Experimental group|The cold gel pack will be applied to the nape.
224259879|NCT04998526|OTHER|Placebo group|The gel pack kept at room temperature will be applied to the nape.
224259880|NCT02518360|OTHER|Osteopathic|Body adjustment in three sessions (20 minutes/session).
224259881|NCT02518360|OTHER|Auto Stretching|The patients realize auto stretching in three sessions (20 minutes/session).
224259882|NCT03172286|DEVICE|Radiofrequencer|Patients will be treated with a radiofrenquencer switched on or off depending on the attributed group after randomization
224259883|NCT04733755|DIETARY_SUPPLEMENT|Beauty Image|1.97g/package; 2 packages one day for 8 weeks
224259884|NCT04733755|DIETARY_SUPPLEMENT|Placebo Control|Placebo Control; 1.97g/package; 2 packages one day for 8 weeks
224259885|NCT01695239|DRUG|Ixekizumab|Administered SC
224259886|NCT01695239|DRUG|Placebo|Administered SC
224259887|NCT01695239|DRUG|Adalimumab|Administered SC
224259888|NCT00538239|DRUG|ridaforolimus|Four 10 mg tablets taken by mouth for 5 days per week continuously
224259889|NCT00538239|DRUG|Placebo|Four 10 mg tablets taken by mouth for 5 days per week continuously
224259890|NCT02007863|PROCEDURE|Umbilical Cord Blood Transfusion|Following the administration of the preparative therapy, all subjects will undergo UCB transplantation. Umbilical Cord Blood Transfusion will occur on Day 0
224323128|NCT06564844|DRUG|Vinorelbine|Vinorelbine IV (intravenous), Active Comparator
224323129|NCT06564844|DRUG|UFT|UFT Oral route of administration, Active Comparator
224323130|NCT04510857|DEVICE|MOVE-IT Intervention|The MOVE-IT device comprises a custom smart toy and therapy game software to enable repetitive task practice involving the arm and hand.
224323131|NCT04510857|BEHAVIORAL|UCT Control|Participants assigned to the UCT control group will continue to receive their previously prescribed therapy services.
224259891|NCT02007863|DRUG|Fludarabine|Fludarabine 25 mg/m2/day will be administered over 30-60 minutes intravenous infusion on Days -13 through -9 for a total of 5 doses. Fludarabine will not be dose adjusted for body weight.
223773538|NCT01161758|OTHER|Passive cervical mobilisation|Passive cervical mobilization which involved an oscillatory grade III unilateral postero-anterior mobilization applied to the left C5/C6 segment. The mobilization consisted of 3 periods of 1 minute applications with a resting period of 1 minute in between.
224259892|NCT02007863|DRUG|Busulfan|Busulfan IV (Busulfex) will be administered IV every 6 hours on days -8 through -5 for a total of 16 doses. Seizure prophylaxis prior to first dose of busulfan till Day -3 will be administered.
223773539|NCT01161758|OTHER|Manual contact|Manual contact control, which involved light manual contact on the left C5/C6 segment as if to perform the treatment technique. The light manual contact consisted of 3 periods of 1 minute applications with a resting period of 1 minute in between.
224259893|NCT02007863|DRUG|Melphalan|Melphalan 45 mg/m2/day will be administered over 60 minutes intravenous infusion on Days -4 through -2 for a total of 3 doses.
224259894|NCT00004213|DRUG|triapine|
224259895|NCT03781102|BEHAVIORAL|16-Week Diabetes Prevention Program for Mothers and Children|The 16-week intervention is focused on ways to modify behaviors associated with the pathogenesis of Type 2 Diabetes in youth, while engaging participants in fun, active, and interactive food demonstrations, energy balance, and physical activities appropriate for all the family. Weekly sessions will consist of: (1) physical activity upon arrival; (2) small group discussions; (3) hands-on food preparation and tasting opportunities; (4) low- to no-cost fun family physical activities; (5) energy balance activities (e.g. label reading) to increase foundational knowledge; and, (6) opportunities to set new weekly goals.
224259896|NCT04865003|OTHER|treatment of infection|
224259897|NCT06627543|DIAGNOSTIC_TEST|echo|echocardiographic
224259898|NCT03146156|BEHAVIORAL|Lifestyle Intervention|The lifestyle intervention is healthy eating (Medeterranian diet) and exercise to decrease weight by 5-7% compared to prepregnancy weight.
224259899|NCT05629728|BEHAVIORAL|Tai Chi exercise|Sun-style Tai Chi (21 forms)
224259900|NCT04631393|DRUG|Propofol Alfentanil|Propofol and Alfentanil are self-administered by the participant.
224259901|NCT01022983|DRUG|Levosimendan|At least 2 hours before surgery: Infusion of Levosimendan (0,1 microgram/kg/min.). 24 hours of infusion without a bolus.
224259902|NCT01022983|DRUG|Placebo|ml/kg/hours - same infusion rate as active comparator
224259903|NCT00988715|BIOLOGICAL|Pretargeted Radioimmunotherapy|Antibody-streptavidin conjugate and radiolabeled DOTA-biotin, each given IV
223773540|NCT03053895|PROCEDURE|CSDH - Bedside twist drill technique|For patients randomized to bedside drainage of CSDH, the twist-drill procedure will be conducted at the patient's bedside using local anesthetic
224259904|NCT00988715|DRUG|Cyclosporine|Given IV
224259905|NCT00988715|DRUG|Mycophenolate Mofetil|Given PO
224259906|NCT00988715|RADIATION|Total-Body Irradiation|Undergo total-body irradiation
224259907|NCT00988715|PROCEDURE|Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation|Undergo peripheral blood stem cell transplant
224259908|NCT00988715|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo peripheral blood stem cell transplant
224259909|NCT00988715|DRUG|Fludarabine Phosphate|Given IV
224259910|NCT00988715|OTHER|Pharmacological Study|Correlative studies
224259911|NCT00988715|OTHER|Laboratory Biomarker Analysis|Correlative studies
224259912|NCT03333551|DRUG|F18 Florbetapir (amyvid) cardiac PET/CT imaging|Patients with cardiac amyloidosis (AL) undergoing planned plasma cell directed chemotherapy will have F-18 florbetapir (amyvid) cardiac PET/CT imaging prior to starting chemotherapy and six months after onset of treatment.
224259913|NCT00694187|DRUG|Zaleplon|
224259914|NCT04353362|DRUG|Ofloxacin|400 mg, 1 time per day for 5 days
224259915|NCT04353362|DRUG|Amoxicillin|500 mg, 3 times per day for 7 days
224259916|NCT04353362|DRUG|Metronidazole|500 mg, 3 times per day, for 7 days
224259917|NCT00767260|DRUG|BM-MNC+HOT|Autologous Bone Marrow Mononuclear cell Infusion Combined With Hyperbaric Oxygen Therapy
224259918|NCT00767260|DRUG|BM-MNC|Autologous Bone Marrow Mononuclear cell Infusion
224259919|NCT00767260|DEVICE|HOT|Hyperbaric Oxygen Therapy
224259920|NCT00767260|DRUG|SMT|hypoglycemic drugs or exogenous insulin
224259921|NCT00735540|OTHER|Observational|Data summary only
224259922|NCT02173886|DRUG|Bupropion SR and XL|
224259923|NCT04472039|DEVICE|optical coherence tomography (OCT)|OCT visualizes the retinal layers by backreflection of light
224259924|NCT00078039|DRUG|Paliperidone ER|
224259925|NCT03168763|BEHAVIORAL|Video|Participants shown Video 1A or 1B, then shown Video 2A or 2B.
224259926|NCT03168763|BEHAVIORAL|Questionnaires|Questionnaires completed at baseline, after each video viewing, and at completion.
224259927|NCT03850158|DRUG|Indocyanine Green|Indocyanine green is administered intra-venous after dilution with water in a peripheral vein at a dosage of 0.3mg/kg body weight as a bolus injection. The injection will take place during surgery. By using NIR fluorescence imaging ICG is made visible.
224259928|NCT05239195|OTHER|Video Laryngoscope|Laryngoscope with a camera and a video screen
224259929|NCT05239195|OTHER|Direct Laryngoscope|Laryngoscope without a camera or a video screen
224259930|NCT06626841|DIAGNOSTIC_TEST|Pelvic floor muscles contractile capacity and activation|"An initial assessment of the pelvic floor is carried out when athletes arrive at the facility. Participants then complete a FFT workout, which consists of performing as many rounds as possible (AMRAP type) of 20 wallballs, 15 box jumps, and 10 burpees within 15 minutes. These plyometrics and load lifting exercises are chosen to fatigue the PFM and are simple to execute. The pelvic floor assessment is performed again at 3 minutes following the FFT workout.~Measurements of the pelvic floor parameters are conducted by a specialist physiotherapist. The muscle activation and strength of the PFM are obtained using a vaginal dynamometer (i.e. pelvimeter probe fixed at a vertex with two arms that can be separated by up to 25°), connected to the Phenix USB2, Vivaltis (Pelvimètre Phenix, Vivaltis)."
224259931|NCT05502835|DEVICE|pulse pressure variation|Infusion of 2 ml/kg/hr. Ringer's solution guided by pulse pressure variation.
224259932|NCT05502835|OTHER|conventional fluid management|Infusion of 6 ml/kg/hr. Ringer's solution.
224259933|NCT00069758|DRUG|SDX-105|
223679591|NCT07215156|PROCEDURE|Arm 1 Scaling and Root Planing (SRP)|Full-mouth supragingival and subgingival debridement performed with ultrasonic and hand instruments (Gracey curettes). SRP performed to remove plaque and calculus and root-surface decontamination. Standardized oral hygiene instruction is provided after the procedure.
223679592|NCT07215156|DRUG|Arm 2 Metformin Gel 1% (locally delivered)|1% metformin hydrochloride formulated in a gellan-gum gel base (as per protocol). After SRP, gel is delivered subgingivally with a sterile syringe (23-gauge cannula) and left undisturbed for approximately 5 minutes; a periodontal dressing is placed for one week. Gingival crevicular fluid sampling and clinical follow-up at 1, 3, and 6 months.
223679593|NCT07215156|DRUG|Arm 3 Chlorhexidine Gel 0.2% (locally delivered)|0.2% chlorhexidine digluconate gel prepared in carbopol base. After SRP, gel is delivered subgingivally with a sterile syringe and left undisturbed for approximately 5 minutes; a periodontal dressing is placed for one week. Clinical follow-up at 1, 3, and 6 months.
223679594|NCT07214155|DRUG|Cannabis|Cannabis will be administered via smoked inhalation.
223679595|NCT07214155|OTHER|0 mg THC (placebo)|0 mg THC (placebo)
223679596|NCT07215312|DRUG|LY3938577|Administered SC
223679597|NCT07215312|DRUG|Degludec|Administered SC
223679598|NCT07215065|OTHER|Non-Interventional Study|Non-Interventional Study
223679600|NCT07215325|DRUG|Doxycycline monohydrate 200 mg|"Doxycycline monohydrate 200 mg (two 100 mg pills) is used to treat or prevent infections that are strongly suspected to be caused by bacteria. Doxycycline monohydrate is an antimicrobial drug indicated for the treatment of bacterial infections, including sexually transmitted diseases. CDC recommends its use as post-exposure prophylaxis (PEP).~Blood and rectal mucosal samples will be collected before the initiation of doxycycline. Participants will be instructed to take 200 mg of doxycycline by mouth every Monday, Wednesday, and Friday. Additional doses of doxycycline will be permitted on other days if sex without a condom occurs per CDC guidance. After 12 weeks of at least thrice weekly doxycycline, blood and rectal mucosal samples will again be collected for immunologic and microbiome/resistome assays."
223679601|NCT07215325|OTHER|Observation|Standard of care. Blood and rectal mucosal samples.
223679603|NCT07215286|PROCEDURE|Loaded-SNAG|patients will receive SNAGs from standing (Loaded-SNAG), step-stance, or functional position that provokes symptoms. A specialized Mulligan belt was used around the patient's waist and the therapist's hips. The mobilizing force was applied parallel to the facet joint plane (cephalic direction) and over the spinous processes of the respective symptomatic spinal levels. The therapist's hand's ulnar aspect was used over the spinous process of the superior vertebra of the involved segment for flexion glide. The therapist applies accessory glide to targeted zygapophyseal level while the patient actively performs symptomatic movement (e.g., forward flexion), performing repetitions with the therapist maintaining the glide.
223679604|NCT07215286|PROCEDURE|Unloaded-SNAG|patients will receive unloaded SNAG from quadruped position to reduce the axial loading. The therapist applies the equivalent accessory glide at the symptomatic spinal level while the patient performs the symptomatic movement (modified to be non-weight-bearing).
223679605|NCT07215442|OTHER|Warming stimulus starting at 30 C initial temperature|A warming stimulus starting at 30 C initial temperature was applied at a rate of 0.2 C/second until the participant perceived the stimulus or the termination temperature of 42 C was reached.
223679606|NCT07215442|OTHER|Warming stimulus starting at 32 C initial temperature|A warming stimulus starting at 32 C initial temperature was applied at a rate of 0.2 C/second until the participant perceived the stimulus or the termination temperature of 42 C was reached.
223679607|NCT07215442|OTHER|Warming stimulus starting at 34 C initial temperature|A warming stimulus starting at 34 C initial temperature was applied at a rate of 0.2 C/second until the participant perceived the stimulus or the termination temperature of 42 C was reached.
223679608|NCT07215442|OTHER|Warming stimulus starting at 35 C initial temperature|A warming stimulus starting at 35 C initial temperature was applied at a rate of 0.2 C/second until the participant perceived the stimulus or the termination temperature of 42 C was reached.
223679609|NCT07215442|OTHER|Cooling stimulus starting at 30 C initial temperature|A cooling stimulus starting at 30 C initial temperature was applied at a rate of 0.2 C/second until the participant perceived the stimulus or the termination temperature of 18 C was reached.
223679610|NCT07215442|OTHER|Cooling stimulus starting at 32 C initial temperature|A cooling stimulus starting at 32 C initial temperature was applied at a rate of 0.2 C/second until the participant perceived the stimulus or the termination temperature of 18 C was reached.
223679611|NCT07215442|OTHER|Cooling stimulus starting at 34 C initial temperature|A cooling stimulus starting at 34 C initial temperature was applied at a rate of 0.2 C/second until the participant perceived the stimulus or the termination temperature of 18 C was reached.
223679612|NCT07215442|OTHER|Cooling stimulus starting at 35 C initial temperature|A cooling stimulus starting at 35 C initial temperature was applied at a rate of 0.2 C/second until the participant perceived the stimulus or the termination temperature of 18 C was reached.
224259934|NCT06033417|OTHER|Increased lifestyle walking (intervention)|Participants will increase their baseline steps by a minimum of 3,000 extra steps/day, 5-days/week, for 8-weeks. Baseline steps will be assessed using a pedometer over a 7-day period before the intervention, after which a new (higher) daily step target will be assigned. The intervention will take place in the free-living setting, with participants reaching their step goals by engaging in more activities of daily living or via purposeful physical activity. Participants will wear a pedometer throughout the 8-week period to keep track of their steps, and adherence to the protocol will be determined by collecting the stored step data directly from each participant's pedometer on a weekly basis. Participants will be supported in their efforts to meet their daily step targets by engaging in once-weekly walking groups (30-mins/session) led by research staff. They will also receive 20-minute phone calls once every two weeks to set goals and create action plans for reaching their step targets.
223679613|NCT07215494|DRUG|First-Line Dara-BorCyD Treatment|First-Line Dara-BorCyD Treatment Achieves CR, but ASCT is Recommended for MRD-Positive Patients
223679614|NCT07215546|DEVICE|Montage or Montage CT|Application of Montage or Montage-CT Settable Resorbable Bone Putty to the cut sternal edge at the time of closure.
223679615|NCT07215624|OTHER|Non-Interventional Study|Non-interventional study
223679616|NCT07215624|OTHER|Non-Interventional Study|Non-interventional study
223679617|NCT07215624|OTHER|Non-Interventional Study|Non-interventional study
223679618|NCT07215767|DRUG|Stannous fluoride and Potassium nitrate Dentifrice|Fluoride dentifrice
223679619|NCT07215767|DRUG|Stannous fluoride Dentifrice|Fluoride dentifrice
223679620|NCT07215767|DRUG|Potassium nitrate Dentifrice|Non-fluoride dentifrice
223679621|NCT07215767|DRUG|Vehicle Dentifrice|Placebo dentifrice
223679622|NCT07215559|DRUG|Macupatide|Administered SC
223679623|NCT07215559|DRUG|Eloralintide|Administered SC
223679624|NCT07215559|DRUG|Macupatide Placebo|Administered SC
223679625|NCT07215559|DRUG|Eloralintide Placebo|Administered SC
223679628|NCT07215390|DRUG|APL-3007, pegcetacoplan (APL-2)|Complement C3 inhibitor
223679629|NCT07215390|DRUG|APL-3007, pegcetacoplan (APL-2)|Complement C3 Inhibitor
223679630|NCT07215390|OTHER|Placebo, Syfovre|Complement C3 Inhibitor
223679631|NCT07215234|DRUG|SAR446597|Intravitreal injection
223679632|NCT07215234|DRUG|Sham Comparator|Sham periocular injection
223679633|NCT07215260|DRUG|BI 3000202|BI 3000202
223679634|NCT07215260|DRUG|Rosuvastatin|Rosuvastatin
223679635|NCT07215260|DRUG|Digoxin|Digoxin
223773541|NCT03053895|PROCEDURE|CSDH - Operating Room Burr-hole technique|For patients randomized to burr-hole drainage, the procedure will be performed in the operating room under local or general anesthesia based on the surgeon's and anesthesiologist's judgement of the clinical stability of the patient.
223773542|NCT00963690|DEVICE|CloSys Hemostatic Device (HD)|Deploy CloSys HD to achieve hemostasis
224259935|NCT06033417|OTHER|Health education only (control)|Those randomized to the delayed participation group will be instructed to maintain their 'normal' lifestyle activities, thereby avoiding any significant increase in daily step counts beyond their 'baseline' values. Participants will wear a pedometer throughout the 8-week period to keep track of their steps, and adherence to the protocol will be determined by collecting the stored step data directly from each participant's pedometer on a weekly basis. Participants in this group will attend once-weekly group health education sessions (30-minutes/session), in addition to 5-minute, 'touch base' phone calls once every 2-weeks, but these phone calls will not involve goal-setting or action planning. After completing the initial 8-week period, these individuals can then opt to undertake the 'increased lifestyle walking' intervention of 3,000 extra steps/day over 5-days for 8-weeks if desired.
224259936|NCT03922763|PROCEDURE|Anatomical cut|Surgeon-derived cut based on patient's anatomy
224259937|NCT03922763|PROCEDURE|Cutting guide|Angle cut at 132.5 degrees based on cutting guide
224259938|NCT01654484|DRUG|DE-117|Ophthalmic Solution, QD, 28 Days
224259939|NCT01654484|DRUG|0.0015% tafluprost|Ophthalmic Solution, QD, 28 days
224259940|NCT01654484|DRUG|DE-117 and 0.0015% tafluprost|Ophthalmic Solutions, QD, 28 days
224259941|NCT01654484|DRUG|Placebo|Ophthalmic Solution, QD, 28 days
224259942|NCT01591564|BEHAVIORAL|Interpersonal Psychotherapy for youth with SMD (IPT-SMD)|Youth will receive weekly therapy sessions for 16 weeks and then bi-weekly session until week 20. Parent sessions will also be included.
224259943|NCT03552484|BEHAVIORAL|Home Visit Program|Informed consent discussion, documentation; UPDRS I-IV, medical history, vitals, medication reconciliation, patient medical history and comorbidities; home safety assessment; psychosocial assessment of dyad, resource utilization questionnaire, caregiver medical history and comorbidities, MCSI; patient and caregiver short MoCA, satisfaction surveys, EQ5D; counseling, summarizing plan of care
224259944|NCT03552484|BEHAVIORAL|Usual Care/Online Survey|Patients and caregivers, if available, will be asked to complete an online survey that asks about demographics, disease history, resource utilization, and unmet needs. The will be asked to complete a follow-up survey 12 months after completion of the initial survey.
224259945|NCT01548053|OTHER|PC-DATA tool|The implementation plan consists of educational sessions and a dementia care manager (DCM). The educational sessions consist of two components: a 1.5 hour group-based DATA tool implementation workshop with primary care providers (PCPs); and, a 1 hour follow-up session at study mid-point. The DCM will facilitate application of the DATA tool and provide direct support to PCPs during the study.
224259946|NCT05146076|OTHER|home-based physical training|home-based physical training minimum 150 min./week with telemonitoring
224259947|NCT05146076|OTHER|institutional physical training|institutional physical training supervised by physiotherapist 2-3 times 60 min./week
224259948|NCT05636254|DIAGNOSTIC_TEST|MRI Brain and spine|"* MRI Brain~* Ax T2 TSE~* 3D Sag T1~* Ax DWI~* 3D Sag Flair~* Ax SWI~* Post-gad 3D Sag T1~* 3D TOF Circle-of-Willis~* MRI Spine~* Sag T2 whole spine (2 stations)~* Post-gad Sag T1 whole spine (2 stations)"
224259949|NCT05636254|DIAGNOSTIC_TEST|Reference standard diagnostic criteria|"Diagnostic criteria-TBM~* Microbiologic evidence of TB in CSF~* Microbiologic evidence of TB from pulmonary or extrapulmonary sites~* Reasonable clinical certainty OR allied investigations such as CXR/CECT chest/abdomen/PET CT as per clinical indication suggestive of tuberculosis~* Other relevant investigations like CSF analysis not suggestive of alternative diagnosis such as neurocysticercosis/cryptococcal/other fungal infections/other causes of chronic meningitis such as brucella/ nocardia/ syphilis/recurrent viral meningitis/ carcinomatous/ lymphomatous meningitis or non infective causes such as sarcoidoisis/sub-arachnoid hemorrhage etc.~* Reasonable clinical certainty OR allied investigations such as CXR/CECT chest/abdomen/PET CT as per clinical indication ruling out competing diagnoses~* Patients who develop features or test results suggestive of alternative diagnosis with will be considered to be not due to tubercular meningitis"
224259950|NCT02045667|DRUG|Mexiletine|"Mexiletine is a lidocaine-derivate and belongs to the class of 1B antiarrhythmic agents (Vaughan-Williams Classification of Antiarrhytmica). Class I antiarrhythmics have membrane-stabilizing properties. Drugs in this class work by interfering with the fast influx of sodium by inhibition of sodium ionchannels during the fast depolarization phase, thereby decreasing the maximal voltage and upshoot phase of the action potential.~Mexiletine study-medication will be purchased from Stabilimento Chimico Farmaceutico Militare, Firenze, Italy."
224259951|NCT02045667|DRUG|Placebo|Placebo tablets do not contain any active medicinal component.
224259952|NCT06430632|DEVICE|Robotic Gait Training|Participants will complete standing and walking activities while wearing a robotic exoskeleton. Participants will also be asked to complete questionnaires about their walking and function.
224259953|NCT06430632|OTHER|Usual Care Gait Training|Participants will complete standing and walking activities such as body weight-supported treadmill training and conventional overground walking. Participants will also be asked to complete questionnaires about their walking and function.
224259954|NCT05959187|DIAGNOSTIC_TEST|pharmacogenomic testing|Pharmacogenomic testing has emerged as a promising diagnostic tool, allowing clinicians to guide the selection and dosage of antidepressant medications. In theory, pharmacogenomic testing may provide improved drug selection and dosing strategies for patients with genetic alterations related to drug response
224259955|NCT03280953|DIAGNOSTIC_TEST|Assessing fluid responsiveness by PWTT value|PWTT value will be analysed to find the cutoff values compared by esophageal doppler and pulse pressure variation.
224259956|NCT02248051|DRUG|CXA-10|CXA-10 Injectable Emulsion is a sterile emulsion containing CXA-10 in a formulation containing soybean oil, medium chain triglycerides oil, egg phospholipids, sucrose, and disodium EDTA. CXA-10 Injectable Emulsion will be administered intravenously. The active emulsion will be diluted in a vehicle emulsion.
223773543|NCT00963690|PROCEDURE|Standard compression|Use standard compression to achieve hemostasis
223773544|NCT02002494|OTHER|Different positions|Jugular venous blood flow in healthy volunteers in 3 different positions- supine, prone and park bench
223773545|NCT02420106|PROCEDURE|Osteopathic Manipulative Medicine|Osteopathic manipulative medicine involves manual technique to joints and soft tissue to improve movement.
223773546|NCT04103528|OTHER|morning surgery|31 patients will be operated on between 8:00 and 12:00 in the morning.
224259957|NCT00261391|DRUG|Marimastat|
224259958|NCT03548194|DRUG|BNC210|BNC210 300 mg b.i.d
224259959|NCT03548194|DRUG|Placebo|Placebo b.i.d.
224259960|NCT02741687|DRUG|Sitagliptin|Participants will take 100 mg/day for patients with glomerular filtration rate (GFR) \> 50 and 50 mg/day for GFR 30 - 49, beginning on the day prior to surgery and continuing through hospitalization, up to 10 days.
224259961|NCT02741687|DRUG|Placebo|Participants will take one pill daily beginning on the day prior to surgery and continuing through hospitalization, up to 10 days.
223773547|NCT04103528|OTHER|afternoon surgery|31 patients will be operated on between 14:00 and 18:00 in the afternoon.
223773548|NCT00853658|DRUG|Enalapril|Enalapril 10 mg film-coated tablet and administered orally.
223773549|NCT00853658|DRUG|Aliskiren|Aliskiren 150 mg titrated to 300 mg film-coated tablet and administered orally.
224259962|NCT02741687|DRUG|Supplemental insulin (insulin lispro)|"Supplemental insulin lispro will be administered before meals, in addition to scheduled insulin dose, following the supplemental insulin scale protocol. At bedtime, half of supplemental sliding scale insulin starting at blood glucose (BG) \>240 mg/dL will be given. If a patient is unable to eat, supplemental insulin will be administered every 6 hours with the lowest number of units for that appropriate BG level.~For subjects receiving supplemental insulin lispro with BG levels greater than 180 mg/dL, the supplemental insulin scale is as follows:~* BG between 181-220 mg/dL; 2-4 units of insulin lispro~* BG between 221-260 mg/dL; 3-5 units of insulin lispro~* BG between 261-300 mg/dL; 4-6 units of insulin lispro~* BG between 301-350 mg/dL; 5-7 units of insulin lispro~* BG between 351-400 mg/dL; 6-8 units of insulin lispro~* BG \> 400 mg/dL; 7-9 units of insulin lispro"
224259963|NCT02741687|DRUG|Supplemental insulin (insulin aspart)|"Supplemental insulin aspart will be administered before meals, in addition to scheduled insulin dose, following the supplemental insulin scale protocol. At bedtime, half of supplemental sliding scale insulin starting at blood glucose (BG) \>240 mg/dL will be given. If a patient is unable to eat, supplemental insulin will be administered every 6 hours with the lowest number of units for that appropriate BG level.~For subjects receiving supplemental insulin aspart with BG levels greater than 180 mg/dL, the supplemental insulin scale is as follows:~* BG between 181-220 mg/dL; 2-4 units of insulin lispro~* BG between 221-260 mg/dL; 3-5 units of insulin lispro~* BG between 261-300 mg/dL; 4-6 units of insulin lispro~* BG between 301-350 mg/dL; 5-7 units of insulin lispro~* BG between 351-400 mg/dL; 6-8 units of insulin lispro~* BG \> 400 mg/dL; 7-9 units of insulin lispro"
224323132|NCT05569486|DEVICE|Green Light|This is a low-energy device. It produces almost no heat because it uses an LED source for light. The device does not store energy or electrical power that can be discharged later.
224323133|NCT05305950|OTHER|Patient population|Questionnaire, standard of care
224323134|NCT04314401|PROCEDURE|Biospecimen Collection|Undergo collection of blood, tissue, bone marrow, and cerebral spinal fluid samples
223773550|NCT04918680|DEVICE|EcoFit® Total Hip System with implacross® E Polyethylene|The EcoFit® Total Hip System is a primary hip replacement system indicated for patients who are candidates for a primary cementless hip replacement. implacross® E Polyethylene is one of the components in the EcoFit® system.
223773551|NCT02460224|DRUG|LAG525|LAG525 was administered via intravenous (i.v.) infusion
223773552|NCT02460224|DRUG|PDR001|PDR001 was administered via i.v. infusion
223773553|NCT03797638|DEVICE|Finger Force Manipuladum (FFM)|Tasks performed with the device Finger Force Manipuladum (FFM), to assess abilities such as finger individuation but also fine finger force control, finger movement regularity and speed.
224259964|NCT02741687|DRUG|Long acting basal insulin (insulin detemir)|"Long acting basal insulin therapy will be provided as needed, and will be given once daily, at the same time of day. Participants with blood glucose (BG) \>180 mg/dL= start detemir at 0.2 units per kg weight per day and will follow the following adjustment schedule:~* Fasting and pre-meal BG between 100-180 mg/dl without hypoglycemia the previous day: no change~* Fasting and pre-meal BG between \>180-240 mg/dl: increase detemir or glargine dose by 10% every day~* Fasting and pre-meal BG \>241 mg/dl: increase detemir or glargine dose by 20% every day~* Fasting and pre-meal BG \<100 mg/dl: reduce detemir or glargine by 20% or stop if patient is already on less than 0.1 units/kg of body weight"
224323135|NCT04314401|PROCEDURE|Computed Tomography|Undergo CT
224323136|NCT04314401|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
224323137|NCT04314401|OTHER|Medical Chart Review|Medical charts are reviewed and data is collected
224323138|NCT04314401|PROCEDURE|Paracentesis|Undergo paracentesis
224323139|NCT04314401|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
224323140|NCT02043158|BEHAVIORAL|Questionnaire|Questionnaire completion asking questions about quality of life, mood, social support, stress, diet, lifestyle, and demographic information. Questionnaire should take about 60-90 minutes to complete.
224323141|NCT02043158|BEHAVIORAL|Interview|Interview asking questions about the amount of stress participant may be having or have had in the past. It should take about 25-30 minutes to complete the interview.
224323142|NCT05405114|DRUG|NDec - oral decitabine-tetrahydrouridine|Participants will get capsules (oral administration) to take once or twice weekly. The number of capsules will be based on their body weight
223773554|NCT01532765|PROCEDURE|Pars plana vitrectomy and epiretinal membrane peel|23 gauge pars plana vitrectomy with diluted intravitreal triamcinolone for visualization
223773555|NCT01532765|PROCEDURE|ILM peel assisted by ICG|Indocyanine green dye is prepared from 25mg powder vial from AKORN INC., 10 mL diluent provided in kit. This is further diluted to final concentration of 0.5mg/mL using 50% sterile dextrose solution
224259965|NCT02741687|DRUG|Long acting basal insulin (insulin glargine)|"Long acting basal insulin therapy will be provided as needed, and will be given once daily, at the same time of day. Participants with blood glucose (BG) \>180 mg/dL= start detemir at 0.2 units per kg weight per day and will follow the following adjustment schedule:~* Fasting and pre-meal BG between 100-180 mg/dl without hypoglycemia the previous day: no change~* Fasting and pre-meal BG between \>180-240 mg/dl: increase detemir or glargine dose by 10% every day~* Fasting and pre-meal BG \>241 mg/dl: increase detemir or glargine dose by 20% every day~* Fasting and pre-meal BG \<100 mg/dl: reduce detemir or glargine by 20% or stop if patient is already on less than 0.1 units/kg of body weight"
224259966|NCT03413202|DRUG|butylphthalide(NBP)|Standard medical care is in accordance with China Guideline for the diagnosis and treatment of acute ischemic stroke (2014), including medical care for vital signs, control of temperature, blood pressure and glucose, improving cerebral blood circulation, antiplatelet treatment and nutritional supportive care.In addition, 25mg butylphthalide(NBP) injection, and 100ml 0.9% saline by an independent research nurse, sealed with brown bag in order to make the investigators and patients blinded, infusion for 14 days, then, butylphthalide(NBP) capsule for 76 days.
223773556|NCT01532765|PROCEDURE|CE-IOL|Cataract extraction by phacoemulsification and insertion foldable posterior chamber intraocular lens implant
223773557|NCT02797262|DEVICE|Proteus digital health feedback (PDHF) system|Building on the available Proteus devices, the investigators will design and create a PDHF system to transmit the adherence data using mobile technology to allow treatment monitoring that is, direct confirmation of the type, dose, date and time of oral pharmaceutical ingestion using wirelessly observed therapy (WOT).
223773558|NCT01985737|OTHER|Sample collection|
224323143|NCT05405114|DRUG|HU - Hydroxyurea|Participants will get capsules daily (oral administration) according to local labelling
223773559|NCT01384084|PROCEDURE|POP repair plus mini-sling|"For POP, the anterior vaginal wall is dissected from the bladder to expose a vaginal wall area where the mesh will be attached. The procedure is repeated for the posterior vaginal wall. The sacral promontory surface is prepared and 1 non-reabsorbable sutures are placed into the sacral periosteum.~A mini sling system will be used, placing a urethral low-tension tape anchored to the obturator muscles bilaterally at the level of tendinous arc. This mini-sling is a polypropylene monofilament mesh."
223773560|NCT01384084|PROCEDURE|POP repair|For POP repair, the anterior vaginal wall is dissected from the bladder to expose a vaginal wall area where the mesh will be attached. The procedure is repeated for the posterior vaginal wall. The sacral promontory surface is prepared and 1 non-reabsorbable sutures are placed into the sacral periosteum. The peritoneum is closed over the meshes.
223773561|NCT02065674|DRUG|Abroma Augusta Q (mother tincture)|30 drops in 1 cup of water three times a day for 3 months
223773562|NCT04648930|DRUG|Xolair|There was no treatment allocation. Patients administered Xolair by prescription that started before inclusion of the patient into the study were enrolled.
224259967|NCT03413202|DRUG|placebo|Standard medical care is in accordance with China Guideline for the diagnosis and treatment of acute ischemic stroke (2014), including medical care for vital signs, control of temperature, blood pressure and glucose, improving cerebral blood circulation, antiplatelet treatment and nutritional supportive care.In addition, 100ml 0.9% saline by an independent research nurse, sealed with brown bag in order to make the investigators and patients blinded, infusion for 14 days, then, starch capsule for 76 days.
224259968|NCT05891522|PROCEDURE|portable scanner|performing a portable cranial scanner on cerebro-injured intensive care patients
224259969|NCT05891522|PROCEDURE|fixed scanner|performing a conventional fixed cranial scanner on cerebro-injured intensive care patients
223773563|NCT06805903|OTHER|TRansanal Irrigation Adherence scaLe|new trans-anal irrigation self-assessment questionnaire in French
223773564|NCT03876730|OTHER|ICF CP Core Set|Core set
223773565|NCT01620606|BEHAVIORAL|Cognitive Behavioral Therapy & Social Learning|Cognitive Behavioral Therapy \& Social Learning
223773566|NCT01620606|BEHAVIORAL|Education and Support|Education about the GI system, nutrition and food safety
224259970|NCT03416673|PROCEDURE|peCTG+CAF|A connective tissue graft will be reshaped to have extensions mimicking the papillae to augment the inter-dental papillae recessed
223773567|NCT04783129|OTHER|Education program based on 10 monthly lectures|The education program consist of 10 lectures on the management of motor and non-motor alterations associate with PD will be offered by a nurse, physiotherapist, occupational therapist, speech therapist, neurologist, lawyer, nutritionist, and psychologist.
223773568|NCT04783129|OTHER|No intervention|Participants will follow no education program (lecture) and will be instructed to follow their usual routine for the treatment of the disease
223773569|NCT01176552|DRUG|GM-CSF, IFN alpha and IL-2|Treatment during 6 months: GM-CSF, 1 mcg/kg, 3 times per week, subcutaneously, first week of each month; IFN, 10 MIU, 3 times per week, subcutaneously, second week, and IL-2, 1 MIU, 3 tiw, intravenously, third week. Fourth week of each month was free from treatment.
223773570|NCT02637843|DEVICE|Slender Sheath|Comparing outcomes for two different sheaths used during radial CAG/PCI
224259971|NCT03416673|PROCEDURE|CTG+CAF|A connective tissue graft harvested from the palate will be sutured to the gingival recession site and covered with a coronally advanced flap
224259972|NCT04808362|BIOLOGICAL|OMO-103|OMO-103 will be administered intravenously as 30 min infusion once weekly
223773571|NCT00286416|DRUG|omalizumab (Xolair)|
223773572|NCT02192944|DRUG|Chloroquine|Chloroquine base 600 mg single dose. To monitor ECG 12 lead at 0 (pre-dose), 1, 2, 4, 8, 12 and 24 hours after dosing.
223773573|NCT02192944|DRUG|Dihydroartemisinin-piperaquine|Dihydroartemisinin-piperaquine 120/960 mg single dose To monitor ECG 12 lead at: 0 (pre-dose), 1, 2, 4, 8, 12 and 24 hours after dosing.
223773574|NCT03640065|DRUG|freeze-dried probiotic sachets|"* The participants will be instructed to consume the sachets as follow, each sachet powder is mixed with 10 ml of water in a measuring cup, then swish the mixture in the mouth for one minute before swallowing.~* This procedure will be repeated once daily for the following 4 weeks.~* 4 weeks supply will be given to the participants."
224259973|NCT01963663|DRUG|Metformin|metformin 1000 mg daily in two divided doses of 500 mg tablets
224259974|NCT01963663|DRUG|Pioglitazone|pioglitazone 30 mg daily in two divided doses of 15 mg tablets
224323144|NCT05405114|DRUG|Placebo|Participants will get capsules (oral administration) to take once or twice weekly. The number of capsules will be based on their body weight
223773575|NCT03640065|DIETARY_SUPPLEMENT|fermented dairy product ( yogurt)|"* The participants will be instructed to consume the yogurt once daily regularly for the following 4 weeks.~* 4 weeks supply will be given to the participants with instruction to store the yogurt in refrigerator at home"
224259975|NCT01920334|DRUG|Zolpidem CR 12.5mg|Patients will be given zolpidem CR 12.5mg each night for, at least, 3 consecutive nights, including the first night on the Cardiac ICU, when the undergo a full-night polysomnography
224259976|NCT01920334|DRUG|Placebo|Patients will receive placebo pills at night, according to their usual sleep time, from the first night on the Cardiac ICU, until their hospital discharge
224259977|NCT01105299|DRUG|CJ anastrozole 1 mg tablet|
224259978|NCT03822754|BIOLOGICAL|sIPV-bOPV-bOPV vaccination schedule|Single intramuscular injection of the experimental sIPV (0.5 ml) on Day 0, following two doses of bOPV (0.1 ml) on Day 30 and Day 60 respectively. The investigational Sabin strain inactivated poliovirus vaccine (Vero cell)(sIPV) was manufactured by Sinovac Vaccine Technology Co., Ltd. The poliovirus (Live) vaccine type I \& type III (Human Dipoid cell) ( bOPV) was manufactured by Beijing Bio-institute Biological Products Co., Ltd.
224259979|NCT03822754|BIOLOGICAL|wIPV-bOPV-bOPV vaccination schedule|Single intramuscular injection of the control wIPV (0.5 ml) on Day 0, following two doses of bOPV (0.1 ml) on Day 30 and Day 60 respectively.The control wild strain inactivated poliovirus vaccine (wIPV) was manufactured by SANOFI PASTEUR S.A. The poliovirus (Live) vaccine type I \& type III (Human Dipoid cell) ( bOPV) was manufactured by Beijing Bio-institute Biological Products Co., Ltd.
224259980|NCT05936554|DEVICE|whole body vibration|to improve muscle power and balance.
224259981|NCT05936554|OTHER|Functional strength training|used in treatment of hemiparetic cerebral palsy and provides postural stability while promoting balance independence with confidence and muscle power
224259982|NCT03214523|BEHAVIORAL|Sleep Education|The subject will undergo a 30-minute session on sleep education from one of the study coordinators.
224259983|NCT04633863|DEVICE|Artificial tear MDI - 101|Medical device CE marked - artificial tears containing arabinogalactan, trehalose and hyaluronic acid - 10 weeks treatment
224259984|NCT00685464|DRUG|Abciximab|Intravenous.
224259985|NCT00685464|DRUG|Abciximab|Intracoronary
224259986|NCT01044823|OTHER|3D and thermal imaging|subjects will be imaged before and after receiving DMARD therapy
224259987|NCT04621617|DRUG|Albumin|Human albumin will be administered by intravenous infusion at a dose of 1.5 gm/kg/week for 2 weeks followed by HA 40 grams every 7days
224259988|NCT04621617|DRUG|Midodrine|Oral Midodrine will be given at a dose of 7.5 mg three times in a day
224259989|NCT04621617|DRUG|Standard medical therapy (SMT)|SMT will include nutritional support, rifaximin, lactulose or lactitol, diuretics, SBP prophylaxis with norfloxacin, restriction of sodium, multivitamins, and other supportive measures as deemed necessary. LVP will be done as needed. Patients on non-selective beta blockers will continue to do so with dose modifications/withdrawal as per Baveno VI guidelines.
223773576|NCT03893266|OTHER|Interviews|An interview will be realized with each patient in order to precise the issues they have to reconcile their diabetes and their work. Some questions will be posed to the patients and they respond as they wish.
223773577|NCT06184334|DRUG|Solfenacin|pills taken once day
224259990|NCT03584308|DIETARY_SUPPLEMENT|Viusid®|The VIUSID nutritional supplement is presented in the form of envelopes and will be administered orally diluted in water, juice or milk, according to the patient's preference and will be administered 3 times a day, 15 minutes before breakfast, lunch and dinner.
224323145|NCT06197568|DRUG|Lasofoxifene Tartrate (AZU-101)|0.1 μg vaginal dose of AZU-101 weekly for 4 doses
224259991|NCT03584308|DIETARY_SUPPLEMENT|Glizigen®|The GLIZIGEN® product is presented in spray bottles and will be administered orally to swallow, away from meals 2 times a day.
224259992|NCT03584308|DIETARY_SUPPLEMENT|Viusid Placebo|The placebo of VIUSID nutritional supplement is presented in the form of envelopes and will be administered orally diluted in water, juice or milk, according to the patient's preference and will be administered 3 times a day, 15 minutes before breakfast, lunch and dinner .
224323146|NCT06197568|DRUG|Lasofoxifene Tartrate (AZU-101)|0.5 μg vaginal dose of AZU-101 weekly for 4 doses
223773578|NCT06184334|DRUG|Mirabegron|pills taken once day
223773579|NCT06184334|DRUG|Tadalafil 5mg|pills taken once day
223773580|NCT05593796|BEHAVIORAL|cognitive behavioral therapy|12 weekly, individual sessions of manual-guided CBT delivered by trained clinician .
223773581|NCT01941953|DRUG|Metformin and Fluorouracil|metformin 850mg PO BID plus 5FU 425mg/m2 + leucovorin 50mg IV weekly
223773582|NCT05281250|OTHER|Supervised physical exercise|A supervised exercise is randomized. Although this intervention is not standard in our setting, it is a recommended practice, since it is known that rehabilitation strategies in hospitalized patients have different benefits.
223773583|NCT02006238|DEVICE|Farabloc|The participants will be randomly received Farabloc (experimental) for one week, followed by a 7 day washout and then crossed over to received the Nylon fabric (placebo) for one week.
223773584|NCT02006238|DEVICE|Nylon Fabric|The participants will be randomly received Nylon fabric (placebo) for one week, followed by a 7 day washout and then crossed over to receive Farabloc (experimental) for one week.
224259993|NCT03584308|DIETARY_SUPPLEMENT|Glizigen Placebo|The placebo of GLIZIGEN® product is presented in spray bottles and will be administered orally to swallow, away from meals 2 times a day.
224259994|NCT00109512|DRUG|NBI-56418 (GnRH antagonist)|
224259995|NCT00109512|DRUG|placebo|
224259996|NCT04672538|PROCEDURE|Low Vt protocol|Low Vt protocol - tidal volumes (Vt) 6 ml/kg, respiratory rate required for end tidal carbon dioxide (EtCO2) of 36-38 mmHg, PEEP 5 centimeter of water (cm-H20) , I:E ratio 1:2
224323147|NCT06197568|DRUG|Lasofoxifene Tartrate (AZU-101)|1 μg vaginal dose of AZU-101 weekly for 4 doses
224259997|NCT04672538|PROCEDURE|High Vt protocol|High Vt protocol - tidal volumes (Vt) 10 ml/kg, respiratory rate required for EtCO2 of 36-38 mm Hg, PEEP 5 cmH2O, I:E ratio 1:3.
224259998|NCT01465113|DRUG|Omeprazole|28-day run-in phase during which subjects are treated with a proton pump inhibitor (omeprazole 20 mg po q day or an equivalent dose of another proton pump inhibitor).
224259999|NCT01465113|DRUG|Vitamin D3|These patients (indefinite for dysplasia, LGD, or no dysplasia) will take vitamin D3 50,000 IU once a week for 12 weeks following the upper endoscopy.
224260000|NCT01465113|DRUG|Vitamin D3|Due to the risk of progression, subjects with Barrett's esophagus with high grade dysplasia will take vitamin D3 50,000 IU once a week for 2 weeks.
224260001|NCT01465113|PROCEDURE|upper endoscopy|After the run-in phase subjects will undergo an upper endoscopy for Barrett's surveillance or Barrett's mapping as part of routine clinical care. At the time of endoscopy, in addition to large cup forceps biopsies obtained for surveillance or mapping as part of standard care, research biopsies will be obtained for the study. Following vitamin D3 supplementation, all subjects will undergo a repeat upper endoscopy for additional large cup forceps biopsies for measurement of post-treatment mucosal levels.
224260002|NCT01465113|DRUG|Metformin|500mg for the first week, 1000mg during the second week, 1500mg during the third week, maximum dose of 2000mg in the fourth week
224260003|NCT02538549|BEHAVIORAL|ACE4|Activity Challenge 4 is a single player card game that is based on principles of behavioral activation. The game was used with crisis and transitional case management clients, with positive feedback.
224260004|NCT04322513|DIAGNOSTIC_TEST|Biomarkers expression|Evaluation in biomarkers expression between 2 groups
224260005|NCT04943549|DRUG|Bupivacain|Patients will be placed in left lateral position. A low-frequency curved array ultrasound transducer will be used. The ultrasound transducer will be placed in a longitudinal orientation 2-3 cm lateral to the midline to identify the hyperechoic line of the transverse process. After identification of muscles superficial to the transverse process and local infiltration of anesthesia into the superficial tissues, a block needle will be inserted in a craniocaudal direction until contact will be achieved with the transverse process where the tip will lay in the interfascial plane below the erector spinae muscle. A small bolus of local anaesthetic should be given through the block needle; the erector spinae muscle should be visualized, separating from the transverse process. A total of 20 mL bupivacaine 0.25% will be injected into the interfacial plane deep to the erector spinae muscle bilaterally. Forty minutes after the ESPB, the cutaneous sensory block will be assessed.
224260006|NCT04145635|DEVICE|Aortix System|Aortix is a circulatory support device for chronic heart failure patients on medical management who have been hospitalized for acute decompensated heart failure (ADHF) with worsening renal function.
224260007|NCT01139216|DRUG|Daikenchuto (TU-100)|Subjects will receive 2.5g TID (7.5g/day) of TU-100. Dosage form is granule. Subject will take a daily dose divided 3 times per day for 4 weeks.
224260008|NCT01139216|DRUG|Daikenchuto (TU-100)|Subjects will receive 5g TID (15g/day) of TU-100. Dosage form is granule. Subject will take a daily dose divided 3 times per day for 4 weeks.
224260009|NCT01139216|DRUG|Placebo|Subjects will receive daily dose of TU-100 placebo. Dosage form is granule. Subject will take a daily dose divided 3 times per day for 4 weeks.
224323148|NCT06197568|DRUG|Lasofoxifene Tartrate (AZU-101)|0.1 μg vaginal dose of AZU-101 twice-weekly for 8 doses
224323149|NCT06197568|DRUG|Lasofoxifene Tartrate (AZU-101)|0.5 μg vaginal dose of AZU-101 twice-weekly for 8 doses
224323150|NCT05703685|RADIATION|Lung scan|Immediately after the brain scan
224323151|NCT05703685|DRUG|Apremilast|Oral administration of apremilast
224323152|NCT05703685|DRUG|18F-PF-06445974|Injected IV followed by PET scanning
224323153|NCT00867464|OTHER|Cytology Specimen Collection Procedure|Correlative studies
224323154|NCT00867464|OTHER|Laboratory Biomarker Analysis|Correlative studies
224323155|NCT00867464|OTHER|Long-term Follow-up|Undergo extended follow-up
224323156|NCT00867464|OTHER|Questionnaire Administration|Ancillary studies
224323157|NCT03620058|BIOLOGICAL|CART22-65s cells|Autologous T cells transduced with a lentiviral vector to express anti-CD22 scFv TCRz:41BB
223679775|NCT04658862|BIOLOGICAL|Cetrelimab|Participants will receive intravenous Cetrelimab.
223679776|NCT04658862|DRUG|TAR-200|Participants will receive intravesical TAR-200.
223679777|NCT04658862|DRUG|Cisplatin|Participants will receive cisplatin intravenously.
223679778|NCT04658862|DRUG|Gemcitabine|Participants will receive gemcitabine intravenously.
223679779|NCT04658862|RADIATION|Conventional radiation therapy|Participants will receive conventional radiation therapy for bladder (64 gy).
223679780|NCT04658862|RADIATION|Hypo-fractioned radiation therapy|Participants will receive hypo-fractioned radiation therapy for bladder (55 gy).
223773585|NCT05617846|OTHER|Anti-osteoporosis therapy|Bone healing, limb function, and complications of postoperative osteolysis in patients with bone tumors of the extremities treated with anti-osteoporosis therapy.
224260010|NCT00943033|BEHAVIORAL|Mindfulness-Based Cognitive Therapy|Mindfulness-Based Cognitive Therapy for the prevention of depressive relapse/recurrence
224260011|NCT05330533|RADIATION|scrotal duplex|Scrotal colour doppler ultrasonography
224260012|NCT05391594|DEVICE|customized posture support|We will provide customized modifications for seated or standing or walking devices based on the child's segmental level of control
224260013|NCT02285491|DRUG|10ml of bupivacaine 0.5%|This is a local anesthetic that will be used to block the ilioinguinal nerve to alleviate pain at the wound site after lscs
224260014|NCT02285491|DRUG|Placebo|10 ml of saline will be injected as a placebo and the investigator and the patient and the data assessor are all blinded to what the patients received.
223680679|NCT05736484|BEHAVIORAL|Social Support Gamification|Participants sign a pre-commitment contract agreeing to try their best to achieve their daily step goal. Over the 26-week intervention period, participants are endowed 70 points (10/day) weekly and informed they will lose 10 points each day goal is not met. Points are replenished at start of each week. At the end of each week, if the participant has 40 points or more, they will advance a level, or drop a level if they have less than 40 points. The levels include blue (lowest), bronze, silver, gold, platinum (highest). Participants select a family member or friend as a support partner to receive weekly email on participants' progress (points, game level, and average step count). Participants will also work with a virtual health coach by attending group sessions organized by them with other participants through video calls once a month to discuss ways to motivate participants to increase their physical activity.
223680680|NCT01071226|DEVICE|CliniMACS (CD+3, CD+19 depletion)|Patient's in Stratum 1 will receive grafts that have undergone CD3+, CD19+ depletion
223680681|NCT01071226|DEVICE|CliniMACS (CD 34+ positive selection)|Patient's in Stratum 2 will receive peripheral blood progenitor cells that have undergone CD34+ selection
223680682|NCT01071226|OTHER|HSCT|Peripheral Blood Stem Cell Transplant
223680683|NCT00012519|DRUG|indinavir sulfate|
223680684|NCT00012519|DRUG|ritonavir|
223680685|NCT01109160|DRUG|Azithromycin Dihydrate|"Add-on of study-drug (azithromycin) to 'standard of care' at diagnosis of lymphocytic bronchi(oli)tis.~Study-drug regime: 250 mg daily for 5 days, followed by 250 mg every other day until the end of the study-period (6 months treatment)."
223680686|NCT01713764|BEHAVIORAL|Low Carbohydrate Diet|
224260015|NCT05882526|DEVICE|BURSTONE T-LOOP|Split mouth study one side using elastomeric power chain and other side using T loops
224260016|NCT00190541|PROCEDURE|Mesorectal excision with lateral lymph node dissection|Mesorectal excision with lateral lymph node dissection
224260017|NCT00190541|PROCEDURE|Mesorectal excision without lateral lymph node excision|Mesorectal excision without lateral lymph node excision
223680687|NCT01713764|BEHAVIORAL|American Diabetes Association Diet|
223680688|NCT01713764|BEHAVIORAL|Mindfulness and Positive Affect Skills|
223773586|NCT01394926|DRUG|Optison|Optison is a sterile non-pyrogenic suspension of perflutren for IV administration.
223773587|NCT02698358|DEVICE|Epic stent (Boston Scientific)|
223773588|NCT04391010|OTHER|Surgical masks|Surgical masks will be applied in health care providers
223773589|NCT04391010|OTHER|Filtering respirators|Filtering respirators will be applied in health care providers
223773590|NCT03146650|BIOLOGICAL|Ipilimumab|Given IV
224260018|NCT04337658|DRUG|Pertuzumab|Participants will receive 840 milligrams (mg) loading dose of pertuzumab, followed every 3 weeks thereafter by a dose of 420 mg via intravenous (IV) infusion until disease progression, unacceptable toxicity, withdrawal of consent, or study termination.
224260019|NCT04337658|DRUG|Trastuzumab|Participants will receive trastuzumab (8 mg/kg loading dose for Cycle 1, followed by 6 mg/kg for subsequent cycles) administered by IV infusion every 3 weeks until disease progression, unacceptable toxicity, withdrawal of consent, or study termination.
224260020|NCT04337658|DRUG|Fulvestrant|500mg intramuscular injections at day 1, 15, 28 and 4 weeks thereafter
224260021|NCT04337658|DRUG|Capecitabine|1000mg/m2 orally Bid on day 1 to day 14 every 3 weeks until disease progression, unacceptable toxicity, withdrawal of consent, or study termination.
223680689|NCT03621475|DEVICE|Novel restraint|Use of a novel arm restraint
223680690|NCT06492850|GENETIC|FT-002|Intraocular injection of a single dose
223680691|NCT05420350|DRUG|Lamotrigine and Bupropion|Lamotrigine-oral pill taken once or twice a day with varying dosage per study timeline Bupropion-oral pill 100mg taken twice a day
223680692|NCT05420350|DRUG|Placebo|Oral pill matched with lamotrigine to be taken once or twice a day per study timeline Oral pill matched with bupropion to be taken twice a day
223680693|NCT00197158|BIOLOGICAL|Hepatitis B vaccine|
223680694|NCT05173545|DRUG|Mitoxantrone Hydrochloride Liposome Injection|"Every 28 days is a administration cycle, a total of 4 cycles.Until the subject's PD or intolerable or withdrawal (whichever occurs first).~5% Glucose Injection drugs dissolved in 250 ml, intravenous drip for 60 minutes."
223773591|NCT03146650|OTHER|Laboratory Biomarker Analysis|Correlative studies
223773592|NCT03146650|BIOLOGICAL|Nivolumab|Given IV
224260022|NCT03246503|DEVICE|BiliCam estimated bilirubin (BCB)|Images will be obtained using the BiliCam app installed on a commercial smartphone and used to calculated a BCB level. The BCB levels will be used for study purposes only and not used for clinical care
223773593|NCT01935011|OTHER|PD, DBS|PD DBS frequency on swallowing function
223773594|NCT01684384|RADIATION|Functional Respiratory Imaging|HRCT scan at FRC and TLC as taken during an episode of exacerbation and after recovering.
223773595|NCT01196728|DRUG|CM3.1-AC100|SAD study with single ascending subcutaneous doses
224260023|NCT00736190|DRUG|Tenofovir disoproxil fumarate|300-mg tablet (marketed formulation) taken orally once daily
224260024|NCT04121507|DRUG|High dose chemotherapy before allogeneic stem cell transplantation (alloSCT)|High-dose therapy (HDT) prior to alloSCT will consist of FTC
224260025|NCT04121507|PROCEDURE|Bone marrow histology|Bone marrow histology at staging and restaging is only mandatory if the bone marrow was initially involved
224260026|NCT04121507|DIAGNOSTIC_TEST|clinical and laboratory parameters|During staging and restaging examinations, all clinical and laboratory parameters relevant for therapy.
224260027|NCT04121507|DIAGNOSTIC_TEST|PET-CT or CT|Metabolic CR in a PET-CT scan after the last cycle of therapy prior to planned SCT. Consists preferably of a PET-CT or a CT scan according to local practice and other appropriate diagnostic procedures with respect to the sites of primary involvement.
223679782|NCT03050775|DEVICE|Heated Ventilator Circuit|active heat and humidification during anesthesia by warming inspire gases without a heat-moisture exchanger
223679783|NCT03050775|DEVICE|Standard Ventilator Circuit|no active heat and humidification during anesthesia
223679784|NCT05882643|OTHER|moderate to deep neuromuscular blockade|"* Maintaining moderate to deep neuromuscular blockade during an intraoperative period (Train-of-four 0-3 count, post-tetanic count \> 1)~* Rocuronium (intravenous, 1.0 mg/kg at induction period)"
223679785|NCT05882643|OTHER|shallow to minimal neuromuscular blockade|"* Maintaining shallow to minimal neuromuscular blockade during an intraoperative period (Train-of-four 4, post-tetanic count \< 0.9)~* Rocuronium (intravenous, 0.3 mg/kg at induction period)"
223679786|NCT04085367|DRUG|MAL 16.8% cream|Day light photodynamic therapy with MAL 16.8% cream
223679787|NCT04085367|DRUG|MAL Vehicle Cream|Day light photodynamic therapy with MAL vehicle cream
223679788|NCT02374047|DRUG|CAT-2054|
223679789|NCT02374047|DRUG|Placebo|
223679790|NCT02374047|DRUG|CAT-2054-C|
223679791|NCT02374047|DRUG|Atorvastatin|
223679792|NCT05298878|OTHER|Intervention Group: Virtual home-based rehabilitation plus usual outpatient care|"14 supervised exercise virtual sessions with Kinesiologist and 10 independent exercise sessions. Each session lasts 40 minutes. The exercises consist of aerobic training; functional lower and upper body strengthening; balance; and flexibility exercises. During the first 10 minutes of the first session of each week, there is an educational session.~Week 1-2: three supervised virtual sessions Week 3-4: two supervised virtual sessions and one independent session. Week 5-8: one supervised virtual session and two independent sessions."
223679793|NCT06326307|BEHAVIORAL|Tell Show and Do Guidance|In this technique, the dentist tells explains the procedure using the Tell show and do method.
223679794|NCT06326307|BEHAVIORAL|Puppet Guidance|In this technique, the dentist using the puppet to explains the procedure.
223679795|NCT00053781|DRUG|perifosine|
223679796|NCT00733850|DRUG|Kanglaite Injection plus gemcitabine|Intravenous repeating dose
223679797|NCT00733850|DRUG|Gemcitabine|Intravenous repeating dose
223679798|NCT03697174|OTHER|200 ppb ozone group|The exposure group will be exposed to 200 ppb ozone in a chamber for 2 hours while alternating 20-min rest and 10-min exercise periods. The exercise workload will be adjusted to achieve the targeted ventilation of 25 \~ 27 L/min(approximately equal to 15 \~ 18L/min/m2 body surface area). The temperature and relative humidity in the chamber will be maintained at 22±1℃ and 55%±5%, respectively.
223679799|NCT03697174|OTHER|0 ppb ozone group|The control group will be exposed to 0 ppb ozone in a chamber for 2 hours while alternating 20-min rest and 10-min exercise periods. The exercise workload will be adjusted to achieve the targeted ventilation of 25 \~ 27 L/min(approximately equal to 15 \~ 18L/min/m2 body surface area). The temperature and relative humidity in the chamber will be maintained at 22±1℃ and 55%±5%, respectively.
223679800|NCT03106766|DRUG|Acne cream 2X|Twice daily application of facial acne cream 2X after facial cleansing
223679801|NCT03106766|DRUG|Acne cream 1X|Twice daily application of facial acne cream 1X after facial cleansing
223679802|NCT01245517|OTHER|Education|Dietary Phosphorus Education Program
224260028|NCT01556906|DRUG|Lomitapide|Oral administration with escalating doses administered once daily
224260029|NCT00004162|BIOLOGICAL|sargramostim|
224260030|NCT00004162|DRUG|methotrexate|
223679803|NCT02342093|DRUG|30EE+DRSP|Combined oral contraceptive containing 30 mcg of ethinylestradiol + 3 mg of drospirenone (30EE+DRSP), 1 pill once a day with a pause of seven days between the blisters for 6 months
224260031|NCT00004162|DRUG|pegylated liposomal doxorubicin hydrochloride|
224260032|NCT00004162|DRUG|vincristine sulfate|
224260033|NCT03005834|OTHER|incidence of cancers|With a continuous surveillance system to track all subsequent incidents of CVD and/or non-CVD via direct contact in the outpatient department, hospital records, and a mailed questionnaire at least once a year, an incidence of cancers was identified.
224323158|NCT03620058|BIOLOGICAL|huCART19 Cells|Autologous T cells transduced with lentiviral vector to express anti-CD19 scFv TCRζ:4-1BB
223679804|NCT02342093|DRUG|20EE+DRSP|Combined oral contraceptive containing 30 mcg of ethinylestradiol + 3 mg of drospirenone (20EE+DRSP), 1 pill once a day with a pause of four days between the blisters for 6 months
223679805|NCT02048982|BEHAVIORAL|Guideline|Physicians will receive information on the Choosing Wisely Guideline
223679806|NCT02048982|BEHAVIORAL|Cost|Physicians will receive cost information.
223679807|NCT02048982|BEHAVIORAL|Victim|Physicians will receive information on an identifiable victim.
223679808|NCT01985854|DRUG|Propofol|
223679809|NCT01985854|DRUG|Desflurane|
223679810|NCT02368301|DRUG|Elotuzumab in combination with Lenalidomide and Dexamethasone|Elotuzumab in Combination With Lenalidomide Plus Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
223679811|NCT06273371|OTHER|Damira 2000 Infant formula|100% extensive casein hydrolysate Infant formula
223679812|NCT01528423|PROCEDURE|XtremeCT|The scanning protocol for each subject will be as follows: Non-dominant, non-fractured distal radius x 2 with repositioning between scans Non-dominant, non-fractured distal tibia x 2 with repositioning between scans using XtremeCT device and Non-dominant forearm x 2 with repositioning between scans Non-dominant lower leg x 2 with repositioning between scans using standard pQCT device
224260034|NCT03920449|DRUG|Botulinum Toxins|In group I (BT injection), 21 U will be injected in 3 divided doses through the internal anal sphincter at 3,9, and 12 o'clock. In the Egyptian market two commercial forms are available; botulinum toxin type A (Botox 100 IU/vial; Coolock, Dublin, Ireland), and abobotulinumtoxin A (Dysport 500 U/vial; Ipsen Biopharm Ltd, Wrexham, UK). In case of Dysport it should be remembered that dosing is on a ratio of approximately 1 to 3, meaning that 50 IU of Botox have the same effect as 150 IU of Dysport.
223679813|NCT05175118|DEVICE|Minimal invasive surgical fixation of distal radius Fractures|Fixation of distal radius Fractures by minimal invasive technique
224260035|NCT03920449|PROCEDURE|Posterolateral internal sphincterotomy|In group II (PIAS), A 1.5 to 2-cm circumferential skin incision will be placed at 5 o'clock position outside the anal verge using an electrocautery device. Dissection will be proceeded through the intersphincteric groove to separate both IAS and external anal sphincter (EAS). Then, the IAS will be identified by its characteristic white fibers, separated from the anal mucosa, and assessed under direct vision. Subsequently, about 50 % of the IAS will be divided at 5 o'clock position and any skin tags or hypertrophied anal papillae will be removed leaving the skin incision open to allow drainage.
223679814|NCT03789409|DIETARY_SUPPLEMENT|Intermittent Fasting|The aforementioned intermittent fasting in arm/group descriptions.
223679815|NCT03874481|OTHER|Observation|follow up regularly for MACE
223679816|NCT02262312|OTHER|Transient elastography|All patients will have a transient elastography performed as a measure of liver stiffness.
223679817|NCT01911338|DEVICE|Real Time Feedback|Before beginning practice, one of the teachers performed the manipulation and explained the graph parameters as real-time feedback to consider when interpreting the graph, leaving the graphic as the benchmark execution
223679818|NCT01911338|DEVICE|Traditional Learning Method|Two expert teachers in manual therapy provided indications and corrections to the group with a teacher - student ratio of 1:8.
223679819|NCT00879944|OTHER|Blood pressure|Blood pressure will be measured once while patient is seated
223679820|NCT00879944|OTHER|Height|Height will be measured in centimeters at the time of enrollment
223679821|NCT00879944|OTHER|Weight|Weight will be measured in kilograms at enrollment
223679822|NCT00879944|OTHER|BMI|Body Mass Index (BMI) will be calculated from a subject's height and weight
223679823|NCT00879944|OTHER|Waist Circumference|Waist circumference will be measured midway between the lowest rib and the superior border of the iliac crest with an inelastic measuring tape at the end of normal expiration to the nearest 0.1cm
223679824|NCT03467009|BEHAVIORAL|iPACT Intervention|Brief in-person + tailored, daily 8-week text-message secondary prevention intervention.
223679825|NCT03467009|OTHER|Control: Enhanced Usual Care (EUC)|EUC group participants will receive standardized information on cyberbullying.
223679826|NCT03467009|BEHAVIORAL|iPACT Intervention- app|Brief in-person + tailored, daily 8-week message secondary prevention intervention delivered via app.
223679827|NCT03274999|DEVICE|TrueTear™ Application|Intranasal and extranasal application of TrueTear™ device for approximately 3 minutes at Day 0 and Day 14.
223679828|NCT03726567|PROCEDURE|Bariatric surgery|Roux-en-Y surgery
223679829|NCT03076229|BEHAVIORAL|Healthy Marriage Program|Provide the following allowable activities 1) marriage and relationship education/skills, 2) relationship enhancement, 3) premarital education, and 4) divorce reduction.
224260036|NCT05521919|BEHAVIORAL|Sympathetic Nervous System Activation|Participants will complete a task that increases sympathetic nervous system activation.
224260037|NCT05521919|BEHAVIORAL|No-stress|Participants will complete a task that will not affect their sympathetic nervous system activity.
223679830|NCT01097876|DRUG|PF-04447943 25 mg|25 mg PF-04447943 BID for 7 days (period 1) 7 day washout (no drug) 7 days of 5 mg donepezil QD; 14 days 10 mg QD (Period 2) 7 days of 10 mg donepezil QD and 25 mg PF-04447943 BID (Period 3)
223679831|NCT01097876|DRUG|Placebo PF|Placebo BID for 7 days (period 1) 7 day washout (no drug) 7 days of 5 mg donepezil QD; 14 days 10 mg QD (Period 2) 7 days of 10 mg donepezil QD and Placebo BID (Period 3)
223679832|NCT03624530|DRUG|Tyrosine kinase inhibitor (TKIs)|TKI was selected according to the mutation results of ABL kinase region. Imatinib was initiated at a dose of 200mg/d, dasatinib at a dose of 50mg/d, and ponatinib at a dose of 30mg/d. Then increase the dosage of TKI gradually and increase to therapeutic dose within one month. The duration of TKI was 180 days.
223679833|NCT06468384|PROCEDURE|thoracic erector spinae plane (ESP) block|The thoracic erector spinae plane (ESP) block is a regional anesthesia technique used for pain management in complex regional pain syndrome. This procedure involves injecting 20 ml of 0.25% bupivacaine into the deep layers of the erector spinae muscles. The patient is positioned appropriately, and the injection site is identified using anatomical landmarks and ultrasound guidance, at the T2 level. A needle is then inserted perpendicularly until it contacts the transverse process, at which point the local anesthetic is administered. The primary objective is to provide significant pain relief.
223679834|NCT02749123|DRUG|lidocaine 5% patch|10cmx 14 cm transdermal patch sealed in its own pouch
223679835|NCT02749123|DRUG|lidocaine 3.6%, menthol 1.25%|10cmx 14 cm transdermal patch sealed in its own pouch
223679836|NCT02749123|DRUG|Placebo|patch with no active manufactured to have the same look and feel as Lidoderm 10cmx 14 cm transdermal patch sealed in its own pouch
223679837|NCT02898571|DIETARY_SUPPLEMENT|Placebo|Placebo comparitor
223679838|NCT02898571|DIETARY_SUPPLEMENT|Vitamin C|Active treatment
223773596|NCT01347203|DRUG|DPOC-4088|A single oral dose of DPOC-4088 prolonged release tablet 100 mg (Formulation A = 16 hr release formulation)
224260038|NCT02847624|DRUG|tolvaptan|
223679839|NCT02898571|DIETARY_SUPPLEMENT|epicatechin|Active treatment
223679840|NCT00130442|DRUG|PI-88 and dacarbazine|190 mg daily by subcutaneous injection for PI-88 and 1000 mg/m2 on day 1 of each 21 day cycle by intravenous infusion
223679841|NCT00130442|DRUG|dacarbazine or DTIC|intravenous infusion 1000 mg/m2 on day 1 of every 21 day cycle
223679842|NCT05761184|DIAGNOSTIC_TEST|Serum collection for proteomic analysis|Serum collection for proteomic analysis
223773597|NCT01347203|DRUG|DPOC-4088|A single oral dose of DPOC-4088 prolonged release tablet 200 mg (Formulation A = 16 hr release formulation)
223773598|NCT01347203|DRUG|DPOC-4088|A single oral dose of DPOC-4088 prolonged release tablet 100 mg (Formulation B = 20 hr release formulation)
223773599|NCT01347203|DRUG|DPOC-4088|A single oral dose of DPOC-4088 prolonged release tablet 200 mg (Formulation B = 20 hr release formulation)
223679843|NCT01698281|DRUG|AEZS-108|"AEZS-108 (267 mg/m2, 2-hour IV infusion every Day 1 of a 21-day (3-week) cycle. Allowed delay of re-treatment: up to 2 weeks.~Dose reduction: to 210 mg/m2 and 160 mg/m2, if dose limiting toxicity."
223679844|NCT01698281|DRUG|SCCC|"commercially available SSCC (doses below the recommended package insert at the discretion of treating oncologist), on a 21-day cycle (although weekly administration is allowed; note: pegylated liposomal doxorubicin will be administered on a 28-day cycle).~Drugs considered acceptable as SSCC: paclitaxel; nab-paclitaxel; eribulin; pegylated liposomal doxorubicin (PLD); vinorelbine; gemcitabine; capecitabine.~Related to PLD: Per notification from EMA (dated 22-Nov-2011) no new patients should be started on treatment with Caelyx until further notice. Accordingly, this drug may be selected as SSCC treatment option only after such written notice is available."
223679845|NCT01698281|DRUG|Dexamethasone|Recommended prophylactic anti-emetic for AEZS-108: 8 mg dexamethasone.
223679846|NCT00814333|DRUG|Thrombin-JMI|5,000 IU, to nasal mucosa via syringe spray applicator
223679847|NCT00814333|DRUG|Merocel pack|8 cm pack, inserted within the affected side between the septum and inferior turbinate via bayonet forceps
223679848|NCT00627614|OTHER|breast imaging study|"1\. A set of vibro-acoustography (VA) scans will be taken of the breast by an experimental vibro-acoustography device that uses ultrasound for imaging.~2- An ultrasound scan (sonography) of the breast using a clinical ultrasound machine may be taken during the procedure."
223679849|NCT02233946|BEHAVIORAL|computer-facilitated brief intervention|Immediate feedback to patient of screening results and risk for substance use problem, followed by 11 pages of science and true-life stories about health risks of adolescent substance use. Screening results then go to provider who reviews them with patient and gives brief counseling, and refers to an online motivational enhancement therapy intervention for patients at moderate/high risk for substance use problems.
223679850|NCT05843383|DRUG|Ciprofol|Ciprofol group will be started and maintained total intravenous anesthesia with ciprofol and remifentanil
223679851|NCT05843383|DRUG|Propofol|Propofol group will be started and maintained total intravenous anesthesia with propofol and remifentanil
223679852|NCT06079528|DEVICE|Electromagnetic device|"Health wave's generator (Manufactured with Simeds S.r.l. by Machiavelli, Italy, with serial number 11492.) with two separate emission channels and asynchronous operation was employed, along with 100 saved and storable programs that could be altered by the user (intensity, frequency and phase time). The different associated applicators are recognized automatically. Magnetic field strength up to 100 Gauss and output frequency from (1 - 100) Hertz are programmable."
223679853|NCT06079528|OTHER|visceral manipulation therapy|for the pelvic reproductive organs and their related structures (ligaments and fasciae) was applied one session/week for 12 weeks. Each patient was was advised to evacuate her bladder before starting the treatment session, mobility and motility testing of pelvic organs, together with the assessment of fascial tension, was then performed, with detecting restrictions, treatment was applied according to Hebgen
223679854|NCT06079528|OTHER|General advice|were directed for both groups in term of the following: Perform pelvic floor exercises regularly ; avoid constipation and straining; treat the cause of any chronic cough and infection of urethra or bladder; stop smoking; maintain a healthy weight; drinking sufficient amounts of healthy fluids (water); decrease the caffeine intake; and decrease the amount of acidic and spicy foods.
223679855|NCT06079528|OTHER|pelvic floor muscle training|consisted of 24 sessions of 45-60 min each, twice a week, for 12 weeks. The PFMT was divided into four phases. Proprioceptive (3 weeks): where the woman has gained adequate perception of PFM and performed fast and slow contractions; Simple (3 week): performed with the objective of promoting control of fast and slow contractions associated with small functional exercises; Elaborated (3 week): where the exercise evolved into functional exercises of greater amplitude; and Power (3 week): where the maximum voluntary contraction of the pelvic floor was promoted during efforts. In all sessions, contractions were performed for slow and fast fibers
223679856|NCT06465212|DEVICE|TopCon Maestro 2 OCT|Ophthalmic Coherence Tomography
223679857|NCT00773383|DRUG|RG1507|iv 9mg/kg weekly
223679858|NCT00773383|DRUG|erlotinib [Tarceva]|150mg oral daily
223679859|NCT03384693|DRUG|Defibrotide|Defibrotide is an anticoagulant and fibrinolytic agent that has been shown to be an effective treatment in other endothelial disorders such as hepatic veno-occlusive disease.
223679860|NCT02935374|DRUG|Amoxicillin|The children with acute otitis media will be treated with amoxixillin mixture, 100mg/ml, 40mg/kg/d, divided to two daily doses for 7 days.
224260039|NCT02095522|DRUG|Colchicine|Colchicine 1mg per day for one month
223679861|NCT02935374|DRUG|Amoxicillin-Potassium Clavulanate|The children with acute otitis media will be treated with amoxixillin-clavulanate mixture, 80mg/ml, 45mg/kg/d, divided to two daily doses for 7 days.
223679862|NCT02935374|DRUG|Macrolide|The children with acute otitis media with a know allergy to amoxicillin or amoxicillin-clavulanate will be treated with macrolide and monitored separately
223679863|NCT05024318|DRUG|Pembrolizumab|Pembrolizumab 200 mg tobe administered as a 30 minute IV infusion every 21 days for 3 cycles
224260040|NCT02095522|DRUG|Placebo|Placebo
224260041|NCT05991362|DRUG|GFH312 100 mg|Participants receive single dose of GFH312 100 mg orally
224260042|NCT05991362|DRUG|GFH312 200 mg|Participants receive single dose of GFH312 200 mg orally
224260043|NCT05991362|DRUG|GFH312 120mg|Participants receive daily dose of GFH312 120mg orally for fourteen consecutive days
224260044|NCT05991362|OTHER|Placebo|Participants receive placebo matching with GFH312
223679864|NCT05024318|RADIATION|Stereotactic Ablative Radiotherapy|42Gy delivered in 3 fractions
223679865|NCT05024318|PROCEDURE|Nephrectomy|Partial or total nephrectomy performed 9-12 weeks after first dose of Pembrolizumab
223679866|NCT06353230|PROCEDURE|injection 5% phenol in almond oil|Group A were given 5% phenol in almond oil
223679867|NCT06353230|PROCEDURE|injection 15% hypertonic saline|Group B were given hypertonic saline
223679868|NCT06353230|PROCEDURE|injection 50% dextrose water|group C were given 50% dextrose water
223679869|NCT05828771|PROCEDURE|THIN FREE FLAP|Flap design will be performed on the basis of the preoperative perforator mapping. Freestyle flap elevation will be performed under loupe magnification from one of the incisions until the perforators are reached
223773600|NCT02803697|OTHER|Patients|
224260045|NCT00716625|DRUG|sunitinib malate|"SUTENT® Capsule 12.5 mg, depending on the Investigator prescription. Frequency and duration are according to Package Insert as follows. The usual adult dosage for oral sunitinib is 50 mg once daily, 4 weeks on followed by 2 weeks off (Schedule 4/2). This comprises 1 treatment cycle, which may be repeated.~The dosage may be decreased according to the patient's clinical condition."
224260046|NCT01492439|BEHAVIORAL|Cognitive Remediation|The George Brown College Redirection Through Education (RTE) is a supported education program, offered at no fee to students, that facilitates entry into formal education and employment for persons with mental illness. In addition to the supports available to all RTE students, this group will receive a total of twenty 45 minute computer-based cognitive exercise sessions held twice a week using COGPACK (Ver 6.0,www.cogpack.de). This program facilitates practice across a range of cognitive functions, including attention,psychomotor speed,memory, and executive functions. Participants will also take part in 10 weekly group discussion sessions,approximately 60 minutes in duration, focusing on strategies for management of symptoms and other cognitive deficits in an academic setting.
224260047|NCT01492439|BEHAVIORAL|Supported Education|Students enroll in credit courses, such as communications, computer skills, and the psychology of human relations which can lead to eligibility for post-secondary programs. Remedial skills in English, supervised study skills classes and other non-credit courses are included. Vocational testing is offered to help students determine their interests and aptitudes and students try out possible careers as well as their readiness to return to work by engaging in volunteer and work placements. Counsellors are also available to assist students in areas such as learning difficulties and coping with the stresses of school. The overarching goal of this program is to help students explore valued non-illness identities, build confidence, and re-engage with their communities.
224260048|NCT03891095|DRUG|Oxytocin|intranasally administrated
224260049|NCT03891095|DRUG|L-DOPA|orally administered
224260050|NCT03891095|DRUG|Placebos|intranasally administrated and orally administered
223679870|NCT05973396|OTHER|Physical Fatiguing Task only|Control group: 20-25 minutes \[Rogue Echo Bike 20 intervals of 10 second of maximal-submaximal effort to 50 seconds of recovery low intensity effort\] without mentally fatiguing task during low intensity effort pace
223679871|NCT05973396|OTHER|Physical and Mental Fatiguing Task|Experimental group: 20-25 minutes \[Rogue Echo Bike 20 intervals of 10 second of maximal-submaximal effort to 50 seconds of recovery low intensity effort\] with mentally fatiguing task during low intensity effort pace (which includes: stroop test)
223679872|NCT05436366|DEVICE|Soleus loading response in able-bodied participants|Able-bodied participants are enrolled. The robotic ankle device applies ankle joint rotations using a computer-controlled closed-loop algorithm to evoke the soleus loading response during the mid-late stance phase during treadmill walking at a self-selected comfortable fast speed. The algorithm applies ankle perturbations, which are shifts from the natural ankle kinematics to target the soleus loading response in mid-late stance phase every other 4-6 gait cycles. The perturbation magnitude, speed, and timing are controlled by the device to adjust the participant's soleus response. Four-to-five walking bouts are conducted interleaving perturbed and unperturbed walking steps (until collecting data of about 30 perturbed and unperturbed steps per walking bout) leaving at least one unperturbed step before a perturbed step. Changes in the soleus EMG will be compared between perturbed and unperturbed walking steps.
223679873|NCT05436366|DEVICE|Soleus loading response in participants with hemiparesis|Participants with spastic hemiparesis due to a stroke are enrolled. The robotic ankle device applies ankle joint rotations using a computer-controlled closed-loop algorithm to evoke the soleus loading response during the mid-late stance phase during treadmill walking at a self-selected comfortable fast speed. The algorithm applies ankle perturbations, which are shifts from the natural ankle kinematics to target the soleus loading response in mid-late stance phase every other 4-6 gait cycles. The perturbation magnitude, speed, and timing are controlled by the device to adjust the participant's soleus response. Four-to-five walking bouts are conducted interleaving perturbed and unperturbed walking steps (until collecting data of about 30 perturbed and unperturbed steps per walking bout) leaving at least one unperturbed step before a perturbed step. Changes in the soleus EMG will be compared between perturbed and unperturbed walking steps.
223679874|NCT04208581|DRUG|Yiqi Huoxue Huatan granule|Yiqi Huoxue Huatan granule will be administered twice daily for five days a week for 52 weeks,Tiotropium Bromide Powder for Inhalation will be used once daily (18 μg each time) for 52 weeks, Salmeterol / Fluticasone Powder for Inhalation will be used twice daily (50ug/250ug each time) for 52 weeks, Budesonide / Formoterol Powder for Inhalation will be used twice daily (320ug/4.5ug each time) for 52 weeks.
223679875|NCT04208581|DRUG|Placebo Yiqi Huoxue Huatan granule|Placebo Yiqi Huoxue Huatan granule will be administered twice daily for five days a week for 52 weeks,Tiotropium Bromide Powder for Inhalation will be used once daily (18 μg each time) for 52 weeks, Salmeterol / Fluticasone Powder for Inhalation will be used twice daily (50ug/250ug each time) for 52 weeks, Budesonide / Formoterol Powder for Inhalation will be used twice daily (320ug/4.5ug each time) for 52 weeks.
223679876|NCT05906511|DRUG|Dronabinol 5 MG|Dronabinol 5 mg
223679877|NCT05906511|DRUG|Dronabinol 10 MG|Dronabinol 10mg
223679878|NCT05906511|DRUG|2mg Purified THC in an ethanolic solution|2mg Purified THC in an ethanolic solution
223679879|NCT05906511|DRUG|4mg Purified THC in an ethanolic solution|4mg Purified THC in an ethanolic solution
224260051|NCT01924286|DRUG|Prednisone|
224260052|NCT01924286|DRUG|Placebo|
224260053|NCT02349022|RADIATION|[89Zr]Df-IAB2M|
224260054|NCT04280224|BIOLOGICAL|NK Cells|twice a week of NK cells (0.1-2\*10E7 cells/kg body weight)
224260055|NCT00967148|DRUG|Tinzaparin|The treatment arm will receive a subcutaneous injection of tinzaparin (4500U) daily beginning within two days of the decision to operate (within 6 weeks of surgical resection) weeks and continued for 4 weeks following resection.
224260056|NCT00945438|BIOLOGICAL|Influenza virus vaccine 2009-2010 formulation|0.1 mL, Intradermal
224260057|NCT00945438|BIOLOGICAL|Influenza virus vaccine 2009-2010 formulation|0.5 mL, Intradermal
224260058|NCT06557148|DIAGNOSTIC_TEST|18F-Fluoroestradiol PET/CT|Scanned at baseline and again posttreatment within 2 weeks of the restaging FDG PET/CT
224260059|NCT01327781|DRUG|Endoxifen Hydrochloride|Given PO
224260060|NCT01327781|OTHER|Laboratory Biomarker Analysis|Correlative studies
224260061|NCT01327781|OTHER|Pharmacological Study|Correlative studies
224260062|NCT01327781|OTHER|Questionnaire Administration|Ancillary studies
224260063|NCT05990504|DEVICE|ultrasound real-time guidance combined with Dural Puncture Epidural Labor Anagesia|Dural Puncture Epidural is a clinical improvement of Combined Spinal-Epidural and is widely used in Maternal. The implementation step is to complete the epidural puncture, temporarily do not place a tube, puncture the dura mater with a subarachnoid anesthesia needle, but do not directly inject drugs into the subarachnoid space, and then leave an epidural catheter for administration according to epidural block.
223679880|NCT05906511|DRUG|Placebo|Oral placebo and/or vaporized saline
223773601|NCT00573963|DRUG|ropivacaine|2 injections of 20mL 0.375% ropivacaine - one given on each side.
223773602|NCT00573963|DRUG|saline solution|2 injections of 20mL plain saline solution - one on each side.
223773603|NCT03300245|RADIATION|Maxillofacial CT|clinical and maxillofacial CT data will be tabulated and analysed using by computer software e.g. Statistical Package for the Social Sciences (SPSS)
223679881|NCT06961669|DRUG|Anti-BCMA and CD19 CART cells will be injected intravenously on a one-time basis|A single intravenous infusion of anti-BCMA and CD19 CART cells (dose-escalating infusion of 1.0-5.0 x10\^5 CART cells/kg）.
223679882|NCT00023192|DRUG|T-Cell Depleted & CD34+Select/w/StemCell Enriched Product|
223679883|NCT03673410|PROCEDURE|Robotic bariatric surgery - revisional|Using robotic techniques during any revesional bariatric surgery
223679884|NCT03673410|PROCEDURE|Laparoscopic bariatric surgery - revisional|Using laparoscopic techniques during any revesional bariatric surgery
223679885|NCT02113839|PROCEDURE|Spirometry|Before re-breathing (if the patient not performed one 6 months in advance).
223679886|NCT02113839|PROCEDURE|CO Exhaled breath|In current smokers of both arms to confirm that the patient has not smoked in the past three hours and to asses the smoking status (heavy, moderate, light).
223679887|NCT02113839|PROCEDURE|P01|P01 is the negative airway pressure generated during the ﬁrst 100 ms of an occluded inspiration. It's an estimation of the neuromuscular drive to breathe.
223679888|NCT02113839|PROCEDURE|FeNO|The measurement of fraction of exhaled nitric oxide during exacerbations of COPD is higher than normal.
223679889|NCT00780390|OTHER|Autonomic Function Assessment|
223679890|NCT04555473|PROCEDURE|Tumor biopsy|"Both interventions performed at baseline upon study enrolment (pre- and post-NACT for NACT+IDS patients) and at the time of recurrence.~1. Part of each surgical specimen will be used to obtain organoids, whereas part will be frozen for direct comparative analysis of the original tumor (1-6 organoids from each patient).~2. Blood samples will be collected to purify extracellular circulating RNA (cRNAs)."
223679891|NCT03838315|OTHER|Neural Mobilization with Soft Tissue Mobilization|"Cervical Traction for 10mints 7%of body weight with 7 second hold time and 5 second rest time.~Hot Pack for 10mints. Neural mobilization technique includes Median, Radial and Ulnar nerve mobilization. Frequency for neural mobilization is 3 sets of 10 repetitions for each and duration of 10minute.~•Post isometric relaxation technique"
223773604|NCT01632371|DEVICE|Paclitaxel Eluting Balloon + Scoring Balloon|Scoring/cutting balloon lesion predilation; paclitaxel eluting balloon therapy
223679892|NCT03838315|OTHER|Neural Mobilization without Soft Tissue Mobilization|"Cervical Traction for 10mints 7%of body weight with 7 second hold time and 5 second rest time.~* Hot Pack~* Neural mobilization technique includes Median, Radial and Ulnar nerve mobilization Frequency for neural mobilization is 3 sets of 10 repetitions for each and duration of 10minute."
223679893|NCT03493815|PROCEDURE|Transabdominal Ultrasound Guided IUD Insertion|Comparing the utility of ultrasound-guided intrauterine device (IUD) insertion compared to traditional blind insertion
223679894|NCT03493815|PROCEDURE|Traditional Blind IUD Insertion|Comparing the utility of ultrasound-guided intrauterine device (IUD) insertion compared to traditional blind insertion
223679895|NCT02367222|OTHER|Exposed to Arepanrix™ Cohort|Demographic characteristics such as age, sex, area of residence, socio-economic status; medical history such as comorbidities, immune status, vaccine indication, receipt of other vaccines or medications and frequency of healthcare contacts, as well as information on pregnancy status and pre-existing conditions will be collected..
223679896|NCT02367222|OTHER|Unexposed to Arepanrix™ Cohort|Demographic characteristics such as age, sex, area of residence, socio-economic status; medical history such as comorbidities, immune status, vaccine indication, receipt of other vaccines or medications and frequency of healthcare contacts, as well as information on pregnancy status and pre-existing conditions will be collected.
223679897|NCT02919969|DRUG|Pembrolizumab|Pembrolizumab 200 mg will be administered as a 30 minute IV infusion every 3 weeks.
223679898|NCT01842633|DRUG|Paracetamol and Caffeine|Caplets containing 500 milligrams (mg) of paracetamol and 65 mg of caffeine
223679899|NCT01842633|DRUG|Ibuprofen|Caplets containing 200 mg of ibuprofen
223679900|NCT01842633|OTHER|Placebo|Matching placebo caplets
223679901|NCT02138799|DRUG|enzalutamide|oral
223679902|NCT02138799|DRUG|rifampin|oral
223773605|NCT01632371|DEVICE|Paclitaxel Eluting Balloon|Standard balloon lesion predilation; paclitaxel-eluting balloon therapy
223773606|NCT06103513|DRUG|Somatropin|The treatment of children with subcutaneous recombinant human growth hormone (rhGH) is the current gold standard of care for children with diagnosed GHD. This study will serve only to investigate the optimal dose of treatment in the first year of treatment with rhGH.
223773607|NCT05576116|PROCEDURE|Sleeve Gastrectomy AND Pancreas after Kidney Transplantation (Staggered Approach)|"Participants will undergo sleeve gastrectomy a minimum of 3 months prior to Pancreas Transplant. SG will be performed using the standard technique.~Pancreas transplant will be performed as per standard procedure."
223773608|NCT05576116|PROCEDURE|Combined Sleeve Gastrectomy and Pancreas transplantation|Simultaneous SG and pancreas transplantation
223773609|NCT01312766|DRUG|Menotropins|Daily administration, SC, starting dose 150 IU or 225 IU depending on patient age.
224260064|NCT05990504|DEVICE|ultrasound real-time guidance combined with Epidural Labor Anagesia|Epidural is a traditional labor analgesia technique.
224260065|NCT02786160|DIETARY_SUPPLEMENT|HMO|
224260066|NCT02786160|DIETARY_SUPPLEMENT|Dextropur|
224260067|NCT01251068|DEVICE|near infrared spectroscopy: invos 5100|duration:six hours
224323159|NCT05137743|BEHAVIORAL|Apnea and Insomnia Relief (AIR)|This treatment will be offered over six sessions. All appointments will be conducted via telehealth and will last 60 minutes. The main components of the AIR protocol are (a) psychoeducation, (b) motivational interviewing, (c) PAP adherence strategies, and (d) cognitive behavioral therapy for insomnia.
224260068|NCT01251068|DEVICE|INVOS 5100|NIRS device used in this study, the optical field includes a volume of tissue approximately 2 cm deep to the surface probe with a 4-mm source-detector distance, and thus, organ-specific monitoring is feasible in small patients. With informed consent, we applied NIRS probes to the forehead and the lower extremity for cerebral (rSO2C) and peripheric (rSO2P) regional oxygen saturation measurements.
224260069|NCT01251068|DEVICE|near infrared spectroscopy device|NIRS device used in this study, the optical field includes a volume of tissue approximately 2 cm deep to the surface probe with a 4-mm source-detector distance, and thus, organ-specific monitoring is feasible in small patients. With informed consent, we applied NIRS probes to the forehead and the lower extremity for cerebral (rSO2C) and peripheric (rSO2P) regional oxygen saturation measurements.
224260070|NCT04374799|DRUG|Heparin|two doses of heparin
224260071|NCT04374799|DRUG|Placebos|placebo
224260072|NCT05639933|DRUG|HT-001 2% Topical Gel|Topical gel, 2% active
223679903|NCT02621684|OTHER|Community Health Activities Model Program for Seniors (CHAMPS)|"* Physical activity questionnaire for older adults~* Asks about activities in the past 4 weeks~* 41 questions and asks to notate how long the activity took"
223679904|NCT02621684|OTHER|Lifetime Total Physical Activity Questionnaire|"* Questions about leisure time (27) and household activities (5)~* Mark if participated in the activity during the past year, ages 51-65, 35-50, 23-34, and onset of puberty through 21 years"
223679905|NCT02621684|OTHER|Expanded Prostate Cancer Index Composite (EPIC)|"* Measures urinary and sexual function before and after prostate cancer treatment~* 7 questions about urinary function~* 9 questions about sexual function"
223679906|NCT02621684|OTHER|International Physical Activity Prevalence Study Environmental Module|-The 17-item Physical Activity Neighborhood Environment Scale can be used to assess the environmental factors for walking and bicycling in various neighborhoods.
223679907|NCT02621684|OTHER|Godin Leisure-Time Exercise Questionnaire (GLTEQ)|-4 item query of usual leisure time exercise habits
223679908|NCT02621684|OTHER|Questionnaire regarding behavior/lifestyle changes since diagnosis|
223679909|NCT02621684|OTHER|12 week Walking Program|
223679910|NCT02621684|OTHER|12 week Resistance Training Program|
223679911|NCT00354003|BEHAVIORAL|A series of questionnaires|Research participants who previously underwent ß-CIT imaging will be contacted by the staff at IND to enquire whether they would like to receive their ß-CIT scan data. After signing a Research Participant Information and Consent Form, all research participants will be asked to complete a questionnaire prior to receipt of their imaging data. Those research participants requesting imaging data will be sent their data by IND and may review their data with IND (by phone) and/ or with their study investigator. All research participants will be asked to respond to a second questionnaire after receiving their imaging data and to a third study questionnaire approximately six weeks following receipt of their imaging data.
223679912|NCT04877925|DEVICE|standard chest tubes|2 standard postoperative chest tube used
223679913|NCT04877925|DEVICE|coaxial chest tube|1 postoperative smart drain coaxial tube
223679914|NCT03331510|OTHER|Strength testing before and after arthroscopic Latarjet|After patients, based on the ISI-Score, were assigned to treat their shoulder instability with an arthroscopic Latarjet procedure, they are eligible for this study. Strength of different involved muscles, as well as ROM will be measured before and at several time points after surgery.
223679915|NCT03129256|DRUG|Apatinib Mesylate tablet combined with S-1 capsules|Oral use with low-dose Apatinib combined with S-1 until disease progression
223679916|NCT02093351|DRUG|Olaparib|2 x 150mg tablets, twice daily Day 1-5, and Day 27 onwards (Cohort 1), Day 20 onwards (Cohort 2) or Day 39 onwards (Cohort 3)
224260073|NCT05639933|DRUG|HT-001 1% Topical Gel|Topical gel, 1% active
223679917|NCT02093351|DRUG|Tamoxifen|60mg Tamoxifen once daily, Day 10 - Day 13; 20mg Tamoxifen once daily, Day 14 - Day 31
223679918|NCT02093351|DRUG|Anastrozole|1mg Anastrozole once daily Day 10 - Day 24
223679919|NCT02093351|DRUG|Letrozole|2.5mg Letrozole once daily Day 10 - Day 43
223679920|NCT02093351|PROCEDURE|Pharmacokinetic sampling|Blood sampling over 12-24 hour period for pharmacokinetic analysis
223679921|NCT04942457|BEHAVIORAL|Fasting|Prolonged fasting for 7-10 days (caloric intake \<500 kcal in liquid form)
224260074|NCT05639933|DRUG|HT-001 0.5% Topical Gel|Topical gel, 0.5% active
224260075|NCT05639933|DRUG|HT-001 Placebo|Topical gel, vehicle gel
224260076|NCT05726162|DEVICE|biofeedback-based music program|The investigators will provide biofeedback-based music, which incorporates the patient's respiratory information. In a biofeedback-based music group, the patient performs an active respiratory intervention session, which induces a slow breathing pattern. If breathing has been slow enough, the automatic mode is activated to provide music based on patient's own breathing pattern. It automatically will be terminated 30 minutes after intervention.
224260077|NCT05726162|OTHER|Control|The investigators will provide noise-canceling earplugs to minimize bias from noise in the ward.
224260078|NCT02695797|OTHER|IVIG|IVIG (400mg/kg/day for 5 days) with oral prednisolone (60mg for 5days, than decrease by 10 mg every 2 day)
224323160|NCT05137743|BEHAVIORAL|Sleep Education (SE)|This treatment will be offered over six sessions. All appointments will be conducted via telehealth and will last 60 minutes. Topics covered include the sleep cycle, sleep across the lifespan, sleep and the mind, evening activities and the sleep environment, and daytime activities and sleep.
224323161|NCT05544136|DIAGNOSTIC_TEST|18F-FMISO PET/CT scan|18F-FMISO PET/CT scan (only 1 injection) that occurs 5-10 treatment days after RT start
223679922|NCT03146598|OTHER|No intervention as it is a observational study|No intervention as it is a observational study
223679923|NCT06530186|DEVICE|LiviWell Postcoital Vaginal Insert|subjects will use Livi within minutes of completion of sex, and will remove study device in under an hour.
224260079|NCT02695797|DRUG|Prednisolone|IVIG (400mg/kg/day for 5 days) with oral prednisolone (60mg for 5days, than decrease by 10 mg every 2 day)
224260080|NCT06517979|DIAGNOSTIC_TEST|Artificial intelligence (AI)-based diagnostic model|Collect pathological slides of resected lymph nodes of the enrolled patients. Digitise these slides into whole-slide images (WSIs). Analyze the WSIs using the AI model to generate diagnostic results (with or without lymphatic metastasis). No intervention to patients would be performed in this diagnostic test study.
224260081|NCT05823766|BEHAVIORAL|In-Person Outcome Assessment|Assessments will be administered to evaluate participant outcome status
223679924|NCT04748588|DRUG|Anti-SARS-CoV-2 mAb|"Casirivimab/imdesimab 1200mg/1200mg OR sotrovimab 500mg OR bamlanivimab 700mg IV x1.~Casirivimab/imdesimab (REGN) and sotrovimab will be the default agents used (according to local availability) unless both unavailable AND virus strain known to be native or alpha (B.1.1.7) in which case bamlanivimab can be used."
223679925|NCT06229314|DEVICE|Inspiratory muscle training|In this study, the preoperative pulmonary function, respiratory and peripheral muscle strengths, functional capacities, and QoL of AIS patients who were eligible for surgery by the physician were evaluated. Subsequently, individuals underwent surgery. Pulmonary function tests and respiratory muscle strength measurements were performed on the patients approximately two days after surgery. Inspiratory Muscle Training was initiated at 60% of the MIP value. IMT was administered using the Powerbreathe device twice a day with 30x2 breaths. The device was adjusted weekly based on the patient\&#39;s current MIP value, and training continued at 60% of the MIP value . The sham group received IMT at 5% of the measured MIP value, with adjustments made weekly, similar to the IMT group. Patients were asked to keep a daily record of their sessions. IMT was administered for a total of 6 weeks. At the end of the sixth week, initial tests and questionnaires were repeated for individuals in both groups.
223679926|NCT03346356|BEHAVIORAL|Teenagers as cross-age SHCP teachers for younger youth|Implementation of the SHCP using teenagers as cross-age teachers for younger youth
223679927|NCT02585570|DRUG|Phenylephrine|Patients is received phenylephrine 1.0 mcg/kg/min or 0.5 mcg/kg/min for 5 minutes before being placed in the beach chair position.
223679928|NCT05398081|DRUG|Cefuroxime (Zinnat®)|Antibiotic for prophylaxis against surgical site infection following craniotomy and laminectomy Here, Cefuroxime (Zinnat®), a second generation cephalosporin will be used
224260082|NCT05823766|PROCEDURE|3T Magnetic Resonance Imaging (MRI)|Participants will be asked to complete a 3T MRI
224260083|NCT05823766|BEHAVIORAL|Clinical Visit|Patients who screen positive for PTE will have an in-depth clinical visit
224260084|NCT05823766|PROCEDURE|Blood Draw|Blood Draw for Plasma, DNA, Serum, RNA
224260085|NCT05823766|PROCEDURE|EEG|An EEG will be performed on patients who screen positive for PTE at the clinical visit
224260086|NCT05823766|BEHAVIORAL|Telephone Outcome Assessment|Assessments will be administered over the telephone to evaluate participant outcome status and screen for PTE
224260087|NCT03784937|DIAGNOSTIC_TEST|Doppler ultrasound|Each patient received Doppler ultrasound for research of DVT, no matter the risk stratification.
224260088|NCT00488774|OTHER|Placebo|Matching placebo for golimumab, intravenous infusion administered at Week 0
224260089|NCT00488774|DRUG|Golimumab 1 mg per kg|Golimumab 1 mg per kg intravenous (IV) infusion administered at Week 0
224260090|NCT00488774|DRUG|Golimumab 2 mg per kg|Golimumab 2 mg per kg intravenous (IV) infusion administered at Week 0
224260091|NCT00488774|DRUG|Golimumab 4 mg per kg|Golimumab 4 mg per kg intravenous (IV) infusion at Week 0
224260092|NCT01110473|DRUG|ABT-348|An oral dose of ABT-348, once daily on Day 1, Day 8, and Day 15 of each 28 day cycle.
223679929|NCT05398081|DRUG|Ceftriaxone (Rocephin®)|Antibiotic for prophylaxis against surgical site infection following craniotomy and laminectomy Here, Ceftriaxone (Rocephin®) a third generation cephalosporin will be used
223679930|NCT04493515|DRUG|Oral Oxytocin|Administration of oxytocin orally (24 IU)
223679931|NCT04493515|DRUG|Oral Placebo|Administration of placebo orally (24 IU)
223679932|NCT03970889|DEVICE|Klue|Klue is a software program the uses an Apple watch to detect hand motions which are indicative of eating.
223679933|NCT01193296|DRUG|Vildagliptin|
223679934|NCT01193296|DRUG|Sitagliptin|
223679935|NCT05764070|DEVICE|non-invasive auricular vagus stimulation|The only cutaneous nerve of the N. vagus, ramus auricularis, receives sensation from the posterior surface of the auricle, the posterior part of the external auditory canal and the adjacent part of the eardrum. Non-invasive transcutaneous devices stimulate the vagus nerve via the auricular route or from the carotid. This device non-invasively stimulates the auricular branch of the vagus nerve without any action. As a result, it was found that the pain threshold increased and the mechanical pain sensitivity decreased.
223679936|NCT05764070|DEVICE|Placebo Non Invasive Vagus Stimulation|Placebo Non Invasive Vagus Stimulation
223679937|NCT04872270|PROCEDURE|Total Shoulder Arthroplasty|Participant will have total shoulder replacement
224260093|NCT01110473|DRUG|ABT-348|An oral dose of ABT-348, twice daily on Day 1, Day 8, and Day 15 of each 28 day cycle
224260094|NCT01110473|DRUG|ABT-348 and azacitidine|An oral dose of ABT-348 on Day 1, Day 8, and Day 15 of each 28 day cycle. An IV or injection of azacitidine on Days 1-7 of each 28 day cycle.
224260095|NCT01110473|DRUG|ABT-348|An intravenous dose of ABT-348, once daily on Day 1, Day 8, and Day 15 of each 28 day cycle.
224260096|NCT01204294|DRUG|Linagliptin|Linagliptin once daily
224260097|NCT01204294|DRUG|Linagliptin|Linagliptin once daily
224260098|NCT01204294|DRUG|Metformin|Metformin twice or three time per day
224260099|NCT01204294|DRUG|Metformin|Metformin twice or three time per day
224260100|NCT01204294|DRUG|Linagliptin|Linagliptin once daily
224260101|NCT01204294|DRUG|Linagliptin|Linagliptin once daily
224260102|NCT01204294|DRUG|Linagliptin|Linagliptin once daily
224260103|NCT02993380|DIETARY_SUPPLEMENT|Stir-fried olive oil group|Stir-fried olive oil group taking food with extra-virgin olive oil in stir fried food or any food with olive oil in heated under 150 degrees of celsius minimal dose per week is 30gram, providing amount of olive oil with meals is 10gram, three times in a weeks
224260104|NCT02993380|DIETARY_SUPPLEMENT|Natural olive oil group|Natural olive oil group taking food with extra-virgin any food with olive oil in , minimal dose per week is 30grams, providing amount of olive oil with meals is 10gram, three times in a weeks
224260105|NCT06099340|OTHER|muscle-strengthening program|a muscle-strengthening program applied to the ankle muscles (triceps surae and dorsal flexors) in physiotherapy, as a complement to conventional rehabilitation
224260106|NCT03344055|DEVICE|Endocuff Vision (ECV) second generation|"Colonoscopy performed with the use of Endocuff Vision (ECV) second generation at the tip of the scope"
224260107|NCT05428943|DRUG|OPT101|15-mer peptide derived from the sequence of mouse CD154.
223679938|NCT04872270|DRUG|Caffeine Pill|2 week supply of 1000 mg caffeine given postoperatively as part of the pain regimen
223679939|NCT04872270|DRUG|Percocet 10Mg-325Mg Tablet|given postoperatively as standard post-op pain management
223679940|NCT04872270|DRUG|Zofran 4Mg Tablet|given postoperatively as standard post-op management
223679941|NCT01099709|DRUG|Reformulated OXY (oxycodone HCl)|Reformulated OXY 10-mg tablet x 1 dose taken with food.
223679942|NCT01099709|DRUG|Original OxyContin® (OXY) (oxycodone HCl)|Original OxyContin® (OXY) 10-mg tablet x 1 dose taken with food.
223679943|NCT04333043|DIAGNOSTIC_TEST|audiological test, cognitive questionnaires|administration of cognitive and quality of life questionnaires and audiological test
223679944|NCT00002455|BIOLOGICAL|Corynebacterium granulosum P40|
223679945|NCT00002455|PROCEDURE|adjuvant therapy|
223679946|NCT06284629|DEVICE|Neptune|Neptune is a software algorithm that utilizes data from wrist-worn sensors to track Parkinson motor symptoms and displays them in an easy to understand graph. Neptune Care is a mobile app that includes a patient portal, where patients can self-report symptoms, view their motor data and get medication reminders, and a physician portal, where the treating physician can view the objective motor data and patient-reported outcomes prior to a clinical visit.
223679947|NCT06284629|OTHER|Standard clinical care|Treatment and management according to standard clinical care
223773610|NCT01312766|DRUG|Menotropins|Daily administration, SC, starting dose 150 IU or 225 IU depending on patient age.
223773611|NCT01502722|BEHAVIORAL|Effect of ingestion sugary and sweetened drinks on thirst|The participants will drink Water (control group), Decarbonized Pineapple Soda (11% sugar)and Decarbonized Pineapple Diet Soda (1% Sugar and Sucralose). The beverages will be presented chilled but without ice in 500 ml portions in opaque plastic containers and participants will be asked to consume the entire amount within 15 min. The beverages will be tested previously in laboratory in order to obtain their pH and osmolality.
224260108|NCT04244760|BEHAVIORAL|Pain assessment for verbal patients|The pain profile of the patient will be assessed at each time point including biological sample analysis (blood and saliva), quantitative sensory testing (mechanical and thermal), and psychological state via the completion of questionnaires by the patient.
224260109|NCT04244760|BEHAVIORAL|Pain assessment for non-verbal patients|The pain profile of the patient will be assessed at each time point including biological sample analysis (blood and saliva), quantitative sensory testing (mechanical), and psychological state via the completion of questionnaires by the parent of the patient.
224260110|NCT04643197|DEVICE|Barbed PDS suture (STRATAFIX Symmetric PDS Plus)|STRATAFIX Symmetric PDS Plus is a barbed suture.
224260111|NCT04643197|DEVICE|Non-barbed PDS suture (PDS Plus)|Non-barbed suture
224260112|NCT03125473|BIOLOGICAL|VXA-G1.1-NN Oral Vaccine|The drug product will be provided as small white enteric-coated tablets. Multiple tablets will be administered to deliver the high total doses.
224260113|NCT00311974|DRUG|Dihydralazine|
224260114|NCT00974740|DRUG|Atorvastatin|atorvastatin 40 mg (tablet for oral intake) once daily in the evening for 4 weeks, thereafter 80 mg for the remaining treatment period (total treatment period 18 months)
224260115|NCT00974740|DRUG|atorvastatin matching placebo|atorvastatin matching placebo tablets once daily in the evening, corresponding to 40 mg atorvastatin for the first 4 weeks (run-in period), and corresponding to 80 mg atorvastatin thereafter (total treatment period 18 months)
224260116|NCT01560767|DRUG|Femoral Nerve Block|Under aseptic conditions, the femoral artery will be palpated immediately below the inguinal ligament and nerve stimulation will be used to identify the femoral nerve just lateral to the artery. Once the femoral nerve has been identified the block may be performed in the routine manner, using 30 ml of levobupivacaine 0.25%. The precise technique used will be noted on trial documentation.
224260117|NCT01560767|DRUG|peri-articular infiltration|The peri-articular infiltration of multimodal agents will consist of 150 mg of levobupivacaine, 10 mg morphine and 30mg ketorolac diluted in 0.9% saline to make a volume 100 ml. (0.5ml 1:1000 adrenaline will be added to the mixture to reduce blood loss after the operation) Fifty ml of the mixture will be injected into the posterior, medial and lateral soft-tissues just prior to implantation of the TKA components. Care will be taken to avoid excessive infiltration in the area of the common peroneal nerve. Then, while the cement is curing, the anterior soft-tissues including the quadriceps mechanism, the retinacular tissues and the subcuticular tissues will be infiltrated with the remaining 50 ml of peri-articular injection.
224260118|NCT05230563|DEVICE|Ti-LUNG|"Participating clinicians will perform two image interpretations on all cases. One period the clinicians only will perform lung nodule detection on chest CT images, and the other period will perform lung nodule detection on chest CT images with the aid of Taihao lung CT decision support system. In each interpretation, all lung nodule is marked by each radiologist. This test collects chest computerized tomography cases for computer analysis, and evaluates whether the TaiHao lung CT decision support system helps doctors make more accurate diagnoses."
223679948|NCT03590431|DIETARY_SUPPLEMENT|extrinsic iodine in milk|300 ml whole cow's milk delivering ≈ 200 µg iodine (extrinsic iodine, low protein-bound fraction) The whole cow's milk will be produced in an experimental barn feeding supplementary iodine to reach a final iodine concentration of ≈ 50 µg/L. The iodine content of the extrinsically labelled milk will be adjusted to the required concentration (same as intrinsic iodine milk) by adding iodine in form of potassium iodide.
223679949|NCT03590431|DIETARY_SUPPLEMENT|intrinsic iodine in milk|300 ml whole cow's milk delivering ≈ 200 µg iodine (intrinsic iodine, high protein-bound fraction) The whole cow's milk will be produced in an experimental barn feeding supplementary iodine to reach a final iodine concentration of ≈ 600 µg/L. This concentration will define final supplemental iodine given to the participants (adapting the total portion size).
223679950|NCT03590431|DIETARY_SUPPLEMENT|water iodine solution|300 ml water delivering ≈ 200 µg iodine (control)
223679951|NCT05915039|OTHER|Computer Assisted Learning (CAL) Module|The students assigned to Group A will undergo interactive CAL module training by the American Medical Association which outlines how to properly measure blood pressure manually following the American Heart Association guidelines.
223773612|NCT05081739|DIAGNOSTIC_TEST|Prospera Transplant Assessment|"Prospera™ detects allograft rejection noninvasively and with high accuracy by measuring the fraction of dd-cfDNA in the patient's blood, without the need for prior donor or recipient genotyping.~Prospera is a commercially available LDT developed by Natera, Inc. Natera is a laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA)."
224260119|NCT04777734|BIOLOGICAL|efgartigimod|an intravenous infusion of efgartigimod
224260120|NCT04941586|OTHER|Education in pain, Manual Therapy and Exercises|twice a week, lasting 60 minutes, for one month
224260121|NCT04941586|OTHER|Manual Therapy and Exercises|twice a week, lasting 40 minutes, for one month
224260122|NCT02682238|DRUG|BBI-4000, 15%|
224260123|NCT02682238|OTHER|Vehicle gel|
224260124|NCT02909907|DRUG|Botulinum toxin|Botulinum injections into dominant upper extremity using protocol outlined above.
224260125|NCT02909907|OTHER|Placebo|Placebo injections in extensor carpi radialis (ECR) and extensor carpi ulnaris (ECU) per protocol outlined above
224260126|NCT03270462|DRUG|Envarsus XR|Pilot study documenting the neurotoxic side effects including tremors in patients with stable graft who are receiving Tacrolimus (Envarsus XR) following kidney transplantation. Standardized questionnaire will be used to document these symptoms.
223679952|NCT03636698|OTHER|chorioamnionitis|It is a observation research. We didn't intervene anything. The chorioamnionitis groups included the infants whose mothers were diagnosed chorioamnionitis by placental histopathology.
223679953|NCT02996643|DEVICE|Ultrasound Assisted Group|A custom brace standing frame, a medical ultrasound system, a custom pressure measurement system, and in-house Ultrasound measurement software were used to assist brace casting for the intervention group.
223679954|NCT02095496|DEVICE|Intellivent-ASV|12 hours of mechanical ventilation with intellivent-ASV
223679955|NCT02095496|DEVICE|Conventional ventilation|12 hours of mechanical ventilation with pressure support ventilation
223679956|NCT06678633|DEVICE|T-Control® (experimental)|Patients will receive intravesical therapy (1-2 hours) through T-Control®, a new Foley-type silicone catheter with an integrated fluid-control valve into the catheter's distal end, which has three positions.
223679957|NCT06678633|DEVICE|Folysil® (control)|Patients will receive intravesical therapy (1-2 hours) through Folysil® Silicone catheter (Coloplast), the usual clinical practice in the participating center.
223679958|NCT03521804|DEVICE|SoundBite™ Crossing System Active Wire 14|Successful crossing of the CTO into the true arterial lumen distal to the occlusion, following use of the SoundBite™ Crossing Wire during the procedure and using antegrade only approach. An antegrade only approach may involve Antegrade Dissection Re-Entry (ADR) with or without the use of specialized devices (i.e. Stingray). The absence of successful retrograde crossing of a collateral will still be considered an antegrade only approach.
223679959|NCT00266851|DRUG|Azithromycin|600 mg x 3 days, then 600 mg weekly x 11 weeks
223679960|NCT00266851|DRUG|Placebo|Matching placebo
223679961|NCT05762770|PROCEDURE|PICSI|Using HA-binding as a sperm selection tool, the intervention group will have sperm selected physiologically prior to ICSI using PICSI dishes, following ORIGIO recommended methods (CooperSurgical, 2021).
223773613|NCT05081739|PROCEDURE|Endomyocardial biopsy|Subjects will undergo surveillance EMB per the institution's standard clinical care, which is expected to be approximately every other week in months 2 and 3, then monthly through month 6, then every 1-3 months through the end of month 12.
223773614|NCT03176732|DEVICE|Positive Airway Pressure|Participants will use Positive Airway Pressure (PAP) treatment
223773615|NCT06182267|DRUG|L Arginine|toothpaste
223773616|NCT06182267|DRUG|Sodium Fluoride|toothpaste
224260127|NCT02700776|OTHER|Phlebotomy - Blood sampling for GP88 at MM|Women undergoing a screening mammogram will have a blood sample drawn to look for GP88.
224260128|NCT02700776|PROCEDURE|SOC Tissue biopsy|standard of care tissue biopsy if clinically indicated.
224260129|NCT03158467|OTHER|Surveys|Instruments will be administered via the online RedCAP platform. The survey instruments will include a Decision Conflict Scale (DCS), the McGill Quality of Life (MQoL), the Human Connection (THC), and a general demographics questionnaire. Patients will have the opportunity to complete the instruments via a research iPad while in clinic or via a survey link emailed to their private email account.
224260130|NCT04069286|DRUG|Oral Aroeira|Active Group oral Aroeira (Schinus terebinthifolia Raddi), 1 tablet of 640 mg + 1 placebo capsule, once a day, for a period of 4 weeks.
224260131|NCT04069286|DRUG|Omeprazole 20Mg Capsule|Comparator Group omeprazole, 1 20mg capsule + 1 placebo tablet, once a day, for a period of 4 weeks.
224323162|NCT05544136|RADIATION|Chemoradiation therapy|"* 18F-FMISO hypoxia negative patients complete CRT with 70Gy primary tumor and 50Gy de-escalated RT dose to gross nodes (if 50Gy is has pilot efficacy, then 44Gy to gross nodes; if 44Gy has pilot efficacy, then 40Gy to gross nodes).~* 18F-FMISO hypoxia positive patients are taken off study and complete SOC 70Gy CRT to primary tumor and gross nodes."
223679962|NCT02060448|BEHAVIORAL|Emotion awareness training|Four weekly individual treatment sessions focused on increasing awareness of one's emotions.
223679963|NCT02060448|BEHAVIORAL|Cognitive reappraisal|Four weekly individual treatment sessions focused on thinking about stimuli in a way that diminishes one's emotions.
223679964|NCT02428127|DIETARY_SUPPLEMENT|Carbohydrate beverage powder|Carbohydrate beverage powder fortified with multiple micronutrients. 20g of study product will be administered orally twice a day
223679965|NCT02428127|DIETARY_SUPPLEMENT|Calorie matched beverage powder|Calorie matched beverage powder with 80% protein.20g of study product will be administered orally twice a day
223679966|NCT02428127|OTHER|Water|lukewarm water
223679967|NCT03956069|BIOLOGICAL|blood sample|for patient and its parents
223679968|NCT03956069|GENETIC|genome sequencing|whole genome sequencing
223679969|NCT05377073|OTHER|Hatha Yoga|Patients in the yoga group performed warm-up exercises for 10 minutes, standing, sitting and supine positions of Hatha yoga (30 minutes), and relaxation and breathing exercises (20 minutes). The program consisted of one weekly session for a total of eight weeks.
223679970|NCT05377073|OTHER|Stretching|Patients in the stretching group performed warm-up activities (10 minutes), and analytic stretching exercises targeting the following muscles: sternocleidomastoid, splenius, trapeze, triceps, posterior shoulder capsule, paravertebralis, hamstrings, quadriceps, gastrocnemius, soleus and tibialis anterior (40 minutes). Two repetitions of 15 seconds of each stretch were performed, with a 15 seconds interval between repetitions. The sessions ended with diaphragmatic breathing exercises (10 minutes). The program consisted of one weekly session for a total of eight weeks.
224260132|NCT02075463|DRUG|GSK1278863|Film coated tablets containing 1 mg, 2 mg, 5 mg or 25 mg of GSK1278863
224260133|NCT02075463|DRUG|Placebo|Matching placebo tablet for GSK1278863
224260134|NCT03324594|DEVICE|(1) WONDALEAF-CAP, (2) WONDALEAF-ON-MEN, (3) durex-TOGETHER (active comparator)|"1. WONDALEAF-ON-MEN (WLM) is a polyurethane pouch with outstretching adhesive shield. The pouch covers the penis in man user; while the adhesive shield covers the groin regions to provide extra protection for the couples. The pouch is equivalent to marketed polyurethane male; while the adhesive shield is equivalent to marketed polyurethane wound dressing. WLM integrally joined with an adhesive wound dressing, both made of the same polyurethane material.~2. WONDALEAF-CAP (WLC) is a miniature form of WLM: the pouch covers glans penis and the adhesive shield wraps around the shaft of the penis only, thereby emulating the configuration of a donned regular condom on the penis. Because of the adhesive coating, WLC overcomes the problems of slippage when the penis is flaccid.~3. The durex-TOGETHER serves as the active comparator in this study. It is a transparent natural rubber latex male condom which is commercially available."
223679971|NCT00008827|BEHAVIORAL|Behavioral weight loss|
223679972|NCT03198039|BEHAVIORAL|Meditation|Isha Kriya (IK) meditation approximately 12 minutes, twice a day
223679973|NCT03102840|DIAGNOSTIC_TEST|Nasopharyngeal swab|Nasopharyngeal swab will be performed in all participants
223679974|NCT03102840|DIAGNOSTIC_TEST|blood sampling|Blood sampling will be done by finger-prick in a sub-set of participants
223679975|NCT01444677|DRUG|MB12066|MB12066 300mg
223679976|NCT01444677|DRUG|MB12066|MB12066 400mg
223679977|NCT01444677|DRUG|MB12066|MB12066 100mg
223679978|NCT01444677|DRUG|MB12066|MB12066 200mg
223679979|NCT01444677|DRUG|Placebo|Placebo 300mg (single dose), 400mg (single dose), 100mg (multiple dose), 200mg (multiple dose)
223679980|NCT05796336|DEVICE|Lip taping|Steri strip tape and passive baby feeding plate Two methods of lip taping will be used with passive baby feeding plate. Impressions will be taken before starting the treatment (T1) and at the end of treatment (T2) three months later. The effectiveness of the two appliances will be assessed and measured on digital models of the maxillary arch before and after the treatment.
223679981|NCT01555957|DRUG|intravenous lipid|intravenous given daily for 6 weeks
223679982|NCT00718081|DRUG|Oral sufentanil|Oral dosage of sufentanil
223679983|NCT00718081|DRUG|Placebo|Oral dosage of placebo
223679984|NCT03778775|DIAGNOSTIC_TEST|Liver sitffness measurement|Liver sitffness measurement is performed by FibroTouch, a new-generation of transient elastography with the tesing interval between liver sitffness measurement and esophagogastroduodenoscopy less than one week.
223679985|NCT01397825|DRUG|Alisertib (MLN8237)|Alisertib (MLN8237) enteric coated tablet (ECT).
223679986|NCT01397825|DRUG|Rituximab|Rituximab IV infusion.
223679987|NCT01397825|DRUG|Vincristine|Vincristine IV Infusion.
223679988|NCT01323842|PROCEDURE|EDTU|bedside ultrasound imaging by the treating emergency physician
223679989|NCT00815516|DRUG|micafungin|Administered by intravenous infusion
224260135|NCT00804180|BEHAVIORAL|Self-Injection Anxiety Counseling|This 5-session group intervention involves: psychoeducation; physiological treatment of anxiety though the instruction and practice of relaxation techniques; cognitive restructuring for anxiety-reduction; practice physiological and cognitive treatments through in vivo injection procedures; and problem solving strategies to generalize treatment gains.
224260136|NCT05610033|DEVICE|AtaCor StealthTrac Lead|Subjects will receive the AtaCor StealthTrac Lead being evaluated in the study.
224323163|NCT05544136|DRUG|Carboplatin|The chemotherapy used in this protocol is the standard of care for head and neck cancer, cisplatin or carboplatin/5-Fluorouracil
223679990|NCT00815516|DRUG|amphotericin B deoxycholate|Administered by intravenous infusion
223679991|NCT03686644|PROCEDURE|Wearing of night splint ankle foot orthoses (phase A)|"Children wearing of night splint ankle foot orthoses during 6, 7 or 8 days according to the position of inclusion.~An ultrasound of the leg muscles will be realized every morning after removing night splint.~An isokinetic dynamometer will be realize at the beginning of the study and at the end of each phase.~measure of quality of night sleeping will be measured by Visual Analog Scale (VAS) results."
223679992|NCT03686644|PROCEDURE|No wearing of night splint ankle foot orthoses (phase B)|"Children no wearing of night splint ankle foot orthoses during 6, 7 or 8 days according to the position of inclusion.~An ultrasound of the leg muscles will be realized every morning after removing night splint.~An isokinetic dynamometer will be realize at the beginning of the study and at the end of each phase.~measure of quality of night sleeping will be measured by Visual Analog Scale (VAS) results."
223679993|NCT02415855|DRUG|Dabigatran|
223679994|NCT00607932|BEHAVIORAL|behavioral dietary intervention|
223679995|NCT00607932|DIETARY_SUPPLEMENT|Brassica vegetable|
223679996|NCT00607932|DRUG|indole-3-carbinol|follow up at 2,4,6 months post baseline.
223679997|NCT00607932|OTHER|counseling intervention|2, 4, 6 months post baseline
223679998|NCT00607932|OTHER|medical chart review|2,4,6 months post baseline
223679999|NCT00607932|OTHER|questionnaire administration|
223680000|NCT00607932|PROCEDURE|adjuvant therapy|
223680001|NCT05037188|BIOLOGICAL|Low dose BCD-250 injection|A recombinant viral vector AAV5-RBD-S vaccine
223680002|NCT05037188|BIOLOGICAL|High dose BCD-250 injection|A recombinant viral vector AAV5-RBD-S vaccine
223680003|NCT05037188|BIOLOGICAL|Low dose or high dose BCD-250 injection|A recombinant viral vector AAV5-RBD-S vaccine
223680004|NCT05037188|OTHER|Placebo injection|Placebo injection
223680005|NCT03067831|BIOLOGICAL|Stem Cells|Transplantation of purified autologous bone marrow-derived stem cells.
223680006|NCT04341753|OTHER|pulmonary rehabilitation|"the strength' measure of the deltoids, triceps and brachial biceps will be carried out by another technique: the 1-RM technique (with dumbbells);~\- 2 other times, the strength' measure of the deltoids, triceps and brachial biceps will be carried out by handheld dynaometry."
223680007|NCT02684318|DRUG|PM01183 + olaparib|
223680008|NCT04455984|OTHER|Date collection|Retrospective data analysis
223680009|NCT01545843|BEHAVIORAL|Sleep scheduling|8 hours vs. 6 hours time in bed for two weeks, with either 2 hour advance of risetime, or 2 hour delay of bedtime
223680010|NCT01545843|DRUG|Fluoxetine|20-40 mg fluoxetine daily for 8 weeks
223680695|NCT00972933|DRUG|ipilimumab|Excisional Biopsy - baseline Induction ipilimumab 10 mg/kg IV day 0, 21 - baseline and week 3 Complete lymph node dissection - week ≥ 6 Maintenance Ipilimumab 10 mg/kg IV - Days 63 (+28 days) and, 84 (+28 days) - (3 weeks apart, starting 2-4 weeks following definitive lymphadenectomy)
224260137|NCT03059615|DRUG|Nerofe|Nerofe is a first-in-class hormone-peptide with cancer suppressive properties. Nerofe is a derivative of the human hormone-peptide Tumor-Cells Apoptosis Factor (TCApF). It contains 14 amino-acids. Binding Nerofe to the T1/ST2 receptor caused a rapid activation both of Caspase 8 and Bcl-2 mediated downstream in proliferating cancer cells.
224260138|NCT03059615|DRUG|Doxorubicin|Doxorubicin is an anthracycline antibiotic with antineoplastic activity. Doxorubicin, isolated from the bacterium Streptomyces peucetius var. caesius, is the hydroxylated congener of daunorubicin. Doxorubicin intercalates between base pairs in the DNA helix, thereby preventing DNA replication and ultimately inhibiting protein synthesis.
224260139|NCT00462228|DRUG|Memantine|After randomization of the subject, subjects will be titrated up to 20 mg of memantine or placebo per day. Memantine and placebo are provided as 5 mg tablets. Subjects will be started at 5 mg per day. The dose will be increased by 5 mg increments to 10 mg per day (5 mg twice per day), 15 mg per day (5 mg and 10 mg as separate doses) and 20 mg per day (10 mg twice per day). The minimum interval between dose increases will be one week. Subjects will take memantine or placebo for 12 weeks during each part of the crossover study. Subjects are randomized to begin either memantine or placebo in each arm of the study.
224260140|NCT00462228|DRUG|Placebo|After randomization of the subject, subjects will be titrated up to 20 mg of memantine or placebo per day. Memantine and placebo are provided as 5 mg tablets. Subjects will be started at 5 mg per day. The dose will be increased by 5 mg increments to 10 mg per day (5 mg twice per day), 15 mg per day (5 mg and 10 mg as separate doses) and 20 mg per day (10 mg twice per day). The minimum interval between dose increases will be one week. Subjects will take memantine or placebo for 12 weeks during each part of the crossover study. Subjects are randomized to begin either memantine or placebo in each arm of the study.
224260141|NCT00061061|BEHAVIORAL|Behavior Therapy|
224260142|NCT00020605|DRUG|naloxone hydrochloride|
224260143|NCT00466401|DRUG|Simvastatin|
224260144|NCT00466401|DRUG|Ezetimibe|
224260145|NCT03019367|PROCEDURE|Umbilical cord milking UCM|At delivery, the umbilical cord is grasped, and blood is pushed toward the infant 4 times before it is clamped. This procedure infuses a placental transfusion of blood into the preterm neonate and can be done in 15-20 seconds.
224260146|NCT03019367|PROCEDURE|Delayed cord clamping DCC|At delivery, delayed cord clamping will be performed by having the delivering obstetrician delay clamping of the umbilical cord for at least 60 seconds.
224260147|NCT00139594|DRUG|licarbazepine|
223680011|NCT05857423|OTHER|Gentle Human Touch|"Gentle Human Touch procedure has 3 step as follows:~1. Mother/nurse must wash their hands with antimicrobial soap for 3 minutes before starting Gentle Human Touch procedure.~2. Next, mother/nurse must warm their hands.~3. Mother/nurse must place their one hand on the infant's head and the other hand on the lower abdomen that covers the waist and hips of the preterm infant, for 15 minute."
223680012|NCT06341803|DEVICE|Individually Neuronavigated accelerated intermittent theta burst stimulation with Magpro X100|MagproX 100 and Axilium Cobot with Localite camera
224260148|NCT05836896|GENETIC|MDC-CAR-BCMA001 (BCMA directed CAR T-cells)|Single-dose intravenous infusion of MDC-CAR-BCMA001 at the respective dose level following a conditioning chemotherapy
224260149|NCT00824291|DRUG|desvenlafaxine succinate sustained release|50 mg/day oral tablet for 12 weeks
223680013|NCT03571282|DRUG|conbercept|After three monthly injections of conbercept, if no effects was seen in the patients, the patients will receive rescue treatments such as photodynamic therapy (in the macular) or laser photocoagulation (outside the macular).
223680014|NCT01741012|DRUG|Gardasil|0.5 ml Gardasil vaccine in single dose prefilled syringes at Visit 2, Visit 4 and Visit 6
223680015|NCT03247803|DEVICE|air-Q® SP|air-Q SP placement for airway maintenance,
223680016|NCT03247803|DEVICE|Williams Airway Intubator (WA)|WA is placed in subject's oropharynx. If the vocal cords are not in view at the end of the WA, the operator may ask an assistant to perform an airway maneuver (e.g., jaw thrust, anterior jaw lift, or lingual traction) to attempt to bring the vocal cords into view
223680017|NCT00470158|DIETARY_SUPPLEMENT|iron and zinc combined|Children \>= 12 months received an average of 5mg zinc/day, 6.25 Iron/day, and 25IU folic acid/day. children\<12 received half that dose. This dose was alternated daily with placebo. Dissolvable doses were distributed in blister packs and reconstituted with a teaspoon of water. Doses were administered in the morning. For missed doses, the mother gave the child the next morning dose, and a second dose in the evening.
223680018|NCT00470158|DIETARY_SUPPLEMENT|iron and zinc on separate days|Children \>= 12 months received an average of 5mg zinc/day, alternating daily with 6.25 Iron/day, and 25IU folic acid/day. Children\<12 received half that dose. Dissolvable doses were distributed in blister packs and reconstituted with a teaspoon of water. Doses were administered in the morning. For missed doses, the mother gave the child the next morning dose, and a second dose in the evening.
223680019|NCT00470158|DIETARY_SUPPLEMENT|iron|Children \>= 12 months received an average 6.25 Iron/day, and 25IU folic acid/day. Children\<12 received half that dose. This dose was alternated daily with placebo. Dissolvable doses were distributed in blister packs and reconstituted with a teaspoon of water. Doses were administered in the morning. For missed doses, the mother gave the child the next morning dose, and a second dose in the evening.
223680020|NCT00470158|DIETARY_SUPPLEMENT|Zinc|Children \>= 12 months received an average of 5mg zinc/day. Children\<12 received half that dose. This dose was alternated daily with placebo. Dissolvable doses were distributed in blister packs and reconstituted with a teaspoon of water. Doses were administered in the morning. For missed doses, the mother gave the child the next morning dose, and a second dose in the evening.
223680021|NCT00470158|DIETARY_SUPPLEMENT|placebo|Children received daily placebo. Dissolvable doses were distributed in blister packs and reconstituted with a teaspoon of water. Doses were administered in the morning. For missed doses, the mother gave the child the next morning dose, and a second dose in the evening.
223680022|NCT00541463|DRUG|MK0639, indinavir sulfate / Duration of Treatment: 48 Weeks|
223680023|NCT00541463|DRUG|Comparator: nelfinavir mesylate / Duration of Treatment: 48 Weeks|
223680024|NCT02902796|DEVICE|Spinal cord stimulator|Spinal cord stimulator will be programmed to deliver, according to the randomization status of the patient, burst, 1000 hertz, and standard stimulation during each treatment group.
223680025|NCT00133393|DRUG|Pentoxifylline|
224260150|NCT00824291|GENETIC|Genotyping|CYP2D6 genotyping at randomization
224260151|NCT01674491|DIETARY_SUPPLEMENT|black soy peptide|black soy peptide: 4.5g/day for 8 weeks
224260152|NCT01741948|DRUG|Hormonal contraceptive|"The study will follow patients who are first time users of HCs for a full year after initiation. Patients will be followed every 3 months via questionnaires, blood examinations, and gynecologic examination, in case dyspareunia evolves.~First appointment (before initiation of HCs):~Questionnaire FSFI (Female Sexual Function Index) questionnaire. Blood collection for hormones levels and extraction of mononuclear blood cells. A gynecologic exam intended to rule out existing problem which causing dyspareunia.~3,6,9,and 12 months after initiation of HCs or anytime if a patient has dyspareunia:~Questionnaire evaluating possible influence of HCs use (dyspareunia, lubrication and libido).~FSFI questionnaire. Blood collection Gynecologic examination, designated to assess the cause of pain, including assessment of vestibular tenderness, muscle tightness and tenderness, pressure-pain thresholds measurement using vulvar algesiometer, pH measurement and vaginal swab for microscopy."
224260153|NCT00004801|DRUG|monoclonal factor IX replacement therapy|
224260154|NCT00933686|DRUG|Saizen®|Saizen® (Somatropin) 0.006 milligram per kilogram (mg/kg) will be administered subcutaneously daily for 12 months. Dose will be titrated (an increase of 0.2 milligram per day) if the increase in insulin-like growth factor 1 (IGF-1) is less than 50 percent of the baseline value. Dose titrations will be made at Month 1, 3, 7 and 9.
224260155|NCT00933686|DRUG|Placebo and Saizen®|Placebo matched to Saizen® will be administered for the first 6 months followed by treatment with Saizen® (Somatropin) 0.006 mg/kg subcutaneously daily for next 6 months. Saizen® dose will be titrated (an increase of 0.2 milligram per day) if the increase in insulin-like growth factor 1 (IGF-1) is less than 50 percent of the baseline value. Dose titrations will be made at Month 7 and 9.
224260156|NCT05235386|DEVICE|Automated oxygen titration|Automated oxygen administration to maintain the SpO2 target at a predefined value during emergency length of stay
224260157|NCT02924363|DIAGNOSTIC_TEST|Cardiac MRI with or without contrast dye|MRI scans of the heart are performed before and after the MitraClip clinical procedure with an FDA cleared device with or without an FDA approved contrast dye.
224260158|NCT02924363|DIAGNOSTIC_TEST|Blood sample|Blood samples collected to calculate hematocrit for measurements of the CMR extracellular matrix.
223680026|NCT01236118|DRUG|LY2439821|Administered subcutaneously
223680027|NCT02133521|DRUG|DLBS1033|Investigational drug or placebo will be given in addition to the standard therapy, consists of: aspirin enteric-coated tablet 1 x 80 mg daily, simvastatin film-coated tablet 1 x 20 mg daily, and vitamin B complex 1 x 1 tablet
224260159|NCT01383486|DRUG|Naproxen sodium ER (BAYH6689)|Naproxen Sodium ER (BAYH6689): oral tablet upon incidence of pain
224260160|NCT01383486|DRUG|Advil|Commercially available Advil; oral caplet upon incidence of pain
224260161|NCT05174741|OTHER|Conventional Chest Physiotherapy|Diaphragmatic Breathing exercise 15 repetition ACBT \*3 sets/session\*TD Walk (10-15 minutes) \* BD
224260162|NCT05174741|OTHER|Aerobic training Group|"Supervised Conventional Chest Physiotherapy + Aerobic training~Aerobic training on cycle ergometer:~between 50% and 70% Vo2max, perceived exertion up to 11 on Borg scale 20-30 min/session/day"
223680028|NCT02133521|DRUG|Placebo|Investigational drug or placebo will be given in addition to the standard therapy, consists of: aspirin enteric-coated tablet 1 x 80 mg daily, simvastatin film-coated tablet 1 x 20 mg daily, and vitamin B complex 1 x 1 tablet
223680029|NCT06101628|OTHER|Gel nail application|The middle finger of the left hand of each participant will be the experimental group and the little finger will be the control group. After the gel nail is applied to the middle finger of the left hand, SpO2 and pulse values will be measured by pulse oximetry from the left hand middle finger and little finger of the participant
223680030|NCT05265052|DRUG|3D1002 (50 mg)(Phase IIa)|1 tablet of 3D1002 per oral dose
223680031|NCT05265052|DRUG|3D1002 (100 mg)(Phase IIa)|2 tablets of 3D1002 per oral dose
224260163|NCT06197009|DRUG|SCT650C|Administered SC
224260164|NCT02437747|DRUG|SRP + Aloe|Scaling and root planing along with aloe vera application was done
224260165|NCT02437747|PROCEDURE|SRP|Scaling and root planing was done
224260166|NCT03917147|PROCEDURE|Office Hysteroscopy|Patients underwent office hysteroscopy with a 5-mm continuous-flow hysteroscope and endometrial biopsies were taken using miniaturized instruments. Histopathological examination was conducted to confirm the diagnosis.
224260167|NCT01370369|DRUG|Testosterone gel (FE 99903)|
224260168|NCT01330576|PROCEDURE|cooling blanket/mattress|Therapeutic controlled hypothermia (33.5C) using cooling blanket/mattress
224260169|NCT01330576|PROCEDURE|Standard treatment of care at normothermia|Standard treatment of care in 33.5C for 48 hours
224260170|NCT03726892|DEVICE|PCI|Coronary Intervention
224323164|NCT04271709|BEHAVIORAL|Enhanced Intervention Using Patient Navigators|Enhanced support by patient navigators assisted with follow-up eye exam appointment scheduling and arranging transportation over a 1-year period.
223680032|NCT05265052|DRUG|3D1002 (150 mg)(Phase IIa)|3 tablets of 3D1002 per oral dose
223680033|NCT05265052|DRUG|3D1002 monotherapy (Phase IIb)|3D1002 is administered at recommended dose with mimic OxyContin tablets.
223680034|NCT05265052|DRUG|OxyContin monotherapy (Phase IIb)|OxyContin is administered at an initial dose of 10 mg per dose with mimic 3D1002 tablets.
223680035|NCT05265052|DRUG|3D1002 + OxyContin (Phase IIb)|3D1002 is administered at recommended dose, and OxyContin is administered at an initial dose of 10 mg per dose.
223680036|NCT04841200|DRUG|Chinese medicine compound combined with symptomatic treatments|"All patients were given symptomatic treatment according to consensus of Chinese experts on pneumoconiosis treatment (2018).~There are 3 Recipe for the 3 traditional Chinese syndrome.~Yang Qing Chen Fei Granules for syndrome of yin deficiency and heat-dryness, Bao Jin Chen Fei Granules for syndrome of pulmonary qi deficiency, Jin Shui Chen Fei Granules syndrome of deficiency of pulmonary and renal qi~All drugs were made into granules by Sichuan Neo-Green Pharmaceutical Technology Development Co., Ltd.~Each type of granule will be given orally, twice a day, for 52 weeks."
223680696|NCT01864226|DRUG|RO5545965|Multiple ascending doses
223680697|NCT01864226|DRUG|placebo|Multiple ascending doses
224260171|NCT03498794|PROCEDURE|Ureteral stent|"Patients will be randomized into 2 groups:~Group (A): 75 patients with the use of ureteral stent. Group (B): 75 patients with the use of PCN.~How the technique will be applied?~Technique of ureteral stent insertion:~The ureteral stent will be inserted retrograde by using flexible cystoscope.~Technique of PCN insertion:~Percutaneous nephrostomy will be performed in the angiography suite by a urologist with the patient under local anesthesia. All the patients will be given non-nephrotoxic antibiotics pre-operatively."
224260172|NCT03789994|BEHAVIORAL|Affective touch|The affective touch comprises of two elements, namely the signal of care, love and acceptance, and stimulation of CT afferent of the skin. Caregivers will be trained to perform light stroking on stroke survivor's forearm while reviewing happy events with the use of photos.
224260173|NCT03789994|OTHER|Fine motor exercise|Fine motor exercises that are commonly used for rehabilitation.
224260174|NCT01281891|DRUG|LIA|Ropivacaine 0.2% Ketorolac 30 mg Adrenaline 0.1 mg/ml
224260175|NCT01281891|DRUG|I/T morphine|Morphine special 0.1 mg injected intrathecally
224260176|NCT03753230|DEVICE|Electroencephalography|Cerebral measurements from electroencephalography devices while music is presented to the participant
224260177|NCT04643067|DRUG|KPG-818 low dose|The dose levels may be modified according to the results from phase 1b of the study. Dose adjustment is allowed during the study.
224260178|NCT04643067|DRUG|KPG-818 mid dose|The dose levels may be modified according to the results from phase 1b of the study. Dose adjustment is allowed during the study.
224260179|NCT04643067|DRUG|KPG-818 high dose|The dose levels may be modified according to the results from phase 1b of the study. Dose adjustment is allowed during the study.
224260180|NCT04643067|DRUG|Placebo|This is the comparative arm.
224260181|NCT03656367|DIETARY_SUPPLEMENT|Cheddar cheese|The reference product is a commercial matured cheddar cheese
224260182|NCT03656367|DIETARY_SUPPLEMENT|Blended and homogenized cheddar cheese|A blended and homogenized cheddar cheese (a spread) which, compared to the reference, has a minimal protein network and has smaller fat droplet
224260183|NCT03656367|DIETARY_SUPPLEMENT|An analog milk|An anolog milk (i.e. milk with a cheese-like nutritional composition) which, compared to the reference, does not contain a protein network
224260184|NCT03656367|DIETARY_SUPPLEMENT|An analog cheese|This analog cheese (a gel/yoghurt) is produced from the analog milk which, compared to the reference, has a protein network, however it is a network that differs from the reference
223773617|NCT00983814|DRUG|Droxidopa+Carbidopa|3 weeks of open label droxidopa (L-dihydroxyphenylserine (L-DOPS)) (200, 400, or 600mgs TID) monotherapy followed by 3 weeks of droxidopa in combination with carbidopa (25mg or 50mg TID) followed by 2 weeks of double blind continued droxidopa+carbidopa or placebo
224260185|NCT04108572|BEHAVIORAL|Infant feeding|Verbally delivered pre-specified infant feeding message. The messages focus on appropriate milk feeding and establishing complementary feeding and solid food introduction in relation to timing and practical guidance around processes of feeding and provision of additional infant-feeding resources including information leaflet, a magnet, an infant bib and access to an informational website.
223680037|NCT04841200|DRUG|Chinese medicine compound placebo combined with symptomatic treatments|"All patients were given symptomatic treatment according to consensus of Chinese experts on pneumoconiosis treatment (2018).~There are 3 placebo Recipe for the 3 traditional Chinese syndrome.~Yang Qing Chen Fei Granules placebo for syndrome of yin deficiency and heat-dryness, Bao Jin Chen Fei Granules placebo for syndrome of pulmonary qi deficiency, Jin Shui Chen Fei Granules placebo for syndrome of deficiency of pulmonary and renal qi~All drugs were made into granules by Sichuan Neo-Green Pharmaceutical Technology Development Co., Ltd. The appearance, shape, color and packaging of Chinese medicine compound placebo are the same as those of drugs.~Each type of granule will be given orally, twice a day, for 52 weeks."
223680698|NCT00559494|DRUG|Minocycline|Minocycline IV BID x 7 days (first 10 patients 200 mg/dose, subsequent patients adjusted based on pharmacodynamic profiling to 800 mg loading dose, tapered 100 mg each dose to 400 mg then maintain at 400mg until day 7)
223680699|NCT00559494|DRUG|placebo|Normal saline 250cc via central line similar to minocycline arm administration protocol
223680700|NCT00559494|PROCEDURE|SCPP augmentation|maintenance of spinal cord perfusion pressure at 75 mmHg with fluids and inotrope protocol
224260186|NCT02295163|PROCEDURE|Stellate ganglion block|7 ml of 0.5% bupivacaine will subsequently be injected next to the stellate ganglion to produce a sympathetic block.
224260187|NCT02295163|PROCEDURE|Sham procedure|7 ml of 0.9 % sodium chloride will subsequently be injected next to the stellate ganglion
224260188|NCT02405481|BEHAVIORAL|SEPA III|
224260189|NCT01354418|DRUG|Phenylephrine HCl Extended Release|One phenylephrine HCl 30 mg extended release tablet orally
224260190|NCT01354418|DRUG|Phenylephrine HCl Immediate Release|One phenylephrine HCl 10 mg immediate release tablet every 4 hours for three doses
224260191|NCT01972490|DRUG|avastin|Drug: avastin On day 1 of a 14 day treatment cycle, patients received a 2-hour infusion of avastin (5mg/kg) followed by chemotherapy of mFOLFOX6 until progressive disease or unacceptable toxicity.
224260192|NCT01972490|DRUG|mFOLFOX6|mFOLFOX-6 (oxaliplatin, 85mg/m2 on day 1 infused during 2 hours;LV400mg/m2 on days 1 infused during 2 hours, followed by FU 400 mg/m2 intravenous bolus then 2400 mg/m2 continuous infusion for 46 hours)
224323165|NCT04271709|OTHER|Usual Care|Usual Care subjects who failed the screening and needed vision correction were given an eyeglasses prescription and a list of optical shops within 1 mile from their home. These subjects did not receive enhanced support. Scheduling this initial appointment will allow tracking of adherence.
223680701|NCT00559494|PROCEDURE|SCPP control|maintenance of Mean arterial pressure of \>65 mmHg with fluids and inotropes protocol without spinal cord perfusion pressure as target or guiding therapy
224260193|NCT05137821|DEVICE|Er: YSGG laser|Er: YSGG laser decontamination of infected implant surfaces to simulate peri-implantitis therapy
224260194|NCT05137821|OTHER|no therapy|new sealed implant without any surface treatment
224260195|NCT01839279|DRUG|Tizanidine|
224260196|NCT01839279|DRUG|Placebo|
224260197|NCT01839279|DRUG|Moxifloxacin|
224260198|NCT05198947|DRUG|Permethrin Lotion 5%|Topical permethrin 5% lotion to apply on day 1 and repeat after 1 week.
224260199|NCT05198947|DRUG|Permethrin Lotion 5% and Oral Ivermectin 200 mcg/kg|Topical permethrin 5% lotion and oral ivermectin 200 mcg/kg to be taken on day 1 only.
224260200|NCT02184845|DEVICE|Implant NobelActive 3.0|
224260201|NCT01505933|DRUG|Dexmedetomidine|"Administer dexmedetomidine at 1mcg/kg over 10min followed by an infusion of dexmedetomidine at 1mcg/kg/hr and image the upper airway.~After the initial set of images is obtained, the depth of anesthesia will be increased by administering a bolus dose of dexmedetomidine 2mcg/kg followed by increase in the infusion rate to 3mcg/kg/hr. Upper airway images will be repeated 5mins after increasing infusion Image acquisitions will be repeated approximately 5 min after the increase in infusion rate."
224260202|NCT01505933|DRUG|propofol|"Administer propofol bolus at 2mg/kg,followed by an infusion of propofol at 100 mcg/kg/min. Upper airway images will be obtained 5 mins after the patient is stable on this infusion.~After the initial set of images is obtained, the depth of anesthesia will be increased by administering a bolus dose of 1mg/kg propofol and infusion increased to 240mcg/kg/min.~Image acquisitions will be repeated approximately 5 min after the increase in infusion rate."
224260203|NCT01289691|OTHER|One Lung Ventilation|Patients in this group will be ventilated with a mixture of air and oxygen during one lung ventilation.
224260204|NCT01289691|OTHER|One Lung Ventilation|Patients in this group will be ventilated with only oxygen during one lung ventilation.
224260205|NCT01648582|DRUG|Dulaglutide|Administered SC
224260206|NCT01648582|DRUG|Insulin glargine|Administered SC per dosing titration schedule
224260207|NCT01648582|DRUG|Metformin|Administered orally at pre-study prescribed dose, and is not being provided as part of the trial.
224260208|NCT01648582|DRUG|Sulfonylureas|Administered orally at pre-study prescribed dose, and is not being provided as part of the trial.
223680038|NCT06394687|DIETARY_SUPPLEMENT|Milk Protein Concentrate|Milk Protein Concentrate is a powdered dairy product made by removing most of the water from milk and contains a protein content below 90% on a dry matter basis. The product has been modified where some of the colloidal calcium phosphate component is reduced, which results in the dissociation of some of casein micelles, forming loose sub-micelle structures. This change modifies the digestion behaviour to be significantly faster.
223680039|NCT06394687|DIETARY_SUPPLEMENT|Micellar Casein Isolate|Micellar casein isolate is a type of protein supplement derived from milk. It belongs to the casein family of proteins, which includes various forms such as micellar casein, casein hydrolysate, and caseinates. During digestion micellar casein coagulates with both gastric acidification and enzymatic hydrolysis by pepsin, forming large stable curds which slow gastric emptying and provide a slower absorption of amino acids over time.
223680040|NCT05868148|DEVICE|Shoulder iD™ Primary Reversed Glenoid|Device implant via reversed total shoulder arthroplasty
223680041|NCT04896645|DEVICE|Digihaler Albuterol Device by TEVA|Patient with asthma will have their regular albuterol rescue inhaler replaced with Digihaler, they will also be asked to perform gamified spirometry (Aluna) at home
223680042|NCT01905215|BIOLOGICAL|RSV vaccine GSK3003892A (formulation 1)|Intramuscular (IM) vaccination in the deltoid region of the non-dominant arm at Day 0 according to protocol schedule
223680043|NCT01905215|BIOLOGICAL|RSV vaccine GSK3003893A (formulation 2)|Intramuscular (IM) vaccination in the deltoid region of the non-dominant arm at Day 0 according to protocol schedule
223680044|NCT01905215|BIOLOGICAL|RSV vaccine GSK3003895A (formulation 3)|Intramuscular (IM) vaccination in the deltoid region of the non-dominant arm at Day 0 according to protocol schedule
223680045|NCT01905215|BIOLOGICAL|RSV vaccine GSK3003896A (formulation 4)|Intramuscular (IM) vaccination in the deltoid region of the non-dominant arm at Day 0 according to protocol schedule
223680046|NCT01905215|BIOLOGICAL|RSV vaccine GSK3003898A (formulation 5)|Intramuscular (IM) vaccination in the deltoid region of the non-dominant arm at Day 0 according to protocol schedule
223680047|NCT01905215|BIOLOGICAL|RSV vaccine GSK3003899A (formulation 6)|Intramuscular (IM) vaccination in the deltoid region of the non-dominant arm at Day 0 according to protocol schedule
223680048|NCT01905215|DRUG|Placebo comparator|Intramuscular (IM) vaccination in the deltoid region of the non-dominant arm at Day 0 according to protocol schedule
223680049|NCT06536608|OTHER|Massage|"The Oketani Method is based upon practical breastfeeding theory, but is original in its practice. Oketani breast massage improves breastmilk secretion, can prevent and treat problems such as mastitis. In addition, the massage is painless, allowing your body to relax and breathe, something very much appreciated by mothers.~The Oketani breast massage consists of massaging and milking the base of the breasts. These delicate glands are massaged as well as protected."
223680050|NCT03469570|DEVICE|EV1000 Clinical Platform with Assisted Fluid Management (AFM) Feature|Subjects enrolled in the validation study will have their fluid management decisions guided by the AFM Feature.
223680051|NCT04653246|DRUG|Isatuximab|Via IV at predetermined dosage and predetermined days during each cycle
223680052|NCT04653246|DRUG|Lenalidomide|Oral, predetermined dosage and predetermined days during each cycle
223680053|NCT04653246|DRUG|Bortezomib Injection|SQ Oral, predetermined dosage and predetermined days during each cycle
223680054|NCT04653246|DRUG|Dexamethasone|IV or Oral predetermined dosage and predetermined days during each cycle
223680055|NCT06450041|DRUG|Universal Donor (UD) TGFβi NK Cells|Patients will receive a dose of 1x108 UD TGFβi NK cells/kg per treatment cycle on day 8 of each cycle
223680056|NCT06450041|DRUG|Temozolomide|Enteral or IV daily on days 1-5 of each cycle For patients ≥ 0.5 m2: 100 mg/m2/dose For patients \< 0.5 m2: 3.3 mg/kg/dose MAXIMUM dose = 200 mg
223773618|NCT02605512|OTHER|Subclinical cardiac lesions and biomarkers|Functional myocardial dysfunction based on 2D-speckle tracking echocardiography, Anatomical coronary lesions based on Coronary computed tomography angiography, a panel of circulating biomarkers based on blood samples and plasma
223773619|NCT01201252|PROCEDURE|Stool sampling|Stool samples will be collected, tested and genotyped for the presence of rotavirus
224260209|NCT01042665|DRUG|latanoprost 0.005%|Active comparator
224260210|NCT01042665|DRUG|Placebo|Placebo comparator
224260211|NCT00671320|DRUG|valdecoxib|valdecoxib 40 mg tablet by mouth twice daily (BID) on Day 1 and then once daily (QD) on Days 2 to 7
224260212|NCT00671320|DRUG|diclofenac|diclofenac 75 mg capsule by mouth twice daily (BID) for 7 days
224260213|NCT04518631|BEHAVIORAL|8-week mindfulness program|The .b Foundations course is an 8-week mindfulness program developed by Mindfulness in Schools Project (MiSP) for school teachers and personnel. It includes a taster session and 8 weekly sessions. Each session lasts for 1.5 hours with a specific theme (e.g. Lesson 1 waking up from autopilot). Formal and informal mindfulness practices (e.g. mindful eating, body scan, mindful walking, habit releaser etc.), psychoeducation, cognitive exercises, inquiry, and home practice are involved.
224260214|NCT00651131|DRUG|daptomycin|daptomycin i.v. 4 mg/kg q24h for 7-14 days
224260215|NCT02699866|DEVICE|BLT Implant Ø 2.9 mm|Placement of Straumann BLT implants Ø 2.9 mm in central and lateral incisors in the mandible and lateral incisors in the maxilla for single tooth replacement followed by prosthetic loading.
224260216|NCT04834440|DRUG|Ropivacaine|all patients will receive femoral nerve block using same volume of ropivacaine but in different concentrations
223680057|NCT06450041|DRUG|Irinotecan|50mg/m2/dose IV daily on days 1-5 of each cycle
223680058|NCT06450041|DRUG|Dinutuximab|17.5mg/m2/dose IV daily on days 2-5 of each cycle
223680059|NCT06450041|DRUG|GM-CSF|250mcg/m2/dose subcutaneous (preferred) or IV daily on days 6-12 of each cycle
223680060|NCT03667170|BIOLOGICAL|KN035|subcutaneous injection
223680061|NCT02392871|RADIATION|Palliative radiotherapy|
223680062|NCT02392871|DRUG|Dabrafenib and trametinib (combination)|Patients should be taking dabrafenib and trametinib for at least 2 weeks prior to enrolment into the study.
223680063|NCT03919188|PROCEDURE|air temperature control (ATC)|Currently there are no guidelines for setting incubator parameters. The Cochrane database point out for further research (Sinclair, 2002). The investigators aim at evaluating 3 different incubator settings for the INOTHERM incubator (Mediprema, France): second parameter : air temperature control (ATC)
223680064|NCT03919188|PROCEDURE|skin servocontrol (SSC)|Currently there are no guidelines for setting incubator parameters. The Cochrane database point out for further research (Sinclair, 2002). The investigators aim at evaluating 3 different incubator settings for the INOTHERM incubator (Mediprema, France): Third parameter : skin servocontrol (SSC).
223680065|NCT06831058|DRUG|efgartigimod|intravenous efgartigimod weekly with monitoring of ADAMTS13 activity for 8 weeks, followed by an observational period of 8 weeks or until treatment failure.
223680066|NCT06101641|OTHER|Shellac nail polish application|The middle finger of the left hand of each participant will be the experimental group and the little finger will be the control group. After the shellac nail polish is applied to the middle finger of the left hand, SpO2 and pulse values will be measured by pulse oximetry from the left hand middle finger and little finger of the participant
223680067|NCT02339376|DEVICE|Low-frequency repetitive transcranial magnetic stimulation|
223680068|NCT02339376|DEVICE|High-frequency repetitive transcranial magnetic stimulation|
223680069|NCT02339376|DEVICE|Sham repetitive transcranial magnetic stimulation|
223680070|NCT04827667|DIAGNOSTIC_TEST|bronchoalveolar lavage|Bronchoalveolar lavage is performed by instillation and suction of saline in the middle lobe during bronchoscopy. Cytological examination and flow cytometry will be performed to assess PD-1lymphoctes.
223680071|NCT05600621|BEHAVIORAL|Financial Literacy Training (FLT) Workshops|Participants will be assigned to receive FLT workshops which are implemented by community-level agencies in collaboration with the financial institutions. FLT comprises six workshops delivered over 6 weeks. Topics include: a) an introduction to the notion of asset-building; b) coverage of asset-building strategies in detail, e.g., saving; c) coverage of specific topics related to saving, e.g., the importance of saving and how to save, d) an introduction of banking services to participants and e) coverage of basics of borrowing and debt management. Participants from the same location, in this case, clinics are assigned to the same group. Workshops occur on weekends to accommodate participants week-day schedules, including school and/or gardening.
224260217|NCT05994066|OTHER|Demographic data of the individuals were recorded. All participants completed NDI, Chalder Fatigue Scale (CFS) and Pittsburgh Sleep Quality Index (PSQI).|Demographic data of the individuals were recorded. All participants completed NDI, Chalder Fatigue Scale (CFS) and Pittsburgh Sleep Quality Index (PSQI).
224323166|NCT05920733|BEHAVIORAL|Nurse-led health coaching|This project is an 6-month program providing an initial 2-month intensive evaluation and personalized virtual individual health coaching experience that is designed to prepare and equip the participant for improved self-care capacity, motivational insight, health-related problem solving and decision-making. This intensive period will then be followed by monthly 30-minute Nurse Coach assessment and individual coaching 'check-in' virtual visits, continued use of the electronic platform tools and health tracking system, and access to group 'virtual coaching' on tailored topics of interest to the cohort.
223680072|NCT05600621|BEHAVIORAL|Incentivized Matched Youth Savings Accounts (YSA) with income-generating activities (IGAs)|"ALHIV will receive a YSA with a 1:1 matched savings program at a financial institution accredited by the Bank of Uganda. Each YDA will be opened in the name of the adolescent, with their primary caregiver as a co-signer, until the adolescent turns 18 years. The account will then be matched with money from the program on 1:1 rate.~As part of YSA, ALHIV are also trained on investing in income-generating activities (IGA) and are normally allowed to use up to 30% of their matched savings to invest in an IGA to benefit their family. The IGA portion helps promote economic stability for families and enable the ALHIV to afford medical expenses."
223680073|NCT05600621|BEHAVIORAL|A manualized visual-based intervention for ART adherence and stigma reduction using multiple family group approach (Suubi Cartoon).|Participants assigned to this component will participate together with her/his caregiving family, in attending sixteen 60 minute sessions hosted within the community over 16 weeks. Each session involves 6-10 families. Participants will learn from the Suubi Cartoon curriculum about their HIV diagnosis and treatment needs, while coping with family loss, stigma, peer relationships, identity, and family functioning.
223680702|NCT02309619|PROCEDURE|lifting of the gastric tube to the neck for gastro-esophageal anastomosis through trans-substernal or trans-esophageal bed path.|Patients with esophageal cancer (EC) will undergo minimally invasive esophagectomy and be classified into two groups according to the last step of the procedure. The gastric tube will be lifted to the neck for gastro-esophageal anastomosis through trans-substernal path in the trans-substernal group, and through trans-esophageal bed path in the trans-esophageal bed group.
223680703|NCT03387644|DRUG|Pregabalin (PG)|Pregabalin 150 mg one hour before the procedure as premedication.
223680704|NCT03387644|DRUG|Control placebo (C)|Placebo tablets one hour before the procedure as premedication.
223680705|NCT06287567|DRUG|Lusutrombopag Oral Tablet|Participants receive lusutrombopag 3 mg administered orally once a day for up to 4 weeks and doses are adjusted based on platelet counts during week 5-12. If a subject's platelet count remains \< 50x10\^9 /L, the dose could have been increased up to a maximum dose of 6 mg（2 tablets).If a subject's platelet count reaches ≥ 250x10\^9 /L during the first 4 weeks, treatment is stopped and participants are allowed to enter into Titration Study in advance when platelet count drops to ≥100x10\^9 /L.
223680706|NCT01667510|DIETARY_SUPPLEMENT|Cardio Mato|Soft gel capsule for oral use
223680707|NCT01667510|DIETARY_SUPPLEMENT|Placebo|Soft gel capsule without test material
223680708|NCT01211431|DRUG|Reference|Intrathécale morphine is used for post-cesarean pain control
223680709|NCT01211431|DRUG|Experimental|A solution including both ropivacain and diclofenac continuously delivered to the wound is used for post-cesarean pain control
223680074|NCT05600621|BEHAVIORAL|Engagement with HIV treatment-experienced role models who share lived experiences of HIV|Participants will be assigned to small groups with an average of 3-4 peers from the same health clinic, and each ALHIV stays in the same group -- for 9 sessions - with the same role model. This is intended to build trust and rapport not only between the role model and mentee, but also between all group members. The 9 sessions, to be conducted over a 6-month period, include activities, videos, scenarios, and role-playing to facilitate discussion and learning. This is intended to promote their self-esteem, improve their HIV care engagement, reduce stigma and stress, encourage hopefulness, build stronger communication skills with their caregivers and/or family members, enhance safe sexual decision-making, and decrease sexual risk-taking behavior.
223680075|NCT05600621|OTHER|Standard of Care (SOC)|SOC consisting of pediatric ART initiation and monitoring outlined by Uganda's Ministry of Health.
223680076|NCT01699347|DRUG|Intracystic injection of OK432 under US guiding|Intracystic injection of OK432 under US guiding
223680077|NCT01351675|DRUG|Placebo|Oral, once daily
223680078|NCT01351675|DRUG|Bardoxolone Methyl: 20 mg|20 mg, oral, once daily
223680079|NCT03481179|DEVICE|TMS|Repetitive TMS involves application of electric currents in the patient's cortex by a magnetic field applied to the scalp of the patient through an eight-coil connected to a magnetic stimulator (MagStim Rapid² magnetic stimulator-UK). In a small percentage of patients, it may cause some discomfort with a mild headache sensation or nausea. Depending on the parameters, rTMS can increase or decrease corticomotor excitability and by the connection of the motor cortex with the thalamus, influencing spasticity inhibition. The patients will respond to an adverse effects questionnaire and will report the perception of real or sham stimulation.
223680080|NCT03481179|OTHER|Physical therapy|The physical therapy, with an duration of 40-50 minutes, will be focused on the upper limbs and will be based on the principles of neuroplasticity (repetition, intensity, specificity, among others (KLEIM \& JONES, 2008), with a protocol that will cover different exercises and degrees of difficulty, which will be chosen according to the need and capacity of each patient
223680081|NCT01129024|DRUG|Lusutrombopag|tablet
223680082|NCT04039100|OTHER|Family Caregiver Ambassador Support|Family Caregiver Ambassador Support, with former caregivers of patients treated for hematological malignancies, being ambassadors for caregivers of newly diagnosed patients for a period of 12 weeks
224323167|NCT06376851|DIAGNOSTIC_TEST|AI-enabled quantitative coronary plaque analysis (AI-QCPA)|The HeartFlow Plaque Analysis provides plaque identification, quantification, and characterization and is meant to support qualified clinicians to aid in the evaluation and risk assessment of coronary artery disease (CAD). It provides data on the volume and type of plaque present (Calcified, Non-calcified, Low Attenuation), both vessel specific and total volumes, with which physicians can better understand a patient's risk, discuss heart health, and help optimize medical management. Plaque Analysis is calculated using image data from a previously acquired CCTA.
224323168|NCT05602623|DEVICE|Adaptive Optics System (AO)|Subjects will have their higher and lower order aberrations corrected with the AO system.
224323169|NCT02819362|DEVICE|MRI|The magnetic resonance imaging (MRI) will be performed before the two-step surgery: a ductal-MRI sequence (highly weighted sagittal T2) - followed by sequence with axial plane, T2, T1, injection in dynamic sequences, subtractions.
223680083|NCT02631993|RADIATION|Photochemotherapy|Oral 8-Methoxypsoralene (8-MOP), (0.4-0.8 mg/kg), are given 1.5-2 hours before phototherapy. Ultraviolet light type A (UVA, 320-400 nm) is administered in a Waldmann UV1000 supine unit through 26 100-W fluorescent PUVA lamps (Waldmann F85), if needed, UVA is given in a half body unit with 15 100-W PUVA-lamps (Waldmann F85), (Waldmann UV3003K), (Waldmann, Villingen-Schwenningen, Germany). Eye protection is applied during 24 h after oral 8-MOP and the genital area are shielded in males during therapy.The UVA is initiated at 0.2-1.5 J/cm2 and is amplified by 0.25-0.5 J/cm2 after two treatments if photo toxicity is absent. PUVA is given to the patients 3-5 times each week.
223680084|NCT05754840|DRUG|MPL-001|High-CBD arm (MPL-001) a cannabidiol-enriched cannabis herbal extract which contains a 1:25 ratio of THC:CBD. The MPL-001 oil is produced by MediPharm Labs, each ml contains 50mg CBD and 2mg THC.
223680085|NCT05754840|DRUG|MPL-005|Medium-CBD arm (MPL-005) a cannabidiol-enriched cannabis herbal extract which contains a 1:5 ratio of THC:CBD. The MPL-005 oil is produced by MediPharm Labs, each ml contains 25mg CBD and 5mg THC.
223680086|NCT05754840|DRUG|MPL-009|Balanced arm (MPL-009) a balanced 1:1 ratio of THC:CBD. The MPL-009 oil is produced by MediPharm Labs, each ml contains 25mg CBD and 25mg THC.
223680087|NCT04042246|BEHAVIORAL|Information Provision|Provide the information on the importance of the vaccination and tailored vaccination schedule
223680088|NCT03997292|DRUG|Alteplase|According to 0.6-0.9mg / kg alteplase (maximum can not exceed 90mg), of which 10% intravenous injection, the remaining 60 minutes intravenous infusion.
223680089|NCT03997292|DRUG|Urokinase|1.2-1.5 million U dissolved in 100ml sodium chloride injection, 30 minutes intravenously.
223680090|NCT04399746|DRUG|Ivermectin|6mg once daily in day 0,1,7 and 8
223773620|NCT02905305|DEVICE|Contour Advance electrode with controlled dose of dexamethasone base|The Combined Device consists of a standard cochlear implant receiver-stimulator coupled to a Contour Advance electrode loaded with a controlled dose of dexamethasone base.
223773621|NCT02905305|DEVICE|Contour Advance electrode|Standard Contour Advance electrode
223773622|NCT05451576|DIETARY_SUPPLEMENT|Zelnite®|2pc intravenous Zelnite® will be given for 7 weeks (5 days/week).
223773623|NCT05451576|DIETARY_SUPPLEMENT|Placebo|Placebo will be given for 7 weeks (5 days/week).
223773624|NCT03258372|DRUG|Mifepristone|Period 1: mifepristone 300 MG (1 tablet) for a total of 300 MG on Day 1 in Cohort 1; and mifepristone 300 MG (5 tablets) for a total of 1500 MG in Cohort 2; then Period 2: rifampin 300 MG (2 capsules) for a total of 600 MG daily for 14 days for both cohorts; then Period 3: mifepristone 300 MG (1 tablet) for a total of 300 MG on Day 1 in Cohort 1; and mifepristone 300 MG (5 tablets) for a total of 1500 MG in Cohort 2
224323170|NCT05972616|BIOLOGICAL|Natural Matrix Protein (NMP)|human bone allograft
224323171|NCT02988271|OTHER|Interview|Participate in interview
224323172|NCT02988271|PROCEDURE|Meditation Therapy|Complete meditation therapy
224323173|NCT02988271|PROCEDURE|Quality-of-Life Assessment|Complete questionnaires
224323174|NCT02988271|PROCEDURE|Supportive Care|Receive supportive care
223680091|NCT04399746|DRUG|Azithromycin|500mg once daily for 4 days
223680092|NCT04399746|DRUG|Cholecalciferol|400 IU twice daily for 30 days
223680093|NCT05885308|BEHAVIORAL|Otago|Group training is compared with training performed at participants' homes, using an online film
223680094|NCT03748615|DEVICE|Computer Guided ridge splitting in posterior mandible|"The computer guided ridge splitting for patients with atrophic posterior mandible and with residual bone width at least 3 to 5mm of residual ridge.~The selected patients will be informed of the nature of the research work and informed consent will be signed.~Radiographic examination included preoperative digital panoramic radiograph with 1:1 magnification for each patient as a primary survey to obtain an approximation of the available bone height and detect the presence of remaining roots and localized pathosis.~Computer surgical guides are fabricated for partially edentulous patients using teeth and tissue as support for the guide.~The same surgeon performed all surgeries. All surgical procedures were performed under strict aseptic conditions, all patients received nerve block local anesthesia (Articaine 4% 1:100 000 epinephrine).~A crestal incision is made using No. 15 blade extending over the posterior mandible using computer guided surgical stent.~no flap elevation ."
223680095|NCT03454009|BEHAVIORAL|Multimodal hygiene intervention|hygiene supplies including hand sanitizer, hand sanitizer surface disinfectant wipes and tissues, along with the following educational materials: a 2-minute electronic educational video; weekly 30-second electronic videos; and an educational flyer.
223680096|NCT05448820|DRUG|YH001|Anti-CTLA4 antibody
223680097|NCT05448820|DRUG|Envafolimab|Anti-PD-L1 antibody
223680098|NCT05448820|DRUG|Doxorubicin|Anthracycline
223680099|NCT04954248|DIAGNOSTIC_TEST|Injected radiotracer with PET Insert|"1. Informed consent will be obtained before beginning any study procedures.~2. Participants will receive a small quantity of an FDA approved radiotracer. The PET insert is placed within a 3T MRI scanner, where PET and MRI imaging will be completed."
223680100|NCT04239430|DIAGNOSTIC_TEST|Serum Bactericidal Assays|Blood samples will be taken from participants at two time points in the study. Serum Bactericidal Assays from participant serum using relevant MenB and MenACWY strains will be undertaken at 18 and 30 months post two doses of 4CMenB (Bexsero, GSK) and MenACWY-conjugate (Menveo, GSK) vaccine. The Vaccines were given to participants during an earlier clinical trial (Propositive). This trisal is a follow up study.
223680101|NCT01915329|DEVICE|RSS (repetitive sensory stimulation)|"RSS is a high frequency electrical stimulation protocol delivered to the peripheral nerves (median and ulnar nerve) of the hand. The signals are generated by a TENS-stimulator and are conveyed to each finger of the hand via a custom-made hand-shaped device with conductive contacts at each fingertip and at the palmar base.~In case of the sham-stimulation no pulses are transmitted."
223680102|NCT01915329|DEVICE|SHAM-RSS|The same device as in the RSS intervention is used, but no electrical stimuli are transmitted.
223680103|NCT01993836|DRUG|Total intravenous anesthesia with propofol|
223680104|NCT01993836|DRUG|General anesthesia with isoflurane|
223680105|NCT04707547|BIOLOGICAL|immunotherapy with Nivolumab|After subjects had received radiofrequency ablation for two weeks, they were performed by immunotherapy with Nivolumab 200mg.
223680106|NCT04707547|PROCEDURE|Radiofrequency Ablation|The most commonly used local ablation is radiofrequency ablation. In this operation, a radio frequency probe is used to insert the liver cancer under ultrasound or computer tomography guidance, and then the radio frequency waves generated by the current oscillations locally heat the high temperature, causing the liver cancer cells to die.
223680107|NCT02612831|PROCEDURE|Early bariatric surgery|
223680108|NCT02612831|PROCEDURE|Delayed bariatric surgery|
223680109|NCT02195687|BIOLOGICAL|botulinum toxin Type A|botulinum toxin Type A (BOTOX®) injected into bilateral crow's feet line areas.
223680110|NCT02195687|DRUG|Normal Saline|Normal Saline (placebo) injected into bilateral Crow's Feet Line areas.
223680111|NCT02263170|OTHER|MRI (magnetic resonance imaging)|Assessment of the sphincter morphology
223680112|NCT02263170|OTHER|US (ultra sound)|Assessment of the sphincter morphology
223680113|NCT02263170|OTHER|FLIP (functional luminal imaging probe)|Assessment of the biomechanical properties of the sphincter region
223680114|NCT02263170|OTHER|HRAM (high resolution anal manometry)|Assessment of the biomechanical properties of the sphincter region
223680115|NCT01753778|DEVICE|Cryo-Touch III Device|Treatment with Cryo-Touch III
223680116|NCT02155803|DRUG|ACTHAR Gel (adrenocorticotropic hormone)|ACTHAR GEL (adrenocorticotropic hormone) 80 units subcutaneously twice weekly for 12 weeks
223680117|NCT03539809|DIETARY_SUPPLEMENT|L-Amino Acids|6 different ratios of the Branched-chain Amino Acids (BCAA) will be tested for 8 hours each.
224260218|NCT06161350|COMBINATION_PRODUCT|Structured multi-disciplinary approach|Since 2010, a structured multidisciplinary team was formed to evaluate the child medically, support its nutrition, teach, treat and educate the children and parents and guide them through the process to obtain a normal and independent feeding behavior. The multidisciplinary team must have special expertise regarding digestive and nutritional as well as sensory and oral motor problems in children requiring artificial nutrition. The team must at least consist of a pediatrician, a dietician with experience in artificial nutrition in children, a speech therapist and/or physical therapist and a psychologist or orthopedagogue. The team should also be able to rely on a nurse with experience in artificial nutrition, a social assistant and a secretary.
224323175|NCT04438824|DRUG|INCMGA00012|INCMGA00012: 500 mg IV (flat dose) q28 days (+/- 7 days in each cycle)
223680118|NCT05279404|OTHER|electroacupuncture|Electroacupuncture at Neiguan and Jianshi acupoint
223680119|NCT02288377|DRUG|lanreotide|Patients will receive lanreotide 120 mg every 28 days until disease progression
223680120|NCT02288377|DRUG|Placebo|
223680121|NCT03023670|PROCEDURE|cardiopulmonary bypass|Low flow of mixed oxygen / air (1:1L) will be used during the period of cardiopulmonary bypass
223680122|NCT03023670|PROCEDURE|cardiopulmonary bypass|Low rate (4\\min) with low tidal volume ( 2ml/kg ) will be used during the period of cardiopulmonary bypass.
223680710|NCT00149448|BEHAVIORAL|TB Contact Priority Model|
223680711|NCT01206387|DRUG|Desoximetasone Spray 0.25%|Desoximetasone topical spray 0.25% administered to affected area twice a day for 28 days
223680712|NCT01206387|DRUG|placebo comparator|Placebo administered to affected area twice a day for 28 days
223680713|NCT02155946|DEVICE|Transcranial direct current stimulation (tDCS) Soterix Medical Inc. tDCS unit|Active brain stimulation
223680714|NCT02155946|DEVICE|Transcranial direct current stimulation (tDCS) Soterix Medical Inc. tDCS unit|Sham (placebo)
223680715|NCT00235170|DEVICE|drug-eluting stent|Cypher Sirolimus-eluting Coronary stent
224323176|NCT04438824|DRUG|Palbociclib|Palbociclib:125 mg PO daily for 21 days, followed by 7 days off, q28 days
224323177|NCT05646719|DRUG|Phentolamine Opthalmic Solution 0.75%|phentolamine ophthalmic solution 0.75% (Nyxol), a non-selective alpha-1 and alpha-2 adrenergic antagonist
224323178|NCT05646719|OTHER|Placebo|Vehicle for Phentolamine Ophthalmic Solution
224323179|NCT05646719|DRUG|Low dose pilocarpine|Pilocarpine hydrochloride ophthalmic solution 0.4%
224323180|NCT05646719|OTHER|Low dose pilocarpine vehicle|Vehicle for low dose pilocarpine
224323181|NCT05301751|BIOLOGICAL|AG-73305|drug product solution
224323182|NCT04815863|DIAGNOSTIC_TEST|Assessment of somatic symptom disorder with SSS-CN|SSS-CN questionnaire is used to assess the presence and severity of the somatic symptoms
224323183|NCT04815863|DIAGNOSTIC_TEST|Assessment of depressive symptoms disorder with PHQ-9|PHQ-9 questionnaire is used to assess the presence and severity of the depressive symptoms
223680123|NCT02217072|BEHAVIORAL|School intervention|A school-based intervention that builds on the promising Swedish programme SkolFam, but is adapted to a Danish school context. The two main components of the programme are a) comprehensive assessment of the child, involving testing of the child's cognitive and academic abilities and difficulties as well as an evaluation of the child's behaviour, school-related social relations and well-being, and b) a systematic and individually targeted intervention plan, made in collaboration between a psychologist, the teachers, and a special educational teacher at the school (e.g., the reading counsellor).
223680124|NCT02217072|BEHAVIORAL|Parents as Tutors|A home-based intervention, comprising a structured tutoring programme that allows foster parents to systematically support the foster child's school performance. Foster parents will attend an introductory tutor training seminar at which they will be introduced to relevant theory on learning and counselled on tutoring practice. The intervention itself is designed to provide approximately three hours per week of individual home-based tutoring for a period of 40 weeks.
223680125|NCT04156516|BEHAVIORAL|HEART|sexual health intervention
223680126|NCT04156516|BEHAVIORAL|HealthyMinds|Growth mindsets of personality and mental health
223680127|NCT00002967|DRUG|cyclophosphamide|
224323184|NCT04815863|DIAGNOSTIC_TEST|Assessment of anxiety disorder with GAD-7|GAD-7 questionnaire is used to assess the presence and severity of the anxiety disorder
224323185|NCT04586959|DEVICE|Surgery with UM|The experimental group will have MIS with the placement of a uterine manipulator
224323186|NCT04586959|DEVICE|Surgery without UM|The control group will have MIS without the placement of a uterine manipulator
224323187|NCT05623020|DRUG|Elranatamab|Part 1 Dose Level 1 is not randomized. All other cohorts are randomized.
224323188|NCT05623020|DRUG|Daratumumab|Part 1 Dose Level 1 is not randomized. All other cohorts are randomized.
224323189|NCT05623020|DRUG|Lenalidomide|Part 1 Dose Level 1 is not randomized. All other cohorts are randomized.
224323190|NCT05623020|DRUG|Dexamethasone|Randomized
224323191|NCT06220201|DRUG|CC-97540|Specified dose on specified days
224323192|NCT06220201|DRUG|Fludarabine|Specified dose on specified days
224323193|NCT06220201|DRUG|Cyclophosphamide|Specified dose on specified days
224323194|NCT05332912|BEHAVIORAL|Spatial Ability Experience|Participants will engage in puzzle construction, block play, visual search, hide and seek
224323195|NCT03817021|BEHAVIORAL|ECE Provider|Provide online training for Head Start educators
224323196|NCT03817021|BEHAVIORAL|Parent Intervention|Coach parents remotely to educate them on responsive feeding and parenting
224323197|NCT03817021|BEHAVIORAL|Child intervention|Through classrooms lessons cover 3 topics: 1) self-regulation, 2) hunger and fullness, and 3) mindfulness in eating and attention control practices
224323198|NCT04268979|BEHAVIORAL|eSNAP|eSNAP is a web based tool that quickly collects and organizes social support information entered by Family Caregivers (FCGs) into visualizations of the size, quality, and function of support networks. Visualizations can help FCGs catalogue support resources and present them in a new way, which may make them more salient and remind FCGs of their availability.
224323199|NCT04268979|BEHAVIORAL|Caregiver Navigator|The Caregiver Navigator will have social work training and will help Family Caregivers (FCGs) identify and leverage informal and formal social support, including enrolling or directing FCGs to services.
223680128|NCT00002967|DRUG|doxorubicin hydrochloride|
223680129|NCT00002967|DRUG|octreotide pamoate|
223680130|NCT00002967|DRUG|tamoxifen citrate|
223680131|NCT04369924|BEHAVIORAL|Unidimensional Measurement-Based Care|Youth and caregivers will complete a symptom rating scale every session. Clinicians will receive feedback reports summarizing these data, including alerts indicating if the youth is on track for positive treatment outcomes. These feedback reports will be used to support clinical decision-making.
223680716|NCT00706849|DRUG|mipomersen sodium|200 mg /mL
223680717|NCT00706849|DRUG|placebo|1 mL matching placebo
223680718|NCT02873585|DEVICE|Stationary intraoral tomosynthesis|Bitewing radiographs using a stationary intraoral tomosynthesis unit
223680719|NCT02873585|DEVICE|Standard conventional bitewing radiography|Bitewing radiographs using a stationary intraoral tomosynthesis unit will be performed after standard bitewing radiography
223680720|NCT01611454|DEVICE|XPF thyroid collar|Interventionalist wear the experimental (XPF) thyroid collar during fluoroscopy guided interventions.
223680721|NCT01611454|DEVICE|Standard 0.5mm lead equivalent thyroid collar|Interventionalist wear a standard 0.5mm lead equivalent thyroid collar during the same type of comparator fluoroscopy guided interventions. Comparator arm uses same type of lead thyroid collar but the XPF under investigation.
223680722|NCT00821067|DIETARY_SUPPLEMENT|D-ribose|A 6 gm/day (3 gm/bid) dose of D-ribose in water. Each subject will consume oral D-ribose, dissolved in 8 fl. oz of water (1 serving) twice daily, for 2 weeks.
223680723|NCT00821067|DIETARY_SUPPLEMENT|Dextrose|A 6 gm/day (3 gm/bid) dose of dextrose in water. Each subject will consume oral dextrose, dissolved in 8 fl. oz of water (1 serving) twice daily, for 2 weeks.
223680724|NCT01343225|DRUG|atripla|once a day
223680725|NCT01343225|DRUG|darunavir ritonavir raltegravir|as directed
223680726|NCT03269552|DRUG|Carfilzomib|Given IV
223680727|NCT03269552|OTHER|Laboratory Biomarker Analysis|Correlative studies
223680728|NCT03269552|BIOLOGICAL|Rituximab|Given IV
224260219|NCT04028180|OTHER|p-Menthane,3-8-diol (PMD) Topical Repellent|"p-Menthane,3-8-diol (PMD) is a recommended active ingredient, which has been evaluated for safe use by the U.S. Environmental Protection Agency (USEPA)1. According to the USEPA laboratory exposure of animals to the active ingredient, PMD, this resulted in no adverse effects except eye irritation. The eye irritation potential of the finished product formulation has not been studied; therefore as a precaution, the products will be handled in the same way as the active ingredient. The researcher and participant must wear eye protection during application of the product and the potential for eye irritation is described in the Participant Information Sheet. . Participants will be excluded if they have a known allergy to any of the product ingredients, or any skin condition, which may affect their reaction to the product.~There isn't a relevant intervention type hence why other is specified. It is to deter mosquitoes landing on the skin of a human."
224260220|NCT04028180|OTHER|Picaridin Topical Repellent|"Icaridin (trade names include Picaridin) is a known mosquito and midge repellent active ingredient. The active ingredient, Picaridin, has been classified as potentially mildly irritating/uncomfortable to the eyes - participants and researcher will wear safety glasses during handling of the products and the participants will be warned about the potential for irritation during the Informed Consent Procedure. Participants will also be excluded if they have a known allergy to any of the product ingredients, or any skin condition which may affect their reaction to the product.~There isn't a relevant intervention type hence why other is specified. It is to deter mosquitoes landing on the skin of a human."
224260221|NCT01398163|OTHER|1-Fermented Dairy Product (test)|Arm 1 - Intervention 1 (probiotics)
224260222|NCT01398163|OTHER|2-Milk-based non-fermented dairy product(control)|Arm 2 - Intervention 2 (control)
224260223|NCT03730363|DRUG|Pentamidine|Pentamidine will be administered as an IV infusion on treatment day 1-3 of a 21-day cycle 3 cycles using 2, 3, and 4 mg/kg dose escalation schedules. Non-investigational agents will be administered as follows: Ifosfamide 5000 mg/m2, Carboplatin 5 area under curve (AUC), and Etoposide 100 mg/mg2.
224260224|NCT03465163|DEVICE|Deep Brain Stimulation|The device is called the Medtronic Activa PC+S system. Two devices will be implanted per participant. The electrodes will be surgically implanted bilaterally into the hippocampus and anterior nucleus of the thalamus.
224260225|NCT03129763|BEHAVIORAL|60mmHg capsule pressure expansion|With a self-made apparatus composed of a spring-loaded sphygmomanometer and a disposable three-way pipe, the capsule pressure is measured. Increasing capsule pressure till 60mmHg.
224260226|NCT03129763|BEHAVIORAL|70mmHg capsule pressure expansion|With a self-made apparatus composed of a spring-loaded sphygmomanometer and a disposable three-way pipe, the capsule pressure is measured. Increasing capsule pressure till 70mmHg.
223680132|NCT04369924|BEHAVIORAL|Multidimensional Measurement-Based Care|Youth and caregivers will complete battery of questionnaires covering multiple process and outcome domains every session. Clinicians will receive feedback reports summarizing these data, including alerts indicating if the youth is on track for positive treatment outcomes. These feedback reports will be used to support clinical decision-making.
223680133|NCT05818605|BEHAVIORAL|Moderate Intensity Exercise Program|Subjects randomized to the EXER arm will undergo 24 weeks of Moderate Intensity Exercise Training (MIET). Patients will be signed up for 60-minute exercise sessions, 3 times a week
223680134|NCT05254054|OTHER|whole body vibration|The whole body vibration is used when vibrations (mechanical oscillations) of a certain frequency are transferred to the human body. Humans are exposed to vibration through a contact surface that is in a mechanical vibrating state. It has been considered as an alternative and safe method for neuromuscular training and may be incorporated into current neuromuscular rehabilitation programs so as to enhance muscle recovery
223680135|NCT05254054|OTHER|Conventional exercise training|A set of conventional exercises designed for ACL rehabilitation
223680136|NCT00069888|DRUG|Docetaxel|
223680137|NCT00558129|DEVICE|X-STOP®|Surgical implantation of X-STOP IPD device
223680138|NCT00558129|PROCEDURE|Laminectomy|Standard laminectomy techniques will be used and may include laminotomy, foraminotomy and/or laminectomy as appropriate. In some cases at the discretion of the treating physician, fusion may indicated to stabilize the segment.
223680139|NCT01294527|DEVICE|Wireless cardiac stimulator implant to pace the left ventricle for CRT|Transvascular endocardial implantation of wireless pacing Electrode and subcutaneous implantation of Implantable Pulse Generator
223680140|NCT03865797|OTHER|Experimental|Each session will last approximately 15 minutes, taking place during 2 days a week, in a period of 4 weeks. The intervention will be done before the training session. The intervention by motor control will consist of the application of a series of Core exercises. The exercises will be carried out with the subjects in different positions of prone, lateral and supine position, for the Core musculature. The exercises will be repeated 10 times each and there will be 8 different exercises: roll up, mermaid, raised crossed, stretch two leg back, shoulder bridge and leg pull up.The intervention will be done before the training session.
223680141|NCT03865797|OTHER|Control active|Each session will last approximately 15 minutes, taking place during 2 days a week, in a period of 4 weeks. The intervention will be done before the training session. The intervention by motor control will consist of the application of a series of Core exercises. The objective of the application of these exercises is to increase the control of the Core, and therefore improve the stability both central and of members. The exercises will be carried out with the subjects in different positions of prone, lateral and supine position, for the Core musculature. The exercises (13) will be repeated 10 times each and there will be 8 different exercises: roll up, mermaid, raised crossed, stretch two leg back, shoulder bridge and leg pull up.
223773625|NCT02309281|DRUG|aflibercept 2mg|Aflibercept 2mg (Eylea) is intravitreally applied. The first treatment interval with aflibercept will be 4 weeks and corresponding to the treat and extend regime intervals will be increased in 2-weeks-steps.
223773626|NCT05198492|OTHER|Impact of air pollution|To assess the short- and long- term impact of air pollution
223773627|NCT06573190|DIAGNOSTIC_TEST|Transient elastography|Liver Stiffness Measurement, Controlled Attenuation Parameter
223773628|NCT06573190|DRUG|Tenofovir Disoproxil Fumarate|Guided Therapy
223773629|NCT06574243|BEHAVIORAL|Social media education|"The intervention consisted of daily positive messages about aging posted on an Instagram account (@laetapaplateada), created specifically for this study, and was conducted over the course of a week. Examples included The ability to make decisions improves with age and Emotional regulation improves with age (David, 2017). These posts were accompanied by their respective author references"
223680142|NCT04690062|DRUG|Brolucizumab-Dbll|intravitreal injection of Brolucizumab (BEOVU)
223680143|NCT01398878|BEHAVIORAL|Intervention work shift|Shiftwork schedule with elimination of shifts greater than 16 hours in length and at least 8 hours off between shifts for all residents in the Intensive Care Unit
223680144|NCT03016676|OTHER|Spinal Manipulation|High velocity low amplitude thrust (HVLA) to the lumbar region of the spine between L1 and L5 vertebrae. The exact level thrust will be at the discretion of the treating practitioner determined by the level with the greatest perceivable motion restriction. The HVLA thrust will be performed with the patient side lying in a neutral.They take part in 12 treatment visits, 10 to 20 minutes sessions of SM over 2 weeks. Light soft tissue techniques (i.e., active and passive muscle stretching, and ischemic compression of tender points) may be used as needed to facilitate the manual therapy.
223680145|NCT03016676|OTHER|Exercise therapy|Self education, supervised exercise visits, and home exercise. The overall objectives are to help patient's mange their LBP and prevent future LBP recurrences. Total number of visits 12.Each visit starts with 10 minutes of self-care education to help patients establish and monitor goals aligned with the exercise program and enhance their understanding of LBP. Participants will be taught the importance of movement and activity, pain management techniques, and methods for developing spinal posture awareness during activities of daily living (e.g., lifting, pushing, pulling, sitting, getting out of bed, and using a backpack).
223680146|NCT02101814|PROCEDURE|Roux-en-Y gastric bypass (bariatric surgery)|
223680147|NCT03231020|OTHER|Interview|"The proposed research study uses a comparative case study methodology, utilizing multiple sources of data to deeply examine 8-10 cases, each of which is defined as parent(s) of a child (\< 5 years of age) with single ventricle disease who used the mHealth application. One group of cases (4-5) will have used the mHealth application less than recommended (non-adherent to the home monitoring recommendations) or declined to use the application and returned it before the end of the interstage period. The other group of comparison cases (4-5 cases) will have used the application as recommended by the clinical team (adherent) and continued doing so through the interstage period."
223680148|NCT03986073|DRUG|TQ-F3083 capsule 10 mg|Subjects in the low dose group administrated TQ-F3083 capsule 10mg, once daily for 12 weeks.
223680149|NCT03986073|DRUG|TQ-F3083 capsule 20 mg|Subjects in the high dose group administrated TQ-F3083 capsule 20 mg, once daily for 12 weeks.
223680150|NCT03986073|DRUG|TQ-F3083 blank analog capsule|Subjects administrated one TQ-F3083 blank analog capsule orally, once daily for 12 weeks.
223680151|NCT03986073|DRUG|TQ-F3083 blank analog capsule|Subjects administrated two TQ-F3083 blank analog capsules orally, once daily for 12 weeks.
223680152|NCT03986073|DRUG|Linagliptin blank analog tablet|Subjects administrated one Linagliptin blank analog tablet orally, once daily for 12 weeks.
223680153|NCT03986073|DRUG|Linagliptin tablet|Subjects in the positive drug control group administrated one Linagliptin tablet orally, once daily for 12 weeks.
223680154|NCT03633760|DRUG|Bilastine 40mg single dose|Single-dose only cohort treatment duration is 1 day. After the screening period, eligible subjects will be allocated to receive a single dose of 40 mg of bilastine
223680155|NCT03633760|DRUG|Bilastine 20mg single-dose followed by multiple-dose|Single-dose followed by multiple-dose cohort treatment duration of this cohort is 9 days. Subjects will receive a single dose of bilastine 20 mg on the morning of Day 1; and six doses of bilastine 20 mg in the morning from Day 4 to Day 9.
223680156|NCT05214846|BEHAVIORAL|Education and counseling|After obtaining informed consent, the data collection form, Hospital Anxiety Depression Scale (HADS) was applied to both groups by face to face interview. Immediately after the questionnaires were answered, individual education and counseling were giving by the nurse researcher to intervention group for 30 minutes. In addition, the education and counseling given to the participants by the researcher.The experimental group was given a telephone number where they could receive consultancy services for 12 hours a day. Pre-test was applied. One day later, the pregnant woman was called and encouraged to call for all her questions, and she was informed that she would be returned when she called.
223680157|NCT00503945|DEVICE|Nasal continuous positive airway pressure (nCPAP)|
223680729|NCT00920907|BIOLOGICAL|Ipilimumab|Solution, Intravenous, 10 mg/kg, Every 3 weeks (up to 4 doses) in induction phase, every 12 weeks in maintenance phase, 48 weeks
223680730|NCT01176942|DIETARY_SUPPLEMENT|Probiotic bacterium Bifidobacterium lactis|Probiotic placebo controlled intervention
223680731|NCT00356837|PROCEDURE|Ultrasound|use ultrasound to confirm diagnosis of extremity fractures
223680732|NCT06491667|DIAGNOSTIC_TEST|CBC|Explore the role of Neutrophil-lymphocyte ratio C-reactive protein in predicting the imediate and short-term prognosis in ST-segment elevation myocardial infarction
223680733|NCT06491667|DIAGNOSTIC_TEST|C-reactive protein|Explore the role of Neutrophil-lymphocyte ratio C-reactive protein in predicting the imediate and short-term prognosis in ST-segment elevation myocardial infarction
223680734|NCT02616601|DRUG|Generic Fluorouracil Cream|Topical cream, generic formulation of the brand product.
223680735|NCT02616601|DRUG|Carac® (Fluorouracil) Cream|Topical cream, brand product.
223680736|NCT02616601|DRUG|Vehicle Cream|Topical cream, placebo. Has no active ingredient.
223680737|NCT00039871|BIOLOGICAL|PegIntron (peginterferon alfa-2b; SCH 54031)|PegIntron (peginterferon alfa-2b) administered at a dose of 1.5 mcg/kg subcutaneously (SC) once a week (QW) for up to 48 weeks
223680738|NCT00039871|DRUG|REBETOL (ribavirin; SCH 18908)|REBETOL (ribavirin) administered on a weight basis: 800-1400 mg/day orally (PO) for up to 48 weeks
223680739|NCT02186301|DRUG|Rociletinib Mono-Therapy|Rociletinib will be administered twice daily
223680740|NCT02186301|DRUG|Erlotinib Mono-Therapy|Erlotinib will be administered once a day
223680741|NCT04638504|OTHER|ultrasonography|vascular and adipose tissue measurement by ultrasonography
223680742|NCT01490723|DRUG|Rituximab|250 mg/m2 by vein preceding 111In Ibritumomab and (90Y) ibritumomab tiuxetan administration, respectively on Days -22 and -14.
223680743|NCT01490723|DRUG|111In Ibritumomab|(5.0 mCi +/- 10% of 111In) by vein immediately following the infusion of rituximab on Day -22.
223680744|NCT01490723|PROCEDURE|Planar Scintigraphy Imaging|Day -22, -21 to -16: Planar scintigraphy whole-body imaging started on Day -22 post 111In Ibritumomab infusion prior to voiding, and repeated 3-6 hours later (including Single Photon Emission-Computed Tomography/Computed Tomography (SPECT/CT) scan of the abdomen). Whole-body planar scintigraphy imaging will be repeated between 22-26 hours, then between 70-74 hours, and later between 142-146 hours post 111In Ibritumomab injection.
224260227|NCT03129763|BEHAVIORAL|80mmHg capsule pressure expansion|With a self-made apparatus composed of a spring-loaded sphygmomanometer and a disposable three-way pipe, the capsule pressure is measured. Increasing capsule pressure till 80mmHg.
224260228|NCT03129763|BEHAVIORAL|90mmHg capsule pressure expansion|With a self-made apparatus composed of a spring-loaded sphygmomanometer and a disposable three-way pipe, the capsule pressure is measured. Increasing capsule pressure till 90mmHg.
224260229|NCT03129763|BEHAVIORAL|100mmHg capsule pressure expansion|With a self-made apparatus composed of a spring-loaded sphygmomanometer and a disposable three-way pipe, the capsule pressure is measured. Increasing capsule pressure till 100mmHg.
223680158|NCT01830400|DRUG|Eslicarbazepine Acetate tablets|The Eslicarbazepine Acetate (ESL) Summary of Product Characteristics (SPC) recommended a starting dose of 400 mg once-daily (QD) which was increased to 800 mg QD after one or two weeks. Based on individual response, the dose was increased to 1200 mg QD. Treatment decisions were made by clinicians in agreement with the participant, and were independent of participation in the study.
223680159|NCT04240353|OTHER|COPD digital support service|Use of COPD digital services to record patient symptoms, integrate physiology monitoring, communicate with the clinical team and track interaction
223680160|NCT03800472|DRUG|GLPG3312 IR|GLPG3312 IR tablets, up to 4 single ascending oral doses (A, B, C, D).
223680161|NCT03800472|DRUG|Placebo|Placebo tablets
223680162|NCT03800472|DRUG|GLPG3312 MR|GLPG3312 MR film-coated tablets, up to 4 single ascending oral doses (H, I, J, K).
223680163|NCT03800472|DRUG|GLPG3312 FE MR|GLPG3312 MR film-coated tablets, single oral dose (N) on 2 occasions, i.e. in fed state after a high-fat high-calorie breakfast, and in fasted state.
223680164|NCT03800472|DRUG|GLPG3312 MR|GLPG3312 MR film-coated tablets, up to 2 multiple ascending oral doses (O, P).
223680165|NCT03800472|DRUG|GLPG3312 MR|GLPG3312 MR optimized film-coated tablets, up to 3 multiple ascending oral doses (Q, R, S).
223680166|NCT03800472|DRUG|Placebo|Placebo optimized tablets
223680167|NCT06092060|DIETARY_SUPPLEMENT|the group GS (probiotic)|The probiotic-supplemented group will receive 2 capsules of freeze-dried powder of a probiotic mixture containing the following bacterial strains twice a day, 3-month: Bifidobacterium lactis W52, Lactobacillus brevis W63, Lactobacillus casei W56, Lactococcus lactis W19, Lactococcus lactis W58, Lactobacillus acidophilus W37, Bifidobacterium bifidum W23, Bifidobacterium lactis W51, Lactobacillus salivarius W24
223680168|NCT06092060|DIETARY_SUPPLEMENT|the group GP (placebo)|The placebo group will receive 2 capsules consisting of the probiotic product carrier, which is corn starch and maltodextrin, twice a day, 3-month.
223680169|NCT02677324|DRUG|ABT199|Oral BCL-2 antagonist
223773630|NCT04390152|DRUG|Wharton's jelly derived Mesenchymal stem cells.|IV Wharton's jelly derived Mesenchymal stem cells, two doses
223680170|NCT01221844|DIETARY_SUPPLEMENT|Lattoglobina (Grunenthal) containing bLf|One capsule of Lattoglobina contains 100 mg of bLf. Dosage: one capsule twice a day before meals. In twin pregnancy or in severe anemia the dosage is increased to 2 capsules twice a day before meals
223680171|NCT01221844|DRUG|FerroGrad by Abbott|Dosage: one tablet/day containing 540 mg of ferrous sulfate during meals
223680172|NCT05242861|RADIATION|Brachytherapy|Applicator, dose, schedule, technology, image, 3D print, efficacy, toxicity of brachytherapy
223680173|NCT05805358|DRUG|Hyperpolarized 13C-Pyruvate injection|DNP-MRI for splenic immune function evaluation through hyperpolarized 13C-Pyruvate injection
223680174|NCT03487679|OTHER|Fasting|Participants will undergo one day of habitual eating followed by 36 hours of water-only fasting and final day of habitual eating consuming the exact same diet consumed on the first eating day. Blood draws will be performed on Day 1 in a 10-12 hr fasted state and 2 hour postprandial state and again on Day 3 in a 36hr fasted state and a 2 hour post prandial state. Microbiome samples and blood glucose data will be collected throughout the course of the study.
223680175|NCT04526990|BIOLOGICAL|Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)|Intramuscular administration
223680176|NCT04526990|BIOLOGICAL|Placebo|Intramuscular administration
223680177|NCT05152316|OTHER|Observational study|This is an observational study and no additional interventions will be done except for those that are standard care. Blood and tracheal aspirates will be taken to assess the surfactant protein levels and inflammatory markers including cell counts and cytokine levels.
223680745|NCT01490723|DRUG|90Y IbritumomabTiuxetan|Calculated to deliver not below 10 Gy to normal organs (liver, lungs, kidneys) by vein post rituximab on Day -14.
223680746|NCT01490723|DRUG|Fludarabine|30 mg/m2 intravenously on Days -5, -4, and -3.
223680747|NCT01490723|DRUG|Bendamustine|130 mg/m2 intravenously on D-5, -4 and -3.
223680748|NCT01490723|DRUG|Thymoglobulin|1 mg/kg (based on actual body weight) on Days -2 and -1 will be administrated to patients receiving a cord blood (CB) and a matched unrelated donor (MUD).
224260230|NCT04034290|BIOLOGICAL|GamFluVac|The drug is a vaccine that induces high-level immunity against influenza A viruses
224260231|NCT04034290|OTHER|Placebo|Placebo
224260232|NCT03998150|PROCEDURE|Holmium laser enucleation of the prostate|cystoscopic transurethral enucleation of the prostate using Holmium laser (Asclepion MultiPulse HoPlus 110W and Lumenis pulse 100W and 120W)
224260233|NCT03998150|PROCEDURE|Bipolar plasma kinetic enucleation of the prostate|cystoscopic transurethral enucleation of the prostate using bipolar plasma kinetic energy (KLS Martin Maxium or Covidien Force Triad)
224260234|NCT05925010|DIETARY_SUPPLEMENT|Supplementation with soluble fibre from guar (Optifibre©)|10g of soluble fibre from guar in the form of Optifibre© (dietary food for special medical purposes) is added to the standardized meal (Resource cereal porridge©).
224260235|NCT01350908|OTHER|Blood sampling|30mL of peripherical blood will be collected specially for the study. It's an additional blood sampling compare to the normal follow up of the patient.
224260236|NCT00498654|BIOLOGICAL|Ty800 (Salmonella typhi) Oral Vaccine|
224260237|NCT04364126|DEVICE|Home blood pressure apparatus|Target \<125/80 mmHg
224260238|NCT04364126|OTHER|Clinic blood pressure|Target \<130/80 mmHg
223680178|NCT02590302|OTHER|Implementation Phase|"Core Components of the implementation intervention include:~* Hospital and CMHA project commitment~* Site champion teams (from hospital and CMHA)~* Memorandum of Agreement between Hospital and CMHA~* Pre-intervention site visits~* Education sessions~* Posters/reminders~* Instructional videos (HEADS ED video)~Completed pathway implementation includes EDMHCP site-customization and committee approvals, consequent planning and agreements among ED-CMHA partners, delivery of at least two educational workshops, and EDMHCP availability in the ED. An 8-month period for EDMHCP implementation, with negotiated interim target dates was set for each site."
223680179|NCT02602678|PROCEDURE|Supine then Prone position|One hour in supine position with CPAP (+7 cmH2O) then 15 min in supine position in spontaneous ventilation (wash-out) and one hour in prone position with CPAP (+7 cmH2O)
223680180|NCT02602678|PROCEDURE|Prone then supine position|One hour in prone position with CPAP (+7 cmH2O) then 15 min in supine position in spontaneous ventilation (wash out ) and one hour in supine position with CPAP (+7 cmH2O)
223680181|NCT00981942|DRUG|Imatinib mesylate (Glivec)|400 mg, one tablet daily for 12 or 24 weeks
223680182|NCT06152471|DRUG|SPC-flakes|Aktive drug
223680183|NCT06152471|DRUG|Salovum|Active drug
223680184|NCT06152471|DRUG|Placebo|Placebo drugs
223680185|NCT01108289|OTHER|Oxytocin in Uniject|10 IU Oxytocin delivered intramuscularly immediately after delivery of the baby
223680186|NCT03550651|OTHER|Licorice|Licorice, since years is known for its anti-inflammatory, antimicrobial, antiviral, antiprotozoal, antioxidative, hepatoprotective, cardioprotective, immunomodulatory and antitumour activity. Licorice can be beneficial for oral health. Glycyrrhizin, the sweet component of licorice root has antiplaque property. Pterocarpenes isolated from G. uralensis root extract exerts an antibacterial activity against Streptococcus mutans.
223680187|NCT03550651|OTHER|Hypertonic salt solution|The antiseptic and bactericidal qualities of salt help in removing plaque which is a cause of gingivitis and caries. Warming water with a pinch of table salt can reduce or even be an alternative to anti-inflammatory drugs intra-orally. Its high osmolality reduces inflammation and can be microbicidal. Moreover, efficacy of luke warm hypertonic salt solution has shown antimicrobial, anti-inflammatory and immunomodulatory properties.
223680188|NCT03550651|OTHER|Essential oil|Essential oils have a wide application in folk medicine, food flavoring and preservation as well as in fragrance industries. The antimicrobial properties of essential oils have been known for many centuries. In recent years, a large number of essential oils and their constituents have been investigated for their antimicrobial properties against some bacteria and fungi. Essential oils have the potential to be used as therapeutic agents for chronic gingivitis and periodontitis conditions that have both bacterial and inflammatory components.
223680189|NCT03550651|OTHER|Chlorhexidine Gluconate|Chlorhexidine is a symmetrical bisbiguanide synthetic antiseptic. It is available in three forms, digluconate, acetate and hydrochloride salts. Which have broad spectrum antimicrobial activity; it is effective against both Gram-positive and Gram-negative bacteria including aerobes and anaerobes, yeasts, fungi and lipid enveloped viruses. Chlorhexidine is considered to be the most effective plaque inhibitor against which other antiplaque agents are measured.
223680190|NCT03550651|OTHER|Distilled water|Distilled water is commonly placebo in various research projects and it is also useful in as placebo treatment.
223680191|NCT04062500|OTHER|Mortality and Rehospitalization rate|Mortality and Re-hospitalization of acute decompensated heart failure
223680192|NCT00304369|DRUG|Metronidazole|
223680193|NCT00107926|DRUG|Licarbazepine|
223680194|NCT00107926|DRUG|Placebo|
223680195|NCT00117065|DRUG|Aranesp®|
223680196|NCT00633620|DEVICE|Olympus NBI colonoscope 180 HDTV narrow band imaging (diagnostic test)|colonoscopy withdrawal with NBI mode
223680197|NCT02856893|DRUG|Osimertinib|Osimertinib 60 or 40 mg daily until progression
224323200|NCT02844764|BIOLOGICAL|[StroMed + platelet rich plasma (PRP)]|Patients will be treated with autologous StroMed obtained by the Adipose Ultrasonic Cell Recovery Unit (AUCRU) and Platelet Rich Plasma (PRP) processed by the RegenLab (RegenKit BCT-3) PRP product each as direct injections to the affected joints at the time of initial treatment. Thereafter the affected joints will be treated with direct injections to the joint with Platelet Rich Plasma processed by RegenLab (RegenKit BCT-3) PRP product. Day 0 \[StroMed + platelet rich plasma (PRP)\], Day 7, 14 and 30 \[PRP\]
224323201|NCT05483023|DRUG|18F-fluorofuranylnorprogesterone PET / MRI|Subjects will receive a PET/MRI with 18F-fluorofuranylnorprogesterone tracer
223680198|NCT02856893|DRUG|Gefitinib|Gefitinib 250mg daily until progression
223680199|NCT00963677|PROCEDURE|Nasotracheal Intubation through seeing optical stylet (SOS)|Nasotracheal intubation using seeing optical stylet in the patients with the anticipated difficult intubation. Arm 1:routine anesthesia induction,0.1mg/kg midazolam, 3-8mcg/kg fentanyl, 0.08-0.15mg/kg vecuronium and 0.3mg/kg etomidate, Nasotracheal intubation with seeing optical shikani; Arms 2: Sevoflurane combined with oxyge, 0.3mg/kg Etomidate and 1-2mg/kg succinylcholine for intubation, nasotracheal intubation with seeing optical shikani
223680200|NCT00955227|DIETARY_SUPPLEMENT|Flax seed oil (ALA)|2 capsules each containing 500mg of ALA will be taken once per day for 6 weeks
223680201|NCT00955227|DRUG|Ezetimibe|In total, 30 patients will receive ezetimibe as a drug intervention. The dosage is 10mg pod for 6 weeks
223680202|NCT00048087|DRUG|ZD1839|250 mg by mouth daily each day for 4 weeks.
223680203|NCT00048087|DRUG|Docetaxel|30 mg/m2 by IV on day 1 weekly for the first 3 weeks of each 4 week course.
223680204|NCT03446144|DRUG|IONIS-FB-Lrx|Single Dose of IONIS-FB-Lrx administered once weekly for weeks 1-3, and every other week or less frequently until week 70
223680205|NCT03446144|DRUG|Placebo (sterline saline 0.9%)|Calculated volume to match active comparator. Administered subcutaneously weekly for weeks 1-3, and every other week or less frequently until week 70
223680206|NCT01717144|BEHAVIORAL|therapeutic education program|The educational program consisted of both individual and collective educational consultations with a therapeutic education nurse
223773631|NCT04390152|DRUG|Hydroxychloroquine, lopinavir/ritonavir or azithromycin and placebo (standard therapy)|Standard therapy as per hospital protocol, hydroxychloroquine 400mg + Lopinavir/Ritonavir 400/100 or azithromycin 500mg and Placebo
223773632|NCT00909805|DEVICE|cutaneous suture (Surjet)|cutaneous surjet suture
223773633|NCT00909805|DEVICE|2-octyl-cyanoacrylate (Dermabond® glue)|the cutaneous suture is made with glue only
223680207|NCT01361854|DEVICE|polysomnography|home-based polysomnography with hook-up performed ar at home or in the hospital
223680208|NCT02782078|BIOLOGICAL|Clindamycin and rifampicin dosages|blood samples for clindamycin and rifampicin dosages (for each patient)
223680209|NCT05561010|DRUG|Intra-articular injection of bupivacaine in the knee joint|25 participants will be allocated to the bupivacaine arm.
223680210|NCT05561010|DRUG|Intra-articular injection of placebo in the knee joint|25 participants will be allocated to the placebo arm.
223680211|NCT06345196|BEHAVIORAL|motivational interview|Motivational interviewing will be conducted in four sessions and the session duration will be maximum 40 minutes. The session will be conducted individually and online once a week. For the individual interview, the appropriate day and time will be determined with the individuals with diabetes and the researcher before the first session and the sessions will continue on the same day and time every week. The researcher will remind the participant about the time of the session by calling the participant by phone one day before each session. Motivational interview sessions will be held online on the Whatsapp platform.
223680212|NCT01732653|OTHER|TT+VR|subjects will be walking on a treadmill while negotiating virtual obstacles provided by a computer simulation. The virtual environment will consist of obstacles, different pathways, narrow corridors and distracters, requiring modulations of step amplitude in two planes (i.e., height and width) coordinated with walking behaviour. The speed, orientation, size, frequency of appearance and shape of the targets will be manipulated according to individual needs following a standardized protocol.
223680213|NCT01732653|OTHER|TT alone|The participants will walk on the treadmill, their gait speed over-ground will be measured at the beginning of each week of training. Progression will include increasing the duration of each of the walking bouts and increasing walking speed.
223680214|NCT02311101|DRUG|Mitomycin C|Given intravesically
223680215|NCT02106923|DRUG|1 tablet Empagliflozin/2 tablets Metformin XR|Active Comparator: 1 x Empagliflozin/2x Metformin XR tablets
223680216|NCT02106923|DRUG|10 mg Empagliflozin/1000 mg Metformin XR|Experimental: high dose Empagliflozin/Metformin XR, FDC tablet
224260239|NCT03902548|DRUG|[18F]P16-129|Injection of \< 10 mCi \[18F\]P16-129 followed by PET/CT scanning
224260240|NCT03437265|DRUG|PLENVU powder for oral solution|PLENVU Dose 1 (1 sachet) and PLENVU Dose 2 (2 sachets)
224260241|NCT01717339|OTHER|Sleep Study|
224260242|NCT00647686|DRUG|Fentanyl Transdermal System 25 mcg/h + Askina Derm Overlay|single application
224260243|NCT00647686|DRUG|Fentanyl Transdermal System 25 mcg/h|single application
224260244|NCT02157623|DRUG|Levulan|Levulan application followed by Red or Blue light PDT
223680217|NCT02106923|DRUG|1 tablet 10 mg Empagliflozin/3 tablets Metformin XR|Active Comparator: 1 x Empagliflozin/3 x Metformin XR tablets
223680218|NCT02106923|DRUG|2 tablets 5 mg Empagliflozin/750 Metformin XR|Experimental:2 x low dose Empagliflozin/Metformin XR FDC tablets
223680219|NCT02106923|DRUG|1 tablet Empagliflozin/2 tablets Metformin XR|Active Comparator: 1 x Empagliflozin/2x Metformin XR tablets
223680220|NCT02106923|DRUG|10 mg Empagliflozin/1000 mg Metformin XR|Experimental: high dose Empagliflozin/Metformin XR, FDC tablet
223680221|NCT03485495|DRUG|Divaza|Oral administration.
223680222|NCT03485495|DRUG|Placebo|Oral administration.
223680223|NCT05824520|OTHER|ITS plus OMT|Invasive treatment strategy plus optimal medical therapy
223680224|NCT05824520|OTHER|OMT|Optimal medical therapy alone
223680225|NCT05977361|PROCEDURE|Resiting Epidural Catheter|After a UDP has occurred, epidural catheter will be re-sited in a different intervertebral space. Analgesia will be then maintained according to internal protocol, using PIEB (Programmed Intermittent Epidural Bolus) system. Catheter will be left in place for the first 24-36 hours.
223680226|NCT05977361|PROCEDURE|Intrathecal Catheter Placement|After a UDP has occurred, an intrathecal catheter will be placed through the dural tap. Analgesia will be then maintained according to internal protocol, using PISB (Programmed Intermittent Subarachnoid Bolus) system. Catheter will be left in place for the first 24-36 hours. During this time, a continuous infusion of sterile saline at a rate of 2 mL/h will be maintained. Before removal, an additional bolus of 10 mL of sterile saline will be administered in the intrathecal catheter.
224260245|NCT02157623|OTHER|Red Light PDT|Aktilite™ (red lamp) after Levulan application on lesions
224323202|NCT03458676|PROCEDURE|Advanced Magnetic Resonance Imaging Scan|"AMRI scan performed within 2 weeks before standard of care brain biopsy and tumor removal surgery.~AMRI scan should take less than 1 hour to complete"
223680227|NCT02088242|DRUG|Astaxanthin|Oral supplementation with the food supplement Astaxanthin. Subjects receiving Astaxanthin will be asked to ingest 3 capsules containing 4mg of Astaxanthin each (a daily dose of 12mg).
223680228|NCT02088242|DRUG|Placebo|3 capsules identical in shape, colour and size to the Astaxanthin capsules, which contain only the inactive ingredients of the same formulation.
224260246|NCT02157623|OTHER|Blue Light PDT|Blu-U® (blue lamp) after Levulan application on lesions
224260247|NCT03113708|DRUG|Heparin Sodium|Heparinisation 2-4 mg/kg will be done according to actual body weight or lean body weight.
224260248|NCT01160666|DRUG|Belimumab|Belimumab will be administered at 10 mg/kg at Days 0, 14, 28 and then every 28 days until week 24 for all patients and week 48 for those considered responders at week 28.
224260249|NCT06196307|COMBINATION_PRODUCT|Clinical evaluation, laboratory and cardiac imaging results, medication, surgery, and any hospitalization|"Examination： Electrocardiogram、 imaging examination、 X-ray, CTA, bedside echocardiography.~History of cardiovascular and pulmonary vascular drug therapy: Antithrombotic therapy (type, measurement) , Anticoagulation therapy (type, metering), Other drug treatments (type, measurement)"
224260250|NCT02096185|RADIATION|3 dimensional tomosynthesis imaging|Each operative specimen will be imaged twice using each condition
224260251|NCT02096185|RADIATION|2 dimensional digital imaging|
224260252|NCT01746056|DEVICE|Occlusive Heat Patch|The heat patch will be applied for 2 hours every day for a period of 12 weeks.
224260253|NCT04435847|BIOLOGICAL|HST 001|Participants will receive intradermal injections at 3 timepoints only: week 0, week 6 and week 12. At each of these 3 interventional visits they will receive 0.1 mL X 20 injections spaced approximately 0.8 - 1.2 cm apart from one another of active treatment (HST 001).
223680229|NCT01028690|DIETARY_SUPPLEMENT|Lactobacillus reuteri|Lactobacillus reuteri is a mixture of L. reuteri DSM 17938 and L. reuteri ATCC PTA 6475; will be delivered at a dose of 1x108 CFU of each strain. One dose is to be taken once per day giving a dose of L. reuteri of 2x108 CFU/day. Will be taken daily throughout the entire study, from the day of inclusion to the final analysis at the end of follow-up after eradication therapy. Will be delivered either in a chewable tablet form
223680230|NCT01028690|DIETARY_SUPPLEMENT|Placebo|placebo
223680231|NCT01629199|DRUG|rhEGF(recombinant human Epidermal Growth Factor)|
223680232|NCT01629199|DRUG|placebo of rhEGF(recombinant human Epidermal Growth Factor)|
223680233|NCT01864356|DRUG|NT100|
223680234|NCT01864356|DRUG|Placebo|
223680235|NCT00736515|DRUG|Gliclazide MR and Insulin Glargine Injection|Combination therapy of oral administration of 60-120mg Gliclazide Modified Release Tablet once daily before breakfast and subcutaneous injection of Insulin Glargine Injection once daily before dinner (initial dosage 0.2U/KG/D) for 3 months
223680236|NCT00736515|DRUG|Biosynthetic Human Insulin Injection|Monotherapy of subcutaneous injection of Biosynthetic Human Insulin Injection twice daily (before breakfast and before dinner) (initial dosage 0.4-0.6U/KG/D) for 3 months
223680237|NCT04264052|DIAGNOSTIC_TEST|CBE & MRI|"The diagnostic tests will be consisted by two visits.~In the first visit participants will undergo a medical history assessment and they will complete questionnaires related to the lung function (MRC Dyspnoea score, Dyspnoea-12 questionnaire, and Visual Analogue Scale). A spirometry will be performed to assess the lung function. Bronchoscopy will be performed at rest in a semi-supine position (on a reclined bed) and then during exercise on a treadmill.~In the second visit, spirometry and questionnaires will be performed prior to resting and during exercise measurements on a magnetic resonance imaging (MRI) scan.~Rest: Structural imaging of the neck and chest will be performed followed by dynamic imaging of the airways during several inspiratory and expiratory manoeuvres. No IV contrast media will be used."
223680238|NCT04074239|OTHER|Video triage|The operator at the Medical Helpline will offer the parent who's calling regarding the sick child to assess the child on video, as compared to the routine way; on the telephone.
223680239|NCT04875247|DEVICE|IOLMaster 700 with central topography|The time needed to perform the measurement using the IOLMaster700 equipment with central topography will be recorded.
223680240|NCT04875247|DEVICE|IOLMaster 700 without central topography plus Cassini|The time needed to perform the measurement using the IOLMaster700 equipment without central topography plus the Cassini equipment will be recorded.
223680241|NCT04875247|DEVICE|IOLMaster 700 without central topography plus Pentacam|The time needed to perform the measurement using the IOLMaster700 equipment without central topography plus the Pentacam equipment will be recorded.
224260254|NCT04435847|OTHER|Phosphate Buffered Saline|Participants will receive intradermal injections at 3 timepoints only: week 0, week 6 and week 12. At each of these 3 interventional visits they will receive 0.1 mL X 20 injections spaced approximately 0.8 - 1.2 cm apart from one another of placebo control (Phosphate Buffered Saline).
224260255|NCT04070547|DEVICE|Transcutaneous vagal nerve stimulation|Non-invasive stimulation provided by transcutaneous electrical nerve stimulation device 4hours a day at 25Hz, 250 μs pulse width placed on tragus.
223680242|NCT03103061|DRUG|Lexiscan|Coronary vasodilator
223680243|NCT03479645|BEHAVIORAL|Serial text messages and mailed FIT kit|"1. Pre-alert SMS offering Opt-out of mailed FIT kit~2. Mailed home FIT kit~3. SMS A - Reciprocity message~4. SMS B - Offer for second FIT kit if lost/did not receive~   * Plus SMS A + C if second mailed FIT is requested.~5. SMS C - Salience message"
223680244|NCT02270437|DRUG|ropivacaine, fentanyl, adrenaline|The patients in the cocktail analgesia group received an injection of 200mg ropivacaine, 100ug fentanyl, and 0.25mg adrenaline into knee collateral ligaments, posterior aspect of the capsule, quadriceps tendon, patellar tendon, fat pad, periosteum, and synovium, along with PCIA morphine postoperatively.
223680245|NCT00231374|PROCEDURE|Myelogram|
223680246|NCT00216866|DRUG|Dalteparin|
223680247|NCT00216866|DRUG|Warfarin|
224260256|NCT04070547|DEVICE|Sham stimulation|Sham stimulation will be performed using electrodes 4 hours a day placed on earlobe.
224260257|NCT00316277|BEHAVIORAL|Standard Medical Management (SMM) of Prescription Opiate Abuse|Standard Medical Management in Phase 1 will consist of one hour-long initial visit; one individual 15-20 minute visit later in Week 1; one individual 15-20 minute visit per week through the end of Week 4; one 15-20 minute SMM visit at Week 6 and at Week 8. And in Phase 2, one 30-60 minute initial visit; one 15-20 minute follow-up visit later in Week 1; one individual session (15-20 minutes) per week through Week 12. In addition, participants in Phase 1 will receive BUP/NX at between 8 to 32mg/day; tapering to zero between weeks three and four. Those referred to Phase 2 will receive up to 32 mg/day for three months tapering to zero during month four.
223680248|NCT03865576|DIAGNOSTIC_TEST|Non-invasive ICP measurement|Intracranial pressure will be measured non-invasively using transorbital Doppler ultrasound. Values will be compared to ICP measured by lumbar puncture or implanted ICP sensors
223680249|NCT03549351|OTHER|Measurable residual disease measured by flow cytometry|Measurable residual disease measured by flow cytometry
223680250|NCT00268580|BEHAVIORAL|Asthma Care Pathway|Asthma care provided using standardized asthma care pathway
223680251|NCT03988413|DRUG|25mg|SYHA1402 25mg or Placebo 25mg
223680252|NCT03988413|DRUG|50mg|SYHA1402 50mg or Placebo 50mg
223680253|NCT03988413|DRUG|100mg|SYHA1402 100mg or Placebo 100mg
223680254|NCT03988413|DRUG|200mg|SYHA1402 200mg or Placebo 200mg
223680255|NCT03988413|DRUG|400mg|SYHA1402 400mg or Placebo 400mg
223680256|NCT03988413|DRUG|800mg|SYHA1402 800mg or Placebo 800mg
223680257|NCT04743518|OTHER|Aortic pulse wave velocity|Aortic pulse wave velocity (aPWV) is a measure of aortic stiffness
223680258|NCT04743518|OTHER|carotid intima media thickness (CIMT)|carotid intima media thickness (CIMT)
223680259|NCT00924625|OTHER|Neuromuscular electrical stimulation|Strength of the quadriceps muscles will be tested at the beginning of each session. During administration of the NMES participant will sit with the knees bent at 70 degrees. The force sensing pad will be secured to the ankle joint. Two electrodes will be placed on the thigh muscle; one near the hip and the other near the knee joint. The intensity of NMES will be increased gradually according with tolerance. During each treatment 15 electrically elicited muscle contractions will be administered to each thigh. Each contraction will last 14 sec followed by 1min rest.
224260258|NCT00316277|BEHAVIORAL|Enhanced Medical Management (EMM) of Prescription Opiate Abuse|Enhanced Medical Management in Phase 1 will consist of SMM plus two individual sessions with a counselor per week (45 minutes each) through Weeks 1-4, and one 45-minute counseling visit at Week 6 and at Week 8. And in Phase 2, EMM will consist of the SMM plus two individual sessions with a counselor per week (45 minutes each) during Weeks 1-6 and one individual session with a counselor per week (45 minutes each) during Weeks 7-12. In addition, participants in Phase 1 will receive BUP/NX at between 8 to 32mg/day; tapering to zero between weeks three and four. Those referred to Phase 2 will receive up to 32 mg/day for three months tapering to zero during month four.
223680260|NCT00924625|OTHER|Volitional exercises|The training will include bilateral exercises using resistance equipment (Leg Extension and Leg Press machines). Each resistance exercise will have: (a) dynamic muscle action at moderate repetition velocity (1-2 s concentric, 1-2 s eccentric, 2-3 s interval); (b) 3 sets of 8 repetitions with a load corresponding to 80% of one repetition maximum(1-RM); (c) 2-min rest period between sets and exercises.
223680261|NCT00141570|DRUG|esterified estrogens 0.625 mg and methyltestosterone 1.25 mg|
223680262|NCT01915628|DEVICE|BioMatrix Flex|Percutaneous coronary intervention
223680263|NCT01325792|DEVICE|GORE® BIO-A® Tissue Reinforcement|Retrorectus or intraperitoneal placement of device to reinforce the midline fascial closure after single-staged open complex ventral incisional hernia repair of primary or recurrent anterior abdominal wall hernia.
223773634|NCT00315094|BEHAVIORAL|Caregiving support interventions (FamTechCare)|One set of combined interventions to be tested in this study are nursing interventions for the prevention of catheter-related infection, reactive depression, and HPN home care problem-solving. The other set of combined interventions are for increasing social support and use of a short nap to reduce daily fatigue. Information about all the interventions were incorporated into Internet formats as a booster for reinforcement.
223773635|NCT05491629|OTHER|type of parallel data in a convergent parallel hash pattern (near time)|"The quantitative part of the study is a descriptive study with the Perceived Perioperative Competence Scale-Revised to determine the perceptions of operating room nurses about their competencies.~It is a case study in order to reveal the opinions of the surgical team members about the competencies of the operating room nurses and the affecting factors through individual in-depth interviews and to better explain the current situation at the qualitative stage, which is carried out simultaneously."
223773636|NCT01175655|OTHER|MSC|mesenchymal stromal cells (MSC), aiming for 2 x 106 /kg cells recipient body weight, aiming for a frequency of twice weekly for two weeks
224260259|NCT05462327|PROCEDURE|Low Fresh Gas Flow in Prone Position|In the low fresh gas flow group, the flow rate was reduced to 0.5 L/min
224260260|NCT05462327|PROCEDURE|Normal Fresh Gas Flow in Prone Position|In the normal flow rate group, the gas flow rate was reduced to 2 L/min during the maintenance phase.
224260261|NCT03302780|DEVICE|BreEStim|BreEStim will applied for 10 to 20 minutes.
224260262|NCT03302780|DEVICE|tDCS active|tDCS will be applied for 20 minutes.
224260263|NCT03302780|DEVICE|tDCS sham|
224260264|NCT00388531|DRUG|Depocyte®|Depocyte® is a cytostatic drug
224260265|NCT01180322|DRUG|Cytarabine|"Induction therapy:100 mg/m2/day by continuous intravenous (IV) infusion on days 1-7 (total dose 700 mg/m2)~Consolidation therapy:~Younger adults (18 to 65 years): 3 g/m2/day by IV infusion over 3 hours every 12 hours on days 1, 2, and 3 (total dose 18 g/m2).~Elderly patients (\>65 years): 1 g/m2/day by IV infusion over 3 hours every 12 hours on days 1, 2, and 3 (total dose 6 g/m2)."
223680264|NCT04019587|DIAGNOSTIC_TEST|Fear of Falling Avoidance Behavior Questionnaire administration|The Questionnaire includes 14 items dealing with avoidance behavior. All items will be asked by face to face technique.
223680265|NCT00150644|DRUG|Asoprisnil|Asoprisnil 10mg Tablet, oral Daily for 12 weeks
223680266|NCT00150644|DRUG|Asoprisnil|Asoprisnil 25 mg Tablet, oral Daily for 12 weeks
223680267|NCT00150644|DRUG|Placebo|Placebo Tablet, oral Daily for 12 weeks
223680268|NCT02203084|OTHER|Social Determinants Questionnaire|The questionnaire contains a general background information section common to all medical conditions. It then contains separate sections with medical condition specific questions.
223773637|NCT03333486|DRUG|Cyclophosphamide|Given IV
223773638|NCT03333486|DRUG|Fludarabine Phosphate|Given IV
223773639|NCT03333486|OTHER|Laboratory Biomarker Analysis|Correlative studies
223680269|NCT01056380|DRUG|Nitazoxanide|Tablet, 500 mg with food twice daily for 5 days
223680270|NCT01056380|DRUG|Placebo|Tablet, twice daily with food for 5 days
223773640|NCT03333486|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo PBSCT
223773641|NCT03333486|RADIATION|Total-Body Irradiation|Undergo TBI
223773642|NCT05443425|DRUG|Cholestyramine|Given PO
223773643|NCT05443425|DRUG|Leflunomide|Given PO
223773644|NCT05443425|DRUG|Steroid Therapy|Given steroid therapy
223773645|NCT03113682|BEHAVIORAL|CBT-RD|5-8 sessions of cognitive behavioral therapy for rumination disorder (CBT-RD), held once per week in an outpatient setting.
224260266|NCT01180322|DRUG|Idarubicin|"First induction therapy:~Arm A, C, D:~12 mg/m2/day by IV push on days 1,3,5 (total dose 36 mg/m2). For elderly (\>65 yrs) patients only two doses of idarubicin are foreseen on days 1+3.~Arm B:~12 mg/m2/day by IV push on days 6, 8 10 (total dose 36 mg/m2). For elderly (\>65 yrs) patients only two doses of idarubicin are foreseen on days 6+8.~Second induction therapy:~Arm A, C, D:~12 mg/m2/day by IV push on days 1 and 3 (total dose 24 mg/m2; for all age groups)~Arm B:~12 mg/m2/day by IV push on days 6 and 8 (total dose 24 mg/m2; for all age groups)."
223680271|NCT00235001|DRUG|trandolapril/verapamil|180/2 mg QD
223680272|NCT05465720|BEHAVIORAL|falls-prevention programs|Each group will receive 10-minute warm up, followed by 20-minute exercises in the ICF body function level, 20-minute exercises in the ICF activity level, and finally 10-minute cool down. The 10-minute war up include dynamic mobility exercises of the upper extremity and trunk (ribbons dancing on a chair) and of the lower extremity (marching in place). The 10-minute cool down include flexibility exercises of multiple muscles especially focusing on neck, hamstring, and calf muscles.
223680273|NCT03439527|OTHER|Muscle Precursor Cells (MPCs), ATMP|The advanced therapeutic investigational product, the MPCs, is a living, autologous cell-product isolated from a biopsy of the patient's own musculus soleus.
223680274|NCT01655108|DRUG|Minoxidil|Minoxidil 0.5% /2ml intradermal injection in the scalp ( mesotherapy), weekly sessions, ten weeks
223680275|NCT01655108|DRUG|Saline|Physiological saline solution 0.9% , intradermal injection in the scalp ( mesotherapy), weekly sessions, ten weeks
224260267|NCT01180322|DRUG|Etoposide|"Induction therapy:~Arm A, C, D:~100 mg/m²/day by 1-hour IV infusion on days 1,2,3 (total dose 300 mg/m2). On days 1 and 3 start after idarubicin push. For elderly (\>65 yrs) patients only two doses of etoposide are foreseen on days 1+3.~Arm B:~100 mg/m²/day by 1-hour IV infusion on days 6,7,8 (total dose 300 mg/m2). On days 6 and 8 start after idarubicin push. For elderly (\>65 yrs) patients only two doses of etoposide are foreseen on days 6+8."
224260268|NCT01180322|DRUG|Azacitidine|"Induction therapy:~Arm B and C:~100 mg/m2/day by subcutaneous (SC) injection or 15-minute IV infusion on day 1 to day 5 (total dose 500 mg/m2). Azacitidine is always given prior to idarubicin and etoposide.~Arm D:~100 mg/m2/day by SC injection or 15-minute IV infusion on days 4-8 (total dose 500 mg/m2). Azacitidine is always given prior to idarubicin and etoposide.~Maintenance therapy:~Arm B, C, D:~50 mg/m2/day by SC injection on days 1-5 (total dose 250 mg/m2) every 4 weeks. (Maintenance therapy is scheduled for a total duration of 2 years in patients with continuous CR)"
223680276|NCT03901456|BEHAVIORAL|Care to Plan|Care to Plan (CtP) is an online care planning tool that provides a succinct and clear overview of various types of ADRD caregiver interventions, administers a brief validated assessment of risk, and generates individualized service recommendations for Alzheimer's disease and related dementia (ADRD) caregivers as well as resources that link users to a selected recommendation. Caregivers will complete the tool with the guidance of a CtP interventionist (Senior Care Navigator/Riverside Health System staff). The interventionist will discuss CtP recommendations with caregivers and help caregivers enroll in a recommended support service if so desired.
223680277|NCT03901456|BEHAVIORAL|Usual Care|"Receive care as usual.~Note: If eligible, participants in this control group will be asked if they are interested in enrolling in a similar, additional feature of the study to test the Care to Plan tool following the initial 6-month study."
223680278|NCT03724747|DRUG|BAY2315497 Injection|BAY 2315497 Injection comprises 3 components: the PSMA-specific monoclonal antibody (mAb), the mAb-chelator conjugate, and the thorium-227 labeled mAb-chelator conjugate. BAY 2315497 Injection will be administered on Day 1 of each treatment cycle.
223680279|NCT03724747|DRUG|Darolutamide(BAY1841788)|600 mg (2 X 300 mg tablets), twice daily with food, equivalent to a total daily dose of 1200 mg.
223680280|NCT05043285|BIOLOGICAL|SCTV01C|intramuscular injection
223680281|NCT05043285|OTHER|Placebo|Intramuscular injection
223680282|NCT04608942|DEVICE|Jett Plasma Medical Lift|Plasma Application versus Mechanical Debridement in refractory meibomian gland dysfunction
223680283|NCT04608942|PROCEDURE|Mechanical Debridement|Plasma Application versus Mechanical Debridement in refractory meibomian gland dysfunction
224260269|NCT01180322|DRUG|Lenograstim|"Consolidation therapy:~subcutaneously daily beginning on day 10 until neutrophil count \> 0.5 x 109/l."
224260270|NCT04131621|BIOLOGICAL|Nivolumab/Ipilimumab|Immune checkpoint inhibitor combination
224260271|NCT03517085|GENETIC|DTX401|DTX401 administered as a single peripheral intravenous (IV) infusion
223680284|NCT03119207|BEHAVIORAL|Naptime Protocol|Between midnight and 4:00 every attempt will be made to limit staff entrance into the patient room.
223680285|NCT05912426|BEHAVIORAL|Reduced-sodium potassium-enriched salt|Supply and use of a reduced-sodium, potassium-enriched iodised salt (66% potassium chloride, 34% sodium chloride).
223680286|NCT01079702|DRUG|Everolimus|Everolimus, administrated twice daily at a fixed total dose of 10 mg continuously.
223680287|NCT01079702|DRUG|Capecitabine|Capecitabine administered bid for 14 days followed by 7 days rest. In this study, capecitabine will be dose escalated. The first dose level of capecitabine is 500 mg/m2 twice daily.
223680288|NCT06010875|BIOLOGICAL|CD70 CAR-T cells|After lymphodepletion with Fludarabine and Cyclophosphamide,CAR T cells were transfused intravenically
223680289|NCT06010875|BIOLOGICAL|CD70 CAR-T cells|After lymphodepletion with Fludarabine and Cyclophosphamide,CAR T cells were injected intraperitoneally
223680290|NCT02937220|PROCEDURE|monolithic zirconia crown|New crown material used as final restoration for dental implants
223680291|NCT02937220|PROCEDURE|metal ceramic crown|Conventional crown material used as final restoration for dental implants
223680295|NCT01136278|DRUG|3,4-Methylenedioxymethamphetamine|125 mg, single dose
223680296|NCT01136278|DRUG|Clonidine|150 μg per os
223680297|NCT01136278|DRUG|placebo|capsules identical to MDMA or clonidine
223680298|NCT01988285|OTHER|Specimen Collection|Blood collection, possible saliva collection, possible urine collection, and biopsy collection
223680299|NCT01988285|OTHER|Questionnaires|Subjects will complete a questionnaire utilizing validated symptom-specific instruments (Mayo Dysphagia Scale; GERD-HRQL Scale). The questionnaire will also record patient demographics, medical history, and current and past medication use
223680300|NCT01718340|DRUG|Metformin|metformin tablet 500mg three time per day
223680301|NCT03647189|DEVICE|Hybrid Fractional Laser|Hybrid Fractional Laser
223680302|NCT05938049|DEVICE|IVC ultrasound & Carotid doppler|"bed side ultrasonographic assessement of inferior vena cava maximum and minimum diameters 2 to 5 cm caudal to its junction with the right atrium over a single respiratory cycle , inferior vena cava collapsibility index (IVC-CI) will calculated as (IVC max - IVC min)/IVC max).~carotid doppler assessment (2-3 cm proximal to the carotid bulb in the longitudinal plane) of corrected carotid flow time(systole time/√cycle time) ,carotid artery peak velocity variation calculated as (\[PV max- PV min\]/PV mean) × 100, where PV mean = (PV max + PV min)/2. during three consecutive respiratory cycles. as part of their routine care and assessment"
223680303|NCT04185597|OTHER|HFP Intervention: Delivered by Community Farmers|Homestead food production (HFP) supported by community farmers, Social and Behavior Change Communication (SBCC), strengthened health services, and referrals to health and other services
223773646|NCT03597516|DRUG|RP-G28|powder for reconstitution for oral administration
224260272|NCT03517085|DRUG|steroid regimen|prednisone or prednisolone to manage alanine aminotransferase (ALT) elevation
224260273|NCT00137254|DRUG|Insulin|IV insulin
224260274|NCT00137254|DRUG|Stable Isotopes|IV administration of stable isotopes
224260275|NCT00137254|DRUG|Indocyanine Green|IV administration of ICG
223773647|NCT03597516|DRUG|Placebos|powder for reconstitution for oral administration
223773648|NCT03995758|DEVICE|MOSES|software based modulation of the laser energy delivered from the homium laser source. The software changes the pulsed laser to have two peaks of energy - one to displace water in front of the stone and a second to deliver the laser energy to the stone
223773649|NCT03946163|DIETARY_SUPPLEMENT|cinnamon capsules|each patient will receive sixty capsules, each capsule contained 1gm of cinnamon bark powder and instructed to use it twice daily for one month
223773650|NCT03946163|DRUG|Placebo oral capsule|each patient will receive sixty capsules, each capsule contained placebo and instructed to use it twice daily for one month
224260276|NCT04306783|OTHER|In-home sensor monitoring|-Installed and maintained by Foresite Healthcare
223680304|NCT04185597|OTHER|HFP Intervention: Delivered by agricultural Retailers|HFP supported by retailers, SBCC, strengthened health services, and referrals to health and other services
223680305|NCT04185597|OTHER|Control|Current Standard of Practice
223680306|NCT00305929|DRUG|Treatment with Tookad VTP|
224260277|NCT05148273|BEHAVIORAL|telenursing|7-24 counseling and daily treatment protocol reminders will be given to the intervention group.
224260278|NCT00840476|DRUG|Meloxicam 15 mg Tablets|1 x 15 mg, single-dose fasting
224260279|NCT00840476|DRUG|Mobic® 15 mg Tablets|1 x 15 mg, single-dose fasting
224260280|NCT05580692|PROCEDURE|Biospecimen Collection|Biospecimen Sample Collection
224260281|NCT04514939|OTHER|Elevation of the legs during bed rest|Patients of Group A will will lie in their hospital bed with a moderate leg elevation (between 15 and 30 degrees)
224260282|NCT06210984|DRUG|Low caffeine dose|2 mg/kg dose of caffeine in pill form
224260283|NCT06210984|DRUG|Moderate caffeine dose|5 mg/kg dose of caffeine in pill form
224260284|NCT06210984|DRUG|Placebo|5 mg/kg dose of maltodextrin in pill form
223680307|NCT00305929|DRUG|Treatment with Tookad VTP|Tookad 2 mg/kg
223680308|NCT00305929|DRUG|Treatment with Tookad VTP|2 mg/kg
223680309|NCT03037645|DRUG|SNS-062|SNS-062 will be orally administered twice daily and available in capsules containing either 25 mg or 100 mg of active ingredient.
223680310|NCT04850508|DEVICE|Mapping and ablation with the Advisor HD Grid catheter|"After confirmation of isolation of the first pair of veins, the CMC-20 catheter will be exchanged for the HD Grid catheter. Using the HD Grid catheter, a new map of the left atrium will be made using the high-density settings. Together with the left atrium, the pulmonary veins will be mapped again in search of electro-anatomical gaps. Gaps are defined as a local area from the ablation line reaching inwards the pulmonary vein which still shows activation or fractionated potentials in line with atrial activation whilst pacing remote in the left atrium. The After mapping the first ablation side, the CMC-20 will be reinserted to repeat the protocol for the remaining pair of veins 30 minutes after ablation ended for that side.~If gaps have been found, HD Grid guided additional ablation must be performed to achieve isolation in that vein until isolation is reconfirmed."
223680311|NCT00536393|DRUG|Doxorubicin|
223773651|NCT04672005|DRUG|Folfirinox alternating with Gemcitabine-nab-Paclitaxel|modified Folfirinox every 2 weeks and biweekly Gemcitabine plus Nab-Paclitaxel
223773652|NCT03265626|BEHAVIORAL|Intervention 1: Comprehensive preventive intervention|aims to implement the existing evidence and policy documents Advocacy workshop to politicians, Community mobilization, Awareness creation on women,training community representative, Husband participation
223773653|NCT03265626|BEHAVIORAL|Intervention 2: Awareness creation and community mobilization|Advocacy politicians, Community mobilization, Awareness creation to women, Training community representative
223773654|NCT03265626|OTHER|available standard care|The standard care will be maintained but no other additional intevvenion designed by this study
223773655|NCT05940675|BEHAVIORAL|Food and Nutrition|A key element is that children receive a free of charge healthy do-it-yourself school lunch 4 days per week. The meals adhere to the Nordic Nutrition Recommendations and the Danish Food-Based Dietary Guidelines with focus on fish, wholegrains, fruits and vegetables and drinking water as well as stimulation of children's food literacy. Other intervention components involve the after school clubs, local retail stores and the parents.
224260285|NCT06366048|DIAGNOSTIC_TEST|the different definitions of PHLF according to 50-50 criteria and ISGLS criteria|Our study respectively defined the PHLF according to the 50-50 criteria and the ISGLS criteria in literature review.
224260286|NCT01220635|BEHAVIORAL|Positive Thoughts and Actions Program|Students in the skills group will attend a 12-session (50 minutes each), 12-week program with 4-6 other students. The skills group will take place at school during school hours. Parents in the skill group will be asked to participate in two parent group workshops to take place at their child's school or other participating middle school (2-hours each). In addition, the skill group leader will conduct two individual family meetings with the student and parent(50 minutes each).
224260287|NCT01220635|BEHAVIORAL|Individual Support Program|Students will be individually interviewed (60-90 minutes) at school to review areas of stress and support. The health professional conducting the interview will reinforce the student's strengths, and provide connections to sources of help from caring adults at home and at school. Parents will be called following the assessment to help the family locate appropriate resources if needed (e.g., tutoring resources, school counselor).
224260288|NCT00429286|BEHAVIORAL|Problem Solving Training|A systematic cognitive-behavioral intervention teaching problem solving skills for addressing functional impairment related to breast cancer and its treatment.
224260289|NCT03192163|OTHER|Survey|31 question survey with questions regarding non-identifying demographic information such as age and gender. This survey also contains questions about acne treatment preferences, racial/ethnic background, and cultural identity in addition to a few Willingness to Pay questions.
224260290|NCT01931553|OTHER|Standardized attending morning rounds|
224260291|NCT04694963|PROCEDURE|Blood sample|2 ml venous blood was collected and separated into serum.
224260292|NCT04694963|PROCEDURE|Data collection|"1. Whether the patient has been vaccinated with DPT vaccine and record the time of vaccination;~2. Medication situation of patients in the past year, including rescue drugs, antitussive and expectorant drugs, inhaled corticosteroids and antibiotics;"
223680312|NCT00536393|DRUG|Doxorubicin pegylated|
223680313|NCT01640431|OTHER|Lumbar stabilization exercises|The patients performed exercises for the transversus abdominis and lumbar multifidus muscles for an hour twice a week.
223680314|NCT03896893|OTHER|Skin antisepsis|1% aqueous chlorhexidine gluconate
223680315|NCT03896893|OTHER|Emollient|Aquaphor skin cream
223680316|NCT04253054|OTHER|Cardiovascular risk factors|Different level of cardiovascular risk factors, such as aging, hypertension, diabetes, dyslipidemia, smoke, alcohol drink, obesity and et al, associated with genetics, environments and lifestyles
223680317|NCT04253054|OTHER|Aging related health problems|Aging related health problems
223680318|NCT01261780|DEVICE|MC-5A|45 minutes daily x 10 treatments (given over the course of 2 weeks)
223680319|NCT01261780|DRUG|Sham device|Sham therapy daily x 45 minutes for 10 treatments (given over course of 2 weeks)
223680320|NCT01870323|BEHAVIORAL|SMART Behavioral Group|Test the efficacy of using social media to deliver a physical activity intervention based on social cognitive principles to increase lifestyle physical activity in low-active adolescents (i.e., access to regularly posted physical activity content on a study-specific, restricted access Facebook Group, as well as receipt of weekly video-based behavioral modules).
223680321|NCT01870323|BEHAVIORAL|SMART Informational Group|Test the efficacy of using social media to deliver a physical activity intervention to increase lifestyle physical activity in low-active adolescents (i.e., access to regularly posted physical activity content on a study-specific, restricted access Facebook Group, but does not receive the weekly video-based behavioral modules).
223680322|NCT03603171|DIAGNOSTIC_TEST|DM1-ActivC|A Rasch-built activity and participation scale for clinical use in myotonic dystrophy type 1 (DM1)
223680323|NCT03603171|DIAGNOSTIC_TEST|R-PAct|A Rasch-built Pompe-specific activity scale.
223680324|NCT03603171|DIAGNOSTIC_TEST|Beck depression inventory|A self-reported depression inventory administered verbally or self administered.
223680325|NCT03603171|DIAGNOSTIC_TEST|McGill pain questionnaire|The short form of the MPQ, used to evaluate the qualitative aspect of pain and categorized in three dimensions of pain experience: sensory qualities, affective qualities and overall intensity.
223680326|NCT03603171|DIAGNOSTIC_TEST|Brief Pain Inventory Short-Form|A 9 item self-administered questionnaire used to evaluate the severity of a patient's pain and the impact of this pain on the patient's daily functioning
223680327|NCT03603171|DIAGNOSTIC_TEST|Fatigue and Daytime Sleepiness Scale|A Rasch-built combined fatigue and daytime sleepiness scale (FDSS) specifically designed for patients with DM1.
224260293|NCT04694963|PROCEDURE|Throat swab|"Before the collection of oropharyngeal swabs, instruct the patient to wash the mouth or gargle, fix the patient's head, open the mouth and expose the throat. If necessary, use a tongue depressor to gently press the tongue.~Use the swab to wipe the secretion on both sides of the palatal arch, pharynx and tonsil with a sensitive and gentle action, and quickly withdraw the swab to avoid contacting other parts of the mouth.~Put the swab in the sterile test tube, plug the opening with cotton ball, and send it for inspection and registration in time."
224260294|NCT02514382|DRUG|Bortezomib|Given SC or IV
224260295|NCT02514382|DRUG|Dexamethasone|Given PO, IV, or IM
224260296|NCT02514382|OTHER|Laboratory Biomarker Analysis|Correlative studies
223680328|NCT03603171|DIAGNOSTIC_TEST|Myotonia Behaviour scale|It consists of six framed sentences, which most closely describe the impact of the stiffness on everyday life
223680329|NCT03603171|DIAGNOSTIC_TEST|Hand opening time|A simple test to evaluate clinical myotonia: the patient makes a tight fist for 5 seconds, then rapidly open them and the opening time is measured.
223680330|NCT03603171|DIAGNOSTIC_TEST|Pressure pain threshold|Thresholds for pressure pain were obtained over eight muscles on the left and right side of the body: extensor digitorum communis, deltoid, quadriceps and anterior tibialis. The average value of two measurements will be recorded.
223680331|NCT03603171|DIAGNOSTIC_TEST|Manual muscle testing|The patient is instructed to hold the corresponding limb or appropriate body part to be tested at the end of its available range while the practitioner provides opposing manual resistance. The strength is measured by the modified-MRC scale. The average value of two mesurements is considered. The following muscles were assessed: neck flexors and extensors, hip flexors and extensors, knee flexors and extensors, shoulder abductors, elbow flexors and extensors, ankle dorsiflexors and plantar flexors, wrist flexors and Extensors, digit flexors and extensors and thumb abductors.
223680332|NCT03603171|DIAGNOSTIC_TEST|Quantitative muscle testing|Strength testing using sophisticated strength measuring devices during an isometric contraction. The average value of two measurements is considered; in case of difference \> 10% between measurements, a third attempt is performed. The following muscles are assessed: neck flexors and extensors, hip flexors and extensors, knee flexors and extensors, shoulder abductors, elbow flexors and extensors, ankle dorsiflexors and plantar flexors, wrist flexors and extensors and digit flexors.
224260297|NCT02514382|OTHER|Pharmacological Study|Correlative studies
223680333|NCT03603171|DIAGNOSTIC_TEST|Scale for Assessment and Rating of Ataxia|SARA is a clinical scale which assesses a range of different impairments in cerebellar ataxia.
223680334|NCT03603171|DIAGNOSTIC_TEST|Berg balance scale|It is a 14 item objective measure designed to assess static balance and fall risk in adult populations
223680335|NCT03603171|DIAGNOSTIC_TEST|Quick motor function test|Assessment of proximal motor function.
224260298|NCT02514382|BIOLOGICAL|Wild-type Reovirus|Given IV
224260299|NCT03058003|DIAGNOSTIC_TEST|Posturography Evaluation|Posturography testing using the extended modified Clinical Testing of Sensory Integration in Balance (ext\_mCTSIB) protocol: the subjects will be required to stand on a hard or compliant surface in a comfortable posture, feet shoulder width, with eyes open or closed, arms to the side and free to move, gazing forward, and breathing normally, with head straight, turned right or left, flexed or extended
224260300|NCT03058003|OTHER|Central Sensitization Inventory|Standard chronic pain questionnaire: the subjects will be required to score each of the 25 items on a scale from 0 (never) to 4 (always)
224260301|NCT01714895|OTHER|High insulin eu-hypoglycemic clamp|Primed intravenous insulin infusion at a rate of 1mU/kg/min is given during the whole study duration. Glucose is infused at a variable rate to maintain plasma glucose concentrations 'clamped' at pre-specified levels. Plasma glucose levels will be the same in both study arms.
224260302|NCT01714895|OTHER|Low insulin eu-hypoglycemic clamp|Primed intravenous insulin infusion at a rate of 0.3mU/kg/min is given during the whole study duration. Glucose is infused at a variable rate to maintain plasma glucose concentrations 'clamped' at pre-specified levels. Plasma glucose levels will be the same in both study arms.
223680336|NCT03603171|DIAGNOSTIC_TEST|GSGC|GSGC score provides a detailed picture of motor function by including quantitative measures of four main motor performances (Gait, Walking, Stair, Gower's) and a qualitative global assessment of the manner to accomplish them.
223680337|NCT03603171|DIAGNOSTIC_TEST|30 seconds sit to stand test|It is a measurement that assesses functional lower extremity strenght in older adults.
223680338|NCT03603171|DIAGNOSTIC_TEST|Functional Index-2|Disease-specific functional outcome assessing muscle endurance. In this trial, only the part of the test for the upper extremities is used.
223680339|NCT03603171|DIAGNOSTIC_TEST|Six minute walking test|It is a sub-maximal exercise test used to assess aerobic capacity and endurance. The distance covered over a time of 6 minutes is used as the outcome by which to compare changes in performance capacity.
223680340|NCT03603171|DIAGNOSTIC_TEST|Myotonia (from Individualised Neuromuscular Quality of Life Questionnaire)|A subscale derived from the Individualised Neuromuscular Quality of Life Questionnaire (INQoL). 3 questions reguarding stiffness/myotonia.
223680341|NCT00108108|DRUG|HCD122|
223680342|NCT00732940|DRUG|Belimumab 100 mg SC|Belimumab 100 mg SC for 1 injection on Days 0, 7, 14, and then every two weeks.
223680343|NCT00732940|DRUG|Belimumab 100 mg SC|Belimumab 100mg SC for 2 injections (of 100mg each) on Days 0, 2, and 4, then 100 mg (1 injection) three times per week.
223680344|NCT06393556|OTHER|Virtual reality experience|An immersive VR experience, delivered using a VR head-mounted display, of the real-world environment at the hospital, featuring the pre-operative admission suite, pre-anesthetic bay, operating theatre, postoperative recovery room, and medical staff.
223680345|NCT00168792|DRUG|Tenecteplase|
223680346|NCT00168792|PROCEDURE|PCI|
223680347|NCT03543488|DIAGNOSTIC_TEST|Neuromuscular and functional capacity tests|"The Timed Up and Go test; Maximal knee-extensor muscle strength (isometric and concentric tests) was measured with a Biodex System 3 dynamometer; A B-mode ultrasonography system with a linear-array probe (60 mm, 7.5 MHz) was used to determine VL and RF muscle thickness, pennation angle, fascicle length and tendon CSA. Measurements were obtained with the volunteer seated in the dynamometer, during isometric contraction at 90° of knee flexion.~An 8-channel EMG system was synchronized with the dynamometer through a Windaq data acquisition system and used to evaluate the vastus lateralis and rectus femoris electrical activity during isometric knee-extensor tests."
223680348|NCT02227940|DRUG|Ceritinib|Given PO
223680349|NCT02227940|DRUG|Cisplatin|Given IV
223680350|NCT02227940|DRUG|Gemcitabine Hydrochloride|Given IV
223680351|NCT02227940|OTHER|Laboratory Biomarker Analysis|Correlative studies
223680352|NCT02227940|DRUG|Paclitaxel Albumin-Stabilized Nanoparticle Formulation|Given IV
223680353|NCT02227940|OTHER|Pharmacological Study|Correlative studies
223680354|NCT05824507|DIAGNOSTIC_TEST|Endometrial aspiration biopsies for CE diagnosis|1 ml of aspirate will be taken from the uterine cavity for histopathological examination and immunohistochemistry for CE during general anesthesia for scheduled surgery
223680355|NCT03338413|BEHAVIORAL|Goal Management Training|9 GMT modules will be administered in 9X2 hour sessions (ten groups). Manualized intervention; metacognitive strategies for improving attention and problem solving.
223680356|NCT03338413|BEHAVIORAL|Computerized Cognitive Training|9 modules will be administered in 9x1 hour session (ten groups). Computerized Cognitive Training using commercially available web-based platforms based on neuroplasticity, developed to target skills such as attention, memory, speed of processing and executive functioning. Homework assignment between sessions.
223680357|NCT03706651|DEVICE|Infants hospitalized in health facilities performing Tele-expertise|
223680358|NCT00773838|DRUG|Vorinostat|Four 100 mg vorinostat capsules orally, once daily (QD) by mouth on Days 1-14 of each 21-day treatment cycle.
223680359|NCT00773838|DRUG|Bortezomib|Bortezomib 1.3 mg/m\^2, IV injection QD on Days 1, 4, 8, and 11 of each 21-day treatment cycle.
223680360|NCT00773838|DRUG|Dexamethasone|Five 4 mg Dexamethasone tablets orally, QD on Days 1, 2, 4, 5, 8, 9, 11, and 12 of each 21-day treatment cycle if PD is observed after 2 treatment cycles or if NC to disease is observed after 4 treatment cycles.
223680361|NCT02139059|PROCEDURE|initial urinary drainage|initial urinary drainage is done using nephrostomy or double J stent to stabilize renal functions. this is followed several days later by definitive ureteroscopy.
223680362|NCT02139059|PROCEDURE|direct ureteroscopy|direct ureteroscopy is done without initial urinary drainage and before return to normal chemistry. this is followed follow-up of renal functions for several days before treatment of the contralateral side.
223680363|NCT05780268|BIOLOGICAL|LY3819253|LY3819253 is a neutralizing immunoglobulin G (IgG)-1 monoclonal antibody (mAb) to the receptor binding domain (RBD) of the S protein of SARS-CoV-2
223680364|NCT05780268|BIOLOGICAL|Placebo|Commercially available 0.9% sodium chloride solution
223680365|NCT05780268|BIOLOGICAL|Remdesivir|Antiviral agent
223680366|NCT01116856|OTHER|Exercise|Different groups will carry out different exercise protocols during 16 weeks under the same nutritional intervention.
223680367|NCT02160132|DRUG|Methylprednisolone(intravenously in the 1st-2nd-3rd month )|Methylprednisolone 0.5g/d intravenously for 3 consecutive days in the 1st-2nd-3rd month ,and oral methylprednisolone 0.4mg/kg/d on consecutive days for 6 months.
223680368|NCT02160132|DRUG|Methylprednisolone(intravenously in the 1st-3rd-5th month)|Methylprednisolone 0.5g/d intravenously for 3 consecutive days in the 1st-3rd-5th month ,and oral methylprednisolone 0.4mg/kg/d on consecutive days for 6 months.
223680749|NCT01490723|DRUG|Tacrolimus|"Starting dose of 0.015 mg/kg (ideal body weight) as a 24 hour continuous infusion daily adjusted to achieve a therapeutic level of 5-15 ng/ml. Tacrolimus is changed to oral dosing when tolerated and can be tapered off after day +90 if no Graft versus Host Disease (GVHD) is present.~For patients receiving cord blood (CB) graft, the Graft versus Host Disease (GvHD) prophylaxis will be with Tacrolimus. Tacrolimus will start on D-2 administrated at starting dose 0.03 mg/kg or 0.015 mg/kg (ideal body weight) by vein starting on D -2 and will be tapered around Day +180 if no GvHD is present."
224260303|NCT04936581|PROCEDURE|Open Total Mesorectal Excision|Open approach for Total Mesorectal Excision
224260304|NCT04936581|PROCEDURE|Laparoscopic Total Mesorectal Excision|Laparoscopic approach for Total Mesorectal Excision
224260524|NCT06558500|PROCEDURE|Uterocervical angle|"With the patient in the lithotomy position and empty bladder, care was taken to avoid applying pressure to the cervix with the transvaginal probe. The cervix was aligned in the midline, and the endocervical canal was visualized throughout its length.During cervical measurement, care was taken to ensure that the internal os, external os, and entire endocervical canal were visible in the same image. With the endocervical canal, external os, and internal os linearly displayed on the screen, the angle between the endocervical canal, anterior and posterior uterine segment was measured using the ultrasound's angle measurement feature.For the measurement of the uterocervical angle, the first line of the angle was defined along the endocervical canal used for measuring cervical length, and the second line was drawn from the internal os along the anterior uterine segment for a minimum of two centimeters. The angle between these two lines was recorded as the uterocervical angle in the form."
224260525|NCT04958915|DIAGNOSTIC_TEST|Knee joint 30° flexion scan|The patient was placed in the supine position, and the knee joint was naturally placed in the knee joint special coil, and the knee joint 30° flexion position scan.
224260526|NCT03559907|BEHAVIORAL|Cooking Matters for Parents|Cooking Matters for Parents focuses on teaching parents of young children important lessons about self-sufficiency in the kitchen. Participants have the opportunity to practice fundamental lessons including knife skills, reading ingredient labels, cutting up a whole chicken, and making a healthy meal for a family of four on a budget of ten dollars. Each session includes meal preparation, didactic teaching, and sharing the meal as a group. Instructors share their education and experience and discuss how to choose healthy, affordable fruits and vegetables at the grocery store. Each week, adults take home a bag of groceries after each class so they can practice the recipes taught that day.
224260527|NCT03559907|BEHAVIORAL|Mealtime PREP|Parents are trained to deliver each intervention component during mealtimes using a step-wise, behavioral activation approach. The parent-training prong of the Mealtime PREP intervention incorporates four active ingredients of behavioral activation (1. skills training; 2. goal-setting; 3. activity scheduling; and 4. activity monitoring) to help parents build a family meal routine that is enriched with techniques to promote child food acceptance. Each week, parents will take home healthy groceries to practice making healthy snacks and side dishes in the home.
224260528|NCT06412861|DRUG|Ketamine|0.5 mg/kg ketamine + 1 mg/kg propofol, Ramsey Sedation Score \> 4 will be targeted. For this, if necessary, additional iv 0.5 mg/kg propofol will be administered.
224260529|NCT06412861|DRUG|Fentanyl|1 mcg/kg fentanyl + 1 mg/kg propofol will be administered. Ramsay Sedation Score will be targeted to be \> 4. For this, if necessary, additional iv 0.5 mg/kg propofol will be administered.
224260530|NCT05997797|OTHER|FAAM|The FAAM is made out of two subscales including ADL and Sports subscales that have a complete score of 84 and 32, individually
224260531|NCT04725747|DRUG|Midazolam/Ketamine HCl 3mg-50mg sublingual|Single sublingual administration of Midazolam/Ketamine HCl 3mg-50mg sublingually prior to surgery
223773670|NCT06986694|OTHER|Group B will receive aerobic and strength training and conventional physiotherapy protocol for knee OA only.|"Aerobic Exercises: Walking or Stationary Cycling 2 times a week for 4 weeks Walking: On flat surface/Treadmill~* 10 minutes warm-up, 30 minutes brisk walking, 5 minutes cool down. Cycling: Ergometer cycling~* 10 minutes warm-up, 30 minutes on moderate loading (75% of max. heart rate), 5 minutes cool down. Strengthening Exercises: Quadriceps, Hamstrings, Hip Abductors, Adductors and Calf Muscles Strengthening and Balance Training 2 times a week for 4 weeks.~* Hip Abduction in standing 8-10\*2 RM~* Hip Adduction in standing 8-10\*2 RM~* Knee Flexion and Extension in standing 10\*2 RM~* Knee Squats 8-10\*2 RM~* Sit/stand from chair 10\*2 RM~* Step up and down 10\*2 RM~* Heel raises 10\*2 RM~* Hip Bridges 10\*2 RM Conventional Exercise Program: 2 times per week for 4 weeks Heat Therapy Ultrasound Therapy~* Static Quads activation 10\*2 RM~* SLR 10\*2 RM~* VMO activation 10\*2 RM~* Knee to Chest 5\*2 RM~* Quadriceps, Hamstrings and Calf stretches 5\*2 RM"
224260532|NCT04725747|DRUG|Midazolam 3mg Sublingual|Single sublingual administration of Midazolam 3mg sublingually prior to surgery
224260533|NCT04725747|DRUG|Ketamine 50mg Sublingual|Single sublingual administration of Ketamine HCl 50mg sublingually prior to surgery
224260534|NCT06626165|DRUG|Mirikizumab|Mirikizmgab will be administered based on the result of Geboes score Grade ≥ 3.2.
224323535|NCT05141019|DIAGNOSTIC_TEST|Panel-based pharmacogenetic genotyping|After providing consent, subjects will be randomized to receive either the immediate pharmacogenetic testing arm or the delayed arm. Subjects in both groups will provide a DNA sample by saliva, buccal cell, or blood at study enrollment. Subjects assigned to the immediate pharmacogenetic genotyping group will be tested and will have their results entered into their electronic health record (EHR) and provided to them within 2-4 weeks. Subjects assigned to the delayed pharmacogenetic genotyping group will also be tested, but their results will not be released until after their participation in the study has ended. Subjects in each arm will complete surveys and questionnaires regarding their medication satisfaction, as well as their healthcare utilization use at baseline and then again at 6- and 12-months. Implementation-specific questions will also be asked to assess the feasibility and sustainability of the intervention as well as assessments of intervention fidelity and adaptations.
224323536|NCT04763876|DRUG|Ketorolac Injection 15 mg|A single dose of 15 mg ketorolac administered intramuscularly.
223835236|NCT03504865|OTHER|Placebo|Saline will be administered as the placebo and will be given at the end of the operation.
224260535|NCT06626165|DRUG|Vedolizumab|Vedolizmab will be administered based on the result of Geboes score Grade 3.1.
224260536|NCT01101620|DRUG|Levosimendan|
224260537|NCT03169062|DEVICE|Gated Stationary Chest Tomosynthesis|The technologist will comfortably position the patient laying face up on the imaging table. EKG leads will be placed in appropriate positions to derive an EKG signal. The EKG will be used to trigger the image collection. The subject will be asked to hold his or her breath for 25-30 seconds during the scan. Total patient preparation and imaging time should not exceed 20 minutes.
224260538|NCT01804244|DRUG|TMC278|1 25-mg tablet \[27.5 mg as the hydrochloride salt) taken orally (by mouth) within 10 minutes after completion of a standardized breakfast on Day 1.
224260539|NCT00374231|DRUG|tacrolimus|Tacrolimus is a pill taken orally. Dose, frequency and duration will be decided by the study doctor on a case-by-case basis.
224323537|NCT04763876|DRUG|Ketorolac Injection 60 mg|A single dose of 60 mg ketorolac administered intramuscularly.
224323538|NCT00397111|DEVICE|7T Magnetic Resonance Imaging scanner|Non-significant risk device used for brain imaging
224323539|NCT05798507|DRUG|Avutometinib|Given PO
224260540|NCT00374231|DRUG|mycophenolate mofetil|Mycophenolate mofetil is a pill taken orally. Dose, frequency and duration will be decided by the study doctor on a case-by-case basis.
224260541|NCT00374231|DRUG|Prednisone|Prednisone is a pill taken orally. Dose, frequency and duration will be decided by the study doctor on a case-by-case basis.
224260542|NCT06289738|OTHER|ICF|Matching the answers given to the question set consisting of 6 open-ended questions with ICF
224260543|NCT00868660|DRUG|ZP1848|sc. bolus
224260544|NCT03956420|BEHAVIORAL|Premedication visit|detailed information about surgery, anaesthesia and postoperative period
224260545|NCT03956420|DIETARY_SUPPLEMENT|Preoperative period|avoidance of prolonged fasting, intake of fluids with carbohydrates before surgery
224260546|NCT03956420|DRUG|Preoperative period|administration of melatonin 5 mg in the evening and pregabalin 75 mg one hour before entering the operating theatre
224260547|NCT03956420|OTHER|Postoperative period|Fluids 1 ml/kg/h; Discontinuation of propofol at the moment of drainage and cardiovascular system stabilization; Fluids administered orally 2 hours after extubation; Early mobilisation
224260548|NCT03956420|OTHER|Intraoperative period|deep temperature (necessity to maintain normothermia during the stay in the operating theatre 36 °C. Normothermia should be maintained rather than restored.
224260549|NCT03956420|DRUG|Intraoperative period|Pyralgin 1 g i.v. after induction of anaesthesia; in patients allergic to Pyralginum, Perfalgan 1 g i.v.
224260550|NCT03956420|DRUG|Intraoperative period|Ketamine 30 mg i.v. after induction of anaesthesia
224260551|NCT03956420|DRUG|Intraoperative period|Sevoflurane 1.5 MAC higher in patients \< 60 years old
224260552|NCT03956420|DRUG|Intraoperative period|Propofol infusion in patients at risk of postoperative vomiting (Apfel ≥ 2 points), sevoflurane administration at the moments of strong stimuli from the operating field
224260553|NCT03956420|DRUG|Intraoperative period|Continuous infusion of balanced multi-electrolyte fluids 1-3 ml/kg/h
224260554|NCT00002890|BIOLOGICAL|lintuzumab|
224260555|NCT01117623|DRUG|Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 20 mg|Participants in the dose-escalation cohort received a single 20 mg oral CP tablet of regorafenib on Day 1 of Cycle 1 followed by 1 day off treatment. On Day 3, once-daily continuous dosing with 20 mg oral co-precipitate (CP) tablets was initiated. A cycle was defined as 21 days. For Cycle 2 and subsequent cycles, regorafenib was administered once daily continuously on a 21-day cycle.
224260556|NCT01117623|DRUG|Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 40 mg|Participants in the dose-escalation cohort received a single 40 mg oral CP tablet of regorafenib on Day 1 of Cycle 1 followed by 1 day off treatment. On Day 3, once-daily continuous dosing with 40 mg oral CP tablets was initiated. A cycle was defined as 21 days. For Cycle 2 and subsequent cycles, regorafenib was administered once daily continuously on a 21-day cycle.
224260557|NCT01117623|DRUG|Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 100 mg|Participants in the dose-escalation cohort received a single 100 mg oral CP tablet of regorafenib on Day 1 of Cycle 1 followed by 1 day off treatment. On Day 3, once-daily continuous dosing with 100 mg oral CP tablets was initiated. A cycle was defined as 21 days. For Cycle 2 and subsequent cycles, regorafenib was administered once daily continuously on a 21-day cycle.
224260558|NCT01117623|DRUG|Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 120 mg|Participants in the dose-escalation cohort received a single 120 mg oral CP tablet of regorafenib on Day 1 of Cycle 1 followed by 1 day off treatment. On Day 3, once-daily continuous dosing with 120 mg oral CP tablets was initiated. A cycle was defined as 21 days. For Cycle 2 and subsequent cycles, regorafenib was administered once daily continuously on a 21-day cycle.
224260559|NCT01117623|DRUG|Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 140 mg|Participants in the dose-escalation cohort received a single 140 mg oral CP tablet of regorafenib on Day 1 of Cycle 1 followed by 1 day off treatment. On Day 3, once-daily continuous dosing with 140 mg oral CP tablets was initiated. A cycle was defined as 21 days. For Cycle 2 and subsequent cycles, regorafenib was administered once daily continuously on a 21-day cycle.
224260560|NCT01117623|DRUG|HCC Child-Pugh A expansion cohort: Regorafenib 100 mg|Hepatocellular carcinoma (HCC) Participants with Child Pugh A in the expansion cohort received a single 100 mg oral CP tablet of regorafenib on Day 1 of Cycle 1 followed by 1 day off treatment. On Day 3, once-daily continuous dosing with 100 mg oral CP tablets of regorafenib was initiated. A cycle was defined as 21 days. For Cycle 2 and subsequent cycles, regorafenib was administered once daily continuously on a 21-day cycle.
224260561|NCT01117623|DRUG|HCC Child-Pugh B expansion cohort: Regorafenib 100 mg|Hepatocellular carcinoma (HCC) Participants with Child Pugh B in the expansion cohort received a single 100 mg oral CP tablet of regorafenib on Day 1 of Cycle 1 followed by 1 day off treatment. On Day 3, once-daily continuous dosing with 100 mg oral CP tablets of regorafenib was initiated. A cycle was defined as 21 days. For Cycle 2 and subsequent cycles, regorafenib was administered once daily continuously on a 21-day cycle.
224260562|NCT01117623|DRUG|NSCLC expansion cohort: Regorafenib 100 mg|Non-small cell lung cancer (NSCLC) participants in the expansion cohort received a single 100 mg oral CP tablet of regorafenib on Day 1 of Cycle 1 followed by 1 day off treatment. On Day 3, once-daily continuous dosing with 100 mg oral CP tablets of regorafenib was initiated. A cycle was defined as 21 days. For Cycle 2 and subsequent cycles, regorafenib was administered once daily continuously on a 21-day cycle.
224260563|NCT05915858|OTHER|muscle energy technique|"Group 1: Group 2:~Muscle energy technique (Reciprocal inhibition) Stretching exercises Static stretching 2 weeks (twelve treatment session) patient supine, the treated leg is placed into flexion at the hip and knee, so that the foot rests on the table lateral to the contra-lateral knee (the leg on the side to be treated is crossed over the other, straight leg).~* The angle of hip flexion should not exceed 60 degree.~* The practitioner places one hand on the contra-lateral ASIS to prevent pelvis motion, while the other hand is placed against the lateral flexed knee as this is pushed into resisted abduction to contract piriformis for 7-10 seconds."
224323540|NCT05798507|PROCEDURE|Biospecimen Collection|Undergo blood and tissue sample collection
224323541|NCT05798507|DRUG|Defactinib|Given PO
224323542|NCT06388109|OTHER|Positive Peers mobile app|Positive Peers is a multifunctional mobile app using a mind, body, spirit theme aimed to improve HIV care outcomes.
224323543|NCT04903470|DRUG|Bisacodyl|Biscodyl a stimulant laxative is expected to stimulate rectal contraction and enhance expulsion of Fecobionics
223835237|NCT00391456|BEHAVIORAL|Animal-assisted Therapy|
223773671|NCT06987162|OTHER|Percussive Therapy|PT will be performed by the same researcher using a hand-held massage gun, tapping at a frequency of 30 Hz (rotational speed 1800 rpm/min) with a flat massage head. Each percussive massage session will last for 15 minutes. This frequency of 30 Hz is chosen based on its effectiveness for myofascial release and previous studies have indicated that a 15-minute duration of back massage is beneficial
223773672|NCT06987162|OTHER|Instrument-Assisted Soft Tissue Mobilization|The Graston group performed as IASTM during 4 weeks. After warmup session, Friction free oil or gel was used to facilitate the device to move over the skin. Gua Sha tools were used. The instrument was kept at 45°, moved over the skin from cranial to caudal for 40-120 Sec on the back, while patients were lying in the prone position.The mobilization with sweeping strokes followed by fanning strokes were applied over the Erector spinae, quadratus lumborum, scrolling the device on the muscle belly from the posterior fascia and sacrum.
223773673|NCT06663644|OTHER|Muscle energy technique on iliotibial band|Post isometric relaxation involves the peripheral and central modulating mechanism by activating the muscles and joint mechanoreceptors. It can be effective for a variety of purposes including lengthening a shortened muscles, as a lymphatic or venous pump to aid the drainage of fluid or blood and increasing the range of motion. MET is a manual therapy intervention that can be used to stretch or lengthen muscles and fascia that lack flexibility.
223773674|NCT06663644|OTHER|Hamstring and abdominal muscle activation|The 90/90 exercises for abdominal and hamstring activation rotate the pelvis posteriorly in the sagittal and transverse plane, into a more neutral position. Hamstrings extend the hip, and therefore reciprocally inhibit hip flexors. Hamstrings and abdominals also aid in inhibiting paraspinal muscles via a posterior pelvic tilt / hip extension, a decrease in lumbar extension, and an increase in lumbar flexion.
223773675|NCT06663618|DRUG|prednison|Oral prednison starts at 0.6-0.8mg/kg/d, then tapered and withdrawal in 6 months.
223773676|NCT06663618|DRUG|Mycophenolate mofetil|Oral Mycophenolate mofetil 0.75g bid for 6 months.
223773677|NCT06662565|BEHAVIORAL|Behavioral modification|"It includes:~.- Reducing or eliminating smoking and carbonated drinks.~* Weight loss in overweight or obese individuals.~* Caffeine Reduction: Limiting caffeine intake, especially for those consuming at least 400 mg per day.~* Consume Adequate Water: 6 to 8 glasses of water per day.~* Refrain from consuming fluids 2 to 3 hours before bedtime.~* Identify Bladder Irritants: such as sugar substitutes, citrus fruits, and tomato.~* Increasing fiber intake like fruits, and vegetables to reduce constipation with adequate hydration to make stools softer and easier to pass"
223773678|NCT06662565|OTHER|Pelvic floor down-training|"Pelvic floor down training exercises aimed at promoting relaxation and deconditioning of the pelvic floor muscles (PFM). It will be practiced three sessions per week for 8 weeks.~Biofeedback-Assisted pelvic floor down-training:~Procedure:~* Rectal biofeedback will be inserted.~* The therapist asks the woman to focus on consciously relaxing and releasing the PFM after each contraction or exercise while watching biofeedback screen.~* Then, breathe deeply and fully into her abdomen, allowing her pelvic floor to naturally relax and lengthen.~* And to incorporate relaxation techniques such as visualization, or progressive muscle relaxation to promote overall muscle relaxation and reduce PFM tension.~* Exercises are typically repeated around 10-20 times per session. This number can vary depending on the patient's condition and tolerance, as well as the therapist's assessment and treatment plan."
223773679|NCT06664463|OTHER|Arousal enhancment protocol|"Auditory stimulation: Playing familiar music or personalized playlists tailored to the patient's preferences evokes emotional responses and promotes arousal.~Olfactory stimulation: Using essential oils or fragrances associated with calming or invigorating properties fosters emotional connections and evokes nostalgia through scents linked to positive memories.~Visual stimulation: Displaying photographs of family members or significant events provides comforting visual stimulation and stimulates visual awareness.~Tactile stimulation: Gentle touch or therapeutic massage engages the patient through tactile input, promoting physiological and emotional responses.~Besid thsi protocl also the will recivce routine care throughout study period The control group in this study will receive routine hospital care. This care includes standard medical evaluations, monitoring of vital signs, neurological assessments, and any necessary imaging (such as CT or MRI scans). Patients will also receive s"
223773680|NCT06664463|OTHER|Routine Care|The control group in this study will receive routine hospital care. This care includes standard medical evaluations, monitoring of vital signs, neurological assessments, and any necessary imaging (such as CT or MRI scans). Patients will also receive supportive care, including pain management, hydration, and nutrition, as well as physical, occupational, or speech therapy as needed based on their recovery progress
224260564|NCT05915858|OTHER|stretching exercise|"Following the contraction the practitioner eases the treated side leg into adduction until a sense of resistance is noted; this is held for 10-30 seconds. 2 week (twelve treatment session) practitioner manual stretches the piriformis:~* The patient lies in supine position the affected leg is placed into flexion at hip and knee so that the foot rests on the table lateral to the contra-lateral knee.~* The practitioner places one hand over the contra-lateral ASIS to stabilize the pelvis during the exercise and passively abducts and internally rotates the hip medially till the pain is bearable.~* The process is repeated 3-5 times with a 30"
224260565|NCT00862563|DRUG|Topiramate|Topiramate will be administered orally twice daily beginning on Day 1, Week 1 and continue through Day 7, Week 14. Subjects will be dose titrated as tolerated to a target doses 300 mg topiramate.
224260566|NCT00862563|DRUG|Zonisamide|Zonisamide will be administered orally twice daily beginning on Day 1, Week 1 and continue through Day 7, Week 14. Subjects will be dose titrated as tolerated to a target doses of 2000 400 mg of zonisamide.
224260567|NCT00862563|DRUG|Levetiracetam|Levetiracetam will be administered orally twice daily beginning on Day 1, Week 1 and continue through Day 7, Week 14. Subjects will be dose titrated as tolerated to a target doses of 2000 mg levetiracetam capsules.
224260568|NCT00862563|DRUG|Sugar Pill|Matched placebo will be administered orally twice daily beginning on Day 1, Week 1 and continue through Day 7, Week 14.
224260569|NCT01448434|BIOLOGICAL|Ex- vivo cultured adult allogeneic MSCs|Single intraarticular dose of allogeneic MSCs suspended in 2ml Plasmalyte followed by 2ml of Hyaluronan
224323544|NCT04903470|DRUG|Atropin|Atropin is an anticholinergic drug that is expected to inhibit rectal contractions and make defecation more difficult.
224323545|NCT03499964|DEVICE|Optilume Drug Coated Balloon (DCB)|The Optilume Drug Coated Balloon (DCB) is a guidewire compatible catheter with a tapered atraumatic tip. The distal end of the catheter has an inflatable balloon coated with a proprietary coating containing the drug paclitaxel that facilitates the drug's transfer to the urethral wall upon inflation.
224260570|NCT01448434|BIOLOGICAL|Plasmalyte-A|Single intraarticular dose of 2ml Plasmalyte followed by 2ml Hyaluronan
223773681|NCT06664736|BEHAVIORAL|Exercise|The exercise group performed a home-based exercise program consisting of aerobics 3 days a week with videos and strengthening and stretching exercises 2 days a week with infographics, for 8 weeks.
223773682|NCT06664736|BEHAVIORAL|Physical activity|The control group was advised to increase physical activity
223773683|NCT06594705|DEVICE|JenaValve Trilogy Heart Valve System|TAVR with JenaValve Trilogy Heart Valve System
224323546|NCT03499964|DEVICE|Control Treatment|A control subject may be dilated with either a rod, uncoated balloon or DVIU until the desired result is reached, based on standard of care for the clinical site and treating physician
224323547|NCT04310020|DRUG|Atezolizumab|Given IV
224260571|NCT02042560|OTHER|Blood samples|
224260572|NCT02042560|OTHER|Spleen samples|
224260573|NCT01165060|DRUG|Bezafibrate|Week 0 to 12: 400 mg once daily 1 tablet. Week 13 to 24: 400 mg once daily 2 tablets.
223773684|NCT06601270|OTHER|There are no interventions as the study is purely observational.|There are no interventions as the study is purely observational.
223773685|NCT01157533|DRUG|Vancomycin|Loading dose 30 mg/kg via central or peripheral intravenous infusion. Subsequent doses of vancomycin (15 mg/kg) are considered standard of care.
224260574|NCT06024980|PROCEDURE|Open partial horizontal laryngectomy(OPHL), Type I-III|An open partial horizontal laryngectomy(OPHL) was performed for patients with T2 supraglottic and glottic carcinoma, according to the American Joint Committee on Cancer(AJCC) criteria. Type I OPHL: Entails the resection of the supraglottis, including the pre-epiglottic space and the upper half of the thyroid cartilage. Type II OPHL: Entails the resection of the entire thyroid cartilage, with the inferior limit represented by the upper edge of the cricoid ring. Type III OPHL: Entails the resection of the entire supraglottic, glottic, and part of the subglottic sites, sparing both or at least one functioning crico-arytenoid unit.
224323548|NCT04310020|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
224323549|NCT04310020|PROCEDURE|Computed Tomography|Undergo CT scan
224323550|NCT04310020|RADIATION|Hypofractionated Radiation Therapy|Undergo hypofractionated radiation therapy
224323551|NCT04310020|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
224323552|NCT05498428|DRUG|Amivantamab|Amivantamab will be administered subcutaneously by manual injection.
224323553|NCT05498428|DRUG|Lazertinib|Lazertinib will be administered as an oral tablet.
224323554|NCT05498428|DRUG|Carboplatin|Carboplatin will be administrated by IV infusion.
223773686|NCT05121116|BEHAVIORAL|Online Mindfulness-Based Stress Reduction (MBSR)|Participation in an 8-week MBSR program consisting of pre-recorded mindfulness practices, including a guided body scan in week 1, guided sitting meditation in week 2, mindful yoga practices in week 3 and 4, meditation on difficult emotions in week 5, visualization meditation in week 6, lovingkindness meditation in week 7, and a silent meditation in week 8. Most practices last approximately 30 minutes and participants were encouraged to engage in a mindfulness practice daily or as often as possible. In weeks 2 - 8 participants could choose to alternate the practice introduced each week with practices from previous weeks. Participants had immediate access to all practices but were asked to complete them sequentially and in the order described above over a period of eight weeks. The MBSR program also encourages participants to employ mindfulness in their daily lives, and gives access to educative readings and videos related to the weekly mindfulness practices.
223773687|NCT01985516|OTHER|Instillation into the urethra|5mL of 2% lidocaine gel will be instilled directly into the urethra 5 minutes before catheterization
223773688|NCT01985516|OTHER|pouring the gel on the catheter's tip|5mL of 2% lidocaine gel will be poured on the distal part of the catheter (from the distal tip to 10 cm proximally).
223773689|NCT06987175|OTHER|sadante neo therapy|SAN machine having 3 tube cords on both sides. Each tube cord contains 2 pairs of flat suction cups. We will use 4 pair of flat suction cups in this study. We will place 2 pair on left and two on right para spinal muscles of lumber in prone lying. Due to its automatic suctioning capability, these cups can easily stick to skin. After placing the cups on lumber each patient of group A will receive its stimulation for about 10 minutes every day for about 4 weeks along with conventional exercises.
223835238|NCT04471883|PROCEDURE|Percutaneous coronary interventions|Percutaneous coronary interventions in coronary bifurcation lesions
223835239|NCT02628847|DRUG|sildenafil citrate|
224323555|NCT05498428|DRUG|Pemetrexed|Pemetrexed will be administered by IV infusion.
224323556|NCT05498428|DRUG|Direct Oral Anticoagulant (DOAC)|DOAC will be administered orally.
224323557|NCT05498428|DRUG|Low Molecular Weight Heparin (LMWH)|LMWH will be administered subcutaneously.
224323558|NCT04495699|OTHER|None - observational|If the patient elects to have their stone treated, it will be treated in the usual most clinically appropriate fashion (Shockwave lithotripsy, ureteroscopy, or percutaneous nephrolithotomy). All types of treatment will be analyzed together.
224323559|NCT03915769|DRUG|Ozanimod|Ozanimod is an orally bioavailable, small molecule compound that activates the sphingosine 1-phosphate 1 receptor (S1P1) and the S1P 5 receptor (S1P5), although it is more selective towards S1P1 over S1P5
224323560|NCT03915769|OTHER|Placebo|The placebo is a capsule that contains no study medication but looks exactly like the study medication capsule.
224323561|NCT04028674|DEVICE|Laryngeal Pacing Device|Device is an implantable neurostimulation system designed to deliver low-intensity electrical impulses to nerve structures.
224323562|NCT05936567|DRUG|Povorcitinib|oral; tablet
224323563|NCT05936567|DRUG|Placebo|oral; tablet
224323564|NCT03742102|DRUG|Durvalumab|Durvalumab iv Every 4 weeks (q4w) or 3 weeks (q3w) Arm 6, 7 and 8
224323565|NCT03742102|DRUG|Capivasertib|Capivasertib oral bid 4-week cycles; 3 weeks on (dosing on days 2,3,4 and 5) and 1 week off
224323566|NCT03742102|DRUG|Oleclumab|Oleclumab iv Every 2 weeks (q2w) for first 2 cycles (days 1 and 15 in cycles 1 and 2), then every 4 weeks (q4w) starting at cycle 3 day 1
224323567|NCT03742102|DRUG|Paclitaxel|Paclitaxel iv 4-week cycles: 3 weeks once weekly (q1w) and 1 week off
224323568|NCT03742102|DRUG|Trastuzumab deruxtecan|Trastuzumab deruxtecan iv 3-week cycles (once weekly) q3w
224323569|NCT03742102|DRUG|Datopotamab deruxtecan|Datopotamab deruxtecan iv 3-week cycles (once weekly) q3w
224260575|NCT06024980|PROCEDURE|Transoral endoscopic laser cordectomy|"For patients with T1 glottic laryngeal carcinoma, according to the criteria of the American Joint Committee on Cancer(AJCC), transoral endoscopic CO2 laser(2-40Watts) cordectomy was performed. The classification comprises eight types of cordectomies:~* A subepithelial cordectomy (type I) is a resection of the epithelium of the vocal fold.~* A subligamental cordectomy (type II) is a resection of the epithelium, Reinke's space, and vocal ligament.~* Transmuscular cordectomy (type III), which proceeds through the vocalis muscle.~* Total cordectomy (type IV).~* Extended cordectomy encompasses the contralateral vocal fold and the anterior commissure (type Va).~* Extended cordectomy, which includes the arytenoid (type Vb).~* Extended cordectomy, which encompasses the subglottis (type Vc).~* Extended cordectomy, which consists of the ventricle (type Vd)."
223773690|NCT06987175|OTHER|Conventional exercises|receive conventional exercises only. Conventional exercises will be performed for 20 minutes, each exercise will be performed 20 times with 10 seconds hold.
223773691|NCT06981156|DIAGNOSTIC_TEST|pNANO Assessment|"pNANO assesses patient gait, strength, cerebellar function, visual fields, visual acuity, facial strength, level of consciousness, extraocular movement, dysarthria, and dysphagia~The patient will be assessed by 2-3 different clinicians during each of 2 visits."
223773692|NCT06493513|DEVICE|40Hz stimulation|Exogenous 40Hz stimulation is a physical intervention that induces gamma oscillations, oscillations and pulsations at the corresponding frequency, and may lead to a significant reduction in β-amyloid, reversal of tau protein hyperphosphorylation, and consequently improvement of cognitive function in patients.
223773693|NCT06662981|BEHAVIORAL|preoparative information and education|The intervention will include oral and written education about the operation, nursing and active participation in self-care. The intervention will take place in 3 phases: One week before THA, one day before THA after patient admission and postoperatively, before patient discharge. After a rough description of the operation, the anatomy and functionality of the joint will be presented, underlining the necessity of the operation. Instructions for recognizing and managing potential complications will be given. Patients will be informed about the appropriate post-operative walking aids, walking style, sitting up techniques, standing-up techniques, lying down techniques and getting in and out of the car. There will be a demonstration of muscle strengthening exercises, isometric quadriceps and gluteal exercises, Patients will also be informed about the necessity of prophylactic postoperative antithrombotic and antibiotic treatment.
223773694|NCT06663488|PROCEDURE|Thoracic epidural anesthesia|The epidural needle was inserted At T6-8 space, After verification of the epidural space by resistance loss technique, a test dose of 2 ml of 0.5% bupivacaine was injected. In the Cephalad direction, the epidural catheter was threaded 3 cm into the epidural space. A total dose of 8-12 ml 0.5 percent plain bupivacaine was administered .
223773695|NCT06663488|PROCEDURE|Thoracic spinal anesthesia|Thoracic spinal anesthesia: At T5-T6 or T6-T7, a 27G needle was inserted. The needle's stylet will be removed and the hub observed for free flow of CSF; once flow of clear CSF, 4 ml of isobaric bupivacaine 0.5% plus 0.5 ml of 250 ug morphine was injected
223773696|NCT06663865|DIETARY_SUPPLEMENT|Active|"40g bio-active whey protein concentrate powder containing dairy phospholipids~Other Names:~Active Treatment"
223773697|NCT06663865|DIETARY_SUPPLEMENT|Placebo|"Around 40g pea protein powder not containing dairy phospholipids~Other Names:~Placebo Treatment"
223773698|NCT06659315|BEHAVIORAL|Couples Problem Solving Therapy|A couples-based problem solving program to deal with depression, PMTCT adherence, and couple communication.
223773699|NCT06663267|OTHER|NOT|This retrospective cohort study involves no new interventions. It analyzes existing health data collected from subjects exposed to varying atmospheric conditions to assess impacts on health outcomes.
223773700|NCT06990295|PROCEDURE|Focused Ultrasound Spleen Neuromodulation|A portable focused ultrasound device is used to stimulate the spleen area under real-time imaging guidance. Each session lasts approximately 20 minutes, repeated twice daily for five days.
223773701|NCT03246529|DRUG|BL-8040 1.25 mg/kg + G-CSF|Up to 2 subcutaneous (SC) injections of BL-8040 are anticipated during the study. Injections of G-CSF per standard of care
223773702|NCT03246529|DRUG|Placebo +G-CSF|Up to 2 SC injections of Placebo are anticipated during the study. Injections of G-CSF per standard of care
223773703|NCT02777346|DEVICE|Absorbable|"Wound suture by a resident physician. Two follow-up appointments (first at 4 to 21 days after the suture, according to the sutured site as defined by protocol, second at 6 months) Standardized photography of the wound before the suture and at the two subsequent follow-ups.~Evaluation of the scar with a standardised form by a specialised nurse under medical supervision at the first follow-up and by a panel of investigators at 6 months using the pictures taken at the follow-up appointments."
223773704|NCT02777346|DEVICE|Non absorbable|"Wound suture by a resident physician. Two follow-up appointments (first at 4 to 21 days after the suture, according to the sutured site as defined by protocol, second at 6 months) Standardized photography of the wound before the suture and at the two subsequent follow-ups.~Evaluation of the scar with a standardised form by a specialised nurse under medical supervision at the first follow-up and by a panel of investigators at 6 months using the pictures taken at the follow-up appointments."
223773705|NCT06989983|DRUG|AZD5462 film-coated tablet|Oral, fasted
223773706|NCT06989983|DRUG|[14C]AZD5462 Solution for Infusion|Intravenous, fasted
223773707|NCT06989983|DRUG|[14C]AZD5462 Oral Solution|Oral, fasted
223773708|NCT00006347|RADIATION|indium In 111 monoclonal antibody MN-14|
223773709|NCT00006347|RADIATION|yttrium Y 90 monoclonal antibody MN-14|
223773710|NCT05473312|BEHAVIORAL|Community Sensitization|One event will be developed and delivered for households in each cluster area. Approach and content will be informed by the formative research and CAC input (may include drama and nutrition fairs).
223773711|NCT05473312|BEHAVIORAL|28-day PD/Hearth Sessions|Mothers will come together in a home-like setting to rehabilitate their malnourished child (8 dyads/Hearth), learn and practice new feeding and childcare behaviours (during Covid-19: 4 dyads/Hearth). Curriculum and activities will be informed by CAC, CORE Guide and formative research. Two female facilitators will demonstrate, encourage, convey key messages and guide practices.
223835240|NCT02628847|DRUG|Placebo|
224260576|NCT00002601|BIOLOGICAL|filgrastim|5 ug/kg daily following stem cell reinfusion
224260577|NCT00002601|DRUG|cisplatin|Course 2 - 100 mg/m2 at an infusion rate of 25 mg/hr
224260578|NCT00002601|DRUG|doxorubicin hydrochloride|Course 1 - 150 mg/m2 by continuous intravenous infusion for 96 hours.
223773712|NCT05473312|BEHAVIORAL|Supplemental Print Information|The content will be informed by the formative research and CAC, will reinforce Hearth messages, and be adapted for each gender group. Material will be locally produced, engaging, user friendly, and target an illiterate audience (i.e. culturally relevant images with minimal text).
223773713|NCT05059015|DIAGNOSTIC_TEST|CERVICAL HPV|A screening test with an HPV test is performed by a health professional plus cytology taking, if it reports positive, colposcopy and biopsy are taken, those with a CIN2 + report are directed to receive treatment.
223773714|NCT05059015|DIAGNOSTIC_TEST|SELF SAMPLING HPV|A screening test is performed with an HPV test by self-testing, if it reports positive, women will receive ablative treatment according to eligibility criteria. If they do not meet the criteria for ablation, they will be referred for excisional treatment.
223773715|NCT06043310|DRUG|Nω-nitro-L-arginine methyl ester (L-NAME)|L-NAME will be infused locally through microdialysis catheters.
223773716|NCT06043310|DRUG|Acetylcholine|ACh will be infused locally through microdialysis catheters.
223773717|NCT06043310|DRUG|Sodium Nitroprusside|SNP will be infused locally through microdialysis catheters.
223773718|NCT03117387|DIAGNOSTIC_TEST|Measurements of the level of neuromuscular blockade|Study participant were not prospectively exposed to an intervention. Administration of a moderate or deep neuromuscular blockade is at the discretion of the attending anesthesiologist. Study participants only received diagnostic non-invasive monitoring. In routine clinical care the neuromuscular blockade is monitored non-invasively by either acceleromyography, electromyography or by the TOF-Cuff. In this study participants were monitored by the monitors and were not exposed to any additional risk and no effect of an intervention was assessed in this study.
223773719|NCT06995144|DRUG|Extended Release Torsemide Tablets|Extended release torsemide vs Immediate release torsemide
223773720|NCT06995144|DRUG|Immedate Release Torsemide Tablets|Immediate release torsemide vs Extended release torsemide
223773721|NCT07009457|DRUG|SHR-1316 (sc) Injection|SHR-1316 (sc) injection.
223773722|NCT07009457|DRUG|SHR-1316 Injection|SHR-1316 injection.
223773723|NCT07009457|DRUG|Carboplatin Injection|Carboplatin injection.
223773724|NCT07009457|DRUG|Etoposide Injection|Etoposide injection.
223773725|NCT06680102|DIETARY_SUPPLEMENT|Probiotic|The experimental phase of this study lasts for 8 weeks, with each patient making three visits at weeks 1, 4, and 8.
223773726|NCT06680102|DIETARY_SUPPLEMENT|Maltodextrin|The experimental phase of this study lasts for 8 weeks, with each patient making three visits at weeks 1, 4, and 8.
223773727|NCT03071796|DIETARY_SUPPLEMENT|multivitamin supplement|supplement includes 97 natural extracts
223773728|NCT03071796|DIETARY_SUPPLEMENT|Placebo|liquids with similar appearance and taste like multivitamin supplement for 12 weeks
223773729|NCT07013045|OTHER|Structured Neuromuscular Exercise Group|In the Structured Neuromuscular Exercise group, the exercise program will be administered to patients diagnosed with FMF twice a week for 12 weeks under the supervision of a physiotherapist. The exercises will be performed using a balance board and will include sitting, standing, lunge, modified push-up, and plank positions.
223773730|NCT07013045|OTHER|Neuromuscular Exergaming Program Group|In the Neuromuscular Exergaming group, patients diagnosed with FMF will perform the same exercises as those in the structured neuromuscular exercise program, delivered in an exergaming format using the Smart Exercise Board (SEG-Board). The program will be conducted under the supervision of a physiotherapist, twice weekly for 12 weeks, and will include exercises performed in sitting, standing, lunge, modified push-up, and plank positions.
223773731|NCT05242978|OTHER|Nutrition|acute single dose nutrition intervention
223773732|NCT06684041|DRUG|HRS-5965 capsule|HRS-5965 capsule
223773733|NCT06684041|DRUG|HRS-5965 capsule placebo|HRS-5965 capsule placebo
223773734|NCT07016750|BIOLOGICAL|KB803|Ophthalmic suspension of replication-defective, non-integrating herpes simplex virus (HSV-1) expressing the human collagen VII protein
223773735|NCT07016750|DRUG|Placebo|Vehicle
223773736|NCT06908603|OTHER|Survey using a questionnaire.|The online, self-administered, 16-item questionnaire included several question styles (yes/no questions, closed-ended, multiple choice questions, and statements with Likert scale responses). The questionnaire was adapted from several published AI surveys . Questions were designed to assess three primary areas: AI knowledge, perceptions of AI integration into practice and challenges in implementing AI in the OR practice in Egypt.
223773737|NCT06908811|DIETARY_SUPPLEMENT|Novel Plant Protein Blend|Novel plant protein blend containing 30 grams of protein.
223773738|NCT06908811|DIETARY_SUPPLEMENT|Pea/Rice Protein Blend|Pea/Rice protein blend containing 30 grams of protein
223773739|NCT06908811|DIETARY_SUPPLEMENT|Whey Protein|Whey concentrate protein blend containing 30 grams of protein
223773740|NCT06908811|DIETARY_SUPPLEMENT|Carbohydrate Placebo|Maltodextrin placebo
223773741|NCT06526390|PROCEDURE|f-URS|f-URS with S-UAS
223773742|NCT06526390|PROCEDURE|mini-PCNL|mini-PCNL
223773743|NCT06905873|DRUG|FB102|Route of administration- Intravenous (IV)
223773744|NCT06905873|DRUG|Placebo|Route of administration- Intravenous (IV)
223773745|NCT06646458|OTHER|Healthy Elderly Volunteers|Take the elderly milk power 2 times every day up to 28 days
223773746|NCT04109846|OTHER|Non-euploid embryo transfer|Other than choice of embryo for transfer, all other medical interventions will be standard of care protocols
223773747|NCT04109846|OTHER|Euploid Transfer|Standard of Care Protocol
223773748|NCT06909630|OTHER|Driving pressure group|individual PEEP
223773749|NCT06909123|DRUG|Cabergoline|Cabergoline
223773750|NCT06908733|DRUG|3-4 cycles of Tislelizumab combined with platinum-based chemotherapy, evaluated by MDT and assigned to treatment strategies based on eligibility and patient preference.|Patients deemed eligible to surgery will receive standard lung cancer resection (excluding total pneumonectomy)
223773751|NCT06908993|DRUG|Tepotinib|Tepotinib will be given orally once daily at the dose of 500mg of tepotinib hydrochloride hydrate.
223773752|NCT06908993|DRUG|Pemetrexed (Alimta)|500 mg/m² every 3 weeks
223773753|NCT06908993|DRUG|Vinorelbine|25-30 mg/m² D1, D8, every 3 weeks
223835241|NCT00003175|DRUG|fluorouracil|
224260579|NCT00002601|DRUG|ifosfamide|Course 1 - 14 gm/M2 by continuous intravenous infusion for 96 hours.
224260580|NCT00002601|DRUG|melphalan|Course 2 - 75 mg/m2 infused at a rate of 5 mg/minute
224260581|NCT00002601|PROCEDURE|peripheral blood stem cell transplantation|Administered on Day 0 following high-dose chemotherapy in both courses 1 and 2
223773754|NCT06908993|DRUG|Gemcitabine alone|1250 mg/m² D1, D8, every 3 weeks
223773755|NCT06908993|DRUG|Docetaxel|75 mg/m² every 3 weeks
223773756|NCT06908993|DRUG|Paclitaxel|90 mg/m² D1, D8, D15 every 4 weeks If bevacizumab added: 10 mg/kg D1, D15 every 4 weeks
224260582|NCT05451914|OTHER|My Diabetes Care|My Diabetes Care (MDC) is a multi-faceted patient portal intervention for mobile devices that is designed to help patients better understand their diabetes health data as well as promote and support self-management. MDC uses infographics to facilitate patients' understanding of their diabetes health data (e.g., HbA1c, LDL) and provides literacy level-appropriate and tailored diabetes self-care information.
224260583|NCT06562322|DEVICE|Placebo|Participants will be received placebo PBMT on the quadriceps muscle of both legs, immediately before physical tests, using a device containing 200 LEDs (100 red and 100 infrared)
224260584|NCT06562322|DEVICE|300 J|Participants will be received PBMT at 300 J on the quadriceps muscle of both legs, immediately before physical tests, using a device containing 200 LEDs (100 red and 100 infrared)
224260585|NCT06562322|DEVICE|600 J|Participants will be received PBMT at 600 J on the quadriceps muscle of both legs, immediately before physical tests, using a device containing 200 LEDs (100 red and 100 infrared)
224260586|NCT06562322|DEVICE|1260 J|Participants will be received PBMT at 1260 J on the quadriceps muscle of both legs, immediately before physical tests, using a device containing 200 LEDs (100 red and 100 infrared)
224260587|NCT00395694|DRUG|lamictal|anti-epileptic drug
224260588|NCT06560710|OTHER|vitrectimy|Clinical characteristics and surgical outcomes
223773757|NCT06908993|DRUG|Pembrolizumab|200 mg every 3 weeks
223773758|NCT06908993|DRUG|Nivolumab|240 mg every 2 weeks
223773759|NCT06908993|DRUG|Atezolizumab|1200 mg every 3 weeks
223773760|NCT06908798|DIAGNOSTIC_TEST|fecal calprotectin|fecal calprotectin test measures calprotectin protein in a stool sample. fecal calprotectin acts as a surrogate for gastrointestinal inflammation (e.g., inflammatory bowel disease, infectious gastroenteritis, acute appendicitis, peptic ulcer disease, coeliac disease, non-steroidal anti-inflammatory drugs (NSAID)-induced enteropathy)
223773761|NCT00669357|DEVICE|Abiocor Implantable Replacement Heart|Replacement of heart
224323570|NCT03124329|PROCEDURE|Coronally Advanced Flap|Coronally advanced flap will be performed. Briefly, sulcular incisions will be made. Oblique incisions will be made on each papilla requiring root coverage. In the region coronal to the mucogingival junction (MGJ), mucoperiosteal flap will be elevated. Apical to the MGJ, sharp dissection will be performed to the periosteum allowing split-thickness flap elevation to be performed. Epithelium is removed from the papillae adjacent to the recession and the flap is coronally positioned and stabilized with interproximal sutures and apico-coronal interrupted sutures to close the vertical releasing incisions.
223773762|NCT01818336|DRUG|Penicillin skin test kit|Allergy skin testing is done by puncture and intradermal. If all tests negative, subjects receive an oral amoxicillin challenge.
223773763|NCT03934268|GENETIC|KCNQ2|The researchers extracted DNA from the baby's serum and sent it to WES to get the baby's total exon sequence.
223773764|NCT00358241|PROCEDURE|Nerve block|
223773765|NCT02612207|DEVICE|Bilirubin Binding Capacity by Hematofluorometry Validation|Observation study
223773766|NCT03981406|BEHAVIORAL|Palliative Care|The intervention is one visit to the Fairview Clinics and Surgery Center palliative care clinic, with follow up visits as determined by the palliative care team and the patient.
223773767|NCT03981406|BEHAVIORAL|Standard of Care|Control group will receive standard of care treatment for IPF.
223773768|NCT01856140|BIOLOGICAL|ALLO-ASC(allogeneic adipose derived mesenchymal stem cell) injection|
223773769|NCT01132521|DRUG|ulinastatin|Resolved 4 vials of drugs in 100ml physiological saline solution, intravenously infused for 1-2h, tid, for continuous 7 days.
223773770|NCT01132521|DRUG|placebo|Resolved 4 vials of drugs in 100ml physiological saline solution, intravenously infused for 1-2h, tid, for continuous 7 days.
223773771|NCT02993601|DEVICE|Heartfelt-1|The patients will stand in front of the Heartfelt-1 in order for images to be captured and the volume of their lower legs measured.
223773772|NCT02993601|DEVICE|Weighing scales|The patient will be asked to stand on standard medical weighing scales, to measure their weight.
224260589|NCT00840216|DRUG|Clarithromycin ER 500 mg tablets|1 x 500 mg
224260590|NCT00840216|DRUG|BIAXIN® XL 500 mg tablets|1 x 500 mg
224260591|NCT02526121|PROCEDURE|Phlebotomy|Volume of 400 mL every 3 weeks, 3 times.
224260592|NCT02526121|BEHAVIORAL|Dietary and lifestyle counseling.|Dietary and lifestyle counseling.
224260593|NCT05857774|OTHER|Sonographic measurements|Diaphragm thickness, diaphragm tidal thickening fraction, abdominal muscle thickness, rectus femoris cross-sectional area, maximal diaphragm thickening fraction, abdominal muscle thickening fraction
224260594|NCT05857774|OTHER|Physiological measurements|Airway occlusion pressure, maximal inspiratory pressure, muscle research council score
224260595|NCT05857774|OTHER|Biological measurements|Skeletal troponin-I
224260596|NCT01058668|DRUG|Cariprazine|Patients who meet eligibility criteria will be administered a once daily oral dose of cariprazine for three weeks. Upon completion of the study or early termination, patients will undergo a two week safety follow-up period.
224260597|NCT01058668|DRUG|Placebo|Patients who meet eligibility criteria will be administered a once daily oral dose of placebo for three weeks.
224260598|NCT00817440|OTHER|Exercise|1 hour ergometer cycling on 65% of Vo2max, and then the same as arm 1.
224260599|NCT00817440|OTHER|Fasting|3 days of fasting and then the same as arm 1
224260600|NCT03695692|BEHAVIORAL|pelvic floor exercise and connective tissue massage|Pelvic floor exercises with connective tissue massage will be performed.The massage program is carried out for 18 sessions, 3 days/week in 6 weeks. The exercise program is performed every day for 6 weeks
224260601|NCT03695692|BEHAVIORAL|pelvic floor exercise|The exercise program is performed every day for 6 weeks
224260602|NCT00365430|BEHAVIORAL|safety program|Education, patient involvement, tailored implementation and a computerized registration system
224260603|NCT05955534|DEVICE|TPUG|Tracheostomy shall utilize any FDA approved device for the performance of percutaneous dilatational tracheostomy. PUG shall be performed using the only FDA-cleared device for ultrasound gastrostomy, the PUMA-G System.
224260604|NCT05955534|PROCEDURE|PEG|Each site will perform the procedures of gastrostomy placement using the devices according to their institutional policy and guidelines.
224260605|NCT05955534|PROCEDURE|PRG|Each site will perform the procedures of gastrostomy placement using the devices according to their institutional policy and guidelines.
224260606|NCT04859517|DRUG|ADG20|Single dose of ADG20
224260607|NCT04859517|DRUG|Placebo|Single dose of placebo
224260608|NCT01906918|PROCEDURE|IRPC, Remote preconditioning|The patients will be submitted to 5 minutes of upper limb compression by cuff followed by 5 minutes of reperfusion. This cycle will be repeated 4 times.
224260609|NCT04652856|DEVICE|Electrical Brain Stimulation|Electrical Brain Stimulation (EBS) will be used to disrupt local neural activity in inferior temporal regions (ITC), parahippocampal cortex (PHC), the hippocampus, and control regions. The effects of EBS will be examined on attention and eye movement behavior, and all participants will receive both EBS and sham electrical brain stimulation.
224260610|NCT04652856|DEVICE|Sham Electrical Brain Stimulation|Sham electrical brain stimulation (SEBS) will be applied to inferior temporal regions (ITC), parahippocampal cortex (PHC), the hippocampus, and control regions. The effects of SEBS will be examined on attention and eye movement behavior, and all participants will receive both SEBS and EBS.
224260611|NCT03745963|BEHAVIORAL|Skin-to-skin contact|Infants allocated to the SSC arm will be placed in upright, ventral SSC position (holding of a diaper clad baby on the bare chest of a mother) for a minimum of 15 minutes prior to data collection.
224260612|NCT03745963|DRUG|24% oral sucrose|Administration of 24 percent oral sucrose will occur two minutes prior to the heel lance.
224260613|NCT00935012|DRUG|tafamidis|Once daily 20 mg oral tafamidis (soft gelatin capsule)
224260614|NCT00819312|DRUG|YAZ (SH T00186, BAY86-5300)|20ug ethinylestradiol, 3mg drospirenone, tablet, orally, opd
224260615|NCT03808519|DIETARY_SUPPLEMENT|n3 PUFA-enriched fish oil|3000mg of Eicosapentaenoic acid per day and 1800mg of Docosahexaenoic acid per day
224260616|NCT03808519|DIETARY_SUPPLEMENT|Placebo|Organic Sunflower Oil 5000mg per day
224260617|NCT01442155|DRUG|Capecitabine|Administered according to the Summary of Product Characteristics.
224260618|NCT01442155|BIOLOGICAL|Oxaliplatin|Administered according to the Summary of Product Characteristics.
224260619|NCT04906538|PROCEDURE|all- inside anterior cruciate ligament reconstruction|all- inside anterior cruciate ligament reconstruction with internal suture augmentation technique
224260620|NCT02226432|PROCEDURE|- Postoperative Antagonistic Peripheral Magnetic Stimulation|"Selected patients will be treated with Selective peripheral Neurotomy followed by an standartized cycle of Selective Peripheral Magnetic Stimulation and classic post operative Kinesic Therapy.~* Sham patients (n 10) will be treated with classic post operative Kinesic Therapy.~* Comparision of both groups will be statistified"
224260621|NCT02226432|DEVICE|Selective Peripheral Magnetic Stimulation|"Peripheral 1.5 tesla intensity, 10 Hz of Frequency, with eight saped bovine, of 30 minutes, aplied on antagonistic muscles, twice a week. Intensity will be infrathreshold, 80 per cent of the individual threshold (minimal amount of intensity producing always a muscle motor response in each particular patient)"
224260622|NCT02226432|OTHER|Kinesics|Session of classic Kinetic Rehabilitation and motor exercises, twice a week on Physicians´s office and dayly on patient´s home.
224260623|NCT06098079|DRUG|Naltrexone-Bupropion (NB) Combination|A total daily dosage of two NB 8 mg/90 mg tablets twice daily (32 mg/360 mg) is reached at the start of Week 4.
224260624|NCT06098079|DRUG|Placebo|A total daily dosage of two placebo tablets twice daily (in an identical, non-medicine containing tablet) is reached at the start of Week 4.
223773773|NCT02993601|OTHER|Medical grading of oedema|A member of the research team will assess the severity of the peripheral oedema on a scale of 1-5.
223835242|NCT01012973|BIOLOGICAL|Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321)|Intravitreal injection. Weeks 0 to 20 of Aflibercept Injection every 4 weeks; Weeks 24 to 52 every 4 weeks PRN (pro re nata, on demand); plus additional on Week 60 and 68.
224260625|NCT05628545|BIOLOGICAL|GDKM-100 injection|Participants will received GDKM-100injection (allo-γδ T Cells) Infusion every two weeks.
224260626|NCT01637376|DRUG|Temoporfin|A single dose of 0.04 mg per kilogram of body weight of Temoporfin will be administered by slow intravenous injection into a deep vein (such as the antecubital vein) in not less than 6 minutes and will not be flushed with sodium chloride or any other aqueous solution.
224260627|NCT05770076|DIETARY_SUPPLEMENT|Probiotic lysate (postbiotic and metabiotic)|Each capsule contains 100 mg of cell lysate and DNA fragments of the probiotic strain L. rhamnosus DV - NRRLB-68023 in powder
224260628|NCT05770076|DIETARY_SUPPLEMENT|Placebo|Placebo
224260629|NCT02538627|DRUG|MM-151|MM-151
224260630|NCT02538627|DRUG|MM-121|MM-121
224260631|NCT02538627|DRUG|MM-141|MM-141
224260632|NCT02538627|DRUG|trametinib|trametininb
224260633|NCT05049291|BEHAVIORAL|telehealth advance care planning|An education information sheet containing prognosis and outcomes of acute care and intensive treatments
224260634|NCT00705666|BIOLOGICAL|Peginterferon alfa-2b (SCH 54031)|Peginterferon alfa-2b as monotherapy or in combination with ribavirin will be administered according to the products' labeling.
223773774|NCT02993601|OTHER|Baseline assessements|At the point study participants are recruited, their age, sex, diagnosis, aetiology of heart failure, LVEF (Left ventricular ejection fraction), medical and device therapy, time since diagnosis, BNP (B-type Natriuretic Peptide), CRP (C-Reactive Protein), renal function (EGFR), Haemoglobin, albumin and urinalysis will be assessed unless recent (less that 6 months old) results are available. The number of Heart failure hospital admissions in the last 2 years, LACE score, co-morbidities will also be noted.
223773775|NCT02993601|DEVICE|Water displacement method|This will involve filling a gauge with lukewarm water (27-35oC +-2oC) up to the appropriate level. The appropriate level is determined by the water stabilising after some has flown out of the gauge into the waste bucket. Once the water level is stable the patient, who is sitting on a chair will be gently plunging the foot (naked) in the gauge until their foot is flat on the bottom on the gauge. The water flowing out of the gauge into the measuring bucket will be collected until the flow of water stops. Four small marks with non-toxic /non-permanent pen will be made on the lower leg of the patient to indicate where the water level was at. The water which has been collected in the measuring bucket will be weighted with precision scales to determine the volume of water displaced by the insertion of the foot. The patient's foot will then be dried.
223773776|NCT02993601|DEVICE|Callipers measurements|This will involve making 4 marks on one of the foot/lower leg (small cross) using non-toxic / non- permanent pen. The measurement will consist of making 6 measurements between those marks using callipers, and reporting the distance on a calibrated tape.
223773777|NCT02993601|DEVICE|Measuring tape|The measurements taken using a medical tape measure will involve the circumference of the ankle to be measured as well as the circumference at the level of the arch of the foot. The medical tape used will be a CE marked disposable medical measuring tape to minimise the risk of infection. The measurements will be done on both feet.
223773778|NCT02336984|BIOLOGICAL|HER-2 pulsed DC1|Vaccine administered weekly, with no more than 4 weeks delay over the course of 6 vaccines.
223773779|NCT02336984|DRUG|trastuzumab|The loading dose of Trastuzumab will be 8 mg/kg and the maintenance dose given week 4 will be 6 mg/kg, both standard doses of trastuzumab.
223773780|NCT02336984|DRUG|pertuzumab|Pertuzumab 420 mg IV will be given at the same time as trastuzumab.
223773781|NCT04932174|OTHER|High-intensity Interval Training|"Consisting of the following program:~* Warming up period for 10 minutes at 60-70% of HR max.~* Training phase 4x4 min intervals at 85-90% of HRmax with a 3 min active recovery at 70% of HRmax between each interval.~* Duration of HIIT 4 minute~* Number of interval per session 4~* Duration of rest interval 3 minute 3-10 min cool-down period, giving a total of 60 min."
223773782|NCT04932174|OTHER|Low-intensity Continuous Training|"Consisting of the following program:~* Warming up period for 10 minutes.~* Training phase for 60-minute walking on a treadmill at intensity 40-50% HRR (1- 6) weeks then 60-70% HRR (7-12) weeks.~* cooling down period for 10 minutes."
223773783|NCT04064697|DRUG|Valganciclovir|The experimental intervention consists of taking the treatment Valganciclovir 900 mg morning and evening for 3 weeks
223773784|NCT04905680|DEVICE|CGM lifestyle tracking and coaching|"Participants in the experimental group will go through a total of 5 lifestyle tracking sessions (including baseline), of which 1 will include CGM tracking. For this CGM lifestyle tracking session, experimental group participants will receive real-time feedback through the study applications, which will display the CGM trace.~The data collected during the lifestyle tracking sessions will be discussed with the participants during 3 face-to-face coaching and 2 tele-coaching sessions, where the participants will develop and implement lifestyle change action plans."
223773785|NCT04795505|BEHAVIORAL|Intervention|The subsequent visit was through WeChat-based online consultations. Follow-up, assessments and feedback were done at each visit. After follow-up, medication adherence and risk factor modification status were assessed, then individualized feedback, encouragement and recommendations were provided.
223773786|NCT04795505|BEHAVIORAL|Control|The subsequent visit was through an offline outpatient clinic at 4 different community hospitals. Participants in this group received standard outpatient cardiology follow-up with formal cardiac rehabilitation and secondary prevention
223773787|NCT05916755|DIAGNOSTIC_TEST|Whole Genome Sequencing|Whole genome sequencing (WGS) will be performed in tumor tissue from baseline and from residual disease after neoadjuvant chemotherapy (NACT), if present.
223773788|NCT05916755|DIAGNOSTIC_TEST|RNA-Sequencing|RNA-Sequencing will be performed in tumor tissue from baseline and from residual disease after NACT (if present).
223773789|NCT05916755|DIAGNOSTIC_TEST|Microbiome analysis|Microbiome analysis will be performed in stools and saliva before, during NACT and at the end of adjuvant systemic therapy if adjuvant systemic therapy is clinically indicated.
223773790|NCT05916755|DIAGNOSTIC_TEST|ctDNA analysis|ctDNA analysis will be performed in plasma before and during NACT.
223773791|NCT05916755|DIAGNOSTIC_TEST|TCR-β repertoire sequencing|TCR-β repertoire sequencing will be performed in plasma before and during NACT.
223773792|NCT05916755|DIAGNOSTIC_TEST|PBMCs phenotyping|PBMCs phenotyping will be performed in plasma before and during NACT.
223773793|NCT05916755|DRUG|Pembrolizumab|Pembrolizumab will be given in combination with standard NACT.
223773794|NCT05916755|DRUG|Chemotherapy|Standard NACT will be given.
223773795|NCT02453451|OTHER|2D-/3D-TTE|recording of 3 cardiac cycles
223773796|NCT02453451|OTHER|3D-TEE|with colour-Doppler techniques for recording the ASD and the mitral valve
223773797|NCT02453451|OTHER|Walking Test|for 6 minutes
223773798|NCT02453451|PROCEDURE|MitraClip procedure|catheter-based non-surgical procedure in which the atrioventricular valves were stuck together permanently via a clip (during the regular patient care)
223773799|NCT02366572|OTHER|Control|Non pulse extruded cereal
223773800|NCT02366572|OTHER|Pea protein|Pulse extruded cereal
223773801|NCT02366572|OTHER|Pea starch|Pulse extruded cereal
223773802|NCT02366572|OTHER|Pea fibre + pea starch|Pulse extruded cereal
223773803|NCT02366572|OTHER|Pea protein + pea starch|Pulse extruded cereal
223773804|NCT02366572|OTHER|Pea fibre + pea starch + pea protein|Pulse extruded cereal
223773805|NCT01624545|OTHER|cranial CT scan|Patients in this study arm will receive a cranial CT scan on day 2 and day 30 after evacuation of a chronic subdural hematoma in addition to neurological evaluation on day 2 and 30.
223773806|NCT02139644|DRUG|FS MDPI|"FS MDPI is an inhalation-driven multidose dry powder inhaler (MDPI) containing fluticasone propionate (Fp) and salmeterol xinafoate (Sx) dispersed in a lactose monohydrate excipient and contained within a reservoir. A metered dose of drug is delivered to a dose cup via an air pulse activated when the cap is opened.~During the treatment period, participants were randomized to either 100/12.5 mcg Fp/Sx or 50/12.5 mcg Fp/Sx in the morning and evening for a total daily dose of 200/25 mcg or 100/25 mcg Fp/Sx.~Participants were instructed to rinse their mouth and expectorate (not swallow) after study drug administration."
223773807|NCT02139644|DRUG|Fp MDPI|"Fp MDPI is an inhalation-driven multidose dry powder inhaler (MDPI) containing fluticasone propionate dispersed in a lactose monohydrate excipient and contained within a reservoir. A metered dose of drug is delivered to a dose cup via an air pulse activated when the cap is opened.~During the treatment period, participants were randomized to either 100 mcg or 50 mcg of Fp one inhalation twice a day for a total daily dose of 200 mcg or 100 mcg.~Participants were instructed to rinse their mouth and expectorate (not swallow) after study drug administration."
224260635|NCT00705666|DRUG|Ribavirin (SCH 18908)|Peginterferon alfa-2b as monotherapy or in combination with ribavirin will be administered according to the products' labeling.
224260636|NCT00429962|DRUG|intravitreal ranibizumab|intraocular injection
224260637|NCT00429962|DRUG|intravitreal ranibizumab & photodynamic therapy|intraocular injection photodynamic treatment (LASER) after intravenous injection
224323571|NCT03124329|PROCEDURE|Intrasulcular Tunneling|Initial sulcular incisions are made and small, contoured blades and mini curettes are used to create the recipient pouches and tunnels. The tunnel will be subperiosteal in location. The incision is extended to one adjacent tooth both mesially and distally. This incision maintains the full height and thickness of the gingival component and enables access beneath the buccal gingiva. The connective tissue beyond the mucogingival line will be dissected and free the buccal flap from its insertions to the bone around each tooth. Muscle fibers and any remaining collagen fibers on the inner aspect of the flap, which prevent the buccal gingiva from being moved coronally, are cut. The papillae are kept intact and undermined to maintain their integrity and carefully released from the underlying bone, which allows the coronal positioning of the papillae. An envelope, full-thickness pouch, and tunnel are created and extended apically beyond the mucogingival line by blunt dissection
223773808|NCT02139644|DRUG|Placebo MDPI|Placebo administered via a multidose dry powder inhaler (MDPI) one puff in the morning and one puff in the evening for 12 weeks.
223773809|NCT02139644|DRUG|albuterol/salbutamol|A short-acting β2-adrenergic agonists (SABA), albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI), was provided to be used as needed for the relief of asthma symptoms during both the run-in and treatment periods (to replace the subject's current rescue medication).
223835243|NCT01012973|OTHER|Sham treatment|Sham treatment. Weeks 0 to 52 sham treatment every 4 weeks; plus additional on Week 60 and 68.
224260638|NCT03115957|OTHER|Parenteral Nutrition|Patients who can not tolerate 30% of target energy EN will receive supplemental parenteral nutrition at day 3 or at day 8 after abdominal surgery.
224323572|NCT03124329|BIOLOGICAL|Vestibular Incision Subperiosteal Tunnel Access (VISTA)|The VISTA approach begins with a Vestibular Incision Subperiosteal Tunnel Access. Through this incision a subperiosteal tunnel is created, exposing the facial osseous plate and root dehiscence. This tunnel will be extended at least one or two teeth beyond the teeth requiring root coverage to mobilize gingival margins and facilitate coronal repositioning. Additionally, the subperiosteal tunnel is extended interproximally under each papilla as far as the embrasure space permits, without making any surface incisions through the papilla. The mucogingival complex is then advanced coronally and stabilized in the new position with the coronally anchored suturing technique, which entails placing a horizontal mattress suture apical to the gingival margin of each tooth. The suture is tied to position the knot at the midcoronal point of the facial aspect of each tooth, which is secured with help of composite resin to prevent apical relapse of the gingival margin during initial stages of healing.
224323573|NCT03124329|DEVICE|Leukocyte-Platelet Rich Fibrin (L-PRF)|"Immediately prior to surgery, 72 mL of blood should be drawn from each patient by venipuncture of the antecubital vein and collected in a sterile glass test tube without any anticoagulant. Tubes should be centrifuged at 2,700 rpm for 12 minutes within 2 minutes after blood draw. For individuals on anti-coagulant therapy or supplements to interfere with coagulation, centrifugation will be for 18 minute. After centrifugation, each L-PRF clot will be separated from the portion of red blood cells (red thrombus), obtaining a fibrin clot with a red small portion in order to include the buffy coat richer in leucocytes. The L-PRF clot is condensed and modeled on a sterile surgical plate. L-PRF will be used within 60 minutes after the preparation."
224323574|NCT04523727|DRUG|ferric citrate|oral tablets
223835244|NCT00479596|DRUG|Botox|
224260639|NCT03521973|BIOLOGICAL|PfSPZ Vaccine|Radiation-attenuated, aseptic, purified, cryopreserved Plasmodium falciparum sporozoites (PfSPZ Vaccine)
224260640|NCT03521973|OTHER|Normal Saline|0.9% Sodium chloride
224260641|NCT05180422|DRUG|AMG 510|Continuous once daily (QD) oral dosing (Days 1-21 each cycle) with or without food.
224260642|NCT05180422|DRUG|MVASI|Intravenous (i.v.) infusion every 21 days (i.e. Day 1 of each 21-day cycle).
224260643|NCT06541327|DRUG|Chimeric Antigen Receptor|CAR-T
224260644|NCT04570748|PROCEDURE|Capsule repair|Direct anterior hip arthroplasty with or without capsule repair
224260645|NCT04570748|PROCEDURE|capsulectomy|capsulectomy without repair
224260646|NCT05187065|OTHER|The mobile-based education and exercise program|Starting from the preoperative period, mobile-based patient education, progressive relaxation exercise and knee exercise program will be applied to the patient as a whole. Mobile-based education will include pre-operative and discharge education. The patient will be given a progressive relaxation exercise with the support of the mobile application and the exercises included in the knee exercise program that should be done after the surgery will be shown. Progressive relaxation exercises will be applied twice a day in the afternoon and evening. Postoperative knee exercises will be performed 3 to 5 times a day, depending on the type of exercise. These exercises will be continued regularly for up to 4 weeks after discharge.
224260647|NCT03259139|BEHAVIORAL|Video games and violence|Participants will be randomly assigned to play a video game which contains either (1) no violent content, (2) violent content with swords, or (3) violent content with guns. The game, rated E, is age appropriate and modded to include guns in the appropriate condition.
224260648|NCT02284867|OTHER|immunohistochemistry study|After taking informed written consent,a placental sample will be taken either the patient delivered preterm or at term (term patients will be either control term group or patients with successful treatment of preterm labor). The placental sample taken should have part of the decidua and then the sample will be fixed in 10% neutral-buffered formalin for 24-48 h, routinely processed, embedded in paraffin wax, sectioned at 3 μm thickness, and mounted on 3-aminopropyl-triethoxysilane -coated slides. Serial sections will be immunostained for CD 16 and CD56 . immunohistochemistry study will be done at Ain Shams Maternity Hospital Histopathology department.
224260649|NCT03931616|PROCEDURE|STEMO|STEMO, the intervention, includes prehospital neurological emergency assessment with the option to perform CT and CT-angiography, start specialized treatment at the door-step of the patient's house, including thrombolysis with tissue Plasminogen Activator and blood pressure management (choice of drug at discretion of treating physician), use of telemedicine for image transfer as well as results of point-of-care laboratory, prenotification (e.g. for endovascular treatment), triage and transport.
224260650|NCT03931616|PROCEDURE|Regular care|A regular ambulance, the comparator, not equipped with advanced point-of-care laboratory or CT scanner, without telemedicine and not staffed with a neurologist.
224260651|NCT00553124|DRUG|selenium|
224260652|NCT00553124|DRUG|vitamin E|
224260653|NCT00553124|PROCEDURE|biopsy|
224260654|NCT00553124|PROCEDURE|chemoprevention|
224260655|NCT00553124|PROCEDURE|cryopreservation|
224260656|NCT00553124|PROCEDURE|cytology specimen collection procedure|
224260657|NCT00553124|PROCEDURE|diagnostic procedure|
224260658|NCT00553124|PROCEDURE|gene expression analysis|
224260659|NCT00553124|PROCEDURE|immunohistochemistry staining method|
224260660|NCT00553124|PROCEDURE|laboratory biomarker analysis|
224260661|NCT00553124|PROCEDURE|medical chart review|
224260662|NCT00553124|PROCEDURE|mutation analysis|
224260663|NCT00553124|PROCEDURE|polymerase chain reaction|
224260664|NCT00553124|PROCEDURE|quality-of-life assessment|
224260665|NCT00553124|PROCEDURE|questionnaire administration|
224260666|NCT00553124|PROCEDURE|study of socioeconomic and demographic variables|
224260667|NCT00616863|DRUG|Oxcarbazepine|
224260668|NCT04200586|DRUG|Dapagliflozin|Dapagliflozin, one of the SGLT-2 inhibitors, will be prescribed to DM patients on clinical ground.
224260669|NCT02927639|OTHER|MyDiaText|The intervention will consist of daily text messages sent to the subject's personal mobile device.
224260670|NCT01590563|DEVICE|IUD|Insertion of a spherical IUD, one year follow-up
224260671|NCT03958396|DRUG|Remifentanil Infusion|15 minute remifentanil Infusion of either 0.05, 0.1, 0.15 or 0.2 mcg/kg/min
224260672|NCT02990286|DRUG|Rituximab|Rituximab 500mg concentrate for solution for infusion. One course of IV rituximab consisting of a first infusion of 1000 mg (500 ml solution) rituximab (day 1 infusion), and a second infusion of 1000 mg (500 ml solution) rituximab two weeks later (day 15 infusion)
224260673|NCT02990286|DRUG|Placebo of Rituximab|500 ml of saline (0.9% sodium chloride) for infusion One course of intravenous placebo of rituximab consisting of a first infusion of 500 ml of saline (0.9% sodium chloride) infusion (day 1 infusion), and a second infusion of 500 ml of saline infusion two weeks later (day 15 infusion)
224260674|NCT02990286|DRUG|Mycophenolate Mofetil|"Mycophenolate Mofetil 500mg film-coated tablets~1 gram twice daily on oral route of MMF (= 2 grams daily) for 6 months."
224260675|NCT01309763|BIOLOGICAL|AFFITOPE AD03|s.c. injection
224260676|NCT01309763|BIOLOGICAL|AFFITOPE AD03 + Alum|s.c. injection
224260677|NCT02451163|DIETARY_SUPPLEMENT|wheat polysaccharides|Consumed once daily for 12 weeks.
224260678|NCT02451163|DIETARY_SUPPLEMENT|maltodextrin|Consumed once daily for 12 weeks.
224260679|NCT03865563|DRUG|Retrograde venous infusion of gemcitabine/lipiodol|Access will be gained into the portal vein via a transhepatic approach. The pancreatic tumor-draining veins will be accessed via a catheter positioned in the portal vein, superior mesenteric vein or splenic vein. The catheter is then advanced into the vein draining the segment in which the targeted tumor is located. Tumor location and its venous drainage will be confirmed with sub-selective pancreatic venography and cone-beam CT. Once correct catheter positioning is confirmed, the gemcitabine/Lipiodol® emulsion will be administered under real-time fluoroscopic guidance until the entire dose is administered or until stasis is achieved in the vein through which the drug is being delivered.
224260680|NCT03256695|DRUG|Albuterol sulfate (ABS)|ABS will be administered via eMDPI as per the dose and schedule specified in the arm.
224260681|NCT00346190|DRUG|Alendronate|
224260682|NCT01604941|DRUG|SPD602|50 mg/kg/day orally twice daily for 24 weeks
224260683|NCT06627114|BEHAVIORAL|nutrition education program|"Nutritional Guidance: Emphasizing a balanced diet rich in fruits, vegetables, whole grains, lean proteins, and healthy fats while reducing processed foods, sugars, and saturated fats.~Weight Management: Encouraging gradual weight loss if overweight, as this can significantly improve liver health.~Individualized Plans: Tailoring nutrition education to the individual needs, preferences, and any other underlying health conditions.~Monitoring and Support: Providing ongoing support and education to help participants make sustainable changes and track their progress."
224260684|NCT06627114|DIETARY_SUPPLEMENT|Omega 3 fatty acids|Omega-3 Arm:1000 mg omega-3 fatty acids soft gel capsules twice daily, to be taken orally with meal.
223773810|NCT02139644|DRUG|Beclomethasone dipropionate|QVAR (beclomethasone dipropionate) 40 mcg inhalation aerosol is a pressurized MDI that contains a Food and Drug Administration (FDA)-approved formulation of beclomethasone dipropionate. Patients took 1 puff twice a day from open-label QVAR 40 mcg hydrofluoroalkane (specifically, HFA-134a) metered-dose inhaler (MDI) for the duration of the Run-in Period (14-21 days) and prior to randomization. A clinically equivalent dose of inhaled corticosteroid (ICS) was substituted in countries where QVAR 40 mcg was not available.
223773811|NCT01681082|BEHAVIORAL|Tai Chi training|24 form Yang style Tai Chi. 50 minute sessions, twice weekly.
223773812|NCT05897359|BEHAVIORAL|bCBTMI|This experimental group involves 4 weekly 30-45 minute sessions using the brief CBT and the brief MI models by trained nursing students.
223773813|NCT05897359|BEHAVIORAL|Control|The control group will receive health talks about internet addiction consequences and impacts on young people by nursing students who are not involved in the intervention group to mimic the time and attention spent on the intervention group. These health talks are considered routine care for IA health promotion.
224260685|NCT06627114|OTHER|control group|receive routine care at the outpatient clinic. At baseline, a physician will explain the laboratory test results and the natural history of NAFLD to the patients.
224260686|NCT03264521|OTHER|Surveys|Web surveys about experiences with chronic low back pain, demographics, coding qualitative text.
224260687|NCT01462708|DRUG|[18F]MK-9470|Subjects will be injected with 10 mCi, and not to exceed 11 mCi (not \>10% of 10 mCi limit)of \[18F\]MK-9470, followed by PET imaging.
224260688|NCT06626984|DRUG|Imatinib|Pre-treatment with 600mg Imatinib administered 1 hour prior to intravenous LPS.
224260689|NCT06626984|DRUG|Compound sodium lactate solution|Total of 30 ml/kg administered 90 minutes following intravenous LPS. 30mls/kg (maximum volume of 2500mls) administered in two divided doses (15mls/kg) intravenously. Each bolus will be administered at a fixed rate of 999mls/hr.
224260690|NCT05859984|DRUG|recombinant human interferon ω spray|8 ml/bottle（contain 2 million IU recombinant human interferon ω）
224260691|NCT00582179|PROCEDURE|Standard Pressure Dressing|If hematoma still draining at 5 days post surgery, patients who randomize to Group A will have a standard pressure dressing applied and checked every 24-48 hours for continued draining. If still draining at 10 days post surgery, patient is at end point of study and must return to OR for Irrigation and Debridement of the wound. If infection occurs, patient is at end point of study and must return to OR for I\&D.
224260692|NCT00582179|DEVICE|VAC|If hematoma still draining at 5 days post surgery, patients who randomize to Group B will have a VAC negative pressure device applied and checked every 24-48 hours for continued draining. If still draining at 10 days post surgery, patient is at end point of study and must return to OR for Irrigation and Debridement of the wound. If infection occurs, patient is at end point of study and must return to OR for I\&D.
224260693|NCT05204979|OTHER|Vaginal Versus Sublingual misoprostol|Insertion failures of intra uterine devices and cervical problems seem to occur more often among women who have never delivered vaginally. Several studies have shown the benefit of misoprostol as a cervical ripening agent in nonpregnant women. This trial will compare the effect of vaginal versus sublingual misoprostol prior to insertion of an intrauterine device in multiparous women delivered by CS.
224260694|NCT04313764|DRUG|Bupivacaine Hcl 0.25% ESP block|Ultrasound-guided erector spinae plane block with 20 ml %0.25 bupivacaine, per side
224260695|NCT04313764|DRUG|Bupivacaine Hcl 0.25% infiltration|Wound infiltration with 20 ml %0.25 bupivacaine
224260696|NCT05347459|DRUG|Dapagliflozin|usual and customary doses for type 2 diabetes management
224260697|NCT05347459|DRUG|Empagliflozin|usual and customary doses for type 2 diabetes management
224260698|NCT05347459|DRUG|Canagliflozin|usual and customary doses for type 2 diabetes management
224260699|NCT05347459|DRUG|Sitagliptin|usual and customary doses for type 2 diabetes management
224260700|NCT05347459|DRUG|Saxagliptin|usual and customary doses for type 2 diabetes management
224260701|NCT05347459|DRUG|Linagliptin|usual and customary doses for type 2 diabetes management
224260702|NCT05347459|DRUG|Vildagliptin|usual and customary doses for type 2 diabetes management
223773814|NCT00760279|DRUG|Azithromycin|
223773815|NCT00045994|DRUG|ALT-711|
223835245|NCT01773668|DEVICE|Integrated sensor and infusion set.|
224260703|NCT02308059|OTHER|Ultrasonographic evaluation of nerves in diabetic patients|Ultrasonographic evaluation of peripheral nerves in patients with diabetes mellitus which have peripheral neuropathy
223835246|NCT01449214|PROCEDURE|Ultrasound|Ultrasound-guided technique
223835247|NCT01449214|PROCEDURE|Landmarking|Landmark-guided technique
223835658|NCT05850286|BIOLOGICAL|anti-BCMA CAR-T|Autologous BCMA-directed CAR-T cells, double infusion intravenously at a target dose of 2.0-4.0 x 10\^6 anti-BCMA CAR+T cells/kg.
224260704|NCT02308059|OTHER|Ultrasonographic evaluation of nerves of healthy volunteers|evaluation of peripheral nerves and correlated with group I
224260705|NCT03930732|DRUG|Dupilumab SAR231893|"Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous"
224260706|NCT03930732|DRUG|Inhaled Corticosteroid|"Pharmaceutical form: Inhaled Powder~Route of administration: Oral inhalation"
224260707|NCT03930732|DRUG|Inhaled Long-Acting Beta Agonist|"Pharmaceutical form: Inhaled Powder~Route of administration: Oral inhalation"
224260708|NCT03930732|DRUG|Inhaled Long-Acting Muscarinic Antagonist|"Pharmaceutical form: Inhaled Powder~Route of administration: Oral inhalation"
224260709|NCT03930732|DRUG|Placebo|"Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous"
224260710|NCT03515707|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo ASCT
223773816|NCT05173467|PROCEDURE|Robot-assisted Invasion-controlled Surgery|The concept of invasion-controlled surgery (ICS) for spinal metastasis has been put forward against the spinal instability and neurological dysfunction of frail patients that might not allowed for radical traditional open surgery including improvements of multidisciplinary dynamic assessments, endovascular detachable balloon embolization, minimal-invasion by using expandable working tubes, percutaneous pedicle screws, and some accurate therapy. ICS could provide immediate stability, deformity correction, and recovery of neurological function.
224260711|NCT03515707|DRUG|Busulfan|Given IV or oral
224260712|NCT03515707|DRUG|Etoposide|Given IV
223773817|NCT05173467|PROCEDURE|Traditional-open Surgery|This traditionally requires a midline incision, bilateral muscle strip, and multilevel laminectomy to provide adequate access and safe removal of the tumor.
224260713|NCT03515707|OTHER|Laboratory Biomarker Analysis|Correlative studies
223773818|NCT00147147|PROCEDURE|Gastrectomy with D2 or greater lymph node dissection|
223773819|NCT00147147|DRUG|Gastrectomy+ chemotherapy|
223773820|NCT03328897|DRUG|Omalizumab|injection of 150mg or 300 mg
223773821|NCT03328897|DRUG|Placebo|Injection of placebo
223773822|NCT04245735|DIAGNOSTIC_TEST|perfusion index|To test the objective role of perfusion index in assessing the success of the peripheral nerve block in children under sedation.
223773823|NCT04098692|DRUG|Derazantinib capsule|300 mg derazantinib oral administration (3x100 mg capsules)
223773824|NCT04098692|DRUG|[14C]-Derazantinib solution for infusion|100 μg \[14C\]-derazantinib intravenous administration
223773825|NCT04098692|DRUG|[14C]-Derazantinib capsule|300 mg \[14C\]-derazantinib oral administration (3x100 mg capsules)
223773826|NCT01330940|DIETARY_SUPPLEMENT|Orange soda|32 ounces per day
223773827|NCT01699399|PROCEDURE|water immersion|
224260714|NCT03406156|DRUG|Obinutuzumab|Administered via intravenous infusion
224260715|NCT03406156|DRUG|Bendamustine|Administered via intravenous infusion
224260716|NCT03406156|DRUG|Venetoclax|The venetoclax dose was administered according to a weekly ramp-up schedule over 5 weeks to the recommended daily dose of 400 mg. Venetoclax was continued for a total duration of up to 53 weeks, including the 5-week ramp-up schedule. Participants were instructed to take venetoclax tablets with a meal and water at approximately the same time each day. Venetoclax tablets were to be swallowed whole and not chewed, crushed, or broken prior to swallowing.
224260717|NCT05025137|OTHER|Flexi-Bar Exercise|"In the experimental group, the Flexi-Bar was adopted as the tool for active vibration exercises. Featuring light weight and ease of operation, it weighs only 460 grams and has a vibration frequency of 4-5 Hz. With diversified functions, the Flexi-Bar can improve posture, burn fat, strengthen connective tissue, enhance body shape, and increase muscle strength.~The 12-week Flexi-Bar exercise course in this study was created by two assistant professors specializing in rehabilitation (one with an occupational therapy certificate and the other with a physical therapy certificate). The course, composed of one 60-minute class per week for a total of 12 weeks, progressed gradually from basic activities (e.g., standing with both feet) to advanced activities (e.g., standing with one foot)."
223773828|NCT01699399|PROCEDURE|water exchange|
223773829|NCT01699399|PROCEDURE|air insufflation|
223773830|NCT02248584|DIETARY_SUPPLEMENT|Vitamin C, E and Zinc|Capsule containing vitamin C (50 mg; CVS Quality, USA), vitamin E (60 mg; Nature´s Bounty, USA), and zinc (40 mg; CVS Quality, USA) per day for 60 days.
223773831|NCT03874000|BIOLOGICAL|Sintilimab|Given IV
223773832|NCT03874000|DRUG|Metformin Hydrochloride|Given PO
223773833|NCT00185133|DRUG|Olmesartan medoxomil|
223773834|NCT00185133|DRUG|Amlodipine|
223773835|NCT00941733|DEVICE|IN.PACT Amphirion|Balloon Angioplasty
223773836|NCT00941733|DEVICE|Standard PTA|Balloon Angioplasty
223773837|NCT01889589|OTHER|Surveillance|
223773838|NCT03724604|DIAGNOSTIC_TEST|Neuron-Specific Enolase to Albumin Ratio|Previous studies have shown that inflammation and nutrition-related factors such as CRP/Alb (C-reactive protein-albumin ratio), PLR (platelet-to-lymphocyte ratio), NLR (neutrophil-to-lymphocyte ratio) can help to assess the prognosis of malignant tumors. This study is the first time to combine NSCLC tumor marker NSE and patient nutrition-related indicators Alb to predict the prognosis of patients, trying to find high sensitivity and specificity for NSCLC prognostic indicators to guide clinical work.
223773839|NCT03141502|DEVICE|Skin stretching device (SSD)|By making use of skin viscoelasticity, the special metal crochet of SSD would be embedded in both sides skin of the wound. Multiple cycles of stretching and relaxing wound lead to extended skin, changing the high tension incision into a low tension incision and facilitating the direct suture.
223773840|NCT03141502|PROCEDURE|Skin grafting|the standard technique of skin grafting after wound preparation.
223773841|NCT02731001|RADIATION|Proton therapy|
223773842|NCT02731001|RADIATION|Photon therapy|
223773843|NCT05251792|OTHER|Ocular examination|All participants underwent a detailed examination, including visual acuity, slit lamp biomicroscopy, direct ophthalmoscopy, optometry noncontact tonometry,MPOD measurement and optical coherence tomography (OCT) measurement
223773844|NCT03492307|OTHER|Weight-Based Flow for High Flow Nasal Cannula (HFNC) (2L/kg/minute)|A weight-based flow for HFNC.
223773845|NCT03492307|OTHER|Standard Flow for HFNC (Maximum 8L/minute)|Maximum flow of 8L/minute.
223773846|NCT00057915|BIOLOGICAL|CEA peptide 1-6D|CAP-1(6D) peptide-pulsed, matured, autologous human DC produced by the AastromReplicell™ Cell Production System
223773847|NCT05036642|DEVICE|Compliant Passive Arm Support|The device is a mechanical device that consists of two linkages, elastic bands, a commercial posture brace, and a hook-and-loop fastener. The design of the device, with several compliant elements, ensures that one device fits many without joint alignment concerns. No motors or other actuators add energy into the system, meaning that it is stable.
224260718|NCT05025137|OTHER|Multi-Component exercise|Alternatively, in the control group, the Multi-Component exercise was adopted, which included aerobic, resistance, flexibility, and balance exercises. The course was composed of one 60-minute class per week for a total of 12 weeks. The design was based on the ACSM's recommendations for the multiple-component exercise of the elderly (Chodzko-Zajko et al., 2009) and videos of the National Health Exercises for the Elderly formulated by the Ministry of Health and Welfare (Ministry of Health and Welfare, 2017). The course was created and led by a physical therapist to gradually progress from sitting postures to standing and walking postures. Additionally, the intensity of the exercises was adjusted according to the participants' physical conditions; fitness equipment was introduced when appropriate.
224260719|NCT00387933|DRUG|hydroxyurea|
224260720|NCT00387933|DRUG|imatinib mesylate|
224260721|NCT00387933|DRUG|vatalanib|
224260722|NCT00187928|DRUG|Topiramate|
224260723|NCT01923545|DRUG|PEG-G-CSF|Vial, 3.6mg/day or 6mg/day, single dosing per cycle, for 1 cycle
224260724|NCT01923545|DRUG|G-CSF|Vial, 100ug/m2/day, multiple dosing per cycle(daily administration, up to 10 days), for 1 cycle
224260725|NCT04708028|OTHER|Dog Therapy|The intervention is a therapy dog interaction (e.g. petting) for up to 2 minutes before their appointment and first interaction with the doctor. The subject can pet the dog for as long as they like up until the 2 minute mark.
224260726|NCT03253354|DEVICE|repetitive magnetic stimulation|Neurostimulation
224260727|NCT06557551|OTHER|Thin catheter surfactant|Surfactant given through thin catheter inserted under video laryngoscopy at or after 5 minutes of life
224260728|NCT00625560|DRUG|Entecavir|entecavir 1.0 mg QD
224260729|NCT00625560|DRUG|Lamivudine|lamivudine 100 mg QD
224260730|NCT03342846|DEVICE|rTMS|the first group received 20 Hz and the 2nd group received 1 Hz rTMS daily for 10 days 5 sessions every week on M1.
224260731|NCT01904162|DRUG|400 mg finafloxacin (2 x 200 mg tablets)|
224260732|NCT05124444|GENETIC|High throughput DNA and RNA sequencing|High throughput DNA and RNA sequencing
224260733|NCT06133101|DRUG|Standard Soy Milk|Consumption of commercially available soy milk
224260734|NCT06133101|DRUG|2% Fat Cow's Milk|Consumption of commercially available 2% cow's milk
224260735|NCT02942823|OTHER|"The serious game KOP"|The serious game transfers knowledge about nutrition (food pyramid, energy density of foods, which foods contribute to satiety and which not, energy in liquids, self-reflexive diagnostic tool to analyze daily food intake), physical activity (a motion-control to navigate through the game is partly used, relationship between energy expenditure and energy intake) and psychological aspects (relaxation-exercises, what is stress, stress-coping strategies).
224260736|NCT06468839|BEHAVIORAL|digital addiction management model|The experimental group will implement a digital addiction model. No intervention will be made to the control group.
224260737|NCT04099758|BEHAVIORAL|Mindfulness of the breath meditation|A 10-minute mindfulness of the breath meditation practice
224260738|NCT04099758|BEHAVIORAL|Audio-recording control|10 minute non-fiction audio-recording delivered online
224260739|NCT06499844|DRUG|Acetylcholine|acetylcholine, and acetylcholine + L-NAME (Nitric oxide synthase inhibitor) are locally and acutely delivered to the cutaneous microvasculature to assess endothelium- and nitric oxide-dependent dilation
224260740|NCT05331534|BEHAVIORAL|Eye-tracking assisted attention control training (ACTo)|"ACT is made of 8 sessions of a Dot-Probe Task (DPT). The DPT is a computerized task in which two visual stimuli (one emotional stimulus and one neutral stimulus) are displayed simultaneously on the left and right side of the screen. AB towards or away from emotional stimuli is respectively inferred by faster or slower responses to detect a probe replacing an emotional stimulus than a probe replacing a neutral stimulus. In the ACT therapy, the probe replaces the negative and neutral stimuli with equal frequency.~ACTo will combine ACT with eye tracking methodology, allowing to directly record eye movements of the participants during the task. At each trial, images will be displayed for 2s and the negative image will be replaced by the neutral image (and vice versa) if the patient continues to explore the negative image beyond the first fixation, in order to block any additional attentional engagement."
224260741|NCT05331534|BEHAVIORAL|Attention control training (ACT)|Patients will benefit from the ACT as described above; at each trial, images will remain on screen for 2s.
223835659|NCT05850286|DRUG|VRD-based Regimen|Bortezomib, Lenalidomide and Dexamethasone
224260742|NCT01679327|DRUG|Oxaliplatin|
224260743|NCT01679327|DRUG|Xeloda|
224260744|NCT01679327|DRUG|Calcium folinate (CF)|
224260745|NCT01679327|DRUG|5-FU|
224260746|NCT01679327|DRUG|Bevacizumab|
224260747|NCT06230094|OTHER|moderate intensity|Arm Circles, Leg Swings, Lunges, brisk walk
224260748|NCT06230094|OTHER|high intensity|Arm circles, Leg swings, Lunges, skipping rope
224260749|NCT04366960|DRUG|Enoxaparin|Subcutaneous enoxaparin
224260750|NCT05069480|DEVICE|Virtual reality-based training equipment.|It is a functional upper extremity rehabilitation device to provide specific therapy with augmented feedback. The equipment facilitates intensive task-oriented upper extremity therapy after stroke, traumatic brain injury, or other neurological diseases and injuries. It combines adjustable arm support, with augmented feedback and a large 3D workspace that allows functional therapy exercises in a virtual reality environment.
224260751|NCT05069480|OTHER|Traditional physical therapy program|The traditional physical therapy program aimed for inhibition of spasticity, facilitation of muscle action, and improving the motor functions of the involved upper limbs.
224260752|NCT06042231|BEHAVIORAL|Exercise Intervention|Exercise and education intervention. Participants will be prescribed a tailored exercise program to complete before ('pre-habilitation') and after their AF ablation procedure (rehabilitation).
224260753|NCT06042231|BEHAVIORAL|Education Intervention|Education intervention. Participants will be given a 1-1 education session (up to 3 sessions) before and after their AF ablation procedure. Participants will be given behavioural strategies to improve adherence and compliancec to risk-factor modification.
224260754|NCT03366792|DEVICE|Artemis™ software system|Computerized targeting of mpMRI lesions. The computerized co-registration will then be performed by software within the Artemis™ system and will fuse the MR imaging with real-time ultrasound imaging.
224260755|NCT03545022|PROCEDURE|Acupuncture|"The application of acupuncture was performed in four sessions, 30 minutes prior to surgery, 24, 48 and 72 hours following the surgery, before variables measurements. The points were manually stimulated and the needles were inserted up to 4mm. There were 11 points, applied bilaterally, two of them, point VG20 and Yintang, for anxiety control, only at the preoperative time and not bilateral. The points to reduce pain, edema, and trismus were IG4 (Hegu), F3 (Taichong) and E44 (Neiting), TA21 (Ermen), ID19 (Ting-Kong), E6 (Jiagle) and E7 (Towei) , point B60 (Kunlum) and VB34 (Yanglingquan). All patients received the same treatment in all sessions.~After the needle devices were inserted, the needles were re-stimulated manually once after 10 minutes and removed after more 10 minutes."
224260756|NCT03013530|PROCEDURE|Decision making for ICU patients' care|Study of factors involved in the decision-making for ICU patients' care. Effect of advance directives (AD).
224260757|NCT01530048|DRUG|insulin aspart|A single bolus injection of 0.2 U/kg administered subcutaneously (s.c., under the skin) on two separate dosing visits with a wash-out period 2-15 days in-between
223773848|NCT06533618|DIAGNOSTIC_TEST|Continuous glucose monitoring system|All participants (subjects and controls) applied a Medtronic Guardian4 sensor for seven days.
224260758|NCT02450539|DRUG|Abemaciclib|Administered orally
224260759|NCT02450539|DRUG|Docetaxel|Administered IV
224323575|NCT04632654|BEHAVIORAL|A personalized Physical Activity intervention with fitness graded Motion Exergames (PAfitME)|A total of 7 weekly intervention sessions will occur in a period of 6 weeks. Week 0 is a setup session conducted at the participant's home, including equipment set up, safety instruction, personalized exergame prescription development, exergame physical activity practice, discussion of barriers and strategies, and Q\&A session. Weeks 1 and 2 are coaching sessions delivered by the interventionist using the FaceTime application in iPad, including exergame minutes and prescription review, exergame physical activity practice, discussion of barriers and strategies, and Q\&A session. Week 3 is a progress session conducted at the participant's home. The personalized exergame prescription will be adjusted. This session also will include exergame minutes review, exergame physical activity practice, discussion of barriers and strategies, and Q\&A session. Weeks 4 and 5 are the same as weeks 1 and 2. Week 6 is the final session. Exergame platform will be picked up at the participant's home.
224323576|NCT06152575|DRUG|Elranatamab|Elranatamab will be administered subcutaneously
224323577|NCT06152575|DRUG|Elotuzumab|Elotuzumab will be administered intravenously
224260760|NCT06154096|OTHER|Acute glucagon infusion|All subjects will undergo an amino acid infusion and pancreatic clamp during which they will have stable isotope turnover of glucose and alanine measured in two steady state periods - firstly, with low-dose glucagon infusion and secondly, with high-dose glucagon infusion
224260761|NCT05464186|BEHAVIORAL|Whole milk|Weekly home delivery of whole milk, daily text messages, monthly virtual visits
224260762|NCT05464186|BEHAVIORAL|Nonfat milk|Weekly home delivery of nonfat milk, daily text messages, monthly virtual visits
224260763|NCT02699463|DEVICE|Continous Positive Airway Pressure|CPAP refers to the application of positive airway pressure through a mask and tubing to splint a patients throat open at night. CPAP is considered standard treatment for OSA
224260764|NCT02699463|OTHER|Control Group|Standard sleep hygiene counseling as per published guidelines
224260765|NCT04379739|DRUG|Camrelizumab|camrelizumab 200mg, q3w, i.v., 2-4 cycles;
224323578|NCT06152575|DRUG|Pomalidomide|Pomalidomide will be administered orally
224323579|NCT06152575|DRUG|Dexamethasone|Dexamethasone will be administered orally
223773849|NCT05464147|DEVICE|DynamX Drug-Eluting Coronary Bioadaptor System|DynamX Drug-Eluting Coronary Bioadaptor System Implantation in Coronary Artery Lesion
224260766|NCT06627686|DIAGNOSTIC_TEST|Air way occlusion pressure|Predictive Value of Airway Occlusion Pressure, Maximal Inspiratory Pressure and Their Ratio for Successful Extubation in Patients with Traumatic Brain Injury
224260767|NCT04387786|DRUG|Dornase Alfa|nebulized in-line endotracheal dornase alfa co-administered with albuterol
224260768|NCT05606458|BEHAVIORAL|İntervention Group|Before the procedure, the baby was started to be breastfed (1st stimulus). The mother supported her baby's back and bottom with one hand. He started to touch by positioning the thumb of the other hand to prevent the baby's nose from being blocked, and the other fingers of the same hand to touch the baby's face (2nd stimulus). The mother started to talk to her baby with a gentle tone of voice, sometimes using sentences (lullaby, song, etc.) that she wanted to increase the volume of her voice (3rd stimulus). The mother was in the baby's sight (4th stimulus). Clothes were removed as much as possible for the smell of the mother's skin (5th stimulus). The baby's foot in the mother's arms was warmed in the nurse's hand for a minute. The area was determined, and the baby's heel was wiped with 70% alcohol. It was expected to dry. Heel piercing was performed while the stimuli continued. Heel blood was taken. When the evaluation period is complete, the process is over.
224260769|NCT02587663|PROCEDURE|Contrast-enhanced Magnetic Resonance Imaging|Undergo bilateral breast contrast enhanced MRI
223773850|NCT00452504|DRUG|SRA-444|
224260770|NCT02587663|PROCEDURE|Mammography|Undergo bilateral mammography
224323580|NCT06152575|DRUG|Bortezomib|Bortezomib will be administered subcutaneously or intravenously
224323581|NCT06152575|DRUG|Carfilzomib|Carfilzomib will be administered intravenously
223773851|NCT01643473|BEHAVIORAL|Adherence Intervention|Patients randomized to the TAI group will complete a tailoring survey at the baseline visit to identify the most salient adherence barriers to the individual, which will be used to create an individualized adherence profile. Following completion of the tailoring survey, patients will collaborate with the RA to identify the most suitable mix of intervention strategies for improving medication adherence (i.e., reminder aids, motivational interviewing, case management) that are matched to the barriers outlined on patients' individualized adherence profiles.
224323582|NCT05933005|DEVICE|D-kit/EF1|"D-kit/EF1 delivers interventions through online platforms and can be downloaded to smart devices through the iOS App store or Google Play Store. Games are specifically designed to assist children with delayed cognitive development in the acquisition of foundational cognitive skills.~The core technology of the D-kit/EF1 is the 'reinforcement technique', a technology used in traditional behavioral therapy. Specifically, D-kit incorporates the Discrete Trial Training (DTT) approach into its instructional content to facilitate the acquisition of basic cognitive skills."
224260771|NCT02587663|PROCEDURE|Therapeutic Conventional Surgery|Undergo breast conserving surgery
224260772|NCT02587663|PROCEDURE|Ultrasonography|Undergo bilateral whole-breast ultrasound
224260773|NCT02587663|PROCEDURE|Ultrasonography|Undergo targeted breast ultrasound
224260774|NCT02587663|OTHER|Gadolinium|Contrast agent used in MRI
224260775|NCT02647463|BEHAVIORAL|Attachment and Biobehavioral Catch-up (ABC)|
224260776|NCT04242823|DIAGNOSTIC_TEST|Automated visual evaluation|Participants will undergo primary hrHPV testing and if positive will be referred for VIA per Botswana and WHO guidelines. Participants will also undergo colposcopy, image capture for automated visual evaluation and biopsy at the time of VIA.
224260777|NCT02853643|DRUG|ASN002|Single dose study with food effect
223773852|NCT01643473|OTHER|Attention Control|Health education videos on topics unrelated to medication adherence, hypertension or type 2 diabetes
224260778|NCT02937935|BIOLOGICAL|Protocol Guided Renal Replacement Therapy|In the on-demand group patients would get dialysis only when patient fulfills absolute criteria requiring dialysis such as metabolic acidosis with ph\<7.2, hyperkalemia, refractory fluid overload (non-responsive to diuretics) or oliguria with urine output of less than 0.5ml/kg for more than 24-48 hours from the time of randomization.
224260779|NCT02937935|BIOLOGICAL|On Demand Renal Replacement Therapy|Patients to be randomized to the intervention as per standard of care
223773853|NCT05699863|BEHAVIORAL|Lifestyle intervention|"Lifestyle intervention in the form of individualised dietitian consultation with the overall goal of weight loss.~Intervention includes one initial consultation with a dietician of 1 hour and 15 minutes where participants receive a personalised diet-plan customised to the participants everyday life. After the initial consultation, the participants attend 10 follow-ups of about 25 minutes that are spread out over 4-5 months."
223773854|NCT02284828|DRUG|BIA 2-093|
224323583|NCT05933005|DEVICE|Sham group program|The sham program was designed to provide a similar experience as the experimental group by replacing the content within the same app. The control group uses the same mobile tablet device and accesses the app with the provided control group account. When accessing the app with the control group account, instead of the Adaptive Learning Lesson reflecting the principles of D-kit, educational animations created for educational purposes are provided.
224323584|NCT05882734|DRUG|M1774|In Phase 1b, M1774 will be administered as dosing regimen 1 or dosing regimen 2 until disease progression, death discontinuation criteria or any other reason. The selected dosing regimen of M1774 will be administered in all arms of Phase 2a.
224323585|NCT05882734|DRUG|Cemiplimab|Cemiplimab will be administered as an intravenous infusion every 3 weeks in all arms of Phase 1b and Phase 2a until disease progression, death discontinuation criteria or any other reason.
223773855|NCT04946513|OTHER|Muscle volumes were measured on pre- and postoperative MRI scans.|Muscle volumes were measured on pre- and postoperative MRI scans.
224323586|NCT03813407|DRUG|Sodium Zirconium Cyclosilicate (SZC) Reduced Dose Level|Sodium Zirconium Cyclosilicate (SZC) Dose: Paediatric dose based on body weight equivalent to an adult 2.5 g
224323587|NCT03813407|DRUG|Sodium Zirconium Cyclosilicate (SZC) Dose Level 1 (DL1)|Sodium Zirconium Cyclosilicate (SZC)Paediatric dose based on body weight equivalent to an adult 5 g
224323588|NCT03813407|DRUG|Sodium Zirconium Cyclosilicate (SZC) Dose Level 2 (DL2)|Sodium Zirconium Cyclosilicate (SZC) Paediatric dose based on body weight equivalent to an adult 10 g
224323589|NCT03813407|DRUG|Sodium Zirconium Cyclosilicate (SZC) Dose Level 3 (DL3)|Sodium Zirconium Cyclosilicate (SZC) Paediatric dose based on body weight equivalent to an adult 15 g
223773856|NCT02294292|DRUG|Carvedilol|Carvedilol started to achieve target HR (heart rate) reduction to 60/min, to a lowest permissible 50-55/ min ; provided Systolic Blood Pressure\> 90 mmHg.
223773857|NCT02294292|DRUG|Ivabradine|"Carvedilol started to achieve target HR (heart rate) reduction to 60/min, to a lowest permissible 50-55/ min ; provided Systolic Blood Pressure\> 90 mmHg.~If carvedilol is not tolerated,Ivabradine is added in a dose starting 2.5 mg BD to a maximum of 15 mg/day to ensure targeted heart rate reduction"
223773858|NCT02294292|PROCEDURE|Endoscopic Variceal Ligation|
223773859|NCT04632446|OTHER|Early diagnosis|Early diagnosis. Upgrade program implementation.
223773860|NCT02507089|BEHAVIORAL|Tailored sleep health education materials.|Tailored sleep health materials.
223773861|NCT02507089|BEHAVIORAL|Generic sleep health education materials.|
223773862|NCT00297453|BEHAVIORAL|Internet-based smoking treatment|All participants have access to an Internet-based self-help intervention that includes social support through message boards. All participants have access to 10 weeks of nicotine replacement treatment.
224260780|NCT01808651|DRUG|Fluoxetine|Administered orally
224260781|NCT05164354|OTHER|Aromatherapy|Aromatherapy: It will be applied to each child three times, three days in a row. Each application will be 20 minutes. The application time will be decided together with the patient. At the end of the three-day practice.
224260782|NCT05164354|OTHER|music concert|Music Concert: In this study, a music (lullaby, classical music) to be preferred by the patient or family Children are played for 20 minutes once a day. (morning or afternoon) for three days to help the child sleep. The volume of the music being played will be preserved. Aromatherapy: To be applied each child three times for three consecutive days. Each one The application will take 20 minutes. It will be time to implement The decision is made with the patient. Finally The patient's sleep quality will increase in three days of application. measured by actigraphy.
224323590|NCT03813407|DRUG|Sodium Zirconium Cyclosilicate (SZC) Dose During 28 Day Maintenance Phase|A 28-day period during which SZC is administered orally once daily (QD) to maintain normokalaemia. A dose titration regimen starting with QD administration of the dose of SZC the participants received TID in the CP will be studied in the MP and continued in the LTMP. The maximum dose that can be used is the calculated body weight equivalent to the 15 g adult dose
223773863|NCT00297453|BEHAVIORAL|Individual Counseling|Six individual counseling sessions are provided over a 12 week treatment period. Participants also have access to a 10-week nicotine replacement treatment.
224260783|NCT03151577|PROCEDURE|XEN® Gel Stent implantation|Minimally invasive glaucoma surgery (MIGS) which consists of implanting a XEN® Gel Stent in the irido-corneal angle of the eye to drain the aqueous humour in the sub-conjunctival space to lower the IOP.
223773864|NCT00297453|BEHAVIORAL|self-help|Participants receive a self-help manual and have access to a 10 nicotine replacement treatment.
224260784|NCT05811793|DRUG|Tislelizumab and Bevacizumab|Tislelizumab is a drug material authorized for marketing in China. Tislelizumab will be administered off-label in this study. Subjects with recurrent GBM will receive intrathecal tislelizumab every 3 weeks for six times. Intrathecal administration of Bevacizumab will be performed via Ommaya reservoir or intraventricular catheter.
224260785|NCT00644137|DRUG|pregabalin|Help stop smoking
224260786|NCT00644137|OTHER|cigarettes|help stop smoking with study medication
224260787|NCT03219853|DIETARY_SUPPLEMENT|selenium enriched parsnips|Parsnips which have been grown in a selenium enriched environment
224323591|NCT06555029|BEHAVIORAL|EHR Changes|"Practice-Level:~Changes to the Epic EHR system will include the AAAC process to ask 5 oral health questions, advise for dental attendance, assess the type of referral, and connect with referral and resources"
224323592|NCT06555029|BEHAVIORAL|Medical Staff EHR Training, Clinician CSM theory-based didactic education and skills training|"Provider-Level:~Medical staff to complete EHR training and then deliver the ask, advise, assess, connect (AAAC) strategies to screen, refer, and provide resources for oral health.~Clinician will receive Common-Sense Model of Self- Regulation (CSM) and Social Cognitive Theory based education and skills training for the physician/nurse practitioner to communicate core OH facts to the patient and provide reinforcement of the importance of dental visits to overall health. Clinicians will also document the encounter in EHR."
223773865|NCT00977262|OTHER|High saturated fat shake|milkshake containing 95 gram of fat, high percentage of saturated fat
223773866|NCT00977262|OTHER|High monounsaturated fat shake|milkshake containing 95 gram of fat, high percentage of monounsaturated fat
223773867|NCT00977262|OTHER|High polyunsaturated fat shake|milkshake containing 95 gram of fat, high percentage polyunsaturated fat
223773868|NCT00598689|DRUG|0.3% hypromellose|0.3% hypromellose four times a day for 5 days prior to LASIK surgery
223773869|NCT06054646|BIOLOGICAL|Amnion collagen|A collagen extract sourced from the human amniotic membrane
223773870|NCT06054646|BIOLOGICAL|Platelet-rich plasma|Autologous preparation of PRP
223773871|NCT02864797|OTHER|Health related quality of life collected via CHES|Health related quality of life (QoL) is collected at each follow-up visit using tablets computer and CHES software. Thus, QoL's results are directly presented to clinicians via the CHES, in order to be considered as part of the supportive care strategy at the end of the study
223773872|NCT01169857|DRUG|Velcade|Velcade at 1.3 mg/m2, on days 1, 4, 8 and 11 (=1 cycle). The study will involve 3 cycles of Velcade therapy.
223773873|NCT03542227|OTHER|First-void urine collection|Collection of ca. 20 ml of first-void urine with the Colli-PeeTM device (Novosanis) during visit at the Centre for the Evaluation of Vaccination.
224260788|NCT03219853|DIETARY_SUPPLEMENT|Conventional parsnips|Parsnips which have been grown in a conventional environment
224260789|NCT01943045|BIOLOGICAL|NGM282|
224260790|NCT01943045|OTHER|Placebo|
224323593|NCT06555029|BEHAVIORAL|Standard ADA Oral Health Training|"Provider-Level:~Clinician only: Clinicians will receive standard American Dental Association (ADA) based oral health hygiene training (brushing, flossing, fluoridated water, cleaning dentures) and asked to follow their current oral health care with their patients. The usual care currently is to address oral health issues if the patient complains or has a question. The clinicians will not have skills training nor visual resources for the patient encounter."
223773874|NCT03542227|OTHER|Blood draw|Blood sample collection (5-10 cc) by a study nurse of Centre for the Evaluation of Vaccination.
223773875|NCT02343458|DRUG|GFF MDI (PT003)|Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (GFF MDI; PT003); Glycopyrronium and Formoterol Fumarate Inhalation Aerosol administered as 2 inhalations twice-daily (BID)
223773876|NCT02343458|DRUG|FF MDI (PT005)|Formoterol Fumarate Metered Dose Inhaler (FF MDI; PT005); Formoterol Fumarate Inhalation Aerosol administered as 2 inhalations twice-daily (BID)
223773877|NCT02343458|DRUG|GP MDI (PT001)|Glycopyrronium Metered Dose Inhaler (GP MDI; PT001); Glycopyrronium Inhalation Aerosol administered as 2 inhalations twice-daily (BID)
223773878|NCT02343458|DRUG|Placebo MDI|Placebo (matching) for GFF MDI, FF MDI, and GP MDI administered as 2 inhalations twice-daily (BID)
223773879|NCT04691479|BEHAVIORAL|Motivational Interview (MI) & Adherence Follow-Up|"1. MEntA: Educational \& Training Program~2. Stratification: Identification of Personal Variables (Age, Level of study, Work status, preference of care attention, digital behaviour)~3. Adherence evaluation: Evaluation of Perceived Competence, Quality of Life, Mood, Activities, Social relations and Social Support~4. Identification of Care plan and Schedule next visits~5. Follow-up D30-D60-D90-D180 depending of the care plan, through the channel that belong for each care plan"
223773880|NCT04691479|BEHAVIORAL|Adherence Follow-Up|The nurse takes the compliance of the CPAP device, and ask to the patient if he had some problems.
223773881|NCT03379025|OTHER|Electronic cigarette|electronic cigarette and cartridge refills (also known as pods)
223773882|NCT03540927|BEHAVIORAL|PM+ for entrepreneurs|The intervention arm will receive 5 weekly face-to-face group sessions of Problem Management Plus(PM+ for entrepreneurs). Duration of each session is 2 hours. Session 1 orients participants to the intervention with motivational interviewing techniques to improve engagement,provides information about common reactions to adversity, and trains participants in a basic stress management strategy (slow breathing). Session 2 addresses a participant-selected problem using problem-solving techniques. Sessions 3 and 4 support participants' continued application of problem solving, behavioral activation, and stress management and introduce strategies to strengthen social support networks. In session 5, education about retaining intervention gains and self-care are provided and all learned strategies are reviewed.
223773883|NCT03540927|OTHER|Cash transfer to the Entrepreneurs|The entrepreneurs in the control arm will receive cash transfer only for their businesses.
223773884|NCT01305967|DRUG|SB injection|Infusion SBinjection of 21.87ml/m\^2, Intravenous route, 16times for 2.5 months
224260791|NCT02764853|BEHAVIORAL|Experimental Intervention (STEP-AD)|This experimental intervention will consist of 10 sessions- 1 session of Lifesteps (problem solving for medication adherence) and 9 sessions of an intervention specifically tailored for Black women living with HIV to address trauma/abuse, racial discrimination, HIV stigma, and gender roles expectations in order to improve health outcomes (e.g., medication adherence, viral load), increase resiliency, and enhance adaptive coping strategies.
224260792|NCT02764853|BEHAVIORAL|Enhanced Treatment as Usual (E-TAU)|Participants assigned to the E-TAU condition will receive 1 session of Lifesteps (problem solving for medication adherence) and appropriate services and referrals as needed
223773885|NCT05014009|BEHAVIORAL|FIFA11+ and multidirectional training (MD)|"This intervention initially contains a shortened version of the FIFA11+ injury prevention program including running (straight, hip out, hip in, jump-run-ups), strengthening (planks, squats, nordic hamstring curls), and single-leg balance exercises. The initial part is followed by COD technique modification training, which contains exercises aimed at improving COD technique (safer and more effective body re-direction, use of penultimate step, avoiding knee valgus) and COD braking and re-acceleration impulse.~The duration of each training session is 25-30 minutes. The training is carried out twice per week under supervision with supervisors providing feedback to participants regarding their COD technique. Participants are encouraged to complete a third training session in their own time."
223773886|NCT05014009|BEHAVIORAL|FIFA11+ and linear sprint training (MD)|"This intervention initially contains a shortened version of the FIFA11+ injury prevention program including running (straight, hip out, hip in, jump-run-ups), strengthening (planks, squats, nordic hamstring curls), and single-leg balance exercises. The initial part is followed by a linear sprint training, which contains exercises aimed at improving sprint technique (e.g. sagittal arm and leg movement, trunk lean), use of the stretch-shortening cycle, leg stiffness and propulsive impulse .~The duration of each training session is 25-30 minutes. The training is carried out twice per week under supervision with supervisors providing feedback to participants regarding their sprinting technique. Participants are encouraged to complete a third training session in their own time."
223773887|NCT02326103|DRUG|Ciprofloxacin|Comparison of ciprofloxacin with placebo in alcoholic hepatitis
223773888|NCT02326103|DRUG|Placebo|
223773889|NCT05189574|PROCEDURE|Endoscopic negative pressure therapy|Endoscopic placement of a sponge in/at staple line leaks under negative pressure.
223773890|NCT04209582|DEVICE|measurement of TcPO2 with skin electrode|measurement of TcPO2 with skin electrode
223773891|NCT03936491|DRUG|Methylphenidate|Methylphenidate is a central nervous system stimulant used for the therapy of attention deficit disorder and narcolepsy.
223773892|NCT03936491|DRUG|Atomoxetine|Atomoxetine is a medication used to treat attention deficit hyperactivity disorder (ADHD).\[6\] Use is only recommended in those who are at least six years old.\[6\] It is taken by mouth.\[6\]
223773893|NCT01091311|DEVICE|Blephasteam|Eye lid warming goggles
223773894|NCT01265953|DRUG|SFN-rich broccoli sprout extract capsules|Four weeks SFN-rich broccoli sprout extract (BSE) capsules: 200µmol of SFN, 2 capsules (1 capsule B.I.D.) daily
223773895|NCT01265953|DIETARY_SUPPLEMENT|Gelatin capsule containing microcrystalline cellulose.|Four weeks placebo capsules: 2 capsules (1 capsule B.I.D.) daily
223773896|NCT01151553|DEVICE|CRT Therapy|Screen for enrollment criteria, consented, echocardiogram and electrocardiogram performed, demographics reviewed, obtain blood sample, pre-operative QOL questionnaire and 6 minute hall walk
223773897|NCT05875324|DEVICE|virtual reality application|VR was used for 10 minutes a day in the sitting position for three weeks, twice a week, by watching a walking video before beginning the exercises. Patients were instructed to imagine themselves walking while concentrating on walking and watching the video. The patients were asked to stop watching video by removing their VR glass if they experienced discomfort such as dizziness and nausea during the VR application. They were told to continue watching the video when the discomfort was gone. In cases where similar discomforts recurred, the treatment was terminated.
224260793|NCT01108445|DRUG|Everolimus|Subjects in this treatment arm will receive everolimusRAD001 10 mg orally once daily by mouth on days 1 through 42 for each 42 day cycle.
223773898|NCT05875324|OTHER|exercise|activities included sitting on the side of the bed and mobilizing in and out of the room using a walker. Patients were provided an exercise program for at-home practice.
224260794|NCT01108445|DRUG|Sunitinib|50 mg daily by mouth on days 1 through 28 of each 42 day cycle.
224260795|NCT06370104|BEHAVIORAL|Brief Cognitive Behavioral Therapy for Suicide Prevention|see arm description
224260796|NCT06370104|BEHAVIORAL|Living under control|see arm description
224260797|NCT04188392|DRUG|Pimavanserin|pimavanserin tablet
223773899|NCT06532682|DRUG|dapagliflozin|dapagliflozin 5 MG/10 MG once daily
223773900|NCT06532682|DRUG|ACE inhibitor|ACE inhibitor
223773901|NCT01641887|OTHER|Decision Aid|Patients will use a decision aid administered on a computer.
223773902|NCT02648698|DRUG|Antibiotics|Levofloxacin Tab and Tinidazole Tab are combined in the antibiotic group
223773903|NCT06280365|OTHER|Mulligan Mobilization with Movement Technique|Mobilization Technique
223773904|NCT03103529|OTHER|Active Rehabilitation|
223773905|NCT04877301|DEVICE|Ultrasound guidance|Ultrasound guidance used to facilitate insertion of PIV catheter
223773906|NCT04877301|PROCEDURE|Non-ultrasound guidance|Ultrasound guidance will not be used for insertion of PIV catheter
223773907|NCT01640301|BIOLOGICAL|Aldesleukin|Given SC
223773908|NCT01640301|DRUG|Cyclophosphamide|Given IV
223773909|NCT01640301|DRUG|Fludarabine Phosphate|Given IV
223773910|NCT01640301|OTHER|Laboratory Biomarker Analysis|Correlative studies
223773911|NCT01640301|BIOLOGICAL|WT1-Sensitized Allogeneic T-Lymphocytes|Given IV
223773912|NCT06534515|DEVICE|Tomatis auditory stimulation|Traditional Tomatis Method Protocol
223773913|NCT02451657|OTHER|No Intervention|No intervention was administered in this study
223835660|NCT06634056|DRUG|Pentoxifylline|Pentoxifylline 400 mg orally three times a day and α-Tocopherol IU orally two times a day on day one of radiotherapy and continue treatment for 6 months.
224260798|NCT02066038|DRUG|Erlotinib|150mg po on days 2-15 of each 3 week cycle for 4 cycles and 150mg po per day after 4 cycles until disease progression
224260799|NCT00585286|DEVICE|10,600 nm fractional carbon dioxide laser system|1-3 laser treatments using 20-100 millijoules (mJ) with 100-400 microscopic treatment zones (MTZ)/cm2 per pass and total density of 600-1200 MTZ/cm2
224260800|NCT00932763|DRUG|Amlodipine besylate|10 mg tablets (Torrent Pharmaceuticals, India)
224260801|NCT00932763|DRUG|Norvasc|10 mg dose (Pfizer, USA)
223773914|NCT01716247|OTHER|Mammography (CESM) and MRI|The study consists of the addition of a single contrast enhanced digital mammography examination (CESM) to the routine screening of a woman at increased risk for breast cancer who is also having a breast MRI. Breast MRIs will be read by the radiologist reading breast MRIs on any given day. CESM is a dedicated system, derived from a standard digital mammography unit modified to deliver the dual or multiple energy exposures and visualization of combined images after IV contrast administration. If the patient is having her routine mammogram within 30 days of her MRI, CESM can replace that mammogram Patients will be randomly assigned to one of the radiologists trained to interpret CESM. That radiologist will read the CESM blinded to the results of the breast MRI.This process will be monitored by the research assistant No radiologist will read both the breast MRI and CESM on the same patient.
223773915|NCT01361412|BIOLOGICAL|ToleroMune Ragweed|Intradermal administration 1x8 administrations, 2 weeks apart
223773916|NCT01361412|BIOLOGICAL|Placebo|Intradermal injection 1x8 administrations, 2 weeks apart
223773917|NCT02791139|OTHER|Cardiovascular Magnetic Resonance Imaging (MRI)|Cardiovascular MRI uses interaction of the magnetic properties of body tissues with strong magnetic fields to create heart images.
223773918|NCT02791139|OTHER|Echocardiography|To measure heart chamber size, heart function, blood vessel size and blood vessel function. These measurements will help us understand the type and severity of heart failure.
223773919|NCT02791139|OTHER|Tonometry|Tonometry is a noninvasive method to obtain arterial pressure waveform
223773920|NCT02791139|OTHER|Genetic Testing (Blood)|The blood will be stored for genetic tests and development of cell lines to study genetic risks for aging related diseases and cardiovascular disease.
224260802|NCT04593160|DRUG|Diclofenac potassium- acetaminophen combination|Preoperative single dose of diclofenac potassium(50mg)- acetaminophen(1000mg) combination
224260803|NCT04593160|DRUG|Diclofenac potassium|Preoperative single dose of diclofenac potassium(50mg)
224260804|NCT04593160|DRUG|Placebo|Preoperative single dose of placebo
224260805|NCT00625222|PROCEDURE|transcranial direct current stimulation|1mA, 15 Minutes, constant direct current
223773921|NCT02791139|OTHER|Hand-Grip Strength Measurement|We will measure your hand grip strength using a standard hand dynamometer which is a portable meter that you will use your hands to press on.
223773922|NCT02791139|OTHER|Body Fat Mass Analysis|Body composition will be analysed by a body composition analyser machine onto which you will have to stand on.
223773923|NCT03096548|BEHAVIORAL|Sun Safety Ink! Program|The intervention will be comprised of an online skin cancer prevention training for all tattoo artists of participating studios. The training will include skin cancer rates and risk factors, tattoo rates, recommendations for sun protection practices, a rationale for the relationship of tattoo care and sun safety, and recommended communication strategies for artists to communicate skin cancer prevention to their clients. Additional printed materials (tip-card for clients, posters) to be displayed in tattoo studios, a Sun Safety Ink! website, and social media messages for tattoo studios' Facebook and Pinterest pages will be provided.
223773924|NCT03096548|BEHAVIORAL|Attention Control|Studios and artists in this attention control group will not receive the Sun Safety Ink! program. They will continue to provide standard aftercare instructions to clients. The program will be provided to them at the end of the study.
223773925|NCT01389908|DRUG|olanzapine|Patients will receive doses within the range of 280 mg to 405mg OP Depot, according the physician's judgment, on a 3-week interval.
223773926|NCT03884283|DEVICE|FIBERGRAFT BG Matrix|Subjects who meet the criteria for entrance into the study will undergo posterolateral fusion using FIBERGRAFT® BG Matrix in combination with autograft and bone marrow aspirate (BMA)
223773927|NCT03047616|OTHER|Blood and Urine Collection|
223773928|NCT01877447|DEVICE|Transcranial Direct Current Stimulation|Current Stimulation with cathodal stimulation over right dorsolateral prefrontal cortex. Anodal stimulation over left deltoid region
223773929|NCT02397395|DRUG|Simeprevir (SMV) 150 mg|Simeprevir (SMV) 150 milligram (mg) capsule orally, once daily for a duration of 12 weeks.
223773930|NCT02397395|DRUG|Daclatasvir (DCV) 60 mg|Daclatasvir (DCV) 60 mg tablet, orally, once daily for a duration of 12 weeks.
223773931|NCT06138574|DRUG|Dexmedetomidine|After the induction of general anesthesia, one group (Group: 1) will be administered dexmedotomidin infizyon and group (Group :2)remifentanil
223773932|NCT06138574|DRUG|Remifentanil|Remifentanil
223835661|NCT06634056|OTHER|Placebo|One placebo orally three times a day and another placebo orally two times a day on day one of radiotherapy and continue treatment for 6 months.
224260806|NCT02541227|DRUG|Cerebrolysin|Cerebrolysin dosage, frequency and duration follows local clinical practice in accordance with the terms of the local marketing authorization
224260807|NCT06455332|OTHER|Optic nerve MRI sequence|Systematic optic nerve MRI sequence during the CIS diagnosis work-up. This sequence is not done systematically and not recommended for now (except in case of acute ON). The interventional nature of the study remains minimal
224260808|NCT04525027|DIAGNOSTIC_TEST|intra-abdominal pressure in severe acute pancreatitis|daily intra abdominal pressures in patients admitted to ICU will be measured and noted for intial 5 days and followed up until end outcome
224260809|NCT00235027|OTHER|Adverse Drug Event Monitoring|The intervention in this study is the presentation of medication safety alerts in the electronic medical record to improve patient outcomes and safety.
224260810|NCT05297227|PROCEDURE|Non surgical periodontal Therapy|Non-surgical periodontal therapy comprising oral hygiene instruction and motivation, professional mechanical plaque removal, and subgingival instrumentation will be performed. It consists in the use of an ultrasuond (piezoeletric device) and manual curettes.
224260811|NCT01937182|DRUG|Citalopram|Citalopram 10-40 mg per day administered orally
224260812|NCT01937182|DRUG|Placebo|1/2-2 tablets per day with no intrinsic drug activity
224260813|NCT05031260|DEVICE|applying COMORAL®|The individuals in the experimental group will be asked to come to the clinic to use COMORAL® three times a day, every day except Saturday and Sunday.
224323594|NCT04638660|DRUG|Phentolamine Ophthalmic Solution 0.75%|0.75% phentolamine ophthalmic solution (Nyxol), a non-selective alpha-1 and alpha-2 adrenergic antagonist
224323595|NCT04638660|DRUG|Phentolamine Ophthalmic Solution Vehicle (Placebo)|Topical sterile ophthalmic solution
224323596|NCT06463678|DRUG|IVIEW-1201|Shake well before use and administer 1 drop into the conjunctival sac every 1 hour on Day 1, 2 and 3 when awake; every 2 hours on Day 4-14 when awake; 6 times a day on Day 15-21 with a dosing interval of at least 2.5 hours; 4 times a day on Day 22-28 with a dosing interval of at least 3 hours. The time course of administration is 28 days. After 14 days of dosing, if a patient reaches the primary and secondary endpoints, the investigational drug can be discontinued at the discretion of the investigator.
223773933|NCT05203029|OTHER|Online exercise|Patients in each group will be added to the specific group on Whatsapp, and the schedule and information about the exercise will be explained there. Furthermore, patients will be joined to particular pages on Instagram, and exercises will be performed through Live on that pages. All the patients will exercise for 12 weeks, two or three times every week.
223773934|NCT03028168|OTHER|Yôga|Intervention observing respiratory frequency (RF) of 15- 20 respiratory cycles per minute (rcpm). A standardized 7-minute final relaxation .
224323597|NCT06463678|DRUG|NATACYN®|Shake well before use and administer 1 drop into the conjunctival sac every 1 hour on Day 1, 2 and 3 when awake; every 2 hours on Day 4-14 when awake; 6 times a day on Day 15-21 with a dosing interval of at least 2.5 hours; 4 times a day on Day 22-28 with a dosing interval of at least 3 hours. The time course of administration is 28 days. After 14 days of dosing, if a patient reaches the primary and secondary endpoints, the investigational drug can be discontinued at the discretion of the investigator.
224323598|NCT04175600|DRUG|Selexipag|Selexipag tablet will be administered orally.
223773935|NCT03028168|OTHER|Breathing technique|Intervention uses diaphragmatic breathing, observing slow respiratory frequency, between 5-8 rcpm. A standardized 7-minute final relaxation.
223773936|NCT03028168|OTHER|Control group|Patients will be oriented to keep their pharmacological routine and daily activities, with no structured exercises. They will have to return to the hospital for post-testing after 8 weeks from randomization
223773937|NCT02842060|BEHAVIORAL|myDEx|myDEx will consist of a 6-session online program. Cognizant of challenges maintaining users' attention in a web application and to facilitate delivery through a smartphone, the investigators will design each session to be no more than 20 minutes in length. In the course of these 6 sessions, participants will have a total of 120 minutes of intervention exposure. Across sessions, the investigators will emphasize the importance of sexual decision-making across different partner types, help men consider what type of relationship(s) they want, and align these relationship desires with safer sex practices.
223773938|NCT02842060|BEHAVIORAL|NTHP|The investigators will create a 6-session attention-control comparison to match the intervention in time and attention yet have non-tailored and non-interactive content (NTHP). NTHP will include HIV/STI information currently available on sex education websites. The attention-control condition allows the investigators to avoid confounding due to content and ensures that all participants receive some HIV prevention content given their high vulnerability to HIV. Further, this comparison will help critically examine the extent to which tailoring increases the acceptability to the program, above and beyond having a non-tailored, non-interactive intervention.
223773939|NCT02717949|DRUG|sofosbuvir/ledipasvir|sofosbuvir ledipasvir fixed dose combination given once a day by mouth
223773940|NCT02717949|DRUG|sofosbuvir|sofosbuvir 400 mg given one a daily orally and weight-based ribavirin given twice a day orally
223773941|NCT02717949|DRUG|Ribavirin|ribavirin 1200 mg given orally in divided dose for those \>75kg and 1000 mg in divided dose for those \<75 kg.
224323599|NCT04175600|DRUG|Placebo|Matching placebo tablets will be administered orally.
224323600|NCT05317416|DRUG|Elranatamab|BCMA-CD3 bispecific antibody
224323601|NCT05317416|DRUG|Lenalidomide|Immunomodulatory drug
224323602|NCT05317416|DRUG|Lenalidomide|Immunomodulatory drug
224323603|NCT05317416|DRUG|Elranatamab|BCMA-CD3 bispecific antibody
224323604|NCT05206630|OTHER|ED Physical Therapy|All ED Physical Therapy treatment classifications involve a combination of exercise, range of motion, education, prognostic guidance, and reassurance. Patients are provided with an individualized home exercise plan based on their matched treatment classification and/or active rest.
224323605|NCT02138734|BIOLOGICAL|BCG+N-803( 50mg BCG/ Instillation+ N-803( 400 μg/instillation). )|"BCG and N-803 will be mixed together (with saline) and administered via intravesical instillation weekly for 6 consecutive weeks for induction. Phase IIb includes maintenance treatment consisting of BCG+N-803 for 3 consecutive weeks at 3, 6, 12, 18, 24,30 and 36 months.~An additional 6 week re-induction of BCG+N-803 for patients with eligible disease at 3 months in phase IIb is included."
224323606|NCT02138734|BIOLOGICAL|BCG( 50mg/Instillation)|"BCG will be administered via intravesical instillation weekly for 6 consecutive weeks for induction. Phase IIb includes maintenance treatment consisting of BCG for 3 consecutive weeks at 3, 6, 12, 18, 24, 30 and 36 months.~An additional 6 week re-induction of BCG for patients with eligible disease at 3 months in phase IIb is included."
223773942|NCT04101799|BEHAVIORAL|For Our Children's Sake|Parental support with the aim to support positive parenting and promote healthy child development. Conducted in group-format with weekly 2.hour sessions conducted by trained group leaders according to a programme manual.
223773943|NCT04101799|OTHER|Active control|Participating in everyday activities that may include parenting activities in the control prisons
223773944|NCT02855502|DRUG|Prednisolone|
223773945|NCT02855502|DRUG|Placebo|
223773946|NCT00377767|BEHAVIORAL|To change structure and roles of primary care teams to optimize prevention of obesity|
223773947|NCT06213597|OTHER|routine swallowing rehabilitation|Routine swallowing rehabilitation training mainly included oral and facial muscle training, ice stimulation therapy, Mendelssohn maneuver training, and tongue root resistance training. The subjects were treated twice a day, Monday through Saturday, for 20 min each time for 2 weeks. All operations were performed by the same trained and qualified professional rehabilitation therapist.
223773948|NCT06213597|DEVICE|real repetitive transcranial magnetic stimulation|In the rTMS group, 5 Hz rTMS was applied to the hot spot of the supraglottic motor cortex of the affected hemisphere at a treatment intensity of 80% resting motor threshold for 10 min, with a total of 250 pulses (with an interval of 11 s for every 1 s of continuous stimulation), and the treatment was performed once a day for 6 d per week for 2 weeks.
223773949|NCT06213597|DEVICE|sham repetitive transcranial magnetic stimulation|The sham rTMS group supplemented pseudomagnetic stimulation at the hotspot of the representative area, tilted the magnetic stimulation coil at 90°, and the same noise was emitted by the instrument during the treatment, but no stimulation was performed, and the group was treated once a day, 6d per week, for 2 weeks.
223773950|NCT05684887|OTHER|Digital based contact tracing|"* Listing of contacts by SARS-CoV-2 positive individuals in Mamal Pro app + verification and validation by a health care worker.~* Immediate access to the contact list in Mamal Pro once validated by the health care worker.~* Contacts are immediately notified by text message automatically sent to all contacts with phone numbers and later called by the HCWs responsible for carrying out the contact tracing at the district level.~* Contacts will be invited to go to the nearest testing facilities/units to get tested.~* Those who are unable or refuse to come for testing are followed up by phone for 10 days for the occurrence of COVID-19 symptoms.~* Information about the contact tracing process during communication with contacts are recorded in Mamal Pro digital contact tracing module."
223773951|NCT01918345|BEHAVIORAL|Home-based Physical Activity Program with Health Coach|This arm will receive either a trained CDE or R. Kin as a health coach and a home-based physical activity program for 6 months. Health coaches will provide one-on-one motivational interviewing (MI) and goal-setting, and will account for baseline fitness, resources, childcare, and breastfeeding, to be undertaken at participants' homes or in their communities. Prescriptions will be based on minimum recommendations for moderate-intensity exercise for postpartum women. Participants will maintain at least 150 min/week of moderate activity at a target heart rate of 30-80% with a perceived exertion of 12-15 on the Borg Scale. They will also be counseled on resistance training and pelvic floor exercises. They will receive regular telephone-based coaching to advance goals. Phone-calls will be administered on a weekly basis during weeks 2-8 of the intervention, biweekly basis on weeks 10-12, and monthly basis on weeks 16-24.
223773952|NCT01918345|BEHAVIORAL|Home-based Low-GI Diet Program with Health Coach|This arm will receive a trained CDE health coach and a home-based low-GI diet program for 6 months. Health coaches will provide baseline education during a one-on-one visit and use MI to introduce the dietary intervention. Low GI education will be layered on top of current standard care, which asks women to consume a diet comprised of 45-65% carbohydrates (25 g of dietary fibre), 10-30% protein, and 25-35% fat. As per standard care at the DEPs, this intake will be divided into 3 meals and 2 to 4 snacks. Resources for women will include a low GI dietary food substitution list, a recipe booklet, and a tip sheet on how to lower dietary GI. Women will receive regular telephone-based coaching to advance goals. Phone-calls will be administered on a weekly basis during weeks 2-8 of the intervention, biweekly basis on weeks 10-12, and monthly basis on weeks 16-24.
223773953|NCT05631067|BEHAVIORAL|Remote blood pressure monitoring|Participants will receive a blood pressure monitor to check daily BPs for two weeks post partum
224323607|NCT04481373|BEHAVIORAL|THRIVE|"The ACT components (3-3.5 hours) will focus on clarifying patient values and goals and identifying obstacles that may be getting in the way of living a rich life. Short-and long-term effects of avoidance will be discussed (e.g., avoidance reduces immediate contact with distressing experiences and provides short-term relief but leads to greater dysfunction in long run). Patients will be taught acceptance, mindfulness, and perspective taking to help patient cope with difficult emotions and thoughts that may interfere with living a values-driven life. Individuals will also be encouraged to examine the costs of stigmatization on their life (e.g. avoidance of medical care, sense of isolation).~Education will include medical information about HIV, services available at the clinic, and health needs related to comorbidities. This content to be delivered in 30 minutes."
223773954|NCT05631067|DIAGNOSTIC_TEST|NT proBNP assessment|Participants will have biomarker assessment at 0-2 days postpartum
223773955|NCT01639001|DRUG|Crizotinib|250 mg two times daily \[BID\], oral, on a continuous daily dosing schedule. Cycles are defined in 21 day periods.
223773956|NCT01639001|DRUG|Pemetrexed/Cisplatin|Option 1: Pemetrexed/Cisplatin; Pemetrexed, 500 mg/m\^2, will be administered by intravenous infusion over 10 minutes or according to institutional administration timing on Day 1 of a 21-day cycle. Cisplatin, 75 mg/m\^2 will be administered by infusion after adequate hydration according to institutional practices beginning approximately 30 minutes after the end of the pemetrexed infusion. Pemetrexed and cisplatin will be repeated every 3 weeks for a maximum of 6 cycles.
223773957|NCT01639001|DRUG|Pemetrexed/Carboplatin|Option 2: Pemetrexed/Carboplatin. Pemetrexed, 500 mg/m\^2, will be administered by intravenous infusion over 10 minutes or according to institutional administration timing on Day 1 of a 21-day cycle. Carboplatin, at a dose calculated to produce an AUC of 5 or 6 mg.min/mL will be administered by infusion according to institutional practices beginning approximately 30 minutes after the end of the pemetrexed infusion. Pemetrexed and carboplatin will be repeated every 3 weeks for a maximum of 6 cycles.
223773958|NCT06067074|PROCEDURE|Volar Locking Plate|Surgery
223773959|NCT06067074|PROCEDURE|Plaster Cast|Non-operative treatment with a plaster cast
223773960|NCT00004129|RADIATION|brachytherapy|
223773961|NCT00004129|RADIATION|phosphorus P32|
223773962|NCT01954654|DEVICE|Custom-made compression sleeve and -gauntlet|Device: Compression garments worn for a minimum of six hours per day
223773963|NCT01954654|OTHER|Educational information, recommendation and instruction|Educational information and recommendations about lymphedema and skin care. Instruction in physical exercises to enhance the lymph flow
224260814|NCT04685291|PROCEDURE|Ultrasound-guided block of the supraclavicular nerves|The supraclavicular nerves (SCN) arise from the 3rd and 4th roots of the spinal nerves. After emerging from the spine, they run at the rear margin of the sternocleidomastoid muscle and divide into their three terminal branches. With a high-resolution Ultrasound (US)-probe they can be visualized as a grape-like structure under the skin. At this location, patient's skin is disinfected and covered with a sterile perforated blanket. The US-probe is covered with a sterile sheath. The patient is positioned as comfortably as possible so that the broken clavicle is not mobilized. SCN are shown by US and a 0.5 mm needle is advanced through the patient's skin in order to direct it to the nerves under US-guidance. Both the nerves and the needle are permanently visualized. As soon as the needle tip is placed next to the SCN, 2-3 millilitres of a long-acting LA are injected. The distribution of the LA around the nerves is controlled.
224323608|NCT04481373|OTHER|Treatment as Usual|Patients get usual care at the hospital. Service linkage workers (SLWs) meet with all hospitalized PWH and cover educational aspects of the care.
224323609|NCT04457310|DRUG|CVL-562 (PF-06412562) 1 mg|Each subject will complete 5 test visits each involving the administration of CVL-562 (PF-06412562) (at different doses) or placebo. Each test visit will be separated by at least 48 hours (six half-lives of CVL-562 (PF-06412562)).
224323610|NCT04457310|DRUG|CVL-562 (PF-06412562) 4 mg|Each subject will complete 5 test visits each involving the administration of CVL-562 (PF-06412562) (at different doses) or placebo. Each test visit will be separated by at least 48 hours (six half-lives of CVL-562 (PF-06412562)).
223773964|NCT02114242|OTHER|CSF, blood and urine sampling|PSP and MSA patients will receive CSF and blood sampling at two study visits (baseline and after 12 months).
223773965|NCT02114242|OTHER|clinical measures of disease severity and progression|Questionnaires (quality of life, motricity scales, cognitive scales, depression scales, scale of sleep quality)
223773966|NCT05952505|BIOLOGICAL|Inactivated SARS-CoV-2 vaccine coadministered with vricella vaccine|Subjects will be coadministered with inactivated SARS-CoV-2 vaccine and varicella vaccine.
223773967|NCT05952505|BIOLOGICAL|Inactivated SARS-CoV-2 vaccine coadministered with MMR|Subjects will be coadministered with SARS-CoV-2 vaccine and MMR.
224323611|NCT04457310|DRUG|CVL-562 (PF-06412562) 15 mg|Each subject will complete 5 test visits each involving the administration of CVL-562 (PF-06412562) (at different doses) or placebo. Each test visit will be separated by at least 48 hours (six half-lives of CVL-562 (PF-06412562)).
224323612|NCT04457310|DRUG|CVL-562 (PF-06412562) 25 mg|Each subject will complete 5 test visits each involving the administration of CVL-562 (PF-06412562) (at different doses) or placebo. Each test visit will be separated by at least 48 hours (six half-lives of CVL-562 (PF-06412562)).
223773968|NCT05952505|BIOLOGICAL|Inactivated SARS-CoV-2 vaccine administered alone|Subjects will be immunized with inactivated SARS-CoV-2 vaccine alone
224323613|NCT04457310|OTHER|Placebo|Each subject will complete 5 test visits each involving the administration of CVL-562 (PF-06412562) (at different doses) or placebo. Each test visit will be separated by at least 48 hours (six half-lives of CVL-562 (PF-06412562)).
224323614|NCT06641414|DRUG|Lisaftoclax (APG-2575)|QD, oral administration.
224323615|NCT06641414|DRUG|Azacitidine Injection|QD, hypodermic or intravenous injection.
224323616|NCT06641414|OTHER|Placebo|QD, oral administration.
224323617|NCT06026098|BEHAVIORAL|Artificial Intelligence|Participants will use the Artificial Intelligence assistance tool for case reports.
224323618|NCT06096337|DEVICE|FARAPULSE™ Pulsed Field Ablation (PFA) System|Subjects will undergo a pulsed field ablation procedure using the FARAPULSE™ Pulsed Field Ablation (PFA) System for the isolation of pulmonary veins and posterior wall.
224323619|NCT06096337|DRUG|Anti-Arrhythmic Drug (AAD): Flecainide, Sotalol, Propafenone, Dofetilide, and Dronedarone|Anti-Arrhythmic Drugs (AADs) including, Flecainide, Sotalol, Propafenone, Dofetilide, and Dronedarone will be prescribed and monitored in accordance with local clinical practice and already established guideline-directed therapy for patients with persistent atrial fibrillation (AF).
223773969|NCT04352010|BEHAVIORAL|Res-Up!|Res-Up! is an internet-based intervention focusing on patients' strengths and positive experiences that have effects on distress, protective factors and quality of life. The intervention is based on the Personal Model of Resilience (PMR; Padesky and Mooney, 2012), which is a positive intervention that utilizes patients' strengths to overcome problems.The PMR activates resilient emotions, thoughts, metaphors, images and behaviors in four steps during five sessions about the aquisition of resilient strategies and their use in daily life. A variety of elements based on different psychotherapy approaches (Cognitive Behavioral Therapy, Emotion Focused Therapy, Positive Therapy etc.) are integrated in the program. Participants should work through one module per week. The intervention is conducted as I-CBT via the platform Minddistrict.Res-Up! is administered as a standalone or an add-on treatment to psychotherapy.
223773970|NCT04352010|BEHAVIORAL|REMOTION|REMOTION is an internet-based intervention aimed at transdiagnostically reducing symptom severity and improving emotion regulation of psychotherapy patients. The structure of REMOTION is based on the idea of an extended process model of emotion regulation as postulated by J.J. Gross (2015). The program includes the following modules: introduction, psychoeducation, identification, selection, implementation and modification. A variety of elements based on different psychotherapy approaches (Cognitive Behavioral Therapy, Emotion Focused Therapy, Dialectical Behavior Therapy etc.) are integrated in the program. Participants should work through one module per week. REMOTION is administered as a standalone or an add-on treatment to psychotherapy.
223773971|NCT04352010|OTHER|Wait-Control Group|In the waiting control group participants will answer questionnaires and they will gain access to either REMOTION or Res-Up! after twelve weeks.
223773972|NCT02359396|DRUG|MZRW|MZRWs is composed of Fructus Cannabis (HuoMaRen), Radix et Rhizoma Rhei (DaHuang), Radix Paeoniae Alba (BaiShao), Semen Armeniacae Amarum (KuXingRen), Fructus Aurantii Immaturus (ZhiShi) and Cortex Magnoliae Officinalis (HouPo). All MZRW granules will be prepared by PuraPharm International (H.K.) Limited. The entire manufacturing process, from authenticating the raw materials to the final products, is in strict compliance with the standards of Good Manufactory Practice (GMP) and Chinese Pharmacopoeia.
223773973|NCT05727358|BEHAVIORAL|Group-based Acceptance and Commitment Therapy|G-ACT treatment in this study comprised 7 sessions of 45-60 minutes and was administered throughout the course of the 4-week long trial.
224323620|NCT04671667|DRUG|Carboplatin|Given IV
224323621|NCT04671667|DRUG|Cisplatin|Given IV
224323622|NCT04671667|PROCEDURE|Computed Tomography|Undergo CT
224323623|NCT04671667|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
224323624|NCT04671667|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
224323625|NCT04671667|BIOLOGICAL|Pembrolizumab|Given IV
224323626|NCT04671667|RADIATION|Proton Beam Radiation Therapy|Undergo PBRT
224323627|NCT05143619|OTHER|Survey Administration|Complete surveys
224323628|NCT05090891|DRUG|INCB000928|INCBG000928 will be administered QD orally.
224323629|NCT05090891|DRUG|Placebo|Placebo will be administered QD orally.
224323630|NCT06325683|PROCEDURE|Biopsy Procedure|Undergo biopsy
224323631|NCT06325683|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
224323632|NCT06325683|DRUG|Lomustine|Given PO
224323633|NCT06325683|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
224323634|NCT06325683|BIOLOGICAL|Nivolumab|Given IV
224323635|NCT06325683|BIOLOGICAL|Relatlimab|Given IV
224323636|NCT06325683|PROCEDURE|Surgical Procedure|Undergo surgery
224323637|NCT06577441|PROCEDURE|Biospecimen Collection|Undergo buccal swab and blood sample collection
224323638|NCT06577441|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
224323639|NCT06577441|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
224323640|NCT06577441|DRUG|Decitabine and Cedazuridine|Given PO
224323641|NCT06577441|DRUG|Enasidenib|Given PO
224323642|NCT06378528|DRUG|Ketamine|3 Intravenous ketamine administrations (0.5mg/kg, not to exceed 40mg dose) immediately prior to a psychotherapy session over the span of 6 weeks
223773974|NCT04543734|DEVICE|HemoScreen hematology analyzer|The use of HemoScreen for self-testing of blood values
223773975|NCT01969838|DRUG|Momelotinib|Momelotinib tablet administered orally once daily
223773976|NCT01969838|DRUG|Ruxolitinib|Ruxolitinib tablets administered orally twice daily
223773977|NCT01969838|DRUG|Placebo to match momelotinib|Placebo to match momelotinib tablets administered orally once daily
223773978|NCT01969838|DRUG|Placebo to match ruxolitinib|Placebo to match ruxolitinib tablets administered orally twice daily
224260815|NCT04685291|DRUG|Conventional pain management|"* oral pain medication in patients younger than 70 years: Ibuprofen 400mg (1-1-1) AND Metamizole 500mg (max. 2 tbl. every 6 hours)~* oral pain medication in patients older than or equal 70 years: Acemetacin 60mg (1-1-1) AND Metamizole 500mg (max. 2 tbl. every 6 hours)~* Rescue analgesic medication for all patients: oxycodone hydrochlorid (drops) p.o. (10 mg/ml) 0.1mg/kg p.o. hour~* In the ED Rescue analgesic medication for all patients: Fentanyl 50mcg i.v. (max. 200mcg/hour)"
224260816|NCT04254198|BEHAVIORAL|TERTULIAS structured dialogue peer support groups|"TERTULIAS will involve structured dialogue groups using the model developed and tested by the investigators through their preliminary research. Each group will have 10 women and will meet weekly for two hours over a 12-month period. Group meetings will be conducted in Spanish, led by a team of two FMI facilitators. Facilitation will use the structured dialogue approach. In the last two months of each cohort, participants will be invited to write their own stories or recipes, or produce poetry or art representing their experience to share with the group. These contributions will be gathered and reproduced in booklet form and each participant will receive a copy."
224260817|NCT04254198|BEHAVIORAL|Modified Attention Placebo Control (MAPC)|MAPC participants will receive a phone call every other month from the project coordinator to document that their contact information is up to date, to remind them that they are in the study and to tell them that the study is continuing. Survey data and hair samples will be gathered from them at baseline and 12 months
224260818|NCT03957551|DRUG|Cabozantinib|"Cabozantinib is an oral small molecule potent inhibitor of pro-invasive receptor tyrosine kinases (RTKs).~Cabozantinib will be administered in the tablet form, at three dose levels: 40, 20 and 60 mg per day, in combination with pembrolizumab. The drug is taken continuously for 21 days or 3 weeks. This period of time is defined as one treatment cycle."
224323643|NCT06378528|DEVICE|SmartSleep EEG recording headband|Participants will complete 7 nights of at-home sleep recordings for exploratory analysis
224323644|NCT05501236|DEVICE|Grass S88 Muscle Stimulator|The Grass S88 nerve and muscle stimulator is a widely-used tool in electromyography and nerve conduction studies. During the DISE and second sleep study, fine-wire electrodes will be placed into the hypoglossal nerve or genioglossus muscle. Two more electrodes are placed transcutaneously, proximate to the bilateral branches of the cervicalis innervating the sternothyroid muscle in the anterior neck.
224323645|NCT05461495|BEHAVIORAL|Treatment Group|"This intervention is unique in its emphasis on family support and in providing ongoing availability of the counselor. While the NYUCI is being implemented in several communities, its effectiveness in Chinese and Korean American dementia caregivers has not been tested. The first component of the intervention consists of two individual and four family counseling sessions that include relatives suggested by the caregiver. The second component of the intervention is participation in a support group to provide the caregiver with continuous emotional support and education. The third component of the treatment is participation in an on-line chat group to provide peer support. The fourth component of the treatment is ad hoc counseling the continuous availability of counselors to caregivers and families to help them deal with crises and with the changing nature and severity of their relatives' symptoms over the course of the disease."
223773979|NCT03696121|DRUG|Desmopressin Injection|Single dose 20 micrograms in 50ml Normal Saline as intravenous injection infused over 20 minutes
223773980|NCT03696121|DRUG|Normal saline|Single dose 50ml Normal Saline as intravenous injection infused over 20 minutes
223773981|NCT01513772|DRUG|Dexmedetomidine|Dexmedetomidine(4㎍/mL) : 0.4㎍/kg/hr infusion until extubation
223773982|NCT01513772|DRUG|Normal saline 0.9%|Normal saline(guess as 4㎍/mL) : 0.4㎍/kg/hr infusion until extubation
224323646|NCT06280716|DRUG|Placebo|Subcutaneous injection
224323647|NCT06280716|DRUG|Lebrikizumab|Subcutaneous injection
224323648|NCT06280716|DRUG|Topical Corticosteroid|Topical Corticosteroid
224323649|NCT04675710|PROCEDURE|Conventional Surgery|Undergo surgery
224323650|NCT04675710|DRUG|Dabrafenib|Given PO
223773983|NCT01003431|BIOLOGICAL|Rotavirus Vaccine, Live, Oral, Pentavalent|\[Intervention name: RotaTeq™ administered concomitantly with Tritanrix™ HepB (DTwP)\] Three 2.0 mL oral doses of RotaTeq™ and three 0.5 mL intramuscular injections of Tritanrix™ HepB will be given at the same time with about 1 month between each administration.
223773984|NCT01003431|BIOLOGICAL|Comparator: Rotarix™ administered concomitantly with Tritanrix™ HepB (DTwP)|Two 1.0 mL oral doses of Rotarix™ and three 0.5 mL intramuscular injections of Tritanrix™ HepB will be given at the same time with about 1 month between each administration (the second administration will be Tritanrix™ HepB only).
223773985|NCT01003431|BIOLOGICAL|Comparator: RotaTeq™ administered concomitantly with INFANRIX™ (DTaP)|Three 2.0 mL oral doses of RotaTeq™ and three 0.5 mL intramuscular injections of INFANRIX™ will be given at the same time with about 1 month between each administration.
224323651|NCT04675710|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
224323652|NCT04675710|BIOLOGICAL|Pembrolizumab|Given IV
224323653|NCT04675710|OTHER|Quality-of-Life Assessment|Ancillary studies
224323654|NCT04675710|DRUG|Trametinib|Given PO
224323655|NCT04003038|PROCEDURE|Negative Pressure Wound Therapy|Receive wound care with NPWT
224323656|NCT04003038|PROCEDURE|Wound Care Management|Receive wound care with a standard dressing (bandage)
224323657|NCT05931484|DRUG|Gemfibrozil|Oral Solution
223773986|NCT02348138|OTHER|Isometric handgrip training|The two experimental groups (HBT and ST) will receive intervention with isometric handgrip exercise for 12 weeks, and the HBT group without daily supervision.
223773987|NCT03431077|DRUG|Angiotensin II|Angiotensin II is a peptide hormone naturally produced by the body that regulates blood pressure via vasoconstriction and sodium reabsorption. LJPC-501 (angiotensin II) is being developed for the treatment of hypotension in patients who do not respond to fluids and vasopressor therapy.
223773988|NCT00423436|BEHAVIORAL|Questionnaire|Questionnaires taking about 30-45 minutes to complete.
223773989|NCT00423436|BEHAVIORAL|Interactive Voice Response Telephone System|IVR Only = Phone calls twice weekly, each call lasting less than 5 minutes.
223773990|NCT00423436|BEHAVIORAL|IVR Plus Triage|"IVR system will triage, or sort, the symptom data by symptom severity, notifying health care professionals when a symptom is greater than the set threshold limit."
223773991|NCT06141798|OTHER|Hemodialysis|Number of weekly hemodialysis treatment
223773992|NCT00357864|DRUG|carbachol|
224260819|NCT03957551|DRUG|Pembrolizumab|Pembrolizumab is a humanized antibody which will be administered as an intravenous infusion at a fixed dose of 200 mg once every 3 weeks in combination with cabozantinib.
224260820|NCT05283148|OTHER|Dual-energy X-ray absorptiometry|Measure bone mineral density at the lumbar spine, left total hip, left forearm, and whole body
224260821|NCT05283148|OTHER|Vertebral fracture analysis|Obtain thoracolumbar morphometry in DXA scan, then determine presence and severity of vertebral compression fractures by VFA
223773993|NCT02048384|DRUG|metformin alone (Arm A)|metformin alone
223773994|NCT02048384|DRUG|metformin (Arm B)|rapamycin + metformin
223773995|NCT02048384|DRUG|rapamycin (Arm B)|rapamycin + metformin
223773996|NCT01278459|DRUG|Atorvastatin|4 week treatment, 20mg/day taken orally in tablet form
223773997|NCT02699905|OTHER|phlebotomy|phlebotomy
223773998|NCT00000571|DEVICE|ventilators, negative pressure|
223773999|NCT05060419|DRUG|Meropenem- FL058|"Meropenem-FL058(Meropenem 1000mg plus FL058 1000mg)q8h~Meropenem-FL058(Meropenem 2000mg plus FL058 1000mg)q8h"
223774000|NCT05060419|DRUG|Piperacillin -tazobactam|Piperacillin-tazobactam (piperacillin 4 g plus tazobactam 0.5 g)q8h
224260822|NCT05283148|OTHER|Adult Sickle Cell Quality of Life Measurement System pain impact questionnaire|Calculate patient-reported total pain scores to determine the pain phenotype of each study participant
224260823|NCT06141486|DRUG|Frexalimab|SAR441344 Solution for IV infusion
224260824|NCT06141486|DRUG|Placebo|Solution for IV infusion
224260825|NCT06141486|DRUG|MRI contrast-enhancing agents|IV, as per respective label
224260826|NCT04325659|DEVICE|Bridge Device|An FDA-cleared neuromodulator medical device, marketed for the treatment of opioid withdrawal
224323658|NCT05931484|DRUG|Placebo|Daily dose of Placebo
224323659|NCT03065335|DRUG|Ketamine|N-methyl-D-aspartate (NMDA) glutamate receptor (NMDA-R) antagonist
223774001|NCT05060419|DRUG|Saline|180min
223774002|NCT05060419|DRUG|Saline|30min
223774003|NCT00111644|DRUG|Ceftriaxone|1000mg iv daily
223774004|NCT00111644|DRUG|beta-lactam|750mg iv q 23h for 3-14 days
223774005|NCT00111644|DRUG|beta-lactam|1500mg iv q 12h for 3-14 days
223774006|NCT03084328|DIETARY_SUPPLEMENT|Vitamind D|Patients will be given an over the counter vitamin D supplement of 2000 units of D3 daily for 6 months
223774007|NCT00143858|DEVICE|Pulse Volume Measurement|patients will wear a newly designed calf monitor that will be hooked up to a computer that will monitor leg peripheral pulse volumes which will then be correlated to pressures obtained with Swan Ganz monitoring. The calf monitor is gut two bands with sensors that are wrapped around the ankle and below the knww
223774008|NCT00279123|DRUG|pantoprazole infusion|
223774009|NCT00279123|DRUG|pantoprazole bolus|
223774010|NCT00279123|DRUG|no treatment|
223774011|NCT01159496|DRUG|PF-05212377 (SAM-760)|Oral capsule, once daily for 14 days 1.5 mg, 5 mg, 15 mg, 30 mg and 50 mg
223774012|NCT01159496|DRUG|Placebo|Oral capsule, once daily for 14 days
223774013|NCT02944578|DRUG|Curcumin|"Curcumin (Curcumin C3 Complex®, prepared by Sabinsa Corporation), a constituent of the spice turmeric, is considered to be a low-toxicity, dietary-derived agent with chemopreventive and therapeutic benefits.~Study participants will be instructed to insert four 500 mg (2000 mg total) curcumin capsules once a week (excluding days when they are on their menses). Participants will insert the capsules using the vaginal applicator while lying on their back with their knees bent. Participants will be instructed to gently insert the capsules into the vagina as far as they will go comfortably, similar to a tampon insertion or other common intravaginal drugs.~Cervical cytology, colposcopies and biopsies will be performed at the Baseline, Week 4, 8, 12 and 16 visits to collect samples to analyze for the study outcomes."
223774014|NCT02944578|DRUG|Placebo|"Study participants randomized to the placebo arm will insert four 500 mg (2000 mg total) of the placebo (gelatin) capsules once a week (excluding days when they are on their menses). Participants will insert the capsules using the vaginal applicator while lying on their back with their knees bent. Participants will be instructed to gently insert the capsules into the vagina as far as they will go comfortably, similar to a tampon insertion or other common intravaginal drugs.~Cervical cytology, colposcopies and biopsies will be performed at the Baseline, Week 4, 8, 12 and 16 visits to collect samples to analyze for the study outcomes."
224260827|NCT04325659|DRUG|Lofexidine|FDA-approved medication for the treatment of opioid withdrawal. Participants will receive capsules 4 times daily for 7 days. The active dose is 0.72 mg four times daily for Days 1-5, for a total daily dose of 2.88 mg. Doses on Days 6 and 7 will be 1.44 (2 active, 2 placebo capsules) and 0.72 mg (1 active, 3 placebo capsules), respectively.
224260828|NCT04325659|DRUG|Placebo|Inactive study drug, encapsulated to look like the active study drug. Participants will receive capsules 4 times daily for 7 days.
224260829|NCT04325659|DEVICE|Sham Bridge Device|Inactive Bridge Device which is applied and looks identical to the active Bridge Device
224260830|NCT00292929|DRUG|Intravenous artesunate|
224260831|NCT00095784|DRUG|Decitabine|Given SC
224260832|NCT00095784|OTHER|Laboratory Biomarker Analysis|Correlative studies
224323660|NCT03065335|OTHER|Placebo|Placebo comparator
224323661|NCT03065335|DEVICE|Cobot TS MV robotic arm for TMS|TMS-Cobot TS MV \[Axilum Robotics\] robotic arm for spatial positioning and orientation of the TMS coil
224260833|NCT04131413|DRUG|pNGVL4aCRTE6E7L2|The dose escalation will start from the lowest dose level of 0.3 mg. This dose cohort will consist of 3 participants and a monitoring period of one week after the final dose mandated. If there are 0 participants in the 0.3 dose level cohort that experience dose limiting toxicities (DLT), a new cohort of 3 participants will be vaccinated at the 1.0 mg dose level. If there are 0 participants in the 1.0 mg dose level that experience DLT, then a new cohort of 3 participants will be vaccinated at the 3.0 mg dose level. If there is 1 participant experiencing DLTs, an additional cohort of 3 subjects will be enrolled and treated at the current dose level. If there are 2 or more participants experiencing DLTs in the 3 or additional cohort of 3 vaccinated at the current dose level, then the next lower dose level will be determined as the Maximum Tolerated Dose (MTD).
224260834|NCT00000666|DRUG|Pyrimethamine|
224260835|NCT05582538|DRUG|Ceralasertib|240mg orally BD (dose level 0) on days -6 to 0 prior to day 1 cycle 1 and then on days 22 to 28 of cycle 1 and every subsequent cycle
224323662|NCT03065335|DEVICE|NeurOptics PLRTM-30000 Pupillometer|The Neu-rOptics PLRTM-3000 Pupillometer will use quantitative infrared technology to objectively and accurately measure pupil size and dynamics.
224323663|NCT05481411|DRUG|Olpasiran|Subcutaneous injection
224260836|NCT05582538|DRUG|Durvalumab|1500 mg i.v. day 1 (q28)
224260837|NCT05582538|DRUG|Nab-paclitaxel|100mg/m2 i.v. day 1,8,15 (q28)
224260838|NCT05169931|BIOLOGICAL|RegenerEyes|Biologic eye drop
224260839|NCT01161420|DEVICE|Inspire Upper Airway Stimulation System|Inspire Upper Airway Stimulation System, is a permanent, implantable therapy device, which consists of three implantable components: IPG, stimulation lead, and a sensing lead. In additional the patient receives a remote to activate the therapy.
224323664|NCT05356195|BIOLOGICAL|CTX001|Administered by intravenous infusion following myeloablative conditioning with busulfan.
224323665|NCT04228367|DEVICE|JuggerStitch Meniscal Repair Device|Treatment of torn meniscus with JuggerStitch.
224323666|NCT06191861|BEHAVIORAL|Most hoped for future self|Participants in this condition complete a version of the future possible self task in which they think and write about their most hoped for future self for 20 minutes.
224323667|NCT06191861|BEHAVIORAL|Most feared future self|Participants in this condition complete a version of the future possible self task in which they think and write about their most feared future self for 20 minutes.
224323668|NCT06191861|BEHAVIORAL|Control (trip to zoo)|Participants in this condition think and write about a future trip to the zoo
224323669|NCT06191861|BEHAVIORAL|Balanced future self|Participants in this condition complete a version of the future possible self task in which they think and write about their most hoped for and feared future self for 20 minutes.
224323670|NCT05988138|BEHAVIORAL|Family Promoting Positive Emotions|An 8-week dyadic intervention using cognitive and behavioral skills to up-regulate positive emotions in children and mothers
224323671|NCT05988138|BEHAVIORAL|Psychoeducation|An 8-week comparison condition that offers education in mental health, depression prevention, and accessing mental health resources
224323672|NCT04875624|DIAGNOSTIC_TEST|Bayley Scales of Infant and Toddler Development, Fourth Edition (Bayley-4)|Bayley Scales of Infant and Toddler Development, Fourth Edition (Bayley-4) will be administered by one of the 2 blinded examiners who are unaware of neonatal glycemia status. Bayley-4 examines Cognitive, Language, Motor, Social-Emotional and Adaptive Behavior domains of development and may require up to 120 minutes to complete.
224323673|NCT05640765|OTHER|Best Practice|Receive standard of care services
224323674|NCT05640765|OTHER|Educational Intervention|Receive additional educational and supportive material
224323675|NCT05640765|OTHER|Health Promotion and Education|Participate in BeWell360-CG Care Model sessions
224323676|NCT05640765|OTHER|Questionnaire Administration|Ancillary studies
224323677|NCT05251948|DRUG|Atezolizumab|Atezolizumab is administered by IV infusion on Day 1 of each 21 day cycle. Treatment until progressive disease.
224323678|NCT05251948|DRUG|Capecitabine|Capecitabine is administered orally twice daily on Days 1-14 of each 21 day cycle. Treatment for up to six cycles.
224323679|NCT05251948|DRUG|Oxaliplatin|Oxaliplatin is administered by IV infusion on Day 1 of each 21 day cycle. Treatment for up to six cycles.
224323680|NCT05251948|DRUG|Tiragolumab|Tiragolumab is administered by IV infusion on Day 1 of each 21 day cycle.
224323681|NCT06517459|BEHAVIORAL|Group Lifestyle Balance|The Group Lifestyle Balance (GLB) program is a self-management intervention that has been shown to result in weight-loss and reduce the risk for Type 2 diabetes through increased physical activity and healthy eating behaviors in the general population. The GLB is a direct adaptation of the Diabetes Prevention Program, both developed at the Diabetes Prevention and Support Center at the University of Pittsburgh. The GLB is designed for delivery in a group-based, community setting,4 and has resulted in weight-loss in a variety of settings, such as community centers, churches, worksites, and healthcare systems.
224323682|NCT02835261|OTHER|Sleep Restriction|Mild sleep restriction (-1.5 h/night) over a period of 6 weeks
224323683|NCT06050122|DRUG|Patidegib Topical Gel|Patidegib Gel 2% is a smooth, clear, colorless-to-yellow, viscous, hydro-alcoholic gel for topical administration.
224323684|NCT06050122|DRUG|Patidegib Topical Gel with no active patidegib|Vehicle Gel consists of the excipients of Patidegib Gel with no active patidegib. It is a smooth viscous gel for topical administration.
224323685|NCT06455059|DRUG|Vosoritide|Subcutaneous injection of recommended dose of vosoritide based on weight-band dosing once daily.
224323686|NCT06455059|DRUG|Placebo|Subcutaneous injection of recommended dose of placebo
224323687|NCT05025085|DRUG|AGEN1777|An immunoglobulin gamma (IgG1) antibody
224323688|NCT05025085|DRUG|a PD-1 inhibitor|Anti-programmed cell death protein 1 (Anti-PD-1) antibody monoclonal antibody
224323689|NCT03199469|GENETIC|Resamirigene bilparvovec|Resamirigene bilparvovec is an AAV8 vector containing a functional copy of the human MTM1 (hMTM1) gene.
224260840|NCT00064831|DRUG|Black Cohosh Extract (BCE)|
224260841|NCT05947474|DRUG|ORB-011|Drug: ORB-011 is dosed via IV infusion
224260842|NCT04378751|BEHAVIORAL|Decision aid video|Decision aid video
224260843|NCT04378751|BEHAVIORAL|Genetic counseling informational brochure|Genetic counseling informational brochure
224323690|NCT05715463|OTHER|Resource sheets|Arm 1 is the control arm which will receive the standard of care resource sheets. Patients in this arm will receive cultivated resource sheets for any SDoH-related needs that they screen positive for or request additional information on.
223774015|NCT02666235|PROCEDURE|Remote ischaemic conditioning|Intermittent inflation of an arm blood pressure cuff for 5 minute periods at 200 mmHg separated by a 5 minute rest interval, repeated successively on 4 occasions over a 40 minute period. The intervention will take place on the ward with the patient obscured from the clinical team by a drawn curtain. The clinical team and researchers will be masked to the intervention type.
223774016|NCT02666235|PROCEDURE|Arm cuff placement, no inflation;|Sham procedure involving arm cuff placement, no inflation: A blood pressure cuff will be placed on the arm for 40 minutes. The cuff will not be inflated. The patient will be in bed behind a curtain on the cardiology ward. The curtain will obscure the patient from the attending cardiology team. The clinical team and researchers will be masked to the intervention type.
223774017|NCT04915859|OTHER|Hand Cooling at 12-15 degrees celsius|hand cooling at 12-15 degrees celsius will be performed for active cooling by having participants place their hands on the cooling device set to this temperature
223774018|NCT04915859|OTHER|Hand Cooling at 16-20 degrees celsius|hand cooling at 16-20 degrees celsius will be performed for active cooling by having participants place their hands on the cooling device set to this temperature
223774019|NCT04915859|OTHER|hand and back cooling at 12-15 or 16-20 degrees celsius|hand and back cooling at 12-15 or 16-20 degrees celsius will be performed for active cooling by having participants place their hands on the cooling device set to this temperature while also wearing the back wrap cooling device set to this temperature
223774020|NCT04915859|OTHER|Passive cooling|"participants will sit in a chair and passively cool (no active intervention)"
223774021|NCT04978792|BEHAVIORAL|Online self-compassion intervention|An online self-guided intervention that uses widely available exercises and information.
223774022|NCT04978792|BEHAVIORAL|Active Control|Participants will complete written exercises and breathing exercises that are not associated with self-compassion
223774023|NCT00807092|DRUG|biphasic insulin aspart 30|The initial doses for BIAsp 30 twice-daily regimen will be recommended to start at a total daily dose of 0.3 U/kg body weight and to be equally divided (1/2:1/2) between pre-breakfast and pre-dinner
223774024|NCT00807092|DRUG|biphasic human insulin 30|The initial doses for BHI 30 twice-daily regimen will be recommended to start at a total daily dose of 0.3 IU/kg body weight and to be divided in the ratio of 2/3:1/3 between pre-breakfast and pre-dinner
223774025|NCT00807092|DRUG|metformin|Metformin dose must remain the same as that used prior to the trial.
223774026|NCT04116229|PROCEDURE|Oral glucose tolerance test|After 8 hours fasting overnight, an intravenous catheter is placed in the arm or hand for blood draws. Participants drink 75 grams of an oral glucose drink after baseline blood samples are drawn. More blood draws occur at 10, 20, 30, 60 and 120 min post-glucose drink.
223774027|NCT04116229|BEHAVIORAL|Cognitive testing|For approximately 40 minutes, participants are assessed for cognitive function using computer-based tests available from the NIH Toolbox Cognitive Battery (Weintraub et al., 2013), including attention and executive functioning, episodic memory, working memory, language, processing speed, and immediate recall.
223774028|NCT04116229|PROCEDURE|Magnetic resonance imaging|Magnetic resonance imaging (MRI) scans will be performed in a 3 Tesla MRI scanner over 1.5 hours. Participants will be asked to lay down flat on their backs and to try to stay still throughout the MRI scan. The participant will wear MRI-safe headphones to block out noise due to the MRI scans. Participant comfort will be verbally checked on throughout the scan and the participant will be provided with a 'squeeze ball' to signal the MRI technician that they want to get out of the scanner immediately.
223774029|NCT06573645|DRUG|Rituximab|Patients will be randomized to receive either rituximab 500 mg/m2 or rituximab 375 mg/m2 for six cycles of R-CHOP (21 days per cycle), followed by two maintenance cycles of rituximab (21 days per cycle).
223774030|NCT06573151|DRUG|Selinexor, anti-PD-1 antibody and P-GemOx|Selinexor, 40mg, qw, po; Pegaspargase, 2500U/m2, IM, d1; Gemcitabine, 1000mg/m2, i.v., d1, d8; Oxaliplatin, 130mg/m2, i.v., d1; anti-PD1 antibody, 200mg, d2, i.v. (21d cycle);
224260844|NCT03592420|BEHAVIORAL|Interdisciplinary multicomponent interventions|
224260845|NCT03592420|BEHAVIORAL|Usual care|standard care
224260846|NCT03750357|DEVICE|Primary Relief v 2.0|To prove the effectiveness of Post Operative Pain Solution using Primary relief v 2.0 by Percutaneous Electrical Nerve Stimulation in the auricle.
224260847|NCT06562504|DEVICE|Transcranial direct current stimulation (tDCS)- anodal group|2mA/20mins/session;
224260848|NCT06562504|DEVICE|Transcranial direct current stimulation (tDCS)- sham group|0mA/20mins/session
224260849|NCT06562504|DEVICE|transcranial alternating current stimulation (tACS)-tACS group|1.5 mA/20 min/session; 6HZ, theta
224260850|NCT05411887|DRUG|Rosuvastatin, Olmesartan Medoxomil|Olostar Tablet
224260851|NCT00113958|DRUG|Cinacalcet|
224260852|NCT02332967|OTHER|Whey predominant starter formula|Milk powder product given to babies between 1 week and 4 months
224260853|NCT02332967|OTHER|Whey predominant starter formula + 40% palmitic acid|Milk powder product containing 40% of palmitic acid
224260854|NCT02332967|OTHER|Whey predominant starter formula + 50% palmitic acid|Milk powder product containing 50% of palmitic acid
224260855|NCT05606120|DEVICE|CL TRAUMA femoral stem|Hip arthroplasty according to the instruction for use.
224260856|NCT05331482|OTHER|Training protocol with the cervical device for treatment (CDAT).|Endurance training program of deep cervical flexors and deep cervical extensors with the cervical device for treatment.
224260857|NCT05331482|OTHER|Conventional training protocol|Endurance training program of deep cervical flexors and deep cervical extensors with conventional training protocol.
224260858|NCT06389591|BIOLOGICAL|pp65 RNA loaded lipid particles, pp65 RNA-LPs (Drug Product 1 or DP1)|pp65 RNA loaded lipid particles or pp65 RNA-LPs administered intravenously
224260859|NCT06389591|BIOLOGICAL|RNA loaded lipid particles, RNA-LPs (Drug Product 2 or DP2)|personalized tumor mRNA, pp65 fl LAMP mRNA and DOTAP liposomes or RNA loaded lipid particles, RNA-LPs administered intravenously
224260860|NCT05614765|DRUG|Statin+Ezetimibe compound|Crezet Tablet, Litorvazet Tablet
223774031|NCT04832555|RADIATION|Non elective radiotherapy|Simultaneous integrated boost on CTV volumes, delineated as per guidelines, with the exception of intermediate-low risk, where the CTVs are experimental.
223774032|NCT01229228|DRUG|Naproxen Test|200-mg single dose
223774033|NCT01229228|DRUG|Naproxen Test|400-mg (2 x 200-mg)
223774034|NCT01229228|DRUG|Naprosyn|single dose
223774035|NCT01229228|DRUG|Naprosyn|single dose
224260861|NCT05817110|OTHER|Participant Cohort|Patients coming to the facility for chest x-rays for any reason, will undergo x-rays as ordered by their treating clinician. In case of any nodule detection by qXR, it will be classified either as low-risk (Lung nodule malignancy score ) LNMS or high-risk LNMS confirmed by radiologist. Then if patient is eligible will be included in the study and a CT Scan will be requested upon enrolment of the patient.
224260862|NCT06161506|DEVICE|Elidah Device|The Elidah device is a modified version of the FDA approved ELITONE device cleared for use in the treatment of female stress urinary incontinence. For the current study, only minor modifications have been implemented with respect to the shape of the electrode component, providing a contour better suited to fit the male anatomy.
224260863|NCT01321567|DRUG|rabeprazole sodium|Doses of 10 mg or 20 mg twice daily may be administered orally to reflux esophagitis patients for a further 8 weeks when proton pump inhibitor treatment is ineffective. However, a dose of 20 mg twice daily should only be administered to patients with severe mucosa injury.
224260864|NCT05485064|DRUG|fentanyl|The investigator 1 use fentanyl to sedate patients coordinate with remimazolam
224260865|NCT05485064|PROCEDURE|eletroacupuncture(transcutaneous electrical acupuncture point stimulation )|The investigator 1 use electroacupunture(transcutaneous electrical acupuncture point stimulation )to coordinate with remimazolam
224260866|NCT05485064|DRUG|placebo needle|The investigator 1 use placebo needle to sedate patients coordinate with remimazolam
224260867|NCT05485064|DRUG|remimazolam|The investigator 1 use remimazolam to sedate patients coordinate with eletroacupuncture(transcutaneous electrical acupuncture point stimulation )or placebo needle
223774036|NCT01229228|DRUG|Placebo|single dose
223774037|NCT00636454|BEHAVIORAL|Coping skills training (CST) for chronic pain|Participants will attend 10 sessions lasting between 45 and 60 minutes each. Topics will include relaxation training, managing activity cycles, and changing thought patterns to reduce the negative effects of pain.
223774038|NCT00636454|OTHER|Usual care|Participants will receive the care usually given to patients with knee or hip OA.
223774039|NCT01736280|OTHER|Standard of Care|Any evaluation or treatment under this protocol will be based on standard practice as related to the subjects's digestive disorder.These include but are not limited to biobehavioral interventions including bowel retraining, biofeedback, and other lifestyle interventions, all of which have been shown to be beneficial in the treatment of this type of chronic functional bowel disorder.
224260868|NCT02022150|BEHAVIORAL|Body composition in paracentesis|Takin blood samples and bioelectrical impedance measurmeent, Neuropsychological tests evaluation
224260869|NCT00473772|DEVICE|DEBlue stent vs. Cypher stent|DES vs. DEB with BMS
224260870|NCT06559644|BIOLOGICAL|Hema-NeoTIL01|Patients will receive intravenous infusion of Hema-NeoTIL01, which is a highly specific tumor infiltrating lymphocyte (TIL) product derived from patients' bone marrow or peripheral blood, expanded ex vivo through antigen presentation.
224260871|NCT06321016|OTHER|Physical exercise program|At least two sessions a week for a 6-month supervised and individualized physical exercise program that will have two phases: one that will be carried out in person in the hospital environment taking advantage of medical visits, and a second phase that will allow the patient to carry out the exercise sessions from home with live virtual supervision.
224260872|NCT06321016|OTHER|Type of the physical exercise program|Two types of intervention are proposed depending on the age of the patients: Exercise intervention for adolescents (12 to 18 years): training will be based on strength training (2 - 3 sets of 8 - 12 repetitions) with elastic bands, weights, weights, medicine balls or body weight and aerobic work on a stationary bike, treadmill or other aerobic exercises. Sessions will last about 30-60 minutes (depending on the patient's situation). Exercise intervention for children (4 to 11 years old): The aim will be to work on basic motor skills through play, thus trying to avoid the delay in motor development, and to indirectly work on their physical condition to better cope with the effects of the treatments. Music, games that require movement and materials such as balls, hoops, etc., will be used to motivate the child to move while enjoying themselves. This will be done in sessions of 20 - 40 minutes.
224260873|NCT02129140|DEVICE|Hernia graft/mesh|observational group
224260874|NCT05866263|OTHER|green walking and intelligence gam|The randomized controlled study to examine the effects of green walking and intelligence games on the cognitive skills of individuals aged 50-70 years who had COVID-19 on an outpatient basis were completed with 40 individuals, 20 of which were in the green walking and intelligence game group and 20 were in the control group.
224260875|NCT05288972|DEVICE|Mattress 1|A mattress (M1) with the technical features suitable for scoliosis with supports the spine properly. The mattress will use for 4 weeks, at least 5 days a week, including at least 6 hours of sleep per day.
224260876|NCT05288972|DEVICE|Mattress 2|A mattress with standard technical features (M2). The mattress will use for 4 weeks, at least 5 days a week, including at least 6 hours of sleep per day.
224260877|NCT03855579|DRUG|Levosimendan|Intraoperative infusion of Levosimendan
224260878|NCT03855579|DRUG|Milrinone|Intraoperative infusion of Milrinone
224260879|NCT04293653|OTHER|Protocol for patients above 75 undergoing emergency laparotomy or laparoscopy|See above section
224260880|NCT05498857|DRUG|Intramuscular ephedrine|Patients will receive prophylactic intramuscular ephedrine plus standard spinal anesthesia
224260881|NCT05498857|DRUG|Placebo|Patients will receive prophylactic intramuscular saline plus standard spinal anesthesia
224260882|NCT05105633|DRUG|Tenecteplase|Genetically modified tissue plasminogen activator at a dose of 0.25mg/kg given as an intravenous bolus over 5-10 seconds.
223774040|NCT01645475|DRUG|Desmopressin lyophilisate (Melt)|Patient receives Desmopressin lyophilisate (Melt).
224323691|NCT05715463|OTHER|Community Resource Specialist|The CRS will help guide patients to the necessary community-based resources to help address their specific SDoH needs that impact their health and their ability to access sustained, high quality medical care. This may include forms to arrange for subsidized transportation to and from medical appointments or applications for Section 8 housing. The community resource specialist will reach out to patients in Arm 2 a minimum of 2 times per month, with more interactions guided by patients needs. All outreach attempts and contacts will be documented in EPIC and in REDCap. Actions taken by the CRS will be shared with members of the patient's healthcare team as appropriate (with EPIC notes routed to the rheumatologist and primary care provider, and if indicated and relevant, a social worker, nutritionist, prior CRS, nurse or mental health provider if previously involved in the patient's care).
224323692|NCT05715463|OTHER|Nurse Navigator|The nurse navigator will both work with the CRS to connect the patient with community-based resources, independently connect the patient with relevant resources, and also help coordinate the patient's medical care and mental health needs. The nurse patient navigator will conduct her own needs assessment (the nurse navigator high risk assessment questionnaire at the time of the first conversation with the patient, originally developed as part of the MGB integrated care management program) and her actions will be guided by their responses. She will reach out to patients a minimum of 2 times per month with an increase in communication around patient appointments as reminders, and more frequent communication on a case-by-case basis depending on active illnesses, frequency of outpatient appointments, and needs of the patient. All outreach attempts and contact will be documented in EPIC and in REDCap and similar to the CRS, be shared via EPIC with the care team as indicated.
224260883|NCT05105633|DRUG|Standard Care (which may include intravenous Alteplase)|Patients will receive standard care which may include intravenous alteplase at the standard licensed dose of 0.9 mg/kg up to a maximum of 90mg, 10% as a bolus and the remainder as an infusion over 1 hour.
224260884|NCT03926650|DEVICE|Masimo Sedline Monitor Patient State Index|Masimo Sedline Monitor shows frontal electromyography and patient state index, Train of four monitor shows muscle strength on adductor pollicis muscle
224260885|NCT05442034|BIOLOGICAL|growth factors to help in regeneration|regenerative therapy
224260886|NCT03130335|PROCEDURE|BMA Injection|Bone marrow will be aspirated from the iliac crest and injected into the knee.
224260887|NCT03130335|BIOLOGICAL|BMA|Bone marrow will be aspirated from the iliac crest.
224260888|NCT02913924|DRUG|Clonazepam|fixed-flexible daily dose to a maximum of 2 mg (1 mg twice per day) for the first 8 weeks of the trial
224260889|NCT02913924|DRUG|Placebo|
224260890|NCT00045786|DRUG|CC-1088|400 mg/day (200 mg orally twice a day) 800 mg/day (400 mg orally twice a day) 1200 mg/day (600 mg orally twice a day) 1500 mg/day (500 mg orally three times daily)
224260891|NCT06621784|OTHER|Core stabilization exercises|In most studies, exercises focused on the extremities have been researched. We believe that the positive effects of the core region on walking and postural stability will play a significant role in the treatment of knee osteoarthritis.
223774041|NCT00028834|DRUG|gemcitabine hydrochloride|Given IV
224260892|NCT06621784|OTHER|Classical exercise therapy|In the first group of our study, we prescribed exercises that have been proven effective in many studies, are frequently prescribed, and focus on joint range of motion and quadriceps strengthening
224260893|NCT05299463|DIAGNOSTIC_TEST|Exercise Testing|"* Tele-Six-minute walk test (T6MWT)~* 1 Minute Sit-to-stand test (STS)~* 2-minute symptom-limited Step test (ST)~* 3-metre Timed up and go test (TUG)."
224260894|NCT04884841|OTHER|Patients diagnosed with postoperative complications|Patients diagnosed with postoperative complications (Acute kidney injury, Chronic Kidney disease, Infection, Delirium, MACCE, Myocardial infarction, Postoperative pulmonary complications, major bleeding, ECMO, IABP....)
224260895|NCT04884841|OTHER|Patients without postoperative complications|Patients without postoperative complications
224260896|NCT00835614|DRUG|Cefprozil for oral suspension 250 mg/5 mL|1 x 250 mg/5 mL, single-dose fasting
224260897|NCT00835614|DRUG|CEFZIL® for Oral Suspension 250 mg/5mL|1 x 250 mg/5 mL, single-dose fasting
224260898|NCT02294981|DEVICE|Excimer laser phototherapy|Excimer laser phototherapy is a type of ultraviolet light that is applied to psoriatic plaques. It is administered using a laser in a targeted way so that only the plaques are treated (normal skin is not treated).
224323693|NCT04394546|DEVICE|WATCHMAN FLX LAAC Device|WATCHMAN FLX LAAC Device Implantation
224323694|NCT04394546|DRUG|Non-Vitamin K Oral Anticoagulant|Initiation or continuation of a NOAC drug
224323695|NCT05182372|BEHAVIORAL|Enhanced dCBT-I|Telehealth Coaching
224323696|NCT01894802|DEVICE|Implantation of CRS Arrays|Two Blackrock Microsystems CRS Arrays will be implanted in the motor cortex and sensory cortex of study participants.
224323697|NCT04166487|DRUG|Pembrolizumab|predetermined dose, once per cycle via IV will be administered every 3 weeks, with 21 consecutive days defined as a treatment cycle.
223774042|NCT00028834|BIOLOGICAL|bevacizumab|Given IV
223774043|NCT00028834|OTHER|laboratory biomarker analysis|Correlative studies
224260899|NCT00829712|DRUG|Dexmethylphenidate Hydrochloride|10 mg Tablet
224260900|NCT00829712|DRUG|Dexmethylphenidate Hydrochloride|10 mg Tablet
224260901|NCT00606281|DRUG|Aripiprazole|oral, 24mg/day
224260902|NCT00606281|DRUG|placebo|oral, 0mg(4tablets)/day
224260903|NCT02890069|BIOLOGICAL|PDR001|anti-PD1 antibody
224260904|NCT02890069|DRUG|LCL161|
224260905|NCT02890069|DRUG|Everolimus|
224260906|NCT02890069|DRUG|Panobinostat|
224260907|NCT02890069|DRUG|QBM076|
224260908|NCT02890069|DRUG|HDM201|
224260909|NCT05173350|OTHER|RETAIN KY|The experimental group receives a combination of medical provider services, stay-at-work (SAW)/return-to-work (RTW) coordination services, and other SAW/RTW services. Services offered by the project include individualized intensive vocational services from RETAIN RTW Coordinators, with an emphasis on assistive technology, universal design, and peer support. The project provides training on SAW/RTW best practices and RETAIN, as well as financial incentives to health care professionals. The treatment group is eligible to receive the full set of RETAIN intervention activities.
224260910|NCT05173350|OTHER|Active Comparator|Those in the active comparator arm continue to receive medical services. A RTW coordinator creates a RTW plan with the enrollee and refers them to existing resources. The RTW coordinator works with enrollees for 2.5 hours total.
224260911|NCT03702218|DRUG|Direct Acting Antivirals|"Patients who are given organ transplants from donors that are Ab positive and NAT negative or Ab positive and NAT positive for Hepatitis C will be treated with direct acting antivirals after transplant if they become NAT+ for hepatitis C.~Interventions as follows.~Liver Transplant:~• Combinations of choice:~* Mavyret (glecaprevir/pibrentasvir) - Genotype 1-6~* Harvoni (ledipasvir/sofosbuvir) + Ribavirin - Genotypes 1, 4, 5, 6; GFR\>30~* Epclusa (sofosbuvir/velpatasvir) + Ribavirin - Genotypes 1-6; GFR\>30~Kidney Transplant:~• Combinations of choice:~* Mavyret (glecaprevir/pibrentasvir) - genotype 1-6~* Harvoni (sofosbuvir/ledipasvir) - genotype 1, 4; GFR\>30"
224260912|NCT00003980|DRUG|BIBX 1382|
224260913|NCT02589366|DRUG|Lymphoseek plus Vital Blue Dye|intrapatient comparison of Lymphoseek with Vital Blue Dye in detecting lymph node metastases
224260914|NCT03492320|OTHER|Health Quality of Life Questionnaire Assessment|Western Ontario and McMaster University Osteoarthritis Index (WOMAC), Self-Rated Questionnaire SF36 and Health Related Quality of Life (HRQoL) 15D questionnaire were used as outcome measurement for functionality and disability assessment.
224260915|NCT04516915|DRUG|IMU-838|IMU-838 twice daily at 22.5mg doses for 14 days
224323698|NCT04166487|DRUG|PEMETREXED|administered per standard practice, once per cycle via IV will be administered every 3 weeks, with 21 consecutive days defined as a treatment cycle.
223681077|NCT02360605|BEHAVIORAL|automated telephone reminder|The patients will be contacted at 4 weeks and again at 8 weeks if they have not returned the FIT. ATR will remind the patient of the importance of completing and returning the FIT results and encourage screening completion. There will also be an option where the patient can request another FIT kit be mailed to them, one to hear information on common problems with FIT completion or how to call the clinic if they have questions. Years 2 and 3: 12 months after patients returned their initial FIT (or if they did not return the FIT, 12 months after enrollment) they will be mailed a friendly letter to remind them that it is time for their annual CRC screening and that a FIT kit will be mailed the following week. During the following week the patients will be mailed the FIT kit with addressed stamped envelope and the educational pamphlet they received at enrollment. For follow-up ATR calls, we will use the same protocol as described for the initial screening. Same procedure for year 3.
223681078|NCT02360605|BEHAVIORAL|prevention coordinator|The patients will be contacted at 4 weeks and again at 8 weeks if they have not returned the FIT by a prevention coordinator (PC). PC will call to encourage completion and ascertain any barriers to completion. The PCs will use Health Literacy and motivational interviewing techniques described in the training section to enhance understanding and confidence and reduce ambivalence to completing and returning the FIT. Years 2 and 3: 12 months after patients returned their initial FIT (or if they did not return the FIT, 12 months after enrollment) they will be mailed a friendly letter to remind them that it is time for their annual CRC screening and that a FIT kit will be mailed the following week. During the following week the patients will be mailed the FIT kit with addressed stamped envelope and the educational pamphlet they received at enrollment. For follow-up PC calls, we will use the same protocol as described for the initial screening. Same procedure for year 3.
223774044|NCT06571461|DRUG|Liposomal Irinotecan|Liposomal Irinotecan：i.v. infusion
223774045|NCT06571461|DRUG|Oxaliplatin|Oxaliplatin;：i.v. infusion
224260916|NCT04516915|DRUG|Oseltamivir|Oseltamivir twice daily at 75mg doses for 14 days
224260917|NCT03157193|DRUG|Hyaluronic Acid|Hyaluronic acid gel application as coadjuvant in the treatment of perimplantitis.
224260918|NCT03157193|DRUG|Hydroxypropyl Guar|Hydroxypropyl Guar gel application as sham comparator
224260919|NCT03222557|PROCEDURE|Electroacupuncture|Refer to arm description
224260920|NCT03222557|PROCEDURE|Sham Acupuncture|Refer to arm description
224260921|NCT03222557|DEVICE|Electroacupuncture|Refer to arm description
224260922|NCT03222557|DEVICE|Sham Acupuncture|Refer to arm description
223774046|NCT06571461|DRUG|S-1|S-1: Oral
224260923|NCT03637556|DRUG|DST-0509|Novel iron chelator with improved absorption characteristics
224260924|NCT03637556|DRUG|Jadenu|Commercial iron chelator with standard absorption characteristics
224260925|NCT03637556|DRUG|Exjade|Commercial iron chelator with standard absorption characteristics
224260926|NCT00263588|DRUG|lapatinib|tyrosine kinase inhibitor
224260927|NCT04690985|BEHAVIORAL|Dietary behaviour change|The intervention consists of dietary guidance and behaviour change techniques, which will last for 15 weeks. The experimental group will be required to adhere to a diet consisting of a 12% reduction in calorie and a 1.2-1.5 g/kg body weight/day intake of protein. The participants will receive the dietary behaviour change guidance in 6 times face-to-face meetings and weekly telephone calls. They will also be asked to take daily food diary.
224260928|NCT04690985|OTHER|Social contact|The control group will not be required any dietary changes. The investigator will contact with the control group with the same frequency and numbers of experimental group. But the chat topic will not be related to sarcopenic obesity or dietary guidance.
224260929|NCT03668015|OTHER|Xylitol then Sorbitol gum|Xylitol gum contains 70% xylitol in addition to gum base, natural flavors, soy lecithin, gum arabic, titanium dioxide, carnuba wax. Sorbitol gum was similar except that xylitol was replaced by 63% sorbitol and 2% maltitol and aspartame was included.
223774047|NCT06571461|DRUG|Gemcitabine|Gemcitabine: i.v. infusion
224260930|NCT03668015|OTHER|Sorbitol then Xylitol gum|Sorbitol gum was similar except that xylitol was replaced by 63% sorbitol and 2% maltitol and aspartame was included. Xylitol gum contains 70% xylitol in addition to gum base, natural flavors, soy lecithin, gum arabic, titanium dioxide, carnuba wax.
223774048|NCT06571461|DRUG|Capecitabine|Capecitabine: Oral
223774049|NCT05927441|DEVICE|DragonFly Transcatheter Mitral Valve Repair System|Edge-to-edge repair with DragonFly System
223774050|NCT05495503|DEVICE|Prototype (814A-v1)|Application on PIH located on the dorsal area (2 treatments during the study).
223774051|NCT05495503|DEVICE|Prototype (814B-v1)|Application on PIH located on the dorsal area (2 treatments during the study).
224260931|NCT02947945|DRUG|Reslizumab|All subjects will receive Reslizumab
224260932|NCT03848507|DRUG|albumin 20%|Intravenous administration of 20% albumin during cystectomy
224260933|NCT04532879|DEVICE|HygiPrep (HyGIeaCare System)|Controlled gravity-based high-volume colon irrigation
224323699|NCT04166487|DRUG|CARBOPLATIN|administered per standard practice once per cycle via IV will be administered every 3 weeks, with 21 consecutive days defined as a treatment cycle.
223681079|NCT02360605|BEHAVIORAL|Health literacy appropriate education and demonstration|The Research Assistant (RA) will employ health literacy communication principles in providing a CRC recommendation and brief screening information using the CRC pamphlet and a FIT kit with simplified instructions and accompanying self-addressed, stamped envelope. A scripted message and illustrations will model what the patient needs to do to complete the FIT. The RA will appropriately demonstrate, using the kit, and will suggest patients show the pamphlet and FIT kit to their provider that day and talk to them about screening. Annual screening will be further emphasized at enrollment by giving patients an empowering message about the benefits of completing a FIT annually and telling them they will be mailed a reminder letter and FIT kit and receive outreach phone calls in 12 and 24 months for the next two years as well as a post survey and satisfaction interview over the phone at 6 months.
223681080|NCT00121407|DRUG|Visudyne for injection|
223681081|NCT05039827|OTHER|Mobilization with movement|Heating fermentation was done for 10 minutes as baseline treatment. MWM with wrist extension was given for alternative days in a week as per 3 sessions per week for 4 weeks.
223681082|NCT05039827|OTHER|Soft Tissue Mobilization|Heating fermentation was done for 10 minutes as baseline treatment. Parallel and longitudinal massage was given for alternative days in a week as per 3 sessions per week for 4 weeks
224260934|NCT04528784|DEVICE|Transcutaneous tibial nerve stimulation|Transcutaneous tibial nerve stimulation is a non-invasive electrical stimulation of the posterior tibial nerve, a branch of the sciatic nerve via sacral plexus. In our study the tibial nerve will be stimulated using Transcutaneous Electrical Nerve Stimulation (TENS) unit with two surface adhesive electrodes. The anode will be positioned between 5-10 cm above medial malleolus and posterior to the edge of the tibia and the cathode will be positioned distally on arch of the foot .
224260935|NCT01183910|DIETARY_SUPPLEMENT|Citrus Bioflavanoid Blend|Pill Taken Twice a Day
223681083|NCT02207660|DRUG|Cisplatin,P-HDFL|The P-HDFL regimen was given as follows: In each 21-day cycle, patients received 24-hour infusions of cisplatin at 45 or 50 mg/m2 and 5-FU 2,600mg/m2 plus leucovorin 300 mg/m2 intravenous 24-hour infusion on Day 1. Normal saline hydration (≧1000 mL), dexamethasone, and antiemetics (ondansetron or granisetron) were given prophylactically before each dose of cisplatin.
223681084|NCT01230775|DRUG|Anagrelide retard|"Week 1:~1x1 tablet/d of Anagrelide retard (1 tablet = 2mg; total dose = 2mg/d) will be administered in week 1.~Week 2 Anagrelide retard: Dosing will be titrated up according to response (platelet reduction) to 4 mg/day (=2x1 tablet) in week 2.~Week 3 - Week 4 Anagrelide retard In week 3 and 4, dose will either be increased or decreased to maintain platelets in the normal or close to normal range. The maximum dose is 4 tablets (=8mg Anagrelide) per day.~Maintenance Phase Anagrelide retard During maintenance phase (month 2 - month 12) doses of treatment are adjusted at the highest tolerated level which is able to maintain the platelet count within the normal range."
223681085|NCT01230775|DRUG|Placebo|"Week 1:~1. x1 tablet/d of placebo will be administered in week 1.~   Week 2~   Placebo:~2. x1 tablet/d of placebo will be administered in week 2.~Week 3 - Week 4~Placebo:~In week 3 and week 4 the maximum dose is 4 tablets per day.~Placebo:~In order to guarantee blinding of subjects the number of placebo tablets to be taken by the subject will vary during maintenance period:~Month 2 - month 3: 2x1 tablet/d Month 3 - month 6: 3x1 tablet/d Month 6 - month 9: 4x1 tablet/d Month 9 - month 12: 4x1 tablet/"
223681086|NCT03209453|OTHER|family work shop|Children with developmental delays, under regular rehabilitation programs, participate 6 sessions of family work shop The family work shop had 6 families in one course, 2 hours per week, for a total of 6 weeks.
224260936|NCT01183910|DIETARY_SUPPLEMENT|Calcium Carbonate|Oral Tablet Taken Twice a Day
224260937|NCT02889380|DRUG|No Intervention|This study will retrospectively collect the data from the subjects who had been treated with 0.25 mg of Cetrotide injection daily in a fixed or flexible antagonist protocol with an available ART outcome.
224260938|NCT01644253|BIOLOGICAL|20 mg/kg TRU-016 + Rituximab|"TRU-016: 10 mg/kg for first dose, all subsequent doses 20 mg/kg, IV once weekly for 8 weeks followed by 4 monthly doses~Rituximab: 375 mg/m2 for first dose, all subsequent doses 500 mg/m2, IV once weekly for 8 weeks followed by 4 monthly doses"
224260939|NCT01644253|BIOLOGICAL|10 mg/kg TRU-016 + Rituximab|"TRU-016: 6 mg/kg for first dose, all subsequent doses 10 mg/kg, IV on Day 1, 8 and 15, followed by 5 monthly doses~Rituximab: 375 mg/m2 for first dose, all subsequent doses 500 mg/m2, IV following TRU-016 schedule"
224260940|NCT01644253|BIOLOGICAL|TRU-016 20 mg/kg + Obinutuzumab|"TRU-016: 6 mg/kg on Day 1, 20 mg/kg on Day 8 and 15, then 20 mg/kg once a month for 5 months~Obinutuzumab: 100 mg on Day 1, 900 mg on Day 2, 1,000 mg on Day 8 and 15, then 1,000 mg once a month for 5 months"
224260941|NCT01644253|BIOLOGICAL|TRU-016 6-20 mg/kg + idelalisib + rituximab|TRU-016: 6 mg/kg on Days 15-36 weekly, 10 mg/kg on Days 43 and 50, then 20 mg/kg once a month for 5 months.
224260942|NCT01644253|BIOLOGICAL|TRU-016 10-20 mg/kg + ibrutinib|TRU-016: Dosed weekly for 8 weeks followed by 4 monthly intravenous (IV) infusions. The first dose will be 10 mg/kg and all subsequent doses will be 20 mg/kg.
224260943|NCT01644253|BIOLOGICAL|TRU-016 10-20 mg/kg + bendamustine|TRU-016 dosed 10 mg/kg for the first dose and then 20 mg/kg weekly for 2 cycles, followed by dosing every other week for an additional 4 cycles (cycle = 28 days). Bendamustine (90 mg/m2 on days 2 and 3 of cycle 1 and then days 1 and 2 of cycles 2 to 6) will be infused after completion of TRU-016. If a patient is benefiting with stable disease or better, then TRU-016 may continue to be dosed every 3 weeks after the first 6 cycles; bendamustine will not be dosed beyond 6 cycles.
224260944|NCT00038363|PROCEDURE|Rehabilitation|
224260945|NCT00038363|PROCEDURE|Subacute care|
224260946|NCT05721794|OTHER|A multicentric prospective observational longitudinal cohort study.|Observational study on the accuracy of TPUS and MRI in the investigation of perianal fistulae in CD patients.
224260947|NCT04208724|OTHER|Training|Participate in the training program
224260948|NCT04208724|OTHER|Cancer Screening intervention|Receive cancer screening intervention
224260949|NCT04208724|OTHER|Survey Administration|Ancillary studies
224260950|NCT03429361|OTHER|Health by Mindstrong|Health by Mindstrong is a smartphone application that collects data on a participant's smartphone usage patterns.
224260951|NCT02448160|DEVICE|alfapump|Implantation of alfapump
224260952|NCT02448160|DRUG|salt-poor Human Albumin solution|Patients implanted with an alfapump will receive intermittent salt-poor human albumin solution
224260953|NCT02225314|BEHAVIORAL|Brain Fitness|Brain Fitness is a computer-based cognitive training programs that consists of six types of exercises that train auditory processing speed and accuracy.
223774052|NCT05495503|DEVICE|Prototype (814C-v1)|Application on PIH located on the dorsal area (2 treatments during the study).
224260954|NCT02225314|BEHAVIORAL|InSight|InSight is a computer-based cognitive training program that consists of five types of exercises that train visual processing and working memory.
224260955|NCT02225314|BEHAVIORAL|Active Control|The Active Control arm is a computerized learning program that consists of five programs (i.e., Wright Brothers, History of Britain, Sister Wendy's American Collection, In Search of Shakespeare, and View the Cosmos) designed to improve knowledge about literature, art, and history.
224260956|NCT05892081|BIOLOGICAL|Colloidal oatmeal|The colloid oatmeal had the following component: Colloidal Oat (5gm), stearic acid 5, cretoctryl alcohol 2.5, cetyl alcohol 2.5, koh 02, potassium sorbate 1gm, paraffin oil 5ml, and soft paraffin 10gm
224260957|NCT05892081|BIOLOGICAL|Cold cream|It is composed of stearic acid 5, cretoctryl alcohol 2.5, cetyl alcohol 2.5, koh 02, potassium sorbate 1gm, paraffin oil 5ml, and soft paraffin 10gm
224260958|NCT02431000|PROCEDURE|Sperm and blood collected for analysis|Sperm Collection and Freezing (Cryopreservation), Blood Collection for analysis
224260959|NCT04178122|GENETIC|Result disclosure|Disclosure of clinically confirmed, medically actionable genetic testing results and post-test genetic counseling session.
224260960|NCT04421716|DRUG|Ursolic Acid|Ursolic Acid 150mg
224260961|NCT04421716|DRUG|Curcumin|Curcumin 600mg
224260962|NCT06003335|BEHAVIORAL|Regular message delivery|Regular messages will be sent regularly to each participant over the 12-week study period. As personalisation is a core process in enabling behavioural change, the intervention content, frequency, and timing of the messages will be based on the participants' self-care needs and preferences, which will be surveyed at baseline. If no specific preferences are provided, we will plan the message delivery to decrease in frequency over time as this trend has shown the highest effectiveness in existing studies. The format of messages will be mainly texts, but other formats such as pictures and voice messages will also be considered for addition to the content library to suit a wide range of preferences.
224260963|NCT06003335|BEHAVIORAL|Chat-type support message delivery|Chat-based support will be given to the participants in addition to the regular message delivery. Instant messaging will be used to communicate directly with the participants. We plan to recruit 10 student RAs who have been trained in the delivery of interactive instant messages (IMs) to provide chat-type support to encourage increased physical activity and interaction. Participants will be invited to set physical activity goals and action plans through the chat-type support. Participants will receive a personalised summary of their physical activity weekly and will be encouraged to reflect on this through a real-time chat (around 5 minutes). They will also be encouraged to establish a plan of how they can adjust their physical activity goal going forward. When addressing the participants' queries or any ethical concerns, the student RAs will be instructed to immediately report to the Principal Applicant and supervisors who are experienced and trained research nurses.
224260964|NCT03447535|OTHER|Semi-directive interview (Kiddy Sads)|semi-directive interview (Kiddy Sads) conducted as part of the care
224260965|NCT03447535|OTHER|SDQ questionnaires (strenghs and difficulties questionnaire)|SDQ questionnaires (strenghs and difficulties questionnaire) conducted as part of the care
224260966|NCT04819386|OTHER|Active vision therapy sessions with the NEIVATECH Virtual Reality-based system|The active visual therapy sessions with the NEIVATECH Virtual Reality-based system will be 18 in total, will have an average duration of half an hour and will be distributed over a month as follows: 5 sessions in the first two weeks after enrollment (Monday to Friday) and 4 sessions in the next two weeks (Monday to Thursday).
224260967|NCT06012812|DRUG|SHR-1819 injection|SHR-1819 injection 300 mg Q2W
224260968|NCT04537481|OTHER|Lipid extraction|The sperm samples were used for lipid extraction. Lipids were analyzed using the UPLC-MS system.
224260969|NCT03621995|OTHER|Malondialdehyde and Catalase level measurement|Malondialdehyde and Catalase level measurement by colorimetric method
224260970|NCT00918684|DRUG|Escitalopram|10mg tab daily
224260971|NCT03313323|BIOLOGICAL|89Zirconium-labeled ipilimumab|Metastatic melanoma patients, who are treated with ipilimumab (3 mg/kg), will be infused with 89Zr-labeled ipilimumab within 2 hours after injection of the first and second standard ipilimumab doses. Peripheral blood mononuclear cells (PBMCs) will be collected for immunomonitoring.
224260972|NCT05250323|OTHER|observational tests in face-to-face visit|All necessary evaluations will be carried out for data collection. Also, that same day, the investigators will give the device to participants for the 7-day home assessment
224260973|NCT05226390|BIOLOGICAL|MVA-SARS-2-ST|In this trial MVA-SARS-2-ST will be used. Each vial contains 1 x 107 IU/dose MVA-SARS-2-ST in 0.5 mL as active ingredient. The solution will be used for nebulization and direct administration to the respiratory tract.
224260974|NCT02532439|DEVICE|HR-pQCT|"Xtreme CT® device is a high resolution peripheral quantitative computed tomography (HR-pQCT) used to measure bone density and quantify the bone architecture to 3D at the extremities of the human body.~For the study, the device will be used to assess bone density and microarchitecture at the forearm and shin for a systemic effect. In rheumatoid arthritis, bone density and microarchitecture will also be measured at the metacarpophalangeal."
224260975|NCT02532439|DEVICE|DEXA|The Lunar Dual Energy X-ray Absorptiometry (DEXA) is a third generation multi-captor DEXA device that allow short duration measurements. It measures Bone Mineral Density (BMD) at the spine and the femoral neck
224260976|NCT02532439|DEVICE|pQCT|Peripheral Quantitative Computed Tomography (pQCT) will be performed and measure bone and muscle parameters.
224260977|NCT01640197|DIETARY_SUPPLEMENT|Resveratrol|Transmax (Biotivia). 500mg (1 capsule) per day for 28 days.
224260978|NCT01640197|OTHER|Placebo|Methyl Cellulose. 1 capsule taken once daily for 28 days.
224260979|NCT06559605|PROCEDURE|zirconia barrier|barrier membrane used for guided bone regeneration and augmentation of ridge defect
224260980|NCT06559605|PROCEDURE|titanium mesh|barrier membrane used for guided bone regeneration
223774053|NCT05495503|DEVICE|Prototype (814D-v1)|Application on PIH located on the dorsal area (2 treatments during the study).
223774054|NCT00451425|BEHAVIORAL|motivational intervention in pregnancy|Motivational program including individualized counseling on diet and physical activity
223774055|NCT01782196|DEVICE|Enhanced one piece drainable pouch with Type A mouldable adhesive|
223774056|NCT01782196|DEVICE|Enhanced one piece drainable pouch with Type B mouldable adhesive|
224260981|NCT00484679|DRUG|Triamcinolone Acetonide 10 mg/mL (Kenalog-10)|Triamcinolone Acetonide 10 mg/ml (Kenalog-10) intralesional injection
224260982|NCT06558708|DRUG|GZR101 Injection|Once daily
224260983|NCT06558708|DRUG|GZR33 Injection|Once daily
224323700|NCT04166487|DRUG|PACLITAXEL|administered per standard practice once per cycle via IV will be administered every 3 weeks, with 21 consecutive days defined as a treatment cycle.
223681087|NCT02222025|OTHER|Injury Prevention Programme|The injury prevention program will be included at the beginning of the usual football training by replacing the traditional warm-up. The programme will be conducted by the coaches at least two times a week (with exception of school holidays). The prevention programme contains seven exercises and lasts about 15 min after familiarisation. Three exercises focus on unilateral, dynamic stability of the lower extremities (hopping, jumping and landing). Further, three exercises emphasize whole body and trunk stability. The last exercise contains rolling movements to improve fall technique. The difficulty of each exercise can be progressively increased in five steps. Players start at the level of difficulty which corresponds to their current performance level. They will proceed to the next level when they perform the exercises with good control. This will be assessed by the coaches.
223681088|NCT03630276|DIAGNOSTIC_TEST|Neutrophil/lymphocyte ratio, Platelet /lymphocyte ratio and CRP|Lab
223681089|NCT03291301|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|Cognitive Behavioral Therapy for Insomnia including psychoeducation, sleep restriction, stimulus control, cognitive restructuring, and relaxation.
224260984|NCT06558708|DRUG|Insulin aspart|Once daily
223681090|NCT03291301|OTHER|Acupressure|Acupressure, a non-invasive therapy, is commonly used in Traditional Chinese Medicine
224260985|NCT00402103|DRUG|Aliskiren|All patients received aliskiren 150 mg for the first two weeks; dose was then force-titrated to aliskiren 300 mg for 52 weeks duration
223681091|NCT04171427|OTHER|Lithium liposome|Cosmetic product
224260986|NCT00402103|DRUG|Amlodipine|All patients received amlodipine 5 mg for the first two weeks; dose was then force-titrated to amlodipine 10 mg for 52 weeks duration
224260987|NCT00402103|DRUG|Hydrochlorothiazide|Optional addition of Hydrochlorothiazide (HCTZ)of 12.5 mg with increase to 25 mg was allowed for patients not adequately controlled.
224260988|NCT05569512|DRUG|Uproleselan|Administered by intravenous infusion
223681092|NCT04171427|OTHER|Placebo|Cosmetic product vehicle
223681093|NCT04791527|BEHAVIORAL|Mind-body therapy|Online yoga, meditation, behavior change tips, and nutrition tips
223774057|NCT06128135|OTHER|Technology acceptance questionnaire for prostheses users.|One questionnaire, which is for prosthesis users, where will be 15 questions to identify what kind of activities the person uses the prosthesis, how much is the use time and what is the main problem with the device.
224260989|NCT05569512|DRUG|Fludarabine|Administered by intravenous infusion
224260990|NCT05569512|DRUG|Clofarabine|Administered by intravenous infusion
223774058|NCT06128135|OTHER|Technology acceptance questionnaire for relatives of prostheses users.|One questionnaire, where there will be between 8 questions to analyze which device characteristics, they think cause major discomfort during the use and could be improved.
224260991|NCT05569512|DRUG|Busulfan|Administered by intravenous infusion
224260992|NCT02128308|DRUG|Levofloxacin and Streptomycin added|
224260993|NCT02128308|DRUG|Moxifloxacin and Kanamycin added|
224260994|NCT06545474|DEVICE|bilateral theta burst stimulation|Each stimulation session consists of 600 stimuli applied in bursts of 3 pulses at 50 Hz, with an interstimulus interval of 200 ms. iTBS is administered 20 times for 2 seconds to the left dlPFC, with an intertrain interval of 8 seconds and cTBS continuously for 40 seconds to the right dlPFC in alternating order.
224323701|NCT04166487|DIAGNOSTIC_TEST|InVision|Plasma draw for clinical test performed at C1D1 and C2D1; plasma draw for research testing performed at other timepoints per protocol.
224323702|NCT01760226|DRUG|DA-EPOCH-R for DLBCL, PTLD, AND PMBCL|"Day 1: Rituximab IV~Days 1-4: After rituximab, etoposide, vincristine, and doxorubicin will be given in a vein over 96 hours as a continuous infusion.~Day 5: cyclophosphamide will be given in a vein~Days 1-5: prednisone given by mouth twice a day~G-CSF 5mcg/kg/day will be given under the skin from day 6 until ANC has improved."
223681094|NCT06326970|DIAGNOSTIC_TEST|99mTc-FAPI SPECT imaging|99mTc radionuclide is labeled to a HYINC-FAPI-04 probe as a tracer. SPECT imaging was performed 2 hours after 99mTc-FAPI intravenous injection into the subject, and image processing and quantitative analysis were performed using the Q.Volumetrix MI System software package.
223681095|NCT03742648|OTHER|Physiotherapy|Chest physiotherapy in burn patients in order to treat and prevent post burn respiratory complications like pneumonia etc
223681096|NCT01995045|DRUG|Triamcinolone|Retrobulbar anesthesia
223681097|NCT01995045|DRUG|Bupivicaine Hydrochloride|Retrobulbar anesthesia
223681098|NCT05419427|DRUG|Denosumab|Denosumab 60 MG/ML
223774059|NCT06128135|OTHER|Technology acceptance questionnaire for therapists|One questionnaire, where there will be between 9 questions to analyze which device characteristics, they think cause major discomfort during the use and could be improved.
224260995|NCT06545474|DRUG|SSRI treatment|Participants receive 4 weeks SSRI treatment with escitalopram (10mg/day) as standard drug.
224260996|NCT06559969|DRUG|Intravenous administered opioid|Hydromorphone will be received intravenously using a patient controlled administration pump, as well as patient will have a continuous bupivacaine epidural infusion
224260997|NCT06559969|DRUG|Epidural administered opioid|Hydromorphone will be added to the bupivacaine in the epidural and will have a continuous infusion along with the ability for the patient to receive epidural boluses of the medications by a patient controlled epidural administration pump
224260998|NCT06560528|DRUG|combination with Disitamab Vedotin and with Tislelizumab and Capecitabine|"Subjects will receive Disitamab Vedotin combined with Tislelizumab and Capecitabine for 3 cycles (Q3W) in the neoadjuvant phase and 5 cycles (Q3W) of treatment in the adjuvant phase.~1. Disitamab Vedotin：2.5 mg/kg，Q3W；~2. Tislelizumab：200 mg，Q3W；~3. Capecitabine：1000 mg /m2, PO, bid d1-14, Q3W."
224260999|NCT00835692|DRUG|Clarithromycin|500 mg Tablet
224261000|NCT00835692|DRUG|Biaxin®|500 mg Tablet
223774060|NCT03759223|BEHAVIORAL|Enhanced Problem-Solving Training (E-PST)|E-PST is a combined treatment that is comprised of brief problem-solving training and compensatory cognitive skills training. Randomized participants were assigned 1:1 to E-PST or HLM.
223774061|NCT03759223|BEHAVIORAL|Healthy Living Messages (HLM)|Healthy Living Messages are primary care-congruent messages that consist of simple advice regarding general health behaviors and preventive care. Randomized participants were assigned 1:1 to E-PST or HLM.
223774062|NCT03759223|BEHAVIORAL|Enhanced Problem-Solving Training (E-PST) (non-randomized)|E-PST is a combined treatment that is comprised of brief problem-solving training and compensatory cognitive skills training. Non-randomized participants were assigned to E-PST only.
223774063|NCT03667339|PROCEDURE|Direct Anterior Total Hip Arthroplasty|Direct Anterior Total Hip Arthroplasty
223774064|NCT03624361|DEVICE|Glaucoma device implantation in a stand-alone procedure|"MINIject implant is used to reduce intra-ocular pressure in the eye through a minimally-invasive Glaucoma surgical intervention.~The intervention is to be performed as stand-alone surgery."
223774065|NCT03430466|DRUG|Durvalmab&Tremelimumab&Fulvestrant|Durvalumab and Tremelimumab once in 4 weeks Durvalumab for 13 months Tremelimumab for initial 4 months Fulvestrant : At baseline, then week 2, week 4 and after that every 4 weeks
223774066|NCT02170727|DRUG|DCV/ASV/BMS-791325|
223774067|NCT05174975|BEHAVIORAL|App-based Positive Psychological Intervention|The PPI has included a 12-week PPI lessons. Each lesson has separated into 3 parts: introduction, activity, and feedback. Diabetes-related health education will include the basic knowledge of diabetes, diet, and exercise related videos. Physical records include record of daily blood sugar, blood pressure, HbA1c, diet, and exercise. In terms of dietary records, the amount of carbohydrates of each food will be calculate automatically after documented. Exercise records documents the burn of calories of each exercise (per 30 minutes). Both unit of dietary and exercise are based on Health Promotion Administration's criteria in Taiwan. Moreover, participants are available to have one-on-one instant online consultation with their diabetes educators via App.
223774068|NCT01599650|DRUG|Ranibizumab|
223774069|NCT01599650|PROCEDURE|Laser|laser photocoagulation
224261001|NCT01360138|PROCEDURE|Cervical epidural steroid injection|cervical epidural steroid injection with a solution (5 ml) containing 10 mg triamcinolone acetonide suspension, 1.5 ml of 0.75% levobupivacaine hydrochloride, and 3.5 ml of normal saline (0.9% NaCl)
224261002|NCT04451746|DRUG|Combined Oral Contraceptive|The investigators consistently include patients who have been prescribed hormonal tablets for contraception, namely 1) COCs with bioidentical estrogen; 2) COCs with ethinyl estradiol 30mkg according to the scheme 21 + 7; 3) COCs with ethinyl estradiol 20mkg according to the scheme 21 + 7.
224261003|NCT04828538|DIETARY_SUPPLEMENT|Vitamin D|Daily 4000 IU Vitamin D for 60 days
223774070|NCT00161928|BIOLOGICAL|Group C Meningococcal Polysaccharide-Tetanus Toxoid Conjugate Vaccine (GCMP-TT)|
224261004|NCT04828538|DIETARY_SUPPLEMENT|Omega DHA / EPA|Daily 1000mg Omega DHA/EPA for 60 days
224261005|NCT04828538|DIETARY_SUPPLEMENT|Vitamin C, Vitamin B complex and Zinc Acetate|"Combination 1000 mg Vitamin C, Vitamin B complex\*\* and Zinc Acetate, 100 mg/day for 60 days~\*\*(Vitamin B complex components: B12=1 mg; B6=50 mg; B9=2.5 mg; B1=100 mg; B2=100 mg; B3=14 mg; B7=50 mg)"
224261006|NCT04828538|OTHER|Placebo|Placebo
224261007|NCT05395052|DRUG|FT536|FT536 is an allogeneic natural killer (NK)-cell immunotherapy
224261008|NCT05395052|DRUG|Cyclophosphamide|Lympho-conditioning agent
224261009|NCT05395052|DRUG|Fludarabine|Lympho-conditioning agent
224261010|NCT05395052|DRUG|IL-2|For Cohort AA ONLY: To be combined with FT536 at the MTD or MAD
224261011|NCT05395052|COMBINATION_PRODUCT|Avelumab|Monoclonal antibody
224261012|NCT05395052|COMBINATION_PRODUCT|Pembrolizumab|For Cohorts C/CC, the combination product (monoclonal antibody) will be ONE of the following: pembrolizumab, nivolumab, or atezolizumab.
223774071|NCT04174677|DRUG|Inebilizumab|Infusion of Inebilizumab
223774072|NCT04174677|DRUG|VIB4920|Infusion of VIB4920
223774073|NCT04174677|DRUG|Inebilzumab+VIB4920|Infusion of Inebilizumab and VIB4920
223774074|NCT03323268|DEVICE|PetCO2 monitoring|CO2 analyzer on ventilator expiratory lane. On-line, continuous, and noninvasive monitor. Routine use in anesthesia and intensive care units.
223774075|NCT05100875|BEHAVIORAL|"Social Skills and Emotion Regulation Training SSERT"|The SSERT intervention will broadly consist of the following 10 modules: (1) Introducing the Participant to Treatment; (2-3) Emotional Awareness and Recognition; (4-5) Emotion Regulation and Understanding Emotions in the Context of Psychotic Experiences; (6) Living an Emotionally Engaged Life; (7) Understanding Relationship Patterns in the Context of Psychosis; (8) Changing Undesirable Relationship Patterns; (9) Learning to have agency in Relationships; and (10) Flexibility in Relationships and Transitioning to Trauma-Focused Therapy.
223774076|NCT04487340|BEHAVIORAL|Education|Provide each center with relevant education of guidelines, and help the clinicians to improve medical quality.
223774077|NCT03212586|DRUG|BAY1902607|Escalating doses of BAY1902607; single dose administration; different dosage forms (redosing of BAY1902607 at dose group 4 with different formulations; redosing of BAY1902607 solid formulation at dose group 4 together with food)
223774078|NCT03212586|DRUG|Placebo|Escalating doses of Placebo; single dose administration; different dosage forms (redosing of Placebo at dose group 4 with different formulations; redosing of Placebo solid formulation at dose group 4 together with food)
223835662|NCT06634056|OTHER|α-Tocopherol|Pentoxifylline 400 mg orally three times a day and α-Tocopherol IU orally two times a day on day one of radiotherapy and continue treatment for 6 months.
224261013|NCT05395052|COMBINATION_PRODUCT|Nivolumab|For Cohorts C/CC, the combination product (monoclonal antibody) will be ONE of the following: pembrolizumab, nivolumab, or atezolizumab.
224261014|NCT05395052|COMBINATION_PRODUCT|Atezolizumab|For Cohorts C/CC, the combination product (monoclonal antibody) will be ONE of the following: pembrolizumab, nivolumab, or atezolizumab.
224261015|NCT05395052|COMBINATION_PRODUCT|Trastuzumab|Monoclonal antibody
224261016|NCT05395052|COMBINATION_PRODUCT|Cetuximab|Monoclonal antibody
224261017|NCT05395052|COMBINATION_PRODUCT|Amivantamab|Monoclonal antibody
224261018|NCT05395052|DRUG|IL-2|For Cohorts BB-FF ONLY: To be combined with FT536 + mAb at the MTD or MAD
224261019|NCT06562309|OTHER|take feces and blood samples from patients|this study does not involve any intervention
224261020|NCT06562387|DEVICE|transcranial direct current stimulation|Transcranial direct current stimulation is one of the most studied techniques in noninvasive neuromodulation. With a very good safety profile and low cost, it has been widely used to modulate cognition and behavior in both experimental and clinical settings. A growing body of literature, including randomized controlled trials, reports the clinical benefits of tDCS for many psychiatric symptoms, such as depression, anxiety, psychosis, addiction, and cognitive functions. tDCS has considerable potential as a treatment due to its relative cost, portability, safety, and ease of use compared to other neuromodulation methods. Early studies evaluated the effects of tDCS on the motor cortex; however, more recent research has also focused on its effects on the dorsolateral prefrontal cortex (DLPFC), in particular for treating psychiatric disorders and modulating cognitive performance.
224261021|NCT06562387|OTHER|cognitive stimulation|This brain stimulation program is based on cognitive reserve and neuronal plasticity to improve mental performance through online games. The activities presented in this tool combine different therapeutic exercises, rehabilitation and learning techniques aimed at retraining and improving the skills most needed by each person. The intervention battery has multi-disciplinary tasks organized in a systematic and strategic way. To make these materials accessible, they are presented in the form of simple games that can be easily practiced through any computer or device. These cognitive stimulation tools are aimed at both healthy subjects and people concerned about their brain health, or patients with some kind of injury or decline in the central nervous system.
224261022|NCT06562387|DEVICE|sham transcranial direct current stimulation|Regarding the simulated condition or sham, the equipment has the option inside to program it. It gives the options: Active / sham protocol, by default: ON - enables active stimulation and OFF - enables sham stimulation. The devices will be programmed, such that a few seconds of stimulation are administered at the beginning and end of the programmed time period to mimic the cutaneous perceptions (itching, tingling) that tend to be reported within the first few moments of stimulator on, without being able to modify cortical excitability.
224261023|NCT03526757|OTHER|Standing Pilates protocol|Subjects will be submitted to a bi-weekly, 50-minute session of Pilates exercises focusing on orthostatic position, for twelve weeks. The following equipment will be used: The Cadillac, Reformer and Chair, emphasizing balance training in the orthostatic position.
224261024|NCT03526757|OTHER|Standard Pilates protocol|Subjects will be submitted to a bi-weekly, 50-minute session of the standard sequence of Pilates exercises (traditional sequence of the contemporary / classical method) for twelve weeks. The exercises will be performed using the same equipment used in the intervention group, but following the dorsal decubitus, sedestation and orthostasis, in a time-balanced distribution in each session.
224261025|NCT01149733|DRUG|Tamsulosin|Test 0.4 mg Capsule
224261026|NCT01149733|DRUG|Tamsulosin|Reference Listed 0.4 Capsule
224261027|NCT05456594|OTHER|Conventional bra|This study involves use of a cross-sectional observation and analysis of behavior using a cross-over approach in assessing breast motion while using a conventional bra (bra condition #1).
224261028|NCT05456594|OTHER|Bounceless bra|This study involves use of a cross-sectional observation and analysis of behavior using a cross-over approach in assessing breast motion while using a provided Bounceless bra (bra condition #2a).
224261029|NCT05456594|OTHER|Shefit bra|This study involves use of a cross-sectional observation and analysis of behavior using a cross-over approach in assessing breast motion while using a provided Shefit bra (bra condition #2b).
224261030|NCT04665596|DEVICE|Ultrasound treatment|Ultrasound treatment of calcified aortic valve causing symptomatic aortic valve stenosis in patients who are not eligible for valve replacemen
224261031|NCT00217763|DRUG|3APS|
224261032|NCT03260153|DRUG|Deproteinised Calf Blood Serum Injection|
224261033|NCT03260153|DRUG|Placebo (Sodium Chloride)|
224261034|NCT02632864|RADIATION|Proton arm|Proton beam therapy
224261035|NCT04345653|DRUG|Hydroxychloroquine Sulfate (HCQ)|Open-label, consecutive at-risk subjects allocation with chemoprophylaxis with HCQ.
224323703|NCT01760226|DRUG|Methotrexate|"CNS negative patients with high CNS risk DLBCL will receive age based, intrathecal dosing of MTX on days 1 and 5 of cycles 3 - 6 only.~CNS positive patients will receive age based, intrathecal (within the spinal fluid) MTX twice weekly for 2 weeks past the first negative cytology with a minimum of 4 weeks treatment. Then, weekly for 6 weeks and then every 4 weeks for 6 months.~DLBCL/PTLD/PMBCL CNS prophylaxis for cycles 3-6 ONLY if:~* 2+ extranodal sites~* elevated LDH,~* MYC rearrangement OR~* bone or marrow disease.~ALL OTHERS receive IT MTX cycles 3-6."
223681099|NCT05419427|DRUG|Denosumab-Ref|Denosumab 60 MG/ML
223681100|NCT01179035|OTHER|Transitions Clinic - parolee-targeted care|Subjects receive ongoing primary care from the Transitions Clinic versus ongoing primary care in the San Francisco Department of Public Health affiliated primary care network.
223681101|NCT01179035|OTHER|Expedited Primary Care|Following randomization, subjects receive ongoing primary care in the San Francisco Department of Public Health affiliated primary care network. Appointments are expedited with safety-net primary care providers.
223681102|NCT00590837|DRUG|Lomustine|"Induction: chemotherapy + lomustine (CCNU), 200 mg/m2 orally at day 1.~Consolidation: chemotherapy + lomustine (CCNU), 80 mg orally at day 1.~Reinductions: chemotherapy + lomustine (CCNU), 40 mg orally at day 1."
223681103|NCT06305871|PROCEDURE|Ablation therapy|Ablative treatment of hyperthyroidism
223681104|NCT00290407|DRUG|Rituximab|375 mg/m2, IV (in the vein), once a week for 4 weeks
223681105|NCT00290407|DIETARY_SUPPLEMENT|Beta-Glucan|250 mg, orally (tablet), three times a day for 9 weeks
223681106|NCT00121797|PROCEDURE|urine culture|
223681107|NCT00121797|DRUG|antibiotics according to culture|
223681108|NCT05095493|DIETARY_SUPPLEMENT|Zinc Acetate|50 mg tablet
223681109|NCT05095493|DIETARY_SUPPLEMENT|Placebo|Zinc Acetate matched placebo tablet
223681110|NCT02391896|DEVICE|Dual energy and tomosynthesis xray|
223681111|NCT04425044|OTHER|Other|No Intervention
223681112|NCT01856283|DRUG|Nilotinib 300mg BID|Nilotinib
223681113|NCT00005665|DRUG|interferon alpha|
223681114|NCT00723203|DRUG|panobinostat|40 mg Monday, Wednesday and Friday of every week in a 28 day cycle
223681115|NCT00723203|GENETIC|gene expression analysis|Day 1 and day 28 samples
223681116|NCT00723203|GENETIC|reverse transcriptase-polymerase chain reaction|Day 1 and day 28 samples
224261036|NCT03964935|DRUG|Lycopene|"Prepared by solving lycopene powder in a solvent (ethanol: propylene glycol: water in the ratio of 50:30:20). The solution was then gelled by adding 8% hydroxypropyl cellulose (HPC). The concentration of the prepared gel equals to 2%.~After SRP, the gel delivered into periodontal pocket using insulin syringes, the therapeutic dose is about 2mg/0.1 ml."
224261037|NCT03964935|DRUG|Minocycline HCl 1mg Oral Powder|Minocycline HCl Microspheres, 1mg minocycline powder per cartridge. A locally applied antibiotic that is placed directly into the infected periodontal pocket following SCR.
224323704|NCT01760226|DRUG|Etoposide|Etoposide will be given at 50mg/m2/day on days 1-4 of the first cycle of therapy (dose based on patient height and weight). The doses in later cycles will be adjusted up or down based on the patient's blood test results.
224261038|NCT03964935|OTHER|Distilled water|Used to irrigate periodontal pockets after SRP
224261039|NCT00360763|DRUG|candesartan cilexetil|
223681117|NCT00723203|OTHER|laboratory biomarker analysis|Day 1 and day 28 samples
224261040|NCT03823924|PROCEDURE|Bone mineral density (BMD)|"The bone mineral density (BMD) performed by DXA, which will allow the analysis of bone density (mg / cm²) at the lumbar spine (BMD L1 to L4) and the total hip (non-dominant).~This examination will also allow an analysis of the body composition at the same time (lean mass, fat mass and bone mass for the whole body)."
224261041|NCT00412503|DRUG|Topotecan, Temozolomide|
224261042|NCT04078022|BIOLOGICAL|SF2a-TT15 Shigella Vaccine|0.5 mL of the vaccine is administered via an intramuscular injection into the deltoid muscle on Study Day 1 and Study Day 29.
224261043|NCT04078022|OTHER|Placebo|0.5 mL of normal saline is administered via an intramuscular injection into the deltoid muscle on Study Day 1 and Study Day 29.
224261044|NCT04078022|BIOLOGICAL|S. flexneri 2a strain 2457T Challenge Agent|Each participant will drink 120 mL of sodium bicarbonate buffer solution. Approximately 1 to 2 minutes later, the participant will ingest approximately 1500 cfu of S. flexneri 2a strain 2457T suspended in 30 mL of the bicarbonate buffer solution.
224261045|NCT01798719|BEHAVIORAL|Low Glycemic Index Mediterranean Diet|A list of foods that may be consumed frequently (green foods), sometimes (yellow foods) and never (red foods)
223681118|NCT00002083|DRUG|Peptide T|
223681119|NCT02125643|DRUG|Caffeine|
223835663|NCT05879120|DRUG|Pembrolizumab|Given by IV (vein)
224261046|NCT01798719|BEHAVIORAL|General Advice|Only general advice about diet
224261047|NCT00304538|DRUG|very low dose (VLD) glucagon|
224261048|NCT01370811|DRUG|oxybutynin and clonidine oral solution treatment A|
224261049|NCT01370811|DRUG|oxybutynin and clonidine oral solution treatment B|
224261050|NCT01370811|DRUG|oxybutynin and clonidine oral solution treatment C|
224261051|NCT01370811|DRUG|oxybutynin and clonidine oral solution treatment D|Placebo
224261052|NCT01895335|DRUG|Teriflunomide|Pharmaceutical form: film-coated tablet; Route of administration: oral
224261053|NCT00418938|DRUG|Panitumumab|6mg/kg IV
224261054|NCT00418938|DRUG|Bevacizumab|Either 5mg/kg OR 10mg/kg IV
224323705|NCT01760226|DRUG|Doxorubicin|Doxorubicin will be given at 10mg/m2/day on days 1-4 of the first cycle (dose based on patient height and weight). The doses in later cycles will be adjusted up or down based on the patient's blood test results.
224323706|NCT01760226|DRUG|Vincristine|Vincristine will be given on days 1-4 of each cycle at 0.4mg/m2/day (dose based on patient height and weight).
224323707|NCT01760226|DRUG|Rituximab|Rituximab (375mg/m2/dose) will only be given on Day 1 of each cycle prior to all the other chemotherapy agents. Dose is based on patient height and weight.
224323708|NCT01760226|DRUG|Cyclophosphamide|Cyclophosphamide will be given on Day 5 of each cycle. In cycle 1, the dose will be 750 mg/m2 (based on patient height and weight), and the dose will be adjusted up or down for future cycles based on blood test results.
223681120|NCT02125643|OTHER|Flour|Flour will be administered as the placebo.
223681121|NCT01589627|DEVICE|Wrist Extension Dynasplint|Dynamic Splinting utilizes the protocols of Low-Load, Prolonged-Duration Stretch (LLPS) with calibrated, adjustable tension to increase the Total End Range Time (TERT) to reduce contracture. The Knee Extension Dynasplint for the Experimental group will have tension chambers delivering therapeutic treatment from the device.
223681122|NCT04099771|DRUG|Ketamine|Ketamine infusion
223681123|NCT05503121|DIAGNOSTIC_TEST|3D motion analysis, muscle activation, biomarker analysis|Participants with nonspesific low back pain and control group will be analysed with 3D motion analysis sistem, sEMG and will be checked the biomarkers. Then the data will be compared.
223681124|NCT05086068|DEVICE|Arthrosamid|Intra-articular hydrogel injection comprising of water and cross-linked polyacrylamide.
223681125|NCT04259892|BIOLOGICAL|2019-nCoV PCR|Nasopharyngeal swabs
223835664|NCT05879120|DEVICE|Exablate MRgFUS + neoadjuvant pembolizumab|Given by IV (vein)
224261055|NCT00418938|DRUG|Leucovorin|400mg/m\^2 IV (in the vein)
224261056|NCT00418938|DRUG|Irinotecan|180mg/m\^2 IV (in the vein)
224261057|NCT00418938|DRUG|5-Fluorouracil|400mg/m\^2 bolus IV (in the vein) over 2-4 min, followed by 2400mg/m\^2 continuous IV over 46 hours for the first 2 cycles, increased to 3000mg/m\^2 thereafter if no significant side effects
224261058|NCT00082147|PROCEDURE|Biopsy|Patients will then undergo endorectal coil MR imaging of the prostate gland, including conventional anatomic imaging and dynamic-contrast-enhanced MRI During MR imaging, 4 to 10 needle biopsy cores of the prostate will be obtained using a trans-rectal needle guide system (APT-MRI).
224261059|NCT00115063|BEHAVIORAL|group sessions|group sessions lead by a trained primary care clinic employee
224261060|NCT00115063|DRUG|sibutramine, orlistat, diethylpropion|dosage modified according to package insert instructions at discretion of primary care physicians
224261061|NCT00115063|BEHAVIORAL|Low Calorie Diet, Health One|liquid diet for 8-12 weeks to induce weight loss
224261062|NCT00115063|OTHER|Intensive Medical Combination Therapy for Obesity|"Very Low Calorie Liquid diet, Group Behavioral Therapy, Meal Replacement Therapy, Obesity Pharmacotherapy and a Treatment Toolbox."
224261063|NCT00115063|OTHER|Control Condition|Access to the Mayo Clinic weight management website and usual care from the primary care physician
224261064|NCT05125900|OTHER|Proximal box elevation using one of the tested materials|Each patient randomly received deep proximal margin elevation with one of the tested restorative materials, while the overlying restorations were all the same regular bulk fill resin composite
224261065|NCT05949853|OTHER|the respiratory parameters (AHI) and time spent|interpret the recording will be evaluated for PSG, PV and PV+ASEEGA Apnea Hypopnea Index as assessed by PSG (respiratory signals + electro-encephalography + electro-oculography + chin electromyography), PV (respiratory signals) and PV+ASEEGA (respiratory signals + result of sleep stages and arousals scoring by ASEEGA algorithm based on automatic analysis of one EEG Cz-Pz channel)
223774079|NCT03074734|OTHER|Exposure to secondhand tobacco smoke|The intervention is exposure to secondhand smoke of COPD and asthma patients in outside smoking areas (no specific drugs or devices are tested in this study). Study subjects will be asked to spend at least 15 minutes in the outdoor smoking area, a preferable time of 30-60 mins. During the exposure period (15-60 min) subjects´ respiratory rates will be recorded using RESpeck device, as well as the air quality which will be monitored using AirSpeck device.
224261066|NCT01857947|OTHER|AECOPD Mr proADM|
224323709|NCT01760226|DRUG|Prednisone|Prednisone will be given by mouth at 60mg/m2/dose (based on height and weight) twice a day on days 1-5 of each cycle.
224323710|NCT01760226|DRUG|G-CSF|G-CSF will be given at 5 mcg/kg/day during each cycle, starting on day 6, until the patient's ANC (absolute neutrophil count) is greater than 5000/mcL past nadir.
224261067|NCT00789308|DRUG|Low Molecular Weight Sulfated Dextran (LMW-SD)|Inhibitor of IBMIR
224261068|NCT00789308|DRUG|Heparin|Anticoagulation
224261069|NCT00789308|DRUG|CellCept® (Mycophenolate mofetil) OR Rapamune® (Sirolimus)|Cell proliferation inhibitor
224261070|NCT00789308|DRUG|Prograf® (Tacrolimus) OR Cyclosporine|Calcineurin inhibitor
224261071|NCT00789308|DRUG|Thymoglobulin® (Anti-thymocyte Globulin) - at first transplant|
224261072|NCT00789308|DRUG|Simulect® (Basiliximab) - at 2nd or 3rd transplant|Monoclonal IL-2 receptor blocker
224261073|NCT00789308|DRUG|Klexane® (Enoxaparinsodium)|Anticoagulation Prophylaxis
224261074|NCT00789308|DRUG|Trombyl® or Albyl-E® (Acetylsalicylicacid- ASA)|Anticoagulation Prophylaxis
224261075|NCT00789308|DRUG|Enbrel® (Etanercept)|Anti-Inflammatory Therapy
224261076|NCT02982577|DRUG|Pilocarpine|Spray the basis of 1.54% pilocarpine, 3 times per day (each 8 hours), during 90 days.
223681126|NCT01687556|OTHER|topical EGCG application on acne|two times application of topical EGCG on acne lesion
223681127|NCT03253419|OTHER|Home for Life mobile application|Utilize home application to provide the participant with an understanding and recommendations to potentially decrease home hazards that may lead to risk of falls in their home.
223681128|NCT00274924|BIOLOGICAL|filgrastim|Given subcutaneously or intravenous bolus.
223681129|NCT00274924|BIOLOGICAL|rituximab|Given IV
223774080|NCT04650828|DRUG|TDF|TDF combined with telbivudine (LDT) for 12 months
224261077|NCT02982577|OTHER|Spray without Pilocarpine|Spray without pilocarpine, 3 times per day (each 8 hours), during 90 days.
224261078|NCT04953520|PROCEDURE|ultrasound-CT fusion imaging|The patient undergoes lumbar nerve root block guided puncture needle placement under the guidance of ultrasound-CT fusion imaging
224261079|NCT04953520|PROCEDURE|pure ultrasound guidance|The patient undergoes lumbar nerve root block guided puncture needle placement under the guidance of pure ultrasound guidance
224261080|NCT01718704|DEVICE|Viberect device|Men who begin using the Viberect device 3 days after Foley catheter removal on a daily (or at least 4 times a week) basis for 7-10 minutes in a relaxed setting with sexual thoughts or foreplay for one year. Viberect method can be performed by the person's sexual partner.
224261081|NCT01731457|DRUG|etanercept|adding appropriate dose of etanercept to the perfusion fluid
224261082|NCT00926835|DRUG|paroxetine|6 weeks, 20-50mg/day
224261083|NCT00926835|DRUG|Escitalopram|10-20mg/day for 6 weeks
224261084|NCT00926835|DRUG|Venlafaxine XR|Venlafaxine 75-225mg/day for 6 weeks
224261085|NCT00926835|DRUG|Paroxetine+Bupropion|paroxetine 20-50mg/day + bupropion 150-400mg/day for 6 weeks
224261086|NCT00926835|DRUG|Paroxetine+Lamotrigine|Paroxetine 20-50mg/day + lamotrigine 100-400mg/day for 6 weeks
223681130|NCT00274924|DRUG|carboplatin|Given IV
223681131|NCT00274924|DRUG|cyclophosphamide|Given IV
224261087|NCT00926835|DRUG|Paroxetine+Lithium|Paroxetine 20-50mg/day + lithium 0.5-1.2 mEq/L
223681132|NCT00274924|DRUG|doxorubicin hydrochloride|Given IV
223681133|NCT00274924|DRUG|etoposide|Given IV
223681134|NCT00274924|DRUG|ifosfamide|Given IV
223681135|NCT00274924|DRUG|prednisone|Taken orally
223681136|NCT00274924|DRUG|vincristine|Given IV
224261088|NCT00926835|DRUG|Escitalopram+Mirtazapine|escitalopram 10-20mg/day + mirtazapine 15-45mg/day for 6 weeks
224261089|NCT00926835|DRUG|Escitalopram+Aripiprazole|escitalopram 10-20mg/day + aripiprazole 5-15mg/day for 6 weeks
224261090|NCT00926835|DRUG|Paroxetine + Venlafaxine XR|Paroxetine 20-50mg/day + Venlafaxine 75-225mg/day for 6 weeks
224261091|NCT01075282|DRUG|Insulin Glargine|
224261092|NCT01075282|DRUG|LY2189265|
224261093|NCT01075282|DRUG|Metformin|
224261094|NCT01075282|DRUG|Glimepiride|
223774081|NCT04650828|DRUG|Tenofovir Disoproxil Fumarate 300 MG|TDF monotherapy was continued for 12 months
223774082|NCT05580575|DEVICE|Daily disposable toric soft contact lens|Daily disposable toric soft contact lens
223774083|NCT05580575|DEVICE|Monthly replacement toric daily wear soft contact lens|Monthly replacement toric daily wear soft contact lens
223774084|NCT02488044|DRUG|AEB1102|modified human arginase I
223774085|NCT04595838|DEVICE|Chemo Mouthpiece|Frozen tube that fills the oral cavity used during and after chemotherapy to ease and prevent symptoms of oral mucositis
224261095|NCT01360333|OTHER|tap water, sodium chloride, carbohydrate rich fluid|Ingestion of three different fluids at three different occasions separated by at least one week, A, Tap water. B. Sodium Chloride. C. Carbohydrate rich fluid.
224261096|NCT03352362|DRUG|ibuprofen (caldolor 10 mg / kg)|Dilution caldolor 10 mg / kg in Hartmann solution to 50 mL - 100 mL and intravenous injection for 30 minutes immediately after induction of anesthesia
224261097|NCT03352362|DRUG|propacetamol (denogan 30 mg / kg)|Dilution denogan 30 mg / kg in the dissolved solution to a total of 10 ml and intravenous injection for 10 minutes after the main surgical procedure end
224323711|NCT05972551|DRUG|Romosozumab|Subcutaneous (SC) injection
224323712|NCT05972551|DRUG|Bisphosphonate|Administration determined by investigator according to the local standard of care
224261098|NCT03352362|DRUG|ibuprofen + propacetamol|Dilution caldolor 10 mg / kg in Hartmann solution to 50 mL - 100 mL and intravenous injection for 30 minutes immediately after induction of anesthesia Dilution denogan 30 mg / kg in the dissolved solution to a total of 10 ml and intravenous injection for 10 minutes after the main surgical procedure end
224261099|NCT00700739|DEVICE|DISCOVER™ Artificial Cervical Disc|DISCOVER™ Artificial Cervical Disc
224261100|NCT00700739|DEVICE|ACDF|Cervical CFRP I/F CAGE® and SLIM LOC(R) Anterior Cervical Plate System with allograft
224261101|NCT05997108|DIAGNOSTIC_TEST|CBC|Platelet and red blood cell volume indices
224261102|NCT05269069|OTHER|Assessment of body composition, bone mineral density and bone marrow adiposity.|DXA for body composition and bone mineral density, MRI for bone marrow adiposity and blood tests (leptine, CTX, P1NP)
224261103|NCT01712906|BIOLOGICAL|3.50±0.25logCCID50/ml|Attenuated Mumps vaccine (KMB-17) of 3.50±0.25logCCID50/ml in adults (16-59 years old)，children (5-15 years old or 2-4 years old) and infants (8-23 months old) on day 0.
224261104|NCT01712906|BIOLOGICAL|4.25±0.25 logCCID50/ml|Attenuated Mumps vaccine (KMB-17) of 4.25±0.25 logCCID50/ml in adults (16-59 years old)，children (5-15 years old or 2-4 years old) and infants (8-23 months old) on day 0.
224261105|NCT01712906|BIOLOGICAL|5.00±0.25 logCCID50/ml|Attenuated Mumps vaccine (KMB-17) of 5.00±0.25 logCCID50/ml in adults (16-59 years old)，children (5-15 years old or 2-4 years old) and infants (8-23 months old) on day 0.
223681137|NCT04995796|OTHER|Surveys for Research Purposes|"VISIT #1:~1. Pre-Testing:~   * Pre Knowledge Test~  * Pre SURE (decisional conflict) test~2. Independent DSI/DA Interaction~3. Post-Testing:~   * Post Knowledge Test~  * Post SURE (decisional conflict) Test~  * Acceptability Index~  * Modified Single Item Literacy Screen~  * Additional Demographics~VISIT #2: Check-In Call 1 week later:~After viewing the DSI/DA and completing the post-test components above, the subjects will also complete a 5 minute debrief interview about 1 week later via phone or video conference with a team member to give feedback on their experience using the DSI/DA, including its strengths and weaknesses. This will allow for further improvement and refinement of the DSI."
223681138|NCT00164229|BEHAVIORAL|math|
223681139|NCT00164229|BEHAVIORAL|behavior regulation|
223681140|NCT00740051|DRUG|Linagliptin|5mg once daily
223681141|NCT00740051|DRUG|Linagliptin Placebo|0 mg placebo comparator for part 1 of study (to 18 weeks)
223681142|NCT00740051|DRUG|Glimepiride|1-4mg for part 2 of study (weeks 19-52)
223681143|NCT00661986|DIETARY_SUPPLEMENT|dark chocolate 6 g/day|dark chocolate 6 g/day
223681144|NCT00661986|DIETARY_SUPPLEMENT|dark chocolate 25 g/day|dark chocolate 25 g/day
223681145|NCT04739865|DRUG|Psilocybin|Open label
223681146|NCT06166030|DIETARY_SUPPLEMENT|Nutritional blend (ImmuneRecov).|Effects of 30 days supplementation with ImmuneRecov on Peripheral and Respiratory Muscle Strength, on Lung Function and Immune Response.
223681147|NCT00522964|BEHAVIORAL|behavioral intervention|The intervention is based on Social Cognitive Theory and principles of Chinese culture and practices. The intervention program includes a one-hour small-group session for eight weeks for children and two 2-hour small-group sessions for parents.
223681148|NCT04936464|DEVICE|transcutaneous tibial nerve stimulation (TTNS)|TTNS is a non-invasive, surface electrode therapeutic stimulation technique available for home administration that has been proposed as a treatment for overactive bladder.
223681149|NCT04936464|DEVICE|transcutaneous electrical stimulation (TENS)|The sham intervention is designed to appear almost identical to the TTNS intervention.
223681150|NCT01055496|DRUG|inotuzumab ozogamicin+rituximab +cyclophosphamide+vincristine+prednisone|"Day 1:~Rituximab at 375 mg/m2 Cyclophosphamide at 375 mg/m2 (cohort 1), 550mg/m2 (cohort 2), 750 mg/m2 (cohort 3, 4) Vincristine at 1.4 mg/m2 (max 2 mg)~Day 2 Inotuzumab ozogamicin at 0.8 mg/m2 (cohort 1, 2, 3), 1.3 mg/m2 (cohort 4)~Days 1-5:~Prednisone at 40 mg/m2~Each cycle is 3 weeks, with a maximum of 6 cycles total."
223681151|NCT01055496|DRUG|inotuzumab ozogamicin+rituximab+gemcitabine+cisplatinum+dexamethasone|"Day 1:~Rituximab at 375 mg/m2 Gemcitabine at 500 mg/m2 (cohort 1, 2b, 3b), 1000mg/m2 (cohort 2a, 3a, 4, 5) Cisplatin at 37.5 mg/m2 (cohort 1, 2a), 50mg/m2 (cohort 2b, 3a), 75mg/m2 (cohort 3b, 4, 5)~Day 2:~Inotuzumab ozogamicin at 0.8 mg/m2 (cohort 1, 2a, 2b, 3a, 3b, 4), 1.3mg/m2 (cohort 5)~Days 1-4:~Dexamethasone at 40 mg~Each cycle is 3 weeks, with a maximum of 6 cycles total."
223681152|NCT05884632|RADIATION|Daily Adaptive RadioTherapy|Patients will be treated on the prostate bed with Ethos using daily-adaptive modality with the dose of 59 Gy in 20 daily fractions of 2.95 Gy
223681153|NCT01295931|DRUG|Indocyanine Green (IC-Green)|5 intradermal injections, 25 µg IC-Green in 0.1 mL of saline, in locations on the extremity (i.e. arm or leg) correlating with the tumor draining nodal basin to begin. Corresponding injections performed on the contralateral limbs.
223681154|NCT01295931|PROCEDURE|Imaging|Nonradioactive optical imaging with indocyanine green as a fluorescent contrast agent prior to sentinel lymph node biopsy or lymph node surgery.
223681155|NCT05319093|DRUG|Ozanimod|Three-months, longitudinal observational period
223681156|NCT00181623|DRUG|Recombinant Human Prolactin|
223681157|NCT01116479|OTHER|Blood transfusion|Blood transfusion with packed erythrocytes
223681158|NCT05245396|DRUG|Ref (TF2)|Participants will receive 2 single oral doses of Ref (TF2) on Day 1 in treatment period 1, 2, or 3 of Part A, B, C and D.
223681159|NCT05245396|DRUG|Evobrutinib MR-T1|Participants will receive single oral dose of MR-T1 on Day 1 in treatment period 1, 2, and 3 of Part A.
223681160|NCT05245396|DRUG|Evobrutinib MR-T2|Participants will receive single oral dose of MR-T2 on Day 1 in treatment period 1, 2, and 3 of Part A.
223681161|NCT05245396|DRUG|Evobrutinib MR-T3|Participants will receive single oral dose of MR-T3 on Day 1 in treatment period 1, 2, and 3 of Part A.
223681162|NCT05245396|DRUG|Evobrutinib MR-T4|Participants will receive single oral dose of MR-T4 on Day 1 in treatment period 1, 2, and 3 of Part A.
223681163|NCT05245396|DRUG|Evobrutinib MUPS-C1|Participants will receive single oral dose of MUPS-C1 on Day 1 in treatment period 1, 2, and 3 of Part B.
223681164|NCT05245396|DRUG|Evobrutinib MUPS-C2|Participants will receive single oral dose of MUPS-C2 on Day 1 in treatment period 1, 2, and 3 of Part B.
223681165|NCT05245396|DRUG|Evobrutinib MUPS-C3|Participants will receive single oral dose of MUPS-C3 on Day 1 in treatment period 1, 2, and 3 of Part C.
223681166|NCT05245396|DRUG|Evobrutinib MUPS-C4|Participants will receive single oral dose of MUPS-C4 on Day 1 in treatment period 1, 2, and 3 of Part C.
223774086|NCT04595838|OTHER|Best Supportive Care only|Standard Oral care for Chemotherapy
223774087|NCT01259193|DRUG|Sorafenib and Zoledronic Acid|Sorafenib ,tablet,400mg Bid ,until patient can not tolerance Zoledronic Acid ,powder for injection,4mg per 3 week for 1 year
223774088|NCT06453993|OTHER|Exhaled VOC breath test|To determine longitudinal variation in exhaled VOC concentrations during intended curative therapy for EC cancer.
224261106|NCT01712906|BIOLOGICAL|0 logCCID50/ml|0 logCCID50/ml in adults (16-59 years old)，children (5-15 years old or 2-4 years old) and infants (8-23 months old) on day 0.
224261107|NCT01712906|BIOLOGICAL|Attenuated Mumps vaccine (Zhe Jiang Vacn Bio-pharmaceutical Co., LTD.; NO.20110528-1)|Attenuated Mumps vaccine (Zhe Jiang Vacn Bio-pharmaceutical Co., LTD.; NO.20110528-1) in children (2-4 years old) and infants (8-23 months old) on day 0.
224261108|NCT04863560|OTHER|Auditory Cueing|Metronome beat to step in time with
224261109|NCT04863560|OTHER|Visual Cueing|Lines on the floor to step over
224261110|NCT04863560|OTHER|tactile Cueing|Vibration to step in time with (metronome like)
224261111|NCT03734861|DEVICE|BreatheSmart System|"* BreatheSmart System: a mobile application that tracks medication usage and sends real time reminders~* HeroTracker sensor that counts dosage and monitors real-time medication adherence~* CoheroConnect provider portal that allows the Investigator to monitor adherence"
224261112|NCT03734861|OTHER|Standard of Care|These patients are reminded to adhere to the prescribed standard of care therapy provided by their clinician during their clinical encounters and when the family calls to report an illness.
224261113|NCT04173858|DRUG|Naloxegol|25 mg oral naloxegol once daily.
224261114|NCT05277402|DRUG|ADG116|IV infusion
224261115|NCT05418374|PROCEDURE|Continous Spinal Anestheisa|Continuous spinal anesthesia (CSA) describes subarachnoid blockade maintained by local anesthetics administered through an indwelling spinal catheter. CSA provides fewer episodes of hypotension and no severe hypotension versus single dose bupivacaine also it offers the ability to titrate the dose of local anesthetics needed while maintaining hemodynamic stability.
224261116|NCT01506622|DRUG|Administration of propofol|Propofol 1 mg/kg will be administered to propofol group at the end of anesthesia.
224261117|NCT01506622|DRUG|Administration of fentanyl|Fentanyl 1 mcg/kg will be administered to fentanyl group at the end of anesthesia.
224261118|NCT01506622|DRUG|Administration of saline|Saline will be administered to control group at the end of anesthesia.
224261119|NCT00002562|DRUG|paclitaxel|
224261120|NCT04067739|OTHER|non interventional study|non interventional study
224261121|NCT05439707|DEVICE|transaricular vagus nerve stimulation|The transaricular vagus nerve stimulator was placed in the left ear trunk, which is dominated only by the auricular branch of the vagus nerve. Continuous stimulation was performed at a frequency of 25Hz with pulse width of 300 μs. The stimulation was adjusted to be higher than the perception threshold and lower than the pain threshold. Each stimulation lasted for 30 minutes, three times per day (morning, noon, evening), from 1 day before surgery to 7 days after surgery, and the treatment lasted for 9 consecutive days.
224323713|NCT06317662|DRUG|Asparaginase Erwinia chrysanthemi|Given recombinant crisantaspase IM or crisantaspase IM or IV
224323714|NCT06317662|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
224323715|NCT06317662|BIOLOGICAL|Blinatumomab|Given IV
224323716|NCT06317662|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
223681167|NCT05245396|DRUG|Evobrutinib MR-T adapated|Participants will receive single oral dose of MR-T adapted on Day 1 in treatment period 1, 2, and 3 of Part D.
223681168|NCT01673282|DRUG|Lacosamide|Route of Administration: oral/subcutaneous Form and Dosage: Tablet (50 mg/100 mg/150 mg, 200 mg); Syrup (10 mg/ml); Solution for infusion (10 mg/ml).
223681169|NCT03158792|DRUG|Enoxaparin 20Mg/0.2mL Prefilled Syringe|Enoxaparin 20mg subcutaneously once daily
223681170|NCT03158792|DRUG|Enoxaparin 60Mg/0.6Ml Inj Syringe 0.6Ml|Enoxaparin 30mg subcutaneously once daily. Half of the graduated 60Mg/0.6Ml Inj Syringe is administered
223681171|NCT03446261|DRUG|Rosuvamibe® Tab|Rosuvastatin 5mg/ezetimibe 10mg qd for 8 weeks
223681172|NCT03446261|DRUG|Monorova® Tab|Rosuvastatin 10mg qd for 8 weeks
223681173|NCT02735889|OTHER|No Carbonation|500 ml of beverage consisting of water + 10% glucose and no carbonation
223681174|NCT02735889|OTHER|Low carbonation|500 ml of beverage consisting of water + 10% glucose and low carbonation
223681175|NCT02735889|OTHER|High carbonation|500 ml of beverage consisting of water + 10% glucose and high carbonation
223681176|NCT03935399|DRUG|Oxytocin|10 IU oxytocin (Pitocin) for intramuscular injection
223681177|NCT03935399|DRUG|Saline|1.5 ml preservative free saline for intramuscular injection
223681178|NCT03111069|PROCEDURE|Abdominal Surgery|"Resectable Intra-Abdominal/Pelvic Tumors Group: Participants receive peritonectomy, omentectomy, cytoreduction, (complete surgical tumor resection, no gross residual disease).~Unresectable Intra-Abdominal/Pelvic Tumors Group: Participants receive debulking surgery (90% resection) , with no more than 5mm thick residual implants, totaling no more than 2.5cm2 of residual tumor."
223681179|NCT03111069|DRUG|Doxorubicin|"Dose Escalation: Heated Doxorubicin delivered by Hyperthermic Intraperitoneal Chemotherapy (HIPEC). After abdominal surgery two large bore catheters are placed in the peritoneal cavity through the incision. Starting dose of Doxorubicin is 15 mg/L of HIPEC perfusate.~Dose Expansion Starting Dose: MTD from Dose Escalation."
223681180|NCT03111069|RADIATION|Intra-Operative Radiation|Standard dose brachytherapy delivered to the residual pelvic tumor sites.
223681181|NCT01358279|PROCEDURE|transcranial direct current stimulation|A constant current of 2 mA intensity applied for 20 min over C3 or C4
223681182|NCT01112683|DRUG|Memantine|The drug dosage will follow memantine's standard titration schedule (i.e., 5 mg/d week one, 5 mg/BID week two, 5 \& 10 mg/d divided dose week three, 10mg/BID week four).
223681183|NCT01112683|DRUG|Placebo|These are identically-looking pills to those in the Memantine Arm.
223681184|NCT01813045|PROCEDURE|Cardiac MRI scan|Cardiac MRI scan with assessment of late gadolinium enhancement and T1 mapping.
223681185|NCT01813045|RADIATION|CT-PET scan|Computed Tomography / Positron Emission Tomography scan with 18F-fluciclatide tracer.
223681186|NCT01813045|RADIATION|CT-coronary angiogram|CT-coronary angiogram following CT-PET scan. Standard protocol.
223681187|NCT01373307|BEHAVIORAL|LHA-delivered energy balance classes/activities|4-6 sessions delivered by local LHA to age-appropriate groups (i.e., children/adolescents and adults), based on We Can! And Media Smart Youth curricula.
224261122|NCT05439707|DEVICE|fake transaricular vagus nerve stimulation|The transaricular vagus nerve stimulator was placed in the same position as the experimental group, covered with an insulating film and placed at the site of the stimulation, so that the patient could not actually receive the electrical stimulation. Continuous stimulation was performed at a frequency of 25Hz and pulse width of 300 μs, and the stimulation was adjusted to be higher than the perception threshold and lower than the pain threshold. Each stimulation lasted for 30 minutes, three times per day (morning, noon, evening), from 1 day before surgery to 7 days after surgery, for 9 consecutive days.
223681188|NCT05778643|BEHAVIORAL|TaKeTiNa music therapy|TaKeTiNa music therapy uses a group to perform music together. Each member of the group is needed for the synchronization of the whole group. The group actively makes Music with hands, feet, and the voice. At the same time, the therapist frequently introduces new elements into the process and challenges the group in this playful manner. Through this, patients consistently report an increase in mindful awareness and an alleviation of many depressive symptoms, although these effects have not been shown in controlled studies yet.
224261123|NCT04626154|DIAGNOSTIC_TEST|Objectively monitoring thoracoabdominal asynchrony|Objectively monitoring thoracoabdominal asynchrony
224261124|NCT01447511|DRUG|Control - Warfarin only|A single 10 mg warfarin dose taken at the start of the study period. No other medications taken during this study period.
224261125|NCT01447511|DRUG|Fluconazole - Warfarin|A single 10 mg warfarin dose taken at the start of the study period. 400 mg fluconazole taken every morning starting a week before the start of the study period and continuing throughout the study period.
224261126|NCT01447511|DRUG|Rifampin - Warfarin|A single 10 mg warfarin dose taken at the start of the study period. 300 mg rifampin taken every morning starting a week before the start of the study period and continuing throughout the study period.
224261127|NCT04738448|BEHAVIORAL|Art Therapy Group|The art therapy intervention will be executed by the same Medical University of South Carolina (MUSC) board-certified art therapist for each group. The art therapist is a masters-level, licensed practitioner who has experience working in the healthcare system and treating providers. The same art therapy practices that are utilized in daily practice at MUSC will be employed in this study, with a focus on reducing burnout symptoms. Pilot testing of the intervention has been performed informally at MUSC with positive feedback reported by healthcare providers.
224261128|NCT03893123|OTHER|Observational study, prostate cancer is outcome of interest|Observational study
224261129|NCT06151691|OTHER|Blood collection and Pancreatic ductal adenocarcinoma minimal residual disease detection test|"Blood samples of participants meet the inclusion/exclusion criteria will be collected.~Pancreatic ductal adenocarcinoma minimal residual disease detection test."
224261130|NCT01067833|DRUG|K201 Tablet|oral tablet, x28 days
224261131|NCT01067833|DRUG|Placebo Tablet|oral tablet, x28 days
224261132|NCT01316055|DRUG|Dalfampridine-ER|2 days of single dose 7.5 mg, 4 days of bid dosing, and a 3 day follow-up
224261133|NCT00003470|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|"Adults with an anaplastic astrocytoma that has not responded to standard therapy will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
224261134|NCT02919462|DRUG|Oral vinorelbine|Oral vinorelbine 60-80 mg/m2 on days 1 and 8 (first cycle 60 mg/m2) every 3 weeks, for 4 cycles
224261135|NCT02919462|DRUG|Cisplatin|Cisplatin 80 mg/m2 on day 1 every 3 weeks, for 4 cycles
224261136|NCT02919462|DRUG|Maintenance with Metronomic Oral Vinorelbine|Maintenance with Metronomic Oral Vinorelbine 50 mg three times a week on Monday, Wednesday and Friday continuously until disease progression, patient refusal or excessive toxicity (1 cycle: 3 weeks).
224261137|NCT02919462|DRUG|Pemetrexed|Pemetrexed, 500 mg/m2, day 1 every 3 weeks, for 4 cycles
224261138|NCT02919462|DRUG|Cisplatin|Cisplatin 75 mg/m2, day 1 every 3 weeks, for 4 cycles
224261139|NCT02919462|DRUG|Maintenance with Pemetrexed|Maintenance with Pemetrexed 500 mg/m2 day1 q 21 until disease progression (1 cycle: 3 weeks)
224261140|NCT01188863|DRUG|300 mg LX4211 (150 mg tablets)|Single oral dose of two 150 mg tablets LX4211
224261141|NCT01188863|DRUG|300 mg LX4211 (50 mg tablets)|Single oral dose of six 50 mg tablets LX4211
224261142|NCT01188863|DRUG|300 mg LX4211 (liquid)|Single 30 mL dose of liquid oral solution LX4211 (10 mg/mL)
224261143|NCT05129176|DRUG|Levofloxacin|levofloxacin-tetracycline-containing quadruple regimens
224261144|NCT05129176|DRUG|Metronidazole|Metronidazole-tetracycline-containing quadruple regimens
224261145|NCT02679729|DRUG|AZD5634 for inhalation|Solution, citrate buffer, saline nebulizer solution; strength 0.1 - 5 mg/g; administered by jet nebulizer
224261146|NCT02679729|DRUG|AZD5634 for infusion|Solution, citrate buffer, saline solution for infusion; strength 0.013 mg/mL
224261147|NCT02679729|OTHER|Placebo|inactive substance
223774089|NCT03835442|DRUG|Baclofen|baclofen 10mg tid for 4 weeks
224261148|NCT02915445|BIOLOGICAL|EpCAM CAR-T cells|Patients included will be infused the autologous T cells armed with CAR recognizing EpCAM. After infusion, cytokines and other medical test will be performed.
224261149|NCT05213663|OTHER|assessment|To examine the awareness of parents of Cerebral Palsy children about the disease, physiotherapy and rehabilitation.
224261150|NCT01011855|DEVICE|GEHC IWS 4400 & Giraffe Warmer beds|Clinical care provided first on a GEHC IWS 4400 bed with a proportional heater control algorithm, followed by care provided on a GEHC Giraffe Warmer bed with an adaptive heater control algorithm, followed by care on a GEHC Giraffe Warmer bed with a proportional heater control algorithm.
224261151|NCT01011855|DEVICE|GEHC IWS 4400 & Giraffe Warmer beds|Clinical care provided first on a GEHC IWS 4400 bed with a proportional heater control algorithm, followed by care provided on a GEHC Giraffe Warmer bed with a proportional heater control algorithm, followed by care on a GEHC Giraffe Warmer bed with an adaptive heater control algorithm.
224261152|NCT01011855|DEVICE|GEHC IWS 4400 & Giraffe Warmer beds|Clinical care is first provided on a GEHC Giraffe Warmer bed with an adaptive heater control algorithm, followed by care on a GEHC IWS 4400 bed with a proportional heater control algorithm, followed by care provided on a GEHC Giraffe Warmer bed with a proportional heater control algorithm.
224323717|NCT06317662|DRUG|Calaspargase Pegol|Given IV
223774090|NCT03835442|OTHER|Placebos|placebo tid for 4 weeks
223774091|NCT03282955|DRUG|Lipidem|Lipoplus i.v. lipid emulsion for parenteral nutrition
224261153|NCT01011855|DEVICE|GEHC IWS 4400 & Giraffe Warmer beds|Clinical care is first provided on a GEHC Giraffe Warmer bed with an adaptive heater control algorithm, followed by care on a GEHC Giraffe Warmer bed with a proportional heater control algorithm, followed by care provided on a GEHC IWS 4400 bed with a proportional heater control algorithm.
224261154|NCT01011855|DEVICE|GEHC IWS 4400 & Giraffe warmer beds|Clinical care is first provided on a GEHC Giraffe Warmer bed with a proportional heater control algorithm, followed by care provided on a GEHC IWS 4400 bed with a proportional heater control algorithm, followed by care provided on a GEHC Giraffe Warmer bed with an adaptive heater control algorithm.
224261155|NCT01011855|DEVICE|GEHC IWS 4400 & Giraffe Warmer beds|Clinical care is first provided on a GEHC Giraffe Warmer bed with a proportional heater control algorithm, followed by care provided on a GEHC Giraffe Warmer bed with an adaptive heater control algorithm, followed by care provided on a GEHC IWS 4400 bed with a proportional heater control algorithm.
224261156|NCT04437199|DRUG|Tricaprilin|"Powder formulation will be mixed with 240 mL water and shaken until fully dispersed.~Each dosing unit of 12.5 g of AC-SD-03 contains 5 g of the active ingredients (tricaprilin)"
224261157|NCT04437199|DRUG|Placebo|Powder formulation will be mixed with 240 mL water and shaken until fully dispersed.
224261158|NCT00584753|RADIATION|Positron emission tomography and computed tomography|Positron emission tomography and computed tomography
224261159|NCT00584753|RADIATION|Positron emission tomography and computed tomography|Positron emission tomography and computed tomography
224261160|NCT00584753|RADIATION|Positron emission tomography and computed tomography|Positron emission tomography and computed tomography
224261161|NCT00111787|DRUG|Lapatinib|Daily-monotherapy \[1500 milligrams (mg)\] for 14 days, then daily combination therapy (with weekly paclitaxel) for 12 weeks
224261162|NCT00111787|DRUG|Paclitaxel|Weekly (80mg/m\^2) combination therapy (with daily Lapatinib) for 12 weeks
224261163|NCT01246687|BEHAVIORAL|e-Intervention|Dietary educational programme developed using Transtheoretical Model of Change and delivered via a website specific for Type 2 Diabetes patients.
224261164|NCT05957146|DEVICE|Routine hemodialysis|"* Dialyzers: Cordiax FX80 dialyzers; membrane material HelixonePlus (polysulfone); (Fresenius Medical Care Bad Homburg, Germany)~* Dialysis machines: Baxter Gambro AK 98 (Gambro Lundia AB, Lund, Sweden; part of Baxter Healthcare Corporation)~* Needles for vascular access: Nipro SafeTouch dialysis cath 1.6x25 mm (16G) or 1.9x25 mm (15G); or Nipro SafeTouch Tulip needles (15G; all Nipro Medical Europe Mechelen, Belgium)~* Ultrapure dialysis fluids (less than 0.1 colony forming units/ml, less than 0.03 endotoxin units/ml) will be mixed with AC-F 219/1 or 213/4 liquid acid concentrates and BiBag dry bicarbonate concentrate. Hence, the electrolyte composition of the dialysis fluid will be: Na 138-142 mmol/L; K 2.0-3.0 mmol/L; HCO3 26-35 mmol/L; Ca 1.25-1.50 mmol/L; Mg 0.5 mmol/L; Cl 108.5-109 mmol/L; glucose 5.6 mmol/L; acetate 3 mmol/L. Dialysate flow rate will be 500 mL/min.~* Anticoagulation: nadroparin."
224261165|NCT00284518|BIOLOGICAL|botulinum toxin Type A|Botulinum toxin Type A 300 U, 200 U or 100 U transperineal or transrectal injection on Day 1.
224261166|NCT00284518|DRUG|normal saline|Normal Saline (Placebo) transperineal or transrectal injection on Day 1.
224261167|NCT05475964|DEVICE|Endoscopic ultrasound|Endoscopic ultrasound and biopsy intake of suspected lesions
224261168|NCT03488108|OTHER|Platelet Rich Plasma|Autologous Platelet Rich Plasma (PRP) will be isolated from blood collected from each subject at each treatment time point. 100 cc of PRP will be injected with a 30-gauge needle over the affected part of the scalp, approximately 1/10 cc/injection site. Treatments will take place every 4 weeks for a total of 3 treatments over 12 weeks.
223681189|NCT04824716|PROCEDURE|Postconditioning|The protocol of primary PCI followed by stenting is executed according to the descriptions according to the majority of relevant scientific literature on postconditioning studies and in accordance with the most recent guidelines. In the post conditioned group, after recanalization, the artery is occluded by inflation of stent balloon (4 times for 1-1 minute) followed by 1-1-minute reperfusion, repeatedly. Eight minutes after the start of examination, angiography is made in order to determine blood flow. Intervention is finished by the operator and another angiographic image is made (identical to initial standard projection).
224261169|NCT03488108|DRUG|Minoxidil Foam|Minoxidil 5% topical foam will be applied once daily following manufacturer's instructions for a total of 12 weeks.
224261170|NCT06322485|BEHAVIORAL|Internet-based self-management intervention|An internet-based cognitive-behavioral therapy with six modules.
224261171|NCT03774537|DRUG|Transplantation of hUC-MSCs|Preterm infants at high risk for BPD will receive transplantation of hUC-MSCs through intravenous infusion. Dose A - 1 million cells per kg; Dose B - 5 million cells per kg
224261172|NCT03774537|DRUG|No transplantation of hUC-MSCs|Preterm infants at high risk for BPD will not receive transplantation of hUC-MSCs
224261173|NCT06185088|DEVICE|Coda® Balloon Catheters|A balloon device that will be introduced into participants' intestine over a guide wire to test the radial stretch of the small bowel.
224261174|NCT06185088|DEVICE|Double Balloon Endoscope (DBE)|A balloon device that will be introduced retrograde through the ileostomy and the inter-balloon distance will be increased causing stretch on the intestine to test longitudinal stretch. The DBE will only be used if a participant tolerated the Coda® Balloon Catheter intervention.
224261175|NCT02348281|DRUG|Bicalutamide|150mg, po, qd, d1-28
224261176|NCT05412576|DRUG|Lidocaine Hydrochloride 2% Injection Solution|Injectable
223774092|NCT03282955|DRUG|Lipofundin MCT 20%|Lipofundin MCT 20% i.v. lipid emulsion for parenteral nutrition
224261177|NCT05412576|DRUG|0.9% NaCl|Injectable
224261178|NCT00752466|DRUG|Topiramate; flunarizine|
224261179|NCT01619241|OTHER|PET/CT|F-18 FLT PET/CT
224261180|NCT06485557|DRUG|sintilimab plus platinum-based chemotherapy|The subjects in group A will receive 3 cycles of sintilimab plus platinum-based chemotherapy
224261181|NCT06485557|DRUG|sintilimab plus platinum-based chemotherapy|The subjects in group B will receive 2 cycles of sintilimab plus platinum-based chemotherapy plus 1 cycle of sintilimab
224261182|NCT06485557|DRUG|sintilimab plus platinum-based chemotherapy|The subjects in group C will receive 1 cycle of sintilimab plus platinum-based chemotherapy plus 2 cycles of sintilimab.
224261183|NCT03947658|PROCEDURE|Surgical crown lengthening|Surgical lengthening of teeth with short clinical crown and prosthetic rehabilitation
224323718|NCT06317662|PROCEDURE|Computed Tomography|Undergo CT
224323719|NCT06317662|DRUG|Cyclophosphamide|Given IV
224323720|NCT06317662|DRUG|Cytarabine|Given IT or IV
223774093|NCT01121211|DRUG|Testosterone|Testosterone 300mcg transdermal patch x 24 weeks.
223774094|NCT01121211|DRUG|Placebo|Placebo transdermal patch x 24 weeks
223774095|NCT05776030|DEVICE|Single Speed Ergonomic Wheelchair|"Ergonomic wheelchair. The ergonomic wheelchair was developed by the MADE program and has anterior placed hand rims that are connected with a bicycle chain. In Aim 1, Participants will use the ergonomic wheelchair to test 3 different gear ratios.~1. 2:3~2. 1:1~3. 3:2"
223774096|NCT05776030|DEVICE|Multi-Speed Ergonomic Wheelchair|The multi-speed ergonomic wheelchair will be developed by the MADE program and will use a two-hand rim design so the participant can change gears by changing hand rims.
223774097|NCT00179647|DRUG|lenalidomide|Lenalidomide, 5 mg to 25 mg, QD, orally, for 21 days every 28 days, with or without dexamethasone
223774098|NCT00179647|DRUG|dexamethasone|Dexamethasone, 20 mg to 40 mg, QD, orally, administered under a variety of dosing regimens
223774099|NCT03879629|DRUG|Carvedilol|oral Carvedilol maximally tolerated doses 3.125 mg to 25 mg twice a day
223774100|NCT04154631|BEHAVIORAL|Standard Transdiagnostic Intervention for Sleep and Circadian Dysfunction (TranS-C)|TranS-C is a psychosocial treatment designed to improve sleep and circadian functioning. It is a modular, psychosocial, skills-based approach. In this study, two version of TranS-C will be tested: Standard and Adapted.
223774101|NCT04154631|BEHAVIORAL|Adapted Transdiagnostic Intervention for Sleep and Circadian Dysfunction (TranS-C)|The Adapted version was derived from Standard TranS-C. It was developed to improve the fit of the treatment with the CMHC context.
223774102|NCT04154631|OTHER|Usual Care Delayed Treatment|Usual care in the partner CMHCs typically starts with a case manager who co-ordinates care and refers each client for a medication review and to various rehabilitation programs (e.g., health care, housing, nutrition, finding a job, peer monitoring).
223774103|NCT00733343|DEVICE|Europe: AutoSet CS (USA: VPAP Adapt SV)|At least 3 hours average daily usage time
223774104|NCT03428776|BEHAVIORAL|Standard Compliance-linked incentives|Standard mobile-phone reminders and compliance-linked incentives Electronic immunization records on cloud-based software platform and use of biometric identification
224261184|NCT04366635|PROCEDURE|Impacted third molar surgery|Under local anesthesia, flap will be raised and mesioangular or horizontal impacted third molar tooth will be removed with routine technique. And then extraction socket will be irrigated with salin and will be primarily closed.
224261185|NCT04366635|PROCEDURE|Application of mineralised plasmatic matrix|After extraction of impacted third molar tooth, Mineralized Plasmatic Matrix will be placed to the socket as a graft material and will be covered with Platelet Rich Fibrin membrane. Then wound will be primarily closed.
224261186|NCT04366635|PROCEDURE|Application of β-tricalcium phosphate|After extraction of impacted third molar tooth, β-tricalcium phosphate will be placed to the socket as a graft material and will be covered with Platelet Rich Fibrin membrane. Then wound will be primarily closed.
224261187|NCT04600635|PROCEDURE|Bariatric surgery|Some patients in the cohort are followed by a multidisciplinary team in preparation for bariatric surgery. Others have already undergone bariatric surgery and are being followed up postoperatively.
224261188|NCT01283763|DRUG|Topical Imiquimod|16 weeks
223774105|NCT03428776|BEHAVIORAL|Intelligent Compliance-linked incentives|Intelligent mobile-phone reminders and compliance-linked incentives Electronic immunization records on cloud-based software platform and use of biometric identification
223774106|NCT03428776|OTHER|Record keeping|Electronic immunization records on cloud-based software platform and use of biometric identification
223774107|NCT01747759|OTHER|Kruskal-Wallis and qualitative parameters|
223774108|NCT02138214|PROCEDURE|Thyroidectomy|Undergo total thyroidectomy
223774109|NCT02138214|PROCEDURE|entral lymph node dissection (CLND)|Undergo total thyroidectomy with ipsilateral prophylactic CND
223774110|NCT02138214|OTHER|Quality-of-life assessment|Voice evaluation, interviews, ancillary studies
223774111|NCT02185768|DRUG|idarubicin|
223774112|NCT02185768|DEVICE|Dc- Beads 300-500µm|
223774113|NCT05957978|DRUG|LXE408|Film-coated tablets
223774114|NCT05957978|DRUG|sodium stibogluconate|Dosage/Administration: sodium stibogluconate 20 mg/kg/day intravenous/intramuscular (IV/IM) q.d.
223774115|NCT05957978|DRUG|Paromomycin|Dosage/Administration: paromomycin 15 mg/kg/day IM q.d.
223774116|NCT05443984|DRUG|JP-1366 20mg|1 capsule of JP-1366 20 mg, 1 tablet of esomeprazole placebo (irrespective of meals)
223774117|NCT05443984|DRUG|Esomeprazole 40mg|1 capsule of JP-1366 placebo, 1 tablet of esomeprazole 40 mg placebo (irrespective of meals)
223774118|NCT05731284|PROCEDURE|Platelet rich plasma (PRP) Injection|Randomly picked (like the flip of a coin) by a computer to receive either platelet-rich plasma (PRP) or normal saline. This is a double-blind study. During vaginal prolapse surgery, the surgeon will inject PRP into the vaginal tissue at the surgical site.
223774119|NCT05731284|PROCEDURE|Placebo|Normal saline Injection
223774120|NCT00832429|PROCEDURE|Lymph Node Mapping|Undergo lymph node mapping
223774121|NCT00832429|PROCEDURE|Sentinel Lymph Node Biopsy|Undergo SLN biopsy
223774122|NCT00832429|DRUG|Technetium Tc-99m Sulfur Colloid|Given ID
223774123|NCT00793442|DIAGNOSTIC_TEST|Blood Collection and Assays|The researchers will sample blood upon enrollment, at 6 and 24 hours after the baseline sampling. The researchers will measure 6 different endothelial related biomarkers compromising different components of endothelial permeability and hemostasis.
223774124|NCT01362907|DEVICE|Delefilcon A contact lens|Investigational, silicone hydrogel, single vision, soft contact lens for daily disposable wear
223774125|NCT01362907|DEVICE|Etafilcon A contact lens|Commercially marketed, HEMA-based, single vision, soft contact lens for daily disposable wear
223774126|NCT00881075|DRUG|SeeMore(TM)|single dose intravenous injectable
224261189|NCT01283763|PROCEDURE|Conization|Large loop excision of the transformation zone
224323721|NCT06317662|DRUG|Daunorubicin|Given IV
224323722|NCT06317662|DRUG|Dexamethasone|Given PO or NG or IV
224323723|NCT06317662|DRUG|Doxorubicin|Given IV
224323724|NCT06317662|PROCEDURE|Echocardiography Test|Undergo ECHO
224323725|NCT06317662|PROCEDURE|FDG-Positron Emission Tomography|Undergo FDG-PET
224323726|NCT06317662|DRUG|Leucovorin|Given PO or NG or IV
224323727|NCT06317662|DRUG|Levoleucovorin|Given IV
224323728|NCT06317662|PROCEDURE|Lumbar Puncture|Undergo lumbar puncture
224323729|NCT06317662|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
224261190|NCT04807595|OTHER|None (Observational study)|The data source for this project will be HER2 IHC historical scores, local lab rescoring of historical HER2 fixed tissue slides, independent central retesting or local lab retesting (under special occasions) of HER2 IHC status for enrolled patients who have available tissue, other biomarker testing results based on historical testing and/or testing of archived tissue samples when available, and curated patient-level data. Real-world data sources include electronic health records/electronic medical records (EHR/EMR) and biobank registries. Data from EHR/EMR sources will be curated. Biobank tissue for enrolled patients who have multiple samples available will be selected consecutively when possible and will start with the latest available samples then move backward in time.
224261191|NCT01901783|PROCEDURE|With primary closure|A cancellous block allograft will be placed for ridge augmentation and covered with a barrier membrane. The soft tissue will be primarily closed over the membrane.
224261192|NCT01901783|PROCEDURE|Without primary closure|A cancellous block allograft will be placed for ridge augmentation and covered with a barrier membrane. The soft tissue will not be primarily closed over the membrane.
224261193|NCT00161551|DEVICE|Vitatron T70 DR|
224261194|NCT00395980|DEVICE|surgical table pressure mat|
224261195|NCT05251155|DIAGNOSTIC_TEST|Distant best corrected visual acuity assessment|Measuring distant visual acuity on snellen's chart using two methods and results were converted to equivalent logarithm of minimum angle of resolution to compare accuracy of mobile based chart to the standard vision chart.
224261196|NCT06182449|DEVICE|Virtual Reality Distraction|In a private NICU room, mothers will wear a head-mounted VR device when they will initiate the expression of their maternal milk. The video within the VR system will provide a calm forest environment with waterfalls, animals, and birdsong (INSPIRE® Program). The baby may or may not be present in the room during the intervention. This will be documented.
224261197|NCT06182449|OTHER|Standard Protocol|Mothers will express their maternal milk in a private room in the NICU with their baby or a photo of the baby. Use of any co-interventions for anxiety management (e.g. music) durign this sequence will be documented.
224261198|NCT06562062|PROCEDURE|Extra-articular Lateral Column Lengthening Procedure|Lateral column lengthening (LCL), originally described by Evans, is an established procedure to correct stage II adult acquired flatfoot deformity (AAFD). However, the relative position between the facets is violated, and other problems may include nonunion, malunion, and calcaneocuboid (CC) joint subluxation. Herein, we report a modified extra-articular technique of LCL with hockey-stick osteotomy, which preserves the subtalar joint as a whole, increases bony apposition to enhance healing ability, and preserves the insertion of the calcaneofibular ligament to stabilize the posterior fragment to promote adduction of the forefoot
224261199|NCT01348789|DEVICE|Hair2Go (Mē)|Treatment with Hair2Go (Mē) three times every 2-4 days
224261200|NCT05450653|DEVICE|FETO with Goldballoon Detachable Balloon (GOLDBAL2) along with the delivery Microcatheter (BALTACCI-BDPE100)|A Goldballoon Detachable Balloon (GOLDBAL2) will be inserted in the airway of the fetus with severe congenital diaphragmatic hernia (o/e LHR \<25% with liver up) during the FETO procedure between gestational age 27 weeks 0 days and 29 weeks and 6 days. The fetal tracheal balloon will be removed at between 34 weeks 0 days and 34 weeks 6 days gestation or earlier as indicated.
224261201|NCT06562478|BEHAVIORAL|Zazen Meditation|The sessions will last a maximum of 40 minutes in total, comprising 10 minutes of introduction with general practice instructions, followed by 15 minutes of Zazen meditation practice. The final 15 minutes will be allocated for participants to provide feedback on the session.
224323730|NCT06317662|DRUG|Mercaptopurine|Given PO or NG
224323731|NCT06317662|DRUG|Methotrexate|Given IT or IV or PO or NG
224323732|NCT06317662|DRUG|Methylprednisolone|Given IV
224323733|NCT06317662|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
224323734|NCT06317662|DRUG|Prednisolone|Given PO or NG
224323735|NCT06317662|DRUG|Prednisone|Given PO or NG
223681190|NCT04824716|DEVICE|Percutaneous coronary intervention|Percutaneous coronary intervention as per European Society of Cardiology guidelines.
223681191|NCT01931709|RADIATION|fludeoxyglucose F 18|Undergo FDG PET
223681192|NCT01931709|DEVICE|positron emission tomography|Undergo FDG PET
223681193|NCT01931709|DEVICE|dynamic contrast-enhanced magnetic resonance imaging|Undergo DCE-MRI
223681194|NCT01931709|OTHER|laboratory biomarker analysis|Correlative studies
223681195|NCT03232125|DRUG|Ramosetron|Randomly selected patients of the ramoseton group are given a 0.3 mg of ramosetron after induction.
223681196|NCT03232125|DRUG|Normal saline|In contrast, patients in the control group are given the same volume of normal saline after induction and given a 0.3 mg of ramosetron after measurement of QTc interval.
223681197|NCT01007682|OTHER|Show distressing movie and tell half of the two study groups to suppress memories of the movie|A distressing movie is presented to two groups (one group with high and one group with low working memory capacity). For each of the two groups, half of the participants are instructed to suppress thoughts of the movies after viewing it, while the remaining participants are instructed to allow the occurrence of memories of the movie.
223681198|NCT03003299|DEVICE|Edwards SAPIEN 3/SAPIEN 3 Ultra THV|Edwards SAPIEN 3/SAPIEN 3 Ultra THV system with the associated delivery systems.
223681199|NCT03363425|DRUG|Lidocaine Iv|Lidocaine Iv
223681200|NCT03363425|DRUG|Dexmedetomidine|dexmedetomidine iv
224323736|NCT06317662|DRUG|Therapeutic Hydrocortisone|Given IT
224323737|NCT06317662|DRUG|Thioguanine|Given PO or NG
224323738|NCT06317662|DRUG|Venetoclax|Given PO or NG
224323739|NCT06317662|DRUG|Vincristine|Given IV
224323740|NCT02767804|DRUG|X-396 (ensartinib)|oral ALK inhibitor
224323741|NCT02767804|DRUG|crizotinib|oral ALK inhibitor
224323742|NCT06630104|PROCEDURE|Biospecimen Collection|Undergo hair, buccal, and saliva sample collection
223681201|NCT03363425|DRUG|Normal saline|placebo
224323743|NCT06630104|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
224323744|NCT06630104|OTHER|Electronic Health Record Review|Ancillary studies
224323745|NCT06630104|PROCEDURE|Follow-Up|Undergo CFU
224323746|NCT06630104|OTHER|Genetic Counseling|Receive genetic counselor consultation
224323747|NCT06630104|OTHER|Genetic Testing|Undergo sequencing analysis
224323748|NCT06351345|DRUG|129Xe Hyperpolarized|Each xenon dose will be limited to a volume less than 25% of participant lung capacity (TLC).
224323749|NCT06561386|DRUG|Nivolumab|Specified dose on specified days
223774127|NCT03517267|DIAGNOSTIC_TEST|ultrasound and FNA|The nodule to undergo FNA will be chosen according to TIRADS ACR criteria and the ATA risk criteria ( if there is a disagreement between the methods whether to perform FNA the FNA will be performed ) If both methods do not recommend FNA , but the referring doctor has requested the procedure or the patient is unable to stay on follow up , the FNA will be performed .
224261202|NCT05168735|DRUG|Intravenous Ketamine|Single infusion of intravenous racemic ketamine (0.5mg/kg over 40min)
224261203|NCT05168735|BEHAVIORAL|Brief Mindfulness Exercises|30min guided training in mindfulness meditation immediately prior to infusion
224261204|NCT05168735|BEHAVIORAL|Academic Exercises|30min of mental math and other academic cognitive puzzles completed silently/mentally
224261205|NCT05801484|OTHER|Linezolid continuous infusion|Continuous infusion of 1200 mg linezolid in 24h, after an initial dose of 600 mg linezolid administered as one hour infusion
224261206|NCT04342559|OTHER|Belamy (vaginal moisturizer)|"The conformity of the product use by the research participants will be verified through the filling of the product use diary by the research participants and also by the accounting of the tubes not used in T22.~Interdiction and Restriction~* Keep the test product tightly closed, protected from heat, moisture and out of the reach of children;~* Do not apply any other product to the genital area. Only the use of soap normally used for hygiene will be allowed;~* Do not change genital / vaginal hygiene habits;~* Not having sexual intercourse in the 48 hours (2 days) before the research visits;~* Do not perform a hygienic shower in the genital region within 24 hours (1 day) prior to the research visits;~* Do not perform gynecological / intimate showers during the study period"
224261207|NCT03503318|DRUG|TV-46000|TV-46000 will be administered per dose and schedule specified in the arm.
224261208|NCT03503318|DRUG|Placebo|Placebo matching to TV-46000 will be administered per schedule specified in the arm.
224261209|NCT02687126|DEVICE|Central Venous Catheterization|Ultrasound guided internal jugular venous catheterization
224323750|NCT06561386|DRUG|Relatlimab|Specified dose on specified days
224323751|NCT06561386|DRUG|Pembrolizumab|Specified dose on specified days
223681202|NCT02879396|BEHAVIORAL|PA4LE Program|"1. Medication self-management including medication reconciliation, therapy recommendations, and education by pharmacist (chronic conditions and medications including Beers Criteria)~2. Use of a patient-centered health record that helps guide patients through the care process (portable, health and medication record for elders)~3. Primary care provider and specialist follow-up (patient awareness of discharge action plan and follow-up)~4. Patient understanding of red flag indicators of worsening condition and appropriate next steps~5. Behavioral interventions - Adherence, Lifestyle modifications, Mindfulness \& Lovingkindness meditations to combat anxiety, insomnia and other behavioral symptoms"
223681203|NCT04304547|DRUG|CKD-828, D097, D337, CKD-348 T1, CKD-348 T2|"Subject of sequence A takes IP in the following order:~1. Each tablet of CKD-828 and D097 and D337 be taken at once~2. CKD-348 T1 1 tablet~3. CKD-348 T2 1 tabet"
223681204|NCT04304547|DRUG|CKD-348 T1, CKD-348 T2, CKD-828, D097, D337,|"Subject of sequence B takes IP in the following order:~1. CKD-348 T1 1 tablet~2. CKD-348 T2 1 tablet~3. Each tablet of CKD-828 and D097 and D337 be taken at once"
223681205|NCT04304547|DRUG|CKD-348 T2, CKD-348 T1, CKD-828, D097, D337|"Subject of sequence C takes IP in the following order:~1. CKD-348 T2 1 tablet~2. Each tablet of CKD-828 and D097 and D337 be taken at once~3. CKD-348 T1 1 tablet"
223681206|NCT02853227|OTHER|digital photography|Photographies with digital cameras were taken postoperatively for the documentation, anonymised and used for evaluation of cosmetic results after surgery.
223681207|NCT06506305|DRUG|FB1001|Intravitreal (IVT) injection
223681208|NCT01323920|DRUG|Bortezomib|Bortezomib 1.3 mg/m\^2 IV
223681209|NCT01323920|DRUG|Tacrolimus|Tacrolimus 0.05 mg/kg PO bid
223681210|NCT01323920|DRUG|Methotrexate|Methotrexate 15 mg/m\^2 IV
223681211|NCT00001965|DRUG|Cyclosporine A|
223681212|NCT02915874|BEHAVIORAL|Acceptance and Commitment Therapy|
223681213|NCT00677053|DRUG|TAK-442|Stage I: TAK-442 10 mg, capsules, orally, twice daily and standard care for recurrent ischemic events for up to 24 weeks.
223681214|NCT00677053|DRUG|TAK-442|Stage I: TAK-442 20 mg, capsules, orally, twice daily and standard care for recurrent ischemic events for up to 24 weeks.
223681215|NCT00677053|DRUG|TAK-442|Stage I: TAK-442 40 mg, capsules, orally, once daily and standard care for recurrent ischemic events for up to 24 weeks.
223681216|NCT00677053|DRUG|TAK-442|Stage II: TAK-442 40 mg, capsules, orally, twice daily and standard care for recurrent ischemic events for up to 24 weeks.
223681217|NCT00677053|DRUG|TAK-442|Stage II: TAK-442 80 mg, capsules, orally, once daily and standard care for recurrent ischemic events for up to 24 weeks.
223681218|NCT00677053|DRUG|TAK-442|Stage II: TAK-442 80 mg, capsules, orally, twice daily and standard care for recurrent ischemic events for up to 24 weeks.
223681219|NCT00677053|DRUG|TAK-442|Stage III: TAK-442 160 mg, capsules, orally, once daily and standard care for recurrent ischemic events for up to 24 weeks.
223681220|NCT00677053|DRUG|TAK-442|Stage III: TAK-442 120 mg, capsules, orally, twice daily and standard care for recurrent ischemic events for up to 24 weeks.
223681221|NCT00677053|DRUG|Placebo|Stages I, II \& III: TAK-442 placebo-matching capsules, orally, twice daily and standard care for recurrent ischemic events for up to 24 weeks.
223681222|NCT00993876|DRUG|citalopram|20 to 30 mg per day for 4 weeks
223681223|NCT00993876|DRUG|reboxetine|4 to 8 mg per day for 4 weeks
223774128|NCT04893889|DIAGNOSTIC_TEST|Shear-wave elastography|Myocardial shear wave elastography to assess myocardial stiffness by non-invasively quantifying diastolic myocardial elasticity.
223774129|NCT03383588|DRUG|Bupivacaine|20 ml subcutaneous bupivacaine (Marcaine) 0.25%. Bupivacaine is an anesthetic which can numb an area of the body to relieve pain during surgery or medical procedures, childbirth, and dental work.
224261210|NCT02598323|DEVICE|ultrasound|
224323752|NCT06561386|DRUG|Carboplatin|Specified dose on specified days
224323753|NCT06561386|DRUG|Pemetrexed|Specified dose on specified days
224323754|NCT06561386|DRUG|Cisplatin|Specified dose on specified days
224323755|NCT05783622|DRUG|JANX008|JANX008 is dosed via IV weekly in a 21-day cycle
224323756|NCT05156398|DRUG|Rimegepant|Rimegepant 75mg or 50mg (2 X 25mg) ODT
224323757|NCT05156398|DRUG|Placebo|Matching placebo 75mg or 50mg (2 X 25mg) ODT
224323758|NCT03842228|PROCEDURE|Biopsy Procedure|Undergo tumor biopsy
224261211|NCT01668602|DEVICE|Fast Walking with Fast Functional Electrical Stimulation (FES) Training|Functional electrical stimulation (FES) is a technique that causes a muscle to contract through the use of an electrical current. The therapist applies an electrical current to either the skin over the nerve, or over the bulk of the muscle, and this will cause a muscle contraction. The FES is delivered to 2 muscle groups (dorsiflexor and plantarflexor) timed appropriately with the gait cycle. FastFES gait training sessions may comprise up to six 6-minute bouts of walking with rest breaks between bouts (total 30-minutes of walking). The last training bout (bout 6) may comprise 6-minutes of over ground walking, during which subjects will be asked to walk as fast as they can. For safety, a physical therapist will walk with and guard the subject during over ground walking.
224261212|NCT01668602|OTHER|Fast Walking|Fast walking training sessions will be similar to FastFES in duration, dosage, structure but no FES will be provided.
224261213|NCT04415515|BEHAVIORAL|RN case management|A Registered Nurse (RN) case manager makes phone contact with the member to review medications, health risks, care gaps/barriers, \& to develop a case management plan that focuses on improving medication adherence \& reconciliation, condition-based measures \& outcomes, addressing psycho-social needs, \& intensive post-admission care transition. RNs may refer the member to social workers,specialist providers, \& support programs (including to more intense case management where the primary care physician is notified that RNs may contact them to support treatment \& coordinate services).
224261214|NCT04415515|BEHAVIORAL|Community Health Worker Case Management|In selected UHC markets for defined time periods, members randomized to the treatment arm also received an enhanced version of the SCC that included in-home case management support from non-clinical Community Health Workers (CHW).
224261215|NCT04415515|BEHAVIORAL|RN Standard care coordination and disease management|RN Standard care coordination and disease management
224261216|NCT04815759|OTHER|routine dental restorative procedures|pulp and restorative therapy
224261217|NCT05229133|DEVICE|CLEAR|FEMTO LDV Z8 Surgical Laser is intended for use in Corneal Lenticule Extraction for Advanced Refractive correction (CLEAR), also called Curved Lamellar Resection (CLR), for the reduction or elimination of myopia from -0.50 D to -10.00 D, with astigmatism of 0 D to -5.00 D or without astigmatism, and MRSE of -0.50 D to -12.50 D in the eye to be treated in patients who are 18 years of age or older with documentation of stable manifest refraction over the past year as demonstrated by a change in sphere and cylinder of ≤ 0.50 D in magnitude.
224261218|NCT01468272|DRUG|free comb. beclomethasone DPI and formoterol DPI|free combination of beclomethasone dipropionate 100 ug/unit DPI (two inhalations, total dose 200 ug), and formoterol fumarate 6 ug/unit DPI (four inhalations, total dose 24 ug).
224261219|NCT01468272|DRUG|CHF 1535 50/6 NEXT DPI|four inhalations of CHF 1535 50/6 NEXT DPI, a fixed combination of beclomethasone dipropionate 50 ug plus formoterol fumarate 6 ug (TOTAL DOSE:BDP/FF 200/24 ug)
224261220|NCT02319824|BIOLOGICAL|Autologous NY-ESO-1-specific CD8-positive T Lymphocytes|Given IV
224261221|NCT02319824|OTHER|Laboratory Biomarker Analysis|Correlative studies
224261222|NCT02319824|RADIATION|Palliative Radiation Therapy|Undergo palliative radiation therapy
224261223|NCT05802485|OTHER|collection of blood and tumor samples|"The study consists of the collection of a 25 ml blood sample:~* Before the start of treatment~* Approximately 2 months after the start of induction chemotherapy~* At the end of induction chemotherapy~* Prior to local treatment (radiotherapy, surgery)~* At the time of tumor progression~At the time of collection of tumor material:~* During the initial diagnostic biopsy~* On the operating room in case of surgery~* During a tumor biopsy in case of recurrence or progression (optional) and a questionnaire evaluating the patient's spontaneous physical activities."
224261224|NCT06099652|DRUG|611 300 mg Q2W|611 subcutaneous (SC) injection
224261225|NCT06099652|DRUG|611 450 mg Q2W|611 subcutaneous (SC) injection
224261226|NCT06099652|DRUG|Matching placebo|placebo subcutaneous (SC) injection
224261227|NCT05801315|DEVICE|Glycine powder air polishing|Peri-implant mucositis sites treated with a glycine powder air polishing device (Air-Flow Master Piezon®).
224261228|NCT05801315|DEVICE|Full mouth ultrasonic debridement|Peri-implant mucositis sites are treated with thin ultrasonic tips.
224261229|NCT01636661|DEVICE|tDCS|transcranial direct current stimulation- non-invasive brain stimulation
224261230|NCT00200187|PROCEDURE|low venous pressure general anesthesia|
224261231|NCT00200187|PROCEDURE|combined spinal-epidural anesthesia|
224261232|NCT02374385|BIOLOGICAL|BPSC-1001 (VSVΔG-ZEBOV)|Ebola vaccine candidate
224261233|NCT02374385|OTHER|Placebo|Normal saline
224261234|NCT02139826|DRUG|IX-01|
224261235|NCT02261389|OTHER|Arm B, tumor markers assessment|Tumor markers assessment every three months through the study or until disease recurrence
224261236|NCT02662933|OTHER|Bedside assessment|"The study intervention consists of a bedside functional assessment to be administered to eligible, consented subjects who are hospitalized with a new diagnosis of AML or are undergoing workup for suspected AML diagnosis. All subjects will be enrolled within 5 days of admission to the hospital for known or suspected AML or within 5 days of new confirmed diagnosis of AML obtained during a hospitalization for other indications. All measures will be performed by a trained examiner during a face to face interview.~Bedside assessment measures will be repeated once for subjects who complete induction chemotherapy within 2-8 weeks post discharge from initial hospitalization."
224261237|NCT05867862|OTHER|Test|"A dental consultation of 30 to 45 minutes will be added to the annual visit with a dentist.~If dental treatments are needed, they will be done at the same time, or they will be programmed for another time at the center of dental care (CSD).~Due to the fact that most patient live far away from Nantes and the hospital, teleconsultation for patient in the test groups will happen every 2 months"
224261238|NCT00830349|DRUG|Risperidone|1 mg Tablet
224261239|NCT00830349|DRUG|Risperidone|1 mg Tablets
223681224|NCT00993876|BEHAVIORAL|interpersonal psychotherapy|
223681225|NCT04730414|DRUG|Full-spectrum hemp (0.018% THC)|Topical Application
224323759|NCT03842228|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
224323760|NCT03842228|PROCEDURE|Computed Tomography|Undergo CT
224323761|NCT03842228|DRUG|Copanlisib Hydrochloride|Given IV
224323762|NCT03842228|BIOLOGICAL|Durvalumab|Given IV
224323763|NCT03842228|PROCEDURE|Echocardiography Test|Undergo ECHO
224323764|NCT03842228|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
224323765|NCT03842228|DRUG|Olaparib|Given PO
224261240|NCT04802694|DEVICE|Water-based barrier tape|"The infants in experiment 1 group will be applied water-based barrier tape. The area will be covered by water-based barrier tape to fix nasogastric tube and after waiting 1 minute for drying up it will be fastened by silk tape used in clinic. The silk tape will be 5 cm long and it will be changed in every 24 hours. Following the removal of silk tape on the water-based barrier tape, the skin integrity of the infants will be evaluated through Neonatal Skin Condition Score Scale and the score will be recorded in the chart. Water-based barrier tape will be applied to the area every time the plaster will be changed and current skin condition score will be noted to the chart."
224261241|NCT04802694|DEVICE|Hydrocolloid barrier tape|"As for experiment 2 group, hydrocolloid barrier tape will be used to fix the nasogastric tube. The hydrocolloid barrier tape, which was cut and shaped appropriately beforehand, will be applied to the area in order to stabilize the nasogastric tube and the tube will be stabilized with silk tape used in clinic. The silk tape will be 5 cm long and it will be changed in every 24 hours. Following the removal of silk tape on the hydrocolloid barrier tape, the skin integrity of the infants will be evaluated through Neonatal Skin Condition Score Scale . Since the hydrocolloid barrier tape can stay on the skin for 7 days and be transparent, the assessment of skin condition will be realized for 7 days and noted down to the chart."
224261242|NCT04802694|DEVICE|Silk tape|"The silk tape used in clinic routinely will be used for control group infants to fix the nasogastric tube without any barrier. The silk tape will be 5cm long and it will be changed in every 24 hours. Following the removal of silk tape, the skin integrity of the infants will be evaluated through Neonatal Skin Condition Score Scale and the score will be recorded in the chart."
224261243|NCT03311594|DRUG|Low Alcohol|Low Alcohol Consumption
224261244|NCT03311594|DRUG|Moderate Alcohol|Moderate Alcohol Consumption
224261245|NCT03311594|DRUG|Placebo Alcohol|Placebo Alcohol Consumption
224261246|NCT03311594|OTHER|Pain Induction|10% capsaicin solution placed on forearm and heat induction
224261247|NCT03311594|OTHER|No Pain Induction|Water placed on forearm
224261248|NCT03913065|DIAGNOSTIC_TEST|CT|"Head computed tomography on patients still unconscious 48 hours after cardiac arrest.Visual evaluation of generalized oedema (eye-balling). Manual and automated measurement of the differentiation of gray and white matter (GWR) using circular regions of interest (ROI)."
224261249|NCT04350723|PROCEDURE|Awake Proning|The duration of proning will be a total of 8-10 hours with 1-2 hours break in supine position.
224261250|NCT05405881|OTHER|Proprioception measurement tool|No intervention, as it is a psychometric properties study
224261251|NCT06187441|DRUG|Daratumumab Injection|Patients who have been treated with 12 cycles of Daratumumab-Lenalidomide-Dexamethasone (Dara-Rd) will be randomized between Arm A (continuous therapy) and Arm B (treatment free interval)
224261252|NCT06187441|DRUG|Dexamethasone|Patients who have been treated with 12 cycles of Daratumumab-Lenalidomide-Dexamethasone (Dara-Rd) will be randomized between Arm A (continuous therapy) and Arm B (treatment free interval)
224261253|NCT06187441|DRUG|Lenalidomide capsule|Patients who have been treated with 12 cycles of Daratumumab-Lenalidomide-Dexamethasone (Dara-Rd) will be randomized between Arm A (continuous therapy) and Arm B (treatment free interval)
224261254|NCT03725969|DIETARY_SUPPLEMENT|Camel milk|Camel Milk administered 10 minutes before a mixed meal of carbohydrate and protein; 2-week washout between interventions
224261255|NCT03725969|DIETARY_SUPPLEMENT|Cow milk|Cow milk administered 10 minutes before a mixed meal of carbohydrate and protein;2-week washout between interventions
224261256|NCT01422291|DRUG|paracetamol|1 gr
224261257|NCT01422291|DRUG|morphine|0.1mg/kg intravenous in 100 ml serum physiologic
224261258|NCT01422291|DRUG|Dexketoprofen|50 mg
223681226|NCT04422795|DEVICE|External thermomechanical device delivering cold and vibration stimuli|the thermomechanical device will be placed on the digit 2 cm proximally to the injection site with the ice wings frozen and the vibration mechanism switched on, delivering vibration and cold stimuli to the area for 30 seconds before the intramatricial injection and until needle withdrawal
223681227|NCT04422795|DEVICE|External thermomechanical device without delivering cold and vibration stimuli|the thermomechanical device will be placed on the digit 2 cm proximally to the injection site with the ice wings at unfrozen and the vibration mechanism switched off, for 30 seconds before the intramatricial injection and until needle withdrawal
223681228|NCT04422795|DRUG|Ethyl chloride skin refrigerant spray|Ethyl chloride skin refrigerant spray is applied to the area of injection for 3 seconds immediately before needle insertion
223835665|NCT06282549|DRUG|Telmisartan/Amlodipine/Chlorthalidone(Truset)|Telmisartan/Amlodipine/Chlorthalidone 40/5/12.5 mg or Telmisartan/Amlodipine/Chlorthalidone 80/5/12.5 mg or Telmisartan/Amlodipine/Chlorthalidone 80/5/25 mg
223835666|NCT00514007|DRUG|OSI-906|OSI-906 administered orally
224261259|NCT01422291|DRUG|Paracetamole|1 gr
224261260|NCT05187208|DRUG|Niraparib|"Niraparib 200mg or 300mg (once daily \[QD\])\*~\*The recommended starting dosage of niraparib is 200mg QD. For patients who weigh ≥77 kg and have baseline platelet count ≥150,000/μL, the recommended starting dosage is 300 mg QD."
224261261|NCT05336422|OTHER|training on the risks associated with sun exposure|15-minute power point and presentation on the risks of sun exposure
224261262|NCT04275479|DIAGNOSTIC_TEST|Oral Glucose Tolerance Test|This is a two step process. Subjects will be asked to fast overnight,(no food and only water to drink for at least 8 hours). Then when subjects arrive for the visit,participants will have blood drawn and be asked to drink a sugary liquid. One hour later, another blood sample will be drawn and after two hours a final blood sample will be drawn.
224261263|NCT04275479|OTHER|Modified Oral Glucose Tolerance Test|The participant will be asked to fast overnight (no food and only water to drink for at least 8 hours). There will be no blood drawn during this test, participant will be asked to drink a sugary liquid and to remaining fasting (water only) for the two hour after finishing the drink.
224261264|NCT04275479|OTHER|Modified Mixed Meal Tolerance Test|The participant will be asked to fast overnight (no food and only water to drink for at least 8 hours). The participant will be given a meal supplement to drink in place of breakfast, for example Boost Plus. The participant will be asked to drink the meal supplement and to remaining fasting (water only) for the next two hours.
224261265|NCT04275479|DEVICE|Continuous Glucose Monitor|The participant will be provided a CGM device to wear for 10 days during the study period. The CGM will be blinded (meaning that the participant will not be able to see the results).
224323766|NCT03842228|PROCEDURE|X-Ray Imaging|Undergo x-ray
224261266|NCT04275479|OTHER|Food Diary|The participant will be asked to maintain a detailed food diary for 3 days during the 10 day study period.
224261267|NCT04275479|OTHER|Medical History Questionnaires|The participant will be asked to provide detailed medical history
224261268|NCT04496349|DRUG|APG-115|QOD, 2 weeks on, 1 week off, in repeated 21-day cycles
224261269|NCT04496349|DRUG|APG-2575|APG-2575 given orally each day in cycle, in repeated 21-day cycles
224261270|NCT06025279|OTHER|Ultrasound Scan|Clinical professionals will conduct non-invasive ultrasound scans from the specified body views and subsequently save the acquired data.
224261271|NCT01825798|DRUG|Metformin|Metformin will be dispensed in a liquid suspension of 100 mg/mL. For children 6-9 years of age, metformin will be started at 250 mg at their evening meal for 1 week, followed by the addition of a 250 mg dose at breakfast for 1 week. At the Week 2 visit, if metformin is well-tolerated, the dose will be increased to 500 mg twice daily. For children from 10-17 years of age, metformin will be started at 250 mg at their evening meal for 1 week, followed by the addition of a 250 mg dose at breakfast for 1 week. At the Week 2 visit, if metformin is well-tolerated, the dose will be increased to 500 mg twice daily. At the Week 4 visit, if metformin is well-tolerated, the dose will be increased to 850 mg twice daily.
224261272|NCT01825798|DRUG|Placebo|The placebo hydrochloride oral solution will be prepared to match the appearance, smell and taste of the metformin as closely as possible. For children from 6-9 years of age, placebo will be started at 250 mg at their evening meal for 1 week, followed by the addition of a 250 mg dose at breakfast for 1 week. At the Week 2 visit, if placebo is well-tolerated, the dose will be increased to 500 mg twice daily. For children from 10-17 years of age, placebo will be started at 250 mg at their evening meal for 1 week, followed by the addition of a 250 mg dose at breakfast for 1 week. At the Week 2 visit, if placebo is well-tolerated, the dose will be increased to 500 mg twice daily. At the Week 4 visit, if placebo is well-tolerated, the dose will be increased to 850 mg twice daily.
224261273|NCT00741780|DRUG|Placebo|
224261274|NCT00741780|DRUG|plerixafor|
224261275|NCT00741780|DRUG|granulocyte colony-stimulating factor (G-CSF)|
224261276|NCT03874143|OTHER|mHealth Intervention for Quality of Care|Does use of a specially equipped smartphone make a difference in the diagnosis and treatment by RCom of malaria, pneumonia and diarrhea in children aged 2 to 59 months
224261277|NCT03867838|DEVICE|compliant support|Participants will be given compliant arm support and their reachable workspace measured
224261278|NCT02982161|DRUG|MR308|Over-encapsulated tablet, Dosing frequency: two times daily, Mode of administration: oral
224261279|NCT02982161|DRUG|Tramadol|Over-encapsulated capsule, Dosing frequency: four times daily, Mode of administration: oral
224261280|NCT02982161|DRUG|Placebo|Capsule, Dosing frequency: four times daily, Mode of administration: oral
224261281|NCT01441349|DRUG|IP chemotherapy|"Irinotecan/cisplatin (IP) chemotherapy~* Cisplatin(30 mg/m2) diluted into 150 ml of 0.9% NS for IV over 30 min on day 1 \&8.~* Irinotecan(65mg/m2) diluted into 200ml of 5DW IV over 90 min on day 1 \& 8~* Every 21 days"
224261282|NCT01441349|DRUG|IP chemotherapy plus simvastatin|"* Cisplatin(30mg/m2)diluted into 150 ml of 0.9% NS for IV over 30 min on day 1 \&8~* Irinotecan( 65 mg/m2) diluted into 200ml of 5DW IV over 90 min on day 1\& 8.~* Every 21days.~* Simvastatin 40 mg per day orally D1of cycle 1"
224261283|NCT04308785|DRUG|Atezolizumab|Atezolizumab will be administered at a dose of 1200 mg intravenously on the first day of each 21-day cycle.
224261284|NCT04308785|DRUG|Tiragolumab|Tiragolumab will be administered at a dose of 600 mg intravenously on the first day of each 21-day cycle.
224323767|NCT06138639|GENETIC|SGT-003|Adeno-associated virus serotype SLB101 containing the human microdystrophin gene (h-µD5)
224323768|NCT06484062|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
224323769|NCT06484062|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
223681229|NCT04650061|BEHAVIORAL|Motivational Interview (MI) & Adherence Follow-Up|With MI, the key goal is to empower the patient to commit to follow CPAP therapy, while providing empathic support, in a positive atmosphere, and without prejudice. The nurse does not directly advocate for behavior change (i.e. use CPAP as prescribed), but asks key questions to help the patient explore their feelings about the change, weighs the pros and cons of such change, and allows the patient to realize the discrepancy between the current risk (that is, not using CPAP as directed) and the benefits with good adherence.
223681230|NCT04650061|DEVICE|Adherence Follow-Up|The nurse takes the compliance of the CPAP device, and ask to the patient if he had some problems.
223681231|NCT05224011|DEVICE|Boppli Infant Blood Pressure Monitor|The intervention is a medical device for the non-invasive measurement of blood pressure in infants
224261285|NCT04308785|OTHER|Placebo|Placebo matching to tiragolumab will be administered at a dose of 600 mg intravenously on the first day of each cycle.
224261286|NCT02811003|DEVICE|Rotation Medical Bioinductive Implant|Placement of bioinductive implant over repair of insertional Achilles tendinopathy
224261287|NCT00834873|DRUG|Carvedilol 25 mg tablets|1 x 25 mg
224261288|NCT00834873|DRUG|COREG® 25 mg tablets|1 x 25 mg
224261289|NCT04391270|BEHAVIORAL|blended intervention|A blended intervention group combining the web-based components with face-to-face workshops and posters
224261290|NCT04391270|BEHAVIORAL|web-based intervention|A web-based intervention only referred to the use of internet without traditional face-to-face workshops and posters
224261291|NCT03262051|DIAGNOSTIC_TEST|CYP phenotyping|Phenotyping using a simplified version of the Geneva cocktail
224261292|NCT05272813|DRUG|MS-553|MS-553
224261293|NCT05098743|BEHAVIORAL|Medisafe smartphone mobile application|The medication adherence smartphone mobile application (app) will provide reminders to take individual patient medications and offers medication information and a social support feature.
224261294|NCT05098743|BEHAVIORAL|Printed medication list|Patients will receive a printed out medication list from their electronic medical record.
224323770|NCT06484062|DRUG|Cirtuvivint|Given PO
224323771|NCT06484062|DRUG|Decitabine and Cedazuridine|Given PO
223681232|NCT00293488|DRUG|polyamine analogue PG11047|
224323772|NCT06484062|PROCEDURE|Echocardiography Test|Undergo ECHO
224323773|NCT06484062|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
224323774|NCT06493422|BEHAVIORAL|Reaching Movements|participants will perform a perceptual decision making task while moving their hand.
224323775|NCT04296305|DRUG|Hydromorphone|Given IV after
224261295|NCT04644068|DRUG|AZD5305|Oral PARP inhibitor
224261296|NCT04644068|DRUG|Paclitaxel|IV Anti-microtubule agent
224261297|NCT04644068|DRUG|Carboplatin|IV Platinum chemotherapeutic
224261298|NCT04644068|DRUG|T- Dxd|IV Antibody-drug conjugate
224261299|NCT04644068|DRUG|Dato-DXd|IV Antibody-drug conjugate
224261300|NCT04644068|DRUG|Camizestrant|Oral SERD Molecule
224261301|NCT03610386|OTHER|Adding menthoxypropanediol to the biopsy|Two biopsies of skin (4 mm diameter each) will be taken under local anesthetic in the service of dermatology of Brest CHRU. They will be situated in a pruritic lesion area little or not visible (inside of the arm, the back …). One of the two biopsies will receive menthoxypropanediol topically.
224261302|NCT03610386|OTHER|No adding menthoxypropanediol to the biopsy|Two biopsies of skin (4 mm diameter each) will be taken under local anesthetic in the service of dermatology of Brest CHRU. They will be situated in a pruritic lesion area little or not visible (inside of the arm, the back …). One of the two biopsies will not receive menthoxypropanediol.
224261303|NCT06459258|OTHER|Motion-triggered NMES training protocol|Experimental group subjects undergo a motion-triggered NMES shoulder strengthening training program (3x/week, 30 minutes for 6 weeks) using the Shoulder Pacemaker (NCS Lab Srl, Modena, Italy), a motion activated stimulation device to strengthen muscular disbalances. This is accomplished through varying neuromuscular electrical stimulation intensity based on the angle of motion of the arm producing subtetanic contraction and provoking supraspinal neural adaptations. Electrode placement: electrode 1, inferior to the scapular spine (infraspinatus, teres minor, + posterior deltoid); electrode 2, medial to the medial scapula border (lower trapezius + rhomboids) . Sets x repetitions: 3x20 Levels: Level 1-3; Exercise 1: L1: Supported row, L2: Front raises in 45°, L3 Front raises (thumbs up) Exercise 2: L1: Resisted front raises, L2: Crossbody resisted raises, L3: Crossbody; forehand swing; Exercise 3: L1: Rear dealt fly, L2: Single arm resisted row, L3: Underhand volleyball
224261304|NCT06459258|OTHER|Non-Motion-triggered NMES training protocol|Arm Description: Subjects of the control group undergo a conventional standardized strength training program (3x/week, 30 minutes for 6 weeks) with concentric, eccentric, and functional training exercises.
224261305|NCT00512811|DRUG|furosemide|
224261306|NCT01125163|DIETARY_SUPPLEMENT|Iron Supplement|multivitamin that provides 2mg/kg/day of iron given orally to infants when they are tolerating 120 ml/dg/day of preterm formula or fortified breast milk until they reach 36 weeks adjusted postmenstrual age.
224261307|NCT01125163|DIETARY_SUPPLEMENT|multivitamin|daily oral multivitamin without iron until 36 weeks adjusted postmenstrual age
224261308|NCT03703258|BEHAVIORAL|App-based intervention|A app-based cognitive-behavioral intervention to prevent the development of PTSD and high-risk drinking in recently-victimized adults
224261309|NCT03396354|PROCEDURE|Integrated robotic surgery|Robotic gastrectomy using Single-Site and Firefly technology will be performed. Specifically, two-port surgery using the Single-Site port and an independent trocar along the right flank (for harmonic scalpel) will be used, along with peritumoral injection of indocyanine green via endoscopy the day before surgery to completely visualize the entire lymphatic channel.
224261310|NCT03396354|PROCEDURE|Conventional laparoscopic surgery|conventional laparoscopic gastrectomy will be performed.
224261311|NCT03221205|DEVICE|Sham CPAP|CPAP (ResMed AutoSet S9 with humidifier) to be used by the participant via nasal mask and tube, programmed to apply 0.5 cmH2O (measured at the nasal mask) via a resistance to assure the lack of distal pressure.
224261312|NCT03221205|DEVICE|Therapeutic CPAP|Use of CPAP (ResMed AutoSet S9 with humidifier) through nasal mask and tube with automatized pressure from 4 to 20 cmH2O.
224261313|NCT06103812|DEVICE|Hyalo4 Skin Gel|The evaluation of performance and safety of Hyalo4 Skin Gel in the amelioration of bed wound appearance after 14 days of treatment.
224261314|NCT03227276|DIETARY_SUPPLEMENT|Litramine|2 tablets to be taken 3 times a day after meals
224261315|NCT03227276|DIETARY_SUPPLEMENT|Placebo tablet|2 tablets to be taken 3 times a day after meals
224261316|NCT02183727|DEVICE|L-C Ligament|The L-C Ligament is a bioresorbable, three-dimensional (3-D) braided scaffold made from poly L-lactic acid (PLLA) fiber. One device is used to replace the ACL. The L-C Ligament is an interventional device. The L-C Ligament is comprised of three regions: (1) The femoral tunnel attachment site, (2) The ligament region (intra-articular zone), and (3) The tibial tunnel attachment site. For several months after surgery, the L-C Ligament replaces the function of the ACL. During this time, ligament tissue regenerates within and around the L-C Ligament, which is slowly absorbed and replaced by the ACL.
224323776|NCT04296305|DRUG|Placebo Administration|Given IV after
224323777|NCT04296305|OTHER|Questionnaire Administration|Ancillary studies
224261317|NCT02183727|PROCEDURE|Hamstring Autograft|The gold-standard treatment for ACL reconstruction is autograft tissue. Autograft is a piece of tendon harvested from another part of the patient's body, such as the hamstring or kneecap. In this study, the hamstring tendon from the back of the thigh of the injured (target) leg will be harvested and surgically transferred to replace the torn ACL. The attachment of the autologous tendon in the femoral and tibial bone tunnels will utilize techniques that are similar to those for the L-C Ligament. Over time the replacement tendon resorbs and a new ACL is regenerated.
224261318|NCT06339437|OTHER|ERAS Protocol|Ehanced recovery after surgery protocols were applied
224323778|NCT05014412|DRUG|Elranatamab|BCMA-CD3 bispecific antibody
224323779|NCT00581373|OTHER|water 16 fl oz|water 16 fl oz in AM and repeat in late afternoon
224323780|NCT06545682|DRUG|Alpelisib + Pembrolizumab|Given by mouth (PO) Given by vein (IV)
224323781|NCT04427527|BEHAVIORAL|Multi-level intervention to increase CRC screening|Intervention for the community, providers, patients, clinics and systems
224323782|NCT03696225|BEHAVIORAL|Compensatory Cognitive Training (CCT)|Compensatory Cognitive Training draws from the theoretical literature on compensatory strategy training for other cognitively impaired populations (e.g., Huckans et al., 2013; Twamley et al., 2010; Storzbach et al., 2016). It is a rehabilitation model that aims to teach individuals strategies that allow them to work around cognitive deficits. Consistent with this model and the expert recommendations for civilians and Service members with TBI (Cicerone, 2011), manualized CCT treatment provides training in compensatory attention and learning/memory skills, formal problem-solving strategies applied to daily problems, and the use of external aids such as calendar systems and assistive devices to promote completion of daily tasks (Storzbach et al., 2016).
224261319|NCT02878148|DEVICE|Diagnostic imaging modalities for suspected renal colic|"All patients with suspected acute uncomplicated renal colic included will undergo ultrasonography in addition to unenhanced CT of pelvis and abdomen and plain X-ray of the abdomen.~Imaging examination will be performed according to current guidelines.~Ultrasonography study and colour doppler will include the kidney, ureterovesical joint and ureters. Unenhanced CT will be performed using a dedicated low-dose protocol."
224261320|NCT02354560|DRUG|Erythromycin|Oral Treatment with Erythromycin 250-500mg, twice daily, for 16 weeks.Exact dose is subjected to body weight and will be determined by the study's pediatrician.
224261321|NCT03066050|OTHER|MV Repair|Participants underwent mitral valve repair with annuloplasty and a sub-valvular procedure for severe tethering.
224261322|NCT03066050|OTHER|MV Replacement|Participants underwent mitral valve replacement and complete preservation of the sub-valvular apparatus.
224261323|NCT03066050|OTHER|CABG|Participants underwent coronary artery bypass grafting
224261324|NCT01616550|OTHER|Assessment of pain using the Brief Pain Questionnaire|Patients will complete this questionnaire daily from surgery until discharge from the hospital
224261325|NCT01616550|OTHER|Assessment of pain relief using a Verbal Numeric Scale (VNS)|Patients will assess their pain daily from surgery until discharge from the hospital using the VNS
224261326|NCT01616550|OTHER|Assessment of patient' satisfaction with pain relief|Will be assessed three times a day using a scale from 1 to 4 (1= very unsatisfied, 4= very satisfied)
224261327|NCT01616550|OTHER|Nurse's satisfaction with patient's pain relief and recovery|Will be assessed three times a day using a scale from 1 to 4 (1= very unsatisfied, 4= very satisfied)
224261328|NCT04518956|PROCEDURE|inter maxillary fixation with shockwave therapy|Shockwave therapy device which give 1500-4000 pulses per session with or without anesthesia, and the treatment session takes approximately 5-10 minutes at the day after surgery.
224261329|NCT04518956|PROCEDURE|Inter maxillary fixation and exposure to low intensity pulsed|Low-intensity pulsed ultra sound was applied three times weekly for six weeks from the second day after surgery.
224261330|NCT04518956|PROCEDURE|Inter maxillary fixation|Closed reduction will be done. Intermaxillary fixation (IMF) will be secured after proper reduction of the fractured segments to assure proper occlusion using upper and lower arch bars or eyelet wires for six weeks.
224261331|NCT02709018|DRUG|losartan|Angiotensin receptor blocker (ARB)
224261332|NCT02709018|DRUG|Placebo|Placebo
224261333|NCT04173273|DRUG|Etrasimod|Dose A taken by mouth, once daily.
224261334|NCT04173273|DRUG|Etrasimod|Dose B taken by mouth, once daily.
224261335|NCT04173273|DRUG|Placebo|Etrasimod matching placebo tablet taken by mouth, once daily.
224261336|NCT03476226|OTHER|Cognitive Dysfunction Coping Strategy Teaching Sheet|Demographic sheet, Fact-Cog3, and teaching tool at baseline then week 4 and 8 Fact Cog3 and reinforcement of tool, at week 16 evaluation and Fact-Cog3
224261337|NCT05486338|DEVICE|Hybrid Argon Plasma Coagulation (HAPC)|Gastric mucosal ablation is an endoscopic procedure which uses argonplasma coagulation in combination with submucosal injection to achieve selective ablation to the gastric mucosa and preventing thermal damage to the muscle layer.
224261338|NCT01847235|DRUG|Temozolomide|Temozolomide 200 mg/m2/d in a fasting state for 5 consecutive days (1,000 mg/m2 per 28-day cycle).
224261339|NCT06506188|BEHAVIORAL|LINK model|"The LINK model includes four elements:~(1) linking postpartum HIV testing and PrEP services to early infant vaccination, (2) screening for HIV risk among those who test negative for HIV at the early infant vaccination visit, (3) male partner engagement to support status awareness within couples and PrEP persistence, and (4) community-facility linkage (CFL) peer mom for ongoing support of breastfeeding women using PrEP and follow-up of breastfeeding women who disengage from PrEP care."
224261340|NCT06081972|DIETARY_SUPPLEMENT|Maltodextrin|During the feeding period (4 weeks) two capsules/ day will be administered to subjects randomized in this group containing placebo powder with a breakfast item on a daily basis.
224261341|NCT06081972|DIETARY_SUPPLEMENT|Chicory RG-I|During the feeding period (4 weeks) two capsules/ day will be administered to subjects randomized in this group containing chicory RG-I with a breakfast item on a daily basis.
224261342|NCT06081972|DIETARY_SUPPLEMENT|Carrot RG-I|During the feeding period (4 weeks) two capsules/ day will be administered to subjects randomized in this group containing carrot RG-I with a breakfast item on a daily basis.
224261343|NCT04063878|DEVICE|Conometric Abutment and Conometric Final Cap|Conometric concept developed by Dentsply Sirona Implants for implant systems Ankylos, Astra Tech Implant System and Xive.
224261344|NCT03129373|DEVICE|Cryogenic treatment of warts|Treatment of common and plantar wart by cryotherapy treatment.
224261345|NCT01065610|DRUG|Oxytocin|
224261346|NCT01065610|DRUG|Placebo|
224261347|NCT03579394|PROCEDURE|Retarded IDS (Interval Debulking Surgery)|"Patient will receive 6 courses of i.v carboplatine and paclitaxel every 3 weeks followed by IDS (Interval Debulking Surgery) within 6 weeks from C6D1. After surgery patient will undergo 2 more courses of carboplatine and paclitaxel chemotherapy~Treatment accepted :~Paclitaxel and carboplatin could will be administred according to the site practice and Saint-Paul-de-Vence recommendation (Joly et al, 2017):~* paclitaxel 175 mg/m² + carboplatin AUC 5-6, D1=D21 or~* paclitaxel 80 mg/m² at J1-J8-J15 + carboplatin AUC 5-6, D1=D21 or~* paclitaxel 60 mg/m² D1-D8-D15 + carboplatin AUC2 D1-D8-D15, D1= D21~* Adjuvant therapy and maintenance (optional)according to national recommendations (Saint Paul de Vence)"
224261348|NCT03579394|PROCEDURE|Standard IDS (Interval Debulking Surgery)|"Patient will receive 3 courses of i.v carboplatine and paclitaxel every 3 weeks followed by IDS (Interval Debulking Surgery) within 6 weeks from C3D1. After surgery patient will undergo 5 more courses of carboplatine and paclitaxel chemotherapy.~Treatment accepted :~Paclitaxel and carboplatin could will be administred according to the site practice and Saint-Paul-de-Vence recommendation (Joly et al, 2017):~* paclitaxel 175 mg/m² + carboplatin AUC 5-6, D1=D21 or~* paclitaxel 80 mg/m² at J1-J8-J15 + carboplatin AUC 5-6, D1=D21 or~* paclitaxel 60 mg/m² D1-D8-D15 + carboplatin AUC2 D1-D8-D15, D1= D21~* Adjuvant therapy and maintenance (optional)according to national recommendations (Saint Paul de Vence)"
224261349|NCT05909358|BIOLOGICAL|CAd3|CAd3 candidate vaccine which is one of the investigational products
224261350|NCT05909358|BIOLOGICAL|ChAdox1|ChAdox1 candidate vaccine which is one of the investigational products
224261351|NCT05909358|BIOLOGICAL|rVSV-SUDV|rVSV-SUDV candidate vaccine which is one of the investigational products
224261352|NCT05909358|OTHER|Control|Placebo
223774130|NCT03383588|DRUG|Morphine|intrathecal morphine (Duramorph) 150mcg. DURAMORPH (morphine injection) is a systemic narcotic analgesic for administration by the intravenous, epidural or intrathecal routes. It is used for the management of pain not responsive to non-narcotic analgesics. DURAMORPH (morphine injection) administered epidurally or intrathecally, provides pain relief for extended periods without attendant loss of motor, sensory or sympathetic function.
223774131|NCT03383588|DRUG|Fentanyl|intrathecal fentanyl 10 mcg. Fentanyl (also spelled fentanil) is an opioid which is used as a pain medication and together with other medications for anesthesia.
224261353|NCT03575585|BEHAVIORAL|BEST assessment only|Patients complete the BEST assessment, a self-report measure containing questions about patients' substance use, sexual risk behaviors, and partner risk levels.
224261354|NCT03575585|BEHAVIORAL|BEST assessment plus feedback report|Patients complete the BEST assessment, a self-report measure containing questions about patients' substance use, sexual risk behaviors, and partner risk levels. Based on their responses they also receive a personalized feedback report that .provides individualized risk levels in five behavior domains: 1) number of partners, 2) riskiness of partners, 3) condom use, 4) riskiness of sex acts, and 5) sex under the influence of drugs or alcohol.
224261355|NCT03575585|BEHAVIORAL|Standard Counselor Training|2 hours of training on how to use the BEST patient feedback report
224261356|NCT03575585|BEHAVIORAL|Enhanced Counselor Training|Standard training (2 hrs) plus 8 additional hours (4 modules) of motivation/skills training on a) talking about sex with patients, b) basics of using Motivational Interviewing techniques to review a feedback report, c) teaching patients problem solving skills, and d) teaching patients relationship communication skills.
224261357|NCT05826327|DRUG|Esketamine|The drug esketamine will be added to the experimental group as opposed to the control group.
224261358|NCT05826327|DRUG|Sufentanil|Sufentanil for labour analgesia in the control group
224261359|NCT00815087|DEVICE|Functional electrical stimulation|15 sessions of VitalStim® therapy, 60 minutes per session
224261360|NCT00815087|BEHAVIORAL|Exercise home program|Daily exercise training
224261361|NCT00805402|OTHER|flow cytometry|flow cytometry
224261362|NCT06982027|DEVICE|BlockSynop surface electromyography device|The EMG monitor uses non-invasive surface electrodes that measures electrical activity in response to muscle stimulation. After all electrodes have been placed on the patient, the electrodes will be connected to a prototype non-significant risk device (NSR) BlockSynop surface electromyography device and monitoring of sEMG signal will begin. The device is a non-invasive and non-significant risk device.
224261363|NCT06982027|PROCEDURE|Peripheral nerve block|An injection of numbing medicine near a specific nerve or group of nerves to numb the part of the body undergoing surgery.
224261364|NCT01473953|DRUG|liraglutide-depot|Subjects will be randomised to receive a single dose of liraglutide-depot, at increasing dose levels, injected s.c./subcutaneously (under the skin). Progression to next dose level (max. 8) will be based on safety evaluation.
224261365|NCT01473953|DRUG|placebo|Subjects will be randomised to receive a single dose of liraglutide-depot placebo, at increasing dose levels, injected s.c./subcutaneously (under the skin).
224261366|NCT00772239|DEVICE|Rotation thromboelastometry (ROTEM)|Coagulation measurement
223681233|NCT04999254|OTHER|Medical treatment|"Medical treatment will be based on functional treatment and the doctor will prescribe the RICE protocol. For this, the patient will have to :~* place an ice pack on the sprain~* apply sports rest for three weeks~* compress the sprain with a compression stocking when standing in order to prevent phlebitis. In addition, to avoid this complication, the doctor will prescribe an anticoagulant.~* raise the foot with crutches during the day~* elevate the foot at night or when doing an activity in a sitting position, using a cushion for example.~In addition, the doctor will prescribe anti-inflammatory drugs to ease the pain and physiotherapy to establish proprioception, muscle strength, joint range and dynamic postural balance of the sprain."
223681234|NCT04999254|OTHER|osteopathic treatment|Each patient will be treated as a whole and within a time limit of 45 minutes. The consultation will start with a medical history followed by medical tests. Then, the osteopath will perform osteopathic tests and manual treatment.
223681235|NCT00600145|DRUG|Mirtazapine|15 mg Mirtazapine is administered followed 2 hours later by 20 mg of methamphetamine / placebo (administered at each testing visit)
224261367|NCT00772239|PROCEDURE|Standard coagulation managment procedure|Standard coagulation managment procedure
224261368|NCT02358538|DRUG|Ganaxolone|oral suspension or capsules
224261369|NCT01348438|DEVICE|Medtronic Engager Transcatheter Aortic Valve Implantation System|Transapical implantation of the Medtronic Engager Transcatheter Aortic Valve Implantation System
224261370|NCT01032213|DRUG|Magnesium Sulfate|Group M received 50 mg/kg of magnesium sulphate on 100 ml of isotonic saline over 10 minutes during the anesthesia induction, followed by the 15 mg/kg/h by continuous infusion during the operation
224261371|NCT01032213|DRUG|normal saline|Group S received the same volume of isotonic saline as same method.
224323783|NCT03696225|BEHAVIORAL|Treatment as Usual (TAU)|All TAU participants have an ongoing VA mental health provider and received ongoing mental health care during the course of the study (generally weekly individual or group sessions focusing on evidence-based PTSD treatment).
223681236|NCT00600145|OTHER|Placebo|Placebo
223681237|NCT01213667|DRUG|Ranibizumab|upload (three monthly injections), re-treatment as needed
223681238|NCT04079569|BEHAVIORAL|Tobacco|Quit Smoking For a Healthy Family - This is a family-based psycho-education intervention using lay health worker (LHW) outreach. LHW will be trained to recruit smoke-family dyads and provide education and information about tobacco and health, and smoking cessation resources through 2 small-group education sessions and 2 individual phone calls over a 2-month period.
223774132|NCT03383588|DRUG|Epinephrine|Epinephrine injection is used along with emergency medical treatment to treat life-threatening allergic reactions caused by insect bites or stings, foods, medications, latex, and other causes. Epinephrine is in a class of medications called alpha- and beta-adrenergic agonists (sympathomimetic agents). It works by relaxing the muscles in the airways and tightening the blood vessels.
223774133|NCT03383588|OTHER|Saline solution|20 ml subcutaneous NACL 0.9% - saline solution is the placebo
224261372|NCT02819947|OTHER|This is an observational prospective study.|Investigators will get clinical information including gender, date of birth, height, weight, family history for systemic sclerosis, education, and symptoms of organ involvement of skin, lung, heart, gastrointestinal tract, kidney, musculoskeletal system and laboratory data. Investigators will evaluate nailbed capillary microscope, hand x-ray, 6 minute walk test, echocardiography, computed tomography of chest, pulmonary function test (FVC%, DLCO%), and electrocardiogram as baseline. Investigators permit replacement of previous results within one year from baseline. Participants in the cohort will be followed up annually and investigators will treat SSc patients according to their routine practice in the best interest of patents. Medications for other comorbid conditions are allowed.
224261373|NCT02745054|OTHER|mgt of bleeding concerns/complications of oral anticoagulants|observational study of clincians' management of patients taking oral anticoagulants and having acute significant bleeding or requiring management of bleeding risk before an emergent procedure; observation limited to index hospitalization only
224261374|NCT03155672|BEHAVIORAL|Art therapy|Art Therapy
224261375|NCT06986954|DEVICE|Beacon Tip Catheters|Indicated for use in angiographic procedures by physicians trained and experienced in angiographic techniques. Standard techniques for placement of vascular access sheaths, angiographic catheters, and wire guides should be employed. Beacon Tip Sizing Catheters have marker bands that can be used for anatomical measurements.
224261376|NCT05033678|DEVICE|Diagnostic algorithms|Assessors of teledermoscopy will be randomly assigned to use the results of artificial intelligence when the assess a teledermoscopic case.
224261377|NCT06611579|DEVICE|Transcatheter Tricuspid Valve Replacement|Replacement of the tricuspid valve using a transcatheter approach
224261378|NCT01494532|DRUG|ropinirole/L-dopa|Ropinirole as adjunctive therapy with L-dopa
224261379|NCT01494532|DRUG|placebo/L-dopa|Placebo as adjunctive therapy with L-dopa
224261380|NCT06991608|OTHER|Collection of patient data|This non-interventional study and will not influence treatment decisions
224261381|NCT03221543|DEVICE|ReeVue Indirect Calorimeter|The ReeVue Indirect Calorimeter will be used in this study to measure the resting metabolic rate. The test takes approximately ten minutes to complete. The subject should prepare for the test by avoiding stimulants and exercise on the day of the test, as well as eating meals four hours before the test. The subject will be seated during the test. They will be given a nose clip that looks like a clothes pin to be placed on their nose. A plastic mouth piece that allows all of the air they breathe to come in through the top of the mouth piece and the air they breathe out to go into the ReeVue Calorimeter will also be provided. The subject will remain in this position for ten minutes until the testing is complete.
223681239|NCT04079569|BEHAVIORAL|Healthy Living|"In this comparison arm, participants will receive the same number of contacts on the same schedule and in the same format (2 small group sessions and 2 telephone calls). The comparison LHWs will receive training about Healthy Living focusing on nutrition and physical activity education. Participants will also receive the Smoking Cessation Resource Handout."
223681240|NCT01166243|BIOLOGICAL|Fibrin Pad|Fibrin Pad is a sterile bio-absorbable combination product consisting of two constituent parts- a flexible matrix and a coating of two biological components (Human Fibrinogen and Human Thrombin).
223681241|NCT01166243|PROCEDURE|Standard of Care|Standard of Care is a composite of techniques/methods typically used by the surgeon to control bleeding.
223681242|NCT04581135|OTHER|COVID-19|Research project in which biological material is sampled and health-related personal data are collected and used for further research. Coded data are used.
223681243|NCT00056056|DRUG|bexarotene|The recommended initial dosage of Bexarotene (75 mg Bexarotene capsules to be administered according to body surface area) for patients entered in this trial is 300 mg/m2 /once a day, taken orally, till CCR, PD, unacceptable toxicity, 16 weeks of treatment, whichever comes first
223681244|NCT00056056|DRUG|methoxypsoralen|The dose of methoxypsoralen, as conventional capsules or liquid-filled capsules, is based on the patient's weight. The standard dose of 0.6 mg/kg will be given to all patients three times weekly - Increasing dose of PUVA according to a set protocol after a Minimal Phototoxic Dose (MPD) testing.
224261382|NCT04802655|OTHER|Video-game based exercise - Exergame|Selected Kinect compatible video games from Microsoft Xbox one will be applied in this group. Four video games will be selected for a session (each game will last 10 mins). Video games are active video games which participants have to use their body parts in order to control games.
224261383|NCT04802655|OTHER|Activity Based Exercise Group (AG)|Task-oriented exercises to be performed in standing and sitting positions, including upper extremity and trunk, will be applied to the activity-based exercise group in addition to routine NDT training. Examples for activities; stepping and putting stickers on the wall, treading the play dough placed on a step board within one leg stance; reach-grasp activities progressively from sitting to standing, throwing and catching balls on a balance board.
224261384|NCT06615726|BEHAVIORAL|Regular physical exercise|Best medical treatment plus regular physical exercise. Each subject is equipped with an exercise guidance expert to regularly guide and adjust the exercise plan according to the subject's personal conditions throughout the trial period. After randomization, the exercise guidance expert formulated an individualized aerobic exercise plan based on the subject's preferences and their own exercise abilities. After each exercise, subjects filled out the exercise diary , and reported back to the exercise guidance expert.
224261385|NCT06615726|OTHER|Control group|Best medical treatment
224261386|NCT04564053|DRUG|LNA043|Single intra-articular injection on Day 1
224261387|NCT04564053|DRUG|Placebo|Single intra-articular injection on Day 1
223681245|NCT00056056|PROCEDURE|UV light therapy|Initial UVA light exposure times should be based on the minimal phototoxic dose (MPD) for the specific light source being used. MPD can be determined by irradiating several skin areas 2 cm in diameter with varying light exposure times and determining the exposure time that produces erythema at 72 hours. The initial dose of UVA administered will be 70% of the MPD. The dose of UVA for the subsequent UVA sessions will be increased according to a standard protocol consisting of 20% increments with each successive treatment session depending on the presence of erythema.
224261388|NCT04492540|OTHER|aerobic exercise and MIND diet program|the aerobic exercise in form of treadmill training intensity of exercise moderate intensity, target heart rate (THR) will be60-70% of heart maximum (HR MAX), time of session 60 min initial 10 min warm up exercise on treadmill in low intensity and target phase 40 min intensity will increase until patient reach to THR then intensity decrease until session will be ended by cooling down phase for 10 min . The volunteers will perform exercise 3 times per week for 12 weeks
224261389|NCT04492540|OTHER|MIND diet program|control group will receive diet program for 12 weeks
224261390|NCT04544995|DRUG|Niraparib (Tablet for oral suspension)|Niraparib will be administered as TfOS (Tablet for oral suspension)
224261391|NCT04544995|DRUG|Dostarlimab|Dostarlimab will be administered as IV infusion
224261392|NCT04544995|DRUG|Niraparib (Tablet)|Niraparib will be administered as tablet
224261393|NCT06918002|DRUG|Elranatamab|Elranatamab is given to arm B patients in association with lenalidomide (for consolidation) and arm D patients in monotherapy (for maintenance) as experimental arms
224261394|NCT06918002|DRUG|Lenalidomide (Revlimid®)|In association with daratumumab, bortezomib and dexamethasone (Arm A), in association with elranatamab (Arm B), in monotherapy (Arm C)
224261395|NCT06918002|DRUG|Daratumumab SC (Darzalex)|Daratumumab is given in association with bortezomib, lenalidomide and dexamethasone in induction therapy (all patients) and consolidation arm A
224261396|NCT06918002|PROCEDURE|Autologous Stem Cell Transplantation|ASCT is performed in consolidation for Arm A patients after induction therapy with D-VRD
224261397|NCT06918002|DRUG|Bortezomib (Velcade®)|Bortezomib is given in associtaion with daratumumab, lenalidomide and dexamethasone in induction (all patients) and consolidation Arm A
224261398|NCT06918002|DRUG|Dexamethasone|Dexamethasone is given in association with daratumumab, bortezomib and lenalidomide in induction (all patients) and consolidation Arm A
223681246|NCT00202176|DRUG|Ipratropium Bromide|Nebulized Ipratropium Bromide (4 mL) or saline solution (0.9% NaCl) (4mL) will be administered to subjects once only.
223681247|NCT05577468|DRUG|Tegoprazan|tegoprazan-containing bismuth quadruple therapy or Esomeprazole-containing bismuth quadruple therapy; Route of administration: oral;
223681248|NCT03668418|DRUG|Fluorouracil|The enrolled patients after the surgical operation will undergo to the adjuvant chemotherapy treatment
223681249|NCT03668418|DRUG|Lederfolin|The enrolled patients after the surgical operation will undergo to the adjuvant chemotherapy treatment
223681250|NCT03668418|DRUG|Oxaliplatin|The enrolled patients after the surgical operation will undergo to the adjuvant chemotherapy treatment
223681251|NCT03668418|DRUG|Irinotecan|The enrolled patients after the surgical operation will undergo to the adjuvant chemotherapy treatment
223681252|NCT03668418|DRUG|Docetaxel|The enrolled patients after the surgical operation will undergo to the adjuvant chemotherapy treatment
223681253|NCT03668418|DRUG|Cisplatin|The enrolled patients after the surgical operation will undergo to the adjuvant chemotherapy treatment
223681254|NCT03668418|DRUG|Epirubicin|The enrolled patients after the surgical operation will undergo to the adjuvant chemotherapy treatment
223681255|NCT03668418|DRUG|Gemcitabine|The enrolled patients after the surgical operation will undergo to the adjuvant chemotherapy treatment
223681256|NCT03668418|DRUG|Nab paclitaxel|The enrolled patients after the surgical operation will undergo to the adjuvant chemotherapy treatment
223681257|NCT00008866|BIOLOGICAL|Tetanus Toxoid Vaccine|
223681258|NCT00008866|DRUG|Hydroxyurea|
223681259|NCT00008866|DRUG|Didanosine|
224261399|NCT01216566|DEVICE|Occiflex Device|This device is a computerized robotic platform that allows continuous mobilization of the cervical spine in a three dimensional space. The patients undergoes biweekly 20 minute therapeutic session for 6 weeks
224261400|NCT02217293|DEVICE|Pulsed Radiofrequency|Pulsed radiofrequency (PRF) treatment, a relative novel pain intervention at recent decade, was found to be able to alleviate pain by delivering an electrical field and heat bursts at a temperature less than 42°C to neural tissue in the absence of neural injury. The ultrasound-guided PRF was performed before night splint in intervention group.
224261401|NCT00848653|DEVICE|CRT device|market approved CRT device
223681260|NCT03752411|OTHER|Research Bottle|The purpose of the study is to test a research prescription bottle that will monitor the physical environment inside the bottle.
223681261|NCT03752411|OTHER|Regular prescription Bottle|This will test if the research bottle changes behavior relative to the research bottle
223681262|NCT05669313|DRUG|Rivaroxaban 15 MG|Rivaroxaban 15 mg after inclusion and on the morning after inclusion, i.e., before blood sampling
223681263|NCT04249830|BIOLOGICAL|Allogeneic Stem Cell Transplant|The allogeneic stem cell transplant involves transferring the stem cells from a healthy person (donor) to the participant via infusion.
223681264|NCT04249830|DEVICE|CliniMACS TCR α/β Reagent Kit and CliniMACS CD19|The CliniMACS™system can be used to selectively enrich or reduce specific cell populations based on the magnetic cell selection (MACS) technology developed by Miltenyi Biotec. Cell mixtures can be separated in a magnetic field using one or more immunomagnetic- labeled antibodies specific for the cell types of interest (e.g.TCR αβ+ T cells and CD19+ B cells from HPC(A) products).
223681265|NCT02091505|DRUG|Ranibizumab|
223681266|NCT05153889|OTHER|Hospitalized in Intensive care unit|Patient hospitalized in Intensive care unit with ECG monitoring
223681267|NCT05153889|OTHER|Hospitalized in General cardiology ward|Patient hospitalized in General cardiology ward without ECG monitoring. patients randomized in this group will not be hospitalized in intensive care unit unless an event require intensive care unit monitoring.
223681268|NCT02812888|DRUG|thionamide treatment for 3 months|Hyperthyroid patients would received thionamide treatment (methimazole, propylthiouracil, or propranolol) for 3 months, and euthyroidism would be obtained.
223681269|NCT03608761|DRUG|Rebamipide|rebamipide 2%
224261402|NCT00609557|DRUG|duloxetine|Weeks 0-2 placebo Weeks 2-3 30mg duloxetine Weeks 3-4 60mg duloxetine Weeks 4-12 60-90mg duloxetine Week 13 30 mg duloxetine Week 14 stop
224261403|NCT05526183|BIOLOGICAL|Adeno-viral vector vaccine|The vaccine will be injected intramuscularly, as two doses 28 days apart. Two different dosages will be given to volunteers (low dose: 5x1010 and high dose: 1x1011)
224261404|NCT06623084|OTHER|Platelets characterization|To identify platelet features that correlate with liver disease progression and to study the mechanistic relationship between gut dysbiosis, metabolome composition, inflammation, and platelet activation in chronic liver disease.
224261405|NCT07004322|DRUG|NNC0519-0130|NNC0519-0130 will be administered subcutaneously.
224261406|NCT07004322|DRUG|Placebo|Placebo matched to NNC0519-0130 will be administered subcutaneously.
224261407|NCT06246786|DRUG|Cyclosporin A|Patients will begin treatment at 5mg/kg/day in 2 divided doses until the day before surgery at which time they will stop CsA.
224261408|NCT00209625|DRUG|irinotecan|
224261409|NCT00209625|DRUG|leucovorin|
224261410|NCT00209625|DRUG|fluorouracil|
224261411|NCT07068113|OTHER|DANCE GROUP|home exercise program + 50 min/week brisk walking + 100 min/week dance
224261412|NCT07068113|OTHER|EXERCISE GROUP|home exercise program + 150 min/week brisk walking
224261413|NCT07069036|DRUG|SEP-631|Oral, tablet
224261414|NCT07069036|OTHER|Placebo|Oral, tablet
224261415|NCT07067320|BEHAVIORAL|Bibliotherapy combined with games to overcome fear of the dark|Bibliotherapy combined with games, applied by parents at home. Treatment based on cognitive-behavioural techniques. Duration: 4-5 weeks. Experimental group recived this bibliotherapeutic intervention.
224261416|NCT07067359|DIETARY_SUPPLEMENT|Enteral Nutrition|This study selected patients with esophageal cancer undergoing neoadjuvant therapy as the research subjects. All enrolled patients underwent comprehensive nutritional risk screening and malnutrition assessment prior to enrollment. After the completion of nutritional risk screening and assessment, patients identified with nutritional risk were randomly assigned to two groups: the Standard Nutrition Therapy group (SNT) and the Intensive Nutrition Therapy group (INT). Patients in the SNT group received a conventional nutritional support regimen during hospitalization, which included dietary guidance and necessary nutritional supplements. In addition to the standard regimen, patients in the INT group continued to receive ongoing nutritional counseling and nutritional supplement support after discharge to ensure sustained nutritional support.
224261417|NCT07067983|DIAGNOSTIC_TEST|Results following systematic screening|The GRAPE model's output (positive or negative) determines whether patients require follow-up gastroscopy
223681270|NCT03608761|BIOLOGICAL|autologous serum|AS for 3 months
223681271|NCT03608761|OTHER|autologous serum and rebamipide 2%|rebamipide and autologous serum for 3 months
223681272|NCT00124839|DRUG|Naltrexone|Daily oral administration (capsules): 50mg naltrexone and placebo or 200mg naltrexone and placebo or placebo and naltrexon 50mg or placebo and 200mg naltrexone
223681273|NCT00023127|PROCEDURE|Integrated Pest Management|
223681274|NCT02569827|DRUG|Celgosivir|Celgosivir 150 mg Q6H for 5 days (total of 20 doses = 3000 mg celgosivir total).
223681275|NCT02569827|DRUG|Modipafant 50mg|Modipafant 50 mg Q12H alternating with placebo Q12H for 5 days (total of 10 modipafant doses = 500 mg modipafant)
223681276|NCT02569827|DRUG|Placebo|Placebo Q6H for 5 days
223681277|NCT02569827|DRUG|Modipafant 100mg|Modipafant 100 mg Q12H alternating with placebo Q12H for 5 days (total of modipafant 10 doses = 1000 mg modipafant)
223681278|NCT00065364|BEHAVIORAL|Newborn Individualized Developmental Care Assessment Program|
223681279|NCT04457388|OTHER|Tele-Yoga Therapy|Yoga practices combining with joint loosening exercises (Sukshma Vyayama), postures (Asana), breathing exercises (Pranayama), relaxation techniques and chanting ( A, U, M, and AUM { ૐ}) syllable chants meditation. Each session ended with home practice exercises given to the participants to practice everyday.
224323784|NCT06393660|DEVICE|CliniMACS® CD34 TCR Alpha/Beta|CliniMACS System uses an automated antibody/magnetic beads column system that allows efficient depletion of TCRαβ and CD19+ cells without relevant loss of cell viability. Hematopoietic stem cells are retained in sufficient numbers to permit engraftment and hematopoietic reconstitution. Humanitarian Exemption IDE approval has been obtained for CD34+ cell selection as a method of T-cell depletion.
224323785|NCT06576687|OTHER|Physical Rehabilitation|Exercises include (1) single-limb hops to stabilization, (2) hop to stabilization and reach, (3) unanticipated hop to stabilization, (4) single-limb stance activities, and (5) continuous choice-reaction hopping.
224323786|NCT06577220|BEHAVIORAL|Telephone Recall|Participants receive a scripted telephone recall from a trained patient navigator.
223681280|NCT03487601|OTHER|transcranial direct current stimulation|Active treatment will consist of a mild electrical current (2mA) administered via saline-soaked sponge electrodes placed along the intact scalp for 30 minutes a day for five days.
224261418|NCT05376800|DRUG|BI 907828 (Brigimadlin)|BI 907828 (Brigimadlin)
224261419|NCT01718301|DRUG|boceprevir|
223681281|NCT03487601|OTHER|sham transcranial direct current stimulation|Sham stimulation will involve brief delivery of current in a manner that does not result in changes in neuronal firing patterns, but that is perceived as active treatment by participants.
223681282|NCT01555385|DIETARY_SUPPLEMENT|Breakfast juice|single dose (300 ml) in the morning of study day, 3 separate sessions (high-protein vs. high-carbohydrate vs. low-calorie juice), total duration 3 weeks
224261420|NCT01718301|DRUG|Ribavirin|
224261421|NCT01718301|DRUG|Peginterferon alfa-2a|
224261422|NCT01718301|DRUG|Peginterferon alfa-2b|
224261423|NCT04464200|DRUG|19(T2)28z1xx CAR T cells|2-7 days following the completion of the conditioning chemotherapy, patients will receive the CAR- T cells by IV infusion over 1-3 days depending on the dose level and formulation of the final CAR- T cells.
224261424|NCT06152302|OTHER|Mobility study in dry conditions|Record the movements of the baby's extremities using inertial sensors while the baby moves outside of the water.
224261425|NCT06152302|OTHER|Mobility study in water conditions|Record the movements of the baby's extremities using inertial sensors while the baby moves inside the water.
224261426|NCT04727359|OTHER|FIT64b model project|FIT64b model project: The SHI funds AOK Baden-Württemberg and SVLFG (as an agricultural health insurance fund) have established a contract (duration = at least eight year) with the model hospital for an alternative remuneration / financing of patients treated in the model hospital (FIT64b hospital, UKT). This contract encourages the model hospital an alternative treatment of their patients (with the above mentioned SHI fund), for example fewer inpatient and more outpatient treatment.
224261427|NCT06385184|OTHER|No Intervention|Observational study with no intervention
224261428|NCT05763589|OTHER|No intervention is involved|No intervention is involved
224261429|NCT06785389|DIAGNOSTIC_TEST|Fear of anesthesia, surgery and hospitals scale|The day before surgery, patients will be interviewed using the scales of Fear of anesthesia, surgery and hospitals.
224261430|NCT06785389|DIAGNOSTIC_TEST|State-Trait Anxiety Inventory|The day before surgery, patients will be interviewed using the State-Trait Anxiety Inventory
223774134|NCT03835858|OTHER|Respiratory physiotherapy|The protocol consists of 20 minutes of FR based on nasal washes in sitting, prolonged slow expiration: passive technique of expiratory help applied to the baby through a slow thoracic-abdominal pressure that begins at the end of a spontaneous expiration and continuing to the residual volume. The physiotherapist through the the provoked cough or stimulation of the trachea achieves the expectoration of the sputum.
223835248|NCT03706729|DEVICE|Spraino|"Spraino® is an adhesive polytetrafluoroethylene (PTFE or Teflon) patch developed with the purpose of minimizing lateral shoe-surface friction whenever initial contact is carried out in an inverted position of the ankle joint. Each Spraino® PTFE patch has a minimum durability of 20 hours use and will be provided by the study sponsor, Spraino® ApS. The participants will receive four pairs of Spraino® upon their enrollment to the study."
223835249|NCT00746317|DRUG|GC33|IV administration at 4 escalating dose levels.
224261431|NCT06785389|DIAGNOSTIC_TEST|Nummerical Rating Scale for postoperative pain|In the first postoperative day, patients will be monitored using the Nummerical Rating Scale, which will assess postoperative pain.
224261432|NCT05630950|DEVICE|Smoking cessation mobile application|Mobile application for smoking cessation.
224261433|NCT05630950|BEHAVIORAL|Written material for smoking cessation|Written material for smoking cessation
223681283|NCT04513821|DRUG|Mino-Lok Therapy (MLT)|Standard of Care antibiotics appropriate for the infecting organism plus Mino-Lok therapy to disinfect and save the catheter. Mino-Lok is made available through this expanded access protocol to patients who otherwise do not qualify for the phase 3 clinical trial (NCT02901717) Other Name: Standard of care antibiotics + Mino-Lok
223681284|NCT02290431|DRUG|LBH589 (panobinostat)|Panobinostat (PAN) capsules were supplied at dose strengths of 10 mg and 15 mg. and dosed at 20mg during treatment phase 1 (21 days) and treatment phase 2 (42 days)
223681285|NCT02290431|DRUG|bortezomib|Bortezomib (BTZ) s.c: 1.3 mg/m2 was administered during both treatment phase 1 (21 days) \& treatment phase 2 (42 days).
223681286|NCT02290431|DRUG|dexamethasone|Dexamethasone (Dex): 20mg tablets taken during both treatment phase 1 (21 days \& treatment phase 2 (42 days)
223681287|NCT03033147|DRUG|Amoxicillin/Clavulanate Potassium 875 mg-125 mg oral tablet|2 gm of amoxicillin/ clavulanic acid combination orally 30 minutes before root canal treatment
223681288|NCT03033147|DRUG|Oral placebo|placebo 30 minutes before root canal treatment
223681289|NCT03627390|DRUG|BP-C1|BP-C1, 0.05% solution for injections; doses: 0.035 mg/kg body weight (0.07 mL/kg) intramuscularly once daily for 32 consecutive days
223681290|NCT03627390|DRUG|BP-C2|BP-C2, 0.15% solution for oral use; 15 ml orally once daily for 32 consecutive days
223681291|NCT00314483|DRUG|Mesenchymal Stem Cell Infusion|
223681292|NCT05871515|DEVICE|3D ultrasound|A 3D ultrasound is performed preoperatively to measure various aneurysm characteristics
223681293|NCT04144491|DIETARY_SUPPLEMENT|Probiotic|"Probiotics are defined by the Food and Agricultural Organization (FAO)/WHO as live microorganisms, which when consumed in adequate amounts, confer a health benefit on the host. Lactobacillus rhamnosus GG (LGG) is the most documented probiotic bacteria, with many proven unique characteristics and therewith associated health benefits. No adverse effects of the consumption of LGG in healthy infants have been reported. The Lactobacillus rhamnosus yoba containing yoghurt drink, which is locally produced and subsequently consumed by resource-poor communities in rural Uganda has been described. The strain used in this intervention is a generic variant of LGG, called Lactobacillus rhamnosus yoba 2012. LGG is consumed as part of food all over the world, and is not a drug.~100ml of yoghurt containing Lactobacillus rhamnosus yoba 2012 will be consumed 5 days per week, for 9 weeks."
223681294|NCT04144491|DIETARY_SUPPLEMENT|Placebo|100ml of custard will be consumed 5 days per week, for 9 weeks.
223681295|NCT03528395|OTHER|Semi-immersive virtual reality|Each participant will receive 24 additional sessions of semiinmersive virtual Reality therapy sessions on Monday, Wednesday and Friday, after realizing the conventional therapy sessions. The duration of each VR session will be gradually increased in time-intensity (5 minutes during the first week to 20 minutes during the last week) and motor requirements.
223681296|NCT03528395|OTHER|Conventional Rehabilitation|Conventional rehabilitation consisting of five weekly sessions of Physical therapy and Occupational Therapy, based on a task-oriented approach, lasting 45 minutes each.
223681297|NCT06364293|OTHER|Observational design does not include interventional behavior.|Observational design does not include interventional behavior.
223681298|NCT00821327|DRUG|Gemcitabine, Cisplatin, Sunitinib|"Patients will receive gemcitabine 800 mg/m2 IV (Days 1 and 8), cisplatin 60 mg/m2 IV (Day 1), and sunitinib 37.5 mg PO daily (Days 1-14) of each 21-day cycle.~2\. One cycle of treatment is defined as 21 days (3 weeks). Restaging studies will be performed after every 3 cycles of therapy.~3\. Successive cycles will be initiated every 3 weeks, and will be continued through 6 cycles unless a patient shows evidence of disease progression or intolerable toxicity."
223681299|NCT04469491|DRUG|inhaled type I interferon|The interventional arm includes inhaled interferon (9.6 MUI x2/d for 48 hours, then 9.6 MUI x1/d for 8 to 16 days or discharge), in addition to standard care. In phase B, maximum treatment duration is 8 days.
223681300|NCT04469491|DRUG|WFI water nebulization|The interventional arm includes a WFI water nebulization comparator.
223681301|NCT05346445|DRUG|Fluoxetine 20 MG|Participants received non-hormonal treatment with fluoxetine.
223681302|NCT05346445|DRUG|Citalopram 20mg|Participants received non-hormonal treatment with citalopram.
223681303|NCT02119676|DRUG|Ruxolitinib|"5 mg tablets to be administered by mouth~Ruxolitinib 20 mg twice a day (BID) (Part 1) (NOTE: The starting dose for the randomized portion of study (Part 2) was 15 mg BID based on results from Part 1.)"
223681304|NCT02119676|DRUG|Regorafenib|Regorafenib 160mg once daily for the first 21 days of each 28-day cycle. (NOTE: Dose interruptions and modifications for regorafenib are expected when toxicities occur in which dose interruptions or modifications are appropriate.)
223681305|NCT02119676|DRUG|Placebo|5 mg matching placebo tablets to be administered by mouth
224261434|NCT05231629|DRUG|Dara-VRd intensification, Dara-R maintenance|"Eligible patients are enrolled in arm M for induction therapy, corresponding to 6 cycles of Dara-VRd. Upon confirmation of adequate hematopoietic cell collection and result of MRD1 patients will undergo 1:1 randomization according to the MRD-assigned cohort~• MRD negative cohort - Patients will be randomized between arm A (3 cycles of Dara-VRd intensification followed by 13 cycles of Dara-R maintenance) and arm B (AHCT intensification followed by 13 cycles of Dara-R maintenance) for intensification and maintenance"
224261435|NCT05231629|DRUG|AHCT intensification, Dara-R maintenance|"Eligible patients are enrolled in arm M for induction therapy, corresponding to 6 cycles of Dara-VRd. Upon confirmation of adequate hematopoietic cell collection and result of MRD1 patients will undergo 1:1 randomization according to the MRD-assigned cohort~• MRD negative cohort - Patients will be randomized between arm A (3 cycles of Dara-VRd intensification followed by 13 cycles of Dara-R maintenance) and arm B (AHCT intensification followed by 13 cycles of Dara-R maintenance) for intensification and maintenance"
224261436|NCT05231629|DRUG|AHCT intensification, Tec-Dara consolidation, Tec-Dara maintenance|Eligible patients are enrolled in arm M for induction therapy, corresponding to 6 cycles of Dara-VRd. Upon confirmation of adequate hematopoietic cell collection and result of MRD1 patients will undergo 1:1 randomization according to the MRD-assigned cohort. MRD positive cohort - Patients will be randomized between arm C (AHCT intensification, 3 cycles of Dara-Tec consolidation and 13 cycles of Dara-Tec maintenance) and arm D (AHCT intensification, 3 cycles of Dara-R consolidation and 13 cycles of Dara-R maintenance) for intensification, consolidation and maintenance.
224261437|NCT05231629|DRUG|AHCT intensification, Dara-R consolidation, Dara-R maintenance|Eligible patients are enrolled in arm M for induction therapy, corresponding to 6 cycles of Dara-VRd. Upon confirmation of adequate hematopoietic cell collection and result of MRD1 patients will undergo 1:1 randomization according to the MRD-assigned cohort. MRD positive cohort - Patients will be randomized between arm C (AHCT intensification, 3 cycles of Dara-Tec consolidation and 13 cycles of Dara-Tec maintenance) and arm D (AHCT intensification, 3 cycles of Dara-R consolidation and 13 cycles of Dara-R maintenance) for intensification, consolidation and maintenance.
224261438|NCT05231629|DRUG|Dara-VRd induction|Patients undergo induction therapy with 6 cycles of daratumumab, bortezomib, lenalidomide and dexamethasone
224261439|NCT05714865|DRUG|Surfactant|Laryngoscopy is performed, and BLES® surfactant is administered through BLEScath™ (a thin catheter) into the trachea to a spontaneously breathing preterm infant with respiratory distress syndrome who is being managed on CPAP
224323787|NCT06577220|BEHAVIORAL|Mailed HPV Self-Sampling Kit|Participants receive a mailed kit that allows them to self-collect a cervical sample in their home and return it to a laboratory for human papillomavirus (HPV) testing.
223681306|NCT01230203|PROCEDURE|Computed tomography scan versus color duplex ultrasound|Computed tomography scan versus color duplex ultrasound
223681307|NCT04357691|BEHAVIORAL|Conventional training|Participants will perform a conventional training for 4 weeks, using low-moderate-high-low intensity progression training model
223681308|NCT04357691|BEHAVIORAL|AI-led training|Participants will perform an AI-led training for 4 weeks
223681309|NCT04764266|DIAGNOSTIC_TEST|Heparansulfate and Syndecan 1|Blood samples will be collected from the patient at 5 different time points. Three perfusate samples will be collected during normothermic machine perfusion (4,9ml each).
223681310|NCT03046914|GENETIC|HLA-B*5801 test|Check whether a participant has HLA-B\*5801 allele or not, before administration of allopurinol
223681311|NCT04983303|OTHER|TICK-B group|These interventions will distract the child during venipuncture
223681312|NCT04153214|BEHAVIORAL|cycling|Participants will have a portable pedal machine under their desk and will use it 60minutes per day
223681313|NCT00219544|DRUG|Pregabalin (Lyrica)|pregabalin 150mg/day (75mg BID)
223681314|NCT00219544|DRUG|Pregabalin (Lyrica)|pregabalin 300 mg/day (150mg BID)
223681315|NCT00219544|DRUG|Pregabalin (Lyrica)|pregabalin 600/day (300mg BID)
223681316|NCT00219544|DRUG|Placebo|Placebo
223681317|NCT03491189|DEVICE|Lag screw fixation|surgical fixation
223681318|NCT03491189|DEVICE|Helical blade fixation|surgical fixation
223681319|NCT06325930|DRUG|[14C]-HU6|\[14C\]-HU6 following a single dose of HU6 in healthy, adult male subjects
223681320|NCT06520969|OTHER|Prevelance of Uterine Vein and Uterine Vein System Variations (anatomical study)|Single arm anatomical study describing the prevalance and anatomical variations of superficial and deep veins in endometrial and cervical cancer patients
223681321|NCT05130944|BEHAVIORAL|Entre Nosotras|"A series of five 2-hour group sessions that are administered weekly by two trained female peer facilitators, who are selected by HIAS outreach workers and/or community leaders. The content of the sessions is based on the principles of Psychological First Aid and the Participatory Action Cycle, which is intended to generate community-led problem solving around priority issues affecting their wellbeing.~Entre Nosotras is a community- and strengths-based intervention designed to mobilize social support, strengthen community connectedness, and stimulate collective action to promote the safety and wellbeing of women."
223681322|NCT05130944|BEHAVIORAL|Doing What Matters in Times of Stress|The stress management components are derived from the World Health Organization Doing What Matters in Times of Stress illustrated guide for coping with adversity (World Health Organization, 2020). The illustrated guide and accompanying audio files are publicly available: https://www.who.int/publications/i/item/9789240003927. During five sessions, the intervention involves 15-20 minute exercises covering a range of stress management and coping skills.
223681323|NCT00056498|DRUG|Placebo|Placebo capsule daily for 16 weeks
223681324|NCT00056498|DRUG|Risperdal|Risperdal 4 mg per day for 16 weeks
223681325|NCT01007253|DRUG|PL nasal spray|2 puffs of PL nasal spray (from GlaxoSmithKline) in each nostril once a day for 1 week
223681326|NCT01007253|DRUG|fluticasone furoate (FF)|2 puffs of FF nasal spray in each nostril once a day for 1 week
223681327|NCT01007253|DRUG|PL eye drops|1 drop of placebo eye drops (lubricant eye drops with active ingredients 0.3% glycerin) in each eye once a day for 1 week
223681328|NCT01007253|DRUG|olopatadine (OLO)|1 drop of OLO eye drops in each eye once a day for 1 week
223681329|NCT00576212|BEHAVIORAL|supportive call|Each subject in the intervention group will receive a 10 minute (or longer) biweekly telephone call from a psychologist intended to provide non-judgemental support to TOPFA women with the aim of reducing depression, guilt, isolation, shame, marital discord, and other common psychological sequelae of termination for fetal anomalies.
223681330|NCT02689687|BEHAVIORAL|Support partner|Participants will identify a support partner who will be contacted if the participant is non-adherent to their diuretic and/or weighing-in.
223681331|NCT02689687|BEHAVIORAL|Engagement incentives|Participants will be entered into a daily lottery, for which their participation is contingent on adhering to their diuretic and to weighing-in on the previous day.
223774135|NCT06966323|BEHAVIORAL|Hold me Tight / Let me Go|"Hold Me Tight / Let Me Go (HmT/LmG) is a manualized, group-based behavioral intervention for parents of adolescents aged 12 to 18. Grounded in Emotionally Focused Therapy (EFT) and Hold me Tight for couples. HmT/LmG aims to improve the parent-adolescent relationship by enhancing emotional validation, secure attachment, and effective communication.~The intervention consists of four group sessions for parents, supplemented by three structured individual or dyadic sessions involving both parents and adolescents. Key components include psycho-education, role plays, emotion-focused conversations, and exercises targeting validation, apologizing, and supportive limit setting. Families complete pre- and post-intervention questionnaires and a follow-up assessment to evaluate changes in relationship quality and psychological well-being."
223774136|NCT04524962|BIOLOGICAL|Descartes 30|Mesenchymal Stem Cells or MSCs RNA-engineered to secrete a combination of DNases.
223774137|NCT06040346|DRUG|Meplazumab for Injection|Meplazumab, an erythrocytic stage-macromolecular antibody drug, has the potential to control clinical occurrence of falciparum malaria. Meplazumab is a humanized anti-CD147 immunoglobulin G subclass 2 (IgG2) monoclonal antibody with strong affinity to CD147. CD147 is expressed on erythrocyte lineage cells throughout erythroid development, including mature erythrocytes and is the target for Plasmodium merozoites to allow reorientation and subsequent invasion of the erythrocytes.
223774138|NCT04558736|DRUG|Anti-Thymocyte Globulin (Rabbit)|Given intravenously (IV)
223774139|NCT04558736|DRUG|Fludarabine|Given intravenously (IV)
223774140|NCT04558736|DRUG|Cyclophosphamide|Given intravenously (IV)
223774141|NCT04558736|DRUG|Mesna|Given intravenously (IV)
223774142|NCT04558736|DRUG|G-CSF|Filgrastim is a human granulocyte colony-stimulating factor (G-CSF), produced by recombinant DNA technology. Dosage and Route of Administration: 5mcg/kg subcutaneous or intravenous daily until ANC \>2000 for 2 consecutive days, or as clinically indicated
223774143|NCT04558736|RADIATION|Total Lymphoid Irradiation (TLI)|TLI will be given at 800 cGy total dose in 4 fractions.
224261440|NCT06834308|DEVICE|Transcutaneous electrical nerve stimulation (TENS)|Conventional TENS (100 Hz, 60 ms pulse width) will be applied for 10 minutes prior to and during resistance exercise (2 sets of 10 reps at 60% 1RM leg press). TENS' intensity will be adjusted to produce strong paresthesia without pain. Electrodes will be placed on participant-identified most painful area. Resistance exercise will consist of two sets of ten repetition with 1 min rest
224323788|NCT06577220|BEHAVIORAL|Patient Navigation|Participant receives telephone call from patient navigator within 3-5 days of receipt of self-collection kit. Patient navigator provides one-on-one education on cervical cancer screening and self-collection of cervical sample.
223681332|NCT02689687|BEHAVIORAL|Electronic pill bottle|Participant adherence to their diuretic will be monitored on a daily basis and participants will be contacted if they are non-adherent to this medication.
223681333|NCT02689687|BEHAVIORAL|Bluetooth scale|Participant adherence to stepping on their scale will be monitored on a daily basis and participants will be contacted if they are non-adherent to weighing-in. Participant weight gain will also be monitored, and if weight gain exceeds a specific threshold, the managing physician will be notified through the electronic medical record system. Managing providers will also be sent a weekly report of weight measurements.
223681334|NCT03932968|PROCEDURE|pH-metry during 24 hours|For patients with gastric symptoms such as retrosternal burning, regurgitations, and epigastric pain, a pH-metry will be performed
223681335|NCT00084461|DRUG|romidepsin|Given IV
223681336|NCT00084461|OTHER|laboratory biomarker analysis|Correlative studies
223681337|NCT03492775|DRUG|Obinutuzumab|Obinutuzumab (GA 101) is a first-in-class, potent, intravenously administered type II anti-CD 20 antibody that is developed by Roche AG for the treatment of B-cell malignancies.
223681338|NCT03492775|DRUG|Bendamustine|Bendamustine belongs formally to the alkylators, but has been shown to have a unique mechanism of action. The dose limiting toxicity of bendamustine is its reversible suppression of bone marrow function with drops in leukocyte and thromobocyte counts.
223681339|NCT01575886|OTHER|Teachable Moment Communication Process|The Teachable Moment Communication Process intervention is designed to teach clinicians: (1) the skills necessary to recognize and foster teachable moments in clinical encounters, (2) strategies to effectively elicit the patients' perspective on health behavior change, and express their alignment with that perspective, and (3) the ability to respond to the patient in a non-confrontational manner while providing brief advice appropriate to the patient's expressed level of readiness to change. The Teachable Moment Communication Process intervention consists of two, 3-hour educational training sessions including didactic presentation, skill demonstration through video examples, skills practices with standardized patients, and feedback from peers and the trainers.
223681340|NCT00814801|DRUG|Placebo|Form= tablet, route= oral use. Corresponding placebo tablets confirmed to be indistinguishable from the galantamine tablets will be administered for 24 weeks.
223681341|NCT00814801|DRUG|Galantamine 16 mg/day|Type= exact number, number= 8, 16, unit= mg/day, form= tablet, route= oral use. Patients will receive 8 mg galantamine daily for the first 4 weeks, and 16 mg galantamine daily for the remaining 20 weeks.
223681342|NCT00814801|DRUG|Galantamine 24 mg/day|Type= exact number, number= 8, 16, 24, unit= mg/day, form= tablet, route= oral use. Patients will receive 8 mg galantamine daily for the first 4 weeks, then 16 mg galantamine daily for the following 4 weeks, and 24 mg galantamine daily for the remaining 16 weeks.
223681343|NCT00586664|DRUG|Bepreve (bepotastine besilate ophthalmic solution) 1.5%|sterile ophthalmic solution
223774144|NCT04558736|DEVICE|CliniMACS|The mechanism of action of the CliniMACS Cell Selection System is based on magnetic-activated cell sorting (MACS). The CliniMACS device is a powerful tool for the isolation of many cell types from heterogeneous cell mixtures, (e.g. apheresis products). These can then be separated in a magnetic field using an immunomagnetic label specific for the cell type of interest, such as CD3+ human T cells.
223774145|NCT04558736|BIOLOGICAL|HPC, A Infusion|Given intravenously Day 0-HPC, A Infusion (TCR αβ+/CD19+-depleted graft)
223774146|NCT04558736|BIOLOGICAL|CD45RA-depleted DLI|CD45RA-depleted DLI will be given at least ONE week after engraftment
223774147|NCT04010942|DRUG|Vit D|Injection
223774148|NCT04010942|DRUG|Metformin|tablets
223774149|NCT04010942|DRUG|Clomiphene|Tablet
223774150|NCT04034589|DRUG|Pyrotinib combined with fulvestrant|Pyrotinib 400 mg once daily; Fulvestrant 500 mg administered on days 0, 14 (plus or minus 3 days), 28 (plus or minus 3 days), and every 28 (plus or minus 3 days) days
223681344|NCT00586664|DRUG|placebo comparator|sterile ophthalmic solution
224261441|NCT06834308|DEVICE|SHAM Transcutaneous electrical nerve stimulation (TENS)|The participants will be able to see the same parameters as the conventional TENS (100 Hz, 60 ms pulse width) on the screen, but there will be no actual stimulation. Sham TENS will be applied for 10 minutes prior to and during resistance exercise (2 sets of 10 reps at 60% 1RM leg press). TENS' intensity will be adjusted to 4Hz for all participants in the Sham arm. Electrodes will be placed on participant-identified most painful area. Resistance exercise will consist of two sets of ten repetition with 1 min rest
224323789|NCT05132582|DRUG|Tucatinib|300mg given by mouth (orally) twice daily
223681345|NCT00586664|DRUG|Bepotastine Besilate Ophthalmic Solution 1.0%|sterile ophthalmic solution
223681346|NCT03969966|OTHER|renal replacement therapy as clinically indicated|Continuous renal replacement therapy
223681347|NCT02751931|DRUG|Mirabegron|Participants received initial dose of 25 mg of mirabegron PED25 orally once daily. At weeks 2, 4 or 8, participants were up-titrated to PED50 based on the given dose titration criteria. Following week 24, participants stayed on their individual dose level until week 52 EOS or EOT. Participants with a body weight \>=35 kg received mirabegron tablets or body weight \<35 kg received mirabegron oral suspension. At week 24, participants on mirabegron oral suspension could switch to tablets if the body weight became \>=35 kg or participants on mirabegron tablets could switch to oral suspension if the body weight became \<35 Kg or participants could switch to either of the dosage form for acceptability reasons after sponsor's prior approval and on a case-by-case basis. Mirabegron extended-release granules were reconstituted with water to prepare a mirabegron oral suspension of 8 mg/mL. Administration was via an oral syringe with a sip of water afterwards.
223681348|NCT03460600|OTHER|Optical Coherence Tomography (OCT)|Optical Coherence Tomography is a fairly new imaging technique in ophthalmology
223681349|NCT04705844|DRUG|Adalimumab|adalimumab (160 mg administered as 4×40 mg subcutaneous \[SC\] injections at separate sites on the thigh or abdomen)
223681350|NCT04705844|DRUG|Placebo|placebo (4 SC injections of equal volume administered at separate sites on the thigh or abdomen)
223681351|NCT02677311|PROCEDURE|Blood draw|Blood draws will be performed immediately prior to GnRHa treatment and at 6 and 12 months following treatment completion
223681352|NCT02677311|PROCEDURE|Pelvic Ultrasound|Pelvic ultrasound will be performed immediately prior to GnRHa treatment and at 6 and 12 months following treatment completion
224261442|NCT06119477|OTHER|Bioceramic Putty Apical Plugs|Under local anesthesia and rubber dam isolation, the canal orifice will be prepared gently. The working length and apex diameter value will be recorded as a reference. Afterward, shaping and debridement the root canals will be achieved by gentle instrumentation. The canal will be irrigated copiously with NaOCl, then dried, and filled with Ca(OH)2 dressing. Afterward, the incisor will be temporarily restored. After 14 days the temporary filling and Ca(OH)2 will be removed. Afterward, canals will be irrigated with NaOCl and EDTA and dried. The Bioceramic Putty will be inserted in the apical 4 mm of the canal using the modified cannula and adapted to the canal walls with a hand plugger. The correct placement and thickness of the apical plug will be verified with a periapical radiograph. Afterward, the remainder of the root canal will be filled with gutta-percha with sealer. Finally, a suitable immediate final restoration was made for each case individually.
224323790|NCT05132582|DRUG|Trastuzumab|6mg/kg given into the vein (IV; intravenously) or 600mg injected under the skin (SC; subcutaneous) every 21 days
224323791|NCT05132582|DRUG|Pertuzumab|420mg given by IV every 21 days
224323792|NCT05132582|DRUG|Combination product: Trastuzumab + Pertuzumab|600 mg pertuzumab, 600 mg trastuzumab, and 20,000 units hyaluronidase will be given by subcutaneous injection every 21 days. May be given in place of trastuzumab and pertuzumab individually.
223681353|NCT03115281|DEVICE|PCI|PCI
223681354|NCT01037088|DRUG|Mild dose cannabis|3.53% THC by weight
223681355|NCT01037088|DRUG|Low dose cannabis|1.29% THC by weight
223681356|NCT01037088|DRUG|Cannabis|0.00% THC by weight
223681357|NCT01042782|DRUG|RAD001 and MitomycinC|"RAD001 tablets daily, 5mg, 7.5 mg or 10 mg (3 cohorts)~Mitomycin C 5 mg/m2 i.v. every 3 weeks"
223774151|NCT05949983|OTHER|APA Program|Patients treated and monitored for their breast cancer following the 6-month APA program.
223835250|NCT02501759|PROCEDURE|3 Tesla Magnetic Resonance Imaging|Undergo diagnostic multiparametric endorectal MRI with gadodiamide contrast
223835251|NCT02501759|RADIATION|Gadodiamide|Given IV
224323793|NCT05132582|DRUG|Placebo|Given orally twice daily
223681358|NCT05838989|DEVICE|Prefabricated Orthoses|Participants in this group will be provided with prefabricated wrist orthoses to wear during the day and at night to provide support and immobilization to the wrist. Participants will be instructed to wear the orthoses as directed by their healthcare provider.
223681359|NCT05838989|OTHER|general and lumbrical muscle stretching|Participants in this group will receive supervised general and lumbrical muscle stretching exercises for 10 minutes, three times per week, for 8 weeks. The stretching exercises will be performed under the supervision of a trained therapist and will include a series of exercises designed to stretch the muscles in the hands, wrists, and forearms. In addition, participants will be provided with prefabricated wrist orthoses to wear during the day and at night to provide support and immobilization to the wrist.
223681360|NCT05838989|OTHER|Placebo|Participants in this group will receive placebo treatment consisting of gentle wrist and hand movements. The movements will be performed under the supervision of a trained therapist and will consist of gentle range of motion exercises designed to mobilize the joints in the hands and wrists. Participants will not be provided with any orthoses to wear during the study.
223681361|NCT02708303|OTHER|Mayo Clinic Foregut Surgery Report Card Questionnaire|"Patients will be asked to complete the Mayo Clinic Foregut Surgery Report Card Questionnaire at approximately 8-10 weeks following surgery and then with each surveillance clinic visit or a minimum of once per year for their lifetime. The questionnaire can be completed at their clinic visit, over the telephone, or by mail. The patient's medical record will also be reviewed to gather any other contributing information.~Data collected from the questionnaire will be entered into a database that will be maintained for future research."
223681362|NCT00340574|DRUG|AMA1-C1/Alhydrogel + CpG 7909|
224261443|NCT06119477|OTHER|Single Cone Gutta-percha with Bioceramic Sealer|Under local anesthesia and rubber dam isolation, the canal orifice will be prepared gently. The working length and apex diameter value will be recorded as a reference. Afterward, shaping and debridement the root canals will be achieved by gentle instrumentation. The canal will be irrigated copiously with NaOCl, dried, filled with Ca(OH)2 dressing and temporarily restored. After 14 days the temporary filling and Ca(OH)2 will be removed. Afterward, canals will be irrigated with NaOCl and EDTA and dried. A large sized gutta-percha cone (GC) will be inserted to the working length, The GC was ensured to make tag-back with the apical third of the immature canal and confirmed with a periapical radiograph. Then the immature canal will be gently filled with Bioceramic sealer and the GC will be placed again and another apical radiograph will be taken to confirm that the canal was properly filled. Finally, a suitable immediate final restoration was made for each case individually.
224261444|NCT06119477|OTHER|Combination of Bioceramic Putty and Sealer|"Under local anesthesia and rubber dam isolation, the canal orifice will be prepared gently. The working length and apex diameter value will be recorded as a reference. Afterward, shaping and debridement the root canals will be achieved by gentle instrumentation. The canal will be irrigated copiously with NaOCl, dried, filled with Ca(OH)2 dressing and temporarily restored. After 14 days the temporary filling and Ca(OH)2 will be removed. Afterward, canals will be irrigated with NaOCl and EDTA and dried.~The immature canal will be gently filled with Bioceramic sealer and then 3 to 5 small balls of BP (diameter of 1 mm) will be inserted into the canal orifice and gently plugged with hand pluggers. Afterward, an apical radiograph will be taken to confirm that the canal was properly filled without gaps and voids. Finally, a suitable immediate final restoration was made for each case individually."
224261445|NCT06790394|DRUG|Florbetaben F18|Florbetaben F18 is a radioactive diagnostic agent being developed for the indication of PET imaging of the heart to detect amyloid pathology. All patients will receive two administrations of Florbetaben F18 at a radioactive dose of 300 megabecquerel (MBq).
224261446|NCT02068794|OTHER|Laboratory Biomarker Analysis|Correlative studies
224261447|NCT02068794|PROCEDURE|Mesenchymal Stem Cell Transplantation|Given IP
223681363|NCT01447212|DRUG|Hydromorphone, Injectable|Phase I: 3x daily, up to 500mg per day, for 6 months. Phase II: At 6 months, participants are randomized to either: 1) stay on injectable hydromorphone; 2) switch to oral hydromorphone, for another 6 months.
223681364|NCT01447212|DRUG|Diacetylmorphine, injectable|Phase I: 3x daily, up to 1,000mg per day, for 6 months. Phase II: At 6 months, participants are randomized to either: 1) stay on injectable diacetylmorphine; 2) switch to oral diacetylmorphine, for another 6 months.
223681365|NCT01447212|DRUG|Hydromorphone, liquid oral|Study Phase II: After 6 months of receiving Hydromorphone injectable , participants will be randomized to stay on injectable hydromorphone or switch to oral hydromorphone, for another six months. Oral = experimental; injectable = active comparator
223681366|NCT01447212|DRUG|Diacetylmorphine, liquid oral|Study Phase II: After 6 months of receiving Diacetylmorphine injectable, participants will be randomized to stay on injectable Diacetylmorphine or switch to oral Diacetylmorphine, for another six months. Oral = experimental; injectable = active comparator
223681367|NCT00355277|DRUG|Amitriptyline|
223681368|NCT01585584|DRUG|Boceprevir|All patients will receive a 4-week lead-in with Peginterferon and Ribavirin therapy, followed by 24 weeks of Pegetron 1.5microg/kg + weight-based ribavirin + boceprevir 800mg tid. HCV RNA (Cobas TaqMan) will be measured at baseline and at treatment weeks 4, 6,8,12,16,20,24 and 28, and post-treatment weeks 12 and 24 (to obtain SVR-12 and SVR-24 results).
223681369|NCT06273800|PROCEDURE|Blood sample|Collection of serum sample at the day of start of neo adjuvant treatment
224261448|NCT02068794|BIOLOGICAL|Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter|Given IP
224261449|NCT02068794|PROCEDURE|Echocardiography|Undergo ECHO
224261450|NCT02068794|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
224261451|NCT02068794|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
224261452|NCT02068794|PROCEDURE|Chest Radiography|Undergo chest X-ray
224261453|NCT02068794|PROCEDURE|Single Photon Tomography and Computed Tomography Scan|Undergo SPECT/CT
224261454|NCT02068794|PROCEDURE|Computed Tomography|Undergo CT
223681370|NCT02848443|DRUG|Trifluridine/tipiracil hydrochloride (S 95005)|Film-coated tablets containing 15mg of trifluridine and 7.065mg of tipiracil hydrochloride, or 20mg of trifluridine and 9.42mg of tipiracil hydrochloride, given orally at the dose of 25 or 30 or 35 mg/m2/dose, until unacceptable toxicity according to the investigator, disease progression or patient withdrawal.
223681371|NCT02848443|DRUG|Oxaliplatin|Concentrate for solution for infusion containing 5mg/ml of oxaliplatin, administered intravenously at the dose of 65 to 85 mg/m2, until unacceptable toxicity according to the investigator, disease progression or patient withdrawal.
223681372|NCT02848443|DRUG|Bevacizumab|Concentrate for solution for infusion containing 25mg/ml of bevacizumab, administered intravenously at the dose of 5 mg/kg, until unacceptable toxicity according to the investigator, disease progression or patient withdrawal.
223681373|NCT02848443|DRUG|Nivolumab|Concentrate for solution for infusion containing 10mg/ml of nivolumab, administered intravenously at the dose of 3 mg/kg, until unacceptable toxicity according to the investigator, disease progression or patient withdrawal.
223681374|NCT03874260|DRUG|Fenofibrate|statin(rosuvastatin 10mg or atorvastatin 10mg or atorvastatin 20mg) + choline fenofibrate vs statin(rosuvastatin 10mg or atorvastatin 10mg or atorvastatin 20mg) + choline fenofibrate placebo / once a day, P.O
223681375|NCT05059899|BEHAVIORAL|Exercise group|The exercise group will receive a 12-week home-based exercise programme, with a wearable activity watch to regulate physical activity behaviour. This group will also receive biweekly telephone calls from the investigator.
223681376|NCT02002585|PROCEDURE|Renal denervation|Catheter based renal sympathetic denervation is a endovascular method used for the treatment of resistent hypertension.
223681377|NCT00266864|DRUG|Testosterone Transdermal System (Androderm 5 mg patch)|Testosterone Transdermal System (Androderm 5 mg patch)
223681378|NCT01832168|PROCEDURE|Robotic Assisted Laparoscopic Prostatectomy|Robotic Assisted Laparoscopic Prostatectomy with nerve-sparing technique
223681379|NCT01832168|OTHER|Application of Absorbable Hemostat|Application of Surgicel® SNoW Absorbable Hemostat by Johnson and Johnson on the neurovascular bundle after removal of the cancerous prostate.
223681380|NCT01832168|OTHER|Application of dehydrated human amniotic membrane|Application of dehydrated human amniotic membrane (DHAM) on the neurovascular bundle after removal of the cancerous prostate.
224261455|NCT02068794|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
224261456|NCT06253182|BEHAVIORAL|Self-Guided PEPP Intervention Workbook|The workbook contains 3 modules. To complete the workbook in six weeks (one module every 2 weeks), it is recommended that a dyad schedule at least three 30-minute blocks of time each week. Dyads are asked to work through the modules in order and encouraged to set a pace that works for them.
224261457|NCT06253182|BEHAVIORAL|Self-Guided PEPP Education Workbook|The workbook contains 3 modules. To complete the workbook in six weeks (one module every 2 weeks), it is recommended that a dyad schedule at least three 30-minute blocks of time each week. Dyads are asked to work through the modules in order and encouraged to set a pace that works for them.
224261458|NCT04748796|OTHER|echocardiography|Full echocardiography will be performed at baseline and during the follow-up at H1, H3, H6 and H12.
224261459|NCT04748796|DRUG|Landiolol|Patients randomized to the experimental group will be treated according to the standard of care plus for 2 days with landiolol IV started at a dose of 1 microgram/kg/min and progressively increased every 10 minutes to a maximum of 40 micrograms/kg/min.
224261460|NCT04517604|DEVICE|Magventure MagProx100 with MagOption|The Magventure C-B60 butterfly coil will be used for single-pulse TMS to determine motor threshold. iTBS will be delivered utilizing the MagVentrure MagPro X100 with MagOption stimulator that includes active and placebo coils (C-B65 Butterfly coils) or active-only Cool-B65 Butterfly (figure 8) coil. Only the active setting will be used.
224261461|NCT06954233|DIAGNOSTIC_TEST|Uroflowmetry and questionnaires|Uroflowmetry - urine flow assessment Questionnaires: IPSS, ICIQ-MLUTS, IIEF-5, MSHQ-EjD, EQ-5D-5L
224261462|NCT04359407|OTHER|Prone positioning|Change the positioning of the COVID patients who are intubated and mechanically ventilated from supine to prone
224261463|NCT06514014|DIETARY_SUPPLEMENT|Preterm Infant Formula|Transition from donor human milk to preterm infant formula
224261464|NCT02316548|RADIATION|Intensity-Modulated Radiation Therapy|Postoperative adjuvant IMRT radiotherapy 50.4 Gy in 28 fractions. In patients not getting postoperative adjuvant chemotherapy the radiation treatment must begin within 140 days after cystectomy. For patients getting adjuvant chemotherapy radiation treatment must start within 49 days of completing chemotherapy.
224261465|NCT06455969|DRUG|Goserelin 3.6 MG|Goserelin acetate (Zoladex) is a gonadotropin-releasing hormone agonist (GnRH). GnRH agonists induce a transient increase in sex hormone concentrations, but subsequently inhibit gonadotropin secretion and the production of testosterone in men and estrogen in women. An equilibration period will occur to allow steroid concentrations to reduce.
224261466|NCT06455969|OTHER|Multi-Stressor Training|A 4-week physical training program that mimics military training.
224261467|NCT06455969|DRUG|Testosterone gel (AndroGel 5g)|Male subjects will be randomly assigned to receive a topical testosterone gel (5g dose).
224323794|NCT05561842|PROCEDURE|mHealth US-breast biopsy|During this study, women will undergo an US-guided breast biopsy by a radiologist instead of what is typically performed in Nigerian hospitals, which is either a blind biopsy or surgical excision. US-guided breast biopsy is the standard of care in the United States of America because the accuracy is better than blind biopsy and equal to surgical excision.
224323795|NCT02649387|DRUG|Ibrutinib|Given PO
223681381|NCT03734484|DIAGNOSTIC_TEST|InSight|The InSight algorithm which draws information from a patient's electronic health record (EHR) to predict the onset of severe sepsis, and in this study will be customized to differentiate between various Gram-type infections.
223681382|NCT03492008|OTHER|Conventional technique|Nasogastric tube insertion with patient's head in neutral position
223681383|NCT03492008|OTHER|Contralateral cricothyroid pressure|Cricothyroid pressure is applied externally in the contralateral direction of selected nostril before nasogastric insertion.
223681384|NCT03492008|OTHER|Ipsilateral head turning|Patient's head is turned to the ipsilateral side of the selected nostril before nasogastric tube insertion.
223681385|NCT00004393|DRUG|risperidone|
223681386|NCT05202470|OTHER|TE|After the first meeting, diabetes education videos prepared in two parts a week will be sent to the mobile phones of the individuals. The video submission will be completed in a total of four weeks.
223681387|NCT05202470|OTHER|CE|After the first meeting, diabetes education videos prepared in two parts a week will be sent to the mobile phones of the individuals. The video submission will be completed in a total of four weeks.
224261468|NCT06455969|DRUG|Testosterone gel (AndroGel 1.25g)|Male subjects will be randomly assigned to receive a topical testosterone gel (1.25g dose).
224261469|NCT06455969|DRUG|Estradiol / Levonorgestrel Transdermal System [Climara Pro]|Female subjects will be randomly assigned to receive a estrogen/ progesterone patch.
224261470|NCT06455969|DRUG|Placebo Patch|Female subjects will be randomly assigned to receive a placebo patch identical to the Climara Pro patch.
224261471|NCT06182436|DEVICE|Virtual Reality Distraction|For the experimental treatment, the child will play with the VR device for five minutes prior to the subcutaneous injection to reduce pain. The VR game Dream and the Pico Neo 4 VR headset were designed by Paperplane Therapeutics for the pediatric population. Participants will be able to direct laser beams at magical elements such as trolls and crystals. Since it is a no-success game, participants can enjoy it regardless of their past video game experience.
224261472|NCT06182436|OTHER|Standard Treatment|"Standard care consisting of injecting dupilumab subcutaneously without any distractive measure, with the child having full knowledge of the intervention.~Use of any co-interventions for pain management (music, comforting, child life specialist or other) during this sequence will be documented"
224261473|NCT06788431|DRUG|IMC-001 and Optimal medical treatment|Subjects receive IMC-001 administered by injection once a week for 13 weeks and also receive optimal medical treatment.
224261474|NCT06788431|DRUG|IMC-001 placebo and optimal medical treatment|Subjects receive IMC-001 placebo administered by injection once a week for 13 weeks and also receive optimal medical treatment.
224261475|NCT06043557|PROCEDURE|Drain Placement|Surgical placement of drain based on subject randomization.
224261476|NCT01958294|DEVICE|MICHI Neuroprotection System|
224261477|NCT05679115|BEHAVIORAL|Lifestyle tool|Regular use of the digital Lifestyle tool
224261478|NCT05893342|DIAGNOSTIC_TEST|Preoperative frailty diagnostic|The preoperative evaluation of the patient will be carried out through the application of different scales that evaluate frailty (Edmonton frailty test, Barthel Index, Mini-mental test, Charlson Index) and a postoperative follow-up will be carried out for the diagnosis of complications during the first 90 postoperative days.
223774152|NCT05949983|OTHER|Recommendations for physical activity|Patients treated and monitored for their breast cancer who have received recommendations for physical activity as well as a 6-month activity schedule. To facilitate patient acceptance and participation in this study, patients who will be randomized to the control group will be offered to follow the APA program after one year of inclusion
223774153|NCT05055674|BEHAVIORAL|Motherly app|The Motherly app is organized in four different modules: 1) Library: a collection of brief texts on several topics related to health and pregnancy, 2) Health: journeys with varying degrees of interactivity designed to teach and engage participants in well-established psychological techniques (behavioral activation, cognitive restructuring, emotion regulation, stress management techniques, mindfulness and meditation, sleep hygiene techniques), 3) Pregnancy and motherhood: a module to help mothers keep track of their health care visits, medical exams, and their childrens' development, and 4) Profile: a module allowing participants to keep track of activities and goals completed in the Health module journeys, and to assess depression and anxiety symptoms with brief questionnaires, with results displayed graphically in a timeline and in the the form of short feedback texts.
224261479|NCT05605522|DRUG|[225]-FPI-2059|"\[225Ac\]-FPI-2059 is a targeted alpha therapeutic that consists of an NTSR1-targeting small molecule that is linked to Ac-225, an alpha particle emitting radionuclide. Participants will be dosed through IV administration every 56 days up to four cycles. The dose depends on cohort assignment.~In the Dose Expansion arm, \[225Ac\]-FPI-2059 will be administered at the RP2D as determined in Phase 1 Dose Escalation."
224261480|NCT05605522|DRUG|[111In]-FPI-2058|\[111In\]-FPI-2058 is an imaging agent that consists of an NTSR1-targeting small molecule linked to In-111.Participants will receive \[111In\]-FPI-2058 by IV Injection for imaging once during screening period. The dose is consistent across cohorts.
224261481|NCT05747950|OTHER|Vibration|Vibration is used as an alternative to physical exercise in various areas to increase muscle performance and flexibility, improve balance and proprioception, reduce spasticity and increase bone density.
224323796|NCT02649387|OTHER|Laboratory Biomarker Analysis|Correlative studies
224323797|NCT01334827|OTHER|high volume gel|4 mL HEC
223681388|NCT02372214|PROCEDURE|Training|Patients will have their aneurysm impressed by a 3D printing. The senior vascular surgeon and the residents of this group will be able to practice the procedure in the model as many times as they wish before the surgery. After the training, the EVAR will be performed according to the routine of the hospital.
223681389|NCT00280670|BEHAVIORAL|Cognitive-behavioral therapy|Cognitive behavioral therapy for children with autism and anxiety.
223681390|NCT03036800|DRUG|Saxenda|standard care plus targeted use of Liraglutide (LIRA) 3mg when pre-specified stopping rules for the medication apply. Liraglutide (Saxenda) 6 mg/mL solution for injection in pre-filled pen, administered by subcutaneous injection. Dose escalation to 3.0 mg daily (or maximum tolerated dose)
223681391|NCT03036800|OTHER|Specialist Obesity Management Services|Specialist Obesity Management Services standard of care
223681392|NCT06553859|OTHER|No intervention conducts.|The type and method of breast reconstruction with sillicon implants and ADM implanting is now the standard treatment of breast cancer in korea. no any specific intervention has occurred during the surgery.
223681393|NCT02050126|DEVICE|Lumenis UltraPulse Encore.|Treatment using Lumenis UltraPulse Encore.
223681394|NCT05582954|BEHAVIORAL|EsteemUp|EsteemUp is a guided e-health application based on cognitive-behavioural therapy (CBT). It consists of four modules that take approximately 30 to 45 minutes to complete. Each module includes evidence-based psycho-education, reflection questions, interactive exercises, and homework assignments. The content is delivered both textually and visually, including the use of pictures, infographics and videos. Every week trained e-coaches (trained clinical psychology master students) will provide asynchronous written personalized feedback to each participant on the progress of the program and the exercises via the program platform.
223681395|NCT05582954|BEHAVIORAL|EsteemUp-G|The gamification elements added to this arm include (1) Badges - digital rewards upon completing important milestones within the programme EsteemUp. (2) Unlockable content - downloadable worksheets of the exercises that they have done in the module, (3) A certification of completion at the end of the program, (4) Goal setting (5) Gamification terminology - All homework assignments will be framed as a 'challenge' that needs to be completed, (6) a progress bar that will indicate how far along the participant is in the program
223681396|NCT06579391|DIETARY_SUPPLEMENT|Essential amino acids|Twice daily consumption for two weeks before and one week after surgery.
223681397|NCT06579391|DIETARY_SUPPLEMENT|Alanine|Twice daily consumption for two weeks before and one week after surgery.
223774154|NCT05055674|BEHAVIORAL|COMVC app|The COMVC displays over 30 brief psychoeducational videos on several topics related to general mental health, such as depression, anxiety, stress, sleep, problem solving techniques, among others. Psychoeducation is limited to video only (no interactivity). The content of these videos was developed by clinicians, researchers, and professors from the Psychiatry Department of the Medical School of the University of Sao Paulo and from the Federal University of Rio Grande do Sul. Mental health monitoring is delivered by means of brief questionnaires assessing depression and anxiety symptoms, which can be filled at users' discretion. Users' responses are displayed graphically in a timeline and they receive short feedback texts based on assessment results.
223774155|NCT05918679|BEHAVIORAL|Effects of speech variability on speech motor learning|This intervention will examine whether reducing normal variability of speech could improve error detection and speech motor learning. We will design training tasks to change subjects' speech variability. We will train subjects to decrease/decrease their speech variability. Upon completing the training tasks, subjects will complete a motor learning task.
223835252|NCT02501759|PROCEDURE|Multiparametric Magnetic Resonance Imaging|Undergo diagnostic multiparametric endorectal MRI with gadodiamide contrast
223835253|NCT02501759|PROCEDURE|Transrectal Biopsy|Undergo transrectal MRI-guided biopsy
224323798|NCT01334827|OTHER|low volume gel|2 mL HEC
223835254|NCT02501759|PROCEDURE|Ultrasound-Guided Prostate Biopsy|Undergo TRUS-guided biopsy
224261482|NCT05747950|OTHER|Modified Constraint-İnduced Movement Therapy|Compulsory use therapy is a form of treatment in which the movements of the healthy side are prevented and the use of the weak side is encouraged in the stroke patient.
224261483|NCT05747950|OTHER|Conventional Therapy|Conventional exercises
224323799|NCT01334827|OTHER|vaginal film|"1 x 2 intravaginal quick-dissolving film"
223774156|NCT05918679|BEHAVIORAL|Effects of error-detection training on speech motor learning|This intervention will examine whether improving subjects' ability to detect and estimate auditory perturbation could improve speech motor learning. For this purpose, we will design training tasks to change subjects' estimation of the perturbation magnitude. After completing the training tasks, subjects will complete the motor learning task.
224261484|NCT02252250|PROCEDURE|conventional laparoscopic total mesentery excision|conventional laparoscopic total mesentery excision
224261485|NCT02252250|PROCEDURE|transanal hybrid-laparoscopic total mesentery excision|transanal laparoscopic total mesentery excision for rectal cancer. Mobilize the rectum from down- to-up. Then, set a single incision laparoscopic surgery (SILS) port at the right-low abdomen to resect the lymph nodes of IMA.
224261486|NCT04982614|BIOLOGICAL|Gardasil ® 9|"GARDASIL 9 is a vaccine indicated in girls and women 9 through 45 years of age for the prevention of the following diseases: Cervical, vulvar, vaginal, and anal cancer, and Genital warts (condyloma acuminata) caused by Human Papillomavirus (HPV).~0.5-mL suspension for intramuscular injection as a single-dose vial and prefilled syringe at the following regimen/schedule: 9 through 14 years - 2-dose at 0, 6 to 12 months OR 3-dose at 0, 2, 6 months 15 through 45 years - 3-dose at 0, 2, 6 months"
224261487|NCT05546138|DIAGNOSTIC_TEST|Skin biopsies with quantification of intra-epidermal nerve fibre density|Skin biopsy
224261488|NCT05546138|DIAGNOSTIC_TEST|Perception Threshold Tracking|Transcutaneous stimulation of large and small nerve fibres using weak electrical currents
224261489|NCT05546138|DIAGNOSTIC_TEST|Thermal perception thresholds|Heat and cold perception thresholds
224261490|NCT05546138|DIAGNOSTIC_TEST|Corneal confocal Microscopy|Corneal nerve fibre density, corneal nerve fibre length, corneal nerve branch density
224261491|NCT05546138|DIAGNOSTIC_TEST|MRI|Functional and structural MRI pictures of peripheral nerves and CNS
223681398|NCT03303482|BEHAVIORAL|Enhancing Trauma Awareness (Diane Wagenhals, MEd-Lakeside Global Institute)|The trauma awareness professional development course is delivered in a small group (up to 16 participants; 2.5 hours every other week over 12 weeks). The course provides an environment for professionals to explore in depth the complex nature of trauma, while also recognizing and emphasizing the highly sensitive nature of trauma that is essential to becoming trauma-informed. The course facilitates a heightened awareness and appreciation for trauma-related behaviors and consequences that influence relationships and systems and that persist across generations.
223681399|NCT06246279|BEHAVIORAL|Adaptation to Adolescence and Type 1 Diabetes Management Training Program|The content of the Training Program was created by researchers based on Transition Theory, in line with high-level research results and international guides. Then, the necessary arrangements were made by taking the opinions of 10 experts (child health and disease nursing faculty member, child and adolescent mental health specialist, child endocrinologist, child development specialist, nutrition and dietetics specialist, sports training specialist). The content was finalized in line with the comments received.
223681400|NCT01077154|DRUG|Placebo|Administered subcutaneously for up to 5 years
223681401|NCT01077154|DRUG|Denosumab|Administered subcutaneously for up to 5 years
223681402|NCT02785237|DEVICE|Coroflex® ISAR Drug-eluting stent|Coroflex® ISAR Drug-eluting stent and an Ultimaster® Drug-eluting stent in the second lesion.
223681403|NCT02785237|DEVICE|Ultimaster® Drug-eluting stent|Ultimaster® Drug-eluting stent and a Coroflex® ISAR Drug-eluting stent in the second lesion.
223681404|NCT05337033|DRUG|MPL-001|"CBD50 plus is a medical cannabis oil with flavouring agent produced under Good Manufacturing Practice by MediPharm Labs and purchased for this study. Each ml of oil contains 2 mg/ml of delta-9-THC and 50 mg/ml of CBD.~Participants will receive escalating doses from 0.2-0.4 mg/kg/day of CBD to 0.8-1 mg/kg of CBD per day for four months, with dose increases monthly in 0.2mg/kg increments. Participants will following a weekly weaning protocol."
223681405|NCT05167110|DIETARY_SUPPLEMENT|Placebo|Children assigned to the groups (ASD/ADHD) will be randomly prescribed placebo supplementation for 12 weeks (placebo subgroup).
223681406|NCT05167110|DIETARY_SUPPLEMENT|Probiotic|Children assigned to the groups (ASD/ADHD) will be randomly prescribed supplementation with two GABA- and dopamine-producing strains at a total of 1 x 10 (9) CFU/capsule for 12 weeks (probiotic subgroup).
223681407|NCT05048069|DRUG|Mucosta®SR Tablets 150mg(Rebamipide)|adult patients with gastric mucosal lesions (erosion, bleeding, redness, and edema) of acute gastritis or acute exacerbation of chronic gastritis prescribed with Mucosta®SR Tab. according to the medical considerations of the investigator.
223681408|NCT02392832|BIOLOGICAL|Fourstar® granule, 90 day and 180 day briquettes Bti/Bs|"In 2015: Two sites each in Kakamega and Vihiga counties in western Kenya will be randomly selected and treated with larvicides (intervention) and the other two sites will serve as control (no-intervention). Temporary habitats will be treated with FourStar® controlled release granule formulation, semi-permanent habitats will be treated with 90 day briquettes, and permanent habitats with 180 day briquettes. No retreatment.~Starts from 2016, a total of 34 clusters in the two study sites will be assigned to treatment or control by a block randomization method. The Bti treatment will be the same as in 2015. The retreatment interval will be 4-5 months. After the third treatment, no treatment will be performed for the next 8 months. After this, a cross over will be performed. Previous control sites will receive 3 rounds of the same LLML treatment at appropriate time intervals and previous treatment sites will not receive any LLMLs."
223681409|NCT04067583|OTHER|Physician questionnaire|This is a one-time cross-sectional survey of physicians, conducted electronically; there are no in person visits
223681410|NCT00686998|DRUG|AZD2624|Oral Suspension
223774157|NCT05918679|BEHAVIORAL|Contributions of error awareness to speech motor learning|This intervention will examine the contributions of error awareness to speech motor learning. Subjects will produce a target word while receiving perturbed auditory feedback with different magnitudes. Subjects will be trained to indicate the magnitude of the error they perceived with or without visual feedback.
223774158|NCT05918679|BEHAVIORAL|Enhancing auditory-to-motor mapping with augmented visual feedback|This intervention will determine the contributions of enhanced auditory-to-motor mappings to speech motor learning. We will design training tasks in which we will use visual feedback to provide feedback regarding subjects' accuracy of auditory-to-motor mapping.
224261492|NCT05546138|DIAGNOSTIC_TEST|Nerve conduction studies|Nerve conduction and amplitude of Sural nerve
224261493|NCT05546138|OTHER|Composite scores and questionnaires|Composite scores and questionnaires
224261494|NCT03707171|DRUG|Liraglutide|Liraglutide is a glucagon-like peptide type 1 (GLP-1) analogue. It has been proved that Liraglutide can improve insulin resistance and cognitive function in AD animals. Therefore, it is speculated that Liraglutide may interfere with the occurrence and development of cognitive dysfunction in patients with T2DM. In order to confirm the effects, the investigators conduct an open, prospective, positive controlled study in patients with T2DM.
224261495|NCT03707171|DRUG|placebo|Any hypoglycemic drugs except glucagon-like peptide type 1 (GLP-1) analogue.
224261496|NCT02324660|OTHER|screening test|screening test with peak expiratory flow and respiratory health screening questionnaire to discriminate patients at risk for COPD
224261497|NCT02508662|OTHER|Review of Screening Tests and Molecular Test Results|Review of screening tests and molecular test results in participant's medical records. Study staff and study doctor work together to find an off-label use for an FDA approved therapy that is best for participant.
224261498|NCT01753375|DIETARY_SUPPLEMENT|Vitamin D3|Vitamin D3 given as 50000 IU orally on weekly basis
224261499|NCT01753375|DIETARY_SUPPLEMENT|Placebo|Placebo to be given orally on weekly basis
224261500|NCT01017926|DRUG|Triazolam|Tablets, 0.25 mg, single-dose, 1 period of 3 three days.
224261501|NCT01017926|DRUG|Triazolam|Tablets, 0.25 mg, single-dose, 1 period of 3 three days.
224261502|NCT02286050|OTHER|CF Nursing Program|
224261503|NCT04205266|DRUG|Ferumoxytol|IV iron infusion
224261504|NCT04205266|DRUG|Ferrous Sulfate|oral iron therapy
223681411|NCT00686998|DRUG|Olanzapine|PO BID
223681412|NCT00686998|DRUG|Placebo|
223681413|NCT00035867|DRUG|TLK199 HCl Liposomes for Injection|
223681414|NCT02555241|BEHAVIORAL|Mand Training|The mand training component of treatment will consist of behavioral principles designed to increase the participant's Mean Length of Utterances (MLU) when manding.
223681415|NCT02555241|BEHAVIORAL|Matrix|The matrix training component of treatment will consist of behavioral principles designed to teach labeling of noun-verb and color-shape combinations using matrix training.
223774159|NCT05918679|BEHAVIORAL|Effects of enhanced auditory-motor awareness on speech motor learning|In this intervention, subjects will be trained to control their articulators more accurately and be more aware of their articulators' position and their auditory consequences. After the training tasks, subjects will complete a motor learning task.
224261505|NCT01093989|DIETARY_SUPPLEMENT|Ferrous Sulphate Syrup|Iron therapy will consist of a three-month course of ferrous sulphate syrup. For children with Hb ≥ 7 g/dL, each daily dose will be based on 2 mg iron/kg body weight.
224261506|NCT02566850|DEVICE|Ekso|powered lower extremity exoskeleton
224261507|NCT02486081|DEVICE|smart soccer ball|smart soccer ball was used to measure participant's performance in total time and distance for completion, and acceleration
224261508|NCT02635750|DRUG|BI 409306|
223681416|NCT02555241|BEHAVIORAL|Stimulus Equivalence Training|The stimulus equivalence training component of treatment is designed to examine the emergence of untrained skills following the training of relational skills.
223681417|NCT02511964|BEHAVIORAL|Interval Training at 1% Incline|Six Sessions of Running at 1% incline
223681418|NCT02511964|BEHAVIORAL|Interval Training at 10% Incline|Six Sessions of Running at 10% incline
223681419|NCT01580748|DRUG|Roflumilast|500 microgram once daily for 16 weeks
223681420|NCT06292299|DEVICE|Pneumowave|Pneumowave biosensor(s) will be be used to collect data from chest +/- abdominal movement and compared to standard clinical monitoring data
224261509|NCT02635750|DRUG|Donepezil|
224261510|NCT00465621|DRUG|Xalatan|
224261511|NCT00805779|DEVICE|MagPro R30|Study treatments will be administered by a commercially available MagPro R30, with a cooled figure eight coil. The figure eight coil is placed directly over the posterior tibial nerve and the MagPro R30 will be activated. The coil will stimulate the posterior tibial nerve at 20 pulses per second for a 30 minute session.
224261512|NCT04821349|DEVICE|Capsule endoscopy|"A consecutive series of patients recruited by 12 European centers based on the indication of OGIB will undergo capsule endoscopy examination.~Capsule endoscopy will be performed in each site according to local rules and requirements, and the study protocol will concern only the post-procedure analysis on reading modalities for each patient."
224261513|NCT00089011|DRUG|fludarabine phosphate|Given IV
224261514|NCT00089011|RADIATION|total-body irradiation|Undergo radiotherapy
224261515|NCT00089011|DRUG|mycophenolate mofetil|Given IV or PO
224261516|NCT00089011|DRUG|tacrolimus|Given IV or PO
224261517|NCT00089011|PROCEDURE|peripheral blood stem cell transplantation|Undergo allogeneic peripheral blood stem cell transplant
224261518|NCT00089011|PROCEDURE|nonmyeloablative allogeneic hematopoietic stem cell transplantation|Undergo allogeneic peripheral blood stem cell transplant
224261519|NCT00089011|OTHER|laboratory biomarker analysis|Correlative studies
224261520|NCT06627062|PROCEDURE|moderate and severe subluxated lens extraction|A double-strand polypropylene suture (9-0 or 8-0) was looped and tied to one end of the preloaded CTR, which was then implanted into the capsular bag. The needle was inserted through the main incision, traversed the anterior chamber, under the posterior iris, and exited 2.0 mm behind the limbus at the central zonular weakness. The CTR was secured to the sclera using the knotless Z-suture technique to center the capsular bag, allowing safe insertion of the intraocular lens (IOL).
224261521|NCT03307577|DRUG|UHE-101 Cream|Topical cream containing investigational drug at a concentration of 1%
223681421|NCT05024214|DRUG|Lenvatinib + Envafolimab|"Lenvatinib will be administered with water orally once a day (with or without food) continuously in 28-day treatment cycle.~Envafolimab, 400 mg per dose, subcutaneous injection, dosed on D1 and then D15 of Treatment Cycle 1, and D1 of Treatment Cycle 2 and every subsequent cycles, with every 28 days as one treatment cycle."
223681422|NCT05024214|DRUG|Sunitinib|Sunitinib will be administered with water orally once daily, on a schedule of 4 weeks on treatment followed by 2 weeks off (Schedule 4/2) in 42-day treatment cycle.
223774160|NCT03952793|OTHER|extended biopsy|Additional sample are performed during a biopsy to provide tumor tissues for the organoid technique development
224261522|NCT03307577|OTHER|Vehicle Cream|Topical cream containing no drug (i.e., placebo)
224261523|NCT03647254|BEHAVIORAL|Patient education group|Group meetings with educational sessions will be organised in health center. A group educational intervention was practiced to half of the patients, by one expert patient, so that every patient must attend to one group meeting
224261524|NCT00372983|DRUG|NOV-205|
224261525|NCT05305092|DEVICE|PET/MRI, psychobehavioral tests and questionnaires, serum biomarkers and stool sample|Neuroimaging data were collected by integrated PET/MRI machine, and collected the psychobehavioral data, the serum and stool samples of participants.
224261526|NCT00830258|DRUG|Pravastatin sodium 80 mg tablets|1 x 80 mg
224261527|NCT00830258|DRUG|Pravachol® 80 mg tablets|1 x 80 mg
224261528|NCT03909607|DRUG|Ketamine 0.75 mg/kg|Patients with moderate to severe pain will receive Ketamine at a dose of 0.75mg/kg
224261529|NCT03909607|DRUG|Ketamine 1.0 mg/kg|Patients with moderate to severe pain will receive Ketamine at a dose of 1.0 mg/kg
224261530|NCT03909607|DRUG|Ketamine 1.5 mg/kg|Patients with moderate to severe pain will receive Ketamine at a dose of 1.5 mg/kg
223681423|NCT04944056|OTHER|conventional physiotherapy|"* Ultrasound therapy 3-4 minutes.~* Tibiofemoral AP and PA glides 1 set x10reps x 3 sets.~* Patellar glides 1 set x 5 reps x 3 sets.~* Quads isometrics 1 set x 10 reps.~* Hams self stretching 1 sets x 10 reps.~Home plan:~* Quads isometrics 1 set x 10 reps.~* Hams self stretching 1 sets x 10 reps.~* Active range of motion."
223681424|NCT04944056|OTHER|compression mobilization|"* Ultrasound therapy 3-4 minutes.~* Tibiofemoral AP and PA glides 1 set x10reps x 3 sets.~* Patellar glides 1 set x 5 reps x 3 sets.~* Quads isometrics 1 set x 10 reps.~* Hams self stretching 1 sets x 10 reps.~* Compression mobilization 1 set x 10 reps x 3sets.~Home plan:~* Quads isometrics 1 set x 10 reps.~* Hams self stretching 1 sets x 10 reps.~* Active range of motion."
223681425|NCT02174588|DRUG|Midazolam + propofol|Midazolam and propofol are used for sedation drug. Balanced propofol sedation (BPS) refers to the administration of an opiate, a benzodiazepine, and propofol.
223681426|NCT02174588|DRUG|propofol|propofol are used for sedation drug
223681427|NCT03037723|OTHER|CT simulation|
223681428|NCT01302132|DRUG|ASP1941|Oral solution
223681429|NCT01216371|DRUG|Sunitinib|one-year adjuvant Treatment with Sunitinib, schematic (4:2): 4 weeks (28) 50 mg(milligram) daily, 2 weeks (14) break
223681430|NCT01216371|DRUG|Placebo|one-year Treatment, schematic (4:2): 4 weeks (28) 50 mg(milligram) daily, 2 weeks (14) break,
223681431|NCT03460015|DRUG|Sevoflurane|"During the first 30 minutes after randomization, patients will be treated with propofol (same dosage as the propofol group).~Once the AnaConDa® system is installed, sevoflurane administration will begin (propofol is stopped)."
223681432|NCT03460015|DRUG|Propofol|"In the control group, sedation will be maintained with the above objective (RASS between -4 and -5, BIS between 40 and 60) until the patient is extubated.~In the sevoflurane group, propofol is administrated during the first 30 minutes after the randomization and when the AnaConDa® system is installed propofol is stopped."
223774161|NCT06852742|OTHER|Facial Cream A|The participants will use the Facial Cleanser twice daily (morning and evening). The Facial Cream A will be applied topically evenly over the entire face after cleansing and drying face in the morning and in the evening. The Sunscreen will be applied evenly over the entire face after Facial Cream A in the morning and re-applied after 80 minutes of swimming or sweating, immediately after towel drying, and at least every 2 hours during sun exposure.
223774162|NCT06852742|OTHER|Facial Cream B|The participants will use the Facial Cleanser twice daily (morning and evening).The Sunscreen will be applied evenly over the entire face after cleansing in the morning and re-applied after 80 minutes of swimming or sweating, immediately after towel drying, and at least every 2 hours during sun exposure. The Facial Cream B will be applied in the evening after washing and drying face.
223774163|NCT05620290|DRUG|Definity|Stimulation of Definity microbubbles using Sonalleve device within tumour vasculature
224261531|NCT04449315|OTHER|Young Living Lavender Essential Oil|For qualified patients one to two drops of hospital approved essential oil will be placed on a 4X4 gauze and will be offered to the patient during their infusion visit. This gauze will be placed in a sealable clear plastic bag and the patient will be instructed to use one sniff at a time.
224261532|NCT01497587|DRUG|insulin detemir|Single dose, 0.5 U/kg, administered s.c. (under the skin)
223681433|NCT05340127|DEVICE|CEREBO®|Usability Study
223681434|NCT01419444|BEHAVIORAL|Airflow Exercises for Voicing|Gargling, Cup Bubble Blowing, and Stretch and Flow Exercises will be taught to reduce laryngeal closure and improve airflow through the glottis during voicing.
223681435|NCT03754725|DRUG|Deferiprone pill|1000 mg of deferiprone (oral) BID (15 mg/Kg)
223681436|NCT03754725|DRUG|placebo|patients will receive placebo orally
223681437|NCT03754725|BEHAVIORAL|Montreal Cognitive Assessment|Neurocognitive assessment, lower score indicates lower cognitive level
223681438|NCT01464905|BIOLOGICAL|NU100|0.25 mg SQ, every other day for 12 months
223681439|NCT01464905|BIOLOGICAL|Placebo|1 mL SQ, every other day for 4 months
223681440|NCT01464905|BIOLOGICAL|rhIFN beta-1b|0.25 mg SQ, every other day for 12 months
224261533|NCT04377087|DRUG|Olaparib|Olaparib is a potent oral poly (ADP-ribose) polymerase (PARP) inhibitor that induces synthetic lethality in BRCA1/2 deficient tumor cells through the formation of double-stranded DNA breaks which cannot be accurately repaired, which leads to disruption of cellular homeostasis and cell death.
224261534|NCT00682461|DRUG|Nicotine|Marketed nicotine replacement therapy formulation
224261535|NCT00682461|DRUG|Nicotine|Nicotine prototype
224261536|NCT06183788|BEHAVIORAL|Remote cognitive rehabilitation program|Remote cognitive rehabilitation program will be performed through an online validated platform (Guttmann NeuroPersonalTrainer: https://gnpt.es/) run by the psychologists team. This is a Sanitary Product with CE certification (Sanitary Product RPS/430/2014; International Patent \[PCT/ES2008/00677\]) and here will be used within its approved indications. The rehabilitation program will increase in difficulty and decrease in frequency during the first year of follow-up (V1-V3).
224261537|NCT06450145|DRUG|interferon α-2b|Eligible APL patients with arsenic-resistant relapse will enter the run-in period, and the subjects in the run-in phase will be treated with arsenic combined with venetoclax. After the run-in period, the patients were treated with interferon α-2b, arsenic trioxide for injection and venetoclax until the outcome of CR/PR/PD/ death/withdrawal/loss to follow-up occurred. Tumor assessments were performed every 4 to 6 weeks (as determined by the investigator) during trial treatment. Those who achieved CR/PR/PD/ withdrawal were then returned to standard treatment (treatment regimen was determined by the clinician), and those who completed the combination treatment period of the trial entered the survival follow-up period.
224261538|NCT02484404|DRUG|Olaparib|Olaparib tablets will be given orally on a continuous dosing schedule. The DLT period will be one cycle, 28 days. MEDI4736 (3mg/kg or 10mg/kg IV) and Olaparib tablets (200 mg or 300 mg BID) Ph II - MEDI4736 + Olaparib at RP2D
224261539|NCT02484404|DRUG|Cediranib|Cediranib will be given orally on a continuous dosing schedule. The DLT period will be one cycle, 28 days. MEDI4736 (10mg/kg IV) and Cediranib (15 mg or 20 mg or 30 mg daily) Ph II - MEDI4736 + Cediranib at RP2D
224261540|NCT02484404|DRUG|Durvalumab|Ph I - Durvalumab will be administered once every 2 weeks for 12 months.
224261541|NCT01975116|DRUG|azurin-derived cell-penetrating peptide p28|Given IV
224261542|NCT00954460|DRUG|velaglucerase alfa|up to 60 U/kg, every other week via intravenous infusion
224261543|NCT02490072|DRUG|Dexmedetomidine|Formula for administrated were randomized by computer-generated randomization. The patients and anesthesiologist, who administered and conducted all this trial, were blinded to the medication allocation. An anesthesiologist, who responsible for preparation of medication was the only person, recognized of the randomization code during trial. 10 minutes after anesthetic induction, dexmedetomidine group would start the loading of dexmedetomidine (1μg/kg) during 10 minutes followed infusion of dexmedetomidine(0.5 μg/kg/min). Bispectral index was monitored continuously targeting 40±5. Target concentration of remifentanil and fresofol were controlled stepwise in accordance with BIS. Using the transesophageal echocardiography, we will evaluate the changes of cardiac function including Tei index and cardiac output.
224261544|NCT02490072|DRUG|normal saline(Saline 0.9%)|
224261545|NCT00665925|DRUG|Fostamatinib disodium (R935788)|100 mg tablet, orally, twice-a-day
224261546|NCT00665925|DRUG|Fostamatinib disodium (R935788)|150 mg tablet, orally, once a day
224261547|NCT00665925|DRUG|Placebo|Placebo, orally, either once a day, or twice a day
223681441|NCT03579654|BIOLOGICAL|Proscavax|Proscavax is a prostate cancer vaccine which combines the prostate antigen PSA with immune stimulatory cytokines (IL-2 and GM-CSF).
223681442|NCT04774159|DRUG|Colchicine 0.5 MG Oral Tablet|"Colchicine 0.5 mg tablet daily~Active drug and placebo are of the same appearance and are indistinguishable. All investigators, study personnel and patients will be blinded to drug treatment assignment. Trial treatment supplies must be stored in a secure, limited-access location under the storage conditions specified on the IP supply label."
223681443|NCT04774159|DRUG|Colchicine-Placebo|Colchicine-Placebo tablet
223681444|NCT00027222|PROCEDURE|retinal ablation|
223681445|NCT03666676|OTHER|Signal processing to improve intelligibility|Signal processing will be used to manipulate frequency and amplitude fluctuations in complex sounds.
223681446|NCT06432088|DEVICE|Extended Magnetic Grasper Device|The purpose of this study is to evaluate the safety and effectiveness of the Extended Magnetic Grasper Device in patients undergoing bariatric and/or hiatal hernia procedures, as a liver retractor grasping the liver and/or the tissue surrounding the crus of the diaphragm.
223681447|NCT00533793|PROCEDURE|open fracture reduction|internal fracture fixation: osteosynthesis plates or intra-medullary nails
223774164|NCT05620290|DEVICE|Sonalleve Focused Ultrasound Device|Sonalleve Focused Ultrasound Device
223774165|NCT03761251|BEHAVIORAL|Pet Fish|"Participants will be provided a fish tank with supplies to care for the fish and access to a fish (Betta splendens) from a local pet store. All participants will receive specific instructions for coupling the fish care and diabetes care:~1. feed fish one pellet in the morning after waking; check and record BG reading at that time~2. feed fish one pellet in the evening before dinner; check and record BG reading at that time~3. feed fish one pellet at night before bedtime; check and record BG reading at that time~4. every week clean the tank alternating with test the water quality in partnership with caregiver; review blood glucose readings with caregiver with each weekly fish care activity and problem solve any issues related to the blood glucose pattern.~Each child will also receive two books intended to supplement and enrich their pet fish experience."
223774166|NCT04542629|DRUG|RiTUXimab Injection [Rituxan]|375 MG/M2 /WEEK INFUSION
224261548|NCT02798458|DEVICE|Smartpill|The SmartPill Test is approved by the U.S. Food and Drug Administration (FDA) to measure transit time in the GI tract. This procedure uses the SmartPill capsule, a receiver, and computer software.
224261549|NCT02798458|PROCEDURE|Endoscopic Mucosal Resection|a Sigmoidoscopy is an exam used to evaluate the lower part of the large intestine) during which an Endoscopic Mucosal Resection (removal of a small amount of tissue from the outermost layer of gut wall) will be completed.
224261550|NCT04035187|DRUG|fast itraconazole tablet|100mg dose
224261551|NCT04035187|DRUG|medium itraconazole tablet|100mg dose
224261552|NCT04035187|DRUG|slow itraconazole tablet|100mg dose
224261553|NCT04035187|DRUG|oral itraconazole solution|100mg dose
224261554|NCT00580541|BEHAVIORAL|variety|variety and nonvariety
224261555|NCT01429870|DRUG|Steroid active treatment|Triamcinolone in unguentum leniens 0.1%
224261556|NCT06402799|BEHAVIORAL|Home-based E-biking|The e-biking intervention consists of 3 sessions per week at the beginning of the study and gradually increases over the training period to 6 sessions per week, with three of these sessions being online and group-supervised. Heart rate will be monitored as well as power in Watt at each session.
224261557|NCT05638490|OTHER||no intervention
224261558|NCT04584541|BIOLOGICAL|blood tests|Memory T and B cell response assessment Humoral response assessment (Specific anti-Sars-Cov-2 antibodies characterization)
224261559|NCT04584541|BIOLOGICAL|Nasopharyngeal swabs|SarS-Cov-2 viral load assessment
224261560|NCT04584541|BIOLOGICAL|Stools|SarS-Cov-2 viral load assessment
224261561|NCT01116739|DEVICE|Fluoride varnish|Fluoride varnish will be administered by the COHS quarterly for 2 years.
224261562|NCT01116739|BEHAVIORAL|Oral health education|Oral health education will be provided quarterly for 2 years. It will include information about how to mitigate the known risk factors for early childhood dental caries.
224261563|NCT01116739|OTHER|Dental services delivered by the Indian Health Service.|
224261564|NCT00615667|DRUG|tacrolimus (FK506)|Started: 0.05-0.1mg/kg/d,divided into two daily dose at 12hr; the blood level:5-10ng/ml in induction phase;and 4-6ng/ml in maintenance phase;
224261565|NCT03375957|DRUG|ATx201|two hundred microliters (200 μL) of test article applied to the test site areas of the upper outer arms
224261566|NCT03375957|DRUG|ATx201 Placebo Gel|two hundred microliters (200 μL) of placebo applied to the test site areas of the upper outer arms
224261567|NCT05405023|OTHER|Concentric exercises with wrist mobilization|Participants will receive concentric exercise including wrist flexion, extension, and abduction, adduction, supination and pronation plus wrist mobilizations with movements.
224261568|NCT05405023|OTHER|Concentric exercises without wrist mobilization|Participants will receive concentric exercises only.
224261569|NCT00973219|DRUG|Peg-Interferon alfa 2a + Adefovir dipivoxil, Peg-Interferon alfa 2a + Tenofovir disoproxil fumarate|Peg-Interferon alfa 2a 180ug/week + Adefovir dipivoxil 10mg/day, Peg-Interferon alfa 2a 180ug/week + Tenofovir disoproxil fumarate 245mg/day
224261570|NCT04917991|DIETARY_SUPPLEMENT|Extra Virgin Olive Oil-enriched chocolate spread|the intervention consists in the administration of 100g Extra Virgin Olive Oil-enriched chocolate spread each day for 14 days.
224261571|NCT04917991|DIETARY_SUPPLEMENT|Palm Oil-enriched chocolate spread|the intervention consists in the administration of 100g Palm Oil-enriched chocolate spread each day for 14 days.
224261572|NCT04935580|BIOLOGICAL|GC012F injection|GC012F injection is an autologous dual CAR-T targeted BCMA and CD19. A single infusion of CAR-T cells will be administered intravenously.
224261573|NCT05511935|OTHER|professional development training for CHWs on dental health (GRIN)|multi module online training
224261574|NCT06405243|DRUG|Myoinositol|Myoinositol decreases insulin resistance and consequently increased intracellular glucose uptake, restore the metabolic profile and induce ovulation in PCOS patients with infertility, in addition to its good safety profile
224261575|NCT06405243|DRUG|Chromium|chromium picolinate may potentiates the therapeutic effect of letrozol on pituitary hormones (FSH and LH), improvement of ovulation, normalization of Estrogen level, improvement of endometrial thickness related to ovulation
224261576|NCT06405243|DRUG|l-arginine|new antioxidant that minimizes the inflammatory reaction, the hormonal imbalance, and the metabolic disturbances in PCO
224261577|NCT06405243|DRUG|Letrozole 2.5mg|selective aromatase inhibitor
224261578|NCT03966027|OTHER|Postoperative protocol (Immediate weight bearing)|After ORIF of the ankle fracture, the patient will be randomized to follow an immediate weight bearing rehabilitation protocol using an offloading hindfoot brace
223681448|NCT06897163|DEVICE|Specialized Absorbent Intestinal Tampon|The specialized absorbent intestinal tampon is designed to be self-inserted by participants with ileostomies. It aims to collect ileostomy output and improve the quality of life by reducing complications associated with traditional stoma bags. The study will test different tampon designs and coatings to find the most suitable one for insertion and retention. Participants will be observed and interviewed during the insertion process, and their feedback on discomfort or pain will be collected using a numerical rating scale (NRS). Stool samples will be collected before and after tampon use for microbiota analysis.
223681449|NCT06899074|DIETARY_SUPPLEMENT|Omega 3 Polyunsaturated Fats|Omega-3 PUFA dietary supplement daily for 12 weeks. The intervention is 1 teaspoon of liquid omega-3 containing oil profile 40% EPA / 60% DHA.
223681450|NCT06899074|OTHER|Matching Placebo|The placebo is a matched 1 teaspoon liquid of coconut oil, consisting mainly of saturated fatty acids and lacking omega-3 fatty acids.
223681451|NCT01067547|DRUG|Iron Sucrose.|The total dose of iron sucrose given will be individualised by calculating their iron deficit.
224261579|NCT03966027|OTHER|Postoperative Protocol (Delayed Weight Bearing)|After ORIF of the ankle fracture, the patient will be randomized to follow a standard delayed weight-bearing rehabilitation protocol
224261580|NCT01361633|DRUG|d-cycloserine|single oral administration of 250 mg d-cycloserine
223681452|NCT01067547|DRUG|Iron sucrose|300mg of iron sucrose is given intravenously. Three infusions, each one week apart is given to patients with iron deficiency without anemia. For those patient with anemia, four infusions would be given.
223681453|NCT01135823|PROCEDURE|Patient survey|
223681454|NCT03939156|OTHER|Completion of questionnaires|Completion of questionnaires at the time of study entry
223774167|NCT01563250|DEVICE|Point of Care testing|"The investigators will implement 6 months of randomized testing periods, 2 weeks each. During this 2 week block, cardiac biomarkers will be tested at the bedside in the ED using the Triage Cardiac Panel that will test for CK-MB, Myoglobin, and Troponin I.~Each blood sample that is take for point of care testing will be saved. The plasma from the saved sample will be frozen and the sample will be sent to an off-site testing center for high sensitivity troponin testing.~All patients will be followed at the 30-day mark and those patients who are discharged home from the ED will be followed within 48 hours as well."
224261581|NCT01361633|DRUG|Sugar Pill|Single oral administration 250 mg Sugar Pill
224261582|NCT05090839|BEHAVIORAL|Weekly Emotional Disclosure (WED)|Online writing sessions, each lasting approximately 45 minutes, once a week, conducted virtually. Participants will be instructed to write about either a major traumatic life experience or what the participant did the previous day.
224261583|NCT05090839|BEHAVIORAL|Weekly Emotional Disclosure (WED) Spanish|Online writing sessions, each lasting approximately 45 minutes, once a week, conducted virtually. Participants will be instructed to write about either a major traumatic life experience or what the participant did the previous day in Spanish.
224261584|NCT05281354|OTHER|Multimodal intervention|Treatment to normalise resting energy expenditure according to the observed abnormalities such as anti-inflammatory treatment with Omega 3 in the case of systemic inflammation, treatment with a non-specific beta-blocker such as propanolol in the case of activation of the beta-adrenergic system, appropriate physical activity in the case of sarcopenia, or nutritional support aimed at re-establishing the balance of calorie and protein intake and expenditure, or a combination of these actions
224261585|NCT02203539|OTHER|exposure to normal light|exposure for 60 minutes in duration
224261586|NCT02203539|OTHER|exposure to bright light|exposure to bright light for 60 minutes of duration
224261587|NCT02203539|OTHER|exposure to blue-enriched light|exposure to blue-enriched light for 60 minutes of duration
224261588|NCT02677558|OTHER|Transthoracic Echocardiography|Obese term pregnant women and term pregnant women of normal weight are both undergoing transthoracic echocardiography assessment to establish differences in cardiac function in pregnancy caused by obesity.
224323800|NCT06540079|DEVICE|Solia CSP S lead|The Solia CSP S pacing lead will be implanted in the LBBA for patients who meet all inclusion/exclusion criteria and give written informed consent.
224323801|NCT05862285|DRUG|Ipatasertib|Ipatasertib will be administered as a monotherapy at the same dose, schedule, and with the same administration guidelines that were in effect at the time of participants discontinuation from the parent study.
224261589|NCT02108639|DRUG|DCV 3DAA FDC|
224261590|NCT02108639|DRUG|BMS-791325|
224261591|NCT06006754|OTHER|Observational study|No intervention: observational study
224261592|NCT05874596|BEHAVIORAL|AI-aided clinical feedback system coupled with multi-aspect intervention basd on Behaviour Change Wheel model|Interventions are developed on a psychological model, the Behaviour Change Wheel (BCW) .The fundamental of BCW consists of three essential elements: capability, motivation, and opportunity. Improving individual's capability, providing motivation, and increasing opportunities are goals of behaviour change intervention. To achieve the goals, 9 intervention components have been proposed in the BCW framework, and 6 components will be used in current study.
224261593|NCT04693611|BEHAVIORAL|Individual cognitive stimulation therapy (iCST)|The intervention group will receive 24 individual CS sessions per participant. Each session will last approximately 45 minutes and will have the following structure: session introduction (5 minutes); reality orientation (10 minutes); stimulation of cognitive domain (25 minutes); session closure (5 minutes). The sessions will be led by a previously trained therapist. The intervention program will include several activities based on the principles of CS and adjusted for participants without any neurocognitive disorder.
224261594|NCT04693611|PROCEDURE|Functional near-infrared spectroscopy (fNIRS)|The acquisition by fNIRS will be performed in each CS session in four regions of interest (ROIs) in the prefrontal cortex: left dorsolateral prefrontal cortex (LDLPFC); left medial prefrontal cortex (LMPFC); right medial prefrontal cortex (RMPFC); right dorsolateral prefrontal cortex (RDLPFC).
223681455|NCT03152032|BEHAVIORAL|In-House Vocational Training Programs|At the beginning of the IHVT programs, the job placement for each participant was determined jointly by the participant's interest, the demands of local job markets and the team evaluation. The programs covered 6 to 10 months in length, 5 days a week and 4 to 6 hours a day. The programs contained three sessions: (a) the work-related behavior training session, such as proper appearance, communication and self assertion, and workplace social skills, (b) the on-the-job skill training session where participants gained job-specific training and interventions from job coaches and occupational therapists, and (c) the life balance counseling session including individual and group counseling that aimed to enhance the participants' ability to tackle potential hardships and barriers to work.
223681456|NCT04354961|DRUG|Almonertinib|Almonertinib 110mg PO once daily. A cycle of treatment is defined as 21 days of once daily treatment. Number of Cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.
223681457|NCT02622334|DRUG|Latanoprost|Latanoprost is a ophthalmic solution, available in dose strength as 0.005%.
223681458|NCT02622334|DRUG|Placebo|Matching placebo formulation will be administered in Part A.
223681459|NCT02622334|DRUG|RO5093151|RO5093151 is a ophthalmic solution, available in dose strengths as 0.1%, 0.5% and 1%.
223681460|NCT00572143|OTHER|ca coli follow-up by GP|patients randomized to follow up by GP
223681461|NCT04475809|PROCEDURE|group C|laparoscopy will be performed with 14-16 mmHg intra-abdominal pressure. At the end of the procedure routine method for CO2 removal, passive exsufflation, will be used by applying gentle abdominal pressure to evacuate the residual gas through the port site.
223681462|NCT04475809|PROCEDURE|Group L|laparoscopy will be performed with 8-10 mmHg intra-abdominal pressure and routine passive exsufflation will be applied for CO2 removal at the end of the procedure.
223681463|NCT04475809|PROCEDURE|Group LR|the intra-abdominal pressure will be kept at 8-10 mmHg during laparoscopy. At the end of the procedure pulmonary recruitment maneuver (PRM) will be done; which consists of five manual pulmonary inflations at a maximum pressure of 40 cm H2O and the fifth will be held for 5 seconds. During this procedure, the surgeon is instructed to keep the port sleeve valve fully opened to allow the CO2 to escape the abdominal cavity.
223681464|NCT04475809|PROCEDURE|Group LS|the intra-abdominal pressure will be kept at 8-10 mmHg during laparoscopy. At the end of the procedure, intraperitoneal normal saline (IPS) will be infused for removal of the intra-abdominal CO2; in which we fill the upper part of the abdominal cavity evenly and bilaterally with isotonic normal saline (15-20 mL/kg body weight)
223681465|NCT05954104|DRUG|Calcipotriol|To evaluate the efficacy of Calcipotriol on Alopecia Areata.
223774168|NCT01790412|BEHAVIORAL|Exercise group|Combined two land aerobic sessions and one aquatic activities session
223774169|NCT06567652|DEVICE|catheter ablation|All patients underwent pulmonary vein isolation (and eventually left atrial posterior wall isolation) with the POLARx™ cryoballoon system
223774170|NCT04181918|BEHAVIORAL|AOT|During action observation, participants observe different daily actions (e.g. reading a newspaper; drinking an espresso) divided into up to four motor segments.
223774171|NCT04181918|BEHAVIORAL|MI|During motor imagery, participants imagine themselves performing the same daily actions as in AOT in the absence of motor output
223774172|NCT05699668|DEVICE|OCT Angiography|"2 views per eye (one centered on the fovea, one centered on the optic nerve), in 6x6 mm, using the OCT-A Plexelite®.~Acquisition time per image: about 10 seconds."
223774173|NCT06211647|DRUG|[177Lu]Lu-XT117|\[177Lu\]Lu-XT117 is a radiopharmaceutical therapy in which an beta emitter, Lu-177, is conjugated to XT117. Patients will receive \[177Lu\]Lu-XT117 administration at fixed dose levels at an interval of 6 weeks between each dose.
224261595|NCT06468514|OTHER|neural tensioning technique on radial nerve|the neural group tensioning technique: The test should be performed in approximately 10° of shoulder abduction. The examiner extends the elbow 2 seconds just to the range where the patient notices tension but no pain and then the elbow is flexed. Three sets of 6-8 swings are performed with 1 minute rest in between.
224261596|NCT06468514|OTHER|Sliding technique on radial nerve|The mobilization maneuver begins by identifying the first resistance and the range of extension associated with pain. Maintaining elbow extension within the elastic region of resistance free of pain and/or paresthesia the examiner increases elbow extension and simultaneously allows the wrist to extend as necessary for the radial nerve branches in the forearm to glide proximally. The physical therapist then flexes the wrist while allowing the elbow to flex to cause the radial nerve excursion distally in the forearm.
224261597|NCT00079495|DRUG|NBI-5788|
224261598|NCT04505826|DRUG|OP-1250|Complete Estrogen Receptor ANtagonist (CERAN)
224261599|NCT06127238|DRUG|ST-1898 tablets|Supplied as 5 mg and 40 mg tablets
224261600|NCT06383988|OTHER|Support for Caregiver - Generic List|Receive a generic resource list
224261601|NCT06383988|OTHER|Support for Caregiver - Personalized List|Receive personalized resource list
223774174|NCT03280355|BEHAVIORAL|Singing training|"Each session will contain technical instruction in order to achieve better respiratory control and primary muscular strength, and with focus on techniques for efficient expiration. Sessions will also focus on musical content and interpretation as well as interaction, the social aspects and joy of singing together.~Prior to the trial all singing teachers will participate in a 2 days' workshop, where they will be instructed in sufficient methodology and didactics, and will obtain profound knowledge about the disease pathology and related physiology."
223774175|NCT03280355|BEHAVIORAL|Physical Training|"Physical Training (golden standard training activity in pulmonary rehabilitation) - usual care - is the active comparator in the trial.~The programme is based on the national guidelines for pulmonary rehabilitation, and consists of supervised warm-ups, aerobic exercises, workout (strength), and breathing exercises.~Physical Training is conducted by the local physiotherapists in the local health centres."
223774176|NCT01511887|DRUG|Oral Ibuprofen|10mg/kg oral ibuprofen followed by two 5mg/kg in 12 hours intervals. If there was no improvement after first cycle of treatment this treatment was repeated.
224261602|NCT06383988|OTHER|Internet-Based Intervention - CONNECT|Receive access to CONNECT tool
224261603|NCT06383988|BEHAVIORAL|Patient Navigation|Complete calls with caregiver navigator
224261604|NCT04837105|OTHER|Serious game ARROW CP|"ARROW CP is developed for Microsoft Hololens headset. Feedback on gait performance are delivering to the participant in real time and with delay. Participants have to walk at their maximal speed during sprint session."
224261605|NCT04837105|OTHER|Treadmill|Participant walk on a treadmill at 80% of their maximal speed during maximum 20 minutes (+5 min warm-up / 5 min cool-down)
224261606|NCT05676294|DRUG|Olanzapine|5 mg of oral olanzapine one hour prior to ambulatory surgery
224261607|NCT05676294|DRUG|Placebo|oral matched placebo one hour prior to ambulatory surgery
224261608|NCT00334815|BIOLOGICAL|Bevacizumab|Given IV
224261609|NCT00334815|DRUG|Cisplatin|Given IV
224261610|NCT00334815|DRUG|Docetaxel|Given IV
224261611|NCT00334815|DRUG|Etoposide|Given IV
224261612|NCT00334815|BIOLOGICAL|Filgrastim|Given SC
223681466|NCT06164210|BEHAVIORAL|Snoezelen-Based Occupational Therapy Intervention Group|Snoezelen- Based Occupational Therapy Intervention Different from sensory integration interventions, Snoezelen-based interventions are environments with all sensory stimuli, such as auditory, visual, tactile, gustatory, olfactory, and vestibular stimuli, in the same environment and where therapeutic guidance and commands are not given to the individual. These interventions aim to reduce agitation, depression, and aggression in individuals and increase daily living activities, functional performance, and well-being. Psychiatric clinics, schools, rehabilitation centers, and occupational therapy clinics are some places where it is used. Some materials found in Snoezelen rooms are bubble tubes, fiber optic light cables, projectors, vibrating massagers, light tactile stimulation materials, aromatic scent emitting devices, music sets, and relaxing music and swings.
223681467|NCT03484260|DRUG|Testosterone Product|Men used testosterone product following prescription
223774177|NCT02705131|DEVICE|Balance Chiropractic Therapy|patients are in the sitting position and receive the following treatments.1)Balancing tendon-regulation;2) Balancing osteopathy;3) Balance collaterals-dredging.
224261613|NCT00334815|BIOLOGICAL|Pegfilgrastim|Given SC
224323802|NCT05862285|DRUG|Tiragolumab|Tiragolumab in combination with atezolizumab will be administered at the same dose, schedule, and with the same administration guidelines that were in effect at the time of participants discontinuation from the parent study.
223835255|NCT06285617|DRUG|1-week predisone+1-week celecoxib|20 and 10 mg prednisone in the morning and afternoon, respectively, daily for 1 week; in the second week, these participants received 400 mg celecoxib (a type of nonsteroidal anti-inflammatory drug) on day 1 and 200 mg twice daily for the remaining 6 days until celecoxib withdrawal.
224261614|NCT00334815|RADIATION|Radiation Therapy|Undergo thoracic radiotherapy
224261615|NCT05231460|DRUG|Active Comparator: narcotic regimen with TAP block|"Patient will receive Tap Block to 15ml of 0.5% Ropivacaine and will be administered the following Narcotic Pain Regimen post-operatively:~* PO Oxycodone 5mg, 10mg q4h for moderate and severe pain~* IV Dilaudid 1mg q3h for breakthrough pain"
224261616|NCT05231460|DRUG|Active Comparator: narcotic regimen with no TAP block|"Patient will not receive TAP block and will be administered the following Narcotic Pain Regimen post-operatively:~* PO Oxycodone 5mg, 10mg q4h for moderate and severe pain~* IV Dilaudid 1mg q3h for breakthrough pain"
224261617|NCT05231460|DRUG|non-narcotic regimen with TAP block|"Patient will receive Tap Block to 15ml of 0.5% Ropivacaine and will be administered the following Non-narcotic Pain Regimen post-operatively:~* Toradol 15mg q6h~* Tylenol 1000mg q8h~* Gabapentin 100mg three times a day"
224261618|NCT05231460|DRUG|non-narcotic regimen with no TAP block|"Patient will not receive TAP block and will be administered the following Non-narcotic Pain Regimen post-operatively:~* Toradol 15mg q6h~* Tylenol 1000mg q8h~* Gabapentin 100mg three times a day"
224261619|NCT05695261|BIOLOGICAL|Microbial Transplantation Therapy|"Participants randomized to the MTT/antibiotic arm of PART A will be administered oral MTT capsules over the course of 28 days.~Participant enrolled on PART B will be administered oral MTT capsules over the course of 28 days."
224261620|NCT05695261|DRUG|Antibiotic|"Participants randomized to the MTT/antibiotic arm of PART A will receive oral antibiotics for 7 days prior to the MTT administration visit.~Participant enrolled on PART B will receive oral antibiotics for 7 days prior to the MTT administration visit."
224261621|NCT05695261|OTHER|Placebo (in place of MTT)|Participants randomized to the placebo arm of PART A will be administered oral placebo capsules in place of MTT over the course of 28 days.
224261622|NCT05695261|OTHER|Placebo (in place of antibiotics)|Participants randomized to the placebo arm of PART A will receive oral placebo in place of antibiotics for 7 days prior to the MTT administration visit.
224261623|NCT05695261|OTHER|Oral Immunotherapy (OIT)|Participant enrolled on PART B will be on maintenance peanut oral immunotherapy (OIT) for their clinical care.
224261624|NCT04966169|DEVICE|GentleWave System|The GentleWave hydrodynamic cavitation system is a 510k FDA-approved multisonic energy system that is used in complex root canal procedures.
224323803|NCT05862285|DRUG|Atezolizumab|Atezolizumab will be administered as a monotherapy and in combination at the same dose, schedule, and with the same administration guidelines that were in effect at the time of participants' discontinuation from the parent study.
223774178|NCT02705131|DEVICE|Traction Therapy|patients will received the traction therapy.The patient is sitting and wearing a cloth bag occipital jaw traction comfortable,with head bending forward about 10-15 degrees in comfort.The weight for traction of cervical spondylosis is started at 3 kg, and gradually increased to the maximum weight not more than 6kg according to the standard of 0.5kg each time. The treatment is performed 30 minutes a time per day, 10 times as a course,a total of 2 courses.
223774179|NCT02322697|DRUG|Intravenous administration of L-carnitine|Chronic intravenous administration of L-carnitine (1000mg on each dialysis session) for 1 year in hemodialysis patients
223774180|NCT02158039|DRUG|Ethanol|EUS-guided lavage of a pancreatic cystic neoplasm with ethanol solution. Ethanol was diluted to 80% using normal saline.
223774181|NCT02158039|DRUG|Lidocaine|The final solution contained 1% lidocaine except in subjects allergic to local anesthetics.
223774182|NCT01196871|DRUG|Migalastat HCl|Oral capsules, single dose
223774183|NCT01196871|BIOLOGICAL|Agalsidase Beta|IV infusion, single dose
223774184|NCT01196871|BIOLOGICAL|Agalsidase Alfa|IV infusion, single dose
223774185|NCT04057495|OTHER|further fasting|2 hours of fasting
223774186|NCT04057495|OTHER|white bread consumption|113 grams of white bread consumption
224261625|NCT01818024|DRUG|Single IV dose of GSK2862277|GSK2862277 solution available in a 40 mg vial for IV administration.
224261626|NCT01818024|DRUG|Matching placebo single dose IV infusion|Matching placebo solution available for IV administration.
224261627|NCT01818024|DRUG|Single IH dose of GSK2862277|GSK2862277 nebulised solution available in a 40 mg vial for IH administration.
224261628|NCT01818024|DRUG|Matching placebo single dose IH|Matching placebo nebulised solution available for IH administration.
224261629|NCT01818024|DRUG|Repeat IV dose of GSK2862277|GSK2862277 solution available in a 40 mg vial for IV administration.
224261630|NCT01818024|DRUG|Matching placebo repeat dose IV infusion|Matching placebo solution available for IV administration.
224261631|NCT01818024|DRUG|Repeat IH dose selected of GSK2862277 from Part 2|GSK2862277 nebulised solution available in a 40 mg vial for IH administration.
224261632|NCT01818024|DRUG|Matching placebo repeat dose IH|Matching placebo nebulised solution available for IH administration.
224261633|NCT03756441|BEHAVIORAL|Mindfulness meditation|This intervention is a meditative practice which the individuals will practive in their daily life following the MBHP protocol
224261634|NCT03756441|BEHAVIORAL|Psychotherapy group|Caregivers will learn the technique of group problem solving
224261635|NCT00023881|DRUG|bortezomib|
224323804|NCT05862285|DRUG|Tiragolumab and Atezolizumab|Tiragolumab and Atezolizumab in fixed dose combination administered intravenously (IV) at the same dose, schedule, and with the same administration guidelines that were in effect at the time of participants discontinuation from the parent study.
224323805|NCT05862285|DRUG|Bevacizumab|Bevacizumab will be administered as a monotherapy or in combination with atezolizumab at the same dose, schedule, and with the same administration guidelines that were in effect at the time of participants discontinuation from the parent study.
223774187|NCT04057495|OTHER|mango consumption|330 grams of mango consumption
223774188|NCT01744730|DRUG|Clindamycin|Schedule includes 30-40 mg/kg/day dosed every 6 or every 8 hours with a maximum daily dose of 2.7 grams/day. Dosing greater than 2.7g/day will be allowed for children receiving clindamycin as part of clinical care.
223774189|NCT04798300|PROCEDURE|Newly Introduced Gradient Monolithic Zirconia|Fabrication of full-coverage crowns over posterior teeth using Newly Introduced Gradient Monolithic Zirconia to measure wear
223774190|NCT04798300|PROCEDURE|Full Strength Monolithic Zirconia|Fabrication of full-coverage crowns over posterior teeth using Full Strength Monolithic Zirconia to measure wear
223774191|NCT00844441|OTHER|medical chart review|
223774192|NCT00844441|OTHER|questionnaire administration|
223774193|NCT00844441|PROCEDURE|quality-of-life assessment|
223774194|NCT05768503|DRUG|Experimental drug|The treatment option for the chidamide + sintilimab + bevacizumab is 200 mg of sintilimab IV Drip Q3W, 30 mg of chidamide PO BIW, and bevacizumab 7.5 mg/kg IV Drip Q3W until loss of clinical benefit or development of intolerable toxicity (whichever occurs first), with a maximum treatment duration of 2 years.
223774195|NCT05768503|DRUG|Control Rx|The treatment option for the standard second-line FOLFIRI + bevacizumab therapy group is bevacizumab 5 mg/kg IV Drip Q2W, irinotecan 180 mg/m2 IV Drip Q2W, calcium folinate 400 mg/m2 IV Q2W or calcium levofolinate 200 mg/m2 IV Drip Q2W, 5-fluorouracil 400 mg/m2 IV +2400 mg/m2 CIV (infusion 46-48 hr) Q2W until loss of clinical benefit or development of intolerable toxicity (whichever occurs first), with a maximum treatment duration of 2 years.
223774196|NCT02669186|DRUG|Bupivacaine + Fentanyl|General endotracheal anesthesia augmented with an epidural. The epidural solution intraoperatively and post-operatively will contain fentanyl + bupivacaine titrated to appropriate surgical conditions and post-operative pain control.
224261636|NCT03723044|OTHER|EEG and occulometry|Each participants will spend two sessions of EEG and occulometry during a visual cognitive task where she/her will be presented with multi-stable visual stimuli to gaze at for one or two minutes. Depending on the experimental conditions, the participant will provide or not her/his perceptual state (i.e. which stimulus has been perceived ).
224261637|NCT03243786|BEHAVIORAL|Lifestyle- Supportive Care|The intervention examines dietary and activity patterns, body composition, biomarkers and quality of life in breast cancer patients undergoing radiation therapy
224261638|NCT01510938|DIETARY_SUPPLEMENT|L. acidophilus DDS-1, B. lactis UABLA-12|1 g of probiotic will be reconstituted in 25-50 ml tepid water, juice or age specific baby food and immediately fed once a day (5 billion CFU/daily) for 2-weeks trial period or to the end of acute respiratory infection depending on whatever is longer.
224261639|NCT01510938|DIETARY_SUPPLEMENT|Placebo|1 g in 25-50 ml of tepid water or juice fed once a day for 2-weeks trial period or to the end of acute respiratory infection depending on whatever is longer.
224261640|NCT02921958|BEHAVIORAL|occupational therapy|Family-centered occupational therapy services
224261641|NCT06635135|DRUG|Aticaprant|Aticaprant will be administered orally.
224261642|NCT06635135|OTHER|Placebo|Placebo will be administered orally.
224261643|NCT04797663|DEVICE|Nd-YAG laser|laser hair removal device
224261644|NCT04797663|DRUG|TCA 20%|chemical peel
224261645|NCT06196047|DRUG|Ticagrelor 90 MG|Efficacy and safety of 180 mg loading dose of ticagrelor administered within 24 hours of first-ever ischemic stroke followed by 90 mg bid for 3 months will be assessed through NIHSS, mRS, new ischemic stroke, and possible adverse effects.
224261646|NCT06196047|DRUG|Cilostazol 100 MG|Efficacy and safety of 200 mg loading dose of cilostazol administered within 24 hours of first-ever ischemic stroke followed by 100 mg bid for 3 months will be assessed through NIHSS, mRS, new ischemic stroke, and possible adverse effects.
224261647|NCT02624297|OTHER|Aerobic exercise training|The patients will be submitted to four months of aerobic exercise training, three time a week.
224261648|NCT04084639|DIETARY_SUPPLEMENT|Mycoprotein Ingestion|Ingestion of various doses of mycoprotein compared to placebo control
224261649|NCT03913377|DEVICE|Spectacles|Subjects' own habitual spectacles
224261650|NCT03913377|DEVICE|ACUVUE OASYS®1-Day with HydraLuxe™ Technology|Test 1
224261651|NCT02570958|DRUG|Indocyanine Green|In the operating room ENB will be used to locate the targeted lung tumor. Once the tumor is located, the surgeon will advance a bronchoscope to the tumor, a needle will be passed through the bronchoscope, and the tumor will be injected with 100-150 micro liters of ICG solution at 0.125mg/mL concentration. The tumor is expected to fluoresce using the da Vinci Firefly robotic camera, giving off a bright green hue. Wedge resection of the fluorescent part of the lung will then be performed. The excised specimen will be sent for immediate pathologist analysis. If the tumor is found within the specimen, and the specimen margins are free of tumor cells, then the procedure will be completed. If the tumor cannot be targeted or visualized, or if the tumor is not found in the pathological specimen, or if the margins of the specimen contain tumor cells, then a formal anatomical lobectomy or segmental resection of the lung will be performed to ensure that the tumor is completely excised.
224261652|NCT05106803|DRUG|ciprofloxacin|Antibiotics used in vitro n the study
224261653|NCT02730533|DRUG|Esomeprazole|Proton pump inhibitor
224261654|NCT02730533|DRUG|No PPI treatment|No PPI treatment before ESD procedure
224261655|NCT01260805|DRUG|Reference Drug|Femiane® Ethinylestradiol 0,02mg + Gestodene 0,075mg sugar coated tablets single dose
224261656|NCT01260805|DRUG|Test Drug|Harmonet® Ethinylestradiol 0,02mg + Gestodene 0,075mg sugar coated tablets single dose
224261657|NCT03499353|DRUG|TALAZOPARIB|Talazoparib 1mg/day
224261658|NCT02670161|DRUG|Listed for each disorder below, up to three drugs per disorder (too many characters to list in this field; see Intervention Description)|brain tumors (lamotrigine, levetiracetam, valproic acid), epilepsy (lamotrigine, levetiracetam, valproic acid), mild cognitive impairment (donepezil, rivastigmine, memantine), migraine (amitriptyline, propranolol, topiramate), migraine (sumatriptan, rizatriptan, zolmitriptan), mild traumatic brain injury (omega-3 fatty acids, education only), multiple sclerosis (ACTH, methylprednisolone), neuropathy (duloxetine, pregabalin, amitryptiline), Parkinson's disease (pramipexole, ropinerole, rotigotine), restless legs syndrome (pramipexole, ropinerole, rotigotine), stroke (aspirin, clopidogrel).
224261659|NCT02179294|DRUG|Pethidine|100mg by intramuscular injection, up to 4 hourly in frequency (up to a maximum of 4 doses). The maximum dose being 400mg in 24 hours.
224261660|NCT02179294|DRUG|Remifentanil|"Dedicated intravenous cannula for remifentanil administration PCA protocol~* PCA bolus remifentanil 40 μg~* Lockout interval 2 minutes~In the event of excess sedation being recorded by regular observation of respiratory function, the regimen will be altered by reduction of the remifentanil bolus dose to 30 μg with a lock-out interval of 2 minutes."
224261661|NCT03448094|DIETARY_SUPPLEMENT|Resveratrol|Participants will consume one of the treatment types daily for a period of three months.
224261662|NCT03448094|DIETARY_SUPPLEMENT|Placebo|Participants will consume one of the treatment types daily for a period of three months.
224261663|NCT05701384|DRUG|Lazertinib|160mg po qd
224323806|NCT05862285|DRUG|Entrectinib|Entrectinib will be administered as a monotherapy at the same dose, schedule, and with the same administration guidelines that were in effect at the time of participants discontinuation from the parent study.
223681468|NCT04325984|DRUG|Dexamethasone|To the Dexamethasone group, at the moment of the induction of anaesthesia, dexamethasone 8 mg is administered.
223681469|NCT06381271|PROCEDURE|Transcatheter aortic valve replacement|A total of 500 consecutive patients with NAVR undergoing TAVR will be enrolled at 3-5 centers. Clinical follow-up will be conducted in the periprocedural and after aortic valve implantation at 1 month, 1 year, 2 years, 3 years, 4 years, 5 years, and 10 years
223681470|NCT00507468|PROCEDURE|Transendocaridal Transplantation of Autologous Bone Marrow|Single treatment, harvest and transplant of patients own bone marrow. Cells are delivered to the myocardium via transendocardial delivery catheter.
223681471|NCT04776044|DRUG|ATR-002|150mg tablets for oral intake
223681472|NCT04776044|DRUG|Placebo|matching tablets for oral intake
223681473|NCT00849888|BIOLOGICAL|Serum Free Thymus Transplantation with Immunosuppression|Cyclosporine pre-transplant (trough 180-220ng/ml) until naive T cells develop. Subjects \>4,000/cumm T cells, pre-transplant methylprednisolone or prednisolone 1-2mg/kg/day. All subjects pre-transplant days -5,-4,-3: 3 doses 2mg/kg rabbit anti-thymocyte globulin. Thymus tissue (unrelated donor), donor, \& donor's mother screened for safety. Transplant under general anesthesia into quadriceps. First 2 subjects, FBS cultured thymus is transplanted in 1 leg \& serum free (SF) in other. After first 2 subjects \>10% naïve T cells, 3rd receives only SF thymus. After 3rd subject \>10%naive T cells, 4th subject transplanted. Thymus dose 4-18 grams/m2 body surface area. Thymus biopsy 8-12 weeks post-transplant. Skin biopsy at time of transplant \& thymus biopsy. Followed by immune evaluations.
223774197|NCT02669186|DRUG|Bupivacaine|General endotracheal anesthesia augmented with an epidural. The epidural solution intraoperatively and post-operatively will contain bupivacaine titrated to appropriate surgical conditions and post-operative pain control
224261664|NCT06562959|BEHAVIORAL|Fluid Restriction Program|In order to design the fluid restriction program content (booklet). The fluid restriction program included (a) General small-group discussion sessions, (b) individualized consultations, and (c) follow-up sessions. In the group discussion sessions, children in both the study and control groups were divided into subgroups (6 participants per each). In the group discussion sessions, children in both the study and control groups were divided into subgroups. The sessions were conducted in the meeting room of the Hemodialysis unit lasts for 45 minutes. In the Individualized Consultations, children then were provided tailored, age-appropriate education. The researchers also arranged for regular follow-up for one months.
224261665|NCT06562959|OTHER|Intervention Bundle (Fluid Restriction Program and Auricular Acupressure|the study group received the Fluid Restriction Program and Auricular Acupressure in four acupoints namely, Shenmen, Kidney Concha, Point Zero and Upper Tragus. The researcher's finger gently pressed on each determined acupoints in a circular movement with a clockwise direction for three minutes.
224261666|NCT01675115|DRUG|BNG-1|BNG-1 3 grams TID for 4 weeks
223774198|NCT03550963|OTHER|rice-richen meal|Participants in group one will be provided with rice-richen meal. All participants will be required to test and record blood glucose.
224261667|NCT01675115|DRUG|Aspirin|Aspirin 100 mg QD for 4 weeks
224261668|NCT01592240|DRUG|PBO|Placebo Q28d
224261669|NCT01592240|DRUG|200mg PF-04950615 (RN316)|PF-04950615 200 mg, Q28d
224261670|NCT01592240|DRUG|300mg PF-04950615 (RN316)|PF-04950615 300 mg, Q28d
224261671|NCT01592240|DRUG|PBO|Placebo, Q14d
224261672|NCT01592240|DRUG|PF-04950615|PF-04950615 50mg, Q14d
224261673|NCT01592240|DRUG|PF-04950615|PF-04950615 100 mg, Q14d
224261674|NCT01592240|DRUG|PF-04950615|PF-04950615 150mg, Q14d
224261675|NCT03181620|OTHER|Intermittent Dosing of Medication|Typical sedative/narcotic medication administered for sedation while mechanically ventilated is given in an intravenous intermittent bolus fashion rather than a continuous intravenous drip.
224261676|NCT00465218|PROCEDURE|Prophylaxis of Thrombosis after aortic valve replacement|Two standard prophylactic treatments of thrombosis within the first 3 months postsurgery currently used in our institution: a) daily dose of aspirin (325 mgs; b) daily dose of aspirin (81 mg) plus Warfarin for target INR 2.0-2.5
224261677|NCT05947409|DRUG|SMARTO ONE|The SMARTO ONE® small molecule natural flavonoid compound product is provided by Beijing Jiafurui Biological Technology Co., Ltd. The intervention agent formula consists of extracts from Polygonum cuspidatum leaves, Fructus ligustri lucidi, Prunus mume, Semen ziziphi spinosae, celery, resistant maltodextrin, and steviol glycoside. Each package of the test product (3g) contains a total flavonoid content of 150mg.
224261678|NCT02395809|PROCEDURE|lateral internal sphincterotomy|
224261679|NCT02395809|PROCEDURE|TENS|
224261680|NCT03704103|OTHER|iSage|The provider will choose a treatment algorithm within the iSage app and set the parameters to make insulin dose adjustments no less frequently than every 7 days. The patient is instructed to perform daily fasting glucose measurements and follow the app's recommendations for insulin adjustment.
224261681|NCT01187823|DEVICE|Adaptive servo ventilation|Nocturnal use of Adaptive servo ventilation
224323807|NCT05862285|DRUG|Inavolisib|Inavolisib will be administered as a monotherapy or in combination at the same dose, schedule, and with the same administration guidelines that were in effect at the time of participants discontinuation from the parent study.
224323808|NCT04955366|DRUG|Belatacept|Belatacept is an immunosuppressive medication and will be given as an intravenous infusion at a dose of 5 mg/kg monthly
223681474|NCT00849888|OTHER|Serum Free Thymus Transplantation without immunosuppression|Thymus tissue (unrelated donor), donor, \& donor's mother screened for safety. Transplant under general anesthesia into quadriceps. First 2 subjects: FBS cultured thymus transplanted in 1 leg \& serum free cultured thymus in other leg. After first 2 subjects have thymopoiesis in serum-free biopsy, \>10% naïve T cells, 3rd subject receives only serum free cultured thymus. After 3rd subject \>10% naive T cells, 4th subject receives transplant of only serum free cultured thymus. Dose 4-18grams/m2 body surface area. At time of transplant, skin biopsy. Allograft biopsy \& skin biopsy done 8 to 12 weeks post-transplant. (Graft biopsy not done if subject medically unstable.) Post-transplant, subjects followed by immune evaluations, using blood samples, for two years.
223681475|NCT01843478|OTHER|Self-Collected HPV Test|The HPV self-collected test is followed by results counseling by phone when the result is available (usually 2-3 weeks). Women are encouraged to have Pap testing.
223681476|NCT01843478|OTHER|Usual Care|
223681477|NCT02744001|OTHER|Low Added Sugar Diet|1-week intake of Low Added Sugar Diet 3 day rotating menu
223681478|NCT04250311|DRUG|MMH-407|MMH-407: For oral use.
223681479|NCT04250311|DRUG|Placebo|Placebo: For oral use.
224261682|NCT01187823|DEVICE|Nocturnal oxygen|Nocturnal use of oxygen
224261683|NCT06393530|DRUG|0.9%sodium chloride|Bilateral ESPB under ultrasound guidance (adjusted to the incision line): 2 x 20ml/kg 0,9% normal saline
224261684|NCT06393530|DRUG|0.2% ropivacaine|Bilateral ESPB under ultrasound guidance (adjusted to the incision line): 2 x 20ml/kg 0,2% ropivacaine
224261685|NCT05374850|PROCEDURE|Cervical Interlaminar Epidural Steroid Injection|This intervention is applied mostly for cervical disc herniation.The intervention was carried out under sterile conditions with the C-arm fluoroscopy guidance. It is performed via spinal needle and the needle is inserted into the epidural space, then combined local anesthetics and glucocorticoids is delivered to the epidural space.
224261686|NCT04835116|DRUG|Bupivacaine Hydrochloride 0.25% Injection. Paracetamol 650mg. Orphenadrine 50mg.|Group A patients were administered per-operative peri tract local anesthesia infiltration with 0.25% bupivacaine augmented by post-operative oral analgesia with a combination of Paracetamol 650 mg and Orphenadrine 50mg 6 hourly.
224261687|NCT04835116|DRUG|paracetamol 1000mg. Tramadol 50mg. Dimenhydrinate 50mg.|Group B patients were only given post-operative intra-venous analgesia by Paracetamol 1gm intravenous 8 hourly augmented with a combination of Tramadol 50mg and Dimenhydrinate 50mg as and when required
224261688|NCT04763031|RADIATION|Intra-operative Radiation Therapy - IORT|Single dose of 20 Gy
224261689|NCT04082741|DRUG|BMS-986318|Specified dose on specified days
224261690|NCT04082741|OTHER|Placebo|Placebo Matching BMS-986318
224261691|NCT05089903|BEHAVIORAL|Bulk Order|A mammogram order will be placed using bulk order technology in the EHR in advance of outreach for all patients.
224261692|NCT05089903|BEHAVIORAL|Texting|In addition to outreach, patients will receive text messaging with information regarding the importance of screening, how to schedule a mammogram, and locations available for mammography.
224261693|NCT05089903|BEHAVIORAL|Clinician Endorsement|Outreach informing patients that they are overdue for a mammogram will be signed by the patient's primary care provider.
224261694|NCT05089903|BEHAVIORAL|No Bulk Order|The outreach will ask patients to contact their PCP's office in order to have a mammogram order placed on their behalf.
224261695|NCT05089903|BEHAVIORAL|Standard Endorsement|Patient's will receive outreach from the practice informing them that they are overdue for a mammogram.
224261696|NCT02994836|BIOLOGICAL|Anti-TNF: Infliximab (Infusion)|Infliximab (Infusion 5mg/kg milligram(s)/Kilogram-Intravenous use)(Visit1,visit 3,visit 4,visit 5, visit 6 and visit 7)
224261697|NCT02994836|DRUG|Anti-TNF discontinuation: Physiological saline solution|Physiological saline solution (Infusion-Intravenous use)(Visit1,visit 3,visit 4,visit 5, visit 6 and visit 7)
224261698|NCT02994836|BIOLOGICAL|Anti-TNF:Adalimumab (Subcutaneus)|Adalimumab (Subcutaneus 40 mg milligram(s)-subcutaneus)(Visit 1,visit 2,visit 3,visit 4,visit 5, visit 6 and visit 7).
224261699|NCT02994836|DRUG|Anti-TNF discontinuation: Physiological saline solution|Physiological saline solution (Injection-subcutaneous use)(Visit 1,visit 2,visit 3,visit 4,visit 5, visit 6 and visit 7).
224261700|NCT02751424|DRUG|GSK3342830|A pyrogen free lyophilized formulation, white to yellowish brown powder containing 1000 mg of GSK3342830A (as free base) per vial. The reconstituted solution looks like a clear, colorless to yellow or brownish yellow liquid, free from visible particulate matter will be administered as IV infusion over 1 hour.
224261701|NCT02751424|DRUG|Placebo|A clear and colorless solution containing 0.9% sodium chloride. It will administered as IV infusion over 1 hour.
224261702|NCT01896934|DRUG|Sertraline|50-200mg daily
224261703|NCT02197416|DRUG|dabigatran etexilate|Age and weight appropriate capsule dose (combination of 50 mg, 75 mg and 110 mg capsules) or pellets or oral liquid formulation
224261704|NCT06026267|BIOLOGICAL|20% High Dose Albumin|"A\]. Patients in the conventional albumin Arm will receive Human Albumin 20% 1.5 g/kg body weight (Maximum 100g) on day 1 after the diagnosis, followed by 1 g/kg bodyweight (Maximum 100g)on day 3 along with standard medical therapy.~Duration of albumin over 24 hours."
224261705|NCT06026267|OTHER|Standard Medical Treatment|Standard Medical Treatment
224261706|NCT06026267|BIOLOGICAL|20% Reduced Dose Albumin|"B\]. Patients in the low dose albumin Arm will receive Human Albumin 20% 1.0 g/kg body weight (Maximum 100g) on day 1 after the diagnosis, followed by 0.5 g/kg bodyweight (Maximum 100g) on day 3 along with standard medical therapy.~Duration of albumin over 24 hours."
224261707|NCT02451696|DRUG|Everolimus|This study will measure if the drug called Everolimus effects mTOR signaling (an electrical activity signal in the brain) in patients with Tuberous Sclerosis Complex (TSC) and Focal Cortical Dysplasia (FCD) with treatment resistant epilepsy (TRE) who will be undergoing brain surgery. One group of patients will be treated with Everolimus, for 7-28 days prior to epilepsy surgery and another will not. We will determine if there is a difference in mTOR signaling between the patients who were treated with Everolimus and those who were not
224261708|NCT00967395|OTHER|Healing|"Healing in our study is given be a healer no-touch, who just has to be present in the room."
224261709|NCT00967395|OTHER|Sham healing|"Sham Healing in our study is given be a student no-touch, who just has to be present in the room."
224261710|NCT04589546|DRUG|Nicotinamide treatment|Nicotinamide (500 mg) will be mixed in 50 ml of 0.9% saline and administered intravenously every 12 h for a total of 72 h.
224261711|NCT04589546|DRUG|placebo treatment|For the placebo group, an identical volume of 0.9% saline will be administered in the same manner.
224261712|NCT03348527|DRUG|2-Hydroxyflutamide Depot|Liproca® Depot is a depot formulation containing a bioresorbable, controlled-release,formulation of the nonsteroidal antiandrogen 2-hydroxyflutamide
224261713|NCT03531060|DRUG|IRL790|IRL790 capsule 10 mg
224261714|NCT03531060|DRUG|Placebo|Placebo capsule
224261715|NCT04891276|OTHER|Data collection|Data collection on the national PMSI database
224261716|NCT06498024|OTHER|Kellogg's - rice krispies (control)|One serving size (140g) of whole white rice cereal will be provided. Preparation will be consistently maintained throughout.
224261717|NCT06498024|OTHER|Kellogg's - rice krispies (control) + 125ml milk|One serving size (140g) of whole white rice cereal with 125ml of milk will be provided. Preparation will be consistently maintained throughout.
224261718|NCT06498024|OTHER|Novel cereal (40% Canadian wild rice, 60% fava bean blend) + 125 ml milk|One serving size (140g) of novel cereal (40% Canadian wild rice, 60% fava bean blend) with 125ml of milk will be provided. Preparation will be consistently maintained throughout.
224261719|NCT06498024|OTHER|Novel cereal (40% Canadian wild rice, 60% fava bean blend)|One serving size (140g) of novel cereal (40% Canadian wild rice, 60% fava bean blend) will be provided. Preparation will be consistently maintained throughout.
224261720|NCT06498024|OTHER|Novel cereal (40% Canadian wild rice, 50% fava bean blend) + 10% purple powder (sweet potato)|One serving size (140g) of novel cereal (40% Canadian wild rice, 60% fava bean blend) with a 10% added purple powder (sweet potato) will be provided. Preparation will be consistently maintained throughout.
224261721|NCT06498024|OTHER|Novel cereal (40% Canadian wild rice, 50% fava bean blend) + 10% purple powder (sweet potato) + 125 ml milk|One serving size (140g) of novel cereal (40% Canadian wild rice, 50% fava bean blend) and 10% purple powder (sweet potato) with 125 ml milk. Preparation will be consistently maintained throughout.
224261722|NCT06532006|DRUG|HLX22|HLX22 15mg/kg Q3w
224261723|NCT06532006|DRUG|Pembrolizumab|Pembrolizumab 200mg q3w
224261724|NCT06532006|DRUG|Trastuzumab|Trastuzumab 8 mg/kg loading dose and then 6 mg/kg maintenance thereafter ,Q3W
224261725|NCT06532006|DRUG|Oxaliplatin|Oxaliplatin 130 mg/m2 ,Q3W
224261726|NCT06532006|DRUG|Capecitabine|Capecitabine 1000 mg/m2 bid on Days 1-14 ,Q3W
224261727|NCT05690152|DEVICE|EyeSimplify web-browser-based visual field test|All patients will be in a single arm: patients will have one or both eyes (dependent on inclusion/exclusion criteria) tested with the EyeSimplify visual field test biweekly for 6 months.
224261728|NCT04065646|OTHER|Mobile|
224261729|NCT01342991|PROCEDURE|Laser Haemorrhoidectomy|"The intervention comprises laser haemorrhoidectomy~This procedure will be performed under local anaesthetic with sedation as a day case~The haemorrhoids are excised using sharp dissection (over a clamp) and the cut edges are sealed using CO2 laser.~Pre-operative local anaesthesia will be given"
224261730|NCT01342991|PROCEDURE|Laser Haemorrhoidectomy|"The intervention comprises laser haemorrhoidectomy~This procedure will be performed under local anaesthetic with sedation as a day case~The haemorrhoids are excised using sharp dissection (over a clamp) and the cut edges are sealed using CO2 laser.~Pre-operative local anaesthesia will be given"
224261731|NCT05014828|DRUG|lenvatinib|Administered at the dose of 20 mg orally, once daily.
224261732|NCT05014828|DRUG|Tislelizumab|400 mg administered intravenously on Day 1 of each 42-day cycle
224323809|NCT04955366|DRUG|Abatacept|Abatacept is an immunosuppressive medication and will be given SQ at a dose of 125 mg s.c. weekly
224261733|NCT05006690|OTHER|Clinical Pilates-Based Exercise Training|Clinical Pilates-Based exercise training based on spinal stabilization aim at controlling the position of the trunk over the pelvis to provide optimal energy production and energy transfer to distal segments and involve the cocontraction of muscles, which may restore stability to the spine.
224261734|NCT06238570|DEVICE|Gavi, Merck® (automated vitrification instrument)|"This instrument recently appeared on the market and demonstrated a high effectiveness in terms of processing time and reproducibility for embryo vitrification. To date, no study has analyzed the efficiency of this automated vitrification instrument on oocyte vitrification.~The oocytes will be stored in closed cassettes in liquid nitrogen"
224261735|NCT06238570|DEVICE|Vitrolife system|The oocytes vitrification will be carried out by an authorized technician according to the manual protocol validated and used routinely.
224261736|NCT04186260|BEHAVIORAL|NAFLD-specific weight loss intervention|This is a 12-month NAFLD-specific weight loss intervention that is explicitly tailored for Mexican-American men. It will include recommendations for diet, physical activity, and will utilize risk for NAFLD as a mechanism to engage men in lifestyle modification.
224261737|NCT04186260|OTHER|Wait-list control|Participants in this condition will not receive treatment for 12-months until study comparisons have been made. After 12-months, participants will receive the 12-month NAFLD-specific weight loss intervention.
224261738|NCT02836574|BIOLOGICAL|Renal Autologous Cell Therapy (REACT)|Autologous selected renal cells (SRC).
224261739|NCT02836574|PROCEDURE|Renal Biopsy|a procedure in which a small sample of kidney tissue is removed
224261740|NCT04803162|DIAGNOSTIC_TEST|High-resolution manometry|The parameters of high-resolution esophageal manometry will be compared between EoE patients and controls.
224261741|NCT04803162|DIAGNOSTIC_TEST|Serum biomarkers|The serum levels of IL-5, IL-13, TGF-β1, MBP and eotaxin 3 will be compared between EoE patients and controls.
224261742|NCT04803162|DIAGNOSTIC_TEST|Gastrointestinal Quality of Life index|The Gastrointestinal Quality of Life index (GIQLI) will be compared between EoE patients and controls.
224261743|NCT04803162|DRUG|Omeprazole 20 MG Oral Tablet|The parameters of high-resolution esophageal manometry and serum levels of IL-5, IL-13, TGF-β1, MBP and eotaxin 3 will be compared in the group of patients with EoE at enrollment in the project and after 3 months of treatment with PPIs.
224323810|NCT05538247|DRUG|Indomethacin|Immediate release oral capsules 50 mg, 3 times a day for 6 days
224323811|NCT05538247|DIETARY_SUPPLEMENT|S. boulardii CNCM I-745|Two 250 mg capsules orally twice daily for 14 days
223681480|NCT05945680|DRUG|Placebo|100 mL of normal saline. Administered intravenously at least 10 minutes prior to skin incision.
223681481|NCT05945680|DRUG|Tranexamic acid|Tranexamic Acid (10mg/kg), diluted in 100 ccs of normal saline. Administered intravenously at least 10 minutes before skin incision.
223681482|NCT00208546|DRUG|21Capecitabine + bevacizumab + oxaliplatin|3-weekly cycles: Ca 1000 mg/m2 orally day 1-14, O 130 mg/m2 i.v. day 1 (6 cycles), B 7,5 mg/kg i.v. day 1.
223681483|NCT00208546|DRUG|1Capecitabine + oxaliplatin + bevacizumab + cetuximab|3-weekly cycles: Ca 1000 mg/m2 orally day 1-14, O 130 mg/m2 i.v. day 1 (6 cycles), B 7,5 mg/kg i.v. day 1, Ce 250 mg/m2 i.v. day 1, 8, 15 (day 1 cycle 1: 400 mg/m2).
223681484|NCT01405066|BEHAVIORAL|Radiation Dose Audit Reports|Audit reports by CT technologist, with graphs of radiation dose levels of 20 exams from each of the 4 most common CT exams. Reports show the distribution of radiation dose levels by each exam type, and compares the technologist's dose levels to the overall levels from the clinic where they work and to the United Kingdom's 2003 Reference Dose. Prior to the graphs, the reports include an introductory page explaining the organization of the report and defining the dosimetry metrics. The final page of the report lists exams meriting individual review because their doses are higher than that of the clinic averages.
223681485|NCT01405066|BEHAVIORAL|Educational Seminar: Radiation Dose Reduction|Seminar led by a Radiologic Physicist and Radiologist. Discussion of the parameters associated with radiation dosage from CT exams and methods for changing these parameters to lower radiation dose.
223681486|NCT00981773|DRUG|Maraviroc|Maraviroc 150 mg bid
223681487|NCT00981773|DRUG|Maraviroc|maraviroc 150 mg bid switch 12 weeks later
223681488|NCT00371761|BIOLOGICAL|Pegylated interferon alfa-2b (PegIntron)|Powder for injection in vials ( 100, and 120 microgram strengths), subcutaneous, dose of 1.5 micrograms/kg, weekly for up to 24 weeks
223681489|NCT00371761|DRUG|Adefovir dipivoxil (adefovir)|10 mg adefovir dipivoxil (equivalent to 5.4.5 mg adefovir) tablets, oral, dose of 1 tablet per day for up to 48 weeks
223681490|NCT04445974|BEHAVIORAL|Expand your horizons: More than my skin|'Expand Your Horizon' is a self-help intervention which uses writing exercises to help individuals with poor body image practice focusing on their body-functionality rather than their physical appearance (Alleva et al., 2015). The materials for 'Expand Your Horizon' are freely available (Alleva et al., 2015), and permission has been granted to use and adapt the materials in this research. 'Expand Your Horizon' comprises of three 15 min writing exercises, typically completed over approximately six days. The intervention materials have been adapted for use with a population with skin diseases, and modified to use gender neutral language. Adaptions were made in consultation with experts by experience. The changes were reviewed and approved by the first author of the original intervention to ensure the materials were in keeping with the original intervention.
223681491|NCT04445974|BEHAVIORAL|Creative writing activities|In line with previous studies examining 'Expand Your Horizon' the active control condition will involve creative writing tasks (Alleva et al., 2015). Participants in the intervention condition will complete three 15 minute creative writing exercises, completed over six days.
223681492|NCT05341388|DIAGNOSTIC_TEST|MOCA cognitive evaluation test|Before starting their newly prescribed medication, we will apply MOCA and repeat it at the end of the trial.
223681493|NCT05341388|DIAGNOSTIC_TEST|BDNF levels|Before starting their newly prescribed medication, we will apply MOCA and repeat it at the end of the trial.
223681494|NCT05341388|OTHER|SF-36 test|Before starting their newly prescribed medication, we will apply MOCA and repeat it at the end of the trial.
223681495|NCT05341388|DIAGNOSTIC_TEST|Geriatric depression test|Before starting their newly prescribed medication, we will apply MOCA and repeat it at the end of the trial.
223681496|NCT05506137|DRUG|Pilocarpine|study whether topical pilocarpine drops induce a clinically significant improvement in xerostomia
223681497|NCT05506137|OTHER|Placebo|study whether topical pilocarpine drops induce a clinically significant improvement in xerostomia
223681498|NCT04512339|DRUG|Dupilumab|Dupilumab injections (blinded labels)
223774199|NCT03550963|OTHER|wheaten-richen meal|Participants in group two will be provided with wheaten-richen meal.All participants will be required to test and record blood glucose.
223774200|NCT03062891|PROCEDURE|Online CBT for insomnia|See CBT arm description for information about the CBT intervention. More details can be found in source 4 in the reference list.
223774201|NCT02873169|OTHER|Implantable cardioverter-defibrillator|Collection of clinical, biological, hemodynamic and rhythmic data
224261744|NCT05231824|BEHAVIORAL|Standard Behavioral Weight Loss Treatment|Behavioral weight loss treatment is the current gold standard treatment for obesity.
224261745|NCT05231824|BEHAVIORAL|AI-optimized Behavioral Weight Loss Treatment|AI-optimized Behavioral Weight Loss Treatment will continuously vary intensity (automated text message, videoconference group, individual coaching call) and coach type (paraprofessional or MS-level expert) based on continuously-monitored participant digital data.
224261746|NCT05523895|DRUG|Pimavanserin|Pimavanserin
224261747|NCT05523895|DRUG|Placebo|Pimavanserin matching placebo
224261748|NCT03674892|DEVICE|TrueTear™ intranasal neurostimulator (ITN)|TrueTear™ intranasal neurostimulator (ITN)
224261749|NCT04343001|DRUG|Aspirin|Aspirin 150mg
224261750|NCT04343001|DRUG|Losartan|Losartan 100mg
224261751|NCT04343001|DRUG|Simvastatin|Simvastatin 80mg
224261752|NCT05917925|DIETARY_SUPPLEMENT|COLLAGEN (COL)|The collagen-based supplement will be ingested every day for 12 weeks at the same time.
224323812|NCT05538247|DRUG|Placebo|Two 250 mg capsules that contains no active study ingredient orally twice daily for 14 days
223681499|NCT04512339|DRUG|Placebo|Placebo injections (blinded labels), matching the dupilumab injections in quantity and appearance
223681500|NCT04577339|PROCEDURE|Laparotomy or laparoscopy|"Laparotomy is the opening of the abdominal cavity usually through a midline incision.~Laparoscopy is using minimal access keyhole surgery to perform the surgery instead of laparotomy Interventional radiology is the use of imaging to perform a procedure on the abdomen without surgery, for example, using ultrasound to guide a needle to drain an abscess Best supportive care is usually end-of-life care concentration on relieving symptoms rather than treating the cause."
223681501|NCT01422967|BEHAVIORAL|Balance and muscle strength|Balance test: bi and unipodal balance in the place force Muscle strength: bilateral test of knee in dynamometer isokinetic
223681502|NCT03833947|DRUG|lignocaine+bicarbonate|ETT cuff was filled with mixture of 2% lignocaine with bicarbonate
223681503|NCT03833947|DRUG|lignocaine+dexamethasone|ETT cuff was filled with mixture of 2% lignocaine with dexamethasone
223681504|NCT04589715|OTHER|electroacupuncture|the same as described in experimental arm.
223681505|NCT04589715|OTHER|sham electroacupuncture|the same as described in sham comparator.
223681506|NCT01196039|DRUG|MEMP1972A|Intravenous repeating dose
223681507|NCT01196039|DRUG|placebo|Intravenous repeating dose
223681508|NCT01689909|DRUG|Zolpidem-CR|Zolpidem 6.25 mg or 12.5 mg in tablet form at nighttime 15 minutes before bed for 8 weeks
223681509|NCT01689909|DRUG|Placebo|Placebo in tablet form at nighttime 15 minutes before bed for 8 weeks
223681510|NCT00244842|DRUG|voclosporin|voclosporin 0.2, 0.3, or 0.4 mg/kg po BID
223681511|NCT00244842|DRUG|Placebo|Placebo
223681512|NCT01736657|DEVICE|Red blood cell exchange in sickle cell|One Red Blood Cell Exchange using Spectra Optia Apheresis System per enrolled patient
223681513|NCT04309747|PROCEDURE|nanosecond knife liver cancer ablation|This trial is a prospective, multi-center, single-arm clinical trial. Four hospitals with national medical clinical trial institution qualifications are selected as clinical trial centers. Qualified participants will receive nanosecond pulse ablation therapy according to the routine procedures. The results will be recorded according to the requirements of the primary and secondary efficacy indicators. After then, statistical comparisons of effectiveness and safety of the product will be made according to groups.
223681514|NCT04524338|DEVICE|Transcranial Direct Current Stimulation|Brain Stimulation Devices attached to scalp
223681515|NCT02326311|DRUG|imatinib|Tyrosin kinase inhibitor
223681516|NCT02326311|DRUG|nilotinib|Tyrosin kinase inhibitor
223681517|NCT02326311|DRUG|dasatinib|Tyrosin kinase inhibitor
223681518|NCT00947050|OTHER|dynamic physical exercise|dynamic supine bicycle exercise for 6 minutes
223681519|NCT00099645|DRUG|Mifepristone|
223681520|NCT01049477|OTHER|Music group|The patients randomized to the music group of the study will listen to music 30 minutes in the holding room prior to their c/s. They will then listen to music after their c/s for 30 minutes. They will complete the STAI before and after their c/s.
223681521|NCT01049477|OTHER|Non music group|Patients randomized to the non music group will complete the STAI before and after their c/s, but not listen to music.
223774202|NCT01485952|DRUG|SEN0014196 (Low Dose)|10 mg once daily administration (immediate release capsule)
223774203|NCT01485952|DRUG|SEN0014196 (High Dose)|100 mg once daily administration (immediate release capsule)
224261753|NCT05917925|DIETARY_SUPPLEMENT|PLACEBO (PLA)|The placebo will be ingested every day for 12 weeks at the same time.
224261754|NCT04852393|PROCEDURE|Block|cervical medial branch block
224261755|NCT04156230|DRUG|[18F]GP1 positron emission tomography/computed tomography|A radioactive dose of 250 MBq of the study drug with a total quantity of ≤ 10 µg will be administered as slow intravenous bolus injection over up to 60 seconds. PET/CT examinations will be performed at 120 ± 15 min after the administration of \[18F\]GP1.
224261756|NCT02259244|BEHAVIORAL|Weight reduction program|
224261757|NCT05644587|DRUG|buprenorphine/naloxone|Buprenorphine/naloxone will be used to begin each patient's treatment for opioid use disorder.
224323813|NCT06006637|DEVICE|Cognilum TM: Light Treatment Condition|The children will wear the CognilumTM device for approximately 10 minutes at a time, twice a week, for a period of 10 weeks.
224323814|NCT04711252|DRUG|AZD9833|Dosage formulation: AZD9833 tablets will be administered orally
224323815|NCT04711252|DRUG|Anastrozole|Dosage formulation: Anastrozole tablets will be administered orally.
224323816|NCT04711252|DRUG|Anastrozole placebo|Dosage formulation: anastrozole placebo tablets will be administrated orally.
224323817|NCT04711252|DRUG|AZD9833 placebo|Dosage formulation: AZD9833 placebo tablets will be administrated orally.
224323818|NCT04711252|DRUG|Palbociclib|Dosage formulation: palbociclib tablets/capsules will be administered orally
224261758|NCT01907607|DRUG|PD 0332991|"PD-0332991 was administrated orally, formulated as gelatin capsules of 100 mg and 25 mg respectively.~PD-0332991 was dosed on a flat scale of 125 mg (1 capsule x 100 mg/day, 1 capsule x25 mg/day) will be administrated orally o.d on a 21 days on / 7 days off dosing schedule. One cycle is considered to consist of 4 weeks of PD-0332991 administration.~Patients should be instructed to administrate PD-0332991 with a sufficient amount of water at least 1 hour prior to a meal or at least 2 hours following a meal and to swallow the required number of capsules at approximately the same time on each day."
224261759|NCT02478983|DEVICE|LMA Supreme|The device will be inserted according to manufacturer's guideline. Time of insertion will be recorded. The oropharyngeal airway leak pressure will be measured when the device successfully inserted. The time taken to insert the LMA is recorded and the insertion success rate is documented. The larynx will be visualized with fibreoptic bronchoscope inserted through the LMA. Intraoperative complications will be recorded.
224261760|NCT02478983|DEVICE|LMA Proseal|The device will be inserted according to manufacturer's guideline. Time of insertion will be recorded. The oropharyngeal airway leak pressure will be measured when the device successfully inserted. The time taken to insert the LMA is recorded and the insertion success rate is documented. The larynx will be visualized with fibreoptic bronchoscope inserted through the LMA. Intraoperative complications will be recorded.
224261761|NCT03142165|DRUG|BMS-986263|3 weekly doses of 90 mg infused intravenous administration
224261762|NCT03142165|OTHER|Placebo|Placebo
224261763|NCT03142165|DRUG|Diphenhydramine|50 mg intravenous administration
224261764|NCT03142165|DRUG|Famotidine|20 mg intravenous administration
224261765|NCT01384591|DRUG|N-acetylcysteine|50 mg/kg/dose. 3 total doses: 1 dose on day 1, 2 doses on day 2.
224261766|NCT01384591|DRUG|Losartan|25mg/dose. 3 total doses: 1 dose on day 1, 2 doses on day 2.
224261767|NCT01384591|DRUG|Placebo losartan|Placebo losartan 3 total doses: 1 dose on day 1, 2 doses on day 2.
224261768|NCT01384591|DRUG|Placebo N-acetylcysteine|Placebo N-acetylcysteine 3 total doses: 1 dose on day 1, 2 doses on day 2.
224261769|NCT01959672|PROCEDURE|4-Dimensional Computed Tomography|Correlative studies
224323819|NCT04711252|DRUG|Luteinizing hormone-releasing hormone (LHRH) agonist|Men (when medically applicable) and pre- or peri-menopausal women are required to receive a monthly LHRH agonist.
224323820|NCT06422143|BIOLOGICAL|Pembrolizumab|Intravenous (IV) infusion
223681522|NCT06198140|OTHER|myofascial release and quick icing|In experimental group the individuals will receive myofascial release and quick icing. Quick icing will be on ankle dorsiflexors by using ice pack in the target area. Quick icing will be applied for 10 minutes (time of application 10 seconds and a rest for 20 seconds). This treatment protocol will be 6 times/week for 4 weeks in the hospital setting. Mayofascial release will be given on the target ankle planterflexors. The subjects who will receive Myofascial Release will be positioned in prone with the treatment area exposed. The treatment will be applied by the therapist standing at the side of the patient. Then technique will be applied with different levels by following longitudinal movements according to subject's tolerance for duration of 3 minutes in each sitting. Patients will be given a rest time after each level in order to allow the tissue to soften. This treatment protocol will be 6 times/week for 4 weeks in the hospital setting.
223774204|NCT01485952|DRUG|Placebo|Once daily administration (immediate release capsule)
223774205|NCT05323383|BEHAVIORAL|Mindfulness Meditation|Participants in the mindfulness meditation condition will listen to a 20minute guided mindfulness meditation practice that holds the breath and body as the object of meditation.
224261770|NCT01959672|DRUG|Fluorouracil|Given IV
224261771|NCT01959672|DRUG|Gemcitabine Hydrochloride|Given IV
224261772|NCT01959672|OTHER|Laboratory Biomarker Analysis|Correlative studies
224261773|NCT01959672|DRUG|Leucovorin Calcium|Given IV
224261774|NCT01959672|DRUG|Nelfinavir Mesylate|Given PO
224261775|NCT01959672|BIOLOGICAL|Oregovomab|Given IV
224261776|NCT01959672|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
224261777|NCT01959672|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgical resection
224261778|NCT03593512|PROCEDURE|Deep brain stimulation|Bilateral deep brain stimulation of the pedunculopontine nucleus
224261779|NCT00682500|DRUG|Calfactant|Intratracheal Instillation of 0.5 mL/cm of height of 60 mg/mL suspension in two aliquots at study entry. Repeat dosing 12 hours later if criteria are met.
224261780|NCT00682500|DRUG|Room Air (placebo)|Administration of 0.5 ml/cm height of air at study entry into the trachea. Repeat dosing at 12 hours if criteria are met
224261781|NCT04530656|BIOLOGICAL|Two doses of middle-dose recombinant SARS-CoV-2 vaccine (Sf9 Cell) at the schedule of day 0, 28|Two doses of middle-dose (20µg/ 0.5ml) recombinant SARS-CoV-2 vaccine (Sf9 Cell) at the schedule of day 0, 28.
224261782|NCT04530656|BIOLOGICAL|Two doses of high-dose recombinant SARS-CoV-2 vaccine (Sf9 Cell) at the schedule of day 0, 28|Two doses of high-dose (40µg/ 1.0ml) recombinant SARS-CoV-2 vaccine (Sf9 Cell) at the schedule of day 0, 28.
224261783|NCT04530656|BIOLOGICAL|Three doses of high-dose recombinant SARS-CoV-2 vaccine (Sf9 Cell) at the schedule of day 0, 14, 28|Three doses of high-dose (40µg/ 1.0ml) recombinant SARS-CoV-2 vaccine (Sf9 Cell) at the schedule of day 0, 14, 28
224261784|NCT04530656|BIOLOGICAL|Two doses of placebo at the schedule of day 0, 28（middle-dose group）|Two doses of placebo (0.5ml) at the schedule of day 0, 28
224261785|NCT04530656|BIOLOGICAL|Two doses of placebo at the schedule of day 0, 28（high-dose group）|Two doses of placebo (1.0ml) at the schedule of day 0, 28
224261786|NCT04530656|BIOLOGICAL|Three doses of placebo at the schedule of day 0, 14, 28（high-dose group）|Three doses of placebo (1.0ml) at the schedule of day 0, 14, 28
224323821|NCT06422143|BIOLOGICAL|sac-TMT|IV infusion
224323822|NCT06422143|DRUG|Carboplatin|Participants receive AUC 6 mg/mL/min IV infusion on Day 1 of each 21-day cycle for 4 cycles as background therapy during the study.
224323823|NCT06422143|DRUG|Paclitaxel|Participants receive 200 mg/m\^2 IV infusion on Day 1 of each 21-day cycle for 4 cycles as background therapy during the study.
224323824|NCT06422143|DRUG|Nab-paclitaxel|Participants receive 100 mg/m\^2 IV infusion on Days 1, 8 and 15 of each 21-day cycle for 4 cycles as background therapy during the study.
224323825|NCT06802133|OTHER|Post Market Study|Prospective case series without a concurrent comparator group.
224323826|NCT05166889|DRUG|Tozorakimab|Administered subcutaneously tozorakimab Dose 1 and placebo through Week 52.
224261787|NCT05527561|BEHAVIORAL|Latin dance: Rumba|Latin dance is a kind of sports dance, which originated in Latin America, includes the rumba, samba, Cha Cha Cha, bullfighting dances and cowboy dances. The intensity of the training is increasing in the first 20 minutes, and the intensity is gradually decreasing in the next 5 minutes.
224261788|NCT05527561|BEHAVIORAL|Latin dance: Cha Cha Cha|Latin dance is a kind of sports dance, which originated in Latin America, includes the rumba, samba, Cha Cha Cha, bullfighting dances and cowboy dances. The intensity of the training is increasing in the first 20 minutes, and the intensity is gradually decreasing in the next 5 minutes.
224261789|NCT06356766|OTHER|Telerehabilitation|Modified Duran Protocol via Telerehabilitation
224261790|NCT06356766|OTHER|Face-to-face rehabilitation|Modified Duran Protocol
224261791|NCT04924920|DIAGNOSTIC_TEST|SIGH|To add the Sigh35 to PSV, the ventilator is set in pressure controlled synchronized intermittent mandatory ventilation plus PSV \[SIMV (PC) + PS mode\], with SIMV rate set a 1/min and inspiratory time of 4 seconds. SIMV (PC) = 35 cmH20 of total inspiratory support (PEEP + PS).
224261792|NCT04924920|DIAGNOSTIC_TEST|EEOT|• The EEOT is performed by interrupting the mechanical ventilation for 15 seconds, by using and end-expiratory hold on the ventilator. The ventilator trigger is set at 2 L/min.
224261793|NCT04924920|DIAGNOSTIC_TEST|Fluid challenge|Bolus of fluids of 4 ml/kg given within 10 minutes
224261794|NCT01322880|BEHAVIORAL|Discussion sessions|Those selected were invited to attend a 6 session course on household decision-making with their spouses. Topics included budgeting, household financial management, and negotiation skills
224261795|NCT01322880|BEHAVIORAL|Village Savings and Loans Associations|The approach developed by CARE International develops Village Savings and Loan Associations (VSLAs). A VSLA is a self-selected group of people who pool their money into a fund from which members can borrow. The money is paid back with interest, causing the fund to grow. The regular savings contributions to the Association are deposited with an end date in mind for distribution of all or part of the total funds (including interest earnings) to the individual members, usually on the basis of a formula that links payout to the amount saved. This lump sum distribution provides a large amount of money that members can then use as they want, without restriction.
224261796|NCT02406560|DRUG|tafamidis|fasted
224261797|NCT02406560|DRUG|tafamidis|high fat meal
224261798|NCT02406560|DRUG|tafamidis|
224261799|NCT04543682|DRUG|0.125 ng/kg/min Iloprost|Drug administration through a catheter (inserted at the end of the surgical procedure) begins 24±2 hours after surgery: 0.125 ng/kg/min Iloprost for a duration of 24 hours
223681523|NCT06198140|OTHER|myofascial release|In control group the individuals will receive only myofascial release on ankle planterflexors. The subjects who will receive Myofascial Release will be positioned in prone with the treatment area exposed. The treatment will be applied by the therapist standing at the side of the patient. Then technique will be applied with different levels by following longitudinal movements according to subject's tolerance for duration of 3 minutes in each sitting. Patients will be given a rest time after each level in order to allow the tissue to soften. This treatment protocol will be 6 times/week for 4 weeks in the hospital setting.
223681524|NCT04198818|DRUG|HH2710|HH2710 is a small molecule that potently inhibits both ERK1 and ERK2 protein kinases in the nanomolar range. The kinase selectivity assessment towards a panel of over 400 protein kinases showed that HH2710 barely inhibited other kinases at a concentration up to 1 μM, except the substantial inhibition against ERK1 (MAPK1), ERK2 (MAPK2) and the MAPK pathway upstream kinases MEK and RAF proteins.
223774206|NCT05323383|BEHAVIORAL|Self-hypnosis|Participants in self-hypnosis will listen to a 20-minute audio-guided hypnosis practice with an induction phase, followed by suggestions tailored towards shifts in affect and decentering, and then a re-alerting with post-hypnotic suggestions phase.
224261800|NCT04543682|DRUG|0.25 ng/kg/min Iloprost|Drug administration through a catheter (inserted at the end of the surgical procedure) begins 24±2 hours after surgery: 0.25 ng/kg/min Iloprost for a duration of 24 hours
224261801|NCT04543682|PROCEDURE|open reduction and internal fixation with an angular stable plate (PHILOS)|open reduction and internal fixation with an angular stable plate (PHILOS)
224261802|NCT04322292|DRUG|C-CAR088|"Autologous BCMA-directed CAR-T cells, single infusion intravenously at a target dose of 1.0-9.0 x 10\^6 anti-BCMA CAR+T cells/kg.~Divided into three dose ranges of low(1.0-3.0×10\^6 CAR+T cells/kg),medium(3.0-6.0×10\^6 CAR+T cells/kg) and high(6.0-9.0×10\^6 CAR+T cells/kg).~Other Name: CBM.BCMA Chimeric Antigen Receptor T cell."
224261803|NCT03876639|OTHER|Application of emulsion|Daily application of the assigned formulation on the non-dominant volar forearm for 4 weeks
224261804|NCT03876639|PROCEDURE|Measurement of physiological skin parameters|Weekly measurement of physiological skin parameters using confocal Raman spectroscopy, Corneometer® CM 825, Sebumeter®, Skin-pH-Meter®, AquaFlux® and Epsilon®
224261805|NCT03876639|PROCEDURE|Tape stripping|Removal of 40 adhesive strips after application of a model drug-loaded emulsion and determination of the transepidermal water loss
224261806|NCT01068821|OTHER|Gel pad|A gel pad (mattress) (approximately 3cm thick) is placed under the patient on top of the usual operating room mattress, directly in contact with patient's skin from buttocks to shoulders with the patient in dorsal lithotomy position under general anesthesia. Time in Trendelenburg's position and time operating are both recorded. The position of two bony landmarks (left anterior superior iliac spine and left acromioclavicular joint) are marked before Trendelenburg's position (30 to 45 degrees below horizontal) and immediately after returning the patient to horizontal position.
224261807|NCT01068821|OTHER|Egg crate foam mattress|An egg-crate foam mattress (approximately 5cm thick) is placed under the patient on top of the usual operating room mattress, directly in contact with patient's skin from buttocks to shoulders with the patient in dorsal lithotomy position under general anesthesia. Time in Trendelenburg's position and time operating are both recorded. The position of two bony landmarks (left anterior superior iliac spine and left acromioclavicular joint) are marked before Trendelenburg's position (30 to 45 degrees below horizontal) and immediately after returning the patient to horizontal position.
224261808|NCT03772821|OTHER|Data collection|Between D0 and D90: local and general complications, demographic, clinical, paraclinical and biological data
224261809|NCT03772821|OTHER|Incision/scar measurement|Between D0 and D90
224323827|NCT05166889|DRUG|Tozorakimab|Administered subcutaneously tozorakimab Dose 2 through Week 52.
224323828|NCT05166889|DRUG|Placebo|Placebo administered subcutaneously, equivalent volume to tozorakimab through week 52.
224261810|NCT04730466|OTHER|Neuropsychological rehabilitation|The intervention can be carried out in the research unit or in the Parkinson's association. Each session will consist of a series of cognitive stimulation tasks aimed at improving attention, perception and processing speed. These tasks will be applied through the NeuronUp cognitive neurorehabilitation platform to achieve maximum homogeneity and objectivity in their application. The program is programmed and is identical for all patients. Performing tasks through the platform allows us to objectively record the performance of each patient in all tasks.
224261811|NCT05928156|OTHER|Myeloma Coach or CLL Coach Mobile App|"Symptom Tracking: Subjects will be asked to track their symptoms on a weekly basis, as well as given the opportunity to track these symptoms whenever they would like. Subjects will receive feedback tailored to their symptom severity with coaching on self management, including encouraging them to reach out to their health care team when symptoms are new, severe or increasing in severity. Subjects will also be able to look at graphs of symptom severity over time and share them with family and their health care team.~Medication Adherence Reminders and Tracking, Activities - tools based on CBT (cognitive behavioral therapy) principles can be utilized at any time to manage emotional distress. Learn - information on cancer, its treatment, self managing physical and emotional symptoms, and supportive resources."
224261812|NCT05928156|OTHER|Springboard Beyond Cancer informational website|Springboard Beyond Cancer (https://survivorship.cancer.gov) is designed to make it easy for those in treatment and post-treatment to access essential information to help them manage ongoing cancer-related symptoms, deal with stress, improve healthy behaviors, communicate better with healthcare teams, and seek support from friends and family.
224323829|NCT05327530|DRUG|Avelumab|Participants will receive avelumab intravenous infusion at a dose of 800 milligrams (mg) once every 2 weeks (Q2W) until unacceptable toxicity, withdraw consent or initiation of a new treatment.
223681525|NCT02551627|DIETARY_SUPPLEMENT|Test Product|MMN fortified beverage powder.
223681526|NCT02551627|DIETARY_SUPPLEMENT|Control|Isocaloric beverage powder without micronutrient fortification.
223681527|NCT06432868|DIETARY_SUPPLEMENT|Solarplast (R)|Daily supplementation for 28 days prior to heavy resistance exercise.
223681528|NCT06432868|DIETARY_SUPPLEMENT|Placebo|Daily supplementation for 28 days prior to heavy resistance exercise.
223681529|NCT01285687|DEVICE|acupuncture|Sterile, disposable, FDA-approved acupuncture needles will be used. Acupuncture will be performed bilaterally. The needles will penetrate the skin to a depth of 5-10mm and will be kept in place for no more than 5 minutes. The acupuncture points will be: Li 4, Li 11, St 44, according to Chinese acupuncture mapping. Treatment will be repeated at least 3 times during the hospital stay. Treatment will start in the pediatrics department approximately two hours after discharge from the postoperative unit. The 2nd treatment will be given on the same evening, approximately 4-8 hours after the 1st treatment and the 3rd treatment will be given the following morning, approximately 12-18 hours after the 2nd treatment. Exact treatment times will be recorded in the patient's file.
223681530|NCT03722043|BEHAVIORAL|Parenting Program|Parents will participate in a 5-week parenting program designed to uniquely work with veteran families. The program will target the following areas: mindful parenting strategies, emotional regulation, positive discipline, positive parenting/attachment, and sleep.
223681531|NCT01285947|DEVICE|Thermage|Radiofrequency Device - specific setting will be determined by the location and thickness of skin. Periorbital: 58-140 J/cm2 Midface: 81-124 J/cm2 Abdomen: 95-181 J/cm
223681532|NCT01285947|OTHER|Needle Application|30-gauge needle insertion into skin
223681533|NCT01285947|DEVICE|VBeam Laser|Pulsed Dye Laser at the following settings: 7.5 J, 0.6ms, 10mm, DCD 30/20
223681534|NCT01285947|DEVICE|Ulthera|"Ultrasound Device at the following settings:~Transducer Frequency Depth Image Depth DS 7-3.0 7 MHz 3.0mm 0-8mm DS 4-4.5 4 MHz 4.5mm 0-8mm DS 7-4.5 7 MHz 4.5mm 0-8mm"
223681535|NCT02568982|OTHER|Exams and questionnaires|Blood sample 24hrs urinary cortisol and salivary cortisol, urinary labstick test, EKG, cardiac ultrasound, cardiac CT-scan, arterial and venous US ophthalmology examination spine X-Ray bone densitometry QoL questionnaires (SF-36, QoLCushing, Beck BDI-II)
223774207|NCT05323383|OTHER|Attention Control|Control participants will listen to a 20-minute natural history recording which was chosen as past research has found that individuals who listen to it report this to be a neutral, but relaxing passage, and it has been used as an effective control condition in previous research.
223681536|NCT03142061|PROCEDURE|Electrochemotherapy|Bleomycin plus local electroporation of cutan accessible tumor tissue in patients with advanced inoperable vulva carcinoma
223681537|NCT05222243|DRUG|Direct pulp capping with calcium hydroxide|Capping exposed dental pulps during cavity preparation in primary teeth with calcium hydroxide
223681538|NCT05222243|DRUG|Direct pulp capping with MTA|Capping exposed dental pulps during cavity preparation in primary teeth with MTA
223681539|NCT05222243|DRUG|Direct pulp capping with Formocresol|Capping exposed dental pulps during cavity preparation in primary teeth with zinc oxide eugenol after medication with formocresol
223681540|NCT05983887|OTHER|Therapeutic Climbing|The protocol consists of using an in-door climbing wall as an complementary therapeutic intervention model.
223681541|NCT04920227|PROCEDURE|phacoemulsification;|Group A: class combined with phacoemulsification
223681542|NCT00003101|BIOLOGICAL|filgrastim|
223681543|NCT00003101|DRUG|busulfan|
223681544|NCT00003101|DRUG|lomustine|
223681545|NCT00003101|DRUG|procarbazine hydrochloride|
223681546|NCT00003101|DRUG|thiotepa|
223681547|NCT00003101|DRUG|vincristine sulfate|
223681548|NCT00003101|PROCEDURE|autologous bone marrow transplantation|
223681549|NCT00003101|PROCEDURE|peripheral blood stem cell transplantation|
223681550|NCT05346432|DIETARY_SUPPLEMENT|PS23|PS23 belongs to Lactobacillus paracasei group.Probiotic capsules contain 10 billion CFU (colony forming units) of PS23
223835256|NCT06285617|DRUG|6-weeks predisone|20 and 10 mg prednisone in the morning and afternoon, respectively, daily in the first week, and then reduced by 5 mg/week from the second week until withdrawal in the sixth week.
223681551|NCT01575288|DRUG|Placebo|100g maltose 1/day
223681552|NCT01575288|DRUG|High-dose trehalose|100g 1/day
223835257|NCT02887560|PROCEDURE|transoesophageal echocardiography|
224261813|NCT03953287|DRUG|Paracetamol|A randomized, cross over design
224261814|NCT05041361|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|Cognitive Behavioral Therapy (CBT) is a behavioral (psychotherapeutic) intervention for major depressive disorder (MDD). A highly trained masters' or PhD-level clinician will administer 8 weekly CBT sessions (\~50 minutes each), following the standard cognitive behavioral therapy for depression protocol.
224261815|NCT05041361|DEVICE|Whole-Body Hyperthermia (WBH)|Whole-body hyperthermia (WBH) will be administered by trained research assistants. Preparation for the WBH, the WBH session, and cool down will last 3.5-4 hours, with active WBH lasting up to approximately 140 minutes. WBH will take place in an infrared sauna dome, and the active heating phase will last until the participants has achieved a core (rectal) temperature of 101.3 F.
224261816|NCT00000261|DRUG|30% Nitrous oxide|
224261817|NCT00000261|OTHER|Placebo|No drug (100% oxygen)
224261818|NCT00000261|DRUG|0.2% sevoflurane|
224323830|NCT05327530|DRUG|Sacituzumab Govitecan|Participants will receive sacituzumab govitecan intravenous infusion at dose of 10 milligrams per kilogram (mg/kg) of body weight once a week (Q1W) on Day 1 and 8 of 21-day treatment cycles, in combination with avelumab 800 mg Q2W, until unacceptable toxicity, withdraw consent or initiation of a new treatment.
223681553|NCT03628261|DEVICE|Serious Game|Surface EMG detection for the myoelectric control of the EMG-based serious games and for the EMG assessment during gait will be performed with a wireless system.This device is composed of seven modules (sensor units), each detecting and transmitting two bipolar EMGs at 2 kilo Hertz (kHz). During the evaluation protocol EMGs will be detected from peroneus longus, gastrocnemius medialis, soleus and tibialis anterior muscles of both limbs using pre-gelled electrodes.
223681554|NCT03628261|OTHER|physical therapy|Children receive the regular rehabilitation for the treatment of ankle plantar flexor muscle overactivity and the paresis of ankle dorsal flexor muscle
223681555|NCT02179775|DRUG|propranolol|
223681556|NCT02179775|DRUG|Quince's oxymel|
223681557|NCT02179775|DRUG|placebo|
223681558|NCT03289364|DEVICE|Penguin Cold Caps|Patients will wear Penguin Cold Cap scalp cooling device prior to each chemotherapy administration, during administration, and for four hours following administration.
224261819|NCT00000261|DRUG|0.4% sevoflurane|
224261820|NCT00000261|DRUG|0.6% sevoflurane|
224261821|NCT05675033|DRUG|Serplulimab and Bevacizumab injection|"Serplulimab, 4.5mg/kg, intravenous injection, D1,Q21, until the disease progressed or showed intolerable side effects.~Bevacizumab injection, 7.5mg/kg, intravenous injection, D1, Q21, until the disease progressed or showed intolerable side effects.~Platinum-based chemotherapy: pemetrexed combined with carboplatin, D1-2, Q21, a total of 4 cycles."
223681559|NCT04969003|BEHAVIORAL|Short videos|Intervention videos will each be of 90-second duration and feature four underage professionals (ages 16) acting as simulated patients. All videos will focus on an empowered presenter with depression sharing their personal story regarding depression and describe how social supports from family, friends, and community, as well as professional help assisted them in overcoming symptoms of their illness. The actors will include a transgender male, a cis-gender male, a transgender female, and a cis-gender female.
223681560|NCT03361579|OTHER|Education|c.p. intervention description
223681561|NCT00997438|DIETARY_SUPPLEMENT|Lipoic Acid|300 mg Lipoic acid tablets from Vital Nutrients
223681562|NCT02129218|OTHER|questionnaire administration|Ancillary studies including three day food record, twenty-four hour dietary recall, and a food acceptability questionnaire.
223681563|NCT02129218|OTHER|laboratory biomarker analysis|Correlative studies
223681564|NCT02129218|BEHAVIORAL|Standard Dietary Intervention|Participants will be contacted by a nutritionist, in person every 2 weeks with phone contact on the alternating weeks. At the initial visit, each participant will be given verbal and written patient education materials, including low glycemic load diet recipes, meal plans, food preparation, and grocery shopping information. Individual instruction will be tailored to their baseline dietary preferences (e.g. vegan, allergies, etc).
223681565|NCT02129218|BEHAVIORAL|Intensified Dietary Intervention|Patients will be contacted weekly, in person, by a nutritionist . Participants will take part in a cooking demonstration at the time of their initial visit. The demonstration will be hands-on and participants will be able to sample foods and recipes. In addition to grocery shopping information, participants will be accompanied by a nutritionist to their local grocery store to practice new shopping habits for their target dietary glycemic load. Each participant will also receive weekly random phone calls to assess his or her progress.
223681566|NCT02129218|BEHAVIORAL|Low glycemic load|
223681567|NCT02129218|BEHAVIORAL|Medium Glycemic Load|
223681568|NCT00526877|DRUG|Risperidone|Risperidone long-acting injectable 25 milligram (mg) or 37.5 mg or 50 mg will be administered intramuscularly (into a muscle) depending on Investigator's discretion every 2 weeks for 24 weeks.
223774208|NCT06009952|OTHER|Cryolipolysis and cavitation devices with vegan diet|"Cryolipolysis: In all cases of group A, (OPTIMIZED CRYOLIPOLYSIS 360 DEVICE, model: AF2000-02, made in china) uses a vacuum-based huge applicator (Cool Max) and vacuum medium applicators (either CoolCore or Cool- Curveþ) for the abdomen (30 minutes session twice monthly for three successive3 months).~•Cavitation: in all cases of group B, (CAVITATION DEVICE, Item No.:AU61, Made in china) of 45 KHz frequency (30 min twice weekly for three successive3 months)."
224261822|NCT01112761|DEVICE|Transcranial direct current stimulation|Each type of stimulation will be administered with a time interval of a week in between to prevent any carryover affects.
224261823|NCT01642277|DRUG|Solifenacin|5 mg for 4 weeks with option to increase to 10 mg for an additional 8 weeks
224323831|NCT05327530|DRUG|M6223|Participants will receive M6223 (anti-T cell-immuno-receptor with Ig and ITM domains \[anti-TIGIT\]) intravenous infusion at dose of 1600 mg Q2W in combination with avelumab 800 mg Q2W, until unacceptable toxicity, withdraw consent or initiation of a new treatment.
224323832|NCT05327530|DRUG|NKTR-255|Participants will receive NKTR-255 intravenous infusion at a dose of 3 micrograms per kilogram body weight (mcg/kg) once every 4 weeks (Q4W) in combination with avelumab 800 mg Q2W, until unacceptable toxicity, withdraw consent or initiation of a new treatment.
224323833|NCT06491914|DRUG|Aflibercept 8 mg|Administered by intravitreal (IVT) injection
224323834|NCT05158387|DRUG|Tozorakimab|Administered subcutaneously tozorakimab Dose 1 and placebo through Week 52.
224323835|NCT05158387|DRUG|Tozorakimab|Administered subcutaneously tozorakimab Dose 2 through Week 52.
224261824|NCT00924547|DIETARY_SUPPLEMENT|Docosahexanoic Acid Supplement|"The active treatment will consist of Martek's chewable DHA capsules containing 200mg in each capsule. The treatment will be provided as approximately 25mg/kg/day and 35mg/kg/day.~These dosages will be divided BID-TID and will be given for 4 weeks."
224261825|NCT00924547|DIETARY_SUPPLEMENT|Placebo|Placebo identical to active treatment.
224261826|NCT01932177|DRUG|Everolimus and sorafenib|Everolimus will be given alone during a 2 week run-in period before starting sorafenib. Subsequently sorafenib will be administered twice a day while everolimus will be given once a day continuously.
224261827|NCT01932177|DRUG|Everolimus and sorafenib|Sorafenib will be given alone during a 2 week run-in period before starting everolimus. Subsequently sorafenib will be administered twice a day while everolimus will be given once a day continuously.
224261828|NCT01932177|DRUG|Everolimus and sorafenib|Bid sorafenib will be given every other week alternating with 1 week qd everolimus. Doses will be escalated.
223681569|NCT03396393|DRUG|Dihydroartemisinin tablet|DHA tablet
223681570|NCT03396393|DRUG|Placebo tablet|Placebo tablet
223681571|NCT06423729|DRUG|Nicorandil 10 MG|Patients will receive oral Nicorandil 10 MG twice daily in addition to 2nd generation sulfonylureas , for 3 months.
223681572|NCT01094639|PROCEDURE|Scaling root planing|Deep gum cleaning with local anesthesia
223681573|NCT01094639|PROCEDURE|Supragingival Prophylaxis|Plaque removal
223681574|NCT06318962|BEHAVIORAL|Aviva|Digital phone app for BCBT
223681575|NCT04489160|DRUG|C1 Inhibitor, Human|6000 IU C1-INH
223681576|NCT04489160|DRUG|Placebo|0.9% saline
223681577|NCT03950037|DRUG|Albendazole|Albendazole; 15 mg/k/d divided in two doses (morning and evening), for 30 days, with a ceiling in 1200 mg/d.
223681578|NCT00005863|BIOLOGICAL|filgrastim|
223681579|NCT00005863|DRUG|cytarabine|
223681580|NCT00005863|DRUG|daunorubicin hydrochloride|
223681581|NCT00005863|DRUG|etoposide|
223681582|NCT00005863|DRUG|fludarabine phosphate|
223681583|NCT00005863|DRUG|tretinoin|
223681584|NCT00674167|DRUG|Docetaxel|Three cycles of chemotherapy will be administered before surgery with docetaxel at 30 mg/m² on day 1 and 8 in a 21 day treatment cycles.
223681585|NCT00674167|DRUG|Cisplatin|Three cycles of chemotherapy will be administered before surgery with cisplatin at 30 mg/m² on day 1 and 8 in a 21 day treatment cycle.
223681586|NCT00674167|DRUG|Capecitabine|Three cycles of chemotherapy will be administered before surgery with capecitabine at 750 mg/m² twice daily from day 1 to 14 in a 21 day treatment cycle.
223681587|NCT00421291|BEHAVIORAL|Education|
223681588|NCT00127595|DRUG|gemcitabine, oxaliplatin|
223681589|NCT03505671|PROCEDURE|Acupuncture Therapy|Undergo acupuncture therapy
223774209|NCT05585216|DRUG|platelet-rich plasma|intra-articular combination injections of platelet-rich plasma and hyaluronic acid or intra-articular combination injections of PRP combined with leg swing and quadriceps strengthening exercise
224261829|NCT01932177|DRUG|Everolimus and sorafenib|Sorafenib will be given twice a day for 3 days-on 4 days-off while everolimus will be administered continuously on a daily basis. Doses will be escalated.
224261830|NCT05664087|DRUG|Dental diode laser device Paiwei™（Zhengzhou Gata biotechnology Co.,Ltd.,China） which was 650-670nm with a power of 160mw-220mw.|The tooth extraction sockets were filled with photosensitizer methylene blue. The guide head of the laser periodontal therapy instrument (Dental diode laser device Paiwei™（Zhengzhou Gata biotechnology Co.,Ltd.,China） which was 650-670nm with a power of 160mw-220mw.) was placed in the tooth extraction sockets to probe and move around the tooth extraction sockets for 1 minute. At the end of irradiation, a cotton ball dipped in saline was used to wipe the guide head and rinse the photosensitizer out of the socket
223681590|NCT03505671|OTHER|Best Practice|Receive usual care
223681591|NCT03505671|OTHER|Quality-of-Life Assessment|Ancillary studies
223681592|NCT03505671|OTHER|Questionnaire Administration|Ancillary studies
223681593|NCT01788176|DRUG|Zoledronic acid|One single dose of 5mg intravenous infusion of zoledronic acid (interventional group)
224261831|NCT03136627|DRUG|Tivozanib|Tivozanib (AV-951): Phase 1b study and Phase 2a study: Subjects will receive 1 dose of tivozanib daily for 21 days followed by a 7 day rest period (1 cycle = 4 weeks).
224261832|NCT03136627|DRUG|Nivolumab|Nivolumab: Phase 1b study and Phase 2a study: All subjects will receive IV nivolumab 240 mg every 2 weeks administered over 1 hour.
223681594|NCT01788176|DRUG|Placebo|one single intravenous infusion of 100ml of saline.
223681595|NCT05563480|DRUG|TQB2618 Injection, Pempulimab Injection, Cisplatin Injection, Gemcitabine Hydrochloride Injection|TQB2618 injection: Anti-TIM-3 monoclonal antibody; Penpulimab injection: Humanized Monoclonal Antibody to Programmed Cell Death Protein 1 (PD-1)
223681596|NCT05563480|DRUG|Penpulimab injection, Cisplatin Injection, Gemcitabine Hydrochloride Injection|Penpulimab injection: Humanized Monoclonal Antibody to Programmed Cell Death Protein 1 (PD-1)
223681597|NCT05563480|DRUG|TQB2618 injection; Penpulimab injection|TQB2618 injection: Anti-TIM-3 monoclonal antibody; Penpulimab injection: Humanized Monoclonal Antibody to Programmed Cell Death Protein 1 (PD-1)
223681598|NCT01142518|DRUG|Interferon beta 1a|Interferon beta 1a was administered at a dose of 44 μg x 3 as a subcutaneous self-injection.
223681599|NCT02125474|RADIATION|[177Lu] DOTA-TATE|We have designed a one-arm phase II prospective sequential clinical trial to assess the therapeutic efficacy of 177-Lu-\[DOTA 0, Tyr 3\] octreotate (177-Lu- DOTATATE) applied intravenously in three separate doses to patients with inoperable progressive WDNET.
223681600|NCT05004454|DIETARY_SUPPLEMENT|Bacillus subtilis BS50 spore preparation|Subjects will consume 1 capsule containing 2x10⁹ CFU of a Bacillus subtilis BS50 spore preparation once daily for 42 days.
223681601|NCT05004454|DIETARY_SUPPLEMENT|Maltodextrin|Subjects will consume 1 capsule containing maltodextrin once daily for 42 days.
223681602|NCT00586729|DEVICE|Vashe|Antimicrobial irrigant
223681603|NCT00586729|DRUG|Mafenide acetate|Antimicrobial solution
223681604|NCT02038829|DRUG|Placebo|Placebo
223681605|NCT02038829|DRUG|SUN101 3 mcg|SUN-101 3 mcg bid
223681606|NCT02038829|DRUG|SUN-101 6.25 mcg|SUN-101 6.25 mcg bid
223681607|NCT02038829|DRUG|SUN-101 12.5 mcg|SUN-101 12.5 mcg bid
223681608|NCT02038829|DRUG|SUN-101 50 mcg|SUN-101 50 mcg bid
223681609|NCT02038829|DRUG|Aclidinium|Aclidinium 400 mcg bid
224261833|NCT06627829|DEVICE|Surgically facilitated orthodontics therapy (SFOT) using allograft|Participants will receive Surgically facilitated orthodontics therapy (SFOT) along with bone grafting using particulate allograft and collagen membrane, prior to orthodontics treatment.
224261834|NCT06627829|DEVICE|Surgically facilitated orthodontics therapy (SFOT) using xenograft|Participants will receive SFOT using particulate xenograft and collagen membrane, prior to orthodontics treatment.
224261835|NCT06627829|DEVICE|Usual care|Participants will have conventional orthodontics treatment with Invisalign aligners, without any surgical intervention
224261836|NCT02906540|PROCEDURE|Transpubic symphysis reset therapy group|The patients in the treatment group will undergo daily transpubic symphysis reset therapy for 7 consecutive days.
224261837|NCT02906540|PROCEDURE|Physiotherapy group|The patients in the control group will undergo physiotherapy and a sham treatment.
224261838|NCT02523963|OTHER|family work shop|"1. The family work shop has 5 courses, with 6 families in one course.~2. One course of intervention: 2-3 hours per session, one time per week, for a total of 6 sessions in 6 week periods"
224261839|NCT00147563|DRUG|Eplerenone|
224261840|NCT02091713|OTHER|Functional movement screen|The subjects will undergo movement and balance screens, measures of power, demographic data and biopsychosocial measures. Injury data will be collected through physician exam, self-report, profile data, and healthcare utilization data. Injury data will be collected at baseline and for six iterations, every 60 days, over the course of one year following baseline. Based on the data collected, clinical prediction rules will be used to develop computerized algorithm to predict injury risk in these populations.
224261841|NCT05111223|DEVICE|Real transcranial magnetic stimulation (TMS) before conditioning|Real TMS will be applied using the MagVenture MagPro X100 stimulator with the active side of the Cool-B65 A/P coil before the conditioning phase of the task.
224261842|NCT05111223|DEVICE|Real transcranial magnetic stimulation (TMS) before devaluation test|Real TMS will be applied using the MagVenture MagPro X100 stimulator with the active side of the Cool-B65 A/P coil before the devaluation test phase of the task.
224261843|NCT05111223|DEVICE|Sham transcranial magnetic stimulation (TMS)|Sham TMS will be applied using the MagVenture MagPro X100 stimulator with the placebo side of the Cool-B65 A/P coil.
224261844|NCT02545803|DEVICE|Near-Infrared Spectroscopy (NIRS)|Near infrared spectroscopy (NIRS) is a non-invasive technique that uses near infrared light between 700 and 1100nm which penetrates several centimeters through skin and bone structures. Light is absorbed by chromophores. There are multiple chromophores which can be detected in the NIR spectrum such as water, lipids, melanin, myoglobin, oxygenated hemoglobin and deoxygenated hemoglobin. Each chromophore has a specific absorption spectrum. By using different wavelengths, it is possible to differentiate chromophores. The difference between oxygenated hemoglobin and deoxygenated hemoglobin can be calculated using the modified Beer-Lambert law, resulting in a numeric value which is a representation of the regional cerebral oxygen saturation
224261845|NCT06356103|DIETARY_SUPPLEMENT|Whey-Based Partially Hydrolyzed Formula|Peptamen junior, 100 kcal/100 ml (Nestlé Health Science, Vevey, Switzerland).
224261846|NCT06356103|DIETARY_SUPPLEMENT|received 50% of their caloric requirements as isocaloric polymeric formula (standard ) and 50% standard nutritional feeding according to ESPGHAN guidelines|protein and micronutrient requirements according to the recommended dietary allowance (RDA)
224261847|NCT03605342|DRUG|Buprenorphine|Participants will be started at a dose of 2mg/0.5 mg BUP/NLX and this dose will be increased as needed for stabilization of opioid withdrawal symptoms up to 24 mg per day, which is standard practice.
224261848|NCT03605342|BEHAVIORAL|Cognitive Processing Therapy (CPT)|CPT-C is a manualized, 12-session 1:1 cognitive therapy that has been designed for patients with PTSD. In this study the sessions will be conducted weekly. CPT-C uses Socratic questioning targeting distorted cognitions such as self-blame, hindsight bias, and other guilt cognitions. CPT-C is focused on the cognitive components of the therapy without exposure.
224261849|NCT03605342|BEHAVIORAL|Individual Drug Counseling (IDC)|IDC will serve as the control group. The current standard of treatment for Veterans entering buprenorphine maintenance is to do drug counseling. Standard counseling is the primary means to achieve goals. IDC uses a semi-structured, time-limited addictions-counseling model in a 1:1 setting. The IDC manual provides an organized, concise version of what is currently practiced by most addiction counselors.
224261850|NCT05234788|PROCEDURE|Transfemoral Renal Denervation|Radiofrequency renal denervation using the Iberis Renal Denervation System treated via femoral artery access
224261851|NCT05234788|PROCEDURE|Transradial Renal Denervation|Radiofrequency renal denervation using the Iberis Renal Denervation System treated via radial artery access
224261852|NCT05734677|BEHAVIORAL|Emotion regulation group|90 minute sessions once a week for 8 weeks, in groups of eight participants. DBT, MBT and MBI inspired, psychoeducative intervention.
224261853|NCT04254887|PROCEDURE|EPBD|Small incision of the duodenal nipple + EPBD
224323836|NCT05158387|DRUG|Placebo|Placebo administered subcutaneously, equivalent volume to tozorakimab through week 52.
223835258|NCT00649480|DRUG|BALSALAZIDE DISODIUM CAPSULES, 750 MG|3x750mg, single dose fed
223835259|NCT00649480|DRUG|COLAZAL® Capsules 750 mg|3x750mg, single dose fed
224261854|NCT04254887|PROCEDURE|EST|Large incision of the duodenal nipple + EPBD
224261855|NCT06216561|DRUG|CRS-HIPEC + LSTA1|LSTA1 given with hyperthermic intraperitoneal chemotherapy (HIPEC) at time of cytoreductive surgery (CRS)
224261856|NCT06216561|PROCEDURE|CRS-HIPEC alone|Hyperthermic intraperitoneal chemotherapy (HIPEC) alone (without LSTA1) at time of cytoreductive surgery (CRS)
224261857|NCT02281994|DEVICE|Pulsed Electromagnetic Feld (PEMF) Orthofix Cervical-Stim Model 2205OD|Active devices emit PEMF signal; control devices do not emit PEMF signal.
224261858|NCT00440167|DRUG|Gemcitabine|Gemcitabine 1000 mg/m², d 1, 8 , 15, q d28
224261859|NCT00440167|DRUG|Capecitabine|"Capecitabine 2 x 1000 mg/m²/ d oral, d 1 - 14 followed by 7 days Pause (Flat Dosing)"
224261860|NCT00440167|DRUG|Erlotinib|Erlotinib 150 mg/d oral, daily without break
224261861|NCT05028608|DRUG|Elinzanetant (BAY3427080)|Elinzanetant given orally as a single dose in Period 1 and in Period 2.
224261862|NCT05028608|DRUG|Midazolam|Midazolam given orally as single dose in Period 1 and in Period 2.
224261863|NCT05028608|DRUG|Carbamazepine|Carbamazepine given orally twice daily in Period 2 .
224261864|NCT02086214|DEVICE|Proprioceptive pressure therapy|Proprioceptive pressure therapy using a a LYCRA® compressive sleeve initially used in burn therapy : 15 to 25 mmHg.
224261865|NCT02086214|DEVICE|Control|LYCRA® non-compressive sleeve initially used in burn therapy : \< 5 mmHg.
224261866|NCT05840133|DIAGNOSTIC_TEST|No intervention was required for patients or control group in this study|The patient was treated normally and no intervention was required in this study
224261867|NCT05572437|DEVICE|Music Therapy|Patients randomized to the treatment with music group (classical music), after assessment of anxiety using the APAIS scale, will be given headphones and classical music will be played from their stay in the pre-anesthesia room, during surgery and in the PACU.
224261868|NCT00908128|DRUG|Mycophenolate Mofetil|Mycophenolate Mofetil 500 mg Tablet
224261869|NCT00908128|DRUG|CellCept®|CellCept® Tablets, 500 mg
224261870|NCT00796328|DRUG|Phenylephrine infusion|Up-down, biased coin design
224261871|NCT02557347|BEHAVIORAL|Aggressive fluid management|nursing education, dietary advice, extra hypertonic dialysis cycles
224261872|NCT02842853|BIOLOGICAL|Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine|0.5 mL, Intramuscular
224261873|NCT02842853|BIOLOGICAL|Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine|0.5 mL, Intramuscular
223681610|NCT04916782|OTHER|Quality of life Questionnaire|Quality of life questionnaire
223681611|NCT02705027|DEVICE|Freka®-Trilumina versus Freka®-EasyIn|Direct placement of probe via endoscope
223681612|NCT02579928|DRUG|Ketamine|A single dose of 0.5mg/kg of Ketamine will be administered Intravenously during 40 minutes in the Hospital Research Unit of YNHH. The subject will be monitored continuously during the procedure, and every hour for three hours after the infusion.
223681613|NCT02579928|DRUG|Midazolam|A single dose of 0.045mg/kg of Midazolam will be administered intravenously during 40 minutes in the Hospital Research Unit of YNHH. The subject will be monitored continuously during the procedure, and every hour for three hours after the infusion.
223681614|NCT06415734|DEVICE|rTMS|LF-rTMS of M1 contralateral to the brain lesion for 20 min, 1200 pulses, 120% RMT, treatment cycle of 5 days
223681615|NCT03659786|OTHER|CC-Test|Classification of the oocyte/embryo based on the expression pattern observed in the cumulus cells
223681616|NCT02172066|BEHAVIORAL|Narrative Exposure Therapy (NET)|
223681617|NCT00209508|DRUG|GPI 1485|
223774210|NCT03411525|BEHAVIORAL|Commitment Invitation for Clinicians (Clinician Intervention)|Clinicians will be invited to commit to follow 3 Choosing Wisely® recommendations. Those that choose to commit will sign a written document, appear on in-clinic posters along with their colleagues who have committed to the recommendations, have access to point-of-care Choosing Wisely® patient education handouts, and receive weekly emails with decision support resources.
224261874|NCT03595800|PROCEDURE|Hematopoietic stem cells transplantation|Allogeneic Hematopoietic stem cells transplantation
224261875|NCT04594577|DEVICE|Fluispotter|Fluispotter automated blood sampling system applied for venous blood sampling of 20 10 μL samples in a 20 hours sampling session.
223681618|NCT03654027|DRUG|Anlotinib Plus Docetaxel|Anlotinib (12mg QD PO d1-14, 21 days per cycle) and Docetaxel (75mg/m2 IV d1)
223681619|NCT03654027|DRUG|Docetaxel|Docetaxel (75mg/m2 IV d1)
223681620|NCT05076591|DRUG|IMM2902|a recombinant bispecific monoclonal antibody with high affinity to the dual targets, HER2 and CD47
223681621|NCT04808284|DEVICE|Transcranial direct-current stimulation|A single tDCS session will be delivered to the supplementary motor area (SMA) by a DC stimulator (NeuroConn, Germany). During stimulation, a pair of saline-soaked sponge electrodes (surface 35 cm²) will be used, with one electrode (anode) placed 1,8 cm forward Cz and the other electrode (cathode) over the right supraorbital region, according to the International 10-20 EEG system. Current intensity will be ramp up for 30 seconds until reaches 2 mA, and after 30 minutes current intensity will be ramp down for 30 seconds.
223681622|NCT04808284|DEVICE|Transcranial direct-current stimulation|A single tDCS session will be applied bilaterally over the dorsolateral prefrontal cortex (DLPFC) by a DC stimulator (NeuroConn, Germany). During stimulation, a pair of saline-soaked sponge electrodes (surface 35 cm²) will be placed over F3 (anode) and F4 (cathode), according to the International 10-20 EEG system. Current intensity will be ramp up for 30 seconds until reaches 2 mA, and after 30 minutes current intensity will be ramp down for 30 seconds.
223681623|NCT04808284|DEVICE|Sham Transcranial direct-current stimulation|A single Sham-tDCS session will be applied bilaterally over the dorsolateral prefrontal cortex (DLPFC) or over the supplementary motor area (SMA) by a DC stimulator (NeuroConn, Germany). A pair of saline-soaked sponge electrodes (surface 35 cm²) will be placed according to the International 10-20 EEG system. For SMA , one electrode (anode) will be placed 1,8 cm forward Cz and the other electrode (cathode) over the right supraorbital region. For DLPFC, electrodes will be placed over F3 (anode) and F4 (cathode). Current intensity will be ramp up for 30 seconds until reaches 2 mA, and after 30 seconds current intensity will be ramp down for 15 seconds.
223681624|NCT00000434|BEHAVIORAL|Fit and Strong!|Fit and Strong! is a multi-component exercise and health education program that includes flexibility, aerobic conditioning, strength training, and group discussion/problem solving for lifestyle change.
224261876|NCT02873832|BIOLOGICAL|Blood sample|
224261877|NCT02873832|OTHER|Flow cytometry|
224261878|NCT02873832|OTHER|western blot|
224261879|NCT04089553|DRUG|AZD4635|"In Module 1, participants will receive AZD4635 75 mg capsule orally QD for first 14 days and thereafter will continue to receive 75 mg orally QD Q4W.~In Module 2, participants will receive AZD4635 50 mg / 75 mg capsule orally QD Q2W of 28-day cycle for the first 4 doses and Q4W thereafter.~In both modules, participants will receive treatment until will derive clinical benefit as judged by the investigator or until confirmed disease progression, unacceptable toxicity, started alternative anticancer therapy, withdrawal of consent, or lost to-follow-up, whichever occurs first."
224261880|NCT04089553|DRUG|Oleclumab|In Module 2, participants will receive oleclumab 1500 mg IV (solution for infusion after dilution, 50 mg/mL) Q2W of 28-day cycle for the first 4 doses and Q4W thereafter until will derive clinical benefit as judged by the investigator or until confirmed disease progression, unacceptable toxicity, started alternative anticancer therapy, withdrawal of consent, or lost to-follow-up, whichever occurs first.
224261881|NCT04089553|DRUG|Durvalumab|In Module 1 after monotherapy of AZD4635, participants will receive durvalumab 1500 mg IV (solution for infusion after dilution, 50 mg/mL) Q4W until will derive clinical benefit as judged by the investigator or until confirmed disease progression, unacceptable toxicity, started alternative anticancer therapy, withdrawal of consent, or lost to-follow-up, whichever occurs first.
224261882|NCT02045849|DRUG|GSK2140944 capsule|Immediate release capsule containing GSK2140944 and inactive formulation excipients with a unit dose strength of 500 mg
224261883|NCT02045849|DRUG|GSK2140944 tablet|Immediate release tablet containing GSK2140944 and inactive formulation excipients with a unit dose strength of 750 mg
224261884|NCT02045849|DRUG|Itraconazole capsule|Capsule containing Itraconazole with a unit dose strength of 100 mg
224261885|NCT01064960|DEVICE|Philips MR-guided HIFU system|HIFU is the use of focused ultrasound energy to penetrate through soft tissue and causes localized high temperatures (55°C to 70°C) for a few seconds within the target producing well defined regions of protein denaturation, irreversible cell damage, and coagulative necrosis.
223681625|NCT02328911|DEVICE|Laser treatment|Laser energy will be applied to the skin of the back and feet manually by physician though a device with a movable head, in contact with the skin, that emits therapeutic dual-wavelength infrared laser energy as well as red visible light.
223681626|NCT02328911|DEVICE|Sham treatment|A sham treatment will be applied to the skin of the back and feet manually by physician though a device with a movable head, in contact with the skin, that emits only red visible light.
223681627|NCT02752971|DRUG|Bupivacaine|
223681628|NCT02752971|DRUG|Sodium diclofenac|
223681629|NCT04561427|OTHER|Study of Sleep architecture in children with narcolepsy|Evaluate the cognitive performances, the effects of narcolepsy treatments on sleep architecture and the metabolic status of these children
223681630|NCT05161754|PROCEDURE|Hemostasis|Hot hemostasis include bipolar and monopolar diathermy. Cold hemostasis include surgical knotting of the tonsil pillar and compression.
223681631|NCT04601831|RADIATION|Focal radiation therapy (RT)|"Radiation therapy for phase II:~Definitive 40-50 Gy EQD2 (i.e. 30 Gy in 5 fractions)~Hypofractionated regimen (i.e. 5 fractions in 1-2 weeks) recommended, but other fractionation schemes (10-20 fractions in 2-4 weeks) allowed."
223681632|NCT00437970|DRUG|Pioglitazone|15mg of Pioglitazone taken orally twice a day
223681633|NCT00437970|DRUG|Metformin|500 mg of Metformin taken orally twice a day
223681634|NCT03691324|OTHER|Inhalation technique training and discharge service|Patient drug counselling one-to-one, focusing on inhalation drugs and technique
223681635|NCT06526468|DEVICE|Artificial Intelligence|AI technology will provide novel imaging markers and generate a radiology report with relevant key slice imaging and evaluation results
224261886|NCT01798264|DRUG|ITCA 650 (exenatide in DUROS)|
224261887|NCT00121901|DRUG|glyceryl nitrate|
224261888|NCT04145427|BEHAVIORAL|Control|"Initial Weight Loss consultation~1.5 hour session on how to do implement healthy diet and then have a 2-week follow-up class. Information on how to maintain a healthy combination protein, fat and vegetables daily will be provided provided.~4 lifestyle coaching sessions~Monthly visits for behavioral and dietary coaching as well as medication management."
224261889|NCT04145427|BEHAVIORAL|LCD|"Initial Weight Loss consultation~1.5 hour session on how to do implement healthy diet and then have a 2-week follow-up class. Information on how to maintain a LCD will be provided provided.~4 lifestyle coaching sessions~Monthly visits for behavioral and dietary coaching as well as medication management."
224261890|NCT02471027|PROCEDURE|Neoadjuvant chemotherapy|There is no uniform schemer,commonly used drugs including carboplatin,cisplatin,paclitaxel,vincristine,bleomycin,fluorouracil,ifosfamide,mitomycin,gemcitabine,and so on.Methods including intravenous chemotherapy and artery intervention chemotherapy,also has not been unified.
224261891|NCT03682601|DRUG|5% sinecatechins ointment|Topical 5% sinecatechins ointment will be applied once daily.
224261892|NCT03682601|DRUG|Placebo|Aquaphor/vehicle
224261893|NCT03682601|DRUG|10% sinecatechins ointment|Topical 10% sinecatechins ointment will be applied three times per week up to once daily.
224261894|NCT04018768|OTHER|ibuprofen 600 mg|MRN ending in an EVEN # will receive ibuprofen 600 mg to be taken every 8 hours (TID) as needed (PRN) and oxycodone/acetaminophen (Percocet) 5 mg/325 mg for pain that is not adequately controlled by the ibuprofen.
223681636|NCT05638919|DRUG|Oral Antiviral|Nirmatrelvir plus ritonavir or molnupiravir
223681637|NCT02405936|PROCEDURE|Gynecologic surgery|The researchers prospectively will collect data on all patients undergoing gynecologic surgery at Kangbuk Samsung Hospital since March, 2015.
223681638|NCT05911425|DRUG|envolizumab , sovalteinib|Envolizumab 300mg, Q2W, day 1, subcutaneous injection Soventinib 200mg, Q2W, once daily, orally Every 2 weeks as a cycle.
223681639|NCT00955383|DRUG|GSK2190915|GSK2190915 is a high affinity 5-lipoxygenase-activating protein (FLAP) inhibitor.
223681640|NCT00955383|DRUG|Placebo|Matching placebo
223681641|NCT02103543|OTHER|physical therapy|physical therapy consisting of core strengthening, low back stretching and range of motion 3 sessions
223774211|NCT03411525|OTHER|Health Education Materials to Patients (Patient Intervention)|During the intervention period, the letter and study information sheet that eligible patients will receive in advance of a scheduled appointment with a participating clinician will also be accompanied by a patient education handout from Consumer Reports that is publicly available and may be relevant to their health and health care. Specifically, patients with type 2 diabetes who are 65 and older will receive a handout about diabetes overtreatment, patients with insomnia or anxiety who are 65 and older will receive a handout about overuse of benzodiazepines and sedative-hypnotics, and male patients who are 75 and older with no history of prostate cancer will receive a handout about overuse of PSA tests to screen for prostate cancer.
223681642|NCT02103543|PROCEDURE|lumbar interlaminar epidural steroid injection|single lumbar interlaminar epidural steroid injection
223681643|NCT02103543|DRUG|epidural steroid injection|Dexamethasone 10mg or Depomedrol 40mg, together with Bupivacaine 0.25% (for 3-5mL total injectate volume)
223681644|NCT00998764|DRUG|Bapineuzumab 0.5 mg/kg|I.V., 0.5 mg/kg, infusion every 13 weeks for a total of 16 infusions.
223681645|NCT03477929|DRUG|Ganirelix Acetate|multiple dose of Ganirelix acetate (0.25mg) are administered when the lead follicle is ≥ 14 mm until hCG criteria are met
224261895|NCT04018768|OTHER|Oxycodone/acetaminophen (Percocet) 5 mg/325|MRN ending in an ODD #: will receive the current standard of care postoperative pain management, which is Percocet 5 mg/325 mg every 6 hours PRN.
224261896|NCT02817867|DEVICE|tDCS|Transcranial direct current stimulation (tDCS)
224261897|NCT02817867|DEVICE|TMS|Transcranial magnetic stimulation
224261898|NCT02817867|DEVICE|tDCS + TMS|Association between tDCS and TMS.
224261899|NCT03572868|OTHER|Evaluation of the long term neurodevelopmental outcome|Evaluation of the long-term neurodevelopmental outcome of newborns who have an isolated transverse cerebellar diameter \< 5th centile during the second or the third trimester of pregnancy.
224261900|NCT03714594|DRUG|Dapagliflozin 10mg|Dapagliflozin inhibits subtype 2 of the sodium-glucose transport proteins (SGLT2) which are responsible for at least 90% of the glucose reabsorption in the kidney. Blocking this transporter mechanism causes blood glucose to be eliminated through the urine.\[
224261901|NCT03714594|DRUG|Saxagliptin 5mg|Inhibits DPP-4 and slows inactivation of incretin hormones, thereby increasing blood concentrations and reducing fasting and postprandial glucose concentrations in a glucose-dependent manner in patients with type 2 diabetes mellitus
224261902|NCT03714594|DRUG|Saxagliptin 5mg + Dapagliflozin 10 mg|Please see Intervention 1 and 2
224261903|NCT03153462|BIOLOGICAL|Axicabtagene Ciloleucel|Axicabtagene Ciloleucel and A conditioning chemotherapy regimen of fludarabine and cyclophosphamide will be administered followed by a single infusion of CAR transduced autologous T cells administered intravenously.
224261904|NCT01403194|DEVICE|CPAP/BiPAP|Subjects will be treated with either CPAP or Bi-PAP for three months.
224261905|NCT05224531|DRUG|CS1 Administration|CS1 delayed-release capsules will be supplied with 160 mg active pharmaceutical ingredient (sodium valproate) per capsule. Three dose levels that will be evaluated in this study; study drug will be administered as uneven, divided doses twice daily in the morning and in the evening (1/3 of the daily dose is to be administered between 7 and 9 am; 2/3 of the daily dose is to be administered between 7 and 9 pm).
224261906|NCT06627465|DEVICE|MS Sherpa|The MS Sherpa application is a CE-certified smartphone application (installed on the mobile phone of the patient) that collects digital biomarkers using tests (\~six minutes/test: self-monitoring questionnaires, smartphone 2-MWT, and a smartphone SDMT) once per week in the home environment of the patient.
224261907|NCT06627465|DEVICE|Neurokeys|The NeuroKeys application is a CE-certified application (installed on the mobile phone of the patient) that passively and continuously monitors keystroke dynamics of everyday typing as a digital biomarker.
224261908|NCT04328935|BEHAVIORAL|WET|The manual is based on established CBT interventions in trauma such as exposure. In short, the treatment is that the participant should be able to approach their intrusive memories and by doing this repeatedly, the memory will give rise to less discomfort.
224261909|NCT01366963|BEHAVIORAL|Seated Measurements|"The following measurements will take place in a seated position:~Ruff 1 \& 7 (visual search and attention processes) Trails A \& B (Tests of scanning, mental flexibility and executive processes) Symbol Digit Modalities Test (SDMT)(attention and psychomotor speed) Stroop Test (naming response to certain stimuli) Verbal Fluency (COWA) Randt Wechsler Test of Adult Reading (WTAR)"
224261910|NCT01366963|BEHAVIORAL|Standing Measurements|"The following will be measured in a standing position (at least 5 minutes)~Orthostatic Vital Signs Randt Paired Words Subtest Digits Forward and Backward Alternate COWA test"
224261911|NCT01366963|BEHAVIORAL|Self-Administered Surveys|Center for Epidemiologic Studies Depression Scale (CES-D) Cognitive-Somatic Anxiety Questionnaire (CSAQ) Subjective Neurocognitive Inventory (SNI)
224261912|NCT05181969|DEVICE|Dextran sulfate absorption (LIPOSORBER® D - Kaneka Pharma Europe NV)|Lipoprotein apheresis Method I
224261913|NCT05181969|DEVICE|Lipid filtration (Octo Nova®, Diamed Medizintechnik)|Lipoprotein apheresis Method II
224261914|NCT05181969|DEVICE|Direct absorption of lipoproteins (DALI®; ADS 4008, Fresenius)|Lipoprotein apheresis Method III
224261915|NCT05181969|DEVICE|Therasorb (TheraSorb® - LDL adsorbers, Miltenyi Biotec)|Lipoprotein apheresis Method IV
224261916|NCT00452920|DRUG|docetaxel|
224261917|NCT00452920|RADIATION|cesium Cs 137|
224261918|NCT00452920|RADIATION|radiation therapy|
224261919|NCT04624360|DRUG|Dexamethasone|Intravenous of Dexamethasone 8 mg post clamping of the umbilical cord
224261920|NCT04624360|OTHER|Placebo|2cc 0.9% Saline
224261921|NCT03317444|DRUG|TRC101|Oral suspension
224261922|NCT03317444|DRUG|Placebo|Oral suspension
224261923|NCT02589301|BIOLOGICAL|Pegfilgrastim|
223681646|NCT03477929|DRUG|Cetrorelix Acetate|multiple dose of Cetrorelix acetate (0.25mg) are administered when the lead follicle is ≥ 14 mm until hCG criteria are met
223681647|NCT01360775|BEHAVIORAL|nutritional counseling|Nutritional counseling to caregivers of dependant patients at nutritional risk, Who were participants in the Home Care program conducted by nurses
224261924|NCT02944617|OTHER|Laboratory Biomarker Analysis|Correlative studies
224261925|NCT02944617|DIETARY_SUPPLEMENT|Micronutrient-Fortified Probiotic Yogurt|Receive Activia yogurt
224261926|NCT02944617|DRUG|VEGF-TKI|Must be received as standard of care chemotherapy
224261927|NCT06130215|OTHER|Simple meal management|"* Regular meal: Total Carbs per Day x 0.6 / 3~* Large meal: Total Carbs per Day x 0.6 / 3 x 1.5~* Small (Snack) meal: Total Carbs per Day x 0.6 / 3 x 1.5"
224261928|NCT06130215|OTHER|Precise meal management|precise carbohydrate counting for each meal
224261929|NCT05091151|DRUG|Intranasal dexmedetomidine at dose of 2 mcg/kg and 4 mcg/kg|Intranasal dexmedetomidine were given 45 minutes before the MRI procedure through both nostrils using a 1 mL syringe.
224261930|NCT05238428|BEHAVIORAL|Trust boost|The investigators adapt the wording of the vaccination invitation to foster trust and increase vaccination acceptance.
223681648|NCT02022774|DRUG|Fimasartan|Fimasartan 60 \~ 120 mg/po take one tablet once a day
223681649|NCT02296879|GENETIC|SAIT301|The treatment period will consist of 21-day cycles. On Day 1 of each cycle, SAIT301 will be administered as an intravenous (IV) infusion.
224261931|NCT04602754|DRUG|BERLIM 25/20 ASSOCIATION|Berlim 25/20 association coated tablet.
224261932|NCT04602754|OTHER|EMPAGLIFLOZIN PLACEBO|Empagliflozin placebo coated tablet.
224261933|NCT04602754|OTHER|ROSUVASTATIN CALCIUM PLACEBO|Rosuvastatin calcium placebo coated tablet.
224261934|NCT04602754|DRUG|EMPAGLIFLOZIN|Empagliflozin 25 mg coated tablet.
224261935|NCT04602754|DRUG|ROSUVASTATIN CALCIUM|Rosuvastatin 20 mg coated tablet.
224323837|NCT00823654|OTHER|Blood draw and questionnaires|"Identify eligible premenopausal patients and obtain informed consent ↓ Register patients at Memorial Sloan Kettering Cancer Center~↓ Baseline evaluation: Blood draw and baseline reproductive health questionnaire (Appendix A)/menstrual calendar (Appendix C) / sexual health questionnaires (Appendices E, F, G)~↓ Start planned therapy (or observation)~↓ Evaluation at completion of chemotherapy Blood draw and collection of monthly menstrual calendars~↓ One year post chemo Blood draw and collection of monthly menstrual calendars/follow-up reproductive health questionnaire (Appendix B)~↓ Annual follow-up x 3 years Blood draw and collection of monthly menstrual calendars/follow-up reproductive health questionnaire (Appendix B) )/ sexual health questionnaires (Appendices E, F, G)"
224323838|NCT00823654|OTHER|Blood draw and questionnaires|"Identify eligible premenopausal patients and obtain informed consent ↓ Register patients at Memorial Sloan Kettering Cancer Center~↓ Baseline evaluation: Blood draw and baseline reproductive and sexual health questionnaires (Appendices A, E, F, G)/menstrual calendar (Appendix C)~↓ Year 1 follow up Blood draw and collection of monthly menstrual calendars (Appendix C)/follow-up reproductive and sexual health questionnaires (Appendices B, E, F, G)~↓ Annual follow-up years x 3 if feasible Blood draw and collection of monthly menstrual calendars (Appendix C)/follow-up reproductive and sexual health questionnaires (Appendices B, E, F, G)"
224323839|NCT05049538|PROCEDURE|Biospecimen Collection|Undergo collection of blood and tissue samples
223681650|NCT03689933|DEVICE|Root analog implant|a custom made root analogue implant made from milled titanium
223681651|NCT01214174|DRUG|IBI-10090|
223681652|NCT00458497|DEVICE|Holofiber fabric|Subjects will be given 3 pairs of socks (subjects with foot pain only) and bedding (mattress pad)fabricated from 1.8 dernier polyethylene terephthalate (PET) fabric to which Holofiber particles have been added during fiber manufacture.
223681653|NCT00458497|DEVICE|PET fabric|Subjects will be given 3 pairs of socks (subjects with foot pain only) and bedding (mattress pad)fabricated from 1.8 dernier polyethylene terephthalate (PET)fabric.
223681654|NCT01802970|DRUG|Anakinra plus Standard of Care|Patients will undergo a 2-week run-in treatment of daily anakinra alone. This will be followed by daily anakinra (100 mg SC) plus the physician's chemotherapy ( TPC) choice of standard of care (SOC) for a maximum of 6 months.TPC choice includes nab paclitaxel (100 mg/m\^2 Intravenous on day 1,8 \&15 of a 28 day cycle), or capecitabine (1000mg/m\^2 per oral; BID choice: 14 days on, 7 days off OR 7 days on, 7 days off of a 21 day cycle), or eribulin (1.4 mg/m\^2 intravenous on day 1 \& 8 of a 21 day cycle), or vinorelbine (25mg/m\^2 on day 1,8,15 of a 28 day cycle). After 6 months, patients may continue their SOC treatment alone until disease progression or intolerable toxicity.
223681655|NCT06142227|OTHER|Reading a Pictorial Storybook|The pictorial storybook by children will be chosen by child psychologists. The book will be read to children by researcher. The researcher has a fairy tale therapy certificate. The pictorial storybook reading will start 15 minutes before the dental treatment process and will be completed before the treatment process begins.. The pictorial storybook will be read to children only one time.
223681656|NCT01759888|DRUG|18F-DTBZ|"Subjects will receive a single i.v. administration of approximately 10 mCi 18F-FP-(+)-DTBZ (10 nmole FP-(+)-DTBZ) immediately prior to each scan.~The proposed dose for this study is based on our phase I study. At the proposed human dose of 10 mCi, the whole body effective dose (ED) will be approximately 680 mrem. The estimated human ED is expected to be comparable to or below the range of other approved brain imaging agents, such as 18F-FDG."
223681657|NCT01358071|DRUG|NGR-hTNF|NGR-hTNF: 0.8 mcg/m² as 60 minutes intravenous infusion weekly or every 3 or 4 weeks until confirmed evidence of disease progression or unacceptable toxicity occurs
223681658|NCT01358071|DRUG|Pegylated liposomal doxorubicin|50 mg/m² iv every 4 weeks until confirmed evidence of disease progression
223681659|NCT01358071|DRUG|Doxorubicin|60 mg/m² iv every 3 weeks for a maximum of 8 cycles
223681660|NCT04016584|BEHAVIORAL|Diabetes Pueblo|These adults will receive diabetes education, the Diabetes Pueblo Program, and will complete Curriculum (A), Diabetes Fundamentals, and Curriculum (B), Insulin Success.
223681661|NCT01933789|BEHAVIORAL|Communication Feedback Form for Patients with Serious Illness|"The intervention, based on self-efficacy theory, identifies patients' preferences for communication about end-of-life care (EOLC) and barriers and facilitators to this communication, and collates these data into a feedback form. The feedback forms are tailored to each recipient (clinician, patient, family) to support the communication tasks which that recipient will address. Feedback forms are sent to participants prior to the target clinic visit. The primary clinician's form suggests referral to palliative care if there are potentially unmet palliative-care communication needs. All forms include tips to help the recipient respond to communication preferences appropriately."
223681662|NCT03508427|OTHER|Daily self-monitoring|Toi Même self-monitoring smartphone application plus treatment as usual which includes pharmacological and/or psychological treatment.
223681663|NCT02757950|BIOLOGICAL|Combined diphtheria, tetanus and tricomponent acellular pertussis vaccine [Refortrix (Tdap)]|Subjects were included in the Exposed cohort if they received Refortrix as part of the maternal immunization program in Brazil.
223681664|NCT00145678|BEHAVIORAL|Psychodynamic Therapy|Dynamic deconstructive psychotherapy is a time-limited (12-18 month) manual-based form of psychodynamic therapy that aims to remediate specific neurocognitive capacities responsible for processing of emotional experiences.
223681665|NCT00145678|BEHAVIORAL|Optimized Community Care|individual and group psychotherapy in a private practice, clinic, and/or rehab setting, with an eclectic orientation
224261936|NCT04602754|OTHER|BERLIM 25/20 ASSOCIATION PLACEBO|Berlim 25/20 association placebo coated tablet.
224261937|NCT03094598|OTHER|Leaflet|The length is 1.5 A4 pages, Flesch's Reading Ease Score (RES) is 57 (fairly difficult, comparable to a quality magazine), and Human Interest Score (HIS) is 37 (interesting, comparable to a digest magazine).
224261938|NCT03094598|OTHER|Brochure|The length is 2.5 A4 pages, RES is 43 (difficult, comparable to an academic magazine), and HIS is 25 (interesting, comparable to a digest magazine).
224261939|NCT03094598|OTHER|Booklet|The length is 12 A4 pages, RES is 11 (very difficult, comparable to a scientific magazine), and HIS is 22 (mildly interesting, comparable to a trade magazine).
224323840|NCT05049538|PROCEDURE|Liquid Biopsy|Undergo liquid biopsy
224323841|NCT05049538|OTHER|Pap Smear|Undergo Pap smear
224323842|NCT04986657|DEVICE|ChromoSeq|Novel, streamlined whole genome sequencing approach
224323843|NCT03162627|DRUG|Selumetinib|"Dose Escalation Phase Starting Dose: 50 mg by mouth twice a day on Days 1-28.~Dose Expansion Phase Starting Dose: Maximum tolerated dose from Dose Escalation Phase."
223774212|NCT04614259|DRUG|Bupivacain|"The infraorbital foramen was located at the floor of the orbital rim at about the level of the pupil,The upper lip was folded back and a finger is placed externally at the level of the infraorbital foramen to prevent the needle from the cephalad insertion in the globe of the eye. A 27-gauge needle was bent about 70 degree to ease the insertion through the buccal mucosa over the maxillary process, towards the infraorbital foramen.~After careful aspiration the local anesthetic was injected (injection of 3 ml 0.25% bupivacaine in 1:200.000 adrenaline ,1.5 ml on each side). \[104\] Pressure was needed to be applied for one minute to the area as there is loose adventitious tissue that can lead to swelling and ecchymosis"
223774213|NCT04614259|COMBINATION_PRODUCT|i.v. analgesia|"Using inhalational induction with sevoflurane as tolerated , atracurium 0.5mg/kg to facilitate endotracheal intubation and fentanyl 1 mcg/kg ,Mechanical ventilation was adjusted to maintain 30 to 35 mmHg end-tidal carbon dioxide, anesthesia was maintained with 1.5 % isoflurane and atracurium (0.1 mg/kg every 30 minutes) ,all patients were received intraoperative diclofenac sodium 0.5 mg/kg intramuscular .~Blood pressure and heart rate were measured 5 minutes after endotracheal intubation and every 15 minutes till recovery from the anesthesia then every 15 min in the postoperative care unite for 30 minutes"
224323844|NCT03162627|DRUG|Olaparib|"Dose Escalation Phase Starting Dose: 150 mg by mouth twice a day on Days 1-28.~Dose Expansion Phase Starting Dose: Maximum tolerated dose from Dose Escalation Phase."
224323845|NCT04868539|OTHER|Sleep Restriction with ALAN first, then Sleep Restriction without ALAN|Sleep restriction with 90 lux lighting for 19hr/day first, followed by Sleep restriction with 90 lux lighting for 14hr/day
224323846|NCT04868539|OTHER|Sleep Restriction without ALAN first, then sleep restriction with ALAN|Sleep restriction with 90 lux lighting for 14hr/day first, followed by Sleep restriction with 90 lux lighting for 19hr/day
223774214|NCT05073406|OTHER|Altitude exposure in hypobaric normoxic condition|Altitude exposure with oxygen supplementation to achieve normoxia at altitude
223774215|NCT05073406|OTHER|Altitude exposure in hypobaric hypoxic condition|Altitude exposure with air supplementation to obtain a sham comparator arm
223774216|NCT03065881|DEVICE|RETeval|The RETeval device measures the retina's electrical response to light, called an electroretinogram (ERG). The standards body ISCEV \[1\] recommends collecting normative data for ERGs to provide waveforms and statistically relevant measurements representing the range of ERGs from people with normal vision. LKC Technologies provides this information with their UTAS product line and wishes to collect such a database for the newest device: the RETeval device. As the RETeval device uses a different electrode to measure the ERG, the normal data for the UTAS product line is not transferable to the RETeval device. Ophthalmic practitioners would also like ERG examples of specific retinal disorders to help diagnose patients with abnormal ERGs. The RETeval device is FDA cleared (K142567),
223774217|NCT05087017|OTHER|Intervention group|Patients with medical condition to follow the rehabilitation program will be asked to answer questionnaires to assess their sleep quality.
223774218|NCT03001895|DRUG|18F-DCFPyL PET/CT|18F-DCFPyL PET/CT
223774219|NCT03529630|OTHER|Inverted syringe|Application of mild suction over the mother's inverted nipple using an inverted syringe before each breastfeeding.
223774220|NCT02747316|OTHER|Stable iron isotope 57 (57Fe) labeled iron solution|test meal labeled with 12 mg 57Fe
223774221|NCT02747316|OTHER|Stable iron isotope 58 (58Fe) labeled iron solution|test meal labeled with 12 mg 58Fe
223774222|NCT04720859|DRUG|Canagliflozin 300 MG Oral Tablet|Patients diagnosed with PHH following bariatric surgery by 100g glucose OGTT were prescribed 300mg canagliflozin during two weeks. 100g glucose OGTT response was evaluated after canagliflozin treatment.
223774223|NCT03509948|DRUG|cytisine|cytisine 1.5 mg film-coated tablets
223774224|NCT03221257|DRUG|Pirfenidone (PFD)|Participants will receive PFD titrated up to a target dose of 801 mg taken three times daily as tolerated (3-step titration occurring at 2 week intervals).
223774225|NCT03221257|DRUG|Placebo (Plac)|Participants will receive a Plac, matched to resemble PFD, titrated up to a target dose of 801 mg taken three times daily as tolerated (3-step titration occurring at 2 week intervals).
223774226|NCT03221257|DRUG|Mycophenolate Mofetil (MMF)|Participants will receive MMF titrated up to a target dose of 1500 mg taken twice daily as tolerated (4-step titration occurring at monthly intervals).
223774227|NCT04060940|BEHAVIORAL|Emotion Regulation Therapy: 8-session version|Emotion Regulation Therapy will be administered over 8 individual sessions on a weekly basis, resulting in a total required time commitment of 9 hours over the course of 8 weeks. The initial stage of treatment focuses on psychoeducation about anxiety and depression, individual patterns of these behaviors, emotions in recent situations, and self-monitoring of worry, anxiety, and depression. The sessions focus on the development of skills that help regulate one's emotional experience (i.e., recognizing emotions when they are happening, identifying the meaning of a given emotion experience, and soothing oneself in the context of negative emotional experiences). Following the development of these skills, sessions focus on the application of somatic awareness and emotion regulation skills while imagining emotionally evocative themes. The remaining sessions focus on terminating therapy, relapse prevention, and future goals.
224261940|NCT02793245|OTHER|Questionnaire|Questionnaire on their main characteristics : age, gender, height, weight, smoking
224261941|NCT02793245|OTHER|Simplified pulmonary function test|
224261942|NCT05463848|DRUG|Pembrolizumab|Intravenous infusion
224261943|NCT05463848|DRUG|Olaparib|Pill taken by mouth
224261944|NCT05463848|DRUG|Temozolomide|Pill taken by mouth
224261945|NCT05752552|DRUG|DO-2|Deuterated MET kinase inhibitor
224261946|NCT03110627|DEVICE|VDD ICD (experimental group)|"Patients who are identified on clinical grounds for a single-chamber ICD will randomized to a VDD ICD (experimental group) or single chamber ICD (control group).~The study will compare the Dx-ICD system (experimental) to standard VVI-ICD (control) on the ability to diagnose silent AF in patients without prior AF receiving an ICD for standard indications."
224261947|NCT03110627|DEVICE|Single chamber VVI ICD (control group)|"Patients who are identified on clinical grounds for a single-chamber ICD will randomized to a VDD ICD (experimental group) or single chamber ICD (control group).~The study will compare the Dx-ICD system (experimental) to standard VVI-ICD (control) on the ability to diagnose silent AF in patients without prior AF receiving an ICD for standard indications."
223681666|NCT00597844|OTHER|voice evaluation and fMRI|will undergo voice evaluation and fMRI prior to surgical rehabilitation of UVCP and in approximately one month and six months following treatment.
223681667|NCT00597844|OTHER|undergo voice evaluation and fMRI prior|in approximately one month and six months
223681668|NCT03398278|DRUG|Oxycodone Tamper Resistant|Orally taking Oxycodone Tamper Resistant 40mg in fast state
223681669|NCT03398278|DRUG|OXYCONTIN®|Orally taking OXYCONTIN® 40mg in fast state
223681670|NCT00623584|PROCEDURE|Corneal transplantation|Full thickness penetrating keratoplasty
223681671|NCT00623584|PROCEDURE|Corneal transplantation|Full thickness penetrating keratoplasty
223681672|NCT01888887|OTHER|Cetaphil Daily Facial Cleanser|
223681673|NCT06325475|PROCEDURE|labor with neuraxial labor analgesia|"Pregnant women in Group A will receive neuraxial labor analgesia (dural puncture epidural or combined spino epidural analgesia).~If postpartum analgesic needs arise, patients in Group A will receive 0.0625% bupivacaine via epidural route."
223681674|NCT06325475|PROCEDURE|labour without noroaxial labor analgesia|"Pregnant women in Group B will not receive neuraxial labor analgesia (dural puncture epidural or combined spino epidural analgesia).~If postpartum analgesic needs arise, patients in Group B will receive iboprufen and acetaminophen."
223681675|NCT01337271|PROCEDURE|SBT- PSV|An Spontaneous breathing trial for 30 minutes on pressure support ventilation, which is a commonly used strategy to evaluate readiness for extubation
223681676|NCT01337271|PROCEDURE|SBT - NAVA|An spontaneous breathing trial (SBT) on the ventilatory mode NAVA, with ventilatory support titrated to be similar to the support provided during an SBT on pressure support mode (PSV). NAVA captures the electrical activity of the diaphragm with an esophageal-gastric catheter, and uses the electrical signal to deliver inspiratory pressure proportional to the intensity of patient effort, as well as to trigger and cycle assisted mechanical breaths.
223681677|NCT00020332|DRUG|alvocidib|
223681678|NCT00020332|DRUG|docetaxel|
223681679|NCT01499862|DEVICE|Tibion Bionic Leg|A programmable, carbon-fiber robotic leg orthosis (Tibion Bionic Leg, Tibion Corporation, Sunnyvale, CA) was used during therapy to actively supplement concentric and eccentric quadriceps function on the participant's impaired side. The device uses internal sensors at the foot and knee joint to detect intention of movement and, once a variable force threshold is passed, the devices provides appropriate assistive and resistive adjustments.
223681680|NCT00494845|BEHAVIORAL|Mindfulness|8-week mindfulness program will be compared to an education control group.
223681681|NCT00494845|BEHAVIORAL|Control: Health Education Class|8-week education program
223681682|NCT01527266|DIETARY_SUPPLEMENT|Carbohydrate drink|sucrose beverage
223681683|NCT01527266|DIETARY_SUPPLEMENT|Placebo mouth rinse|placebo; non-caloric sweetened beverage for use as a mouth rinse
223681684|NCT04447872|PROCEDURE|Timing of injectable gonadotropins|Gonadotropins will with be started in the luteal phase or in follicular phase (preceded by Estradiol patches)
224323847|NCT04645810|PROCEDURE|High-Dose-Rate Brachytherapy|High-Dose-Rate Brachytherapy Targeting only to AXUMIN PET Visible Lesion
223681685|NCT03191578|DRUG|RUTI®|Administration of RUTI®
223681686|NCT03191578|DRUG|Placebo|Administration of placebo
223681687|NCT00307879|DRUG|Drug: G-CSF (Dong-A pharmaceutical, Seoul, Korea)|
223681688|NCT00307879|PROCEDURE|collection of mobilized peripheral blood stem cells|
223681689|NCT00307879|PROCEDURE|Intracoronary infusion of mobilized cells|
223681690|NCT02710643|DRUG|OFATUMUMAB|8 weekly infusion of 1000 mg total dose
223681691|NCT04441866|DIAGNOSTIC_TEST|Automated algorithms|Automated algorithms for measuring fetal biometry, and for the reconstruction of standard planes of fetal anatomy
223681692|NCT04441866|DIAGNOSTIC_TEST|Standard technique|Standard ultrasound examination without use of automated algorithms for measuring fetal biometry, and for the reconstruction of standard planes of fetal anatomy
223681693|NCT05025540|DIAGNOSTIC_TEST|ultrasonic imaging|Two-dimensional ultrasound images of the patient's kidneys were obtained by ultrasound imaging.
223681694|NCT00050687|DRUG|Gallium maltolate|
224323848|NCT06216366|DRUG|Sodium Chloride 0.9% Inj pre-exposure|Sterile normal saline 0.9% administered IV as a placebo immediately before hyperbaric chamber exposure
224323849|NCT06216366|DRUG|Sodium Chloride 0.9% Inj post-exposure|Sterile normal saline 0.9% administered IV as a placebo immediately after hyperbaric chamber exposure
224323850|NCT06216366|DRUG|Recombinant human plasma gelsolin pre-exposure|rhu-pGSN administered IV at a dose of 24 mg/kg immediately before hyperbaric chamber exposure
223681695|NCT03539796|PROCEDURE|Dural puncture epidurals (DPE)|Using the Arrow Epidural Kit (AK-05560) an epidural will be placed using the LOR to saline or air technique. A 26g Gertie Marx needle will be inserted through the Touhy epidural needle and used to puncture the dura; clear, free flowing CSF will return in the needle, but no medications will be injected. The 26g spinal needle will be removed, and the epidural catheter inserted through the epidural needle 3-5cm in the epidural space. A test dose with 3mL 1.5% Lidocaine with 1:200,000 epinephrine will be used to confirm the absence of intrathecal or intravascular catheter placement. The epidural catheter will then be dosed with 0.5% Bupivacaine in 5mL increments until a T4 dermatome level is reached. Epidural fentanyl 100mcg will be administered during initial dosing, and morphine-PF 3mg will be given via epidural after delivery of the fetus.
223681696|NCT03539796|PROCEDURE|Traditional epidurals (EPI)|Using the Arrow Epidural Kit (AK-05560) an epidural will be placed using the LOR to saline or air technique. The catheter will be inserted 3-5cm in the epidural space. A test dose with 3mL 1.5% Lidocaine with 1:200,000 epinephrine will be used to confirm the absence of intrathecal or intravascular catheter placement. The epidural catheter will then be dosed with 0.5% Bupivacaine in 5mL increments until a T4 dermatome level is reached. Epidural fentanyl 100mcg will be administered during initial dosing, and morphine-preservative free (PF) 3mg will be given via epidural after delivery of the fetus.
223835260|NCT05286515|OTHER|Hybrid Peroperative PT|The intervention will consist of an in-person evaluation assessing the subject's functional level, lower and upper extremities range of motion, strength and endurance. The remaining sessions will be conducted via telehealth. The program will consist of two sessions per week up to six weeks. The program will start approximately 8 to 7 weeks before the scheduled surgery date.
223835261|NCT05286515|OTHER|Standard Clinical Practice PT|This group will follow the protocols established by the PT facility they chose. They will finish treatment two to three weeks before the surgery date, similar to the intervention group.
223681697|NCT03539796|PROCEDURE|Combined-spinal epidural technique (CSE)|Using the Arrow Epidural Kit (AK-05560) an epidural will be placed using the LOR to saline or air technique. A 26g Gertie Marx needle will be inserted through the Touhy epidural needle and used to puncture the dura; clear, free flowing CSF will return in the needle and 12mg bupivacaine, 10mcg fentanyl, 200mcg morphine-PF. The 26g spinal needle will be removed, and the epidural catheter inserted through the epidural needle 3-5cm in the epidural space. No epidural test dose will be given immediately compared to the above procedures secondary to intrathecal injection of local anesthetic with this CSE technique. Only after approximately 1 hour after intrathecal injection will a test dose of 3mL 1.5% Lidocaine with 1:200,000 epinephrine will be used to confirm the absence of intrathecal or intravascular catheter placement. The epidural catheter will then be dosed with 0.5% Bupivacaine for the remainder of the procedure if necessary.
223681698|NCT02217540|OTHER|Standard protocol|Control group intervention is the physiotherapy treatment standard protocol proposed by the Spanish Rheumatology Society for shoulder dysfunction
223681699|NCT02217540|OTHER|Mulligan Concept Mobilisation with Movement|The internal hand of the physiotherapist stabilises participants´ shoulder girdle and with the thenar eminence of the other hand, performs a posterior-lateral glide of the humeral head. Participants are asked to raise the affected arm in the point of pain onset while the physiotherapist sustains the gliding force to humeral head. The physiotherapist tries to maintain the glide at right angles to the plane of movement throughout the entire range while participants are requested to perform an active elevation. Participants are instructed that the mobilisation procedure, including shoulder movement, had to be pain free
223774228|NCT04060940|BEHAVIORAL|Emotion Regulation Therapy: 16-session version|Emotion Regulation Therapy will be administered over 16 individual sessions on a weekly basis, resulting in a total required time commitment of 18 hours over the course of 16 weeks. The initial stage of treatment focuses on psychoeducation about anxiety and depression, individual patterns of these behaviors, emotions in recent situations, and self-monitoring of worry, anxiety, and depression. The sessions focus on the development of skills that help regulate one's emotional experience (i.e., recognizing emotions when they are happening, identifying the meaning of a given emotion experience, and soothing oneself in the context of negative emotional experiences). Following the development of these skills, sessions focus on the application of somatic awareness and emotion regulation skills while imagining emotionally evocative themes. The remaining sessions focus on terminating therapy, relapse prevention, and future goals.
223774229|NCT06171867|DEVICE|PNEUMACRIT|Monitoring of breathing
223774230|NCT00725426|DRUG|Bosutinib|
223774231|NCT06491550|DRUG|AZD4144- Part A|Part A: Participants will be administered a single dose of AZD4144 on Day 1 via Intravenous (IV) infusion.
223774232|NCT06491550|DRUG|Placebo- Part A|Part A: Participants will be administered a single dose of placebo on Day 1 via IV infusion.
223774233|NCT06491550|DRUG|AZD4144- Part B|"Part B: Participants will be administered a single dose of AZD4144 on Day 1 and Day 12 via IV infusion.~Participants will be administered multiple doses of AZD4144 from Day 4 to Day 11 via IV infusion."
223774234|NCT06491550|DRUG|Placebo- Part B|Part B: Participants will be administered a single dose of placebo on Day 1 and Day 12via IV infusion. Participants will be administered multiple doses of placebo from Day 4 to Day 11 via IV infusion.
223774235|NCT06491550|DRUG|Rosuvastatin and Furosemide- Part C|Participants will be administered a single oral dose of 10 mg Rosuvastatin and 1 mg Furosemide.
224261948|NCT04479527|DRUG|Camrelizumab|Camrelizumab for injection is used to treat patients with relapsed or refractory classic Hodgkin lymphoma who have undergone at least second-line chemotherapy. Approved by the Drug Administration (NMPA) on March 4, 2020, for the treatment of patients with advanced hepatocellular carcinoma who have previously received sorafenib therapy and/or oxaliplatin-containing chemotherapy.Apatinib Mesylas is a small-molecule VEGFR tyrosine kinase inhibitor. It mainly treats malignant tumors by inhibiting VEGFR to play an anti-angiogenic effect. It has been approved by the China Food and Drug Administration (CFDA) in November 2014. It is used as a monotherapy for advanced gastric adenocarcinoma or gastric-esophageal junction adenocarcinoma that has progressed or relapsed after receiving two kinds of systemic chemotherapy. Apatinib Mesylas can effectively inhibit VEGFR2 at very low concentrations, and higher concentrations can also inhibit PDGFR, c-Kit and c-Src and other kinases.
224261949|NCT06491420|OTHER|fixation with arthroscopy|the pipkin fracture is fixed with the help of arthroscopy and percutaneous methods.
224261950|NCT06560827|BIOLOGICAL|CT011 CAR-GPC3 T Cells Injection|The dose selection for this trial was mainly based on the preliminary safety and efficacy results of CT011-HCC-01 trial in subjects with advanced HCC, in which 3 and 5 subjects in the 2.5 × 108 cell and 5.0 × 108 cell dose groups, respectively, completed a single infusion of CT011. The results showed that the two dose groups of CT011 were generally well tolerated in HCC subjects who failed to standard treatment, with controllable safety, and showed preliminary anti-tumor efficacy.
224261951|NCT04698473|OTHER|NCPAP|NCPAP infants will be randomized into two different non invasive ventilation groups
224261952|NCT04698473|OTHER|NIPPV|NIPPV NCPAP infants will be randomized into two different non invasive ventilation groups
224261953|NCT04366544|OTHER|Part A1: Survey|Online
224261954|NCT04366544|OTHER|Part A2: Sample collection|Blood and Stool
224261955|NCT04366544|OTHER|Part B:|EEG and fMRI
224261956|NCT00586989|PROCEDURE|Upper endoscopy with biopsy|Endoscopy with biopsy 6 weeks after the initial endoscopy
224261957|NCT00636129|BEHAVIORAL|Relaxation Response + Stress Management Curriculum|Subjects will receive 8 weeks of Stress Management curriculum and guidance through 20 minute Relaxation Response with a research coordinator. They will also practice 20 minutes of Relaxation Response at home daily.
224261958|NCT00107991|DRUG|etanercept|etanercept 50 mg/week subcutaneous injection
224261959|NCT03781622|DEVICE|WOLF Thrombectomy Device|Mechanical thrombectomy for the neurovasculature
224323851|NCT06216366|DRUG|Recombinant human plasma gelsolin post-exposure|rhu-pGSN administered IV at a dose of 24 mg/kg immediately after hyperbaric chamber exposure
224323852|NCT06216366|OTHER|Hyperbaric chamber|High-pressure profile equivalent 35 minutes at a depth of 30 meters of sea water
224261960|NCT02479763|PROCEDURE|Waveform-confirmed loss-of-resistance|Using waveform analysis to confirm thoracic epidural space
224323853|NCT05486728|DRUG|SHJ002/Vehicle|Topical ophthalmic
224323854|NCT02412228|DRUG|Ixazomib|"Cycle 1:~Ixazomib: 4mg/day 1, 8, 15~Cycles 2-6:~Ixazomib: 4mg/day 1, 4, 8, 11, 15, 18,~Maintenance:~Ixazomib at 4 mg days 1, 8 and 15 of a 28 day cycle for 1 ½ years"
223681700|NCT01117792|DEVICE|subcutaneous implantable defibrillator (S-ICD) system|implantable defibrillator system
223681701|NCT02964403|DRUG|Cox-2|
223681702|NCT02964403|DRUG|Indomethacin|
223681703|NCT06171490|OTHER|NP2-4mg|NP2-4 mg is a new product containing tobacco-derived nicotine.
223681704|NCT06171490|OTHER|NP2-6 mg|NP2-6 mg is a new product containing tobacco-derived nicotine.
223681705|NCT06171490|OTHER|Loz-4mg|The Loz-4mg reference product is a commercially available 4mg nicotine lozenge.
223681706|NCT06171490|OTHER|Gum-4mg|The Gum-4mg reference product is a commercially available 4mg nicotine gum.
223681707|NCT00470912|DRUG|sunscreen RV 2547C|
223681708|NCT04656483|OTHER|Telemedicine Video Feedback Intervention|Mother-child dyads will take part into a 6 video-conference sessions of Video Feedback (vVF). The vVF will be standardized according to previously published RCTs. Specifically, the 6 vVFI sessions will be organized in two subsequent phases: 4 sessions based on sharing the focus on different relational themes, and 2 sessions of interactive integration. In more specific terms, during the first set of 4 sessions the psychologist will review with mothers' segments of the videotapes obtained during the baseline assessment and will focus on four different relational themes: responsiveness, physical stimulation, teaching, and parenting experience. During the interactive integration session, the insights developed from the first 4 videoconferences will be applied to the real-time interaction between the parent and his/her infant under the guidance of the psychologist.
223681709|NCT04656483|OTHER|Psychoeducational Booklet Intervention|Mothers of this condition will receive an informative booklet addressing the same themes included in the experimental intervention (responsiveness, physical stimulation, teaching, and parenting experience), but not tailored on their own infant status.
223681710|NCT02049671|DRUG|Growth Hormone Therapy|
223681711|NCT05888571|PROCEDURE|prepectoral breast reconstruction|Patients receive immediate prepectoral breast reconstruction
223681712|NCT05888571|PROCEDURE|Tiloop Mesh implantation|Patients receive immediate prepectoral breast reconstruction with Tiloop Mesh
223681713|NCT01721577|DRUG|AXL1717|IGF-1 receptor inhibitor
223681714|NCT01894815|DRUG|Escitalopram oxalate|The investigators will use 10mg and 20mg pills. The investigators will up-titrate escitalopram from 10 to 20mg/day according to the patient tolerability. The maximum dose (20mg/day) is sought to be achieved at week 3.
223681715|NCT01894815|DEVICE|transcranial direct current stimulation|The anode will be applied over the F3 area and the cathode over the F4 area. The current dose is 2mA, current density is 0.8 A/m2. Electrodes will be 5x5cm in size. The investigators will apply 15 daily, consecutive tDCS sessions (excluding weekends) and after that one session per week until the primary endpoint.
223774236|NCT06491550|DRUG|Rosuvastatin, Furosemide, and AZD4144 Part C|Participants will be administered a single oral dose of 10 mg Rosuvastatin, 1 mg Furosemide and a single dose of AZD4144 via IV infusion.
223774237|NCT02338752|BIOLOGICAL|MV|MV is an intravenous intralipid suspension with 5 various vaccines, including DPT (diphtheria, pertussis, and tetanus ), typhoid, Staphylococcus aureus, paratyphoid A and B. Accessories include microbial A, lecithin, Twain-80, span 20 and soy-bean oil for injection. Inject 0.5 ml of the mixture subcutaneously every week. Best reaction after injection was defined as showing regional red and swollen at the injection point and mild fever and to achieve this, dose increasing or reduction is acceptable.
224261961|NCT05764096|OTHER|No intervention|No intervention
223681716|NCT01894815|OTHER|Sham tDCS + Placebo Pill|This group receives sham tDCS and placebo pill.
223681717|NCT05894122|DIAGNOSTIC_TEST|DM-DIV MITRA®|Comparison of phenylalanine concentrations in the new device with those in the current device (blotter).
223681718|NCT04052724|BEHAVIORAL|Intervention group LINGI|Intervention based on cognitive behavioural therapy principles and culturally adapted to Lithuanian population. Intervention's main purpose is to reduce caregiver burden and increase quality of life. Intervention contains psycho-educational elements as well as examples and exercises.
223681719|NCT03053765|OTHER|training in IPT|Follow-up training in IPT to determine which best enhances fidelity
223681720|NCT04757428|PROCEDURE|Endocrown|Endocrown
223681721|NCT03318718|DRUG|Anesthesia with non-depolarizing NMBA Rocuronium|Non- depolarizing NMBA Rocuronium will be used until full paraspinal muscle Relaxation. Muscle relaxation during surgery will be performed using intraoperative boli intermediate duration non-depolarizing NMBA, rocuronium (0.3 mg/kg) until good surgical conditions are achieved.
223681722|NCT03318718|DIAGNOSTIC_TEST|TOF measurement|TOF (Train-of-four) measurements will be performed at baseline 5 minutes after induction after the effect of succinylcholine will have run off. Moreover, TOF measurements will be performed 5 minutes after each rocuronium bolus
223681723|NCT03318718|DIAGNOSTIC_TEST|MEP measurement|MEPs (motor evoked potentials) are routinely obtained after intubation and before surgery, then every 10min during the critical preparation and closing phases of surgery and every 5min during the correction phase. In addition MEPs will be measured after the administration of the NMBA rocuronium. Baseline values for amplitudes and latencies are obtained directly prior to the start of the correction phase of the surgery.
223681724|NCT01640093|DRUG|Abiraterone acetate, 250 mg (uncoated, current commercial tablet)|Type=exact number, unit=mg, number=250, form=tablet, route=oral. Administered once under fasted conditions.
223681725|NCT01640093|DRUG|Abiraterone acetate, 500 mg (coated, reformulated tablet)|Type=exact number, unit=mg, number=500, form=tablet, route=oral. Administered once under fasted conditions.
223681726|NCT01640093|DRUG|Abiraterone acetate, 250 mg (coated, reformulated tablet)|Type=exact number, unit=mg, number=250, form=tablet, route=oral. Administered once under fasted conditions.
223681727|NCT01640093|DRUG|Abiraterone acetate, 500 mg (coated tablet, slower in vitro dissolution)|Type=exact number, unit=mg, number=500, form=tablet, route=oral. Administered once under fasted conditions.
223681728|NCT01778179|DRUG|Tri-luma|"Pre-procedure phase (From Baseline up to Week 2) treated daily for their solar lentigines with the investigational drug (Tri-Luma® cream) for 2 weeks.~Post-procedure phase (From week 2 up to Week 13 - Visit )~\- Tri-Luma® cream treatment phase (from week 5 up to week 13 - visit 3 up to visit 5):The investigational drug (Tri-Luma® cream) will be applied again (group 1) for a minimum of 4 weeks and up to 8 weeks, according to the Global Improvement of solar lentigines and absence of PIH."
223681729|NCT01778179|PROCEDURE|Cryotherapy (CRY-AC3® device)|Procedure performed at week 2.
224261962|NCT05635812|OTHER|Neuropsychological assessment|neuropsychological assessment and clinical scales duration: 3 hours
224261963|NCT05635812|OTHER|EEG experimentation|duration: 1 hour
223681730|NCT02220127|RADIATION|GKR with a single shot of the 8 mm collimator|Gamma Knife Radiosurgery (GKR) with a single shot of the 8 mm collimator at an isodose above 90%.
223774238|NCT02338752|OTHER|Standard Treatment|Patient will receive a comprehensive histological and imaging check up to evaluate the histological type, stage of the disease and performance status. Then the patient will receive standard treatment, in brief, surgical resection for early stage patients and systemic treatment including chemotherapy for advanced stage patients, according to NCCN guide line.
223774239|NCT04699331|DEVICE|Transcranial Direct Current Stimulation|Transcranial direct current stimulation is a form of noninvasive neuromodulation that uses constant and low direct current delivered via electrodes on the scalp.
223774240|NCT02315235|BIOLOGICAL|Normal saline|Normal saline is injected in one leg of patient.
224261964|NCT05635812|OTHER|Oculometry experimentation|duration: 30 minutes
224261965|NCT02754089|DRUG|Rhus Coriaria L.(Rhus)|500 mg twice daily after meals for 6 weeks
224261966|NCT02754089|DRUG|Placebo|500 mg twice daily after meals for 6 weeks
224261967|NCT04626414|DRUG|Ferric maltol capsule|single dose of 30 mg capsule
224261968|NCT04626414|DRUG|Ferric maltol suspension|single dose of 30mg (5ml) oral suspension
224261969|NCT00506831|DRUG|Imatinib mesylate|100 mg orally daily increased by 100 mg/day every 2 weeks to maximum of 400 mg daily as tolerated. Treatment for 6 months total.
224261970|NCT03933592|PROCEDURE|Serratus anterior block|after induction of anesthesia and Patients will be placed in the lateral position with the diseased side up. A linear ultrasound transducer (10-12 MHz) will be placed over the mid-axillary region of the thoracic cage in a sagittal plane. The rib will be counted inferiorly and laterally, until the fifth rib is identified in the mid-axillary line. The following muscles will be identified easily overlying the fifth rib: the latissimus dorsi (superficial and posterior), teres major (superior) and serratus muscle (deep and inferior). The needle (22- G, 50 - mm Touhy needle) will be introduced in-plane with respect to the ultrasound probe targeting the plane superficial to the serratus muscle. Under continuous ultrasound guidance a bolus of 30 ml of 0.25% levobupivacaine 30 mint before skin incision. At the end of surgery, surgeon will put the catheter deep to serratus muscle and get it out with chest tube and fix it followed by an infusion of 5 ml/hour of 0.125% Levobupivacaine.
224261971|NCT03933592|PROCEDURE|thoracic epidural|In group I: thoracic epidural inserted at low thoracic level in sitting position then test dose will be administered to detect any complications then a bolus of 10 ml of 0.25% levobupivacaine 30 mint before skin incision followed by an infusion of 5 ml/hour of 0.125% levobupivacaine after surgery.
224261972|NCT01770223|DRUG|boceprevir|
224261973|NCT01770223|BIOLOGICAL|PegIFN-2b|
224261974|NCT01770223|DRUG|RBV|
224261975|NCT00499759|BEHAVIORAL|Resting vitals|The fitness assessments will include the assessment of resting vitals including, blood pressure, heart rate, and hemoglobin saturation (pulse oximeter).
224261976|NCT00499759|BEHAVIORAL|Body Composition|Body composition and body circumference measurements (anthropometry) will be the only assessments performed multiple times during the study to monitor possible changes in the body composition and swelling of the patients. Body composition analyses will be performed via skinfold measurements following generalized three-site skinfold equations for male and females as recommended by the ACSM, 2005 and via the utilization of a bioelectrical impedance body fat analyzer device.
224261977|NCT00499759|BEHAVIORAL|Timed Get-up and Go test (TGUG).|"The functional mobility of the subjects that will participate in the study will be assessed through the Timed Get-up and Go test (TGUG). The administration of the TGUG includes measuring a distance of 3 meters from the legs of a straight-backed armchair with a seat height of approximately 46 centimeters. The subject will be asked to sit with the back against the chair with the arms on the arm rests. When instructed to begin the test (on the command Go), the subject will have to stand upright then walk at a normal walking pace toward the 3 meters mark placed on the ground, turn around, return to the chair, and sit down. The stopwatch was started on the word Go and stopped when the subject gets back to starting position."
224261978|NCT00499759|BEHAVIORAL|Cardiorespiratory assessment|The cardiorespiratory assessment will be performed on a recumbent cycle ergometer. Subjects will be asked to cycle at a target submaximal intensity of 60 % of their percentage of heart rate range until a RPE (Rate of Perceived Exertion) of 7 is reached on the modified Borg Scale or when the subject requests termination. The Borg modified RPE scale is a scale ranging from 0 to 11 where 0 means no exertion at all and 11 equals to an exertion of absolute maximum. The total time cycling and heart rate (HR) at the end of the test will be recorded immediately after the test is completed.
224261979|NCT00499759|BEHAVIORAL|Handgrip evaluation|Handgrip strength will be tested using a handgrip dynamometer. Subjects will be asked to stand and hold the handgrip dynamometer in one hand lined with the forearm that will be placed beside the body. Maximum grip strength is then determined without swinging the arm and by squeezing the handgrip dynamometer as hard as possible using one brief maximal contraction with no extraneous body movement. The test will be administered three times for each hand with a one-minute rest in between trials. The best score within the three trials for each arm will be the one that will be used for analysis.
223681731|NCT02220127|RADIATION|GKR with a single shot of the 4 mm collimator|Gamma Knife Radiosurgery (GKR) with a single shot of the 4 mm collimator at an isodose between the 40% and 90%.
223681732|NCT02497976|BIOLOGICAL|Certolizumab pegol|400 mg
223681733|NCT02497976|DRUG|Placebo|Normal saline
223681734|NCT00277641|DRUG|Lamotrigine|25 mg or 100 mg
223681735|NCT00277641|DRUG|placebo|identical tablets to study drug
223681736|NCT01277081|DRUG|Paracetamol hot drink|Hot drink containing paracetamol
223681737|NCT01277081|DRUG|Paracetamol tablets|Paracetamol tablets
223681738|NCT06147973|BEHAVIORAL|Acceptance-based Treatment (ABT)|Participants will be provided with psycho-education, skill-builders, and other coaching to promote weight loss and healthy lifestyle changes.
223681739|NCT06147973|BEHAVIORAL|Health Education (HE) Comparison|Participants will be provided with psych-education and resources to promote weight loss and healthy lifestyle changes. They will not be provided with directives.
223681740|NCT02330328|OTHER|No Telemetry Monitoring|
223681741|NCT02330328|DEVICE|Telemetry Monitoring|
223681742|NCT01772511|BEHAVIORAL|Questionnaire|All patients entering on this trial will have been enrolled on an oncology clinical trial and are receiving active anti-cancer treatment on that study.
223774241|NCT02315235|BIOLOGICAL|stem-cell|"Granulocyte colony-stimulating factor (G-CSF) is injected into subcutaneous for three days prior to the blood collection (D-3 to D-1). Peripheral mononuclear stem-cell is collected by Cobe spectra apheresis system in D-day.~The stem-cell (mononuclear cell) is injected into the muscle in the other side leg of patient."
223774242|NCT04905056|OTHER|Ablation therapy|Ablation therapy in the treatment of lung cancer presenting as ground-glass nodules
223774243|NCT03437200|DRUG|Nivolumab|Induction phase: Nivolumab IV 240 mg on days 1, 15 and 29 followed by a maintenance phase (to start on day 43) of Nivolumab IV 240 mg q2 weekly for up to 1 year.
223774244|NCT03437200|DRUG|Ipilimumab|Induction phase: Ipilimumab IV 1 mg/kg on day 1 followed by a maintenance phase (to start on day 43) of Ipilimumab IV 1 mg/kg q6 weekly for up to 1 year.
223774245|NCT03437200|OTHER|Chemoradiation|All patients will receive standard fractionation radiation therapy (RT) scheme: 50Gy in 25 fractions over 5 weeks (i.e. 2Gy per fraction), concurrently with 3 cycles of 2 weeks of FOLFOX (oxaliplatin 85 mg/m2, leucovorin 200 mg/m2, bolus fluorouracil 400 mg/m2, and infusional fluorouracil 1600 mg/m2 over 48 h), followed by 3 cycles of 2 weeks of FOLFOX without RT.
223774246|NCT02072850|DEVICE|Coronary pressure wire|Guidewire-based coronary pressure- and temperature recordings (coronary thermodilution) with and without hyperaemia induced by intravenous administration of adenosine (140 ug/kg/min) in patients with acute ST-elevation myocardial infarction treated by emergency PCI.
223774247|NCT02072850|OTHER|Magnetic resonance imaging of the heart|Cardiac magnetic resonance imaging (MRI) with gadolinium contrast imaging at baseline (\~ day 2) and 6 months (all participants) and in 30 subjects at 4 time-points (\< 12 hours, days 2, 7-10 and at 6 months).
223774248|NCT05892848|DIAGNOSTIC_TEST|serum ostecalcin,serum sclerostin and parathroid profile|evaluation of bone turnover markers in blood
223774249|NCT06034158|DRUG|single-dose madopar, single-dose propranolol, and single-dose placebo by order|Participants will take madopar, propranolol, and placebo (orange juice) each once in three separate sessions. The interval between every two sessions will be at least 3 days.
223774250|NCT06034158|DRUG|single-dose madopar, single-dose placebo, and single-dose propranolol by order|Participants will take madopar, placebo(orange juice), and propranolol each once in three separate sessions. The interval between every two sessions will be at least 3 days.
223774251|NCT06034158|DRUG|single-dose propranolol, single-dose madopar, and single-dose placebo by order|Participants will take propranolol, madopar, and placebo(orange juice) each once in three separate sessions. The interval between every two sessions will be at least 3 days.
223774252|NCT06034158|DRUG|single-dose propranolol, single-dose placebo, and single-dose madopar by order|Participants will take propranolol, placebo(orange juice), and madopar each once in three separate sessions. The interval between every two sessions will be at least 3 days.
223774253|NCT06034158|DRUG|single-dose placebo, single-dose propranolol, and single-dose madopar by order|Participants will take placebo(orange juice), propranolol, and madopar each once in three separate sessions. The interval between every two sessions will be at least 3 days.
223774254|NCT06034158|DRUG|single-dose placebo, single-dose madopar, and single-dose propranolol by order|Participants will take placebo(orange juice), madopar, and propranolol each once in three separate sessions. The interval between every two sessions will be at least 3 days.
223774255|NCT02149342|DRUG|Hexylaminolaevulinate cream|0.2% Hexylaminolaevulinate (Hexvix, Photocure) mixed with Unguentum M (Allmiral) cream (2014)
223774256|NCT02149342|DRUG|Methylaminolaevulinate cream|MAL 16% is used as photosensitizer for daylight-PDT
223774257|NCT00000707|DRUG|Pentamidine isethionate|
223774258|NCT03467633|BEHAVIORAL|High-intensity interval training|Participants in the HIIT group will receive 3-weeks of tri-weekly supervised exercise sessions at the UOHI prior to their scheduled electro-cardioversion. The session will last 23 minutes in duration and consist of a 2-minute warm-up at 50% of peak power output (PPO), 2 x 8-minute interval training blocks of 30 seconds at 80-100% of PPO interspersed with 30-seconds of active recovery and a 1-minute cool down at 25 % of PPO. The sessions will be lead by a Registered Kinesiologist.
223774259|NCT00038922|DRUG|rhIL-11|
223774260|NCT02072967|OTHER|Ribomustin|Routine practice
223774261|NCT02072967|OTHER|rituximab|Routine practice
223774262|NCT01129141|PROCEDURE|Tele-PTM|Telephone-based Progressive Tinnitus Management (Tele-PTM) is a novel home-based telehealth program that involves a series of seven telephone appointments, conducted at approximately 1, 2, 3, 4, and 5 weeks, and 3 and 6 months after enrollment is finalized. Telephone education was provided by the Study Psychologist at weeks 1, 3, and 5, and month 6; and by the Study Audiologist at weeks 2 and 4, and month 3.
223774263|NCT01129141|PROCEDURE|Wait List Control|Wait List Control subjects received Tele-PTM after completing the 6-month questionnaires. Participants assigned to Wait List Control were instructed that they could receive any available tinnitus services, and that they would receive Tele-PTM following completion of the 3- and 6-month questionnaires.
223681743|NCT04801316|BEHAVIORAL|Steady Feet exercise programme|"Steady Feet (SF) is a 6-month community-based structured exercise programme aimed at improving physical strength and balance among older adults (aged 60 years and above) who are at high risk of falls.~This exercise programme was developed by Changi General Hospital's physiotherapists and exercise physiologist from evidence found in the literature."
224261980|NCT00499759|BEHAVIORAL|Dynamic muscular endurance|Subjects will be asked to squat to a 75 degree knee angle with moderate speed, pressing back against the ball at all times. This is repeated as many repetitions as it takes for the subject to report an RPE of 7 or wishes to stop. The second test is the biceps curl exercise. The biceps curls exercise test will follow a protocol developed at the Rocky Mountain Cancer Rehabilitation Institute (RMCRI), Greeley, Colorado. The protocol involves the administration of the exercise biceps curls, done with dumbbells. Subjects will be asked to perform as many repetitions as possible during an alternated biceps curl exercise using a percentage of their body weight as resistance.
224261981|NCT01094054|PROCEDURE|Adjustable gastric banding|Placement of adjustable gastric band - laparoscopically
223681744|NCT04801316|BEHAVIORAL|Steady Feet Video|About an hour-long video showcasing the exercise steps of the Steady Feet exercise programme
223681745|NCT01178996|BIOLOGICAL|Thymosin alpha 1|Thymosin alpha 1 (Zadaxin) 1.6 mg/day, two times weekly in the morning, by subcutaneous injection for 48 weeks.
223681746|NCT01178996|DRUG|Ribavirin|Ribavirin 1000 mg (\<75 kg) or 1200 mg (\>75 kg) daily with food divided in two doses orally for 48 weeks
223774264|NCT01334866|PROCEDURE|Minimally invasive coronary artery bypass graft surgery|The MICS CABG procedure can bridge the gap between percutaneous coronary intervention (PCI) and standard sternotomy. The key components are direct vision, creating anastomoses with traditional instruments and proximal aortic location.
223774265|NCT00495716|DRUG|acyclovir|800 mg acyclovir orally 3 times daily for 2 days at the start of a genital herpes recurrence
223774266|NCT00495716|DRUG|acyclovir|400 mg acyclovir orally twice daily for 1 year
223774267|NCT05859295|DEVICE|Red Low-Level Light Therapy|Visible red light (633nm) projected onto the face using an light emitting diode (LED) mask
223774268|NCT04084353|OTHER|Intrapartum fetal monitoring training and quality improvement project|Intrapartum fetal monitoring training
223774269|NCT04519658|DRUG|CIN-107|CIN-107 tablets by mouth once daily
223774270|NCT04519658|DRUG|Placebo|placebo tablets by mouth once daily
223774271|NCT02210429|PROCEDURE|Elbow Fracture Fixation|
223774272|NCT02989207|PROCEDURE|Trabeculectomy|The current standard surgical treatment for glaucoma remains trabeculectomy. Wound healing modulation with antifibrotic agents, like MMC and 5-fluorouracil (5-FU), has been shown to increase the success of glaucoma filtering surgery in high-risk eyes
223774273|NCT02989207|DEVICE|Baerveldt tube surgery|All glaucoma drainage devices consist of a tube which is inserted into the anterior chamber of the eye, draining aqueous humour to a plate which maintains a minimum bleb size and allows the collection of aqueous humour to be absorbed into the surrounding tissue.
223774274|NCT02989207|DRUG|mitomycin-C|This is an anti scarring agent whcih is an standard adjunctive treatment in glaucoma surgery
223774275|NCT01427296|DRUG|Polyethylene glycol|HalfLytely and Bisacodyl Tablet Bowel Prep Kit, administered as 1 bisacodyl tablet followed by HalfLytely oral solution in a total liquid volume of approximately 2 L
224323855|NCT02412228|DRUG|Cyclophosphamide|"Cycle 1:~Cyclophosphamide: 50 mg/day continuous daily~Cycles 2-6:~Cyclophosphamide: 50 mg/day continuous daily"
224323856|NCT02412228|DRUG|Dexamethasone|"Cycle 1:~Dexamethasone: 20 mg/day 1, 8, 15~Cycles 2-6:~Dexamethasone: 20 mg/day 1, 4, 8, 11, 15, 18"
224323857|NCT06564792|BEHAVIORAL|Contingency management|Once weekly contingency management visit involving 15 minutes+ of motivational interviewing and provision of incentives for stimulant-negative urine tests and/or tenofovir-positive urine tests.
224323858|NCT04778449|OTHER|Medical Chart Review|Medical charts are reviewed
224323859|NCT04778449|OTHER|Questionnaire Administration|Complete questionnaires
224323860|NCT01550575|DEVICE|Non Boston Scientific Systems|Spinal cord stimulation, RF, IDS etc.
223774276|NCT01427296|DRUG|Oral sodium phosphate solution|OsmoPrep tablets (48 g), administered as 32 total tablets in a total liquid volume of approximately 2 L
223774277|NCT00482079|DRUG|MK0431, sitagliptin phosphate / Duration of Treatment: 21 Weeks|
223774278|NCT00482079|DRUG|Comparator: placebo (unspecified) / Duration of Treatment: 21 Weeks|
223774279|NCT04596540|DRUG|SEL-212 low-dose|"SEL-212 low-dose Drug: SEL-037 (0.2 mg/kg) SEL-037, PEGylated uric acid specific enzyme (uricase) Other Names: Pegadricase, pegsiticase~Drug: SEL-110.36 (0.1 mg/kg) Other Names: SEL-110, ImmTOR"
223774280|NCT04596540|DRUG|SEL-212 high-dose|"SEL-212 high-dose Drug: SEL-037 (0.2 mg/kg) SEL-037, PEGylated uric acid specific enzyme (uricase) Other Names: Pegadricase, pegsiticase~Drug: SEL-110.36 (0.15 mg/kg) Other Names: SEL-110, ImmTOR"
223774281|NCT04596540|OTHER|Placebo|Normal saline
223774282|NCT03228004|BEHAVIORAL|Glooko MeterSync|The participant and caregiver will receive a reminder via text or email to upload glucose data via Glooko on a biweekly basis.
223774283|NCT05961774|DEVICE|Transcranial magnetic stimulation|The stimulation point is the lumbar multifidus hotspot. The parameters will be set at frequency 10 Hz, 50 number of pulses, 40 train of stimulation (5 seconds stimulation and 25 seconds inter-stimulation interval). The position of coil will be placed tangentially at 45 degrees on the LM hotspot. The stimulation will be 20 minutes.
223774284|NCT05961774|DEVICE|Neuromuscular electrical stimulation|The neuromuscular electrical stimulation will be set as interferential current 6000 Hz, amplitude 20-50 Hz with scanning mode, duration 20 minutes, intensity to elicit the LM contraction.
224323861|NCT01550575|DEVICE|Boston Scientific Systems|Spinal cord stimulation, RF, IDS etc
224323862|NCT06524375|DRUG|Venetoclax|Venetoclax tablets will be administered as per the schedule specified in the arm.
224323863|NCT06524375|DRUG|cBTKi Monotherapy|Commercially available cBTKi (ibrutinib or acalabrutinib, or zanubrutinib) will be administered in accordance with its prescribing label.
224323864|NCT03888105|DRUG|Odronextamab|Administered by intravenous (IV) infusion
224323865|NCT06044337|DRUG|BIIB059 (litifilimab)|Administered as specified in the treatment arm.
224323866|NCT04231851|DRUG|Glasdegib|Given PO
224323867|NCT04231851|DRUG|CPX-351|Given IV
224323868|NCT05461170|DRUG|VIR-2218|VIR-2218 given by subcutaneous injection
224323869|NCT05461170|DRUG|VIR-3434|VIR-3434 given by subcutaneous injection
224323870|NCT05461170|DRUG|NRTI|NRTI given orally.
224323871|NCT01479842|DRUG|BTK inhibitor PCI-32765|Given PO
224323872|NCT01479842|BIOLOGICAL|rituximab|Given IV
223774285|NCT02674022|DIETARY_SUPPLEMENT|Prenatal supplement|Treatment with a standard and optimized prenatal supplement, dependent on laboratory evaluations of participants.
223774286|NCT02044536|OTHER|No intervention|retrospective data review
223774287|NCT06109428|DRUG|HTX-011|400 mg
223774288|NCT06109428|DRUG|Bupivacaine Hydrochloride|125 mg
223774289|NCT06109428|DRUG|Ibuprofen|400 mg
224323873|NCT01479842|DRUG|bendamustine hydrochloride|Given IV
224323874|NCT01479842|OTHER|pharmacogenomic studies|Correlative studies
224323875|NCT01479842|OTHER|pharmacological study|Correlative studies
224323876|NCT01479842|OTHER|laboratory biomarker analysis|Correlative studies
224323877|NCT04301843|DRUG|Eflornithine|DFMO (difluoromethylornithine) will be given at a dose of 1000 mg/m2 BID on each day of study.
224323878|NCT03651700|DEVICE|Active TMS|Active TMS will be at 90% motor threshold
224323879|NCT03651700|DEVICE|Sham TMS|Sham TMS will be administered
224323880|NCT03651700|BEHAVIORAL|CILT|60-90 minutes of CILT will be administered during each treatment session
224323881|NCT04889872|DEVICE|SAPIEN 3 / SAPIEN 3 Ultra / SAPIEN 3 Ultra RESILIA|Patients will be implanted with a SAPIEN 3 / SAPIEN 3 Ultra / SAPIEN 3 Ultra RESILIA heart valve
223681747|NCT01178996|BIOLOGICAL|PEGinterferon alfa2a|180 mcg, once weekly in the evening, by subcutaneous injection for 48 weeks
224323882|NCT05587712|DRUG|Sotatercept|SC injection every 3 weeks (Q3W) of 0.3 mg/kg. Dosage may be adjusted based on protocol-specific guidelines.
224323883|NCT04443348|RADIATION|Radiation Therapy Boost|Participants randomized to the low-dose or high-dose RT boost group will be receiving treatment on Day 1-3 of Cycle 1 of pembrolizumab. Proton therapy may be used in the high dose RT group.
223681748|NCT01178996|DRUG|Placebo|Placebo
223681749|NCT00170963|DRUG|valsartan/amlodipine|
223681750|NCT05143359|DIAGNOSTIC_TEST|Wharfe and Pederson difficulty index|Efficiency of Wharfe and Pederson Difficulty index in extraction of third molars.
223681751|NCT05143359|DIAGNOSTIC_TEST|Winters difficulty index|Efficiency of Winters Difficulty index in extraction of third molars.
223681752|NCT03579030|DRUG|Placebo oral capsule|Placebo capsule matched to an RTA 1701 capsule
223681753|NCT03579030|DRUG|RTA 1701 capsules|Capsule containing RTA 1701, multiple dosages
223681754|NCT00745225|DRUG|Pioglitazone|pioglitazone 15mg daily for 12 weeks, then 30mg daily for 84 weeks
223681755|NCT00745225|DRUG|placebo comparator|1 capsule daily, 96 weeks.
223681756|NCT05811533|OTHER|Spencer's MET with conventional therapy|Patients will be asked to lie in a side lying position with the affected shoulder above. The therapist will stabilize the shoulder girdle with the proximal hand and the distal hand provided force into the restrictive barrier of shoulder in 7 different movements. During all the movements, patients will ask to use their muscle energy 20% against the slight resistance offered by the therapist for 3-5 seconds. The patient then asks to relax and exhale after that shoulder joint will move beyond the barrier to achieve the next barrier. After 20 sec of rest, this technique will be repeated 3-5 times
223681757|NCT05811533|OTHER|Post-Facilitation Stretch with conventional therapy|Muscle Energy Technique \[Post Facilitation Stretch)\] for the shoulder joint will be applied with 3 repetitions per set, 1 session per day. Patient will be instructed to perform a full strength contraction of the muscle to be stretch for 10 seconds. The muscle is then allow to fully relax, whereupon a rapid stretch of the affected muscle will be performed and will held in position by the physician for 15 sec. Patient will be asked to relax and whole cycle will be repeated
223681758|NCT01911637|DRUG|VBY-036|Study drug VBY-036
223681759|NCT01911637|DRUG|Placebo|Placebo
223681760|NCT01966432|BEHAVIORAL|Referral to Treatment|Patients receive a referral to treatment for substance abuse, with up to 2 follow-up phone calls. Patients are re-screened at followup visits.
223681761|NCT01966432|BEHAVIORAL|Brief Intervention|Patients receive a brief intervention aimed at reducing substance use, and are re-screened at followup visits.
223681762|NCT03013127|DRUG|Pembrolizumab|Pembrolizumab is a humanized antibody used in cancer immunotherapy.
223681763|NCT04087928|DEVICE|FMV_flex|Fisiocomputer EVM (Endomedica, Italy) for application of FMV to flexor muscles of the upper limb (brachial biceps and carpal flexors).
223681764|NCT04087928|DEVICE|FMV_ext|Fisiocomputer EVM (Endomedica, Italy) for application of FMV to extensors muscles of the upper limb (triceps brachial and carpus extensors).
223681765|NCT05610085|DRUG|Levetiracetam Injection|Neonates will be treated with intravenous levetiracetam 60mg/kg for first line management of seizures, and if seizures persist will be randomized to receive higher dose Levetiracetam or standard of care phenobarbital
223681766|NCT05610085|DRUG|Phenobarbital Sodium Injection|Standard of care for neonatal seizures
223681767|NCT02524977|BEHAVIORAL|Decision Support|Provision of recommended antithrombotic therapy based on atrial fibrillation decision support tool that uses both stroke and bleeding risk
223681768|NCT02524977|BEHAVIORAL|Educational Intervention Only|Educational conference series
223681769|NCT04049227|DRUG|Abemaciclib|Given PO
223681770|NCT04049227|DRUG|Letrozole|Given PO
223681771|NCT04049227|PROCEDURE|Therapeutic Conventional Surgery|Undergo standard of care hysterectomy
223681772|NCT05871983|DEVICE|MUNICH TRANSCATHETER MITRAL VALVE REPLACEMENT SYSTEM|"The replacement valve consists of a self-expanding, tri-leaflet, dry bovine -pericardial valve. The dry tissue allows the valve to be conveniently pre-loaded. The key characteristics of Munich valve are:~* Nitinol stent frame~* Bovine pericardium~* Polyester skirt~* Anchoring system allows anchoring the frame to the annulus~* Hooks are used to reduce the mobility of the native leaflets and decrease risk of embolization.~The Munich TMVR system design proposed for this clinical investigation represents a significant evolution from previous TMVR designs:~* Transfemoral / transseptal access~* Self-expanding~* Dry pericardium (can be pre-loaded)~* No anchors~* 27 Fr delivery catheter (~* Sizes: 40/48/55mm~* Height 30 mm The valve is available in 3 sizes with a 30mm profile and has been designed to reduce the complexity of implantation in comparison to other TMVR systems."
223774290|NCT06109428|DRUG|Acetaminophen|1 g
224323884|NCT04443348|DRUG|Pembrolizumab|"Neoadjuvant Phase: Day 1 (once every 6 weeks) of Cycles 1-4 (by intravenous infusion) over about 30 minutes.~Adjuvant Phase: Pembrolizumab may be given post-surgery for up to 4 cycles (once every 6 weeks) by intravenous infusion over about 30 minutes. Pembrolizumab after surgery is optional and should be discussed with the study doctor."
224323885|NCT04443348|DRUG|Paclitaxel|Starting Week 3 and administered once per week for 12 weeks (up to 12 doses) by intravenous infusion over about 30 minutes.
223681773|NCT06231836|DEVICE|High flow nasal cannula (HFNO)|O2 is administered by HFNO with flow 70L/min and the FiO2 is set at 40%,
223681774|NCT06231836|DEVICE|nasal cannula|O2 is administered by nasal cannula at 6L/min
223681775|NCT06424665|DRUG|FZ-AD005|Every 21 days for 1 cycle. Subjects will receive an intravenous infusion of FZ-AD005 until confirmed progression, unaccepted toxicity, or any criterion for withdrawal from the study.
223774291|NCT06109428|DEVICE|Luer lock applicator|Applicator for instillation
223774292|NCT06415643|OTHER|Islet organoids transplantation|autologous transplantation of ex vivo expanded islet organoids.
223681776|NCT00584740|DRUG|AIN457|10 mg/kg
223835262|NCT02213055|DRUG|LICEMD|Parents/guardians of infested children will provide consent for their child's participation. Infested children whose parents agree to use the investigational product will be enrolled on the experimental arm of the study using the LiceMD product as treatment. Participants will be examined for lice count and scalp irritation the day after the first application, and one and two weeks after the first application.
224323886|NCT04443348|DRUG|Carboplatin|"Carboplatin is optional for TNBC patients and should be discussed with the study doctor.~Starting Week 3 and administered once per week for 12 weeks (up to 12 doses) by intravenous infusion over about 30 minutes."
224323887|NCT04443348|DRUG|Cyclophosphamide|Starting Week 15 and administered every 2 weeks for 4 cycles (up to 4 doses) into your vein (by intravenous infusion).
224323888|NCT04443348|DRUG|Doxorubicin|Starting Week 15 and administered every 2 weeks for 4 cycles (up to 4 doses) into your vein (by intravenous infusion). Doxorubicin will be administered after pembrolizumab.
224323889|NCT04443348|DRUG|Capecitabine|"Capecitabine after surgery is optional for TNBC patients and should be discussed with the study doctor.~Starting 3-6 weeks after surgery, administered orally twice daily for 6 courses, each 3 weeks long (for a total of 18 weeks)."
224323890|NCT04227847|DRUG|SEA-CD70|Given into the vein (IV; intravenously) on Days 1 and 15 of each treatment cycle
224323891|NCT04227847|DRUG|azacitidine|75mg/m\^2 injected under the skin (SC; subcutaneous) or given into the vein (IV; intravenously) on Days 1 through 7 of each treatment cycle.
224323892|NCT04227847|DRUG|Venetoclax|400 mg /day PO, continuously; administered with ramping
224323893|NCT03832998|DRUG|Erenumab Dose 1|Participants in the low body-weight group at day 1 and who are randomized to Dose Level 1 will receive this dose.
224323894|NCT03832998|DRUG|Erenumab Dose 2|Participants in the low body-weight group at day 1 who are randomized to Dose Level 2 and participants in the high body-weight group at day 1 who are randomized to Dose Level 1 will receive this dose.
224323895|NCT03832998|DRUG|Erenumab Dose 3|Participants in the high body-weight group at day 1 who are randomized to Dose Level 2 will receive this dose.
224323896|NCT03832998|OTHER|Placebo|Placebo matching dose for erenumab dose 1, 2 and 3.
224323897|NCT05055830|DRUG|The OPTIC study is collecting PK data on children prescribed understudied drugs of interest per standard of care.|The goal of this study is to characterize the pharmacokinetics of understudied drugs for which specific dosing recommendations and safety data are lacking. The prescribing of drugs to children will not be part of this protocol. Taking advantage of procedures done as part of routine medical care (i.e. blood draws), this study will serve as a tool to better understand drug exposure in children receiving these drugs per standard of care.
224323898|NCT05251701|DEVICE|Personal KinetiGraph® (PKG®) System|The PKG® System includes a wrist-worn device that records and measures movement patterns in conditions such as Parkinson's disease.
224323899|NCT03295981|DRUG|Zoledronic Acid|4 mg of zoledronic acid (Zometa) will be added to each bag of bone cement
224323900|NCT03802019|OTHER|LNC Cigarettes + Colored Packaging|After completing a 5-day baseline period of smoking their own brand, participants will be randomized to a 30-day experimental period when they will receive low nicotine content cigarettes in one of four types of packaging: gray, red, blue, or plain.
223681777|NCT00584740|DRUG|Placebo|Matching placebo to AIN457
224261982|NCT01094054|BEHAVIORAL|Dietary and lifestyle modification|"Dietary and lifestyle modification~Subjects will meet with a dietitian and a psychologist on a weekly basis and consume a diet matched to that of the banding arm"
224261983|NCT02464657|DRUG|Nivolumab|"Phase I Starting Dose of Nivolumab: 1 mg/kg by vein on Day 24 of a 28 day cycle.~Phase II Starting Dose of Nivolumab: Maximum tolerated dose from Phase I."
224261984|NCT02464657|DRUG|Idarubicin|Phase I and Phase II dose of Idarubicin 12 mg/m2 by vein daily for 3 on Days 1 - 3 of a 28 day cycle.
224261985|NCT02464657|DRUG|Cytarabine|Phase I and Phase II dose of Cytarabine (Ara-C) 1.5 g/m2 by vein daily on Days 1 - 4 of a 28 day cycle.
224261986|NCT02464657|DRUG|Solu-medrol|Phase I and Phase II dose of Solu-medrol 50 mg by vein daily for 3 - 4 days with Ara-C on Days 1 - 4 of a 28 day cycle.
224261987|NCT02464657|DRUG|Dexamethasone|Phase I and Phase II dose of Dexamethasone 10 mg by vein daily for 3 - 4 days with Ara-C on Days 1 - 4 of a 28 day cycle.
224323901|NCT03802019|OTHER|Own Brand|After completing a 5-day baseline period of smoking their own brand, participants will be randomized to a 30-day experimental period when they will receive their own preferred brand of cigarette (i.e., control).
224323902|NCT05634499|DRUG|Giredestrant|Participants will receive giredestrant 30 milligrams (mg) taken orally (PO) once a day (QD) on Days 1 to 28 of each 28-day cycle for 6 cycles. After completion of 6 cycles, the participant and investigator can choose to continue study treatment for an additional 18 cycles or discontinue study treatment and receive investigator-determined care.
224323903|NCT05558475|BEHAVIORAL|Virtual Coaching|The core coaching components are motivational support, clinical health education, and technical support. The specific objectives are: support PTBS engagement, foster subsequent treatment adherence, ensure appropriate implementation of guidelines for Sleep Restriction Therapy and Stimulus Control, identify and triage PTBS candidates who are not appropriate or need more intensive treatments, and provide PTBS course technical support.
223774293|NCT03781076|BEHAVIORAL|Sleep Intervention|The study therapist will outline the biopsychosocial model of mTBI recovery, highlighting the shift from biological injury to behavior (especially sleep behavior) as key driver of symptoms. The intervention will then apply well-established strategies from the pediatric psychology and insomnia literatures, encouraging conjoint problem-solving by parent and youth with the shared goal of maximizing nocturnal sleep. These include: pre-planning, problem-solving, development of a positive routine, commitment to sleep-promoting behaviors, self-monitoring, and positive reinforcement. The therapist will also teach a brief, self-guided pre-sleep relaxation exercise that has been used in insomnia treatment to maximize the benefit of additional sleep opportunity.
224261988|NCT04654182|DRUG|Chlorhexidine Gluconate|Product used in accordance with manufacturers Hand Hygiene instructions
224261989|NCT00287131|PROCEDURE|Procedure - Adoptive cell transfer|Procedure - Adoptive cell transfer
224261990|NCT04471922|DRUG|Anaprazole Sodium enteric-coated tablet|Multiple ascendinng dose, anaprazole 60mg QD(60mg QD group), 80mg QD(80mg QD group), 100mg QD(100mg QD group) , 7 days, fasting oral administration.
224261991|NCT04471922|DRUG|Placebo|Multiple dose, 1 tablet QD (60mg QD,80mg QD and 100mg QD group), 7 days, fasting oral administration.
224261992|NCT04471922|DRUG|Active controlled (rabeprazole)|Multiple dose, rabeprazole 20mg QD (60mg QD,80mg QD and 100mg QD group), 7 days, fasting oral administration.
224261993|NCT04322344|DRUG|Escin|treatment with escin or escinate sodium
224261994|NCT04322344|DRUG|standard therapy|antiviral drugs
223681778|NCT01903525|DRUG|Docosahexaenoic acid (DHA)|Subjects presenting with a new concussion within 4 days of their initial injury will be identified and screened for eligibility from the investigators' regularly scheduled clinic patients. Subjects who enroll will complete 5 scheduled visits, although additional visits may be clinically indicated for symptom evaluation and treatment. All assessments done for this study are routinely done as part of the standard clinic visits for concussion at the Sports Medicine Center. Subjects will be randomized to either DHA or placebo in a 1:1 ratio, and receive enough DHA or placebo capsules to reach the target dose of 2 g of DHA per day (or placebo) until the day of their next appointment. Subjects will be instructed to take 4 capsules (2 at breakfast and 2 at dinner) for 12 weeks.
223774294|NCT03550924|PROCEDURE|low flow passive oxygenation|low flow passive oxygenation during laryngoscopy with 10l/min oxygen via standard nasal prongs
224261995|NCT04786496|BEHAVIORAL|ITP+SA Wise intervention|Intervention designed to promote well-being and resilience in late adolescents and young adults. It includes two components: a self-affirmation (SA) activity and an ITP intervention. The SA component includes a list of values so that they could choose the three most important for them. Next, they are asked to write why those selected values are the most important to them. The ITP component resembled the intervention developed by David S. Yeager and colleagues and it was adapted to first year university students. It consisted of three parts. First, participants are asked to read scientific studies that provide evidence that behaviors are controlled pathways in the brain that have the potential to be changed under the right circumstances. Second, participants read several testimonials purportedly written by second year university students to bring credibility to the ITP. Finally, participants are asked to write their own version of such a narrative (self-persuasive writing exercise).
224261996|NCT04786496|BEHAVIORAL|ITP Wise intervention|Intervention designed to promote well-being and resilience in late adolescents and young adults based on four general types of change strategies: (1) scientific knowledge, (2) generation of new meanings, (3) commitment through action, and (4) active reflection. It includes the ITP component described above for the ITP+SA Wise intervention.
224261997|NCT04786496|BEHAVIORAL|Control condition|The control intervention was designed to have a similar structure than the experimental interventions, including also reading and writing tasks, but that they were not in any way related to the contents of the experimental interventions. In particular, participants were asked to read an article about the fire that took place in the Notre Dame cathedral in Paris that had been recently published in a newspaper. Starting from the accident of the Notre Dame cathedral, the article focuses on reflecting on the problem of heritage conservation and analyzing the situation of other important cathedrals. After reading the article, the participants were asked to write a few lines evaluating in their opinion the importance of the conservation of historical buildings such as those mentioned and how much of the public economic budget should be used for heritage conservation.
224261998|NCT01429363|PROCEDURE|Targeted disc decompression|The Targeted disc catheter is connected to Neurotherm TDD unit and heating protocol is started.In this heating protocol temperature gradually increases from 65C to 90C during a time period of 12 minutes;
224261999|NCT04537663|DRUG|Bacille Calmette-Guérin (BCG)|Participants in the intervention group will be vaccinated with the licensed BCG vaccine (Danish strain 1331, SSI, Denmark) using the standard vaccination technique for this vaccine (intradermal injection in the left upper arm).
224262000|NCT04537663|DRUG|Placebo|Intradermal injection of sterile 0.9% NaCl.
224262001|NCT04710290|DIETARY_SUPPLEMENT|Beta-Glucan|Solid beverage powders, capsules and placebo were randomly assigned. The main components of the solid beverage powder are beta-glucan combined with glutamine and immunoglobuin.and the main component of the capsule is beta-glucan . The main ingredient of placebo is corn starch.
224262002|NCT04710290|DIETARY_SUPPLEMENT|Glutamine|Solid beverage powders, capsules and placebo were randomly assigned. The main components of the solid beverage powder are beta-glucan combined with glutamine and immunoglobuin.and the main component of the capsule is beta-glucan . The main ingredient of placebo is corn starch.
224262003|NCT04710290|DIETARY_SUPPLEMENT|Immunoglobuin|Solid beverage powders, capsules and placebo were randomly assigned. The main components of the solid beverage powder are beta-glucan combined with glutamine and immunoglobuin.and the main component of the capsule is beta-glucan . The main ingredient of placebo is corn starch.
224262004|NCT04710290|DIETARY_SUPPLEMENT|Corn starch|Solid beverage powders, capsules and placebo were randomly assigned. The main components of the solid beverage powder are beta-glucan combined with glutamine and immunoglobuin.and the main component of the capsule is beta-glucan . The main ingredient of placebo is corn starch.
224262005|NCT02222064|BEHAVIORAL|Mindfulness|Mindfulness is a psychological intervention based on increasing skills of non-judgemental awareness using meditations. In this study a self-directed 8 week course of mindfulness will be used involving self-help materials in the form of a book and 8 guided meditations on audio files.
224262006|NCT06219031|OTHER|no intervention|no intervention
224262007|NCT01028586|DRUG|Safinamide, MAO-B inhibitor|Safinamide, MAO-B inhibitor 50 mg: once-daily orally for 78 weeks in addition to their dose of DA-agonist.
224262008|NCT01028586|DRUG|Safinamide, MAO-B inhibitor|Safinamide, MAO-B inhibitor 100 mg: once-daily orally for 78 weeks in addition to their dose of DA-agonist.
224262009|NCT01028586|DRUG|Placebo|matching placebo tablets
224262010|NCT02488239|DEVICE|CRT-P indicated patients|Patients who are indicated for a CRT-P device are planned to be implanted with a CRT-P device
224262011|NCT04854460|DRUG|Revemact|1 tablet contains 6 mg Ivermecin
224262012|NCT04854460|DRUG|Stromectol (first dose)|2 tablet contain 6 mg Ivermecin
224262013|NCT04854460|DRUG|Stromectol (second dose)|2 tablet contain 6 mg Ivermecin
224262014|NCT05915559|PROCEDURE|Tonsillectomy|Tonsillectomy
224262015|NCT05915559|OTHER|daily follow-up|daily follow-up of clinical parameters (pain, feeding) and analgesia adapted to the pain
223774295|NCT03550924|PROCEDURE|high flow passive oxygenation|high flow passive oxygenation during laryngoscopy with 120l/min oxygen via THRIVE system
223774296|NCT04958733|PROCEDURE|Autologous bone grafting|Autologous bone grafting is the excess bone obtained from graft preparation and the coring reamer
223774297|NCT04958733|PROCEDURE|Absence of autologous bone grafting|Donor sites will be left unfilled
223774298|NCT01687166|DEVICE|Blazer Open-Irrigated Ablation Catheter (Boston Scientific)|
224262016|NCT03206086|DRUG|Eltrombopag|Daily dose - Non-Asian (\>=12): 150 mg Non-Asian (6-11): 75 mg East Asian, South East Asian (\>=12): 75 mg East Asian, South East Asian (6-11): 37.5 mg
224262017|NCT03283982|DEVICE|Robotic Ventral Hernia Repair with IPOM|Minimally invasive ventral hernia repair with intraperitoneal mesh placement, using the da Vinci robotic platform
224262018|NCT03283982|DEVICE|Laparoscopic Ventral Hernia Repair with IPOM|Minimally invasive ventral hernia repair with intraperitoneal mesh placement, using the laparoscopic platform
224262019|NCT03591276|DRUG|Chemotherapy Drugs, Cancer|IV pembrolizumab 200 mg flat dose with IV PLD 30 mg/m2 (chemotherapy drugs) every 3 weeks in eligible breast cancer patients.
224262020|NCT03071562|OTHER|Yoga-mindfulness|"Sample class:~Warm-up~(15 minutes) Standing poses~(15 minutes) Balance poses~(15 minutes) Abdominals \& back bends (10 minutes) Cool-down~(5 minutes) Seated meditation Alternate nostril breathing Bellows breath Shoulder/neck stretches Cat-cow Forward fold Sun salutations Warrior 1 Warrior 2 Triangle Extended side angle Reverse warrior High lunge with twist Tree pose Standing holding knee Modified warrior 3 (chair support) Half moon~Bird-dog Side plank Bridge Cobra Sphinx Corpse pose Side-lying Seated om~Every month, a smudging ceremony will take place with an Aboriginal Elder for 5-10 minutes at the start of the class."
224262021|NCT06426225|OTHER|General Anesthesia|General Anesthesia Applied Group 2 Patients.
224262022|NCT06426225|OTHER|Spinal Aneshtesia|Spinal Anesthesia and Ketofol Sedation Applied Group 1 Patients.
224262023|NCT06559657|DEVICE|eKare Insight, imitoMeasure Mobile App, Visitrak|The wound size of the patients was measured with three different methods. Wound depth was measured using manual method and three-dimensional imaging devices.
224262024|NCT06124339|BEHAVIORAL|Physical Activity|There will be three sessions a week over the course of 16 weeks.
224262025|NCT06124339|BEHAVIORAL|Cognitive Activity (VR)|There will be three sessions a week over the course of 16 weeks.
224262026|NCT06124339|BEHAVIORAL|Physical and Cognitive Activity|There will be three sessions a week over the course of 16 weeks.
224262027|NCT04435574|DRUG|Lactoferrin|Bovine Lactoferrin 100mg sachets.
224262028|NCT04435574|DRUG|Ferrous Sulfate|6mg/kg of ferrous sulfate.
224262029|NCT02145273|BEHAVIORAL|Interpersonal Psychotherapy for Depression -Group|
223681779|NCT01903525|DRUG|Placebo|Subjects presenting with a new concussion within 4 days of their initial injury will be identified and screened for eligibility from the investigators' regularly scheduled clinic patients. Subjects who enroll will complete 5 scheduled visits, although additional visits may be clinically indicated for symptom evaluation and treatment. All assessments done for this study are routinely done as part of the standard clinic visits for concussion at the Sports Medicine Center. Subjects will be randomized to either DHA or placebo in a 1:1 ratio, and receive enough DHA or placebo capsules to reach the target dose of 2 g of DHA per day (or placebo) until the day of their next appointment. Subjects will be instructed to take 4 capsules (2 at breakfast and 2 at dinner) for 12 weeks.
223681780|NCT05305417|PROCEDURE|Autologous Regenerative Endodontic Treatment|The intervention consist in achieve an access to the teeth root canal system, do a chemico-mechanical preparation each root canal for to be obturated with an autologous biological scaffold and bioactive biomaterials to maintain teeth free of signs/symptoms caused by pulp necroses and periapical lesions
223681781|NCT05305417|PROCEDURE|Conventional Root Canal Treatment|The intervention consist in achieve an access to the teeth root canal system, do a chemico-mechanical preparation each root canal for to be obturated with an inert biomaterial to maintain teeth free of signs/symptoms caused by pulp necroses and periapical lesions
223681782|NCT02973607|PROCEDURE|Nephrectomy|This is observational in design.
223681783|NCT03657303|DEVICE|Magnetic resonance imaging (MRI)|Participants will undergo an initial (baseline) MR examination, followed by repeat MR examinations at approximately 1 month and 1 year following the baseline examination.
223681784|NCT02299778|DIETARY_SUPPLEMENT|13C6-p-aminobenzoic acid|
223774299|NCT01687166|DEVICE|FDA Approved Open-Irrigated Ablation Catheter|
223774300|NCT06137456|DEVICE|Exoskeletal robotic therapy for walking.|Exoskeletal robotic therapy for walking. Therapy sessions were scheduled for 40 minutes each. The study group performed exoskeleton walking and balance exercises 3 days a week.
223774301|NCT06137456|OTHER|Conventional exercise therapy|Conventional treatment consisted of walking and balance exercises, stretching, strengthening, and mobility exercises, for 40 minutes, 5 days a week.
224262030|NCT04378309|BEHAVIORAL|ePREP|6-session online psychoeducational program with supporting coach calls
224262031|NCT05920629|BEHAVIORAL|Alcohol consumption|After written consent, patients will enter a run-in period of 2 weeks where they will be asked not to drink any alcohol beverage. Patients with a successful run-in period will be randomized on a 1:1 basis stratified by baseline LVEF (\<50% vs. ≥50%), sex and study site. 110 patients will be assigned to moderate alcohol consumption (1 standard unit a day), and 110 patients to abstinence (no alcohol beverages) for 3 months. We will perform a first echocardiography at randomization and a second at 3 months' follow-up.
224262032|NCT05930769|PROCEDURE|Gynecological laparoscopic surgery without augmented reality|Minimally invasive gynecological surgery assisted by laparoscope.
224262033|NCT05930769|PROCEDURE|Gynecological laparoscopic surgery with augmented reality|Minimally invasive gynecological surgery assisted by laparoscope with the display of additional information through augmented reality.
224262034|NCT04149691|DRUG|CPL304110|CPL304110 is to be administered orally as hard gelatine capsules once daily in 28-day cycles.
224262035|NCT03218150|PROCEDURE|cranioplasty|". The margins of the craniectomy defects exposed, and the bone flaps fixed in their original positions using wires or titanium plates with screws. As prophylaxis, all patients intravenously administered with pre- and postoperative antibiotics.~In cases of artificial substitutes , The polymethyemethacrylate implant fixed to the defective region with titanium plates and self-tapping screws."
224262036|NCT06826846|OTHER|Serratus posterior superior intercostal plane block (single-shot)|30 mL of 0.25% bupivacaine will be injected as single-shot block 20 mins prior to surgery
224262037|NCT06826846|OTHER|Serratus posterior superior intercostal plane block (catheter)|In addition to administration of 30 mL of 0.25% bupivacaine prior to surgery, a catheter will be placed in the area to administer bolus of 1 mg/kg of 0.25% bupivacaine every 8 hours postoperatively.
223774302|NCT05371535|DEVICE|MatrixOssTM Bone Graft plus Bio-Gide membrane|To verify the efficacy and safety of MatrixOssTM Bone Graft developed and manufactured by Collagen Matrix, Inc. for bone defect repair caused by tooth extraction.
223774303|NCT02966171|DRUG|HMPL-453|oral administration
223774304|NCT02755831|DEVICE|CPAP|Continuous Positive Airway Pressure (CPAP) Therapy for Obstructive Sleep Apnea
223774305|NCT02755831|OTHER|Pre-natal care|Standard Pre-Natal Care
224323904|NCT03874754|OTHER|Tailored Technology-Enhance Home-based exercise program (iHBE)|The tailored technology enhanced home-based exercise (iHBE) program is a 12-week program with 1 assessment home visit session, 5 home visits and 7 phone follow ups during exercise. The technologies, a wearable device, and a smartphone application, will be used as a tool to monitor physical performance (heart rate \[HR\], step count), provide immediate feedback, send daily reminding message through Mobile Ecological Momentary Assessment (mEMA). The coded raw data without personal identification information from the wearable device will be sent to the servers where the investigators can store it in the database alongside the mEMA data and create custom reports showing Heart Rate (HR) 30 minute before each Ecological Momentary Assessment (EMA) survey, showing HR and previous self-report responses before/ after each automatically triggered EMA.
223774306|NCT06197451|OTHER|Turkish Version of M. D. Anderson Dysphagia Inventory|Turkish Validation and Cultural Adaptation of M. D. Anderson Dysphagia Inventory in Neurologic Patients
223774307|NCT04317248|DRUG|Cyclophosphamide|Intravenous drip，250mg/m\^2 per time，two days before each times of MSDCV therapy，total 6 times, in order to improve the immunosuppressive microenvironment of tumor，reduce CD4+CD25+FOXP3+regulatory T cells (Tregs）
223774308|NCT04317248|BIOLOGICAL|Multiple Signals loaded Dendritic Cells Vaccine|one time every 4 weeks during 0 weeks to 20 weeks, about 5\*10\^7 cells per time, intravenous driptotal 6 times;
223774309|NCT02348528|DRUG|Lenalidomide|
224262038|NCT06389448|DEVICE|pCLE-gastr|After identifying the location of the lesion through white light endoscopy, the pCLE operation is performed to acquire images from the specific gastric lesions, and finally the ESD routine is performed.
224262039|NCT06452030|BEHAVIORAL|Specific sensorimotor control training|Participants allocated to the specific motor control group will receive sensorimotor training of the multifidus muscle.
224262040|NCT06452030|BEHAVIORAL|Aspecific extension training|Participants allocated to the aspecific group will receive spinal extension exercises.
224262041|NCT06452030|BEHAVIORAL|Fascia training|Participants allocated to the fascia group will receive general movement exercises.
224262042|NCT06847074|BEHAVIORAL|Multimodal Exercise|Each 60-minute class will include a 10-minute warm-up (i.e., stretches for the major muscles and walking on the spot), 40 minutes of training, and a 10-minute cool down (i.e., stretches and relaxation techniques).Instructors will use heart rate monitors to continuously track intensity during and across all sessions.
224262043|NCT06847074|BEHAVIORAL|Cognitve and Social Activities|Each 60-minute class will include 30 minutes of cognitive enrichment activities and 30 minutes of activities that promote social interactions.
224262044|NCT04228822|OTHER|Low carbohydrate diet|25-35% of carbohydrates from total energy intake
224262045|NCT05846139|COMBINATION_PRODUCT|PerioTabs® brushing solution|PerioTabs® contains a non-antibiotic biofilm removal complex called NitrAdine®.Its anti-biofilm action is based on the combination of surfactant-induced protein denaturation and slow release of a non-toxic concentration of hypochlorite (0.02%).
224262046|NCT05846139|COMBINATION_PRODUCT|Chlorhexidine 0.12 %|chlorhexidine 0.12 % toothpaste and chlorhexidine 0.2% mouth rinse
224262047|NCT03396939|DEVICE|Orthosis|All participants in the experimental group will be given an orthotic device for a 12-week period to use alongside their functional goal- and task-oriented training program.
224262048|NCT00608322|DRUG|Inhaled nitric oxide|Inhaled nitric oxide, 40 parts per million, for six hours.
224262049|NCT00608322|OTHER|Sham inhaled nitric oxide|Sham inhaled nitric oxide administration, 0 parts per million, for six hours.
224262050|NCT04491422|COMBINATION_PRODUCT|Integrated Next Steps Counseling with Real-Time Drug Level Feedback|Integrated next steps counseling with real-time drug level feedback using point-of-care urine tenofovir testing at quarterly visits
223774310|NCT02348528|DRUG|Dexamethasone|
223774311|NCT02296112|DRUG|trametinib|Given PO
223774312|NCT02296112|OTHER|laboratory biomarker analysis|Correlative studies
223774313|NCT02296112|OTHER|pharmacological study|Correlative studies
223774314|NCT02543931|DRUG|Meriva|Meriva is an enhanced-bioavailability, curcuminoid-enriched turmeric dietary supplement that is sold over the counter in the United States and other countries.
223774315|NCT02543931|DRUG|placebo|Placebo capsules containing inert ingredients
223774316|NCT02645994|DEVICE|Target Controlled Infusion|Used to control intravenous propofol delivery with target plasma concentratioins changed manually
223774317|NCT02645994|DEVICE|Closed Loop Anesthesia Delivery System|Used to deliver propofol automatically titrated to achieve a target BIS 50, and maintain it between 40 and 60.
223774318|NCT04540861|DRUG|Siponimod|1 or 2 mg film-coated tablets. The tablets have to be taken orally once daily and swallowed whole with water, with or without food.
223774319|NCT03955042|DRUG|Pemetrexed|Pemetrexed 900 mg/m\^2 on Day 1 of each 21-day cycle. Supportive medications of ibuprofen, folic acid, vitamin B12, and dexamethasone.
223774320|NCT02442830|DEVICE|Early Video Capsule Endoscopy|"The intervention is the use of video capsule endoscopy as the first test in a patient presenting to the ED with active bleeding. The capsule allows for visualization of the entire GI tract.~Once a capsule has been given to a study patient, a staff member will use the capsule's real-time viewer to see if there is any active bleeding in the stomach. If bleeding is seen the investigators will pursue an upper endoscopy. If no bleeding is seen a staff member will review the entire findings of the capsule and make a decision regarding which therapeutic measure to pursue."
223774321|NCT06481059|RADIATION|Head and Neck cancer post-radiotherapy|Head and Neck Cancer patients who received radiotherapy after 6 months
223774322|NCT02451566|DEVICE|Ovation Prime Abdominal Stent Graft System|
224262051|NCT02761525|OTHER|silver nanoparticles|Allocation was randomized. Evaluate the effectiveness of silver nanoparticles incorporated into an innocuous gel and dished in oral mucosa surface to then compare with another innocuous gel without silver nanoparticles to reduce microbial colony forming units of pathogenic potential.
223774323|NCT05936255|BEHAVIORAL|Give to Others Module|Negative interpersonal beliefs are targeted via cognitive-behavioral strategies, including evaluation of cognitive distortions, and activity planning and tracking.
223774324|NCT03940378|DRUG|Levamisole Hydrochloride|Levamisole Hydrochloride Levamisole Hydrochloride 25mg/tablet; 150mg/d; po;
223774325|NCT03940378|DRUG|Anlotinib Hydrochloride Capsules|Anlotinib Hydrochloride Capsules Anlotinib Hydrochloride Capsules 12mg / capsule; 12mg/d; po;
223774326|NCT04380207|DRUG|QPX7728|antibiotic
223774327|NCT04380207|DRUG|Placebo|Placebo comparator
223774328|NCT04380207|DRUG|QPX2014|antibiotic
223774329|NCT01516879|BIOLOGICAL|Evolocumab|Administered by subcutaneous injection once a month
223774330|NCT01516879|BIOLOGICAL|Placebo|Administered by subcutaneous injection once a month
223774331|NCT01516879|DRUG|Atorvastatin|Background lipid lowering therapy: 10 mg or 80 mg atorvastatin orally once daily.
223774332|NCT01516879|DRUG|Ezetimibe|Background lipid lowering therapy: ezetimibe 10 mg orally once a day
223774333|NCT01516879|OTHER|Diet Only|Diet only, no lipid lowering background drug given
223774334|NCT00183872|DRUG|irinotecan, docetaxel|docetaxel 30 mg/m2 IV infusion days 1 and 8, with irinotecan 65 mg/m2 IV infusion on days 1 and 8.
223774335|NCT06147011|OTHER|3D printed educational model|Slide-based presention plus 3D printed thyroid fine needle aspiration model
223774336|NCT05244031|PROCEDURE|superficial erector spina plane block|The investigators performed superficial erector spina plane block to that patient group for postoperative analgesia
223774337|NCT05244031|PROCEDURE|Standard (opioid-based) analgesia|The investigators performed intravenous opioid infusion with PCA to that patient group for postoperative analgesia
223774338|NCT00557791|DRUG|Bevasiranib|Three doses (1.0mg, 2.0mg, 2.5mg) of bevasiranib administered intravitreally every 8 weeks
223774339|NCT00557791|DRUG|ranibizumab|Lucentis® (0.5 mg) administered intravitreally every 4 weeks.
223774340|NCT03989193|DEVICE|Computer guided alveolar ridge splitting technique|"The bone splitting technique could be performed using the piezoelectric system, calibrating the device on D1 setting and using profuse saline irrigation. The preparation sequence begins with CS3 insert until a total depth of 10mm was achieved across the entire extension of the ridge. The procedure continued with the CS1 insert and finally the CS2 insert.~The vertical bone cuts through the cortical layer: At the distal end of the horizontal split, a vertical cut will made with the high-speed bur within the vicinity of the buccal plate to start the separation, with a full vertical depth of 13 mm. Final design of the splitting cut was L-shaped split. At the distal and the mesial end of the horizontal split, a vertical cut was made with the high-speed bur for a full vertical depth of 13mm."
223774341|NCT06413199|OTHER|Hyper Training|Experimental group will perform 2 training session per week for 2 months, 1 set of 10 unloaded repetitions in arms as a warm-up, 4 sets with a goal of 8-12 Reps with 90 seconds rest between sets. 1.5 second concentric and 1.5 second eccentric contraction of bench press, The elbows had to be fully locked out to be counted as a repetition.
223774342|NCT06413199|OTHER|1 Repetition maximum training group|2 training session per week for 8 weeks, 1 set of 10 unloaded repetitions in arms as a warm-up, 1 Repetition maximum training group consisted of 5 attempts to lift as much weight as possible one time for that training visit with 90 seconds of rest between attempts, the load was progressively increased each attempt to try to reach or exceed their previous 1 repetition maximum.
223774343|NCT01720069|DRUG|VR506|VR506 inhalation powder delivered via a new dry powder inhaler device
223774344|NCT03784950|BEHAVIORAL|Rating tool|eConsult Specialty Reviewers are asked to rate the quality of other specialists' recently completed eConsult exchanges on the following four dimensions: 1) efforts to elicit additional information from PCPs, when needed; 2) medical decision making; 3) inclusion of educational content for PCPs, when appropriate; 4) perceived effect on the PCP-specialist relationship (i.e., overall tone of the eConsult exchange)
223774345|NCT03784950|BEHAVIORAL|Feedback|eConsult Specialty Reviewers receive confidential feedback via email on their performance (top performer vs not a top performer) as compared to colleagues in their specialty. Feedback is based on other reviewers ratings of their eConsult exchanges on the following four dimensions: 1) efforts to elicit additional information from PCPs, when needed; 2) medical decision making; 3) inclusion of educational content for PCPs, when appropriate; 4) perceived effect on the PCP-specialist relationship (i.e., overall tone of the eConsult exchange)
223774346|NCT03445416|BEHAVIORAL|POL arm|A popular opinion leader intervention designed to increase routine vaccination among young black men who have sex with men.
223774347|NCT03445416|BEHAVIORAL|Comparison arm|A popular opinion leader intervention designed to increase routine vaccination among young black men who have sex with men.
223774348|NCT04507958|DIAGNOSTIC_TEST|auscultation by using conventional stethoscope without PPE|In thoracic patients undergoing general anesthesia with endotracheal tube/endobronchial blocker, Clinician will check the position of endotracheal tube and endobronchial blocker under fiberscope. Afterward, investigator A will perform auscultation with traditional auscultation, then investigator B with electronic stethoscope under full PPE, to examine bilateral breathing sound.
223774349|NCT04507958|DIAGNOSTIC_TEST|auscultation by using electronic stethoscope in full PPE|In thoracic patients undergoing general anesthesia with endotracheal tube/endobronchial blocker, Clinician will check the position of endotracheal tube and endobronchial blocker under fiberscope. Afterward, investigator A will perform auscultation with traditional auscultation, then investigator B with electronic stethoscope under full PPE, to examine bilateral breathing sound.
223774350|NCT00508742|BIOLOGICAL|13-valent Pneumococcal Conjugate Vaccine|1 dose at 2, 4, 6 and 12 months of age
223774351|NCT00508742|BIOLOGICAL|7 valent pneumococcal conjugate vaccine|1 dose at 2, 4, 6 and 12 months of age
223774352|NCT05588596|BEHAVIORAL|Trauma Resiliency Mindfulness-Informed Intervention|The total duration of the intervention was once a week for eight weeks. The aim of the intervention was to teach patients a range of trauma recovery mindfulness skills
223774353|NCT00379470|DEVICE|NovoTTF-100A|multiple four-week courses of continuous NovoTTF-100A treatment
223774354|NCT04568122|DEVICE|Saliva test kit|Kit including tube with closed reagents using loop-mediated isothermal amplification (LAMP) assay to detect SARS-CoV-2 virus.
223774355|NCT00774488|OTHER|Glucose dependent insulinotropic polypeptide (GIP)|GIP-Infusions for 4 h in a postprandial concentration
224323905|NCT04916730|BEHAVIORAL|Standard of Care|Participants in this arm will receive nutritional counseling from the study dietician but will not be required to adopt a 10-hr eating window.
223774356|NCT01613339|OTHER|Balance training using Body awareness therapy|Once a week, 1 hour for 8 weeks.Body awareness training may be performed by physiotherapist. Exercises are performed in standing, sitting and lying. Example of exercises are weight-balancing in standing and relaxation exercises.
223774357|NCT00650039|DRUG|placebo|valdecoxib 40 mg (two 20-mg tablets) by mouth followed by valdecoxib 20 mg 1 to 12 hours after the first dose or 12 hours after the first dose, but no later than midnight on Day 1; then, placebo BID by mouth on Days 2 to 5.
224262052|NCT02761525|OTHER|placebo|Compare with another innocuous gel without silver nanoparticles to reduce microbial colony forming units of pathogenic potential using the same procedure to dished the gel.
224262053|NCT03023449|DRUG|Nitric Oxide|Inhaled Nitric Oxide gas
224262054|NCT00587730|DEVICE|GE Attenuation Corrected Hawkeye Camera|GE Hawkeye AC system and 360˚ camera orbit
224262055|NCT06157905|DRUG|Oral Tofacitinib citrate|oral tofacitinib citrate was initiated at 5 mg twice daily after ruling out contraindications
224262056|NCT05877339|DIAGNOSTIC_TEST|Survey|Survey
224262057|NCT03614039|DIETARY_SUPPLEMENT|"Symbiter Forte"|"Symbiter Forte which contains combination of smectite gel (250 mg), and biomass of 14 alive probiotic strains: Lactobacillus + Lactococcus (6×1010 CFU/g), Bifidobacterium (1×1010/g), Propionibacterium (3×1010/g), Acetobacter (1×106/g)"
224262058|NCT03614039|DIETARY_SUPPLEMENT|Placebo|
224262059|NCT06072339|OTHER|Lung Ultrasound for PEEP setting|NIV is started and adjusted by the physiotherapist. For the adjustment of PEEP, the ultrasound probe is placed on the thorax, facing the intercostal space having obtained the highest score during the initial LUS (synonym of the worst pulmonary aeration) and the images observed in real time. PEEP is increased until the physiotherapist cannot see any additional benefit on pulmonary aeration or appearance of a patient discomfort or an increasing of air leaks.
224262060|NCT06072339|PROCEDURE|Non invasive ventilation session|"The session will be done via a mouthpiece preferably, or a face mask if it is impossible for the patient to close their mouth properly or to hold the mouthpiece.~The duration of the NIV session will be defined by the prescribing doctor (usually between 30 and 60 minutes), without being able to be less than 30 minutes. The session will be stopped in the event of the appearance of one of the contraindications to NIV mentioned above."
224262061|NCT06072339|BIOLOGICAL|Arterial blood gas|Arterial blood gas will be done at inclusion, at Visit 1 (at the 30th minute from the start of the 1st Non-invasive ventilation session) and at Visit 2 (at the 60th minute from the start of the 1st Non-invasive ventilation session) in both groups of patients in order to calculate the Pa02/Fi02 ratio.
224262062|NCT06072339|OTHER|Interview on pain and comfort|The investigator physiotherapist interviews the participant to measure pain and comfort scores using a visual analogue scale (score from 0 to 10).
224262063|NCT05303987|DRUG|Propofol sedation|"After induction with sevoflurane then Propofol will be initiated.~If adequate sedation cannot be attained then a ketamine rescue can be given."
224262064|NCT05303987|DRUG|Dexmedetomidine sedation|"After induction with sevoflurane then Dexmedetomidine will be given.~If adequate sedation cannot be attained then a ketamine rescue can be given."
224262065|NCT06192368|DEVICE|INSPIRE|Virtual reality application for relaxing.
224262066|NCT06192368|DEVICE|Tablet|Gaming tablet
224262067|NCT06145412|DRUG|Xevinapan|Xevinapant (oral dose of 200mg per day on days 1-14 every 21 days for 3 cycles)
224262068|NCT06145412|DRUG|Cisplatin|Cisplatin (2-3 cycles, with 100mg/m2 per cycle q3 weeks)
224262069|NCT06145412|RADIATION|External beam|60 - 66 Gy in 2 Gy fractions for patients without gross disease and 70 Gy for patients with early recurrence) with concurrent cisplatin (40 mg/m2 once weekly)
224262070|NCT05776420|BEHAVIORAL|Food voucher|A voucher of $65 (or $85 for people in larger households) that can be redeemed for food at grocery stores.
224262071|NCT00834444|DRUG|Famciclovir 500 mg Tablets|1 x 500 mg, single-dose fasting
224262072|NCT00834444|DRUG|Famvir® 500 mg Tablets|1 x 500 mg, single-dose fasting
223774358|NCT00650039|DRUG|valdecoxib|valdecoxib 40 mg (two 20-mg tablets) by mouth followed by valdecoxib 20 mg 1 to 12 hours after the first dose or 12 hours after the first dose, but no later than midnight on Day 1; then, valdecoxib 20 mg once daily (QD) by mouth on Days 2 to 5.
223774359|NCT00650039|DRUG|valdecoxib|valdecoxib 40 mg (two 20-mg tablets) by mouth followed by valdecoxib 20 mg 1 to 12 hours after the first dose or 12 hours after the first dose, but no later than midnight on Day 1; then, valdecoxib 20 mg twice daily (BID) by mouth on Days 2 to 5.
223774360|NCT01205724|DRUG|turoctocog alfa pegol|Single dose (low) administered intravenously (into the vein)
223774361|NCT01205724|DRUG|turoctocog alfa pegol|Single dose (medium) administered intravenously (into the vein)
223774362|NCT01205724|DRUG|turoctocog alfa pegol|Single dose (high) administered intravenously (into the vein)
223774363|NCT06250101|BEHAVIORAL|Enhanced Conversational Recast treatment|In the context of child-friendly activities, the clinician prompts the child to attempt to use the grammatical form targeted in the treatment. The clinician immediately restates the child's attempt (i.e., the recast), correcting any ungrammatical elements. Clinicians elicit and recasts 24 utterances per session.
224262073|NCT02875314|DRUG|Induction|vincristine, cisplatin, cyclophosphamide, etoposide, high-dose methotrexate
224262074|NCT02875314|DRUG|Single Cycle Intensive Chemotherapy|Carboplatin, thiotepa, etoposide
224262075|NCT02875314|DRUG|Tandem 3 Cycle Intensive Chemotherapy|Carboplatin, thiotepa
224262076|NCT02927210|DRUG|Dimethandrolone Undecanoate|Single doses of DMAU in castor oil/benzyl benzoate injections intramuscularly (IM) (80 mg, 240 mg, 480 mg, and 800 mg) or administered subcutaneously (SC) (50 mg, 100 mg and 200 mg).
224262077|NCT02927210|DRUG|Placebo|Placebo injections that look like the DMAU injections but with no active ingredients
224262078|NCT00525746|BEHAVIORAL|Interview|Interview lasting about 50 minutes.
224262079|NCT06300216|DRUG|Octreotide microspheres|20mg/30mg Q4W
224262080|NCT00617396|DRUG|Quetiapine (50 mg/day-100mg/day)|Subject begin with a dose quetiapine of 50mg for 2 weeks, increasing to 100mgs for the remainder of the study. (8 weeks total)
224262081|NCT06013150|DRUG|Epinephrine|Participants in Part 1 of the study will receive single dose either 1mg, 1.3mg or 1.5mg of an inhaled single dose of Epinephrine or placebo delivered via DMC-IHI device.
224262082|NCT06013150|DRUG|Placebo|Participant in Part 1 of the study will receive matching doses of placebo
223681785|NCT04688879|PROCEDURE|intra-arterial urokinase thrombolysis|Under local anaesthesia, the right femoral artery was punctured in accordance with the Seldinger technique, and a 6-Fr sheath, 10 cm in length, was implanted. Selective catheterization of the SMA was performed with 4-Fr catheter. The SMA angiography was performed to identify the filling defect. Thrombolysis was performed using a 5-Fr multiple-sideport infusion catheter (100cm with sideport of 7cm, 14 ports or 100cm with sideport of 15cm, 30 ports, Cook, Bloomington, IN, U.S.A). The tip of the microcatheter was embedded in the thromboembolism, which was fragmented at the time of thrombolysis. Thrombolysis was performed locally in the SMA with a bolus of urokinase
223681786|NCT04698265|BIOLOGICAL|Human amniotic suspension allograft (ASA)|Human amniotic suspension allograft (ASA) intra-articular injection.
223681787|NCT05965297|DEVICE|DeltaFil|Cavities are prepared using rotary instruments/diamond burs. Afterwards, the cavity is conditioned (using DeltaFil conditioner) and cleaned, with subsequent insertion of a conventional restorative glass-ionomer (DeltaFil). During the curing phase and after finishing Riva Coat will be applied to all restoration surfaces for moisture protection.
224262083|NCT05749887|PROCEDURE|salvage surgery|"Open/minimally invasive salvage surgery performed when cervical biopsy and/or PET/CT scan ( SUVmax ≥2.5 ) indicate patients with residual tumor intrapelvic 4-12 weeks after standard CCRT.~Surgery type:~1. No parametrial involvement, extrafascial hysterectomy;~2. There is parametrial involvement, extensive hysterectomy(Q-MC);~3. Only bladder invasion, anterior pelvic exenteration;~4. Only rectal invasion, posterior pelvic exenteration or total pelvic exenteration;~5. Invasion of bladder and rectum, total exenteration.~6. The pelvic lymph nodes are removed at the same time when 18F -FDG PET /CT indicates that the SUVmax is ≥ 2.5."
224262084|NCT02893735|OTHER|Charisma-Diamond|The surfaces were etched using 35% phosphoric acid for 30 s. The etched surfaces were rinsed and dried. Nano-hybrid resin composite system was used Charisma-Diamond in combination Gluma2 Bond etch\&rinse adhesive. The composite increments were carefully placed between the matrix strip and tooth by using a hand instrument. The composite resin restorations were light-cured (600 mW/cm²). Occlusion was checked with thin articulating papers. Restoration surfaces were finished and polished with fine finishing diamond burs, stones and rubber cups whereas; proximal and labial surfaces were contoured and polished with finishing strips. The treatments were completed by instructing the patients about the oral hygiene measures for cleaning their restorations with toothbrush and dental floss.
224262085|NCT02893735|OTHER|Filtek-Z550|The surfaces were etched using 35% phosphoric acid for 30 s. The etched surfaces were rinsed and dried. Nano-hybrid resin composite system was used Filtek-Z550 in combination with Adper™ Single Bond 2 etch\&rinse adhesive. The composite increments were carefully placed between the matrix strip and tooth by using a hand instrument. The composite resin restorations were light-cured (600 mW/cm²). Occlusion was checked with thin articulating papers. Restoration surfaces were finished and polished with fine finishing diamond burs, stones and rubber cups whereas; proximal and labial surfaces were contoured and polished with finishing strips. The treatments were completed by instructing the patients about the oral hygiene measures for cleaning their restorations with toothbrush and dental floss.
224262086|NCT03556618|BEHAVIORAL|Whole Person Care (WPC) Reentry Program - Pre & Post Release services|Social network intervention to provide care coordination and social support during youth reentry before release and post-release from jail.
224262087|NCT06558890|DEVICE|Transcranial Alternating Current Stimulation|Transcranial Alternating Current Stimulation
224262088|NCT06559085|PROCEDURE|Laproscopic posterior mesh rectopexy (Wells or LPMR)|After complete rectal mobilization, a mesh is inserted between the sacrum and the posterior rectum, sutured into the rectum, and fixed to the promontory. The mortality rates ranged from 0% to 1.2%, and recurrence rates ranged from 0% to 11% There was an overall improvement in continence (74%-100%), with conflicting results regarding constipation. New-onset constipation in 5% to 44% of patients was reported
224262089|NCT06559085|PROCEDURE|Laparoscopic lateral mesh rectopexy (Orr-Loygue)|This procedure involves complete mobilization of the rectum with two mesh strips sutured laterally to the rectal wall on both sides, and they were suspended to the promontory. There are several studies on this procedure using a laparoscopic approach. Lechaux et al. performed laparoscopic Orr-Loygue rectopexy in 35 patients. Incontinence improved in 27% of patients, and constipation improved in 19% but worsened in 27%. The recurrence rate was 3% (1/35) after a mean follow-up of 36 months. A study on 46 patients with laparoscopic Orr-Loygue procedure with posterior mobilization found a significant reduction in incontinence score after 1 year, but there were no changes in the use of laxatives. The recurrence rate was 4% after a median follow-up of 1.5 years
224262090|NCT02213263|BIOLOGICAL|PF-05280586|PF-05280586 (rituximab-Pfizer) concentrate for solution for infusion 375mg/m2 administered via IV infusion on Days 1, 8, 15, and 22
224262091|NCT02213263|BIOLOGICAL|MabThera®|MabThera® (rituximab-EU) concentrate for solution for infusion 375mg/m2 administered via IV infusion on Days 1, 8, 15, and 22
224262092|NCT04522258|DIETARY_SUPPLEMENT|Dietary fiber|Fermentable cereal bran
224262093|NCT04522258|DIETARY_SUPPLEMENT|Placebo|Refined cereal flour
224262094|NCT03006757|OTHER|titanium dioxide denture base|
224262095|NCT02087553|BIOLOGICAL|Transfusion of red blood cells|(non-experimental) PRBC transfusion
224262096|NCT02087553|BIOLOGICAL|Infusion of albumin/saline|(non-experimental) albumin/saline infusion
224262097|NCT05752721|BEHAVIORAL|Transition to Online Ordering|The intervention food pantry will transition to online ordering at least once.
224262098|NCT06446869|DIETARY_SUPPLEMENT|Gyntima Menopause|Combination of Levilactobacillus brevis KABP-052, Lactiplantibacillus plantarum KABP-051 and Pediococcus acidilactici KABP-021
224262099|NCT06446869|OTHER|Placebo|Placebo comparator
224262100|NCT01188681|DRUG|TRU-016 and bendamustine|TRU-016 at 20 mg/kg, weekly by IV infusion x 2 cycles, then every 14 days x 4 cycles PLUS bendamustine (70 mg/m2 by IV infusion on Days 1 and 2 of every 28-day cycle, for 6 cycles
224262101|NCT01188681|DRUG|Bendamustine|Bendamustine at 70 mg/m2 by IV infusion on Days 1 and 2 of every 28-day cycle, for 6 cycles
224262102|NCT01188681|DRUG|15 mg/kg TRU-016 and bendamustine|TRU-016 at 15 mg/kg, weekly by IV infusion x 2 cycles, then every 14 days x 4 cycles PLUS bendamustine (70 mg/m2 by IV infusion on Days 1 and 2 of every 28-day cycle, for 6 cycles
224262103|NCT01188681|DRUG|20 mg/kg TRU-016 and bendamustine|TRU-016 at 20 mg/kg, weekly by IV infusion x 2 cycles, then every 14 days x 4 cycles PLUS bendamustine (70 mg/m2 by IV infusion on Days 1 and 2 of every 28-day cycle, for 6 cycles
224323906|NCT04916730|BEHAVIORAL|Time Restricted Eating|Participants in this arm will adhere to a daily, consistent self-selected 10-hr eating window for the course of the study intervention period as well as receive nutritional counseling from the study dietitian.
224323907|NCT06120504|DRUG|PF-08046045|Given into the vein (IV; intravenously)
224323908|NCT05134948|DRUG|BMS-986213|Specified dose on specified days
224323909|NCT04379011|DRUG|Brivaracetam|Escalating brivaracetam dose to 150 mg twice daily for 3 months
224323910|NCT04379011|OTHER|Placebo|Placebo twice daily for 3 months
224323911|NCT06393374|BIOLOGICAL|Pembrolizumab|Pembrolizumab 400 mg intravenous (IV) infusion q6w
224323912|NCT06393374|BIOLOGICAL|Sacituzumab tirumotecan|Sacituzumab tirumotecan 4 mg/kg IV infusion q2w
224323913|NCT06393374|DRUG|Capecitabine|Capecitabine 1000 mg/m\^2 to 1250 mg/m\^2 by mouth BID
224323914|NCT06292923|DRUG|Foralumab|"Foralumab nasal solution is a preservative-free, sterile, clear, colorless-to-slightly-yellow solution filled in an Aptar Unidose nasal atomizer device. Each Unidose device contains 0.13 mL foralumab placebo nasal solution, sufficient for administration to a single nare. Two Aptar Unidose devices will be used for a single dose (one device per nare).~Each Unidose device contains foralumab nasal solution, supplied at either 25 μg foralumab or 50 μg foralumab, sufficient for administration into a single nare."
224323915|NCT06292923|OTHER|Placebo|Foralumab placebo nasal solution is a preservative-free, sterile, clear, colorless-to-slightly-yellow solution filled in an Aptar Unidose nasal atomizer device. Each Unidose device contains 0.13 mL foralumab placebo nasal solution, sufficient for administration to a single nare. Two Aptar Unidose devices will be used for a single dose (one device per nare).
224323916|NCT05555745|DEVICE|Audio-based behavioral activation intervention|Access to audio-based behavioral activation intervention
224323917|NCT05555745|DEVICE|Audio-based self-monitoring intervention|Access to audio-based self-monitoring intervention
224323918|NCT05479734|BEHAVIORAL|mHealth Intervention|A smartphone app (mHealth app) will deliver daily tailored messages with tips on monitoring and promoting child development and positive parenting tips.
224323919|NCT03945825|DRUG|AF03|A squalene-in-PBS emulsion stabilized by nonionic surfactants, sorbitan oleate and macrogol cetostearyl ether
224323920|NCT03945825|BIOLOGICAL|Delta Inulin-CpG55.2|A combination adjuvant supplied as two separate components, Delta Inulin (Sypharma Pty Ltd.) and CpG55.2 (Nikko Denka Avecia and Sypharma Pty Ltd)
224323921|NCT03945825|BIOLOGICAL|Influenza Virus Quadrivalent Inactivated Vaccine|2018/2019 Fluzone QIV and 2019/2020 Fluzone QIV vaccines will be given with 90 days interval
224323922|NCT03945825|BIOLOGICAL|Quadrivalent Recombinant Seasonal Influenza Vaccine|2018/2019 Flublok QIV and 2019/2020 Flublok QIV vaccines will be given with 90 days interval
224323923|NCT05784922|OTHER|Educational Lung Cancer Screening (LCS) Video|An educational video on lung cancer screening tailored to Hispanic current and former smokers.
224323924|NCT05474378|DRUG|B7-H3CART|"B7-H3CART will be administered administered locoregionally (either ICV or both ICV and intratumorally (IT)) at one of the following doses:~Dose Level -1: 5 x 10\^6 CAR+ cells (+/- 20%) Dose Level 1: 10 x 10\^6 CAR+ cells (+/- 20%) Dose Level 2: 25 x 10\^6 CAR+ cells (+/- 20%) Dose Level 3: 50 x 10\^6 CAR+ cells (+/- 20%) Dose Level 4: 100 x 10\^6 CAR+ cells (+/- 20%)~B7-H3CART Dose Dose Level -1 (DL-1): 5 x 106 B7-H3CART+ cells (± 20%) Dose Level 1 (DL 1): 10 x 106 B7-H3CART+ cells (± 20%) Dose Level 2 (DL2): 25 x 106 B7-H3CART+ cells (± 20%) Dose Level 3 (DL3): 50 x 106 B7-H3CART+ cells (± 20%) Dose Level 4 (DL4): 100 x 106 B7-H3CART+ cells (± 20%)~Repeated every 28 days (-7 / +14 days) as long as infusion criteria are met for a total of 6 doses, with an option for an additional 6 doses, up to a total of 12."
224323925|NCT05424224|DEVICE|MagVita|rTMS system
224323926|NCT03604302|DEVICE|fMRI Paradigms|T2\*-weighted images will be acquired with a single-shot gradient echo echo-planar imaging (EPI) sequence in the axial orientation (TR=2500ms, TE=30ms, FA=80°, slice thickness=4 mm, FOV= 240mm2, matrix=64×64) covering the whole brain.
224323927|NCT04334941|DRUG|Atezolizumab|Given IV
224323928|NCT04334941|PROCEDURE|Biopsy Procedure|Undergo tumor biopsy
224323929|NCT04334941|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
224323930|NCT04334941|PROCEDURE|Computed Tomography|Undergo CT scan
224323931|NCT04334941|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223681788|NCT05965297|DEVICE|Riva Self Cure HV|Cavities are prepared using rotary instruments/diamond burs. Afterwards, the cavity is conditioned (using Riva conditioner) and cleaned, with subsequent insertion of a conventional restorative glass-ionomer (Riva Self Cure HV). During the curing phase and after finishing Riva Coat will be applied to all restoration surfaces for moisture protection.
223681789|NCT00930982|DRUG|Ciprofloxacin (Cipro, BAYQ3939)|Inhalation of 32,5mg Ciprofloxacin inhaled twice a day
223681790|NCT00930982|DRUG|Placebo|Inhalation of matching placebo twice a day
223681791|NCT02272543|DIETARY_SUPPLEMENT|Fish surimi peptide|
223681792|NCT01568307|DRUG|Participants will be prescribed an approved selective serotonin re-uptake inhibitor (SSRI) antidepressant.|The choice of SSRI will be based on clinical judgement and prescribed in line with standard dosing approved by the Therapeutic Goods Administration (TGA).
224323932|NCT04334941|DRUG|Talazoparib|Given PO
224323933|NCT05338697|DIAGNOSTIC_TEST|Transcranial Magnetic Stimulation (TMS)|No intervention used. This study is using TMS to obtain motor evoked potential (MEP), a prognostic biomarker. The TMS procedure is being conducted during the first week of hospitalization, which required registration under an IDE. Only TMS devices that have received 510(k) clearance from the FDA are used in this study, consisting of MEGA-TMS and MagStim 200-2.
224323934|NCT03622775|BIOLOGICAL|Daratumumab|Given IV
223681793|NCT04637906|DIETARY_SUPPLEMENT|Bioarginina®|Food supplement based on 1,66 grams of L-arginine
223681794|NCT00034749|DRUG|Risperidone|
223774364|NCT01228929|OTHER|Environmental Chamber Condition Change Intervention|For condition change studies, the chamber will operate between 65 and 85 degrees F and 25% and 80% RH with air flow turned off or set to a maximum of 3-4 m/s. For this type of study, we will have the subject acclimate to a set of environmental conditions (approximately 20-30 minutes) and take a set of measurements. Then we will change the conditions (rate of change is 3 degrees F/hour and 3% RH/hour), have the subject acclimate to these conditions (later on the same day or on another day) and take another set of measurements. The expected study length is approximately two hours for a single visit. Subjects may be asked to return for additional visits to accommodate a variety of chamber conditions (temp, humidity, airflow) within the prescribed limits above.
224323935|NCT06461403|DEVICE|Inhaler Trainer System|The system consists of an instrumented training inhaler capable of accurately measuring the real-time inspiratory airflow achieved by the user when they perform their inhale maneuver. The inhaler trainer system consists of a detachable/disposable mouthpiece and a reusable electronics module. The electronics module measures flow/pressure achieved by the patient and wirelessly transmits this data to a PC. The PC software analyzes the real-time inhalation flow data to enable the monitoring of the following quantities: Flow Rate, Duration, and Maximum Pressure Slope. These quantities will be used in the computation of the assessment metric, providing the user with real-time feedback about their inhalation technique. In addition, the software includes features to support the human study and provides fully functional inhaler education features for the expert test evaluators.
224323936|NCT06461403|OTHER|Initial Inhaler Use Assessment|Patients will undergo an initial assessment of their respiratory inhaler technique for their respiratory inhaler devices using device-specific checklists
224323937|NCT06461403|OTHER|Inhaler Use Instruction|Participants will then be given step-by-step verbal instructions and a copy of written instructions by the trained educator describing appropriate inhaler technique for their respiratory inhalers.
224323938|NCT06233110|DRUG|Fostamatinib|Fostamatinib will be administered as part of the initial dose escalation cohort and then two candidate doses will be identified to be administered for the safety expansion cohort.
224323939|NCT06233110|DRUG|Ruxolitinib|Ruxolitinib 10mg BID will be administered in combination with Fostamatinib in each of the study arms.
224323940|NCT05023252|OTHER|mobile application|VetThrive is a mobile smartphone application that monitors and transmits mobile sensor and utilization data. This app is deployed in Veteran patients who passively self-track their behaviors and psychiatric symptoms.
224323941|NCT02843425|OTHER|Regular Diet|Participants follow their normal diet (not including beans for 8 weeks)
224323942|NCT02843425|OTHER|Navy Beans (Canned)|Participants add 1/2 cup of canned beans per day to their diets for the first 2 weeks. This is increased to 1 cup per day for the following 6 weeks of the study.
224323943|NCT06355531|DRUG|FNP-223|Oral tablets
223681795|NCT02676128|BEHAVIORAL|Twine Collaborative Care Application|This application features a 24-hour medication clock that displays ART dosing schedule and allows participants to record the doses taken. It also features an interactive health coaching feature which will be used to provide support, encouragement, and resources to participants.
223681796|NCT02676128|BEHAVIORAL|Information-Motivation-Behavioral Skills Model of ART Adherence|Combines brief motivational interviewing, cognitive behavior therapy, and problem-solving skills to help participants formulate and follow ART adherence goals.
223681797|NCT04230564|DRUG|azacitidine|Patients taking azacitidine
223681798|NCT04230564|DRUG|venetoclax|patients taking venetoclax
223681799|NCT04230564|DRUG|glasdegib|patients taking glasdegib
223681800|NCT06290973|PROCEDURE|surgery of varicose veins|including ablation with radiofrequency, phlebectomy and saphenectomy.
223681801|NCT04323605|OTHER|"Outpatient assistance program for transplant patients (AMA-ALLO) based on a navigation nurse"|"Integration of a post-transplant navigation nurse starting at the first post-transplant consultation (starting from D100 +/- 10 days post-transplant). Different times for post-transplant telephone monitoring (every week for the first 2 months, then every 15 days for the next 3 months then once a month for 7 months)"
223681802|NCT02288143|DRUG|COOL-COS|"Controlled ovarian stimulation will start on the second or third day of a menstrual cycle:~* Oral clomiphene citrate: 100 mg/day until the day of the triggering.~* Oral letrozole: 7.5 mg/day during the first 5 days of the controlled ovarian stimulation.~* hMG: 150 IU every other day beginning on the day 6 of the controlled ovarian stimulation.~The triggering will be performed using urinary hCG (5,000 IU subcutaneous).~* 1-2 days after the identification of one follicle ≥ 17 mm~* 0-1 days after the identification of one follicle ≥ 19 mm."
223681803|NCT00400114|DRUG|Irinotecan|Irinotecan (50mg/m2)once weekly in weeks 1, 2, 4, 5, 7, and 8
223681804|NCT00400114|DRUG|Cisplatin|Cisplatin (65mg/m2)once weekly in weeks 1, 2, 4, 5, 7, and 8
223681805|NCT00400114|PROCEDURE|Radiation|Radiation 50 Gy (weeks 4-9)
223681806|NCT00400114|PROCEDURE|Surgery|Esophagectomy
223681807|NCT00400114|DRUG|sunitinib (Sutent)|sunitinib (Sutent), dose range of 12.5mg - 50mg OD x 1 year post op.
223681808|NCT02224118|DRUG|CNTO 3649 10 mcg/kg|A single dose of 10 mcg/kg of CNTO 3649 will be administered as subcutaneous injection to healthy adult Japanese men.
223774365|NCT03941210|OTHER|Detection of molecular Biomarkers|MicroRNA expression profile analysis by flow cytometry
223774366|NCT00700011|DRUG|Clofarabine|10 mg/m2 x 5 days per 4 to 6 week cycles
223774367|NCT00700011|DRUG|Clofarabine|5 mg/m2 x 5 days per 4 to 6 week cycles
224323944|NCT06355531|DRUG|Placebo|Oral tablets
224323945|NCT03083665|DRUG|Placebo|"* Pharmaceutical form: Film-coated tablets~* Route of administration: Oral use"
224323946|NCT03083665|DRUG|Brivaracetam|"* Pharmaceutical form: Film-coated tablets~* Concentration: 25 mg tablets and 50 mg tablets~* Route of administration: Oral use"
224323947|NCT05769062|PROCEDURE|Single digit pelvic exam|The exam takes approximately 5 minutes and uses a single digit to palpate the pelvic floor muscles, during which patients will rate pain on a scale of 0-10 at 5 paired locations.
224323948|NCT04981912|DRUG|HDMP + rituximab as a means of debulking prior to initiating venetoclax.|"* Patients will receive HDMP + Rituximab for 1 cycle, followed by reassessment of Tumor Burden,~* If Tumor Burden classification is low after HDMP + Rituximab (lymph nodes \< 5cm in diameter AND absolute lymphocyte count \< 25k/uL), patients will initiate venetoclax dose ramp-up, with ramp-up schedule according to venetoclax package insert.~* Patients who still have a disease burden (lymphadenopathy \> 5 cm or ALC \> 25k/iL) that meets criteria for medium or high risk of TLS after 1 cycle of HDMP + Rituximab are given the option to repeat a 2nd cycle of HDMP + Rituximab prior to venetoclax dose ramp-up."
224323949|NCT05601583|DEVICE|Continuous Glucose Monitor (CGM)|FDA-cleared FreeStyle Libre Glucose Monitoring System manufactured by Abbott. Integrated continuous glucose monitoring system that provides continuous glucose measurements every minute to provide glucose levels, trends and alerts.
223681809|NCT02224118|DRUG|CNT0 3649 30 mcg/kg|A single dose of 30 mcg/kg of CNTO 3649 will be administered as subcutaneous injection to healthy adult Japanese men and multiple doses of 30 mcg/kg of CNTO 3649 will be administered to participants with type 2 diabetes mellitus as subcutaneous injections once weekly for 4 weeks.
223681810|NCT02224118|DRUG|CNTO 3649 100 mcg/kg|A single dose of 100 mcg/kg of CNTO 3649 will be administered as subcutaneous injection to healthy adult Japanese men and multiple doses of 100 mcg/kg of CNTO 3649 will be administered to participants with type 2 diabetes mellitus as subcutaneous injections once weekly for 4 weeks.
223681811|NCT02224118|DRUG|CNTO 3649 300 mcg/kg|A single dose of 300 mcg/kg of CNTO 3649 will be administered as subcutaneous injection to healthy adult Japanese men.
223681812|NCT02224118|DRUG|Placebo|Matching Placebo to CNTO 3649 will be administered to both healthy volunteers and participants with type 2 diabetes mellitus.
223681813|NCT00964080|DRUG|MBP-426/Leucovorin/5-FU|MBP-426 will be administered at a dose of 170 mg/m2 every three weeks. Leucovorin will be administered at a dose of 400 mg/m2 after the MBP-426 infusion and in the absence of allergy/infusion reaction. 5-FU is administered concurrently with the leucovorin infusion and after the MBP-426 administration as a 46-hour continuous infusion of 2400 mg/m2.
224262104|NCT02937948|OTHER|Adaptative treatment plan|"Each patient will have 3 scanners before treatment initiation. One corresponding to an empty bladder, one to an intermediate one, one to a full bladder."
224262105|NCT02937948|RADIATION|External radiotherapy|At the time of each fraction of external radiotherapy, the most appropriate plan (empty, intermediate, full bladder) covering the target and sparing the organs at risk is chosen.
224262106|NCT06397339|OTHER|INTACT Program|"The INTACT Program has three components:~1. provide a training for Primary Care Providers (PCPs) training in screening, diagnosis, and care for ADRD,~2. at the PCP level, provide quarterly webinars. Topics will address driving and dementia; communication tips for someone with dementia; eating and drinking in advanced dementia; and advanced care planning for dementia.~3. At the clinic level, provide a workflow model for cognitive evaluation and setting a plan for the newly diagnosed patient. The INTACT intervention lasts 12 months and Continuing Medical Education credits will be available to PCPs who complete the INTACT training program"
224262107|NCT03853005|OTHER|HVHDF|Patients will receive HVHDF treatment for 48 hours. HVHDF will be performed via indwelling central venous catheter. The blood flow will be 180-240 ml/min, and ultrafiltration rate will be 70 ml/kg/h during HVHF. The substitute fluid will be infused with pre-dilution. Heparin will be used for anti-coagulation, whose initial dose will be 15-25 U/kg, and maintenance dose is 5-15 U/kg/h. aPTT time maintained between 60-80 second and will be checked every 12 hours.
224262108|NCT03853005|OTHER|controlled|Patients will receive the usual care
224262109|NCT00076817|BIOLOGICAL|ALVAC-HIV (vCP205)|Canarypox virus vector vaccine
224262110|NCT00076817|BIOLOGICAL|ALVAC-HIV (vCP205)|Canarypox virus vector vaccine placbo
224262111|NCT03060863|BEHAVIORAL|2. Executive Functioning|Interventions will occur in 3 biweekly visits plus technology-based practice. The investigators will use computer-based working memory training to improve Executive Functioning (EF) and will use a working memory training game that has been used with children this age (N-back task).
224262112|NCT03060863|BEHAVIORAL|3. Food Bias|The investigators will use attention-bias retraining techniques that have been tested in adults that have children practice approach and avoidance attentional strategies using a joystick and food images (healthy and unhealthy foods). Interventions will occur in 3 biweekly visits. Children in this arm will use a computer-based approach avoidance task to reduce attentional biases for food by using a joystick to push away images of nonhealthy foods and pull closer images of healthy foods.
224262113|NCT03060863|BEHAVIORAL|4. Emotion Regulation|Interventions will occur in 3 biweekly visits plus home practice. The investigators will use assisted relaxation training where children are trained to monitor and control their heart rate and skin conductance using biofeedback in a computer-game context (Journey to Wild Divine).
224262114|NCT03060863|BEHAVIORAL|5. Future orientation|"Interventions will occur in 3 biweekly visits. Children will participate in an interview protocol designed to enhance their capacity to visualize upcoming future events and describe them in detail, with the goal to make the future become present."
224262115|NCT03829670|DIAGNOSTIC_TEST|Cytochrome P450 test|Blood samples will be drawn for cytochrome P450 testing.
223681814|NCT02531100|DEVICE|BonyPid 500TM implantation concomitantly to SOC treatment|BonyPid 500TM implantation concomitantly to SOC treatment
223681815|NCT02531100|OTHER|SOC treatment only|Standard of care treatment (Manual and ultrasonic debridement, and surface decontamination)
223681816|NCT02393586|DRUG|Faropenem|Single oral dose
223681817|NCT02393586|DRUG|Amoxicillin/clavulanic acid 500mg/125mg|Single oral dose
223681818|NCT02393586|DRUG|Rifampicin|Single oral dose
223681819|NCT04281953|DIAGNOSTIC_TEST|High frequency audiometry|Simple hearing test
223681820|NCT04281953|OTHER|Short-Form 36-Item Questionnaire (SF-36)|Questionnaire on quality of life (Short Form 36 Item- SF-36)
223681821|NCT04281953|OTHER|Hearing handicap inventory for adults/elderly (HHIA/HHIE)|Questionnaire on Hearing loss (Hearing handicap inventory for adults/elderly- HHIA/HHIE)
223681822|NCT04281953|OTHER|Tinnitus handicap inventory (THI)|Questionnaire on Tinnitus (Tinnitus Handicap Inventory)
224323950|NCT06411613|OTHER|CC Program|The CC Program will be delivered through the existing HBPC infrastructure at VA Puget Sound Health Care System. Each HBPC team is comprised on a lead physician or nurse practitioner, nurse, pharmacist, nutritionist, social worker, psychologist, therapist, and chaplain. At a minimum, subsequent clinical encounters and assessments for each Veteran will be scheduled no less than on a quarterly basis and more often as needed based on the HBPC team's clinical judgment. On a monthly basis, the entire HBPC team will conduct MDC meetings to review each Veteran's medical plan. The Program aims to provide patient-centered, whole-person and team-based care, shared decision-making, active symptom management, advance care planning and end-of-life care.
224323951|NCT00980954|DRUG|carboplatin|Intravenously
224323952|NCT00980954|DRUG|cisplatin|Intravenously
224323953|NCT00980954|DRUG|paclitaxel|Intravenously
224323954|NCT00980954|RADIATION|intensity-modulated radiation therapy|Daily fractions
224323955|NCT00980954|RADIATION|standard external beam radiation therapy|Daily fractions
224323956|NCT00980954|RADIATION|Optional brachytherapy boost|Low-dose rate (20-25 Gy single application) or high-dose rate (12-18 Gy 2-3 applications), dependent on external beam dose.
224323957|NCT06245096|BEHAVIORAL|Cognitive Behavioral Therapy|Sessions will focus on skills such as behavioral activation, mood tracking, identifying and reframing automatic thoughts, assertion training and smart goals.
224323958|NCT06245096|BEHAVIORAL|Acceptance and Commitment Therapy|Sessions will focus on skills such as mindfulness, acceptance and willingness training, values clarification, committed action, defusion, and self-as-context.
224323959|NCT05120726|BIOLOGICAL|Dehydrated human amnion/chorion membrane|Dehydrated human amnion/chorion membrane (dHACM) has been commercially available for nearly 15 years. dHACM has been shown to elute growth factors including platelet-derived growth factors, fibroblast growth factors (PDGF), fibroblast growth factors (FGF), transforming growth factor beta 1 (TGF-β1), epidermal growth factor (EGF), vascular endothelial growth factor (VEGF), and placental growth factor (PlGF). Additionally, dHACM exerts immunomodulatory effects by releasing anti-inflammatory interleukins and factors which help regulate the matrix metalloproteinase (MMP) activity. Furthermore, dHACM has also been shown to stimulate mesenchymal stem cell migration and recruitment. dHACM is routinely utilized in the management of chronic wounds including diabetic ulcer and venous ulcers.
224323960|NCT02519348|BIOLOGICAL|Tremelimumab|Tremelimumab will be administered by IV infusion according to doses and frequency mentioned in arms' description.
224323961|NCT02519348|BIOLOGICAL|Durvalumab|Durvalumab will be administered by IV infusion according to doses and frequency mentioned in arms' description.
224323962|NCT02519348|BIOLOGICAL|Bevacizumab|Bevacizumab 15 mg/kg will be administered by IV infusion every 3 weeks until confirmed progressive disease, withdrawal of consent, lost to follow-up, or development of other reason for treatment discontinuation, whichever occurred first.
224323963|NCT02659241|DRUG|Adavosertib|Given PO
224323964|NCT02659241|OTHER|Laboratory Biomarker Analysis|Correlative studies
224323965|NCT06315257|DRUG|PVX7|PVX7 Immunotherapy
224323966|NCT05371093|BIOLOGICAL|Axicabtagene Ciloleucel|A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells
224323967|NCT05371093|DRUG|Cyclophosphamide|Administered intravenously
224323968|NCT05371093|DRUG|Fludarabine|Administered intravenously
224323969|NCT05371093|DRUG|Lenalidomide|Administered orally
224323970|NCT05371093|DRUG|Rituximab|Administered intravenously
224323971|NCT05371093|DRUG|Doxorubicin|Administered intravenously
223681823|NCT03282331|PROCEDURE|Standard oxygenation|Electrical impedance tomographic evaluation of lung morphology variations according to the preoxygenation technique : Comparison of Standard Oxygenation, High Flow Nasal Oxygen Therapy, and NonInvasive Ventilation
223681824|NCT03282331|PROCEDURE|High flow nasal oxygenation|Electrical impedance tomographic evaluation of lung morphology variations according to the preoxygenation technique : Comparison of Standard Oxygenation, High Flow Nasal Oxygen Therapy, and NonInvasive Ventilation
224323972|NCT05371093|DRUG|Vincristine|Administered intravenously
224323973|NCT05371093|DRUG|Prednisone|Administered orally
224323974|NCT05371093|DRUG|Bendamustine|Administered intravenously
224323975|NCT03165734|DRUG|Pacritinib|Oral administration. Supplied in capsules containing 100 mg (as the free base) in red cap/gray body size 0 opaque hard gelatin capsules. The inactive ingredients are microcrystalline cellulose, magnesium stearate, and polyethylene glycol 8000. Each capsule contains 146 mg of pacritinib citrate, which is equivalent to 100 mg pacritinib free base
224323976|NCT03165734|DRUG|Physician's Choice medications|Physician's Choice medications will be selected and administered according to the investigator's judgement. Investigators can select individual P/C agents but cannot combine agents or give them sequentially.
224323977|NCT05329194|DRUG|Tezepelumab|Participants will be receiving subcutaneous injection of tezepelumab.
224323978|NCT03524430|PROCEDURE|Core needle biopsy|"1st core needle biopsy for RDA (2 specimens): Time Point: 35 +/-4 days after initiation of chemotherapy.~If no change is made to the therapy, a second biopsy (2 specimens) will be performed at 55 +/- 5 days after therapy initiation.~If there is a change of drugs, the second biopsy (2 specimens) will be performed at \~2-3 weeks after initiation of new drugs; Timing by type of drug schedule 3-weekly: at 16 days +/- 2 days, Bi-weekly: at day of 2nd dose preferably before drug admin., Weekly: at day of 4th dose preferably before drug admin."
224323979|NCT06145282|DRUG|Non-myeloablative haploidentical peripheral blood stem cell transplantation with briquilimab and abatacept|All participants will receive the same dose of the investigational briquilimab antibody and abatacept added to the NIH-established regimen of alemtuzumab-TBI-sirolimus and infusion of filgrastim-mobilized peripheral blood hematopoietic cells from haploidentical related donors.
224323980|NCT06492616|DRUG|Elacestrant|Administered as oral tablets
224323981|NCT06492616|DRUG|Anastrozole|Administered as oral tablets
224323982|NCT06492616|DRUG|Letrozole|Administered as oral tablets
224323983|NCT06492616|DRUG|Exemestane|Administered as oral tablets
224323984|NCT06492616|DRUG|Tamoxifen|Administered as oral tablets
224323985|NCT05691478|PROCEDURE|Bone Scan|Undergo bone scintography
224323986|NCT05691478|DRUG|Cabozantinib S-malate|Given PO
224323987|NCT05691478|DRUG|Cisplatin|Given IV
224323988|NCT05691478|PROCEDURE|Computed Tomography|Undergo CT
224323989|NCT05691478|DRUG|Doxorubicin Hydrochloride|Given IV
224262116|NCT05350137|PROCEDURE|100% oxygen|During one-lung ventilation with an open chest, the non-ventilated lung collapses initially due to the inherent elastic recoil properties of the lung. Once passive venting has ceased, further collapse will then be wholly dependent on ongoing gaseous uptake and absorption atelectasis. Improved inflation-deflation method is currently the most widely used method in clinical practice. After dividing all the targeted vascular and bronchial structures, the lung of the operating side was re-inflated with 100% oxygen. After the operative lungs is completely expanded, perform pure oxygen mechanical single lung ventilation for the healthy lung, waiting for clear presentation of the plane between the targeted segment and the other segments.
224262117|NCT05350137|PROCEDURE|Carbon dioxide|During one-lung ventilation with an open chest, the non-ventilated lung collapses initially due to the inherent elastic recoil properties of the lung. Once passive venting has ceased, further collapse will then be wholly dependent on ongoing gaseous uptake and absorption atelectasis. The solubility coefficient for carbon dioxide is 0.57. The rapid diffusion properties of carbon dioxide would be expected to speed lung collapse and so facilitate surgery. After the targeted segment structures were successfully dissected, the collapsed intraoperative lung was completely re-expanded with carbon dioxide. After the operative lungs is completely expanded, perform pure oxygen mechanical single lung ventilation for the healthy lung, waiting for clear presentation of the plane between the targeted segment and the other segments.
224262118|NCT02849093|OTHER|Non-invasive OCT imaging|Optical Coherence Tomography (OCT) to capture high resolution cross-sectional images of tissue microstructures using infra-red radiation.
224262119|NCT00794456|DRUG|Passiflora ; Crataegus and Salix|1 tablet PO twice a day
224262120|NCT00794456|DRUG|Valeriana|1 tablet PO twice a day
224262121|NCT02543632|DEVICE|Parachute Implant System|The CardioKinetix Parachute Implant partitions an enlarged ventricle into dynamic and static chambers. The static chamber is a portion of the left ventricular volume that is taken out of circulation. Stresses placed on the partitioned myocardium and the forces transmitted to the apical segment are decreased both in diastole and systole, eliminating the forces responsible for left ventricular dilation. In addition to this regional unloading, the reduction in size of the dynamic chamber results in a decrease of the myocardial stress in the normal myocardium via Laplace Law, providing a global unloading of the ventricle.
224323990|NCT05691478|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
224323991|NCT05691478|DRUG|Methotrexate|Given IV
224323992|NCT05691478|PROCEDURE|Surgical Procedure|Undergo surgery
224323993|NCT05691478|PROCEDURE|X-Ray Imaging|Undergo X-ray
224323994|NCT03630211|DRUG|Cyclophosphamide|Stem Cell Mobilization
224323995|NCT03630211|DRUG|Mesna|Stem Cell Mobilization
223681825|NCT03282331|PROCEDURE|noninvasive ventilation|Electrical impedance tomographic evaluation of lung morphology variations according to the preoxygenation technique : Comparison of Standard Oxygenation, High Flow Nasal Oxygen Therapy, and NonInvasive Ventilation
223681826|NCT03217981|OTHER|Sepsis protocol|Adherence to the sepsis protocol
223681827|NCT01121731|DRUG|Interferon α-5|3 MIU or safe dose used three times a week (TIW) in alternate days in monotherapy. 29 days of treatment. Subcutaneous injection.
223681828|NCT01121731|DRUG|Interferon-α5 plus Interferon-α 2b|Interferon-α5 plus Interferon-α 2b. 1.5 MIU each, or safe dose used TIW in alternate days in combined therapy. 29 days of treatment. Subcutaneous injection.
223681829|NCT01121731|DRUG|Interferon α-2b (INTRON® A)|3 million IU TIW in alternate days in monotherapy. 29 days of treatment. Subcutaneous injection.
223681830|NCT05678049|DIAGNOSTIC_TEST|Synovial fluid analysis|"For patients with knee under tension at the joint level, the symptomatology often requires evacuation by puncture under ultrasound guidance. The intervention will be performed only for patients for whom this therapeutic indication exists anyway by their physicians.~After making the evacuation we will want to use this liquid for Microscopic and Spectrophotometric evaluation"
223681831|NCT04678479|DRUG|Ganaxolone|ganaxolone
224262122|NCT01367145|DRUG|OMACOR|4 capsules OMACOR 1g per day
224262123|NCT01367145|DRUG|Placebo|4 capsules placebo per day
224262124|NCT00256165|DEVICE|Tissue valve|Aortic valve replacement
224323996|NCT03630211|DRUG|Rituximab|Transplantation Conditioning
224323997|NCT03630211|DRUG|Alemtuzumab|Transplantation Conditioning
224323998|NCT03630211|DRUG|Thiotepa|Transplantation Conditioning
224323999|NCT03630211|DRUG|GM-CSF|Transplantation Conditioning
224324000|NCT03630211|DRUG|Intravenous immunoglobulin|Transplantation Conditioning
224324001|NCT03630211|RADIATION|Total Body Irradiation|Transplantation Conditioning
224324002|NCT03630211|DRUG|Anti Thymocyte Globulin|Transplantation Conditioning
224324003|NCT03151629|OTHER|Standard of Care|Drugs routinely administered for metastatic prostate cancer per local standard.
224324004|NCT05460533|BIOLOGICAL|Tisagenlecleucel|Tisagenlecleucel will be infused based on institutional guidelines. Reinfusion of tisagenlecleucel will occur 30-60 days following the first dose.
224324005|NCT05389449|DRUG|Danicopan|Oral tablet
224324006|NCT05642780|DRUG|SKB264|be administrated as an intravenous (IV) infusion on Day 1,15, 29 of each 42-day cycle;
224324007|NCT05642780|DRUG|Pembrolizumab|be administrated as an intravenous (IV) infusion on Day 1 of each 42-day cycle;
223681832|NCT03860883|PROCEDURE|Wide Local Excision = 1cm Margin|"A wide local excision involves removing an extra safety margin of skin surrounding the original melanoma site, to ensure that any remaining scattered melanoma tumour cells that may have been left behind after the first initial biopsy/surgery are removed."
223681833|NCT03860883|PROCEDURE|Wide Local Excision = 2cm Margin|"A wide local excision involves removing an extra safety margin of skin surrounding the original melanoma site, to ensure that any remaining scattered melanoma tumour cells that may have been left behind after the first initial biopsy/surgery are removed."
223681834|NCT02873403|DEVICE|KNEEMO knee brace|Bespoke knee brace made by additive manufacturing
223681835|NCT02873403|DEVICE|Popular knee brace|Customized knee brace used in the management of medial knee ostearthritis
223681836|NCT03915860|DRUG|Trifarotene|Topical Cream
224324008|NCT06066424|DRUG|Rimiducid|Given by (IV) vein
224324009|NCT06066424|DRUG|TROP2-CAR-NK Cells|Given by (IV) vein
224324010|NCT06066424|DRUG|Fludarabine phosphate|Given by (IV) vein
224324011|NCT06066424|DRUG|Cyclophosphamide|Given by (IV) vein
224324012|NCT06234423|DRUG|CUSP06|Antibody drug conjugate (ADC)
224324013|NCT05264857|BEHAVIORAL|Thyroid Nodule Management Education|Participants will receive information about thyroid nodules and their management
224324014|NCT05630547|DRUG|SAR443820|Tablet by oral administration
223681837|NCT02195011|DEVICE|SIR-Spheres|Radioembolization will be administered once by injection through a trans-femoral catheter into the hepatic artery.
223681838|NCT02195011|DRUG|Regorafenib|All patients will take regorafenib 160mg orally once daily on Days 1-21 of each 28-day cycle.
223681839|NCT02194608|DEVICE|Home telehealth system|Participants will receive a weighing machine, glucometer, and a sphygmomanometer connected through a Bluetooth system from their home to the Telehealth center via a HUB.
223681840|NCT02551250|DEVICE|annual noncontrast MRI|liver MRI without contrast agents T2 weighted image, T1 in/out of phase, diffusion weighted images with b-values of 0, 500 mm2/s
223681841|NCT02551250|DEVICE|biannual ultrasonography|liver ultrasonography for HCC screening performed by experienced sonologists
223681842|NCT00617643|DRUG|Nevirapine without dose escalation|Fixed dose combination tablets of stavudine 30mg,lamivudine 150mg and nevirapine tablets 200mg twice daily at initiation of antiretroviral therapy in patients receiving rifampicin for tuberculosis therapy
223681843|NCT00617643|DRUG|Nevirapine initiation with dose escalation|Triomune® 30 (according to body weight) one tablet once daily (am) plus Zerit® 30 + Epivir 150mg once daily (pm) for two weeks
223681844|NCT02577432|DRUG|fentanyl|Give 25 micro grams fentanyl intrathecal with one syringe. Then immediately give 10 mg hyperbaric bupivacaine intrathecally with an other syringe.
223681845|NCT02577432|DRUG|fentanyl|Mix 25 micro grams fentanyl with 10 mg hyperbaric bupivacaine in one syringe. Give them intrathecally.
223681846|NCT02577432|DRUG|Hyperbaric bupivacaine|Give 25 micro grams fentanyl intrathecal with one syringe. Then immediately give 10 mg hyperbaric bupivacaine intrathecally with an other syringe.
223681847|NCT02577432|DRUG|hyperbaric bupivacaine|Mix 25 micro grams fentanyl with 10 mg hyperbaric bupivacaine in one syringe. Give them intrathecally.
223681848|NCT00294281|DEVICE|Vagus Nerve Stimulation (VNS) Therapy|The VNS Therapy System Pulse Generator is an implantable, multi-programmable bipolar pulse generator. The pulse generator will deliver electrical signals to the vagus nerve via bipolar leads. A programming wand and software system enable non-invasive programming, functional assessments, interrogation, and data retrieval.
223681849|NCT04661254|OTHER|Lymphapheresis|\- From the blood product of lymphapheresis: Autologous naïve regulatory CD45RA+CD4+CD25+FoxP3+ T lymphocytes (Tregs) selected and amplified ex vivo; obtained by selection and sorting of CD4+CD25 +CD127lowCD45RA+ cells, derived from lymphapheresis and amplified ex vivo for 10 +/- 1 days, under cGMP condition in the presence of IL2 and Rapamycin
223681850|NCT02556164|PROCEDURE|Electroacupuncture|Acupuncture is an alternative medicine methodology that treats patient by various techniques including inserting small, thin needles at specific points of body. Electroacupuncture (EA), like the name implies, combines classical acupuncture and low electric current running through the needles, which are often used to enhance a treatment.
223681851|NCT02556164|OTHER|Body-worn sensor technology|Three-dimensional acceleration and angular velocity of shanks, thighs and the trunk were measured using wearable sensors each included a triaxial accelerometer and a triaxial gyroscope (LEGSys™ and BalanSens™ - BioSensics, Boston, MA)
223681852|NCT01853618|DRUG|Tremelimumab|3.5 mg/kg or 10 mg /kg intravenous (IV) every 4 weeks times 6 doses and then every 12 weeks for 2 years
223681853|NCT01853618|PROCEDURE|RFA|Performed on Day 36
223681854|NCT01853618|PROCEDURE|TACE|Performed on Day 36 and may be repeated (as per standard of care) on months 3, 7, and 13, and every (q)6 months thereafter (if indicated)
223681855|NCT01853618|PROCEDURE|Cryoablation|Performed on Day 36
223681856|NCT00471614|DRUG|NucleomaxX (contains uridine)|Escalated doses of NucleomaxX tid
223681857|NCT00947505|DEVICE|HairMax LaserComb 2009, 7 Beam|Device application 3 times week (non-consecutive days), for 26 weeks
223681858|NCT00947505|DEVICE|HairMax LaserComb|Device application 3 times week (non-consecutive days), for 26 weeks
223774368|NCT02231242|BIOLOGICAL|Autologous Stem Cell Transplantation|"Patients will be stimulated with Granulocyte Colony Stimulating Factor (G-CSF) 3 consecutive days. Bone marrow will be harvested under sedation and, after being processed in the laboratory, the buffy coat (TNC) of 10 mL will be infused intrathecally.~Intrathecal Autologous Bone Marrow TNC"
223774369|NCT00150020|DRUG|Enteric-coated mycophenolate sodium (EC-MPS)|
223774370|NCT03454438|PROCEDURE|Referral strategies|Two referral strategies will be compared to usual care, i.e. the control group. Patients will be followed for one year.
223774371|NCT01600586|DEVICE|Pacifier-Activated-Lullaby system (PAL).|Pacifier-Activated-Lullaby system (PAL).
223774372|NCT03069027|PROCEDURE|External nasal nerve block|Three single (midline injection) and 4 paired (bilateral injection) sites to block the external nasal sensation.
223774373|NCT03069027|DRUG|saline adrenaline|
223774374|NCT03069027|DRUG|Xylocaine, adrenaline|
224324015|NCT05630547|OTHER|Placebo|Tablet by oral administration
224324016|NCT04338776|DEVICE|UroLift|"The UroLift System is indicated for the treatment of symptoms due to urinary outflow obstruction secondary to benign prostatic hyperplasia (BPH).~During the procedure, an implant is delivered into the prostatic lobe obstructing the urethra and restricting urine flow. The distal end of the device is used to compress the lobe then the implant is delivered to retain the lobe in position, thereby increasing the urethral opening and reducing the fluid obstruction through the prostatic urethra."
224324017|NCT04338776|DEVICE|Rezum|"The Rezūm™ System is intended to relieve symptoms, obstructions, and reduce prostate tissue associated with BPH.~The Rezūm System is manufactured by Boston Scientific and consists of a radiofrequency (RF) generator and a single-use transurethral delivery device.~The Rezūm System utilizes radiofrequency current to generate wet thermal energy in the form of water vapor, which is then injected into the transition zone and/or median lobe of the prostate tissue in controlled 9-second doses. The vapor that is injected into the prostate tissue rapidly disperses through the interstitial space between the tissue cells. As the vapor cools, it condenses immediately on contact with tissue and the stored thermal energy is released,reducing the volume tissue adjacent to the urethra."
223774375|NCT06103942|DIAGNOSTIC_TEST|CO2 angiography|A supplemental CO2 angiography will be performed before and after the stent graft placement.
224262125|NCT06625502|BEHAVIORAL|Culturally-Affirming Racial Equity Framework|The CARE framework is a process-focused, protocol- based, and modular approach to promote mental health equity. It focuses on cultivating the therapeutic alliance across patient-provider differences in the first 3-4 treatment sessions, the critical window for engaging patients in care. Target processes include transparent communication, client-centeredness, client activation, and an affirming and comprehensive approach to assessment and treatment planning. Case conceptualization and treatment planning is collaborative, and guided by the individual clinician based on evidence-based treatments. The therapist receives ongoing biweekly supervision in Alliance-Focused Training and consultation sessions with a group-specific expert.
224262126|NCT05852626|OTHER|Redistribution of diabetes care between nurses and physicians|It will be proposed that nurses and physician share the clinical care of patients with type 2 diabetes, with complementing actions
224262127|NCT05852626|OTHER|Individualized glycemic target|Define the target of individualized glycemic treatment for patients with the support of a tool on the website, which will encourage the intensification and de-intensification of treatment when appropriate
224262128|NCT05852626|OTHER|Minimum care recomendations|It will be proposed to carry out the minimum necessary assessments that, annually, nurses and physicians must do to ensure the adequacy of quality indicators in the care of diabetes in the PHC
224262129|NCT05852626|OTHER|No intervention|Primary care health teams will follow their rotine care of type 2 diabetes
224262130|NCT04231422|COMBINATION_PRODUCT|Platelet-rich plasma|12mL of platelet-rich plasma injected into cavernosal bodies bilaterally
224262131|NCT03379883|PROCEDURE|Pulsed radiofrequency (P-RF)|"Intra articular RF~Insertion of the RF cannula within the joint. The recommended parameters are a pulse width of 20 msec and a rate of 2 Hz at 42°C for 10min.~Genicular nerve RF ablation.~The RF probe will be placed. A 50 Hz-frequency sensorial stimulation will be applied with a threshold of \< 0.6 V"
224262132|NCT03379883|PROCEDURE|Platelet rich plasma (PRP)|Under ultrasound guidance while the patients in a sitting position. In total, 3 to 8 mL of PRP will be injected via the inta-articular route
224262133|NCT01658774|DRUG|Albendazole|Single 400mg dose
224262134|NCT01658774|DIETARY_SUPPLEMENT|Vitamin C|500 mg Vitamin C
224262135|NCT02951247|DEVICE|Hearing Aid|Successor of Phonak Virto V90-10 NW O
224262136|NCT00761163|OTHER|Resistance Exercise|The subjects will complete 2 resistive exercise sessions on non-consecutive days that will be supervised by our laboratory staff. The following exercises will be performed using the Keiser Sports Health equipment in Ismail Health, Exercise, and Nutrition Center: seated row, double leg press, seated leg curl, chest press, and leg extension. The subjects will individually perform 3 sets of 8-10 repetitions at an exercise intensity of 70% of pre-determined maximal strength for these exercises. Each repetition will be performed in a slow (six to eight seconds) uniform fashion, giving equal time to the concentric (muscle shortening) and eccentric (muscle lengthening) portions. One minute of rest will be allowed between sets. The last repetition of the third set of each exercise will be done to voluntary fatigue or the performance of 12 repetitions.
224262137|NCT00761163|OTHER|Aerobic Exercise|The subjects will complete 2 aerobic exercise sessions on non-consecutive days that will also be supervised by our laboratory staff. The subjects will perform 45 minutes of aerobic exercise on a stationary bike at an exercise intensity of 70% of their heart-rate reserve.
224262138|NCT00761163|OTHER|Control (Non-exercise)|The subjects will also complete 2 non-exercise sessions on non-consecutive days that will also be supervised by our laboratory staff. These sessions will consist of incorporating diversionary tasks throughout a 45 minute period consisting of a variety of motor and psychological tasks (tests of hand steadiness, alertness, optical illusions, mental acuity, etc.)
224262139|NCT01939080|PROCEDURE|Exercise training with supervised sessions|
224262140|NCT02744287|BIOLOGICAL|BPX-601|Autologous T cells genetically modified with retrovirus vector containing PSCA-specific CAR and an inducible MyD88/Cluster Designation (CD)40 (iMC) co-stimulatory domain
224262141|NCT02744287|DRUG|Rimiducid|Dimerizer infusion to activate the iMC of the BPX-601 cells for improved proliferation and persistence
224262142|NCT07016230|DRUG|Tarlatamab|Patients enrolled in both cohorts will receive treatment with tarlatamab at the dose of 1 mg on D1, 10 mg on D8 and D15 and Q2W thereafter in a 28-day cycle. Tarlatamab will be administrated in intravenous route until disease progression, unacceptable toxicity, or consent withdrawal.
223681859|NCT02588001|DRUG|Enzalutamide|All patients will receive enzalutamide 160 mg (four 40 mg capsules) orally once daily. The treatment will be started at Visit 0 within one week after enrollment. Visit 1 is at 2 weeks after the treatment started; clinical assessments are conducted on adverse events and the Japanese version of the Functional Assessment of Cancer Therapy-Prostate (FACT-P) scales. Patients who are considered to be adequate by the investigator can continue the treatment with 12-week cycle visit (counted from initial dose) until patients meet withdrawal criteria. Patients will be followed up at 2 and 3 years after enrollment and at 3 years after the last participant enrollment.
223681860|NCT02044328|DRUG|Icotinib|Icotinib is administered 125 mg three times per day.
223681861|NCT06116240|DRUG|TQB2450 injection|TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1).
223681862|NCT06116240|DRUG|AL2846 capsule|AL2846 is a multi-targeted tyrosine kinase receptor inhibitor
223774376|NCT01800071|DRUG|MVA-EBNA1/LMP2 vaccine|
223774377|NCT01043965|DRUG|Metformin|Metformin 850mg
224262143|NCT05652257|DRUG|[14C]-brensocatib|Oral solution.
224262144|NCT03342339|OTHER|cognitive examination|mini mental test of Parkinson, Hospital Anxiety and Depression Scale, 5 words by Dubois, fast test frontal assessment, Trail Making Test
224262145|NCT03342339|OTHER|viewing of video|viewing during 5 minutes scale of differential emotions and Positive and Negative Affect Scale
224262146|NCT03342339|OTHER|Iowa Gambling Task|Test of Iowa Gambling Task
224262147|NCT01885949|DRUG|Tivozanib|Oral
224262148|NCT01885949|DRUG|Enzalutamide|oral
224262149|NCT01616225|DRUG|Saizen (Human Growth Hormone)|Subjects will receive the standard protocol treatment, as well as adjuvant GH. One 3.33 mg vial Human Growth Hormone(10 IU Saizen®) will be self-administered daily by subcutaneous injection. GH treatment will start 14 days before FSH start and will continue until the day of the HCG treatment.
224262150|NCT01616225|DRUG|Saizen (Human Growth Hormone)|Subjects will receive the standard IVF treatment, as well as adjuvant GH as above. One 3.33 mg vial Human Growth Hormone(10 IU Saizen®) will be self-administered daily by subcutaneous injection. GH treatment will start on the same day as the FSH start and will continue until the day of HCG treatment.
224262151|NCT01616225|DRUG|No Saizen Control (Standard IVF Protocol)|All patients will be administered an oral contraceptive (Marvelon®). FSH treatment (daily subcutaneous injections of 450 IU Gonal-F®; Serono Canada) must begin 4 days after OCP stop, providing both of the following criteria are met. Pituitary downregulation with GnRH antagonist (Cetrotide®, Serono Canada) 0.25mg daily (subcutaneous injection) and LH (Luveris®, Serono Canada) 75 IU daily (subcutaneous injection) will be initiated when one or both of the following criteria are satisfied. Monitoring will continue until a lead follicle reaches ≥18 mm, at which time HCG (Ovidrel®, Serono Canada) 250 mcg will be administered by subcutaneous injection. Oocytes will be retrieved 36 hours after HCG treatment. Luteal support for the endometrium (90 mg progesterone (8% progesterone gel; Crinone® gel), administered intravaginally once daily) will begin one day after oocyte retrieval and will be maintained at least until day 31 of gestation.
224262152|NCT03755050|OTHER|general and specific data|General and specific data collected
224262153|NCT03580915|BEHAVIORAL|Functional Literacy Program|The intervention will be provided twice weekly in 2-hour sessions, over 8 weeks. The 16 intervention sessions will provide the opportunity for participants to learn functional literacy skills to (1) manage an apartment, (2) access community resources, (3) manage finances, (4) access free recreational activities. All sessions will address literacy skills needed to complete basic daily life activities in the home and community environments. Literacy skills will first be learned and practiced within the supported shelter, and then extended to the community.
224262154|NCT03580915|BEHAVIORAL|Usual Care Management Services|The control group will receive the usual housing services without additional intervention.
224262155|NCT00743535|PROCEDURE|Transobturatory correction of anterior defect plus TOT|"Longitudinal vaginal incision 1 cm far from esternal urethral meatus. Bladder dissecting and identification of ischiatic spines. Bilateral transobturator insertion of anterior mesh through high and low trans-obturatory approach. Mesh anchorage.~Small incision sites in the femoral/pelvic fold. Bilateral transobturator insertion of mesh by means of mono-use needle"
224262156|NCT00743535|PROCEDURE|Transobturatory correction of anterior defect plus TVT|"Longitudinal vaginal incision 1 cm far from esternal urethral meatus. Bladder dissecting and identification of ischiatic spines. Bilateral transobturator insertion of anterior mesh through high and low trans-obturatory approach. Mesh anchorage.~Small incision sites at sovrapubic level. Bilateral retropubic insertion of mesh by means of mono-use needle."
224324018|NCT05713253|DEVICE|ELITA System|Each subject will receive a SILK lenticule removal procedure on one eye and a commercially available laser vision correction procedure on their fellow eye (Feasibility Phase). Subjects will receive a lenticule removal procedure on both eyes to reduce or eliminate myopic refractive errors (Pivotal Phase). The second eye treatment will be considered only after the first eye 1-week follow up visit has been completed and safety criteria are met.
224324019|NCT03305588|DEVICE|Unframed Virtual Cone|The patient will undergo stereotactic radiosurgery. Radiosurgery is a single non-surgical radiation treatment and will be done as an outpatient procedure. High-energy radiation will be delivered to a small, precise area of the patient's brain using a linear accelerator. A face mask (unframed) will be placed over the patient's face to keep their head from moving during the procedure. During the procedure, the study doctor will confirm the exact location that needs to be treated using x-rays and optical imaging cameras. The face mask will hold the patient's head to prevent it from moving and to focus the x-rays and aim them on a small area in the thalamus of the patient's brain. For most patients, the actual time on the radiosurgery treatment machine is 30 to 60 minutes. The face mask will be removed after the treatment.
224324020|NCT05956665|BEHAVIORAL|Shed-MEDS deprescribing intervention|See single arm description
224324021|NCT06285240|DRUG|MK-1167|1 mg and 5 mg oral capsules
224324022|NCT06285240|DRUG|Donepezil|10 mg oral tablets
224324023|NCT06285240|DRUG|Placebo|MK-1167 matching placebo administered oral capsules
223681863|NCT06116240|DRUG|Pemetrexed disodium for injection|Pemetrexed disodium is a multi-target antifolate antineoplastic drug.
223681864|NCT06116240|DRUG|Cisplatin injection|Cisplatin is a chemotherapy drug.
223681865|NCT03556488|DIAGNOSTIC_TEST|US air bronchogram score|"On ultrasonographic examination, lung consolidation is defined as a subpleural echo-poor region or one with tissue- like echotexture, depending on the extent of air loss and fluid predominance, which is clearly different from the normal pattern.~The air bronchogram is characterized as: absent, static, dynamic, dynamic with areas of lung recruitment."
223681866|NCT02821663|BEHAVIORAL|vocal intervention|10 x 60 min. sessions of vocal intervention
223681867|NCT04138966|DEVICE|Nol-Index|Multiparametric monitor that studies that establishes an index as a surrogate to nociception
223681868|NCT04138966|DEVICE|Skin Conductance|Measures skin conductance as a surrogate to nociception
223681869|NCT01146860|DRUG|BNO 1016|sugar coated tablets with dry extract (80 mg) of 5 herbal drugs; dosage: 480 mg per day (2 tablets t.i.d.) duration: 15 days
223681870|NCT01146860|DRUG|Placebo|sugar coated tablets with identical appearance to active treatment; frequency: 2 tablets t.i.d. duration 15 days
223681871|NCT01650129|DRUG|biphasic insulin aspart 50|Administered subcutaneously (s.c., under the skin) twice daily for 24 weeks. Injected immediately before breakfast and dinner
223681872|NCT01650129|DRUG|biphasic human insulin 50|Administered subcutaneously (s.c., under the skin) twice daily for 24 weeks. Injected 30 minutes before breakfast and dinner
223681873|NCT00151203|DRUG|Clarithromycin, Lenalidomide, Dexamethasone|"Dexamethasone (Decadron®) will be given orally at a dose of 40 mg on days 1, 2, 3, 8, 15 and 22 during the first cycle and once a week on days 1, 8, 15, and 22 for each subsequent cycle.~Clarithromycin (Biaxin®) will be given orally at a dose of 500 mg twice a day beginning on day 2 of cycle 1.~Lenalidomide (Revlimid®) will be given orally at a dose of 25 mg daily beginning on day 3 and ending on day 21 of cycle 1 and on days 1-21 of subsequent cycles."
223681874|NCT00728143|DIETARY_SUPPLEMENT|Highly viscous polysaccharide enriched biscuits|10 g of highly viscous polysaccharide
223681875|NCT02916121|DIETARY_SUPPLEMENT|folic acid 5 mg/cap|the intervention includes folic acid 5 mg/d and vitamin B12 500 ug/d
223681876|NCT02916121|OTHER|Placebo|placebo
224324024|NCT05732402|DRUG|Povetacicept|Administered by subcutaneous injection every 4 weeks
224324025|NCT04678414|BEHAVIORAL|Healthcare Activity|Attend focus group
224324026|NCT04678414|OTHER|Survey Administration|Complete survey
224324027|NCT06112626|BEHAVIORAL|CHG Skin Treatment Video|Short CHG skin treatment video that reviews the rationale/importance of CHG bathing, and the appropriate process for bathing
224324028|NCT05573126|DRUG|Vosilasarm|Vosilasarm is an orally administered investigational selective androgen receptor modulator (SARM)
224324029|NCT05573126|DRUG|Elacestrant|Oral SERD
224324030|NCT05573126|DRUG|Everolimus|mTOR Inhibitor
224324031|NCT01861106|PROCEDURE|Allogeneic HSCT|Stem cell transplant
224324032|NCT01861106|DRUG|Busulfan Test dose|0.8 mg/kg IV infusion over 3 hours one time dose administered 5 to 14 days prior to start of preparative regimen (Days -11 to -20)
224324033|NCT01861106|DRUG|Fludarabine (Fludara, Berlex Laboratories)|40 mg/m2 IV (in the vein) over 30 minutes (in the vein) once daily on Days -6, -5, -4, and -3 or 30 mg/m2 IV over 30 minutes (in the vein) once daily on Days -6, -5, -4, -3, and -2
224324034|NCT01861106|DRUG|Busulfan (Busulfex)|3.2 mg/kg IV (in the vein) over 3 hours once daily on Days -6, -5, -4 and -3 (weight based dosing). If in Arm B and if poor or very poor risk clonal chromosomal abnormalities, busulfan will also be given on day -2.
224324035|NCT01861106|DRUG|Cyclophosphamide (CTX, Cytoxan)|14.5 mg/kg IV (in the vein) infusion over 30 minutes once daily on days -6 and -5 (weight based dosing) or 50 mg/kg IV infusion over 2 hours on day -6 (weight based dosing). For post-transplant, 50/kg IV once daily x2 doses on days +3 and +4
224324036|NCT01861106|PROCEDURE|Total Body Irradiation (TBI)|200 cGy on Day -1
224324037|NCT01861106|DRUG|Mycophenolate mofetil (MMF)|15mg/kg IV over 2 hours BID starting on day +5 will continue until day +35 (+/- 2 days)
224324038|NCT01861106|DRUG|Tacrolimus|0.02mg/kg IV continuous infusion over 24 hours starting on day +5 until day +180
224324039|NCT01861106|BIOLOGICAL|Equine Anti-Thymocyte Globulin|(Deleted this intervention per amendment I): 30mg/kg IV (in the vein)once daily x 3 days on Days -6, -5, -4 (3 doses total)
224324040|NCT06066528|DRUG|Survodutide|once weekly subcutaneous injection
224324041|NCT06066528|DRUG|Placebo|once weekly subcutaneous injection
223681877|NCT02306031|DRUG|Prescribe ARTIFICIAL TEAR|From one week before surgery, and control group received artificial tear (Sina Darou Laboratories Company, Tehran, Iran) as a placebo every 6 hours. Theses drops continued up to 6 weeks with the same dose after operations
224324042|NCT06466187|DRUG|PF-08052666|Given into the vein (IV; intravenously)
224324043|NCT06500481|PROCEDURE|Biospecimen Collection|Undergo blood and CSF sample collection
224324044|NCT06500481|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
224324045|NCT06500481|RADIATION|Involved-Field Radiation Therapy|Undergo IFRT
223681878|NCT02306031|DRUG|Prescribe diclofenac sodium drop 0.1%|From one week before surgery, case group received diclofenac sodium drop 0.1% (Sina Darou Laboratories Company, Tehran, Iran) every 6 hours.Theses drops continued up to 6 weeks with the same dose after operations
223681879|NCT01341392|DRUG|CKD-501|Subjects received CKD-501 0.5mg once daily for 10 days. Subjects received amlodipine 10mg once daily for 10 days. Subjects received CKD-501 0.5mg and amlodipine 10mg for 10 days.
224324046|NCT06500481|PROCEDURE|Lumbar Puncture|Undergo LP
224324047|NCT06500481|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
224324048|NCT06500481|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
224324049|NCT06500481|RADIATION|Proton Beam Craniospinal Irradiation|Undergo pCSI
224324050|NCT06500481|OTHER|Quality-of-Life Assessment|Ancillary studies
224324051|NCT04428151|DRUG|Lenvatinib|20 mg once daily, taken as oral capsules
224324052|NCT04428151|BIOLOGICAL|Pembrolizumab|200 mg 30-minute IV infusion on day 1 of each 21-day cycle
224324053|NCT04428151|DRUG|Docetaxel|75 mg/m\^2 administered as an IV infusion on day 1 of each 21-day cycle
224324054|NCT04428151|DRUG|Capecitabine|1250 mg/m\^2 twice daily on days 1-14 of each 21-day cycle, taken as oral tablets
224324055|NCT04428151|DRUG|Paclitaxel|80 mg/m\^2 administered as an IV infusion on days 1, 8, and 15 of each 21-day cycle
224324056|NCT04428151|DRUG|Cetuximab|400 mg/m\^2 loading dose, followed by 250 mg/m\^2 administered as an IV infusion on days 1, 8, and 15 of each 21-day cycle
224324057|NCT04428151|DRUG|Lenvatinib|24 mg once daily, taken as oral capsules
224324058|NCT04982926|DRUG|TAS2940|Study participants with solid tumors and EGFR or HER2 aberrations will receive TAS2940 tablets daily at increasing doses until MTD is reached.
224324059|NCT04982926|DRUG|TAS2940|Study subjects with select solid tumors characterized by EGFR or HER2 aberrations will receive TAS2940 at the dose identified during Dose Escalation phase.
224324060|NCT05828511|DRUG|Linvoseltamab|Linvoseltamab will be administered by intravenous (IV) infusion
224324061|NCT05672199|DRUG|Efavaleukin alfa|Subcutaneous (SC) injection
224324062|NCT05672199|DRUG|Placebo|SC injection
224324063|NCT06150742|DEVICE|Niyad (nafamostat mesylate)|Niyad (nafamostat mesylate) lyophilized
224324064|NCT06150742|DEVICE|Placebo (0.9% NaCl)|0.9% NaCl
224324065|NCT03604315|PROCEDURE|Computed Tomography|Undergo FDG PET/CT
224324066|NCT03604315|PROCEDURE|Computed Tomography|Undergo \[18F\]FTT PET/CT
224324067|NCT03604315|RADIATION|Fludeoxyglucose F-18|Given IV
224324068|NCT03604315|RADIATION|Fluorine F 18 Fluorthanatrace|Given IV
224324069|NCT03604315|PROCEDURE|Positron Emission Tomography|Undergo FDG PET/CT
224324070|NCT03604315|PROCEDURE|Positron Emission Tomography|Undergo \[18F\]FTT PET/CT
224324071|NCT05672992|OTHER|Spatial-frequency domain imaging (SFDI)|SFDI is a method using near-infrared (NIR) light to generate wide field images (\>10 x 10 cm) of tissue optical properties (absorption and scattering coefficients) at sub-surface depths of 1-10 mm. With SFDI the tissue surface (skin) is illuminated by a rapid sequence of sinusoidal light patterns of varying spatial frequency and at different optical wavelengths. Collected camera images are then processed to yield maps of sub-surface optical properties.
224324072|NCT03481530|DEVICE|Continuing Glucose Monitor System|glucose monitoring
224324073|NCT03969329|DRUG|Etelcalcetide|Etelcalcetide has been shown to be safe and efficacious in treating adult chronic kidney disease (CKD) patients with secondary hyperparathyroidism (SHPT) by simultaneously controlling intact parathyroid hormone (iPTH), calcium (Ca), and phosphorus and has recently been approved for use in adult patients with secondary hyperparathyroidism (SHPT) treated with hemodialysis in both the United States and Europe
224324074|NCT04427384|DEVICE|GammaTile|Surgically Targeted Radiation Therapy
224324075|NCT00918775|OTHER|Follow-Up Care|Undergo follow-up
224324076|NCT00918775|OTHER|Laboratory Biomarker Analysis|Correlative studies
224324077|NCT06023498|OTHER|Manual Therapy and Exercise|"The 20-minute manual therapy procedures will include:~* Distraction-manipulation: manually assisted segmental lumbar traction manipulation using a specialized treatment table~* Neural mobilization: rhythmic stretches of the sciatic and femoral nerves75~* Hip, sacroiliac and lumbar facet mobilizations to improve joint mobility~* Soft tissue mobilization of lumbopelvic and lower extremity muscles using manual pressure over taut bands/myofascial trigger points and post-isometric (contract-relax) stretching techniques."
224324078|NCT06023498|OTHER|Intramuscular Electroacupuncture|As described previously
224324079|NCT00977470|DRUG|Erlotinib|150 mg taken orally once daily
224324080|NCT00977470|DRUG|Hydroxychloroquine|1000 mg taken orally once daily after erlotinib
224324081|NCT04232566|PROCEDURE|Bariatric surgery|Evaluate liver fibrosis by elastography before gastric bypass surgery.
224324082|NCT04844879|DEVICE|NextAR TKA system|The NextAR TKA system is a surgical guidance system which measures intra-operatively the effect of prosthesis alignment and positioning on soft tissue balance.
224324083|NCT02844738|BIOLOGICAL|[StroMed + platelet rich plasma (PRP)]|Patients will be treated with autologous StroMed obtained by the Adipose Ultrasonic Cell Recovery Unit and Platelet Rich Plasma processed by the RegenLab (RegenKit BCT-3) PRP product each as direct injections to the affected joints at the time of initial treatment. Thereafter the affected joints will be treated as direct injections to the joint with Platelet Rich Plasma processed by the RegenLab (RegenKit BCT-3) PRP product. Day 0 \[StroMed + platelet rich plasma (PRP)\], Days 7 and 14 \[PRP\]
224324084|NCT05065502|BEHAVIORAL|Academic Detailing (AD)|"The National Resource Center for Academic Detailing (NaRCAD) describes AD as an innovative, one-on-one outreach education technique that helps clinicians provide evidence-based care to their patients. Using an accurate, up-to-date synthesis of the best clinical evidence in an engaging format, academic detailers ignite clinician behavior change, ultimately improving patient health. A successful AD visit is highly interactive, always a dialogue, and assesses a clinician's individual needs, beliefs, attitudes, issues, and concerns in order to promote better.\[practice\]."
224324085|NCT05065502|BEHAVIORAL|LEAP|Learn. Engage. Act. Process (LEAP) program is a structured 6-month core curriculum plus 6 monthly collaborative sessions. The LEAP quality improvement program engages frontline teams in sustained incremental improvements of EBPs over a six-month period, allowing space for busy clinicians to learn and immediately apply fundamental QI skills. LEAP encompasses: 1) a structured, accessible curriculum based on the Institute for Healthcare Improvement's (IHI) Model for Improvement and Plan-Do-Study-Act cycles of change; 2) team-based, hands-on learning, and 3) coaching support and a QI network to enhance learning and accountability.
224324086|NCT04699838|DRUG|Cisplatin|Cisplatin
224324087|NCT04699838|DRUG|Carboplatin|Carboplatin
224324088|NCT04699838|DRUG|Etoposide|Etoposide
224324089|NCT04699838|DRUG|Durvalumab|Durvalumab
224324090|NCT04699838|DRUG|Ceralasertib|Ceralasertib
224324091|NCT05139017|BIOLOGICAL|Zilovertamab vedotin|Intravenous (IV) Infusion 1.5 mg/kg, 1.75 mg/kg, 2.0 mg/kg, 2.25 mg/kg, 2.5 mg/kg
224324092|NCT05139017|BIOLOGICAL|Rituximab|IV Infusion 375 mg/m\^2
224324093|NCT05139017|DRUG|Gemcitabine|IV Infusion 1000 mg/m\^2
224324094|NCT05139017|DRUG|Oxaliplatin|IV Infusion 100 mg/m\^2
224324095|NCT05139017|DRUG|Bendamustine|IV Infusion 90 mg/m\^2
224324096|NCT05139017|DRUG|Granulocyte Colony-Stimulating Factor (G-CSF)|Prophylactic G-CSF will be administered at each cycle of zilovertamab vedotin as per the institutional guidelines.
224324097|NCT06642246|BEHAVIORAL|Intervention|During a 7-week intervention phase, parent-child dyads will be provided a sleep duration goal paired with a loss-framed financial incentive (virtual account) starting with deductions each time the sleep goal is not met, will be sent sleep guidance text messages, and will receive weekly performance feedback text messages.
224324098|NCT06273904|DEVICE|Active transcranial focused ultrasound (tFUS)|Active non-invasive low-intensity focused ultrasound will be delivered using a proprietary head-worn device and control software from Attune Neurosciences. On an active stimulation day, focused ultrasound will be delivered to the brain region of interest using parameters from published research that are demonstrated to safely cause temporary changes in the activity in that brain area.
224324099|NCT06273904|DEVICE|Sham transcranial focused ultrasound (tFUS)|Non-active low-intensity ultrasound will also be conducted using a proprietary head-worn device and control software from Attune Neurosciences. On the sham stimulation day, the device will be activated in a manner that produces similar sensory effects (i.e., low-volume beeping-type noise from the device) but also prevents delivery of a focused ultrasound beam to the brain area of interest or any other brain area.
224324100|NCT06660810|DRUG|Talimogene Laherparepvec|"Talimogene laherparepvec (HSV-1 \[strain JS1\]/ICP34.5-/ICP47-/hGM-CSF) is an oncolytic immunotherapy, formerly known as OncoVEXGM-CSF, an immune-enhanced, oncolytic herpes simplex virus type 1 (HSV-1)~Patients will be treated with neoadjuvant radiation and weekly intratumoral injections of talimogene laherparepvec"
224324101|NCT06660810|RADIATION|Neoadjuvant Radiation|"Treatment given as a first step to shrink a tumor before the main treatment, which is usually surgery, is given.~Patients will be treated with neoadjuvant radiation and weekly intratumoral injections of talimogene laherparepvec"
224324102|NCT06660810|PROCEDURE|Surgery|Surgery will be performed 4-6 weeks from the end of radiation therapy to allow for resolution of acute toxicities per current standard of care
224324103|NCT05328934|DEVICE|SoftHand Pro|Performance assessments utilizing the SoftHand Pro over an 8-week period.
224324104|NCT05328934|DEVICE|Ossur i-Limb|Performance assessments utilizing the i-Limb over an 8-week period.
224324105|NCT06624670|DRUG|Spesolimab|Solution for infusion
224324106|NCT06624670|DRUG|Placebo matching to spesolimab|Placebo matching to spesolimab
224324107|NCT06624670|DRUG|Prednisone|Prednisone
224324108|NCT06624670|DRUG|Prednisolone|Prednisolone
223681880|NCT01341392|DRUG|amlodiopine|Subjects received CKD-501 0.5mg once daily for 10 days. Subjects received amlodipine 10mg once daily for 10 days. Subjects received CKD-501 0.5mg and amlodipine 10mg for 10 days.
223681881|NCT01341392|DRUG|CKD-501 amlodipine|Subjects received CKD-501 0.5mg once daily for 10 days. Subjects received amlodipine 10mg once daily for 10 days. Subjects received CKD-501 0.5mg and amlodipine 10mg for 10 days.
223681882|NCT02299518|DRUG|mitoxantrone hydrochloride|Given IV
223774378|NCT01588912|DRUG|Telbivudine|If virologic response, which means HBV DNA \< 50 IU/mL, is shown at 24 weeks, telbivudine monotherapy is maintained and in the event that virologic response is not shown, tenofovir add-on therapy is done
223774379|NCT01588912|DRUG|Tenofovir|If virologic response, which means HBV DNA \< 50 IU/mL, is shown at 24 weeks, telbivudine monotherapy is maintained and in the event that virologic response is not shown, tenofovir add-on therapy is done
223774380|NCT01588912|DRUG|Entecavir|Maintain the entecavir through the study period
223774381|NCT02669290|OTHER|Guided|LV lead placement will be guided by left ventricular systolic function information from MUGA
223774382|NCT02669290|OTHER|Non-guided|LV lead placement will be conventional posterolateral placement
223774383|NCT03563768|PROCEDURE|One-stop strategy group|Percutaneous coronary intervention (PCI) will be performed on the same operating table immediately after the endovascular aortic repair (EVAR)
223774384|NCT02877550|DRUG|Obinutuzumab|Obinutuzumab: 1000 mg, i.v. infusion; d1, 8, 15 C1 and d1 C2-6
223681883|NCT02299518|DRUG|etoposide|Given IV and PO
223774385|NCT02877550|DRUG|Venetoclax|p.o. once daily according to dose level (DL) or MTD
223774386|NCT01346384|DEVICE|laryngeal tube (VBM Medizintechnik)|laryngeal tube number 4
223774387|NCT00931307|DEVICE|Lotrafilcon A contact lens|Silicone hydrogel, spherical, soft contact lens
223774388|NCT04932265|DIETARY_SUPPLEMENT|HRG80™ Red Ginseng|Capsules containing red ginseng preparation HRG80 capsules, 200 mg - reference product
223774389|NCT04932265|COMBINATION_PRODUCT|HRG80™ Red Ginseng + gamma cyclodextrin|Chewable tablets containing red ginseng preparation HRG80 (100 mg) incorporated in gamma-cyclodextrin (GCD) - experimental modified product
223774390|NCT05821010|COMBINATION_PRODUCT|Lyophilized fecal microbiota transplantation capsules|Oral administration (capsule)
223774391|NCT05821010|COMBINATION_PRODUCT|Placebo capsules|Oral administration (capsule)
223774392|NCT05821010|DIETARY_SUPPLEMENT|A. soehngenii|Oral administration (capsule)
223774393|NCT05821010|DIETARY_SUPPLEMENT|Pasteurized A. muciniphila|Oral administration (capsule)
223774394|NCT05821010|DIETARY_SUPPLEMENT|B. animalis subsp. lactis|Oral administration (capsule)
223774395|NCT05821010|DIETARY_SUPPLEMENT|Fructo-oligosaccharides|Oral administration (dissolved in water)
223774396|NCT05381792|DIAGNOSTIC_TEST|Bacterial gene markers test|Bacterial gene markers test using qPCR
223774397|NCT04431232|DEVICE|Endoscopic Band Ligation|Band ligation of the gastric body for weight loss
223774398|NCT06573177|OTHER|Referral to the gender identity service.|Referral to the national gender identity service consisting of the Sexological Clinic, Child and Adolescent Mental Health Center, and Department of Growth and Reproduction in the Capital Region of Denmark.
223774399|NCT01103531|BEHAVIORAL|Aerobic and Resistance Exercise|Aerobic and resistance exercise for 24 exercise training sessions over an 8-week period (three times weekly).
224324109|NCT05452122|OTHER|Auditory and Electrical Stimulation|Electrical and auditory stimulation will be applied during sleep.
223681884|NCT02299518|DRUG|cytarabine|Given IV
223681885|NCT02299518|DRUG|selinexor|Given PO
223681886|NCT02299518|OTHER|laboratory biomarker analysis|Correlative studies
223681887|NCT02299518|OTHER|pharmacological study|Correlative studies
223681888|NCT02257671|DRUG|Oral contraceptive|Neovletta
223681889|NCT04668612|DEVICE|Dual-bolus|Dual-bolus (50/50% with second part over 2 hours) for all meals after 6:00 p.m.
223681890|NCT04668612|DEVICE|Standard bolus|Standard boluses for all meals
223681891|NCT00133978|OTHER|Glutamine|0.35 gm/kg/day parenterally and 30 gms/day enterally
223774400|NCT01103531|BEHAVIORAL|Educational information about health topics|A counselor will meet with participants for 24 sessions (3 times/week) over an 8-week period to present and discuss information that includes topics on health and wellness, and lifestyle topics such as healthy eating, meditation, sleep hygiene, and cancer screening.
223774401|NCT06024954|OTHER|aromatherapy|"Patients in the aromatherapy group use 5% lavender oil with a diffuser for 15-20 minutes in accordance with the Aromatherapy-Clinical Guideline For Midwives. NHS.~Trust 1-15) has been applied. The diffuser was placed 30 cm from the participants and five (5) drops of essential lavender oil were placed on the filter paper. Within 10-15 minutes after the completion of the inhalation, data collection forms were applied again, and pain, anxiety, blood pressure, pulse and respiratory rate were evaluated."
223774402|NCT06024954|OTHER|music therapy|"The relaxing music group listened to specially composed MusiCure® compositions in soft rhythm, including melodies with harp, cello, strings and sound elements from nature (eg rain, bird, forest sound). Listened with headphones for 20 minutes."
223774403|NCT06024954|OTHER|aromatherapy and music therapy|Inpatients will be given music with a loudspeaker with the effect of aromatherapy inhaler for three consecutive days. Within 10-15 minutes after the completion of the inhalation, data collection forms will be applied again, pain, anxiety, blood pressure, pulse, respiratory rate were evaluated.
223835667|NCT03936309|OTHER|Scar Deactivation Surface Release Technique protocol|▪ Alternating placement of Spring Ten (0.30x40 mm) acupuncture needles to surround scar left in place for a treatment duration of 20 minutes. Needles will be placed at intervals of 1cm to 1.5 cm and will surround the scar with a maximum of 20 needles per treatment.
223835668|NCT03936309|OTHER|Scar Infiltration with 0.25-1% Lidocaine|▪ Will consist of calculation of 3 mg/kg dose of 0.5-1% Lidocaine and a dermal followed by subcutaneous injection using 1.5 inch 25 G needle and syringe appropriate for volume based on calculated dose.
224324110|NCT03589846|DEVICE|Grass S88 Muscle Stimulator|The Grass S88 nerve and muscle stimulator is a widely-used tool in electromyography and nerve conduction studies. Under anesthesia, fine-wire electrodes will be placed into the right genioglossus muscle (in the floor of the mouth) and the right palatoglossus muscle (in the anterior tonsillar pillar).
224324111|NCT04515784|BEHAVIORAL|Safety Aid Reduction Treatment for PTSD|START-PTSD includes many of the key elements found in empirically supported treatments for PTSD including: a) psychoeducation regarding the development and maintenance of PTSD; and b) exposure to internal sensations and external situations that are connected to one's fear/distress response via identification and elimination of safety aids. Known safety aids to be covered include: cognitive avoidance (e.g., using mental distractions to avoid trauma-related images); situational avoidance (e.g., avoiding crowded market places); checking behaviors (e.g., checking doors, windows, locks, and perimeters more often than necessary); reassurance seeking (e.g., excessively watching the news); other compulsive behaviors (e.g., checking the location of exits); use of companions (e.g., relying on someone to attend a social gathering); and use of alcohol and certain substances (e.g., consuming alcohol to reduce anxiety).
224324112|NCT06321302|DRUG|BI 764524|BI 764524
224324113|NCT06321302|DRUG|Sham comparator to BI 764524|Sham comparator to BI 764524
224324114|NCT06321302|DRUG|Aflibercept (Eylea®) - US only|Aflibercept (Eylea®) - US only
224324115|NCT05648500|DRUG|Cenerimod|Cenerimod will be supplied as a film-coated tablets at the dose of 4 mg.
224324116|NCT05648500|DRUG|Placebo|Matching placebo will be supplied as identical film-coated tablets formulated with the same excipients but without the active ingredient, cenerimod.
224324117|NCT06152224|DEVICE|The Leva Pelvic Health System|The Leva Pelvic Health System includes an intra-vaginal device that pairs with a smartphone application to provide real-time visual feedback about pelvic floor muscle performance during usage.
223681892|NCT00133978|OTHER|Antioxidants|500 micrograms of selenium/day parenterally and selenium 300 microgram, zinc 20 mg, beta carotene 10 mg, vitamine E 500 mg and vitamin C 1500 mg per day enterally
223681893|NCT00133978|OTHER|Glutamine + Antioxidants|0.35 g/kg/day glutamine parenterally and 30 g/day of glutamine enterally. 500 mcg selenium parenterally plus the following administered enterally: selenium 300 mcg, zing 20 mg, beta-carotene 10 mg, vitamin E 500 mg and vitamin C 1500mg
223681894|NCT00133978|OTHER|Placebo|Normal saline intravenously and EN placebo formula (from Fresenius Kabi, Germany)
223681895|NCT00225927|PROCEDURE|radioguided seed localization for nonpalpable breast cancers|radio-labelled (I-125) titanium seed inserted via needle into nonpalpable breast lesion and gamma probe used to guide surgery
223681896|NCT06492343|OTHER|fMRI based neurofeedback|participants will receive neurofeedback from their brain in order to modify their own brain function
223681897|NCT03667300|DRUG|Evogliptin|This group will take daily evogliptin 5mg per oral, not linagliptin.
223681898|NCT03667300|DRUG|Linagliptin|This group will take daily linagliptin 5mg per oral, not evogliptin
223681899|NCT01488344|DRUG|triple kinase inhibitor BIBF1120|triple kinase inhibitor BIBF1120 is given in addition to low-dose cytarabine
223681900|NCT05926076|OTHER|Treatment plan|Patients with different diagnoses will get different treatment options
223681901|NCT04504058|OTHER|routine clinical treatment|Participants will be informed that this is not a treatment study and it involves naturalistic follow-up without any extra intervention. They will otherwise follow the routine clinical treatment procedure.
223681902|NCT03625908|DEVICE|OCT-guided PCI|Patients will receive PCI under OCT-guidance. Predefined criteria for optimization of PCI under OCT-guidance will be recommended to achieve as far as possible.
223681903|NCT03625908|DEVICE|Angiography-guided PCI|Stent optimization using high-pressure non-compliance balloon will be highly recommend. Balloon size would not be less than the stent diameter.
223774404|NCT04713384|DEVICE|Integrative tele-rehalitation of chronic stroke survivors using custom therapeutic games|20 sessions of playing therapeutic games using both arms while siting at a table at home. Arms hold either generic game controllers, or BrightBrainer therapeutic controllers. Sessions involve a variety of games that train motor and cognitive function in an integrative way. The games are rendered by the BrightBrainer system. Games adapt and are winnable, benefiting well-being (reducing depression). Each session may generate many hundreds of arm repetitions, finger movement and grasps, depending on session duration. Data on arm reach as well as game outcomes and vitals are uploaded to an secure server. These data allow researchers to remotely monitor compliance to protocol and longitudinal progress. Caregivers are present at each session, and provide feedback as well as subjective ratings of the system.
223774405|NCT05468840|DRUG|Ketamine Hydrochloride|see study arm description
224324118|NCT03688126|BEHAVIORAL|Self-Guided Lifestyle Intervention|Lifestyle intervention that involves providing participants with education, support, and tangible tools to assist them in developing and carrying out healthier lifestyle practices.
224324119|NCT03688126|BEHAVIORAL|Structured Lifestyle Intervention|Lifestyle intervention that involves a structured program of diet, physical and cognitive exercise, and management of cardiometabolic risks.
224324120|NCT05009069|RADIATION|Radiotherapy|Weeks 1-5: 45-50.4Gy in 25-28 fractions to the pelvis on Days 1-5 every week.
224324121|NCT05009069|DRUG|Capecitabine|Weeks 1-5: Capecitabine 825 mg/m\^2 orally twice daily (bid) 5 days/week during radiotherapy.
224324122|NCT05009069|DRUG|Fluorouracil|Weeks 1-5: fluorouracil (5-FU) 225 mg/m\^2 intravenously (IV) over 24 hours 5 days/week during radiotherapy.
224324123|NCT05009069|DRUG|Atezolizumab|Weeks 8, 11 and 14: Atezolizumab 1200 mg IV on Day 1 of each 21-day cycle for 3 cycles.
223681904|NCT03681223|DEVICE|Vertessa® Lite Y mesh|Via randomization, 50 surgical subjects will receive Vertessa® lite Y mesh for the treatment of vaginal vault prolapse. The patient will be blinded as to which mesh they receive.
223681905|NCT03681223|DEVICE|Restorelle® Y mesh|Via randomization, 50 surgical subjects will receive Restorelle® Y mesh for the treatment of vaginal vault prolapse.The patient will be blinded as to which mesh they receive.
223681906|NCT03681223|PROCEDURE|Laparoscopic sacrocolpopexy|The subject's surgeon will decide if their patient should have laparoscopic sacrocolpopexy upon their clinical evaluation
223774406|NCT05468840|DRUG|Normal saline|see study arm description
223681907|NCT03681223|PROCEDURE|Robotic assisted laparoscopic sacrocolpopexy|The subject's surgeon will decide if their patient should have robotic assisted laparoscopic sacrocolpopexy upon their clinical evaluation
223681908|NCT00555308|OTHER|emergency department targeted ultrasound imaging|bedside ultrasound performed by emergency physician to identify hydronephrosis
223681909|NCT05561075|DIETARY_SUPPLEMENT|Pterostilbene cocrystal|One capsule with Pterostilbene cocrystal
223681910|NCT05561075|DIETARY_SUPPLEMENT|Pterostilbene free form|One capsule with Pterostilbene free form
223681911|NCT02715297|RADIATION|SRT to the resection cavity|46 Gy total dose will be delivered in 2 Gy per fraction, or 36 Gy delivered in 3 Gy per fraction, 5 fractions within 1 week. Doses will have to cover 95% of the PTV with the prescribed dose. The clinical target volume (CTV) will be defined as the resection cavity of the recurrent glioblastoma plus a margin of 5mm. A CTV to PTV margin of 1 to 3mm will be added according to technique used for immobilisation.
223681912|NCT06437704|OTHER|Brain training game Lumosity|. Group A, the experimental group will be trained using five selected games i.e. Speed Match, Memory Matrix, Tidal treasure, Ebb and Flow and Lost in Migration from Lumosity for a period of 30 sessions , 30 min/ day over the span of 6 weeks.
223681913|NCT06437704|OTHER|Simulation game simcity buildit|Group B, the active control will be trained for the same number of sessions using a simulation game, SimCity Build it, for a period of 30 sessions , 30 min/ day over the span of 6 weeks.
223681914|NCT00002952|BIOLOGICAL|MART-1 antigen|Melan-A peptide loaded PBMCs (sc, q3wk x 3)
223681915|NCT00002952|BIOLOGICAL|recombinant MAGE-3.1 antigen|
223681916|NCT00002952|BIOLOGICAL|recombinant interleukin-12|rhIL-12 (4 mcg, sc, days 1, 3 and 5 of every 3 wk cycle)
223681917|NCT03647787|OTHER|observational study|This study is a longitudinal observational study
223681918|NCT04879602|BEHAVIORAL|suction with bronchoscopy|suction with bronchoscopy
223681919|NCT04309799|DEVICE|Tear Restore Mask|The Tear Restore Mask will be used for 10 minutes
223681920|NCT04783688|OTHER|Full Face Snorkel Mask (FFSM)|A mask used for snorkeling that covers the entire face, as opposed to a conventional snorkel, which is held in the mouth only.
223681921|NCT01622283|DRUG|Levocetirizine|Levocetirizine
223681922|NCT01622283|DRUG|Cetirizine|Cetirizine
223774407|NCT02575664|DRUG|Buprenorphine|Buprenorphine 5 microg/h/7 days
223774408|NCT02575664|DRUG|Placebo|Placebo patch
223774409|NCT02447991|DRUG|Rizatriptan|During the study either placebo or Rizatriptan will be given to subjects to take during the treatment phase of this study.
223681923|NCT01190787|DRUG|velcade subcutaneous melphalan prednisone|"INDUCTION Velcade will be given as subcutaneous (SC) injection. Each cycle will be repeated every 28 days.~Melphalan will be given orally. Each cycle will be repeated every 28 days. Prednisone will be given orally.Each cycle will be repeated every 28 days. MAINTENANCE Velcade will be given a SC injection. Each cycle will be repeated every 28 days."
223681924|NCT01190787|DRUG|velcade cyclophosphamide prednisone|"INDUCTION Velcade will be given as subcutaneous (SC) injection. Each cycle will be repeated every 28 days.~Cyclophosphamide will be given orally. Each cycle will be repeated every 28 days.~Prednisone will be given orally.Each cycle will be repeated every 28 days. MAINTENANCE Velcade will be given a SC injection. Each cycle will be repeated every 28 days."
223681925|NCT01190787|DRUG|velcade prednisone|"INDUCTION Velcade will be given as subcutaneous (SC) injection. Each cycle will be repeated every 28 days.~Prednisone will be given orally.Each cycle will be repeated every 28 days. MAINTENANCE Velcade will be given a SC injection. Each cycle will be repeated every 28 days."
223774410|NCT02447991|DRUG|Placebo|During the study either placebo or Rizatriptan will be given to subjects to take during the treatment phase of the study.
224262157|NCT04827394|DEVICE|Neonatal warming mattress|Babies will be warmed with a standard neonatal transport warming mattress immediately after birth.
224262158|NCT04827394|DEVICE|Sterile polyethylene wrap|Babies will be wrapped in a sterile polyethylene wrap prior to arrival at the warmer.
224262159|NCT03500094|DRUG|Migalastat HCl 150 mg|migalastat HCl 150 mg capsule
224262160|NCT04323683|GENETIC|Microarray|High throughput technique for determining global gene expression of the condition of interest
224262161|NCT03565926|OTHER|Manual Therapy|"1. Articulation technique L4-S1~2. Lumbar neuromuscular technique~3. Fascial technique of crossed hands~4. Posteroanterior mobilizations of the lumbar vertebrae"
224262162|NCT03565926|OTHER|Hypopressive exercises|Protocol 5 Hypopressive exercises
224262163|NCT07025954|PROCEDURE|Cesarean delivery|"All patients were delivered via cesarean section with standardized perioperative management, including preoperative preparation (e.g., autologous bloodreserve, corticosteroid administration for foetal lungmaturation, etc.), surgical approach, and postoperative care.~Conservative management (intentional placental retention in situ with local resection and pelvic devascularization) was primarily employed, while peripartum hysterectomy was reserved for those with extensive invasion or failed conservative treatment."
224262164|NCT03605030|DEVICE|Novel Lead Based Armboard|Novel Lead Based Armboard
224262165|NCT03605030|DEVICE|Standard Armboard|Standard Armboard (without lead)
224262166|NCT04342650|DRUG|Chloroquine Diphosphate|150mg tablets Note: Tablets used in the study were Chloroquine Diphosphate (produced by Farmanguinhos/Fiocruz), and the dosing stated in the clinicaltrials.gov refers to chloroquine base (in mg).
224262167|NCT04342650|DRUG|Placebo oral tablet|150mg placebo tablets
224262168|NCT07027306|PROCEDURE|Posterior stabilization (pedicle screws)|"* Any other type of solely vertebral augmentation (stents, etc.), specify~* Posterior stabilization (pedicle screws)~* Posterior stabilization (pedicle screws) with kyphoplasty/vertebroplasty~* Posterior stabilization (pedicle screws) with screw augmentation~* Posterior stabilization (pedicle screws) with screw augmentation and kyphoplasty/vertebroplasty~* Posterior stabilization (pedicle screws) with vertebral osteotomy (pedicle subtraction osteotomy or similar)~* Combined posterior and anterior stabilization"
224262169|NCT05047536|DRUG|KZR-261|KZR-261 for Injection is a lyophilized drug product supplied in single-use vials delivering 75 mg of KZR-261.
224262170|NCT03786172|BEHAVIORAL|Smoking cessation Intervention|"* A 10 to 15 minute standardised counseling session performed peri-operatively by an ENT resident, and based on the 5 As motivational interviewing model (Ask, Advise, Assess, Assist, Arrange)~* A motivational gadget distributed to the patients~* Nicotine replacement therapy (NRT), consisting of nicotine transdermal patches for 8 weeks, offered to the patients"
224262171|NCT03786172|BEHAVIORAL|Usual care|A 10-second brief advice to quit smoking, performed peri-operatively by an ENT resident
224262172|NCT05513274|BEHAVIORAL|Pain Psychology Neuroscience + Written Emotional Disclosure|A 15 to 20-minute exercise which they examine variables in themselves that suggest that their pain is driven by central nervous system processes. Participants will then write for 20 minutes about their very deepest thoughts and feelings about the most traumatic experience of their lives. A 10-minute break followed by writing again for 20 minutes about how they have come to understand what happened and how they have changed because of the event.
223681926|NCT05946304|BEHAVIORAL|moderate-intensity continuous exercise training (MICT) group|Exercise session: Warm-up: 60-70% peak heart rate (HR) - 10min; Training: 70-85% peak HR - 35min; Cool-down: 60-70% peak HR - 15min.
223681927|NCT05946304|BEHAVIORAL|high-intensity interval training (HIIT) group|Warm-up: 60-70% peak heart rate (HR) - 10min; Training: 85-95% peak HR - 25 minutes (4x4-minutes of high-intensity intervals interspersed with 3 minutes of low-intensity intervals); Cool-down: 60-70% peak HR - 10min.
223681928|NCT05428189|DIAGNOSTIC_TEST|Plaque Disclosing Agent|A plaque disclosing agent is applied on teeth to detect plaque. Air-polishing will be used as main instrument for biofilm and stains removal, followed by ultrasonic scaling.
223681929|NCT05428189|DEVICE|Airpolishing and ultrasonic debridement|Air-polishing will be used as main instrument for biofilm and stains removal, followed by ultrasonic scaling.
223681930|NCT02014870|OTHER|1:1000 Live wild-type A/California/H1N1 2009|1:1000 dilution of neat virus
223681931|NCT02014870|OTHER|1:100 Live wild-type A/California/H1N1 2009|1:100 dilution of neat virus
223681932|NCT02014870|OTHER|1:10 Live wild-type A/California/H1N1 2009|1:10 dilution of neat virus
223681933|NCT00211744|DRUG|topiramate|
223681934|NCT03433729|OTHER|Patient agenda form|On arrival at the clinic patients are given an agenda form to prompt them to think about what issues they wished to discuss with their doctor. The form contains a prompt list of items they can tick, free space to write their own items, and a prompt to consider what is the most important issue for them and what they would like to happen before they leave their clinic appointment.
223681935|NCT03357939|DRUG|HLX03|A single dose of 40 mg HLX03 in 0.8 mL in subcutaneous injection.
223681936|NCT03357939|DRUG|adalimumab|A single dose of 40 mg Humira in 0.8 mL in a pre-filled syringe
223681937|NCT01874678|DRUG|TS-1/Cisplatin|
224262173|NCT05513274|BEHAVIORAL|Pain Psychology Neuroscience + Healthy Habits Disclosure|This condition is a 15 to 20-minute exercise that patients complete in which they examine variables in themselves that suggest that their pain is driven by central nervous system processes in their brains. Followed by writing for 20 minutes a letter to a person of their choosing describing healthy behaviors, a 10 minute break and then a second 20 minute writing task describing a time when they performed a healthy behavior.
224262174|NCT05513274|BEHAVIORAL|Health Behavior Control + Written Emotional Disclosure|This 15 to 20-minute exercise that relates to healthy behaviors. Participants are asked to examine various domains of their own health behavior as engaged in over the past 24 hours (e.g., nutrition, sleep, exercise, hygiene, social connections). Participants will then write for 20 minutes about their very deepest thoughts and feelings about the most traumatic experience of their lives. A 10-minute break followed by writing again for 20 minutes about how they have come to understand what happened and how they have changed because of the event.
224262175|NCT05513274|BEHAVIORAL|Health Behavior Control + Healthy Habits Disclosure|This 15 to 20-minute exercise that relates to healthy behaviors. Participants are asked to examine various domains of their own health behavior as engaged in over the past 24 hours (e.g., nutrition, sleep, exercise, hygiene, social connections). Followed by writing for 20 minutes a letter to a person of their choosing describing healthy behaviors, a 10 minute break and then a second 20 minute writing task describing a time when they performed a healthy behavior.
224262176|NCT07035925|DEVICE|ECMT-100|Colloidal hydrogel
224262177|NCT06703346|DRUG|Experimental: Letetresgene autoleucel|Drug: Letetresgene autoleucel Letetresgene autoleucel will be administered. Drug: Cyclophosphamide Cyclophosphamide will be used as a lymphodepleting chemotherapy. Drug: Fludarabine Fludarabine will be used as a lymphodepleting chemotherapy.
224262178|NCT00834275|DRUG|Cefadroxil 500 mg Capsules|1 x 500 mg
224324124|NCT05009069|DRUG|Tiragolumab|Weeks 8, 11 and 14: Tiragolumab 600 mg IV on Day 1 of each 21-day cycle for 3 cycles.
223681938|NCT01456377|DRUG|predinose oral|1 mg for kg for 3 wekees
223681939|NCT01456377|DRUG|placebo group|use a oral placebo
223681940|NCT01067924|BEHAVIORAL|Motivational interviewing|Intervention arm will receive 2 motivational interviewing session aimed at increasing maintenance of physical activity upon the completion of a supervised exercise program. Motivational interviews will occur at the end of the structured program and at 3 months post program completion. Outcomes will be collected at 6 months post-program.
223681941|NCT00430131|PROCEDURE|Cognitive Orientation to Occupational Performance|
224262179|NCT00834275|DRUG|DURICEF® capsules 500 mg|1 x 500 mg
224262180|NCT04981262|DIETARY_SUPPLEMENT|Stimulance|Intervention with Prebiotic supplement
224324125|NCT05183035|DRUG|Fludarabine|Intravenous (IV) infusion
223681942|NCT00430131|PROCEDURE|Contemporary Treatment Approach|
223681943|NCT00712062|DRUG|Pemetrexed|500 mg/m2 given as an injection into a vein over 10 minutes once every 21 days until progression or unacceptable toxicity.
223681944|NCT02735499|DRUG|onabotulinum toxin A|Onabotulinum toxin A is installed into the bladder and EMDA (Electromotive Drug Application) is applied for 30 minutes
223681945|NCT01114230|DRUG|AGS-16M8F|IV
223681946|NCT03513107|OTHER|ospeoporosis score|"* Scores will be calculated as indicated in their respective studies after collecting the data pertaining to them (Crandall, 2015); (Cass \& Shepherd, 2013); (Reginster, et al., 2004); (Adler, et al., 2003); (Cadarette, et al., 2000); (Weinstein \& Ulery, 2000); (Black, et al., 1998); (Lydick, et al., 1998).~* Data will be treated as dichotomous for both DXA T-scores and screening scores (i.e. Osteoporosis (Yes or NO) versus positive/negative score)."
223681947|NCT02036554|DRUG|Everolimus|Decrease the level of Tacrolimus and add on Everolimus instead of Mycophenolic acid which is standard treatment.
223681948|NCT02036554|DRUG|Tacrolimus|Decrease the level of Tacrolimus and add on Everolimus instead of Mycophenolic acid which is standard treatment.
224262181|NCT05680935|DIAGNOSTIC_TEST|blood microRNA|all patients will receive blood (20 ml) from the cubital vein for microRNA isolation.
224262182|NCT05680935|DIAGNOSTIC_TEST|plaque and intima microRNA|The resulting surgical material will be sent for microRNA isolation.
224262183|NCT05680935|DIAGNOSTIC_TEST|histological examination of the plaque|The resulting surgical material (atherosclerotic plaque) will be sent for histological examination.
224262184|NCT05680935|DIAGNOSTIC_TEST|blood level trimethyl N-oxide|all patients will receive blood (20 ml) from the cubital vein for determination of plasma trimethyl N-oxide (TMAO) content.
224324126|NCT05183035|DRUG|Cytarabine|Intravenous (IV) infusion
224324127|NCT05183035|DRUG|Gemtuzumab Ozogamicin|Intravenous (IV) infusion
223681949|NCT02036554|DRUG|Mycophenolic acid|Decrease the level of Tacrolimus and add on Everolimus instead of Mycophenolic acid which is standard treatment.
224262185|NCT05469997|BEHAVIORAL|Mediterranean-Ketogenic Diet|In the MeDi-KD group, the participants will adhere to a modified Mediterranean-ketogenic diet. The ketogenic component of the diet will require limiting the intake of carbohydrates to about 10% of all calories consumed in a day, while obtaining most of the energy from healthy fats, mostly from plant-based sources (\~70-75% of your daily caloric intake) and lean proteins (\~15-20% of your daily caloric intake). The ketogenic ratio (the ratio of fat to carbohydrates) will be gradually increased during the first week from 1:1 to 3:1. The Mediterranean component of the diet will encourage the participants to consume more green leafy vegetables, nuts, and olive oil, while limiting the consumption of processed or fried food, red meat, full-fat dairy, and sweets.
224262186|NCT05469997|DIETARY_SUPPLEMENT|Mediterranean diet supplemented with medium-chain triglyceride oil|"The participants will adhere to the Mediterranean diet. In addition, they will be asked to take two daily doses of medium-chain triglyceride oil (MCT oil).~The MCT oil supplement (Nutiva MCT oil, Nutiva Inc.) is approved by Health Canada (NPN: 80086912) and will be used according to its approved condition of use (i.e., source of medium-chain fatty acids which supports energy production in the body at a cellular level \[ATP\]). Each serving of this product provides 130 Calories from MCTs (14 g) with a C8-C10 ratio of 60:40. Nutiva MCT oil can be mixed into any beverage of choice, but cannot be used for cooking.~participants will start the intervention by taking 5 mL of MCT oil twice daily for the first day to acclimate their bodies to the supplement and gradually increase the dose to 14 g BID by the end of week 1. The participants may be asked to increase the dose to 20 mL of MCT twice daily if tolerability remains positive."
224262187|NCT06891313|DEVICE|Piezo Surgery.|Using bone cutting inserts.
224262188|NCT06891313|PROCEDURE|Bone Discs|Selected bone discs diameters mounted on contra angled hand piece and external irrigation hand piece at gear ratio 1:1.
224262189|NCT07057193|DRUG|Dexmedetomidine group (D group)|patients will receive intravenous dexmedetomidine (0.25 μg/kg diluted with normal saline to a volume of 5 ml solution) 10 min before the end of the surgical procedure.
224262190|NCT07057193|DRUG|Ketamine group (K group)|patients will receive intravenous ketamine (0.25mg/kg diluted with normal saline to a volume of 5 ml solution) 10 min before the end of the surgical procedure.
224262191|NCT07057193|DRUG|Midazolam group (M group)|patients will receive intravenous midazolam (0.05 mg/kg diluted with normal saline to a volume of 5 ml solution) 10 min before the end of the surgical procedure.
224262192|NCT07057193|OTHER|5ml of normal saline|patients will receive 5ml of normal saline intravenous10 min before the end of the surgical procedure as placebo.
224262193|NCT06563141|OTHER|traction and mobilization|The patient undergoes a 15-minute infrared therapy session, followed by flexibility and stretching exercises targeting the trunk and four extremities muscles. Land manipulation techniques are used for cervical, dorsal, and lumbar spine to assess and treat spinal dysfunctions. Deep breathing exercises with rib mobilization are also performed to promote respiratory function and thoracic flexibility. The session aims to improve overall health.
224262194|NCT06563141|OTHER|active exercise therapy|Patients with adolescent idiopathic scoliosis will receive exercise programs from seven major schools under SOSORT, focusing on realigning the spine, rib cage, shoulders, and pelvis to normal anatomical postures.
224262195|NCT03100019|DIETARY_SUPPLEMENT|Resveratrol|
224262196|NCT03100019|DRUG|Placebo|
224262197|NCT07051252|DRUG|HBS-201|On Days 1-7, participants will take HBS-201 17.8 mg per day (one 17.8 mg tablet) and on Days 8-14, participants will take HBS-201 35.6 mg per day (two 17.8 mg tablets).
224262198|NCT07062315|BEHAVIORAL|Chronotype-matched time-restricted eating|A 12 weeks time-restricted eating intervention that match participants' chronotype
224262199|NCT07062315|BEHAVIORAL|Chronotype-unmatched time-restricted eating|A 12 weeks time-restricted eating intervention that not match participants' chronotype
224262200|NCT07067268|DRUG|Adjuvant therapy|Tislelizumab: 200 mg IV on day 1, every 3 weeks Capecitabine: 1000 mg/m² orally twice daily on days 1-14，every 3 weeks Treatment duration: 8 cycles
224262201|NCT07067502|DEVICE|Biphasic cuirass ventilator which is a type of negative pressure ventilator will be applied to patients on the intervention arm|As opposed to patients being placed on Non invasive ventilation (CPAP or BiPAP) the intervention arm patients will be placed on the Biphasic cuirass ventilator which is a form of negative pressure ventilator.
224262202|NCT07067450|DRUG|Immune Checkpoint Inhibitors ( pembrolizumab, tislelizumab, sintilimab, camrelizumab, and toripalimab)|The immune checkpoint inhibitors used for adjuvant therapy after surgery were consistent with those used during the neoadjuvant treatment before surgery, including pembrolizumab, tislelizumab, sintilimab, camrelizumab, and toripalimab.
224262203|NCT07067450|OTHER|Observation|Postoperative observation is conducted without the use of any anti-tumor treatment.
223681950|NCT00510965|DRUG|Intravitreal injection ranibizumab|Monthly intravitreal injection of 0.5mg ranibizumab in one eye over one year
224262204|NCT07068906|DRUG|CAR-T cells chimenric antigen receptor T cells|CT1194C cells infusion
224262205|NCT07067905|DRUG|68Ga-XT771|68Ga-XT771 is injected intravenously with a dose of 4-8 mCi
224262206|NCT07069283|BEHAVIORAL|Self-Compassion Program|Program includes four basic practices: breathing meditation, walking meditation, body scan, and mindful movement. Consciously focusing on what is happening allows people to observe and accept what they are experiencing in their bodies, minds, and the world around them at that moment. Mindfulness practices are an 8-week practice consisting of 2-2.5 hour sessions per week by a trained instructor, mindfulness meditation practices, yoga practices, examining the psychological and physiological aspects of stress, and recently including the concept of self-compassion. In addition, daily practices are given to participants, and a suitable day is determined as a retreat day. The aim is to enable individuals to reveal and experience their thoughts, emotions, and bodily sensations and to increase emotional tolerance by revealing avoidance behaviors. Individuals learn to return to and accept intense bodily sensations and emotional discomfort with mindfulness.
224262207|NCT07067528|BEHAVIORAL|A novel PTLD clinical diagnostic algorithm|A clinical diagnostic algorithm designed to help TB clinicians identify patients at risk of post-tuberculosis lung disease (PTLD) at the end of TB treatment. The algorithm is implemented as a visual aid and structured questionnaire integrated into routine care. Clinicians use it to screen TB survivors and refer suspected PTLD cases to a post-TB clinic for confirmatory evaluation and management.
224324128|NCT05183035|DRUG|Azacitidine|Intravenous (IV) infusion or subcutaneous injection
224324129|NCT05183035|DRUG|Venetoclax|Orally via tablet or powder suspension
223681951|NCT04479462|PROCEDURE|total joint arthroplasty|The surgery includes primary, revision or partial joint arthroplasty.
223774411|NCT04262258|DIETARY_SUPPLEMENT|Blueberry enriched diet|The blueberry intervention will consist of participants ingesting two servings of 19 g freeze dried blueberry powder (equivalent to 250 g whole blueberries) daily for six weeks. Subjects will ingest the freeze dried blueberries orally. Freeze dried blueberry powder will be mixed with 8-10 ounces of water and consumed. Subjects will be asked to rinse the cup to wash any remaining blueberries off of the cup and consume the rinse water. Subjects will be given a two week supply at baseline (week 0) and a four week supply when they return for their blood draw at week 2. Subjects will be asked to return empty packets and check-off daily records as a measure of compliance.
224262208|NCT07068945|BEHAVIORAL|Group of 17-year-old patients living in Nice and receiving psychiatric care|Prospective study aiming to determine the annual prevalence of 17-year-old patients living in Nice who attend hospital-based child and adolescent psychiatry services. Secondary objectives include: estimating prevalence among under-18 psychiatric patients; describing clinical and sociodemographic profiles (sample of 100 patients); mapping 1-year care trajectories; evaluating clinical outcomes; assessing transition preparedness (to adult psychiatry); and identifying factors associated with psychiatric care continuity at 12 months.
223681952|NCT02128100|DRUG|Folfirinox|"* Oxaliplatin 85 mg/m² for over 2 hours,~* Leucovorin 400n mg/m² for over 2 hours,~* Irinotecan 180 mg/m² for over 90 minutes, along with Leucovorin infusion~* Fluorouracil 400 mg/m² as a fast infusion over 15 minutes~* Fluorouracil 2400 mg/m² as a slow infusion over 46 hours"
224262209|NCT07069205|BEHAVIORAL|Tele-nursing supported respiratory exercises|This intervention consists of a structured tele-nursing supported respiratory exercise program including abdominal breathing, pursed-lip breathing, and effective coughing techniques. The training is delivered through educational booklets and videos over a 12-week period, aiming to improve respiratory function and patient self-management in tuberculosis patients.
224262210|NCT07068854|OTHER|HPP mango juice group|During each intervention period, participants will be instructed to consume 500 mL of juice/day in two doses, 250 mL in the morning and 250 mL in the afternoon
224262211|NCT07068854|OTHER|control juice|During each intervention period, participants will be instructed to consume 500 mL of juice/day in two doses, 250 mL in the morning and 250 mL in the afternoon
223681953|NCT02128100|RADIATION|Stereotactic Body Radiation Therapy|5 treatments of stereotactic ablative radiotherapy (SABR) over the course of two weeks with a minimum of 36 hours in between each treatment.
223681954|NCT05959005|OTHER|No intervention|There is no intervention.
223681955|NCT04079673|PROCEDURE|Patient controlled epidural analgesia|Patient controlled epidural analgesia with marcaine 0.66mg/ml +fentanyl 1.75mcg/ml for postoperative pain control
223681956|NCT04079673|DRUG|Intravenous patient controlled analgesia|Intravenous patient controlled analgesia with morphine 1mg/ml for postoperative pain control
223681957|NCT04598256|PROCEDURE|Endoscopic procedure|Esophagogastroscopy and colonoscopy
223681958|NCT01753050|DEVICE|Stroke volume monitoring|Pulse contour stroke volume monitoring
224262212|NCT07068087|PROCEDURE|Preoperative sioldosin to facilitate ureteric access sheath insertion in RIRS|group A (study group) that included 21 patients who received silodosin 'one capsule 8 mg per day for 1 week preoperatively
224262213|NCT07068087|PROCEDURE|ureteric access sheath insertion in RIRS without silodosin (Placebo)|group B (study group) that included 21 patients who received Placebo'one capsule per day for 1 week preoperatively
224262214|NCT07066046|PROCEDURE|Colonoscopy|"This single-center, randomized, open-label clinical trial will assess the effectiveness of artificial intelligence (AI)-assisted colonoscopy versus standard high-definition colonoscopy in detecting and characterizing colorectal lesions. Conducted over 12 months in São Paulo, Brazil, the study will include 100 adult patients undergoing elective colonoscopy.~Participants will be stratified by age and randomized (1:1) after sedation. All lesions will be resected, recorded, and analyzed histologically. The intervention group will also include AI output data (CAD EYE).~The primary goals are to evaluate adenoma detection rate (ADR) and AI diagnostic accuracy. Given the global burden of colorectal cancer (CRC), particularly in developing countries, this study aims to provide real-world data on the impact of AI in CRC screening."
224262215|NCT07067840|DEVICE|Treated with the triple branched stent graft system|Participants treated with the triple branched stent graft system
224262216|NCT07069504|OTHER|AI-based role play|Participants will role play informed consent scenarios with a generative AI-driven patient simulation designed to mimic a realistic consent discussion for an endoscopic procedure.
224262217|NCT07069504|OTHER|Peer role play|Participants will role play informed consent discussions with a peer (i.e., another participant randomized to this group)
224262218|NCT07069465|DIAGNOSTIC_TEST|flotufolastat F 18|PSMA-PET scan with Posluma agent (x2)
224262219|NCT07069465|DRUG|Relugolix 120 MG|Administration of oral ADT for 3 and 6 weeks
224262220|NCT07069465|DIAGNOSTIC_TEST|Serum PSA and Testosterone|Serum PSA and testosterone at study initiation and again at 3 and 6 weeks after initiation of ADT
224262221|NCT07067372|DEVICE|FireMagic™ Magbot Ablation Catheter|All patients signed informed consent forms, enrolled in the trial, underwent surgical treatment for rapid arrhythmia using XX, and were discharged after follow-up data collection. The total duration for each subject is estimated to be approximately 7 days.
224262222|NCT07069049|OTHER|electroacupuncture|Sterile acupuncture needles (Huatuo brand, specification: 0.25mm\*40mm) were applied to Hegu (Li4), Neiguan (PC 6), Guanyuan (CV 4) and Sanyinjiao (SP 6) by twidling, rotating, lifting and thrusting for 30 seconds. After getting qi (a feeling of acid, numbness, weight and swelling), the electronic acupuncture instrument (SDZ-II type, Huatuo brand) was connected, and the continuous wave was 50HZ. The current intensity was 1-5mA (preferably as much as the patient could tolerate without pain).
224324130|NCT02974582|BEHAVIORAL|Exposure to smoking advertising with coupon|Direct mail marketing of smoking advertising with discount coupon
224324131|NCT02974582|BEHAVIORAL|Exposure to smoking advertising without coupons|Direct mail marketing of smoking advertising without discount coupon
224324132|NCT02974582|BEHAVIORAL|Exposure to non health related images|Control group
224324133|NCT04016558|BEHAVIORAL|StreamLine|"StreamLine is an education/disease management program that focuses on systematic methods to identify and resolve specific blood glucose problems, primarily through changes in carbohydrate consumption, and use of basal and bolus insulin. Participants will attend a brief, four-hour meeting with a Certified Diabetes Educator (CDE) and, using standardized blood glucose data, will learn how to employ a five-point blood glucose management system to identify and resolve blood glucose problems (e.g., excursions, lows) that have the greatest HbA1c or hypoglycemic impacts.~Participants will then meet individually (30 minutes) with their CDE to review their blood glucose data, identify a specific blood glucose problem, and use the five-point program to create a plan to address the problem. Four additional individual meetings (30 minutes) will occur at approximately two to three-week intervals to best support individualized and participant-tailored management-change efforts."
224324134|NCT04016558|BEHAVIORAL|TunedIn|"TunedIn utilizes emotion regulation-based strategies to help participants observe that how they feel affects what they do regarding diabetes management. Participants will attend two highly interactive group workshops (6 hours followed by 2 hours) facilitated by a psychologist or social worker experienced in diabetes. Each will identify and discuss common emotional responses related to blood glucose management (e.g., over-reacting, avoiding, and lack of mindfulness).~Between the two workshops (two weeks), participants will complete a feeling log to document feelings, situation/context, and resolution around specific management events. Two individual meetings with the interventionist (30 minutes) will allow participants to identify and address a specific diabetes distress-related problem. Four web-based video group meetings (60 minutes, monthly) will continue to support participants over time."
224324135|NCT04016558|BEHAVIORAL|FixIt|"FixIt combines components of StreamLine and TunedIn to allow participants to explore feelings and expectations alongside the identification of problematic blood glucose patterns. StreamLine will be co-facilitated by a psychologist/social worker experienced in diabetes and a CDE. Participants will attend two group workshops (six hours followed by four hours), separated by two weeks.~Between the two workshops, participants will record their blood glucose data and keep a parallel feeling log to provide context. Four individual meetings with an interventionist (30 minutes) will allow participants to identify and address a specific blood glucose problem and create a plan to address it. Full discussion of diabetes distress-related aspects of the plan will take place to enhance mindfulness and identify typical emotion regulation strategies to ease problem resolution. Three web-based video group meetings (60 minutes, monthly) will continue to support participants over time."
224324136|NCT06529731|DRUG|Interferon gamma-1b|ACTIMMUNE/Interferon gamma-1b is a single-chain polypeptide containing 140 amino acids that is produced by fermentation of a genetically engineered Escherichia coli bacterium containing the DNA which encodes for the recombinant protein. Interferon gamma-1b is part of a drug regimen used to treat Chronic Granulomatous Disease, or CGD. CGD is a genetic disorder, usually diagnosed in childhood, that affects some cells of the immune system and the body's ability to fight infections effectively.
224324137|NCT06529731|BIOLOGICAL|Donor Leukocyte Infusion (DLI)|Donor lymphocyte infusion is a procedure that transfers healthy white blood cells (lymphocytes) from a bone marrow or stem cell donor to a recipient's blood. An infusion of healthy lymphocytes helps the recipient's immune system get rid of remaining cancer cells if they have a relapse after a bone marrow or stem cell transplant for blood cancer.
224324138|NCT06042608|PROCEDURE|intercostobrachial nerve block|injection of local anesthetic to target the intercostobrachial nerve in the axilla
224324139|NCT02364557|RADIATION|Stereotactic Body Radiotherapy|"Patients receive 1, 3, or 5 fractions of radiation, beginning within 6 weeks of study entry.~* For metastases in the peripheral lung, patients receive a single fraction of 30 Gy or 3 fractions for a total of 45 Gy.~* For a single liver metastases, patients receive a single fraction of 30 Gy.~* For metastases in the abdominal-pelvic or liver (\>1), patients receive 3 fractions for a total of 45 Gy.~* For metastases in the central lung or mediastinal/ cervical lymph nodes, patients receive 5 fractions for a total of 50 Gy.~* For spinal metastases, patients receive 1 fraction of 20 Gy.~* For non-spinal osseous metastases, patients receive 3 fractions for a total of 30 Gy.~* For thoracic/cervical spine metastases, patients receive 5 fractions for a total of 35 Gy."
223681959|NCT02635646|OTHER|Family and interdisciplinary approach|"Family and interdisciplinary approach that includes:~1. nutritional counseling,~2. physical activity counseling,~3. psychological counseling,~4. metformin 850mg twice at day for 12 months All this with the purpose to improve insulin resistance and insulin secretion in patients with prediabetes. Patients must attend a monthly session together with his family where they will receive the nutritional, physical activity and psychological counseling."
223681960|NCT02635646|OTHER|individual approach|"individual approach that includes:~1. nutritional and physical activity counseling in individual appointments,~2. metformin 850mg twice at day for 12 months, All this with the purpose to improve insulin resistance and insulin secretion. The patients must attend a monthly follow-up individually."
223681961|NCT05404984|OTHER|Dry cupping with core stabilization exercises|12 patients will receive dry cupping technique for 10 minutes followed by 10 repetitions of each core stabilization exercise in different positions. All the patients will receive this treatment once a week for 6 weeks.
223681962|NCT05404984|OTHER|Core stabilization exercises|A total of 12 patients will perform 10 repetitions of each core stabilization exercise in different positions. All the patients will receive this treatment once a week for 6 weeks.
223681963|NCT04770077|OTHER|Intubation on manikin|Training of medical student to focus on manikin vocal cord before intubation
223774412|NCT05544877|BEHAVIORAL|Integrated 5-day Gratitude Exercise and Behavioral Activation Program|The 5-day intervention integrates a brief behavioral activation (BA) and a gratefulness exercise (GE) program. BA is composed of a lab-based idea generation and planning phase as well as a home-based performing phase with regard to pleasurable activities. GE is a idea generation task about aspects in life participants are grateful for about. It is performed once lab-based and daily with a home-based diary.
223774413|NCT03046680|OTHER|Health Coaching|
223774414|NCT03046680|OTHER|Multiprofessional Team|
223774415|NCT06531460|DIETARY_SUPPLEMENT|Fish oil enteral supplementation|Omega-3 (4.2 g), administered through an enteral feeding tube, three days before surgery
223774416|NCT06531460|DIETARY_SUPPLEMENT|Fish oil oral supplementation|Omega-3 (4.2 g), orally administered enriched nutritional formula, drinking at home three days before surgery
223774417|NCT06531460|DIETARY_SUPPLEMENT|Enteral nutrition without fish oil|Enteral formula without omega-3 administered through an enteral feeding tube, three days before surgery
224324140|NCT02364557|PROCEDURE|Surgery|All surgical resections will be approached with intent of an R0 resection (rendering the patient with no evidence of measureable disease and pathologic negative margin) and must occur within 6 weeks of study entry. Approach to surgery will be based upon the treating surgeon. An open, laparoscopic, or thorascopic approach is acceptable.
224324141|NCT05290402|OTHER|JEEVA (new digital health navigator app)|An app can be used on a mobile phone or tablet.
223774418|NCT06531460|DIETARY_SUPPLEMENT|Oral nutritional supplement without fish oil|Oral nutritional supplement without omega-3 orally administered, drinking at home three days before surgery
223774419|NCT00459134|DIETARY_SUPPLEMENT|ArginMax|Given orally
224262223|NCT07069049|OTHER|Sham-electroacupunture|Sham electroacupuncture was applied at the non-meridian and non-acupoint sites 3mm apart from the acupoints in the experimental group. The acupuncture method was shallow acupuncture, only 1-4mm through the skin.
224262224|NCT07068815|DEVICE|Fu's Subcutaneous Needling|Participants were seated while the practitioner identified affected muscles (sternocleidomastoid, scalene, splenius capitis, and upper trapezius) via sliding palpation. After routine disinfection, a disposable FSN needle (Nanjing Paifu Medical Technology Co., Ltd., Jiangsu, China) was inserted parallel to the subcutaneous loose connective tissue surrounding the affected muscle. Once fully inserted, the soft tube stand was secured in the slot. After confirming no pain, the practitioner performed smooth, gentle, fan-shaped swaying movements (120° angle, \~100 times/min) with the index and ring fingers. This was accompanied by reperfusion activities-resistance-based contraction and relaxation of the affected muscles, performed collaboratively by the practitioner and participant. Each set comprised 20 swaying movements and 10 seconds of reperfusion, repeated three times per muscle.
224262225|NCT07068815|DRUG|Flunarizine Hydrochloride|Participants in the drug group were administered 5 mg flunarizine hydrochloride capsules nightly before sleep for 4 weeks.
224262226|NCT07067541|DRUG|Control lidocaine cream|lidocaine cream alone
224262227|NCT07067541|DRUG|Experimental lidocaine cream + moisturizer cream|lidocaine cream + moisturizer cream
224262228|NCT07067606|DEVICE|ultrasound contrast|All participants will be subjected to full history taking, full clinical examination, laboratory investigations (complete blood count, erythrocyte sedimentation rate \[ESR\], C-reactive protein \[CRP\], blood urea, serum creatinine, serum glutamic-oxaloacetic transaminase \[SGOT\], serum glutamate-pyruvate transaminase \[SGPT\], immunological tests (antinuclear and anti-DNA antibodies and C3 and C4 levels), urine analysis, and 24-h urinary protein). SLE disease activity index (SELDAI) will be also calculated for every patient. (8) Musculoskeletal examination with power Doppler, the ultrasound examination will be performed at the musculoskeletal ultrasonography unit at the rheumatology division of the internal medicine department. Bilateral musculoskeletal US examinations of hands and wrists with power Doppler (PD) evaluation will be done for all patients. US examinations were performed using the standardized scanning technique according to EULAR guidelines for musculoskeletal US in rheumatolog
224262229|NCT07067307|DRUG|melatonin|melatonin 20 mg tablet once daily at bedtime
224262230|NCT07067307|DRUG|Placebo|Placebo once daily at bedtime
224262231|NCT07067437|RADIATION|single-fraction very accelerated partial breast irradiation|Adjuvant accelerated partial breast brachytherapy, with interstitial multicatheter technique, in one fraction.
224262232|NCT07069322|BEHAVIORAL|Richards-Campbell Sleep Questionnaire (RCSQ)|\- Score 0 = Very poor sleep, 100 = Very good sleep
224262233|NCT07067996|PROCEDURE|erector spinae plane block|erector spinae plane block will be given as intraoperive analgesia for patients undergoing Extracorporeal shock wave lithotripsy
224262234|NCT07067996|DRUG|Nalbuphine|Nalbuphine will be given as intraopertive analgesia for patients undergoing Extracorporeal shock wave lithotripsy
224262235|NCT06089239|OTHER|High Intensity Coaching|External coaching is a commonly used strategy to change practice, especially for multi-site collaboratives where implementation requires customization to the site. Coaches serve as skill builders who train organizational personnel in quality improvement processes and develop proficiency in the targeted practice area (i.e., fall prevention).
224262236|NCT06089239|OTHER|Low Intensity Coaching|External coaching is a commonly used strategy to change practice, especially for multi-site collaboratives where implementation requires customization to the site. Coaches serve as skill builders who train organizational personnel in quality improvement processes and develop proficiency in the targeted practice area (i.e., fall prevention).
224324142|NCT02877394|DEVICE|Squatting Assist Device|The Squatty Potty is a 7 inch tall stool to assist subjects in maintaining a squatting position while using a toilet. While sitting on the toilet, the subject supports her feet on the Squatty Potty.
224324143|NCT02877394|DEVICE|Sham Squatting Assist Device|This stool will be 2 inches tall and be similar in appearance to the Squatty Potty. While sitting on the toilet, the subject supports her feet on the 2 inch high stool.
224324144|NCT04363957|OTHER|Brachytherapy video|Patients will watch a video that contains information about brachytherapy
224324145|NCT04363957|OTHER|Standard Brachytherapy Consent Process|Patients will have the standard clinical brachytherapy consent and education including discussion with their physician.
224324146|NCT06534671|DRUG|diltiazem|IV diltiazem (0.25 mg/kg) will be given over 2 minutes, with ECG and blood pressure measurements at baseline, 2, 5, 7, 10, 15 and 20 minutes. If at 10 minutes there is no QT shortening, and blood pressure is stable, an additional dose (0.35 mg/kg) will be given with ECG and blood pressure measurements at 17, 20, 22, 25, 30 and 35 minutes.
224324147|NCT06517888|COMBINATION_PRODUCT|AAVAnc80-antiVEGF via Akouos Delivery Device|AAVAnc80-antiVEGF is a sterile suspension intended to be administered via intracochlear administration as a single dose using the Akouos Delivery Device
223774420|NCT00459134|DIETARY_SUPPLEMENT|Placebo|Given orally
223774421|NCT00829621|OTHER|75 mmHg suction|Incisional Vacuum Assisted Closure (IVAC) Device, set to 75 mmHg suction throughout the duration of the IVAC use.
223774422|NCT00829621|OTHER|125 mmHg|Incisional Vacuum Assisted Closure (IVAC) Device, set to 125 mmHg suction throughout the duration of the IVAC use.
223774423|NCT02520245|DRUG|REGN2810|Patients will receive REGN2810 by intravenous (IV) infusion
223774424|NCT00787410|DRUG|ZD1839|250mg tablet, once daily, orally administered
223774425|NCT06572215|DRUG|Dapagliflozin|On Day 3 to 16, participants will take 10mg dapaglifozin (SGLT-2 inhibitor) orally once daily.
224324148|NCT02573766|PROCEDURE|Neurofeedback Training|Neurofeedback Group + Sham Neurofeedback Group: Participants participate in sessions for a minimum of 2 treatments a week for a maximum of 10 weeks for a total of 20 sessions.
224324149|NCT02573766|PROCEDURE|Electroencephalogram|"Participants undergo an EEG at baseline, during each neurofeedback session, within 7 days of the conclusion of treatment, and again in one month.~Standard of care group receives EEG at baseline, 1 week after neurofeedback group completes sessions, and again in one month."
224324150|NCT02573766|BEHAVIORAL|Pain Scale|Participants in neurofeedback groups asked to rate their pain on a scale of 0 (no pain) to 10 (the worst pain) prior to each session of neurofeedback, and again at the conclusion of the session.
224324151|NCT02573766|BEHAVIORAL|Questionnaires|Seven questionnaires regarding symptoms and quality of life completed at baseline, 1 week after neurofeedback sessions, and again in one month.
224324152|NCT06143839|DRUG|Vyxeos liposomal|Standard of care JZP351 administered intravenously over 90 minutes.
224324153|NCT00271180|DEVICE|Device|
224324154|NCT06960096|OTHER|DBS combined with fMRI|Participants will undergo fMRI scanning while their DBS device is either turned OFF or ON. BOLD (blood oxygen level dependent) changes in response to DBS will be evaluated across PD participants. These scans and DBS procedure will be used for research purposes only and are not for treatment or diagnostic purposes.
224324155|NCT06963554|BEHAVIORAL|Project Support|The Project Support intervention involves up to four 60-minute individual counseling sessions focused on teaching caregivers how to listen to and comfort their child. Participants will receive didactic instruction and feedback on their use of the skills in role-plays with a treatment provider and with their child. In the role-plays the provider first demonstrates how to use the skill in a brief example of typical situations in which the skill could be used. In these examples the caregiver takes on the role of their child and the provider takes on the role of the caregiver. Subsequently the caregiver and provider switch roles so the caregiver has an opportunity to practice executing the skill. The provider helps the caregiver process their experience of each role-play and provides real-time, targeted feedback to help the caregiver develop their ability to use the skills.
223681964|NCT00545285|PROCEDURE|Total Hip Arthroplasty|Surgical implantation of specific hip replacement components for treatment of osteoarthritis
223681965|NCT00239525|DEVICE|3-D ultrasound scanner|The availability of color flow Doppler combined with effective ultrasound contrast agents in transcranial sonography serves as a low cost, bedside method for evaluation and management of patients with cerebrovascular disease in spite of the image degrading properties of the skull.
223681966|NCT00239525|DRUG|Perflutren Protein-Type A Microspheres for injection|Activated DEFINITY® (Perflutren Lipid Microsphere) Injectable Suspension is indicated for use in patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border.Bolus: The recommended dose for activated DEFINITY® is 10 microliters (μL)/kg of the activated product by intravenous bolus injection within 30-60 seconds, followed by a 10 mL saline flush. If necessary, a second 10 microliters (μL)/kg dose followed by a second 10 mL saline flush may be administered 30 minutes after the first injection to prolong contrast enhancement. Infusion: The recommended dose for activated DEFINITY® is via an IV infusion of 1.3 mL added to 50 mL of preservative-free saline. The rate of infusion should be initiated at 4.0 mL/minute, but titrated as necessary to achieve optimal image enhancement, not to exceed 10 mL/minute.
223681967|NCT01171664|DRUG|Placebo|Tablet, one BID
223681968|NCT01171664|DRUG|STAHIST|STAHIST in tablet form dosed one BID
223681969|NCT02793648|DRUG|Ascorbic Acid|Two daily oral doses of 200mg of encapsulated vitamin C twice a day, administered at breakfast and dinner
223681970|NCT02793648|DRUG|Alpha tocopherol|Two daily oral doses of 200mg of encapsulated vitamin E twice a day, administered at breakfast and dinner
223774426|NCT00572650|DRUG|vildagliptin|16 volunteers in each group of mild renal impairment patients and their matched healthy volunteers will receive once daily doses of 100mg LAF237 for 14 days.
224324156|NCT06963554|BEHAVIORAL|Case Management Services|"Case management services, or treatment as usual, may involve referrals for financial resources or donated goods, as well as assistance with court, law enforcement, or information about orders of protection. The nature of these services depends on the needs identified by the family and case manager. There is currently no standard treatment offered to families on the waitlist. This condition will receive individually tailored services, as needed."
224324157|NCT06456346|DRUG|Bomedemstat|Oral capsule
224324158|NCT06456346|DRUG|Hydroxyurea|Oral capsule
224324159|NCT06456346|DRUG|Bomedemstat placebo|Oral capsule placebo
224324160|NCT06456346|DRUG|Hydroxyurea placebo|Oral capsule placebo
224324161|NCT03603002|DIAGNOSTIC_TEST|Post-SABR Biopsy|Post-SABR Biopsy
224324162|NCT05971693|DEVICE|OMNYPULSE Bi-Directional Catheter with TRUPULSE Generator|Participants will undergo catheter ablation with the PF ablation system consisting of the TRUPULSE generator (delivers PF energy through the study catheter) and the OMNYPULSE bi-directional catheter (indicated for use in catheter-based cardiac electrophysiological mapping \[stimulating and recording\] and, when used with a Generator, for cardiac ablation).
224324163|NCT06644170|BEHAVIORAL|Behavioral Intervention|Attend individual visits
224324164|NCT06644170|BEHAVIORAL|Group Therapy|Attend group visits
224324165|NCT06644170|DRUG|Psilocybin|Given PO
224324166|NCT06644170|OTHER|Questionnaire Administration|Ancillary studies
224324167|NCT03219502|OTHER|Best Practice|Receive standard of care
224324168|NCT03219502|OTHER|Quality-of-Life Assessment|Ancillary studies
224324169|NCT03219502|OTHER|Questionnaire Administration|Ancillary studies
224324170|NCT03219502|PROCEDURE|Repetitive Transcranial Magnetic Stimulation|Undergo rTMS
224324171|NCT03219502|PROCEDURE|Sham Intervention|Undergo sham rTMS
223681971|NCT02793648|DRUG|PLACEBO|Two daily oral doses of 200mg of encapsulated placebo, administered at breakfast and dinner
223681972|NCT00162955|DRUG|Valsartan|Patients allocated into ARB administration group take Valsartan (80mg/day) from the day of the start of 1st CHOP until the completion of all the evaluations.
223681973|NCT04284150|DRUG|Dexmedetomidine; Midazolam;|Treatment of supraventricular tachycardia in patients with non-cardiac surgery by dexmedetomidine during the perioperative period
224324172|NCT03978624|DRUG|Pembrolizumab|200 mg IV on day 1 and day 22
224324173|NCT03978624|DRUG|Entinostat|5 mg given orally on day 1, day 8 and day 15
224324174|NCT03978624|PROCEDURE|Procedure/Surgery|A radical cystectomy is a surgical procedure to remove the entire urinary bladder and maximal transurethral resection of bladder tumor (TURBT) is a surgical procedure used to remove as much of the bladder tumor as possible.
224324175|NCT05929833|BEHAVIORAL|BETTER (Brain Injury, Education, Training, and Therapy to Enhance Recovery)|The six components of BETTER include: 1) assessment of patient/family needs and referral to community-based resources; 2) patient goal setting and review of goals; 3) health care coordination; 4) availability of clinical interventionist to patient/family; 5) training on self- and family-management and brain injury coping skills; and 6) warm hand off/referral to the state-affiliated Brain Injury Association at the end of the intervention for additional resources.
224324176|NCT05929833|OTHER|Usual Care|Usual care discharge planning process and follow up (e.g., verbal and written discharge instructions, with guidance on medications, outpatient therapy, and follow-up appointments)
224324177|NCT05334329|BIOLOGICAL|Antineoplastic Immune Cell|Given COH06 IV
224324178|NCT05334329|BIOLOGICAL|Atezolizumab|Given IV
224324179|NCT05334329|PROCEDURE|Biospecimen Collection|Correlative studies
224324180|NCT05334329|DRUG|Cyclophosphamide|Given IV
224324181|NCT05334329|DRUG|Fludarabine|Given IV
224324182|NCT06220396|PROCEDURE|Right Heart Catheterization with Hemodynamics and Limited Echocardiogram|"Right Heart Catheterization (RHC) with Hemodynamics and Limited Echocardiogram is an invasive procedure that involves insertion of a catheter through a blood vessel in the neck, groin, or arm to the right side of the heart. Hemodynamic measurements such as the blood pressure inside the veins, heart, and arteries as well as measurements of blood flow and how much oxygen is in the blood will be completed during the catheterization procedure. It is a way to see how well the heart is working during your procedure. During the RHC procedure a limited echocardiogram, using ultrasound waves, will be collected to evaluate the structure and function of the heart.~All measurements will be conducted at rest and during exercise using a supine cycle ergometer"
224324183|NCT06220396|PROCEDURE|Magnetic Resonance Imaging (MRI)|"MRI is a medical imaging technique that uses a magnetic field and computer-generated radio waves to create detailed images of the organs and tissues in your body. CMR Imaging will assess myocardial structure, function, and fat content.~An additional limited MRI sequence of the the abdomen and one sequence in the thigh will be used to evaluate for visceral adipose tissue (VAT) as a measurement of body composition."
224324184|NCT06220396|PROCEDURE|Dual X-ray absorptiometry (DEXA) scan|A DEXA scan measures the amount of fat in the body using an x-ray that measures bone, calcium and fat.
224324185|NCT04347239|DRUG|Placebo|Placebo
224324186|NCT04347239|DRUG|Leronlimab (700mg)|Leronlimab (PRO) 140 is a humanized IgG4, monoclonal antibody (mAb) to the C-C chemokine receptor type 5 (CCR5)
224324187|NCT06159725|DRUG|CMTX-101|CMTX-101 is a humanized monoclonal antibody administered as a single IV infusion over approximately 60 minutes.
224324188|NCT06159725|DRUG|Placebo|Placebo is normal saline administered as a single IV infusion over approximately 60 minutes.
224324189|NCT02481349|OTHER|Best Practice|Undergo standard of care
223681974|NCT06300593|DIAGNOSTIC_TEST|Measurement and comparison of leucocytosis and concentrations of C-reactive protein (CRP), interleukin-1 (IL-1), IL-6, IL-10, Tumor Necrosis Factor (TNF-alpha) in PCOS phenotypes A, B, C and D|A venous blood sample of approximately 10 ml will be collected in the morning after 8 hours of fasting to determine and compare the above parameters of peripheral blood in the four study arms
223681975|NCT06300593|DIAGNOSTIC_TEST|Evaluation of the correlation of serum concentrations of selected inflammatory markers (leucocytosis, CRP, IL-1, IL-6, IL-10, TNF-alpha) with metabolic and hormonal parameters|A venous blood sample of approximately 10 ml will be collected in the morning after 8 hours of fasting to test the above correlations in the four study arms
223681976|NCT05278637|DRUG|Aspirin|Aspirin 81mg/day x 4 weeks, Aspirin 325mg/day x 4 weeks. or Aspirin 325mg/day x 4 weeks, Aspirin 81mg/day x 4 weeks.
223681977|NCT05278637|DRUG|Ticagrelor|Ticagrelor 90mg BID x 4 weeks
223681978|NCT00800462|DRUG|Oxybutynin Cl|15 mg qd for 3 months
223681979|NCT00800462|DRUG|Trospium Cl|20mg bid for 3 months
223681980|NCT00800462|DRUG|Darifenacin Hydrogen Bromide (HBr)|15 mg qd for 3 months
224324190|NCT02481349|OTHER|Informational Intervention|Receive DVD for home practice
224324191|NCT02481349|OTHER|Quality-of-Life Assessment|Ancillary studies
224324192|NCT02481349|OTHER|Questionnaire Administration|Ancillary studies
224324193|NCT02481349|OTHER|Yoga|Complete couple-based Hatha yoga program
224324194|NCT06736990|DRUG|CAL101|Intravenous infusions of CAL101 every 4 weeks over 24 weeks
224324195|NCT06736990|DRUG|Placebo|Intravenous infusions of placebo every 4 weeks over 24 weeks
224324196|NCT06851507|DRUG|Fluorouracil 5-FU|Participants in the fluorouracil arm will apply fluorouracil twice daily for 2-3 weeks (depending on body area).
224324197|NCT06851507|DRUG|Fluorouracil/Calcipotriene|Participants in the fluorouracil/calcipotriene will apply fluorouracil/calcipotriene twice daily for 4 days to the affected area.
224324198|NCT06323928|DRUG|Lu AG09222|Lu AG09222 will be administered per the arm description.
224324199|NCT06323928|DRUG|Placebo|Placebo matching to Lu AG09222 will be administered per the arm description
224324200|NCT05713799|DRUG|Placebo|Placebo
224324201|NCT05713799|DRUG|Mirabegron|selective beta3-AR agonist approved
224324202|NCT05713799|DRUG|Alpha-lipoic acid|ALA is an antioxidant that is available over the counter
224324203|NCT06850922|DRUG|RO7446603|Participants will receive RO7446603 as an IVT injection per the schedule described in the treatment arms.
224324204|NCT06850922|DRUG|Aflibercept|Participants will receive aflibercept as an IVT injection per the schedule described in the treatment arm.
224324205|NCT06850922|DRUG|Faricimab|Participants will receive faricimab as an IVT injection per the schedule described in the treatment arms.
224324206|NCT04201262|BIOLOGICAL|Ravulizumab|Participants will receive a weight-based loading dose of ravulizumab via IV infusion on Day 1, followed by weight-based maintenance doses on Day 15, then once every 8 weeks until end of the Long-Term Extension Period.
224324207|NCT05466929|BEHAVIORAL|TeACH System Resources|Patients who screen positive for anxiety will receive psychoeducation and mental health recommendations (e.g., evidence-based apps) selected for use with the TeACH System through a collaborative, stakeholder-engaged approach completed in phases 1 and 2 of this project.
224324208|NCT06088290|DRUG|Lurbinectedin|IV Infusion
224324209|NCT06088290|DRUG|Doxorubicin|Short IV push or bolus (according to label)
224324210|NCT03076255|PROCEDURE|Computed Tomography|Undergo CT simulation
224324211|NCT03076255|DEVICE|Medical Device|Given thermoplastic mask
224324212|NCT03076255|DEVICE|Medical Device|Given MID
224324213|NCT03076255|PROCEDURE|Cone-Beam Computed Tomography|Undergo CBCT imaging
224324214|NCT06104319|DRUG|GSK4532990|GSK4532990 will be administered
224324215|NCT03664609|DEVICE|Deep Brain Stimulation|Deep Brain Stimulation in patients with Parkinson Disease, Dystonia and Essential Tremor.
224324216|NCT03515512|DRUG|Enasidenib|Enasidenib may help block the over production of IDH2, which when mutated, can overproduce metabolites and compounds that contribute to the growth of tumors and cancerous cells
224324217|NCT06206421|DRUG|Fezolinetant|oral
224324218|NCT06206421|DRUG|Placebo|oral
224324219|NCT04520373|OTHER|Best Medical Management: Occupational and Physical Therapy|Observation while undergoing Occupational and Physical Therapy for 6 months
224324220|NCT04520373|BIOLOGICAL|Autologous, Adipose Derived Mesenchymal Stem Cells|The mesenchymal stem cells will be collected and expanded from the patients' adipose tissue.
224324221|NCT06411249|DRUG|Belimumab (GSK1550188)|GSK1550188 will be administered subcutaneously.
224324222|NCT06236009|DRUG|TAK-004|TAK-004 subcutaneous injections.
224324223|NCT06236009|DRUG|Placebo|Matching- placebo subcutaneous injections.
224324224|NCT01810913|DRUG|Atezolizumab|Given IV
224324225|NCT01810913|PROCEDURE|Biopsy Procedure|Undergo biopsy
224324226|NCT01810913|PROCEDURE|Biospecimen Collection|Undergo collection of blood
224324227|NCT01810913|BIOLOGICAL|Cetuximab|Given IV
224324228|NCT01810913|DRUG|Cisplatin|Given IV
224324229|NCT01810913|PROCEDURE|Computed Tomography|Undergo CT
224324230|NCT01810913|DRUG|Docetaxel|Given IV
224324231|NCT01810913|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
224324232|NCT01810913|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
224324233|NCT01810913|OTHER|Survey Administration|Ancillary studies
224324234|NCT05684978|DRUG|Perampanel|The purpose of this study is to determine the efficacy of Perampanel, an approved antiseizure medication, in the treatment of refractory status epilepticus (RSE), to identify determinants of outcomes, and establish safety.
224324235|NCT03307785|DRUG|Niraparib|Niraparib is a potent, orally active PARP1 and PARP2 inhibitor being developed as a treatment for patients with tumors that harbor defects in the homologous recombination DNA repair pathway or that are driven by PARP-mediated transcription factors.
224324236|NCT03307785|DRUG|TSR-042|TSR-042 is a humanized monoclonal antibody that binds with high affinity to PD-1 resulting in inhibition of binding to programmed death receptor ligands 1 and 2 (PD-L1 and PD-L2).
224324237|NCT03307785|DRUG|Carboplatin-Paclitaxel|Carboplatin in combination with paclitaxel is a chemotherapy treatment that has been shown to be efficacious against a variety of different tumor types, including non-small cell lung cancer \[NSCLC\], ovarian cancer, endometrial cancer, and head and neck cancer.
224324238|NCT03307785|DRUG|Bevacizumab|Bevacizumab is a chemotherapy treatment that has been shown to be efficacious against a variety of different cancer types, including colon cancer, lung cancer, glioblastoma, and renal-cell carcinoma. Bevacizumab is in the angiogenesis inhibitor and monoclonal antibody families of medication. It works by slowing the growth of new blood vessels.
224324239|NCT03307785|DRUG|TSR-022|"TSR-022 is a monoclonal antibody against TIM-3 (also called HAVCR2), an immune checkpoint receptor. Immune checkpoint proteins are molecules that help to regulate the immune system so it does not mistakenly attack healthy cells. However, they can also keep immune cells from recognizing and killing cancer cells.~TIM-3 is found on the surface of certain T-cells, including tumor-infiltrating T-cells, that have left the bloodstream and migrated into the tumor environment. By binding to and blocking TIM-3, TRS-022 allows for T-cells to become activated so as to enhance T-cell-mediated attacks on tumors. These attacks reduce their growth."
224324240|NCT03307785|DRUG|Carboplatin-Pemetrexed|Pemetrexed and platinum therapy in combination with pembrolizumab (anti-PD-1 antibody) has proven to be efficacious in a first line setting for nonsquamous NSCLC patients
224324241|NCT03307785|DRUG|Carboplatin-Nab-Paclitaxel|Nab-paclitaxel is a formulation of paclitaxel that is indicated for locally advanced or metastatic NSCLC, as first-line treatment in combination with carboplatin in patients who are not candidates for curative surgery or radiation therapy. Nab-paclitaxel has shown increased ORR and time to progression in metastatic breast cancer compared with solvent-based paclitaxel and has shown antitumor activity and improved ORR compared with solvent-based paclitaxel as first-line therapy in patients with NSCLC.
224324242|NCT05036330|OTHER|Clinical Evaluation|Undergo speech and swallow evaluation
224324243|NCT05036330|PROCEDURE|Physical Examination|Undergo examination of TEP and laryngectomy stoma
224324244|NCT05036330|OTHER|Quality-of-Life Assessment|Complete questionnaires
224324245|NCT05036330|OTHER|Questionnaire Administration|Complete questionnaires
224324246|NCT05971173|DRUG|Juven|Nutritional supplements
224324247|NCT05971173|DRUG|Centrum Silver 50+|Over the counter nutritional supplement
224324248|NCT06397872|DRUG|100 mg Resmetirom Tablet|Once daily oral dose for 6 days
224324249|NCT03141437|OTHER|Best Practice|Receive standard of care
224324250|NCT03141437|OTHER|Educational Intervention|Receive educational materials
224324251|NCT03141437|OTHER|Internet-Based Intervention|Use decision-making website
224324252|NCT03141437|OTHER|Questionnaire Administration|Ancillary studies
224324253|NCT03952637|BIOLOGICAL|AAV9-GLB1|The risks of administering this treatment in a subject with GM1 gangliosidosis are not completely known. The major risk associated with intravenous infusion is from the subject s immunological response to the viral capsid and/or the beta-gal protein. To reduce this possibility, immune modulation therapy is being started prior to vector delivery and maintained for six months afterward. There is a theoretical risk that the integration of a small percentage of the rAAV vector DNA into the host cell genome could cause cellular transformation to cancer cells and lead to a malignancy. This has never been seen in subjects receiving intravenous AAV9 gene therapy so the risk of this complication, is likely very low.
224324254|NCT03952637|PROCEDURE|Abdominal ultrasound|Abdominal ultrasound will be performed as part of screening and safety follow- up studies. The ultrasound will be performed in a radiology department and will take approximately 20-30 minutes.
224324255|NCT03952637|DRUG|Rituximab|We are proposing the use of immune modulation to transiently deplete B-cells using rituximab. It will be infused at -21 days and -14 days before gene transfer.
224324256|NCT03952637|DRUG|Sirolimus|Sirolimus is a macrocytic lactone that inhibits T lymphocyte activation and proliferation by inhibiting activation of mammalian Target of Rapamycin (mTOR) kinase that suppresses cytokinedriven T-cell proliferation. We plan to give sirolimus from day -21 to Day 90 with option to extend to day 365 if clinically indicated.
224324257|NCT03952637|DRUG|Methylprednisolone|Subjects will receive IV methylprednisolone 1 mg/kg or a maximum dose of 50 mg, 60-120 minutes prior to vector administration on day 0 to mitigate potential acute innate immune response against the vector.
224324258|NCT03952637|DRUG|Prednisone|Prednisone (oral solution, dose 0.5 mg/kg) will be taken daily on Days 1-3.
223681981|NCT03230305|OTHER|Ethnographic interview|"If a patient is invited to participate in the a clinical trial, inclusion's status (included or/not) will be sought.~* If included: an ethnographic interview will be held with patient (or his representant) who agreed to participate in the clinical trial, his family caregivers, his physician(s) in charge of him and the trial and, and clinical studies technician responsible for management.~* If not included, an ethnographic interview has offered to him, his caregivers, his physician(s) in charge of him and the trial and clinical studies technician responsible for management. In parallel, the reasons for non-inclusion are collected from a pre-established epidemiological questionnaire.~If a patient is not invited to participate,an ethnographic interview will be held with his physician(s) in charge of him and the clinical trial and with clinical studies technician responsible for management.The reasons for non-invitation will be collected from an epidemiological survey multiple choices."
223681982|NCT01791556|OTHER|HIV-1 viral load testing|
223681983|NCT00645788|DRUG|Ciprofloxacin (Cipro Inhale, BAYQ3939)|32.5 mg ciprofloxacin DPI corresponding to 50 mg Ciprofloxacin PulmoSphere Inhalation powder twice a day for 28 days
223681984|NCT00645788|DRUG|Placebo|50 mg matching placebo powder formulation twice a day for 28 days
223681985|NCT00645788|DRUG|Ciprofloxacin (Cipro Inhale, BAYQ3939)|48.75 mg ciprofloxacin DPI corresponding to 75 mg Ciprofloxacin PulmoSphere Inhalation powder twice a day for 28 days (Arm 3 and Arm 4 was introduced after amendment 2)
224324259|NCT03952637|DIAGNOSTIC_TEST|Audiology assessment with ABR|The audiology assessment will be performed in the Audiology Clinic using a standard audiogram to measure thresholds for pure tones and speech, word recognition, tympanometry, and otoacoustic emissions if the subject is capable and tolerant of these measures. The assessment will take approximately 30 minutes. The ABR is a noninvasive neurophysiologic test to evaluate electrical signal transmission from the 8th cranial nerve to the brainstem and the cortex in response to specific tones. Electrodes are placed on the scalp and on each earlobe. An earphone gives off a brief click or tone and the electrodes pick up the brain's responses to these sounds and record them. This will be performed by a trained neurophysiology technician to monitor possible change in hearing during treatment. The procedure will be performed in the Interventional Radiology suite while the subject is sedated following the MRI, fMRI, and MRS of the brain.
224324260|NCT03952637|DIAGNOSTIC_TEST|Bone density scan (DEXA)|Type II subjects - This is a noninvasive enhanced form of X-ray that is used to measure bone loss. Loss of bone density is a known complication with GM1 gangliosidosis due to decrease in weight-bearing activities with disease progression. The procedure will be performed in the Nuclear Medicine Department. The subject s femur, spine, and whole body will be scanned at baseline and then yearly for 3 years. The procedure will take approximately 10 minutes and may be limited due to the subject s cooperation.
224324261|NCT03952637|DIAGNOSTIC_TEST|Electrocardiogram (EKG)|Performed as part of screening and for safety before sedated procedures. The ECG will take approximately 10 minutes and may be limited due to the subject s cooperation.
224324262|NCT03952637|DIAGNOSTIC_TEST|Echocardiogram|Performed as part of screening. The Echo will be done in the Echo Lab and may take approximately 20-30 minutes. The exam may be limited due to the subject s cooperation level.
223681986|NCT00645788|DRUG|Placebo|75 mg matching placebo powder formulation twice a day for 28 days (Arm 3 and Arm 4 was introduced after amendment 2)
223774438|NCT00774995|BIOLOGICAL|EngerixTM-B|Intramuscular injection, one dose.
223681987|NCT01205178|DRUG|Chloroquine|The current gold standard for radical cure of P. vivax malaria in many areas of the world is chloroquine (CQ); typically 600 mg day 1, 600 mg day 2, 300 mg day 3 for clearance of the acute parasitemia. After this Tafenoquine will be given and subject will be followed up.
223681988|NCT01205178|DRUG|Primaquine|Primaquine (PQ) is another 8 aminoquinoline drug available for Malaria treatment
223681989|NCT01205178|DRUG|Tafenoquine|Once daily on Day 1 only. For Part B and C of this study Chloroquine will be given to treat Malaria
223681990|NCT04381338|OTHER|Pulmonary and Motor Rehabilitation|Pulmonary and Motor Rehabilitation in ICU
223681991|NCT02901665|OTHER|FCC intervention|Communication to all NICU families that they should be in the NICU a minimum of 4 hours/day.
223681992|NCT00495079|DRUG|Marqibo® (vincristine sulfate liposomes injection)|Dosing was done every 7 days (± 3 days) on Days 1, 8, 15, and 22 with no less than 4 days between dosing days. Dose calculations were based on body surface area using the subject's height (from Screening) and actual weight for each course.
223681993|NCT03888638|PROCEDURE|Hepatectomy|Removal of a part of the liver because of tumor
223681994|NCT04308811|BIOLOGICAL|platelet rich plasma|Platelet rich plasma and intrauterine balloon applied intrauterine after hysteroscopic adhesiolysis of intrauterine adhesions
223681995|NCT04308811|COMBINATION_PRODUCT|amniotic membrane graft group|amniotic membrane applied on the intrauterine balloon after hysteroscopic lysis of intrauterine adhesions
223681996|NCT04308811|DEVICE|Intrauterine balloon|intrauterine balloon applied intrauterine after hysteroscopic lysis of intrauterine adhesions
223681997|NCT03960021|RADIATION|RFA interventions|Each patient is treated with 2 RFA interventions. Abiopsy of one metastasis is done at each RF session. Histological samples are sent to the Bio-pathology department of Institut Bergonié for tumor infiltrating lymphocytes counting. Primary outcome results from this counting (stromal TILs ≥ 20% is considered as a significant level, a comparative measurement before and after RF will be performed). In parallel blood samples are performed before and after RFA to analyze the kinetics of peripheral blood T lymphocytes subsets, tumoral circulating cells and tumoral DNA.
223681998|NCT01281527|DRUG|Paliperidone Palmitate|50 - 150 mg eq. every 30 days
223681999|NCT03559426|DRUG|Antipsychotic Reduction|Antipsychotic medication is gradually reduced and discontinued if possible. A flexible individualised antipsychotic reduction schedule is devised for each patient by the research team, based on the participant's initial antipsychotic regime. Antipsychotic dose is reduced incrementally every two months, with flexibility to speed up or slow down the schedule in discussion with the patient. The antipsychotic reduction extends over a period of between six to 12 months, although this may be extended according to individual circumstances.
223682000|NCT03559426|DRUG|Antipsychotic Maintenance|Participants continue to receive antipsychotic treatment at the original dose for the 24 month duration of the trial. Increases or minor adjustments to antipsychotic medication are permitted.
223682001|NCT00459979|DRUG|sunitinib malate|Sunitinib will be dosed at 50 mg p.o. daily
223682002|NCT00459979|PROCEDURE|conventional surgery|nephrectomy
223682003|NCT02820701|PROCEDURE|OMT|Osteopathic Manipulative Treatment to low back region
223682004|NCT04456010|OTHER|Questionnaire|Eligible patients will be selected from our electronical database and invited via email to participate.
223682005|NCT00505882|DRUG|Pramlintide|Pramlintide will be started at 15 mcg (2.5 units) subcutaneously immediately prior to major meals and it will be increased by 15mcg every 3 days as tolerated (i.e. nausea, vomiting, upset stomach) to a maximum dose of 60 mcg (10 units) before meals. If significant nausea persists at 45 or 60 mcg level, the dose should be decreased to 30 mcg (5 units) before meals. If the 30 mcg dose is not tolerated, investigator will evaluate for possibility of withdrawing the pramlintide. The dose of preprandial short acting insulin (eg: Novolog/Humalog) will be reduced by 30 to 50% at the start of pramlintide 15 mcg (2.5 units) and then will be adjusted every time the dose of pramlintide is increased by 15 mcg (2.5 units) as needed based on blood glucose readings.
223682006|NCT00505882|DRUG|Glargine|
223682007|NCT00505882|DRUG|Lispro|
223682008|NCT00505882|DRUG|Aspart|
223682009|NCT02655393|DIETARY_SUPPLEMENT|Mitopure|
223682010|NCT00625573|DRUG|Abraxane|100mg/m2 every week X's 3
223682011|NCT03920072|DRUG|Burosumab|Burosumab is a sterile, clear, colourless and preservative free solution supplied in single-use 5ml vials containing 1mL of burosumab at a concentration of 30mg/mL
223682012|NCT00570232|DRUG|Erlotinib|150 mg per day by mouth for 12 months
223682013|NCT03385083|BEHAVIORAL|Step count monitoring with consulting|Subject counseled on step counts at initial visit and 2 and 4 weeks
223682014|NCT03385083|BEHAVIORAL|Step count monitoring without consultation|Subject counseled on step counts at initial visit
223682015|NCT03385083|DEVICE|Fitbit tracker|Fitbit tracker given to participant
224262237|NCT07067931|OTHER|Exercise stroboscopic|In this study, balance and plyometric exercises will be performed by one group using stroboscopic glasses.
223682016|NCT05760118|OTHER|Patient Participation Form|A form that consists of revised osteoporosis knowledge test, osteoporosis self-efficacy scale, and osteoporosis health belief scale.
224262238|NCT07067931|OTHER|training|routine training program
224262239|NCT07067931|OTHER|Exercise|balance and plyometric exercises
224262240|NCT07068282|DRUG|Cholecalciferol (vitaminD3)|Vitamin D3 mouthwash was prepared for COVID-19 participants, to compare between the saliva only (control group), and with the use of mouthwash in saliva after the participants swish for 60 seconds (experimental group) and compare the effect of vitamin D over the virus in saliva, from both groups by testing via RAT and R-PCR.
224262241|NCT07068620|DEVICE|Home-based cognitive training|"All interventions will be carried out for both groups of participants, with either minimal or extensive cSVD.~Upon enrollment, each participant will undergo two hospital visits (visit 1 at day 0, visit 2 at day 7), followed by a home-based cognitive training across 10 days (days 15-24), two more hospital visits (visit 3 at day 26, visit 4 at day 33), and finally a follow-up cognitive testing at home after 6 months."
224262242|NCT07069296|DIAGNOSTIC_TEST|blood samples were collected from participants|Blood samples obtained
224262243|NCT07069296|DIAGNOSTIC_TEST|blood samples|Blood sampling
224324263|NCT03952637|OTHER|Electroencephalogram (EEG) awake and extended overnight|Completed at baseline. The subject will also have an EEG if clinically indicated (for example encephalopathy, seizures, or other change in neurological status or if changes on the previous study are deemed to warrant a follow up study) during post treatment follow up. The procedures will be conducted in the Neurology Testing Department. The total time for an awake EEG, including lead placement, is approximately 40 minutes. An extended overnight EEG will take approximately 12 hours. The exam may be limited due to the subject s cooperation level.
224324264|NCT03952637|DIAGNOSTIC_TEST|Laboratory tests|Performed on blood and urine include safety labs, clinically indicated labs and research collections. Additional specimens may be collected for the PI s biorepository or as clinically indicated. Blood volumes for clinical diagnostic testing and research will be consistent with Clinical Center laboratory guidelines.
224324265|NCT03952637|PROCEDURE|Lumbar puncture|Performed to obtain cerebrospinal fluid (CSF) to measure GM1 ganglioside, beta-gal enzyme, AAV antibodies, Pentasaccharide biomarkers and other research tests. CSF will also be sent for cell count and differential, glucose, protein, and culture as well as CSF neurotransmitters. The amount of CSF obtained will be less than or equal to 0.75 mL/kg body weight. The procedure will be performed while under sedation following MRI imaging. If a sedated MRI is not being performed, then the LP will be performed in consultation with the pediatric consult service using conscious sedation and local anesthesia. The procedure will take approximately 15 minutes.
224324266|NCT03952637|PROCEDURE|Brain MRI/MRS/fMRI|Magnetic resonance imaging (MRI), functional MRI (fMRI) and spectroscopy (MRS) Procedure/Surgery - The subject will undergo noncontrast MRI, including DTI sequences, fMRI, and MRS in the 3T scanner using the same image acquisition sequences and the same MRS voxels to capture the same metabolites as prior sequencing under natural history protocol 02-HG0107. The MRI, fMRI, and MRS will be interpreted for signs of disease progression or stabilization and any signs of treatment toxicity by two board-certified radiologists with specialty training in neuroradiology. The scan will require anesthesia. Sedation will be administered by the anesthesia service after a preanesthesia consultation to assess risk. The type of sedation and whether the subject will be intubated for the procedure will be at the discretion of the anesthesia service.
223682017|NCT05371171|PROCEDURE|skin graft|In the experimental group, the operative plan was to consider taking a 15% larger amount than necessary and replace over-harvested skin back onto the donor site in an island manner. Any remaining skin graft was returned to the donor site and a polyurethane dressing \[Alleyvn, Smith, \& Nephew\] was placed on the regrafted skin for fixation
223682018|NCT05371171|PROCEDURE|no skin graft|In the experimental group, the operative plan was to consider taking a 15% larger amount than necessary and replace over-harvested skin back onto the donor site in an island manner. Any remaining skin graft was returned to the donor site and a polyurethane dressing \[Alleyvn, Smith, \& Nephew\] was placed on the regrafted skin for fixation
223682019|NCT00423748|DRUG|ambrisentan|
223682020|NCT06302738|DIAGNOSTIC_TEST|polysomnography|patients will undergo a home sleep study to evaluate the presence of sleep disorders
223682021|NCT06402253|BEHAVIORAL|Music composition / edition|"Participants in this group will complete two 1-hour music composition training intervention sessions per week over the course of 3 months (24 sessions total). These sessions will take place in the participating schools\&#39; premises, during normal hours corresponding to their advisory period class; or in participating centers during extracurricular activities' periods.~The curriculum for these music composition lessons has been developed specifically for this project, in collaboration and based on the educational music composition programs from the American Composers Orchestra (ACO).~Lessons review basic structural musical concepts, practicing active listening and music appreciation skills, teaching about the use of music-composition specific software (i.e., Soundtrap), and helping the students in expressing themselves / their identity through music, learning about musical story-telling through the creation of their own musical pieces from scratch."
223682022|NCT06402253|BEHAVIORAL|Photography composition / edition|"Participants in this group will complete two 1-hour photography/visual-arts composition/edition intervention sessions per week over the course of 3 months (24 sessions total). These sessions will take place in the participating schools\&#39; premises, during normal hours corresponding to their advisory period class; or in participating centers during extracurricular activities' periods.~The curriculum for these photography composition lessons has been developed specifically for this project, in collaboration and based on educational photography/film programs from Downtown Community TV Center (DCTV).~Lessons review basic structural photography/visual-arts concepts, practicing visual-arts appreciation skills, teaching about the use of photography edition specific software (i.e., Photoshop), and helping the students in expressing themselves/their identity through photography, learning about visual story-telling through the creation of their own photographical projects from scratch."
223682023|NCT04183751|OTHER|scale study|Forms and questionnaires will be used. The data will be collected by the researchers by face to face interview technique.
223682024|NCT04647890|DRUG|FT011|Two x 100mg capsules once daily for 12 weeks
224262244|NCT07067424|OTHER|Lavender Aromatherapy|Participants will inhale lavender essential oil via cotton pads placed near the nose for 20 minutes prior to colonoscopy. The application will take place in a pre-procedure waiting area under nurse supervision.
224262245|NCT07067424|OTHER|Bergamot Aromatherapy|Participants will inhale bergamot essential oil through cotton pads placed near the nose for 20 minutes before the colonoscopy procedure, under the supervision of clinical staff.
223682025|NCT04647890|DRUG|FT011|Two x 200mg capsules once daily for 12 weeks
223682026|NCT04647890|DRUG|Placebo|Two placebo capsules once daily for 12 weeks
223682027|NCT02414503|DRUG|8IU intranasal oxytocin|
224262246|NCT07067424|OTHER|Placebo Inhalation|Participants will inhale an odorless substance (distilled water) using the same method and duration as the intervention groups, to simulate the aromatherapy procedure.
224262247|NCT07067463|DRUG|Orelabrutinib|Orally
224262248|NCT07067463|DRUG|Placebo|Orally
224324267|NCT03952637|BEHAVIORAL|Neurocognitive testing|Type II Subjects - The Vineland-3 will be administered under the supervision of a psychologist. The Vineland-3 provides several types of scores, measure of personal and social independence designed to examine the domains of communication, daily living skills, social skills and motor development. Other standard neurocognitive instruments may be used depending on the subject s ability, and some visits will (may) include a measure of intelligence /cognitive development if the child is able to achieve a basal score. Neurocognitive testing will take approximately 2-3 hours depending on subject cooperation. The assessments will not address sensitive topics. Type I Subjects - Bayley Scales of Infant and Toddler Development (BSID-III), a well-normed and validated, examiner-administered evaluation of cognition, language, and motor skills for children from birth to 42 months of age.
224324268|NCT03952637|OTHER|Neurology exam|Neurology exam will be performed by a neurologist in the screening and followup appointments to monitor for any adverse reactions and to assess for clinical response to the treatment. The exam will be scripted for consistency within subject visits and between subjects and will take approximately 30 minutes to one hour. The exam will be videotaped. The exam may be limited due to the subject s cooperation level.
224324269|NCT03952637|BEHAVIORAL|PICC or other Central line placement|PICC line or other central line placement will be done under sedation in Interventional Radiology. The procedure will be done under sedation and may take 20 minutes. A chest Xray will be done after placement to confirm correct positioning of the catheter.
224324270|NCT03952637|PROCEDURE|Skeletal survey|A skeletal survey will be performed to assess the degree of skeletal involvement of the disease. This will include X-rays of the a/p lateral spine, chest, and pelvis. The exam will take approximately 30 minutes. The exam may be limited due to the subject s cooperation level.
224324271|NCT03952637|PROCEDURE|Skin biopsy|Skin biopsy will be performed on subjects who have not already had a skin biopsy under the 02-HG-0107 protocol. The procedure will be done under sedation using local anesthetic. After washing the skin with chlorhexidine and numbing the skin with injectable lidocaine, a 3mm circle of skin is removed under sterile conditions and the wound is dressed. The entire procedure takes approximately 5 minutes.
224324272|NCT03952637|PROCEDURE|Speech and modified barium swallow study|Performed as a marker of response to treatment and safety. The swallow assessments will include a parental swallowing questionnaire and cranial nerve assessment. The NIH Swallowing Questionnaire from the Speech Language Pathology Section is designed to identify the presence and or absence of functional swallowing dysfunction as perceived by the subject and or caregiver. This 4point scale assists with further identification of clinical/research assessments of oral pharyngeal swallowing function if indicated in the form of a modified barium swallow. In addition to swallow assessments, tape recording of speech will also be included with diadochokinetic tasks and sustained phonations as well as speech if able. Recordings will be stored on a shared drive accessible only by the study team. The assessment may take approximately 30 minutes to 1 hour.
224324273|NCT03952637|PROCEDURE|Ophthalmology exam|The ophthalmology exam will be performed by an ophthalmologist in the screening and follow-up appointments to support subtype diagnosis and assess efficacy. Pictures of bilateral macula will be taken and saved to a secure database. OCT will also be performed. These exams will only be administered to Type I subjects.
223682028|NCT02414503|DRUG|24IU intranasal oxytocin|
224324274|NCT03016377|BIOLOGICAL|iC9-CAR19 cells|Three dose levels are being evaluated: dose level -1 (1 x 10\^5), dose level 1 (5 x 10\^5), and dose level 2 ( 1x 10\^6)
224324275|NCT03016377|DRUG|Rimiducid|Subjects with CRS and ICAN will assign one of two dose levels (DL)s of rimiducid with the standard treatment: 0.05 mg/kg or 0.1 mg/kg for subjects with CRS and 0.01mg/kg or 0.1mg/kg for subjects with ICAN. Subjects will first be enrolled on DL 1 and then enrolled on DL 2, and 0.4mg/kg rimiducid will be given to subjects who did not respond to the initial dose.
224324276|NCT03016377|DRUG|Cyclophosphamide|900 mg/m\^2 IV over 1 hour on day 4 of lymphodepleting chemotherapy.
224324277|NCT03016377|DRUG|Fludarabine|25 mg/m\^2/day IV over 30 minutes administered for 3 consecutive days.
223682029|NCT02414503|DRUG|Placebo|
223682030|NCT02414503|DEVICE|OptiNose Breath Powered Bi|
223682031|NCT00025805|DRUG|G-CSF|
223774439|NCT02143518|BIOLOGICAL|Na-GST-1/Alhydrogel®|The Na-GST-1 candidate vaccine contains the recombinant Na-GST-1 protein expressed by Pichia pastoris. Purified Na-GST-1 was subsequently adsorbed onto aluminum hydroxide gel (Alhydrogel®) and suspended in a solution containing 10% glucose and 10 mM imidazole. The final concentration of Na-GST-1 in the drug product is 0.1 mg/ml whereas that of Alhydrogel® is 0.8 mg/ml. Different doses of Na-GST-1 will be delivered by injecting different volumes of the 0.1 mg/ml Na-GST-1 preparation.
223835669|NCT03936309|OTHER|Physical therapy|▪ Will be a referral to physical therapy specifying McKenzie protocol treatment for the presenting complaint. The McKenzie protocol is a form of standard of care physical therapy in which the physical therapist tries to find a cause and effect relationship between the positions the patient usually assumes while sitting, standing, or moving, and the location of pain because of those positions or activities. The therapeutic approach requires a patient to move through a series of activities and test movement to gauge the patient's pain response. The approach then uses that information to develop an exercise program designed to centralize or alleviate the pain.
223682032|NCT01731184|DRUG|Midazolam|Midazolam (Hypnovel) at 0.04 mg /kg with morphine titration (first bolus: 0.1 mg/kg then 3 mg every 5 minutes).
223682033|NCT06254820|BIOLOGICAL|influenza B/Connecticut/1/21 virus part a dose arm 1|Medium dose, expected to be approximately 10\^6 tissue culture infective dose 50% (TCID50)/mL (titer may be adjusted based on stock titer)
223682034|NCT06254820|BIOLOGICAL|influenza B/Connecticut/1/21 virus part a dose arm 2|High dose, expected to be approximately 10\^7 TCID50/ mL (titer may be adjusted based on stock titer)
223682035|NCT06254820|BIOLOGICAL|influenza B/Connecticut/1/21 virus part b dose 1|Extension of one of the Part A dose arms; which one is to be determined (TBD) depending on outcome of Part A, AND/OR Dose Arm 3
223682036|NCT06254820|BIOLOGICAL|influenza B/Connecticut/1/21 virus part b dose 2|Addition of a 3rd dose, TBD depending on outcome of Part A
223682037|NCT05024643|PROCEDURE|Endonasal endoscopy|"Complete sphenoethmoidectomy; Draf type IIa, IIb, and III according to defect location.~Defect less than 3 mm closed by a plug of fat and facia lata or middle turbinate mucosa.~Defect more than 3 mm closed by underlying facia lata, underlying cartilage, and overlay facia lata."
223682038|NCT05144334|DRUG|BTX-1188|One 28 day cycle of treatment will consist of 4 weeks of treatment with BTX-1188 administered orally per dosing schedule.
224324278|NCT04330365|BEHAVIORAL|Whole Health Team (WHT) Intervention Arm, Primary Care Group Education (PC-GE) Intervention Arm, Usual Primary Care (UPC) Arm|Participants will be randomly assigned at the individual level to either WHT, PC-GE or Usual Primary Care, stratified by site, sex, and use of prescribed opioids for chronic pain. The follow-up period for the three arms will be 12 months. The primary outcome is change in pain interference. Secondary outcomes include change in pain intensity, functioning, quality of life, changes in use of pain medications, including opioids (if applicable) and changes in nonpharmacological pain self-management activities. After the baseline assessment, masked telephone assessments will be administered to participants at 3, 6, 9, and 12 months.
224324279|NCT05624996|DRUG|Carboplatin|Given IV
224324280|NCT05624996|DRUG|Cisplatin|Given IV
224324281|NCT05624996|PROCEDURE|Computed Tomography|Undergo CT and/or PET/CT
224324282|NCT05624996|BIOLOGICAL|Durvalumab|Given IV
224324283|NCT05624996|DRUG|Etoposide|Given IV
224324284|NCT05624996|RADIATION|Image Guided Radiation Therapy|Undergo IGRT
224324285|NCT05624996|DRUG|Nab-paclitaxel|Given IV
224324286|NCT05624996|DRUG|Osimertinib|Given PO
224324287|NCT05624996|DRUG|Paclitaxel|Given IV
224324288|NCT05624996|DRUG|Pemetrexed|Given IV
224324289|NCT05624996|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
224324290|NCT05624996|OTHER|Questionnaire Administration|Ancillary studies
224324291|NCT05624996|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
223682039|NCT05758441|BEHAVIORAL|Mentoring to be Active plus Family|Ten, structured peer mentoring sessions (once a week) covering new content each week and guided skill-building and practice. The MPBA sessions target increasing daily physical activity and replacing sugary drinks with water for hydration. Mentoring sessions are conducted virtually. A 6-month family reinforcement program follows with a reinforcement packet sent to child participants' homes once a month.
223682040|NCT05758441|BEHAVIORAL|Tracking Health and Fitness|10 self-guided, self-paced modules mailed to child participants home.
223682041|NCT06554704|BEHAVIORAL|Isometric hand grip test|The five-minute heart rate variability and respiration rate will be measured for each condition including resting in supine, sitting and standing position, as well as the isometric hand grip test in supine, sitting and standing position.
223682042|NCT06242197|OTHER|written advice|written advice (in leaflet form) was given to CRC patients to give to first degree relatives, or send to first degree relatives directly. this leaflet contained information about cancer risk and recommended screening methods.
223682043|NCT00933777|DRUG|Combination of sorafenib and everolimus|Dose finding: Treatment with defined dose of sorafenib of 2x400 mg with increasing dose of everolimus (2.5 mg, 5 mg, 7.5 mg, 10 mg) Extension: Treatment with defined dose of sorafenib of 2x400 mg with everolimus 7.5 mg
223682044|NCT02207946|DRUG|IncobotulinumtoxinA|Active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).
223682045|NCT02207946|DRUG|Placebo|Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).
223682046|NCT03175055|DEVICE|Phoenix|The study to assess safety and efficacy of Phoenix medical exoskeleton.
223682047|NCT01278927|BEHAVIORAL|Exercise|Participants assigned to the Exercise arm will receive a packet of materials from the study interventionist, along with a brief personalized introduction to the home-based exercise intervention.
223682048|NCT01278927|BEHAVIORAL|Stress Management|Participants will receive a packet of materials from the study interventionist, along with a brief (10 minute) standardized introduction to the self-administered intervention.
223682049|NCT01278927|BEHAVIORAL|Exercise and Stress Management|Participants will receive a packet of materials from the study interventionist, along with a brief (15 minute) personalized introduction to the interventions.
223682050|NCT01278927|OTHER|Standard Care|Patients randomized to standard care only will be informed of their assigned condition and receive the DVD.
223682051|NCT06297785|BEHAVIORAL|Gut-directed hypnotherapy|Gut-directed hypnotherapy for patients with irritable bowel syndrome (IBS). Gut-directed hypnotherapy (8 sessions), will be given online in a group setting.The hypnosis treatment is administered by a nurse specially trained in Cognitive Behavioral Therapy (CBT) and hypnotherapy. The treatment is based on the North Carolina protocol. Patients will assess gastro-intestinal symptom severity before, during and after treatment, as well as at follow-up.
223682052|NCT06086015|DEVICE|transcranial alternating current stimulation (tACS)|2mA tACS over right hemisphere, at positions F4, P4, T8 (10-10 convention)
224324292|NCT05564377|DRUG|Alpelisib|Given PO
223682053|NCT05117671|OTHER|data collection to classify infection status|Review of medical records of all selected cases (TKA/THA patients) to classify infection status according to different classifications (EBJIS, MSIS/ICM 2013, ICM 2018).
223835670|NCT06250309|DIETARY_SUPPLEMENT|Dietary assignment|A total of 48 subjects will be randomized by a computer program into one of two groups: MD or WD. Participation in each dietary arm lasts 8 weeks, with a 6 week washout period in between each arm.
224324293|NCT05564377|DRUG|Binimetinib|Given PO
224324294|NCT05564377|PROCEDURE|Biopsy Procedure|Undergo biopsy
224324295|NCT05564377|PROCEDURE|Biospecimen Collection|Undergo blood collection
224324296|NCT05564377|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
224324297|NCT05564377|PROCEDURE|Bone Scan|Undergo bone scan
224324298|NCT05564377|PROCEDURE|Computed Tomography|Undergo CT
224324299|NCT05564377|PROCEDURE|Echocardiography Test|Undergo ECHO
224324300|NCT05564377|DRUG|Fluorouracil|Given IV
224324301|NCT05564377|DRUG|Fulvestrant|Given IM
224324302|NCT05564377|DRUG|Ipatasertib|Given PO
224324303|NCT05564377|DRUG|Leucovorin|Given IV
224324304|NCT05564377|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
224324305|NCT05564377|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
224324306|NCT05564377|PROCEDURE|Mutation Carrier Screening|Undergo tumor mutational screening
224324307|NCT05564377|DRUG|Neratinib Maleate|Given PO
224324308|NCT05564377|DRUG|Nilotinib Hydrochloride Monohydrate|Given PO
224324309|NCT05564377|DRUG|Olaparib|Given PO
224324310|NCT05564377|DRUG|Oxaliplatin|Given IV
224324311|NCT05564377|DRUG|Paclitaxel|Given PO or IV
224324312|NCT05564377|DRUG|Palbociclib|Given PO
223774440|NCT02143518|BIOLOGICAL|CpG 10104|Unmethylated cytosine-guanine dinucleotides (CpGs) are found in bacterial DNA in the expected frequency predicted by random usage, whereas their occurrence is suppressed 4-fold in vertebrate DNA. In vertebrate DNA CpG motifs are also usually methylated. Bacterial CpG-DNA motifs are recognized by the human innate immune system via Toll-like Receptor-9 (TLR-9), a pathogen-associated molecular pattern (PAMP) receptor that is expressed, in particular, by antigen-presenting dendritic cells. Interactions between CpG-DNA and TLR9 rapidly activate antigen-presenting dendritic cells to upregulate co-stimulatory molecules and to produce Th1-polarizing cytokines such as interleukin-12 and interferon gamma. CpG 10104 is a short synthetic oligodeoxynucleotide of the following sequence: 5'-TCG TCG TTT CGT CGT TTT GTC GTT-3'.
223774441|NCT06994143|DRUG|CLN-978|Specified dose on specified days
223682054|NCT05667415|DRUG|disulfiram and cisplatin|on the first day of treatment, patients were given intravenous drip of 80mg/m2 cisplatin, and 21 days was a course of treatment, lasting for 6 courses. Take 400mg disulfiram orally every day, and continue to use it until the end of chemotherapy. According to the patient's tolerance to disulfiram, the dose of disulfiram can be re-evaluated during the treatment, and the lowest dose is 125mg per day. The clinical symptoms, signs and adverse reactions of patients were observed, and the treatment effect of patients was evaluated after two consecutive cycles with 3 weeks as a cycle.
223682055|NCT05667415|DRUG|cisplatin|on the first day of treatment, patients were given 80mg/m2 cisplatin intravenously, and 21 days was a course of treatment, lasting for 6 courses.
223682056|NCT05027295|DRUG|riboflavin ophthalmic solution|Administration of riboflavin one drop every 2 minutes during administration of continuous UVA light for 7.5 minutes.
223682057|NCT05027295|DRUG|riboflavin ophthalmic solution|Administration of riboflavin one drop every 2 minutes during administration of pulsed UVA light for 15 minutes
223774442|NCT06321484|BIOLOGICAL|Cytokine-Induced Memory-like Natural Killer Cells|Cytokine Induced Memory-like Natural Killer (CIML NK) Cells Autologous, cytokine induced memory-like natural killer cells, via intraperitoneal (IP) infusion per protocol.
223774443|NCT06321484|DRUG|Interleukin 2|Low dose subcutaneous IL-2 will be administered every other day for 5 doses after CIML NK cell infusion
223774444|NCT04862468|COMBINATION_PRODUCT|Perivascular dexamethasone|Dexamethasone delivery around target vein segment(s)
223774445|NCT04862468|COMBINATION_PRODUCT|Perivascular sham|Saline delivery around target vein segment(s)
224324313|NCT05564377|BIOLOGICAL|Panitumumab|Given IV
224324314|NCT05564377|PROCEDURE|Positron Emission Tomography|Undergo PET
224324315|NCT05564377|DRUG|Selumetinib Sulfate|Given PO
224324316|NCT05564377|DRUG|Sotorasib|Given PO
224324317|NCT06791122|DEVICE|Digital therapeutic (CT-155)|Digital therapeutic (CT-155) - in the form of a smartphone app
224324318|NCT04221178|OTHER|Cessation of continuous matinenace therapy|Cessation of maintenance therapy for participants in sustained MRD-negative remission while under careful observation
224324319|NCT06308562|DEVICE|Fuzzy Wale Compression Stockinet|EdemaWear is a tubular, circular knit elastic stockinet fabricated with elastic, vertically oriented fuzzy wales, with the compression provided by the elastic, horizontal oriented Lycra® spandex yarns knitted in between. The stockinet is applied from the foot to the popliteal crease, over the affected area. EdemaWear can be applied in direct contact with the skin or over a wound care dressing. Sizing is based on leg circumference. EdemaWear is indicated for edema management of various etiologies (lymphedema, chronic venous insufficiency, congestive heart failure), and optimizing wound healing. The stockinette is often combined with other boxed compression sets. The manufacturer's stated dosage of EdemaWear is 8-12mmHg when used alone.
224324320|NCT05149755|DEVICE|Medtronic Evolut PRO+ TAVR System, or Evolut FX TAVR System, and guideline-directed management and therapy (GDMT)|Patients will have a Transcatheter Aortic Valve Replacement (TAVR) with either an Evolut PRO+ TAVR, or Evolut FX TAVR, heart valve, and given clinical site-determined guideline-directed management and therapy (GDMT).
224324321|NCT03217747|DRUG|Avelumab|Given IV
224324322|NCT03217747|BIOLOGICAL|Ivuxolimab|Given IV
224324323|NCT03217747|RADIATION|Radiation Therapy|Undergo radiation therapy
224324324|NCT03217747|BIOLOGICAL|Utomilumab|Given IV
224324325|NCT04046991|DEVICE|high-definition transcranial direct current stimulation|High definition transcranial direct current stimulation (HD-tDCS) involves the application of low-intensity current through electrodes placed on the scalp. It is believed to elicit brain effects by producing incremental shifts in the resting membrane potential of large numbers of neurons, which alters neuronal firing rates and thus modulates patterns of brain activity in potentially behaviorally-relevant ways. HD-tDCS differs from conventional transcranial direct current stimulation (tDCS) because it employed smaller electrodes configured in such a way as to deliver more focal stimulation of the brain.
223682058|NCT03635411|DIETARY_SUPPLEMENT|Nicotinamide Riboside and Pterostilbene|Nicotinamide riboside and pterostilbene manufactured by Basis
223682059|NCT03635411|DIETARY_SUPPLEMENT|Placebo|Sugar pill manufactured to mimic Basis supplement.
223682060|NCT02642549|BEHAVIORAL|Girls for Health|"The G4H '1000 Hours' Bridge Program will offer English, science and math training, career workshops, opportunity to 'shadow' a health provider, a mentored safe space club to facilitate economic empowerment, training on gender equity and human rights, and communication/leadership skills. Cash transfers for vacations will be provided to support participation. Girls who receive 5 credits on their SSCE exams and pass the health training institute (HTI) entrance exam are eligible for admission. A Foundational Science Training (FST) program will be provided to the '1000 Hours' participants who gain admission to a HTI to strengthen their ability to the pass the HTI weeding exams. The FST will focus on English, math and science training, and safe spaces for social support development."
224324326|NCT04046991|BEHAVIORAL|modified constraint-induced language therapy|Modified constraint-induced language therapy (mCILT) is a behavioral language therapy that invokes use-dependent learning in communicative interactions by requiring spoken output and restricting use of alternative forms of communication, such as gestures, as a substitute for spoken output. Other key elements of CILT include massed practice of goal-directed speech and shaping of desired responses by increasing response demands as participants improve. MCILT differs from traditional constraint-induced language therapy (CILT) in three ways: 1) it will be done as an individual therapy with the examiner in the role of a communication partner; 2) treatment will be delivered in short sessions (1 hour rather than a more typical 3-4 hour session); 3) targeting nouns + semantically related verbs to generate noun + verb phrases in treatment, a modification that may be better suited to addressing syntactic structure.
224324327|NCT04106414|DRUG|Nivolumab|Nivolumab 480 mg every 4 weeks.
224324328|NCT04106414|DRUG|BMS- 986205|BMS-986205 100 mg every 4 weeks.
224324329|NCT04797767|DRUG|Cladribine|Given IV
224324330|NCT04797767|DRUG|Cytarabine|Given IV
224324331|NCT04797767|DRUG|Mitoxantrone|Given IV
224324332|NCT04797767|BIOLOGICAL|Recombinant Granulocyte Colony-Stimulating Factor|Given subcutaneously
224324333|NCT04797767|DRUG|Venetoclax|Given PO
224324334|NCT04797767|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
224324335|NCT04797767|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
224324336|NCT04797767|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
224324337|NCT06077760|BIOLOGICAL|Intismeran autogene|IM injection
223682061|NCT02830984|PROCEDURE|EST+LBD+ENBD|Nasobiliary drainage after endoscopic sphincterotomy plus large-balloon dilation in treating of large bile duct stones
223682062|NCT02830984|PROCEDURE|EST+LBD|Without nasobiliary drainage after endoscopic sphincterotomy plus large-balloon dilation in treating of large bile duct stones
223682063|NCT04252521|DRUG|metoclopramide|10 mg Metpamid in 100 ml normal saline solution
223682064|NCT04252521|DRUG|dexketoprofen trometamol|50 mg dexketoprofen trometamol in 100 ml normal saline solution
223682065|NCT04252521|DRUG|metoclopramide+dexketoprofen trometamol|10 mg metoclopramide+50 mg dexketoprofen trometamol in 100 ml normal saline solution
223682066|NCT01633593|DRUG|Donepezil|5 mg PO a day, during 2 weeks
223682067|NCT05201456|DEVICE|LithoVue Elite System|The LithoVue Elite System is intended to be used to visualize organs, cavities and canals in the urinary tract (urethra, bladder, ureter, calyces and renal papillae) via transurethral or percutaneous access routes. It can also be used in conjunction with endoscopic accessories to perform various diagnostic and therapeutic procedures in the urinary tract.
223682068|NCT03961477|OTHER|Interferential therapy|Exercise therapy
223682069|NCT03447977|OTHER|cervical|cervical spine manual therapy
223682070|NCT03447977|OTHER|thoracic|thoracic spine manual therapy
223682071|NCT03447977|OTHER|exercises|exercises for pain
223682072|NCT04382677|BEHAVIORAL|Promoting First Relationships ®|"Promoting First Relationships ® is based on attachment theory and is strengths-based. The 12 week intervention is delivered in the home of the family. Each week has a theme for discussion, handouts, an activity, and time for joining - checking in with the parent, listening to their concerns, and establishing a positive, supportive relationship. The provider videotapes playtime between parent and child, and alternates weeks watching the video with the parent, reflecting about the needs of both parent and child (reflective observation). PFR consultation strategies include Joining, Positive Feedback, Instructive Feedback, Reflective Questions and Comments, and Instruction with Handouts. These core strategies enhance parents' sense of security and competency. The provider helps the parent develop greater empathy and understanding of the child's needs and feelings, and helps the parent to identify their own feelings and needs around parenting."
224324338|NCT06077760|BIOLOGICAL|Pembrolizumab|IV infusion
224324339|NCT06077760|OTHER|Placebo|IM injection
224324340|NCT04402788|DRUG|Atezolizumab|Given IV
224324341|NCT04402788|PROCEDURE|Biospecimen Collection|Undergo blood and tissue collection
224324342|NCT04402788|PROCEDURE|Computed Tomography|Undergo CT
224324343|NCT04402788|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223682073|NCT04382677|OTHER|Resource & Referral|This condition consists of 1) Resource \& Referral assistance provided over the phone, and 2) Local Services Resource Packet. Throughout the intervention period, the provider makes monthly phone calls to offer further support to families, answer questions, and provide additional resources. The provider has at least four interactions with each family served. In addition, families in this condition have the Resource and Referral Specialist's phone number and they can call if an additional need arises. The resource packet includes local information organized by type of need or resource. These packets are updated regularly as services change over time.
223682074|NCT05419999|DEVICE|Soterix 1x1 tDCS mini CT|During stimulation, a current flows between the electrodes passing through the brain to complete the circuit. tDCS is hypothesized to modulate intrinsic neuronal activity by enhancing neuronal resting potential, or altering the likelihood that a neuron will (or will not) depolarize.
223682075|NCT05419999|OTHER|Sham Soterix 1x1 tDCS Mini CT|Sham setting is used on the Soterix transcranial electrical stimulator
223682076|NCT05419999|BEHAVIORAL|Written Exposure Therapy (WET)|An exposure-based, behavioral psychotherapy for PTSD.
223682077|NCT05005793|DRUG|Sodium bicarbonate|Oral sodium bicarbonate at 0.5 mEq/kg-lean body weight/day
223682078|NCT05005793|DRUG|Placebo|Placebo at 0.5 mEq/kg-lean body weight/day
224324344|NCT04402788|PROCEDURE|Positron Emission Tomography|Undergo PET
224324345|NCT04402788|RADIATION|Radiation Therapy|Undergo radiation therapy
224324346|NCT06312137|BIOLOGICAL|Sacituzumab tirumotecan|Sacituzumab tirumotecan to be administered as 4mg/kg IV infusion q2w for up to 24 weeks
224324347|NCT06312137|BIOLOGICAL|Pembrolizumab|Pembrolizumab to be administered 400mg by IV infusion q6w for up to 42 weeks
224324348|NCT06312137|DRUG|Cisplatin|Cisplatin is administered as 75 mg/m2 IV infusion q3w for up to 12 weeks as background treatment in neoadjuvant phase
224324349|NCT06312137|DRUG|Pemetrexed|Pemetrexed will be administered in the neoadjuvant phase as 500 mg/m2 IV infusion q3w for up to 12 weeks as background treatment in participants with nonsquamous NSCLC.
223774446|NCT06996015|OTHER|Cognitive behavior therapy|The treatment session will begin with a 10-minute conventional therapy, including a 5-minute hot pack applied to the cervical region and a 5-minute Myofascial Release (MFR) using skin rolling and cross-hand techniques to relax and stretch the fascia layers. This will be followed by a 10-minute application of Sustained Natural Apophyseal Glides (SNAGs), where the physiotherapist will guide the patient's active neck movements with accessory glides to improve joint ROM and reduce pain. Lastly, a 20-minute Cognitive Behavioral Therapy (CBT) session will include visual aids, explanations of cervical spine biomechanics, pain pathways, ergonomics, and posture management. Patients will receive manuals summarizing key points and be encouraged to engage actively. The 40-minute session will be conducted twice weekly for four weeks
224324350|NCT06312137|DRUG|Gemcitabine|Gemcitabine will be administered in the neoadjuvant phase as 1000 mg/m2 or 1250 mg/m2 IV infusion on day 1 and day 8 q3w for up to 24 weeks as background treatment in participants with squamous NSCLC.
224324351|NCT06312137|DRUG|Carboplatin|Carboplatin will be administered in the neoadjuvant phase as AUC 5 mg/mL/min or AUC 6 mg/mL/min IV infusion q3w for up to 12 weeks as background treatment.
224324352|NCT06312137|DRUG|Paclitaxel|Paclitaxel will be administered in the neoadjuvant phase as 175 mg/m2 or 200 mg/m2 IV infusion q3w for up to 12 weeks as background treatment.
224324353|NCT06312137|DRUG|Rescue medication|Participants are allowed to take rescue medication to prevent hypersensitivity and/or infusion reactions as a premedication to study treatment. At the discretion of the investigator, participants are provided with a prescription for rescue medications. Recommended rescue medications are antihistamine, H2 receptor antagonist, acetaminophen or equivalent, dexamethasone or equivalent. A steroid mouthwash (dexamethasone or equivalent) may be given as prophylaxis for stomatitis/oral mucositis.
224324354|NCT06481852|DRUG|MTT with antibiotic preconditioning + fiber supplementation|MTT will in a capsule form composed of freeze-dried, encapsulated intestinal microbiota from healthy donors. Fiber supplementation will be 10-14 gm oral fiber supplement. Patients will be followed at week 1, week 2, week 4, week 12, and week 24. Patient will undergo stool sample collection at baseline, week 1, week 4, and week 12, blood sample collection at baseline, week 4, and week, 12. In addition, patient will undergo an echocardiogram, six-minute walk test (6MWT) and quality of life questionnaire at baseline and at week 12.
224324355|NCT06481852|DRUG|MTT with antibiotic preconditioning + placebo supplementation|MTT will in a capsule form composed of freeze-dried, encapsulated intestinal microbiota from healthy donors. Patients will be followed at week 1, week 2, week 4, week 12, and week 24. Patient will undergo stool sample collection at baseline, week 1, week 4, and week 12, blood sample collection at baseline, week 4, and week, 12. In addition, patient will undergo an echocardiogram, six-minute walk test (6MWT) and quality of life questionnaire at baseline and at week 12.
224324356|NCT06481852|OTHER|MTT with placebo + placebo supplementation.|MTT will in a capsule form composed of freeze-dried, encapsulated intestinal microbiota from healthy donors. Patients will be followed at week 1, week 2, week 4, week 12, and week 24. Patient will undergo stool sample collection at baseline, week 1, week 4, and week 12, blood sample collection at baseline, week 4, and week, 12. In addition, patient will undergo an echocardiogram, six-minute walk test (6MWT) and quality of life questionnaire at baseline and at week 12.
224324357|NCT04103892|DRUG|CLE-100|1 tablet of CLE-100 administered once daily
224324358|NCT04103892|DRUG|placebo|1 tablet of placebo administered once daily
224324359|NCT05198830|DRUG|Carboplatin|Given IV
224324360|NCT05198830|DRUG|Cisplatin|Given IV
224324361|NCT05198830|PROCEDURE|Computed Tomography|Undergo CT and FDG-PET/CT
224324362|NCT05198830|BIOLOGICAL|Durvalumab|Given IV
224324363|NCT05198830|PROCEDURE|FDG-Positron Emission Tomography|Undergo FDG-PET/CT
223682079|NCT05744258|DEVICE|Bio-electrical impedance analysis|"Bio-electrical Impedance Analysis will be performed by trained personnel. BIA will be performed after fasting for at least 6 hours. Subjects should refrain from intensive physical activity the day be-fore the measurement. For women, measurements will be performed outside menstruating periods. Subjects will lay down on an examination couch with bare feet. Any jewelry will be removed.~Reactance and resistance will be obtained. Phase angle will be calculated according to the formula:~PhA (°) = (reactance/ resistance° x (180°/π). Body composition, including muscle mass and percentage body fat will be calculated."
223682080|NCT06967064|DRUG|lidocaine cream|Group U receives 1 mL of lidocaine cream extracted using a syringe and evenly applied across the entire posterior surface of the LMA cuff by carefully spreading the cream to ensure uniform coverage, while Group N receives 1 mL of lidocaine cream also extracted using a syringe but applied without ensuring even distribution, resulting in a patchy or non-uniform application.
223682081|NCT06967064|OTHER|Placebo|No lidocaine cream will be applied to the LMA
223682082|NCT05387915|RADIATION|Radiation Therapy|Undergo reduced dose radiation therapy
223682083|NCT01503866|DRUG|bardoxolone methyl|oral, single dose
223682084|NCT03773003|DIETARY_SUPPLEMENT|Probiotics|"The administered probiotics are readily available on the market and contain~* Bifidobacterium breve, B. infantis, B. lactis, B. longum~* Lactobacillus acidophilus, L. bulgaricus, L. casei, L. crispatus, L. fermentum, L. paracasei, L. plantarum, L. reuteri, L. rhamnosus, L. salivarius~* Streptococcus thermophilus"
223682085|NCT03773003|DIETARY_SUPPLEMENT|Placebo|Identically looking to verum, containing corn starch.
223682086|NCT01702636|DRUG|Tranexamic Acid|
223682087|NCT01702636|DRUG|Placebo|
223682088|NCT04813627|PROCEDURE|Regular blood sample collection for ctDNA assessment|Blood samples for in vitro testing of ctDNA status will be drawn at study visits every 3 months for 21 months
223682089|NCT01848041|DRUG|RVL-1201|RVL-1201 0.1% Ophthalmic Solution
224324364|NCT05198830|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
224324365|NCT05198830|DRUG|Methoxyamine|Given PO
224324366|NCT05198830|DRUG|Pemetrexed|Given IV
224324367|NCT05198830|RADIATION|Radiation Therapy|Undergo thoracic radiation
224324368|NCT06282510|DRUG|Povidone Iodine Topical|Topical intranasal povidone iodine (10%) twice daily for 5 days
224324369|NCT06339008|DRUG|LY3650150|Administered SC
224324370|NCT06339008|DRUG|Placebo|Administered SC
224324371|NCT06339008|DRUG|Standard therapy for INCS|Administered as intranasal spray
224324372|NCT05672576|DRUG|Cenerimod|Cenerimod will be supplied as film-coated tablets at the dose of 4 mg.
223682090|NCT01848041|DRUG|RVL-1201 Vehicle Placebo|RVL-1201 Vehicle Placebo
224324373|NCT05672576|DRUG|Placebo|Matching placebo will be supplied as identical film-coated tablets formulated with the same excipients but without the active ingredient, cenerimod.
224324374|NCT04897009|PROCEDURE|Biospecimen Collection|Undergo blood and tissue collection
224324375|NCT05552469|DRUG|DFV890|DFV890 Single Agent
224324376|NCT06345066|DRUG|Tirzepatide|Administered SC.
224324377|NCT06345066|DRUG|LY3841136|Administered SC.
224324378|NCT06345066|DRUG|Placebo|Administered SC.
224324379|NCT02510456|DEVICE|Diffuse Optical Spectroscopy Imaging (DOSI) - Neoadjuvant Chemo (NAC) Cohort|Participants will have up to 9 DOSI scans at 6 different time points during the course of their neoadjuvant chemotherapy. The time course of chemotherapy may vary between 3-9 months depending on the type chemotherapy subjects receive. Depending on chemotherapy schedule, subjects may or may not be asked to participate in all the 6 measurement time points. The number of DOSI scans each subject requires will be decided during consent. Each DOSI scan will take about 30-60 minutes, although scans at infusion time point will take longer in total due to repeated or continuous measurements.
224324380|NCT02510456|DEVICE|Diffuse Optical Spectroscopy Imaging (DOSI) - Non-NAC Cohort|Participants will have 1 DOSI scan at baseline. The DOSI scan will take about 30-60 minutes.
224324381|NCT06546930|BEHAVIORAL|DREAM intervention|"Virtual Peer Groups (VPGs)~Participants will have multiple opportunities to attend a VPG on a specific topic during their 6-12 month participation period. The VPG topics will include the following:~* Diabetes technology - basics or advanced use (audience-dependent)~* Family relationships and diabetes~* Diabetes in real life - school, work, social gatherings, travel~* Wellbeing and support when living with diabetes~* Working with your diabetes care team - who to call for what~* Eating and activity - what's different with T1D?~In-Person Events will be held quarterly to facilitate participant interaction and community-building. These gatherings will feature ice-breaker activities, refreshments, and hands-on learning opportunities, including the chance to interact with specific diabetes devices and engage with healthcare professionals and representatives from diabetes technology companies."
224324382|NCT03690011|GENETIC|CD7.CAR/28zeta CAR T cells|"Three dose levels will be evaluated:~* Dose level one: 1×10\^7 cells/m\^2~* Dose level two: 3×10\^7 cells/m\^2~* Dose level three: 5x10\^7 cells/m\^2~* Dose level four: 1×10\^8 cells/m\^2"
224324383|NCT05895786|DRUG|PF-06823859|anti-interferon beta therapy
224324384|NCT05895786|DRUG|Placebo|Placebo for PF-06823859
224324385|NCT06052059|DRUG|IV Tulisokibart|Humanized monoclonal antibody that binds human tumor necrosis factor-like cytokine 1A (TL1A), administered intravenously
224324386|NCT06052059|DRUG|IV Placebo|Placebo matching IV tulisokibart
224324387|NCT06052059|DRUG|SC Tulisokibart|Humanized monoclonal antibody that binds human tumor necrosis factor-like cytokine 1A (TL1A), administered subcutaneously
224324388|NCT06052059|DRUG|SC Placebo|Placebo matching SC tulisokibart
224324389|NCT05097989|DRUG|ALXN2050|Oral tablets
224324390|NCT05097989|DRUG|Placebo|Oral tablets
224324391|NCT03392064|BIOLOGICAL|AMG 119|Investigational, adoptive cellular immunotherapy for the treatment of small cell lung cancer
224324392|NCT05363319|DRUG|Cemiplimab|solution for injection via intravenous (IV) infusion
224324393|NCT05363319|DRUG|Platinum-based chemotherapy|IV administration
224324394|NCT04117958|DRUG|AMG 199|AMG 199 is a BiTE® molecule designed to direct T cells towards MUC17-expressing cells.
224324395|NCT02690545|BIOLOGICAL|ATLCAR.CD30 cells|For Phase Ib, in adults and separately in children, two doses will be investigated: 1x10\^8 cells/m\^2 and 2x10\^8 cells/m\^2. Phase II patients will receive the dose level decided upon in Phase I.
224324396|NCT03517579|DEVICE|Cervical Collar Therapy Indicator (COTI)|"Study Device; The CoTI has 3 components;~* A collar unit: a gamma detector wrapped around a body part-neck in this case and contains a scintillating crystal and a silicon photomultiplier. The photon pulse signal is then converted to digital signals (measuring the counts per second). Usually two detectors are placed in specified positions.~* A cable that connects the collar unit to the Control Unit~* A control unit that collects the signals and transmits it wirelessly to a hand-held computer tablet.~Two types of collar devices will be used: the lower activity and the medium activity~1. Lower activity collar for patients with Graves' disease as well as diagnostic I-123 scan in thyroid cancer patients. These patients typically receive 0.2-1.2 m Ci of I-123/I-131.~2. Medium activity collar for Patients with thyroid cancer after 131-I ablation, for which patients typically receive 30-100 mci of I-131."
224324397|NCT05885555|BIOLOGICAL|Ianalumab|Intravenous infusion, prepared from concentrate solution
224324398|NCT05675722|BIOLOGICAL|biologic vaginal-construct implantation|biologic Tissue Engineered Vagina (TEV), which provides an epithelial layer for the luminal aspect and a smooth muscle layer for protecting the openness of the hollow tube, mimicking the cellular orientation and architecture of the vagina. Autologous cells isolated from vagina/vulva remnants offset any potential for immunological rejection.
223682091|NCT00540618|DRUG|MEDI-507|Compare in a placebo controlled manner, the disease activity of three dosing regimens of MEDI-507 (Monoclonal Antibody)
224324399|NCT06845358|BIOLOGICAL|BCG TICE strain|BCG TICE strain is an attenuated, live culture preparation of the BCG strain of Mycobacterium bovis.
224324400|NCT06845358|OTHER|Sodium Chloride, 0.9%|0.9% Sodium Chloride Injection
223682092|NCT00540618|OTHER|Placebo|
223682093|NCT00540618|DRUG|MEDI-507|Monoclonal Antibody (5 mg for 12 weeks and 5 mg for 6 weeks)
223682094|NCT00540618|DRUG|MEDI-507|Administered 7 mg for 4 weeks by injection (Monoclonal Antibody)
223682095|NCT00333346|DRUG|Administration of tramadol intravenously|
223682096|NCT00007059|DRUG|mycophenolate mofetil|
224324401|NCT06845358|OTHER|Sterile Water for Injection|A sterile, nonpyrogenic preparation of water for injection which contains no bacteriostat, antimicrobial agent or added buffer and is supplied only in single-dose containers to dilute or dissolve drugs for injection
224324402|NCT06430801|DRUG|IV Tulisokibart|Humanized monoclonal antibody that binds human tumor necrosis factor-like cytokine 1A (TL1A), administered intravenously
224324403|NCT06430801|DRUG|SC Tulisokibart|Humanized monoclonal antibody that binds human TL1A, administered subcutaneously
224324404|NCT06430801|OTHER|IV Placebo|Placebo matching IV tulisokibart
224324405|NCT06430801|OTHER|SC Placebo|Placebo matching SC tulisokibart
224324406|NCT05109728|DRUG|[177Lu]Lu-DOTA-TATE|"Group 1: \[177Lu\]Lu-DOTA-TATE, dose level 0 (150mCi) administered every 4 weeks. Three provisional dose levels (Dose level +2: 250 mCi; Dose level +1: 200 mCi; Dose level -1: 100 mCi) will be assessed.~Group 3: \[177Lu\]Lu-DOTA-TATE, dose level 0 (150mCi) administered every 3 weeks. Three provisional dose levels (Dose level +2: 250 mCi; Dose level +1: 200 mCi; Dose level -1: 100 mCi) will be assessed."
224324407|NCT05109728|DRUG|[68Ga]Ga-DOTA-TATE|2 MBq/kg of body weight (0.054 mCi/kg), with a minimum dose of 100 MBq (2.7 mCi) and maximum dose of 200 MBq (5.4 mCi)
224324408|NCT05109728|OTHER|Temozolomide|"Concomitant Phase: Temozolomide 75mg/m2/d p.o until last day of EBRT.~Maintenance Phase: Temozolomide p.o 150 mg/m2/d during cycle 1 then 200 mg/m2/d for the following cycles if tolerated well in Cycle 1. 6 cycles total (1 cycle = every 28 days)"
224324409|NCT05109728|OTHER|Radiotherapy|2 Gy/day, 5 days per week followed by 2 days of rest, for 6 consecutive weeks
224324410|NCT04924075|DRUG|Belzutifan|Belzutifan, 120 mg, oral, once daily (QD) until progressive disease or discontinuation.
224324411|NCT06122649|DRUG|apremilast|Oral tablet
223682097|NCT06436664|OTHER|Tooth brushing|Firstly, the toothbrush must be positioned at a 45° angle to the gingival margin. Secondly, the brush should be moved back and forth in small horizontal jerks. Thirdly, with a vertical movement, the brush should be moved in the occlusal direction, i.e. upwards in the lower jaw and downwards in the upper jaw to remove debris.
224324412|NCT06122649|DRUG|Placebo|Oral tablet
224324413|NCT06682429|DEVICE|Telerehabilitation|The telerehabilitation system will deliver rehabilitation treatment sessions via a secured internet-connected computer. TR sessions will be a combination of games, exercises, stroke education, assessments, in addition to videoconferencing with therapists to discuss progress, issues, goals, and changes to the treatment plan.
224324414|NCT05091424|DRUG|Mosunetuzumab|Participants will receive subcutaneous (SC) mosunetuzumab
224324415|NCT05091424|DRUG|Tocilizumab|Participants will receive intravenous (IV) tocilizumab as needed for cytokine release syndrome (CRS) events.
224324416|NCT05091424|DRUG|Venetoclax|Participants will receive daily oral venetoclax
224324417|NCT05887934|DEVICE|X-Ray Fluorescence Analyzer|The XRF analyzer (the ThermoFisher Niton XL3t GOLDD+) is a portable x-ray fluorescent analyzer specifically configured to measure low levels of metals, lead in particular, in bone. The device is designed to rapidly assess cumulative lead exposure, not to support or sustain human life.
224324418|NCT03118466|DRUG|Etoposide|A Drug that interfere with the action of topoisomerase enzymes (topoisomerase I and II). Topoisomerase enzymes control the manipulation of the structure of DNA necessary for replication.
224324419|NCT03118466|DRUG|Cytarabine|Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA.
224324420|NCT03118466|DRUG|Lenalidomide|It may act by inhibiting the growth of new blood vessels (angiogenesis) in tumors, enhancing the status of the immune system, or decreasing cytokine and growth factor production
224324421|NCT03118466|DRUG|Mitoxantrone|It interfere with cell reproduction
224324422|NCT04794816|OTHER|Questionnaire Administration|Complete questionnaire
224324423|NCT05377320|OTHER|Clinical Decision Aid|The clinical decision aid tool will be used at the subject's first visit (Week 0), Week 12 and Week 24.
224324424|NCT05377320|OTHER|Standard Care|Cardiology clinic visits will take place at the subjects first visit (Week 0), Week 12 and Week 24.
224324425|NCT06019767|BEHAVIORAL|Cognitive Processing Therapy|CPT is a type of cognitive behavioral therapy recommended for the treatment of PTSD. Delivered over 12 sessions with an emphasis on addressing trauma-related cognitions and challenging trauma-related beliefs. Includes homework assignments. For this study, CPT will be conducted in groups.
224324426|NCT04988386|DRUG|Acoramidis (AG10)|Acoramidis (AG10) twice daily
224324427|NCT06239116|DRUG|Part A: RM-718 or placebo (matched to specific RM-718 dose cohort)|Single ascending dose of RM-718 or placebo (matched to specific RM-718 Part A dose cohort)
224324428|NCT06239116|DRUG|Part B: RM-718 or placebo (matched to specific RM-718 dose cohort)|Multiple ascending doses of RM-718 or placebo (matched to specific RM-718 Part B dose cohorts)
223682098|NCT06391190|DRUG|Albumin-Bound Paclitaxel, cisplatin, Sintilimab|with Albumin-Bound Paclitaxel 50-75mg/m2, cisplatin 25-40 mg/m2 weekly for up to 5 cycles during radical radiation; followed by Sintilimab 200mg Q3W for 8 cycles
223682099|NCT02996032|OTHER|Vascular and Pulmonary Ultrasound|
224324429|NCT06239116|DRUG|Part C: RM-718|Multiple ascending doses of RM-718 (specific to Part C single cohort)
224324430|NCT04628767|PROCEDURE|Biopsy Procedure|Undergo tissue biopsy
224324431|NCT04628767|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
224324432|NCT04628767|DRUG|Cisplatin|Given IV
224324433|NCT04628767|PROCEDURE|Computed Tomography|Undergo CT
224324434|NCT04628767|DRUG|Doxorubicin Hydrochloride|Given Iv
224324435|NCT04628767|BIOLOGICAL|Durvalumab|Given IV
224324436|NCT04628767|DRUG|Gemcitabine Hydrochloride|Given IV
224324437|NCT04628767|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
224324438|NCT04628767|DRUG|Methotrexate|Given IV
224324439|NCT04628767|BIOLOGICAL|Pegfilgrastim|Given via injection
224324440|NCT04628767|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
224324441|NCT04628767|DRUG|Vinblastine Sulfate|Given Iv
224324442|NCT06496451|OTHER|Spinal tap for CSF collection|"A spinal tap will be done on you by your choice of bedside or in the interventional radiology (IR) suite in the Shands (Neuromedicine) hospital. This procedure will be done by trained technicians under medical supervision or the principal investigator. Local anesthesia will be used to numb the site of injection on your back. We plan to collect about 4 tablespoons of spinal fluid."
224324443|NCT06496451|OTHER|Venipuncture for blood sample|a sample of blood (approximately 4-5 tablespoonfuls) will be collected
224324444|NCT05215951|DRUG|osimertinib|Dose Formulation: tablet； Dosage Level(s): osimertinib 80 mg QD for oral administration; Dosage formulation, dose reduction:40 mg QD for oral administration
224324445|NCT06967558|BIOLOGICAL|Exendin 9-39|Exendin 9-39 is a competitive antagonist of the GLP-1 receptor
224324446|NCT06967558|BIOLOGICAL|Saline|Saline
224324447|NCT06965114|PROCEDURE|Biospecimen Collection|Undergo blood sample and buccal swab collection
224324448|NCT06965114|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow biopsy and aspiration
224324449|NCT06965114|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy and aspiration
223682100|NCT00893620|DEVICE|Zenith(R) Connection Endovascular Covered Stent with the Zenith® Branch Endovascular Graft-Iliac Bifurcation and Zenith Flex(R) AAA Endovascular Graft|These devices will be used in patients with an unsuitable distal sealing site for the standard Zenith(R) iliac leg component proximal to the common iliac bifurcation to maintain internal iliac artery patency with endovascular aneurysm repair.
224324450|NCT06965114|DRUG|Cladribine|Given IV
224324451|NCT06965114|PROCEDURE|Computed Tomography|Undergo CT
224324452|NCT06965114|BIOLOGICAL|Rituximab|Given IV
224324453|NCT06965114|DRUG|Tovorafenib|Given PO
224324454|NCT06235151|DRUG|Copper Cu 64 PSMA I&T|Radiopharmaceutical PET imaging tracer injected intravenously for staging of prostate cancer.
224324455|NCT06176768|DRUG|LY3972406|Administered orally
224324456|NCT06176768|DRUG|Placebo|Administered orally
224324457|NCT05093634|DRUG|Setmelanotide|Subcutaneous Injection
224324458|NCT05093634|DRUG|Placebo|Subcutaneous Injection
224324459|NCT04390399|BIOLOGICAL|N-803|Recombinant human super agonist interleukin-15 (IL-15) complex
224324460|NCT04390399|DRUG|Aldoxorubicin HCl|Aldoxorubicin hydrochloride
224324461|NCT04390399|BIOLOGICAL|PD-L1 t-haNK|PD-L1 t-haNK suspension for infusion
224324462|NCT04390399|DRUG|Nab-paclitaxel|Benzenepropanoic acid, β-(benzoylamino)-α-hydroxy-(2aR, 4S, 4aS, 6R, 9S, 11S, 12S, 12aR, 12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a, 3, 4, 4a, 5, 6, 9, 10, 11, 12, 12a, 12b-dodecahydro-4,11-dihydroxy-4a, 8, 13, 13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca\[3,4\]benz\[1,2-b\]oxet-9-y1ester,(αR,βS)-(9CI) bound to albumin
224324463|NCT04390399|DRUG|Gemcitabine|2', 2'-difluoro 2'deoxycytidine, dFdC
224324464|NCT04390399|DRUG|Cyclophosphamide|2-\[bis(2-chloroethyl)amino\]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
224324465|NCT04390399|DRUG|5-Fluorouracil|5-fluoro-2,4 (1H,3H)-pyrimidinedione
224324466|NCT04390399|DRUG|Leucovorin|L-Glutamic acid, N-\[4-\[\[(2-amino-5-formyl-1,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)methyl\]amino\]benzoyl\]-, calcium salt
224324467|NCT04390399|PROCEDURE|SBRT|Stereotactic Body Radiation Therapy
224324468|NCT04390399|DRUG|Irinotecan liposome|Irinotecan hydrochloride trihydrate is (S)-4,11-diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo1H-pyrano\[3',4':6,7\]-indolizino\[1,2-b\]quinolin-9-yl-\[1,4'bipiperidine\]-1'-carboxylate, monohydrochloride, trihydrate
224324469|NCT06646016|DRUG|Methoxsalen|Sterile solution used in conjunction with photopheresis procedure.
224324470|NCT06646016|DRUG|Infliximab|Infliximab will be administered intravenously.
224324471|NCT06646016|DRUG|Vedolizumab|Vedolizumab will be administered intravenously.
224324472|NCT06297291|DEVICE|Paradise Ultrasound Renal Denervation Treatment|"The Paradise Ultrasound Renal Denervation System (Paradise Ultrasound RDN) is an FDA-approved catheter-based system to treat hypertension by ablating the nerves around the renal arteries, disrupting the overactive sympathetic nerves that can cause high blood pressure. The Paradise procedure uses ultrasound energy to calm the nerves near the kidneys to help lower blood pressure.~Treatment is usually done in an outpatient setting and typically takes about an hour to perform. As a part of the treatment, a small flexible tube (catheter) is guided into the blood vessels near the kidneys and 7 seconds of ultrasound energy is applied 2-3 times. Both sides are treated and then the catheter is removed, leaving nothing behind. After the procedure, some people go home the same day or some stay overnight."
224324473|NCT04560335|BEHAVIORAL|Coach to FIt|"CoachToFit: Those randomized to CoachToFit will have the CoachToFit app downloaded to their phone by the peer coach and will work with the coach to initialize the app. Individuals will receive an activity tracker compatible with Android OS and iOS (Amazfit Bit) and a Bluetooth scale (Smart Body scale). Participants will be instructed by the peer to complete at least two CoachToFit modules per week. Modules take about~15 minutes to complete and have embedded knowledge quizzes and end with a choice of three goals to practice over the next week. They will also set up a time for the first 20-minute coaching call, which will then continue weekly."
224324474|NCT04560335|BEHAVIORAL|Treatment as Usual|Veterans randomized to the treatment as usual arm will continue to access all services of the VA Pittsburgh, and will participate in three research interviews. After the first meeting, all participants will meet with a peer coach (peer specialists) who will discuss with them the importance of losing weight (using a structured conversation that follows a handout which is provided to the participant). The handout was developed with input from a VA dietitian as well as Veterans and is graphically appealing, with a simple layout, and provides information on diet and activity as well as the local MOVE! schedule
224324475|NCT06444360|BEHAVIORAL|IMPACT|The IMPACT intervention includes 10 sessions: 2 sessions of HIV sexual risk reduction (RR) counseling, 1 session focused on orienting and rationale of behavioral activation (BA), 6 sessions integrating BA and sexual RR counseling (including PrEP or ART and HIV care), and 1 final session on strategies for slip-ups and recurrence management.
224324476|NCT06444360|BEHAVIORAL|eSOC|The eSOC group includes 2 sessions of HIV sexual RR counseling.
224324477|NCT04508049|DEVICE|qMT-MRI to detect fibrosis.|The hypothesis underlying this proposal is that qMT would reliably detect development of renal fibrosis at both 1.5T and 3.0T in subjects with RVD. Patients will be studied with MRI (for fibrosis) and CT (for renal function).
224324478|NCT03006978|DEVICE|TearCare|
224324479|NCT03006978|DEVICE|Warm Compress|
224324480|NCT05217641|BIOLOGICAL|BG505 MD39.3 mRNA|Administered by IM injection
224324481|NCT05217641|BIOLOGICAL|BG505 MD39.3 gp151 mRNA|Administered by IM injection
224324482|NCT05217641|BIOLOGICAL|BG505 MD39.3 gp151 CD4KO mRNA|Administered by IM injection
224324483|NCT04230109|DRUG|Sacituzumab Govitecan|Sacituzumab Govitecan via iv, predetermined dosage per protocol, two days per 21-day cycle, for 4 cycles (monotherapy cohort)
224324484|NCT04230109|DRUG|Pembrolizumab|Pembrolizumab via iv, predetermined dosage per protocol, per 21-day cycle, for 4 cycles (combination cohort)
224324485|NCT04989556|OTHER|Interview|Participate in interview
224324486|NCT04989556|OTHER|Palliative Therapy|Receive standard symptom management by palliative care team
223682101|NCT04176042|BEHAVIORAL|Track 1|Intervention + Follow-up
223682102|NCT04176042|BEHAVIORAL|Track 2|Wait list + Intervention
223682103|NCT00871507|DRUG|JNJ-38431055 Dose 1|Liquid suspension/solution of JNJ-38431055 administered as a single dose
223682104|NCT00871507|DRUG|Sitagliptin 100 mg|Capsule containing 100 mg of sitagliptin administered as a single dose.
223774447|NCT06996015|OTHER|Cervical Stabilization Exercises|"The treatment session will last 40 minutes, twice a week for 4 weeks. It begins with a 10-minute conventional treatment: a 5-minute hot pack application to the cervical region followed by a 5-minute Myofascial Release (MFR) using the skin rolling technique. Natural wax will be applied for smooth strokes. MFR will engage all fascia layers with superficial strokes, progressing to deeper fascia using cross-hand stretch, depending on the pain tolerance.~Next, SNAGs (Sustained Natural Apophyseal Glides) will be applied for 10 minutes. The patient, seated, will actively move the painful joint through its range of motion while the therapist applies a glide force. This will be repeated 10 times for 3 sets.~Then session includes 20 minutes of Cervical Stabilization Exercises (CSE) with bracing in neurodevelopment stages (supine, prone, quadrupedal, bipedal), holding each position for 10 seconds. Isometric exercises and functional training with elastic bands and exercise balls follow."
223774448|NCT04169295|OTHER|Gynecologists' feedback on ART-Birth rates|At the time of their fresh embryo transfer couples will receive a document with the following feedback: a photo of their transferred embryo, the number of cryopreserved embryos, the quality rating of the transferred embryo's and couple's personalized IVF-prognosis (i.e. their chance on a live birth from the current IVF-cycle, including the transfer of fresh and if available cryopreserved embryos), calculated by entering eight background characteristics and five IVF-laboratory results into a prognostic model.
223774449|NCT04169295|OTHER|Control group|At the time of their fresh embryo transfer couples will receive a document with the following feedback: a photo of their transferred embryo and the number of cryopreserved embryos
223774450|NCT00441337|BIOLOGICAL|MDX-1106|patients will receive a single dose of MDX-1106 as a 60 minute infusion.
223774451|NCT00452335|DRUG|Lubiprostone|12 mcg capsule once daily (QD)
223774452|NCT00452335|DRUG|Lubiprostone|12 mcg capsule twice daily (BID)
223774453|NCT00452335|DRUG|Lubiprostone|24 mcg capsule twice daily (BID)
224324487|NCT04989556|OTHER|Palliative Therapy|Receive provider initiated remote contact
224324488|NCT04989556|OTHER|Quality-of-Life Assessment|Ancillary studies
224324489|NCT04989556|OTHER|Questionnaire Administration|Complete questionnaire
224324490|NCT00582296|BEHAVIORAL|questionnaires, telephone interview, optional blood drawn|Initial CGS Visit (All Prospective Participants)Clinical assessment (screening, family \& personal history of CA, surgeries) 6 Month Follow-Up Phone Interview (Prospective) Follow-Up Questionnaire (prospective and retrospective) Retrospective Initial Interview Participants may also donate an additional blood, serum, saliva, urine, or stool sample for research, (in addition to the blood drawn for clinical testing) or for the sole purpose of research testing (in absence of clinical testing or prior external testing).
224324491|NCT00582296|BEHAVIORAL|questionnaires, telephone interview and optional blood drawn|Initial CGS Visit (All Prospective Participants)Clinical assessment (screening, family \& personal history of CA, surgeries) 6 Month Follow-Up Phone Interview (Prospective) Follow-Up Questionnaire (prospective and retrospective) Retrospective Initial Interview Participants may also donate an additional blood, serum, saliva, urine, or stool sample for research, (in addition to the blood drawn for clinical testing) or for the sole purpose of research testing (in absence of clinical testing or prior external testing).
224324492|NCT03680586|DRUG|Radiation Therapy|Undergo ultra low-dose radiation
224324493|NCT04788277|PROCEDURE|Biospecimen Collection|Undergo collection of urine samples
224324494|NCT03972657|DRUG|REGN5678|Administered as per the protocol
224324495|NCT03972657|DRUG|Cemiplimab|Administered as per the protocol
224324496|NCT06274801|DRUG|Seralutinib|Capsule containing seralutinib
224324497|NCT06274801|DEVICE|Gereic Dry Powder Inhaler|Generic dry powder inhaler for seralutinib delivery
224324498|NCT04246281|DEVICE|SPRINT Peripheral Nerve Stimulation (PNS) System|The SPRINT System delivers mild electrical stimulation to the nerves in your low back. The SPRINT System includes up to two leads (small wires) that are placed through your skin into your low back. The leads attach to devices worn on your body that deliver stimulation (called Stimulators).
224324499|NCT04246281|PROCEDURE|Standard interventional management of low back pain|Your doctor will determine which procedure or intervention is appropriate for your back pain. You may receive radiofrequency ablation, spinal cord stimulation, surgery, or another procedure or treatment, as appropriate.
224324500|NCT05772884|OTHER|Supervised Exercise Intervention|Exercise duration will be gradually increased as tolerated to 50 min/session, with intensity ramping up to 65-75% HRmax by week 3. On-site exercise sessions will occur along a pre-marked walking path, and a trained staff member will walk alongside the participant to monitor their heart rate. Speed will be manipulated to achieve desired intensity and to sustain heart rate in the target zone. Heart rate will be monitored and recorded via telemetry during the on-site exercise sessions. Step cadence (i.e., steps/minute) will also be monitored and recorded during the on-site sessions and discussed with participants as a way to understand and track their speed when completing off-site walking sessions on their own.
224324501|NCT04028843|BEHAVIORAL|Healthy Beginnings|The program includes a 24 week intensive behavior modification program that targets healthy gestational weight gain through self-monitoring of weight and activity data, automated prescriptive feedback from the smartphone application, personalized feedback from counselors and, evidence-based behavioral intervention delivered throughout pregnancy.
224324502|NCT05580458|BIOLOGICAL|Shingrix|Shingrix is a recombinant, adjuvanted vaccine for prevention of herpes zoster. It is supplied as lyophilized recombinant VZV surface gE antigen for reconstitution with AS01B adjuvant suspension. Each Shingrix dose will be 0.5mL and administered by IM injection in the deltoid region of the upper arm.
224324503|NCT06560645|DRUG|PRT7732|PRT7732 capsules will be self-administered once daily at the dose-level assigned
224324504|NCT02543320|OTHER|LORETA Neurofeedback Training|Undergo LORETA neurofeedback training
224324505|NCT02543320|OTHER|Questionnaire Administration|Ancillary studies
224324506|NCT00539162|BEHAVIORAL|Questionnaire|Questionnaires completed at baseline and during each follow up visit.
224324507|NCT06562192|DRUG|[68Ga]Ga-NNS309|Radioligand imaging agent
224324508|NCT06562192|DRUG|[177Lu]Lu-NNS309|Radioligand therapy
224324509|NCT04921956|DRUG|Concizumab|Injected under the skin (subcutaneous, sc) once daily, individual dose adjustment.
223774454|NCT04069793|DEVICE|Commercially available device|A commercially available and registered with the FDA prosthesis equipped with a powered single-degree of freedom wrist and powered hand.
224324510|NCT06972719|BEHAVIORAL|Experimental Arm|Participants will be randomized to SOC plus the video.
224324511|NCT06972719|BEHAVIORAL|SOC Arm|Participants will be randomized to SOC counseling.
224324512|NCT02337452|OTHER|Questionnaire Administration|Ancillary studies
224324513|NCT02337452|BEHAVIORAL|Web Site|Communicate via family outreach program website
224324514|NCT04604509|DRUG|Bupropion Hydrochloride Controlled-release|Given PO
224324515|NCT04604509|DRUG|Nicotine Replacement|Given via nicotine patch, lozenges, or gum
224324516|NCT04604509|OTHER|Questionnaire Administration|Ancillary studies
224324517|NCT04604509|OTHER|Tobacco Cessation Counseling|Receive behavioral smoking cessation counseling
224324518|NCT04604509|DRUG|Varenicline|Given PO
223682105|NCT00871507|DRUG|Placebo|Placebo suspension/solution and Placebo capsule administered as single doses
223682106|NCT00871507|DRUG|JNJ-38431055 Dose 2|Liquid suspension/solution of JNJ-38431055 administered as a single dose
223682107|NCT03347578|DIAGNOSTIC_TEST|Ultrasonography|Diaphragmatic ultrasound was performed to investigate diaphragmatic function after thoracic surgery
223682108|NCT04879979|BEHAVIORAL|MAAT|MAAT consists of 8 weekly visits of 45 minutes duration and can be delivered effectively through videoconference technology (Vidyo). Participants will be asked to download the Vidyo App on their mobile phone or tablet. Vidyo is a HIPPA compliant, encrypted software with adequate bandwidth for highest quality videoconferencing intended for telehealth. It is the primary software for UPMC Telemedicine. Survivors are provided a workbook to reinforce learning, mastery and application of skills in daily life covered in each MAAT visit. The workbook provides reading structured within each of the 8 visits with guides for application of strategies as homework
223682109|NCT02417493|BEHAVIORAL|Simulation of epinephrine self-injection|
223682110|NCT06221527|PROCEDURE|conventional group|fixation of parasymphyseal fracture using two four-hole titanium miniplates that will be placed on inferior border and another one on superior border
223682111|NCT03999151|BEHAVIORAL|Exercise and Diet|Behavioral program provides access to educational materials + clinical texting program (Arm A) + participant portal, text messaging, and coaching (Arms B-D)
223682112|NCT06969521|BEHAVIORAL|Visual acoustic biofeedback: ORDER|In visual-acoustic biofeedback treatment, elements of traditional articulation treatment are used, including auditory models, verbal descriptions of correct articulator placement, cues for repetitive motor practice via images and diagrams of the vocal tract as visual aids. These strategies are supplemented with a dynamic display of the speech signal in the form of the real-time LPC (Linear Predictive Coding) spectrum (Sona-Match module of PENTAX Sona- Speech software). Because correct vs incorrect productions of /r/ contrast acoustically in the frequency of the third formant (F3), participants will be cued to make their real-time LPC spectrum match a visual target characterized by a low F3 frequency. They will be encouraged to attend to the visual display while adjusting the placement of their articulators and observing how those adjustments impact F3. Knowledge of performance feedback will typically involve reference to the location of the third peak on the visual display.
223682113|NCT06969521|BEHAVIORAL|Perception Training: ORDER|Description: Perceptual training involves self-paced presentation of auditory stimuli via a computerized software program (Gorilla). Stimuli are organized into three separate tasks. In tasks 1 and 3, which train category goodness judgment, participants will hear 75 naturally produced speech tokens containing /r/ from various speakers, with a balance of correct and incorrect productions. They will classify each /r/ as correct or incorrect and receive feedback on the accuracy of their classification. Tasks 1 and 3 differ in that task 1 will feature a subset of items designed to provide focused practice on a specific context (e.g., initial /r/ as in red; /r/ as syllable nucleus as in sir), with increasing difficulty over time, whereas task 3 will feature randomly selected items representing all contexts and difficulty levels. In task 2, participants will hear 75 items drawn from the synthetic rake-wake continuum used in the identification task administered at baseline, but they will recei
223682114|NCT06712875|DRUG|Trametinib and Nivolumab|Trametinib combined with nivolumab (Cohort A)
223682115|NCT06712875|DRUG|Dabrafenib, trametinib, nivolumab|Dabrafenib + trametinib combined with nivolumab (Cohort B)
223682116|NCT01689116|DRUG|Bardoxolone Methyl 20mg|Oral
223682117|NCT01689116|DRUG|Bardoxolone Methyl 80mg|Oral
223682118|NCT01689116|DRUG|Bardoxolone Methyl Placebo|Oral
223682119|NCT01689116|DRUG|Moxifloxacin 400mg|Oral
223682120|NCT01689116|DRUG|Moxifloxacin Placebo|Oral
223774455|NCT04069793|DEVICE|Non FDA registered device|An experimental, non FDA registered prosthesis equipped with a multi function wrist and a powered hand.
224324519|NCT02549638|GENETIC|DNA Extraction|We will then extract DNA from tissue sections and blood and use a custom targeted sequencing panel of 23 cancer driver genes with significant mutations in squamous cell carcinoma that we have developed to find the prognostic biomarkers. The DNA will be used in a PCR reaction to generate amplicons for library preparation using Illumina Nextera XT library preparation protocol and targeted sequencing on the Illumina Hiseq sequencer. The reads will be aligned to the HG19 using BWA aligner and variant detection performed with Agilent SureCall and GATK analytic tools.
224324520|NCT06186765|DEVICE|Axonics SNM System (Model 4101)|Safety and performance/effectiveness assessment of the recharge free Axonics SNM System (Model 4101 in participants with overactive bladder (OAB) or fecal incontinence (FI).
224324521|NCT06405087|DRUG|Vedolizumab SC|Vedolizumab subcutaneous injection.
224324522|NCT06405087|OTHER|No Intervention|As this is an observational cohort, no intervention will be administered.
224324523|NCT05622682|OTHER|Observational only: Serology and flow cytometry for ALL cohort participants|Blood samples from ALL cohort participants will be tested to measure antibodies to vaccine-preventable diseases and immune recovery
224324524|NCT05622682|OTHER|Observational only: Infection rates|Number of infections during the study period will be obtained from both ALL cohort and healthy control participants and captured for comparison and evaluation of infection rates during the first year off-chemotherapy.
224324525|NCT04608149|DEVICE|Carpediem System|Continuous renal replacement therapy
224324526|NCT03298451|DRUG|Durvalumab|Durvalumab IV (intravenous infusion).
224324527|NCT03298451|DRUG|Tremelimumab (Regimen 1)|Tremelimumab IV (intravenous infusion).
224324528|NCT03298451|DRUG|Tremelimumab (Regimen 2)|Tremelimumab IV (intravenous infusion).
224324529|NCT03298451|DRUG|Sorafenib|Sorafenib, as per standard of care
223774456|NCT07000201|DRUG|One hour prior to admission to the operating room, patients will receive the study medication (as premedication) by mouth with a sip of water;|group I patients will receive two capsules of pregabalin (Lyrica) 75 mg (total = 150 mg), group II patients will receive two capsules of gabapentin (Conventin) 300 mg (total = 600 mg), and group III patients will receive a matching placebo in the form of two capsules of powdered multivitamin by mouth.
223774457|NCT06996002|OTHER|Rhomboids Strengthening Exercise|"1. Seated Bent Row in Sitting position,3 sets of the exercise program with 12 repetitions per set, 3 times per week.~2. Bent Over Row in standing position, 3 sets, 12 repetitions, 3 times per week.~3. Lat Pull Down in sitting position with 12 repetitions per set, 3 times per week.~4. Shoulder Horizontal Abduction in lying position with 3 sets of the exercise program with 12 repetitions per set, 3 times per week.~5. Band pull apart performed 4sets, 12 repetitions, and 10 seconds rest for 2 mints, 3 times per week.~6. Prone lateral raise with 3 sets of the exercise program with 12 repetitions per set, 3 times per week.~Conventional treatment Modalities:~Trans-cutaneous Electric Nerve Stimulation (TENS) and Hot pack, postural exercises and stretching exercises"
224324530|NCT03298451|DRUG|Durvalumab (Regimen 1)|Durvalumab IV (intravenous infusion).
224324531|NCT03298451|DRUG|Durvalumab (Regimen 2)|Durvalumab IV (intravenous infusion).
224324532|NCT06481891|DRUG|Sotagliflozin|Sotagliflozin will be administered as a tablet(s), orally once daily.
224324533|NCT06481891|DRUG|Placebo|Placebo will be administered as a tablet(s) (identical to the sotagliflozin tablet in appearance), orally once daily.
224324534|NCT05952804|BIOLOGICAL|Immune Globulin Infusion (Human), 10% Solution|Given IV
224324535|NCT05952804|BIOLOGICAL|Anti-CD19 CAR T Cells Preparation|Given CAR-T treatment
224324536|NCT05952804|OTHER|Saline|Given IV
223682121|NCT05671133|DIAGNOSTIC_TEST|Clinician Decision Support Tool|Clinician Decision Support Tool that provides information about patient's statistical probability of suicide attempt in next 1 month
224324537|NCT05952804|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
224324538|NCT05952804|OTHER|Survey Administration|Ancillary studies
224324539|NCT05952804|OTHER|Electronic Health Record Review|Ancillary studies
224324540|NCT05480943|DIETARY_SUPPLEMENT|Thiamine repletion|If a participant is determined by clinical characteristics or biomarker results to be thiamine deficient, thiamine supplementation was provided.
224324541|NCT05223829|DRUG|Brexanolone|Brexanolone will be administered as a continuous IV infusion over 20 hours under medical observation
224324542|NCT05466994|OTHER|IPAD|Participant will play a game through (standard camera) participants will be able to the hospital room and decals as they appear in the real world
224324543|NCT05466994|OTHER|Augmented Reality|Participants will play a game through (devices camera and application) let us participants view the real world
224324544|NCT06486454|DEVICE|HistoSonics Edison System|Histotripsy with the HistoSonics Edison System for the full or partial destruction of liver tumors
224324545|NCT03546972|OTHER|Behavioral, Psychological or Informational Intervention|Take part in DDP
223682122|NCT03090321|BEHAVIORAL|Stand Prompt|The participant will receive a notification asking them to stand or walk if they have been sitting for longer than 60 minutes
223682123|NCT03090321|BEHAVIORAL|Step Prompt|The participant will receive a notification if they are below 5000 steps by 3pm each day asking them to get to 10000 steps.
223682124|NCT03090321|BEHAVIORAL|Cluster Prompt|The participant will receive daily information notifications specific to the activity cluster they fall into based on the activity data collected in phase 1 of the study
223682125|NCT03090321|BEHAVIORAL|Read AHA website|Daily reminder to read the newsfeed from the American Heart Association (AHA) website, this is a control arm
223682126|NCT04029480|DRUG|Ertugliflozin 5 mg|Ertugliflozin 5 mg, oral, 1 tablet QD
223682127|NCT04029480|DRUG|Ertugliflozin 15 mg|Ertugliflozin 15 mg, oral, 1 tablet QD
223682128|NCT04029480|DRUG|Placebo to ertugliflozin 15 mg|Placebo to ertugliflozin 15 mg, oral, 1 tablet QD
223682129|NCT04029480|DRUG|Placebo to ertugliflozin 5 mg|Placebo to ertugliflozin 5 mg, oral, 1 tablet QD
223682130|NCT04029480|BIOLOGICAL|Insulin|The initiation and titration of insulin will be at the discretion of the investigator, based on local/regional/country guidelines.
223682131|NCT04029480|DRUG|Metformin|Participants will receive stable dose of background metformin.
223682132|NCT04782531|OTHER|peripheral ECG|Subjects will be placed in supine position. The systematic use of a headset will reduce the noise inherent to the machine. A cardiac synchronization system using peripheral ECG allows the synchronization with the subject's heart rate.
223682133|NCT04782531|OTHER|Standard MRI|Standard MRI examination using a torso coil consists of morphological and phase-contrast flow sequences(standard and EPI acquisitions).
223682134|NCT06256159|OTHER|12 MSWS questionnaire|The subject has to perform different gait assessments and fill out the 12-item multiple sclerosis walking scale questionnaire in one visit. Maximum 8 weekes after the first visit the subject has to fill out the same questionnaire again.
223682135|NCT06486077|DIETARY_SUPPLEMENT|Power Line Program|Power Line program consisting of 4 nutritional supplements: a meal replacement shake, a vegetable based green drink, a vascular health product, and a pre-meal fiber supplement
224324546|NCT03546972|OTHER|Behavioral, Psychological or Informational Intervention|Take part in HT
224324547|NCT03546972|OTHER|Questionnaire Administration|Ancillary studies
224324548|NCT01174108|DEVICE|Miltenyi CD34 Reagent System|The CliniMACS CD34 Reagent System is a medical device that is used in vitro to select and enrich specific cell populations.
224324549|NCT01174108|OTHER|Donor derived G-CSF mobilized PBC|Cell Therapy
224324550|NCT04650178|OTHER|Quality-of-Life Assessment|Ancillary studies
224324551|NCT04650178|OTHER|Questionnaire Administration|Complete questionnaire
224324552|NCT05634785|BIOLOGICAL|ATLCAR.CD30 Cells|The cellular product consists of ATLCAR.CD30 cells will be administered via intravenous injection, over 5 - 10 minutes after lymphodepletion. The expected volume will be 1 - 50 mL, the prescribed dose will be 2 × 108 CAR-T cells per meter square and the maximum dose will be 5 × 108 CAR-T cells per meter square.
224324553|NCT05634785|DRUG|Cyclophosphamid|Two to 14 days prior to the initial ATLCAR.CD30 infusion, subjects will receive a lymphodepletion regimen that includes 300 mg per square meter of intravenous cyclophosphamide.
224324554|NCT05634785|DRUG|Fludarabine|Two to 14 days prior to the initial ATLCAR.CD30 infusion, subjects will receive a lymphodepletion regimen that includes daily 30 mg per square meter of intravenous fludarabine infusion for 3 days.
224324555|NCT06358950|DRUG|ALKS 2680|Oral tablet of ALKS 2680 for once daily administration
224324556|NCT06358950|DRUG|Placebo|Oral tablet containing matching placebo for once daily administration
224324557|NCT05846399|DRUG|Amoxicillin/clavulanate|Amoxicillin-clavulanate 875-125mg by mouth twice daily for 1 day or Ciprofloxacin 500mg by mouth twice daily and clindamycin 450mg by mouth twice daily for 1 day
224324558|NCT05846399|DRUG|Ciprofloxacin|Amoxicillin-clavulanate 875-125mg by mouth twice daily for 5 days or Ciprofloxacin 500mg by mouth twice daily and clindamycin 450mg by mouth twice daily for 5 days
224324559|NCT05846399|DRUG|Clindamycin|Amoxicillin-clavulanate 875-125mg by mouth twice daily for 5 days or Ciprofloxacin 500mg by mouth twice daily and clindamycin 450mg by mouth twice daily for 5 days
224324560|NCT05846399|OTHER|Placebo (microcrystalline cellulose)|Placebo (microcrystalline cellulose) by mouth twice daily by mouth for 5 days
224324561|NCT05846399|PROCEDURE|Wound management|Wound management includes hemostasis, copious irrigation, removal of foreign bodies, and excisional debridement of devitalized tissue. If only punctures are present, lancing of the punctures is not typically required unless infection has already developed. Local anesthesia (1% lidocaine hydrogen chloride (HCl) with epinephrine 1:100,000; 200mg/20mL vial) will be used prior to irrigation (30mL of povidone-iodine in 1L of 0.9% sodium chloride (NaCl) solution and/or 118mL of 3% hydrogen peroxide) and debridement. Open wounds will be irrigated and debrided at bedside. Wounds will be covered with soft dressings in place until first follow-up at day 2.
224324562|NCT06288399|OTHER|No treatment given|No treatment given
224324563|NCT05768932|DRUG|BAL0891|BAL0891 is a dual inhibitor of threonine tyrosine kinase (TTK) and polo-like kinase 1 (PLK1)
224324564|NCT05768932|COMBINATION_PRODUCT|Tislelizumab|Tislelizumab a humanized IgG4 anti-PD-1 monoclonal antibody
224324565|NCT05768932|COMBINATION_PRODUCT|Paclitaxel|Paclitaxel is a natural product with antitumor activity
223682136|NCT05737225|DEVICE|Near Infrared Spectroscopy (NIRS)|We will place Near Infrared Spectroscopy (NIRS) electrode on the foot to evaluate regional tissue oxygen saturation in both lower extremities before the performing regional anesthesia (popliteal sciatic nerve block) and then during the procedure.
223682137|NCT05555940|DEVICE|Transcranial magnetic stimulation|The stimulation sites of the true TMS group were mPFC-amygdala functional junction and SSRIs/SNRIs treatment, while the sham TMS group was treated with reversed magnetic head sham stimulation and SSRIs/SNRIs treatment.
223682138|NCT04476589|DIAGNOSTIC_TEST|Functional MRI|measurement of functional brain networks
223682139|NCT02965287|OTHER|Serum metabolomics profiling|The serum samples will be used to get a metabolomic profile
223682140|NCT02361346|DRUG|MT-3724 Phase 1|Intravenous dosing Days 1, 3, 5, 8, 10 and 12; MT-3724 infusion over 2 hours on each dosing day over 28 day initial cycle and then 21 week repeat cycles for up to 5 total cycles.
223682141|NCT02361346|DRUG|MT-3724 Phase 2|Intravenous dosing on Days 1, 3, 5, 8, 10 and 12; MT-3724 infusion over 1 hour on each dosing day over 21 day cycle up to 6 cycles and then can be continued for 6 additional cycles.
223682142|NCT03593460|DRUG|Synthetic PreImplantation Factor|peptide
224324566|NCT04036305|DRUG|0.9% Sodium Chloride Injection|All participants will be injected subcutaneously with a single 0.5ml dose
224324567|NCT04036305|DRUG|Lidocaine Injection 2%|All participants will be injected subcutaneously with a single 0.5ml dose
224324568|NCT04036305|DRUG|Bupivacaine Injection 0.5%|All participants will be injected subcutaneously with a single 0.5ml dose
224324569|NCT04441567|OTHER|Right-size clinic visits|The curve created in Phase 1 will be used to guide the number of clinic visits based on PROMs reported by the participants in Phase 2.
224324570|NCT06087458|BIOLOGICAL|VOY-101|VOY-101
224324571|NCT04050709|BIOLOGICAL|PD-L1 t-haNK|PD-L1 t-haNK Suspension for Infusion
224324572|NCT05827081|DRUG|Ribociclib|Ribociclib 400 mg orally once daily on days 1-21 of a 28 day cycle followed by 7 days rest
224324573|NCT05827081|DRUG|Letrozole|Letrozole 2.5 mg orally once daily continuously
224324574|NCT05827081|DRUG|Ansastrozole|Anastrozole 1 mg orally once daily continuously.
224324575|NCT05827081|DRUG|Goserelin|Goserelin administered subcutaneously at 3.6 mg once every 4 weeks if the one-month depot formulation is used or at 10.8 mg once every 3 months if the three-month depot formulation is used
224324576|NCT05827081|DRUG|Leuprolide|Leuprolide administered subcutaneously at 3.75 mg once every 4 weeks if the one-month depot formulation is used or at 11.25 mg once every 3 months if the three-month depot formulation is used
224324577|NCT05827081|DRUG|Exemestane|Exemestane 25 mg once daily continuously
224324578|NCT03633721|DRUG|Cannabis|7% delta9-THC cigarettes will be smoked by 'light the cigarette' (30 sec), 'get ready' (5 sec), 'inhale' (5 sec), 'hold smoke in lungs' (10 sec) and 'exhale.' Participants will smoke 3 puffs in this manner, with a 40-sec interval between each puff.
224324579|NCT03633721|OTHER|Placebo|0% THC cigarettes will be administered to HIV negative women. Participants will be instructed to 'light the cigarette' (30 sec), 'get ready' (5 sec), 'inhale' (5 sec), 'hold smoke in lungs' (10 sec) and 'exhale.' Participants will smoke 3 puffs in this manner, with a 40-sec interval between each puff.
224324580|NCT03068819|DRUG|CIML NK Cell Infusion|-Day 0
224324581|NCT03068819|PROCEDURE|CD3+ T Cell Product Infusion|-Day -1
224324582|NCT03749317|DRUG|IVIEW-1201|IVIEW-1201; QID; one drop per eye, four times per day (QID) for 7 days
224324583|NCT03749317|DRUG|Placebo|Placebo drug; QID; one drop per eye, four times per day (QID) for 7 days
223682143|NCT05821517|DEVICE|Helmet virtual reality.|"Use of a  virtual reality  (VR) headset of  Pico G2  type with  HypnoVR  software and audio headset  Taotronics BH22  during all the reduction care"
224324584|NCT02457832|BEHAVIORAL|Adapted Tango Dancing|Composed of simple steps, tango involves frequent movement initiation and cessation, multi-directional perturbations and varied rhythms. Participants focus on trunk control and stepping strategies, coordination, somatosensory awareness, attention to partner, path of movement, and aesthetics. Sessions will begin with a typical dance class warm-up consisting of breathing, limbering and postural alignment to upbeat music. Novel step elements will be introduced every class period. Those with PD will partner with an individual without PD. After novel step introduction, the instructor will present rhythmic training, which is indispensable to partnered dancing. Participants will learn 'typical' rhythms from tango and Latin dances, based upon the system of quicks (Q) and slows (S), ubiquitously used in ballroom dance training to understand the temporal relationship of movement to music.
224324585|NCT02457832|BEHAVIORAL|Behavioral Control (BC) Condition|Group health education sessions adapted to the needs of individuals with PD, about pharmacological management, nutrition, sleep disorders, cognitive deficits, bereavement coping, mobility, balance and home safety.
224324586|NCT06974591|OTHER|Dental splints|Each participant will receive six custom-made dental splints to incrementally increase their VDO. These splints will alter the VDO in increments from 5 to 30 mm, specifically: 5, 10, 15, 20, 25, and 30 mm.
223682144|NCT05821517|DRUG|Administration of METHOXYFLURANE|Self administered inhalated methoxyflurane (maximal inhaled dose : 3 mL)
223682145|NCT05821517|DRUG|Standard of care|An anticipated analgesia protocol composed of PARACETAMOL 1g +/- OXYNORM 5 mg or 10 mg according to patients weight and pain intensity as evaluated by a simple numeric rating scale is administred prior to the reduction procedure. Inhaled equimolar mixture of oxygen and notrous oxyde (MEOPA) at a 15L/min flux is administered concomitantly to the reduction procedure.
223682146|NCT00505492|DRUG|Carboplatin|AUC 5 by vein once every 28 Days
223682147|NCT00505492|DRUG|Cisplatin|40 mg/m\^2 by vein (IV) Weekly Over 4 Hours
223682148|NCT00505492|DRUG|Paclitaxel|135 mg/m\^2 by vein (IV) Once Every 28 Days
223682149|NCT01006603|DRUG|Saxagliptin|5 mg, oral tablet, once daily
223682150|NCT01006603|DRUG|Glimepiride|1, 2, 3, 4 or 6 mg, oral encapsulated tablet, once daily
223682151|NCT06111547|DRUG|TAK-279|TAK-279 oral tablet.
223682152|NCT06111547|DRUG|Placebo|TAK-279 30 mg or 60 mg (2\*30mg) matching placebo tablet.
223682153|NCT01465685|DRUG|3,4-Methylenedioxymethamphetamine|125 mg per os, single dose
223682154|NCT01465685|DRUG|Methylphenidate|1 hour before MDMA/placebo 60 mg methylphenidate per os, single dose
223682155|NCT01465685|DRUG|Placebo|capsules identical to MDMA or methylphenidate
223682156|NCT06983015|PROCEDURE|sticky bone|extraction socket will be augmented using a sticky bone.
223682157|NCT06983015|PROCEDURE|xenograft mixed with cross-linked hyaluronic acid|Socket will be augmented with a mixture of xenograft and cross linked hyaluronic acid.
223682158|NCT06657638|DIAGNOSTIC_TEST|Thoracentesis|Aspiration of pleural effusion
223682159|NCT06985186|DRUG|Ultra-Long GnRH Agonists + Letrozole|All patients will receive a depot injection of the long-acting GnRH agonist, intramuscularly, once (11.25mg) or every 28 days (3.75mg) for at least 3 months prior to embryo transfer. Upon initiation of the GnRH agonist, patients will also receive 2.5mg of Letrozole every 12h for 60 days. The start of therapy will be during the menstrual phase of the cycle.
223682160|NCT06985186|DRUG|Ultra-Long GnRH Agonists|All patients will receive a depot injection of the long-acting GnRH agonist, intramuscularly, once (11.25mg) or every 28 days (3.75mg) for at least 3 months prior to embryo transfer. The first injection of GnRH agonist will be administered during the menstrual phase of the cycle.
223682161|NCT06984939|DEVICE|Grasp|Participants assigned to the intervention group will be instructed to squeeze the Grasp ball at regular intervals of approximately every 1-2 seconds. This action will activate a melody played through a speaker connected to the iPad, accompanied by a dynamic wavy line displayed on the screen. Participants will begin squeezing the Grasp ball at least 10 seconds prior to the start of the procedure and will continue until the procedure is completed.
223682162|NCT06979687|PROCEDURE|knotless barbed suture closure of the hysterotomy at caesarean section|Use of Medtronic V-loc 180 suture (VL) for a 2 layer closure of the caesarean hysterotomy rather than the standard 2 layer closure using the 910 polyglactin suture (SS).
223682163|NCT06979687|PROCEDURE|Standard 2 layer closure of caesarean hysterotomy using 910 polyglactin suture (SS)|Standard 2 layer closure using the 910 polyglactin suture (SS)
223835671|NCT04474223|DRUG|Dexamethasone|"In mother in whom 2° AVB or AV interval \>170 ms has been diagnosed in the fetus:~Dexamethasone 8 mg po/day for 10 days. Then dexamethasone 4 mg po/ day through 28 weeks 6 days gestational age (GA); then 3 mg/day from 29 wks 0 days to 29 wks 6 days GA; then 2 mg/day until delivery"
224324587|NCT06974591|OTHER|Dentures|Participants in this group will participate in balance and gait testing both with and without their dentures to examine how the presence or absence of dentures affects postural stability and movement.
224324588|NCT06974734|DRUG|PF-08046037|Given into the vein (IV; intravenous)
224324589|NCT06974734|DRUG|sasanlimab|Given under the skin (SQ; subcutaneous)
223682164|NCT06820307|DRUG|Suzetrigine|Tablets for Oral Administration.
223682165|NCT06820307|DRUG|DRSP/EE|Combination Tablets for Oral Administration.
223682166|NCT06820307|DRUG|NGM/EE|Combination Tablets for Oral Administration.
223682167|NCT05533125|DRUG|Rituximab|Rituximab 1000mg in 250ml NaCl 0.9% intravenously with usual premedication
223682168|NCT05533125|DRUG|Placebo|Placebo in 250ml NaCl 0.9% intravenously with usual premedication
223682169|NCT06986291|DIAGNOSTIC_TEST|Imaging and biomarkers|MR imaging of the heart, ECG and TTE measurements, blood sample
223682170|NCT06585930|BIOLOGICAL|Blood sample|Additional 8.1 ml blood sample
223682171|NCT06987448|PROCEDURE|Semi-direct onlay restoration using CAD/CAM hybrid composite block|This refers to restorations fabricated from nano-ceramic hybrid composite blocks via chairside CAD/CAM workflow and cemented to permanent molars affected by MIH (molar-incisor hypomineralization).
223682172|NCT06987448|PROCEDURE|Semi-direct onlay restoration using CAD/CAM hybrid ceramic block|This refers to restorations fabricated from polymer-infiltrated hybrid ceramic blocks using a digital workflow, then cemented to MIH-affected permanent molars.
223682173|NCT06990425|PROCEDURE|Groin closure with PDS suture|Closure of the groin will be performed with PDS suture
223682174|NCT06990425|PROCEDURE|Groin closure suture material|Closure of the groin will be performed with Vicryl suture
224324590|NCT06976619|DRUG|Liraglutide Pen Injector|Liraglutide 0.6mg
224324591|NCT06976619|OTHER|Saline Injections|Saline in syringes to serve as placebo for single blind study
224324592|NCT04790630|OTHER|Computerized Cognitive Remediation of Executive Functioning (CCR-EF)|computerized experimental brain-training treatment
224324593|NCT04790630|OTHER|Active Control|computerized intervention that follows recommendations for cognitive fitness
224324594|NCT06455449|COMBINATION_PRODUCT|Anifrolumab (blinded)|Anifrolumab treatment delivered subcutaneously, once weekly for 52 weeks
224324595|NCT06455449|OTHER|Placebo|Matched placebo delivered subcutaneously, once weekly for 52 weeks
224324596|NCT06455449|COMBINATION_PRODUCT|Anifrolumab (unblinded, open label)|At Week 52, all study participants on anifrolumab or placebo will receive open label anifrolumab once weekly for an additional 52 weeks
224324597|NCT06576037|DRUG|CBP-1019|Given by vein (IV)
224324598|NCT06576037|DRUG|Oxaliplatin|Given by vein (IV)
224324599|NCT06576037|DRUG|Leucovorin|Given by vein (IV)
223682175|NCT06995586|DIETARY_SUPPLEMENT|Vitamin C, Omega 3 PUFA (EPO/DHA), Lignin, Lactulose|This is a randomized and controlled trial with an intervention group that will be administered orally daily in addition to the Optimal Medical Therapy (OMT), namely 1000 mg Vitamin C, 840 mg EPO/DHA, 2130 mg Lignin \& 720 mg Lactulose and a control group that will receive only the OMT.
223682176|NCT06994481|DIAGNOSTIC_TEST|optic nerve sheet diameter measurement|Both groups will undergo bilateral optic nerve sheath diameter measurement with ultrasonography after induction, after airway manipulations, and before awakening.
223682177|NCT06994312|DRUG|Nafamostat Mesylate|Anticoagulation with Nafamostat Mesylate for SIC Patients Undergoing Hemofiltration
223682178|NCT06994312|DRUG|sodium citrate|Anticoagulation with Sodium Citrate for SIC Patients Undergoing Hemofiltration
223774458|NCT06996002|OTHER|Conventional Exercises|"Conventional Treatment~1. hot pack for 10 min,~2. Trans-cutaneous Electric Nerve Stimulation (TENS) will be applied, with pulse duration of 250 microseconds at a frequency of 80 Hz for 15 min in the sub occipital region and the trapezius bilaterally.~3. Stretching exercises of tight muscles 2 sets of 15 min.~4. Posture correction exercises:~releasing muscles of anterior part of the trunk, neck, shoulder."
224324600|NCT06576037|DRUG|5-FLUOROURACIL|Given by vein (IV)
224324601|NCT06576037|DRUG|Bevacizumab|Given by vein (IV)
224324602|NCT06576037|DRUG|Pembrolizumab|Given by vein (IV)
224324603|NCT06576037|DRUG|Enzalutamide|Given by mouth
224324604|NCT06462235|DRUG|Part A: ATM-AVI Single Dose, Cohorts 1-4|Single intravenous infusion of aztreonam-avibactam over 3 hours to assess pharmacokinetics, safety, and toleration.
224324605|NCT06462235|DRUG|Part B: Multiple-dose ATM-AVI, Cohorts 1-4|Multiple intravenous infusions of aztreonam-avibactam over 3 hours, repeated every 6-8 hours up to 14 days to assess pharmacokinetics, safety, toleration, and efficacy.
224324606|NCT06805461|DEVICE|RenovoCath®|Intra-arterial catheter delivery of chemotherapy agents for the collection of real-world data.
224324607|NCT05691491|PROCEDURE|Biopsy Procedure|Undergo biopsy
224324608|NCT05691491|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
224324609|NCT05691491|PROCEDURE|Computed Tomography|Undergo CT scan
224324610|NCT05691491|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
224324611|NCT05691491|DRUG|Temozolomide|Given orally (PO)
224324612|NCT05691491|DRUG|Tuvusertib|Given PO
224324613|NCT05836857|BEHAVIORAL|Cannabis (Marijuana)|The level of interest in learning more about cannabis for cancer pain, we can better facilitate a patient-centered approach to comprehensive treatment plans through patient education.
224324614|NCT05836857|BEHAVIORAL|Cannabidiol (CBD)|The level of interest in learning more about cannabis for cancer pain, we can better facilitate a patient-centered approach to comprehensive treatment plans through patient education
224324615|NCT02812667|DRUG|Nivolumab + Plinabulin|
224324616|NCT06337318|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
224324617|NCT06337318|PROCEDURE|Computed Tomography|Undergo CT and/or PET/CT scan
224324618|NCT06337318|BIOLOGICAL|Mosunetuzumab|Given SC
224324619|NCT06337318|PROCEDURE|Positron Emission Tomography|Undergo PET/CT scan
224324620|NCT06337318|BIOLOGICAL|Rituximab|Given IV
224324621|NCT06337318|BIOLOGICAL|Rituximab and Hyaluronidase Human|Given SC
224324622|NCT05638295|PROCEDURE|Biopsy Procedure|Undergo tumor biopsy
224324623|NCT05638295|PROCEDURE|Biospecimen Collection|Undergo collection of blood
224324624|NCT05638295|PROCEDURE|Computed Tomography|Undergo CT scan
224324625|NCT05638295|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
224324626|NCT05638295|BIOLOGICAL|Panitumumab|Given IV
224324627|NCT05638295|DRUG|Sotorasib|Given PO
224324628|NCT06322238|DIAGNOSTIC_TEST|PGx panel test|In this prospective, non-randomized, step-wedge design controlled clinical study (PREPARE-MAYO Rochester, Mayo Clinic Health System), pre-emptive genotyping of a panel of clinically relevant PGx-markers, for which CPIC guidelines are available.
224324629|NCT06574048|DRUG|saline placebo|IV saline bolus
224324630|NCT06574048|DRUG|Dexamethasone|10mg IV Dexamethasone
224324631|NCT06143956|DRUG|LY3305677|Administered SC. ISA specific interventions will be listed in the ISA.
224324632|NCT06143956|DRUG|LY3841136|Administered SC. ISA specific interventions will be listed in the ISA.
224324633|NCT06143956|DRUG|Tirzepatide|Administered SC. ISA specific interventions will be listed in the ISA.
224324634|NCT06143956|DRUG|Placebo|Administered SC. ISA specific interventions will be listed in the ISA.
224324635|NCT06143956|DRUG|LY3549492|Administered orally. ISA specific interventions will be listed in the ISA.
224324636|NCT06521398|OTHER|Doula Support|Doula support including care coordination to mental and medical health services in the NICU, with a warm handoff to a community doula to continue the support once infants leave the HUP NICU.
224324637|NCT01552434|BIOLOGICAL|Bevacizumab|Given IV
224324638|NCT01552434|BIOLOGICAL|Cetuximab|Given IV
224324639|NCT01552434|OTHER|Laboratory Biomarker Analysis|Optional correlative studies
224324640|NCT01552434|OTHER|Pharmacological Study|Optional correlative studies
224324641|NCT01552434|DRUG|Temsirolimus|Given IV
224324642|NCT01552434|DRUG|Valproic Acid|Given PO
224324643|NCT05662241|DRUG|Obexelimab|Obexelimab is a monoclonal antibody that co-engages CD19 and FcγRIIb to inhibit B cell activity
224324644|NCT05662241|OTHER|Placebo|Placebo
224324645|NCT05946213|PROCEDURE|Biospecimen Collection|Undergo blood and urine sample collection
224324646|NCT05946213|PROCEDURE|Bone Scan|Undergo bone scan
224324647|NCT05946213|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
224324648|NCT05946213|RADIATION|External Beam Radiation Therapy|Undergo EBRT
224324649|NCT05946213|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223682179|NCT06994247|BEHAVIORAL|Motivational Telephone Call|This intervention consists of a single, personalized motivational telephone call delivered by a medical doctor, one month after initiation of CPAP treatment, uniquely timed to address early barriers and enhance self-efficacy. Unlike standard care or automated follow-ups, it offers tailored support based on patient experience, making it a low-cost yet targeted behavioral strategy to improve adherence. Content of the telephone call includes inquiry about patient's experience with CPAP therapy, identification of barriers to regular use, education on the health benefits of consistent CPAP usage, and personalized motivational messages aimed at increasing compliance.
223682180|NCT06995365|OTHER|Risk Prediction Model|This study analyzes retrospective electronic health record (EHR) data from older adults to refine and validate a predictive model for other conditions in future studies.
223682181|NCT06994429|DIAGNOSTIC_TEST|MRI Techniques for Graft Function Assessment|"\### Intervention Description~The intervention in this study is the use of advanced MRI techniques for assessing liver transplant graft function. It includes:~* \*\*Diffusion Weighted Imaging (DWI):\*\* To evaluate tissue integrity and detect early graft dysfunction.~* \*\*Dynamic Contrast-Enhanced MRI (DCE-MRI):\*\* To assess vascular complications and blood flow in the graft.~* \*\*Blood Oxygenation Level-Dependent (BOLD) MRI:\*\* To monitor oxygenation levels, indicative of graft health.~These MRI methods provide a non-invasive, comprehensive assessment of liver graft function, distinguishing this intervention from traditional invasive methods like biopsy."
223682182|NCT06994546|DEVICE|ArtiBest ® Intra articular Injection|single intra articular injection of 3 ml (one syringe) per knee joint. Each syringe contains 20 mg/mL sodium hyaluronate.
223682183|NCT06993818|OTHER|Gingival Crevicular Fluid|Periodontal clinical parameters and examination of asprosin levels in gingival crevicular fluid and serum samples
223682184|NCT06993818|DIAGNOSTIC_TEST|Serum Asprosin|Periodontal clinical parameters and examination of asprosin levels in gingival crevicular fluid and serum samples
223682185|NCT06995417|OTHER|Smoking counseling|"The investigator, upon enrollment, will initiate a standardized strategy from clinical practice: the investigator will conduct brief counseling (minimal advice) using the administration of of a questionnaire that will include, in addition to questions about current and past, the administration of the Fagerstrom test to measure physical dependence on nicotine and questions to investigate intention to quit smoking (Mondor test)"
223682186|NCT06994741|OTHER|Quantitative movement analysis|During their reeducation, patient can go through an quantitative movement analysis. Inside a movement laboratory, we observe their gait with 5 passageways.
223682187|NCT06993961|DEVICE|Ultrasound|Ultrasound (US) measurement of optic nerve sheath diameter (ONSD) was performed.
223682188|NCT06994728|DEVICE|Left STN-DBS on, right STN-DBS off first|There will not be any change to baseline DBS stimulation settings, only each side will be sequentially turned off during cognitive and freezing of gait assessments.
223682189|NCT06994728|DEVICE|Right STN-DBS on, left STN-DBS off first|There will not be any change to baseline DBS stimulation settings, only each side will be sequentially turned off during cognitive and freezing of gait assessments.
223682190|NCT06995092|OTHER|Music therapy|Patient will receive a 15-minute RAS session immediately before patient standard physiotherapy session. The RAS session will consist of metronome beats matched to your walking cadence. After completing the RAS sessions, patient will continue with the standard rehabilitation program as usual.
223682191|NCT06995092|OTHER|Standard physiotherapy program|Patient will receive the standard physiotherapy program without the RAS pre-gait training. Therapy will include sessions aimed at improving balance and gait, conducted for 15 minutes during each session. Assessments will be conducted at baseline, after completing the therapy, and during two follow-up evaluations.
223682192|NCT06471140|OTHER|magnetic resonance imaging (MRI)|MRI performed three times during pregnancy and 6 months postpartum
224324650|NCT05946213|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
224324651|NCT05946213|OTHER|Quality-of-Life Assessment|Ancillary studies
224324652|NCT05946213|OTHER|Questionnaire Administration|Ancillary studies
224324653|NCT05946213|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
224324654|NCT06806852|DRUG|BI 770371|BI 770371
224324655|NCT06806852|DRUG|Pembrolizumab|Pembrolizumab
224324656|NCT06806852|DRUG|Cetuximab|Cetuximab
224324657|NCT06651281|DRUG|Tulisokibart|Humanized monoclonal antibody that binds human tumor necrosis factor-like cytokine 1A (TL1A), administered subcutaneously
224324658|NCT06651281|DRUG|Placebo to tulisokibart|Placebo matching SC tulisokibart
224324659|NCT06421636|DRUG|REGN7999|Administered subcutaneous (SC)
224324660|NCT06421636|DRUG|Placebo|Administered SC
224324661|NCT06976268|DRUG|BHV-8000|BHV-8000 10 mg. Participants will take blinded investigational product (IP) once daily
224324662|NCT06976268|DRUG|BHV-8000|BHV-8000 20 mg. Participants will take blinded investigational product (IP) once daily
224324663|NCT06976268|DRUG|Placebo|Matching placebo taken once daily
224324664|NCT03580499|DIETARY_SUPPLEMENT|Vitamin B6|Given PO
224324665|NCT03580499|OTHER|Questionnaire Administration|Ancillary studies
224324666|NCT05172726|DRUG|tapinarof cream, 1%|applied topically once daily
224324667|NCT06521463|DEVICE|WATCHMAN FLX Pro LAAC Device|WATCHMAN FLX Pro LAAC Device Implantation
224324668|NCT05988931|BEHAVIORAL|Web Program + App|Youth receive a brief interactive web program made available online to prevent alcohol misuse. The parent/caregiver app addresses monitoring and skill building for parents to communicate with the child about preventing underage drinking and drug use.
224324669|NCT05988931|BEHAVIORAL|Web Program + App + Text Messages|Youth receive a brief interactive web program made available online to prevent alcohol misuse. This is followed by 8 weeks of supportive text messages. The parent/caregiver app addresses monitoring and skill building for parents to communicate with the child about preventing underage drinking and drug use.
224324670|NCT06038929|DEVICE|Vagal nerve stimulant|Vagus nerve stimulation involves using a device to stimulate the vagus nerve with electrical impulses. The implanted electrodes transmit electrical impulses travel to areas of the brain to treat conditions (intractable epilepsy, depression) and also send electrical impulses to the stomach.
224324671|NCT04839497|COMBINATION_PRODUCT|Autologous Volar Fibroblast Injection into the Terminal Limb of Amputees|Autologous Volar Fibroblasts Treatment- harvested from patient's biopsied volar skin. Intradermal injection of Volar fibroblasts in the residual limb of transtibial amputees.
224324672|NCT06293469|PROCEDURE|Accelerated Flap Coverage Surgery|Timing of the flap surgery is with a goal of 72 hours from injury
224324673|NCT06293469|PROCEDURE|Standard of Care Flap Timing|Timing of the flap surgery is the standard of care flap timing for the participating institution.
224324674|NCT06609148|DIETARY_SUPPLEMENT|De Simone formulation probiotic|Subjects will be given De Simone formulation probiotic 900 billion CFU, 3 times per day for 21-24 days
224324675|NCT06609148|DIETARY_SUPPLEMENT|Placebo|Subjects will be given a placebo for 21-24 days
224324676|NCT06934369|OTHER|Strategies to improve HIV care engagement|Based on the barriers to HIV care experienced by the pre-intervention cohort, we will design a system intervention to be implemented at the Radiotherapy Centre at Parirenyatwa Hospital. This intervention will include 2-3 components, each intended to improve engagement in HIV care or address specific barriers to HIV care. It may include strategies like improving documentation of HIV-related information in oncology patient records, improving processes for referrals and access to HIV-related prescriptions, and supporting better communication between oncology and HIV clinical care teams.
224324677|NCT06551181|BIOLOGICAL|RSVPreF3 OA investigational vaccine|One dose of the RSVPreF3 OA investigational vaccine is administered intramuscularly at Day 1.
224324678|NCT06551181|DRUG|Placebo|One dose of placebo is administered intramuscularly at Day 1.
224324679|NCT05412069|DEVICE|Fecobionics|Fecobionics is a novel device to be inserted through the anal canal into rectum for studying defecation. Anorectal manometry, balloon expulsion test, and anal ultrasonography will be used as reference.
224324680|NCT05755620|BIOLOGICAL|Influenza Virus Quadrivalent Inactivated Vaccine|A seasonal quadrivalent inactivated influenza vaccine (IIV4), prepared from influenza viruses propagated in embryonated chicken eggs, protecting against 2 influenza A subtypes and 2 influenza B subtypes.
224324681|NCT05755620|OTHER|Sodium Chloride, 0.9%|0.9% Sodium Chloride Injection
224324682|NCT05755620|BIOLOGICAL|VRC-FLUNPF099-00-VP (H1ssF_3928)|The vaccine consists of modified nucleoside messenger RNA (mRNA) encapsulated in lipid nanoparticles (LNP), comprised of four lipid components: (ALC-307 (ionizable lipid), DSPC, cholesterol, and ALC-0159 \[PEG lipid\]).
224324683|NCT05972694|DIETARY_SUPPLEMENT|Freeze dried grape powder|46g/d freeze-dried grape powder
223682193|NCT06994221|DIAGNOSTIC_TEST|18F FAPI-42 PET/CT scan|During the hospital stay, participants will receive an 18F FAPI-42 PET/CT scan. 18F FAPI-42 is a new fibroblast activation protein (FAP)-specific tracer used for fibrosis imaging. PET/CT will be performed using the ultra-high-resolution digital PET/CT uEXPLORER (United Imaging, Shanghai, China)
223682194|NCT06994650|DRUG|HRS9531|HRS9531 will be administered by Subcutaneous injection
223682195|NCT06994650|DRUG|Placebo|Matching Placebo will be administered by Subcutaneous injection
223682196|NCT06518512|DEVICE|Automated Vision Assessment and Impairment Detection through Gaze Analysis (AVIGA) system|"AVIGA is an automated method and system for vision assessment of a subject. The method includes the following: determining a set of test patterns for the subject based on a preliminary assessment of an eye of the subject; displaying the set of test patterns sequentially to the subject; collecting data on the subject's gaze in response to each test pattern displayed; and correlating central vision function of the subjects to the collected gaze data.~Subjects perform the AVIGA test monocularly and pursue a pre-determined target moving in a customized waveform across the computer screen. The trail of the gaze points generated by the subject following the target is simultaneously recorded and stored.~1. Static Fixation Evaluation (SFE)~2. Static Perimetry Assessment (SPA)~3. Static Perimetry Sensitivity Assessment (SPSA)~4. Pursuit"
223682197|NCT06995274|BIOLOGICAL|Umbilical Cord Blood Infusion (Autologous and Allogeneic)|"The intervention consists of three intravenous infusions of umbilical cord blood (UCB) in a pediatric patient diagnosed with both eosinophilic duodenitis (ED) and autism spectrum disorder (ASD). The first infusion uses autologous UCB stored at a certified cord blood bank. The second and third infusions use allogeneic UCB units selected from a hospital-based donor cord blood bank. Donor units are matched at a minimum of 3 out of 6 HLA loci (HLA-A, B, DRB1) and contain ≥ 3×10⁷ total nucleated cells per kilogram of body weight.~Each infusion is administered intravenously via peripheral vein at the Cell Therapy Center of CHA Bundang Medical Center. Prior to each infusion, the participant receives premedication with intravenous chlorpheniramine maleate (0.6 mL/10 kg) to reduce the risk of allergic reactions. For allogeneic infusions, oral cyclosporine (0.07 mL/kg twice daily) is administered for 7 days (3 days before, day of, and 3 days after infusion) to minimize immune-mediated reactions"
223682198|NCT06688331|BIOLOGICAL|ex vivo expanded CD4+CD25+CD127- regulatory T cells (Tregs)|regulatory T cells with the phenotype CD3(+)CD4(+)CD25(high)CD127(-)doublet(-)lin(-)
223682199|NCT06688331|BIOLOGICAL|Anti-CD20 (rituximab)|rituximab
223682200|NCT06688331|OTHER|Placebo|intrevenous 0,9% NaCl
223682201|NCT06688331|OTHER|Treg sham|intrevenous 0,9% NaCl
223682202|NCT06689696|DEVICE|miLens system|The miLens system consists of the miLens contact lens made of soft, biocompatible materials, the miLens imaging system, and miLens analysis software.
223682203|NCT06508476|BIOLOGICAL|Amnion Chorion membrane|it is a placental allograft.
223682204|NCT06508476|PROCEDURE|connective tissue graft|it is an autograft
223682205|NCT02586883|OTHER|bronchial ddp test|bronchial ddp test during endoscopy, nasal smear, bronchial smear
223682206|NCT06629558|DRUG|Silver Nitrate|bronchoscopic lung volume reduction in management of localized emphysema
223682207|NCT06629558|DRUG|Nano-silver nitrate|bronchoscopic lung volume reduction in management of localized emphysema
223682208|NCT06629558|DEVICE|Bronchoscopic lung volume reduction|bronchoscopic lung volume reduction in management of localized emphysema
223682209|NCT06049355|OTHER|Exercise Intervention|Undergo Exercise Together exercise program, a supervised group exercise program delivered online, using a live remote format
223682210|NCT06049355|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
223774459|NCT07002567|OTHER|Implicit motor imagery|Implicit motor imagery is the ability to engage with the projection and manipulation of the body schema from a first-person perspective. Implicit motor imagery skills were evaluated Recognize App Recognize Hand Hand Laterality Task with, developed by NOI group. (http://www.noigroup.com/ Recognise).
223682211|NCT06049355|OTHER|Educational Intervention|Receive educational materials
223682212|NCT06878235|OTHER|Assessment of the functional status|assessment of their functional status using the French version of the PLSFRS scale during a routine multidisciplinary assessment every 3-6 months for all patients with motor neurone disease, as recommended by the FILSLAN network
223682213|NCT06876506|DIAGNOSTIC_TEST|Venepuncture|Whole blood flow cytometry analysis of T-/B-lymphocyte subsets, regulatory B cells and regulatory T cells. Serological detection (immunoassay) of allergen-specific IgE and IgG4
223682214|NCT06876506|DRUG|Allergen Specific Immunotherapy|Test group receiving venom allergen immunotherapy as part of standard and routine care pathway (treatment commencement NOT for study purposes, cohort selected of those who are routinely commencing treatment).
223682215|NCT06876506|DRUG|Allergen Specific Immunotherapy|Test group receiving pollen allergen immunotherapy as part of standard and routine care pathway (treatment commencement NOT for study purposes, cohort selected of those who are routinely commencing treatment).
223682216|NCT01406405|PROCEDURE|Posterior/Transforaminal Lumbar Interbody Fusion (P/TLIF), Anterior Cervical Discectomy and Fusion (ACDF)|Lumbar or cervical fusion
223682217|NCT06710717|BIOLOGICAL|CD19 CAR-T cells|Study participant will be given single infusion of autologous CD19 CAR-T cells following lymphodepletion chemotherapy
223682218|NCT06709716|DRUG|Quadratus Lumborum Block (QLB)|Pre-operative quadratus lumborum block with liposomal bupivacaine
223682219|NCT06709716|DRUG|Quadratus lumborum block|Pre-operative quadratus lumborum block with saline
223682220|NCT06709716|DRUG|Local Anesthetic Solution|Intraoperative injection of 0.25% bupivacaine at each incision site
223682221|NCT06709716|DRUG|Local Anesthetic Solution|Intraoperative injection of saline at each incision site.
223682222|NCT04932798|DIAGNOSTIC_TEST|Resting ECG (if first visit is done on site only)|"The standard 12-lead electrocardiogram is a representation of the heart's electrical activity recorded from electrodes on the body surface.~This test requires around 15 minutes of the participant's time."
223682223|NCT04932798|DIAGNOSTIC_TEST|24-hour ambulatory electrocardiographic monitoring (Holter) (if first visit done on site only)|The Holter monitor is a type of portable electrocardiogram (ECG) worn continuously for 24 hours.
223682224|NCT04932798|DIAGNOSTIC_TEST|3-month AF detection monitoring using the Apple Watch|Patients with irregular heart rates will be notified by the Apple Watch and instructed to confirm the rhythm by using the integrated ECG recording system. This simply requires touching the watch with a finger from the opposite hand and provides a 30 seconds one-lead ECG recording of diagnostic quality. These tracing will be transferred to the study team for analysis using a dedicated email.
223774460|NCT07002567|OTHER|Explicit motor imagery|In explicit motor imagery, the person simulates a specific motor movement, that is, the individual is aware that she is imagining the movement.Explicit motor imagery skills were evaluated with Movement Imagery Questionnaire for Children (MIQ-C), mental chronometry and box block test.
223774461|NCT00535886|DIETARY_SUPPLEMENT|Man-made Trans FA|EA as 6% of total energy
223774462|NCT00535886|DIETARY_SUPPLEMENT|Natural Trans FA|VA as 6% of total energy
223774463|NCT00535886|DIETARY_SUPPLEMENT|Oleic Acid|OA as 6% of total energy
224324684|NCT04997109|OTHER|APPLES-tele|The APPLES-tele intervention is 5 weekly telehealth sessions of therapist-demonstrated tasks, delivered over a 6 week period. Infant participants wear a soft-constraint harness (C-Mitt) on their less affected arm for 6 hours per day, while their parent encourages them to use their more affected arm to complete play-based activities as instructed by the study therapist. As the infant experiences success, heavier objects are provided. During times when the C-Mitt is not worn, parents engage therapist-demonstrated bimanual play of increasing difficulty.
224324685|NCT04997109|BEHAVIORAL|Parent-centered Approach (PCA) Support Intervention|The PCA support intervention is 5 weekly telehealth sessions delivered over a 6 week period. The PCA curriculum includes 5 basic principles of positive parenting from Triple P: ensuring a safe engaging environment, creating a positive learning environment, using assertive discipline, having reasonable expectations, and looking after yourself as a parent. All of these elements, when taught to parents in an individualized manner, can help promote responsivity, structure and expectations that are tailored to their child's condition and developmental stage. In addition, a curriculum of CP-specific knowledge will address the challenges unique to parents of children with CP, such as understanding principles of infant learning of new movements, challenges and solutions for self-directed activity in infants with CP.
224324686|NCT04997109|BEHAVIORAL|Standard of Care|Participants will receive the usual care from being followed in high-risk infant follow-up (HRIF) programs in the Early Detection and Intervention (EDI) Network.
224324687|NCT05643482|DEVICE|Hyperbaric Oxygen Treatment|Pressurization at 2.0 ATA with 100% oxygen
224324688|NCT05643482|OTHER|Placebo gas|Pressurization at 2.0 ATA with 10.5% oxygen to mimic normal air
224324689|NCT04341064|BEHAVIORAL|SHINE Intervention|\[see arm/group descriptions\]
224324690|NCT05053750|DRUG|Paclitaxel/Bev (control)|Given by PO
224324691|NCT05053750|DRUG|Paclitaxel/Bev + ZA (experimental)|Given by PO
224324692|NCT05424406|BEHAVIORAL|Active phototherapy|Timed bright light exposure delivered in a controlled laboratory setting (10,000 photopic lux) designed to delay the DLMO to 4 am or later.
224324693|NCT05424406|BEHAVIORAL|Control phototherapy|Timed less intense light exposure delivered in a controlled laboratory setting (100 photopic lux) that still has a perceptible alerting effect but is not designed to shift circadian phase.
224324694|NCT05424406|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|Cognitive strategies will identify stressors (e.g., dysfunctional beliefs about sleep) and intervene on worry and rumination with cognitive reappraisal and active coping. Sessions will be conducted by a trained behavioral sleep medicine provider via telemedicine to increase accessibility.
224324695|NCT05424406|BEHAVIORAL|Sleep education control|Sleep duration recommendations will be equivalent to the CBT group (8 hours of sleep opportunity) to ensure that outcomes are not confounded by time in bed. Materials in the sleep education control condition will be separated into weekly electronic materials monitored for engagement and completion.
223774464|NCT03967418|BEHAVIORAL|Cognitive and clinical assessment|The content of the assessment will be the same for all subjects and will consist of a cognitive assessment (neurocognition, social cognition, metacognition, emotional reactivity) and a clinical assessment (impulsivity, personality, psychiatric and addictive comorbidities)
224324696|NCT04447768|DRUG|Obinutuzumab|"Cycle 1, Day 1- 100 mg~Cycle 1, Day 2 - 900 mg~Cycle 1, Day 8 - 1000 mg~Cycle 1, Day 15 -1000 mg~Cycle 2, Day 1 to Cycle 6, Day 1- 1000 mg"
224324697|NCT04447768|DRUG|Venetoclax|"Cycle 1, Day 22 to 28 -20 mg daily~Cycle 2, Day 1 to Day 7 -50 mg daily~Cycle 2, Day 8 to Day 14- 100 mg daily~Cycle 2, Day 15 to Day 21- 200 mg daily~Cycle 2, Day 22 to Day 28 - 400 mg daily~Cycle 3, Day 1 to end of Cycle 12-24 - 400 mg daily"
224324698|NCT04290663|DRUG|Systematic RAI-treatment|Administration of 3.7 GBq (100 mCi) or 1,1 GBq (30 mCi) of I131 at the choice of the investigator after rhTSH-stimulation
224324699|NCT04290663|OTHER|Decision of RAI-treatment guided by a post-operative assessment|"The decision-making for the administration of an adapted RAI-treatment will be taken according to the following criteria:~* No RAI treatment if Tg/LT4 ≤1 ng/mL and rhTSH-sTg ≤10 ng/mL and normal diagnostic RAI-scintigraphy~* 1.1 GBq after rhTSH if Tg/LT4\>1 ng/mL or rhTSH-sTg\>10 ng/mL and normal diagnostic RAI-scintigraphy.~* 3.7 GBq after rhTSH if metastatic lymph-node(s) detected on diagnostic RAI-scintigraphy without distant metastasis~* 3.7 GBq after hormone withdrawal if distant metastasis detected on diagnostic RAI-scintigraphy or on the hybrid CT scan of the SPECT-CT acquisition"
224324700|NCT02367040|DRUG|Copanlisib (Aliqopa, BAY80-6946)|Copanlisib is supplied as lyophilized preparation in a 6 mL injection vial. The total amount of copanlisib per vial is 60 mg. The solution for IV infusions is obtained after reconstitution with normal saline solution. Dosing will be administered on Days 1, 8 and 15 of each 28-day cycle. Copanlisib will be administered before rituximab.
224324701|NCT02367040|DRUG|Placebo|Placebo is supplied as lyophilized preparation in a 6 mL injection vial. The developed placebo lyophilisate is equivalent to the 60 mg copanlisib formulation, with regard to the composition of excipients and the instructions for reconstitution and dose preparation. Placebo dosing will be administered on Days 1, 8 and 15 of each 28-day cycle. Placebo will be administered before rituximab.
224324702|NCT02367040|DRUG|Rituximab|Rituximab dose 375 mg/m2 body surface weekly during Cycle 1 on Days 1, 8, 15 and 22, and then on Day 1 of Cycles 3, 5, 7 and 9.The solution for IV infusions is obtained after reconstitution of a calculated concentration of 1 to 4 mg/ml rituximab into an infusion bag containing sterile, pyrogen-free sodium chloride 9 mg/ml (0.9%) solution for injection or 5% D-Glucose in water.
224324703|NCT06332014|DRUG|Prolia|Partcipants will receive subcutaneous (SC) injections of Prolia Q6M.
224324704|NCT03069937|DRUG|Docetaxel|The docetaxel dose is a 75mg/m2 intravenous (given through the vein) injection.
224324705|NCT03069937|DRUG|Degarelix|Degarelix will be given as a subcutaneous (given under the skin) injection in the abdomen. The first dose will be a 240mg dose; all other doses will be 80 mg.
224324706|NCT05454488|OTHER|Focal Cryoablation|Participants will have the Focal cryoablation placed by the needles in such a way that the area of affected tissue is much smaller and focus just on the tumor tissue and surrounding area
224324707|NCT05454488|OTHER|Standard of Care|Participants will receive a prostate biopsy.
223682225|NCT06715280|DRUG|Riociguat (Adempas)|Oral riociguat administered according to established dose-adjustment scheme. Riociguat will be administered starting at at 1mg three times per day. If patient systolic blood pressure maintains at 95mmHg or higher, the dose will be increased 0.5mg every 2 weeks up to a maximum dose 2.5mg three times per day over 8-week period
223682226|NCT02104739|DRUG|Exenatide|Single subcutaneous injection (10 mcg)
223682227|NCT02104739|DRUG|Saxagliptin|Single dose orally (5 mg)
223774465|NCT05247190|BEHAVIORAL|Treating self-criticism|A psychological treatment given i a group format targeting self-criticism. The treatment is based on treatment principles from Cognitive behavior therapy, Self-compassion, Acceptance and Commitment Therapy and also contains psychoeducation. The group treatment consists of 8 sessions delivered once a week for 2 hrs during 8 weeks in a child- and adolescent psychiatric outpatient setting.
223774466|NCT07012213|DRUG|Patients in group A received .5 g/kg/h dexmedetomidine infusion after general anesthesia, in group B received 1 ml (100 mic) dexmedetomidine intranasal spray before induction.|Patients in group A received .5 g/kg/h dexmedetomidine infusion after general anesthesia, in group B received 1 ml (100 mic) dexmedetomidine intranasal spray before induction.
223774467|NCT06271772|DRUG|Difluprednate Ophthalmic|Difluprednate 0.05% is a corticosteroid used to reduce inflammation in the eye. Participants will receive one drop of 0.05% difluprednate four times daily beginning 24 hours after the initiation of antibiotics for 1 week, decreased by 1 drop weekly for a total of 4 weeks of steroid therapy.
224324708|NCT05454488|OTHER|Quality-of-life Questionnaires|Participants will fill out questionnaires.
224324709|NCT04581512|DRUG|EP0042|EP0042 Oral 20 mg 50 mg capsules
224324710|NCT04581512|DRUG|Venetoclax|Venetoclax
224324711|NCT04581512|DRUG|Azacitidine (AZA)|Azacitidine
224324712|NCT06385080|BIOLOGICAL|Amivantamab|Amivantamab will be administered subcutaneously.
224324713|NCT06385080|BIOLOGICAL|Pembrolizumab|Pembrolizumab will be administered intravenously.
224324714|NCT06385080|DRUG|Paclitaxel|Paclitaxel will be administered intravenously.
224324715|NCT06385080|DRUG|Carboplatin|Carboplatin will be administered intravenously.
224324716|NCT06294834|OTHER|Part 1 of intervention A - Wheelchair skills training modules|"Clinicians will review a suite of training videos in a prescribed order that discuss motor learning principles, safe spotting, and how to complete 15 intermediate and advanced skills:~1. Opening/closing doors~2. getting over a gap~3. getting over a threshold~4. ascending a low curb~5. descending a low curb~6. ascending a high curb~7. descending a high curb~8. performing a stationary wheelie~9. descending a high curb in a wheelie position~10. descending a steep incline in a wheelie position and stopping~11. ascending stairs~12. descending stairs~13. completing a floor-to-chair transfer~14. car transfers~15. folding and unfolding wheelchair"
223682228|NCT02104739|DRUG|Exenatide extended-release (ER)|Subcutaneous injection (2mg) weekly for 6 weeks
223682229|NCT02104739|OTHER|Placebo|Placebo tablets and Placebo (normal saline) injections
223682230|NCT05218954|DIAGNOSTIC_TEST|Biomechanical analysis of risk fall|Biomechanical analysis of risk fall in terms of balance
224324717|NCT06294834|OTHER|Part 2 of intervention A - Asynchronous feedback from a remote trainer|Participants will practice of wheelchair skills paired with remote feedback. Participants will be reminded to practice once per week. The participant will practice any number of the 15 skills for a self-selected duration. Following each practice session, the participant will upload video(s) of the skills practiced and a session log, indicating any difficulties they encountered. The remote trainer will then review the video-recordings and reply to the participant with feedback.
224324718|NCT06294834|OTHER|Intervention B: Education on wheelchair provision|Participants will be provided with access to web-based wheelchair provision education modules. When the content is viewed will be self-selected by participants. Participants will be asked to complete a feedback survey at the end of the modules. Participants will receive weekly reminders to complete the intervention until a feedback survey completed.
224324719|NCT06616649|DEVICE|Spinal cord stimulator implant|Participants will receive intervention in the operating room setting
224324720|NCT05560451|BEHAVIORAL|Peer health coach intervention|Eligible participants will be randomly assigned to receive a telehealth delivered peer health coach intervention to promote health outcomes and behavior change among Veterans with multimorbidty.
224324721|NCT06312176|DRUG|Sacituzumab tirumotecan|IV infusion
224324722|NCT06312176|BIOLOGICAL|Pembrolizumab|IV infusion
224324723|NCT06312176|DRUG|Paclitaxel|IV infusion
224324724|NCT06312176|DRUG|Nab-paclitaxel|IV infusion
223682231|NCT06747130|DRUG|Montelukast|A 10-mg tablet will be given orally immediately and every day thereafter for 10 days or until recovery, defined as the discontinuation of the follow up appointment by the attending physicians, whichever is shorter
223774468|NCT06271772|DRUG|Rose Bengal|Study participants receive RB-PDT within 48 hours of randomization. All participants will receive a 30-minute loading dose of topical Rose Bengal (0.1% RB in 0.9% sodium chloride) which will be applied in 3-minute intervals to the de-epithelialized cornea. This will be followed by irradiation with a 6mW/cm2 custom-made green LED source for 15 minutes (5.4J/cm2). Repeat cornea culture will be collected within 24 hours after the procedure.
223774469|NCT06271772|DRUG|Moxifloxacin Ophthalmic|Topical moxifloxacin 0.5% is a fluoroquinolone antibiotic that is used to treat bacterial infections. This is a standard therapy for bacterial keratitis.
223774470|NCT07022756|BEHAVIORAL|Honoraria|A $20 honorarium for each appointment attended with completed bloodwork if requested.
223774471|NCT07022756|BEHAVIORAL|Outreach|A personalized outreach service specific for rheumatic disease.
223774472|NCT06694701|DRUG|Emapalumab-Izsg|The drug is administered at a dose of 6mg/kg of body weight on day 0 and repeated dosing of 3mg/kg of body weight is provisioned for days 3, 6, 9, 12, 15, 19, 23 and 27 provided that the stopping rule does not apply.
223774473|NCT06694701|DRUG|Emapalumab-Izsg|The drug is administered at a dose of 6mg/kg of body weight on day 0, 6mg/kg of body weight on day 3, 6mg/kg of body weight on day 6 and repeated dosing of 3mg/kg of body weight is provisioned for days 9, 12, 15, 19, 23 and 27 provided that the stopping rule does not apply.
224324725|NCT06312176|DRUG|Capecitabine|oral tablet
224324726|NCT06312176|DRUG|Liposomal doxorubicin|IV infusion
223682232|NCT06747130|DRUG|Montelukast Placebo|A 10-mg tablet will be given orally immediately and every day thereafter for 10 days or until recovery, defined as the discontinuation of the follow up appointment by the attending physicians, whichever is shorter
224324727|NCT06017609|DRUG|JTT-861 Capsules|Active drug capsules containing JTT-861
223682233|NCT04211233|DEVICE|invasive subdural grid electrode|A subdural EEG-electrode (PLATIN 1x4 or 1x6; Ad-Tech Medical Instrument Corporation, Oak Creek, WI, USA, Figure 1) will be implanted in the subdural space frontotemporal intraoperatively and diverted separately from the wound area. Afterwards, invasive Monitoring will be performed for 7 days and the grid will be removed simply by pulling out.
223682234|NCT04211233|OTHER|Control arm|Standard Treatment based on Brain Trauma Foundation
224324728|NCT06017609|DRUG|Placebo Capsules|Placebo capsules matching in appearance to the active drug capsules
224324729|NCT05047913|DRUG|18F-FTX|Given By IV
224324730|NCT06533059|DRUG|ALTA2618|Oral ALTA2618 tablets will be administered at protocol-defined dose
224324731|NCT04429087|DRUG|BI 764532 - parenteral 1|BI 764532 - parenteral 1
224324732|NCT04429087|DRUG|BI 764532 - parenteral 2|BI 764532 - parenteral 2
224324733|NCT05899673|DRUG|Fazirsiran Injection|Fazirsiran will be injected subcutaneously.
224324734|NCT04624659|DRUG|Etavopivat Tablets Low dose|200 mg once daily
223682235|NCT06880367|BEHAVIORAL|The intervention is an audio-proprio-phonatory training|The audio-proprio-phonatory training involves engaging in group workshops and performing exercise sessions independently, following the guidance provided by the specialist, over a duration of five weeks
223774474|NCT06694701|DRUG|Placebo|250ml of 0.9% sodium chloride. The drug is administered on day 0 and repeated dosing is provisioned for days 3, 6, 9, 12, 15, 19, 23 and 27 provided that the stopping rule does not apply
223774475|NCT06690398|DRUG|Lumateperone high dose|Lumateperone administered orally once daily
223774476|NCT06690398|DRUG|Lumateperone low dose|Lumateperone administered orally once daily
224324735|NCT04624659|DRUG|Etavopivat Tablets High dose|400 mg once daily
224324736|NCT04624659|DRUG|Placebo Tablets|Placebo once daily
224324737|NCT04624659|DRUG|Etavopivat Tablets|Selected dose once daily
224324738|NCT03696043|OTHER|Axium Steatlh Image Guidance|The Axiem Stealth imaging guidance system uses a probe (AxiEM Registration Probe) and a side mount emitter (AxiEM Side Mount Emitter) to register the patient's head in relation to the probe. A trajectory (entry point and target) is then planned. This registration process takes an estimated 5-15 minutes to perform. A separate stylet (StealthStation EM Stylet) is designed specifically for the catheter and slides down the center of the catheter. A burr-hole is created at the predefined precise location and the catheter is passed to the target under electromagnetic guidance.
224324739|NCT03696043|OTHER|EVD placement|A sterile field is prepared about 10-12 centimeters posterior to the eye and about 2-3 cm lateral to the midline of the skull. An incision is made at this point and a burr hole is created using a hand drill. The catheter is advanced in a trajectory perpendicular to the skull, which results in a direction that is towards the ipsilateral medial canthus and ipsilateral tragus which are other landmarks that can be used.
224324740|NCT05494697|DRUG|Rintatolimod|Rintatolimod (poly I : poly C12U)
224324741|NCT05304416|DIAGNOSTIC_TEST|Fiberoptic Endoscopic Evaluation of Swallowing|This procedure involves inserting a flexible laryngoscope that contains a light source and video camera on the end through the open passage of the nose towards the back of the throat in order to visualize the swallowing mechanism.
223774477|NCT06690398|DRUG|Placebo|Matching Placebo administered orally once daily
223774478|NCT06086535|PROCEDURE|Intercostal nerve cryoanalgesia vs BRILMA blockade|For BRILMA block, 0.4 ml/kg of 0.3% ropivacaine will be injected and a catheter will be placed on the 4th intercostal space after surgery. For intercostal nerve cryoanalgesia an external cryogenizer system will be used during surgery
224324742|NCT05304416|DIAGNOSTIC_TEST|Simultaneous FEES and Videofluoroscopy instrumental swallowing exam|This procedure involves inserting a flexible laryngoscope that contains a light source and video camera on the end through the open passage of the nose towards the back of the throat in order to visualize the swallowing mechanism. The participant will be asked to perform some voicing tasks, once completed, a videofluoroscopic swallowing exam will occur at the same time. This is like a moving x-ray of the participant swallowing foods and liquids (barium).
224324743|NCT05304416|DIAGNOSTIC_TEST|Videofluoroscopy instrumental swallowing exam (VFSS)|This is like a moving x-ray of the participant swallowing foods and liquids (barium).
224324744|NCT05304416|OTHER|Voluntary Cough Peak Expiratory Flow (PEF) Testing|Cough PEF will be performed to index a participant's physiologic airway defense capacity and strength. Testing will occur with the participant seated upright at 90 degrees using an analog peak flow meter with a one-way expiratory valve that prevents a participant from breathing air in from the device to reduce contamination.
224324745|NCT05304416|OTHER|Reflex Cough Screen|Participants will be seated upright and administered reflex cough testing via a disposable adult aerosol mask with an attached nebulizer that contains a solution to elicit a cough response.
224324746|NCT05304416|OTHER|Lingual Pressure Testing|Lingual strength will be evaluated using the Iowa Oral Pressure Instrument (IOPI). Participants will be seated upright, and the SLP will place the IOPI air-filled sensing bulb in the midline anterior position on the participant's tongue, posterior to the alveolar ridge.
224324747|NCT05304416|DIAGNOSTIC_TEST|Speech Testing|"Speech assessment will occur with the participant comfortably seated headset microphone with a lapel windscreen connected to a TASCAM DR40 to allow for high-quality audio recordings. Individuals will be asked to perform two maximal performance speech tasks that include vowel prolongation of /a/, and a Diadochokinetic (DDK) rate task to examine SMR for production of the word buttercup."
224324748|NCT05845021|COMBINATION_PRODUCT|Surgeon-Initiated Bone Health Referral Pathway|Described in arm description
224324749|NCT04939597|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
224324750|NCT04939597|PROCEDURE|Cognitive Assessment|Complete cognitive testing
224324751|NCT04939597|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
224324752|NCT04939597|DRUG|Memantine Hydrochloride|Given PO
224324753|NCT04939597|DRUG|Placebo Administration|Given PO
224324754|NCT04939597|OTHER|Questionnaire Administration|Ancillary studies
224324755|NCT04564339|DRUG|Ravulizumab|Dosages (loading and maintenance) will be based on the participant's body weight.
224324756|NCT04564339|DRUG|Placebo|Dosages (loading and maintenance) will be based on the participant's body weight.
224324757|NCT04564339|OTHER|Background Therapy|Participants will receive background therapy consistent with the standard of care.
224324758|NCT02964078|DRUG|Pembrolizumab|Pembrolizumab: 200 mg every 3 weeks, 12 doses planned. This is considered the investigational part of the combination. The infusion time is 1 hour.
224324759|NCT02964078|DRUG|Interleukin-2|Interleukin-2: 8 admissions to hospital, each with 5 doses planned. This is considered the standard part of the combination. The standard interleukin-2 dose is 600,000 international units per kilogram per dose, with a maximum of 66,000,000 (for patients over 110 kg, which is 242 pounds). The dose is usually set at the start of the treatment and not adjusted. The infusion time is 15 minutes.
224324760|NCT03589326|DRUG|Ponatinib|Ponatinib Tablets.
224324761|NCT03589326|DRUG|Imatinib|Imatinib Tablets.
224324762|NCT03589326|DRUG|Vincristine|Vincristine IV injection.
224324763|NCT03589326|DRUG|Dexamethasone|Dexamethasone Tablets.
224324764|NCT03589326|DRUG|Cytarabine|Cytarabine IV infusion.
224324765|NCT03589326|DRUG|Methotrexate|Methotrexate IV infusion.
224324766|NCT03589326|DRUG|Prednisone|Prednisone Tablets.
223774479|NCT07023432|DRUG|Belzutifan|Given by PO
223774480|NCT07023432|OTHER|Active Surveillance|Given by Observation
223774481|NCT07025616|BEHAVIORAL|Buteyko|The Buteyko breathing exercise is a method that encourages nasal breathing, reducing breathing volume, and using breath-holding exercises to normalize breathing pattern
223774482|NCT07025616|DRUG|Asthma reliever and controller|Asthma reliever and controller according to GINA (Global Initiative for Asthma) guideline
224324767|NCT05993546|DEVICE|vacuum assisted sheath|allows for simultaneous suction with continuous irrigation throughout the case to enhance visibility and facilitate stone retrieval
224324768|NCT05993546|DEVICE|passive suction via conventional sheath|conventional access sheath for stone retrieval using current technique via passive suction
224324769|NCT04484142|DRUG|DS-1062a|DS-1062a will be administered as an intravenous (IV) infusion once every 3 weeks
224324770|NCT02477618|DRUG|SAGE-547|
224324771|NCT02477618|DRUG|Placebo|Placebo
224324772|NCT05184569|DRUG|Verdiperstat|Oral, extended release (ER) tablet
224324773|NCT01892722|DRUG|Interferon beta-1a|Administration once weekly via i.m. injections.
224324774|NCT01892722|DRUG|Fingolimod|"Administrated orally once daily:~0.5 mg capsule for patients over 40 kg or 0.25 mg capsule for patients 40 kg or less."
224324775|NCT01892722|DRUG|Placebo capsule|Matching placebo capsule required for double-dummy masking to blind formulations.
224324776|NCT01892722|DRUG|Placebo i.m. injection|Matching placebo i.m. injection required for double-dummy masking to blind formulations.
224324777|NCT03435952|DRUG|Pembrolizumab|200 mg by intravenous infusion starting on Day 0, and continuing every 3 weeks for up to 12 months.
224324778|NCT03435952|BIOLOGICAL|Clostridium Novyi-NT|"Participants given a single dose of Clostridium Novyi-NT by intratumoral injection on Day 8.~Clostridium Novyi-NT administered starting with Cohort 1 at a dose of 3 x 10\^4 spores followed by dose escalation."
224324779|NCT03435952|DRUG|Doxycycline|Starting on Day 15, participant takes Doxycycline by mouth 2 times a day for the rest of participant's life to lower the risk of further growth of Clostridium novyi-NT
224324780|NCT06809595|OTHER|Placebo|A substance that is designed to have no therapeutic value
224324781|NCT06809595|DRUG|MM120 (LSD D-Tartrate)|A psychoactive substance that mediates effects mainly through an agonist activity in the serotonin 2A receptor (5-HT2A)
224324782|NCT04056247|OTHER|Plasma sample collection|Collect at least two plasma samples
223774483|NCT06511869|DRUG|AZD4205|AZD4205 capsules administered at 150 mg orally, once daily, in 28-day cycle.
223774484|NCT07025174|DRUG|PD-1/CTLA-4 Dual Functional Antibody|"PD-1/CTLA-4 Dual Functional Antibody (iparomlimab and tuvonralimab injection):~5 mg/kg intravenous infusion every 3 weeks (day 1 of each 21-day cycle) for up to 6 cycles, with potential for maintenance therapy continuation. Used in combination with GP regimen in experimental arm only. This is a novel dual-functional antibody targeting both PD-1 and CTLA-4 pathways simultaneously."
223774485|NCT07025174|DRUG|Gemcitabine, Cisplatin|Gemcitabine 1000 mg/m² d1,8+Cisplatin 25mg/m² d1,8
223774486|NCT07025174|DRUG|Anlotinib|10mg po d1-14 q3w
224324783|NCT07115043|DRUG|AZD6750|AZD6750- CD8 guided IL-2
224324784|NCT07115043|DRUG|rilvegostomig|Rilvegostomig- PD1-TIGIT bispecific antibody
224324785|NCT02087852|OTHER|salvia for germline DNA|
223774487|NCT07025174|DRUG|Oxaliplatin + 5-Fluorouracil/Leucovorin|XELOX (oxaliplatin 130mg/m² d1+capecitabine 1000mg/m² d1-14 q3w) or FOLFOX6 (Oxaliplatin 85 mg/m², leucovorin 400 mg/m², fluorouracil 400 mg/m² intravenous bolus followed by fluorouracil 2400 mg/m² 46 hours, q2w)
223774488|NCT07024914|DRUG|Oxygen|Oxygen supplementation via nasal cannula at a rate of 3 lit/min during 30sec Sit-To-Stand Test among COPD patients without resting hypoxemia
223774489|NCT07024914|DRUG|medical air|Medical Air supplementation via nasal cannula at a rate of 3 lit/min during 30sec Sit-To-Stand Test among COPD patients without resting hypoxemia
224324786|NCT02087852|BEHAVIORAL|the Kidney Cancer Questionnaire|Patients will complete the appropriate surveys on either paper or on the computer/iPad in the office using REDCap software. If patients are unable to complete their questionnaires at the time of their in-office visit, a link to the questionnaires in REDCap will be emailed to them. The survey data that is collected in REDCap will be stored in REDCap. Clinic staff may also call patients to remind patients to complete questionnaires.
224324787|NCT02087852|BEHAVIORAL|Family History Questionnaire (when applicable)|Patients will complete the appropriate surveys on either paper or on the computer/iPad in the office using REDCap software. If patients are unable to complete their questionnaires at the time of their in-office visit, a link to the questionnaires in REDCap will be emailed to them. The survey data that is collected in REDCap will be stored in REDCap. Clinic staff may also call patients to remind patients to complete questionnaires.
224324788|NCT02087852|OTHER|Blood draw|
224324789|NCT02087852|BEHAVIORAL|Epidemiologic Questionnaire|Patients will complete the appropriate surveys on either paper or on the computer/iPad in the office using REDCap software. If patients are unable to complete their questionnaires at the time of their in-office visit, a link to the questionnaires in REDCap will be emailed to them. The survey data that is collected in REDCap will be stored in REDCap. Clinic staff may also call patients to remind patients to complete questionnaires.
224324790|NCT05932654|DRUG|BSI-045B|Patients will be treated with BSI-045B.
224324791|NCT04725006|DEVICE|Spinal cord stimulation system|These systems are indicated as an aid in the management of chronic intractable pain of the trunk and/or limbs, including unilateral or bilateral pain associated with the following: failed back surgery syndrome, intractable low back pain and leg pain. Stimulation will be applied to the system using an external stimulator to see if sensations can be evoked in the participant's limb/foot.
224324792|NCT03007420|DRUG|Occipital Nerve Block (ONB) using lidocaine and dexamethosone|Patients enrolled in the study will be randomized to receive either an ONB or a CMBB. The assignment of the procedure will be randomized however neither the patients nor the investigator will be blinded to the procedure. Patients randomized to receive an ONB will receive the block with dexamethasone 2mg (steroid) each site with 3ml 1% lidocaine (local anesthetic), for a total of two sites.
224324793|NCT03007420|DRUG|Cervical Medial Branch Block (CMBB) using lidocaine and dexamethosone|Patients enrolled in the study will be randomized to receive either an ONB or a CMBB. The assignment of the procedure will be randomized however neither the patients nor the investigator will be blinded to the procedure. Patients randomized to receive CMBB will receive the block with dexamethasone 1.5mg (steroid) each site with 2 ml 1% lidocaine (local anesthetic), for a total of three sites on each side.
224324794|NCT06708949|DRUG|Drugs Nivolumab|Given by IV Infusion
223774490|NCT07024303|DRUG|Psychotropic medication (at discretion of psychiatrist)|The timing and dose of medication will be determined by the prescribing provider. Most medications are delivered daily and some medications may be delivered more than once per day. Providers are expected to adhere to professional guidelines for prescribing.
224324795|NCT06708949|DRUG|Ipilimumab|Given by IV Infusion
224324796|NCT06708949|DRUG|BMS-986213 (Relatlimab-Nivolumab FDC)|Given by IV Infusion
224324797|NCT06520098|DRUG|Venetoclax|VENCLEXTA is indicated for the treatment of patients with chronic lymphocytic leukemia (CLL) with 17p deletion, as detected by an FDA approved test, who have received at least one prior therapy.
224324798|NCT06520098|DRUG|Ibrutinib, Acalabrutinib, Zanubrutinib|IMBRUVICA is a kinase inhibitor Acalabrutinib is a selective, irreversible small molecule inhibitor of BTK. Zanubrutinib is BTK inhibitors
224324799|NCT04291859|DRUG|Lu AF28996|capsule, orally, doses and dose escalation scheme will be decided upon at dosing conferences
224324800|NCT05537025|DRUG|ARO-MMP7 Inhalation Solution|ARO-MMP7 by inhalation of nebulized solution
224324801|NCT05537025|DRUG|Placebo|Calculated volume of normal saline (0.9% NaCl) to match active treatment by inhalation of nebulized solution
224324802|NCT06855498|DRUG|povorcitinib|Study drug will be taken orally as defined by the protocol.
224324803|NCT06810804|DRUG|NBQ72S|Patients will receive the study drug every 28 days
224324804|NCT01655251|BEHAVIORAL|Intervention|
224324805|NCT05020236|DRUG|Elranatamab|subcutaneous
224324806|NCT05020236|DRUG|Daratumumab|Daratumumab / hyaluronidase, subcutaneous
224324807|NCT05020236|DRUG|Pomalidomide|oral
224324808|NCT05020236|DRUG|Dexamethasone|oral
224324809|NCT06979596|DRUG|MK-5684|Tablet for oral administration.
224262249|NCT07067619|BEHAVIORAL|Pain-acceptance intervention|"The intervention start with a conversation and inquiry about the participant's pain while continuously validating his experience and creating a shared understanding of their struggles and difficulties due to the pain.~Next, the experimenter explain the relations between distress, pain and suffering, emphasizing that in many cases trying to control our pain, emotions and thoughts leads us to undesirable results through emotional avoidance, anger and escape. This explanation will be accompanied with commonly used metaphors to enhance participants' understanding. Afterwards, participants are familiarized with the strategy of emotional acceptance of pain. The strategy will be comprehensively explained and participants will practice it with the experimenter twice: Firstly, by practicing with the mental exercise of STOP (i.e. Stop, Take a step back, Observe, Procced Mindfully); Secondly by practicing the pain acceptance strategy while feeling moderate pain, and discuss their experience."
224324810|NCT06979596|DRUG|Fludrocortisone/ Fludrocortisone acetate|Tablet for oral administration.
224324811|NCT06979596|DRUG|Dexamethasone/Dexamethasone acetate|Tablet for oral administration.
223682236|NCT06880367|DIAGNOSTIC_TEST|high-density electroencephalogram (HD-EEG)|HD-EEG examination with 256 channels distributed throughout the skull that record resting brain connectivity(10 min).
223682237|NCT05903469|OTHER|Implicit Attitude Test|The IAT (Implicit Attitude Test) is a method of indirectly measuring the relative strength of associations between different concepts stored in memory based on reaction times on computer. The general idea behind this measure is that an individual will be much faster to categorize an object into a predetermined category, if this categorization is consistent with their own way of processing information.
224324812|NCT06979596|DRUG|Rescue Medications|Hydrocortisone or hydrocortisone/hydrocortisone acetate administered via intramuscular injection as rescue medication.
224324813|NCT06979596|DRUG|Fulvestrant|Administered via intramuscular injection.
224324814|NCT06979596|DRUG|Exemestane|Tablet for oral administration.
224324815|NCT06979596|DRUG|Megestrol acetate/Medroxyprogesterone acetate|Tablet for oral administration.
224324816|NCT06979596|DRUG|Tamoxifen|Tablet for oral administration.
224324817|NCT06979596|DRUG|Letrozole|Tablet for oral administration.
224324818|NCT06980948|GENETIC|ST-503|Genomic Medicine
224324819|NCT06980948|PROCEDURE|Sham (No Treatment)|Sham Procedure
224324820|NCT06979505|DRUG|GV101|GV101 suspension
224324821|NCT06979505|DRUG|GV101 placebo|GV101 placebo suspension
224324822|NCT06324357|DRUG|Zongertinib|Zongertinib
224324823|NCT06324357|DRUG|Trastuzumab deruxtecan|Trastuzumab deruxtecan
224324824|NCT06324357|DRUG|Trastuzumab emtansine|Trastuzumab emtansine
223682238|NCT06900426|OTHER|10 PEEP|Using 10cmH2O PEEP during anesthetic induction monitored by EIT.
223682239|NCT06900426|OTHER|ZEEP|No PEEP
223682240|NCT06900426|OTHER|5PEEP|Using 5cmH2O PEEP
223682241|NCT04537377|GENETIC|VTX-801|"The investigational medicinal product (VTX-801) is a replication-deficient recombinant adeno-associated viral vector (rAAV) consisting of an AAV liver tropic capsid containing a single-stranded DNA genome carrying a shortened version of the ATP7B gene (ATP7B-minigene).~After reconstitution VTX-801 will be administered as a single dose intravenous (IV) administration per patient, at up to 3 different dose levels."
223682242|NCT04227301|OTHER|blood sampling|blood sampling for measurement of bone markers after a fasting period of at least 6 hours
223682243|NCT05772702|DEVICE|Closed-loop tACS|Individual alpha tACS
223682244|NCT06361511|OTHER|High Linoleic Acid Foods|Two food products containing 6g of high linoleic safflower oil each will be consumed each day for a total of 12g daily
223682245|NCT06361511|OTHER|High Oleic Acid Foods|Two food products containing 6g of high oleic safflower oil each will be consumed each day for a total of 12g daily
223682246|NCT06801847|BEHAVIORAL|Socialization|Socialization lasting from 30-60 minutes each session
223682247|NCT06801847|BEHAVIORAL|Walking|Twice weekly walking (30 minutes)
223682248|NCT06801847|BEHAVIORAL|Moderate Exercise|Twice weekly moderate exercise (30 minutes)
223835672|NCT04474223|DRUG|IVIG|"In a mother in whom 2° AVB has been diagnosed in the fetus:~One dose of IVIG \[1g/kg of maternal weight (max dose 70 g)\] at diagnosis of 2° AVB (within 12 hours of detection by mother via home monitoring and within 6 hours of confirmation by echocardiogram). A fetal AV interval \> 170 ms will not be treated with maternal IVIG, only dexamethasone."
224324825|NCT06324357|DRUG|Trastuzumab|Herceptin®
224324826|NCT06324357|DRUG|Capecitabine|Xeloda®
224324827|NCT06588218|OTHER|Watermelon|2.5 cups of whole fresh watermelon (\~375 grams, 115 kcals, 0.5g fat, 1.5g fiber, 17,225mcg lycopene, 30.75mg vitamin C) of fresh watermelon daily for six weeks
224324828|NCT06588218|OTHER|Belvita Breakfast Sandwich + 12 oz Water|Belvita breakfast sandwich; 115 kcals, 1.5g fiber, 4.5g fat, 0mg lycopene, 0mg vitamin C) as well as 12 ounces of water
224324829|NCT06841354|BIOLOGICAL|Sacituzumab tirumotecan|IV Infusion
224324830|NCT06841354|BIOLOGICAL|Pembrolizumab|IV Infusion
224324831|NCT06841354|DRUG|Rescue Medication|Participants receive the following pre-medications before sacituzumab tirumotecan infusion: Histamine-1 (H1) receptor agonist, histamine-2 (H2) receptor antagonist, acetaminophen or equivalent, dexamethasone or equivalent infusion. Participants are also recommended to receive prophylactic steroid mouthwash (dexamethasone or equivalent).
224324832|NCT06841354|DRUG|Paclitaxel|IV Infusion
224324833|NCT06841354|DRUG|Nab-paclitaxel|IV Infusion
224324834|NCT06841354|DRUG|Gemcitabine|IV Infusion
224324835|NCT06841354|DRUG|Carboplatin|IV Infusion
224324836|NCT06079879|DRUG|Bomedemstat|Oral Capsule
224324837|NCT06079879|DRUG|Anagrelide|Oral Capsule
224324838|NCT06079879|DRUG|Busulfan|Oral Tablet
224324839|NCT06079879|DRUG|Interferon alfa/pegylated interferon alfa 2a/pegylated interferon alfa 2b|Subcutaneous Solution
224324840|NCT06079879|DRUG|Ruxolitinib|Oral Tablet
224324841|NCT06532656|DRUG|Lenacapavir|Tablets administered orally without regard to food
224324842|NCT06532656|DRUG|BIC/LEN FDC|Tablets administered orally without regard to food
224324843|NCT06021054|DRUG|Veligrotug (VRDN-001)|Veligrotug (VRDN-001) is a humanized monoclonal antibody directed against the IGF-1 receptor
224324844|NCT06021054|DRUG|Placebo|5 IV infusions of placebo
224324845|NCT06340568|DRUG|BNT323/DB-1303|intravenous (IV) infusion
224324846|NCT06340568|DRUG|Doxorubicin|IV bolus or infusion
223774491|NCT07024303|BEHAVIORAL|Behavioral therapy|Functional communication training (FCT) will be delivered for 1 hour every week in-vivo or via telehealth. This timing and dosage has been shown effective in previous research. However, caregivers will be encouraged to practice the treatment procedures as often as possible on their own. Treatment will be delivered by a therapist and/or caregiver for those receiving in-vivo therapy and caregivers will deliver treatment with coaching from a therapist when using telehealth.
223774492|NCT07025538|OTHER|Best Practice|Receive SOC treatment
223774493|NCT07025538|OTHER|Biomarker Analysis|Undergo GHVD biomarker analysis
223774494|NCT07025538|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223774495|NCT07025538|OTHER|Questionnaire Administration|Ancillary studies
223774496|NCT07025538|DRUG|Ruxolitinib|Given PO
223774497|NCT07023458|DIAGNOSTIC_TEST|Brief-P|Executive function test in preschool children with OSA
223774498|NCT07025681|BIOLOGICAL|Erythropoietin alfa|Erythropoietin 4000 IU Injection, for subcutaneous injection.
223774499|NCT07024186|PROCEDURE|Xenogeneic Collagen Matrix|Xenogeneic Collagen Matrix The xenogeneic collagen matrix is a biomaterial used to promote soft tissue regeneration and support healing in dental implant procedures.
223774500|NCT07024186|PROCEDURE|subepithelial connective tissue graft|ubepithelial Connective Tissue Graft The subepithelial connective tissue graft is a biological tissue taken from the patient's own palate or other donor sites to promote healing and aesthetic outcomes around dental implants.
223774501|NCT07025486|BEHAVIORAL|HabitWorks|Smartphone delivered interpretation bias exercises, symptom tracking
223774502|NCT07025486|BEHAVIORAL|Symptom TRacking|Self-assessment via symptom surveys
223774503|NCT07024732|BIOLOGICAL|PST-611|PST-611 is a naked plasmid DNA encoding human transferrin administered into the ciliary muscle
223774504|NCT07025590|BEHAVIORAL|Moderate-intensity continuous movement and Antipsychotics intervention|On the basis of Antipsychotics intervention, Patients in the exercise group should start exercise intervention as soon as possible after completing baseline examination, and need to complete a training plan of at least 36 times, 3 times/week. At the beginning of each training session, patients need to warm up for 5-10 minutes, mainly jogging and stretching exercises. After the warm-up, the patient enters the training phase, the heart rate reserve is 70% to 85%, and after the training, the patient performs 10-15 minutes of recovery exercise, mainly jogging, slow walking and stretching. The specific exercise plan is formulated according to the patients' own aerobic capacity assessment, and the principle of formulation is gradual and individual. At each training session, patients were asked about their perceived fatigue level to adjust the training intensity.
223774505|NCT07025590|DRUG|Antipsychotics intervention(sertraline, escitalopram, fluoxetine, duloxetine, paroxetine, venlafaxine, and fluvoxamine)|Patients maintained regular medication during the intervention period, and returned to the doctor every two weeks, and the psychiatrist decided whether to maintain the current dose or gradually reduce the dose based on the patient's symptoms and diagnosis. Psychiatrists, unaware of patient groupings, use supportive measures to help manage adverse reactions.
223774506|NCT06420336|PROCEDURE|Quadratus lumborum block|After induction of anesthesia and securement of appropriate airway device, the patient will be placed in position for the QL block. Using ultrasound guidance, the pediatric anesthesiology attending will perform unilateral QL block on the side of the anterior iliac bone graft harvest. The dose will be 0.2% ropivacaine, 1 mL per kilogram to a max of 20 mL with an additive of dexamethasone 4 mg. Ultrasonography will be used to identify external oblique, internal oblique, transverse abdominus and quadratus lumborum muscles. A 50 mm-150 mm block needle will be advanced under ultrasound guidance. Ropivacaine will be injected slowly with frequent aspiration to rule out incorrect needle placement. The anesthetic is deposited at the lateral edge of the QL after penetrating the transversus abdominus aponeurosis. Injection will continue to be observed with real time US guidance.
224324847|NCT06340568|DRUG|Paclitaxel|IV infusion
224324848|NCT06241560|DRUG|BI 1015550|BI 1015550
224324849|NCT06241560|DRUG|Pirfenidone|Pirfenidone
224324850|NCT05519683|DEVICE|TEA|The TEA device administers a mild electrical shock through the skin, similar to acupuncture. Location sets are described in the protocol, which will be shared with results reporting but are not provided here to maintain masking and, therefore, to safeguard scientific integrity.
224324851|NCT05519683|DRUG|Lexapro|This arm will receive treatment with the chemical neuromodulator escitalopram (Lexapro) at 10 mg once per day for 8 weeks. Lexapro is often used as a standard treatment for IBS.
224324852|NCT06983899|OTHER|Aerobic Exercise|Complete virtual home-based aerobic interval training sessions
224324853|NCT06983899|OTHER|Exercise Intervention|Receive stationary bike, HR monitor, BP monitor, SPO2 monitor
224324854|NCT06983899|OTHER|Educational Intervention|Receive general healthy lifestyle guidebook
224324855|NCT06983899|PROCEDURE|Dual X-ray Absorptiometry|Undergo DEXA
224324856|NCT06983899|OTHER|Electronic Health Record Review|Ancillary studies
224324857|NCT06983899|OTHER|Cardiopulmonary Exercise Testing|Ancillary studies
224324858|NCT06983899|OTHER|Physical Performance Testing|Ancillary studies
224324859|NCT06983899|OTHER|Questionnaire Administration|Ancillary studies
224324860|NCT06983899|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
224324861|NCT06983899|PROCEDURE|Pulmonary Function Test|Undergo PFT
224324862|NCT04973683|DRUG|AL101|Given IV
224324863|NCT04973683|PROCEDURE|Therapeutic Conventional Surgery|Undergo standard of care surgery
224324864|NCT06087640|BIOLOGICAL|aQIV or aTIV|Participants receive a 0.5-mL intramuscular dose of aQIV or aTIV on Day 1. A 0.5 mL dose of aQIV contains nominally 15 µg of hemagglutinin (HA) of each of the 2 influenza type A strains and each of the 2 influenza B strains (total of 60 µg HA). A 0.5 mL dose of aTIV contains nominally 15 µg of HA of each of the 2 influenza type A strains and of the influenza B strain (total of 45 µg HA). The strain composition of aQIV and aTIV is that recommended by the World Health Organization (WHO) for quadrivalent and trivalent influenza vaccines, respectively, contemporaneous to the timing of the study.
223835673|NCT03466151|DEVICE|Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System|Treatment of subjects eligible for percutaneous transluminal coronary angioplasty (PTCA) as per study requirements
224324865|NCT06087640|BIOLOGICAL|QIV or TIV|Participants receive a 0.5-mL intramuscular dose of the non-adjuvanted QIV or TIV on Day 1. A 0.5 mL dose of QIV contains nominally 15 μg of HA of each of the 2 influenza type A strains and each of the 2 influenza B strains (total of 60 μg HA). A 0.5 mL dose of TIV contains nominally 15 μg of HA of each of the 2 influenza type A strains and of the influenza B strain (total of 45 μg HA). The strain composition of QIV and TIV is that recommended by the WHO for quadrivalent and trivalent influenza vaccines, respectively, contemporaneous to the timing of the study.
224324866|NCT06807190|DRUG|Insulin Icodec|Participants will be treated with commercially available Awiqli according to routine clinical practice at the discretion of the treating physician.
224324867|NCT06551142|BIOLOGICAL|GSK5764227|GSK5764227 will be administered
224324868|NCT06551142|DRUG|Cisplatin|Cisplatin will be administered
224324869|NCT06551142|DRUG|Carboplatin|Carboplatin will be administered
224324870|NCT06551142|BIOLOGICAL|Atezolizumab|Atezolizumab will be administered
224324871|NCT06551142|BIOLOGICAL|Pembrolizumab|Pembrolizumab will be administered
224324872|NCT06551142|BIOLOGICAL|Durvalumab|Durvalumab will be administered
224324873|NCT06551142|BIOLOGICAL|Cetuximab|Cetuximab will be administered
224324874|NCT06551142|BIOLOGICAL|Bevacizumab|Bevacizumab will be administered
224324875|NCT02101853|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic HSCT
224324876|NCT02101853|DRUG|Asparaginase|Given IM or IV
224324877|NCT02101853|BIOLOGICAL|Blinatumomab|Given IV
224324878|NCT02101853|DRUG|Cyclophosphamide|Given IV
224324879|NCT02101853|DRUG|Cytarabine|Given IT and IV or SC
224324880|NCT02101853|DRUG|Dexamethasone|Given PO or IV
224324881|NCT02101853|DRUG|Etoposide|Given IV
224324882|NCT02101853|DRUG|Leucovorin Calcium|Given IV or PO
224324883|NCT02101853|DRUG|Mercaptopurine|Given PO
224324884|NCT02101853|DRUG|Methotrexate|Given IT, IV, and PO
224324885|NCT02101853|DRUG|Mitoxantrone|Given IV
224324886|NCT02101853|DRUG|Mitoxantrone Hydrochloride|Given IV
224324887|NCT02101853|DRUG|Pegaspargase|Given IV
224324888|NCT02101853|OTHER|Pharmacological Study|Correlative studies
224324889|NCT02101853|RADIATION|Radiation Therapy|Undergo cranial radiation therapy
223835674|NCT03466151|DEVICE|Resolute Integrity™ Zotarolimus-Eluting Coronary Stent System|Treatment of subjects eligible for percutaneous transluminal coronary angioplasty (PTCA) as per study requirements
223835675|NCT06096974|DRUG|YL-17231|YL-17231 will be administered orally once daily in a continuous regimen
224324890|NCT02101853|DRUG|Therapeutic Hydrocortisone|Given IT
224324891|NCT02101853|DRUG|Thioguanine|Given PO
224324892|NCT02101853|DRUG|Vincristine|Given IV
224324893|NCT02101853|DRUG|Vincristine Sulfate|Given IV
224324894|NCT06651632|DEVICE|Aquablation Therapy|The AquaBeam Robotic System and the HYDROS Robotic System utilize high-velocity sterile saline waterjet to resect prostate tissue, guided by real-time visualization through cystoscopy and transrectal ultrasound imaging. This minimally invasive surgical procedure is called the Aquablation therapy.
224324895|NCT06651632|PROCEDURE|Radical Prostatectomy|Radical prostatectomy is a surgery that is performed through an incision in the lower abdomen or perineum, or with a laparoscope or robotic system to remove the entire prostate gland.
224324896|NCT06815432|GENETIC|15.GPC3-CAR T cells|"Four different dosing schedules will be evaluated. The following dose levels will be evaluated:~DL1: 5x10\^6 DL2: 1x10\^7 DL3: 5x10\^7 DL4: 1x10\^8"
224324897|NCT05380921|DEVICE|standard EEG|all subjects will receive both a standard EEG and a dry electrode EEG
224324898|NCT05380921|DEVICE|dry electrode EEG|all subjects will receive both a standard EEG and a dry electrode EEG
224324899|NCT05934526|DRUG|Placebo|Matching capsule containing placebo
224324900|NCT05934526|DRUG|Seralutinib|Capsule containing seralutinib
224324901|NCT05934526|DEVICE|Generic Dry Powder Inhaler|Generic dry powder inhaler for seralutinib or placebo delivery
224324902|NCT06522737|DRUG|Duvelisib|oral capsules
224324903|NCT06522737|DRUG|Gemcitabine|solution for intravenous infusion
224324904|NCT06522737|DRUG|Bendamustine|solution for intravenous infusion
224324905|NCT03294460|DRUG|Alcohol (Oral)|Oral Self-administration
224324906|NCT03294460|DRUG|Alcohol (IV)|IV Self-administration
224324907|NCT03294460|DRUG|Alcohol (Ethanol)|IV and Oral Self-administration
224324908|NCT04129138|OTHER|Survey Administration|Complete survey
224324909|NCT06654882|DRUG|TNFi (Tumor Necrosis Factor inhibitor) medication|"Adalimumab 10 kg (22 lbs) to \<15 kg (33 lbs) 10 mg every other week\* 15 kg (33 lbs) to \<30 kg (66 lbs) 20 mg every other week ≥30 kg (66 lbs) 40 mg every other week~Etanercept~≥63 kg (138 lb) 50 mg weekly \<63 kg (138 lb) 0.8 mg/kg weekly"
224324910|NCT06654882|DRUG|Abatacept|"10 kg to \<25 kg 50 mg once weekly 25 kg to \<50 kg 87.5 mg once weekly~≥50 kg 125 mg once weekly"
224324911|NCT06654882|DRUG|Tocilizumab|"\<30 kg 162 mg once every 3 weeks~≥30 kg 162 mg once every 2 weeks"
224324912|NCT06654882|DRUG|Tofacitinib|"10 to \<20 kg 3.2 mg (3.2 mL oral solution) BID 20 to \<40 kg 4 mg (4 mL oral solution) BID~≥40 kg 5 mg (one 5 mg tablet or 5 mL oral solution) BID"
224324913|NCT06817720|DRUG|olverembatinib|GIven by PO
224324914|NCT06641908|DRUG|M3554|M3554 will be administered at an escalated dose until Maximum tolerated dose (MTD) and/or a safe recommended Dose is determined in participants with STS (dose escalation A) and glioblastoma and IDH wildtype (dose escalation B).
224324915|NCT06307574|BEHAVIORAL|bpMedManage|In this 16-week RCT, a total of 100 older adults with MCI will be recruited. There are two treatment arms, bpMedManage-S and bpMedManage-P with 50 participants in each arm. Participants randomized into the bpMEDManage-S intervention arm will use a smartphone application with medication reminders plus receive education with standardized information on hypertension and antihypertensive medications on the education portal. Participants in the bpMedManage-P group will use a smartphone to receive education with standardized information on hypertension and antihypertensive medications on the education portal. Both groups will complete baseline assessments followed by 4 weeks of medication adherence monitoring. At the end of the adherence monitoring period, participants will be randomized into one of the two treatment arms. Immediate outcomes will be assessed 4 weeks after beginning of the intervention. Follow-up outcomes will be assessed 12 weeks after the beginning of the intervention.
223774507|NCT06420336|PROCEDURE|Local anesthetic infiltration|After induction of anesthesia and securement of appropriate airway device the patient will be turned over to the surgical team to proceed with the operation. The surgeon will proceed with usual injection of local anesthetic as their standard of care; this medication will be charted by the circulating nurse in the Medication Administration Record with local anesthetic type and amount. At the conclusion of the procedure, to maintain the blind, the patient will have a bandage placed where the QL block would have been performed.
223774508|NCT07024433|PROCEDURE|Tubeless anesthesia|"1. Anesthesia Induction: Implement TCI with propofol and remifentanil; insert a laryngeal mask for SIMV ventilation, and monitor vital signs including IBP and end-tidal CO2.~2. Nerve Blocks: Perform ultrasound-guided paravertebral, pleural surface, and vagus nerve blocks using local anesthetics.~3. Anesthesia Maintenance: Adjust remifentanil for spontaneous breathing; maintain propofol and BIS levels; manage heart rate and blood pressure with fluids and medication as needed, without using inhaled anesthetics.~4. Postoperative Analgesia: Provide PCIA with morphine for pain management."
223774509|NCT07024433|PROCEDURE|Traditional tracheal intubation|"1. Anesthesia induction using propofol, sufentanil, and rocuronium is performed, with DLT or single-lumen tube insertion at BIS≤60 for single-lung ventilation, maintaining appropriate oxygen and ventilation parameters.~2. Anesthesia is maintained with sevoflurane, propofol, and remifentanil, supplementing rocuronium every 30-40 minutes for muscle relaxation, with BIS maintained at 40-60.~3. Post-surgery, ultrasound-guided thoracic paravertebral block and PCIA are used for analgesia, with extubation following standard recovery procedures."
223774510|NCT07025642|DRUG|Urodynamic evaluation before and after solifenacin treatment.|Cystometry performed at 1 month before and 1, 6 months following/after treatments will be analyzed.
223774511|NCT07025642|DRUG|Urodynamic evaluation before and after mirabegron treatment.|Cystometry performed at 1 month before and 1, 6 months following/after treatments will be analyzed.
223774512|NCT07025642|DRUG|Urodynamic evaluation before and after combined treatment with solifenacin and mirabegron.|Cystometry performed at 1 month before and 1, 6 months following/after treatments will be analyzed.
223774513|NCT07025642|DRUG|Urodynamic evaluation before and after Botulinum toxin (Botox) injection.|Cystometry performed at 1 month before and 1, 6 months following/after treatments will be analyzed.
224324916|NCT06170788|BIOLOGICAL|Sacituzumab tirumotecan|IV infusion
224324917|NCT06170788|BIOLOGICAL|Pembrolizumab|IV infusion
224324918|NCT06170788|DRUG|Supportive care measures|Participants are allowed to take supportive care measures at the discretion of the investigator. Prophylactic supportive care measures may include but are not limited to antiemetic agents, antidiarrheal agents, granulocyte and erythroid growth factors, and blood transfusions
224324919|NCT06336148|DRUG|ACTM-838|Escalating doses of ACTM-838 in Part 1a and recommended dose in Part 1b
224324920|NCT06649812|PROCEDURE|Biopsy Procedure|Undergo optional tumor biopsy
224324921|NCT06649812|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
224324922|NCT06649812|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration and biopsy
224324923|NCT06649812|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow aspiration and biopsy
224324924|NCT06649812|PROCEDURE|Computed Tomography|Undergo CT
224324925|NCT06649812|DRUG|Ibrutinib|Given PO
224324926|NCT06649812|DRUG|Lenalidomide|Given PO
224324927|NCT06649812|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
224324928|NCT06649812|BIOLOGICAL|Obinutuzumab|Given IV
224324929|NCT06649812|PROCEDURE|Positron Emission Tomography|Undergo PET
224324930|NCT06649812|DRUG|Prednisone|Given PO
224324931|NCT06649812|DRUG|Venetoclax|Given PO
224324932|NCT06982378|DRUG|GLP-1 receptor agonist|on and not on treatment
224324933|NCT06857006|PROCEDURE|brain metastases radiosurgery|Radiosurgery is the use of a focal high dose of radiation therapy to ablate or kill a tumor. This trial will enroll patients with brain metastases 4 cm or less in greatest diameter and will compare 0mm margin to a 2mm margin for treatment.
224324934|NCT06660654|DRUG|Raludotatug deruxtecan|IV administration Q3W
224324935|NCT06658912|OTHER|TOPS Classes|Attend Dietician-Led Sessions
224324936|NCT03460769|OTHER|Data Management and Monitoring|The Coordinating and Data Management Center (CDMC) at MD Anderson Cancer responsible for the coordination and data management for the Evaluation of a mixed meal test for Diagnosis and characterization of Type 3c diabetes mellitus secondary to pancreatic cancer and chronic pancreatitis (DETECT), which is part of the NIH U01 funded Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer (CPDPC).
224324937|NCT06662292|BEHAVIORAL|Mobile STRIDES app (psychoeducation features)|Twelve theory-based physical activity behavior change lessons/modules during the course of the 3-month intervention.
224324938|NCT06662292|BEHAVIORAL|Mobile STRIDES app (self-regulation features)|Personalized physical activity goals focused on moderate-to-vigorous intensity aerobic physical activity and steps. Physical activity (tracked with a Fitbit wearable smartwatch and synced with the Mobile STRIDES app) tracking component, displaying team and individual progress. Weekly individualized feedback messages crafted by a trained professional for the first month of the intervention.
224324939|NCT06662292|BEHAVIORAL|Mobile STRIDES app (social support training features)|For the experimental group, the Mobile STRIDES app also includes five social support training lessons/modules (during the course of the 3-month intervention) focused on providing guidance related to effective communication when exchanging social support for physical activity within a team. In addition, six team feedback messages will be delivered to respective teams throughout the course of the 3-month intervention to reinforce content taught via the training lessons/modules. A weekly poll will also be administered that complements the social support training lessons, with cumulative results displayed.
224324940|NCT06660186|DEVICE|Rigid Sternal Fixation|The surgeon will close the sternum (breastbone) using the SternalPlate system. The SternalPlate System consists of implants and instruments used to hold the two halves of the sternum together.
224324941|NCT06660186|DEVICE|Wire Cerclage|The surgeon will close the sternum (breastbone) using Wire Cerclage. Wire Cerclage consists of stainless steel wires used to hold the two halves of your sternum together.
224324942|NCT05516524|DIAGNOSTIC_TEST|Home sleep apnea test|Level II home sleep apnea testing evaluates for obstructive sleep apnea in the home environment with parental supervision.
224324943|NCT05516524|DIAGNOSTIC_TEST|PSG|Overnight sleep study in the sleep laboratory with continuous monitoring by clinical staff.
224324944|NCT02897063|DRUG|Droxidopa|Single oral dose 300 mg
224324945|NCT02897063|DRUG|Midodrine|Single oral dose 10 mg
223682249|NCT06524453|BEHAVIORAL|Wheelchair accessible exercise program|"1. Stretching exercise~   * Dynamic and static~  * Neck, shoulder, elbow, wrist, trunk~  * 10 minutes~2. Aerobic exercise~   * High intensity interval training~  * Arm ergometer or wheelchair running~  * 20 mins~3. Strengthening exercise~   * Shoulder and chest, elbow joint major muscle; shoulder and trunk stabilization exercise~  * 3 sets of 10~  * 20 minutes~4. Stretching exercise~   * Dynamic and static~  * Neck, shoulder, elbow, wrist, trunk~  * 10 minutes"
223682250|NCT02151136|DRUG|24% sucrose|
223682251|NCT02151136|DRUG|Sterile water|
223682252|NCT02151136|OTHER|Standard care|The current standard of care at the study site is use of topical anesthetic (Ametop or EMLA), upright holding of toddler by parent/caregiver during procedure, use of age appropriate nurse directed distraction, and sucking on a pacifier (if normally used by child)
223682253|NCT04514302|DRUG|Placebo|Placebo of saline solution of equal volume and infusion. Content of the infusion bag and tubing will be concealed with opaque covering.
223682254|NCT04514302|DRUG|Anti-SARS-CoV-2 equine immunoglobulin F(ab')2 fragments (INOSARS)|INOSARS is a polyvalent passive immunization based on anti-SARS-CoV-2 immunoglobulin F(ab')2 fragments from hyperimmune equine serum. Inactive ingredients: water for injection, sodium chloride and less than 10% of total protein content.
223682255|NCT02048293|DRUG|Remifentanyl, Ultiva®|Anesthetic induction for orotracheal intubation. Group O
223682256|NCT02048293|DRUG|Remifentanil Laboratorios Chalver de Colombia S.A.|Anesthetic induction for orotracheal intubation. Group A
223682257|NCT02048293|DRUG|Fada Remifentanilo|Anesthetic induction for orotracheal intubation. Group B
223682258|NCT05587348|BEHAVIORAL|Best Practice Advisory|Provider will get Best Practice Advisory or Message from DCE in intervention practices
223682259|NCT05587348|BEHAVIORAL|Peer Support|Patients referred to DSMES classes will be randomized to get a peer supporter
223682260|NCT05288777|DRUG|T-DM1|Dosed at 3.6 mg/kg of body weight every 3 weeks for Her2/neu+ patients for a total duration of 14 cycles.
223682261|NCT05288777|DRUG|Capecitabine|Dosed at 825 mg/m2 +/- 150mg twice per day for a total duration of 6 months
223682262|NCT05288777|RADIATION|External Beam Radiation Therapy 0|Dose of 40 Gy in 15 fractions to the whole breast or chest wall followed by consideration of a 10 Gy in 4 fraction boost to the lumpectomy cavity for a total duration of 15-19 days. Internal mammary nodal, dissected axilla coverage, and boost will be at the radiation oncologist's discretion.
223682263|NCT05288777|RADIATION|External Beam Radiation Therapy 1|Dose of 40 Gy in 15 fractions to either the breast or chest wall along with comprehensive nodal radiation followed by consideration of a 10 Gy in 4 fraction boost for a total duration of 15-19 days. Internal mammary nodal, dissected axilla coverage, and boost will be at the radiation oncologist's discretion.
223682264|NCT02071147|OTHER|No Clinical Follow up|
223682265|NCT02071147|OTHER|Quality of Life questionnaire|
223774514|NCT07023796|PROCEDURE|Autologous fat filtration|Patients who underwent a surgical procedure and autologous fat processing for subsequent fat filtration.
224324946|NCT02897063|DRUG|Placebo|sugar pill
224324947|NCT06298149|BEHAVIORAL|Turtle Island Tales|All participating families will receive a monthly lesson targeting a healthy behavior (increase fruit/vegetable intake, decrease added sugar intake, increase physical activity, decrease sedentary/screen time, promote healthy sleep, and promote emotional regulation) over the course of one year.
224324948|NCT06985953|OTHER|TrialTalk™|TrialTalk™ is a communication tool that focuses on making the options visible and accessible while involving patients in the discussion.
224324949|NCT06981078|DRUG|Verekitug|Verekitug (UPB-101) formulated solution
224324950|NCT06981078|OTHER|Placebo|Matching Placebo to Verekitug (UPB-101)
224324951|NCT06587490|RADIATION|stereotactic ablative radiotherapy|Stereotactic ablative radiotherapy is a highly focused radiation treatment that gives an intense dose of radiation concentrated on a tumor, while limiting the dose to the surrounding organs.
224324952|NCT06588478|DRUG|Pirtobrutinib|Administered Orally.
224324953|NCT06586515|DRUG|LY3962673|Administered orally.
224324954|NCT06586515|DRUG|Cetuximab|Administered intravenously.
224324955|NCT06586515|DRUG|Gemcitabine|Administered intravenously.
224324956|NCT06586515|DRUG|nab-paclitaxel|Administered intravenously.
224324957|NCT06586515|DRUG|Oxaliplatin|Administered intravenously.
224324958|NCT06586515|DRUG|leucovorin|Administered intravenously.
223682266|NCT02071147|OTHER|Patient satisfaction Questionnaire|Conducted at Research clinic.
223682267|NCT04199936|DEVICE|Electrical Muscle stimulation|Electrical muscle stimulation
223682268|NCT05384275|DEVICE|High Flow Nasal Therapy|High Flow Nasal Oxygen (Airvo2 Device)
223682269|NCT04376177|DIAGNOSTIC_TEST|Ultrasound|Echodoppler imaging of upper limbs performed by trained operators at rest and during provocative maneuvers for TOS diagnosis.
223682270|NCT04376177|DIAGNOSTIC_TEST|angiography|Angiography (arterial and/or venous) of upper limbs performed by trained operators at rest and during provocative maneuvers such for TOS diagnosis.
223682271|NCT04376177|DIAGNOSTIC_TEST|questionnaires|Use of standard questionnaires (MASC, DASH, SF36) for the evaluation of upper limb symptoms self-completed by the patients at admission.
223682272|NCT04376177|DIAGNOSTIC_TEST|Transcutaneous oximetry|Mesurement of transcutaneuos oxygen pressure on both forearms performed at rest and during provocative maneuversfor TOS diagnosis.
223682273|NCT04376177|DIAGNOSTIC_TEST|plethysmography|Photoplethysmography of the forearms or fingers performed at rest and during provocative maneuvers for TOS diagnosis
223682274|NCT04376177|DIAGNOSTIC_TEST|Electromyogram|Electromyography of the upper limbs with encoding of the physician for the presence or abnsence of signs of plexis compression (impairment of the response on C8 T1 erea
223682275|NCT04376177|DIAGNOSTIC_TEST|Standard X-Ray|Standard X-Ray performed for the research of apophysomegaly or additionnal cervical rib.
223835676|NCT05205720|PROCEDURE|Celiac plexus block|The surgeon is instructed to perform a single celiac plexus block under direct vision. 10ml 0.5% ropivacaine is injected into the nerve in both sides.
224324959|NCT06586515|DRUG|Irinotecan|Administered intravenously.
224324960|NCT06586515|DRUG|5-fluorouracil|Administered intravenously.
224324961|NCT06599593|DIETARY_SUPPLEMENT|SQ-LNS|CHW provides all children ages 6-24 months who do not have acute malnutrition with SQ-LNS (Enov'nutributter; Nutriset; 20 g/day, approximately 100-120 calories).
223774515|NCT07025083|BEHAVIORAL|Adapted Family Check-Up Online|The Family Check-Up Online is a digital intervention that includes an assessment, computer-generated feedback, and intervention modules that focus on improving family relationships and parenting skills in order to reduce child mental health problems and to improve child self-regulation. These modules include Healthy Behaviors for Stressful Times, Positive Parenting, Rules and Consequences, Supporting School Success, and Communication. In addition, two modules for Latinx families are being added in the adapted version. This version represents a deep adaptation.
223774516|NCT07025083|BEHAVIORAL|Original Family Check-Up Online|This version is the original Family Check Up Online translated into Spanish without the adaptions. This represents a surface-level adaptation.
224324962|NCT06599593|OTHER|Integrated Nutritional Screening|In conjunction with SMC administration, CHWs screen children for MUAC. CHW refers children with MUAC \&lt;12.5 to the CSPS for MAM/SAM care and to receive all standard nutritional program.
223774517|NCT06878937|BEHAVIORAL|Peer Delivered Psychoeducation Program|The peer delivered psychoeducation program is the only intervention being tested in this pilot evaluation study.
223774518|NCT07023497|DRUG|Intrathecal morphine|Intrathecal morphine with fixed-dose fentanyl and ropivacaine
223774519|NCT05987462|OTHER|Green walking|The researcher provided detailed information to the patients about green walking. For the randomized MI patients, two groups were formed, and they engaged in a 50-minute green walking three days a week for 12 weeks, under the guidance of the researcher. The green walk group's walks were scheduled differently for the two subgroups. The first subgroup had their 50-minute walk on Monday, Wednesday, and Saturday, while the second subgroup had their walks on Tuesday, Thursday, and Sunday. This arrangement ensured a standardized time interval between green walks for both groups.
223774520|NCT07035067|OTHER|No intervention|No specific intervention is assess in this study.
223774521|NCT06878443|OTHER|Vaginal probiotics|Probiotics from Canadian company Lallemand Health Solutions are stored at room temperature and administered vaginally.
223774522|NCT07033793|BEHAVIORAL|GApp|Participants receive only digital support with health information, self-assessment tests, preventive advices and games. No educational sessions are provided, and the focus is solely on digital preventive advice used autonomously.
223774523|NCT07033793|BEHAVIORAL|GappE|"Participants receive preventive interventon delivered via digital support (smartphone app) including health information, self-assessment tests, preventive advices and games).~In addition to the App used autonomously, they will participate in 5 group educational sessions proposed by a physiotherapist (once every two weeks)."
223774524|NCT07039344|OTHER|Conventional method of Palliative care Training (Group A)|Group A receive training through the 2-step Conventional method. The first step comprises 1 didactic lecture / week (1 hour) for 10 weeks leading towards the second step of 1 skill session / week for 1 hour under instructor supervision for 6 weeks.
223835677|NCT05205720|DRUG|Ropivacaine|Mixed solution for nerve block, made of 0.75% ropivacaine (Naropin, Astrazeneca AB) diluted in different proportions.
224324963|NCT06843239|BIOLOGICAL|Tibulizumab|Anti BAFF/IL-17 antibody
224324964|NCT06843239|OTHER|Placebo|Placebo (inactive)
224324965|NCT05029336|BIOLOGICAL|Depletion of CD3/CD19 in an autologous stem cell transplant|The purpose of this study is to determine the safety and feasibility of CD3/CD19 depleted autologous stem cell transplant for the treatment of life threatening autoimmune disease. We will perform CD3/CD19 depletion using the CliniMACs device as a means of purging autoreactive T and B cells from the transfused autologous stem cell product, while retaining some immune function, namely natural killer cells and monocytes in the product.
224324966|NCT06988371|BEHAVIORAL|Reduced nicotine regulatory environment|In this regulatory environment, participants' usual combustible cigarette will not be available in the Experimental Tobacco Marketplace and reduced nicotine content cigarettes will be the only available combustible cigarette.
224324967|NCT06988371|BEHAVIORAL|Restriction on characterizing flavors in combustible nicotine products|In this regulatory environment, menthol and other characterizing flavors in combustible nicotine products will not be available in the Experimental Tobacco Marketplace. Tobacco- or no-flavored combustible nicotine products will be the only combustible nicotine products available.
224262250|NCT07068724|COMBINATION_PRODUCT|Gluma Desensitizer and ER:CR;YSGG laser combination|Participants in this group received both treatments: Gluma was applied using the same method as in Gluma, followed by Er,Cr:YSGG laser therapy using the same parameters and technique as in laser.
224262251|NCT07068724|DEVICE|Er,Cr:YSGG laser|Participants received Er,Cr:YSGG laser treatment (Water-Lase iPlusTM; Biolase® Technology Inc., Irvine, CA, USA). Laser parameters were set as follows: 2780 nm wavelength, 0.25 W power, 20 Hz frequency, 140 μs pulse duration, and 30 seconds exposure time. The MZ6 tip (660 μm diameter, 6 mm length, 1 mm spot size) was used in non-contact mode from a 1 mm distance, perpendicular to the dentin surface, with 0% water and 10% air spray. All laser applications followed international safety standards and protocols.
224262252|NCT07069439|BEHAVIORAL|Turkish Version of the P-DrHy-Q|Participants will complete the Turkish-translated version of the Parent-reported Drug Hypersensitivity Quality of Life Questionnaire (P-DrHy-Q), which includes 12 items assessing psychosocial burden in two domains: mental health and social activity. A subgroup of participants (n ≈ 20) will complete the same questionnaire again after 14 days to assess test-retest reliability
224262253|NCT07069270|DRUG|Vunakizumab (IL-17A inhibitor)|Vunakizumab , 240mg, D1, subcutaneous injection, Q4W.
224262254|NCT07069270|DRUG|Adebrelimab|Adebrelimab, 1200 mg, D1, intravenous drip, Q3W
224262255|NCT07069270|DRUG|Chemotherapy|Etoposide, 100mg /m², D1-3, IV, Q3W. Carboplatin, AUC 5, D1, IV, Q3W
224262256|NCT07067281|PROCEDURE|Lichtenstein Tension-Free Mesh Hernioplasty|Open surgical repair of inguinal hernia using a tension-free mesh technique. A standard polypropylene mesh is placed over the posterior wall of the inguinal canal and fixed with non-absorbable sutures under spinal or local anesthesia. This is a conventional method widely used in open hernia surgery.
224262257|NCT07067281|PROCEDURE|Laparoscopic Transabdominal Preperitoneal (TAPP) Repair|Laparoscopic approach to inguinal hernia repair performed under general anesthesia. Three ports are used to access the abdominal cavity, and a peritoneal flap is created to place a large polypropylene mesh in the preperitoneal space. The mesh is fixed with tacks or glue, and the peritoneal flap is closed. This minimally invasive method is designed to reduce postoperative pain and enhance recovery.
223835678|NCT05837975|DEVICE|FREE Walk Exoskeleton|Using a robotic exoskeleton to help with lower limb activities that are difficult due to neurological diseases. Used at home for individual patient training.
224324968|NCT06988371|BEHAVIORAL|Restriction on characterizing flavors in noncombustible nicotine products|In this regulatory environment, menthol and other characterizing flavors in noncombustible nicotine products will not be available in the Experimental Tobacco Marketplace. Tobacco- or no-flavored noncombustible nicotine products will be the only noncombustible nicotine products available.
224324969|NCT05618925|DRUG|N803|nogapendekin alfa inbakicept (also known as ALT-803; recombinant human superagonist interleukin-15 (IL-15) complex \[also known as IL 15N72D:IL-15RαSu/IgG1 Fc complex\])
224324970|NCT05618925|BIOLOGICAL|CD19t-haNK suspension|Derived from the parental NK-92 (aNK) cell line, CD19 t-haNK is a human, allogeneic, NK cell line that has been engineered to express a CAR targeting CD19. Similar to the haNK cell line, CD19 t haNK has also been engineered to produce endoplasmic reticulum-retained IL 2 and the high-affinity (158V) variant of the Fcγ receptor (FcγRIIIa/CD16a), and thereby has enhanced CD16-targeted ADCC capabilities. CD19 t-haNK is similar to PD L1 t-haNK, differing only in the CAR that is expressed (CD19 vs PD-L1).
224324971|NCT05618925|DRUG|Cyclophosphamide|Cyclophosphamide is a synthetic antineoplastic drug chemically related to the nitrogen mustards. The chemical name for cyclophosphamide is 2-\[bis(2-chloroethyl)amino\]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate and has the molecular formula C7H15Cl2N2O2P•H2O and a molecular weight of 279.1.
224324972|NCT05618925|DRUG|Fludarabine|Fludarabine phosphate is a fluorinated nucleotide analog of the antiviral agent vidarabine, 9-β-D-arabinofuranosyladenine (ara-A) that is relatively resistant to deamination by adenosine deaminase. The chemical name for fludarabine phosphate is 9H-Purin-6-amine, 2-fluoro-9-(5-0-phosphono β-D-arabino-furanosyl) (2-fluoro-ara-AMP). The molecular formula of fludarabine phosphate is C10H13FN5O7P and it has a molecular weight of 365.2.
224324973|NCT05618925|DRUG|Rituximab|Rituximab is a genetically engineered chimeric murine/human monoclonal IgG1 kappa antibody directed against the CD20 antigen. Rituximab has an approximate molecular weight of 145 kD and has a binding affinity for the CD20 antigen of approximately 8.0 nM.
224324974|NCT05123807|OTHER|Cytoreductive surgery|(an operation to remove as much tumor tissue as possible) with hyperthermic intraperitoneal chemotherapy
224324975|NCT04787744|PROCEDURE|PET-directed Local Therapy using Surgery|Surgery will be used to treat metastases.
224324976|NCT04787744|RADIATION|PET-directed Local Therapy using Radiation|"Radiation therapy will be used to treat metastases.~Radiation options include:~1. Stereotactic body radiotherapy (SBRT) using 1-10 fractions~2. Conventionally fractionated radiotherapy using elective nodal radiotherapy and a simultaneous integrated boost to involved nodes~The selection of the form of metastasis-directed radiotherapy for each metastasis will be determined using shared decision-making between the treating physician and the Veteran."
224324977|NCT04787744|OTHER|Salvage Local Therapy for locally recurrent disease|For Veterans who have a local recurrence in addition to oligorecurrent metastatic lesions, they will undergo salvage local therapy using brachytherapy, SBRT, surgery, cryotherapy or HIFU. The selection of modality of salvage local therapy will be determined using shared decision-making between the treating physician and Veteran.
224324978|NCT04787744|DRUG|Goserelin, Histrelin, Leuprolide & Triptorelin|Androgen deprivation therapy (ADT) using an LHRH agonist
223682276|NCT02269748|PROCEDURE|Tunnel technique with subepithelial connective tissue|After harvesting a connective tissue graft from the palate, the graft is placed under a gingival tunnel prepared over the donor site.
223682277|NCT02269748|PROCEDURE|Coronally advanced flap|After harvesting a connective tissue graft from the palate, the graft is placed under a gingival flap which is repositioned coronally
223682278|NCT02269748|DRUG|Analgesic Therapy|Ibuprofen 600 mg TID
223682279|NCT03845374|DEVICE|Hyper-CL™ lens|Use of the Hyper-CL™
223682280|NCT04399031|DRUG|E-cigarette e-liquid|Participants will self-administer an experimenter-provided e-cigarette.
223682281|NCT00234403|DRUG|gefitinib and fulvestrant|
223682282|NCT00596856|BEHAVIORAL|Development and dissemination of priority oral health risk assessment and referral guidelines - PORRT|The RCT will compare passive distribution of guidelines by mail to an in-office intervention consisting of guideline distribution combined with educational outreach providing training in guideline use and patient mediated information provided by the risk and referral assessment tool (PORRT). The three-arm trial will consist of 25 medical practices that have never participated in IMB and 25 practices that are currently participating, both of which will receive the guidelines through the mail, and 25 practices currently participating in IMB that will receive the more intense in-office training intervention.
223682283|NCT01702831|DRUG|Busulfan|Once daily intravenous (IV) busulfan at a dose of 3.2 mg/kg or equivalent pharmacokinetics directed dose for three consecutive days (days -5 to -3), option 1 OR Once daily intravenous (IV) busulfan at a dose of 3.2mg/kg or equivalent pharmacokinetics directed dose for three consecutive days (days -6 to -4), option 2.
223682284|NCT01702831|DRUG|Melphalan|"I.V. reduced dose of melphalan (140mg/m2) on day -2, followed by an autologous stem cell transplant on day 0 (day -1 will be a rest day) - this is referred to as Option 1 dosing schema OR I.V. reduced dose of melphalan (140mg/m2) on day -3 followed by autologous stem cell transplant on day 0 (days -2 and -1 will be rest days). This is referred to as Option 2"
223682285|NCT01702831|DRUG|Lenalidomide|Oral lenalidomide 10mg per day (on all 28 days of a 28 day cycle) for the first three cycles and then escalated to 15 mg daily if clinically appropriate to do so. The lenalidomide maintenance will start on day 100 post ASCT and continue till disease progression.
223682286|NCT00884377|DRUG|Sodium stibogluconate (Pentostam)|intravenous 20 mg/kg/day for 10 days
223682287|NCT00884377|DEVICE|ThermoMed|ThermoMed heat treatment device, one treatment
223682288|NCT01887340|DRUG|Carboplatin|"\- carboplatine: Dose (mg) = AUC x (GFR + 25)~* GFR : glomérulaire filtration (ml/min)~* AUC : area under curve (mg/ml x min)"
223682289|NCT01887340|DRUG|Etoposide|100 mg/m2 D1 to D5
223682290|NCT01887340|DRUG|Cisplatin|20 mg/m2 de D1 to D5
223682291|NCT03613480|OTHER|Motivational Interviewing|Regular sessions of Motivational Interviewing at 2 weeks and then at monthly intervals for a period of 6 months
223682292|NCT02003365|DRUG|FX006 10 mg|Extended-release formulation
224324979|NCT04787744|DRUG|ADT + Nilutamide, Flutamide, & Bicalutamide|ADT adding anti-androgen therapy to an LHRH agonist
223682293|NCT02003365|DRUG|FX006 40 mg|Extended-release formulation
224324980|NCT04787744|DRUG|Degarelix & Relugolix|ADT using an LHRH Antagonist.
224324981|NCT04787744|DRUG|ADT + Docetaxel +/- prednisone|Enhanced SST using chemohormonal therapy
224324982|NCT04787744|DRUG|ADT + Abiraterone + Prednisone|Enhanced SST using Abiraterone + Prednisone
224324983|NCT04787744|DRUG|ADT + Abiraterone + Methylprednisolone|Enhanced SST using Abiraterone + Methylprednisolone
224324984|NCT04787744|DRUG|ADT + Apalutamide|Enhanced SST using ADT + Apalutamide
224324985|NCT04787744|DRUG|ADT + Enzalutamide|Enhanced SST using ADT + Enzalutamide
224324986|NCT04787744|RADIATION|Prostate-directed Radiation for De novo oligometastatic prostate cancer|"Veterans in ARM 1 will receive prostate-directed RT only and NO treatment to any nodal or distant metastatic sites.~Acceptable dose/fractionations include 55 Gy in 20 fractions and 36 Gy in 6 fractions.~Veterans in ARM 2 should receive prostate-directed local therapy using radiotherapy or radical prostatectomy in addition to PET-directed local therapy to metastases."
224324987|NCT06659744|DRUG|New use of semaglutide injection|New use of semaglutide injection dispensing claim is used as the exposure.
224324988|NCT06659744|DRUG|New initiation of sitagliptin|New initiation of sitagliptin dispensing claim is used as the reference.
224324989|NCT06984341|BIOLOGICAL|P-CD19CD20-ALLO1 Cells|P-CD19CD20-ALLO1 cells will be administered intravenously as per the schedule specified in the protocol.
224324990|NCT06984341|DRUG|Cyclophosphamide|Cyclophosphamide will be administered intravenously.
224324991|NCT06984341|DRUG|Fludarabine|Fludarabine will be administered intravenously.
224324992|NCT06984341|DRUG|Rimiducid|Rimiducid will be used as a rescue therapy in the event of the occurrence of severe or life-threatening adverse events. It will be administered intravenously.
224324993|NCT06654752|OTHER|Immediate Oral Antibiotics|Increase airway clearance and start 14 days of preselected oral antibiotics right away
223682294|NCT02003365|DRUG|TCA IR 40 mg|Immediate-release formulation
223682295|NCT05787288|BIOLOGICAL|Extracellular Vesicles from Mesenchymal Stem Cells|Umbilical cord mesenchymal stem cell-derived extracellular vesicle preparation; Specification: 5ml, with extracellular vesicle concentration of 1 × 109 particles/ml in the preparation;
223682296|NCT03293797|BEHAVIORAL|Abbreviated-Mindfulness-based Therapy|A-MBT will be delivered in group format, 120 minutes per week, for 5 consecutive weeks with 10-20 participants per group.
223682297|NCT04064788|OTHER|Consecutive Modified Constraint-Induced Movement Therapy|Consecutive mCIMT group received 6 hours per day mCIMT sessions for consecutive 10 days. Accompanied by a physiotherapist in 1 hour of the 6-hour restriction period, the family was guided within the remaining period and the activities were adapted to daily life.
223682298|NCT04064788|OTHER|Traditional physiotherapy|Traditional physiotherapy within a specific program
223682299|NCT04064788|OTHER|Intermittent Modified Constraint-Induced Movement Therapy|Intermittent mCIMT group received mCIMT session 6 hours per day for 10 days, spread over 5 weeks (two days per week). Accompanied by a physiotherapist in 1 hour of the 6-hour restriction period, the family was guided within the remaining period and the activities were adapted to daily life.
223682300|NCT03829774|DEVICE|Primary Relief v 2.0|The test product or device called Primary Relief v 2.0 will be used for the study. The study will be conducted for a period of two to three months with the treatment period of 3 - 4 days i.e single treatment (installation). The additional time taken will be to define the characteristics of the patient population and to recruit appropriate patients. Finally, there will be a data analysis and report writing period. Overall, the study is expected to 3 months. The device will be placed onto the auricle part of the ear for percutaneous electrical nerve stimulation.
223835679|NCT05837975|OTHER|Traditional Rehabilitation|Traditional rehabilitation refers to the use of conventional therapeutic methods.
223835680|NCT02196961|DRUG|Nivolumab|adjuvant treatment of completely resected Merkel cell carcinoma
224324994|NCT06654752|OTHER|Tailored Treatment: Oral Antibiotics only if Additional Treatment needed|Increase airway clearance and start preselected oral antibiotics later if symptoms get worse or do not get better according to prespecified criteria
224324995|NCT06859099|DRUG|Riliprubart Prefilled Pen (PFP)|Pharmaceutical form: Solution Route of administration: Subcutaneous injection
224324996|NCT04923958|DIAGNOSTIC_TEST|Novel mycobacterial culture techniques|We will evaluate tests intended to make culture more sensitive, faster, and have less contamination.
224324997|NCT04923958|DIAGNOSTIC_TEST|Novel sputum smear microscopy techniques|We will evaluate new staining techniques or visualization methods to increase the sensitivity of smear microscopy.
224324998|NCT04923958|DIAGNOSTIC_TEST|Sputum-based molecular assays|We will evaluate semi-automated or automated molecular assays intended for use at near point of care or point of care.
224324999|NCT04923958|DIAGNOSTIC_TEST|Tongue swab-based molecular assays|We will evaluate semi-automated or automated molecular assays intended for use at near point of care or point of care.
224325000|NCT04923958|DIAGNOSTIC_TEST|Urine LAM assays|We will evaluate urine LAM assays incorporating techniques such as analyte concentration, higher sensitivity or specificity antibodies, or enhanced visualization to improve LAM detection.
224325001|NCT04923958|DIAGNOSTIC_TEST|Blood-based host immune response assays|We will evaluate assays measuring host immune response parameters intended for use at near point of care or point of care.
224325002|NCT04923958|DIAGNOSTIC_TEST|Breath-based assays|We will evaluate assays assessing volatile organic compounds or exhaled breath condensate for near point of care of point of care detection of TB.
224325003|NCT04923958|DIAGNOSTIC_TEST|Artificial intelligence-based digital health tools|We will evaluate AI-based algorithms evaluating images (chest x-ray, ultrasound) or sounds (cough sounds, lung sounds) including an Infrasound-to-ultrasound e-stethoscope (Level 42 AI, USA).
224325004|NCT04923958|DIAGNOSTIC_TEST|Phage-based assays|We will evaluate assays using phages to lyse mycobacterial cells for detection of DNA or antigens.
224325005|NCT04923958|DIAGNOSTIC_TEST|Cartridge-based molecular assays for detecting drug resistance|We will evaluate semi-automated or automated molecular assays intended for use at near point of care or point of care.
224325006|NCT04923958|DIAGNOSTIC_TEST|Sequencing-based assays for detecting drug resistance|We will evaluate targeted and whole genome sequencing assays.
224325007|NCT06859788|DRUG|Ebselen|Glutathione peroxidase mimetic
224325008|NCT06989112|DRUG|Trastuzumab deruxtecan|Experimental therapy by intravenous infusion
224325009|NCT06989112|DRUG|Rilvegostomig|Experimental therapy by intravenous infusion
223682301|NCT03829774|DRUG|Paracetamol|A control group, receiving a standard treatment as follows: primary choice of analgesic was intravenous paracetamol, 1 gram, and if the pain relief was inadequate, diclofenac inj. If pain persisted in spite of these measures, 50 mg tramadol was administered intravenously
223682302|NCT01533129|DRUG|Testogel 50 mg transdermal gel|50mg testosterone gel implementation on every night
223682303|NCT01533129|DRUG|Testosterone 250mg injection|The testosterone 250mg ester IM injections performed in three weeks.
223682304|NCT03249389|BIOLOGICAL|Blood sample|patients will have a blood sample of 20 ml (4 x 5ml) for inclusion, the J1 of each course and at the end of treatment
224262258|NCT01030133|DEVICE|Operator Role Real TMS|"In two of the four visits, the participant will be assigned to the operator condition receiving Real TMS. The participant will be assigned a partner and both participants will participate in a numeric-combination-guessing task. Performance on this task will be directly related to the painfulness of a series of thermal stimuli that participants receive. The operator's performance will control the painfulness delivered to both participants. Each participant will play each role twice."
224262259|NCT01030133|DEVICE|Receiver Role Real TMS|"In two of the four visits, the participant will be assigned to the receiver condition receiving Real TMS. The participant will be assigned a partner and both participants will participate in a numeric-combination-guessing task. Performance on this task will be directly related to the painfulness of a series of thermal stimuli that participants receive. The receiver's performance on the task will be unrelated to his/her stimulus painfulness. Each participant will play each role twice."
224262260|NCT01030133|DEVICE|Operator Role Sham TMS|"In two of the four visits, the participant will be assigned to the operator condition receiving Sham TMS. The participant will be assigned a partner and both participants will participate in a numeric-combination-guessing task. Performance on this task will be directly related to the painfulness of a series of thermal stimuli that participants receive. The operator's performance will control the painfulness delivered to both participants. Each participant will play each role twice."
224262261|NCT01030133|DEVICE|Receiver Role Sham TMS|"In two of the four visits, the participant will be assigned to the receiver condition receiving Sham TMS. The participant will be assigned a partner and both participants will participate in a numeric-combination-guessing task. Performance on this task will be directly related to the painfulness of a series of thermal stimuli that participants receive. The receiver's performance on the task will be unrelated to his/her stimulus painfulness. Each participant will play each role twice."
224262262|NCT01030133|DEVICE|All Participants Operator Role|All participants in Operator Role (Receiving real or sham TMS)
224262263|NCT07068243|DRUG|1.0% lidocaine with epinephrine (1:100,000)|"The block will be performed by advancing the needle into the posterior rectus sheath compartment, with the local anesthetic deposited posterior to the rectus abdominis muscle and anterior to the posterior rectus sheath.~Drug: 20 mL injection of 1.0% lidocaine with epinephrine (1:100,000) on each side (40mL total/subject)"
224262264|NCT07068568|DRUG|Sonidegib|Sonidegib was administered orally at a dose of 200 mg once daily as per approved guidelines. The intervention was applied in a real-world clinical setting to patients with histologically confirmed, locally advanced periocular basal cell carcinoma (laBCC) deemed unsuitable for surgical resection or radiotherapy due to the tumor's extent or proximity to critical ocular structures. A flexible, individualized dose modulation strategy was implemented to manage adverse effects and optimize patient adherence. Modifications included temporary treatment interruptions or reduced dosing frequency, tailored to each patient's clinical status and tolerance. The goal of the intervention was to achieve local tumor control while preserving ocular structures, visual function, and cosmetic appearance. All patients received regular multidisciplinary follow-up, including ophthalmologic and dermatologic assessments.
224262265|NCT07069023|OTHER|breathing exercise group|Oncology patients with nausea, vomiting and fatigue were given breathing exercises throughout the treatment.
224262266|NCT07069023|OTHER|reiki group|Oncology patients with nausea, vomiting and fatigue received reiki throughout the treatment.
224262267|NCT07068334|COMBINATION_PRODUCT|Traditional Physical Therapy|Short foot exercises. Towel-curl exercise. Heel raise exercise. Calf stretch.
224262268|NCT07068334|COMBINATION_PRODUCT|Traditional Physical Therapy + FAKTR|"Short foot exercises. Towel-curl exercise. Heel raise exercise. Calf stretch.~FAKTR Functional and Kinematic Treatment with Rehabilitation) technique:~The FAKTR (Functional and Kinematic Treatment with Rehabilitation) technique applied is a modified IASTM technique in the pain-provocative position (incorporating static positions, motions, functional movements, resistance, and proprioceptive positions)."
224262269|NCT07067645|PROCEDURE|Horizontal Vaginal Cuff Closure Technique|In this arm, patients undergoing vaginal hysterectomy with lateral suspension will receive horizontal closure of the vaginal cuff. After removal of the uterus, the vaginal cuff is closed in a transverse (right-to-left) direction using standard absorbable sutures. The technique aims to maintain or optimize the anatomical axis and preserve vaginal length in the horizontal plane. The entire procedure is performed under general or regional anesthesia by an experienced surgical team.
224262270|NCT07067645|PROCEDURE|Vertical Vaginal Cuff Closure Technique|In this arm, patients undergoing vaginal hysterectomy with lateral suspension will receive vertical closure of the vaginal cuff. After the uterus is removed, the vaginal cuff is closed in a cranio-caudal (top-to-bottom) orientation using absorbable sutures. This technique is hypothesized to better support apical structures and reduce tissue tension. Procedures are performed under general or regional anesthesia with standardized operative technique.
224262271|NCT01944761|BEHAVIORAL|Exercise Program|"Designed to improve cardio-respiratory fitness, the exercise program will be conducted for 12 weeks at a frequency of 3-4 sessions per week. Each exercise session will be conducted after school for a total duration of 90 minutes (group sessions) or 30 minutes (home-based sessions). Group session activities will include i) warm-up (i.e. walk/jog, games) \[10 mins\], ii) aerobic training/fitness games \[30 mins\], iii) organized sports \[30 mins\], iv) cool down (i.e. stretching, low intensity games) \[10 mins\] and v) snack and reward (15 mins).~Participants in the Group setting had three 90-minute group sessions per week. Participants in the Combined setting had two 90-minute group sessions and two 30-minute individual home-based sessions per week."
224262272|NCT01654458|BEHAVIORAL|GyneGals Support Group|12-week online (i.e. Internet-based), professionally-facilitated support group
224325010|NCT06989112|DRUG|Pembrolizumab|Immunotherapy by intravenous infusion
224325011|NCT06989112|DRUG|Carboplatin|Standard of Care (SoC) chemotherapy by intravenous infusion
223682305|NCT03490162|DRUG|DM1157|DM1157 is a novel anti-malarial drug that is derived from chloroquine. DM1157 maintains the efficacy of chloroquine and has molecular features that overcome resistance to chloroquine.
223682306|NCT03490162|OTHER|Placebo|Placebo
223682307|NCT06458426|DEVICE|shock-absorbing prosthesis|the intervention will test the difference between rigid and shock-absorbing pylons, while the same prosthetic foot is applied in each condition.
223682308|NCT03729687|COMBINATION_PRODUCT|radiotherapy, capecitabine, oxaliplatin|5x5 Gy radiotherapy in 1 week, 4 cycles of CAPOX (capecitabine 1000 mg/m2 x2 d 1-14, oxaliplatin 130 mg/m2 d 1 every third week), surgery
223682309|NCT01459848|BEHAVIORAL|block play|30 minutes of block play
223682310|NCT01459848|BEHAVIORAL|baby dvd|30 minutes of dvd viewing
223682311|NCT00057122|DRUG|Isoniazid|300mg
223682312|NCT00057122|DRUG|Rifapentine|Rifapentine 900 mg
223682313|NCT00057122|DRUG|Rifampin|Rifampin 600 mg
223682314|NCT06281301|OTHER|education tool|Participants will have 15 minutes to review the single sided card and then the survey will be administered. Participants will then be surveyed again within 1-2 weeks after initial completion to assess how well information was retained.
223682315|NCT06281301|OTHER|no additional information|Survey will be administered without reviewing the single sided card
223682316|NCT05275660|DRUG|HFB30132A|Participants randomized to HFB30132A will be administered dose 1 in cohort 1. Participants in Cohort 2 will receive HFB30132A dose 2.
223682317|NCT05275660|OTHER|Placebo|Participants randomized to placebo will receive the same volume of solution as participants on active treatment.
223682318|NCT03735173|PROCEDURE|ReUnion TSA, pegged design|ReUnion total shoulder arthroplasty system, pegged design
223682319|NCT03735173|PROCEDURE|ReUnion TSA, keeled design|ReUnion total shoulder arthroplasty system, keeled design
223682320|NCT00622739|DRUG|Ziprasidone|Subjects will be treated openly with Ziprasidone for 6 weeks. Dose will be titrated from 20 mg to a maximum of 160 mg. Arm 1 will have the dose of Ziprasidone titrated at a rate of 20 mg every 2 days, reaching the maximum dose in 14 days. Final dose of Ziprasidone will be determined by symptoms reduction and the presence or absence of side effects.
223682321|NCT00622739|DRUG|Ziprasidone|Subjects will be treated openly with Ziprasidone for 6 weeks. Dose will be titrated from 20mg to a maximum of 160mg. Arm 2 will have the dose of Ziprasidone titrated at a rate of 20mg every 3-4 days, reaching the maximum dose in 25 days. Final dose of Ziprasidone will be determined by symptoms reduction and the presence or absence of side effects.
223682322|NCT04985188|DIAGNOSTIC_TEST|Quantitative ultrasound (QUS) technique|Measurement of quantitative ultrasound parameter using clinical US machine (RS85)
223682323|NCT00321724|DRUG|cediranib maleate|Given orally
223682324|NCT00321724|OTHER|laboratory biomarker analysis|Correlative studies
223682325|NCT05969327|DRUG|Vitamin D|oral supplementation of two different doses
223682326|NCT05637658|OTHER|Exercise|aerobic exercise
223682327|NCT03387150|BIOLOGICAL|VRC07-523LS|Administered by intravenous (IV) infusion, subcutaneous (SC) injection, or intramuscular (IM) injection, depending on which group participants are in
223682328|NCT03387150|BIOLOGICAL|Placebo|Sodium Chloride for Injection USP, 0.9%; administered by IM injection
223682329|NCT01158508|PROCEDURE|Remote ischemic preconditioning|Transient lower limb ischemia will be induced by inflation of a blood pressure cuff on the thigh. Four five minute cycles of ischemia will be performed, each followed by five minutes of reperfusion with the cuff down. This procedure will be performed in four rounds, typically on post-hemorrhage days 2, 3, 6 and 9.
223682330|NCT02680899|BEHAVIORAL|Curricular Intervention|The intervention is a novel grades 7 and 8 InSciEd Out curriculum in mental health and addiction called My Mind, My Body.
223682331|NCT04522531|OTHER|Open cinetic chain shoulder exercise on unstabil ground|Open cinetic chain shoulder exercise will be performed on BOSU which provides an unstabil ground. This exercises will be include PNF (flexion-adduction-external rotation pattern), PNF (flexion-abduction-external rotation pattern), scapular plan abduction, external rotation while keeping shoulder in 45 degree abduction. The weight which used during exercise planned according to individuals body weight: 0-59 kg: 3 kg; 60-69 kg: 4 kg; 70-85 kg: 5Kg. Exercises will be carried out in 3 phases consisting of concantric, isometric and eccentric phases. Each phase will be lasted 3 seconds. The time will be checked by using a metronome.
223682332|NCT02937272|DRUG|LY3200882|Administered orally
223682333|NCT02937272|DRUG|LY3300054|Administered intravenously
223682334|NCT02937272|DRUG|Gemcitabine|Administered intravenously
223682335|NCT02937272|DRUG|nab-Paclitaxel|Administered intravenously
223682336|NCT02937272|DRUG|Cisplatin|Administered intravenously
223682337|NCT02937272|RADIATION|Intensity Modulated Radiotherapy|
223682338|NCT05039853|BEHAVIORAL|Brief cognitive task-based intervention|Memory reminder procedure, playing the computer game, Tetris , on a smart-device using mental rotation +/- Boosters
223682339|NCT05039853|BEHAVIORAL|Placebo activity|Listening to a pod-cast on a smart-device for approximately 15 minutes.
223682340|NCT00171678|DRUG|Diclofenac Topical Sodium Gel 1%|
223682341|NCT06331845|DRUG|Gemcitabine|1000 mg/m2 on Days 1 and 8
223682342|NCT06331845|DRUG|Cisplatin|a total of 80-100 mg/m2 for d1-3
223682343|NCT06331845|DRUG|Paclitaxel protein-bound|260 mg/m2 on Day 1
223682344|NCT06331845|DRUG|Capecitabine|a dose of 1-1.25 g/m2 twice daily in in 2 weeks for one cycle
223682345|NCT06331845|DRUG|Tislelizumab|200 mg on Day 1
223682346|NCT00435500|DRUG|Fluoride varnish|
223682347|NCT03901703|OTHER|Physiotherapy and Rehabilitation|The children in each group will receive 6 weeks of functional strengthening exercises targeting each muscle group according to the arm they are included in.
223682348|NCT02637128|DRUG|artemether-lumefantrine (AL)|Dispersible formulation of artemether-lumefantrine (Coartem-D™; 20mg artemether/120mg lumefantrine per tablet, Novartis, Switzerland) administered twice a day for 3 days according to manufacturer recommended dosing for weight
223682349|NCT02637128|DRUG|artesunate-amodiaquine (ASAQ)|Co-formulated artesunate-amodiaquine (25mg artesunate/67.5mg amodiaquine and 50mg artesunate/135mg amodiaquine tablets) administered once a day for 3 days, according to manufacturer recommended dosing for weight
223682350|NCT00334074|DRUG|Clofarabine and Cytarabine|Phase II Trial of Clofarabine and Cytarabine in Relapsed Standard-Risk AML and Untreated High-Risk MDS in Adult Patients, and Untreated AML in selected Elderly Patients at high risk of anthracycline toxicity
224325012|NCT06989112|DRUG|Paclitaxel|Standard of Care (SoC) chemotherapy by intravenous infusion
224325013|NCT06989112|DRUG|Docetaxel|Standard of Care (SoC) chemotherapy by intravenous infusion
224325014|NCT06989437|DRUG|ponsegromab|Double-Blind ponsegromab Treatment
224325015|NCT06989437|DRUG|placebo|Double-Blind placebo Treatment
224325016|NCT06989593|BEHAVIORAL|Narrative Medicine Journaling Intervention|Participants will complete the GAD-7 anxiety assessment at baseline. They will then receive a physical journal containing 5 structured, therapeutic writing prompts designed to help process emotions related to their child's diagnosis. Prompts focus on processing experiences with diagnosis, addressing uncertainty, coping with stigma, and developing resilience. Parents will be instructed to complete the 5 journal entries, spending 15-20 minutes on each writing session at least once per week. Following completion of the journaling intervention, participants will complete a follow-up GAD-7 assessment and take part in a 30-45 minute qualitative interview to further assess perceived changes in anxiety, stress, and coping strategies, and to gather feedback on potential group-based writing programs.
224325017|NCT03796884|DRUG|Linaclotide|Given PO
224325018|NCT03796884|OTHER|Placebo|Given PO
224325019|NCT05785767|DRUG|fianlimab|Every three weeks (Q3W) as intravenous (IV) co-infusion
224325020|NCT05785767|DRUG|cemiplimab|Q3W as IV co-infusion
224325021|NCT05785767|DRUG|Placebo|Q3W as IV co-infusion
224325022|NCT01638546|OTHER|Laboratory Biomarker Analysis|Correlative studies
224325023|NCT01638546|OTHER|Placebo Administration|Given PO
224325024|NCT01638546|DRUG|Temozolomide|Given PO
224325025|NCT01638546|DRUG|Veliparib|Given PO
224325026|NCT02844751|BIOLOGICAL|[StroMed + platelet rich plasma (PRP)]|\[Day 0\] - Because no enzymes or drugs are added with this mechanical process, the resulting cell concentrate still contains the extra-cellular matrix. In addition, the cells have not been altered by manipulation with enzymes or culturing. This autologous, cell concentrate is of minimal risk to the patient with no artificial ingredients added. Also Platelet Rich Plasma processed by the RegenLab (RegenKit BCT-3) PRP product and by direct injection to the affected joint.
223682351|NCT03620825|OTHER|Dehydration by sauna exposure|Participants repeatedly undergo sauna exposures until they loose 3% of their body weight.
223774525|NCT07039344|OTHER|Pedagogical (LWPPR) method of Palliative care Training (Group B)|Group B will receive training through the 5-steps pedagogy method including: the 1st step (learn), in which didactic lectures will be given to the students leading to the 2nd step (video watch), a 30 minutes video on Palliative care. The students first see the video in the class on multimedia with explanation and then share to the students in what's up group for frequent watching as per need. In the 3rd step (practice), students practiced their skills on a low fidelity simulator under instructor supervision on a scheduled day of the week in the nursing skill lab for 6 weeks. The errors will be corrected on the spot. A total of 11 groups will make with a ratio of 5 in each group. In the 4th step (perform), students perform their skill in real-life situations through the clinical rotation under supervision. Finally, the 5th step (Retain) will be established through self-directed learning in which an additional one-hour skill session / week will be provided to the students.
223774526|NCT06717438|DRUG|BPN14770|Capsules for oral administration
224325027|NCT02844751|BIOLOGICAL|[PRP] platelet rich plasma|Additional treatments with Platelet Rich Plasma processed by the RegenLab (RegenKit BCT-3) PRP product and by direct injection to the affected joint. Days 7,14 and 30
224325028|NCT02844751|BIOLOGICAL|[PRP] platelet rich plasma|Additional treatments with Platelet Rich Plasma processed by the RegenLab (RegenKit BCT-3) PRP product and by direct injection to the affected joint. Days 30 and 60
224325029|NCT06992115|BEHAVIORAL|Mediterranean-DASH Intervention for Neurodegenerative Delay (MIND) Diet|A dietary pattern which promotes the intake of olive oil, fish, leafy greens \& other vegetables, fruits, whole grains, and legumes, and discourages processed foods, red meat, and sugar.
224325030|NCT06992115|BEHAVIORAL|Small Group|Education and social support on topics related to multiple sclerosis such as disease-modifying therapies and MRI in MS.
224325031|NCT03786081|DRUG|Tisotumab Vedotin|Given into the vein (IV)
224325032|NCT03786081|DRUG|Bevacizumab|Given via IV
224325033|NCT03786081|DRUG|Pembrolizumab|Given via IV
224325034|NCT03786081|DRUG|Carboplatin|Given via IV
224325035|NCT06174987|DRUG|T-DXd|T-DXd (DS8201a) will be administered as an intravenous (IV) infusion, on Day 1 of each 21-day cycle according to the dosage regimens
224325036|NCT06862622|BEHAVIORAL|Computer-based visuomotor sequence learning and interference|The behavioral sequence learning and interference paradigm allows the experimental manipulation of sequence memory after long-term consolidation achieved through individualized longitudinal practice and serves the extraction of the primary behavioral outcome. The learning task requires participants to respond with keypresses on a standard computer keyboard of visual targets. Participants will implicitly (without being made aware) learn sequential regularities provided through the recurring order of cued keys contrasted with random keys. Participants will practice the learning task remotely over consecutive days until a stable performance plateau is reached. During this phase, data will be collected online, and behavioral change will be monitored in real time. Then participants will undergo the behavioral interference intervention, in which the initially learned sequence memory will be perturbed through (implicit) exposure to new sequential information (i.e., interference).
224325037|NCT06668571|DRUG|Ketamine|The subjects will receive 1:1 single IV racemic ketamine (dosed @0.5 mg/kg actual body weight) (n=15) 40-min infusion in an MRI scanner, followed by an optional open-label ketamine infusion (available to everyone) 1-7 days after the initial treatment
224325038|NCT06668571|DRUG|Normal Saline|The subjects will receive 1:1 single IV normal saline/placebo (n=15) 40-min infusion in an MRI scanner, followed by an optional open-label ketamine infusion (available to everyone) 1-7 days after the initial treatment
223682352|NCT03620825|DRUG|Indomethacin|Participants take indomethacin in tablet form the evening before and the morning of the visit to induce intestinal permeability
223682353|NCT02448680|BIOLOGICAL|Coagulation FVIIa (Recombinant)|A cross over design to assess the efficacy of 2 separate dose regimens (75 µg/kg and 225 µg/kg) of Coagulation Factor VIIa (Recombinant) for the treatment of bleeding episodes in hemophilia A or B patients with inhibitors to Factor VIII or Factor IX
223774527|NCT06717438|DRUG|Placebo|Capsules for oral administration
223774528|NCT07038239|DIAGNOSTIC_TEST|Skin biopsy|under the arm using a 3 mm punch, with local anaesthesia, in the investigating centres.
224325039|NCT06914128|DRUG|BAY 3713372|Daily oral administration
223682354|NCT04676555|DRUG|Ocrelizumab|There is no treatment allocation. Patients administered Ocrelizumab by prescription that have started before inclusion of the patient into the study will be enrolled.
223682355|NCT04676555|DRUG|Ofatumumab|There is no treatment allocation. Patients administered Ofatumumab by prescription that have started before inclusion of the patient into the study will be enrolled.
223682356|NCT05171829|OTHER|Track U|Track U diary
223682357|NCT02779387|DRUG|Goserelin Acetate|
223682358|NCT03771547|DIAGNOSTIC_TEST|ERCP|
223682359|NCT01857310|DIETARY_SUPPLEMENT|5 mg folic acid and 30 mg elemental zinc|
223682360|NCT01857310|DRUG|Placebo Comparator: Placebo|
223774529|NCT07038239|DIAGNOSTIC_TEST|Blood sample|"3 classical 4ml tubes samples per patients, using the routine blood sampling technique, in the investigating centres.~For children, blood sampling volume will be adapted to the patient's weight according to L.1121-1 of the French public health code."
223774530|NCT07043023|DRUG|Lidocaine (drug)|Lidocaine 2%, bolus of 0.075 ml/kg real weight (i.e. 1.5 mg/kg) then IVSE at 0.05 ml/kg/h (i.e. 1 mg/kg/h) for 48 hours
223774531|NCT07043023|DRUG|Placebo|Placebo (sodium chloride 0.9%), bolus of 0.075 ml/kg of real weight then IVSE at 0.05 ml/kg/h for 48h
223774532|NCT06721949|DRUG|Taurine|Taurine is a naturally occurring amino sulfonic acid commonly found in the body. It is marketed as a natural health product/supplement and plays an important role in the body.
223774533|NCT06721949|DRUG|Placebo|The placebo capsule is visually identical to the taurine capsule.
224262273|NCT06938295|DIAGNOSTIC_TEST|Comparative Use of High-End and Mid-End Intestinal Ultrasound Devices for IBD Disease activity assessment|This study compares two intestinal ultrasound (IUS) devices-a high-end machine (Samsung RS85) and a mid-end machine (Siemens ACUSON S2000)-for assessing ileocolonic inflammation in IBD patients. The high-end device offers advanced imaging features, including high-resolution, speckle reduction, and extended field of view, allowing for detailed visualization of the bowel wall and vascularity. The mid-end device, while more basic, provides essential IUS functions for examining bowel wall thickness, structure, and inflammation markers. Both devices are used in a single clinical session, with results compared against tandem ileo-colonoscopy as the reference standard. This unique dual approach enables evaluation of the diagnostic performance of each device type. If comparable, the mid-end device may offer a cost-effective solution, increasing access to routine IUS in various healthcare settings, especially where high-end technology is limited.
224262274|NCT00477594|DRUG|mipomersen sodium|200 mg/ml, in 1 ml solution for subcutaneous injection.
224262275|NCT06945042|OTHER|Arm A|The intervention will consist of systematic financial navigation with consistent screening and intervention on any financial related issues. All patients randomized to the financial navigational group will be contacted by clinical trial staff assigned to the study to screen for financial needs. Based on the results of this assessment, the clinical trials staff will refer to the appropriate services for personalized recommendations and assistance provided by Atrium Health personnel including financial navigators, nurse navigators. All the resources provided to the patient, including counseling, will be free of charge. Assessment will be performed once per month for 6 months.
224262276|NCT06945042|OTHER|Arm B|All patients randomized to the Standard of Care arm will have access to the financial distress resources (Financial Navigation and Nurse Navigation) as per current clinical policy which is per patient or clinician request. Utilization of these resources will be tracked to assess and describe the per-protocol population. All the resources provided to the patient, including counseling, will be free of charge as per institutional policy.
224262277|NCT06224803|DIETARY_SUPPLEMENT|Compound plant extracts|Total supplement including bitter melon (Momordica charantia) fruit extract, celery (Apium graveolens) seed extract, baker's yeast (Saccharomyces cerevisiae) cell wall extract, acerola (Malpighia emarginata) fruit extract, grape (Vitis vinifera) seed extract, green tea leaf extract, and hydrolyzed soy protein powder.
224262278|NCT06224803|DIETARY_SUPPLEMENT|Indigestible dextrin|Indigestible dextrin as placebo intervention
224262279|NCT06495138|DEVICE|StableEyes|"Gaze stabilization exercises using the StableEyes device for the incremental vestibular-ocular reflex adaptation approach.~The StableEyes device consists of a lightweight head unit with a 9-dimension inertial measurement unit and electrostatic micro-mirror that dynamically controls the 2-dimensional position of a 1-milliwatt red laser projected on a wall 1 meter in front of the subject. StableEyes is controlled via a lightweight control unit with a touchscreen interface tethered by cable to the head unit."
224262280|NCT03191305|DRUG|Coumadin|Patients in Coumadin Group would be administered Coumadin with overlap of heparin for first two days followed by Coumadin given orally ,dose being adjusted according to INR .The INR range would be between 2-3.it would be given once a day. The total duration Of coumadin would be six months.
224262281|NCT03191305|DRUG|Rivoroxaban|The dose protocol would be similar to the one used in Deep Venous Thrombosis. 15 mg PO q12hr for 21 days with food, Then 20 mg PO qDay for 6 months.
224262282|NCT01802645|DRUG|Cetuximab|
224262283|NCT01802645|DRUG|Bevacizumab|
224262284|NCT01802645|DRUG|Irinotecan|
224262285|NCT01802645|DRUG|Oxaliplatin|
224262286|NCT01802645|DRUG|5-FU|
224262287|NCT01802645|DRUG|Folinic Acid|
224262288|NCT03597724|OTHER|Questionnaire composed of 13 choice questions.|In this Discrete Choice Experiment (DCE), patients will be asked to choose which one of two hypothetical patients (Patient A and Patient B) suffering from sarcopenia with different levels of outcomes deserves the most the treatment. After completion of the choice tasks, respondents will be asked how difficult they found the choice tasks on a seven-point scale and to questions on their socio-economic and disease characteristics.
224262289|NCT01705483|DRUG|ASP9853|oral
224262290|NCT01705483|DRUG|Docetaxel|intravenous (IV)
224262291|NCT01705483|DRUG|Paclitaxel|Taxol
224262292|NCT06067919|OTHER|decision tree for the choice of intraoperative antibiotic prophylaxis|Presentation of a decision tree to anaesthetists to guide the choice of intraoperative antibiotic prophylaxis
224262293|NCT02256722|DRUG|KUC 7483 CL|
224262294|NCT02256722|DRUG|Bisoprolol|
224262295|NCT02256722|DRUG|Propranolol|
224262296|NCT02256722|DRUG|Acipimox|
224262297|NCT02256722|DRUG|Salmeterol|
224325040|NCT06661915|PROCEDURE|Biospecimen Collection|Undergo buccal swab and blood sample collection
224325041|NCT06661915|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration and biopsy
224325042|NCT06661915|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow aspiration and biopsy
224325043|NCT06661915|DRUG|Decitabine and Cedazuridine|Given PO
224325044|NCT06661915|DRUG|Iadademstat|Given PO
224325045|NCT06361940|DRUG|Aromatase inhibitors or tamoxifen|Choice of endocrine therapy (aromatase inhibitors or tamoxifen) would be decided by medical oncologist, following a review of the patient's medical history and menstrual status.
224325046|NCT06993610|BIOLOGICAL|Tibulizumab Dose A|Anti BAFF/IL-17 antibody. ZB-106
224325047|NCT06993610|BIOLOGICAL|Tibulizumab Dose B|Anti BAFF/IL-17 antibody. ZB-106
224325048|NCT06993610|OTHER|Placebo|ZB-106 Placebo
224325049|NCT06994338|DRUG|Tirzepatide|Tirzepatide injections (2.5mg, 5.0mg)
223682361|NCT03665857|BEHAVIORAL|a multicomponent intervention|"1. School-level policies Students will not be allowed to drink sugar-sweetened beverage or eat unhealthy snacks in schools and drinking water will be advocated.~2. Monitoring of students' weight and height Students will be monitored their weight and height monthly.~3. Promotion of physical activity Students will be required to perform at least 60 minutes of moderate to vigorous physical activity each day in school and increase their physical activity outside school (reaching 30 minutes per weekday and one hour per weekend day).~4. Health education activities Health education activities will be provided for students (10 sessions, 40 minutes per session, 2-3 weeks once), parents and school teachers.~5. The mobile application The mobile application will disseminate health education knowledge among students, parents and teachers, monitor and provide feedback of students' BMI status and diet and physical activity behaviors."
223682362|NCT02910375|OTHER|Cohort A|Venous sampling (n=13) will be performed in the hospital at D0 (prior to first golimumab injection), D3, D7, D14 (prior to second injection), D28, M0D0 (right before injection at week 6), M0D3, M0D7, M1D0 (4 weeks after M0D0, week 10), M1D3, M1D7, M2D0 (8 weeks after M0D0, week 14), M3D0 (12 weeks after M0D0, week 18) Dried blood spot sampling (n=39) will be performed at D0 (prior to first golimumab injection), D1, D2, D3, D4, D5, D6, D7, D10, D14, D15, D16, D17, D18, D19, D20, D21, D28, D35, M0D0 (right before injection at week 6), M0D3, M0D7, M1D0 (4 weeks after M0D0, week 10), M1D1, M1D3, M1D5, M1D7, M1D9, M1D14, M1D21, M2D0 (8 weeks after M0D0, rig week 14), M2D1, M2D3, M2D5, M2D7, M2D9, M2D14, M2D21, M3D0 (12 weeks after M0D0, week 18)
223682363|NCT02910375|OTHER|Cohort B|Venous sampling (n=8) will be performed at M0D0 (right before new golimumab injection), M0D3, M0D7, M1D0 (4 weeks after M0D0, right before next injection), M1D3, M1D7, M2D0 (8 weeks after M0D0, right before next injection), M3D0 (12 weeks after M0D0, right before next injection) Dried blood spot sampling (n=20) will be performed at M0D0 (right before new golimumab injection), M0D3, M0D7, M1D0 (4 weeks after M0D0, right before next injection), M1D1, M1D3, M1D5, M1D7, M1D9, M1D14, M1D21, M2D0 (8 weeks after M0D0, right before next injection), M2D1, M2D3, M2D5, M2D7, M2D9, M2D14, M2D21, M3D0 (12 weeks after M0D0, right before next injection)
223682364|NCT01041378|DRUG|dexamethasone|Intravenous dexamethasone (0.5mg/kg) before incision
223774534|NCT02802280|OTHER|Cardiovascular risk in HCV patients|"Cardiovascular risk assessement (through Flow-mediated vasodilatation FMV, measurement of endothelial function biomarkers, carotid ultrasound, etc.)~This is a prospective study. The only intervention planned will consist of performing different tests that define the individual cardiovascular risk. These tests will be carried out on a single group cohort at different times.~Notwithstanding, the investigators will record the exposure to DAA to assess any change in CVR.~Anti-HCV regimens will be used according to clinical practice as indicated into the current guidelines (1)~(1)European Association for Study of Liver. EASL Recommendations on Treatment of Hepatitis C 2015. J Hepatol. 2015 Jul;63(1):199-236. doi: 10.1016/j.jhep.2015.03.025. Epub 2015 Apr 21. PubMed PMID: 25911336."
223682365|NCT05606653|OTHER|Measurement of critical airway closing pressure|Measurement of critical airway closing pressure
224262298|NCT01195038|BIOLOGICAL|Recombinant Influenza HA Vaccine (H5N1)|one booster dose of 45 μg rHA derived from A/Indonesia/05/2005 strain
224325050|NCT06994338|DRUG|Placebo injections|Placebo injections
224325051|NCT06997588|DRUG|Alpelisib|"Oral Film-Coated Tablet (FCT):~* Group 1: 250 mg once daily~* Group 2, 6 to \<18 years: 125 mg once daily (starting dose)~Granules:~• Group 2, 2 to \<6 years: 50 mg once daily (starting dose)"
224325052|NCT06995872|DRUG|rhIL-15|rhIL-15 will be given at a dose of 0.13-2 mcg/kg/day (based on dose level) as a continuous IV infusion for 5 days each cycle.
224325053|NCT06995872|DRUG|Dinituximab|Dinituximab will be given at a dose of 17.5 mg/m\^2/dose by IV on days 2-5 of each cycle.
224325054|NCT06995872|DRUG|Temozolomide|Temozolomide will be given orally (PO) at a dose based on weight on days 1-5 of each cycle beginning with cycle 2.
223682366|NCT05606653|OTHER|Respiratory function tests|CO2 response test
224262299|NCT05383807|BEHAVIORAL|Warna-Warni Waktu|Six videos and eighteen reinforcer activities
224262300|NCT04053153|DEVICE|Exercise equipment (a musical instrument that is based on the Medical Didgeridoo)|exercise equipment (a musical instrument that is based on the Medical Didgeridoo)
224262301|NCT02468518|DRUG|Vitamin E capsule|Capsules will be distributed to each participant free of cost
224262302|NCT04830462|DRUG|Rifampicin 300 Mg Oral Capsule|Rifampicin 600 mg orally once daily for 4 months
224262303|NCT04830462|DRUG|Isoniazid 300 Mg ORAL TABLET|Isoniazid 300 mg daily for 6 months
224262304|NCT05471596|DEVICE|NeuWave Microwave Ablation System|The NEUWAVE System supports target ablation or linear coagulation in surgical liver resection procedures. The System offers a versatile probe portfolio, multi-probe synchrony and CO2 cooling to help control the shape, size and burn pattern of your ablations.
224262305|NCT04247945|BIOLOGICAL|Cotransplant with MSCs|Co-transplantation of MSCs during allogeneic HSCT
224262306|NCT01524185|BEHAVIORAL|FamilyLive|Multi-therapist family mental health treatment for families with a history of intergenerational neglect and trauma
224262307|NCT01524185|BEHAVIORAL|Standard Mental Health Treatment|Standard trauma-informed mental health treatment
224262308|NCT02875392|OTHER|275mg Oligo Fucoidan + 275mg HS Fucoxanthin|Fucoidan is a water-soluble dietary fiber which is extracted from brown seaweed. Slimy surface of brown seaweed has unique ingredients and different kind of brown seaweed has slightly different effectiveness.The subject of this study focus on assessing the impact on the metabolism of fatty liver and liver fibrosis after taking oral FucoHiQ capsules.
224262309|NCT02875392|OTHER|placebo pills|taking placebo pills as if patients are under treatment.
224262310|NCT03133260|DIAGNOSTIC_TEST|Troponin|Troponin will be measured before surgery and postoperative at days 1,2 and 3.
223774535|NCT07048392|BEHAVIORAL|Retrieval-based word learning: Repeated Spaced Retrieval condition|"Each child will learn 8 novel nouns referring to unfamiliar plants and animals (nepp) and a related meaning (a nepp likes rain) in the context of a story book. Four of the nouns will be will be learned using repeated spaced retrieval. In this condition, they will initially hear the information and be asked to retrieve it. Thereafter, they will be asked to retrieve it after hearing 3 intervening words. After each retrieval attempt, they will hear the target information again. This procedure will occur on two consecutive days."
223682367|NCT05606653|OTHER|pharyngometry|measure of the pharyngometry
223682368|NCT04761627|DRUG|Ustekinumab|Participants will receive subcutaneous (SC) injection of ustekinumab.
223682369|NCT04761627|DRUG|ABP 654|Participants will receive SC injection of ABP 654.
223682370|NCT03342300|DRUG|pegylated liposomal doxorubicin|Several efforts have been made to improve the toxicity profile of conventional anthracyclines, including the use of liposomal encapsulation technology,such as pegylated liposomal doxorubicin.
223682371|NCT03342300|DRUG|pirarubicin|Another effort has been made to improve the toxicity profile of conventional anthracyclines is the development of novel anthracycline analogs,such as pirarubicin.
223682372|NCT03588247|PROCEDURE|transcatheter aortic valve implantation|Patients with severe aortic valve stenosis undergo transcatheter aortic valve implantation
223682373|NCT03551080|BIOLOGICAL|Lipopolysaccharide|Endotoxin at 0.8 ng/kg of body weight administered intravenously (Escherichia Coli, Lot nr G3E0609, United States Pharmacopeia Rockville, MD)
223774536|NCT07048392|BEHAVIORAL|Retrieval-based word learning: Repeated Study condition|"Each child will learn 8 novel nouns referring to unfamiliar plants and animals (nepp) and a related meaning (a nepp likes rain) in the context of a story book. Four of the nouns will be will be learned using repeated study trials only (with no retrieval practice). In this condition, they will simply hear the information (word \& meaning) as part of the story. This procedure will occur on two consecutive days."
223774537|NCT06732375|BEHAVIORAL|Mindset Moments|"MM™ includes: 1) CBT; 2) resilience training; 3) mindfulness-based stress reduction; 4) peer support; and 5) family conversations delivered in small virtual groups, with a mentor who facilitates resilience-building conversations prompted from Skill of the Week lessons."
224325055|NCT06995872|DRUG|Irinotecan Hydrochloride|Irinotecan will be given at a dose of 50 mg/m\^2/dose by IV on days 1-5 of each cycle beginning with cycle 2.
224325056|NCT06997497|DRUG|MK-1084|Oral tablet
224325057|NCT06997497|DRUG|Oxaliplatin|Per label
224325058|NCT06997497|DRUG|Leucovorin/levofolinate calcium|Per label
224325059|NCT06997497|DRUG|5-Fluorouracil|Per label
224325060|NCT06997497|BIOLOGICAL|Cetuximab|Per label
224325061|NCT06997497|DRUG|Bevacizumab|Per label
224325062|NCT05903131|BEHAVIORAL|Telemedicine behavioral weight intervention|Weekly telephone calls during the first month, biweekly during the next 5 months, and then monthly for the last 7 months (12 months total). Each telephone session will be 30 minutes long.
224325063|NCT05903131|DRUG|Progestin|Released via the levonorgestrel-releasing IUD.
224325064|NCT05903131|BEHAVIORAL|Enhanced usual care|1-3 page handouts
224325065|NCT05903131|DRUG|Levonorgestrel-releasing IUD.|Standard of care
224325066|NCT04166409|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
224325067|NCT04166409|DRUG|Carboplatin|Given IV
224325068|NCT04166409|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
224325069|NCT04166409|OTHER|Questionnaire Administration|Ancillary studies
224325070|NCT04166409|DRUG|Selumetinib Sulfate|Given PO
224325071|NCT04166409|DRUG|Vincristine Sulfate|Given IV
224325072|NCT06590428|OTHER|Therapeutic Drug Monitoring for Linezolid|TDM with dose adjustment for trough concentration \>2.5 mg/L LZD
224325073|NCT04778761|BEHAVIORAL|Home ACP Video|A video focused on Advance Care Planning and Hospice for patients with serious illness
224325074|NCT06864585|DRUG|Avibactam sodium/Ceftazidime hydrate|The recommended adult dosage is 2.5 g (0.5 g of avibactam and 2 g of ceftazidime) administered by intravenous infusion over a period of 2 hours 3 times daily. For peritonitis, intra-abdominal abscess, cholecystitis, and liver abscess, Zavicefta should be co-administered with a metronidazole injection.
223682374|NCT03551080|BIOLOGICAL|Placebo|Saline administered intravenously
223682375|NCT00931346|DRUG|FTC/TDF|emtricitabine/tenofovir disoproxil fumarate
223682376|NCT00931346|DRUG|Placebo|Placebo
223682377|NCT05204875|RADIATION|X-ray Velocimetry|X-ray Velocimetry (XV) technology images the motion of the lungs, determines airway volumes and measures regional lung ventilation during spontaneous breathing.
223682378|NCT00689091|DEVICE|Bispectral Index Monitor|Comparison of two different alerting protocols. One using the bispectral index monitor and one using the MAC alerting protocols.
223682379|NCT00689091|DEVICE|Electronic MAC alert|Comparison of two different alerting protocols. One using the bispectral index monitor and one using the MAC alerting protocols.
223682380|NCT00521911|BEHAVIORAL|Cognitive Behavioural Therapy|
223682381|NCT01634178|DRUG|Apremilast|Tablet for oral administration
223682382|NCT00208182|DRUG|Risperidone|
223682383|NCT05606146|DEVICE|IUB SEAD|The investigative device, the IUB SEAD™, is a novel spherical endometrial ablation device developed to allow for simple, office-based chemical EA to treat benign causes of the symptom of HMB
223682384|NCT02644200|DEVICE|Gelatin tannate|
223682385|NCT02157207|DIETARY_SUPPLEMENT|Antioxidant|Comparison of antioxidant supplementation with a placebo. Effects of race and age and race in repsonse to the supplementation will be evaluated.
223682386|NCT02157207|OTHER|Placebo|Comparison of antioxidant supplementation with a placebo. Effects of race and age and race in repsonse to the supplementation will be evaluated.
223682387|NCT05867342|DRUG|Epinephrin|Topical application of 2 pieces of Epinephrin (1:1,000)-soaked cottonoid in nasal cavity
224325075|NCT06672237|BIOLOGICAL|nexiguran ziclumeran|nexiguran ziclumeran 55 mg by single IV infusion
224325076|NCT06672237|DRUG|Normal Saline as Placebo|Normal saline (0.9% NaCl) by single IV infusion
224325077|NCT05668741|DRUG|VX-522 mRNA therapy|Oral inhalation using nebulizer.
224325078|NCT05668741|DRUG|IVA|Tablet for oral administration.
224325079|NCT06863272|DRUG|Docetaxel|Administered via Intravenous (IV) infusion at a specified dose on specified days
223682388|NCT05867342|DRUG|1% lidocaine with epinephrin 1:100,000|4 ml intranasal infiltration of 1% lidocaine with epinephrine (1:100,000) at 2 sites (2 ml infiltration at each site)
223682389|NCT05867342|DRUG|Saline|4 ml intranasal infiltration of saline at 2 sites (2 ml infiltration at each site)
223682390|NCT05953714|OTHER|incision side cleaning with antiseptic products|A pilot study was conducted with six pregnant women to clarify the use of the data collection tools and the implementation plan during the study process. After that, the data collection forms were finalized. In the 6 operating room, two different solutions (PI and CG) were applied, according to the preference of the physician, to clean the surgical field. The study was carried out by adding a CG shower application to the physician's preferred solution (for a total of 3 groups). Pregnant women who were admitted to the obstetrics clinic were informed about the purpose, scope, duration, and method of the study by one of the researchers. Follow-up of the women was done for 7 day duration following postnatal to assess postoperative for comfort, pain, wound complications by the nurse researcher. At discharge, cultures were taken from the abdominal wounds of the participants
223682391|NCT02259790|DRUG|Telmisartan/amlodipine fixed-dose combination tablet|
223682392|NCT02259790|DRUG|Telmisartan|
223682393|NCT02259790|DRUG|Amlodipine|
223682394|NCT01410552|DEVICE|PARADYM DR model 8550; PARADYM CRT model 8750; PARADYM RF DR model 9550; PARADYM RF CRT model 9750; PARADYM RF CRT SonR model 9770|PARADYM ICD and CRT-d with PARAD+ algorithm available
223774538|NCT07045896|DRUG|Fucoidan|Background Therapy: Continued pre-existing conventional RA treatment at stable doses Intervention: Oral fucoidan Dosage Form: Size-0 gelatin capsules containing 1000mg fucoidan powder Dosage: 2000mg (2 capsules) per dose, twice daily (BID) Duration: 12 weeks continuous treatment
224325080|NCT06863272|DRUG|Ifinatamab Deruxtecan|Administered via IV infusion at a specified dose on specified days
224325081|NCT06863272|DRUG|MK-5684|Administered orally at a specified dose on specified days
224325082|NCT06863272|DRUG|Abiraterone|Administered orally at a specified dose on specified days
224325083|NCT06863272|DRUG|Enzalutamide|Administered orally at a specified dose on specified days
224325084|NCT06616194|DRUG|Rimegepant|Rimegepant 75 mg orally disintegrating tablets
224325085|NCT06616194|DRUG|Placebo|Matching placebo oral disintegrating tablets
224325086|NCT06991738|DIAGNOSTIC_TEST|68Ga-DOTA-TATE PET Scan|68Ga-DOTATATE is administered via intravenous injection of 5 1 mCi in a volume of 3 - 5 ml containing up to 50 micrograms \[68Ga\] DOTATATE.
224325087|NCT06991738|OTHER|Amino acid infusions|Appropriate amino acid solutions infused for this purpose should have a total lysine and arginine content between 18g and 25g and have an osmolality of \<= 1050 mOsmol. Concomitant administration of an amino acid infusion with the study drug 177Lu-DOTA-EB-TATE is for renal protection.
224325088|NCT06991738|DRUG|177Lu-DOTA-EB-TATE|Each single-dose vial contains sodium acetate (24.6 mg/mL), gentisic acid (3.7 mg/mL), L-ascorbate (0.445 mg/mL), DTPA (0.051 mg/mL). 177Lu-DOTA-EB-TATE, is a long-acting radiopharmaceutical for PRRT. It consists of a somatostatin analog peptide (TATE) conjugated with a truncated Evans blue (EB) molecule and the metal chelator 1,4,7,10-tetraazacyclodecane-1,4,7,10-tetraacetic acid (DOTA) with the radioisotope 177Lu stably complexed.
224325089|NCT06517017|DRUG|Isatuximab|Subcutaneous isatuximab will be administered weekly on a 28-day cycle during the first two cycles, and every two weeks of a 28-day cycle thereafter. Dexamethasone will be administered on the days of isatuximab administration and can be discontinued after two cycles of therapy, or continued at discretion of investigator. Lenalidomide, will be added after two cycles of therapy have been completed.
224325090|NCT06812052|RADIATION|Radiation Therapy|In this study, patients will receive a hypofractionated course of radiation therapy of 2.85 Gy x 15 fractions (42.75 Gy). If there are 2 or more patients with dose-limiting toxicities, the radiation course will be de-escalated to 2.7 Gy x 15 fractions (40.5 Gy).
224325091|NCT06812052|RADIATION|Hypofractionationed Radiation Therapy|This group is receiving hypofractionated radiation therapy (shorter course of RT)
224325092|NCT06699602|DRUG|Cemiplimab|cemiplimab IV flat
224325093|NCT06699602|DRUG|Fianlimab|fianilmab IV flat
223682395|NCT00991952|DRUG|alvocidib|Given IV
223682396|NCT00991952|DRUG|irinotecan hydrochloride|Given IV
223682397|NCT00991952|OTHER|laboratory biomarker analysis|Correlative studies
223682398|NCT01704898|DRUG|Efavirenz 600 Test-Stocrin 600 Reference|
224325094|NCT04678336|BIOLOGICAL|CART123 cells; cyclophosphamide; fludarabine|CART123 cells following lymphodepleting chemotherapy in pediatric patients with relapsed/refractory AML. Subjects will be treated with a single IV dose of CART123 cells on Day 0.
224325095|NCT06998966|BEHAVIORAL|Algorithmic Defaulting (Indication-Based Default)|PPIs are frequently overprescribed, and the CareConnect default prescription setting of 90 days with three refills (360 pill days) exceed standard guidelines (in most cases, 60 pill days). It is unclear whether this is the most appropriate workflow. Given that deprescribing PPIs carries minimal risk for most patients, this initiative will assess whether modifying defaulted prescription lengths influences prescribing behavior while ensuring physicians retain full decision-making authority.
223682399|NCT01704898|DRUG|Stocrin 600 Reference-Efavirenz 600 Test|
223682400|NCT06331676|PROCEDURE|Tissue collection|Eutopic and ectopic endometrium biopsies, additional blood and peritoneal fluid sampling
223682401|NCT06331676|OTHER|Data collection|Questionnaire on menstrual health and history of hormone treatments for the research purpose
223682402|NCT05920902|OTHER|routine therapy of acute ischemia stroke|Routine therapy of acute ischemia stroke based on the guidelines, which generally includes two parts: evaluation and medicine treatment. Evaluation includes peripheral blood test, radiologic examination, electrophysiological examination, ultrasonic examination. Medicine treatment includes drug therapy and rehabilitation.
223682403|NCT02616471|DIETARY_SUPPLEMENT|High-fat cheese|
223682404|NCT02616471|DIETARY_SUPPLEMENT|Low-fat cheese|
223682405|NCT02616471|DIETARY_SUPPLEMENT|No-cheese/carbohydrate|
223682406|NCT00597337|BEHAVIORAL|FearNot|Behavioral: Three sessions of FearNot!v.2.0 software interaction over a three-week period (each session lasting approximately 30 minutes)
223682407|NCT05479773|DEVICE|Standard NIV mask|The hospital standered NIV mask
223682408|NCT05479773|DEVICE|Lumena NIV mask|aerosol-reducing mask
223774539|NCT07045896|DRUG|Corn starch|Background Therapy: Continued pre-existing conventional RA treatment at stable doses Intervention: Oral Corn starch as Placebo Dosage Form: Size-0 gelatin capsules containing 1000mg Placebo powder Dosage: 2000mg (2 capsules) per dose, twice daily (BID) Duration: 12 weeks continuous treatment
223774540|NCT04206982|PROCEDURE|Destruction of Marshall bundles|Destruction of Marshall bundles by ethanol 96% infusion (2 separate injections of 5ml on 1 minute each) followed by ablation of the distal coronary sinus bundles, the ridge and the saddle.
223774541|NCT04206982|PROCEDURE|Pulmonary veins isolation|Achievement of a wide disconnection of the right and left pulmonary veins.
224325096|NCT06998966|BEHAVIORAL|Active Physician Choice|PPIs are frequently overprescribed, and the CareConnect default prescription setting of 90 days with three refills (360 pill days) exceed standard guidelines (in most cases, 60 pill days). It is unclear whether this is the most appropriate workflow. Given that deprescribing PPIs carries minimal risk for most patients, this initiative will assess whether requiring providers to actively select prescription lengths influences prescribing behavior while ensuring physicians retain full decision-making authority.
224325097|NCT07000357|DRUG|AZD0780|Participants will receive oral AZD0780 once daily
224325098|NCT07000357|DRUG|Placebo|Participants will receive oral placebo once daily
224325099|NCT06998134|DEVICE|Extension assist knee ankle foot orthosis (EA-KAFO)|A lower limb exoskeleton that has one actuated degree of freedom at the knee (flexion/extension) and a passive degree of freedom at the ankle (plantar/dorsiflexion).
224325100|NCT06992609|DRUG|Durvalumab|Durvalumab (IV) every 4 weeks until a maximum of 24 months.
224325101|NCT02994069|DRUG|Cisplatin|Cisplatin
224325102|NCT02994069|RADIATION|XRT|Radiation Therapy
224325103|NCT06670287|OTHER|Single-Sensor Tracking (In-Lab)|In-lab sleep tracking using only raw accelerometer data from a single sensor collected and processed with legacy actigraphy algorithms.
224325104|NCT06670287|OTHER|Multi-Sensor Sleep Tracking (In-Lab)|In-lab sleep tracking using raw accelerometer data and additional sensors collected and processed with machine learning.
224325105|NCT06670287|OTHER|Multi-Sensor Sleep Tracking (At-Home)|At-home sleep tracking using raw accelerometer data and additional sensors collected and processed with machine learning.
224325106|NCT05212168|BIOLOGICAL|VXA-G1.1-NN|Norovirus GI.1 Norwalk VP1 Vaccine, Oral E1-/E3-Deleted Replication Defective Recombinant Adenovirus 5 with dsRNA Adjuvant
224325107|NCT05212168|OTHER|Placebo Tablets|Oral tablets similar in appearance and number to active vaccine tablets
224325108|NCT05212168|BIOLOGICAL|Norovirus GI.1 Norwalk Virus Inoculum|Norwalk Virus Inoculum Lot 01-09NV
224325109|NCT07001475|DRUG|BI 3031185|BI 3031185
224325110|NCT07001475|DRUG|Placebo|Placebo matching BI 3031185
224325111|NCT03671226|OTHER|Questionnaire Administration|Given questionnaire
224325112|NCT00936390|DRUG|bicalutamide|Administered orally at a dose of one 50 mg tablet per day, beginning within (before, same day as, or after) 10 days of the date of the first LHRH agonist (antagonist) therapy administration and continuing for a total duration of 6 months.
224325113|NCT00936390|DRUG|flutamide|Administered orally at a dose of 250 mg (two 125-mg capsules) three times a day for a total daily dose of 750 mg, beginning within (before, same day as, or after) 10 days of with the date of the first LHRH agonist (antagonist) therapy administration and continuing for a total duration of 6 months.
224325114|NCT00936390|DRUG|LHRH agonist (antagonist) therapy|LHRH agonist (antagonist) therapy consists of leuprolide, goserelin, buserelin, triptorelin, or degarelix. The manufacturer's instructions should be followed. The first administration occurs with the start of anti-androgen treatment 8 weeks prior to the start of RT. The total duration of LHRH agonist (antagonist) therapy is 6 months.
224325115|NCT00936390|RADIATION|Dose-Escalated Radiation Therapy|External beam radiotherapy (EBRT) as 3D Conformal Radiotherapy (3DCRT) or intensity-modulated radiation therapy (IMRT). Brachytherapy is optional, at the discretion of the treating physician. Patients treated entirely via EBRT receive 79.2 Gy delivered in 1.8 Gy fractions. Patients who receive brachytherapy as a component of their RT receive 45 Gy EBRT in 1.8 Gy fractions. Low-dose brachytherapy boost occurs following the EBRT portion of treatment no more than 4 weeks following its completion.High-dose rate brachytherapy boost is delivered in 2 fractions separated by a minimum time span of 6 hours and the implant(s) may be performed during the EBRT portion of the treatment or within 1 week prior to its initiation or following its completion.
224325116|NCT05905783|DRUG|Placebo|Solution for injection
224325117|NCT05905783|DRUG|Izokibep|Solution for injection
224325118|NCT06988800|DEVICE|Paced breathing wellness breathing sessions|The paced breathing condition used timed auditory and visual cues to guide participants through breathing cycles at a rate of five breaths per minute, designed to stimulate the parasympathetic nervous system and promote relaxation. The audiovisual cues included spoken instructions, music, and breath-like sounds. The tonal audio cues rose in pitch during inhalation and fell during exhalation, creating a clear auditory signal for breath pacing. The same harmonic drone used in the mindfulness intervention provided a calming background, though here it was combined with the rhythmic pacing. Visually, the pacing was synchronized with the image of a lotus flower opening during inhalation and closing during exhalation, reinforcing the breathing rhythm.
223774542|NCT04206982|PROCEDURE|Linear ablation in the left and right atria|Ablation of the mitral, the roof, and the cavo-tricuspid isthmus.
223774543|NCT07051057|DIAGNOSTIC_TEST|Survey using a questionnaire.|A survey was constructed to collect the data of oral hygiene and nutritional habits and obesity
223774544|NCT07042425|OTHER|Computer based cognitive telerehabilitation|An intervention group received computer-based cognitive training with online monitoring and a control group that received conventional cognitive training by an occupational therapist
224325119|NCT06988800|DEVICE|Mindfulness video sessions|The audio component of the mindfulness intervention featured a female narrator guiding participants through mindfulness exercises, focusing on breath awareness and cultivating non-judgmental attention to thoughts and feelings. Ambient tonal sounds, including a harmonic drone with slow timbral changes, played softly in the background to support relaxation. Importantly, no rhythmic audio cues were included to avoid inducing breathing entrainment. This setup emphasized passive, mindful observation rather than active breath control, encouraging participants to observe their bodily sensations and thoughts without judgment.
224325120|NCT07003919|COMBINATION_PRODUCT|DBV712 250 mcg|DBV712 250 mcg epicutaneous system.
224325121|NCT07003919|COMBINATION_PRODUCT|Placebo|DBV712 matching placebo epicutaneous system.
223774545|NCT07048028|DRUG|Chitosan Low Molecular Weight (20-200 Mpa.S)|A 0.2 % (w/v) low-molecular-weight chitosan solution (50-190 kDa, ≥75 % deacetylation) prepared fresh in 1 % acetic acid, pH ≈ 6.0. Ten mL is delivered into the root canal over 30 s and left in situ for an additional 30 s (total contact 60 s), followed by a 5 mL sterile saline flush
223774546|NCT07048028|DRUG|Sodium Hypochlorite|Commercial 2.5 % (w/v) sodium hypochlorite endodontic irrigant. Ten mL is delivered over 30 s and left for 30 s (total contact 60 s), then flushed with 5 mL sterile saline
223774547|NCT07048028|DRUG|EDTA chelating agents|Ready-to-use 17 % EDTA solution (pH ≈ 7.3) for smear-layer removal. Ten mL is delivered over 30 s and left for 30 s (total contact 60 s), then flushed with 5 mL sterile saline
223774548|NCT07050641|DRUG|SCTB39-1|SCTB39-1, IV
223774549|NCT06741397|DRUG|CAB LA|Injections administered IM gluteal.
223774550|NCT06741397|DRUG|New formulation of CAB LA|Injections administered IM gluteal.
223774551|NCT06893822|DIETARY_SUPPLEMENT|Griffonia simplicifolia|Griffonia simplicifolia 1x/day
223774552|NCT06893822|OTHER|Placebo|Placebo 1x/day
223682409|NCT00582816|DEVICE|Clinimacs Cell Separation System|Depletion of T-cells
223682410|NCT00582816|DRUG|conditioning chemotherapy|Methylprednisolone, Equine ATG, Cyclosporine, Fludarabine, Melphalan, Thiotepa and Rituximab.
223682411|NCT00582816|OTHER|DLI|NK Cell selected DLI
223682412|NCT00350454|DEVICE|rapamycin-eluting Stent with permanent polymer|due to randomization, rapamycin-eluting stent with permanent polymer will be implanted
223682413|NCT00350454|DEVICE|rapamycin-eluting stent with biodegradable polymer|due to randomization, rapamycin-eluting stent with biodegradable polymer will be implanted
223682414|NCT00350454|DEVICE|polymer-free, rapamycin-eluting stent|due to randomization, polymer-free.rapamycin-eluting stent will be implanted
223774553|NCT06550427|DIAGNOSTIC_TEST|ctDNA analyzed by phased variant|this observational cohort study is to investigate the correlation between ctDNA analyzed by phased variant and the early outcome of the disease.
223774554|NCT07051434|OTHER|Regional Analgesic Block|Preoperative regional analgesic block performed as part of routine clinical care in selected patients undergoing mastectomy (e.g., PECS block, paravertebral block, or other truncal blocks).
223774555|NCT07051590|DEVICE|cad cam|Occlusion assessment in CAD CAM restorations
223774556|NCT07051590|DEVICE|3D printer|Crowns produced with 3D technology
224262311|NCT03133260|DRUG|Acetylsalicylic acid|100mg acetylsalicylic acid will be started in case of MINS if no contraindication, it will be continued after hospital discharge. We will evaluate cardiovascular complications till 1 year after surgery
224262312|NCT03133260|DRUG|Statin|40mg atorvastatin will be started in case of MINS if no contraindication, it will be continued after hospital discharge. We will evaluate cardiovascular complications till 1 year after surgery
224262313|NCT06555458|DRUG|Dexmedetomidine|Patient group to be given dexmedetomidine
224262314|NCT06555458|DRUG|Saline|Patient group to be given salin
224262315|NCT06339645|PROCEDURE|PRP|Patients who meet all eligibility requirements for entry into the study of intravesical PRP injection
224262316|NCT04742543|DEVICE|SootheVR: AppliedVR, Los Angeles, California a head-mounted display|"For the study group, virtual reality content will be shown to the participant for the duration of the conization procedure through a head-mounted display, RelieVRTM. The default VR content for the trial will be swimming with dolphins or any other content chosen by the participant"
224262317|NCT05491187|DRUG|0.5% bupivacaine heavy|Spinal anesthesia with 0.5% bupivacaine heavy at L3-L4 intervertebral space using Quincke's spinal needle in sitting position, single administration for each patient
224262318|NCT05491187|DRUG|0.5% bupivacaine heavy with fentanyl|Spinal anesthesia with 0.5% bupivacaine heavy with fentanyl at L3-L4 intervertebral space using Quincke's spinal needle in sitting position, single administration for each patient
224262319|NCT03599193|DRUG|Tazarotene Lotion, 0.1%|DFD-03 (Tazarotene Lotion, 0.1%) applied Twice Daily for 1 minute and rinsed off
224262320|NCT03599193|DRUG|Tazarotene Cream, 0.1%|Tazorac® (tazarotene) Cream, 0.1% applied Once Daily and left for approximately 12 hours
224262321|NCT00789386|DRUG|Remifentanil|Remifentanil (Ultiva ®; Glaxo-Smith-Kline; Vienna, Austria) at an initial dose of 0.24 µg kg-1 min-1 will be applied iv during 60 minutes.
224262322|NCT00789386|DRUG|Midazolam|Midazolam (Dormicum®; Roche; Vienna, Austria) will be applied iv as active placebo at a dose of 7.5 µg.kg-1.min-1 over 10 minutes to mimic typical central nervous side effects of remifentanil.
224262323|NCT04722198|DIETARY_SUPPLEMENT|PS128|daily ingestion 2 capsules of Lactobacillus plantarum PS128 (\>10 billion CFU/capsule)
224262324|NCT00394303|DRUG|Intraoperative continuous insulin infusion|Nomogram specified in appendix
224262325|NCT00394303|OTHER|Control|Glucose management according to the discretion of the anesthesiologist aimed to maintain glucose levels \<200 mg.dl, reflecting current practice.
224262326|NCT06626932|RADIATION|18 FDG (Fludeoxyglucose 18F)|18-f FDG
224262327|NCT05213052|OTHER|Topical cream|Topical cream applied to painful joint or muscle
224262328|NCT00018213|DRUG|Naltrexone Hydrochloride|
224262329|NCT00018213|DRUG|Transdermal Nicotine|
224262330|NCT03932045|DEVICE|SYB Filler (SF-01)|Apply up to 1.0 ml of the test device (SF-01) and the contrast device (Ellansé M) to both sides of the nasolabial fold.
224262331|NCT03932045|DEVICE|Ellansé M|Apply up to 1.0 ml of the test device (SF-01) and the contrast device (Ellansé M) to both sides of the nasolabial fold.
224262332|NCT00571935|DRUG|insulin aspart|
224262333|NCT00571935|DRUG|soluble human insulin|
224262334|NCT01310998|BEHAVIORAL|High intensity exercise|4x4 intervals
224262335|NCT01949805|DRUG|Peg-P-IFN-alpha-2b (AOP2014)|Pegylated interferon alpha 2b given Q2W as SC injection
224262336|NCT01949805|DRUG|Hydroxyurea|Hydroyurea capsules taken daily po
224262337|NCT00835705|DRUG|amoxicillin-clavulanic acid|400 mg-57 mg chewable tablet
224262338|NCT00835705|DRUG|Augmentin®|400 mg-57 mg chewable tablet
224262339|NCT04790526|OTHER|Eccentric Exercises Dose|Eccentric exercise will be done treadmill in control environment. The treadmill will be declined to 16 degree and 3 sessions of 10 minutes duration will be given wit 1 minute of rest in each session. 10 minutes of warm up and cool down session will be given that includes stretching and stationary bicycle with out any resistance
223774557|NCT07051785|DRUG|Fruquintinib+Irinotecan Liposome+Capecitabine|"Stage 1: Participants received fruquintinib, irinotecan liposome, and capecitabine for 6-8 cycles. If no disease progression was observed after the initial treatment, patients were transitioned to maintenance therapy with fruquintinib and capecitabine.~Stage 2: if the primary endpoint of progression-free survival (PFS) was met in the first stage, participants were eligible for the second stage. Participants were randomly assigned to two groups (A and B), Group A: Fruquintinib + irinotecan liposome + capecitabine. After 6-8 cycles of treatment, patients who had no disease progression were transitioned to maintenance therapy with Fruquintinib + capecitabine"
224262340|NCT03417076|DRUG|Bexagliflozin|Bexagliflozin tablets, 20 mg, and bexagliflozin by IV
224262341|NCT03049631|DIETARY_SUPPLEMENT|Raspberry and fructooligosaccharide|Red raspberries (1 cup equivalent) with fructooligosaccharide (8 g)
224262342|NCT03049631|DIETARY_SUPPLEMENT|Raspberry|Red raspberries (1 cup equivalent)
224262343|NCT01750294|DRUG|Chlorthalidone|
224262344|NCT01706094|OTHER|Head Position|"Head position during the first 48 hours from admission of patients with acute ischemic stroke.~This trial is organized as a cluster randomised trial to a policy of flat head position or upright head position. Clusters will be months, so that all patients admitted during a given month will be positioned either in the flat down head position (intervention) or upright head position (control). This will allow health teams to follow a monthly protocol without changing position between patients."
224262345|NCT05360394|DEVICE|Paclitaxel Coated Balloon|CAS treated with PCB only
224262346|NCT05360394|DEVICE|Paclitaxel Coated Balloon and Stent Graft|CAS treated with PCB first before deployment of stent graft
224262347|NCT06596226|BEHAVIORAL|Pathways Parent Mediated Intervention|Pathways-trained research clinicians will conduct 90-minute weekly coaching sessions with caregivers in the family's home or other convenient location. Caregivers will receive a written version of the program manual. Sessions will review information about social communication, infusing mutual gaze in social sensory routines, and using naturalistic developmental behavioral strategies. Interventionists will demonstrate intervention strategies and provide caregivers with practice feedback and self-reflection.
224262348|NCT06596226|BEHAVIORAL|Pathways Parent Mediated Intervention without Mutual Gaze|Pathways-trained research clinicians will conduct 90-minute weekly coaching sessions with caregivers in the family's home or other convenient location. Caregivers will receive a written version of the program manual. Sessions will review information about social communication, social sensory routines, and naturalistic developmental behavioral strategies described in the program manual. Interventionists will demonstrate intervention strategies and provide caregivers with practice feedback and self-reflection.
224325122|NCT07001332|DEVICE|Elevate|The Elevate System is a catheter- mounted, self-expanding and retrievable, continuous-flow pump, designed to unload the left ventricle by actively transporting blood from the left ventricle into the ascending aorta, thus augmenting cardiac output and maintaining systemic arterial pressure during complex/high-risk coronary interventions. Subjects will receive an Elevate prior to their high-risk percutaneous intervention.
224325123|NCT07001332|DEVICE|Impella|Subjects will receive an Impella prior to their high-risk percutaneous intervention.
224325124|NCT05156762|PROCEDURE|Bariatric surgery|Patients randomized to the bariatric surgery study arm will undergo either a laparoscopic sleeve gastrectomy or a laparoscopic gastric bypass - this decision would be a joint decision made between the study participant and the bariatric surgeon after consideration of the patient's overall goals with weight loss and discussion of the risks and benefits of each procedure.
224325125|NCT05156762|BEHAVIORAL|Medical weight loss|Study participants randomized to the medical weight loss study arm will have consultations with nutritionists, dieticians, and endocrinologists, and will make dietary and lifestyle changes in an effort to lower their BMI to ≤ 40 kg/m2. Patients may also be placed on pharmacotherapy to assist with weight loss.
224325126|NCT05156762|OTHER|Patient research surveys|Patients will have a telemedicine visit every 3 months with an orthopaedic surgery physician assistant to review their latest BMI and to complete a patient research survey to assess the patient's feelings regarding their progress. The telemedicine visits every 3 months are unique to the clinical trial and these visits would not otherwise occur if the patient was not enrolled in the trial. If patients are found to not be advancing toward the BMI goal of ≤ 40 kg/m2, these patient research surveys can be used to make individualized adjustments, based on recommendations from dieticians and the medical nutritionist.
224325127|NCT05156762|PROCEDURE|Total joint arthroplasty (TJA)|Once the study participant meets the target BMI goal of ≤ 40 kg/m2, they will undergo TJA. Patients will be followed for 2 years after undergoing TJA.
224325128|NCT05156762|OTHER|Usual standard of care|"Patients randomized to the usual standard of care study arm will be counseled on the importance of losing weight to optimize their BMI and will be provided with referral information (name and clinic number) to either the bariatric surgery or medical weight loss clinics. They will be urged to make an appointment or to seek any other interventions they choose to help lower their BMI, but no appointments will be made for them. A follow up visit in 6 months and 1 year will be made for them in the arthroplasty clinic to reassess their progress. Referral information will again be provided at 6 months if no progress has been made."
224325129|NCT06671496|DRUG|Zasocitinib|Zasocitinib tablets.
224325130|NCT06671496|DRUG|Placebo|Zasocitinib matching placebo.
224325131|NCT07006116|OTHER|Synchronous/asynchronous online course|"* Synchronous weekly 90-120-minute-long sessions that will be conducted on a videoconferencing platform (i.e., Zoom). If participants miss a synchronous session.~* Asynchronous online course: available segments of the online course with asynchronous instructional materials delivered 2-4 days in between sessions, and supplemental course materials that will be received by mail."
224325132|NCT07127874|DRUG|PHN-012|PHN-012 is an ADC
224325133|NCT06868238|DRUG|Magtrace|Participants will receive a single injection of Magtrace into the breast during their mastectomy.
224325134|NCT06619509|DRUG|Brigimadlin|Brigimadlin
224325135|NCT07008378|BIOLOGICAL|P-CD19CD20-ALLO1 Cells|P-CD19CD20-ALLO1 Cells will be administered intravenously as per the schedule specified in the protocol.
224325136|NCT07008378|DRUG|Cyclophosphamide|Cyclophosphamide will be administered intravenously.
224325137|NCT07008378|DRUG|Fludarabine|Fludarabine will be administered intravenously.
224325138|NCT07129993|DRUG|Dato-DXd|Dato-DXd will be administered as an intravenous (IV) infusion every three weeks (Q3W) at a dose of 4 mg/kg or 6 mg/kg in Part A or RP3D in Part B
224325139|NCT07129993|DRUG|Carboplatin|Carboplatin will be administered as an intravenous (IV) infusion every three weeks (Q3W) at a dose of AUC 4.5 or 5.0 mg•min/mL
223774558|NCT07051785|DRUG|Bevacizumab+Irinotecan Liposome+Capecitabine|Stage 2: if the primary endpoint of progression-free survival (PFS) was met in the first stage, participants were eligible for the second stage. Participants were randomly assigned to two groups (A and B), Group B: Bevacizumab + irinotecan liposome + capecitabine. After 6-8 cycles of treatment, patients who had no disease progression were transitioned to maintenance therapy with bevacizumab + capecitabine
223774559|NCT07051772|OTHER|mobility skills testing session|A mobility skills testing session using the Qualisys system (Trinoma), when carrying out specific tasks plus 7-day recording of activity using an accelerometer.
223774560|NCT06748040|OTHER|Timing of return of results|Participants will be randomized to immediate versus delayed return of PGx results.
224262349|NCT00073580|DRUG|Angiomax (bivalirudin) anticoagulant|): 250 mg vial administered as 0.75 mg/kg intravenous (IV) bolus and 1.75 mg/kg/h IV infusion for the duration of the procedure with the option to increase or decrease the infusion rate in 0.25 mg/kg/h increments or to administer additional 0.1-0.5 mg/kg boluses to maintain an activated clotting time (ACT+) \>300 seconds. A low-dose infusion could be administered in the preoperative phase (up to 48 hours before the procedure) and in the postoperative phase (up to 14 days after the procedure) as clinically indicated for management of HIT/TS. An initial dose of 0.1 mg/kg IV bolus followed by an IV infusion of 0.2 mg/kg/h titrated to a desired activated partial thromboplastin time (aPTT), eg, 1.5-2.5 times baseline aPTT, was recommended.
224262350|NCT04410380|BEHAVIORAL|Electronic tablet provision with teaching|Spanish-speaking parents are provided with an electronic tablet and taught how to use it to access health information for their children.
224262351|NCT05539157|DRUG|JCXH-211|JCXH-211 administered once every 28 days
224262352|NCT05561166|OTHER|EPIDREAM Questionnaire|EPIDREAM Questionnaire (questionnaire about dreams and epileptic seizures)
224262353|NCT04939571|OTHER|Registry of preterm born infants with treatment-requiring ROP|All prematurely born infants who develop treatment requiring ROP and are treated (independent of the kind of treatment modality) at a center that participates in the registry are eligible for database entry.
224262354|NCT00687206|DRUG|Valsartan 160mg plus HCT 25mg|valsartan 160 mg once a day for 6 months plus hydrochlorothiazide 25 mg a tablet once a day for 6 months
224262355|NCT00582387|GENETIC|specimen samples|blood, urine and tissue
224262356|NCT00582387|BEHAVIORAL|questionnaires|
224262357|NCT02832960|DRUG|Levothyroxine|The intervention will start with Levothyroxine 50 mcg daily (reduced to 25 mcg in subjects \<50 kg of body weight or if known coronary heart disease - previous myocardial infarction or symptoms of angina pectoris) vs. matching placebo; at 3 months, if the serum TSH level is \<0.4 mU/L, dose will be reduced by 25 mcg; TSH \>=0.4 and \<4.6 mU/L, no change to dose; TSH \>=4.6 mU/L, additional 25 mcg. The process will be repeated at 12 months, then annually; mock titration will be performed in the placebo group. The maximum possible dose of Levothyroxine which will be prescribed is 150 mcg (after 4 increments of 25 mcg at 3 months, 1, 2, 3 years; from the starting dose of 50 mcg).
224262358|NCT02832960|DRUG|Placebo|Control patients will obtain a placebo pill of the same characteristics as the intervention drug, and mock titration will be carried out identically to the intervention drug. Pharmaceutical composition of placebo (100 mg): Lactose monohydrate 66 mg, Maize starch 25 mg, Gelatin 5 mg, Croscarmellose sodium 3.5 mg, Magnesium stearate (vegetable source) 0.5 mg.
224262359|NCT06059755|OTHER|Cross education|For strength training resistance exercises with a load of 60% of one repetition maximum will be performed targeting the muscle involved in upper limb function. Strength will be measured using the grip strength test/hand held dynamometer. Patients will undergo 45 minute session per day, 3 days per week for 6 weeks.
224262360|NCT06059755|OTHER|Mirror Therapy|Participants will be asked to sit in front of a table of appropriate height with their arms resting on the table and a mirror (35 cm × 35 cm) placed between the patient's arms. The non-affected arm will be placed in front of the mirror and the affected arm will be placed and obscured. Appropriate movement tasks will be selected according to the function of the affected upper limb. This exercise will be performed 45 minutes per day, 3 times per week for 6 weeks
224262361|NCT03625973|BEHAVIORAL|3D-RT|Objects printed using 3D printing media will be used as stimuli in Reminiscence Therapy
224262362|NCT03625973|BEHAVIORAL|RT-Verbal|Verbal cues will be used as stimuli in Reminiscence Therapy
224262363|NCT02452619|OTHER|Hyperbaric oxygen therapy|Hyperbaric oxygen therapy
224262364|NCT04423835|PROCEDURE|Paley's Principle osteotomy|. The osteotomy line of all patients was designed according to Paley's principles. The lateral incision was applied in all patients and the osteotomy lines were marked on the humerus with the assistance of C-arm radiographs. An isosceles triangle template was used for osteotomy, and the medial cortex was left intact. K-wires were used to fix the osteotomy laterally.
224262365|NCT01173835|BEHAVIORAL|Incentives for being tobacco free|Students who join the program will be entered into regularly scheduled drawings throughout the school year to earn incentives for being tobacco free.
224262366|NCT00767481|DRUG|Travoprost/Brinzolamide|Eye drop suspension, once daily
224262367|NCT00767481|DRUG|Cosopt|Eye drop solution, one drop BID
224262368|NCT02864836|PROCEDURE|Samples collection|5 samples collected for each patient (tumor biopsy, healthy tissue around the tumor, blood, urine and saliva), quantification of isotopes, measure of mRNA expression of proteins 4 samples for each patient (healthy tissue, blood, urine and saliva), quantification of isotopes, measure of mRNA expression of proteins
224325140|NCT07129993|DRUG|Cisplatin|Cisplatin will be administered as an intravenous (IV) infusion every three weeks (Q3W) at a dose of 70 mg/m2
223835263|NCT02213055|DRUG|Standard Head lice product|The most common treatments are pesticide-based, over-the-counter remedies of permethrin (1%), or pyrethrin-based products.After baseline scalp exam for lice count and preexisting signs of irritation, parents who agree to the comparison arm may purchase any other head lice treatment of their choice. All treatments are to be done at home by a parent or guardian. All participants will be examined for lice count and scalp irritation the day after the first application, and one and two weeks after the first application. Participants may also be examined by parents or the school nurse at any time if signs of irritation or re-infestation occur. If the child is still found to be infested during any examination, the school nurse will instruct the parent/guardian to retreat.
223682415|NCT01231854|DRUG|Ciclosporin|In accordance with the current guideline concerning the use of ciclosporin in dermatology and the current guideline management of hand eczema the daily oral dosage of ciclosporin microemulsion is 2.7 to 4.0 mg/kg bodyweight (half of the total daily dosage will be administered in the morning and in the evening). To enable both body-weight adjusted treatment and double-blind treatment patients will be allocated to 2 different dosages depending on their body weight (50-74.9 kg: daily dosage 200 mg; 75-100 kg: daily dosage 300 mg).
223682416|NCT01231854|DRUG|Alitretinoin|In accordance with the current guideline management of hand eczema alitretinoin will be administered orally in a constant daily dosage of 30 mg.
223682417|NCT00055224|DEVICE|Threat of shock|During threat, a participant could receive a shock. During safe, a participant could not receive as shock. Participants selected their highest tolerable level of shock.
223682418|NCT02067052|PROCEDURE|Surgery, radiotherapy and chemotherapy|Surgery: vulvectomy and lymphadenectomy Radiotherapy: 180 cGy / day per 5 days untill maximum dose 4500 - 5940 cGy Chemotherapy: vulvectomy, lymphadenectomy
223682419|NCT02067052|PROCEDURE|Surgery|Vulvectomy \& lymphadenectomy
223682420|NCT01609478|DRUG|indacaterol|indacaterol acetate 75 µg or indacaterol acetate 150 µg delivered via Concept 1 inhaler
223682421|NCT01609478|DRUG|placebo|placebo delivered via Concept 1 inhaler
223682422|NCT01609478|DRUG|mometasone furoate|via Twisthaler inhaler
223682423|NCT03063671|DRUG|Ketamine, bupivacine,dexmedetomidine|thoracic epidural catheter insertion at T4-5
223682424|NCT02474225|DRUG|Intravitreal injection (bevacizumab or ranibizumab)|The intravitreal anti-vascular endothelial growth factor agent of 0.1 ml of bevacizumab (2.5 mg/0.1 ml) or ranibizumab (1 mg/0.1 ml)
223682425|NCT02953158|OTHER|Haas Avocado|Hypocaloric weight loss diet
223682426|NCT02953158|BEHAVIORAL|Dietary Counseling|Dietary Counseling
223682427|NCT01450111|DRUG|Lacosamide|Lacosamide 50 mg, tablet, once in the morning on Day 1
223682428|NCT01450111|DRUG|Lacosamide|Lacosamide 100 mg, tablet, once in the morning on Day 1 Lacosamide 100 mg, tablet, twice daily Day 5 to Day 8 and once in the morning on Day 9
223682429|NCT01450111|DRUG|Lacosamide|Lacosamide 200 mg, tablet, once in the morning on Day 1 Lacosamide 200 mg, tablet, twice daily Day 5 to Day 8 and once in the morning on Day 9
223682430|NCT01450111|OTHER|Placebo|Placebo matched with Lacosamide 50 mg tablet once in the morning on day 1.
223682431|NCT01450111|OTHER|Placebo|Placebo matched with Lacosamide 100 mg, tablet, once in the morning on Day 1 Placebo matched with Lacosamode 100 mg, tablet, twice daily Day 5 to Day 8 and once in the morning on Day 9
223682432|NCT01450111|OTHER|Placebo|Placebo matched with Lacosamide 200 mg, tablet, once in the morning on Day 1 Placebo matched with Lacosamide 200 mg, tablet, twice daily Day 5 to Day 8 and once in the morning on Day 9
223682433|NCT02487823|DRUG|BKM120 in combination with LH-RH agonists (suprefact) and bicalutamide|BKM 120, LH-RH agonists and Bicalutamide
223682434|NCT06008834|PROCEDURE|First-day discharge protocol|Enhance Recovery after Surgery (ERAS) protocol consisting in perioperative mesures and first-day hospital discharge with domiciliary follow-up
223682435|NCT04431427|DEVICE|Biliary drainage with PC-SEMS|partially covered metallic biliary stent insertion during ERCP
223682436|NCT04431427|DEVICE|Biliary drainage with U-SEMS|Uncovered metallic biliary stent insertion during ERCP
223835264|NCT00231894|DRUG|Pioglitazone|pioglitazone 30-45 mg/day
224262369|NCT02770690|DRUG|ethyl chloride spray|apply the spray for 5 seconds on the dorsal hand before propofol iv injection
224262370|NCT02770690|DRUG|lidocaine|apply lidocaine under the tourniquet state before propofol iv injection
224262371|NCT02770690|DRUG|placebo|apply normal saline before propofol iv injection
224262372|NCT05330780|OTHER|Breathing Room|8 total group classes performed twice a week over the course of 4 weeks, with IMTs utilized during the classes as well as 3 days outside of the class days at 5 sets of 5 breaths completed 5 times a day
224262373|NCT06335927|DRUG|HAIC-GEMOX+Cadonilimab+Regorafenib|HAIC-GEMOX: Gemcitabine 1000mg/m2 on Day 1 + Oxaliplatin 85mg/m2 on Day 1, every 3 weeks (Q3W), for up to 6 treatment cycles in combination with Cadonilimab (6mg/kg, D2, Q3W) and Regorafenib (80mg QD, Q3W)
224262374|NCT06558968|OTHER|aesthetic functional space maintainers|evaluate the use of Polyetheretherketone 'PEEK' and monolithic zirconia 'Bruxzir' as esthetic functional band and loop space maintainers.
224262375|NCT01881763|DRUG|Ketamine|Ketamine 1-2 mgr/ kg IV
224262376|NCT01881763|DRUG|Methohexital|Methohexital 0.5-1mg/kg IV
224262377|NCT00265226|BIOLOGICAL|Intra-dermal administration of Mycobacterium w|Mw Vaccine is given as oral suspension. Total 6 doses are given 0.2 ml at baseline and then 0.1 ml after interval of 2 weeks upto 8 weeks
224262378|NCT04595669|BEHAVIORAL|Personalised advise|personalised dietary advice in combination with feedback on dietary behaviour and health status (i.e. waist circumference, blood pressure, cholesterol, glucose and triglycerides)
224262379|NCT00327457|BEHAVIORAL|Help with physician office and patient management|
224262380|NCT00327457|BEHAVIORAL|Tailored physician recommendation letter|
224262381|NCT03215641|DEVICE|Fitbit|The Fitbit is a consumer-grade personal activity tracker. It is used to track physical activity. Patients will be given devices at the beginning of the study, and they will continue to use it for 7 weeks. Their data will be collected on a weekly basis, and patients will receive feedback on their level of activity based on the Fitbit data.
224262382|NCT02757287|DRUG|FSH-CTP + DESOGESTREL|"Hormones measured on day of 7th menstrual cycle day , day of pre-ovulatory bolus of GnRH and the day after the bolus ( estradiol, FSH, Progesterone, LH)~\- Quality of Life questionnaire the day after the bolus"
224262383|NCT00063687|DRUG|Oxypurinol|
224262384|NCT03690349|OTHER|Skin test|Demographic data review, Disease severity evaluation, Treatment evaluation and Skin prick test for 16 common aeroallergens
224262385|NCT04511156|OTHER|Foundational Helping Skills|Each site will implement three waves of Foundational Helping Skills training. Each training will include 12 trainees each, with a minimum of 2 trainers per training. Each site will include pre and post research days, where they will collect primary and secondary outcomes with support from research staff (trained raters, actors, and qualitative researcher). Each site will qualitatively assess the training after the first wave to identify any areas for modification, and after the second and third waves to develop recommendations for future implementation.
224262386|NCT06122155|DEVICE|Transcranial direct current stimulation (Anodal)|20-minutes, 2 mA anodal tDCS delivering through two 5 cm x 7 cm electrodes
224325141|NCT07129993|DRUG|Gemcitabine|Gemcitabine will be administered as an IV infusion at a dose of 1000 mg/m2 on Day 1 and 8 of every 3 week cycle.
224325142|NCT06252649|DRUG|FOLFIRI Regimen|Combination of irinotecan, leucovorin, and 5-fluorouracil given via IV infusion Q2W.
224325143|NCT06252649|DRUG|Sotorasib|Immediate-release solid dosage form administered orally.
223774561|NCT06620133|OTHER|Pain education and patient-led goal setting|8 week program delivered via five, up to 1-hour telehealth sessions. The sessions will be scheduled at approximately fortnightly intervals. Participants will also be prescribed approximately 30 minutes of online activities with each session. Pain education will be based on Explain Pain and the curriculum will have specified learning objectives adapted for each individual participant. Participants will access the online education curriculum through Pathwright. For patient-led goal setting, the healthcare practitioner will take an initial history of the participants physical activity behaviours and problems related to their back pain. The participant will prioritise their problems according to impact in their life. Strategies will then be discussed, and the participant will, in collaboration with the healthcare practitioner, set goals and strategies to work on independently between sessions.
223774562|NCT06620133|OTHER|Guideline-based written advice|Participants will receive guideline-based written information for the management of chronic low back pain. This will include information about the prognosis of low back pain and treatment options to consider.
223774563|NCT06895837|OTHER|Severe-energy restriction|The participants will receive only 25% of their estimated energy needs.
224262387|NCT06122155|DEVICE|Transcranial direct current stimulation (Sham)|20-minutes, 0 mA anodal tDCS delivering through two 5 cm x 7 cm electrodes
224262388|NCT04205279|OTHER|Experimental: Treadmill training|Participants will be given thirteen slips and thirteen trips in stance and walking, followed by two slips and two trips at a higher intensity (posttest). Subjects would be consented if they would like to undergo fMRI pre and post-training. Participants not willing to undergo imaging would not be excluded. Three day training consisting of blocks of five consecutive gait-slips at varying intensities will be provided. Individuals with stroke would undergo an additional session (total 4 training sessions over 4 weeks (1session/week) since these individuals get easily fatigued and also might need more training sessions with sufficient rest interval to induce reactive adaptation. Training at a specific level will persist until the subjects show a recovery step response in at least 3/5 trials in a single block. Once subjects successfully adapt to this level, the perturbation intensity will be increased until they show a recovery response in at least 3/5 trials.
224325144|NCT06252649|DRUG|Panitumumab|Administered via IV infusion Q2W.
224325145|NCT06252649|DRUG|Bevacizumab-awwb|Administered via IV infusion Q2W.
224325146|NCT06694571|BEHAVIORAL|Skin cancer prevention educational presentation and activities|"An intervention visit, lasting up to 90 minutes, will take place during fall, immediately following completion of a baseline survey. This intervention visit may be divided into 2 days, depending on the length of the class periods at the participating schools. During the intervention visit, participants will receive general education on skin cancer and skin cancer prevention, complete a skin cancer risk self-assessment tool, and create a sun protection action plan for an outdoor activity.~One month later, participants will receive a brief (15-minute) post-intervention survey via email and/or text."
224325147|NCT06919354|BIOLOGICAL|GNTI-122|GNTI-122 is an investigational cell therapy manufactured from a participant's own blood cells and is intended to help correct an imbalance of certain types of cells found in participants with Type 1 Diabetes.
224325148|NCT06866405|BIOLOGICAL|RSVpreF|Single Dose
224325149|NCT06866405|BIOLOGICAL|Placebo|Single Dose
224325150|NCT06679114|BEHAVIORAL|Acceptance and Commitment Therapy|The single-session ACT group intervention will involve a mixture of didactic instruction, discussion, metaphors, and experiential activities. ACT activities will help women notice and accept that negative thoughts, emotions, and experiences while being displaced by war are part of migratory and post-migratory life. ACT activities will also help them identify, reorient towards, and commit to values-consistent behaviors through effective goal-setting. The single-session will be approximately 3 hours long.
224325151|NCT06679114|BEHAVIORAL|Attention control|Usual care will be minimally enhanced by providing participants with an educational information session that provides information on health promotion.
224325152|NCT01955460|BIOLOGICAL|Aldesleukin|Given IV
224325153|NCT01955460|DRUG|Cyclophosphamide|Given IV
224325154|NCT01955460|DRUG|Fludarabine Phosphate|Given IV
224325155|NCT01955460|OTHER|Laboratory Biomarker Analysis|Correlative studies
224325156|NCT01955460|BIOLOGICAL|NGFR-transduced Autologous T Lymphocytes|Given IV
224325157|NCT01955460|BIOLOGICAL|TGFbDNRII-transduced Autologous Tumor Infiltrating Lymphocytes|Given IV
224325158|NCT07005128|DRUG|Tarlatamab|Tarlatamab will be administered as an intravenous (IV) infusion.
224325159|NCT07005128|DRUG|Durvalumab|Durvalumab will be administered as an IV infusion.
224325160|NCT07005128|DRUG|Carboplatin|Carboplatin will be administered as an IV infusion.
224325161|NCT07005128|DRUG|Etoposide|Etoposide will be administered as an IV infusion.
224325162|NCT07010159|DRUG|KPL-387|administered by subcutaneous injection
224325163|NCT07010159|DRUG|Placebo|administered by subcutaneous injection
224325164|NCT06625593|DRUG|BG-C137|Administered intravenously
224325165|NCT06862869|DRUG|Alectinib|"Participants will have received alectinib adjuvant treatment for resected stage II-IIIB ALK-positive NSCLC in routine clinical practice.~NOTE: No intervention will be provided in this study as the study is observational."
224325166|NCT06615050|DRUG|Tacrolimus (Tac)|Tablet or intravenously (IV)
223774564|NCT06895837|OTHER|Severe-energy restriction with exercise|The participants will run on the treadmill for 30 minutes and receive 25% of their estimated energy needs.
223774565|NCT07051161|PROCEDURE|bronchoscope|procedure performed by bronchoscopy
223774566|NCT06855147|DRUG|[14C]HRS9531|A single dose of \[14C\]HRS9531 injected subcutaneously.
223774567|NCT06830005|DEVICE|Rho AI software|Rho is a AI enabled opportunistic pre-screening computer-aided detection and notification software for low bone mineral density.
224325167|NCT06615050|DRUG|Methotrexate (MTX)|Intravenously (IV)
224325168|NCT06615050|DRUG|Ruxolitinib (Rux)|Tablet
224325169|NCT06615050|DRUG|Cyclophosphamide|Intravenously (IV)
224325170|NCT06615050|DRUG|Mycophenolate mofetil (MMF)|Tablet or intravenously (IV)
223774568|NCT06491394|DRUG|Lactoferrin|an iron-binding protein
224325171|NCT07013201|DRUG|Delgocitinib cream|Topical application
224325172|NCT07013201|DRUG|Vehicle cream|Topical application
223774569|NCT06491394|DIAGNOSTIC_TEST|iron|Iron in kidney and heart tissues
223774570|NCT06491394|DIAGNOSTIC_TEST|MDA, TAC, and GSH|Oxidative stress levels in kidney and heart tissues
224325173|NCT06262178|BEHAVIORAL|Parenting-STAIR Modular (PSTAIR-M)|12-16 PSTAIR-M treatment sessions (approximately 12-16 weeks).
224325174|NCT06262178|BEHAVIORAL|Treatment as Usual (TAU)|Weekly treatment sessions of an established EBT. The total number of sessions/weeks will be determined by the EBT and clinic protocols.
224325175|NCT06869187|DRUG|ABX-002|ABX-002 oral solution in 1-mL cyclic olefin polymer prefilled syringes, taken on an empty stomach first thing in the morning followed by 240 mL (8 oz) of water.
224325176|NCT05536739|DEVICE|Robotic hip exoskeleton|The intervention is an experimental robotic hip exoskeleton in a powered state providing assistance to the user that has been previously developed by the team. It is used to improve walking gait performance.
224325177|NCT05536739|OTHER|No hip exoskeleton|The intervention will serve as a baseline where participants will be asked to perform the tasks without wearing a hip exoskeleton.
224325178|NCT05536739|DEVICE|Unpowered hip exoskeleton|The intervention is an experimental robotic hip exoskeleton in an unpowered state that has been previously developed by the team. It is used to improve walking gait performance.
224325179|NCT06685757|DRUG|Felzartamab|Participants will receive felzartamab by intravenous infusion.
224325180|NCT06685757|DRUG|Placebo|Participants will receive 0.9% saline solution by intravenous infusion.
224325181|NCT07016412|DRUG|Ensifentrine 3 mg|Administered by a standard jet nebulizer, twice daily for 28 consecutive days
224325182|NCT07016412|DRUG|Glycopyrrolate 21.25 mcg|Administered by a standard jet nebulizer, twice daily for 28 consecutive days
224325183|NCT07016412|DRUG|Glycopyrrolate 42.5 mcg|Administered by a standard jet nebulizer, twice daily for 28 consecutive days
224325184|NCT07016412|DRUG|Placebo|Administered by a standard jet nebulizer, twice daily for 28 consecutive days
224325185|NCT07015983|DRUG|CC-97540|Specified dose on specified days
224325186|NCT07015983|DRUG|Fludarabine|Specified dose on specified days
224325187|NCT07015983|DRUG|Cyclophosphamide|Specified dose on specified days
224325188|NCT07015047|DIETARY_SUPPLEMENT|Magnesium L-Threonate|Participants in this arm will take 1 gram of magnesium L-threonate (Magtein), provided in capsule form, once daily in the evening for 4 weeks. This supplement is known for its ability to cross the blood-brain barrier and may enhance sleep architecture, autonomic recovery, and cognitive function.
223682437|NCT01419067|PROCEDURE|Radical Surgery or Limited Surgery|Patients will be selected for radical surgery based on the neurosurgeon's assessment that a Gross-Total Resection may be achieved with acceptable post-operative morbidity. The goal of surgical intervention in this study should be to facilitate tumor control, keeping surgical morbidity to a minimum. Common indications for surgical intervention directed at the tumor will include establishing a tissue diagnosis, tumor control by radical resection, relieving tumor mass effect to reduce symptoms and decreasing the target volume for proton therapy by planned volume reduction surgery. These indications can be achieved through radical or limited surgery.
223774571|NCT06491394|DIAGNOSTIC_TEST|Nrf2|Nrf2 expression in kidney and heart tissues
223774572|NCT06491394|DIAGNOSTIC_TEST|AMPK|AMPK levels in heart and kidney tissues
223774573|NCT06491394|DIAGNOSTIC_TEST|HO-1|HO-1 levels in kidney and heart tissues
223774574|NCT06491394|DRUG|glycerin|GLY intramuscular injection for rhabdomyolysis induction
224325189|NCT07015047|OTHER|Placebo|Identical-looking inert capsule taken nightly for 4 weeks. Used as a comparator to magnesium L-threonate to assess changes in sleep, recovery, and performance metrics.
224325190|NCT07013487|BIOLOGICAL|V181|Participants will receive a single 0.5 mL SC dose of V181 on Day 1.
224325191|NCT07013487|BIOLOGICAL|Placebo|Participants will receive a single 0.5 mL SC dose of placebo on Day 1.
224325192|NCT06624059|DRUG|Alectinib|"Cohort B1: participants will receive oral alectinib twice daily (BID) for up to 5 years.~Cohort B2: Participants will receive oral alectinib BID for 3 cycles (cycle length = 3 weeks) prior to surgery, and for up to 5 years after surgery."
224325193|NCT06624059|DRUG|Cisplatin|"Cohort B1: Participants will receive intravenous (IV) cisplatin on Day 1 of each cycle for up to 4 cycles (cycle length = 3 weeks).~Cohort B2: Participants will receive IV cisplatin on Day 1 of each cycle for up to 3 cycles (cycles length = 3 weeks) prior to surgery."
224325194|NCT06624059|DRUG|Carboplatin|"Cohort B1: Participants will receive IV carboplatin on Day 1 of each cycle for up to 4 cycles (cycle length = 3 weeks).~Cohort B2: Participants will receive IV carboplatin on Day 1 of each cycle for up to 3 cycles (cycle length = 3 weeks) prior to surgery."
224325195|NCT06624059|DRUG|Pemetrexed|"Cohort B1: Participants will receive IV pemetrexed on Day 1 of each cycle for up to 4 cycles (cycle length = 3 weeks).~Cohort B2: Participants will receive IV pemetrexed on Day 1 of each cycle for up to 3 cycles (cycle length = 3 weeks) prior to surgery."
223774575|NCT04097067|RADIATION|Radiation Therapy|Low dose radiotherapy with 20 Gy (10x2Gy)
223774576|NCT06677190|DRUG|Belzutifan|A Hypoxia-Inducible Factor-2 alpha inhibitor, 40 mg immediate-release tablet, taken orally per protocol.
223774577|NCT06908057|OTHER|Blood Draw|We will draw blood to measure islet-related autoantibodies and celiac disease markers with a combined research method, blood sugar, C-peptide (an indicator of insulin production that controls sugar levels) and hemoglobin A1c. Additional blood will be collected for the study of biomarkers of T1D and for long-term storage for potential future use.
223774578|NCT05181007|DRUG|Mefanamic Acid|mefanamic acid once every 6 hours on Day 4 and Day 5, Ciprofol on Day 1 and Day 5
223774579|NCT05181007|DRUG|Valproate|valproate once daily on Day 4 to Day 8, Ciprofol on Day 1 and Day 8
223774580|NCT02078583|DRUG|Fentanyl|
223774581|NCT02078583|DRUG|Remifentanil|
224325196|NCT07015437|DEVICE|INTERCEPT Blood System for RBCs|RBCs treated with the INTERCEPT Blood System for RBCs
224325197|NCT07015437|OTHER|Infusion of autologous radiolabeled RBCs|Subject will receive a single intravenous infusion of approximately 10 to 30 mL of autologous Day 35 51Cr radiolabeled RBCs and fresh 99mTc RBCs.
224325198|NCT07013474|DRUG|ibuzatrelvir|tablet
224325199|NCT07013474|DRUG|remdesivir|injection, for intravenous use
224325200|NCT07013474|DRUG|placebo for ibuzatrelvir|tablet
224325201|NCT07013474|DRUG|placebo for remdesivir|injection, for intravenous use
224325202|NCT07012057|DRUG|Deucravacitinb|Participants will receive a 6mg pill taken 2 times per day over 24 weeks and an optional extension period
224325203|NCT06875882|BEHAVIORAL|Occupational Stress in Surgeons and Musicians|Participants will complete 5 questionnaires about participants demographics, burnout rates, and anxiety levels after participants consent to this study. These questionnaires will be sent to participants via email and should take about 15-20 minutes to complete.
224325204|NCT06868914|DEVICE|TMS (MagVenture MagPro 100 with MagOption)|"TMS will be applied using the MagVenture MagPro 100 with MagOption (MagVenture Inc, Alpharetta, GA) stimulator with a figure-of-8 TMS coil.~Each subject will receive 3 active TBS (3-,4-, and 5-pulse TBS) and 1 sham TBS on 4 visits separated by at least 48 hours."
224325205|NCT04657068|DRUG|ART0380|Participants will receive ART0380 by mouth either intermittently (either once daily 3 days on, 4 days off; days 2-4 and 9-11;or days 1-3 and 8-10) or continuously (once daily each day) in 21 day cycles.
224325206|NCT04657068|DRUG|Gemcitabine|Gemcitabine was administered on Days 1 and 8 of a 21-day cycle.
224325207|NCT04657068|DRUG|Irinotecan|Irinotecan will be administered as a 90-minute infusion on Days 1 and 8 of a 21 day cycle.
224325208|NCT05410145|DRUG|D3S-001|Oral
224325209|NCT05410145|DRUG|Pembrolizumab|Intravenous
224325210|NCT05410145|DRUG|Cisplatin|Intravenous
224325211|NCT05410145|DRUG|Carboplatin|Intravenous
224325212|NCT05410145|DRUG|Pemetrexed|Intravenous
224325213|NCT05410145|DRUG|Cetuximab|Intravenous
224325214|NCT06253117|DRUG|Pirfenidone|"Pirfenidone Days 1-7: 267 mg PO TID (801 mg/day) Days 8-14: 534 mg PO TID (1602 mg/day) Day 15 and thereafter: 801 mg PO TID; not to exceed 2403 mg/day~Duration of treatment- total 6 months"
224325215|NCT06253117|DRUG|Placebo|Placebo
223682438|NCT01419067|DEVICE|Proton Therapy|Proton therapy will be started once a final treatment plan has been developed and approved. There is no time limit for the interval from enrollment to when proton therapy commences. The total prescribed dose will be 54CGE administered at 1.8CGE per fraction. The time course of administration will be one fraction per day, 5 days per week, for a period of 6 weeks. Radiation will be prescribed to the planning target volume which will include the tumor bed encompassed by an anatomically defined margin meant to include subclinical microscopic disease, and an additional geometric margin that is meant to account for the technical limitations associated with planning and administering daily fractionated treatment. Making radiation therapy safer through the use of proton therapy.
224325216|NCT07023029|DRUG|Etavopivat|Etavopivat will be administered orally.
224325217|NCT07023029|DRUG|Moxifloxacin|Moxifloxacin will be administered orally.
224325218|NCT07023029|DRUG|Placebo|Placebo matching Etavopivat will be administered orally.
224325219|NCT06629779|DRUG|PF-06821497|Oral continuous
223682439|NCT01419067|DRUG|^1^8F-fluorodeoxyglucose|This is a contrast media that will be given intravenously to aid in tumor visualization.
223682440|NCT01419067|DRUG|^1^1C-methionine|This is a contrast media that will be given intravenously to aid in tumor visualization.
224325220|NCT06629779|DRUG|Placebo|Oral continuous
224325221|NCT06629779|DRUG|Enzalutamide|Oral continuous
224325222|NCT06630351|BEHAVIORAL|Behavioral Counseling|Participate in MCP-C
224325223|NCT06630351|OTHER|Discussion|Participate in virtual group discussions
224325224|NCT06630351|OTHER|Health Promotion and Education|Receive reading exercises and workbook materials
224325225|NCT06630351|OTHER|Interview|Ancillary studies
224325226|NCT06630351|OTHER|Questionnaire Administration|Ancillary studies
224325227|NCT06691659|DIAGNOSTIC_TEST|CT-DACE|Photon Counting CT scan
224325228|NCT07022119|DRUG|VX-407|Suspension for oral administration.
224325229|NCT07022119|DRUG|Placebo|Suspension for oral administration.
224325230|NCT07023666|DRUG|Deferoxamine|Deferoxamine is used to reduce excess iron accumulation after monitoring iron levels. Adjustment to therapy will be based on iron burden assessments throughout the study duration.
224325231|NCT07023666|DRUG|Deferasirox|Deferasirox is used for iron chelation therapy based on iron burden assessment throughout the study.
224325232|NCT07023666|DRUG|Deferiprone|Deferiprone is used for iron chelation therapy used throughout the study.
224325233|NCT07023666|DEVICE|Echocardiography|This device uses ultrasound waves to create images of heart to help evaluate the heart's structure and function. This allows the detection of abnormalities of heart due to iron overload through out the study.
224325234|NCT07023666|DEVICE|Electrocardiogram (ECG)|The Electrocardiogram (ECG) device records the electrical activity of the heart. It is crucial for identifying arrhythmias and conduction abnormalities, which can be exacerbated by iron accumulation in the heart.
224325235|NCT07023393|DEVICE|Intraoperative spinal measurement system|The design is a prospective study to evaluate the effectiveness of a novel intraoperative spinal measurement tool to assist the surgeon with achieving preoperatively planned alignment-related parameters during surgery.
224325236|NCT07025434|PROCEDURE|Hip Bump Manipulation|This technique is a high velocity low amplitude thrust (HVLAT) directly posterior to the greater trochanter which theorizes the quick stretch of the external rotator muscles and may improve a malpositioned femoral head within the acetabulum.
224325237|NCT07025434|PROCEDURE|Sham (No Treatment)|Iliac Crest Sham Manipulation
224325238|NCT07025837|DEVICE|iRESTORE Illumina LED Face Mask and Neck & Chest Mask|A pair of light-emitting diode (LED) therapy devices designed for at-home use. The facial and neck/chest masks deliver low-level red light therapy through embedded LEDs to improve visible signs of skin aging.
224325239|NCT06698627|DEVICE|Daily Disposable Continence Device|The Poise® Impressa® is an over-the-counter intravaginal device for women over the age of 21 years with SUI. It is a disposable, one-time use tampon-like device that comprises a core, cover, and applicator. The device is inserted and removed like a vaginal tampon and comes in three sizes.
224325240|NCT06698627|DEVICE|Monthly Disposable Continence Device|The Revive® is another over the counter vaginal insert for the treatment of SUI. This is a self-deployable, double-loop pessary device.
224325241|NCT06632600|DRUG|LXE408|LXE408 administered by oral route
224325242|NCT06632600|DRUG|Placebo|Placebo administered by oral route
224325243|NCT06632600|DRUG|Benznidazole|Benznidazole administered by oral route (administered as standard of care)
223682441|NCT04395508|DRUG|Pertuzumab and Trastuzumab Fixed-Dose Combination for Subcutaneous Administration (PH FDC SC)|PH FDC SC is given as a fixed dose (i.e. non-weight based) subcutaneous injection. Two dosage configurations of PH FDC SC may be administered in the study: a 15-millilitre (mL) loading dose consisting of 1200 milligrams (mg) pertuzumab and 600 mg trastuzumab and a 10-mL maintenance dose consisting of 600 mg pertuzumab and 600 mg trastuzumab. Participants who have had ≥6 weeks since their last P+H IV, PH FDC SC, or are receiving trastuzumab SC treatment must receive a loading dose before continuing with maintenance doses for subsequent administrations. Note that participants receiving trastuzumab SC only (i.e. without pertuzumab) must receive a loading dose regardless of time since last treatment.
223682442|NCT00715416|DEVICE|Nitinol stent|Interventions are performed percutaneously from either an antegrade or an over-the-bifurcation approach. After insertion of an 6 French sheath, 5000 IU of heparin are administered intra-arterially. After passage of the stenosis/occlusion with the guide wire, patients are randomized to either PTA or primary stent implantation. For standardized documentation of the lesion morphology and comparability during follow-up, a ruler is fixed at the patients thigh with the distal end exactly overlapping at the upper edge of the patella. As a bail-out procedure in the PTA group, stent placement is performed in cases with a residual stenosis of more than 30% in the worst view angiogram.
223682443|NCT00715416|PROCEDURE|Nitinol Stent Placement|Balloon angioplasty compared to primary stent implantation for long segment superficial femoral artery lesions
223682444|NCT05425576|DRUG|OT-101|OT-101 in combination of pembrolizumab
223682445|NCT03458806|DIAGNOSTIC_TEST|AS Algorithm 1|Machine learning algorithm, generated from ECG and PCG recordings, distinguishing moderate-to-severe or greater aortic stenosis from controls having structurally normal hearts with no greater than mild valvular heart disease at any location.
223682446|NCT03458806|DIAGNOSTIC_TEST|AS Algorithm 2|Machine learning algorithm, generated from ECG and PCG recordings, distinguishing moderate-to-severe or greater aortic stenosis from controls having any findings other than moderate-to-severe or greater aortic stenosis.
223682447|NCT03458806|DIAGNOSTIC_TEST|MR Algorithm 1|Machine learning algorithm, generated from ECG and PCG recordings, distinguishing moderate-to-severe or greater mitral regurgitation from controls having structurally normal hearts with no greater than mild valvular heart disease at any location.
223682448|NCT03458806|DIAGNOSTIC_TEST|MR Algorithm 2|Machine learning algorithm, generated from ECG and PCG recordings, distinguishing moderate-to-severe or greater mitral regurgitation from controls having any findings other than moderate-to-severe or greater mitral regurgitation.
223682449|NCT03383731|PROCEDURE|Group 1|the surgical method of standard 3-port 23 gauge pars plana vitrectomy + internal limiting membrane peeling + air-fluid exchange + silicone oil infusion
223682450|NCT03383731|PROCEDURE|Group 2|the surgical method of standard 3-port 23 gauge pars plana vitrectomy + internal limiting membrane peeling + inverted internal limiting membrane insertion + air-fluid exchange
223682451|NCT05687604|BEHAVIORAL|multiple behavior change therapy|goals related to their physical activity, smoking, and/or obesity, and will be asked to meet those goals weekly/daily. Participants will also be asked to record their weight, activity, and/or cigarette smoking daily, and will complete 16 telehealth sessions with study staff across the 12 months of the study. Will have physical measures taken or extracted from the medical record at baseline, 3 months, 6 months, and 12 months.
223682452|NCT01139424|DEVICE|endoscopic suturing|endoscopic suturing of the anastomotic leak
223682453|NCT00000495|BEHAVIORAL|diet, reducing|
223682454|NCT00000495|BEHAVIORAL|diet, sodium-restricted|
224325244|NCT06873789|DRUG|INCB177054|INCB177054 will be administered at protocol defined dose.
224325245|NCT06873789|DRUG|Retifanlimab|Retifanlimab will be administered at protocol defined dose.
224325246|NCT07024342|DEVICE|Liner perforated with very small diameter holes|A commercially available, elastomeric liner perforated with very small holes (approximately 0.3 mm diameter) to allow perspiration to drain. This liner is worn between the skin and the participant's prosthetic socket.
224325247|NCT07024342|DEVICE|Liner perforated with somewhat larger diameter holes|A commercially available, elastomeric liner perforated with somewhat larger holes (approximately 1.5 mm diameter) to allow perspiration to drain. This liner is worn between the skin and the participant's prosthetic socket.
224325248|NCT07024342|DEVICE|Liner-liner|A thin, special purpose half-ply sock which may reduce the effects of perspiration. The liner-liner is worn between the skin and the participant's as-prescribed liner.
224325249|NCT07024342|DEVICE|As-prescribed liner|A commercially available, elastomeric liner with no perforations. This liner is worn between the skin and the participant's prosthetic socket.
224325250|NCT06671483|DRUG|Zasocitinib|Zasocitinib over-encapsulated tablets.
224325251|NCT06671483|DRUG|Active Comparator|Active comparator capsule.
223682455|NCT00000495|BEHAVIORAL|alcohol restriction|
223682456|NCT00000495|BEHAVIORAL|exercise|
223682457|NCT02065115|OTHER|Cryotherapy (ice pack)|
223774582|NCT02078583|DRUG|Normal saline|
223774583|NCT06620757|DRUG|Single antiplatelet therapy (SAPT)|Observational study of effectiveness and safety of SAPT (either with acetyl-salycilic acid or clopidogrel) after LAAO with Lambre device in patients with high risk of bleeding
223774584|NCT03578484|DIAGNOSTIC_TEST|Aesthetic assessment 3D breast scanning|Vectra TM - Canfield Inc breast scan. 3D digital photography scan.
224325252|NCT06671483|DRUG|Placebo|Zasocitinib or active comparator matching placebo.
224325253|NCT07027839|DRUG|Intravenous Ethanol|Intravenous ethanol infusion before PET Scan
224325254|NCT07027839|DRUG|18F-PF-06445974|Injected IV followed by PET scanning
224325255|NCT06690892|DIETARY_SUPPLEMENT|Ready-to-eat beef in frozen, 5-oz packages|The dietary intervention lasts 12 weeks for each individual. Participants in the experimental group will receive this intervention. Each participant will acquire 5 portions of ready-to eat beef in frozen packages per week, and consume 5 portions per week (1 portion of sirloin cap steak strips, 1 portion of shredded chuck roast, 1 portion of petite shoulder medallions, and 2 portions of ground beef crumbles); each portion of ready-to-eat beef in this intervention will weigh 5 ounces.
223774585|NCT06928168|OTHER|Total sleep deprivation|This group will perform an incremental running test, conducted until exhaustion, in: - a control condition (usual sleep) - a one-night condition of partial sleep deprivation - a one-night partial sleep deprivation condition with 5 nights of prior extension. The order of conditions will be randomized.
223774586|NCT06928168|OTHER|partial sleep deprivation|This group will perform an incremental running test, conducted until exhaustion, in: - a control condition (usual sleep) - a one-night condition of partial sleep deprivation - a one-night partial sleep deprivation condition with 5 nights of prior extension. The order of conditions will be randomized.
223774587|NCT06928168|OTHER|Reproductibility|This group will perform an incremental running test, driven to exhaustion, after a night of total sleep deprivation twice, at least two weeks apart.
223774588|NCT06945575|OTHER|Opus loop|17X25SS will used to fabricate opus loop which is L shaped loop with helix
223774589|NCT06945575|OTHER|T loop|17X25SS wire will be used to fabricate T-loop which is a T shaped loop
223774590|NCT00043693|BEHAVIORAL|Family Intervention for Dual Diagnosis|The family intervention for dual diagnosis program lasts for up to 3 years and includes both single and multiple-family group formats.
223774591|NCT00043693|BEHAVIORAL|Family psychoeducation program|The family psychoeducation program consists of 6 weekly sessions.
223774592|NCT05162976|BIOLOGICAL|Nivolumab|Given IV
224325256|NCT06690892|DIETARY_SUPPLEMENT|Ready-to-eat beef in frozen, 1-oz packages|The dietary intervention lasts 12 weeks for each individual. Participants in the control group will receive this intervention. Each participant will acquire 5 portions of ready-to eat beef in frozen packages per week, and consume 5 portions per week (1 portion of sirloin cap steak strips, 1 portion of shredded chuck roast, 1 portion of petite shoulder medallions, and 2 portions of ground beef crumbles); each portion of ready-to-eat beef in this intervention will weigh 1 ounce.
224325257|NCT06700668|DEVICE|MIT Powered Knee|MIT powered knee prosthesis developed by the MIT Biomechatronics Group.
224325258|NCT06699212|COMBINATION_PRODUCT|ASP-1929 Photoimmunotherapy|ASP-1929 IV infusion followed by illumination with light dose of 50 J/cm\^2 for superficial lesions and 100 J/cm for interstitial lesions within 24 +/- 4 hours after the end of ASP-1929 infusion (up to 24 months)
224325259|NCT06699212|BIOLOGICAL|Pembrolizumab|200 mg Q3W or 400 mg Q6W, IV infusion over 30 minutes (up to 24 months)
224325260|NCT06699212|DRUG|Carboplatin|Area under the curve (AUC) 5 mg/mL/min IV infusion, Q3W up to 6 cycles
224325261|NCT06699212|DRUG|Cisplatin|100 mg/m\^2 IV infusion, Q3W up to 6 cycles
224325262|NCT06699212|DRUG|5-fluorouracil|1000 mg/m\^2 per day from Days 1-4 of each cycle, IV infusion, Q3W up to 6 cycles
224325263|NCT06699212|DRUG|Paclitaxel|100 mg/m\^2 IV infusion given on Days 1 and 8, Q3W up to 6 cycles or 175 mg/m\^2 IV infusion given on Day 1, Q3W up to 6 cycles
224325264|NCT06699212|DRUG|Docetaxel|75 mg/m\^2 IV Infusion, Q3W up to 6 cycles
224325265|NCT07027826|DEVICE|Esophageal string test|The esophageal string test consists of a gelatin or cellulose capsule containing a nylon string. The capsule dissolves allowing the nylon string to absorb esophageal secretions which can be analyzed for various inflammatory mediators.
223774593|NCT05162976|DRUG|Oral Azacitidine|Given PO
223774594|NCT06306118|DEVICE|Multiple stereotactic Tumor Biopsies during a Brain Tumor Resection|For pre-resection biopsy cases (3 target per patient), the targets will be selected from metabolite hotspots on MR-spectroscopy imaging and/or amino acid tracer uptake hotspots on PET imaging. Depending on the tumor location and surgical procedure, all biopsies will be performed via one single or multiple entry points.
223774595|NCT04356716|DRUG|Sildenafil|Initial Sildenafil dosage will be weight dependent. Participants will start at 40 mg daily (20mg in the morning, 20 mg in the evening) or 60 mg daily (40mg in the morning and 20 mg in the evening). Sildenafil dosage may be increased to up to 80mg daily (20-40mg in the morning and 20-40mg in the evening) based on the response to lower doses. If the participant has not had improvement after initial treatment, the dose may be increased, at the discretion of the study physician.
223774596|NCT04356716|OTHER|Standard of Care Sildenafil|Medical record review of participants that receive Sildenafil as part of standard of care.
223774597|NCT04356716|DIAGNOSTIC_TEST|Ocular Coherence Tomography-Angiography (OCT-A)|Retinal photographs will be taken at each study visit.
223774598|NCT04356716|OTHER|Visual Acuity (VA)|Visual acuity will be measured with Snellen Eye Chart at each study visit.
223774599|NCT00320281|DRUG|botulinum toxin A|Injection of BTXA into cervical and upper back muscles based on treatment plan prescribed for each participant individually based on muscle soreness and tightness. Injections occured on one single clinic visit.Both the saline and BTXA were dosed in 25 cc syringes and looked the same for the physician performing the injections to ensure both participant and study physician remained blinded.
223774600|NCT00320281|OTHER|placebo|Injection of normal saline into cervical and upper back muscles was also based on treatment plan prescribed for each participant individually based on muscle soreness and tightness. Injections occured on one single clinic visit. Both the saline and BTXA were dosed in 25 cc syringes and looked the same for the physician performing the injections to ensure both participant and study physician remained blinded.
223774601|NCT05297994|BIOLOGICAL|Flu-M [Inactivated split influenza vaccine]|solution for intramuscular injection, 0.5 ml
223774602|NCT05297994|BIOLOGICAL|Inactivated influenza split vaccine|solution for intramuscular injection, 0.5 ml
223774603|NCT04747938|DEVICE|Energy accumulator|All subjects treated with thermal therapy using the Energy Accumulator by acupoint concepts. The course included 8 sessions of treatment, twice every week for 4 weeks. Each session lasted for 30-45 minutes. During heat therapy, the ceramic nozzle of the Energy Accumulator was lightly pressed in contact of the skin, without any contact medium, and moved slowly along the meridians with some circular movements.
223774604|NCT04747938|BEHAVIORAL|Home exercise program|Home exercises aimed at providing gentle mobilization at the shoulder and were capable of carrying out at home. Patients were requested to perform the movements on a daily basis within the first 4 weeks of treatment. Four movements were involved: Movement 1 - Pendular Exercise, Movement 2 - Circle Exercise, Movement 3 - Wall Climbing Exercise, and Movement 4 - Lie on bed and move both arms up and down.
223774605|NCT01876121|DRUG|Celecoxib|oral
223682458|NCT03923322|DRUG|Botanical Tincture|Study participants will meet with the Investigator at baseline and week 2, 6, and 10 after the study period begins. Trial continuation criteria at 2 weeks after the start of the study includes abdominal pain intensity and stool frequency. Participants randomized to Botanical Tincture will have a 2-week withdrawal period. On the visits study participants may expect to be asked about epidemiologic information, IBS medications, IBS Quality of Life survey instruments, and daily diary of pain scale, bloating scale, and number of bowel movements.
223774606|NCT00113113|DRUG|Rubitecan|
223774607|NCT02120339|DRUG|Carvedilol|
223774608|NCT02522897|DRUG|Ranibizumab|
223774609|NCT02522897|DEVICE|Laser|
223774610|NCT05534282|BEHAVIORAL|Interaction-focused Music Therapy with Children and Significant Others (INMUT-KB) (exp. group)|Interaction-focused music therapy with children with cancer and their significant others, delivered by trained music therapists.
223774611|NCT05534282|BEHAVIORAL|Music Therapy with Children (MUT-K) (exp. group)|Interaction-focused music therapy with children with cancer without the involvement of significant others, delivered by trained music therapists.
223774612|NCT05534282|BEHAVIORAL|Interaction-focused Music Therapy with Children and Significant Others (WG-KB) (control group)|Study participants randomized to this group receive the intervention INMUT 10 weeks after the experimental groups.
223774613|NCT02010424|OTHER|control group|standard IVF protocol
223774614|NCT02010424|DEVICE|Primo Vision embryo culture dish (CE labeled, Vitrolife)|
223774615|NCT04251559|OTHER|oral glucose loading test|oral glucose loading test was performed to all participants. gestational diabetes and control group were compared in terms of menarche age.
223774616|NCT03849638|OTHER|Gait training with real time biofeedback|"Patients presenting asymmetry of the kinematic parameters of the step to the evaluation with sensorized treadmill, will undergo gait training program.~The training program consists of 20 session (1 session/day) of gait training. Daily gait training will last 30 minutes as distributed:~* 5 minutes of heating at a comfortable speed for the patient~* Three 5-minute sessions of gait training with biofeedback interspersed with a break of 5 minutes each."
223774617|NCT00687505|DRUG|FP-1039|Intravenous weekly administration
223774618|NCT06468644|DRUG|chemoradiotherapy （CRT）+sintilimab 1|radiotherapy (50.4Gy/1.8Gy/28f)+chemotherapy (paclitaxel 150mg/m2 D1+cisplatin 25mg/m2 D1-3，Q3W)+Sintilimab (200mg, iv, D1, Q3W) Consolidation therapy: Sintilimab: 200mg, iv, D1, Q3W
223774619|NCT06468644|DRUG|CRT+sintilimab 2|radiotherapy (60Gy/2Gy/30f)+chemotherapy (paclitaxel 150mg/m2 D1+cisplatin 25mg/m2 D1-3，Q3W)+Sintilimab (200mg, iv, D1, Q3W) Consolidation therapy: Sintilimab: 200mg, iv, D1, Q3W
224325266|NCT06758414|BEHAVIORAL|Cognitive Behavioral Therapy for Chronic Pain (CBT-CP)|Cognitive Behavioral Therapy for Chronic Pain (CBT-CP) will be conducted in accordance with the Cognitive Behavioral Therapy for Chronic Pain: Therapist Manual and the VA Evidence-Based Practice (EBP) roll-out training. CBT-CP consists of a 12-session protocol, including an initial assessment session (BL assessment; Session 1), 10 content-specific sessions (pain education, goal-setting, cognitive and behavioral skill building; Sessions 2-11), and a booster session scheduled approximately one month after the final CBT-CP session (Session 12). Participants randomized to the CBT-CP condition (n = 30) will complete one 60-minute individual session per week. Each CBT-CP session will be led by a trained study interventionist using a manualized curriculum, following a basic structure including review of previous session material, introduction of new information or skills, and discussion of how to implement learned material into a home action plan.
224325267|NCT06758414|BEHAVIORAL|Health & Wellness (H&W)|Health \& Wellness (H\&W) was developed by VISN 5 MIRECC investigators and consists of psychoeducation on topics related to physical and emotional wellbeing. Its structure is similar to CBT-CP (10 weekly individual 60-minute sessions, no booster session). Each Health \& Wellness session will be led by a trained interventionist using a manualized curriculum that includes review of previous session material, introduction of new information, and discussion of a range of health-related topics (physical activity/exercise, nutrition/healthy eating, managing medications and side effects, and addictive behaviors (e.g., substance use, gambling, eating) that do not include pain. Typical sessions include discussion of the impact of the topic on overall health and well-being, identifying benefits and challenges to improving or maintaining health in that area, and strategies to address challenges in that area.
224325268|NCT06706622|DRUG|Lu AF82422|Solution for infusion
224325269|NCT06706622|DRUG|Placebo|Commercially available saline solution
224325270|NCT07137455|DEVICE|EDEN Intracardiac Electrogram Recording and Classifying System|EDEN will be used to record and classify intracardiac electrograms obtained in the practice of medicine.
224325271|NCT06710548|BEHAVIORAL|REVITALIZE Intervention|A remotely delivered tele-health intervention to address cancer fatigue that is based on an acceptance-based approach. The intervention includes 8 one-on-one weekly sessions and 2 booster sessions with trained psychology doctoral students based at University of Colorado. Sessions will focus on fatigue education, Acceptance and Commitment Therapy (ACT) skills, and behavior changes. Wi-Fi enabled tablets and keyboards will be provided to participants if needed. All sessions will be conducted via the Zoom platform and will either be videotaped or audiotaped.
224325272|NCT06710548|BEHAVIORAL|Educational Materials|The educational materials arm will receive specialized cancer survivorship educational materials created by the National Cancer Institute
223774620|NCT02352324|OTHER|Fluid responsiveness tests|After the end of surgery in ICU the positive end-expiratory pressure (PEEP) test of 15 cm H2O for 300 seconds will be performed. Following PEEP test, the two-step fluid load test of 6 ml/kg balanced crystalloid solution will be performed sharing in two portions: Initial mini FLT (mFLT) of 1.5 ml/kg within 1 min (approximately 100 mL) followed by the registration of continuous CI and traditional fluid responsiveness parameters and the rest of standard FLT (4.5 mL/kg) within 5 minutes (approximately 350 mL) followed by transpulmonary thermodilution, registration of continuous cardiac index (CI) and classic fluid responsiveness parameters.
223774621|NCT03794765|DRUG|Ceftriaxone|Injection ceftriaxone 1 gm will be prepared by reconstitution of the crystallised powder form in 100 ml of normal saline. This preparation will then be infused slowly over thirty minutes, after intradermal testing for hypersensitivity. Inj ceftriaxone 1gm IV will be given twelve hourly.
223774622|NCT03794765|DRUG|Metronidazole|Injection metronidazole 500 mg is available from pharmacies in solutions of 100 ml. It will be infused slowly over thirty minutes, three times per day
223774623|NCT03794765|OTHER|Placebo infusion|Similar placebo infusion
223774624|NCT02690246|OTHER|questionnaire|a questionnaire based study
223774625|NCT02629146|DRUG|Midazolam|
223774626|NCT02629146|DRUG|Fentanyl|
223682459|NCT03923322|OTHER|Placebo|Study participants will meet with the Investigator at baseline and week 2, 6, and 10 after the study period begins. Trial continuation criteria at 2 weeks after the start of the study includes abdominal pain intensity and stool frequency. On the visits study participants may expect to be asked about epidemiologic information, IBS medications, IBS Quality of Life survey instruments, and daily diary of pain scale, bloating scale, and number of bowel movements.
223682460|NCT06636266|OTHER|Survey using a questionnaire.|This research will examine any potential differences in the professional identity of Scottish chiropractors utilising the Chiropractic Professional Identity Embodiment Scale (CPIES) and the Subtype Orientation Scale (CPISOS).
223682461|NCT06630819|OTHER|1.8 ml of 4% Articaine|Buccal infiltration of 1.8 ml of 4% Articaine
223682462|NCT06630819|OTHER|3.6 ml of 4% Articaine|Buccal infiltration of 3.6 ml of 4% Articaine.
223682463|NCT04966741|DRUG|Setmelanotide|SC injection once daily.
223682464|NCT04726397|RADIATION|Reduced margin adaptive radiotherapy|Reduced (5 mm) clinical target volume margin with weekly contrast-enhanced adaptive radiation on the MR-Linac treatment machine
223682465|NCT05340907|DEVICE|Virtual Reality Device|A virtual reality headset is a heads-up display (HUD) that allows users to interact with simulated environments and experience a first-person view (FPV). VR headsets replace the user's natural environment with virtual reality content, such as a movie, a game or a pre-recorded 360-degree VR environment that allows the user to turn and look around, just as in the physical world. Patient undergoing bronchoscopy will be given the device before and during the procedure.
223682466|NCT01784393|RADIATION|chemoradiation|
223682467|NCT00276913|DRUG|STA-5312|
223682468|NCT06595030|DEVICE|Active Lighting Intervention|The TLI will allow researchers to use a light source that will control how the circadian system is stimulated and provide the participants with options as to how the light treatment will be delivered.
223682469|NCT06595030|DEVICE|Control Lighting Intervention|The TLI will allow researchers to use a light source that will not stimulate the circadian system and provide the participants with options as to how the light treatment will be delivered.
223682470|NCT05662462|DEVICE|DEXCOM G7 PRO Continuous Glucose Monitor|Participants in the intervention arm will be provided with DEXCOM® G7 PRO CGM sensors and transmitters. The Dexcom G7 CGM system is accurate and safe in pregnant individuals with diabetes. Participants will be taught how to place and remove CGM sensors by a trained research nurse, and will be given sensors to change themselves at home every 10 days. Of note, the DEXCOM® G7 PRO can be applied as a patch on the abdomen, arm, or upper buttocks, is well-tolerated in pregnancy, and does not require calibration. Our mHealth app will allow for wireless synchronization with the CGM sensor so that data are seamlessly reported back to the healthcare team.
223682471|NCT05662462|DEVICE|Patient mHealth app linked to a provider dashboard|The mHealth app is based on our team's prototype intervention developed at our study site. The mHealth app provides diverse functions, including education, reminders, care goals, care pathway recommendations, CGM data and PROs reporting and monitoring, messaging and video conferencing, and a calendar function. Content is based on clinical guidelines for diabetes in pregnancy. Participants will be directed to appropriate resources and online learning to help them navigate the app and its resources. PROs in the mHealth app will be embedded to address health and social needs, and rule-based algorithms will provide tailored care goals, show care pathways, and establish the frequency of elicited PROs.
223682472|NCT05662462|BEHAVIORAL|Care team coaching for medical and social needs (HUB)|"Participants will be screened at enrollment and throughout the intervention for social needs using a survey adapted from validated instruments, such as the Accountable Health Communities Health-Related Social Needs Screening Tool. The care team will refer participants with affirmative responses to the HUB through the provider dashboard to address social needs (e.g., food insecurity, housing, employment). HUB community health workers will perform comprehensive social needs assessments and connect participants to community resources through care pathways, a defined action plan addressing patient needs which is recorded and tracked."
223682473|NCT05662462|DEVICE|Provider dashboard|The ACHIEVE intervention will include a bi-directional dashboard that displays information about individuals, including priority care goals and pathways, and recommendations generated via PROMPT. Healthcare team members can access the dashboard embedded within a portal to modify or update information and close the loop on participant tasks. The dashboard will present recommendations for participant goals and pathways provided by the PROMPT algorithms. Providers can use these recommendations or manually select ones for the participant. Providers can sequence goals and pathways by level of complexity. Both the HUB and the healthcare team can perform ongoing assessments of HUB pathway selections and assess recurring needs through the provider dashboard.
223682474|NCT03490279|DIETARY_SUPPLEMENT|Lactoferrin CRX|Patients will be asked to take lactoferrin CRX as already mentioned (blindly).
223682475|NCT03490279|OTHER|Placebo|Patients will be asked to take placebo as already mentioned (blindly).
223774627|NCT02629146|DRUG|Isotonic saline|
223774628|NCT03554122|PROCEDURE|Shotblocker|Patients spinal injections were performed with Shotblocker placed onto injection site
223774629|NCT03554122|PROCEDURE|Placebo|Patients spinal injections were performed without Shotblocker
223774630|NCT03258476|DRUG|Guanfacine Extended Release|Intuniv (guanfacine) is a prescription medicine used to treat attention deficit hyperactivity disorder (ADHD) in children who are at least 6 years old. An open-label trail of guanfacine extended release (GXR 1-4 mg/daily; Intuniv™) suggested benefits in improving behavioral and emotional regulation in children and adolescents with symptoms of traumatic stress. However, to date no controlled clinical trial has been completed assessing the effects of GXR on traumatic stress symptoms in youths
223774631|NCT03258476|BEHAVIORAL|Mindfulness Skills Therapy|Mindfulness is a therapy for anxiety and stress. Mindfulness forms of therapy involve regulation of attention, maintaining it in immediate experience, regardless of the valence and desirability of the experience. To reduce anxiety, Mindfulness encourages observing and accepting anxiety-related thoughts
223774632|NCT03258476|DRUG|Placebo|Placebo oral capsule
223774633|NCT05708079|PROCEDURE|Endovascular thrombectomy|An endovascular thrombectomy is the removal of a thrombus (blood clot) under image guidance. A thrombectomy is most commonly performed for an arterial embolism, which is an arterial blockage often caused by atrial fibrillation, a heart rhythm disorder.
223774634|NCT00827372|DRUG|Pazopanib|Pazopanib will be administered at a starting dose of 800 mg orally once each day.
223774635|NCT01111656|DRUG|Interferon beta-1b group|Patients receive interferon beta-1b 250ug subcutaneously every other day
223774636|NCT01111656|DRUG|Interferon beta-1b/Atorvastatin group|Patients receive interferon beta-1b 250ug subcutaneously every other day AND atorvastatin 40mg every day (oral)
223835265|NCT00231894|BEHAVIORAL|Life style diet group|life style diet education group 1x/week
224325273|NCT07115199|PROCEDURE|Remote Patient Monitoring|The patients randomized to this intervention will get set up with remote patient monitoring. For these patients, blood pressure management and medication adjustment will be based on remote blood pressure measurements.
224325274|NCT06877858|DRUG|Methadone hydrochloride|Methadone loading dose initiation (vs. standard initiation in the TAU arm)
224325275|NCT06876649|DRUG|Pirtobrutinib|Administered orally.
224325276|NCT06876662|DRUG|Pirtobrutinib|Administered orally.
223682476|NCT04331197|DRUG|Clomiphene Citrate 50mg|Clomid 50 mg, 2 tablets orally every day from day 2-5 of the period for 5 days
223682477|NCT04331197|DRUG|Letrozole 2.5mg|Femara 2.5 mg, 2 tablets orally every day from day 2-5 of the period for 5 days
223682478|NCT00234910|DRUG|Tenofovir DF|TDF 300mg QD for 72 wks
223682479|NCT00234910|DRUG|lopinavir/ritonavir with 2 Nucleoside RTIs|LPV/rSGC 400/100mg BID + 2 nucleoside RTIs as prescribed by the Investigator for 72 wks
223682480|NCT06576739|PROCEDURE|Spinal Manipulation|Daily administration of combination of vitamin B6,,vitamin B12, and folic acid
223682481|NCT03486145|DIETARY_SUPPLEMENT|fruit and vegetable juice supplement|"FVS was provided by Isagenix International LLC in identically sealed bottles labeled labeled B. Subjects were not told which supplement they received. Each bottle contained one serving (two ounces) of the supplement."
223682482|NCT03486145|DIETARY_SUPPLEMENT|Placebo|"PRU was provided by Isagenix International LLC in identically sealed bottles labeled labeled A. Subjects were not told which supplement they received. Each bottle contained one serving (two ounces) of the supplement."
223682483|NCT04732897|PROCEDURE|dynamic dressing|Dynamic dressing is made by bandages of the foot with gauze pad, stretchable adhesive tape and elastic compression band
223682484|NCT02783469|GENETIC|Identification of genetic causes of diabetic neuropathic pain|
223682485|NCT04517955|DEVICE|Transcatheter Aortic Valve Implantation (TAVI)|Transcatheter Aortic Valve Implantation with Evolut R or Evolut Pro
223682486|NCT02048280|PROCEDURE|NAVA level|Peak inspiratory pressure will be measured at each NAVA level
223682487|NCT02048280|OTHER|NAVA level|Increase NAVA level every 3 minutes
223682488|NCT00247221|BEHAVIORAL|MI/Family Check-up|The experimental intervention integrates an individual Motivational Interview (MI) for the adolescent with a brief family intervention, the Family Check-Up. Follow-up interviews will be conducted at 3, 6, and 12 months after the baseline intervention.
223682489|NCT00247221|BEHAVIORAL|MI only|An individual motivational interview (IMI only) will be conducted at 3, 6, and 12 months after the baseline intervention to assess outcome.
223682490|NCT02171559|DRUG|Enoxaparin prefilled syringes|
223682491|NCT02171559|DRUG|Dabigatran etexilate capsules|
223682492|NCT01965886|PROCEDURE|Medial approach|Total knee replacement performed through a longitudinal incision medial to the patella
223682493|NCT01965886|PROCEDURE|Keblish approach|Total knee replacement performed through a longitudinal incision lateral to the patella
223682494|NCT06035770|OTHER|Mental Health First Aid (educational training program)|"The MHFA program is a 12-hour face-to-face training program delivered in four sessions of three hours each across four consecutive weeks by two accredited MHFA instructors. The class was administered in small groups with a maximum of 10-15 students.The program included didactic lectures and role playing to teach students how to recognize and react to the signs and symptoms of mental health illness. Participants enrolled in the intervention group received an accompanying manual with content that covered helping people in mental health crises and/or the early stages of mental health problems.~The mental health problems addressed during the training session included depressive symptoms, anxiety, psychotic disorders, and substance use disorders. The mental health crisis situations included suicidal thoughts/attempts and behaviors, acute stress reactions,panic attacks, and acute psychotic behaviors."
223682495|NCT03207919|BEHAVIORAL|Lullaby Project|Pregnant women will participate in 3 group sessions. They will write and record a lullaby, and then listen to each recorded lullaby and reflect on their experience.
223682496|NCT00284492|PROCEDURE|Traditional chinese medicine type acupuncture|10 acupuncture sessions
223835266|NCT00231894|OTHER|Placebo|placebo comparator capsules
223835267|NCT00747981|PROCEDURE|Thoracic CT Scan|Perform a CT Scan and an endoscopy
223835268|NCT02986828|DRUG|platelet rich plasma|Ultrasound-guided 3cc PRP injection between proximal carpal tunnel and median nerve.
224325277|NCT06487481|PROCEDURE|Surgical resection|Planned surgical resection (all participants) 4 weeks after completion of the preoperative RT
224325278|NCT06487481|RADIATION|Preoperative RT|Preoperative RT at escalating doses in daily fractions over approximately 2-3 weeks; 2 weeks (DL1), or 3 weeks (DL2 or DL3) based on assigned Cohort and Dose Level (DL). Cohorts are by mitotane status at enrollment: Cohort 1 (with detectable mitotane levels), Cohort 2 (never had or without detectable mitotane levels), Cohort 3 (either).
224325279|NCT07033494|BIOLOGICAL|MK-2214|IV infusion
224325280|NCT07033494|DRUG|Placebo|IV infusion
224325281|NCT07035431|DEVICE|Endo-SPONGE|The intervention involves the placement of an Endo-SPONGE in the leakage cavity, and applying suction to facilitate drainage.
224325282|NCT06057402|DRUG|Elranatamab|Elranatamab is a heterodimeric humanized full-length bispecific IgG2 kappa antibody that targets BCMA on MM cells and CD3 on T cells
223682497|NCT00284492|BEHAVIORAL|Self Care|Lifestyle advice on diet, physical activity
223682498|NCT05121493|OTHER|Platelet Poor Plasma Tear Drops|Participant blood will be drawn and processed by the University of Rochester Transfusion Medicine and Blood Bank. Processing will isolate the platelet free fraction of the blood plasma. After processing, plasma should contain ≤ 5% concentration of white blood cells (WBC), red blood cells (RBC), and platelets when compared to the concentration before processing.
223682499|NCT05121493|OTHER|Platelet Rich Plasma Tear Drops|Participant blood will be drawn and processed by the University of Rochester Transfusion Medicine and Blood Bank. Processing will isolate the platelet fraction of the blood plasma. After processing, plasma should contain ≤ 5% concentration of WBC and RBC and 100 x 10³ μl or ≥ 50% recovery of platelets when compared to the pre-platelet count.
224325283|NCT06710418|OTHER|Activity Tracking|Ancillary studies
224325284|NCT06710418|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
224325285|NCT06710418|PROCEDURE|Cognitive Assessment|Ancillary studies
224325286|NCT06710418|OTHER|Electronic Health Record Review|Ancillary studies
224325287|NCT06710418|OTHER|Packed Red Blood Cell Transfusion|Undergo PRBC transfusion
224325288|NCT06710418|OTHER|Quality-of-Life Assessment|Ancillary studies
224325289|NCT06699797|DEVICE|Acclaim Cochlear Implant|Participants with the Acclaim CI device will be tested during follow-up with their hearing results compared to baseline (before the device implant procedure).
224325290|NCT02512926|DRUG|Carfilzomib|Carfilzomib in combination with cyclophosphamide and etoposide for children with relapsed and refractory solid tumors and leukemias
224325291|NCT02512926|DRUG|Cyclophosphamide|
223682500|NCT02410785|DEVICE|Polyglucosamine|ß-1,4 polymer of D-glucosamine and N-acetyl-D-glucosamine from the shells of crustaceans
223682501|NCT02410785|OTHER|Placebo|Placebo tablet
223682502|NCT00957593|DRUG|Oxytocin|Continuation of oxytocin once in active labor
223682503|NCT00957593|DRUG|Oxytocin discontinuation|Oxytocin will be stopped once in active labor
223682504|NCT00263939|BEHAVIORAL|Homing in on Health|A peer (non-health professional) delivered intervention to enhance patient self-efficacy for chronic disease self-management. Developed as a modification of the Stanford Chronic Disease Self-Management Program.
223682505|NCT06139692|DRUG|Dexmedetomidine|Patients receive perioperative sedation with dexmedetomidine
223682506|NCT06139692|DRUG|Midazolam|Patients receive perioperative sedation with midazolam
223682507|NCT02328469|DRUG|symptomatic therapy|patients will receive symptomatic therapy with antipyretics, analgetics, antiemetics and parenteral hydration: metamizole, paracetamol, thiethylperazine, saline
223682508|NCT02328469|DRUG|Ceftriaxone or Doxycycline|beside symptomatic therapy (metamizole, paracetamol, thiethylperazine, saline), patients with proven or probable Lyme neuroborreliosis will be treated with ceftriaxone 2 g intravenously once daily for 14 days OR doxycycline 100 mg orally twice daily for 14 days
223682509|NCT02328469|OTHER|questionnaire|Control subjects will be asked to answer a questionnaire asking about the presence and frequency of nonspecific symptoms.
223682510|NCT02328469|DRUG|Acyclovir|Patients will be treated with intravenous acyclovir 10 mg per kg three times daily for 14 to 21 days.
223682511|NCT03964337|DRUG|Cabozantinib|Cabozantinib 40 mg by mouth daily for 4 weeks.
223682512|NCT03964337|PROCEDURE|Radical Prostatectomy|Radical prostatectomy as part of routine medical care.
223682513|NCT03875170|OTHER|Experimental|The technique will be carried out with the subjects in the positions of supine, prone and lateral position, for the flexor muscles of the hip, hamstrings and quadriceps, where the musculature and the joint to be treated will be taken to a range of functional mobility. The subject will be asked to perform an isometric contraction, with a series of 3 seconds for sustained contraction and a rest between contraction of 2 to 3 seconds after activating the Golgi apparatus, making an inhibition of the stimulus and bringing the joint and muscle to the highest possible range of motion without pain.
223682514|NCT03875170|OTHER|Control|The active stretching technique will be performed for the hip, quadriceps and hamstring flexors with a voluntary antagonist activation to relax the agonist muscle, holding the movement to be performed for 30 seconds to stimulate the neuromuscular spindle and produce a relaxation of the muscle fibers.
223682515|NCT01546129|DEVICE|Dianatal Obstetric Gel (Cross-linked polyacrylic acid)|Dianatal (approx. 30 mL in total) will be intermittently administered to the birth canal after vaginal examination in labor using the Dianatal applicator or the syringe or the fingers. Dianatal Stage I is used during labor stage I, Dianatal Stage 2 is used during stage 2. After rupture of the membranes supplementary Dianatal is applied within 5 to 20 minutes.
223682516|NCT01551446|DRUG|Bardoxolone Methyl|Oral, once daily
223682517|NCT06126731|DRUG|Enzalutamide 40mg|Enzalutamide is presented in 40mg yellow film-coated tablets. They are supplied in a cardboard wallet incorporated a PVC/PCTFE/aluminium blister pack which holds 28 tablets. Each carton contains 4 wallets (112 tablets in total)
223682518|NCT06126731|DRUG|Amoxicillin 500mg|"Red / Buff coloured size '0' capsules containing white to off white powder printed with 'AMOXY 500 ' in black ink~OR~White to off-white granular powder filled in hard gelatine capsule shells size '0'. Scarlet colour cap, buff colour body printed with 'AMOXY' on cap and '500' on body~OR~White/Maroon size '0' capsules containing white to yellowish granular powder"
223682519|NCT06126731|DRUG|Metronidazole 400mg|"Yellow, circular (11mm), biconvex, film-coated tablets with '400' debossed on one side and plain on other side~OR~White to off white coloured, caplet shaped (17.00 x 6.00 mm) film-coated tablets, debossed 400 on one side and plain on other side~OR~Off-white coloured, round, biconvex uncoated tablets engraved MZ 400 \& break line on one side and plain on other"
223682520|NCT06126731|DRUG|Vancomycin 125mg|"Grey/pink 17.8 ± 0.40 mm hard capsules each containing 125mg, containing white to off white congealed liquid mixture as solid mass~OR~Dark blue and brown hard capsules, imprinted with 3125 in red ink~OR~Brown 21.4 ± 0.40 mm hard capsule, containing white to off white congealed liquid mixture as solid mass"
223682521|NCT06126731|DRUG|Ciprofloxacin 500g|"White to off white, capsule shaped, film coated tablets, with a score line on one side and debossed with 'F22' on the other side. The tablet can be divided into equal doses. The size is 18.2 mm x 8.1 mm~OR~White, caplet shaped film-coated tablets debossed with '500' on one side and plain on the other side~OR~White to off-white, capsule shape, biconvex with bevelled edge, film coated tablet with inscription 'CI' on one side and plain on the other side~OR~White, oval shaped film-coated tablets debossed 'C500' on one side and breakline on other side"
223682522|NCT03160859|OTHER|Control|Unsedated colonoscopy with water exchange (WE) where the residual air in the colon will be removed and water will be infused to guide insertion through an airless lumen. Infused water is removed predominantly during insertion.
223682523|NCT03160859|DEVICE|Study method|Unsedated colonoscopy with water exchange (WE + cap) and the addition of a cap fitted to the colonoscope.
223835269|NCT02986828|DRUG|Normal saline|Ultrasound-guided 3cc normal saline injection between proximal carpal tunnel and median nerve.
224325292|NCT02512926|DRUG|Etoposide|
224325293|NCT05888623|DEVICE|Computer Assisted Detection|Computer-assisted polyp detection system that utilizes artificial intelligence (AI) during colonoscopy
223682524|NCT02915120|PROCEDURE|Real Pulsed Radiofrequency|"Pulsed Radiofrequency uses radiofrequency current in short (20 ms), high-voltage bursts; the silent phase (480 ms) allows time for heat elimination, generally keeping the target tissue below 42° C. The Radiofrequency (RF) electrode will be inserted through the canula, and RF lesions will be generated by applying pulsed RF treatment to the inferomedial (IM), superomedial (SM), and superolateral (SL) GN branches for 8 minutes at 42°C."
223682525|NCT02915120|PROCEDURE|Sham Pulsed Radiofrequency|Control patients will undergo the same procedure. The sensorial and motor stimulations will be applied too. The RF electrode will be then inserted through the cannula, and RF lesions will be simulated without applying pulsed RF treatment to the IM, SM and SL, GN branches for 8 minutes each GN branch and the temperature of the electrode tip was not raised.
224325294|NCT07041281|DRUG|spironolactone 25 mg orally once daily|Participants with hypertensive disorders of pregnancy will receive 25mg capsules of spironolactone to self-administer daily over the 12-week duration of the study treatment.
224325295|NCT07041281|DRUG|Placebo tablet to match spironolactone|Participants with Hypertensive disorders of pregnancy will receive placebo equivalent capsules to self-administer daily over the 12-week duration of the study treatment.
224325296|NCT06723158|OTHER|Virtual reality (VR) glasses with relaxation module|The relaxation module will include immersive video and audio components as a distraction from the medical procedures.
224325297|NCT06722261|BEHAVIORAL|Strategic and Interactive Signing Instruction|Evidence-based instructional methods, grounded in cognitive, sociocultural, and linguistic theories, are applied to interventions that support sign language development in deaf children.
224325298|NCT03907488|PROCEDURE|Biospecimen Collection|Undergo peripheral blood collection
224325299|NCT03907488|DRUG|Brentuximab Vedotin|Given IV
224325300|NCT03907488|PROCEDURE|Computed Tomography|Undergo PET/CT or CT scan
224325301|NCT03907488|DRUG|Dacarbazine|Given IV
224325302|NCT03907488|DRUG|Doxorubicin Hydrochloride|Given IV
224325303|NCT03907488|BIOLOGICAL|Filgrastim|Given SC or IV
224325304|NCT03907488|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
224325305|NCT03907488|BIOLOGICAL|Nivolumab|Given IV
224325306|NCT03907488|BIOLOGICAL|Pegfilgrastim|Given SC
224325307|NCT03907488|PROCEDURE|Positron Emission Tomography|Undergo PET/CT scan
223682526|NCT05294120|DEVICE|Reflectance ConfocaL Microscopy And Optical Coherence Tomography Guided|"Patients will undergo RCM/OCT with an imaging specialist in the Dermatology Service.~This is not expected to take longer than 30 minutes. Prior to imaging, a digital photograph will be taken of the biopsy proven BCC."
223682527|NCT05294120|RADIATION|Radiation Therapy|After the completion of skin imaging, patients will undergo simulation and tumor radiotherapy. An equivalent total dose in 2 Gy fractions (EQD2) of 45-46 Gy will be delivered for treatment.
223682528|NCT05959603|DRUG|Vancomycin|Powdered vancomycin will be locally administered once during surgery. The vancomycin will be placed in the surgical bed at several layers: around the hardware and before muscle apposition and above the fascia. This is done before the closure of the muscular fascia and skin by the neurosurgeon. The vancomycin will not be mixed in the bone graft.
223682529|NCT02953509|DRUG|Magrolimab|Administered intravenously
223682530|NCT02953509|DRUG|Rituximab|Administered intravenously on Days 8, 15, and 22 during Cycle 1, followed by 1 dose on Day 1 for Cycles 2 through 6, and Day 1 for every other cycle until Cycle 13
223682531|NCT02953509|DRUG|Gemcitabine|Administered intravenously on Days 11, 23 for Cycle 1 and Days 2 and 15 for Cycles 2 to 4
223682532|NCT02953509|DRUG|Oxaliplatin|Administered intravenously on Days 11, 23 for Cycle 1 and Days 2 and 15 for Cycles 2 to 4
223682533|NCT02953509|DRUG|Allopurinol|Administered orally during Cycle 1
223682534|NCT04808700|OTHER|Follow-up of Episealer implant|Follow-up and radiographic evaluation in patients who received an Episealer implant
223835270|NCT02986828|DEVICE|Ultrasound|
224325308|NCT03907488|OTHER|Quality-of-Life Assessment|Ancillary studies
223682535|NCT04500756|DRUG|Metformin|Smaller studies have suggested that metformin may reduce the rate at which aortic aneurysms enlarge. This study will test this question: does metformin prevent AAAs from growing larger?
223835271|NCT02631083|OTHER|Breakfast, lunch, snack and dinner|These meals (cereal, rice and bread meals) will be tested in subjects for their glycaemic response (CGMS) and substrate utilization (calorimeter)
224325309|NCT03907488|OTHER|Questionnaire Administration|Ancillary studies
224325310|NCT03907488|RADIATION|Radiation Therapy|Receive radiation therapy
224325311|NCT03907488|DRUG|Vinblastine Sulfate|Given IV
224325312|NCT06886009|DRUG|Spevigo®|Intravenous
224325313|NCT06876142|DRUG|Mirdametinib|Capsules taken by mouth twice a day (2-12mg) for days 1-21 days of each 28 day cycle
224325314|NCT06876142|DRUG|Sirolimus|Tablets taken by mouth once a day for days 1-28 days of each 28 day cycle. Loading dose of 12 mg on Day 1 Cycle 1 with 4 mg being taken for the remaining doses.
224325315|NCT06709014|DRUG|buntanetap/posiphen|30mg capsule by mouth once daily for 18 months
224325316|NCT06709014|DRUG|Placebo|Placebo capsule by mouth once daily for 18 months
224325317|NCT07038369|DRUG|ATV-1601|"Drug: ATV-1601~• Oral ATV-1601"
224325318|NCT07038369|COMBINATION_PRODUCT|ATV-1601 + Fulvestrant|"Drug: ATV-1601~* Oral ATV-1601 Drug: Fulvestrant~* Intramuscular Injection"
224325319|NCT06578585|DRUG|Ubrogepant|Tablet
224325320|NCT06578585|DRUG|Lu AG09222|Solution for injection/infusion
224325321|NCT06578585|DRUG|Placebo|Solution for injection/infusion
224325322|NCT06729164|BEHAVIORAL|Strategic and Interactive Signing Instruction|Evidence-based instructional methods guided by cognitive, sociocultural, and linguistic theories that are applied to interventions supporting sign language development among deaf children.
224325323|NCT06729164|BEHAVIORAL|Business-As-Usual Instruction|Teachers will teach business-as-usual without the inclusion of SISI.
224325324|NCT06721299|DRUG|Clenbuterol|Beta-Agonist
224325325|NCT07044297|DRUG|MK-8527|Oral tablet
224325326|NCT07044297|DRUG|FTC/TDF|Oral tablet
224325327|NCT07044297|DRUG|Placebo to MK-8527|Placebo tablet matched to MK-8527
224325328|NCT07044297|DRUG|Placebo to FTC/TDF|Placebo tablet matched to FTC/TDF
224325329|NCT06887205|PROCEDURE|Lymphovenous bypass (LVB)|At the time of axillary lymph node dissection (ALND) or inguinal lymph node dissection (ILND) in the melanoma patient population.
224325330|NCT06926660|DRUG|Vicadrostat|Vicadrostat
224325331|NCT06926660|DRUG|Empagliflozin|Empagliflozin
224325332|NCT06926660|DRUG|Placebo matching vicadrostat|Placebo matching vicadrostat
224325333|NCT07047690|DRUG|Nemolizumab|Subcutaneous Injection
224325334|NCT07047690|DRUG|Placebo|Subcutaneous Injection
224325335|NCT07047118|DRUG|JSB462|Administered orally, daily and continuously (100 mg or 300 mg QD) until disease progression per PCWG3-modified RECIST v1.1 as assessed by the investigator, the occurrence of unacceptable toxicities, death, participant decision or investigator decision
224325336|NCT07047118|DRUG|AAA617|administered at 7.4 GBq intravenously every 6 weeks for up to 6 doses, unless there is disease progression per PCWG3-modified RECIST v1.1 as assessed by the investigator, the occurrence of unacceptable toxicities, death, participant decision or investigator decision
224325337|NCT07046819|DRUG|Tirzepatide|A 2.5mg, 5mg, and 7.5mg subcutaneous injection will be given once weekly for 12 weeks.
224325338|NCT07046819|OTHER|Placebo|A 2.5mg, 5mg, and 7.5mg subcutaneous injection will be given once weekly for 12 weeks.
224325339|NCT06723535|DRUG|BMS-986278|Specified dose on specified days
224325340|NCT06887959|DRUG|Suzetrigine|Tablets for oral administration.
224325341|NCT06728085|BEHAVIORAL|Baseline Assessment For Mother-Daughter Day HPV Campaign|"Pre-Implementation:~Identify, screen, and enroll mother-daughter dyads in the study to participate in the upcoming Mother-Daughter Day event on HPV vaccination and screening.~Complete baseline surveys with enrolled participants. Distribute reminder cards and send text messages to mother-daughter dyads who agree to participate in the mother-daughter day campaign."
223682536|NCT04500756|OTHER|Placebo|One group will be randomized to receive the study drug Metformin and the other group will receive a placebo
223682537|NCT06361797|OTHER|Rotator cuff repair augmented with whole bone marrow|Bone marrow derived from the proximal humerus will be aspirated during the rotator cuff repair. At the end of the procedure, the aspirate will be injected back into the joint space.
223835272|NCT04268836|DEVICE|Optimal Acuity Clear-K® Low Vision Aid System treatment|The treatment involves irradiation of the cornea with low energy light in a treatment pattern that produces corneal shape change.
224325342|NCT06728085|BEHAVIORAL|Implement Mother-Daugther Day HPV Campaign|"Tailor and adapt to context: Mother-Daughter Day campaigns will be tailored and adapted to the local contexts within the 18 LGA.~Trained community health workers will implement the tailored Mother-Daughter Campaign by providing education on cervical cancer control and educational materials on HPV vaccination and HPV screening.~Engage mothers and daughters with on-site access to services: This includes offer of onsite vaccinations to girls by study nurse as well as offer of onsite self-collection screening kits to mothers and caregivers in a private area, along with instructions on how to use and return the sample.~Distribute gift bags with HPV vaccination cards, follow-up reminders, and linkage cards for participants with positive test results, as community health workers continue to provide onsite support and assistance."
224325343|NCT06728085|BEHAVIORAL|Post-Implementation Follow-Up|"A follow-up invitation will be sent to participate in a consultative phone call with study health workers to review self-collection results.~Participants with positive HPV test results will be linked to follow-up care and treatment."
224325344|NCT07049575|DRUG|Ruxolitinib Cream|Ruxolitinib cream applied topically to the affected area as a thin film twice daily.
224325345|NCT07044700|DRUG|Jardiance|Jardiance
224325346|NCT07044700|DRUG|non-SGLT2 inhibitors|non-SGLT2 inhibitors
224325347|NCT07049952|DEVICE|taVNS|Active or inactive non-invasive vagus nerve stimulation of the auricular branch of the vagus nerve paired with 2 oral feedings/day for 14d
224325348|NCT07049952|COMBINATION_PRODUCT|NAC and taVNS|NAC 100 mg/kg diluted 1:3 with sterile water (or equal volume sterile water), q6h NG 1h before a feed for 4d prior to delivering active or sham taVNS paired with 2 feeds/day for 14d with NAC (or sterile water).
224325349|NCT07049952|DEVICE|inactive taVNS|inactive transcutaneous auricular vagus nerve stimulation with 2 feeds/day x 14 days
224325350|NCT07049952|COMBINATION_PRODUCT|sterile water and inactive taVNS|Sterile water per NG tube every 6h for 4 days, then continuing with 14days of inactive taVNS paired with oral feeding
224325351|NCT05846789|DRUG|SOC Chemotherapy|SOC Chemotherapy will be given AUC 6 IV q3 weeks for a maximum of 9 infusions.
224325352|NCT05846789|DRUG|Tocilizumab|Tocilizimab 8 mg/ actual body weight in kg IV q4 weeks
224325353|NCT06741072|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
224325354|NCT06741072|DRUG|Dulbecco''s Phosphate-Buffered Saline|Given SC
224325355|NCT06741072|BIOLOGICAL|Peptide Vaccine|Given OSU-2131 SC
224325356|NCT06741072|BIOLOGICAL|QS21|Given SC
224325357|NCT06884254|DRUG|EG1206A|EG1206A 420mg is ongoing to be administered after 840mg loading dose.
223682538|NCT06361797|OTHER|Rotator cuff repair augmented with concentrated bone marrow|Bone marrow derived from the proximal humerus will be aspirated during the rotator cuff repair. This volume will be concentrated and, at the end of the procedure, the concentrate will be injected back into the joint space.
224325358|NCT06884254|DRUG|Perjeta|Perjeta 420mg is ongoing to be administered after 840mg loading dose.
224325359|NCT04595422|OTHER|Educational Intervention|Undergo training consisting of a 60-minute educational session
224325360|NCT04595422|OTHER|Educational Intervention|Receive lung cancer screening educational materials
224325361|NCT04595422|OTHER|Questionnaire Administration|Complete questionnaire
224325362|NCT04595422|OTHER|Survey Administration|Ancillary studies
224325363|NCT06735248|BIOLOGICAL|mRNA-1195|IM injection
224325364|NCT06735248|BIOLOGICAL|Placebo|IM injection
224325365|NCT06407115|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|CBT in this study will consist of a series of 6-10, 30-45-minute sessions with the care manager. These 1-on-1 sessions will occur every week or every other week virtually. Content will be focus on addressing unhelpful thinking and small behavioral changes that may help participants better manage their pain.
224325366|NCT06407115|BEHAVIORAL|Enhance Fitness|Participants will be encouraged to enroll in instructor-led exercises classes for up to an hour, 3 days per week. These classes can be accessed from home. Data plans and tablets are available to aid participants that need them to gain access to the classes.
224325367|NCT06407115|OTHER|Care Coordination|Care manager will meet with patient in virtual sessions once a month to create a care plan and monitor progress. Care manager will assess social determinants of health and link participants to resources in the community as appropriate. In addition, participants will take monthly assessments about pain and mood to help guide clinical decision making.
224325368|NCT06890884|BIOLOGICAL|Zilovertamab vedotin|IV infusion
224325369|NCT06890884|BIOLOGICAL|Rituximab|IV infusion
224325370|NCT06890884|DRUG|Cyclophosphamide|IV infusion
224325371|NCT06890884|DRUG|Doxorubicin|IV infusion
224325372|NCT06890884|BIOLOGICAL|Rituximab Biosimilar|IV infusion
224325373|NCT06890884|DRUG|Prednisone|Oral administration or IV infusion
224325374|NCT06890884|DRUG|Prednisolone|Oral administration or IV infusion
224325375|NCT06890884|BIOLOGICAL|Polatuzumab vedotin|IV infusion
224325376|NCT06890884|DRUG|Rescue Medication|Participants receive rescue medication at the investigators discretion, per approved product label. Recommended rescue medication is Granulocyte Colony-Stimulating Factor (G-CSF).
224325377|NCT06169176|OTHER|RAPA-501 Autologous T stem cells|Experimental: Intermediate size expanded access cohort. Single-agent RAPA-501 T stem cells, (80 x 10EE6 cells per infusion; acceptable dose range of RAPA-501 T stem cells is 20-to-80 x 10EE6 cells per infusion.
224325378|NCT07054684|DRUG|BHV-1400|BHV-1400 is delivered subcutaneously (SC)
224325379|NCT07054515|DRUG|AZ-3102|Oral dispersible tablets
224325380|NCT07054515|DRUG|Placebo|A matching placebo will be administered in the same regimen as the intervention
224325381|NCT04921449|OTHER|ED Physical Therapy|All ED Physical Therapy treatment classifications involve a combination of exercise, range of motion, education, prognostic guidance, and reassurance. Patients are provided with an individualized home exercise plan based on their matched treatment classification and/or active rest.
224325382|NCT04921449|OTHER|Usual Care|Includes any diagnostic imaging, patient education and reassurance, and administration or prescribing of analgesic medications, as per the treating physician's usual and customary practice.
224325383|NCT07045194|DEVICE|Virtue Sirolimus AngioInfusion Balloon|Percutaneous Coronary Intervention
224325384|NCT07045194|DEVICE|AGENT™ Paclitaxel Drug-Coated Balloon|Percutaneous Coronary Intervention
224325385|NCT04476953|DRUG|Placebo|Placebo looks exactly like the study drug, but it contains no active ingredient.
224325386|NCT04476953|DRUG|Fisetin|\~20 mg/kg/day oral, NG or D tube course for 2 consecutive days
224325387|NCT06309966|DRUG|BHV-7000|BHV-7000 50 mg. Participants will take blinded investigational product (IP) once daily
224325388|NCT06309966|DRUG|BHV-7000|BHV-7000 75 mg. Participants will take blinded investigational product (IP) once daily
224325389|NCT06309966|DRUG|Placebo|Matching placebo taken once daily
224325390|NCT07055282|DRUG|Empagliflozin (Jardiance®)|Empagliflozin (Jardiance®), 10 mg tablet taken orally once daily for 4 weeks. Dispensed at baseline by the Investigational Drug Service. It will be administered at home by participants.
224325391|NCT07056309|DRUG|Remternetug (Test)|Administered SC
224325392|NCT07056309|DRUG|Remternetug (Reference)|Administered SC
224325393|NCT06860607|BEHAVIORAL|Evaluate the effects of Environmental Enrichment (EE) on alcohol consumption|This study investigates how different environments and activities affect alcohol consumption and related outcomes.
224325394|NCT06717347|BIOLOGICAL|Zilovertamab vedotin|IV infusion
224325395|NCT06717347|BIOLOGICAL|Rituximab|IV infusion
224325396|NCT06717347|DRUG|Cyclophosphamide|IV infusion
224325397|NCT06717347|DRUG|Doxorubicin|IV infusion
224325398|NCT06717347|BIOLOGICAL|Rituximab Biosimilar|IV infusion
224325399|NCT06717347|DRUG|Prednisone|Per Approved Product Label
224325400|NCT06717347|DRUG|Prednisolone|Oral administration
224325401|NCT06717347|DRUG|Vincristine|IV infusion
224325402|NCT06717347|DRUG|Rescue medication|Participants receive rescue medication at the investigator's discretion, per approved product label. The recommended rescue medication is granulocyte colony-stimulating factor (G-CSF).
224325403|NCT06742086|DRUG|Venetoclax|Oral Tablet
224325404|NCT06732401|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
224325405|NCT06732401|DRUG|Ceralasertib|Given PO
224325406|NCT06732401|PROCEDURE|Computed Tomography|Undergo CT scan
224325407|NCT06732401|BIOLOGICAL|Durvalumab|Given IV
224325408|NCT06732401|PROCEDURE|Echocardiography Test|Undergo echocardiography
224325409|NCT06741228|OTHER|Placebo|A substance that is designed to have no therapeutic value
224325410|NCT06741228|DRUG|MM120 (LSD D-Tartrate)|A psychoactive substance that mediates effects mainly through an agonist activity in the serotonin 2A receptor (5-HT2A)
224325411|NCT04569591|DRUG|Acthrel|Intravenous administration of ovine CRH (Acthrel (Registered Trademark) 1 mcg/kg up to a maximum dose of 100 mcg) results in selective increase in ACTH activity of pituitary adenomas within two minutes and peaks between 10-15 minutes.
224325412|NCT07060716|DIAGNOSTIC_TEST|donor-derived cell-free DNA test|A donor-derived cell-free DNA (dd-cfDNA) test used to measure the concentration of total cell-free DNA and the fractional abundance of the dd-cfDNA.
224325413|NCT07060807|BIOLOGICAL|Patritumab deruxtecan|Administered via intravenous (IV) infusion
224325414|NCT07060807|DRUG|Paclitaxel|Administered via IV infusion
224325415|NCT07060807|DRUG|Nab-paclitaxel|Administered via IV infusion
224325416|NCT07060807|DRUG|Capecitabine|Administered via oral tablets
224325417|NCT07060807|DRUG|Liposomal doxorubicin|Administered via IV infusion
224325418|NCT07060807|BIOLOGICAL|Trastuzumab deruxtecan|Administered via IV infusion
224325419|NCT06752356|BIOLOGICAL|Immune globulin (human) 10% solution for intravenous administration|Kedrion intravenous immunoglobulin (IVIg) 10%
224325420|NCT04784663|BEHAVIORAL|Messaging|Four brief video messages, each approximately 1.5 minutes in length, focused on facilitating treatment seeking by addressing barriers and improving attitudes. Intervention delivered to participant by study mobile app downloaded to participants' own smartphone.
224325421|NCT04784663|OTHER|Wait list control|one push notification each week thanking individuals for participation, informing them that they will receive messages in the near future or reminding them of the length of the study.
224325422|NCT06751589|DRUG|Tirzepatide|2.5 mg administered using a pre-filled injector once weekly for 4 weeks and then increase to 5 mg once weekly.
224325423|NCT07058064|PROCEDURE|Electrocardiogram|"All participants receive a standard 12-lead ECG when they present for follow-up 1 year after completion of anthracycline-based therapy. All participants will also record a 6-lead Kardia (AliveCor, Mountain View, CA, USA) and 1-lead Apple Watch (Apple, Cupertino, CA, USA) ECG with Mayo-owned or participant-owned devices.~Longitudinal participants will receive an Apple Watch to use during this study if they do not have their own (and agree to download the app) and will be able to transmit ECGs anytime anywhere from their Apple Watch from before the initiation, all through the treatment, up to 1-year after anthracycline-based therapy. For validation, these participants will transmit ECGs from their smart watch at the time of routine follow-up visits (at 3-, 6- \& 9-months post therapy visits) along with 6-lead Kardia ECGs, and 12-lead standard ECGs."
224325424|NCT07058064|PROCEDURE|Echocardiogram|All participants will have an echocardiogram as part of standard of care when they present for their follow-up 1 year after completion of anthracycline-based therapy.
223682539|NCT04276363|BEHAVIORAL|Thrive Professional Learning plus ParentCorps|led by the NYC Department of Education. Professional Learning sessions are tailored to the needs of pre-K teachers and leaders, and include topics aligned with the district's quality standards that support child instructional goals.
223682540|NCT04276363|BEHAVIORAL|Thrive Professional Learning only|Part of the Professional Learning Track system for all Pre-K for All teachers and leaders. The NYC DOE schedules Thrive Professional Learning training days for staff on non-attendance days. Teachers attend four Professional Learning days annually, and leaders attend three days annually, over a two-year period.
223682541|NCT04276363|BEHAVIORAL|Inspire Professional Learning|Delivered to leaders in groups of 20 - 40 three times a year over the same two-year period. Content covers best practices in Family Engagement and Social Emotional Learning and includes an experiential approach to behavior change that asks learners to take the perspective of others and consider their own beliefs and assumptions about students, families, teachers and leaders
223682542|NCT05617209|OTHER|thrombin generation measurement|Thrombin generation will be measured in Platelets rich plasma induced either by 1 pM TF or 10 pM TF concentration in presence of different aTFPIAb concentrations (0; 0.5 µg/ml; 0.75 µg/ml; 1.0 µg/ml; 2.0 µg/ml; 4.0 µg/ml)
223682543|NCT05658575|DRUG|Dapansutrile|An initial loading dose of 2000 mg dapansutrile on Day 1 followed by a maintenance regimen of 1000 mg dapansutrile twice daily starting 12 hours later through the second dose on Day 7, inclusive.
223682544|NCT05658575|OTHER|Placebo Tablet|An initial loading dose of matching placebo (to mimic dapansutrile dosing) on Day 1 followed by a maintenance regimen of matching placebo twice daily starting 12 hours later through the second dose on Day 7, inclusive.
223682545|NCT06455995|BEHAVIORAL|DEPTH|All conditions will receive a reduced-energy, low-fat dietary prescription (1200-1500 kcal/d, \< 30% energy from fat), physical activity goals (\> 200 min/wk of moderate- to vigorous-intensity physical activity \[MVPA\]) and a cognitive behavioral intervention. To minimize the effect of other eating temporal variables on outcomes, guidance on the eating window length and the number of eating occasions in the day will be consistent across all three conditions. Thus, the three conditions will be instructed to have their first eating occasion \< 60 minutes of awakening, and eat their three meals and one snack within a 12-hr eating window.
223682546|NCT06455995|BEHAVIORAL|DEPTH-Morning|Morning will also have time-based energy intake goals of 70% of kcal within the first 6 hrs of the eating window and 30% of kcal within the last 6 hrs of the eating window (a morning-loaded energy distribution).
223682547|NCT06455995|BEHAVIORAL|DEPTH-Evening|Evening will also have time-based energy intake goals of 30% of kcal within the first 6 hrs of the eating window and 70% of kcal within the last 6 hrs of the eating window (an evening-loaded energy distribution).
223682548|NCT00812760|DRUG|levodopa|1 tablet of 200 mg levodopa plus 50 mg benserazide
223682549|NCT05530629|DEVICE|resistance training|resistance training lasts for 12 weeks, three times a week, one hour each time, and the program of resistance training in the experimental group was divided into 10 exercises: Chest press, Lat pull down, Shoulder press, Squat, Leg extension, Leg curl, Bicep curl, Triceps extension, abdominal crunches, lower back exercises.
223682550|NCT05530629|DEVICE|Normal P.E. course|Carry out general teaching content according to the college syllabus lasts for 12 weeks , three times a week, one hour each time, and the program of Normal P.E. course in the control group will be Physical recovery exercises, learn and practice queue formation, calisthenics, five step fists, long fist and Basic movements of Gymnastics gradually changed by week.
223682551|NCT02522871|DEVICE|OCS™ Liver System|
223682552|NCT02522871|OTHER|Control|
224325425|NCT07058064|PROCEDURE|LVEF echocardiogram|Participants will undergo a limited LVEF echocardiogram at the 6-month post therapy visit.
223682553|NCT02562690|OTHER|Thrombin generation assays, TEG and GTT|Thrombin generation assays, Thromboelastography (TEG), and Global Thrombosis Test (GTT)
223682554|NCT04138979|DRUG|cyclophosphamide|First use of chemotherapy after breast cancer
223682555|NCT00377130|OTHER|Self Administered Stress Management|"The SSMT kit includes a DVD and booklet will discuss the sources and manifestations of stress during chemotherapy and the potential benefits of stress management training. The videotape/DVD and booklet will also include brief instruction in paced breathing, progressive muscle relaxation with guided imagery, and use of coping self-statements as well as recommendations for practicing the techniques before the start of chemotherapy and using them after the start of treatment. The exercise combines abbreviated progressive muscle relaxation training with use of relaxing mental imagery. The positive thinking exercise provides participants with brief instruction in the use of coping self-statements using techniques borrowed from stress inoculation training."
223682556|NCT03195296|OTHER|No intervention|No intervention related to the study is foreseen
223682557|NCT05062395|PROCEDURE|Computed Tomography|Undergo FDG PET CT
223682558|NCT05062395|OTHER|Fludeoxyglucose F-18|Undergo FDG PET CT
223682559|NCT05062395|OTHER|Low Carbohydrate High Fat Diet|low carbohydrate and high fat diet for 48-72 hours
223682560|NCT05062395|PROCEDURE|Positron Emission Tomography|Undergo FDG PET CT
223682561|NCT02620371|PROCEDURE|modified pectoral block|"Modified Pecs block was performed under general anesthesia, and 15 min. before skin incision. We performed the modified Pecs block or the  Pecs II block by using a two needle approach instead of one. The first puncture is a Pecs I block with 10 ml of local anesthetic injected between the two pectoralis muscles, and the second puncture injects 20 ml of local anesthetic between the Pectoralis minor muscle and the serratus muscle. This breaks through the 'axillary door' and will reach the long thoracic nerve and reliably at least two intercostal nerves.~We used A high frequency linear US probe is used for this block. a broadband linear array probe, with an imaging depth of 3-4cm. starting from the lateral third of the clavicle and moving distally and laterally to the mid axillary line."
223682562|NCT04330105|DEVICE|ECG, HolterECG ,Echocardiography|ECG, HolterECG ,Echocardiography to determine any type of arrythmia,ischaemic heart disease,valvular heart disease,systolic and diastolic dysfunction
223682563|NCT00691119|BEHAVIORAL|Relaxation and Visualization Therapy|Twenty minutes of facilitated relaxation and visualization therapy five days a week for six weeks. Self practice of 20 minutes per day for the next six weeks.
223682564|NCT00691119|OTHER|Health education|Facilitated health education sessions, twenty minutes, five times a week for six weeks.
223682565|NCT02218177|DRUG|Aflibercept|anti-VEGF treatment for wet age related macular degeneration
223682566|NCT02218177|DRUG|Ranibizumab|anti-VEGF treatment for wet age related macular degeneration
223682567|NCT02218177|PROCEDURE|Combination Photodynamic Therapy|Use of cold laser with an intravitreal injection of dexamethasone to treat wet age related macular degeneration
223682568|NCT05034666|BEHAVIORAL|Before the education program|Before applying the education program of the endotracheal cuff pressure inflation to the participating anaesthetists.
223682569|NCT05034666|BEHAVIORAL|After the education program|After applying the education program of the endotracheal cuff pressure inflation to the participating anaesthetists.
223682570|NCT03511898|DRUG|THR-149 dose level 1|single intravitreal injection of THR-149 dose level 1
223774637|NCT04135131|OTHER|pilates mat exercises and home exercises|Patients with low back pain were randomized into pilates (group 1) or home exercise group (group 2) 3 times/week for 8 weeks. Pilates mat exercise program comprised three sessions a week for 8 weeks (Monday, Wednesday, and Friday), with each session being scheduled for 1 h (5-min warm-up, 50-min exercise, and 5-min cooling) and each set comprising 10 repetitions. The home exercise program included the pelvic tilt in the supine position, hamstring stretch, hip flexors and lumbar extensor stretch, bridge, strengthening the abdominal muscles, cat/camel exercises in the crawl position, leaning on the forearms in the prone position, strengthening the back extensors, and crossed-arms/legs lift exercises.
223774638|NCT02412267|DRUG|O-ICE (ofatumumab, Ifosfamide, Carboplatin, Etoposide)|Ofatumab in combination with ICE (Ifosfamide, Carboplatin, Etoposide) are given to subjects according to protocol schedule
223774639|NCT00001631|PROCEDURE|Magnetic resonance imaging|
223774640|NCT01055392|DRUG|Lithium Carbonate|lithium carbonate tablets, 150 mg to 450 mg (target serum lithium level 0.25 mEq/L - 0.5 mEq/L), divided in two doses, two years.
223774641|NCT01055392|DRUG|Placebo|Identical placebo tablets were administered twice-a-day for two years.
223774642|NCT04876027|DRUG|GLP-1 RAs|GLP-1 receptor agonist is a glucagon-like peptide 1 analog, which is related to improving blood sugar control, weight loss and appetite suppression, and reducing cardiovascular risk.
223774643|NCT04876027|OTHER|calorie restricted diet|Calorie restricted diet can improve insulin sensitivity, liver fat in patients with visceral obesity, and metabolism and hormone levels in obese women with PCOS.
223774644|NCT00123240|BEHAVIORAL|Low calorie high carbohydrate diet|65% carbohydrate, 15% protein, 20% fat (7% SFA, 8% MFA, 4% PUFA), P/S 0.63, 152 mg cholesterol/1500 kcal
223682571|NCT03511898|DRUG|THR-149 dose level 2|single intravitreal injection of THR-149 dose level 2
223682572|NCT03511898|DRUG|THR-149 dose level 3|single intravitreal injection of THR-149 dose level 3
223774645|NCT00123240|BEHAVIORAL|Low calorie high fat/protein diet|High Fat/Protein Diet: 10% carbohydrate, 25% protein, 65% fat (26% SFA, 25% MFA, 9% PUFA), P/S 0.33, 458 mg cholesterol/1500 kcal
223774646|NCT02293005|DRUG|Alisertib|50 mg twice a day on Days 1-7 of each 21-day study cycle.
223774647|NCT02360540|OTHER|Gestalt estimation|
223774648|NCT02642913|DRUG|Enzalutamide|
223774649|NCT02642913|DRUG|Enzalutamide with Sorafenib|
223774650|NCT05378867|BIOLOGICAL|TRS003|"* TRS003, 5 mg/kg IV every 14 days with mFOLFOX6 for 1 cycle followed by switch to:~* Bevacizumab®, 5 mg/kg IV every 14 days with mFOLFOX6 for 1 cycle followed by switch to:~* TRS003, 5 mg/kg IV every 14 days with mFOLFOX6 until end of treatment due to PD, intolerability or other cause for stopping treatment. Intensive PK sampling will be performed after 7 cycles of this TRS003 switch period"
223774651|NCT05378867|BIOLOGICAL|China-approved Bevacizumab|• Bevacizumab®, 5 mg/kg IV every 14 days with mFOLFOX6 for 1 cycle
224262389|NCT04205279|OTHER|Experimental: Overground training|"Slips and trips could be induced under either of the limbs. The specialized walkway consists of two sliding platforms, each of which is mounted on two rows of low friction linear bearings (friction coefficient = 0.02). The base plate of each platform is bolted separately onto the top of a force platform embedded in the floor. An electronic-mechanical latch system is used to control the 2 states of the support platform; that is, the locked state for regular walking and the release state to initiate slipping are carefully controlled. The sliding top of the platform is released after the heel strike (vertical force to exceed 2% of the body weight). The slip distance would be adjusted between 30 to 60 centimeters depending upon the different population and their physical capacity."
223682573|NCT00129909|DRUG|fixed dose combination therapy|
223682574|NCT00725842|BIOLOGICAL|Peg-IFN alfa-2b|Peg-IFN alfa-2b administered in accordance with approved labeling
223682575|NCT00725842|DRUG|Ribavirin|Ribavirin administered in accordance with approved labeling
224325426|NCT07058064|OTHER|Apple Watch|"Longitudinal participants will receive an Apple Watch to use during this study if they do not have their own (and agree to download the app) and will be able to transmit ECGs anytime anywhere from their Apple Watch from before the initiation, all through the treatment, up to 1-year after anthracycline-based therapy. For validation, these participants will transmit ECGs from their smart watch at the time of routine follow-up visits (at 3-, 6- \& 9-months post therapy visits) along with 6-lead Kardia ECGs, and 12-lead standard ECGs.~Longitudinal participants will be asked to transmit weekly cardio fitness (estimates of peak VO2) from baseline to 1-year post therapy."
224325427|NCT07058064|PROCEDURE|Biospecimen collection|Undergo blood draw
224325428|NCT07058064|OTHER|Questionnaires|Participants fill out 2 questionnaires: 1) the Kansas City Cardiomyopathy-12 (KCCQ-12) Questionnaire, and 2) the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ) ore 30 (EORTC QLQ-C30) to evaluate health related quality of life and heart failure symptoms.
224325429|NCT07058064|OTHER|Cardio-pulmonary exercise test|Undergo CPET to assess the response of heart and lungs to exercise.
223682576|NCT01044329|DRUG|Bevacizumab|Intravitreal, 1.25 mg, 3 times, one month apart.
223682577|NCT01044329|DRUG|Triamcinolone Acetonide|Intravitreal, 2 mg, 2 times, two months apart.
223682578|NCT00201162|DIETARY_SUPPLEMENT|Soy|Dietary supplement of isolated soy protein containing isoflavones
223682579|NCT00201162|DIETARY_SUPPLEMENT|Placebo|dietary supplement casein placebo
223682580|NCT04951739|PROCEDURE|Peroral endoscopic myotomy|Peroral endoscopic myotomy involves an initial incision on the internal lining of the oesophagus. This permits entry of the endoscope to within the wall of the oesophagus, where the muscle will be exposed. The inner layer of the muscle near the lower oesophagal sphincter will be cut (this is termed myotomy). At the conclusion of the procedure, the oesophagal incision will be closed with standard endoscopic clips.
223682581|NCT00801671|PROCEDURE|cPAP|After reaching target level of BP patients will be randomized in active group (cPAP) and control group (sham-cPAP)
223682582|NCT03380936|DRUG|Tacrolimus Extended Release Oral Tablet [Envarsus]|Switching from current version of tacrolimus to the extended release, once a day version (Envarsus) and titrating dose to achieve an optimal trough level. Goal trough tac level \> 8 ng/ml, MPA at 720 mg bid unless medically contraindicated, prednisone at current dose (5mg) or continue taper to 5mg per center standard of care protocol.
223682583|NCT03380936|OTHER|Plasma Exchange and IVIG (Intravenous Immunoglobulin )|Plasma exchange x 5 treatments, each followed by IVIG 200 mg/kg except last dose of 1 gm/kg. Rituximab 375 mg/m2 following final plasma exchange treatment.
223682584|NCT03029637|DEVICE|RBBs with no or minimal preparation of their abutment teeth|Placement of resin bonded bridges on teeth with no or minimal cutting of their supporting teeth
223682585|NCT03029637|DEVICE|RBBs with routine tooth preparation of their abutment teeth|Placement of resin bonded bridges on teeth after routine cutting of their supporting teeth
223682586|NCT04860908|OTHER|no intervention, observation only|no intervention, observation only
223682587|NCT02325843|OTHER|human bone marrow MSC|The arms of active comparator :human bone marrow MSC subconjunctival injection once time. If persistent epithelial defect was noted thereafter, a second MSC injection was performed.
223682588|NCT02492737|DRUG|AG881|AG-881 administered continuously as a single agent dosed orally on Days 1 to 28 of a 28-day cycle. Patients may continue treatment with AG-881 until disease progression or development of other unacceptable toxicity
223774652|NCT05378867|DRUG|mFOLFOX6|"The mFOLFOX6 regimen is:~* Oxaliplatin, 85 mg/m2 administered IV over 2 hours~* LCV, 400 mg/m2 administered over 2 hours concurrent with oxaliplatin~* 5-FU, 400 mg/m2 given as a slow IV push (bolus) over 5 minutes administered immediately after LCV~* 5-FU, 2400 mg/m2 administered IV over 46 hours by infusion pump beginning immediately after FU IV bolus."
224325430|NCT07058064|OTHER|6 minute walk test|Complete a 6MWT, to see how far participants can walk on a hard, flat surface for 6 minutes
224325431|NCT07058064|OTHER|Grip strength test|A hand-held device called a dynamometer will be used to measure the muscle strength in hand/forearm
224325432|NCT05286814|DRUG|Floxuridine|HAIP FUDR and Dexamethasone treatment on D1 of every cycle. Floxuridine: (0.12 mg/kg x ideal average body weight in kg X 30 mL \[pump volume\] / Pump Flow Rate)
223682589|NCT03858439|OTHER|Dietary|Low sodium, low protein dietary recommendation
223682590|NCT02858700|BIOLOGICAL|dosage of the umbilical cord blood Procalcitonin for diagnosing of IBNP|
223682591|NCT01715129|DRUG|Triptorelin Pamoate 11.25mg|
223682592|NCT00712556|RADIATION|fluorine 18-fludeoxyglucose positron emission tomography|fluorine 18-fludeoxyglucose is a radioactive isotope used in PET to detect cancer tumors
223774653|NCT05527028|OTHER|Occupational Therapy Services|Investigators will complete an initial assessment based on a thorough chart review and observation of the participants activities of daily living during week one. The resident will receive approximately 30 minutes a day of direct student OT service delivery. Additional intervention may be delivered through an indirect, collaborative, or consultative service delivery model. Students will use a workload measurement tool to track the amount of time and types of intervention provided to these residents. The intervention will be delivered by two pairs of OT students under the direction of a registered OT. Student OTs will have access to Point Click Care and will document daily and will be required to document indirect and non-direct time for each resident.
223774654|NCT02787356|DRUG|TDS Lidocaine 5%; generic|TDS Lidocaine 5%; generic
223774655|NCT02787356|DRUG|TDS Lidocaine 5%; RLD|TDS Lidocaine 5%; RLD
223774656|NCT03102099|PROCEDURE|contrast-enhanced ultrasound group|The contrast-enhanced ultrasound patients will undergo biopsy with contrast-enhanced ultrasound guidance.
223774657|NCT03102099|PROCEDURE|conventional ultrasound group|The conventional ultrasound group will undergo biopsy with conventional ultrasound guidance.
223835273|NCT04447443|DIETARY_SUPPLEMENT|Prebiotic Fiber Supplement + loperamide hydrochloride capsule|"2-week sequential supplementation with prebiotic fiber supplement (3.5g, twice a day).~The initial dose of loperamide hydrochloride capsules is 4 mg (2 capsules) followed by 2 mg/4 h if diarrhea persists."
223682593|NCT06156124|DIAGNOSTIC_TEST|Psychological tests and psychosocial questionnaires|Assessment of psychological functioning of adolescents (including occurrence of internalizing and externalizing problems, coping with adolescent crisis), family functioning (siblings relations, parental attitudes, parentification), functioning at school (school achievement, extracurricular activities), relations with peers (time spending with peers, number of friends, quality of relations). Further, the sociodemographic variables will be also measured.
223682594|NCT04613401|OTHER|questionnaire (observational study)|questionnaire about hospitalisation rates, complications (bleeding, infection, thrombosis), quality of life (Kansas-Score), depression (PHQ8)
223682595|NCT02793622|DRUG|Monthly Sulfadoxine-Pyrimethamine (SP) During Pregnancy|
223682596|NCT02793622|DRUG|Monthly Dihydroartemisinin-Piperaquine (DP) During Pregnancy|
223682597|NCT01964456|OTHER|Joint perception task|
223682598|NCT01964456|BEHAVIORAL|Body Shape Questionnaire|
223682599|NCT01964456|OTHER|Measure of the heart rate|
224262390|NCT04205279|OTHER|Experimental: Surefooted training|During the first minute of each block, subjects would experience no perturbations followed by 3 minutes of single or multi-directional perturbations. A one minute break between each condition would be provided. Subject's fatigue would be assessed by Fatigue severity scale to determine the tolerability of 30 minute training protocol. The expected duration to complete the test would be a maximum of 1 hour including the preparation and training time.
224262391|NCT00778453|OTHER|Hospital-based mCIT|restraint of the unaffected arm and practice of the affected arm
224262392|NCT00778453|OTHER|Hospital-based BIT|bilateral symmetric, repetitive arm training
224262393|NCT00778453|OTHER|Hospital-based TR|hospital-based traditional rehabilitation : OT or PT or therapist-based training
224262394|NCT00778453|OTHER|Home-based mCIT|restraint of the unaffected arm and practices of the affected arm
224262395|NCT00778453|OTHER|Home-based BAT|bilateral symmetric, repetitive arm training
224262396|NCT00778453|OTHER|Home-based TR|home-based traditional rehabilitation:OT or PT or therapist-based training
224262397|NCT04372238|BEHAVIORAL|RAPIDS Intervention|RAPIDS intervention combines a behavioral intervention along with hands-on training to use fentanyl test strips.
224262398|NCT04372238|BEHAVIORAL|Standard OEND|In the attention-matched control arm, participants will receive standardized overdose education and naloxone distribution (OEND) training, with attention-control visits at 1, 2, and 3 months. Participants will receive a naloxone kit after completion of the first session, and information regarding where to obtain additional naloxone at subsequent visits. They will have contact with study staff at month 6 and 12 follow-up visits to capture outcome and covariate data.
224262399|NCT03278041|PROCEDURE|Submental flap for palatal reconstruction|"Under General Anesthesia the tumor in the maxilla will be resected (partial maxillectomy) with a safety margin, then the defect will be reconstructed immediately by :~Submental artery flap : from submental area with 1 cm distance from inferior mandibular border in paddle shape.~* 1st step will be identify the facial artery and vein,~* 2nd step dissection and extend toward midline in subplatsmal plane. The flap contains submental artery and vein.~* 3rd step creating submucous tunnel between vestibular border of post maxillectomy defect and to extraoral incision .~The flap will be through the oral cavity and will be anchored to the intact remaining hard plate with bone sutures by 2-0 vicryl® suture."
223682600|NCT05939778|BIOLOGICAL|TH-SC01(Umbilical cord mesenchymal stem cells)|"5+7 principle:~1\. In medium and high dose groups, 5 subjects were included in each dose group in the first step, and the first 3 subjects had good safety The investigator evaluated safety and efficacy data and could enroll a fourth and fifth subject.~1. If the number of successful participants in these 5 subjects is less than 2, the study in this dose group will be ended due to drug ineffectiveness, and the researcher will evaluate the safety and enter the next dose group.~2. If the number of successful participants in these 5 cases is greater than or equal to 2, then proceed to the second step.~2\. 7 subjects were included in the second step."
223682601|NCT00479271|BEHAVIORAL|Home based, flexible, stepped care intervention|Home based, flexible, stepped care intervention
223682602|NCT00479271|BEHAVIORAL|Home based, flexible, stepped care intervention after 6 months. Families will be free to choose any health care they desire during the waiting period.|Home based, flexible, stepped care intervention after 6 months. Families will be free to choose any health care they desire during the waiting period.
223682603|NCT00941577|DRUG|AIR645|AIR645 (blinded) by nebulization, range of doses, maximum of one dose per day, maximum of 6 doses in 22 days.
223682604|NCT00941577|DRUG|Physiologic saline solution|Placebo (blinded) by nebulization, range of doses, maximum of one dose per day, maximum of 6 doses in 22 days.
223682605|NCT03596632|DRUG|Fenebrutinib|200-mg (100 µCi) oral solution 14C/12C\]-fenebrutinib
223682606|NCT04705740|OTHER|ERCP|ERCPs performed annually by an endoscopist
223682607|NCT04260932|BIOLOGICAL|CD19/CD20 Dual-CAR-T cells|CD19/CD20 Dual-CAR-T cells are prepared via lentiviral infection. 5 days prior to infusion of CAR-T cells, subjects receive fludarabine at dose 30mg/m2/day and cyclophosphamide treatment at dose 250mg/m2 for 3 days and take a rest at least for 2 days before infusion. CD19/CD20 Dual-CAR-T cells will be intravenously infused with a escalated dose of 1-6×106 cells/kg.
223682608|NCT00000128|DEVICE|Bifocal Spectacle Lenses|
223682609|NCT02100709|DEVICE|BiLevel Noninvasive Ventilation|Positive pressure applied through an oro-nasal mask. The pressure is altered between inspiration and expiration.
224262400|NCT03278041|DEVICE|maxillary obturator|immediate surgical obturator
224262401|NCT06182462|DEVICE|Virtual Reality Distraction|"The experimental group will receive a VR video game called DREAM DENTAL designed specifically for this study. Pharmaceutical treatment during the procedure such as the use of injected local anesthesia will be used if the procedure requires. Children will be able to play for the entire duration of the dental procedure. The VR video game aims at reducing anxiety in children aged 6 to 17 years old by means of immersive distraction. The VR headset offers children with the ability of viewing the game they are playing in real time while simultaneously obstructing the partial view they would normally have of the procedure. In the event of non-cooperation during the appointment, any retake or re-scheduling appointments will be compiled by the research assistant or resident dentist. One parent will be allowed in the room during the dental procedure and their presence will be recorded."
223682610|NCT05357729|DEVICE|MultiSense® remote monitoring|At hospital, the patient will be monitored with conventional monitoring devices as well as the MultiSense® solution (at least one hour with a reference monitor). After hospital discharge, the patients will be remotely monitored by their healthcare professional using the MultiSense® solution.
223682611|NCT05349253|DIETARY_SUPPLEMENT|Garlic extracts|One intake in total
223682612|NCT05349253|DIETARY_SUPPLEMENT|Placebo|One intake in total
223682613|NCT02721186|DRUG|MDA with DHAp and SLD Primaquine|
223774658|NCT02588118|DRUG|propofol|Propofol 2 mg/kg (t0) followed by cisatracurium 0.1 mg/kg 1 min (t2). Patients will be monitored using bispectral index monitoring for propofol and Relaxometer mechanomyograph neuromuscular monitoring for cisatracurium. Serial arterial blood samples (5 ml) were withdrawn in EDTA-tubes before cisatracurium administration, 1, 3, 5, 7, 10, 13, 16, 19, 22, 25, 30, 60 and 90 min following administration. Blood samples were assayed in duplicate using high performance liquid chromatograph for Pharmacokinetic analysis.
223835274|NCT04447443|DIETARY_SUPPLEMENT|Maltodextrin + loperamide hydrochloride capsule|"2-week sequential supplementation with placebo of of maltodextrin (3.5g, twice a day).~The initial dose of loperamide hydrochloride capsules is 4 mg (2 capsules) followed by 2 mg/4 h if diarrhea persists."
224262402|NCT06182462|DEVICE|Dental Clinic's Standard Treatment|The control group will only receive a care-as-usual approach. This includes viewing cartoons on a muted mounted television set and the use of pharmaceutical treatment during the procedure such as the use of injected local anesthesia, according to the procedure. In the event of non-cooperation during the appointment, any retake or re-scheduling appointments will be compiled by the research assistant. One parent will be permitted to be present in the room during the procedure as part of the clinic's usual protocol and their presence will be recorded. Children allocated to the control group will be offered the possibility to try the VR game after the study period if they choose to do so.
224262403|NCT05744830|OTHER|Overdenture|15 patients will receive removable complete dentures, then a single implant is placed in the midline of the mandible, then loaded with the denture.
224262404|NCT05744830|OTHER|Complete Denture|15 patients will only receive removable complete dentures
224262405|NCT06013527|OTHER|Supervised Training|"Two different classes over alternate weeks twice per week :~1. 60-minute step aerobics class (Given week 1,3,5,7)~2. 60 minutes circuit training class (Given week 2,4,6,8)~Each class will include warm-up and cool-down periods both lasting 10-15 min. The exercise period of 30 minutes the maximum target RPE would be set at 14-16 on a 20-point BORG scale, a level of exercise that feels somewhat hard or hard and coincides with about 86-92% of maximal heart rate, 76-85% of maximal VO 2 and 5-7 metabolic equivalents (METs) ideal for improving the related domains of QoL and Cardiovascular endurance (12). During the first 3 weeks, the participants would exercise at a lower level of RPE (approximately 11-13), to adapt to the training and so that newly recruited participants could also join the group without difficulty."
224262406|NCT06013527|OTHER|Individually tailored home program|The type of home training would mainly consist of endurance training such as walking, Nordic walking, or aerobic training, but it would also include jumps and leaps like step aerobics to promote bone health. The Participants will be asked to perform these thrice per week.
224262407|NCT05256160|OTHER|TMS Paired-Pulse assessment of cortical excitability|Using the paired-pulse TMS paradigm, intracortical inhibition and facilitation of cortical circuitry will be assessed by stimulating the motor cortex and using the electromyographic (EMG) response of a target muscle as readout. In such studies, a conditioning stimulus modulates the amplitude of the motor-evoked potential (MEP) produced by the test stimulus. Depending on the inter-stimulus interval, effects can be attributed to different aspects of cortical processing. Brief intervals (1-5 ms) will be used to assess short-interval intracortical inhibition (SICI) and short-interval intracortical facilitation (SICF), intermediate intervals (7-20 ms) to assess intracortical facilitation (ICF) and long intervals (50-200 ms) to assess long-interval intracortical inhibition (LICI).
224262408|NCT05256160|OTHER|Autonomic activity|Autonomic function will be determined using continuously recorded EKG and used as covariates to investigate any systematic impact on cortical excitability measures collected with the paired-pulse protocols.
224262409|NCT06960915|DEVICE|immersive virtual reality|The research procedure will be the realization of reminiscence workshops in immersive virtual reality. The residents will be equipped with a virtual reality headset where they will enjoy 360° panoramas that will immerse them in the heart of villages in the Amiens basin and in particular their village based on 3 to 5 images per village: church square, village square, town hall, emblematic places, etc.
224262410|NCT06960915|DEVICE|classic reminiscence workshops|It will be compared to classic reminiscence workshops in which the organizer will propose to discuss memories and past experiences using photographs, objects or music in the control arm.
224262411|NCT03836040|DRUG|Erenumab Dose 1|Participants in the low body-weight group at day 1 and who are randomized to Dose Level 1 will receive this dose.
224262412|NCT03836040|DRUG|Erenumab Dose 2|Participants in the low body-weight group at day 1 who are randomized to Dose Level 2 and subjects in the high body-weight group at day 1 who are randomized to Dose Level 1 will receive this dose.
224262413|NCT03836040|DRUG|Erenumab Dose 3|Participants in the high body-weight group at day 1 who are randomized to Dose Level 2 will receive this dose.
224262414|NCT03836040|OTHER|Placebo|Placebo matching dose for erenumab dose 1, 2 and 3.
224262415|NCT06549465|BIOLOGICAL|In-111 rosopatamab tetraxetan|A single dose of 148 ± 37 MBq In-111 rosopatamab tetraxetan will be administered as an IV infusion over a period of 10 minutes.
224262416|NCT06549465|BIOLOGICAL|45 kBq/kg Ac-225 rosopatamab tetraxetan|45 kBq/kg Ac-225 rosopatamab tetraxetan will be administered as an IV infusion over a period of 10 minutes. Doses will be given two weeks apart for a total of two doses.
224262417|NCT06549465|BIOLOGICAL|55 kBq/kg Ac-225 rosopatamab tetraxetan|55 kBq/kg Ac-225 rosopatamab tetraxetan will be administered as an IV infusion over a period of 10 minutes. Doses will be given two weeks apart for a total of two doses.
223682614|NCT03015480|BEHAVIORAL|Remote counseling|For an 8 week period, patients will be asked to enter dietary information into the MyFitnessPal mobile application or website. Dietitians will access this information and provide personalized motivational interview phone calls on a weekly basis. After the initial 8 weeks, patients will receive a dietitian follow-up phone call around 5 and 11 months later.
223682615|NCT04572516|DRUG|BTX A Topical|In group A (topical group) ,topical application in the form of merocel soaked with 20 units of BTX\_A (2ml) will be placed at each side of the nasal cavity for 30 minutes.
223682616|NCT04572516|DRUG|BTX A Injection|In group B (injected group), 20 units of BTX\_A(2ml) will be injected submucosally in each inferior turbinate using insulin syringe needle after local anesthesia using 10% xylocaine spray .
223682617|NCT00722371|DRUG|Sitagliptin phosphate|Sitagliptin 100 mg tablet (blinded) orally once daily for 54 weeks.
223682618|NCT00722371|DRUG|Pioglitazone hydrochloride|Pioglitazone 15 mg, 30 mg, or 45 mg tablets or capsules (blinded) orally once daily for 54 weeks. Participants randomized to receive pioglitazone 45 mg as monotherapy or in combination with sitagliptin were to start on pioglitazone 30 mg at Week 1 and undergo uptitration to pioglitazone 45 mg at Week 4.
223774659|NCT02588118|DRUG|Cisatracurium|Propofol 2 mg/kg (t0) followed by cisatracurium 0.1 mg/kg 1 min (t2). Patients will be monitored using bispectral index monitoring for propofol and Relaxometer mechanomyograph neuromuscular monitoring for cisatracurium. Serial arterial blood samples (5 ml) were withdrawn in EDTA-tubes before cisatracurium administration, 1, 3, 5, 7, 10, 13, 16, 19, 22, 25, 30, 60 and 90 min following administration. Blood samples were assayed in duplicate using high performance liquid chromatograph for Pharmacokinetic analysis.
223774660|NCT03508089|OTHER|Ocular fundus on patient with Multiple Sclerosis|Ocular fundus on patient with Multiple Sclerosis
223774661|NCT03508089|OTHER|Ocular Fundus on voluntary person|Ocular Fundus on voluntary person
223774662|NCT00002181|DRUG|Cidofovir|
223774663|NCT05706259|DIETARY_SUPPLEMENT|Soft gelatin 200000 IU vitamin D3 capsule|Weekly single dose for 3-weeks
224262418|NCT06549465|BIOLOGICAL|60 kBq/kg Ac-225 rosopatamab tetraxetan|60 kBq/kg Ac-225 rosopatamab tetraxetan will be administered as an IV infusion over a period of 10 minutes. Doses will be given two weeks apart for a total of two doses.
224262419|NCT00849030|DRUG|Anastozole (Arimidex)|1mg, orally, once daily
224262420|NCT00849030|DRUG|Tamoxifen (Nolvadex)|20mg, orally, once daily
224262421|NCT00849030|DRUG|Anastozole (Arimidex) placebo|1mg, orally, once daily
224262422|NCT00849030|DRUG|Tamoxifen (Nolvadex) placebo|20mg, orally, once daily
224262423|NCT00271492|DRUG|Atrasentan|1 10mg capsule to be taken daily for 6 month study period.
224262424|NCT00271492|DRUG|Atrasentan|1 10mg capsule per day for the 6 month study period.
224262425|NCT00271492|DRUG|atrasentan|One 10 mg capsule per day for 6 month study period
224262426|NCT06081634|BEHAVIORAL|Enhancing cognitive reserve|Intervention in group format (6-8 patients) consisting of 12 weekly sessions, each lasting approximately 60 minutes. The aim of this intervention is to offer a series of strategies to increase academic and/or work achievements, leisure and free time activities, as well as an improvement in the level of neurocognitive functioning. Most of the tasks to be carried out are based on the use of pencil and paper with audiovisual support. Technological resources such as the use of the Internet and some telephone applications will also be used in some sessions. For those sessions in which the practice of mindfulness techniques will be promoted, a virtual reality device will be used per patient.
224262427|NCT06081634|OTHER|Treatment as Usual|The group will only receive the pharmacoloical treatment according to the based guidelines.
224262428|NCT06626620|DRUG|Magnesium Sulphate infusion|Received IV magnesium sulfate (50 mg/kg up to a maximum dose of 2 g) administered over 20 minutes
224262429|NCT06626620|DRUG|Terbutaline Infusion|Received IV terbutaline (10 mcg/kg bolus followed by a continuous infusion of 0.4 mcg/kg/min) for up to 4 hours
224262430|NCT05334875|DIAGNOSTIC_TEST|Electroretinogram (ERG)|Applying electrodes to assess retinal function
224262431|NCT05334875|DIAGNOSTIC_TEST|Visual evoked potential (VEP)|Applying electrodes to assess visual pathway function
224262432|NCT05490563|DRUG|SLS-005|SLS-005
224262433|NCT05490563|DRUG|Placebo|Placebo (sodium chloride injection, 0.9%, USP)
224262434|NCT03001596|PROCEDURE|Neoadjuvant Chemoradiotherapy|Before surgery, patients in this group receive neoadjuvant chemoradiotherapy. A total dose of 40 Gy is delivered in 20 fractions (5 fractions per week) for 4 weeks. Chemotherapy is delivered concomitantly and composed of four cycles of paclitaxel 50mg per square meter of body-surface area and cisplatin 25mg per square meter of body-surface area weekly at the intervals of radiotherapy. After neoadjuvant therapy of 4-8 weeks, minimally invasive esophagectomy is performed.
224262435|NCT03001596|PROCEDURE|Neoadjuvant Chemotherapy|Before surgery, patients in this group receive neoadjuvant chemotherapy. Chemotherapy is delivered and composed of two cycles of paclitaxel 135mg per square meter of body-surface area and cisplatin 75mg per square meter of body-surface area every 4 weeks. After neoadjuvant therapy of 4-8 weeks, minimally invasive esophagectomy is performed.
224262436|NCT03001596|PROCEDURE|Minimally Invasive Esophagectomy|After neoadjuvant therapy, patients in groups receive minimally invasive esophagectomy
224262437|NCT05812118|BEHAVIORAL|Physical active learning|The intervention will last for 8-10 weeks. The ALPHYL intervention will be conducted in physical education (PE) and non-PE lessons by teachers. In addition to the PE lessons, at least three physically active activities in subjects other than PE will be conducted every day (5 days per week), with a total duration of approximately 30 minutes of light and moderate-to-vigorous physical activity per day. The weekly dose of physically active learning will thus be 100-150 minutes, so that a volume of 800-1200 minutes is foreseen during the 8-10 weeks. The PE classes will also be conducted in a mix of cooperative learning, non-linear pedagogy and health-based PE.
224262438|NCT01791062|DEVICE|HYTOP®|HYTOP® will be implanted once during surgery.
224262439|NCT04816773|DEVICE|EVOLUTION® NitrX™|EVOLUTION® NitrX™ Keeled Tibia and EVOLUTION® NitrX™ CS/CR Femur With Cruciate Sacrificing Insert
223682619|NCT00722371|DRUG|Matching placebo to sitagliptin|Matching placebo to sitagliptin orally once daily for 54 weeks.
223682620|NCT00722371|DRUG|Matching placebo to pioglitazone|Matching placebo to pioglitazone tablets or capsules orally once daily for 54 weeks.
223682621|NCT00722371|DRUG|Metformin|Metformin 500 mg (open-label) was to be initiated as rescue therapy to participants not meeting specific glycemic goals. The dose of metformin may have been uptitrated and adjusted, at the discretion of the investigator, up to the maximum approved dose in the country of origin.
223682622|NCT01092832|DRUG|voriconazole|"Subjects 12 - \<18 yrs (excluding subjects 12 - 14 yrs weighing \<50kg): For IC, the loading dose is 6 mg/kg IV q12h on Day 1, followed by 4 mg/kg IV q12h thereafter. Oral therapy, if given, will be administered at a dose of 200 mg q12h. For EC, no loading dose is required, and subjects will be initiated on 3 mg/kg IV q12h. Oral therapy, if given, will be administered at a dose of 200 mg q12h.~Subjects 2 - \<12 yrs, and subjects 12 - 14 weighing \<50kg: For IC, the loading dose is 9 mg/kg IV q12h on Day 1, followed by 8 mg/kg IV q12h thereafter. For EC, no loading dose is required, and subjects will be initiated on 4 mg/kg IV q12. Oral therapy, if given, will be administered at a dose of 9 mg/kg q12h (maximum initial dose of 300 mg).~Subjects will be treated for a minimum of 14 days for invasive candidiasis/candidemia or a minimum of 7 days for esophageal candidiasis. Subjects will be treated for up to a maximum of 42 days."
223682623|NCT00298753|PROCEDURE|fluid restriction for 14 days (15ml fluid per kg weight)|
223682624|NCT03139942|DEVICE|Optical spectral reflectance and autofluorescence imaging|When a suitable area of tissue is identified by the clinician during a patient's colonoscopy (e.g., a polyp), the imaging probe is inserted into the colonoscope so that it can view the tissue. Optical spectral reflectance and autofluorescence imaging is then performed to collect white light reflected by, and fluorescent light emitted from, the tissue. This is then analysed by hardware and software components in the external analysis unit.
223682625|NCT04223492|DIAGNOSTIC_TEST|Liquid biopsy|A blood sample containing circulating tumor DNA and circulating tumor cells.
223682626|NCT04223492|DIAGNOSTIC_TEST|Multi-parametric MRI|Multi-parametric MRI combines different imaging protocols in one session to measure more functional items than perfusion alone, addressing different aspects of tumor biology.
223682627|NCT06409832|DRUG|Rimegepant 75 mg|Patients using Rimegepant 75 mg orally disintegrating tablet every other day as migraine prevention
224262440|NCT04166162|BEHAVIORAL|Brief Intervention Motivational Interviewing (BIMI) Intervention|BIMI is a 15-minute brief interview in person or via video chat with participating youth. The interview will be focused on discussing the impact of drinking alcohol on one's health and how to set personal goals so that alcohol use does not become a problem. A follow up phone or video call at 3 and 6 months post initial interview will also be conducted which will track on the progress of setting and keeping personal goals.
224325433|NCT05286814|DRUG|5-Fluorouracil|IV systemic chemotherapy on D1 and D15 of every cycle, beginning C2D1; treatment assigned by Arm. Arm 1: will receive either FOLFOX (leucovorin, 5-FU and oxaliplatin) or FOLFIRI (leucovorin, 5-FU and irinotecan). FOLFOX: oxaliplatin (85 mg/m2) and leucovorin (400 mg/m2) IV infusion administered concurrently via Y-Line over 120 minutes, then a 46-hour infusion of 5FU (2000 mg/m2) administered via an ambulatory device on site. FOLFIRI: irinotecan (150 mg/m2) and leucovorin (400 mg/m2) IV infusion administered concurrently via Y-Line over 30 minutes, then a 46-hour infusion of 5FU (2000 mg/m2) administered via an ambulatory device on site.
224325434|NCT05286814|DRUG|Irinotecan|IV systemic chemotherapy on D1 and D15 of every cycle, beginning C2D1; treatment assigned by Arm. Arm 1: will receive either FOLFOX (leucovorin, 5-FU and oxaliplatin) or FOLFIRI (leucovorin, 5-FU and irinotecan); FOLFIRI: irinotecan (150 mg/m2) and leucovorin (400 mg/m2) administered concurrently via Y-Line over 30 minutes, then a 46-hour infusion of 5-FU (2000 mg/m2) administered via an ambulatory device on site.
224325435|NCT05286814|DEVICE|Intera 3000 Hepatic Artery Infusion Pump (HAIP)|Intera 3000 HAIP will be filled with mixture of Floxuridine and Dexamethasone in 25,000 units heparin/saline (Heparin + 0.9% Sodium Chloride) on Day 1; Days 1-14 of every cycle pump will perfuse drugs to liver. On Day 15 of each cycle, the pump will be emptied and filled with 30,000 units heparin/saline (Heparin + 0.9% Sodium Chloride); Days 15-28 of every cycle will perfuse heparin/saline to liver.
223682628|NCT02068768|DEVICE|Avenue® L Interbody Fusion System (LDR Spine)|PEEK, intervertebral cage for interbody fusion of the lumbar spine
223682629|NCT04180449|OTHER|Screening for dysphagia along clinical routine|Screening for dysphagia using the water swallow test in intermediate care unit patients
223682630|NCT03947411|DRUG|Oseltamivir Phosphate|Take the dosage of Oseltamivir Phosphate recommended according to the instructions.support treatment such as antiasthmatic, expectorant and antipyretic use only in need.
223682631|NCT03947411|DRUG|Xiyanping injection+Oseltamivir Phosphate|Take the dosage of Oseltamivir Phosphate recommended according to the instructions.Xiyanping injection intravenous administration of 0.4mL/kg/day ,QD for 7-10 days.support treatment such as antiasthmatic, expectorant and antipyretic use only in need.
223682632|NCT05098977|PROCEDURE|Heart rate variability measurement|HRV will be measured at the moment of patients' admission to the cardiac catheterization laboratory on the top of therapy guided by European guidelines. Both, time- and frequency-domain parameters (respectively, SDNN, SDANN, RMSSD and LF, HF, LF/HF ratio) of the HRV will be obtained using a validated medical device during 5-minute segments before and after revascularization of the culprit artery. In addition, HRV will be evaluated in ambulatory setting, at 1 month and at 6 months after the index event. Obtained interbeat interval data will be further analysed using a dedicated software in order to derive specified HRV parameters.
224325436|NCT05286814|DRUG|Oxaliplatin|IV systemic chemotherapy on D1 and D15 of every cycle, beginning C2D1; treatment assigned by Arm. Arm 1: either FOLFOX (leucovorin, 5-FU and oxaliplatin) or FOLFIRI (leucovorin, 5-FU and irinotecan); FOLFOX: oxaliplatin (85 mg/m2) and leucovorin (400 mg/m2) administered concurrently via Y-Line over 120 minutes, then a 46-hour infusion of 5-FU (2000 mg/m2) administered via an ambulatory device on site. Arm 2: GemOx (gemcitabine \[800 mg/m2 IV over 30 minutes\] and oxaliplatin \[85 mg/ m2 IV over 120 minutes\])
224325437|NCT05286814|DRUG|Leucovorin|IV systemic chemotherapy on D1 and D15 of every cycle, beginning C2D1; treatment assigned by Arm. Arm 1: will receive either FOLFOX (leucovorin, 5-FU and oxaliplatin) or FOLFIRI (leucovorin, 5-FU and irinotecan); FOLFOX: oxaliplatin (85 mg/m2) and leucovorin (400 mg/m2) administered concurrently via Y-Line over 120 minutes, then a 46-hour infusion of 5-FU (2000 mg/m2) administered via an ambulatory device on site. FOLFIRI: irinotecan (150 mg/m2) and leucovorin (400 mg/m2) administered concurrently via Y-Line over 30 minutes, then a 46-hour infusion of 5-FU (2000 mg/m2) administered via an ambulatory device on site.
224325438|NCT05286814|DRUG|PDS01ADC|PDS01ADC will be administered by subcutaneous injection on Day 15 of every cycle. Cycle 1 at 12 mcg/kg; Cycle 2 reduced to 8 mcg/kg with the addition of systemic chemotherapy, to continue for further cycles. Note: any dose reduction in FUDR = 50% due to liver enzyme elevations means that the dose of PDS01ADC will be reduced to 4 mcg/kg.
224325439|NCT05286814|DRUG|Gemcitabine|IV systemic chemotherapy on D1 and D15 of every cycle, beginning C2D1; treatment assigned by Arm. Arm 2: GemOx (gemcitabine \[800 mg/m2 IV over 30 minutes\] and oxaliplatin \[85 mg/ m2 IV over 120 minutes\])
224325440|NCT05286814|DRUG|Dexamethasone|HAIP FUDR and Dexamethasone treatment on D1 of every cycle. Dexamethasone: (1 mg/day X pump volume / pump flow rate)
223682633|NCT05098977|PROCEDURE|Percutaneous coronary intervention|Coronary angiography and PCI will be performed using femoral or radial approach after local anesthetic infiltration with Lidocaine and arterial sheath placement. Following the culprit lesion detection and guidewire placement, thromboaspiration and glycoprotein IIb/IIIa inhibitors will be left to the operator decision. Also, the choice of coronary stenting technique and stent sizing will be performed according to the operator experience. Antiplatelet and anticoagulant drugs will be administered in concordance with latest European guidelines.
223682634|NCT00555425|BEHAVIORAL|Behavioral: Buprenorphine/naloxone maintenance (Mtn)|Mtn is designed to reflect usual care by primary care physicians and includes weekly drug counseling (DC) and referral to ancillary services. Dtx and Mtn will be identical for the first 4 weeks (stabilization) following randomization. In Mtn, Bup will continue unchanged for the remainder of the study.
223682635|NCT00555425|BEHAVIORAL|Behavioral: Buprenorphine/naloxone detoxification (Dtx)|Dtx and Mtn will be identical for the first 4 weeks (stabilization) following randomization. In Dtx, the dosage of Bup will be tapered to zero over the next 3 weeks, and patients will not receive additional Bup for the remainder of the study. Dtx patients will be offered thrice-weekly DC beginning during the taper and naltrexone will be offered 7 days following the last dose of Bup.
223682636|NCT00344942|DRUG|triamcinolone acetonide|220µg/day or a double spray into each nostril once daily for 12 weeks'treatment
223682637|NCT00344942|DRUG|placebo|a double spray into each nostril once daily
223682638|NCT02721771|PROCEDURE|Ultrasound examination|echocardiographic diastology and bilateral B-line pattern will be assessed. Optic nerve sheath diameter will be assessed.
223682639|NCT03048136|DRUG|Nivolumab|Specified dose on specified days
223682640|NCT03048136|DRUG|Ipilimumab|Specified dose on specified days
223682641|NCT00294710|DRUG|Aliskiren|
224325441|NCT04350138|BIOLOGICAL|Meningococcal Group B Vaccine|A combination vaccine consisting of rMenB and OMV NZ.
224325442|NCT04350138|OTHER|Placebo|150mM sodium chloride (0.9% saline solution).
224325443|NCT06636656|DRUG|BI 3032950 intravenous (Part A)|BI 3032950 intravenous (Part A)
224325444|NCT06636656|DRUG|BI 3032950 subcutaneous (Part B)|BI 3032950 subcutaneous (Part B)
224325445|NCT04967664|DRUG|Qutenza (capsaicin) 8% topical system|High concentration capsaicin
224325446|NCT04967664|DRUG|capsaicin 0.04% topical system|Low-dose capsaicin control
223774664|NCT05706259|DIETARY_SUPPLEMENT|Orodispersible (sachet) 200000 IU vitamin D3|Weekly single dose for 3-weeks
223774665|NCT01010984|DEVICE|LC beads loaded with Doxorubicin|During each TACE, 2 vials (1 vial, 75mg Doxorubicin) of 100-300 micrometer size LC beads loaded with doxorubicin will be delivered to the liver tumor(s). Total Doxorubicin dose for each TACE is 150mg
223774666|NCT00608829|DEVICE|GORE TAG® Thoracic Endoprosthesis|Implant
224325447|NCT06143891|DRUG|Belumosudil|Pharmaceutical form:Tablet-Route of administration:oral
224325448|NCT06143891|DRUG|Placebo|Pharmaceutical form:Table-Route of administration:oral
224325449|NCT06143891|DRUG|Prednisone|Pharmaceutical form:Tablet-Route of administration:oral
224325450|NCT06143891|DRUG|Prednisolone|Pharmaceutical form:Tablet-Route of administration:oral
224325451|NCT06767124|DIETARY_SUPPLEMENT|Ketogenic Supplement|Commercially available ketone ester drink
224325452|NCT06767124|OTHER|Placebo Drink|Placebo drink containing sunflower oil.
224325453|NCT07055516|DRUG|NT-0796|Orally administered capsules
224325454|NCT07055516|DRUG|Placebo|Orally administered capsules
224325455|NCT06796907|DRUG|GSK5733584|GSK5733584 will be administered intravenously (IV).
224325456|NCT06796907|DRUG|Dostarlimab|Dostarlimab will be administered IV.
223682642|NCT03240744|BIOLOGICAL|Inactivated EV71 vaccine (human diploid cell, KMB-17)|3.0 EU of inactivated enterovirus 71 vaccine (KMB-17) on day 0, 28.
223682643|NCT02582177|DRUG|Candicort®|Apply on the affected area and around it twice a day
223682644|NCT02582177|DRUG|Nizoral®|Apply on the affected area and around it twice a day
223682645|NCT02582177|DRUG|Baycuten N®|Apply on the affected area and around it twice a day
223682646|NCT02582177|DRUG|Canesten®|Apply on the affected area and around it twice a day
223682647|NCT03295565|DRUG|Cabazitaxel|Cabazitaxel 25mg/m2 IV, once every 3 weeks
223682648|NCT03295565|DRUG|Abiraterone|Abiraterone 1000mg oral, taken daily + Prednisone 5mg oral, 2 times a day
223682649|NCT03295565|DRUG|Enzalutamide|Enzalutamide 160mg oral taken daily
224325457|NCT06796907|DRUG|Bevacizumab|Bevacizumab will be administered IV.
224325458|NCT06796907|DRUG|Anticancer therapy 3|Anticancer therapy 3 will be administered IV.
224325459|NCT06796907|DRUG|Anticancer therapy 4|Anticancer therapy 4 will be administered IV.
224325460|NCT06641466|DRUG|Rimegepant|Rimegepant 75 mg ODT for 7 days
224325461|NCT06641466|DRUG|Placebo Comparator|Matching placebo oral disintegrating tablets for 7 days
224325462|NCT06641466|DRUG|Standard of Care|Standard of care for acute treatment as needed
224325463|NCT06641466|DRUG|Rimegepant|Rimegepant 75 mg ODT for acute treatment as needed
224325464|NCT04370795|DRUG|Sirolimus|Post transplant immunosuppressant drug
224325465|NCT04370795|DRUG|Busulfan|Conditioning drug
223682650|NCT01567228|OTHER|CHICA GIS (enhanced electronic medical record)|An electronic medical record enhanced with geographic information systems will assist physicians in directing patients to community resources for increasing physical activity, preventing dental caries or addressing school problems
223682651|NCT05955976|OTHER|BIOPSY|biopsy
223682652|NCT04065165|DRUG|Telotristat Ethyl|250 mg TID orally
223682653|NCT04065165|DRUG|Lanreotide|120 mg Q4W deep subcutaneous injection in the superior external quadrant of the buttock or in the upper outer thigh
224262441|NCT04166162|BEHAVIORAL|Tomando Buenas Decisiones (TBD) Intervention|The program is adapted from the Guiding Good Choices (GGC) program and will be conducted by a trained facilitator lasting for about 2 hours per session. The program discusses about the best ways to help one's child make good decisions with regards to avoiding alcohol, drugs, and other problem behaviors that may not be healthy to them as well as ways to have good communication and good connections within one's family.
224262442|NCT04166162|BEHAVIORAL|Social Development Strategy (SDS) Intervention|SDS is a 2 hour broad-focused environmental intervention consisting of short presentations and workshops designed to provide skills and models for positive human interaction between employees to fellow employees, employees to their children and employees to their supervisors.
224325466|NCT04370795|DRUG|Horse -Anti-thymocyte|Immune suppression conditioning drug
224325467|NCT04370795|DRUG|G-CSF|Used to prevent infection and neutropenic fevers caused by chemotherapy
224325468|NCT04370795|RADIATION|Total Body Irradiation (TBI)|Conditioning (only patients in Group 1 will receive TBI)
224325469|NCT04712097|DRUG|Mosunetuzumab|Participants will receive intravenous (IV) mosunetuzumab in a step-up dosing schedule on Days 1, 8, and 15 of Cycle 1, and on Day 1 of Cycles 2-12
224325470|NCT04712097|DRUG|Lenalidomide|Participants will receive oral lenalidomide once daily on Days 1-21 of Cycles 2-12 (M + Len) or Cycles 1-12 (R + Len)
224325471|NCT04712097|DRUG|Rituximab|Participants will receive IV rituximab on Days 1, 8, 15, and 22 of Cycle 1, then on Day 1 of Cycles 3, 5, 7, 9, and 11
224262443|NCT04166162|BEHAVIORAL|BTC Training Session|BTC training session consists of trainings, discussions and tools focused on community mobilization for the assessment and implementation of evidence-informed preventive interventions addressing community health and behavior problems. Each training session lasts about 4 hours.
223682654|NCT05677672|BIOLOGICAL|Human TH-SC01 Cell Injection|Single injection of 0.6×10\^7,1.2×10\^8, 1.8×10\^8 cells/kg
224262444|NCT01909713|DRUG|Facial Cleanser and Moisturizer SPF 30|Cetaphil® DermaControl™ Foam Wash and Moisturizer SPF 30
224262445|NCT01011413|DRUG|Efavirenz 600mg|3 x EFV 200 milligram (mg) tablets once daily
223682655|NCT05677672|OTHER|Saline solution|saline solution will be given at the same quantity and following the same schedule
223774667|NCT02192684|DRUG|Pioglitazone|45 mg daily Insulin sensitizing
224262446|NCT01011413|DRUG|Efavirenz 400mg|2 x EFV 200 milligram (mg) tablets plus 1x matched EFV placebo tablet once daily
224262447|NCT03207152|BIOLOGICAL|Influenza A/California/04/09|Good Manufacturing Practices-certified Influenza A/California/04/09 3.5x10(4) TCID50 in 1 mL in DPBS delivered by intranasal drops
223774668|NCT02192684|DRUG|placebo|Compare with pioglitazone
224262448|NCT05278403|OTHER|Virtual reality and video games|Use of a software in stroke patients' rehabilitation.
224262449|NCT05278403|OTHER|Neurological physiotherapy|Application of conventional physical therapy techniques.
224262450|NCT05592808|DEVICE|Extracorporeal Shockwave Therapy (ESWT)|Extracoporeal shock wave, 2000 shots/time, once a week for 3 weeks, shock wave freqency: 10Hz, total energy: 166 mJ/mm2, Pressure 2.5 Bar
224262451|NCT05592808|OTHER|Low-Dye Taping|After ESWT application, Low-Dye Taping will be applied 3 times, once a week.
224262452|NCT05592808|OTHER|Kinesio Taping|After ESWT application, Kinesio Taping will be applied 3 times, once a week.
224325472|NCT04712097|DRUG|Tociluzumab|Tocilizumab will be administered as needed to manage cytokine release syndrome (CRS) events
224325473|NCT06760481|DRUG|Tiragolumab|Given by IV
224325474|NCT06760481|DRUG|Atezolizumab|Given by IV
224325475|NCT06760481|RADIATION|Radiation Therapy|Given by IV
224325476|NCT06769659|DRUG|NPT 2042|NPT 2042 is a new drug being developed as an anti-seizure treatment
224325477|NCT06769659|OTHER|Placebo|Placebo Comparator
224325478|NCT06890416|BIOLOGICAL|RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE|Intramuscular injection
224325479|NCT06890416|BIOLOGICAL|HZ/su VACCINE|intramuscular injection
224325480|NCT07063420|OTHER|Continuous Glucose Monitor (CGM) + Patient Centered Multi-Agent Decision Support System (PCM-DSS)|Continuous Glucose Monitor (CGM) + Patient Centered Multi-Agent Decision Support System (PCM-DSS) PCM-DSS
224325481|NCT07063420|OTHER|Continuous Glucose Monitor (CGM) + Usual Care|Continuous Glucose Monitor (CGM) + Usual Care (Physician)
224325482|NCT07061977|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
224325483|NCT07061977|RADIATION|Brachytherapy|Undergo brachytherapy
224325484|NCT07061977|DRUG|Carboplatin|Given IV
224325485|NCT07061977|PROCEDURE|Chest Radiography|Undergo chest x-ray
224325486|NCT07061977|DRUG|Cisplatin|Given IV
224325487|NCT07061977|PROCEDURE|Computed Tomography|Undergo CT scan
224325488|NCT07061977|RADIATION|External Beam Radiation Therapy|Undergo EBRT
224325489|NCT07061977|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
223682656|NCT03381833|DRUG|LJPC-401|subcutaneous injection, up to 20 mg per week from week 26 to 52
223682657|NCT03381833|DRUG|LJPC-401|subcutaneous injection, up to 20 mg per week from week 1 to 52
223682658|NCT02447705|DRUG|telbivudine|telbivudine replace Lamivudine
223682659|NCT04303923|PROCEDURE|Ultrasonography|The diameters of both the radial artery and the distal radial artery were measured by ultrasonography.
223682660|NCT01504061|OTHER|Mederma N&I|Topical gel applied three times a day for eight weeks.
223682661|NCT01504061|OTHER|Mederma Ultra Gel|Topical gel applied once daily for eight weeks.
223682662|NCT02442401|DEVICE|The negative pressure wound therapy|
223682663|NCT03410264|BEHAVIORAL|CR-EXP|See arm/group descriptions
223682664|NCT03410264|BEHAVIORAL|EXP-CR|See arm/group descriptions
224325490|NCT07061977|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
224325491|NCT07061977|DRUG|Paclitaxel|Given IV
224325492|NCT07061977|BIOLOGICAL|Pembrolizumab|Given IV
224325493|NCT07061977|PROCEDURE|Positron Emission Tomography|Undergo PET scan
224325494|NCT06172296|PROCEDURE|Biospecimen Collection|Undergo blood and urine sample collection
224325495|NCT06172296|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
224325496|NCT06172296|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
224325497|NCT06172296|DRUG|Carboplatin|Given IV
224325498|NCT06172296|DRUG|Cisplatin|Given IV
224325499|NCT06172296|PROCEDURE|Computed Tomography|Undergo CT scan
224325500|NCT06172296|DRUG|Cyclophosphamide|Given IV
224325501|NCT06172296|BIOLOGICAL|Dinutuximab|Given IV
223682665|NCT03410264|BEHAVIORAL|Stress Management|See arm/group descriptions
223682666|NCT00233909|DRUG|Zosuquidar|
223682667|NCT00233909|DRUG|gemtuzumab ozogamicin|
223682668|NCT05843773|PROCEDURE|Low Load Strength Training under Blood Flow Restriction|"The first training includes one initiation/warm up set and two sets of normal training. Every set lasts 60 seconds and the patient is asked to bend and stretch the knee with a standard speed of 20°/s.~From the second to the ninth training, the patient will have one warm up set plus three trainings sets. The speed of execution will be increased every training.~The 20-40% range of the 1RM will be applied according to the values of the theoretical maximal strength.~If no strength progression is observed in the three last training sessions, the speed of execution will automatically be increased by 15°/s.~In order to keep the training intensity low and to not overload the knee, participants will be instructed to control the intensity with the Borg CR10. The volunteers will have to keep their efforts between 2/10 and 4/10. They will also be asked to stay in the range defined thanks to the theoretical maximal strength shown by the screen."
223682669|NCT03448874|DEVICE|Seal-G MIST System|Seal-G MIST is an adjunct device that will be applied adjunctively to cover standard closure techniques.
223682670|NCT06000267|PROCEDURE|Intubation|All the patients will be ventilated with face mask and intubated before elective surgery
223682671|NCT01932879|OTHER|Blackberry|Participants will be fed a higher fat, typical American diet for two 1-week periods. Participants must consume only and all food provided during the intervention periods.
223682672|NCT01932879|OTHER|Jello|
223682673|NCT00021372|DRUG|estramustine phosphate sodium|
223682674|NCT00021372|DRUG|paclitaxel|
223682675|NCT05354674|DRUG|Bevacizumab|"AEM A：The specialist's decision to add bevacizumab to chemotherapy will be based on their own judgment~ARM B：The patient's PET/CT imaging, pathology, and clinical information were input into the signature, and the FOLFOX+Bevacizumab regimen was selected when the output label was 1. FOLFOXIRI chemotherapy regimen was selected when the output label was 0"
223682676|NCT02989987|BEHAVIORAL|Narrative Exposure Therapy|
223682677|NCT02989987|BEHAVIORAL|Social Support|A local counselors provides social support on demand.
223682678|NCT04032574|COMBINATION_PRODUCT|Herbal Medicinal Product|
224325502|NCT06172296|DRUG|Doxorubicin|Given IV
223682679|NCT04032574|OTHER|Placebo|
223682680|NCT03383705|DEVICE|VBeam Prima|Up to four treatments will be performed every 4-6 (±1) weeks.
223682681|NCT02398994|DRUG|Intravenous Methylprednisolone|
223682682|NCT02398994|DRUG|Intravenous Immunoglobulin|
223682683|NCT00167869|BEHAVIORAL|dairy peptides|
223682684|NCT02995369|DEVICE|DryShield|DryShield (DS) is an all-in-one isolation system. It combines the tasks of fluid evacuation, tongue and cheek retraction, and serves as a bite block. Its design allows it to suction and isolate half the oral cavity at a time.
223682685|NCT02995369|OTHER|Cotton rolls|Cotton Roll Isolation requires placing cotton rolls along the buccal mucosa, especially over the parotid glands ducts for maxillary teeth. For the mandibular teeth, the cotton rolls are placed in the buccal vestibule and the floor of the mouth (between the lower buccal mucosa and underneath and/or between the tongue). With this technique, a high-speed evacuation of saliva and water is used.
223682686|NCT03109912|BEHAVIORAL|Personalized-Coaching Interventions|At the baseline fitness assessment, participants receive exercise prescriptions based upon their individual assessment. One of the ultimate exercise prescription goals is to achieve 30-minutes of an endurance-style exercise 5 times/week which may vary depending upon baseline fitness assessment. Aside from team sports, endurance-style exercise prescriptions may include simply walking, jump roping or stair climbing to more complex Tabata-style workouts. Two additional physical therapy (PT) 30-minute appointments are scheduled about 4-6 weeks and 8-10 weeks from enrollment. These 30-minute PT follow-up appointments will vary based on initial assessment and previous exercise prescription success but will include strength training for major muscles groups and/or flexibility exercises with yoga as well as reinforcement of previously learned techniques. PT will add additional individualized recommendations.
223682687|NCT03109912|BEHAVIORAL|Motivational Messages|Intervention participants are enrolled to receive motivational messages starting 14 days after enrollment via preferred contact method (SMS, telephone call and/or email) every 3-4 days over the 6-month study period.
223682688|NCT03109912|BEHAVIORAL|Online Exercise Tutorials|Participants are given access to Do More, B'More, Live Fit webpage which includes spotlighted exercises, instructional exercise photos and videos.
223774669|NCT02564471|DRUG|Chloroquine|FDA approve dosing schedule
224325503|NCT06172296|PROCEDURE|Echocardiography Test|Undergo ECHO
224325504|NCT06172296|DRUG|Etoposide|Given IV
224325505|NCT06172296|PROCEDURE|FDG-Positron Emission Tomography and Computed Tomography Scan|Undergo FDG PET
224325506|NCT06172296|PROCEDURE|Hematopoietic Cell Transplantation|Undergo stem cell infusion
224325507|NCT06172296|DRUG|Irinotecan|Given IV
224325508|NCT06172296|DRUG|Isotretinoin|Given PO
224325509|NCT06172296|PROCEDURE|Leukapheresis|Undergo apheresis
224325510|NCT06172296|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
224325511|NCT06172296|DRUG|Melphalan|Given IV
224325512|NCT06172296|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
224325513|NCT06172296|RADIATION|Radiation Therapy|Undergo radiation therapy
224325514|NCT06172296|PROCEDURE|Radionuclide Imaging|Undergo I-MIBG scan
224325515|NCT06172296|OTHER|Survey Administration|Ancillary studies
224325516|NCT06172296|DRUG|Temozolomide|Given PO or via NG or G tube
224325517|NCT06172296|DRUG|Thiotepa|Given IV
224325518|NCT06172296|DRUG|Topotecan|Given IV
224325519|NCT06172296|PROCEDURE|Tumor Resection|Undergo tumor resection surgery
224325520|NCT06172296|DRUG|Vincristine|Given IV
224325521|NCT03896750|DRUG|PA-824|PA-824, a nitroimidazooxazine, used in prior studies of pretomanid is a novel TB treatment that is being investigated for use with other TB drugs to shorten and/or simplify regimens to treat either drug susceptible or resistant disease. After fasting for a minimum of 8 hours, subjects will receive one dose of 200 mg of pretomanid orally under direct supervision with 240 mL of water and a mouth check will be done.
224325522|NCT06763146|DRUG|Finerenone (Kerendia, BAY948862)|Retrospective cohort analysis using the investigator or a delegate at the study site collects secondary/historic data of finerenone usage (patient demographic and clinical characteristics, diagnosis-related, treatment-related, and laboratory data) from clinic specific medical records.
224325523|NCT05621291|DIAGNOSTIC_TEST|NGS testing|antigen immunophenotype agnostic approach for disease detection using blood and bone marrow samples
224325524|NCT04929041|PROCEDURE|Biopsy Procedure|Undergo tissue biopsy
224325525|NCT04929041|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
224325526|NCT04929041|PROCEDURE|Computed Tomography|Undergo CT
224325527|NCT04929041|PROCEDURE|Echocardiography Test|Undergo ECHO
224325528|NCT04929041|BIOLOGICAL|Ipilimumab|Given IV
224325529|NCT04929041|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
224325530|NCT04929041|BIOLOGICAL|Nivolumab|Given IV
224325531|NCT04929041|PROCEDURE|Positron Emission Tomography|Undergo PET
224325532|NCT04929041|OTHER|Quality-of-Life Assessment|Ancillary studies
224325533|NCT04929041|RADIATION|Radiation Therapy|Undergo radiation therapy
224325534|NCT06664619|DRUG|Fp/ABS|Inhalation powder
224325535|NCT06664619|DRUG|FP|Inhalation powder
224325536|NCT06664619|DRUG|ABS|Inhalation powder
223682689|NCT03109912|BEHAVIORAL|Social Support and Peer Challenges|Participants are invited to join the Do More, B'More, Live Fit Activity Group via the FitBit Dashboard and are invited to friend the study team members and other exercise-intervention participants in order to take part in FitBit step-goal challenges.
223774670|NCT02564471|DRUG|Atovaquone and Proguanil|FDA approve dosing schedule
223774671|NCT02564471|DRUG|Doxycycline|FDA approve dosing schedule
224325537|NCT06664619|DRUG|Placebo|Inhalation powder
224325538|NCT06827002|DRUG|Dichrostachys glomerata|DGE were procured from Gateway Health Alliances, Fairfield in 400 mg and 300 mg capsules.
224325539|NCT06827002|DRUG|Cissus quadrangularia|CQR-300® were procured from Gateway Health Alliances, Fairfield in 400 mg and 300 mg capsules.
224325540|NCT06827002|DRUG|Dextrin|Placebo capsules containing 400 mg of dextrin, looking identical to DGE and CQE were also procured from Gateway Health Alliances, Fairfield, California, USA.
224325541|NCT06827002|DRUG|Semaglutide (Rybelsus®)|Oral semaglutide (Rybelsus®) was purchased and then repackaged into capsules looking identical to DGE, CQE and placebo capsules.
224325542|NCT07065331|DRUG|AZD8630|Single inhaled dose of AZD8630 via dry powder inhaler.
224325543|NCT07065331|DEVICE|Dry powder inhaler|Single inhaled dose of AZD8630 via dry powder inhaler.
224325544|NCT07063745|DRUG|BMS-986504|Specified dose on specified days
224325545|NCT07063745|DRUG|Pembrolizumab|Specified dose on specified days
223774672|NCT02564471|BIOLOGICAL|Rabies Vaccine|FDA approve dosing schedule
223774673|NCT04307758|OTHER|Muscle Strength Assesment-Make Test|For the make test, the examiner applies resistance in a fixed position and the person being tested exerts a maximum effort against the dynamometer and examiner. The examiner is only required to sustain an isometric contraction and read the highest value on an Hand Held Dynamometer.
224325546|NCT07063745|OTHER|Placebo|Specified dose on specified days
224325547|NCT07063745|DRUG|Cisplatin|Specified dose on specified days
224325548|NCT07063745|DRUG|Carboplatin|Specified dose on specified days
224325549|NCT07063745|DRUG|Pemetrexed|Specified dose on specified days
224325550|NCT07063745|DRUG|Paclitaxel|Specified dose on specified days
224325551|NCT07063745|DRUG|Nab-paclitaxel|Specified dose on specified days
224325552|NCT06778863|DRUG|CLSP-1025|CLSP-1025 will be administered by IV infusion
224325553|NCT06813781|DRUG|AZD5004|Dose 1
224325554|NCT05198674|DEVICE|Renal Denervation (Symplicity Spyral™)|Device: Symplicity Spyral™ multi-electrode renal denervation system. After a renal angiography according to standard procedures, subjects are treated with the renal denervation procedure.
224325555|NCT06789406|DEVICE|Axonics SNM System INS Model 5101 (R20)|Participants treated with the rechargeable Axonics SNM System Model 5101 also referred to as R20. Commercial devices used in this study are within their intended use as described in each geography's approved instructions for use.
224325556|NCT06829823|DRUG|N-803 and BCG|Combination therapy N-803 plus BCG
224325557|NCT06829823|DRUG|N-803 and Gemcitabine|Combination therapy N-803 plus Gemcitabine
224325558|NCT07061964|PROCEDURE|Biospecimen Collection|Undergo tissue, urine, and blood sample collection
224325559|NCT07061964|PROCEDURE|Computed Tomography|Undergo CT
224325560|NCT07061964|PROCEDURE|Cystoscopy|Undergo cystoscopy
224325561|NCT07061964|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
224325562|NCT07061964|BIOLOGICAL|Pembrolizumab|Given IV
224325563|NCT07061964|RADIATION|Photon Beam Radiation Therapy|Undergo photon beam RT
224325564|NCT07061964|PROCEDURE|Positron Emission Tomography|Undergo PET
224325565|NCT07061964|OTHER|Questionnaire Administration|Ancillary studies
224325566|NCT07061964|PROCEDURE|Transurethral Resection of Bladder Tumor|Undergo TURBT
224325567|NCT07069712|DRUG|AZD0901|AZD0901 will be administered as an IV infusion.
224325568|NCT07069712|DRUG|Rilvegostomig|Rilvegostomig will be administered as an IV infusion.
224325569|NCT07069712|DRUG|Trastuzumab Deruxtecan (T-DXd)|T-DXd will be administered as an IV infusion.
224325570|NCT07069712|DRUG|Capecitabine|Capecitabine (Fluoropyrimidine) will be administered orally as chemotherapy standard of care.
224325571|NCT07069712|DRUG|5-Fluorouracil (5-FU)|5-FU (Fluoropyrimidine) will be administered as an IV infusion as chemotherapy standard of care.
224325572|NCT07069712|DRUG|FLOT Chemotherapy|FLOT (5-FU, leucovorin, oxaliplatin, and docetaxel) Chemotherapy will be administered as an IV infusion.
224325573|NCT03524092|DRUG|Mirikizumab SC|Administered SC
224325574|NCT03524092|DRUG|Mirikizumab IV|Administered IV
223682690|NCT03761771|DEVICE|colonoscopy withdrawal with the ADS monitoring|During the testing of trained ADS, when the system doubts colonic lesions from the input data of the test images, a rectangular frame was displayed in the endoscopic image to surround the lesion. If the system confirmed it as the colonic lesions, a sound of reminder will be played and the types of lesions (non-adenomatous polyps, adenomatous polyps and colorectal cancers) will be classified by the system. We adopted several standards to define the identification and classification of colonic lesions: 1) when the system identified and confirmed any lesion in the images of no polyps or cancers, the results were judged to be false-positive. 2) when the system both confirmed and correctly localized the lesions in images (IoU \> 0.3), the results were judged to be true-positive. 3) when the system did not confirm or correctly localize the lesions, the results were judged as false-negative. 4) when system confirmed no lesions in the normal images, the results were judged to be true-negative.
223682691|NCT04294745|PROCEDURE|Buccal infiltration|Injection of local anaesthetic parallel to the Long axis of the tooth in the depth of buccal sulcus
223682692|NCT04294745|PROCEDURE|Inferior alveolar nerve block|Standard technique of mandibular nerve block
223682693|NCT02514954|DRUG|Biochaperone® Combo|Subcutaneous injection of an individualized dose
223682694|NCT02514954|DRUG|Humalog® Mix25|Subcutaneous injection of an individualized dose
223682695|NCT02919384|OTHER|2% oxygen concentration in the incubator|"At the time that embryos are changed from cleavage stage media to blastocyst stage media on day 3 of development, half of a given patient's embryos will randomly be placed in an incubator set at 2% oxygen concentration. The splitting of the embryos will be done under low magnification such that the embryologist will have no ability to bias allocation of embryos to 2% or 5% oxygen based on embryo morphology on day 3. The embryos will remain in this incubator until their developmental assessments on day 5 and 6."
223682696|NCT02566408|OTHER|One-on-one interview|Undergo one-on-one interview about KAPs towards PA
223682697|NCT02566408|OTHER|Survey Questions|Complete survey
223682698|NCT00746200|PROCEDURE|(electro)acupuncture|Frequency of electrostimulation: 15Hz; Duration of electrostimulation: 20min;
223682699|NCT00746200|PROCEDURE|sham acupuncture|Superficial acupuncture needle stimulation at non-acupoints with TENS applied for seconds
223682700|NCT05301374|BEHAVIORAL|Watching Cartoon|Children in the cartoon group before the procedure, they chose one of the cartoons predetermined by the researchers. The children in the cartoon group started watching a cartoon of their choice 2 minutes before the procedure and they kept watching until the procedure was ended.
223682701|NCT04013399|DEVICE|Continuous Positive Airway Pressure|The device is an auto-adjusting pressure device with an integrated humidifier. Pressure is adjusted based on airway resistance.
223682702|NCT06053710|DEVICE|Wearable bioimpedance sensor|The investigational device is an electronic bioimpedance-based, body-worn, battery-powered sensor intended to monitor changes in fluid volume. It is designed as an adhesive patch with four integrated electrodes.
223682703|NCT04692727|OTHER|Exercise program|"* Hamstring, quadriceps, gastrocnemius, iliopsoas, iliotibial band (ITB), lateral and medial retinaculum stretching exercises~* Isometric exercises of vastus medialis, gluteus medius and external rotators~* Isotonic exercises of vastus medialis, gluteus medius and external rotators~* Closed kinetic chain exercises~* Balance and coordination exercises~* Core stabilization exercises"
223682704|NCT04692727|OTHER|McConnel patellar taping technique|Individuals are placed in a supine position with their knees extended and the quadriceps relaxed. A 5 cm wide hypoallergenic band is applied transversely over the patella without affecting the position of the patella. Then, it is started at the lateral edge of the patella with a rigid tape. The tape is terminated at the medial femoral condyle after a medial pull and / or medial tilt to the patella.
223774674|NCT04307758|OTHER|Muscle Strength Assesment-Break Test|For the break test, the examiner applies resistance sufficient to overcome the maximum effort of the person being tested and cause the subject's joint to move in the opposite direction, which results in an eccentric contraction. During this test the limb must move at a constant velocity while the person being tested is asked to achieve a maximum contraction. In addition, the examiner must read the force output reading at the exact time the subject's limb begins to move from the Hand Held Dynamometer.
224262453|NCT04544618|DEVICE|Virtual reality operating room simulation|The virtual reality simulation will begin with the participant sitting on a hospital bed wearing the virtual reality headset and holding the controllers. Participants will be oriented to the environment and provided with an explanation of how to navigate through the simulation (for approximately 2 minutes). Next, participants will explore the virtual operating room for a minimum of 5 minutes, or longer if desired. Following the exploration period, the scripted portion of the simulation will be begin. Here, participants will be taken through the mock anesthetic induction process (the virtual anesthetist will speak to the patient and walk them through the steps and the virtual nurse will assist). The simulation ends after the virtual oxygen mask is placed over the participant's mouth and the screen darkens.
224262454|NCT04532996|BEHAVIORAL|Trauma-focused psychodynamic psychotherapy|"This psychotherapy addresses disruptions in narrative coherence and affective dysregulation by exploring the psychological meanings of symptoms and their relation to traumatic events. The therapist works to identify intrapsychic conflicts, intense negative affects, and defense mechanisms related to the PTSD syndrome using a psychodynamic formulation that provides a framework for intervention. The transference provides a forum for patients to address feelings of mistrust, difficulties with authority, fears of abuse, angry and guilty feelings, and fantasies.~This treatment will be provided in-person or over teletherapy as the public health situation demands."
224262455|NCT02331108|DRUG|Selection of anesthetic induction technique|Standard anesthesia care will be provided after induction based on randomization. Temperatures will be monitored every 15 minutes
224262456|NCT01216020|DRUG|cetuximab|"* Cetuximab is given according to the standard mode of administration: loading dose : 400 mg/m2 one week before the start of radiotherapy (week -1), followed by a weekly dose of 250 mg/m2 during the weeks of the treatment with radiotherapy.~* Radiotherapy: Doses: Clinical sites of disease (T e N) : total dose of 70 Gy given with a fractional dose of 2 Gy/day; prophylactic nodal volume (N) : total dose of 50 Gy given with a fractional dose of 2 Gy/day ; Treatment technique: conformal 3D. Intensity modulated radiotherapy (IMRT), also with simultaneous boost (SIB), is allowed."
224325575|NCT03524092|DRUG|Placebo SC|Administered SC
224325576|NCT06897358|DRUG|Leniolisib|Planned dose will range from 10 mg twice daily to 70 mg twice daily
224325577|NCT07062016|OTHER|Non-Interventional Study|Non-interventional study
224325578|NCT07070219|DRUG|CTD402 CAR T Cell Injection|CAR T cells
224262457|NCT01216020|DRUG|cisplatin (associated to radiotherapy)|"* CDDP dose: 40 mg/mq in a single weekly 1-hour infusion preceded by adequate hydration, diuretics e antiemetic premedication.~* Radiotherapy: Doses: Clinical sites of disease (T e N) : total dose of 70 Gy given with a fractional dose of 2 Gy/day; prophylactic nodal volume (N) : total dose of 50 Gy given with a fractional dose of 2 Gy/day ; Treatment technique: conformal 3D. Intensity modulated radiotherapy (IMRT), also with simultaneous boost (SIB), is allowed."
224325579|NCT07067138|DEVICE|Expression Networks for highLIGHting Tumor vulnerabilities (ENLIGHT)|This is a computational algorithm that takes RNA-seq data from tumor FFPE blocks and, given a list of pre-specified treatments, generates as output the predicted responses to those treatments.
224325580|NCT07067138|DEVICE|TruSight(R) Oncology 500|TSO500 uses formalin-fixed, paraffin-embedded (FFPE) tumor blocks to generate a 523-gene DNA panel (with tumor mutational burden and microsatellite instability) to assess for biomarkers linked to FDA-approved, on-label therapies as well as whole-exome RNA-seq that can be used with the ENLIGHT algorithm.
224325581|NCT07067138|DEVICE|TruSeq Matched Tumor Normal Whole Exome Sequencing Assay|The TruSeq Matched Tumor-Normal Whole Exome Sequencing assay is a next-generation sequencing assay that uses tumor DNA from formalin-fixed, paraffin-embedded (FFPE) tumor blocks and germline DNA drawn from blood to provide extended sequencing information on the tumor as well as any pathogenic variants, likely pathogenic variants, and variants of uncertain significance in 156 genes from the normal blood sample.
224325582|NCT06767683|DRUG|ALKS 2680, 4mg|Oral tablet containing 4 mg of ALKS 2680 for once daily administration
224262458|NCT01363817|DRUG|BMS-906024|
224262459|NCT01363817|DRUG|Dexamethasone|
224262460|NCT03206749|DRUG|VX-150|Participants received VX-150 1500 milligram (mg) as first dose, followed by VX-150 750 mg dose every 12 hours (q12h) for 2 days.
224262461|NCT03206749|DRUG|HB/APAP|Participants received HB 5 mg/APAP 325 mg every 6 hours (q6h) for 2 days.
224325583|NCT06767683|DRUG|ALKS 2680, 6mg|Oral tablet containing 6 mg of ALKS 2680 for once daily administration
224325584|NCT06767683|DRUG|ALKS 2680, 8mg|Oral tablet containing 8 mg of ALKS 2680 for once daily administration
224325585|NCT06767683|DRUG|ALKS 2680, 10mg|Oral tablet containing 10 mg of ALKS 2680 for once daily administration
224325586|NCT06767683|DRUG|ALKS 2680, 14mg|Oral tablet containing 14 mg of ALKS 2680 for once daily administration
224325587|NCT06767683|DRUG|ALKS 2680, 18mg|Oral tablet containing 18 mg of ALKS 2680 for once daily administration
224325588|NCT07039175|BEHAVIORAL|MINDSET|A behavior-change model informed mailed informational packet with tailored health information regarding the impacts of smoking/drinking on chronic disease and the benefits of stopping, followed by a brief motivational telephone booster call from a behavioral health provider.
224325589|NCT07039175|OTHER|Usual Care|All Veterans involved in this study will have a standard primary care (PC) appointment, which may include conversations/interventions related to drinking and smoking. This appointment is not controlled by the study team and we cannot comment on the extent to which smoking/drinking will or will not be discussed in the primary care appointment but we imagine this can range from no discussion/intervention at all to extensive conversations with the provision of medications, brief advice, etc.
224325590|NCT05642195|BIOLOGICAL|Montanide (Registered Trademark) ISA-51 VG Adjuvant|H1299 cell lysate with Montanide (Registered Trademark) ISA-51 VG adjuvant vaccine via subcutaneous injections once every cycle (1 cycle=28 days) for 6 cycles (i.e., 6 vaccinations). Dose Level 1 (DL1) starting dose is 20 mcg lysate protein in 2-2.5 mL Montanide (Registered) ISA-51 VG adjuvant; lysate concentration will be 8-10 mcg/mL. Additional 2 vaccine injections for subjects with immunologic response and NED.
224325591|NCT05642195|BIOLOGICAL|H1299 Cell Lysates|H1299 cell lysate with Montanide (Registered) ISA-51 VG adjuvant vaccine via subcutaneous injections once every cycle (1 cycle=28 days) for 6 cycles (i.e., 6 vaccinations). Dose Level 1 (DL1) starting dose is 20 mcg lysate protein in 2-2.5 mL Montanide (Registered Trademark) ISA-51 VG adjuvant; lysate concentration will be 8-10 mcg/mL. Additional 2 vaccine injections for subjects with immunologic response and NED.
224325592|NCT05642195|DRUG|N-803|N-803 via subcutaneous injection in the abdomen at dose of 15 ug/kg every 4 weeks, on Day 1 of each cycle. N-803 dosing will be calculated using a weight obtained within 5 days prior to the first dose. Dose re-calculated at the beginning of each subsequent cycle in the event of a 10% or greater weight change.
224325593|NCT05642195|DEVICE|Ventana PD-L1 (SP263 or SP142) assay|FDA-approved assays used off-label for study as treatment determining in-vitro diagnostic devices to assess subject PD-L1 quantitation. Testing will be performed on provided archival samples or on fresh sample that is collected at screening for confirmation of diagnosis; no additional sample collection for purposes of PD-L1 testing.
224325594|NCT06311227|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
224325595|NCT06311227|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
224325596|NCT06311227|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
224325597|NCT06311227|PROCEDURE|Computed Tomography|Undergo CT scan
224325598|NCT06311227|PROCEDURE|Lumbar Puncture|Undergo lumbar puncture
224325599|NCT06311227|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
224325600|NCT06311227|DRUG|Venetoclax|Given PO
224325601|NCT07071974|DRUG|BI 456906 formulation A|BI 456906 formulation A
224325602|NCT07071974|DRUG|BI 456906 formulation B2|BI 456906 formulation B2
224325603|NCT04303780|DRUG|AMG 510|21 day cycles
224262462|NCT03206749|DRUG|Placebo|Participants received placebo matched to VX-150 and HB/APAP for 2 days.
224262463|NCT03302949|DIETARY_SUPPLEMENT|Lacprodan® DI-8090|Whey protein concentrate. 100g powder contains 392 kcal (1646 kJ), hereof 80% protein.
224262464|NCT01298609|DEVICE|Occipital Stimulation|Occipital Nerve Stimulation will be used in each study arm using the Eon Mini neuromodulation system
224262465|NCT05572996|DRUG|Inhaled Treprostinil|
224325604|NCT04303780|DRUG|Docetaxel|21 day cycles
224325605|NCT06810141|BIOLOGICAL|rMBCG|1-19.2e8 colony-forming units (CFU) of rMBCG
224325606|NCT06561828|DEVICE|continuous Theta Burst Stimulation (cTBS)|Continuous theta burst stimulation (three TMS pulses delivered at 50Hz with the bursts delivered at 5Hz for a total of 600 pulses per site).
223682705|NCT04692727|OTHER|Femoral rotational taping technique|This technique is applied in a standing position and hip extreme external rotation. Taping is started on the vastus medialis and is pulled diagonally from the anterior of the leg to the lateral and ends on the trochanter major.
223682706|NCT03769376|DEVICE|Bio-Oss®|Bio-Oss® xenograft bone material will be placed into the socket following tooth extraction.
223682707|NCT03769376|DEVICE|Salvin-Oss®|Salvin-Oss® xenograft bone material will be placed into the socket following tooth extraction.
223682708|NCT03653871|BEHAVIORAL|Performing Arts Instruction|Professionally delivered performing arts curriculum
223682709|NCT01346215|BIOLOGICAL|heparin sodium|5000 UI/mL
223682710|NCT01346215|BIOLOGICAL|heparin sodium|5000 UI/mL
223682711|NCT01799382|OTHER|Rapid on-site evaluation|Rapid on-site evaluation consists on the cytological evaluation of samples obtained during a diagnostic procedure by a pathologist present in the diagnostic suite. In the present study, cytological samples obtained with EBUS-TBNA during bronchoscopy will be evaluated.
223682712|NCT01799382|DEVICE|EBUS-TBNA|EBUS-TBNA is a needle aspiration procedure guided by endobronchial ultrasounds performed during bronchoscopy
223682713|NCT05260281|DEVICE|MONA algorithm|most artificial intelligence algorithms, like the MONA algorithm used in this study, are trained on 45-degree fundus photographs. In order to incorporate the use of the algorithm, the study intervention consists of taking 1 extra 45-degree fundus photograph per eye per patient using the Zeiss Cirrus Photo 800 system.
223682714|NCT05860101|OTHER|Compassion-Focused Therapy|Compassion Focused Therapy (CFT) is based on the premise that we have three emotion regulation systems, the threat, drive and soothing systems. It has been suggested that our psychological wellbeing is dependent on maintaining a balance between these three systems, and if we lose this balance, e.g. the threat or drive systems become more dominant, then we start to experience emotional difficulties (Gilbert, 2009). In this study, participants are given various exercises to develop their soothing system, and help them to balance overactive threat.
223682715|NCT02005198|OTHER|No treatment given|Subject will only fill out a questionnaire when entering the non-interventional study
223682716|NCT02763592|DRUG|Lidocaine|The aim of this study is to evaluate the impact of 5% lidocaine medicated plaster on allodynic symptoms of localized neuropathic pain after knee surgery
223682717|NCT02763592|OTHER|placebo plaster|This is a randomized, placebo-controlled, double-blind, parallel-group clinical trial comparing 5% lidocaine medicated plaster (5LP) and placebo whether neuropathic pain symptoms (dynamic mechanical allodynia, pressure, hot and cold) have a different chronological improvement with 5LP compared to placebo. Pain intensity and pain relief, sleep and quality of life and osteoarthritis severity are also assessed.
223774675|NCT02471924|OTHER|Trans thoraciq cardiac ultrasonography|Establish a diagnosis power of the ΔITVAo ( aortic velocity peak )measured with cardiac Trans thoraciq ultrasonography after passiv leg rising to predict hypotension after spinal anesthesia for elective caesarean. Every patients participate for 30 minutes (time to perform the echography). Outside echographic evaluation, medical taking of participating patients will be exactly the same than what is done for all elective caesarean section.
223774676|NCT02908438|DRUG|Gonadotrophin releasing hormone agonist(GnRHa)|GnRHa group receive three injections of GnRHa(Decapeptyl) ,0.1 mg s.c. on the day of ET, and D3 and D6 after ET in addition to routine LPS.
223682718|NCT03149848|DRUG|Cabotegravir|It will be available as a white aquarius film coated tablet for oral administration. CAB Tablet is composed of GSK1265744B (micronized) lactose monohydrate, microcrystalline cellulose, hypromellose, sodium starch glycolate, magnesium stearate
223774677|NCT03405467|OTHER|general and specific data|General and specific data collected
223682719|NCT03149848|DRUG|Rifabutin|It will be available as an opaque red-brown hard gelatin capsules containing 150 mg of rifabutin for oral administration. These capsules are composed of rifabutin, microcrystalline cellulose, sodium lauryl sulphate, magnesium stearate, and silica gel
223682720|NCT04786509|DIAGNOSTIC_TEST|Field tests|In this study we used three different standardized running tests, one sub-maximal test - Cooper 2400 m (C), and two maximal (all-out) tests - 100 m sprint (S) and shuttle run (SR).
223682721|NCT00862108|DRUG|Methylphenidate|mg/kg dose: 0.7\~1.2mg/kg PO daily morning intake 8 weeks
223682722|NCT01244490|DRUG|Extended-release Guanfacine Hydrochloride|Tablet, once daily, optimised dose (1mg to 7mg based on age and weight), 6-week maintenance duration on optimised dose.
223774678|NCT05745740|DRUG|RC48-ADC|RC48-ADC 1.5/2.0 mg/kg by intravenous (IV) infusion, given on Day 1 of each 14-day cycle
223774679|NCT05745740|DRUG|Pyrotinib|Pyrotinib 400 mg by oral once a day.
224262466|NCT02870686|PROCEDURE|ERCP without the use of fluoroscopy|ERCP removal of stone technique without the use of fluoroscopy involves: (1) catheter with wire achieve bile duct, (2) confirmation of bile duct achievement with catheter aspiration of bile, (3) performance of endoscopic biliary sphinctertome, (4) stone removal with balloon or basket- number of stones removed should compare number detected on EUS, (5) confirmation of complete stone clearance with radiocontrast.
224262467|NCT02870686|PROCEDURE|ERCP with the use of fluoroscopy|ERCP removal of stone technique with the use of fluoroscopy involves: (1) catheter with wire achieve bile duct, (2) confirmation of bile duct achievement with fluoroscopy images, (3) performance of endoscopic biliary sphinctertome, (4) stone removal with balloon or basket, (5) confirmation of complete stone clearance with radiocontrast.
224262468|NCT03900013|PROCEDURE|Injectable platelet rich fibrin combined with DFDBA|The i-PRF will be mixed with bone graft then will be placed into the intraosseous defect
224262469|NCT03900013|PROCEDURE|Demineralized Freeze Dried Bone Allograft|Demineralized Freeze Dried Bone Allograft alone will be placed into the intraosseous defect
224262470|NCT02803827|OTHER|Rapid diagnostics|Participants will have enteric specimens obtained using a flocked rectal swab, which will be transported in 2 mL Cary Blair medium. These will be tested using the BioMerieux BioFire FilmArray GI panel.
224262471|NCT02803827|BIOLOGICAL|Probiotic|The probiotic given will be Lactobacillus reuteri DSM 17938, 5x10e8 cfu/mL x 60 days, suspended in vegetable oil.
224262472|NCT02803827|OTHER|Placebo|The placebo will be the vegetable oil vehicle and look identical to the probiotic.
224262473|NCT03332082|PROCEDURE|Tooth positioner|Orthodontic Tooth positioners treatment have been used in the Orthodontic Industry for many years. These positioners are used for small minor movements to complete the final smile. These positioners are made from a biocompatible and FDA approved clear silicone material after the teeth have been set to the final position.
223774680|NCT04538014|DRUG|Lu AF88434|Oral solution
224325607|NCT06561828|DEVICE|intermittent Theta Burst Stimulation (iTBS)|Intermittent theta burst stimulation (three TMS pulses delivered at 50Hz with the bursts delivered at 5Hz for 2 seconds followed by a break of 8 seconds for a total of 600 pulses per site).
223774681|NCT04538014|DRUG|[11C]-Lu AF88434|\[11C\]-Lu AF88434, and a radioactive dose not exceeding 400 MBq at each PET examination, intravenous bolus injection
223774682|NCT02805257|DRUG|Mitomycin-C|Intraoperative and postoperative injections of mitomycin-c/Mitosol
223774683|NCT02805257|OTHER|Balanced Salt Solution|Intraoperative and postoperative injections of BSS
223774684|NCT02805257|PROCEDURE|Ahmed Glaucoma Valve Implant|Implantation of Ahmed Valve in study eye
223774685|NCT01621373|DRUG|propofol administration|Single IV bolus propofol start at 1 mg/kg. Dose will be adapted based on predefined scoring systems with +/-0.5 mg/kg.
223774686|NCT03319043|DRUG|Chanqin granules|All patients enrolled in the research are treated with Budesonide + Formoterol Fumarate dry powder (160/4.5ug bid) for inhalation. Patients in treatment group are given additional Chanqin granules 10g three times a day; and analogous for the controlled group.
224325608|NCT06561828|DEVICE|sham Theta Burst Stimulation (sham TBS)|iTBS or cTBS delivered with placebo side of A/P coil.
224325609|NCT06856226|OTHER|Arm 1|Short tandem repeat (STR) analysis from genomic DNA extracted from biospecimens.
224325610|NCT06843473|OTHER|No treatment given|No treatment given
224325611|NCT05554328|PROCEDURE|Biopsy Procedure|Undergo tumor biopsy
224325612|NCT05554328|PROCEDURE|Biospecimen Collection|Undergo blood collection
224325613|NCT05554328|PROCEDURE|Bone Marrow Aspiration and Biopsy|Undergo bone marrow aspiration or biopsy
224325614|NCT05554328|PROCEDURE|Computed Tomography|Undergo CT scan
224325615|NCT05554328|PROCEDURE|Echocardiography Test|Undergo ECHO
224325616|NCT05554328|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
224325617|NCT05554328|DRUG|Olaparib|Given PO
224325618|NCT05554328|DRUG|Selumetinib Sulfate|Given PO
223682723|NCT01244490|DRUG|Atomoxetine Hydrochloride|Capsule, once daily, optimised dose (10mg to 100mg based on weight), 8-9-weeks maintenance duration on optimised dose
223682724|NCT01244490|DRUG|Placebo Comparator|Placebo
223682725|NCT02400411|OTHER|Wheat bread|
223682726|NCT02400411|OTHER|margarine|
223682727|NCT02400411|OTHER|ham|
223682728|NCT02400411|OTHER|soup|
223682729|NCT02400411|OTHER|rye bread|
223682730|NCT01486810|DRUG|Lisdexamfetamine|Patients will be titrated to the tolerated dose over a two week period, with a maximum of 140mg daily, and then maintained on the highest tolerated dose for four weeks
223682731|NCT01486810|BEHAVIORAL|medication management|All participants will receive medication management counseling and individual therapy using a structured compliance enhancement manual designed for pharmacotherapy trials in subjects with substance use disorders.
223682732|NCT00133731|DRUG|Otamixaban (XRP0673)|
223682733|NCT00133731|DRUG|Unfractionated Heparin|
223682734|NCT00133731|PROCEDURE|Percutaneous Coronary Intervention|
223682735|NCT00474682|DRUG|Micronized dispersible ferric pyrophosphate|
223682736|NCT02165176|DRUG|Oral cannabis|
223774687|NCT02160873|OTHER|chocolate milk|12 oz, 7-8 hours prior to exercise trial (night before)
223774688|NCT02160873|OTHER|flavor-matched placebo|12 oz, non-caloric flavor-matched placebo
223774689|NCT00270491|DRUG|Paclitaxel|
223774690|NCT00270491|DRUG|Capecitabine|
223774691|NCT02766608|DRUG|BFF MDI 320/9.6 μg|Blinded Treatment
223774692|NCT02766608|DRUG|BFF MDI 160/9.6 μg|Blinded Treatment
223774693|NCT02766608|DRUG|FF MDI 9.6 μg|Blinded Treatment
223774694|NCT02766608|DRUG|BD MDI 320 μg|Blinded Treatment
223774695|NCT02766608|DRUG|Symbicort® TBH 400/12 μg BID|Open Label
223774696|NCT00667784|BEHAVIORAL|Questionnaire|Questionnaires completed before the bone marrow or stem cells are collected, after the transplant, and 6 months after the transplant.
223774697|NCT01804959|DIETARY_SUPPLEMENT|Vivomixx probiotics|
223774698|NCT05561998|DEVICE|TalkingMats|TalkingMats is a low-technology communication framework, to help people with communication difficulties to express their views. It uses a simple system of picture symbols, placed on a textured mat, that allow people to indicate their feelings about various options within a topic by placing the relevant image below a visual scale. Three sets of symbols are used, one set for the topics of the conversation, one set for the options within each topic and one set consisting of the value scale under which the options are placed.
224262474|NCT01846091|OTHER|Laboratory Biomarker Analysis|Correlative studies
224262475|NCT01846091|BIOLOGICAL|Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter|Given IT
224262476|NCT04345640|OTHER|no intervention|no intervention
224262477|NCT00721162|BIOLOGICAL|Ramucirumab|Participants will receive ramucirumab at 8 milligrams/kilogram (mg/kg) administered over 1 hour every other week (every 14 days). Treatment will continue until there is evidence of disease progression, intolerable toxicity, or other withdrawal criteria are met.
224262478|NCT02987985|DRUG|Acetaminophen, gabapentin|acetaminophen 15 mg/kg, gabapentin 10 mg/kg
224262479|NCT02987985|DRUG|Acetaminophen|acetaminophen 15 mg/kg
224262480|NCT02987985|DRUG|Ketamine , Lidocaine , Dexmedetomidine|Ketamine 0.5 mg/kg, Lidocaine 1 mg/kg, Dexmedetomidine 0.3 mcg/kg
224262481|NCT02987985|DRUG|Fentanyl, Dexmedetomidine|Fentanyl 0.5 mcg/kg, Dexmedetomidine 0.3 mcg/kg
224262482|NCT02987985|DRUG|Dexamethasone , Ondansetron|Dexamethasone 150 mcg/kg, Ondansetron 50 mg/kg
224262483|NCT02987985|DRUG|Sevoflurane|Sevoflurane (dose titrated to effect)
224262484|NCT02987985|DRUG|Sevoflurane, Fentanyl|Sevoflurane (dose titrated to effect), Fentanyl as needed (dose at anesthesiologist's discretion)
224262485|NCT04364087|DIAGNOSTIC_TEST|Oral glucose tolerance test|Oral glucose tolerance test with 75 g glucose (75 g OGTT) will be performed to those with normal fasting glucose and HbA1C levels. Women will be recommended to have normal diet for 3 days and overnight fasting for at least 8 hours. The blood withdrawal will be performed twice: (i) fasting and (2i) 2 hours after solution administration. The volume of blood for each test is 2 ml. Impaired glucose tolerance will be diagnosed when two-hour glucose levels of 140 to 199 mg/dL (7.8 to 11.0 mmol/l) (American Diabetes Association, 2018).
224325619|NCT03841097|DRUG|Extended Release Tacrolimus Tablets|The primary objective is to assess the change in pulse wave velocity (PWV) and vascular compliance measurements from baseline to 12-24 months after transplant in kidney recipient subjects on LCPT compared to those on IR-Tac.
224325620|NCT03841097|DRUG|Immediate Release Tacrolimus Capsule|The primary objective is to assess the change in pulse wave velocity (PWV) and vascular compliance measurements from baseline to 12-24 months after transplant in kidney recipient subjects on LCPT compared to those on IR-Tac.
224325621|NCT06439576|DRUG|Faricimab|The dosing and treatment duration of the studied medicinal product is at the discretion of the physician in accordance with clinical practice and labeling in China.
224325622|NCT02759744|DEVICE|ultrasound image-guided ablation device|ultrasound image-guided focal ablation - may be either laser ablation or cryotherapy
224325623|NCT03914612|DRUG|Carboplatin|Given IV
224325624|NCT03914612|PROCEDURE|Computed Tomography|Undergo CT scan
224325625|NCT03914612|DRUG|Paclitaxel|Given IV
224325626|NCT03914612|BIOLOGICAL|Pembrolizumab|Given IV
224325627|NCT03914612|OTHER|Placebo Administration|Given IV
223682737|NCT00400153|DRUG|Atrovent Respimat (20 mcg)|
223682738|NCT00400153|DRUG|COMBIVENT MDI (36/206 mcg)|
223682739|NCT00400153|DRUG|Combivent Respimat (20 mcg/100 mcg)|
223682740|NCT00400153|DRUG|Placebo via corresponding inhaler for blinding purposes|
223682741|NCT04564885|DEVICE|BAGUERA®C Cervical Disc Prosthesis|surgery
223682742|NCT04564885|DEVICE|Mobi-C Cervical Disc|surgery
223682743|NCT00983697|PROCEDURE|therapeutic conventional surgery|
223682744|NCT00983697|RADIATION|fludeoxyglucose F 18|
223682745|NCT00159562|BEHAVIORAL|individual education|individual sessions of psycho-education
223682746|NCT00159562|BEHAVIORAL|Group education|group psycho-education in 10 weekly sessions and then a session every third month for two years
223682747|NCT00971620|BIOLOGICAL|Botulinum toxin type A|Given as an intralesional injection.
223774699|NCT05561998|OTHER|Usual conversation method|The standard procedure during needs-assessment conversation and conversations planning the provision of home care services.
223774700|NCT05981651|OTHER|non-intervention|non-intervention
223774701|NCT05095480|DRUG|Red Yeast Rice Pill|Taking Lesstat
223774702|NCT05095480|DRUG|Placebo|Placebo receiving group
224325628|NCT03914612|OTHER|Quality-of-Life Assessment|Ancillary studies
224325629|NCT03914612|OTHER|Questionnaire Administration|Ancillary studies
224325630|NCT06152237|GENETIC|TSHA-102|TSHA-102 is a recombinant, non-replicating, self-complementary AAV9 (scAAV9) vector encoding for the miniMECP2 gene. TSHA-102 is a one-time intrathecal (IT) administration.
224325631|NCT06696768|BIOLOGICAL|Bevacizumab|Given IV
223682748|NCT00971620|OTHER|Placebo|Given as an intralesional injection
223682749|NCT05364801|OTHER|Survey|Online anonymous survey
223682750|NCT04715334|DEVICE|Mollii suit|The Mollii suit is a new technology of electrical stimulation in the form of whole-body garment with multiple electrodes individually programmed to stimulate the selected muscles. Based on preliminary studies, it is suggested that the Mollii suit improves spasticity. Recent studies also proposed that it improves mobility, gait, function and quality of life. However, these studies are based on qualitative and subjective measures.
223682751|NCT02040727|BEHAVIORAL|Resistance Training|Supervised strength training 3 days per week for 24 weeks
223682752|NCT02040727|BEHAVIORAL|No Resistance Training|No supervised strength training throughout the study
223682753|NCT00393042|DRUG|Dexmethylphenidate|10, 20, 25-30 mg.
223682754|NCT00393042|DRUG|Mixed Amphetamine Salts, ER|10, 20, 25-30
223682755|NCT00393042|DRUG|placebo|randomized placebo week during each 4 week period
223682756|NCT02763969|DRUG|BMS-986202|
223682757|NCT02763969|DRUG|Placebo|
223682758|NCT02763969|DRUG|Interferon alpha-2a recombinant|
223682759|NCT02763969|DRUG|Famotidine|
223682760|NCT02763969|DRUG|Ustekinumab|
223682761|NCT05280483|DRUG|ABSK021 with fed state|25 mg ABSK021 (1x25 mg ABSK021 capsule) with food
223682762|NCT05280483|DRUG|ABSK021 with fasted state|25 mg ABSK021 (1x25 mg ABSK021 capsule) without food
223682763|NCT00330161|DRUG|vorinostat|Given orally
223682764|NCT00330161|OTHER|laboratory biomarker analysis|Correlative studies
223682765|NCT03777631|PROCEDURE|Catheter ablation|CA should be performed within 1-6 months from the onset of cerebral infarction. CA is based on pulmonary vein isolation, with atrial ablation as required.
223682766|NCT02655770|DRUG|Liraglutide|
223682767|NCT02655770|DRUG|Placebo|
223774703|NCT01575340|DIETARY_SUPPLEMENT|fish oil encapsuled|2 g/d (4 capsules of 500 mg)for 9 weeks
223774704|NCT04660981|BEHAVIORAL|Antenatal education|Training Program on Fear of Childbirth Based on Motivational Interview Method
223774705|NCT03616210|PROCEDURE|Protective ventilation|Protective ventilation strategy with tidal volume of 6 to 7 ml.kg-1 of predicted body weight and PEEP of 6 to 8 cmH2O.
223774706|NCT04756219|OTHER|Contact Video|No additional information necessary.
223774707|NCT04756219|OTHER|Contact Text|No additional information necessary.
223774708|NCT04756219|OTHER|Education Video|No additional information necessary.
224325632|NCT06696768|PROCEDURE|Biopsy Procedure|Undergo tumor biopsy
224325633|NCT06696768|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
224325634|NCT06696768|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
224325635|NCT06696768|BIOLOGICAL|Emavusertib|Given PO
224325636|NCT06696768|DRUG|Fluorouracil|Given IV
224325637|NCT06696768|DRUG|Leucovorin Calcium|Given IV
224325638|NCT06696768|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
224325639|NCT06696768|DRUG|Oxaliplatin|Given IV
224325640|NCT06696768|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
224325641|NCT06759558|DRUG|Zuranolone|Zuranolone is a neuroactive steroid that works by modulating the activity of the gamma-aminobutyric acid (GABA) receptor in the brain.
224325642|NCT06503146|DRUG|[18F]FAPI-74|Participants will receive a single intravenous (IV) dose of \[18F\]FAPI-74 prior to PET/CT imaging.
224325643|NCT06503146|DRUG|[18F]FDG|18F-FDG PET/CT or PET/MRI imaging will be done per standard of care.
224325644|NCT06516952|DRUG|Povorcitinib|Oral Tablet
224325645|NCT06516952|DRUG|Placebo|Oral Tablet
224325646|NCT07075198|DEVICE|Caesar Foot|The investigators developed a bimodal, passive mechanical prosthetic foot called the Caesar Foot. The Caesar Foot has two modes: one optimized for walking, and one optimized for higher-energy activities like running. It has a switching device that was designed such that when it switches modes, it inherently accounts for the alignment and stiffness differences between walking and running feet (such as the longer length, higher stiffness, and different ground contact points required for running feet). Therefore, it should be largely comparable to a daily use prosthesis / walking foot when in walking mode, and an running specific prosthesis / running blade when in running mode. This foot is attached and aligned to the user's usual prosthetic socket.
224325647|NCT06443463|DRUG|BHV-7000|BHV-7000 50 mg. Participants will take open-label investigational product (IP) once daily
224325648|NCT06443463|DRUG|BHV-7000|BHV-7000 75 mg. Participants will take open-label investigational product (IP) once daily
224325649|NCT04858334|PROCEDURE|Biospecimen Collection|Undergo collection of blood
224325650|NCT04858334|PROCEDURE|Computed Tomography|Undergo CT or CT/MRI
224325651|NCT04858334|PROCEDURE|Magnetic Resonance Imaging|Undergo CT/MRI
224325652|NCT04858334|DRUG|Olaparib|Given PO
224325653|NCT04858334|DRUG|Placebo Administration|Given PO
224325654|NCT06928662|DRUG|Decitabine|Given IV
224325655|NCT06928662|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration and/or biopsies
224325656|NCT06928662|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow aspiration and/or biopsies
224325657|NCT06928662|PROCEDURE|Chest Radiography|Undergo chest X-rays
224325658|NCT06928662|DRUG|Cytarabine|Given IV
223682768|NCT03008564|OTHER|Ultrasound scanning of the lower limb in volunteers|"Several reference points will be marked by anatomical landmarks and/or ultrasound: the anterior superior iliac spine; base of patella; apex of the femoral triangle A measuring tape will be used to measure the anterior superior iliac spine (landmark); the base of the patella (landmark); apex of femoral triangle (ultrasound); and distal most portion of adductor canal (Point B described earlier; ultrasound). We will then measure the ASIS to: 1) base of patella; 2) apex of femoral triangle; and 3) Point B. We will repeat the same procedure on the opposite leg. Once complete, the volunteer will be allowed to dress and leave. The procedure should take approximately 10-20 minutes for each volunteer. The following things will be recorded for each subject:~* Age~* Gender~* Weight~* Height~* BMI~* Distance of ASIS to base of patella~* Distance of Point A to base of patella~* Distance of Point B to base of patella~* Distance of apex of femoral triangle to base of patella"
223682769|NCT00824070|DRUG|Besifloxacin hydrochloride|Instill besifloxacin study medication in the study eye prior to making an incision for cataract extraction surgery.
223774709|NCT04756219|OTHER|Education Text|No additional information necessary.
223774710|NCT03173222|PROCEDURE|Electroacupuncture|A combined procedure with acupuncture and electric current stimulation. Local electroacupuncture will be given in group EA 1, while local with distal electroacupuncture will be given in group EA 2.
223774711|NCT04599881|DRUG|PTR-01|IV recombinant collagen 7 at 3 mg/kg given weekly for 4 doses, followed by bi-weekly for 7 doses
224325659|NCT06928662|PROCEDURE|Echocardiography Test|Undergo ECHO
224325660|NCT06928662|BIOLOGICAL|Filgrastim|Given SC
224325661|NCT06928662|DRUG|Fludarabine|Given IV
224325662|NCT06928662|PROCEDURE|Hematopoietic Cell Transplantation|Given via infusion
223682770|NCT00824070|DRUG|moxifloxacin hydrochloride|Instill moxifloxacin study medication in the study eye prior to making an incision for cataract extraction surgery.
223682771|NCT00824070|DRUG|gatifloxacin|Instill gatifloxacin study medication in the study eye prior to making an incision for cataract extraction surgery.
223774712|NCT06454513|PROCEDURE|general anesthesia|Different anesthesia methods
223774713|NCT02454426|DRUG|Vortioxetine|open label treatment
223774714|NCT06531733|DEVICE|Sleep Promoting (pink noise)|Participants will be provided with comfortable headphones to wear throughout their daytime sleep opportunity. The headphones will deliver a continuous pink noise sound no greater than 50 decibels. Participants will be allowed to turn down the sound of the pink noise if they find it too loud. Participants will wear the headphones with no noise during the placebo condition.
223835275|NCT03190083|DEVICE|2-dimensional mammogram|This is standard of care for breast cancer diagnosis. The new breast cancer patients will be scheduled for the mammogram after diagnosis at the time of surgical appointment. The radiologist reviewing the tomosynthesis images will be separate and blinded from the radiologist who reviewed the initial 2-D mammogram.
224325663|NCT06928662|DRUG|Idarubicin|Given IV
224325664|NCT06928662|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
224325665|NCT06928662|PROCEDURE|Pheresis|Undergo apheresis
224325666|NCT06928662|RADIATION|Total-Body Irradiation|Undergo TBI
224325667|NCT06928662|PROCEDURE|Biospecimen Collection|Undergo collection of blood
224325668|NCT07134426|OTHER|D10-phenanthrene|All study participants (Former Daily Smokers and Non-smokers) will be asked to vape D10-phenanthrene to see how their lungs breakdown a class of cancer-causing chemicals known as polycyclic aromatic hydrocarbons \[PAHs\].
224325669|NCT05034198|BEHAVIORAL|Coping Power Program (CPP)|CPP is an evidence-based intervention designed for students with externalizing behavior disorder. CPP consists of twelve 45-minute sessions. This EBP has been found to be effective at reducing aggressive behavior, covert delinquent behavior and substance abuse among aggressive boys, with gains maintained at one-year follow-up. Growth curve analyses showed that CPP had linear effects for three years after intervention on reductions in aggressive behavior and academic behavior problems.
224325670|NCT05034198|BEHAVIORAL|Cognitive behavioral therapy (CBT) for Anxiety Treatment in Schools (CATS)|CATS is an adaptation of Friends for Life (FRIENDS). The adapted protocol retains the core elements of evidence-based CBT for anxiety and the FRIENDS group format. Investigators implemented planned adaptations to the protocol based on collective experience. Changes were made to the language, cultural methods, number of sessions, and activities while maintaining the 5 essential components of the treatment. This resulted in a briefer (8-session) and more feasible, engaging and culturally appropriate protocol for urban under-resourced schools than the original FRIENDS.
224325671|NCT05034198|BEHAVIORAL|Check-in/Check-out (CI/CO)|CI/CO is a targeted, Tier 2 intervention for students at risk of developing externalizing and internalizing mental health disorders. CI/CO is designed to provide immediate feedback (i.e., at the end of each class period) to students, based on the use of a daily report card. This feedback is developmentally sensitive. CI/CO implementers meet individually with students for a brief 'check-in' in the morning and a brief 'check-out' in the afternoon. Research on the use of CI/CO has shown it to be effective in reducing externalizing and internalizing problems with elementary school students. CI/CO will be offered to individual students for a three-month period of time, which is the same time-frame needed for the implementation of CPP.
224325672|NCT03968224|DRUG|Dapagliflozin/Metformin|Two tablets of Metformin 850 mg every 12 hours were provided in combination with Dapagliflozin 10 mg per day. Each participant received diet and exercise intervention according to their BMI and current physical condition.
224325673|NCT03968224|DRUG|Metformin|Two tablets of Metformin 850 mg every 12 hours were provided. Each participant received diet and exercise intervention according to their BMI and current physical condition.
224325674|NCT06466798|DRUG|Nivolumab|Nivolumab infusions will be given intraventricularly once every other week for 12 weeks. Dosing will be based upon patient body weight.
224325675|NCT06466798|DRUG|Methotrexate|2 mg methotrexate infusions will be given intraventricularly daily for 4 consecutive days per week every other week for 12 weeks.
224325676|NCT06466798|DRUG|5-Azacytidine|10 mg 5-Azacytidine infusions will be given intraventricularly once weekly for twelve consecutive weeks.
224325677|NCT05436327|BEHAVIORAL|Geriatric Assessment|Clinical staff receive (a) training in GA and workflow management strategies (\<60 minutes) at baseline, (b) monthly facilitation and technical support calls (15-30 minutes) for 12 months, and (c) a group-based quarterly call for 12 months. For 12 months, clinical staff implement GA strategies during visits with older adult (65+) patients planning to receive new chemotherapy regimen and their care partners/caregivers.
224325678|NCT05904080|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
224325679|NCT05904080|DRUG|Cabozantinib S-malate|Given PO
224325680|NCT05904080|PROCEDURE|Computed Tomography|Undergo CT scan
223774715|NCT06531733|DEVICE|Wake Promoting (blue enriched light plus a nap)|Participants randomized to the blue-enriched light and nap condition will have the blue-enriched light turned on during their nighttime stay in the lab. The light will be turned off for up to one hour during the nap. During the placebo condition, participants will have an overhead room light of \~150 lux illuminated throughout their nighttime stay in the lab. This light level reflects an older NASA standard which was used in the design of some Artemis vehicles. During the placebo condition, participants will be asked to engage in quiet activities such as reading for one hour.
224262486|NCT05404594|BEHAVIORAL|Maternal vocal contact|"Two consecutive venipuncture (order randomly balanced) within a short period of time will be realized with and without the presence of the mother talking/singing to her VPI infant.~In this intervention group, the mother will be supported to talk or to sing to her infants during before and during the venipuncture."
224262487|NCT02241863|BEHAVIORAL|Multifaceted intervention|Supportive intervention: care giver, health care providers, and patient's family members (including disease knowledge, treatment t of the disease, medication problems or adverse effects, the importance of medication adherence, supervision taking medications by the patients as prescribed). patient education: about the disease and treatment, consuming regularly the pills motivational intervening, self-monitoring planning. Patients will attend in five motivational interviewing sessions regularly to facilitating and engaging intrinsic motivation within the patients in order to change medication adherence behavior.
224262488|NCT02241863|BEHAVIORAL|Routine counseling|
224262489|NCT06414733|BIOLOGICAL|Combination of MVF-HER-2 (597-626) and MVF-HER-2 (266-296) emulsified with ISA 720|Three intramuscular (IM) injections (separated by 21 days) of a mixture of two peptides {MVF-HER-2(597-626) and MVF-HER-2 (266-296)} vaccine emulsified in ISA 720 vehicle. The combined vaccine preparation consists of 1.5mg of each of the HER-2 vaccine emulsified with a Montanide ISA 720, and will be administered in a final volume of 1.0 ml. Patients may also receive 6 months booster shots.
224262490|NCT05554419|DRUG|Azacitidine|Given IV or SC
224262491|NCT05554419|PROCEDURE|Bone Marrow Aspiration and Biopsy|Undergo bone marrow aspiration and biopsy
224262492|NCT05554419|DRUG|Cytarabine|Given IV
224262493|NCT05554419|PROCEDURE|Echocardiography Test|Undergo ECHO
224262494|NCT05554419|DRUG|Liposome-encapsulated Daunorubicin-Cytarabine|Given IV
224325681|NCT05904080|BIOLOGICAL|Ipilimumab|Given IV
224325682|NCT05904080|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
224325683|NCT05904080|BIOLOGICAL|Nivolumab|Given IV
224325684|NCT07075523|OTHER|Brain magnetic resonance imaging, neurocognitive assessments, quality of life questionnaire, biomarkers|Pathognomonic magnetic resonance imaging; neurocognitive assessments with the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS); quality of life assessment with the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30; measurement of liquid biomarkers.
224325685|NCT07076472|DRUG|Aminolevulinic Acid Intravenous Formulation SONALA-001|Given IV
224325686|NCT07076472|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
224325687|NCT07076472|PROCEDURE|Computed Tomography|Undergo CT
224325688|NCT07076472|OTHER|Electronic Health Record Review|Ancillary studies
224325689|NCT07076472|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
224325690|NCT07076472|PROCEDURE|MRI-Guided Focused Ultrasound Ablation|Undergo transcranial MRgFUS
224325691|NCT06740799|DRUG|Quizartinib|Participants will receive a single oral dose of 30 mg
224325692|NCT04533646|DRUG|Insulin|Participants will be asked to dose insulin during the first week using fixed doses. During the second week of the study, participants will dose insulin based on carbohydrate counting. Blood sugar control will be compared between the 2 weeks to determine the outcomes of the study.
224325693|NCT04533646|DEVICE|Continuous glucose monitor (CGM)|Participants will be required to wear a CGM to measure glucose trends
224325694|NCT06469151|DRUG|AZD5148|Participants will receive AZD5148 (dose 1, dose 2, dose 3 or dose 4) as an IM injection or IV bolus
224325695|NCT06469151|DRUG|Placebo|Participants will receive matching doses of placebo as an IM injection or IV bolus
224325696|NCT06212999|DRUG|Povorcitinib|Oral; Tablet
224325697|NCT04888988|OTHER|Best Practice|Receive standard of care
223774716|NCT04824547|OTHER|exercise|All exercises programs will applied two sessions per week, totally eight week..
223774717|NCT04787666|PROCEDURE|Using of non-invasive mask ventilation, high-flow oxygen therapy through a nasal cannula (high-flow nasal oxygenation) and non-invasive ventilation with a helmet|Using of non-invasive mask ventilation, high-flow oxygen therapy through a nasal cannula (high-flow nasal oxygenation) and non-invasive ventilation with a helmet for tackling the problem of respiratory failure
223774718|NCT04527263|DIAGNOSTIC_TEST|measurement of urinary 5-HIAA|urinary assessment of 5-HIAA
223774719|NCT00209313|DRUG|Acyclovir|Acyclovir 800 mg twice daily or placebo
224262495|NCT05554419|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
224262496|NCT05554419|DRUG|Venetoclax|Given PO
223774720|NCT03942718|OTHER|Exercise|Participants will obtain an individualized exercise program based on entrance examination on treadmill.
224262497|NCT00848146|PROCEDURE|Endoscopically assisted Laparoscopic Cholecystectomy Surgery|Using endoscopic instruments a small incision will be made in the gastric wall and the endoscope will be advanced into the insufflated peritoneal cavity. At least one laparoscopic trocars will be placed through the abdominal wall for laparoscopic instrument insertion to manipulate and cut tissue. The flexible endoscope will provide visualization of the surgical field and flexible endoscopic instruments may be used to augment surgical manipulation with the laparoscopic instruments. The gallbladder will be removed through the stomach and out of the mouth. Endoscopic clips, sutures or tissue anchors (TAS)will be used to close the gastrotomy.
224262498|NCT03077880|PROCEDURE|intra-operatory measurement during implant placement|mucoperiosteal flap, soft tissue thickness measurement, implant insertion
224262499|NCT05373173|BEHAVIORAL|Tele-assessment + In-person assessment|All consented families will complete an initial home-based tele-assessment visit via Zoom that includes the TAP-Preschool and a brief symptom-focused developmental interview with a consented clinician. The initial tele-assessment session includes interviewing and developmental assessment to mimic real-world use of TAP-Preschool. After the session, the examiner will record the clinical diagnosis issued (ASD, other developmental concerns, or typical development) and complete two diagnostic certainty ratings. All initial TAP-Preschool administrations will be recorded via Zoom, and 50% of administrations (randomly selected) will be co-scored by a blinded examiner, unaware of prior assessment results and diagnostic decision, to evaluate inter-rater reliability. Within 7 days of the remote assessment, families will participate in an in-person diagnostic assessment including common comprehensive measures of ASD, cognitive skills, and adaptive behavior.
224262500|NCT05373173|BEHAVIORAL|Tele-assessment only|Consented families will complete home-based tele-assessment via Zoom that includes the TAP-Preschool. Each participant will have recent data available from comprehensive evaluation tools (ADOS-2, cognitive functioning, adaptive skills). After the session, participating caregivers will provide information about acceptability and challenges.
224262501|NCT04178850|BIOLOGICAL|GB242|GB242: Dosing of 3 mg/kg, intravenous drip, to be completed over 120 minutes, dosing at weeks 0, 2, 6, 14 and 22, a total of 5 doses; MTX:Dosage and administration at enrollment are maintained (10\~15mg/week), oral administration, a total of 30 doses; Folic acid: 5-10mg/week, oral administration, a total of 30 doses
224262502|NCT04178850|BIOLOGICAL|Infliximab|Infliximab: Dosing of 3 mg/kg, intravenous drip, to be completed over 120 minutes, dosing at weeks 0, 2, 6, 14 and 22, a total of 5 doses; MTX:Dosage and administration at enrollment are maintained (10\~15mg/week), oral administration, a total of 30 doses; Folic acid: 5-10mg/week, oral administration, a total of 30 doses
224262503|NCT04269642|DRUG|PT320 2.0mg Placebo|PT320 2.0mg Placebo
224262504|NCT04269642|DRUG|PT320 2.0 mg|Exenatide slowly released formulation
224262505|NCT04269642|DRUG|PT320 2.5 mg|Exenatide slowly released formulation
224262506|NCT04398056|DRUG|Chemotherapy plus radiotherapy and Toripalimab|"1. Chemotherapy:~   The PF regimen included 5 g/m2 5-fluorouracil via a continuous intravenous infusion over 120 h and an intravenous administration of 100 mg/m2 cisplatin on day 1 for a maximum of six cycles.~2. Radiotherapy, intensity-modulated radiation therapy (IMRT), PTVnx:66-70Gy/30-33F; PTVnd:66～70Gy/30～33F; PTV1:60～64Gy/30～33F; PTV2:50～54Gy/30～33F, 5 fractions per week, for 6 weeks~3. Toripalimab 240mg every three weeks (Q3W) began on the first day of radiotherapy until an intolerable toxicity, or disease progression, or withdrawal of consent, or the investigator determines that he or she has to withdraw from treatment, or has been treated for up to 2 years."
224262507|NCT03779334|DRUG|Risdiplam|Risdiplam will be administered orally.
224262508|NCT04649593|DIETARY_SUPPLEMENT|Samarin|Half of the group with a high AFL value will have a glass of Samarin to drink
224262509|NCT06101771|DIAGNOSTIC_TEST|echoCARDIOGRAPHY|Assessment of epicardial fat thickness in children with familial dyslipidemia
224262510|NCT02649179|DRUG|Ropivacaine|All wounds were infiltrated with 0.75% ropivacaine 14ml at port sites before wound closure(6ml for epigastric port ,6ml for umbilical port ,and 4ml for working port) . The study drugs will be applied to the skin, subcutis, fascia, and parietal peritoneum through the port sites at the end of surgery.
224262511|NCT02649179|DRUG|0.9% saline|All wounds were infiltrated with 0.9% saline 14ml at port sites before wound closure(6ml for epigastric port ,6ml for umbilical port ,and 4ml for working port) . The study drugs will be applied to the skin, subcutis, fascia, and parietal peritoneum through the port sites at the end of surgery.
224262512|NCT06515405|DRUG|Hydrocortisone|"Cohort members will be considered to be exposed to early hydrocortisone if either:~1. They receive early hydrocortisone started on postnatal day 1 or 2 and given for more than seven consecutive days OR~2. They receive early hydrocortisone started on postnatal day 1 or 2 and are being cared for in a PROHYDRO unit but die on or before postnatal day 8.~PROHYDRO units are defined as units who, at the time the baby was born, had implemented a protocol for use of prophylactic hydrocortisone as part of routine care for babies born less than 28 weeks' gestation. A unit may change from being a non-PROHYDRO unit to a PROHYDRO unit if a new early hydrocortisone protocol is introduced during the study period (2016-2023)."
224262513|NCT03388853|DRUG|Acetylcysteine/Doxofylline|Acetylcysteine/Doxofylline 1200/400 mg Effervescent Tablet once daily for four weeks.
224262514|NCT03388853|OTHER|Placebo|Placebo once daily for four weeks.
224262515|NCT03934476|BEHAVIORAL|Ketogenic diet|The study subjects randomized for this intervention will observe the ketogenic diet, as prescribed by the protocol.
224325698|NCT04888988|OTHER|Exercise Counseling|Meet with certified exercise instructor
224325699|NCT04888988|OTHER|Exercise Intervention|Participate in the EXCAP program
224325700|NCT04888988|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223682772|NCT05666115|DIETARY_SUPPLEMENT|Probiotic group|During the first 4 weeks, patients will be instructed to take two capsules of Enterelle plus (Bromatech lab, Manno, Switzerland) during morning time, before or after breakfast. Enterelle plus contains specific strains, i.e., S boulardi, E faecium, and acidophilus, that contribute to reduce the mycotic flora and modulate the gastrointestinal transit. For the next 8 weeks, participants will be told to ingest two capsules of Adomelle (Bromatech lab, Manno, Switzerland) at night, during or right after dinner. Adomelle contains several strains, including Bifidobacterium breve, that help to reduce abdominal fat, pain, and gas, and control the frequency of deposition
223682773|NCT05666115|OTHER|Exercise group|This type of intervention has shown to benefit patients with several chronic conditions 23, including axSpA 13. Exercises combined high knees, lunges, basic burpees, plank, skipping, mountain climbers, and squats with jumps. The training routine will be conducted three times per week, and each session will last around 8 minutes (2 sets of 4 minutes, with a 10 second rest between them). All sessions will be individually tailored and supervised by a senior professional with a degree in Physiotherapy and Sciences of Physical Activity and Sport. Overall, participants will be told to continue exercising if low to moderate bearable pain appeared during training.
223682774|NCT00533091|BIOLOGICAL|MEDI-545|"MEDI-545 is supplied as a sterile liquid containing 0.75 mL of MEDI-545 solution at a concentration of 100 mg/mL in a 3 mL single-use glass vial.~Dosage, frequency and duration: MEDI-545 (0.3, 1.0, 3.0, or 10.0 mg/kg) will be administered via infusion over at least 60 minutes every 2 weeks for 26 weeks."
223774721|NCT03052985|PROCEDURE|urinary incontinence, pelvic organ or rectal prolapse surgery|The observatory is planned for following women after surgery for urinary incontinence, pelvic organ prolapse, or rectal prolapse whatever the type of surgery (by laparoscopy, laparotomy or vginal route) or the use of a mesh
224325701|NCT04888988|OTHER|Neuropathy Assessment|Undergo tactile sensitivity test
224325702|NCT04888988|OTHER|Questionnaire Administration|Ancillary studies
224325703|NCT03460977|DRUG|Mervometostat (PF-06821497)|Oral continuous
224325704|NCT03460977|DRUG|Enzalutamide|Oral continuous
224325705|NCT06751563|BEHAVIORAL|Behavioral Text Messages and Produce Box Delivery|Participants will receive a produce box delivered weekly to the participants home customized based on the participants cooking preferences and household size. Participants will also receive a daily text message aimed to support a healthy diet and lifestyle. These texts will include information to build participants' knowledge and skills for healthy eating. The participants will also include weekly goals that focus on eating a healthy diet. Participants will receive automated, personalized feedback via text messages based on participant goal attainment and daily responses.
224262516|NCT03934476|BEHAVIORAL|Exercise HIIT|The study subjects randomized for this intervention will observe the HIIT exercise programme, as prescribed by the protocol.
224262517|NCT06465927|OTHER|Clinical data collection|Clinical data of elderly acute appendicitis patients with an appendicolith who underwent emergency appendectomy were collected and analyzed.
224262518|NCT05183191|OTHER|Controlled hypoglycaemic state while driving with a driving simulator|Participants arrive in the morning after an overnight fast. During the controlled hypoglycaemic state, participants drive on a designated circuit using a driving simulator. Initially, a euglycaemic state (5.0-8.0 mmol/L) is kept stable and blood glucose is then progressively declined targeting at a level between 3.0-3.5 mmol/L by administering insulin. Blood glucose is kept stable in the hypoglycaemic range for 30 minutes. Thereafter, blood glucose is raised again and kept stable for another 30 minutes at an euglycaemic level between 5.0-8.0mmol/L. During the procedure, the investigators analyse counterregulatory hormones. Heart rate, skin conductance, CGM values, eye movement and facial expression are recorded by a smart-watch, a CGM device, an eye-tracker and an onboard camera, respectively. Participants are blinded to the blood glucose values during the procedure and have to rate their symptoms and their driving performance on a 0-6 scale every 15 minutes.
224262519|NCT00797160|DRUG|propofol|2mg/Kg IV in bolus before tracheal intubation
224262520|NCT02275962|DRUG|K-877|
224262521|NCT02275962|DRUG|Rifampin|
224262522|NCT01660594|OTHER|CT calcium scoring|CT Calcium scoring was performed in the patients as an imaging test in addition to the traditional assessment on the same day of patients attending the chest pain clinic on the first visit. This was performed with standard protocol and the absolute calcium score was calculated.
224262523|NCT01684774|DRUG|Bupivacaine|
224262524|NCT03246763|BEHAVIORAL|Integrated community-healthcare childhood obesity treatment|"The intervention will include nutrition and fitness programming at a local community center. The program will be open at least two sessions per week, each session lasting at least 1 hour. The program coordinator will run the programming, which will consist of wellness activities. Each session will include at least 60 minutes of exercise and/or active play, and each session will have an additional special theme. For example, one session might include a cardio focused class, and one session might include a yoga class. The number and which sessions the participants attend each week is voluntary; clinic staff will recommend participation in as many sessions per week as possible. Participation is voluntary, and patients may opt-out at any time. Participants will be told that they can indicate to their provider or the program coordinator at any time either by phone or during the clinic appointment that they wish to opt-out of the study and its assessments."
224262525|NCT03508011|DRUG|IMP4297|The dose levels will be escalated following a modified 3+3 dose escalation scheme.
224262526|NCT06560593|DRUG|NTQ5082|single ascending dose, randomized, double-blind study，with 8 dose groups preset. The first cohort will be the sentinel group, consisted of 2 subjects receiving NTQ5082 capsules. The remaining cohorts required 8 subjects each, with 6 receiving NTQ5082 capsules and 2 receiving placebo.
224262527|NCT06560593|DRUG|Placebo|multiple ascending dose, randomized, double-blind study，with 3 dose groups preset. All cohorts required 8 subjects each, with 6 receiving NTQ5082 capsules and 2 receiving placebo.
224262528|NCT05512104|PROCEDURE|bone marrow aspirate and biopsy|fiow cytometry of bone marrow aspirate
224262529|NCT05735795|OTHER|Carbon Black Tattoo|SPOT ENDOSCOPIC MARKER is an FDA (American Food and Drug Administration) approved Carbon Black Tattoo paint that has been used for a long time to mark lesions in the gastrointestinal tract.
224262530|NCT04836494|DRUG|BBP-671|BBP-671, oral suspension
224262531|NCT04836494|DRUG|Placebo|Placebo matching BBP-671
224262532|NCT04836494|DRUG|BBP-671|BBP-671, tablet
223682775|NCT00533091|OTHER|Placebo|"Dosage form: Placebo is supplied as a sterile liquid containing a 0.75 mL solution in a 3 mL single-use vial.~Dosage, frequency and duration: Placebo (0.3, 1.0, 3.0, or 10.0 mg/kg) will be administered via infusion over at least 60 minutes every 2 weeks for 12 weeks.~Thereafter, subjects will receive MEDI-545, at the dose specified in the dose cohort they are assigned, every 2 weeks for an additional 12 weeks."
223682776|NCT01951859|OTHER|Neuropathy/Ulcer Homeopathic topical cream|This is a GRAS topical agent containing homeopathic ingredients
223682777|NCT02927405|DRUG|Gabapentin|anticonvulsant drug that is used for neuropathic pain.
223682778|NCT02927405|PROCEDURE|TAP Block|a procedure done anesthetize the anterior abdominal wall
223682779|NCT01216605|DRUG|Syntocinon 24 IU|
223682780|NCT01216605|DRUG|Placebo|
223682781|NCT03128151|BEHAVIORAL|Educational program for clinicians: implementation of a package of clinical prevention measures of NMB|Intraoperative neuromuscular monitoring and pharmacological reversion of NMB according to data sheet
223682782|NCT04632914|OTHER|trunk stabilizing exercise|trunk stabilizing exercise is a group of exercise which train the anterior thoracic cage and abdominal muscles in the form of static contraction of these muscles from a different position supine, sitting and standing.
223682783|NCT04632914|OTHER|cardiac rehabilitation programe|all patients continue this routine physiotherapy program for 40-60min.the patients incorporated into a variety of exercises conducted through arm ergometer,leg ergometer and treadmill.also the patients perform deep breathing exercise and coughing ececise
223682784|NCT00769327|DRUG|imatinib mesylate|
223682785|NCT00769327|DRUG|nilotinib|
223682786|NCT00769327|GENETIC|cytogenetic analysis|
223682787|NCT00769327|GENETIC|fluorescence in situ hybridization|
223682788|NCT00769327|GENETIC|microarray analysis|
223682789|NCT00769327|GENETIC|mutation analysis|
223682790|NCT00769327|GENETIC|polymerase chain reaction|
223682791|NCT00769327|GENETIC|polymorphism analysis|
223682792|NCT00769327|OTHER|laboratory biomarker analysis|
223682793|NCT04537780|OTHER|Placebo|Placebo tabled every day
223682794|NCT04537780|DRUG|Montelukast|Montelukast 10 mg daily at bed time.
223682795|NCT03024580|DRUG|Megestrol Acetate 160Mg Tablet|Megestrol acetate 160 mg PO daily
223682796|NCT03024580|DRUG|Anastrozole 1Mg Tablet|Anastrozole 1 mg PO daily OR
223682797|NCT03024580|DRUG|Letrozole 2.5Mg Tablet|Letrozole 2.5 mg PO daily OR
223682798|NCT03024580|DRUG|Exemestane 25 MG|Exemestane 25 mg PO daily
223682799|NCT03024580|DRUG|Tamoxifen 20Mg Tablet|Tamoxifen 20 mg PO daily
223682800|NCT03024580|DRUG|Fulvestrant 50Mg Solution for Injection|Fulvestrant 500 mg IM d1, d14, d28 and q28 days
223682801|NCT00965328|PROCEDURE|CVVH 4 to 2 L/h|CVVH is initiated at 4L/h and is converted to 2L/h after 60 min
223682802|NCT00965328|PROCEDURE|CVVH 2 to 4L/h|CVVH is initiated at 2L/h and is converted to 4L/h after 60 min
224262533|NCT01175135|DRUG|PF-02545920|5 mg tablet every 12 hours for 28 days
224262534|NCT01175135|DRUG|PF-02545920|15 mg tablet every 12 hours for 28 days
224262535|NCT01175135|DRUG|Placebo|One tablet/capsule every 12 hours for 28 days
224262536|NCT01175135|DRUG|Risperidone|3 mg capsule every 12 hours for 28 days
224262537|NCT00529464|PROCEDURE|Fluorescence Spectroscopy|Pictures of the cervix will be taken before and after the application of acetic acid. A clean probe will be placed against the cervix that sends out light and reads how much light is absorbed by the tissue.
224262538|NCT00529464|PROCEDURE|Colposcopy|A standard colposcopy will be performed.
224262539|NCT00529464|PROCEDURE|LEEP Procedure|A small heated wire loop is used to remove a cone-shaped piece of abnormal tissue. Procedure is performed on the same day as the colposcopy exam.
224262540|NCT02364258|DRUG|Rosuvastatin|Rosuvastatin 10mg tablet (ages 8-21 years); 1 time dose given per oral at the start of the study day.
224262541|NCT02364258|DRUG|Atorvastatin|Atorvastatin 10mg tablet (ages 8-21 years); 1 time dose given per oral at the start of the study day.
224262542|NCT00003725|DRUG|valrubicin|
224262543|NCT00003725|PROCEDURE|conventional surgery|
224262544|NCT04194476|DIAGNOSTIC_TEST|StatStrip blood glucose meter and strips|We'll use a drop of heel-stick blood to test blood glucose on the glucose meter. About 200-300 ul of blood from the same stick site will be collected, centrifuged to get plasma for testing of glucose level in a laboratory biochemistry analyzer.
224262545|NCT06319976|OTHER|open chain exercises for rotator cuff muscles|open chain exercises for rotator cuff muscles, three times per week for six weeks.
224262546|NCT06319976|OTHER|Advices for postural correction|Advices for postural correction like neutral position of head and neck, aliening the shoulder and hip and using a foot stool to rest the feet.
224262547|NCT01886222|OTHER|Long-term mild hypothermia|Hypothermia will be induced within 6 hours of injury and maintained at 34-35℃ for 5 days.Then the patients will be passively rewarmed to a temperature of 36 to 37˚C at a rate no greater than 0.5˚C/4 hours.
224262548|NCT01886222|OTHER|Normothermia|Patients assigned to the normothermia group will be kept at 36-37℃.
224262549|NCT02100917|DRUG|DMB-3111|
224262550|NCT02100917|DRUG|trastuzumab|
224262551|NCT04692155|DRUG|Ublituximab|Ublituximab (900mg) will be administered as an intravenous infusion through a dedicated line.
224262552|NCT04692155|DRUG|Umbralisib|Umbralisib(800mg)will be administered orally once daily within 30 minutes of starting a meal.
224262553|NCT01438203|PROCEDURE|Thrust manipulation|Thrust manipulation is a passive procedure which involves a high velocity low amplitude thrust to the spinal region
224262554|NCT01438203|PROCEDURE|Non-thrust manipulation|Non-thrust manipulation involves a low amplitude, low speed mobilization to the targeted region while adjusting the procedure based on patient feedback
224262555|NCT02579733|DRUG|Azathioprine|
224262556|NCT02579733|DRUG|Placebo|
224262557|NCT04571294|PROCEDURE|removal of para-aortic lymphnodes (PALN)|During pancreaticoduodenectomy, para-aortic lymphnodes (PALN) will be removed for the surgeon
224262558|NCT04037722|DIETARY_SUPPLEMENT|Whey|45 g whey + 20 g maltodextrin
224262559|NCT04037722|DIETARY_SUPPLEMENT|3-OHB + Whey|50 g ketone + 45 g whey + 20 g maltodextrin
224262560|NCT00940563|DRUG|Imatinib|
224325706|NCT06751563|BEHAVIORAL|Behavioral Text Message Program and Produce Voucher|Participants will receive a weekly produce voucher redeemable at a local market vendor for fresh produce of the participant's choice. Participants will also receive a daily text message aimed to support a healthy diet and lifestyle. These texts will include information to build participants' knowledge and skills for healthy eating. The participants will also include weekly goals that focus on eating a healthy diet. Participants will receive automated, personalized feedback via text messages based on goal attainment and daily responses.
224325707|NCT05571839|DRUG|PF-08046049|Given into the vein (IV; intravenous)
224325708|NCT07081997|COMBINATION_PRODUCT|Palopegteriparatide|Palopegteriparatide is supplied as a solution with a concentration of 0.3 mg/mL in a single-patient-use prefilled pen intended for subcutaneous injection.
224325709|NCT06632444|DRUG|Survodutide|Subcutaneous injection
224325710|NCT06632444|DRUG|Placebo|Subcutaneous injection
224325711|NCT05327946|DRUG|BI 770371|BI 770371
224325712|NCT05327946|DRUG|ezabenlimab|ezabenlimab
224325713|NCT06903468|PROCEDURE|Novel cavity marking technique|A novel cavity marking technique will be performed on all participants during their breast conservation surgery. For this technique, cavity marking will be in a clockwise fashion per breast starting with the superior margin of the tumor bed. The superior margin of the left breast will be marked with a single large clip, followed by a double clip for the lateral margin, a triple clip for the inferior margin, and a quadruple clip for the medial margin. The superior margin of the right breast will be marked with a single large clip, followed by a double clip for the medial margin, a triple clip for the inferior margin and a quadruple clip for the lateral margin. Margins with multiple clips will always have one large clip with the remaining clips standard medium size.
224325714|NCT07081932|DRUG|Nerandomilast|Nerandomilast
224325715|NCT07081932|DRUG|Bosentan|Bosentan
224325716|NCT06664814|DRUG|ManNAc|2 grams twice daily by mouth
224325717|NCT03929159|PROCEDURE|Biospecimen Collection|Undergo blood biospecimen collection
224325718|NCT06840483|DRUG|Zelenectide pevedotin (BT8009)|Participants will receive zelenectide pevedotin on Days 1, and 8 of every 21-day cycle.
224325719|NCT05865405|BEHAVIORAL|MS CATCH|Participants will respond to a set of surveys every month to increase communication on mood with their clinician.
223682803|NCT01380938|DRUG|Peginterferon alpha-2a + Ribavirin|"Administration of ribavirin at a dosage of 1000 or 1200 mg per day based on body weight \< or \> 75 kg for 24 weeks (Arm A).~Treatment duration of 48 weeks with standard fixed dose of ribavirin (800 mg/day) (Arm B).~These schedules will be compared with diagram of standard therapy with 800 mg daily of ribavirin for 24 weeks (Arm C)"
224325720|NCT07085091|DRUG|ALX2004|ALX2004 is a novel ADC targeting EGFR. Drug: ALX2004 IV Infusion
224325721|NCT07085091|DRUG|ALX2004|ALX2004 is a novel ADC targeting EGFR. Drug: ALX2004 IV infusion
224325722|NCT07085091|DRUG|ALX2004|ALX2004 is a novel ADC targeting EGFR. Drug: ALX2004 IV infusion
223682804|NCT03705936|DEVICE|rTMS|rTMS is a non-invasive brain stimulation technique. It can regulate brain activities with electrical pulses sent to the brain through electromagnetic induction.
223682805|NCT05604183|PROCEDURE|non-invasive hyperspectral retinoscopy|The Principal Investigator or a trained medical nurse (under the supervision of the principal investigator) will take an image of the retina of the patient with the Mantis Photonics hyperspectral retinoscopy camera.
223682806|NCT05604183|PROCEDURE|blood sample|The Principle Investigator or a trained medical nurse (under the supervision of the Principal Investigator) will draw a small blood sample according to the standard medical procedures for drawing blood samples.
223682807|NCT05604183|DIAGNOSTIC_TEST|Test of cognitive ability on tablet computer with CoGNIT software|The Principle Investigator or a trained medical nurse (under the supervision of the Principal Investigator) will give the patient to perform the digital cognitive test on a commercial tablet computer. The Principal Investigator or the medical nurse will be available for the patient to ask questions while the test is ongoing.
224325723|NCT06765213|DIAGNOSTIC_TEST|Open Ended Oral Food Challenge|Allergens determined to be sensitized will be brought in for an oral challenge to that food.
224325724|NCT06765213|OTHER|Early Introduction|Infants that are not sensitized will have the food introduced to their diet at regular intervals.
224325725|NCT00336024|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous PBSC resuce
224325726|NCT00336024|DRUG|Carboplatin|Given IV
224325727|NCT00336024|DRUG|Cisplatin|Given IV
224325728|NCT00336024|DRUG|Cyclophosphamide|Given IV
224325729|NCT00336024|DRUG|Etoposide|Given IV
224325730|NCT00336024|BIOLOGICAL|Filgrastim|Given IV or SC
224325731|NCT00336024|OTHER|Laboratory Biomarker Analysis|Correlative studies
224325732|NCT00336024|DRUG|Leucovorin Calcium|Given IV or orally
224325733|NCT00336024|DRUG|Methotrexate|Given IV
224325734|NCT00336024|OTHER|Quality-of-Life Assessment|Ancillary studies
224325735|NCT00336024|DRUG|Thiotepa|Given IV
224325736|NCT00336024|DRUG|Vincristine Sulfate|Given IV
224325737|NCT04994873|BEHAVIORAL|STEP|Behavioral intervention to increase positive affect
224325738|NCT04994873|BEHAVIORAL|Enhanced TAU|Standard care plus a phone app with a personalized safety plan
224325739|NCT06617845|DEVICE|Stimulation Set A and B|Subjects will receive one stimulation parameter set first for 3 months and then the other for three months. Sets will include Set A (145 Hz high frequency stimulation) and Set B (Low frequency stimulation less than 40 Hz, which is similar to stimulation frequencies used during cortical stimulation). The 145 Hz stimulation will be set to cycling (1 min on, 5 min off) while the low frequency setting will be continuous. Both sets include stimulation parameter sets that have been used in clinical practice as a part of standard of care. However, it is unclear which set is better or whether they are similarly effective.
224325740|NCT06484621|BEHAVIORAL|Acceptance and Commitment Therapy-Based Physical Activity Intervention|Provides experiential training in values-clarification and acceptance strategies to increase autonomous motivation for achieving self-determined physical activity goal via group-based workshops, email feedback, and brief support calls.
224325741|NCT06484621|BEHAVIORAL|Physical Activity Education Control|Provides didactic instruction on physical activity and behavioral strategies for achieving prescribed physical activity goals via group-based workshops, email feedback, and brief support calls.
224325742|NCT04594642|DRUG|AZD0486 IV|AZD0486 is a bispecific antibody targeting CD19 on tumor cells and CD3 on T-cells leading to T cell-mediated cytotoxicity of malignant B cells
224325743|NCT07089706|BIOLOGICAL|mRNA-1283.251 Variant-containing Formulation|Sterile liquid for injection
224325744|NCT07087860|OTHER|Best Practice|Receive standard of care
224325745|NCT07087860|PROCEDURE|Biospecimen Collection|Undergo collection of blood and urine samples
224325746|NCT07087860|PROCEDURE|Central Venous Cannula Insertion|Undergo central line placement
224325747|NCT07087860|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
224325748|NCT07087860|DRUG|Enfortumab Vedotin|Given IV
224325749|NCT07087860|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
224325750|NCT07087860|BIOLOGICAL|Pembrolizumab|Given IV
224325751|NCT07087860|PROCEDURE|Plasmapheresis|Undergo TPE
224325752|NCT07087860|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
224325753|NCT07087860|OTHER|Questionnaire Administration|Ancillary studies
224325754|NCT07088068|DRUG|Teplizumab|Pharmaceutical form: Solution for injection Route of administration: Intravenous infusion
224325755|NCT07088068|OTHER|Placebo|Pharmaceutical form: Solution for injection Route of administration: Intravenous infusion
224325756|NCT06906302|BEHAVIORAL|RISE|RISE is personalized, trauma-informed, empowerment-oriented and variable-length, consisting of an initial 60-minute session and up to 7 additional 45-minute sessions (1-8 sessions total).
223682808|NCT01150474|DRUG|Belladonna and Opium Suppositories|Belladonna (16.2 mg) and opium (60 mg) suppositories administered rectally immediately following surgery and every 8 hours for 16 hours for a total of 3 doses.
223682809|NCT01150474|DRUG|Placebo Suppositories|Placebo suppositories administered rectally immediately following surgery and every 8 hours for 16 hours for a total of 3 doses.
223682810|NCT01423604|DRUG|Capecitabine|Capecitabine starting dose - 2000 mg/m\^2 (1000 mg/m\^2 twice a day (BID)) (NOTE: Frequency of administration may be adjusted during the study.)
223682811|NCT01423604|DRUG|Ruxolitinib|Ruxolitinib starting dose - 15 mg BID (NOTE: Starting dose of randomized study drug may be 10 mg BID based on results from safety run-in study. Dose of ruxolitinib may be increased during randomized study.)
223682812|NCT01423604|DRUG|Placebo|Placebo matching ruxolitinib
223774722|NCT03735966|DRUG|Pyrotinib plus trastuzumab and docetaxel and carboplatin|pyrotinib: 320mg orally daily，6cycles; trastuzumab:8mg/kg iv load followed by 6mg/kg iv 3-weekly for a total of 6cycles; docetaxel:after the biological window, 100mg/m2 for a total of 6 cycles carboplatin:d1 ，AUC 6 iv 3-weekly for a total of 6 cycles
223774723|NCT02261818|BEHAVIORAL|Meetings with peer mentors|Peer mentors provide social support to address depressive symptoms
224262561|NCT00776763|DRUG|Avastin intravitreal injection|1,25 mg of Bevacizumab (Avastin) will be intravitreally injected 4 weeks interval in the proliferative retinopathies groups (exudative age related macular degeneration and proliferative diabetic retinopathy)
224262562|NCT00934323|DRUG|Amaryl M SR 1/500 mg|single oral administration in period 1 for TR sequential group, and in period 2 for RT sequential group
224262563|NCT00934323|DRUG|Amaryl M SR 2/500 mg|single oral administration in period 2 for TR sequential group, and in period 2 for RT sequential group
224262564|NCT02114788|OTHER|Internet-based|
224262565|NCT04398147|BIOLOGICAL|Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)|Intramuscular administration
224262566|NCT04398147|BIOLOGICAL|Placebo|Intramuscular administration
224262567|NCT02485951|PROCEDURE|Central air injection|Air was injected inside the trephination site in the central injection group.
224262568|NCT02485951|PROCEDURE|Peripheral air injection|Air was injected at the corneal periphery outside the trephination site.
224262569|NCT05235854|DRUG|Injection of corticosteroids (Diprostène®)|Diprostène® will be injected into the knee. This is a 1 ml syringe of Betamethasone 2 mg, suspension for injection in pre-filled syringe.
224262570|NCT01165047|DRUG|Nitric Oxide|Nitric oxide, 80 ppm in air or oxygen will be administered using the GeNO nitrosyl delivery system with a standard nasal cannula at a flow rate of 4 LPM.
224262571|NCT00747305|DRUG|sunitinib malate|
224262572|NCT00747305|GENETIC|gene expression analysis|
224262573|NCT00747305|GENETIC|reverse transcriptase-polymerase chain reaction|
224262574|NCT00747305|GENETIC|western blotting|
224262575|NCT00747305|OTHER|immunohistochemistry staining method|
224262576|NCT00747305|OTHER|laboratory biomarker analysis|
224262577|NCT00747305|PROCEDURE|adjuvant therapy|
224262578|NCT00747305|PROCEDURE|neoadjuvant therapy|
224262579|NCT00747305|PROCEDURE|therapeutic conventional surgery|
224262580|NCT01934205|DRUG|GSK2140944 (Single dose)|A lyophilized formulation, pale yellow to grayish yellow cake containing 750 mg of GSK2140944 (as free base) per vial, Administered intravenously as a single dose.
224262581|NCT01934205|DRUG|GSK2140944 (Multiple dose)|A lyophilized formulation, pale yellow to grayish yellow cake containing 750 mg of GSK2140944 (as free base) per vial, Administered intravenously every 12 hours for 5 doses (3 days).
224262582|NCT04221347|OTHER|blood sampling|blood samples will be taken in specified time points
224325757|NCT06906302|BEHAVIORAL|Advocacy-based ECAU|Advocacy-based ECAU is a single 60-minute trauma-informed counseling intervention that includes supportive education, validating and empathetic statements, safety planning, resource provision and referrals.
224325758|NCT05730036|DRUG|Linvoseltamab|REGN5458 will be administered by intravenous (IV) infusion
224325759|NCT05730036|DRUG|Elotuzumab|Elotuzumab will be administered by IV infusion
224325760|NCT05730036|DRUG|Pomalidomide|Pomalidomide capsules will be administered by mouth (PO)
224325761|NCT05730036|DRUG|Dexamethasone|Dexamethasone tablets/capsules will be administered PO and/or by IV infusion
224325762|NCT07091123|DEVICE|Pain pump|Spinal catheter place under local anesthesia.
224325763|NCT07091123|DRUG|Bupivacain 0.625%/Fentanyl 2mcg/ml|A solution containing fentanyl 2 mcg/mL and bupivacaine 0.625 mg/mL at an infusion rate of 0.5 ml/hr.
224325764|NCT07091123|DEVICE|Spinal Cord Stimulator (SCS)|"Two spinal cord stimulation leads will then be advanced under fluoroscopy to the target area, typically around T7-T9 in the posterior epidural space.~Currently, there are six manufacturers of spinal cord stimulation devices with implanted programmable generators or receivers."
223682813|NCT05343468|DEVICE|The MapHabit System|"The MapHabit System (MHS) is a commercially available visual mapping software application that utilize visual, audio, and text media to create step-by-step visual guides to assist individuals and their caregivers in structuring and accomplishing activities of daily living (ADLs). The goal of the application is to develop and facilitate habits and routines using structured visual and auditory stimuli that can be customized by the user and can include educational and lesson-based material in addition to ADLs. The application was made available to families through compatible smartphones and tablets.~The MHS is a general wellness product and there is no regulatory oversight of the MapHabit System mapping functionality. This functionality is not a regulated medical device."
223682814|NCT00424255|DRUG|Lapatinib|Dual ErbB1/2 inhibitor
224325765|NCT07089992|DRUG|Pembrolizumab|Q 6 weeks IV infusion Day 1 of each 6-week cycle, up to 8 doses
224325766|NCT07090668|DEVICE|taVNS device|"Sparrow Link taVNS device from Spark Biomedical, a non-invasive, adhesive earpiece placed on the tragus of the ear to deliver vagal nerve stimulation. The stimulation level is titrated by the investigator to a perceptible but comfortable intensity. Patients cannot adjust the settings themselves, though adjustments can be made upon request.~The device consists of a disposable earpiece connected by a cable to a battery-powered controller (3 AAA batteries). It emits a biphasic, rectangular waveform with a 100 µs interphase and a maximum output of 95V."
224325767|NCT06743308|OTHER|Best Practice|Other Best Practice best practice, standard of care, standard of care, standard of care, standard therapy Undergo standard of care oncology follow-up visits
224325768|NCT06743308|OTHER|Questionnaire Administration|Ancillary studies
224325769|NCT05417282|DRUG|MW151|Females: 20 mg MW151 daily (10 mg capsule BID), for 28 days; Males: 10 mg MW151 daily (10 mg capsule QD), for 28 days.
224325770|NCT05105841|DRUG|Venetoclax|Oral Tablet
224325771|NCT05105841|DRUG|Ibrutinib|Oral Capsule
224325772|NCT05105841|DRUG|Obinutuzumab|Intravenous (IV) Infusion
224325773|NCT06745258|OTHER|External Facilitation|Multi-component facilitation strategy to address identified implementation needs
224325774|NCT07084129|OTHER|personalized dosing adjustment of vancomycin|A personalized vancomycin PK model that incorporates kidney injury biomarkers will be used for vancomycin dose adjustments to achieve goal AUC levels.
224325775|NCT06523166|PROCEDURE|Transesophageal echocardiography (TEE)|TEE will be performed using a 3D probe. TEE images will be acquired at the standard 0, 45, 90, and 135 degree views along with a 3D acquisition encompassing the entire LAA, device, left pulmonary vein and lateral mitral annular landmarks.
224325776|NCT06523166|PROCEDURE|Cardiac CTA|Cardiac CTA will be performed with ECG gating using systems with ≥ 64 detector rows and with temporal resolution that is at least 175 msec (rotation speed ≤ 350 msec for single source systems). Cardiac CTA images will be acquired for the entire cardiac cycle without ECG phase specific pulsing and with contrast appropriately timed for peak left atrial/arterial phase contrast enhancement. In addition, a targeted end systolic only delayed phase image set (45 seconds after the arterial phase scan and limited to the left atrium and appendage device) will be acquired.
224325777|NCT06906900|DEVICE|TTF-200M and TTF-200A systems|Participants will receive one cycle and treatment will continue as long as the doctor thinks it is in the participant's best interest.
224325778|NCT04633239|DRUG|Abemaciclib|Given PO
224325779|NCT04633239|PROCEDURE|Biopsy Procedure|Undergo tumor biopsy
224325780|NCT04633239|PROCEDURE|Biospecimen Collection|Undergo collection of blood
224325781|NCT04633239|DRUG|Olaparib|Given PO
223682815|NCT00424255|RADIATION|Chemoradiation|Radiation plus platinum based chemotherapy
224325782|NCT06730646|BEHAVIORAL|Health effects|Participants in this arm will watch 3 short videos about the smoking-related diseases during the survey data collection.
224325783|NCT06730646|BEHAVIORAL|Tobacco industry manipulation|Participants in this arm will watch 3 short videos about how the tobacco industry uses targeted marketing and manipulative tactics aimed at youth and young adults during the survey data collection.
224325784|NCT06730646|BEHAVIORAL|Secondhand smoke|Participants in this arm will watch 3 short videos about the risks of secondhand smoke exposure during the survey data collection.
224325785|NCT06730646|BEHAVIORAL|Mentral health|Participants in this arm will watch 3 short videos about the effects of smoking on mental health during the survey data collection.
224325786|NCT06730646|BEHAVIORAL|Social acceptability|Participants in this arm will watch 3 short videos about how smoking is socially unacceptable in China during the survey data collection.
224325787|NCT06730646|BEHAVIORAL|Control|Participants in this arm will watch 3 short videos about drinking bottled water during the survey data collection. These messages display specific water products and describe hydration as a healthy activity.
224325788|NCT06909253|DRUG|Ravulizumab|Ravulizumab, concentrate for solution for infusion
224325789|NCT06910657|BIOLOGICAL|IDOV-Immune (oncolytic vaccinia virus)|IDOV-Immune is a genetically engineered oncolytic vaccinia virus designed to selectively infect and destroy tumor cells while stimulating the immune system. This study investigates IDOV-Immune as a single intravenous infusion in a first-in-human, Phase 1, dose-escalation trial in participants with advanced solid tumors. The dose will escalate based on safety data, with a goal of identifying the recommended Phase 2 dose (RP2D).
224325790|NCT06910969|BEHAVIORAL|HORIZONS Intervention|Therapist-delivered multidisciplinary group-based telehealth intervention comprised of 8 sessions
224325791|NCT06910969|BEHAVIORAL|Minimally enhanced usual care|Receiving a standardized booklet with evidence-based information on chronic GHVD management and HST survivorship recommendations
223682816|NCT00424255|OTHER|Placebo|Placebo
223682817|NCT01173887|DRUG|VCAP/AMP/VECP(mLSG15)|VCAP(Vincristine Sulfate, Cyclophosphamide Hydrate, Doxorubicin Hydrochloride, Prednisolone); AMP(Doxorubicin Hydrochloride, Ranimustine, Prednisolone); VECP(Vindesine Sulfate, Etoposide, Carboplatin, Prednisolone)
223682818|NCT01173887|BIOLOGICAL|KW-0761|VCAP/AMP/VECP(mLSG15) + KW-0761
223682819|NCT03737071|BEHAVIORAL|Low Carbohydrate Diet|Ketogenic dietary intervention
223682820|NCT03737071|BEHAVIORAL|Simple Calorie Restriction Diet|Simple calorie restriction dietary intervention
223682821|NCT03489954|OTHER|Evaluation|Deep cervical flexor muscle endurance, neck position sense and body balance will be measured.
223682822|NCT03766282|DEVICE|ECMO|Extracorporeal membrane oxygenation (ECMO) temporarily supports patients with severe cardio-respiratory failure
223682823|NCT00812695|DEVICE|CPAP|Gold standard treatment for Obstructive sleep apnea
224325792|NCT07088718|DRUG|Tirzepatide|New use of tirzepatide dispensing claim is used as the exposure.
224325793|NCT07088718|DRUG|Dulaglutide|New use of dulaglutide dispensing claim is used as the reference.
224325794|NCT06138405|BEHAVIORAL|Immediate intervention Group|The immediate intervention group will be video recorded in office and participate in the training workshop and assessment methods two months after.
224325795|NCT06138405|BEHAVIORAL|Delayed intervention (control) Group|The delayed training group will also be video recorded in office but will wait an additional two months and then participate in the training and assessment methods as with the original training group.
224325796|NCT07089784|DRUG|MK-2828|Oral capsule of MK-2828 taken once per day for 28 days.
223682824|NCT00357929|PROCEDURE|Permissive hypercarbia|
223682825|NCT03206905|PROCEDURE|Endoscopic Sleeve Gastroplasty|endoscopic, rather than surgical approach, to perform sleeve gastroplasty
223682826|NCT03206905|BEHAVIORAL|Diet and Exercise|nutritional/exercise counseling
223682827|NCT06146998|OTHER|3D health education model|explanation combined with 3D health education model
223682828|NCT06146998|OTHER|Verbal explanation|Regular explanation
223682829|NCT06052215|BEHAVIORAL|Online Information Cards Education|Providing family planning education to women through online information cards
223682830|NCT03304444|DRUG|Bupivacaine|bupivacaine hydrochloride used in TAP block
223682831|NCT03304444|DRUG|liposomal bupivacaine|liposomal bupivacaine used in TAP block
223682832|NCT00327470|DRUG|Pegaptanib Sodium 0.3 mg|Pegaptanib Sodium dosed every 6 weeks in affected eye.
223682833|NCT00002805|BIOLOGICAL|filgrastim|
223682834|NCT00002805|DRUG|cladribine|
223682835|NCT00002805|DRUG|cytarabine|
223682836|NCT00002805|DRUG|etoposide|
223682837|NCT00002805|DRUG|methotrexate|
223682838|NCT00002805|DRUG|mitoxantrone hydrochloride|
223682839|NCT00002805|DRUG|therapeutic hydrocortisone|
223682840|NCT00002805|PROCEDURE|allogeneic bone marrow transplantation|
223682841|NCT00002805|PROCEDURE|autologous bone marrow transplantation|
223682842|NCT00002805|PROCEDURE|peripheral blood stem cell transplantation|
223682843|NCT00002805|RADIATION|low-LET cobalt-60 gamma ray therapy|
223682844|NCT00002805|RADIATION|low-LET electron therapy|
223682845|NCT00002805|RADIATION|low-LET photon therapy|
223682846|NCT02362568|PROCEDURE|Ultrasound cervical exploration|The cervical ultrasound exploration will consist in the ultrasound measurement of the length between the hyoid bone and the skin and the length between the thyroid cartilage and the skin. The ultrasound cervical exploration will be performed in all patients admitted in the postoperative room after a planned surgery performed under general anesthesia.
223682847|NCT01226121|BIOLOGICAL|Clostridial collagenase injectable|Finger manipulation performed 1, 2, or 4 days following collagenase injection
223682848|NCT02581943|DRUG|Carboplatin|Given IV
224325797|NCT07089784|DRUG|Placebo|Placebo to match MK-2828 oral capsule, taken once per day for 28 days.
224325798|NCT06542874|DRUG|NNC0487-0111 subcutanous|NNC0487-0111 administered subcutanously (under the skin)
224325799|NCT06542874|DRUG|Placebo (NNC0487-0111 subcutanous)|NNC0487-0111 placebo administered subcutanously (under the skin)
224325800|NCT06542874|DRUG|NNC0487-0111 oral|NNC0487-0111 administered orally (in the mouth)
224325801|NCT06542874|DRUG|Placebo (NNC0487-0111 oral)|NNC0487-0111 placebo administered orally (in the mouth)
224325802|NCT06904066|DRUG|aldesleukin|Aldesleukin 600,000 IU/kg IV (based on total body weight) over 15 minutes approximately every 8 hours beginning within 24 hours of cell infusion and continuing for up to 4 days (maximum 10 doses).
224325803|NCT06904066|DRUG|cyclophosphamide|300 mg/m\^2 IV infusion over 30 minutes. Daily x 3 doses on days -5, -4, -3.
224325804|NCT06904066|DRUG|fludarabine phosphate|30 mg/m\^2 IV infusion over 30 minutes administered immediately following cyclophosphamide on day -5, -4, -3. Participants with renal dysfunction receive a lower dose of fludarabine.
224325805|NCT06904066|BIOLOGICAL|Individual Patient TCR-Transduced PBL|Up to 1.5x10\^11 total cells for non-transplant subjects. 1x10\^10 total cells for post-alloHSCT subjects.
223682849|NCT02581943|OTHER|Laboratory Biomarker Analysis|Correlative studies
223682850|NCT02581943|DRUG|Paclitaxel|Given IV
223682851|NCT02581943|BIOLOGICAL|Pembrolizumab|Given IV
223682852|NCT02581943|OTHER|Quality-of-Life Assessment|Ancillary studies
223682853|NCT02115126|BIOLOGICAL|LMP2A-loaded conventional DC vaccine|"Vaccine #1 will be administered 9-13 weeks status post peripheral blood stem cell (PBSC) infusion. At the time of vaccination, ANC must be \> 1.5.~Vaccine #2, the booster vaccine, will be administered 4 weeks +/- 7 days status post vaccine #1. At the time of vaccination, ANC must be \> 1.5.~Vaccines will be administered following standard institutional practice for IV infusions using a peripheral or central line and following sterile technique. On the day of vaccination, the patient will be given a total dose of 3 x 107 cells in 30ml of normal saline per vaccination."
223682854|NCT02115126|BIOLOGICAL|DUK-CPG-001|"On the day of vaccination, for those patients who are randomized to receive DUK-CPG-001, a single vial will be dispensed to the nurse, upon request, by Duke ICS. DUK-CPG-001 will be thawed at room temperature right before use and 0.5 ml (5 mg) will be injected subcutaneously immediately after vaccination.~DUK-CPG-001 will be stored at -20ºC until use. It will be stored in the Duke Investigational Chemotherapy Service pharmacy.~Using standard institutional guidelines and sterile technique for subcutaneous injections, 5 mg of DUK-CPG-001 will be injected subcutaneously immediately after each vaccination."
223682855|NCT02758405|DRUG|Bupivacaine|0.125% Bupivacaine plus fentanyl 2mcg/ml
223682856|NCT02758405|DRUG|Fentanyl|0.125% Bupivacaine plus fentanyl 2mcg/ml
223682857|NCT02758405|DEVICE|Infusion pump|Infusion pump set to deliver programmed intermittent epidural boluses (PIEB) plus patient-controlled epidural analgesia (PCEA).
223682858|NCT06067659|OTHER|Extracorporeal shock wave therapy|ESWT (EMS Swiss DolorClast® Classic) application will be applied to patients in groups 1 and 3 with a frequency of 15 Hz, a 2000 shock wave and an energy density of 2.5 bar. In practice, patients will be asked to lie in the prone position and keep the knee and hip joints in a neutral position. By placing a towel roll under the ankle, the heel will be stabilized to be applied. Using the ultrasound gel as an intermediate, the ESWT device will be applied to the medial part of the calcaneus.
223682859|NCT06067659|OTHER|Kinesiology taping|The material used in the taping will be 5 cm wide and 0.5 mm thick Kinesio® Tape. In practice, the patients were placed in the prone position and the ankle would be dorsiflexed at 10 degrees, and the band would be divided into 4 equal parts on the metatarsals of the 1/3 of the foot from the cruis, starting from the calcaneus. Then, taping will be performed from the medial to the lateral of the calcaneus, passing over the area where the pain is intense. Patients will be asked not to remove the applied tape for 3 days.
223682860|NCT06067659|OTHER|Extracorporeal shock wave therapy+Kinesiology taping|Patients in this group will be treated with both extracorporeal shock wave therapy and kinesiotape.
223682861|NCT03271294|DEVICE|Exair Transvaginal Mesh|Exair transvaginal mesh system for the treatment of pelvic organ prolapse
223682862|NCT00311480|BIOLOGICAL|Influenza vaccine surface antigen adjuvanted with MF59|
223682863|NCT01415089|BEHAVIORAL|FOCUS-Web|A 3-session individually tailored, interactive, web-based program providing support and education for cancer patients and one of their family caregivers.
223682864|NCT03274375|DRUG|IA session|10 IA sessions performed in 28 days maximum, using TherasorbTM adsorbers which contain sheep derived polyvalent antihuman-immunoglobulin coupled to SepharoseTM CL-4B.
223682865|NCT03274375|DRUG|Rituximab|"Concomitantly, Rituximab will be given each week for 4 weeks (one injection by week +/- 3 days):~* at least 1 day before each IA session~* the last injection will occur after the last session IA (minimum one day after)"
223682866|NCT01987947|DRUG|Placebo|Two administrations by subcutaneous injection
223682867|NCT01987947|DRUG|Quilizumab|Two administrations by subcutaneous injection
223774724|NCT01428492|DRUG|GSK2110183|The oral, once daily dose of GSK2110183 will be dependent on the cohort to which a subject is assigned. Subjects enrolled in Cohort 1 will receive 75 mg GSK2110183 once daily. Dose escalation in Schedule A and Schedule B will follow 25 mg increments in a 3+3 dose escalation procedure up to a maximum of 150mg daily or until MTD is reached, whichever comes first, for each schedule. GSK2110183 will continue at daily dosing until treatment discontinuation criteria is met.
224262583|NCT02120677|DRUG|Itraconazole|Itraconazole comes in the form of capsules and liquid (oral solution). It is FDA approved for treatment of systemic Blastomycosis, Histoplasmosis and Aspergillosis in immunocompromised and non-immunocompromised patients at doses ranging from 200mg to 400mg daily. The current FDA approved dosage recommendation for treating toenail onychomycosis (nail fungus) is 200mg PO per day for 3 months. Test materials in this study will be prepared as an ointment (compounded in petrolatum jelly).
224262584|NCT00967135|DRUG|Pregabalin|150 mg oral dose of pregabalin twice daily for 5 consecutive days.
224262585|NCT00967135|DRUG|Placebo|Matching oral placebo twice daily for 5 consecutive days.
224262586|NCT01945450|DRUG|Antibiotic prophylaxis|antibiotic prophylaxis as following: 24 hours coverage with Ampicillin 2 grams\*4, Gentamycin 240 mg\*1, Clindamycin 600 mg\*3
224262587|NCT01945450|DRUG|Ampicillin|
224262588|NCT01945450|DRUG|Gentamycin|
224262589|NCT01945450|DRUG|Clindamycin|
224262590|NCT06225362|DEVICE|Quatera 700|Phacoemulsification device
224262591|NCT06225362|DEVICE|Centurion|Phacoemulsification device
224262592|NCT04474990|DRUG|Tradipitant|NK-1 Receptor antagonist
224262593|NCT05714930|OTHER|Treat-to-target as a new treatment concept|After trial initiation, the study personnel in the intervention centers will receive a training on T2T and shared decision making (SDM). Patients in the intervention centers will receive 6-weekly visits for at least 24 weeks with therapeutic adjustments to achieve remission. In case of stable remission for 6 weeks at week 24, the patients switch to 12-weekly visits until the end of the trial at week 120. In case of flare, the patient switches to 6-weekly visits for 24 consecutive weeks. Pharmaceutical treatment decisions will be guided by current treatment standards and will be taken in accordance with SDM between patients and treating physicians.
224262594|NCT04113109|DRUG|LCZ 696|Treatment with LCZ696 is unblinded in this study. After the two acute study days, subjects will be provided LCZ696 50 mg bid for two weeks. At the end of those two weeks subjects will report to the Clinical Research Center (CRC) for a dose escalation visit. If their tolerance, blood pressure, potassium, and eGFR meet escalation criteria they will be given LCZ696 100 mg bid for three weeks. (If they do not meet escalation criteria they will be continued on LCZ696 50 mg bid.) After three weeks, they will return to the CRC for the next escalation visit. If they meet criteria for escalation they will be given LCZ 200 mg bid for ten days. (If they do not meet escalation criteria they will be continued on the highest tolerated dose).
224262595|NCT04113109|DRUG|Icatibant|Icatibant will be given intravenously at 100 µg/kg over one hour followed by 20 µg/kg/hr during each study day.
224262596|NCT04113109|DRUG|placebo|Placebo (vehicle) will be given at the same rate as icatibant.
224262597|NCT04113109|DRUG|Para-aminohippurate|Para-aminohippurate (PAH) will be given at a dose of 8 mg/kg loading dose followed by a 12 mg/min steady-state infusion during each study day.
224262598|NCT04113109|DRUG|Iohexol|Iohexol will be given as 5 mL of iohexol solution (3.235 g iohexol) intravenously on each study day.
224262599|NCT06627127|DEVICE|Target stimulation (HGN, AC, GG, Strap muscles)|Stimulation of the HGN or GG along with AC or strap muscles.
224262600|NCT06140082|GENETIC|GSTP1 A313G （AA）|Patients with pulmonary malignant tumors receiving platinum-containing chemotherapy regimen were included in the retrospective and prospective bidirectional cohort study to collect the basic information of the subjects, including gender, age, smoking history, primary site, basic liver and kidney function, chemotherapy regimen, etc. The polymorphisms of glutathione S transferase (GSTP1 A313G) were detected by Sanger dideoxy termination sequencing. The wild type (AA) and mutant type (AG/GG) were divided into two groups.
224262601|NCT04516460|DEVICE|Interventional arm: endoscopic resection plus PuraStat®|Interventional arm: PuraStat® applied through a catheter delivery system via the endoscope is used to prevent bleeding after endoscopic resection of colorectal neoplastic lesions
224262602|NCT04197492|RADIATION|Hypofractionated Stereotactic Radiotherapy|Hypofractionated stereotactic radiotherapy (CyberKnife, 25Gy/5fx)
224262603|NCT04197492|DRUG|Anlotinib|Anlotinib once daily (12mg/d) on days 1-14 of a 21-day cycle.
224262604|NCT04313751|BEHAVIORAL|Education, Physical Activity, and Stress Management Program|Twelve weekly classes for one hour focused on CVD risk factor education using the Su Corazón Su Vida curriculum and coping skills training followed by a 45 minute exercise class and 15 minute stress management session. Then they will return for one hour for continued support, a forty-five minute exercise class, and fifteen minute stress management session.
224325806|NCT06904066|DEVICE|TruSight Oncology (TSO) 500|TSO500 sequencing panel performed in the NCI Laboratory of Pathology to detect TP53 or RAS mutations
223682868|NCT03021564|OTHER|cardiopulmonary resuscitation|Basic cardiopulmonary resuscitation : external electric shock, external cardiac massage, adrenaline injection ...
223682869|NCT03374618|OTHER|Blood sample|Blood sample to quantify and qualify netosis in vivo and ex vivo after different stimulations in SSC, SLA and healthy controls
223682870|NCT06396182|OTHER|group (A ) study group :virtual reality cycling by fully immersive Head-Mounted Display virtual reality (Oculus Quest virtual reality (VR) headset with hand controller).|"group (A ) study group : virtual reality cycling by fully immersive Head-Mounted Display virtual reality (Oculus Quest virtual reality (VR) headset with hand controller):~The VR cycling session utilized the VZFIT VR Exercise Bike (VZFIT, Cambridge, MA), games were selected as preliminary pilot trials indicated these games to be most intense. Players maneuvered during VR gameplay by pedaling and steering their virtual character by leaning their bodies left and right. (Daniel et al., 2020).~group (B) control group :Cycling by traditional stationary bike: Participants will require to continuously pedal using the pulse oximeter for HR monitor. Research personnel monitored participants during the session adjusting pedal-resistance to ensure that the participants stayed within their target HR zone. (Daniel et al., 2020)."
223682871|NCT03872414|BEHAVIORAL|Anterior cingulate cortex activation|"Functional Magnetic Resonance Imaging Participants in the experimental group will be trained using functional magnetic resonance imaging to regulation brain activity in anterior cingulate cortex.~The anterior cingulate cortex is a brain region that is known to be involved in emotion processing. Activation of this region is expected to improve emotion processing."
223682872|NCT03872414|BEHAVIORAL|Primary auditory cortex activation|"Functional Magnetic Resonance Imaging Participants in each group will be trained using functional magnetic resonance imaging to regulation brain activity in primary auditory cortex. The primary auditory cortex is a brain region that is NOT specifically involved in emotion processing. Activation of this region is NOT expected to improve emotion processing; and thus activation of this brain region serves as control/placebo condition in the current design (placebo comparator)."
223682873|NCT03920384|BEHAVIORAL|Experimental intervention arm|Psychological therapy for psychosis with new therapy components
223682874|NCT03920384|BEHAVIORAL|Active control arm|Standard psychological therapy for psychosis without new therapy components
223682875|NCT05117957|DRUG|Sorafenib|Subjects will receive sorafenib 600mg orally daily. When dose reduction is necessary during the treatment of HCC, the sorafenib dose should be reduced to 400mg once daily. Escalation of sorafenib from a daily dose of 600mg to 800mg (400mg twice daily) is allowed if the subject who is tolerating the 600mg sorafenib dose level well. Treatment will continue until progression, unacceptable toxicity, withdrawal of consent, or study end, whichever occurs first.
223682876|NCT02685475|DRUG|Axillary Brachial Plexus Blocks|All patients received ultrasound-guided axillary brachial plexus block (ABPBs) with the mixture of 10 mL lidocaine 2% and 20 mL bupivacaine 0.5%.
223682877|NCT00739271|OTHER|Early feeding|
223682878|NCT00739271|OTHER|late feeding after bowel sounds return|Traditional method
223682879|NCT03503890|DRUG|rovalpituzumab tesirine|intravenous
223682880|NCT04112589|DRUG|Quizartinib|Quizartinib at different doses in the phase I (40mg-14 days; 60mg-14 days; 60mg-7days, 40mg-7days). RP2D in the phase II part.
223682881|NCT04112589|DRUG|Fludarabine|30 mg/m2 intravenous days 1 to 4 of the cycle
223682882|NCT04112589|DRUG|Cytarabine|2 g/m 2 intravenous days 1 to 4 (1 g/m2 in patients older than 59) of the cycle
223682883|NCT04112589|DRUG|Idarubicin|10 mg/ 2 intravenous days 1 to 3 of the cycle
223682884|NCT04112589|DRUG|glycosylated G-CSF|daily dose of 300 mcg/m 2 , from day -1 until day 5 of the cycle
223682885|NCT03444077|DIAGNOSTIC_TEST|Use of the Trauma Induced Coagulopathy Clinical Score (TICCS) as a diagnostic tool.|The TICCS will be calculated on the site of injury for the patients taken in charge in the intervention group. Those patients will be classified in two categories regarding their TICCS value. Patients with TICCS ≥ 10 will be classified as in need for DCR; while patients with TICCS \< 10 will be classified as not in need for DCR.
223682886|NCT03444077|DIAGNOSTIC_TEST|Regular care|Patients from the control group will be evaluated by clinicians using the local usual clinical Tools.
223682887|NCT03444077|OTHER|STTTOPPP the bleeding|"* Surgical team pre-activation~* Trauma team pre-activation~* Transfusion team pre-activation~* Tranexamic acid (administration of 1 gram of TXA if documented hyperfibrinolysis)~* O negative RBC transfusion as soon as possible~* Plasma and Platelets transfusion as soon as possible~* Permissive hypotension (restrictive use of crystalloids: no more than 500 milliliters before definitive control of the bleeding is achieved)~* Prophylaxis (initiate antithrombotic prophylaxis as soon as the bleeding is under control and coagulation tests are normal, first evaluation before the 24th hour after trauma)"
223682888|NCT03444077|OTHER|Regular Care|Regular local pre-hospital care.
223682889|NCT04597060|DEVICE|Thermomechanical system with corticosteroids|The device in this study using Novoxel - Tixel®
223682890|NCT04597060|OTHER|corticosteroid injection|corticosteroid injection using TA 10mg/ml
223682891|NCT00432601|BEHAVIORAL|type of decision aid|We will be comparing two decision aids (MCC vs. NCCN) in terms of their impact on decision making and patient-physician communication.
223682892|NCT02556476|PROCEDURE|mechanical ventilation|ventilator support for the patients presenting with acute respiratory failure
223682893|NCT02556476|PROCEDURE|neuromuscular blockade|paralysis of the skeletal muscles in order to optimize mechanical ventilation, especially during ARDS
223682894|NCT02556476|PROCEDURE|renal replacement therapy|the procedures used to treat acute kidney injury
223682895|NCT02556476|PROCEDURE|non-invasive ventilation|Procedure used for ventilation support in patients with congestive heart failure, pulmonary edema, COPD and some other conditions.
223682896|NCT03986762|DRUG|Clavulanic Acid|\~10 days of Clavulanic Acid
224325807|NCT06496867|PROCEDURE|Early Internal Fixation|Early internal fixation of the LC1 fragility fracture of the pelvis will be defined as percutaneous anterior and/or posterior pelvic internal fixation with cannulated screw(s), medullary implant(s), or sacroiliac joint fusion device(s). The implant number, design, diameter, thread type (fully-threaded or partially-threaded), sacral segment (S1, S2, S3, or any combination there of), length, trajectory including sacroiliac or transsacral-transiliac, application with or without a washer, and ingrowth or ongrowth surface designs will be at the discretion of the treating surgeon.
224325808|NCT06496867|OTHER|Nonoperative Care with Early Rehabilitation|Nonoperative care with early rehabilitation will consist of nonoperative treatment of the pelvis fracture, including early consultation of the physical therapist, physiotherapist, or local equivalent rehabilitation provider at the time of randomization for a first attempt at mobilization of the patient within 24 hours of randomization. Patients who are unable to ambulate with assistance after five or more days of attempted mobilization by rehabilitation providers may be considered for delayed internal fixation treatment at the discretion of the patient and the treating surgeon. Delayed internal fixation after five or more days of attempted mobilization by rehabilitation providers will not be considered a treatment crossover event.
224325809|NCT07092865|BIOLOGICAL|Adjuvanted RSVPreF3 vaccine|1 dose of adjuvanted RSVPreF3 vaccine administered intramuscularly at Visit 1 (Day 1).
224325810|NCT07096063|DRUG|Tirzepatide|New use of tirzepatide dispensing claim is used as the exposure.
224325811|NCT07096063|DRUG|Dulaglutide|New use of dulaglutide dispensing claim is used as the comparator.
224325812|NCT07096063|DRUG|Semaglutide|New use of semaglutide dispensing claim is used as the exposure/comparator.
224325813|NCT07096063|DRUG|Sitagliptin|New use of sitagliptin dispensing claim is used as the comparator.
224325814|NCT06587659|DEVICE|Transcranial Magnetic Stimulation|The MagPro R30 is an advanced, high performance magnetic stimulator designed primarily for non-invasive clinical use. The non-invasive brain stimulation system will be used to deliver active repetitive electromagnetic pulses in this research study's treatment of post-traumatic stress disorder.
224325815|NCT06587659|DEVICE|Robotic Arm|This robotic system is based on a commercially available collaborative robot. The robot is mounted on a cart which holds the robot controller and the TMS power supply and pulse-generation computer. The robotic system will be used for TMS coil positioning/targeting.
223682897|NCT03122301|DRUG|Stellate Ganglion Block injection with bupivicaine|A computer-generated 1:1 block randomization scheme will be used to assign participants to receive either a SGB with bupivacaine or a sham injection with saline. Randomization will be performed by the injectionist immediately before the injection procedure by opening an opaque envelope to reveal the participant number and group assignment printed on an index card.
223682898|NCT03122301|DRUG|Saline|sham injection with saline
223682899|NCT02555280|DEVICE|coflex® Interlaminar Technology|Decompression plus coflex® Interlaminar Technology
223682900|NCT02555280|PROCEDURE|Decompression|Decompression alone
223682901|NCT03924271|DIAGNOSTIC_TEST|Iron deficiency testing|Blood sample for complete iron status
223682902|NCT04983953|DEVICE|cHS|Clinical decision support system for diagnosing intracranial haemorrhage
223682903|NCT01171833|DRUG|Sevoflurane|2.0 vol% prefilled in a corrugated circuit.
223682904|NCT01171833|DRUG|Desflurane|6.0 vol% prefilled in a corrugated circuit.
223682905|NCT01171833|DRUG|Isoflurane|1.2 vol% prefilled in a corrugated circuit.
223682906|NCT00453388|PROCEDURE|Allogeneic Bone Marrow Transplantation|Undergo allogeneic bone marrow transplant
223682907|NCT00453388|DRUG|Cyclophosphamide|Given IV
224325816|NCT04627428|BIOLOGICAL|RPESC-RPE-4W|RPESC-RPE-4W
224325817|NCT05705219|DIAGNOSTIC_TEST|3D-MPUS|Participants will receive approximately \< 20 minutes ultrasound scan to locate the lesion followed by acquisition of 3D-MPUS acquisition.
224325818|NCT07104084|DEVICE|lavage chlorhexidine|Patient will receive a chlorhexidine lavage for 3 minutes following total hip component placement followed by saline lavage.
224325819|NCT07104084|DEVICE|lavage povidone-iodine|Patient will receive povidone-iodine lavage for 3 minutes following total hip component placement followed by saline lavage.
224325820|NCT06548360|DRUG|Ruxolitinib Cream|Ruxolitinib cream applied topically to the affected area as a thin film twice daily.
224325821|NCT06548360|DRUG|Vehicle Cream|Matching vehicle cream applied topically to the affected area as a thin film twice daily.
224325822|NCT06381492|DEVICE|MRI|MRI using DTI technology
224325823|NCT06381492|DEVICE|Ultrasound (US)|Standard US
224325824|NCT06381492|DEVICE|Neuromuscular electric stimulation (NMES)|Standard NMES
224325825|NCT01621594|DEVICE|Cannon Aquilion ONE CT system|To test the diagnostic accuracy of low-radiation dose CT coronary angiography for detecting significant coronary artery stenosis and to determine the prognostic value of low-radiation dose CT coronary angiography for discriminating patient risk of death or major adverse cardiac events.
223682908|NCT00453388|DRUG|Cyclosporine|Given IV or PO
223682909|NCT00453388|DRUG|Fludarabine Phosphate|Given IV
223682910|NCT00453388|OTHER|Laboratory Biomarker Analysis|Correlative studies
223682911|NCT00453388|DRUG|Mycophenolate Mofetil|Given PO
223682912|NCT00453388|PROCEDURE|Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic stem cell transplant
223682913|NCT00453388|RADIATION|Total-Body Irradiation|Undergo TBI
223682914|NCT00745615|DRUG|Laquinimod|Laquinimod tablets/capsules will be administered as per the dose and schedule specified in the respective arms.
223682915|NCT00745615|DRUG|Placebo|Placebo matching to laquinimod will be administered as per the dose and schedule specified in the respective arms.
223682916|NCT00907062|DIETARY_SUPPLEMENT|Ginkgo biloba|60 mg Ginkgo biloba per capsule, standardized to 15 mg ginkgofavonglycosides per pill
223682917|NCT03405636|DEVICE|Xeltis Pulmonary Valved Conduit|RVOT reconstruction
224325826|NCT06833073|BIOLOGICAL|Intismeran autogene|IM injection
224325827|NCT06833073|BIOLOGICAL|BCG|Intravesicular instillation. BCG is a preparation of Bacillus Calmette-Guerin.
224325828|NCT07108205|DEVICE|Paired reading analysis|Paired side be side evaluation Each reader will assess- Image Quality (IQ) \& Diagnostic Confidence Ratings will be recorded using a 5-point Likert scale
224325829|NCT06096844|DRUG|Carboplatin|Given IV
224325830|NCT06096844|PROCEDURE|Computed Tomography|Undergo CT scan
224325831|NCT06096844|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
224325832|NCT06096844|DRUG|Nab-paclitaxel|Given IV
224325833|NCT06096844|DRUG|Paclitaxel|Given IV
224325834|NCT06096844|BIOLOGICAL|Pembrolizumab|Given IV
224325835|NCT06096844|DRUG|Pemetrexed|Given IV
224325836|NCT06096844|PROCEDURE|Positron Emission Tomography|Undergo PET
224325837|NCT06096844|OTHER|Questionnaire Administration|Ancillary studies
224325838|NCT06437834|OTHER|Information Sheet|Information sheet describing the importance of vaccines and preventive care as well as contact information for patient navigators.
224325839|NCT06437834|OTHER|High-touch connect|Engagement with a patient navigator.
224325840|NCT06479824|DEVICE|TRAIPTA (Trans-Atrial Intra-Pericardial Tricuspid Annuloplasty)|In TRAIPTA, catheter tools cross the wall of the heart to enter the pericardial space surrounding the heart, encircle the heart around the atrioventricular groove, and apply tension to reshape and narrow the heart to help the leaky tricuspid valve to function better. After placing the belt, a closure device is deployed to close the puncture in the right atrial appendage.
224325841|NCT04579224|PROCEDURE|Biospecimen Collection|Undergo blood and urine sample collection
224325842|NCT04579224|PROCEDURE|Bone Scan|Undergo bone scan
224325843|NCT04579224|PROCEDURE|Computed Tomography|Undergo CT
224325844|NCT04579224|DRUG|Docetaxel|Given IV
224325845|NCT04579224|DRUG|Eribulin Mesylate|Given IV
224325846|NCT04579224|DRUG|Gemcitabine Hydrochloride|Given IV
224325847|NCT04579224|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
224325848|NCT04579224|DRUG|Paclitaxel|Given IV
224325849|NCT04579224|BIOLOGICAL|Sacituzumab Govitecan|Receive IV
224325850|NCT06772597|DRUG|Setmelanotide|Setmelanotide (daily subcutaneous injection)
224325851|NCT05653219|BIOLOGICAL|Ianalumab|Concentrate for solution for infusion for intravenous use
224325852|NCT05653219|DRUG|Eltrombopag|Film-coated tablet for oral use
224325853|NCT05653219|DRUG|Placebo|Concentrate for solution for infusion for intravenous use.
224325854|NCT04939610|DRUG|68Ga-FAP-2286|68Ga-FAP-2286 IV administered as imaging agent for PET scan.
224325855|NCT04939610|DRUG|177Lu-FAP-2286|"Phase 1:~Patients with positive uptake of 68Ga-FAP- 2286 will receive a fixed dose of 177Lu-FAP-2286 IV administered every 6 weeks for a maximum of 6 doses. Doses range between 3.7 and 9.25 GBq (100-250 mCi).~Phase 2:~Monotherapy: Patients with positive uptake of 68Ga FAP 2286 will receive a fixed dose of 177Lu FAP 2286 IV administered at the RP2D determined in Phase 1 dose escalation in every 4 weeks.~Combination therapy: Patients with positive uptake of 68Ga FAP 2286 will receive 177Lu-FAP-2286 based on dose escalation (starting with dose level 1) followed by dose expansion at selected dose."
224325856|NCT05809596|DEVICE|WATCHMAN FLX Pro LAAC Device|Treatment with a WATCHMAN FLX Pro Left Atrial Appendage Closure Device
224325857|NCT06191315|DRUG|Dupilumab|Pharmaceutical form: Injection solution Route of administration: Subcutaneous
224325858|NCT06191315|DRUG|Placebo|Pharmaceutical form: Injection solution Route of administration: Subcutaneous
223774725|NCT01428492|DRUG|Bortezomib|Bortezomib (1.0 mg/m2) will be administered on days 1, 4, 8, and 11 of each 21-day cycle for cohort 1 for up to 8 cycles. Bortezomib (1.3 mg/m2) will be administered on days 1, 4, 8, and 11 of each 21-day cycle for up to 8 cycles. Bortezomib (1.5 mg/m2) will be administered on days 1, 8, and 15 of each 21-day cycle for up to 8 cycles.
224325859|NCT06765109|DRUG|Neladalkib (NVL-655)|Oral tablet of Neladalkib (NVL-655)
224325860|NCT06765109|DRUG|Alectinib|Oral capsule of alectinib
224325861|NCT06116136|DRUG|S095029|Participants will be treated with S095029 via intravenous (IV) infusion every 3 weeks (Q3W).
224325862|NCT06116136|DRUG|pembrolizumab 200 mg (KEYTRUDA ®)|Participants will be treated with 200 mg of pembrolizumab via intravenous (IV) infusion every 3 weeks (Q3W).
224325863|NCT06667700|DRUG|Molnupiravir|Molnupiravir administered orally as two 400 mg film-coated tablets every 12 hours for 5 days (a total of 10 consecutive doses)
224325864|NCT06667700|DRUG|Placebo|Molnupiravir-matching placebo administered orally as two film-coated tablets every 12 hours for 5 days (a total of 10 consecutive doses)
224325865|NCT06118515|DRUG|Letermovir|Letermovir is a novel inhibitor targeting the cytomegalovirus (CMV) viral enzyme, effectively disrupting the production of additional CMV virions. Letermovir has demonstrated potent, selective, and reversible inhibition of CMV activity in preclinical studies.
224325866|NCT05711615|PROCEDURE|Biopsy Procedure|Undergo tissue biopsy
224325867|NCT05711615|PROCEDURE|Biospecimen Collection|Undergo blood and tissue sample collection
224325868|NCT05711615|PROCEDURE|Computed Tomography|Undergo CT scan
224325869|NCT05711615|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
224325870|NCT05711615|DRUG|Pegylated Liposomal Doxorubicin Hydrochloride|Given IV
223774726|NCT01428492|DRUG|Dexamethasone|Dexamethasone will be given orally at a fixed dose of 20 mg only on days of bortezomib dosing in both Schedule A and Schedule B.
224325871|NCT05711615|DRUG|Peposertib|Given PO
224325872|NCT02339571|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
224325873|NCT02339571|PROCEDURE|Computed Tomography|Undergo CT scan
224325874|NCT02339571|PROCEDURE|Echocardiography Test|Undergo ECHO
224325875|NCT02339571|BIOLOGICAL|Ipilimumab|Given IV
224325876|NCT02339571|PROCEDURE|Magnetic Resonance Elastography|Undergo MRI
224325877|NCT02339571|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
224325878|NCT02339571|BIOLOGICAL|Nivolumab|Given IV
224325879|NCT02339571|BIOLOGICAL|Sargramostim|Given SC
224325880|NCT06624228|DRUG|Bimekizumab|Study participants will receive bimekizumab at pre-specified time points.
224325881|NCT06624228|DRUG|Risankizumab|Study participants will receive risankizumab at pre-specified time points.
224325882|NCT06624228|DRUG|Placebo|Study participants will receive placebo at pre-specified time points.
224325883|NCT06577454|DEVICE|TMS (MagVenture MagPro 100 with MagOption)|TMS will be applied using the MagVenture MagPro 100 with MagOption (MagVenture Inc, Alpharetta, GA) stimulator with a figure-of-8 TMS coil.
224325884|NCT03816345|PROCEDURE|Biospecimen Collection|Undergo collection of blood, CSF, tissue, stool and urine samples
224325885|NCT03816345|BIOLOGICAL|Nivolumab|Given IV
224325886|NCT07100964|DRUG|nerandomilast|nerandomilast
224325887|NCT07100964|DRUG|carbamazepine|carbamazepine
224325888|NCT07099092|DEVICE|TUS PirC|120 seconds of 100 Hz low-intensity transcranial ultrasound stimulation targeting piriform cortex
224325889|NCT07099092|DEVICE|TUS Amy|120 seconds of 100 Hz low-intensity transcranial ultrasound stimulation targeting amygdala
224325890|NCT07099092|DEVICE|TUS Sham|120 seconds of 100 Hz low-intensity transcranial ultrasound stimulation targeting white matter
224325891|NCT07102147|BEHAVIORAL|High Touch Outreach|Gain-framed message, informational flyer, and direct request
224262605|NCT04313751|OTHER|Wait-list|The wait-list control group will receive 12 weekly one hour education and coping skills training sessions followed by a 45 minute exercise class and a 15 minute stress management session.
224262606|NCT03325881|DRUG|SHP465|SHP465 capsule 6.25 mg orally once daily for 4 weeks
224262607|NCT03325881|DRUG|Placebo|Placebo matching to SHP465 capsule orally once daily for 4 weeks
224262608|NCT03135301|DRUG|letrozole plus metformin|letrozole 5 milligram tablets plus metformin 850 milligram tablets
224262609|NCT03135301|DRUG|letrozole|letrozole 5 milligram tablets
224262610|NCT05613972|OTHER|Brief Suicide and Trauma Therapy|12-week trauma therapy
224262611|NCT03679091|DRUG|low-dose ticagrelor|low-dose ticagrelor (60.0 mg once daily) for 7 days,followed by a 2-week washout period then a 7 days crossover phase of clopidogrel (75mg once daily).
224262612|NCT03679091|DRUG|Clopidogrel|clopidogrel (75mg once daily) for 7 days,followed by a 2-week washout period then a 7 days crossover phase of low-dose ticagrelor (60.0 mg once daily).
224262613|NCT02551640|OTHER|FeatForward App (on study smartphone)|"The FeatForward mobile app will have the following features:~Messaging: Educational messages tailored to user's medical conditions and motivational messages tailored to user's stage of change.~Tracking: Ability to track physical activity, weight, blood pressure, blood glucose and heart rate.~Community: Users in later stages of change able to encourage and motivate one another through groups.~Educational Library: To provide educational tips and health information. Provider Engagement: Ability for physicians to view patient data, and send messages to patients.~Monthly depression assessments: The app will prompt users to complete a monthly voluntary depression assessment.~Social Support: Those using the FeatForward app will also have access to a Facebook group."
224262614|NCT02933658|DRUG|Telmisartan|
224262615|NCT02933658|DRUG|Amlodipine|
224262616|NCT02933658|DRUG|Rosuvastatin|
224262617|NCT03060486|DEVICE|HYBENX®|"The mixture was then introduced inside the root canal using the pre-dosed syringe for 20 seconds with a sterile paper point with and up and down movement.~Finally, the canal was rinsed with sterile saline water using a syringe with a side-vented 30 G needle."
223682918|NCT05765656|BEHAVIORAL|GP - pharmacist collaboration and pharmacist motivational interviewing|"1. Patients in the GP-CP clusters randomized to the intervention arm will be offered a joint GP-CP deprescribing intervention by their GP.~2. After the encounter, the patients will go to the pharmacy to get their medication dispensed. They will be given education materials. The pharmacist will plan with the patients 3 Motivational Interviews which will address the risks of using BZDR, and the benefits and modalities of stopping them. The pharmacists will receive a 2-day training course in MI. They will be given guidelines on BZDR deprescribing. If required, the pharmacists will be supported in their first MI.~3. Following each interview, the pharmacist will inform the GP by means of a formalized report of the points discussed. The pharmacist will inform the GP of the patient's choice or not to get involved in a deprescribing process and of the protocol followed. The objective of this exchange is to formalize the joint GP-CP intervention and to secure the deprescribing of BZDR."
224262618|NCT03676634|BIOLOGICAL|rBV A/B|Recombinant Botulinum Vaccine A/B, rBV A/B
224262619|NCT02730650|OTHER|Platelet Rich Therapy (PRT)|Platelet Rich Therapy (PRT) involves injection of patient's own platelets and fibrin.Topical anesthetic will be applied to the face for a period of fifteen minutes prior to the injection. For PRP preparation, 8 cc of blood will be collected from each patient just before each procedure. Approximately 0.3-0.4 cc of PRP will be injected into each standardized injection point in a superficial manner. The injections points are 6 points on each side of the face along the inferior border of cheek and mid-cheek (12 total). The PRP injection will be followed by 10-15 minutes of icing.
224262620|NCT02121067|DRUG|Levonorgestrel Intrauterine System (LNG-IUS)|The LNG-IUS will be inserted at two-weeks postpartum (day 14-20 postpartum) in all 50 women enrolled
224262621|NCT04873063|DRUG|Beclomethasone dipropionate|BDP 3 mg bid (R product) BDP 6 mg qd (T product)
223682919|NCT04932070|DIETARY_SUPPLEMENT|Berberine|2 daily oral doses (one before lunch and one dinner) of 550 mg of berberine tablets
223682920|NCT02554851|DRUG|recombinant human Epidermal Growth Factor (rhEGF)|The Heberprot-P® is a parenteral formulation, which is in a lyophilized powder vial presentation containing 75μg of recombinant Epidermal Growth Factor (rhEGF) for local application (intralesional) with the therapeutic potential to promote granulation and wound healing of DFU. The rhEGF is a polypeptide of 53 amino acids and has the ability to stimulate fibroblasts, keratinocytes and vascular endothelial cells proliferation. Then it contributes to its properties in scar tissue formation. The action mechanism is based on the interaction with specific receptors located on specifics cell membranes. The rhEGF was developed through recombinant DNA technology and it has been produced by biotechnological methods in Saccharomyces cerevisiae yeast line.
223682921|NCT02554851|OTHER|Placebo|This group will receive the standard medication and the placebo drug. The placebo drug has the same formulation, except for the fact that it does not contain the recombinant human Epidermal Growth Factor (rhEGF).
223682922|NCT02481427|PROCEDURE|Unicondylar Knee Replacement|UKA involves only the replacement of affected medial compartment. In the study, the operation will be performed through standard medial parapatellar incision with midline skin incision, but the knee joint and fascia will be opened like in standard Oxford minimally invasive incision. The procedure will be performed by using Oxford Microplasty instrumentation and following Microplasty surgical technique (Biomet Orthopedics). Intraoperative local infiltration analgesia is used for postoperative pain management. Drain is not used.
223682923|NCT02481427|PROCEDURE|Total Knee Replacement|TKA is performed through a standard medial parapatellar incision, which provides easy access to the knee joint. Skin incision is done to midline. Intramedullary guide is used for alignment of femoral and tibia saw cuts and component positions. Components will be cemented in position. The patella will not be resurfaced. Intraoperative local infiltration analgesia (LIA) is used for postoperative pain management. Drain is not used.
223682924|NCT02909803|OTHER|Lentil Variety|Participants will consume 8 varieties of lentils that are cooked by boiling
223682925|NCT02909803|OTHER|White Bread|Participants will consume white bread on at least two different test days
223774727|NCT00030589|DRUG|bexarotene|
223774728|NCT00030589|DRUG|methoxsalen|
224262622|NCT03799874|DRUG|Inhaled Carbon Monoxide at 200 ppm|Inhaled Carbon Monoxide at 200 ppm for 90 minutes daily for 3 days.
224262623|NCT03799874|OTHER|Inhaled Medical air|Inhaled Medical Air for up to 90 minutes daily for 3 days.
224325892|NCT07106762|DRUG|Iza-bren|Specified dose on specified days
223682926|NCT03787563|DRUG|Herbal Tea|All participants will be given the intervention in an infusion tea bag. Participant will be instructed to take one tea bag three times a day at before breakfast, lunch and dinner meals. At the time of randomization both active and placebo infusion bag will be provided.There will be one day of washout period after 2 days on treatment.
223682927|NCT03787563|DRUG|Placebo Tea|Similar looking inert placebo tea.
224325893|NCT07106762|DRUG|Cisplatin|Specified dose on specified days
224325894|NCT07106762|DRUG|Gemcitabine|Specified dose on specified days
224325895|NCT07106762|DRUG|Carboplatin|Specified dose on specified days
224325896|NCT05497778|DRUG|Gemcitabine|Given by IV (vein)
224325897|NCT05497778|DRUG|Nab paclitaxel|Given by IV (vein)
224325898|NCT05497778|DRUG|IM156|Given by PO
224325899|NCT07112378|DRUG|dupilumab|Administered as defined in the protocol
224325900|NCT04837118|OTHER|Educational Intervention|Receive handouts containing dietary recommendations
224325901|NCT04837118|OTHER|Quality-of-Life Assessment|Ancillary studies
224325902|NCT04837118|OTHER|Questionnaire Administration|Ancillary studies
224325903|NCT04837118|OTHER|Resistance Training|Participate in a resistance training program
224325904|NCT06919874|BEHAVIORAL|Thinking out Loud Session|Participants will complete one thinking out loud session (approx. 60 minutes). The session will be led by a yoga therapist (see below) either in person at the hospital or via Zoom. Individual patients, caregivers or patient-caregiver dyads will attend the session. Each participant will need to either bring their own device or will use an institutional loaner device if no personal device is available. During the session, participants will be asked to download the app from the device appropriate app store and open the app. Then, we will implement the thinking out loud methods asking participants to continuously think out loud, meaning verbalizing their thoughts as they move through the user interface of the app. The sessions will be audio recorded with permission obtained during the consent process. Specific feedback will be requested using a semi-structured interview approach
224325905|NCT07109726|DRUG|TER-2013|Oral Capsules
224325906|NCT07109726|DRUG|Fulvestrant injection|Fulvestrant 500 mg Intramuscular Injection
224325907|NCT07116525|DEVICE|Paddle-Shaped, High-Density, Multi-Electrode Mapping Catheter|High-density, multi-electrode mapping catheter will be used for the procedure.
224325908|NCT06130553|DRUG|AZD3470|AZD3470 is a novel, potent and selective, second-generation, MTAP-selective, inhibitor of PRMT5.
224325909|NCT05554393|DRUG|Azacitidine|Given IV or SC
224325910|NCT05554393|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
224325911|NCT05554393|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
224325912|NCT05554393|DRUG|Cytarabine|Given IV
224325913|NCT05554393|DRUG|Daunorubicin Hydrochloride|Given IV
224325914|NCT05554393|DRUG|Venetoclax|Given PO
224325915|NCT06920043|DRUG|Efimosfermin|Efimosfermin will be administered as a subcutaneous injection.
224325916|NCT06920043|DRUG|Placebo|Placebo will be administered as a subcutaneous injection.
224325917|NCT06918119|DEVICE|Transcutaneous stimulation|DS8R (Digitimer LLC) for transcutaneous neurostimulation.
224325918|NCT07116434|BEHAVIORAL|Discovery Program|"The Discovery Program is a novel, hybrid intervention specifically designed to address the psychosocial barriers faced by adolescents and young adults with T1D. This intervention integrates three key components:~1. Patient-Reported Measures~2. In-Clinic Collaborative Goal Setting~3. Personalized Mobile Health Communications~The Discovery Program will be delivered over a 3-month intervention period, followed by a 6-month follow-up to assess outcomes. This approach not only aims to improve glycemic control but also seeks to enhance diabetes self-management behaviors, reduce diabetes distress, and build problem-solving skills among participants. The integration of clinical informatics, personalized support, and mobile health technology distinguishes this intervention from traditional diabetes care practices, which often overlook psychosocial factors affecting health outcomes."
224325919|NCT06923137|DRUG|BNT162b2|BNT162b2
224325920|NCT06923072|DRUG|Baricitinib|Participants will be instructed to take baricitinib 4mg oral daily for 24 weeks (with or without food)
223682928|NCT05646472|DIAGNOSTIC_TEST|Frailty multidimensional assessment|"Each Centre will administer SUNFRAIL frailty assessment tool to the enrolled older adults and, according to the specific alerts triggered by the answers provided, older adults will be subjected (at the same time or subsequently) to one or more validated in-depth tests (already included in the SUNFRAIL+ platform) in order to perform further diagnostic or dimensional evaluations.~During the observation phase, subjects will be given different health promotion activities, depending on the assessment.~During the follow-up phase, 6 months after enrolment, SUNFRAIL tool and in-depth tests will be administered again. In addition, during the follow up, the extent to which exposure to interventions has influenced the quality of life of older adults will be measured and the number of users enrolled by territorial services, based on user care needs. In addition, the level of satisfaction and usability of the SUNFRAIL+ solution by health and social care professionals will be measured."
223682929|NCT04856865|BIOLOGICAL|Low dose ADP101|Active powder formulation
223682930|NCT04856865|BIOLOGICAL|High dose ADP101|Active powder formulation.
224325921|NCT06920992|BEHAVIORAL|Working memory and set-switching tasks|A behavioral task that requires subjects to switch between stimulus- response contingencies based on a colored contextual cue. In addition, a behavioral task that requires subjects to memorize a set of visual stimuli. Subjects will then be presented with a test set and will be asked to indicate whether any stimulus therein is not part of original memorized set.
224325922|NCT07118839|DRUG|Full Dose MDMA|3 MDMA dosing (Experimental) sessions: Session 1 - 80mg to 120mg MDMA HCl; Session 2 - 80mg to 180mg MDMA HCl; Session 3 - 80mg to 180mg MDMA HCl
224325923|NCT07118839|BEHAVIORAL|MDMA-AT|inner-directive psychotherapy will be conducted throughout the study; Lykos Therapeutics MDMA-AT Manual
224325924|NCT07118839|DRUG|Active Placebo Dose MDMA|3 MDMA dosing (Experimental) sessions in which participants will receive 40mg MDMA HCl max at each session.
224325925|NCT06915753|DRUG|TYRA-430|Oral TYRA-430 given daily.
224325926|NCT06932562|DRUG|Linvoseltamab|Administered per the protocol
224325927|NCT06932562|DRUG|Daratumumab|Administered per the protocol
224325928|NCT06932562|DRUG|Lenalidomide|Administered per the protocol
224325929|NCT06932562|DRUG|Dexamethasone|Administered per the protocol
224325930|NCT06932029|BEHAVIORAL|SMBP with clinical pharmacist support|Self-measured blood pressure with clinical pharmacist support
224325931|NCT06915766|DRUG|Bezuclastinib|Drug: Bezuclastinib Tablets
224325932|NCT07121959|DRUG|Metformin|Oral Tablet
224325933|NCT07121959|DRUG|Belzutifan|Oral Tablet
224325934|NCT07133191|COMBINATION_PRODUCT|Selatogrel|"Selatogrel is a reversible P2Y12 receptor antagonist for subcutaneous administration.~A single dose of 16 mg selatogrel will be administered as a liquid formulation from a sealed prefilled syringe in an autoinjector forming an integral ready-to-use, single-dose drug delivery system."
224325935|NCT07133191|COMBINATION_PRODUCT|Matching placebo|A single dose of placebo will be administered as a liquid formulation from a sealed prefilled syringe in an autoinjector forming an integral ready-to-use, single-dose drug delivery system.
224325936|NCT05125952|DEVICE|Viasys Avea Ventilator|Measuring dynamic airway driving pressure and static airway driving pressure during pressure support breath, and static airway driving pressure during a volume control breath. Measuring airway occlusion pressure during pressure support breath.
224325937|NCT05125952|DEVICE|Philips Respironics NM3 device|Measuring static airway driving pressure during pressure support breath
224325938|NCT05125952|DEVICE|Servo U ventilator|Measuring static airway driving pressure and p0.1 during pressure support breath.
224325939|NCT05125952|DEVICE|Vyaire SmartCath adult nasogastric tube with Esophageal balloon|Measuring static and dynamic esophageal driving pressure during pressure support breath, and esophogeal pressure change during airway occlusion maneuver.
224325940|NCT06934889|DRUG|ERAS-801|will be administered orally at the assigned dose once daily starting on Cycle 1 Day 1.
223682931|NCT04856865|BIOLOGICAL|Pooled Placebo|Placebo powder
223682932|NCT02982785|BEHAVIORAL|Standard post-operative rehabilitation|
223682933|NCT01163032|DRUG|tasimelteon|20 mg tasimelteon capsules, PO daily for 6 months
223682934|NCT01163032|DRUG|Placebo|Placebo capsules, PO daily for 6 months
224262624|NCT05446519|BEHAVIORAL|Survey|Survey is proposed to all pilots who are members of the National Union of Airline Pilots
223682935|NCT00728767|OTHER|Brief intervention|"The intervention consists of a brief conversation based on the principles of motivational interviewing, including Rollnicks scales to assess the motivation and importance for change. The intervention has duration of about 10 minutes and qualifies as a hybrid between a minimal intervention and a brief intervention.~The intervention also consists of two leaflets ('Good advice about drinking less' and 'Learn more about alcohol') on the harmful in having an alcohol above recommended limits, and a sheet about local alcohol treatment possibilities.~The Intervention group is also offered a brief telephone follow up call 4 weeks later. The purpose of this is to maintain the participant's motivation to reduce drinking.~Employees had been instructed to ask these questions during the intervention: What are you already doing to restrain your drinking? And What can you do more?"
223682936|NCT00728767|OTHER|Control group|The intervention consists of two leaflets ('Good advice about drinking less' and 'Learn more about alcohol') on the harmful in having an alcohol use above the recommended limits, and a sheet about local alcohol treatment possibilities.
223682937|NCT04119154|DIAGNOSTIC_TEST|Contrast Microhalography (CEM)|Fine needle aspirates evaluated by CEM device
223682938|NCT00766961|PROCEDURE|Trans-catheter arterial embolization|Trans-catheter arterial embolization
223682939|NCT00766961|PROCEDURE|Surgery|Surgery
223682940|NCT01464723|DRUG|Ranibizumab|Intravitreal injections of 0.5 mg ranibizumab administered monthly for the first 4 months, and then as needed for a total duration of 12 months.
223682941|NCT03127787|DIAGNOSTIC_TEST|CMV Assay|Molecular diagnostic test to detect CMV
223682942|NCT02306499|PROCEDURE|ICSI|Intracytoplasmic Sperm Injection
224262625|NCT02216981|BEHAVIORAL|Cognitive Behavioural Therapy (CBT)|
224262626|NCT05152745|OTHER|Placebo OGGT|"After overnight fasting, blood glucose level was assessed through a capillary drop blood The control group participants ingested glucose solution alone (OGTT) prepared with 75 g of anhydrous oral glucose as prescribed by the ADA, dissolved in 200 ml of water. Blood glucose level was also measured at 30 (t30), 60 (t60), 90 (t90) and 120 (t120) minutes immediately after intervention, for each participant, in control and intervention groups.~Glucometer equipment, strips for glucose meters (One Touch Select Plus) and sterilized lancets (Sarstedt normal 21G) were used to measure blood glucose concentrations, taking due care of safety and asepsis."
224262627|NCT05152745|OTHER|Ginger aqueous extract|"After overnight fasting, blood glucose level was assessed through a capillary drop blood The intervention group participants ingested glucose solution alone (OGTT) prepared with 75 g of anhydrous oral glucose as prescribed by the ADA, dissolved in 200 ml of water, followed by 100mL of ginger extract (0.2g). Blood glucose level was also measured at 30 (t30), 60 (t60), 90 (t90) and 120 (t120) minutes immediately after intervention, for each participant, in control and intervention groups.~Glucometer equipment, strips for glucose meters (One Touch Select Plus) and sterilized lancets (Sarstedt normal 21G) were used to measure blood glucose concentrations, taking due care of safety and asepsis."
224262628|NCT05950919|OTHER|TASKPEN|"The package of integrated HIV/NCD services:~1. Integrated non-communicable/HIV care (one stop shop for services)~2. WHO PEN protocols, algorithm, \& training materials adapted for Zambia~3. Access to cardio-metabolic condition screening \& laboratory monitoring~4. Non-communicable disease-focused electronic medical record module~5. Strengthened NCD medication supply chain"
224325941|NCT06934889|DRUG|ABBV-637|will be administered intravenously over one hour (+/- 10 min) once every 28 days on the first day of the new cycle.
224325942|NCT06934889|DRUG|ABBV-155|will be administered intravenously over at least 30 minutes once every 21 days on the first day of the new cycle.
224325943|NCT06934889|DRUG|Temozolomide|Temozolomide will be continued for 6 cycles after radiation.
224325944|NCT06934889|RADIATION|Radiotherapy|will be given as per standard of care radiation for GBM
224325945|NCT06933329|DRUG|Zelenectide pevedotin (BT8009)|Participants will receive zelenectide pevedotin on Days 1, and 8 of every 21-day cycle.
224325946|NCT07094061|DEVICE|fMRI|Participants will have an MRI to scan participants brains and will wear skin conductance electrodes on the hand and fill out questionnaires. Scanning will take approximately 90 minutes. While lying in the scanner, participants will be asked to perform some tasks. The tasks will be presented to participants visually on a screen in the scanner and eye movements will also be tracked during some of these tasks. Participants will respond to stimuli with button presses that are recorded by computer.
224325947|NCT07094061|BEHAVIORAL|Questionnaires and surveys|Participants will have multiple visits during this study and fill out various surveys at these visits.
223682943|NCT06243627|OTHER|Sunscreen C Color 2.0 SPF 70|Sunscreen C color 2.0 SPF 70 will be applied topically on half of the face.
223682944|NCT06243627|OTHER|Sunscreen C Color 3.0 SPF 70|Sunscreen C color 3.0 SPF 70 will be applied topically on half of the face.
223682945|NCT06243627|OTHER|Sunscreen M Very Light SPF 50|Sunscreen M very light SPF 50 will be applied topically on half of the face.
223682946|NCT06243627|OTHER|Sunscreen M Golden Color SPF 50|Sunscreen M golden color SPF 50 will be applied topically on half of the face.
223682947|NCT06288373|DRUG|Camrelizumab|Camrelizumab is administered at 200mg, q3w (second and third cycles) before radical surgery
223682948|NCT06288373|DRUG|Cisplatin|Cisplatin：75-80mg/m2, D1-D2，q3w (3 cycles)，intravenous infusion, administered at a rate of 1mg/min.
223682949|NCT06288373|DRUG|Nab paclitaxel|Nab paclitaxel: 260 mg/m2，D1，q3w （3 cycles），intravenous infusion, administered over 30min.
223682950|NCT06288373|PROCEDURE|Radical surgery|Radical surgery
223682951|NCT06288373|RADIATION|external beam radiation therapy (EBRT) + brachytherapy|Radiation therapy per standard of care
223682952|NCT06288373|DRUG|Cisplatin|Chemotherapy administered concurrent with radiation therapy，cisplatin 40 mg/m2 IV once per week (QW) for 5 weeks
224262629|NCT03713866|DIAGNOSTIC_TEST|EP Imaging and Testing|"Magnetic Resonance Imaging: pre-procedure imaging is standard care prior to catheter ablation procedures for VT to document anatomy of the heart.~120-Lead Body Surface Mapping: a 120-lead ECG will be recorded using a standardized mapping protocol. 120 disposable radiolucent silver chloride (Ag/AgCl) surface electrodes will be placed on the torso in 18 strips and connected via cables to an advanced acquisition system.~Noninvasive programmed stimulation (NIPS) study will be performed using the patient's implanted defibrillator, and is part of standard practice during a VT catheter ablation."
224262630|NCT03104231|OTHER|three-dimensional (3D) movie|Brief VR-3D will be shown using the oculus glasses and a smartphone. Then, patients will be asked several questions from the prepared questionnaire.
224262631|NCT04837469|PROCEDURE|fissure sealant application|fissure sealants were placed after differnt adhesive strategies used
224262632|NCT02188628|DEVICE|H-Man|H-man is a portable end-effector planar upper limb robot.
224262633|NCT02188628|OTHER|Additional Conventional Therapy|Repetitive goals based arm therapy
224262634|NCT04367519|DIAGNOSTIC_TEST|Ultrasound measurement of Optic nerve sheath diameter|Ocular ultrasonography was performed with the patients placed in supine position with closed eyes. A layer of ultrasound gel was applied over the closed upper eyelid and the liner high frequency probe 7 - 12 MHz of SonoSite M-Turbo ultrasound machine was placed on the temporal area of the eyelid with the hand holding it resting on the forehead of the patient. The probe is then adjusted to a suitable angle in order to display the entry of the optic nerve into the globe. ONSD is then measured 3mm behind the globe in the transverse plane perpendicular to the optic nerve. For each eye one measurement will be made and the reported ONSD corresponds to the mean of the two values obtained for each patient. it was performed for all enrolled parturients within 24 hour before delivery and at 24 hour post-delivery.
224262635|NCT05780463|DRUG|MP0420|MP0420 is a multi-valent DARPin® molecule (designed ankyrin repeat protein), consisting of 5 DARPin® domains.
224262636|NCT05780463|DRUG|Placebo|Commercially available 0.9% sodium chloride solution
224262637|NCT05780463|BIOLOGICAL|Remdesivir|Antiviral agent
224262638|NCT01724463|OTHER|Severe Sepsis Management Bundle|"Management Bundle includes:~1. Securing Intravenous Access~2. Obtaining Blood Culture~3. Antibiotic Administration~4. Goal Directed Fluid Bolus Therapy~5. Oxygen Administration~6. Measuring Serum Lactate Levels"
224262639|NCT05921981|BEHAVIORAL|Multisensorial Stimulation|Multisensory stimulation in newborns involves the deliberate and simultaneous activation of multiple sensory modalities to provide sensory experiences that promote development and enhance learning. Newborns are naturally inclined to explore and make sense of their environment through their senses, including touch, sight, sound, taste, and smell.
224262640|NCT05921981|BEHAVIORAL|White Noise|White Noise
224262641|NCT03131895|DRUG|30 mg dexlansoprazole capsules manufactured at TOB|Dexlansoprazole delayed-release.
224262642|NCT03131895|DRUG|30 mg dexlansoprazole capsules manufactured at TPC|Dexlansoprazole delayed-release.
224262643|NCT03131895|DRUG|60 mg dexlansoprazole capsules manufactured at TOB|Dexlansoprazole delayed-release.
224262644|NCT03131895|DRUG|60 mg dexlansoprazole capsules manufactured at TPC|Dexlansoprazole delayed-release.
224262645|NCT01969123|DRUG|Drug: EVP-6124|
224262646|NCT01969123|DRUG|Placebo|
224262647|NCT05968638|OTHER|Regular Diet|Regular Diet
224262648|NCT05968638|OTHER|Ketogenic Diet|Ketogenic Diet
224262649|NCT01146223|OTHER|laboratory biomarker analysis|Correlative studies
224262650|NCT00540423|DRUG|SB-497115-GR 12.5mg|SB-497115-GR 12.5mg tablet once a day
224262651|NCT00540423|DRUG|SB-497115-GR 25mg|SB-497115-GR 25mg tablet once a day
224262652|NCT00540423|DRUG|SB-497115-GR 12.5mg matching placebo|SB-497115-GR 12.5mg matching placebo x1 or 2 tablet once a day
224262653|NCT00540423|DRUG|SB-497115-GR 50 mg|SB-497115-GR 25mg tablet x2 once a day
224262654|NCT04077645|BEHAVIORAL|Sun salutations|This group will be asked to participate in 25 minutes of low-to-moderate intensity Yoga. This acute session will include engaging in sun salutations, breathing exercises and relaxation. Sun salutations involves performing 10 postures in a particular sequence, and then repeating that sequence. Some of the positions include bending over and touching one's toes, and lying belly-down on the ground and pushing up from ground while arching backwards. The activity will begin as a low intensity activity for the first 5 minutes, and the intensity will be gradually increased. Participants' heart rate will be measured before and after the intervention. The intervention will be delivered by a video displayed on a tablet device. An orientation session in the beginning will familiarize participants with the activity.
224325948|NCT07094061|BEHAVIORAL|Behavioral tasks and eye tracking|Participants will perform behavioral tasks while having eye-tracking hardware monitor participants eye movements. A video camera will be used to record eye movements during the behavioral tasks.
224325949|NCT06934239|DEVICE|Artificial intelligence (AI) decision-support tool|"The intervention is an AI decision-support tool to help radiologists interpret 3D screening mammograms. For exams randomized to this intervention arm, the first image displayed to the radiologist upon opening an exam on the viewing station will be a one-page, standardized AI report showing the overall exam risk (elevated, intermediate, or low), image region markings, lesion scores from 1-100 (100 being the highest suspicion), bounding boxes, and relevant slice locations for 3D exams. Radiologists can toggle markings on/off and retain full control over the final interpretation of the exam as positive or negative (i.e., they can choose to ignore the AI information).~Randomization occurs 1:1 at the exam level via automated code at image acquisition. Returning patients in year two will be re-randomized. Radiologists cannot filter their exam lists by AI availability or risk, and randomization will be independently managed at each participating health system."
224325950|NCT06169852|DEVICE|Unilateral dual-target (STN/GPi) DBS|Participants will be randomly assigned either DBS stimulation in the STN alone, GPi alone, or a combination of stimulation in the STN and GPi.
224325951|NCT07141706|DRUG|DB-1317|Administered I.V.
224325952|NCT06931405|DRUG|BLU-808|Oral administration
224325953|NCT06931405|DRUG|Placebo|Oral administration
224325954|NCT06508021|DRUG|Andecaliximab|Dose level A or B
224325955|NCT06508021|DRUG|Placebo|Blinded
224325956|NCT06508021|DRUG|Andecaliximab|Dose level A or B (or age adjusted dose)
223682953|NCT02750215|DRUG|Capmatinib (INC280)|treatment with Capmatinib (INC280)
223682954|NCT04599179|DEVICE|self-expandable metal stent|self-expandable metal stent endoscopic positioning
223682955|NCT01700868|OTHER|Vegan diet|A diet devoid of any animal products. Low-fat, low-Glycemic Index, vegan diet.
223682956|NCT01700868|OTHER|American Diabetes Association guidelines|Participants will follow individualized diet plans following ADA guidelines
223682957|NCT03248700|OTHER|Vitamin A tracer|A stable isotope tracer of vitamin A was given orally.
223682958|NCT02192840|PROCEDURE|Coronary angioplasty with stent implantation|Coronary angioplasty in bifurcation lesion with drug-eluting stent implantation: BiOSS or regular DES (rDES)
223682959|NCT01307020|DRUG|Dexketoprofen Trometamol|Dexketoprofen Trometamol low dose, oral film-coated table, once
223682960|NCT01307020|DRUG|Dexketoprofen Trometamol|Dexketoprofen Trometamol high dose, oral film-coated table, once
223682961|NCT01307020|DRUG|Tramadol Hydrochloride|Tramadol Hydrochloride low dose, oral film-coated table, once
223682962|NCT01307020|DRUG|Tramadol Hydrochloride|Tramadol Hydrochloride high dose, oral film-coated table, once
223682963|NCT01307020|DRUG|Ibuprofen|Ibuprofen 400 mg, oral film-coated table, once
223774729|NCT00030589|PROCEDURE|UV light therapy|
223774730|NCT04557722|PROCEDURE|0-30° Biplanar Fluoroscopic Puncture Techniques for Percutaneous Nephrolithotomy|after retrograde instillation of contrast through the ureteric catheter; the puncture of the desired calyx by using the 0-30 degree technique of C-Arm.
223774731|NCT04557722|PROCEDURE|New 0-90° Fluoroscopic Puncture Techniques for Percutaneous Nephrolithotomy|after retrograde instillation of contrast through the ureteric catheter; the puncture of the desired calyx by using the 0-90 degree technique of C-Arm.
224325957|NCT06934135|DEVICE|Bilateral Near-Infrared Transcranial Photobiomodulation (tPBM)|The system delivers 808 nm near-infrared light via fiber optics through a headset forming \~12 cm² beams at EEG sites AF3/AF4 (dorsolateral prefrontal cortex). Participants are randomized to: (1) Continuous Wave (CW, high dose) \~350 mW/cm² (\~8.4 W total); (2) Continuous Wave Low Dose (CW\_LOW) \~50 mW/cm² (\~1.2 W); (3) Pulsed Wave (PW) peak \~1050 mW/cm², 42 Hz, 33% duty cycle (avg \~350 mW/cm²); or (4) Sham device with identical cues but no light. Sessions last 429 s, 3×/week for 6 weeks (18 total). Sham matches duration/procedures. Outcomes include depressive symptoms (HAMD-17, QIDS, SDQ), FDG-PET, and EEG.
224325958|NCT06508320|BIOLOGICAL|mRNA-1083|IM injection in a deltoid muscle.
224325959|NCT06172478|DRUG|HER3-DXd|Intravenous infusion 5.6 mg/kg administered Q3W on Day 1 of each 21-day cycle
224325960|NCT06935097|BEHAVIORAL|Mediterranean diet-based Intervention|"Through existing collaboration with the Harris Health system's innovative food pharmacy, participants will be provided fresh fruit, vegetables and other foods every other week during the study.~Participants will receive olive oil and walnuts during the 8 week intervention (consistent with the PREDIMED6 intervention) to supplement their (and their families') diet during the 8-week intervention (while personalized education about diet, food choices and preparation is still occurring)."
224325961|NCT06939361|OTHER|Smaller endotracheal tube|"* Inner diameter 7.0 mm (for patients with a height ≥ 64 inches)~* Inner diameter 6.5 mm (for patients with a height \< 64 inches)"
223682964|NCT01307020|DRUG|Placebo|Placebo, oral film-coated table, once
223682965|NCT01307020|DRUG|Dexketoprofen Trometamol + Tramadol Hydrochloride|DKP-TRIS low dose - TRAM.HCl low dose, oral film-coated table, once
223682966|NCT01307020|DRUG|Dexketoprofen Trometamol + Tramadol Hydrochloride|DKP-TRIS low dose - TRAM.HCl high dose, oral film-coated table, once
223682967|NCT01307020|DRUG|Dexketoprofen Trometamol + Tramadol Hydrochloride|DKP-TRIS high dose - TRAM.HCl low dose, oral film-coated tablet, once
223682968|NCT01307020|DRUG|Dexketoprofen Trometamol + Tramadol Hydrochloride|DKP-TRIS high dose - TRAM.HCl high dose, oral film-coated tablet, once
223682969|NCT00000750|DRUG|Zidovudine|
223682970|NCT02380690|BEHAVIORAL|Peer Coach Assignment|Veterans will be assigned a peer coach to meet with for 6 months to discuss pain self-management.
223682971|NCT04673279|DIAGNOSTIC_TEST|serology|An enzyme linked immunosorbent assay (ELISA) developed and validated in Argentina which detects antibodies against two viral antigens, trimeric spike and the receptor binding domain (RBD) of the spike protein.
223682972|NCT03343418|DRUG|Desmopressin|Desmopressin is to be administered as an intravenous infusion after discontinuation of cardiopulmonary bypass and administration of protamine. Subjects are to be given desmopressin 0,3 microgram.kg-1. After desmopressin infusion, bleeding treatment will follow the predefined standardized treatment regimen.
223774732|NCT04593992|DEVICE|HTEMS|high-tone external muscle stimulation
223774733|NCT04593992|DEVICE|Placebo|Placebo stimulation
223774734|NCT01690403|DRUG|rifapentine (M000473)|"Pharmaceutical form:tablet~Route of administration: oral"
223774735|NCT01690403|DRUG|EFZ EMT TDF|"Pharmaceutical form:tablet~Route of administration: oral"
223682973|NCT03343418|DRUG|Placebo|0.9% saline is to be administered as an intravenous infusion after discontinuation of cardiopulmonary bypass and administration of protamine. Patients randomized to the control group will receive the infusion of 100 milliliters (mL) 0.9% saline (SF0,9%). After 0.9% saline infusion, bleeding treatment will follow the predefined standardized treatment regimen.
223682974|NCT02553668|DRUG|Oxygen (FiO2 1,0)|Participants will inhale Oxygen (FiO2 1,0) via Facemask for 3 hours.
223682975|NCT02553668|DEVICE|Facemask|
223682976|NCT04413227|DRUG|Pegylated Recombinant Human Endostatin（PEG-ENDO）|PEG-ENDO 1 mg/kg or 2 mg/kg or 4 mg/kg or 6 mg/kg or 8 mg/kg+Docetaxel 75 mg/m2，once every 3 weeks at day 1
223682977|NCT04045418|DEVICE|Laser doppler|"A laser doppler flowmetry will be used to measure the microcirculatory characteristics of meridian phenomena. The probes will be left at relevant measuring sites. Blood flow curve and Perfusion units (PU ) will be recorded constantly.~1. Healthy control group and COPD group The probes will be left at Shenmen (HT7) and Shaohai (HT3) of the Heart meridian, Taiyuan (LU9) and Chize (LU5) of the Lung meridian for 5 minutes.~2. Healthy intervention group Two sessions of moxibustion will be performed in the Heart meridian and Lung meridian successively."
223682978|NCT00727532|DRUG|Sorafenib|400mg by mouth twice daily for 28 consecutive days
223682979|NCT00829933|DRUG|DU-176b tablets|DU-176b tablets taken once daily for up to 12 weeks
223682980|NCT00829933|DRUG|Warfarin potassium tablets|Warfarin potassium tablets taken once daily for up to 12 weeks
223682981|NCT02311218|DIETARY_SUPPLEMENT|Lactobacillus reuteri DSM 17938 and PTA 5289|Subjects in the test group are given one lozenges with Lactobacillus reuteri DSM 17938 and PTA 5289 in the morning and one in the evening
224262655|NCT04077645|BEHAVIORAL|Aerobic exercise|This group will be asked to walk on the treadmill for the same amount of time (i.e. 25 minutes) at a moderate intensity (50-70% of their maximum heart rate). Participants will receive an initial 5-minute orientation and then begin at a self-selected speed for the first 5 minutes. Heart rate will be measured and monitored by an undergraduate research assistant. Speed will be increased after 5 minutes if participants have not reached the moderate zone. If participants still have not reached the target heart rate zone by the 10-min mark, the incline of the treadmill will be increased by a 5% grade until the zone is reached.
223682982|NCT02311218|DIETARY_SUPPLEMENT|Placebo|Placebo lozenges with no Lactobacillus reuteri DSM 17938 and PTA 5289
224262656|NCT04077645|BEHAVIORAL|Seated rest|This group will be watching educational videos for the same amount of time as the intervention groups. An orientation session of 5 minutes will be held in the beginning. Participants will be watching videos on general health related topics, such as healthy eating, while being seated in a quiet room, free of distractions.
224262657|NCT06497972|OTHER|White bread (control, 32 grams, 14.4 grams of carbohydrate)|32 grams of white bread, providing 14.4 grams of carbohydrate, which was incorrectly dosed and matched only half the carbohydrate in the rice cakes.
224262658|NCT06497972|OTHER|Brown rice cake|A 40g rice cake made of 100% brown rice (providing 31 grams of carbohydrate)
224262659|NCT06497972|OTHER|Wild rice (25%) and brown rice (75%) cake|A 40g rice cake made of a blend of 25% wild rice and 75% brown rice (providing 31 grams of carbohydrate)
224262660|NCT06497972|OTHER|White bread (control, 66 grams, 31 grams of carbohydrate)|66 grams of white bread, providing 31 grams of carbohydrate, this arm was added after the mistake in the first control dosing was discovered, so this arm was not randomized and was completed after the first three.
224262661|NCT01214590|DEVICE|VascuActive device|self treatment by the patient, for 4 weeks, 3 sessions per day, approximately 30 minutes per session
224262662|NCT02223585|OTHER|Animal-based protein diet|
224262663|NCT02223585|OTHER|Vegan-based protein diet|
224262664|NCT05444647|PROCEDURE|stool and blood collection|Patients will collect fecal and blood samples prior to treatment and at the time of response evaluation, and completion of therapy using a standard stool-collection-kit. At the day of stool sampling, patients fill out a brief questionnaire about established factors that can change the microbiome such concurrent use of antibiotics and proton pump inhibitors.
224262665|NCT01053585|DRUG|Baclofen|Baclofen suspension 40mg (single dose 90 minutes prior to physiologic measurement)
224262666|NCT01053585|DRUG|Placebo|Placebo single 'dose' 90 minutes prior to study
224262667|NCT05333107|DRUG|NNC0385-0434 G|Participants will receive oral dose of NNC0385-0434 G tablet either for the initial 10-day treatment period (period 1) or 5-day treatment period (period 2).
224262668|NCT05333107|DRUG|NNC0385-0434 F|Participants will receive oral dose of NNC0385-0434 F tablet either for the initial 10-day treatment period (period 1) or 5-day treatment period (period 2).
224262669|NCT05333107|DRUG|NNC0385-0434 B|Participants will receive oral dose of NNC0385-0434 B tablet either for the initial 10-day treatment period (period 1) or 5-day treatment period (period 2).
224262670|NCT05837832|DIETARY_SUPPLEMENT|Milk-based phospholipids|Powder based, fat-rich fraction of whey dissolved in water. Contains lactose.
224262671|NCT00360607|DRUG|Magnex (Sulbactam Sodium/Cefoperazone Sodium 1:1) Pfizer Ltd.|
224262672|NCT00360607|DRUG|Fortum (Ceftazidime for injection USP) Glaxo Smith Kline Pharmaceuticals Limited|
224262673|NCT00360607|DRUG|Metrogyl (Metronidazole Injection IP) J.B.Chemicals & Pharmaceuticals Ltd.|
224262674|NCT00360607|DRUG|Mikacin (Amikacin Sulphate Injection IP) Aristo Pharmaceuticals Ltd.|
224262675|NCT02280863|DEVICE|Medtronic Hybrid Closed-loop System - Android Platform|A continuous glucose sensor and insulin delivery system designed for continuous closed-loop control with the PID-IFB (proportional-integral-derivative insulin feed-back) algorithm using an Android controller.
224262676|NCT02280863|DEVICE|Medtronic Hybrid Closed-loop Integrated System|A fully integrated continuous glucose sensor and insulin delivery system designed for continuous closed-loop control with the PID-IFB (proportional-integral-derivative insulin feed-back) algorithm
224262677|NCT00196963|BIOLOGICAL|Meningococcal (vaccine)|
224262678|NCT01326494|DRUG|Arm 1 Oral Cortico Steroids|"Prednisolone: 1 mg / kg per day course of dose for 5 days up to child's weight of 20 kgs.~Dexamethasone: 0.3mg/kg per dose for 3 days (minimum weight 20 kgs )"
224262679|NCT02277093|DRUG|Pacritinib|
224262680|NCT06559878|DIAGNOSTIC_TEST|13C-α-Ketoisocaproic Acid Breath Test|13C-α-Ketoisocaproic acid with L-Leucine soluted in citric acid drink. The solution is administered orally during metabolic visits (3.-5.).
224262681|NCT06559878|DIETARY_SUPPLEMENT|Ethanol|6% ethanol soluted in normal saline is given intravenously during one metabolic visit.
224325962|NCT06939361|OTHER|Larger endotracheal tube|"* Inner diameter 8.0 mm (for patients with a height ≥ 64 inches)~* Inner diameter 7.5 mm (for patients with a height \< 64 inches)"
224325963|NCT06940440|DRUG|IFx-Hu2.0|"Therapeutic Classification:~• Innate immune agonist~Route of Administration:~• Intralesional"
224325964|NCT06940440|DRUG|Pembrolizumab|"Therapeutic Classification:~• Immunotherapy (Immune checkpointinhibitor)~Route of administration:~• Intravenous (IV) infusion"
224325965|NCT06941272|BIOLOGICAL|Patritumab Deruxtecan|IV Infusion
224325966|NCT04419181|DRUG|Docetaxel|Dose: 75 mg/m2 q3w
224325967|NCT04419181|DRUG|Carboplatin|Dose: area under the concentration-time curve \[AUC\] 6 q3w
224325968|NCT04419181|DRUG|Trastuzumab|Dose: 8-mg/kg loading dose, 6-mg/kg maintenance dose q3w
224325969|NCT04419181|DRUG|Pertuzumab|Dose: 840-mg loading dose, 420-mg maintenance dose q3w
224325970|NCT04419181|DRUG|Trastuzumab emtansine|Dose: 3.6mg/kg q3w
224325971|NCT06938867|BIOLOGICAL|SNIPR001 consists of genetically modified bacteriophages specifically targeting Escherichia coli|SNIPR001 is a live biotherapeutic product
224325972|NCT06938867|OTHER|Placebo 10 mL|Placebo 10 mL matching to SNIPR001 will be administered.
224325973|NCT06942936|DRUG|AZD5004|AZD50004 is administered orally as a tablet.
224325974|NCT06942936|DRUG|Itraconazole|Itraconazole is administered orally as a capsule.
224325975|NCT06942936|DRUG|EE/LNG|EE/LNG is administered orally in the form of tablet.
224325976|NCT06940752|DEVICE|VINTAGE (Ventricular Intramyocardial Navigation for Tachycardia Ablation Guided by Electrograms)|Non-surgical catheter approach called VINTAGE will be used to treat ventricular arrhythmias arising from difficult-to-reach portions of the heart.
224325977|NCT03946449|DRUG|ARO-AAT|solution for subcutaneous injection
224325978|NCT01719055|DEVICE|neurostimulation system|Trial stimulation period, followed by permanent implant of a neurostimulation system for subjects with a positive trial outcome
224325979|NCT07146022|DRUG|VDPHL01 QD|VDPHL01 Extended Release (ER) Tablet
224325980|NCT07146022|DRUG|Placebo|Placebo tablet
224325981|NCT07146022|DRUG|VDPHL01 BID|VDPHL01 Extended Release (ER) Tablet
224325982|NCT07146022|DRUG|Placebo|Placebo tablet
224325983|NCT07140913|DRUG|Xanomeline/Trospium Chloride|Specified dose on specified days
224325984|NCT07140913|DRUG|Lithium|Specified dose on specified days
224325985|NCT07140913|DRUG|Valproate|Specified dose on specified days
224325986|NCT07140913|DRUG|Lamotrigine|Specified dose on specified days
224325987|NCT07140913|DRUG|Placebo|Specified dose on specified days
224325988|NCT06611410|DEVICE|Test Lenses (stenfilcon A)|Daily disposable, soft contact lenses worn for one week.
224325989|NCT06611410|DEVICE|Control Lenses (omafilcon A)|Daily disposable, soft contact lenses worn for one week.
224325990|NCT04816604|DRUG|GB002 (seralutinib)|Capsule containing GB002 (seralutinib)
224325991|NCT04816604|DEVICE|Generic Dry Powder Inhaler|Generic dry powder inhaler for GB002 (seralutinib) delivery
224325992|NCT06946550|DEVICE|1470nm non-ablative fractional laser|Patients with scarring alopecia will be treated with the non-ablative Sciton HALO laser (1470nm).
224325993|NCT06946797|DRUG|Nivolumab|Specified dose on specified days
224325994|NCT06946797|DRUG|Ipilimumab|Specified dose on specified days
224325995|NCT06946797|DRUG|Carboplatin|Specified dose on specified days
224325996|NCT06946797|DRUG|Paclitaxel|Specified dose on specified days
224325997|NCT06946797|DRUG|Pemetrexed|Specified dose on specified days
224325998|NCT06946797|DRUG|Cisplatin|Specified dose on specified days
224325999|NCT03634267|RADIATION|Internal Radiation Therapy|Undergo brachytherapy
224326000|NCT03634267|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI scan
224326001|NCT06947928|DRUG|IFx-Hu2.0|"Therapeutic Classification:~• Innate immune agonist~Route of Administration:~• Intralesional"
224326002|NCT06947928|DRUG|Placebo|"Route of Administration:~• Intralesional"
224326003|NCT06947928|DRUG|Pembrolizumab|"Therapeutic Classification:~• Immunotherapy (Immune checkpoint inhibitor)~Route of administration:~• Intravenous (IV) infusion"
224326004|NCT06948097|DRUG|fostamatinib|The study intervention is fostamatinib, administered orally starting at 100 mg daily for 14 days, escalating to 100 mg BID for 14 days, then 150 mg BID for 28 days, based on tolerability. Patients will be monitored for 28 additional days and randomized to receive either fostamatinib or placebo, along with standard of care.
224326005|NCT06948097|DRUG|Placebo|Placebo tablets will match fostamatinib, starting at 100 mg daily for 14 days, escalating to 100 mg BID for 14 days, and then 150 mg BID for 28 days, based on tolerability. Patients will be monitored for an additional 28 days.
223682983|NCT03473457|BIOLOGICAL|CART therapy in Acute myeloid leukemia(AML)|one kind of CD38-CART/CD33-CART/CD56-CART/CD123-CART/CD117-CART/CD133-CART/CD34-CART/Mucl-CART therapy in Acute myeloid leukemia(AML)
223682984|NCT02338336|DRUG|Nowarta110|Nowarta110 contains fig extract as the main drug substance, and colloidal silver is used as a medium for penetration of fig extract into the wart lesion. Liquid for topical administration.
223682985|NCT02338336|DRUG|Placebo|Matching placebo liquid for topic administration.
223682986|NCT01986933|DRUG|nemolizumab (CIM331)|
223682987|NCT01986933|OTHER|Placebo|
223682988|NCT00534261|DRUG|Interferon beta-1a|IM injection
223682989|NCT03119701|DRUG|Interferon Beta-1A|Lyophilisate for solution for injection.
223682990|NCT03119701|DRUG|Placebo|Lyophilisate for solution for injection as placebo.
223682991|NCT02421003|PROCEDURE|heart surgery|
224326006|NCT07148089|DRUG|SGT-501|IV for infusion
224326007|NCT07148128|DRUG|WEF-001|Starting dose of 0.3 mg/m2 q4wks IV, dose escalation
224326008|NCT07149155|BEHAVIORAL|Stress First Aid for Harm Reduction Workers|The intervention was a 2-hour, in-person SFA/HRW training followed by 30-minute monthly learning collaboratives to address occupational stress of harm reduction workers.
224326009|NCT06948838|BEHAVIORAL|RBPM|Standardized blood pressure measurement and treatment protocols in clinical practice.
224326010|NCT06948838|OTHER|MII|Team-based interventions including multiple evidence-proven interventions such as clinician decision support, monitoring medication non-adherence, use of combination pills, and formulary modifications.
223682992|NCT00958490|OTHER|Walking program|4 week physical activity walking program
224326011|NCT03345576|DEVICE|Testosterone and LPWS|Twelve patients will undergo 1 year of supervised training examining the effects of testosterone replacement therapy (TRT) and long pulse width stimulation (LPWS) in persons with denervated spinal cord injury.
224326012|NCT03345576|DRUG|Testosterone and standard NMES|Twelve patients will undergo 1 year of supervised training examining the effects of testosterone replacement therapy (TRT) and standard surface neuromuscular electrical stimulation (NMES) in persons with denervated spinal cord injury.
224326013|NCT06952504|BIOLOGICAL|Pembrolizumab|Intravenous (IV) Infusion
224326014|NCT06952504|DRUG|Carboplatin|During the Induction Phase, participants receive carboplatin AUC 5 (mg/mL/min) on Day 1 of each 3-week cycle for 6 cycles (up to approximately 4 months) via IV infusion.
224326015|NCT06952504|DRUG|Paclitaxel|During the Induction Phase, participants receive paclitaxel 175 mg/m2 on Day 1 of each 3-week cycle for 6 cycles (up to approximately 4 months) via IV infusion.
224326016|NCT06952504|DRUG|Docetaxel|During the Induction Phase, participants may receive docetaxel (in place of paclitaxel) 75 mg/m2 on Day 1 of each 3-week cycle for 6 cycles (up to approximately 4 months) via IV infusion.
224326017|NCT06952504|BIOLOGICAL|Sacituzumab Tirumotecan|IV Infusion
224326018|NCT04172532|PROCEDURE|Biopsy Procedure|Undergo tissue collection
224326019|NCT04172532|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
224326020|NCT04172532|PROCEDURE|Computed Tomography|Undergo CT
224326021|NCT04172532|RADIATION|Hypofractionated Radiation Therapy|Undergo hypofractionated radiation therapy
224326022|NCT04172532|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
224326023|NCT04172532|DRUG|Peposertib|Given PO
224326024|NCT04172532|OTHER|Placebo Administration|Given PO
224326025|NCT07158034|DEVICE|Lenire Device|The Lenire device is a non-invasive stimulation system designed to reduce the symptoms of chronic subjective tinnitus. It includes a controller that is connected to headphones for sound delivery to the ears and a mouthpiece that provides mild electrical stimulation to the surface of the tongue. Users are recommended to use the device for 60 minutes daily, either in two consecutive 30-minute sessions or at different times throughout the day, for a minimum of 36 hours.
224326026|NCT07154615|OTHER|Observational Only|No intervention is included in this study
224326027|NCT07158476|DRUG|Meloxicam 15 mg|PO once/day for 1 week
224326028|NCT07158476|DRUG|Medrol 4 MG Oral Tablet Includes Medrol Dosepak|PO 6 day taper
224326029|NCT07158476|DRUG|Gabapentin 300 mg|PO every 8 hours for 1 week
224326030|NCT07158476|DRUG|Hydrocodone 5Mg/Acetaminophen 325Mg Tab|PO 1-2 tabs every 4 hours as needed (total of 28 pills)
224326031|NCT07158476|DRUG|Ketorolac 10 Mg Oral Tablet|PO every 6 hours for 5 days
224326032|NCT07159490|DEVICE|Standard-of-care prosthetic foot|Widely prescribed prosthetic foot of stiffness category appropriate to the participant's body weight and activity level.
224326033|NCT07159490|DEVICE|Standard-of-care prosthetic foot with heel-stiffening wedge|Widely prescribed prosthetic foot with a wedge inserted between the heel and foot keels intended to stiffen the behavior of the heel.
223682993|NCT05557318|DEVICE|Vaginal swab for RT-PCR|Screening for Bacterial vaginosis (BV) / Trichomonas / Chlamydia trachomatis / Candida albicans
223682994|NCT05557318|DEVICE|Vaginal swab for culture|Screening for Group B streptococcus / Neisseria gonorrhoeae / Escherichia coli
223682995|NCT05557318|DEVICE|Metabolic gas signatures detected by Ainos Flora (operated by participant)|The participant operates the Ainos Flora to collect signatures of metabolic gases in the vagina by herself.
223682996|NCT05557318|DEVICE|Metabolic gas signatures detected by Ainos Flora (operated by medical staff)|The medical staff operates the Ainos Flora to collect signatures of metabolic gases in the participant's vagina.
224326034|NCT07159490|DEVICE|Standard-of-care prosthetic foot of one category greater stiffness|Widely prescribed prosthetic foot of one stiffness category greater than usually prescribed based on the participant's body weight and activity level.
223682997|NCT02866851|OTHER|Monitoring by Web-application|Patients have to log in a web-application every day (from D5) to indicate their temperature and the presence of gravity sign in case of fever.
223682998|NCT02300727|DRUG|Curcumin-MTD|0.33g-3g by ingested mouth wash three times per day for 4-6 weeks until unacceptable toxicity develops- to determine the maximum tolerated does (MTD).
223682999|NCT02300727|DRUG|Mouthwash-standard pharmacy preparation|"Standard mouth wash preparation administered by ingested mouth rinse three times per day.~The standard mouth rinse contains 40% Benadryl, 40% Maalox, and 20% of 1% Viscous Lidocaine."
224326035|NCT07159490|DEVICE|Dual keel prosthetic foot|A prosthetic foot with two forefoot keels intended for load carriage applications.
224326036|NCT07159490|DEVICE|Powered ankle-foot|A powered prosthetic ankle-foot.
224326037|NCT05416307|DRUG|ELA026|Multiple doses of ELA026
224326038|NCT07157787|DRUG|ALXN1920|Participants will receive ALXN1920 SC infusion.
224326039|NCT07157787|DRUG|Placebo|Participants will receive Placebo SC infusion.
224326040|NCT06052306|DRUG|BAY3546828|Intravenous (IV) infusion on Day 1 of each cycle.
224326041|NCT07158814|DRUG|Respiratory Syncytial Virus (RSV) Preventive Monoclonal Antibody|ACIP Recommended Preventive Monoclonal Antibody
224326042|NCT07162038|BIOLOGICAL|mCD19-CAR-CD28-CD3-zeta.(anti-CD19 CAR) retroviral vector-transduced allogeneic peripheral blood lymphocytes (PBL)|CAR-T cell infusion given at four escalating dose levels (DL1: 3 x 10\^4 cells/kg, DL2: 1 x 10\^5 cells/kg, DL3: 3 x 10\^5 cells/kg, DL4: 1 x 10\^6 cells/kg) with a dose de-escalation dose (DL-1: 1 x 10\^4 cells/kg), if needed.
224326043|NCT07162038|DRUG|Fludarabine|Pre-transplant: 30 mg/m\^2 IV infusion over 30-60 minutes once daily for 5 days from day -6 through day -2
224326044|NCT07162038|DRUG|Cyclophosphamide|"Pre-transplant: 14.5 mg/kg/day IV daily for 2 days pre-transplant on day -6 and day -5.~Post-transplant: 25 mg/kg/day on day +3 and day +4."
224326045|NCT07162038|DRUG|Mycophenolate Mofetil|15 mg/kg orally or IV three times daily (max 1000 mg/dose) starting on day +5, continued through day +35 post-transplant.
224326046|NCT07162038|DRUG|Sirolimus|Loading dose of 6 mg orally given on day +5, then maintenance dose starting at 2 mg orally daily on day +6 with dose adjustments to maintain a trough of 5-12 ng/ml, continued through day +60 post-transplant.
224326047|NCT07162038|DEVICE|CD19 Flow Cytometry Assay|Assay used to determine CD19+ status
223683000|NCT02300727|DRUG|Curcumin|After maximum tolerated dose (MTD) is determined, MTD by ingested mouth wash three times per day for 4-6 weeks until mucositis is resolved, disease progression, or unacceptable toxicity develops.
223683001|NCT01952470|DRUG|Dornase Alfa|Once daily, 2.5ml inhaled dornase alfa (evening if able) with inhalational breathing routine (IBR). IBR consists of 4 slow deep breaths followed by 6 relaxed breaths, repeated until nebuliser is complete, coughing when the patient feels the need to expectorate. The patient will be instructed to sit in an upright position with upper limb support as able.
224326048|NCT07162038|DEVICE|CD19 Immunohistochemical Assay|Assay used to determine CD19+ status
224326049|NCT07162038|RADIATION|Total Body Irradiation|400 centigray (cGy) to be delivered in 2 fractions as 200 cGy per fraction twice a day on Day -1 pre-transplant.
224326050|NCT07159828|BIOLOGICAL|AXN-2510|AXN-2510 is an antibody with PD-L1 blocking and VEGF inhibition activity in one drug. This is called a bispecific antibody, because it has 2 activities. This immuno-oncology treatment is in development for the treatment of solid tumors. AXN-2510 is differentiated from other PD-L1 and VEGF bispecific antibodies by its ability to inhibit multiple VEGF molecules and also increased antibody-dependent cellular cytotoxicity (ADCC) that can directly kill PD-L1-positive tumor cells.
224326051|NCT07166120|BEHAVIORAL|Usual care|Usual care will be informed by practice guidelines (standard of care, brief advice, and guideline awareness).
224326052|NCT07166120|BEHAVIORAL|Precision treatment|Precision treatment will be informed by practice guidelines (standard of care, brief advice, and guideline awareness), plus patient-specific risk feedback and personalized tobacco treatment recommendations using patients' clinical, genetic, and biomarker information, adapted for oncology.
224326053|NCT07168356|DRUG|Bepirovirsen|Bepirovirsen will be administered.
224326054|NCT07160244|BIOLOGICAL|Multivalent Group B streptococcus vaccine|Multivalent Group B streptococcus vaccine
224326055|NCT07160244|BIOLOGICAL|Placebo|Saline Control
224326056|NCT07160244|BIOLOGICAL|Infanrix hexa|Vaccine administered in a subset of infant participants as per the national immunization schedule
224326057|NCT07160244|BIOLOGICAL|Prevenar 20|Vaccine administered in a subset of infant participants as per the national immunization schedule
224326058|NCT07160244|BIOLOGICAL|Pediarix|Vaccine administered in a subset of infant participants as per the national immunization schedule
224326059|NCT07160244|BIOLOGICAL|Prevnar 20|Vaccine administered in a subset of infant participants as per the national immunization schedule
224326060|NCT07160244|BIOLOGICAL|Infanrix|Vaccine administered in a subset of infant participants as per the national immunization schedule
224326061|NCT07169630|DRUG|18F-PF974|Injected IV followed by PET scanning
224326062|NCT07169630|DRUG|18F-florbetaben|Injected IV followed by PET scanning
224326063|NCT07170540|DRUG|Cashew sublingual immunotherapy|Glycerinated cashew extract for use in sublingual immunotherapy
224326064|NCT07170540|DRUG|Placebo sublingual immunotherapy|Glycerinated saline for placebo sublingual immunotherapy
223683002|NCT01952470|DRUG|Isotonic Saline.|Once daily, 5ml inhaled 0.9% normal saline (evening if able) with inhalational breathing routine (IBR). IBR consists of 4 slow deep breaths followed by 6 relaxed breaths, repeated until nebuliser is complete, coughing when the patient feels the need to expectorate. The patient will be instructed to sit in an upright position with upper limb support as able.
223683003|NCT03787043|DRUG|FDC(MP-513 10mg/Metformin XR 750mg)|
223683004|NCT00004190|DRUG|gemcitabine hydrochloride|
223683005|NCT00004190|DRUG|oxaliplatin|
223683006|NCT04278274|PROCEDURE|artificial intelligence prediction system|The tumor ROI in the post- neoadjuvant treatment MRI images will be manually delineated, and further subjected to the AI prediction system arm to verify the predictive accuracy of this AI prediction system in identifying the pCR individuals from non-pCR patients with LARC.
223683007|NCT04278274|PROCEDURE|the radiologists|The enrolled patients will be assigned to the trained experienced radiologists to evaluate their predictive accuracy in identifying the pCR individuals from non-pCR patients
223683008|NCT02019901|OTHER|Nurse-led clinic|
223683009|NCT03907839|OTHER|clinical trials|examined two type of training on cognitive parameters for COPD patients
223683010|NCT00663442|DRUG|OROS methylphenidate|18, 36, 54 mg
223683011|NCT04220853|DIAGNOSTIC_TEST|Rhinomanometry in patients after septoplasty and/or turbinoplasty|Rhinomanometry is an examination used to assess changes in resistance and airflow in patients after septoplasty and/or turbinoplasty.
224326065|NCT05101213|BIOLOGICAL|Virus-specific Cytotoxic T-lymphocytes|Given IV
224326066|NCT07178314|DEVICE|Transcutaneous Tibial Nerve Stimulation (TTNS)|Participants will perform self-implemented at-home transcutaneous tibial nerve stimulation using a transcutaneous electrical nerve stimulation (TENS) unit. Participants will be instructed to use the TENS unit to deliver stimulation to the tibial nerve on one ankle for a 30-minute session, three times per week for 12 weeks upon receipt of the device. Intensity will be based on the participant's tolerance, just above the perception threshold but not painful.
224326067|NCT07175025|BEHAVIORAL|Narrative Exposure Therapy (NET)|Narrative Exposure Therapy (NET) is the PTSD intervention for the treatment group.
224326068|NCT07182240|DEVICE|LC-OCT Imaging|handheld imaging device will take high resolution images of lesion
224326069|NCT07173101|DEVICE|Semiconductor embedded headband|"Week 1-3: Participants will be provided with either an active semi-conductor headbands OR a sham headband, absent of semi-conducting fabric. Participants will be instructed to wear them \>18 hours per day and report their daily device usage.~Week 4-5: Washout. Participants will not wear any headbands that were provided.~Week 6-8: Participants who wore sham headbands in intervention A will be provided with active semi-conductor embedded headbands and instructed to wear them \>18 hours per day, and vice versa."
224326070|NCT07173101|DEVICE|Sham Headband|"Week 1-3: Participants will be provided with either an active semi-conductor headbands OR a sham headband, absent of semi-conducting fabric. Participants will be instructed to wear them \>18 hours per day and report their daily device usage.~Week 4-5: Washout. Participants will not wear any headbands that were provided.~Week 6-8: Participants who wore sham headbands in intervention A will be provided with active semi-conductor embedded headbands and instructed to wear them \>18 hours per day, and vice versa."
223683012|NCT04220853|DIAGNOSTIC_TEST|Acoustic rhinometry in patients after septoplasty and/or turbinoplasty|Acoustic rhinometry is an examination used to assess changes in the cross-sectional area of the nasal passage in patients after septoplasty and/or turbinoplasty.
223683013|NCT05599776|OTHER|Smart ring assisted physiotherapeutic intervention|the effect of a smart ring (Oura), a wearable activity tracker assisted physiotherapeutic intervention on the risk of poor outcome measured on patient reported post-operative outcome (Oxford Knee Score) 12 months after a primary total knee replacement.
224262682|NCT06559878|DIETARY_SUPPLEMENT|Lipid Emulsion|Lipid emulsion, heparin and normal saline are given intravenously during one metabolic visit.
224262683|NCT06559878|OTHER|Normal Saline|Normal saline is given intravenously during one metabolic visit.
224262684|NCT00299871|DRUG|LIXISENATIDE (AVE0010)|
224262685|NCT01943877|PROCEDURE|scaling root planing|scaling root planing
224262686|NCT01943877|DRUG|Propolis|experimental
224262687|NCT01995162|DEVICE|Energy expenditure estimation|Volunteers were asked to wear sensors during about 12 hours, one day. They wore 2 research sensors that estimate energy expenditure: Armband and Actiheart. They also wore a smartphone (in a front pant pocket) that collected accelerometry data.
224262688|NCT02903407|DRUG|Midazolam|IV midazolam will be administered as a continuous infusion to maintain set goal sedation level of RASS 0 to -2.
224262689|NCT02903407|DRUG|Propofol|IV propofol will be administered as a continuous infusion to maintain set goal sedation level of RASS 0 to -2.
224262690|NCT02903407|DRUG|Dexmedetomidine|IV dexmedetomidine will be administered as a continuous infusion to maintain set goal sedation level of RASS 0 to -2.
224262691|NCT00525213|DRUG|Rob 803|two capsules per day during 12 weeks
224262692|NCT00525213|DRUG|Placebo|two capsules per day during 12 weeks
224262693|NCT05143047|BEHAVIORAL|Medication counseling|"Participants will receive a customized written medication instruction sheet which includes a picture of an oral dosing syringe indicating the patient's dose as well as a chart showing medication name, dose, route, frequency, duration, next dose due, side effects, and storage information. In addition, participants will be shown how to draw up their child's dose using an oral syringe and then will be asked to practice this task (show-back). Teach-back will be used to ensure participant's understanding of medication details."
224262694|NCT04801654|DIAGNOSTIC_TEST|blood sample|preoperative and at 6 months and 1 year follow-up after the surgery the patients will take a blood sample
224262695|NCT00154739|DRUG|Gemcitabine|
224262696|NCT00154739|DRUG|Cisplatin|
224262697|NCT00154739|DRUG|Epirubicin|
224262698|NCT05630612|DRUG|Sparsentan|6 weeks of treatment with sparsentan or irbesartan. This will be administered in a double-blind fashion.
224262699|NCT04168398|DRUG|Combination drug|Anticoagulation
224262700|NCT06562465|PROCEDURE|dietary and exercise management|Dietary and exercise management: dietary management by providing tailored recipes, health education lectures, science competitions, etc；exercise management:develop weekly and monthly exercise plans for children of different ages, and have physical education teachers lead them in exercising.
224262701|NCT06562465|PROCEDURE|no dietary and exercise management|NO dietary and exercise management:do not implement dietary and exercise management related to the experimental group
224262702|NCT00615823|DRUG|Atorvastatin|Patients were assigned to receive 10 mg of atorvastatin for 6 months (supplied by JiaLin Pharmaceutical Co., Beijing, China). The dose was adjusted to 5mg daily if serum transaminase levels increased by less than three times the upper limit of normal or creatine kinase levels increased to less than five times the upper limit of normal. If serum transaminase and creatine kinase levels remained normal and low-density lipoprotein level greater than 3.4mmol/L after 4 weeks of therapy, the dose of drug was increased to 20mg once daily.
224262703|NCT00615823|DRUG|Placebo|Patients were assigned to receive 10 mg of placebo for 6 months (supplied by JiaLin Pharmaceutical Co., Beijing, China). The dose was adjusted to 5mg daily if serum transaminase levels increased by less than three times the upper limit of normal or creatine kinase levels increased to less than five times the upper limit of normal. If serum transaminase and creatine kinase levels remained normal and low-density lipoprotein level greater than 3.4mmol/L after 4 weeks of therapy, the dose of drug was increased to 20mg once daily.
224262704|NCT00216736|DRUG|Dexamethasone|Single dose oral dexamethasone 8mg at time of ED discharge
224262705|NCT00216736|DRUG|placebo|Single dose oral placebo at ED discharge
224262706|NCT00002220|DRUG|Indinavir sulfate|
224262707|NCT00002220|DRUG|Efavirenz|
224262708|NCT00002220|DRUG|Levocarnitine|
224262709|NCT00002220|DRUG|Adefovir dipivoxil|
224262710|NCT00759317|DRUG|venlafaxine (Effexor)|Matching capsules containing either venlafaxine 37.5 mg. or placebo will be prepared by the UCLA Pharmacy for the initial phase of the study. For the open-label phase of the study, subjects will receive the medication and dosage that is clinically indicated by the subject's primary physician in the community. After a one-week placebo lead-in, subjects will be randomly assigned to receive one capsule of either venlafaxine or placebo, with the dosage increase every two days until subjects receive four capsules daily (subjects will achieve a dose 150 mg. of venlafaxine after 7 days). The first dose will be administered in the morning, with subsequent capsules added on a b.i.d. schedule.
224262711|NCT02622386|DRUG|Riboflavin|Riboflavin (Vitamin B2) 400 mg capsule taken daily for 12 weeks.
224262712|NCT02622386|OTHER|Placebo|Matching placebo capsule taken daily for 12 weeks.
224262713|NCT02890992|DRUG|alirocumab SAR236553 (REGN727)|Pharmaceutical form: solution Route of administration: subcutaneous injection
224262714|NCT02890992|DRUG|statins|Pharmaceutical form: tablet Route of administration: oral
224262715|NCT02890992|DRUG|ezetimibe|Pharmaceutical form:tablet Route of administration: oral
224262716|NCT02890992|DRUG|cholestyramine|Pharmaceutical form:tablet Route of administration: oral
224262717|NCT02890992|DRUG|fenofibrate|Pharmaceutical form: tablet Route of administration: oral
224262718|NCT02890992|DRUG|omega-3 fatty acids|Pharmaceutical form: tablet Route of administration: oral
224262719|NCT02890992|DRUG|nicotinic acid|Pharmaceutical form: tablet Route of administration: oral
224326071|NCT07176234|BEHAVIORAL|Treatment|The Linking Exercise for Advancing Daily Stress (LEADS) Management intervention integrates a family-based intervention to address chronic stressors to promote behavioral skills for increasing PA in overweight AA adolescents and their parents. Based on Lazarus and Folkman's Stress and Coping Model, Family Systems, and Social Cognitive Theories, the proposed intervention integrates components that build coping skills (mindfulness, deep breathing, active coping, cognitive reframing), self-esteem (self-affirmation), and positive parenting practices (parent support, nurturance, family routines).
224326072|NCT07176234|OTHER|Health Education|Attention Control Comparator
224326073|NCT07160608|DRUG|Placebo|Participants will receive placebo.
224326074|NCT07160608|DRUG|Tarperprumig|Participants will receive tarperprumig.
224326075|NCT07181161|DRUG|AZD0516|AZD0516 will be administered via intravenous infusion.
224326076|NCT07181161|DRUG|AZD9574|AZD9574 will be administered orally.
224326077|NCT07186543|BEHAVIORAL|Cognitive Behavioral Therapy (CBT) Worksheets|The researchers will provide instructions for participants to complete a packet of worksheets teaching introduction to cognitive behavioral therapy (CBT), affect regulation, cognitive restructuring, and problem solving.
223683014|NCT01015001|PROCEDURE|Active rTMS x sham (placebo) rTMS|"Seventeen right-handed patients with DSM-IV TR diagnosis of schizophrenia were randomized in two groups. One arm received 20 sessions of 20 minutes each of low-frequency (1Hz) rTMS applied over the left temporoparietal cortex (LTPC).~The other arm received sham (placebo) stimulation over the LTPC for the same period of time. All patients were considered as having refractory schizophrenia and in use of at least 400mg/day of clozapine and referred auditory hallucinations."
223683015|NCT01015001|PROCEDURE|sham rTMS|same coil, same number of pulses but using an angled coil(90degres) over the frontotemporal region
223683016|NCT01015001|PROCEDURE|(1Hz) rTMS applied over the left temporoparietal cortex|20 sessions lasting 20 minutes each of low-frequency (1Hz) rTMS applied over the left temporoparietal cortex (LTPC).
223683017|NCT04319679|DEVICE|Extracorporeal shockwave therapy|6 times during 2 weeks
223683018|NCT04319679|DEVICE|Sham therapy|6 times during 2 weeks
223683019|NCT02276573|BIOLOGICAL|buccal cavity sample|
223683020|NCT03767595|DEVICE|ProACT Adjustable Continence Therapy for Men|The ProACT therapy consists of two small, adjustable silicone balloons connected with tubing to a port. During a minimally invasive outpatient procedure, the balloons are surgically placed in the area where the prostate was removed or resected.
223683021|NCT02005289|BIOLOGICAL|MOR00208|Given by IV infusion
223683022|NCT02005289|DRUG|lenalidomide|Given PO
223683023|NCT02005289|OTHER|Correlative Studies|Correlative studies associated with this trial will focus on the effects of MOR00208 alone and in combination with lenalidomide on immune effector cell number and function.
223683024|NCT05652348|OTHER|Establishment of organoid cultures and in vitro sensitivity testing|Generating patient-derived tumor organoid models as well as orthotopic mouse models from peritoneal carcinomatosis lesions and to investigate their response to different therapies.
223683025|NCT05539703|OTHER|Invitation to get a 2nd booster dose of COVID-19 vaccine|Participants in the intervention group will receive an invitation to get a 2nd COVID-19 booster dose. Those who accept the invitation to be vaccinated will receive the vaccine through their municipality's vaccination service.
223683026|NCT06031389|DRUG|Henagliflozin|On the basis of hypoglycemic therapy, the patients in the intervention group were given the drug treatment of hengglinide, once a day, 10mg or 5mg each time, taken in the morning, for 12 months.
223683027|NCT06031389|DRUG|Placebo|On the basis of basic treatment, patients in the blank control group were given starch tablets once a day, 10mg or 5mg each time, taken in the morning for 12 months.
223683028|NCT03507530|OTHER|Assessments|Falls related assessments, functional physical performance evaluations and quality of life assessments.
223683029|NCT00811642|DRUG|Posaconazole|400mg BID oral suspension for 12 weeks
223683030|NCT05394493|DRUG|avelumab|as provided in real world setting
223683031|NCT05394493|DRUG|axitinib|as provided in real world settings
223683032|NCT00176189|DEVICE|All ceramic FPDs|
223683033|NCT00383773|PROCEDURE|Retinal endo vascular surgery|
223683034|NCT02954042|DEVICE|Pelvital probe|Pelvital probe
223683035|NCT02954042|DEVICE|Placebo Probe|Placebo Probe
223683036|NCT06400875|DEVICE|InnovaMatrix® AC Sterilized, Porcine Placental Extracellular Matrix (ECM)|weekly application of sterilized, porcine placental ECM followed by standard of care wound therapy and compression therapy
223774736|NCT05158946|BEHAVIORAL|Future Oriented Group Training|This study's experimental condition consisted of a Future Oriented Group Training (FOGT), originally developed in 2008 by van Beek et al. (2009). Participants followed this training weekly, over a period of 9 weeks in groups of 6 to 10 participants. The sessions, which lasted one and a half hours each, were each led by one trainer.
223774737|NCT06069492|OTHER|Wheat-containing food|One daily serving of 38 grams wheat-containing pasta contains either 5000 mg wheat protein (standard-dose group) or 650 mg wheat protein and 4350 gluten-free flour (low-dose group)
223774738|NCT06428747|DIAGNOSTIC_TEST|b. Detection of micro particles and their subtypes by flow cytometery on(BECKMAN COULTER CytoFLEX flow cytometer).|detection of micro-particles
223683037|NCT02242591|DRUG|Ropivacaine 7,5 mg/ml|
223683038|NCT02242591|DRUG|Saline|
223683039|NCT04824027|PROCEDURE|Harmonic motion imaging|Harmonic motion imaging (HMI) is a non-invasive ultrasound elasticity imaging technique that yields a quantitative relative measurement of tissue stiffness suitable for comparisons between individuals and over time. This technique induces dynamic tissue vibrations internally for tissue elasticity characterization. Participants will be asked to lie down on their back, hold still with shallow breathing while pictures/images are taken of the breast where the tumor is located using an ultrasound without any invasive procedures.
223683040|NCT03643471|DEVICE|MRI|Magnetic resonance imaging with advanced sequences including volumetry, spectroscopy and tractograpghy.
223683041|NCT04244812|OTHER|Moxibustion|"Two sessions of moxibustion will be performed in the Heart meridian and Lung meridian successively.~Intervention in the Heart meridian: moxibustion will be performed above Shaohai (HT3) for 15 minutes. During moxibustion, the probes of laser doppler flowmetry will detect the microcirculatory characteristics of three measuring sites, which include the midpoint of the Heart meridian along the left forearm, Chize (LU5) of the Lung meridian, and the midpoint of the Lung meridian along the left forearm.~Intervention in the Lung meridian: moxibustion will be performed above Chize (LU5) for 15 minutes. During moxibustion, the probes of laser doppler flowmetry will detect the microcirculatory characteristics of three measuring sites, which include the midpoint of the Lung meridian along the left forearm, Shaohai (HT3) of the Heart meridian, and the midpoint of the Heart meridian along the left forearm."
223683042|NCT04244812|DEVICE|Laser doppler flowmetry|Laser doppler flowmetry will be used to detect the microcirculatory characteristics of meridian phenomena
223683043|NCT00675207|DRUG|Brimonidine purite 0.15%|A single drop of brimonidine purite 0.15% ophthalmic solution administered topically in the eye 3 times daily.
223683044|NCT00675207|DRUG|Dorzolamide 2%|A single drop of dorzolamide 2% ophthalmic solution administered topically in the eye 3 times daily.
223774739|NCT03613857|DRUG|Clopidogrel|8 tablets 75 mg clopidogrel loading dose before PCI
223774740|NCT03613857|DRUG|Ticagrelor 90mg|2 tablets 90 mg brilique before PCI
223774741|NCT02843789|DRUG|Tocilizumab|
223774742|NCT00013897|DRUG|Atazanavir|
223774743|NCT00013897|DRUG|Lamivudine/Zidovudine|
224326078|NCT07186543|BEHAVIORAL|Practice Experiences for School Reintegration (PrESR)|Participants will receive an overview of cognitive behavioral therapy skills in virtual reality (VR) and then have the opportunity to practice using skills in a brief immersive experience designed to mimic difficult school and social experiences. Session begin with goal setting and conclude with a debrief summary following the VR experience. Prior to discharge and following the conclusion of the VR sessions, participants will be invited to collaborate on a safety planning intervention informed by their experiences in VR that addresses school and social experiences.
224326079|NCT07187297|DEVICE|Thermage FLX|The Thermage FLX System ('System') is a monopolar, capacitively coupled radiofrequency System designed for use in non-invasive dermatological procedures
224326080|NCT07184775|DEVICE|Continuous glucose monitor|Continuous glucose monitors are sensors that detect interstitial blood glucose measurements and relay values from their sensor to a receiver (typically a cell phone) to document values every 5 minutes.
224326081|NCT07184775|DEVICE|Glucometer|Glucometer measurement involves a patient performing a finger stick with a lancet to draw blood. They then apply blood to a test strip which is analyzed by a glucometer. The glucose measurement provided by the glucometer is then recorded by the patient in a glucose log.
224326082|NCT07188805|DRUG|Finerenone (Kerendia, BAY94-8862)|Finerenone in different doses, treatment duration will be 90±3 days
224326083|NCT07188805|DRUG|Placebo|Placebo to finerenone, treatment duration will be 90±3 days
224326084|NCT05067504|DEVICE|Octave-Ultherapy treatment|Micro-focussed ultrasound delivered below the surface of the skin.
224326085|NCT07195123|BEHAVIORAL|SMART-IBD|Daily medication and diary completion reminders are provided to participants. Additional psychoeducational content regarding self-management skills will be provided in-app.
224326086|NCT07193550|DRUG|Zanzalintinib|Participants will take zanzalintinib 100mg daily by mouth
224326087|NCT07190222|DRUG|Lunsekimig|Pharmaceutical form: solution for injection in prefilled syringe - Route of administration: Subcutaneous injection
224326088|NCT07190222|DRUG|Placebo|Pharmaceutical form:s olution for injection - Route of administration: Subcutaneous injection
224326089|NCT07190209|DRUG|Lunsekimig|Pharmaceutical form: solution for injection in prefilled syringe Route of administration: Subcutaneous injection
223683045|NCT00675207|DRUG|Brinzolamide 1%|A single drop of brinzolamide 1% ophthalmic solution administered topically in the eye 3 times daily.
223683046|NCT06194851|DRUG|Oxytocin nasal spray|Veteran participants will self-administer 40 IU of intranasal oxytocin 30 minutes before the start of each bCBCT session.
223774744|NCT00013897|DRUG|Efavirenz|
223774745|NCT02609126|DRUG|EP-104IAR|Single, ultrasound-guided injection of EP-104IAR into the knee
223774746|NCT02609126|DRUG|Vehicle|Single, ultrasound-guided injection of vehicle placebo into the knee
223774747|NCT03603886|BEHAVIORAL|Telemedicine Pain Management Intervention (immediate group)|Four weekly telemedicine pain management sessions with a trained provider. Intervention will be delivered via video conferencing platform, and each session will last between 30 and 45 minutes. Intervention topics will include: pain psychoeducation, pain coping tools, pain communication, and pain-related stress management.
224326090|NCT07190209|DRUG|Placebo|Pharmaceutical form: solution for injection Route of administration: Subcutaneous injection
223683047|NCT06194851|DRUG|Saline nasal spray|Veteran participants will self-administer 40 IU of the placebo (intranasal saline spray) 30 minutes before the start of each bCBCT session.
223683048|NCT06194851|BEHAVIORAL|Brief Cognitive-Behavioral Conjoint Therapy|Eight sessions of standardized bCBCT, a manualized couple-based intervention for PTSD designed to simultaneously reduce PTSD and enhance relationship and functioning.
223683049|NCT05164666|BIOLOGICAL|TAK-103|TAK-103 intravenous infusion
223683050|NCT05112991|DRUG|Envafolimab+Lenvatinib|"Envafolimab: 400mg envafolimab was administered once in D1 and D15 of the first treatment cycle and once in D1 of each subsequent 28 day cycle.~Lenvatinib: the recommended Phase 2 dose (RP2D) orally 20mg QD during each 28-day cycle."
224326091|NCT07191314|DEVICE|nasopharyngeal airway obstructive sleep apnea (NPA-OSA) device|The NPA-OSA is a flexible, medical-grade silicone, tube-like device that is self-inserted into the user's nasopharyngeal airway through one nostril prior to sleep and worn throughout the night to reduce or alleviate snoring and obstructive sleep apnea.
224326092|NCT07192952|DRUG|Finerenone (Kerendia, BAY94-8862)|Finerenone in different doses, treatment duration will be 270±7 days.
224326093|NCT07194265|DEVICE|TAVR with DurAVR® THV|Transcatheter aortic valve replacement (TAVR)
224326094|NCT07194265|DEVICE|TAVR with SAPIEN THV series or the Evolut THV series|Transcatheter aortic valve replacement (TAVR)
224326095|NCT07195682|DRUG|BMS-986506|Specified dose on specified days
224326096|NCT07202247|DRUG|Antiandrogen Therapy|Given ADT
224326097|NCT07202247|BEHAVIORAL|Behavioral Intervention|Receive fasting reminders via Oncpatient Companion Mobile Application
224326098|NCT07202247|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
224326099|NCT07202247|PROCEDURE|Cardiac Computerized Tomographic Angiography|Undergo a coronary computerized tomography angiography
224326100|NCT07202247|PROCEDURE|Computed Tomography|Undergo CT
224326101|NCT07202247|OTHER|Electronic Health Record Review|Ancillary studies
224326102|NCT07202247|OTHER|Internet-Based Intervention|Complete survey and food diary collection via Oncpatient Companion Mobile Application
224326103|NCT07202247|BEHAVIORAL|Lifestyle Counseling|Receive diet and lifestyle counseling
224326104|NCT07202247|OTHER|Medical Device Usage and Evaluation|Wear an activity tracker
224326105|NCT07202247|OTHER|Nutritional Intervention|Receive AHA HHD guidelines
224326106|NCT07202247|OTHER|Nutritional Intervention|Receive AHA Life Essential 8 recommendations with personalized caloric intake
224326107|NCT07202247|OTHER|Questionnaire Administration|Ancillary studies
224326108|NCT07202247|RADIATION|Radiation Therapy|Undergo RT
224326109|NCT07202247|OTHER|Referral|Receive a referral to an endocrinologist
224326110|NCT07202247|DRUG|Semaglutide|Given SC
224326111|NCT07202247|OTHER|Short-Term Fasting|Participate in an overnight fast
224326112|NCT07202247|DRUG|Tirzepatide|Given SC
224326113|NCT07196046|DIETARY_SUPPLEMENT|Supplement 2|A dietary supplement administered daily for 30 days. This supplement is being evaluated as part of a randomized, double-blind, crossover study to assess its effect on joint comfort. This product may be a placebo.
224326114|NCT07196046|DIETARY_SUPPLEMENT|Supplement 3|A third dietary supplement administered daily for 30 days. This supplement is being evaluated as part of a randomized, double-blind, crossover study to assess its effect on joint comfort. This product may be a placebo.
224326115|NCT07196046|DIETARY_SUPPLEMENT|Supplement 1|A dietary supplement administered daily for 14 days. This supplement is being evaluated as part of a randomized, double-blind, crossover study to assess its effect on joint comfort. This product may be a placebo.
224326116|NCT07202702|DEVICE|tDCS|Applying tDCS to determine if it facilitates learning of a video game task
223683051|NCT05112991|DRUG|Envafolimab|Envafolimab: 400mg envafolimab was administered once in D1 and D15 of the first treatment cycle and once in D1 of each subsequent 28 day cycle.
224326117|NCT07202572|DEVICE|TRIPP VR Meditation|Participants engage with the TRIPP virtual reality meditation program for 2 weeks. The TRIPP platform delivers guided mindfulness and breathing exercises through an immersive VR environment designed to promote relaxation and emotional regulation. Sessions are delivered via VR headset and used on a regular schedule (e.g., daily or as prescribed).
223683052|NCT03944187|DIAGNOSTIC_TEST|Transvaginal sonography|Transvaginal sonography for measurement of cervical length, fetal head circumference and fetal head to cervix angle .
224326118|NCT07202572|BEHAVIORAL|Sham VR|Participants engage with a sham virtual reality experience for 2 weeks. The sham VR consists of non-therapeutic, visually engaging content without meditative, guided mindfulness, or relaxation components. It is designed to mimic the immersive nature of the TRIPP VR platform without delivering active therapeutic content.
224326119|NCT06525064|OTHER|Health-E You app|"When clinics are in the intervention condition, all patients presenting for any reason will get a study weblink 24 hours before the visit; walk-ins will get a study link code in clinic. If the participants agree to participate and meet study criteria, the participants will get a survey link and then Health-E You content to complete before the visit. Previously enrolled males will not be enrolled again to maintain the research study's integrity. Thus, participants will only have one opportunity for administration to the Health-E You app.~Participants will be considered to have completed the Health-E You app if the participants answer all of the app's initial tailoring questions and receive recommendations for SRH topics to discuss with the clinician. As a technology-based intervention, no direct interactions with interventionists with participants are required."
224326120|NCT04033510|OTHER|Standard of Care Interventions to convert patient from atrial fibrillation to normal rhythm|Direct current cardioversion, PVAI-atrial fibrillation ablation, Minimally Invasive Surgical Maze procedure, Medications
224326121|NCT03297125|DEVICE|Standard Magnetic Resonance Imaging (MRI)|Standard MRI.
224326122|NCT03297125|DEVICE|Advanced MRI.|Perfusion and diffusion MRI.
224326123|NCT07206797|DEVICE|Functional Electrical Stimulation|Functional electrical stimulation will be applied to the ankle muscles. The resulting torque will be collected, and ultrasound data will be obtained during stimulation.
224326124|NCT07206797|DEVICE|Transcutaneous (Non-Invasive) Spinal Cord Stimulation|Non-invasive spinal cord stimulation will be applied. The resulting torque data will be collected, and ultrasound data will be obtained during stimulation.
224326125|NCT07206797|DEVICE|Ultrasound|Ultrasound data will be collected from the shin muscles during FES and tSCS.
224326126|NCT07206615|OTHER|Endoscopic marker|Study to confirm the safety and performance of the Laborie Spot Ex Endoscopic Marker in accordance with the approved labelling/instructions for use (IFU).
224326127|NCT07206888|DIAGNOSTIC_TEST|Imaging|Ultrasound imaging or ultrasound imaging with light (i.e., photoacoustic imaging)
224326128|NCT07195916|DRUG|INCA036873|Intravenously (IV)
224326129|NCT07197918|DEVICE|portable MRI scanner|Participants will receive 2-3 portable MRI scans: \<6 hours, 6-24 hours, and within 12 (+/- 12) hours of conventional MRI
224326130|NCT07199231|OTHER|AI clinical reference tool|Residents will use OpenEvidence clinical reference tool in the course of routine clinical care. They must also use a Gold Standard clinical reference tool (e.g. PubMed, UpToDate) to mitigate risk.
224326131|NCT07201922|DRUG|Nerandomilast|Nerandomilast
224326132|NCT07201922|DRUG|Placebo|Placebo
224326133|NCT07204977|DRUG|Acamprosate calcium|tablet
223683053|NCT05957211|DRUG|0.09% cyclosporine A ophthalmic solution|Cequa is an ophthalmic solution used to treat moderate to severe dry eye disease. The typical dosage is one drop in each eye, twice a day. The drug is packaged in sterile, single use bottles.
223835276|NCT03190083|DEVICE|digital breast tomosynthesis (DBT)|The radiation dose from this/these procedure(s) will be no more than 0.4mSv for a bi-lateral breast tomosynthesis. The new breast cancer patients will be scheduled for the mammogram after diagnosis at the time of surgical appointment. The radiologist reviewing the tomosynthesis images will be separate and blinded from the radiologist who reviewed the initial 2-D mammogram.
223683054|NCT03916315|BEHAVIORAL|Transdiagnostic Treatment|"The Unified Transdiagnostic Protocol (PUT) is a cognitive-behavioral treatment focused on emotions. The PUT was developed to be applicable to anxiety disorders, mood disorders, as well as other disorders in which anxiety and emotional dysregulation play an important role, such as many somatoform and dissociative disorders.~The PUT proposal includes 8 modules, of which 5 are nuclear, it is recommended to give these modules between 11 to 17 sessions with a duration of one hour each."
223683055|NCT00697944|DRUG|Amphotericine in liposome (Ambisome®)|2 IV infusions separated by one week 10 mg/kg per injection
223683056|NCT02528539|OTHER|ITP|"The study participants will receive weekly acupuncture treatment plus education on self-management for 10 weeks after axillary node dissection, then a total of five follow up acupuncture treatments once every 3 months at 6, 9, 12, 15, and 18 months. The education and self management will be reinforced monthly by telephone visit.~Acupuncture points include: LI 4, LV3, HT3, SP9, GB 20, KD 3, Yintang, and Ashi points"
223683057|NCT01693588|OTHER|Pain Management Bundle|The Pain Management Bundle will be implemented for all postoperative neurosurgical patients admitted to nursing units at the University of Florida.
223683058|NCT01881490|DEVICE|MRE|Developing the Pediatric Crohn's Disease Intestinal Damage Score (pMEDIC score) and the Pediatric MRE-Based Activity Index (PICMI)
223683059|NCT03403335|BEHAVIORAL|Mindfulness Based Practices for Health Care Professionals in Training|Eight weekly sessions including didactic lecture, discussion, homework, gentle yoga, and meditation and mindfulness exercises
223683060|NCT02206581|DEVICE|Hydration Monitor|
223683061|NCT01766661|PROCEDURE|Hand-sewn coloanal anastomosis|After low anterior rectal resection due to low rectal neoplasm patients undergo intestinal reconstructions as hand-sewn coloanal anastomosis with protective loop ileostomy.
223683062|NCT01766661|PROCEDURE|Two staged Turnbull-Cutait procedure|After low anterior rectal resection due to low rectal neoplasm patients undergo intestinal reconstructions as two staged Turnbull-Cutait procedure anastomosis without protective ileostomy.
223683063|NCT01766661|PROCEDURE|Ultralow anterior rectal resection with total mesorectal excision|Standard ultralow anterior rectal resection with total mesorectal excision
223683064|NCT00782795|DRUG|Pioglitazone|Participants randomized to pioglitazone receive 30 mg taken once daily for 48 weeks.
223683065|NCT00782795|DRUG|Placebo|
223683066|NCT01161030|DIETARY_SUPPLEMENT|Almonds|
223683067|NCT05771064|BEHAVIORAL|Gentle Moves|A safe physical activity program which consists of a brief motivational enhancement and three movements to be performed in a seated position; and two movements in the standing position. The intervention will be delivered by a research coach.
223683068|NCT00004407|DRUG|immune globulin|
223683069|NCT06573866|BEHAVIORAL|Preventive Participatory workplace intervention|The Participatory Workplace Intervention (PPWI) is a process intervention in which a trained process facilitator guides an employee and their manager in identifying work-related obstacles or changes and finding solutions to overcome or manage these obstacles. Its primary goal is to achieve consensus between employee and manager with respect to the most obstructive obstacles for functioning at work and feasible solutions. Following consensus, the stakeholders formulate and agree upon a plan of action and execute the plan. In a subsequent meeting, the implementation of the plan of action will be evaluated. Six months after the evaluation, a follow-up will take place to determine whether new obstacles have emerged and whether a new cycle of process steps should be initiated.
223683070|NCT05800730|OTHER|refined carbohydrate breakfast|After wearing CGM on Day 1, participants will be provided with breakfast A once daily on Day 3, Day 4, Day 7, Day 8, Day 10, Day 12. Breakfast A contains white bread (50g) and milk powder (25g). Since lunch and dinner would serve as wash-out meals, participants will be free to choose food but provide a record of their diets.
223683071|NCT05800730|OTHER|whole grain breakfast|After wearing CGM on Day 1, participants will be provided with Breakfast B once daily on Day 5, Day 6, Day 9, Day 11. Breakfast B contains plain oats (35g) and milk powder (25g). Since lunch and dinner would serve as wash-out meals, participants will be free to choose food but provide a record of their diets.
223683072|NCT05800730|OTHER|energy-restricted diet|After completing the baseline data and biological sample collection, the ERD group volunteers underwent a 10-day dietary intervention from day 3 to day 12. During this period, a standard breakfast was provided to all volunteers daily by the research staff through the school cafeteria. The ERD group volunteers still had their lunch and dinner provided by the research staff through the school cafeteria to ensure their daily energy intake was controlled between 1200-1500 kcal.
223683073|NCT05800730|OTHER|time-restricted diet|After completing the baseline data and biological sample collection, the volunteers in the TRD group will undergo a 10-day dietary intervention from day 3 to day 12. The TRD group needs to adjust their breakfast eating time to after 10:00 am daily, and they are free to choose their own lunch and dinner according to their dietary habits but must finish their meals before 4:00 pm. During this time window, no other energy-providing foods should be consumed.
223683074|NCT01729585|PROCEDURE|Massage Therapy|The Massage Therapy protocol consists of a series of 5 massages administered over 10 (+2) weeks. Length of time for each visit will be approximately 1.5 - 2 hours Typically, a series of treatments over time allows the body time to integrate tissue related changes and potentially maintain a more healthy musculoskeletal state. Based on expert opinion in the field of MT, following a series of massage treatments administered over time, one can anticipate tissue changes. By adding time between treatments, data will describe the ability of subjects to maintain changes over progressively longer periods of time. Treatment protocol will be based on the application of myofascial trigger point therapy (Timberlake, 1999) to musculoskeletal areas of the body often affected by disease progression in CF.
223683075|NCT06309355|DRUG|YR001 ointment|The intervention is YR001 ointment on a range of body surface area for multiple topical administration
223683076|NCT06309355|OTHER|Placebo|The intervention is Placebo on a range of body surface area for multiple topical administration
223683077|NCT05008211|OTHER|Information-Motivation-Behavioral skills (IMB) model-based intervention|A six-week programme
223683078|NCT05008211|OTHER|Control - usual care|he nurse will provide an one-hour face-to-face session to introduce the choices of domiciliary NIV and teach the patient or his/her family on how to operate and maintain the ventilator, interface and accessories, and also how to handle the common problems
223683079|NCT05591742|DIETARY_SUPPLEMENT|FEMIDUR®|"Femidur® consist of 2 vaginal lactobacillis; Lactobacillus rhamnosus GR-1® and Lactobacillus reuteri RC-14®. One tablet a day.~Placebo Z Cap V-3 Pla; mainly maltodextrin"
224326134|NCT07206550|BEHAVIORAL|Framing|The participants will receive different messages using different terms and behavioral framings, encouraging them to review their EHRs and report any potential errors. These wording variations are expected to induce variance in subjects' behaviors with regard to the likelihood of reviewing EHRs, as well as discovering and reporting potential errors in them.
223683080|NCT05591742|OTHER|Placebo Z Cap V-3 Pla|Consist mainly of maltodextrin. One tablet a day.
223683081|NCT04095832|PROCEDURE|Epidural anesthesia|Epidural anesthesia using standardized technique
223683082|NCT04798495|OTHER|Multimodal interdisciplinary rehabilitation programme (HAPPY)|A 6-month multimodal interdisciplinary rehabilitation programme abbreviated HAPPY was tested. The programme consisted of motivating interviewing technique, individual dialogues with fixed subjects, individual supervised physical exercise training, relaxation exercises, nutritional counselling, and group sessions (a combination of topics and exchange of experiences) with patients and relatives. To reach patients at home, the team phoned patients, who were also given tablets with access to the project's homepage and a digital physical exercise programme.
223683083|NCT02092272|BEHAVIORAL|instructional exercise video source|instructional exercise video source
223683084|NCT01998815|PROCEDURE|Laparoscopic Roux-en-Y gastric bypass surgery|
223683085|NCT01460589|PROCEDURE|timing to initiate the adjuvant chemotherapy|Chemotherapy regimen: FOLFOX-6, every 2weeks, total 12 cycles treatment day1: Oxaliplatin 85mg/m2 day1: Leucovorin 200mg/m2 day1: 5-FU 400mg/m2 IV bolus and 2,400mg/m2 over 46 hours
223683086|NCT03768973|PROCEDURE|Elective cardiac surgery|Both groups will undergo elective cardiac surgery as an intervention.
223683087|NCT01070758|DRUG|Lanreotide autogel|The dose of Lan-ATG will be calculated according to the surface area of the patient. The dose used in adults is usually 60 mg injection once a month, and we will adapt the patient's dose according to the body surface area and also according to the daily dose of Octreotide used with the pump. The starting dose will be 40 mg/m².
223683088|NCT05199740|OTHER|in vitro analysis|in vitro analysis of mesoangioblasts from mtDNA mutation carriers
223683089|NCT04908657|DRUG|Sildenafil 20 MG|oral sildenafil 20 mg three times per day for 3 years
223683090|NCT05859256|OTHER|Experimental|The intervention consists of the application of a treatment protocol based on an initial active warm-up consisting of 3 active exercises, walking for 1 minute performing slow and controlled movement of the ankle, raising the heels, 15 repetitions, dorsiflexion of the ankle in the standing position. gentleman, 15 reps. Subsequently, the floss band will be placed, performing again the 3 active warm-up exercises with the band on. After this, the passive manual techniques will be carried out for the remaining time, removing the flossing at the end of the latter, and actively mobilizing again.
223683091|NCT05859256|OTHER|Control|The same procedures will be carried out, but placing the flossing without tension and performing the Kaltenborn manual techniques without sliding and without joint mobilization.
223683092|NCT01834118|PROCEDURE|Renal Denervation|Sympathetic nerve ablation via transcatheter renal denervation
223683093|NCT04232306|DRUG|Liposomal bupivacaine|Bupivacaine liposome injectable suspension
223683094|NCT04232306|DRUG|Bupivacaine HCl|Bupivacaine HCl surgical-site incision infiltration
223683095|NCT04854642|DRUG|Ladarixin|A single oral dose of 400 mg of ladarixin (two 200 mg capsules) was administered to healthy male and female volunteers under fed (Test treatment) and fasting (Reference treatment) conditions in two consecutive study periods, according to a two-way crossover design, with a wash-out interval of at least 14 days between the two administrations.
223683096|NCT01372982|DRUG|Letrozole|Letrozole Tablets 2.5 mg of Dr.Reddy's Laboratories Limited
223683097|NCT01918722|DRUG|ICH-1(herbal medicine with Hirudo, Tabanus)|8herbals (with 2 herbals of Activating blood stagnation and expelling blood stasis herbs) one dose, bid, for 10 days
223683098|NCT01918722|DRUG|placebo|placebo herbal medicine, one dose,bid, for 10 days
223683099|NCT01918722|DRUG|ICH-2(herbal medicine without Hirudo, Tabanus)|(6herbals, without 2 herbals of promoting blood stasis) one dose, bid, for 10 days
223683100|NCT00566644|DEVICE|levonorgestrel-releasing intrauterine system|
223683101|NCT00566644|OTHER|questionnaire administration|
223683102|NCT00566644|PROCEDURE|observation|
223683103|NCT03794960|BIOLOGICAL|TOL-3021|A plasmid expression vector containing the coding sequences for full-length human proinsulin.
223683104|NCT03794960|OTHER|TOL-3021 Placebo|TOL-3021 Placebo
223683105|NCT05320627|DRUG|Edoxaban|Eligible patients will receive Edoxaban tablet once a day for 12 weeks
223683106|NCT05611177|OTHER|machine learning analysis|We will use robust machine learning approaches, such as Random Forest, XGBoost or Neural Networks.
223683107|NCT00119600|DRUG|AMG 114|
223683108|NCT05500066|DEVICE|Aequalis Flex Revive Shoulder System|"The AEQUALIS FLEX REVIVE Shoulder System is intended for use as:~* A replacement of shoulder joints in primary anatomic or in primary reverse~* A replacement of other shoulder joints devices in case of revisions if sufficient bone stock remains.~The system also allows for conversion from anatomic to reverse shoulder prosthesis in case of revision."
223683109|NCT03249220|DEVICE|Placement of the CBMS Probe|Patients will be treated according to standard care in place at the investigation site, when intra-ventricular drainage is needed. Patients will receive the new multifunctional device (CBMS Probe) instead of the single function device generally used. Drainage will be performed by routine standards. Temperature, intracranial pressure and cerebral blood flow will be recorded. Treatment decision will be made by the neurointensive care specialist based on standard care.
223835277|NCT02025205|DEVICE|Endobronchial Valve|Endoscopic Lung Volume Reduction with Zephyr Endobronchial Valve
223835278|NCT04239365|DIAGNOSTIC_TEST|WLE followed by NBI or NBI followed by WLE (crossover design)|EMR scar is inspected using WLE followed by NBI or vice versa
224326135|NCT07208669|DIAGNOSTIC_TEST|ACT-BP Intervention|In our intervention units, the study team will change the unit-based protocols to follow the ACT-BP intervention. First, it prompts the nurse to identify if a patient is experiencing hypertensive emergencies or cardiac symptoms. If so, it suggests calling the physician. If not, it prompts assessment for pain, anxiety, nausea, or hunger and provides evidence-based suggestions. It also prompts monitoring to enhance patients' safety in the case of rapidly rising BP. This algorithm will provide a path for ensuring patients receive appropriate treatment.
224326136|NCT07202598|DRUG|Emapalumab|Emapalumab will be administered via IV infusion once a month. The initial dose of emapalumab is 3 mg/kg followed by a second dose of 3 mg/kg after 3 days. Subsequently, the dose is 3 mg/kg once a month for five additional doses.
224326137|NCT07210463|DRUG|NT 201|Clostridium Botulinum neurotoxin A (150 kiloDalton \[kD\], free of complexing proteins), powder for solution for injection.
224326138|NCT07210463|DRUG|NT 201 Placebo|NT 201 matching-placebo.
224326139|NCT07211867|BEHAVIORAL|Enhearten with EMI|Enhearten is a digital intervention that is designed to foster adherence to medications for addiction treatment (MAT) and treatment retention while considering the unique needs of pregnant and postpartum women, and recently it has been adapted to include features designed to decrease self-stigma among app-users
224326140|NCT07211867|BEHAVIORAL|Waitlist Control Group|Participants will receive access to Enhearten with EMI following the trial.
224326141|NCT07210437|DIAGNOSTIC_TEST|Tests of sympathetic inhibition|Bolus phenylephrine infusion using the Oxford technique will generate the need to inhibit sympathetic activity. Similarly, resting state Mayer waves will be assessed with regard to heart rate and blood pressure responses.
224326142|NCT07210437|DIAGNOSTIC_TEST|Tests of above level sympathetic activation|Cold pressor test of the hand will be used to cause sympathetic activation. Valsalva's maneuver will assess the ability to buffer against blood pressure fall (phase II).
224326143|NCT07210437|DIAGNOSTIC_TEST|Testing of below level sympathetic activation|Cold pressor test of the foot and bladder pressor response will be tested.
224326144|NCT07213934|RADIATION|Proton therapy|Proton therapy is a type of radiation therapy that uses protons rather than x-rays. It painlessly delivers radiation to treat some types of cancer.
224326145|NCT07213934|DRUG|Pembrolizumab|PDL-1 immunotherapy drug
224326146|NCT07209514|DEVICE|Implantable SCS with Closed Loop mechanism|Participants will be treated with an implantable spinal cord stimulation system programmed to deliver differentially multiplexed targeting pulse program with closed-loop adjustment using evoked compound action potential feedback. All subjects will first undergo a short percutaneous trial phase of spinal cord stimulation. Those who meet trial success criteria will then receive permanent implantation with a paddle lead and the implantable pulse generator. After implantation, closed-loop DTM therapy will be enabled and optimized at each follow-up visit. The goal of the intervention is to evaluate feasibility, safety, and effectiveness of closed-loop DTM spinal cord stimulation in patients with painful diabetic peripheral neuropathy.
224326147|NCT07215052|OTHER|Walking Warm-up|6 minutes treadmill walking at comfortable self-selected pace, 0% incline.
224326148|NCT07215052|OTHER|Suspension Training Warm-up|6 minutes TRX suspension warm-up (reverse lunges 45s, squats 60s, jump squats 45s, rows 30s, push-ups 30s, with 30s rests).
224326149|NCT07211386|PROCEDURE|Erector Spinae Plane Block|The abdominal viscera, from the stomach to midway through the sigmoid colon, derives its sensory innervation from afferent fibers that travel with, but are distinct from, the sympathetic nerve fibers from the 5th thoracic (T5) to the 2nd lumbar (L2) spinal levels (Moore et al). These fibers converge at the celiac plexus, located near the celiac artery and the aorta. From there, they bifurcate into the paravertebral sympathetic chain and subsequently ascend to the spinal cord and integrate into the central nervous system (Lohse et al). The celiac plexus block is an invasive procedure performed by an interventional anesthesiologist or palliative care specialist to lyse the celiac plexus and has been shown to reduce pain and opiate use in patients suffering from GI malignancy (Ashlock et al). While there are multiple methods to perform a celiac plexus block, it involves a steep needle trajectory either posteriorly through the retroperitoneum or anteriorly through the abdominal wall close
224326150|NCT07210606|DRUG|Trazodone + PAP therapy|The central apnea index and the apneic threshold will be compared under two conditions: trazodone or placebo. In addition, participants will get PAP therapy during both the conditions.
223683110|NCT03688425|DEVICE|IOL implantation experimental|Implantation of trifocal IOL POD F GF consisting of light distribution order: far \> intermediate \> near
223774748|NCT03603886|BEHAVIORAL|Telemedicine Pain Management Intervention (waitlist group, intervention administered following 4-week waitlist period)|"Four week waitlist period during which participants receive treatment as usual. Following the waitlist period, participants will receive the telemedicine pain management intervention:~Four weekly telemedicine pain management sessions with a trained provider. Intervention will be delivered via video conferencing platform, and each session will last between 30 and 45 minutes. Intervention topics will include: pain psychoeducation, pain coping tools, pain communication, and pain-related stress management."
224326151|NCT07210606|DRUG|Oxygen + PAP therapy|The central apnea index and the apneic threshold will be compared under two conditions: oxygen or room air. In addition, participants will get PAP therapy during both the conditions.
224326152|NCT07214285|DRUG|A-DOPAMINE|Intracerebral infusion of anaerobic dopamine.
224326153|NCT07214285|DEVICE|A-DOPAMINE|Intracerebral infusion of anaerobic dopamine with pump device.
224326154|NCT07213921|PROCEDURE|Dermabrasion|First, both sides of the wound will be sutured together with a subcutaneous (bottom) layer of stitches. Next, a predetermined, concealed randomization number will be obtained which will specify which side, A or B, will be treated with dermabrasion. An electrocautery scratch pad will be used along the wound edge of the intervention side until pin-point bleeding is achieved. This will add no additional time to the standard of care surgery time. The wound will then be closed with an epidermal (top) layer of stitches, as is the standard of care.
224326155|NCT07213986|DEVICE|Vibrant Capsule|The Vibrant capsule is designed to alleviate chronic constipation by stimulating the colon through gentle vibrations. The Vibrant capsule will be swallowed and tracked through the digestive system of spinal cord injury patients.
224326156|NCT07215507|BEHAVIORAL|Discovery Rounding|"For certain patients with appropriate clinical risk factors, our service has adopted a policy of discovery rounding. This method involves solely electronic health record chart review prior to the 8am attending-led Antepartum team discussion where the patient's overnight events are discovered, clinical courses discussed, and daytime plans proposed. Discovery rounding consolidates bedside physician-patient encounters to one mid-morning interaction, forgoing early morning disturbances."
223683111|NCT03688425|DEVICE|IOL implantation active comparator|Implantation of trifocal IOL POD F GF consisting of light distribution order: far \> near \> intermediate
223683112|NCT04759027|OTHER|subacromial distance measurement|distance between acromion and humerus
223774749|NCT02676206|OTHER|Classical music|Classical music will be played over the headphones
224326157|NCT07215507|BEHAVIORAL|Standard Rounding|The current standard of rounding on the Antepartum service involves a preliminarily bedside encounter with patients between 5-7am by a resident +/- medical student before an attending physician-led Antepartum team discussion from 8-9am. The patient is then rounded on for a second time in the late morning by the entire Antepartum team where patient concerns are heard and care plans for the day are relayed/reiterated/cemented.
224326158|NCT07215702|DRUG|AZD4144|Intravenous solution of AZD4144 will be administered to randomised participants according to the treatment arm to which they have been assigned.
224326159|NCT07215702|DRUG|Placebo|Intravenous solution of Placebo will be administered to randomised participants according to the treatment arm to which they have been assigned.
224326160|NCT07215351|DIETARY_SUPPLEMENT|Dietary supplement for digestive health|Dietary supplement contains cascara sagrada bark powder, cape aloe leaves extract, senna leaf powder, frangula bark powder fennel seed powder, bentonite clay, burdock root powder, licorice root extract, slippery elm bark powder, Capiscum annuum L. Fruit powder, milk thistle seed powder, hydroxypropyl methylcellulose, and silicon dioxide.
224326161|NCT07215351|DIETARY_SUPPLEMENT|placebo capsule|Contains hydroxypropyl methylcellulose and cellulose
224326162|NCT07210411|DIAGNOSTIC_TEST|Tests of sympathetic inhibition|Bolus phenylephrine infusion using the Oxford technique will generate the need to inhibit sympathetic activity. Similarly, resting state Mayer waves will be assessed with regard to heart rate and blood pressure responses.
224326163|NCT07210411|DIAGNOSTIC_TEST|Tests of above level sympathetic activation|Cold pressor test of the hand will be used to cause sympathetic activation. Valsalva's maneuver will assess the ability to buffer against blood pressure fall (phase II).
224326164|NCT07210411|DIAGNOSTIC_TEST|Testing of below level sympathetic activation|Cold pressor test of the foot and bladder pressor response (in individuals with SCI) will be tested.
224326165|NCT07210411|DEVICE|Epidural stimulation|Currently implanted epidural stimulation will be used during diagnostic testing.
224326166|NCT07210411|DEVICE|Transcutaneous stimulation|Transcutaneous stimulation will be used for participants with spinal cord injury without an implanted stimulator during diagnostic testing.
224326167|NCT07215091|BEHAVIORAL|Brief Motivational Intervention|"The study includes a 3-component motivational intervention based on the Theory of Planned Behavior. The components include motivational interviewing (MI); mobile health monitoring; and action planning.~MI is used to build a positive attitude towards physical activity (PA). Mobile health monitoring will be conducted with a Fitbit to monitor steps per day. The last component of the intervention includes action planning to design a PA program that fits their abilities and lifestyle. The research team will develop a PA grid that includes aerobic, strength, and flexibility PA options. The PA grid provides an opportunity to personalize the action plan by choosing from a 'menu' to match interests. Following the in-person baseline visit, participants will be called approximately every 2 weeks (4-5 phone contacts) during the 3-month intervention period to review and update their action plan."
224326168|NCT07213687|DRUG|Low dose intravenous ketamine|Patients in the treatment group will be administered through a Ketamine IV bolus of 0.5 mg/kg during the induction phase with propofol of 3 mg/kg, followed by a continuous infusion of ketamine of 0.2 mg/kg/hr. Before induction, a lidocaine bolus of 1.5 mg/kg will be given, and the same dose of lidocaine will be administered every 15 to 20 minutes after induction of anesthesia until the start of skin closure. Patients in control group will receive a conventional GA with fentanyl 2µg/kg given during induction of anesthesia and one fourth of initial dose of fentanyl will be given over 20-30 minutes.
224326169|NCT07210632|DRUG|Nivolumab|Participants will receive a single infusion of nivolumab following an infusion of nivolumab-IRDye800 (nivo800), for a combined total dose of 240 mg. This dosing applies to all cohorts except Cohort 1, which is designated as the safety group. Each cohort, other than Cohort 1, will receive no more than 240 mg in total of nivolumab and nivo800 combined. Participants will then undergo planned Standard of Care (SOC) surgical resection 1 to 4 days after the infusion.
224326170|NCT07210632|DRUG|Nivolumab-IRDye800|Participants will receive an infusion of nivolumab-IRDye800 (nivo800). Nivo800 has never been assessed in patients before and therefore Cohort 1 will receive only a test dose to determine the safety (3 participants). Cohorts 2-4 will receive escalating doses of nivo800, keeping the overall dose nivolumab + nivo800 no more than 240 mg. Participants will undergo planned Standard of Care surgical resection at 1-4 days after infusion.
224326171|NCT07215689|DIETARY_SUPPLEMENT|KSM-66 Ashwagandha® capsule|Single off-white capsule contains 300mg Ashwagandha root extract powder only
223683113|NCT05523518|DEVICE|The Buzzy®|From one minute before the location of the catheter and until the end of the procedure, the researchers will place the Buzzy® device approximately 5cm above the area where the procedure will take place, with its wings under it. The gel in its wings will have been previously frozen solid in a refrigerator. In this way, vibration and cold will be applied, and immediately afterwards, vein entry will be performed. (For the children's safety, a piece of thin sterile gauze will be placed on the area in order to prevent direct contact between the ice wings and the skin.)
223683114|NCT05523518|DEVICE|The AccuVein®|In this group, the veins in the area where the entry is to be performed will be visualized with the AccuVein® infrared vein visualization device, and the standard catheter implementation will be performed in the vein which is decided on for entry.
223683115|NCT04644445|DIETARY_SUPPLEMENT|Bariatric Full Liquid Diet|Patient's will receive a Bariatric Full Liquid Diet (standard bariatric clear liquid diet + protein shakes) to be started 4 hours after surgery
223683116|NCT05091203|DRUG|Vitamin D|To investigate role of vitamin D in follicular maturation and number of mature follicles which help in the success of IVF procedure
223683117|NCT06240507|PROCEDURE|ultrasound-guided posterior tibial nerve pulsed radiofrequency|The posterior tibial nerve (PTN) was identified with a 5-12 MHz linear ultrasonography (US) probe at the level of the medial malleolus, where it runs posterior to the posterior tibial artery. Using the in-plane technique, a 22-gauge, 10-cm radiofrequency cannula was inserted under US guidance and advanced until the tip was adjacent to the nerve. Pulse radiofrequency was applied at 42°C for 240 s with a pulse width of 20 ms
223774750|NCT02934139|DRUG|Cavosonstat|CFTR modulator that stabilizes CFTR
223774751|NCT02934139|OTHER|Placebo|Matched placebo
224326172|NCT07215689|OTHER|Placebo Capsule(s)|Single off-white capsule contains starch powder only
223774752|NCT02227160|BEHAVIORAL|10 weekly group meetings|10 weekly group meetings with up to five other men and women at Grady Health System
224326173|NCT07215845|DEVICE|MRI|Reader confidence using standard lumbar MRI techniques on diagnosing pars stress injuries will be compared to advanced techniques. Additionally, various software/MRI sequences will be tested to evaluate image quality and to improve resolution compared to institution pars MRI scan protocols.
224326174|NCT07216430|BIOLOGICAL|wSp vaccine|wSp vaccine will be administered as intramuscular (IM) injections of 0.5 mL (thus 1 mg total protein). wSp vaccine is supplied as single-dose glass vials in saline (0.9% sodium chloride) at 2 mg protein/mL, with aluminum hydroxide at 1.2 mg elemental Al/mL. Dose 1 will be given in the left thigh at 7 months of age, and dose 2 will be given in the right thigh at 9 months of age.
224326175|NCT07216430|BIOLOGICAL|Saline (0.9% NaCl)|Saline will be administered as intramuscular (IM) injections of 0.5 mL. Dose 1 will be given in the left thigh at 7 months of age and dose 2 will be given in the right thigh at 9 months of age.
224326176|NCT07215897|OTHER|Grocery Support Monthly Program|$80 monthly (adjusted by household size), re-loadable cash card for use at food retailers to purchase fresh and packaged foods, baby food and formula, and/or non-alcoholic drinks
224326177|NCT07215897|OTHER|Grocery Support One-Time Payment|No intervention is provided during the 12-month evaluation period. A $960 one-time (adjusted by household size) cash card for use at food retailers provided after the 12 month evaluation period to purchase fresh and packaged foods, baby food and formula, and/or non-alcoholic drinks
224326178|NCT07216391|DRUG|Antithymocyte Globulin (ATG)|Thymoglobulin
224326179|NCT07216391|DRUG|Teplizumab|Intravenous infusions of teplizumab given for 14 consecutive days. Each infusion takes about 30 minutes and is followed by an observation period of at least 30 minutes.
224326180|NCT07215949|DRUG|Zilucoplan®|Subcutaneous injections of zilucoplan will be administered daily. The dose is dependent on the body weight of the patient. Each patient will receive a kit with prefilled syringes.
224326181|NCT07216352|OTHER|AGE Serum|AGE serum is a topical that contains a high concentration of 30% Proxylane and a synergistic blend of fruit-derived flavonoids (blueberry, pomegranate) and Cassia alata extract.
224326182|NCT07216300|PROCEDURE|Osteopathic Manipulative Treatment|Manual Medicine applied either by a physician or a medical student
224326183|NCT07216183|PROCEDURE|Walk|Treadmill walking
224326184|NCT07216183|PROCEDURE|Yuga post|Participants conduct a yuga post which involves their efforts but not load on their residual limbs
224326185|NCT07216183|DEVICE|E-SWEAT Sensor|Mounting the E\_SWEAT sensor to monitor the lactic density, pressure, and temperature inside the socket
224326186|NCT07216248|DRUG|relugolix + ARPI|Step 1: Continuous treatment with relugolix + ARPI
224326187|NCT07216248|DRUG|Intermittent- Relugolix or androgen deprivation therapy (ADT) + ARPI|Intermittent treatment with relugolix + ARPI.
224326188|NCT07216248|DRUG|relugolix or androgen deprivation therapy (ADT) + ARPI|Step 2: Standard-of-care, continuous treatment with relugolix or androgen deprivation therapy (ADT) + ARPI.
224326189|NCT07216248|DRUG|relugolix + ARPI.|Step 2: Intermittent treatment with relugolix + ARPI.
224326190|NCT07215871|BIOLOGICAL|A/Mallard/Ohio-99/MM4/1989 H10N7|Low pathogenicity avian influenza virus H10N7
224326191|NCT07216469|DIAGNOSTIC_TEST|Magnetic Resonance Elastography (MRE)|Patients will undergo a cardiac MRI with the addition of continuous free-breathing and breath-held MRE sequences.
224326192|NCT07216105|DRUG|FT836|FT836 drug product is administered as an intravenous infusion on multiple days schedule at treatment cycle.
224326193|NCT07216105|DRUG|Paclitaxel|IV infusion ; 80 mg/m2 QW; Days -21, -14, and -7
224326194|NCT07216105|DRUG|Cetuximab|Cetuximab administration will begin on Day -4 at the recommended initial dose of 400 mg/m2 as a 120-minute IV infusion
224326195|NCT07216105|DRUG|Trastuzumab|trastuzumab administration will begin on Day -4 at an initial dose of 4 mg/kg as a 90-minute IV infusion.
224326196|NCT07216196|BEHAVIORAL|Pathways and Resources for Engagement and Participation (PREP)|Pathways and Resources for Engagement and Participation (PREP) is a collaborative problem-solving intervention that targets environmental barriers-physical, social, attitudinal, familial, and institutional-while leveraging adolescent and family strengths. Caregivers are integrated as key supports. The five-step process includes: (1) make goals, (2) map out a plan, (3) make it happen, (4) measure outcomes, and (5) move forward. We will set four activity-based transition goals using the Transition Planning Inventory-2nd Edition and Goal Attainment Scaling. Providers will use guided discovery to help adolescents and caregivers identify strategies that modify activities or environments to support participation in transition activities. Adolescents and caregivers will implement strategies between sessions and revise strategies with the provider in future sessions if unsuccessful. Participants will complete 12 weekly 60-min remote PREP sessions over 12-16 weeks.
224326197|NCT07216261|OTHER|Implementation Strategy: Foundational Support|The primary goal of SWELL is to compare implementation approaches while also gathering information on clinical effectiveness of the EBP in its new context. All sites will be randomized to receive 1) foundational REP implementation support alone or 2) foundational REP and Reach+Equity. We propose that low intensity implementation support that promotes engagement with SWELL (defined as foundational support), will be sufficient for some but not all facilities to successfully incorporate SWELL into routine practice.
224326198|NCT07216261|OTHER|Implementation Strategy: Reach+Equity Bundle|We hypothesize that adding the Reach+Equity bundle to foundational REP, compared to foundational REP alone, will result in superior implementation outcomes.
224326199|NCT07216001|DRUG|Omega-DEK|Participants take 2 capsules, twice daily (BID).
224326200|NCT07216001|DRUG|L-carnitine|Participants take 250 mg L-carnitine administered as a 2.5 mL oral solution twice daily (BID). L-carnitine is provided to participants only during the 12-week open-label trial.
224326201|NCT07216001|DRUG|Placebo|A placebo of palm kernel oil to match Omega-DEK is provided. Participants take 2 capsules, twice daily (BID).
224326202|NCT07216378|DRUG|Sebetralstat|Oral Plasma Kallikrein Inhibator
224326203|NCT07215858|BIOLOGICAL|BPL-1357 IM|Quadrivalent, inactivated, whole-virus vaccine containing 4 different wild-type avian viruses given intramuscularly.
224326204|NCT07215858|BIOLOGICAL|BPL-1357 IN|Quadrivalent, inactivated, whole-virus vaccine containing 4 different wild-type avian viruses given intranasally.
224326205|NCT07215858|OTHER|Placebo IM|Placebo given intramuscularly.
224326206|NCT07215858|OTHER|Placebo IN|Placebo given intranasally.
224326207|NCT07216014|DRUG|Interleukin 23|After obtaining the patient's informed consent, the drug treatment mainly consisting of interleukin-23 monoclonal antibody was carried out. Basic information and medical history of the patients were collected, and the treatment process of the patients was followed up. The drug regimen was adjusted based on the physician's experience. Follow-up and disease assessment were conducted at 0, 4, 8, 16, 24, 48, and 54 weeks, respectively. Blood, stool, and tissue samples were collected at the corresponding follow-up time points for gastrointestinal endoscopy, imaging examinations, laboratory index tests, self-assessment of symptoms by the subjects, assessment of adverse reactions, and nutritional risk screening, etc. The efficacy and safety of IL-23 inhibitor treatment for CD or UC were comprehensively evaluated.
224326208|NCT07216014|DEVICE|Interleukin 23|After obtaining the patient's informed consent, the drug treatment mainly consisting of interleukin-23 monoclonal antibody was carried out. Basic information and medical history of the patients were collected, and the treatment process of the patients was followed up. The drug regimen was adjusted based on the physician's experience. Follow-up and disease assessment were conducted at 0, 4, 8, 16, 24, 48, and 54 weeks, respectively. Blood, stool, and tissue samples were collected at the corresponding follow-up time points for gastrointestinal endoscopy, imaging examinations, laboratory index tests, self-assessment of symptoms by the subjects, assessment of adverse reactions, and nutritional risk screening, etc. The efficacy and safety of IL-23 inhibitor treatment for CD or UC were comprehensively evaluated.
224326209|NCT07216573|DEVICE|HemoSphere Vita Monitor, VitaWave or VitaWave Plus Finger Cuff Adult, ForeSight Large Sensors|Devices are applied for monitoring throughout the duration of the procedure.
223683118|NCT06240507|PROCEDURE|fluoroscopy-guided intralesional radiofrequency thermocoagulation|The painful heel and calcaneal spur were visualized under lateral fluoroscopy. A 22-gauge, 10-cm radiofrequency cannula was inserted and advanced until the needle tip reached the calcaneal spur tip. When the needle tip contacted the spur, local anesthetic was administered through the cannula and radiofrequency ablation was performed at 80°C for 90 s.
223683119|NCT01596673|DRUG|45-mg hydrocodone bitartrate extended-release tablet (crushed or intact)|"Phase B:~Eligible subjects will be randomized to treatment sequence XY or YX whereby treatment X is 60 mL of a noncarbonated flavored beverage and treatment Y is hydrocodone bitartrate powder at a dose strength of 45-mg reconstituted in 60 mL of a noncarbonated flavored beverage.~Phase C:~Eligible subjects will be randomly assigned to 1 of 4 treatment arms:~Treatment A: intact placebo tablet, 60 mL noncarbonated flavored beverage, 1 crushed 45-mg hydrocodone bitartrate extended-release tablet.~Treatment B: intact placebo tablet, hydrocodone bitartrate powder at a dose strength of 45-mg in 60 mL of a noncarbonated flavored beverage and 1 crushed placebo tablet.~Treatment C: intact 45-mg hydrocodone bitartrate extended-release tablet, 60 mL noncarbonated flavored beverage, and 1 crushed placebo tablet Treatment D: intact placebo tablet, 60 mL noncarbonated flavored beverage, and 1 crushed placebo tablet."
223683120|NCT01596673|DRUG|Placebo|Placebo will consist of 60 mL of a non-carbonated beverage without the addition of active treatment
223683121|NCT02430506|BIOLOGICAL|Placebo|This is the identical buffer solution in which AERAS-402 is formulated.
223683122|NCT02430506|BIOLOGICAL|AERAS-402|Given to 8 participants that were QFT-G(-) at screening and 8 participants that were GFT-G(+) at screening.
223683123|NCT03213353|DRUG|Tablet paracetamol, guaifenesin and phenylephrine HCL|Each subject will receive two tablets, each containing 250 mg paracetamol, 100 mg guaifenesin, and 5 mg phenylephrine hydrochloride
223683124|NCT03213353|DRUG|Vicks Active SymptoMax Plus powder for oral solution|Each subject will receive one sachet, containing 500 mg paracetamol, 200 mg guaifenesin, and 10 mg phenylephrine hydrochloride
223683125|NCT01915264|DRUG|Acarbose/Metformin (Glucobay M, BAY81-9783)|Acarbose (25/50mg) and Metformin (500mg) in fixed dose combination.
223683126|NCT00562627|DRUG|ropivacaine|intraoperative and 1. postoperative day
223683127|NCT00562627|DRUG|adrenaline|intraoperative LIA (IV and IA) and continuous EDA
223683128|NCT00562627|DRUG|ketorolac|intraoperative and 1. postoperative day
223683129|NCT00562627|DRUG|morphine|intraoperative
223683130|NCT00562627|DRUG|fentanyl|continuous postoperatively
223683131|NCT00562627|DRUG|bupivacaine|continuous postoperatively
223683132|NCT02048189|DRUG|LEVEMIR|
223683133|NCT02048189|DRUG|APIDRA|
223683134|NCT01139840|DIETARY_SUPPLEMENT|vitamin D2|Study Supplement
223683135|NCT01139840|DIETARY_SUPPLEMENT|vitamin D3|Study Supplement
223683136|NCT01994499|DEVICE|Videothoracoscopy drainage|videothoracoscopy drainage of pleural effusion
223683137|NCT01994499|DRUG|Medical drainage|Medical pleural drainage
223683138|NCT00625742|BEHAVIORAL|Graded Resistance Training|Resistance training sessions twice weekly using Thera-bands.
223683139|NCT00625742|BEHAVIORAL|Aerobic Exercise|Walking or running for 3-4 minutes at 70-80% of your maximum predicted heart rate.
223683140|NCT00625742|DRUG|Melatonin|20 mg by mouth (PO) Daily
223683141|NCT00625742|DIETARY_SUPPLEMENT|Juven|90 calories of Juven, twice a day.
223683142|NCT00625742|DRUG|Atenolol|Atenolol will only be taken if there's evidence of increased sympathetic activity (resting heart rate \>110 beats/min) or resting energy expenditure (REE) \> 110% of predicted.
223683143|NCT00625742|DRUG|Ibuprofen|Ibuprofen 1200mg/day in three divided doses.
223683144|NCT03264170|DIAGNOSTIC_TEST|Prediction of pregnancy outcome|The intervention group will receive the individualised prediction of their pregnancy (as a percentage). The prediction is calculated by a validated, accurate mathematical model using specific background information and ultrasound data for each participant.
223683145|NCT00333892|PROCEDURE|leukapheresis|pack of cells as per protocol
223683146|NCT01709578|DRUG|Sarilumab|Pharmaceutical form:solution Route of administration: subcutaneous
223683147|NCT01709578|DRUG|placebo|Pharmaceutical form:solution Route of administration: subcutaneous
223683148|NCT01709578|DRUG|hydroxychloroquine|Dispensed according to the local practice.
223683149|NCT01709578|DRUG|methotrexate|Dispensed according to the local practice.
223683150|NCT01709578|DRUG|sulfasalazine|Dispensed according to the local practice.
223683151|NCT01709578|DRUG|leflunomide|Dispensed according to the local practice.
223683152|NCT04050371|DRUG|200 mg emtricitabine and 300 mg tenofovir disoproxil fumarate|All study participants received daily observed therapy with FTC/TDF.
223683153|NCT01107418|DRUG|RO5185426|dosage b) orally twice daily, days 1-15 (morning dose)
224326210|NCT07216144|BEHAVIORAL|Centralized patient outreach for lung cancer screening|Centralized patient outreach for lung cancer screening will be conducted by the lung screening team and will consist of a letter followed by telephone contact. One week following the mail invitation, a senior patient coordinator (SPC) will make telephone contact with individuals to pre-screen eligibility determination based on pack-year smoking history. Up to three telephone contact attempts will be made within two weeks.
224326211|NCT07216209|BEHAVIORAL|EXERCISE TRAINING WITH OR WITHOUT MEDICATION|All patients will be offered a lab exercise regimen. For completion of Aim 2, only three or four visits are necessary, amounting to approximately 4 hours of the patient's time. The initial visit will be for pre-exercise screening. If the patient is deemed healthy enough to participate, an exercise test to determine the ventilatory threshold of the participant will be conducted and the VO2 determined. In the subsequent visits, the patient will perform exercise for 30 minutes at 15% above the volunteer's ventilatory threshold. Ideally, the patients will be able to complete a minimum of three sessions prior to surgery.
224326212|NCT07216079|DRUG|rilzabrutinib|Pharmaceutical form:Tablet-Route of administration:Oral
224326213|NCT07215910|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT/VMAT
224326214|NCT07215910|RADIATION|Volume Modulated Arc Therapy|Undergo IMRT/VMAT
224326215|NCT07215910|RADIATION|Pencil Beam Scanning|Undergo PBS
224326216|NCT07215910|PROCEDURE|Intensity-Modulated Proton Therapy|Undergo IMPT
224326217|NCT07215910|DRUG|Temozolomide|Given PO
224326218|NCT07215910|DRUG|Vorasidenib|Given PO
224326219|NCT07215910|DRUG|Placebo Administration|Given PO
224326220|NCT07215910|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
224326221|NCT07215910|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
224326222|NCT07215910|OTHER|Questionnaire Administration|Ancillary Studies
224326223|NCT07215806|DRUG|Evobruitnib|Participants received Evobruitnib at a dose of 45 mg orally twice daily on Days 4 to 17.
224326224|NCT07215806|DRUG|Combined oral contraceptive [ethinyl estradiol/ norethisterone (EE/NET)]|Participants received combined oral contraceptive (COC) \[0.03 milligrams (mg) of Ethinyl Estradiol (EE)\], 0.5 mg of Norethisterone (NET)\] orally on Day 1 and 15.
224326225|NCT07215975|DRUG|Luspatercept|According to the product label
224326226|NCT07216287|OTHER|No Intervention: Observational Cohort|No intervention, observational cohort study
224326227|NCT07216274|DEVICE|QT Ultrasound Breast Scanner|Undergo Quantitative Transmission Imaging (QTI) using the QT Ultrasound Breast Scanner
224326228|NCT07216274|OTHER|Questionnaire Administration|Ancillary studies
224326229|NCT07216365|DRUG|Caffeine Citrate|"High Dose Group:~Caffeine citrate administered as a 20 mg/kg loading dose followed by a 10 mg/kg/day maintenance dose starting at 7 days of life. Dose escalation up to 12.5 mg/kg/day may be performed based on clinical indications. The drug is administered either intravenously or orally in a blinded fashion.~Standard Dose Group:~Caffeine citrate administered as a 20 mg/kg loading dose followed by a 5 mg/kg/day maintenance dose starting at 7 days of life. Dose escalation up to 7.5 mg/kg/day may be performed based on clinical indications. The drug is administered either intravenously or orally in a blinded fashion."
224326230|NCT07216599|DEVICE|Photoacoustic imaging and multispectral imaging|Use photoacoustic and Kent imaging devices that can image vasculature and assess tissue perfusion on the foot.
223683154|NCT01107418|DRUG|RO5185426|dosage c) orally twice daily, days 1-15 (morning dose)
223683155|NCT01107418|DRUG|RO5185426|dosage d) orally twice daily, days 1-15 (morning dose)
224326231|NCT07215962|BIOLOGICAL|Nivolumab + ipilimumab|According to the product label
224326232|NCT07215962|BIOLOGICAL|Nivolumab + ipilimumab + platinum-based chemotherapy|According to the product label
224326233|NCT07215962|BIOLOGICAL|Immuno-oncology-based therapy (excluding nivolumab-based regimens) with chemotherapy|According to the product label
224326234|NCT07215962|BIOLOGICAL|Other dual-immuno-oncology therapy with chemotherapy|According to the product label
224326235|NCT07216560|DRUG|7MW4911|study drug
223683156|NCT01107418|DRUG|RO5185426|960 mg orally twice daily, from day 22 onward
223774753|NCT02227160|BEHAVIORAL|Outpatient counseling and support groups|Usual mental health care
223774754|NCT05239806|BIOLOGICAL|SCTV01C|Day 0; intramuscular injection
224326236|NCT07216612|OTHER|Community Restitution Apprenticeship-Focused Training (CRAFT)|Twenty-five participants will be randomly assigned to the intervention arm. Participants will receive the standard services of the Day Report Program plus enrollment in the CRAFT model. CRAFT involves completion of community service activities designed to develop career-related skills and placement in an apprenticeship with a local employer. Participants may also be offered the opportunity to enroll in Jobs and Hope West Virginia, a recovery-oriented employment program that supports individuals in recovery and employers hiring a recovery workforce. Enrollment in Jobs and Hope WV is encouraged but voluntary.
223683157|NCT01107418|DRUG|RO5185426|dosage a) orally twice daily, days 1-15 (morning dose)
223683158|NCT00597701|DRUG|Baclofen|Baclofen 10 mg by mouth every 8 hours for 72 hours or until discharge if before 72 hours.
223683159|NCT00597701|DRUG|Placebo|Placebo
223683160|NCT00597701|DRUG|Lorazepam|"Lorazepam was provided to all subjects (both arms of the study), as indicated by clinical condition. Standard symptom-triggered dosing of lorazepam for alcohol withdrawal was used. That is, the size and the frequency of the dose of lorazepam was determined by the severity of the alcohol withdrawal symptoms."
223683161|NCT03121339|BIOLOGICAL|VXA-A1.1 H1 Tablet Vaccine (small)|Tableted oral H1 vaccine (\~140 mg tablet)
223774755|NCT05239806|BIOLOGICAL|SCTV01E|Day 0; intramuscular injection
223774756|NCT05239806|BIOLOGICAL|Sinopharm inactivated COVID-19 vaccine|Day 0; intramuscular injection
223774757|NCT05239806|BIOLOGICAL|Comirnaty|Day 0; intramuscular injection
224326237|NCT07216612|OTHER|Standard Employment Model|Twenty-five participants will be randomly assigned to the comparator arm. Participants will receive the standard services of the Day Report Program, which include cognitive behavioral therapy (CBT) supports with small incentives such as gift cards, small giveaways, or hosted events determined by Day Report Program case coordinators. Participants may also be offered the opportunity to enroll in Jobs and Hope West Virginia, a recovery-oriented employment program that provides workforce support for individuals in recovery and employers. Enrollment in Jobs and Hope WV is encouraged but voluntary. All participants will also have access to free public transportation through the Mountain Transit Authority to commute to and from work.
224326238|NCT07216495|OTHER|Exercise|Cardiorespiratory training via treadmill walking for 30 minutes; participants will be supervised by a trained exercise physiologist.
224326239|NCT07216417|BEHAVIORAL|Yoga|Physical Yoga postures
224326240|NCT07216417|BEHAVIORAL|Mindfulness|breathing cues or meditation practice
224326241|NCT07216118|BEHAVIORAL|Tailored Resources|Participants will be texted resource lists and warm referrals specific to health-related social needs (HRSN) on a screener. Their clinician will be sent screener results and asked to talk about and address HRSN at the visit without additional guidance. If the family requested to meet with the social worker on the screener, a message will also be sent to the clinic social worker. Participants will be offered physical resources related to disclosed HRSN (e.g., food box for food insecurity).
224326242|NCT07216118|BEHAVIORAL|Universal Empowerment|Regardless of disclosed health-related social needs (HRSN), participants will be texted resource lists and warm referral links for food, housing, and transportation needs. At clinic visit, all will be offered physical resources and the opportunity to meet with a social worker. In place of screening results, clinicians will be sent a message requesting that, when seeing the patient in clinic, they use the provided, easily accessible empowering script about HRSN.
224326243|NCT07216118|BEHAVIORAL|Text Messages without Community Health Workers (CHW)|Participants will receive text messages once per month for 3 months. Messages will state that community-based resources to address health-related social needs (HRSN) are available if needed, with a link to opt-in to resource lists and warm referral links. Messages will include contact information for the study and clinical teams for optional HRSN discussion. CHW will not be assigned.
224326244|NCT07216118|BEHAVIORAL|Text Messages and Community Health Workers (CHW)|Participants will receive text messages about health-related social needs (HRSN) resources as described in arms without CHW but will also be assigned trained CHW from local community organizations to support connection with resources to address HRSN.
224326245|NCT07215936|DRUG|Arm A:Dose_dense Capecitabine in Colorectal cancer|Appling dose \_dense Capecitabine 1750mg/m2 for one week then one week off Cycle repeated every 2 weeks
224326246|NCT07215936|DRUG|Arm B : standard dose Capecitabine|Pateints will receive capecitabine 1000 mg/m2 for 2 weeks then one week off
224326247|NCT07215884|DRUG|Aripiprazole 10 MG|The effects of aripiprazole on stuttering and various behavioral and neural outcomes will be studied compared to placebo.
224326248|NCT07215884|DRUG|Placebo|Placebo will be compared against aripiprazole for effect on stuttering and various behavioral and neural markers.
224326249|NCT07216508|DEVICE|Libre 3+|Blinded CGM will be worn by all participants
224326250|NCT07216092|OTHER|Gut-directed Hypnotherapy|Gut-directed hypnotherapy is an evidence-based treatment that combines hypnosis with therapeutic suggestions that target the gut-brain connection. Through relaxation, imagery, and suggestions, patients learn to better control their pain.
224326251|NCT07216534|OTHER|Survey Administration|Ancillary studies
224326252|NCT07216534|OTHER|Virtual Technology Intervention|View standard streetscape
224326253|NCT07216534|OTHER|Virtual Technology Intervention|View digital twin of streetscape
224326254|NCT07216534|OTHER|Virtual Technology Intervention|View opposite digital streetscape
224326255|NCT07216157|PROCEDURE|Standard multilayer closure without sealant|Patients will undergo standard skull base reconstruction using mucosal flap repositioning and absorbable hemostatics (e.g., Surgicel®, TachoSil®), without application of any fibrin or synthetic sealant. This serves as the control group for comparison with sealant-assisted closures.
224326256|NCT07216157|DEVICE|Fibrin sealant application|Following standard multilayer closure, patients in this group will receive topical application of a fibrin-based biological sealant (Tisseel®). The intervention aims to assess its effectiveness in preventing postoperative cerebrospinal fluid (CSF) leak and promoting mucosal healing after endoscopic endonasal skull base surgery.
224326257|NCT07216157|DEVICE|Synthetic polyethylene glycol-based sealant|After standard multilayer closure, a synthetic two-component sealant (Adherus®, composed of polyethylene glycol and polyethylenimine) will be applied to reinforce the reconstruction site. This group is used to evaluate the efficacy and safety of synthetic sealant in preventing CSF leaks and supporting wound healing.
224326258|NCT07216040|BEHAVIORAL|HOPE-LC~Espanol|12-week online group therapy program grounded in principles of Acceptance and Commitment Therapy and tailored specifically to living with Long COVID as a chronic condition. HOPE-LC provides community and hope; fostering resilience, adjustment, and critical coping strategies in the face of this debilitating chronic condition.
224326259|NCT07216703|BIOLOGICAL|Pembrolizumab|Intravenous (IV) Infusion
224326260|NCT07216703|BIOLOGICAL|Sacituzumab Tirumotecan|IV Infusion
224326261|NCT07216703|BIOLOGICAL|Bevacizumab|IV Infusion
224326262|NCT07216703|DRUG|Paclitaxel|IV Infusion
224326263|NCT07216703|DRUG|Cisplatin|IV Infusion
224326264|NCT07216703|DRUG|Carboplatin|IV Infusion
223683162|NCT03121339|BIOLOGICAL|VXA-A1.1 H1 Tablet Vaccine (large)|Tableted oral H1 vaccine (\~275 mg tablet)
223683163|NCT01258270|PROCEDURE|Postop Dressing|The AQUACEL® Ag Surgical Dressing is a silver impregnated, waterproof, adhesive dressing that sticks to the skin around the wound and blocks bacteria from the outside.
224326265|NCT07216703|DRUG|Rescue Medications|Participants receive the following rescue medications prior to sac-TMT infusion, per approved product label: histamine-1 receptor antagonist, histamine-2 receptor antagonist, acetaminophen or equivalent, and dexamethasone or equivalent. Participants are also recommended to receive prophylactic steroid mouthwash (dexamethasone or equivalent).
224326266|NCT07215923|BIOLOGICAL|ATI-1013 (0.2 g)|Single intravenous (IV) infusion of ATI-1013, 0.2 g total dose.
224326267|NCT07215923|BIOLOGICAL|ATI-1013 (0.8 g)|Single IV infusion of ATI-1013, 0.8 g total dose.
224326268|NCT07215923|BIOLOGICAL|ATI-1013 (3.2 g)|Single IV infusion of ATI-1013, 3.2 g total dose.
224326269|NCT07215923|OTHER|Placebo|Matching placebo (vehicle) IV infusion.
223774758|NCT05239806|BIOLOGICAL|SCTV01E|Day 180; intramuscular injection
224326270|NCT07216066|DRUG|ALN-SNCA|Administered per the protocol
224326271|NCT07216066|DRUG|Placebo|Administered per the protocol
224326272|NCT07216482|DRUG|Enlicitide|Oral Tablet
224326273|NCT07216482|DRUG|Rosuvastatin|Oral Capsule
224326274|NCT07216482|DRUG|Placebo for Enlicitide|Oral Tablet
224326275|NCT07216482|DRUG|Placebo for Rosuvastatin|Oral Capsule
224326276|NCT07216170|DEVICE|SOFIA Flow 88 Aspiration Catheter|The investigational device is the SOFIA Flow 88 Aspiration Catheter with the MV Flow Aspiration Pump and MicroVention Tubing Kit and is intended for use in the revascularization of patients with acute ischemic stroke secondary to intracranial large vessel occlusive disease (within the internal carotid, middle cerebral - M1 segment) within 8 hours of symptom onset.
224326277|NCT07215780|DEVICE|Sitz Bath|Warm water sitz bath, 7 nights, 10 minutes each
224326278|NCT07216053|DIAGNOSTIC_TEST|Point of care lung ultrasound|Point-of-care lung ultrasound (POC LUS) in their first 4 hours of life and be scored based on three established scoring systems
224326279|NCT07216339|OTHER|Standard 6MWT|ATS-standard instructions, no electronic system; Conducted in hallway measuring total length of 90ft (27.4 meters). Patients will walk down-and-back. A seated rest period of ≥10 min separates the two tests to minimize fatigue carry-over.
223683164|NCT01258270|PROCEDURE|Postop Dressing|A standard island dressing consists of adhesive tape and gauze.
223683165|NCT03406923|OTHER|Health literacy-psychosocial support|The intervention is based upon enhancing patient health literacy-related attributes by (1) addressing the barriers to patients' self-efficacy by working with the patient to minimize the barriers (2) clarifying the patient beliefs about diabetes and diabetes medications, and (3) developing personalized action plans. We will tailor the intervention to each patient, so, the details of the content of each session will depend on the individual's self-efficacy, beliefs in illness and medicines, and health literacy level obtained at baseline. In addition to the 45-minute scheduled sessions, patients will be able to call the clinical pharmacist on the phone during the 6-week session at their discretion, for patient-driven support for self-management of goals and skills.
223683166|NCT01314612|BEHAVIORAL|Cognitive-Behavioral Insomnia and Nightmare Group|Group based cognitive-behavioral therapy meeting weekly for 90 minutes over the course of 9 weeks. Utilizes stimulus control, sleep scheduling, and progressive muscle relaxation to address symptoms of insomnia. Imagery rehearsal and rescripting are used to address nightmare symptoms.
223683167|NCT02749669|OTHER|Qualitative research|Semi-structured Interviews
223683168|NCT01030627|DEVICE|Springfusor infusion pump|Women will receive a loading dose and maintenance therapy using an IV infusion administered by the Springfusor® pump. Women will receive a 8 mL loading dose containing 4g magnesium sulfate heptahydrate (MgSO4\*7H2O) 50% solution, which is approximately 2 mmoL magnesium/mL. The loading dose of 8mL with 4 g MgSO4 will be administered using the Springfusor® pump. The administration of the loading dose will be immediately followed by a maintenance infusion. The maintenance dose of 4 g (8 cc, 50% MgSO4) will be administered with the Springfusor® pump continuously over four hours. The pump will be started immediately after the initial bolus and the 4g dose repeated (and syringe replaced) every four hours. Maintenance therapy will be administered for at least 24h. Treatment will be discontinued when clinically indicated. Drug administration will be initiated at the sites and, when necessary, the patient will be transferred, with the Springfusor pump in situ, to the local referral site.
223683169|NCT00902161|DRUG|MK0893|Single dose of MK0893 1000 mg (ten 100 mg tablets)
223683170|NCT00902161|DRUG|MK0893-matched Placebo|Single dose of placebo to MK0893 (ten tablets)
223683171|NCT00902161|DRUG|Propranolol Hydrochloride (HCL)|Propranolol tablets titrated up to 80 mg three times daily over a four week period. Total treatment was approximately 7 weeks.
223683172|NCT00988325|DRUG|Tamiflu|oral repeating dose
223683173|NCT00937781|GENETIC|RNA analysis|
223683174|NCT00937781|GENETIC|gene expression analysis|
223683175|NCT00937781|GENETIC|microarray analysis|
223774759|NCT06177340|DEVICE|visualization of the sacrospinous ligament|visualization of the sacrospinous ligament by the Nanoscope system during sacrospinofixation
223774760|NCT02629510|DRUG|Tachosil|
223774761|NCT04315389|DEVICE|(1) Mobile Assistant Balance Robot|MRBA: Robotic wheelchair with a planar compliant robotic arm to provide balance assistance to the user at the pelvis and hip, during sit to stand, standing and walking tasks in indoor and controlled outdoor level environments.
223835279|NCT06381635|DIETARY_SUPPLEMENT|Manuka honey mixed with aloe vera gel|a mix gel of manuka honey and with aloe vera honey (1:1) mixed in water bath to get a homogenous mix is then packed in unmarked bottles.
224326280|NCT07216339|OTHER|Gamified 6MWT|identical course but child carries a RFID tag; at each lap the child taps an on an RFID reader, awarding a point and leveling-up an on-screen avatar; Conducted in hallway measuring total length of 90ft (27.4 meters). Patients will walk down-and-back.A seated rest period of ≥10 min separates the two tests to minimize fatigue carry-over.
224326281|NCT07215832|DRUG|selinexor|
224326282|NCT07216027|DRUG|PF-08049820|Tablet
224326283|NCT07216027|DRUG|Placebo|Tablet
224326284|NCT07216456|BEHAVIORAL|Improving Engagement with Vaginal Dilator Therapy after Pelvic Radiation|The intervention includes coping strategies from cognitive behavioral therapy (e.g., progressive muscle relaxation) and acceptance and commitment therapy (e.g., mindfulness), as well as psychoeducation (e.g., how to use dilators), to enhance engagement with vaginal dilator therapy.
223683176|NCT00937781|GENETIC|polymerase chain reaction|
223683177|NCT00937781|OTHER|immunohistochemistry staining method|
223774762|NCT04315389|DEVICE|(2) Transfer Assistive Cobot|TAC: Intelligent powered wheelchair equipped with a robotic arm that is capable of lifting payload up to 110kg, and perform a totally dependent transfer in a semi- autonomous fashion
223774763|NCT05449639|DEVICE|Relief implantation|The device will be implanted by endoscopic procedure by a standard resectoscope.
223774764|NCT05831293|BEHAVIORAL|Mindfulness Based Stress Reduction Program|In each session, three sections were discussed and reviewed: (1) last week's experiences, (2) training, and (3) practice. Each session usually began with mindfulness and meditation exercises, followed by group discussion, review of homework activities, and introduction to new exercises. Participants were asked to complete 15-30 minutes of daily practice each week.
223774765|NCT03002181|OTHER|Education|70 minute education session.
223774766|NCT00475826|DRUG|Statins and Ezetimibe|
223774767|NCT05073536|DEVICE|mini-sized MCE|Enrolled participants were randomly allocated into the normal-sized MCE group or mini-sized MCE group in a 1:1 ratio.
223774768|NCT05073536|DEVICE|normal-sized MCE|Enrolled participants were randomly allocated into the normal-sized MCE group or mini-sized MCE group in a 1:1 ratio.
223774769|NCT01024127|OTHER|Laboratory Biomarker Analysis|Correlative studies
223774770|NCT05069662|OTHER|Directive Interview|One directive interview conducted by telephone
223774771|NCT03746860|DRUG|Tablet, Dispersible|1 tablet/day with 12 SQ-HDM per lyo-tablet
223774772|NCT02334735|BIOLOGICAL|DC Vaccine|"DCs pulsed with 100µg/mL peptide (NY-ESO-1 and Melan-A/MART-1)~10 to 15 x 106 DCs per peptide antigen (NY-ESO-1 and Melan-A/MART-1) (total not to exceed 50 x 10\^6 cells)"
223774773|NCT02334735|BIOLOGICAL|Montanide Vaccine|250 µg peptide (NY-ESO-1 and Melan-A/MART-1) and 1.1 mL Montanide ISA-51 VG
223774774|NCT02334735|BIOLOGICAL|Poly-ICLC|1.4 mg
223774775|NCT03143829|OTHER|eSSET-CINV|This intervention is an educational intervention, a serious game, which allows older adults under treatment for cancer to practice making self-care decisions for an avatar who is being sent home after their first chemotherapy treatment. This serious game is coupled with a discussion with a nurse about choices related to managing nausea and vomiting at home.
223774776|NCT00158379|DRUG|Paclitaxel|4 cycles of Carboplatin AUC 5 every 3 weeks. 12 weekly infusions of 80 mg/m² Taxol®
223774777|NCT04944875|PROCEDURE|Group headphone|The patients in the first group wore the headphones but did not listen the music or maternal voice. The standard sedation method was applied to all patients.
223774778|NCT04944875|PROCEDURE|Group music|The patients in the second group listened to classical music (Vivaldi's The Four Seasons violin concertos) by sound- isolating headphones through the procedure.The standard sedation method was applied to all patients.
223774779|NCT04944875|PROCEDURE|Group maternal voice|The patients in the third group listened to maternal voice by sound- isolating headphones through the procedure.The standard sedation method was applied to all patients.
223774780|NCT03529526|DRUG|KN046|"The modified phase I 3 + 3 study design was used in dose escalation from low dose to high dose to determine the MTD.Sequential assignment of Patient cohorts to one of five dose levels of KN046: 0.3 mg/kg,1 mg/kg,3 mg/kg,5 mg/kg,10 mg/kg."
223774781|NCT00672477|DRUG|Methylnaltrexone|
223774782|NCT00672477|DRUG|Placebo|
223774783|NCT05840653|OTHER|psychotherapeutic intervention|The group that will receive 5-week positive psychotherapy-based hope placement psychoeducation
223774784|NCT04946240|OTHER|Supervised (BRACE) Group|Supervised (BRACE) protocol include static, dynamic and anticipatory balance exercises, chair rise, stair climbing and floor transfer comes under the category of resistance exercises. 6 minutes walk test, marching in space and cycling comes in aerobic. count reverse for 50 remember 5 words, 5 animals, repeat 5 words, spell forward and backwards and cont even numbers comes in cognitive exercises.
223774785|NCT04946240|OTHER|Conventional Balance Exercises Group|The home plan included Balance and Resistance exercises of BRACE protocol were provided to the control group but that was not supervised. Control group participants were also same assessed as the S-BRACE group. Before giving the training plan for home, it was elaborated in detail. For the convenience of participants, the BRACE protocol was also translated into Urdu and was given in the printed form. The data were collected at baseline, after 3 weeks, 6, 9 and then after 12 weeks of training
223774786|NCT03230279|PROCEDURE|Sacroiliac joint fusion|Minimally invasive SIJ fusion will be performed under general anesthesia with fluoroscopy. Using SI-LOK®, Sacroiliac Joint Fixation System, Globus Medical Inc. (Audubon, PA), this procedure involve placement of 2 to 3 implants across the SIJ to achieve stabilization and arthrodesis.
223774787|NCT03230279|PROCEDURE|Sacroiliac joint radiofrequency ablation|Sacroiliac joint radio frequency ablation will be performed using either conventional or cooled radiofrequency ablation techniques aimed at the S1-S3 lateral branches and the L5 dorsal ramus. The choice between conventional or cooled RFN will be determined by the provider expertise.
223774788|NCT00333034|DRUG|Etanercept|
223774789|NCT04971382|DRUG|Curcumin|Curcumin (1,7-bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione) or diferuloylmethane is an important bioactive constituent and hydrophobic polyphenol that isolated from the rhizome of the turmeric plant (Curcuma longa) . Curcumin will be used in combination with xenograft after ridge splitting surgery
223774790|NCT00612612|DRUG|obatoclax mesylate|Given IV
223774791|NCT00612612|DRUG|fludarabine phosphate|Given IV
223774792|NCT00612612|BIOLOGICAL|rituximab|Given IV
223774793|NCT00612612|OTHER|laboratory biomarker analysis|Correlative study
223774794|NCT05982743|DIETARY_SUPPLEMENT|Lactobacillus casei strain Shirota fermented milk|Participants will take one bottle (65 ml) of Yakult® drink daily, containing at least 6.5 x 10\^9 CFU of Lactobacillus casei strain Shirota, for a period of 4 weeks. Subsequently, there will be a two-week follow-up period.
223774795|NCT03843502|DRUG|Kava Dietary Supplement|Participants will be given three 75mg kava capsules.
223774796|NCT02348489|DRUG|SGI-110 (guadecitabine)|Investigational medicinal product
223774797|NCT02348489|DRUG|Treatment Choice|Choice of one: cytarabine, decitabine, or azacitidine
223774798|NCT01957189|DRUG|Dutasteride and Tamsulosin|0.5mg dutasteride once a day on Day 1 Period A , and Day 5 Period C,0.2mg Tamsulosin once a day on Day 1 to Day 7 in Period B and Period C
224326285|NCT07216326|BEHAVIORAL|Racial Justice Activism Intervention ARM|"The Our Voices Matter RJA intervention is a block-stratified randomized, group behavioral intervention designed for Black and Latinx adolescents and young adults (AYAs). The curriculum will specifically focus on the principles of activism, organizing, policy development, and legal advocacy. Participants will have didactic sessions, which include policy debates, keynote lectures, seminars, and trainings led by local leaders, community activists, and other experts on civil rights. Participants will learn how to use data to understand how structural racism and discrimination (SRD) influence life. Participants will understand and analyze policy and develop action plans to influence SRD. Additionally, the program will create a network of supportive peers. After the RJA training, small groups will meet monthly via videoconference for 1-year post-intervention. This intervention aims to equip Black and Latinx AYAs with civic and grassroots organizing knowledge and peer support."
224326286|NCT07216326|BEHAVIORAL|Adulting 101- Control Arm|"Adulting 101: Life Skills attention control is a 5- day in-person program (Figure 4) that will meet for the same number of sessions and duration as the intervention. This attention control is based on the Project Life program,84 developed initially for individuals supporting youth transitioning out of foster care to teach life skills for independent living. This curriculum is delivered through didactic and interactive modules that provide knowledge and informational resources, along with hands-on activities and life skills demonstrations. Sessions include: 1) Community Building, 2) Career Preparation, 3) Education, 4) Money Management, 5) Health and Nutrition, 6) Home Management, and 7) Story Sharing, which culminates with a Day of Action. Participants will learn skills for adulthood and gain experience developing career and education goals. Like the intervention condition, participants will actualize their skills on the final day, called the Day of Action."
224326287|NCT07216404|PROCEDURE|Biospecimen Collection|Undergo blood and urine sample collection
224326288|NCT07216404|OTHER|Counseling|Participate in therapy sessions
224326289|NCT07216404|OTHER|Interview|Ancillary studies
224326290|NCT07216404|DRUG|Psilocybin|Given PO
224326291|NCT07216404|OTHER|Survey Administration|Ancillary studies
224326292|NCT07216222|DEVICE|Deep Brain Stimulation|Deep brain stimulation via the Responsive Neurostimulator (RNS) device.
224326293|NCT07216664|OTHER|Multisensory early oral administration of human milk|M-MILK is implemented starting on day 3 of life, during the day shift, after every hands-on care, during the beginning of a full gavage feeding, and up to 4 times a day. Infants receive M-MILK in small droplets via a 1-ml syringe. M-MILK will cease upon oral feeding initiation. Infants will receive either mother's own milk or donor's milk based on availability. Infants may receive up to 1 mL of milk each time based on their cues and responses. The 1 mL volume intake is included as part of their oral caloric intake. M-MILK is provided by research nurses or parents.
224326294|NCT07216131|DRUG|AZD0780|AZD0780 will be administered orally.
224326295|NCT07216131|DRUG|Metformin|Metformin will be administered orally.
224326296|NCT07216677|OTHER|Chronic Disease Intervention CDI|Intervention for the management of a chronic eye disease
224326297|NCT07216586|DRUG|ZYNRELEF 400Mg-12Mg Extended-Release Solution|A single 14 mL dose of HTX-011 containing 400 mg bupivacaine and 12 mg meloxicam will be applied intraoperatively to the surgical site. This FDA-approved formulation is designed to provide sustained analgesia for up to 72 hours following total knee arthroplasty.
224326298|NCT07216586|PROCEDURE|Ultrasound-Guided Adductor Canal Block|A board-certified anesthesiologist or regional anesthesia-trained provider will perform an ultrasound-guided adductor canal block under sterile conditions while the patient remains under spinal anesthesia. A high-frequency linear ultrasound probe will be used to visualize the adductor canal and saphenous nerve.
224326299|NCT07216586|DRUG|Ropivacaine 0.5% Injectable Solution|A single injection of 30 mL of 0.5% ropivacaine will be administered into the adductor canal to provide postoperative analgesia. This dose is standard for adductor canal blocks and is intended to minimize motor blockade while providing effective pain control.
224326300|NCT07216690|DRUG|Cannabis|Cannabis brownie, 25mg THC
224326301|NCT07216690|DRUG|Pregnenolone 250 mg|Pregnenolone, low dose, one 250mg pregnenolone capsule and one 0 mg pregnenolone capsule
224326302|NCT07216690|DRUG|Pregnenolone 500 mg|Pregnenolone, high dose, two 250 mg pregnenolone capsules
224326303|NCT07216690|DRUG|Placebo|Placebo capsule, 0mg
224326304|NCT07216690|DRUG|Placebo brownie|Placebo brownie, 0mg THC
224326305|NCT07216443|BIOLOGICAL|Orca-T|An allogeneic stem cell and T-cell immunotherapy biologic
224326306|NCT07216846|OTHER|DNA care pathway|"Pharmacogenomic test results will be transmitted to the participant's primary care physician to support medication optimization and prescribing decisions. Follow-up assessments will be conducted by telephone approximately 14 days after enrollment and then monthly for six months. These structured interviews will capture information on falls, fall-related injuries, medication changes, adverse drug effects, and new medical conditions.~Participants will also complete a monthly calendar to document medication changes, falls, and fall-related injuries. Medical records from the participant's primary care physician will be reviewed for corroborating information on falls, fall-related injuries, medication changes, medication-related side effects, and newly diagnosed medical problems."
224326307|NCT07216794|DRUG|Alendronate|70 mg oral capsules
224326308|NCT07216794|OTHER|Placebo|Matching ALN placebo oral capsules
224326309|NCT07216898|BEHAVIORAL|Chemical Exposure Prevention|Education on potential toxic chemicals found within personal care products and safer alternatives during community-engaged clean beauty events.
224326310|NCT07216885|DEVICE|Solv Multi-Pass Hemodialysis System|Solv Multi-Pass Hemodialysis System
224326311|NCT07216924|BEHAVIORAL|Personalised Remapping Training|Participants will receive training across multiple days with text being shifted in real time as it is being read from locations covered by scotoma to locations determined by personalization procedure .
224326312|NCT07216924|BEHAVIORAL|RSVP personalized remappi|Participants will read one word at a time presented in rapid succession at fixation with text being shifted from scotoma locations to locations determined by personalization procedure.
224326313|NCT07216924|BEHAVIORAL|Reading text in the wild with remapping|Participants will read short texts presented in natural scenes in virtual reality with text being shifted from scotoma locations to locations determined by personalization procedure.
224326314|NCT07217119|DRUG|Belantamab mafodotin|Belantamab mafodotin will be administered.
224326315|NCT07217119|DRUG|Feladilimab|Feladilimab will be administered.
224326316|NCT07217080|BEHAVIORAL|Effect of Electrical Stimulation on Sleep|Direct electrical stimulation of thalamic nuclei and cortical structures using clinically implanted depth electrodes will allow assessing the effect of stimulation on sleep oscillations.
224326317|NCT07216989|OTHER|Fasting|fast with water for up to 60 hours while wearing continuous glucose monitors
224326318|NCT07217002|OTHER|Online Educational Modules|Online educational modules for clinicians that describe optimal antibiotic use and provide strategies to communicate with families about antibiotic prescribing for ARTIs. Modules are assigned through CHOP's internal learning website and assigned to every single primary care provider.
224326319|NCT07217002|OTHER|Prescribing Feedback Reports|Prescribing feedback reports distributed quarterly that show clinicians how their prescribing compares to their peers and to professional guideline recommendations. Will include metrics of overall prescribing and show choice and duration for antibiotics given ear infections, Strep throat, sinus infections, and pneumonia. The goal of the feedback reports is to show clinicians how often they are prescribing antibiotics, and when they do prescribe antibiotics are they doing so with right antibiotic and for the correct duration.
224326320|NCT07217002|OTHER|Clinical Decision Support|Clinical decision support built into the electronic health record to help clinicians choose the right antibiotics for the right number of days. Using information from guidelines and clinical pathways created by CHOP to help providers continue to optimize their prescribing practices.
224326321|NCT07217002|OTHER|Live, hybrid in-person and online educational sessions|Live, hybrid in-person and online educational sessions that explain the project, describe best prescribing practices and allow clinicians to talk directly with project team members. Study leaders visit all 31 practices across the network.
224326322|NCT07216781|GENETIC|Injectable Plasmid Klotho Gene Therapy|Injection of plasmid-delivered Klotho gene therapy
224326323|NCT07216976|DEVICE|Percept™ PC with Adaptive DBS (aDBS™)|"Subjects for whom meet the LFP screening criteria and can be acceptably configured on the Best aDBS mode (Dual or Single Threshold) will receive Best Mode aDBS treatment and enter the aDBS Evaluation Phase."
224326324|NCT07217184|DRUG|Belantamab mafodotin|Belantamab mafodotin will be administered.
224326325|NCT07217184|DRUG|Isatuximab|Isatuximab will be administered.
224326326|NCT07216833|DRUG|Decitabine|"Participants will receive dose level 1 (DL1). If 2 of 3 participants experience dose limiting toxicity (DLT) on DL1, then the dose will be de-escalated to DL1-1. If 2 of 3 participants experience DLT on DL1-1, then no further de-escalation will occur and no additional participants will be enrolled.~DL1: Intravenous (IV) administration of decitabine 20 mg/m2 from Days 1-5~DL1-1: Intravenous (IV) administration of decitabine 20 mg/m2 from Days 1-4"
224326327|NCT07216833|DRUG|Nivolumab|"Nivolumab will be used as a fixed dose in combination with de-escalating dose levels (DL1, DL1-1) of decitabine.~Participants will receive 480 mg of nivolumab on Day 8 every 4-week cycle."
224326328|NCT07217314|DEVICE|Spinal Stimulation|Participants will lay on their back and have small electrodes placed on the center of their backs and several leg muscles. The back electrodes, connected to a battery-operated unit, will send an electrical current to the spine. The leg electrodes will record muscle activity. This will take approximately 2 hours to complete on each day. The 2 hours includes set-up/placement of the electrodes, 4 trials of stimulation with breaks, and removal of electrodes after testing.
224326329|NCT07217223|DEVICE|Spaced Transcranial Direct Current Stimulation (tDCS)|tDCS will be self-administered at home under the supervision of a trained clinical research coordinator using the Soterix Medical mini-CT device with remote monitoring via a secure videoconferencing platform (e.g., Microsoft Teams).The device is designed for safe, remote tDCS delivery. Participants will be treated using a stimulation at 2 mA, with a 30-second ramp-up and ramp-down phase.
224326330|NCT07217301|DRUG|IBI363|Investigational product will be administered by IV infusion
223683178|NCT00937781|OTHER|laboratory biomarker analysis|
223683179|NCT00301821|BIOLOGICAL|epratuzumab|
223683180|NCT00301821|BIOLOGICAL|rituximab|
223683181|NCT00301821|DRUG|cyclophosphamide|
223683182|NCT00301821|DRUG|doxorubicin hydrochloride|
223683183|NCT00301821|DRUG|prednisone|
223683184|NCT00301821|DRUG|vincristine sulfate|
223683185|NCT00892918|DRUG|Moxifloxacin ophthalmic solution 0.5% ; Gatifloxacin ophthalmic solution 0.3%|Each drug will be given 4 times a day, 1 drop each time to the operated eye, for 21 days.
223683186|NCT00195871|DRUG|Prednisone, vincristine, daunorubicin , cyclophosphamide , L.-asparaginase, cytosine-arabinoside, methotrexate, etoposide|coventional dosages
223683187|NCT00195871|PROCEDURE|hematopoietic stem cell allograft|conventional procedures
224326331|NCT07217301|DRUG|Control Arm|Comparator product will be administered by IV infusion
223683188|NCT03206957|DIAGNOSTIC_TEST|Funduscopic examination and retinal photography|A standardized funduscopic examination and retinal photography will be performed by an ophthalmologist focusing on optic nerve.
223683189|NCT03206957|DIAGNOSTIC_TEST|Serum levels of endostatin and angiogenesis factors|Serum levels of endostatin, angiopoietin and vaso endothelial growth factor will be analyzed
223683190|NCT03206957|DIAGNOSTIC_TEST|Renal and low urinary tract Doppler ultrasound|"Measurements of each kidney will include maximum renal bipolar length in a sagittal plane, renal width and thickness in an axial plane perpendicular to each other at the level of renal hilum and cortical thickness. Intensity of corticomedullary differentiation will estimated.~Doppler ultrasound examination will assess renal arterial resistivity indexes"
223683191|NCT03206957|DIAGNOSTIC_TEST|Urinalysis|Urinalysis assessments will include assessments of microalbuminuria and microalbuminuria to creatinuria ratio. A spot urine sample will be collected from first morning void.
223683192|NCT03206957|DIAGNOSTIC_TEST|Anthropometric measures and vitals signs|weight, height and blood pressure will be assessed
223683193|NCT05503316|OTHER|Dynamic balance training|Participants will receive dynamic balance training while walking on the GRAIL device.
223683194|NCT05503316|OTHER|Traditional gait rehabilitation|Participants will receive traditional gait rehabilitation that also includes balance training while walking but not on the GRAIL device.
223774799|NCT00272701|DRUG|Esomeprazole|
223774800|NCT00272701|DRUG|Other PPI marketed in Sweden|
224326332|NCT07217275|OTHER|Community Resiliency Model (CRM)|CRM is an evidence-based mindfulness approach that provides patients with a biological perspective on behavioral health and stress reactions. CRM teaches six (6) mindfulness-based skills to address body sensation perception to attenuate symptoms of stress and anxiety, which in turn contribute to reducing pain and stress response. Trained specialists will introduce mindfulness skills to athletes, educate them on how to apply the skills, and observe athletes practicing the skills via Zoom®. Participants will be randomized to work with a mindfulness specialist at the baseline visit for 90 minutes and at follow-up visits for 15-30 minutes over Zoom®. The team's mindfulness specialists will deliver the evidence-based mindfulness training.
224326333|NCT07217275|OTHER|Control|Participants will receive written discharge instructions on postoperative pain management interventions given to all patients seeking care at Emory. The handout includes guidance on when to take prescribed pain medications and how to implement non-pharmacological pain management approaches, such as cryotherapy or aroma therapy. To mitigate attention biases, study staff and clinical staff will meet with control arm participants at each follow-up visit for 15-30 minutes to review the handout. This minimally enhanced usual care attention-based control group design has been successfully utilized in other trials to mitigate biases and dropouts.
224326334|NCT07216963|BEHAVIORAL|Community Paramedic Standard of Care (CP SOC)|Participants randomized to CP SOC will receive 1) community paramedic standard of care after initial response to overdose; 2) Medications for Opioid Use Disorder (MOUD), harm reduction referrals, and linkages to health and social programs as needed; 3) long-term follow-up care with community paramedics in the field after initial contact.
224326335|NCT07216963|BEHAVIORAL|CROSSROADS|The community paramedic (CP)standard of care (SOC) has three basic components across the sites. The core components of the CP SOC are that CPs: 1) are deployed via 911 as an opioid and/or stimulant overdose response; 2) provide Medications for Opioid Use Disorder (MOUD), harm reduction service referrals, and link patients to health and social programs as needed; and 3) provide long-term follow-up care in the field after initial contact. The CROSSROADS intervention will utilize these SOC aspects and build in technology-supported medical-legal partnerships (MLP) via Docs for Health (D4H) that identifies and addresses health-harming legal needs (HHLN). While CP SOC may refer to services that address some HHLN, the key component of the CROSSROADS intervention is the direct identification and addressing of HHLN via D4H.
224326336|NCT07217249|PROCEDURE|Descemet membrane endothelial keratoplasty|Replacement of the recipient corneal endothelial and Descemet membrane with healthy tissue from a donor cornea.
224326337|NCT07217197|DEVICE|Observational study to evaluate a Respiratory Monitoring System (RMS) with a Tracheal Sound Sensor (TSS) for detecting and predicting opioid induced respiratory Depression (OIRD).|Expert clinicians will evaluate the ability of the RMS sensor and diagnostic algorithms to detect and predict true OIRD events in post-operative patients routinely managed with opioid medications. Expert clinicians will adjudicate detailed reference data and EMR data to identify a true OIRD event. The definition of a true OIRD event will be based upon the PRODIGY Study definition and RTM definition of a true event. Performance of the RMS will be based upon the sensitivity, specificity, positive predictive value, and negative predictive value for detecting true OIRD events.
224326338|NCT07217262|BEHAVIORAL|Educational Intervention|Participants will receive the Proactive Costs of Care Guide that covers health insurance, employment, and finding personal and community support. They will also receive the Proactive Costs of Care Cost Tracker to help track medical costs. This one-time intervention can be completed in-person, by video, or by phone. A trained lay educator will spend approximately 30 minutes reviewing health insurance and discussing the 2-3 topics most relevant to the participant. All of the materials are available in a paper version or electronic version.
224326339|NCT07217236|DIAGNOSTIC_TEST|AI-ECG driven ECG monitoring|Participants identified as high-risk for CIED implantation by the AI-ECG system will receive a continuous cardiac rhythm monitor for up to 7 days.
224326340|NCT07216937|DEVICE|BTE hearing aid with compatible earmolds|Hearing aids will be fit with three different types of customized ear tips. They will only wear each ear tip group for the duration of the test (total = 20 minutes). Hearing aids will be programmed to a simulated mild, flat, sensorineural hearing loss of 40 dB HL from 250-8000Hz. A short washout period will follow completion of testing with ear ear tip group.
224326341|NCT07217171|DRUG|EVOLVE104|EVOLVE104 is provided as a solution for injection via IV infusion
224326342|NCT07217171|DRUG|EVOLVE104|Dose levels for Phase 1b will be determined based on the outcome of Phase 1a
224326343|NCT07216911|BEHAVIORAL|CC|Participants are exposed to an online cannabis store condition that includes claims about neutral product attributes.
224326344|NCT07216911|BEHAVIORAL|PAC|"Participants are exposed to an online cannabis store condition that includes CC plus claims about each product's effects on mental health (e.g., Calming) and symptom relief (e.g., Helps with: Stress)."
224326345|NCT07216911|BEHAVIORAL|WL|Includes CC plus a mental health warning label about the negative impact of THC on anxiety and depression.
224326346|NCT07217028|DRUG|Cetuximab (EGFR inhibitor)|Given IV
224326347|NCT07217028|DRUG|18F-NOTA-ABY-030|Given Bolus Injection
224326348|NCT07217028|PROCEDURE|Positron Emission Tomography (PET)|Undergo PET/CT
224326349|NCT07217353|DEVICE|Bouquet Speculum|Novel Bouquet Speculum used for endometrial biopsies
224326350|NCT07216729|DIETARY_SUPPLEMENT|Lactobacillus reuteri DSM 17938|5 drops (100 million CFUs) daily for 46 days of L. reuteri DSM 17938 in sunflower oil, medium chain triglyceride oil, and silicon dioxide.
224326351|NCT07216729|OTHER|Placebo|5 drops daily for 46 days of placebo consisting of inactive ingredients from probiotic supplement, specifically sunflower oil, medium chain triglyceride oil, and silicon dioxide.
224326352|NCT07217340|BEHAVIORAL|Dream Yoga Inspired Intervention|This customized contemplative training will guide participants in exploring techniques used in Tibetan Dream Yoga, including somatic awareness and intention-setting prior to sleep. Strategies in Tibetan Dream-Yoga manuals are thus transferred to a modern context and adapted as a group intervention. Goals will be set for dreaming that include gaining a degree of volitional influence over the dream. Participants will be instructed on how to work with their dream-world self-concept, which can include changing the environment deliberately, making other individuals appear, and switching identities with other individuals in the dream. Wearable devices will be used to present cues during sleep both to provoke lucidity and to remind individuals of Dream-Yoga exercises to be engaged during sleep. The intervention includes both wake- and sleep-based instructions, with instructions on learning to apply the new orientation in their daily lives. Participants will be contacted individually to assure
223774801|NCT04552782|BEHAVIORAL|Alcohol CBM|Trains approach or avoidance responses to alcohol cues.
224262720|NCT04960917|BEHAVIORAL|Evaluation of ehealth literacy workshop|Intervention components will include a three session workshop, enabling participants to raise their knowledge of the different available health resources and how to find them, their ability to determine which health resource is reliable, their ability to use the health information online to make health decisions, their knowledge of the online services offered by HMOs/Ministry of Health, and their ability to navigate HMO and preform actions such as set an appointment, find a doctor, and find contact information
224262721|NCT03916861|DEVICE|Bioelectrical Impedance Analysis|We use Inbody S20 analysis to measure fluid status before each hemodialysis session to guide fluid removal.
223683195|NCT02935543|BIOLOGICAL|CART 19|CART19 cells transduced with a lentiviral vector to express anti-CD19 scFv TCRz:41BB administered by IV infusion. Subjects will receive 1-5 x 10\^8 transduced CAR T cells as a split dose over three days as follows:Day 1, 10% fraction: 1-5x10\^7 CART19 cells, Day 2, 30% fraction: 3x10\^7-1.5x10\^8 CART19 cells, Day 3, 60% fraction: 6x10\^7-3x10\^8 CART19 cells
223683196|NCT03758326|OTHER|Body App|Participants will indicate areas of concern on a virtual manikin using an electronic online interface. Body measurements will also be collected.
223683197|NCT02670343|DRUG|Oral Testosterone Undecanoate|Subjects will receive a single dose containing 158 mg of testosterone undecanoate, equivalent to 200 mg testosterone.
223683198|NCT01837771|DEVICE|Diaphragmatic stimulation|
223683199|NCT00494065|OTHER|Home exercise|Patient education will be provided by trained therapists under the supervision of licensed chiropractic clinicians. Patients will attend four, 1 hour, one-on-one sessions.
223683200|NCT00494065|OTHER|Chiropractic Spinal Manipulative Therapy + Home exercise|The number and frequency of treatments will be determined by the individual chiropractor, based on patient-rated symptoms, disability, palpation, and pain provocation tests. Up to 20 treatments will be provided over the 12 week treatment period, each treatment visit lasting from 10-20 minutes. Treatment will include manual spinal manipulation and mobilization.
223774802|NCT04552782|BEHAVIORAL|PTSD CBM|Trains approach or avoidance responses to trauma cues.
223774803|NCT04552782|BEHAVIORAL|Alcohol Sham|Will not train approach or avoidance responses.
223774804|NCT04552782|BEHAVIORAL|PTSD Sham|Will not train approach or avoidance responses.
223774805|NCT00487110|DRUG|Tropisetron|a comparison of the analgesic action of paracetamol versus tropisetron+paracetamol
224262722|NCT03916861|PROCEDURE|Physician-guided|This intervention used physical examination as guided to adjust fluid therapy together with the chart record of intake and output per day
224262723|NCT02760732|DEVICE|drug eluting balloon; cutting balloon|Patients eligible for inclusion criteria were randomised to study group for percutaneous transluminal coronary angioplasty with a strategy of cutting balloon pre-dilation first and then drug eluting balloon.
224262724|NCT02760732|DEVICE|drug eluting stent|with a strategy of drug-eluting stent implantation alone for de novo coronary artery lesions.
224262725|NCT04012892|COMBINATION_PRODUCT|CD19 CART|CD19 CART
224262726|NCT06063460|DIAGNOSTIC_TEST|Periodontal examination|Periodontal Examination Routine In routine periodontal examination, measurements of plaque score, gingival score, pocket depths, and attachment loss will be utilized.
224262727|NCT06063460|OTHER|baseline questionnaire about sociodemographic characteristics, smoking habits, oral hygiene habits, halitosis, smell and taste perception|"Each patient participating in the study will complete a questionnaire detailing their age, gender, height, weight, smoking status, frequency of dental brushing, diabetes status, total annual household income, and Covid-19 history. In addition, a visual analogue scale and self-reported periodontal status questionnaire will be completed.~Personal Periodontal Condition Questionnaire This questionnaire comprises of eight questions regarding the participants' periodontal condition.~Graphical Analog Scale Patients were asked to rate their perception of taste, smell, and bad breath between 0 and 100 on this scale. Sense of smell (0-I cannot smell at all, 100-I can smell perfectly), sense of taste (0-I cannot taste at all, 100-I can smell perfectly), mouth. The odor will be graded from 0 (no bad breath) to 100 (extremely awful breath)."
224262728|NCT06063460|OTHER|phase I periodontal treatment|Phase I periodontal treatment will be applied by same expert.
224262729|NCT06063460|OTHER|1. month periodontal evaluation and repeat questionnaire|Periodontal examination will be performed in the 1st month, filling the questionnaire about halitosis, smell and taste perception.
224262730|NCT06063460|OTHER|3. month periodontal evaluation and repeat questionnaire|Periodontal examination will be performed in the 3rd month, filling the questionnaire about halitosis, smell and taste perception.
224262731|NCT00193960|PROCEDURE|1) Intraocular pressure 2) visual acuity|
224262732|NCT01277276|DEVICE|Diffuse optical spectroscopy and Near infrared spectroscopy|Diffuse optical spectroscopy and Near infrared spectroscopy are non-invasive methods measure tissue hemodynamics in real time, direct quantitative information and insights treatment-associated toxicity.
224262733|NCT06562374|DEVICE|Low Frequency Ultrasound Therapy|The ultrasound will be delivered at a frequency of 33 kHz at power levels of 4-10 Pascals with a program of 1.6 seconds on and 1.6 seconds off. The generators will be encased in epoxy within the Osteoarthritis baths. The intervention will be repeated on every second or third day to allow time for healing
224262734|NCT06157268|OTHER|Natural history and non therapeutical therapy|"This study concerns a natural history study part and a muscle fatigability part.~For the natural history study no interventions will be used. For the muscle fatigability part non therapeutical therapies will be used. This includes endurance tests, isokinetic dynamometry and repetitive nerve stimulation."
224262735|NCT05621694|BEHAVIORAL|Tai Chi Easy|A meditative movement practice that includes simple qigong movement/breath practices and single, repeated tai chi movements taught to generate a meditative state and flow
224262736|NCT02287844|OTHER|XOS|5 g of XOS everyday for 4 weeks.
224262737|NCT02287844|OTHER|INU-XOS|1 g of XOS and 3 g of inulin everyday for 4 weeks.
224262738|NCT02287844|OTHER|Placebo|6.64 g of maltodextrins everyday for 4 weeks.
224262739|NCT03236311|DRUG|SAR407899|Pharmaceutical form: Capsule Route of administration: Oral
224262740|NCT03236311|DRUG|Placebo|Pharmaceutical form: Capsule Route of administration: Oral
224262741|NCT03236311|DRUG|Adenosine|Pharmaceutical form: Solution for injection Route of administration: Intravenous
224262742|NCT03236311|DRUG|Regadenoson|Pharmaceutical form: Solution for injection Route of administration: Intravenous
223774806|NCT00487110|DRUG|paracetamol|a comparison of the analgesic action of paracetamol versus tropisetron+paracetamol
223683201|NCT03718325|DEVICE|Burst-SCS|The treatment arm used in the study is clinically-effective burst spinal cord stimulation (Burst-SCS). The device used to deliver Burst-SCS is the St. Jude Medical Invisible Trial System.
223683202|NCT03718325|DEVICE|Sham SCS|The placebo control arm used in the study is sham spinal cord stimulation (sham SCS). The device used to deliver sham SCS is the St. Jude Medical Invisible Trial System.
223683203|NCT02931591|DRUG|Metformin|Metformin is administered as an oral solution
223683204|NCT02931591|DRUG|Growth Hormone|Growth Hormone- no specific band
223683205|NCT02931591|DRUG|Placebo|
223683206|NCT04545359|BEHAVIORAL|Alpha-based neurofeedback|"Twelve 21-minute sessions (minimum of 1 session and maximum of 3 sessions per week) of auditory alpha-based neurofeedback with the Melomind device developed by myBrain Technologies (France). Recording of felt relaxation, perceived stress level, anxiety level pre-post sessions.~Electrophysiological: Recording of EEG signals on 32 electrodes every two sessions."
223683207|NCT04545359|BEHAVIORAL|Sham neurofeedback|"Twelve 21-minute sessions (minimum of 1 session and maximum of 3 sessions per week) of an auditory sham neurofeedback with the Melomind device developed by myBrain Technologies (France). Sham feedback is based on the real feedback of the participants in the Experimental arm. Recording of felt relaxation, perceived stress level, anxiety level pre-post sessions.~Electrophysiological: Recording of EEG signals on 32 electrodes every two sessions."
223683208|NCT02514317|PROCEDURE|percutaneous treatment|
223683209|NCT02514317|DEVICE|Ultrasound|
223683210|NCT00002567|BIOLOGICAL|filgrastim|
223683211|NCT00002567|DRUG|etoposide|
223683212|NCT00002567|PROCEDURE|peripheral blood stem cell transplantation|
223683213|NCT00002567|RADIATION|low-LET electron therapy|
223774807|NCT01201434|DIETARY_SUPPLEMENT|Bio-25 probiotic|2 tablets per day for 6 months
223683214|NCT00002567|RADIATION|low-LET photon therapy|
223683215|NCT03858478|DRUG|Biktarvy arm|BIKTARVY : one tablet QD, every day between D0 and M12 includind - TAF (25mg) / FTC (200mg) / BICTEGRAVIR (50mg)
223683216|NCT03454321|OTHER|Infiltration|The subacromial injection will be performed under ultrasound guidance to accurately inject the subacromial bursae. After skin disinfection with povidone, the injection will be performed with a 21G needle. The bursae will be injected with 2 ml of lidocaine 2% and 1 ml of betamethasone.
223683217|NCT04040868|DEVICE|the TiRobot system|The TiRobot system (TINAVI Medical Technologies Co. Ltd.) is a multi-indication orthopedic surgical robot that can be used in spinal, pelvic, and limb surgeries performed via an open or a minimally invasive approach
223683218|NCT04040868|DEVICE|Freehand|conventional fluoroscopy-assisted
223774808|NCT03207412|BIOLOGICAL|hAECs|human amniotic epithelial cells
224262743|NCT03236311|DRUG|13N-ammonia|Pharmaceutical form: Solution for injection Route of administration: Intravenous
224262744|NCT03236311|DRUG|82Rubidium|Pharmaceutical form: Solution for injection Route of administration: Intravenous
224262745|NCT02273492|DRUG|Asasantin ER|
223683219|NCT04877223|OTHER|No intervention|No intervention
223683220|NCT00623116|DRUG|Short withdrawal of testosterone, gonadotropins or estrogenic compounds (see below)|clinical examination, biochemical profile, and genetic characterization. Possibility to stop hormone therapy with drugs containing testosterone (Atmos®, Testim®, Testogel®, Nebido®, Panteston®, Sustanon®), FSH (Gonal-F®, Puregon®), hCG (Pregnyl®), estrogenic compounds (such as Estrofem®, Divigel®, Estrena®, Climara®, Estradot®, Evorel®, Femseven®: Merimono®, Progynova®, Ovestin®, Zumenon®, Estrogel®, Femoston®, Femoston combi®, Divina®, Divitren®, Indivina®, Estalis sekvens®, Evorel sequi®, Novofem®, Trisekvens®, Activelle®, Estalis®, Evorel conti®, Kliogest®, Mericomb®, Mericomb Mite®, Merigest®: Angeliq®) for 3 mo to assess reversibility of GnRH-deficiency will be offered.
223683221|NCT01314911|DRUG|Oseltamivir|Subjects were prescribed Oseltamivir twice daily for 5 days, and each dose consisted of one capsule of Oseltamivir 75 mg.
223683222|NCT01314911|DRUG|Placebo|Subjects were prescribed the matching placebo twice daily for 5 days, and each dose consisted of one capsule of placebo.
223774809|NCT03207412|PROCEDURE|Minimally invasive implantation|Minimally invasive implantation with ultrasound guidance
223774810|NCT02687880|PROCEDURE|Testicular biopsy|Subjects will undergo a surgical procedure to harvest their testicular tissue.
223774811|NCT06491004|DIAGNOSTIC_TEST|PTX3 assay|PTX3 dosage by the in vitro medical device in evaluation.
224262746|NCT02273492|OTHER|Standardized breakfast|
224262747|NCT02680444|BEHAVIORAL|Self-Administered Mindful-Reappraisal Exercise|Combining the practice of mindful acceptance of negative events combined with a reappraisal of the event by examining its positive aspects.
224262748|NCT02680444|BEHAVIORAL|Self-Administered Reappraisal-Only Exercise|A reappraisal of daily negative events by examining the positive aspects.
224262749|NCT02680444|BEHAVIORAL|Self-Administered Event Recall Exercise|Recall a negative event that took place that day.
224262750|NCT01406080|DRUG|Adapalene|Apply approximately 1 gram of Differin 0.3% every night on the entire face, except near the eye region.
224262751|NCT01406080|DRUG|Tretinoin|Apply approximately 1 gram of Tretinoin emollient cream 0.05% every night on the entire face, except near the eye region.
223774812|NCT01016795|DRUG|r-metHuSCF and Filgrastim|Patients were randomized in a 1:1 ratio to either chemotherapy combined with 10 µg/kg/d Filgrastim (control arm B), administered by subcutaneous injection for 14 days, or the combination of 10 µg/kg/d Filgrastim and SCF administered subcutaneously at a dose of 20 µg/kg/d (experimental arm A) for 8 days. Different injection sites were used for each cytokine.
223835280|NCT02153294|PROCEDURE|low tidal volume|Patients are randomized and ventilated with a low tidal volume (4-6 ml/kg PBW)
223835281|NCT02153294|PROCEDURE|high tidal volume|Patients are randomized and ventilated with a high tidal volume (8-10 ml/kg PBW)
224262752|NCT01528163|DRUG|Cabazitaxel|from 20 mg/m2 to 25 mg/m2. Intravenous injection every three weeks.
224262753|NCT01528163|DRUG|Methotrexate|From 40 mg/m2 (first cycle) to 50 mg/m2. Intravenous injections every three weeks.
224262754|NCT02074020|DRUG|Blisibimod|Administered via subcutaneous injection once per week
224262755|NCT02074020|DRUG|Placebo|Administered via subcutaneous injection once per week
224262756|NCT05779943|DRUG|Furosemide|Given IV
224262757|NCT05779943|OTHER|F18-rhPSMA-7.3|Given IV
223683223|NCT06115031|DRUG|Remimazolam|General anesthesia will be induced and maintained using continuous infusion of intravenous remimazolam.
223683224|NCT06115031|DRUG|Propofol|General anesthesia will be induced and maintained using target-controlled infusion of intravenous propofol.
223683225|NCT00306202|DRUG|Dasatinib|"Tablets, Oral, If necessary in participants who could not swallow, tablets were dispersed into 30 cc of 100% fruit juice with no preservatives (minute maid lemonade or orange juice or apple juice). Starting Dose Level of 60 mg/m\^2; Escalated/Dose Level 2 of 80 mg/m\^2. Once daily (QD), as long as clinical benefit was maintained.~Intra-participant dose escalation was allowed based on tolerance and on individual response. The starting dose for subsequent participants in a stratum may have been escalated depending on safety, assessed by prior intra-participant dose-escalation, and lack of efficacy in previous participants. Treatment courses were defined as 3 weeks (21 days plus any required delay); for participants who stayed on treatment \> 12 months, courses after 12 months were defined in quartiles of 13 weeks. Participants were to be followed until death or up to 5 years after end-of-treatment (EOT)."
223683226|NCT00306202|DRUG|Dasatinib|"Tablets, Oral, If necessary in participants who could not swallow, tablets were dispersed into 30 cc of 100% fruit juice with no preservatives (minute maid lemonade or orange juice or apple juice). Starting Dose Level of 60 mg/m\^2; Escalated/Dose Level 2 of 80 mg/m\^2. QD, as long as clinical benefit was maintained.~Intra-participant dose escalation was allowed based on tolerance and on individual response. The starting dose for subsequent participants in a stratum may have been escalated depending on safety, assessed by prior intra-participant dose-escalation, and lack of efficacy in previous participants. Treatment courses were defined as 3 weeks (21 days plus any required delay); for participants who stayed on treatment \> 12 months, courses after 12 months were defined in quartiles of 13 weeks. Participants were to be followed until death or up to 5 years after EOT."
223683227|NCT00306202|DRUG|Dasatinib|"Tablets, Oral, If necessary in participants who could not swallow, tablets were dispersed into 30 cc of 100% fruit juice with no preservatives (minute maid lemonade or orange juice or apple juice). Starting Dose Level of 60 mg/m\^2; Escalated/Dose level 2 of 80 mg/m\^2, Escalated/Dose level 3 of 100 mg/m\^2, and Escalated/Dose level 4 of 120 mg/m\^2. QD, as long as clinical benefit was maintained.~Intra-participant dose escalation was allowed based on tolerance and on individual response. The starting dose for subsequent participants in a stratum may have been escalated depending on safety, assessed by prior intra-participant dose-escalation, and lack of efficacy in previous participants. Treatment courses were defined as 3 weeks (21 days plus any required delay); for participants who stayed on treatment \> 12 months, courses after 12 months were defined in quartiles of 13 weeks. Participants were to be followed until death or up to 5 years after EOT."
223683228|NCT01565837|DRUG|Ipilimumab|Ipilimumab 10mg/kg administered intravenously over 90-minute period every 3 weeks for a total of four doses as tolerated. Maintenance ipilimumab (10 mg/kg intravenously every 3 months) will be administered beginning Week 24, as long as there is clinical benefit in the opinion of the investigator using immune related response criteria, and there are no novel or unexpected Grade 3 or 4 toxicities.
223683229|NCT01565837|RADIATION|Stereotactic Ablative Radiosurgery (SART)|Definitive radiotherapy will be administered to up to 1-5 lesions using SART techniques after initial dose of ipilimumab. Radiotherapy will be timed before start of 3rd cycle of ipilimumab treatment to maximize synergy (week 6).
223683230|NCT04473625|OTHER|Stool Sample Collection|Subjects participating in the study will provide a stool sample within 30 days of enrollment.
223683231|NCT03150485|DEVICE|JJVC Fitting Guides|Subjects who are habitual contact lens wearers with Presbyopic correction or Presbyopic symptoms, at least 40 years of age and no more than 70 years of age, will be fitted, according to the fitting guides, with either the Multifocal Contact Lens or an Toric Multifocal Contact Lens if refractive cylinder power of the eye is between -1.00 to -1.50. The Intervention is approximately 30-90 minutes of wear time during a 1-day visit.
223683232|NCT02097537|DRUG|Methacholine Chloride (SK-1211)|
223683233|NCT00141583|DRUG|Enalapril 20 mg bd|
223683234|NCT00141583|DRUG|Candesartan 8 mg bd|
223683235|NCT02369562|PROCEDURE|Evaluation of the failure rate of dental implants|Evaluation of the failure rate of dental implants, from the time of implant insertion (any time between 1980 and August 31st 2014) until September 2015
223835282|NCT06234137|DRUG|Docetaxel|75mg/m2 iv escalating to 100mg/m2 iv 3-weekly
223835283|NCT06234137|DRUG|Carboplatin|AUC=6 min/mL iv 3-weekly
223835284|NCT06234137|DRUG|Inetetamab|8mg/kg iv loading dose, followed by 6mg/kg iv 3-weekly
224262758|NCT05779943|PROCEDURE|Positron Emission Tomography|Undergo PET/CT scan
224262759|NCT05779943|PROCEDURE|Computed Tomography|Undergo PET/CT scan
224262760|NCT05877274|OTHER|Sodium channel mutation|Mutation of the genes SCN9A and SCN10A, which encode for Sodium channel 1.7 and 1.8.
224262761|NCT00807495|DRUG|Alisertib|Alisertib capsules
224262762|NCT00870662|DEVICE|AFS System|AFS System with patient specific flow rate
224262763|NCT05548465|DRUG|Remifentanil Hydrochloride|Subjects will receive remifentanil anesthesia for operative analgesia.
224262764|NCT05548465|DRUG|Sufentanil Citrate|Subjects will receive sufentanil and remifentanil anesthesia for operative analgesia.
224262765|NCT00911274|DRUG|Mycophenolate Mofetil|250 mg Capsule
224262766|NCT00911274|DRUG|CellCept®|250 mg Capsule
224262767|NCT03632031|DEVICE|Oasis Extracellular Matrix|Patients will receive OASIS Extracellular Matrix according to the Instruction for Use
224262768|NCT00857038|DRUG|Doxycycline|Doxycycline tablets, 100mg daily
224262769|NCT00857038|DRUG|Placebo|Placebo tablets 100mg
224262770|NCT04393818|BEHAVIORAL|Intervention App|Participants allocated to the intervention App will receive access to a fully operational mobile phone App. The App will be used to deliver psychoeducational materials (written and audio-visual), including: emotional training (mindfulness, moral harm, skills to manage emotions), lifestyles behaviour promotion (physical activity, diet, substance abuse, sleep disorders), work environment, and social support.
224262771|NCT04376203|PROCEDURE|Thyroidectomy|Typical Thyroidectomy
224262772|NCT03198923|BIOLOGICAL|natural killer and natural killer T cell|The eligible patients are infused with 10 doses of (2-2.5)x10\^9 NK and NKT cells in one course of treatment.
224262773|NCT03774303|OTHER|Mobile application|A mobile application that will be used to prepare families for day surgery
224262774|NCT03774303|OTHER|current practice|the current practice used to prepare families for day surgery
224326353|NCT07217340|BEHAVIORAL|Sleep Health Enhancement program|The control group will receive a modified version of the Health Enhancement Program (HEP), which was developed as an active control condition for mindfulness-based interventions, with a particular focus on sleep hygiene. It controls for several non-specific factors such as expectations of positive change, group support, behavioural activation, facilitator attention, at-home practice, treatment duration, and format (MacCoon et al., 2012; Rosenkranz et al., 2013). Our modified HEP will be structurally equivalent to the Dream-Yoga condition, with high similarity on non-program-specific factors, including timing and number of sessions. The two VR sessions will focus on health enhancement. Participants will be taught positive health-enhancing practices, such as healthy diet and gentle exercise, with activity-based sessions covering exercise, sleep, dreaming, stress, anxiety, nutrition, journaling, music enjoyment, and drawing. Home practice and implementation of health-enhancing habits will
224326354|NCT07217210|DIETARY_SUPPLEMENT|Multi-ingredient preworkout supplement|Experimental supplement.
224326355|NCT07216755|DEVICE|Respiratory Muscle Training (RMT)|Participants perform supervised respiratory muscle training (RMT) using a handheld resistive breathing device designed to strengthen the inspiratory and expiratory muscles. Training sessions are conducted 5 days per week for approximately 4-6 weeks. Each session includes a series of resisted breathing maneuvers with progressively increased load as tolerated. The device is calibrated to maintain a constant pressure threshold to ensure consistent training intensity.
224326356|NCT07216755|DEVICE|Sham Respiratory Muscle Training|Participants use an identical handheld breathing device with minimal resistance, providing no meaningful training stimulus. The training schedule and session duration match those of the active RMT group to maintain participant blinding.
224326357|NCT07216755|DIETARY_SUPPLEMENT|Dietary Supplement: Beetroot Juice Concentrate|Participants consume a standardized dose of concentrated beetroot juice daily for the duration of the training period (approximately 4-6 weeks). The supplement provides a fixed quantity of dietary nitrate known to enhance nitric oxide availability and support vascular and metabolic function during exercise.
224326358|NCT07216755|DIETARY_SUPPLEMENT|placebo beverage|Participants consume a placebo beverage identical in color, taste, and appearance to the nitrate supplement but containing no active nitrate. The beverage is consumed daily following the same schedule as the active supplement.
224326359|NCT07216820|PROCEDURE|Ultrasound-Guided Interscalene Brachial Plexus Block|"Single 16 mL injection (15 mL 0.5 % bupivacaine + 1 mL dexamethasone 4 mg) at the C5-C6 root level under ultrasound guidance.~Performed pre-operatively as standard care for shoulder surgery. Arm Cross-Reference: Standard Interscalene Block (Control)"
224326360|NCT07216820|PROCEDURE|Phrenic-Sparing Block Combination (Experimental)|"Infraclavicular: 15 mL 0.5 % bupivacaine + 1 mL dexamethasone (4 mg) injected around the cords of the brachial plexus beneath the clavicle under ultrasound guidance.~Distal Suprascapular: 12 mL 0.5 % bupivacaine + 1 mL dexamethasone (4 mg) injected at the suprascapular notch under ultrasound guidance to provide complete shoulder coverage while minimizing phrenic nerve involvement.~Arm Cross-Reference: Phrenic-Sparing Block Combination (Experimental)"
224326361|NCT07216313|DRUG|Denifanstat|Once daily
224326362|NCT07216313|DRUG|Resmetirom|Once daily
224326363|NCT07215988|OTHER|Non-Interventional Study|Non-interventional study
224326364|NCT07216716|OTHER|Health App Recommendation Tool (HART)|"In 2023, over 11 million family members provided 19.2 billion hours of unpaid care for people with dementia in the U.S. Caregivers face significant physical and emotional challenges, while many individuals with ADRD prefer to stay in their homes. Mobile health apps offer support but often lack user-friendly guidance and are hard to navigate.~The Health App Recommendation Tool (HART) bridges this gap by assisting ADRD caregivers in finding suitable health apps. It evaluates users' daily needs and preferences, using end-user informed points of measurement to match them with objectively reviewed apps within the HART App Library. This user-centered tool, shaped by ongoing feedback, simplifies app discovery, ensuring personalized recommendations that enhance caregiving and improve quality of life."
224326365|NCT07217145|BIOLOGICAL|PREVENT|The proposed study will assess the effectiveness of clinic-based outreach to increase vaccination rates for HPV at community clinics in rural counties.
224326366|NCT07216807|OTHER|Video Education|Video education was provided from the cirrhosis.ca website.
224326367|NCT07216807|OTHER|Text education|Text education was provided from the University of Michigan patient education materials
224326368|NCT07216742|DRUG|hMG subcutaneous injection|daily subcutaneous injection
224326369|NCT07216742|DRUG|Placebo|daily subcutaneous injection
224326370|NCT07217067|DRUG|PKN605|PKN605 is an oral formulation
224326371|NCT07217067|OTHER|Placebo|Matching placebo
224326372|NCT07216235|DRUG|Saroglitazar magnesium 1 mg|Saroglitazar magnesium 1 mg once daily, orally each morning before breakfast
224326373|NCT07216235|DRUG|Placebo|Matching Placebo once daily, orally each morning before breakfast
223683236|NCT01843595|BEHAVIORAL|REFIT Intervention|The intervention will include 2 face-to-face group meetings, weekly check-in sessions, weekly tailored feedback, and weekly lessons focused on specific weight loss behaviors. All participants will be encouraged increase their physical activity to approximately 250 minutes of moderate to vigorous physical activity per week.
223774813|NCT01016795|DRUG|r-metHuSCF and Filgrastim|Patients were randomized in a 1:1 ratio to either chemotherapy combined with 10 µg/kg/d Filgrastim (control arm B), administered by subcutaneous injection for 14 days, or the combination of 10 µg/kg/d Filgrastim and SCF administered subcutaneously at a dose of 20 µg/kg/d (experimental arm A) for 8 days. Different injection sites were used for each cytokine.
223683237|NCT02779712|PROCEDURE|Remote ischaemic conditioning|1 dose (=4 cycles) of intermittent upper limb ischaemia (1 cycle = 5minutes inflation to 20mmHg above systolic BP, 5 minutes deflation). Dose escalation: (i) Recruits 1-20 receive this cycle once (ii) Recruits 21-40 receive a second dose of 4-cycles one hour after the first. (iii) Recruits 41-60 receive further dosing, twice daily until day 4.
223683238|NCT02779712|PROCEDURE|Sham|4 cycles of intermittent sham procedure (1 cycle = 5 minutes inflation to 30 mmHg, 5 minutes deflation), matching the dose escalation described in the intervention
223835285|NCT06234137|DRUG|Pyrotinib|400mg orally daily
223835286|NCT00394511|PROCEDURE|low-LET photon therapy|
224326374|NCT07216872|DEVICE|Deep TMS (DTMS)|The Deep TMS group will receive 30 active sessions in 15 visits (i.e., 2 treatments per visit) over a period of 3-5 weeks in the Acute Treatment Phase. In the Maintenance Treatment \& Follow-up phase subjects will receive one treatment session per week from the end of the Acute Treatment Phase until the 6-month follow-up visit. All treatment sessions will consist of 2 treatments per day with a 30 minute interval in between. Each treatment will last approximately 20 minutes.
224326375|NCT07216872|DEVICE|Sham (No Treatment)|The control group will receive 30 Sham sessions in 15 visits (i.e., 2 treatments per visit) over a period of 3-5 weeks in the Acute Treatment Phase. In the Maintenance Treatment \& Follow-up phase subjects will receive one treatment session per week from the end of the Acute Treatment Phase until the 6-month follow-up visit. All treatment sessions will consist of 2 treatments per day with a 30 minute interval in between. The control group will receive inactive/sham treatment with identical parameters to the Deep TMS treatment.
224326376|NCT07217327|DIAGNOSTIC_TEST|DistaSense and Polysomnography|All subjects will be evaluated by DistaSense and reference device for respiratory rate and heart rate.
224326377|NCT07216859|OTHER|AI-Enabled Identification (EchoNet-Liver)|AI-generated notifications to clinicians about possible undiagnosed liver disease (MASLD and/or Cirrhosis) detected from Transthoracic Echocardiogram
224326378|NCT07216768|BEHAVIORAL|Ballet Class|Participants will attend weekly ballet classes following either Level 1 or Level 2 Ballet For All Kids (BFAK) curriculum.
224326379|NCT07217288|DEVICE|Non Pneumatic compression device|"Non-Pneumatic Compression Device (NPCD) is a wearable, portable system providing gradient sequential compression through shape-memory alloy actuators instead of air pressure. Frequency: 5 sessions per week for 8 weeks.~Intensity: Moderate, rhythmic static and dynamic compression applied distally to proximally, allowing safe lymphatic drainage.~Time: 40 minutes per session, once daily."
224326380|NCT07217288|OTHER|Complete Decongestive therapy|"Complete Decongestive Therapy (CDT), is the gold-standard, non-invasive treatment for lymphedema. It combines manual lymphatic drainage (MLD), compression bandaging, exercise therapy, and skin care to reduce limb swelling and improve lymphatic flow.~Frequency: 5 sessions per week for 8 weeks. Intensity: Gentle manual drainage with multilayer compression Time: 60 minutes per session. Type: Therapist-guided manual and compression therapy followed by self-management.~CDT aims to decongest the limb, prevent fibrosis and infection, and enhance mobility and quality of life in post-mastectomy lymphedema patients."
224326381|NCT07216950|BEHAVIORAL|Knowledge and Interpersonal Skills to Develop Enhanced Relationships|KINDER is an 8-week intervention that consists of three facilitated group discussion sessions conducted over Zoom with a small group of caregivers, in addition to self-paced lessons delivered using a printed or PDF workbook, depending on participant preference. Throughout KINDER, caregivers reflect on their relationship, including how their behavior toward the care recipient may need to change considering new vulnerabilities with dementia, and how to communicate about topics that often contribute to conflict, such as balancing safety and independence (e.g., driving).
224326382|NCT07216950|BEHAVIORAL|Healthy Living for the Caregiver|Caregivers in the control arm will receive a workbook that covers 8 weeks of content focused on healthy living (e.g., nutrition).
224326383|NCT07217132|OTHER|Post-market Study|Prospective case series without a concurrent comparator group.
224326384|NCT07217015|DRUG|KT-621|Oral drug
224326385|NCT07217015|OTHER|Placebo|Oral placebo matched to KT-621
224326386|NCT05008198|OTHER|Transcranial Magnetic Stimulation|Transcranial Magnetic Stimulation is delivered as part of routine care and is not managed by this observational study.
224326387|NCT04917042|DRUG|Tazemetostat|Subjects will receive 520 mg/m2/dose (subjects 12-17 years old) or 800 mg of tazemetostat orally twice daily in 28 day cycles. Subjects will receive treatment with tazemetostat up to 2 years or until disease progression or unacceptable toxicity occurs.
224326388|NCT06330207|BEHAVIORAL|Clinical decision support tool|The intervention involves two strategies. The first strategy is education where at baseline participants will complete the one-hour online Smiles for Life oral health educational module on acute dental problems, which includes NTDC management. This module can be completed in multiple sessions. Providers will be asked to share the certificate of completion that is provided to them via the website by passing a post knowledge test. The second strategy is CDST. Providers who completed NTDC module certificate will pilot test the CDST which is an algorithm that walks the ED provider thru patient's signs and symptoms and identifies guideline-recommended treatments available in the ED.
223683239|NCT04019418|DIETARY_SUPPLEMENT|Maltodextrin (carbohydrate)|A drink containing 300ml of water and 75g of maltodextrin
223683240|NCT04019418|OTHER|Exercise|30 minutes on a cycle ergometer working at 75% VO2 max
224262775|NCT02719665|DIETARY_SUPPLEMENT|SPM Emulsion, Dose-modality|"Phase 1a Dose-Finding oral SPM administration of increasing dose (15ml, 30ml, and 60ml) by the following schedule:~Days 1 to 5: 15 ml; Days 6 to 14: Washout, no SPM administration; Days 15 to 19: 30 ml; Days 20-28: Washout, no SPM administration; Days 29-33: 60 ml"
223683241|NCT04019418|OTHER|Rest|30 minutes laying on a bed
223683242|NCT04019418|OTHER|Water|A drink containing 300ml of water
223683243|NCT00957385|DRUG|Revlimid|10mgs PO daily for 21 days of each 28 day cycle. Number of cycles: total of 24 or until subject relapses or unacceptable toxicity develops.
223683244|NCT02857361|DRUG|Sublingual ketamine wafers|Two sublingual ketamine 25 mg wafers
223683245|NCT03887403|BEHAVIORAL|Multimodal Intervention|
223683246|NCT03887403|OTHER|Usual care|
223683247|NCT03269461|DEVICE|Angiography and Optical Coherence Tomography evaluations|coronary stent implantation followed by Angiography and Optical Coherence Tomography evaluations
223683248|NCT00255801|DRUG|Targretin® (bexarotene)|
224262776|NCT02719665|DIETARY_SUPPLEMENT|SPM Softgel, Dose-Modality|Phase 1b Dose-Finding oral softtel SPM administration of two different doses (2 softgel vs 4 softgel) Days 0 to 5: 2 SPM softgel; Days 6 to 21: Washout, no SPM administration; Days 22 to 26: 4 SPM softgel; Days 27-42: Washout, no SPM administration
224262777|NCT02719665|DIETARY_SUPPLEMENT|Placebo Softgel|Days 43-47: 4 Placebo softgel; Day 48-64 Washout
223683249|NCT00255801|DRUG|pegylated liposomal doxorubicin hydrochloride|
223683250|NCT01836224|DRUG|Terlipressin|Terlipressin (1.3mcg/min i.e 2mg over 24 hr to max of terlipressin 5.2mcg/min i.e. up to 8mg over 24hr) .The dose to be increased every 15min from start dose by 1ml and to decrease by 0.5ml every 15min keeping MAP (Mean Arterial Pressure) \>65 .Terlipressin 2mg in 48ml,1ml=42mcg=0.67mg/min, max dose 8mg/day- 8ml/hr of infusion.
223683251|NCT01836224|DRUG|Noradrenaline|Noradrenaline 2amp (4000mcg in 50ml) at 6ml/hr = 7.5mcg/min and dose maximum 60mcg/min 24ml/hr double strength. The dose to be increased every 15min from start dose by 1ml and to decrease by 0.5ml every 15min keeping MAP (Mean Arterial Pressure)\>65
223683252|NCT00130273|BEHAVIORAL|Managed problem solving|Participants in the managed problem solving group will have four study visits and will receive three phone calls for the first 3 months of the study, and one phone call every month for the following 9 months. At each study visit, participants will identify barriers to adherence. During the phone calls, participants will be asked about any steps they have taken to improve their adherence. A medication event monitoring system (MEMS) will be used to assess participants' treatment adherence. MEMS uses microelectronic monitors on the caps of medication bottles to record the timing and frequency of bottle openings. Participants whose adherence has decreased or remained the same at the end of 12 months will be evaluated for regimen changes. Blood collection at the beginning and end of the study will be used to measure viral load and CD4 count.
223683253|NCT00130273|BEHAVIORAL|Standard care|Participants will receive standard of care for 12 months.
223683254|NCT01394718|DRUG|Intravenous Acetaminophen|Scheduled doses of 15 mg/kg of IV acetaminophen will be administered to the treatment arm of the study for a total of 8 doses over a 48 hour period post-operatively.
223683255|NCT01394718|OTHER|Placebo|Saline placebo will be given at the time of skin closure intra-operatively and will continue to receive IV saline for 44 hours post-operatively. Doses will be administered every 6 hours (total of 8 doses).
223683256|NCT06243224|OTHER|High intensity interval training|High intensity will be calculated based on load (watt) at % 75-85 of VO2 max analyzed during the CPET in HIIT group.Patients will perform 4 minutes of active high-intensity training with this load. Patients will perform for 1 minute each with a load (watt) of 50-60% of VO2 max in the interval phase.HIIT program will be performed with a horizontal ergometric bicycle (Ergoline GmbH ergoselect5, Serial no:2020010104, Germany ) for 3 sessions per week, each session being 30 minutes, for a total of 12 sessions for 4 weeks in the cardiopulmonary rehabilitation laboratory.
223683257|NCT06243224|OTHER|Moderate intensity continuous training|Moderate intensity will be calculated based on load (watt) at % 50-60 of VO2 max analyzed during the CPET in MICT group. Patients will complete their training sessions without changing this load determined during the treatment process.MICT program will be performed with a horizontal ergometric bicycle (Ergoline GmbH ergoselect5, Serial no:2020010104, Germany ) for 3 sessions per week, each session being 30 minutes, for a total of 12 sessions for 4 weeks in the cardiopulmonary rehabilitation laboratory.
223683258|NCT02667327|DRUG|Granexin gel|Granexin gel contains active pharmaceutical ingredient, aCT1 peptide, for topical application to diabetic foot ulcers once a week for up to 12 weeks or until wound closure, whichever comes first.
223683259|NCT02667327|OTHER|Vehicle gel|The vehicle gel formulation is hydroxyethyl cellulose that does not contain the active aCT1 peptide. Vehicle gel will be applied topically to diabetic foot ulcers once a week for up to 12 weeks or until wound closure, whichever comes first.
223683260|NCT06143553|DRUG|Paclitaxel Polymeric Micelles for Injection|Subjects are given 300 mg/m2 of Paclitaxel Polymeric Micelles for Injection without special infusion device,intravenously administrated for ≥ 3 hours.Three weeks constituted one course of treatment.
223683261|NCT06143553|DRUG|Eribulin Mesilate injection|Subjects are given 1.4 mg/m2 of Eribulin Mesilate injection on days 1 and 8 of the 21-day cycle.
223683262|NCT06143553|DRUG|Capecitabine Tablets|Subjects are given 1000-1250mg/m2 of Capecitabine Tablets on days 1 to 14 of the 21-day cycle ,and twice a day (once in the morning and once in the evening; Total daily dose 2000-2500mg/m2).
223683263|NCT06143553|DRUG|Gemcitabine Hydrochloride for Injection|Subjects are given 800-1200mg/m2 of Gemcitabine Hydrochloride for Injection on days 1, 8 and 15 of the 28-day cycle.
223683264|NCT06143553|DRUG|Vinorelbine Tartrate Injection|Subjects are given 25mg/m2 of Vinorelbine Tartrate Injection every first day of the week.
223683265|NCT06143553|DRUG|Paclitaxel (albumin-bound)|Subjects are given 260mg/m2 of Paclitaxel (albumin-bound) on day 1 of the 21-day cycle,intravenous administration for more than 30 minutes.
223683266|NCT06094127|DEVICE|Endovascular aortic treatment|Use of ZTA to treat diseases in the descending thoracic aorta, such as thoracic aortic aneurysm and penetrating aortic ulcer.
223683267|NCT05929079|DRUG|Retatrutide|Administered SC
223683268|NCT05929079|DRUG|Placebo|Administered SC
223683269|NCT03609398|BIOLOGICAL|RVF Vaccine|1.0 mL dose given SQ in upper arm
223683270|NCT01276197|OTHER|Story-Telling DVD|DVD will contain both informational and story-telling components.
223683271|NCT01276197|OTHER|Non-Storytelling DVD|DVD will contain only informational component.
223683272|NCT01966692|DRUG|Fluticasone Propionate Formulation 1|Fluticasone Propionate dry powder inhaler Formulation 1
223683273|NCT01966692|DRUG|Fluticasone Propionate Formulation 2|Fluticasone Propionate dry powder inhaler Formulation 2
223683274|NCT01966692|DRUG|Fluticasone Propionate Formulation 3|Fluticasone Propionate dry powder inhaler Formulation 3
223683275|NCT01966692|DRUG|Fluticasone Propionate Formulation 3*|"Fluticasone Propionate dry powder inhaler Formulation 3\*~\*(The asterisk) A different set of capsules from the same batch of formulation 3 is given to the subject to assess the within-subject variability and to ensure that the study is sufficiently powered to show bioequivalence between two replicates of the same formulation."
223683276|NCT00067912|DRUG|Duloxetine Hydrochloride|
223683277|NCT00067912|DRUG|Venlafaxine Extended Release|
223683278|NCT01362595|DRUG|leucine|"Dosage of leucine will be dependent on body surface area (BSA):~leucine 700 mg/m2/dose by mouth three times a day"
223683279|NCT02469038|DEVICE|AccuCath catheter|Ultrasound-guided insertion of an AccuCath catheter during a standard of care procedure.
223683280|NCT02469038|DEVICE|Control|Ultrasound-guided insertion of a conventional IV catheter during a standard of care procedure.
223683281|NCT01357200|OTHER|enteral formula|Complete feeding of study enteral formula, route and regime prescribed by the physician.
223683282|NCT02206243|DRUG|Embozene Microspheres|Intraarterial application
223774814|NCT01016795|DRUG|Chemotherapy plus Filgrastim|Patients were randomized in a 1:1 ratio to either chemotherapy combined with 10 µg/kg/d Filgrastim (control arm B), administered by subcutaneous injection for 14 days, or the combination of 10 µg/kg/d Filgrastim and SCF administered subcutaneously at a dose of 20 µg/kg/d (experimental arm A) for 8 days. Different injection sites were used for each cytokine.
223774815|NCT01112995|DIETARY_SUPPLEMENT|Lactobacillus rhamnosus|1 pill formulation to be given once a day for 4 weeks
223683283|NCT05715879|DIAGNOSTIC_TEST|covid infection|patients with covid infection which was proved with positive test
223683284|NCT05715879|BIOLOGICAL|admission to hispital|patients with sever covid disease, who was admitted in hospital
223683285|NCT05427955|PROCEDURE|One-level Erector Spinae Plane Block|One-level Erector Spinae Plane Block will be performed unilaterally, under US guidance, before the surgical operation, after the induction of anesthesia, and when the patient is placed in the lateral decubitus position. In applications, 30 ml of 0.25% bupivacaine will be injected at the T5 level.
223683286|NCT05427955|PROCEDURE|Bi-level Erector Spinae Plane Block|Bi-level Erector Spinae Plane Block will be performed unilaterally, under US guidance, before the surgical operation, after the induction of anesthesia, and when the patient is placed in the lateral decubitus position. In applications, 15 ml of 0.25% bupivacaine at T4 level and 15 ml of 0.25% bupivacaine at T6 level will be injected.
223683287|NCT03663153|OTHER|SEMA4C high value follow-up group|Serum samples will be collected every 3 months for the first year after surgery and then every 6 months to first progression defined as death or recurrence of the breast cancer or until 5 years since last patient in, whichever occurs first. Imaging examination and biopsy or surgery if necessary are recommended for patients with elevated SEMA4C. Serum SEMA4C levels will be tested in single center in order to decrease bias and be measured using a double antibody sandwich ELISA method using in-house SEMA4C detection kits.
223683288|NCT03663153|OTHER|SEMA4C low value follow-up group|Serum samples will be collected every 3 months for the first year after surgery and then every 6 months to first progression defined as death or recurrence of the breast cancer or until 5 years since last patient in, whichever occurs first. Imaging examination and biopsy or surgery if necessary are recommended for patients with elevated SEMA4C. Serum SEMA4C levels will be tested in single center in order to decrease bias and be measured using a double antibody sandwich ELISA method using in-house SEMA4C detection kits.
223683289|NCT02825407|DIETARY_SUPPLEMENT|Oral physiology|
223774816|NCT01112995|DIETARY_SUPPLEMENT|Sugar pill (placebo)|placebo identical to the active product will be given
223774817|NCT05652751|DRUG|nerve growth factor|The patient first received an intramuscular injection of NGF or saline into the gluteus maximus.The 20ug nerve growth factor (NO.S20060051, Jinlujie) will be obtained from Hiteck Biopharmaceutical Co., Ltd, Wuhan, China. mNGF will be dissolved in 1 ml sterile water for injection and then injected intramuscularly at gluteal muscle, once a day for 4 weeks. Dose modification is not allowed for mNGF.
223683290|NCT01234818|DEVICE|Mirena (LNG-IUS)|* General Name/Brand name: Mirena - Bayer ② Active ingredient: levonorgestrel 52mg ③ Description: Mirena is a hormone-releasing T-shaped intrauterine system. A removal thread is attached to a loop at the end of the vertical stem of the T-body.
223683291|NCT00355901|DRUG|Visilizumab (Nuvion®; HuM291)|
223683292|NCT00636987|DEVICE|Biocor and Biocor Supra valves|Replacement for a diseased, damaged, malformed aortic or mitral heart valve
223683293|NCT04730167|OTHER|Neurological and neuropsychological assessments / MRI / PET scan / Video-oculography.|Essential data for this study are those collected during the concussion assessment, carried out as part of routine care at Princess Grace Hospital (medical background; history of sports practice and history of concussions; data extracted from clinical and neuropsychological evaluations, from imaging exams (MRI and PET-Scan) and from eye-tracking evaluation).
223683294|NCT01251146|DRUG|Bisoprolol|Bisoprolol will be administered at a dose of 5 milligram (mg) once daily for 2 weeks. If heart rate is less than or equal to 65 beats per minute (bpm), then the initial dose will be administered for another 2 weeks. If the heart rate remains greater than 65 bpm, then the dose will be further increased to 7.5 mg once daily for 2 weeks. After 2 weeks, if the heart rate is less than or equal to 65 bpm, the increased dose will be administered for another 2 weeks. If the heart rate is still greater than 65 bpm, then the dose will be further increased to 10 mg once daily for 2 weeks. After 2 weeks, if the heart rate is less than or equal to 65 bpm, the increased dose will be administered for another 2 weeks.
223774818|NCT05652751|DRUG|physiological saline|Other patients will receive 1ml volume of physiological saline (PS) injected into the gluteal muscle, once a day for 4 weeks.
223835287|NCT04181541|PROCEDURE|Provider type: Physicians|In this cohort, women will receive second trimester medical abortion care from physicians
223835288|NCT04181541|PROCEDURE|Provider type: Midlevel Providers|In this cohort, women will receive second trimester medical abortion care from midlevel providers.
223835289|NCT03753217|DEVICE|qCON Monitor|supervision by qCON monitor of the depth of anesthesia
223835290|NCT03375814|DRUG|Crocin|This group (osteoarthritic patients) can receive crocin with conventional therapy
223683295|NCT01251146|DRUG|Atenolol|Atenolol will be administered at a dose of 50 mg once daily for 2 weeks. If heart rate is less than or equal to 65 bpm, then the initial dose will be administered for another 2 weeks. If the heart rate remains greater than 65 bpm, then the dose will be further increased to 75 mg once daily for 2 weeks. After 2 weeks, if the heart rate is less than or equal to 65 bpm, the increased dose will be administered for another 2 weeks. If the heart rate still greater than 65 bpm, then the dose will be further increased to 100 mg once daily for 2 weeks. After 2 weeks, If the heart rate is less than or equal to 65 bpm, the increased dose will be administered for another 2 weeks.
223683296|NCT03524079|DRUG|Ajmaline 17-(Chloroacetate) Monohydrochloride|Ajmaline 17-(Chloroacetate) Monohydrochloride(1mg/kg in 5 minutes)
223683297|NCT01739400|DRUG|Macitentan 10 mg tablet, once daily.|Macitentan 10 mg tablet, once daily.
223683298|NCT00414427|PROCEDURE|Intraarticular steroids|
223683299|NCT06519110|DRUG|Neratinib tablets|In the first week, take Neratinib tablets 120mg orally, in the second week take Neratinib tablets 160mg orally, and from the third week until the end of treatment, take Nilotinib tablets 240mg orally (from Cycle 1 Day 15 until the end of treatment).
223683300|NCT02876640|PROCEDURE|Biospecimen Collection|Undergo blood and urine sample collection
223683301|NCT02876640|DRUG|Retinoid 9cUAB30|Given PO
223683302|NCT02876640|PROCEDURE|Therapeutic Conventional Surgery|Undergo tumor resection surgery
223683303|NCT04965909|OTHER|Online physiotherapy protocol based on pain neuroscience education and gradual exposure to movement.|Online group therapeutic program (small groups), applied for 3 months.
223683304|NCT01216995|BIOLOGICAL|Dose A|ADRC Dose A
223683305|NCT01216995|BIOLOGICAL|Placebo|Placebo Comparator
223683306|NCT01810965|PROCEDURE|First evaluation phase : no intervention / Second evaluation phase: bloodletting of 7 ml/kg (with a maximum of 500ml)|
223683307|NCT04997590|BIOLOGICAL|Umbilical cord blood mononuclear cells|injection of CB-MNCs (cell count 1×108 cells/time) was performed once every 2 week for a total of 3 times.
223683308|NCT04997590|DRUG|Staphylococcal Enterotoxin C|injection of staphylococcal enterotoxin C was performed once every 2 week for a total of 3 times.
223683309|NCT01630785|DEVICE|Intraoperative Neurophysiological Monitoring IONM|Intraoperative Neurophysiological Monitoring IONM device. Manufacturer: Inomed, Emmendingen, Germany
223683310|NCT01402895|OTHER|Exercise|Transversus abdominus exercise
223683311|NCT01402895|OTHER|Mobilizations|The physiotherapist will perform mobilizations to the L-spine and SI joints with the participant in a specific position.
223683312|NCT01643603|DRUG|Dasatinib|Patients receive dasatinib PO every day (QD) for 6 months.
223683313|NCT01643603|OTHER|laboratory biomarker analysis|Correlative studies
223683314|NCT05196399|DRUG|Aprocitentan (Formulation A)|A single oral dose of 25 mg.
223683315|NCT05196399|DRUG|Aprocitentan (Formulation B)|A single oral dose of 25 mg.
223683316|NCT05992571|OTHER|Placebo|Ingestion of a taste-matched calorie-free placebo drink followed by 90 minutes of rest.
223683317|NCT05992571|DIETARY_SUPPLEMENT|β-OHB|Ingestion of a high dose \[R\]-3-hydroxybutyl \[R\]-3-hydroxybutyrate (0.6 g β-OHB/kg body weight) followed by 90 minutes of rest.
223683318|NCT01507454|DRUG|estradiol, 25 mcg|Vaginal tablets for 6-12 weeks according to product labelling
223683319|NCT02990156|DEVICE|Coil Embolization System|deposits coils in the aneurysm sac by electrolytical detachment; coil types include Complex Finish, Complex Frame, and Helical. The coils are made of a platinum - tungsten alloy, have a minimum diameter of 2 mm and a maximum diameter of 24mm. The intended use of the Microport NeuroTech Coil Embolization System is for the endovascular embolization of intracranial aneurysms.
223683320|NCT02990156|DEVICE|Cotrol device from Medronic|Control device from Medronic (include AxiumTM Detachable Coils and AxiumTM Prime Detachable Coils) are manufactured by ev3 (Medtronic, Irvine, California, USA);
223683321|NCT03298776|DEVICE|I-Scan|I-Scan is a digital enhancement technique. These endoscopes already have greater definition compared to many standard endoscopes but they also utilise a 'zoom' function and digital image enhancement.
223683322|NCT03298776|DIAGNOSTIC_TEST|Standard endoscopy|Patients referred for standard endoscopy to receive standard of care only
223683323|NCT03722199|DIETARY_SUPPLEMENT|flavanols (subgroup of polyphenols, subgroup of phenolics, natural substances)|single intake of capsules with flavanols (subgroup of polyphenols, subgroup of phenolics, natural substances)
223683324|NCT03722199|OTHER|Placebo|single intake of capsules with a placebo
223683325|NCT01487473|BEHAVIORAL|Mindfulness-Based Stress Reduction|An 8-week structured group program that was developed to improve psychological and physical symptoms associated with pain. It incorporates a variety of mindfulness meditation exercises including mindful yoga, sitting meditation, and body scan to facilitate attention, acceptance, and awareness of one's experiences.
223683326|NCT04054063|DRUG|HSK3486+ etomidate|
223683327|NCT03261180|OTHER|Best Practice|Receive regular diet
223683328|NCT03261180|OTHER|Laboratory Biomarker Analysis|Correlative studies
223774819|NCT05652751|DEVICE|EA|"Patients take supine position. After skin disinfection with 75% ethanol routine disinfection, the stainless needle (size 0.25mm×40mm, Hua Tuo brand, Suzhou Medical Supplies Company Ltd in Jiangsu, China) will be inserted in GV20（Baihui) and the stainless needle(size 0.25mm×25mm, described above) will be inserted in GV26 (Shuigou), acupoints will be stimulated manually until patients feel soreness, distension or heaviness (the reaction of De Qi). Then, the needles are stimulated by using an acupuncture point nerve stimulator (HANS-200, Nanjing Jinsheng, Ltd., China) with a frequency of 2/100 Hz and an intensity of 3 mA for 40 min (a homemade relay cycled power to the electrode for 6 sec on and 6 sec off), 28 days as a course of treatment, once a day."
223774820|NCT05652751|DEVICE|sham EA|The only difference between sham EA intervention and EA intervention is that the stimulator is connected to the needle handle without power for 40 min intervention.
223774821|NCT03869775|DEVICE|perfusion index monitor|perfusion index measured in patients undergoing spinal anesthesia with non-invasive perfusion index monitor
223683329|NCT03261180|DIETARY_SUPPLEMENT|Nutritional Intervention|Receive Nestle Impact AR
223683330|NCT02834377|OTHER|Treatment algorithm targeting individual cardiac output|
223683331|NCT03028350|DRUG|Ifetroban Oral Capsule|Subjects will be treated with oral ifetroban daily for 8 weeks
223683332|NCT03028350|DRUG|Placebo Oral Capsule|Subjects will be treated with oral placebo daily for 8 weeks
223683333|NCT06259201|DEVICE|Vagus Nerve Stimulation|Vagal nerve stimulation (VNS) involves the use of a device to stimulate the vagus nerve with electrical impulses twice per day (AM \& PM) for two minutes each. It is an approved treatment for treatment resistant epilepsy and depression.
223774822|NCT03869775|DIAGNOSTIC_TEST|ewing test|ewing tests will be applied to diabetic patients undergoing spinal anesthesia for cardıovascular autonomous neuropathıa diagnosis
223683334|NCT03718182|DIETARY_SUPPLEMENT|Cholecalciferol|vitamin D3 daily oral supplement
223683335|NCT05386823|DRUG|HF1K16|HF1K16 for Injection doses will be calculated based on subject weight measured at admission, and diluted in sterile saline (0.9% sodium chloride). Doses will be administered using an IV infusion pump over a period of approximately 60 minutes at 2.5 mL/min.
223774823|NCT03975348|DEVICE|High flow nasal cannula|High flow of warm and humidified oxygen/air mixture delivered through nasal cannula
223683336|NCT05386823|DRUG|Placebo|Placebo will be sterile saline (0.9% sodium chloride) which will be administered using an IV infusion pump over a period of approximately 60 minutes at 2.5 mL/min.
223683337|NCT02156531|BEHAVIORAL|Self-Administered, Active Cognitive Bias Modification (CBM)|Cognitive Bias Modification (CBM) is a novel treatment delivered via a downloadable computer program. CBM retrains individuals' attention away from negative/threatening stimuli and toward more balanced attention toward neutral stimuli.
223683338|NCT02156531|BEHAVIORAL|Self-Administered, minimally effective attention-control version of the CBM program|Identical to the active CBM program except that during the presentation of the trails where a disgusted face is present, the probe will appear with equal frequency (50-50) in the position of disgusted or neutral face. This, the balanced (random) presentation of the probe in this condition is not designed to explicitly train attention away from threat and toward neutral stimuli, in contrast to the active version of CBM.
223683339|NCT00225303|DRUG|TMC125|
223683340|NCT05260970|PROCEDURE|Rectus muscle reapproximation at cesarean section|Rectus muscle reapproximation: Continuous Suturing of rectus muscles with 2.0 Vicryl (Ethicon) at Cesarean section.
223683341|NCT05468385|DEVICE|Vagus nerve stimulation via tragus|The device will send stimulus intensity of around 0.5mA via tragus in the left ear (based on participants' subjective report), delivered with a pulse width of 0.5 ms at 25 Hz. Stimulation will be active for 30 seconds, followed by a break of 30 seconds.
223683342|NCT05468385|DEVICE|Sham stimulation via earlobe|The device will send stimulus intensity of around 0.5mA via the earlobe in the left ear (based on participants' subjective reports), delivered with a pulse width of 0.5 ms at 25 Hz. Stimulation will be active for 30 seconds, followed by a break of 30 seconds.
223683343|NCT02188342|BEHAVIORAL|HIT|12 HIT exercise sessions in 31 days on a stationary cycle ergometer
223683344|NCT05113342|DRUG|Descartes-25|allogeneic Mesenchymal Stem Cell product.
223683345|NCT06226467|BEHAVIORAL|Neurobehavioral Affective Control Training|"The N-ACT program comprises a series of eight training sessions, lasting one hour each, over two months. N-ACT sessions will be guided by a cognitive training coach (supervised by a licensed mental health clinician), who will explain intervention procedures and rationale, offer relevant psychoeducation, and use motivational interviewing principles to provide encouragement and support. In addition to coach-led content, participants will spend about half of each weekly training session (\~30 minutes) practicing two computer-based adaptive training tasks targeting affective control."
223774824|NCT03975348|DEVICE|Continuous positive airway pressure|Positive airway pressure applied through a sealed face mask
223774825|NCT03975348|DEVICE|Facemask|Oxygen therapy through a conventional facemask
223774826|NCT00059657|DRUG|Ecraprost in lipid emulsion|
223774827|NCT03855722|PROCEDURE|RIPC|Remote Ischaemic Preconditioning
223774828|NCT03855722|PROCEDURE|Sham-RIPC|Sham procedure
223683346|NCT04110262|OTHER|High dietary sodium intake|Fourteen day feeding period of high dietary sodium (3400 mg/day)
223683347|NCT04110262|OTHER|Low dietary sodium intake|Fourteen day feeding period of low dietary sodium (2300 mg/day)
223683348|NCT05410392|BEHAVIORAL|Physical exercise intervention|Home-based physical exercise with the use of a stationary recumbent style bike.
223683349|NCT05410392|BEHAVIORAL|Cognitive exercise intervention|Home-based cognitive exercise with the use of smartphone to complete cognitive activities.
223683350|NCT05410392|BEHAVIORAL|Health education|Provision of general information about a variety of topics
223683351|NCT05837819|DEVICE|Active Lighting Intervention|Lighting intervention using high light levels designed to effect the circadian system
223683352|NCT05837819|DEVICE|Control Lighting Intervention|Lighting intervention using low light levels designed to not effect the circadian system
223683353|NCT05086939|DRUG|Autologous MSCs|Intra-articular injection 40 million/4 ml.
223683354|NCT05086939|DRUG|Allogenic MSCs|Intra-articular injection 40 million/4 ml.
223683355|NCT05086939|DRUG|Hyaluronic Acid|Intra-articular injection 60mg / 3 ml .
223683356|NCT03410823|BEHAVIORAL|PUSH|Strength components of the muscle performance intervention are performed using a portable progressive resistive exercise device (Shuttle® MiniPress, Contemporary Design Company, P.O. Box 5089, Glacier, Washington 98244). Muscle performance focuses on bilateral hip extensors, hip abductors, knee extensors, and plantar flexors. Balance and strength are addressed with additional exercises performed while standing. The endurance intervention begins with 2-3 minutes of continuous upper and lower extremity active range of motion (AROM) with the participant sitting in order to increase the participants' heart rate (HR) or exertion closer to the target zone. The participant is then asked to walk on level surfaces and/or up and down steps to keep the HR within the training zone for 20 minutes.
223683357|NCT03410823|DIETARY_SUPPLEMENT|Protein|Participants will receive a whey-based protein supplement in the form of a powder containing 27.6g of protein. This dose induces maximum muscle protein synthesis post-exercise. Participants will mix the supplement in 8 oz of water (or other beverage) or soft food (e.g., yogurt, soup) and consume immediately following each exercise session with the study PT. On days when they do not have a physical therapy visit with the study PT, participants will be instructed to take the supplement at the meal time closest to the time of scheduled PT visits to maintain regular daily dosing schedule.
223683358|NCT03410823|DIETARY_SUPPLEMENT|Nutrition|Participants receive 2000 IU vitamin D3, 600 mg calcium, and a multivitamin daily for the duration of the study. Nutritional counseling is also provided. Participants are screened at baseline to assess nutritional risk using the Mini Nutritional Assessment-Short Form and contacted by a registered dietician (RD) within 7 days of baseline testing Those who score ≤7 (malnourished) and participants with baseline serum albumin 2.5-3.5 g/dl receive a visit from an RD with follow-up a week later. Participants who score 8-11 (at risk of malnutrition) and have serum albumin level \>3.5 g/dl receive a phone call from the RD and may receive an in-person visit if warranted. Those screening in the normal range (12-14) and have serum albumin level \>3.5 g/dl receive a phone call from the RD. Weight is monitored every 4 weeks. Those who lose 2% or more body weight receive a call from the RD. Those who lose 5% or more body weight between baseline and follow-up may be referred to an RD.
223683359|NCT05249192|DEVICE|Immediate urinary catheter removal|Urinary catheter removal immediately after the end of the surgical procedure before exiting the operating room.
223683360|NCT05249192|DEVICE|Early urinary catheter removal|urinary catheter removal on the first postoperative day (6 a.m)
223683361|NCT03988543|BEHAVIORAL|Patient Self-management|Enhanced care (EC) approach aimed to engage participants actively, and to increase self-efficacy, in the monitoring and managing of their symptoms. After patients complete the current EHR-integrated symptom monitoring, they will receive web-based, patient-centered information to gain knowledge on cancer-related outcomes, improve self-management skills, improve communication skills, and empower them to improve motivation and self-management.
223683362|NCT05725096|DIAGNOSTIC_TEST|Coronary Computed Tomography Angiography|Intervention strategies according to CCTA results
223683363|NCT05725096|OTHER|Traditional cardiovascular risk stratification|Intervention strategies according to traditional cardiovascular risk stratification based on Chinese guidelines for lipid management (2023)
223683364|NCT06449963|BEHAVIORAL|Health Belief Model Education|"Participants in this group will receive a structured training program with the aim of increasing daily water consumption and reducing symptoms of dehydration. The program is based on the principles of the Health Belief Model and includes the following components:~Initial and mid-Program training: Will be conducted by a trained health educator, each lasting 60 minutes. Two weeks after the first training, the same training will be given again for reinforcement purposes.~Session Content: Covers the importance of hydration, strategies to increase water intake (using reminders, setting goals, integrating water-rich foods), and the health benefits of adequate hydration (e.g., improved cognitive function, better physical health).~Training Materials: Booklet prepared for training. Behavioral Strategies: Practical tips for overcoming barriers to drinking more water, such as setting daily water intake goals and using diaries to track progress."
223774829|NCT06404580|PROCEDURE|R anastomosis|R anastomosis
223835291|NCT03375814|DRUG|Placebo Oral Tablet|The group that takes Placebo Oral Tablet. They received the conventional treatment and Placebo Pills..
223835292|NCT04110873|DRUG|Antroquinonol Capsule 50mg|patients will receive Antroquinonol 50mg per day (QD) on Day 1 for 12 weeks
223835293|NCT04110873|DRUG|Antroquinonol Capsule 100mg|patients will receive Antroquinonol 100mg per day (QD) on Day 1 for 12 weeks
223683367|NCT05803603|BEHAVIORAL|Stipend and Social Work Supports|Same as arm description
223683368|NCT05198609|PROCEDURE|FOLFOX-HAIC|Hepatic arterial infusion of oxaliplatin (85mg/m2,IA,day 1, hour 0-2), fluorouracil (400mg/m2,IA,day 1, hour 3), leucovorin (400mg/m2, IV,day 1, hour 2-3) and fluorouracil (2400mg/m2, IA, hour 3-23) repeated every 4 weeks for a total of six times
223683369|NCT05198609|DRUG|Camrelizumab|Camrelizumab was administered 200mg intravenously for 30-60 minutes every 2 weeks, and the maximum cumulative duration of Camrelizumab is 2 years. The shortest time interval between two administrations should not be less than 12 days.
223683370|NCT05198609|DRUG|Apatinib|Apatinib was administered orally 250mg once per day
223683371|NCT05128929|DRUG|Hymecromone (H01)|800 mg oral H01 two times a day (total dose: 1600 mg/day).
223683372|NCT05128929|DRUG|Placebo|Oral tablet placebo (inactive ingredients) two times a day.
223683373|NCT06275490|BIOLOGICAL|Partially Demineralized Dentin Block|"The extracted tooth will undergo grinding using the tooth transformer device. The produced dentin graft will be of a particle size 400-800 μm. Afterwards.~-Prepare the partially demineralized dentin block, the L-PRF membranes will be cut into small pieces and mixed with the dentin particles at a ratio of 2 membranes to 0.5 g of dentin, providing a 1:1 volume ratio. The liquid fibrinogen will be added to the homogeneous mixture, and while shaping the mixture into the desired form it will be gently stirred for approximately 10 seconds. Within a few minutes, the fibrinogen will convert into fibrin primarily from the activated blood platelets in the chopped L-PRF membranes. This process will effectively trap the biomaterial and the L-PRF pieces, forming a sturdy block known as the dentin block, which serves as a convenient and compact graft .The extracted socket will be filled with partially demineralized autogenous dentin graft."
223683374|NCT06275490|BIOLOGICAL|L-PRF block|The same procedure will be performed for preparing the L-PRF block by mixing the L-PRF membranes with xenograft. In both groups, the placed graft will be covered with a L-PRF membrane .The L-PRF clots obtained after 12 min of centrifugation will be placed in the Xpression box (IntraSpin, Intra-Lock, Florida, USA) for 5 min to gently compress (by gravity) into membranes.
223683375|NCT05660980|DRUG|Once daily CAB tablet + RPV tablet|Tablet
223683376|NCT05660980|DRUG|Long acting CAB injectable + long acting RPV injectable|Injectable
223683377|NCT05660980|DRUG|Long acting CAB injectable + long acting RPV injectable|Injectable
223683378|NCT02742246|BEHAVIORAL|Individual clinician-provided CBT|Individual clinician-provided CBT
223683379|NCT02742246|BEHAVIORAL|CBT4CBT|CBT computer program assisted therapy
223683380|NCT02480907|BEHAVIORAL|Workshop Group|Workshop support group
223683381|NCT02480907|BEHAVIORAL|Internet-based support group|Internet based support group with E-mail coaching
223683382|NCT00809029|OTHER|GIP (glucose dependent insulinotropic peptide) infusion|an intravenous infusion of GIP (glucose dependent insulinotropic peptide)or placebo will be administered at a rate of 2 pmol/kg/min and maintained for 240 minutes.
223683383|NCT04173208|OTHER|Fecal microbial transplant|Fecal microbial transplant
223683384|NCT04173208|OTHER|Placebo|Placebo
223683385|NCT05002153|OTHER|Fecal microbiota transplantation (FMT)|FMT is the process of transferring stool from a healthy donor to another.
223683386|NCT05002153|OTHER|Placebo|Placebo capsules consist a combination of agarose in normal saline/glycerol (the same vehicle as in a FMT capsules)
223683387|NCT05675605|DRUG|TY-1091|TY-1091(10mg,100mg) , once a day, oral administration Dose level is from 20mg to 800mg
223683388|NCT00599781|GENETIC|gene transduced PBL and/or gene transduced HSC|infusions of autologous PBL and/or HSC transduced with retroviral vectors encoding ADA
223683389|NCT06207578|PROCEDURE|implant placement using crestal sinus approach|a Full thickness flap will be elevated at the edentulous site with two vertical releasing incision. After flap reflection, the preparation of osteotomy will be prepared following standard implant system protocol preparation of the osteotomy. Drilling will be done gently till reaching 0-1mm from the sinus floor, then implant placement will take place and the implant itself will be used to gently elevate the sinus up to 3-5mm
223683390|NCT06207578|PROCEDURE|Implant placement using osseodensification|The implant motor will be adjusted on reverse mode with 800 to 1200 rpm. According to the desired implant dimension, Densah bur diameter will be used and then implant placement.
223683391|NCT00464243|DRUG|volinanserin|oral administration
223683392|NCT00464243|DRUG|placebo|oral administration
223683393|NCT06387537|PROCEDURE|Conventional physical therapy|Patients in this group will recieve hot pack, ROM exercises, strengthening exercises and Kaltenborn mobilizations. A total of 12 sessions, 3 sessions per week for 4 consecutive weeks. Sets and repetitions will be increased progressively.
223683394|NCT06387537|PROCEDURE|Scapular mobilization.|Scapular Mobilizations: Glides- superior, inferior, distraction, upward and downward rotation (5 sets, 10 reps, 30 sec break in 1 session).Every session will be given for 30 minutes and a total of 12 sessions would be conducted over a period of 4 consecutive weeks.
223683395|NCT02519387|DRUG|Buprenorphine Transdermal Patch|
223774830|NCT04156308|OTHER|Osteopathic Manipulative Treatment (OMT) - Temp1|A total of 3 techniques selected from a list of 7 available techniques common to all centers will be applied in each session. The choice of techniques will be based on the results of the examination performed, the particularities of the patient and the clinical experience of the osteopath. In each session the techniques can change under the criteria of the osteopath. However, they will always be 3 and always within the list of available techniques.
223683396|NCT04338984|DRUG|General anesthetic|Fentanyl is administered at induction - standard dose 5 mcg/kg. Further dosing is based on a multiderivative assessment of nociception (NOL index) and ancillaries such as heart rate and mean arterial blood pressure.
223835294|NCT04110873|DRUG|Placebo oral capsule|patients will receive placebo per day (QD) on Day 1 for 12 weeks
223683397|NCT04338984|DRUG|Ropivacaine 0.5% Injectable Solution|"Bilateral single shot erector spinae plane block is performed before induction of general anaesthesia.~Ropivacaine 0.5% total dose 3mg/kg with Dexamethasone 8mg/20 ml Ropivacaine 0.5%."
223683398|NCT01695200|DIETARY_SUPPLEMENT|Omega-3 fatty acids|
223683399|NCT03081221|DIAGNOSTIC_TEST|USG|
223683400|NCT06532799|BIOLOGICAL|Tumor Infiltrating Lymphocytes (TIL)|Tumor Infiltrating Lymphocytes (TIL) IV
223683401|NCT06532799|DRUG|Cyclophosphamid|Cyclophosphamide will be administered as an intravenous (IV) infusion for two days.
223683402|NCT06532799|DRUG|Fludarabine|Fludarabine will be administered as an intravenous (IV) infusion for five days.
223683403|NCT06532799|DRUG|Interleukin-2|After TIL infusion, IL-2 will be started as a bolus administration every eight hours, for a maximum of eight doses.
223683404|NCT06532799|DRUG|Pembrolizumab|Intravenous (IV) infusion
223683405|NCT05997680|BEHAVIORAL|Parent-child yoga|The 45-minute yoga sessions are structured to include an opening and a closing ritual that remain the same throughout the 8 weeks, between which an active and a calming parts are scheduled. The active and calming parts are embedded in stories that align with the developmental level and interests typical of 4-to-6-year-olds. Each session is clearly structured with each exercise and transition well described in the Yoga for Little Hearts Yoga Program Manual. In addition to the yoga sessions, at-home exercises (5 min) including breathing, meditation and mindfulness activities will be explained to participants. We will ask them to practice them at home at least 3 times every week, for the 8-week duration of the intervention. Including the yoga session and home exercises, the 8-week intervention thus includes at least 60 minutes of yoga per week. Parents will be encouraged to pursue the at-home exercises after the end of the 8-week yoga program, up to the 6-month follow-up.
223683406|NCT05959746|OTHER|AI-STROKE application|Complete neurological exam of stroke patients will be filmed by healthcare workers and themselves using the AI-STROKE application
223683407|NCT06631469|BEHAVIORAL|Personalised behavioural sustainable and healthy dietary recommendations|Personalised dietary plan and standardised behavioural support (based on previous personalised nutrition trials and usual care in dietetic practice), plus the addition of receiving personalised behavioural support and strategies.
223683408|NCT06631469|BEHAVIORAL|Personalised sustainable and healthy dietary recommendations|Personalised dietary plan and standardised behavioural support and strategies (based on previous personalised nutrition trials and usual care in dietetic practice).
223683409|NCT04377490|OTHER|venous ultrasound|Venous ultrasound will be performed on patients once a week, every week from the day of admission in Amiens Hospital until the day of patient discharge
223683410|NCT04377490|BIOLOGICAL|blood sample|blood sample for coagulation and hemostasis analysis will be withdrawn from artery catheter from the day of admission in Amiens Hospital until the day of patient discharge
223683411|NCT03428477|DRUG|Icosapent Ethyl|Composition: soft amber to light yellow, oblong gelatin capsules. One capsule contains 1g pure EPA-EE Dose: 4 capsules per day
223683412|NCT03428477|OTHER|Placebo|"Composition: soft, amber to light yellow, oblong gelatin capsules containing light mineral oil:~Dose: 4 capsules per day"
223683413|NCT05968508|DRUG|BAT1806 prefilled subcutaneous injection/RoActemra® (from EU)|A total of 150 subjects are planned to be enrolled and 1:1randomized to receive single dose of 162 mg/0.9 mL BAT1806 injection, or RoActemra® (from EU) subcutaneously.
223683414|NCT05113394|DRUG|HDM sublingual Immunotherapy|HDM-SLIT tablet (Odactra®/Acarizax®) is a rapidly dissolving, freeze-dried, oral lyophilizate for oromucosal treatment, which contains a 1:1 mixture of two allergen extracts derived for the cultivated house dust mites, D. pteronyssinus and D. farinae. These species are included in SLIT tablet and subcutaneous immunotherapy administered for the treatment of allergic rhinitis and asthma in the pediatric and adult populations. The tablet dissolves within seconds after contact with a wet surface such as the oral mucosa. Participants will be administered the drug sublingually for 3 years.
223683415|NCT05113394|DRUG|Placebo|Placebo sublingual therapy
223683416|NCT03553836|BIOLOGICAL|Pembrolizumab|Administered as an intravenous (IV) infusion every 3 weeks (Q3W)
223683417|NCT03553836|OTHER|Placebo|Administered as an IV infusion every 3 weeks (Q3W)
223683418|NCT06642935|DEVICE|Totally implantable cochlear Implant|Totally implantable cochlear Implant
223683419|NCT05443802|DRUG|Insulin 0.05 IU/kg/h|In the experimental arm, the patients will be given an insulin dose of 0.05 IU/kg/h.
223683420|NCT05443802|DRUG|Insulin 0.10 IU/kg/h|In the control arm, patients will receive an insulin dose of 0.10 IU/kg/h.
223683421|NCT03220438|DEVICE|Transcranial Magnetic Stimulation|Transcranial Magnetic Stimulation
223683422|NCT04062123|DRUG|Dexmedetomidine|Subjects in this group will receive a intravenous infusion of this drug, during a portion of the study. Dose will be targeted to a brain effect site concentration of 0.15 ng/ml, using pharmacokinetic modelling within the STANPUMP algorithm that accounts for subject's age, gender, height, \& weight.
223683423|NCT04062123|DRUG|Propofol|Subjects in this group will receive a intravenous infusion of this drug, during a portion of the study. Dose will be targeted to a brain effect site concentration of 0.7 mcg/ml, using pharmacokinetic modelling within the STANPUMP algorithm that accounts for subject's age, gender, height, \& weight.
223683424|NCT04062123|DRUG|Fentanyl|Subjects in this group will receive a intravenous infusion of this drug, during a portion of the study. Dose will be targeted to a brain effect site concentration of 0.9 ng/ml, using pharmacokinetic modelling within the STANPUMP algorithm that accounts for subject's age, gender, height, \& weight.
223683425|NCT04062123|DEVICE|Peripheral Nerve Stimulation|Experimental acute pain stimulus will be delivered using a nerve stimulator. These painful shocks will be paired randomly with some of the experimental cues.
223683426|NCT04062123|DRUG|Placebo|Crystalloid IV solution will be infused, with no active drug.
223683427|NCT05475340|DEVICE|Focused Ultrasound|The DWL Doppler ultrasound device enables visual and auditory waveform confirmation of the middle cerebral artery, and optical tracking technology (e.g., AntNeuro Visor2™ system) may be used in tandem with the Brainsonix ultrasound device to track a patient's brain in virtual space as well as their physical location, thereby ensuring accurate placement.
223683428|NCT05737771|DRUG|DWC202213|DWC202213
223683429|NCT05737771|DRUG|DWJ1563|DWJ1563
223683430|NCT05737771|DRUG|DWP16001|DWP16001
223683431|NCT06479395|OTHER|Pediatric Endurance and Limb Strengthening (PEDALS) program|Participants will perform pediatric endurance and limb strengthening (PEDALS) program. The stationary cycling intervention will be performed 3 times per week, for a total of 24 sessions, within 8 weeks period. The longer session duration is designed to allow adequate rest intervals between set (1-3 minutes). A generalized stretching program will be performed prior to cycling for mental relaxation for 6-7 minutes. Ankle-foot orthosis if used for walking. Each 60 minutes cycling session will be divided into 2 phases: (1) lower-extremity strengthening and (2) cardiorespiratory endurance.
223683432|NCT06479395|OTHER|Task-Oriented Training (TOT)|The experimental protocol consists of task-oriented training program (TOT) .it will be performed 3 times per week, for a total of 24 sessions, within 8 weeks period. Before each training session, there will be a warm-up period with 5 to 10 minutes of dynamic activities (e.g., jogging). After training, there will be a cool down period with 5 to 10 minutes of dynamic stretching exercises. In addition to rest intervals. after training session, there will be a 48-hour rest interval to prevent muscle fatigue and injury.
223683433|NCT01687621|PROCEDURE|Diagnostic Algorithm for Community Based Worker for Omphalitis|After obtaining guardian informed written consent, newborns aged 1-10 days presenting to the health facility for routine or sick visits would undergo 2 independent, parallel evaluations; first, by a ZamCAT Field Monitor (community level worker from our existing study) and the second by a Zambian medical doctor (gold standard). A US board of pediatrics-certified pediatrician will perform a third independent assessment of a photo of the cord remotely. Using the on-site clinician as the gold standard, the community-based algorithm and the photo assessment will be tested for concordance and the sensitivity and specificity of the algorithm will be generated. Likewise, the remote pictorial assessment will be compared to the gold standard to determine reliability of diagnosis from photographs alone.
223683434|NCT00000832|BIOLOGICAL|MF59|
223683435|NCT00000832|BIOLOGICAL|rgp120/HIV-1 SF-2|
223683436|NCT00634270|DRUG|Sirolimus|This phase II study will evaluate children and adults with neurofibromatosis type-1 (NF1) and plexiform neurofibromas treated with sirolimus. It is divided in two strata. The first stratum will evaluate time to progression (TTP) in children and adults with NF1 and progressive plexiform neurofibromas with the potential to cause significant morbidity treated with sirolimus. The second stratum will evaluate objective radiographic response to sirolimus in children and adults with NF1 and inoperable plexiform neurofibromas with the potential to cause significant morbidity that do not have documented progression of the PN at time of trial entry.
223683437|NCT06289621|BEHAVIORAL|False Safety Behavioral Elimination Treatment (FSET)|5-session transdiagnostic treatment for anxiety disorders and post-traumatic stress disorder (PTSD)
223683438|NCT06289621|BEHAVIORAL|Enhanced Standard Care|Participants in the enhanced standard care control group will receive treatment as usual and a list referrals.
223683439|NCT01415193|PROCEDURE|Selective Tibial Nerve block|Use of selective pain block.
223683440|NCT01415193|PROCEDURE|Sciatic Nerve Block|Use of Sciatic Nerve Block
223683441|NCT01479985|OTHER|CDM Tool|Participants will be required to complete the CDM tool and receive a tailored print out of their contraceptive options based on survey answers
223683442|NCT00805376|DRUG|DNX-2401|Surgical procedure precisely injects DNX-2401 through a catheter (small tube) into brain tumor.
223683443|NCT00805376|PROCEDURE|Tumor Removal|Surgical Tumor Resection
223683444|NCT00673270|DRUG|Fludrocortisone|50 µg of fludrocortisone per os
223683445|NCT00673270|DRUG|Hydrocortisone|50 mg of intravenous hydrocortisone
223683446|NCT00673270|DRUG|Placebo of Fludrocortisone|Tablet of placebo of Fludrocortisone
223683447|NCT00673270|DRUG|Placebo of Hydrocortisone|2 ml of isotonic saline solution
223683448|NCT05476484|DRUG|SQ SLIT-tablet|SQ grass SLIT-tablet and/or SQ house dust mite SLIT-tablet
223683449|NCT04903379|OTHER|Education|An explanation of contemporary pain science and a description of effective treatment strategies used by people with a history of persistent pain.
223683450|NCT05765227|DEVICE|Lehfilcon A multifocal contact lenses|Investigational silicone hydrogel multifocal contact lenses
223683451|NCT05765227|DEVICE|Lotrafilcon B multifocal contact lenses|Commercially available silicone hydrogel multifocal contact lenses
223683452|NCT05765227|DEVICE|Hydrogen peroxide-based cleaning and disinfection system|Commercially available cleaning and disinfection system for silicone hydrogel contact lenses
223683453|NCT02538861|DIAGNOSTIC_TEST|SPECT Imaging Test at Baptist hospital|Single Photon Emission Tomography (SPECT) testing at Baptist Hospital.
223683454|NCT02538861|DIAGNOSTIC_TEST|CT Angiography and CT myocardial perfusion at West Kendall Baptist Hospital|The combined approach of CT Angiography and CT myocardial perfusion with new Revolution CT scanner
223683455|NCT02538861|DIAGNOSTIC_TEST|SPECT Imaging Test at West Kendall Baptist Hospital|Single Photon Emission Tomography (SPECT) testing at West Kendall Baptist hospital.
223683456|NCT02777749|DRUG|Bupivacaine|15 cc's of 0.5% bupivacaine or 50 cc's of 0.25% short-acting bupivacaine (SB), intramuscular injection
223683457|NCT06052098|DEVICE|The disposable pulmonary radiofrequency ablation catheter and pulmonary radiofrequency ablation system|Procedure: In combination with guided bronchoscopy and CBCT, the ablation catheter is placed in the target lesion. CBCT confirms the tool in the lesion, adjusts the position of the ablation catheter, and monitors the extent of ablation.
223683458|NCT06052098|DEVICE|The disposable percutaneous radiofrequency ablation needle and pulmonary radiofrequency ablation system|Procedure: The ablation needle is punctured into the lesion under CT guidance. The extent of the ablation is monitored by CT.
223683459|NCT05198700|DIETARY_SUPPLEMENT|Probiotic Formulation|Participants will be asked to take one sachet daily, containing 1 billion CFU of the probiotic formula. Sachets must be dissolved in warm water or mother's milk before consumption.
223683460|NCT05198700|DIETARY_SUPPLEMENT|Placebo|Participants will be asked to take one sachet containing the placebo daily. Sachets must be dissolved in warm water or mother's milk before consumption.
223683461|NCT00662532|DRUG|Minocycline HCl|1mg microspheres for professional subgingival administration into periodontal pockets two times throughout the duration of the trial
223683462|NCT02280083|DRUG|Botulinum Toxin Type A for Injection|"HengLi002(Botulinum Toxin Type A for Injection,also known as HengLi®)"
223683463|NCT02280083|DRUG|placebo|placebo
223683464|NCT01850602|DRUG|PA21|
223683465|NCT01850602|DRUG|Sevelamer hydrochloride|
223683466|NCT04999774|DIAGNOSTIC_TEST|Different diagnostic tests|Each SAC will be tested with all tests
223683467|NCT01595945|PROCEDURE|Gastric bypass|Subjects with a planned gastric bypass surgery are followed-up for resting metabolic rate.
223683468|NCT01595945|BEHAVIORAL|Caloric restriction|Subjects receive caloric restriction as calculated by an online weight management program and are followed-up for resting metabolic rate.
223683469|NCT05314985|OTHER|Prehab intervention|Individual training program containing strengthening, sensori-motor, joint mobilisation and endurance exercises as well as educational inputs concerning perioperative procedure and instructions on e.g. how to walk with crutches.
223683470|NCT00367770|DRUG|Tracleer®|Patients will receive up to 125 mg b.i.d. of Tracleer.
223683471|NCT05338398|DEVICE|Bocaliner|Bocaliner is a soft, orally inserted device that has been demonstrated to increase the oral retention of oral, topical therapies such as mouthwashes and gels.
223683472|NCT05338398|DRUG|Benzydamine|Benzydamine is an anti-inflammatory and antibiotic mouthwash that has shown promise for the treatment of radiation-induced oral mucositis.
223683473|NCT00155870|BEHAVIORAL|questionnaires|
223683474|NCT03838783|DRUG|Insulin Degludec|50% of the patient's daily basal insulin dose delivered through once daily insulin degludec injected in the morning; 50% of the basal insulin to be delivered through previously established CSII
223683475|NCT01562067|DEVICE|ultrasound examination|ultrasound and doppler studies to evaluate size and vascularity of tumor during radiotherapy
223683476|NCT00416897|DRUG|chemotherapy|
223683477|NCT00416897|DRUG|dexamethasone|
223683478|NCT00416897|PROCEDURE|plasmapheresis|
223774831|NCT04156308|OTHER|Combined Exercises|A home-based pattern of combined exercises based on stretching, active anti-resisted exercises and joint mobility exercises focused on the cervico-dorsal and scapulo-thoracic regions. Whose clinical effectiveness has shown significant positive changes in pain levels and cervical functionality
223683479|NCT02771587|DIETARY_SUPPLEMENT|Alcohol and energy drink|Multiple oral dose of alcohol Multiple oral dose of energy drink
223683480|NCT02771587|DIETARY_SUPPLEMENT|Alcohol|Multiple oral dose of alcohol
223683481|NCT02771587|DIETARY_SUPPLEMENT|Energy drink|Multiple oral dose of energy drink
223683482|NCT02771587|DIETARY_SUPPLEMENT|Placebo|Multiple oral dose of water Multiple oral dose of non-caffeinated soft drink
223683483|NCT01108978|DRUG|Placebo|Dehypotin® 40 mg/day or placebo, once a day, shortly after baseline for 12 consecutive weeks
223683484|NCT01108978|DRUG|Dehypotin|Dehypotin® 40 mg/day or placebo, once a day, shortly after baseline for 12 consecutive weeks
223774832|NCT01448746|DRUG|low molecular weight heparin|40mg 12 hours before surgery and 12 hours later surgery
223774833|NCT02837744|DEVICE|Axiostat®|Axiostat Chitosan Hemostatic dressing belongs to an advanced class of wound dressing that stops bleeding within few minutes of application by providing an active mechanical barrier.
223774834|NCT03959865|DRUG|Long-acting GLP-1RA|Dulaglutide 0.75 or 1.5 mg /week or Exenatide once weekly 2 mg
223683485|NCT01155479|DRUG|Preladenant 2 mg tablet|Preladenant 2 mg oral tablet taken twice daily
223683486|NCT01155479|DRUG|Preladenant 5 mg tablet|Preladenant 5 mg oral tablet taken twice daily
223683487|NCT01155479|DRUG|Preladenant 10 mg tablet|Preladenant 10 mg oral tablet taken twice daily
223774835|NCT03959865|DRUG|Short-acting GLP-1RA|Liraglutide 0.6 mg or 1.2 mg or 1.8 mg / day or exenatide 10 mcg or 20 mcg bid or lixisenatide 10 mcg or 20 mcg / day.
223774836|NCT03959865|DRUG|Human-based GLP-1RA|Liraglutide 0.6 mg or 1.2 mg or 1.8 mg / day or dulaglutide 0.75 or 1.5 mg / week
223774837|NCT03959865|DRUG|Exendin-based GLP-1RA|Exenatide 10 mcg or 20 mcg day or 2 mg / week or lixisenatide 10 mcg or 20 mcg / day.
223774838|NCT03959865|DRUG|Fixed ratio BI/GLP-1RA combination|Insulin degludec / liraglutide (0.036/U) or insulin glargine / lixisenatide (0.5 mcg/U)
223774839|NCT03959865|DRUG|Flexible BI/GLP-1RA combination|GLP-1RA (Liraglutide or dulaglutide or exenatide or lixisenatide) and basal insulin (BI, glargine, degludec, detemir, NPH insulin)
223774840|NCT01304888|OTHER|Cash + nutrition education|Cash transfer of 150 Mexican pesos (equivalent to approximately 14 USD at the time) per month. The size of the cash transfer and the amount of food was the same for all households, i.e. no adjustments for family size or composition were made. Households received the transfer once every 2 mo. Beneficiary households were required to attend nutrition and health education sessions and had to participate in program related logistic activities in order to receive the benefits. These program conditionalities, however, were not strictly enforced.
223774841|NCT01304888|OTHER|Food basket + nutrition education|Monthly food basket with a cost to the program of 150 pesos. The amount of food was the same for all households, i.e. no adjustments for family size or composition were made. The basket contained a number of staple and basic food products and powdered whole milk (Liconsa), which is fortified with Zn, Fe, Vitamin C, and folate. The composition of the food basket conformed to the Mexican norm for food aid programs (NOM-169-SSA1-1998). Households received the transfer once every 2 mo. Beneficiary households were required to attend nutrition and health education sessions and had to participate in program related logistic activities in order to receive the benefits. These program conditionalities, however, were not strictly enforced.
223774842|NCT01304888|OTHER|Food basket w/o nutrition education|A monthly food basket with a cost to the program of 150 pesos. The amount of food was the same for all households, i.e. no adjustments for family size or composition were made. The basket contained a number of staple and basic food products and powdered whole milk (Liconsa), which is fortified with Zn, Fe, Vitamin C, and folate. The composition of the food basket conformed to the Mexican norm for food aid programs (NOM-169-SSA1-1998). Households received the transfer once every 2 mo. Beneficiary households were not required to attend nutrition and health education sessions.
223774843|NCT01304888|OTHER|Control|No benefits were provided
223774844|NCT02886572|RADIATION|Stereotactic radiosurgery|Linear-accelerator-based, single-isocenter, image-guided stereotactic radiosurgery
223774845|NCT00000189|DRUG|Gepirone|
223774846|NCT02873624|PROCEDURE|Laparoscopic cholecystectomy|
223683488|NCT01155479|DRUG|Rasagiline 1 mg capsule|Rasagiline 1 mg oral capsule taken once daily
223683489|NCT01155479|DRUG|Placebo for Rasagiline 1 mg capsule|Placebo for rasagiline 1 mg oral capsule taken once daily
223683490|NCT01155479|DRUG|Placebo for Preladenant|Placebo for preladenant 2 mg, 5 mg, or 10 mg oral tablet taken twice daily
223683491|NCT03018665|DRUG|Exenatide|subcutaneous injection，5ug twice a day the first month，10ug twice a day the second and third month
223683492|NCT03018665|DRUG|BIAsp30|subcutaneous injection，fit dosage twice a day in three months
223683493|NCT03018665|DRUG|Metformin|oral，0.85g，twice a day in three months
223683494|NCT00612898|DRUG|apricitabine|800mg BID apricitabine orally for 48 weeks
223683495|NCT00612898|DRUG|lamivudine|150mg BID lamivudine orally for 48 weeks
223683496|NCT01566760|DRUG|fesoterodine fumarate|One capsule of 4 mg PF-00695838 Formulation SR1 under fasting conditions, single dose
223683497|NCT01566760|DRUG|fesoterodine fumarate|One capsule of 4 mg PF-00695838 Formulation SR2 under fasting conditions, single dose
223683498|NCT01566760|DRUG|fesoterodine fumarate|One capsule of 4 mg PF-00695838 Formulation SR1 under fed conditions, single dose
223683499|NCT01566760|DRUG|fesoterodine fumarate|One capsule of 4 mg PF-00695838 Formulation SR2 under fed conditions, single dose
223683500|NCT01566760|DRUG|fesoterodine fumarate|one extended-release tablet of commercially available fesoterodine fumarate 4 mg under fasting conditions, single dose
223683501|NCT01197443|BEHAVIORAL|Parent-only Group|Parent-only group will include the same skills and techniques to promote weight loss as given to the parent + child group, but the information will be delivered only to the parent. Parent group will be compared to the parent group of the parent + child treatment arm. The focus will be on implementing skills learned to assist the child in weight management. The treatment length is set for 12 weekly meetings and bi-monthly meetings during months 4 and 5. Each group session will be 60-min including weigh-ins. Group meetings focus on behavior change, weight loss, healthy eating and activity for the overweight child and parent.
223774847|NCT05075317|BEHAVIORAL|Standard cardiac rehabilitation|Standard, multi-dimensional cardiac rehabilitation program.
223774848|NCT05075317|BEHAVIORAL|Time-Restricted Eating|Counselling to restrict their eating to between 11 am and 7 pm and to consume water-only for the remaining 16 hours per day
223774849|NCT06077006|OTHER|questionnaires Only|questionnaires Only
223774850|NCT04190745|DRUG|Toripalimab+Apatinib mesylate|Toripalimab 240mg, ivgtt, Q3w Apatinib mesylate 250mg PO. QD
223774851|NCT04190745|DRUG|paclitaxel|paclitaxel 80mg/m2, q3w
223683502|NCT01197443|BEHAVIORAL|Parent + Child Group|The treatment for participants in the parent + child group will be administered in two separate groups, one for the parents and one for the child. Treatment will include the same skills and techniques to promote weight loss as given to the parent-only group, but the information will be delivered to both the parent and child. The treatment length, session schedule, treatment content and follow-up assessments are same as the parent-only group.
223683503|NCT06438627|DRUG|TPC combined with Apatinib and Camrelizumab|Nab-Paclitaxel, Cisplatin, and Capecitabine Chemotherapy Combined With Apatinib and Camrelizumab
223683504|NCT06438627|DRUG|GP Combined With Camrelizumab|Gemcitabine, Cisplatin regimen Combined With Camrelizumab
223683505|NCT00095927|DRUG|Amifostine|Given subcutaneously
223683506|NCT00095927|DRUG|Carboplatin|Given IV
223683507|NCT00095927|DRUG|Paclitaxel|Given IV
223683508|NCT00095927|RADIATION|radiation|Given once daily for 4 weeks and then twice daily for 2 weeks.
223683509|NCT06356701|DIETARY_SUPPLEMENT|Cancer nutritional treatment regimen (Spirulina Bifidobacterium Capsules, Fish Oil Grape Seed Blueberry Soft Capsules, Ganoderma Spore Oil Soft Capsules)|"Medication for Research :~* Spirulina Bifidobacterium Capsules~* Fish Oil Grape Seed Blueberry Soft Capsules;~* Ganoderma Lucidum Sporoderm Oil Soft Capsules; oral administration. non-squamous cell carcinoma Drug: Pemetrexed+Cisplatin (or carboplatin)~  * Sintilimab Injection/Camrelizumab/Tislelizumab/Atezolizumab Injection IV infusion squamous cell carcinoma Drug:Paclitaxel+ Cisplatin (or carboplatin)~ * Sintilimab Injection/Camrelizumab/Tislelizumab/Atezolizumab Injection IV infusion"
223683510|NCT03573102|DRUG|SGLT2 inhibitor|SGLT2 inhibitor 10 mg/day
223683511|NCT03573102|DRUG|ACE inhibitor|ACE inhibitor once daily
223683512|NCT00950261|RADIATION|tri-weekly cisplatin|cisplatin 75mg/m2 every 3 weeks, intravenous, 3 cycles
223683513|NCT05673564|PROCEDURE|Anatomical Resection|Based upon the segmental anatomy of the liver according to Couinaud system, AR was defined as resection of 1 or more complete hepatic segments in our study, including bisegmentectomy, right hemihepatectomy, left hemihepatectomy, extended right hemihepatectomy, extended left hemihepatectomy, single segmentectomy, caudate lobectomy, or a combination of these. NAR, known as wedge resection, was defined as resection of the tumor with a margin of normal parenchyma without regard to hepatic anatomy.
223683514|NCT06119022|PROCEDURE|Invasive coronary angiography|Patients with positive myocardial ischemia either in CT-MPI guided arm or SPECT-MPI guided arm will scheduled to undergo invasive coronary angiography.
223683515|NCT06119022|OTHER|routine medical treatment|Patients with negative myocardial ischemia either in CT-MPI guided arm or SPECT-MPI guided arm will scheduled to have routine medical therapy instead of invasive coronary angiography.
223683516|NCT01216267|DRUG|Lansoprazole|lansoprazole 30 mg HS x 7 days
223683517|NCT01216267|DRUG|lansoprazole|lanzoprazole 30 mg HS for 7 days
223683518|NCT03583242|DRUG|Antiangiogenic Agents|3 Intravitreal injections of 0.05 ml of Aflibercept (40 mg/ml) during 3 months (one per month) The clinical management of the patients will be adapted to the treatment standards of the Ophthalmology Service of the Hospital de la Santa Creu and Sant Pau, without the realization of this study influencing such process.
223683519|NCT03583242|DRUG|Corticosteroid|1 Injection of dexamethasone intravitreal implant 0.7mg. The clinical management of the patients will be adapted to the treatment standards of the Ophthalmology Service of the Hospital de la Santa Creu and Sant Pau, without the realization of this study influencing such process.
223683520|NCT05752266|DIETARY_SUPPLEMENT|AMILI Probiotic pills|AMILI (AMILI Pte Ltd) will analyze stool samples provided by participants, and assign each participant a type of probiotic pill from the 5 different types of probiotic pills commercially available in AMILI retail store.
223683521|NCT05752266|DIETARY_SUPPLEMENT|Placebo pills|Placebo pills contaning maltodextrin with similar appearance to Probiotic pills will be provided to participants allocated to the Placebo Arm.
223683522|NCT02873520|DRUG|Chemotherapy|Cisplatin：60mg/m2，5-FU：500mg/m2,Physiological saline 100ml:IV (in the vein) once a week with a total of six times.
223683523|NCT02873520|BIOLOGICAL|Precision Cell Immunotherapy|DC cell suspension (1×10\*7 DC+physiological saline + 0.25% human bloodalbumin)1ml for each infusion, subcutaneous injection for each infusion, 3 cycles, each cycle received two infusions on day 19, 20; 40, 41; 61, 62. PNAT/PMAT cell suspension (1-6×109 PNAT + physiological saline + 0.25% human bloodalbumin) 300ml for each infusion, IV (in the vein) for each infusion, 3 cycles, each cycle received one infusions on day 21, 42, 63.
223683524|NCT01633437|DRUG|CX157|CX157 Modified Release Tablet 125 mg administered twice per day on study days 4-11 and in the morning of study day 12.
223683525|NCT01633437|OTHER|Placebo|Placebo administered twice per day on study days 4-11 and in the morning of day 12.
223683526|NCT04626466|OTHER|Biological investigations|(complete blood count, platelet count, renal function evaluation)
223683527|NCT00005566|BEHAVIORAL|Desperation Scale|
223683528|NCT02929784|DEVICE|Intervention|Device: neuroConn\_CE\_DC-STIMULATOR. Anodal stimulation to affected hemisphere.
223683529|NCT02929784|DEVICE|Sham|no meaningful stimulation will be given.
223683530|NCT04118582|OTHER|Body composition and resting metabolic rate analisys|
223683531|NCT00407290|DRUG|neostigmine|
223683532|NCT01275547|DRUG|s-ketamine & midazolam|s-ketamine 6 mg intranasal midazolam 0.75 mg intranasal
223774852|NCT02497768|OTHER|Chewing of nuts|The volunteers will be asked to chew and spit 8 portions (4-5 g) of nuts (pistachios or Brazils) on two separate visits. They will provide samples for particle sizing. Two portions will be used as practice samples in order to measure the number of chews. Two portions will be sieved. Two portions will be measured by laser diffraction. Two portions will be frozen for later lipid analysis.
223774853|NCT01124890|DEVICE|early percutaneous coronary intervention|
223774854|NCT01124890|DEVICE|late percutaneous coronary intervention|
223683533|NCT01275547|DRUG|Morphine PCA|2 mg Morphine i.v. all 12 minutes as a patient controlled system
223683534|NCT01252303|BEHAVIORAL|Nutrisystem|Nutrisystem meal replacements for 12 weeks
223683535|NCT03926546|BEHAVIORAL|ERP for Individuals|Comparing Group vs. Individual ERP for OCD
223683536|NCT06136988|DRUG|Docetaxel for Injection (Albumin-bound)|Docetaxel for Injection (Albumin-bound) 60 or 75 mg/m\^2, Intravenous infusion, Q3W
223683537|NCT06136988|DRUG|SG001|Recombinant Anti-PD-1 Fully Human Monoclonal Antibody Injection, 360 mg, Intravenous infusion, Q3W
223683538|NCT06136988|DRUG|Cisplatin for injection|Cisplatin for injection, 25 mg/m\^2, Intravenous infusion, D1-D3, Q3W
223683539|NCT06136988|DRUG|Paclitaxel|Paclitaxel 135 mg/m\^2, Intravenous infusion, Q3W
223683540|NCT06136988|RADIATION|Simultaneous Radiotherapy|Radiotherapy (28×1.8Gy)
223683541|NCT05836779|DRUG|CBL-514 injection|CBL-514 will be administered at the raised area of cellulite.
223683542|NCT02718950|DRUG|Liraglutide 3.0 mg|Subjects will use liraglutide 3.0 mg for 2 weeks
223683543|NCT02625883|OTHER|Interview|Interview by validated Quality-of-life-questionnaire
223683544|NCT05448976|OTHER|Saliva and serum sampling|Saliva were collected to analyze the selected markers as unstimulated samples during the early hours of the day. The saliva was centrifuged and then transferred into Eppendorf tubes. Venous puncture was performed after saliva collection and 10 mL of blood samples were collected by qualified staff (MFD) from each participant. Saliva and serum were then stored at -80 °C until analysis.
223774855|NCT00519480|DRUG|GSK189075|GSK189075 will be available as an oral tablet with dosing strengths of 500 milligrams and 250 milligrams.
223683545|NCT04710277|OTHER|Opioid-sparing multimodal pain management|Ice pack applied to abdominal incisions for 20 minutes every 2 to 3 hours for 24 hours after surgery and scheduled acetaminophen and NSAID for 96 hours after surgery. Narcotic pain medication for severe breakthrough pain.
223683546|NCT04710277|OTHER|Usual care|Scheduled acetaminophen and NSAID for 24 hours after surgery. Narcotic pain medication for severe breakthrough pain.
223683547|NCT00124397|DRUG|Atorvastatin|
223683548|NCT03600688|DEVICE|Edwards Cardioband System|Transcatheter mitral valve repair
223683549|NCT00470184|DRUG|capecitabine|Oral
223683550|NCT00470184|DRUG|oxaliplatin|IV
223683551|NCT00470184|GENETIC|gene expression analysis|Correlative Study
223683552|NCT00470184|GENETIC|microarray analysis|Correlative Study
223683553|NCT00470184|GENETIC|reverse transcriptase-polymerase chain reaction|Correlative Study
223683554|NCT00470184|PROCEDURE|adjuvant therapy|Metastatic growth control
223683555|NCT00470184|PROCEDURE|biopsy|Examination of tissue type
223683556|NCT00470184|PROCEDURE|conventional surgery|Tissue removal
223683557|NCT00470184|PROCEDURE|neoadjuvant therapy|Tumor shrinkage
223683558|NCT00470184|PROCEDURE|quality-of-life assessment|Correlative Study
223683559|NCT00470184|RADIATION|radiation therapy|Undergoing radiation therapy
223683560|NCT04628832|BEHAVIORAL|PMP Use Mandate Letter|A letter with reminders about the mandate to check the PMP when prescribing opioids.
223683561|NCT04628832|BEHAVIORAL|Prescribing Information Letter|A letter with information about the prescriber's patients who received co-prescriptions. The letters will provide clinical background on the harms of co-prescribing and encourage prescribers to avoid co-prescribing in the future.
223774856|NCT00519480|DRUG|Metformin|Metformin will be available as an immediate release oral tablet with dosing strengths of 500 milligrams and 850 milligrams.
223774857|NCT00519480|DRUG|Placebo|Placebo will be available as an oral tablets.
223774858|NCT01176591|DRUG|Placebo session 1, Aprepitant session 2|placebo in session 1, Aprepitant 80 mg in session 2, oral administration.
223774859|NCT01176591|DRUG|Placebo session 1, Placebo session 2|Placebo, one per session, oral administration
223835295|NCT06320275|BEHAVIORAL|Storytelling Intervention|A storytelling fertility awareness video intervention, approximately 10 minutes in length, guided by a situation-specific theoretical framework and storytelling/narrative communication theory, was developed by the researchers.
223683562|NCT04628832|BEHAVIORAL|Prescribing Information + PMP Use Mandate Letter|A letter combining the content of the PMP Use Mandate Letter and the Prescribing Information Letter. This letter will remind prescribers about the PMP use mandate and provide information about the prescriber's patients who received co-prescriptions.
223683563|NCT00290979|DRUG|insulin glulisine|
223683564|NCT05629104|OTHER|There is no intervention since it is an observational study patients are treated according to clinical praxis|No intervention
223683565|NCT05271708|DRUG|Fespixon cream|Bounded by the midpoint of the scar, each patient received two topical scar formulations consisting of Fespixon cream on one side, and placebo cream on the other side. Treatment was given twice a day for 84 days.
223683566|NCT05271708|DRUG|Placebo Cream|Bounded by the midpoint of the scar, each patient received two topical scar formulations consisting of Fespixon cream on one side, and placebo cream on the other side. Treatment was given twice a day for 84 days.
223683567|NCT04387825|DRUG|ADSVF application in the right hand|40 ml of fat was mixed with 2 ml of ADSVF and placed in 1-ml and 3-ml syringes. Using a 19-gauge blunt cannula (0.8 mm), 0.5 ml was applied to the radial and ulnar edge of each metacarpal phalangeal (MP) and interphalangeal (IP) joint in contact with each neurovascular digital pedicle and 3 ml was applied to each side of the metacarpal trapezius joint, together with 10 ml distributed subcutaneously throughout the palm of the hand and 10 ml evenly distributed on the back of the hand
223683568|NCT05502640|OTHER|Education model|Chicken legs will be used for each student in the study. Intermittent and continuous suture techniques will be studied on the incision made on the chicken leg.
223683569|NCT05502640|OTHER|Routine Education model|In the study, 15 cm x 20 cm sponge will be used for each student. Intermittent and continuous suture techniques will be practiced on the sponge.
223683570|NCT00021671|DRUG|Erythromycin|
223683571|NCT00021671|DRUG|Nevirapine|
223683572|NCT00021671|DRUG|Ampicillin sodium|
223683573|NCT00021671|DRUG|Metronidazole|
223683574|NCT02240147|BEHAVIORAL|home-based exercise training|During a 30 minute face-to-face motivational interview with an exercise specialist, the patient will be advised and coached about his exercise prescription, on how to implement it in his own daily life and on how to prevent relapse. Furthermore, the patients will receive instructions on how to monitor their exercise intensity and on recognizing adverse signals. During the following 12 weeks, patients will be asked to exercise 4.5 hours per week within the prescribed exercise intensity range according to the guidelines.
223683575|NCT01740843|DEVICE|transcranial direct current stimulation (tDCS) (NeuroConn DC-stimulator)|The anode is fixed on the primary cortex and the cathode will be fixed on the contralateral supraorbital region.
223683576|NCT03742440|BIOLOGICAL|GrafixPL PRIME|GrafixPL PRIME
223683577|NCT02483533|DRUG|LIPO-202|
223683578|NCT02483533|DRUG|Placebo|
223683579|NCT01168960|BEHAVIORAL|Cognitive behavioral therapy for alcohol dependence|12-session behavioral treatment that incorporates behavioral skills training targeting high-risk drinking behavior.
223683580|NCT02416310|DEVICE|TEAS|According to ancient Chinese medical books, acupoints SP6 and ST36 are chosen and identified.The patients in TEAS group received electrical stimulation with the 'disperse-dense' waves. Non-acupoint is located 2cm interior to the ST36 and SP6.For group TEAS and Sham, TEAS will be administered 30 minutes prior to surgery and continued until the end of the surgery.Control patients will receive the same treatment without electrical stimulation.
223683581|NCT06239623|DRUG|JSI-1187|Use ERK inhibitor JSI-1187 to treat solid tumor
223683582|NCT01975987|DEVICE|Bonfils fiberscope|
223683583|NCT01067443|DRUG|Liposomal amphotericin B (AmBisome®) and sodium stibogluconate|AmBisome® one dose of 10mg/kg body weight (IV) on day 1 followed by 10 days of SSG at 20mg/kg body weight (IV/IM) from days 2-11
223683584|NCT01067443|DRUG|Liposomal amphotericin B + miltefosine|AmBisome® one dose of 10mg/kg body weight (IV) on day 1 followed by 10 days Miltefosine at 2.5mg/kg body weight (oral) from days 2-11
223774860|NCT02044887|OTHER|physical activity|The characteristics of the PCD and CF and motivation will be evaluated to increase the AF through the (Test Prochaska-Diclemente). For 3 months will receive instructions to perform AF autonomously (walking, preferably in the vicinity of the place of residence). The intervention will be conducted by a professional of the health center so only couples of the intervention group will have knowledge of the specific recommendations of the AFISDEMYF. It is an intervention that has demonstrated its effectiveness in the PEPAF study (large, Sanchez et al. 2009) adapted, designed and implemented by primary care professionals for patients with dementia and for family members who care for them.
223683585|NCT01067443|DRUG|Miltefosine|Monotherapy course of Miltefosine at 2.5mg/kg body weight (oral) from days 1-28
223683586|NCT02309866|GENETIC|Genetic testing|Genetic testing for mutations in known and novel genes underlying RP and allied diseases
223683587|NCT02832583|DEVICE|Regenkit BCT-HA Cellular Matrix|To assess the efficacy of PRP-HA on skin rejuvenation, thirty one patients with chronological aging including wrinkles, dull and dry skin with loss of elasticity and firmness. The patients received three PRP-AH injection sessions 4 weeks apart into the cheeks.
223683588|NCT03448055|DIETARY_SUPPLEMENT|Immunocal|cysteine-rich whey protein isolate
223683589|NCT00458874|BEHAVIORAL|CIMT results|"Both groups will receive a weekly confidential packet of scripted materials (e.g. educational materials, class schedules, feedback from diet/exercise logs). The R-CIMT group will also receive an CIMT report which contains a copy of one of their own ultrasound scans, with a comparison normal scan. This report will also include the CIMT thickness, an interpretation that states their measurements are in the highest quartile for persons of their age and gender, and associated CVD risk. Interpreting Your CIMT Results tutorial will be included in the first weekly packet to educate subjects on the detection of atherosclerosis with carotid ultrasound. The CIMT results are withheld from the W-CIMT group until the end of their study participation along with the CIMT tutorial."
223683590|NCT02598570|DRUG|duvelisib|Duvelisib will be administered orally as a fixed dose in 28-day cycles.
223683591|NCT04584697|BIOLOGICAL|COVI-AMG|COVI-AMG is a fully human SARS-CoV-2 neutralizing monoclonal antibody (mAb).
223683592|NCT04584697|DRUG|Placebo|Diluent solution
223683593|NCT03520244|BEHAVIORAL|Exercise + Holistic Education|The exercise group will undertake a 12-week supervised progressive high intensity interval training program supplemented with 6 bi-weekly group-based holistic education sessions.
223683594|NCT02004639|RADIATION|Masticators sparing techniques|
223683595|NCT02004639|OTHER|electro-acupunture treatment|electro-acupunture treatment and sham-EA
223683596|NCT04080687|DEVICE|Ankle-foot orthosis|Ankle-foot orthosis of any type (unilateral or bilateral, standard or carbon fiber, for support or correction)
223774861|NCT02855294|DRUG|COC containing 30 μg of EE and 3mg of drospirenone|treatment for 6 consecutive cycles. Each treatment cycle consisted of 3 weeks of pill treatment followed by a 1-week pill-free period.
223683597|NCT02607566|BEHAVIORAL|Yoga|
223683598|NCT02607566|BEHAVIORAL|Standard Exercise Program|twice weekly aerobic exercise program, 60 minutes for 12 weeks
223683599|NCT01673750|OTHER|Questionnaire|The primary outcome, characterizing body image among HIV infected adolescents, will be measured using a questionnaire administered to study participants through Audio Computer Assisted Self-Interview (ACASI) technology.
223683600|NCT01082822|BIOLOGICAL|cell sheet pellets and cell sheet fragment|the denuded root surface area was calculated to determine the size of the transplanted cell sheet in the of proportion of the 2cm X 2cm cell sheet to the 1cm X 1cm denuded area
223683601|NCT01302015|BIOLOGICAL|RNL-Vascostem®|
223683602|NCT04584307|DRUG|Elotuzumab|Elotuzumab 10-20mg/kg
223683603|NCT04584307|DRUG|Pomalidomide|Pomalidomide 2mg
223683604|NCT06108986|OTHER|tabata training|this include tabata training thrice a week for six weeks
223683605|NCT06108986|OTHER|plyometric training|this include plyometric training thrice a week for six weeks
223683606|NCT04635670|DIETARY_SUPPLEMENT|Pro-/prebiotic Mix|Soluble powder for oral use of pre-/probiotic mix 3.0 g twice daily.
223683607|NCT04635670|DIETARY_SUPPLEMENT|Placebo|Soluble powder for oral use twice daily.
223774862|NCT04010617|DEVICE|Pharyngeal Electrical Stimulation (PES)|PES will be delivered by a commercial device (Phagenyx, Phagenesis Ltd, Manchester, UK), which comprises a nasogastric feeding catheter that houses stimulation ring-electrodes and a computerised base station that delivers stimulation in the range 1-50 mA at 5 Hz.
223683608|NCT05222490|DEVICE|Thermal Camera images acquisition - FeetSee|Thermal images will be collected according to the instructions for use of the Feetsee device.
223683609|NCT05222490|DEVICE|Thermal Camera images acquisition - Reference|After 15 minutes of resting, thermal images from the reference device will be collected according to their manufacturer
223683610|NCT05796778|PROCEDURE|subomohyoid plane block|The block needle was inserted in line with the probe in a lateral-to-medial orientation toward the suprascapular nerve. Local anesthetic solution was then injected after negative aspiration for blood to achieve circumferential spread around the neurovascular bundle
223683611|NCT05796778|PROCEDURE|Interscalene brachial plexus block|The block needle is usually advanced in plane in a lateral-to-medial direction through the middle scalene muscle to contact the nerve roots and inject local anesthetic around them.
223683612|NCT01884727|DIETARY_SUPPLEMENT|Salt Water|Subjects to arrive fasted and will spend two 24-h periods inside the metabolic chamber (ASEA or salt water) with a one week interval between visits. Blood will be drawn at 9 am prior to consumption of salt water or breakfast, and at 11 am after consumption of salt water and breakfast. Subjects will receive a second portion of salt water at 10:15 pm just prior to bedtime. The energy content of meals will be identical at each visit.
223683613|NCT01884727|DIETARY_SUPPLEMENT|ASEA water|Subjects to arrive fasted and will spend two 24-h periods inside the metabolic chamber (ASEA or salt water) with a one week interval between visits. Blood will be drawn at 9 am prior to consumption of ASEA water or breakfast, and at 11 am after consumption of ASEA water and breakfast. Subjects will receive a second portion of ASEA water at 10:15 pm just prior to bedtime. The energy content of meals will be identical at each visit.
223683614|NCT02029599|DRUG|Fang yi qing feng shi granule|10g, Oral,Three each time, 3 times a day,for 3 months;
223683615|NCT02029599|DRUG|placebo|10g, Oral,Three each time, 3 times a day,for 3 months
223683616|NCT02029599|DRUG|Methotrexate|7.5-15mg per week，All patients should be used
223683617|NCT02029599|DRUG|Acetaminophen tablets|Oral,0.5g, 1\~2 times a day, when vas=10
223683618|NCT06041776|DRUG|Befotertinib + Icotinib placebo|"The initial dose of Befotertinib is 75 mg orally once daily (QD) for 21 days, and then increased to 100 mg orally QD in the absence of serious side effects , CTCAE grade ≥ 2 headache or thrombocytopenia during the 21 days.~Befotertinib can be taken on an empty stomach or after meals, and the medication is used until the disease relapses or intolerable toxicity occurs, or the treatment lasts for 3 years (disease recurrence includes local recurrence and/or distant metastasis)~Icotinib placebo 125 mg three times daily, on an empty stomach or in combination with food, use medication until the disease relapses or intolerable toxicity occurs or treatment lasts for 2 years (disease recurrence includes local recurrence and/or distant metastasis)."
223774863|NCT01764100|GENETIC|Mesenchymal stromal cells|Mesenchymal stromal cells (MSC) intravenous infusion at least two fixed doses of mesenchymal stem cells (1 ± 0.5 x 106/kg recipient body weight for each injection) with 5 to 7 days of interval one from the other, derived from HLA unrelated donor different from the HSC donor (third party donor).
223835296|NCT04575675|DRUG|Dapagliflozin|Dapagliflozin 10mg once daily
223835297|NCT04575675|DRUG|Sacubitril-Valsartan|Sacubitril-Valsartan, maximal tolerated dosage
223774864|NCT04506450|PROCEDURE|Peripheral nerve block|"In this group, four nerve blocks will be associated to ensure adequate anesthesia and analgesia during hip surgery.~Lumbar plexus and sciatic nerve blocks will be performed with a needle connected to an electrical nerve stimulation. The needle will be advanced until contraction of the femoral quadriceps muscle and plantar or dorsal flexion of the foot will be detected respectively. For both, a mixture of mepivacaine and levobupivacaine will be injected.~Lateral femoral cutaneous nerve block will be performed with the ultrasound technique. After identifying the nerve, a needle will be inserted with an in plane approach and will be injected.~Lateral branch of iliohypogastric nerve block will be executed with the De Visme approach. Along the iliac crest (range between 7 and 11 cm from the anterior superior iliac spine) a needle will be inserted until bone contact is found. Then a mixture of mepivacaine and levobupivacaine will be injected."
223774865|NCT04506450|PROCEDURE|Spinal anesthesia|"In this group, spinal anesthesia will be performed to ensure anesthesia during surgery, while lumbar plexus block will be performed to ensure postoperative analgesia Spinal anesthesia will be performed with a 25 G needle and 12 mg 0.5% levobupivacaine will be injected.~Lumbar plexus block will be performed with a needle connected to an electrical nerve stimulation. The needle will be advanced until contraction of the femoral quadriceps muscle will be detected. 20 ml 0.5% levobupivacaine will be injected."
223774866|NCT01466816|DIETARY_SUPPLEMENT|test meals with various fatty acid compositions|Three different milkshakes with a U13C palmitate tracer added
223774867|NCT04932304|DEVICE|Transcranial direct current stimulation (tDCS)|
223774868|NCT04932304|DEVICE|Sham Transcranial direct current stimulation (tDCS)|Sham Transcranial direct current stimulation (tDCS)
223774869|NCT00408993|DRUG|Duloxetine Hydrochloride|60 mg every day (QD) (morning or evening), by mouth (PO)
223774870|NCT00408993|DRUG|Placebo|Placebo every day (QD), by mouth (PO)
223774871|NCT00520416|PROCEDURE|Carbon dioxide angiogram|see description of procedure
223774872|NCT06282627|OTHER|Observational study|No intervention. Observational study
223774873|NCT02654080|BIOLOGICAL|HIV-1 nef/tat/vif, env pDNA vaccine|1500 mcg to be administered as 0.5 mL intramuscular (IM) in the deltoid of the non-dominant arm (unless medically contraindicated) using the Ichor Medical Systems TDS EP device
223774874|NCT02654080|BIOLOGICAL|rVSV HIV envC vaccine|1 × 10\^7 PFU to be administered as 1 mL IM in the deltoid of the non-dominant arm (unless medically contraindicated)
223774875|NCT02654080|BIOLOGICAL|Placebo|"Sodium Chloride for Injection, USP 0.9%;~At Months 0, 1, and 3: administered as 0.5 mL IM in the deltoid of the non-dominant arm (unless medically contraindicated) using the Ichor Medical Systems TDS EP device.~At Months 6 and 9: administered as 1 mL IM in the deltoid of the non-dominant arm (unless medically contraindicated)."
223774876|NCT03738865|DRUG|G-Pen|1 mg subcutaneous injection of G-Pen (glucagon injection) administered via auto-injector
223774877|NCT03738865|DRUG|Novo Glucagon|1 mg subcutaneous injection of Novo Glucagon (glucagon injection)
223835298|NCT04575675|DRUG|Beta blocker|Cardio-selective beta-blocker, including carvedilol, bisoprolol, metoprolol or nebivolol
223835299|NCT04575675|DRUG|Mineralocorticoid Receptor Antagonist|Mineralocorticoid receptor antagonist, including spironolactone or eplerenone
223835300|NCT04575675|DEVICE|Cardiac resynchronization therapy and/or implantable cardioverter defibrillator|CRT-P, CRT-D or ICD if clinically indicated
223835301|NCT00962663|DRUG|ICA-105665|Subjects randomized to receive ICA -105665 will receive 200 mg BID
223683619|NCT06041776|DRUG|Icotinib + Befotertinib placebo|"Icotinib 125 mg three times daily, on an empty stomach or in combination with food, use medication until the disease relapses or intolerable toxicity occurs or treatment lasts for 2 years (disease recurrence includes local recurrence and/or distant metastasis).~The initial dose of Befotertinib placebo is 75 mg orally once daily (QD) for 21 days, and then increased to 100 mg orally QD in the absence of serious side effects , CTCAE grade ≥ 2 headache or thrombocytopenia during the 21 days.~Befotertinib placebo can be taken on an empty stomach or after meals, and the medication is used until the disease relapses or intolerable toxicity occurs, or the treatment lasts for 3 years (disease recurrence includes local recurrence and/or distant metastasis."
223683620|NCT06097780|GENETIC|NestaCell®|Human Dental Pulp Stem Cells (hDPSCs).
223683621|NCT00768469|DRUG|Neratinib|Administered orally, continuous, once daily.
223683622|NCT00768469|DRUG|Paclitaxel|Administered IV, on days 1, 8, 15 of 28 day cycle.
223683623|NCT03042273|DIETARY_SUPPLEMENT|High Strength Cranberry|Softgel capsule
223683624|NCT03042273|DIETARY_SUPPLEMENT|Placebo|Soy oil to match High Strength Cranberry Softgel Capsule
223683625|NCT02236481|DRUG|Anakinra|
223683626|NCT02236481|DRUG|TNF alpha inhibitors|
223683627|NCT02102360|DEVICE|Anorganic Bovine Bone|used to improve periodontal regenerative procedures.
223683628|NCT02102360|DEVICE|Enamel Matrix Derivative|used to improve periodontal regenerative procedures.
223683629|NCT03859206|OTHER|Medical thoracoscopy|• With the closed biopsy forceps, step by step, fibrinous septae were perforated, the pleural space was irrigated with saline and fluid and fibrinopurulent material were aspirated and removed from the pleural cavity, the entire pleural cavity was inspected and biopsies were obtained from suspicious areas carefully by the biopsy forceps under vision. Multiple lesions were encountered, multiple biopsies were taken \& If no lesion, biopsy from parietal pleura was obtained from any sites.
223683630|NCT03911219|OTHER|eHealth system support for symptom management via CANKADO|Regular use of eHealth support system CANKADO by the patient: symptom self-reporting triggering alerts to the patient; in addition to standard of care symptom management.
223683631|NCT03706898|DRUG|Elpida®|Elpida® capsules, 20mg
223835302|NCT00962663|DRUG|Ibuprofen|Subjects randomized to receive Ibuprofen will receive placebo to ICA-105665 at all scheduled dosing times on Days 1 to 4 and a single dose of 800 mg Ibuprofen on the morning of Day 4.
223835303|NCT00962663|DRUG|Placebo|"Subjects randomized to receive placebo will receive placebo to ICA~-105665 at all scheduled dosing times on Days 1 to 4 and placebo to Ibuprofen on the morning of Day 4."
223683632|NCT03706898|DRUG|Dolutegravir|Dolutegravir, film-coated tablets, 50mg
223683633|NCT03706898|DRUG|Sofosbuvir|Sofosbuvir, film-coated tablets, 400mg
223683634|NCT03706898|DRUG|Daclatasvir|Daclatasvir, film-coated tablets, 60mg
223683635|NCT01725412|DIETARY_SUPPLEMENT|Thiamine 300mg PO once daily|
223683636|NCT01725412|DIETARY_SUPPLEMENT|placebo|
223683637|NCT00883844|DRUG|Nucleos(t)ide analogue treatment with a peginterferon add-on strategy|peginterferon 1.5 microgram/kg once a week Treatment with one of the approved nucleos(t)ide analogues
223683638|NCT00883844|DRUG|Nucleos(t)ide analogue treatment|Treatment with one of the approved nucleos(t)ide analogues
223683639|NCT05526209|PROCEDURE|using longitudinal relaxing incision as a technique for recurrence prevention in ventral hernia|using longitudinal relaxing incision as a technique for recurrence prevention in ventral hernia
223683640|NCT00272727|BEHAVIORAL|Dialog tool for caregivers|
223683641|NCT00741962|DIETARY_SUPPLEMENT|VR-3 Herbal Blend|This is a liquid blend of various reputed adaptogenic herbs. The dosage will be 2ml of liquid per day.
223683642|NCT00741962|DIETARY_SUPPLEMENT|Placebo|The placebo will be a similar tasting liquid as VR-3 Herbal blend. The dosage will be 2ml of liquid per day.
223683643|NCT05632289|OTHER|osteopathic manipulative therapy|osteopathic manipulative therapy : manuel therapy
223683644|NCT05632289|OTHER|sham osteopathic manipulative therapy|placebo of osteopathic treatment
223683645|NCT01766193|PROCEDURE|vaginal delivery|
223683646|NCT01766193|PROCEDURE|forceps extraction|vaginal delivery by forceps extraction
223683647|NCT01766193|PROCEDURE|vacuum extraction|vaginal delivery by vacuum extraction
223683648|NCT01766193|PROCEDURE|cesarean section|
223683649|NCT03768297|PROCEDURE|dual zone concept|immediate implant with bone fill till soft tissue level
223683650|NCT04693026|DRUG|Remdesivir|Remdesivir 100 IV Infusion as a lyophilized powder
223683651|NCT04693026|DRUG|Baricitinib|Baricitinib oral tablet form
223683652|NCT04693026|DRUG|Tocilizumab|Tocilizumab IV Infusion
223683653|NCT02219113|PROCEDURE|Arthroscopic surgery|
223683654|NCT02219113|PROCEDURE|Liposuction|
223683655|NCT02219113|DEVICE|ADRC isolation|ADRC isolation performed using Celution 800/CRS System (Cytori Therapeutics Inc) according to manufacturer's protocol
223683656|NCT02219113|OTHER|Intraarticular administration of autologous ADRC|
223683657|NCT05161039|DEVICE|Serranator|Serranator® PTA Serration Balloon Catheter manufactured by Cagent Vascular
223683658|NCT05161039|DEVICE|POBA|Plain balloon angioplasty device
223683659|NCT03835728|DRUG|Ocrelizumab|Subjects will be randomized in a 1:1 fashion to receive infusion of Ocrelizumab (2 doses at 300 mg and 1 dose at 600 mg) or matched placebo. The 2 300 mg doses will be administered at day 2 and day 14. The 600 mg dose will be administered during the 6 month visit. The drug will be administered via infusion three times throughout the trial period: after the initial screening, at two weeks from initial infusion, and at 6 months.
223683660|NCT03835728|DRUG|Saline|This will be the matching placebo used in the study.
223683661|NCT03487978|DIAGNOSTIC_TEST|resting-state functional MRI|"1. To ensure inter-ictal fMRI, confirm that the subject has no migraine for at least 48 hours before the procedure.~2. Record the time difference between the date on the day of fMRI and the date of the last headache attack and record whether the headache on the day of fMRI is absent or not.~3. On the third day after MRI, examine whether the subject has headache or not."
223683662|NCT04918901|COMBINATION_PRODUCT|NO Severe COVID-19|Non-severe and critically ill patients with COVID-19
223683663|NCT06159101|DRUG|HLX13|A single dose (0.3 mg/kg) of HLX13 via intravenous infusion.
223683664|NCT06159101|DRUG|CN-sourced ipilimumab|A single dose (0.3 mg/kg) of CN-sourced ipilimumab via intravenous infusion.
223683665|NCT06159101|DRUG|EU-sourced ipilimumab group|A single dose (0.3 mg/kg) of EU-sourced ipilimumab via intravenous infusion.
223683666|NCT06159101|DRUG|US-sourced ipilimumab group|A single dose (0.3 mg/kg) of US-sourced ipilimumab via intravenous infusion.
223683667|NCT04942197|OTHER|use pregnancy management application|Pregnant women who used pregnancy management application, which tells patients what she need to know during pregnancy, when to perform tests, and what precautions to take for your baby.
223683668|NCT01552707|BIOLOGICAL|XCEL-MT-OSTEO-ALPHA|"Isolation and ex-vivo expansion of mesenchymal stem cells (MSC) obtained from each patient's bone marrow under GMP conditions at Xcelia, División de Terapias Avanzadas delBanc de Sang i Teixits. After expansion, MSCs are fixed in allogenic bone tissue and implanted in instrumented spinal fusion."
223683669|NCT01552707|PROCEDURE|Standard treatment|Instrumented spinal fusion together with patient's bone iliac crest
223683670|NCT04894214|DIAGNOSTIC_TEST|Arterial blood gas (ABG)|Arterial blood gasses will be drawn during baseline PCV, and every 15 minutes during FCV and VCV respectively. pO2 (mmHg), pCO2 (mmHg) and pH will be recorded.
223683671|NCT04894214|OTHER|Recording of hemodynamic monitoring|Hemodynamic parameters (invasive arterial blood pressure (mmHg) and heart rate (beats per minute)) will be recorded every 5 minutes.
223683672|NCT04894214|OTHER|Recording of respiratory monitoring|Tidal volume (ml), respiratory rate (breaths per minute), minute volume (l/min), dynamic compliance (ml/cmH2O), resistance (cmH2O/l/min), plateau pressure (cmH2O), mean airway pressure (cmH2O), positive end-expiratory pressure (cmH2O), peak inspiratory pressure (cmH2O) and fraction of inspired oxygen will be recorded every 5 minutes.
223683673|NCT03952299|DRUG|Oxybutynin Transdermal Patch|Transdermal patch of oxybutynin will be used instead of oral oxybutynin.
223683674|NCT03952299|DRUG|Oral Oxybutynin|Oral administration of oxybutynin (5mg) every 8 hours in the hospital.
223683675|NCT02935400|DRUG|Hemin|Hemin will be administered under a separate protocol or for clinical treatment, and samples will be collected under this protocol before and after treatment.
223683676|NCT06312670|DRUG|EPI-7386|600 mg orally administered twice daily
223683677|NCT06312670|DRUG|Enzalutamide|160 mg administered orally once daily, with or without food
223683678|NCT06312670|DRUG|Androgen Deprivation Therapy (ADT)|LHRH agonist/antagonist or orchiectomy
223683679|NCT06033976|PROCEDURE|Endoscopic submucosal dissection (ESD)|Endoscopic injection of fluid into the gastrointestinal submucosal space followed by endoscopic knife dissection around and under the lesion so as to remove the lesion specimen in one piece with lesion free resection margins.
223774878|NCT01006044|BIOLOGICAL|autologous dendritic cells|Patients will receive standard first-line therapy (surgery before radio-chemotherapy) along with the experimental treatment. The experimental treatment consists in subcutaneous vaccination with a suspension of autologous dendritic cells (cells from the same patient) produced by cell culture from monocytes from the same patient extracted by leukapheresis and pulsed with a lysate of the patient´s tumoral tissue. The first four vaccines will be administered on a monthly basis, concomitantly with the standard chemo and radiotherapy treatments, the next four vaccines, every other month and the four last vaccinations every three months.The results obtained will be compared with those of an historical control study, where patients received a standard treatment without the experimental vaccine.
223774879|NCT04532697|OTHER|Uncaria Rhynchophylla (Gou-Teng)|Uncaria Rhynchophylla (Gou-Teng) is a kind of Chinese Medicine. All eligible subjects will be randomly assigned to receive a treatment of either Uncaria Rhynchophylla or placebo for 16 weeks followed by 8 weeks observation. The patient will be asked to take 1.2 g of the granule in the morning and another 1.2 g in the evening.
223835304|NCT00111254|PROCEDURE|Microdermabrasion|Treatment will consist of 3 passes in different directions (horizontal, vertical and oblique) with the microdermabrasion handpiece (Parisian Peel, Prestige model, medical microdermabrasion device).
223683680|NCT05944328|OTHER|systematic and structured review of patient pharmacotherapeutic treatment plans|"The intervention consisted of a systematic and structured review of patient pharmacotherapeutic treatment plans to identify problems or situations of risk related to pharmacological treatments and to propose changes or improvements to optimise them. phases:~Individualised review of pharmacological treatment plans to detect drug-related problems:~Indication, Appropriateness, Effectiveness, Safety When a drug-related problem was detected according to the above criteria, the pharmacist proposed an adjustment to the pharmacotherapeutic plan. The proposals could include: discontinuation of the drug, change of drug, change to a therapeutic equivalent, initiation of treatment, change of dosage, change of frequency or intensified monitoring.~The proposals made by the pharmacist were assessed and agreed upon by a committee comprising the doctors responsible and the pharmacist. Thereafter, the consensual proposals for change were discussed with the patient."
223683681|NCT05012878|BEHAVIORAL|Cardiac rehabilitation - high intensity interval training (HIIT)|During cardiac rehabilitation (12-weeks, 3 sessions/week), exercise training will comprise of 4x4-min high intensity aerobic intervals at a rating of perceived exertion 15-17 (hard to very hard), interspersed by a 3-min active recovery at a rating of perceived exertion 11-13 (fairly light to somewhat hard). Warm-up (4-min) and cool-down (3-min) at a light intensity.
223683682|NCT05012878|BEHAVIORAL|Cardiac rehabilitation - moderate intensity continuous training (MICT)|During cardiac rehabilitation (12-weeks, 3 sessions/week), exercise training will comprise of 34-min of continuous aerobic exercise at a rating of perceived exertion 11-13 (fairly light to somewhat hard). Warm-up (3-min) and cool-down (3-min) at a light intensity.
223683683|NCT05012878|BEHAVIORAL|Cardiac rehabilitation - control|Participants will receive exercise advice in line with usual hospital discharge procedures. This involves exercise physiologists providing verbal and written information on achieving the national physical activity guidelines (150min/week of moderate intensity exercise) 60 and range of movement exercises for surgical patients with sternotomy. However, no structured or supervised exercise training program or other contact with participants will be provided after hospital discharge, to reflect the usual care process for patients that decline cardiac rehabilitation.
223683684|NCT05012878|BEHAVIORAL|Cardiac rehabilitation - observational|During cardiac rehabilitation (12-weeks), program frequency and exercise training protocol will align with clinical care decisions and/or patient choice rather than random assignment.
223683685|NCT04034953|DIAGNOSTIC_TEST|Faecal Immunochemical Test|Faecal Immunochemical Test detects if there is any hemoglobin presents in stools, so even tiny amount of blood in stool can be found.
223683686|NCT04034953|DIAGNOSTIC_TEST|Prostate-Specific Antigen Test|PSA blood test is used to measure the level of PSA in blood. When the PSA level is higher than normal, it may represent prostate cancer or benign prostate hyperplasia. Patient who have high PSA level should receive additional tests.
223683687|NCT04034953|DIAGNOSTIC_TEST|Mammogram|Each sides of breast will be taken imaging in 2 different views.The breast will be pressed between 2 plastic plates to flatten and spread the breast tissue for clear imaging.
223683688|NCT00000843|DRUG|Adefovir dipivoxil|
223683689|NCT00484185|DRUG|BeneFIX (coagulation factor IX (recombinant))|BeneFIX will be administered according to physician's discretion.
223683690|NCT06299371|DRUG|Adebrelimab|Adebrelimab IV
223683691|NCT06299371|DRUG|paclitaxel for injection (albumin bound)|paclitaxel for injection (albumin bound) IV
223683692|NCT06299371|DRUG|Cisplatin or Carboplatin|Cisplatin or Carboplatin IV
223683693|NCT03952390|OTHER|control|
223683694|NCT03952390|OTHER|sepsis|
223683695|NCT04607798|DEVICE|Radiofrequency and pulsed electro-magnetic fields treatment|Radiofrequency and pulsed electro-magnetic fields treatment of the vaginal canal to maintain an internal temperature of approximately 42 C for the proximal thermometer and 45 C for the mid and distal thermometers for 15 minutes.
223683696|NCT01814280|OTHER|Medication review|Medication review performed by either a clinical pharmacist or a clinical pharmacologist
223683697|NCT00933218|DIETARY_SUPPLEMENT|polyphenols (non-alcoholic beer)|1.0 - 1.5 l non-alcoholic beer per day; 3 weeks before and during a marathon run
223683698|NCT00933218|DIETARY_SUPPLEMENT|beverage without polyphenols|1.0 - 1.5 l of beverage without polyphenols (otherwise the same composition as non-alcoholic beer) per day; 3 weeks before and during a marathon run
223683699|NCT04769999|BEHAVIORAL|Simple cognitive task|A brief memory reminder cue followed by playing the computer game Tetris for 25 minutes using mental rotation instructions. Option for subsequent booster sessions (self-administered/researcher-assisted).
223683700|NCT04444830|DRUG|Sprix|Intranasal Ketorolac - used as directed for an appropriate, previously established indication
223683701|NCT00459056|DRUG|Carvedilol CR + Lisinopril|Participants were given Carvedilol CR + Lisinopril for three months. Oral medication. Carvedilol CR and Lisinopril combination therapy was initiated at 20 mg and 10 mg, respectively. Patients returned one week later and doses of carvedilol CR and lisinopril were increased to 40 mg and 20 mg, respectively, depending on blood pressure.
223774880|NCT04532697|OTHER|Placebo|All eligible subjects will be randomly assigned to receive a treatment of either Uncaria Rhynchophylla or placebo for 16 weeks followed by 8 weeks observation. The patient will be asked to take 1.2 g of the granule in the morning and another 1.2 g in the evening.
223683702|NCT00459056|DRUG|Lisinopril + HCTZ|Participants were given Lisinopril + HCTZ for three months. Oral medication. Lisinopril + HCTZ combination therapy was initiated at 12.5 mg and 10 mg, respectively. Patients returned 1 week later and doses of hydrochlorothiazide and lisinopril were increased to 25 mg and 20 mg, respectively, depending on blood pressure levels.
223683703|NCT00170924|DRUG|Valsartan|
223683704|NCT03216928|DIAGNOSTIC_TEST|Blood test|
223774881|NCT00010218|DRUG|karenitecin|
223683705|NCT03430453|PROCEDURE|Measure of the minimal intensity of stimulation during ultrasound guided peripheral nerve blockade|A needle is placed at the target under ultrasound guidance, the nerve stimulator is turned on and the intensity increased until motor response is observed. The Minimal Intensity of Stimulation is recorded before injection of local anesthetic
223683706|NCT02283177|DRUG|crenolanib|
223683707|NCT02283177|DRUG|cytarabine|
223683708|NCT02283177|DRUG|daunorubicin|
223683709|NCT02283177|DRUG|idarubicin|
223683710|NCT04152980|DRUG|Pentoxifylline|The intervention consists of intravenously administered pentoxifylline. Pentoxifylline , a methylxanthine, is an off patent drug for neonates and currently registered for peripheral artery disease treatment in adults. Pentoxifylline acts as a cyclic adenosine monophosphate(cAMP)-phosphodiesterase inhibitor that suppresses tumor necrosis factor alfa (TNF-α) and modulates important parts of the inflammatory response and also reduces the production of other inflammatory cytokines, such as IL-1α, IL-6, and IL-8.
223683711|NCT00990275|OTHER|ethanol|subjects will ingest 3 ounces of vodka mixed with fruit juice within 30 min.
223683712|NCT05504772|GENETIC|Whole Genome Sequencing|Each tumor sample will be sequenced and analyzed in parallel with its matched normal (germline DNA from the same patient) to enable the identification of somatic aberrations.
223683713|NCT05504772|GENETIC|RNA seq|Results will be used for bioinformatics analysis for fusion transcripts and gene expression.
223683714|NCT05504772|GENETIC|DNA Methylation|Genome-wide assessment of DNA methylation will be conducted on all samples where possible.
223683715|NCT05504772|GENETIC|Targeted Panel Sequencing|"Targeted panel sequencing may be performed:~1. When WGS is not feasible or appropriate, e.g., insufficient DNA from fresh or frozen sample or only Formalin-Fixed Paraffin-Embedded (FFPE) material is available~2. When mosaicism is suspected~3. When indicated for a disease type"
223683716|NCT05504772|GENETIC|High Throughput Sequencing (in vitro)|High throughput drug screening will be attempted for tumors from Cohort 1 (high-risk cancers with survival \<30%) and selected tumor types.
223683717|NCT05504772|GENETIC|Patient Derived Xenograft (PDX)(in vivo)|In vivo drug testing in patient derived xenograft (PDX) will be attempted for tumors from Cohort 1 (high-risk cancers) and selected tumor types.
223774882|NCT05836038|BEHAVIORAL|Visio-Tactile Stimulation|They will see their virtual hand touched while simultaneously feel their opposite real hand touched in the same pattern.
223683718|NCT05504772|OTHER|Liquid Biopsy|Liquid biopsy will be investigated as a non-invasive method for diagnosis of tumors that are difficult to biopsy directly, understanding tumor heterogeneity, monitoring of treatment response, and detection of minimal residual disease (MRD)/relapse in leukemia, solid and CNS tumors.
223683719|NCT01101191|DRUG|Reformulated OXY (oxycodone HCl)|Reformulated OXY 80-mg tablet x 1 dose taken without food.
223683720|NCT01101191|DRUG|Original OxyContin® (OXY) (oxycodone HCl)|Original OxyContin® (OXY) 80-mg tablet x 1 dose taken without food.
223683721|NCT04926454|DRUG|Dexmedetomidine|"Patients will be monitored using standard monitoring (heart rate, non-invasive blood pressure, ECG and pulse oximetery) After the child is adequately anesthetized, intra-venous access with appropriate size cannula will be obtained Appropriate size LMA (2 and 2.5) will be inserted and patients will be allowed to breathe spontaneously.~patients will receive 0.25% Bupivacaine (0.3ml/Kg) with 1 μg/kg dexmedetomidine After general anaesthesia"
223683722|NCT04803682|BEHAVIORAL|Preventive Intervention|Participate in ASPIRE and mentorship program
223683723|NCT04803682|BEHAVIORAL|Questionnaire Administration|Ancillary studies (pre and post questionnaire)
223683724|NCT01891045|BEHAVIORAL|OQ-45.2 no feedback|Completion of the OQ-45.2 before each session, but no feedback to therapists or patients
223683725|NCT01891045|BEHAVIORAL|OQ-45.2|Completion of the OQ-45.2 with real-time feedback to the therapist and full use of the suggested interventions every week of the treatment program
223683726|NCT06271473|PROCEDURE|vitrectomy + ILM peeling +/- planned foveal detachment via subretinal injection of ringer's solution.|vitrectomy + ILM peeling +/- planned foveal detachment via subretinal injection of ringer's solution.
223683727|NCT02530047|GENETIC|MSC-INFβ|"MSC-INFβ administered on an outpatient basis via intraperitoneal (IP) infusion.~Starting dose: 10\^5 MSC/kg once a week for 4 treatments."
223683728|NCT02530047|BEHAVIORAL|Questionnaires|Symptom questionnaire completed once a week for 4 weeks.
223683729|NCT04493840|DRUG|Shenfu Injection|80ml Shenfu Injection + 70ml 5% glucose injection, ivdrip, within 30 minutes before PCI and 1 to 5 days (once a day) after PCI (6 times in total). Drug titration time should be no less than 30 minutes.
223683730|NCT04493840|DRUG|5% Glucose Injection|150 ml 5% glucose injection, ivdrip, within 30 minutes before PCI and 1 to 5 days (once a day) after PCI (6 times in total). Drug titration time should be no less than 30 minutes.
223683731|NCT02678598|DRUG|Micafungin|Intravenous
223683732|NCT03761797|DRUG|TRADIANCE® Combination Tablets AP|Fixed dose combination
223683733|NCT03761797|DRUG|TRADIANCE® Combination Tablets BP|Fixed dose combination
223774883|NCT06004310|BEHAVIORAL|Pulmonary Rehabilitation|Participants will be participated a 06 weeks comprehensive outpatient pulmonary rehabilitation which includes endurance training, strength training, patient education, relaxation techniques, psychological support and nutritional counselling.
223774884|NCT04812353|OTHER|Follow-up of Io-Fix type fixation|Follow-up of patients who underwent a foot- or ankle reconstruction surgery using the Io-Fix system
223774885|NCT06309147|DRUG|BMS-9894923|50 mg capsules, oral administration
223683734|NCT05942209|DIAGNOSTIC_TEST|ECO-LEAK transvaginal ultrasound|After performing the colorectal anastomosis, the patient is monitored postoperatively both clinically and analytically, with serial laboratory tests including PCR and procalcitonin. In the absence of symptoms on the 4th to 5th day an ultrasound - ecoenema is performed. First, the Foley catheter is inserted via the transanal route with instillation of 180cc of serum under ultrasound guidance with a probe in the vagina, using a sagittal and midline cut. In case there is the appearance of free pelvic fluid (previously absent) or an increase in free fluid compared to the baseline examination (fluid present at the beginning of the examination) around the anastomosis/pelvic area, the test will be considered positive.
223683735|NCT05942209|DIAGNOSTIC_TEST|ECO-LEAK with CT-Scan or rectoscopy|After performing the colorectal anastomosis, the patient is monitored postoperatively both clinically and analytically, with serial laboratory tests including PCR and procalcitonin. In the absence of symptoms on the 4th to 5th day, a CT scan or rectoscopy is performed, along with an ecoenema.
223683736|NCT05942209|DIAGNOSTIC_TEST|CT-Scan or rectoscopy|After performing the colorectal anastomosis, the patient is monitored postoperatively both clinically and analytically, with serial laboratory tests including PCR and procalcitonin. In the absence of symptoms on the 4th to 5th day, a CT scan or rectoscopy is performed
223774886|NCT05114603|DRUG|HLX208|level 1:600mg po Bid level 2:900mg po Bid
223683737|NCT00879879|DRUG|losartan|50 mg losartan taken daily by mouth in capsule form for 1 year
223683738|NCT04873271|DEVICE|Medtronic Implantable Tibial Neuromodulation (TNM) System|Tibial neuromodulation (TNM) devices are implantable devices that provide stimulation to the tibial nerve.
223683739|NCT02581839|DRUG|Eribulin Mesylate|Most subjects will begin eribulin mesylate at 1.4 mg/m2 administered intravenously over 2 to 5 minutes on Days 1 and 8 of a 21-day cycle.
223774887|NCT05702320|OTHER|the heating procedure|The patients will undergo a heating procedure.
223774888|NCT05971212|BEHAVIORAL|Behavioural sleep clinic access|Access to behavioural Sleep Clinic
223774889|NCT02126254|DEVICE|Hemodynamic group|NICAS guided treatment
223774890|NCT01322204|DRUG|Codeine|One single oral dose of 1 mg/kg of codeine
223774891|NCT02030678|DRUG|irinotecan|Irinotecan monotherapy (trade name: Aili; batches 180103AG \[40 mg\] and 171231AG \[100 mg\]) will be administered intravenously at a dose of 100 mg/m2 on days 1 and 8 of each 3-week cycle.
223774892|NCT03412643|DRUG|Doxorubicin|60 mg/m2 IV Day 1 every 2 weeks or 3 weeks at investigator's discretion for a total of 4 cycles
223774893|NCT03412643|DRUG|Cyclophosphamide|600 mg/m2 IV Day 1 every 2 weeks or 3 weeks at investigator's discretion for a total of 4 cycles
223774894|NCT03412643|DRUG|Weekly Paclitaxel|80 mg/m2 IV weekly for 12 doses
223774895|NCT03412643|DRUG|Trastuzumab|loading dose of 8 mg/kg IV; then 6 mg/kg IV every 3 weeks for Cycles 2-4
223683740|NCT02581839|DEVICE|MRI|An MRI will be completed at week 1, week 12 and every 12 weeks after cycles 4+ while on study eribulin mesylate
223683741|NCT02581839|DRUG|Pre-Medication: Zofran|Zofran at 8mg orally. Given at the discretion of the treating physician
223683742|NCT02581839|DRUG|Pre-Medication: Decadron|decadron at 8mg orally. Given at the discretion of the treating physician
223683743|NCT02312427|DRUG|Suspending DPP-4 inhibitor, in outpatient service|After baseline data collection, DPP-4 inhibitor (sitagliptin, vildagliptin, alogliptin, linagliptin, teneligliptin, anagliptin or saxagliptin) will be suspended for one month and serum BNP will be measured. The DPP-4 inhibitor will be resumed and after another month, serum BNP will be measured again.
223683744|NCT02312427|DRUG|Starting DPP-4 inhibitor after treatment of heart failure|After hospitalization, medication for diabetes will be suspended. During the treatment for heart failure, drugs other than DPP-4 inhibitor will be resumed when required. After the stabilization of heart failure, DPP-4 inhibitor will be resumed (or administered if it was not prescribed before hospitalization) and serum BNP before and after the initiation of DPP-4 inhibitor will be measured.
223683745|NCT02312427|DRUG|Suspending DPP-4 inhibitor after treatment of heart failure|After hospitalization, medication for diabetes may be suspended or continued. During the treatment for heart failure, drugs including DPP-4 inhibitor will be resumed when required. After the stabilization of heart failure, DPP-4 inhibitor will be suspended and serum BNP before and after the suspension of DPP-4 inhibitor will be measured.
223683746|NCT02188043|BEHAVIORAL|Relay Model|"The Clinical staff hand out and collect lifestyle - questionnaires to admitted patients, and screen by 10 alcohol questions (AUDIT) , and report score to outpatient Alcohol Clinic.~Based on the questionnaire that the patient filled out, the Alcohol therapist perform a brief Motivational Intervention on patients with an AUDIT score of 8+, focusing the patients alcohol consumption habits and offer an appointment to patients with an AUDIT score of 16+."
223683747|NCT03804073|RADIATION|standard treatment|3000 cGy in 10 daily fractions
223683748|NCT03804073|RADIATION|short course treatment|2000 cGy in 4 fractions administered twice a day
223683749|NCT04880330|DEVICE|Cryo-Auriculotherapy|1 session of cryo-auriculotherapy with device with nitrous oxyde on 15 auricular points.
223683750|NCT04880330|DEVICE|Sham comparator|1 session of cryo-auriculotherapy with device without nitrous oxyde on 15 auricular points.
223683751|NCT00954252|DRUG|CHF 5074|1x, oral capsule, single dose
223683752|NCT00954252|DRUG|placebo|placebo, oral capsule, single dose
223683753|NCT00954252|DRUG|CHF 5074|2x, oral capsule, single dose
223683754|NCT00954252|DRUG|CHF 5074|4x, oral capsule, single dose
223683755|NCT00954252|DRUG|CHF 5074|8x, oral capsule, single dose
223683756|NCT00954252|DRUG|CHF 5074|16x, oral capsule, single dose
223683757|NCT00954252|DRUG|CHF 5074|24x, oral capsule, single dose
223683758|NCT01797172|PROCEDURE|Percutaneous Cervical Nucleoplasty|Cervical nucleoplasty is a method of percutaneous disc decompression using a 19 Gauge Trocar 3 inch spine needle (ArthroCare Co., Sunnyvale, CA, USA) which is brought to the annulus fibrosis of the herniated disc. If in the correct position, the stylet is withdrawn and the Perc DC SpineWand (ArthroCare Co., Sunnyvale, CA, USA) is introduced. The procedure relies on so-called Coblation technology which involves removing a portion of the nucleus tissue by using radio frequency energy. More specific, it results in ablation of a portion of nucleus tissue, not with heat, but with a low-temperature (typically 40-70° C) plasma field of ionized particles.
223683759|NCT01797172|PROCEDURE|Pulsed Radio Frequency|Pulsed Radio Frequency involves placement of a needle close to the to-be-treated nerve or dorsal root ganglion (DRG). The position is checked radiographically and by motor and sensory nerve stimulation. When the needle has been placed correctly an electrode is introduced, which conducts short bursts of radio frequency energy to nervous tissue. It is known as a non- or minimally neurodestructive technique, alternative to radio frequency heat lesions using so-called thermocoagulation. No nerve damage takes places as the temperature of the tip of the needle does not exceed 42°C. This is achieved by relatively long pauses between pulses which allow generated heat to dissipate and prevent the development of any thermal lesion.
223683760|NCT00868179|DRUG|Pradax|Pradax (dabigatran etexilate) is a prodrug that when converted to the active from in the liver and plasma it becomes a reversible, competitive direct thrombin inhibitor. Thrombin catalyses the conversion of soluble fibrinogen into soluble fibrin, the final step in the coagulation cascade. Pradax competitively blocks the active site of both free and clot-bound thrombin, preventing the development of a thrombus. they will take 110 mg 1-4 hours post op. and 220mg daily until 10 days post op.
223683761|NCT01874990|DIETARY_SUPPLEMENT|high sodium diet|The high-sodium diet was obtained by adding 6g of sodium chloride to the individual's regular diet
223683762|NCT01874990|DIETARY_SUPPLEMENT|low-salt diet|
223683763|NCT06165627|DEVICE|Lehfilcon A toric contact lenses|Commercially available soft contact lenses worn as indicated
223683764|NCT06165627|DEVICE|Comfilcon A toric contact lenses|Commercially available soft contact lenses) worn as indicated
223774896|NCT03412643|DRUG|Pertuzumab|loading dose of 840 mg IV; then 420 mg IV every 3 weeks for Cycles 2-4
223683765|NCT06165627|DEVICE|CLEAR CARE|Commercially available hydrogen peroxide-based solution for daily cleaning and disinfection of contact lenses used as indicated
223683766|NCT02095314|BIOLOGICAL|Pentavalen|Batch 5010613
223683767|NCT00579085|DRUG|Ketamine|IV Ketamine .35mg/kg times ten days.
223683768|NCT00579085|OTHER|IV NSS|Placebo inactive ingredients
223683769|NCT00579085|OTHER|Normal Saline|"INFUSION PLAN:~All patients will be infused intravenously with 100 ml of normal saline for four hours (25 ml/hr) daily for 10 days.Both patient arms will receive 2mg of Versed x two doses IV. They will also receive Clonidine (0.1 mg, po)"
223683770|NCT04219462|DEVICE|active extracorporeal shock wave|Ultrasound gel was used as a coupling agent, and the applicator of extracorpral shock wave therapy (ESWT) will be held perpendicular to the treatment surface throughout the treatment. Men in this group (n= 20) men receive ESWT twice weekly for 3 consecutive weeks and repeated after a 3-week rest period, for a total of 12 treatment sessions. The patients will receive ESWT for 15 minutes at an energy level of 0.09 and a frequency of 120 shocks/min (1800 pulses per session). Shockwaves were delivered to the distal, mid, and proximal penile shaft, as well as to the left and right crura + 5 mg sildnafil once daily for 3 months
223683771|NCT04219462|DEVICE|sham extracorporeal shock wave|twenty men will receive sham treatment underwent identical therapy with ESWT application with a similar appearance and sound as the active extracorporal shock wave therapy (ESWT), although shock wave propagation to the tissue wills be blocked by a metal plate that will inserted into the sham applicator + sildenafil 5mg once daily for 3 months.
223683772|NCT01141777|DIETARY_SUPPLEMENT|Spirulina platensis|Subjects received 19g daily of supplement averagely.This was supplied as powder daily, in packs that lasted for 2weeks each. Each subject was therefore seen every two week to obtain new stock of supplements and evaluate compliance
223683773|NCT01141777|DIETARY_SUPPLEMENT|Soya bean|Each subject received 19g of supplement on average daily. Subjects were seen every two weeks to evaluate compliance and obtain a new stock.
223683774|NCT04136756|DRUG|NKTR-255|NKTR-255 administered by IV infusion every 21 or 28 days to establish safety and tolerability
223683775|NCT04136756|DRUG|NKTR-255 Q21|NKTR-255 administered by IV infusion every 21 days to establish safety and tolerability
223683776|NCT04136756|DRUG|Rituximab|Rituximab administered intravenously at specified dose on specified days
223683777|NCT04136756|DRUG|Daratumumab|Daratumumab administered subcutaneously at specified dose on specified days
223683778|NCT01167985|DEVICE|IABN|Patients with single canal teeth diagnosed with infected pulp and periapical lesion, and need root canal treatment, will be asked to participate in the study. The study group will have their canal sealed with endodontic sealer + the nanoparticles. The control group will have their canal sealed with the conventional sealer alone. The patients will be invited to 4 follow ups during which a clinical and radiological examinations will be performed.While preparing the post, a sample of the sealer will be taken to evaluation in the lab.
223683779|NCT01167985|DEVICE|IABN|patients with molar teeth diagnosed with healthy pulp or irreversible pulpitis, and need root canal treatment, will be asked to participate in the study. After cleaning the teeth following a standard protocol, a sterile cotton wool will be placed in the pulp chamber. provisional restoration with and without nanoparticles will seal the teeth between apointments. After a month the cotton wool will be taken out and tansferred to the laboratory. The root canal treatment will continue following the standard protocol.
223774897|NCT03412643|DIAGNOSTIC_TEST|Celcuity CELx HSF|Prior to drug interventions 3, 4,and 5, the Celcuity CELx HSF diagnostic test will be conducted to assess HER2 signaling activity
223683780|NCT01167985|DEVICE|IABN|Patients with single canal teeth diagnosed with infected pulp and periapical lesion, and need root canal treatment, will be asked to participate in the study. The study group will have their canal sealed with endodontic sealer + the nanoparticles. The control group will have their canal sealed with the conventional sealer alone. The patients will be invited to 4 follow ups during which a clinical and radiological examinations will be performed.While preparing the post, a sample of the sealer will be taken to evaluation in the lab.
223683781|NCT01727778|BIOLOGICAL|Anti-GRP78 monoclonal IgM antibody PAT-SM6|
223683782|NCT06516367|OTHER|Ain Shams University Screening Tool for Malnutrition, Sarcopenia, and Cachexia (ASUST-MSC)|25 items dichotomous questionnaire
223774898|NCT01347021|PROCEDURE|sacrospinous colpopexy versus high uterosacral colpopexy|Women with uterine prolapse grade III or IV were randomly allocated to the sacrospinous colpopexy or high uterosacral colpopexy with vaginal hysterectomy.Before the surgery P-Qol questionnaire were completed and urogynecological examination include de POP-Q system was done. All patients underwent clinical check-ups 1, 6 and 12 months postoperatively. Each check-up included clinical examination and questionnaire.
223774899|NCT06573515|DEVICE|high tone power therapy|female patients will receive high-tone power therapy using a device (HiTop 191 Medizintechnik, Rimbach, Germany) duration 30 minutes at 2 sessions per week for 6 weeks
223774900|NCT06573515|DEVICE|interferential current therapy|female patients will receive interferential current therapy using Enraf-Nonius (ENDOMED 484, Germany)The electrode pairs will placed at a distance of at least 2.5 cm from each other. The utilized parameters will have a base frequency of 4,000 Hz, a modulation frequency range of 10 Hz-20 Hz, spectrum mode triangular, and slope 1/1 in a quadripolar manner with a beat frequency of 80 Hz. duration of treatment session 20 minutes 2 sessions per week for 6 weeks
223774901|NCT06573515|DEVICE|conventional physical therapy|female patients will receive conventional physical therapy modalities in the form of (ultrasound, massage, stretching, and strengthening exercises) 2 sessions per week for 6 weeks
223774902|NCT01922596|DRUG|Ropivacaine|
223683783|NCT05573412|OTHER|Cellular analysis|Previously cryopreserved samples will be analyzed for total nucleated cell count (TNC), cell viability and proliferative potential
223683784|NCT00469261|DRUG|Doxycycline|Doxycycline 100 mg bid for seven days after enrollment
223683785|NCT00469261|DRUG|Current medical therapy for AMI|Current medical therapy for AMI
223683786|NCT02547883|DRUG|Cessation of statin|The intervention evaluated is the cessation of statin
223683787|NCT04231591|DIAGNOSTIC_TEST|NT-proBNP|Collect serum NT-proBNP levels in singleton ACHD patients and a comparative normotensive control group at time of admission for delivery to characterize negative predictive values for intrapartum and postpartum cardiac events.
223683788|NCT05346367|RADIATION|SRT|SRT
223683789|NCT05346367|RADIATION|fSRT|fSRT
223683790|NCT01113476|DRUG|Nab-paclitaxel|Starting dose of 50 mg/m\^2 on Day 1, 8 + 15 every 28 days (+/- 2 days)
223683791|NCT01113476|DRUG|Bevacizumab|Starting dose of 5 mg/m\^2 on Day 1 + 15 every 28 days (+/- 2 days)
223683792|NCT01113476|DRUG|Gemcitabine|1000 mg/kg Day 1, 8 + 15 every 28 days (+/- 2 days)
223683793|NCT02528266|DEVICE|Nerve Capping Device|
223683794|NCT02707159|DRUG|Nab paclitaxel / gemcitabine|Patients will receive gemcitabine/nab-paclitaxel combination chemotherapy
223683795|NCT01179997|DEVICE|Interventricular pacing delay optimization by using Tissue Doppler-derived displacement curves|
223683796|NCT01179997|DEVICE|Electrocardiographic optimization of the interventricular pacing delay according to QRS width|
223683797|NCT00806507|PROCEDURE|Echocardiograms|Additional views performed in 5-10 minutes of regularly scheduled echocardiograms.
223774903|NCT01922596|DRUG|Placebo|
223774904|NCT01892475|BEHAVIORAL|Incentive-based physical activity program|"Drivers will be offered rewards valued at a day's rental for meeting daily step targets over the specified number of days each month from Months 1 to 4, where steps will be tracked by a step counter. They will also be offered incentives for meeting the following criteria:~1. Accurately predicting step target attainment the following months (SGD10)~2. Wearing and providing step data over the month (SGD10 and a chance to win 1 of 3 cash prizes valued at SGD500)"
223683798|NCT00806507|PROCEDURE|Blood Test|Measuring of hormones and metabolic proteins (such as sugars and acids).
223683799|NCT00060398|BIOLOGICAL|epoetin alfa|
223683800|NCT00060398|DRUG|dexamethasone|
223683801|NCT03494348|DEVICE|Medial Congruent Polyethylene (MC)|One group receives the conventional CR surface and the other the new MC articular surface
223683802|NCT00989573|DRUG|Placebo|oral administration of placebo once-daily for 8 weeks
223683803|NCT00989573|DRUG|OPC-6535|oral administration of OPC-6535 25 mg once-daily for 8 weeks
223683804|NCT00989573|DRUG|OPC-6535|oral administration of OPC-6535 50 mg once-daily for 8 weeks
223683805|NCT03680430|RADIATION|Adaptive radiation therapy|Patients will be treated by preoperative or definitive radiotherapy for a limb STS, using an intensity-modulated conformal irradiation (with a static or dynamic technic), over 5 to 7 consecutive weeks. The total dose delivered will be of 50 Gray (preoperative RadioTherapy), or 60 to 70 Gray (exclusive RadioTherapy).
223683806|NCT04617535|DRUG|REGN10933+REGN10987 combination therapy|Administered intravenously (IV) single dose
223683807|NCT06003569|BEHAVIORAL|BACK-S|"BACK = Better Asthma Control for Kids:~The BACK -Standard package includes a tailor-and-adapt to context strategy of approaches necessary to implement BACK in schools based on our past work, operationalized as an implementation blueprint to coordinate with partner roles of child/family, schools, healthcare teams and community resource agencies. This includes a facilitation strategy to support problem-solving through regular learning collaborative meetings for asthma navigators (bi-weekly), school nurses (monthly to bi-monthly) and health care champions (quarterly)."
223683808|NCT06003569|BEHAVIORAL|BACK-E|The BACK-Enhanced package includes the BACK-Standard package plus an Enhanced strategy to develop interrelationships with students/family, schools, and community agencies providing resources to address social determinants of health.
223683809|NCT02843737|OTHER|Polysomnography under spontaneous breathing|Patient will come to the sleep laboratory to perform the polysomnography under spontaneous breathing prescribed by the clinician
223683810|NCT05669248|DIAGNOSTIC_TEST|mid covid-19 patients|Collect the patient's whole blood for testing
223683811|NCT05055245|OTHER|cycles|Patients are grouped according to the number of IVF/ICSI cycles.
223683812|NCT01574833|DEVICE|pulsed electromagnetic field|PEMF treatment
223683813|NCT01574833|DEVICE|sham|sham treatment
223683814|NCT01990144|DRUG|Bendamustine+Rituximab|"Patients will receive :~* Rituximab 375 mg/m2 intravenously on day 1\*~* Bendamustine 90 mg/m2 intravenously on days 2 and 3\*\* Treatment will be administered on a 28-day cycle basis.~  * Administration of rituximab during cycle 1 is postponed to day 8, thereafter on day 1.~    * After the first cycle, bendamustine can be administered on days 1-2 or days 2-3 according to Institutional/patient/physician choice."
223683815|NCT03687970|OTHER|Brief Pain Inventory|-A self-administered questionnaire used to evaluate the severity of a patient's pain and the impact of this pain on the patient's daily functioning. The patient is asked to rate their worst, least, average, and current pain intensity (4 items which generate the PAIN SEVERITY score), list current treatments and their perceived effectiveness, and rate the degree that pain interferes with general activity, mood, walking ability, normal work, relations with other persons, sleep, and enjoyment of life (7 items which generate the PAIN INTERFERENCE score) on a 10 point scale.
223683816|NCT03687970|OTHER|Hospital Anxiety and Depression Scale|"* 14 item scale with even of the items relating to anxiety and seven relating to depression~* Each item on the questionnaire is scored from 0-3 and this means that a patient can score between 0 and 21 for either anxiety or depression"
223774905|NCT01892475|BEHAVIORAL|3-month follow up|After the 4-month RCT, drivers will be incentivized to wear the step counter for another 3 months (i.e. Months 5 to 7) to test if effects of the rewards are sustained once the reward is no longer in place. For wearing their step counter and providing their step data, drivers will receive a modest cash incentive (amounting to SGD10) each month as well as the chance to win 1 of 3 cash prizes valued at SGD500.
223835305|NCT05181943|DEVICE|Simpler diode laser|Non-contacting irradiation for 30 seconds on three intraoral sites repeated four times
223774906|NCT02680691|OTHER|Robot, then conventional training|Robot assisted gait training from the baseline, then conventional gait training at 4 weeks after baseline
223774907|NCT02680691|OTHER|Conventional, then robot training|Conventional gait training from the baseline, then robot assisted gait training at 4 weeks after baseline
223683817|NCT03687970|OTHER|Neuropathic Pain Symptom Inventory|-The NPSI questionnaire utilized in this study includes eight parameters (i.e., burning pain, squeezing pain, pressure pain, electric shock pain, stabbing pain, tingling pain, pins and needles pain and allodynia \[pain provoked by light touch\]). Each of the parameters includes recall of the past 24 hours
223683818|NCT03687970|PROCEDURE|Diode Laser fiber type Selective Stimulator|"-Each patient will have an A and C fiber stimulation. Stimulation will be performed on the dorsum of the foot using stimulation previously published parameters to elicit burning pain, which is from activation of C-fibers and pinprick pain from A-fibers"
223683819|NCT03687970|PROCEDURE|Quantitative sensory testing|"* Quantitative sensory testing will be performed on the dorsal mid-foot and the ipsilateral shoulder will serve as control area~* Cold and warm detection thresholds, cold and heat pain thresholds, mechanical detection thresholds, and wind-up ratio"
223683820|NCT03687970|PROCEDURE|Conditioned pain modulation efficiency|-Immersion of a hand up to the wrist to a thermostat-controlled water bath maintained at 12 degrees Celsius, and the application of a heat stimulus on the contralateral forearm.
223683821|NCT03687970|OTHER|Spontaneous pain at baseline on 0-10 Numerical Rating Scale (NRS)|"-The subjects are asked to rate the intensity of their current pain on a 0-10 scale - 0 denoting no pain and 10 denoting worst imaginable pain."
223683822|NCT01967381|DRUG|Methamphetamine (Desoxyn®)|The pharmacodynamic effects of methamphetamine (Desoxyn®) will be determined during placebo, oxazepam (Serax®), naltrexone (Revia®) and combined oxazepam and naltrexone maintenance.
223683823|NCT00817479|DRUG|Dexamethasone|20 MG OF DEXAMETHASONE OR PLACEBO
223683824|NCT00817479|DRUG|Placebo|Placebo saline
223774908|NCT02762409|OTHER|experimental|corresponding to surviving individuals of a hospitalization in intensive care in a department having set up the program of reduction of the discomforts collected by the patients of intensive care during a minimal period of 5 months. The program is so defined as factor of exposure and supposed protector of development of anxio-depressive disorders.These patients will have been included in the study IPREA3 in 17 centers of the interventional group of the study IPREA3 during the months of April, 2015 and October, 2015
223683825|NCT04808999|DRUG|Pembrolizumab Injection|200 mg IV infusion
223683826|NCT04030026|DRUG|NAL ER|Participants received NAL ER 27 mg QD, 27 mg BID, 54 mg BID, 108 mg BID, 162 mg BID.
223683827|NCT04030026|DRUG|Placebo|Participants received Placebo tablet (matching NAL ER ).
223774909|NCT02762409|OTHER|control|"The patients not exposed in the supposed factor protector of development of anxio-depressive disorders will be constituted by the patients estimated in the study IPREA3 corresponding to surviving individuals of a hospitalization in intensive care in a department having never operated the program of reduction of the discomforts collected by the patients of intensive care. These patients will have been included in the study IPREA3 in 17 centers of the group control some study IPREA3 during October 2014 and April, 2015"
223774910|NCT00054002|PROCEDURE|adjuvant therapy|Lung surgery
223774911|NCT00054002|PROCEDURE|conventional surgery|Lung surgery
223774912|NCT00054002|DRUG|porfimer sodium|iv
223774913|NCT03475641|DRUG|Femoral nerve blockade|The femoral nerve blockade with lidocain is combined to the tumescent anesthesia.
223774914|NCT03475641|PROCEDURE|The current standard treatment|Tumescent anesthesia.
223835306|NCT05181943|DRUG|Conventional symptomatic treatment|Conventional treatment using oracure, BBC spray, miconaz three times daily
223835307|NCT01782326|DRUG|QVA149|QVA149 will be supplied in a capsule form in blister packs for use in the Novartis Concept 1 SDDPI.
223774915|NCT03946332|BEHAVIORAL|Physical exercises|patients will benefit regularly from a physical exercises program during their hospitalization. When going back home, they will be given a practical help kit with specific equipment (dumbbell, elastic), an actimeter with heart rate monitoring (in order to have an objective collection of the physical practice in addition to a self-evaluation) and a physical exercises program on paper and video supports, that patients would have learnt during their hospitalization.
223774916|NCT03946332|BEHAVIORAL|Optional physical exercises|patients will be proposed for the physical exercises and will practice them if they want.
223774917|NCT04848285|OTHER|Early Mobilization|Additional 2 or more sessions of out-of-bed activity to the standard stroke care, focused in active sitting, standing and walking assisted by physiotherapists
223774918|NCT04848285|OTHER|Standard care|Standard protocol of mobilization in acute stroke patients admitted to the Stroke Unit at the discretion of the nursing and physiotherapy staff
223774919|NCT02912351|OTHER|Patient record review, Radiographs, and questionaires.|KSS-Objective Knee Scores, KSS Subsets, Radiographs and Patient Satisfaction
223774920|NCT00961259|DRUG|Fenofibric Acid 35 mg Tablet|1 x 35 mg tablet administered after an overnight fast of at least 10 hours
223683828|NCT02776202|DRUG|Fludarabine monophosphate|"The HSCT preparative regimen will consist of~* Thymoglobulin: 2.5 mg /kg/day intravenously (IV) on Days -8 through -5~* Fludarabine: 35 mg/m2/day IV on Days -8 through -4~* Melphalan: 140 mg/m2 IV on Day -3~* Rest on Day -2 and -1~* Day 0 is the day of transplant~* GVHD prophylaxis: sirolimus beginning on Day -1 for at least one year and mycophenolate mofetil (MMF) from Day -3 to +45 or to 7 days after neutrophil engraftment, whichever is later."
223683829|NCT00523367|PROCEDURE|24 hour pH testing|24 hour pH testing will be used to screen patients
223683830|NCT02179138|DRUG|TFV 1% gel|
223683831|NCT05175053|OTHER|Renal replacement therapy|Continuous renal replacement therapy using continuous venovenous hemodiafiltration (CVVHDF)
223683832|NCT05175053|OTHER|Best medical management|The best medical management continues until the patient meets absolute indication of renal replacement therapy
223683833|NCT03464370|OTHER|Measure of emotional stressors|"For the Epileptic Group~* Rapid interrogation, completing the clinical data~* A scale of impact of the precipitating factors of crises~* An emotional Stroop~* A task of detecting emotional targets against threatening information~* A measure of the perception of emotions using film clips~* A scale of measurement of perceived stress~* The transfer of psychiatric scales~For the healthy volunteers group :~* A rapid interrogation, gathering the possible medical history, the level of studies, the manual laterality~* An emotional Stroop~* A task of detecting emotional targets against threatening information~* A scale of measurement of perceived stress~* A measure of the perception of emotions using film clips~* A rapid neuropsychological assessment"
223683834|NCT06051045|DRUG|Bulevirtide|Hepcludex, 2 mg daily subcutaneous injection
223683835|NCT05483998|DRUG|TLC-2716|TLC-2716
223683836|NCT05483998|OTHER|Placebo|Placebo to match
223683837|NCT01931072|BEHAVIORAL|High-intensity interval training|Interval training 3 times a week for 8 weeks
223683838|NCT01931072|BEHAVIORAL|Moderate training|Moderate training 3 times a week for 8 weeks
223683839|NCT04480424|BIOLOGICAL|GAMUNEX-C|Intravenous Immune Globulin (Human), 10% Caprylate/Chromatography Purified.
223683840|NCT04480424|DRUG|Standard Medical Treatment|SMT per local policies or guidelines.
223683841|NCT05763485|PROCEDURE|Anti reflux mucosal ablation (ARMA)|"In patients fulfilling the inclusion criteria and being randomized for ARMA, the procedure using argon plasma coagulation involves two semicircular ablations of the mucosa of the EGJ in a butterfly shape of a width of 2 cm. The approximate duration of the procedure is 30min.~Follow includes objective evaluation of reflux disease by reflux questionnaires, esophagogastroduodenoscopy, esophageal manometry, pH metry."
223683842|NCT05763485|PROCEDURE|Sham procedure|In patients fulfilling the inclusion criteria and being randomized for sham procedure, the procedure involves esophagogastroduodenoscopy with the same set of movements and duration as the ARMA procedure without the actual ablation.
223683843|NCT03646240|DRUG|ABI-009|For dose finding, ABI-009 will start at 5 mg/m2/dose IV, once a week for three weeks, in cohorts of 3 participants each using the standard 3+3 dose-finding design
223683844|NCT03333538|BIOLOGICAL|GamEvac-Lyo (component A)|Biological: GamEvac-Lyo (vaccine) vaccination, single administration, component A
223683845|NCT03333538|OTHER|Placebo|Placebo vaccination
223774921|NCT00961259|DRUG|Fenofibric Acid 35 mg Tablet|3 x 35 mg tablets administered after an overnight fast of at least 10 hours
223774922|NCT00961259|DRUG|Fenofibric Acid 105 mg Tablet|105 mg tablet administered after an overnight fast of at least 10 hours
223774923|NCT03704545|OTHER|Pharmaceutical consultation at the hospital|During 20 minutes, the patient will be educated about chronic obstructive pulmonary disease treatments and their use.
223774924|NCT03704545|OTHER|Pharmaceutical consultation at the pharmacy|During 20 minutes, the patient will be educated about chronic obstructive pulmonary disease treatments and their use.
223774925|NCT03704545|OTHER|Follow-up pharmaceutical consultation at the pharmacy|During 10 minutes, the patient will get more information about his chronic obstructive pulmonary disease treatments and their use.
223774926|NCT00665119|DRUG|remifentanil|0.05 mcg.kg-1.min-1 for 30 minutes by continuous endovenous infusion
223774927|NCT00665119|DRUG|placebo|NaCl 0.9 %
223774928|NCT03611803|DEVICE|Physiotherapy + Robotic-device|Daily use of an exoskeleton (robotic-device) on 5 successive days as well as daily physiotherapy sessions
223683846|NCT03333538|BIOLOGICAL|GamEvac-Lyo (component B)|Biological: GamEvac-Lyo (vaccine) vaccination, single administration, component B
223774929|NCT03611803|OTHER|Physiotherapy only|Participants will engage in daily physiotherapy sessions (without the exoskeleton) and/or home-based sit-to-stand exercises
223774930|NCT04543422|DIETARY_SUPPLEMENT|Green tea|Green tea extract capsules
223774931|NCT04543422|OTHER|Placebo|Placebo containing inert material.
223774932|NCT01324024|DRUG|Lisdexamfetamine|In a counterbalanced fashion, participants would receive titrated doses of LDX 20 to 60 mg/d for 4 weeks followed by a 2-week washout and then crossed over to the placebo tablets for another 4 weeks. All women will start with LDX 20 mg/d and then be titrated to 40 mg/d after 1 week and 60 mg/d after 2 weeks (as tolerated).
223774933|NCT01324024|DRUG|Placebo|In a counterbalanced fashion, participants would receive placebo tablets for 4 weeks followed by a 2 week washout, then will receive titrated doses of LDX 20 to 60 mg/d for 4 weeks.
223683847|NCT03333538|BIOLOGICAL|GamEvac-Lyo|Biological: GamEvac-Lyo (vaccine) vaccination, therapeutic scheme: the sequential introduction of components A and b with an interval of 21 days
223683848|NCT02782923|DEVICE|STISIM driving simulator|This simulator is complete with computerized driving scenarios and driving hardware, has been validated in numerous studies and allows for a more comprehensive investigation of driving performance. The simulated course recreates standard turns, traffic intersections, pedestrian crosswalks, lane changes and several hazardous conditions routinely encountered during driving situations.
223683849|NCT03975140|PROCEDURE|Hypersensitive acupoint group|The first five acupoints in the sensitization sequence were pressed using the traditional Chinese medicine acupoint pressing technique, and each acupoint was pressed for two minutes.
223683850|NCT03975140|PROCEDURE|Hyposensitive acupoint group|The last five acupoints in the sensitization sequence were pressed using the traditional Chinese medicine acupoint pressing technique, and each acupoint was pressed for two minutes.
223683851|NCT03765879|OTHER|Verum VGAIT (Video-Guided Acupuncture Imagery Treatment)|In VGAIT treatment sessions, participants will re-watch the video of an avatar receiving acupuncture treatment, and they will be asked to vividly imagine that the treatment is being concurrently applied on themself.
223683852|NCT03765879|OTHER|Sham VGAIT (Video-Guided Acupuncture Imagery Treatment)|In sham VGAIT treatment sessions, participants will re-watch this video of an avatar receiving the sham acupuncture treatment, and they will be asked to vividly imagine that the treatment is being concurrently applied on themself.
223683853|NCT04683042|DEVICE|Transcutaneous Electrical Nerve Stimulation (TENS) with PT|Use of TENS units along with routine PT therapy
223683854|NCT04683042|OTHER|PT only|Routine PT therapy only
223683855|NCT04701164|DRUG|ANX005|Solution for intravenous infusion
223683856|NCT04701164|DRUG|Placebo|Solution for intravenous infusion
223683857|NCT06080737|OTHER|quality of life questionnaire|telephone interview to assess mortality and quality of life in the population included in a trial
223683858|NCT06571760|DEVICE|Vertex Pulmonary Embolectomy System|Use of Vertex Pulmonary Embolectomy System to treat pulmonary embolism.
223683859|NCT05016180|DRUG|Ropivacaine|Before the induction of anesthesia, ropivacaine is used for bilateral transversus abdominis plane block in a volume of 20 mL of each side
223683860|NCT00140465|DRUG|Clopidogrel|after PCI
223683861|NCT00140465|DRUG|Clopidogrel|after PCI
223683862|NCT02418156|DEVICE|CorMatrix ECM for Vascular Repair|Standard femoral arterial interventional procedure using CorMatrix ECM for vascular repair.
223683863|NCT03970746|BIOLOGICAL|PDC*lung01|PDC\*lung01 includes, in similar proportion, seven active agents, made of irradiated human plasmacytoid dendritic cells (PDC) loaded separately with a distinct synthetic peptide encoded by a lung tumor antigen, namely NY-ESO-1, MAGE-A3, MAGEA4, Multi-MAGE (an epitope common to several MAGE-A antigens), SURVIVN, MUC1 or a peptide derived from the Melan-A antigen.
223683864|NCT03970746|DRUG|Keytruda Injectable Product|The intention and decision to prescribe the anti-PD-1 monotherapy as SoC (TPS≥50%) must have been made by the investigator before and regardless of the patient's participation in the study.
223683865|NCT03970746|DRUG|Alimta Injectable Product|For patients with non-squamous NSCLC included in Cohorts A1 and A2, maintenance by pemetrexed (IV every 3 weeks) can be administered according to SoC.
223774934|NCT02129179|DRUG|Glucagon-Like Peptide 1|
223774935|NCT01923181|DRUG|semaglutide|Once-daily oral administration as tablets.
223774936|NCT01923181|DRUG|semaglutide|Once-weekly,injected s.c./subcutaneously (under the skin) using a pen
223774937|NCT01923181|DRUG|oral placebo|Once-daily oral administration as tablets.
223774938|NCT02393495|DEVICE|intrauterine device TCu 380A|
223774939|NCT05733988|PROCEDURE|Bailout edge to edge|Edge to edge repair is the suture of the mitral valve leaflets in the regurgitant spot. It can be used as a bailout procedure when the first attempt of mitral valve repair with other surgical techniques is not satisfactory at intraoperative echo control. In this case, a second run of cardiopulmonary bypass is carried out, the heart is reopened and an edge-to-edge is performed.
223774940|NCT02691455|DEVICE|Baerveldt Glaucoma Implant 350-mm2 / BG101-350|
223774941|NCT02691455|PROCEDURE|Transscleral Diode Laser Cyclophotocoagulation|Recommended setting are 2000 milliwatt (mW) for 2 seconds, 1850 mW for 3 seconds or 1750 mW for 4 second duration, titrating the energy up or down just below where a pop is heard.
223774942|NCT02691455|DEVICE|Ahmed Model FP7 Flexible Plate|
223774943|NCT02691455|DEVICE|Baerveldt Glaucoma Implant 250-mm2 / BG103-250|
223774944|NCT06309082|PROCEDURE|Amputation|Amputation was performed on diabetic foot ulcer
223774945|NCT06309082|PROCEDURE|Debridement|Debridement of diabetic foot ulcers was performed
223774946|NCT06205511|DIAGNOSTIC_TEST|Oral HPV Sample|The study participant will be asked to provide an oral swish and spit sample. This sample collection will follow the procedure published by (Herrero et al 2013). The specimen is collected by a 15-second rinse followed by a 15-second gargle using 15 ml of an alcohol-based mouth wash such as a commercially available product, Scope. The 15-ml samples will then be stored at -20 and then shipped on dry ice to Dr. Anna Giuliano's laboratory in Tampa Florida for HPV testing. At present Dr. Giuliano's laboratory is using the DDL SPF10 LiPA assay for sample analysis. An oral exam will be performed for each patient by the Vivent Dentist within 30 days of the collection of the HPV sample. If a referral is needed to an oral surgeon or Ears, Nose, and Throat specialist this will be done within 60 days of the dentist visit. The HPV results will not be shared with the participants as these are research study results and not part of standard of care.
223683866|NCT05985824|PROCEDURE|Pranayama breathing exercise|"Pranayama is an important step in yoga, way of life, and is translated as the science of breathing, breath control, willful breathing. This alternating breathing-out action also balances the sympathetic and parasympathetic nervous systems, giving the person a state of calm, providing relaxation and positively affecting fatigue. Application steps; Right hand Nasika mudra is performed. Nasika mudra is the mudra where the second and third fingers of the right hand are folded into the palm and the other fingers are exposed. Then the right nostril is closed with the first finger of the right hand. Start by breathing through the left nostril. Then the left nostril is closed with the fourth finger and the breath is held. While the left nostril is closed, the right nostril is opened and inhaled. Breathe again through"
223683867|NCT02405104|DRUG|chlorzoxazone|ATC-code: M03BB03
223683868|NCT02405104|DRUG|Placebo|Placebo
223683869|NCT02405104|PROCEDURE|THA|Surgical treatment of osteoarthrosis in the hip, by replacement.
223683870|NCT02405104|PROCEDURE|TKA|Surgical treatment of osteoarthrosis in the knee, by replacement.
223683871|NCT03818633|DEVICE|Elastic abdominal binder|Each woman in the intervention group is fitted with an elastic abdominal binder at the time of procedure completion just before leaving the operating room. The binder is placed snuggly tight (keeping in mind patient's comfort) on top of the hospital gown with the incision positioned at the middle part of the binder. The patients are encouraged to wear binders at all time. However, periods of break from wearing the binder are allowed at their convenience.
223683872|NCT01445626|DRUG|dexamethasone intravitreal implant 0.7 mg|Dexamethasone intravitreal implant 0.7 mg was dosed previously according to general clinical practice.
223683873|NCT03171428|PROCEDURE|Hepatectomy|Surgery for liver tumors is the removal of a part of the liver affected by a tumor.
223683874|NCT06984900|OTHER|Group Aerobic Exercise Session|"The Aerobic Exercise Program is designed to improve mood and reduce stress among university students through structured, moderate-intensity aerobic activities.~Session Structure: Participants engage in moderate-intensity aerobic exercises such as treadmill walking or running, tailored to individual fitness levels, ensuring accessibility and inclusivity. Each session consists of a 10-minute warm-up, 30 minutes of aerobic exercise, and a 5-minute cool-down.~This intervention incorporates a dual assessment approach using the Profile of Mood States (POMS) and the Perceived Stress Scale (PSS) to evaluate mood and stress levels both before and after exercise. Participants complete these assessments multiple times, allowing for a nuanced understanding of how aerobic exercise influences mood and stress over time."
223683875|NCT06986278|DEVICE|tDCS|Stimulation will be applied at an intensity of 2 mA for 20 minutes, with an average ramp-up and ramp-down rate of 0.1 mA/s, using rectangular electrodes of 35 cm² (resulting in a current density of 0.06 mA/cm²) covered with sponges moistened with 0.9% saline solution. A Sooma tDCS™ direct current stimulator (Sooma Oy Ltd, Helsinki, Finland), certified for clinical use, will be used. The anode will be placed over the Cz stimulation site, and the cathode will be placed on the right shoulder. The electrode will be secured to the participant's head using a neoprene cap (Neuroelectrics, Barcelona, Spain) and to the shoulder with a crepe bandage.
223683876|NCT06986278|DEVICE|shamtDCS|The sham tDCS group will use the same device and electrode placement as the active stimulation group. The protocol will consist of a 10-second ramp-up to 1 mA, followed by a 7-second ramp-down to 0.3 mA, which will be maintained for 19 minutes and 40 seconds, and a final 3-second ramp-down to 0 mA. This sham stimulation method is integrated into the Sooma stimulator.
223683877|NCT06389994|DEVICE|Esophageal String Test|The EnteroTracker® capsule is supplied in pouches, each pouch containing a single capsule. The device is comprised of an ingestible capsule that contains a weighted ball and a highly absorbent nylon string. The looped portion of the string is secured externally to the patient's cheek and the rest of the capsule is swallowed by the patient.
223683878|NCT06989567|DRUG|L-citrulline|This intervention uses intravenous L-citrulline as an acute treatment for vaso-occlusive crisis (VOC) in sickle cell disease, administered as a 50 mg/kg IV bolus followed by a 9 mg/kg/hr continuous infusion. Unlike other studies that evaluate oral citrulline or chronic VOC prevention, this study focuses on real-time symptom resolution in the emergency department setting by targeting impaired nitric oxide production and vasoconstriction. The selected dosing regimen was optimized in prior studies to achieve a therapeutic plasma concentration associated with improved pain scores and reduced opioid use, distinguishing it mechanistically and clinically from other interventions.
223683879|NCT06989567|OTHER|Placebo|Placebo intravenous (IV) treatment designed to match the appearance and administration schedule of L-citrulline
223683880|NCT06607874|OTHER|Non-Interventional Study|Non-Interventional study
223683881|NCT06598527|RADIATION|Stereotactic body radiotherapy (SBRT)|"Radiation source: 6MV photon linear gas pedal is used. Position immobilization: supine position, hands up, vacuum bag or styrofoam immobilization.~Radiotherapy plan design: 4DCT positioning, radiotherapy plan design at 20% respiratory time-phase CT, isocentric irradiation, IMRT or VMAT design.~Definition of target area:~Gross tumor volume (GTV) includes the primary tumor in the lung, excluding lymph nodes. Internal target volume (ITV); Internal target volume (ITV) is formed by the fusion of 10 respiratory phases of GTV; Planning target volume (PTV) is formed by expanding the ITV by 0.5 cm in all directions."
223683882|NCT06598527|DRUG|Tislelizumab|PD-L1 inhibitor
223683883|NCT06598527|DRUG|Chemotherapy|platinum-based double-agent chemotherapy
223683884|NCT06994169|DRUG|Glofitamab|Glofitamab received for DLBCL in Early Phase Access
223683885|NCT06995105|PROCEDURE|TACE|The first day of TACE treatment is the first day (D1). TACE is started on D1. Subsequent TACE is arranged by the investigator based on a comprehensive assessment of the patient's physical condition, disease progression, adverse reactions, etc. The total number of TACEs shall not exceed 4 times, with at least 4 weeks between each two times.
223683886|NCT06995105|DRUG|Sintilimab combined with Bevacizumab|Sintilimab (200 mg) combined with bevacizumab (Dayoutong injection, 15 mg/kg), intravenous infusion, once every 3 weeks, until the patient is intolerant or the tumor progresses
223774947|NCT04361357|OTHER|whey protein|whey protein powder was added on the basis of standardized enteral nutrition preparation.
223774948|NCT05689840|PROCEDURE|Receiving inpatient surgical intervention|Receiving inpatient surgical intervention in Peking Union Medical College Hospital
223683887|NCT06995105|BIOLOGICAL|individualized anti-tumor new antigen iNeo-Vac-R01 injection|The individualized anti-tumor new antigen iNeo-Vac-R01 injection was commissioned by Hangzhou Nuanjin Biotechnology Co., Ltd., and all patients were admitted into the therapeutic intervention group. According to the results of previous non-clinical studies, the individualized mRNA injection of 100 μ g was a tolerable dose.
223683888|NCT06994780|PROCEDURE|dynamic compliance guided PEEP titration|In order to find the individualized optimal PEEP value, PEEP will be increased at 2-minute intervals with a maximum peak pressure of 45 cmH2O and a driving pressure of 15 cmH2O. Recruitment will be performed. When the target is reached, the PEEP value will be adjusted to the value at which the highest dynamic compliance is achieved by decreasing it.
223683889|NCT04461509|DRUG|18F-PSMA|"Imaging (comparing standard and experimental high resolution diffusion-weighted imaging \[DWI\] MRI with 18F-PSMA)~Other Names:~18F-DCFPyL Injection prostate-cancer-specific radiotracer"
223683890|NCT06218264|DIETARY_SUPPLEMENT|Ingestion of an amino acid supplement|Oral intake of a supplement containing amino acids
223683891|NCT06842316|OTHER|1 blood sample, 40 mL (collection during a blood test, part of the standard of care for this disease)|Mononuclear and polynuclear peripheral blood cells from subjects suffering from IMID will be exposed in vitro to different inflammatory inducers with and without the concomitant addition of at least 4 different pCB extracts spectrum complete (full spectrum) including a dominant CBD extract and low in THC (\<0.2%), 1 dominant THC extract, 1 balanced THC/CBD extract and 1 dominant CBG extract. The same analyzes will be carried out in the presence of a recognized anti-inflammatory (for example hydrocortisone or dexamethasone) which will thus be used as a positive control.
223683892|NCT05941832|DEVICE|ANNE Chest Sensor|Wearing ANNE Chest Sensor for 6 weeks
223683893|NCT05829200|DEVICE|Transcranial Doppler (TCD)|All individuals who are consented for elective or urgent carotid endarterectomy would be eligible to participate. If patient gives consent, they would undergo an approximately 30-60 minute TCD study. We will collect the number of high intensity transient signals (HITS). The patient would undergo surgery regardless of the TCD result.
223683894|NCT00460369|DRUG|sulfadoxine-pyrimethamine|"tablets 1,25/25 mg~1 tablet per 20 kg of body weight Single drug intake"
223683895|NCT00460369|DRUG|artemether-lumefantrine|"tablets 20/120 mg~* 1 tablet twice daily for 3 days below 15 kg of bodyweight~* 2 tablets twice daily for 3 days below 24 kg of bodyweight~* 3 tablets twice daily for 3 days below 35 kg of bodyweight"
223683896|NCT00460369|DRUG|amodiaquine-artesunate coformulation|"one 25mg/67,5mg tablet, once daily for 3 days below 9 kg~one 50/135mg tablet, once daily for 3 days below 18 kg"
223683897|NCT04540939|BEHAVIORAL|Mindfulness-Based Cognitive Therapy|"There will be 8 sessions and these will be approximately 2 hours long. Over the 8-weeks participants will learn several mindfulness meditation techniques. Each session will involve group discussion and feedback. Participants will be asked to practice these techniques at home, and keep a log of mood, and stress ratings.~Audio files with exercises will be given to participants so that they can practice at home between sessions."
223683898|NCT04540939|BEHAVIORAL|Muscle Relaxation Therapy|Each MR session is approximately 2 hours. Over the 8-weeks you will learn how to relax your body using a step-by-step process in which you alternate between squeezing and relaxing your muscles. You will learn about your body's natural response to stress and how to use muscle relaxation during your everyday life. Each session will also involve group discussion and feedback. You will be asked to practice these techniques at home, and keep a log of your mood, and stress ratings. You will receive audio files with exercises so you can practice at home between sessions.
223683899|NCT02763761|DRUG|Infliximab + Prednisone|Prednisone dose will be decreased every 3 days for 18 days
223683900|NCT02763761|DRUG|Methylprednisolone + Prednisone|Prednisone dose will be decreased every 4 days for 40 days
223683901|NCT03905473|BEHAVIORAL|Accelerometer measurements|To validate the questionnaires about physical activity, some patients will be wearing an accelerometer for one week. An accelerometer is a little device worn in a belt around the hip, which can measure intensity of the patient's activity level. The accelerometer is worn 24 hours a day for one week and is only removed when bathing.
223683902|NCT01128751|PROCEDURE|Embol-X intra-aortic emboli filter|Patients in this arm receive intra-aortic filter designed to catch solid debris for neuroprotection during surgery.
223683903|NCT01128751|PROCEDURE|DBT dynamic bubble trap|Patients in this arm receive a dynamic bubble trap to reduce gaseous micro-emboli from cardiopulmonary bypass for neuroprotection during surgery
223683904|NCT01128751|PROCEDURE|Control group|In comparison to arm 1 and 2, patients in this arm do not receive an additional intervention during surgery
223683905|NCT01981759|DRUG|D-Cycloserine|Participants will receive 10 administrations of 50 mg of D-Cycloserine by mouth one hour before CBT sessions, weekly, in weeks 3-12.
223683906|NCT01981759|OTHER|Placebo|Participants will receive 12 weekly administrations of placebo by mouth 1 hour before CBT sessions, from weeks 1-12.
223774949|NCT01257204|DRUG|Placebo|Tablets, oral, 0 mg, once daily, for 24 weeks
223683907|NCT01981759|BEHAVIORAL|Cognitive Behavioral Therapy|Participants will engage in a Cognitive Behavioral Therapy treatment plan designed for psychotic delusions. The program will consist of 12 one hour sessions, once weekly from study week 1-week 12.
223683908|NCT03810144|GENETIC|Vectra MBDA Test|Vectra Guided versus Usual Care
223683909|NCT04138888|DRUG|Olmesartan Medoxomil/Hydrochlorothiazide 40 Mg/25 Mg film-coated tablets for oral use|Olmesartan Medoxomil/Hydrochlorothiazide is manufactured by Pharmtechnology LLC, Republic of Belarus. Each tablet contains 40 mg of olmesartan medoxomil and 25 mg of hydrochlorothiazide.
223683910|NCT04138888|DRUG|Olmetec® Plus 40 Mg/25 Mg film-coated tablets for oral use|Olmetec® Plus is manufactured by Daiichi Sankyo Europe GmbH, Germany. Each tablet contains 40 mg of olmesartan medoxomil and 25 mg of hydrochlorothiazide.
223683911|NCT01541202|DRUG|rhNRG-1|10 hours per day i.v drip for the first 10 days (0.6ug/kg/day), followed by weekly 10 minutes i.v bolus (0.8ug/kg/day), from the 3rd week for 23 weeks
223683912|NCT01541202|DRUG|Placebo|10 hours per day i.v drip for the first 10 days (0ug/kg/day), followed by weekly 10 minutes i.v bolus (0ug/kg/day), from the 3rd week for 23 weeks
223683913|NCT02642874|DRUG|Methocarbamol|Methocarbamol twice daily
223683914|NCT02642874|DRUG|Calcium Carbonate|Calcium carbonate twice daily
223683915|NCT05868018|BEHAVIORAL|Education|This was an observational study of changes in evidence based confidence and behavior across 4 physical therapy programs. Students received their typical physical therapy education and we measured changes in evidence based practice confidence and behaviors across programs throughout the curriculum.
223683916|NCT06145607|DRUG|ABBV-CLS-7262|ABBV-CLS-7262
223683917|NCT05625620|DEVICE|Active Transcranial Pulse Current Stimulation|Active tPCS will be delivered through a pair of saline-soaked (0.9% NaCl) surface sponge electrodes (7 × 5 cm2, for the anodal cerebellar electrode; 8 × 6 cm2 for the cathodal spinal electrode). Anodal stimulation will be applied on the scalp over the cerebellum area (2 cm under the inion) and the cathode will be placed over the spinal lumbar enlargement (2 cm under T11). During anodal stimulation, a constant current of 2 mA will be applied for 20 minutes.
223683918|NCT05625620|DEVICE|Sham Transcranial Pulse Current Stimulation|Sham tPCS will be delivered through a pair of saline-soaked (0.9% NaCl) surface sponge electrodes (7 × 5 cm2, for the anodal cerebellar electrode; 8 × 6 cm2 for the cathodal spinal electrode). Anodal stimulation will be applied on the scalp over the cerebellum area (2 cm under the inion) and the cathode will be placed over the spinal lumbar enlargement (2 cm under T11). During anodal stimulation, a constant current of 2 mA will be applied for 20 minutes. Electric Current will be ramped down 5 seconds after the beginning of the stimulation to make this condition indistinguishable from the experimental active stimulation.
223683919|NCT00344240|BEHAVIORAL|Functional circuit training with lifestyle behavior|
223683920|NCT03593434|DRUG|hyperpolarized Xenon gas|This present study will utilize existing study visits for the NHLBI study, with patients opting-in to have all of the procedures performed twice, with an intervening ACT, during one their study visits.
223683921|NCT06325904|PROCEDURE|Uniportal VATS|"* single port video-assisted thoracoscopic surgery in the 5th intercostal space~* performed under general anesthesia.~* pleural fluid/pus was drained~* pleural adhesions was removed"
223683922|NCT06325904|PROCEDURE|Tube thoracostomy|"* Chest tube is inserted in 5th mid-axillary line~* performed under local anaesthesia"
223683923|NCT01452009|DRUG|Travoprost Ophthalmic Solution, 0.004% (New Formulation)|Travoprost Ophthalmic Solution, 0.004% given one drop once daily
223683924|NCT01452009|DRUG|TRAVATAN®|TRAVATAN® administered one drop once daily
223774950|NCT01257204|DRUG|Daclatasvir|Tablets, oral, 60 mg, once daily, for 12, 16, or 24 weeks
223774951|NCT01257204|DRUG|Pegylated interferon alfa-2a|Solution for injection, subcutaneous injection, 180 µg/0.5 mL, once weekly, for 12, 16, or 24 weeks
223774952|NCT01257204|DRUG|Ribavirin|Tablets, oral, 800 mg, twice daily, for 12, 16, or 24 weeks
223683925|NCT03937700|DEVICE|CPWalker Robotic Exoskeleton|The CPWalker rehabilitation platform is a robotic device composed by an exoskeleton linked to a walker that provides support and balance to a child during overground training. The device is able to implement user's partial body weight support (PBWS) and allows the adaptation of exercises to the patient's capabilities by means of individual controllers for each joint, which increases the modularity of the system. Each joint of the CPWalker can operate in a range of modes with varied levels of robotic assistance or resistance
223683926|NCT01764035|BEHAVIORAL|Body Scan (BS) Meditation Intervention|This intervention consists of 4 individual 60-minute sessions (week 1, 2, 4, and 6) in which participants learn the body scan meditation exercise and practice it at home, daily, lying in bed at their usual bedtime after going to bed (and when waking up at night, unable to go back to sleep). The Body-Scan meditation consists of a 30-minute exercise during which participants are guided to focus their attention on certain parts of their body (e.g. toes, feet). The core skill involves gradually adopting an observant, non-judgmental, and accepting stance towards bodily sensations, including feelings and thoughts.
223683927|NCT01764035|BEHAVIORAL|Brief Supportive Psychotherapy (SP)|SP is a common form of non-specific psychotherapy available to patients with bipolar disorder in the community. It focuses on addressing a patient's current concerns, supporting a patient's adaptive coping skills, improving self-esteem, and expressing feelings and the therapeutic alliance. Using a conversational style, SP involves conveying empathy, validation, comforting and supporting patients in coping with distress about current life issues as well as providing encouragement and praise, clarification and opportunity to vent. SP will match BS in length, number of sessions and delivery schedule (four, 60-minute sessions, week 1, 2, 4, 6).
223683928|NCT04620395|DIAGNOSTIC_TEST|Punch biopsy|A standardized biopsy kit is used for a synovial fluid tap and subsequent acquisition of up to 7 Punch biopsies through an introducer (part of the kit)
223683929|NCT05277961|RADIATION|Ultraviolet radiation|UV6 tubes
223683930|NCT04357366|DRUG|Anakinra|Treatment with 100mg Anakinra subcutaneously (sc) once daily for ten days
223683931|NCT00403403|DRUG|Bevacizumab|Bevacizumab 15 mg/kg by intravenous (IV) infusion on Day 1 of each of the first four 21-day cycles during chemotherapy, followed by single agent administration until disease progression, unacceptable toxicity, discontinuation from study, or death.
223683932|NCT00403403|DRUG|Chemotherapy|Chemotherapy = cisplatin (or carboplatin) + etoposide. Cisplatin 75 mg/m² IV on Day 1 of each of the first four 21-day cycles OR carboplatin (area under the curve \[AUC\]=5 mg/mL/min, per Calvert formula) IV on Day 1 of each of the first four 21-day cycles; etoposide 100 mg/m² on Days 1-3 of each of the first four 21-day cycles.
223683933|NCT00403403|DRUG|Placebo|Placebo 15 mg/kg by intravenous (IV) infusion on Day 1 of each of the first four 21-day cycles during chemotherapy, followed by single agent administration until disease progression, unacceptable toxicity, discontinuation from study, or death.
223683934|NCT01889940|BEHAVIORAL|Training for professionals (Spinal Cord Injury Unit staff).|"Prior to the training, separate focus groups for professionals, patients \& families are conducted to determine each party's needs and worries.~Tailored training for professionals (customized according to focus groups contents) consists of 12 hours distributed in 2 days (1 day per week). It includes theoretical and practical exercises on early detection of PD, communication skills, management of psycho-emotional reactions, family interventions and teamwork alternatives. Standard motivational interviewing techniques for improving empathy skills and communication styles are employed.~Additionally, optional on-demand small group or individual coaching sessions (after training) will be offered (50-60 minutes per session) during a 6-months period."
223683935|NCT04078178|DIETARY_SUPPLEMENT|Niagen|Nicotinamide Riboside
223683936|NCT04078178|DIETARY_SUPPLEMENT|Placebo Comparator|Placebo
223683937|NCT04006119|BIOLOGICAL|Ad-RTS-hIL-12|"* intratumoral injection of Ad-RTS-hIL-12~* 2.0 x 10\^11 viral particles (vp) per injection"
223683938|NCT04006119|DRUG|Veledimex|20mg/day 15 oral daily doses of veledimex
223683939|NCT04006119|DRUG|Cemiplimab-Rwlc|Infusion every 3 weeks (350mg)
223683940|NCT02718001|DEVICE|Edwards EVOQUE Eos Mitral Valve Replacement System|Replacement of the mitral valve through a transcatheter approach
223683941|NCT05957055|BEHAVIORAL|parental training in behavior management|Parental training in behavior management - online group sessions (4-6 families within group) with trained specialist, 10 once-weekly sessions. To continue to pharmacotherapy, the parents/legal guardians are required to participate in at least 8 out of 10 sessions.
223683942|NCT05957055|DRUG|Lisdexamfetamine|Once-daily pharmacotherapy with lisdexamfetamine (608137-32-2, SUB32146), administered orally, for a duration of 6 months with initial dose of 30mg and dose optimization for 5-7 weeks (visits after 1st, 3rd and 5th week of therapy to adjust dose, in 20mg steps).
223774953|NCT00856024|BIOLOGICAL|Peginterferon alfa-2b|PegIntron 80 μg, PegIntron 100 μg, or PegIntron 120 μg. The duration of the complete treatment and the doses of pegylated interferon alfa 2b should have been prescribed according to local guidelines, and according to the investigating physician's orientation.
223774954|NCT00856024|DRUG|Ribavirin|Ribavirin 250 mg. The duration of the complete treatment and the doses of ribavirin should have been prescribed according to local guidelines, and according to the investigating physician's orientation.
223774955|NCT06467266|DIAGNOSTIC_TEST|Acute Haemodynamic Study|Multisite temporary pacing
223774956|NCT04162951|PROCEDURE|Ordinary approach paravertebral block|Ultrasound guided thoracic paravertebral block. At the appropriate dermatome, the needle (22-gauge, 8-10-cm, short bevelled spinal needle, or a Touhy needle if a catheter is to be placed) is inserted 2.5-3 cm lateral to the spinous process and advanced perpendicular to the skin in all planes to contact the transverse process at a variable depth (2-4 cm) depending on the build of the individual. The needle is then walked above the transverse process and gradually advanced until a loss of resistance to air or saline, or a subtle 'click' is felt as the superior costotransverse ligament is penetrated, usually within 1-1.5 cm from the superior edge of the transverse process.
223683943|NCT05957055|DRUG|Methylphenidate|Once-daily pharmacotherapy with methylphenidate (prolonged-release tablet, 298-59-9, SUB03254MIG), administered orally, for a duration of 6 months with initial of 18mg dose optimization for 5-7 weeks (visits after 1st, 3rd and 5th week of therapy to adjust dose, in 18mg steps).
223683944|NCT06590324|DRUG|Apabetalone|100-mg capsule, twice daily oral administration with meals
223683945|NCT06055985|OTHER|Placebo|Study participants will receive placebo orally administered as tablet at pre-specified time points during the study.
223683946|NCT06055985|DRUG|UCB0022|Study participants will receive UCB0022 dose A or B orally administered as tablet at pre-specified time points during the Treatment Period.
223683947|NCT06210282|DIAGNOSTIC_TEST|Focused lung ultrasound (FLUS)|We will use a 14-zone scanning approach. Each hemithorax is divided into anterior, lateral, and posterior surfaces. The anterior and lateral surfaces on each hemithorax are divided into an upper and lower quadrant. The posterior surfaces on each hemithorax are divided into an upper, middle, and lower quadrant. Each quadrant represents a scanning zone. Each scanning zone should be assessed using FLUS. The participating general practitioners use point-of-care ultrasound on a weekly basis before trial commencement and will use the ultrasonography device already available to them.
223683948|NCT06210282|OTHER|Usual Care|Participants assigned to the control group will receive the GP's usual care of adults (≥ 18 years) presenting with symptoms of an acute LRTI where the GP suspects CAP. Usual care will be used as a pragmatic comparator to reflect the current standard examinations and care of these patients in general practices in Denmark. Usual care is recommended to follow applicable guidelines from the Danish Society of General Practitioners (DSAM) and Lægehåndbogen \[The Doctor's Handbook\].
223683949|NCT05300152|PROCEDURE|pulpotomy procedure and Histological evaluation|Sixty primary teeth in thirty children aged 7-9 years selected from Outpatient dental clinic Pedodontic and Endodontic Departments, Suez Canal University. divided into group I includes 30 teeth treated with ACTIVA BioACTIVE Base/Liner and group II includes 30 teeth treated by MTA with standard pulpotomy procedure Patients will be recalled after 15 and 30-days . 15 teeth from group I and 15 teeth from group II will be extracted after 15 days then subjected to decalcification then15 teeth from group I and 15 teeth from group II will be extracted after 30 days \& subjected to decalcification procedure in 20% EDTA at 4 °C for approximately 5 weeks then embedded in paraffin. Serial sections will be cut at 5 µm thickness. Deparaffinize the sections by 2 changes of xylene for 10 minutes each. Stain in Harris hematoxylin solution for 8 minutes. mount with xylene based mounting medium for conventional histological assessment using light microscope
223683950|NCT05300152|DIAGNOSTIC_TEST|Immunohistochemistry Protocol for Fibronectin Antibody|"1. Deparaffinization/Rehydration~   * Slides heated in an oven at 65C for 1 hour.~  * De-paraffinization~2. Antigen Retrieval~   * Immersion of slides into staining dish containing Antigen Retrieval Solution.~  * Placing the staining dish into rice cooker.~  * When turned to warm, unplug cooker~  * Allow to cool down for 20 min~3. Staining~   * Wash slides with TBST for 5 min on a shaker.~  * Inactivate endogenous peroxidase by 3% hydrogen peroxide for 10 min.~  * Block slides with blocking solution for 1 hour.~  * Dilute primary antibody in blocking buffer~  * Apply primary antibody to each section and incubate overnight in humidified chamber~  * Wash slides three times with TBST"
223683951|NCT05300152|DIAGNOSTIC_TEST|Immunohistochemistry Protocol for Osteopontin Antibody|will be carried out via avidin-biotin-peroxidase complex method using a VECTASTAIN ABC Kit . Sections will be deparaffinized by xylene and graded ethanol then treated with 20 µg/ml Proteinase K for 10 min. to prevent endogenous peroxidase activity, sections is incubated for 30 min in 0.3% H2O2/methanol then treated with 0.1% blocking serum albumin and incubated with primary antibody for 30 min. Rabbit polyclonal anti-osteopontin and goat polyclonal anti-RANKL will be used. dilution of primary antibodies used will be osteopontin (1 : 6000-8000). After being washed with phosphate-buffered saline several times, sections will be incubated with biotinylated IgG for 30 min and subsequently with streptavidin-horseradish peroxidase for 30 min. Following several washes with phosphate-buffered saline, 3,3'-diaminobenzidine substrate will be applied. As a negative control, non-immune serum will be used instead of primary antibody.
223774957|NCT04162951|PROCEDURE|Retrolaminar paravertebral block|In the retrolaminar approach to TPVB or retrolaminar block (RB), local anesthetic (LA) is injected into the retrolaminar plane to achieve a truncal sensory block like that of traditional TPVB. It has been postulated that during RB, LA spreads from the injection plane to the thoracic paravertebral space (TPVS) through the superior costotransverse ligament (SCTL). Retrolaminar block will be performed under ultrasound guidance, as a single injection.
223774958|NCT00215774|DRUG|Flecainide|Flecainide 2 - 3 x 100 mg/d The main difference between the two active therapy groups is the duration of treatment.
223774959|NCT04569045|DEVICE|HA+Lidocaine|20 mg
223774960|NCT04569045|DEVICE|HA|20 mg
223774961|NCT02375412|PROCEDURE|Pre-operative measurement of heart rate variability|Pre-operative measurement of heart rate variability in patients undergoing elective major abdominal surgery
223774962|NCT01160107|DRUG|RP followed by MPR|Induction (4 cycles):Lenalidomide 25 mg/die for 21 days followed by a 7 days rest period and Prednisone at 50 mg three times a week continuously . Consolidation (6 cycles): Melphalan 2 mg three times a week, Prednisone 50 mg three times a week, and Lenalidomide 15 mg/die for 21 days followed by a 7 days rest period. According to the results of the first stage the decisions are as follows: 1. Starting a second stage, at the same dose of lenalidomide for MPR cycles, if grade 3-4 adverse events are 25-50% and PR \> 50%; 2. The study stop (if PR \<40% and grade 3-4 adverse events \>25-30%) 3. A new first stage may be started: - Lenalidomide 20 mg/die if grade 3-4 adverse events are \< 25-30%, independently from efficacy; - Lenalidomide 10 mg/die if grade 3-4 adverse events are \> 50% and PR rate \> 50%. Maintenance: Lenalidomide 10 mg/day from day 1 to 21, followed by a 7-day rest period and Prednisone 25 mg three times a week.Each cycle will be repeated every 28 days, until PD.
223774963|NCT00004357|DRUG|Methylprednisolone|IV
223774964|NCT00004357|DRUG|Prednisolone|Oral
223774965|NCT04140994|DEVICE|rTMS device|Participants will participate in 1 session of neuronavigated (TMS Navigator, Localite, Schloss Birlinghoven, D-53757, Sankt Augustin, Germany ) iTBS (patterned form of TMS) coupled with motor learning.
223774966|NCT02698501|DRUG|MEDI9929|MEDI9929 700mg (3 doses in total, 4-week intervals), administered intravenously
223774967|NCT02698501|DRUG|Placebo|Placebo (3 doses in total, 4-week intervals), administered intravenously
223774968|NCT06168175|DRUG|Sodium lactate|2 mmol/kg, intravenous, daily for 5 consecutive days
223774969|NCT06168175|DRUG|Placebo|intravenous, daily for 5 consecutive days
223774970|NCT00507052|DRUG|N-acetylcysteine|
223774971|NCT02501330|DRUG|Bosutinib|The recommended adult dose of bosutinib is 500 mg orally once daily with food. For newly-diagnosed chronic phase CML, the recommended dose is 400 mg. The dose may be adjusted appropriately according to the patient's condition; however, the maximum dose is 600 mg once daily.
223774972|NCT01329497|OTHER|systemic dietary instruction|systemic dietary instruction based on continuous quality improvement (CQI) team-oriented approach
223774973|NCT05904600|DEVICE|Respiratory muscle training|The training of the intervention group will have an initial workload of 30% of maximal inspiratory and expiratory pressures, which will be increased weekly by 10% according to tolerance, if not tolerated by 5%. In addition, patients will be instructed to maintain a normal respiratory rate (12-16 breaths per minute). Moreover, they will continue their usual treatment.
223774974|NCT05904600|DEVICE|Control group|In the control group, the respiratory muscle training will be simulated by using the device without load throughout the study period using an opaque adhesive tape surrounding the device to mask the valve position.
223774975|NCT03891082|PROCEDURE|B-Lynch|A 70 mm round bodied hand needle on which a No. 2 absorbable suture is mounted is used to puncture the uterus 3 cm from the right lower edge of the uterine incision and 3 cm from the right lateral border. The mounted No. 2 absorbable suture is threaded through the uterine cavity to emerge at the upper incision margin 3 cm above and approximately 4 cm from the lateral border
223774976|NCT03891082|PROCEDURE|BALLOON INSERTION|Insert the balloon portion of the catheter in the uterus; making certain that the entire balloon is inserted past the cervical canal and internal ostium. NOTE: Avoid excessive force when inserting the balloon into the uterus. Place a Foley catheter in patient bladder to collect and monitor urine output. To ensure maintenance of correct placement and maximize tamponade effect, the vaginal canal may be packed with iodine or antibiotic soaked vaginal gauze at this time.
223774977|NCT01863446|DEVICE|Lighting1|Ocular light exposure to a red wavelength light
223774978|NCT01863446|DEVICE|Lighting2|Ocular light exposure to a blue/green wavelength light
223774979|NCT00722644|BEHAVIORAL|Cognitive Behavioral Stress Management|
223774980|NCT01459406|DIETARY_SUPPLEMENT|Glucose|500 ml water drink containing 40g glucose
223774981|NCT01459406|DIETARY_SUPPLEMENT|Fructose|500 ml water drink containing 40g fructose
223774982|NCT01459406|DIETARY_SUPPLEMENT|Fructan|500 ml water drink containing 40g fructan
223774983|NCT01459406|DIETARY_SUPPLEMENT|Fructose and glucose|500 ml water drink containing 40g fructose and 40g glucose
223683952|NCT04617795|DEVICE|Omnipod 5 Automated Insulin Delivery System|"The Omnipod 5 is a single hormone insulin delivery system intended for the management of diabetes in persons requiring insulin. Continuous subcutaneous insulin infusion may be delivered by user-defined settings (manual mode) or automatically adjusted in response to feedback from a continuous glucose monitor (CGM).~The Omnipod 5 can automatically increase insulin delivery based on sensor glucose values from the continuous glucose monitor (CGM) and can decrease or suspend delivery of insulin when the glucose value falls below or is predicted to fall below predefined threshold values.~The Omnipod 5 is designed to assist patients with diabetes in achieving glycemic targets set by their health care providers."
223683953|NCT00472459|PROCEDURE|Photodynamic therapy with Metvix 160 mg/g cream|
223683954|NCT03442764|DRUG|mavacamten|MYK-461
223683955|NCT03442764|DRUG|Placebo|Placebo
223683956|NCT02746367|OTHER|Diagnostic test (LDT)|Proteomic assay
223683957|NCT04850313|DEVICE|ProProKera Plus®|ProKera® is a sutureless form of CryoTek amniotic membrane that is clipped into a dual polycarbonate ring system with the epithelial side up when in contact with the ocular surface.
223683958|NCT03271229|BIOLOGICAL|Concentrated Bone Marrow Aspirate (BMAC)|Participants will have a knee injected with BMAC stem cells harvested from the iliac crest
223683959|NCT03271229|BIOLOGICAL|Platelet-Rich Plasma (PRP)|Participants will have a knee injected with Platelet-Rich Plasma (PRP) obtained from a venous whole blood draw from the antecubital vein.
223683960|NCT04916002|DRUG|vidutolimod|Participants will receive vidutolimod for up to 2 years as follows: 10 mg IT weekly for 7 doses after which vidutolimod will be administered every 3 weeks (Q3W). The first dose of vidutolimod may be administered subcutaneously (SC) or IT at the discretion of Investigator. All subsequent doses will be IT. The initial 7 doses of vidutolimod, delivered on a weekly dosing schedule, must be completed before starting the Q3W vidutolimod dosing schedule.
223683961|NCT04916002|DRUG|cemiplimab|Participants will receive cemiplimab for up to 2 years as follows: 350 mg IV infusion over 30 minutes at week 1 dose 1 (W1D1) and Q3W thereafter.
223683962|NCT06324708|DIAGNOSTIC_TEST|DXA|Patients will undergo a femoral and lumbar DXA
223683963|NCT02395016|DRUG|nimotuzumab|nimotuzumab,400mg/w，Intravenous infusion over 60 minutes,Until disease progression or intolerable toxicity or subjects ask to leave the test.
223683964|NCT02395016|DRUG|Gemcitabine|Gemcitabine，1000mg/m2，Intravenous infusion over 30 minutes,Once every three weeks, rest one week (d1,8,15; q28d), Every 4 weeks for a period,Until disease progression or intolerable toxicity or subjects ask to leave the test.
223683965|NCT02395016|OTHER|Placebo|Placebo，400mg/w，Intravenous infusion over 60 minutes,Until disease progression or intolerable toxicity or subjects ask to leave the test.
223683966|NCT04094051|DRUG|Ibrutinib|In the retrospective period, clinical information of approximate 500 patients with CLL/SLL prior to the study initiation will be collected retrospectively through chart review. There will be one time follow-up to collect data on disease progression, survival status and patient-reported outcomes.
223835308|NCT01782326|DRUG|Long acting B2 agonist (LABA) and inhaled corticosteroid (ICS)|Salmeterol/fluticasone dry inhalation powder delivered via the Accuhaler device.
223835309|NCT05040490|DRUG|sugammadex as reversal drugs|use sugammadex to reverse neuromuscular blockade
223835310|NCT00114842|PROCEDURE|MR colonography|
223683967|NCT06168695|DEVICE|removable anterior expansion screw|"For the upper and lower arches, precise and profound alginate impressions were obtained and plaster study models were created. The removable appliance was constructed using acrylic resin with bilateral occlusal coverage for posterior teeth. The removable appliance was inserted in the patient's mouth and the patient was recalled after 24 hours to check the appliance fit.~Patient was recalled every four weeks until the dental cross-bite was corrected."
223683968|NCT06168695|DIAGNOSTIC_TEST|Speech and language evaluation|"speech evaluation was done by a Phoniatrician and all children were subjected to the Protocol of speech evaluation before expansion screw appliance insertion and after complete correction of anterior crossbite using an articulation test, intelligibility test, and spectrographic analysis.~* Articulation test: Five speech sounds were chosen to be studied /s/, /s /, /z/, /z/, /∫ /. The consonants were tested in the initial, medial, and final word positions.~* Speech intelligibility test : The general intelligibility score was calculated using Speech intelligibility in context: 5 -point scale:~* Spectrographic analysis: Using the computerized speech lab, the child was seated in an upright position \& allowed to talk freely \& repeated syllables were said to him/her."
223683969|NCT06168695|OTHER|Oral Health Related Quality of Life (OHRQoL) Assessment|The Child Perceptions Questionnaire (CPQ 8-10) in Brazilian version was used to gauge how the anterior cross bite affected the children's OHRQoL. It has twenty-five items total, broken down into four health domains (subscales): five questions each about oral symptoms (OS), five questions about functional limitations (FL), five questions about emotional wellbeing (EW), and ten questions about social well-being (SW). The responses never (0), once/twice (1), occasionally (2), often (3), and every day/almost every day (4) are provided for each question on an ordinal scale. The sum of the scores for all questions is used to calculate the scores for each subscale. The CPQ 8-10 was used to assess the OHRQoL before appliance insertion and after complete correction of anterior crossbite.
223683970|NCT02024282|DEVICE|Use of C-reactive protein (CRP) point of care test|
223683971|NCT02024282|OTHER|Brief intervention and parent leaflet|"Brief interventions are commonly used to give opportunistic advice, discussion, negotiation or encouragement. Mostly they take between 5 to 10 minutes. We developed a brief intervention: we'll ask the clinicians to ask 3 specific questions, namely Are you concerned?, What exactly concerns you? and Why does this concern you?. This intervention is easy to implement in daily practice and no additional training is required.~We developed a parent information leaflet that gives information about what they can do when their child is ill, which signs are important to follow up and when they really should get advice from a clinician. This could make it easier for them to cope with an ill child. The clinician could use this leaflet to give advice and make clear when they have to re-consult their physician to re-evaluate the child. Our hypothesis is that through creating this safety net, the improper demand for antibiotics could be reduced."
223683972|NCT02024282|DEVICE|Finger Pulse Oximeter|All physicians will be asked to perform a measurement of the oxygen saturation on all children and enter the results on the case report form. The selected device is a clip-on system suitable for use in children, which measures oxygen saturation in the capillary blood as well as the pulse rate.
223683973|NCT03306706|DIETARY_SUPPLEMENT|Whole pea muffins|2 muffins containing whole peas
223683974|NCT03306706|DIETARY_SUPPLEMENT|Split pea muffins|2 muffins containing split peas
223683975|NCT03306706|DIETARY_SUPPLEMENT|Wheat muffins|2 muffins containing wheat
223683976|NCT03203278|BEHAVIORAL|Web-based exercise programme|Aerobic, resistance and balance exercises
223683977|NCT04551729|BEHAVIORAL|Lifestyle advice for liberal fluid intake|Lifestyle advice for liberal fluid intake for 3 months
223683978|NCT01547780|DRUG|[11C]PBR28 and Positron Emission Tomography (PET)|Brain PET with \[11C\]PBR28. 11C\]PBR28 is a new PET ligand that images TSPO with high levels of specific binding.
223683979|NCT03038685|BEHAVIORAL|Strokecoach.be - digital coaching program for stroke patients|The stroke coach gives patients two education sessions during hospitalization (risk factor management, review of medications and clinical evolution). During these sessions, study participation will be proposed. Eligibility will partially depend on their historical use of the internet and e-mail. The aim is to have the digital platform personalized for his/her individual needs, risk factors and remaining neurologic signs/symptoms. Tips and tricks to deal with lifestyle modification will be delivered on regular basis. Meanwhile, patients will be asked to complete on a pre-specified frequency their data regarding their cardiovascular risk profile. Additionally, participants will be contacted at 0.5-1-2 and 6 months by phone calls or videoconsultancy. To standardize, an adapted, digital version of the standardized WSO Post-Stroke Checklist shall be used as a decision-support flowchart. A report of the consultation will be derived after the videoconsultancy.
223835311|NCT05517720|OTHER|Aria Trio complete Facial System|Renew Serum, Brighten Serum, and Refine Serum.
223835312|NCT02166086|PROCEDURE|Endoscopy|Endoscopy involving advanced imaging techniques
223835313|NCT01767129|DRUG|AVP-923-45|One capsule twice daily for 14 days
223835314|NCT01767129|DRUG|Placebo|One capsule twice daily for 14 days
223835315|NCT02445885|PROCEDURE|PCI|Guideline directed Percutaneous Coronary Intervention
223835316|NCT00399178|DRUG|Transdermal delivery system|
223835317|NCT04437771|OTHER|Safety and efficacy assessments|Long term disease and gene therapy specific safety evaluations and efficacy assessments
223683980|NCT02195414|DEVICE|NeoVas BCS|The NeoVas First-in-Man study is a prospective, two centers, single arm trial, which will enroll a total of 30 patients. The hypothesis of this study is to evaluate clinical feasibility, safety, and efficacy of NeoVas sirolimus-eluting bioresorbable coronary scaffold in the treatment of patients with de novo coronary lesion. The primary endpoint is a composite endpoint of cardiac death, target vessel related myocardial infarction, and ischemia driven target lesion revascularization (TLF) at 1 month follow up. At 6 months, 1, 2, 3, 4 and 5 years follow-up, clinical endpoints include TLF (its individual components), Patient-oriented cardiac event (all cause death, all MI, and all revascularization) target vessel revascularization, scaffold thrombosis.
223683981|NCT00738192|DRUG|Fentanyl citrate|Fentanyl 0.5 μg/kg delivered intravenously immediate at the end of remifentanil pump finished
223683982|NCT00738192|DRUG|Sufentanil citrate|Sufentanil 0.05 μg/kg delivered intravenously immediate at the end of remifentanil pump finished
223683983|NCT00738192|DRUG|Butorphanol tartrate|Butorphanol 0.01 mg/kg delivered intravenously immediate at the end of remifentanil pump finished
223683984|NCT05589090|BEHAVIORAL|Super Skills for Life program|Children in the experimental group received eight sessions of the Super Skills for Life protocol. The intervention was implemented using a structured manual for the therapist and a workbook for the children \[Orgilés, M., Espada, J.P., Ollendick, T.H. \& Essau, C. (2022). Programa Super Skills. Manual del aplicador. Elche, ES: Universidad Miguel Hernández\]. The intervention was administered via an online virtual platform for eight weeks, with each session lasting approximately one hour.
223683985|NCT01418560|PROCEDURE|renal sympathetic modification|Device: THERMOCOOL® Catheter Renal sympathetic modification with a catheter-based procedure
223683986|NCT04386915|DRUG|GST-HG141 tablets|This trial includes single-dose studies and multiple-dose studies, The single-dose study included six dose groups of 50 mg, 100 mg, 200 mg, 300 mg, 400 mg, and 500 mg. Based on the results of a single dose, select 1 to 3 doses from 100mg, 200mg, 300mg, and 400mg to conduct multiple dose studies.
223683987|NCT04386915|DRUG|Placebo|This trial includes single-dose studies and multiple-dose studies, The single-dose study included six dose groups of 50 mg, 100 mg, 200 mg, 300 mg, 400 mg, and 500 mg. Based on the results of a single dose, select 1 to 3 doses from 100mg, 200mg, 300mg, and 400mg to conduct multiple dose studies.
223683988|NCT00814879|DRUG|Raltegravir|400 mg BID
223683989|NCT00814879|DRUG|Atazanavir|300 mg BID
223683990|NCT00814879|OTHER|Standard treatment regimen|N(t)RTI(s) based backbone plus ritonavir boosted PI
223683991|NCT02140476|DEVICE|Bipolar vessel sealing and cutting device|This device will be used in half of the patients with thyroid goiter and half of the patients with papillary thyroid cancer.
223683992|NCT02140476|PROCEDURE|Conventional thyroidectomy|Tie and suture technique. This device will be used in half of the patients with thyroid goiter and half of the patients with papillary thyroid cancer.
223683993|NCT00174239|DRUG|cabergoline|
223683994|NCT00174239|DRUG|controlled-release levodopa / carbidopa|
223683995|NCT00463073|DRUG|Cetuximab|
223683996|NCT00463073|DRUG|Bevacizumab|
223683997|NCT00463073|DRUG|Irinotecan|
223683998|NCT05930587|OTHER|Cold water immersion|Cold water immersion (15 degree celsius, 20 minutes)
223683999|NCT03988959|PROCEDURE|resection of mucoeidermoid carcinoma|Surgical resection parotid with preservation of facial nerve
223684000|NCT01382511|DRUG|Simvastatine|80 mg
223684001|NCT04541251|DRUG|Camrelizumab + Nab-paclitaxel + Carboplatin|The patients will receive three cycles (one cycle is defined as every 21 days +/- 3 days) of neoadjuvant therapy with camrelizumab 200 mg, nab-paclitaxel 260 mg/m2, and carboplatin AUC 5. This will then be followed by surgery.
223684002|NCT04174014|PROCEDURE|Recruitment manoeuvre|PEEP increment and decrement
223684003|NCT00647218|DRUG|Post-operative adjuvant therapy|Adriamycin 60 mg/m2 IV over 20 minutes and Cytoxan 600 mg/m2 IV over 1 hour will be given every three weeks for 4 cycles.
223684004|NCT00647218|DRUG|neoadjuvant therapy|Paclitaxel 175 mg/m2 IV every 3 weeks x 3 cycles
223684005|NCT00647218|PROCEDURE|therapeutic surgical procedure|Modified radical mastectomy or segmental mastectomy plus axillary dissection 6-8 weeks following completion of chemotherapy/Radiotherapy.
223684006|NCT00647218|RADIATION|Radiation therapy with concurrent Paclitaxel|Radiation to breast 4680 cGy/26 fractions with concurrent Paclitaxel 30 mg/m2, twice per week
223684007|NCT00647218|DRUG|Hormonal Therapy|After completion of postoperative adjuvant Adriamycin and Cytoxan, hormonal therapy should be given at the discretion of the treating physician for all post-menopausal ER and/or PR positive patients. It is also recommended for pre-menopausal patients who are ER and/or PR positive.
223684008|NCT05340647|PROCEDURE|Preserflo microshunt|Implantation of Preserflo microshunt (Santen) to lower intraocular pressure
223684009|NCT05340647|PROCEDURE|Trabeculectomy|Trabeculectomy surgery to lower intraocular pressure
223684010|NCT05340647|PROCEDURE|Other MIGS|Other MIGS than Preserflo microshunt (e.g., XEN gel stent, iStent inject) to lower intraocular pressure
223684011|NCT01277042|BIOLOGICAL|GSK580299 (CervarixTM)|3-dose schedule intramuscularly vaccination (Months 0, 1 and 6)
223684012|NCT01277042|BIOLOGICAL|Engerix-BTM|3-dose schedule intramuscularly vaccination (Months 0, 1 and 6)
223684013|NCT06142526|DEVICE|DividPro film|DividPro Film is a sterile biodegradable translucent film that served as a physical barrier for preventing the adhesion between two adjacent layers of tissue in wound healing process.
223684014|NCT04856670|PROCEDURE|Cataract surgery|Cataract surgery- Manual or femtosecond laser assisted
223684015|NCT00588952|DRUG|Ketamine and Placebo|Two test days will involve administration of placebo and Ketamine (0.23 mg/kg, loading dose and infusion rate 0.58 mg/kg/minute) intravenously for 60 minutes
223684016|NCT00360152|PROCEDURE|Fine needle aspiration biopsy (FNAB)|
223684017|NCT00360152|PROCEDURE|Sentinel Lymph Node Biopsy|
223684018|NCT06138054|BEHAVIORAL|MI-CBTech|"Three in-person MI sessions focused on identifying goals for community integration (in the areas of vocational, recreational, social, or independent living activities) and unhelpful thinking that tends to get in the way of those goals, building motivation for goals, introducing participants to the CBT model and its potential benefits, and downloading and orienting them to the mobile phone application.~Six weeks of mobile phone application use to guide participants through CBT. Weekly content will be provided to learn and practice CBT skills to address unhelpful thinking and problem solving to address obstacles to goal attainment. There will be brief content pages worksheets to guide participants through practice. The worksheets will be tailored to each participant, framing the skills around their pre-identified goals and unhelpful thinking patterns. The application will also include access to crisis resources."
223684019|NCT06138054|BEHAVIORAL|Mindfulness control|"Three in-person supportive therapy sessions focused on empathic listening during client-led discussions of presenting concerns, introducing participants to mindfulness (defined as noticing and paying attention to the present moment without judgment), and downloading and orienting them to the mobile phone application. Participants will be informed of potential benefits of mindfulness, including stress reduction and increased self-awareness.~Six weeks of mindfulness training mobile application use to help participants learn to practice mindfulness through a gradual, self-guided training program. The application offers a library of information about mindfulness, 12 different audio-guided mindfulness exercises, goal-setting and tracking, customizable reminders, and access to crisis resources."
223684020|NCT01461057|DRUG|Capecitabine|1000 mg/m2 twice daily, from the evening of Day 1 to the morning of Day 15 of each cycle
223684021|NCT01461057|DRUG|Cisplatin|80 mg/m2 on Day 1 of each cycle
223684022|NCT01461057|DRUG|Pertuzumab|loading dose of 840 mg, then 420 mg once every three weeks
223684023|NCT01461057|DRUG|Pertuzumab|840 mg once every three weeks
223684024|NCT01461057|DRUG|Trastuzumab|loading dose of 8 mg/kg for Cycle 1 and a dose of 6 mg/kg for subsequent cycles
223684025|NCT03072771|DRUG|Blinatumomab|-Blinatumomab is a bispecific T cell engaging antibody
223684026|NCT03072771|PROCEDURE|Autologous stem cell transplant|-Standard of care
223835318|NCT01843452|RADIATION|RADIOTHERAPY|"External beam radiotherapy (daily fraction dose 1.8Gy) on Monday through Friday starting on study day 1.~* Days 1-28, dose of 36 Gy in 1.8 Gy/fraction (20 fractions) to the clinical target volume 1 (CTV1) including the primary tumor and involved lymph nodes and areas at risk for metastatic spread (which includes gross tumour volumes (GTV) and a 1-cm expansion, mesorectal space, inguinal, femoral, external iliac, internal iliac, and common iliac vessels).~* Days 29-45, a boost dose of 23.4 Gy in 1.8 Gy/fraction (13 fractions) to the GTV."
223774984|NCT06401681|OTHER|Balance training|The balance exercises consist of single limb stances with eyes open and closed, single-leg hops with stabilization, and single-leg hops and reach. Thirty-second breaks will be provided between exercise sets. Progressions for single-leg stance exercises involve longer durations and introduction of unstable surfaces. Progressions for hopping exercises involve longer hopping distances. To progress to the next level, participants must complete a balance training session without any errors. Errors include 1) touching the floor or bracing with the opposite limb, 2) excessive lateral trunk flexion or hip abduction, 3) hands coming off hips (hop tasks) or shoulders (stance tasks), 4) missing the landing target, 5) using the reach leg for a substantial amount of weight bearing.
223774985|NCT06133621|OTHER|dosage dRVVT|Blood test dRVVT assay on two tubes of blood in the haemostasis laboratory of the Center de Biologie et de Pathologie Est
223774986|NCT03899116|OTHER|deflation of pneumatic tourniquet|gradual deflation with variable degrees
223774987|NCT05571501|DEVICE|Gait assessment using the GAITRIte walkway|10-20 walking assessment using the GAITRite walkway
223774988|NCT03323905|DEVICE|Symphony MRI guided High Intensity Focused Ultrasound (HIFU)|The use of the MRI-HIFU for the ablation of leiomyomas
223774989|NCT04554433|DRUG|Ethanol with Asprin|"Group ( A ) which will receive the new protocol will be categorized into sub-groups according to the medical conditions , inclusion criteria , investigations and symptoms .~1. Inhaling alcohol vapor through nostrils .~2. Inhalation of Alcohol vapor driven by Oxygen .~3. Inhalation of Alcohol vapor driven by oxygen in case of ARDS.~4. Ethyl Alcohol infusion into the airway . Investigations will be made before starting the protocol and follow up data will be collected every day .~Follow up test will be done according to the schedule . PCR test will be done according to the duration of each technique to evaluate the final results ."
223774990|NCT00009230|DRUG|Celecoxib|
223774991|NCT02252081|DRUG|metformin|500 to 1500 mg orally per day for 16 weeks if eGFR \> 45 ml/min; 500 to 1000 mg orally per day for 16 weeks if eGFR =\< 45 ml/min
223774992|NCT02252081|DRUG|Placebo|placebo pill(s) orally per day for 16 weeks
223774993|NCT01738152|OTHER|HLA vaginal gel (HyaloGYN®),|Each participant will receive a HLA vaginal gel (HyaloGYN®), which is an over-the-counter, colorless gel to be administered for hydration and lubrication of the vaginal epithelium for women suffering dryness,as well as to the vulva for women suffering from vulvar symptoms. All participants will be instructed to insert the HLA gel into the vagina (with applicator) daily for the first 2 weeks, and then 3 times per week for 10 weeks. The women with vulvar symptoms at the baseline assessment will additionally be instructed to apply the HLA gel onto the vulva (manually) daily for the first 2 weeks, and then 3 times per week for 10 weeks. The participants will be assessed at 12 weeks. Participants receiving benefit from HyaloGYN®, as operationalized by improvement in both vaginal pH and VAS score will continue using the product 3 times per week for another 12 weeks and will receive a final vulvovaginal assessment at 24 weeks post-HLA treatment initiation.
223774994|NCT01738152|BEHAVIORAL|questionnaires|Assessment Form as part of routine clinical care. Participants will be asked to complete questionnaires at the baseline initial evaluation, 4-6 weeks, 12-14 weeks, and 22-24 weeks. The study information collected will be found in the standardized Clinical Assessment Form that patients complete as part of routine clinical care, along with an additional survey pertinent to the aims of the study. At 24 weeks, participants will complete an additional questionnaire that will ask questions regarding their experience with HyaloGYN® and their acceptability of and satisfaction with the product. Study participants must see the FSM NP or GYN clinician for the targeted exams at the study follow-up time points (4-6 weeks, 12-14 weeks, 22-24 weeks). PhD follow-up visits can be based upon the treatment plan of the patient. The study questionnaires and moisturizer diaries will be completed and collected during follow-up appointments with the GYN clinician or FSM NP.
223774995|NCT02660736|DRUG|Albiglutide Liquid Auto-injector|Albiglutide liquid is provided as a fixed-dose, disposable auto-injector containing albiglutide liquid (50 mg). The auto-injector delivers the study treatment in an injection volume of 1.0 mL for the 50 mg dose
223774996|NCT02660736|DRUG|Albiglutide Lyophilized DCC Pen Injector|Albiglutide is supplied as prefilled DCC Pen Injector. Each DCC contains lyophilized albiglutide 50 mg. When the injector pen product is reconstituted a neutral, isotonic solution is produced. The pen delivers albiglutide in an injection volume of 0.5 mL
223774997|NCT02660736|DRUG|Placebo Liquid Auto-injector|Liquid albiglutide matching placebo is provided as a fixed-dose, disposable autoinjector containing placebo liquid. The auto-injector delivers the placebo in an injection volume of 1.0 mL for the 50 mg placebo dose.
223774998|NCT02660736|DRUG|Placebo Lyophilized DCC Pen injector|Placebo is supplied as prefilled DCC Pen Injector. Each DCC contains matching placebo. When the injector pen product is reconstituted a neutral, isotonic placebo solution is produced. The pen delivers the placebo in an injection volume of 0.5 mL.
223774999|NCT04407897|RADIATION|Stereotactic radiotherapy|Three different dose fractionation schemes will be available: 45 Gy in 3 fractions, 50 Gy in 5 fractions, and 60 Gy in 8 fractions.
223775000|NCT02312310|DIETARY_SUPPLEMENT|Cocoa Flavanol|12 weeks administration of cocoa flavanol
223775001|NCT01702792|BIOLOGICAL|Tumor Vaccine|Tumor cells obtained at the time of surgery are irradiated with 10,000 Gy and freeze fractured. Lysate at 1x107 tumor cell equivalent (TCE) will be used for vaccination with adjuvant, Montanide ISA 51 VG.
223775002|NCT04259190|BEHAVIORAL|interoceptive exposure|Repeated 60-second trials of voluntary hyperventilation, each followed by a 15-second rest period. Participants will complete a minimum of 8 trials and continue additional trials until ratings of their most feared predicted outcome fall less than or below 5% likelihood.
223684027|NCT03072771|DRUG|Carmustine|-Carmustine is an alkylating agent. It will be sourced from commercial supply. Institutional guidelines will be followed for storage, preparation, and administration of carmustine.
223684028|NCT03072771|DRUG|Etoposide|-Etoposide is a semi-synthetic podophyllotoxin derivative. It will be sourced from commercial supply. Institutional guidelines will be followed for storage, preparation, and administration of etoposide.
223684029|NCT03072771|DRUG|Cytarabine|-Cytarabine, commonly known as Ara-C, is a synthetic nucleoside. It will be sourced from commercial supply. Institutional guidelines will be followed for storage, preparation, and administration of cytarabine.
223684030|NCT03072771|DRUG|Melphalan|-Melphalan is an alkylating agent. It will be sourced from commercial supply. Institutional guidelines will be followed for storage, preparation, and administration of melphalan.
223684031|NCT03072771|PROCEDURE|Peripheral blood draws|-Day +42, Day + 43, Day +56, and Day +100
223684032|NCT01908738|DRUG|paracervical block with 1%lidocaine|"To determine effectiveness of paracervical block, lidocaine spray and only oral analgesic drugs for pain relief during endometrial biopsy.~Pain score(NRS) immediately after procedure and 15 minutes Group 1(1%Lidocaine) Group 2(10%Lidocaine spray) Control group(Placebo) Pain score immediately Pain score 15 minutes"
223684033|NCT01908738|DRUG|10%lidocaine spray|
223684034|NCT05733403|DRUG|isotonic solution|Isotonic solutions are IV fluids that have a similar concentration of dissolved particles as blood.
223684035|NCT05733403|DRUG|Noradrenaline|Noradrenaline itself is classified as a sympathomimetic drug: its effects when given by intravenous injection of increasing heart rate and force and constricting blood vessels make it very useful for treating medical emergencies that involve critically low blood pressure.
223684036|NCT06177574|DRUG|BIC/FTC/TAF|TEST and TREAT strategy: Study group will start the intervention at the first visit with their healthcare provider.
223684037|NCT01445054|DRUG|111Indium CHX-A|111Indium CHX-A will be administered intravenously over a 10-15 minute period using an intravenous catheter
223684038|NCT03137576|PROCEDURE|Paravertebral Block (PVB)|PVB consists in the injection of low concentration Ropivacaine (30 ml, 0.3%) in the paravertebral space (defined by the anterior aspect of the ribs, the vertebral body and the parietal pleura. The space is identified under ultrasonographic guidance by a dedicated Anesthesiologist.
223684039|NCT03137576|PROCEDURE|Erector Spinae Plane Block (ESPB)|ESPB consists in the injection of low concentration Ropivacaine (30 ml, 0.3%), in the anatomical plane between the Erector Spinae muscles and deeper surface of Rhomboid muscle. The space is identified under ecographic guidance, laterally to the spinous process of T5. The diffusion of the anesthetic solution along the space can be echographically appreciated.
223775003|NCT05750524|OTHER|reflexology hand massage|Reflexology massage methods applied randomly to both trial groups.
223775004|NCT05750524|OTHER|classical hand massage|Classical hand massage methods applied randomly to both trial groups.
223775005|NCT00901329|DEVICE|NexGen Gender Fixed Bearing Knee prosthesis|new female prosthesis
223684040|NCT03914508|BEHAVIORAL|Memory + Behavioral Weight Loss|BWL and memory enhancement (M+BWL) will be integrated to capitalize on the strengths of both treatments. All participants will be taught general behavioral weight loss skills including to decrease caloric intake and increase physical activity, self-monitoring, goal setting, managing high-risk situations, meal planning, slowing eating, problem solving, social support, cognitive restructuring, lapse and relapse prevention skills, and maintaining weight loss. The proposed M+BWL program provides memory interventions based on the literature, including eating attentively, memory of previous meal, memory skills for planning, effects of diet on memory and the relationship between memory and satiety. The M+BWL program will also utilize experiential learning during the group program such as practicing memory enhanced skills during eating.
223684041|NCT01288976|DEVICE|MitraClip|The MitraClip System includes a MitraClip device, a Steerable Guide Catheter, and a MitraClip Delivery System that enables placement of the MitraClip device on the mitral valve leaflets
223684042|NCT01288976|DRUG|Medical Management|The Non-Surgical Medically Managed Heart Failure (HF) Group consists of patients with mitral regurgitation (MR) in whom the MR is managed non-surgically based on standard hospital clinical practice. Patients with MR who receive a pacemaker, Implantable Cardiac Defibrillator (ICD) and/or Cardiac Resynchronization Therapy (CRT) treatments may be included
223684043|NCT01288976|PROCEDURE|Mitral Valve Surgery|The Mitral Valve Surgery Group consists of patients with MR in whom the MR is managed surgically (repair or replacement) based on standard hospital clinical practice. Patients with concurrent coronary artery bypass grafting (CABG) or aortic/tricuspid valve or and other cardiac procedure except atrial fibrillation surgery are excluded.
223684044|NCT01852357|OTHER|Neurofeedback|The intervention will be 24 sessions of beta/sensorimotor rhythm (SMR) neurofeedback.
223684045|NCT01852357|OTHER|Sham Neurofeedback|Feedback generated by data not associated with the current participant.
223684046|NCT02800954|BIOLOGICAL|blood samples|
223684047|NCT02800954|BIOLOGICAL|Bone marow samples|
223684048|NCT01867073|OTHER|Biomarker|
223684049|NCT05249777|DRUG|TD0069 hard capsule|TD0069 hard capsule (800 ± 7.5% mg/capsule) contains 600 mg fine powder of mixed herbal medicines and 200 mg excipients.
223684050|NCT05249777|DRUG|TD0069 Placebo|TD0069 placebo (800 ± 7.5% mg/capsule) contains excipients
223684051|NCT01520831|DRUG|biphasic insulin aspart 30|One single dose of 0.3 U/kg body weight administered subcutaneously (s.c., under the skin) at one of four study days
223684052|NCT01520831|DRUG|biphasic insulin aspart 50|One single dose of 0.3 U/kg body weight administered subcutaneously (s.c., under the skin) at one of four study days
223684053|NCT01520831|DRUG|biphasic insulin aspart 70|One single dose of 0.3 U/kg body weight administered subcutaneously (s.c., under the skin) at one of four study days
223684054|NCT01520831|DRUG|insulin aspart|One single dose of 0.3 U/kg body weight administered subcutaneously (s.c., under the skin) at one of four study days
223684055|NCT00817687|DRUG|mycophenolate mofetil [CellCept]|As prescribed; + early biopsy
223684056|NCT00817687|DRUG|mycophenolate mofetil [CellCept]|As prescribed; + standard treatment
223684057|NCT06506071|DIAGNOSTIC_TEST|Spectral CT|Myocardial tissue characterization with Spectral CT
223684058|NCT01554631|DRUG|Acarbose (Glucobay ODT, BAYG5421)|
223684059|NCT01554631|DRUG|Acarbose (Glucobay, BAYG5421)|
223684060|NCT02176824|BEHAVIORAL|Total Sleep deprivation, Sleep Phase Advance, and Bright Light Therapy|Sleep deprivation, Sleep phase advance, and Bright light therapy
223684061|NCT02176824|BEHAVIORAL|Partial Sleep deprivation, Sleep Phase Delay, and Low amber light.|
223684062|NCT02176824|OTHER|Treatment as usual|
223684063|NCT00558376|DRUG|polyethylene glycol|Single time 3 liters PEG, 250 cc every 15 minutes the day before colonoscopy
223684064|NCT00558376|DRUG|Sodium phosphate|Sodium phosphate 45cc, 2 doses 4 hours apart the day before colonoscopy
223684065|NCT01742676|DRUG|ADVAGRAF|oral
223684066|NCT01742676|DRUG|PROGRAF|oral
223684067|NCT00649311|DRUG|eplerenone|Eplerenone 50 mg oral film-coated tablet once daily for 8 weeks. If blood pressure was uncontrolled (DBP ≥ 90 mmHg) at Week 4, the dose was increased to eplerenone 100 mg oral film-coated tablet once daily for 4 weeks.
223684068|NCT00649311|DRUG|Losartan|Losartan 50 mg oral capsule once daily for 8 weeks. If blood pressure was uncontrolled (DBP ≥ 90 mmHg) at Week 4, the dose was increased to losartan 100 mg oral capsule once daily for 4 weeks
223684069|NCT01823510|DRUG|Ticagrelor + Aspirin|Single loading doses of Ticagrelor (180 mg) and ASA (325 mg), followed by daily dosing for 5-7 days (ticagrelor 90 mg twice daily + ASA 81 mg once daily).
223684070|NCT01823510|DRUG|Clopidogrel + Aspirin|Single loading doses of Clopidogrel (600 mg) and ASA (325 mg), followed by daily dosing for 5-7 days (clopidogrel 75 mg + ASA 81 mg once daily).
223684071|NCT03503851|DEVICE|MitraClip implantation|Device to approximate the mitral valve leaflets
223684072|NCT00112398|PROCEDURE|Extended interventions by advanced level prehospital providers|may include rapid sequence intubation (RSI) airway management, blood transfusions, surgical procedures, etc.
223684073|NCT02392533|OTHER|Education|Education
223684074|NCT02607644|DEVICE|Laryngeal Mask Airway (LMA)|Laryngeal Mask Airway (LMA) for Control group
223684075|NCT02607644|DEVICE|Laryngeal Tube (LT)|Laryngeal Tube (LT) for Intervention group
223684076|NCT03544788|DEVICE|Cirvo™ Therapy|The Cirvo(TM) (also referred to as the Radial Medical Compression System) is a mobile wearable medical device that applies graded intermittent mechanical sequential compression for the treatment of venous leg ulcers (VLU).
223684077|NCT02379845|DEVICE|NBTXR3|One intratumor implantation by injection
223684078|NCT02379845|DEVICE|Radiation therapy|5 weeks/50 Gy (5 x 2 Gy by week)
223684079|NCT03054090|OTHER|Quality Improvement Support|Practices will receive a blended strategy of quality improvement facilitation to help participating practices incorporate PCOR clinical and organizational findings while building their overall practice capabilities. Primary care practices will be provided tools and training to improve the rates of screening and treatment of risk factors for heart attacks and strokes, as well as other chronic illnesses and the delivery of preventive services.
223684080|NCT03230201|PROCEDURE|Lymph node dissection|Lymph node dissection during radical nephroureterectomy
223684081|NCT00611871|DRUG|Propranolol|40mg propranolol, followed 2 hrs after with 60mg propranolol, immediately following memory recollection
223684082|NCT00611871|DRUG|Placebo|40mg placebo, followed 2 hrs after with 60mg placebo
223684083|NCT01257360|DRUG|Panitumumab|Panitumumab 6 mg/kg BW will be administered IV every 2 weeks (q2w) on day -14, 1, 15, 29 (and 43, in case radiotherapy is still ongoing due to delays) of the radiotherapy.
223684084|NCT01257360|RADIATION|Radiation of the pelvis|Radiation is applied at single doses of 1.8 Gy at the ICRU 50 reference point, once daily, five times a week, adding up to 28 fractions over almost 6 weeks and a total reference dose of 50.4 Gy.
223684085|NCT00959374|DEVICE|V-Loc 180/90 Wound Closure Device|Barbed absorbable suture
223684086|NCT00959374|DEVICE|3-0 Monocryl Absorbable Sutures|3-0 Monocryl Absorbable Suture (non-barbed)
223684087|NCT05891964|DRUG|Secukinumab Injection|Injection Secukinumab 150mg subcutaneously will be administered at weeks 0, 1, 2, 3, 4, and then monthly for 5 months.
223684088|NCT00859261|PROCEDURE|Experimental 3D Breast Ultrasound imaging|Subjects will be seated and have the indicated breast positioned in the 3D breast ultrasound imaging device. An ultrasound gel will be applied to the breast by the technician. The breast will be gently compressed between the ultrasound plates to facilitate the 3D (dimensional)breast imaging. This imaging session will take approximately 30 minutes to complete.
223775006|NCT00901329|DEVICE|NexGen LPS-Flex Fixed Bearing Knee prosthesis|standard knee prosthesis
223775007|NCT00491244|DRUG|Peginterferon alfa-2a and ribavirin|Pegylated interferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 135 ug/week plus ribavirin (Copegus, F. Hoffman-LaRoche) 200 mg/day for 24 to 48 weeks (genotype 1: 48 weeks, genotype 2: 24 weeks)
223684089|NCT00859261|PROCEDURE|Experimental Photoacoustic Imaging|Subjects will be placed in a seated position for the photoacoustic tomography(PAT) imaging. The subjects will be given a laser protective mask to wear. Each subject will be instructed how to wear this mask(goggles) to protect their eyes during the imaging session. Pulse monitor leads may be placed on their chest to allow the computer to record the images of blood flow in the breast. The breast will be placed on the laser device platform and positioned so that the laser beam is appropriately directed to the targeted area of the breast. During the imaging the temperature of the skin under laser light, will be checked often with a thermometer to make sure that the skin is not getting too hot. This laser based imaging scan will take approximately 10 minutes to complete.
223684090|NCT04510571|OTHER|Evaluating Postoperative Pain After Root Canal Treatment with Protaper Next|Patients were randomly separated into two groups and root canal treatments were completed with Protaper Next file systems. Instrumentation time for each system was noted and patients were given a pain scale which included visual analog scale for 6, 24, 48 and 72 hours after treatment.Postoperative pain scores and instrumentation times were analyzed statistically with chi square test and student t test.
223684091|NCT04510571|OTHER|Evaluating Postoperative Pain After Root Canal Treatment with Reciproc Blue Files|Patients were randomly separated into two groups and root canal treatments were completed with Reciproc Blue file systems. Instrumentation time for each system was noted and patients were given a pain scale which included visual analog scale for 6, 24, 48 and 72 hours after treatment.Postoperative pain scores and instrumentation times were analyzed statistically with chi square test and student t test.
223684092|NCT00015938|BIOLOGICAL|filgrastim|
223684093|NCT00015938|DRUG|docetaxel|
223684094|NCT00015938|DRUG|vinorelbine|
223684095|NCT03849027|DRUG|Methoxyflurane|Inhaled methoxyflurane will be administered using the disposable field inhaler device (Penthrop®) according to the recommended dosing schedule.
223684096|NCT03849027|DRUG|Placebo|The sham inhaler will have one droplet of methoxyflurane applied to the outer surface, but no drug in the vaporization chamber to give off the prominent odour with no analgesic effect, partially blinding the participants to the test.
223684097|NCT04459767|DRUG|Vupanorsen|80 mg subcutaneous injection
223684098|NCT04459767|DRUG|Placebo|Subcutaneous injection
223684099|NCT02262052|OTHER|MRDTI|MRDTI is primary diagnostic test for management of suspected ipsilateral DVT
223684100|NCT06514443|OTHER|survey|survey exploring barriers and faciltiators for physical activity
223684101|NCT04451642|PROCEDURE|Peripheral nerve block|Peripheral nerve block consists of the administration of a local anaesthetic into the nerves to inhibit nerve transmission in a specific part of the body. Ultrasound or Nerve stimulator could be used to locate the peripheral nerve. A needle is placed through the anatomical references to administer local anaesthetic around the peripheral nerve. Single-shot or continuous blocks are performed preoperatively and postoperatively as current practice in the surgery theatre. Using ultrasound, in-plane or out-plane approach could be performed. Peripheral nerve block provides excellent intraoperative and postoperative analgesia decreasing the need for intravenous pain drugs. Interscalene block, supraclavicular block, safene block, femoral block, BRILMA block are different kinds of peripheral nerve block using in the anaesthestic current practice.
223684102|NCT00048711|DRUG|N-acetylgalactosamine 4-sulfatase|
223684103|NCT03700879|RADIATION|MRI,MRA,Carotid ,vertebrobasilar and Transcranial Doppler|Patients presented with clinical picture and radiography suggestive of acute ischemic stroke will be subjected to a comprehensive evaluation with MRI,MRA,Carotid ,vertebrobasilar and Transcranial Doppler
223684104|NCT01221103|DRUG|Combination of dexamethasone, ofatumumab and bendamustine|"* Ofatumumab (liquid concentrate for infusion in glass vials) infused iv on day 1 at 300 mg during the first cycle, followed by infusions of 1000 mg on day 1 of each subsequent cycle~* Bendamustine (powder dissolved in sterile water) infused iv over 30-60 minutes at the dose of 120 mg/m2 (days 2,3 every 21 days) or 120 mg/m2(days 2,3 every 28) or 90 mg/m2 (days 2,3 every 28 days) depending on toxicity~* Dexamethasone administered i.v. at 40 mg (days 1,2,3,4)"
223684105|NCT01146210|OTHER|laboratory biomarker analysis|Correlative studies
223684106|NCT02284178|OTHER|Enhanced oropharyngeal suction|Deep oropharyngeal suction with catheter every 4 hours
223684107|NCT02284178|OTHER|Usual Care|Oral suction with suction swab every 4 hours
223684108|NCT01680549|DRUG|Gabapentin|Gabapentin 600mg PO pre-operatively and continued postoperatively 300 mg PO q8 hours x 3 days.
223684109|NCT00569829|BEHAVIORAL|cognitive behavioral therapy|1 to 16 weekly sessions of modular cognitive behavioral therapy, each lasting 60-80 minutes
223684110|NCT00242983|PROCEDURE|quality-of-life assessment|
223684111|NCT03256188|BEHAVIORAL|Active classroom|30 minutes of moderate-to-vigorous physical activity
223684112|NCT05868720|DRUG|Risperidone, Aripiprazole|The patients who are randomized to Risperidone group will receive Risperidone at a dose of 1mg/day during the study period that is for 6 weeks. The patients who are randomized to Aripiprazole group will receive Aripiprazole at a dose of 2mg/day during the study period that is for 6 weeks.
223684113|NCT03238846|OTHER|Three month dispensing of ART in CARGs|Patients enrolled in the three-month ART dispensing arm will receive a 90-day supply of ART in CARGs from their provider for the duration of the study. Each CARG will consist of 6-12 stable patients on ART and will meet in the community and select a group member to collect their ART at the facility every 3 months. Patients can have unscheduled clinic visits when unwell. Viral loads for the group will be collected at 12 and 24 months at the facility.
223775008|NCT00491244|DRUG|Peginterferon alfa-2a|Pegylated interferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 135 ug/week for 24 to 48 weeks (genotype 1: 48 weeks, genotype 2: 24 weeks)
223775009|NCT00318487|PROCEDURE|Bilateral sinus augmentation with immediately loaded dental implants|Bilateral sinus augmentation with immediately loaded dental implants will be used.
223775010|NCT02984397|DRUG|Ketotifen Fumarate|Ketotifen is a second-generation noncompetitive H1-antihistamine and mast cell stabilizer. It is most commonly sold as a salt with fumaric acid, ketotifen fumarate, and is available in two forms. In its ophthalmic form, it is used to treat allergic conjunctivitis, or the itchy red eyes caused by allergies. In its oral form, it is used to prevent asthma attacks.
223684114|NCT03238846|OTHER|Six month dispensing of ART in CARGs|Patients enrolled in the three-month ART dispensing arm will receive a 90-day supply of ART in CARGs from their provider for the duration of the study. Each CARG will consist of 6-12 stable patients on ART and will meet in the community and select a group member to collect their ART at the facility every 6 months. Patients can have unscheduled clinic visits when unwell. Viral loads for the group will be collected at 12 and 24 months at the facility.
223684115|NCT04396496|DRUG|Daratumumab Injection|"DARA is a human monoclonal antibody that specifically recognizes the CD38 molecule that is expressed at a high level in a variety of hematological malignancies, including myeloma cells.~DARA injection will be given with oral lenalidomide for up to 12 four week cycles."
223684116|NCT02906969|OTHER|Colonoscopy Educational Video|Brief Video utilization to assess comprehension and evaluation bowel preparation quality
223684117|NCT02906969|OTHER|Placebo Educational Video|Brief Video utilization to provide placebo information and evaluation bowel preparation quality
223684118|NCT00827580|DRUG|Eniluracil|
223684119|NCT02162641|PROCEDURE|Sentinel lymph node biopsy|
223684120|NCT02609698|DEVICE|Coroflex ISAR|This stent platform has a thin-strut cobalt-chromiun alloy backbone, no polymer, microporous surface.
223684121|NCT02609698|DRUG|3 months DAPT|
223684122|NCT02609698|DRUG|6 months DAPT|
223684123|NCT03486717|DEVICE|Virtual reality goggles|Patients will act as their own control over two different dental appointments. One appointment will consist of wearing the virtual reality googles, the other appointment will be conducted without them. The goggles have a small screen inside of them along with headphones. This device will play an a movie or cartoon that will immerse the patient during treatment.
223684124|NCT04132882|DRUG|Sodium Thiosulfate (STS)|
223684125|NCT01483690|DRUG|Decitabine|10 mg/m2/day given IV over 1 hour on days 1 through 5 and days 15 through 19.
223684126|NCT01483690|DRUG|Vorinostat|180 mg/m2/day (Max dose=400mg daily) given orally on days 2 through 7 and days 16 through 21.
223684127|NCT01483690|DRUG|Vincristine|1.5 mg/m2/day (Max dose 2 mg) given IV push on days 10, 17, 24 and 31.
223775011|NCT02984397|DRUG|Placebo|
223775012|NCT02984397|OTHER|Standard of Care|
223775013|NCT05548075|DRUG|Psilocybin|Up to 25mg of Psilocybin on 2 occasions.
223775014|NCT05548075|BEHAVIORAL|Therapeutic support|Psychological and physical therapeutic support
223684128|NCT01483690|DRUG|Dexamethasone|20 mg/m2/day divided BID given orally on days 8 through 12 and 22 through 26.
223684129|NCT01483690|DRUG|Mitoxantrone|10 mg/m2/day given on days 8 and 9 as a short IV infusion over 5-15 minutes; do not infuse over less than 3 minutes
223684130|NCT01483690|DRUG|Pegaspargase|2500 international units/m2/day IM or IV on days 10 and 24.
223684131|NCT01483690|DRUG|Methotrexate|"Given intrathecally to all patients the dose defined by age below.~* 8 mg for patients age 1-1.99~* 10 mg for patients age 2-2.99~* 12 mg for patients 3-8.99 years of age~* 15 mg for patients \>9 years of age~CNS 1 or 2 patients get doses on day 8, 22 and 35 and CNS 3 patients should get doses on day 8, 15, 22, 29 and 35"
223684132|NCT03092804|PROCEDURE|ventriculo-peritoneal shunting|A mainstream therapy for NPH. It involves the device of CSF flow control of shunts and accessories(CFDA(I)20143665605)
223684133|NCT04534465|DRUG|Polyethylene glycol (MiraLAX, BAY81-8430)|Oral solution, 17g polyethylene glycol, one time
223684134|NCT04534465|DRUG|Mannitol|Oral, 2g, 4g, 6g, 8g and 10g mannitol, one time
223684135|NCT02301585|PROCEDURE|Passive Leg Raising Test|Before decision on fluid administration a passive leg raising test is performed. The results are interpreted according to a treatment protocol. If the test indicates fluid irresponsiveness optimization of circulation will be done with vasopressors or inotropes.
223684136|NCT02301585|PROCEDURE|Standard of care|Patients are treated according to Surviving Sepsis Guidelines
223684137|NCT00478881|DRUG|Vardenafil HCl (Levitra, BAY38-9456)|vardenafil hydrochloride 10 mg film-coated tablets twice daily (BID) for oral (by mouth) intake for 6 weeks
223684138|NCT00478881|DRUG|Placebo|vardenafil hydrochloride-matching film-coated tablets BID for oral intake for 6 weeks
223684139|NCT04387760|DRUG|Hydroxychloroquine|"400mg BID PO day 1 then 200mg BID PO from day 2 to day 10.~In addition to Hydroxychloroquine all patients will receive the standard care (according to local Bahrain COVID19 guidelines). Any patient who is fit for discharge, can be discharged and medications will be stopped on discharge."
223684140|NCT04387760|DRUG|Favipiravir|"1600mg BID PO day 1600mg BID PO day 2 to day 10.~In addition to Favipiravir all patients will receive the standard care (according to local Bahrain COVID19 guidelines). Any patient who is fit for discharge, can be discharged and medications will be stopped on discharge."
223684141|NCT04387760|OTHER|Routine care for COVID-19 patients|Supportive care according to local guidelines
223684142|NCT05368272|OTHER|Processed electroencephalography|Acquisition of raw EEG data from processed EEG monitor. Analysis of data acquired for prespecified bandwidth properties
223684143|NCT05368272|OTHER|Postoperative delirium assessment|Twice daily assessment for the incidence of postoperative delirium using validated tool (questionnaire)
223684144|NCT02457273|DRUG|TLC 388|40 mg/m2 of TLC 388, given as a 30 (+3) minute intravenous infusion, on Days 1, 8 and 15 of a 28-day cycle until PD, unacceptable toxicity or consent withdrawal occurs.
223684145|NCT04520893|PROCEDURE|ventilator setting vcv with pause|ventilator setting vcv with pause
223684146|NCT04520893|PROCEDURE|ventilator setting vcv|ventilator setting vcv without pause
223684147|NCT04520893|PROCEDURE|ventilator setting pcv-vg|ventilator setting with pcv-vg
223684148|NCT00737464|DRUG|methoxy polyethylene glycol-epoetin beta [Mircera]|iv (120, 200 or 360 micrograms) every 4 weeks for 12 weeks.
224262778|NCT05527639|BEHAVIORAL|strength training program|12-weeks of strength training consisting of warm ups, dead-lifts, squats and cool down exercises
223684149|NCT02090868|OTHER|Oral Intake Screening Tool|A screening tool developed from a literature review and expert opinion. It will be used by nurses to assess patients receiving non-invasive ventilation ability to eat and drink orally and suggest what actions should be taken if they are unable to do so
223684150|NCT03022227|OTHER|telemedicine|telemedicine applied to adult cochlear implant users' follow-up
223684151|NCT05262725|BEHAVIORAL|Values-based Behavioral Activation|Initially, patients complete a values assessment in which they identify personal values in various life domains. With the assistance of a clinician, patients set incremental behavior goals to move their daily actions to better align with their self-reported values. Goal completion allows the patient to achieve outcomes consistent with recovery, and they potentially experience enjoyment, self-efficacy, and confidence as they progress through the treatment.
223684152|NCT04505397|DRUG|SKL24741|An inhibitor of voltage-gated sodium channels and a possible activator of Big Potassium channels. Administered as an oral dose in the form of a capsule or tablet.
223684153|NCT04505397|DRUG|Placebo|Sugar pill manufactured to mimic SKL24741
223684154|NCT00244166|DRUG|prednisolone|
223684155|NCT00872027|DRUG|Escitalopram|10 mg of escitalopram administered enterally with the option for dose escalation to 20 mg after 3 to 5 weeks if the medical condition is stable and no liver disease presents
223684156|NCT00872027|DRUG|Placebo|Placebo pills for 8 weeks
223684157|NCT04733378|PROCEDURE|Peri-operative neurological monitoring|Pre- and post-operative cerebral MRI, standardized neurological examinations at 4, 12, 24 months and neuropsychological evaluation with a Bayley III test (Bayley Scale of Infant and Toddler Development, Third Edition) at 24 months.
223684158|NCT03079180|OTHER|Strength training at 80% 1RM|Detailed in Arms section's
223684159|NCT03079180|OTHER|Strength training at 55% 1RM|Detailed in Arms section's
223684160|NCT04432337|PROCEDURE|The role of the activation of the NLRP3 inflammasome after cardiac surgery|Determine the effect on the inflammatory response post extracorporeal circulation mediated by the NLRP3 inflammasome, in patients after cardiac surgery
223684161|NCT01046370|BEHAVIORAL|Amygdala Retraining Program|Mind-body intervention.
223684162|NCT00193388|DRUG|Topotecan|
223684163|NCT04633460|DIETARY_SUPPLEMENT|Ketone ester|A nutraceutical ketone ester (KE), (R)-3-hydroxybutyl (R)-3-hydroxybutyrate which provides systemic ketosis
223684164|NCT04633460|DIETARY_SUPPLEMENT|placebo drink|KE free placebo drink
223684165|NCT05755165|BEHAVIORAL|Depression|\~90-second selfie video of an adolescent discussing her history of depression, treatment, and recovery
223775015|NCT01276327|DRUG|Linagliptin + Pioglitazone|Medium doses, oral administration
223684166|NCT05755165|BEHAVIORAL|Depression, adjusted|\~90-second selfie video of an adolescent discussing her history of depression, treatment, and recovery - and including explicit reference to the role of anti-Black racism as a contributing factor
223684167|NCT05755165|BEHAVIORAL|Control|\~90-second selfie video of an adolescent discussing everyday activities and interests, with no reference to depression or racism.
223684168|NCT01516528|PROCEDURE|Spirometry|Assessment of lung function by spirometry
223775016|NCT01276327|DRUG|Linagliptin + Pioglitazone|Medium doses, oral administration
223775017|NCT01276327|DRUG|Linagliptin/Pioglitazone|Medium dose oral administration
223775018|NCT01276327|DRUG|Linagliptin/Pioglitazone|Medium dose oral administration
224262779|NCT05198622|PROCEDURE|Intercostobrachial Nerve Preserving Axillary Lymph Node Dissection|"A single standardized technique will be used in all of the patients. For patients undergoing mastectomy, ALND will be carried out using the incision given for mastectomy. A separate incision may be required for patients undergoing breast conservation surgery. Flaps of skin and subcutaneous tissue will be raised and dissection will be carried out till the edge of pectoralis major muscle. Clavipectoral fascia will be opened to gain access to axillary fat and the nodes. These will be removed en block and the intercostobrachial nerve will be completely preserved during this dissection.~All of the surgeons carrying out the intervention would have completed formal training (Fellowship Level) in breast surgery."
223775019|NCT06572878|OTHER|Cognitive training|Cognitive training will follow a group format, with each group consisting of 4-16 participants. Each group will be in a private, independent room for their training sessions and will not interact with participants from other groups. The cognitive training task components will specifically focus on attention, learning and memory, executive function, perceptual-motor skills, and language.
223775020|NCT06572878|OTHER|Physical training|Physical training will follow a group format, with each group consisting of 4-16 participants. Each group will be in a private, independent room for their training sessions and will not interact with participants from other groups. The physical training task components will specifically focus on strength, balance, agility, gait, low-volume aerobic, and flexibility.
223835319|NCT01843452|BIOLOGICAL|PANITUMUMAB|6 mg/kg IV administered over 60 min infusion on days 1,15 and 29.
224262780|NCT05198622|PROCEDURE|Intercostobrachial Nerve Sacrificing Axillary Lymph Node Dissection|"A single standardized technique will be used in all of the patients. For patients undergoing mastectomy, ALND will be carried out using the incision given for mastectomy. A separate incision may be required for patients undergoing breast conservation surgery. Flaps of skin and subcutaneous tissue will be raised and dissection will be carried out till the edge of pectoralis major muscle. Clavipectoral fascia will be opened to gain access to axillary fat and the nodes. These will be removed en block and the intercostobrachial nerve will be sacrificed during this dissection.~All of the surgeons carrying out the intervention would have completed formal training (Fellowship Level) in breast surgery."
224262781|NCT00044434|DRUG|bupropion (Wellbutrin)|
224262782|NCT02331563|DRUG|Dexmedetomidine|ultrasound guided transvers abdominis plane block
224262783|NCT02331563|DRUG|0.25 % bupivacaine|ultrasound guided transvers abdominis plane block
223684169|NCT06505629|BEHAVIORAL|the online Paired Emotion Reading Intervention (PERI)|In the PERI, all children will receive three books about emotion knowledge. The paired reading groups will read and discuss these books over the next six weeks. Before starting the reading sessions, the paired groups will meet online via video to get to know each other and set reading goals. During the reading process, participants will check in daily with their reading progress. From the second week to the fifth week, participants will engage in weekly online discussions about the reading content. These discussions, led by the urban children, will follow a semi-structured discussion guide. The discussions aim to deepen the children's understanding of the book content and facilitate the application of emotion-related knowledge and emotion regulation strategies in their daily lives. The discussion sessions will be recorded and uploaded for regular review by the researchers.
223835320|NCT01843452|DRUG|MITOMYCIN|10 mg/m2 IV administered over 15 min infusion on days 1 and 29.
223835321|NCT01843452|DRUG|CAPECITABINE|825mg/m2 orally twice daily on study days 1 through 45.
223684170|NCT06505629|BEHAVIORAL|the online Paired General Reading Intervention (PGRI)|Apart from the differences in the reading materials and discussion topics, all other aspects are identical to the PERI group. In the online PGRI, children will read three books of their choice, and discussions will center around general reading experiences and feelings.
223835681|NCT03184662|OTHER|HIPA|"inclusion in a program with 2 weekly sessions of structured physical activity of 1 hour in a dedicated structure, under the supervision of a graduated coach.~First 3 months : physical reconditioning 3 months and after: alternating sessions of physical strengthening and intermittent high-intensity physical activity Adaptation of the intensity of the program according to evaluation tests every 3 months"
224262784|NCT01237691|BEHAVIORAL|HOPE supervision|HOPE entails a warning session (Orientation Hearing) where the rules of parole are laid out and parolees are told that any violation of stated parole conditions will be sanctioned with a brief jail term (typically a few days in jail). HOPE includes regular random drug testing.
224262785|NCT01237691|BEHAVIORAL|Parole-as-usual|Parolees are supervised under standard parole supervision practice in California.
224262786|NCT00035139|DRUG|methylphenidate|
224262787|NCT01174186|DRUG|Adalimumab|Tumor Necrosis Factor (TNF) alpha inhibitor given 40 mg subcutaneously every other week except the first time where 80 mg is given
224262788|NCT05274763|OTHER|Quality-of-Life Assessment|Ancillary studies
224262789|NCT05274763|OTHER|Questionnaire Administration|Ancillary studies
224262790|NCT05274763|PROCEDURE|Spiritual Therapy|Deliver or undergo Compassion Centered Spiritual Health (CCSH) session
224262791|NCT06241963|DEVICE|Active Comparator: Unilateral real High definition transcranial direct current stimulation|Improvement of cortical excitability, unilateral stimulation was effective, and no side effects were observed
224262792|NCT06241963|DEVICE|Active Comparator: Bilateral real High definition transcranial direct current stimulation|Improved cortical excitability, the effect was more obvious than unilateral stimulation, the effect lasted longer, and no side effects were observed
224262793|NCT06241963|DEVICE|Sham Comparator: Sham High definition transcranial direct current stimulation|The sham stimulation is mainly used for blank control, control variables, and exclude the interference of other factors
224262794|NCT01555086|PROCEDURE|Limited pelvic Lymphadenectomy|approximately 10-14 lymph nodes are removed
224262795|NCT01555086|PROCEDURE|Extended pelvic Lymphadenectomy|approximately 20 lymph nodes are removed
224262796|NCT02960295|DEVICE|1-Self-monitoring of blood glucose|"Self-monitoring of blood glucose 4 times daily: fasting and 1-hour after each meal. Results will be recorded and transmitted in real-time via a Bluetooth connection to a cellphone app installed on study enrollment. Intervention: At every office visit and at every telephone (virtual) visit the patient's physician will review glucose results and make adjustments in diet, activity, or medication to bring glucose into desired range."
224262797|NCT02960295|DEVICE|2-Self-weighing|Self-weighing on electronic scale at least once a week. Results will be recorded and transmitted in real-time via a Bluetooth connection to a cellphone app installed on study enrollment. Consultation with the nutritionist will be obtained for women gaining in excess of or less than that indicated for her pre-pregnancy BMI, per Institute of Medicine (IOM) standards.
223684171|NCT05791981|BEHAVIORAL|Harmony & Health Intervention|"Participants will attend group in person sessions 2 times each week for 8 weeks. The sessions will be 45 minutes long. In each session, there will be an introduction, 30 minutes of gentle yoga-based poses and breathing exercises, and then 10 minutes of guided relaxation and scripture meditation.~Participants will be instructed to practice the exercises at home 2 times each week during the entire 6-month period. You will be given instructions and a yoga mat, belt, and block. After your Week 9 assessment, you will attend in-person or Zoom sessions 1 time each month over the final 4 months of the study"
223684172|NCT05791981|BEHAVIORAL|Attention Control|Participants will attend group in-person health education sessions 2 times each week for 8 weeks. The sessions will be 45 minutes long and will include discussions of disease prevention and other health and well-being topics. After your Week 9 assessment, you will have the ability to attend additional in-person or Zoom health education sessions 1 time each month over the final 4 months of the study.
223684173|NCT05791981|DEVICE|Fitbit|Participants will be given a Fitbit and instructions on how to use it. The Fitbit will record your physical activity and report it to the study staff.
223684174|NCT03251677|PROCEDURE|Surgical procedure, Hysterectomy|Surgical removal of the uterus
223684175|NCT06253689|DEVICE|Defecation Posture Modification Device|Patients assigned to the experimental arm will be asked to use the defecation posture modification device to aid with bowel movements during the postoperative period.
223684176|NCT06069648|BEHAVIORAL|printed screening decision aid|a booklet form of screening decision aid containing information of cervical cancer screening options
223684177|NCT06069648|BEHAVIORAL|a leaftlet|a leaflet containing information about healthy lifestyles
223684178|NCT06069648|BEHAVIORAL|mobile screening decision aid|a mobile app format of screening decision aid containing information of cervical cancer screening options
223684179|NCT01453660|OTHER|Endo-PAT2000 testing|Endo-PAT2000 testing is done six times during the study. Baseline Assessment Time 1 Cycle 1, Day 1 (Pre-chemotherapy)Time 2 Cycle 1, Day 1 (After 1st dose of cisplatin), Time 3 Cycle 1, Day 2 (Before second cisplatin dose of cycle 1), Time 4 Cycle 1, Day 5 (After last cisplatin dose of cycle 1), End-of-Study Assessment Time 5 (14-34 weeks from Time 1; e.g., 1-12 weeks following completion of the last cycle of first-line chemotherapy) Long-Term Follow Up Assessment Time 6 (24-30 months from Time 1)
223684180|NCT01453660|OTHER|Endo-PAT2000 testing|Time 1: A baseline assessment will be performed in the fasting state including Endo-PAT2000, vital signs, waist circumference, fasting blood draw, \& urine sample. This will be considered Day 1 of the study for this group of patients. Time 2 (2-5 hours from Time 1): Two to five hours after Time 1, patients will undergo assessment of blood pressure \& heart rate, including orthostatics \& Endo-PAT2000 testing. Time 5 -- End of Study visit (14-34 weeks from Time 1): At a time point 14 to 34 weeks later than Time 1 patients will undergo study testing in the fasting state. This includes Endo-PAT2000 testing, vital signs including orthostatics, waist circumference, fasting blood draw, \& urine sample. The Surgery-Only Group will not have any assessment at Time 3 (Day 2) or Time 4 (Day 5) due to logistical concerns. Long-Term Follow Up Assessment Time 6 (24-30 months following Time 1)
223684181|NCT04300920|DRUG|N-acetyl cysteine|600 mg N-acetylcysteine (NAC) oral tablets three times daily for 24 months.
223684182|NCT04300920|DRUG|Placebo|Matching oral placebo tablet three times daily for 24 months.
223684183|NCT02017600|DRUG|ND-420|ND-420 50 mg/m2 on day1
223684184|NCT02017600|PROCEDURE|Surgery|After induction chemotherapy, participants will be receive right or left thoracotomy for curative resection by total or subtotal thoracic esophagectomy.
223684185|NCT02017600|DRUG|Cisplatin|cisplatin 70 mg/m2 on day1
223684186|NCT02017600|DRUG|fluorouracil|fluorouracil 700 mg/m2 daily, day1 to day4
223684187|NCT05944224|DRUG|SPH4336|SPH4336 Tablets ：Orally, 400mg once a day ; 28 days/cycle
223684188|NCT05944224|DRUG|Cadonilimab|Intravenous infusion, 6mg/Kg,28 days/cycle
223684189|NCT03976245|DRUG|Etanercept|injection
223684190|NCT03976245|DRUG|tofacitinib|tablet
223684191|NCT03586518|DIAGNOSTIC_TEST|Cardiac MRI scan|"A non-contrast cardiac MRI (CMR) scan at 3-Tesla platform (Skyra, Siemens Medical Imaging, Erlangen, Germany).~This non-contrast CMR scan will principally determine: Left ventricular (LV) mass and volumes/ejection fraction and; fibrosis using T1 mapping."
223684192|NCT03586518|DIAGNOSTIC_TEST|Echocardiogram|Assessments will include: LV size and function as per the American Society of Echocardiography guidelines. In addition specific focus will be paid end-diastolic integrated backscatter measurements.
223835682|NCT03184662|OTHER|Counseling PA|Counseling of physical activity according to recommendations from the working group on Physical Activity of the SFD
223684193|NCT03586518|PROCEDURE|Cardiac explantation|A limited post-mortem will be performed to retrieve patients' hearts for preparation and storage at St George's University, London where direct comparison will be made between levels of scarring seen directly under the microscope between that on the MRI scans.
223684194|NCT03586518|DIAGNOSTIC_TEST|48-Hour continuous cardiac monitoring|Attach continuous Holter monitor (Schiller, medilog®AR12 plus/AR4 plus/FD5 plus, Baar, Switzerland) that will start before dialysis and terminate just before the subsequent dialysis treatment 48h later.
223684195|NCT03586518|DIAGNOSTIC_TEST|Blood samples|Collect blood samples from the arterial needle before dialysis. Approximately 30 millilitres of blood will be collected and then be pipetted into cryotubes and frozen at -80°C in an electronically monitored freezer for analysis in batches throughout the study. These samples will be used to investigate the relationship between circulating biomarkers of fibrosis, the MRI scans and the histological samples.
223684196|NCT04482478|DIETARY_SUPPLEMENT|Extract of Dolichos lablab Linne (EDL)|Investigational product (EDL): once a day, 2 tablets orally intake (Extract of Dolichos lablab Linne 715 mg/day)
223684197|NCT04482478|OTHER|Placebo oral tablet|Placebo: consumed in the same way as the investigational product
223684198|NCT04733118|DRUG|Trastuzumab and Pertuzumab (FDC SC) and T-DM1|"Patients will receive Trastuzumab and Pertuzumab as a subcutaneous fixed-dose combination (PH FDC SC) (± ET depending on HR status) for 8 3-week cycles, on day 1 only. ET will consist of letrozole for post-menopausal women or tamoxifen ± ovarian function suppression (OFS) for pre-menopausal women administered continuously. Men will receive tamoxifen.~After completing neoadjuvant therapy, a final breast MRI will be performed 2 weeks prior to surgery. Surgery will be performed within 4 weeks after completion of the last cycle of PH FDC SC.~Adjuvant systemic therapy will start within 4 weeks from surgery. There will be three different cohorts depending on pathological report:~* Cohort A: PH FDC SC ± ET for 10 additional 3-week cycles~* Cohort B: T-DM1 ± ET for 10 cycles~* Cohort C: T-DM1 ± ET for 10 cycles, with possibility of physician's choice chemotherapy before adjuvant T-DM1."
223684199|NCT01706692|BIOLOGICAL|Adalimumab|all dosages, frequencies and durations prescribed
223684200|NCT01706692|BIOLOGICAL|Etanercept|all dosages, frequencies and durations prescribed
223684201|NCT01706692|BIOLOGICAL|Infliximab|all dosages, frequencies and durations prescribed
223684202|NCT01706692|BIOLOGICAL|Ustekinumab|all dosages, frequencies and durations prescribed
223684203|NCT01706692|DRUG|Cyclosporine A|all dosages, frequencies and durations prescribed
223684204|NCT01706692|DRUG|Fumaric acids|all dosages, frequencies and durations prescribed
223684205|NCT01706692|DRUG|Methotrexate|all dosages, frequencies and durations prescribed
223684206|NCT01706692|DRUG|Other anti-psoriatic systemic treatments|all dosages, frequencies and durations prescribed
223684207|NCT05806775|BEHAVIORAL|Low-load resistance training with blood flow restriction|A licensed physical therapist, will deliver intervention to all participants (2x/wk, 8 wks) using an FDA-cleared BFR system, the Delfi PTSII (Delfi Medical Innovations). The pressure cuff will be placed at the most proximal portion of the limb and dosed following standard BFR guidelines: 1 set of 30 reps, then 3 sets of 15 reps at 20-30% 1RM with a minimum of 60% and a maximum of 80% limb occlusion pressure. At 60-80% limb occlusion pressure there is diminished venous outflow to induce the necessary metabolic effect while still allowing arterial flow for safety. Individual limb occlusion pressures will be determined at the beginning of each session automatically by the Delfi PTSII device.
223684208|NCT01554696|DRUG|peficitinib|oral
223684209|NCT01554696|DRUG|Placebo|oral
223775021|NCT06572878|OTHER|Combined cognitive and physical training|Combined cognitive and physical training will follow a group format, with each group consisting of 4-16 participants. Each group will be in a private, independent room for their training sessions and will not interact with participants from other groups. The combined cognitive and physical training components will specifically focus on a single cognitive task and simultaneously handle a single physical task.
223775022|NCT06572878|OTHER|Passive information activities|In passive informational activities, which include a variety of puzzles, audiobooks, and diverse reading materials such as newspapers or listening to news content.
223775023|NCT01794949|DEVICE|Resolute Integrity stent|Drug eluting stents used to treat coronary artery blockages
223775024|NCT06561113|OTHER|Caffeine intake|One cup of Turkish coffee contains 60 mg/65 ml (1 Turkish coffee cup) of caffeine. Participants will be instructed to sit for 10 minutes before drinking coffee. To prepare the Turkish coffee, 5 g of ground dry coffee will be mixed in 100 mL of tap water and left to boil in a coffee machine. When the first boil starts, it will be removed from the machine and poured into the cup. Then, 65 ml of Turkish coffee will be given to the subjects to ensure oral caffeine intake.
223775025|NCT00207441|BEHAVIORAL|Arthritis Self management program|
223775026|NCT00207441|BEHAVIORAL|Chronic Disease Self Management Program|
223775027|NCT04193813|OTHER|Observational|Observational study
223775028|NCT06449911|PROCEDURE|HIFU|300 lines and 10,200 dots will be performed to each half lower two-thirds of the face and submental area of every participant.
223775029|NCT05209191|BEHAVIORAL|Student Athlete Wellness Portal|A web-based design that illustrates various opioid misuse and diversion resistance strategies.
223775030|NCT01306136|BEHAVIORAL|Prolonged Exposure|15 psychotherapy sessions focused on helping clients overcome avoidance behaviors and emotionally process trauma-related memories
223775031|NCT01306136|BEHAVIORAL|Usual care|Per usual care, patients are referred to a mental health provider within the health care setting.
223775032|NCT03766646|DEVICE|Optiflow|45l.min oxygen
223684210|NCT01554696|DRUG|methotrexate|oral
223684211|NCT04801225|DEVICE|Non-invasive electromagnetic stimulation for acute stroke treatment|Bilateral electromagnetic stimulation to improve blood flow in ischemic regions of acute stroke as an adjunct to current standard-of-care
223684212|NCT05394129|DIAGNOSTIC_TEST|SurePath™|In the liquid-based cytology, a fine-needle aspirated sample is immediately inserted into a container containing a commercially available preservative solution without a separate slide-smearing procedure and immediately after the fine-needle aspiration.
223684213|NCT06546969|DRUG|Gemcitabine|1000mg/m2 via intravenous infusion on days 1 and 8 of every 21-day cycle for up to 8 cycles. After the 16 weeks of trial participation, participants will continue chemoimmunotherapy per standard of care.
223684214|NCT06546969|DRUG|Cisplatin|25mg/m2 via intravenous infusion on days 1 and 8 of every 21-day cycle for up to 8 cycles. After the 16 weeks of trial participation, participants will continue chemoimmunotherapy per standard of care.
223684215|NCT06546969|DRUG|Durvalumab|1500mg via intravenous infusion on day 1 of every 21-day cycle for up to 8 cycles. After the 16 weeks of trial participation, participants will continue chemoimmunotherapy per standard of care.
223684216|NCT06546969|RADIATION|Spatially Fractionated RT|Administered to 1 measurable lesion on cycle 2-day 1
223684217|NCT06546969|DEVICE|Deep Hyperthermia|Deep hyperthermia alone will be delivered to the same lesion on cycle 3-day 1 and cycle 4-day 1
223684218|NCT05372536|OTHER|parent-led home-administered low-dose Cytarabine|Parents to the included participants are offered to administer the protocolized low-dose bolus (injection) Cytarabine in their children's CVCs at home. The administration procedure is developed as a simple and safe non-touch technique. The parents receive a video and paper-based guideline and information material followed by a 3-step nurse-led education program. The parents can administer the Cytarabine at home when they (and the child/adolescent) feel safe and comfortable managing the procedure and when the nurses are sure that the parents can manage the procedure at home. The first dose of Cytarabine is always administered at the hospital.
223684219|NCT05843396|BEHAVIORAL|Neonatal Massage|caregivers providing therapeutic touch techniques on their neonate
223684220|NCT02397564|DEVICE|Er:YAG laser, traditional and fractional settings|Half the scar will be treated with traditional ablative setting and the other half will be treated with the fractional ablative setting
223684221|NCT06481176|BEHAVIORAL|12-Week RLS Exercise Program|"Participants will complete 12 weeks of an evidence-based exercise program that has been used for people with RLS, designed for people with RLS, and was informed by exercise guidelines outlined by the American College of Sports Medicine (ACSM) and the American Heart Association, and Center for Disease Control.~The program includes three sessions per week for 12 weeks including:~* cardiovascular exercise (e.g., walking/jogging, bicycling) for 30 minutes/day on at least 3 days/week at a moderate-to-vigorous intensity~* strength training on 2 non-consecutive days/week targeting major muscle groups for approximately 30 minutes~* Stretching all major muscle groups on three or more days per week"
223684222|NCT01041495|DRUG|cyclobenzaprine ER (AMRIX)|active drug
223684223|NCT01041495|DRUG|placebo|matching placebo for cyclobenzaprine ER (AMRIX)
223684224|NCT05676593|DEVICE|Freestyle Libre 2|The FSL will be placed on patient for 28 days to measure interstitial glucose
223684225|NCT05676593|OTHER|Therapeutic education|Therapeutic education
223775033|NCT02990663|OTHER|Use of blood pressure lowering medication at bedtime|Blood pressure lowering medications will be switched (one at a time as tolerated) to bedtime, or maintained at bedtime if already taken at that time. All decisions related to which, and how many, medications to switch are at the discretion of the care provider.
223684226|NCT00075439|DRUG|gefitinib|Given orally
223684227|NCT00075439|OTHER|laboratory biomarker analysis|Correlative studies
223684228|NCT03905109|DRUG|ABX464|ABX464 is a new anti-inflammatory drug. In the treatment arm, patients will receive dose A or Dose B of ABX464 orally once daily for 52 weeks.
223684229|NCT03905109|DRUG|Placebo|In the placebo group, patients will receive dose A or B ABX464-matching-placebo orally once daily for 52 weeks.
223684230|NCT01993095|BEHAVIORAL|Home-based, DVD-delivered physical activity|Subjects will be participating in a home-based physical activity program that focuses on flexibility, toning and balance. Exercises will be progressive over the six-months and will highlight modifications for varying levels. This program will be delivered on 3 DVDs. Participants will be asked to exercise with the DVD at least three times per week.
223684231|NCT01993095|BEHAVIORAL|Behavioral: Usual care/Wait list|Participants in this arm will receive a DVD that focuses on healthy aging topics but does not include physical activity. They will receive the FlexToBa DVD after the completion of the 6-month follow-up testing.
223684232|NCT03584373|DRUG|Ketorolac Oral Tablet [Toradol]|Ketorolac is a prescribed NSAID with strong analgesic activity. Ketorolac will be administered post surgery to compare pain outcomes to that of Percocet.
223684233|NCT03584373|DRUG|Acetaminophen|Acetaminophen is an over-the counter pain medication that will be administered post surgery to compare pain outcomes to that of Percocet.
223684234|NCT03584373|DRUG|Oxycodone Acetaminophen|Percocet is a prescribed opioid medication to manage pain. Percocet will be administered post surgery to compare pain outcomes to that of non-opioid analgesia.
223684235|NCT01487577|DRUG|Mycophenolate mofetil|Based on individual pharmacokinetics data, mycophenolate mofetil will be administered by continuous infusion to target a desired AUC exposure
223684236|NCT04618887|PROCEDURE|pallidotomy|deep brain nuclei lesion of GPi
223684237|NCT04618887|PROCEDURE|deep brain stimulation|deep brain stimulation of GPi
223684238|NCT05048082|DRUG|pegsitacianine|An intraoperative nanoparticle-based fluorescence imaging agent comprised of micelles covalently conjugated to indocyanine green (ICG).
223684239|NCT05048082|PROCEDURE|Tumor resection surgery|Standard of care surgical removal of cancerous lung lesion
223684240|NCT03780400|BEHAVIORAL|Osteoarthritis Physical Activity Care Pathway|The intervention includes brief physical activity (PA) counseling delivered via phone by a PA Counselor trained in relevant aspects of PA and motivational interviewing. During the initial call, the PA counselor will assess readiness for change in PA and will utilize appropriate PA counseling components to assess participant's PA preferences/needs, as well as referral to PA resources and goal setting. Approximately two weeks after the initial call, the PA counselor will contact participants to check in on whether they have successfully connected with PA programs or resources discussed, review progress toward PA goals and set new goals. Participants will be provided with linkage to PA programs and resources to include: self-directed, group classes/community, physical therapy and other clinical/supervised programs. Three months after the initial call, the PA counselor will call participants to assess PA and stage of change using appropriate PA counseling components and goal setting.
223684241|NCT03174899|RADIATION|Diffusion weighted magnetic resonance imaging|All MRI examinations will be performed with a 1.5-T scanner (Acheiva, Philips, and Netherland). All MRI scans will be obtained with the following parameters: Repetition time (TR); 1580 MS, echo time (TE); 60 MS, slice thickness; 1-5 mm, receiver bandwidth; 1158 kHz/pixel, field of view (FOV); 40 cm, matrix size; 164 × 159. ADC value of the kidneys will be calculated with Diffusion weighted magnetic resonance imaging gradient b-values of 0 and 1000s/mm2. In the axial ADC map, a region of interest (ROI) will be placed for measurement of ADC values on the renal parenchyma of both kidneys, without any preference for cortex or medulla. Three circular ROIs of size 1 cm2 will be placed-one each at the upper pole, inter-polar region, and lower pole of both kidneys-and 6 total ROIs from bilateral kidneys will be averaged for each patient.
223684242|NCT04782960|DRUG|Iocal anaesthetic bupivacaine|Local anaesthetic Subconjunctival bupivacaine
223684243|NCT04782960|DRUG|Placebo|0.9 saline
224262798|NCT02960295|DEVICE|3-Self-checking of blood pressure|Self-checking of blood pressure at least weekly with sphygmomanometer. Results will be recorded and transmitted in real-time via a Bluetooth connection to a cellphone app installed on study enrollment. Patients with elevated blood pressure will be requested to come to Obstetrics Triage immediately for further assessment.
224262799|NCT02960295|DEVICE|4-Checking fetal heart rate|Patient will record her fetus' heart rate with a Doppler device at least once weekly. The patient will immediately report to Labor and Delivery for any fetal heart rate below 100 beats per minute or greater than 160 beats per minute over a 10 minute observation period.Those reporting a fetal heart rate outside of the normal range will be requested to come to ObstetricTriage for further assessment.
224262800|NCT02960295|PROCEDURE|5-Visits with caregivers|Telephone visits will alternate with in-office visits.Those failing to keep appointments will be contacted and reappointed at a mutually convenient time.
224262801|NCT03165669|DEVICE|"Viscospring PostuRite - medium model"|Cervical pillow use, 30-minutes instruction session supported by a brochure
224262802|NCT03165669|OTHER|Education|30-minutes educational session delivered by a physical therapist and supported by an informative brochure.
224262803|NCT00887419|BEHAVIORAL|Coping Skills Training|Patients meet individually with therapist for 6 sessions to learn coping skills for stress management, behavioral activation, and communication.
224262804|NCT00887419|BEHAVIORAL|Education|Patients meet individually with a health educator for 6 sessions in a presentation/discussion format to receive basic information on the etiology and treatment of chronic pain.
224262805|NCT02462681|DRUG|paravertebral block|Thoracic paravertebral blocks will be performed as described by Moore and Katz. Intradermal lidocaine will be used at the site of the needle insertion. The superior aspect of the spinous processes of T1- T6 will be marked. The skin entry points will 3 cm laterals to the marks. A 22- gauge quincke spinal needle attach to extension tubing to a syringe containing study drugs will be used. The needle will be inserted perpendicular to the skin for a distance of 2 to 4 cm until the transverse process will contact. The needle will be withdrawn and walk cephalad off the transverse process and advance for a further 1.5 to 2 cm.
224262806|NCT06386354|DIAGNOSTIC_TEST|Train-of-four|Patients submitted to general anesthesia with neuromuscular block will be monitored at their arrival to the Post-Anesthesia Care Unit to assess the presence of residual neuromuscular block.
224262807|NCT01098591|OTHER|cell therapy|
224262808|NCT01701323|BIOLOGICAL|Ex-Vivo Expanded Cord Blood Progenitor Cell Infusion|Given IV
224262809|NCT01701323|DRUG|Cytarabine|Given IV
224262810|NCT01701323|DRUG|Filgrastim|Given SC or IV
224262811|NCT01701323|DRUG|Fludarabine Phosphate|Given IV
224262812|NCT03601403|DEVICE|inhaler technique|The first day of the intervention consisted primarily of ventilatory re-education. During the realization of the technique, he was videotaped with a Tablet so that later the patient could be seen and on the video to be able to give him the guidelines for the correction. On the second and third day of the intervention, ventilation re-education was performed and the inhalation technique was subsequently trained.
224262813|NCT00003223|DRUG|fenretinide|200 mg/day PO, days 1-25 q 28 days x 6 cycles.
224262814|NCT04378621|DRUG|TNF-α inhibitor OR JAK inhibitor|Pharmacological anti-rheumatic treatment
224262815|NCT04378621|OTHER|Hand training|Physical hand training 10 min twice daily while on stable treatment
224262816|NCT04554290|DIAGNOSTIC_TEST|temporal artery biopsy|description of temporal artery biopsy features, and its correlation with diagnosis of giant cell arteritis or other differential diagnoses.
224262817|NCT06244043|OTHER|Initial Coaching Call|Participant will receive initial coaching call with a team member. This coaching call will either be interventional (i.e., include content intended to prompt their adherence and benefit from the HMP app) or informational (i.e., include content intended to control for the time and attention of attending a coaching session, but not intended to provide specific benefits).
224262818|NCT06244043|OTHER|Email Support|Email-based support throughout study period
224262819|NCT06244043|OTHER|Text Messages|All participants with receive text messages encouraging them to engage in the practices taught in the app.
224262820|NCT00480038|OTHER|WHODAS II|To determine the measurement characteristics of WHODAS II (World Health Organization Disability Assessment Schedule)
223775034|NCT02990663|OTHER|Use of blood pressure lowering medication in the morning|Blood pressure lowering medications will be switched (one at a time as tolerated) to morning, or maintained in the morning if already taken at that time. All decisions related to which, and how many, medications to switch are at the discretion of the care provider.
224262821|NCT01718873|DRUG|Bevacizumab|5 mg/kg every 2 weeks for up to 24 weeks. After 24 weeks, those patients without disease progression will receive bevacizumab 7.5 mg/kg every 3 weeks until progression of disease or unacceptable toxicity.
223775035|NCT00928317|DRUG|ART621|3.0mg/kg s.c.
224262822|NCT01718873|DRUG|Oxaliplatin|85mg/m2 IV every 2 weeks for up to 24 weeks
224262823|NCT01718873|DRUG|levo-folinic acid|200 mg/m2 IV before 5-fluorouracil infusion, every 2 weeks up to 24 weeks
224262824|NCT01718873|DRUG|5-fluorouracil|400 mg/m2 IV bolus followed by 2400 mg/m2 IV infusion over 46 hours, every 2 weeks for up to 24 weeks (given in mFOLFOX-6 schedule)
224262825|NCT01718873|DRUG|Capecitabine|1000mg/m2 by mouth, twice a day for 10 days, every 2 weeks for up to 24 weeks(given in mOXXEL schedule)
224262826|NCT04682951|PROCEDURE|Decompressive Craniectomy|
224262827|NCT01169753|DRUG|Placebo|Oral tablet every morning for 2 weeks
224262828|NCT01169753|DRUG|Armodafinil|Three 50 mg tablets orally every morning for 2 weeks.
224262829|NCT01440179|DRUG|SAR3419|Pharmaceutical form: concentrate solution for infusion Route of administration: intravenous
224262830|NCT03703154|DRUG|Envarsus|Patients will then be randomized in the ratio of 2:1 with 20 being in the study arm and 10 in the control arm. Envarsus will be prescribed by the transplant team per conversion guidelines. The transplant team will monitor drug levels, per the dosing guidelines.
224262831|NCT03703154|DRUG|Tacrolimus|The patient's physician will prescribe drug according to standard practice.
224262832|NCT00205777|DRUG|Bazedoxifene Acetate|BZA 20mg, daily, oral
224262833|NCT00205777|OTHER|Placebo|Placebo, daily, oral
224262834|NCT00755677|OTHER|Pulses|subjects consume 1 pulse food daily for eight weeks
224262835|NCT00170677|DRUG|Topotecan|Topotecan 4,0 mg/m² administered in day 1, 8 und 15 as i.v. infusion for 30 minutes. A cycle lasts 28 days.
224262836|NCT00170677|DRUG|Topotecan|Topotecan 1,25 mg/m²/day, day 1-5 as i.v. infusion of 30 minutes. Repeat after 21 day.
224262837|NCT01824940|BEHAVIORAL|Standard care|"Standard Care:~* Exclusive breastfeeding promotion for all infants, birth to 6 months~* Strengthened PMTCT (prevention of mother to child transmission of HIV) services~* Strengthened Village Health Worker system"
224262838|NCT01824940|OTHER|WASH|"WASH:~* Standard care interventions~* Provide household ventilated pit latrine, water treatment solution, and monthly liquid soap, two hand-washing facilities and protected infant play space~* Provide interpersonal communication interventions promoting feces disposal in a latrine, HWWS (hand washing with soap), drinking water treatment, hygienic weaning food preparation, and preventing babies from putting dirt and animal feces in their mouths."
224262839|NCT01824940|DIETARY_SUPPLEMENT|Infant and young child feeding|"IYCF:~* Standard care interventions~* Provide 20 g/d Nutributter from 6-18 months~* Provide interpersonal communication interventions promoting optimal use of locally available foods for complementary feeding after 6 months, continued breastfeeding and feeding during illness."
224262840|NCT01824940|OTHER|WASH and Nutrition|"WASH AND IYCF interventions~* Standard care interventions~* All WASH interventions~* All IYCF interventions"
224262841|NCT02588144|PROCEDURE|[standard STN]|High frequency deep brain stimulation with variable (best individual) stimulation on subthalamic contacts
224262842|NCT02588144|PROCEDURE|[STN+SNr]|high frequency deep brain stimulation of combined (best individual) subthalamic and nigral stimulation
224262843|NCT02401906|OTHER|MRI|
224262844|NCT04110236|BEHAVIORAL|PriCARE|PriCARE is a group caregiver training program designed to improve child behaviors, caregiver-child relationships, parenting capacity, and reduce caregiver stress. Sessions occur in the primary care clinic or virtually. PriCARE uses the 3 P skills (Praise, Paraphrase and Point-out-Behavior). The training starts with skills on giving attention to children's positive, pro-social behaviors, while ignoring minor misbehaviors. The second part of the training teaches skills for giving effective commands in order to set age-appropriate limits and increase compliance. PriCARE includes a stress education section that contextualizes the use of these skills with the types of behaviors and problems exhibited by many children living with psychosocial adversity and familial stress. Caregivers are encouraged to practice the skills with their child in between sessions. Since PriCARE's initial and successful pilot, the intervention has been enhanced in order to increase engagement and effectiveness.
224262845|NCT04110236|BEHAVIORAL|Positive Discipline Module|The PriCARE Positive Discipline Module is a pilot group caregiver training program designed to teach caregivers positive discipline techniques, including appropriate timeout procedures. The sessions are offered in the primary care setting or virtually. This training will supplement the content of the main PriCARE intervention and provide caregivers with skills for addressing difficult behaviors not reduced through positive attention and strategic ignoring. This module will be offered to a subset of CHOP participants who were randomized to the intervention arm, successfully completed the main study interviews, and attended at least 4 out of the 6 PriCARE sessions.
224262846|NCT05633862|DRUG|BI 1015550|BI 1015550
224262847|NCT05521360|BEHAVIORAL|Autonomic Modulation Training|AMT is a six week online behavioral intervention comprised of two components. The first component is an adapted (to online format) version of an established and publicly available HRVBF protocol (Lehrer et al, 2013, Biofeedback).The second is the integration of meta-cognitive coping skills and autonomic modulation breathing techniques into the HRVBF protocol (Arpaia \& Andersen, 2019 Frontiers in Psychiatry; Andersen, Arpaia \& Gustafsberg, 2021 Int J Emerg Ment Health and Human Resilience).
224262848|NCT02630797|DIETARY_SUPPLEMENT|Blueberry Baseline|Before the study beginning, eligible participants will receive a radioactive tracer, Ca-41, by iv infusion. A total of 150 days will be required for the equilibration of tracer in the body i.e. elimination from soft tissue and deposition in the bone. After equilibration, a baseline period of 42 days will occur, during which no blueberry products will be provided.
224262849|NCT02630797|DIETARY_SUPPLEMENT|Blueberry Low|One food or beverage product containing freeze-dried blueberry powder equivalent to 0.75 cups of fresh blueberries will be provided daily for 42 days.
223684244|NCT04728672|OTHER|Kinesio Tape|Kinesio Tape
223684245|NCT04728672|OTHER|Micropore Tape|Micropore Tape
223684246|NCT02571400|OTHER|Continued use of opioid analgesics >90 days post-surgery|Exposure of interest: continued use of opioid analgesics \>90 days post-surgery
223684247|NCT03931343|PROCEDURE|Bilateral 20 ml 0.25 % Bupivacaine with 2mg preservative free dexametasone and 5mcg/ml epinephrine injected between multifidus and longissimus muscle with USG guidance|Thoracolumbar interfascial plane block: Bilateral 20 ml 0.25 % Bupivacaine with 2mg preservative free dexametasone and 5mcg/ml epinephrine injected between multifidus and longissimus muscle with USG guidance
223684248|NCT03931343|PROCEDURE|Bilateral 20 ml 0.25 % Bupivacaine with 2mg preservative free dexametasone and 5mcg/ml epinephrine injected between the erector spinae muscles and transverse process with USG guidance|Erector spinae plane block: Bilateral 20 ml 0.25 % Bupivacaine with 2mg preservative free dexametasone and 5mcg/ml epinephrine injected between the erector spinae muscles and transverse process with USG guidance
223684249|NCT02326545|BEHAVIORAL|MindLight|MindLight is a video game that uses neurofeedback as part of game mechanics. Participants play for 5 hours total over 3 weeks. Measures taken pre, post, and 3-month follow-up.
223684250|NCT02326545|BEHAVIORAL|Online CBT|Five sessions of power point slides that cover primary concepts and homework of cognitive behavioral therapy. Adapted for children. Measures taken pre, post, and 3-month follow-up.
223684251|NCT04494022|DIAGNOSTIC_TEST|contrast enhanced ultrasound|Perflubutane enhanced ultrasound for evaluating hepatic tumor
223684252|NCT05998928|DRUG|Fludarabine + Cyclophosphamide + BCMA-GPRC5D CAR-T Cells|"fludarabine 30 mg/m2 and cyclophosphamide 300 mg/m2 both on three consecutive days during D-7 to D-3~BCMA-GPRC5D CAR-T Cells on day 0"
223684253|NCT00336180|BEHAVIORAL|HealthWise South Africa curriculum|18 classroom lessons
223684254|NCT03823378|DRUG|Elsubrutinib|Elsubrutinib capsule will be administered orally.
223684255|NCT03823378|DRUG|Upadacitinib|Upadacitinib tablet will be administered orally.
223684256|NCT03823378|DRUG|Placebo for elsubrutinib|Placebo capsule for elsubrutinib will be administered orally.
223684257|NCT03823378|DRUG|Placebo for upadacitinib|Upadacitinib placebo tablet will be administered orally.
223684258|NCT02337348|OTHER|Optical coherence tomography|Preintervention imaging
223684259|NCT02337348|RADIATION|Coronary angiography|Conventional coronary intervention
223684260|NCT02001025|DEVICE|Absorb scaffold|
223775036|NCT00928317|DRUG|ART621|1.5mg/kg s.c.
224262850|NCT02630797|DIETARY_SUPPLEMENT|Blueberry Medium|Two food or beverage products containing freeze-dried blueberry powder equivalent to 1.5 cups of fresh blueberries will be provided daily for 42 days.
224262851|NCT02630797|DIETARY_SUPPLEMENT|Blueberry High|Four food or beverage products containing freeze-dried blueberry powder equivalent to 3 cups of fresh blueberries will be provided daily for 42 days.
224262852|NCT06394973|DRUG|T4090 0.2%|1 drop in the conjunctival cul-de-sac of each eye once daily at 8:00 PM (±1 hour) from Day 1 to the day before the End of treatment visit (Visit #5 - Week 7).
224262853|NCT06394973|DRUG|T4090 0.3%|1 drop in the conjunctival cul-de-sac of each eye once daily at 8:00 PM (±1 hour) from Day 1 to the day before the End of treatment visit (Visit #5 - Week 7).
223684261|NCT02001025|DEVICE|Xience stent|
223684262|NCT04163822|OTHER|no intervention|no intervention, only observation
223684263|NCT00058539|DRUG|rhuMAb 2C4 (pertuzumab)|
223684264|NCT05976438|DRUG|Amlodipine|Amlodipine 5mg and Amlodipine 10mg will be one of the study drugs the patients will receive.
223684265|NCT05976438|DRUG|Chlortalidone|Chlortalidone 25mg will be one of the study drugs the patients will receive.
223684266|NCT04385927|BEHAVIORAL|e-Net for Parents of Neurodiverse Children|One-on-one distance coached intervention; approx. 12 sessions at 60-90 minutes.
223684267|NCT02963831|BIOLOGICAL|ONCOS-102|ONCOS-102 was administered by intraperitoneal infusion at weekly intervals for 6 weeks.
223684268|NCT02963831|DRUG|Durvalumab|Durvalumab was administered by IV infusion once every four weeks for a total of 10 (Cohort A) or 12 four-week cycles.
223684269|NCT02963831|DRUG|Cyclophosphamide|A bolus dose of 300 mg cyclophosphamide (CPO) was administered IV 1 to 3 days before the first infusion of ONCOS-102.
223684270|NCT05036720|BEHAVIORAL|LTP+Dads|"LTP+Dads is a 12 - session group integrated parenting intervention which includes a pictorial calendar, consisting of stages of child development from birth to 3 years. It includes parent-child play and other activities that promote parental involvement, learning, and attachment.~The second component of the intervention is Cognitive Behaviour Therapy (CBT) adapted from the Jeanne Miranda manual (Group CBT for Depression) focusing on three areas: thoughts and your mood, activities and your mood, people interaction and your mood.~The third component of intervention is content taken from Ed Bader's manual (Focus on Fathers) includes importance of fathers in child development, stress management at work and home, budgeting, anger management, conflict resolution and time management."
223684271|NCT05036720|BEHAVIORAL|LTP+ Optional mother component|LTP+ is comprised of two components; Learning through play (LTP) and Cognitive Behavior Therapy (CBT). The LTP+ is a low-literacy, sustainable program intended to provide parents with information on the healthy growth and development of their young children. The LTP research-based activities enhance children's development while simultaneously promoting attachment security through building parents' ability to read and be sensitive to their children's cues and through active involvement in their children's development. Plus the Thinking Healthy Program (THP) which adopts 'here and now' problem-solving approach. THP uses cognitive behavior therapy (CBT) techniques of active listening, changing negative thinking, and collaboration with the family.
223684272|NCT01943708|DEVICE|SPAP|Novel Auto-algorithm for Auto-CPAP device
223684273|NCT01943708|DEVICE|CPAP|Standard CPAP therapy
223775037|NCT00928317|DRUG|ART621|0.75mg/kg s.c.
223775038|NCT00928317|DRUG|Placebo|Placebo s.c.
223775039|NCT00828646|DRUG|BMS-708163|Capsules, Oral, 50 mg, once daily, 14 days
223775040|NCT00828646|DRUG|BMS-708163|Capsules, Oral, 100 mg/day, once daily, 14 days
223775041|NCT00828646|DRUG|BMS-708163|Capsules, Oral, 75 or 100 mg/day, once daily, 14 days
223775042|NCT00828646|DRUG|Placebo|Capsules, Oral, once daily, 14 days
223775043|NCT01037309|DRUG|PRO044 SC|Subcutaneous injection, once a week, for five weeks
223684274|NCT04224883|PROCEDURE|Continuously feeding|Daily amount of feeding were continuously pumped for 24 hours. EN preparation pumping scheme was as follows: The initial pumping speed was average pumping volume of total enteral nutrition in one day, and gastric residual volumes is checked every 4 hours. If it is not tolerable, the speed of the pumping is reduced by half on the original speed. GRV\<200mL were considered markers of good tolerance.Feeding intolerance was defined as GRV\>200 mL. If GRV\>500mL, EN was stopped and reassessed after 4 hours.
223684275|NCT04224883|PROCEDURE|16-hours feeding|Daily amount of feeding were continuously pumped for 16 hours.EN preparation pumping scheme was as follows: The initial pumping speed was average pumping volume of total enteral nutrition in one day, and gastric residual volumes is checked every 4 hours.If it is not tolerable, the speed of the pumping is reduced by half on the original speed. GRV\<200 mL were considered markers of good tolerance. Feeding intolerance was defined as GRV\>200 mL. If GRV\>500mL, EN was stopped and reassessed after 4 hours.
223684276|NCT04224883|PROCEDURE|intermittent feeding|Daily amount of feeding were divided into four meals, each meal are pumped within 60mins or 120mins through stomach tube. EN preparation pumping scheme was as follows: If the volume of each meal is less than or equal to 250ml(≤250ml), pump in within 60min, if volume is greater than 250ml(\>250ml), pump in within 120min and gastric residual volumes is checked before each intermittent feeding. If it can be tolerated, the velocity of the pumping can be increased by half of the original speed.If it is not tolerable, the speed of the pumping is reduced by half on the original speed. GRV\<200 mL were considered markers of good tolerance. Feeding intolerance was defined as GRV\>200 mL. If GRV\>500mL, EN was stopped and reassessed after 4 hours.
223684277|NCT03977454|PROCEDURE|Nerve Block|"Nerve blocks (QLB/LFCNB) to be placed preoperatively with DEX/MPA, per standard of care of anesthesia block service.~1. QLB: 40ml 0.2% ropivacaine with 5 mg DEX/ 40 mg MPA~2. LFCNB: 20ml 0.2% ropivacaine with 5 mg DEX/ 40 mg MPA"
223684278|NCT03977454|PROCEDURE|Periarticular Injection (PAI)|"Intraoperatively, the surgeon will perform PAI per standard of care with the medications:~1\. 60 ml 0.2% ropivacaine and 10 mg DEX/ 80 mg MPA"
223684279|NCT03977454|DRUG|Ropivacaine|60 ml 0.2% ropivacaine
223684280|NCT03977454|DRUG|Dex|10 mg DEX/ 80 mg MPA
223684281|NCT05584371|DIETARY_SUPPLEMENT|Free Beta-hydroxybutyrate|Participants will be asked to ingest 10 grams of beta-hydroxybutyrate, diluted in water and sweetened with Stevia, every morning between 9:00 and 11:00 for four weeks.
223684282|NCT00477581|DRUG|exenatide|subcutaneous injection (5mcg or 10mcg), twice a day
223684283|NCT00477581|DRUG|sitagliptin|oral administration (100mg), once a day in the morning
223684284|NCT06143111|DEVICE|Flotrac Group|Haemodynamic parameters were collected simultaneously by the Flotrac monitoring.
223684285|NCT06143111|DEVICE|BioZ Group|Haemodynamic parameters were collected simultaneously by the thoracic bioimpedance (BioZ.com™)monitoring.
223684286|NCT04365257|DRUG|Prazosin|Participants in this arm will receive the study drug as outlined in the arm description.
223684287|NCT04365257|OTHER|Standard of care|Participants in this arm will receive standard of care.
224262854|NCT06394973|DRUG|Rhopressa®|1 drop in the conjunctival cul-de-sac of each eye once daily at 8:00 PM (±1 hour) from Day 1 to the day before the End of treatment visit (Visit #5 - Week 7).
224262855|NCT03142152|DEVICE|Carillon Mitral Contour System|The Carillon implant is designed to be deployed, tensioned, and locked in the coronary vein in order to reshape the mitral annulus and thus reduce mitral annular dilation and mitral regurgitation.
224262856|NCT03142152|OTHER|Guideline Directed Heart Failure Medication|Heart failure medication per ACC/AHA guidelines
224262857|NCT06307639|DIAGNOSTIC_TEST|Measurement of PGK2 and ACRV1 levels in the semen of infertile males undergoing testicular sperm extraction (TESE).|Measurement of PGK2 and ACRV1 levels in the semen of infertile males undergoing testicular sperm extraction (TESE).
224262858|NCT03334058|DRUG|ARGX-113|human IgG1-derived Fc fragment that binds to human neonatal Fc receptor (FcRn)
224262859|NCT00318188|PROCEDURE|standardized reeducation and readaptation program|
224262860|NCT00194363|BEHAVIORAL|Strength training|13 weeks of supervised strength training (twice weekly for 90 minutes per session), 39 weeks of unsupervised strength training (twice weekly for 90 minutes per session)
224262861|NCT00174551|DRUG|prazosin|
224262862|NCT01103843|DRUG|Loading Dose Arm|Subjects who are thienopyridine naive will be randomized 1:1 to either clopidogrel 600 mg or prasugrel 60 mg loading dose at the time of PCI. A Verify Now P2Y12 platelet assay will measure platelet reactivity. Cross over to loading dose and maintenance dose of alternate medication will occur based on level of platelet reactivity.
224262863|NCT01103843|DRUG|Maintenance Dose Arm|Verify Now P2Y12 platelet assay will measure platelet reactivity. Cross over to a loading dose and maintenance dose of alternate medication will occur based on level of platelet reactivity.
224262864|NCT05485662|OTHER|Hydroxyapatite toothpaste|10% Hydroxyapatite toothpaste
224262865|NCT05485662|OTHER|Sodium Fluoride Toothpaste|1450 parts per million sodium fluoride toothpaste
224262866|NCT01539564|DRUG|Minocycline HCl Microspheres|
224262867|NCT00343213|PROCEDURE|colposcopy|
224262868|NCT03552003|OTHER|Treatment for clinical practise|Prospective data collection with the aim to to develop a prognostic index for elderly patients with newly diagnosed cHL
224262869|NCT06102148|OTHER|PNF Group|Exercise training and PNF training
224262870|NCT06102148|OTHER|Control Group|Exercise training
224262871|NCT04423380|DRUG|SH3051 capsule treatment|Starting dose 20mg,oral administered twice daily.If tolerated subsequent cohorts will test increasing doses (40mg,60mg,80mg,100mg) of SH3051.
224262872|NCT04828616|DRUG|DP303c injection|DP303c injection, every 3 weeks (Q3W)
224262873|NCT00367133|PROCEDURE|Standard of Care Group|Standard of care group: conventional treatment consisting of focal/grid photocoagulation.
224262874|NCT00367133|DRUG|1mg triamcinolone acetonide|Intravitreal injection of 1mg of triamcinolone acetonide at baseline. At each 4-month interval visit, the investigator will assess whether persistent or recurrent DME is present that warrants retreatment with the randomization assigned treatment. Retreatment, when indicated, will be performed within four weeks after the follow-up visit. Retreatment should not be performed sooner than 3.5 months from the time of the last treatment.
223684288|NCT03452527|BIOLOGICAL|ICON-1|ICON-1 0.6 mg by intravitreal injection
223684289|NCT03452527|BIOLOGICAL|aflibercept|aflibercept 2 mg by intravitreal injection
223684290|NCT05084729|DEVICE|Imagio OA/US|Imagio optoacoustic
223684291|NCT06329843|DEVICE|Picterus Jaundice Pro (JP)|"Picterus Jaundice Pro photos will be obtained of enrolled subjects each time the patient has a serum bilirubin level obtained. Up to five paired measurements will be obtained per enrolled subject. The study nurse will place the proprietary calibration card over the subject's sternum and take six Picterus Jaundice Pro photos using a study iPhone within one hour of the serum bilirubin draw. This process takes less than one minute. After the study photos are obtained, the study nurse will record the serum and Picterus Jaundice Pro values in the data-recording log.~In the event an enrolled infant requires phototherapy, a light occlusive adhesive patch will be placed over the center of the chest before phototherapy initiation. When a serum bilirubin level is obtained, the research nurse will remove the patch for a brief moment to take Picterus Jaundice Pro pictures (within one hour of the serum value draw)."
223684292|NCT05155462|OTHER|One or two phone call|Phone call to collect patient data
223684293|NCT03255330|DRUG|Gabapentin|Gabapentin will be given approximately 3 months until no chronic neuropathic pain is present
223684294|NCT03255330|DRUG|Metamizol|Standardized treatment
223684295|NCT03255330|DRUG|Tramadol|Standardized treatment
223684296|NCT01782001|DIETARY_SUPPLEMENT|vitamin A|vitamin A with placebo
223775044|NCT01037309|DRUG|PRO044 IV|Intravenous injection, once a week, for five weeks
223775045|NCT05673694|DRUG|EG017|According to the dosage group of the program, once a day.
223775046|NCT00191321|DRUG|Teriparatide|
223775047|NCT01788540|DRUG|Intralipid|IV infusion of intralipid 20% is administrated on the day of vaginal egg collection in a dose of 9 mg/ml total blood volume corresponding to intralipid 2 ml 20% diluted in 250 ml saline over 30-60 minutes.the intralipid infusion is then repeated within the 1st week of positive pregnancy test and every 2 weeks till end of first trimester
223775048|NCT03185624|DRUG|Rifaximin|Antibiotics
223775049|NCT00268125|DEVICE|Acupression's bracelet|
223775050|NCT00268125|BEHAVIORAL|Hygiene and dietetic advices|
223775051|NCT01850199|OTHER|Smart telemedicine remote monitoring for gestational diabetes|Intervention consists of a telemedicine platform which includes artificial intelligence tools to analyse glucose values and guarantee an optimal glucose control from the diagnosis of gestational diabetes to delivery.
223775052|NCT01850199|OTHER|Usual management|Usual care will be provided, including face-to-face visits
223775053|NCT01284647|DRUG|Teprenone capsule and placebo of sucralfate|Teprenone 1 capsule (50mg)+placebo of sucralfate 4tab, tid×8 weeks.
223775054|NCT01284647|DRUG|Sucralfate and placebo of teprenone|Placebo of teprenone 1 capsule+ sucralfate 4 tab(1.0), tid×8 weeks
223775055|NCT03983590|OTHER|Visual Analogic Scale|VAS are collected in the first 24 hours after inclusion, 15 minutes, during and 15 minutes after the bed bath. Each time of collection are noted.
223775056|NCT04777279|BEHAVIORAL|individual physical exercise group|The participants in physical exercise group will receiving individual physical exercise lead by physiological therapist for 60 minutes/ three times weekly for 12 weeks.
223775057|NCT04777279|DIETARY_SUPPLEMENT|individual Branched-Chain Amino Acids supplements group|The participants in nutrition supplements group will receiving Branched-Chain Amino Acids 5 g Branched-Chain Amino Acids every day for 12 weeks.
223775058|NCT04777279|OTHER|combination of physical exercise and nutrition supplements group|The participants in physical exercise group will receiving physical exercise lead by physiological therapist for 60 minutes/ three times weekly for 12 weeks and 5 g Branched-Chain Amino Acids every day for 12 weeks.
223775059|NCT03264625|DRUG|Cholecalciferol (2000iu qd)|Patients will receive oral Cholecalciferol (2000IU qd) apart from routine therapy for PD
223775060|NCT03264625|OTHER|Routine therapy for PD|Patients randomized to the placebo group will receive routine therapy for PD.
223775061|NCT04713748|DEVICE|Tasso-SST on Demand|Participants will collect a small blood sample using the Tasso-SST OnDemand device during a serology blood draw visit already scheduled for the MURDOCK C3PI Study (Pro00105703). Participants will be provided a kit that includes written, step-by-step instructions that include pictures. Participants will also have the option to watch a brief video on using the device, available online, prior to collection. Both blood samples will be spun and processed for serum. Serum will be frozen and shipped to the lab at Duke for antibody testing. Antibody results will be compared between the two methods.
223775062|NCT04713748|OTHER|Regular Phlebotomy|Participants will have a small blood sample collected via regular venipuncture.
223775063|NCT00698958|PROCEDURE|Ambulatory adaptation to non- invasive mechanical ventilation for 7 days|Ambulatory adaptation to non- invasive mechanical ventilation for 7 days
223775064|NCT00698958|PROCEDURE|Hospital based adaptation to non- invasive mechanical ventilation for 7 days|Hospital based adaptation to non- invasive mechanical ventilation for 7 days
223775065|NCT04436094|PROCEDURE|Orthodontic extrusion|"An orthodontic attachment will be bonded to the core of the experimental tooth. Orthodontic brackets American Orthodontics Roth prescription. 0.022 slot will be bonded to the adjacent teeth. A passive rectangular stainless steel wire (0.016X0.022) will be inserted in the adjacent teeth with a step down and a coil at the site of the experimental tooth.~Orthodontic extrusion will start using a light overlay wire of 0.012 NiTi and then continued by elastic chains/ threads extending between the attachment on the tooth and the stabilizing wire. The patient is followed up for appliance activation every 3-4 weeks and extrusion is performed until an adequate ferrule effect of 2 mm is present all around the tooth circumference (in addition to the biologic width). So the extrusion is completed when the tooth is 4-4.5 mm from the alveolar bone crest as judged by periapical radiographs."
223684297|NCT01782001|DIETARY_SUPPLEMENT|vitamin A and zinc|combination of vitamin A and zinc supplements
223684298|NCT04200040|BIOLOGICAL|OrienX010 injection|"OrienX010 to be used in this study have been developed and manufactured by OrienGene Biotechnology Ltd.~Dacarbazine to be used in this study was manufactured by Sinopharm A-Think Pharmaceutical Co., Ltd."
223684299|NCT04200040|DRUG|Dacarbazine (DTIC)|Dacarbazine to be used in this study was manufactured by Sinopharm A-Think Pharmaceutical Co., Ltd.
223684300|NCT01686802|DRUG|oral morphine|
223684301|NCT01686802|DRUG|Ibuprofen|
223775066|NCT04436094|PROCEDURE|Immediate implant placement|The patient is anaesthetized. Atraumatic extraction of the badly broken down teeth will be performed using peroiotome. Luxation should be done mesiodistally and not buccolingually, to avoid damaging the buccal plate. After tooth removal, a curette is used to confirm that the location of the buccal plate is intact. Standard drilling procedures are performed according to the manufacturer's instructions. Then the implant is placed in the prepared site. Temporization should be done using composite 3M Filtek Z250 XT material. Finally, a porcelain fused to zirconia crown will be performed.
223775067|NCT02358746|OTHER|combined endo/epicardial approach|
223775068|NCT02358746|OTHER|stepwise approach|endocardial scar homogenization only at the first VT ablation procedure
223775069|NCT01727531|DRUG|Chloroquine diphosphate|250 mg chloroquine once a day by mouth beginning one week prior to beginning radiation therapy and continue for a total of five weeks
223775070|NCT03428516|DEVICE|Fixed CPAP|CPAP is a device that applies continous fixed positive pressure to the airways in order to keep them opened during sleep
223775071|NCT03428516|DEVICE|Auto-adjusting CPAP|Auto-adjusting CPAP is a device that applies auto-adjusting continous positive pressure to the airways in order to keep them opened during sleep
223775072|NCT05569785|OTHER|Resistance Exercise Therapy|"4 weeks of Resistance Exercise Therapy. This is a 4 week resistance exercise training programme that can be completed at home. The programme is designed to be progressive. It was designed by a bariatric physiotherapist and an exercise physiologist. This exercise programme will be discussed at the screening visit, educational material will be provided to the participants who are randomised to the intervention RET group.~Safety advice will be given to each eligible participant to ensure that if they feel unwell, develop chest pain/tightness, then they must seek advice from GP/urgent care if necessary. The exercises will need to be performed at least three times a week. Compliance will be monitored with Fitbit downloads at each visit. Fitbits will be worn during exercise sessions only."
223775073|NCT01166984|DRUG|AB103|Single intravenous infusion at doses of 7.5 µg/kg, 37.5 µg/kg, 150 µg/kg, or 450 µg/kg administered over approximately 10 minutes
223684302|NCT02129777|DRUG|Namilumab|Namilumab subcutaneous injection
223684303|NCT02129777|DRUG|Placebo|Placebo subcutaneous injection
223684304|NCT01537107|DRUG|vismodegib|Given PO
223684305|NCT01537107|DRUG|sirolimus|Given PO
223684306|NCT01537107|PROCEDURE|positron emission tomography|Correlative studies
223684307|NCT01537107|PROCEDURE|computed tomography|Correlative studies
223684308|NCT01537107|OTHER|pharmacological study|Correlative studies
223684309|NCT01537107|OTHER|laboratory biomarker analysis|Correlative studies
223684310|NCT01537107|RADIATION|fludeoxyglucose F 18|Correlative studies
223684311|NCT04195737|PROCEDURE|Ossix volumax collagen matrix|Under LA horizontal incision is made.Split-full-split thickness flap is elevated.The remaining soft tissue of the anatomic interdental papillae deepithelialized.Coronal advancement of the flap obtained and closed using sling suture.
223684312|NCT04195737|PROCEDURE|Connective Tissue Graft|Under LA parallel incisions is made 1-2 mm first molar to canine.Graft incision 1 mm coronal to the horizontal flap incision.Through this incision designed graft thickness is obtained.The graft obtained between the two horizontal incisions has a 1 mm coronal strip that require depithelisation with a knife and closed using interrupted suture.
223775074|NCT01166984|DRUG|Placebo|Single intravenous infusion of normal saline (0.9% sodium chloride) administered over approximately 10 minutes
223775075|NCT02658851|DEVICE|J-Plasma|Bovie Medical Corporation's J-Plasma® helium based plasma technology is a hemostatic tool for the cutting, coagulation, and ablation of soft tissue.
223775076|NCT03032926|BEHAVIORAL|Open Trial|Behavioral Intervention
223775077|NCT06271096|DRUG|Intra muscular Midazolam|ROUTE OF ADMINISTRATION AND DRUG EFFICACY COMPARED
223684313|NCT01001299|DRUG|Drug cocktail|Drug cocktail (caffeine, warfarin + vitamin K, omeprazole, dextromethorphan, midazolam) orally once daily, day 1 and day 20
223684314|NCT01001299|DRUG|RO5185426|960 mg orally twice daily
223775078|NCT06271096|DRUG|Intravascular Diazepam|ROUTE OF ADMINISTRATION AND DRUG EFFICACY COMPARED
223775079|NCT03480555|DIETARY_SUPPLEMENT|Replenish Protein|Subjects randomized to this group will receive 2 g of protein/kg/day (acceptable range as 1.8 - 2.2 g of protein/kg/day) for day 6-14.
223775080|NCT03480555|DIETARY_SUPPLEMENT|Standard protein|Subjects randomized to this group will receive 0.8 - 1 g of protein/kg/day for day 6-14
223775081|NCT01601834|DRUG|PF-06273340 or Placebo|PF-06273340 will be administered as an extemporaneously prepared solution for all doses. Correspondingly, placebo doses will be administered as solution.
223684315|NCT02585128|OTHER|Delirium assessment|During the first post-procedural five days all patients will be evaluated on a daily basis for delirium occurrence by the CAM (Confusion Assessment Method) or CAM - ICU (Confusion Assessment Method - Intensive Care Unit)
223684316|NCT02585128|OTHER|MMSE (Mini Mental State Examination)|
223684317|NCT02585128|OTHER|Barthel index|
223684318|NCT02585128|OTHER|HADS (Hospital Anxiety and Depression Scale)|
223684319|NCT02585128|OTHER|MNA-SF (Mini Nutritional Assessment - Short Form)|
223684320|NCT02585128|DEVICE|NIRS (Near-Infrared Spectroscopy)|Regional cerebral oxygen saturation monitoring during TAVI procedure
223684321|NCT02585128|OTHER|CIRS (Cumulative Illness Rating Scale)|
223684322|NCT01784627|BEHAVIORAL|c-ASBI|Participants in the c-ASBI group will complete a computerized screen for alcohol, cannabis, tobacco and other drugs, then view their screen score and 10 pages of information about the health effects of substance use and true-life stories on the computer. Their provider will see a report of their screen results and provide advice to stop or decrease their use, or, for those at high risk, referral to complete a computerized motivational enhancement therapy intervention.
223684323|NCT01565499|DRUG|Nab-paclitaxel|
223684324|NCT05628688|DIAGNOSTIC_TEST|Insight Pro Device for Diagnosis|Insight Pro Device for Diagnosis of Lymphatic and Venous Disorders
223684325|NCT00006367|BIOLOGICAL|filgrastim|
223684326|NCT00006367|DRUG|busulfan|
223684327|NCT00006367|DRUG|cytarabine|
223684328|NCT00006367|DRUG|idarubicin|
223684329|NCT00006367|PROCEDURE|peripheral blood stem cell transplantation|
223684330|NCT03348787|BEHAVIORAL|Behavioral and Cognitive Therapies|"Group intervention of 6 weekly sessions of one hour and 30 minutes based on the psychoeducational therapeutic principles and CBT type 3 wave Accept Voices applied to HAV"
223684331|NCT00260078|DRUG|Atazanavir|200 mg to 400 mg orally daily
223684332|NCT00260078|DRUG|Darunavir|300 mg or 600 mg orally twice daily
223684333|NCT00260078|DRUG|Efavirenz|Dosage dependent on participant
223684334|NCT00260078|DRUG|Nevirapine|Dosage dependent on participant
223684335|NCT00260078|DRUG|Ritonavir|50 mg or 100 mg orally twice daily
223684336|NCT00260078|DRUG|Tenofovir disoproxil fumarate|300 mg orally daily
223684337|NCT00260078|PROCEDURE|Pharmacokinetic Study|Intensive PK study will occur at least once. This will require a 24-hour inpatient visit.
223684338|NCT05110547|BIOLOGICAL|blood collection|2 additional 5ml EDTA tubes, with assays for the following markers: 24S and 27 hydroxycholesterol (gas chromatography-mass spectrometry, GC-MS), Neurofilaments (SIMOA), oxydative phosphorylation (OXPHOS) and quantitative measurement of intracellular ATP (ELISA), Very long chain fatty acids (GC-MS), Octanoyl CoA (HPLC), Uric acid, MDA assay (TBAR assay kit), and Lipid panel.
223684339|NCT03116347|BIOLOGICAL|HYQVIA|Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase (IGI, 10% with rHuPH20)
223684340|NCT03116347|BIOLOGICAL|KIOVIG|100 mg/ml solution for Immune Globulin Intravenous Infusion
223684341|NCT03116347|BIOLOGICAL|Cuvitru|200 mg/ml solution for Immune Globulin Subcutaneous Injection
223684342|NCT04738929|OTHER|Extra virgin coconut oil or extra virgin olive oil|"Subjects consumed standard breakfast meals containing extra virgin coconut oil or extra virgin olive oil"
223684343|NCT06222359|DEVICE|COMPASS|Digital CBT to treat psychological distress in Multiple Sclerosis (MS)
223684344|NCT05644847|OTHER|Whole Body Vibration Training|WBV training will be performed on a commercial vibrating platform (Healthmate HM01-08VF Gym Fitness Equipment Step Vibration Machine, China), which produces vertical sinusoidal vibrations. Participants in the dynamic WBV group will be provided with dynamic exercises along with WBV training. The vibration speed level will be progressed from level 5 to level 10 during the course of the treatment sessions
223684345|NCT05644847|PROCEDURE|Core Stability Training|Core stability exercises will include pelvic bridge, straight leg bridge, modified kneeling with elbow support and leg lifts and squats, with 60 seconds rest interval between each activity. All these core exercises will be performed on a stable surface and will be progressed in difficulty by increasing the no. of repetitions and no. of sets on a weekly basis. Every session will be preceded by 5 minutes of warm-up and end with 5 minutes of cool-down exercises.
223684346|NCT04679545|DRUG|CBD|A water-soluble sublingual tablet containing 20 mg of CBD.
223684347|NCT04679545|DRUG|Placebo|An inactive compound.
223684348|NCT04443751|DRUG|SHR-1702|SHR-1702 monotherapy, administered IV
223684349|NCT01255787|DRUG|Vortioxetine|Vortioxetine tablets
223684350|NCT01255787|DRUG|Placebo|Vortioxetine placebo-matching tablets
223684351|NCT01866553|DRUG|Nilotinib|300 mg capsule BID oral use
223684352|NCT01866553|DRUG|Pegylated interferon α-2b|25 - 40 microgram per week for subcutaneous use
223684353|NCT03085277|DIETARY_SUPPLEMENT|Bovine Colostrum|Bovine colostrum (BC) is the first milk from cows after birth and we suggest that BC may be used to supplement MM, instead of infant formula or DM. BC is a rich source of protein (up to 150 g/L) and bioactive components, including lactoferrin, lysozyme, lactoperoxidase, immunoglobulins, and various growth factors, such as, IGF-I and -II, EGFs, and TGF-β. BC has repeatedly been shown to have beneficial effects in a well-established piglet model of preterm infants, using various feeding regimens, including a gradual regimen that would mimic enteral feeding for preterm infants without access to MM during the first week.
223684354|NCT03085277|DIETARY_SUPPLEMENT|Preterm Formula|Preterm formula is a type of infant formula designed for preterm infants. It is used when mother's own milk is not available or not in sufficient amount as the enteral feeding for preterm infants in hospitals that do not have donor human milk.
223684355|NCT00476047|COMBINATION_PRODUCT|Tositumomab and Iodine I 131 Tositumomab|Give IV
223684356|NCT02355600|OTHER|Oocyte retrieval|Tamoxifen given at a fixed dose for invasive breast cancer adjuvant hormonotherapy or for breast cancer prophylaxis.
223684357|NCT03170232|DRUG|Danirixin 35 mg tablets|Danirixin 35 mg (as hydrobromide hemihydrate salt) is a white film coated oval shaped tablet. It will be provided in a labeled high-density polyethylene (HDPE) bottle with desiccant.
223684358|NCT03170232|DRUG|Placebo|Placebo is a white film coated oval shaped tablet. It will be provided in a labeled HDPE bottle with desiccant.
223684359|NCT03170232|DEVICE|Metered dose inhaler (MDI) sensor device|MDI sensor devices will be fitted onto rescue medication MDI devices to electronically record rescue medication usage.
223684360|NCT03170232|DRUG|Rescue medication|Subjects may continue to use rescue medication(s) via their usual route. Allowed medications are: short acting beta agonists (SABA) (e.g., albuterol/salbutamol); short acting muscarinic antagonists (SAMA) (e.g., ipratropium); short acting combination (SABA/SAMA) bronchodilators, (e.g. Duoneb, Combivent)
223684361|NCT06028100|PROCEDURE|sacral erector spinae plane block|espb from bilateral sacral level 2 with 20 ml %0,25 bupivacaine
223775082|NCT01601834|DRUG|PF-06273340 or Placebo|PF-06273340 will be administered as an extemporaneously prepared solution for all doses. Correspondingly, placebo doses will be administered as solution.
223775083|NCT02681926|PROCEDURE|VISITAG|Paroxysmal atrial Fibrillation (PAF) ablation with contact force technology
223684362|NCT03249493|OTHER|Blood sample on DBS|"We will take 5 mL of whole blood at ART initiation, 6, 12 and 24 months of follow up after ART initiation. Blood will be transferred on DBS cards.~HIV Viral Load measurements will be done and HIV Drug Resistance measurements will be performed in case of 2 consecutive VL results \> 1000 cp/mL"
223684363|NCT02730897|PROCEDURE|Central/Peripheral|Central versus peripheral location of the primary tumor
223775084|NCT05933837|DIAGNOSTIC_TEST|Troponin I|Measurements of plasma Troponin I 6-12 hours and on the first four postoperative days after surgery.
223775085|NCT05574348|OTHER|Osteopathic Protocol in 2 Sessions (PO2S)|"PO2S works on the principle that there is a concordance between the author's Preferential Torsion Pattern (PTP) and the rotatory direction of osteopathic dysfunctions.~The PO2S consists of two sessions of 30 minutes each, one week apart. A 13-item clinical examination is performed at the first session. It focuses on caused pain tests, and classifies patients in left or right PTP. During the first session 14 normalizations of joint, muscular, ligament and visceral dysfunctions are performed systematically. During the second session 10 normalizations of joint, muscular, ligament and visceral dysfunctions are performed .~PO2S is an innovative osteopathic protocol for back pain."
223684364|NCT03381157|OTHER|Observational General Movements Assessments|GMs assessment has been increasingly used to predict motor dysfunction, especially the Cerebral Palsy (SP), since its introduction 25 years ago. The GMs assessment is based on the visual holistic perception of normal and abnormal movements of the body. This approach focuses on spontaneous movements of the baby rather than reflexes, tonus, and reactions
223684365|NCT02931266|DEVICE|PASS MIS®|Posterior mini-invasive osteosynthesis
223684366|NCT03498001|DRUG|GLP-1 agonists|Liraglutide: 6 mg/ml Semaglutide: 1.34 mg/ml Dulaglutide: de 0.75 mg ou 1.5 mg
223684367|NCT03498001|PROCEDURE|Cardiac MRI|T3 myocardial MRI (total acquisition time : 1h) performed before initiation of treatment and measuring the concentration of intramyocardial triglycerides (\[TG\] by NMR spectroscopy, parameters of cardiac morphology (myocardial mass, (epicardial fat surface, pericardial fat surface), function (LVEF, SV, TDV, PFR, TPFR) and tissue parameters (extracellular volume, left myocardial fibrosis volume).
223684368|NCT03498001|OTHER|Follow up by phone|at 2 and 4 mois
223684369|NCT00586326|DEVICE|MammoSite Radiation Therapy System|The MammoSite is a balloon catheter that is designed to position a radioactive source inside the lumpectomy cavity. The MammoSite applicator is inserted into the cavity created by the tumor removal surgery. The MammoSite applicator is then inflated and expands to fill the cavity.
223684370|NCT02968589|BEHAVIORAL|Training|
223684371|NCT03549403|BEHAVIORAL|Patient-centered telephone education|The intervention will be carried out in accordance with the guidelines and the contents of the patient-centered telephone education intervention in the same way with every patient. The education call duration is approximately 15 to 30 minutes.
223684372|NCT02122731|DRUG|Amiloride|5 mg(daily of amiloride was added to patients triple antihypertensive therapy and increased to 10 mg/daily if office blood pressure at 4 weeks was above 130/80 mmHg.
223775086|NCT05440682|PROCEDURE|CP group|Pre- post-cranioplasty and 6 months follow-up MRI assessment. Each MRI session lasts about 60 minutes and will measure Diffusion Tensor Imaging, Tractography and resting state fMRI.
223684373|NCT06111391|DEVICE|Osstell® device (Integration Diagnostics Ltd.).|After trans-mucosal abutments were removed and the smart pegs were attached to the fixtures, resonance frequency analysis was done to assess implant stability.The implant stability quotient (ISQ) was used to quantify stability via the Osstell® device (Integration Diagnostics Ltd.).
223684374|NCT02054871|PROCEDURE|RIPC|A standard, CE-approved tourniquet cuff will be placed around one arm of the patient. It will then be inflated to a pressure of 200mmHg for 5 minutes. For patients with a systolic blood pressure \>185mmHg, the cuff will be inflated to at least 15mmHg above the patient's systolic blood pressure. The cuff will then be deflated and the arm allowed reperfuse for 5 minutes. This will be repeated so that each patient receives a total of 3 ischaemia-reperfusion cycles. Additional, blood and urine samples will be collected on Day 1, Day 2 and Day 3 post procedure.
223684375|NCT03742908|DRUG|Cefazolin/clindamycin|Local implant immersion and/or breast pocket irrigation
223684376|NCT01733927|DEVICE|Rapid testing for HIV|The research team members were trained and certified in administering the OQA testing through the AIDS International Consortium in Philadelphia (WHCI), USA. During the recruitment process, participants were informed about the nature of the test, the length of time for results, and what procedures would be involved in self-administering the OQA test. After providing informed consent, including the release of information for research use, participants demonstrated their ability to properly take an OQA sample using a popsicle stick as a proxy for the testing device.
223684377|NCT02972762|DRUG|Diprivan|anesthesia will be maintained with remifentanil and Diprivan.we use Diprivan close-loop to control the anesthesia depth,and the anesthesia depth will be detected with BIS machine.the usage of remifentanil、ropivacaine、sufentanil and cisatracurium in both arms is no difference.
223684378|NCT00739492|BEHAVIORAL|financial incentives|financial incentives based on attaining weight loss goals
223684379|NCT03221075|OTHER|Registry|There is no intervention.
223684380|NCT01525121|OTHER|Expiratory Rib Cage Compression|The therapist hands were positioned on the lower ribs, and the force was applied every two breaths only during the expiration, synchronizing the maneuver rate with the patient's respiratory rate. Then, the patients underwent a suctioning procedure, and a hyperinflation maneuver consisting of a 10 minutes period under pressure support ventilation of 35 cmH2O was done. In control intervention instead of the compressive maneuver the patients were kept on normal ventilation.
223684381|NCT00882700|DRUG|Cefdinir 300 mg Capsule (Sandoz, Austria)|
223684382|NCT00882700|DRUG|Omnicef Cefdinir 300 mg Capsule (Abbott Laboratories, USA)|
223684383|NCT03494777|BEHAVIORAL|Incentivization based on high adherence|When a participant comes for a regular clinic visit, s/he will have the MEMS data extracted, and if adherence over the previous month \>=90%, will participate in a prize drawing.
223684384|NCT03494777|BEHAVIORAL|Incentivization based on timely clinic visit|When a participant comes for a regular clinic visit on the day s/he is scheduled, s/he will participate in a prize drawing.
223684385|NCT03494777|BEHAVIORAL|Annual adherence prize drawing|Participants will have a chance to take part in an annual drawing where eligibility is based on the average adherence during that year.
223684386|NCT03494777|BEHAVIORAL|Annual viral suppression-based prize drawing|Participants will have a chance to take part in an annual drawing where eligibility is based on showing viral suppression.
223684387|NCT03494777|BEHAVIORAL|Year 2 booster|Those participants not showing viral suppression at month 12 will be randomized in a 1:1 fashion to receive an additional intervention component or continue receiving the same intervention arm as in Year 1.
223684388|NCT03882008|DRUG|Abatacept|All the subjects will receive Abatacept subcutaneous injection once a week for 24 weeks
223684389|NCT00965510|BEHAVIORAL|care coordination|patients receive care coordination to improve their type II diabetes
223684390|NCT05854927|DIAGNOSTIC_TEST|3D T1 MRI sequences injected with fat saturation and black blood|3D T1 MRI sequences injected with fat saturation and black blood
223684391|NCT05658536|BEHAVIORAL|6-Week Self-Management Group|The goal of the 6-session group-based intervention for patients with Post-COVID is to teach patients behavioral strategies known to be helpful in managing several common Post-COVID symptoms, including fatigue, memory and attention issues, poor sleep, breathlessness, coping with anxiety and uncertainty, and stress management. It is currently available to patients who are seen in the Post-COVID-19 Rehabilitation and Recovery Clinic at UW and the Post-COVID-19 Clinic in VAPSHCS Rehabilitation Care Services.
223684392|NCT02879240|OTHER|Animated Cartoon|An animated cartoon chosen by the parents is displayed on a smartphone attached on the spacer of the child.
223684393|NCT02879240|OTHER|Black screen|A video displaying a black screen is used as control, and displayed on a smartphone attached on the spacer of the child.
223684394|NCT03931668|DRUG|TPN-672|single dose of TPN-672 maleate tablet
223684395|NCT05674552|DRUG|Exogenous ketone ester|500 mg/kg over 5 min administered by nasogastric tube, followed after 1 hr by repeated hourly doses of 125 mg/kg for 8 hrs.
223684396|NCT02009384|DRUG|Ipilimumab|administration of IV ipilimumab for up to 4 cycles
223684397|NCT03442400|DEVICE|Volcano iFR/FFR Verrata Plus coronary pressure/flow wire|We will measure the degree of flow-limitation of intermediate severity coronary steonses using the iFR/FFR Verrata Plus coronary pressure/flow wire before and after transcatheter aortic valve replacement.
223684398|NCT00407680|DRUG|Intensive therapy Valsartan,Fluvastatin|
223684399|NCT00718237|BIOLOGICAL|Rotavirus Vaccine, Live, Oral, Pentavalent (V260, RotaTeq™)|Rotateq orally administered 3 times
223684400|NCT00718237|BIOLOGICAL|Comparator: Comparator: Placebo (unspecified)|Placebo orally administered 3 times
223684401|NCT06165770|PROCEDURE|laparoscopy|Conservative or surgery treatment for cornual pregnancies
223775087|NCT01410110|BEHAVIORAL|Cognitive Training + Work Therapy|Cognitive training for 5 hours per week for 13 weeks and 15 hours of work therapy
223775088|NCT01410110|BEHAVIORAL|Work Therapy|20 hours per week of work therapy
223684402|NCT04739176|OTHER|One-on-one rehabilitation program including computerized mirror therapy in addition to standard rehabilitation.|atients will be admitted to the day hospital 2 days a week for 9 weeks. They will participate in a one-on-one rehabilitation program conducted by a multidisciplinary team including a physiotherapist, psychomotor therapist, occupational therapist and a physical activity monitor. Patients will also participate in 12 computerized mirror therapy sessions (twice a day, 2 days a week, from week 4 to 6 of the program).
223684403|NCT00804037|PROCEDURE|Injection Snoreplasty|Injection of 0,5 ml of the sclerosing agent into the soft palate (3 points)
223684404|NCT03189381|RADIATION|Cohort A|Cohort A - WBRT dose = 25 Gy, SIB dose = 42 Gy, # of daily fractions = 10, SIB dose in EQD2 = 49.7 Gy
223684405|NCT03189381|RADIATION|Cohort B|Cohort B - WBRT dose = 20 Gy, SIB dose = 40 Gy, # of daily fractions = 8, SIB dose in EQD2 = 50.0 Gy
223684406|NCT02315443|DRUG|Nerinetide (NA-1)|
223775089|NCT06534697|DRUG|Naropin, 0.2% Injectable Solution in Sodium chloride|Preoperative fascia iliaca block with 40 ml volume of naropin 0,25% in sodium chloride
223775090|NCT06534697|DRUG|Naropin, 0.2% Injectable Solution in dextrose 5%|Preoperative fascia iliaca block with 40 ml volume of naropin 0,25% in dextrose 5%
223684407|NCT02315443|DRUG|Placebo|
223684408|NCT00251004|DRUG|Everolimus|oral, bis in diem/twice a day (bid)
223684409|NCT00251004|DRUG|Mycophenolic Acid (MPA)|2 oral capsules of mycophenolic acid 360mg administered bid
223775091|NCT06534697|DRUG|Dextrose 10 % in Water|Preoperative fascia iliaca block with 40 ml volume of dextrose 10%
223775092|NCT05769894|OTHER|No intervention given|No intervention is planned. Blood samples will be taken at different stages.
223775093|NCT06569576|BEHAVIORAL|Wellness program|It combines seated yoga exercises, mindfulness, and social participation activities and discussions, and can be delivered in-person or via tele-health.
223775094|NCT00764140|BIOLOGICAL|tumor growth factor concentration|spot urine or blood collection will be used to measure specific tumor growth factor
223775095|NCT05726656|OTHER|traditional physical therapy session|manual lymph drainage-pneumatic compression and skin care
223775096|NCT05726656|OTHER|wii console based exercise|execise session using the wii console video games
223775097|NCT02317640|DRUG|Testosterone Gel applied by a pump|After being diagnosed with low testosterone levels the participant will be given a 30-day supply of the Testosterone/placebo gel (40.5 mg/day). The gel is to be applied every morning on clean and dry area of skin of the upper arms and shoulders.
223775098|NCT02317640|OTHER|Stand Training|Stand training with BWST with manual assistance. Participant is placed on treadmill in an upright position and suspended in a harness by an overhead cable. A trainer will aid the participant in pelvis and trunk stabilization, by applying anterior forces at the pelvis and/or posterior forces at the shoulders and ensure that the trunk and pelvis are not flexed or hyper-extended.
223684410|NCT00251004|DRUG|Cyclosporine A (CsA)|CsA dose adjustments were based on CsA trough levels (C0).
223684411|NCT00251004|DRUG|Basiliximab|All patients received two 20 mg doses of basiliximab administered intravenously. The first dose was to be given within 2 hours prior to transplant surgery and the second dose was to be administered on day 4, or each dose could have been administered according to local practice.
223684412|NCT00251004|DRUG|Corticosteroids|Oral corticosteroids were administered according to local practice during the trial. At the same center, all patients were to follow the same steroid administration protocol.
223684413|NCT03538574|BEHAVIORAL|CBT-I|CBT-I is a behavioral treatment for insomnia
223684414|NCT03538574|BEHAVIORAL|MAP-I|MAP-I is a mindfulness meditation treatment for insomnia
223684415|NCT05384977|DRUG|[14C]-NV-5138|Single dose, given as oral solution, 1600 mg
223684416|NCT03824509|OTHER|Chart Review|"Study staff at PBMC (Cardiologist and two clinical researchers) will be responsible for maintaining all data related to this study in REDCap. Patient data to be included in this secondary data analysis will originate from MMC and PBMC.~Case-patient data to be included from MMC will be identified by an EPIC data request from Enterprise Reporting. The elements of the data request will be patients who have had a stroke or TIA, atrial fibrillation, and a transthoracic echocardiogram at MMC from 2014-2017."
223684417|NCT03889483|DEVICE|NeuroCatch™ Platform|The NeuroCatch™ Platform consists of software and hardware that captures brain health information. The platform intends to provide a quick, portable and easy to use solution for the acquisition, display, analysis, storage, reporting and management of electroencephalograph (EEG) and event-related potential (ERP) information.
223684418|NCT00322153|DRUG|memantine ER|28mg(7mg capsules) once daily and oral administration for 24 weeks.
223684419|NCT00322153|DRUG|Placebo|Matching placebo oral administration once daily.
223684420|NCT03277833|DIETARY_SUPPLEMENT|Gynostemma Pentaphyllum(Dungkulcha) Extract(400mg/day)|Gynostemma Pentaphyllum(Dungkulcha) Extract(400mg/day), parallel design
223684421|NCT03277833|DIETARY_SUPPLEMENT|Placebo|Placebo, parallel design
223684422|NCT05047627|BEHAVIORAL|Smartphone-Based Digital Intervention|The digital intervention will be a prototype, and the current trial will be used to continue to both develop and refine the intervention. The current intervention will be based on a combination of cognitive-behavioral principles. As with prior research, the mobile platform will be delivered via Qualtrics, a HIPAA compliant and mobile-friendly platform. The cognitive-behavioral therapy will be primarily based on components with strongest support in digital interventions. The app will continuously collect passive sensing data on patterns in 1) sleep duration and quality;(2) light (3) location; (4) movement (5) social contact including duration and frequency of incoming and outcoming calls and text messages; (6) screen time; and (7) heart rate variability; (8) sound levels captured through passively collected smartphone The platform will deliver interactive interventions where participants will view texts and images, and it will also allow user interaction.
223684423|NCT00591578|DRUG|Azilsartan Medoxomil|Azilsartan Medoxomil 20 mg, tablets, orally, once daily for 2 weeks; titrated to 40 mg, tablets, orally, once daily for up to 22 weeks.
223684424|NCT00591578|DRUG|Azilsartan Medoxomil|Azilsartan Medoxomil 20 mg, tablets, orally, once daily for 2 weeks; titrated to 80 mg, tablets, orally, once daily for up to 22 weeks.
223684425|NCT00591578|DRUG|Valsartan|Valsartan 80 mg, tablets, orally, once daily for 2 weeks; titrated to 320 mg, tablets, orally, once daily for up to 22 weeks.
223684426|NCT00328978|DRUG|Quetiapine|
223684427|NCT06133738|OTHER|Standardized Exercise Program|"Participants will be asked to attend to the department for 8 supervised physiotherapy sessions designed to strengthen lower limb muscles. Eight sessions were chosen as this number should be able to achieve improvements in pain and function. Standardized exercises sessions will be held once weekly in the health center and will be supervised by the researcher. In addition, participants will be requested to perform the prescribed exercises 3 times per week at home, with 1-2 days rest interval between the exercise's sessions.~The program is comprised of a minimum of 4 and a maximum of 6 individualized lower limb exercises to be performed 4 times per week (once in the health center and 3 times at home). All exercise programs will include at least 2 knee extensor strengthening exercises, 1 hip abductor strengthening exercise, 1 hamstring strengthening exercise, 1 calf strengthening exercise, and 1 other exercise will be chosen based on assessment findings."
223684428|NCT06133738|OTHER|Internet based Cognitive Behavioral Therapy|"This intervention will be given to participants in intervention group. This is a link to access pre-recorded online sessions of CBT.~The iCBT link contained eight 35- to 45-minute sessions, designed to be completed weekly, each provided an explanation of a cognitive or behavioural pain coping skill. Session 1 provided an overview, including a therapeutic rationale of CBT, followed by training in progressive muscle relaxation. Sessions 2 through 7 taught brief relaxation skills, activity-rest cycling, pleasant activity scheduling, cognitive restructuring, pleasant imagery, and problem-solving. Session 8 consolidated the learnt and taught strategies for long-term skill use. Each session has to be completed within the same week where the physiotherapy session is given.~The researcher has developed a website that contained all the CBT materials."
223684429|NCT06133738|OTHER|Educational Materials|All participants will receive a link to access online educational material about chronic knee pain. This is a YouTube link that consists of 5 sessions, with each lasting for 5-7 minutes, and is comprised of general information about the following: healthy eating, osteoarthritis and X-Ray, physical activity, the full pain experience, and proper footwear. Participants will be encouraged to access the educational material at their own leisure and pace.
223684430|NCT01165567|DRUG|sarpogrelate|sarpogrelate, 300mg/day,duration: 4 weeks
223684431|NCT01412918|DEVICE|The Inhibitor™ Tinnitus Masking Device|The Inhibitor™ Tinnitus Masking Device
223684432|NCT04652180|PROCEDURE|Esophagectomy|In this monocentre randomized controlled trial, we compare robot-assisted thoracic approach with conventional open transthoracic Ivor Lewis esophagectomy.
223775099|NCT02317640|DEVICE|Electrical Stimulation|Electrical Stimulation (ES) will be applied via bifurcated leads and self-adhesive reusable surface electrodes. The electrodes will be applied over the motor points of both legs. Two electrodes will be used for contracting each muscle.
223684433|NCT04604847|DIAGNOSTIC_TEST|blood test|blood test to explore BDNF level
223684434|NCT05879510|DIAGNOSTIC_TEST|68Ga-NY104 PET/CT|"Participants will be administered a single, intravenous bolus of 68Ga-NY104 The recommended administered activity of 68Ga-NY104 is 1.8-2.2 MBq per kilogram bodyweight, subject to variation that may be required owing to variable elution efficiencies obtained during the lifetime of the 68Ga / 68Ga generator.~The CT and PET imaging session will begin approximately 45 to 75 minutes after 68Ga-NY104 administration."
223684435|NCT05930366|PROCEDURE|Gingival depigmentation using microsurgery|GINGIVAL DEPIGMENTATION USING MICROSURGICAL BLADE AND MAGNIFICATION LOUPES
223684436|NCT05930366|PROCEDURE|Gingival Depigmentation using Diode Laser|GINGIVAL DEPIGMENTAION USING DIODE LASER
223684437|NCT03462290|DRUG|botulinum toxin type A|Botulinum toxin type A, powder for solution, 25 international units (IU), injected towards the sphenopalatine ganglion using MultiGuide
224262875|NCT00367133|DRUG|4mg triamcinolone acetonide|4mg intravitreal triamcinolone acetonide injection at baseline. At each 4-month interval visit, the investigator will assess whether persistent or recurrent DME is present that warrants retreatment with the randomization assigned treatment. Retreatment, when indicated, will be performed within four weeks after the follow-up visit. Retreatment should not be performed sooner than 3.5 months from the time of the last treatment.
223684438|NCT03462290|DRUG|placebo|solution without botulinum toxin A, injected towards the sphenopalatine ganglion using MultiGuide
223684439|NCT02510755|OTHER|MRI|
223684440|NCT02392715|DEVICE|Inspiratory muscle training with Threshold by respironics|"Inspiratory muscle training~15 minutes, 3x/weeks, 36 sessions~Intensity: 15% of PiMax during the first week. Then increment of 5% each session until 60% of PiMax after the first month. The PiMax will be reassessed after 12 and 24 sessions in order to readjust the 60% of PiMax."
223684441|NCT02392715|DEVICE|Sham Inspiratory muscle training|"with Threshold by respironics~15 minutes, 3x/weeks, 36 sessions~Intensity: 5 centimeters of water (cmH20)"
223684442|NCT03099070|BEHAVIORAL|Stress|Trier Social Stress Test
223684443|NCT03099070|OTHER|Fasting|12-hour fasting prior to study visit
223684444|NCT03455764|DRUG|MCS110|MCS110 is a colony-stimulating factor-1 (CSF-1) inhibitor. It is a human monoclonal antibody which binds CSF-1.
223684445|NCT03455764|DRUG|Dabrafenib|Dabrafenib attack different proteins that promote the growth of cancerous cells
223684446|NCT03455764|DRUG|Trametinib|Trametinib attack different proteins that promote the growth of cancerous cells
223684447|NCT05946655|DRUG|Ofloxacin + Metronidazole|Ofloxacin 2x200mg orally for 10 days + Metronidazole 1x500 mg vaginally for 10 days
223684448|NCT04954170|DIAGNOSTIC_TEST|IRRTM|IRRT at maximal 90° abduction and maximal external rotation is performed with the shoulder at maximal 90° rotation and the elbow flexed to 90° (Fig. 2). The patient is then asked to resist the external rotation force applied perpendicular to the forearm by the investigator. The test is considered positive if the patient could not hold the position or if he or she showed weakness of resisted internal rotation compared with the other side. It should be noted the maximal 90° abduction and maximal external rotation is active range of motion. Passive motion may affect the result of the test because of severe pain.
223684449|NCT04954170|DIAGNOSTIC_TEST|the lift-off test|The lift-off test is performed by placing the hand of the affected arm on the back (at the position of the midlumbar spine) and asking the patient to internally rotate the arm to lift the hand off the back \[9\]. The test is considered positive if the patient is unable to lift the arm posteriorly off the back or if he or she performs the lifting manoeuvre by extending the elbow or the shoulder. Weakness is also as a positive result.
223684450|NCT04954170|DIAGNOSTIC_TEST|the belly-press test|The belly-press test is performed with the arm at the side and the elbow flexed to 90°, by having the patient press the palm into his or her abdomen by internally rotating the shoulder \[3, 5\]. The test is considered positive (1) if the patient shows a weakness in comparison with the opposite shoulder or (2) the patient pushes the hand against the belly by wrist flexion, despite instruction to the contrary.
223775100|NCT04549740|DIAGNOSTIC_TEST|salivary alpha amylase level measurement|Saliva samples will be obtained to estimate salivary alpha amylase
223775101|NCT05795387|OTHER|Video-based self-regulated training on the mental status exam|Authentic patient videos for self-regulated training as well as written e-course material, both on the mental status exam
223775102|NCT05795387|OTHER|E-course with written material on the mental status exam|Written material on the mental status exam
223775103|NCT05540223|DEVICE|DREAMS 3G RMS|Subject undergoes implantation of DREAMS 3G RMS
223775104|NCT05540223|DEVICE|Xience DES|Subject undergoes implantation of Xience DES
223775105|NCT03619733|OTHER|no intervention|this is an observational study. no intervention is planned
223775106|NCT01955876|DRUG|Lanthanum Carbonate (Fosrenol, BAY77-1931)|Patients treated with Fosrenol in daily clinical practice.
223775107|NCT00539526|DRUG|Bimatoprost 0.03%|bimatoprost 0.03%, 1 drop nightly for 3 months
223775108|NCT00539526|DRUG|travoprost 0.004%|travoprost 0.004% eye drops, 1 drop nightly for 3 months
223775109|NCT00539526|DRUG|latanoprost 0.005% eye drops|latanoprost 0.005%, 1 drop nightly for 3 months
223684451|NCT04954170|DIAGNOSTIC_TEST|the IRLS test|IRLS test is evaluated with the affected arm of the patient was held by the examiner at maximum internal rotation \[10\]. The back of the hand is then passively lifted away from the body until almost full internal rotation is reached. Then, the patient is asked to actively maintain this position. The test is considered positive when the patient fails to maintain the position and the hand lagged.
223684452|NCT04954170|DIAGNOSTIC_TEST|the bear-hug test|The bear-hug test is performed with the palm of one side placed on the opposite shoulder and fingers extended and the elbow positioned anterior to the body \[3\]. The patient is then asked to hold that position when the examiner tried to pull the patient's hand from the shoulder with an external rotation force applied perpendicular to the forearm. The test is considered positive if the patient could not hold the hand against the shoulder or if he or she showed weakness compared with the other side.
223684453|NCT04954170|DIAGNOSTIC_TEST|IRRT 0°|IRRT at 0° abduction and 0° external rotation is performed with the arm at the side and the elbow flexed to 90° (Fig. 1). The patient is then asked to resist the external rotation force applied by the investigator. The test is considered positive if the patient could not hold the position at the side or if he or she showed weakness of resisted internal rotation compared with the other side. The test is negative if patients only complain of pain.
223684454|NCT04954170|DIAGNOSTIC_TEST|Diagnostic arthroscopy|At the time of surgery, general anaesthesia was administered and the patient was placed in beach-chair position. A complete arthroscopic exploration of the glenohumeral joint and the subacromial space was performed through a standard posterior portal. The senior author performed a complete arthroscopic exploration. Arthroscopic evaluation of the rotator cuff was considered the gold standard for making the definitive diagnosis. Evaluation of the SSC was carried out with both a 30° arthroscope and a 70° arthroscope.
223684455|NCT01326559|DRUG|Docetaxel, Cisplatin, 5-FU and Cetuximab|"Induction phase (Weeks 1-9):~Drug Docetaxel Docetaxel 75 mg/m2 IV, D1 every 3 weeks for 3 cycles~Drug Cisplatin Cisplatin 75 mg/m2 IV, D1 every 3 weeks for 3 cycles~Drug Fluorouracil Fluorouracil 750 mg/m2 IV, D1-4 every 3 weeks for 3 cycles~Concurrent phase (weeks 10-16):~Drug Docetaxel Docetaxel 15 mg/m2 IV, D1 weekly for 7 weeks (Weeks 10-16)~Drug Cetuximab Cetuximab 400 mg m2 IV, D1 initial dose, then 250 mg/m2 weekly for 7 week (Weeks 10-16)~IMRT (60 Gy to GTV or biological dose equivalent): 2 Gy/fraction/day, D1-5 per week, for 6 weeks (Weeks 11-16)"
223684456|NCT01247181|OTHER|Mobile phone text message|Weekly message with motivational content
223684457|NCT01247181|OTHER|Usual care|Usual care provided at clinic
223775110|NCT00286143|DRUG|Fentanyl|Fentanyl is added to epidural Bupivacaine to be administered to neonates having thoracotomy for lung resections.
223775111|NCT06532903|OTHER|Selective muscle electrostimulation with exponential current|An electroevaluation will be performed, with an exponential current generator equipment, using Meditea® brand Neuromatic 700 equipment, which consists of a first application of the current, the pulse width (in milliseconds) in which a contraction is achieved will be sought. frank, visible and selective of the facial muscle that is being stimulated. The purpose is to identify the pulse width and the lowest intensity to obtain a frank, visible and selective contraction, understood as the best quality.
223775112|NCT06532903|OTHER|Facial muscle reeducation in front of the mirror|"Muscle re-education: Symmetrical facial movements will be requested, activating the muscles of the affected side, avoiding the participation of the unaffected side. We will work with the patient sitting in front of a mirror, asking him to perform the following actions or gestures: raise his eyebrows, frown, close his eyes (tightly and blink), smell an unpleasant odor, show his fangs, blow a kiss, blow , fake smile (lip corner pulled back horizontally), frank smile (lip corner pulled back and up, showing teeth), kiss and pout. The functional capacity of the mouth will be trained, inflating the cheekbones and moving the air from one side to the other, avoiding compensations. Depending on the degree of facial dysfunction and its condition, the kinesiologist will perform a stretch reflex, facilitation of movement and/or inhibition of it. Three series of five repetitions of each gesture described will be done."
223775113|NCT03393611|DRUG|CPX-351|Salvage Chemotherapy: CPX-351 at 120 u/m2 on Days -21, -19, and -17
223775114|NCT03393611|DRUG|Fludarabine|Fludarabine 150 mg/m2 (30 mg/m2/day x 5 days, Day -7 to Day -3)
223775115|NCT03393611|DRUG|Melphalan|Melphalan 140 mg/m2 (Day -2)
223775116|NCT03393611|DRUG|Rabbit Anti-Human T-Lymphocyte Globulin|Rabbit ATG (rATG)-thymoglobulin 4.5 mg/kg (1.5 mg/kg/day x 3 days)
223775117|NCT03393611|BIOLOGICAL|Haplo-Cord Stem Cell Transplantation|Allogeneic stem cell transplantation using a haploidentical donor and umbilical cord blood unit.
223684458|NCT00439465|BIOLOGICAL|Ex-vivo expanded effector cells|This trial will test if the combination of infusing ex vivo expanded cytotoxic effector cells with IL-2 and GM-CSF post-transplant will accelerate immune reconstitution, resulting in an effector cell-versus-myeloma effect and, possibly, improved clinical outcomes.
223684459|NCT02148146|DRUG|Omegaven|Fish oil emulsion given 1g/kg/day as infusion
223684460|NCT04533685|BEHAVIORAL|Portal Reminders for Influenza Vaccination: Direct scheduling link|Patients receive reminder/recall messages via the patient portal to get an influenza vaccination that include a direct scheduling link, enabling the patient to directly schedule a flu vaccination only visit
223684461|NCT04533685|BEHAVIORAL|Portal Reminders for Influenza Vaccination: No direct scheduling link|Patients receive reminder/recall messages via the patient portal to get an influenza vaccination (no direct scheduling link included)
223775118|NCT00951067|OTHER|Exercise, Elevation, and Compression Garment|"Patients will be asked to daily:~* exercise~* elevate arm~* wear an arm compression garment"
223775119|NCT00951067|DEVICE|E0650 PCD with non-sequential waveform|Use of an E0650 PCD with non-sequential waveform for two hours every day.
223775120|NCT00951067|DEVICE|E0651 PCD with sequential, non-gradient waveform|Use of an E0651 PCD with sequential, non-gradient waveform for two hours every day
223775121|NCT00951067|DEVICE|E0652 PCD with sequential, gradient waveform|Use of an E0652 PCD with sequential, gradient waveform for two hours every day.
223684462|NCT04533685|BEHAVIORAL|Pre-Commitment Prompt|Patients receive a pre-commitment prompt asking about their intention to get an influenza vaccination
223684463|NCT04533685|BEHAVIORAL|Pre-Appointment flu vaccine reminders|Patients receive modified pre-appointment reminders for upcoming scheduled appointments that include language encouraging patients to ask the provider for the flu vaccine
223684464|NCT01608854|OTHER|Antibiotic Protocol|Patients were given postoperative antibiotics according to their randomization; antibiotic type and dosage were determined by the attending physician.
223684465|NCT04221230|DRUG|NMRA-335140|Active Drug
223684466|NCT04221230|DRUG|Placebo|Placebo
223684467|NCT00371007|DRUG|MK0431, sitagliptin phosphate / Duration of Treatment: 12 Weeks|
223684468|NCT00371007|DRUG|Comparator : placebo (unspecified) / Duration of Treatment: 12 Weeks|
223684469|NCT02774733|DEVICE|spirometer;Intraocular pressure;Color doppler imaging|
223684470|NCT03615508|DRUG|10% phenylephrine|10% phenylephrine is a drug that can be used to dilate patient's eyes at their yearly eye examination. All enrolled subjects will receive this drug for their eye dilation.
223684471|NCT04841226|DEVICE|Long-term indwelling Foley catheter|Foley Catheter inserted for up to 28-days
223684472|NCT02022176|OTHER|Glucose Uptake|Glucose uptake is measured by oral glucose tolerance test and euglycemic clamp
223684473|NCT02022176|OTHER|Resting metabolic rate|Resting metabolic rate is measured by indirect calorimetry after an over-night fast
223684474|NCT02022176|OTHER|Nitrite infusion|Sodium nitrite or saline was infused at escalating doses at a rate of 1, 10 or 100 nmol kg-1 min-1 (10 minutes per dose) in a randomized, double blinded cross-over fashion
223684475|NCT01871064|DEVICE|TOF-Watch SX® Monitoring of NMB|Participants will have the extent of NMB monitored by a TOF-Watch SX®.
223684476|NCT02021656|DRUG|LDV/SOF|90/400 mg FDC tablet administered orally once daily without regard to food
223684477|NCT04898621|DIETARY_SUPPLEMENT|75g fructose solution|Subjects will drink a bottle of 350 ml solution containing 75g fructose per day for 4 weeks.
223684478|NCT04898621|DIETARY_SUPPLEMENT|150g fructose solution|Subjects will drink a bottle of 700 ml solution containing 150g fructose per day for 4 weeks.
223684479|NCT05772988|DIETARY_SUPPLEMENT|Beta-alanine|Beta-alanine
223684480|NCT05772988|DIETARY_SUPPLEMENT|Maltodextrin|Maltodextrin
223684481|NCT04325555|DRUG|PrEP|The investigators measure self-reported PrEP status as exposure, i.e., PrEP status is not confirmed via matched medical records or any other type of information directly collected form subjects.
223684482|NCT01377285|DRUG|ARB|"Angiotensin II receptor antagonists ,these medicines have names that end in sartan.For examples:losartan,candesartan,irbesartan,olmesartan,telmisartan,valsartan"
223684483|NCT01377285|DRUG|Pentoxifylline|This medication is used to improve the symptoms of a certain blood flow problem in the legs/arms (intermittent claudication due to occlusive artery disease)
223684484|NCT01377285|DRUG|Placebo (for Pentoxifylline)|Sugar pill manufactured to mimic Pentoxifylline 400mg tablet
223684485|NCT01198171|OTHER|Laboratory Biomarker Analysis|Correlative studies
223684486|NCT01198171|OTHER|Study of Socioeconomic and Demographic Variables|
223684487|NCT00019110|BIOLOGICAL|human papillomavirus 16 E7 peptide|
223684488|NCT00019110|BIOLOGICAL|synthetic human papillomavirus 16 E6 peptide|
223684489|NCT04215133|OTHER|exercise therapy|inspiratory muscle training consists of strengthening exercise with threshold Inspiratory muscle training device and calf muscle training consist of isotonic and isometric strengthening exercise for calf muscle. All groups will receive compression therapy at the same time.
223684490|NCT05740995|DRUG|neoadjuvant anti-PD-1 plus chemotherapy|"Patients will be given preoperative treatment as below once recruited:~1. Chemotherapy is delivered and composed of two cycles of Nab-paclitaxel 135mg per square meter of body-surface area and cisplatin 75mg per square meter of body-surface area every 3 weeks;~2. PD-1 antibody is delivered 200 mg (iv, in 30 minutes) every 3 weeks;~3. After neoadjuvant therapy of 3-4 cycles, esophagectomy is performed. We advise starting 4 cycles of identical chemoimmunotherapy in 6w after surgery."
223684491|NCT00596362|DRUG|AVASTIN|a single injection of Avastin at the outpatient clinic. This will be done as follows: the pupil in the eye being treated will be enlarged with a liquid solution. Thirty minutes later, a numbing solution and then a cleansing solution will be put in to the eye. Finally, an injection of Avastin will be given into the eye. Right after this injection, your eye will be examined by your doctor. The pressure in your eye will also be tested before and after the injection. Patients will use antibiotic drops for 5 days following the injection. Following the injection, you will have weekly examinations for four weeks in the office.
223684492|NCT00207571|BEHAVIORAL|Computer|
223775122|NCT00951067|DEVICE|E0652 PCD with peristaltic pulse waveform|Use the E0652 PCD with peristaltic pulse waveform for two hours every day.
223684493|NCT03562871|BIOLOGICAL|IO102|test immunotherapy
223684494|NCT03562871|BIOLOGICAL|pembrolizumab (Keytruda)|anti-PD-1 immunotherapy
223775123|NCT06533605|DRUG|SSGJ-706|Bispecific antibody
223775124|NCT01318564|DRUG|Metformin|500 - 1000 mg by mouth twice a day with either via a MEMS device pill bottle (medication event monitoring system) or by unit-dosing (blister packaging) with attached Med-ic device (electronic compliance monitoring for blistered medication).
223775125|NCT01318564|BEHAVIORAL|Questionnaires|Completion on Day 1 and after Month 3. Each questionnaire to take about 30 minutes to complete.
223775126|NCT03280277|PROCEDURE|Contrast-enhanced Magnetic Resonance Imaging|Undergo ferumoxytol-enhanced MRI
223684495|NCT03562871|DRUG|Carboplatin (Carboplatin Kabi)|chemotherapy
223684496|NCT03562871|DRUG|Pemetrexed (Pemetrexed Alvogen)|chemotherapy
223684497|NCT02043379|DRUG|IVIG|Those randomized to the study arm will receive a one time dose of IVIG at 12 our post-Cardiopulmonary bypass. This is significantly early than our current standard of care.
223775127|NCT03280277|DRUG|Ferumoxytol|Given IV
223775128|NCT01592630|DRUG|0.2% ropivacaine|On-Q pumps containing 0.2% ropivacaine to be attached to TAP catheters
223684498|NCT02043379|OTHER|Placebo|If the subject is randomized to the placebo group they will receive a volume of normal saline that is equivalent to the volume of IVIG to be administered based on their weight.
223684499|NCT06536231|PROCEDURE|Remote ischemic conditioning|Remote ischemic conditioning (RIC) procedure comprise three repetitions of brachial cuff inflation to 200 mmHg for five minutes following deflation to 0 mmHg for another five minutes. The procedure overall took 30 minutes.
223684500|NCT02266043|DEVICE|Pre-epiglottic baton plate (PEBP)|"modified acrylic palatal plate in which a velar extension resembling a spur or baton shifts the base of the tongue forward.~This treatment is the standard care for infants with Pierre-Robin-Like Phenotype in the participating study centers and not assigned by protocol."
223684501|NCT03504930|OTHER|Impact of biotherapy on postoperative morbidity in ulcerative colitis|Impact of biotherapy on postoperative morbidity, quality of life, sexual function, sexual health in ulcerative colitis
223684502|NCT04153071|DEVICE|OPUS system|Each subject will have a single cutaneous treatment of their lower abdomen, with variable treatment parameters. Punch biopsies will be obtained from each treatment section, for in-vivo histological evaluations.
223684503|NCT00259675|DRUG|carboplatin/gemcitabine, carboplatin/taxol|
223684504|NCT02457585|DRUG|remicade (anti tumor necrosis factor inhibitor)|single arm:remicade treatment group
223684505|NCT05530876|OTHER|Telerehabilitation with virtual game|It will be applied 10 sessions of remote rehabilitation in women with and without breast cancer, in order to promote physical activity.
223684506|NCT00744458|OTHER|Treatment contract|Patients signs in for a agreement - to respect a regular follow-up at the health facility.
223684507|NCT00744458|OTHER|Tracing and recall at home by a community worker|The local health committee sends out a member to trace the patient and to motivate him to take up again regular treatment visits.
223684508|NCT00744458|OTHER|Incentive|Incentive by giving free treatment after a 4-month regular follow-up
223684509|NCT02037152|BEHAVIORAL|Body scan exercise|"The body scan includes 20 minutes of guided audio-- the pre-recorded voice of a narrator instructs the user to systematically direct attention to various parts of the body. The audio content is adapted from the body scan exercises traditionally taught in evidence-based mindfulness interventions."
223684510|NCT04600011|OTHER|Physical and occupational therapy (PT/OT)|"Neurologic-specialized and -certified physical and occupational therapists will provide each participant with an initial in-person PT/OT evaluation/treatment session with oversight from a Movement Disorders Neurologist, followed by 4 virtual home visits with tele-PT/OT and care partner supervision every 2 weeks, and culminating with a final in-person evaluation, all with a focus on personalized training in core areas contributing to a patient's individual fall risk, much like in-person visits. Virtual home safety surveillance with the mobile virtual platform is an additional feature of this intervention that aims to optimize the home environment to reduce external factors contributing to fall risk."
223684511|NCT04600011|OTHER|Home Safety Evaluation (HSE)|The VIRTUAL HOME SAFETY EVALUTIONS (HSE)-ONLY ARM where participants ONLY receive the virtual home safety evaluations and surveillance that are built into the original protocol of three of the four tele-OT visits that is being used in Arm 1. The study duration for Arm 2 is about 6 weeks of the primary intervention as described with 3-month and 6-month follow-up calls. The mobile virtual platform for Arm 2 is comprised of a tablet OR smartphone that will be guided through the home by the care partner only and not the patient.
223684512|NCT03798899|DRUG|Methoxyflurane|PENTHROX 3mL inhalation vapour, liquid
223684513|NCT03798899|DRUG|Normal Saline|Placebo
223684514|NCT02874768|DRUG|Dexmedetomidine|Patient receives continuous intravenous infusion of dexmedetomidine (infusion dosage range: 0.1 \~ 0.7 mcg/kg/h)
223684515|NCT02874768|DRUG|Propofol|Patient receives continuous intravenous infusion of propofol (infusion dosage range: 0.3 \~ 1.6 mg/kg/h)
223684516|NCT00282347|DRUG|Rituximab|Rituximab was provided as a sterile solution for injection.
223684517|NCT00282347|DRUG|Placebo|Placebo was provided as a sterile solution for injection.
223684518|NCT00282347|DRUG|Mycophenolate mofetil|
223684519|NCT00282347|DRUG|Methylprednisolone|
223684520|NCT00282347|DRUG|Diphenhydramine|
223684521|NCT00282347|DRUG|Acetaminophen|
223684522|NCT00282347|DRUG|Prednisone|
223684523|NCT05388123|DRUG|Low dose vemurafenib plus rituximab|Vemurafenib 240 mg twice daily for 8 weeks with concurrent rituximab 375 mg/m2 every 2 weeks followed by maintenance consolidative rituximab 4 times every 2 weeks post-vemurafenib
223684524|NCT04386824|OTHER|Erectil dysfunction|A complete ophthalmological examination including best-corrected visual acuity using the decimal system (BCVA), measurement of intraocular pressure (IOP) and axial length (AL), slit-lamp examination and dilated fundus examination
223684525|NCT00356122|DRUG|Docetaxel|70 mg/m\^2 administered intravenously (IV) on Day 1 for Cycles 1-6 (the treatment cycle is 3 weeks)
223684526|NCT00356122|DRUG|Oxaliplatin|100 mg/m\^2 administered IV on Day 1 for Cycles 1-6
223684527|NCT00356122|DRUG|Bevacizumab|15 mg/kg administered IV on Day 1 for Cycles 1-6, and every 3 weeks during maintenance therapy for a total treatment of one year, until disease progression or death due to any cause, whichever occurs first.
223684528|NCT00491556|PROCEDURE|Early Initiation of Highly Active Anti-Retroviral Therapy|Treatment: TDF/FTC/ATV/r (preferred), AZT/3TC/ATV/r or other recommended NRTI backbone with ATV/r. Duration: Subjects in the experimental group who achieve virologic control by week 24 and maintain good control through 48 weeks will then de-intensify to ATV/r alone and will be followed for an additional two years.
223684529|NCT00491556|PROCEDURE|Standard Care|Progression: Subjects on the standard care arm will begin therapy when the CD4+ T cell count drops below 350 cells/mm3 or other clinical criteria necessitating treatment as determined by the site clinician occur. Treatment: HAART with TDF/FTC/ATV/r (preferred), AZT/3TC/ATV/r, or other recommended ATV/r based HAART regimen according to current DHHS standard of care. Duration: three years.
223684530|NCT00990457|BEHAVIORAL|Weight Loss Diets Plus Exercise|"The weight loss diet will be either a low-carbohydrate diet or a low-fat, low-calorie diet. All participants will also be enrolled in a supervised exercise program.~The supervised exercise training sessions will take place three times a week for 6 months. Each session will last 1 to 1 ½ hours and will include aerobic exercise and weight training."
223684531|NCT03488758|OTHER|CMF|Taking a infant formula based on cow milk protein fractions, 4-5 feeds per day given by bottle, 180-210 ml/feed, total 800-900ml per day for one mounth
223684532|NCT03488758|OTHER|GMF|Taking a infant formula based on whole goat milk, 4-5 feeds per day given by bottle, 180-210 ml/feed, total 800-900ml per day for one mounth
223684533|NCT06072209|BEHAVIORAL|Behavioral Activation|\- instruction to create a list of individual positive activities. - instruction to include daily positive activities and fill out a mood protocol, which covers the time period shortly before, during and after the activity.
223684534|NCT06072209|BEHAVIORAL|Mindfulness and Gratitude|\- instruction to fill out a mindfulness diary: reflection of daily pleasant situation, instructing the participants to revisit the impressions of their 5 senses during this situation, in addition they should specify how long they have actually dealt with
223684535|NCT06072209|BEHAVIORAL|Combination of Behavioral Activation and Mindfulness and Gratitude|This group will do a combination of the two intervention types.
223684536|NCT05907538|OTHER|Interoceptive accuracy measurement|Interoceptive accuracy will be measured using the Respiratory Occlusion Discrimination Task (ROD task; Van Den Houte et al., 2021). The ROD task measures how good subjects are at distinguishing the lengths of short (max 620 milliseconds) inspiratory occlusions (or respiratory interruptions).
223684537|NCT05907538|OTHER|Interoceptive sensibility measurement|Interoceptive sensibility will be measured using two self-report questionnaires, the The Interoceptive Sensitivity and Attention Questionnaire (ISAQ; Bogaerts et al., 2022) and the the Three-domain Interoceptive Sensations Questionnaire (THISQ; Vlemincx et al., 2021)
223684538|NCT05907538|OTHER|Interoceptive awareness measurement|Interoceptive awareness will be measures using a visual analogue scale (VAS)
223684539|NCT02828501|PROCEDURE|Spinal Manipulation|A spinal manipulation is a high velocity, low amplitude thrust through a physiological barrier in order to elicit a cavitation.
223684540|NCT00538343|DRUG|berubicin hydrochloride (RTA 744)|
223775129|NCT01592630|DRUG|Saline|On-Q pumps containing saline to be attached to TAP catheters
223684541|NCT05455619|DRUG|Evexomostat|Evexomostat (SDX-7320) is a synthetic copolymer-drug conjugate of a novel MetAP2 inhibitor.
223684542|NCT06574464|OTHER|BIG SCORE|"The trauma BIG score is used to predict posttraumatic injury severity and mortality. It was originally designed for the pediatric population. The score is calculated using the Base Deficit (BD), International Normalized Ratio (INR), and Glasgow Coma Scale (GCS) score on admission using the following formula:~BIG score = (admission BD) + (2.5 × INR) + (15 - GCS)."
223684543|NCT06574464|OTHER|Glasgow coma scale|The Glasgow Coma Scale is a neurological assessment tool used to evaluate the level of consciousness of a patient. It assesses three items: eye-opening (spontaneous, 4 points; to verbal stimuli, 3 points; to pain stimuli, 2 points; no response, 1 point); verbal responses (oriented, 5 points; confused but coherent speech, 4 points; inappropriate words, 3 points; incomprehensible speech, 2 points; no response, 1 point); and motor responses (obeys commands, 6 points; localizes pain, 5 points; withdraws from pain, 4 points; flexes in response to pain, 3 points; extends in response to pain, 2 points; no response, 1 point). The total GCS score is obtained by summing the scores for the three items, and it ranges from 3 to 15.
223684544|NCT06574464|OTHER|Revised Trauma Score|The Revised Trauma Score (RTS) is a physiological scoring system used to assess the severity of a traumatic injury. It considers three key parameters, Glasgow Coma Scale (GCS), Systolic Blood Pressure (SBP), and Respiratory Rate (RR), with a total score of 12 points. The study team retrospectively computed the RTS on admission by retrieving the GCS score, SBP, and RR per minute from the hospital's automated systems and archives.
223775130|NCT02802345|DRUG|Nintedanib|
223775131|NCT02802345|DRUG|Placebo|
223775132|NCT02802345|DRUG|Sildenafil|
223775133|NCT03973190|PROCEDURE|Immediate alveolar regeneration after exodontia|The extractions will be performed under local anesthesia, without making a mucoperiosteal flap, making an intraassucular incision and using appropriate periotomes, elevators and forcépes, minimizing the surgical trauma of surrounding tissues. Thorough curettage of the alveolus will be performed at the time of extraction to ensure removal of all granulation tissue and stimulate bleeding from the bone base, to form blood clot and promote healing. The sutures will be removed after 7 days of surgery, except for patients in group 3, in which sutures will not be made.
224262876|NCT06843252|DEVICE|Transcranial direct current stimulation (tDCS)|The active-tDCS treatment will consist of a constant 2mA current applied during daily 30-minute sessions with a 30 second ramp up and ramp down at the start and end of the stimulation. The anode electrode will be placed over the left dorsolateral prefrontal cortex (DLPFC) and the cathode electrode over the right DLPFC.
223775134|NCT03973190|PROCEDURE|installation of dental implant and collection of biological material|The material was collected for histological analysis, extracted with trephine drill of 2.0 mm in diameter. Samples were removed before the incision. A linear incision was then made on the alveolar ridge in the region and flap detachment. The initial insertion of the implant was performed using the contra-angle at 30 rpm, the final insertion of the implant was performed with manual torque wrench, where the insertion torque was measured and the value was tabulated, not exceeding 60 N. cm. The component was installed with a maximum torque of 20 N and SmartPeg® (Integration Diagnostics AB, Göteborg, Sweden) was adapted. The prosthetic component was installed with a maximum torque of 20 N and SmartPeg® (Integration Diagnostics AB, Göteborg, Sweden) was adapted. the tabulated values and the incision was sutured.
223684545|NCT06574464|OTHER|Injury Severity Score|The Injury Severity Score (ISS) is an anatomical scoring system used to assess the severity of injuries sustained by trauma patients. It provides a numerical value based on the anatomical regions of the body affected by trauma and the severity of those injuries. The ISS is calculated by dividing the body into six regions: the head/neck, face, chest, abdomen/pelvis, extremities, and external. Each region is assigned a score ranging from 1 to 6, with 1 indicating minor injury and 6 indicating severe injury. The highest score from each region is squared and then the scores are summed to calculate the overall ISS.
223684546|NCT03368118|DRUG|ABX464|All subjects will receive ABX464 given at 50 mg o.d for an overall period of 48 months.
223684547|NCT05505227|BEHAVIORAL|Stigma-reduction training|While the details will be finalized by the intervention working group after the key modifiable features of OUD-stigma among rural HCPs are isolated in Aim 1, our intervention will include several new elements that distinguish it from existing stigma-reduction interventions. The prototype intervention includes several modules aimed at decreasing stigma, increasing knowledge about medications for OUD, and increasing willingness to prescribe buprenorphine (see Table 3) among rural HCPs currently in practice.
223684548|NCT05505227|BEHAVIORAL|Placebo|HCPs affiliated with clinics in the control arm will receive no training but will be provided with a link to the SAMHSA website where prescribers can learn more about buprenorphine prescribing and apply to receive an X-waiver.
223684549|NCT00000375|DRUG|Nortriptyline-lithium (NOR-Li)|
223684550|NCT00000375|PROCEDURE|Bilateral electroconvulsive therapy (ECT)|
223684551|NCT00000375|DRUG|Continuation therapy|
223835322|NCT00197912|BIOLOGICAL|tumor antigen loaded autologous dendritic cells|DC vaccination regime consists of primary 10 intradermal injections of 1-2 weeks interval (q1w x 4 → q2w x 6). HLA-A2 positive patients are treated with p53, survivin and telomerase peptide-pulsed dendritic cells, and HLA-A2 negative patients are treated with allogeneic tumor lysate pulsed dendritic cells. 50 mg cyclophosphamide (Sendoxan®, Baxter A/S) is administered p.o. twice a day bi-weekly and 200 mg celecoxib (Celebra®, Pfizer) is given p.o. every day. From the 2nd vaccine, 2 MIU Interleukin-2 is administered s.c. on day 2-6.
223684552|NCT00000375|BEHAVIORAL|Continuation ECT|
224262877|NCT06843252|DEVICE|Sham tDCS|Sham-tDCS treatment will consist of the same montage as the active-tDCS but the electric current will be applied only in the first and final 30s of stimulation.
224262878|NCT00532077|DRUG|rhPTH(1-34)|
224262879|NCT00532077|DRUG|SB-751689 100 mg|
224262880|NCT00532077|DRUG|SB-751689 400 mg|
224262881|NCT05990127|DRUG|AK104|AK104 IV, q3w
224262882|NCT05990127|DRUG|Tislelizumab|Tislelizumab IV, q3w
224262883|NCT05990127|DRUG|carboplatin|carboplatin IV, q3w
224262884|NCT05990127|DRUG|Pemetrexed|Pemetrexed IV, q3w (for Nonsquamous NSCLC)
224262885|NCT05990127|DRUG|Paclitaxel|Paclitaxel IV, q3w (for squamous NSCLC)
224262886|NCT01299662|DRUG|Poly ICLC|One 1.6 mg subcutaneous injection of the study drug, poly ICLC in the upper arm.
224262887|NCT02336074|DRUG|Combination Antiretroviral Therapy (cART)|Likely consisting of an Nucleoside reverse-transcriptase inhibitor (NRTI) backbone i.e. Truvada plus a ritonavir-boosted protease inhibitor (PI) e.g. Darunavir + ritonavir. Prescribed at week 0 for the duration of the study.
224262888|NCT02336074|DRUG|Raltegravir|All participants will be dispensed sufficient supplies of Raltegravir to ensure they have sufficient medication to last to the next study visit. Raltegravir is supplied in marketed pack with 30 tablets per bottle.
224262889|NCT02336074|DRUG|Vorinostat|"Vorinostat (suberoylanilide hydroxamic acid abbreviated to SAHA) inhibits the histone deacetylases HDAC1, HDAC2, HDAC3 (Class I) and HDAC6 (Class II).~Vorinostat is supplied as capsules containing 100mg vorinostat and the following inactive ingredients: microcrystalline cellulose, sodium croscarmellose and magnesium stearate."
224262890|NCT02336074|BIOLOGICAL|ChAdV63.HIVconsv (ChAd)|Dosage: 5x1010vp .This dose is obtained by injecting 0.37ml of the vaccine at 1.35x1011vp/ml without dilution. This prime vaccination is administered intramuscularly (IM) into the deltoid muscle of the non-dominant arm at post-randomisation week 00.
224262891|NCT02336074|BIOLOGICAL|MVA.HIVconsv (MVA)|Dosage: 2x108pfu Administration: This dose is obtained by injecting 0.23 ml of the vaccine IM at 8.6x108pfu/ml without dilution. This boost vaccination is administered intramuscularly (IM) into the deltoid muscle of the non-dominant arm at post-randomisation week 08 Day 1 (2 prior to start of vorinostat)
224262892|NCT01426568|BEHAVIORAL|Multi-Convergent Therapy|Cognitive Behavioural Therapy Relaxation Techniques Meditation Stress Management
224262893|NCT04548141|OTHER|Questionnaire|Scoring of the IPAQ is performed according to references. Scoring of the SAPHIR has been submitted for copyright protection (involves a series of 23 additions)
224262894|NCT00627796|DRUG|Lanreotide-Autogel 120 mg|ATG120 mg is given as deep subcutaneous injection into the buttock. Each patient receives one deep subcutaneous injection of ATG120 mg at Visit 1 (V1) and subsequent injection every 4 weeks for 3 injections. Based on GH levels, the dosing interval has been determined as follows: if GH levels were \> 2.5 mcg/l, ATG 120 mg is given every 4 weeks while if they were \< 2.5 mcg/l ATG 120 mg is administered every 6 weeks for another 3 injections. Afterwards, the dose is maintained as above except in patients with GH levels \<1 mcg/l receiving ATG 120 mg every 8 weeks. The estimated duration of treatment is 48-52 weeks according with dose titration.
224262895|NCT02035163|PROCEDURE|Two sites cryoablation|Two ganglionic plexi around atrium was performed with 90-second cryoablation.
223684553|NCT03991546|BEHAVIORAL|Acceptance and Commitment Therapy Delivered via an Automated Mobile Messaging Robot|Mobile messages utilizing the principles of Acceptance and Commitment therapy. These messages were developed in collaboration with a pain psychologist who specializes in treating chronic pain with Acceptance and Commitment therapy. Subjects received twice-daily messages for two weeks following their orthopaedic procedure.
223684554|NCT00993044|DRUG|Irinotecan|"Dose Level 1 Irinotecan 30 mg/m2/day IV on day 1,2,3,4 and 5 Vincristine 1.5mg/m2 (2mg max dose) IV on day 1,8 Temozolomide 100 mg/m2 PO on day 1,2,3,4 and 5 Bevacizumab 15mg/kg IV on day 1~Dose Level 1.5\* Irinotecan 40 mg/m2/day IV on day 1,2,3,4 and 5 Vincristine 1.5mg/m2 (2mg max dose) IV on day 1,8 Temozolomide 100 mg/m2 PO on day 1,2,3,4 and 5 Bevacizumab 15mg/kg IV on day 1~Dose Level 2 Irinotecan 50 mg/m2/day IV on day 1,2,3,4 and 5 Vincristine 1.5mg/m2 (2mg max dose) IV on day 1,8 Temozolomide 100 mg/m2 PO on day 1,2,3,4 and 5 Bevacizumab 15mg/kg IV on day 1~Dose Level -1 Irinotecan 20 mg/m2/day IV on day 1,2,3,4 and 5 Vincristine 1.5mg/m2 (2mg max dose) IV on day 1,8 Temozolomide 100 mg/m2 PO on day 1,2,3,4 and 5 Bevacizumab 15mg/kg IV on day 1~\* Dose escalation will proceed from dose level 1 to dose level 2 and de-escalate to dose level 1.5 if DLT is observed on dose level 2"
223684555|NCT00993044|DRUG|Vincristine|"Dose Level 1 Irinotecan 30 mg/m2/day IV on day 1,2,3,4 and 5 Vincristine 1.5mg/m2 (2mg max dose) IV on day 1,8 Temozolomide 100 mg/m2 PO on day 1,2,3,4 and 5 Bevacizumab 15mg/kg IV on day 1~Dose Level 1.5\* Irinotecan 40 mg/m2/day IV on day 1,2,3,4 and 5 Vincristine 1.5mg/m2 (2mg max dose) IV on day 1,8 Temozolomide 100 mg/m2 PO on day 1,2,3,4 and 5 Bevacizumab 15mg/kg IV on day 1~Dose Level 2 Irinotecan 50 mg/m2/day IV on day 1,2,3,4 and 5 Vincristine 1.5mg/m2 (2mg max dose) IV on day 1,8 Temozolomide 100 mg/m2 PO on day 1,2,3,4 and 5 Bevacizumab 15mg/kg IV on day 1~Dose Level -1 Irinotecan 20 mg/m2/day IV on day 1,2,3,4 and 5 Vincristine 1.5mg/m2 (2mg max dose) IV on day 1,8 Temozolomide 100 mg/m2 PO on day 1,2,3,4 and 5 Bevacizumab 15mg/kg IV on day 1~\* Dose escalation will proceed from dose level 1 to dose level 2 and de-escalate to dose level 1.5 if DLT is observed on dose level 2"
224262896|NCT00906399|DRUG|BIIB017 (peginterferon beta-1a)|Supplied as a liquid in pre-filled syringes to deliver 0.5 mL of 0.25 mg/mL (125 µg dose), self-administered by subcutaneous injection.
224262897|NCT00906399|DRUG|Placebo|Matched placebo provided in pre-filled syringes, to deliver 0.5 mL self-administered by subcutaneous injection.
224262898|NCT00836758|DEVICE|Analysis with AED and manual PSG scoring|The CPAP device will be set-up at a sub-therapeutic pressure and will remain at this pressure for the entire night, if tolerated. Then the events will be analyzed with Automatic Event Detection (AED) and manual PSG scoring.
223684556|NCT00993044|DRUG|Temozolomide|"Dose Level 1 Irinotecan 30 mg/m2/day IV on day 1,2,3,4 and 5 Vincristine 1.5mg/m2 (2mg max dose) IV on day 1,8 Temozolomide 100 mg/m2 PO on day 1,2,3,4 and 5 Bevacizumab 15mg/kg IV on day 1~Dose Level 1.5\* Irinotecan 40 mg/m2/day IV on day 1,2,3,4 and 5 Vincristine 1.5mg/m2 (2mg max dose) IV on day 1,8 Temozolomide 100 mg/m2 PO on day 1,2,3,4 and 5 Bevacizumab 15mg/kg IV on day 1~Dose Level 2 Irinotecan 50 mg/m2/day IV on day 1,2,3,4 and 5 Vincristine 1.5mg/m2 (2mg max dose) IV on day 1,8 Temozolomide 100 mg/m2 PO on day 1,2,3,4 and 5 Bevacizumab 15mg/kg IV on day 1~Dose Level -1 Irinotecan 20 mg/m2/day IV on day 1,2,3,4 and 5 Vincristine 1.5mg/m2 (2mg max dose) IV on day 1,8 Temozolomide 100 mg/m2 PO on day 1,2,3,4 and 5 Bevacizumab 15mg/kg IV on day 1~\* Dose escalation will proceed from dose level 1 to dose level 2 and de-escalate to dose level 1.5 if DLT is observed on dose level 2"
224262899|NCT04225364|DRUG|camrelizumab|Participants will receive camrelizumab, 200mg, intravenously over 30 - 60 minutes, day 1 of every 3 weeks for 6 weeks. Discontinuation will be considered due to toxicity, withdrawal of consent, or end of study. Every 3-week treatment period was considered to be a cycle.
224262900|NCT04225364|DRUG|Paclitaxel for injection (albumin-bound)|Paclitaxel for injection (albumin-bound): 260mg/m2(in total), ivgtt d1, d8, q3w，for 2 cycle
224262901|NCT04225364|DRUG|Cisplatin|75mg/m2(in total), ivgtt d1-d3, q3w, for 2 cycles
224262902|NCT01408654|BEHAVIORAL|Peer Companionship|Peer companionship is provided at least four times per month over two years in the form of friendly visiting, supportive phone calls, and some instrumental support.
224262903|NCT05173298|DRUG|atezolizumab plus bevacizumab|1200 mg of atezolizumab plus 15 mg/kg of body weight of bevacizumab intravenously every 3 weeks
224262904|NCT04892420|DRUG|Dexamethasone|The patients receive 20ml plain bupivacaine (0.5%) + 8 mg dexamethasone (2ml) in adductor canal block after spinal anesthesia.
224262905|NCT04892420|DRUG|Dexmedetomidine|The patients receive 20 ml plain bupivacaine(0.5)+25 microgram dexmedetomidine( diluted in 2 ml normal saline) in adductor canal block after spinal anesthesia .
224262906|NCT04892420|DRUG|Magnesium sulfate|The patients receive 20 ml plain bupivacaine(0.5)+200 milligram magnesium sulphate (2 ml of magnesium 10%) in adductor canal block after spinal anesthesia.
224262907|NCT04892420|DRUG|Bupivacain|The patients receive 20ml plain bupivacaine (0.5%) + 2 ml of Normal saline in adductor canal block after spinal anesthesia.
224262908|NCT04020796|DIETARY_SUPPLEMENT|Beetroot juice|Thirty-seven hypertension, with age 40-70 years were randomized to receive a 500ml volume of beetroot juice contains 11.5 mmol of inorganic nitrate or mineral water in a single moment.
224262909|NCT01212276|DRUG|MORAb-028|Cohort 1: 0.1 mg/kg IV on study day 1 only Cohort 2: 0.2 mg/kg IV on study day 1 only Cohort 3: 0.5 mg/kg IV on study day 1 only Cohort 4: 1.0 mg/kg IV on study day 1 only
224262910|NCT05498662|DEVICE|T3 Pro dental implant system|treatment of tooth loss with T3 Pro dental implants
224262911|NCT06550869|PROCEDURE|Anterior Quadratus Lumborum Block at the lateral supra-arcuate ligament under laparoscopic direct vision|The urologists find the inner arcuate ligament. The scalp needle is inserted from the midpoint of the lower edge of the inner or outer arcuate ligament towards the head to the dorsal side of the diaphragm. After withdrawing without blood, air, or cerebrospinal fluid, 2 ml of normal saline is first administered to observe the fluid spreading towards the head Then, 20 ml of 0.375% ropivacaine hydrochloride injection is administered.
224262912|NCT06550869|PROCEDURE|Local infiltration anesthesia|The urologists give local infiltration anesthesia with 20 ml of 0.375% ropivacaine hydrochloride injection.
224262913|NCT02618460|DEVICE|Non contrast-enhanced magnetic resonance imaging|
224262914|NCT03265860|DEVICE|IntraVoxel Incoherent Motion sequence|The IVIM diffusion sequence with a duration of 2 minutes is added to the imaging protocol.
224262915|NCT03103360|DEVICE|videopupillometer|Measure of pupillary diameter and pupillary pain index via an infrared camera Each measure lasts approximately 20 seconds
224262916|NCT03103360|PROCEDURE|skin incision|performed under general anesthesia by the surgeon, at the beginning of an elective or emergency surgery.
224262917|NCT05163691|DRUG|5 Methoxy N,N Dimethyltryptamine|GH001 administered via inhalation
224262918|NCT05163691|DRUG|Placebo|GH001 Placebo administered via inhalation
224262919|NCT00353457|DRUG|Capecitabine, Oxaliplatin and Cetuximab|Capecitabine 825mg/m2 po BID D1-15 of 21 x2 cycles (Cyle 1 and 2), Capecitabine 825mg/m2 po BID weekly Sun PM-Fri AM x2 cycles (cycle 3 and 4), Capecitabine 825mg/m2 po BID D1-15 of 21 x4 cycles (cycle 5,6,7,8) Oxaliplatin 130mg/m2 IV Day 1 every 3 weeks x2 cycles (Cycle 1 and 2), Oxaliplatin 50mg/m2 IV weekly every Monday x2 cycles (Cycle 3 and 4), Oxaliplatin 130mg/m2 IV day 1 every 3 weeks x4 cycles (Cycles 5,6,7,8) Cetuximab 400mg/m2 IV cycle 1 day1, Cetuximab 250mg/m2 Day 1,8,15 of 21 for cycles 1-8
224262920|NCT00353457|RADIATION|Radiation|45 Gy in 25 fractions, 3-fraction boost 5.4 Gy
224262921|NCT01124786|DRUG|CO-1.01|1250 mg/m2 intravenous infusion weekly for 3 weeks every 4 weeks
224262922|NCT01124786|DRUG|Gemcitabine|1000 mg/m2 intravenous infusion weekly for 7 weeks followed by 1 week rest, then weekly for 3 weeks every 4 weeks
224262923|NCT00544492|DEVICE|catheter for AV fistula cannulation|catheters for buttonhole technique (blunt, bevel point), catheters for rope ladder technique (sharp, bevel point or sharp, cylindrical point)
224262924|NCT04739735|PROCEDURE|Dental Local Anaesthesia|lower primary molar teeth indicated for extraction will be given a local anaesthetic injection according to the random allocation to one of the two arms mentioned previously
224262925|NCT02054819|OTHER|Induction chemotherapy and concurrent radiation|Cycle 1: irinotecan 65mg/m2 and cisplatin 30 mg/m2 on Day 1 and 8 Q 21 days Cycles 2-4: irinotecan 65 mg/m2, and cisplatin 30 mg/m2 Day 1 and 8 Q 21 days PLUS radiation therapy 66 Gy/7weeks/33 daily fractions
223684557|NCT00993044|DRUG|Bevacizumab|"Dose Level 1 Irinotecan 30 mg/m2/day IV on day 1,2,3,4 and 5 Vincristine 1.5mg/m2 (2mg max dose) IV on day 1,8 Temozolomide 100 mg/m2 PO on day 1,2,3,4 and 5 Bevacizumab 15mg/kg IV on day 1~Dose Level 1.5\* Irinotecan 40 mg/m2/day IV on day 1,2,3,4 and 5 Vincristine 1.5mg/m2 (2mg max dose) IV on day 1,8 Temozolomide 100 mg/m2 PO on day 1,2,3,4 and 5 Bevacizumab 15mg/kg IV on day 1~Dose Level 2 Irinotecan 50 mg/m2/day IV on day 1,2,3,4 and 5 Vincristine 1.5mg/m2 (2mg max dose) IV on day 1,8 Temozolomide 100 mg/m2 PO on day 1,2,3,4 and 5 Bevacizumab 15mg/kg IV on day 1~Dose Level -1 Irinotecan 20 mg/m2/day IV on day 1,2,3,4 and 5 Vincristine 1.5mg/m2 (2mg max dose) IV on day 1,8 Temozolomide 100 mg/m2 PO on day 1,2,3,4 and 5 Bevacizumab 15mg/kg IV on day 1~\* Dose escalation will proceed from dose level 1 to dose level 2 and de-escalate to dose level 1.5 if DLT is observed on dose level 2"
223684558|NCT06422754|DEVICE|Becure GmbH|Becure Balance System
223684559|NCT04609475|PROCEDURE|Osseodensification technique|Implant bed preparation will be performed according to the manufacturer's guidelines, densifying burs (Densah® Burs) will be used sequentially in densifying mode (counterclockwise drill speed 800-1500 rpm with copious irrigation) to achieve the planned osteotomy diameter and desired ridge expansion. The implant will be then placed in the prepared osteotomy
223684560|NCT04609475|PROCEDURE|Motor driven expanders' technique|The technique consisted of preparing the implant bed by progressively increasing the size of the osteotomes until the desired expansion will be achieved. At the planned implant site, a pilot drill 1000 rpm with irrigation until the desired length, then expansion with the series of ridge spreaders and finally using the final drill. The implant will be then placed in the prepared osteotomy.
223684561|NCT03228199|OTHER|Intervention group|Will immediately receive a free pair of presbyopic glasses through the Clear Vision Workplace program. These glasses will correct the worker's vision at their usual working distance, and will not correct astigmatism.
223684562|NCT03228199|OTHER|Control Group|Will be deferred to receive spectacles as above, after the 12 week evaluation period.
223684563|NCT04134351|OTHER|Bronchial challenge test|Bronchial challenge test with sphingosine-1-phosphate
223684564|NCT04768998|OTHER|Observational of different courses of SARS-CoV-2 infection in different phases (acute vs. post-acute) and settings|Observatory Cohorts focusing (I) on subjects after SARS-CoV-2 infection that are recruited from the general population (POP), and on subjects with acute SARS-CoV-2 infections recruited (II) in university hospital high-care settings or (III) general health care.
223684565|NCT05408065|DRUG|Triamcinolone Hexacetonide and hyaluronic acid|infiltration under fluoroscopy
223684566|NCT05408065|DRUG|Triamcinolone Hexacetonide|infiltration under fluoroscopy
223684567|NCT04008381|BIOLOGICAL|Ex-vivo Expanded γδ T Lymphocytes|Patients receive ex-vivo expanded γδ T Lymphocytes (Dose escalation, 2\*10\^6, 4\*10\^6, 8\*10\^6 of cells per kg of body weight).
223835323|NCT02702934|OTHER|Test meal|Participants received in random order a test meal (900Kcal, 100g carbohydrates) containing rusks prepared with amylose-rich wheat flour or conventional flour. Blood samples were collected at fasting and every 30 minutes over 4 hours. Breath hydrogen was evaluated as a marker of intestinal fermentation. Participants underwent Visual Analogue Scale to assess subjective appetite sensations.
223835324|NCT00804869|DEVICE|PalmScan A2000 ultrasonography system (Micro Medical Devices, Calabasas, CA)|PalmScan biometric measurements
223835325|NCT00804869|DEVICE|Standard A-mode ultrasound (Eye Cubed™, Ellex, Adelaide, Australia).|A-mode biometric measurements group
223684568|NCT00161421|DRUG|Oral Testosterone|200 mg (Formulation A) Day 1 400 mg (Formulation A) Day 2, fasting; Day 3, with food 200 mg (Formulation B) Day 8, fasting 400 mg (Formulation B) Day 9, fasting; Day 10, with food
223684569|NCT00161421|DRUG|Leuprolide (Lupron)|7.5 mg injection into muscle (once) (Day -14)
223684570|NCT00161421|DRUG|Dutasteride|24.5 mg load (3.5 mg x 7 capsulesDay -14 only) 0.5 mg daily (Day -13 to day -1)
223684571|NCT05352061|BEHAVIORAL|CBT for Syndemics and Adherence Factors|Each hour-long session is conducted via zoom or in person with a study clinician. Sessions focus on HIV medication adherence, coping with life stressors, and managing other challenging situations (e.g., possible traumatic experiences, drug and alcohol use and sexual behavior) that may affect mental or HIV-related health.
223684572|NCT01576887|DRUG|Bardoxolone Methyl 20 mg|Oral, once daily
223684573|NCT01576887|DRUG|Placebo|Oral, once daily
223684575|NCT00734747|DEVICE|Medigus SRS endoscopic stapling system|The system is designed to staple the stomach to the esophagus in 2 or 3 locations using a quintuplet of standard B shaped, 4.8 mm titanium staples in each location.
223684576|NCT05560646|DRUG|OG-6219|OG-6219 Dose 1, Dose 2, Dose 3 BID: Participants will receive (orally) OG-6219 tablets during treatment cycles.
223684577|NCT05560646|DRUG|Placebo|Participants will receive (orally) OG-6219 Placebo tablets BID during treatment cycles.
223684578|NCT06985992|PROCEDURE|Group morphine|Group Morphine: Spinal anesthesia will be applied to patients who will undergo caesarean section using a combination of 2 ml (10 mg) bupivacaine + 0.1 ml (100 mcg) morphine + 0.5 ml saline
223684579|NCT06985992|PROCEDURE|Group morfin+dexamethasone|Group morfin+dexamethasone: Spinal anesthesia will be applied to patients who will undergo a caesarean section using a combination of 2 ml (10 mg) bupivacaine + 0.1 ml (100 mcg) morphine + 0.5 ml (2 mg) dexamethasone
223684580|NCT06986096|BEHAVIORAL|Aerobic-strength training and nutritional counseling|The intervention consists of a structured program that includes aerobic-strength training (1h training, 3 times per week) conducted by professional trainers combined with nutritional counseling.
223684581|NCT06986096|BEHAVIORAL|Cognitive training and stretching.|The intervention consists of a structured program that includes cognitive training combined with stretching training (90mins training, 2x per week).
223684582|NCT06184737|BEHAVIORAL|iSIPsmarter|iSIPsmarter is a technology-based behavioral and health literacy intervention. It is comprised of six Internet-delivered Cores, an integrated short message service (SMS) strategy to engage users in tracking SSB behaviors, and the incorporation of a cellular enabled scale for in-home weight tracking. Participants will be prompted (via email or text) to self-monitor their sugar-sweetened beverage intake. iSIPsmarter is a highly interactive, structured, and self-guided program that uses strategies previously proven to promote behavior change. iSIPsmarter also incorporates a stepped care approach to re-engage users who struggle to complete components.
223684583|NCT06184737|BEHAVIORAL|Patient Education (PE)|The PE website will include scientifically accurate information that is typical of nutrition education websites and will include information about SSB recommendations, types of SSB and portion size, SSB-related health risks, energy balance information, identifying personal motivators and barriers to reducing SSB intake, interpreting SSB nutrition labels, and recognizing media influences and misclaims in SSB advertisements, as well as printable forms to track SSB and weight. Unlike iSIPsmarter, the content will not be tailored and will be presented all at once.
223684584|NCT04070911|OTHER|WATER|ORAL WATER
223684585|NCT04070911|OTHER|ICE APPLICATION|ICE APPLICATION
223684586|NCT06985459|DEVICE|PIP extension deficit treated with an exercise RMF orthosis|The RM orthoses will be worn between 6-12 hours per day during functional use.
223684587|NCT06985459|DEVICE|PIP extension deficit treated with a placebo RMF orthosis|"The placebo orthosis has the same design as the exercise RM orthoses, but without a difference in the extension or flexion angle, respectively, to the adjacent finger - therefore neutralizing the quadriga phenomena, which is the effect that makes RM orthoses work."
223684588|NCT06985459|DEVICE|PIP flexion deficits treated with a placebo RMF orthosis|"The placebo orthosis have the same design as the exercise RM orthoses, but without a difference in the extension or flexion angle, respectively, to the adjacent finger - therefore neutralizing the quadriga phenomena, which is the effect that makes RM orthoses work."
223684589|NCT06985459|DEVICE|PIP flexion deficits treated with an exercise RME orthosis|The dedicated orthosis wearing time is 6-12 hours per day during functional use.
223684590|NCT06984848|COMBINATION_PRODUCT|Oral7® mouth spray contains Natural Enzymes (Lactoperoxidase, Glucose Oxidase, Lactoferrin, Lysozyme), Calcium, Xylitol, Aloe Vera, Natural peppermint.|This study aims to evaluate the effectiveness of an enzymatic-containing mouth spray (Oral7®) on xerostomia symptoms, unstimulated salivary flow rate, and oral health-related quality of life (OHRQoL) in older patients with xerostomia
224262926|NCT02054819|OTHER|Consolidation: Radiation therapy to metastatic sites|At least 60 Gy total (taking into account a possible 3 Gy x 4 pre-treatment or equivalent) to all metastatic sites. For brain, 2.5 Gy x 14 to whole brain to follow stereotactic radiosurgery (SRS).
224262927|NCT01676064|DRUG|ringer lactate solution|
224262928|NCT01676064|OTHER|restrictive fluid regime|
224262929|NCT00075608|BIOLOGICAL|filgrastim|16mcg/kg IV daily beginning three days prior to stem cell collection through last day of stem cell collection
224262930|NCT00075608|DRUG|melphalan|140-200 mcg/kg IV over two days
224262931|NCT00075608|PROCEDURE|autologous stem cell transplantation|infusion of previously collected stem cells on Day 0
223775135|NCT03973190|DEVICE|ISQ analysis|The prosthetic component already installed. On it is adapted the SmartPeg® (Integration Diagnostics AB, Göteborg, Sweden). According to the manufacturer, the device generates a series of signals with different frequencies in Hertz (Hz) and these values are immediately converted to ISQ (Implantation Stability Coefficient), providing fast and accurate monitoring. The calibration is performed on the buccal and palatal surfaces of the intermediaries, that is, each implant was submitted to 2 readings. The readings were captured and tabulated for further analysis. were repeated at intervals of 7 to 10 days, 30 days and 60 days, for evaluation of SSI in the period of osseointegration. With the objective of not subjecting the implant to torque and torque during this period and to avoid interfering with the osseointegration process, the micro-pillars were covered with the micro-pillar protection screws with digital pressure only.
223775136|NCT02155439|DRUG|5-fluorouracil|antimitotic drug
223775137|NCT02155439|DRUG|Triamcinolone|
223775138|NCT06170333|DRUG|8% sulphur and A. vera soap|Patients in experimental arms will receive the combination of 8% sulphur and A. vera soap for four weeks along with 2% ketoconazole shampoo for a week.
223775139|NCT05236790|DIAGNOSTIC_TEST|Detection and classification and size measurement of polyp by Artificial Intelligence (Cad eye) and the Scale Eye|Detection and classification and size measurement of polyp by Artificial Intelligence (CADeye) and Scale Eye This study will be conducted in multiple phases: phase 1 (pilot phase, n=40 polyps, about 60 patients) to evaluate the feasibility of applying Scale Eye in real-time practice, training endoscopists to work with CADe and CADx and determining the sample size and reference standard to evaluate SCALE-EYE during the second phase of the study (randomized controlled trial), phase 2 will evaluate the performance of SCALE-EYE and CAD-eye in real-time practice. The sample size for phase 2 (RCT comparing visual with scasle eye) will be based on the pilot data allowing to compare relative accuracy of size measurement with scale eye versus visual size estimation. After completion of phase 2 later phases will use instruments such as snare and/or forceps as reference measurement devices compared to relative accuracy of measurement when using scale eye.
223684591|NCT06987344|OTHER|Field-based closed kinetic chain exercise with progressively increased time under tension|This intervention is uniquely characterized by the integration of field-based closed kinetic chain (CKC) exercises with a systematically increased eccentric time under tension (TUT), specifically tailored for university-level soccer players. Unlike conventional strength training protocols, which are often gym-based and rely on traditional resistance machines or free weights, this program emphasizes functional, sport-specific movement patterns performed on the field, enhancing ecological validity and transfer to soccer performance.
223684592|NCT06987344|OTHER|Regular soccer training routines|Trained three times a week: two days were dedicated to functional and tactical on-field training, while the third day was reserved for a two-hour gym session focused on flexibility, muscular strength, and endurance development.
223684593|NCT06242743|OTHER|Scalpel blade needles|Patients were assigned to IANB injection by double scalpel blade bevel needles.
223684594|NCT06242743|OTHER|standard blade needles|Patients were assigned to IANB injection by standard blade bevel needles.
223775140|NCT05323305|PROCEDURE|ultrasound guided regional block|Bupivacaine injection by the use of ultrasound in the pectointercostal fascial plane in one group and in the trasversus thoracic plane in the other group.
223775141|NCT01817972|BIOLOGICAL|Certolizumab pegol|Subcutaneous injection
223775142|NCT01817972|DRUG|Azathioprine|50mg tablets
223775143|NCT06531668|DIETARY_SUPPLEMENT|Beyond Hormone|Participants will take three capsules once daily with their morning meal for the duration of three menstrual cycles.
223775144|NCT06531668|OTHER|Placebo|Participants will take three capsules once daily with their morning meal for the duration of three menstrual cycles.
223775145|NCT05026957|DEVICE|SharedHeart|A smartphone application
223775146|NCT05878366|OTHER|Seasonal Malaria Chemoprophylaxis (under 5 year old) implemented by the MoH without DOT|Standard approach for SMC strategy used by the Ministry of Health (without directly-observed therapy) and without any interference of the study team. Implemented over 4 rounds, carried out in June-October 2023 with \~30 days between rounds.
223684595|NCT03344523|DRUG|Iron protein succinylate oral solution|Iron protein succinylate oral solution
223684596|NCT03344523|OTHER|standard treatment|standard treatment
223684597|NCT01397097|DRUG|LNG-IUS (BAY 86-5028)|LCS12 insertion will occur at randomization visit (Visit 2). Duration of study treatment is 12 months with an follow-up extension for up to 3 years
223684598|NCT01397097|DRUG|68 mg etonorgestrel implant for subdermal use (Nexplanon)|Implant insertion will occur at randomization visit (Visit 2). Duration of study treatment is 12 months, may be continued up to 3 years under standard care.
223684599|NCT06990152|OTHER|MCTs and fiber|Water-soluble powder containing medium-chain triglycerides, soluble and unsoluble fiber.
223684600|NCT06990152|OTHER|Placebo powder|Water-soluble powder containing no medium-chain triglycerides and no fiber.
223684601|NCT06993376|PROCEDURE|PENG block|Group LESBP: 28 patients will receive single shot LESPB after spinal induction. Group PENG: 28 patients will receive single shot PENG after spinal induction.
224262932|NCT00075608|PROCEDURE|stem cell infusion|infusion of previously collected stem cells on Day 0
224262933|NCT02177617|DRUG|Botox injection|Participants will receive a tailored dose of Botox to address their Cervical Dystonia symptoms
224262934|NCT02177617|BEHAVIORAL|Physical Therapy|Participants will undergo physical therapy sessions with a physical therapist trained in movement disorders. Participants will be instructed to continue these exercises five times per week, and will be called weekly by the investigator to check progress.
224262935|NCT02177617|PROCEDURE|Transcranial magnetic stimulation (TMS)|For these tests, participants will sit in a chair that looks like one found at the dentist's office. A nerve stimulator will be placed on the wrist of the right hand to stimulate the median and ulnar nerves. The intensity of the nerve stimulator will be gradually increased until the right thumb begins to twitch. A magnetic coil will be placed on the scalp on the left side of the head, overlying the brain's motor cortex, to stimulate the brain's output to the muscles in the opposite hand. This procedure will be repeated using the left wrist and the right side of the head.
224262936|NCT05845723|DRUG|tocilizumab|Participants will receive intravenous infusion of tocilizumab 8mg/kg every 4 weeks for 24 weeks.
224262937|NCT05845723|DRUG|tofacitinib|Participants will receive tofacitinib 5mg twice a day for 24 weeks of treatment.
223684602|NCT06993376|PROCEDURE|ESPB|Group LESBP: 28 patients will receive single shot LESPB after spinal induction. Group PENG: 28 patients will receive single shot PENG after spinal induction.
223684603|NCT06862648|DEVICE|Acoustic Stimulation Therapy Device|The SUI-100 Device is a non-invasive device designed for the treatment of stress urinary incontinence (SUI) in females.
223684604|NCT06862648|DEVICE|Sham Acoustic Stimulation Therapy Device|The sham intervention uses the same device setup with sham procedures.
223684605|NCT03757390|DRUG|Exforge® tab 5/160mg, Crestor® tab 10mg|co-administration of Amlodipine 5mg/Valsartan 160mg(combination drug) and Rosuvastation 10mg
223684606|NCT03757390|DRUG|CJ-30060 5/160/10mg|Fixed-dose combination drug containing Amlodipine 5mg and Valsartan 160mg and Rosuvastatin 10mg
223684607|NCT06993558|PROCEDURE|Poly-L-Lactic Acid (Sculptra) injection|1 to 2 sessions at intervals of 4 to 6 weeks are planned with PLLA (Sculptra®, Galderma Laboratories). PLLA will be injected into the face or neck region using a blunt cannula. For reconstitution, 7 ml of saline solution and 1 ml of 1 % lidocaine will be used. 5 minutes of massaging for 5 times a day are recommended.
223684608|NCT06993558|PROCEDURE|Calcium Hydroxyapatite|For CaHA treatment (Radiesse®, Merz Pharma; HarmonyCa®, Allergan), 1 session is planned. The face (cheeks, jawline) or neck will be augmented using a blunt cannula, either diluted (Radiesse® 1:0.2 - 1:2) or undiluted (HarmonyCA®) depending on the product and the region being treated.
223684609|NCT06993558|PROCEDURE|Radiofrequency Microneedling|For RFMN treatment (Genius®, Lutronic Medical Systems), 1 to 3 sessions at intervals of 6 to 8 weeks are planned. Prior to treatment, subjects were given topical anesthesia (23% lidocaine, 3.5% tetracaine) under occlusion for at least 1.5 hours. The face will be treated with an RFMN system, using parameters adjusted for each anatomical location. Each region received three passes with 50 - 70 % overlap, starting with the longest needle setting. A minimum total energy of 1000 J will be aimed. Treatment will be performed using forced cooled air (Cryo6, Zimmer Aesthe cDivision).
223684610|NCT06994910|OTHER|Maitland mobilization techniques|Participants with temporomandibular joint dysfunction received Maitland mobilization techniques applied to the TMJ over a defined treatment period. Outcomes were assessed at baseline (pre-intervention) and after completion of the intervention (post-intervention)
223684611|NCT06995534|OTHER|splint|static wrist-hand splint + education on activity modification and positioning in daily life
223684612|NCT06995534|OTHER|Exercise Therapy|Home-based Exercise Therapy + Education on activity modification and positioning in daily life
223684613|NCT06994624|OTHER|Nutritional intervention|A plant-based diet
223684614|NCT06993649|BEHAVIORAL|Experimental High Reality Simulator|The process steps including normal labour skills will be shown on d1= High Reality simulator (full-size, computer-based, time-setting, expressions of pain from the mother, performed with a female robotic simulator, Noelle S575 Mother and Newborn simulator), d2= Medium Reality simulator (full-size, fetal heart sounds can be listened, SB32878U full-length birth model, timed with a simple hand-held monitor, birth process is performed with an automatic birth system) and d3= simulated woman (manual delivery of the baby, Gaumard S500 Half-Length Birth Simulator on which the midwifery student will apply the labour scenario) will be done to each student in the group respectively.
223684615|NCT06993649|BEHAVIORAL|Experimental Medium Reality Simulator|The process steps including normal labour skills will be shown on d2= Medium Reality simulator (full-size, fetal heart sounds can be listened, SB32878U full-length birth model, timed with a simple hand-held monitor, birth process is performed with an automatic birth system) will be done to each student in the group respectively.
223684616|NCT06993649|BEHAVIORAL|Experimental Simulated Woman|Then, the process steps including normal labour skills will be shown d3= simulated woman (manual delivery of the baby, Gaumard S500 Half-Length Birth Simulator on which the midwifery student will apply the scenario of labour by the midwifery student) will be done to each student in the group respectively.
223684617|NCT06993519|OTHER|Probin Pocket Depth reduction|Probin Pocket Depth reduction in millimetres before and after treatment
223684618|NCT06994403|DIETARY_SUPPLEMENT|Durum wheat pasta enriched with carob flour|Participants will consume 68 g of durum wheat pasta enriched with carob flour (231 kcal), providing 50 g of available carbohydrates. The pasta will be served with 55 g of tomato sauce prepared with 2.5 g of extra virgin olive oil.
223684619|NCT06994403|DIETARY_SUPPLEMENT|Standard durum wheat pasta|Participants will consume 63 g of standard durum wheat pasta (221 kcal), providing 50 g of available carbohydrates. The pasta will be served with 55 g of tomato sauce prepared with 2.5 g of extra virgin olive oil.
223684620|NCT06994403|DIETARY_SUPPLEMENT|White bread reference meal|Participants will consume 84 g of white bread (225 kcal), providing 50 g of available carbohydrates. The bread will be served with 55 g of tomato sauce prepared with 2.5 g of extra virgin olive oil.
223684621|NCT06995482|DRUG|KSHN001034|"Test Product: KSHN001034, 5 mL vial containing 113 mg/mL of KSHN001034, equivalent to 100 mg/mL of fulvestrant. Manufactured for Kashiv Biosciences LLC, USA.~• 6 subjects will receive low dose of KSHN001034 IM on Days 1, 8, 15, and 22."
224262938|NCT05845723|DRUG|cyclophosphamide|Participants will receive intravenous infusion of cyclophosphamide 0.5g biweekly for 24 weeks.
224262939|NCT01129986|DEVICE|DermaStream|Five treatment days. On each day DermaStream application for up to 4 hours of saline streaming.
224262940|NCT01665508|DRUG|Nebivolol|Patient to start nebivolol and have repeat testing in 3 months
224262941|NCT03946787|OTHER|Eye Movement Desensitization and Reprocessing (EMDR) Therapy|The reprocessing and desensitization of each traumatic memory occurs in eight phases. In the first two phases, the therapist identifies targets and develops a treatment plan, enhances and develops personal resources, before working on traumatic memories. In stages 3 to 6, reprocessing and desensitization of memory is done. The patient focuses on the image of the event, negative beliefs and associated bodily sensations, while moving the eyes from side to side, following the therapist's fingers or other dual attention stimuli (eg, manual touch, auditory stimulation). Phases 7 and 8 are closing and reassessing, where the therapist determines if the memory has been processed properly.
224262942|NCT03946787|OTHER|Treatment as Usual|TAU will consist of the psychopharmacological approach appropriate to each patient according to the evaluation of a psychiatrist of childhood and adolescence's outpatient service.
224262943|NCT00750243|DRUG|LT-NS001|1200 mg b.i.d. p.o. for 7.5 days
224262944|NCT00750243|DRUG|Naprosyn®|500 mg b.i.d. p.o. for 7.5 days
224262945|NCT03272685|DRUG|Very Low Nicotine Content Cigarettes|0.4 mg nicotine/g tobacco; 9 mg tar
224262946|NCT03272685|DRUG|Normal Nicotine Content Cigarettes|15.8 mg nicotine/g tobacco; 9 mg tar
224262947|NCT02555137|OTHER|'prediction score' and 'rule-out criteria'|The combination of the 'prediction score' and the 'rule-out criteria' constitutes an accurate follow-up after PE aimed at diagnosing CTEPH in early stages.
224262948|NCT02355847|OTHER|Lectures|Lectures
224262949|NCT01450592|OTHER|No drug|Diabetic Population
224262950|NCT01450592|OTHER|No drug|Non-Diabetic Population
224262951|NCT06039735|OTHER|Chemotherapy and/or autologous hematopoietic stem cell transplantation|Didn't interfere patients' treatment plan. Patients with chemotherapy (lenalidomide,bortezomib and dexamethasone) and/or autologous hematopoietic stem cell transplantation(ASCT) which is assessed by clinical doctors and only conventional treatments were used
223684622|NCT06995482|DRUG|KSHN001034|"Test Product: KSHN001034, 5 mL vial containing 113 mg/mL of KSHN001034, equivalent to 100 mg/mL of fulvestrant. Manufactured for Kashiv Biosciences LLC, USA.~• 6 subjects will receive medium dose of KSHN001034 IM on Days 1, 8, 15, and 22."
223684623|NCT06995482|DRUG|KSHN001034|"Test Product: KSHN001034, 5 mL vial containing 113 mg/mL of KSHN001034, equivalent to 100 mg/mL of fulvestrant. Manufactured for Kashiv Biosciences LLC, USA.~• 6 subjects will receive high dose of KSHN001034 IM on Days 1, 8, 15, and 22."
223684624|NCT06995482|DRUG|KSHN001034|"Test Product: KSHN001034, 5 mL vial containing 113 mg/mL of KSHN001034, equivalent to 100 mg/mL of fulvestrant. Manufactured for Kashiv Biosciences LLC, USA.~• 6 subjects will receive low dose of KSHN001034 SC on Days 1, 8, 15, and 22."
223684625|NCT06995482|DRUG|KSHN001034|"Test Product: KSHN001034, 5 mL vial containing 113 mg/mL of KSHN001034, equivalent to 100 mg/mL of fulvestrant. Manufactured for Kashiv Biosciences LLC, USA.~• 6 subjects will receive medium dose of KSHN001034 SC on Days 1, 8, 15, and 22."
223684626|NCT06995482|DRUG|Fulvestrant|"Reference Product: Faslodex® (Fulvestrant), 5 mL pre-filled syringe containing 250 mg/5 mL of fulvestrant, administered as two 5 mL injections (total 500 mg) via intramuscular (IM) injection. Marketed by AstraZeneca.~• 2 subjects will receive 500 mg Fulvestrant IM on Days 1 and 15."
223684627|NCT06995248|BEHAVIORAL|Laughter Yoga|Laughter yoga sessions are a behavioral intervention regularly conducted to help participants reduce stress, build social connections, and enhance overall well-being.
223684628|NCT06994234|BEHAVIORAL|In-Place Slow Jogging|ultra-jogging training was carried out 5 times a week, and each training session lasted for 30 minutes.
223684629|NCT06993987|OTHER|Descriptive analysis|The descriptive analysis of qualitative variables (reason for admission) will be carried out in the form of frequencies and percentages. Quantitative variables will be described in terms of averages, medians or standard deviations, as required.
223684630|NCT06993883|DRUG|Venetoclax|observational study for the result of venetoclax use combined with chemotherapy in AML patients in Sohag governorate
223684631|NCT06994585|DRUG|Drinklear|Our hospital invites outpatient patients aged 20 to 75 years who are scheduled to undergo colonoscopy and are willing to participate in this research study. After obtaining informed consent and signing the consent form, participants will be randomly assigned to receive either Polyethylene Glycol (Niflec Powder, China Chemical \& Pharmaceutical Co., Ltd., Taiwan) or Picosulfate Sodium/Citric Acid/Magnesium Oxide (Drinklear Powder, China Chemical \& Pharmaceutical Co., Ltd., Taiwan) as the bowel preparation for colonoscopy.
223684632|NCT06994585|DRUG|Niflec|Our hospital invites outpatient patients aged 20 to 75 years who are scheduled to undergo colonoscopy and are willing to participate in this research study. After obtaining informed consent and signing the consent form, participants will be randomly assigned to receive either Polyethylene Glycol (Niflec Powder, China Chemical \& Pharmaceutical Co., Ltd., Taiwan) or Picosulfate Sodium/Citric Acid/Magnesium Oxide (Drinklear Powder, China Chemical \& Pharmaceutical Co., Ltd., Taiwan) as the bowel preparation for colonoscopy.
223684633|NCT06995404|PROCEDURE|TAP Block Group|Patients in the TAP group will receive a bilateral Transversus Abdominis Plane (TAP) block under ultrasound guidance prior to surgery after general anaesthesia, with the local anesthetic administered between the internal oblique and transversus abdominis muscles. A total of 40 mL of 0.25% bupivacaine will be used for the procedure.
223684634|NCT06995404|PROCEDURE|M-TAPA Block group|Patients in the M-TAPA group will receive a bilateral Thoracoabdominal Nerve Block through Perichondrial Approach (M-TAPA) under ultrasound guidance prior to surgery after general anaesthesia. A total of 40 mL of 0.25% bupivacaine will be used for the procedure.
223684635|NCT06995638|BEHAVIORAL|Web-based Cognitive Training (with strategy)|Participants will learn to play a complex online game using specific guidance or strategy.
223684636|NCT06995638|BEHAVIORAL|Web-based Cognitive Training (without strategy)|Participants will learn to play a complex online game without specific guidance or strategy.
223775147|NCT05878366|OTHER|Seasonal Malaria Chemoprophylaxis (under 5 years old) with DOT|SMC will be implemented with the same number of rounds and the same timing as in active comparator arm but village health workers will visit the participants at home to administer each dose of study treatment (with DOT-directly-observed therapy)
223684637|NCT06995079|PROCEDURE|Postoperative pain assessment of patients who underwent block|Postoperative pain assessment of patients who underwent block
223684638|NCT06994702|DEVICE|MRI without mask|MRI in position of cerebral radiotherapy treatment without mask
223684639|NCT06994702|DEVICE|MRI with mask 1|MRI in position of cerebral radiotherapy treatment with mask 1
223684640|NCT06994702|DEVICE|MRI with mask 2|MRI in position of cerebral radiotherapy treatment with mask 2
223684641|NCT06993779|OTHER|Deep learning system for prognostication prediction in upper tract urothelial carcinoma|develop and validate a deep learning system for prognostication prediction in upper tract urothelial carcinoma based on CT radiomics and whole slide images.
223775148|NCT05878366|OTHER|Seasonal Malaria Chemoprophylaxis (under 10 years old) with DOT|SMC will be implemented as in arm 2 but age of participants is extended up to 10 years: each dose of study treatment (with DOT-directly-observed therapy) distributed at home by village health workers.
223684642|NCT06994637|OTHER|Liquid Hourglass|The liquid hourglass to be used in the study is made of high-quality plastic material, approximately 14 cm long. It contains colored liquid gel. When the hourglass is turned, the colored liquid gel inside flows downwards in the form of bubbles, drop by drop. It is suitable for use by all age groups of children. The visual and moving nature of the liquid hourglass may distract the child during the blood collection process.
223684643|NCT06994637|OTHER|Spiky Ball|The spiky ball to be used in the study is a ball made of sturdy environmentally friendly plastic, approximately 6 cm in size. This ball has a hard body with thorns on it and provides tactile stimulation by pricking the child's fingers. The pressure applied by the thorns on the balls to the hand can reduce pain, muscle tension and stress by stimulating the nerve endings more quickly. It is suitable for use by children over the age of two. The tactile stimulation on the spiky ball can distract the child during the blood collection process.
223684644|NCT06994455|PROCEDURE|scaling and root planing along with antibiotic intervention|doxycycline gel exhibits bacteriostatic activity against prevalent periodontal pathogens
223684645|NCT06994455|PROCEDURE|scaling and root planing along with antibiotic intervention|the formulation of doxycycline and incorprating it with PLGA nano-particles will increase the absorption rate in gingival sulcus
223684646|NCT06994455|PROCEDURE|scaling and root planing|control group in the study
223684647|NCT06993506|DRUG|SKB264 Monotherapy or Combination Therapy|The interventions in this study comprised SKB264 monotherapy or combination therapy involving SKB264. The specific combination regimens were determined based on real-world clinical practice.
223684648|NCT06994390|DEVICE|tDCS|This group will receive single-phase direct current with an intensity of 2 mA up. Electrodes with a size of 35cm² (5 x 7 centimeters) will be used. Electrodes will be placed on the scalp, fixed with elastic bands, and immersed in 10 to 12 mL of saline solution.
223684649|NCT06994390|DEVICE|sham intervention|The device displays will be identical across active and sham groups, and to ensure blinding, an active current will be applied for 30 seconds at the beginning and end of the sham stimulation to mimic the sensation of the current ramp experienced in active stimulation. Stimulations of less than 3 minutes of tDCS do not induce cortical excitability effects, according to Nitsche and Paulus (2000), being safely inactive for the expected results.
223684650|NCT06994572|DRUG|CT-01|Investigational small-molecule degrader targeting transcription factors in HCC. Used as monotherapy or with everolimus in dose-escalation/expansion settings. Specific to protocol CT-01-CD-1.
223684651|NCT06994572|DRUG|EVEROLIMUS|Approved mTOR inhibitor used in combination with CT-01 for HCC in this study. Evaluated for safety, tolerability, and PK/PD in CT-01-CD-1 protocol.
223684652|NCT06995547|DEVICE|implant overdenture|Each patient will be receive two dental implants for overdenture fixation
223684653|NCT06993948|DEVICE|Transthoracic echocardiography|Transthoracic echocardiography (TTE) was carried out. The assessment of left ventricular ejection fraction (LVEF) relied primarily on two-dimensional echocardiography using visual estimation.
223684654|NCT02516267|DEVICE|Multiplate ADP®|Patients will be evaluated by platelet function testing (Multiplate ADP®) daily until the value obtained\> 46 AU, when they will be immediately released to CABG
223684655|NCT01591850|DRUG|RO5093151|Single oral dose
223684656|NCT01591850|DRUG|atazanavir|Multiple oral doses
223684657|NCT01591850|DRUG|ketoconazole|Multiple oral doses
223684658|NCT01591850|DRUG|rifampicin|Multiple oral doses
223684659|NCT01591850|DRUG|ritonavir|Multiple oral doses
223684660|NCT04657107|DRUG|S-ketamine|K1 group: pregnant women received 0.2mg/kg S-ketamine, intravenous drip;
223684661|NCT04657107|OTHER|normal saline|Saline group: pregnant women received saline, intravenous drip
223684662|NCT04657107|DRUG|S-ketamine|K2 group: pregnant women received 0.3mg/kg S-ketamine, intravenous drip;
223684663|NCT06056765|DEVICE|"Minilith, Storz, Swiss"|shock waves
223775149|NCT04632940|DRUG|Pamrevlumab|Pamrevlumab will be administered per dose and schedule specified in the arm description.
223775150|NCT04632940|DRUG|Placebo|Placebo will be administered per schedule specified in the arm description.
223775151|NCT04632940|DRUG|Corticosteroids|Systemic deflazacort or equivalent potency of corticosteroids administered orally
223775152|NCT02661828|OTHER|Two-Week Antidepressant Taper Regimen|Days 1-7: 50% of baseline antidepressant dose taken; Days 8-14: 25% of baseline antidepressant dose taken; Day 15: Stop antidepressant.
223775153|NCT02661828|OTHER|One-Week Antidepressant Taper Regimen|Days 1-3: 50% of baseline antidepressant dose taken; Days 4-7: 25% of baseline antidepressant dose taken; Day 8: Stop antidepressant.
223684664|NCT02386670|OTHER|tDCS + CR|"First, the intervention sessions will be administered 5 days/week for 8 weeks (induction phase). Then, for 5 days once every 6 months (consolidation phase).~tDCS session: anode over Fz \& cathode over Iz; direct current: 2 mA (current density=0.57A/m2) for 30 min. at the beginning of each group session.~Cognitive Remediation (CR) will also be administered. Sessions last 2 hours each day in a group supervised by trained interventionists. Participants will also complete CR exercises online at home. CR will consist of computer-based exercises relevant to attention, processing speed, executive function, and verbal and working memory with titrated difficulty levels. Performance feedback will reinforce progress. Strategic monitoring and bridging discussions will promote transfer of cognitive gains to everyday tasks.~During COVID-19, booster sessions can be provided either in-person or virtually (except for tDCS that cannot be done remotely)."
223684665|NCT02386670|OTHER|sham tDCS + sham CR|"First, the intervention sessions will be administered 5 days/week for 8 weeks (induction phase). Then, for 5 days once every 6 months (consolidation phase).~tDCS session: anode over Fz \& cathode over Iz; direct current: 2 mA (current density=0.57A/m2) for 1 minute, then the current will be 0 mA for 29 minutes at the beginning of each group session.~Cognitive Remediation (CR) will also be administered. Sessions last 2 hours each day in a group supervised by trained interventionists. Participants will also complete CR exercises online at home. CR will consist of computer-based exercises relevant to attention, processing speed, executive function, and verbal and working memory without titrated difficulty levels.~During COVID-19, booster sessions can be provided either in-person or virtually (except for sham tDCS that cannot be done remotely)."
223684666|NCT06684522|DRUG|Upadacitinib 15 MG|Upadacitinib 15mg daily
223684667|NCT06689202|OTHER|The Hiroshima University - Dental Behavioral Inventory (HU-DBI) by Kawamura will be used as a validated instrument to assess oral health-related knowledge, attitudes, and behaviors (KAB).|The assessment will include 20 HU-DBI items, which employ a dichotomous response format (agree/disagree). However, only 12 items will be used to calculate the overall KAB score, which will range from 0 to 12, with higher scores indicating better oral health KAB.
223684668|NCT06689202|OTHER|The Hiroshima University - Dental Behavioral Inventory (HU-DBI) by Kawamura will be used as a validated instrument to assess oral health-related knowledge, attitudes, and behaviors (KAB)|The assessment will include 20 HU-DBI items, which employ a dichotomous response format (agree/disagree). However, only 12 items will be used to calculate the overall KAB score, which will range from 0 to 12, with higher scores indicating better oral health KAB.
223684669|NCT03640520|OTHER|FACETS: Pediatric Resuscitation|Family-centered \& Trauma-informed Support in Pediatric Resuscitation (FACETS: Pediatric Resuscitation) is an online skills training module for health care professionals involved in pediatric resuscitation in general EDs. The module combines didactic information and scenario-based learning with opportunities for the learner to practice applying their knowledge of FCC practices at key choice points in realistic pediatric resuscitation case scenarios. Training content is guided by evidence regarding FCC practices that are effective in reducing concurrent and ongoing emotional distress in children and family members, and in promoting child and family involvement and satisfaction with care.
223684670|NCT03640520|OTHER|Control|An online training module in which participants will receive information and policy education about national pediatric readiness standards for all EDs (including a brief mention of family-centered care as one of these standards), with no specific skills training in FCC. The module provides practice-relevant knowledge related to pediatric differences and pediatric readiness
223684671|NCT05542745|DEVICE|palatal and buccal retraction|comparison
223684672|NCT06717334|DIAGNOSTIC_TEST|Low Dose CT imaging|at baseline and at Year 1.
223684673|NCT06717334|OTHER|blood draws|at baseline and at Year 1.
223684674|NCT06717334|OTHER|screening questionnaire|at baseline and at 1 year after registration.
223775154|NCT00002010|DRUG|Fluconazole|
223684675|NCT01094561|DRUG|Synthetic Human Secretin|Subjects will each undergo a Secretin-Enhanced Magnetic Resonance Cholangiopancreatography (S-MRCP) and a Secretin-Enhanced Endoscopic Ultrasound (S-EUS) evaluation, at a dose of 0.2 ucg/kg per exam. Synthetic Human Secretin, provided by the Repligen Corporation, will be administered by IV bolus injection over 30 seconds followed by a 30 second saline flush. The maximum dose of secretin will be 18.5 ucg.
223684676|NCT01094561|PROCEDURE|Secretin-Enhanced Magnetic Resonance Cholangiopancreatography|
223684677|NCT01094561|PROCEDURE|Secretin-Enhanced Endoscopic Ultrasound|
223775155|NCT03291912|PROCEDURE|Chuna Manual Therapy|"* Unique manual therapy in traditional Korean medicine~* Mandatory techniques for neck part and selective techniques for other part (if necessary)~* Selective techniques depends on a patient's condition (judged by traditional Korean medicine doctor)"
223684678|NCT05953090|DEVICE|7-0940|A non-hormonal and non-steroidal gel that supports vulvovaginal mucosal conditions and speeds up recovery post vaginal rejuvenation. It is a suitable alternative to vaginally administered estrogen and topical corticosteroids, that promotes a moist healing environment leading to faster re-epithelialization. The gel relieves symptoms such as itchiness, tenderness, dryness, burning sensation, painful intercourse (dyspareunia), painful urination (dysuria), rectal and defecating pain. It improves erythema, mucosal tissue thinning, erosions, fissures, ulcerations, scarring/adhesions and swelling. It is indicated for long-term use to maintain the health of the vaginal mucosa without the side effects of vaginally administered hormonal therapy and topical corticosteroids.
223775156|NCT03291912|PROCEDURE|Usual care|"1. Physical therapy based on traditional Korean medicine theory~   * Electrical stimulation: either Meridian muscle interferential current electricity or Meridian transcutaneous electricity~  * Heat stimulation: either Hot pack or Infrared lamp~2. Patient education~   * Physical and pathological explanation of cervicogenic dizziness~  * Cause and risk factors of cervicogenic dizziness~  * Functions of muscles related to cervicogenic dizziness~  * Home exercising to self-manage cervicogenic dizziness"
223775157|NCT00199862|DRUG|Iodine-124 labeled humanized A33 (antibody)|Patients will receive a single intravenous or intraarterial infusion of 10mg huA33, labeled with 4mCi-10mCi of 124I in 5-30ml of 5% HSA in normal saline (NS), over 5-10 minutes. On study days 2, 3, and/or 4 patients will have the option to receive up to 2g/kg of IVIG. Patients will be evaluated with 124I-huA33 positron-emission tomography (PET) with ex vivo quantitation of tumor uptake.
223775158|NCT06406205|DRUG|Voclosporin（QL1074）|QL1074 23.7 mg BlD will be administered as a fixed dose without the use of therapeutic drugmonitoring. The protocol contains provisions for management of dose based on safety concerns, in particular, BP and renal function，can be managed by dose reduction and temporary of QL1074 to interruption.
223684679|NCT06711952|DIAGNOSTIC_TEST|Subjective Cognitive Decline-Questionnaire (SCD-Q)|The SCD-Q is an established instrument to quantify self-perceived cognitive decline. In addition to the self-perceived cognitive complaints, a 24 items questionnaire of informants is part of SCD-Q. The self-reported SCD-Q will be included in the standard health questionnaire that all patients of the memory clinic of the LMU Department of Psychiatry and Psychotherapy are required to complete before the examination date. The health questionnaire will be sent per mail. All routine clinical procedures will remain unchanged.
223684680|NCT06711952|DIAGNOSTIC_TEST|Cognitive Failure Questionnaire (CFQ)|The Cognitive Failure Questionnaire (CFQ) is a questionnaire for measuring self-reported subjective failures in cognition, memory and motor functions in everyday life. The German CFQ consists of 32 items related to everyday possibilities of error, whose frequency in the last six months is to be estimated by means of a five-point rating scale.
223684681|NCT06711952|DIAGNOSTIC_TEST|biomarkers|"Blood plasma and serum samples will be collected by the project staff according to standard operating procedures used at LMU Munich and subsequently processed and measured at the Department of Psychiatry and Psychotherapy to quantify the blood-based biomarkers for AD using Elecsys immunoassays running on a Cobas e402 analyzer.~Only available clinical and biomarker data will be used (Routine cerebrospinal fluid biomarkers, routine imaging biomarkers)."
223684682|NCT06711952|DIAGNOSTIC_TEST|Cognitive Tests|"The investigators plan to examine the patients´ visuospatial performance on site with a digital clock-drawing test, which has been validated in large community-based studies.~The Functional Activities Questionnaire (FAQ) shall be filled out by an informant. FAQ is a reliable and valid measure of activities of daily living. The results of the routine neuropsychological tests (Consortium to Establish a Registry for AD, Mini-Mental-State Examination) will be used in the analysis."
223684683|NCT00396032|DRUG|placebo|For the initial treatment, 2 mL of placebo instilled into each lumen of the HD catheter; subsequent treatments were 2 mL of open-label tenecteplase
223684684|NCT00396032|DRUG|tenecteplase|For the initial treatment, 2 mL of reconstituted lyophilized tenecteplase instilled into each lumen of the HD catheter; subsequent treatments were 2 mL of open-label tenecteplase
223684685|NCT06921356|BEHAVIORAL|Coach-Directed Tailored DASH Groceries Plus Lifestyle Intervention|Participants assigned to the C-DASH group will meet by telephone with the study coach for 1 hour, and then have brief weekly conversations (about 15-30 minutes) by phone during the first three months. During these weekly calls, the study coach will assist participant with selecting fruits, vegetables, nuts, and beans. During months 4-6, the study coach will continue to work with participant to set goals for following the DASH-Life way of eating, but the study will no longer provide a weekly food allowance to purchase groceries.
223684686|NCT06921356|BEHAVIORAL|Self-Shopping DASH diet advice|Participants assigned to the S-DASH group will receive a brochure about the DASH eating plan. For the first three months, Participants will also receive a gift card to shop at a local supermarket. During months 4-6, participants will be asked to continue following the DASH eating plan listed in the brochure but will no longer be provided the grocery gift card.
223684687|NCT00139867|DRUG|PARCOPA|
223684688|NCT06556654|DEVICE|TRBR Device|The GORE® Tissue Reinforcement for Breast Reconstruction device is intended to reinforce the soft tissue surrounding the tissue expander in preparation for the breast implant in post-mastectomy breast reconstruction
223684689|NCT06786494|OTHER|Tart Cherry Juice|Individuals will be asked to consume 240 mL (i.e., 8 ounces) at approximately 5 pm and 240 mL (i.e., 8 ounces) of tart cherry juice at approximately 1 hour before bedtime for 4 weeks.
223684690|NCT06786494|OTHER|Placebo juice|Individuals will be asked to consume 240 mL (i.e., 8 ounces) at approximately 5 pm and 240 mL (i.e., 8 ounces) of placebo juice at approximately 1 hour before bedtime for 4 weeks.
223684691|NCT05519644|OTHER|Sleep Deprivation|The sleeping protocol will be monitored by investigators and personnel with experience in sleep medicine. Participants will be required to reduce sleep by 50% of normal, for 4 consecutive nights, to observe potential deficits in physical and cognitive performance
223684692|NCT05519644|OTHER|Heart Rate|HR will be assessed by wrist-based acceleration with cloud technology (Polar Unite™, Polar USA). This monitor is less burdensome than other sleep monitoring technologies and less likely to interfere with normal sleep and activity demands of the cadets. Each participant will be fitted with the watch for acclimatization and then establish 3-day baseline patterns for 3 nights before the sleep loss protocol.
223684693|NCT05519644|OTHER|Sleep Monitoring|Sleep will be assessed by wrist-based acceleration with cloud technology (Polar Unite™, Polar USA). This monitor is less burdensome than other sleep monitoring technologies and less likely to interfere with normal sleep and activity demands of the cadets.Each participant will be fitted with the watch for acclimatization and then establish 3-day baseline patterns for 3 nights before the sleep loss protocol.
223684694|NCT05519644|OTHER|Diet|Diet will be included and the same meals will be available for all subjects while controlling for caffeine. Participants will be given food during each intervention week.
223775159|NCT06406205|DRUG|Placebo|Placebo softgel capsules, identical to 7.9 mg QL1074, will be provided. The administration plan and dosage management regulations are the same as QL1074.
223775160|NCT03395431|OTHER|Fingerprick autologuos blood (FAB)|Intervention involves the instillation of whole blood obtained from the prick of a clean finger 4 times a day.
223775161|NCT00947583|BIOLOGICAL|Osteocel Plus|biologic
223775162|NCT03521492|DIAGNOSTIC_TEST|serum vitamin D , calcium , parathyroid hormone and albumin level|measuring serum level of Vit. D, PTH, Calcium, and Albumin levels
223775163|NCT05104372|OTHER|Hypertonic Saline Nasal Irrigation and Gargles (HSNIG)|Nasal washout and gargles
223775164|NCT05857527|COMBINATION_PRODUCT|Custom EMG triggered Soterix taVNS stimulation with CIMT therapy in lab|Participants will receive taVNS stimulation paired with 40 hours of constraint-induced movement therapy. The new device will automatically trigger stimulation using EMG muscle sensors worn during the therapy session. Phase 1 will occur in the lab, and ongoing notifications will be made to the EMG system to test feasibility of automatic stimulation
223775165|NCT05857527|COMBINATION_PRODUCT|Custom EMG triggered Soterix taVNS stimulation with CIMT therapy in home|Participants will receive taVNS stimulation paired with 40 hours of constraint-induced movement therapy. The new device will automatically trigger stimulation using EMG muscle sensors worn during the therapy session. Phase 2 will occur in the home and will assess the quality of the CIMT therapy provided with the automated EMG system.
223684695|NCT05519644|OTHER|Exercise Performance|Since weight training is now a crucial part of any warfighter's physical preparation, we will have subjects perform weight training workouts emphasizing all major muscle groups on Days 2, 3 and 4
223684696|NCT05519644|BEHAVIORAL|Surveys, McGill Pain Questionnaire, Shortened Profile of Mood States, Pittsburg Sleep Index|These will be administered on Days 1 and 5 of each intervention trial to assess different behavioral outcomes.
223684697|NCT05519644|OTHER|Cognitive performance|Automated Neuropsychological Assessment Metrics (ANAM), Cambridge Neuropsychological Test Automated Battery. (CANTAB),Gradual-onset Continuous Performance Task (GRAD-CPT),Face-Name Task will be used to assess cognitive function and performance.
223684698|NCT05519644|OTHER|Marksmanship Performance|The Virtual Training Simulator (VirTra V-100) system (VirTra Corporate HQ, Tempe, AZ) is used by both military and law enforcement agencies to provide training. The V-100 and associated compatible weapons are equipped with recoil kits for unsurpassed live-fire simulation, at distances up to 2,000-m, authoring capabilities for the creation of customized scenarios on 4 individual firing lanes. Multiple metrics of marksmanship (total number of shots fired/silhouette target presentation, percentage of targets successfully hit/min, the radial distance of a shot from the center on target, shot group tightness, and time from target presentation to trigger pull) will be collected during each visit.
223684699|NCT05519644|OTHER|Quick Board|Upper body and lower body reaction tests will be assess using Quick Board Analysis on days 1 and 5 of the sleep restriction intervention.
223684700|NCT05519644|OTHER|Advanced Medical Technologies Inc, Jump Test|Whole body power will be assessed with a repetitive jump test. Power (peak, average, curve functions) will be assessed using an AMTI force plate with Accupower 2.0 software (Advanced Mechanical Technology Inc, Watertown, MA).
223684701|NCT05519644|OTHER|CGM/CKM|Continuous Ketone/Glucose Monitor will be applied at the start of Test Day 1. The sensor will be checked by the study team at each test day and will be removed and replaced by a fresh sensor at \~2- week intervals during the study. The sensor will be removed at the end of the final test day.
223684702|NCT05519644|BIOLOGICAL|Blood Draw|Blood samples will be collected according to the schedule in Figure 1.
223684703|NCT05519644|DIETARY_SUPPLEMENT|Ketone Supplement|Participants will take a diester of hexanoic acid (a ketogenic medium chain fatty acid) and (R)-1,3 butanediol (C6 Di-ester) during one of the trial interventions
223684704|NCT06781333|BIOLOGICAL|hMSC|Participants will come in person to receive one intravenous infusion of approximately 25 million cells up to 20 minutes.
223684705|NCT05680727|PROCEDURE|transcranial magnetic stimulation|Transcranial magnetic stimulation (TMS) is a focal, non-invasive form of brain stimulation that has FDA clearance for depression. In this study, a form of TMS called accelerated intermittent theta burst stimulation will be administered under the supervision of a physician with TMS expertise. This protocol will be modeled after the FDA cleared Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT) protocol, but the patented SAINT rsfc targeting algorithm will not be used for either arm.
223684706|NCT01909453|DRUG|LGX818|LGX818- Orally 100 mg and 50 mg capsules
223684707|NCT01909453|DRUG|MEK162|MEK162- Orally 15 mg tablets
223684708|NCT01909453|DRUG|vemurafenib|Tablets in bottles or blisters 240 mg
223684709|NCT06926114|DEVICE|Microlearning intervention|thirteen students will be included into the microlearning group will receive sequential daily learning units over ten days, . Pretest, immediate post-test, and one-month post-intervention assessments will be performed using standardized MCQ and SAQ instruments. Learner engagement, time investment, and content clarity will be additionally evaluated via structured surveys.
223684710|NCT06926114|DEVICE|Traditional block-format module group|eleven students will be inclued into the self block module group will engage in a comprehensive two-day self-learning module. Pretest, immediate post-test, and one-month post-intervention assessments will be performed using standardized MCQ and SAQ instruments. Learner engagement, time investment, and content clarity will be additionally evaluated via structured surveys.
223684711|NCT06820450|OTHER|Blood test|A blood test (2 x 5 ml dry tubes) will be taken to analyze steroid profiles
223775166|NCT06268821|DEVICE|FreeStyle Libre 2 Flash Glucose Monitoring System|Glucose sensors to be worn continuously for 3 months with data used to monitor and manage diabetes treatment and to inform lifestyle choices (diet and exercise)
223775167|NCT05281731|DEVICE|Sonobiopsy|Ultrasound combined with microbubbles to facilitate sampling of biomarkers from brain tumors via blood-based liquid biopsy
223684712|NCT06820450|OTHER|urine sample|a 20 ml urine sample will be taken to analyze steroid profiles
223684713|NCT06820450|OTHER|vaginal sample|to characterize the microbiota.
223684714|NCT06909019|BEHAVIORAL|Control (QR) Labels|Participants will view two fast-food restaurant menus presented in a random order. Each menu will include main, side, dessert, and drink items, and each menu item will be displayed with an image of the item, name, price, and total calories. For main items only, Control (QR) labels will be displayed beneath each item. Participants will be instructed to select at least 1 and up to 4 menu items for a hypothetical meal order. Participants will be required to select a main item and, optionally, up to 3 additional items (drinks, sides, desserts).
223684715|NCT06909019|BEHAVIORAL|Low Climate Impact Labels|Participants will view two fast-food restaurant menus presented in a random order. Each menu will include main, side, dessert, and drink items, and each menu item will be displayed with an image of the item, name, price, and total calories. For main items only, Low Climate Impact labels will be displayed beneath each item. Participants will be instructed to select at least 1 and up to 4 menu items for a hypothetical meal order. Participants will be required to select a main item and, optionally, up to 3 additional items (drinks, sides, desserts).
223775168|NCT05281731|PROCEDURE|Research blood|No more than 10 minutes prior to ultrasound sonication, 10 minutes after ultrasound sonication, 30 minutes after ultrasound sonication (optional at the discretion of the PI), and 60 minutes after ultrasound sonication (optional at the discretion of the PI)
223775169|NCT05281731|GENETIC|Cancer Personalized Profiling|Cancer Personalized Profiling by deep Sequencing will be used to compare the frequency of tumor-specific variants in the blood before and after sonobiopsy.
223775170|NCT05281731|DEVICE|Definity®|Being used off-label in this trial
223775171|NCT02737566|BEHAVIORAL|Standard Care + Financial Incentives|Tobacco cessation counseling plus pharmacotherapy and financial incentives for quitting.
223775172|NCT02737566|OTHER|Standard Care|Tobacco cessation counseling plus pharmacotherapy.
223684716|NCT06909019|BEHAVIORAL|High Climate Impact Labels|Participants will view two fast-food restaurant menus presented in a random order. Each menu will include main, side, dessert, and drink items, and each menu item will be displayed with an image of the item, name, price, and total calories. For main items only, High Climate Impact labels will be displayed beneath select items. Participants will be instructed to select at least 1 and up to 4 menu items for a hypothetical meal order. Participants will be required to select a main item and, optionally, up to 3 additional items (drinks, sides, desserts).
223684717|NCT06909019|BEHAVIORAL|Traffic Light Labels|Participants will view two fast-food restaurant menus presented in a random order. Each menu will include main, side, dessert, and drink items, and each menu item will be displayed with an image of the item, name, price, and total calories. For main items only, Traffic Light labels will be displayed beneath each item. Participants will be instructed to select at least 1 and up to 4 menu items for a hypothetical meal order. Participants will be required to select a main item and, optionally, up to 3 additional items (drinks, sides, desserts).
223684718|NCT06909019|BEHAVIORAL|Climate Grade Labels|Participants will view two fast-food restaurant menus presented in a random order. Each menu will include main, side, dessert, and drink items, and each menu item will be displayed with an image of the item, name, price, and total calories. For main items only, Climate Grade labels will be displayed beneath each item. Participants will be instructed to select at least 1 and up to 4 menu items for a hypothetical meal order. Participants will be required to select a main item and, optionally, up to 3 additional items (drinks, sides, desserts).
223684719|NCT06908174|DIAGNOSTIC_TEST|ADOS-2|The subjects in case group will receive the ADOS-2 assessment to confirm their diagnosis.
223684720|NCT04268498|DRUG|Bortezomib|1.3 mg/m2 administered Subcutaneous (SC) or intravenous (IV) on days 1, 4, 8 and 11 of a 21 day treatment cycle for participants randomized to Arm A.
223684721|NCT04268498|DRUG|Dexamethasone|"20 mg or 40 mg per dose administered by mouth (PO) or IV.~Participants randomized in Arm A:~20 mg/dose on days 1, 4, 8 and 11 on a 21 day treatment cycle;~Participants randomized in Arm B:~Cycles 1 through 8 - 40mg/dose on days 1, 8 and 15 on a 28-day cycle~Participants randomized in Arm C:~Cycle 1-2 - 40 mg/dose on days 1, 8, 15 and 22 on a 28-day cycle; Cycles 3-8 - 40mg/dose on Days 1, 8, 15 on a 28-day cycle;"
223775173|NCT01772953|DRUG|Treosulfan|This is a phase II, open-label, nonrandomized, prospective study of a preparative regimen consisting of treosulfan, fludarabine and low-dose total body irradiation (TBI) for children with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) undergoing allogeneic hematopoietic cell transplantation (HCT).
223775174|NCT02799082|DRUG|Vehicle|topical treatment for photodynamic therapy combining vehicle application and subsequent illumination with broad or narrow spectrum light sources (after 3 h of drug incubation).
223775175|NCT02799082|DRUG|BF-200 ALA|topical treatment for photodynamic therapy combining drug application and subsequent illumination with broad or narrow spectrum light sources (after 3 h of drug incubation).
223684722|NCT04268498|DRUG|Lenalidomide|"10 or 25 mg/day capsules administered PO.~Participants randomized in Arm A:~25 mg/day capsules on Days 1 through 14 of a 21 day cycle.;~Participants randomized in Arm B:~Cycles 1 through 8 - 25 mg/day capsules on Days 1 through 21 of a 28 day cycle;~Participants randomized in Arm C:~Cycles 1 - 25 mg/day capsules on Days 2 through 21 of a 28 day cycle; Cycles 2 through 8 - 25 mg/day capsules on Days 1 through 21 of a 28 day cycle;~Maintenance Therapy:~10 mg capsules on Days 1 through 21 on a 28 days cycle."
223775176|NCT04212507|DIAGNOSTIC_TEST|The serum level of Claudin-3 and intestinal Fatty acid binding protein|The serum level of Claudin-3 and intestinal Fatty acid-binding protein between patients with psoriasis and controls Understanding the interplay between microbiota, gut barrier and inflammation may contribute to the development of new methods of preventing onset or exacerbations of psoriasis and new therapeutic approach for psoriasis.
223775177|NCT00694460|BIOLOGICAL|Three 1 mL doses of Rabies vaccine and two JE vaccine|Vaccination with purified chick embryo cell rabies vaccine 1.0 mL intramuscularly on Day 0, Day 7 and Day 28 (a total of 3 doses) and Beijing 1 strain of inactivated, lyophilized Japanese Encephalitis vaccine 0.25 mL subcutaneously on Day 0 and Day 7 (a total of 2 doses)
223775178|NCT00694460|BIOLOGICAL|Three 0.5 mL doses of Rabies vaccine and two JE vaccine|Vaccination with purified chick embryo cell rabies vaccine 0.5 mL intramuscularly on Day 0, Day 7 and Day 28 (a total of 3 doses) and Beijing 1 strain of inactivated, lyophilized Japanese Encephalitis vaccine 0.25 mL subcutaneously on Day 0 and Day 7 (a total of 2 doses)
223775179|NCT00694460|BIOLOGICAL|Three 0.1mL doses of Rabies Vaccine and two JE vaccine|Vaccination with purified chick embryo cell rabies vaccine 0.1 mL intradermally at one site on Day 0, Day 7 and Day 28 (a total of 3 doses) and Beijing 1 strain of inactivated, lyophilized Japanese Encephalitis vaccine 0.25 mL subcutaneously on Day 0 and Day 7 (a total of 2 doses)
223684723|NCT04268498|DRUG|Acetaminophen|"650 mg administered PO.~Participants randomized to Arm C:~Cycles 1 through 8 - 650 mg administered on Days 1, 8 and 15."
223684724|NCT04268498|DRUG|Diphenhydramine|"25 mg administered via IV~Participants randomized to Arm C:~Cycles 1 through 8 - 25 mg administered on Days 1, 8 and 15."
223684725|NCT04268498|DRUG|Montelukast|10 mg administered PO to participants randomized to Arm C prior to the first 4 doses of Daratumumab.
223684726|NCT04268498|DRUG|Carfilzomib|"20 mg or 56 mg/m2 per dose administered via IV.~Participants randomized to Arm B:~Cycle 1 - 20 mg/m2 per dose on Day 1 and 56 mg/m2 per dose on days 8 and 15 of a 28 day cycle; Cycles 2 through 8 - 56 mg/m2 per dose on days 1, 8 and 15 of a 28 day cycle;~Participants randomized to Arm C:~Cycle 1 - 20 mg/m2 per dose on Day 2 and 56 mg/m2 per dose on days 8 and 15 of a 28 day cycle; Cycles 2 through 8 - 56 mg/m2 per dose on days 1, 8 and 15 of a 28 day cycle"
223684727|NCT04268498|DRUG|Daratumumab|"16 mg/kg administered via IV or 1800 mg SC, per treating physician discretion.~Participants randomized to Arm C:~Cycles 1 though 2 - 16 mg/kg IV or 1800 mg SC on days 1, 8, 15, and 22 of a 28 day cycle; Cycles 3 through 6- 16 mg/kg IV or 1800 mg SC on days 1 and 15 of a 28 day cycle; Cycles 7 through 8 - 16 mg/kg IV or 1800 mg SC on day 1 of a 28 day cycle"
223684728|NCT04268498|BIOLOGICAL|Autologous Stem Cell Transplant (ASCT)|Participants who are MRD positive at the conclusion of 8 cycles of study treatment, and were able to have their stem cells that were extracted, will receive ASCT from participants' bone marrow samples.
223684729|NCT05988320|PROCEDURE|Pranayama breathing exercise|"Pranayama is an important step in yoga, way of life, and is translated as the science of breathing, breath control, willful breathing. This alternating breathing-out action also balances the sympathetic and parasympathetic nervous systems, giving the person a state of calm, providing relaxation and positively affecting fatigue. Application steps; Right hand Nasika mudra is performed. Nasika mudra is the mudra where the second and third fingers of the right hand are folded into the palm and the other fingers are exposed. Then the right nostril is closed with the first finger of the right hand. Start by breathing through the left nostril. Then the left nostril is closed with the fourth finger and the breath is held. While the left nostril is closed, the right nostril is opened and inhaled. Breathe again through"
223684730|NCT06919068|DIAGNOSTIC_TEST|Colon capsule endoscopy|PillCam Colon 2
223684731|NCT01382147|DRUG|Ara-C, Mitoxantrone, Daunorubicin, Thioguanin|Chemotherapy
223684732|NCT06268730|OTHER|SinuSonic|The SinuSonic is a commercially available, over-the-counter, self-applied nasal device designed to enhance physical well-being by reducing nasal congestion via simultaneous administration of acoustic vibration and gentle oscillating expiratory pressure.
223775180|NCT00694460|BIOLOGICAL|Two 0.1mL doses of Rabies vaccine and two JE vaccine|Vaccination with purified chick embryo cell rabies vaccine 0.1 mL intradermally at one site on Day 0 and Day 28 (a total of 2 doses) and Beijing 1 strain of inactivated, lyophilized Japanese Encephalitis vaccine 0.25 mL subcutaneously on Day 0 and Day 7 (a total of 2 doses)
223684733|NCT05423912|BEHAVIORAL|Keeping on Course Program|MCI dyads engaging in the testing aim of the Keeping on Course Program take part in group meetings lasting 90 to 120 minutes over the course of 6 virtual meetings. Participants are asked to take part in structured quantitative interviews at baseline and 4 and 8 weeks post-intervention. A subsample of participants will be invited to take part in a virtual, semi-structured 30-60 minute qualitative interview focused on their experiences in and perceptions of the intervention.
223684734|NCT04174040|BEHAVIORAL|Gross's Process of Emotion Regulation Model Interventions|"Interventions were based on Gross's Process Model which include the basis concepts of cognitive-behavioral therapy and carried on with five semi-structured sessions. Cognitive-behavioral theories accept the existence of a thought process (attention-perception-interpretation) that appears in the mind about the event just before the anger emerges. Therefore, anger studies with cognitive-behavioral approach generally proceed with the steps of gaining awareness about this concealed thought, identifying behavioral response and avoidance attitudes and thus regulating emotion. It consists of five 90-minute group sessions structured in this context. While being an accredited cognitive behavioral therapist, investigator have qualified to manage these approach.~The effectiveness of these semi-structured sessions were evaluated by using:~1. Pretest application of STAXI~2. Taking feedback after each intervention session~3. Posttest application of STAXI~4. Follow-up test application of STAXI"
223684735|NCT04174040|BEHAVIORAL|Musical Rhythm Interventions|"This musical group rhythm intervention was continued with 90 minute long five sessions. The students participated in the practice together with a music expert and lead researcher. The lead researcher took on the role of observer in these sessions. Each session was continued with warming, improvisation and targeted semi-structured rhythm practices aiming anger regulation. The effectiveness of these semi-structured sessions were evaluated by using:~1. Pretest application of STAXI~2. Taking feedback after each intervention session~3. Posttest application of STAXI~4. Follow-up test application of STAXI"
223775181|NCT00694460|BIOLOGICAL|Two doses of JE vaccine|Vaccination with Beijing 1 strain of inactivated, lyophilized Japanese Encephalitis vaccine 0.25 mL only subcutaneously on Day 0 and Day 7 (a total of 2 doses)
223775182|NCT01778192|DRUG|Polyethylene glycol|-group 1 (same day PEG) received 4 L of PEG at 6 hours before procedure on the day of the colonoscopy
223775183|NCT01778192|DRUG|Polyethylene glycol|-group 2 (split PEG, N=50) received 2 L of PEG at 6:00 p.m the evening before colonoscopy and 2 L of PEG at 4-6 hours before procedure
223775184|NCT01778192|DRUG|Sodium picosulphate with magnesium citrate|-group 3 (SPMC 2) received one sachet of SPMC at 6 p.m the evening before colonoscopy and another sachet of SPMC at 4-6 hours before procedure
223775185|NCT01778192|DRUG|Sodium picosulphate with magnesium citrate|-group 4 (SPMC 3) received one sachet of SPMC at 6 p.m and the other sachet at 9 p.m the evening before colonoscopy and another sachet at 4-6 hours before procedure.
223775186|NCT05038137|BEHAVIORAL|Time restricted feeding|Participants will eat all food during a self selected 8 hour eating window prior to 8:00 PM.
223775187|NCT05038137|BEHAVIORAL|Control|Participants will have a daily eating period equal to or greater than 12 hours.
223684736|NCT04174040|BEHAVIORAL|Musical Rhythm Integrated Gross's Emotion Regulation Process Interventions|"The students participated in the practice together with a music expert and lead researcher. The lead researcher ensured the integration of rhythm applications into the Process Model through cognitive-behavioral semi-structured interventions. Five semi-structured 90-minute group sessions were performed. The effectiveness of the experiment was evaluated by using:~1. Pretest application of STAXI~2. Taking feedback after each intervention session~3. Posttest application of STAXI~4. Follow-up test application of STAXI"
223684737|NCT04166227|PROCEDURE|Hip Arthroscopy|Patients in the Hip Arthroscopy group will undergo arthroscopy in the supine position under general anesthesia, with all procedures performed by two subspecialty-trained hip arthroscopists. An algorithmic surgical approach will be utilized to sequentially address pathology in the central and peripheral compartments of the hip based on both preoperative imaging findings and intraoperative findings. Emphasis will be placed on labral preservation and refixation, with osseous decompression under fluoroscopic guidance.
223684738|NCT04166227|PROCEDURE|Total Hip Arthroplasty|Patients randomized to the Total Hip Replacement (THR) group will undergo THR via a direct anterior approach. A slightly oblique skin incision measuring approximately 8 cm will be used, starting 3 cm distally and laterally to the anterosuperior iliac spine. The intervals between tensor fascia lata (TFL) and sartorius will be developed superficially, and between rectus femoris and gluteus minimus deeper. Capsulotomy will be performed. A double osteotomy of the femoral neck will be performed to facilitate removal of the head followed by traditional preparation of the acetabulum using an offset reamer and the acetabular component will be inserted. Next, the superior capsule will be released to elevate the femur to allow access to the femoral canal, followed by standard preparation by use of an offset broach and the stem will be implanted
223684739|NCT04914416|DIETARY_SUPPLEMENT|Verum T1|Verum T1 is a placebo: microcristalline cellulose. Daily dosage is 1000 mg in 3 capsules.
223684740|NCT04914416|DIETARY_SUPPLEMENT|Verum T2|Verum T2 is a 11500AAIU/g white kidney bean extract. Daily dosage is 1000 mg in 3 capsules.
223684741|NCT04914416|DIETARY_SUPPLEMENT|Verum T3|Verum T3 is a 11500AAIU/g white kidney bean extract. Daily dosage is 565 mg in 3 capsules
223684742|NCT04914416|DIETARY_SUPPLEMENT|Verum T4|Verum T4 is a 17500AAIU/g white kidney bean extract. Daily dosage is 1000 mg in 3 capsules
223684743|NCT04914416|DIETARY_SUPPLEMENT|Verum T5|Verum T5 is a 17500AAIU/g white kidney bean extract. Daily dosage is 371 mg in 3 capsules
223684744|NCT04914416|DIETARY_SUPPLEMENT|Verum T6|Verum T6 is a 34200AAIU/g white kidney bean extract. Daily dosage is 1000 mg in 3 capsules
223684745|NCT04914416|DIETARY_SUPPLEMENT|Verum T7|Verum T4 is a 34200AAIU/g white kidney bean extract. Daily dosage is 512 mg in 3 capsules
223684746|NCT04914416|DIETARY_SUPPLEMENT|Verum T8|Verum T8 is a 34200AAIU/g white kidney bean extract. Daily dosage is 190 mg in 3 capsules.
223684747|NCT04914416|DIETARY_SUPPLEMENT|Verum T9|Verum T9 is a polyphenol mix extract ( olive leaf, and blackcurrant extract). Daily dosage is 1000 mg in 3 capsules
223684748|NCT04914416|DIETARY_SUPPLEMENT|Verum T10|Verum T10 is a polyphenol mix extract ( olive leaf, and blackcurrant extract). Daily dosage is 500 mg in 3 capsules
223684749|NCT04914416|DIETARY_SUPPLEMENT|Verum T11|Verum T11 is a polyphenol mix extract ( olive leaf, pomelo, pomegranate, and blackcurrant extract). Daily dosage is 900 mg in 3 capsules
223684750|NCT04914416|DIETARY_SUPPLEMENT|Verum T12|Verum T12 is a polyphenol mix extract ( olive leaf, pomelo, pomegranate, and blackcurrant extract). Daily dosage is 600 mg in 3 capsules
223684751|NCT04914416|DIETARY_SUPPLEMENT|Verum T13|Verum T13 is a polyphenol mix extract ( olive leaf, pomelo, pomegranate, and/or blackcurrant extract) with white kidney bean extract. Daily dosage is 1000 mg in 3 capsules.
223684752|NCT04914416|DIETARY_SUPPLEMENT|Verum T14|Verum T14 is a polyphenol mix extract ( olive leaf, pomelo, pomegranate, and/or blackcurrant extract) with white kidney bean extract. Daily dosage is 900 mg in 3 capsules.
223684753|NCT04914416|DIETARY_SUPPLEMENT|Verum T15|Verum T15 is a polyphenol mix extract ( olive leaf, pomelo, pomegranate, and/or blackcurrant extract) with white kidney bean extract, Zinc, and, black currant leaf extracts. Daily dosage is 1000 mg in 3 capsules.
223684754|NCT04914416|DIETARY_SUPPLEMENT|Verum T16|Verum T16 is a polyphenol mix extract ( olive leaf, pomelo, pomegranate, and/or blackcurrant extract) with white kidney bean extract, and Zinc. Daily dosage is 1000 mg in 3 capsules.
223684755|NCT04914416|DIETARY_SUPPLEMENT|Verum T17|Verum T17 is a placebo: microcristalline cellulose. Daily dosage is 1000 mg in 3 capsules.
223684756|NCT06939894|BEHAVIORAL|Drama activities|iintervention group will paticipate drrama activities aabout pain assessment of a patient.
223684757|NCT01373489|BEHAVIORAL|Technology-Assisted Case Management|The TACM intervention uses the FORA 2-in-1 Telehealth System for diabetes to link a case manager to poorly controlled diabetics in real time. Patients will be assigned the FORA 2-in-1 Telehealth System and provided glucose test strips to allow testing at least once a day. They will be asked to perform glucose testing and blood pressure measurement using the FORA system once daily. They will be asked to upload the measurements daily as soon as possible after the test is performed. The nurse case manager will have access to a secure server to which the uploaded measurements are stored in real time. Medications are titrated under supervision of a primary care and endocrinology physicians
223684758|NCT00174330|DRUG|atorvastatin|
223684759|NCT00174330|DRUG|amlodipine|
223684760|NCT04591860|DEVICE|Laparoscopic or robot-assisted hiatal closure (sutures only vs. absorbable mesh vs. pledgeted sutures) and fundoplication according to Toupet|Patients are scheduled to undergo laparoscopic or robot-assisted surgery for a large symptomatic hiatal hernia.The hiatal closure will be done with sutures, pledgeted sutures or absorbable mesh (Phasix™ST mesh). After cruroplasty a fundoplication according to Toupet will be done additionally.
223684761|NCT02586285|DRUG|S-Adenosyl Methionine|500mg-1000mg,iv,qd
223684762|NCT05405127|OTHER|traditional physical therapy|breathing exercises 10 repetitions, 1set, 3 days/week and targeted abdominal muscles. Total 6 sessions were given each consisting of 30 minutes.
223684763|NCT05405127|OTHER|core stability exercises|core stability along with breathing exercise 10 repetitions, 1set, 3 days/week and targeted core muscles. Total 6 sessions were given consisting of 30 minutes.
223684764|NCT05404360|DEVICE|BrainsWay Deep TMS HAC/H7-Coil|The BrainsWay HAC/H7-Coil Deep TMS System is composed of four main components: an electromagnetic H7/HAC-Coil, TMS stimulator, cooling system and positioning arm.
223684765|NCT05404360|DEVICE|BrainsWay Deep TMS Sham Coil|"The experimental system has two coils in the same helmet, a sham and active coil.~The sham coil has a similar acoustic artifact as the active coil and it administers a superficial stimulation to maintain blinding. The system assigns the active or sham coil based on the patient ID during the high frequency treatment."
223684766|NCT04285580|DRUG|Bimatoprost SR|Consists of 1 Bimatoprost SR administration in the study eye.
223684767|NCT04285580|DRUG|LUMIGAN|Treatment with LUMIGAN 0.01% begins on Day 1. The drop will be instilled once daily in the evening to the study eye throughout the duration of the study.
223684768|NCT01409759|PROCEDURE|Perforator based interposition flap|The flap is designed based on a selected perforator and locally available, preferably normal skin adjacent to the burn scar contracture. The flap consists of skin and underlying subcutaneous tissue. Based on the pre-operative defined perforator, the required length and width and the available preferable normal skin, a design for the perforator flap is made.
223775188|NCT01187238|DRUG|cisplatin|in experimental arm, the eligibility patients will be received the same radiotherapy as radical radiotherapy alone group, and also will received concurrent chemotherapy with the regimen of cisplatin 40mg/m2, weekly,from week 1 to week 7
223684769|NCT04285099|DEVICE|Application of dual system in frequency A|The investigators set two values of frequency (130, 60Hz) in IPG and allow the patients to change the frequencies freely using the patient controller. Technician randomly sets 130 Hz, 60HZ to A or B.
223684770|NCT04285099|DEVICE|Application of dual system in frequency B|The investigators set two values of frequency (130, 60Hz) in IPG and allow the patients to change the frequencies freely using the patient controller. Technician randomly sets 130 Hz, 60HZ to A or B.
223684771|NCT05352490|DIAGNOSTIC_TEST|calculate LUS score|calculate LUS score
223684772|NCT01736384|PROCEDURE|Gastric bypass or cholecystectomy|
223775189|NCT00144573|DRUG|MRA(Tocilizumab)|
223775190|NCT00245557|DRUG|Sertraline|"Oral Sertraline Dosage started at 25 mg a day, with increases up to maximum dosage strength of 200 mg a day.~Duration of treatment was 12 weeks."
223775191|NCT02242786|RADIATION|External beam radiation therapy|
223775192|NCT01348529|BEHAVIORAL|Internet CBT|Internet-delivered cognitive behavioral therapy with therapist support.
223775193|NCT04922593|DRUG|LY03010; paliperidone palmitate|LY03010 is white to off-white sterile aqueous extended-release suspension of paliperidone palmitate for IM injection.
223775194|NCT04922593|DRUG|INVEGA SUSTENNA|INVEGA SUSTENNA (234 mg, 156 mg) is manufactured by Janssen Pharmaceuticals, Inc and is commercially available.
223775195|NCT01564225|DRUG|EDI200|Cohort 1 will be dosed at 3 mg/kg/dose. Cohort 2 will be dosed at 10 mg/kg/dose. Both cohorts will receive 2 doses/week for a total of 5 doses.
223775196|NCT03174977|DRUG|18F-Raltegravir|A single microdose of 18F-Raltegravir will be given to individuals currently being treated for HIV-1 with antiretroviral therapy.
223684773|NCT02029339|DEVICE|Continuous topical triple-tube irrigation and suction|"The triple-tube device was continuous operated: instilled the topical solution through the washing tube, delivered negative pressure therapy at 100 - 125 mmHg continuously through the inner tube of sleeve tubes through the central negative pressure device in the wall of the ward. The outer tube was used for normalize and balance the distribution of the negative pressure around the inner tube to allow the solution to penetrate through the dressing to cover the wound, and protecting the inner tube from getting stuck with the sucked tissue. All tubes are all commercially available (Medical Silicone Tubing, Forbest Manufacturing Co., Ltd, China)."
223684774|NCT02029339|DEVICE|SOC|Debridement, offloading, standard moist wound care, and conventional NPWT without continuous irrigation are the fundamental SOC for Open Abdomen with complicated abdominal infections.
223684775|NCT02269826|DEVICE|Vagisan® Moisturising Cream|Once in the evenings before going to bed, intravaginally with the help of the applicator included (approximately 2.5 g per application) and perivaginally one fingertip unit (approximately 0.5 g per application).
223684776|NCT02269826|DEVICE|Gynomunal® vaginal gel|Once in the evenings before going to bed, intravaginally with the help of the applicator included (approximately 2.5 g per application) and perivaginally one fingertip unit (approximately 0.5 g per application).
223684777|NCT00076024|DRUG|Placebo|5 mg twice daily \[bid\] continuous dosing
223684778|NCT00076024|DRUG|Docetaxel|Standard of care drug administration
223684779|NCT00076024|DRUG|AG-013736 (axitinib)|5mg twice daily \[bid\] continuous dosing
223684780|NCT00076024|DRUG|Docetaxel|Standard of care drug administration
223684781|NCT01155219|DRUG|Geltim LP 1 mg/g|one drop in the conjunctival sac of each eye in the morning (84 days).
223684782|NCT01155219|DRUG|Xalatan|one drop in the conjunctival sac of each eye in the morning (84 days).
223684783|NCT03124238|OTHER|Massage|Massage therapy localized to the back of the individuals for a duration of 30 minutes
223684784|NCT04333771|DRUG|SHR0302|The placebo group will take drugs orally for 24 weeks, and then switch to SHR0302 dose1 for 28 weeks, in the meanwhile, SHR0302 dose1 group and SHR0302 dose2 group will continue taking drugs for the whole 52 weeks.
223684785|NCT04333771|DRUG|Placebo|The placebo group will take drugs orally for 24 weeks, and then switch to SHR0302 dose1 for 28 weeks, in the meanwhile, SHR0302 dose1 group and SHR0302 dose2 group will continue taking drugs for the whole 52 weeks.
223684786|NCT03912896|BEHAVIORAL|Taekwondo|Children will participate in a 7-week taekwondo program.
223684787|NCT00848575|DEVICE|Flexible Endoscope|
223684788|NCT01179893|BIOLOGICAL|IVIG|Intravenous immunoglobulin
223684789|NCT01179893|PROCEDURE|PLEX|Plasma exchange: removal of pathogenic antibodies and constituents and replacement with albumin.
223684790|NCT03688009|BEHAVIORAL|Mindfulness-Based Family Psycho-Education (MBFBE)|Six sessions includes: 1. Working with Caregiving Stress; 2. The Struggles of a Caregiver; 3. The Struggles of a Person in Recovery; 4. The Path of Recovery; 5. A Supportive Caregiving; and 6. Review of Learning.
223684791|NCT03688009|BEHAVIORAL|Family Psycho-Education (FPE)|Six sessions includes: 1. Working with Caregiving Stress; 2. The Struggles of a Caregiver; 3. The Struggles of a Person in Recovery; 4. The Path of Recovery; 5. A Supportive Caregiving; and 6. Review of Learning.
223684792|NCT03418623|DRUG|GET73|GET73 300 mg oral capsules, administered three times a day on Visit 2 and 4, and twice a day on Visit 3 and 5.
223684793|NCT03418623|OTHER|Placebo|Placebo oral capsules, administered three times a day on Visit 2 and 4, and twice a day on Visit 3 and 5.
223684794|NCT02528175|DEVICE|Magnetic resonance-guided focused ultrasound|Targeted warming of the tumor via 3 weekly MR-guided ultrasound procedures. Concurrent with radiation and chemotherapy.
223684795|NCT02528175|RADIATION|Standard Radiation|30.6 Gray (Gy) over 17 fractions concurrent with chemotherapy (institutional standard).
223684796|NCT02528175|DRUG|Chemotherapy|3.5 weeks concurrent with radiation therapy (institutional standard).
223684797|NCT04469426|OTHER|Interactive online informational and peer support app|The app contains LARS information, bowel function diaries, and online platform with trained peer support mentor
223684798|NCT05541068|DEVICE|Bioimpedance analysis|Bioimpedance analysis to achieve assessments of fluid status, especially dry-weight, was performed with the portable Biomasc touch i8 (MaltronInternationl, Essex, UK).
223684799|NCT05550649|PROCEDURE|embolization|Prophylactic arterial embolization is performed for the artery in the diseased blood supply area. The embolization material: gelatin sponge particles are recommended, and micro-steel ring can be used as an auxiliary if necessary; after operation, symptomatic and supportive treatment such as acid suppression, hemostasis, blood transfusion, and fluid replacement are given according to the condition.
223684800|NCT01511666|DEVICE|Prehospital mechanical compressions, intraarrest cooling and in hospital ECLS|ECLS states for extracorporeal life support.
223684801|NCT01511666|OTHER|Standard care|Standard care as per recent guidelines will be provided.
223684802|NCT01455376|DRUG|hyperosmolar sodium lactate|Patients in this group received intravenous infusion of hyperosmolar sodium lactate at 1.5 ml.KgBW-1 within 15 minutes before neurosurgery
223684803|NCT06156475|PROCEDURE|Proprioception exercises|Patients trained for proprioception exercises.
223684804|NCT06156475|PROCEDURE|Proprioception exercises with Electromyographic Biofeedback|Patients trained for Proprioception exercises with Electromyographic Biofeedback
223684805|NCT06156475|PROCEDURE|Wand Exercise|Patients were educated with wand exercises.
223684806|NCT01840839|DEVICE|brain stimulation|
223684807|NCT01840839|DEVICE|Sham Stimulation|
223684808|NCT03350984|DRUG|NPH insulin|NPH insulin twice daily, 2/3 in the morning and 1/3 in the night. A correctional dose of lispro insulin will be given for any blood glucose \>180 mg/dL.
223684809|NCT03350984|DRUG|Glargine and Lispro insulin|Half of the total Glargine and Lispro insulin dose will be given as glargine once daily, either in the morning or in the evening, depending on when the patient was enrolled. The other half of the total daily insulin dose was given as Lispro; doses were divided equally between breakfast, lunch, and dinner.
223684810|NCT01203254|DRUG|Colesevelam|Colesevelam 625 mg tablet; 3 times daily 2 tablets
223684811|NCT01203254|DRUG|Placebo|Placebo tablet: 3 times daily 2 tablets
223684812|NCT04195126|DEVICE|CytoSorb haemadsorption device|CytoSorb (Cytosorbents Inc.) aspecific blood purification device used in an extracorporeal circulation system without dialysis column. Anticoagulation is managed by siodium citrate-Calcium system, using the Gambro CVVHDF capable device.
223684813|NCT00642473|DRUG|Erlotinib|Participants will receive erlotinib 150 milligrams (mg) orally daily for 4 weeks.
223684814|NCT00642473|DRUG|Metronidazole Actavis|Metronidazole actavis 1% topical cream will be applied on the face and chest twice daily for 4 weeks.
223684815|NCT00642473|OTHER|Non-active Moisturizing Cream|Left side of the face and chest will be treated according to local standard procedures (ie, with non-active moisturizing cream).
223684816|NCT05817279|DIAGNOSTIC_TEST|Optical coherence tomography|"Optical coherence tomography: OCT is a non-invasive CE-certified diagnostic modality based on light interferometry. An OCT scan visualizes an area with a diameter of 6mm thereby revealing the skin and adnexal structures with a depth of approximately 1.5mm.~3mm punch biopsy: the patients included in this study underwent a 3mm punch biopsy conform regular care. The subsequent histopathological examination of the biopsy specimen serves as ground truth diagnosis of the lesions (gold standard)"
223684817|NCT01175837|OTHER|questionnaire administration|Ancillary studies: Pre- and post-fasting side effect questionnaires
223684818|NCT01175837|OTHER|preventative dietary intervention|24, 36, or 48 hour fast prior to chemotherapy
223684819|NCT01175837|OTHER|laboratory biomarker analysis|Correlative studies
223684820|NCT01563146|OTHER|Data collection|Each participating centre will be requested to generate a coded list of all stool samples taken during the study period (June 1st 2006- May 31st 2007) and analysed for rotavirus, in children aged ≤5 years.
223684821|NCT04289350|DIAGNOSTIC_TEST|fetal heart rate variability|An observational study. No intervention
223684822|NCT00132561|DRUG|Sulfadoxine/pyrimethamine and artesunate|
223684823|NCT04280146|BEHAVIORAL|daily energy intake|Investigate daily energy intake according to eating rate and food processing
223684824|NCT03589014|DRUG|Propranolol|Patients randomized to the experimental arm will receive propranolol on top of standard recommended treatment for CCM. Initial oral dose of 40 mg bid will be uptitrated to 80 mg bid in the absence of excessive bradycardia or hypotension. Doses as low as 10 mg bid and up to 160 mg bid, 20 to 320mg daily, are acceptable according to tolerability.
223684825|NCT04944628|DIETARY_SUPPLEMENT|Probiotic|Probiotic in liquid format (oil suspension) administered 10 drops once daily for 2 weeks (2x10\^9 cfu/day)
223684826|NCT02524093|BEHAVIORAL|Positive Mental Training|Positive Mental Training consists of twelve eighteen minute audio tracks. Each is listened to in turn every day, once a day for a week (or at least 5 days in a week). This means that to use the treatment properly you need to spend 18 minutes a day for 12 weeks listening to it. Each track guides the listener through different instructions which aim to build skills and bring about positive change. The programme begins with simple relaxation, going on to support the creation of pictures in your head of safe places and a more positive future.
223684827|NCT02524093|OTHER|treatment as usual|
223684828|NCT04815746|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)-based skills|The CBT skills target reducing anxiety, (e.g., relaxation), changing negative appraisals (e.g., cognitive restructuring), coping skills training (e.g., enhancing adaptive skills), behavioral activation, interpersonal skills (e.g., communication skills) and building or enhancing social networks. The intervention will be administered online, and each module will last about 1-hour.
223684829|NCT04815746|BEHAVIORAL|Standard Education|Patients randomized to standard clinical care will receive standard education based on various resources (e.g., National Cancer Institute) relevant to pancreatic cancer.
223684830|NCT04920318|COMBINATION_PRODUCT|tDCS + language therapy|In this study fMRI-guided noninvasive neuromodulation will be applied, called Transcranial Direct Current Stimulation (tDCS) to the frontal and parietal brain regions that show reduced activation but still are structurally intact. TDCS will be paired with personalized speech-language therapy to enhance language functions.
223684831|NCT04920318|COMBINATION_PRODUCT|sham TDCS + language therapy|sham control will be applied with language therapy to the same regions as active TDCS.
223775197|NCT05884034|OTHER|Telerehabilitation|Subjects will participate in a six-week self-care education program with weekly synchronous meetings using Google Meet or WhatsApp and an informative booklet containing guidelines for performing physical activities at home and information on healthy eating, mental health and routine management, with a schedule for weekly organization.
223684832|NCT05782465|PROCEDURE|Blood Collection, processing and analyses|20ml of blood will be drawn from study participant at the baseline visit for molecular analyses.
223684833|NCT05782465|PROCEDURE|Gastroscopy and biopsies collection|Study participant will undergo gastroscopy with collection of gastric mucosal biopsies at the baseline visit to ascertain OLGIM status and for molecular analyses. Study participant will undergo surveillance gastroscopy for gastric cancer at years 2 and 4 to assess whether they have reached endpoint.
223684834|NCT05782465|DIAGNOSTIC_TEST|Urea Breath Test|Study participant will fast for 6 hours or overnight before undergoing the Urea Breath Test (UBT) to test for current H. pylori infection. Breath collection will be performed before ingestion of 13C urea, and at specified time intervals after ingestion.
223684835|NCT05558267|DIETARY_SUPPLEMENT|Standard Table Salt|Standard Table Salt is administered orally. It is transferred to unmarked saltshakers by non-blinded research coordinators. The unmarked saltshaker is delivered to the participant during dialysis.
223684836|NCT05558267|DIETARY_SUPPLEMENT|Salt Substitute|"Salt Substitute is available as a crystalized powder. It substitutes potassium chloride for sodium chloride, and thus contains about 50% less sodium than standard table salt.~Salt Substitute is administered orally. It is transferred to unmarked saltshakers by non-blinded research coordinators. The unmarked saltshaker is delivered to the participant during dialysis."
223684837|NCT06846385|BIOLOGICAL|Placebo|A single dose was administered
223684838|NCT06846385|BIOLOGICAL|MG-K10 Humanized Monoclonal Antibody Injection|MG-K10 Humanized Monoclonal Antibody Injection
223684839|NCT04370899|OTHER|lifestyle assessment|"A semi-quantitative assessment of the consumption of different food groups will be carried out using a frequency questionnaire validated by the Spanish population27. This questionnaire consists of 137 food items and will be obtained by the dietitian of our Unit (see annex).~The child population and/or their parents will be instructed on how to fill the data in the food diary for a period of 3 days, in order to be able to analyse the nutritional composition of the intake and the effect on the lipid profile. The first food register, will be obtained at the collection visit before starting any type of treatment. Another food diary will be included after one year.~Physical activity will be collected from the Minnesota Test and we will ask about the consumption of tobacco."
223684840|NCT05283928|DEVICE|OsseoDensification (OD) protocol|Osseodensification is a drilling process by which bone is being compacted and auto-grafted in an outwardly expanding direction from the osteotomy. When the osseodensification drills are being rotated in a reversed, non-cutting direction a strong and dense layer of bone is formed along the walls and base of the osteotomy.
223684841|NCT05283928|DEVICE|standard drilling (SD) protocol (NobelReplace® Conical)|osteotomy preparation through bone excavation is necessary in implant site development for the placement of dental implants. The process involves a forward cutting process with removal of bone tissue creating appropriate size osteotomy for the dental implant.
223684842|NCT03544775|PROCEDURE|Isolated General Anesthesia|No nerve block identified through physician billing codes
223684843|NCT03544775|PROCEDURE|Peripheral Nerve Block|Nerve block identified through physician billing codes
223684844|NCT04911426|BEHAVIORAL|Telehealth|The telehealth intervention is delivered with an app developed for this research. The intervention features live video calling, messaging, appointment reminders; clinical support is provided by licensed clinicians.
223684845|NCT06272669|DEVICE|Active-tDCS|For active-tDCS condition, participants will receive stimulation on the dorsolateral prefrontal cortex with ramp up and ramp down mode for 10 seconds, eliciting a tingling sensation on the scalp that fades over seconds. Following that, a twenty-minute executive functional training task will be initiated five minutes subsequent to the stimulation mode, and the stimulation will be terminated when the training task ends.
223684846|NCT06272669|DEVICE|Sham-tDCS|For sham-tDCS condition, participants will receive initial stimulation with ramp up and ramp down mode for 30 seconds, eliciting a tingling sensation on the scalp then it will be discontinued. Participants will also receive the twenty-minute executive functional training task five minutes subsequent to the stimulation mode.
223684847|NCT00743782|DRUG|Synthetic Human Parathyroid Hormone 1-34|
223684848|NCT03981822|COMBINATION_PRODUCT|VP-102 and applicator|In part A, VP-102 will be applied for either 2, 6 or 24 hours with each regimen compared to placebo. For part B, 2 of the regimens from part A will be chosen for Part B with each compared to Placebo. Only 4 arms are actually being studied.
223684849|NCT03981822|COMBINATION_PRODUCT|Placebo|The placebo single-use applicator contains the same formulation as the VP-102 applicator but does not contain the active pharmaceutical ingredient cantharidin
223684850|NCT06460493|DRUG|Ensifentrine 3 mg twice daily|All subjects will receive ensifentrine.
223684851|NCT05595369|DRUG|Experimental: Paxlovid 25 day dosing|Drug: Paxlovid 25 day dosing Paxlovid (nirmatrelvir 300mg, ritonavir 100mg) bid x 25 days See NCT05965726 (Paxlovid Sub-study)
223684852|NCT05595369|DRUG|Experimental: Paxlovid 15 day dosing|Drug: Paxlovid 15 day Dosing Paxlovid (nirmatrelvir 300mg and ritonavir 100mg) bid x 15 days then ritonavir 100mg bid plus nirmatrelvir matching placebo bid x 10 days See NCT05965726 (Paxlovid Sub-study)
223684853|NCT05595369|DRUG|Placebo Comparator: Control|Drug: Control ritonavir 100mg taken bid plus nirmatrelvir matching placebo bid bid x 25 days See NCT05965726 (Paxlovid Sub-study)
223684854|NCT06475118|OTHER|Dynamometry measurement, myokine dosing, sarcopenia calculation|Blood sampling during standard pre-therapeutic care (at the same time with a standard blood testing) and dynamometry measurement. Retrieval of scanographic imaging and calculation of the L3 SMI index
223684856|NCT05355402|DRUG|Olezarsen|Olezarsen will be administered by SC injection.
223684857|NCT05355402|DRUG|Placebo|Olezarsen-matching placebo will be administered once every 4 weeks by SC injection for up to 49 weeks.
223684858|NCT06273540|DRUG|STP7 (mavoglurant) or Placebo|"STP7 (mavoglurant) or Placebo twice a day (BID) from Days 3 to 9 according to the following dosing schedule: Day 3: 50 mg BID; Day 4: 100 mg BID; Days 5-9: 200 mg BID, and will take only the morning dose of STP7 (200 mg) on Day 10.~Cocaine / Saline~Participants will undergo cocaine/saline i.v. challenge sessions according to the schedule and doses:~* Screening (Session 1, Day -2): 20 mg cocaine, followed by a saline infusion, followed by 40 mg cocaine~* Baseline (Session 2, Day 1): saline or 20 mg cocaine followed by either 20 mg cocaine or saline.~* Baseline (Session 3, Day 2): saline or 40 mg cocaine followed by either 40 mg cocaine or saline.~* Treatment (Session 4, Day 9): saline or 20 mg cocaine followed by either 20 mg cocaine or saline.~* Treatment (Session 5, Day 10): saline or 40 mg cocaine followed by either 40 mg cocaine or saline."
223684859|NCT04991480|DRUG|ART4215|Participants will receive ART4215 by mouth daily in 21-day cycles.
223684860|NCT04991480|DRUG|Talazoparib|Talazoparib will be administered at a dose of 1 mg or 0.75 mg by mouth daily in 21-day cycles.
223684861|NCT04991480|DRUG|Niraparib|Niraparib will be administered at a dose of 200 mg or 300 mg by mouth daily in 21-day cycles.
223684862|NCT05627661|DEVICE|Biosensor|Noninvasive wearable biosensor device worn on the primary affected wrist or upper arm for as much time as is feasible for 7-10 days
223684863|NCT00309660|DRUG|Rosiglitazone|
223684864|NCT04307745|OTHER|Primary prevention|The primary prevention that the 4 groups put in place for the upper limp athletes
223684865|NCT02651714|DRUG|Tradipitant|
223684866|NCT02651714|DRUG|Placebo|
223684867|NCT05853627|BEHAVIORAL|Memory reactivation procedures|In the Mismatch condition, a different, unexpected mismatch will be incorporated into the reactivation. In the Standard condition, the participant will read the narrative the same way each time.
223684868|NCT05853627|DRUG|Propranolol|Propranolol will be administered 60-min prior to each of six weekly 10-20 min. traumatic memory reactivation sessions.
223684869|NCT01622127|DEVICE|Parietex ProGrip™|ProGrip™ mesh is a lightweight (40g/m2) monofilament polypropylene or polyester mesh with resorbable polylactic acid (PLA) micro-grips, which provide self-gripping properties during the first few months after implantation.
223684870|NCT01976078|DRUG|Midazolam/Ranitidine/Esomeprazole|Each of the three drugs will be given at 10% of their usual doses for age/weight.
223684871|NCT01515540|DRUG|lidocaine|5% lidoderm patch
223684872|NCT01515540|DRUG|placebo|placebo
223775198|NCT05884034|OTHER|Education|Participants will receive an informative booklet containing guidelines for performing physical activities at home and information on healthy eating, mental health and routine management, with orientations on the importance of reading and implementing the guidelines described in the booklet.
223684873|NCT05988697|DRUG|Combind asprin with Trametinib and Dabrafenib|Treatment drug: Dabrafenib 150 mg BID, Trametinib 2 mg QD, Aspirin 100 mg/tablet, 1 tablet/time, QD
223684874|NCT05272215|PROCEDURE|Bariatric surgery|Pre- and post-bariatric surgery (3, 6, 12 months postoperative and yearly)
223684875|NCT05272215|PROCEDURE|Body contouring surgery|Pre- and post body contouring surgery (3, 6, 12 months postoperative and yearly)
223684876|NCT05929066|DRUG|Retatrutide|Administered SC
223775199|NCT05904964|DRUG|Disitamab vedotin|Disitamab Vedotin 2mg/kg was injected every 2 weeks,
223775200|NCT05904964|OTHER|Endocrine therapy|Doctors choose endocrine therapy independently
223684877|NCT05929066|DRUG|Placebo|Administered SC
223684878|NCT01850264|DEVICE|Application of quadripolar / bipolar LV electrodes|
223684879|NCT00978107|BIOLOGICAL|MVA-FCU1, flucytosine|"1. TG4023: single IT injection; possibility to re-administer once,~   * Percutaneous IT injections, under radiological or ultrasound imaging guidance~  * Dose-escalating schedule of administration: 107 pfu (Cohort #1), 108 pfu (Cohort #2) and 4x108 pfu (Cohort #3),~  * MTD injected to up to 3 different lesions (Cohort #4)~2. 5-FC (5-fluorocytosine)/flucytosine~   * Dose and dosing schedule:~     * Daily starting dose of 200 mg/kg; daily dose will be adjusted after measurement of 5-FC plasma concentration at steady state, which should be kept below 100 mg/L~    * Duration: 2 weeks.~  * Possible routes of administration:~     * PO: 500 mg tablets, qid~    * IV: 1% 250 mL vials, 45-minute infusions."
223684880|NCT02987660|PROCEDURE|Topography Guided LASIK|Corneal surgery for refractive error correction
223684881|NCT02987660|PROCEDURE|Small Incision Lenticular Extraction|Refractive surgical procedure for the correction of myopia with or without astigmatism
223684882|NCT02987660|DEVICE|WaveLight EX500 Excimer Laser System|As used for corneal stroma ablation (refractive error correction). The treatment is intended to last the subject's lifetime.
223684883|NCT02987660|DEVICE|VisuMax Surgical Laser|As used for lenticule creation/removal (refractive error correction). The treatment is intended to last the subject's lifetime.
223684884|NCT06267430|BEHAVIORAL|Kleuter Extra training program|The intervention was described in the included arm/group explanation.
223775201|NCT04705077|DRUG|SR419|2 formulations of SR419, SR419 suspension and SR419 capsule will be used in the study.
223775202|NCT05900947|OTHER|analysis of carotid atherosclerotic plaque|To assess the presence of air pollutants (benzene, toluene, xylene, and ethylbenzene) or of microplastics within tissues from atherosclerotic plaques by Chromatographic analyses.
223775203|NCT01748994|DRUG|Pioglitazone|30mg per day for four months
223775204|NCT01748994|DRUG|Placebo|
223775205|NCT04901884|DRUG|PET/MR with 18F-FDG|(18F) Fluorodeoxyglucose (FDG) will be administered by intravenous injection at a dose of 4-5 MBq/kg.
223684885|NCT03624400|BEHAVIORAL|Internet-based CBT-I|The adapted Internet-based CBT-I for adolescents with ASD includes sleep hygiene, restriction of time in bed, stimulus control, cognitive therapy, and relaxation techniques. The treatment consists of 8 weekly modules and each module consists of several website pages that will be presented in a fixed order, with preprogrammed modules containing information, interactive questionnaires, descriptions of exercises and movies.
223684886|NCT03624400|BEHAVIORAL|Internet-based psychoeducation|Internet-based psychoeducation contains information about ASD, sleep difficulties and aspects of sleep hygiene. The intervention takes place in 8 weeks modules.
223684887|NCT01933711|DRUG|rituximab|
223684888|NCT02789878|DRUG|Goserelin|Androgen Deprivation Therapy
223684889|NCT02789878|DRUG|Prednisone|Corticosteroid
223684890|NCT02789878|DRUG|Abiraterone|CYP17 inhibitor
223684891|NCT02789878|DRUG|Apalutamide|Androgen-receptor antagonist
223684892|NCT01087242|DRUG|Tang-min Lin pill|Tang-min Lin pill 6g,tid,treat 12 weeks.
223684893|NCT00715000|PROCEDURE|Oral rehydration therapy|oral rehydration solution
223775206|NCT00658346|DRUG|Treatment initiation for HIV-1 group O infected patients|"The first line regimen is adapted according to the hemoglobin level and the AgHBs status :~* If Hb \> 8 g/ml and negative AgHBs : AZT-3TC (DUOVIR) + LPV/RTV (ALUVIA)~* If Hb \<= 8 g/ml and negative AgHBs : TDF-3TC (LAMIVIR-S) + LPV/RTV (ALUVIA)~* If positive AgHBs : TDF + 3TC + LPV/RTV (ALUVIA)"
223775207|NCT00658346|DRUG|Treatment initiation for HIV-1 group M infected patients|"The first line regimen is adapted according to the hemoglobin level and the AgHBs status :~* If Hb \> 8 g/ml and negative AgHBs : AZT-3TC (DUOVIR) + LPV/RTV (ALUVIA)~* If Hb \<= 8 g/ml and negative AgHBs : TDF-3TC (LAMIVIR-S) + LPV/RTV (ALUVIA)~* If positive AgHBs : TDF + 3TC + LPV/RTV (ALUVIA)"
223775208|NCT01628276|BEHAVIORAL|Cog Rehab|Cognitive rehab for MS patients
223775209|NCT03128697|BEHAVIORAL|Satiating diet|
223775210|NCT03128697|BEHAVIORAL|Control diet|
223775211|NCT02658110|DIETARY_SUPPLEMENT|Whey Protein|20 g whey protein isolate (Arla Foods Ingredients Group) added to 200ml water and served as a beverage
223775212|NCT02658110|OTHER|Mixed Macronutrient Breakfast Meal|A standardised mixed-macronutrient breakfast served to all participants. The macronutrient distribution of the breakfast is 13% protein, 70% carbohydrate, 17% fat (1958 kJ; 468 kcal total)
223775213|NCT02658110|OTHER|Mixed Macronutrient Lunch Meal|A standardised mixed-macronutrient lunch served to all participants. The macronutrient distribution of the lunch is 14% protein, 51% carbohydrate, 35% fat (3506 kJ; 838 kcal total)
223775214|NCT02112565|DRUG|RNR inhibitor COH29|Given PO
223775215|NCT02112565|OTHER|laboratory biomarker analysis|Correlative studies
223775216|NCT02112565|OTHER|pharmacological study|Correlative studies
223775217|NCT05483244|OTHER|discontinuous weaning|"Each day, a respiratory therapist evaluated whether a spontaneous breathing trial could be performed. Patients of the discontinuous weaning group were disconnected from the respirator during the spontaneous breathing phases which could then take place via heat moist exchanger, high-flow therapy and/or speaking valve without pressure support by the respirator (spontaneous breathing trial with heat moist exchanger).~Heart rate, respiratory rate, blood pressure and mental condition of the patient (i. e. stress, fear) were monitored carefully for five to ten minutes and the Rapid Shallow Breathing Index was calculated. If the patient could keep the Rapid Shallow Breathing Index stable under 105/min/l (without a significant increase) over five minutes, the spontaneous breathing trial was regarded as successful and the weaning could be started. The duration of spontaneous breathing trial was extended according to the individual situation of the patient."
223684894|NCT00715000|PROCEDURE|classical hydration via intravenous infusion|intravenous infusion
223684895|NCT04634838|DEVICE|MedCu Antibacterial Wound Dressings with Copper Oxide|Comparison between the efficacy of antibacterial wound dressings containing copper oxide microparticles to improve the wound healing of pressure sores and post-op wounds as compared to silver wound dressings
223684896|NCT06255834|DRUG|IPG11406|"IPG11406 Activity: An antagonist of the GPR183 Dosage form: Tablet Strength: 0.5 mg, 10 mg and 40 mg Storage：15 \~ 25 °C in a tightly sealed container, protect from light Administration: In each cohort, IPG11406 or placebo tablets are orally administered once on Day 1 (Part A) or daily for 10 days from Day 1 to Day 10 (Part B) in a fasted state. Oral doses will be administered with 240 ml of water. Tablets should not be chewed or crushed.~Participants in the FE Cohort will receive a second single dose of IPG11406 following a standardized high fat meal upon ≥4 days washout period after the first dose.~IPG11406 Placebo Placebo tablets: tablets identical to IPG11406 tablets"
223684897|NCT03284437|BEHAVIORAL|Early Cognitive Training|Choose level of activity (e.g., coloring, holding objects) based on occupational therapist assessment.
223684898|NCT06256120|DIAGNOSTIC_TEST|Restrictive|3 mL/kg/hour Ringer Lactate will be given peroperatively to the restrictive group (Group R).
223684899|NCT06256120|DIAGNOSTIC_TEST|Liberal|7 ml/kg/hour Ringer Lactate will be given peroperatively to the liberal group (Group L).
223684900|NCT03707184|PROCEDURE|Computed Tomography|Undergo PET/CT scan
223684901|NCT03707184|DRUG|Fluciclovine F18|Given IV
223684902|NCT03707184|PROCEDURE|Positron Emission Tomography|Undergo PET/CT scan
223684903|NCT05267665|BEHAVIORAL|Brief Family Intervention (BFI)|A 2-session psychoeducational and skills-based family intervention.
223684904|NCT04704154|DRUG|Regorafenib, (Stivarga, BAY73-4506)|"Intake orally, starting with 3x 30 mg tablets every day (once daily.) for 21 days of every 28-day cycle (21 days on, 7 days off).~If the starting dose is well tolerated dose can be escalated to 120 mg (4x30 mg tablets)."
223684905|NCT04704154|DRUG|Nivolumab (Opdivo)|480 mg administered on Day 1 of each treatment cycle.
223684906|NCT03419221|PROCEDURE|PET/CT Positron emission tomography (PET) using small radiotracers, a special camera and a computer to evaluate organ and tissue functions|"Open-label randomized controlled superiority trial in patients with SAB without infective endocarditis at the time of inclusion comparing whole-body PET/CT in arm A and routine care with performance of imaging studies according to anamnesis and clinical symptoms in arm B. To demonstrate that PET/CT is associated with a 20% higher frequency of detection of DFI during SAB, the inclusion of 145 patients in each arm is required.~Randomization will be stratified on centre and SAB setting of acquisition (healthcare vs community)."
223684907|NCT03419221|OTHER|Patients' routine care with performance of explorations based on anamnesis and clinical symptoms|Patients' routine care with performance of explorations based on anamnesis and clinical symptoms
223684908|NCT01303887|DRUG|Rituximab|Rituximab 375mg/m2 IV day 1,repeated every 21 days for 8 cycles. All patients who have achieved a CR or PR to induction therapy will receive rituximab maintenance (375mg/m2 every 2 months for 2 years).
223684909|NCT01303887|DRUG|Cyclophosphamide|Cyclophosphamide 250mg/m2 PO day 1-3, repeated every 21 days for 4 (R-FC) or 8 cycles (R-CVP)
223684910|NCT01303887|DRUG|Vincristine|Vincristine 1.4mg/m2 IV day 1,repeated every 21 days for 8 cycles.
223684911|NCT01303887|DRUG|Prednisolone|Prednisolone 40mg/m2 PO day 1-5, repeated every 21 days for 8 cycles.
223684912|NCT01303887|DRUG|Fludarabine|Fludarabine 40mg/m2 PO day 1-3,repeated every 21 days for 4 cycles
223684913|NCT05327959|DEVICE|Clavicle open reduction and internal fixation|Clavicle open reduction and internal fixation using the A.L.P.S. Clavicle Plating System
223684914|NCT01057771|BEHAVIORAL|Meditation|Eight weeks of training in mindfulless meditation. Weekly group sessions of 2.5 hours, with 45 minutes/day of practice.
223684915|NCT01057771|BEHAVIORAL|Exercise|Eight weeks of training in moderately strenuous exercise. Weekly group sessions of 2.5 hours, with 45 minutes/day of practice.
223684916|NCT01949454|DRUG|Fluorometholone 0.1% ophthalmic solution|
223684917|NCT01949454|OTHER|Artificial tears (Placebo)|Artificial tears (Placebo)
223684918|NCT04845373|OTHER|Mediterranean diet|Diet intervention:Mediterranean diet
223684919|NCT04845373|OTHER|Control diet: Low fat diet|Low fat diet
223684920|NCT02068456|DRUG|Roflumilast|
223684921|NCT04251715|DRUG|Dexamethasone|Given intraarterially via HAI pump
223684922|NCT04251715|DRUG|Floxuridine|Given intraarterially via HAI pump
223684923|NCT04251715|DEVICE|Implanted Medical Device|Implanted hepatic arterial infusion pump by surgical oncology, to deliver HAI therapy
223684924|NCT04251715|DRUG|Irinotecan|Given IV
223684925|NCT04251715|DRUG|Leucovorin|Given IV
223684926|NCT04251715|DRUG|Oxaliplatin|Given IV
223684927|NCT04251715|OTHER|Quality-of-Life Assessment|Ancillary studies
223684928|NCT06075251|BEHAVIORAL|I-InTERACT-North|I-InTERACT-North is a virtual stepped-care positive parenting program. It comprises online psychoeducational modules as well as live therapy and coaching sessions. The program lasts anywhere from 1 to 16 weeks depending on parents' progress.
223684929|NCT01583920|RADIATION|focal salvage HDR prostate brachytherapy|Treatment will be delivered using 192-Ir HDR afterloading. Dose prescription is 2 fractions of 13.5 Gy each, delivered 1 week apart.
223684930|NCT02978560|DIAGNOSTIC_TEST|fluorescence-mediated photoplethysmography|Indocyanine green dye (ICG) will be injected intravenously as a sterile solution at a dose of 0.5 mg/kg, and then imaging of skin will be done with a fluorescence camera. The ICG-angiogram sequence will consist of 1.5 x 2.0-cm field-of-view ICG fluorescence images acquired at the rate of approximately 30/sec during a period of about 15 seconds. Following acquisition of the initial transit angiogram sequence, several additional 15-second-long image sequences will be acquired during the next half-hour, but without any additional injections.
223684931|NCT05882071|DRUG|Sodium/glucose cotransporter-2 inhibitors (SGLT2i)|Sodium/glucose cotransporter-2 inhibitors (SGLT2i)
223684932|NCT06109285|DEVICE|iROP DL|First, to evaluate the i-ROP DL system for autonomous ROP screening. To demonstrate the sensitivity and specificity of the i-ROP DL system on images obtained by technicians in the neonatal intensive care unit (NICU) setting to detect more than mild ROP (MTMROP), defined as type 2 or worse from the Early Treatment for ROP study) compared to an image-based reference standard diagnosis (RSD).
223684933|NCT03223753|OTHER|Educational Intervention|Receive educational handouts about to physical activity
223684934|NCT03223753|OTHER|Internet-Based Intervention|Access limited version of device app/website
223684935|NCT03223753|OTHER|Internet-Based Intervention|Access full version of interactive reward-based device app/website
223684936|NCT03223753|OTHER|Laboratory Biomarker Analysis|Correlative studies
223684937|NCT03223753|DEVICE|Medical Device Usage and Evaluation|Wear physical activity tracking device
223684938|NCT03223753|OTHER|Quality-of-Life Assessment|Ancillary studies
223684939|NCT03223753|OTHER|Questionnaire Administration|Ancillary studies
223684940|NCT02882074|DRUG|Human albumin|human albumin 5% during surgery
223684941|NCT02882074|DRUG|Hydroxyethyl starch|6% Hydroxyethyl starch 130/0.4 during surgery
223684942|NCT01840995|PROCEDURE|ultrasonographic measurement of optic nerve sheath diameter|A thick layer of gel is applied on the upper closed eyelid. The linear 13- to 6-MHz ultrasound probe is then placed in the gel, without exerting pressure on the eye. Two measurements are taken for each optic nerve: one in the transverse plane, with the probe being horizontal, and one in the sagittal plane, with the probe being vertical. The final ONSD is the mean of these measurements.
223684943|NCT05651568|OTHER|Periodized resistance training|"It consists of patients who will receive periodized resistance training 3 sessions per week for 8 weeks. Resistance training has been performed according to FITT principal and as per ACSM recommendation.~Frequency:~Three days in a week~Intensity:~60% intensity with one repetition maximum and 10% intensity were added each the two weeks.4 sets and 8-12 rep as per ACSM criteria. There will be rest of 60 second after every set and 120 seconds after every exercise.~Type:~8 types of resistance exercises were performed. There were 4 set of each exercise with 8 to 12 repetitions. These exercises are smith press, seated press, squat, lying dumbbell leg curls, leg extension, leg press, standing barbell, lying barbell and sit ups.~Time:~40 minutes per session."
223835326|NCT03389893|DRUG|Dupilumab|Dupilumab, an interleukin (IL)-4 receptor alpha (IL-4Rα) antagonist, is indicated for the treatment of adult patients with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. (FDA approved on March 28, 2017.)
223775218|NCT05483244|OTHER|continuous weaning|"Each day, a respiratory therapist evaluated whether a spontaneous breathing trial could be performed. In the case of continuous weaning, spontaneous breathing trial was supported by the respirator, but the positive endexpiratory pressure was lowered to an individual level (between 5 and 10 mbar) resulting in very little pressure support (spontaneous breathing trial trial under continuous positive airway pressure condition).~Heart rate, respiratory rate, blood pressure and mental condition of the patient (i. e. stress, fear) were monitored carefully for five to ten minutes and the Rapid Shallow Breathing Index was calculated. If the patient could keep the Rapid Shallow Breathing Index stable under 105/min/l (without a significant increase) over five minutes, the spontaneous breathing trial was regarded as successful and the weaning could be started. The duration of spontaneous breathing trial was extended according to the individual situation of the patient."
223775219|NCT03032003|OTHER|Cysticlean|2 BID for 15 days
223684944|NCT05651568|OTHER|High intensity interval training|"It consists of patients who will receive high intensity interval training 3 sessions per week for 8 weeks for 30 to 35 minutes.~Active phase: Two weekly sessions of four times four minutes at 90-95% of individual heart rate maximum, separated by three minutes of active rest period and one weekly session of ten times one minute with maximal intensity, separated by one minute of active rest. The exercise mode will be treadmill or outdoor walking/running or cycling (self-selected)."
223684945|NCT02331160|BEHAVIORAL|Rebozo|Shaking of the maternal pelvis by the midwife to increase the spontaneous cephalic version rate in breech presentation.
223684946|NCT06298604|DEVICE|EUS-guided standard fine needle biopsy|Using the echoendoscope, a pancreatic lesion or liver parenchyma will be identified, and a 19-gauge standard fine needle biopsy device (Boston Scientific, USA) is inserted on it to obtain the sample or specimen.
223684947|NCT06298604|DEVICE|EUS-guided motorized fine needle biopsy|Using the echoendoscope, a pancreatic lesion or liver parenchyma will be identified, and a 20-gauge motorized fine needle biopsy device (Limaca, Israel) is inserted on it to obtain the sample or specimen.
223684948|NCT00084591|DRUG|capecitabine|
223684949|NCT00084591|PROCEDURE|conventional surgery|
223684950|NCT00084591|PROCEDURE|neoadjuvant therapy|
223684951|NCT00084591|RADIATION|radiation therapy|
223684952|NCT01633580|DRUG|corifollitropin alfa|long acting FSH
223684953|NCT03571477|DEVICE|ApneaBand|Mesure of oxygen saturation (oximetry), pulse wave (photoplethysmography), electrodermal activity and movements (tri-axial accelerometer)
223684954|NCT04909151|DEVICE|Robot-assisted gait training (walking speed: 0.5km/h)|Robot-assisted gait training RAGT, WALKBOT-G, is a walking training equipment that can reproduce natural motions by adjusting the leg length and adjusting the motion with the actuator of the ankle joint.
223684955|NCT04909151|DEVICE|Robot-assisted gait training (walking speed: 0.8km/h)|Robot-assisted gait training RAGT, WALKBOT-G, is a walking training equipment that can reproduce natural motions by adjusting the leg length and adjusting the motion with the actuator of the ankle joint.
223684956|NCT04909151|DEVICE|Robot-assisted gait training (walking speed: 1.1km/h)|Robot-assisted gait training RAGT, WALKBOT-G, is a walking training equipment that can reproduce natural motions by adjusting the leg length and adjusting the motion with the actuator of the ankle joint.
223684957|NCT01653782|BEHAVIORAL|Kundalini yoga|Guided training twice a week for six weeks. Self instructing cd for home practice
223684958|NCT01653782|BEHAVIORAL|Self care advice|"Evidence based advice from caregiver about keeping active, exercise and a written self care pamphlet The Back book"
223684959|NCT01653782|BEHAVIORAL|Exercise|"Strength training at a gym supervised by a physical therapist twice a week during 6 weeks. Self training instruction was provided. A written self care pamphlet The Back book"
223684960|NCT05124418|DIAGNOSTIC_TEST|palatal masticatory mucosa thickness measurement|Measure the thickness of palatal masticatory mucosa by a dynamic navigation system (Navident®, ClaroNav Inc., Toronto, Canada) and periodontal probe piercing.
223684961|NCT01142128|DRUG|Nexium (esomeprazole magnesium)|one 40 mg capsule per day for one month
223684962|NCT01142128|DRUG|Placebo to Nexium|one capsule per day for one month
223684963|NCT01142128|DRUG|Viokase 16 (pancrelipase) + Nexium|Viokase 16 (pancrelipase) + Nexium capsules are given per day for one month with the addition of esomeprazole magnesium, one 40mg capsule per day for one month
223684964|NCT01142128|DRUG|Viokase 16 + placebo to Nexium|Viokase 16 pancrelipase tablets are given per day for one month with one capsule of placebo to esomeprazole magnesium, one per day for one month
223684965|NCT00611039|DRUG|Darunavir 900mg + ritonavir 100 mg once a day|Darunavir 900mg + ritonavir 100 mg once a day
223684966|NCT00611039|DRUG|Darunavir 600mg + ritonavir 100mg twice day|Darunavir 600mg + ritonavir 100mg twice day
223775220|NCT03032003|OTHER|Placebo|2 BID for 15 days
223775221|NCT02510846|BEHAVIORAL|Intensive educative management|5 hours a week
223775222|NCT01455675|DRUG|IgY|Avian polyclonal anti-pseudomonas antibodies (IgY)
223775223|NCT01455675|DRUG|Placebo|Placebo, 70 ml gargling solution, once daily
223775224|NCT01956175|DEVICE|Electrical pharyngeal stimulation|Electrical pharyngeal stimulation via an intraluminal catheter (Phagenesis Ltd.) once daily for 10 minutes on three consecutive days. The intensity of the electrical stimulation is determined following the calculation of suitable sensory threshold, tailored to the individual participants. After determining the optimal stimulation intensity, 10 minutes of stimulation are delivered.
223775225|NCT01956175|DEVICE|Sham stimulation|The intraluminal catheter (Phagenesis Ltd.) for electrical pharyngeal stimulation is placed. The intensity of the electrical stimulation is determined following the calculation of suitable sensory threshold, tailored to the individual participants. After the optimal stimulation intensity has been determined, no electrical stimulation is delivered.
223775226|NCT04801446|DEVICE|Soterix Medical 1X1 tDCS stimulator (active C-tDCS)|Patients will be randomized to active treatment (C-tDCS) vs sham stimulation in a 3:1 ratio. There will be 6 dose tiers, reflecting increasing intensity and duration of stimulation: Tier 1 - 1 mA, single 20 - min cycle; Tier 2- 2 mA, single 20 min cycle; Tier 3 - 1 mA, 2 cycles of 20 min/20 min off; Tier 4- 2 mA, 2 cycles of 20 min/20 min off; Tier 5 - 1 mA, 3 cycles of 20 min/20 min off; Tier 6 - 2 mA, 3 cycles of 20 min/20 min off.
223775227|NCT04801446|DEVICE|Soterix Medical 1X1 tDCS stimulator (sham stimulation)|Patients will be randomized to active treatment (C-tDCS) vs sham stimulation in a 3:1 ratio. Patients in the sham stimulation arm at all the tiers will have the headgear and electrodes in place, and the switch for sham stimulation will be on, i.e. no prolonged electrical stimulation will be delivered.
223775228|NCT03726112|DEVICE|SpotOn Specs|SpotOn Balance glasses consists of unique visual stimuli (SpotOn's Neuro Balance Active Spots) applied to specific zones in the peripheral visual field
223775229|NCT03726112|DEVICE|Sham Specs|Sham device
223775230|NCT04766879|DEVICE|Transfluthrin|Passive emanator with formulated transfluthrin
223775231|NCT04766879|DEVICE|Placebo|Passive emanator with formulated inert ingredients
223775232|NCT02417454|DIETARY_SUPPLEMENT|ProbioStick|"One sachet daily, without or without meals (3 x 10\^9 CFU per sachet)~(Lactobacillus helveticus R0052 and Bifidobacterium longum subsp. longum R0175)"
223775233|NCT02417454|OTHER|Placebo|One sachet daily, without or without meals (0 CFU per sachet)
223775234|NCT02181231|DRUG|venlafaxine XR|slow titration up to maximum dose of 300mg per day, will remain on venlafaxine XR for up to 32 weeks
223684967|NCT05478954|DRUG|Sulfadoxine pyrimethamine|"Sulphadoxine is a slowly eliminated sulphonamide. It is used in a fixed dose combination of 20 parts sulphadoxine with 1 part pyrimethamine given orally or intramuscularly.~The medicine is no longer recommended for the treatment of malaria. However, it is being used for Intermittent Preventive Treatment during pregnancy (IPTp) and as a co-packaged combination with amodiaquine for seasonal malaria chemoprevention.~Sulphadoxine is readily absorbed from the GIT. It is widely distributed in body tissues and fluids and crosses the placenta into foetal circulation. It is also readily detectable in breast milk. It is excreted predominantly as the unchanged drug."
223684968|NCT05478954|DRUG|Amodiaquine|"Amodiaquine is a Mannich base 4 amino-quinoline that interferes with parasite haem detoxification. It is more effective than chloroquine in both chloroquine sensitive and resistant P. falciparum infections. However, there is cross-resistance between chloroquine and amodiaquine.~It is readily absorbed in the GIT and rapidly converted in the liver to the active metabolite, desethylamodiaquine. Desethylamodiaquine is responsible for all the antimalarial effect. Adverse effect of amodiaquine includes abdominal discomfort and vomiting weakness and when used for prophylaxis it causes agranulocytosis. Amodiaquine is recommended as a partner drug in artemisinin based combination therapy."
223684969|NCT03000127|DRUG|AndroGel 1 % Topical Gel|testosterone gel
223684970|NCT03000127|DRUG|Placebos|Placebo gel
223684971|NCT05977725|DIAGNOSTIC_TEST|Hand Doppler Ultrasound|Hand Doppler Ultrasound to assess the Hand Acceleration Time (HAT)
223684972|NCT04643171|DEVICE|high intensity elliptical training|30 patients will receive 30 minutes of high intensity interval training on elliptical trainer, 5 times per week, for 12 week
223684973|NCT04643171|DEVICE|electrocaupuncture|30 patients will receive 30 minutes of electroacupuncture on bilateral PC 4 and PC 6 for 5 times per week, for 12 week
223684974|NCT00377975|DRUG|Ephedrine|
223684975|NCT00377975|DRUG|Pioglitazone|
223684976|NCT00377975|DRUG|Caffeine|
223684977|NCT00393640|PROCEDURE|Early and regular breast milk expression|Breast pump given to be used on regular intervals
223775235|NCT02181231|DRUG|buprenorphine|randomized to either buprenorphine or placebo, dose range from 0.2 mg/ qd to 2mg/ qd
223775236|NCT02181231|DRUG|Placebo|patients will remain on venlafaxine XR and be randomized to receive either placebo or buprenorphine for 8 weeks. at the end of the 8 weeks those who did not receive buprenorphine will be offered the opportunity to try it.
223775237|NCT05559619|DRUG|Calcium carbonate|1000 mg of natural calcium carbonate once daily for 12 weeks
223775238|NCT05559619|DRUG|Vitamin D3|1000 IU vitamin D3 once daily for 12 weeks
223835327|NCT03389893|DRUG|Placebo|Placebo will contain the identical formulation as the dupilumab formulation without the active mAb and will be given by exactly the same route and schedule through Day 28.
223835328|NCT01471067|DRUG|Melphalan|140 mg/m2 by vein on Day -2 only for Fludarabine + Melphalan group.
223684978|NCT00579007|BEHAVIORAL|telephone interviews|Telephone interviews take place before the first counseling appointment (baseline), and 1 week, 6 months and 12 months post-notification of the individual's genetic test results. In the event that a participant chooses not to undergo genetic testing, follow-up interviews will take place 1 month, 6 months and 12 months after the initial counseling visit.
223684979|NCT03199339|DRUG|TBA-7371|The test product is TBA-7371 25 mg/ml oral suspension formulation and TBA-7371 matching placebo oral suspension.
223684980|NCT03199339|DRUG|Placebo|The test product is TBA-7371 25 mg/ml oral suspension formulation and TBA-7371 matching placebo oral suspension.
223684981|NCT04568343|DEVICE|Capsule endoscopy|We use two capsule endoscopy for evaluation their diagnostic yield. Patient will recieve different capsule endoscopy:The Endocapsule (EC-10) and CapsoCam Plus (Capsovision) capsule
223684982|NCT00613197|DRUG|Epanova|4g/day in divided doses
223684983|NCT03551353|OTHER|Group before Video-assisted feedback|Ten anesthesia residents will be included in this group. Preoperative evaluation in terms of general anesthesia will be completed for a patient before anesthesia induction. After receiving informed consent from the patient resident will complete the preparations by checking the above-mentioned list (anesthesia machine, operating room desk, monitorization methods, aspirator systems, operating room gas systems, waste systems and other anesthesia equipment) then induction will be started. All these steps will be recorded with a camera system. Once the anesthetic application is completed and all stages are recorded, the video records will be evaluated in terms of ASA guideline
223684984|NCT03551353|OTHER|Group after Video-assisted feedback|Before the second phase of the study, the resident will be informed about the guideline (checkout procedure) by a staff. Then induction of general anesthesia in another patient will be recorded at all stages. Once the anesthesia application is complete, the camera record will be monitored. Differences and developments or possible similar mistakes between the records will be discussed.
223684985|NCT04300374|OTHER|The Paediatric Anaesthesia Emergence Delirium scale assesment which was recorded postoperatively|routine remifentanil infusion during general anesthesia
223684986|NCT00926588|DRUG|Stepped care|Structured algorithms for stepped care analgesic management and explicit decision rules for adjusting treatment are new tools developed for this study.
223684987|NCT02866487|PROCEDURE|Bronchoscopy|A diagnostic bronchoscopy will be conducted for clinical indications in children referred to the University of Virginia Children's Hospital for evaluation of respiratory symptoms
223684988|NCT02803515|BIOLOGICAL|peripheral venous blood samples|peripheral venous blood samples measured preoperatively and postoperatively HIPEC (Day 1, day 3 and day 5 postoperative)
223684989|NCT00000253|DRUG|10% N2O|
223835329|NCT01471067|DRUG|Fludarabine|10 mg/m2 by vein on Days -7 to -4 for Melphalan + Thiotepa + Fludarabine group, or 40 mg on Days -5 to -2 for Fludarabine + Melphalan group.
223835330|NCT01471067|DRUG|Mycophenolate mofetil|15 mg/kg (actual body weight with a maximum dose of 1 gram twice daily) by vein or by mouth twice a day from Days -3 to +100 in the absence of Graft vs Host Disease (GvHD).
223684990|NCT00000253|DRUG|20% N2O|
223684991|NCT00000253|DRUG|30% N2O|
223684992|NCT00000253|DRUG|40% N2O|
223684993|NCT04375475|DIETARY_SUPPLEMENT|Bright Changyou probiotic flavored yogurt|Oral consumption of Bright Changyou probiotic flavored yogurt 100 g at a time and twice per day for 28 days. The experimental product has similar package and taste as the comparators.
223684994|NCT04375475|DIETARY_SUPPLEMENT|Bright Changyou lactobacillus flavored yogurt|Oral consumption of Bright Changyou lactobacillus flavored yogurt 100 g at a time and twice per day for 28 days.
223684995|NCT04375475|DIETARY_SUPPLEMENT|Bright flavored yogurt|Oral consumption of Bright flavored yogurt 100 g at a time and twice per day for 28 days.
223684996|NCT02385188|DRUG|Imiquimod|topical 5% imiquimod cream 3 times a week for 16 weeks.
223684997|NCT02385188|DRUG|paracetamol|
223684998|NCT02385188|DRUG|lidocaine in Vaseline ointment|
223684999|NCT00571376|OTHER|Health information technology and exchange|Health information technology includes electronic health records, electronic prescribing, and electronic results notification and/or viewers. Health information exchange includes use of central repositories of data and peer-to-peer models.
223685000|NCT01400438|OTHER|questionnaires|delivery of questionnaires and self-psychological interview
223685001|NCT01400438|OTHER|questionnaires|delivery of questionnaires and self-psychological interview
223685002|NCT04148677|DIETARY_SUPPLEMENT|Protoves M1®|A combination of two alkaloid, Protopine and Nuciferine (Protoves-M1 ®)
223685003|NCT05443360|DIETARY_SUPPLEMENT|DENSITY™ (Amorphous calcium carbonate, ACC)|"1. Dosage form: tablet~2. Dose(s): 1000 mg /tablet, comprising 500 mg amorphous calcium carbonate per tablet (calcium element 200mg)~3. Dosing schedule: The usual dose for oral use is 2 ACC tablets (400 mg calcium element) twice daily given after breakfast and dinner."
223685004|NCT05443360|DIETARY_SUPPLEMENT|Crystalized calcium carbonate (CCC)|"1. Dosage form: tablet~2. Dose(s): 1000 mg /tablet, comprising 500 mg crystalized calcium carbonate per tablet (calcium element 200mg)~3. Dosing schedule: The usual dose for oral use is 2 CCC tablets (400 mg calcium element) twice daily given after breakfast and dinner."
223685005|NCT05442775|DRUG|Reldesemtiv|Oral tablet
223835331|NCT01471067|DRUG|Tacrolimus|Starting dose 0.03 mg/kg or 0.015 mg/kg (ideal body weight) by vein starting on Day -2 and tapered around Day +180 if no Graft vs Host Disease (GvHD) is present.
223835332|NCT01471067|PROCEDURE|Cord Blood Infusion|Cord blood infusion on Day 0. Each participant will receive cells from one unexpanded cord blood sample plus cells from a second cord blood sample that has undergone fucosylation.
223835333|NCT01471067|DRUG|Rituximab|375 mg/m\^2 by vein on Day -10 for B cell malignancy.
223685006|NCT01020539|DRUG|Fludarabine|Conditioning Regimen
223685007|NCT01020539|DRUG|Busulfan|Conditioning Regimen
223685008|NCT01020539|DRUG|GVHD Prophylaxis|Can be FK506 (Tacrolimus/Prograf®), mycophenolate mofetil ((MMF)/Cellcept®), or methotrexate (MTX, amethopterin)
223685009|NCT01020539|DRUG|Gemtuzumab Ozogamicin|Dose Escalation
223685010|NCT01020539|DRUG|Anti-Thymocyte Globulin|Unrelated Donors only
223685011|NCT01020539|DRUG|Isotretinoin|JMML patients only
223685012|NCT04849325|DEVICE|Sirolimus-eluting Iron Bioresorbable Peripheral Scaffold System (IBS Titan™)|Subjects in this arm will be treated with IBS Titan™.
223685013|NCT04849325|DEVICE|Percutaneous Transluminal Angioplasty (PTA) Device|Subjects in this arm will be treated with PTA device.
223685014|NCT02537795|DEVICE|deep brain stimulation|Electrical stimulation of the anterior limb of the internal capsule or bed nucleus of the stria terminalis
223685015|NCT02537795|PROCEDURE|anterior capsulotomy|
223685016|NCT04455360|OTHER|Eye Movement Desensitisation and Reprocessing Recent traumatic Event Protocol|EMDR is a form of psychotherapy treatment whereby the client verbally relates a narrative of a traumatic episode or emotionally disturbing material in brief sequential doses while simultaneously focusing on an external stimulus. The EMDR Recent-Traumatic Events protocol (R-TEP) aims to enable an individual to process memories of the event in order to reduce psychological morbidity. EMDR R-TEP should be delivered within 3-months of the onset of a traumatic event.
223685017|NCT05386485|OTHER|None intervation|Observational Study
223685018|NCT04991428|OTHER|Transcranial direct current stimulation|tDCS is a form of non-invasive brain stimulation. tDCS is an established research tool for non-invasive modulation of neuroplasticity. It uses low-intensity DC currents to modulate spontaneous neuronal network activity by altering the resting membrane potential. Anodal tDCS has been shown to increase cortical excitability, reduce regional levels of GABA enhance LTP and synaptic plasticity.
223685019|NCT01631019|BEHAVIORAL|Mobile-phone-based Home Exercise Training Program|Patients in the mobile phone group were asked to perform daily endurance exercise training under mobile phone guidance, and the adherence was reported back to the central server. The level of endurance walking was re-assessed and re-adjusted initially on regular clinical visits every four weeks during the first three months. During this period of time, the adherence to protocol was reinforced by telephone from health professionals whenever patients missed one day of their walking training detected by the central system. Patients were asked to continue their exercise program at home at a fixed walking speed, and return to the clinic at 1, 2, 3 and 6 months.
223685020|NCT01631019|BEHAVIORAL|Home Exercise Training Program|all the subjects were assessed by an incremental shuttle walking test (ISWT) (24) for estimation of exercise endurance. Baseline spirometry and body mass index (BMI) were recorded. The adherence and compliance of the home-based exercise training program was assessed by monitoring the frequency of performance and the duration of the endurance walking program recorded on the central system every week. Patients were asked to continue their exercise program at home at a fixed walking speed, and return to the clinic at 1, 2, 3 and 6 months.
223685021|NCT02382250|BEHAVIORAL|Survey|Survey will be given to all participants
223685022|NCT01606254|DRUG|Paliperidone palmitate|Paliperidone palmitate aqueous suspension for injection 0.5, 1.0, 1.5 milliliter equivalent to 50, 100, 150 mg paliperidone respectively as intramuscular injection on Days 1, 8, 36 and 64.
223685023|NCT03315091|DRUG|Treatment A - AZD1775 administered under fasted conditions|Premedication with Kytril (granisetron) 1 mg intravenously or Zofran (ondansetron) 8 mg intravenously within 30 to 40 minutes prior to administration of the AZD1775 capsules. Single dose 300 mg AZD1775, (3 x 100 mg, printed capsules) administered orally under fasted conditions. The drug class of AZD1775 is Wee-1 kinase inhibitor.
223685024|NCT03315091|DRUG|Treatment B - AZD1775 administered under fed conditions.|"Premedication with Kytril (granisetron) 1 mg intravenously or Zofran (ondansetron) 8 mg intravenously within 30 to 40 minutes prior to administration of the AZD1775 capsules.~Single dose 300 mg AZD1775, (3 x 100 mg, printed capsules) administered orally under fed conditions.~The drug class of AZD1775 is Wee-1 kinase inhibitor."
223775239|NCT05559619|DEVICE|laser acupuncture therapy|The patient was in crock lying for stimulation of acupoints in abdomen and lower limbs then asked to be in side lying for stimulation of acupoints in the back. After disinfection of the skin and careful localization of the acupoints, low level laser therapy (LLLT) (model: Lis 1050, SN: EM 13481014, manufactured by EME srl, Italy) was applied bilaterally on Dazhu (BL 11), Ganshu(BL 18), Pishu (BL20), Shenshu (BL23), Zusanli (ST 36), Sanyinjiao (Sp6), Jingmen(GB25), Yanglingquan (GB34) andXuanzhong (GB39) acupoints, while it was applied in the midline on Guanyuan (CV4) andMingmen (GV4) acupoints. Each acupoint was irradiated for 60 sec, with total duration of 20 min, wave length of 905 nm, average radiant power output of 12 mW, energy density of 2 J/cm2, pulse radiation of 200 ms and pulse frequency of 5000 Hz
223685025|NCT04766372|OTHER|Behaviour change|Using needs supportive, self-determination theory-based, components to improve the physical activity behaviours of adolescent girls.
223685026|NCT04543409|BIOLOGICAL|Benralizumab|Solution for injection in a single accessorized prefilled syringe (APFS) will be administered subcutaneously (SC), 1 mL fill volume
223685027|NCT04543409|BIOLOGICAL|Matching placebo|Matching placebo solution for injection in APFS, 1 mL fill volume. Placebo solution will be administered subcutaneously (SC), 1 mL fill volume
223685028|NCT02147912|OTHER|Aerobic Exercise|Aerobic exercise intervention consists of lower (treadmill and cyclette) and upper arts (arm ergometer Davenbike®) training, as well as calisthenic exercises with increasing intensity from a minimum of 80% to a maximum workload for lower arts in a minimum time.
223685029|NCT02563132|PROCEDURE|Carbon dioxide insufflation|Carbon dioxide insufflation during diagnostic colonoscopy
223685030|NCT02093026|DRUG|Rituximab|Participants will receive rituximab 1 gram IV on Days 1 and 15 of each course of retreatment.
223685031|NCT02093026|DRUG|Methotrexate|Participants will receive methotrexate 10-25 mg/week orally or parenterally.
223685032|NCT02093026|DRUG|Methylprednisolone|Participants will receive methylprednisolone 100 mg IV 30 minutes prior to each rituximab infusion.
223685033|NCT02093026|DRUG|Folic Acid|Participants will receive folic acid \>= 5 mg/week or equivalent.
223685034|NCT03493659|BEHAVIORAL|Standing during Concept Test|The participants will stand with a standing desk at an ergonomically correct height during the administration of the Concept Test.
223685035|NCT03493659|BEHAVIORAL|Standing during regular tutorial session|The participants will stand with a standing desk at an ergonomically correct height during their regular tutorial sessions.
223685036|NCT03493659|BEHAVIORAL|Standing during Concept Test and regular tutorial session|The participants will stand with a standing desk at an ergonomically correct height during the administration of the Concept Test and during their regular tutorial sessions.
223775240|NCT01728467|DRUG|RVX000222|capsule, 200 mg, administer with food, 100 mg twice daily 10-12 hrs apart, 31-35 days
223775241|NCT01728467|DRUG|Placebo, RVX000222|capsule, administer with food, twice daily 10-12 hrs apart, 31-35 days
223775242|NCT00393549|DEVICE|NeuroPath|
223775243|NCT01809626|DRUG|Zolpidem|
223775244|NCT01809626|OTHER|Placebo|
223835334|NCT01471067|DRUG|ATG|"1.25 mg/Kg by vein on Day -4.~1.75 mg/Kg by vein on Day -3."
223835335|NCT01471067|DRUG|Busulfan|Busulfan per standard of care, test dose either as an outpatient prior to admission or as an inpatient on Day -9. Busulfan pharmacokinetics performed with test dose and the first dose on Day -7 per standard of care. Doses of Days -5 and -4 subsequently adjusted to target an AUC of 4,000 microMol.min-1.
223835336|NCT01471067|DRUG|Clofarabine|30 mg/m\^2 IV Day -7 to Day -4;
223835337|NCT01471067|RADIATION|Total Body Irradiation (TBI)|2 Gy in AM of Day -3.
223775245|NCT04112693|PROCEDURE|Esophageal biopsies during Peroral Endoscopic Myotomy (POEM)|"In total, 14 biopsies are performed with a pediatric biopsy forceps belonging to the study center: 3 biopsies at 3-6 cm above cardia, contralaterally from POEM, of which 2 are placed in nitrogen and 1 in formol for histopathological analysis; 3 biopsies at the cardia, contralaterally from POEM, of which 2 are placed in nitrogen and 1 in formol for histopathological analysis; 4 biopsies of the muscularis propria (exposed during POEM) at 3-6 cm above cardia, of which 3 are placed in nitrogen and 1 in formol for histopathological analysis; 4 biopsies of the muscularis propria at the cardia, of which 3 are placed in nitrogen and 1 in formol for histopathological analysis; The biopsies intended for histopathological analysis will be analyzed in FFOCT before histopathological analysis. The FFOCT analysis take place for the patient inclued after than 10 november 2020.~The biopsies are taken by the gastroenterologist who performs the POEM and is assisted by an endoscopy-specialized nurse."
223775246|NCT02520531|DEVICE|Scorpio PS (posterior stable)|Implantation of total knee prosthesis
223775247|NCT02520531|DEVICE|Scorpio NRG PS|Implantation of total knee prosthesis
223775248|NCT04740606|DEVICE|Augmented Reality Navigation System|Investigators will assess the nodules based on the CT images of subjects before procedure. And then, the appropriate intra-airway path planned by the Augmented Reality Navigation System will be selected. The bronchoscopy with intra-airway navigation under the guidance of the Augmented Reality Navigation System will be performed and the following surgical information will be record.
223775249|NCT04007536|OTHER|No Intervention|No Intervention
223775250|NCT01792661|OTHER|Enhanced MyChart|Subjects randomized into the MyChart receive an additional site on their MyChart containing 35 extra educational links specific to CKD, targetting care for stage 3b and stage 4 patients.
223775251|NCT01792661|OTHER|Patient Navigator|The Patient Navigator aids subjects in education of their CKD, timely scheduling of appointments, plus determining and overcoming barriers to their CKD health care. The Patient Navigator's job is not part of routine medical care.
223775252|NCT01792661|OTHER|MyChart|Sign-up to MyChart is optional for Cleveland Clinic patients. Subjects enrolled into the study are signed-up for MyChart (if not already signed-up) during the consenting process.
223775253|NCT04865094|OTHER|cyclic merocyanine|long-UVA absorber
223775254|NCT04865094|OTHER|placebo|placebo
223775255|NCT01159067|DRUG|deferasirox|Given orally
223775256|NCT03376204|OTHER|No intervention|No intervention
223775257|NCT02340559|BEHAVIORAL|Meta-cognitive Training|
223685037|NCT00518973|DRUG|Quetiapine|Subjects will start with 25mg hs on day 1, 25mg bid on day 2, 25mg am and 50mg hs on day 3, 50mg bid on day 4, 50mg am and 75mg hs on day five, and 75mg bid on day six. Dosage will be increased further on an individual basis as determined by the study physician and as tolerated by the subject with a maximum dosage of 400 mg. Dose can be reduced as determined by clinical judgment. In order to determine the most effective dose, the dose of Quetiapine (or placebo) will be titrated at intervals by staff according to the previously stated guidelines, the Pittsburgh Quetiapine Medication Management Assessment and Interview. Subjects will be interviewed about the factors described above and medication dose will be adjusted upward or downward depending upon symptom persistence or side effects.
223685038|NCT00518973|DRUG|Placebo|Subjects will start with 25mg hs on day 1, 25mg bid on day 2, 25mg am and 50mg hs on day 3, 50mg bid on day 4, 50mg am and 75mg hs on day five, and 75mg bid on day six. Dosage will be increased further on an individual basis as determined by the study physician and as tolerated by the subject with a maximum dosage of 400 mg. Dose can be reduced as determined by clinical judgment. In order to determine the most effective dose, the dose of placebo will be titrated at intervals by staff according to the previously stated guidelines, the Pittsburgh Quetiapine Medication Management Assessment and Interview. Subjects will be interviewed about the factors described above and medication dose will be adjusted upward or downward depending upon symptom persistence or side effects.
223685039|NCT02684487|DRUG|vitamin D3|Patients will be given 400,000 IU of vitamin D3 within 24 hours of severe sepsis onset followed by weekly doses of 25,000 IU until 90 days or death, whichever comes first.
223685040|NCT02684487|DRUG|Placebo|Patients will be given placebo within 24 hours of severe sepsis onset followed by weekly doses of placebo until 90 days or death, whichever comes first.
223685041|NCT04756180|DRUG|Omega-3-acid ethyl ester or Placebo|Omega-3-acid ethyl ester 2 gm/day for first 4 week followed by 4gm/day for 8 week
223685042|NCT04744038|DEVICE|Positive Airway Pressure (PAP) Therapy|PAP therapy supplies pressurized air from the flow generator to the upper airway via air tubing and a mask to prevent the repetitive collapse of the upper airway during sleep.
223685043|NCT02218983|DEVICE|Limited Transthoracic Echocardiogram (LTTE, SonoSite Ultrasound)|
223775258|NCT02340559|BEHAVIORAL|Psychoeducational group|
223775259|NCT02442700|DRUG|pitavastatin|Treatment A = administration pitavastatin for 12 weeks
223775260|NCT02442700|DRUG|placebo|Treatment B = administration placebo for 12 weeks
223775261|NCT02930434|DIETARY_SUPPLEMENT|cholecalciferol|Administration of vitamin D3
223775262|NCT04003597|OTHER|Usual-salt diet|Subjects followed their usual-salt diet but were asked to consume an equivalent in-house produced brown or white sliced pan bread equivalent in composition to the low-salt version but with its more typical salt content (1.2 g/100 g).
223835338|NCT00503568|BIOLOGICAL|Ad100-gp96Ig-HLA A1|Dose Schedule 1 (DS-1): 4x10\^7 cells bi-weekly, maximum 9 vaccines/patient; Dose Schedule 2 (DS-2): 2X10\^7 cells weekly, maximum 18 vaccines/patient; Dose Schedule 3 (DS-3): 1x10\^7 cells twice weekly, maximum 36 vaccines/patient
223835339|NCT01146808|DRUG|Adefovir dipivoxil and hepatitis B vaccination|Adefovir 10mg po daily, or adjusted for renal function and option for Hepatitis B vaccination, double dose
223685044|NCT02218983|OTHER|Usual care|
223685045|NCT05953376|DRUG|Calcium Gluconate|There will be 2 study arms, one will receive 2g IV calcium with the initial transfusion and the other will only receive calcium supplementation based on routine ionized calcium levels and/or physician discretion.
223685046|NCT00002681|BIOLOGICAL|aldesleukin|
223685047|NCT00002681|BIOLOGICAL|daclizumab|
223685048|NCT03625271|DEVICE|The PEER Report|PEER Interactive references a subject's QEEG to a normative and then symptomatic database. By comparing a given subject's QEEG to a database of QEEGs of subjects who have tried and responded to a specific medication, PEER provides useful information regarding the response of neurophysiologically similar subjects to a wide number of medications - providing clinicians with useful information as to medication outcomes before a medication regime is started. Clinicians have also reported that negative findings (in which neurophysiologically similar subjects reported resistant outcomes for certain medications) can be extremely useful in reducing trial and error. It has also been used to help select the medication that best matches the QEEG brainwave pattern.
223685049|NCT05023824|DRUG|alpha-blocker or 5-ARI withdrawal|Withdrawal of either alpha-blocker or 5-ARI
223685050|NCT05023824|DRUG|Maintenance of alpha-blocker and 5-ARI|Maintenance of alpha-blocker and 5-ARI
223685051|NCT00501579|DRUG|Difluprednate|
223685052|NCT00501579|DRUG|Prednisolone Acetate|
223685053|NCT00415454|GENETIC|Ad5-yCD/mutTKSR39rep-ADP|Single injection on day 1 at one of five dose levels
223685054|NCT00121173|BIOLOGICAL|pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine|recombinant DNA vaccine
223685055|NCT01754909|DRUG|Enalapril|Enalapril once a day, orally, as 2.5 , 5, or 10 mg tablets to be given in escalating doses, to subjects undergoing radiotherapy for lung cancer
223685056|NCT01754909|DRUG|placebo|Placebo, once a day, orally, as 2.5 , 5, or 10 mg tablets to be given in escalating doses, to subjects undergoing radiotherapy for lung cancer
223685057|NCT04081233|PROCEDURE|surgical stabilization|Surgical procedure utilizing any commercially available internal rib fixation system
223685058|NCT04081233|PROCEDURE|Usual care|Usual care typically consists of breathing exercises and pain control,often including opioids
223685059|NCT01677312|PROCEDURE|Pancreatic Biopsy|A FNA needle will be used to biopsy the pancreatic mass. The rates of diagnostic accuracy (%) will be assessed. Diagnostic accuracy is defined as the proportion of patients in whom a definitive diagnosis can be obtained within a predetermined number of FNA passes.
223685060|NCT01677312|PROCEDURE|Histological Samples|The proportion of patients (%) in whom a histological tissue can be obtained when performing a biopsy of the pancreas using a specific needle will be assessed.
223685061|NCT00822809|DRUG|Catumaxomab|"Catumaxomab will be infused 4 times within 11 days as follows:~10 µg on day 0, 20 µg on day 3, 50 µg on day 7, 150 µg on day 10"
223685062|NCT00822809|DRUG|Prednisolone|25 mg premedication
223685063|NCT04746872|DIAGNOSTIC_TEST|Alinity m HR HPV|A qualitative in vitro test that amplifies and detects HR HPV DNA in cervical tissue samples.
223685064|NCT01792570|DRUG|RPV + DRV/r|Switch to dual HAART
223685065|NCT01792570|DRUG|continue the PI/r-containing HAART.|Continue the on-going triple drug HAART.
223685066|NCT02301611|DRUG|TLPLDC|Autologous tumor lysate, particle-loaded dendritic cell vaccine
223685067|NCT02301611|DRUG|Placebo|
223685068|NCT00860977|DRUG|valacyclovir|oral valacyclovir 500mg twice daily
223685069|NCT00860977|DRUG|Placebo|Odourless placebo tablet identical to valacyclovir in appearance and taste, to be taken twice daily
223685070|NCT00977808|DEVICE|Closed-Loop, Model Predictive Control (MPC)|Subjects used the OmniPod Insulin Management System (Insulet Corp.) and Insulin lispro (Eli Lilly, Indianapolis, IN). MPC algorithm suggested insulin boluses every 15 min, which, if accepted, were programmed into the insulin pump by the attending physician. Otherwise, the admission remained the same as in the open-loop admission (i.e. meals, sleep, etc...).
223685071|NCT00977808|DEVICE|Open-Loop|This admission was to assess the subjects' level of glucose control and created a base to compare the performance of the closed-loop system. Subjects monitored their own blood glucose values and administer their basal/bolus as they would at home. Subjects used their own insulin pumps and Insulin lispro (Eli Lilly, Indianapolis, IN). Otherwise, the admission remained the same as in the closed-loop admission (i.e. meals, sleep, etc...).
223685072|NCT02895009|DEVICE|experimental group|Participants allocated to the experimental group will receive a short term postoperative puncture site compression via TR Band. TR Band deflation is commenced at the 1st hour and completed at the 3rd hour, and the TR Band is removed at the 12th hour.
223685073|NCT02895009|DEVICE|control group|Participants allocated to the control group will receive a routine long term postoperative puncture site compression via TR Band. TR Band deflation is commenced at the 2nd hour and completed at the 6th hour, and the TR Band is removed at the 24th hour.
223685074|NCT06169228|DEVICE|mandibular advancement|The multidisciplinary sleep unit assessment and follow-up protocol will be followed for this group of patients based on the Spanish Clinical Practice Guideline of the Spanish Sleep Society (SES) on the use of mandibular advancement devices in the treatment of patients with obstructive sleep apnea
223685075|NCT03256890|BEHAVIORAL|MB-BP Intervention|MB-BP customizes Mindfulness-Based Stress Reduction (MBSR) to participants with hypertension. It consists of nine 2.5-hour weekly group sessions and a 7.5-hour one-day session. Content includes education on hypertension risk factors, hypertension health effects, and specific mindfulness modules focused on awareness of BP determinants such as diet, physical activity, anti-hypertensive medication adherence, alcohol consumption, and stress reactivity. Students learn a range of mindfulness skills including body scan exercises, meditation and yoga. Homework consists of practicing skills for ≥45 min/day, 6 days/week. Participants are given a home BP monitor. Participants with uncontrolled hypertension are offered to have their physicians notified, if not already overseen for uncontrolled hypertension; those without a physician are worked with to provide access within health insurance constraints.
223685076|NCT03256890|OTHER|Enhanced Usual Care Control|"Control group participants receive an educational brochure from American Heart Association entitled Understanding and Controlling Your High Blood Pressure Brochure (product code 50-1639). Every participant is provided with a validated home blood pressure monitor (Omron, Model PB786N), that as an evidence-based approach to lower blood pressure, would be considered enhanced usual care at this time. All participants who have uncontrolled hypertension (blood pressure \>140/90 mmHg) will be offered to have their physicians notified, if not already being overseen for uncontrolled hypertension. For participants with uncontrolled hypertension who do not have a physician, we work participants to provide access within constraints of their health insurance."
223685077|NCT03923985|DIETARY_SUPPLEMENT|Probiotic containing Lactobacillus Crispatus|1 tablet / day of probiotic (275 mg of live probiotic lactic ferments: 10 Mld L. fermentum (SGL 10), 10 Mld L. gasseri, 10 Mld L. casei, 10 Mld L. acidophilus, 10 Mld L. crispatus) during 2 months.
223685078|NCT05373771|OTHER|Care pathway|Implementation of care pathway as part of hybrid type 2 implementation effectiveness study
223685079|NCT04291001|DEVICE|ENG implant|This is an FDA-approved contraceptive device
223685080|NCT04291001|DRUG|oral ulipristal acetate|This is an FDA-approved oral emergency contraceptive
223685081|NCT00065130|DRUG|human insulin|
223685082|NCT00065130|DRUG|insulin NPH|
223775263|NCT04003597|OTHER|Reduced-salt diet|Subjects randomized to start on the reduced-salt diet were asked to restrict their consumption of dietary salt using a combination of pragmatic dietary advice as well as the replacement of bread and a limited number of other foods with equivalent foods which had lower salt content; these were provided to the participants. At the beginning of the salt restriction period, a research nutritionist provided the subjects with a list of the common salt-containing food (salted and naturally salty) and were asked to limit the consumption of such, as feasible. The subjects received in-house prepared 'low-salt (\<0.3 g/100 g)' brown or white sliced pan bread as well as no-salt margarine/butter, and were given luncheon meats with no added salt if desired (optional).
223685083|NCT00065130|DRUG|insulin aspart|
223685084|NCT06497036|DRUG|GP404141|subcutaneous injection
223685085|NCT06497036|DRUG|Nplate|subcutaneous injection
223685086|NCT02004392|DRUG|EVP-6124|
223685087|NCT00174291|DRUG|Somatropin|Liquid, daily to final height Maximum Dosage: 50 µg/kg/day
223685088|NCT00876798|DRUG|Lixivaptan|Capsules, 25mg lixivaptan or matching placebo once daily. Study medication can be titrated up to 50mg or 100mg once daily. Acceptable dosages are once daily administration of 25mg, 50mg, or 100mg as a single dose.
223685089|NCT00876798|DRUG|Placebo|Capsule. Subjects will be randomized (3:1) on an outpatient basis to 25 mg lixivaptan or matching placebo, once daily.
223775264|NCT04417491|DEVICE|Dry Needling|Real dry needling will be conducted according to the fast-in and fast-out principle. The intervention will be applied until a total of four local twitch responses will be elicited
223685090|NCT00781508|DRUG|sildenafil|Changes in left ventricular filling pressure 1 hour after the administration of a single oral dose of sildenafil 50 mg.
223685091|NCT00781508|OTHER|Placebo|Changes in left ventricular filling pressure 1 hour after oral administration of placebo
223685092|NCT01923168|DRUG|alpelisib|BYL719 + Letrozole
223685093|NCT01923168|DRUG|buparlisib|BKM120 + Letrozole
223685094|NCT01923168|DRUG|Placebo|Placebo (of BYL719 or BKM120) + Letrozole
223685095|NCT02970201|OTHER|EpxDialysis|The EpxDialysis intervention consists of automated SMS text or voice messages delivered to the patient's preferred phone number three times per week. These messages provide details about the subject's upcoming hemodialysis session, anticipatory guidance regarding clinically-concerning symptoms, as well as the option for direct call routing to the dialysis center for rescheduling sessions.
223685096|NCT04044027|BEHAVIORAL|S.P.A.R.K (Speaking to the Potential, Ability and Resilience inside Kids) Teen Pregnancy Prevention and Mentoring|S.P.A.R.K is a curriculum-based group intervention for youth ages 11-17 living in out-of-home foster care. The curriculum consists of 23 topical lessons made up of a combination of educational and interactive activities on each topic. The curriculum covers four Adult Preparation Subjects (healthy relationships, educational and career success, healthy life skills, adolescent development) as well as mentoring, bully prevention, emotional competency, self-efficacy, communication, conflict resolution, and pregnancy prevention.
223685097|NCT02313454|DEVICE|Intranasal Tear Neurostimulator|Neurostimulation applied intranasally and extranasally.
223685098|NCT04676971|DRUG|hzVSF-v13|Dosage form: 100mg / 200mg of hzVSF-v13 (40 mg/mL in a 5 mL vial) Frequency: Dose at Day 1, 3, 7, D14(if necessary)
223685099|NCT04676971|DRUG|Placebo (Normal saline solution)|Dosage form: 0.9% NaCl Solution Frequency: Dose at Day 1, 3, 7, D14(if necessary)
223685100|NCT01417182|DRUG|18F-DCFBC|A bolus of 10 mCi (370 MBq) of 18F-DCFBC will be injected once into the IV line by slow push IV push.
223685101|NCT00412490|BEHAVIORAL|Questionnaire|Written survey at 1 Month \& 6 Months post surgery.
223685102|NCT00412490|BEHAVIORAL|Interview|One-on-One meeting lasting about one hour, at 1 Month \& 6 Months post surgery.
223685103|NCT02744937|DRUG|Aspirin|aspirin is continued by its regular dosing
223685104|NCT03418571|BIOLOGICAL|ALX-0171 1.5 mg/kg|ALX-0171 1.5 mg/kg was administered via a single inhalation once daily for 3 consecutive days.
223685105|NCT03418571|OTHER|Placebo|Placebo was administered via a single inhalation once daily for 3 consecutive days.
223685106|NCT04325399|OTHER|Volitional help sheet|
223775265|NCT04417491|DEVICE|Sham Needling|Sham dry needling with be conducted with a sham needle device. This needle has a blunt tip and retractable handle that created the illusion of a needle penetrating the skin. When this needle touches the skin, a pricking sensation will be created. However, when pressure will be increased, the shaft of the needle disappears into the handle creating a sensation on the patient
223775266|NCT01849341|DRUG|Roflumilast alternated days|500 mcg per day on alternate days (roflumilast 500μg eod) for 2 weeks
223685107|NCT00847639|DRUG|lenalidomide|"Lenalidomide maintenance therapy will start within 60 to 90 days after allogeneic HCT at a starting dose of 10mg PO once daily.~Dose escalation and de-escalation are performed depending on tolerability of lenalidomide.~The dose range is 5mg every other day and 5 to 25 mg daily from days 1-21 followed by 7 days of rest for 12 cycles (each cycle 28 days)."
223775267|NCT01849341|DRUG|Roflumilast 500 mcg per day|
223775268|NCT00103649|DRUG|xaliproden (SR57746A)|
223775269|NCT01581203|DRUG|Asunaprevir (ASV)|
223775270|NCT01581203|DRUG|Daclatasvir (DCV)|
223775271|NCT01581203|DRUG|Pegylated-interferon alfa 2a (PegIFN)|
223775272|NCT01581203|DRUG|Ribavirin (RBV)|
223775273|NCT03154697|OTHER|Data collection of sleep disturbances in individuals with SMS|Data related to Smith-Magenis syndrome and sleep disturbances are collected through a web or phone survey
223685108|NCT06418464|DEVICE|AP-A Dosage Decision Support System|The AP-A Dosage Decision Support System represents a new solution in diabetes care, offering customized insulin dosage recommendations to patients. This system is a product of integrating four pivotal modules: the individualized model learning module, the risk-sensitive control module, the Bayesian optimization module, and the safety constraint module. Together, they establish a robust framework that employs advanced computational methodologies to deliver precise and personalized insulin dosage guidance, significantly improving the effectiveness and safety of diabetes treatment plans. The actual injection dose in the intervention group was executed by the doctor after approval based on the recommendation of the AP-A Dosage Decision Support System.
223685109|NCT02376829|DEVICE|Invisalign System|The Invisalign® System is indicated for the alignment of teeth during orthodontic treatment of malocclusion
223685110|NCT05846477|DEVICE|MySpine|patient specific guide for screw positioning
223685111|NCT03614767|DIAGNOSTIC_TEST|urodynamics|Bladder filling and pressure is measured by the insertion of probes within the bladder, urethra and anorectum.
223685112|NCT01261832|DRUG|antiplatelet therapy|Dual antiplatelet therapy is defined as combination therapy with aspirin and clopidogrel and triple antiplatelet therapy is defined as combination therapy with aspirin,clopidogrel and cilostazol.
223685113|NCT03642093|COMBINATION_PRODUCT|Nutritional Intervention|Nutritional Supplementation for all subjects and Pancreatic Enzyme Replacement Therapy only for subjects with Exocrine Pancreatic Insufficiency
223685114|NCT03642093|BEHAVIORAL|Physical Activity Intervention|Walking and Inspiratory Muscle Training
223685115|NCT05695664|DRUG|Ibuprofen 800 mg|Intravenous injection of ibuprofen 800 mg
223685116|NCT05695664|DRUG|Ketorolac Injection|Intravenous injection of Ketorolac 30 mg
223685117|NCT02656212|DRUG|epicatechin|30 mg (+)-epicatechin, taken orally, one pill/day in the morning
223685118|NCT02656212|DRUG|Placebo|Placebo pill, taken orally, one pill/day in the morning
223685119|NCT03889171|BEHAVIORAL|Behaviour|Comparison to psychological, medical and emotional Influencing communication and achievement factors to Oncogenetics tests
223685120|NCT01546064|DEVICE|Choledocho-choledochostomy with T-tube|In the anastomosis between the common bile duct of the graft and the common bile duct of the recipient, a tutorial T-tube is inserted in the bile duct lumen and will be removed from the patient on third month postoperatively.
223685121|NCT01546064|DEVICE|Choledocho-choledochostomy without T-tube|The termino-terminal anastomosis between common bile duct of the graft and common bile duct of the recipient is performed without any T-tube.
223685122|NCT02908867|OTHER|Therapeutic Strategies|Using questionnaires (Erectile Function of International Index and American Impairment Scale) and search in public markets using semi structured form
223685123|NCT05041530|DEVICE|REBUILD Bioabsorbable|REBUILD is an investigational medical device designed to be used with third-party suture to distribute suture tension in abdominal wall closures.
223685124|NCT01439347|DRUG|Vincristine Sulfate Liposomes Injection (VSLI)|2.25 mg/m\^2 (without any dose cap) as an IV infusion over 60 minutes.
223685125|NCT01439347|DRUG|Vincristine Sulfate Injection (VSI)|1.4 mg/m\^2 with a 2 mg dose cap as an IV infusion over 10 minutes.
223685126|NCT00284076|DRUG|L-arginine|
223685127|NCT04161300|OTHER|Foam Rolling (FR)|FR auto-massage will place the foam roller between their ischial tuberosity and a hard surface (i.e., the floor) with their legs held in an extended position, keeping their ankles relaxed and oriented upward. For FR in the lumbar region, participants use their weight to slide the FR through the erector of the lumbar and thoracic spine. The total approximate duration will be about 10-15 minutes.
223685128|NCT04161300|OTHER|Control Group (CG)|The CG did not receive any intervention.
223685129|NCT04161300|OTHER|Orthopaedic Manual Physical Therapy Group (OMPT)|Based on the protocol used by Espí-López et al.: a) Unspecific and bilateral lumbar thrust (L5-S1), one of each side were performed; b) Hip joint decompression, performing 25 repetitions c) Hip rotator stretch with hip and knee flexion, 15 repetitions; d) Femorotibial decompression, 25 reps. e) Quadriceps femoral muscle compression and traction, 25 repetitions; f) Opening of the internal and external femorotibial interline, 15 repetition; g) Ankle decompression, 3 repetitions; h) Posteroanterior and anteroposterior mobilization of head and base of fibula, 25 repetitions. The total duration will be approximately 10-15 minutes.
223685130|NCT03582644|OTHER|Cryotherapy|Crushed ice (1kg) inside a plastic bag (24x34x0,08 cm). The positioning of the plastic bags will cover the entire knee surface (Anterior, lateral and posterior region). After the positioning of the ice bags, they will be fixed with an elastic bandage (compression). To protect the skin against frost bites, all the knee surface will be covered with a moistened operative field (45x50x0,01 cm, 100% cotton)
223685131|NCT05837143|BIOLOGICAL|JV001|JV001 (AAV9/modTERT) will be delivered by a percutaneous method in the catheter laboratory. Dose: 2×10\^11vg/kg，or 6×10\^11vg/kg.
223685132|NCT05337930|DEVICE|Happyr App|"The Happyr app offers three main areas:~(A) A mood diary in which a user can keep track of emotional wellbeing by answering three short questions.~(B) A pain diary in which a user and supporter can record headache attacks by answering a set of predefined questions whenever a user experiences or has experienced a headache attack.~(C) An overview section in which entries from the mood and pain diary are visualized for the user. In this section, a PDF document can also be exported with a summary of data from the symptom diary that can be taken to the clinician.~A standardized notification is sent to each user at 6pm local time to remind them about logging their mood and symptoms of a headache attack."
223685133|NCT00857402|DIETARY_SUPPLEMENT|Peanuts|30g of peanuts daily for 4 weeks (directly observed). This dose of peanuts is equivalent to 1 gram of arginine.
223775274|NCT05375513|OTHER|PMI@Home|"Personalized multidomain interventional program by combining tailored lifestyle interventions that targets 5 domains: physical activity, cognition, diet, sleep, and vascular risk factors. These interventions are tailored based on participants' baseline profile and progress in intensity following the principles of personalized medicine. All aspects of the PMI@home will be delivered remotely, at participants' homes, using a digital platform with scheduled bi-weekly 1-to1 coaching sessions. Delivery of interventions and assessments are centralized with 5 trained staff at the sponsor site (London) to assure logistics, standardization, and quality control."
223685134|NCT00857402|DIETARY_SUPPLEMENT|Daboqolo|30g of Daboqolo per os daily for 4 weeks (given supervised). 30g of Daboqolo is equivalent to 0.1 g of arginine.
223685135|NCT03156361|DRUG|HDV insulin lispro 100 UNIT/mL|Hepatic Directed Vesicle (HDV) added to commercial insulin lispro
223685136|NCT03156361|DRUG|Insulin Lispro 100 Units/mL|Sterile Water for Injection added to commercial insulin lispro
223685137|NCT02219243|BEHAVIORAL|Online Interpretation Training Condition 1|The online computerized training is a web-based tool that modifies how children interpret ambiguous scenarios.
223685138|NCT02219243|BEHAVIORAL|Online Interpretation Training Condition 2|The online computerized training is a web-based tool that modifies how children interpret ambiguous scenarios.
223685139|NCT00848003|DRUG|Bifidobacterium animalis subsp. lactis strain BB-12|Bifidobacterium animalis subsp. lactis (B. lactis) strain BB-12 (BB-12) probiotic supplemented yogurt, 4 ounces taken orally for 10 days
223685140|NCT00848003|DRUG|Placebo|Strawberry flavored yogurt
223685141|NCT00655460|PROCEDURE|glucose control with computer generated recommendations|Insulin dosing will be recommended by the computer tools based on subject glucose values. Bedside clinicians will have the ablity to accept or reject the suggested dose.
223685142|NCT02506569|DEVICE|Implantable Cardioverter Defibrillator therapy|Tachycardia Fast Heart Beat
223685143|NCT02506569|OTHER|Magnetic Resonance Imaging (MRI)|MRI scan of the head and lower body parts
223685144|NCT04661553|DEVICE|"Mueller's polarimetric colposcopy Group 1"|"Determination of the best polarimetric biomarkers reflecting the status of the cervical microstructure throughout its remodeling process due to the pregnancy in a population with a low-risk premature birth. This polarimetric biomarkers should make it possible to accurately determine the time remaining before childbirth for a normal pregnancy and, therefore, to monitor the regular advancement of the gestation."
223685145|NCT04661553|DEVICE|"Mueller's polarimetric colposcopy Group 2"|"Determination of the best polarimetric biomarkers reflecting the status of the cervical microstructure throughout its remodeling process due to the pregnancy in a population at high-risk of preterm birth.~This polarimetric biomarkers should make it possible to accurately determine the time remaining before childbirth for an abnormal pregnancy and, therefore, to predict premature childbirth."
223685146|NCT02775201|PROCEDURE|Plantaris release under ultrasound guidance|In patients diagnosed with Achilles tendinopathy the plantaris tendon will be released using a small incision at the medial ankle under ultrasound guidance by a consultant radiologist
223685147|NCT02775201|PROCEDURE|Plantaris excision surgically|In patients diagnosed with Achilles tendinopathy the plantaris tendon will be excised in theatre by a consultant orthopaedic surgeon
223685148|NCT02875925|OTHER|MTM|Medication management is a process that ensures each patient's medications are assessed to determine the appropriateness, effectiveness, safety, and convenience of each medication for the patient. Medication management is fully integrated with the care team. Pharmacists provide this service to identify, prevent, and resolve drug therapy problems improve outcomes.
223685149|NCT01411930|DRUG|Intramuscular olanzapine, aripiprazole|"1. 1st clamp: single intramuscular 10.0 mg dose of olanzapine~2. 2nd clamp: single intramuscular 9.75 mg dose of aripiprazole"
223685150|NCT01411930|DRUG|Intramuscular aripiprazole, olanzapine|"1. 1st clamp: single intramuscular 9.75 mg dose of aripiprazole~2. 2nd clamp: single intramuscular 10.0 mg dose of olanzapine"
223775275|NCT05375513|OTHER|Brain Health Pro|"Online Modules:~* Motivation, Self-Efficacy, Positive Health, Environment and Genetic risk~* Physical Activity~* Cognitively Stimulating Activities~* Diet~* Sleep~* Social and Psychological Health~* Vascular health~* Vision and Hearing~* Lifestyle Risk Impact Surveys~* Goal Setting"
223775276|NCT06554574|DRUG|LTG-305|Part A: Single-Ascending dose cohorts; Part B: Multiple-ascending dose cohorts
223775277|NCT06560541|OTHER|UKMRC9|UKMRC9 is a low glycemic index and polyphenol-rich red pigmented rice
223775278|NCT06560541|OTHER|White rice|White rice refers to a local polished rice
223775279|NCT06572553|DRUG|Faricimab|Faricimab (faricimab-svoa; Vabysmo), a bispecific antibody that inhibits both VEGF-A and Ang-2, was developed by Roche/Genentech, and dual-pathway inhibition may provide stronger and longer-lasting efficacy in the treatment of retinal vascular disease relative to anti-VEGF therapy alone.
223775280|NCT00077259|DRUG|epothilone D|
223775281|NCT05430386|DRUG|HS-10241|"Dose escalation: HS-10241 and Almonertinib will be administered in combination. Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and confirmed disease progression.~Dose expansion: HS-10241 and Almonertinib will be administered in the dose identified in Part 1 to further investigate the safety, tolerability, pharmacokinetics, and efficacy of this combination therapy."
223775282|NCT03588169|DIETARY_SUPPLEMENT|semi-structured interviews|"About 30 minutes and touching on the following subjects:~* perception of hospital meals~* patient representation of ONS~* taking ONS and feelings about it"
223775283|NCT03354676|OTHER|MetS+|Data processing from Patient Medical Files
223775284|NCT03354676|OTHER|MetS-|Data processing from Patient Medical Files
223685151|NCT06256627|DRUG|recombinant human interference'- α- 1b, interleukin-2, thalidomide, Venentoclax and Azacitidine|"Patients in arm1 were randomly divided into two groups, namely the  interference'- α- 1b, interleukin-2, thalidomide treatment group and the VA treatment group. After receiving a two cycle protocol, patients were evaluated for the endpoint of the trial and their MRD conversion rate was calculated.~Patients in arm2 will receive triple maintenance treatment, completing three alternative regimens into one cycle. The regimen maintenance treatment will be maintained for a total of 8 cycles. Each medication regimen takes 28 days as a cycle. The number of days administered per cycle can be adjusted based on the patient's blood count."
223685152|NCT02499458|OTHER|None- observational study|
223685153|NCT05509946|DRUG|Single dose of celecoxib 400 mg and pregabalin 150 mg|Single dose of celecoxib 400 mg and pregabalin 150 mg
223685154|NCT05509946|DRUG|Repeated dose of celecoxib 200 mg and pregabalin 75 mg|Repeated dose of celecoxib 200 mg and pregabalin 75 mg started 3 days before surgery
223775285|NCT04336969|BEHAVIORAL|4T Education and Care|CGM data will be used to create customized weekly or monthly feedback to the participant/family by secure MyChart message.
223685155|NCT05509946|DRUG|Placebo|Placebo
223775286|NCT02449759|BEHAVIORAL|ACT Intervention Group|A six chapter, 58 page self-help manual based on the principles of Acceptance and Commitment Therapy
223775287|NCT05352139|PROCEDURE|Resection (removal) of the degenerative tissue using the Hydrocision TenJet system|During the procedure, the TenJet device will remove degenerative tendinopathic tissue using pressurized saline without causing harm to the healthy tendon fibers.
223685156|NCT04447612|DRUG|Durvalumab|Intravenous infusion of durvalumab 1500mg every 4 weeks for 13 cycles (1 year), starting 1 week before start of induction chemotherapy
223685157|NCT04447612|DRUG|Cisplatin|Induction phase: cisplatin 100mg/m2 on day 1 via intravenous infusion every 3 weeks for 3 cycles Concurrent phase: cisplatin 100mg/m2 starting on day 1 of radiation therapy via intravenous infusion every 3 weeks for 3 cycles
223685158|NCT04447612|DRUG|Gemcitabine|Induction phase: gemcitabine 1000mg/m2 on day 1 and day 8 via intravenous infusion every 3 weeks for 3 cycles
223685159|NCT02200783|DEVICE|TripTable|Details of the device previously described, designed to medical operator radioprotection. No changes in radial technique beyond the use of the supportive device will be performed.
223685160|NCT02200783|DEVICE|Radial|Standard radial artery catheterization procedure, performed for the purpose of coronary angiography and ad hoc angioplasty if necessary.
223775288|NCT05352139|DEVICE|Hydrocision Tenjet System|The TenJet system will be used during surgery to remove the damaged tissue from the joint
223775289|NCT01258205|DRUG|AMG 139|Four dose levels of AMG 139 administered as multiple doses IV or SC in healthy volunteers (Part A) and subjects with moderate-severe Crohn's disease (Part B).
223775290|NCT01723904|DRUG|Rotigotine|Application of Rotigotine up to 8 mg/24 h patches for 24 hours.
223775291|NCT04694833|BEHAVIORAL|Motor and cognitive virtual reality-based assessments|Motor and cognitive testing in virtual reality
223775292|NCT04694833|BEHAVIORAL|Motor and cognitive virtual reality-based serious games|Serious games implemented in virtual reality to rehabilitate motor and cognitive impairments.
223775293|NCT00374777|DRUG|zolpidem MR|oral
223775294|NCT00374777|DRUG|nitrazepam|oral
223775295|NCT00374777|DRUG|placebo|oral
223775296|NCT03251924|DRUG|BMS-986226|specified dose on specified days
223775297|NCT03251924|BIOLOGICAL|Nivolumab|specified dose on specified days
223775298|NCT03251924|BIOLOGICAL|Ipilimumab|specified dose on specified days
223775299|NCT03251924|BIOLOGICAL|Tetanus Vaccine|specified dose on specified days
223775300|NCT04989257|DRUG|Ticagrelor-based dual-antiplatelet therapy|Aspirin with ticagrelor
223775301|NCT04989257|DRUG|Clopidogrel-based dual-antiplatelet therapy|Aspirin with clopidogrel
223775302|NCT01256905|DRUG|Armodafinil|Armodafinil 150 mg
223685161|NCT02200783|DEVICE|Femoral|Standard femoral artery catheterization procedure, performed for the purpose of coronary angiography and ad hoc angioplasty if necessary. The supporting device will be the patient's own body, placing the material above the legs.
223685162|NCT02793193|DIETARY_SUPPLEMENT|Probiotic|Probiotic B.longum 1714 will be donated by Alimentary Health Ltd. (Cork, Ireland) and each sachet contains 10 billion CFU
223685163|NCT02793193|DIETARY_SUPPLEMENT|Placebo for antibiotic|The placebo supplementation is identical-looking to the antibiotic Xifaxan ®
223685164|NCT02793193|DRUG|Antibiotic|Antibiotic Xifaxan ® will be 200mg per tablet
223685165|NCT02793193|DIETARY_SUPPLEMENT|Placebo for probiotic|The placebo identical-looking to the probiotic B.longum 1714
223685166|NCT00272753|DRUG|budesonide/formoterol Turbuhaler|
223685167|NCT00272753|DRUG|formoterol Turbuhaler|
223685168|NCT00272753|DRUG|salbutamol|
223685169|NCT00176722|OTHER|table tilt|One group randomized to table tilt. One group will be flat.
223685170|NCT04330196|DIAGNOSTIC_TEST|Oral glucose tolerance test|Participant ingests 75g of glucose
223685171|NCT04330196|DIAGNOSTIC_TEST|Ingestion of placebo|Participant ingests 700mg of aspartame
223685172|NCT01859585|DRUG|Parecoxib|Parecoxib 40 mg intravenous
223685173|NCT01859585|DRUG|Ketorolac|Ketorolac 30 mg intravenous
223685174|NCT01902251|DRUG|Enzalutamide tablet|Oral
223685175|NCT01902251|DRUG|Enzalutamide capsule|Oral
223685176|NCT00959335|DRUG|Bicalutamide 50 mg Film-Coated Tablets (Casodex) (Astrazeneca Pharmaceutical LP, USA)|
223685177|NCT00959335|DRUG|Bicalutamide 50 mg Film-Coated Tablets (Sandoz Inc., USA)|
223685178|NCT02992561|BEHAVIORAL|FORNET (adapted version)|
223685179|NCT03925168|BEHAVIORAL|Music therapy|Music therapy will be administered according to the Eyre (2008) decision tree model. According to this model, the patient chooses his or her preferred musical intervention at the beginning of each session. Choices include: sing songs, compose a song, listen to songs, play instruments, have an imagery experience, listen to music, improvise, and use music for relaxation.
223685180|NCT06556966|DRUG|LY03020|LY03020 for one single dose
223685181|NCT06556966|DRUG|Placebo|Placebo for one single dose
223685182|NCT01108276|DEVICE|Convatec engenex negative pressure wound therapy|ConvaTec Engenex® is a negative pressure wound therapy that stimulates wound healing and promotes granulation tissue formation, removal of wound exudate and infectious materials by the application of negative pressure to wounds. It utilizes Bio-Dome™ Dressing technology to effectively control infection, drainage and odor while promoting granulation and wound healing at 75mmHg pressure.
223685183|NCT00902395|DRUG|Midazolam|Oral midazolam 1.0 mg/kg (maximum 20 mg)
223685184|NCT00902395|BEHAVIORAL|Protective stabilization|Children will receive a protective stabilization (physical restrain) with sheet fixed with tapes.
223685185|NCT00902395|DRUG|Midazolam, ketamine|Combined oral midazolam (0.5 mg/kg) and ketamine (3 mg/kg) (MK)
223685186|NCT03265392|OTHER|Bread|Serving of wheat bread providing 50 g of carbohydrates
223685187|NCT03265392|OTHER|Water|250 mL of water
223685188|NCT03265392|OTHER|Lemon juice|250 mL of lemon juice
223685189|NCT03265392|OTHER|Tea|250 mL of tea
223685190|NCT03265392|OTHER|Peas|20 peas
223685191|NCT01563822|BIOLOGICAL|Follicular fluid|The intervention is flushing the uterine cavity with 2 ml of clear follicular fluid surrounding mature oocytes after ovum pick-up through an IUI catheter
223685192|NCT03929718|DRUG|Spironolactone|receive spironolactone treatment after CTI ablation
223685193|NCT03929718|DRUG|No Spironolactone|no spironolactone treatment
223685194|NCT04605263|DEVICE|STN-PPN DBS Surgery|Subject will undergo standard bilateral STN DBS surgery and have 2 additional leads placed in the same burr with bilateral PPN targets
223685195|NCT04605263|PROCEDURE|Deep Brain Stimulation Surgery (DBS)|DBS lead implantation of bilateral STN
223685196|NCT02519673|DEVICE|Measurement of stromal tissue ablation|Stromal tissue consumption will be estimated preoperatively by WaveLight Allegretto EX-500 laser and central corneal thickness will be measured by Pentacam. One month after refractive surgery, during follow-up,central corneal thickness will be again measured by Pentacam.
223685197|NCT03425227|OTHER|FRED EXERGAME|biofeedback with physiological constants as follows: systolic blood pressure, diastolic blood pressure, heart rate and blood oxygen saturation
223685198|NCT01215864|DRUG|TCD-717|"Patients will receive TCD-717 at the following dose levels:~2, 4, 7, 10, 14, 19, 25, 31, 39, 49 or 61 mg/m\^2"
224262952|NCT05108467|DIAGNOSTIC_TEST|Point of care Lactate|"StatStrip Lactate is a handheld, point-of-care (POC) meter that brings lactate testing directly to the bedside. Lactate measured with blood gas analyzers is problematic for bedside care. Blood gas analyzers require arterial samples, large sample volumes (100-200 μL), and long analysis times (up to 2.5 minutes). In addition, blood gas analyzers are complex to use, stationary, and expensive to purchase and run.~StatStrip Lactate testing is as easy as bedside glucose testing. Single-use, pre-calibrated biosensors provide the fastest turnaround time (13 seconds) from the smallest whole blood sample (0.6 μL) with excellent correlation to central laboratory reference methods."
224262953|NCT01278095|DRUG|GLPG0555 solid dispersion|solid dispersion capsules, 50 mg, single dose
224262954|NCT01278095|DRUG|GLPG0555 nanosuspension|Nanosuspension, 50 mg, single dose
224262955|NCT04468867|DIAGNOSTIC_TEST|Automated whole breast ultrasound|This will be performed by a band 6 radiographer and will be done at baseline, post 2 cycles of chemotherapy and end of treatment chemotherapy
224262956|NCT04468867|DIAGNOSTIC_TEST|Breast MRI|This will be performed by band 6 or 7 radiographer with MRI training
224262957|NCT03490058|DRUG|Truvada|A fixed dose of oral co-formulated tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC) will be used as PrEP.
224262958|NCT03810703|DRUG|Placebo oral capsule|Placebo oral capsule
224262959|NCT03810703|DRUG|d-amphetamine 10 mg oral capsule|d-amphetamine 10 mg oral capsule
224262960|NCT03810703|DRUG|d-amphetamine 20 mg oral capsule|d-amphetamine 20 mg oral capsule
224262961|NCT03105947|OTHER|Coconut oil|50g extravirgin coconut oil daily for four weeks
224262962|NCT03105947|OTHER|Butter|50g butter daily for four weeks
224262963|NCT03105947|OTHER|Olive oil|50g extra virgin olive oil daily for four weeks
224262964|NCT04583657|OTHER|Eggs|Consumption of two eggs (control or test) per day during three months
224262965|NCT03530852|DEVICE|Relizorb|Tube feeds run across device to digest fats.
224262966|NCT06559631|BEHAVIORAL|Indigenously Adapted CRA|Treatment group will receive psychotherapy based on CRA which is an evidence based approach. This adapted version of CRA also consists emotional management, behavioral interventions, drug addiction treatment and islamically integrated psychotherapy for drug addiction and comorbid mental disorders.
224262967|NCT06558942|DEVICE|incisional negative pressure wound technology|Negative pressure device used directly on closed or sutured incisions
224262968|NCT01218360|DRUG|Physician standard-of-care|Participants will be treated according to their physician's routine practice and the respective Summary of Product Characteristics (SmPC).
224262969|NCT00858780|DRUG|Etanercept|50 mg etanercept once weekly + methotrexate
224262970|NCT00858780|DRUG|Etanercept|25mg etanercept once weekly + methotrexate
224262971|NCT00858780|DRUG|Placebo|Placebo comparator once weekly + methotrexate
224262972|NCT04172480|OTHER|Blood sampling|Peripheral blood sampling on EDTA
224262973|NCT00748722|DEVICE|CT Angiography|Injection of contrast material (iodine)
224262974|NCT00863330|BIOLOGICAL|Tumor Infiltrating Lymphocytes (TIL)|Tumor harvest process tumor infiltrating lymphocytes. Non myeloblative chemotherapy consisting of cyclophosphamide and fludarabine. Infusion of TIL cells followed by high dose IL-2.
224262975|NCT00429481|BIOLOGICAL|Rotarix|
224262976|NCT03602339|DRUG|Gadoterate (Dotarem/Clariscan)|Patients received a single dose of 0.5 molar gadoterate (0.1 mmol per kg body weight) intravenously.
224262977|NCT03602339|DRUG|Gadobutrol (Gadavist/Gadovist, BAY86-4875)|Patients received a single dose of 1.0 molar BAY86-4875 (0.075 mmol per kg body weight) intravenously.
224262978|NCT02632968|PROCEDURE|Pinhole surgery with and without buttons|
224262979|NCT02946424|DRUG|Placebo Oral Capsule|12 month course of daily placebo
224262980|NCT02946424|DRUG|Simvastatin|12 month course of daily simvastatin
224262981|NCT02929472|BEHAVIORAL|Physical exercise|The intervention group (INT, n = 17, 7 boys) who attended at least 75% of PA classes and met more than 50% of food goals.The exercise sessions took 90 minutes, in order to assure at least 60 minutes of physical exercise, during 12 weeks. The sessions were always taught by the same staff, and were composed of: 10 minutes of warm-up; 30 minutes of circuit training; 15-minute of pre-sports and recreational games;and 5 minutes resting activities.
224262982|NCT02929472|BEHAVIORAL|without physical exercise|The control one (CONT, n = 18, 6 boys), with a minimum or less than 49% attendance in PA classes, and were not involved in the nutrition education program.
224262983|NCT00006258|BIOLOGICAL|filgrastim|
224262984|NCT00006258|DRUG|cisplatin|
224262985|NCT00006258|DRUG|cyclophosphamide|
224262986|NCT00006258|DRUG|etoposide|
224262987|NCT00006258|DRUG|methotrexate|
224262988|NCT00006258|DRUG|vincristine sulfate|
224262989|NCT00006258|PROCEDURE|adjuvant therapy|
224262990|NCT00006258|RADIATION|radiation therapy|
224262991|NCT04353986|DRUG|Sofosbuvir and Ledipasvir|fixed dose tablet containing 400 mg sofosbuvir and 90 mg ledipasvir
224262992|NCT05214716|DIAGNOSTIC_TEST|FilmArray Pneumonia panel|A rapid molecular diagnostic test designed to detect 27 bacterial and viral species and 6 major resistance genes from respiratory specimens.
224262993|NCT02324452|DRUG|Fluoropyrimidine (capecitabine or 5-fluorouracil)|Patient that are a heterozygous carrier of a DPYD variant will receive a reduced dosage of capecitabine or 5-fluorouracil (25-50% reduction, depending on which SNP is identified). The dose will be titrated in subsequent cycles, to achieve maximal safe exposure. Patients that are wild type (not carrying any of the for DPYD variants) will receive a normal (full) dose.
224262994|NCT02316054|DEVICE|MPHI|addictive value of MPHI to management of high risk cardiovascular type 2 diabetes
223685199|NCT03333733|BEHAVIORAL|HENRY|"HENRY is an 8-week programme delivered in Children's Centres, aiming to provide parents with skills and knowledge to support healthy lifestyles in preschool children and their families. It is currently delivered in \~ 35 local areas across England and Wales by trained health and community practitioners. Training includes:~Centre Level Training: to equip staff with knowledge and skills to promote and provide healthy nutrition within early years settings and support parents to provide healthy family lifestyles and nutrition for their families. The theoretical underpinning combines proven models of behaviour change including the Family Partnership Model, motivational interviewing and solution-focused support.~Practitioner Level Training: to deliver the 8-week HENRY programme, which aims to build parents' skills, knowledge and confidence to change old habits and provide healthier nutrition for their young children."
223685200|NCT03299114|OTHER|Whirlpool|
223685201|NCT06533137|OTHER|Neutral ginger-flavored drink described as energizing, hypoglycemic, caffeine-based drink|"It is a neutral ginger-flavored drink with no energizing properties, although it was presented as particularly energizing, hypoglycemic, caffeine-based, and designed to reduce fatigue and improve performance."
223685202|NCT06533137|OTHER|Neutral ginger-flavored drink|A neutral ginger flavoured drink described as an energizing, hypoglycemic, caffeine-based drink, which is designed to reduce fatigue and improve performance.
223685203|NCT06533137|OTHER|Neutral ginger-flavored drink|A neutral ginger-flavored beverage bescribed as a mineral salt-based drink
223685204|NCT04722835|PROCEDURE|Bronchoscopy with Bronchoalveolar Lavage (BAL)|"1. Bronchoscopy w/ (BAL): The bronchoscope will be introduced through mouth and directed into the right middle lobe bronchus for bronchial lavage. The BAL will be performed with two 60-mL aliquots (total of 120 ml) of saline in each of medial and lateral segments of Right Middle Lobe (RML) (total 240 ml lavage).~2. Albuterol Administration: The subjects will inhale 2 puffs of respiratory medication albuterol, then repeat the breathing test.~3. Peak Flow Measurement: Subjects will breathe in fully then out forcefully into the handheld device.~4. Pulmonary Function Test w/ Spirometry: will be used for determination of COPD and its severity. The PFT measures breathing capacity and lung function with different types of breathing maneuvers including flow-volume curve, single breath CO diffusing capacity, and total lung capacity.~5. Blood draw~6. Medical Health and Symptom Questionnaires~7. Physical Exam by study doctor to determine suitability and safety for participation."
223685205|NCT04068896|BIOLOGICAL|NGM120 30mg|NGM120 30mg Subcutaneous Injection
223685206|NCT04068896|BIOLOGICAL|NGM120 100mg|NGM120 100mg Subcutaneous Injection
223685207|NCT04068896|BIOLOGICAL|NGM120 30mg with Gemcitabine and Abraxane|NGM120 30mg Subcutaneous Injection together with gemcitabine (1000 mg/m2 weekly for first 3 weeks of the 4-week cycle) and Abraxane (125 mg/m2 weekly for first 3 weeks of the 4-week cycle).
223685208|NCT04068896|BIOLOGICAL|NGM120 100mg with Gemcitabine and Abraxane|NGM120 100 mg Subcutaneous Injection together with gemcitabine (1000 mg/m2 weekly for first 3 weeks of the 4-week cycle) and Abraxane (125 mg/m2 weekly for first 3 weeks of the 4-week cycle).
223685209|NCT04068896|BIOLOGICAL|NGM120 100mg Q3W|NGM120 100mg Subcutaneous Injection every 3 weeks
223685210|NCT04068896|OTHER|Placebo|Placebo
223685211|NCT01461161|DRUG|bardoxolone methyl|oral, single dose
223685212|NCT01655186|DRUG|Bardoxolone Methyl|
223685213|NCT01655186|DRUG|Placebo|
223685214|NCT02470715|GENETIC|Molecular profile|Patients and their treating physician will obtain the patient's genetic risk assessment
223685215|NCT03763565|BIOLOGICAL|Bivalent or Quadrivalent HPV vaccines|Vaccination with at least one dose of Bivalent or Quadrivalent HPV vaccines at least 5 years ago at the ages of 20-45 years
223685216|NCT03763565|OTHER|Control group|Thai women who did not receive HPV vaccination, either by bivalent or quadrivalent HPV vaccine but have received Pap smear at their ages 20-45 years at least 5 years ago from the current enrollment time
223685217|NCT00910468|PROCEDURE|Robot-assisted Laparoscopic myomectomy|Robot-assisted Laparoscopic myomectomy
223685218|NCT02398227|BEHAVIORAL|HOPE|Cognitive Behavioral Treatment for PTSD in Battered Women
223685219|NCT02398227|BEHAVIORAL|PCT|Present Centered Therapy for PTSD
223685220|NCT02262182|OTHER|KP group|
223685221|NCT02262182|OTHER|KM group|
223685222|NCT00618839|BIOLOGICAL|StrataGraft Skin Tissue|StrataGraft™ skin tissue is provided as a suturable circular patch of stratified epithelial tissue composed of a living dermal matrix (containing dermal fibroblasts) overlaid with human epidermal cells (NIKS™ cells).
223685223|NCT00618839|PROCEDURE|Cadaver allograft|The standard of care for temporary coverage of full thickness skin defects is coverage with cadaver allograft until the wound can be autografted.
223775303|NCT05383846|OTHER|Experimental Narrative Exposure Therapy|"NET (Schauer et al., 2011) is an evidence-based, short-term, manualised treatment for complex trauma, aiming to reduce symptoms of traumatic stress in individuals. NET combines principles of CBT, Testimony Therapy, and Exposure Therapy.~This is a multiple baseline single case series design which focuses on assessing the posited exposure and autobiographical memory integration components of Narrative Exposure Therapy; no comparator will be included."
223685224|NCT03709641|DEVICE|Restylane Defyne|Restylane is a gel of hyaluronic acid generated by Streptococcus species of bacteria, chemically crosslinked with BDDE, stabilized and suspended in phosphate buffered saline at pH=7 and concentration of 20 mg/mL
223685225|NCT05165589|DEVICE|ActiveInsights accelerometer device|Accelerometer device
223685226|NCT01086839|DRUG|sodium chloride 6%|"* one ampoule sodium chloride 6% per day~* inhalation use~* for 28 days"
223685227|NCT01086839|DRUG|sodium chloride 0,9%|"* one ampoule sodium chloride 0,9% per day~* inhalation use~* for 28 days"
223685228|NCT05587465|DEVICE|Lobster Device|The intervention is performed percutaneously using the dedicated instrument set.
223685229|NCT05742386|BEHAVIORAL|Communication training|Clinics will host an AAT workshop. A trained facilitator will use a standard script and slides to deliver workshop in-person or over Zoom; clinical staff who are unavailable will take the workshop later on their own.
223775304|NCT02811198|OTHER|No intervention|
223775305|NCT00834301|DIETARY_SUPPLEMENT|Oral Multivitamin|Oral Multivitamin
224262995|NCT01299935|BEHAVIORAL|Transcendental Meditation|The Transcendental Meditation program is the principal mind-body approach of Maharishi Ayurveda, originating from the ancient Vedic tradition and introduced 50 years ago by Vedic scholar and teacher Maharishi Mahesh Yogi. The Transcendental Meditation technique is described as a simple and natural procedure that is practiced 20 minutes twice a day while sitting comfortably with the eyes closed. Practice of the Transcendental Meditation technique does not require any changes in personal beliefs, philosophy or lifestyle. During the practice a unique state of restful alertness is gained. Acute and chronic physiological effects have been documented. The course is taught by instructors certified by Maharishi Foundation - USA.
224262996|NCT01299935|BEHAVIORAL|Health Education|health education is taught in a clinical setting using standard AHA recommendations for proper diet, exercise and control of substance usage but without a stress management component.
224262997|NCT02504333|DRUG|nab-paclitaxel|Day 1-8-15: Intravenous, 125 mg/m2 over 30 minutes
224262998|NCT02504333|DRUG|gemcitabine|Day 1-8-15: Intravenous, 1.000 mg/m2 over 30 minutes
224262999|NCT02504333|DRUG|m-FOLFOX|Day 28 according to the dose levels stablished in Phase I
224263000|NCT02504333|DRUG|nab-paclitaxel|Day 1-8-15: Intravenous 30 minutes according to the dose levels stablished in Phase I
224263001|NCT02504333|DRUG|gemcitabine|Day 1-8-15: Intravenous 30 minutes according to the dose levels stablished in Phase I
224263002|NCT02615249|BIOLOGICAL|Metal Allergen Epicutaneous Patch|48 hour application of metal allergen patch to diagnose contact dermatitis
224263003|NCT00242554|DRUG|Zoledronic acid|
224263004|NCT04056585|PROCEDURE|Ultrasound guided axillary plexus block|Ultrasound guided axillary plexus block with 1.5% mepivacaine 30 ml
224263005|NCT04056585|PROCEDURE|Intermittent pneumatic compression maneuver|Following ultrasound guided axillary plexus block, the pneumatic compression maneuver of upper arm is composed of 6 repeated inflation-deflation periods; inflation with a pressure of 200 mmHg for 30 seconds and deflation for 10 seconds each.
224263006|NCT01192932|RADIATION|Chest CT scan|"Supine CT scan after full inspiration. Acquisition parameters: (Topogram 35 mA 120 kV 512 mm length)~* 90 quality ref mAs with care-dose ON~* 120 kV~* Pitch 1.4~* Rotation time 0.33 s~* Acquired images 64 x 0.6 mm"
224263007|NCT00574847|DRUG|Escitalopram|Dosage will range from 5 mg to 20 mg once a day for the duration of the study (6 weeks). Tablets are in 5 mg or 10 mg form, depending upon the dosage the patient is prescribed.
224263008|NCT00574847|DRUG|Placebo|Placebo dosage will range from 5 mg to 20 mg once a day for the duration of the study (6 weeks). Tablets are in 5 mg or 10 mg form, depending upon the dosage the patient is prescribed.
224263009|NCT02254005|DRUG|bivatuzumab mertansine|
224263010|NCT05226533|DRUG|DWRX2003|Intramuscular injection of DWRX2003
224263011|NCT05226533|DRUG|Placebo|Intramuscular injection of placebo
224263012|NCT00070148|DRUG|Megestrol Acetate|Megace by mouth for 12 weeks
224263013|NCT00070148|DRUG|Oxandrolone 20 mg|20 mg/day for 3 months (12 weeks)
224263014|NCT00452218|DRUG|Sorafenib|200 mg daily and dose escalated to a maximum of 400 mg twice daily
224263015|NCT05108948|BEHAVIORAL|Quality of life questionnaires|Oswestry Disability Index Scoliosis Research Society-22R Short Form 36 Health Survey Questionnaire Tobacco, Alcohol, Prescription medication, and other Substance use Core Outcome Measures Index : back and neck
224263016|NCT05108948|PROCEDURE|Radiography|Spinal radiography : full, face, profile
224263017|NCT06432751|OTHER|Post Operative Acute Kidney Injury|"Serum creatinine increase by 0.3 mg/dl within 48 h OR Serum creatinine ≥ 1.5-1.9 times baseline within 7 days~Baseline creatinine is defined as the last pre-operative value available in the medical file"
224263018|NCT00833300|DRUG|Haloperidol|"* 2.5 mg-10 mg IV q6h for 24 hours and 2.5 mg-5 mg IV prn, up to 40mg in 24 hours.~* Reassess in 24 hours.~* Delirium absent - Continue dose for 24 hours then discontinue.~* Delirium present - Increase dose 5 mg-10 mg IV q6h for 24 hours and 2.5 mg-5 mg IV prn, up to 40 mg in 24 hours.~* Reassess in 24 hours.~* Delirium absent - Continue dose for 24 hours then discontinue.~* Delirium present - Discontinue current drug therapy and select one of:~  1. Quetiapine up to 100 mg/day~ 2. Risperidone up to 6 mg/day~ 3. Loxapine up to 50 mg/day~ 4. Methotrimeprazine up to 75 mg/day~* Reassess in 24 hours.~* Delirium absent - Continue for 24 hours then discontinue.~* Delirium present - Treatment at discretion of attending physician."
223685230|NCT05742386|BEHAVIORAL|Communication training enhanced with standing orders optimization|"Clinics will host an AAT workshop, as in the other trial arm.~Clinic representatives will attend working meetings on putting HPV vaccine standing orders into clinic workflow. Clinics will then orient their staff to the standing orders. Finally, clinic representatives will discuss their use of standing orders in a learning collaborative."
223685231|NCT02694718|DRUG|Capecitabine|Capecitabine is available as 50 mg and 500 mg tablets. It will be administered as a 1000mg/m\^2 bid orally on Days 1-14, and at a dose of 825mg/m\^2 bid on Days 22-35 and 43-56.
223685232|NCT02694718|DRUG|Oxaliplatin|Oxaliplatin is available in vials containing 50 mg or 100 mg. It will be administered as a oxaliplatin 130mg/m\^2/d intravenously on Day 1 and 50mg/m\^2/d on Days 22, 29, 43 and 50 prior to radiotherapy up to Week 9 followed by surgery period.
223685233|NCT02925793|DRUG|DS107|
223685234|NCT02925793|OTHER|Vehicle cream|
223685235|NCT03239691|DRUG|ACT-709478 for oral use|Hard gelatin capsules for oral administration formulated at strengths of 10 mg and 100 mg
223685236|NCT03239691|DRUG|Placebo|Matching placebo available as matching capsules for oral administration
223685237|NCT02071927|DRUG|CB-839|Single-agent CB-839
223685238|NCT02071927|DRUG|CB-Aza|CB-839 in combination with standard dose azacitidine
223685239|NCT03301974|PROCEDURE|conjunctival autograft with fibrin glue|Simple pterygium excision under local anesthesia performed then closure of the bare sclera by fibrin glued conjunctival autograft in 20 eyes of 20 patients (group 1).
223685240|NCT03301974|PROCEDURE|sutured conjunctival autograft|Simple pterygium excision under local anesthesia performed then closure of the bare sclera by sutured conjunctival autograft in 20 eyes of 20 patients (group 2).
223685241|NCT03301974|PROCEDURE|sutureless and glue-free conjunctival autograft|Simple pterygium excision under local anesthesia performed then closure of the bare sclera by sutureless and glue free conjunctival autograft in 20 eyes of 20 patients (group 3)
223685242|NCT02573701|DRUG|Guideline treatment (Risperidone, administered orally)|"Participants will receive the Guideline Treatment (risperidone, administered orally) plus Behavioral Intervention: psychosocial treatment included psychoeducation social skills healthy life style habits exercise in group"
223685243|NCT02573701|BEHAVIORAL|"Psychosocial treatment"|"Participants will receive the Guideline Treatment (risperidone, administered orally) plus Behavioral Intervention: psychosocial treatment included psychoeducation social skills healthy life style habits exercise in group"
223685244|NCT02573701|DRUG|Treatment as Usual (any other antipsychotic)|Participants will receive the Treatment as Usual (atypical antipsychotic) plus Behavioral Intervention: psychosocial treatment assigned by clinician.
223685245|NCT00914303|DRUG|AZD3241|Oral Tablet, Repeated Administration
224263019|NCT00833300|DRUG|Olanzapine|"* 2.5 mg-10 mg po/ng/og bid and 2.5 mg po/ng/og prn, up to 20 mg in 24 hours.~* Reassess in 24 hours.~* Delirium absent - Continue dose for 24 hours then discontinue.~* Delirium present - Increase dose 5 mg-10 mg bid and 2.5 mg po/ng/og prn, up to 20 mg in 24 hours.~* Reassess in 24 hours.~* Delirium absent - Continue dose for 24 hours then discontinue.~* Delirium present - Discontinue current drug therapy and select one of:~  1. Quetiapine up to 100 mg/day~ 2. Risperidone up to 6 mg/day~ 3. Loxapine up to 50 mg/day~ 4. Methotrimeprazine up to 75 mg/day~* Reassess in 24 hours.~* Delirium absent - Continue for 24 hours then discontinue.~* Delirium present - Treatment at discretion of attending physician."
224263020|NCT03937557|DIAGNOSTIC_TEST|photofinder levicam|Exam frontal, bilateral Temporal and occipital scalp by photofinder levicam and compare the pros and cons with the data from scalp biopsy.
224263021|NCT01732224|DRUG|Tenofovir + Telbivudine|Tenofovir (300 mg/day) plus telbivudine (600 mg/day).
224263022|NCT01732224|DRUG|Tenofovir|In tenofovir arm subjects will receive tenofovir (300 mg) once daily.
224263023|NCT04615741|BEHAVIORAL|Trauma Informed Yoga|One licensed yoga instructor, trained in trauma-informed yoga delivery, will lead the online sessions. Participants will be instructed to engage in the class from a mat or chair in their home or move between them as the class unfolds. The instructor will begin the class by introducing the week's theme (e.g. grounding and safety, non-attachment, imprints of the past and impacts on our reactions to COVID-19, connection to nature), followed by a breath practice (10 min), a yoga practice (50 min), a meditation practice (10 min), and closing words (10 min).
223685246|NCT00914303|DRUG|Placebo Tablet|Oral Tablet. Repeated Administration
223685247|NCT04080076|DRUG|Acthar 80 UNT/ML Injectable Solution|ACTHar 80 Units SQ 1042 x Week
223685248|NCT04080076|DRUG|Oral Tab Tacrolimus|Oral Tab Tacrolimus (1.0 mg PO BID) in combination with ACTHar 80 Units SQ 2 X week
223685249|NCT04549974|OTHER|Heat exposure|Participants will be exposed to heat exposure via a water-perfused suit to increase internal body temperature by 1.5 degrees Celsius.
223685250|NCT02345746|DRUG|Oxaliplatin|infusion over 12 hours via HAI
223685251|NCT02345746|DRUG|Folinic Acid|as a 2-hour infusion via HAI on day 2
223685252|NCT02345746|DRUG|5-Fluorouracil|Following Folinic Acid as a continuous infusion over 48 hours on days 2, 3
223685253|NCT03020446|DEVICE|Sorbion Dressing|Sorbion dressing will be placed on venous leg ulcer and changed weekly for 4 weeks
223685254|NCT00256282|DRUG|Vinorelbine|30 mg/m2 IV over 6-10 min every 14 days
224263024|NCT04615741|BEHAVIORAL|Trauma Informed Psychotherapy|Two licensed counsellors (MSW-trained) will co-facilitate the online version of this program. Facilitators will begin the session by introducing the week's theme (e.g. setting goals while working from home, being mindful, health coping) (10 min), followed by a lecture and activity to integrate learning (e.g. large and small group discussion using Zoom break out rooms, journaling) (70 min), and closing words (10 min).
224263025|NCT04309773|DRUG|Bezafibrate (400mg) in addition to standard 15-20 mg/kg/jour UDCA therapy|Bezafibrate (400mg) in addition to standard 15-20 mg/kg/jour UDCA therapy Treatment duration : 24 months Bezafibrate/AUDC : daily oral dose
224263026|NCT04309773|DRUG|Placebo of Bezafibrate in addition to standard UDCA therapy|Placebo of Bezafibrate (400mg) in addition to standard 15-20 mg/kg/Day UDCA therapy Treatment duration : 24 months Placebo/AUDC : daily oral dose
224263027|NCT03257228|GENETIC|comparative semiquantitative immunohistochemistry|
224263028|NCT03873363|DEVICE|PS TKA|Implantation of a posterior stabilized (cruciate substituting) Total Knee Arthroplasty.
224263029|NCT03873363|DEVICE|CR TKA|Implantation of a cruciate retaining Total Knee Arthroplasty.
223685255|NCT00256282|DRUG|Docetaxel|40mg/m2 IV over 1 hour every 14 days
223685256|NCT00256282|DRUG|Sargramostim|250 mcg/m2 subcutaneous (SQ) daily (QD) x 10 days
223685257|NCT05428982|PROCEDURE|Postoperative Modified Trendelenburg position|Patients underwent the laparoscopic hysterectomy were positioned in a Modified Trendelenburg position (20 °) postoperative for 6 hours at ward.
223685258|NCT00667446|DRUG|Leuprolide Acetate 3 Month Depot|
223775306|NCT03731494|BIOLOGICAL|Nickel oral hyposensitization treatment|Nickel oral hyposensitization treatment (NiOHT) was performed with hard gelatin capsules containing Nickel sulphate (NiSO4) at different dosages (0.1 ng, 1 ng, 10 ng, 0.1 μg, 0.5 μg) and microcrystalline cellulose as excipient (TIO Nickel, Lofarma SpA, Milan, Italy). Treatment was given 3 times a week increasing progressively the dose from 0.1 ng to 3 μg in 10 weeks with a maintenance phase of 1,5 μg a week for a period of 12 months. After 6 months, patients were allowed to gradually reintroduce nickel-rich foods, starting with those with a maximum of 100 mcg of nickel content. For all the treatment period, information on the appearance of side effects or more severe adverse reactions and the need for antiallergic drugs (corticosteroids, antihistamine drugs) were collected.
223775307|NCT06410105|DEVICE|CLEAR ALIGNERS|The CA group included 13 patients treated with clear aligners Tree-dimensional images were captured using a CBCT scan (KaVo® Dental GmbH, Bismarckring, Germany). Te pre-treatment imaging parameters were 120 kV, 5 mA, 0.3 mm voxel size, and a feld of view of 230×170 mm
223775308|NCT06533839|PROCEDURE|Permanent colostomy|A long-term (permanent) colostomy will be performed in the diseased colon or rectum.
223775309|NCT02061241|PROCEDURE|Pacing in vein at site of latest mechanical activation|Pacing in vein at site of latest mechanical activation
223685259|NCT01016704|BEHAVIORAL|Incentive|Participants assigned to the experimental condition are reinforced via monetary incentives for demonstrating superior delivery of an evidence treatment to clients
223775310|NCT02061241|PROCEDURE|Pacing in other suitable vein|Pacing in other suitable vein
223775311|NCT00059475|DRUG|Glycoprotein 100 (GP100): 209-217 (210M)|
223775312|NCT00059475|DRUG|Interleukin-2 (IL-2)|720,000 IU/kg as an intravenous bolus over a 15 minute period every 8 hours and continuing for up to 4 days (a maximum of 12 doses).
223775313|NCT00059475|DRUG|Montanide ISA 51|
223775314|NCT00059475|DRUG|Melanoma antigen recognized by T-cells (MART)-1: 27-35|
223775315|NCT00059475|DRUG|27-35 (27L): melanoma antigen recognized by T-cells (MART)-1|
223775316|NCT00059475|DRUG|melanoma antigen recognized by T-cells (MART)-1: 26-35(27L)|
223775317|NCT03086798|PROCEDURE|Magill forceps|Magill forceps techniques to facilitate nasotracheal tube advancement into trachea
223775318|NCT03086798|PROCEDURE|cuff inflation|cuff inflation techniques to facilitate nasotracheal tube advancement into trachea
223775319|NCT05316857|DRUG|Orelabrutinib + Rifampin|Orelabrutinib + Rifampin
223775320|NCT05316857|DRUG|Orelabrutinib + Itraconazole|Orelabrutinib + Itraconazole
223775321|NCT01025700|DRUG|Cesemat|1 mg capsule per day for 21 days
223775322|NCT02041455|DRUG|Melatonin and Placebo|
223775323|NCT02041455|DRUG|Amitriptyline and Placebo|
223775324|NCT02041455|DRUG|Melatonin and Amitriptylin|
223775325|NCT06205290|BIOLOGICAL|Liso-cel|Specified dose on specified days
223775326|NCT06205290|DRUG|Idelalisib|Specified dose on specified days
223775327|NCT06205290|DRUG|Rituximab|Specified dose on specified days
223775328|NCT06205290|DRUG|Bendamustine|Specified dose on specified days
223775329|NCT06205290|DRUG|Fludarabine|Specified dose on specified days
223775330|NCT06205290|DRUG|Cyclophosphamide|Specified dose on specified days
223685260|NCT02655146|DRUG|triptorelin 0.1|a single dose of decapeptyl 0.1 s.c. on the 3rd day of embryo transfer with routine luteal phase support.
223685261|NCT02655146|DRUG|E2|Patients will be on the Progynova tablets 4-10mg daily at least 14 days.
223685262|NCT02655146|DRUG|Progesterone|After ultrasound and hormorne tests, progesterone 100mg intramuscular injection is allocated with Progynova.
223685263|NCT02655146|DRUG|triptorelin 3.75mg|as a pretreatment of E2 in some subjects with a fail history of hormonal artificially endometrium preparing.
223685264|NCT04647487|DRUG|LY3484356|Administered orally.
223685265|NCT00746408|OTHER|Expert system guided tailored information|The prototype is realised by a web-based information system. The HTML web-interface guides the user through the search process by querying the information demand. This is done by an integrated expert system. The expert system uses a rule based inference to determine an internal diagnosis. Based on this internal diagnosis the system searches quality labeled websites and presents relevant information to the user.
223775331|NCT01067079|OTHER|No vaccine administered; subjects only have blood sampling for immunogenicity|No vaccine administered; subjects only have blood sampling for
223775332|NCT02617589|DRUG|Nivolumab|
224263030|NCT02253329|PROCEDURE|Dietary protein plus NMES during the day|Neuromuscular electrical stimulation after a protein bolus, performed during the day
223685266|NCT02829983|DRUG|Clarithromycin|Use of 500mg of Clarithromycin twice a day for 3 days
223775333|NCT02617589|DRUG|Temozolomide|
223775334|NCT02617589|RADIATION|Radiotherapy|
223775335|NCT02711657|OTHER|Fibrocyte measurement and lung function test.|
223775336|NCT00463450|DRUG|Gynodian® Depot (BAY86-5032)|Injection monthly
223775337|NCT00463450|DRUG|BAY86-4980|orally
223775338|NCT02523833|DRUG|Salbutamol|Salbutamol after spirometry, plethysmography and forced oscillation technique.
223775339|NCT04719910|OTHER|Visual exposure to taped food preparation|Patients in the study group can watch the preparation of the the type of food she prefers to eat normally.
223775340|NCT04719910|OTHER|Visual exposure to topics not related to food|Patients in the placebo group can choose a video that is relaxing but not related to food.
223775341|NCT01649856|DRUG|CHOP|CHOP chemotherapy: cyclophosphamide, doxorubicin, vincristine, prednisone/prednisolone; 6 or 8 cycles
223775342|NCT01649856|DRUG|rituximab [MabThera/Rituxan]|The first rituximab dose will be administered intravenously on Day of Cycle 1 at a dose of 375 mg/m2. Subsequent doses of 1400 mg are administered subcutaneously on Day 1 of each cycle, for a further 7 cycles
223775343|NCT01649856|DRUG|rituximab [MabThera/Rituxan]|375 mg/m2 intravenously on Day 1 of each cycle, 8 cycles
223775344|NCT00622635|DRUG|Indacaterol 300 μg|Indacaterol 300 μg was provided in powder filled capsules with a single-dose dry-powder inhaler (SDDPI).
223685267|NCT02829983|DRUG|Placebo|Use of placebo tablets twice a day for 3 days.
223685268|NCT02829983|OTHER|One-stage full-mouth ultrasonic debridement (FMUD)|One session of Periodontal debridement using ultrasonic device.
223775345|NCT00622635|DRUG|Placebo to indacaterol|Placebo to indacaterol was provided in powder filled capsules with a single-dose dry-powder inhaler (SDDPI).
223775346|NCT00622635|DRUG|Salmeterol 50 μg|Salmeterol 50 μg was provided in powder filled capsules with a multi-dose dry-powder inhaler (MDDPI).
223685269|NCT03004248|BIOLOGICAL|Botulinum Toxins, Type A|Intramuscular Injection
223775347|NCT04162704|DEVICE|EpiCheck|If the EpiCheck test is positive at the time of inclusion, the test is repeated prior to the fourth and sixth instillation with Mitomycin as well as prior to the subsequent two cystoscopies. If the EpiCheck test is negative at the time of inclusion, no further tests will be performed.
224263031|NCT02253329|PROCEDURE|Dietary protein plus NMES prior to sleep|Neuromuscular electrical stimulation after a protein bolus, performed prior to sleep
224263032|NCT03349632|DEVICE|verofilcon A contact lenses|Investigational spherical silicone hydrogel contact lenses for daily disposable wear
224263033|NCT03349632|DEVICE|senofilcon A contact lenses|Commercially available spherical silicone hydrogel contact lenses for daily disposable wear
224263034|NCT03349632|DEVICE|stenfilcon A contact lenses|Commercially available spherical silicone hydrogel contact lenses for daily disposable wear
224263035|NCT03349632|DEVICE|etafilcon A contact lenses|Commercially available spherical silicone hydrogel contact lenses for daily disposable wear
224263036|NCT01468688|DRUG|STI571|
224263037|NCT01468688|DRUG|BKM120|BKM120 combination therapy
224263038|NCT00870558|DRUG|ethiodized oil|Given as an intra-arterial infusion
224263039|NCT00870558|RADIATION|iodine I 131 ethiodized oil|Given as an intra-arterial infusion
224263040|NCT02480660|BEHAVIORAL|Educational Video|The video highlights key elements found in the existing literature critical for transition including understanding and taking charge of their health, creating a medical summary, learning more about health insurance, introducing the idea of organizing a health care transition team and creating a plan. The video also educates patients on the opportunities to take a tour of an adult floor, talk with social workers and learn more about adult providers during their hospital stay.
224263041|NCT03285438|DRUG|Reduced dose of DOAC|The patient will receive apixaban 2.5 mg twice daily or rivaroxaban 10 mg once daily during a mean follow-up period of 36 months (12 to 65 months)
224263042|NCT03285438|DRUG|Full dose of DOAC|The patient will receive apixaban 5 mg twice daily or Rivaroxaban 20 mg once daily during a mean follow-up period of 36 months (12 to 65 months)
224263043|NCT01112462|DRUG|Paracetamol 500 mg/Phenylephrine 5 mg tablets|2 tablets to be administered orally with 240 ml of water with a 24 hour follow-up period
224263044|NCT01112462|DRUG|Paracetamol 1000 mg/Phenylephrine 10 mg sachet|1 sachet dissolved in 240 ml water and administered orally with a 24 hour follow-up period
224263045|NCT02144844|BEHAVIORAL|Insight-Plus Cognitive Behavioral Intervention|Insight-Plus is a 6-session, manualized, cognitive behavioral intervention (CBI) culturally tailored for a diverse group of rural low-income women at low and high risk for antepartum depression.
224263046|NCT03719040|DEVICE|Physiologic pacing device implant|An alternative and potentially more effective pacing strategy for patients with electrical conduction abnormalities is physiologic pacing. Physiologic pacing is achieved by delivering a pacing stimulus to a cardiac conduction structure, such as the bundle of His or left bundle branch (LBB) of the His-Purkinje system, with a permanent lead. Physiologic pacing activates the heart through the native His-Purkinje conduction system, thus offering the most physiologic pacing approach to correct electrical dyssynchrony. Physiologic pacing has emerged as a feasible and safe alternative to pacemaker therapy and CRT with clinical and electrophysiological advantages.
224263047|NCT05432115|DRUG|Tetracyclin|Amoxicillin 1000mg bid +Tetracycline 500mg tid/qid +Bismuth+Esomeprazole 40mg bid
224263048|NCT02923349|DRUG|INCAGN01949|Initial cohort dose of INCAGN01949 monotherapy at the protocol-defined starting dose, with subsequent cohort escalations based on protocol-specific criteria. The recommended dose will be taken forward into expansion cohorts.
224263049|NCT00567463|DEVICE|Fluticasone|Fluticasone 250mcg for 3 months followed by 100mcg for 9 months, one puff once a day at supper time
224263050|NCT01902719|BEHAVIORAL|Community Health Worker (CHW) Intervention|Receipt of training in use of home blood pressure machine, education about diet, exercise and physical activities to lower blood pressure, and continued support from a trained community health worker.
224263051|NCT01902719|BEHAVIORAL|Communication Skills Training|"Receipt of Do My PART (P-Prepare for Visit, A- Act at visit, R-Review doctor's recommendations, T-Take home recommendations)communication skills training."
224263052|NCT01902719|BEHAVIORAL|Problem Solving Skills Training|Receipt of a 9-week group based self-management intervention designed to help patients identify and solve self-identified barriers to hypertension control.
224263053|NCT03759704|DRUG|Hyperpolarized 13CPyruvate|Bolus injection of study drug during MRSI.
224263054|NCT06809140|DRUG|Enfortumab vedotin|1.25 mg/kg (maximum dose 125 mg)
224263055|NCT06809140|DRUG|Pembrolizumab|200 mg
224263056|NCT07127094|DRUG|Test Product (Glimcoza)|Tablet formulation
224263057|NCT07127094|DRUG|Reference (R) Twymeeg®|Tablet formulation
224263058|NCT02751827|OTHER|Blood sample|"One blood sample before treatment initiation (Cycle 1 Day predose) for pharmacogenomics~One blood sample at the end of the firth month of treatment (postdose) for pharmacokinetic"
224263059|NCT06012019|OTHER|Biological sampling in Periodontitis Case|"Periodontal bacteria, gingival fluid, unstimulated saliva and blood collection;~J+7 : tooth extraction : gingival explant sampling~J+15 : Healing control"
224263060|NCT06012019|OTHER|Biological sampling in Gingivitis Case|"Periodontal bacteria, gingival fluid, unstimulated saliva and blood collection;~J+7 : tooth extraction or pre-prosthetic periodontal surgeries : gingival explant sampling~J+15 : Healing control"
224263061|NCT06012019|OTHER|Biological sampling in Control Case|"Periodontal bacteria, gingival fluid, unstimulated saliva and blood collection;~J+7 : tooth extraction or pre-prosthetic periodontal surgeries : gingival explant sampling~J+15 : Healing control"
223775348|NCT02290587|OTHER|Brain MRI - Clinical and cognitive evaluation|"Neuropsychological evaluation :~* Questionnaire for depression and anxiety~* Evaluation of executive functions~* Evaluation of attention, information processing speed, verbal memory and working memory~Theory of mind evaluation~Clinical Evaluation~MRI Evaluation :~* morphological MRI~* functional MRI with two tasks of theory of mind : eyes test and test of attribution of intention"
223775349|NCT02290587|DEVICE|MRI|
223775350|NCT00051116|DRUG|CC-5013|
223775351|NCT00341224|BEHAVIORAL|Group-mentoring intervention|Group mentoring used to teach social skills to middle school students
224263062|NCT06022588|DRUG|Sodium butyrate, 1-13C, 99%, Cambridge Isotope Laboratories, Inc.USA|a solution containing butyrate of which 12C of the last 4 carbon positions of butyrate were replaced by 13C butyrate. Participants received 0.80 gram 13C-butyrate (7.3 mMol butyrate / 29 mMol 13C) dissolved in 50 mL water at baseline
223775352|NCT02550613|DEVICE|The imaging biomarkers determined by MR-PET|The purpose of this study is to explore the ability of integrated MRI/PET to detect and evaluate treatment outcome in HCC patients. This study using 18F-FDG PET and functional MRI (DCE-MRI, Diffusion-weighted MRI, MR spectroscopy).
223775353|NCT04558476|BIOLOGICAL|Convalescent Plasma|2 units of convalescent plasma
223775354|NCT04558476|OTHER|Standard of Care|Gold Standards
223775355|NCT01399359|BEHAVIORAL|Counseling session|
223775356|NCT01399359|OTHER|Questionnaire 1|Questionnaire 1 assesses the recall and understanding of risk information given during the counseling session.
223775357|NCT01399359|OTHER|Questionnaire 2|Questionnaire 2 focuses on what factors, other thana the numerical risk-benefit analysis of SERM intake, are important in the decision-making process of women at increased risk for breast cancer.
223775358|NCT01399359|OTHER|online questionnaire|
224263063|NCT06022588|DRUG|U-13C6, 99%; Cambridge Isotope Laboratories, Inc.USA|a glucose solution in which all six 12C carbons were replaced by 13C D-Glucose. Participants received 0.75 gram 13C-glucose (4.2 mMol D-glucose/ 25 mMol 13C) dissolved in 50 mL water at baseline
224263064|NCT06022588|DIAGNOSTIC_TEST|Breath test|Breath tests were performed at the following time points baseline, 0.5, 1, 1.25 1.5, 1.75, 2, 2.25, 2.5, 3, 3.5 and 4 hours after ingestion of 13C-butyrate and 13C-glucose. Breath samples were obtained by blowing a single breath of air through a straw into a test tube. Two breath samples were collected at all mentioned time points. Measurement of 13CO2 is performed using mass spectrometry (IDMicro Breath, Compact Science Systems, Newcastle-Under-Lyme, United Kingdom) using procedures described earlier for galactose and methacetin breath tests, and expressed as an absolute increase in the 13CO2-to-12CO2 ratio in delta permil (δ‰).
224263065|NCT06022588|DIAGNOSTIC_TEST|Exercise + breath test|The intervention groups performed a standardized bicycle ergometer exercise test of 30 minutes and semi-continuous peripheral blood lactate monitoring. The bicycle ergometer protocol consists of three phases. The first 10 minutes of exercise was used to gradually increase the workload until submaximal exercise intensity was reached which is defined as a circulating blood lactate level between 3 and 5.5 mmol/L. From minute 10 to 20 submaximal exercise intensity was maintained by adjusting the workload based on lactate measurements. Minute 20 to 30 was used to reach maximal exercise intensity, the workload was increased by 10% of the submaximal workload until exhaustion
224263066|NCT03087747|PROCEDURE|Percutaneous cholecystostomy|Placement of drainage catheter into gallbladder lumen in order to evacuate inflamed content.
224263067|NCT00613145|DRUG|Capecitabine and Sorafenib|"During Cycle 1, patients will receive capecitabine alone for the first 7 days (Cohort A will receive 750 mg/m2 of capecitabine twice daily). For Days 8-14 of Cycle 1, patients will receive capecitabine (750 mg/m2 twice daily for Cohort A) combined with sorafenib (400 mg twice daily); on Days 15-21 of Cycle 1, patients will receive sorafenib alone (400 mg twice daily). Beginning with Day 1 of Cycle 2 and all treatment cycles thereafter, patients will be dosed as follows:~Cohort A will receive sorafenib orally at 400 mg twice daily for 21 days, and capecitabine orally at 750 mg/m2 twice daily for the first 14 days of a 21-day treatment cycle."
224263068|NCT00613145|DRUG|Capecitabine and Sorafenib|During Cycle 1, patients will receive capecitabine alone for the first 7 days Cohort B will receive 1000 mg/m2 of capecitabine twice daily for the first 7 days of Cycle 1). For Days 8-14 of Cycle 1, patients will receive capecitabine (1000 mg/m2 twice daily for Cohort B) combined with sorafenib (400 mg twice daily for both cohorts); on Days 15-21 of Cycle 1, patients will receive sorafenib alone (400 mg twice daily). Beginning with Day 1 of Cycle 2 and all treatment cycles thereafter, patients will be dosed as follows: Cohort B will receive sorafenib orally at 400 mg twice daily for 21 days, and capecitabine orally at 1000 mg/m2 twice daily for the first 14 days of a 21-day treatment cycle.
224263069|NCT02723721|DRUG|Picato gel|apply on and 1 cm around the lesion, 0.47 g of Picato® gel 150 µg/g, once a day on 3 consecutive days.
224263070|NCT04254718|BEHAVIORAL|Digital Storytelling|Creation of a digital story about the infant with video and music selected by parents
224263071|NCT04666116|DIETARY_SUPPLEMENT|Dietary supplementation in patients with covid disease admitted to hospital|Dietary supplementation in patients with covid disease admitted to hospital
224263072|NCT03568838|DRUG|Enoxaparin|Patients allocated to the experimental arm will receive a parenteral (IA/IV) bolus dose of enoxaparin (0.75 mg/kg) pre PPCI followed by an infusion of 0.75 mg/kg over a 6-hour period to be started as soon as possible when PPCI starts.
224263073|NCT02097160|OTHER|Vitamin D fortified yogurt and cheese products|
224263074|NCT02097160|OTHER|Control Group 1|
224263075|NCT07038447|BIOLOGICAL|KITE-363|A single infusion of CAR-transduced autologous T cells administered intravenously
224263076|NCT07038447|DRUG|Fludarabine|Administered intravenously
224263077|NCT07038447|DRUG|Cyclophosphamide|Administered intravenously
224263078|NCT07046910|DIAGNOSTIC_TEST|Sub study (Active): Two Lung MRI study with two navigational Bronchoscopy|Hyperpolarized Xenon-129 MRI twice with navigational bronchoscopy twice
224263079|NCT07046910|DRUG|Hyperpolarized Xenon129|Lung transplant recipient with hyperpolarized Xe129 in MRI as an inhalation contrast agent
223685270|NCT06477809|DEVICE|ARIA Glasses ( Augmented Reality in Audio )|ARIA stands for Augmented Reality in Audio. The ARIA Device consists of Augmented Reality glasses connected by cord to a dedicated mobile phone that has the ARIA app installed. The glasses include cameras, speakers and an inertial measurement unit. The phone app uses artificial intelligence to convert camera vision from the glasses into a soundscape that includes words and unique sounds identifying specific objects nearby, and an audio rendering of depth that estimates the user's distance from solid matter. This soundscape is delivered to the user via an amplifier that enables volume control and switch-off. The soundscape is designed to augment rather than replace natural hearing, increasing the user's perceptual access to details in the nearby environment.
223685271|NCT06312969|BEHAVIORAL|Video game based training|"Type of intervention: Cognitive training through 3 types of video games:~* Serious games or brain-training games.~* Exer-gaming~* Skill-training games~Method of administration: The patient will receive the treatment for a period of 12 weeks, in which they will commit to use the video games of the intervention with the following pattern:~* Brain-training game: sessions of 7-12 minutes with a frequency of 4 days a week.~* Exer-gaming: sessions of 15-20 minutes 2 days a week.~* Skill-training games: sessions of 15-20 minutes 2 days a week."
223685272|NCT00001860|DRUG|Sandostatin LAR Depot versus transsphenoidal surgery|
224263080|NCT06760312|PROCEDURE|Root canal shaping with Continuous Rotation|The root canal shaping is conducted with a continuous rotation kinematic.
223685273|NCT03505931|DEVICE|Implantation of Eluvia stent|Implantation of Eluvia stent
223685274|NCT00791232|DRUG|extended-release (ER) OROS paliperidone|
224263081|NCT06760312|PROCEDURE|Root canal shaping with Apical Reverse|The root canal shaping is conducted with a apical reverse kinematic.
224263082|NCT06760312|PROCEDURE|Root canal shaping is conducted with Apical slow-down kinematic.|The root canal shaping is conducted with a apical slow-down kinematic.
224263083|NCT07068074|PROCEDURE|Wide local Excision|A wide local excision (WLE) is a surgical procedure performed to cut out an abnormal lesion and some surrounding normal tissue.
224263084|NCT07068074|PROCEDURE|Sentinel Lymph Node and Wide Local Excision|A wide local excision (WLE) is a surgical procedure performed to cut out an abnormal lesion and some surrounding normal tissue. This is sometimes followed by a sentinel lymph node (SLN) biopsy, in which lymph nodes that cancer cells could spread to are removed as well.
224263085|NCT07067918|OTHER|Upper Body Plyometric Training|"Upper Body Plyometric Training - Intervention Description:~A 12-week upper-body plyometric training protocol designed to enhance explosive upper-extremity power in elite male kickboxers. Exercises included medicine ball chest passes, overhead throws, plyometric push-ups, clap push-ups, and rotational medicine ball throws. Training was performed three times per week (20-30 minutes per session) in addition to regular kickboxing practice."
224263086|NCT07067918|OTHER|Lower Body Plyometric Training|"Lower Body Plyometric Training - Intervention Description:~A 12-week lower-body plyometric training program targeting explosive leg strength and anaerobic performance in elite male kickboxers. The program included countermovement jumps, squat jumps, lateral hurdle jumps, plyometric bounding, tuck jumps, and depth jumps. Sessions were conducted three times per week (20-30 minutes each), alongside regular kickboxing training."
224263087|NCT07067489|BEHAVIORAL|Balneotherapy|Participants receive 20-minute balneotherapy sessions involving full-body immersion in thermal-mineral spring water at a therapeutic spa facility. Sessions are conducted five days per week over a three-week period. Water temperature and mineral content are standardized according to institutional protocols. The intervention is designed to provide analgesic, anti-inflammatory, and muscle-relaxant effects through thermally induced vasodilation and neuromuscular modulation.
224263088|NCT07067489|BEHAVIORAL|Whole-Body Vibration Exercise|"Participants perform whole-body vibration (WBV) exercises using the Compex Winplate platform (Uniphy Elektromedizin GmbH \& CoKG), certified under ISO 9001:2000 and DIN EN ISO 13485:2003. The exercise protocol includes static squats, dynamic squats, bridge exercises, dynamic weight shifting, and toe raises. Vibration is applied at a frequency of 30-40 Hz and amplitude of 2-4 mm for 40-60 seconds per set, with two sets per session and a 3-minute rest between sets. WBV is applied following a standardized exercise program, and the full intervention is delivered five days per week for three weeks."
224263089|NCT07069231|DEVICE|the test group were placed in an Argon plasma reactor|the test group were placed in an Argon plasma reactor
224263090|NCT03656536|DRUG|Pemigatinib|Pemigatinib at the protocol-defined dose administered orally once daily as continuous therapy schedule (a cycle is 3 weeks).
224263091|NCT03656536|DRUG|Gemcitabine|Gemcitabine 1000 mg/m\^2 administered as an intravenous infusion on Days 1 and 8 of every 3-week cycle for up to 8 cycles.
224263092|NCT03656536|DRUG|Cisplatin|Cisplatin 25 mg/m\^2 administered as an intravenous infusion on Days 1 and 8 of every 3-week cycle for up to 8 cycles.
224263093|NCT06384495|PROCEDURE|REAL-A|one session of 2mA for 20 minutes to the right ventro-lateral cerebellum
224263094|NCT06384495|PROCEDURE|REAL-C|one session of 2mA for 20 minutes to the right ventro-lateral cerebellum
224263095|NCT06384495|PROCEDURE|SHAM|one session of sham tDCS for 20 minutes to the right ventro-lateral cerebellum.
224263096|NCT03862911|RADIATION|palliative radiotherapy|Radiotherapy for patients in the standard arm should follow the principles of palliative radiotherapy as per the individual institution, with the goal of alleviating symptoms or preventing imminent complications. Patients in this arm should not receive stereotactic doses or radiotherapy boosts. Recommended dose fractionations in this arm will include 8 Gy in 1 fractions, 20 Gy in 5 fractions, and 30 Gy in 10 fractions.
224263097|NCT03862911|RADIATION|Stereotactic ablative radiotherapy|"Lung: Tumors 5 cm or less surrounded by lung parenchyma 48 Gy/4#, or 54 Gy/3#, daily or every second day Within 2 cm of mediastinum or brachial plexus 60 Gy/8#, daily~Bone: Any bone 35 Gy/5#, or 24 Gy/2#, daily~Brain: Stereotactic lesions (no whole brain RT) \<2cm 20-24 Gy/1#, once 2-3 cm 18 Gy/1#, once Metastases only: 35Gy/5# to PTV, daily Whole brain + Mets: 35Gy to metastases, daily 20 Gy whole brain, daily~Liver: 54 Gy/3#, every second day~Adrenal/Pancreas: 40 Gy/5# / 35Gy/7#, daily~Lymph Node: 40 Gy/5#, daily"
224263098|NCT06458023|DEVICE|TetraGraph (TM) NMT Monitor|TetraGraph is a unique, EMG-based portable device for quantitative (objective) monitoring of neuromuscular function. It is a precise and easy to use tool for monitoring depth of block, ensuring adequate recovery of muscle function, and aiding the clinician to reduce the incidence of residual block.
224263099|NCT05625399|DRUG|Nivolumab + Relatlimab|Specified dose on specified days
223775359|NCT06529328|OTHER|core stability|"In this study the experimental group will perform core stability exercises 3 times per week for an 8-week period and each session of 30 to 45 minutes, the core stability exercises will work on abdominals and trunk muscles with challenges.Subjects received 25 min conventional therapy in addition to 30 30-minute trunk stabilization exercise program conducted for 3 days\\week on non-consecutive days.~Passive stretching exercises are applied to all tight muscles, including the hamstrings and calf muscles in the lower limb. It is performed five times initially, building up to ten repetitions, stretching for 5 times, and then allowing relaxation for 5time. Strengthening exercises for back, hip, and knee extensor muscles (for 10 minutes)."
223775360|NCT01336478|PROCEDURE|Infusion of donor derived ex-vivo selected NK cells to patients after transplant|Infusion of donor derived ex-vivo selected NK cells to patients after transplant
223685275|NCT02632838|DEVICE|iHealth BP7-Wireless Blood Pressure Wrist Monitor,|The mHealth group will ask to use iHealth BP7-Wireless Blood Pressure Wrist Monitor at home. This monitor is a fully automatic wrist cuff blood pressure monitor that uses the oscillometric principle to measure blood pressure and pulse rate. The monitor works with mobile devices to test, track and share vital blood pressure data. The Bluetooth sync system allows the monitor to send BP measures and pulse rate to patients' mobile devices. The free iHealth app automatically keeps a history of BP data and gives patient the option to share their blood pressure data with their provider. In addition to keep the data on the mobile device, patient also receive a free and secure cloud account. Vital data on the cloud allows patients to access from any computer and to share with their provider.
223775361|NCT01336478|PROCEDURE|Haematology / Blood chemistry sampling|Haematology / Blood chemistry sampling, collection of blood for ancillary lab research
223775362|NCT03812718|DEVICE|Endotracheal tube (ETT)|After induction of anaesthesia patient will be intubated with polyvinyl chloride (PVC) ETT for maintaining intraoperative ventilation. Anaesthesia will be maintained with propofol and the administration rate will be controlled by a feedback loop facilitated by BIS monitoring using the closed-loop anaesthesia delivery system (CLADS). A BIS value of 50 will be used as the target point for induction and maintenance of GA.
223775363|NCT03812718|DEVICE|ProSeal Laryngeal Mask Airway (PLMA)|After induction of anaesthesia ProSeal Laryngeal Mask Airway (PLMA) will be inserted for maintaining intraoperative ventilation. Anaesthesia will be maintained with propofol and the administration rate will be controlled by a feedback loop facilitated by BIS monitoring using the closed-loop anaesthesia delivery system (CLADS). A BIS value of 50 will be used as the target point for induction and maintenance of GA.
223775364|NCT04229719|DRUG|N-acetyl-5-methoxytryptamine|1.2 mg of melatonin powder will place in the osteotomy site before the insertion of the implant.
224263100|NCT05625399|DRUG|rHuPH20|Specified dose on specified days
224263101|NCT05989412|OTHER|Patient health questionnaire-9 via the Your Research application|Both intervention arms will have 4-weekly screening with either lenient follow-up or screening with stricter follow-up for a time period of one year. Data will be collected via an app designed by Your Research which runs on Microsoft Azure server, as the primary of participants' response collection. A dedicated backup system will serve as a secondary data collection.
224263102|NCT04191304|BIOLOGICAL|Benralizumab|Benralizumab solution for injection in an accessorised prefilled syringe (APFS) will be administered subcutaneously (SC) every 4 weeks
224263103|NCT04191304|BIOLOGICAL|Placebo|Matching placebo solution for injection in an APFS will be administered SC every 4 weeks
224263104|NCT05717192|DEVICE|InterVapor®-System|"The InterVapor System uses heated water vapor to ablate the airways and parenchyma within targeted regions of the lung. Lung remodeling occurs after an initial localized inflammatory response and a subsequent healing and repair. The remodeling of the tissue results in reductions in tissue and air volume in the targeted regions of the lung. The remodeled lung tissue does not re-inflate as a result of collateral ventilation.~The lung volume reduction of diseased hyper-inflated lung segments after InterVapor treatment is expected to increase elastic recoil by reducing the most compliant segments of the lung, decompressing segments of healthier lung allowing for alveolar recruitment, and improving the mechanical efficiency of the respiratory muscles. These mechanical changes are anticipated to improve pulmonary function, exercise capacity and quality of life."
224263105|NCT06204991|BIOLOGICAL|ADP-TILIL7|Autologous tumor infiltrating lymphocytes genemodified (by a lentiviral vector) to produce IL-7 upon antigen engagement
224263106|NCT06204991|DRUG|Cyclophosphamide|Lymphodepleting Chemotherapy
224263107|NCT06204991|DRUG|Fludarabine Phosphate|Lymphodepleting Chemotherapy
224263108|NCT06204991|DRUG|Proleukin|IL-2
224263109|NCT06359847|DRUG|ST-1898 tablets|Tablets: 5 mg and 40 mg
224263110|NCT05181982|OTHER|FIT contract with global treatment budget|Several SHI funds have established a contract (duration = at least eight year) with the model hospital for an alternative remuneration / financing of patients treated in the model hospital (FIT hospital, Pfalzklinikum). This contract encourages the model hospital an alternative treatment of their patients (insured with the involved SHI funds), for example fewer inpatient and more outpatient treatment. The contract is based on a global treatment budget (pre-defined fix budget for a specified number of patients independent from the setting of treatment in the hospital).
224263111|NCT00944294|DRUG|binodenoson|30-second intravenous injection (bolus) of binodenoson (1.5 mcg/kg) and a 6-minute intravenous infusion of placebo
224263112|NCT00944294|DRUG|adenosine|30-second intravenous injection (bolus) of placebo and a 6-minute intravenous infusion of adenosine (140 mcg/kg/minute)
224263113|NCT01966666|DRUG|TPI-287 2 mg/m2|2 mg/m2 of TPI-287 diluted with 500mL 0.9% sodium chloride. TPI-287 is a microtubule inhibitor belonging to the taxane diterpenoid (taxoid) family, and specifically to the abeotaxane class.
224263114|NCT01966666|DRUG|TPI-287 6.3 mg/m2|6.3 mg/m2 of TPI-287 diluted with 500mL 0.9% sodium chloride. TPI-287 is a microtubule inhibitor belonging to the taxane diterpenoid (taxoid) family, and specifically to the abeotaxane class.
224263115|NCT01966666|DRUG|TPI-287 20 mg/m2|20 mg/m2 of TPI-287 diluted with 500mL 0.9% sodium chloride. TPI-287 is a microtubule inhibitor belonging to the taxane diterpenoid (taxoid) family, and specifically to the abeotaxane class.
224263116|NCT01966666|DRUG|Placebo|500mL 0.9% sodium chloride.
223685276|NCT04365062|DEVICE|Excimer laser and drug coated balloon|Excimer laser and drug coated balloon
223775365|NCT03027466|BEHAVIORAL|Self-affirmation induction|Participants will be randomly assigned to one of 4 conditions as part of a 2 (Integrated affirmation: Affirmation texts present versus absent) X 2 (Baseline affirmation: questionnaire present versus absent) design (these affirmations are described below). Those in the control condition will receive no changes to the app (standard of care control condition). Booster affirmation: Participants will receive an integrated affirmation every time they spontaneously report experiencing a craving. These will show up in a screen that shows Tips. We will be able to assess how many times participants reported experiencing a craving and thus saw a booster message.
223775366|NCT03251248|DRUG|MSB11455|Subjects will receive MSB11455 either on Period 1 Day 1 or Period 2 Day 1.
223775367|NCT03251248|DRUG|Neulasta|Subjects will receive Neulasta either on Period 1 Day 1 or Period 2 Day 1.
223685277|NCT04365062|DEVICE|Excimer laser and plain balloon|Excimer laser and plain balloon
223685278|NCT04365062|DEVICE|plain balloon and drug coated balloon|plain balloon and drug coated balloon
223685279|NCT02859818|OTHER|therapeutic education program|
223685280|NCT01343901|DRUG|Bevacizumab|Participants with mCRC and having exclusively liver or liver and lung metastases who were receiving bevacizumab as part of first line treatment for potentially resectable liver metastases as per treating physician's discretion will be observed. All concomitant medications as used in routine clinical practice are allowed.
223775368|NCT05004922|OTHER|Embryo transfer into upper cavity|Transfer of embryos in upper cavity
223775369|NCT05004922|OTHER|Embryo transfer into midcavity|Transfer of embryos in mid cavity
223775370|NCT03378596|DIETARY_SUPPLEMENT|L-citrulline + L-arginine|L-citrulline + L-arginine - sachet dissolved in water
223775371|NCT03378596|DIETARY_SUPPLEMENT|L-arginine|L-arginine - sachet dissolved in water
223775372|NCT03378596|DIETARY_SUPPLEMENT|L-citrulline|L-citrulline - sachet dissolved in water
223775373|NCT03378596|DIETARY_SUPPLEMENT|Placebo|Placebo (corn starch) - sachet dissolved in water
223775374|NCT00627406|DRUG|Buserelin and Pregnyl|Subcutaneous injection 0.5 mg and 1500 IU
223685281|NCT06194019|DEVICE|lung ultrasonography|N-terminal pro-brain natriuretic peptide (NT-proBNP) as a biomarker for detection volume overload.
223685282|NCT02810340|BIOLOGICAL|Adjuvanted MCV-5|Contains 5 μg each of N. meningitidis A, C, Y, W, and X polysaccharides, 2.42 mg sucrose, 0.40 mg sodium citrate, 0.098 mg tris (trometamol), 7.8 to 33.4 μg tetanus toxoid, 11.7 to 50.1 μg cross reactive material of diphtheria toxin (CRM), and 125 μg Al3+adjuvant.
223685283|NCT02810340|BIOLOGICAL|Non-Adjuvanted MCV-5|Contains 5 μg each of N. meningitidis A, C, Y, W, and X polysaccharides, 2.42 mg sucrose, 0.40 mg sodium citrate, 0.098 mg tris (trometamol), 7.8 to 33.4 μg tetanus toxoid, and 11.7 to 50.1 μg cross reactive material of diphtheria toxin (CRM).
223685284|NCT02810340|BIOLOGICAL|Menactra®|Menactra® vaccine was a clear to slightly turbid solution supplied in a 0.5 mL single dose vial. Each 0.5 mL dose of vaccine was formulated in sodium phosphate buffered isotonic sodium chloride solution to contain four mcg each of meningococcal A, C, Y, and W-135 polysaccharides conjugated to approximately 48 μg of diphtheria toxoid protein carrier and residual amounts of formaldehyde of less than 2.66 μg (0.000532%), by calculation.
223685285|NCT05249335|DRUG|OST|The subject will receive Orafang for colonoscopy
223685286|NCT05249335|DRUG|2L-PEG/Asc|The subject will receive 2L-PEG/Asc for colonoscopy
223685287|NCT05523687|DRUG|[14C]-PC14586|Single, oral dose of \[14C\]-PC14586
223685288|NCT03468569|OTHER|Functional Movement Screen|
223685289|NCT05880823|DEVICE|Synergy cervical disc system|motion preservation disc
223775375|NCT00627406|DRUG|Pregnyl|Subcutaneous injection 5000 IU
223685290|NCT04077476|BEHAVIORAL|Online Yoga + Facebook|Each week, the research team will post a prompt for discussion to encourage participation. Prompts will be developed in the beginning stages of the project based on data from the current R34 study and with guidance from consultant Waibel. Participants will be encouraged to post about their experiences with the intervention and stillbirth (emotional support), share resources, (informational support), and offer feedback and advice (appraisal support). Participants will not be required to adhere to certain criteria for engagement (e.g., number of posts, etc.), other than their weekly log in. This is to account for different types of engagement when using social networking as a means of support (e.g., posting, just reading); the benefits of each type of engagement are person-specific. The page will be moderated by members of the research team, who will post prompts and ensure content is updated and appropriate. No members can be added to the group without approval from the research team.
223775376|NCT00627406|DRUG|Buserelin and Pregnyl|Subcutaneous injection 0,5 mg and 1500 IU + 1500 IU after 7 days
223775377|NCT00627406|DRUG|Pregnyl|Subcutaneous injection 5000 IU
223775378|NCT01334931|RADIATION|Large field of view arm|Patients will be allocated in the large field of view arm. Coronary angiography will be performed with large field of view lens (25 cm)
223775379|NCT01334931|RADIATION|Medium field of view|Patients will be allocated in the medium field of view arm. Coronary angiography will be performed with medium field of view lens (20 cm)
223775380|NCT01067703|PROCEDURE|Remote Ischemic Preconditioning|RIPC will be induced during anesthesia by four 5-min cycles of upper limb ischemia and 5-min reperfusion using a blood-pressure cuff inflated to a pressure 200 mm Hg, whereas the pressure has to be at least 20 mm Hg greater than the systolic arterial pressure measured via the arterial line.
223775381|NCT01067703|PROCEDURE|Control/sham procedure (blood pressure cuff)|Sham placement of the blood pressure cuff around a dummy arm inflated to a pressure of 200 mm Hg with four cycles of 5 min inflation and 5 min deflation.
223775382|NCT01898793|DRUG|Fludarabine|
223775383|NCT01898793|DRUG|Cyclophosphamide|
223775384|NCT01898793|PROCEDURE|Leukapheresis|
223775385|NCT01898793|BIOLOGICAL|Cytokine-induced killer cells|
223775386|NCT01898793|BIOLOGICAL|IL-2|
223775387|NCT01898793|DRUG|ALT-803|
223775388|NCT01898793|PROCEDURE|Peripheral blood for correlative studies|-Screening, Day 0 prior to CIML NK infusion, Day 1, Day 3, Day 7, Day 8, Day 10, Day 14, Day 21, Day 28, Day 42, Day 60, Day 100, 6 months, 9 months, 12 months, and at disease relapse
223775389|NCT01898793|PROCEDURE|Bone marrow for correlative studies|-Screening, Day 8, Day 14, Day 28, Between Day 42 and 60, Day 100, at disease relapse
223775390|NCT05596526|BIOLOGICAL|recombinant zoster vaccine|Shingrix® vaccine will be administered in two vaccinations on Day0 and Day60
223775391|NCT02240888|BIOLOGICAL|0,5 mg Prevenar i.m.|
223775392|NCT02240888|BIOLOGICAL|0,5 mg seasonal influenza vaccine i.m.|
223775393|NCT02367313|DRUG|Vapendavir|Vapendavir 264 mg twice daily
223775394|NCT02367313|DRUG|Vapendavir|Vapendavir 528 mg twice daily
223775395|NCT02367313|DRUG|Placebo|Placebo twice daily
223775396|NCT06449573|OTHER|Exercise capacity|cardiopulmonary exercise test used assessment of exercise capacity
223775397|NCT04551105|DIAGNOSTIC_TEST|Reader Group X - Session 1|"Each rater in Reader Group X will interpret the dataset A cases in different random order without BR-USCAD DS and interpret the dataset B cases in different random order with BR-USCAD DS."
223775398|NCT04551105|DIAGNOSTIC_TEST|Reader Group Y - Session 1|"Each rater in Reader Group Y will interpret the dataset A cases in different random order with BR-USCAD DS and interpret the dataset B cases in different random order without BR-USCAD DS."
223775399|NCT04551105|DIAGNOSTIC_TEST|Reader Group X - Session 2|"Each rater in Reader Group X will interpret the dataset A cases in different random order with BR-USCAD DS and interpret the dataset B cases in different random order without BR-USCAD DS."
223775400|NCT04551105|DIAGNOSTIC_TEST|Reader Group Y - Session 2|"Each rater in Reader Group Y will interpret the dataset A cases in different random order without BR-USCAD DS and interpret the dataset B cases in different random order with BR-USCAD DS."
223775401|NCT06333626|DIETARY_SUPPLEMENT|multi-vitamin carbohydrate|oral multi-vitamin carbohydrate beverage
223775402|NCT01035879|DRUG|MBX-2982|tablets and capsule once daily
223775403|NCT01035879|DRUG|MBX-2982|tablets and capsule once daily
223685291|NCT04077476|BEHAVIORAL|Online Yoga|Participants will complete a series of videos covering basic poses and safety techniques, tracked using the Wistia plugin software. Once complete, they will be able to access the library of pre-selected classes (range in time from 10-90 minutes). Participants will be asked to complete at least 60 minutes of yoga per week; participants may choose any classes to yield 60 minutes. Preliminary data from the current R34 study suggests 60 minutes is a feasible amount of time for yoga participation. There is no upper limit to the number of minutes participants can complete.
223685292|NCT02261025|DRUG|acetylsalicylic acid|75-100mg,per day
223685293|NCT02251522|DEVICE|ConforMIS Total Knee Replacement System|Total knee replacement system using a patient specific implant.
223685294|NCT02251522|DEVICE|Off-the-Shelf Knee Replacement System|Total knee replacement system not using a patient specific implant.
223685295|NCT03945175|DRUG|MYDAYIS|MYDAYIS treatment will be given at a minimum dose of 12.5mg/day and will increase in increments of 12.5mg, up to 37.5mg, based upon clinical response and tolerability.
223685296|NCT03945175|DRUG|Placebo|During the two-week, placebo lead-in, all patients will receive 12.5mg of placebo at Visit 1 and Visit 2.
223685297|NCT04252833|DRUG|CT-044|CT-044 HCl is a reactive species decomposition accelerant
223775404|NCT01035879|DRUG|MBX-2982|tablets and capsule once daily
223775405|NCT01035879|DRUG|Sitagliptin|tablets and capsule once daily
223685298|NCT00122733|DRUG|loxapine|
223685299|NCT00688207|DRUG|Rosiglitazone (Extended Release)|open-label, single, oral, 4mg dose
223685300|NCT01983150|BEHAVIORAL|Crush the Crave Application|Crush the Crave (CTC) allows users to customize a quit plan by choosing a quit date and then deciding whether to quit now or cut down the number of cigarettes they smoke every week up to the quit date. CTC reminds users of money saved and health improvements. Based on contingency reinforcement, rewards are provided, which smokers can then choose to share with their social network via Facebook. Supportive text messages tailored to their specific quit plan and where they are in the quitting experience are provided. CTC allows tracking of daily smoking habits and cravings as well as craving triggers or psychosocial determinants by recording when, where and why smoking occurred. Online distractions to help smokers deal with cravings are provided.
223685301|NCT01983150|BEHAVIORAL|On the Road to Quitting - Self Help|"The control group will receive an evidence-based self-help guide known as On the Road to Quitting that has been developed by Health Canada for young adult smokers. Participants will be able to both view the self-help guide via the internet and will receive a printed version of the guide."
223685302|NCT03917433|BEHAVIORAL|Virtual Reality Exposure Therapy|Participant completes virtual reality exposure therapy for acrophobia involving walking across a plank at higher and higher levels in a virtual city environment.
223685303|NCT03917433|BEHAVIORAL|Tactile Feedback|In the real world, the participant walks across an actual wooden plank on the floor, which mirrors the plank in the virtual world.
223685304|NCT03917433|BEHAVIORAL|Point-based Rewards|Participant has the opportunity to pop balloons upon reaching the ends of the plank to gain points. Participant's popping instrument in the virtual world upgrades as more points are accumulated.
223685305|NCT01536275|OTHER|Late parenteral nutrition|Withholding parenteral nutrition during the first 7 days of ICU stay
223775406|NCT01035879|DRUG|placebo|tablets and capsule once daily
223775407|NCT03128749|BEHAVIORAL|Mindfulness Based Intervention|"The mindfulness based intervention protocol used in this project is adapted from the original and validated MBCT program for depression (Segal, Williams \& Teasdale, 2002). Two more sessions, focused on obsessive symptoms specfic to each participant, will be included. Those two sessions will be adapted from the manual The Mindfulness Workbook for OCD (Hershfield and Corboy, 2013)."
223775408|NCT03128749|DRUG|Treatment as Usual|The psychiatric referee will follow OCD guidelines modifying or potentiating drug treatments if needed.
223775409|NCT01243385|DRUG|Metformin|Metformin Lifelong follow-up at a target dose of 2 x 1000 mg daily Until progression, unacceptable toxicity or refusal
223685306|NCT05860374|DRUG|Recombinant oncolytic herpes simplex virus type 1 (R130)|R130, a modified herpes simplex virus-Ⅰ (HSV-1) containing the gene coding for anti-CD3 scFv/CD86/PD1/HSV2-US11
223685307|NCT03716570|DRUG|BIIB054|Administered as specified in the treatment arm.
223685308|NCT03716570|DRUG|Placebo|Administered as specified in the treatment arm.
223685309|NCT02088515|DRUG|Nedaplatin|
223685310|NCT02088515|DRUG|Cisplatin|
223685311|NCT02088515|DRUG|Docetaxel|
223685312|NCT00870233|BEHAVIORAL|online platform WEBCORE|Enrollees will be sent weekly email reminders to login to WEBCORE from home. Participants will be expected to complete the questionnaire once pre-operatively and then weekly starting 7 days after surgery until the 6-week post-operative period has ended.
223685313|NCT04110600|OTHER|Coffee effect on early gastric motility|this group 100ml coffee after two hours
223685314|NCT04110600|OTHER|Efficacy pepper mint oil on motility|This group 100me pepper mint oil after 2 hours
223685315|NCT00825773|DEVICE|Percutaneous Transluminal Coronary Angioplasty|Patients will be randomly assigned (2:1) to one of two treatment arms (the Excel DES or the Cypher DES). Randomization will be stratified by study site and number of vessels intended to be treated by the site investigator. Randomization will be accomplished through use of envelope randomization at the sites using the pre-assigned envelope randomization system. The study patient is considered enrolled upon randomization.
223685316|NCT06421818|DRUG|Baitouweng Tang|Baitouweng Decoction is composed of four herbs: Baitouweng, Rhizoma coptidis, Phellodendri huangbai and Qin Pi.
223685317|NCT06421818|OTHER|Placebo|The same volume and color as Baitouweng Decoction.
223685318|NCT00004644|DRUG|acyclovir|
223685319|NCT05999942|DRUG|Liposomal Amikacin for Inhalation|Administered via the Pari LC STAR™ nebulizer.
223685320|NCT03291418|DRUG|ATB-346 OR Placebo|Comparison of gastrointestinal effects
223775410|NCT04108039|DRUG|GnRh antagonist|In the antagonist cycle, LH suppression will be accomplished by subcutaneous (SC) injections of 0.25 mg of Cetrorelix or Ganirelix starting in the presence of follicles \>14mm or E2 levels \>400 pg/ml and continuing until ovulation triggering to avoid LH surge in COS
223685321|NCT03291418|DRUG|Naproxen sodium|Comparison of gastrointestinal effects
223685322|NCT03221764|DRUG|Amiodarone with CoSeal|CoSeal Surgical Sealant (Baxter Healthcare) consist of 2 formulations of synthetic polyethylene glycols, a dilute hydrogen chloride solution along with a sodium phosphate/sodium carbonate solution. These separate solutions are mixed at the time of application to form a hydrogel. Amiodarone hydrochloride powder (1mg/kg) will be mixed with CoSeal at the time of application to form an amiodarone containing hydrogel. The dosing of amiodarone is based on previous study using amiodarone hydrogel in post-operative coronary artery bypass patients \[8\]. This hydrogel will be delivered utilizing a CO2 driver along the pulmonary vein and arterial anastomoses, and to the surface right and left atria.
223685323|NCT03221764|DEVICE|CO2 driver|The amiodarone hydrogel will be delivered utilizing a CO2 driver along the pulmonary vein and arterial anastomoses, and to the surface right and left atria.
223685324|NCT00349271|PROCEDURE|Stem cell|Stem cell
223685325|NCT00349271|DRUG|Filgrastime (G-CSF)|Filgrastime (G-CSF)
223775411|NCT04108039|DRUG|Micronized progesterone|Micronized progesterone protocol to avoid LH surge in COS, from stimulation day 1 and continuing until ovulation triggering.
223775412|NCT01769157|DRUG|L-carnitine|
223775413|NCT01769157|DRUG|Placebo|
223685326|NCT00349271|DRUG|Standart therapy|All drug with clinical evidence of benefical effect in Chagas disease
223685327|NCT01723696|DIETARY_SUPPLEMENT|Vitamin C +prenatal vitamin|Pregnant smoking women will be randomized to daily vitamin C (500 mg) versus daily placebo
223685328|NCT01723696|DIETARY_SUPPLEMENT|Placebo tablet+prenatal vitamin|
223685329|NCT01768247|DRUG|HCG (human chorionic gonadotropin)|150 international units (IU) of HCG for seven days subcutaneously concomitantly with estrogens in preparation endometrium cycles fro frozen embryos replacement
223685330|NCT00378079|OTHER|Counseling Only|Counseling only in prison, with passive referral to drug abuse treatment upon release
223685331|NCT00378079|DRUG|Counseling + Transfer|Counseling only in prison, with opportunity to enter methadone maintenance upon release
223685332|NCT00378079|DRUG|Counseling + Methadone|Counseling and methadone maintenance in prison, with opportunity to continue that treatment upon release
223685333|NCT05658523|BIOLOGICAL|Bivalent Moderna|A single standard dose of the bivalent Moderna (mRNA-1273.214) COVID-19 vaccine containing equal amounts of mRNAs (25μg of each mRNA sequence) that encode the prefusion stabilized spike glycoproteins of the ancestral SARS-CoV-2 (Wuhan-Hu-1) and the Omicron variant (B.1.1.529 \[BA.1\]) with mRNAs encapsulated in lipid nanoparticles, will be administered on day 0 of the study.
223685334|NCT05658523|BIOLOGICAL|Novavax|A single dose of Novavax contains 5μg of SARS-CoV-2 spike protein and is adjuvanted with Matrix-M. Adjuvant Matrix-M contains, per 0.5 mL dose: Quillaja saponaria saponins fraction A (42.5 micrograms) and Quillaja saponaria saponins fraction C (7.5 micrograms), will be administered on day 0 of the study.
223685335|NCT02902679|DRUG|BMS-986177|
223685336|NCT03905447|DRUG|PC945|Nebulized PC945 5mg OD for 28 days with an optional extended treatment period of a further 56 days.
223685337|NCT03905447|DRUG|Standard of Care|Standard of Care antifungal medication
223685338|NCT05447221|DIAGNOSTIC_TEST|The diagnosis of Artificial Intelligence and pathologists|Pathologists and AI will assess the severity of intestinal metaplasia and judge the tumor area of whole slide images of gastric biopsy specimens independently. In addition, the pathologists can not see the diagnosis of AI.
223685339|NCT04551339|DIETARY_SUPPLEMENT|PreserVision AREDS formulation soft gels or tablets|Two tabs taken daily for three months
223685340|NCT04551339|DIETARY_SUPPLEMENT|Multivitamin with 11mg of zinc|One tab taken daily for three months
223685341|NCT00003395|DRUG|arsenic trioxide|
223685342|NCT03486275|DEVICE|Hygie|Prototype video game called Hygie, accessible on the Internet, on the 5 most common reasons of consultation in general practice using 9 articles from independent journals based on evidence (reviews by Prescrire and Minerva).
223685343|NCT03486275|DEVICE|Source articles|9 articles from independent journals based on evidence (reviews by Prescrire and Minerva), about the 5 most common reasons of consultation in general practice, accessible on the Internet.
223685344|NCT02982278|BEHAVIORAL|Community-based Intervention under Nurse Guidance after Stroke|CINGS is a 12-week nurse coordinated, Community Health Worker intervention structure. Intervention home visits will be conducted by the CHW and will include home-based training in self-care and self-management strategies alongside strategies to address risk of negative stroke outcomes that will be determined once these risk factors are identified and community-engaged approaches to their resolution derived. CHW efforts will be guided via televideo interactions with nurse coordinator. During home-visits, self-reported assessments will be collected via RedCap as well as assessments collected by the CHW and research nurse (weight, blood pressure, medication adherence). After baseline, participants randomized to the intervention group will have home visits, once a week for the first month, and biweekly for the other two months, conducted by the CHW. Additionally, there will be post-intervention follow-up assessments at 3, 6, and 12-month time intervals.
223685345|NCT01432210|OTHER|Post-prandial Feeding Study|
223685346|NCT00264862|PROCEDURE|DynaCT|
223685347|NCT03229460|OTHER|standard low flow therapy|In the standard low flow therapy oxygen group, oxygen at a flow rate of 10 liters per minute or more.
223685348|NCT03229460|DEVICE|high flow nasal oxygen therapy|The patient will receive high flow nasal of humidified oxygen, set between 30 to 60 l/min. The inspired fraction of oxygen (FiO2) will be adjusted in order to obtain a SpO2 \>92%.
223685349|NCT03229460|DEVICE|association of high flow nasal oxygen therapy and non invasive positive pressure ventilation|The patient will receive successively in a day NPPV and O2-HFN. The NPPV will be applied with an airway humidification achieved by using a heated humidifier and a facial mask adapted to the morphology of the patient. The settings will be adjusted as follow : an inspiratory pressure between 6 to 14 cmH2O, in order to obtain a tidal volume between 7 to 10 ml/kg of predicted weight, a positive expiratory pressure between 0 to 10 cmH2O in order to obtain a SpO2 \>92% with the minimal FiO2.
223685350|NCT01063777|OTHER|A 12 week exercise therapy program and patient education.|"The exercise protocol includes exercises from former studies on comparable patient populations. The intensity of the strength- and flexibility exercises meets the American College of Sports Medicine's (ACSM) recommendations for developing and maintaining muscular fitness in adults.Patients will be required to exercise for 60 minutes, three days a week for 12 weeks. Patient's attendance to the exercise program (compliance) will be registered by the physical therapists.~All patients included in the study will receive two individual and three small-group (6-7 patients) sessions lasting one hour each time."
223685351|NCT01063777|OTHER|Patient education|All patients included in the study will receive two individual and three small-group (6-7 patients) sessions lasting one hour each time.
223685352|NCT03680469|BEHAVIORAL|standard early rehabilitation|The standard early rehabilitation program is an intervention regularly utilized in the stroke center of National Taiwan University Hospital. Activities performed in the standard early rehabilitation program within 24-72 hours of onset include(1) bed exercises including the joint range of motion exercise, bridge exercise, the straight leg raising exercise, stretching exercises, and facilitation techniques, and (2) functional training in which the patients are instructed to engage in the repetitive and systematic practice of tasks, such as rolling or sitting supported on the bed.
223685353|NCT03680469|BEHAVIORAL|adding early out-of-bed mobilization|Early mobilization treatment involving out-of-bed, task-specific activities including rolling and sitting up, sitting unsupported out of bed, and standing within 24-72 hours of onset and accounting for more than two thirds of the treatment time in early rehabilitation .
223685354|NCT05982067|OTHER|mindfulness-based phsycial exercise intervention|The intervention is 12 weeks, two times a week. The MIPE intervention will be conducted in a hybrid way, a combination of face-to-face and at home, by a qualified mindfulness therapist and a qualified sport coach. Specifically, the participants will attend the face-to-face sessions once every two weeks and in other weeks, they will perform the intervention at home using videos and templates. The face-to-face sessions will be conducted at the health care centre. The intervention of each session will include 1) introduce the theme of this session, 2) mini lectures about the theme; 3) mindfulness practice related to the theme; 4) tips of keeping mindfulness during PE; 5) warm up: lead with mindfulness words; 6) resistance exercise; 7) cool down: lead with mindfulness words; 8) discussion.
224263117|NCT04325139|OTHER|Questionnaire|Before colonoscopy, the following information was obtained by the colonoscopists through asking patients: the characteristics of last stool, the time of drinking first dose of laxative, the time of first defecation, the time of drinking last dose of laxative. The beginning time of colonoscopy was also recorded. During withdrawal phase, the quality of bowel preparation was evaluated based on BBPS scale.
224263118|NCT04723134|COMBINATION_PRODUCT|Folinic acid calcium salt|Folinic acid (2.5%) by combination with Placebo
223685355|NCT05982067|OTHER|health education|The number of sessions, duration, frequency, group size and delivery modality will be similar to the intervention group. The topics of the health education are the care of common diseases in the older adults, including hypertension, diabetes, osteoporosis, COPD, dementia, depression. Each session is about 70 min (same as intervention group), including 10-20 min lecture and 50-60 discussion and sharing.
223685356|NCT02551952|DEVICE|MentalPlus®|Validate the MentalPlus® digital game as neuropsychological test of cognitive assessment pre and postoperative on study the internal consistency and validity of content and construct (convergent) MentalPlus® of the evaluated patients. Study the influence of age, gender and level of education of surgical patients in performance for the use of electronic devices (laptop, tablet, mobile) and digital games. Investigate the rehabilitation capacity of cognitive functions after training sessions with MentalPlus® game. Evaluate the effect of training with MentalPlus® game in brain networks involved in executive function, memory and attention by means of fMRI this is a brain imaging study.
223685357|NCT01897376|PROCEDURE|Pfannenstiel incision|Pfannenstiel incision at time of cesarean section
223685358|NCT01897376|PROCEDURE|vertical skin incision|vertical skin incision at time of cesarean section
223685359|NCT03895762|DRUG|Abstral Oral Disintegrating Tablet (ODT)|Opioid(Fentanyl)
223685360|NCT03219463|DIETARY_SUPPLEMENT|Ginger|3g ginger powder supplement once a day with meals (preferably in the morning) for a duration of 8 weeks. Powder can be mixed with juice or water.
224263119|NCT00003003|BIOLOGICAL|sargramostim|
223685361|NCT01500343|DRUG|Saccharomyces boulardii|1 gram per day, during 3 months
223685362|NCT01233687|DRUG|AMG 102 and erlotinib|"Dose Level -2 Dose level -1 Dose Level 0 AMG 102 5 mg/kg 7.5 mg/kg 15 mg/kg Erlotinib 150 mg 150 mg 150 mg~The first cohort of patients in the phase I portion will start at dose level 0 of AMG102."
223685363|NCT00876603|PROCEDURE|ACDF|Anterior cervical decompression and fusion
223685364|NCT00876603|PROCEDURE|Cervical laminoplasty|Cervical laminoplasty
224263120|NCT00003003|DRUG|mitomycin C|
224263121|NCT00003003|DRUG|mitoxantrone hydrochloride|
224263122|NCT06463041|OTHER|Experimental, comparator and control|How does implementing a GetUp Assist device in addition to a daily low-intensity functional or traditional training program affect Norwegian female office workers' physical health after 12 weeks?
224263123|NCT01815320|PROCEDURE|Contrast-enhanced ultrasound (CE-US)|
224263124|NCT01815320|DEVICE|SonoVue|
224263125|NCT00006376|DRUG|chemotherapy|
224263126|NCT00006376|DRUG|tipifarnib|
224263127|NCT00002764|BIOLOGICAL|filgrastim|
224263128|NCT00002764|DRUG|doxorubicin hydrochloride|
224263129|NCT00002764|DRUG|ifosfamide|
224263130|NCT00002764|PROCEDURE|conventional surgery|
224263131|NCT03428750|BIOLOGICAL|EN3835|Collagenase clostridium histolyticum
224263132|NCT03428750|BIOLOGICAL|Placebo|Placebo
224263133|NCT06182722|DIAGNOSTIC_TEST|Mental assessments|Patients will receive psychiatric rating scales evaluation every visit.
224263134|NCT04547192|OTHER|Improving initial care of the injured|Improvement in Care Processes
224263135|NCT05213286|DIAGNOSTIC_TEST|Application of ZAQ and RAADS-R-DK|Test of the questionnaires in each of the three groups.
224263136|NCT04981704|DRUG|Poziotinib|Poziotinib Tablets
224263137|NCT04981704|DRUG|Itraconazole|Itraconazole Oral solution
224263138|NCT04981704|DRUG|Phenytoin|Phenytoin Capsules
224263139|NCT04981704|DRUG|Paroxetine|Paroxetine Tablets
224263140|NCT06433388|DEVICE|MRI|Magnetic Resonance Imaging (MRI) is a non-invasive imaging technology that produces three dimensional detailed anatomical images. Patients will be subjected to MRI scans and imaging of the kidneys and liver
224263141|NCT04723693|OTHER|Qualitative Interview|A single one hour semi structured qualitative interview
224263142|NCT03953703|DRUG|Levocarnitine|Levocarnitine 1000 mg twice per day for 6 weeks
224263143|NCT03953703|DRUG|Placebo|Placebo 1000 mg twice per day for 6 weeks
224263144|NCT03969628|DIAGNOSTIC_TEST|ICCMS|Risk caries assessment will consider ICCMS criteria
224263145|NCT05751993|BEHAVIORAL|ADAPT|The intervention is testing the feasibility of a reinforcement learning model to pull in participants' behavioral data (calories, activity, and weight) and use this data along with participants' past behavioral goal achievements to deliver the type of message that should be most effective for a given participant at a given time. At each decision point (morning, midday, and evening on a daily basis), the system evaluates which behaviors a participant is eligible to receive a message about (eating, activity, self-weighing), which intervention options a participant is eligible to receive, and then chooses what type of behavioral message a participant should receive. Over time, the model uses participant data and response to interventions to better tailor message choice.
224263146|NCT04862767|DRUG|TASO-001((TGF-β2 targeting anti-sense oligonucleotide)|96 hour continuous infusion
224263147|NCT04862767|COMBINATION_PRODUCT|Aldesleukin|SC, Bid
224263148|NCT00876967|DEVICE|metallic single use blade|metallic single use blade
224263149|NCT00876967|DEVICE|plastic single use blade|plastic single use blade
224263150|NCT00876967|DEVICE|metallic reusable blade|metallic reusable blade
224263151|NCT04692558|BIOLOGICAL|HYALURONIC ACID|Hyaluronic acid will be applied on denuded root surface after reflection of isolated gingival recession.
224263152|NCT04692558|PROCEDURE|coronally advanved flap with connective tissue harvesting|Coronally advanced flap surgery with connective tissue harvesting from palate
224263153|NCT00535912|PROCEDURE|Stem cells autograft|Treatment by Intensive Chemotherapy and autograft
224263154|NCT06467513|DRUG|Esketamine hydrochloride injection|The low dose esketamine hydrochloride group was given 0.2mg/kg at induction of anesthesia, the high dose esketamine hydrochloride group was given 0.4mg/kg at induction of anesthesia, and the blank control group was not given Esketamine hydrochloride injection at induction of anesthesia.
224263155|NCT03319108|OTHER|Exercise|Pulmonary Rehabilitation Program for 8 weeks
224263156|NCT03954808|OTHER|Motor Imagery Training|Motor imagery training will be designed for the individual basis with standard protocols
224263157|NCT03954808|OTHER|Traditional physiotherapy|Traditional physiotherapy within a specific program
224263158|NCT05275699|DRUG|68Ga-FAPI|Intravenous injection of one dosage of 18.5-22.2MBq (0.5-0.6 mCi)/Kg 68Ga-FAPI. Tracer doses of 68Ga-FAPI will be used to image lesions of keloid by PET/CT.
224263159|NCT04432753|BEHAVIORAL|Lung Cancer Screening Decision Aid with Incidental Findings Information|The intervention consists of a previously tested and developed brief lung cancer screening video decision aid with the addition of information on incidental findings for lung cancer screening.
224263160|NCT04432753|BEHAVIORAL|Lung Cancer Screening Decision Aid without Incidental Findings Information|The intervention consists of a previously tested and developed brief lung cancer screening video decision aid that does not include information on incidental findings.
224263161|NCT06649006|DRUG|Blinatumomab|IV infusion
224263162|NCT03497130|OTHER|skin care regimen|These participants will be asked to apply skin care regimen, the Vaseline® Moisturizer twice a day and use Dove® Soap daily for 2 weeks.
224263163|NCT05372744|OTHER|Active Placebo labelled as antidepressant|Participants receive an active nasal spray that is in fact a placebo with a specific framing in regards to its affect-regulatory characteristics, respectively.
224263164|NCT06020430|RADIATION|CTV omitted or delineated|Patients who responded to the induction therapy (immunotherapy and chemotherapy) were randomly (1:1) assigned into CTV-omitted radical radiotherapy group or CTV-delineated radiotherapy group.
224263165|NCT04002648|PROCEDURE|Right minithoracotomy|Incision of the right chest between 3rd and 4th or 4th and 5th intercostal space
224263166|NCT04002648|PROCEDURE|Sternotomy|Longitudinal resection of the sternum
224263167|NCT00158925|DEVICE|EASYTRAK EPI lead|EASYTRAK EPI lead
224263168|NCT00393250|OTHER|Hypnosis|Subjects receive hypnosis (experimental intervention) during 4 weeks of face-to-face encounters with a physician trained in hypnosis. For 6 weeks following the instruction period, the participants will perform daily self- hypnosis using customizable digital media.
224263169|NCT00393250|OTHER|Control|Subjects in the control arm of the study will receive face-to-face education regarding sickle cell disease for the same length and frequency as the treatment group hypnosis encounters before crossing over to the experimental intervention arm of the study
224263170|NCT04474587|OTHER|Indirect calorimetry|Measurements of REE by indirect calorimetry
224263171|NCT04707963|DIETARY_SUPPLEMENT|Peanut protein powder|Peanut protein powder will be provided to participants who will be instructed to consume 72g daily, mixed with water
224263172|NCT04707963|BEHAVIORAL|Full body resistance training|Participants will undergo supervised resistance training two times per week (5 exercises, 3 sets of 8-12 repetitions per set)
224263173|NCT06258746|DRUG|[14C]HSK31679|A single oral dose of 160 mg/100 μCi \[14C\]HSK31679 after fasting for at least 10 hours.
223775414|NCT04198779|DEVICE|APPLI|The support with the digital application is including a 10-minutes training about the use of the digital application at the beginning of the study. Patient will have to register information about their Heart failure disease (weight, shortness of breath, fatigue, mood, cardiologist appointments, blood results, ...). During each routine consultation, patients will be encouraged to use the digital app, and the obstacles encountered will be explored and resolved. In addition, participants will receive an email containing relevant information and, every three months, an email reminder of the use of the application.
223775415|NCT03120091|DEVICE|Real-time continuous blood glucose monitoring system(CGMS)|A total of 20 patients were enrolled for the place of CGMS.CGMS were placed on the right chest wall of each patients and recorded the interstitial glucose. Arterial blood glucose (ABG) were recorded every four hours. The duration of monitoring set was 5 days.CGMS were compared with ABG at the same time point. A total of 600 pairs of glucose level were collected
223775416|NCT04832204|DRUG|Apatinib and Camrelizumab for Injection|Apatinib 250mg, Qd, oral administration,SHR-1210 200mg, q3w one week later, intravenous administration, continuous administration until the disease progresses or an intolerable adverse reaction occurs.
223685365|NCT00846170|DRUG|co-biotic|give probiotic 2 t/day
223685366|NCT00846170|DRUG|placebo 2T/day|cross over of patients from study arm to placebo arm
223685367|NCT00829985|BIOLOGICAL|Glycerinated German Cockroach Allergenic Extract|Concentrated (1:20 w/v) daily doses of glycerinated German cockroach allergenic extract placed under the tongue to dissolve. The extract is also administered during the preliminary dosing visits in up to five escalating doses or until the maximum study dose (420 microliters, 1:20 w/v) is achieved.
223685368|NCT00829985|BIOLOGICAL|Placebo|Daily doses of cockroach allergenic extract placebo placed under the tongue to dissolve
223685369|NCT04112498|DRUG|relatlimab|Specified dose on Specified days
223685370|NCT04112498|DRUG|nivolumab|Specified dose on Specified days
223775417|NCT00745732|DRUG|ZD6474 (ZACTIMA)|ZD6474 (ZACTIMA) beginning at 100 mg once a day by mouth
223775418|NCT00745732|RADIATION|Radiation Therapy|"Phase I: 45 Gy at 3 Gy per fractions once a day.~Phase II: 45 Gy at 3 Gy per fraction once a day or 66-70 Gy at 2 Gy per fraction once a day."
223685371|NCT04112498|DRUG|rHuPH20|Specified dose on Specified days
223685372|NCT06416995|DIAGNOSTIC_TEST|first trimester serum diagnostic test|First trimester serum vasohibin-1, vasohibin-2, cardiotropin-1 and endocan concentrations predict adverse perinatal outcomes
223685373|NCT03631797|PROCEDURE|Microvascular reactivity evaluation|Microcirculation will be evaluated for each patient before surgery with a laser speckle contrast imaging (LSCI) placed on the forearm. Tests will be performed for evaluation of endothelium reactivity: Iontophoresis.
223685374|NCT06254222|OTHER|No intervention|No intervention
223685375|NCT01115582|DRUG|Cholic acid|"The IUPAC name for cholic acid is 3 alpha,7alpha,12 alpha-trihydroxy-5 beta-cholanoic acid. The international nonproprietary name (INN) is cholic acid.~Each patient will be given a box containing a 1 month supply of study drug. Each bottle will contain 90 capsules; each capsule will contain either 50 or 250 mg of manufactured cholic acid depending upon the child's weight. The study drug will be taken orally, in divided doses (as determined by the investigator), for a total daily dose of 10-15 mg/kg body weight. Parents of infants and young children who are unable to swallow the TBM cholic acid capsule will be instructed to sprinkle the contents of the capsule over 1-2 teaspoons of plain applesauce and feed it to the child."
223685376|NCT05089071|DEVICE|Assist by artificial intelligence system for colon polyp detection|Assist by artificial intelligence system for colon polyp detection
223685377|NCT00810927|PROCEDURE|Suction cup application|he IOP will be raised by a 11 mm diameter, standardized suction cup placed on the temporal sclera with the anterior edge at least 1 mm from the limbus.
223685378|NCT00810927|PROCEDURE|Laser Doppler flowmetry|Measurement of choroidal blood flow
223685379|NCT00810927|PROCEDURE|Measurement of intraocular pressure|
223685380|NCT05776602|DIAGNOSTIC_TEST|Fast MRI (Neuromix)|Diagnostic performance, correlation, agreement
223685381|NCT04426760|PROCEDURE|Transcervical resection of fibroids|Transcervical resection of fibroids
223775419|NCT01965067|DRUG|sugammadex|"sugammadex 4.0 mg/kg is administered in deep block state(1 - 2 PTCs) in different temperature state~Reversal effect of sugammadex in temperature state"
223775420|NCT06161909|DRUG|sintilimab|200mg fixed dose Q3W,1 year
223775421|NCT03219944|PROCEDURE|Platelet Rich Fibrin|: Platelet Rich Fibrin for soft tissue augmentation around implant in the aesthetic zone
223685382|NCT04426760|PROCEDURE|Myomectomy per laparoscopy or laparotomy|Myomectomy per laparoscopy or laparotomy
223685383|NCT03324581|DRUG|OPC-64005|OPC-64005 film coated tablets
223685384|NCT03324581|DRUG|Atomoxetine|Atomoxetine gelatin capsules
223685385|NCT03324581|DRUG|Placebo|OPC-64005-matching placebo film coated tablets and atomoxetine-matching placebo gelatin capsules
223685386|NCT00442884|BEHAVIORAL|Trier Social Stress Test (TSST)|
223775422|NCT03219944|PROCEDURE|sub epithelial connective tissue graft|sub epithelial connective tissue graft for soft tissue augmentation around implant in the aesthetic zone
223775423|NCT02066298|DRUG|Mometasone 220mcg BID|Mometasone is an ICS
223775424|NCT02066298|DRUG|Tiotropium Respimat 5mcg QD|Tiotropium is a LMA
223775425|NCT02066298|DRUG|Placebo|
223775426|NCT01963689|OTHER|Intervention Group 2|Massage with Ylang Ylang Essence was applied for 30 seconds on the handle and the sternum area
223775427|NCT01963689|OTHER|Intervention Group 1|Massage with Ylang Ylang essential oil in the wrist and in the region of the sternum
223685387|NCT05106790|BEHAVIORAL|Educational support with peer counseling|This group will receive peer counseling therapy sessions will be led by doctors who specialize in hypertension. Patients and their families will be the focus of the sessions. Face-to-face sessions will take roughly 25-30 minutes. Patients will receive spoken and written instructions based on their abilities during these sessions. The counseling sessions are geared toward overcoming both general and personal obstacles. The educational component will be delivered through smart booklets. Information on hypertension, blood pressure self-monitoring, and frequent systolic blood pressure (SBP) tests, as well as body weight and serum cholesterol values, are included in the instructional support. Food control, exercise therapy, and hypertension problems and their management will also be explored as non-pharmacological therapeutic approaches.
223685388|NCT05106790|BEHAVIORAL|mHealth intervention|"This group will receive mHealth intervention will include daily written and voice messages, and once weekly an educational-led video. This intervention module will be delivered through WhatsApp."
223685389|NCT05106790|BEHAVIORAL|mHealth intervention and Educational support with peer counseling|This group will receive both Educational support (Smart booklets) with peer counseling sessions on a monthly basis and mHealth intervention will include daily written and voice reminders, and once weekly an educational led video.
223685390|NCT03575481|DIAGNOSTIC_TEST|The RAT and The TST|The RAT (ReoGo; Motorika Medical, Caesarea, Israel) The TST protocol included the conventional, repetitive, task-oriented training of the affected arm.
223685391|NCT06400927|OTHER|HF-guided VA|VA guided recommendation
223685392|NCT06400927|OTHER|Standard-of-care|Standard-of-care
223685393|NCT03498664|DEVICE|cap for mucosectomy|endoscopic mucosal resection of colonic lesions with a plastic cap for mucosectomy
223685394|NCT03498664|DEVICE|standard snare for polypectomy|endoscopic mucosal resection of colonic lesions with standard inject and cut mucosectomy
223685395|NCT01203176|PROCEDURE|Hysteroscopic polypectomy|Hysteroscopy is a well established minimally invasive surgery method for diagnostic and intervention operations inside the uterine cavity. Using this method one can observe the endometrium and remove polyps.
223685396|NCT00706069|DRUG|Vinorelbine oral|Vinorelbine at dose levels of 30mg, 40mg, 50mg, 60mg oral every Monday, Wednesday and Friday
223685397|NCT00706069|DRUG|Capecitabine|Capecitabine at dose levels of 800 mg/m2, 950mg/m2, 1100mg/m2, 1250mg/m2 per os from day 1 to day 14 every 21 days
223685398|NCT04340427|DRUG|TQB3455|TQB3455 tablets is a small molecule oral drug inhibiting IDH2 mutation.
223685399|NCT02274038|DRUG|Baseline 18F-thymidine (FLT) PET/CT|FLT is a fluoro-labelled thymidine analog used as a radiotracer of tumor proliferation in PET/CT imaging. This baseline scan will be used to compare post-therapy FLT-PET/CT in order to assess change in tumor accumulation of FLT.
223685400|NCT02274038|DRUG|"Post-therapy 18F-thymidine (FLT) PET/CT to assess for pemetrexed induced tumor FLT flare"|"FLT is a fluoro-labelled thymidine analog used as a radiotracer of tumor proliferation in PET/CT imaging. This scan will be performed on the day of starting pemetrexed therapy (within 24hrs of starting pemetrexed) and used to compare to baseline FLT-PET/CT in order to assess change in tumor accumulation of FLT. The objective is to assess for early pemetrexed induced changes in tumor accumulation of FLT known as FLT flare."
223685401|NCT02274038|DRUG|Post-therapy 18F-thymidine (FLT) PET/CT to assess for pemetrexed induced changes in tumor proliferation|FLT is a fluoro-labelled thymidine analog used as a radiotracer of tumor proliferation in PET/CT imaging. This scan will be performed 2-4 weeks after starting pemetrexed therapy and used to compare to baseline FLT-PET/CT in order to assess change in tumor accumulation of FLT. The objective is to assess for pemetrexed induced changes in tumor accumulation of FLT as a surrogate measure of tumor proliferation.
223685402|NCT03783702|DRUG|OxyCODONE 5 Mg (milligram) Oral Tablet|Oxycodone will be the second-line treatment in the control group and the third-line treatment in the experimental group.
223685403|NCT03783702|DRUG|Ibuprofen 600 Mg (milligram) Oral Tablet|Patients in the experimental group will receive ibuprofen 600mg as the second-line analgesic.
223685404|NCT03783702|DRUG|Acetaminophen 650 MG (milligram) Oral Tablet|All patients will receive acetaminophen as the first-line analgesic.
223685405|NCT04473482|BEHAVIORAL|Michigan Alcohol Improvement Network-Alcohol Reduction and Treatment tool|The intervention corrects misconceptions about alcohol use, liver disease, and alcohol treatment and matches patients to their top three choices of treatment while providing them with brief explanations of each treatment option.
223775428|NCT01963689|OTHER|Intervention Group 3|Put a drop of essential oil of ylang ylang in cotton located within the freshener and inhale throughout their work shift
224263174|NCT06474936|BEHAVIORAL|Food education|During the consultations are planned at least 6 nutritional education sessions in which the general nutritional advice provided by the Mediterranean Diet will be exposed, and some paper materials can be delivered according to the needs of each individual. 3 in-person meetings and 3 online meetings are planned. Both online and in-person food education sessions will be conducted by experienced nutrition experts monthly. These sessions will cover a range of topics, including the principles of the Mediterranean diet, practical cooking skills, meal-planning strategies, and tips for incorporating Mediterranean-style dishes into daily life
223685406|NCT03239028|BEHAVIORAL|Observational|
224263175|NCT05758623|DEVICE|Device|The experimental group was treated with magnesium containing biodegradable polymer bone repair material produced by Shenzhen Zhongke Jingcheng Medical Technology Co., Ltd. Control group application β- Tricalcium phosphate bioceramics for treatment.
223685407|NCT03007069|OTHER|Mineralized plasmatic matrix (MPM).|By using venoud blood from the patient, together with bone graft, a centrifuge will be used to obtain the top layer after centrifuging blood at 3000 RPM, for 10 minutes , Which will result if sticky bone graft consistency after mixing.
223685408|NCT03007069|OTHER|Autogenous bone graft (gold standard).|Exposed implant threads are to be covered with autogenous bone and collagen membrane.
223685409|NCT03704701|DIAGNOSTIC_TEST|Cardiac MRI and contrast-enhanced cardiac CT|Cardiac MRI Contrast-enhanced cardiac CT
223685410|NCT01662414|DIETARY_SUPPLEMENT|Whey protein|1 sachect (10 g) 2times/ day
223685411|NCT01662414|DIETARY_SUPPLEMENT|Soy protein|1 sachect (10g) 2times/day
223685412|NCT05475782|PROCEDURE|Spyglass-guided lithotripsy|Spyglass-guided lithotripsy
223685413|NCT05475782|PROCEDURE|ESWL|ESWL+ERCP
223685414|NCT01030367|DRUG|PETN, ISDN|Oral dosing of organic nitrates PETN 2x 80mg per day ISDN 2x40mg per day
223775429|NCT02670590|BEHAVIORAL|diet|diet
223685415|NCT05352776|DEVICE|AtaCor EV-ICD Lead|Subjects will receive the AtaCor EV-ICD Lead being evaluated in the study.
223685416|NCT02070471|DRUG|Placebo|Placebo
223775430|NCT02393313|PROCEDURE|Cataract surgery|Rayner T-flex Toric IOLs (573T / 623T; Rayner Intraocular Lenses Ltd,East Sussex, United Kingdom) will be implanted in the lens capsule
223685417|NCT02070471|DRUG|LC28-0126 Dose A|LC28-0126 Dose A
223685418|NCT02070471|DRUG|LC28-0126 Dose B|LC28-0126 Dose B
223685419|NCT02070471|DRUG|LC28-0126 Dose C|LC28-0126 Dose C
223685420|NCT00001282|DRUG|Zidovudine (AZT) & Interleukin-2 (IL2)|
223685421|NCT00003171|DRUG|bryostatin 1|
223685422|NCT01212133|DRUG|liraglutide|Self-administered subcutaneously (under the skin) once daily at any time, independent of meals, in the abdomen, thigh or upper arm.
223685423|NCT03699384|DRUG|Azacitidine|AZA 75 mg/m\^2 SC or IV D 1-7 28 day cycle x 1
223685424|NCT03699384|DRUG|Avelumab|Avelumab 10mg/kg IV D1, D15, 28d cycle Until progression or MRD If MRD-, tx x 1 yr or go to allo SCT
223685425|NCT01306877|DEVICE|EEA Hemorrhoid and Prolapse Stapling Set|Surgical device
223685426|NCT01306877|DEVICE|Endosurgery Proximate PPH03 Stapling Set|Surgical device
223685427|NCT04204785|BEHAVIORAL|Noise Reduction Education|OR staff will be offered education regarding the importance of minimizing noise in the OR. There will also be reminder signs and posters for the duration of the post-education period.
223685428|NCT05697978|DEVICE|Monofocal intraocular lens Clareon (Alcon LLC)|monofocal aspheric lens implanted in eyes of patient during routine cataract surgery
223685429|NCT03302520|DEVICE|NovoMax, BioAlpha Inc, Seong-nam, Korea|CaO-SiO2-P2O5-B2O3 glass ceramics spacer
223685430|NCT03302520|DEVICE|PEEK cage|PEEK cage
223685431|NCT00116792|PROCEDURE|Percutaneous Coronary Intervention (PCI)|
223685432|NCT01437800|DRUG|Glimepiride / Extended release Metformin (4/850 mg).|One tablet of Glimepiride/metformin extended release (4/850 mg) was administered as a single oral dose, to all patient in fasting.
223685433|NCT01211587|DRUG|safinamide|Safinamide will be provided in tablets equivalent to 50 mg in blisters. After randomization, patients receiving safinamide will take two 50 mg tablets once per day for 12 weeks (weeks 1-12). During the open label phase, patients will receive 100mg of safinamide once per day (two 50 mg tablets) for 12 weeks (weeks 13-24).
223775431|NCT02393313|DEVICE|Rayner T-flex Toric IOLs|
223775432|NCT01323699|BEHAVIORAL|Cognitive Behavioral Therapy|A modified version of existing Cognitive Behavioral Treatment and Self-management manuals.
224263176|NCT02319655|PROCEDURE|Air tamponade|Air tamponade
224263177|NCT02319655|PROCEDURE|Balanced salt solution filling|BSS filling
224263178|NCT05213624|DRUG|BI 764198|BI 764198
224263179|NCT05213624|DRUG|Placebo|Placebo matching BI 764198
224263180|NCT01339247|DRUG|Paxil CR 25 mg manufactured by SmithKline Beecham (Cork) Limited - Cidra - Puerto Rico|Paroxetine Hydrochloride 25 miligrams(mg) tablet with controlled release (Paxil CR), once a day, manufactured by SmithKline Beecham (Cork) Limited - Cidra - Puerto Rico (reference formulation)
224263181|NCT01339247|DRUG|Paxil CR 25 mg manufactured by GlaxoSmithKline Inc. - Mississauga - Canada|Paroxetine Hydrochloride 25 mg tablet with controlled release (Paxil CR), once a day, manufactured by GlaxoSmithKline Inc. - Mississauga - Canada (test formulation)
224263182|NCT00921674|DRUG|ivermectin|Each subject will receive single doses of (i) 30 ml ivermectin oral solution (30 mg) and (ii) 10 x 3 mg tablets of ivermectin (30 mg) in 2 separate dosing periods. Doses will be administered 20 minutes after a standard breakfast.
224263183|NCT01150422|OTHER|Alternative follow-up|After mifepristone administration, women will be provided with a second semi-quantitative pregnancy test and a self-administered checklist. Women will be instructed to complete the checklist and perform the pregnancy test at home on an assigned data two weeks after mifepristone administration. On the assigned date, women will also be contacted by phone by the clinic staff. Women will be asked to confirm whether they completed the pregnancy test and checklist and asked to report on the results of both tests. Provider will review the women's responses to the checklist and confirm whether, based on the woman's responses, she should return for a follow up visit. During the follow-up phone call, women will also be asked about the satisfaction and acceptability of the alternative follow-up procedure.
224263184|NCT06267339|DEVICE|transcranial random noise stimulation|This intervention will give children tRNS during reaching or grasping repetitive movements.
224263185|NCT06267339|DEVICE|Sham stimulation|This intervention will give children sham stimulation during reaching or grasping repetitive movements.
224263186|NCT05154890|DRUG|Pegtarviliase IV|Administered IV
224263187|NCT05154890|DRUG|Pegtarviliase SC|Administered SC
224263188|NCT02180321|DRUG|Tranexamic Acid|10mg/kg of tranexamic acid loading infusion for 15 min from beginning of the surgery, then continuous infusion throughout the surgery for 5mg/kg/hr
224263189|NCT02180321|DRUG|normal saline|10mg/kg of normal saline loading infusion for 15 min from beginning of the surgery, then continuous infusion throughout the surgery for 5mg/kg/hr
224263190|NCT04159285|BEHAVIORAL|EffEKTiv 2.0 group CBT as continuation treatment after ECT in depressed patients|Group CBT with a maximum number of 8 participants. Group is half-open allowing a starting date right after completion of acute ECT treatment. Patients participate for 15 sessions, which are framed by 2 individual sessions before joining the group and one individual session at treatment end.
224263191|NCT04159285|OTHER|Treatment as usual|Can include continuation ECT, psychopharmacological treatment, individual psychotherapy
224263192|NCT06626607|DRUG|CCB use|Postoperative antihypertensive medication includes CCB
224263193|NCT06626607|DRUG|non-CCB use|Postoperative antihypertensive medication does not include CCB
224263194|NCT05452707|OTHER|Observation and questionnaire of active therapy|There will be an observation of the usual care; no intervention will be added.
224263195|NCT02889107|OTHER|personal frequency modulated systems|patients used personal frequency modulated systems for at least 4 hours daily for 10 weeks
224263196|NCT01883713|DEVICE|Brain Oximetry|Non invasive brain oximeter will be applied on the patient's forehead to monitor the brain oxygen saturation throughout the surgery.
224263197|NCT06023433|DEVICE|Elastomeric powerchain|Canine distalization by engaging the elastomeric power chains onto the canine brackets.
224263198|NCT02897375|DRUG|Carboplatin|Given IV
224263199|NCT02897375|DRUG|Cisplatin|Given IV
224263200|NCT02897375|DRUG|Palbociclib|Given PO
223685434|NCT01211587|DRUG|placebo|Identical placebo tablets will be provided in blisters. After randomization, patients receiving placebo will take two tablets once per day for 12 weeks (weeks 1-12). During the open label phase, patients will receive 100mg of safinamide once per day (two 50 mg tablets) for 12 weeks (weeks 13-24).
223685435|NCT01859104|BEHAVIORAL|Use of smartphone app|
223685436|NCT00004727|DRUG|aspirin|
223685437|NCT00004727|DRUG|ticlopidine|
223685438|NCT03754192|RADIATION|perfusion Computed Tomography|Will be carried before liver surgery
223685439|NCT05840029|PROCEDURE|VIDEO-ASSISTED THORACOSCOPIC SURGERY|A minimally invasive approach, to not only drain the pleural effusion but also evaluate macroscopic pleural disease and, when possible, resect gross tumor.
223685440|NCT00474656|DEVICE|High-frequency oscillation|
223685441|NCT00474656|DEVICE|Conventional lung-open mechanical ventilation|
223685442|NCT06066801|PROCEDURE|Bedside blind bone biopsy procedure|It was performed in the patient's room under aseptic conditions. Pain relievers were given orally within the hour preceding the procedure. Superficial anesthesia was performed firstly subcutaneously and then on the periosteum, Inhaled anesthesia was started concomitantly. Following a short incision with a scalpel, the trocar inside a cannula was inserted through healthy skin at a minimum distance of 2 cm from the ulcer edge, close to the bone, preferentially on dorsal foot side. When the trocar was firmly inserted into the bone, it was pulled out from the cannula. Biopsy needle was then slipped into the cannula and twisted into the bone clockwise. Biopsy needle was then pulled out and the bone was pushed out with the ejector pin into a sterile surgical drape and divided in two parts.
223685443|NCT00539097|DIETARY_SUPPLEMENT|Juven (Ross Products) protein supplement|Juven supplement oral x 3 weeks postop
223685444|NCT06283927|PROCEDURE|Re-resection|Resection of the recurrent tumor
223685445|NCT06283927|DRUG|Temozolomide|Re-challenge Temozolomide chemotherapy
223685446|NCT06283927|DRUG|Lomustine|Second line chemotherapy with Lomustine
223685447|NCT06283927|RADIATION|Re-irradiation|Re-irradiation with single dose, fractionated, or hypofractionated radiation of the recurrent tumor
223685448|NCT06283927|PROCEDURE|Experimental therapy|Experimental phase I therapy with oncolytic virotherapy or immunotherapy (this list is not exhaustive)
223685449|NCT06283927|OTHER|Best supportive care|Best supportive care, focused on alleviating symptoms
223685450|NCT03684252|BEHAVIORAL|CBT-based intervention|Cognitive Behavioral Therapy (CBT) that uses acceptance and mindfulness strategies, together with commitment and behavior change strategies.
223685451|NCT03684252|OTHER|Treatment as Usual|Participants' will receive treatment as usual.
223685452|NCT05968365|DEVICE|electronic Vision-aid Device|Electronic blind aid is a non-invasive electronic aid product for the visually impaired. The product converts visual signals into tactile signals. The Vision Pro is designed for people with poor or no visual perception. The product does not change the previous travel mode of the visually impaired, and provides additional external information for the visually impaired on the basis of their existing cognition. The product can provide the visually impaired person with additional external information based on the cognition in front of them. The product can feedback the environmental information within 2.52.5 meters in front of the visually impaired person in the form of electrical stimulation to the visually impaired person. The visually impaired person can be stimulated by the tongue current to help them identify obstacles and give early warning. Avoid obstacles and give early warning.
223685453|NCT05635188|PROCEDURE|Intestinal ostomy confection|Surgical procedure for fecal diverting
223685454|NCT00422318|DRUG|Benzbromarone (drug)|
223685455|NCT00006389|DRUG|bryostatin 1|Given IV
223685456|NCT00006389|DRUG|cisplatin|Given IV
223685457|NCT00006389|OTHER|laboratory biomarker analysis|Correlative studies
223685458|NCT04330820|DRUG|Venetoclax Oral Tablet|"This study will investigate the combination of a fixed maximum venetoclax dose with increasing cytarabine doses plus mitoxantrone in a fixed dose in phase I. In Phase II cytarabine will be given at MDT or RP2D that assessed in phase I.~The venetoclax dose of 400 mg will be reached by a ramp up over 3 days. Parallel chemotherapy with cytarabine and mitoxantrone will start on day 3."
223685459|NCT02943252|DRUG|Apatinib|apatinib 500 mg in tablet once daily
223685460|NCT02943252|DRUG|S1|S-1 40-60mg bid, days 1-14 , every 3 weeks
223685461|NCT00939952|DRUG|ertapenem|500 mg IV once
223685462|NCT02138526|DRUG|pazopanib|pazopanib 800mg OD without food
223685463|NCT02138526|OTHER|continental breakfast|pazopanib 600mg OD with food
223775433|NCT03540901|DRUG|ACETAZOLAMIDE oral capsule|Administration of 125mg acetazolamide in the morning, 250mg in the evening, starting 24 hours before departure to 3100m
223775434|NCT03540901|DRUG|Placebo oral capsule|Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3100m
223775435|NCT05750381|OTHER|Micrococcus luteus Blis Q24 balm|Balm formulation containing probiotic bacteria Micrococcus luteus Q24 for topical applications.
223775436|NCT05750381|OTHER|Placebo balm|Placebo balm formulation for topical applications.
223775437|NCT05754320|DEVICE|Tension band wire fixation|Tension band wire fixation
223775438|NCT05754320|DEVICE|Plate fixation|Tension band wire fixation
223775439|NCT03043612|DEVICE|Cook Sof-Flex® Double Pigtail Ureteral Stent coextruded with doxazosin|Placement of drug-coated ureteral stent when temporary ureteral stenting is indicated following ureteroscopy for urolithiasis
223775440|NCT03043612|DEVICE|Cook Sof-Flex® Double Pigtail Ureteral Stent|Placement of a commercially available ureteral stent when temporary ureteral stenting is indicated following ureteroscopy for urolithiasis
223775441|NCT05870280|BEHAVIORAL|nurse coaching|Group coaching will be applied to individuals with diabetes, 5-8 people.
223775442|NCT01657201|DRUG|SYP-1018 200mg|SYP-1018 200mg, Intravenous administration
223775443|NCT01657201|DRUG|Voriconazole 200mg|Voriconazole 200mg, Intravenous administration
223775444|NCT01858454|PROCEDURE|HALS|In HALS, a trocar of 5-mm calipers was inserted through the umbilicus. Next, suprapubic transverse skin incision of 3-4cm in length was made and a wound retractor (Alexis; Applied Medical, Rancho Santa Margarita, CA) was inserted through the suprapubic opening.
223775445|NCT01858454|PROCEDURE|Open surgery|In open surgery, the patient was placed in the supine position and the operation was carried out in a standard manner as described elsewhere \[Luciano AA. Myomectomy. Clin Obstet Gynecol 2009;52:362-71.\].
223775446|NCT03808506|DIAGNOSTIC_TEST|Fecal calprotectin|Stool test to look at baseline burden of inflammation
223775447|NCT06525883|OTHER|No intervation|No intervention was made to the groups
223775448|NCT04173221|OTHER|Sublingual SDF-Measurement with communication and interpreting checklist to the treating physician|Sublingual SDF-Measurement at admission and after 24h, with communication and interpreting checklist to the treating physician
223775449|NCT04173221|OTHER|Sublingual SDF-Measurement without communication and interpreting checklist to the treating physician|Sublingual SDF-Measurement at admission and after 24h, without communication and interpreting checklist to the treating physician
223775450|NCT05080582|BEHAVIORAL|Mother-Scented Simulated Hand|Preterm neonates wrapped with a warm Mother-Scented Simulated Hand during the invasive procedures
223775451|NCT05080582|BEHAVIORAL|NICU Standard Care|Neonates were placed in a side-lying position, while their extremities were flexed close to the body and wrapped with rolled sheets or towels to simulate the intrauterine posture.
223775452|NCT00381394|DRUG|sitamaquine|
223775453|NCT00884481|OTHER|Natalizumab|Participants treated with Tysabri
223775454|NCT02632149|DEVICE|PINS Vagus Nerve Stimulator|
223775455|NCT03888144|DRUG|Oxycodone|5 mg of oxycodone taken by mouth every 6 hours for 5 days
223775456|NCT03888144|DRUG|Ketorolac|10 mg of ketorolac taken by mouth every 6 hours for 5 days
223775457|NCT04268017|DEVICE|FeetMe Monitor|"For gait parameters' evaluation, the investigator asks the participant to move in a straight line over a 10-meter mat. The participant had to start the feet in line and then start walking at a comfortable speed. During this time, the investigator records the gait parameters from the FeetMe Monitor® and Gaitrite® system.~An operator asked the patient to repeat 3 trials. The same sequence was repeated by three other operators. The same measurement is done 7 days later.~A questionnaire is given to assess the ergonomics of the device"
223775458|NCT02188017|DRUG|Acthar gel|Given 80 units daily for 10 days, then randomized to receive either 40 or 80 units twice a week
223775459|NCT02784418|PROCEDURE|Chronic Total Occlusion Percutaneous Coronary Intervention|Chronic Total Occlusion Percutaneous Coronary Intervention (CTO PCI), as per standard clinical practice
223775460|NCT02784418|PROCEDURE|Sham Procedure|Sham Procedure: Bilateral arterial access, without angiography or PCI being performed
223775461|NCT02866682|DRUG|Prograf|Brand Drug for the duration of the study.
223775462|NCT02866682|DRUG|Tacrolimus|Generic
223775463|NCT00671281|DRUG|Tranexamic acid|Oral form, 100mg, tid (three times per day), 3 days before/the day of/6 days after the surgery
223775464|NCT00671281|DRUG|Placebo|Placebo, Oral form, three times a day, 3 days before/day of/6 days after surgery
223775465|NCT01794325|OTHER|Trans-radial|Coronary angiography performed through trans-radial access
223775466|NCT01794325|OTHER|Trans-femoral|Coronary angiography performed through trans-femoral access
223775467|NCT04418882|OTHER|management and follow up of all open fractures|to evaluate the development of sepsis after an open fracture and then, if there is a development of a pseudarthrosis too.
223775468|NCT03792594|OTHER|arthroscopic repair with bone marrow concentration|arthroscopic repair with bone marrow concentration
223775469|NCT03792594|OTHER|arthroscopic repair|arthroscopic repair only
223775470|NCT01793064|BEHAVIORAL|Adaptive Intervention (AI)|Adaptive Intervention Group (AI) receives adaptive step goals and feedback/incentives based on personal physical activity performance.
223775471|NCT01793064|BEHAVIORAL|Static Intervention (SI)|"Static Intervention group (SI) receives a static usual care goal of 10,000 steps/day and feedback/incentives for uploading their pedometer to the study website."
223775472|NCT00278707|DRUG|GTA: Glyceryltriacetate|
223775473|NCT03348891|OTHER|Tumor biopsy specimens and blood samples|Tumor biopsy specimens (if feasible) and blood samples will be collected at Baseline, Week 6 Day 1 (blood sample only) and Week 12 Day 1.
223775474|NCT03556657|OTHER|Music Therapy|Patient receives 6 sessions of music therapy with a board-certified music therapist. Patient will learn various music interventions for pain management that he/she will utilize at home.
223775475|NCT00101855|PROCEDURE|An evidence based tailored web site|
223775476|NCT00470951|PROCEDURE|open rectal resection|open rectal resection
223775477|NCT00470951|PROCEDURE|laparoscopic rectal resection|laparoscopic assisted rectal resection
223775478|NCT01490177|DRUG|Food proteins|Oral ingestion of Food proteins
223775479|NCT04691869|DEVICE|Achilles EXPII|Portable ultrasound machine that measures a patient's bone density at the calcaneus.
223775480|NCT01750268|BEHAVIORAL|Medical Management Counseling|Brief alcohol and medication counseling
223775481|NCT01750268|DRUG|Topiramate|Experimental medication
223775482|NCT01750268|DRUG|Placebo|Placebo comparator
223775483|NCT04830449|DRUG|HCP1904-2|Take it once daily for 8 weeks orally.
223775484|NCT04830449|DRUG|RLD2001-2|Take it once daily for 8 weeks orally.
223685464|NCT03052933|DRUG|Copanlisib|"For phase I study, participants will receive copanlisib (in combination with gemcitabine) IV infusion at a dose of 45 mg or 60 mg on Days 1, 8, and 15 of each 28-day treatment cycle. During phase I study, participants will be treated at the level of 45 mg/dose (level+0), or 60 mg/dose (level+1) of copanlisib. Maximal tolerated dose will be determined by modified 3+3 design including level-1 dose de-escalation.~For phase II study, copanlisib dose level, determined during phase I study, will be administered on Days 1, 8, and 15.~Maximum 6 cycles of gemcitabine and copanlisib combination and subsequent copanlisib monotherapy in participants with ≥ SD to copanlisib and gemcitabine until maximum 12 cycles will be given for this study."
223685465|NCT03052933|DRUG|Gemcitabine|For phase I/II study, participants will receive gemcitabine (in combination with copanlisib) IV infusion at fixed dose of 1,000 mg/m2 on Days 1 and 8 of each 28-day treatment cycle until maximum 6 cycles.
223685466|NCT05599919|DRUG|Nitric Oxide|The Sponsor designed a dual chamber nasal spray bottle for NORS administration. Components are mixed from two chambers to create the final NO-producing formulation. The liquid contains NO at 0.11 ppm\*hour, which acts as a viricidal agent. Instructions for storing, preparing, and administering the study treatment will be provided to participants.
223685467|NCT05635058|OTHER|The Reminisence Therapy|Reminiscence sessions were held in a meeting room in the nursing home and arranged in accordance with the interviews. In the reminiscence sessions, mnemonic materials selected specifically for the determined interview topic were used. The materials to be used in the reminiscence sessions were determined in accordance with the education level and cultural characteristics of the participants. In the sessions, topics such as childhood life, work life, religious holidays, national holidays, old songs, military ceremonies, wedding ceremonies, gardening and field work were shared. In the reminiscence sessions, the participants were encouraged to verbally express the feelings and thoughts they remembered about the mnemonics. The interviews were recorded by the researcher and each session lasted 45-60 minutes. At the end of the reminiscence session, the topics addressed in the session were summarized by the researcher, the following weeks topic was determined and the interview was concluded.
223685468|NCT04315935|DRUG|Butorphanol and Propofol|The two groups were given propofol for sedation, BG for butorphanol for analgesia and FG for fentanyl for analgesia
223685469|NCT04315935|DRUG|Fentanyl and Propofol|Fentanyl (0.7-10 μ g / kg / h) analgesia and Propofol (1-4 mg / kg / h) sedation
223685470|NCT02376283|DRUG|Prasugrel|
223685471|NCT02376283|DRUG|Clopidogrel|
223685472|NCT02376283|DRUG|ticagrelor|
223685473|NCT00450775|DRUG|Dermatix Q|Dermatix Q applied twice daily
223685474|NCT03800082|BEHAVIORAL|at heart (changed from HEARTPA♀N during usability testing)|An integrated smartphone and web-based intervention (at heart) to provide evidence-informed symptom triage and self-management support to reduce pain and increase health-related quality of life (HRQoL) in women with heart disease. The intervention for participants randomized to the treatment group will consist of regular use of a progressive WebApp that is managed by a Chatbot named 'Holly', in addition to usual care, for a period of 3 months.
223685475|NCT05074173|BEHAVIORAL|Text|These blood pressure values will be automatically uploaded twice daily from a Bluetooth device to a phone application to allow the participant and healthcare team track their blood pressure.
223685476|NCT01933815|DRUG|TPI 287|TPI 287 is a microtubule inhibitor belonging to the taxane diterpenoid (taxoid) family, and specifically to the abeotaxane class. TPI 287 is an Investigational Drug.
223685477|NCT01933815|DRUG|Bevacizumab|Avastin (bevacizumab) is an FDA approved drug indicated for multiple cancers, including as a single agent for GBM for adult patients with progressive disease following prior therapy. Single agent effectiveness is based on improvement in objective response rate; no data is available demonstrating improvement in disease-related symptoms or survival with bevacizumab.
223685478|NCT01712321|DRUG|Vilazodone|Vilazodone 20mg or 40mg taken once daily by mouth
223685479|NCT01712321|DRUG|Placebo|Placebo matching Vilazodone 20mg or 40mg, taken once daily by mouth
223685480|NCT03548571|BIOLOGICAL|Dendritic cell immunization|Intradermal injection
223685481|NCT03548571|DRUG|Adjuvant temozolomide|After a 4-week break, patients were then to receive up to six cycles of adjuvant temozolomide according to the standard 5-day schedule every 28 days at 150 mg per square meter for the first cycle and thereafter increase to 200 mg per square meter beginning with the second cycle.
223685482|NCT00046111|DRUG|topotecan|A topoisomerase I inhibitor used for ovarian and lung cancer treatment
223685483|NCT03193125|DIETARY_SUPPLEMENT|L-Carnitine|500 mg tablets of L-Carnitine taken 3 times daily before meals.
223685484|NCT03193125|DIETARY_SUPPLEMENT|Placebo|500 mg tablets of L-Carnitine taken 3 times daily before meals.
223685485|NCT05287542|OTHER|Hypnotic suggestion|The intervention group will receive four weekly 60 min. sessions with hypnosis treatment including induction followed by hypnotic suggestion.
223685486|NCT05287542|OTHER|Mindfulness|The active control group will receive four weekly 60 min. sessions of induction and mindfulness-based instructions.
223685487|NCT02116478|PROCEDURE|surgical proximal medial gastrocnemius recession|proximal medial gastrocnemius recession
223685488|NCT01076075|DRUG|Sitagliptin phosphate|Phase A (Weeks 0-24): Sitagliptin 100 mg once a day for 24 weeks; Phase B (Weeks 24-54): Sitagliptin 100 mg once a day for 30 weeks
223685489|NCT01076075|DRUG|Comparator: placebo to pioglitazone|Phase B (Weeks 24-54): placebo to pioglitazone 30 mg once a day for 30 weeks
223685490|NCT01076075|DRUG|Comparator: placebo to Sitagliptin|Phase A (Weeks 0-24): placebo to Sitagliptin 100 mg once a day for 24 weeks; Phase B (Weeks 24-54): placebo to Sitagliptin once a day for 30 weeks
223685491|NCT01076075|DRUG|Comparator: pioglitazone|Phase B (Weeks 24-54): pioglitazone 30 mg once a day for 30 weeks
223685492|NCT01076075|DRUG|Glimepiride or gliclazide|Phase A (Weeks 0-24): stable dose, as prescribed by investigator, of glimepiride or gliclazide; Phase B (Weeks 24-54): stable dose, as prescribed by investigator, of glimepiride or gliclazide
223775485|NCT03435393|PROCEDURE|Catheter ablation|Mapping of the epicardium and ablating areas of long fractionated potentials
223685493|NCT01076075|DRUG|Metformin|"Phase A (Weeks 0-24): stable dose, as prescribed~by investigator, of metformin; Phase B (Weeks 24-~54): stable dose, as prescribed by investigator, of~metformin"
223685494|NCT01076075|DRUG|Pioglitazone rescue therapy|Phase A (Weeks 0-24): participants not meeting specific glycemic goals will receive pioglitazone (open label) at a dose determined by the investigator. These participants will not initiate Phase B (Weeks 24-54) double blind pioglitazone.
223685495|NCT05451342|DIAGNOSTIC_TEST|Integrated Transcriptomics, Metabolomics, and Lipidomics Profiling|Blood samples and BALD samples will be collected for further integrated transcriptomics, metabolomics, lipidomics analysis, and exosome extraction.
223685496|NCT04694456|OTHER|cytokines dosage|Mesure of cytokines concentration in serum
223685497|NCT04694456|PROCEDURE|test of walk|patient must walk during 6 minutes on a flat surface
223685498|NCT04694456|PROCEDURE|Manual muscular test|test performed to evaluate the patient muscular weakness
223685499|NCT04694456|PROCEDURE|Motrice fonction mesurement|scale allowing the evaluation of patient posture and upper body movements
223685500|NCT03114059|DIAGNOSTIC_TEST|Glaucoma diagnostics|Heidelberg Retinal Topography, Visual field, intraocular pressure, medication anamnesis, Retinal Nerve Fibre Layer Thickness, Pachymetry, Sonography, full ophthalmological examination
223775486|NCT00021307|DRUG|carboplatin|
223775487|NCT00021307|DRUG|temozolomide|
223775488|NCT00509197|DRUG|Placebo (sham inhaler)|
223775489|NCT00509197|DRUG|Fluticasone|Fluticasone 250mcg bid for one month
223775490|NCT00670124|DEVICE|Hypothermia by the use of Blanketrol II, Cincinnati Sub-Zero|The patients are placed on a cooling mattress and body-core temperature is regulated to 33° C.
223775491|NCT02157311|DRUG|Four consecutive days on treatment and 3 days off|All patients will take a combination of three of these treatment with a weekly strategy of 4 consecutive days on treatment followed by 3 days off treatment
223685501|NCT04862858|OTHER|Educational Intervention|The educational intervention will involve guideline-based treatment recommendation information for providers via fax/mail and phone and provide resources via mail and phone for patients to learn more about ways to reduce their cardiovascular risk.
223685502|NCT06104371|DEVICE|Magtrace|Sentinel lymph node tracer and metastatic lymph node clip
223685503|NCT05038904|DRUG|Acalabrutinib|100 mg oral capsule
223685504|NCT04177238|DIETARY_SUPPLEMENT|Fruit concentrate - either cherry or blueberry|Fruit (cherry or blueberry concentrate) supplement from a company named Active-Edge (https://active-edge.co.uk/).
223685505|NCT02845518|PROCEDURE|Cardiac magnetic resonance imaging (cMRI)|"Right ventricular contouring and indexed aortic flow measurement from cMRI will be performed locally with the dedicated software used in clinical practice by the physicians of each centre. Cardiac index and RVEF will be derived from these measures. MRI interpretation will be performed blind with respect of clinical and RHC data.~A self-administered questionnaire made up of 2 Likert scales will be given to all patients on visits V1, V2 or V3 and V9.~To constitute a biobank for diagnosis and prognosis purposes blood samples will be taken at visits V1, V2 or V3 and V9."
223685506|NCT04545203|OTHER|Slow-stroke back massage|Slow-stroke back massage was performed to the breast cancer patients in intervention group. The SSBM sessions were administered 10 minutes before and after chemotherapy treatment.The SSBM was applied for 20 minutes in total, on each cycle. The intervention group received 20-minute SSBM sessions 3 chemotherapy cycle in addition to the routine care.
223775492|NCT03087591|OTHER|Laboratory Biomarker Analysis|Correlative studies
223775493|NCT03087591|BIOLOGICAL|siRNA-transfected Peripheral Blood Mononuclear Cells (PBMC) APN401|Given IV
223775494|NCT05123248|DEVICE|Blinded Group|Participants in the blinded group will be wearing the sensor for 14 days without a reader. Glucose levels will be recorded from the interstitial fluid every 15 minutes using intermittent/ flash glucose scanning. After 14 days, participants are required to scan the sensor themselves or with the assistance of a CRC to a designated blinded-reader.
223775495|NCT05123248|DEVICE|Unblinded group|Participants in the non-blinded group are required to wear the CGM sensor for 14 days with an open reader. Glucose levels will be recorded from the interstitial fluid every 15 minutes using intermittent/ flash glucose scanning. The participant will be required to upload their glucose readings no longer than 8 hours by scanning the reader provided.
223775496|NCT05395377|BEHAVIORAL|Registered Dietitian/Nutritionist|Participants received a FitBit Flex and Intensive Lifestyle Intervention coaching via telephone with Registered Dietitian/Nutritionist.
223775497|NCT05395377|BEHAVIORAL|Diabetes Prevention Program|Modified DPP group classes lead by a Registered Dietitian and Exercise Physiologist.
223685507|NCT03949491|PROCEDURE|3D medical models|Using 3D medical models of the abdomen, a virtual plan will assist reconstruction to clearly define and 3D model the normal and aberrant vascular anatomy of the donor site in order to decrease both operative time and dissection time. This will also allow for the proposal of incision lines to match the corresponding volumetric analysis of the transposed tissue in order to facilitate the creation of a patient specific tailored flap, which will improve the aesthetic outcomes, decrease donor site complications and improve patient satisfaction
223685508|NCT03069118|BEHAVIORAL|Treatment - Workit Health Online Program|"The Workit Health program is an adaptive recovery in your pocket harm reduction and sobriety solution that provides 24-hour access to adaptive lessons, mentorship, written and audio driven therapeutic exercises and tools, and peer-to-peer coaching. Users access our online site and enter an initial 90-day program that takes a holistic approach to recovery by addressing the physical, mental, emotional, and social aspects of addiction. As they advance, they move through successive levels that include lessons, activities, and assignments. Bonus materials, such as meditations and suggested reading, give users timely opportunities to dive deeper into a problem they are struggling with that day. Workit Health implements evidence-based strategies such as CBT, DBT, and MI."
223685509|NCT03069118|BEHAVIORAL|Control - Resource List|Tailored list of resources.
223685510|NCT02524964|DRUG|sodium tanshinone IIA sulfonate|eligible participants were randomized to receive sodium tanshinone IIA sulfonate injection (drip 80 mg/day for 7 days immediately after PCI)
223685511|NCT02524964|OTHER|control|equivalent volume of sodium chloride solution
223685512|NCT01771185|PROCEDURE|Duodenal jejunal bypass plus sleeve gastrectomy|Metabolic Surgery Duodenal jejunal bypass plus sleeve gastrectomy
223685513|NCT01771185|DRUG|Best medical treatment (Metformin ; gliclazide)|Metformin 2 g/day; gliclazide 30 mg
223775498|NCT05395377|BEHAVIORAL|Weight Watchers, Reimagined|Participants in this group were provided with an online access code to enroll in WW and could choose the format of their choice- group, online, and/or smartphone app.
223775499|NCT05395377|BEHAVIORAL|DPP or RDN Counseling + Medication|Participants met with a weight management specialist to receive weight loss medications, as well as, receiving either the DPP or Registered Dietitian coaching. Medications utilized in this study were Phentermine and Metformin. Metformin was prescribed if the participant could not tolerate Phentermine.
223685514|NCT01445886|DRUG|Indigo Naturalis Extract in Oil|The participants applied indigo naturalis extract in oil topically to one of two bilaterally symmetrical psoriatic finger nails twice daily for 24 weeks.
223685515|NCT01445886|DRUG|Calcipotriol Solution|The participants applied calcipotriol solution topically to one of two bilaterally symmetrical psoriatic finger nails twice daily for 24 weeks.
223685516|NCT03769103|DRUG|Osimertinib|Daily oral osimertinib
223775500|NCT05395377|OTHER|Bariatric Surgery Evaluation|Participants (BMI \> 40) were offered a consultation with the bariatric surgical program that requires lifestyle weight management during the first 6 months. Participants were also able to choose to receive one of the other 4 intervention options in the first six months prior to consideration for bariatric surgery.
223685517|NCT03769103|RADIATION|Stereotactic radiotherapy|1-5 fractions of stereotactic radiotherapy
223685518|NCT02106039|PROCEDURE|intensive monitoring|
223685519|NCT00553865|DRUG|OJP-2028|Experimental: 1mg/day, 2mg/day, 4mg/day for 8 weeks. Placebo Comparator: Placebo.day for 8 weeks. Reference group(Group 5): Reference Drug/day for 8 weeks.
223685520|NCT01860573|DRUG|Amino acids|
223685521|NCT05628961|DRUG|HOPO 14-1|HOPO 14-1 contains the active pharmaceutical ingredient (API) 3, 4, 3-LI(1, 2-HOPO) formulated with a permeability enhancer, sodium oleate, in capsule form.
223685522|NCT04798807|DIAGNOSTIC_TEST|Nutritional screening|
223685523|NCT00995865|BIOLOGICAL|XRX-001 Inactivated yellow fever vaccine|Inactivated yellow fever vaccine, alum adsorbed, High dose = 2.3 x 10\^8 VE/0.5mL and Mid dose = 2.2 x 10\^7 VE/0.5mL
223685524|NCT00995865|BIOLOGICAL|Placebo|NaCl Injectable 0.9%
223685525|NCT05997472|DIAGNOSTIC_TEST|evaluation af mobility and balance|evaluation af mobility and balance Timed Up and Go Test Berg Balance Scale
223685526|NCT01456273|PROCEDURE|Traditional Medical Consultation|Group A will be divided into 2 subgroups : A1- Traditional medical consultation + placebo, and A2- traditional medical consultation plus omeprazole
223685527|NCT01456273|PROCEDURE|Therapeutic Encounter|"Group B (who receive care Therapeutic Encounter) will be divided in subgroup B1, which will receive the Drug Therapy Classic and 2 in group B who received placebo."
223685528|NCT04926727|OTHER|Survey|Observational study
223685529|NCT04689438|DIAGNOSTIC_TEST|gingival crevicular fluid|GCF samples were collected in the morning hours 24-48 hours after clinical periodontal measurement.
223685530|NCT00000523|BEHAVIORAL|exercise|
223685531|NCT04426903|OTHER|webFitForAll|PT training participants use the webFitForAll exergaming computer platform as the physical training component (PT)
223685532|NCT04426903|OTHER|BrainHQ|CT training participants use the language adapted version of the BrainHQ program as the cognitive training component (CT)
223685533|NCT05080660|DRUG|LY3526318|Administered orally.
223685534|NCT05080660|DRUG|Placebo|Administered orally.
224263201|NCT05941065|OTHER|Balancing gel cream|Skin balancing gel cream will be applied onto clean skin morning and night
224263202|NCT05389722|DRUG|CC-92480|Specified dose on specified days
224263203|NCT05389722|DRUG|Rifampin|Specified dose on specified days
224263204|NCT05389722|DRUG|Itraconazole|Specified dose on specified days
224263205|NCT05389722|DRUG|Digoxin|Specified dose on specified days
224263206|NCT05389722|DRUG|Rosuvastatin|Specified dose on specified days
224263207|NCT05507801|OTHER|High Protein Milkshake|A milkshake with high protein level; including whey protein, fat free strawberry yogurt and whole milk - 337 kcal, 27 g carbohydrate, 57 g protein, 16 g fat.
224263208|NCT05507801|OTHER|Normal Milkshake|A milkshake with normal protein level; including nesquik (strawberry), fat free strawberry yogurt, whole milk, double cream, whey protein and sweetener - 331 kcal, 64 g carbohydrate, 17 g protein, 19 g fat.
224263209|NCT01792726|RADIATION|Boost to the tumour bed|Boost to the tumour bed, with whole breast EBRT delivered according to local policy.
224263210|NCT00193804|RADIATION|IMRT|IMRT in cervical cancers
224263211|NCT01543360|PROCEDURE|Axillary strategy|The first two attempts at central venous catheterization will be performed via the distal approach (axillary vein). The third and fourth attempts at central venous catheterization will be performed by the medial approach (subclavian vein). The same puncture material/devices will be used in both arms of the study.
223685535|NCT02602977|OTHER|Multiple-dose Remote Ischemic Preconditioning|"A blood-pressure cuff with handheld rubber inflation balloon and manometer is placed on the non-dominant arm of the subject. The cuff will be placed proximally from the elbow with the most proximal part of the cuff placed in the armpit. The cuff will be inflated to 250 mmHg after which a 5 minute countdown is started. After 5 minutes the pressure is released and the 5 minute countdown for reperfusion is started. This concludes one cycle out of a total of four.~1 RIPC-dose consists of 4 cycles of 5 minute ischemia followed by 5 minute reperfusion as described above.~Multiple-dose RIPC consists of a daily dose of 1 RIPC as described above for 7 consecutive days."
223685536|NCT02602977|OTHER|Single-dose Remote Ischemic Preconditioning|"A blood-pressure cuff with handheld rubber inflation balloon and manometer is placed on the non-dominant arm of the subject. The cuff will be placed proximally from the elbow with the most proximal part of the cuff placed in the armpit. The cuff will be inflated to 250 mmHg after which a 5 minute countdown is started. After 5 minutes the pressure is released and the 5 minute countdown for reperfusion is started. This concludes one cycle out of a total of four.~1 RIPC-dose consists of 4 cycles of 5 minute ischemia followed by 5 minute reperfusion as described above.~Single-dose RIPC consists of 1 dose of RIPC as described above"
223685537|NCT02602977|BIOLOGICAL|LPS infusion|To achieve a controlled inflammatory state, 30 subjects (multiple-dose RIPC group \[n=10\], single-dose RIPC group \[n=10\] and control group \[n=10\]) will receive LPS intravenously. The LPS at a dose of 2 ng/kg iv will be injected in 1 minute.
223685538|NCT00002065|DRUG|Disulfiram|
223685539|NCT05026190|DIAGNOSTIC_TEST|transrectal ultrasound|we perform trus to identify the cause of azospermia and its type either obstructive or not
223685540|NCT04604691|DRUG|Blinatumomab for Injection|Blinatumomab will be administered as a continuous intravenous (CIV) infusion at a constant flow rate over four weeks followed by a two-week infusion free interval.
223685541|NCT06994520|OTHER|Cannabidiol (CBD)|5%CBD cream
223685542|NCT06994520|DRUG|Triamcinolone (TAC) 0.1% cream|comparator
223685543|NCT06708377|OTHER|dry needling of masseter|"Experimental group included Dry needling of masseter muscle for 30 second to 2 minutes into the trigger point.~Conventional heating pad or face pad for 15 minutes. Therapeutic ultrasound with Frequency: 3MHz, Intensity: 0.75 - 1 W/cm2, Time: Based on treatment head and pulse factor. Temporomandibular joint mobilization (Maitland)-caudal glide, anterior-posterior glide, grade II, III, IV 3 reps x 3 sets per session. 6 x 6 exercise protocol of Rocabado, 6 reps per exercise x 6/day."
223685544|NCT06708377|OTHER|myofascial massage therapy on masseter muscle|Control group included Myofascial massage - sliding and kneading, for 30 minutes per session/3x per week. Conventional heating pad or face pad for 15 minutes. Therapeutic ultrasound with Frequency: 3MHz, Intensity: 0.75 - 1 W/cm2, Time: Based on treatment head and pulse factor. Temporomandibular joint mobilization (Maitland)-caudal glide, anterior-posterior glide, grade II, III, IV 3 reps x 3 sets per session. 6 x 6 exercise protocol of Rocabado, 6 reps per exercise x 6/day
223685545|NCT03856775|DEVICE|Quantitative EEG and Seizure detector|Paediatric intensive care unit nurses, residents or fellows will perform hourly review of a bedside graphical display of the previous hour's epoch of quantitative EEG for seizure patterns. One page of quantitative EEG data represents one hour of recording. The graphical display will include a seizure-detection marker, seizure probability indicator, bilateral rhythmicity spectrogram and bilateral amplitude integrated EEG.
223685546|NCT03838965|DEVICE|biobeat sensor|biobeat sensor is a noninvasive sensor of the the hymodynamic measures during the childbirth and after 24 hours.
223685547|NCT03012516|BEHAVIORAL|PAP-treatment by physiotherapist|
223685548|NCT03012516|BEHAVIORAL|Ordinary PAP-treatment at the health care center|
223685549|NCT01173861|BEHAVIORAL|Physical activity counseling|20-30 minutes of face-to-face physical activity counseling using motivational interviewing followed by 3 20 minute telephone counseling sessions.
223685550|NCT00000762|BIOLOGICAL|rgp120/HIV-1MN|
223685551|NCT00000762|BIOLOGICAL|rgp120/HIV-1 SF-2|
223685552|NCT00000762|BIOLOGICAL|gp160 Vaccine (MicroGeneSys)|
223685553|NCT06157060|DIAGNOSTIC_TEST|circulating tumor DNA|blood sample and tissue specimen for circulating tumor DNA will be done to patient with hepatocellular carcinoma
223775501|NCT05912946|DRUG|Interferon|The patient was seated in the seat and rested quietly. A three-way urinary tube was indwelled to drain urine. Interferon solution was configured according to the ratio of 3 million IU interferon +49ml normal saline. The urinary tube was clamped and the interferon solution was injected through the water inlet tube and retained for 30 minutes.
223685554|NCT05612022|PROCEDURE|AVF creation|AVF is surgically created in the forearm by an anastomosis between a vein and an artery
223685555|NCT05612022|PROCEDURE|AVG creation|Surgery is done using an artificial plastic tube that connects an artery to a vein
223685556|NCT04004130|OTHER|Ultrasound imaging|Ultrasound imaging of the lumbar spine/subarachnoidal space
223685557|NCT06382805|OTHER|Physiotherapy program|The physiotherapy program will consist of cold-pack, US, transcutaneous electrical stimulation (TENS) and home exercise program. Cold-pack will be applied for 15 minutes. Continuous ultrasound will be applied on lateral epicondylitis with a 5-cm ultrasound head at a dose of 1.5W/cm2 for 5 minutes and a frequency of 1-MHZ. TENS application will be performed with the BTL 4000 combination device. TENS will be applied for 20 minutes, increasing the intensity of the current until the patient feels it. The treatment program will last for a total of two weeks, 5 days a week.
223685558|NCT06382805|OTHER|Kinesio Tape|The longitudinal muscle technique will be applied from the origin to the insertion of the forearm extensor muscles by a researcher with a Kinesio tape application certificate. In addition, transverse kinesio tape will be applied on the elbow using the fascia correction technique. The treatment program will last for a total of two weeks, 5 days a week.
223775502|NCT05912946|DRUG|Sodium Hyaluronate|The patient was seated in the seat and rested quietly. A three-way urinary tube was indwelled to drain urine. The urinary tube was clamped and the sterile sodium hyaluronate solution was injected through the water inlet tube and retained for 30 minutes.
223775503|NCT05912946|DRUG|Sodium Chloride Injection|The patient was seated in the seat and rested quietly. A three-way urinary tube was indwelled to drain urine. The urinary tube was clamped and the sodium chloride injection was injected through the water inlet tube and retained for 30 minutes.
223775504|NCT03229330|PROCEDURE|Low-level Light Therapy|Low-level Light Therapy 660nm (red laser), 1 to 3 Joules, irradiation time and number of points varied.
223775505|NCT03229330|COMBINATION_PRODUCT|Conventional treatment|Topical treatment: essential fatty oil, hydrogel, papain gel, petrolatum gauze, calcium or silver alginate, zinc oxide and barrier cream; and high compression bandage SurePress
223775506|NCT03286959|PROCEDURE|PCR with calcium hydroxide|
223775507|NCT03286959|PROCEDURE|PCR with RMGIC|
223775508|NCT03286959|PROCEDURE|PCR with direct composite|
223775509|NCT05968612|DRUG|Lumacaftor 200 mg/Ivacaftor 125 mg Film-Coated Tablet|Film-coated tablet administered orally.
223775510|NCT05968612|DRUG|Lumacaftor 200 mg Film-Coated Tablet Formulation|Film-coated tablet administered orally.
223775511|NCT05466318|DRUG|Chidamide|30 mg oral twice weekly for 2 weeks
223775512|NCT05466318|DRUG|Cladribine|6 mg/m2 intravenously once daily @ Day -7 \~ -3
223775513|NCT05466318|DRUG|Gemcitabine|2500 mg/m2 intravenously @ Day -7, -3
223775514|NCT05466318|DRUG|Busulfan|3.2 mg/kg intravenously once daily @ Day -7 \~ -4
223775515|NCT05466318|DRUG|Carmustine|300 mg/m2 intravenously @ Day -8
223775516|NCT05466318|DRUG|Etoposide|200 mg/m2 intravenously once daily @ Day -7 \~ -4
223685559|NCT06382805|OTHER|High Intensity Laser therapy|High intensity laser applications will be performed using the BTL-6000 (BTL Company, UK) device. The first 5 sessions will be applied to the painful area for 75 seconds at a dose of 4W 6 J/cm2 (analgesic effect) by making circular movements from the center to the outside. The remaining 5 sessions will be applied to the painful area with linear movements for 12 minutes and 30 seconds at a dose of 6W 100-150 J/cm2 (biostimulation effect). The treatment program will last for a total of two weeks, 5 days a week.
223685560|NCT05375747|DRUG|Remimazolam|For induction and maintenance of anesthesia, total intravenous anesthesia is performed using continuous intravenous infusion of remimazolam and remifentanil.
223685561|NCT05375747|DRUG|Propofol|For induction and maintenance of anesthesia, total intravenous anesthesia is performed using continuous intravenous infusion of propofol and remifentanil.
223685562|NCT03989167|OTHER|Clinical decision support|Computer-based support tool for identification of patients with high levels of total cholesterol or LDL-C, at high risk of being affected by FH.
223685563|NCT01695148|DIETARY_SUPPLEMENT|β-Carotene Biofortified Maize Flour|
223775517|NCT05466318|DRUG|Cytarabine|400 mg/m2 intravenously once daily @ Day -7 \~ -4
223775518|NCT05466318|DRUG|Melphalan|140 mg/m2 intravenously @ Day -3
223775519|NCT05466318|PROCEDURE|Autologous hematopoietic stem cell transplant|autologous hematopoietic stem cells infusion after ChiCGB or BEAM chemotherapy
223775520|NCT01415505|DRUG|Nebivolol, Valsartan and Hydrochlorothiazide|Nebivolol 5 mg (tablet), oral administration Nebivolol 10 mg (tablet), oral administration Nebivolol 20 mg (tablet), oral administration Valsartan 160 mg (tablet), oral administration Valsartan 320 mg (tablet), oral administration Hydrochlorothiazide 12.5 mg rescue medication (capsules), oral administration. Hydrochlorothiazide 25 mg rescue medication (capsules), oral administration
223775521|NCT05643066|DRUG|0.1 mg/kg esketamine|Esketamine 0.1 mg/kg was intravenously injected first.
223775522|NCT05643066|DRUG|0.2 mg/kg esketamine|Esketamine 0.2 mg/kg was intravenously injected first.
223775523|NCT05643066|DRUG|0.9% saline|0.9% saline was intravenously injected first.
223775524|NCT05643066|DRUG|Propofol|Propofol 1 mg/kg was injected immediately. Afterward, propofol 0.5 mg/kg was administered to maintain the target sedation level (MOAA/S of less than three).
223775525|NCT03689010|DRUG|Azelaic acid foam 15%|Azelaic acid foam 15%
223775526|NCT03689010|DRUG|Finacea® (Azelaic acid Foam) 15%|Azelaic acid foam 15%
223775527|NCT03689010|DRUG|Vehicle of the test product|Vehicle of the test product
223775528|NCT05809518|DRUG|Propofol injection|sedation after cardiac surgery
223775529|NCT05809518|DRUG|Dexmedetomidine injection|sedation after cardiac surgery
223685564|NCT01695148|DIETARY_SUPPLEMENT|White Maize Flour|
223685565|NCT00719264|DRUG|RAD001(everolimus)|10 mg qd
223685566|NCT00719264|DRUG|interferon alfa-2a|dose escalated from 3 MIU (million international unit) during week 1, 6 MIU during week 2, and 9 MIU during week 3
223685567|NCT00719264|DRUG|bevacizumab|10 mg/kg every 2 weeks
223685568|NCT01568801|BEHAVIORAL|SingaPACE|Individuals in the intervention group will go through an integrated program of community based health and social care, based on intake and ongoing evaluation by the SingaPACE team.
223685569|NCT00531986|DRUG|Lopinavir-Monotherapy|Patients on triple HAART will be switched to LPV/r-monotherapy
223685570|NCT00531986|DRUG|HAART|Patients will continued their current HAART
223685571|NCT00003409|DRUG|motexafin gadolinium|
223685572|NCT00003409|RADIATION|radiation therapy|
223685573|NCT01084447|DEVICE|inspiratory muscle training|This daily respiratory exercise was performed from the 2nd day following surgery by using a linear pressure resistance device (Threshold ® IMT - Health Scan Products; USA)was initially set at 40% of the maximal inspiratory pressure, obtained in the 2nd post-operative day, being adjusted to every new maximal inspiratory pressure measurement.
223685574|NCT01084447|DEVICE|control group|In placebo muscular training the daily respiratory exercise was performed from the 2nd day following surgery by using a linear pressure resistance device (Threshold ® IMT - Health Scan Products; USA)no load until the 30th post-operative day.
223685575|NCT02366598|OTHER|Hemp shake|Hemp protein shake
223685576|NCT02366598|OTHER|Soybean shake|Soybean protein shake
223685577|NCT02366598|OTHER|Control|Non-protein shake
223685578|NCT00454831|DEVICE|HEP-40 chitosan|Enzymatically Hydrolyzed Polychitosamine-40 kDa
223775530|NCT05809518|DRUG|Dexmedetomidine and Propofol|sedation after cardiac surgery
223775531|NCT02621606|DRUG|[11C]MK-6884|IV bolus dose of \~370 MBq \[11C\]MK-6884
223775532|NCT02764749|DIETARY_SUPPLEMENT|cranberry (poly)phenol containing supplement|Sustained intake of 9 grams of freeze-dried cranberry powder per day (2x 4.5 grams daily over 1 month). The powder is dissolved in water and administered as a drink.
223775533|NCT02764749|DIETARY_SUPPLEMENT|Placebo comparator: cranberry (poly)phenol deprived supplement|Sustained intake (2x 4.5 grams daily over 1 month) of a control supplement dissolved in water
223775534|NCT00274716|DRUG|MK0736|
223775535|NCT00274716|DRUG|MK0916|
223775536|NCT00274716|DRUG|Placebo|
223775537|NCT02309385|DRUG|8% Dexamethasone Sodium Phosphate - Visulex|
223775538|NCT02309385|DRUG|15% Dexamethasone Sodium Phosphate - Visulex|
223775539|NCT02309385|DRUG|Prednisolone Acetate (1%) Eye Drops|
223775540|NCT01162005|DRUG|Tacrolimus|dosage : 0.1-0.2 mg/kg/day divided two target trough level : 5 - 10 ng/mL Total duration (tacrolimus) : 1 year
223775541|NCT00134277|PROCEDURE|Infragenual dilatation|Infragenual dilatation
223685579|NCT02318576|OTHER|Cognitive Training|Computerized Cognitive Training: The online computer training program will be administered on the participants' home computer. The training program will consist of a total of 36 sessions (3 times/week for 12 weeks). Each session will last no more than 60 minutes and consist of five different cognitive exercises designed to improve cognitive processing speed, memory and executive function. All exercises will involve visual stimuli and a motor response (key or button press). Exercises will be adaptive to participants' individual ability and start with minimal difficulty.
223775542|NCT00134277|PROCEDURE|Infragenual dilatation with stenting|Infragenual dilatation with stenting
223685580|NCT05458726|DRUG|Osimertinib|Osimertinib or chemotherapy
223775543|NCT00134277|PROCEDURE|Infragenual dilatation with cutting balloon|Infragenual dilatation with cutting balloon
223685581|NCT01178255|DRUG|homeopathic q-potencies|individualised homeopathic medicines
223685582|NCT01178255|DRUG|Placebo|placebo
223685583|NCT01178255|OTHER|homeopathic case history taking type I|one special homeopathic technique for case history taking
223685584|NCT01178255|OTHER|homeopathic case history type II|another type of homeopathic case history taking
223685585|NCT02172170|DRUG|BI 10773 single rising dose|
223685586|NCT02172170|DRUG|Placebo|
223775544|NCT00134277|PROCEDURE|Laser therapy|Laser therapy
223775545|NCT04891549|PROCEDURE|Tension band fixation|Fracture fixation of the patella fracture with tension band.
223685587|NCT01483586|DRUG|kanglaite gelcap|3 KLTc gelcap capsules four times a day throughout the study (12 months). Each gelcap contains .45g KLT per capsule
223685588|NCT01483586|DRUG|Kanglaite gelcap|6 KLTc gelcaps taken four times a day throughout the study (12 months). Each gelcap contains .45g KLT
223685589|NCT06274905|DRUG|EMLA|EMLA cream
223685590|NCT06274905|DRUG|Ethyl chloride|Ethyl chloride
223685591|NCT06274905|DRUG|Aqueous cream BP|Aqueous cream
223685592|NCT05682248|DEVICE|Transcranial magnetic stimulation|Transcranial magnetic stimulation
223685593|NCT05682248|DEVICE|Sham Transcranial magnetic stimulation|Sham Transcranial magnetic stimulation
223775546|NCT04891549|PROCEDURE|Plate fixation|Fracture fixation of the patella fracture with a plate.
223775547|NCT00982319|DRUG|Broccoli sprout extract|100 µmols of sulforaphane (dissolvable)
223775548|NCT00982319|DRUG|Mango juice|150 mL of mango juice
223775549|NCT03847181|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Rivaroxaban at a dose of 15 or 20 mg once daily
223775550|NCT03847181|DRUG|Apixaban (Eliquis)|Apixaban at a dose of 2.5 or 5 mg twice daily
223775551|NCT03847181|DRUG|Warfarin|Warfarin dose as prescribed by medical practitioner
223775552|NCT05427149|DRUG|25 mg MgSO4 (Magnezyum Sulfat %15, Biofarma, Istanbul, Turkey)|It will be evaluated whether there is postpinal shivering in the cases.
223775553|NCT06146244|PROCEDURE|sinus lift|Implant placement on grafted sinus vs antral autogenous bone
223685594|NCT04682873|DRUG|Enisamium Iodide|"Capsule formulations of the active product (enisamium iodide 500 mg; Investigational medicinal product 1 \[IMP-1\]).~1 capsule Amizon® Max contains: enisamium iodide 500 mg.~Amizon® Max (active ingredient: enisamium iodide; IMP-1 will be administered as 1 capsule 4 times a day, every 6 hours (total dose 2,000 mg per day). Capsule will be taken orally (swallowed whole), together with a sufficient amount of liquid (preferably water).~Treatment will start on Day 1 (randomization) and for up to 168 hours after the first dose administration i.e. Day 7 or Day 8. The site staff will ensure that the IMP (1 capsule) is taken every 6 hours by the study subjects.~For documentation purposes, the IMP-1 packs (empty blister / blister with unused capsules) will be kept at the site and drug accountability forms are completed."
223685595|NCT04682873|DRUG|Placebo|"Capsule formulations of the reference product placebo Amizon® Max (IMP-2), will be identical in appearance (size, shape, and color), taste, and smell as the active formulation capsule.~1 capsule placebo Amizon® Max contains: placebo (no active substance).~Amizon® Max placebo (IMP-2), will be administered as 1 capsule 4 times a day every 6 hours. Capsule will be taken orally (swallowed whole), together with a sufficient amount of liquid (preferably water).~Treatment will start on Day 1 (randomization) and for up to 168 hours after the first dose administration i.e. Day 7 or Day 8. The site staff will ensure that the IMP (1 capsule) is taken every 6 hours by the study subjects.~For documentation purposes, the IMP-2 packs (empty blister / blister with unused capsules) will be kept at the site and drug accountability forms are completed."
223685596|NCT04946461|DRUG|Dexamfetamine Sulfate 5 Mg Oral Tablet|The dosage is set based on the recommendation of the practitioner. Dexamphetamine is administered twice a day, with an interval of 4 hours.
223685597|NCT04946461|DRUG|Lisdexamfetamine Dimesylate|The dosage is set based on the recommendation of the practitioner. Lisdexamphetamine is only administered once a day.
223685598|NCT04946461|BIOLOGICAL|blood samples|The blood samples will be taken at set times: 0, 2, 4, 6, 9 and 12 (hours)
223685599|NCT00660556|DEVICE|Archimedes Constant Flow Pump & System|Pump implanted in abdomen with intrathecal delivery (catheter) for pain.
223685600|NCT06168760|DIAGNOSTIC_TEST|Anthropometric Measurements|Anthropometric measurements of the hand were measured with a digital caliper. Anthropometric measurements were determined as hand length, width and finger lengths, taking into account previous studies. Manual dexterity was evaluated with the 9-Hole Peg Test.
223685601|NCT00582283|DRUG|I124-NM404|I-124-NM404
223685602|NCT02547714|DRUG|Secukinumab (AIN457)|Secukinumab was supplied as 150 mg doses, provided in 1 mL prefilled syringes.
223685603|NCT00381251|DRUG|Formulations A and B of Premarin/MPA 0.45 mg/0.5 mg and PREMPRO0.45 mg/0.5 mg|
223685604|NCT03311620|PROCEDURE|Endobronchial ultrasound (EBUS) transbronchial needle aspirate (TBNA)|Biopsy samples will be collected from patients scheduled to undergo EBUS TBNA using 19g and 22g needles
223685605|NCT00474838|DRUG|intensive insulin group|Once daily long acting insulin and preprandial rapid acting insulin injection
223685606|NCT00474838|DRUG|Oral AntiDiabetic Drug (glimepiride and metformin)|glimepiride and metformin combined therapy
223685607|NCT03512015|OTHER|The Lung Cancer App - LuCApp|The Intervention Arm receiving LuCApp (The Lung Cancer App) in addition to standard care
223685608|NCT03512015|OTHER|Standard care|The Standard-of-Care patients receiving following the same schedule identified for LuCApp patients with paper questionnaires during clinic visits, or at home (having received paper questionnaires during the previous visit) or via telephonic interviews with the research team.
223775554|NCT06146244|DEVICE|resonance frequency analysis|analysis of the ISQ evolution and its changes after 3 months of placing the implant in native or regenerated bone, always in the antral area
223685609|NCT00752024|DEVICE|YL-1 type of intracranial hematoma puncture needle|"YL-1 type of intracranial hematoma puncture needle(Pat. NO.is ZL：93244252•8) was originated by Beijing WanTeFu Medical Apparatus Co.Ltd in 1997. With integration of needle and bur drill it is designed as hard tunnel.By the technique of skull self-holding, the puncture needle can being fixed in the target of haematoma for several days.This technique is convenient, simple and safe.~To position haematoma's location, drills 3 millimeter holes in the localization point of puncture, then insert the drainage tube to inhale haematoma, gives the filament resolver interrupted for liquefication drainage afterward."
223775555|NCT00099697|DRUG|DHEA|
223775556|NCT02164682|PROCEDURE|IV PCA group|The IV PCA is performed by injecting fentanyl 15 mcg/kg with the following regimen
223775557|NCT02164682|PROCEDURE|IV PCA+ caudal block group|The IV PCA is performed by injecting fentanyl 15 mcg/kg with the following regimen + caudal block was 0.15% ropivacaine 1.2 cc/kg; a total volume of 100 cc, basal 2 cc, bolus 0.5 cc, and lockout time 15 minutes.)
223685610|NCT00752024|DRUG|dehydrating agent, haemostatic|In the treatment, under the convention we use the dehydrator for patients, the ultra early patient may use anti-filament medicinal preparation 6- amino-caproic acid 6-12g/d, intravenous drip, the period of revolution does not surpass for 24 hours, then just right for the illness treatment.
223685611|NCT03269110|DIAGNOSTIC_TEST|SRS 2, CBCL, BRIEF-P|This study does not involve an intervention.
223775558|NCT02479425|PROCEDURE|patient positioning|positioning patients, every 2 hours, either to standard (right, back, left sides) or only to right and left sides
223685612|NCT05152862|PROCEDURE|Laser|Retinal laser photocoagulation
223685613|NCT05152862|PROCEDURE|Anti VEGF|Anti-VEGF intravitreous injection
223685614|NCT06157398|OTHER|Increased EPA, DHA, fruit, and vegetable intake|Participants will receive food deliveries for approximately 4-weeks via online ordering, meal delivery, and dietician counseling.
223685615|NCT04166149|DIAGNOSTIC_TEST|dd-cfDNA Blood Test|The cfDNA measurement isolated from the peripheral blood contains small amounts from the graft. The blood sample is collected in Cell-Free DNA BCT (blood collection) tubes. These are measured by their difference in SNP (single nucleotide polymorphisms) genotype to determine the ratio of donor to recipient through shotgun sequencing. Higher levels of dd-cfDNA in a patient experiencing rejection is measured as a higher percentage of the total cf-DNA.
223775559|NCT00000465|PROCEDURE|angioplasty, transluminal, percutaneous coronary|
223775560|NCT00000465|PROCEDURE|coronary artery bypass|
223775561|NCT00804297|DRUG|Octreotide (drug)|
223685616|NCT03987373|OTHER|non-interventional|This study is a non-interventional, observational study. After completing 12-month treatment from DACAB trial, investigators would not make any interventions or impact on subjects' therapeutic strategy.
223685617|NCT03558412|COMBINATION_PRODUCT|CODOX-M/IVAC|Given ivgtt
223685618|NCT03558412|DRUG|Decitabine|Given ivgtt
223685619|NCT06321029|BEHAVIORAL|Diabetes Tune-Up Group|The eDTU and iDTU interventions will consist of 6 weekly group sessions lasting 90 minutes per session offered over a 6-8 week period. Each series will be co-facilitated by one diabetes care and education specialist and one behavioral health interventionist. Enrollment in each series will consist of 4-10 patients per group. The intervention components integrate key strategies that have been demonstrated to be effective in previous studies: motivational interviewing and introduction to stages of change; diabetes education; cognitive behavioral therapy with a particular emphasis on identification of cognitive distortions, thought stopping and cognitive reframing; emotional regulation; social support and miscarried helping; and behavioral strategies to support diabetes self-management. Each session will involve a psychoeducational portion, group discussion, and take-home assignments to be completed between sessions.
223685620|NCT01920009|BEHAVIORAL|Pharmacist counselling session with a motivational interview|"The intervention:~The patient will be invited by the community pharmacist for two consultations the first 2 weeks after discharge and the second after 3 months.~The intervention group consultation:~Community pharmacy consultation around 2 weeks The consultation will take place in the pharmacy a face to face consultation for 20 minutes including; Motivational interview session, the pharmacists will incorporate the key motivational interview skills in their consultation Express empathy, develop discrepancy, role with resistance, support self efficacy.~The sessions will aim to develop a partnership between the pharmacist with the patient and exchange information to facilitate an informed decision. Furthermore both the pharmacist and the patient will negotiate behaviour and reach an agreement. The goal is to access motivation and elicit commitment to change behaviour in this case would be adherence to life saving medication"
223685621|NCT02779465|DRUG|Vitamin D3|Participants with chronic hepatitis B will take 800 IU of vitamin D3 per day by mouth besides the anti-virus treatment with nucleos(t)ide medicine
223685622|NCT01389518|DRUG|Active|1 capsule de active (fixed combination of acetaminophen, chlorpheniramine and phenylephrine) administered in four 4-hour period of wakefulness in between at 07:00 and 23:00 (five daily doses) for two or three consecutive days
223685623|NCT01389518|DRUG|Placebo|1 capsule administered in four 4-hour period of wakefulness in between at 07:00 and 23:00 (five daily doses) for two or three consecutive days
223685624|NCT05715723|DRUG|Reamberin|Reamberin® in the average daily dose of 10 ml/kg daily
223775562|NCT04025918|DEVICE|Vasopressor automated delivery system|"Novel closed-loop system incorporating:~1. Continuous non-invasive arterial pressure (CNAP) monitor that measured and recorded hemodynamic data in real time.~2. Controller algorithm loaded onto a laptop computer that monitored the hemodynamic data from CNAP and determined if vasopressors should be administered.~3. Two syringe pumps loaded with phenylephrine and ephedrine that was activated by the controller algorithm."
223775563|NCT04025918|DRUG|Phenylephrine|Phenylephrine is a vasopressor drug that was administered when the participant's systolic blood pressure fell below 90% of baseline systolic blood pressure, with heart rate of at least 60bpm.
223685625|NCT05341934|OTHER|Evaluative Conditionning Task|A word will appear in one of the four quadrants on the computer screen. They will have to answer the word as quickly as possible by pressing the space bar. They will also be told that an image will be displayed briefly (400 ms) in the same quadrant by pressing the answer key. This procedure will be repeated for 120 trials: 30 trials with alcohol-related Conditional Stimulus (CS), 30 trials with CS related to non-alcoholic beverages and 60 trials with the CS of filling. The CS referring to alcohol will be the words Beer, Wine …; The CS referring to soft drinks will be the words Coca-Cola, Fanta… and Filling CS referring to vegetables and fruits will be: Apple, Banana…In experimental conditions, alcohol-related CS will be followed by negative Unconditional Stimuli (US) (images from the International Affective Picture System (Lang, Bradley, \& Cuthbert, 1997)), CS referring to soft drinks linked to positive images and CS referring to fruits and vegetables will be linked to neutral US.
223775564|NCT04025918|DRUG|Ephedrine|Ephedrine is a vasopressor drug that was administered when the participant's systolic blood pressure fell below 90% of baseline systolic blood pressure, with heart rate of less than 60bpm.
223685626|NCT04168697|BEHAVIORAL|Wim Hof method|8-week behavioral modification intervention instructing the participants in a combination of breathing exercises, cold exposure and meditation
223775565|NCT04025918|DEVICE|Manual vasopressor delivery system|"Manual dosing system consisting:~1. Non-invasive intermittent blood pressure monitor that measured and recorded blood pressure at 1-minute intervals.~2. Attending anesthesiologist that noted the blood pressure readings and manually administered phenylephrine or ephedrine according to the algorithm."
223775566|NCT05637151|OTHER|clamp time of umbilical|The umbilical cord was clamped immediately or late for more than 30s
223685627|NCT05602649|DRUG|Cannabis|Cannabis will be orally ingested
223685628|NCT05602649|DRUG|Placebo|Placebo will be orally ingested
223685629|NCT06206213|BEHAVIORAL|Assessment of two different locomotion types.|Exposure to virtual environment by the HMD in two different locomotion styles.
223685630|NCT06631209|DEVICE|Transcranial Magnetic Stimulation (TMS)|Specifically, Continual Theta Burst Stimulation
223685631|NCT06631209|OTHER|Sham|Sham TMS
223685632|NCT06172465|OTHER|EOIP|Ultrasound guided External oblique intercostal block will be performed bilaterally.
223685633|NCT06172465|OTHER|OSTAP|Ultrasound guided oblique subcostal transversus abdominis plane block will be performed bilaterally.
223685634|NCT03306810|OTHER|AG service|The AG service group is divided to two 200 patients groups: 1) with AGS 2) with AGS extended to first control in 3 months (AG- nurse may be contacted by phone). Patients are followed up up to 5 years.
223685635|NCT02278341|DRUG|Roxadustat|Participants received initial dose of roxadustat orally as a tablet in doses of 100 mg, 150 mg or 200 mg, according to the average weekly dose of epoetin or darbepoetin alfa prior to randomization. Participants' roxadustat dosage was adjusted every 4 weeks to maintain Hb level within the target range 10.0 to 12.0 g/dL. Dose adjustment steps were as follows: 20, 40, 50, 70, 100, 150, 200, 250, 300, and 400 mg. Oral iron treatment of 200 mg was allowed for supplementation to support erythropoiesis. Treatment with intravenous iron was allowed only if certain protocol criteria were met.
223685636|NCT02278341|DRUG|Epoetin alfa|Participants received epoetin alfa via intravenous or subcutaneous injection, once a week, twice a week, or three times a week (TIW). Epoetin alfa dosage was adjusted to maintain Hb level within the target range. Dosing of epoetin alfa was per UK SmPC of Eprex®. Participants received IV iron supplementation according to the standard of care.
223685637|NCT02278341|DRUG|Darbepoetin alfa|Participants received darbepoetin alfa via intravenous or subcutaneous injection, once a week or once every other week. Darbepoetin alfa dosage was adjusted to maintain Hb level within the target range. Dosing of darbepoetin alfa was per EU SmPC of Aranesp®. Participants received IV iron supplementation according to the standard of care.
223685638|NCT02278341|DRUG|Iron|Oral iron treatment was recommended for supplementation to support erythropoiesis and as first-line treatment for iron deficiency, unless participant was intolerant to this treatment. For participants receiving roxadustat the recommended daily dose was 200 mg of elemental iron. Participants were advised to take roxadustat at least 1 hour before or 1 hour after oral iron. Intravenous iron supplementation for participants receiving roxadustat was allowed if all of the following criteria were met: The participant's Hb level had not responded adequately to roxadustat following two consecutive dose increases or reached the maximum dose limit, and participant's ferritin was \< 100 ng/mL (\< 220 pmol/L) or TSAT \< 20%, or the participant was intolerant of oral iron therapy. For participants treated with epoetin alfa or darbepoetin alfa, IV iron supplementation was given according to standard of care.
223685639|NCT05851105|BIOLOGICAL|α-globin restored autologous hematopoietic stem cells|α-globin restored autologous hematopoietic stem cells modified with LentiHBA T\>C
223685640|NCT04902326|BEHAVIORAL|Automated educational text messages|"During the first two weeks, participants receive a series of educational messages delivered via text message. These messages welcome participants to the study, set expectations for the next 12 months, and establish a general level of knowledge among all participants on prediabetes, the Diabetes Prevention Program (DPP), and metformin.~For the next 11.5 months, participants receive three automated text messages per week that provide evidence-based educational content about prediabetes and tips on prevention. Additionally, participants receive monthly messages reminding them about their health insurance plan's coverage of the DPP at no cost and coverage of metformin as a low co-pay medication, and monthly messages providing feedback on their participation in the DPP and use of metformin in the previous calendar month. Participants' PCPs receive quarterly chart updates about participation in the DPP and use of metformin, and A1c results at enrollment and 6 and 12 months."
223685641|NCT04902326|BEHAVIORAL|Autonomy-supportive automated educational text messages|Participants receive the same text messages as in the automated educational text message intervention, but the thrice weekly messages have been modified, where applicable, to support the participant's autonomy, in accordance with principles of Self-Determination Theory. Participants' PCPs receive quarterly chart updates about participation in the DPP and use of metformin, and A1c results at enrollment and 6 and 12 months.
223685642|NCT04902326|BEHAVIORAL|Financial incentives|Participants in this arm have the opportunity to earn a financial incentive ranging from $50 to $250 per month for taking an evidence-based action to prevent T2DM (i.e., engagement in a DPP or fill of a metformin prescription) in the previous month.
223775567|NCT04231344|DEVICE|Laryngoscopy|Laryngoscopic examination of patients with GERD by two physicians
223685643|NCT04902326|BEHAVIORAL|Tailored text messages|Participants receive twice-weekly tailored text messages that link evidence-based actions to prevent T2DM to the participant's self-identified top values, roles, and strengths. Text messages are also tailored, when possible, to participants' self-reported importance of taking action to try to prevent T2DM (i.e., participating in the DPP or taking metformin), confidence in being able to take such preventive action, and past preventive actions taken.
223685644|NCT02604017|DRUG|ABT-493/ABT-530|Tablet; ABT-493 coformulated with ABT-530
223685645|NCT00740246|DRUG|VIT-45|15 mg/kg up to a maximum dose of 1,000 mg of iron as VIT-45 over 15 minutes intravenously
223685646|NCT00740246|DRUG|Placebo|for weight \>33 kg, 250 cc of normal saline and for weight ≤33 kg, 100 cc of normal saline over 15 minutes intravenously
223685647|NCT02906384|RADIATION|hippocampus avoidance|conformal avoidance of the hippocampal neural stem-cell compartment during prophylactic cranial irradiation
223685648|NCT04578080|DEVICE|Transcranial direct current stimulation|Anodal or Sham tDCS will be applied in 1.5 mA, 20 mins before conventional physical therapy for 5 days. All experiments will be performed in random order for each subject.
223685649|NCT06521450|PROCEDURE|anti incontinence surgery|anti incontinence surgery with prolapse surgery will be performed simultaneously
223685650|NCT04297657|OTHER|Counselling|o An appointment was made with the women in the experimental group at a time when they were available and a suitable environment was arranged in the hospital. The counselling programme of the experimental group was conducted in four sessions one week apart. In addition, each woman in the experimental group was given a counselling booklet and compact disc. The interviews lasted between 15- 45 minutes. The topics of interest among women were noted in the interviews and after the information on the subject was received, feedback was given to the relevant woman through a phone call.
223685651|NCT02810353|DEVICE|Differential rapid maxillary expansion|Twenty-five patients will be submitted to rapid maxillary expansion using the expander with differential opening. Appliance anchorage will be provided by bands adapted either on the maxillary first permanent molars or on the second deciduous molars and circumferential clamps will be bonded to the maxillary deciduous canines. If the maxillary second deciduous molars will be banded, a lingual extension wire will be placed in the partially erupted maxillary first permanent molars. Both anterior and posterior screws will be activated with a complete turn a day during 6 days. Then, only the anterior screw will be additionally activated for 4 more days. After the active period of RME, the screws will be fixed with acrylic resin and the appliance will be kept as a retainer for 6 months.
223685652|NCT02810353|DEVICE|Conventional rapid maxillary expansion|Twenty-five patients will undergo rapid maxillary expansion using conventional Hyrax expander. Bands will be adapted either on the maxillary first permanent molars or on second deciduous molars and circumferential clamps will be bonded to the maxillary deciduous canines. Similarly to the experimental group, a lingual extension wire will be placed in the partially erupted maxillary first permanent molars if the maxillary second deciduous molars will be banded. The expander screw will be activated with a complete turn a day during 6 days. After the expansion active phase, the screw will be fixed with acrylic resin and the appliance will be kept in the dental arch as a retainer for 6 months.
223685653|NCT03066973|BEHAVIORAL|BREATHING EXERCISE|The intervention group was instructed on breathing exercise according to the established trial protocol.
223685654|NCT01117051|DRUG|placebo|placebo
223685655|NCT01117051|DRUG|prucalopride|1 or 2 mg prucalopride once daily before breakfast
223685656|NCT05596123|BEHAVIORAL|Therapeutic Chinese foot massage|Participants in the TCFM group will receive six weekly 25-minute TCFM sessions by a therapist. Each session will start with an assessment of the legs and toes of the affected extremity for broken skin and lesions, which the therapist will try to avoid. The participant will be positioned with support to their foot and legs, with the sole directed downward and the therapist directly in alignment with the soles of the foot. The therapist will sequentially perform the following four steps for each TCFM session.
223685657|NCT05596123|BEHAVIORAL|Placebo massage|The same therapist will give six weekly 25-minute placebo massage sessions to participants in the placebo massage group. These sessions will include assessing the affected extremity's legs and toes for lesions and broken skin in order to avoid them during the massage, as well as gentle foot and toe rubbing without any point stimulation or other TCFM techniques.
223775568|NCT05854147|DIAGNOSTIC_TEST|Treadmill Training With Visual and Auditory Cues|Comparison of Effects of Treadmill Training With Visual and Auditory Cues
223775569|NCT05854147|DIAGNOSTIC_TEST|Treadmill Training Without Visual and Auditory Cues|Comparison of Effects of Treadmill Training Without Visual and Auditory Cues
223685658|NCT02398279|DIETARY_SUPPLEMENT|L-Arginine|Experimental supplement
223685659|NCT02398279|OTHER|Placebo|Placebo capsules in the same color and shape with the experimental supplement
223685660|NCT04809636|OTHER|This is not an interventional study|While this is not an intervention, there will be separate participants for the survey study and for the other components of the study (focus groups, interviews, conjoint analysis, piloting the vignettes
223685661|NCT05440149|RADIATION|No PMRT for mastectomy / No regional RT for BCS|"* Regional RT includes high-tangent field, and can include undissected axilla.~* The definition of high-tangent is that the upper margin of the radiotherapy field located within 2 cm of the humeral head to include axillary levels I and II.~* Both hypofractionated and conventionally fractionated radiation therapy are allowed, and 3-dimensional or intensity modulated radiotherapy are allowed. The electron beam can also be used."
223685662|NCT05440149|RADIATION|PMRT for mastectomy / WBI + Regional RT for BCS|"* Regional RT includes high-tangent field, and can include undissected axilla.~* The definition of high-tangent is that the upper margin of the radiotherapy field located within 2 cm of the humeral head to include axillary levels I and II.~* Both hypofractionated and conventionally fractionated radiation therapy are allowed, and 3-dimensional or intensity modulated radiotherapy are allowed. The electron beam can also be used."
223685663|NCT02911207|BEHAVIORAL|patients choose one creative activity and one physical activity|taking part in 2 activities (a creative one and a physical one)
223685664|NCT03447197|PROCEDURE|The use of extracorporeal circulation|The use or not of extracorporeal circulation during the coronary artery bypass procedure.
223685665|NCT04643470|DRUG|Zanubrutinib|Administered as specified in the treatment arm
223685666|NCT04643470|DRUG|Placebo|Placebo to match zanubrutinib
223685667|NCT01087866|DRUG|Metformin|
223685668|NCT01087866|DRUG|Insulin|
223685669|NCT00005934|DRUG|5-Azacytidine|
223685670|NCT01894412|BIOLOGICAL|Etanercept (Enbrel)|
223685671|NCT01894412|BIOLOGICAL|HD203|
223685672|NCT00550056|BEHAVIORAL|Narrative Exposure Therapy|Six session of Narrative Exposure Therapy
223685673|NCT00550056|BEHAVIORAL|Trauma Counselling|Six sessions of Trauma Counselling, using a variety of skills incl. exposure methods following the skills of the therapist
223685674|NCT05956379|OTHER|exercise|Physical therapists will provide personalized aerobic exercise program prescriptions in the preparatory period based on the results of exercise-related assessments, and the training intensity is based on the results of the maximum exercise test, with moderate intensity for 24 weeks, \>=3 cardio workouts per week. The form of aerobic exercise can be carried out in the form of treadmill walking, walking, jogging, cycling, aerobic dance, ball games, swimming, rope skipping, stepping exercises, etc. When the exercise reaches the target intensity, we will adjust the training intensity process according to personal ability. The physical therapist will again adjust the content of the aerobic exercise program at week 12 based on the reassessment of the exercise capacity.
223685675|NCT02545231|DRUG|Pitavastatin 1mg|To compare different doses of statins on atherosclerosis progression and neointimal hyperplasia
223685676|NCT02545231|DRUG|Pitavastatin 4mg|To compare different doses of statins on atherosclerosis progression and neointimal hyperplasia
223685677|NCT02545231|DRUG|Placebo|To compare different doses of statins on atherosclerosis progression and neointimal hyperplasia
223685678|NCT05602311|DRUG|General anesthetic|Monitoring the changes of brain functional connectivity and assess cognition in two groups after general anesthesia
223685679|NCT04699253|DEVICE|SanaCoach Heart failure|Patients will be using the SanaCoach heart failure for at least 6 months during the study period. SanaCoach heart failure is a web application that will be guiding the patient through a regular, systematic assessment of patient's health and wellbeing as well as regular education sessions. The assessment frequency ranges from daily to monthly, based on the settings provided by the health care provider. Furthermore, it provides a repository for patient's care plan to give insight into the course and treatment of the disorder and offers the possibility to contact the health care provider through the web application.
223685680|NCT00366340|BIOLOGICAL|13-valent pneumococcal conjugate vaccine|Single 0.5mL dose given at 2, 3, 4 and 11 to 12 months of age
223775570|NCT02527720|BEHAVIORAL|Mindfulness Therapy|BBMT is a simplified form of MM. Its core components are near resonance-frequency breathing (RFB), mindfulness training, positivity and inward attention. A key component in BBMT is to be mindful of breathing whenever possible, and breathe at near resonance frequency (RF), known as heart rate variability biofeedback. The human cardiovascular system is known to have resonance characteristics, with the first RF at \~0.1 Hz. RF varies between 4.5 and 7 cycles per minute. Breathing at RF stimulates the cardiovascular system to oscillate at that frequency at a very high amplitude and greatly stimulates the baroreflex system. RFB is known to reduce depression and stress symptoms as well as various diseases related to malfunction of the autonomic nervous system, such as asthma and hypertension.
223775571|NCT04100226|DIETARY_SUPPLEMENT|Vitamin D3 (1.25 (OH)2 cholecalciferol)|"Vitamin D 3 in a dose of 200.000 IU intramuscular injection every 2 weeks for 3 months for Vitamin D deficient interstitial lung disease patients and every month for 3 months for vitamin D insufficient interstitial lung disease patients.~calcium supplementation in form of ca carbonate 600 mg oral capsule once daily for 3 months for all patients."
223775572|NCT01694706|DRUG|faldaprevir|medium dose of faldaprevir
223685681|NCT00366340|BIOLOGICAL|7-valent pneumococcal conjugate vaccine|Single 0.5mL dose given at 2, 3, 4 and 11 to 12 months of age
223685682|NCT06338605|OTHER|no intervention, observational study of AKI under CDK4/6 inhibitor treatment|no intervention
223685683|NCT00354900|DRUG|Aprotinin|
223775573|NCT01694706|DRUG|faldaprevir|medium dose of faldaprevir
223775574|NCT01694706|DRUG|omeprazole|medium dose of omeprazole
223685684|NCT03597217|DRUG|PF-05221304|3, 10, 50 mg
223685685|NCT03597217|DRUG|PF-05221304|50 mg multiple dose
223685686|NCT03597217|DRUG|Placebo|Placebo
223685687|NCT01110070|DEVICE|ChonDux|Comparison of ChonDux plus microfracture to microfracture only
223685688|NCT01110070|DEVICE|ChonDux|single use device
223685689|NCT03152422|DIAGNOSTIC_TEST|Urinary proteomics|Urinary proteomics for risk stratification and graft monitoring in recipients of a heart transplant
223685690|NCT06057155|DIAGNOSTIC_TEST|ultrasound optic nerve sheath diameter assessment|ultrasound optic nerve sheath diameter assessment
223775575|NCT01694706|DRUG|faldaprevir|medium dose of faldaprevir
223775576|NCT02229955|DRUG|Cyclosporine ophthalmic solution|1 drop twice/day for 12 weeks to both eyes
223775577|NCT04790149|OTHER|Conventional Rehabilitation|Motor Imagery Training combined with Active functional exercises
223685691|NCT00132106|DRUG|phentolamine|
223685692|NCT03745430|DRUG|Ramucirumab|8 mg/kg (days 1 and 15, q4w) until disease progression
223685693|NCT02598336|DEVICE|Structured Light Plethysmography|Non contact device that uses light to record displacement of the anterior thorax and abdomen region
223685694|NCT02598336|DEVICE|Pneumotachograph Spirometry|Device that measures airflow at the mouth using a mouthpiece
223685695|NCT06268145|DRUG|ECC5004|A single dose tablet of 50 mg of the current tablet formulation (F1) or new tablet formulation (F2) administered orally.
223685696|NCT00489190|DRUG|Insulin Glulisine|
223685697|NCT03662243|BEHAVIORAL|Multicomponent reading and writing treatment|Intervention procedures incorporated into the program include drilling on sight words to improve immediate recognition of common words; engaging in Multiple Oral Reading procedures to increase reading fluency; practicing oral spelling of sight words to improve spelling accuracy; generating written sentences to improve accurate spelling and use of written conventions (e.g., punctuation, capitalization); and summarizing and subsequently writing sentences about read material to establish strategies to enhance reading comprehension and promote written expression.
223685698|NCT05413278|BEHAVIORAL|Behavioral|Patient education, information and empowerment
223685699|NCT02392845|DRUG|Combination of Docetaxel (DTX) and Epirubicin (EPI)|Six cycles of densified DTX+EPI chemotherapy (2 weeks per cycle) for each patient
223685700|NCT04784104|DRUG|Bupivacaine HCl 0.5% Injectable Solution|30 ml of bupivacaine (Bupivacaine HCl %0.5) and prilocaine (Priloc HCl %2) 1:1 mixture will be prepared in a way that there will be 5 mcg adrenaline per ml. (14 ml. bupivacaine, 14 ml. prilocaine and 2 ml saline with 5 mcg adrenaline per ml.)
223685701|NCT04784104|DRUG|Prilocaine HCl 2% Injectable solution|30 ml of bupivacaine (Bupivacaine HCl %0.5) and prilocaine (Priloc HCl %2) 1:1 mixture will be prepared in a way that there will be 5 mcg adrenaline per ml. (14 ml. bupivacaine, 14 ml. prilocaine and 2 ml saline with 5 mcg adrenaline per ml.)
223685702|NCT04784104|DRUG|Adrenaline amp. 0.5 mg|30 ml of bupivacaine (Bupivacaine HCl %0.5) and prilocaine (Priloc HCl %2) 1:1 mixture will be prepared in a way that there will be 5 mcg adrenaline per ml. (14 ml. bupivacaine, 14 ml. prilocaine and 2 ml saline with 5 mcg adrenaline per ml.)
223685703|NCT04784104|PROCEDURE|Ultrasound guided supraclavicular block with coronal oblique method|The blocks will be performed by an experienced anesthesiologist with a USG guidence.
223775578|NCT04790149|OTHER|NEUROM + tDCS|NEUROM combined to tDCS
223685704|NCT04784104|PROCEDURE|Ultrasound guided lateral sagittal infraclavicular block|The blocks will be performed by an experienced anesthesiologist with USG guidence.
223685705|NCT02389075|PROCEDURE|Pinch biopsies|Biopsies obtained during colonoscopy or flexible sigmoidoscopy.
223685706|NCT02389075|PROCEDURE|Flexible sigmoidoscopy|Offered to subjects with ankylosing spondylitis who do not meet criteria for colonoscopy
223685707|NCT00057681|DRUG|Lithium carbonate|Titrated until blood level is 1.1 to 1.3 mEq/L
223685708|NCT00057681|DRUG|Valproate|Titrated until blood level is 111 to 125 ug/mL
223685709|NCT00057681|DRUG|Risperidone|Titrated by weight until dose is 2.0 mg BID to 3.0 mg BID
223685710|NCT05216601|BIOLOGICAL|MVC-COV1901|Approximately 40 participants who previously completed two (Group A) or three (Group B) doses of MVC-COV1901 will receive 1 doses of MVC-COV1901 at Visit 2 (Day 1) via intramuscular (IM) injection in the deltoid region. Group A and B
223685711|NCT05216601|BIOLOGICAL|MVC-COV1901(Beta)-15|Approximately 40 participants who previously completed two (Group A) or three (Group B) doses of MVC-COV1901 will receive 1 doses of MVC-COV1901(Beta)-15 at Visit 2 (Day 1) via intramuscular (IM) injection in the deltoid region
223685712|NCT05216601|BIOLOGICAL|MVC-COV1901(Beta)-25|Approximately 40 participants who previously completed two (Group A) or three (Group B) doses of MVC-COV1901 will receive 1 doses of MVC-COV1901(Beta)-25 at Visit 2 (Day 1) via intramuscular (IM) injection in the deltoid region
223685713|NCT01315236|DRUG|Liposomal amikacin for inhalation (LAI)|"* Liposomal amikacin for inhalation is provided as a sterile aqueous liposomal dispersion for inhalation via nebulization.~* 590 mg of liposomal amikacin for inhalation is administered once daily using the PARI Investigational eFlow® Nebulizer.~* Administration time is approximately 13 minutes.~* Liposomal amikacin for inhalation will be administered for 84 days in the double-blind, randomized portion of the study.~* Subjects can continue with 84 additional days of dosing in the open label extension."
223685714|NCT01315236|DRUG|placebo|"* Placebo is provided as a sterile aqueous lipid dispersion for inhalation via nebulization.~* Administration procedures, volume and administration time are similar to LAI.~* Placebo will be administered for 84 days only during the double-blind, randomized portion of the study."
223685715|NCT01618812|PROCEDURE|Lateral lengthening osteotomy of calcaneus|Use of artificial bone graft
223775579|NCT04790149|OTHER|NEUROM|protocol to induce motor recovery
223775580|NCT00975975|DRUG|Basiliximab|Basiliximab given 1 time on Day +7 or Day +9.
223775581|NCT01252251|DRUG|RAD001 (Everolimus) and Pasireotide (SOM230) LAR|Patients will be treated with SOM-230 (pasireotide) LAR 60mg IM once every 28 days and with RAD001 (Everolimus) 10mg PO daily. Each cycle is 28 days. An optional biopsy may be requested required after weeks of therapy. The biopsy may be performed between days 28 and 42.
224263212|NCT01543360|PROCEDURE|Subclavian strategy|The first two attempts at central venous catheterization will be performed by the medial approach (subclavian vein). The third and fourth attempts at central venous catheterization will be performed by the distal approach (axillary vein). The same puncture material/devices will be used in both arms of the study.
224263213|NCT01837914|PROCEDURE|Maxillary expansion|
224263214|NCT01837914|PROCEDURE|Adenotonsillectomy|
224263215|NCT03195595|DEVICE|mitral valve replacement|early postoperative outcome regarding pain in minimal invasive technique
224263216|NCT03195595|DEVICE|conventional mitral valve replacement|early postoperative outcome regarding pain in conventional median sternotomy
224263217|NCT01496495|DRUG|ARRY-614, p38/Tie2 inhibitor; oral|Part 1: multiple dose, escalating; Part 2: multiple dose, single schedule
224263218|NCT03811418|DRUG|Trastuzumab|"administered as combined therapy with pertuzumab and vinorelbine or docetaxel.~Trastuzumab will be administered as an IV loading dose of 8 milligrams per kilogram (mg/kg) on day 1 of cycle 1 (1 cycle length = 21 days), and 6 mg/kg Q3W on day 1 of subsequent cycles until progressive disease, intolerable toxicity, or death."
224263219|NCT03811418|DRUG|Pertuzumab|"administered as combined therapy with Kanjinti® and vinorelbine or docetaxel.~Pertuzumab will be administered as an IV loading dose of 840 milligrams (mg) on day 1 of cycle 1 (1 cycle length = 21 days), and 420 mg Q3W on day 1 of subsequent cycles until progressive disease, intolerable toxicity, or death."
224263220|NCT03811418|DRUG|Vinorelbine|"administered as combined therapy with Kanjinti® and pertuzumab.~Vinorelbine will be administered as an IV dose of 25 milligrams per kilogram (mg/kg) on days 1 and 8 of cycle 1 (1 cycle length = 21 days), and 25mg/kg up to 30 mg/kg (as per treating physician discretion) Q3W on day 1 of subsequent cycles until progressive disease, intolerable toxicity, or death."
223685716|NCT00442468|OTHER|Non-interventional study.|This is a non-interventional (no drug treatment administered), prevalence (observational) study.
223685717|NCT00240474|DRUG|Telmisartan 80 mg + hydrochlorothiazide 12.5 mg|
223685718|NCT00240474|DRUG|Amlodipine 10 mg + hydrochlorothiazide 12.5 mg|
223685719|NCT05999539|DEVICE|Transtibial prosthesis|A transtibial prosthesis to be used for at least one year.
223685720|NCT02483052|DEVICE|RejuvenAir|RejuvenAir
223685721|NCT05065775|DEVICE|Dexmedetomidine|Single intranasal dexmedetomidine dose of 100 µg. Intranasal dexmedetomidine will be administered shortly after induction of anesthesia using a mucosal atomization devise (LMA MAD Nasal™)
223685722|NCT03186885|BEHAVIORAL|Healthy Frio In-Person Family-focused Intervention|Participants learn about energy balance behaviors, skills to support health behavior change, managing personal wellness, and parenting strategies. Sessions use interactive learning strategies to elicit knowledge and experience of participating families to encourage families to learn from each other. YMCA staff members lead a 50-minute group exercise session after each health education session to help participants meet their commitment of engaging in PA at least 3 times/week.
223685723|NCT03186885|BEHAVIORAL|Healthy Frio Remote Technology Family-focused Intervention|Tablet computers will be used as the platform to deliver the health education content for the FI-RT. Each session will present the class content and guide the participants to complete class activities. Videos of health education and class activities (e.g., cooking demonstrations, exercise demonstrations) will be embedded in the lesson. Interactive assessment questions with feedback will be presented throughout the session to check for understanding of the content. Viewing time and responses to the assessment questions will be recorded to evaluate progress and comprehension. Participants will view the health education sessions at home as a family and discuss the content as prompted by lesson instructions.
223685724|NCT03186885|BEHAVIORAL|Control|Participants receive standard of care
223685725|NCT03115580|DEVICE|Rotational atherectomy|"Rotational atherectomy for the treatment of bifurcation lesions to remove plaque with minimal injury to adjacent normal arterial segments and potentially reduce plaque shifting, the snow plow effect."
223685726|NCT03115580|DEVICE|Cutting Balloon Angioplasty|Cutting balloon is a special balloon catheter with three or four microsurgical blades attached longitudinally to its surface, suitable for creating discrete longitudinal incisions in the atherosclerotic target coronary segment during balloon inflation. Lesion preparation will be performed using Cutting Balloon or conventional balloon
223685727|NCT04111952|DEVICE|CO2 laser|A single session of CO2 vaginal laser treatment
223685728|NCT04111952|DEVICE|Sham laser|A single session of sham laser treatment.
223685729|NCT05115890|OTHER|Exercise training|Patients with HFpEF will undergo 8 weeks of exercise training.
223685730|NCT00814125|DRUG|Anastrozole (Arimidex)|1mg, orally, once daily
223685731|NCT00814125|DRUG|Tamoxifen (Nolvadex)|20mg, orally, once daily
223685732|NCT00814125|DRUG|Nolvadex placebo|
223685733|NCT00814125|DRUG|Arimidex placebo|
223685734|NCT05829187|DRUG|Dihydroartemisinin|dihidroartemisinin dose of 2-4 mg/Kg Body weight taken for 3 days
223685735|NCT05829187|DRUG|Piperaquine|piperaquine at a dose of 16-32 mg/Kg body weight taken for 3 days
223685736|NCT05829187|DRUG|Primaquine|Primaquine dose 0.25 mg/kg body weight given to uncomplicated Plasmodium falciparum patients on the first day only
223685737|NCT05829187|DRUG|Momordica Charantia Extract|Momordica charantia extract capsules at a dose of 325 mg were given to patients for 3 days
223685738|NCT02628665|DRUG|photosensitizer(photofrin)|photosensitizer(photofrin): 2mg/kg
223685739|NCT02628665|DEVICE|630 nm laser irradiation (DIOMED)|630 nm laser irradiation (DIOMED): The diseased tissue with laser irradiation in 1200 seconds.
223685740|NCT00589784|DRUG|Sunitinib|The study drug will be administered on an outpatient basis. The starting dose will be 50 mg daily for 28 days (4 consecutive weeks) followed by 14 days off for patients not on CYP3A4 inducers or inhibitors. A cycle equals 42 days.
223685741|NCT02669238|DEVICE|Nexplanon®|Subcutaneous implant (Nexplanon®) containing etonogestrel 68 mg
223685742|NCT02669238|DRUG|Minidril®/Leeloo®|continuous per os administration of oestroprogestative treatment. 1 pill a day First line: Minidril® (Levonogestrel 0.15 mg / Ethinylestradiol 0.03 mg) Second line: Leeloo® (Levonogestrel 0.1 mg / Ethinylestradiol 0.02 mg)
223685743|NCT03127956|DRUG|Olumacostat Glasaretil Gel, 5.0%|Gel containing Olumacostat Glasaretil
223685744|NCT04639037|DEVICE|Automated adjustment of vasopressor|The objective of this randomized controlled superiority study is to demonstrate that, in patients admitted to intensive care after a major surgery, tight control of MAP using a closed-loop system for vasopressor administration will result in MAP being more often within a MAP range of 80-90 mmHg compared to the same management without this automated closed-loop system (nurse adjustment of vasopressor administration)
223685745|NCT04639037|DEVICE|Manual adjustment of vasopressor|Fluid and vasopressor will be delivered as standard of care (manual adjustment of both fluid and vasopressor infusion rate by the nurse)
223685746|NCT00521001|DRUG|everolimus|
223685747|NCT00521001|DRUG|temozolomide|
224263221|NCT03811418|DRUG|Docetaxel|"administered as combined therapy with Kanjinti® and pertuzumab.~Docetaxel will be administered as an IV dose of 75 milligrams per square meter (mg/m\^2) on day 1 of cycle 1 (1 cycle length = 21 days), and 75 mg/m\^2 (up to 100 mg/m\^2 as per treating physician discretion) Q3W on day 1 of subsequent cycles until progressive disease, intolerable toxicity, or death."
224263222|NCT02728999|PROCEDURE|Steep Trendelenburg|"•Subjects who undergo steep Trendelenburg will remain in 30 degrees of Trendelenburg, and the da Vinci robot will be docked.~After subjects are asleep an arterial line will be place in one wrist by the anesthesiologist. It will be removed at the conclusion of the procedure."
223685748|NCT04245462|OTHER|No intervention|Cross-sectional
223685749|NCT03809793|OTHER|Exercise Program|12-week walking based intervention (3 sessions per week)
223685750|NCT03809793|DIAGNOSTIC_TEST|DXA|Participants will undergo an assessment of body composition (DXA)
223685751|NCT03809793|DIAGNOSTIC_TEST|MRI|used to measure fat stored in the liver
224263223|NCT02728999|PROCEDURE|Decreased Trendelenburg|"•Subjects who undergo decreased Trendelenburg will be taken out of Trendelenburg to the minimal angle possible that enables adequate visualization, as determined by the primary surgeon, at which time robot will be docked.~After subjects are asleep an arterial line will be place in one wrist by the anesthesiologist. It will be removed at the conclusion of the procedure."
224263224|NCT06628076|DIAGNOSTIC_TEST|Culture specific antibiotic therapy|Samples will be cultured on MacConkey agar. Morphological identifications of growth isolates by Gram staining, colony features and conventional biochemical tests. All isolates will be identified to species level using automated bacterial identification systems.
224263225|NCT06628076|DIAGNOSTIC_TEST|Antibiotic|Strains confirmed as A. baumannii will be examined for their different antibiotic susceptibility by modified Kirby Bauer\&#39;s disc diffusion method on Mueller Hinton Agar.
224263226|NCT06628076|DIAGNOSTIC_TEST|Biofilm assessment|The biofilm formation activity of A. baumannii isolates will be tested using the microtitre plate technique
224263227|NCT06628076|DIAGNOSTIC_TEST|nanoparticle zinc oxide|Detection of the effect of ZnO NPs on the biofilm producer MDR A. baumannii strains using the same method
224263228|NCT06628076|DIAGNOSTIC_TEST|Molecular detection of antibiotic resistance|\- Evaluation the effect of ZnO NPs on the expression of some efflux pump genes, and biofilm related genes in MDR A. baumannii isolates using Real time PCR technology.
224263229|NCT00264966|DRUG|ASM8|
224263230|NCT01522820|BIOLOGICAL|DEC-205/NY-ESO-1 Fusion Protein CDX-1401|Given intranodally
224263231|NCT01522820|OTHER|Laboratory Biomarker Analysis|Correlative studies
224263232|NCT01522820|OTHER|Pharmacological Study|Correlative studies
224263233|NCT01522820|DRUG|Sirolimus|Given PO or PEG
224263234|NCT00669162|DRUG|Docetaxel|20mg/m2 IV weekly for 7 weeks
224263235|NCT00669162|RADIATION|Radiation Therapy|66.0 Gy delivered in 33 daily fractions at 2.0 Gy/fx
224263236|NCT00669162|DRUG|Casodex and Zoladex (or Lupron)|Casodex 50 mg po daily for 6 months, and Zoladex 10.8 mg sc q 3 mos x 2 (or Lupron 22.5 mg im q 3 mos x 2)
224263237|NCT02799992|PROCEDURE|689 nm Laser Treatment of the Macula|
224263238|NCT02799992|PROCEDURE|Half Dose Photodynamic Therapy|
224263239|NCT01706757|DEVICE|go-cart|conducts exercises with the help of a go-cart
224263240|NCT03822130|DRUG|Arterial catheter infusion chemotherapy|Arterial catheter infusion chemotherapy
224263241|NCT03822130|DRUG|Sodium Bicarbonate|Arterial catheter infusion Sodium Bicarbonate
224263242|NCT03822130|DRUG|Systemic Chemotherapy|Systemic Chemotherapy
224263243|NCT03822130|DRUG|Oral Chemotherapy|Oral Chemotherapy
224263244|NCT04737863|PROCEDURE|Endodontic retreatment|Root canal retreatment in cases with secondary root canal infection
224263245|NCT02284750|PROCEDURE|Percutaneous coronary intervention|
224263246|NCT02412852|DRUG|Sodium nitrite|Sustained release formulation of sodium nitrite
224263247|NCT02412852|DRUG|Placebo|Placebo tablets containing same excipients and coatings used in the active tablets, without sodium nitrite being added.
224263248|NCT03110874|DRUG|one-way education|'Fluterol Inhalation Capsule(fluticasone propionate 250 μg, salmeterol xinafoate 72.5 μg) : one-way education'
224263249|NCT03110874|DRUG|two-way education|'Fluterol Inhalation Capsule(fluticasone propionate 250 μg, salmeterol xinafoate 72.5 μg) : two-way education'
224263250|NCT02330939|OTHER|Low fat- Low glycemic index meal|
224263251|NCT02330939|OTHER|MUFA- Low glycemic index meal|
224263252|NCT02330939|OTHER|SAFA- Low glycemic index meal|
224263253|NCT02330939|OTHER|Low fat- High glycemic index meal|
224263254|NCT02330939|OTHER|MUFA- High glycemic index meal|
224263255|NCT02330939|OTHER|SAFA- High glycemic index meal|
224263256|NCT02044731|BEHAVIORAL|Active and Healthy Families|A pediatric overweight/obesity intervention delivered through five bi-weekly family-based group sessions.
224263257|NCT03142022|OTHER|No intervention - Diagnostic polysomnography at 1 year after lung transplantation|
224263258|NCT04880616|DRUG|NBI-827104|Capsules for oral administration
224263259|NCT04880616|DRUG|Placebo|Capsules matching NBI-827104 for oral administration
224263260|NCT01961947|BIOLOGICAL|ASP7374|subcutaneous
224263261|NCT01961947|BIOLOGICAL|approved egg-derived TIV|subcutaneous
224263262|NCT00250263|DRUG|(agent for immunotherapy) Staloral|"Immunotherapy agent for sublingual daily use. First week (vial containing the concentration 10 IR/ml) Day 1 - 1 pressure Day 2 - 2 pressures Day 3 - 4 pressures Day 4 - 6 pressures Day 5 - 8 pressures Day 6 - 10 pressures~Second week (300 IR/ml) (vial containing the concentration 300 IR/ml) Day 7 - 1 pressure Day 8 - 2 pressures Day 9 - 4 pressures Day 10 - 6 pressures Day 11 - 8 pressures~Maintenance phase Day 12 to 364 - 8 pressures daily~The first year will be followed by a second year open label period (optional)- 8 pressures daily"
224263263|NCT00250263|DRUG|Placebo|"Matching placebo for sublingual use. Same schedule used for the intervention ACTIVE group.~First week (vial containing placebo) Day 1 - 1 pressure Day 2 - 2 pressures Day 3 - 4 pressures Day 4 - 6 pressures Day 5 - 8 pressures Day 6 - 10 pressures~Second week (300 IR/ml) (vial containing placebo) Day 7 - 1 pressure Day 8 - 2 pressures Day 9 - 4 pressures Day 10 - 6 pressures Day 11 - 8 pressures~Maintenance phase Day 12 to 364 - 8 pressures daily"
224263264|NCT03030664|DIETARY_SUPPLEMENT|L.reuteri|Each day, at about the same time, the subjects will be given 5 drops (1x10\^8 CFU) of the study product in connection with feeding
224263265|NCT03030664|DRUG|Placebo|Same formulation as study product, without probiotics.
224263266|NCT06354023|DRUG|Recombinant human growth hormone|All participants will receive six weeks of treatment. Once per week, they will receive one intra-articular injection of 2cc (15IU) recombinant human growth hormone in their affected knee. The injection will also contain 1cc (1%) Lidocaine and 1cc (0.5%) Marcaine and Epinephrine for anesthetic purposes. The participants will receive a total of 6 growth hormone injections.
224263267|NCT01051349|BIOLOGICAL|BIIB019 (Daclizumab)|Administered as specified in the treatment arm.
224263268|NCT01051349|BIOLOGICAL|trivalent seasonal influenza vaccine|All participants who participate in the 2013-2014 influenza vaccine substudy will receive the vaccine at the study site
224263269|NCT05921864|OTHER|Passive heat exposure|Participants will be exposed to heat in a chamber.
224263270|NCT05921864|OTHER|Active heat exposure|Participants will participate to a 6-hour run.
224263271|NCT01066858|DRUG|Tenofovir disoproxil fumarate (TDF)|Some participants will receive varying doses of TDF during pregnancy or breastfeeding as part of the larger study (IMPAACT 1077 PROMISE).
224263272|NCT06143202|DEVICE|Freestyle Libre 3 Continuous Glucose Monitor|Pediatric participants will wear a blinded Freestyle Libre 3 CGM. Data will not be available, and therefore the device will not be used to modify medical management.
224263273|NCT05724784|BEHAVIORAL|Flourish|Flourish is a text messaging program that aims to improve coping following cyberbullying and reduce suicide risk among youth.
224263274|NCT06129084|GENETIC|FGFR Testing|Determine whether ctDNA testing for FGFR provides the same results as the standard tissue testing.
224263275|NCT01844843|DEVICE|TCD-10023 drug eluting stent|Implantation of new drug eluting stent in coronary artery lesions
224263276|NCT05578443|DRUG|10g Astragalus|Astragalus tablets 10g, warm water to drink, once a day, take for 1 year, during which routine treatment should also be carried out.
224263277|NCT05578443|BEHAVIORAL|Routine treatment|Limit water and sodium intake. Raise the head of the bed. Standardized amount of exercise. Low temperature diet and small meals. Avoid alcohol, coffee and dehydration. The treatment lasted for 3 months.
224263278|NCT05578443|DRUG|20g Astragalus|Astragalus tablets 20g, warm water to drink, once a day, take for 1 year, during which routine treatment should also be carried out.
224263279|NCT03262103|BIOLOGICAL|Intratumoral (IT) Poly ICLC 0.5 mg|0.5 mg IT once/week (week 1)
224263280|NCT03262103|BIOLOGICAL|Intratumoral (IT) Poly ICLC 1.0 mg|1.0 mg IT once/week (week 1)
224263281|NCT03262103|BIOLOGICAL|Intramuscular (IM) Poly ICLC|1 mg IM twice weekly (weeks 3-6)
224263282|NCT03262103|PROCEDURE|Radical Prostatectomy|as per standard care
224263283|NCT00909753|DRUG|Ursodiol|Ursodiol Tablets, 500 mg
224263284|NCT00909753|DRUG|Urso Forte™|Urso Forte™ Tablets, 500 mg
224263285|NCT06559904|OTHER|Mediterranean diet|"The 'Mediterranean Diet Education Document', prepared by the researcher, which includes general information about the characteristics of the Mediterranean diet and the portion sizes that should be followed daily and weekly, and information on how often, how much and when to consume food groups, was provided as a diet education, and information was provided on how to record three-day food consumption.~A nutrition education compatible with the Mediterranean diet, organized by the researcher according to the individual's daily needs, was provided and a sample menu was explained to the individual face to face."
224263286|NCT02943538|DEVICE|Telemedicine|Monitoring and control is performed through telematics platform integrated management of chronic NOMHAD, configurated to respond the patients specific needs.
224263287|NCT02943538|DEVICE|Telephone|A telephone control of their state and evolution will be made through the nursing staff of the unit.
224263288|NCT02943538|OTHER|Conventional care|Conventional care provided in the unit to patients with IBD -high moderate complexity.
223685752|NCT03809793|DIAGNOSTIC_TEST|Hyperinsulinaemic Euglycaemic Clamp|Participants will arrive at the laboratory after an overnight fast (\>10 h) to undergo a Hyperinsulinaemic euglycaemic clamp to assess whole-body insulin sensitivity. Plasma glucose will be measured at regular intervals and muscle biopsies will be obtained from the vastus lateralis muscle of one leg before and after 2 hours of the clamp.
223685753|NCT03809793|DIAGNOSTIC_TEST|VO2 Max|Assessment of maximum aerobic capacity.
223685754|NCT03809793|DIAGNOSTIC_TEST|Continuous Glucose Monitor|CGM sensor will be inserted to measure insulin sensitivity over a 24hr period.
223685755|NCT03809793|PROCEDURE|Muscle Biopsies|Participants will undergo muscle biopsies pre and post the hyperinsulinemic euglyceamic clamp from the vastus lateralis.
223685756|NCT03809793|DRUG|Acipimox 250 MG|Participants will be randomised into two groups. One group will be prescribed Acipimox that will be taken 1 hour prior to each exercise session. The other group will take no drug.
223685757|NCT02821910|DRUG|High dose FDC Empagliflozin/Linagliptin/Metformin XR, fed|High dose Empagliflozin/Linagliptin/Metformin extended release (XR) fixed dose combination (FDC) tablet
223685758|NCT02821910|DRUG|1 tab Empagliflozin +1 tab Linagliptin +2 tabs Metformin XR|1x Empagliflozin + 1x Linagliptin + 2x Metformin extended release (XR) tablets
223685759|NCT02821910|DRUG|High dose FDC Empagliflozin/Linagliptin/Metformin XR, fasted|High dose Empagliflozin/Linagliptin/Metformin extended release (XR) fixed dose combination (FDC) tablet
223685760|NCT02821910|DRUG|1 tab Empagliflozin +1 tab Linagliptin +2 tabs Metformin XR|1x Empagliflozin + 1x Linagliptin + 2x Metformin extended release (XR) tablets
223685761|NCT02821910|DRUG|Low dose FDC Empagliflozin/Linagliptin/Metformin XR, fed|Low dose Empagliflozin/Linagliptin/Metformin extended release (XR) fixed dose combination (FDC) tablet
223685762|NCT02821910|DRUG|1 tab Empagliflozin +1 tab Linagliptin +2 tabs Metformin XR|1x Empagliflozin + 1x Linagliptin + 2x Metformin extended release (XR) tablets
223685763|NCT01289782|DRUG|Placebo|150 mg capsule once daily for 12 weeks in addition to PegIFN alpha-2a and RBV for 48 weeks
223685764|NCT01289782|DRUG|TMC435|150 mg capsule once daily for 12 weeks in addition to PegIFN alpha-2a and RBV for 24 or 48 weeks
223685765|NCT01289782|DRUG|Peginterferon alpha-2a (PegIFN alpha-2a)|One subcutaneous (under the skin) injection containing 0.5 mL solution with 180 mcg PegIFN alpha-2a once weekly for up to 48 weeks.
223685766|NCT01289782|DRUG|Ribavirin (RBV)|200-mg tablets of RBV (body-weight adjusted dose) taken orally (by mouth) twice daily for up to 48 weeks.
223685767|NCT01410539|DEVICE|OCT guided PCI|OCT guided PCI. Only thrombectomy in case of negative OCT findings (other than uncovered struts).
223775582|NCT03868436|DRUG|Methoxyflurane 3mL|As soon as possible following enrollment and initial procedures, the patient will be supplied with a PENTHROX™ kit which includes one inhaler containing 3 mL of MEOF for pain management. A member of the research team will train the patient to self-administer MEOF. PENTHROX™ is an approved (trademarked) product in Canada and is commercially available in a combination blister pack with one 3 mL sealed bottle and one PENTHROX™ inhaler with the Activated Carbon (AC) chamber.
223685768|NCT01410539|DRUG|OCT guided medical therapy|OCT guided medical therapy. Tailored antiplatelet therapy.
223685769|NCT01386905|DEVICE|BAROnova™ TransPyloric Shuttle™ (TPS™)|Subjects will undergo an endoscopic procedure to deliver the TPS™ into the stomach. The TPS™ moves freely without any physical attachment or invasive anchoring to tissue to reduce gastric outflow.
223685770|NCT04499599|OTHER|Dinner|Study subjects will consume a standardized ready-to-eat meal as dinner.
223685771|NCT04499599|OTHER|Fasting|Subjects in all groups will be asked to consume a standardized ready-to-eat dinner meal before 5 pm on day 1 and then fast overnight for approximately 15 hours.
223685772|NCT04499599|OTHER|Study food|Study subjects will either continue to fast for 6 hours (Fast Group), consume either a breakfast (Breakfast Group) or a Fast Bar (Fast Bar Group).
223685773|NCT02913040|OTHER|High Flow Nasal Cannula|Oxygen delivery through Heated Humidified High Flow Nasal Cannula
223685774|NCT02913040|OTHER|Low Flow Nasal Prongs|Oxygen delivery through Low Flow Nasal Prongs
223685775|NCT04884776|DIETARY_SUPPLEMENT|Microbiome immunity formula|Microbiome immunity formula contains probiotics blend (3 Bifidobacteria, 10 billion CFU per sachet)
223685776|NCT04884776|DIETARY_SUPPLEMENT|Active placebo|Active placebo contains active vitamin
223685777|NCT06488547|OTHER|Diaphragmatic breathing (DF)|Diaphragmatic breathing (DF), also known as belly or abdominal breathing, is a technique that can teach people how to use their diaphragm correctly while breathing, in order to activate the parasympathetic branch of the autonomic nervous system and to control stress.
223685778|NCT06488547|OTHER|Progressive Muscle Relaxation (PMR)|"Progressive Muscle Relaxation (PMR) is a technique that is helpful in the reduction of stress.~PMR by alternately tensing and relaxing different muscle groups in the body helps participants to become more aware of physical sensations and can be particularly helpful to muscle tension and relaxation."
223685779|NCT05078918|OTHER|Comprehensive care program|Comprehensive care program includes education and re-evaluation process. Education using video-materials to help patients adapt to the new normal before and after surgery. And re-evaluation patient's needs 1 month after surgery and arrangement resources.
223685780|NCT05078918|OTHER|Usual care|Usual care includes encouraging deep breathing and exercise using inspirometer, postoperative early ambulation, giving information at discharge and follow up 1 month after surgery.
223685781|NCT04076527|DRUG|UDCA|Routine data is collected for UDCA therapy.
223685782|NCT04076527|DRUG|Ocaliva|Routine data is collected for OCA therapy.
223685783|NCT00715169|DRUG|MLN1202|10 mg/kg dose of MLN1202 administered via IV infusion administered approximately 30 minutes to an hour
223685784|NCT00715169|OTHER|Placebo|Placebo consist of 0.9% saline solution administered as a 10 mg/kg dose via IV infusion administered approximately 30 minutes to an hour
223685785|NCT02597634|DRUG|SST-0225|SST-0225 is a cream formulation for topical application. Each 5.4 g dose is formulated to topically deliver 400 mg of ibuprofen. The cream contains sodium ibuprofen and various salts.
223685786|NCT02597634|DRUG|Placebo|Placebo IP will be the same vehicle as SST-0225 vehicle without the active ingredient, ibuprofen. It will be matched in appearance, smell, consistency, and color to SST-0225 topical ibuprofen cream.
223685787|NCT01218282|BEHAVIORAL|Home exercise training|20-30 min/day for at least 4 days/week
223685788|NCT01218282|BEHAVIORAL|NO Exercise Training|No intervention
223685789|NCT01025154|DRUG|Clofarabine|Induction Cycle: 20 mg/m\^2 IV over approximately 1 hour daily for 5 days (days 1-5)
223685790|NCT01025154|DRUG|Idarubicin|Induction Cycle: 10 mg/m\^2 IV over approximately 30 minutes daily for 3 days (days 1-3), following clofarabine by 1 to 2 hours
223685791|NCT01025154|DRUG|Cytarabine|Induction Cycle: 1 g/m\^2 IV over approximately 2 hours daily for 5 days (days 1-5), follow clofarabine by 3 to 6 hours.
223685792|NCT02040285|DRUG|Bisacodyl & PEG-CS|"the day before the CTC:~* low fiber diet~* at 15.00: 2 tablets of bisacodyl (5 mg)~* at 17.00: 1 litre of PEG-CS~* liquid diet~the day of the exam:~* at home: 2 tablets of bisacodyl (5 mg)~* at the Hospital (3 hours after tablets intake): 90 ml of Iopamidol in 500 ml of water~* at the Hospital (5 minutes after Iopamidol intake): 10 mg of Metoclopramide mono chlorohydrate monohydrate im"
223685793|NCT02040285|DRUG|Iopamidol|"the day before CTC:~* low fiber diet~* at 15.00: 90 ml of Iopamidol in 250 ml of water~* at 17.00: 90 ml of Iopamidol in 250 ml of water~* at 20.00: start liquid diet"
223685794|NCT01262209|DEVICE|portable CCTV|This is a small handheld mini screen intended to improve reading.
223685795|NCT01262209|DEVICE|Telescopes, telemicroscopes and microscopes|These are either worn like glasses, or held in one's hand and are intended to improve distance vision (like details of a hockey game), intermediate vision (like reading a sign), or 'up-close' vision (like reading small print).
223685796|NCT01262209|DEVICE|Absorptive filters|These are worn like glasses, and have tinted colour lenses. They are intended to improve contrast sensitivity, or being able to tell light from dark (like reading gray letters on a white background).
223685797|NCT03239665|BEHAVIORAL|Pharmacist-led Intervention (PHARM)|60 minute didactic lecture about vaccinations.
223685798|NCT03239665|BEHAVIORAL|Peer-led Intervention (PEER)|60 minute peer led small group intervention including skits and other educational material
223775583|NCT05833984|DRUG|IMM01|IMM01 (1.0, 1.5, 2.0 mg/kg) QW IV in the dose escalation part. IMM01 (dose determined in the dose escalation part) QW IV in the dose expansion part.
223685799|NCT03812432|DEVICE|Near-infrared fluorescence cholecystocholangiography|Device: Real-Time Fluorescence Imaging (VISERA ELITE II Imaging System). These device is used to identify anatomy, using infrared light that causes the indocianine green to fluoresce.
223685800|NCT00772083|BEHAVIORAL|Educational brochure|This brochure will educate anemic blood donors regarding the possible causes of their anemia, and based on age will make recommendations for who should seek consultation with a physician.
223685801|NCT00772083|BEHAVIORAL|Standard pamphlet|The BloodCenter of Wisconsin's default action when a potential donor has been found to be anemic is to provide a standard pamphlet with very basic nutritional information.
223685802|NCT01406925|DRUG|Placebo control|Placebo cream
223685803|NCT01406925|DRUG|NRL001 cream|Cream for single-dose intra-anal application
223685804|NCT03436810|PROCEDURE|Motor imagery|Motor imagery (MI) will be trained for the individuals by imagination of the movement. Program of MI includes 1) body relaxation and awareness 2) visual imagery 3) kinesthetic imagery and 4) refocusing of body and environment.
223685805|NCT03436810|PROCEDURE|Health education|Topic of Health education (HE) consists of 1) Changes caused by stroke 2) Complications after stroke 3) Emotional changes after stroke 4) Living at home after stroke 5) High blood pressure and stroke and 6) Preventing recurrent stroke.
223685806|NCT03436810|PROCEDURE|Task-Oriented Circuit Class Training|Program of Task-Oriented Circuit Class Training (TOCCT) consists of warm up and perform tasks 1) Stepping forward-backward onto block 2) Stepping sideway onto block 3) Heel lifts in standing to strengthen affected planter-flexor muscles 4) Standing with a decreased base and reach for object 5) Standing up from chair, walking a short distance, and returning to chair 6) Symmetrical walking and 7) Walking at fast speed.
223685807|NCT00797342|DRUG|PF-04629991|Oral; Sequential single dose escalation; three fourteen-day treatment periods per subject in the first cohort; randomized sequence of treatments (one placebo and two PF-04629991 doses)
223685808|NCT00797342|DRUG|PF-04629991|Oral; Sequential single dose escalation; three fourteen-day treatment periods per subject in the second cohort; randomized sequence of treatments (one placebo and two PF-04629991 doses)
223685809|NCT00797342|DRUG|PF-04629991|Oral; sequential single dose escalation; three fourteen-day treatment periods per subject in the third cohort; randomized assignment to treatment (placebo or PF-04629991)
223685810|NCT05682573|DIAGNOSTIC_TEST|hospitalized patient|Collect the patient's whole blood for testing
223685811|NCT04033523|BEHAVIORAL|HIIT|The HF group performed HIIT (3-min intervals at 40% and 80%VO2peak) on a bicycle ergometer for 30 min/day, 3 days/week for 12 weeks
223685812|NCT05370456|DEVICE|Local application of a HA gel for the treatment of MAGRs with mCAF technique and XCM|After local anaesthesia, mCAF technique with two releasing vertical incisions will be performed. XCM will be adapted on the root surfaces and positioned at the level of the cemento-enamel junction and HA gel will be applied.
223685813|NCT05370456|PROCEDURE|Treatment of MAGRs with mCAF technique and XCM|After local anaesthesia, mCAF technique with two releasing vertical incisions will be performed. XCM will be adapted on the root surfaces and positioned at the level of the cemento-enamel junction.
223685814|NCT03251664|DIETARY_SUPPLEMENT|Food groups consumed|
223685815|NCT00542451|DRUG|Paclitaxel|Every week for 12 weeks
223685816|NCT00542451|DRUG|Trastuzumab|Once a week for twelve weeks Then once a week or once every three weeks for 40 weeks
223685817|NCT03046173|OTHER|concentrated growth factors|These patients were randomly assigned to receive concentrated growth factors, hydroxyapatite and autogenous bone at bone defect sites in the experimental group.
223685818|NCT03046173|OTHER|hydroxyapatite and autogenous bone|These patients were randomly assigned to receive hydroxyapatite and autogenous bone at bone defect sites in the control group.
223685819|NCT03500471|PROCEDURE|Robotic-assisted Total Gastrectomy|Robotic-assisted total gastrectomy with D2 lymph node dissection will be performed with curative treated intent according to the patients' or their legal representatives'willing to choose robotic-assisted total gastrectomy and exclusing T4b、bulky lymph nodes or distant metastasis case by diagnostic laparoscopy. The alimentary canal reconstruction method is selected as esophageal jejunal R-Y anastomosis. Whether to reinforce the anastomotic manually is decided by the surgeon's experience. The reconstruction can be carried out by extracorporeal or intracorporeal anastomosis.
223685820|NCT03500471|PROCEDURE|Laparoscopic-assisted Total Gastrectomy|Laparoscopic-assisted total gastrectomy with D2 lymph node dissection will be performed with curative treated intent according to the patients' or their legal representatives'willing to choose laparoscopic-assisted total gastrectomy and exclusing T4b、bulky lymph nodes or distant metastasis case by diagnostic laparoscopy. The alimentary canal reconstruction method is selected as esophageal jejunal R-Y anastomosis. Whether to reinforce the anastomotic manually is decided by the surgeon's experience. The reconstruction can be carried out by extracorporeal or intracorporeal anastomosis.
223775584|NCT05833984|DRUG|Tislelizumab|Tislelizumab 200mg Q3W IV
223775585|NCT04768036|OTHER|IMPROVE DD VTE Tool|"Universal SMART on FHIR platform-based EHR-embedded IMPROVE VTE CPR with electronic order entry incorporated into required admission and discharge EHR workflow."
223775586|NCT06461104|BEHAVIORAL|Structured Physical Activity Programme|A somatic examination will also be conducted by a sports physician, which will include the assessment of muscle strength, cardiorespiratory fitness, walking gait, blood pressure, and body mass index (BMI). Based on this evaluation, the sports physician will design a personalised physical activity programme for the participants in the intervention group.
223775587|NCT06461104|BEHAVIORAL|Psychoeducational Programme|The control group undergoes a 12-week psychoeducational programme on nutrition and PA, consisting of 8 sessions. Led by a dietitian and psychologist, topics include PA benefits, healthy eating, and sedentary lifestyle risks. The experimental group receives 3 sessions on dietary habits before starting PA intervention, ensuring differentiation. It's expected the experimental group directly benefits from exercise, while the control group benefits from PA education. At the trial's end, control group members can join the PA programme for free.
223775588|NCT00295672|DRUG|Vinorelbine|
223775589|NCT02112097|DRUG|Gadolinium|"For Left Upper Arm Total Persistent % subdermally, on MRI at 6 hrs, 12 hrs, and 24 hrs.~Gadolinium Magnevist® (gadopentetate dimeglumine)~.1cc/ diluted with .9cc normal saline subcutaneously for 30 patients, and subdermally with ASIS Device for 30 patients."
224263289|NCT03222921|PROCEDURE|High tibial osteotomy|Patients undergoing high tibial osteotomy are investigated by a pressure insole for post-operative weight bearing behavior
224263290|NCT05600894|PROCEDURE|Biospecimen Collection|Undergo collection of blood and buccal samples
224263291|NCT05600894|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
224263292|NCT05600894|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
224263293|NCT05600894|DRUG|Decitabine and Cedazuridine|Given PO
224263294|NCT05600894|DRUG|Venetoclax|Given PO
224263295|NCT06476977|PROCEDURE|Dorsal webspace combined corticosteroid and anesthetic injection|The dorsal webspace injection consists of a 1cc mixture of 0.5cc triamcinolone (Kenalog) 10mg/mL and 0.5cc 1% lidocaine for analgesic purposes.
224263296|NCT06476977|PROCEDURE|Palmar combined corticosteroid and anesthetic injection|The palmar injection consists of a 1cc mixture of 0.5cc triamcinolone (Kenalog) 10mg/mL and 0.5cc 1% lidocaine for analgesic purposes.
224263297|NCT05726669|OTHER|Self-help materials for depression|Self-help materials for depression based on cognitive behavioural therapy have been created and tailored to those with PH by researchers involved in this project, using the evidence base and theory plus clinical experience. The Medical Research Council Frameworks for complex interventions (Craig et al., 2008; Skivington et al., 2021) have been followed as well as the quality appraisal tool for self-help interventions in depression (Cape, 2015). The self-help materials will be shared for feedback with a readership panel of people with PH and caregivers who are members of Pulmonary Hypertension Association UK (a charity for people with PH) prior to being given to participants. The self-help materials will be provided online or posted in paper form to the intervention group and will take four weeks for the person to complete at home (one booklet per week).
224263298|NCT01306838|DIETARY_SUPPLEMENT|MicroLipid and fish oil|Infants in treatment arm will receive the same nutrition support as control group before they tolerate enteral feeding at 20 ml/kg/day. Then they will receive study oils when feeds reach 30 ml/kg/day.
224263299|NCT01306838|OTHER|Routine care|Routine care
224263300|NCT06306404|DRUG|Estrogens and Progestogens|"Menopausal Hormone Therapy, formerly known as Hormone Replacement Therapy (HRT), is a medical treatment that involves the use of hormones to relieve the symptoms of menopause and to reduce the risk of certain long-term health conditions associated with menopause. Menopause is a natural biological process that occurs when a women's ovaries stop producing effects, and her estrogen and progesteron hormone levels subsequently decrease. MHT typically involves administration of a combination of sec steroids.~In this study MHT consists of estradiol transdermal patches (50 mcg (Systen), which provide a stable release of estradiol and lead to more stable blood levels. This is combined with 200 mg progesterone (Utrogestan tablets for 2 weeks) adjusted to the menstrual cycle to prevent endometrium carcinoma according to the international MHT guidelines."
224263301|NCT06306404|BEHAVIORAL|Cognitive behavioral therapy for insomnia (CBTi), and circadian rhythm therapy|"CBTi is a guided, internet-based cognitive behavioral therapy program for insomnia, containing information and exercises on sleep. It consists of five online sessions:~1. Psycho-education on sleep, disordered sleep and sleep hygiene (i.e. general guidelines about health and environmental factors influencing sleep),~2. Sleep restriction (i.e. restrict time in bed to the average sleep time) and stimulus control training (i.e. reinforce association of bed with sleeping),~3. Rumination and relaxation techniques,~4. Cognitive restructuring (i.e. changing misconceptions about sleep),~5. Relapse prevention."
224263302|NCT02351700|DRUG|IV Caldolor|IV Caldolor (IV ibuprofen) intraoperatively and postoperatively
224263303|NCT02351700|DRUG|IV Placebo|IV Placebo intraoperatively and postoperatively
224263304|NCT00583999|OTHER|no interventions, only regular blood-draw|No interventions, only regular blood-draw (liver biopsy obtained per routine during the surgery)
224263305|NCT00841542|DRUG|Amlodipine Besylate|10 mg Tablet
224263306|NCT00841542|DRUG|Norvasc®|10 mg Tablet
224263307|NCT06563037|OTHER|No intervention|This is an observational study
224263308|NCT03847688|DEVICE|Transcranial Magnetic Stimulation|Patient receive Transcranial Magnetic Stimulation for treatment resistant depression as part of their routine care.
224263309|NCT00418145|DRUG|megadose oral methylprednisolone|1400 mg qd/5 days
224263310|NCT00418145|DRUG|IV methylprednisolone|1000 mg/qd/5 days
224263311|NCT01554007|OTHER|Observation study|No intervention was administered to the participants specifically for the purpose this study. Participant could be on any drug therapy.
224263312|NCT02421822|OTHER|Fitwits office tool and games|Physician-led narration of Fitwits office tool during well child and subsequent visits over one year with distribution of Fitwits games during first visit.
224263313|NCT03730272|DRUG|analgesic drugs and methods|the patient will receive analgesic treatment at the discretion of the physician in charge
224263314|NCT01242098|DRUG|Fixed dose combination salmeterol / fluticasone|Branded fixed-dose combination inhaled corticosteroid / long-acting beta2-agonist therapy
224263315|NCT01242098|DRUG|Fixed-dose combination beclometasone dipropionate / formoterol|Branded fixed-dose combination inhaled corticosteroid / long-acting beta2-agonist therapy
224263316|NCT00706277|DRUG|propofol|propofol 2mg/kg for induction of anesthesia; followed by propofol 6 mg/kg/hour
224263317|NCT00706277|DRUG|propofol|propofol 2mg
224263318|NCT00706277|DRUG|remifentanil|remifentanil 0,25mcg/kg/hour
224263319|NCT00706277|DRUG|fentanyl|fentanyl 100mcg
224263320|NCT00706277|DRUG|Sevoflurane/Nitrous Oxide|maintenance of anesthesia with sevoflurane and nitrous oxide
224263321|NCT04811235|DEVICE|Near Infra-Red Spectroscopy (NIRS) Sensor|The NIRS sensor is laid on top of the dura, at the site of the SCI, and emits near-infrared light signals into the cord to measure tissue oxygenation and tissue hemodynamics in real-time.
223685821|NCT01796496|OTHER|Manipulative Therapy Techniques|"* Global Technical bilateral pelvis: The technique involves inserting a small spine rotation and make a slack in three stages.~* Indirect technique of lumbar roll in rotation for bilateral L3: to reduce the slack and make the body drop simultaneously, together with a high speed contraction pectoral muscles and triceps, iliac crest leading caudad which produces a rotation of the vertebra underlying joint space opening.~* Dog-technic on D12: this technique reduces the slack in the abdomen toward the hand in contact with D12. Next, the therapist conducted a thrust in the direction of the reduction."
223685822|NCT01796496|OTHER|Functional Technique|The therapist presses the two anterior superior iliac spines to open the back of the pelvis, this maintained throughout the technique. Then patient is asked to breathe deeply and exhale, sacrum makes a flexion-extension respectively. These movements should be symmetrical and of equal duration in time.
223685823|NCT02552615|OTHER|body awareness therapy|
223685824|NCT02552615|OTHER|core stabilization exercises|
223685825|NCT02552615|OTHER|traditional exercises|
223685826|NCT05407610|PROCEDURE|Conventional Radiofrequency ablation of the genicular nerves|Conventional Radiofrequency treatment of the genicular nerves of the knee blocks the transmission of painful stimuli from the sensory genicular nerves of the knee to the central nervous system by means of a thermal lesion created using RF current.
223775590|NCT02112097|DRUG|Gadolinium|"For Left Upper Arm Total Persistent % subcutaneously, on MRI at 6 hrs, 12 hrs, and 24 hrs.~Gadolinium Magnevist® (gadopentetate dimeglumine)~.1cc/ diluted with .9cc normal saline subcutaneously for 30 patients, and subdermally with ASIS Device for 30 patients."
223775591|NCT02112097|DRUG|Gadolinium|For Left Upper Arm Relative Prolongation Ability Score or total Persistent % of Gadolinium subdermally over total Persistent % of Gadolinium subcutaneously on MRI.
223775592|NCT02112097|DRUG|Efficacy of Enbrel subcutaneously at Week 12|"sPGA 50 n(%) as Efficacy of Enbrel subcutaneously at Week 12, in terms of Proportion of patients who achieve a score of clear or minimal by the Static Physician Global Assessment (sPGA) and the proportion of patients with a reduction of PASI of at least 50% from baseline.~The sPGA is a 6-category scale ranging from 5 = severe to 0 = none indicating the physician's overall assessment of the psoriasis severity focusing on indurations, erythema, and scaling. Treatment success of clear or minimal consists of none or minimal elevation in plaque, up to faint red coloration in erythema, and none or minimal fine scale over \< 5% of the plaque."
223775593|NCT02112097|DRUG|Efficacy of Enbrel subcutaneously at Week 24|"sPGA 50 n(%) as Efficacy of Enbrel subcutaneously at Week 24, in terms of Proportion of patients who achieve a score of clear or minimal by the Static Physician Global Assessment (sPGA) and the proportion of patients with a reduction of PASI of at least 50% from baseline.~The sPGA is a 6-category scale ranging from 5 = severe to 0 = none indicating the physician's overall assessment of the psoriasis severity focusing on indurations, erythema, and scaling. Treatment success of clear or minimal consists of none or minimal elevation in plaque, up to faint red coloration in erythema, and none or minimal fine scale over \< 5% of the plaque."
223685827|NCT05407610|PROCEDURE|Cooled Radiofrequency ablation of the genicular nerves|Cooled RF treatment causes a larger lesion size compared to conventional RF by means of internal cooling of the probe.
223685828|NCT05407610|PROCEDURE|Sham procedure|Sham procedure with placing of needles subcutaneously.
223685829|NCT00014027|DRUG|Docosahexaenoic acid (DHA)|
223685830|NCT00014027|DRUG|Eicosapentaenoic acid|
223685831|NCT05293509|DRUG|Fludarabine|40 mg/m2/day i.v.- by vein
223685832|NCT05293509|DRUG|Dexamethasone|25 mg/m2/day i.v.-by vein
223685833|NCT05293509|DRUG|Cyclophosphamide|100 mg/m2 IV-by vein
223685834|NCT05293509|DRUG|Bortezomib|Four doses of bortezomib at a dose of 1.3 mg/m2 -injection under the skin
223685835|NCT05293509|DRUG|Rituximab|Four doses of rituximab at a dose of 375 mg/m2- by vein
223685836|NCT05293509|DRUG|Busulfan|110 mg/m2 i.v-by vein
223685837|NCT05293509|DRUG|Cyclophosphamide (Cy)|by vein
223685838|NCT05293509|DRUG|Tacrolimus (or cyclosporine)|by vein
223685839|NCT05293509|DRUG|Mycophenolate mofetil (MMF)|given by PO
223685840|NCT05293509|DRUG|Rabbit ATG|by vein
223685841|NCT06386731|OTHER|Intermittent Phototherapy|2-hour phototherapy application in the intervention group
223685842|NCT03519386|COMBINATION_PRODUCT|G2-TR intraocular implant containing travoprost|Provided in Arm/Group descriptions.
223685843|NCT03519386|DRUG|Sham surgery + active-comparator eye drops|Sham surgery plus postoperative active-comparator eye drops (timolol maleate ophthalmic solution, 0.5%).
223685844|NCT04885439|BEHAVIORAL|NextSteps|Intervention sessions are delivered by a Masters level trained interventionist. During sessions, the interventionist will: conduct the weekly symptom screen, review content, answer questions, ensure skills mastery through homework review, and work with participants to develop action plans and identify/overcome barriers to self-care/caregiving. Patients and caregivers will receive individual calls from the interventionist for sessions 1, 2, and 3, and participate together for sessions 4, 5, and 6 via speakerphone.
223685845|NCT01016899|RADIATION|electronic brachytherapy|Post market observational study recording data form patients with skin cancer treated with electronic brachytherapy. Treatment is standard of care, and can vary in dose and fractionation schedule from patient to patient depending on radiation oncologist's judgement for best treatment for the patient.
223685846|NCT05225337|OTHER|Time restricted feeding (TRF)|8-h eating window Ad libitum food intake from 12-8 pm every day Fasting from 8-12 pm every day (16-h fast)
223685847|NCT05225337|OTHER|Daily calorie restriction|25% energy restriction every day Diet counseling provided
223685848|NCT03474315|DIAGNOSTIC_TEST|Multivariate assessment|Patient's status assessment according to clinical evaluation and data acquired from the implanted device.
223685849|NCT01227148|OTHER|Tightly glucose control|A continuous insulin infusion (50 IU of Actrapid HM) in 49.5 ml of 0.9 percent sodium chloride with the use of a pump was started when blood glucose level exceeded 140 mg/dl to maintain a blood glucose level of between 120 and 140 mg per deciliter. The dose of insulin was adjusted according to whole-blood glucose levels, measured at one-four-hour interval in arterial blood or arterial catheter was not available. The insulin dose was adjusted by a neuro-fuzzy method
223685850|NCT01227148|OTHER|Conventional glucose control|a continuous insulin infusion was delivered when the blood glucose level exceeded 200 mg/dl and insulin level was then adjusted to maintain a blood glucose level of between 180 and 200 mg per deciliter.
223685851|NCT04341662|BEHAVIORAL|E-MOTIVE intervention|"The E-MOTIVE intervention consists of three elements: 1) a strategy for early detection of PPH, which allows triggering of the 'first response' treatment bundle; 2) a 'first response' bundle called MOTIVE, based on the WHO guideline recommendations and consisting of uterine Massage, Oxytocic drugs, Tranexamic acid, IV fluids and Examination \& Escalation; and 3) an implementation strategy, focusing on simulation-based training with peer-assisted learning, local E-MOTIVE champions, feedback of actionable data to providers, calibrated drape with trigger line, and MOTIVE emergency trolley and/or carry case."
223685852|NCT04341662|BEHAVIORAL|Usual care|Health facilities will continue to follow usual care as per the baseline period for the remainder of the intervention phase.
223685853|NCT05659966|BEHAVIORAL|Plant-based diet|Participants will receive a behavioral intervention on a plant-based diet in partnership with a local restaurant.
223685854|NCT05659966|OTHER|Voucher only|Participants will receive vouchers to a local restaurant. Participants will not attend nutrition classes but will receive a class at the end of the 12-week study.
223685855|NCT01582854|DRUG|Actovegin|Actovegin solution for infusion and Actovegin tablets
223685856|NCT01582854|DRUG|Placebo|Actovegin placebo-matching solution for infusion and Actovegin placebo-matching tablets
223685857|NCT00704080|DRUG|XL765 (SAR245409)|Gelatin capsules supplied in 5-mg, 10-mg, and 50-mg strengths; continuous daily dosing
223685858|NCT00704080|DRUG|Temozolomide|Capsules supplied in 5-mg, 20-mg, 100-mg, 140-mg, 180-mg, and 250-mg strengths; dosed at 200 mg/m2/day for 5 consecutive days, repeated every 28 days
223685859|NCT00485147|PROCEDURE|Recording of GPS during a free walking in a public park|Analyse the clinical change after surgery from GPS measurements and compare it with laboratory measurement.
223685860|NCT06177808|DEVICE|Wolverine cutting balloon|As an intervention method for calcified coronary lesion modification, intervention group will undergo PCI after using the Wolverine cutting balloon for calcium modification.
223685861|NCT06177808|DEVICE|Non-compliant balloon|As an intervention method for calcified coronary lesion modification, intervention group will undergo PCI after using the Non-compliant balloon for calcium modification.
223685862|NCT03101267|DRUG|ASP4070|Intradermal vaccination at 2-week intervals
223685863|NCT03101267|DRUG|Placebo|Intradermal vaccination at 2-week intervals
223685864|NCT06247683|DEVICE|trifocal intraocular lens|cataract extraction and implantation of a posterior chamber trifocal intraocular lens
223685865|NCT06371508|BEHAVIORAL|Education based on breast cancer and breast examination|Training for the intervention group will be provided with a 40-45 minute training organized by one of the researchers.
223685866|NCT06779136|DRUG|Placebo|Every four weeks, subcutaneous injection，Switch to MG-K10 treatment after 24 weeks of administration
223685867|NCT05992324|DEVICE|Caption LungAI|Caption LungAI is a software that is designed to help non-expert healthcare professionals acquire diagnostic quality images on an 8-zone lung protocol for both healthy patients and patients presenting with pathology such as B-Lines.
223685868|NCT05423249|DRUG|Ferrous sulfate|Oral ferrous sulfate 325 mg once daily, containing 65 mg of elemental iron to treat non-anemic iron deficiency
223685869|NCT05423249|DRUG|Prenatal|Oral prenatal vitamin once daily for both groups
223685870|NCT05423249|DRUG|Docusate Sodium|Oral docusate sodium 100 mg twice daily as needed, to treat constipation secondary to oral iron supplementation
223685871|NCT05423249|DRUG|Ascorbic Acid 500Mg Tab|Oral ascorbic acid 500 mg daily, to improve absorption of oral iron
223685872|NCT05423249|DRUG|Placebo|Oral placebo pill once daily
223685873|NCT04414514|DRUG|Ruxolitinib 1.5% Cream|Topical Ruxolitinib 1.5% Cream
223685874|NCT06047548|DRUG|Tirzepatide|Administered SC
223685875|NCT06047548|DRUG|Placebo|Administered SC
223685876|NCT05027360|DRUG|SNP - Sodium Nitroprusside|The primary objective of our study is to assess the efficacy and safety of SNP as part of the treatment regimen of AHF patients and to identify predictors of efficacy.
223685877|NCT02854475|PROCEDURE|Venous blood collection|weekly within two weeks
223685878|NCT02854475|PROCEDURE|Raman spectroscopy|weekly within two weeks, on the volar forearm, using a RiverDiagnostics gen2-SCA Skin Composition Analyzer
223685879|NCT04178369|OTHER|Proximal And Distal Tibiofibular Joint Manipulations|"For PTFJ, the experimental intervention will be based on previously published methods. Physiotherapist will make contact with the fibular head, extending to the popliteal fossa. The associated soft tissue will be pulled in a lateral direction until the metacarpophalangeal joint will be firmly stabilized behind the fibular head.~For DTFJ, the experimental intervention will be conducted according to previously published methods. Physiotherapist will grasp and stabilize the distal tibia with one hand and grasp the distal fibula between the finger and thenar eminence of the other hand. The fibula will be translated posteriorly until the restrictive barrier (end range) will be engaged. Then a high-velocity, low-amplitude thrust will be applied through the fibula in a posterior-superior direction."
223685880|NCT04178369|OTHER|Bobath Treatment|All participants will be given a 6-week-long physiotherapy and rehabilitation program based on the Bobath concept for 5 days a week, 45 minutes each. The techniques will be applied by a physiotherapist who is specialized in Bobath concept. 35 different techniques will be used to improve the selective control and weight transfer of the pelvis in sitting, standing and supine/side lying positions. Moreover, soft tissue mobilization will be also used to relieve tension and loosen stiff tissues to provide biomechanical alignment and reduce pain.
223685881|NCT06020638|DEVICE|Experimental group|THE EFFECTS OF NASOPHARYNGEAL SUCTION POSITIVE PRESSURE
223685882|NCT06020638|DEVICE|control group|THE EFFECTS OF NASOPHARYNGEAL SUCTION NEGATIVE PRESSURE
223685883|NCT01871103|PROCEDURE|The dorsal homodigital island flap|The dorsal homodigital island flap is used for tissue reconstruction in different regions of the finger.
223685884|NCT03464565|DEVICE|Penumbra System|Penumbra System
223685885|NCT01269788|DRUG|Fluoxetine|20 mg , oral , daily 30 mins before breakfast, for 6 weeks
223685886|NCT01269788|DRUG|Omeprazole|20 mg , oral , daily 30 mins before breakfast, for 6 weeks
223685887|NCT01269788|DRUG|placebo|oral , daily 30 mins before breakfast, for 6 weeks
223685888|NCT01269788|DRUG|Omeprazole|20 mg , oral , daily 30 mins before breakfast, for 6 weeks
223685889|NCT01269788|DRUG|Fluoxetine|20 mg , oral , daily 30 mins before breakfast, for 6 weeks
223685890|NCT01269788|DRUG|placebo|oral , daily 30 mins before breakfast, for 6 weeks
223685891|NCT01222403|BIOLOGICAL|Fluad_MF59-adjuvanted trivalent influenza subunit vaccine|
223685892|NCT01222403|BIOLOGICAL|Vantaflu_MF59-adjuvanted trivalent influenza subunit vaccine|
223685893|NCT02063971|OTHER|Soothing (formulation number: F#1048-082) and antiaging creams (F#841-020 and F#1374-002)|
223775594|NCT02112097|DRUG|Efficacy of Enbrel subcutaneously at Week 36|"sPGA 50 n(%) as Efficacy of Enbrel subcutaneously at Week 36, in terms of Proportion of patients who achieve a score of clear or minimal by the Static Physician Global Assessment (sPGA) and the proportion of patients with a reduction of PASI of at least 50% from baseline.~The sPGA is a 6-category scale ranging from 5 = severe to 0 = none indicating the physician's overall assessment of the psoriasis severity focusing on indurations, erythema, and scaling. Treatment success of clear or minimal consists of none or minimal elevation in plaque, up to faint red coloration in erythema, and none or minimal fine scale over \< 5% of the plaque."
223685894|NCT06082271|DEVICE|Class III medical Hydrolyzed Collagen Peptides PEP-52 (Peptys)|Anti-inflammatory and regenerative effect, 5 mg/ml
223685895|NCT06082271|DRUG|Cortisone|DEPO-MEDROL 40 mg/ml + 1 cc di NAROPINA 0,75% 7,5 mg/ml
223685896|NCT02064075|DRUG|Lactated Ringer's solution|15-50 ml/kg Lactated-Ringer's solution was given intravenously every day until discharge.
223685897|NCT02064075|DRUG|Hydroxyethyl starch|15 ml/kg Lactated-Ringer's and 15-50 ml/kg hydroxyethyl starch solution was given intravenously every day until discharge.
223685898|NCT01362751|OTHER|No intervention|This study is an observational cohort study \> no interventions
223685899|NCT01125501|DIETARY_SUPPLEMENT|Protandim|The product Protandim used in this study have ingredients derived from five botanical sources \[Bacopa monniera, Silybum marianum (milk thistle), Withania somnifera (Ashwagandha), Camellia sinensis (green tea), and Curcuma longa (turmeric)\].
223685900|NCT04779931|BEHAVIORAL|Convoy-Pal|12 week mobile self-management intervention with palliative care resources.
223685901|NCT05917769|OTHER|Rocabdo exercises|"The exercises created by Dr. Rocabado, will be performed by the patient at home, consist of six different exercises and six repetitions of each exercise, performed six times per day.~It consists of Tongue 'Clucking', Controlled TMJ Rotation on Opening, Mandibular Rhythmic Stabilization, Upper Cervical Distraction, Axial Extension of the Cervical Spine and Shoulder Girdle Retraction. This group will only perform Rocabdo exercises."
223685902|NCT05917769|OTHER|Postural correction exercises|"* Posture correction exercises will be performed six times a day for six days.~* Patient will be assessed on the first day and then on the last day of the treatment, i.e., on 6th day the patient will be re-assessed after they have performed posture correction exercises.~* Posture correction exercises consist of chin tuck in, chest stretch, wall stretch, on your Back chest stretch and face down arm lifts."
223685903|NCT04598789|OTHER|no intervention|no intervention, observational study
223685904|NCT02747654|GENETIC|genotype|Patients were randomly assigned to a standard treatment group; INH dose of 300 mg or 200 mg based on the body weight) or model-based treatment group; INH dose determined based on developed model,
223685905|NCT00663949|DRUG|Captopril|25 mg captopril tablet q8h
223685906|NCT00663949|DRUG|Captopril + Pentoxifylline|patients takes captopril tablets 25 mg q8h and pentoxifylline 400 mg q8h
223685907|NCT01028378|DEVICE|T-CAT topography-guided LASIK treatment with the Allegretto Wave Eye-Q 400 Hz Excimer Laser|
223685908|NCT04783675|DRUG|Rituximab|Rituximab (375 mg/m2) will be given as a single intravenous infusion after remission
223685909|NCT05158647|OTHER|normal saline|10-ml 0.5% isobaric bupivacaine and 1ml normal saline were prepared for IIIH blockade
223685910|NCT05158647|DRUG|MgSo4|10 ml 0.5% isobaric bupivacaine and 1ml of MgSo4 10% (100 mg) were used
223685911|NCT04673123|OTHER|Core stabilization exercises|"In our study, core stabilization exercises to be applied in the intervention group are arranged according to the patients with stroke and will be at three different difficulty levels. Exercises will be done on the back (hooked) and sitting positions where the risk of falling is low. First of all, activation of the transversus abdominis muscle, which is the basis of core stabilization, will be taught to patients. With this activation at the first level, the healthy side, at the second level the affected side, and at the third level, reciprocal upper and lower extremity movements will be requested. In addition to these, there will be exercises to bridge and curl up in supine position, and weight transfer in sitting position. In order to increase the difficulty level of the exercises, first of all, the number of exercises will be increased and then it will be asked to move on to the next level."
223685912|NCT04673123|OTHER|Multifactorial Education Program|The content of this program includes rehabilitation practices that are routinely applied in stroke rehabilitation and that patients will receive at the specified hospital. In the content of these applications; patient-specific upper and lower extremity stretching, and strengthening exercises; application of functional electrical stimulation (FES) to upper and lower extremity muscles; balance, coordination and gait training are included. he content of multifactorial fall prevention training includes the first brochure titled '' General Recommendations for the Prevention of Fall in Chronic Stroke Patients '', which will include general recommendations for preventing falling according to the fall risk factors specific to the stroke, and the recommendations to minimize the risk of falling in the home. A second brochure titled 'Suggestions for Making Your Home Safer' will be given. The information in these brochures will also be communicated to patients face to face verbally
223685913|NCT02642939|DRUG|Mifepristone|Mifepristone is an antagonist of the GR-II (glucocorticoid) receptor, yet has little affinity for the GR-I (mineralocorticoid) receptor. Mifepristone is also a potent antagonist at the progesterone receptor, and may block the androgen receptor to a limited degree.
223775595|NCT02112097|DRUG|Efficacy of Enbrel subdermally at Week 12|"sPGA 50 n(%) as Efficacy of Enbrel subdermally at Week 12, in terms of Proportion of patients who achieve a score of clear or minimal by the Static Physician Global Assessment (sPGA) and the proportion of patients with a reduction of PASI of at least 50% from baseline.~The sPGA is a 6-category scale ranging from 5 = severe to 0 = none indicating the physician's overall assessment of the psoriasis severity focusing on indurations, erythema, and scaling. Treatment success of clear or minimal consists of none or minimal elevation in plaque, up to faint red coloration in erythema, and none or minimal fine scale over \< 5% of the plaque."
223775596|NCT02112097|DRUG|Efficacy of Enbrel subdermally at Week 24|"sPGA 50 n(%) as Efficacy of Enbrel subdermally at Week 24, in terms of Proportion of patients who achieve a score of clear or minimal by the Static Physician Global Assessment (sPGA) and the proportion of patients with a reduction of PASI of at least 50% from baseline.~The sPGA is a 6-category scale ranging from 5 = severe to 0 = none indicating the physician's overall assessment of the psoriasis severity focusing on indurations, erythema, and scaling. Treatment success of clear or minimal consists of none or minimal elevation in plaque, up to faint red coloration in erythema, and none or minimal fine scale over \< 5% of the plaque."
223775597|NCT02112097|DRUG|Efficacy of Enbrel subdermally at Week 36|"sPGA 50 n(%) as Efficacy of Enbrel subdermally at Week 36, in terms of Proportion of patients who achieve a score of clear or minimal by the Static Physician Global Assessment (sPGA) and the proportion of patients with a reduction of PASI of at least 50% from baseline.~The sPGA is a 6-category scale ranging from 5 = severe to 0 = none indicating the physician's overall assessment of the psoriasis severity focusing on indurations, erythema, and scaling. Treatment success of clear or minimal consists of none or minimal elevation in plaque, up to faint red coloration in erythema, and none or minimal fine scale over \< 5% of the plaque."
223775598|NCT02112097|DRUG|PASI 75 n(%) subcutaneously at Week 12|PASI 75 n(%) as Efficacy of Enbrel subcutaneously at Week 12, in terms of the proportion of patients who achieved a reduction in score of at least 75% from baseline by the PASI.
223775599|NCT02112097|DRUG|PASI 75 n(%) subcutaneously at Week 24|PASI 75 n(%) as Efficacy of Enbrel subcutaneously at Week 24, in terms of the proportion of patients who achieved a reduction in score of at least 75% from baseline by the PASI.
223775600|NCT02112097|DRUG|PASI 75 n(%) subcutaneously at Week 36|PASI 75 n(%) as Efficacy of Enbrel subcutaneously at Week 36, in terms of the proportion of patients who achieved a reduction in score of at least 75% from baseline by the PASI.
223775601|NCT02112097|DRUG|PASI 75 n(%) subdermally at Week 12|PASI 75 n(%) as Efficacy of Enbrel subdermally at Week 12, in terms of the proportion of patients who achieved a reduction in score of at least 75% from baseline by the PASI.
223775602|NCT02112097|DRUG|PASI 75 n(%) subdermally at Week 24|PASI 75 n(%) as Efficacy of Enbrel subdermally at Week 24, in terms of the proportion of patients who achieved a reduction in score of at least 75% from baseline by the PASI.
223775603|NCT02112097|DRUG|PASI 75 n(%) subdermally at Week 36|PASI 75 n(%) as Efficacy of Enbrel subdermally at Week 36, in terms of the proportion of patients who achieved a reduction in score of at least 75% from baseline by the PASI.
223775604|NCT02112097|DRUG|Adverse Reactions of Enbrel subcutaneously|Adverse Reactions of Enbrel subcutaneously at Week 36, in number of Injection site reactions, Heart failure, Allergic Reactions, Blood problems/low blood counts, Nervous system, Infections, Malignancies, Immunogenicity, and Autoantibodies.
223775605|NCT02112097|DRUG|Adverse Reactions of Enbrel subdermally at Week 36|Adverse Reactions of Enbrel subdermally at Week 36, in number of Injection site reactions, Heart failure, Allergic Reactions, Blood problems/low blood counts, Nervous system, Infections, Malignancies, Immunogenicity, and Autoantibodies.
223775606|NCT02112097|DRUG|Gadolinium|"For Right Upper Arm Total Persistent % subdermally, on MRI at 6 hrs, 12 hrs, and 24 hrs.~Gadolinium Magnevist® (gadopentetate dimeglumine) .1cc/ diluted with .9cc normal saline subcutaneously for 30 patients, and subdermally with ASIS Device for 30 patients."
223775607|NCT02112097|DRUG|Gadolinium|"For Right Upper Arm Total Persistent % subcutaneously, on MRI at 6 hrs, 12 hrs, and 24 hrs.~Gadolinium Magnevist® (gadopentetate dimeglumine) .1cc/ diluted with .9cc normal saline subcutaneously for 30 patients, and subdermally with ASIS Device for 30 patients."
223685914|NCT05623865|OTHER|kinesiotaping|"Kinesio tape will be attached with lymphedema technique.~The bands will be removed prior to each assessment so that they do not affect the evaluator's blinding. After evaluation, the new tape will be fitted by the invesitgatör"
223685915|NCT05623865|OTHER|exercise|"Wrist, finger, elbow range of motion and stretching exercises will be taught to the patients and given as home exercises.~In addition, patients will be given a leaflet containing illustrated and explanatory exercise visuals."
223685916|NCT06258473|COMBINATION_PRODUCT|Multicomponent decentralized care|"1. Training and support on Simple app for HTN/DM management \& training NCD corner clinicians on clinical guidelines and establish team-based care for Upazila level NCD corner~2. CHCPs conduct BP/BG screening, monitoring, lifestyle counseling, dispensing of medications, follow-up overdue patients at CCs \& CHCP care coordination supported by Simple app at community clinics~3. CHWs assist in screening, counselling, referral, and follow-up for CHW at village level"
223775608|NCT02112097|DRUG|Gadolinium|For Right Upper Arm Relative Prolongation Ability Score or total Persistent % of Gadolinium subdermally over total Persistent % of Gadolinium subcutaneously on MRI.
223685917|NCT06258473|COMBINATION_PRODUCT|mHealth|Training and support on Simple app for HTN/DM patient management \& training NCD corner clinicians on clinical guidelines of Upazila Health complex
223685918|NCT00701623|DRUG|heparin|patients will receive the application of one of two types of heparin directly on the injured area
223685919|NCT00701623|DRUG|heparin|patients will receive the application of one of two types of heparin directly on the injured area
223685920|NCT00701623|DRUG|folder water|patients will receive the application of folder water directly on the injured area
223685921|NCT01262352|DRUG|Ivacaftor|150 mg tablet, oral use, twice daily every 12 hours (q12h)
223685922|NCT01262352|DRUG|Placebo|Tablet, oral use, twice daily every 12 hours (q12h)
223685923|NCT00419809|DRUG|SB-681323 oral tablets|
223685924|NCT02153879|DRUG|Fenofibrate|fenofibrate 145/day for 12 weeks
223685925|NCT02153879|DRUG|Niacin plus laropiprant|Niacin 2 g/day plus Laropiprant for 12 weeks
223685926|NCT02792621|DIETARY_SUPPLEMENT|Acipimox|Oral supplement containing Acipimox 250mgs as the active ingredient in blinded label tablet form.
223685927|NCT02792621|DIETARY_SUPPLEMENT|placebo|The placebo supplement will contain only cellulose microcrystalline. This is an inert substance widely used in many pill and tablet formulations. It is an insoluble fibre and is not absorbed into the blood stream therefore is unlikely to cause toxicity when taken orally.
223685928|NCT00645710|DRUG|gemcitabine hydrochloride|Given IV
223685929|NCT00645710|DRUG|floxuridine|Given via hepatic arterial infusion
223685930|NCT00645710|GENETIC|proteomic profiling|Correlative studies
223685931|NCT00645710|OTHER|matrix-assisted laser desorption/ionization time of flight mass spectrometry|Correlative studies
223685932|NCT00645710|OTHER|liquid chromatography|Correlative studies
223685933|NCT00645710|RADIATION|yttrium Y 90 anti-CEA monoclonal antibody cT84.66|Given IV
223685934|NCT00645710|OTHER|laboratory biomarker analysis|Correlative studies
223685935|NCT00645710|OTHER|mass spectrometry|Correlative studies
223685936|NCT00645710|OTHER|pharmacological study|Correlative studies
223685937|NCT05664698|BEHAVIORAL|SKILLS-ER|The intervention (SKILLS-ER) has been developed by the research group, and aims to increase a participant's emotion regulation capacity by targeting different stages of the emotion regulation process proposed by the extended process model of emotion, i.e. identification, selection, implementation and monitoring (Sheppes, Suri \& Gross, 2015). SKILLS-ER will comprise of eight sessions and include identification and differentiation of emotions, tolerance/acceptance of emotions, education of different regulatory skills, as well as on how to select, implement and monitor strategies. Sessions will take place at the Uppsala child- and adolescent psychiatry outpatient unit and consist of activating and experiential exercises administered by a clinical psychologist. Participants will gain access to internet-delivered material, such as homework assignments in-between sessions. SKILLS-ER will be delivered individually to the participants, where their parents will be involved in some sessions.
223775609|NCT04901117|DRUG|Amoxicillin|Use according to the drug combination options selected by each center.
223775610|NCT04901117|DRUG|Clarithromycin|Use according to the drug combination options selected by each center.
223775611|NCT04901117|DRUG|Tetracycline|Use according to the drug combination options selected by each center.
223775612|NCT04901117|DRUG|Metronidazole|Use according to the drug combination options selected by each center.
223775613|NCT04901117|DRUG|Bismuth Potassium Citrate|Use according to the drug combination options selected by each center.
223775614|NCT04901117|DRUG|Colloidal Bismuth Pectin|Use according to the drug combination options selected by each center.
223685938|NCT01185834|DEVICE|Lotrafilcon A upgrade soft contact lens|Silicone hydrogel contact lens approved for daily wear and extended wear up to 30 consecutive nights.
223775615|NCT04901117|DRUG|Vonoprazan fumarate|Use according to the drug combination options selected by each center.
223775616|NCT00000415|PROCEDURE|Physical activity|
223775617|NCT00000415|DRUG|Calcium supplement|
223775618|NCT02840877|BEHAVIORAL|DOT Adherence Monitoring|Study participants will meet with a study-employed DOT worker daily during weekdays throughout the course of their TB treatment
223775619|NCT03779997|BEHAVIORAL|Video-based DOT Application|Participants will be asked to record daily videos of themselves confirming daily ingestion of their buprenorphine. Clinical staff (i.e. physicians, nurses and medical assistants) of patients enrolled in the intervention group will be given training and the opportunity to review medication taking videos.
223775620|NCT05589545|DEVICE|Prosthetic full-arch rehabilitation using a PEEK-acrylic resin prosthesis|A prosthetic full-arch rehabilitation of atrophic maxillae using a PEEk-acrylic resin prosthesis supported by an ensemble of standard dental implants and zygomatic dental implants, following the All-on-4 Hybrid Concept.
223775621|NCT04993352|DRUG|recombinant anti-vascular endothelial growth factor (VEGF) humanized monoclonal antibody ophthalmic injection|0.05mL (12.5mg/0.5mL/vial) HLX-04-O solution at a 4-week interval for intravitreal injection
223685939|NCT01063933|DRUG|Peramivir|Peramivir is a liquid for parenteral administration. Cohort I: Peramivir, 10 mg/kg intravenously (IV) every day (QD) (maximum of 600 mg/day) for 5 days or until hospital discharge, whichever comes first. Cohort II: Peramivir 12 mg/kg IV QD (maximum of 600 mg/day) for 5 days or until hospital discharge, whichever comes first. Cohort III: Peramivir 16 mg/kg QD (maximum of 600 mg/day) for 5 days or until hospital discharge, whichever comes first. Proposed doses for subjects in Cohorts IV, V, VI, and VII are 18, 18, 14 and 12 mg/kg, respectively, IV, QD for 5 days or until hospital discharge, whichever comes first. IV peramivir will be administered over 60 minutes.
223685940|NCT03989739|DEVICE|Da Vinci|
223685941|NCT03148119|DRUG|QRH-882260 Heptapeptide|topical spray; fluorescently-labeled peptide composed of a 7-amino acid sequence \[Gln-Arg-His-Lys-Pro-Arg-Glu\] attached via a 5 amino acid linker \[Gly-Gly-Gly-Ser-Lys\] to a near-infrared fluorophore, Cy5. The complete peptide sequence is written as: Gln-Arg-His-Lys-Pro-Arg-Glu-Gly-Gly-Gly-Ser-Lys(Cy5)-NH2, and is abbreviated as: QRHKPRE-GGGSK-(Cy5)-NH2.
223685942|NCT03148119|DEVICE|Scanning Fiber Endoscope|Endoscope used for providing the light via laser to image the area of interest in the colon after the QRH has been sprayed and rinsed.
223685943|NCT02235727|DRUG|GBR 900|
223685944|NCT02235727|DRUG|Placebo|
223685945|NCT02420782|DRUG|ASP6282|oral
223685946|NCT02420782|DRUG|Itraconazole|oral
223685947|NCT02420782|DRUG|Pilocarpine|oral
223685948|NCT02420782|DRUG|Placebo|oral
223685949|NCT02420782|DRUG|Midazolam|oral
223685950|NCT04572360|OTHER|Cardiorespiratory Exercise|Each exercise session (40-60 minutes) will include warm-up, aerobic training, resistance training, cool-down, as well as inspiratory muscle training
223685951|NCT04572360|OTHER|Modified Bai He Gu Jin Tang|The Chinese herbal formula of Modified Bai He Gu Jin Tang will be prescribed in granules. A dose of 10g a day (5g, b.i.d) will be ingested. Patients will dissolve a sachet of granules (5.0g) in 200ml of hot water, twice a day after breakfast and dinner, seven days a week for three months.
223685952|NCT02618356|DRUG|Raltitrexed and S-1|"Raltitrexed 3mg/m2 intravenously guttae, d1 and S-1,bid,po,d1-d14,every three weeks for a cycle.~BSA (body surface area) S-1 dosage \<1.25 m2 80 mg/d~* 1.25m2 - \<1.5 m2 100 mg/d~* 1.5 m2 120 mg/d"
223685953|NCT01450904|PROCEDURE|Quadriceps incision < 2 cm|MIS-TKA was performed with less than 2 cm Quadriceps incision length
223685954|NCT01450904|PROCEDURE|Quadriceps incision 2-4 cm|MIS-TKA was performed with 2 to 4 cm Quadriceps incision length
223685955|NCT01450904|PROCEDURE|Quadriceps incision > 4 cm|MIS-TKA was performed with more than 4 cm Quadriceps incision length
223685956|NCT00373061|DRUG|Xolair®|This being an observational study, the study protocol does not specify any dose regimen.
223685957|NCT03367247|BEHAVIORAL|BOLSTER|BOLSTER provides patients and caregivers with education and skills training, symptom management, and support across care settings over a four-week period.
223685958|NCT03367247|OTHER|Enhanced Discharge Planning (EDP)|EDP provides patients and caregivers a single session of education and skills training, symptom management, and support.
223685959|NCT04059367|DRUG|NNC9204-1177|Increasing doses of NNC9204-1177 administered s.c. (subcutaneously, under the skin) in the stomach area once-weekly for 11 weeks
223685960|NCT04059367|DRUG|Cocktail of 5 already approved drugs|5 medicines as tablets, capsules or syrup to be taken with water on Day 1 and Day 78 of the study
223685961|NCT04615585|OTHER|Aloe vera after SRP|Subgingival administration of Aloe vera gel was preceded by flushing the area with saline to wash away any debris. Aloe vera (1cc) gel was applied subgingivally using atraumatic needle. Patients were instructed not to rinse or drink any liquid for at least 30 minutes. The application was performed at baseline and after 1 and 2 weeks.
223685962|NCT04615585|PROCEDURE|Scaling and root planing (SRP)|Removal of supragingival and sub-gingival calculus and debris was performed, followed by smoothing root surfaces and removing cementum or dentine that is impregnated with calculus and toxins.
223775622|NCT01641588|BEHAVIORAL|posture: sitting or standing|Intervention: postural position - whether seated or standing. The person carries out a battery of cognitive executive functioning assessments delivered via a laptop and carried out with the laptop keyboard while either seated or standing.
223685963|NCT03812627|OTHER|Blood, urine, hair, synovial fluid and peri-prosthetic tissue collections|"All inpatient subjects: following samples will be collected during hospitalization:~Twice blood and urine collections:~1. at the beginning of hospitalization: 10 ml of blood + 5 ml of urine;~2. at the end of hospitalization: 5 ml of blood + 5 ml of urine. Synovial fluid collection: 1 ml Peri-prosthetic tissue collection: about 1 cm3 Hair collection: a single hair of 0.5 cm diameter"
223775623|NCT05479175|DRUG|Ibuprofen|Ibuprofen
223775624|NCT05479175|DEVICE|Diode laser|Diode laser
223775625|NCT05479175|DEVICE|Nonactive Diode laser|Nonactive Diode laser
223775626|NCT03993418|DIETARY_SUPPLEMENT|stevia|This arm will be required to consume 5 stevia drops twice daily in habitual drinks
223775627|NCT01469676|DEVICE|Filtering group LG-6, Pall Biomedical Products|In Filtering group, a Leukocyte filter (LG-6, Pall Biomedical Products) was placed on the CPB arterial line circuit, trying to filter the white blood cells.
223775628|NCT00650533|DRUG|Glimepiride Tablets 1 mg|1mg, single dose fed
223775629|NCT00650533|DRUG|Amaryl® Tablets 1 mg|1mg, single dose fed
223775630|NCT04725175|DRUG|PIPE-307|Single and multiple ascending oral doses of PIPE-307 tablets
223775631|NCT04725175|DRUG|Placebo oral tablet|Single and multiple ascending oral doses of matching Placebo tablets
223775632|NCT00229684|DRUG|Tesaglitazar|2 mg once daily in oral form
223685964|NCT03812627|OTHER|Autopsy|Dead patients will be autopsied: hair, urine, blood, peri-prosthetic tissue and viscera (liver, kidney, spleen, brain, heart, lung) sampling for each autopsy.
223685965|NCT01325220|DRUG|arbaclofen|5 mg bid
223685966|NCT01325220|DRUG|arbaclofen|10 mg bid
223685967|NCT01325220|DRUG|arbaclofen|10 mg tid
223685968|NCT01325220|DRUG|Placebo|tid
223775633|NCT00229684|DRUG|pioglitazone|45 mg once daily in oral form
223775634|NCT00145834|BEHAVIORAL|community based trial|
223775635|NCT03574025|OTHER|Questionnaire|To telephone the patient/family to look into how the patient is doing, moderate/severe brain damage.
223775636|NCT02100267|DRUG|Methacholine Chloride (SK-1211)|Subjects received saline and 0.039-25 mg/mL of Methacholine chloride
223775637|NCT04401124|OTHER|no intervention|no intervention
223775638|NCT01297842|DRUG|Ertapenem|Ertapenem 1 gram per day for 7 to 14 days
223775639|NCT01297842|DRUG|Meropenem or Imipenem|Meropenem or Imipenem 0.5 to 1 gram 3 to 4 times per day for 7 to 14 days
223775640|NCT00094380|DRUG|CTLA4-IgG4m (RG2077)|
223775641|NCT00094380|DRUG|Cyclophosphamide|
223775642|NCT03333005|DRUG|APX001 with Standard of Care anti-fungal agent|safety assessment
223775643|NCT03243916|RADIATION|TACE plus Cyber knife|Patients with histologically confirmed MHCC(Massive Hepatocellular Carcinoma) will receive TACE therapy,after 1 or 2 week's recovery from hepatic insufficiency ,the targeted and staged cyber knife will be given
223775644|NCT04412902|DRUG|adjuvant therapy|Adjuvant chemotherapy and/or radiotherapy
223775645|NCT03189251|OTHER|Dietary intakes|Analysis of association between consumption of high excess free fructose (EFF) beverages (high fructose corn syrup sweetened soft drinks, fruit drinks, apple juice)
223685969|NCT03754231|OTHER|Heart rate monitoring|"The heart rate of recruited patients will be monitored for 15 minutes over 2 phases:~i) 10 minutes at rest ii) 5 minutes during physical activity in the form of walking or playing"
223685970|NCT03754231|OTHER|Respiratory rate monitoring|"The heart rate of recruited patients will be monitored for 15 minutes over 2 phases:~i) 10 minutes at rest ii) 5 minutes during physical activity in the form of walking or playing"
223775646|NCT00510029|DRUG|GAP-134|atrial fibrillation 24-hr IV infusion; 1-minute IV bolus; PO
223775647|NCT05448001|DRUG|JP-1366 20mg|JP-1366 20 mg 1 capsule, Lansoprazole 30 mg placebo 1 capsule before meal
223775648|NCT05448001|DRUG|Lansoprazole 30mg|JP-1366 20 mg placebo 1 capsule, Lansoprazole 30 mg 1 capsule before meal
223685971|NCT00130351|DEVICE|formoterol|
223685972|NCT03091972|PROCEDURE|Pulmonary vein isolation|A pulmonary vein isolation procedure will be performed using radiofrequency ablation with contact force monitoring.
223685973|NCT03091972|PROCEDURE|Contact force assisted left atrial linear ablation|Left atrial linear ablation (Roof line and Anterior line) after pulmonary vein isolation during catheter ablation for persistent atrial fibrillation monitoring contact force.
223685974|NCT03091972|PROCEDURE|left atrial linear ablation without contact force monitoring|Left atrial linear ablation (Roof line and Anterior line) after pulmonary vein isolation during catheter ablation for persistent atrial fibrillation without monitoring contact force.
223685975|NCT00344890|PROCEDURE|Anterior Cervical Discectomy and Fusion|1,2,3,or 4 level surgery
223685976|NCT01092065|DRUG|AFQ056 with L-dopa|hard gelatin capsule to be taken bid for six weeks
223685977|NCT01092065|DRUG|Placebo|hard gelatin capsule to be taken bid for six weeks
223685978|NCT04459429|DEVICE|Change of cannula size|During nasal High Flow Therapy with fixed flow of 8 l/min, the cannula size will be changed from smaller-to-larger or larger-to-smaller
223685979|NCT00540371|OTHER|Port wine stain Birthmark|Port wine stain Birthmark
223685980|NCT01975831|DRUG|Durvalumab|Durvalumab was administered as an intravenous (IV) infusion over 60 (± 5) minutes.
223685981|NCT01975831|DRUG|Tremelimumab|Tremelimumab was administered as an intravenous (IV) infusion over 60 (± 5) minutes.
223685982|NCT00107952|DRUG|Telavancin|Telavancin 10 mg/kg/day IV for up to 21 days.
223685983|NCT00107952|DRUG|Vancomycin|Vancomycin 1 Gm IV q 12 hrs for up to 21 days
223685984|NCT05546853|DRUG|NP137|NP137 will be administrated at the first day of each cycle (CnD1) of 14 days as an IV infusion at 9 or 14 mg/kg.
223685985|NCT05546853|DRUG|Oxaliplatin|Oxaliplatin will be administreted at the first day of each cycle (CnD1) of 14 days as an IV infusion at 85 mg/m²
223685986|NCT05546853|DRUG|Irinotecan|Irinotecan will be administreted at the first day of each cycle (CnD1) of 14 days as an IV infusion at 150 mg/m²
223685987|NCT05546853|DRUG|Calcium levofolinate|Calcium levofolinate will be administreted at the first day of each cycle (CnD1) of 14 days as an IV infusion at 100 mg/m²
223685988|NCT05546853|DRUG|5 FU|5 FU will be administreted at the first day of each cycle (CnD1) of 14 days as an IV infusion at 2400 mg/m2 as a continuous intravenous infusion over 46 hours.
223685989|NCT01216007|DRUG|propofol|In the TIVA group, IV access will be obtained as per BCCH routine, with caregiver present. 2% lidocaine 1 mg/kg will be administered via IV to prevent venous pain before induction of anaesthesia with propofol, as per BCCH standard. Induction of anaesthesia will be achieved with an IV bolus of propofol 5 mg/kg and remifentanil 2.5 mcg/kg. Anaesthesia will be maintained with an infusion of propofol 200-400 mcg/kg/min and remifentanil 0.1-0.2 mcg/kg/min. Once the subject is under general anaesthesia, the anaesthesiologist will place a second IV cannula, specifically for the collection of blood samples. This cannula will not be in the same limb as the propofol infusion.
223685990|NCT01216007|DRUG|sevoflurane|In the volatile anaesthesia group, induction of anaesthesia will be achieved with inhalation of sevoflurane (5-8% in O2/air). Maintenance of anaesthesia will continue with a volatile agent of the anaesthesiologist's choice.
223685991|NCT01401959|DRUG|Eribulin|1.4 mg/m\^2 IV Days 1 and 8, every 21 days for six cycles
223685992|NCT01401959|DRUG|Trastuzumab|6 mg/kg IV Day 1 every 21 days
223685993|NCT04074876|DEVICE|Pulmonary echography|"Pulmonary echography during preoperative evaluation for patients undergoing urgency orthopedic surgery for femur fracture.~Pulmonary ultrasound will evaluate the presence of one of four patterns defined by Lung Ultrasound Score in the 6 fields for each hemithorax of the patient (2 anterior, 2 lateral and 2 posterior). Each region is defined by axillary lines (anterior and posterior) and then is divided into 2 subregions (superior and inferior), thus defining the 6 fields. For a comprehensive exam, all intercostal spaces in the setting of each field will have to be examined by sliding the probe along them . A score will be used for each field that will have this definition:~* 0: normal pattern (A-lines)~* 1: multiple B lines (at least 3 for field), well defined.~* 2: B lines coalescent~* 3: consolidation of any dimension"
223685994|NCT01456910|BEHAVIORAL|Resistance Training Program|Frequency, volume, repetitions, load, interval
223685995|NCT02702596|OTHER|Measurement-Based Integrated Care|Measurement-Based Integrated Care (MBIC) synthesizes the science of integrated health care and incorporates the strategies of measurement-based care. concept of MBIC for the treatment of depression includes: systematic assessment of symptoms, antidepressant treatment side effects and medication adherence and incorporation of a Depression Care Manager (DCM) to track patients and keep them engaged in care using behavioral interventions
223685996|NCT02702596|BEHAVIORAL|Depression Education Fotonovela|"Depression education that uses a unique, culturally adapted depression fotonovela titled Secret Feelings developed by Cabassa, Molina and Baron (2012). The fotonovela is a popular comic-book style pamphlet that portrays a dramatic story using photographs and dialogue bubbles, which has become an effective tool for engaging Hispanic audiences and increasing knowledge about specific health issues"
223685997|NCT02702596|BEHAVIORAL|Standard Education|The the use of a pamphlet to educate people about depression.
223685998|NCT05811650|BEHAVIORAL|Oral Health Counseling and promotion|The intervention was cluster randomized control trial in design. We select six schools for the intervention group and six schools for the control group. Follow-up of the intervention was done after six months of baseline. Impact of the intervention was assessed among the same participants who enrolled in the baseline. The interventions were done in every three months.
223685999|NCT00887744|DEVICE|Aperius® Percutaneous Interspinous Spacer|Implantation of the Aperius® device
223686000|NCT00600054|BIOLOGICAL|nimotuzumab (anti EGFR humanized monoclonal antibody)|150 mg/m2 I.V. Induction phase: infusions once a week for 8 weeks. Consolidation phase: infusions once every 2 weeks for 10 weeks. Patients may then continue on the consolidation regimen of nimotuzumab, until disease progression or the occurrence of unacceptable toxicity.
223686001|NCT02879149|DEVICE|AUGMENT® Bone Graft|AUGMENT® Bone Graft
223686002|NCT02879149|PROCEDURE|Standard of Care|Autologous Bone Graft
223686003|NCT05896579|BEHAVIORAL|Exercise training|Exercise training will include supervised high-intensity interval training for \~35 minutes 3x/week on an upright stationary bicycle and unsupervised continuous aerobic exercise for \~30 minutes 2x/week.
223686004|NCT02051816|DEVICE|Video Laryngoscopy|
223686005|NCT02051816|DEVICE|Apneic Oxygenation|
223686006|NCT02051816|DEVICE|Direct Laryngoscopy|
223686007|NCT02051816|DEVICE|No Apneic Oxygenation|
223686008|NCT05888012|DEVICE|basket catheter|Stone extraction is completed with either a basket or balloon catheter at the time of ERCP. The basket catheter is made of nickel-titanium wires which can be manipulated to trap and withdraw stones.
223686009|NCT05888012|DEVICE|balloon catheter|Stone extraction is completed with either a basket or balloon catheter at the time of ERCP. The balloon catheter is made of latex, which is inflated after passing the stone, thus pushing the stone outwards.
223686010|NCT00042029|DRUG|MK0869, aprepitant|
223686011|NCT00042029|DRUG|Comparator: placebo|
223686012|NCT03120988|BIOLOGICAL|Lavage with Platelet Poor Plasma (PPP)|Lavage of 50cc PPP
223686013|NCT02454231|BIOLOGICAL|Transplantation of circulating CD14+CD34+cells|intramuscular injection of circulating EPC at leg level
223686014|NCT02454231|BIOLOGICAL|Transplantation of BM MNC|intramuscular injection of BM MNC at leg level
223686015|NCT01097798|DRUG|Aliviador|The study medication should be applied regimen of 8/8 hours over 2 days.
223686016|NCT01097798|DRUG|Gelol|The study medication should be applied regimen of 8/8 hours over 2 days.
223686017|NCT05245279|DIAGNOSTIC_TEST|3 dimensional ultrasound investigation|Images that contributed to the determination of placental volume and 3-DPD indices were obtained at the time of visit. All 3-D scans ultrasound measurements were performed by a Voluson 730 Expert ultrasound machine equipped with a multifrequency probe (2-5 MHz) to acquire images. Each sample was examined using 3-D rendering mode, in which the colour and gray value information was processed and combined to supply 3-D image. For laterally located placentas, the investigator positioned the transducer on a slight lateral inclination to obtain proper images. Power Doppler window was placed over the placenta to map the vascular tree from basal to chorionic plates. The 3-D static volume box was placed over the entire placenta volume. The sweep angle was set at maximum 70°. Each image was recovered from the disk in succession for processing. During gestation, the investigator recorded one sample from each patient.
223686018|NCT05245279|DIAGNOSTIC_TEST|2 dimensional ultrasound investigation|The two-dimensional (2-D) transabdominal conventional study provided data about fetal position, biometry, body movements and fetal heart rate as well as placental localization. The factorial default setting 'Obstetrics' was applied in 2-D mode.
223686019|NCT03400982|DIAGNOSTIC_TEST|Bone densitometry measurement|Bone densitometry and measurement of body composition
223686020|NCT01509690|OTHER|Multidisciplinary, intensive and collaborative care|"No specific study drugs, devices or procedures are involved.~Subjects will be seen in a multidisciplinary, intensive management clinic involving a renal physician, a clinical pharmacist trained in renal pharmacotherapy and a renal coordinator. The main aim of this clinic is to provide multidisciplinary, intensive and consistent care in the first 3 to 4 months after HD initiation to streamline the management of the patients. Specific objectives of this clinic include providing patients with educational materials and information to enable a better understanding of their disease process, providing uniform anemia and renal bone disease management, increasing permanent HD access \[arteriovenous (AV) fistula or graft\] placement, increasing transplant referrals, providing suitable vaccinations to all patients, as well as reducing hospitalizations for fluid overload, uncontrolled hypertension and anemia-related complications."
223686021|NCT03794882|COMBINATION_PRODUCT|Quadratus Lumborum Block|30 mL of .25% bupivacaine with 2.5mcg/mL epinephrine will be injected on both sides of the mid-abdomen posterior to the mid-axillary line.
223686022|NCT03794882|PROCEDURE|Standard Medical Management|Standard medical management typically includes perioperative multimodal analgesia utilizing acetaminophen, opioids, non-steroidal anti-inflammatory drugs, and dexamethasone
223686023|NCT05260346|DIETARY_SUPPLEMENT|Cranberry juice|composition: Water, cranberry juice concentrate
223686024|NCT05260346|DIETARY_SUPPLEMENT|Placebo|composition: Water, dextrose, citric acid, malic acid, fumaric acid, colorants, xanthan gum, natural flavor, emulsion
223686025|NCT00897338|OTHER|flow cytometry|laboratory analysis
223686026|NCT00897338|OTHER|fluorescence activated cell sorting|laboratory analysis
223686027|NCT00897338|OTHER|immunohistochemistry staining method|laboratory analysis
223686028|NCT00897338|OTHER|immunologic technique|laboratory analysis
223686029|NCT00897338|OTHER|biomarker analysis|laboratory analysis
223686030|NCT05043376|DRUG|Standard of care|Standard COVID-19 care as per the hospital guidelines
223686031|NCT05043376|DIETARY_SUPPLEMENT|BLIS K12|Daily 2 oral BLIS K12 tablets for up to 14 days.
223686032|NCT00450385|DRUG|Rituximab|Rituximab 375 mg/m2 on day 1 for 6 to 8 cycles
223686033|NCT00450385|DRUG|Cyclophosphamide|Cyclophosphamide 750 mg/m2 IV on day 1 for 6 to 8 cycles
223686034|NCT00450385|DRUG|Doxorubicin|Doxorubicin 50 mg/m2 on day 1 for 6 to 8 cycles
223686035|NCT00450385|DRUG|Prednisone|Prednisone 40 mg/m2 orally days 1-5, repeated every 21 days for 6 to 8 cycles.
223686036|NCT00450385|DRUG|Vincristine|Vincristine 1.4 mg/m2 (maximum = 2 mg) IV on day 1 for 6 to 8 cycles
223686037|NCT04066764|DRUG|Rivaroxaban|15mg twice daily for 3 weeks after operation, later 20mg once daily until 3 months after the filter is removed. Application: oral
223686038|NCT04066764|DRUG|Warfarin|3mg for 5 days after the operation, later 0.75mg to 18mg depending on INR (2.0-3.0) until until 3 months after the filter is removed. Frequency: once daily Application: oral
223686039|NCT04066764|DRUG|Nadroparin|Dose: 1mg/kg Duration: 5 days after the operation Frequency: twice daily Application: subcutaneous
223686040|NCT00227071|BEHAVIORAL|exercise|
223686041|NCT02468011|OTHER|vibration|vibration will be applied at 35 Hz
223686042|NCT04600310|DEVICE|ULTRAPREP|ULTRAPREP device for reducing OR prep times.
223686043|NCT04600310|DEVICE|No Intervention|Conventional skin preparation technique
223686044|NCT00419679|PROCEDURE|x-ray diffraction of human hair|
223686045|NCT01286831|DRUG|[14C]GW642444|Single 200μg dose of \[14C\]GW642444 given on Day 1.
223686046|NCT04839575|DRUG|Latiglutenase|Administered orally (daily)
223686047|NCT04839575|DRUG|Placebo|Administered orally (daily)
223686048|NCT00629278|BIOLOGICAL|trastuzumab|
223686049|NCT00629278|DRUG|aromatase inhibition therapy|
223686050|NCT00629278|DRUG|cyclophosphamide|
223686051|NCT00629278|DRUG|docetaxel|
223686052|NCT00629278|DRUG|doxorubicin hydrochloride|
223686053|NCT00629278|DRUG|epirubicin hydrochloride|
223686054|NCT00629278|DRUG|fluorouracil|
223686055|NCT00629278|DRUG|paclitaxel|
223686056|NCT00629278|DRUG|releasing hormone agonist therapy|
223686057|NCT00629278|DRUG|tamoxifen citrate|
223686058|NCT00629278|PROCEDURE|adjuvant therapy|
223686059|NCT00629278|RADIATION|radiation therapy|
223686060|NCT04948931|OTHER|Lavender aromatherapy|The application will be once a day, every day for four weeks. Each session will take five minutes.
223686061|NCT04948931|OTHER|Rosemary aromatherapy|The application will be once a day, every day for four weeks. Each session will take five minutes.
223686062|NCT04948931|OTHER|Control|The application will be once a day, every day for four weeks. Each session will take five minutes.
223686063|NCT02962843|BEHAVIORAL|IY TCM|The Incredible Years Teacher Classroom Management program is a manualized program for teachers and staff in school and day-care settings to strengthen teacher classroom management strategies, to reduce negative behavior and promote prosocial behavior, as well as school readiness in children. Two qualified IY TCM group-leaders (facilitators) train teachers and staff in groups through six full-day workshops (a total of 42 hours).Workshop 1: Building Positive Relationships with Students, Workshop 1b: Preventing Behavior Problems -The Proactive Teacher, Workshop 2: The Importance of Teacher Attention, Coaching and Praise, Workshop 3: Motivating Children Through Incentives, Workshop 4 \& 5: Decreasing Inappropriate Behavior and Workshop 6: Emotional Regulation, Social Skills \& Problem Solving.
223686064|NCT03739788|DRUG|BMS-986165|Oral administration of tablet and 15-minute intravenous BMS-986165 solution for infusion
223686065|NCT03458598|PROCEDURE|Rectus sheath block|Rectus sheath block under ultrasound
223686066|NCT03458598|PROCEDURE|Bilateral rectus sheath catheter|A nerve block catheter known as a continuous rectus sheath block is inserted by the surgeon at the end of the operation. An infusion of 0.2% ropivacaine is delivered through this for up to 48 hours post-operatively.
223686067|NCT03458598|DRUG|Patient controlled opioid analgesia (PCA)|Patients in both groups will have PCA dilaudid or morphine prescribed for the post-operative period.
223686068|NCT03458598|PROCEDURE|Subcutaneous injection saline placebo|Subcutaneous injection of 1ml of normal saline under ultrasound guidance at the same site bilaterally as rectus sheath blockade is performed
223686069|NCT02539615|DEVICE|ForeCYTE Breast Aspirator|
223686070|NCT04726098|DRUG|Dexamethasone high dose|High doses: dexamethasone 20 mg/day 5 days + 10 mg/day 5 days (total 10 days)
223686071|NCT04726098|DRUG|Dexamethasone low dose|Low doses: dexamethasone 6 mg/day 10 days.
223775649|NCT05520216|DEVICE|Spinal mouse (idiag m360)|A noninvasive Spinal Mouse device will be used to measure the thoracic kyphosis and lumbar lordosis angle of the spinal column in the sagittal plane. It will be displayed on the computer aided software screen where the thoracic and lumbar region angles are calculated by swiping over the spinal processes from top to bottom with the Spinal Mouse (IDIAG m360) device. Measurements will be taken while standing on a flat surface. The volunteer will take off his upper clothes and shoes during the examination. Relax your arms and torso will be positioned next to you. The distance between the feet will be approximately waist width and parallel to each other, the knees will be straight and face motionless. He will stand where he feels comfortable. A Spinal Mouse examination will be performed and data will be recorded.
223686072|NCT04028661|DEVICE|3D printed Modified Twin Block Appliance|It is a functional appliance for mandibular advancement designed digitally on virtual models.
223775650|NCT05520216|BEHAVIORAL|chest circumference measurement|Measurements will be taken from the axillary (4th rib level - two fingers below the axilla), epigastric (xiphoid process level) and subcostal (9th rib level) regions at the time of normal, maximal inspiration, and maximal expiration using a tape measure while the patient is in a sitting position. The tape measure will be placed in the area to be measured. Care will be taken that there is no folding or horizontal level difference in the tape measure and that the fingers are not under the tape measure. Normal respiration will be measured first and recorded in centimeters (cm). The patient will then be asked to take a deep, long breath towards the bottom of the tape measure. The value obtained will be recorded as the deep inspiration value. Immediately after deep inspiration, the patient will be asked to make a deep and long expiration. The obtained value will be recorded as deep expiration.
223686073|NCT02178683|DRUG|Tacrolimus and MMF.|First dose of Tacrolimus is given day -4, this continues through day +365. First dose of MMF is given within 4 hours of stem cell infusion, this continues through day +365.
223686074|NCT02831907|PROCEDURE|Cardiac surgery|All cardiac surgery procedures with the use of cardiopulmonary bypass
223686075|NCT05471076|BIOLOGICAL|426c.Mod.Core-C4b 30 mcg|Administered via injection as a split dose into the deltoid muscle (both left and right).
223686076|NCT05471076|BIOLOGICAL|426c.Mod.Core-C4b 100 mcg|Administered via injection as a split dose into the deltoid muscle (both left and right).
223686077|NCT05471076|BIOLOGICAL|426c.Mod.Core-C4b 300 mcg|Administered via injection as a split dose into the deltoid muscle (both left and right).
223686078|NCT05471076|OTHER|Placebo|Administered via injection as a split dose into the deltoid muscle (both left and right).
223686079|NCT05471076|BIOLOGICAL|BG505|A soluble, cleavage-competent, trimeric HIV-1 envelope glycoprotein gp140 formulated at 2 mg/mL, 0.55 mL per vial, in 20 mM Tris, 100 mM NaCl, pH 7.5 will be admixed with 3M-052-AF (5 mcg) + Alum (500 mcg
223686080|NCT03407339|OTHER|Shared Oral Care intervention|"One hour of teaching in oral hygiene and oral diseases to health care professionals at the intervention nursing homes.~The dentists will make an assessment of the elderly's oral hygiene at baseline, after three and six months using a mucosal and plaque score. During the six months, a dentist will be doing ward rounds at each nursing home in a specific time interval. In dialog with the resident and the healthcare professional, the dentist will present individual advice on how to perform oral care based on the resident's oral care routines, oral hygiene status, and the resident's physical and cognitive function level."
223775651|NCT05520216|BEHAVIORAL|Maximum Breath Hold Test|During the breath-hold measurement, the subject will sit in a chair with a backrest. He will take a deep breath through his nose. We do not want maneuvers (Valsalva and Müller) and diaphragm contractions that will affect the breath-hold time, so volunteers will be observed throughout the test. The test will be terminated as soon as involuntary diaphragm contractions are seen. This test will be applied 3 times by resting the volunteer with breaks for 5 minutes. The average of 3 test results will be taken (Lin, Y. C.: Effect of O2 and CO2 on breath hold breaking point. In The Physiology of Breath Hold Diving. (eds): CEG Lundgren, M Ferringo, Undersea and Hyperbaric Medical Society Inc, Bethesda, Maryland, p: 75-87 1987.).
223686081|NCT04473573|DEVICE|Spartan Cube CYP2C19 System|Using buccal material, determine the genotype of the \*2, \*3 and \*17 SNPs of the CYP2C19 gene on the Spartan Cube CYP2C19 System.
223686082|NCT02631356|DRUG|Ringer's lactate solution|
223686083|NCT02631356|DRUG|Succinylated gelatin|
223686084|NCT01376557|DRUG|75 mg LX4211|Subjects will receive 75 mg LX4211 once daily
223686085|NCT01376557|DRUG|200 mg LX4211|Subjects will receive 200 mg LX4211 once daily.
223686086|NCT01376557|DRUG|400 mg LX4211|Subjects will receive 400 mg LX4211 once daily.
223686087|NCT01376557|DRUG|200 mg LX4211|Subjects will receive 200 mg LX4211 twice daily.
224263322|NCT00849823|BEHAVIORAL|Male Sexual Health Program|"An attention equivalent control condition entailing a 60-minute one-to-one session that will didactically teach teens about several aspects of male sexual health. The content and objectives are related only to knowledge acquisition. In addition to this program, teens randomized to the control condition will receive standard-of-care services from the clinic. This involves the provision of free condoms (one size fits all condoms) and a brief (nurse-delivered) counseling message to practice safer sex."
224263323|NCT00849823|BEHAVIORAL|Focus on the Future Program|A 60-minute, theory-guided program designed to increase the quality and frequency of teens' condom use within the context of making safer choices regarding partners and sexual behaviors. The program is explicitly designed to increase the quality and frequency of teen's condom use.
224263324|NCT02307994|DRUG|75IU uFSH|
224263325|NCT04494607|DIETARY_SUPPLEMENT|lowest Glycemic Index for a selected type fo cereal product|determination of lowest Glycemic Index for a selected type fo cereal product
224263326|NCT05149209|PROCEDURE|cervical restoration|A class v cavity will be prepared after local anesthesia has been given as required. Rubber dam isolation will be done. Selective enamel etching and a universal adhesive agent (Beautibond, Shofu, Japan) will be applied over all the cavity surfaces. Followed by, placement of restorative material according to the randomization sequence. Finally, restoration finishing and polishing will be done.
224263327|NCT01714622|PROCEDURE|subtotal gastrectomy with gastroduodenostomy|
224263328|NCT01714622|PROCEDURE|subtotal gastrectomy with Roux-en-Y gastrojejunostomy,|
224263329|NCT01714622|PROCEDURE|total gastrectomy with Rou-en-Y esophagojejunostomy|
223686088|NCT01376557|DRUG|Placebo|Subjects will receive placebo once daily.
223686089|NCT01721980|DRUG|GLPG0974|
223686090|NCT01721980|DRUG|Placebo|
223686091|NCT02940106|DEVICE|Cryotop device|a different device for oocyte vitrification (with a very high cooling rate)
223686092|NCT02940106|DEVICE|CBSvit device|a different device for oocyte vitrification (with a lower cooling rate)
223686093|NCT01390220|DRUG|USL261|
223686094|NCT01390220|DRUG|Placebo|
223686095|NCT01989260|DEVICE|Anti-adhesive gel|4mls of anti-adhesive gel coated to the randomized ovary
223686096|NCT01466543|DRUG|Zydena (Udenafil)|Zydena (Udenafil) 100 mg, one time
223686097|NCT01466543|DRUG|Placebo|Placebo
223686098|NCT06299423|DEVICE|Howdy Senior® device|Standard perioperative management plus three preoperative and twelve postoperative (until 90 days after surgery) HOWDY Senior® device assessments.
223686099|NCT02045303|DEVICE|Contact Ultrasound Therapy|Following our protocol, the ultrasound wound therapy will start with contact ultrasound until it meets criteria to switch to noncontact ultrasound therapy.
223686100|NCT02045303|DEVICE|Noncontact Ultrasound Therapy|Transition from contact to noncontact ultrasound when criteria for transition is met per our protocol.
224263330|NCT03564587|BEHAVIORAL|AWAKE|Behavioral intervention called Achieving Wellness After Kancer in Early Life (AWAKE) is focused on increasing hope in order to improve quality of life and health-promoting behaviors in survivors of young adult cancer. The AWAKE mobile app contains eight modules for participants to complete over 8 weeks with the ability to review prior modules. Participants receive a prompt on their mobile device weekly to complete each module and/or they will receive a text reminder. The app includes health education messaging, weekly homework assignments, the ability to track progress towards goals with self-monitoring and graphical depictions of progress, videos of inspirational materials, and a portal for interacting with their coach.
224263331|NCT05770388|DEVICE|App Take Care of Your Mood|The app provides psychoeducational information, contains several thematic modules (mindfulness, emotional regulation, healthy lifestyle habits, safety plan for crisis management, among others), allows mood monitoring, contains motivational messages and videos aimed at promoting help-seeking in mental health, and information on available support services.
224263332|NCT05770388|BEHAVIORAL|Reminder messages and counseling|Participants receive reminder messages (by email and chat) encouraging them to use the app and to request a counseling session (via phone call, videoconference or chat) with a clinical psychologist if they think it is necessary.
224263333|NCT06043388|BIOLOGICAL|Omicron BA.4/5-Delta strain recombinant novel coronavirus protein vaccine (CHO cells)|Inoculate one dose, 0.5ml，Intramuscular injection into the deltoid muscle of the upper arm
224263334|NCT06043388|BIOLOGICAL|Placebo|Inoculate one dose, 0.5ml，Intramuscular injection into the deltoid muscle of the upper arm
224263335|NCT03406598|OTHER|Patients in shock|Analysis of sublingual microcirculation by nurses in ICU patients in shock to predict needs for fluid challenge, vasopressors or transfusion.
224263336|NCT02027337|DRUG|20 mcg ethinylestradiol /3 mg drospirenone|One contraceptive pill in each day of 28 day cycle. Number of Cycles: 12
224263337|NCT02027337|DRUG|20 mcg ethinylestradiol/3 mg drospirenone and Selmevit|One contraceptive pill in each day of 28 day cycle. Number of Cycles: 12. Two pills of Selmevit in each day during 30 days, repeat of the course every 3 months.
224263338|NCT02027337|DRUG|30 mcg ethinylestradiol/3 mg drospirenone|One contraceptive pill in each of 21 days, than 7 days break. Number of Cycles: 12
224263339|NCT02027337|DRUG|30 mcg ethinylestradiol/3 mg drospirenone and Selmevit|One contraceptive pill in each of 21 days, than 7 days break. Number of Cycles: 12 Two pills of Selmevit in each day during 30 days, repeat of the course every 3 months.
224263340|NCT02027337|DRUG|35 mcg ethinylestradiol/2 mg cyproterone|1 contraceptive pill in each day of 28 day cycle. Number of Cycles: 12
224263341|NCT02027337|DRUG|35 mcg ethinylestradiol/2 mg cyproterone and Selmevit|One contraceptive pill in each day of 28 day cycle. Number of Cycles: 12. Two pills of Selmevit in each day during 30 days, repeat of the course every 3 months.
224263342|NCT03214588|DRUG|TAK-831|TAK-831 tablets
224263343|NCT03214588|DRUG|TAK-831 Placebo|TAK-831 placebo matching tablets
223686101|NCT03063203|DRUG|Decitabine|"* After 2 cycles, patients with progressive disease or relapse (a clear progression with at least \>20% bone marrow blasts and an increase of at least 50% from prior biopsy) should be removed from protocol and proceed to salvage treatment according to center preference~* Transplant eligible patients who achieve CR, CRc, or CRi, after 3 cycles with a suitable donor will proceed to conditioning regimen and transplant~* Transplant eligible patients with PR after 3 cycles may be removed from protocol and proceed to salvage treatment according to center preference~* Transplant eligible patients with a suitable donor who achieve mLFS, CR, CRc, or CRi, may proceed to transplant after at 3 cycles~* Transplant ineligible patients with (CR, CRc or CRi, PR) will continue on maintenance doses~* Transplant ineligible patient with SD after cycle 4 may be removed from protocol and proceed to alternative treatment or continue on protocol according to treating physician's preference."
223686102|NCT03063203|PROCEDURE|Bone marrow biopsy/aspirate|"* Baseline, Cycle 1 Day 10, Cycle 1 Day 28, Cycle 2 Day 28, Cycle 3 Day 28, and Progression or relapse~* Biopsy/aspirate on Cycle 1 Day 10 is for participants enrolled at Washington University only~* Biopsy/aspirate on Cycle 2 Day 28 is at the discretion of the treating physician"
223686103|NCT03063203|PROCEDURE|Peripheral blood draw|-Baseline, Cycle 1 Day 10, Cycle 1 Day 28, Cycle 2 Day 28, Cycle 3 Day 28, and Progression/Relapse
223686104|NCT03063203|PROCEDURE|Skin biopsy|"* Optional but if refuse skin biopsy then participant can provided buccal swab~* There is no required time frame for this sample - it may have been collected months or even years prior to the first dose of decitabine~* If WBC at time of enrollment is \>30,000/µl, skin biopsy should be collected at the time of C1D28 bone marrow biopsy or thereafter"
223686105|NCT03063203|PROCEDURE|Buccal swab|-Baseline (if skin biopsy declined) and Cycle 2 Day 28
223686106|NCT00555139|DRUG|GSK561679 tablet|GSK561679 tablets are white film-coated tablets, containing 200 (milligrams) mg of the free base, GSK561679A.
223686107|NCT00555139|DRUG|GW876008 tablet|GW876008 tablets are white to off-white round film-coated tablets, containing 100 mg of GW876008X (free base).
223686108|NCT00555139|DRUG|alprazolam|Alprazolam capsules 0.25 mg are hard gelatine capsules containing 1 tablet of commercial alprazolam (Xanax 0.25).
223686109|NCT00555139|DRUG|Placebo|GW876008 placebo tablets will visually match the active GW876008 tablets. GSK561679 placebo tablets will visually match the active GSK561679 tablets. Placebo to match Alprazolam is a hard gelatine capsule that will visually match the active but containing only a filler.
223686110|NCT00026611|BIOLOGICAL|Dryvax vaccine|
223686111|NCT05517460|OTHER|Auricular acupressure|The participant in Intervention period will receive acupressure on ear Shenmen point, ear Large intestine point, ear Rectumn point and ear San Jiao point.
223686112|NCT05517460|OTHER|health education|health education for self-care and medication adherence
223686113|NCT02318108|OTHER|Mentored organizational change|Practices are given basic education related to population-based care and are supported by physician peer mentors and given feedback on performance.
223686114|NCT02318108|OTHER|Education only|Practices are given basic education related to population-based care and are given feedback on performance.
223686115|NCT04946227|DRUG|Pembrolizumab 200mg +Paclitaxel 80mg/m2|Pembrolizumab 200mg +Paclitaxel 80mg/m2
223686116|NCT03448081|DRUG|SNA-120|SNA-120 (0.5%) active ointment
223686117|NCT03448081|DRUG|Placebo|Vehicle Ointment
223686118|NCT03448081|DRUG|Calcipotriene|Calcipotriene ointment (0.005%)
223686119|NCT01856023|DRUG|High Dose Interleukin-2|
223686120|NCT01856023|DRUG|Ipilimumab|
223686121|NCT00755911|BIOLOGICAL|Tissue Repair Cells (TRC)|30-50 ml of bone marrow is aspirated from subject and processed into TRC autologous bone marrow tissue graft. 10ml of TRC will be absorbed onto gelfoam carrier and placed in extraction socket.
223775652|NCT05520216|BEHAVIORAL|Sit and Reach|While the participant is sitting on the floor with his back to the wall and his legs are fully extended in front of him, his knees should be in full contact with the floor. The box will be placed on the sole of the participant's feet (without shoes) in full contact with the volunteer's feet. The participant will be instructed to lean forward as slowly as possible, keeping their fingertips level with each other and their legs straight on the floor. He will be asked to slowly lie down along the ruler three times, and on the third attempt the volunteer will be instructed to reach out as far as possible and hold for 2 seconds. This value will be saved
223686122|NCT00755911|DEVICE|Control|Control subjects only receive standard gelfoam carrier. It promotes healing after tooth extraction
223686123|NCT04132375|DRUG|INM004|"The IMP dose to be studied will be 4 mg of protein/kg of subject's weight. Each vial contains 25 mg protein/mL. Therefore, each subject must receive 0.16 mL/kg.~The IMP will be added to the 100 mL infusion bag of saline solution. Doses will be administered as an infusion at 2.0 mL/min over 50 min with an interval of 24 h between doses."
223686124|NCT04132375|DRUG|Placebo|"The IMP dose to be studied will be 4 mg of protein/kg of subject's weight. Each vial contains 25 mg protein/mL. Therefore, each subject must receive 0.16 mL/kg.~The IMP will be added to the 100 mL infusion bag of saline solution. Doses will be administered as an infusion at 2.0 mL/min over 50 min with an interval of 24 h between doses."
223686125|NCT04082039|OTHER|convetional PCA method unsing only 1-channel|Ch-1 (flow 2 ml/hr with bolus 2ml/30min lock-out): fentanyl 16 µg/kg, ketorolac 2 mg/kg, ondansetron 12 mg (total volume 100 ml with normal saline); Ch-2 (flow 2ml/h): 100ml normal saline only (for blinding)
223686126|NCT04082039|OTHER|utilizing 2-channel|Ch-1 (flow 2 ml/hr with bolus 2ml/30min lock-out): fentanyl 16 µg/kg (total volume 100 ml with normal saline; Ch-2 (flow 2ml/h fixed): ketorolac 2 mg/kg, ondansetron 12 mg (total volume 100 ml with normal saline)
223686127|NCT00796354|DRUG|MOVICOL|sealed laminated sachet, 1 - 3 sachets daily for 4 weeks
223686128|NCT00796354|DRUG|Sugar Pill|sealed laminated sachet, 1 - 3 sachets daily for 4 weeks
223686129|NCT00829283|BEHAVIORAL|Behavioral Weight Loss|weekly individual sessions for 6 months
223686130|NCT00829283|BEHAVIORAL|Behavioral Weight Loss + Guided self-help Cognitive-behavioral Therapy|weekly BWL sessions for 4 weeks and 6-8 CBT sessions for 5 months
223686131|NCT00829283|DRUG|Placebo|One pill daily
223686132|NCT00829283|DRUG|Sibutramine/Orlistat|Sibutramine 15 mg daily or Orlistat 120mg TID
223775653|NCT01581346|OTHER|Exercise intervention|Pts were instructed to train at least 5 times/ week in the inpatient setting. After discharge pts were instructed to train in a home-based setting at least 3 times/week for a period of 8 weeks.
223686133|NCT01411072|DRUG|gemcitabine|Gem 1000 mg/m2 IV weekly for 3 weeks then one week off of each 28 day cycle
223775654|NCT06573541|DEVICE|Use of ultrasound|Use of ultrasound in the initial management of patients in shock
223686134|NCT01411072|DRUG|5-fluorouracil|5-FU 425 mg/m2 and Leucovorin 20 mg/m2 IV day 1, 2, 3, 4, and 5 of each 28 day cycle
223775655|NCT05989399|DIAGNOSTIC_TEST|circulating neutrophils|evaluation of circulating neutrophils level
223686135|NCT00453960|DIETARY_SUPPLEMENT|Genivis|54 mg/day daily for 6 months
223686136|NCT00453960|DRUG|Norethisterone Acetate|tablets 10mg/day from day 16 to 25 of menstruation
223686137|NCT00453960|OTHER|placebo|tablets daily for 6 months
223686138|NCT05186428|OTHER|carrying out standard care|The adaptation of the diuretic treatment will be made according to the possible diuresis records and the weighing of the patient every 2 days.
223686139|NCT05186428|OTHER|adult diaper|the diuresis which will be calculated by making the difference between the weight of the soiled protection weighed and the weight of the dry protection
223686140|NCT05958693|DRUG|Artemether-lumefantrine|"Artemether-lumefantrine will be administered for 3 days according to body weight (Days 0 and 8 hours after, 1 and 2). Dosage depending on body weight or age if weight cannot be determined.~Dosage: 1 tablet contains 20 mg artemether and 120 mg lumefantrine Dosage per weight: 1 tablet (5 to \<16kg); 2 tablets (15 to \<25kg); 3 tablets (25 to \<35kg), 4 tablets for \>35 kg) Dosage per age, if weight cannot be determined: 1 tablet (6 months old to 3 years old); 2 tablets (4 to 8 years old); 3 tablets (9-13 years old), 4 tablets (\>13 years old)"
223686141|NCT05958693|DRUG|Primaquine|For Pf patients, primaquine at 0.75 mg base/kg body weight single dose will be given on Day 3 for Pf patients; For Pv patients primaquine will be withheld for 28 days and will be given after Day 28 follow-up, at 0.25 mg base/kg per day for 14 days.
223686142|NCT00536861|DRUG|erlotinib|"Level 1 : erlotinib 100 mg/day from day -7 to the time of completion of 10 fractions of cranial irradiation, followed by 150 mg/day until disease progression or toxicity~Level 2 : erlotinib 150 mg/day from day -7 before cranial irradiation, followed by 150 mg/day until disease progression or toxicity"
223775656|NCT03775005|RADIATION|standard treatment|3000 cGy in 10 daily fractions
223775657|NCT03775005|RADIATION|short course treatment|1800 cGy in 4 fractions administered twice a day
223775658|NCT03003676|BIOLOGICAL|ONCOS-102|Engineered oncolytic adenovirus expressing Granulocyte-macrophage colony stimulating factor (GM-CSF)
223775659|NCT03003676|DRUG|Cyclophosphamide|Pre-treatment
223775660|NCT03003676|DRUG|Pembrolizumab|PD1 blockade
223686143|NCT01039012|OTHER|Tai Chi|Participants randomized to the Tai Chi group select a Tai Chi school from a pre-screened list of community-based Tai Chi programs and enroll for 9 months. Participants are asked to attend classes twice a week for the first month and once a week for the remaining 8 months. They are also asked to practice at home, or attend more classes for 2-3 additional hours per week. While in the study they are also encouraged to follow the standard care as recommended by their physician.
223686144|NCT01039012|OTHER|Standard Care|Participant follow the standard care recommended by their physician.
223686145|NCT05965648|BEHAVIORAL|Families FORWARD (Focusing on Relationships, Well-being, and Responsibility aheaD)|Families FORWARD aims to engage families in planning for adulthood earlier and more actively. Program skills include communication and problem-solving; guided practice in setting realistic goals, breaking down goals into incremental action steps, and problem-solving barriers to goal attainment; repeated engagement in future-oriented communication; and training on how to navigate transition-related and adult services. Parents/caregivers will participate in six or seven telehealth sessions (60-75 minutes each). Youth on the autism spectrum will have the option of participating in up to three program sessions to increase collaborative planning within the family. Families will identify and work toward individualized transition planning goals that may fall within any area of planning or functioning (e.g., housing, education, guardianship).
223686146|NCT02923544|PROCEDURE|YUMI manipulator|
223686147|NCT06057740|BEHAVIORAL|Acceptance and commitment therapy (ACT)|ACT is a psychological intervention that aims to improve psychological flexibility, the ability to hold thoughts and emotions lightly in a given context and pursue valued ends (Hayes et al., 1999; Twohig \& Levin, 2017).
223686148|NCT06057740|BEHAVIORAL|Cognitive behavioral therapy (CBT)|CBT is a psychological intervention which targets cognitions and behaviors in attempt to change emotions.
223686149|NCT04573647|DRUG|Cenegermin-Bkbj 0.002% Ophthalmic Solution [OXERVATE]|Research subjects will use oxervate in affected eye following approved treatment regimen and have their eye measured with optical coherence tomography and a Cochet-Bonnet esthesiometer at various time points before, during and after treatment.
223686150|NCT05982431|OTHER|Traditional physical therapy program|60-minutes exercise program, three times a week on alternate days for 12 successive weeks
223686151|NCT05982431|OTHER|Kinsio taping|One full strip of kinesiology taping tape and one half-length strip were needed for the kinesiology taping application
223686152|NCT05982431|OTHER|placebo Kinsio taping|One full strip of kinesiology taping tape and one half-length strip were needed for the placebo kinesiology taping application
223686153|NCT04718103|BIOLOGICAL|GSK3511294|GSK3511294 was administered using a pre-filled syringe.
223775661|NCT05269524|BEHAVIORAL|Internet-delivered tailored cognitive behavior therapy|Therapists-supported tailored 10-week treatment for depression in older adults.
223775662|NCT06269328|OTHER|Total ıntravenous anesthesia with propofol and remifentanil for anesthetic maintenance|For anesthesia induction, intravenous propofol was used at doses of 1-2 mg/kg, fentanyl at 2mcg/kg, lidocaine at 1mg/kg, and rocuronium at doses of 1mg/kg. After then anesthesia maintained with propofol iv 75-100 µg kg-1 min-1 and remifentanyl iv 0.05-0.2 µg kg-1 min-1 infusion.
223686154|NCT04718103|BIOLOGICAL|Placebo|Placebo was administered as normal saline using a pre-filled syringe.
223686155|NCT04387383|DEVICE|Acupuncture|Disposable acupuncture needles (0.30 mm in diameter and 25-40 mm in length) are inserted at a depth of 10-30 mm obliquely into scalp acupuncture points (Baihui, Toulinqi) or straightly into body acupuncture points (Taichong, Zhangmen, Sanyinjiao, Zhongwan, Guanyuan, Tianshu, Zusanli). Electroacupuncture will be applied to the abdominal points at fast and dispersed waves through electric needle stimulator (ES-160 6-Channel Programmable Electro-acupuncture) for 30 min. The intensity is adjusted to a level at which patients feel comfortable.
223686156|NCT04387383|DEVICE|Sham-acupuncture|Disposable acupuncture needles (0.30 mm in diameter and 25-40 mm in length) are inserted at the same way as in the acupuncture group but on sham-acupuncture points (Sham-Baihui, Sham-Toulinqi, Sham-Taichong, Sham-Zhangmen, Sham-Sanyinjiao, Sham-Zhongwan, Sham-Guanyuan, Sham-Tianshu, Sham-Zusanli). The sham points are non-acupuncture points nor located on meridians
223686157|NCT04167956|DEVICE|ultrasound and CT|Experimental: ultrasound combined with CT guided Active Comparator: CT guided
223686158|NCT02756065|OTHER|no intervention|no intervention is used
223686159|NCT00136604|BIOLOGICAL|Tritanrix-HepB/Hib-MenAC|Combined Diphtheria, Tetanus, Whole Cell Pertussis, Hepatitis B, Haemophilus influenzae Type b meningococcal AC-tetanus toxoid conjugate Vaccine
223686160|NCT00136604|BIOLOGICAL|Mencevax ACWY|GSK Biologicals' Meningococcal serogroups A, C, W135 and Y polysaccharide vaccine
223686161|NCT00136604|BIOLOGICAL|Tritanrix-HepB/Hiberix|Combined Diphtheria, Tetanus, Whole Cell Pertussis, Hepatitis B Vaccine, Haemophilus influenzae type b conjugate vaccine
223686162|NCT00136604|BIOLOGICAL|Meningitec|Wyeth's MenC CRM197 conjugated vaccine, Meningitec
223686163|NCT01309893|DEVICE|Investigational Lens|Lenses worn on a daily wear basis for one week
223686164|NCT01309893|DEVICE|Air Optix Aqua lens|Lenses worn on a daily wear basis for one week
223686165|NCT02798614|DEVICE|10-day cast|Removal of plaster cast fixation 10 days after reduction
223686166|NCT01879540|BIOLOGICAL|aTIV|Adjuvanted Trivalent Influenza Virus Vaccine (surface antigen, inactivated, adjuvanted with MF59C.1, egg-derived)
223686167|NCT01644370|DRUG|HAART|as per Thai HIV Treatment guidelines
223686168|NCT02951676|PROCEDURE|Extraction|Extraction of impacted third molar teeth
223686169|NCT03143491|DRUG|SOR007 (Uncoated Nanoparticulate Paclitaxel) Ointment|1 mL of SOR007 applied topically to the ectocervix once-weekly for four weeks.
223686170|NCT02352584|BIOLOGICAL|GC3110A(Quadrivalent)|GC3110A(Quadrivalent), 0.5ml, intramuscular, a single dosing at Day 1
223686171|NCT02352584|BIOLOGICAL|GC Flu(Trivalent)|GC Flu Pre-filled Syringe Inj.(Trivalent), 0.5ml, intramuscular, a single dosing at Day 1
223686172|NCT02352584|BIOLOGICAL|GC3110A(Trivalent)|GC3110A(Trivalent), 0.5ml, intramuscular, a single dosing at Day 1
223686173|NCT02686190|OTHER|Luxtherapy|
223686174|NCT02778360|DEVICE|Neurofeedback NFT|"The ADHD@Home Device is composed of a software for NF Training deployed on a Windows tablet, and connected to an EEG headset and an amplifier.~The training is personalized according to patient's characteristics."
223686175|NCT02778360|DRUG|Methylphenidate MPH|Drug prescribed with a first titration period until an optimal dose.
223686176|NCT04351776|OTHER|VR-Biofeedback|Participants will be instructed to use the Mindful Aurora application
223686177|NCT04351776|OTHER|VR-Distraction|Participants will be instructed to use one of three applications
223686178|NCT04351776|OTHER|360 Video|Participants will be instructed which video to view
223686179|NCT03654430|OTHER|Echocardiography|Two echocardiographies will be performed in healthy newborns: The first between day 2 and day 5 of life, the second between day 60 and day 90 of life
223686180|NCT04652739|DRUG|Lycopene Softgel, 10 Mg|Patients were given 10 mg of lycopene softgel capsules once daily for two months. The active ingredient in each capsule consists of 10 mg lycopene from natural tomato extract.
223686181|NCT04652739|DRUG|Prednisolone|Patients were given 40 mg of prednisolone tablets once daily in the morning for one month, afterwards, the dose was tapered along the following month. Incremental reduction of 10 mg each week for the first three weeks, followed by 5 mg reduction in the last week, was the tapering protocol in this study. The active ingredient in each tablet consists of Prednisolone metasulfobenzoate sodium 31.44 mg (equivalent to 20 mg of Prednisolone).
223686182|NCT01795066|DEVICE|EUS-FNB with 25-gauge (Echotip ProCore; Cook Endoscopy Inc, Limerick, Ireland)|
223686183|NCT01449695|BEHAVIORAL|Life style counseling|A nurse-based intervention with face-to-face contacts based on motivational interviewing techniques and influence on behavioral determinants. Well-trained nurses in our hospital will apply these behavioral change interventions. An individual contact will take about twenty minutes.
223686184|NCT01449695|BEHAVIORAL|an individualized web portal|This website shows patient's lab results, life style issues, blood pressure and weight in various risk monitors. These lab results and lifestyle changes will be visualized in risk monitors and provide structural feedback to the patient. The results of the screening and the two additional visits can be seen by the patient.
223686185|NCT01449695|BEHAVIORAL|individual and group consultations|group consultations with peers and a nurse individual consultation with a nurse
223686186|NCT05038176|BEHAVIORAL|MANUP|Intervention will include diabetes education, diabetes support with a focus on coping techniques (based on John Henryism concepts), physical activity engagement and motivational text messages.
223686187|NCT03109847|DRUG|Metformin Hydrochloride|Given Orally
223686188|NCT03109847|OTHER|Radioactive Iodine|Undergo radioactive iodine treatment
223686189|NCT03109847|OTHER|Placebo|Given orally
223686190|NCT01296243|DRUG|Tesetaxel|Tesetaxel capsules will be administered orally once every 21 days until progression, as defined by Prostate Cancer Working Group 2 (PCWG2) criteria. The duration of protocol therapy will not exceed 12 months. Treatment will be initiated at a dose of 27 mg/m2; dose escalation to a maximum of 35 mg/m2 is allowed in Cycle 2 depending on tolerability.
223686191|NCT03954327|DRUG|Emtricitabine (FTC)/Tenofovir Disoproxil (TDF)|Emtricitabine (FTC) 200 mg/Tenofovir Disoproxil (TDF) 300 mg by mouth once per day
223686192|NCT03954327|DRUG|Raltegravir|Raltegravir (RTF) 600 mg two tablets by mouth once per day
223686193|NCT03954327|DRUG|Placebo Oral Capsule [CEBOCAP]|Two capsules identical to Raltegravir and one capsule identical to Truvada with no active ingredients by mouth once per day
223686194|NCT03839927|OTHER|Validity and reliability of Life-Space Assesment|Life-Space Assesment and SF-36 surveys will be applied. The reliability and validity of the results will be analyzed.
223686195|NCT00997542|DRUG|Allopurinol|
223686196|NCT00997542|DRUG|Placebo|
223686197|NCT03924466|DRUG|68GaNOTA-Anti-HER2 VHH1|"All subjects will receive at least one single intravenous injection of the IMP followed by a total body PET/CT prior to receiving standard-of-care therapy.~A second injection of the IMP can be administered before or during standard-of-care treatment, depending on cohort."
223686198|NCT06387433|BEHAVIORAL|mobile app use|The experimental group will use the mobile application while controlled group will not use mobile application. Investigators will assess the effectiveness of mobile application in ensuring medication adherence and self-management among diabetics in Pakistan
223686199|NCT03763227|DRUG|Intravitreal ranibizumab (IVR) injection|Intravitreal ranibizumab (IVR) injection in patients with retinal dystrophy and macular cysts who have not responded to treatment with carbonic anhydrase inhibitors
223686200|NCT03763227|DRUG|Carbonic Anhydrase Inhibitor (CAI) therapy|Carbonic anhydrase therapy (Oral or Topical) in patients with retinal dystrophy and macular cysts
223686201|NCT04411862|DIETARY_SUPPLEMENT|Phosphatidyl Choline|2.1 g Phosphatidylcholine daily in addition to lifestyle modification
223686202|NCT04411862|BEHAVIORAL|Lifestyle modification|Lifestyle modification and health education by Clinical Pharmacist
223686203|NCT02793843|DRUG|Ondansetron (Zofran)|Intravenous administration of 4 mg ondansetron 15 minutes before spinal anesthesia
223686204|NCT02793843|DRUG|Dexamethasone (Decadron)|Intravenous administration of 8 mg dexamethasone 15 minutes before spinal anesthesia
223686205|NCT02793843|OTHER|Spinal anesthesia|Intrathecal anesthesia by 10 mg hyperbaric marcain, 5 mcg sufentanyl and 150 mcg morphine using 27 G spinal needle (27 G Quincke needle)
223686206|NCT01120834|DRUG|azacytidine|"* Dose level 1: azacitidine 55 mg/m2 on days 1-5~* Dose level 2: azacitidine 75 mg/m2 on days 1-5~* Dose level 3: azacitidine 55 mg/m2 on days 1-5~* Dose level 4: azacitidine 75 mg/m2 on days 1-5~Each cycle = 28 days. Subjects may receive up to 6 cycles."
223686207|NCT01120834|DRUG|vorinostat|"* Dose level 1: oral vorinostat at 300 mg BID on Days 1-7.~* Dose level 2: oral vorinostat at 200 mg BID on Days 1-7.~* Dose level 3: oral vorinostat at 300 mg BID on Days 1-14.~* Dose level 4: oral vorinostat at 200 mg BID on Days 1-14.~Each cycle = 28 days. Subjects receive up to 6 cycles."
223775663|NCT06269328|OTHER|Inhalation anesthesia with sevoflurane for anesthetic maintenance|For anesthesia induction, intravenous propofol was used at doses of 1-2 mg/kg, fentanyl at 2mcg/kg, lidocaine at 1mg/kg, and rocuronium at doses of 1mg/kg. After then anesthesia was maintained with inhalation anesthetic (50% O2/Air with Sevoflurane 2% )
223686208|NCT02596282|PROCEDURE|Neonatal circumcision under topical anesthesia|"The standard procedure for neonatal circumcision is as follows: combined analgesia was topical 2.5% lidocaine and 2.5% prilocaine \<1 gm applied 60 minutes and 40mg acetaminophen suppository 30 minutes prior to surgery. Infants were given a 24% sucrose solution pacifier if needed. Infants under 2 weeks of age received subcutaneous Vitamin K 1 mg. The perineum cleaned, and the penis swabbed with povidone iodine. Hemostats were applied at 3 and 9 o'clock positions and the glans pushed down. Traction was applied before placing the Mogen clamp, the clamp was closed for 5 minutes and the foreskin removed with a scalpel.~Petroleum jelly (e.g., Vaseline) was applied to the glans and the wound covered with sterile gauze. Infants were observed for one hour. Mothers were instructed in wound care."
223686209|NCT00321893|DRUG|Budesonide|Inhaled Budesonide 800 micrograms (ug) twice daily for one year.
223686210|NCT00321893|OTHER|Placebo|Inhaled placebo twice daily for one year.
223686211|NCT00769483|DRUG|MK-0646|Starting Dose Level: 5 mg/kg given intravenously over 60 minutes Days 1, 8, 15, 22 of 28 Day Cycle.
223775664|NCT00215293|DEVICE|Cervical I/F Cage|
223775665|NCT00215293|DEVICE|Autograft or allograft with a plate, or autograft alone.|
223686212|NCT00769483|DRUG|Gemcitabine|1000 mg/m\^2 given intravenously over 1-1/2 hours Days 1, 8, and 15 of each 28 Day Cycle.
223686213|NCT00769483|DRUG|Erlotinib|100 mg by mouth daily.
223686214|NCT05649202|OTHER|Xpert® HCV Viral test|an additional sample of 5 ml of blood will be taken for real-time HCV PCR by Xpert®, in addition to the blood samples taken as part of routine care.
223686215|NCT05649202|OTHER|FibroScan® test|A non invasive test made on a small area of skin coated with a gel
223686216|NCT00209651|DRUG|Campto, Topotesin|q00 mg/m2, IV (in the vein) on day 1,15 of each 28 day cycle.
223686217|NCT00209651|DRUG|TS-1|80 mg/m2, PO (oral) on day 1\~14 of each 28 day cycle.
223686218|NCT04123028|OTHER|observatory|observation for 1 year period
223686219|NCT05265377|DEVICE|Stelo|Use of Stelo exoskeleton in nine rehabilitation sessions
223686220|NCT04631991|DIAGNOSTIC_TEST|Comprehensive ophthalmologic examination|Measurements of best-corrected visual acuity, refractive error, intraocular pressure, axial length, slit lamp examination of the anterior segment, dilated fundus examination, and optical coherence tomography angiography imaging.
223775666|NCT05008510|DRUG|Sabizabulin|Sabizabulin (Veru-111)
223775667|NCT05008510|DRUG|Sacituzumab Govitecan-hziy|Sacituzumab govitecan-hziy
223775668|NCT05008510|DRUG|Sabizabulin/Sacituzumab govitecan-hziy Combo|Sabizabulin/Sacituzumab govitecan-hziy Combo therpy
223686221|NCT02948101|BIOLOGICAL|Anti-CSF1 Monoclonal Antibody PD-0360324|Given IV
223686222|NCT02948101|DRUG|Cyclophosphamide|Given PO
223775669|NCT00399438|DRUG|Placebo|Tablets, Oral, once daily, 2 weeks
223775670|NCT00399438|DRUG|BMS-562086|Tablets, Oral, once daily, 2 weeks
223686223|NCT02948101|OTHER|Laboratory Biomarker Analysis|Correlative studies
223686224|NCT03702296|OTHER|Ear plugs and eye masks|Patients in the intervention arm will be provided with ear plugs and eye masks and instructed on the use of these during sleep
223686225|NCT03227341|OTHER|Exercise|8 week exercise program including breathing exercises consisted of pursed-lip breathing, diaphragmatic breathing and thoracic expansion exercises, relaxation and stretching exercises, upper and lower extremity muscle strength training, and aerobic exercises. In addition, bronchial hygiene techniques and dyspnea-reducing positions
223686226|NCT05694000|DEVICE|On-Stimulation|"The surgical electrode implanted in hippocampus by a pulse generating device is on."
223686227|NCT05694000|DEVICE|Off-Stimulation|"The surgical electrode implanted in hippocampus by a pulse generating device is off."
223686228|NCT04853303|DEVICE|Hypnosis VR|Children will be required to wear a VR gadget for hypnosis when they are experiencing chemotherapy-induced nausea and vomiting, sleep quality or pain. The duration is 15 minutes.
223686229|NCT01958112|DRUG|GSK1120212 (trametinib)|Trametinib dose is 1.5 mg orally once per day
223686230|NCT01958112|DRUG|GSK2141795|The dose of GSK2141795 is 50 mg orally once per day
223686231|NCT00600860|OTHER|No interventions|Only registration of clinical practice
223686232|NCT01781169|DIETARY_SUPPLEMENT|Oral supplementation of vitamin D|Weekly oral supplementation of 50,000 IU vitamin D (cholecalciferol) for eight weeks to the obese males compared with the normal-weight males. The chemical form of vitamin D is cholecalciferol capsuled as fine powder.
223686233|NCT02732743|DIETARY_SUPPLEMENT|Physiomanna® Baby|Dosage 1g/kg body, 2 cycles (if applicable)
223686234|NCT00999921|DRUG|Tamoxifen|Tamoxifen is given at 10 mg once daily between Day 5 and Day 25 of menstrual cycle for 3 cycles.
223686235|NCT00999921|DRUG|Evening Primrose Oil|Evening Primrose Oil is given at 1000 mg two times daily for 3 months.
223686236|NCT03608423|DEVICE|Minimally-invasive endoscopy-guided surgery|Surgery started within 8 hours of onset of spontaneous intracerebral hemorrhage.
223686237|NCT00610584|PROCEDURE|acupuncture|arm 1: verum acupuncture group: 12 interventions (semi-standardised): 8 in the first 4 weeks and 4 in the next 4 weeks + rescue medication (up to 2 doses of second-generation oral antihistamines daily (e.g. 2 x 1 cetirizine dihydrochloride/daily))
223686238|NCT00610584|PROCEDURE|minimal (sham)acupuncture|arm 2: minimal (sham) acupuncture group: 12 interventions (standardised): 8 in the first 4 weeks and 4 in the next 4 weeks + rescue medication (up to 2 doses of second-generation oral antihistamines daily (e.g. 2 x 1 cetirizine dihydrochloride/daily))
223686239|NCT00610584|DRUG|cetirizine dihydrochloride (rescue medication)|arm 3: rescue medication (up to 2 doses of second-generation oral antihistamines daily (e.g. 2 x 1 cetirizine dihydrochloride/daily)) alone
223686240|NCT03977428|OTHER|standard of care|No intervention, this a patient registry and is purely an observational study
223686241|NCT05068895|OTHER|liquid chromatography-mass spectrometry|Metabolomics is a rapidly evolving high-throughput technology that allows the measurement of the entire complement of metabolites generated by biochemical reactions under certain conditions in biological fluids or tissues. This technology has been used extensively to identify biomarkers in various cancers, nervous system diseases, cardiovascular diseases, pituitary diseases, and other diseases. The identification of biomarkers can be clinically useful for a more accurate diagnosis, prognosis, and treatment choice as well as disease monitoring. Among mass spectrometry (MS) methods, liquid chromatography-mass spectrometry (LC-MS) has been recognized as a robust metabolomics tool and has been widely applied in metabolite identification and quantification due to its high sensitivity, peak resolution, and repro- ducibility.
223686242|NCT05409820|PROCEDURE|use of different spinal anesthesia techniques|Comparison of spinal anesthesia with 5 mg hypobaric bupivacaine and 5 mg hyperbaric bupivacaine in outpatients
223686243|NCT01210287|DRUG|nucleoside analog reverse transcriptase inhibitor|tablets 100mg qd
223686244|NCT03037268|DEVICE|Lytro Plenoptic Camera and 28D lens|"* visual acuity measured, intraocular pressure obtained, eyes dilated as part of a standard exam for intended patient visit~* screened and consented for study~* subjected to bilateral plenoptic ophthalmoscopy~* mydriatic, single-field fundus images obtained~* images reviewed for quality and diagnostic utility by a masked grader"
223686245|NCT00169884|BEHAVIORAL|cognitive-behavioural therapy|
223686246|NCT04466228|DEVICE|non-invasive transcranial electrical stimulation|Non-invasive transcranial electrical stimulation across the prefrontal cortex.
223775671|NCT00759967|PROCEDURE|Microneurography|Muscle sympathetic nerve activity measurement will be obtained using microneurography. Approximately 10-20% of microneurography recordings are not interpretable due to technical problems. For this reason, blood samples will be collected at the same time that the microneurography is to be done. These test will be done at 3 time points throughout the study.
223775672|NCT00759967|PROCEDURE|Bioimpedance testing|bioimpedance measurement of extracellular fluid volume will be measured at the end of each 3 month period. This test will be done at 3 time points throughout the study.
223775673|NCT02121145|BIOLOGICAL|Vivotif|3 oral doses
223775674|NCT02121145|BIOLOGICAL|Typherix|one intramuscular dose
223775675|NCT01675713|BEHAVIORAL|Intensive lifestyle intervention|Lifestyle modification program focusing on increasing physical activity level, adjusting energy intake and learning coping strategies
223686247|NCT02728778|DRUG|incobotulinumtoxin A|Application of botulinum toxin A into the forehead
223686248|NCT02728778|PROCEDURE|Acupuncture|Application of acupuncture into the forehead
223686249|NCT01771575|OTHER|Placebo device|Placebo device
223686250|NCT01771575|DEVICE|PoNS™ device|The PoNS™ device uses electrotactile waveform in conjunction with the Cranial Nerve - Non-Invasive NeuroModulation (CN-NINM) intervention. This involves using both balance and gait training methods to stabilize symptoms, regain balance \& gait, and affect the functional transfer of improved stability and mobility to activities of daily living. It is based on a body of work focused on developing the tongue-based human-machine interface and application of this technology for balance, vision, and auditory substitution and more recently as neuromodulation for brain rehabilitation after injury and disease.
223686251|NCT00224627|PROCEDURE|Capsule GIVEN IMAGING LTD|
223686252|NCT02770469|BEHAVIORAL|Linguistically and Culturally Tailored Information|Participants received linguistically and culturally tailored information on diet and nutrition, physical activity, managing treatment side effects, follow-up care plans, complementary and alternative medicine, reducing environmental exposure to estrogen, navigating cancer-related financial issues, family history, body image, sexuality, and advances in breast cancer research.
223686253|NCT02770469|BEHAVIORAL|Cognitive-Behavioral Stress Management|Participants learned and practiced skills related to mindfulness, relaxation, stress reduction, rational thinking, improving coping, enhancing social support, anger management, and assertiveness training.
223686254|NCT01253330|OTHER|Text Message Reminders|During baseline (Participant 1st Arm) or Month 3 Visit (Comparison 1st Arm), the study staff member will demonstrate for the teen how to log-on to the calendar system and set up reminders. Teens will be able to set their own reminders and add other reminders in addition to those that are asthma related.
223775676|NCT03893227|OTHER|Questionnaire|Patients and healthy controls will fill out a questionnaire
223775677|NCT02966080|DRUG|HEP-IV|
223775678|NCT06034366|DRUG|0.01% atropine|0.01% atropine (3 ml unit-concentration, preservative-free) once nightly in both eyes for 48 weeks,
223686255|NCT04590079|DEVICE|Conventional pain treatment with daily sessions with innovative medical device, Remedee One, for pain management by Millimeter Band Radiation|Conventional pain treatement with daily sessions with innovative medical device for pain management (radiation in millimeter band) at the rate of 1 to 3 sessions by day of 40 minutes for 3 months.
223686256|NCT00004017|PROCEDURE|conventional surgery|
223686257|NCT00004017|RADIATION|iodine I 131 monoclonal antibody TNT-1/B|
223686258|NCT02959164|DRUG|Decitabine|"Dose escalation starting at 0.1mg/kg, subcutaneously administered on twice weekly schedule for three weeks of a 28 day cycle.~Dose Escalation Schedule Dose Level/Dose of Decitabine per cycle Level -2: 0.1 mg/kg SQ twice weekly for 1 week; Level -1: 0.1 mg/kg SQ twice weekly for 2 weeks; Level 1\*: 0.1 mg/kg SQ twice weekly for 3 weeks; Level 2: 0.2 mg/kg SQ twice weekly for 3 weeks;~\*Starting Dose Level"
223686259|NCT02959164|DRUG|Gemcitabine|"Fixed infusion rate of 900 mg/m2, IV over 90 min, on Days, 1, 8 and 15 of a 28-day cycle.~Dose Escalation Schedule Dose Level/Dose of Decitabine per cycle Level -2: 0.1 mg/kg SQ twice weekly for 1 week; Level -1: 0.1 mg/kg SQ twice weekly for 2 weeks; Level 1\*: 0.1 mg/kg SQ twice weekly for 3 weeks; Level 2: 0.2 mg/kg SQ twice weekly for 3 weeks;~\*Starting Dose Level"
223686260|NCT03015883|RADIATION|Diffusing Alpha Radiation Emitters Therapy (DaRT)|An intratumoral insertion of a seed(s), loaded with Radium-224, securely fixed in the seeds. The seeds release by recoil into the tumor short-lived alpha-emitting atoms.
223686261|NCT04538196|OTHER|Resident education on documentation and coding|Surgery residents will receive education on documentation and coding at the beginning of a particular surgical rotation vs the control group who will receive no education on documentation
223686262|NCT03360786|OTHER|Specific intervention|Series of progressive exercises targeted at balance, adaptation, dividing attention, head on neck control, visual + education on concussion identification and concussion education
223686263|NCT03360786|OTHER|Control intervention|Education on concussion and concussion identification in addition to typical cardiovascular warmups
223686264|NCT03096015|BEHAVIORAL|Intensive Comprehensive Aphasia Program|
223775679|NCT06034366|OTHER|0.9% sodium chloride|placebo eye drops (0.9% sodium chloride, 3 ml unit-concentration, preservative-free) once nightly in both eyes for 48 weeks
223775680|NCT00994916|DRUG|3,4 diaminopyridine|3,4 diaminopyridine up to 80 mg daily in divided doses
223686265|NCT01440062|DRUG|Verum arm receiving Vitamin D oil|oil: 20000 IU/g tablet: 400 IU/g every second day
223686266|NCT01440062|DRUG|low dose arm receiving neutral oil and 400 IU/g of Vitamin D every second day|neutral oil and a low dose of vitamin D
223686267|NCT04867434|DRUG|RZL-012|small synthetic molecule for submental fat reduction
223686268|NCT04867434|DRUG|Placebo|Placebo
223686269|NCT00002585|DRUG|pyrazoloacridine|
223686270|NCT03858465|DRUG|Ephedrine|intravenous 25 mg of ephedrine
223686271|NCT03858465|DRUG|Phenylephrine|intravenous 0,3 mg of phenylephrine
223686272|NCT01872234|DEVICE|Two-lead CRT-P|The two lead CRT-P will consist of a dual chamber pacemaker, a right atrial lead and a left ventricular lead.
223775681|NCT00007800|BEHAVIORAL|Behavioral Group Weight Loss Intervention|
223686273|NCT05029973|DRUG|HAIC|hepatic arterial infusion (HAI) of oxaliplatin, fluorouracil/leucovorin (FOLFOX) treatment
223686274|NCT05029973|DRUG|Sintilimab|200mg IV d1,Q3W
223686275|NCT05029973|DRUG|Bevacizumab Biosimilar|7.5mg/kg IV d1,Q3W
223686276|NCT04956770|PROCEDURE|Implantation surgery|"The intervention involves the implantation of:~* a neurostimulator: the Activa® RC from Medtronic~* a stimulation electrode paddle array: the Specify™ SureScan® 5-6-5 from Medtronic"
223686277|NCT02385136|DRUG|Temozolomide|
223686278|NCT00079131|BIOLOGICAL|oblimersen sodium|Given IV
223686279|NCT00079131|OTHER|pharmacological study|Correlative studies
223686280|NCT00079131|OTHER|laboratory biomarker analysis|Correlative studies
223686281|NCT02704910|BEHAVIORAL|Subthalamic stimulation|Assess difference of amplitude (in degree) of the postural deviation between both condition of unilateral condition of subthalamic nucleus
223686282|NCT05366673|OTHER|massage|Perform a 10-minute back massage every day for a week
223686283|NCT06077708|DIETARY_SUPPLEMENT|Vitamin D3K2|Non-surgical periodontal treatment was applied to all individuals included in the study. 2 drops of the preparation containing 25 µg D3 \[1000 IU\] and 11.25 µg K2 in each drop were given per day to participants in the test group.
223686284|NCT06077708|OTHER|Saline Solution|Non-surgical periodontal treatment was applied to all individuals included in the study and saline solution (0.9% NaCl) was given as placebo, 2 drops per day to particiapants in the control group.
223686285|NCT05295797|BEHAVIORAL|Dance Program|Participants will take 2 in person dance classes led by peer dance instructors per week for 12 weeks
223686286|NCT01392521|DRUG|Copanlisib + Refametinib (BAY86-9766)|Copanlisib will be administered as an IV infusion weekly for 3 weeks in combination with Refametinib (BAY86-9766) at varying dose levels. Refametinib (BAY86-9766) is administered orally twice a day starting at Day 4 of Cycle 1.
223686287|NCT01392521|DRUG|Copanlisib + Refametinib (BAY86-9766)|Copanlisib will be administered as an IV infusion weekly in combination with Refametinib (BAY86-9766) at varying dose levels. Refametinib (BAY86-9766) is administered orally twice a day starting at Day 6 of Cycle 1 on a 4 day on, 3 day off schedule.
223686288|NCT04671173|DEVICE|Measurement of the Intra-Compartmental Pressure with the MY01 device|"All Participants will be monitored for clinical signs of symptoms of ACS, including the 7 Ps at a minimum of every 4-6 hours.~The Intra-Compartmental Pressure of the anterior compartment of the leg will be monitored with the MY01 device. The device should be inserted five centimeters (5 cm) from the fracture, if possible, in the muscle belly. The affected limb will then be splinted in a standard U-slab with no pressure on the monitored device."
223686289|NCT03500679|BIOLOGICAL|ExPEC4V|Participants will receive ExPEC4V vaccine as an IM injection on Days 1 and 181.
223775682|NCT00007800|BEHAVIORAL|Motivational Interviewing|
223775683|NCT03264157|DRUG|HRIG|A 20 IU/kg dose of BPL HRIG will be given on Day 0 via IM injection.
223775684|NCT03264157|DRUG|HyperRAB|A 20 IU/kg dose of Comparator HRIG will be given on Day 0 via IM injection.
223775685|NCT03264157|BIOLOGICAL|RabAvert|A 1.0 ml dose of active vaccine (2.5 IU/ml) will be given IM on 5 occasions: on Days 0, 3, 7, 14, and 28.
223775686|NCT00288496|DRUG|polyethylene glycol bowel lavage solution|
223686290|NCT03500679|BIOLOGICAL|Placebo|Participants will receive placebo as an IM injection on Days 1 and 181.
223686291|NCT00404703|DRUG|bevacizumab [Avastin]|15mg iv on day 1 of each 3 week cycle
223686292|NCT00404703|DRUG|Platinum-based chemotherapy|As prescribed
223686293|NCT03473938|DEVICE|Spatz3 AIGB|Implantation of Spatz3 AIGB balloon.
223686294|NCT03300518|DRUG|Follitropin Beta;MSD|Patients will start stimulation with a daily s.c. injection of follitropin beta( 300IU Puregonon;MSD) menstrual cycle day 2 or 3.
223686295|NCT03300518|DRUG|Ganirelix|A daily administration of ganirelix (0.25 mg Orgalutran; MSD) was introduced when the leading follicle is near 13mm, and was repeated up to the time of hCG administration.
223686296|NCT03300518|DRUG|hCG|Ovulation was triggered when the leading follicles reach 18-20mm and at least two follicles 17-18mm , HCG 10000 IU is used to trigger
223775687|NCT05864339|BEHAVIORAL|A designed empathy intervention|Students watch 4 smokers' videos, read the textual materials, fill out the HEMs and discuss a quit counseling plan for an assigned smoker using the 5As counseling skilll.
223775688|NCT05864339|BEHAVIORAL|Smoking cessation counseling tutorial|Students watch 4 smokers' videos, read the textual materials, and discuss a quit counseling plan for an assigned smoker using the 5As counseling skill.
223686297|NCT03300518|DRUG|estradiol valerate|Estradiol valerate (progynova,Schering) daily dose of 4 mg (2 mg twice a day) was given orally, started 7 days before the presumed onset of menses and administered up to 2 days of the next menstrual cycle
223686298|NCT01962922|DRUG|LCP-Tacro|once-daily extended release tablet
223686299|NCT01962922|DRUG|Tacrolimus -IR|twice daily capsules
223686300|NCT04073329|OTHER|post operative measure of reduction|measurement was used to grade quality of reduction according to Matta's system . In accordance with prior studies, adequate (or anatomic) reductions with 0-1 mm of displacement were compared to inadequate (imperfect or poor) reductions with \> 1 mm displacement . For the CT-based method, postoperative pre-digital (prior to 2000) and digital CT images were independently assessed in the axial, sagittal, and coronal planes, and residual gap and step displacement were measured along the articular surface at the level of the weight-bearing dome. Adequate reductions on postoperative CT were defined as \< 1 mm step and \< 5 mm gap displacement and inadequate reductions as ≥ 1 mm step and/or ≥ 5 mm gap displacement.
223686301|NCT04128332|RADIATION|Pre-operative stereotactic ablative body radiotherapy|Stereotactic ablative body radiotherapy is a highly focused radiation treatment that gives an intense dose of radiation concentrated on a tumour, while limiting the dose to the surrounding tissues.
223686302|NCT03368573|DEVICE|QbTest|QbTest is a computerised assessment which takes approximately 20mins. The test combines a continuous performance test alongside an infrared camera which measures the participant's movements. The infrared camera measures motor activity of the participant whilst they undertake the task. During the test, the participant is presented with continuously changing stimuli. Embedded within these stimuli is a given target. Participants have to respond by pressing a hand-held button only when the target appears. Attention is measured through omission errors and reaction time to response. Impulsivity is assessed through commission errors and anticipatory errors. Motor activity is measured through head movements during the task. The test is approved by the FDA (Ref: K133382) and CE marked.
223686303|NCT04319822|OTHER|blood sample and muscular biopsy|blood sample and muscular biopsy
223686304|NCT00391261|DRUG|Metformin|open-label, flexible dosing
223686305|NCT01759485|DRUG|Vitamin D3|once weekly oral drops preparation at a daily dose of 2000 IU X 7 = 14,000 IU per week (about 60 drops each week).
223686306|NCT01759485|DRUG|placebo|
223686307|NCT04923165|DEVICE|robotic assisted intervention|Robotic treatment of the upper limb (30 sessions, 5 times a week) using a set of 4 robotic devices: Motore (Humanware); Amadeo, Diego, Pablo (Tyromotion). The training will include motor-cognitive exercises specifically selected to train spatial attention, vision and working memory, praxis, executive function, and speed of processing.
223686308|NCT04923165|DIAGNOSTIC_TEST|biochemical analyses|ematochemical and biochemical serum analyses at T0 and at T1; oxidative stress analyses;
223686309|NCT04923165|DEVICE|BIA, hand grip|bioimpedentiometric analyses of muscular mass (T0 and T1) , muscular force with hand grip
223686310|NCT04923165|DIAGNOSTIC_TEST|nutritional assessment, MNA|nutritional status assessment with MNA, body mass index measurements, weight loss detection, food income detection
223686311|NCT04658173|DRUG|remimazolam-alfentanil combination|Group remimazolam-alfentanil combination received 10 µg/kg alfentanil and 0.3mg/kg remimazolam over 30 seconds, followed by an infusion of remimazolam at 0.2 to 1 mg/kg/hr and alfentanil at 0 to 1ug/kg/min. In case of the sudden patient movement, and difficulty in maneuvering the endoscope, remimazolam 0.1mg/kg was used in the form of bolus, as rescue drugs, and alfentanil 5ug/kg when additional analgesia is needed
223686312|NCT04658173|DRUG|propofol-alfentanil combination|Group propofol-alfentanil combination received 10 µg/kg alfentanil and 1 mg/kg propofol over 30 seconds followed by an infusion of propofol at 2 to 6 mg/kg/hr. In case of the sudden patient movement, and difficulty in maneuvering the endoscope, propofol 0.5 mg/kg was used in the form of bolus, as rescue drugs，and alfentanil 5ug/kg when additional analgesia is needed
223686313|NCT01418027|OTHER|Intensive exercise|Subjects conduct an aerobic exercise at 65-80% maximum oxygen consumption for 30 minutes each day, five days a week, totally for 6 months.Subsequently, moderate physical activity(3.0-6.0 MET s) at 150 min/wk for 6 months.
223686314|NCT01418027|OTHER|Conventional exercise|Subjects receive moderate physical activity(3.0-6.0 MET s) at 150 min/wk(30 min per day, five days a week) for 12 months.
223686315|NCT02882373|DIETARY_SUPPLEMENT|Arginine|Given PO
223686316|NCT02882373|DRUG|Placebo|Given PO
223686317|NCT03555773|PROCEDURE|Lipogems|After local surgical drainage of the perianal disease, micro-fragmented adipose tissue is injected circumferentially into the submucosa surrounding the internal fistula orifice and in the perianal tissue along the residual fistula tract.
223686318|NCT00423696|BIOLOGICAL|bevacizumab|
223686319|NCT00423696|DRUG|capecitabine|
223686320|NCT00423696|DRUG|fluorouracil|
223686321|NCT00423696|DRUG|irinotecan hydrochloride|
223686322|NCT00423696|DRUG|leucovorin calcium|
223686323|NCT03231982|DRUG|Group I|Machkhan Tab. 8/5 mg + Atacan Tab. 8 mg placebo + Norvasc Tab. 5 mg placebo for 8 weeks or Machkhan Tab. 16/5 mg + Atacan Tab. 16 mg placebo + Norvasc Tab. 5 mg placebo for 8 weeks
223686324|NCT03231982|DRUG|Group II|Atacan Tab. 8 mg + Norvasc Tab. 5 mg + Machkhan Tab.8/5 mg placebo for 8 weeks or Atacan Tab. 16 mg + Norvasc Tab. 5 mg + Machkhan Tab.16/5 mg placebo for 8 weeks
223686325|NCT00013195|BEHAVIORAL|Telephone Care|
223686326|NCT01616134|OTHER|Korea red ginseng|Intervention group were administered with 4 capsules (2 g) each of powdered red ginseng (6-year old , rootlets) 40 minutes before breakfast, lunch and dinner, totaling 12 capsules (6 g) per day, for 12 weeks
223686327|NCT01616134|OTHER|Placebo|The subjects in the Control group were given the same quantity of placebos also three times a day for 12 weeks.
223686328|NCT03098771|PROCEDURE|the cell transplantation group|Patients with atherosclerotic lower limb ischemia will be randomly assigned to the cell transplantation group, which peripheral blood CD34+ cells transfected with ActiveMax® recombinant human vascular endothelial growth factor 165 (VEGF165) gene will be transplanted into the muscles of ischemic limbs in elderly patients with atherosclerotic lower limb ischemia.
223686329|NCT03098771|DRUG|the control group|Patients with atherosclerotic lower limb ischemia will be randomly assigned to the control group, which 9% physiological saline will be injected into the muscles of ischemic limbs.
223686330|NCT06473987|OTHER|Personalized cognitive-sensorimotor VR/AR training|Thinking task integrated walking and balance training program
223686331|NCT06473987|OTHER|Traditional dual-task training|Walking and balance training similar to standard of care group but will also perform additional thinking tasks during training
223686332|NCT06473987|OTHER|Standard of Care|Standard walking and balance training
223686333|NCT03913325|OTHER|PREVSAM model|A person-centred rehabilitation plan, including coordinated measures within primary health care as well as in collaboration with participants' employers, and when relevant the Swedish Public Employment Agency
223686334|NCT03913325|OTHER|Treatment as usual (standard treatment)|Treatment as usual (ordinary/standard) treatment. Can include unimodal or multimodal treatment of physiotherapy solely and/or occupational therapy
223686335|NCT00254774|DRUG|quetiapine fumarate or valproate|
223686336|NCT04424524|OTHER|Direct-to-pharmacy oral PrEP refill visits|Programmatic direct-to-pharmacy oral PrEP refill visits supported with client HIV self-testing
223686337|NCT01846520|OTHER|educational intervention|Receive FCPCI home education sessions
223686338|NCT01846520|BEHAVIORAL|telephone-based intervention|Receive FCPCI telephone support sessions and 24 hour telephone support
223686339|NCT01846520|PROCEDURE|quality-of-life assessment|Ancillary studies
223686340|NCT01846520|OTHER|questionnaire administration|Ancillary studies
223686341|NCT05000333|OTHER|Self-questionnaire|The study will be proposed to caregivers who work at Centre Hospitalier Intercommunal de Villeneuve-Saint-Georges, who agree to answer the questionnaire anonymously
223686342|NCT02891616|DRUG|fludeoxyglucose F 18|
223686343|NCT02891616|DEVICE|Positron emission tomography-computed tomography|
223686344|NCT02891616|DRUG|18F-fluorothymidine|
223686345|NCT02891616|DEVICE|Positron emission tomography-magnetic resonance imaging|
223686346|NCT00495131|DRUG|Pegylated interferon alfa-2a plus ribavirin|Pegylated interferon alfa-2a (Pegasys, F. Hoffmann-LaRoche) 180 ug/week plus ribavirin (Robatrol, F. Hoffmann-LaRoche) 1000-1200 mg/day (\<75 kg, 1000 mg/day; \>= 75 kg, 1200 mg/day) for 24 weeks
223686347|NCT00495131|DRUG|Pegylated interferon alfa-2a plus ribavirin|Pegylated interferon alfa-2a (Pegasys, F. Hoffmann-LaRoche) 180 ug/week plus ribavirin (Robatrol, F. Hoffmann-LaRoche) 1000-1200 mg/day (\<75 kg, 1000 mg/day; \>= 75 kg, 1200 mg/day) for 48 weeks
223686348|NCT00451139|DRUG|artemether/lumefantrine|
223686349|NCT00451139|DRUG|quinine|
223686350|NCT00451139|DRUG|atovaquone/proguanil|
223686351|NCT02982512|DRUG|Dexmedetomidine|Administration of dexmedetomidine a different concetrations
223686352|NCT03224546|BEHAVIORAL|Contingency Management|Subjects will receive payments for providing cocaine negative urine samples.
223686353|NCT00744471|BIOLOGICAL|tanezumab|Tanezumab 10 mg IV every 8 weeks
223686354|NCT00744471|BIOLOGICAL|tanezumab|Tanezumab 5mg IV every 8 weeks
223686355|NCT00744471|BIOLOGICAL|tanezumab|Tanezumab 2.5 mg IV every 8 weeks.
223686356|NCT00744471|BIOLOGICAL|Placebo|Placebo to match tanezumab IV every 8 weeks
223686357|NCT01775462|DRUG|EDI200|3 or 10 mg/kg of EDI200
223686358|NCT02786524|BEHAVIORAL|Specialized Symptom Management and Supportive Care|Based on Patients who score 5 or higher on the Baseline Patient Palliative Care Survey that will identify patients that will most benefit from specialty palliative care
223686359|NCT01041729|DRUG|Atorvastatin|Patients with Peripheral Arterial Disease in Fontaine Stage II treated with Atorvastatin 40mg/day during 12 months
223686360|NCT01041729|DRUG|Standard Medical Treatment|"Patients with Peripheral Arterial Disease in Fontaine Stage II without treatment with Atorvastatin 40mg/day during 12 months.~Standard Medical Treatment."
223686361|NCT00644748|DRUG|gabapentin|"Gabapentin oral capsules:~Week 0: Day 1: 300 mg; Day 2: 600 mg (2 doses of 300 mg); Day 3: 900 mg (3 doses of 300 mg), maintained until the end of the week; After this point, the total daily dose was divided in 3 equal doses. Week 1: Day 1: 1200 mg; Day 2 to 7: 1800 mg Week 2: Day 1: 2100 mg; Day 2 to 7: 2400 mg Week 3: Day 1: 2700 mg; Day 2 to 7: 3600 mg Weeks 4 to 11: 3600 mg"
223686362|NCT05806671|DRUG|Dalpiciclib|Dalpiciclib 125 mg/day orally continuously dosed for 3 weeks followed by 1 week off
223686363|NCT05806671|DRUG|Pyrotinib|Pyrotinib 320mg/day orally continuously
223686364|NCT05806671|DRUG|Fulvestrant|Fulvestrant 500mg intramuscularly on Days 1 and 15 of Cycle 1, and then on Day 1 of each subsequent 28 day cycle
223686365|NCT01616082|BEHAVIORAL|Low Calorie Diet (LCD)|A Diet History Questionnaire was completed and subjects had dietary counseling and were provided shakes. The low calorie diet began, to continued for a period of 8 weeks.
223686366|NCT01616082|DRUG|Phentermine|"Individuals not on track to achieve their target weight by four weeks received the drug Phentermine to promote weight loss. Then, following eight weeks LCD (or four weeks LCD + four weeks LCD+Phentermine), in the event that they did not achieve the target weight loss, subjects were given the option to continue with the LCD + Phentermine for up to an additional 12 weeks, under a doctor's supervision.~Protection Against Risk:~* Prior to administering any phentermine, a history and physical including EKG will be conducted (at the screening visit) and will be used to determine whether the participant is clear to receive the medication.~* Participants will see the study doctor or nurse practitioner at every study visit after the drug is initiated."
223686367|NCT02847468|OTHER|FDG Positron Emission Tomography|Subject will performed Positrons Emission tomography (PET) with 18F-Fluorocholine (FDG) before treatment with Sorafenib is started and 1 month after treatment started.
223686368|NCT02847468|OTHER|FCH Positron Emission Tomography|Subject will performed Positrons Emission tomography (PET) with 18F-Fluorocholine (FCH) before treatment with Sorafenib is started and 1 month after treatment started.
223686369|NCT00976573|BIOLOGICAL|bevacizumab|Given IV
223686370|NCT00976573|DRUG|carboplatin|Given IV
223686371|NCT00976573|DRUG|everolimus|Given orally
223686372|NCT00976573|DRUG|paclitaxel|Given IV
223686373|NCT02370771|PROCEDURE|Biological sampling|Biological sampling to identify by label-free proteomic analysis of a combination of serum biomarkers in patients with Erosive and non erosive hand Osteoarthritis
223686374|NCT02370771|DEVICE|Radiographic evaluation|Radiographic assessments using Bone Mineral Analyser and Hand MRI will be done in patients with Erosive and non erosive hand Osteoarthritis
223686375|NCT04322214|DRUG|Cobicistat 150 MG|once daily cobicistat (150 mg QD) for 5 days
223686376|NCT04322214|DRUG|Placebo|once daily lactose capsules (as aspect cobicistat capsules)
223686377|NCT04322214|DRUG|GHB|single oral dose of GHB (25 mg/kg) on days 5 and 17
223686378|NCT04488211|OTHER|Survey|The IVM survey will be structured as a series of open questions and multiple-choice questions.
223686379|NCT02277613|BIOLOGICAL|AMI MultiStem cells|AMI MultiStem cells administration in coronary artery with a micro-infusion catheter.
223686380|NCT02277613|OTHER|Sham|Sham procedure using Micro-Infusion Catheter in coronary artery without injection.
223686381|NCT03816501|OTHER|music|The preference of the patients will be listened to preoperatively through the headphones
223686382|NCT03816501|OTHER|no music|the patients will not be listened
223686383|NCT02789722|OTHER|Yerba Mate Extract|Yerba Mate extract capsules 750 mg
223686384|NCT02789722|OTHER|Placebo|Take 3 capsules, 3 times daily for 28 days.
223686385|NCT04412161|PROCEDURE|Liver transplantation|Living donor liver transplantation
223686386|NCT02096874|DRUG|Bevacizumab|Intravitreal injection of 1.25mg/0.05 cc each 5 weeks for the first 3 months then PRN for six month
223686387|NCT02621710|OTHER|Questionnaire 3 months post-operatively|
223686388|NCT00248066|DRUG|RESTEN-MP|
223686389|NCT05481450|DIETARY_SUPPLEMENT|Nutritears®|Strength: Lutein/Zeaxanthin - 20/4 mg; Curcuminoids 200 mg; Vitamin D3 600 IU (Total capsule weight ≈670 mg)
223686390|NCT05481450|DIETARY_SUPPLEMENT|Placebo|Soybean oil capsule (Total capsule weight ≈670 mg)
223686391|NCT05402410|DIAGNOSTIC_TEST|Hepatic venous pressure gradient|All patients underwent measurement of HVPG under local anesthesia.
223686392|NCT05025228|DRUG|Paracetamol|Paracetamol given orally or intravenously
223686393|NCT03757013|DRUG|Apremilast|Apremilast
223686394|NCT06684873|DRUG|AK112 Injection|AK112 injection plus chemotherapy was administered to all eligible patients
223686395|NCT03670836|DEVICE|Dilapan|Dilapan-S® is a mechanical method for cervical ripening using rods made of a patented hydrogel Aquacryl, it is marketed in form of rods of 3 and 4 mm diameter. It is FDA approved for cervical ripening.
223686396|NCT03670836|DRUG|Misoprostol|"25mcg of Misoprostol will be administered orally every 2 hours (maximum of 6 doses)~Misoprostol is a prostaglandin E1 analog approved for treatment and prevention of gastric ulcers. The use of Misoprostol appears to be safe and effective for induction of labor when used in low dose."
223686397|NCT06730750|DRUG|BMS-986490|Specified dose on specified days.
223686398|NCT06730750|DRUG|Bevacizumab|Specified dose on specified days.
223686399|NCT01598363|DRUG|Digoxin|Oral, Day 1 and Day 10
223686400|NCT01598363|DRUG|Rosuvastatin|Oral, Day 1 and Day 10
223686401|NCT06871124|DEVICE|transcranial electrical stimulation|Anodal transcranial electrical stimulation (A-tES) is a widely used and well tolerated non-invasive electrical stimulation paradigm that promotes adaptive neuroplasticity and may prevent or reduce pathological sequela following brain injury. It has been used in a wide variety of neurologic and psychiatric disorders for cognitive and motor rehabilitation.
223686402|NCT06871124|DEVICE|Sham Comparator|Sham comparator consist of A-tES in the beginning and end of stimulation block but no stimulation during the actual stimulation period.
223686403|NCT05629637|BEHAVIORAL|Mindfulness-Based Resilience Training (MBRT)|MBRT is designed to enhance resilience in the presence of acute and chronic LEO stressors. MBRT will be delivered in a hybrid format. An intensive, 22-hour in-person training will be offered, followed by 4 weekly 90-minute zoom classes. The in-person portion of the training will span 3 days: 4 hours day 1, 6 hours day 2, and 6 hours day 3. MBRT contains experiential and didactic exercises including body scan, sitting and walking meditation, mindful movement and discussions. MBRT is designed to address stressors inherent to police work, including critical incidents, job dissatisfaction, public scrutiny, and interpersonal, affective and behavioral challenges.
223686404|NCT06938945|BEHAVIORAL|Digitized patient-reported outcomes|Patients fill out the PRO scale regularly online through a specific cell phone program or website, which intelligently analyzes the patient's physical condition, gives symptom management recommendations (which are based on clinical guidelines and expert consensus, and are updated monthly by oncology clinical experts during the study period), and sends alerts to clinical caregivers when the scale scores are abnormal.
223686405|NCT06158113|DRUG|Baricitinib 4 milligram Oral Tablet|4 milligrams once daily
223686406|NCT01683019|DEVICE|NeoSync EEG Synchronization Therapy|Generate low-energy sinusoidal magnetic field above the scalp with frequency equal to the subject's intrinsic alpha frequency (IAF). Treatment is 30 minutes, administered 5 days per week for 4 weeks.
223686407|NCT01683019|DEVICE|Sham NeoSync EEG Synchronization Therapy|A device that looks and sounds similar to the active treatment, but no magnetic field is generated.
223686408|NCT01343927|BEHAVIORAL|Weekly yoga classes|Manualized 12-week Hatha yoga intervention developed specifically for chronic low back pain in adult populations; classes meet once each week at community-based locations.
223775689|NCT02411721|BEHAVIORAL|Animal Assisted Intervention|"1. Initial conversation between dog handler and child. The purpose hereof is to let the child express any fear he experiences towards the examination. The presence of the dog allows the child to project his emotions on the dog and to speak more freely about his anxiety.~2. The dog handler informs the child on the various stages of the procedure. For this a booklet has been prepared in which a dog is the patient undergoing an MRI-scan. The child can identify with the dog in the story, and at the same time feel comforted by the dog present.~3. Procession of emotions. The child will play freely with the dog. The purpose hereof is to create a soothing atmosphere. In stroking the soft, friendly animal the child may feel more relaxed and therefore less anxious towards the examination."
223686409|NCT01343927|BEHAVIORAL|Individual physical therapy treatment|12 weeks of fifteen individual physical therapy sessions divided as follows: Week 1 intake appointment; weeks 2-4 two appointments per week; weeks 5-12 one appointment per week.
223686410|NCT01343927|BEHAVIORAL|Education|"Participants given The Back Pain Helpbook and periodic newsletters addressing back pain and self care."
223686411|NCT04604158|BEHAVIORAL|Elly Mobile Phone Application|The Elly mobile phone application delivers daily audio recording aimed at reducing anxiety, stress, loneliness, and social isolation.
223686412|NCT06275607|BEHAVIORAL|Cognitive Behavioral Affective Therapy|Active training in regulating anger.
223686413|NCT06275607|BEHAVIORAL|Emotional Discussion|General discussion of emotions; no therapy or training is offered.
223686414|NCT01570920|BEHAVIORAL|physical training|walking many times a week
223686415|NCT05732220|BEHAVIORAL|EMA assessment|Subjects will be asked to complete 3 waves of ecological momentary assessment (EMA) about smoking cues and smoking consumption via mobile phone at the first, second and third month after baseline (total 6 weeks)
223686416|NCT05732220|BEHAVIORAL|EMA-based cessation counselling|Subjects will receive tailored peer counselling based on the participants' EMA responses at 1-month and 3-month telephone follow-ups.
223686417|NCT05732220|BEHAVIORAL|Usual peer counselling|Subjects will receive peer counselling through telephone during follow-ups (usual care), in which the counsellor will apply the 5As model and motivational interviewing techniques.
223686418|NCT01645904|BEHAVIORAL|Audiotaped Focus Group|Participation in a focus group regarding web-based program designed to improve communication of health and health history information among family members affected by Lynch syndrome.
223686419|NCT01645904|BEHAVIORAL|Demographic Questionnaire|Complete questions about demographics (age, race, marital status) and medical history. This visit should take about 1 hour to complete.
223686420|NCT01645904|BEHAVIORAL|Audiotaped Interview|"Group 2: Patients provide feedback regarding initial version of My Family Garden website.~Group 3: Patients provide feedback regarding final version of My Family Garden website."
223686421|NCT01645904|BEHAVIORAL|WAMMI Inventory|Patients complete Website Analysis and MeasureMent Inventory. This visit should take about 90 minutes to complete.
223686422|NCT01015053|PROCEDURE|bilateral ultrasound-guided rectus sheath block|Ultrasound is used to guide the deposition of Ropivacaine 0.2% 1cc/kg in the posterior sheath of the rectus muscle containing the peripheral nerves that innervate the abdomen.
223686423|NCT01015053|PROCEDURE|Wound infiltration|Ropivacaine 0.2% 1cc/kg is injected subcutaneously at the site of incision by the surgeon.
223686424|NCT01964131|DRUG|D961H sachet 20 mg|"Each subject will be randomised evenly to one of Treatment: A--\>B (Sequence 1) or Treatment: B--\>A (Sequence 2).~Treatment A: D961H sachet 20 mg Treatment B: D961H HPMC capsule 20 mg"
223686425|NCT01964131|DRUG|D961H HPMC capsule 20 mg|"Each subject will be randomised evenly to one of Treatment: A--\>B (Sequence 1) or Treatment: B--\>A (Sequence 2). Treatment A: D961H sachet 20 mg Treatment B: D961H HPMC capsule 20 mg"
223686426|NCT02373878|BEHAVIORAL|Telecoaching plus Plate|A wellness coach proactively contacted the participants every two weeks during treatment, using motivational interviewing. In addition, she provided a portion control plate.
223686427|NCT02373878|BEHAVIORAL|Usual Care|Subjects were provided with institutional pamphlets on healthy eating and exercise habits
223686428|NCT05640804|DRUG|CTTQ Dasatinib tablet|Dasatinib tablet is an oral tyrosinekinase inhibitor produced by Chia Tai Tianqing Pharmaceutical Group.
223686429|NCT05640804|DRUG|Sprycel Dasatinib tablet|Sprycel Dasatinib tablet is an oral tyrosinekinase inhibitor produced by Bristol Myers Squibb.
223686430|NCT03166878|BIOLOGICAL|UCART019|Day 0: 10% of total dose Day 1: 30% of total dose if patient is stable (no significant toxicity) from prior dose. D2: 60% of total dose if patient is stable (no significant toxicity) from prior dose
223686431|NCT03070444|DEVICE|CTC retainer|The CTC retainer consists of 0.8 hard Remanium® wire (Dentaurum, Germany) and is bonded with Tetric Flow (Ivoclar Vivadent, Liechtenstein) to the lower canines directly after debonding.
223686432|NCT03070444|DEVICE|Essix retainer maxilla|The Essix retainer is made of 1 mm Essix C+® Plastic (Dentsply, USA) and is handed out to the patient the same day after removal of fixed appliances.
223686433|NCT03070444|DEVICE|Essix retainer mandible|The Essix retainer is made of 1 mm Essix C+® Plastic (Dentsply, USA) and is handed out to the patient the same day after removal of fixed appliances.
223686434|NCT03070444|PROCEDURE|Alginate impression|Alginate impressions are taken to made the cuspid-to-cuspid and Essix retainers, respectively. Dental casts are obtained at the debond appointment and at the follow-up visits after 6, 18 and 60 months.
223686435|NCT03070444|OTHER|Questionnaire|A questionnaire is completed at the follow-up visits.
223686436|NCT03457688|DIETARY_SUPPLEMENT|prebiotic inulin-type fructans|
223686437|NCT03457688|DIETARY_SUPPLEMENT|placebo maltodextrin|
223686438|NCT05533723|PROCEDURE|Endoscopic epidural neuroplasty|"EEN catheter, iDolphine S2 (Meta Biomed Co., Ltd, Osong, Korea) was placed in the epidural space through sacral hiatus. EEN was done on the target segments.~During EEN, normal saline was infused into epidural space under epiduroscopic vision. Dexamethasone (5 mg), 0.3% mepivacaine 10 mL, and hyaluronidase (3000 IU) were injected through catheter at the target segments. Holmium-Yag laser was used to cut epidural fibrous bands and for coagulation of epidural bleeding."
223686439|NCT05533723|PROCEDURE|Percutaneous epidural neuroplasty (PEN)|PEN catheter, EDEN-CC (JMT, Yangju, Korea) was placed in the epidural space and neural foramen . PEN was done on the target segments. Dexamethasone (5 mg), 0.3% mepivacaine 10 ml, and hyaluronidase (3000 IU) were injected through the PEN catheter.
223686440|NCT00950287|DEVICE|No intervention|The recordings will be performed in neonatal units with the preterm infant remaining in usual condition with limitations of external stimulation during the study period. The usual monitor will remain in function. The intervention of the nurses in case of apnea will not be modified during the study period. The recording will be obtained from derivation of the signal usually recorded by the monitor in use completed in one centre by a polysomnographic recording (Medtronics France SA), in order to test a possible influence of the sleep status on the detection.
223686441|NCT05012761|DRUG|SR419 capsules|Ascending single and multiple doses of SR419 orally
223686442|NCT05012761|DRUG|Placebo|Ascending single and multiple doses of placebo orally
223686443|NCT04629885|DRUG|Oxytocin 400 IU vaginal gel|
223775690|NCT00786916|DRUG|normal saline|A blood pressure cuff is placed with its distal-most margin 10 cm proximal to the intravenous catheter insertion site and is inflated to 40 mmHg of pressure greater than the patient's pre-procedure systolic blood pressure. Subjects will receive saline placebo IV (Group A) prior to initiating propofol infusion. Five minutes after administration of the study agent, tourniquet pressure is released and propofol infusion will be immediately initiated.
223775691|NCT00786916|DRUG|lidocaine|A blood pressure cuff is placed with its distal-most margin 10 cm proximal to the intravenous catheter insertion site and is inflated to 40 mmHg of pressure greater than the patient's pre-procedure systolic blood pressure. Subjects will receive lidocaine 0.25 mg/kg IV (Group B) prior to initiating propofol infusion. Five minutes after administration of the study agent, tourniquet pressure is released and propofol infusion will be immediately initiated.
223686444|NCT04629885|DRUG|Placebo|Matching placebo gel with identical appearance to the test product, used as reference treatment.
223686445|NCT06557525|BEHAVIORAL|Neurofeedback|Subjects will receive neurofeedback training by visual stimulation using a software program on a PC or tablet (monitor) with reference to EEG data acquired with a portable electroencephalograph (EEG) to provide feedback on the state of the DLPFC in the brain. The DLPFC status of the subject's brain is then fed back to the subject to continue stimulating the subject's reward system. Before and after these neurofeedback training sessions, fMRI imaging will be performed to confirm changes in brain activity.
223686446|NCT05415683|DIAGNOSTIC_TEST|DV-SSP Imaging|DeepView utilizes imaging data from DFUs to aid in health care providers' assessment of wound healing potential. It is intended to be used as an aid to health care providers in the management of DFU wounds and not as a standalone prediction device.
223686447|NCT00032097|DRUG|motexafin gadolinium|
223686448|NCT00032097|RADIATION|radiation therapy|
223686449|NCT02112006|PROCEDURE|0.5% bupivacaine injected in the forearm|Median, Ulnar, and Radial nerve blocks performed in the forearm
223686450|NCT02112006|PROCEDURE|20-30ml of 0.5% bupivacaine.|supraclavicular, infraclavicular, or axillary nerve block using 20-30ml of 0.5% bupivacaine.
223686451|NCT04444349|DRUG|Coenzyme Q10|Coenzyme Q10 is a cardiovascular health supplement. It is a component of the electron transport chain and participates in aerobic cellular respiration, which generates energy in the form of ATP. The ingredients in Coenzyme Q10 help regulate the body's production of free radicals, strengthen the arteries and heart, and reverse oxidation.
223686452|NCT04444349|DIETARY_SUPPLEMENT|Standard Medical Therapy|Patients only received standard medical therapy without CoQ10.
223686453|NCT05647096|DEVICE|NucleoCapture device|100ml NucleoCapture selective DNA adsorber
223686454|NCT06433570|GENETIC|multiplex PCR|Detection of Krupple Like Factor -1(KLF1/ EKLF) DNA Mutations in Beta Thalassemia Patients using multiplex PCR
223686455|NCT04088656|OTHER|Systems Analysis and Improvement Approach for Hypertension Screening and Treatment Optimization|The Systems Analysis and Improvement Approach to Optimize the Hypertension Care Cascade for People Living with HIV (SAIA-HTN) is a five-step systems analysis and iterative improvement cycle intervention which will be implemented by study nurses and district managers in intervention facilities. Components of the intervention include joint care cascade analysis, patient flow mapping and continuous quality improvement, aimed to incrementally improve hypertension screening, diagnosis, treatment and care in the HIV+ population at intervention health facilities.
223686456|NCT05191979|OTHER|Exercise regiment (aerobic exercise on bike)|Subjects participating in the current study will be trained progressively and intensively for 12 months primarily on bike indoors and outdoors
223686457|NCT05023798|DEVICE|ATD (device test)|Medical device test (no intervention)
223686458|NCT04832087|DRUG|Teduglutide|Standard of care Teduglutide dosing
223686459|NCT00543855|DRUG|3 mg Donepezil hydrochloride|"Observation Period: Two Donepezil hydrochloride placebo tablets once daily by mouth after breakfast for 2 weeks.~Treatment Period: One 3 mg Donepezil hydrochloride tablet by mouth plus one Donepezil hydrochloride placebo tablet by mouth, once daily for 12 weeks (Day 1- Day 84) after breakfast."
223686460|NCT00543855|DRUG|5 mg Donepezil hydrochloride|"Observation Period: Two Donepezil hydrochloride placebo tablets once daily by mouth after breakfast for 2 weeks.~Treatment Period: One 3 mg Donepezil hydrochloride tablet by mouth plus one Donepezil hydrochloride placebo tablet by mouth, once daily after breakfast for Day 1- Day 14 (2 weeks).~Followed by one 5 mg Donepezil hydrochloride tablet by mouth plus one Donepezil hydrochloride placebo tablet by mouth, once daily after breakfast for Day 15- Day 84 (10 weeks)."
223686461|NCT00543855|DRUG|10 mg Donepezil hydrochloride|"Observation Period: Two Donepezil hydrochloride placebo tablets once daily by mouth after breakfast for 2 weeks.~Treatment Period: One 3 mg Donepezil hydrochloride tablet by mouth plus one Donepezil hydrochloride placebo tablet by mouth, once daily after breakfast for Day 1- Day 14 (2 weeks).~Followed by one 5 mg Donepezil hydrochloride tablet by mouth plus one Donepezil hydrochloride placebo tablet by mouth, once daily after breakfast for Day 15- Day 42 (4 weeks).~Followed by two 5 mg Donepezil hydrochloride tablets (10 mg) by mouth, once daily after breakfast for Day 43 - Day 84 (6 weeks)."
223686462|NCT00543855|DRUG|Placebo|"Observation Period: Two Donepezil hydrochloride placebo tablets once daily by mouth after breakfast for 2 weeks.~Treatment Period: Two Donepezil hydrochloride Placebo tablets by mouth, once daily for 12 weeks (Day 1- Day 84) after breakfast."
223686463|NCT05780606|OTHER|Exposed to UV|Two healthy volunteers will be exposed to UV or visible light in the forearm region. Suction bubbles, and skin biopsies will be performed in test areas, suction bubbles for transcriptome, biopsies for immunohistochemistry
223686464|NCT06004908|DEVICE|MRI|a type of scan that uses strong magnetic field sand radio waves to produce detailed images of the inside of the body
223686465|NCT01425775|DRUG|vitamin D 25(OH)D|2000IU/day for 12 months
223686466|NCT01425775|OTHER|Placebo|2000IU/day of vitamin D will be compared to similar looking tablets of placebo for 12 months
223686467|NCT05272085|PROCEDURE|Ultrasound Guided Lavage|After local anesthesia of subcutaneous tissue, lavage will be performed under the guidance of ultrasound using an 18-gauge needle with injectors filled with 4 ml of saline. The needle will be advanced to the center of the calcific deposit. The injector will be kept as parallel to the ground as possible. The plunger of the injector will be pushed with a gently pressure and then released. Calcific deposits are expected to be filled into the syringe along with saline. It is predicted that the clear saline will gradually turn white and become cloudy due to the incoming calcific deposits. When the color of the liquid becomes cloudy, the syringe will be removed without moving the needle, and a new syringe containing 4 ml saline will be placed in its place. Thus, the aspirated calcific deposits will not be reinjected. The same process will be repeated with a new saline filled syringe. After the procedure, 2 ml dexamethasone and 3 ml lidocaine will be injected in subacromial bursa.
223686468|NCT05272085|PROCEDURE|Ultrasound Guided Subacromial Bursa Injection|2 ml dexamethasone and 3 ml %2 lidocaine will be injected in the subacromial bursa using a 21-gauge needle under ultrasound guidance.
223686469|NCT00188331|BEHAVIORAL|Neuropsychological Testing|neuropsychological testing with traditional tests, CANTAB and six elements test as well as questionnaires
223686470|NCT01850433|BEHAVIORAL|Internet based CBT for body dysmorphic disorder|
223686471|NCT06233760|OTHER|Rheumatic diseases Mistreatment Scale (RDMS)|In 2012 Giraldo-Rodríguez developed and validated the Geriatric Mistreatment Scale (GAS), prior to its application, translation, cultural adaptation, and validation were performed.
223686472|NCT06233760|OTHER|Health Assessment Questionnaire (HAQ)|The HAQ is based on five patient-centered dimensions: disability, pain, medication effects, costs of care, and mortality
223686473|NCT06233760|OTHER|Depression, Anxiety and Stress Scale (DASS-21)|DASS-21 is a set of three self-report scales designed to measure the emotional states of depression, anxiety, and stress. Each of the three DASS-21 scales contains 7 items, divided into subscales with similar content
223775692|NCT00786916|DRUG|lidocaine|A blood pressure cuff is placed with its distal-most margin 10 cm proximal to the intravenous catheter insertion site and is inflated to 40 mmHg of pressure greater than the patient's pre-procedure systolic blood pressure. Subjects will receive lidocaine 0.5 mg/kg IV (Group C) prior to initiating propofol infusion. Five minutes after administration of the study agent, tourniquet pressure is released and propofol infusion will be immediately initiated.
223775693|NCT03243331|DRUG|Gedatolisib|Gedatolisb will be intravenously administered on Day 1, Day 8 and Day 15 of every 21 day cycle at a dose of 110 mg or 180mg depending on cohort assignment.
223775694|NCT03243331|DRUG|PTK7-ADC|PTK7-ADC will be administered on Day 1 of every 21 day cycle at a dose of 1.4mg/kg or 2.8 mg/kg depending on cohort assignment.
223775695|NCT01734746|PROCEDURE|Tracerinjection|The intervention concerns the tracerinjection for detection of the sentinel node.
223775696|NCT04279925|DEVICE|ORIF (Open reduction internal fixation): locally-made miniplate and screw|Fracture lines in this group underwent open reduction internal fixation (ORIF) procedure which consists of realignment of the bone achieved from surgical mean and stabilization of the bone fragments by using locally-made miniplate and screw produced by the Faculty of Engineering Universitas Indonesia. The plate used in the study is a straight plate with 4 and 5 holes with the dimension of 17mm long, 4 mm wide and 0.56 mm thick.
223775697|NCT04279925|DEVICE|ORIF: Imported miniplate and screw|Fracture lines in this group underwent open reduction internal fixation (ORIF) procedure which consists of realignment of the bone achieved from surgical mean and stabilization of the bone fragments by using Biomet® miniplate 1.5 produced by Biomet, included in the Lorenz® Plating System Midface. The particular plate used in the study is a straight plate with 4 holes, 17mm length and 0.6mm thick, coded 01-7047 in the catalog. Biomet® screw 1.5 utilized in this study is also produced by Biomet, included in the Lorenz® Plating System Midface. The dimension of the screw is 4mm length, 1.5 mm diameter, and coded 91-6104 1.5 mm X-Drive Self drilling screws.
223775698|NCT00338351|BIOLOGICAL|Pneumococcal (vaccine)|
223775699|NCT03462667|BEHAVIORAL|Stoma Boot Camp|Educational session designed to prepare people for living life with a stoma.
223686474|NCT06233760|OTHER|Brief Resilient Coping Scale|Brief Resilient Coping Scale is a 4-item measure designed to capture tendencies to cope with stress in a highly adaptive manner
223775700|NCT03462667|OTHER|Standard of Care|Patients receive normal pre-surgery standard of care.
223775701|NCT00530023|DEVICE|MiniMed Paradigm REAL-Time System|MiniMed Paradigm 722 insulin pump The transmitter The sensor Paradigm Link Glucose Meter The ComLink
223686475|NCT06233760|OTHER|WHOQOL-BREF|WHOQOL-BREF is a 26-item instrument consisting of four domains: physical health, psychological health, social relationships, and environmental health; it also contains QOL and general health items
223686476|NCT06233760|OTHER|Routine assessment of patient index data 3 (RAPID-3)|RAPID- 3 measures: function, pain, and patient global estimate of status. Each of the 3 individual measures is scored 0 to 10, for a total of 30
223686477|NCT06233760|OTHER|Big Five Inventory|The BFI-10 is a 10-item scale measuring the Big Five personality traits Extraversion, Agreeableness, Conscientiousness, Emotional Stability, and Openness.
223686478|NCT06233760|OTHER|Family APGAR Questionnaire|Family APGAR questionnaire is used to evaluate family function, in the context of family medical care
223686479|NCT02306733|DRUG|Ergometrine|100 women with atonic PPH will receive Ergometrine 400µgm (Methergin® Novartis, Switzerland) slowly intravenous (iv).
223686480|NCT02306733|DRUG|Oxytocin|100 women with atonic PPH will receive Oxytocin 10 IU(Syntocinon® Novartis, Switzerland) slowly intravenous. iv and group 2 will receive oxytocin
223686481|NCT05125887|OTHER|Questionnaire|Patients diagnosed positive for COVID on an outpatient basis will respond to a questionnaire by mail, at 24 month of diagnosis. This questionnaire will make it possible in particular to collect intercurrent events (hospitalization, emergencies, etc.).
223686482|NCT01383668|DRUG|sirolimus|Given PO
223686483|NCT01383668|DRUG|gold sodium thiomalate|Given IM
223686484|NCT01383668|OTHER|pharmacological study|Correlative studies
223686485|NCT01383668|GENETIC|RNA analysis|Correlative studies
223686486|NCT01383668|GENETIC|polymerase chain reaction|Correlative studies
223686487|NCT02582255|BIOLOGICAL|Sabin mOPV2|"Polio Sabin™ Mono Two (oral) is a licensed, monovalent, live attenuated poliomyelitis virus vaccine of the Sabin strain Type 2 (P 712, Ch, 2ab), propagated in MRC5 human diploid cells. Each two-drop dose (0.1 mL) contains not less than 105.0 CCID50 of Type 2. Magnesium chloride is used as a stabilizer. Polio Sabin™ Mono Two (Oral) contains trace amounts of neomycin sulphate and polymyxin B sulphate.~One dose of vaccine (0.1 mL) is contained in two drops which are delivered from the polyethylene dropper supplied with vaccine."
223686488|NCT01744912|DRUG|Ublituximab|Ublituximab is a novel monoclonal antibody targeting CD20
223686489|NCT01744912|DRUG|Lenalidomide|Lenalidomide has both immunomodulatory and anti-angiogenic properties which could confer antitumor and antimetastatic effects
223686490|NCT06523192|OTHER|Questionnaires|No intervention
223686491|NCT03268148|DEVICE|LaserPen|low level laser is used before heel-lancing for newborn screening
223686492|NCT00375375|DRUG|Lactulose|
223686493|NCT00847171|BIOLOGICAL|allogeneic GM-CSF-secreting breast cancer vaccine|"Day 0 : Allogeneic GM-CSF-secreting Breast Cancer Vaccine administered as:~12 intradermal injections of a divided total dose of 5 x108 cells."
223686494|NCT00847171|BIOLOGICAL|trastuzumab|"Patient HAS received prior Trastuzumab within the last two weeks, give Trastuzumab 2 mg/kg weekly on Day -1 for 5 weeks.~Patient has NOT received Trastuzumab within the last two weeks, give On Cycle 1, Day -1 ONLY, Loading dose 4 mg/kg"
223775702|NCT00621439|DRUG|Pegylated Interfon Alpha 2B|Patients will receive PEG-IFN 6 mcg/kg subcutaneously 4 days prior to surgery. Patients will be premedicated with acetaminophen 700 mb orally prior to the injection. Only one dose of drug will be given. Enucleation will follow in 4 days.
223775703|NCT00621439|DRUG|Placebo|Patients will receive placebo.
223775704|NCT02760186|PROCEDURE|Altitude Exposure|Altitude Exposure
223775705|NCT05546606|DEVICE|ECCO2R|ECCO2R therapy using the Xenios platform, CE-marked medical device of the firm Xenios AG (Heilbronn, Germany), including the following components: Xenios console, iLA active iLA Kit IPS and Novaport Twin (18Fr, 22Fr or 24 Fr) cannulas The maximal duration of ECCO2R therapy with one circuit will be of 29 days in agreement with the regulatory approval of the patient kit.
223686495|NCT00847171|DRUG|cyclophosphamide|Cyclophosphamide 200mg/m2 IV in NS 100ml over 30 minutes on Day -1 ONLY. Note: there are no dose modifications for Cyclophosphamide.
223775706|NCT00497120|DRUG|acetazolamide|
223686496|NCT00847171|OTHER|flow cytometry|Samples will be analyzed by flow cytometry using Cell Quest software
223686497|NCT00847171|OTHER|immunoenzyme technique|
223686498|NCT00847171|OTHER|immunohistochemistry staining method|Measuring Immune Priming In Vivo By Vaccine Site Biopsies
223686499|NCT00847171|OTHER|laboratory biomarker analysis|
223686500|NCT00847171|OTHER|pharmacological study|
223686501|NCT00847171|PROCEDURE|biopsy|skin biopsy to be performed on day 3 and day 7 for cycle 1 and 3 only
223686502|NCT05578157|DIAGNOSTIC_TEST|Feeling Hot sensor|The Feeling Hot sensor is a proof-of-concept system, which can measure overnight penile, thigh and air temperature.
223686503|NCT02895633|OTHER|Ecography|Standard Doppler ultrasound and perfusion imaging after injection of Sonovue
223686504|NCT02895633|OTHER|CT scan|With injection of Iomeron 400
223686505|NCT02895633|OTHER|MRI|With injection of gadolinium (Multihance)
223686506|NCT04369170|DEVICE|prosthesis connected directly to the implants|dental prostheses connected directly to the dental implants
223686507|NCT04369170|DEVICE|Intermediate abutment|dental prostheses connected with an intermediate abutment to the implant
223686508|NCT00436930|BIOLOGICAL|autologous tumor cell vaccine|Given subcutaneously
223686509|NCT00436930|BIOLOGICAL|sargramostim|Given subcutaneously
223686510|NCT00436930|BIOLOGICAL|therapeutic autologous dendritic cells|Given subcutaneously
223775707|NCT00497120|DRUG|placebo|
223775708|NCT00497120|PROCEDURE|uvulopalatopharygoplasty|
223775709|NCT02541721|DEVICE|LabiaStick#01|"This medical device has emollient agents whose main function is to increase the skin hydration, provide physical protection and decrease the symptoms and possibility of recurrence of vulvar dermatoses.~The medical device should be applied once daily, in the evening, after a gentle washing (plain water with no cleansing products), on the affected non-hairy vulvar area."
223775710|NCT03395535|PROCEDURE|Primary Selective Laser Trabeculoplasty Treatment Pathway|"Primary Selective Laser Trabeculoplasty Treatment (followed by medications as required) Pathway.~First treatment is SLT, 100 shots of laser over 360 degrees. If this does not reach the target IOP then repeat laser (once only) is given. If IOP not at target additional treatment with all standard medications may be used and ultimately surgery (trabeculectomy ).~All available medical treatments (eye-drops) are permitted according to a pre-specified intervention protocol described in detail in the publicly available trial protocol. This begins with prostaglandin analogues, then beta-blockers followed by alpha agonists or carbonic anhydrase inhibitors. The full range of available doses, treatments and drugs is beyond this short summary."
223686511|NCT06040879|PROCEDURE|PERICAPSULAR NERVE GROUP BLOCK COMBINED WITH LATERAL FEMORAL CUTANEOUS NERVE BLOCK|During and after the surgery, a group of patients received intravenous morphine analgesia via PCA (concentration 1mg/ml, bolus dose of 1mg, lock time 10 minutes, maximum dose 10mg/4 hours). The remaining group of patients receive pain relief by PENG block and LFCN block. In this group, the ultrasound probe was placed horizontally from the anterior superior iliac spine, and was moved along the femoral arc defining the pubic spine. Then, the transducer was rotated 45 degrees, moved parallel to the femoral arch identifying the anterior inferior iliac spine (AIIS), iliopubic eminence (IPE) and inferior lumbosacral head. The ultrasound probe was moved lightly until the upper end of the femoral head was identified. Next, a 120 mm Tuohy 18G anesthetic needle was used under ultrasound guidance, which was moved lateral to medial in the plane between the ultrasound transducer and the superior tip of the femoral head. Then, 10 mL of ropivacaine 0.25% was injected through the anesthetic needle tip
223686512|NCT02417844|DRUG|tamsulosin (Astellas)|
223686513|NCT02417844|DRUG|Tamsulosin HCL|
223686514|NCT00728078|DRUG|thalidomide|thalidomide 50mg tid for 6 months
223686515|NCT01785095|DRUG|FSH (Follicle Stimulating Hormone)|
223686516|NCT05838235|OTHER|Adapted Physical Activity program|The Adaptated Physical Activity program will consist of a Personalized Training Program
223686517|NCT02922595|DEVICE|Intubation through ILMA®|"It will be placed into patient's larynx through the mouth in accordance with manufacturer's recommendations by experienced airway providers.~Intubation will then be peformed"
223686518|NCT02922595|DEVICE|Intubation through ILTS®|"It will be placed into patient's larynx through the mouth in accordance with manufacturer's recommendations by experienced airway providers.~Intubation will then be peformed"
223686519|NCT00048451|DRUG|paricalcitol|
223686520|NCT05921318|COMBINATION_PRODUCT|Beijing protocol|"For patients \<55 years and HCT-CI≤ 3：Ara-C(4g/m2/day,-9 days),Bu(9.6mg/kg,-8 days to -6 days),Cy(1,800mg/m2/day,-5 days to -4 days),semustine(250mg/m2,-3 days),ATG(7.5-10 mg/kg,-5 to -2 days)~For patients ≥ 55 years or HCI-CI\>3：Ara-C(2g/m2/day,-10 days to -9 days),Bu(9.6mg/kg,-8 days to -6 days),Flu(30mg/m2/day,-6 days to -2 days),Cy(1,000mg/m2/day,-5 days to -4 days),semustine(250mg/m2,-3 days),ATG(7.5-10 mg/kg,-5 to -2 days)."
223686521|NCT05748080|OTHER|Eating apples|the eating of 2 apples a day for a period of 6 weeks
223686522|NCT05753033|DRUG|SR750 tablet|Ascending single and multiple doses of SR750 orally
223686523|NCT05753033|DRUG|Placebo|Ascending single and multiple doses of placebo orally
223686524|NCT00730444|DRUG|Iobenguane I 123 Injection|1-10 mCi administered intravenously
223686525|NCT03375229|OTHER|Dry Needling|"It will be used acupuncture needles, individually packaged and sterilized, with 0.25 mm of thickness and 0.40 mm of length. The therapist will perform the grip in upper trapezius on the site of one of the two previously marked locations, according to the subject group allocation, and will insert the needle in the skin with help of a guide tube and will deepen the needle approximately 10 to 15 mm inside the trigger point. The needle will be moved up and down as in the fast-in and fast-out technique described by Hong and the movement will be repeated during 30 seconds in a cadence of approximately 1 Hz. The protocol will be the same for the groups that will receive the application directly on the trigger point and for the group that will receive the application away from the trigger point"
223686526|NCT03375229|DEVICE|Low-Level Laser Therapy|The laser protocol used the PainAway Laser™ cluster equipment composed of one pulsed infrared laser of 905 nm, four red LEDs of 640 nm, and four infrared LEDs of 875 nm, with full device aperture of 4 cm2, total delivered energy of 39,8 J, a magnetic field of 35 Mt and treatment time of 300 seconds. The equipment was turned on only for the DNP group and it remained in slight contact with the skin during 300 s for all groups.
223686527|NCT03034200|DRUG|ONC201|625mg ONC201 will be given on two consecutive days each week
223686528|NCT06518694|DRUG|Βeta-Blockers discontinued (with tapering)|"The experimental group will undergo discontinuation of their beta-blockers treatment during the study period.~The tapering of beta-blocker will start on the day after randomisation and is based on a reduction by half-dose every 48 hours (1/2 maximally recommended dose for 48 hours, then ¼ maximally recommended dose for 48 hours) until reaching the minimal recommended dosage (1/8 maximally recommended dose) for 48 hours before complete interruption of treatment. Consequently, the tapering will not be needed in patients already receiving the minimal recommended dosage (i.e., 1/8 dose) at inclusion, and these patients will be instructed to stop taking beta-blockers the day after randomisation."
223686529|NCT01466179|BIOLOGICAL|Blinatumomab|Continuous intravenous infusion over four weeks per treatment cycle
223686530|NCT01456507|DRUG|ALO-02 (Oxycodone Naltrexone)|single dose of ALO-02 capsule under fasting condition
223686531|NCT01456507|DRUG|ALO-02 (Oxycodone Naltrexone)|single dose of ALO-02 capsule under fed condition
223686532|NCT01456507|DRUG|ALO-02 (Oxycodone Naltrexone)|ALO-02 with the ALO-02 pellets sprinkled on applesauce, and administered under fasting conditions.
223686533|NCT01640626|OTHER|Health Education package|Health Education package that covers key health messages about the proper personal hygiene practices will be given to school children in the intervention school. The package consisted of many items such as posters, comic book, song video, competitions, drawing activities, puppet show, etc.
223686534|NCT00749580|DRUG|Switch NRTIs as a Backbone to Raltegravir|This is a multicenter, pilot randomized, controlled study to evaluate the safety and efficacy of raltegravir in patients switched from a stable boosted PI-based regimen with a NRTI backbone to raltegravir instead of their current NRTIs. A stable boosted PI-based regimen is defined as having a documented HIV RNA \<75 copies/mL for ≥ 3 months prior to study entry, while receiving a boosted PI-based with NRTI backbone. Additionally, patients must not have had HIV RNA ≥ 75 copies/mL during the three months prior to study entry. Approximately 25 patients will be enrolled in the raltegravir treatment arm (Group 1) and approximately 25 patients in the continuation of the current NRTI backbone regimen treatment arm (Group 2). Patients will be randomly assigned 1:1 to a treatment group.
223686535|NCT05417243|OTHER|Trauma life support training|Clusters are randomised for their residents to be trained in one of two trauma life support training programs or to continue providing standard care.
223686536|NCT02725853|DEVICE|tDCS|Application of 1.5 mA tDCS for 30 minutes
223686537|NCT02725853|DEVICE|sham tDCS|Application of sham tDCS for 30 minutes
223686538|NCT02725853|BEHAVIORAL|personalized practice|arm exercise consisting of whole arm movement within a restricted elbow range of motion
223686539|NCT02725853|BEHAVIORAL|non-personalized practice|arm exercise consisting of unrestricted whole arm movement
223686540|NCT05830903|BEHAVIORAL|VR-assisted occupational training|VR-assisted occupational training
223686541|NCT02119169|DEVICE|Pigtail catheter|pigtail catheter for pleural drainage
223686542|NCT04152031|OTHER|Prompting|Participants receive medication reminders on a smartphone. The reminders are generated through machine learning algorithms that automate the process of medication prompting according to successful medication contexts that occurred in the past.
223686543|NCT05281952|PROCEDURE|endoscopic ligation|the surgical ligation of one or both sphenopalatine arteries by endoscopic way.
223686544|NCT05281952|PROCEDURE|Supra-selective embolization|occlusion of the terminal branches of the nasal external carotid artery.
223686545|NCT02587039|PROCEDURE|Remote ischemic pre-conditioning|Remote ischemic preconditioning is exposure to a brief period ischemia to an area or limb that is not involved in surgery. This intervention is believed to reduce the incidence of cerebral (brain) ischemia during cardiac surgery.
223686546|NCT02587039|BEHAVIORAL|Delirium Assessment|The Delirium assessment consist of a validated psychiatric screening tool called the Confusion Assessment Method. We will use this tool to determine if patients have any confusion after surgery.
223686547|NCT02588937|DRUG|EntecaBell ODT. 0.5mg|
223775711|NCT03395535|DRUG|Primary Medical Treatment Pathway|"Primary Medical Treatment Pathway (multiple medications, as required). If IOP not at target additional treatment with all standard medications may be used and ultimately surgery (trabeculectomy ).~All available medical treatments (eye-drops) are permitted according to a pre-specified intervention protocol described in detail in the publicly available trial protocol. This begins with prostaglandin analogues, then beta-blockers followed by alpha agonists or carbonic anhydrase inhibitors. The full range of available doses, treatments and drugs is beyond this short summary."
223775712|NCT00770016|DRUG|Levothyroxin|Dosage regulation will follow the local recommendations of treatment
223775713|NCT02710630|DRUG|Dabigatran etexilate tablet E1|
223775714|NCT02710630|DRUG|Dabigatran etexilate tablet D1|
223775715|NCT02710630|DRUG|Dabigatran etexilate tablet C1|
223775716|NCT02710630|DRUG|Dabigatran etexilate tablet B1|
223775717|NCT02710630|DRUG|Dabigatran etexilate tablet A1|
223775718|NCT02710630|DRUG|Dabigatran etexilate capsule|
223686548|NCT02588937|DRUG|Baraclude Tab. 0.5mg|
223686549|NCT02556827|OTHER|Obtaining a blood sample|Total oxidant capacity (TOC), total antioxidant capacity (TAC), oxidative stress index (OSI), paraoxonase-1 (PON-1), aryl esterase (ARES), myeloperoxidase (MPO), tumor necrosis factor-alpha (TNF-α), interleukin-1beta (IL-1β), matrix metalloproteinase-1 (MMP-1) and matrix metalloproteinase-9 (MMP-9) levels in venous blood were measured.
223686550|NCT02556827|DEVICE|Reflectance confocal microscopy|1mm2-sized 10 images were taken from right cheek and forehead; the number of demodex, follicle, the number of mite per follicle, the number of infested follicle and the number of mite per infested follicle were calculated with RCM. And photoaging severity were also assessed by using RCM.
223686551|NCT02556827|DEVICE|Sebumeter|Sebum rate at forehead and right cheek were evaluated with sebumeter
223775719|NCT00365859|DRUG|Aripiprazole|Tablets, Oral, 2, 5, 10, or 15 mg, once daily, 52 weeks
223775720|NCT03681301|OTHER|virtual reality simulator|Additional self-directed learning and practice using virtual reality simulator
223775721|NCT02232529|DRUG|MIN-101|
223775722|NCT02232529|DRUG|Placebo|
223686552|NCT02556827|DEVICE|Video dermoscopy|Dermoscopic photoaging scale were assessed by using video dermoscopy.
223686553|NCT04467931|DRUG|ACEI/ARB|Veterans will be categorized as exposed to ACEI/ARB if they have one or more pharmacy fills for an oral ACEI or an ARB in the 90 days (± 14 days) prior to each Veteran's index date. Sacubitril/valsartan (Brand name: Entresto®) will be excluded from ARB exposures.
223686554|NCT04467931|DRUG|Non-ACEI/ARB|Veterans will be categorized as exposed to a non-ACEI/ARB if they have one or more pharmacy fills for an oral non-ACEI or ARB medication in the 90 days (± 14 days) prior to each Veteran's index date and NO fills for an ACEI/ARB medication in the 90 days (± 14 days) prior to each Veteran's index date. Specific drug classes include: aldosterone receptor antagonist, beta-blocker, calcium channel blocker, centrally-acting drug, direct arterial vasodilator, direct renin inhibitor, thiazide diuretic, loop diuretic, and potassium sparing diuretic.
223686555|NCT04467931|DRUG|ACEI|Veterans will be categorized as exposed to an ACEI if they have one or more pharmacy fills for an oral ACEI in the 90 days (± 14 days) prior to each Veteran's index date and NO fills for an oral ARB in the 90 days (± 14 days) prior to each Veteran's index date.
223686556|NCT04467931|DRUG|ARB|Veterans will be categorized as exposed to an ARB if they have one or more pharmacy fills for an oral ACEI in the 90 days (± 14 days) prior to each Veteran's index date and NO fills for an oral ACEI in the 90 days (± 14 days) prior to each Veteran's index date. Sacubitril/valsartan (Brand name: Entresto®) will be excluded from ARB exposures.
223686557|NCT04119310|OTHER|Lumbar-thrust mobilization|The intervention group will receive passive spinal rotational grade V thrust-mobilization, based on Maitland's approach. The intervention will be performed with the subject in right sidelying and left sidelying. The operator's palpating hand is placed over the L2-3 intervertebral space, and the other hand bends both legs of the participant up to the range at which the L2-3 midposition is found. The participant is then asked to straighten the lower leg and hook the upper leg over it with the upper leg's knee positioned over the side of the plinth. While the lower component is kept still, the participant's trunk is rotated until the hip starts to lift off from the plinth. The bottom hand and uppermost hand rest under a pillow and the chest wall, respectively. With the starting position settled, the operator stands behind the participant, takes up the slack within the spine and then provides a grade V thrust- mobilization while stabilizing the uppermost shoulder.
223686558|NCT04119310|OTHER|Sham thrust-mobilization|Subjects are positioned in right sidelying. The experimenter holds both knees with one arm while placing their opposite hand on the participant's lumbar spine. The experimenter performs 1 min of ﬂexion and extension passive range of motion without reaching physiological end range in either direction of movement. This is repeated with the subject in left sidelying.
223686559|NCT02857179|PROCEDURE|bariatric surgery|gastric bypass Or gastric banding Or Biliopancreatic diversion with duodenal switch Or sleeve gastrectomy Or endoscopic procedure (Endobarrier,…)
223686560|NCT04038931|OTHER|Liver biopsy collection|Liver biopsy collection to Confirm suitability of T1DM, total or partial pancreatectomy patient's liver cells to be used as future personalized cell replacement therapy.
223686561|NCT05465746|DIAGNOSTIC_TEST|24-hour ambulatory blood pressure monitoring (ABPM)|Using a WatchBPO3 AFIB device (Microlife) placed around the left upper arm, BP measurements will be recorded every twenty minutes during the day and every thirty minutes at night, over a twenty-four-hour period. The device will automatically calculate the BP and the twenty-four-hour average BP, day, night, and cumulative BP load
223686562|NCT05465746|DIAGNOSTIC_TEST|Three-dimensional transthoracic echocardiography|Using an EPIQ CVx (Philips) echocardiograph with an ultrasound sector transducer, 3D-TTE will be performed to assess the LVM index.
223686563|NCT03004222|DRUG|Bupivacaine|20 ml of 0.5% Bupivacaine
223686564|NCT03004222|DRUG|Placebos|
223686565|NCT03670927|OTHER|Environmental, occupational and lifestyle-related exposures|A standardized questionnaire will be administered by a trained interviewer in order to gather information about occupational and residential history, demographic and socioeconomic characteristics and lifestyle factors. At the end of the interview, a saliva sample will be systematically proposed
223686566|NCT02266914|DEVICE|Magnetic Resonance Elastography driver|A driver is required for MRE. The driver utilizes sound waves to produce vibrations. Images of these vibrations are captured with Magnetic Resonance scanner to produce images that indicate stiffness in an organ.
223686567|NCT00428662|DEVICE|drug eluting nonpolymeric nanoporous stent|
223686568|NCT05241483|DIAGNOSTIC_TEST|mesure valition|Possible diseases that may occur as a result of the patient's vital values with artificial intelligence systems
223686569|NCT04342273|DRUG|KW-6356|KW-6356 will be administered once daily as therapeutic at Day 1 through Day 7
223686570|NCT04342273|DRUG|KW-6356|KW-6356 will be administered once daily as supratherapeutic dose at Day 1 through Day 7
223686571|NCT04342273|DRUG|Placebo|Placebo will be administered once daily at Day 1 through Day 7
223686572|NCT04342273|DRUG|Moxifloxacin|Placebo will be administered once daily at Day 1 through Day 6, followed by Moxifloxacin once daily at Day 7.
223686573|NCT02906904|OTHER|Case Intervention|24-hour sleep deprivation protocol, polysomnographic monitoring of the recovery sleep, triggering of parasomniac episodes by auditory stimulations, thermoalgic stimulation (Modulator Sensory Analyzer Thermal Stimulator®) during wakefulness, parasomniac episodes, NREM stage 2 ans SWS
223686574|NCT02906904|OTHER|Control Intervention|24-hour sleep deprivation protocol, polysomnographic monitoring of the recovery sleep, thermoalgic stimulation (Modulator Sensory Analyzer Thermal Stimulator®) during wakefulness, NREM stage 2 ans SWS
223686575|NCT04210778|BEHAVIORAL|Cognitive orientation to daily occupational performance (CO-OP)|The CO-OP is a client-centered, goal directed approach aimed at enabling individuals to identify strategies that will improve daily function. A Weekly (1hr) session is delivered remotely via video conferencing.
223775723|NCT03224468|DRUG|Medical Marijuana|Patients in this group can choose when, where, and how much medical marijuana to use.
223775724|NCT03934229|DIETARY_SUPPLEMENT|Daily intake of study product|Daily intake of Bifidobacterium animalis ssp. lactis 420 or placebo for a 6-month period
223775725|NCT02461589|DRUG|semaglutide|Administered subcutaneously ( s.c., under the skin) once daily. All subjects will follow a 4-week dose-escalation regimen except subjects who received semaglutide flexible dosing.
223686576|NCT04210778|BEHAVIORAL|Computerized Cognitive Training (BrainHQ, posit science)|The BrainHQ training targets multiple cognitive domains. The training will be delivered remotely, using a web-based program. Training progresses in an adaptive, individualized manner, based on individual progression of each participant . Participants are required to practice a minimum of half hour, three times a week (total of 1.5hr)
223686577|NCT05446636|DEVICE|Huawei bracelet|Huawei bracelet was used to continuously record maternal respiration, heart rate, temperature and sleep data, and then calculate maternal circadian rhythm state
223686578|NCT04204122|DRUG|Vigamox|-FDA approved medication
223686579|NCT04204122|DRUG|Placebo|-The placebo is artificial tear drops
223775726|NCT02461589|DRUG|liraglutide|Administered subcutaneously ( s.c., under the skin) once daily. All subjects will follow a 4-week dose-escalation regimen.
223775727|NCT02461589|DRUG|placebo|Administered subcutaneously ( s.c., under the skin) once daily.
223775728|NCT06173817|DEVICE|isocapnic hyperventilation|isocapnic hyperventilation (iHV) increases the elimination of methanol to the extent that it could replace haemodialysis for elimination purposes when haemodialysis is not required for the correction of acidosis, and alcohol dehydrogenase (ADH) is completely blocked by an antidote.
223775729|NCT00036166|DRUG|FK463|
223775730|NCT04790045|DRUG|Venetoclax|Core-needle biopsy to be performed before starting treatment in patients candidates to venetoclax-based regimens
223775731|NCT04284423|DIAGNOSTIC_TEST|joint fluid lactate|Analysis of lactate level in joint fluid to determine presence of septic joint
223775732|NCT03200392|DEVICE|laser root surface conditioning & laser DGG harvesting|laser root surface bio-modification (single application) and placement of harvested de-epithelialized gingival graft (DGG) followed by coronal repositioned flap for gingival recession Miller's I, II defect coverage
223775733|NCT03200392|DEVICE|laser root surface conditioning & blade DGG harvesting|laser root surface bio-modification (single application) and scalpel blade harvesting of de-epithelialized palatal graft (Zucchelli et al. 2010) and coronal repositioned flap for gingival recession Miller's I, II defect coverage
223686580|NCT02090075|DRUG|apixaban|5 po or 2.5 po bid.
223686581|NCT02090075|DRUG|warfarin|
223686582|NCT00144131|DRUG|Aranesp®|
223686583|NCT06278662|OTHER|video directly observed therapy (vDOT)|The first intervention of within the CIRCUS study is video directly observed therapy (vDOT). The intervention consists of taking recording of daily inhalation use and receiving four feedback sessions of an asthma nurse based on these home recordings.
223686584|NCT03622528|RADIATION|Chest CT scan|Standard dose chest CT scan
223686585|NCT04693884|DRUG|Cannabis|Cannabis of (\~10% THC concentration \<1% CBD concentration) will be smoked.
223686586|NCT04693884|DRUG|Cannabis|Cannabis of (\~10% THC concentration \<1% CBD concentration) will be vaporized.
223775734|NCT03200392|PROCEDURE|blade DGG harvesting|De-epithelialized palatal graft harvested using scalpel blade (Zucchelli et al. 2010) and coronal repositioned flap for gingival recession defect coverage
223775735|NCT00426023|DRUG|Cyclosporine A 0,05% eye drop|Cyclosporine A 0.05% eye drops will be administered 2 times daily for six months in the first year of the study and in the second year of the study in a cross-over manner(from March to September)
223686587|NCT04693884|DRUG|Cannabis|Cannabis of (\~10% CBD concentration \<1% THC concentration) will be smoked.
223686588|NCT04693884|DRUG|Cannabis|Cannabis of (\~10% CBD concentration \<1% THC concentration) will be vaporized.
223775736|NCT00426023|DRUG|ketotifen fumarate 0.025% eye drops|ketotifen fumarate 0.025% eye drops 2 times daily for 6 months in the first year of the study (from March to September) and 6 months in the same period in the second year of the study in cross over manner.
223775737|NCT04067141|DEVICE|somofilcon A|Contact Lens
223775738|NCT04067141|DEVICE|nelfilcon A|Contact Lens
223775739|NCT01259986|PROCEDURE|Laser treatment|Laser treatment of using 635 nm laser with a dose of 3.0 J/cm\^2 to small area (2cm x 2cm) of vitiligo once to twice a week for a total of 12 weeks.
223775740|NCT01717235|DRUG|Ropinirole hydrochloride CR Tablets 2mg|Ropinirole is an orally administered non-ergoline dopamine agonist. Ropinirole is indicated for the treatment of the signs and symptoms of idiopathic Parkinson's disease.
223686589|NCT03958383|BIOLOGICAL|hu14.18-IL2|A recombinant fusion protein linking the monoclonal antibody (mAb) hu14.18 with interleukin-2 (IL2), administered IT
223686590|NCT03958383|RADIATION|Radiation Therapy|Palliative radiation therapy
223686591|NCT03958383|BIOLOGICAL|Nivolumab|Human programmed death receptor (PD-1) blocking antibody, given IV
223686592|NCT03958383|BIOLOGICAL|Ipilimumab|Monoclinal antibody that targets cytoxic T-lymphocyte-associated protein 4 (CTLA-4), given IV
223686593|NCT04602689|DRUG|Human fibrinogen concentrate|Spread the Human fibrinogen concentrate/Aprotinin/Thrombin/Calcium chloride hydrate mixture on iatrogenic ulcer after ESD
223686594|NCT03489551|DRUG|Haldol|
223686595|NCT00143117|DRUG|UK-390,957|
223686596|NCT01465061|BEHAVIORAL|Online support group|Joining online support group
223686597|NCT03310710|DEVICE|Viabahn BX stent|Viabahn BX stent graft used as the branch device with a fenestrated EVAR graft
223686598|NCT00054717|DRUG|Tipranavir|
223686599|NCT00054717|DRUG|Ritonavir(r)|
223686600|NCT00054717|DRUG|Comparator Protease Inhibitor (CPI)|
223686601|NCT06532331|DRUG|ONO-7475|Specified dose on specified days
223686602|NCT06532331|DRUG|ONO-4538|Specified dose on specified days
223686603|NCT06532331|DRUG|Nab-paclitaxel|Specified dose on specified days
223686604|NCT06532331|DRUG|Gemcitabine|Specified dose on specified days
223686605|NCT03861923|OTHER|Dry needling|Trigger point dry needling to trigger points in the shoulder or parascapular muscles using monofilament needle (i.e., acupuncture needle). Clean needle approach using sterile needles.
223686606|NCT03861923|OTHER|Sham Dry Needling|Sham needle approach using a finishing nail in a tube sheath. The finishing nail will be placed over the trigger point so that the patient perceives a sharp sensation. The tube (not the nail) will be moved up and down to mimic the action of needling.
223775741|NCT03566641|DEVICE|Negative pressure wound therapy|The application of a vacuum across the surface of a wound through a foam dressing cut to fit the wound.
223686607|NCT03861923|OTHER|Therapeutic Exercise|Exercise including flexibility, range of motion, strengthening will be provided by the treating physical therapist based on the impairments identified.
223686608|NCT06535919|BEHAVIORAL|Treatment as Usual|Individuals will receive residential level of care followed by treatment at their partial hospitalization program.
223686609|NCT04795427|DRUG|asciminib|Asciminib comes in 20 mg and 40 mg tablets and is taken orally twice daily
223686610|NCT04795427|OTHER|best available treatment|Best available treatment will be based on investigator's choice identified prior to randomization. Dose and frequency will depend on label and institutional guidelines for various BAT
223686611|NCT04350866|BEHAVIORAL|Expert Recommendations for Implementing Change bundle of strategies|"* Develop a formal implementation blueprint/checklist~* Conduct educational meetings~* Develop and distribute educational materials~* Organize implementation meetings~* Facilitation~* Increase demand with marketing to patients~* Promote adaptability"
223686612|NCT04350866|BEHAVIORAL|Brief Behavioral Treatment for Insomnia|"An adapted version of Cognitive Behavioral Therapy for Insomnia (CBT-I) that is focused on behavioral components stimulus control and sleep restriction (the four rules):~1. Reduce time awake in bed.~2. Don't go to bed unless ready for sleep.~3. Don't stay in bed unless asleep.~4. Get up and out of bed at the same time everyday.~Delivered weekly to bi-weekly over 4-6 sessions, with each session typically 30 minutes or less, consistent with other interventions delivered in PCMHI."
223686613|NCT05114538|BEHAVIORAL|Reciprocal Imitation Training|RIT is a relatively straightforward, brief NDBI. It employs four simple strategies to target motor imitation and IJA during play: (1) contingent imitation of the child's verbal and nonverbal behavior, (2) linguistic mapping, (3) direct elicitation of object and gesture imitation following the child's interest, and (4) contingent reinforcement. It has been used at low intensities (e.g., 1-3 hours per week) over short periods of time (e.g., 10-12 weeks) to produce robust changes in pivotal skills. It is easy to learn and can be implemented with fidelity by undergraduate-level therapists with limited backgrounds in ASD, as well as by parents and siblings.
223686614|NCT05228184|DRUG|Tirosint®-SOL|Dosage will be according to the USPI and Standard of Care.
223686615|NCT05228184|DRUG|Levothyroxine Sodium|Tablets will be crushed and dissolved in solution. Dosage will be according to the USPI and Standard of Care.
223686616|NCT04565236|BIOLOGICAL|Recombinant Factor VIII (Kovaltry, BAY81-8973) Treatment Group 1|"25 to 50 IU of Kovaltry per kg body weight given via intravenous (IV) infusion twice weekly, three times weekly, or every other day according to individual requirements for 6 months.~The dose decisions are at the discretion of the investigator."
223686617|NCT04565236|BIOLOGICAL|Recombinant Factor VIII (Kovaltry, BAY81-8973) Treatment Group 2|"12 year-old: 25 to 50 IU of Kovaltry per kg body weight given via intravenous (IV) infusion twice weekly, three times weekly, or every other day for 6 months.~\>12 year-old: 20 to 40 IU of Kovaltry per kg of body weight given via intravenous (IV) infusion two or three times per week for 6 months.~The dose decisions are at the discretion of the investigator."
223686618|NCT04565236|BIOLOGICAL|Recombinant Factor VIII (Kovaltry, BAY81-8973) Treatment Group 3|"15 to 50 IU of Kovaltry per kg body weight (minimum dose: 250 IU) given via intravenous (IV) infusions at least once a week.~The dose decisions are at the discretion of the investigator."
223686619|NCT05088863|OTHER|flaxseed|40g of flaxseed per day
223686620|NCT02974309|BEHAVIORAL|Sleep Extension|All youth in this condition are asked to extend their sleep to 10 hours or at least one hour, whichever is longer
223686621|NCT02974309|BEHAVIORAL|Routine|All youth in this condition are asked to follow the routines set by their clinical care team.
223686622|NCT04423939|BEHAVIORAL|Acceptance and Commitment Therapy (ACT)|The ACT sessions will be tailored to the clinical challenges of HCT. Sessions are with a mental health professional and are 45-60 minutes in duration and include both the participant and caregiver.
223686623|NCT06207617|PROCEDURE|Immediate implant placement + customized healing abutment|Immediate implant placement in fresh extraction molar sites + customized healing abutment fabricated by adding flowable composite to the temporary cylindrical abutment mimicking the shape of the socket at the marginal gingiva, then it will be screwed to the implant. no grafting material included in this arm
223686624|NCT06207617|PROCEDURE|Immediate implant placement + xenogeneic bone graft material + customized healing abutment|Immediate implant placement in fresh extraction molar sites + xenogenic bone graft + customized healing abutment fabricated by adding flowable composite to the temporary cylindrical abutment mimicking the shape of the socket at the marginal gingiva, then it will be screwed to the implant.
223686625|NCT02285283|DRUG|Itraconazole|
223775742|NCT03566641|OTHER|standard care dressing|The application of a standard care dressing (instead of negative pressure wound therapy) across the surface of wound.
223775743|NCT03868904|DEVICE|OCS Lung System|No active interventions are part of this study. This study will collect long-term survival and BOS data in subjects who were part of the INSPIRE trial.
223775744|NCT01038921|DRUG|Melatonin|8 mg dose of Melatonin
223775745|NCT01038921|DRUG|Placebo|Placebo
223775746|NCT06390735|BEHAVIORAL|Mommy ReachOut Intervention|The momy reachOut intervention is a web-based psycho-education with 4 sessions, released over a two week period.
223686626|NCT02285283|DRUG|Placebo|
223686627|NCT06080048|DRUG|SOR102|SOR102 capsules
223686628|NCT06080048|DRUG|Placebo|Matching placebo capsules
223686629|NCT06000488|BEHAVIORAL|Reflective Writing Workshop Sessions|Three workshops of 75 minutes. Trained PA and/or MD student facilitators will then use prepared materials to guide each group through a series of prompts, each eliciting written reflections of varying lengths. While all participants are encouraged to reflect, write, and share their responses, participation at all levels remains optional.
223686630|NCT05349682|DIAGNOSTIC_TEST|dynamic contrast enhanced MRI|An MRI study of the knee will be done to check the degree of osteoarthritis and blood flow to the affected knee. This scan will take about 1-2 hour(s).
223775747|NCT01978119|DRUG|FSC|Subject will be administered FSC 250 mcg/50 mcg via dry powder inhalation device or multi-dose dry powder inhalation device BID for each treatment period
223775748|NCT01978119|DRUG|Placebo|Subject will be administered placebo via dry powder inhalation device or multi-dose dry powder inhalation device BID for each treatment period
223775749|NCT02322606|DRUG|TAK-137 5 mg tablet, TAK-137 placebo tablet|
223775750|NCT02322606|DRUG|TAK-137 5 mg tablet, TAK-137 placebo tablet|
223775751|NCT02322606|DRUG|TAK-137 5 mg tablet, TAK-137 placebo tablet or TAK-137 0.5 mg tablet, TAK-137 placebo tablet|
223775752|NCT02322606|DRUG|TAK-137 5mg tablet, TAK-137 placebo tablet|
223686631|NCT05349682|PROCEDURE|geniculate artery embolization|The physician will perform a diagnostic angiography, where they will take pictures of vessels near the knee that will be treated. Once the artery to be treated is identified, the doctor will guide a thin wire called a microwire, and a plastic tube called a microcatheter to the targeted artery, and more pictures of vessels at the knee will be taken. This picture will be used to see if there are any abnormal vessels at the knee, such as abnormal blood flow, abnormal vessel connections (between the veins and arteries), or new blood vessel growth. Once the targeted artery at the knee is confirmed, the doctor will inject enough particle embolic (Embozene) to slow or stop the blood flow in the geniculate artery. Once all vessels are treated, a final angiogram (pictures of blood vessels) will be performed to ensure that the blood flow has slowed.
223686632|NCT05499650|BEHAVIORAL|Supervised Exercise Regiment|Subjects will undergo supervised aerobic exercise. There will be a set goal mean energy expenditure of at least 1000 kcal/wk after a two-week ramp-up period. The protocol will include 30 minutes of moderate-intensity exercise with a treadmill and cycle ergometry, two times weekly. Strenuous resistance training and swimming will be withheld from this protocol due to the potential concerns for safety in exacerbating dissections. Heart rate and ratings of perceived exertion will be quantified during the therapy with a standard set heart rate ad pulse pressure threshold for discontinuing exercise protocols.
223686633|NCT06048718|DRUG|Trastuzumab-Deruxtecan (T-DXd)|Trastuzumab-deruxtecan is a human HER2-directed antibody-drug conjugate (ADC) composed of humanized anti-HER2 immunoglobulin G1 (IgG1) monoclonal antibody (mAb) with the same amino acid sequence as trastuzumab, covalently linked to the membrane-permeable topoisomerase I inhibitor payload, DXd, an exatecan derivative, via a stable tetrapeptide-based linker, selectively cleaved within tumor cells.
223686634|NCT05749432|DRUG|Hemay181|Hemay181 will be given intravenously on the first day per cycle, and the treatment cycle is 21-days.
223686635|NCT04626310|BEHAVIORAL|Dialectical behavior therapy - emotion regulation skills training|"Arm 1. Dialectical behavior therapy - emotion regulation skills training follows the emotion regulation skills DBT Skills Training Manual Second Edition and the DBT Skills Training Handouts and Worksheets Second Edition. This group involves 6 weekly sessions.~Arm 2. Dialectical behavior therapy - interpersonal effectiveness skills training follows the interpersonal effectiveness skills DBT Skills Training Manual Second Edition and the DBT Skills Training Handouts and Worksheets Second Edition. This group involves 6 weekly sessions."
223686636|NCT04626310|BEHAVIORAL|Dialectical behavior therapy - interpersonal effectiveness skills training|Arm 2. Dialectical behavior therapy - interpersonal effectiveness skills training follows the interpersonal effectiveness skills DBT Skills Training Manual Second Edition and the DBT Skills Training Handouts and Worksheets Second Edition. This group involves 6 weekly sessions.
223686637|NCT04626310|BEHAVIORAL|Interpersonal psychotherapy|Arm 3. Non-skills-oriented interpersonal psychotherapy group follows evidence-based principles on common factors in a group therapy context. This group involves 6 weekly sessions.
223686638|NCT06311877|DIETARY_SUPPLEMENT|mBerry|mBerry tablets (.4 grams), which contain protein within the miracle berry called miraculin.
223686639|NCT06311877|OTHER|No intervention|The control group will not received intervention.
223686640|NCT01617148|DRUG|Aflibercept|Patients received 2 mg (0.05 mL) of intravitreal aflibercept injection administered monthly for the first 3 months, followed by 2 mg (0.05 mL) once every 2 months as per the drug label for the next 9 months.
223686641|NCT06278233|DEVICE|Transcranial direct current stimulation|TDCS involves applying a weak electrical current across the head through electrodes placed on the scalp and modulating the resting membrane potential of neurons in the underlying cortex.
223686642|NCT02069418|RADIATION|18F-FLT-TEP|Patients are going to have two 18F-FLT-TEP : one during the two weeks before the beginning of erlotinib and the second one will occur during the second week after the initiation of erlotinib.
223686643|NCT02069418|RADIATION|18F-FDG-TEP|Patients are going to have two 18F-FDG-TEP : one during the two weeks before the beginning of erlotinib and the second one will occur during the second week after the initiation of erlotinib.
223686644|NCT00405327|BIOLOGICAL|Tumor lysate-pulsed dendritic cell (DC) vaccine|Tumor lysate-pulsed dendritic cell vaccine
223686645|NCT00405327|OTHER|Hematopoietic stem cell transplantation (HSCT)|Hematopoietic stem cell transplantation (HSCT)
223686646|NCT04873128|GENETIC|Multi-OMICS|Measurement of gene expression in immune cells (Human Peripheral Blood Mononuclear Cell (PBMCs) or total blood) using functional genomics, proteomics, metabolomics and lipidomics tools and compare the dynamics of immune response before and after vaccination against COVID-19.
223686647|NCT02901639|OTHER|counseling|
223686648|NCT05447962|BEHAVIORAL|Community-to-Clinic Linkage Implementation Program in Barbershops (CLIP)|Multilevel intervention designed to mitigate adverse social determinants of health (SDoH) via linkage to care, health system navigation, and referral to social services.
223686649|NCT05447962|BEHAVIORAL|Barbershop-Based Facilitation (BF)|Trained and qualified facilitators assist community health workers (CHWs) to: 1) increase their confidence in delivering CLIP; 2) understand participants' concerns and beliefs about hypertension (HTN); and 3) develop skills in lifestyle counseling to help the men initiate lifestyle modification.
223686650|NCT00287079|DRUG|Rebif®|44 microgram (mcg) IFN beta-1a sc once a week (qw) for 96 weeks
223686651|NCT00287079|OTHER|No Treatment|No treatment for 96 weeks
223686652|NCT02758977|PROCEDURE|ALPPS|For detailed information please refer to description of experimental arm
223686653|NCT02758977|PROCEDURE|TWO STAGE HEPATECTOMY|For detailed information please refer to description of active comparator arm
223686654|NCT02822547|DRUG|Peginterferon alfa-2a|Patients will receive Peginterferon alfa-2a according to the standard medical practice
223686655|NCT05791903|OTHER|Nursing Care Based on Kolcaba's Comfort Theory|Comfort-orientated care
223686656|NCT02380820|DEVICE|Airsoft Duo mattress|A multi-layer mattress for pressure sore prevention. Made by NAUER FOAMPARTNER AG et OBA AG (Germany).
223775753|NCT02322606|DRUG|TAK-137 5 mg tablet, TAK-137 placebo tablet|
223775754|NCT02322606|DRUG|TAK-137 5mg tablet, TAK-137 placebo tablet|
223686657|NCT02380820|DEVICE|Softform Premier mattress (in static mode)|A multi-layer mattress for pressure sore prevention. Made by INVACARE MSS (United Kingdom).
223686658|NCT04218123|DRUG|Venlafaxine|Daily oral intake 37.5 mg
223686659|NCT04218123|DRUG|Placebo oral tablet|Daily oral intake
223686660|NCT00423670|DRUG|boceprevir (SCH 503034)|200 mg capsules taken as 800 mg orally three times daily (TID)
223686661|NCT00423670|DRUG|peginterferon-alfa 2b (PegIntron)|1.5 μg/kg subcutaneously (SC) once weekly (QW)
223686662|NCT00423670|DRUG|ribavirin|200 mg capsules in doses of 800 to 1400 mg/day (based on weight) taken orally divided twice daily
223686663|NCT00423670|DRUG|ribavirin (low-dose)|200 mg capsules in doses of 400 to 1000 mg/day (based on weight) taken orally divided twice daily
223686664|NCT05832021|PROCEDURE|Open reduction and internal fixation (under WALANT)|Open reduction and internal fixation with volar Henry approach under WALANT.
223686665|NCT05832021|PROCEDURE|Open reduction and internal fixation (under peripheral nerve block)|Open reduction and internal fixation with volar Henry approach under peripheral nerve block.
223686666|NCT00286611|PROCEDURE|Blood and salivary sampling of amifostine|Sampling of blood and saliva to test for amifostine levels.
223686667|NCT03590197|DRUG|Melatonin 3 mg|Melatonin 3 mg/ day with Valproate
223686668|NCT03590197|OTHER|Placebo|Placebo with Valproate
223686669|NCT03901118|DRUG|chiauranib|in the phase of pilot trial, 25mg orally once daily; in the formal phase, 50mg orally once daily
223686670|NCT03901118|DRUG|etoposide|50mg orally once daily for 21 days, 7 days off, every 28 days for a cycle, 6 cycles at most
223686671|NCT03901118|DRUG|paclitaxel|60mg/m2, i.v infusion on day 1, 8 and 15, every 21 days for a cycle, 6 cycles at most
223686672|NCT01861171|DIETARY_SUPPLEMENT|Green Tea|Twenty women with obesity and pre-hypertension, aged 28-59 years, with stable body weight were randomized to receive a daily supplement of 3 capsules that contained either 500mg of green tea extract (GTE) or a matching placebo for 4 weeks, with a washout period of 2 weeks between the treatments.
223686673|NCT05637671|DRUG|oxybutynin ER|One study group will receive 10 mg of oxybutynin ER orally once daily for 12 weeks.
223686674|NCT05637671|DRUG|Paroxetine CR|the other group will receive 12.5 mg of paroxetine CR orally once daily for 12 weeks.
223686675|NCT01071473|OTHER|12 Week Exercise Intervention|Trial of a 12-week period of combined endurance and resistance training in survivors of childhood cancer who were treated with doxorubicin and/or daunorubicin and have impaired cardiac function.
223686676|NCT00508768|DRUG|Oral SCIO-469 capsule|
223686677|NCT04942353|BEHAVIORAL|Home-based Exercise Rehabilitation.|Based on physical therapist or exercise physiologist assessment, subjects will receive an individualized exercise prescription for frequency, duration, and intensity of walking and strength training (including exercises using light-weight hand-weights and upper and lower body exercises using resistance bands). Research team will provide updated exercise prescription based on Garmin watch/Datos app activity data and Datos app data (including Borg scale).
223686678|NCT04942353|BEHAVIORAL|Usual Care|Patients receive a standardized recommendation to increase their walking activity to 30 minutes 5 days/week.
223686679|NCT03613597|DRUG|etoposide plus lobaplatin|Thoracic intensity modulated radiation therapy (IMRT) + etoposide plus lobaplatin
223686680|NCT03613597|DRUG|etoposide plus cisplatin|Thoracic intensity modulated radiation therapy (IMRT) + etoposide plus Cisplatin
223686681|NCT01082640|DRUG|Febuxostat|Febuxostat capsules
223686682|NCT01082640|DRUG|Placebo|Febuxostat placebo-matching capsules
223686683|NCT03636711|OTHER|antibiotic protocol, according to a syndromic approach|Description of patients who benefited or not the antibiotic protocol, according to a syndromic approach and analysis of the causes of non-adherence to the protocols
223686684|NCT02671162|DRUG|Wheat|3 times a day each time 2 capsules before eating meal for 8 weeks.
223686685|NCT02671162|DRUG|Fumaria|3 times a day each time 2 capsules before eating meal for 8 weeks.
223686686|NCT00413478|DRUG|5-Azacytidine|Starting dose level: 75mg/m\^2 subcutaneously daily for seven days. Treatment cycles will be repeated every 3-8 weeks.
223686687|NCT00776685|BEHAVIORAL|Personality-targeted interventions|Motivational and cognitive behavioural interventions targeting four personality profiles. 2 90 minute group sessions with personality-matched peers facilitated by a trained teacher and co-facilitator
223686688|NCT00156572|PROCEDURE|Sodium supplementation|
223686689|NCT00156572|PROCEDURE|Fluid restriction|
223686690|NCT00162721|DRUG|doxorubicin, ifosfamide, cisplatin|
223686691|NCT03577171|DRUG|ABI-H0731|Participants will receive 300mg QD of ABI-H0731 tablets orally.
223686692|NCT03577171|DRUG|SOC ETV|Participants will receive SOC ETV (0.5 mg QD) orally as per approved package insert.
223686693|NCT03577171|DRUG|Placebo Oral Tablet|Participants will receive matching QD placebo tablets orally.
223686694|NCT00315354|OTHER|Low glycemic index diet|Feeding protocol, all foods prepared in a metabolic kitchen
223686695|NCT00315354|OTHER|Low fat diet|Feeding protocol, all foods prepared in a metabolic kitchen
223686696|NCT00315354|OTHER|Very low carbohydrate diet|Feeding protocol, all foods prepared in a metabolic kitchen
223775755|NCT03295201|OTHER|Active cycle of breathing techniques (ACBT)|ACBT involves three phases (Breathing control, chest expansion exercise, and huff coughing). These phases will apply with a sequence to remove secretion. ACBT will apply 1 per a week for 6 weeks.
223775756|NCT03295201|OTHER|Postural Exercise|Postural exercise program will include thoracic vertebra mobilization, pectoral stretching, scapula and thoracic extensors strengthening and core stability exercises. Postural exercise program will apply 1 per a week for 6 weeks.
223775757|NCT01224262|BIOLOGICAL|Fluzone® (2010/2011 Inactivated Trivalent Influenza Vaccine)|A single vaccination of Fluzone alone
223775758|NCT01224262|BIOLOGICAL|LIQ001 (0.45mg)|A single vaccination of 0.45 mg LIQ001
223775759|NCT01224262|BIOLOGICAL|LIQ001 (1.8mg)|A single vaccination of 1.8 mg LIQ001
223775760|NCT06129058|DEVICE|At-home transcranial direct current stimulation (tDCS)|30 minutes session 5 days/week for 3 weeks.
223775761|NCT06129058|DEVICE|Sham at-home tDCS|30 minutes session 5 days/week for 3 weeks.
223775762|NCT00036920|DRUG|canfosfamide hydrochloride|
223775763|NCT00733824|DRUG|AMD3100|
223686697|NCT03598634|PROCEDURE|administration of riboflavin for epi-off cross-linking|riboflavin 0.1% in 20% dextran solution
223686698|NCT03598634|PROCEDURE|administration of riboflavin for epi-on cross-linking|riboflavin 0.1% in 15% dextran solution supplemented with tris-hydroxymethylaminomethane and sodium ethylenediminetetraacetic acid
223686699|NCT04577352|DRUG|Vatiquinone|Vatiquinone will be administered per dose and schedule specified in the arm.
223686700|NCT04577352|DRUG|Placebo|Placebo will be administered per schedule specified in the arm.
223775764|NCT00733824|DRUG|G-CSF|
223775765|NCT00733824|PROCEDURE|Apheresis|
223775766|NCT01813604|BIOLOGICAL|Group A: Trivalent Oral Polio Vaccine|Group A will receive 3 doses of trivalent oral polio vaccine (tOPV) at 6, 10 and 14 weeks of age. A challenge dose of tOPV will be administered at 18 weeks of age.
223775767|NCT01813604|BIOLOGICAL|Group B: Bivalent Oral Polio Vaccine|Group B will receive 3 doses of bivalent oral polio vaccine (bOPV) at 6, 10 and 14 weeks of age. A challenge dose of tOPV will be administered at 18 weeks of age.
223775768|NCT01813604|BIOLOGICAL|Group C: Inactivated Polio Vaccine|Group C will receive 2 doses of inactivated polio vaccine (IPV) at 6 and 14 weeks of age. IPV will be administered intramuscularly using standard needle and syringe. A challenge dose of tOPV will be administered at 18 weeks of age.
223775769|NCT01813604|BIOLOGICAL|Group D: fractional IPV (f-IPV)|Group D will receive 2 doses of fractional inactivated polio vaccine (f-IPV) at 6 and 14 weeks of age. f-IPV (one-fifth dose of IPV) will be administered intradermally using MicroJet 600 microneedle hub by NanoPass Technologies. A challenge dose of tOPV will be administered at 18 weeks of age.
223775770|NCT01813604|BIOLOGICAL|Arm E: f-IPV and bOPV|Group E will receive 2 doses of f-IPV at 6 and 14 weeks of age with bOPV at 10 weeks of age. f-IPV will be administered intradermally using MicroJet 600 microneedle hub by NanoPass Technologies. A challenge dose of tOPV will be administered at 18 weeks of age.
223775771|NCT02168166|BEHAVIORAL|Executive Function Training|
223775772|NCT02168166|BEHAVIORAL|Placebo|Placebo version of executive function training
223775773|NCT05267067|OTHER|respiratory exercises|Manual respiratory exercises versus respiratory exercises with pressure meter
223775774|NCT04687956|PROCEDURE|LYMPHA|Axillary reverse mapping is performed before surgery, axillary lymph node resection is performed, and 'LYMPHA' (Lymphatic microsurgical preventing healing approach) is performed, and the surgery is terminated. Subsequently, the occurrence of lymphedema is followed up.
223686701|NCT01830075|BEHAVIORAL|Consultations|The patients receive two consultations with a spiritual counsellor. In these consultations life evens and life goals are discussed.
223686702|NCT01278303|DEVICE|Treatment of Aortic Wall Injury|A Cheatham covered platinum stent will be implanted in the Descending aorta to repair coarctation of the aorta in qualified patients.
223686703|NCT05196178|PROCEDURE|Spinal cord stimulation|Paddle-shaped Spinal cord stimulation electrode with 16 contacts (AdaptiveStim® 39, 565;Medtronic, USA) will be implanted into the epidural space at the thoracic levels ranging from T10 to T12.
223686704|NCT05832827|DRUG|MK-3475|Pembrolizumab will be administered at a dose of 200 mg by intravenous infusion every 21 days (3 weeks) for up to 35 cycles.
223686705|NCT05832827|DRUG|Lenvatinib|Lenvatinib will be administered at a dose of 8 mg orally QD every 21 days (3 weeks) for up to 4 cycles in the induction phase, followed by 20 mg QD for up to 31 cycles in the maintenance phase. Then, further maintenance therapy with lenvatinib will be allowed until progression or unacceptable adverse events.
223686706|NCT05832827|DRUG|Carboplatin|Carboplatin will be administered at a dose of AUC 5 intravenously every 21 days (3 weeks) for up to 4 cycles in the induction phase.
223686707|NCT05832827|DRUG|Paclitaxel|Paclitaxel will be administered at a dose of 175 mg/m\^2 intravenously every 21 days (3 weeks) for up to 4 cycles in the induction phase.
223686708|NCT03734744|DIETARY_SUPPLEMENT|Vitamin D3|Vitamin D is a fat-soluble vitamin that plays an important role in immune modulation in addition to its classical roles in regulation of calcium homeostasis and bone health
223775775|NCT04687956|PROCEDURE|control|In the control group, axillary lymph node resection is performed and the surgery is terminated without additional procedures. Subsequently, the occurrence of lymphedema is followed up.
223775776|NCT05586867|PROCEDURE|Blood test|15 mL of blood to follow the evolution of hepcidin and erythroferrone levels
223775777|NCT01243944|DRUG|ruxolitinib tablets|Starting dose of 10 mg BID with individualized dose titration ranging from 5 mg QD to 25 mg BID based on safety and efficacy
223775778|NCT01243944|OTHER|Best Available Therapy (BAT)|Best Available Therapy (BAT) will be selected by the Investigator for each participant. BAT may not include experimental agents (i.e. those not approved for the treatment of any indication) as well as a limited number of other selected drugs in accordance with the protocol-defined requirements.
223775779|NCT03962972|OTHER|Frailty evaluation|"It will be used a questionnaire that is called:The Centre of Excellence Self-Administered questionnaire (CESAM). The score of this questionnaire and its stratification of frailty in four levels with incident adverse health events in older community dwellers will be compare with validated frailty indexes which are the Cardiovascular Health Study frailty index, Study of Osteoporotic Fracture index, Rockwood frailty index, 6-ietm brief geriatric assessment (BGA), Program of Research on the Integration of Services for the Maintenance of Autonomy (PRISMA-7) and b) two other frailty index developed over the COVID-19 pandemic which are Évaluation SOcio-GÉriatrique (ESOGER) and CriblAge et REcommandations (CARE)."
223775780|NCT04262999|OTHER|effect of sodium valproate on alveolar bone level|Comparative evaluation of bone mineral density and levels of marginal alveolar bone in patients with epilepsy on sodium valproate drug therapy.Comparative evaluation of periodontal parameters in all the patients who are on sodium valproate drug therapy.
223686709|NCT00669760|OTHER|non-interventional study|does not apply
223686710|NCT03701321|DRUG|Bortezomib|Given SC
223686711|NCT03701321|BIOLOGICAL|Daratumumab|Given IV
223686712|NCT03701321|DRUG|Dexamethasone|Given PO
223686713|NCT03701321|DRUG|Venetoclax|Given PO
223686714|NCT04335422|DEVICE|Robotic group (Upper extremity robot-assisted training plus routine physical and rehabilitation medicine program)|"Upper extremity robot-assisted training will include facilitated shoulder flexion-extension, internal-external rotation, abduction-adduction, elbow flexion-extension, forearm supination-pronation, wrist flexion-extension, ulnar-radial deviation, hand finger flexion-extension movements by means of visual feedback with a 3-dimensional virtual environment in which the patient is asked to perform various tasks such as object reaching, grasping, holding, dropping activities by playing computer games.~Routine physical and rehabilitation medicine program including physical therapy and exercises, walking and balance training, and occupational therapy to improve daily living activities will be given."
223686715|NCT04335422|BEHAVIORAL|Control group (routine physical and rehabilitation medicine program)|Routine physical and rehabilitation medicine program including physical therapy and exercises, walking and balance training, and occupational therapy to improve daily living activities will be given.
223775781|NCT04262999|OTHER|effect of levetiracetam on alveolar bone level|Comparative evaluation of bone mineral density and levels of marginal alveolar bone in patients with epilepsy on levetiracetam drug therapy.Comparative evaluation of periodontal parameters in all the patients who are on levetiracetam drug therapy.
223686716|NCT03190369|DEVICE|Hylan G-F 20 (GZ402662/SAR402662)|"Pharmaceutical form: Solution for injection~Route of administration: Intra articular"
223686717|NCT03190369|DRUG|Placebo|"Pharmaceutical form: Solution for injection~Route of administration: Intra articular"
223686718|NCT04349085|DEVICE|Effective PBMT/sMF|A cluster with 20 diodes, manufactured by Multi Radiance Medical® (Solon, OH, USA), will be used: 4 diodes of 905 nm (1.25 average power, 50 W of peak power for each diode), 8 diodes of 850 nm (40 mW of average power for each diode) and 4 diodes of 633 nm (25 mW average power for each diode). Effective PBMT/sMF will be applied in direct contact with the skin and light pressure in: 4 sites in the knee extensor/hip flexor muscles, 3 sites in the knee flexor/hip extensor muscles and 1 site in the plantar flexor muscles. The effective PBMT/sMF will be applied to both lower limbs. The dose used for applications will be approximately 270 J for knee extensors/hip flexors, 180 J for knee flexors/hip extensors, and 60 J for plantar flexors.
223775782|NCT04262999|OTHER|effect of sodium valproate+levetiracetam on alveolar bone level|Comparative evaluation of bone mineral density and levels of marginal alveolar bone in patients with epilepsy on sodium valproate+levetiracetam drug therapy.Comparative evaluation of periodontal parameters in all the patients who are on sodium valproate+ levetiracetam drug therapy.
223775783|NCT04262999|OTHER|control group|Control group individuals will be systemically healthy.
223775784|NCT03310541|DRUG|AZD5363|AZD5363 400mg PO twice daily for 4 days on, 3 days off, every week
223775785|NCT03310541|DRUG|Enzalutamide|Enzalutamide 160 mg PO once daily
223775786|NCT03310541|DRUG|Fulvestrant|500mg IM days 1, 15, 29 (cycle 2 day 1) and then every 4 weeks
223686719|NCT04349085|DEVICE|Placebo PBMT/sMF|A cluster manufactured by Multi Radiance Medical® (Solon, OH, USA) with 20 diodes will be used: Placebo PBMT/sMF will be applied in direct contact with the skin and light pressure in: 4 sites in the knee extensor/hip flexor muscles, 3 sites in the knee flexor/hip extensor muscles and 1 site in the plantar flexor muscles. The placebo PBMT/sMF will be applied to both lower limbs. The dose used for applications will be approximately 0 J per diode. The sounds and signals emitted from the device as well as the information displayed on the screen will be identical, regardless of the type of treatment (active or placebo).
223686720|NCT01623986|DEVICE|Mespere Venus 1000 System|An adhesive patch (connected to the Mespere Venus 1000 System) is placed on the neck of the subject, to determine if the CVP values displayed by the device correlates with right atrial pressure values obtained by echocardiography(standard clinical practice)
223686721|NCT01623986|DEVICE|Echocardiography machine|Use of ultrasound to estimate right atrial pressure from analyzing inferior vena cava (IVC).
223686722|NCT05333783|BEHAVIORAL|Augmented Reality Exposure Therapy Based on ExposXR software|The ExposXR software is developed by The Stress Trauma Anxiety Research Clinic at Wayne State University, U.S.A. When it is used inside a Augmented Reality hardware such as Hololens, it renders artificial phobic objects into what the participants see. The treatment consist of a one-session treatment for cynophobia using Augmented Reality.
223686723|NCT05895799|OTHER|Tuition from a expert clinical trainer|Each group was initially provided with an online tutorial on the complete physical examination of the cardiovascular system as performed on a standardized patient by the trainer. At the beginning of each session, the trainer performed the examination on a hybrid patient wearing the auscultation vest and provided additional teaching, explanations, and rationale. Following the demonstration, each participant was invited to perform repeated physical examinations in front of their peers with real-time one-to-one feedback from the trainer. After each performance, the participant was encouraged to critique their own performance(s), peers were invited to provide some insights, and the trainer gave some overall feedback. At the end of the session and after each participant had had the opportunity to perform the complete examination at least once, the participants were taken through a range of abnormal signs using the auscultation vest with explanations provided by the trainer.
223686724|NCT04026581|BEHAVIORAL|Speech generating device (SGD) evaluation including BCI access|At the initial evaluation the participants will review the full range of AAC options and speech generating devices (SGDs) and complete a speech and language evaluation. The second evaluation date will involve a trial of SGDs matched to the participant's assessment results. The third visit is the trial of an AAC system with BCI access. Should the dry electrode headgear for BCI access prove ineffective, then the gel electrode cap will be offered to the participant for trial. At the end of the third visit, the evaluation results will be discussed with participant and family, and they will be asked to select the preferred SGD.
223686725|NCT04026581|BEHAVIORAL|Training and treatment|Participants receive training on the selected SGD followed by monthly treatment sessions from the SLP who monitors performance. In some cases the participants' SGD will be an AAC system with BCI access. In this case training will also include an identified system support person. Use of the SGD is monitored on a monthly basis through home visits and/or tele-practice sessions, when requested. Technical support for the SGD is provided on an as needed basis or when requested by the participant or support person.
223686726|NCT02783885|DRUG|immunotherapy|
223686727|NCT04870736|PROCEDURE|Mout-to-mouth ventilation|Chest rising during basic life support will be recorded as No breath (no visible chest rising) and Breath (chest rising) by the observer.
223686728|NCT04870736|PROCEDURE|Mout-to-mouth ventilation with quantitative analysis|Chest rising during basic life support will be recorded and evaluated (breath by breath) in QCPR Skill Reporter software
223686729|NCT04900168|DEVICE|Intracranial pressure monitoring|An invasive method to monitor the intracranial pressure of patient
223686730|NCT00400790|DRUG|propofol|Propofol used as the primary anaesthetic agent
223686731|NCT00400790|DRUG|desflurane|Desflurane used as the primary anaesthetic
223686732|NCT02011893|DEVICE|Tonic Stimulation|Prodigy Neurostimulation System with associated components
223686733|NCT02011893|DEVICE|Burst Stimulation|Prodigy Neurostimulation System with associated components
223686734|NCT00229918|DRUG|triamcinolone acetonide|
223686735|NCT04488107|DRUG|FCN-437c|\- FCN-437c is a selective and potent CDK4/6 dual inhibitor, with broad antitumor activity in preclinical pharmacology models, favorable physical and pharmacokinetic (PK) properties, and acceptable toxicity profile in nonclinical studies.
223686736|NCT04488107|DRUG|Letrozole 2.5mg|"* Letrozole is the latest generation of aromatase inhibitor. Letrozole lowers estrogen levels in postmenopausal women, which may slow the growth of certain types of breast tumors that need estrogen to grow in the body.~* Letrozole is used to treat breast cancer in postmenopausal women. It is often given to women who have been taking tamoxifen (Nolvadex, Soltamox) for 5 years."
223686737|NCT05990998|DRUG|68Ga-DOTATATE and 68Ga-FAPI|Each patient receive a single intravenous injection of 68Ga-FAPI or 68Ga-DOTATATE (2-4mCi) , and undergo PET/CT scan at 40-60 min post injection.
223686738|NCT06256757|PROCEDURE|fenestration|Thoracic EndoVascular Aortic Repair (TEVAR) with fenestrations
223686739|NCT03541876|OTHER|Collection of data|"The following data will be collected by the physician :~sociodemographic profile (age, sex, country of birth of child and parents); clinical manifestations; endoscopic aspects (esophagus, duodenum, stomach); different methods of diagnosis of infection; different primary and secondary bacterial resistance profiles ; different first and second line therapeutic combinations; different first and second line bacterial eradication rates ; different signs of side effects and tolerance of first and second line treatments; different methods of bacterial eradication control."
223686740|NCT05151601|DIETARY_SUPPLEMENT|Experimental|2 x sachets per day
223686741|NCT05151601|OTHER|Placebo|2 x sachets per day
223686742|NCT00002576|DRUG|cyclophosphamide|
223686743|NCT00002576|DRUG|doxorubicin hydrochloride|
223686744|NCT00002576|DRUG|mitoxantrone hydrochloride|
223686745|NCT00002576|DRUG|prednisolone|
223686746|NCT00002576|DRUG|vincristine sulfate|
223686747|NCT04733612|OTHER|Informative messages|"In addition to their standard treatments, an informative SMS (text message) on diabetes was sent to the intervention group three to four times a week for six months.~The short messages were in the form of a short sentence for the subject and the predicate. The messages sent have been prepared in such a way that they do not exceed 1 SMS quota and are less than 160 characters on mobile phones."
223686748|NCT05368532|OTHER|Temperature|The temperature will be reduced for approximately one hour.
223686749|NCT03211962|OTHER|Analysis of urinary levels of TIMP2 and IGFBP7 within 6 hours after cardiac circulatory arrest|Analysis of urinary levels of TIMP2 and IGFBP7 within 6 hours after cardiac circulatory arrest
223686750|NCT03157960|OTHER|Blueberry drink|Participant receive blueberry drink
223686751|NCT03157960|OTHER|Blueberry and pizza|Participant receive blueberry drink and a slice of pizza
223686752|NCT03157960|OTHER|Soft beverage|Participant receive a soft beverage drink
223686753|NCT03157960|OTHER|Soft beverage and pizza|Participant receive a soft beverage drink and a slice of pizza
223686754|NCT03157960|OTHER|Fructose|Participant receive a drink containing fructose
223686755|NCT03157960|OTHER|Fructose and pizza|Participant receive a fructose drink and a slice of pizza
223686756|NCT01019811|PROCEDURE|The innervated sensory cross-finger flap|The innervated sensory cross-finger flap is a modified method for repair fingertip degloving injury
223686757|NCT01905111|DRUG|BI 853520|BI 853520 once daily in a dose escalation schedule
223686758|NCT04433143|DRUG|Minocycline hydrochloride capsules were taken orally|Lumenis OneTM, OPT tender system produced by American Medical Science Company; Use four of the filters. Acne filter has a wavelength of 400-600/800-1200nm. Three pulses were used for treatment, with a pulse width of 5.0ms, a pulse delay of 30ns, and an energy density of 15j /cm2. The instrument parameters were selected according to the skin lesion characteristics, age and tolerance.
223686759|NCT02886156|DEVICE|CPAP|CPAP plus BSC group Participants in the CPAP plus BSC group will receive CPAP treatment plus the aforementioned BSC intervention. CPAP treatment (LOTUS AUTO; Curative Medical Technology Inc., Beijing, China) will be initiated using standard clinical practice at each center. Participants in both groups will be asked to continue their usual medical care during the trial.
223686760|NCT02886156|DIETARY_SUPPLEMENT|BSC|BSC only group Participants in the BSC only group will receive advice regarding lifestyle modification, sleep hygiene, naps, exercise, caffeine, and diet, and avoiding alcohol consumption, but no specific weight loss program, diet, or salt restriction will be suggested.
223686761|NCT01241240|DRUG|bimatoprost/brimonidine tartrate/timolol ophthalmic solution (Triple Combination Therapy)|One drop of Triple Combination Therapy administered to each eye, twice daily for 12 weeks.
223686762|NCT01241240|DRUG|Fixed Combination 0.2% brimonidine tartrate/0.5% timolol ophthalmic solution|One drop of Fixed Combination 0.2% brimonidine tartrate/0.5% timolol ophthalmic solution administered to each eye, twice daily for 12 weeks.
223686763|NCT06115668|OTHER|Positive end-expiratory pressure 5 (PEEP 5)|Fixed positive end-expiratory pressure of 5 cmH2O will be maintained throughout the duration of surgery
223686764|NCT06115668|OTHER|Individualized positive end-expiratory pressure (PEEPIND)|Patients will receive the individualized positive end-expiratory pressure. Titration process will be started after establishment of pneumoperitoneum: setting the initial PEEP to 5 cmH2O, then increasing positive end-expiratory pressure (PEEP)according to the gradient of 2 cmH2O every 3 min, calculating static compliance (Cstat) according to the formula: \[Cstat = VT/Pplat - PEEP\] (Pplat = plateau pressure), then gradually increasing positive end-expiratory pressure , until the calculated Cstat shows a downward trend, set its previous PEEP (corresponding to PEEP for high Cstat) as the optimal PEEPIND for this patient. The highest PEEP is limited to 20 cmH2O
223775787|NCT03560219|DIAGNOSTIC_TEST|Biomarkers, Cardiac Magnetic Resonance Imaging, Echocardiography, Flow Mediated Dilatation, Genetic Analysis|"Key variables that will be recorded include the following:~* Clinical~  * Age~ * Gender~ * BMI~ * Diabetes Mellitus~ * Hypertension~ * Heart Failure~ * Ischemic Stroke / TIA~ * Thromboembolism~ * Coronary Artery Disease~ * Peripheral Arterial Disease~ * Glomerular Filtration Rate~* Contrast-enhanced MRI~  o Presence and extent of atrial fibrosis~* Biomarkers~  * IL-6~ * CRP~ * D-dimer~ * Fibrinogen~* Transthoracic Echocardiography~  * LA Volume Index (LAVI)~ * LA Strain, Global~ * LA Strain rate, Positive peak, Global~ * LA Strain rate, early negative peak, Global~ * LA Strain rate, late negative peak, Global~ * LA Emptying Fraction (LAEF)~ * LVH~ * LVEF~* Endothelial function o FMD"
223775788|NCT03167294|DEVICE|AquaBeam System|Aquablation
223686765|NCT04622982|OTHER|Multidisciplinary treatment of obesity (diet + vitamin D + exercise + psychotherapy)|"Body weight reduction was induced by a low-energy mixed diet (55 % carbohydrates, 30 % lipids and 15 % proteins) providing 600 kcal less than individually estimated energy requirements based on the measured REE. The energy content and macronutrient composition of the diets adhered to the nutritional recommendations of the American Diabetes Association.~Patients were administered vitamin D supplement only if they presented a value of 25-hydroxyvitamin D (25OHD) \<30 ng/ml in blood tests at the beginning.~Patients were following an individualized physical activity plan within the hospital and were aided by a psychodynamic approach therapist."
223686766|NCT00450112|DEVICE|Gel-200|Single Intra-articular Injection
223775789|NCT01170897|DRUG|PEGPH20|PEGylated Recombinant Human Hyaluronidase
223775790|NCT06294002|OTHER|Dynamic neuromuscular stabilisation group|DNS group protocol involved 5 min a moderate intensity warm-up, 40 minutes of DNS movements according to the DNS approach, different diaphragmatic breathing, mobility and controlled movement exercises and 5 minutes of cool-down. Exercises gradually increased in complexity and difﬁculty level regarding DNS training principles. The participants were instructed to refrain from engaging in high-intensity anaerobic or anaerobic resistance training throughout the study period to prevent potential disruptions in the study results.
223775791|NCT06294002|OTHER|Whole body vibration group|WBV was performed on the Power Plate Next Generation vibration platform (Power Plate North America, Chicago, IL). All training routines were approximately 50 minutes long, commencing with 5 minutes of moderate-intensity warm-up and concluding with a cool-down period. The program consisted of 8-10 static and dynamic exercises for PS that progressively increased in difficulty and complexity. During the training process, the frequency increased from 20 to 35 Hz in the last week of the experiment; the exercise duration was from 20 - 60 seconds (in the previous week), followed by 1-minute seated rest. Moreover, the complexity and difficulty of exercise increased over the experimental period. The resting period between sets was constant from the start to the end of the training process. During the experiment, the WBV intervention group performed three weekly training sessions.
223775792|NCT06294002|OTHER|Dynamic neuromuscular stabilisation with whole body vibration group|The MIX group underwent a two-month training program consisting of three weekly sessions, including a 50-minute exercise program with a 5-minute warm-up and cool-down period. The training included 20 minutes of WBV and 20 minutes of DNS training, following previous research and training recommendations. VIBRO exercises were performed on the Power Plate Next Generation vibration platform, with 6-8 exercises for balance and PS. Participants were advised not to engage in high-intensity anaerobic or anaerobic resistance training. The training protocol was adapted from previous research.
223775793|NCT01807273|OTHER|Walking test|
223775794|NCT03898245|DEVICE|apply tDCS|Intensity 2mA, 20minues, 4 times (post operation in 30min, in 4hrs, next day morning and next day afternoon) anodal tDCS applied over the left DLPFC cathodal tDCS applied over the right DLPFC
223775795|NCT03898245|DEVICE|Sham tDCS|Intensity 0mA, 40 seconds, 4 times (post operation in 30min, in 4hrs, next day morning and next day afternoon) anodal tDCS applied over the left DLPFC cathodal tDCS applied over the right DLPFC
223775796|NCT00131287|DRUG|Extract of Agaricus blazei Murill|
223775797|NCT03951129|PROCEDURE|hemodialysis catheter insertion|The State-Trait Anxiety Inventory (STAI) and Visual Analogue Scale (VAS) scoring will be performed after informing all groups and after the procedure
223775798|NCT01416805|BEHAVIORAL|Computerized Cognitive Behavioral Therapy|Those who choose to participate will be enrolled in the 14 week study (18 weeks for phase II). They will required to attend 3 assessments - pre-treatment (week 0), mid-treatment (week 8), and post-treatment (week 14) (and a 4th assessment for a 1 month Follow-up for Phase II at week 18). This group will follow the CCBT protocol (Camp Cope-A-lot), which is the computer-assisted intervention for anxious children being examined in this study. The first 6 levels of this program are skill building levels to be completed by the user in his/her own home. The remaining 6 levels are completed with the therapist and consist of exposure tasks and rehearsal geared toward each child.
223775799|NCT01416805|BEHAVIORAL|Treatment as usual|Those who choose to participate will be enrolled in the 14 week study (18 weeks for phase II). They will required to attend 3 assessments - pre-treatment (week 0), mid-treatment (week 8), and post-treatment (week 14) (and a 4th assessment for a 1 month Follow-up for Phase II at week 18). Those in this group will not receive the CCBT, and instead will undergo therapy for their anxiety as they usually would, whether by using medication or working with a therapist.
223775800|NCT05169294|OTHER|Telerehabilitation Program|Telerehabilitation program: Intervention will be applied by video interview for eight weeks, 3 days a week, 45 minutes a day through the Zoom application. The application is free and can be installed on desktop or laptop computers, tablets and smartphones. The content of the activities to be done for that session by phone call to the parent before the interventions; Information will be given about the preparations such as keeping the materials on the table, suitable environment for that week's session and camera angle. Instructions and tips for parent support during the intervention will be given before and during the session. Intervention will be focused on fine motor skills, handwriting skills and activities of daily life of the individuals.
223775801|NCT05169294|OTHER|Written Home Program|Home program: After the evaluations, the activities towards the determined goals will be communicated to the parents as a home program in written and electronic format. Instructions and key points for the correct implementation of the activities will be presented to the parent, both in writing and verbally; The parent will be able to send questions and receive feedback to the therapists over the phone at any stage of the eight-week home program intervention process. No intervention will be applied to the child through direct video calls.
223775802|NCT01813526|OTHER|Experimental Infant Formula|Nutritionally complete free amino acid-based medical food.
223686767|NCT03444987|GENETIC|Measurement of protein expression in tissues.|"The followings markers will be estimated in tissue~1. FAP, a marker of fibroblast activation, using quantitative real time polymerase chain reaction qRTPCR (mRNA level) and ELISA (protein level).~2. Markers of autophagy including LC3 and p62 using qRTPCR (mRNA level) and by immunohistochemical analysis.~3. Phosphorylated protein kinase B (pAKT) level by ELISA (protein level).~4. Markers of oxidative stress (Malondialdehyde as lipid peroxide) by a colorimetric method.~5. Reduced glutathione, an antioxidant marker by a colorimetric method"
223686768|NCT01451268|DRUG|Panobinostat|10mg upto 40mg Panobinostat dose escalation in consequent cohorts; frequency: three times a week, every week; duration: one year
223686769|NCT01451268|DRUG|Panobinostat|Start of Arm B after completion of Arm A; initial dose-level: one level below MTD of Arm A; 10mg upto 60mg Panobinostat dose escalation in consequent cohorts; frequency: three times a week, every other week; duration: one year
223686770|NCT03433027|DRUG|BB-401|BB-401 1.92ug/mL Intratumoral Injections, every week for up to 8 weeks
223686771|NCT01384643|DRUG|Propofol|Induction of anesthesia: Propofol 1 mg/kg, sufentanil 1.0-3.0 µg/kg and rocuronium 50 mg IV Maintenance of anesthesia (pre CPB): Propofol 120-600 µg ∙ kg-1 ∙ h-1 , sufentanil 0.15-0.3 µg ∙ kg-1 ∙ h-1, vecuronium 8-10 mg/h IV infusion Maintenance of anesthesia (during CPB): Propofol 120-600 µg ∙ kg-1 ∙ h-1 IV infusion Weaning from CPB: Sufentanil 50 µg IV Maintenance of anesthesia (post CPB): Propofol 120-600 µg ∙ kg-1 ∙ h-1 , sufentanil 0.15-0.3 µg ∙ kg-1 ∙ h-1, vecuronium 8-10 mg/h IV infusion Propofol infusion rate is titrated using bispectral index (40-60).
223686772|NCT04399174|DEVICE|US|
223686773|NCT05153473|DEVICE|Total Hip Arthroplasty Revision|Hip revision surgery is performed to repair an artificial hip joint (prosthesis) that has been damaged over time due to an infection, or due to normal wear and tear of the prosthetic hip. Revision surgery helps to correct the problem so the hip can function normally again.
223686774|NCT02433327|OTHER|PEWS - trigger tool|PEWS - trigger tool A PEWS tool is a simple physiological scoring system that can be calculated at the patient's bedside, using parameters, which can easily be measured. Both PEWS tool consist of 7 parameters to be measured, and each individual measuring result would provide the patient with a score from 0-4. The 7 scores should then be added together giving the total PEWS. The children included into the study will be monitored using one of the two different PEWS models. Both model includes measuring vital signs with different intervals according to the child's conditions. Underlying both PEWS tool are algorithms of action for intervention in the critically ill child, interprofessional guidelines and guidance for standardised monitoring.
223686775|NCT02433327|OTHER|RM - trigger tool|RM - trigger tool A PEWS tool is a simple physiological scoring system that can be calculated at the patient's bedside, using parameters, which can easily be measured. Both PEWS tool consist of 7 parameters to be measured, and each individual measuring result would provide the patient with a score from 0-4. The 7 scores should then be added together giving the total PEWS. The children included into the study will be monitored using one of the two different PEWS models. Both model includes measuring vital signs with different intervals according to the child's conditions. Underlying both PEWS tool are algorithms of action for intervention in the critically ill child, interprofessional guidelines and guidance for standardised monitoring.
223686776|NCT00573196|RADIATION|Far infrared|Far infrared radiation (5μm to 15μm wavelength)
223686777|NCT04428775|DRUG|ALZT-OP1a (cromolyn)|"1. Mast cell stabilizer~2. Neuroinflammatory microglial modulator~3. anti-inflammatory"
223775803|NCT04163393|PROCEDURE|Percutaneous Coronary Intervention|PCI with robotic assistance
223686778|NCT05428293|DRUG|A1: Ibuprofen/Acetaminophen Fixed dose combination oral suspension (Laboratorios Silanes S.A. de C.V.)|Formula : 100 mg/ 125 mg /5mL Pharmaceutical Form: Oral suspension Dosage: 5mL (100 mg/125mg) Administration way: oral
223686779|NCT05428293|DRUG|A2: Ibuprofen (Advil®, Pfizer S.A. de C.V.)|Pharmaceutical Form: oral suspension Formula: 2 g/100 mL Dosage: 5 mL(100 mg of Ibuprofen) Administration way: oral
223775804|NCT04163393|DEVICE|Percutaneous Coronary Intervention using R-One assistance|PCI with robotic assistance
223686780|NCT05428293|DRUG|A3: Acetaminophen (Tylenol®, from Janssen-Cilag, S.A. de C.V.)|Pharmaceutical Form: oral suspension Formula: 3.2 g/100 mL Dosage: 3.9 mL (125 mg) Administration way: oral
223686781|NCT03360825|DEVICE|TetraGraph|The TetraGraph is a dedicated neuromuscular stimulator / recorder intended to evoke, record, and analyze muscle action potentials during surgical procedures
223686782|NCT00258843|BIOLOGICAL|Inactivated Poliomyelitis vaccine|0.5 mL, intramuscular (IM)
223686783|NCT00258843|BIOLOGICAL|Inactivated Poliomyelitis vaccine|0.5 mL, IM
223686784|NCT03964844|OTHER|No intervention|No intervention
223686785|NCT05082610|DRUG|HMBD-002|IgG4 monoclonal antibody (mAb) targeting the V-domain immunoglobulin suppressor of T cell activation (VISTA) receptor.
223686786|NCT05082610|DRUG|Pembrolizumab|IgG4 mAb with high specificity of binding to the PD-1 receptor, thus inhibiting its interaction with PD-L1 and programmed cell death ligand 2 (PD-L2).
223686787|NCT05450978|DRUG|Lamotrigine|Anti-seizure concentrations
223686788|NCT05450978|DRUG|Levetiracetam|Anti-seizure concentrations
223775805|NCT04590755|BEHAVIORAL|Interactive father-child sessions and website|The Run Daddy Run intervention will consist of 5 (inter)active sessions for fathers and their children + 1 follow-up session, each session lasting 90 minutes. These sessions will be given to 8 groups of +- 13 families (fathers and their children), guided by 2 facilitators and will take place every 2 weeks, at a location in the neighborhood of fathers and children (e.g. school of the children). Additionally, a website will be available for the fathers and their children, with additional information about the project, tips and information about being active together (e.g. movement breaks, fundamental movement skills, etc.) and limiting screen time. In addition, fathers and their children will also log their goals on this website, and between two sessions (= a period of 2 weeks) they will be asked to keep track of their co-PA on this website, aiming to reach their goal.
223775806|NCT04959084|OTHER|Laser acupuncture therapy and pelvic floor training|The laser will be applied directly to the skin over acupuncture points and each point receive a shoot of 65 seconds followed by Pelvic floor exercises for 15 min.
223775807|NCT03976440|OTHER|Renal Replacement Therapy (RRT) start|At the discretion of the nephrologist, treatment modality will be selected among CVVH, CVVHDF or SLED. Whatever the RRT modality, the investigators will adopt RCA as the standard anticoagulation strategy
223686789|NCT05450978|DRUG|Oxcarbazepine|Anti-seizure concentrations
223686790|NCT04214249|PROCEDURE|Biospecimen Collection|Undergo collection of blood
223775808|NCT05438953|BIOLOGICAL|Vaccination with MVA vaccine ( IMVANEX® and JYNNEOS®)|Participant of these arm will receive 2 doses of MVA vaccine spaced 28 days apart
223686791|NCT04214249|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
223686792|NCT04214249|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
223686793|NCT04214249|PROCEDURE|Computed Tomography|Undergo CT
223686794|NCT04214249|DRUG|Cytarabine|Given via continuous IV infusion
223686795|NCT04214249|DRUG|Daunorubicin Hydrochloride|Given IV
223686796|NCT04214249|PROCEDURE|Echocardiography Test|Undergo ECHO
223686797|NCT04214249|PROCEDURE|Hematopoietic Cell Transplantation|Undergo HSCT
223686798|NCT04214249|DRUG|Idarubicin Hydrochloride|Given IV
223686799|NCT04214249|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
223686800|NCT04214249|BIOLOGICAL|Pembrolizumab|Given IV
223686801|NCT04214249|PROCEDURE|Punch Biopsy|Undergo a skin punch biopsy
223686802|NCT06138145|OTHER|Video|Different videos were shown for the generic and appeal groups. No videos were shown to the control or ink-pen incentive groups
223686803|NCT06138145|BEHAVIORAL|Survey|Survey about participant's demographics, information source trust, and clinical trials knowledge. Also includes question about whether the participant is interested in enrolling in the Pediatric Trials Notification System.
223686804|NCT03837522|DIAGNOSTIC_TEST|Procurement Biopsy: Frozen section|Frozen sections are prepared by freezing and slicing the tissue sample; importantly, they can be done in about 15 to 20 minutes. Frozen sections are done when an immediate answer is needed, but do not provide optimal quality.
223686805|NCT03837522|DIAGNOSTIC_TEST|Procurement Biopsy: Permanent section|Permanent sections are prepared by placing the tissue in fixative (usually formalin) to preserve the tissue, processing it through additional solutions, and then placing it in paraffin wax. After the wax has hardened, the tissue is cut into very thin slices, which are placed on slides and stained. The process normally takes several days.
223686806|NCT05488756|OTHER|Group 1|Physical therapy agents and isometric exercise training will be applied to the patients. These will be administered a combination of transcutaneous electrical nerve stimulation, ultrasound, a hot pack, and isometric training 3 times a week for 4 weeks by the physical therapist.
223686807|NCT05488756|OTHER|Group 2|Physical therapy agents and deep cervical flexor muscle training will be applied to the patients. These will be administered a combination of transcutaneous electrical nerve stimulation, ultrasound, a hot pack, and muscle training 3 times a week for 4 weeks by the physical therapist. Training of the craniocervical flexor muscles is going to be focused on the deep flexor muscles such as longus capitis and longus colli muscles, making neck flexion, not the head.
223686808|NCT05488756|OTHER|Group 3|Physical therapy agents and core stabilization training will be applied to the patients. These will be administered a combination of transcutaneous electrical nerve stimulation, ultrasound, a hot pack, and stabilization training 3 times a week for 4 weeks by the physical therapist. These exercises will be performed for 10 repetitions with 10 seconds of contraction and 5 seconds of relaxation.
223686809|NCT03906188|OTHER|LitEmotion|LitEmotion is a serious video game programmed for helping managing emotions. The experimental group will play during 3 weeks while the control group will not play. The sample will play during 21 days, one session daily, around 45 minutes. After the 21 sessions the group will stop playing during 3 weeks. Therefore, the scales are done three times. In the very beginning (before playing), 21 days after playing, and, finally, 21 days no playing.
223686810|NCT02889276|OTHER|Functional Resistance Training|Supervised group-based Functional Resistance Training
223686811|NCT02889276|BEHAVIORAL|Unsupervised activity|General activity to meet 150 minutes of moderate intensity activity per week
223686812|NCT02399007|DEVICE|Total Hip System made in China (SUN, CoCr, Duraloc, Marathon)|SUN Hip stem,CoCr Femoral Head,Duraloc Porocoat Sector acetabular shell,Marathon 10D polyethylene liner (ETO)
223686813|NCT02399007|DEVICE|Total Hip System made outside of China (Summit, CoCr, Duraloc, Marathon)|Summit Porocoat STD,CoCr Femoral Head,Duraloc Porocoat Sector acetabular shell,Marathon 10D polyethylene liner (ETO)
223686814|NCT00527670|PROCEDURE|Normal Controls|The control group will have small slivers of tissue removed from the skin and abdomen during surgery to compare genomic information.
223686815|NCT00527670|PROCEDURE|Recurrent Hernia|This group will have small slivers of tissue removed from the skin and abdomen during hernia repair surgery to find genetic proof of hernias being inherited.
223686816|NCT00752596|DRUG|Azimilide 2HCl|One tablet of 125 mg/day azimilide 2HCl, taken until the study is terminated
223775809|NCT04083989|OTHER|Integrative medicine-based multimodal treatment|Multimodal inpatient treatment program based on anthroposophic medicine, including individual and group psychotherapy, family therapy, art therapies and specific nursing applications such as embrocations, rhythmical massage and oil dispersion baths.
223686817|NCT00035347|DRUG|IV azithromycin|500 mg once daily
223686818|NCT00035347|DRUG|ceftriaxone|1 gram once daily for 2 to 5 days
223686819|NCT00035347|DRUG|oral azithromycin|2 x 250 mg once daily
223686820|NCT00035347|DRUG|IV levofloxacin|500 mg once daily
223686821|NCT00035347|DRUG|oral levofloxacin|500 mg once daily
223686822|NCT00064298|DIETARY_SUPPLEMENT|fruit and vegetable extracts|Given orally
223686823|NCT00064298|DIETARY_SUPPLEMENT|placebo|Given orally
223686824|NCT03286127|OTHER|specialized palliative care|specialized palliative care provided in different settings
223775810|NCT03830671|DRUG|18-month regimen containing 6 anti-TB drugs|Investigational regimen:3Am-Mfx-PZA-X-Y-Z/3Am3-Mfx-PZA-X-Y-Z/12 Mfx-PZA-X-Y-Z.X、Y、Z are the drugs susceptible or possibly susceptible to mycobacterial bacilli(The candidated drugs to be selected are:Cs-Cycloserine,Pto-Protionamide,Clr-Clarithromycin,PAS-sodium para-aminosalicylate,E-ethambutol,Bdq-Bedaquiline,Cfz-Clofazimine,Lzd-linezolid).The abbreviation of the name of each drug in the regimen is explained as follows: PZA-pyrazinamide，Am-Amikacin，Mfx-moxifloxacin）and the total duration of the regimen is 18 months
223686825|NCT04439565|GENETIC|movement|aortic dissection or aneurysm patients this is an observation cohort study about a Non-syndromic Familial Aortic Dissection without intervention.
223686826|NCT03016143|BIOLOGICAL|Allantoic Split Inactivated Seasonal flu Vaccine|Allantoic split inactivated seasonal influenza vaccine has been prepared on eggs and is made from inactivated parts of the following influenza virus strains: NIBRG-121xp (A/California/7/2009 (H1N1)v and А/PR/8/34 (H1N1)), NYMC X-217 (A/ Victoria/361/2011(H3N2) and А/PR/8/34 (H1N1)), NYMC BX-49 (B/Texas/06/2011 (Yamagata lineage) - like High Yield Reassortant (1:1:6) With B/Lee/40 NP, B/Panama/45/90 NS genes).
223686827|NCT03016143|BIOLOGICAL|VAXIGRIP|Vaxigrip - Seasonal Influenza, split virion, inactivated vaccine. Sanofi Pasteur Serial Number N3E681V
223686828|NCT06047184|DRUG|BEBT-209 capsules|BEBT-209 capsules, 25mg once daily, or 25mg, 50mg, 75mg, 100mg, 150mg each time, twice daily, were administered continuously for 3 weeks and discontinued for 1 week, and 4 weeks were used as a treatment cycle.
223775811|NCT00354926|BIOLOGICAL|AME-133v (LY2469298)|IV 4X weekly X 4
223775812|NCT02540239|DRUG|2L PEG|
223775813|NCT02540239|DRUG|2L PEG+simethicone|
223686829|NCT06047184|DRUG|Letrozole tablets|Letrozole tablets, 2.5mg each time, once a day for 4 weeks, 4 weeks as a treatment cycle.
223686830|NCT06047184|DRUG|Fulvestrant|Fulvestrant, injection, 500mg each time, 1 time on day 1 and day 15 of the first cycle, and once on the first day of each cycle from the second cycle, 4 weeks as a treatment cycle
223686831|NCT03614975|BIOLOGICAL|Flucelvax inactivated influenza vaccine|Participants randomized to this study influenza vaccine arm will receive Flucelvax inactivated influenza vaccine at baseline after the baseline blood draw is complete. (Provided that this vaccine is available clinically in time for the study.)
223686832|NCT03614975|BIOLOGICAL|Fluzone inactivated influenza vaccine|Participants randomized to this study influenza vaccine arm will receive Fluzone inactivated influenza vaccine at baseline after the baseline blood draw is complete. (Provided that this vaccine is available clinically in time for the study.)
223686833|NCT00466492|PROCEDURE|Sedation or no sedation during mechanical ventilation|No sedation to critically ill patients
223686834|NCT04042935|DRUG|Alpha Lipoic Acid|Stage II-IVB HNSCC patients receiving concurrent systemic therapy and radiation in the definitive, adjuvant, or palliative setting will receive ALA according to their prescribed dose level. ALA will be taken orally or per feeding tube. It will start 1 week prior to the start of CRT, continue on through CRT, and then continue for 2 weeks after the completion of CRT. Patients will be given dosing diaries to document date and time of each drug administration as well as any missed doses. They will also have weekly visits to report AEs and concurrent medications, have a history and physical exam, report VAS pain scores and OMAS scores, and fill FACT-HN surveys.
223686835|NCT01569464|DRUG|Rotigotine|"Transdermal patch containing Rotigotine formulated in an adhesive matrix. Subjects were to be treated with their optimal dose which consisted of one of the dose strengths below:~Rotigotine 1 mg /24 hr, Rotigotine 2 mg/ 24 hr, Rotigotine 3 mg/ 24 hr, One patch every 24 hours~7 weeks (titration plus maintenance)"
223686836|NCT01569464|OTHER|Placebo|"Placebo patches titrated from 1 mg/ 24 hr - 3 mg/ 24 hr or until effective or maximum dose was reached.~Placebo 1 mg/ 24 hr, Placebo 2 mg/ 24 hr, Placebo 3 mg/ 24 hr, one patch every 24 hours.~7 weeks (titration plus maintenance)"
223775814|NCT04803929|BIOLOGICAL|anti-ILT3 CAR-T|Autologous T cells genetically modified with anti-ILT3 CAR
223686837|NCT03551925|BEHAVIORAL|Treatment as Usual Plus Occupational Therapy|The IMeds consists of a three-step process that leads the client from the reflection of past performance, to goal setting, and onto strategy identification and implementation. This intervention guides the client through identifying strategies in the following six areas: altering the medication management activity, advocacy, assistive technology, environmental modifications, and securing refills on time (Schwartz et al., 2017).
223686838|NCT03551925|BEHAVIORAL|Treatment as Usual|A clinical pharmacist counsels participants on proper medication adherence.
223686839|NCT00296608|DRUG|fluorouracil|
223686840|NCT00296608|DRUG|leucovorin calcium|
223686841|NCT00296608|PROCEDURE|conventional surgery|
223686842|NCT00296608|RADIATION|radiation therapy|
223775815|NCT01804556|PROCEDURE|Myofascial trigger point injections on gastrocnemius muscle|On the first visit (T0), we record numeric rating scale (NRS), the frequency of cramps and insomnia severity index using questionnaires. Then we check trigger points of gastrocnemius muscle and inject lidocaine 1 \~ 2 ml each up to four points. One week later (T1) we record numeric rating scale (NRS), the frequency of cramps and insomnia severity index again, check trigger points, and if any, inject lidocaine. If the patient do not come, we get numeric rating scale (NRS), the frequency of cramps and insomnia severity index over the telephone. Two weeks after the first visit (T2), we repeat the procedure of the first visit (T0). And four weeks after the first visit (T3) we record numeric rating scale (NRS), the frequency of cramps and insomnia severity index through face-to-face interview or by telephone.
223775816|NCT06227780|OTHER|Alpha Auditory Entrainment|"Alpha Brainwave Entrainment (AAE) stimulus: starts at high theta range (7-Hz) through high alpha (13-Hz) in 2 Hz steps on a 500 Hz sine carrier tone~Target frequency: 10 Hz~Delivery: headphones/speakers"
223775817|NCT06227780|OTHER|Sham|"Sham stimulus: carrier tone alone~Target frequency: N/A~Delivery: headphones/speakers"
223775818|NCT01826500|OTHER|blood test|blood test
223775819|NCT05673720|DEVICE|active tDCS paired with active MBM|Active tDCS with a constant current intensity of 2 milli ampere( mA)will be applied for 20 minutes per session for 5 times via the Soterix 1x1 tDCS mini-CT Stimulator device with headgear and saline-soaked surface sponge electrodes. The meditation intervention will be applied simultaneously with tDCS for 20 minutes per session for 5 times by a recorded meditation.
223686843|NCT05956210|DEVICE|Evaluation of implementation regarding Philips Healthdot as monitoring device of hospitalized patients at one surgical ward|Hospitalized patients at one surgical ward will receive a Healthdot as monitoring device which will be used as primary monitoring after 3 months of preparation with education of hospital staff, improving infrastructure and training with application, activation and interpretation
223686844|NCT03687164|OTHER|Group Medical Visits|Patients will attend group medical visits in groups of 6 -10. Groups will have a set curriculum and patients will meet with the provider one on one to assess individual needs at each session.
223686845|NCT04983212|OTHER|periodontal control|patient were called and visited in the dentistry department and gingival sulcus were gentle probed to assess gingiva and peri-implant tissues status
223686846|NCT04144465|DRUG|NORADRENALIN|DRUG THAT IS IMPROVING TISSUE AND ORGAN PERFUSION
223686847|NCT04144465|DRUG|PHENYLEPHRINE|DRUG THAT IS IMPROVING TISSUE AND ORGAN PERFUSION
223686848|NCT04445116|DEVICE|Action Video Game Treatment|Endeavor™ is a digital, non-drug investigational treatment that is delivered through an action video game and is designed to target cognitive deficits in adolescence and young adults with pediatric onset MS.
223686849|NCT01025765|DRUG|Pioglitazone|Pioglitazone(30mg qd) for 4 weeks of run-in period and 8 weeks of combination treatment with Peginterferon alfa-2b (1.5/μg per kg) per week plus Ribavirin 1000-1200 mg/day (≥ 75 kg, 1200 mg; \< 75 kg, 1000mg).
223686850|NCT01025765|DRUG|Acarbose|Acarbose (50 mg/per meal) for 4 weeks of run-in period and 8 weeks of combination treatment with Peginterferon alfa-2b (1.5/μg per kg) per week plus Ribavirin 1000-1200 mg/day (≥ 75 kg, 1200 mg; \< 75 kg, 1000mg).
223686851|NCT01025765|DRUG|Metformin|Metformin (500 mg tid) 4 weeks of run-in period and 8 weeks of combination treatment with Peginterferon alfa-2b (1.5/μg per kg) per week plus Ribavirin 1000-1200 mg/day (≥ 75 kg, 1200 mg; \< 75 kg, 1000mg). From week 13, all the subjects will receive pegylated interferon alfa plus ribavirin for 40 weeks.
223775820|NCT05673720|DEVICE|sham tDCS paired with sham MBM|For sham stimulation, the electrodes will be placed in the same positions as for active stimulation, but the stimulator will only deliver 2 mA current for 30 seconds. The sham MBM intervention will be delivered via a CD player that will look identical in both active and sham MBM.
223775821|NCT00088296|PROCEDURE|Blood Draw|
223775822|NCT01856972|PROCEDURE|Instrument Assisted Soft Tissue Mobilization|IASTM treatment: will be performed with the sound assisted soft tissue mobilization tool #5. Patient will be placed in the prone position with the ankle in a relaxed position. The treating therapist will perform 10 scanning strokes in the caudal, cephalic, medial, lateral directions for a total of 40 strokes over the Gastrocnemius/Soleus complex. The therapist can then perform more concentrated strokes in areas noted by the therapist as tight, with a maximum treatment time of 5 minutes.
223686852|NCT03539224|DRUG|Dolutegravir (DTG)|DTG 50 mg tablet will be orally administered once daily with or without food upto 48 weeks
223686853|NCT03539224|DRUG|Lamivudine (3TC)|Lamivudine will be dispensed as 300 mg white, diamond shaped, scored, film coated tablets. It will be orally administered once daily with or without food upto 48 weeks.
223686854|NCT03932097|BEHAVIORAL|REAL Parenting|REAL Parenting digital intervention emphasizing parent-teen/young adult communication on drinking/risks of drinking/risks of alcohol abuse, with the addition of a communication component on the risks of nicotine and marijuana use, with the goal of reducing alcohol, nicotine and marijuana use in college students.
223686855|NCT03932097|OTHER|Active Control Materials|NIAAA materials on underage drinking for parents
223775823|NCT01856972|PROCEDURE|Rearfoot joint mobilization|A high velocity-low amplitude distractive thrust is directed at the talocrural joint. The procedure is performed with the patient in the supine position. The therapist interlaces hands over the dorsum of the foot with 5th digit placed on talus. The therapist slightly pronates and dorsiflexes the foot. Tension is taken up in a caudal direction until the soft tissue barrier is engaged. A distractive thrust is then applied. This is performed up to 2 times. If the therapist notes a cavitation, the patient is progressed to ROM exercises. If there is no cavitation is noted by the therapist the thrust mobilization is reapplied.
223775824|NCT01856972|OTHER|Static stretching/ROM exercises|Gastrocnemius stretch at wall 3 sets of 30 second holds. Soleus stretch at wall 3 sets of 30 second holds. Standing bilateral dorsiflexion on step x30 with full ROM. Standing bilateral plantar flexion on step x30 with full ROM.
223775825|NCT05389124|BEHAVIORAL|Partial abstinence from oral hygiene|One quadrant of the dentition will be protected from oral hygiene for 3 weeks.
223775826|NCT02304094|DRUG|methylprednisolone|the steroid group shall receive a single injection of 1 mL methylprednisolone \[40 mg\] and 1 mL 2% lignocaine
223775827|NCT02304094|OTHER|Manual manipulation|the manipulation group shall have the lesser MTPJs of the affected foot manually manipulated using a high velocity, low amplitude thrust technique
223775828|NCT05961293|DEVICE|NeuroGlove|NeuroGlove is a non-invasive device that provides peripheral somatosensory stimulation to the hand of a stroke victim during acute, subacute, or chronic phases of a stroke. NeuroGlove provides sensory stimulation in the forms of pneumatic puffs of air. There is some early evidence that early peripheral sensory stimulation may improve neurological outcomes following an ischemic stroke.
223686856|NCT06136442|DRUG|Atogepant|atogepant in real life in Italy
223686857|NCT02576769|OTHER|No intervention|
223686858|NCT04651101|DIAGNOSTIC_TEST|coronary angiography|extent of coronary artery disease in invasive coronary angiography
223686859|NCT02723318|BEHAVIORAL|Financial Coaching|One-to-one financial coaching intervention to support savings, income, and credit while reducing debt using available tools in the community development field.
223686860|NCT02723318|BEHAVIORAL|Access to Referrals to Social Services|
223686861|NCT02881333|GENETIC|Blood samples|
223686862|NCT04877873|BEHAVIORAL|Gait analysis pre- and post- surgery|None (observational)
223686863|NCT00017485|DRUG|HPPH|
223686864|NCT03533686|DEVICE|Adhear Bone Conduction System|Non-invasive bone conduction hearing device using adhesive
223686865|NCT03533686|DEVICE|Bone anchored hearing aid (BAHA)|Non-invasive bone conduction hearing device using a headband
223686866|NCT01585012|DEVICE|Cervical cap (Focus Touch™ Conception System)|Cervical cap
223686867|NCT00245583|DRUG|Topiramate|minimum does of 50mg/day
223686868|NCT00245583|DRUG|Placebo|matching tablet
223686869|NCT00205400|PROCEDURE|medical care delivery model|
223686870|NCT02587247|DRUG|TF2 antibody/68Ga-IMP-288|TF2 antibody coupled with 68Ga-IMP-288
223686871|NCT03657966|BIOLOGICAL|DCVAC/OvCa|activated dendritic cells (DCVAC/OvCa) for immune maintenance after chemotherapy
223686872|NCT03657966|DRUG|Standard of Care Chemotherapy|either carboplatin and gemcitabine or carboplatin and paclitaxel followed by DCVAC/OvCa
223686873|NCT03316183|OTHER|Perioperative and postoperative management|Cerebral oximetry informed perioperative management
223686874|NCT03419975|DRUG|TJO-002|Administrate the drugs for clinical trial one drop once daily at the same time (9 p.m. ± 1 hour) for a study eye
223686875|NCT03419975|DRUG|Latanoprost|Administrate the drugs for clinical trial one drop once daily at the same time (9 p.m. ± 1 hour) for a study eye
223775829|NCT03675659|DRUG|intra-articular injection|intra-articular injection with magnesium sulfate with four injections at weekly intervals
223686876|NCT01652911|DEVICE|Sernova Cell Pouch|The Cell Pouch™ is an implantable medical device for transplantation of donor islets for Type-1 diabetes as an alternative to the current standard of care using intraportal delivery of islets.
223686877|NCT03190642|DRUG|Methylprednisolone|Administration of 1000mg vs 125mg methylprednisolone preoperatively in orthognathic surgery.
223686878|NCT00676221|DRUG|Myfortic|"Mycophenolate Mofetil (Cellcept) discontinued at Baseline visit. Mycophenolate Sodium(Myfortic)commenced the following day at equimolar doses orally BID.~Cellcept 1000mg bid = Myfortic 720mg bid"
223686879|NCT01046760|BEHAVIORAL|Language Assessment|Patients underwent an assessment performed with School Performance Test, Syntactic Awareness Test and a Peabody Picture Vocabulary Test.
223686880|NCT02609997|PROCEDURE|Phacomulsification lens removal cataract surgery with single-piece Intraocular lens(IOL) implantation|The phacoemulsification lens removal cataract surgery is performed with single-piece IOL.During Phacoemulsification.
223686881|NCT02609997|PROCEDURE|Phacomulsification lens removal cataract surgery with three-piece Intraocular lens(IOL) implantation|The phacoemulsification lens removal cataract surgery is performed with three-piece IOL.During Phacoemulsification.
223686882|NCT02609997|DRUG|Subconjunctival dexamethasone|All patients received subconjunctival dexamethasone (2 mg) during surgery. Topical anesthesia, consisting of a single drop of 0.5% proparacaine (Alcaine, Alcon Laboratories), was administered three times at intervals of 5 minutes prior to surgery
223686883|NCT02609997|DEVICE|Viscoelastic materials|viscoelastic materials are used to protect corneal endothelial cells
223686884|NCT02609997|DRUG|proparacaine|0.5% proparacaine (Alcaine, Alcon Laboratories)
223686885|NCT00825851|DRUG|Transdermal nicotine patch|15mg/16h + 10mg/16h to be used 24h
223686886|NCT00825851|DRUG|Placebo patch|
223686887|NCT00825851|BEHAVIORAL|Smoking cessation|
223686888|NCT00825851|BEHAVIORAL|Continuous smoking|subjects smoke 20 cigarettes per day
223686889|NCT02545595|DRUG|Sugammadex 1 mg/kg|
223686890|NCT02545595|DRUG|Sugammadex 2 mg/kg|
223686891|NCT02545595|DRUG|Sugammadex 4 mg/kg|
223686892|NCT02414139|DRUG|Capmatinib|"Capmatinib was administered orally, at a dose of 400 mg on a continuous twice daily dosing schedule.~Capmatinib was administered to participants in Cohorts 1a, 1b, 2, 3, 4, 5a and 5b in a fasted state. For Cohorts 6.1. 6.2 and 7, capmatinib was administered either with or without food."
223686893|NCT01087697|DEVICE|Neo-Urinary Conduit|Implantation with the autologous Neo-Urinary Conduit
223686894|NCT01765660|BIOLOGICAL|Mesenchymal stem cells|Mesenchymal stem cells will be intravenously infused via a central venous catheter(at a dose of 1×10\^6 cells/kg, over 15 mins) every two weeks, four times for a cycle.
223686895|NCT01765660|BIOLOGICAL|Non-mesenchymal stem cells|Other second line drugs are taken.
223775830|NCT02744924|BEHAVIORAL|Physical activity intervention|"The intervention is comprised of 5 steps:~1. Goal setting: Over a step-counter (smartphone app) participants learn about their daily average step count. They are coached to set individual goals~2. Fitness assessment: To recommend suitable frequency and intensity of walking program using mapped trails~3. Structured walking groups: Promoted and communicated via app. Participants can additionally organize walking groups of their own.~4. Feedback: Participants will see individual and group data over the step-counter app, and they can communicate with others via a communication app. They will be incentivized to reach goals through a gamification approach.~5. Invite friends: After 12 weeks, participants are encouraged to invite people who fulfil the inclusion criteria to join the project"
223686896|NCT03174249|BEHAVIORAL|Exposure therapy|Daily training at an in-patient ward during four plus four weeks, separated by a home training period of 6-8 weeks.
223686897|NCT05325710|BEHAVIORAL|Study nurse intervention|Contact everay 4 months with a dedicated study nurse
223686898|NCT00101829|DRUG|Rituximab|1000 mg intravenous infusion
223686899|NCT03712254|DRUG|Fosphenytoin|Patients with trigeminal neuralgia that due to acute exacerbations of trigeminal neuralgia pain are admitted for fosphenytoin loading are the subjects of interest.
223686900|NCT05272644|BEHAVIORAL|surface electromyographic biofeedback assisted pelvic floor muscle training|participants will be doing surface electromyographic biofeedback assisted pelvic floor muscle training for 2 months
223686901|NCT05272644|BEHAVIORAL|surface electromyographic biofeedback and electrical stimulation|participants will be doing surface electromyographic biofeedback and electrical stimulation assisted pelvic floor muscle training for 2 months
223686902|NCT03631355|DRUG|Tranexamic Acid|One gram of intravenous tranexamic acid will be administered before tourniquet inflation and 1 gram of IV TXA before closure of the incision.
223686903|NCT05942859|DIAGNOSTIC_TEST|Artificial Intelligence and Machine Learning technology|Artificial Intelligence describes computer software designed to mimic human cognitive function. Machine learning is a type of artificial intelligence in which the model created is exposed to data, identifies patterns, and recognises relationships between features seen in the data and the 'ground truth'. This technology will be applied to participants ECGs.
223686904|NCT02837081|OTHER|Prospective audit strategy of antimicrobial stewardship|applying prospective audit as a different strategy of antimicrobial stewardship
223686905|NCT02837081|OTHER|preauthorization strategy of antimicrobial stewardship|applying preauthorization as one strategy of antimicrobial stewardship
223686906|NCT03900962|OTHER|Home-based resistance training|"Patients completed two home-based resistance training sessions each week on non-consecutive days for 12 weeks. The programme was delivered online via individual playlists on Youtube (YouTube, San Bruno, California, USA), with each playlist involving an individually-prescribed series of pre-recorded exercise videos. Each session involved a dynamic warm-up followed by 11 resistance exercises using body weight and resistance bands, and finished with static stretching. Participants completed 1-2 sets of 5-12 repetitions at 4-7 on a modified 10-point rating of perceived exertion scale, which corresponded to qualitative descriptors of moderate to hard. Resistance training stimuli were progressed weekly by increasing the external load, modifying the exercise selection, increasing the number of repetitions, and/or increasing the number of sets."
223686907|NCT03900962|OTHER|Walking intervention|After the initial baseline assessment, participants recorded the number of steps they walked daily for seven days using a waist-worn pedometer. Participants maintained their usual physical activity levels during this period. Participants were then encouraged to increase their total steps walked each day by 5% each week during the 12-week intervention.
223686908|NCT04063527|DRUG|adjuvant chemotherapy|combination of paclitaxel and carboplatin
223686909|NCT03711227|DIAGNOSTIC_TEST|Procalcitonin lab test|A procalcitonin order bundle will be created for admitted patients with pneumonia. This prepopulated bundle includes an initial and 24 hour procalcitonin level.
223686910|NCT03291171|BEHAVIORAL|MyPlan 2.0|MyPlan 2.0 consists of five sessions. During these five sessions the following behaviour change techniques are used to motivate users to be more physically active or to sit less: exploring risk perceptions and perceived benefits, exploring social support, providing feedback, action planning, coping planning and monitoring.
223686911|NCT03230669|OTHER|cbt4cbt|This arm receives treatment as usual and in addition are given access to an online therapy, cbt4cbt. If placed in this group, individuals are asked to use the online therapy for a minimum of 30 minutes each week for the trial duration of 8 weeks.
223686912|NCT04036643|RADIATION|PET-MRI|Hybrid PET / MRI machine for simultaneous acquisition of functional and molecular information of different natures coupled with the high anatomical resolution of MRI.
223686913|NCT00951782|DEVICE|High frequency TMS|deep TMS HADD coil
223686914|NCT00951782|DEVICE|Sham TMS|sham deep TMS HADD coil
223775831|NCT05476003|PROCEDURE|Ultrasound-guided Bilateral superficial cervical plexus block|"This nerve block is typically performed in the supine or semi-sitting position, with the head turned slightly away from the side to be blocked to facilitate operator access.~Under strict aseptic condition, the linear ultrasound transducer should be placed on the lateral neck, overlying the sternocleidomastoid muscle at the level of its midpoint (approximately the level of the cricoid cartilage). Once the sternocleidomastoid muscle has been identified, the transducer is moved posteriorly until the tapering posterior edge is positioned in the middle of the screen.~Once the plexus has been identified and using In-Plane approach, the needle is passed from medial to lateral through the skin, platysma and investing layer of deep cervical fascia and the tip is placed adjacent to the plexus.~Following negative aspiration, 1 mL of local anesthetic is injected to confirm the proper injection site. The remainder of the local anesthetic (5ml) is administered to envelop the plexus."
223775832|NCT05476003|DRUG|Midazolam|All patients will be premedicated with Midazolam (0.02mg/Kg).
223775833|NCT02879838|OTHER|Blood sample|Biobank. Analysis of cytokines and DNA polymorphisms
223775834|NCT06321705|DRUG|CS1|CS1 delayed release capsules will be supplied with 160 mg active pharmaceutical ingredient (API) per capsule. Three dose levels will be administered in this expanded access study at the same dose the patient received in the parent study (CS1-003) of 480 mg, 960 mg, or 1920 mg. All patients will later have the option to be titrated to the most efficacious and safe dose determined from the ongoing CS1-003 study when completed.
223775835|NCT00153101|DRUG|Telmisartan|
223775836|NCT00153101|DRUG|Combination of Telmisartan and Ramipril|
223775837|NCT00153101|DRUG|Ramipril|
223775838|NCT01739322|BIOLOGICAL|Prick test Platanus acerifolia allergen extract|"This is an open, unblinded and non randomized biological as proposed by the Nordic Guidelines.~Four concentrations of Platanus acerifolia allergen extract, together with a positive and negative control, using 10 mg/ml histamine dihydrochloride solution and a glycerinated phenol saline solution, respectively, will be tested in every patient in duplicate on the volar surface of the forearm. This test will be referred to as the Titrated Skin Prick test."
223686915|NCT00951782|DEVICE|Low frequency TMS|Deep TMS - HADD coil
223686916|NCT01113047|DRUG|Aliskiren/Amlodipine and Aliskiren/Amlodipine/HCTZ|Aliskiren 300 mg / Amlodipine 10 mg/HCTZ 12.5 mg
223686917|NCT02797054|BEHAVIORAL|Tailored educational materials|The tailored intervention will use participants' baseline survey responses to generate tailored educational messages about the HPV vaccine. These educational messages will reflect the top concerns indicated by the participant about the HPV vaccine. Additional tailoring will occur in the form of images matched to self-reported race and age, and using participants' first name in the information presented.
223775839|NCT03030612|DRUG|ARGX-110|ARGX-110 will be administered intravenously.
223775840|NCT03030612|DRUG|AZA|AZA will be administered subcutaneously/intravenously.
223775841|NCT02678611|DIETARY_SUPPLEMENT|Basis 250|
223775842|NCT02678611|DIETARY_SUPPLEMENT|Basis 500|
223775843|NCT02678611|DIETARY_SUPPLEMENT|Placebo|
223775844|NCT02610140|DRUG|Anetumab ravtansine (BAY94-9343)|Starting dose: 6.5 mg/kg administered as IV infusion over 1 h every 3 weeks until disease progression or treatment withdrawal for any reason. Dose reductions are permitted.
223775845|NCT02610140|DRUG|Vinorelbine|Starting dose: 30mg/m\^2 administered as an IV infusion over 6 to 10 min every week until disease progression or treatment withdrawal for any reason. Dose reductions are permitted per standard practise.
223686918|NCT02797054|BEHAVIORAL|Untailored educational materials|"The untailored intervention will present educational information on the iPad that is not responsive to participants' baseline questionnaire answers and instead is derived directly from the HPV Vaccine Information Sheet that has been created by the Centers for Disease Control and Prevention."
223686919|NCT02797054|BEHAVIORAL|Usual care|Those in the usual care arm will be provided with a paper version of the Post Intervention Survey. This will be provided to participants after their clinic visit is completed.
223686920|NCT00457964|DRUG|RAD001|5 and 10 mg/day or 30, 50, 70mg/week
223686921|NCT06423989|COMBINATION_PRODUCT|IVIG|treatment of subfertility
223686922|NCT02717377|BEHAVIORAL|physical activity|
223686923|NCT04644783|DIAGNOSTIC_TEST|Blood test assay|Participants will have their blood drawn and be evaluated with a new blood assay that screens a large number of foods (more than 20) in a culture plate. Participants will be asked to eat the identified safe foods by the the blood assay.
223686924|NCT05546801|OTHER|questionnaire|questionnaire on postnatal development
223686925|NCT00291733|DRUG|Levetiracetam|500mg (2 tabl of 250) for one week and 1000mg (4 tabl of 250) for one week
223686926|NCT00291733|DRUG|Placebo|Placebo tabl
223686927|NCT00602745|DRUG|S-1|oral administration
223686928|NCT00602745|DRUG|5-Fluorouracil|intravenous bolus
223686929|NCT01369485|DEVICE|(VERV™ System)|Active electrode patches are worn for 12 weeks, one per week. The patch is placed by the subject. All subjects will have access to active patches for 9 months after the sham-controlled 12-week portion of the study is complete.
223686930|NCT01369485|DEVICE|Sham version of (VERV™ System)|Inactive (sham) electrode patches are worn for 12 weeks, one per week. The patch is placed by the subject. All subjects will have access to active patches for 9 months after the sham-controlled 12-week portion of the study is complete.
223686931|NCT01363414|DRUG|0.18% sodium hyaluronate|one drop of preservative-free, hypotonic 0.18% sodium hyaluronate in one eye
223686932|NCT01363414|DRUG|0.9% sodium chloride solution|one drop of sterile 0.9% sodium chloride solution in the other eye
223686933|NCT05832476|OTHER|No intervention|No intervention
223686934|NCT04955860|OTHER|Dental model analysis|No interventional treatment intervention will be made for individuals. Digital dental models taken for orthodontic recording will be examined.
223686935|NCT01747018|BIOLOGICAL|Platelet-rich Plasma|
223686936|NCT00416728|DRUG|Aliskiren|
223686937|NCT00416728|DRUG|Valsartan|
223686938|NCT02048579|BEHAVIORAL|Behavior Therapy + Motivational Interviewing|
223686939|NCT00943943|DRUG|G-CSF|10 microgram/kg subcutaneous injection based on adjusted ideal body weight and administered in the evening (prior to the Plerixafor). The 1st dose on day -1 and every other day for 7 total doses. G-CSF administration of 7 every-other-day doses will be repeated every 28 days.
223686940|NCT00943943|DRUG|Plerixafor|A fixed dose of 240 mcg/kg subcutaneous injection in the abdomen, calculated on ideal body weight. The 1st dose on day -1 and every other day for 7 total doses. Plerixafor administration of 7 every-other-day doses will be repeated every 28 days.
223686941|NCT00943943|DRUG|Sorafenib|"First dose will be given right after G-CSF and plerixafor injections. Drug doses will be separated by intervals of approximately 12 hours (+/-2 hours).~Dose Level 0 = 400 mg orally twice daily."
223686942|NCT02699216|DEVICE|Electrical Stimulation of the Retina|Transpalpebral micro-current electrical stimulation treatment for 3 consecutive days followed by a short wash-out period of 2 days.
223686943|NCT03280043|PROCEDURE|Hematoma|Hematoma requiring return to operating room.
223686944|NCT01847911|OTHER|Self instructed video learning|A complete video lesson of neonatal resuscitation including initial resuscitative maneuvers and administration of ventilation with a SIB and a T-piece resuscitator presented in the primary language of the participating center or university (Spanish or English). A portable kit with a newborn mannequin will be provided for independent video guided practice during the session.
223686945|NCT01847911|OTHER|instructor training|a pre-validated OSCE neonatal resuscitation program
223686946|NCT04178356|OTHER|Proprioceptive Neuromuscular Facilitation Training|The Proprioceptive Neuromuscular Facilitation Training will be performed using patterns and techniques in various positions for abdominal and back muscles' facilitation and strengthening. Supine, side-lying, and sitting positions will be used. There will be a rest of about 20 sec between sets. Warm-up for 10 min, main exercises for 25 min, cool-down for 10 min (a total of 45 min), 5 times a week for 4 weeks.
223775846|NCT05337501|OTHER|Collecting data|Anamnesis, clinical examination, Quantitative Sensory Testing (following DFNS, German Research Network on Neuropathic Pain, protocol), visual TOJ (Temporal Order Judgement) task
223775847|NCT03374124|DIAGNOSTIC_TEST|sinonasal outcome test-22|Evaluate the nasal mucosal inflammation condition and overall quality-of-life of CRS patients
223775848|NCT00151645|DRUG|activated lymphocytes|
223775849|NCT02589119|DRUG|MSC-AFP|Eligible patients will be treated with a fistula plug that has been coated with autologous mesenchymal stromal cell.
223775850|NCT03169153|DEVICE|Lotrafilcon B contact lenses|Silicone hydrogel contact lenses used as per their Conformité Européenne (CE) marking
223775851|NCT03169153|DEVICE|Senofilcon C contact lenses|Silicone hydrogel contact lenses used as per their Conformité Européenne (CE) marking
223775852|NCT00000601|DRUG|estrogen replacement therapy|
223775853|NCT00000601|DRUG|estrogens|
223775854|NCT00000601|DRUG|progesterone|
223775855|NCT00000601|DRUG|hormone replacement therapy|
223775856|NCT02928692|DRUG|Minocycline|
223775857|NCT02928692|DRUG|Placebo|
223775858|NCT04509531|BEHAVIORAL|Wise Intervention (SA, ITP and resilience)|The intervention will be based on four general types of change strategies: (1) scientific knowledge, (2) generation of new meanings, (3) commitment through action, and (4) active reflection. This will include activities such as reading scientific information about social behavior and its role in people's well-being and mental health, the meaning of online victimization experiences and ways to react to them, experiences of other young people of their age, and self-persuasion exercises that involve an active commitment to change. Furthermore, it provides a number of strategies to manage everyday conflicts among adolescents. This intervention teaches them new ways to manage these difficulties through different actions (relaxation, distraction, sports, etc.). Finally, they are asked to plan the strategies they will use in the future in the face of some difficulties and to recommend some guidelines for another adolescent who may be going through a similar situation.
223775859|NCT04509531|BEHAVIORAL|Standard preventive intervention|The control intervention will involve scientific information and education about internet risks such as sexting and grooming.
223775860|NCT05855629|DIETARY_SUPPLEMENT|Oral Lactobacillus Rhamnosus, D-chiro-inositol, Inulin Capsule|Lactobacillus Rhamnosus 1,5 х 10\*9, Inulin 25mg, D-chiro-inositol 250mg
223775861|NCT05855629|DRUG|Topical Adapalene, Benzoyl Peroxide Gel|Adapalene 1mg/g, Benzoyl Peroxide 25mg/ml
223775862|NCT03176108|BEHAVIORAL|Cognitive Behavorial Therapy (CBT)|Cognitive Behaviorial Therapy (CBT)
223775863|NCT03176108|BEHAVIORAL|Body mediation|Body mediation (theatre)
223775864|NCT05350293|OTHER|Molded abutment|"The waxed plastic abutment will dismantle, wedged, and poured using a Ni-Cr mixture then it will be trimmed to make it ready to make the permanent restoration over it.~The prostheses will be cemented above the abutment using dual-cure resin cement then the final restoration (crown and abutment) will be fixed using a screw-retained manner."
223686947|NCT04178356|OTHER|Control Group|Ultrasound, TENS, massage, and exercise will be used with each other because in most of the physical therapy clinics these modalities are used together for such problems as a conventional treatment. After massage application, hamstring and paravertebral muscles stretching and also stabilizing exercises will be prescribed, each one for ten times in each session.
223686948|NCT01609101|DEVICE|C-MAC ® videolaryngoscope|C-MAC ® videolaryngoscope
223686949|NCT01609101|DEVICE|Coopdech® videolaryngoscope|Coopdech® videolaryngoscope
223686950|NCT01609101|DEVICE|McGrath® Series 5 videolaryngoscope|McGrath® Series 5 videolaryngoscope
223686951|NCT01609101|DEVICE|Glidescope® Cobalt videolaryngoscope|Glidescope® Cobalt videolaryngoscope
223686952|NCT01609101|DEVICE|King Vision® videolaryngoscope|King Vision® videolaryngoscope
223686953|NCT01609101|DEVICE|Venner® videolaryngoscope|Venner® videolaryngoscope
223686954|NCT01609101|DEVICE|McGrath® MAC|McGrath® MAC (Aircraft Medical, Edinburgh, UK)
223686955|NCT03869827|OTHER|necrotizing enterocolitis|Collection of necrotizing enterocolitis diagnosis, as well as its severity, are based on the classification of Belle modified in 3 stages: 1) Suspected, 2) Proven, 3) Advanced
223686956|NCT04783142|OTHER|High-fiber, low-protein diet|Diet will consist of at least 15g fiber above baseline and less than 10% of calories from protein.
223686957|NCT04783142|OTHER|Low-fiber, high-protein diet|Diet will consist of less than 15g fiber and greater than 18% of calories from protein
223686958|NCT00003950|DRUG|cyclosporine|
223686959|NCT00003950|DRUG|CPT-11|
223686960|NCT04950114|DRUG|GFB-887|GFB-887 is a potent, small molecule inhibitor of TRPC5.
223686961|NCT04043780|DEVICE|Decompression prototype splint for carpal tunnel syndrome|This group will wear during 6 weeks a decompression prototype splint. They we be informed to wear it as long as possible during the 6 weeks.
223686962|NCT04043780|DEVICE|Standard splint for carpal tunnel syndrome|This group will wear during 6 weeks a standard splint. They we be informed to wear it as long as possible during the 6 weeks.
223686963|NCT01358773|OTHER|multidisciplinary intervention|Comparison of the polysomnography results, blood collection parameters, resting metabolic rate values, body composition variables, carotid artery thickness values, abdominal and subcutaneous fat and lung function variables baseline, middle and at the end of the one year of interdisciplinary weight loss program combined exercise training with physiotherapy, clinical, nutritional and psychological therapies.
223686964|NCT05638477|BEHAVIORAL|Free-viewing eye tracking|Participants will watch 20 minutes of video clips while their eye movements, pupil size and blink rate are recorded
223686965|NCT01522586|DRUG|DWP09031|DWP09031 50mg/100mg/400mg/200mg/800mg/1200mg/1600mg/2000mg single dosing
223686966|NCT01522586|DRUG|Placebo|placebo comparator 50mg/100mg/400mg/200mg/800mg/1200mg/1600mg/2000mg single dosing
223686967|NCT05641675|DIAGNOSTIC_TEST|right heart catheterization|Connect to a heart monitor to record heart rate, blood pressure and blood oxygen levels Place sterile sheets on chest and neck (or groin area) Clean the skin over the neck or groin Give local anaesthetic to numb the area (this may sting a little when it is given) Gently pass a catheter into a vein to the heart Record pressure readings from the heart chambers and lungs Give medication, depending on heart's pressure readings Remove the catheter and apply pressure where it was inserted
223686968|NCT02962154|RADIATION|Coronary CT Angiography|The coronary CT angiography will assess for coronary artery stenosis, plaque characteristics, calcifications, and other factors.
223686969|NCT02962154|OTHER|Mood Symptom Scale|"Some or all of the following questionnaires will be conducted to assess mood symptoms:~Beck Depression Inventory, Hamilton Depression Rating Scale (24-item), Montgomery Asberg Depression Rating Scale (MADRS), Mood and Anxiety Symptom Questionnaire (MASQ), QIDS, Young Mania Rating Scale"
223686970|NCT02962154|OTHER|Anxiety Symptom Scale|"Some or all of the following questionnaires will be conducted to assess anxiety symptoms:~Beck Anxiety Inventory, Spielberger State/Trait Anxiety Inventory (STAI), GAD-7 Anxiety Questionnaire, Penn State Worry Questionnaire (PSWQ)"
223686971|NCT02962154|OTHER|Chronic Stress Inventories|"Some of all of the following questionnaires will be conducted to assess chronic stress:~Chronic stress inventories: Cohen Perceived Stress Scale, Holmes and Rahe Stressful Life Events Scale, Karasek Job Strain Questionnaire, Conner-Davidson Resilience Scale, PTSD Checklist"
223686972|NCT02962154|OTHER|Psychosocial Function Questionnaires|"Some of all of the following questionnaires will be conducted to assess psychosocial function:~Type A Personality Scale, NEO Personality Inventory, Positive and Negative Affect Schedule (PANAS), Behavioral Inhibition/Behavioral Approach Scale (BIS/BAS)"
223686973|NCT02962154|OTHER|General Health and quality of life questionnaires|"Some of all of the following questionnaires will be conducted to assess quality of life:~EQ-5D Health Questionnaire, Seattle Angina Questionnaire, International Index of Erectile Function (ILEF-5), Pittsburgh Sleep Quality Scale, Morningness Eveningness Questionnaire"
223686974|NCT02962154|OTHER|Magnetic Resonance Imaging|First, subjects will undergo a resting cardiac MR perfusion study to establish baseline (pre-stress) measures of cardiovascular function. Second, subjects will undergo a series of brain magnetic resonance imaging studies (T1-weighted anatomical MRI, diffusion tensor imaging, resting state functional MRI) to establish baseline (pre-stress) measures of brain function and structural correlates. Third, investigators will use a well-validated cognitive task to induce mental stress by testing subjects' working memory for a series of emotionally arousing or neutral images, while repeating the functional MRI scan. Finally, subjects will undergo a repeat cardiac MR perfusion study while being tested on the same mental stress task.
223686975|NCT03276819|PROCEDURE|Samples collection|OPML biopsy or resection, biopsy of normal oral mucosa, surgical specimen of HNSCC, saliva samples, buccal brushes, blood samples
223775865|NCT05350293|OTHER|3D printed abutment|A marker or Scan body appropriate for the type of implant will be placed on the laboratory implant substitute, a digital scan of the marker will be done in the lab, and the scanned image will be transferred to a computer design software where the prosthesis is designed, In the printing phase, the final prosthesis will be manufactured using a stepwise metal powder supply and a laser fusion process. Making the abutment ready to make the permanent restoration over it. The prostheses will be cemented above the abutment using dual-cure resin cement then the final restoration (crown and abutment) will be fixed using a screw-retained manner.
223775866|NCT01492140|PROCEDURE|Subdermal Injection|Injection of dermal filler
223775867|NCT01492140|DEVICE|Artiste Assisted Injection System|The Artiste™ Assisted Injection System is an air-powered device used to assist clinicians in injecting fluids into the body. The Artiste System was designed specifically to assist in the delivery of dermal fillers for the aesthetic correction of facial wrinkles, folds, and scars.
223775868|NCT00887341|DRUG|tocilizumab [RoActemra/Actemra]|8mg/kg iv every 4 weeks for 6 infusions; first infusion 1h duration, subsequent infusions 31 minutes duration
223775869|NCT00887341|DRUG|tocilizumab [RoActemra/Actemra]|8mg/kg iv every 4 weeks for 6 infusions; each infusion 1h duration
223775870|NCT05264805|DRUG|0.25% Bupivacaine|20ml of 0.25% Bupivacaine subcutaneous infiltration at port site wound.
223775871|NCT06408285|DRUG|TQC3927 powder for inhalation|TQC3927 is a targeted inhibitor.
223775872|NCT06408285|DRUG|TQC3927 powder for inhalation placebo|TQC3927 powder for inhalation placebo contains no active substance.
223775873|NCT00224159|BEHAVIORAL|Drug and Dietary behavior|
223775874|NCT01336127|BEHAVIORAL|Occupational Therapy|Patients in the experimental group will receive 10 weeks (maximum 16 hours) occupational therapy according to a treatment protocol, which is based on the Dutch evidence based guideline for occupational therapy in Parkinson's Disease and refined for this study.
223775875|NCT02264834|DRUG|Levobupivacaine 0.1% + Sufentanil 0.2µg/ml|Levobupivacaine 0.1% + Sufentanil 0.2µg/ml
223775876|NCT02264834|DRUG|Levobupivacaine 0.07% + Sufentanil 0.3µg/ml|Levobupivacaine 0.07% + Sufentanil 0.3µg/ml
223775877|NCT02264834|PROCEDURE|Lumbar epidural analgesia|Introduction of a catheter in lumbar epidural space
223775878|NCT02774109|DIETARY_SUPPLEMENT|Fish oil|Five 1000mg fish oil soft capsules per day (each capsule containing 350mg EPA and 250mg DHA) for 8 weeks
223775879|NCT02774109|DIETARY_SUPPLEMENT|Placebo|Five 1000mg sunflower oil soft capsules per day for 8 weeks
223775880|NCT02774109|PROCEDURE|Hotpacking|Hotpacking 15min on low back, three times a week for 8 weeks
223775881|NCT02774109|PROCEDURE|Transcutaneous electrical nerve stimulation (TENS)|Transcutaneous electrical nerve stimulation (TENS) 15min on low back, three times a week for 8 weeks
223775882|NCT01169324|OTHER|Alteration of DBS stimulator settings|Alteration of DBS stimulator settings
223686976|NCT03276819|BEHAVIORAL|Psychological and Sociological evaluation|Cohort B ....
223686977|NCT03276819|BEHAVIORAL|Intensive and sustained smoking cessation program|Evaluation of efficacy of the smoking cessation program (intensive and sustained versus minimal)
223686978|NCT03276819|BEHAVIORAL|Tobacco and alcohol status follow-up|Evaluation of the tobacco and alcohol status all along the study (questionnaires)
223686979|NCT02319356|DIETARY_SUPPLEMENT|Beetroot juice|(BRJ, containing NO3-, 6.2 mmol/day, administered as 500ml Beet it Sport Shots, James White drinks, Ipswich uk)
223686980|NCT02319356|DIETARY_SUPPLEMENT|Placebo beetroot juice|(PL, NO3-depleted beetroot juice, administered as 500ml Placebo Beet it Sport Shots, James White drinks, Ipswich uk)
223775883|NCT01470755|DRUG|salbutamol|Metered dose inhaler, 100µg+300µg per puff, administered one day
223775884|NCT01470755|DRUG|Salbutamol - dose2|Metered dose inhaler, 100µg+500µg per puff, administered one day
223775885|NCT01470755|DRUG|Salbutamol -dose3|Metered dose inhaler, 200µg+600µg per puff, administered one day
223775886|NCT01470755|DRUG|salbutamol -dose4|Metered dose inhaler, 200µg+200µg per puff, administered one day
223775887|NCT03103620|DEVICE|COBRA PzF Coronary Stent System|COBRA PzF Coronary Stent System
223775888|NCT02885233|BEHAVIORAL|Free From Falls Online|Subjects in the active group will participate in the Free From Falls Online Program consisting of 8 weekly 30 minute webinars providing education about risk factors for falls and fall prevention strategies; self-assessment exercises to evaluate understanding of the material; video-based exercise program targeting balance, posture, strength and flexibility to be performed at least 3 times per week; supplementary, downloadable printed material for both education and exercise; and a social forum to allow participants to interact with each other.
223775889|NCT02885233|BEHAVIORAL|Waitlist Control|"Subjects in the waitlist control condition will receive an educational brochure developed by the National Multiple Sclerosis Society called Minimizing Your Risk of Falls: A Guide for People with MS, which includes information on identifying risk factors for falling and fall risk management approaches with no exercise component; will inform their provider that they have fallen at least twice in the previous 2 months and discuss subsequent falls over the course of the 5-month study; and will be invited to participate in the Free From Falls Online Program at study completion."
223775890|NCT02362399|DRUG|sildenafil citrate|single oral dose of 50 mg
223775891|NCT02362399|OTHER|placebo|single oral dose of placebo tablet
223775892|NCT04369027|DIAGNOSTIC_TEST|passive leg raising|"passive leg raising: to raise the legs of the patients by adjusting the angle of the patient's bed during one minute.~Tidal volume challenge: an increas by 2ml/Kg of the tidal volume during one minute"
223775893|NCT02323191|DRUG|Atezolizumab|Participants will receive atezolizumab intravenously at a fixed dose of 1200 milligram (mg) q3w.
223686981|NCT05730816|DRUG|Magnesium sulfate|Intravenous infusion of magnesium sulfate prior to intraoperative chemotherapy with cisplatin.
223686982|NCT05730816|DRUG|Normal Saline|Intravenous infusion of normal saline.
223686983|NCT02765776|OTHER|Observational retrospective cohort to describe RAL data|"This is an observational retrospective cohort in real world to describe RAL data, including NUC-sparing regimens, in aged HIV patients.~In this retrospective analysis all naïve patients on raltegravir-based regimens and all patients switched to raltegravir-based regimens will be considered. For raltegravir-based regimens the investigators mean raltegravir as third agent in a triple regimen with NRTIs and also raltegravir-based regimens in NUC-sparing therapies. Data will be collected from medical records. The Time horizon for patient follow-up for outcome is at least 12 months."
223686984|NCT06404424|DEVICE|Efferon LPS|"Efferon LPS, a medical device, which is a single-use cartridge filled with a polymeric adsorbent that selectively adsorbs endotoxin via surface-immobilized ligand and excessive cytokines via its intrinsic porosity.~This device is routinely used for extracorporeal therapy of sepsis to improve hemodynamic function and abrogate septic shock.~Plasma exchange procedures will be carried out with a replacement volume of 2 plasma volumes with fresh frozen plasma and albumin solution.~Each patient is scheduled to undergo two separate hemoperfusions lasting 8-10 hours within 48 hours.~60 minutes before the start of hemoperfusion, additional administration of antimicrobial drugs is performed, taking into account their elimination during plasma exchange and adsorption"
223686985|NCT06404424|DEVICE|Efferon CT|"Efferon CT, a medical device, which is a single-use cartridge filled with a polymeric adsorbent that adsorbs excessive cytokines via its intrinsic porosity.~This device is routinely used for extracorporeal therapy of cytokine storm syndrome in the course of severe SARS-CoV-2.~Plasma exchange procedures will be carried out with a replacement volume of 2 plasma volumes with fresh frozen plasma and albumin solution.~Each patient is scheduled to undergo two separate hemoperfusions lasting 8-10 hours within 48 hours.~60 minutes before the start of hemoperfusion, additional administration of antimicrobial drugs is performed, taking into account their elimination during plasma exchange and adsorption"
223686986|NCT00190515|DRUG|5FU+l-leucovorin|5FU+l-leucovorin
223686987|NCT00190515|DRUG|UFT+Leucovorin|UFT+Leucovorin
223686988|NCT00989690|DRUG|docetaxel|
223686989|NCT00989690|DRUG|erlotinib hydrochloride|
223686990|NCT00989690|DRUG|pemetrexed disodium|
223686991|NCT00989690|GENETIC|fluorescence in situ hybridization|
223686992|NCT00989690|GENETIC|mutation analysis|
223686993|NCT00989690|GENETIC|proteomic profiling|
223686994|NCT00989690|OTHER|immunohistochemistry staining method|
223686995|NCT00989690|OTHER|laboratory biomarker analysis|
223686996|NCT00989690|OTHER|matrix-assisted laser desorption/ionization time of flight mass spectrometry|
223686997|NCT00989690|PROCEDURE|breath test|
223686998|NCT03978715|OTHER|No intervention-retrospective study|This is a retrospective study. No intervention
223686999|NCT02034422|DIETARY_SUPPLEMENT|Oral Antioxidant|Consisting of vitamins C, E and alpha lipoic acid.
223687000|NCT02034422|OTHER|Exercise rehabilitation|8 weeks of exercise rehabilitation
223687001|NCT05596396|BEHAVIORAL|LifeHack|Participants assigned to LifeHack will follow a six week-guided online intervention with a fixed structure where the themes are delivered in a predefined order, and the contents get unlocked sequentially. The first mandatory module is the introduction module which also functions as a goal-setting module. Following this, students complete one mandatory module per week (and the optional modules if they choose to do so) delivered sequentially, starting with the theme of mood, studies, social life and finally, self-esteem. Students complete the themes one by one and the consecutive themes (and modules) are unlocked only after completing the main module of the assigned theme.
223687002|NCT05596396|BEHAVIORAL|LifeHack-C|Participants assigned to LifeHack-C will receive the same guided online intervention, but they can choose what theme they would like to start with, when to work on it and how many modules they wish to complete. After completing the introduction module, the participants will be advised to complete two modules per week and at least four in total. Therefore, the program's duration will be approximately two and six weeks. However, participants can follow the program at their own pace.
223687003|NCT01511185|DRUG|liraglutide|A single dose of 7.5 mcg/kg administered subcutaneously in random order
223687004|NCT01511185|DRUG|placebo|A single dose administered subcutaneously in random order
223687005|NCT03088215|DEVICE|shock-waves|Application of shock-waves (radial and focused)
223687006|NCT02780323|DRUG|CELBESTA®|1 tablet of CELBESTA® and 1 tablet of CELEBREX® placebo, twice daily for 6 weeks
223687007|NCT02780323|DRUG|CELEBREX®|1 tablet of CELEBREX® and 1 tablet of CELBESTA® placebo, twice daily for 6 weeks
223687008|NCT02780323|DRUG|CELEBREX® placebo|1 tablet of CELBESTA® and 1 tablet of CELEBREX® placebo, twice daily for 6 weeks
223687009|NCT02780323|DRUG|CELBESTA® placebo|1 tablet of CELEBREX® and 1 tablet of CELBESTA® placebo, twice daily for 6 weeks
223687010|NCT02577783|DRUG|PDD regimen: doxorubicin hydrochloride iposome, bortizomib and dexamethasone|doxorubicin hydrochloride iposome (duomeisu) plus bortizomib (velcade) and dexamethasone (disaimisong)
223687011|NCT02577783|DRUG|PAD regimen: bortizomib, dexamethasone and doxorubicin|doxorubicin (duoroubixing) plus bortizomib (velcade) and dexamethasone (disaimisong)
223687012|NCT04552730|DRUG|Cenegermin-Bkbj|Topical Cenegermin-bkbj 6 times per day for 8 weeks.
223687013|NCT01525173|DRUG|0.1% brimonidine tartrate ophthalmic solution|1 drop of 0.1% brimonidine tartrate ophthalmic solution 3 times per day for 12 weeks.
223687014|NCT01525173|DRUG|0.01% bimatoprost ophthalmic solution|1 drop of 0.01% bimatoprost ophthalmic solution once per day for 12 weeks.
223687015|NCT01525173|DRUG|0.2% hypromellose lubricant eye drops|1 drop of 0.2% hypromellose lubricant eye drops 3 times per day for 12 weeks.
223775894|NCT02323191|DRUG|Emactuzumab|Participants will receive emactuzumab intravenously in ascending dose levels with a starting dose of 500 mg.
223775895|NCT05754086|BEHAVIORAL|Clear Speech|"This behavioral modification asks participants to speak more clearly, as if they were speaking to someone with a hearing loss."
223775896|NCT05754086|BEHAVIORAL|Less Clear Speech|"This behavioral modification asks participants to speak less clearly, as if they were in a room with many people and they were mumbling something to the person next to them that they didn't want other people in the room to hear."
223775897|NCT04995380|PROCEDURE|Early Cholecystectomy|Cholecystectomy performed within 10 days from onset of symptoms
223687016|NCT01525173|DRUG|latanoprost 0.005% ophthalmic solution|1 drop of latanoprost 0.005% ophthalmic solution once daily as run-in therapy for 30 days only.
223687017|NCT04673084|DEVICE|negative pleural suction|by comparing the effect of water seal alone of chest tube in one groups of trauma patients and the effect of both water seal and suction in other group
223687018|NCT03268473|OTHER|Experimental|Experimental: Non-surgical periodontal therapy in patient with OSAS and Periodontitis
223687019|NCT03268473|OTHER|Control|Control: Non-surgical periodontal therapy in Periodontitis
223687020|NCT03706222|DRUG|elbasvir/grazoprevir|Comedications during elbasvir/grazoprevir will be recorded and analyzed for potential drug-drug interaction.
223687021|NCT04706416|DIETARY_SUPPLEMENT|N-acetyl glucosamine (NAG)|Patients with novel coronavirus (COVID-19) will be treated with N-acetylglucosamine (NAG) (700 mg every 12 hours) as first-line treatment for 30 days, along with standard of care.
223687022|NCT04706416|OTHER|Control|Patients do not receive treatment with N-Acetylglucosamine. They may receive other treatments at the discretion of the treating physician, as with the treatment group.
223687023|NCT04478331|BEHAVIORAL|Technology-based physical activity interventions|The technology groups will receive a PA program for 12 weeks. These PA programs will be given twice a week and include: 5-10 minutes of warm-up, 20-40 minutes of aerobic exercise and muscle strengthening via circuit training composed of 8-10 exercises with 8-12 repetitions per exercise for 2-3 series, and 5-10 minutes of stretching. In addition, advice and counseling will be given about walking activities to achieve the recommendations.
223687024|NCT05294536|DRUG|Liraglutide injection,RD12014|single dose, s.c. injection
223687025|NCT05294536|DRUG|Liraglutide injection,Victoza|single dose, s.c. injection
223687026|NCT01733849|OTHER|Stool sample|Samples will be tested to determine the presence or absence of rotavirus.
223687027|NCT01733849|OTHER|Data collection|Log books
223687028|NCT04594954|DIETARY_SUPPLEMENT|Diet|A high-protein low carbohydrate diet (HPLC) diet would be prescribed to the patients. HPLC (high-protein low carbohydrate) diet would comprise of energy as 20-25 Kcal/Kg IBW/day (amounting to 700- 800 Kcal less than the usual dietary intake), Protein as 1.2-1.5 gm/Kg IBW/day i.e. 30% of the total calories as proteins, 52% of carbohydrates 18% of fats with dietary fiber as 25 g/day. The protein requirements would be met with modular high protein, low calorie supplements.
223687029|NCT04594954|OTHER|FMT|"Stool Administration Procedure (ILBS FMT Protocol)~* 500 mL filtrates will be delivered through the UGI Endoscopy into proximal jejunum \[(2 to 3 minutes per 50 ml).\]~* The recipient will be kept nil per oral for at least 4 hours prior to the stool instillation.~* 100 mL freshly thawed sample will be given once in 15 days for 3 doses~* Non-absorbable antibiotics will be avoided in the patient from the time of enrollment into the study and therapy initiation.~* Intravenous antibiotics will be continued as per institutional protocol in the event of active sepsis based on culture and sensitivity.~* The patient will be allowed to consume liquid diet two hours after the procedure."
223687030|NCT04594954|OTHER|Physical Activity|"Physical Activity:~The exercise program would consist of brisk walking. Brisk walking is defined as the walking intensity of 60-70% of their respective age-predicted maximum heart rate (target heart rate) 27,28. Speed of 5- 6 kmph considered as a brisk walking in most of the studies preferably on a treadmill for a duration of 30-45 minutes30 or brisk walking (walking faster than normal pace, measure 5000 steps continuously by pedometer). Same amount of physical activity would be prescribed to both the groups for 5 days a week for 30 -45 min."
223687031|NCT05091502|DIAGNOSTIC_TEST|Personalised musculoskeletal modeling|Magnetic resonance images, electromyography and dynamometry data will be used to develop personalised musculoskeletal models
223687032|NCT03455049|OTHER|Andrographis Paniculata Ext|Give the Androgaphis paniculata in prediabetes and normal subject for 14 days.
223687033|NCT00775385|DRUG|Standard Chemotherapy|Pemetrexed Cisplatin Schedule : CDDP 75 mg/m² D1, pemetrexed 500 mg/m² D1 D1=D21, 4 cycles
223687034|NCT00775385|DRUG|Customized Treatment|"Mutated EGFR : Erlotinib 150mg/day (1 year)~Wild-type EGFR or undetermined depends on ERCC1 status :~* ERCC1 high : no treatment~* ERCC1 low or undetermined : Pemetrexed Cisplatin, 4 cycles (63 days)"
223687035|NCT00425633|DRUG|Homeopathic Potassium Dichromate|5 pellets under tongue q12h until extubation
223687036|NCT00238537|DRUG|Alteplase t-PA|
223687037|NCT04385407|DRUG|Sofosbuvir + Simeprevir + Ribavirin|
223687038|NCT06207565|PROCEDURE|Vestibular Flap Group|Achieving the vestibular flap, a 1-cm long horizontal vestibular access incision using a 15c blade 3-4mm apical to the mucogingival junction of the hopeless tooth, exposing the alveolar bone. Flap dissection in a coronal direction to detach the periosteum is completed, forming a sub-periosteal tunnel.
223687039|NCT06207565|PROCEDURE|Single Flap Approach group|A modified envelope flap originally reported as an access flap for single implant insertion in areas of esthetic relevance will be performed. A sulcular incision on the labial aspect extending at least one tooth mesial and distal to the implant site (permitting enough accessibility for bone augmentation) is done. The flap is reflected by performing a split-thickness flap elevation starting from the interproximal incisions, leaving the anatomical papillae in situ. While the full-thickness flap elevation is performed on the labial aspect of the included surgical area, starting at the sulcus, and reaching at least 3 mm apical to the bone crest.
223687040|NCT04432220|DRUG|Anticoagulation group(Apixaban group)|Apixaban 5mg twice daily (2.5mg twice daily if meets dose-reduction criteria) for 2 years
223687041|NCT03014492|DEVICE|Q Collar|Collar designed to mitigate slosh in the brain
223687042|NCT00249158|DRUG|Risperidone|
223687043|NCT05261451|OTHER|Workshop|Participants will engage in three 1 hour workshops about trauma informed care. They will complete pre and post measure before engaging in the workshops
223687044|NCT06403631|OTHER|observational|Data will be gathered longitudinally from participants newly diagnosed with multiple sclerosis. Participants will fill in online questionnaires measuring flow, mindfulness, positive mental health, anxiety and depression. The questionnaires, including both scaled and open-ended questions, will be proposed at the project start (T1) and 6 months later (T2).
223775898|NCT02752997|OTHER|Pharmacist discharge medication services|Included in arm descriptions
223687045|NCT01736332|DRUG|Vicks VapoInhaler|2 inhalations each nostril every 2 hours for 6 doses on day 1, one dose on morning of day 2
223687046|NCT01736332|OTHER|Poppy seeds|45 g in liquid at 9 am and 5 pm on day 1
223687047|NCT04140136|DIETARY_SUPPLEMENT|Tocotrienols|Tocotrienols as a potent antioxidant to modulate oxidative stress and inflammatory response
223687048|NCT04140136|DIETARY_SUPPLEMENT|Placebo|The placebo is similar in appearance, but does not contain tocotrienols and consist of palm oil
223687049|NCT02903212|BIOLOGICAL|Autologous apoptotic cells injection|cells injection
223687050|NCT04891731|DRUG|AI or TAM|This is an observational study, the researcher will describe the ratio of E2 control between leuprorelin plus TAM or leuprorelin plus AIs patients based on the actual clinical use.
223687051|NCT01539317|DRUG|Topical liquid lidocaine|active intervention drug numbs the hypersensitive mucosa of the vulvar vestibule
223687052|NCT01539317|DRUG|Topical saline|saline applied to the vestibule mucosa will not reverse the local tenderness
223687053|NCT04705363|BEHAVIORAL|High Dialectal|A virtual health assistant that will consist of an interactive computer-generated doctor with voice that used high dialectal variation that will guide participants through the interaction.
223687054|NCT04705363|BEHAVIORAL|Low Dialectal|A virtual health assistant that will consist of an interactive computer-generated doctor with voice that used low dialectal variation that will guide participants through the interaction.
223687055|NCT04705363|BEHAVIORAL|Non-Dialectal|A virtual health assistant that will consist of an interactive computer-generated doctor with voice that used no dialectal variation that will guide participants through the interaction.
223687056|NCT04705363|BEHAVIORAL|Text-only|A virtual health assistant that will consist of photos of the computer-generated doctor with text that will guide participants through the interaction. No voice will accompany the photos or text.
223687057|NCT01776385|OTHER|Blood sampling|Biological: ISET and CellSearch Methods Sampling of blood - ISET and CellSearch Methods
223687058|NCT01776385|OTHER|Control Group|Biological: ISET and CellSearch Methods Sampling of blood - ISET and CellSearch Methods
223687059|NCT04350398|OTHER|Hippotherapy|The horse is an excellent collaborator in situations of physical and mental disability, whether temporary or consolidated. It provides support to humans towards an impairment (anatomical or physiological), a disability, or a restriction of participation as defined by the WHO in 2001. Hippotherapy has a direct action on the sensorimotor capacities of the individual but also on their cognitive capacities, such as attention, memory, psychomotricity, emotions, perceptions, the sequencing of complex movements, or the experience of oneself and the functions of time. Overall, the strong demand from the sensitive, sensory and motor spheres promotes and interacts with the mechanisms linked to the execution of tasks in the cognitive domain (memory, attention, executive functions, speed of information processing, etc.) through the interactions of several neural networks.
223687060|NCT04350398|OTHER|Conventional therapy|Personalized care pathway after/during the cancer treatment takes into consideration all aspects of the disease, allowing to coordinate the intervention of the professionals that the patient might need in order to better preserve her quality of life while answering questions about cancer, prevention, treatments, or life after illness. The MIS mobilizes a chain of skills and support by providing patients: radiologists, pathologists, surgeons, oncologists, and radiation therapists, nuclear doctors, physiotherapists, cardiologists, psychologists, psychiatrists, nurses, social workers, nutritionists, dieticians, onco-geneticists, osteopaths, homeopaths, acupuncturists, sexologists, addictologists, algologists, and vascular physicians.
223687061|NCT01423149|DRUG|Combretastatin A-4 Phosphate|Combretastatin A-4 Phosphate is administered on Day 0 and Day 7 (+/- 2 days). If the treating ophthalmologist notes any leakage from CNV in the study eye on a fluorescein angiography during the study or an increase in subretinal fluid on an optical coherence tomography measurement, retreatment with Combretastatin A-4 Phosphate is recommended with up to 3 additional treatments. The retreatment visit(s) could occur during a scheduled visit or at an additional visit 1 week after a regular study visit. A post-retreatment follow-up visit is necessary.
223687062|NCT02531334|DIETARY_SUPPLEMENT|TA-65|2 pills of TA-65 or placebo daily for 12 weeks. Subjects will be monitored weekly for side effects and every 4 weeks for compliance and safety monitoring. The whole intervention is a randomized double blind study for a duration of 27 weeks; 12 weeks for TA-65 or placebo allocated randomly and after a 3 week washout period, allocation to the alternate supplement TA-65 or placebo.
223687063|NCT02117427|BIOLOGICAL|MDGN201 TARGTEPO|Erythropoietin secreted by TARGTEPO transduced with MDGN201
223687064|NCT02285660|PROCEDURE|4D PET-CT Scan|
223687065|NCT02285660|OTHER|No intervention|
223687066|NCT02730208|DRUG|Tezacaftor/Ivacaftor|TEZ 100 mg/IVA 150 mg fixed-dose combination tablet.
223687067|NCT02730208|DRUG|Ivacaftor|IVA 150 mg tablet.
223687068|NCT02730208|DRUG|Placebo|Placebo matched to TEZ/IVA fixed-dose combination tablet.
223687069|NCT02730208|DRUG|Placebo|Placebo matched to IVA tablet.
223687070|NCT01206673|OTHER|Blood sampling|One blood sampling is required for the research
223687071|NCT02890290|DIETARY_SUPPLEMENT|Marine Protein hydrolysate|The participants will take the supplement in form of tablets and will be instructed to take five tablets twice a day, preferably in relation to meals, however, not the dinner meal. Each tablet contains 300 mg of marine protein hydrolysates (Nx6.25). The tablets are produced by Flexipharma AS.
223687072|NCT02890290|DIETARY_SUPPLEMENT|Placebo|Placebo tablets will be made based on gum arabicum. The tablets are produced by Flexipharma AS.
223775899|NCT06158633|DRUG|Prevora|"Prevora Stage 1, a topical, intra-oral solution of chlorhexidine acetate 100mg/ml followed immediately by Prevora Stage 2 which is a topical solution of polymethylmethacrylate. Prevora Stage 1 and Prevora Stage 2 are applied topically using a small brush and sequentially to the teeth and gum line of the patient/participant.~All subjects will receive at total 4 applications of Prevora 1 and 2. One on Day 1, 14 days, 3 months and 4 months."
223687073|NCT02978131|OTHER|Histopathological study|
223687074|NCT02978131|OTHER|Molecular study (Polymerase chain reaction)|
223687075|NCT00245219|BEHAVIORAL|Education|The education group meetings focused on providing patients with information about their disease as well as methods to manage their illness and its side effects. Facilitators emphasized the theme of perceived control during all sessions, discussing how participants are in control of their illness experience and can have more control of their lives. A different topic was addressed in each session. Weekly homework assignments asked patients to write down something new they had learned from the session regarding how to take control of their lives. Meeting topics were as follows: Overview of breast cancer, treatment types and side effects, nutrition and diet management, exercise, body image, communication issues, relationships, and sexuality.
223687076|NCT00245219|BEHAVIORAL|Peer support|The peer support group meetings focused on fostering purpose in life by providing participants with opportunities to support and care for one another. Patients completed a weekly diary of critical experiences or current life problems as homework, and were then encouraged to share these experiences in the group meetings. The group facilitator encouraged participants to help one another with these issues, and share how they had dealt with similar problems.
223687077|NCT04641520|OTHER|Shoulder clinical testing with isokinetic strength assessment|All the participants had a shoulder clinical testing including shoulder rotators range of motion and isokinetic rotator muscle strength testing
223687078|NCT01827358|DRUG|Mupirocin calcium|Mupirocin calcium cream 2% applied topically to umbilicus and perianal area every 8 hours for 5 days, for a total of 15 applications
223687079|NCT01827358|DRUG|Mupirocin calcium|Mupirocin calcium ointment 2% will be applied intranasally every 8 hours for 5 days, for a total of 15 applications
223687080|NCT01687374|DRUG|1-84 parathyroid hormone|100 micrograms of 1-84 parathyroid hormone daily for 8 weeks, subcutaneous injection.
223687081|NCT01687374|DRUG|Placebo|Saline injection daily for 8 weeks.
223687082|NCT00510952|DRUG|Insulin Lispro Protamine Suspension|Patient adjusted dose, once daily (QD) or twice daily (BID), injected subcutaneous (SC) x 24 weeks
223687083|NCT00510952|DRUG|Insulin Glargine|Patient adjusted dose, once daily (QD), injected subcutaneous (SC) x 24 weeks
223687084|NCT03918668|BEHAVIORAL|Women with recent diagnosis of breast cancer|To evaluate dietary habits of a group of women with pre and post-surgical breast cancer
223687085|NCT03551262|DEVICE|OTSC|Positioning of OTSC in bleeding peptic ulcer
223687086|NCT03551262|DEVICE|TTS clip|Positioning of TTS clip in bleeding peptic ulcer
223687087|NCT03457233|DRUG|Gonadotropins|1\) Gonadotrophines is started on day 2 with HMG(merional, IBSA) ,until the day of HCG administration
223687088|NCT03457233|DRUG|GNRH antagonist|cetrorelix 0,25mg s.c is given using flexible protocol, it is given when at least one follicle reaches size 14 mm to prevent premature lutenization ,until the day of hCG administration
223687089|NCT03457233|DRUG|Human chorionic gonadotropin Chorimon|10000 IU of HCG are given intramuscular when 2 or more mature follicles reach 18 - 20 mm
223687090|NCT03457233|DRUG|Natural progesterone|400 mg vaginal tablets twice daily from the day of ovum pick up till HCG tesing
223687091|NCT00048893|BIOLOGICAL|recombinant fowlpox-CEA(6D)/TRICOM vaccine|4 x 10\^8 pfu given monthly subcutaneously for three doses in the first series and three doses on each of the intermediate and late re-immunizations (total 9 doses).
223687092|NCT00048893|BIOLOGICAL|recombinant vaccinia-CEA(6D)/TRICOM vaccine|rV-CEA (6D)/Tricom concomitantly with sargramostim (rGM-CSF). 1.2 x 10\^8 pfu x 1 dose subcutaneously.
223687093|NCT00048893|BIOLOGICAL|filgrastim|5 mcg/kg/day subcutaneously
223687094|NCT00048893|BIOLOGICAL|sargramostim|100 mcg daily for 4 consecutive days at the same site as the rF-CEA (6D)/Tricom vaccine. The first dose will be given with the vaccine.
223687095|NCT00048893|DRUG|cyclophosphamide|"First induction chemotherapy: 2700 mg/m\^2 per cycle (900 mg/m\^2 per day intravenous over 1 hour for 3 consecutive days, days 1-3).~Second induction: 600 mg/m\^2 per cycle (600 mg/m\^2 intravenous over 1 hour day 1.~Immune depleting chemotherapy: 2400 mg/m\^2 per cycle (600 mg/m\^2 per day intravenous over 1 hour for 4 consecutive days, days 1-4)."
223687096|NCT00048893|DRUG|doxorubicin hydrochloride|60 mg/m\^2 per cycle (60 mg/m\^2 slow intravenous push day 1).
223687097|NCT00048893|DRUG|fludarabine phosphate|120 mg/m\^2 (30 mg/m\^2 per day intravenous over 30 minutes for 4 consecutive days (days 1-4)).
223775900|NCT03089190|DIETARY_SUPPLEMENT|DC7-2|Effects on appetite
223775901|NCT03089190|DIETARY_SUPPLEMENT|DC7-2 + potato protein isolate|Effects on appetite
223775902|NCT03089190|DIETARY_SUPPLEMENT|Potato protein isolate|Effects on appetite
223775903|NCT03089190|DIETARY_SUPPLEMENT|Placebo|Inactive whey protein, not expected to affect appetite.
223775904|NCT00002980|DRUG|decitabine|
223775905|NCT04181710|PROCEDURE|Kidney transplant|Organ preserved in preservation solution
223687098|NCT00048893|DRUG|paclitaxel|160 mg/m\^2 per cycle (53.3 mg/m\^2 per day by continuous intravenous infusion over 24 hours for 3 consecutive days 1-3).
223687099|NCT00048893|DRUG|Mesna|"Percent equals fraction of total daily cyclophosphamide dose. Initial: 20% of cyclophosphamide dose given intravenously (IV) mixed with cyclophosphamide.~3 hours post completion of cyclophosphamide: 20% intravenously (IV) or 40% by mouth (PO) 6 hours post completion of cyclophosphamide: 20% intravenously (IV) or 40% by mouth (PO) 9 hours post completion of cyclophosphamide: 20% intravenously (IV) or 40% by mouth (PO)"
223687100|NCT02717845|DEVICE|Ellipse|diagnostic CT scan imaging
223687101|NCT02717845|DEVICE|Tomofix|diagnostic CT scan imaging
223687102|NCT02691962|DEVICE|Xen Matrix AB|Xen Matrix™ AB Surgical Graft is an acellular, sterile, non-pyrogenic porcine dermal matrix packed dry for use in the reconstruction of soft tissue deficiencies. The device surfaces are coated with the antibacterial agents Rifampin and Minocycline in a bioresorbable L-Tyrosine succinate polymer carrier.
223687103|NCT06330688|PROCEDURE|percutaneous cholecystostomy|PC is a minimally invasive, nonsurgical, image-guided intervention that aims to drain and decompress the gallbladder by placing a pigtail catheter through the abdominal wall into the gallbladder lumen.
223687104|NCT05806684|OTHER|ROP|Correlation between neonatal indirect bilirubin jaundice and ROP.
223687105|NCT02325856|DEVICE|Bioimpedance Spectroscopy|Bioimpedance Spectroscopy is a safe tool to evaluate the fluid status in hemodialysis patients.
223687106|NCT02325856|BEHAVIORAL|Clinical judgement|
223687107|NCT02054468|DRUG|Single-Shot Propofol|Single-shot propofol induction dose (1.5-2.5mg/kg body mass)
223687108|NCT02054468|DRUG|30min infusion Propofol|30min of propofol infusion (4-6mg/kg/h)
223687109|NCT02054468|DRUG|Remifentanil infusion|Remifentanil infusion (0.1-0.2µg/kg/min)
223687110|NCT02054468|DRUG|Rocuronium (0.07mg/kg/body mass)|Rocuronium (0.07mg/kg/body mass)
223687111|NCT02054468|DRUG|Rocuronium (0.1mg/kg/body mass)|Rocuronium (0.1mg/kg/body mass)
223687112|NCT02054468|DRUG|Rocuronium (0.15mg/kg/body mass)|Rocuronium (0.15mg/kg/body mass)
223687113|NCT02054468|DRUG|Rocuronium (0.2mg/kg/body mass)|Rocuronium (0.2mg/kg/body mass)
223687114|NCT02054468|DRUG|Rocuronium (0.3mg/kg/body mass)|Rocuronium (0.3mg/kg/body mass)
223687115|NCT02054468|DRUG|Rocuronium (0.45mg/kg/body mass)|Rocuronium (0.45mg/kg/body mass)
223687116|NCT01603238|DRUG|[14C]-LC15-0444|A single oral administration of \[14C\]-LC15-0444 50 mg, containing 4.9 MBq \[14C\]. Subjects in the fasted state will receive the drug as a capsule, with 240 ml of water.
223687117|NCT01604109|DRUG|10 % w/v CPP-ACP paste|Apply once a day at school by school teacher, following fluoride toothbrushing after lunch
223687118|NCT01604109|DRUG|the paste without CPP-ACP|Apply once a day at school by school teacher, following fluoride toothbrushing after lunch.
223687119|NCT02104973|BEHAVIORAL|Lifestyle counseling|We will intent to modify the diet of the children. The intervention is designed to promote the increase the intake of fruits and vegetables and to reduce the high density foods consumption.
223687120|NCT00138411|DRUG|Ciprofloxacin 500 mg|
223687121|NCT00138411|DRUG|ETI-204 (Anthim)|
223687122|NCT06336161|DRUG|Fentanyl|to compare between Ultrasound-Guided ESPB and Ultrasound-Guided CEI for postoperative pain relief in patients who underwent lumbosacral surgeries.
223687123|NCT00867477|PROCEDURE|Breathing Test|Exhale into NO breath analyzer for 10 seconds, repeated 3 times (before radiation therapy starts, after completing radiation therapy, and after scheduled PET scan).
223687124|NCT00867477|BEHAVIORAL|Respiratory Symptoms Questionnaire|3 page questionnaire about breathing and any symptoms experienced, at each of 2 NO breathing tests.
223687125|NCT00867477|PROCEDURE|Pet Scan|Between 40 and 50 days after the end of the radiation therapy. Ten (10) participants will receive a second PET scan within 2-7 days after the first PET scan in order to check reproducibility.
223687126|NCT05650528|DRUG|QG101-23-0 capsules|Single and Multiple Dose for oral
223687127|NCT05650528|DRUG|Placebo|Single and Multiple Dose for oral
223687128|NCT03624829|OTHER|Shared care|The intervention is an adapted version of shared care with close collaboration by services and professional groups, mainly localized in three GP centers. At each GP center one clinical psychologist specialist from the community mental health center (CMHC) works two and a half day a week, and a psychiatrist from the CMHC work at each GP center 1-2 hours a week. The psychologist and the psychiatrist are available for the GPs for consultation and discussions, and they give assessments and brief treatments to patients as requested by the GPs. Other primary health and social care and other specialized mental health or substance addiction services are involved or consulted according to needs of the patients.
223687129|NCT02355977|DRUG|minocycline|Periocline dental ointment
223687130|NCT02355977|PROCEDURE|surface and root planning|surface and root planning
223687131|NCT03469674|RADIATION|Vaginal brachytherapy|Internal radiation of the vaginal vault using a vaginal cylinder, 21 Gy in 3 out-patient sessions over 2 weeks
223687132|NCT03469674|RADIATION|External beam radiotherapy|External beam pelvic radiotherapy on a linear accelerator, 48.6 Gy in 27 out-patients sessions over 5.5 weeks
223687133|NCT03469674|OTHER|Observation|No radiation therapy, but active follow-up and quality of life questionnaires as in the groups who have adjuvant treatment
223687134|NCT02340273|DEVICE|Therapeutic ultrasound|Patients receive therapeutic ultrasound daily for 4 hours of continuous therapy at 3 megahertz (MHz) frequency and 0.132 Watts/cm2.
223687135|NCT02340273|DEVICE|Placebo therapeutic ultrasound|"Patients receive sham therapeutic ultrasound daily for 4 hours."
223687136|NCT03638843|PROCEDURE|Gastric mucosal devitalization|Gastric mucosal devitalization is an endoscopic procedure which uses argon plasma coagulation to result in selective damage to the gastric mucosa and submucosa.
223687137|NCT00320359|DRUG|Intravenous topotecan/cisplatin|"Topotecan 1 mg/m2 should be administered intravenously over a period of 30 minutes on days 1-5. Then a 30 minute saline flush should be administered followed by the cisplatin on day 5.~Cisplatin 75 mg/m2 given as an intravenous infusion at the rate of 1 mg/min on day 5 after topotecan."
223687138|NCT00320359|DRUG|Intravenous etoposide/cisplatin|"Cisplatin 75 mg/m2 given as an intravenous infusion at the rate of 1 mg/min on day 1. Cisplatin should be given simultaneously to post-hydration to ensure a high volume fluid.~Etoposide 100 mg/m2 should be administered after cisplatin intravenously over a period not less than 30 minutes on days 1 -3."
223687139|NCT02793128|DRUG|UGN-101 instillations|Treatment with UGN-101 once weekly for a total of 6 times; in a retrograde fashion. Patients who will demonstrate complete response (CR) will be treated with UGN-101 once monthly as a maintenance therapy for a total of 11 instillations or up to the first recurrence whichever comes first.
223687140|NCT03052543|DEVICE|BIS™ Complete 2--Channel Monitor|monitor depth of anesthesia
223687141|NCT00677430|BEHAVIORAL|Questionnaire|A brief questionnaire packet will be completed.
223687142|NCT00677430|PROCEDURE|Digital Imaging|Photographs of the breast(s) will be taken with two different types of digital cameras (2D and 3D). The photos will be used to develop automated methods for evaluating the appearance and shape of the breasts.
223687143|NCT01652300|BEHAVIORAL|two educational sessions|The test group had two educational sessions lasting 1 hour, focused on oral and dental health and especially on oral and dental health during pregnancy
223687144|NCT01652300|BEHAVIORAL|no education|women in the control group received no education
223687145|NCT05963893|BEHAVIORAL|Uni4Move to sit less and move more|Co-create and implement an action plan to move more and sit less in the university context
223687146|NCT04483687|DRUG|Filgotinib|Tablets administered orally once daily
223687147|NCT04483687|DRUG|Placebo to Match Filgotinib|Tablets administered orally once daily
223687148|NCT02850133|OTHER|aerobic exercise training|aerobic exercise training for 36 sessions within 12-16 weeks
223687149|NCT04075370|OTHER|Neuropsychological Testing|Measure cognition function and cognitive reserve in patients before, during and after radiation therapy using cumulative scores of Hollingshead Index, North American Adult Reading Test, HVLT-R, TMT A\&B and COWA over time.
223687150|NCT03843242|DEVICE|Pacemaker with Fixed long AV delay|Fixed AV delay was applied in the first 3 months of pacemaker implantation according to previously proposed definition.
223687151|NCT03843242|DEVICE|Pacemaker with VpS® algorithm on|"1. After first 3 months of pacemaker implantation, the patients will be randomized into two groups (Vp-suppression algorithm on group vs. IRS-plus algorithm on group) using a centralized randomization system.~2. In Vp-suppression algorhithm on group, Vp suppression algorithm of Enitra 8 DR-T pacemaker will be turned on at 3month visit after enrollment.~3. The patient will be followed at 3-month after enrollment and at 6-month and 12-month after applying the specific algorithm."
223687152|NCT03843242|DEVICE|Pacemaker with IRSplus algorithm on|"1. After first 3 months of pacemaker implantation, the patients will be randomized into two groups (Vp-suppression algorithm on group vs. IRS-plus algorithm on group) using a centralized randomization system.~2. In IRS-plus algorithm on group, IRS plus algorithm of Enitra 8 DR-T pacemaker will be turned on at 3 month visit after enrollment.~3. The patient will be followed at 3-month after enrollment and at 6-month and 12-month after applying the specific algorithm."
223687153|NCT04029532|DEVICE|Respiratory exchange ratio|Ask participants to supine on bed, using a ventilator hood cover upon their head. Measure respiratory exchange ratio for 15 minutes.
223687154|NCT04029532|DEVICE|Heart rate variability|Ask participants to supine on bed for 10 minutes, connect electrodes on their right wrist. Measure heart rate variability for 5 minutes.
223687155|NCT04029532|DEVICE|Body composition|Ask participants to supine on bed for 10 minutes, connect electrodes on their right wrist and right foot. Measure body composition.
223687156|NCT04029532|BEHAVIORAL|Eating behavior|Fill in questionnaire (Three-Factor Eating Questionnaire, revised 18-item, TFEQ-18).
223687157|NCT04029532|BEHAVIORAL|Physical activity recall|Fill in questionnaire (Seven-days Physical Activity Recall, 7-d PAR).
223687158|NCT04029532|BEHAVIORAL|Depression|Fill in questionnaire (Mongomery-Asberg Depression Rating Scale, MADRS).
223687159|NCT04029532|BEHAVIORAL|Body image|Fill in questionnaire (multi-directional self-body relationship questionnaire (MBSRQ), figure rating scale (FRS)).
223775906|NCT04148079|OTHER|physical therapy|low frequency currents (galvanic or TENS), medium frequency currents (interferential) and high frequency currents (short wave diathermy), all combined with an individualized exercise program and massage therapy
223775907|NCT00004327|DRUG|octreotide|
223687160|NCT02359851|BIOLOGICAL|Pembrolizumab|Given IV
223687161|NCT02359851|OTHER|Laboratory Biomarker Analysis|Correlative studies
223687162|NCT04533477|PROCEDURE|Reconstructing forked corpus spongiosum (FCS)|During the routine standardized surgery, the FCS should be cut off along both sides of the middle urethral plate before dissecting the glans wings and then dissected along the penile tunica albuginea closely from the near to the far side of the penis until the top of the penis head was reached. The corpus spongiosum on both sides will be reserved for the two wings of the glans. The two wings of the glans should be carefully expanded to at least the 3 o'clock and 9 o'clock positions of the penis. Some cases of small glans should be dissected to the 2 o'clock and 10 o'clock positions to close the two wings of the glans with no tension when performing glansplasty. Additionally, the original FCS on both sides should be combined at the coronal sulcus, thereby covering the surface of the new urethra.
223687163|NCT04533477|PROCEDURE|Routine standardized surgery|When the urethral plate can be preserved after degloving, the investigators chose the surgical method according to the width of the urethral plate. If the width of the urethral plate is ≥6 mm, tubularized incised plate (TIP) urethroplasty will be performed, whereas if the width of the urethral plate is \<6 mm, the onlay island flap (ONLAY) technique will be performed. When the urethral plate can not be preserved after degloving, transverse preputial island flap urethroplasty (Duckett) will be performed.
223687164|NCT01888003|DRUG|Iron sucrose|AMG patients will receive a standardized and well-accepted intravenous dose of 200 mg of iron sucrose (Venofer®) at -14 days and -7 days before their planned surgery, and if indicated, based upon laboratory testing on the day of their surgery (if patient has a Hgb \< 13.0 g/dL and hematocrit between 30% and 39%, for males and females). An additional dose will be given on postoperative day 2.
223687165|NCT01888003|DRUG|Epoetin Alfa|AMG patients will receive a standardized and well-accepted subcutaneous dose of 40,000 IU of epoetin alfa (PROCRIT®) plus an intravenous dose of 200 mg of iron sucrose (Venofer®) at -14 days and -7 days before their planned surgery, and if indicated, based upon laboratory testing on the day of their surgery (if patient has a Hgb \< 13.0 g/dL and hematocrit between 30% and 39%, for males and females).
223687166|NCT01888003|OTHER|Blood Transfusion|An evidence-based, goal-directed blood transfusion protocol will be applied in AMG, CTG, and NAG patients during and after their surgical procedure to control for health provider variation in transfusion criteria and practices. This blood conservation protocol will consist primarily of the application of a restrictive transfusion trigger (Hgb \< 8 g/dl) (21,22) but will also take into consideration the patient's intraoperative estimated allowable blood loss and hemodynamic stability.
223687167|NCT04993222|DRUG|Amphotericin B liposome for injection|IV infusion
223687168|NCT04993222|DRUG|AmBisome®|IV infusion
223687169|NCT00785967|BIOLOGICAL|Various vaccines|VAQTA: 1.0ml IM at weeks 24 \& 48; Pneumovax 23: 0.5ml IM at screening; Td ADSORBED: 0.5ml IM at screening; phiX174 bacteriophage: 0.02ml/kg body weight IV at weeks 28, 32, 36, 40.
223687170|NCT06424418|DEVICE|Robotic Scope Cleaner|The device is used to clean the scope when it visualization becomes obstructed during a surgical procedure.
223687171|NCT00215579|DRUG|Depot Risperidone Microsphere (Consta)|
223687172|NCT06518889|PROCEDURE|Selective Dorsal Rhizotomy|Selective Dorsal Rhizotomy (SDR) is an irreversible neurosurgical procedure where 50-70% of the sensory nerve roots are cut at the spinal level. The procedure is used to reduce lower limb spasticity permanently and is augmented by intensive rehabilitation for at least two years after surgery to optimise outcomes.
223687173|NCT03385161|PROCEDURE|Botulinum toxin A|
223687174|NCT03385161|PROCEDURE|Ethanol|
223687175|NCT00055471|DRUG|ZD4054 10 mg|1 x 10 mg oral tablets once daily
223687176|NCT00055471|DRUG|ZD4054 15 mg|1 x 10 mg + 2 x 2.5 mg oral tablets once daily
223687177|NCT00055471|DRUG|ZD4054 22.5 mg|2 x 10 mg + 2 x 2.5 mg oral tablets once daily
223687178|NCT05308940|DRUG|TB001|once-daily subcutaneous injection, on Day 1 in SAD stage
223687179|NCT05308940|DRUG|TB001|once-daily subcutaneous injection, on Days 1-7 in MAD stage
223687180|NCT05308940|DRUG|Placebo|once-daily subcutaneous injection, on Day 1 in SAD stage
223687181|NCT05308940|DRUG|Placebo|once-daily subcutaneous injection, on Days 1-7 in MAD stage
223687182|NCT01935310|DRUG|Imiquimod|"From the group of subjects who met the inclusion criteria, 22 people were selected randomly (using a random number table) since a 20-25% loss to follow up was calculated and the least amount of patients needed were 17.~During the study participants applied imiquimod cream 5% (Virosupril ® laboratories Roemmers) in the periocular area during the night, three times a week, on nonconsecutive days, for 12 weeks (3 months). If patients presented irritative dermatitis a topical 0.05% desonide cream was administered and applied for less of 5 days until symptoms improved."
223687183|NCT03190356|DEVICE|Soberlink Cellular Device|Soberlink Cellular Device delivers real-time blood alcohol results to people who support individuals in recovery. MAP platform helps monitor and support compliance with discharge plans while providing tools to improve outcomes for behavioral health diagnoses.
223687184|NCT01854944|DRUG|Brexpiprazole 1mg to 4mg|
223687185|NCT00127621|PROCEDURE|early tracheotomy|
223687186|NCT00127621|PROCEDURE|prolonged endotracheal intubation|
223687187|NCT02285556|BEHAVIORAL|psychological rehabilitation training|The main content is self-awareness training, social and moral strengthening, impulse control training , problem solving training , situational awareness training , HIV prevention, social skills training under the family atmosphere , family social skills training , interpersonal skills training, community interaction skills training , psychiatric symptoms of self-monitoring skills training and so on.
223687188|NCT02285556|BEHAVIORAL|physical and neurological rehabilitation training|The main content is drug rehabilitation exercise and functional physical training. Rehabilitation led by the discipline cadres , practice once a day, each lasting about 15 minutes .
223687189|NCT02285556|RADIATION|rTMS 10HZ high frequency stimulation|Stimulate the dorsolateral prefrontal and parietal lower part , 4 weeks of therapeutic intervention (5 times / week).
223687190|NCT02285556|RADIATION|fake rTMS 10HZ high frequency stimulation|Fake stimulate the dorsolateral prefrontal and parietal lower part , 4 weeks of therapeutic intervention (5 times / week).
223687191|NCT03742089|DEVICE|Bone Anchored Hearing Surgery|This is a observational study of pediatric patients undergoing bone anchored hearing surgery. The collected will be used to assess the implant stability development of the Ponto BHX implant during up to 24 months after implantation in a pediatric population undergoing BAHS. The study will also monitor the Ponto BHX implant safety and survival throughout the study period.
223687193|NCT03983278|OTHER|School Model|Free delivery of glasses at the school within two weeks after screening
223687194|NCT03983278|OTHER|Referral Model|After the primary screening children referred to nearby Vision Center/ secondary center for refraction and delivery of free glasses.
223687195|NCT03983278|OTHER|Referral Model + Cost Recovery|"After the screening children referred to Vision Center for refraction and delivery of free glasses with the option to purchase upgrade glasses"
223687196|NCT04110067|OTHER|Small Incision Lenticule Extraction (SMILE) with Visumax (Carl Zeiss Meditec, Jena)|Creation of a corneal tissue disk called lenticule and extraction through a minimally invasive incision, utilizing only a femtosecond laser
223687197|NCT02101112|DRUG|Apixaban|
223687198|NCT02788162|DRUG|Coppertone (BAY 987517)|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.(Formulation Number - X71-144)
223687199|NCT01449643|DEVICE|Threshold|
223687200|NCT01449643|DEVICE|Sham Threshold|
223687201|NCT05505994|DRUG|DWP16001|DWP16001 A mg tablet
223687202|NCT05505994|DRUG|Dapagliflozin|Dapagliflozin tablet
223687203|NCT05505994|DRUG|DWP16001 Placebo|DWP16001 Placebo tablet
223687204|NCT05505994|DRUG|Dapagliflozin Placebo|Dapagliflozin Placebo tablet
223687205|NCT04401527|DRUG|Sodium Nitrite|Continuous intravenous infusion of Sodium Nitrite Injection
223687206|NCT04401527|DRUG|Normal Saline|Continuous intravenous infusion of Normal Saline
223687207|NCT00004904|BIOLOGICAL|anti-thymocyte globulin|
223687208|NCT00004904|BIOLOGICAL|filgrastim|
223687209|NCT00004904|DRUG|cladribine|
223687210|NCT00004904|DRUG|cyclophosphamide|
223687211|NCT00004904|DRUG|etoposide|
223687212|NCT00004904|DRUG|methylprednisolone|
223687213|NCT00004904|DRUG|tacrolimus|
223687214|NCT00004904|PROCEDURE|allogeneic bone marrow transplantation|
223687215|NCT00004904|PROCEDURE|in vitro-treated peripheral blood stem cell transplantation|
223687216|NCT01683773|BIOLOGICAL|AERAS-402|Intramuscular needle injection 1x10\^11 vp
223687217|NCT01683773|BIOLOGICAL|MVA85A|Intradermal needle injection 1x10\^8 pfu
223687218|NCT01150331|DRUG|Levetiracetam/Clonazepam|Association of two anti-epileptic drugs in first line
223687219|NCT01150331|DRUG|Clonazepam/Placebo levetiracetam IV|Association of placebo to an active comparator (clonazepam)
223687220|NCT02125604|DRUG|dimethyl fumarate|capsules administered according to the prevailing product label
223687221|NCT04756674|OTHER|No intervetion will be used|No intervention will be used
223687222|NCT04124718|GENETIC|high caries experience|DNAs were obtained from epithelial cells in buccal mucosa and were extracted with Genomic DNA Isolation Kit
223687223|NCT01724320|DRUG|OTX008|OTX008 given daily without interruption, subcutaneously. Starting dose: 65 mg/day
223687224|NCT05088655|DRUG|Hetrombopag Olamine Tablet|Hetrombopag Olamine Tablet (T: test formulation) Hetrombopag Olamine Tablet (R: reference formulation)
223687225|NCT04864210|DRUG|Liposomal bupivacaine|Surgeons will perform an intercostal nerve block in the operating room under thoracoscopic guidance while the patient is asleep under anesthesia. This intervention (block) is one of the standards of care but the medication (liposomal bupivacaine) currently is not FDA approved for this type of block.
223687226|NCT04864210|DRUG|Bupivacaine|An anesthesiologist trained in regional anesthesia will perform a paravertebral block in the hospital's pain service unit. This intervention is standard of care and will use plain bupivacaine with epinephrine as the medication
223687227|NCT04340063|DEVICE|Gait training performed on a treadmill|Participants randomized to the Control group will complete high intensity gait training on a treadmill.
223687228|NCT04340063|DEVICE|Gait training performed in a Movement Amplification Environment|The Experimental group will perform all gait training within the movement amplification environment. To create the movement amplification environment, the investigators have constructed a cable-driven robot, the Agility Trainer. The Agility Trainer applies small forces to the pelvis that increase the difficulty to maintain forward walking
223687229|NCT06278415|OTHER|Physiological based cord clamping|see Arm Description
223687230|NCT06278415|OTHER|Differed cord clamping|see Arm Description
223687231|NCT01876810|DRUG|Gemfibrozil|600 mg of gemfibrozil (one capsule) twice daily for two weeks.
223687232|NCT01876810|DRUG|Placebo|One lactose pill twice a day for two weeks.
223687233|NCT00548587|DRUG|E5555|
223687234|NCT00548587|DRUG|Placebo|
223687235|NCT06975982|OTHER|No intervention|No intervention
223687236|NCT06574412|DRUG|cardonilizumab combined with renvastinib|Preoperative: Cardenilimab: 10 mg/kg qd intravenously, one cycle every 21 days, administered on the first day of each cycle, a total of 4 cycles. Lenvatinib: Weight \&lt;60kg, 8mg, once a day, orally, for 4 cycles Weight \&gt;60kg, 12mg, once a day, orally, for a total of 4 cycles Surgery: The patient is receiving 4 cycles of cardenilimab + Standard radical nephrectomy was performed within 30-40 days after the end of lenvatinib treatment. Postoperative: Cardenilimab: 10 mg/kg qd intravenously, 1 cycle every 21 days, administered on the 1st day of each cycle, a total of 8 cycles Lenvatinib: body weight \&lt;60 kg, 8 mg, once a day, orally , a total of 8 cycles, weight \&gt; 60kg, 12mg, once a day, orally, a total of 8 cycles.
223687237|NCT04768907|DRUG|MaaT013|
223687238|NCT06575933|DRUG|MK-1084|Oral administration
223687239|NCT06575933|DRUG|Midazolam|Oral administration
223687240|NCT06575933|DRUG|Digoxin|Oral administration
223687241|NCT04577027|DRUG|Topical travoprost 0.004% solution|30 Patches treated with Topical Travoprost 0.004% solution: Topical travoprost 0.004% solution once daily (1 drop for each 2.5 x 2.5 cm2) for 3 months.
223687242|NCT04577027|DEVICE|Fractional CO2 laser|30 Patches treated with Fractional CO2 laser: Fractional CO2 laser sessions twice monthly for 3 months, parameters settings as follows: Energy\\ dot 100mj, pulse duration 5ms, density level 17, pattern: array, depth level 1, 2 passes used
223687243|NCT04577027|DEVICE|Excimer laser|30 Patches treated with Excimer laser: Excimer laser sessions will be repeated twice weekly on the selected patch only, The starting dose will be 200 mj /cm2, an increase of 100 mJ/cm2 in the following session if no erythema appears, an increase of 50 mJ/cm2 every session till the appearance of erythema that lasts 24 hours or more.
223687244|NCT04577027|OTHER|Combination therapy|30 Patches treated with Combination therapy: Fractional CO2 laser twice per month followed by application of topical travoprost 0,004% daily and excimer laser twice weekly .
223687245|NCT04577027|OTHER|Excimer laser and travoprost|30 Patches treated with Excimer laser twice weekly and topical travoprost once daily for 3 months
223687246|NCT04577027|OTHER|fractional CO2 laser and topical travoprost|30 Patches treated with fractional CO2 laser twice monthly and topical travoprost once daily for 3 months
223687247|NCT05733065|OTHER|saliva sample|Adult twins will be asked to send saliva samples in a reply envelope to Maastricht University, department of Genetics and Cell Biology, where they will be frozen and stored before analysis. DNA will be extracted from the saliva using a commercially available kit according to the manufacturer's instructions.
223687248|NCT05733065|OTHER|questionnaire|Along with saliva samples, adult twins, will be asked to complete a questionnaire about their health. Study subjects will be asked to self-report height and weight. Additionally, questions will focus on cardiometabolic risk, including questions about smoking, physical activities, medical diagnoses, current medications, family history of cardiometabolic disease, and for female twins an obstetric and gynaecological history, including number of pregnancies and pregnancy complications (such as gestational diabetes and pre-eclampsia). The questionnaire will take the form of a self-completed, web-based questionnaire which will be hosted by the Qualtrics platform (Qualtrics.com). This platform is supported by the University of Maastricht due to its security and privacy measures.
223687249|NCT01598571|DRUG|Fostamatinib|Fostamatinib 50 mg tablet
223687250|NCT01598571|DRUG|Fostamatinib|Fostamatinib 100 μg \[14C\] R406 intravenous micro tracer dose
223687251|NCT04438733|DRUG|test-anastrozole tablet (Salutas Pharma GmbH)|Subjects were allocated to one of two groups randomly and equally with a 21-day washout interval between the two periods.All of them were randomized (1:1) to receive anastrozole as a single oral dose of the test drug or a single 1.0-mg oral dose of Arimidex
223687252|NCT04438733|DRUG|reference-anastrozole tablet (Arimidex)|Subjects were allocated to one of two groups randomly and equally with a 21-day washout interval between the two periods.All of them were randomized (1:1) to receive anastrozole as a single oral dose of the test drug or a single 1.0-mg oral dose of Arimidex
223687253|NCT03413267|OTHER|Custard|Food matrix: custard (liquid emulsion)
223687254|NCT03413267|OTHER|Flan|Food matrix: flan (soft gel)
223687255|NCT03413267|OTHER|Sponge cake|Food matrix: sponge cake (porous and spongy)
223775908|NCT05234346|DRUG|150 mg 5-ALAPhosphate + SFC|2 capsules in the morning after breakfast (before 11 AM) and 1 capsule in the evening after a snack or after dinner (before 8 PM) orally with water for 21 days.
223775909|NCT05234346|OTHER|Placebo|No Description for the intervention
223687256|NCT03413267|OTHER|Biscuit|Food matrix: biscuit (thick and crunchy)
223687257|NCT06006533|OTHER|taping|Kinesio taping will be applied in accordance with the fascia correction technique, including the plantar flexor muscles, and it will be requested to stay on the skin for 3 days.
223687258|NCT06006533|OTHER|massage|Percussive Massage will be applied to the posterior part of the sural fascia, including the plantar flexor muscles, 3 times a week for 5 minutes.
223687259|NCT02732522|DRUG|Sublingual misoprostol|
223687260|NCT02732522|DRUG|Vaginal misoprostol|
223687261|NCT01459939|DIETARY_SUPPLEMENT|Rose-hip powder capsules|5 x 0,5 g rose-hip powder capsules BID the first 3 weeks and decreasing to 5 x 0,5 g QD the following 9 weeks
223687262|NCT01459939|DIETARY_SUPPLEMENT|Placebo|5 x 0,5 g placebo powder capsules BID the first 3 weeks and decreasing to 5 x 0,5 g QD the following 9 weeks
223687263|NCT05368077|PROCEDURE|Adenotonsillectomy|Adenotonsillectomy is a standard surgical procedure for pediatric OSA treatment, which involves removal of hypertrophied tonsils and adenoids.
223687264|NCT03668366|DRUG|S-1|The patients will receive IMRT combined with S-1 concurrent chemoradiotherapy. The specific treatment description is included in arm description.
223687265|NCT00967928|DRUG|RAD001|RAD001 will be administered orally as 5 mg qod, 5 mg qd, or 10mg qd continuously from study Day 1 until the end of whole pelvic radiation therapy unless the patient develops progression of disease or unacceptable toxicity prior to that.
223687266|NCT00967928|DRUG|Cisplatin|Cisplatin will be administered intravenously once weekly at 40mg/m2 for 6 weeks. The preferred administration day is Monday.
223687267|NCT00967928|RADIATION|External Beam Whole Pelvis Radiation Therapy|Patients will receive 180 cGy daily fraction Monday through Friday x 25 days (4500 cGy total) using a four field technique throughout the entire treatment with all fields treated each day.
223687268|NCT04973189|DRUG|SHR-1707|A single dose of SHR-1707 by intravenous (IV) infusion in healthy young adults.
223687269|NCT04973189|DRUG|Placebo|A single dose of matching SHR-1707 placebo by intravenous (IV) infusion in healthy young adults.
223687270|NCT04973189|DRUG|SHR-1707|A single dose of SHR-1707 by intravenous (IV) infusion in elderly subjects.
223687271|NCT04973189|DRUG|Placebo|A single dose of matching SHR-1707 placebo by intravenous (IV) infusion in elderly subjects.
223687272|NCT04727281|OTHER|Quality of life assessment using the Kidney Disease Quality of Life 36 (KDQOL-36) short form and Malnutrition-Inflammation Score|"Data about nutritional status using the Malnutrition-Inflammation Score, and Quality of life assessment using the Kidney Disease Quality of Life 36 (KDQOL-36) short form. Dialysis related data, The time needed for the patient to recover from a dialysis session (in minutes), Detailed history taking, Thorough physical examination, Laboratory Investigations:~• Hemoglobin , Serum sodium and potassium , Serum creatinine and blood urea , Serum phosphorus, serum calcium , Serum PTH level , Serum albumin ,CRP ,Total iron-binding capacity ."
223687273|NCT00386971|DIETARY_SUPPLEMENT|L-carnitine|3 grams daily in liquid form by mouth
223687274|NCT00386971|OTHER|placebo|1 oz sweet tasting liquid daily by mouth
223687275|NCT04969796|OTHER|REACH Hope|REACH VA (Resources for Enhancing All Caregivers Health in Department of Veterans Affairs) and the DoD's Virtual Hope Box. For REACH Hope, as the caregiver and interventionist work on strategies one-on-one, these will be integrated into the Hope Box for the caregiver to use between and after sessions.
223687276|NCT02974101|OTHER|registration of AdaptiveStim|
223687277|NCT04841746|BEHAVIORAL|Physical therapy that include a standardized cycling training with functional electrical stimulation|Immediately after the discharge of the intensive care unit, patient with a severe form of the COVID-19 will be admitted in the rehabilitation hospital. Rehabilitation will consist in physical therapy twice a day, 30 minutes, 5 days a week. One session will be dedicated to a standardized cycling training (TECHNOGYM RECLINE EXCITE 700). All participants will follow the same 4-week rehabilitation protocol representing a total of 1200 minutes. Participants randomized in the experimental group will received functional electrical stimulation administered to surface electrodes attached to lower limb muscles (quadriceps, hamstrings, gluteus maximus and triceps). Electrical stimulation will be delivered appropriately to the muscle during cycling regarding the angle of the pedal by a stimulator (Motimove-8 de 3Fit Fabricando Faber).
223687278|NCT04841746|BEHAVIORAL|Physical therapy that include a standardized cycling training with no additional functional electrical stimulation|Immediately after the discharge of the intensive care unit, patient with a severe form of the COVID-19 will be admitted in the rehabilitation hospital. Rehabilitation will consist in physical therapy twice a day, 30 minutes, 5 days a week. One session will be dedicated to a standardized cycling training (TECHNOGYM RECLINE EXCITE 700). All participants will follow the same 4-week rehabilitation protocol representing a total of 1200 minutes. Participants randomized in the control group will received no additional functional electrical stimulation during cycling.
223687279|NCT02723253|RADIATION|Radiotherapy|Radiotherapy was applied as conformal 3-D technique and was delivered with photon energies of 10 - 15 MV. The beams were delivered by an Elekta Precise Linac equipped with standard multi leaf collimators (MLC). A daily online check of isocenter position was performed using portal imaging, with set-up correction in case of displacement \> 0.5 cm in any direction. Radiation dose delivered to PTV2 was 45 Gy (1.8 Gy/fraction) with a concomitant boost dose to the PTV1 of 10 Gy with accelerated fractionation at 2.2 Gy/fraction, five consecutive days for week.
223687280|NCT02723253|DRUG|Tom-OX|The concurrent chemotherapy consisted of 15 min intravenous infusion Raltitrexed (Tomudex ®) 3 mg/m2 and a two-hours intravenous infusion of Oxaliplatin (Eloxatin ®) at 130 mg/m 2, 20 min after raltitrexed, on days 1, 17, 35.
223687281|NCT04491097|DEVICE|Panavia V5 resin cement|Missing lateral incisor teeth will be restored by zirconia ceramic RBFDs and adhesively bonded with Panavia V5 resin cement.The preperation and restoration of the tooth will be done according to to the guidelines for ordinary prosthetic techniques.
223687282|NCT04491097|DEVICE|Panavia F2.0 resin cement|Missing lateral incisor teeth will be restored by zirconia ceramic RBFDs and adhesively bonded with Panavia F2.0 resin cement.The preperation and restoration of the tooth will be done according to to the guidelines for ordinary prosthetic techniques.
223687283|NCT02102971|PROCEDURE|Hepatocellular carcinoma|Participants undergoing a liver resection/liver transplantation surgery. During the liver surgery a small piece of tissue will be removed to undergo additional laboratory testing.
223775910|NCT05273892|BEHAVIORAL|Diet + Activity + Sleep|Personalized lifestyle behavior change counselling
223687284|NCT05054244|OTHER|standard wound treatment|Standard treatment includes dressings, debridement, antibiotics, and bacterial load relief. The dressing will be performed according to wound characteristics with change every two days including primary dressing (alginates, hydrofiber dressing, antimicrobial dressing, gelling fiber dressing), with silver if infected, and secondary protective dressing (foam with polyurethane) in wounds with formed granulation tissue. The progression of the wound and the need for specific treatment will be evaluated weekly by dermatologist and vascular surgeon specializing in wound care, and appropriate treatment conducted according to wound assessment (antibiotics, bandage, dressing change, debridement, amputations).
223687285|NCT05054244|PROCEDURE|Hyperbaric oxygenation (HBOT)|The HBOT sessions will be performed 5 days a week, in multi-place chamber at 2.4 atm absolute (ATA) and 100% O2 with effective treatment lasting for 90 min. The sessions will be supervised by doctors trained in hyperbaric medicine.
223687286|NCT02158260|BEHAVIORAL|Position changing|
223687287|NCT01250288|OTHER|Personal Health Management System|BHIX and LIPIX are offering novel personal health management system to members of its community. These community members, also referred to as consumers, will include patients \& their designated proxies. BHIX's system will allow patients to perform various tasks, including, but not limited to, viewing medications, medical allergies and lab results. LIPIX's system is primarily a mechanism forc consumers/patients to communicate directly with their physician through a secure messaging portal. Healthcare providers of these patients, who are affiliated with BHIX, will also be able to view the data entered by consumers in this personal health management system through the RHIO's health information exchange. Thus, the intervention of a personal health management system is being offered to both groups, however in different forms.
223687288|NCT02284971|BIOLOGICAL|CDX1127|
223687289|NCT02284971|RADIATION|SBRT|
223687290|NCT04509739|BEHAVIORAL|Music intervention|"At 9 months of age, families will start the 12 - session intervention in a controlled laboratory space. In the initial session, caregivers will be given a brief orientation to intervention, including introducing them to the musical toys they will be using during the sessions with their infants and the lab environment. They will also be trained techniques through which they can synchronize the infant's movements to the experimenter's movements, such as clapping hand, tapping feet.~The remaining sessions will be scheduled in groups of 2-3 infant/parent dyads. In each session, a music CD with 15 minutes of selected children's music will be played and a musically trained experimenter will facilitate the sessions to engage the infants and parents to move to musical beats, using different musical toys, such as infant drums and maracas. Parents will be instructed to not to repeat any of these activities outside of the lab setting for the period of the study."
223687291|NCT03565471|DIAGNOSTIC_TEST|Echocardiography|Standard echocardiography.
223687292|NCT03565471|DIAGNOSTIC_TEST|Right side catheterization|Right side catheterization with the purpose of measuring pulmonary vascular pressures and blood saturation.
223687293|NCT03565471|DIAGNOSTIC_TEST|Exercise test|Exercise test on a supine bicycle with gradual increase in work load while wearing a mask that measures ventilation, oxygen uptake, carbon dioxide release and respiratory exchange rate.
223687294|NCT03565471|DIAGNOSTIC_TEST|Holter monitor|Holter monitor worn for 2 whole days registering heart rate.
223687295|NCT05537090|DRUG|BV100|Rifabutin for Infusion
223687296|NCT05537090|DRUG|Midazolam|Syrup for oral administration
223687297|NCT01607840|PROCEDURE|transcranial direct current stimulation|delivery of transcranial direct current stimulation or sham for 20 to 60 minutes
223687298|NCT05932784|DEVICE|transesophageal echocardiography|Utilizing transesophageal echocardiography (TEE) during resuscitation allows medical professionals to determine if a patient's aortic valve is being compressed while receiving chest compressions, providing valuable insight to optimize the resuscitation process.
223687299|NCT05828095|BIOLOGICAL|INO-6160, 2 mg|ID EP at month 0,1,3 and 6
223687300|NCT05828095|BIOLOGICAL|Trimer-4571 / 100 mcg 3M-052-AF (5 mcg) + Alum (500 mcg)|IM at month 3 and 6
223687301|NCT02199860|DRUG|SD I|
223687302|NCT02199860|DRUG|SD II|
223687303|NCT02199860|DRUG|Placebo|
223687304|NCT03206073|DRUG|Durvalumab|1500 mg of durvalumab via intravenous (IV) infusion on Day 1 of each cycle until patients meet off treatment criteria
223687305|NCT03206073|DRUG|Tremelimumab|300 mg of tremelimumab via intravenous (IV) infusion on Day 1 of cycle 1
223687306|NCT03206073|BIOLOGICAL|Pexa-Vec|3 x 10E\^8 plaque-forming unit (pfu) (Dose Level (DL) 1) via intravenous (IV) infusion for 4 doses: Day 12, Day 2, Day 16 of Cycle 1 and Day 2 of Cycle 2.
223687307|NCT03206073|BIOLOGICAL|Pexa-Vec|1 x 10E\^9 pfu (DL 2) via intravenous (IV) infusion for 4 doses: Day 12, Day 2, Day 16 of Cycle 1 and Day 2 of Cycle 2.
223687308|NCT03332771|DRUG|Sotagliflozin (SAR439954)|"Pharmaceutical form: tablet~Route of administration: oral"
223687309|NCT03332771|DRUG|Glimepiride|"Pharmaceutical form: capsule~Route of administration: oral"
223687310|NCT03332771|DRUG|Metformin|"Pharmaceutical form: tablet~Route of administration: oral"
223687311|NCT03332771|DRUG|Placebo|"Pharmaceutical form: tablet~Route of administration: oral"
223687312|NCT03332771|DRUG|Placebo|"Pharmaceutical form: capsule~Route of administration: oral"
223775911|NCT05273892|BEHAVIORAL|Diet + Activity|Personalized lifestyle behavior change counselling
223687313|NCT00096954|DRUG|omalizumab (Xolair)|Omalizumab (Xolair) was administered subcutaneously every 2 or 4 weeks. The dose (mg) and dosing frequency were determined by serum total IgE level (IU/mL), measured before the start of treatment, and body weight (kg). Assignment of the study drug dose was determined by using the study drug-dosing table. Doses of \> 150 mg were divided among more than one injection site to limit injections to no more than 150 mg per site.
223687314|NCT00096954|DRUG|placebo|The dose of placebo consisting of sucrose, L-histidine, L-histidine hydrochloride monohydrate, and polysorbate 20 was administered by subcutaneous injection every 2 or 4 weeks.
223687315|NCT02414659|PROCEDURE|Umbilical cord blood collection, in-utero|Umbilical cord blood was collected during cesarean, after delivery of the baby and after clamping of the cord. Blood was collected into a standard blood donation bag with (Capacity: 450 mL) a 16 G venipuncture needle. Needle was left in place after umbilical vein is collapsed and no more blood flow happens spontaneously.
223687316|NCT02460445|PROCEDURE|Phlebotomy|Scheduled standard phlebotomy every three months from month 3 to 12 of follow-up.
223687317|NCT02460445|DRUG|ethinylestradiol|35 mcg ethinylestradiol qd for 21 days per month as usual clinical practice.
223687318|NCT02460445|DRUG|Cyproterone Acetate|2 mg cyproterone acetate qd for 21 days per month as usual clinical practice.
223687319|NCT02855073|BIOLOGICAL|ReJoinTM|adipose derived mesenchymal progeinitor cells
223687320|NCT02855073|DRUG|Sodium Hyaluronate|Sodium Hyaluronate Injection
223687321|NCT00654121|DRUG|Actrapid HM|56 subjects will receive metabolically active insulin by subcutaneous injections for 36 months (twice daily)
223687322|NCT04176497|DRUG|68Ga-HBED-CC-PSMA|Radioactive tracer used during imaging to help detect PSMA expressing tumor cells.
223687323|NCT06084689|DRUG|Ezabenlimab + BI907828|A treatment cycle consists of 3 weeks. Both treatments will be administered on Day 1 of each cycle.
223687324|NCT04347096|BEHAVIORAL|mHealth Intervention|"The mHealth Intervention will provide sedentary workers with evidence-based information on diet, physical activity and sedentary behavior, and tailored feedback on their responses to daily records. Key features of this intervention will include individualized feedback and multimedia presentation in the form of web app. The intervention group will also receive a reliable device for wireless physical activity tracking for monitoring step counts.~The web app will consist of seven major components: (1) daily healthy eating goals and records; (2) daily physical activity goals and records; (3) daily stand-up goals and records; (4) advice and reminder; (5) educational and motivational tools; (6) personal and team health ranking; and (7) online social network. In addition, the intervention will be enhanced with follow-up booster coaching calls bi-monthly at 2, 4, 6, 8 months after the 12-week intervention."
223687325|NCT04347096|BEHAVIORAL|Control Intervention|The control intervention group will receive educational tools, which will provide knowledge on benefits of physical activity and healthy eating, health risks of sitting and unhealthy diets, and recommendations on physical activity and a balanced healthy diet for good health.
223687326|NCT05621460|OTHER|500mL carbonated water|Drink 500mL carbonated water immediately prior to head-up tilt test
223687327|NCT05621460|OTHER|500mL still water|Drink 500mL still water immediately prior to head-up tilt test
223687328|NCT05621460|OTHER|50mL still water|Drink 50mL still water immediately prior to head-up tilt test
223687329|NCT02435329|OTHER|Baseline comparison of microcirculation and bone metabolism|Baseline comparison of microcirculation and bone metabolism among the 5 different groups
223687330|NCT04478123|DRUG|Romiplostim|Romiplostim 3.0 mcg/kg SC on Day +1 and Romiplostim 2.0 mcg/kg SC on Day +8 after HDT-AHCT. Beyond Day +8, patients will be treated weekly until platelet count is \>50,000/mcL, without any platelet transfusions in the prior 48 hours. All doses after the second Romiplostim dose will be titrated as per Table 3, based on weekly CBC/platelet counts. Patients will receive a maximum of six weekly doses of romiplostim.
223687331|NCT02496962|DRUG|Atorvastatin|atorvastatin were taken daily for 5 days
223687332|NCT02496962|DRUG|placebo|placebo were taken daily for 5 days
223687333|NCT00463203|DRUG|Bevacizumab|10 mg/kg every 2 weeks
223687334|NCT00463203|DRUG|Irinotecan|125 mg/m2 non-EIAED or 340 mg/m2 EIAED every 2 weeks
223687335|NCT06706596|OTHER|Screening for TB symptoms|Individuals will be screened for cough, blood in sputum, fever, weight loss, night sweats and chills lasting for \>2 weeks
223687336|NCT06706596|DIAGNOSTIC_TEST|Chest X-ray|Chest X-ray will be performed to diagnose or exclude TB
223687337|NCT02026960|DEVICE|RNA extraction and amplification from biopsy specimens|
223687338|NCT06432634|OTHER|Standard care|The pre-operative educational session has a duration of 40 minutes and covers pre-operative education, breathing exercises (diaphragmatic breathing, deep breathing techniques and sustained maximal inflation), and airway clearance techniques (directed cough, huffing, and chest physiotherapy). Patients are instructed to perform these techniques ten times per waking hour, every day. The in-patient peri-operative session incorporates intermittent positive pressure breathing inhalation (IPPB) administered for 15 minutes twice daily. Inhalation therapy involving mucolytics and bronchodilators is administered three times per day, and early mobilization is encouraged until discharge. Upon discharge, participants are encouraged to continue practicing breathing exercises, deep breathing techniques, and maintaining an active level of activity.
223687339|NCT06432634|OTHER|Comprehensive pulmonary rehabilitation programs|"1. Warm-up and cool-down exercises: stretching various muscle groups for a duration of 15 to 20 minutes and a slow 3-minute walk~2. Aerobic training: using a lower-limb cycle ergometer for a duration of 30 to 40 minutes. Initiated warm-up at 0 wattages for 5 minutes. Incrementally increased wattages within 5-10 minutes until reaching the 40-80% heart rate reserve or 4 to 6 of modified Borg scale for at least 20 minutes. Concludes with a 5-minute cool-down period at 10 wattages.~3. The resistance training involves both upper and lower limbs:~（1） Upper Limb Resistance Training: Shoulder lift, abduction, and horizontal abduction exercises are performed. Each exercise is repeated for three sessions comprising 10 repetitions each. A 0.5-2 kg dumbbell is utilized for resistance.~（2） Lower Limb Resistance Training: Sit-to-stand exercises are performed. Each session consists of three sets of 10 repetitions."
223687340|NCT05887375|DRUG|Sugammadex|Sugammadex will be used to reverse rocuronium neuromuscular blockade (NMB). Dose will be according to participant actual body weight.
223687341|NCT05887375|DRUG|Neostigmine|Neostigmine will be used to reverse rocuronium NMB. Dose will be according to participant actual body weight.
223687342|NCT05887375|DRUG|Glycopyrrolate|Glycopyrrolate will be co-administered with neostigmine during reversal of rocuronium NMB. Dose will be according to participant actual body weight.
223687343|NCT05887375|DRUG|Rocuronium|To achieve NMB, participants will receive the steroidal neuromuscular blocking agent Rocuronium Bromide administered via IV infusion and dosed according to participant actual body weight. It will be used per label to maintain muscle relaxation as an adjunct to general anesthesia.
223687344|NCT06358131|DEVICE|Endoscopy|upper and lower endoscopy
223687345|NCT04444895|DRUG|Lanadelumab|Lanadelumab SC injection
223687346|NCT05085288|DEVICE|Intermittent electrical stimulation system (IES) treatment and turning patient every two hours|The investigators propose to assess whether addition of the IES system and the use of standard of care wound care and wound prevention reduces the morbidity of sacral and ischial pressure injuries by decreasing progression of stage 1 and stage 2 ulcers or facilitates their healing compared to standard wound care in an inpatient critical care population.
223687347|NCT05085288|OTHER|Turning population every two hours|The investigators propose to assess whether current standard of care wound care and wound prevention reduces the morbidity of sacral and ischial pressure injuries.
223687348|NCT04999982|OTHER|Screening|Parent-report screening for remediable, unmet social needs.
223687349|NCT04999982|OTHER|Resource Packet|"Provision of packet of resource sheets (Family Resource Booklet) detailing local community-based resources to address these needs, with needs that respond to family's requests highlighted."
223687350|NCT04999982|OTHER|Resource Navigation|Navigation to resources, care coordination, and parent support provided by a trained bachelors-level interventionist.
223687351|NCT04999982|OTHER|Care as usual|Screening for social needs annually at well-child visits as recommended by the AAP followed by provision of information as needed by the family.
223687352|NCT03581786|BIOLOGICAL|TORIPALIMAB INJECTION(JS001 ) combine with chemotherapy|TORIPALIMAB INJECTION(JS001 ) combine with chemotherapy
223687353|NCT03581786|DRUG|Placebos|placebo combine with chemotherapy
223687354|NCT01561027|DRUG|CNV1014802|Administered as specified in treatment arm.
223687355|NCT01561027|DRUG|Placebo|Administered as specified in treatment arm
223687356|NCT05523323|DRUG|Lenvatinib|Lenvatinib, 20 mg (two 10-mg oral capsules) administered QD
223687357|NCT05523323|BIOLOGICAL|Pembrolizumab|Pembrolizumab (MK-3475), 200 mg, every 3 weeks (Q3W) by intravenous (IV) infusion for up to 35 3-week cycles
223687358|NCT05523323|DRUG|Placebo|Lenvatinib-matching placebo, oral capsules, administered once daily (QD)
223687359|NCT01083927|PROCEDURE|Rotational Narrow Strip Conjunctival Graft|Surgical technique
223687360|NCT01083927|PROCEDURE|Full Conjunctival Graft|Surgical technique
223687361|NCT00494598|DRUG|Sufentanil|200 mcg intra-arterial one time bolus
223687362|NCT03435640|DRUG|NKTR-262|"During Phase 1 Doublet: Patients receive escalating doses of NKTR-262 IT (starting dose 0.03 mg) in 3-week treatment cycles. During Phase 1 Doublet (Cohort A), Phase 2 Doublet: Patients were to receive the RP2D of NKTR-262.~During Phase 1 Triplet (Cohort B), and Phase 2 Triplet: Patients receive the RP2D of NKTR-262."
223775912|NCT02015234|DRUG|TNX-102 SL|TNX-102 SL 2.8 mg taken daily at bedtime.
223687363|NCT03435640|DRUG|bempegaldesleukin|"During Phase 1 Doublet (Cohort A), and proposed Phase 2 Doublet: Patients receive 0.006 mg/kg bempegaldesleukin administered in 3-week treatment cycles.~During Phase 1 Triplet (Cohort B), and proposed Phase 2 Triplet: Patients receive 0.006 mg/kg bempegaldesleukin administered in 3-week treatment cycles."
223687364|NCT03435640|DRUG|nivolumab|During Phase 1 Triplet (Cohort B), and proposed Phase 2 Triplet: Patients receive a nivolumab flat dose of 360 mg administered in 3-week treatment cycles.
223687365|NCT04648501|OTHER|Dual-task training|Dual-task (CIBT- experimental) group participants will receive 10 minutes of warm up, 40 minutes of CIBT training and 10 minutes of cool down exercises. CIBT program includes performing four types of cognitive tasks during sit to stand, standing with feet apart, one leg, tandem standing, multidirectional reaching, stair climbing and walking (10 metres) tasks. The four cognitive tasks will include: counting backwards by subtracting 4 numbers (for mental tracking ), naming fruits, vegetables, or animals (for working memory), auditory cues for performing activities, example, perform heel raise when you hear the alphabet H (for improving attention and auditory discrimination), short story telling (for verbal fluency). In addition, falls prevention strategies will be taught.
223687366|NCT03882775|DRUG|Bivalirudin|Patients would be given anticoagulant therapy with bivalirudin in acute STEMI during emergency PCI operation.
223687367|NCT03882775|DRUG|Heparin|heparin with or without gpi during emergency PCI.
223687368|NCT03676985|DRUG|ZKAB001 5mg/kg|5mg/kg/times bi-week IV administration of ZKAB001
223687369|NCT03676985|DRUG|ZKAB001 10mg/kg|10mg/kg/times bi-week IV administration of ZKAB001
223687370|NCT03676985|DRUG|ZKAB001 15mg/kg|15mg/kg/times bi-week IV administration of ZKAB001
223687371|NCT05012787|BIOLOGICAL|CpG 1018/Alum-adjuvanted SCB-2019 vaccine|Participants will receive 1 intramuscular (IM) injection of 30 microgram (mcg) SCB-2019 with CpG 1018/Alum adjuvant on Day 1 and on Day 22.
223687372|NCT05012787|BIOLOGICAL|Havrix|Participants will receive Havrix (Hepatitis A vaccine) containing 1440 Enzyme-linked Immunosorbent Assay (ELISA) units (EL.U.) in 1.0 mL dose on Day 1.
223687373|NCT05012787|OTHER|Placebo; 0.9% saline|Participants will receive 1 IM injection of SCB-2019-matching placebo on Day 22.
223687374|NCT06319352|DEVICE|Active UroShield|Participants will have an active device (i.e., ultrasound energy is being produced by actuator) attached to their urinary catheter tube.
223687375|NCT06319352|DEVICE|Sham UroShield|Participants will have an inactive device (i.e., no ultrasound energy being produced by the actuator) attached to their urinary catheter tube. All other aspects of the sham device (look, weight, feel, sound, and operation) are identical to the active device.
223687376|NCT01927302|BEHAVIORAL|Treatment Focusing on Naming Objects|Treatment will be administered from week 0 until week 12.
223687377|NCT01927302|BEHAVIORAL|Treatment Focusing on Improving Spelling Abilities|Treatment will be administered from week 0 until week 12.
223687378|NCT01927302|BEHAVIORAL|Treatment Focusing on Improving Sentence Processing|Treatment will be administered from week 0 until week 12.
223687379|NCT01927302|BEHAVIORAL|No Treatment|No treatment will be administered.
223687380|NCT03354975|BEHAVIORAL|Experiential Training|Participants in the experiential training will be provided with information about using exposure therapy to treat patients with anxiety via lecture-style teaching. Then, they will themselves undergo a one-session phobia treatment for spiders.
223687381|NCT03354975|BEHAVIORAL|Training-As-Usual|The training-as-usual condition will incorporate passive and active learning components. The first half of the training will include lecture-style teaching about using exposure therapy to treat patients with anxiety. The second half of training will incorporate active learning components (e.g., role plays) to reinforce concepts discussed in the first half of training.
223687382|NCT00572897|DRUG|Fludarabine, Melphalan +/- ATG|"Conditioning regimen for Allogenic Stem Cell Transplant:~Related Donor Fludarabine days -6 to -2 (30mg/m2 IVPB over 30 minutes daily) Melphalan days -3 to -2 (70mg/m2 IVPB over 30 minutes daily)~Unrelated Donor Fludarabine days -6 to -2 (30mg/m2 IVPB over 30 minutes daily) Melphalan days -3 to -2 (70mg/m2 IVPB over 30 minutes daily) ATG (Thymoglobulin®) days -3 to -1 (0.5 mg/kg IV on day -3 \[given over 6 hours\], and 2 mg/kg on days -2 and -1 \[given over 4 hours\])"
223687383|NCT01347307|RADIATION|SBRT for Benign Extradural Spine Tumors|14-25 Gy / 1 fraction OR 21-27 Gy / 3 fractions (7-9 Gy per fraction) OR 25-30 Gy / 5 fractions (5-6 Gy per fraction)
223687384|NCT01347307|RADIATION|SBRT for Vertebral/Paraspinal Metastases|12-16 Gy / 1 fraction OR 21-27 Gy / 3 fractions (7-9 Gy per fraction) OR 25-30 Gy / 5 fractions (5-6 Gy per fraction)
223687385|NCT06707870|OTHER|Cervical retraction exercise|"Neck retraction exercises are performed on patients either in sitting or standing in an upright position while pushing their chin backward and simultaneously raising their head within the pain-free range (3 seconds hold)of 10 repetitions in each session at sitting position. Conventional treatment (TENS (2 to 10 Hz),10 mints, Heating pad, stretching of tight muscles Trapezius and SCM)should be included.~The patients will received 20-30-minute sessions on 3 alternate days for two consecutive weeks, making it a total of 6 sessions. Patients were advised to revisit after 4 weeks (1 month from the baseline) for follow-up."
223687386|NCT06707870|OTHER|Facet oscillatory mobilization|"Facet joint oscillatory mobilization on the cervical spine C2-C7(6 to 10 repetitions in each session) in the sitting position.~Conventional treatment (TENS (2 to 10 Hz) 10 mints, Heating pad, stretching of tight muscles Trapezius and SCM) should be included.~The patients will received 20-30-minute sessions on 3 alternate days for two consecutive weeks, making it a total of 6 sessions. Patients were advised to revisit after 4 weeks (1 month from the baseline) for follow-up."
223687387|NCT03593941|OTHER|Standard Diet|Participants will consume the standard diet provided in care home
223687388|NCT02857595|BEHAVIORAL|Online Behavioral Weight Loss program|
223687389|NCT02857595|BEHAVIORAL|Weight Loss Nomogram|
223687390|NCT02857595|BEHAVIORAL|Bite Counter|
223687391|NCT00792077|DRUG|Lenalidomide|5 mg daily for 56 days.
223687392|NCT04835467|DEVICE|Dual-modal OCT-FLIm|Intracoronary imaging using dual-modal OCT-FLIm catheter
223687393|NCT05437835|DRUG|Ropivacaine|Ropivacaine 20 ml injection into the subparaneural space of sciatic nerve
223687394|NCT04927000|DRUG|Tofacitinib|in tofacitinib treatment group，we added tofacitinib 5mg/BID in the basic treatment in all subjects.
223687395|NCT06790290|BIOLOGICAL|Formulation B|IVT PCV-25
223687396|NCT06790290|BIOLOGICAL|Formulation C|IVT PCV-25
223687397|NCT06790290|BIOLOGICAL|Formulation D|IVT PCV-25
223687398|NCT06790290|BIOLOGICAL|Prevnar20|20 valent pneumococcal conjugate vaccine
223687399|NCT02075970|DRUG|Epoetin Alpha|"Infant study 1: VLBW infant study subjects (weighing 1.0 to 1.5 kg at birth) who are otherwise receiving standard clinical care will be treated with Epoetin Alpha according to a dosing algorithm.~Infant study 2:~Dosing algorithm will be determined by results of Infant Study 1."
223687400|NCT02075970|DRUG|Biotinylated Red Blood Cells|Biotinylated red blood cells will be transfused to infants to determine red blood cell lifespan.
223687401|NCT02016339|BEHAVIORAL|Standard care|24-h consultation telephone line to the sleep nurses to answer questions regarding CPAP usage. Patients were reviewed at 1 month and at 3 month intervals during the first year and every 6 months thereafter in the CPAP clinic by the nurse. Additional visits or phone calls by sleep specialist if doubts about a patient's compliance or willingness to continue with the therapy.
223687402|NCT02016339|BEHAVIORAL|Intensive care|Standard group care plus: Involvement of the patient's partner or family necessary. Extra education on sleep apnea and CPAP by sleep specialists via a 15-min videotape. 10- to 15-min lecture from the sleep clinic's nurses after CPAP titration study. Phone calls by nurses at 2 and 7 days. Early review of patients by sleep specialists at 15 and 30 days. Home visits by sleep nurses, if there doubts about a patients adherence
223687403|NCT03083860|DEVICE|BEI|BrainMARC Ltd. has demonstrated in recent years the ability to extract effective attention markers from averaged ERP waves sampled with a single EEG channel (two electrodes). In addition, BrainMARC has developed a template matching method to extract the attention-related markers at the single-trial level. An index (termed Brain Engagement Index - BEI) can then be generated from a 1-minute, single-channel sample.
223687404|NCT01225536|DRUG|ARQ 736|Subjects in this study will receive ARQ 736 orally at dose levels specified for their respective dose cohorts. Dosing will begin at 900 mg/day (first cohort) and escalate until the recommended Phase 2 dose or maximum tolerated dose is determined. Cycles will be repeated in four-week (28-day) intervals until progression of disease, unacceptable toxicity, or another discontinuation criterion is met. In the case of toxicity, dose adjustment will be permitted.
223687405|NCT04389814|DIAGNOSTIC_TEST|Biochemical markers|Multiple biomarkers of myocaridial ishemia will be obtained serially to calculate thier time of their release according to their release kinetics
223775913|NCT06216951|PROCEDURE|Vital Pulpotomy|Vital pulpotomy involves the removal of the coronal pulp, while MTA is used to seal the root orifices. It is clear that vital pulp treatments for symptomatic pulpitis are a more reliable, cost-effective, and generally easier option than root canal treatment (RCT) once the mineral trioxide aggregate (MTA) is introduced in dentistry. In vital pulpotomy, as opposed to RCT, tooth healing and symptoms are diminished while the vitality of the tooth is maintained. Furthermore, vital pulpotomy is a significantly more practical and economical treatment alternative than RCT.
223775914|NCT04819360|DRUG|VESIcare 10Mg Tablet|"Vesicare® 10 mg per day for 12 weeks~Vesicare 10mg 12 weeks"
223775915|NCT04819360|DRUG|Botox 100 UNT Injection|1 injection of Botox® 100 UNT
223687406|NCT01948310|DRUG|Ranolazine|Comparison of Ranolazine 1000mg twice per day versus placebo twice per day
223775916|NCT03544983|BEHAVIORAL|Web + Streamlined Telephone Genetic Information|Tailored and interactive web-based education designed to incorporate all aspects of standard genetic counseling followed by a streamlined genetic counseling session with a board-certified genetic counselor.
223775917|NCT06078735|DEVICE|Vascular closure with LockeT device|For subjects that are assigned to the LockeT device arm, the healthcare professional will place the LockeT with suture above the wound to achieve compression instead of manually holding pressure on the sutures. After hemostasis is achieved and prior to ambulation the LockeT will be removed followed by suture removal.
223775918|NCT02154815|OTHER|Questionnaires : Patient-Reported Outcomes|Patient-Reported Outcomes completion every six months prior to surgery, at hospital discharge, and at 3, 6,12, 24, 36, 48, 72 months
223775919|NCT01591681|DEVICE|Pump suspension|The study laptop will communicate to the pump causing a suspension based on output from the algorithm which predicts hypoglycemia based on the continuous glucose sensor trend.
223775920|NCT05405673|DIAGNOSTIC_TEST|Fecal immunochemical test (FIT)|A kind of stool test
223775921|NCT06293417|DRUG|Ezetimibe/fenofibrate (Ezefeno) and moderate-intensity statin|Treatment group
223775922|NCT06293417|DRUG|Dose escalation of moderate-intensity statin|Control group
223775923|NCT02327208|DIETARY_SUPPLEMENT|Control|
223775924|NCT02327208|DIETARY_SUPPLEMENT|Protein|
223775925|NCT02327208|DIETARY_SUPPLEMENT|Carbohydrate|
223775926|NCT05942456|DIAGNOSTIC_TEST|ELISA: enzyme-linked immunosorbent assay|enzyme-linked immunosorbent assay
223775927|NCT04512274|DEVICE|Test Article|Omeza Collagen Matrix
223775928|NCT02678039|DEVICE|Fluoroscopy|Device: Fluoroscopy Patients lie prone on X-ray compatible operating table and an X-ray device obtains X-ray images of epidural catheter placement. An epidural catheter is placed with local anesthesia as a needle that is advanced into the epidural space. A catheter is then placed through the needle to the desired location and the needle is removed. After the catheter is placed, a test dose of 1.5% lidocaine with 5ug/cc epinephrine is injected into the catheter to exclude intravascular placement. Following this, a continuous infusion of 1/8% bupivacaine is started at 4ml/hr. After surgery, the bupivacaine infusion may be adjusted with bolus injections of 2ml and/or increase in the infusion rate by 2ml/hr up to a maximum of 14ml/hr
223687407|NCT01948310|BEHAVIORAL|Aerobic Exercise|Aerobic exercise 3 times per week, 45 minutes per session at an intensity of 10-20 beats per minute below the angina threshold (heart rate at which angina symptoms began on the stress test)
223687408|NCT01948310|DRUG|Placebo|Comparison of placebo twice per day vs. Ranolazine 1000mg twice per day
223687409|NCT03442387|OTHER|Frame of numerical information|Each group received only one frame of information.
223687410|NCT06084728|DIAGNOSTIC_TEST|Color Doppler ultrasonography|in a longitudinal plane, the dorsal clitoral artery, which is sampled on the outer surface of the clitoral body as previously described. With the same longitudinal approach, the terminal branch of the posterior labial artery (a branch of the internal pudendal artery) was visualized posterolaterally to the labia majora
223687411|NCT03226873|BEHAVIORAL|Peer Navigation|Peer education, counseling, and facilitation of PrEP care
223687412|NCT05912452|OTHER|Percussion Massage Therapy|Individuals who receive percussion massage therapy will be treated with a 5-minute medium-frequency percussion massage on the deltoid muscle group every other day. Percussion massage therapy will be applied in a total of 10 sessions and will be completed in 20 days.
223687413|NCT05912452|OTHER|Kinesiotaping|the Kinesiotape group; Kinesiotape banding will be done with 25% tension by applying a Y band to the deltoid muscle group. After the application, the Kinesio band will stay on the participant for 2 days. The next day, the participant will rest. This cycle will be repeated for 20 days.
223687414|NCT05912452|OTHER|Dynamic stretching|Dynamic stretching exercises will be applied to the shoulder flexor and abductor muscle groups in the Dynamic Stretching Group with 10 repetitions. As in percussion massage therapy, these exercises will be performed under the supervision of a physiotherapist every other day. The application will continue for 20 days.
223687415|NCT03277521|OTHER|Intermittent theta burst stimulation|Intermittent theta burst stimulation (iTBS) is a non-invasive brain stimulation technique that can increase corticomotor excitability.
223687416|NCT03929484|DEVICE|Nasal reservoir cannula|The experimental oxygen mask (nasal reservoir cannula) fits over a standard nasal cannula. The system is designed to reduce administered oxygen to deliver an equal or higher fraction of inspired oxygen (FiO2) per oxygen delivered (L/min) compared with a standard nasal cannula alone.
223687417|NCT00674778|PROCEDURE|Any percutaneous cardiovascular procedure|
223687418|NCT00775944|BEHAVIORAL|Proactive telephone support|Pro-active telephone counselling allows for repeated, sequenced calls to be made by quitline counsellors to smokers and for counselling to be provided during accepted calls.
223687419|NCT00775944|BEHAVIORAL|Reactive (standard) telephone support|Reactive counselling usually involves the provision of evidence-based information to support quit attempts without any or with only very brief counselling to accompany it.
223687420|NCT00775944|DRUG|Offer of voucher for cost-free Nicotine Replacement Therapy|Offer of voucher for cost-free Nicotine Replacement Therapy over the telephone
223687421|NCT00920829|DRUG|Naltrexone 50 Mg|Naltrexone 25 or 50 mg per titration schedule
223687422|NCT00920829|DRUG|Placebo|placebo
223687423|NCT05793437|BEHAVIORAL|permissive hypercapnia|Tidal volume (6-8ml/kg) and respiratory rate is adjusted to achieve the objective values of PaCO2:45～55mmHg
223687424|NCT05793437|BEHAVIORAL|normocapnia|Tidal volume (8-10ml/kg) and respiratory rate is adjusted to achieve the objective values of PaCO2:35～45mmHg
223687425|NCT05684731|BIOLOGICAL|KM1|Administer via intraperitoneal infusion for 3 or 6 doses Q3D.
223687426|NCT05684731|DRUG|Chemotherapy|"Physician's Choice of carboplatin (preferred) or cisplatin，gemcitabine, taxane (paclitaxel, docetaxel or nab-paclitaxel) or pegylated liposomal doxorubicin，with or without bevacizumab.~Administer beginning in Week 5 or Week 6."
223687427|NCT04533880|DEVICE|DBM|Demineralized bone matrix (Allosync, CDMB Putty, Arthrex, Naples, FL)
223687428|NCT04533880|DEVICE|Calcium phosphate cement|Quickset, Arthrex, Naples, FL
223687429|NCT04533880|OTHER|Autologous bone graft|Autologous bone grafting involves utilizing bone obtained from the same individual receiving the graft
223687430|NCT03375827|OTHER|IGCDG|The IGCDG reviews topics of concern for patients with metastatic breast cancer.
223687431|NCT03665415|BEHAVIORAL|NDGameSquad|The intervention will be delivered within participants' homes. Participants will be provided a gaming console and exergames. Participants will be encouraged to meet a goal of 60 minutes/day of MVPA for the duration of the intervention by playing the exergames at least three times per week and engaging in non-screen based physical activity on other days. Participants will receive a booklet that includes a curriculum for playing weekly challenges. Participants will wear a FitBit during their exergaming sessions. Participants and parents meet bi-weekly with a health coach via video-chat using the exergame console. Sessions will identify and encourage specific physical activity, healthy eating, and healthy sleep habits. At the school site, participants will receive additional check-ins, engagement support, and health curricula from classroom teachers during the first 10 weeks of the intervention.
223687432|NCT04082832|DRUG|Cu(II)ATSM|oral suspension
223687433|NCT04082832|DRUG|Placebos|oral suspension
223687434|NCT02394678|DEVICE|AngioJet Thrombectomy System|Mechanical removal of blood, using a pressurised jet of water, from ventricles of patients suffering from intraventricular haemorrhage
223687435|NCT04974918|PROCEDURE|Facial Artery Perforator-Based Nasolabial Flaps in The Reconstruction of large Lip defects post traumatic or post tumor resection.|A perforator near the defect was selected to accomplish a sufficient arc of rotation without tension. The flap was designed to cover the defect based on one perforator and to hide the donor site in the nasolabial fold. An incision on one side of the flap was made to the subcutaneous tissue. Undermining of the flap until the perforators were identified. After the perforators were identified, the flap was redesigned and an incision was made circumferentially. Dissection of the pedicle was performed until tension-free transposition was done to cover the defect, and the distal perforators were sacrificed to help flap movement.
223687436|NCT05654441|BIOLOGICAL|Influenza vaccine|0.5 mL single-dose injection
223687437|NCT05654441|BIOLOGICAL|Placebo|0.5 mL single-dose injection with no therapeutic effect
223687438|NCT03265327|DIETARY_SUPPLEMENT|Oral supplement containing omega-3 and omega-6|An oral supplement containing omega-3 and omega-6
223687439|NCT03265327|DIETARY_SUPPLEMENT|Oral supplement containing coconut and olive oil|An oral supplement containing coconut oil and olive oil
223687440|NCT05592834|BEHAVIORAL|positive deviance hearth strategy|"The PD-program is run for 3-months with 2 weeks (12 days) of nutrition education and rehabilitation sessions (NERS) conducted in each month. Each day session includes an half hour education session and a one and half hour peer led cooking session. Caretakers learn how to rehabilitate their malnourished children under the supervision and the support of caregivers who have well-nourished children (positive deviants). Children are nutritionally assessed by trained nutrition assistants or clinician on the 1st day of the NERS sessions and after three months.~During the rehabilitation sessions, caregivers learn how to prepare nutrient-rich meals for their children from locally available food identified during the positive deviance-inquiry, and actively practice good feeding and hygiene practices. Caregivers together prepare food menus based on the PD-inquiry good foods or what they can conveniently access but of equal nutritional value."
223687441|NCT05592834|BEHAVIORAL|Parent facilitator trainings|Primary caregivers of children with CP residing in the study setting are trained as parent facilitators by expert physical rehabilitation therapist . Trained parent facilitators then hold fellow caregiver workshops each lasting approximately two hours long and includes between 6-10 caregivers. To ensure quality and consistency of the workshops, the Parent Facilitators follow a detailed manual adapted from the Carer-2-Carer Programme translated into Lusoga, the local language. No expert therapists is involved in the parent facilitator training workshops. Parent facilitator training workshops involve 7 sessions that expose caregivers to understanding CP and how to improve body functioning: session1: what is CP? session2: CP as a way of life, Session 3: Getting my child's body ready to move, Session 4: Eating and drinking a healthy diet, Session 5: communication, Session 6: Play, and Session 7: Central visual impairment.
223687442|NCT05592834|OTHER|Control|This group will receive neither the PD nor the PFT interventions but care as usual
223687443|NCT00443612|DRUG|Irbesartan/Hydrochlorothiazide|Administration of irbesartan 150 mg/day + hydrochlorothiazide 12.5 mg
223687444|NCT00443612|DRUG|Irbesartan|Administration of irbesartan 150 mg/day
223687445|NCT02005328|DEVICE|Tested product : DC161-DP0291|Application of product in the mouth twice daily
223687446|NCT02005328|DEVICE|Tested product : DC161-DP0292|Application of product in the mouth twice daily
223687447|NCT02005328|DEVICE|Tested product : DC161-DP0293|Application of product in the mouth twice daily
223687448|NCT02005328|DEVICE|Reference product: solution for oromucosal sprays|Application of product in the mouth twice daily
223687449|NCT03824028|DEVICE|Clareon® IOL AutonoMe™ automated preloaded delivery system|Disposable injector preloaded with the Clareon IOL for precise IOL insertion during cataract surgery
223687450|NCT01607268|PROCEDURE|Magnetic Resonance Spectroscopy Imaging|Proton magnetic resonance spectroscopy \[1H-MRS\] is an emerging imaging tool that allows for non-invasive assessment of brain neurochemistry in human subjects. This technique allows for in vivo quantification of the concentration of neurotransmitters and metabolites in discrete brain regions through detection of hydrogen nuclei in these molecules. Autonomic failure patients will undergo a single imaging session lasting 30 to 90 minutes (0.5-1.5 hours) in the Vanderbilt Human Imaging Institute.
223687451|NCT06385990|DRUG|UTD1|UTD1: 30mg / m², once a day on days 1-5; capecitabine: 1000mg / m², days 1-14, oral, twice / day; 21 days a treatment cycle of 6-8 cycles.
223687452|NCT02849665|OTHER|Kangaroo Position|
223687453|NCT04830644|DRUG|Iguratimod|Iguratimod orally twice a day
223687454|NCT04830644|DRUG|Placebo|Placebo orally twice a day
223687455|NCT04867239|OTHER|A two-day education progra|During the camp, the multidisciplinary team provided disease information, lifestyle modification, nutrition, and exercise.
223687456|NCT04768985|DRUG|Treatment A: Acalabrutinib tablet|Participants will receive fixed single doses of acalabrutinib tablet in 2 treatment periods, under fasted conditions.
223687457|NCT04768985|DRUG|Treatment B: Acalabrutinib capsule|Participants will receive fixed single doses of acalabrutinib capsule in 2 treatment periods, under fasted conditions.
223687458|NCT01955980|DRUG|Budesonide|Inhalation
223687459|NCT01955980|DRUG|Budesonide|Nasal Spray
223687460|NCT02530567|PROCEDURE|Intervention|All patients performing the biopsy will have an MRI to carry out the necessary measures.
223687461|NCT04259554|DEVICE|OFC rTMS|repetitive transcranial magnetic stimulation over right orbito-frontal cortex with 1Hz (360 pulses in 6 trains á 60 pulses with 30s intertrain-interval)
223687462|NCT04177927|DEVICE|Capnostream 20p / Coviden|The special nasal canule is used for detection carbondioxide from breathe of patients
223687463|NCT04177927|DEVICE|Rutine monitoring|peripheric Oxygen saturation is monitored.
223687464|NCT02477267|DRUG|SL spray|
223687465|NCT02477267|DRUG|SL film|
223687466|NCT01037322|DRUG|cannabidiol|cannabidiol given in olive oil drops, 5 mg twice daily
223775929|NCT02678039|PROCEDURE|Traditional|An epidural catheter is placed before surgery with the patient sitting at bedside. The catheter is placed with local anesthesia using indirect indicators of proper placement: depth of needle insertion and ability to inject solution through the needle ('loss of resistance'). After needle placement in the epidural space, an epidural catheter is threaded through the needle 3-4 cm and the needle removed. After catheter is placement, a test dose of 1.5% lidocaine with 5ug/cc epinephrine is injected into the catheter to exclude intravascular placement. Following this, a continuous infusion of 1/8% bupivacaine is started at 4ml/hr. After surgery, the bupivacaine infusion may be adjusted with bolus injections of 2ml and/or increase in the infusion rate by 2ml/hr up to a maximum of 14ml/hr.
223687467|NCT01037322|DRUG|placebo in drops|olive oil containing no drug given in drops twice daily
223687468|NCT02793011|DRUG|Dexamethasone|Oral dexamethasone elixir (0.5mg/ml or 4 mg/ml) mixed with Ora-sweet or simple syrup to mask the taste. Or 1 mg or 4 mg dexamethasone capsules if age appropriate
223687469|NCT02793011|DRUG|Placebo|Placebo liquid (Ora-sweet or simple syrup) or Placebo capsule
223687470|NCT04535765|OTHER|early warm water sitz bath|The experimental group started the warm water sitz bath 6 hours after the end of the hemorrhoid surgery.
223687471|NCT04535765|OTHER|Regular time warm water sitz bath|According to the routine, the control group started the warm water sitz bath on the first day after the hemorrhoid surgery.
223687472|NCT01711879|DRUG|Aflibercept|Details covered in arm description
223687473|NCT05692167|DRUG|Topical dexmedetomidine|Patients will receive mixture of one milliliter of dexmedetomidine-HCl and local anesthetic
223687474|NCT05692167|DRUG|Reginal dexmedetomidine|Patients will receive mixture of bupivacaine 0.5% (4.5 ml) + lidocaine 2% (4.5 ml) + dexmedetomidine 50 μg (1 ml) in peribulbar block
223687475|NCT04426201|DRUG|CYT107|IM administration at 10µg/kg twice a week for three weeks and up to 7 administrations according to Hospital length of stay
223687476|NCT04426201|DRUG|Placebo|Same number, volume and frequency of IM administration of saline
223687477|NCT04160481|DIETARY_SUPPLEMENT|FruitFlow|300mg tomato extract
223687478|NCT04160481|DIETARY_SUPPLEMENT|Placebo|Maltodextrin
223687479|NCT00503438|DEVICE|Salto Talaris Ankle|Salto Talaris Anatomic Ankle total joint prosthesis
223775930|NCT01464528|DRUG|Hyaluronan|single use of 10 mL of the hyalobarrier gel intrauterine immediately following hysteroscopic surgery
223687480|NCT04542538|OTHER|No intervention, observational study|
223687481|NCT05768971|OTHER|Mild diet|
223687482|NCT05768971|OTHER|Provocative diet|
223687483|NCT03892473|OTHER|Community mental health teams (CMHT)|Community mental health teams (CMHTs) delivering evidence-based interventions to people with SMI, inspired by the Flexible Assertive Community Treatment (FACT) service delivery model.
223687484|NCT03892473|OTHER|Care as usual (CAU)|Care as usual (CAU) usually consisting of inpatient psychiatric care or outpatient care prescribing medication.
223687485|NCT03071198|PROCEDURE|TME|"1. Find the hypogastric nerve trunk in front of sacral promontory and protect it,be careful to use electrocautery hemostasis biased toward the side of rectal when handle lateral ligament of rectum and middle rectal artery and avoid to damage the pelvic plexus.~2. At least a 2-cm margin to the lower edge of the tumor is adequate for distal bowel resection. Resect 5cm length distal rectal or all of the mesorectum.Check the integrity of the mesorectum in postoperative routine examination. Double stapling method is used for all low anastomosis operations."
223687486|NCT03071198|RADIATION|Concurrent chemo-radiotherapy|Three-dimensional conformal radiotherapy as following: CTV 44Gy/22 times＋GTV1 6Gy/3 times(2Gy/time/day，5 days a week，totally 5 weeks),if rectal tumors do not regress obviously, additional GTV2 is necessary, 5.4Gy/3 times (1.8Gy/time/day). At the same time, Capecitabine (850mg/m2, two times every day) will be taken on radiotherapy day
223687487|NCT03071198|DRUG|neoadjuvant CT|CAPEOX protocol:Oxaliplatin 130mg/m2 ivgtt 2-6h dl;(Capecitabine 1000mg/m2 2 times a day lasts for 14 days Repeat every 3 weeks
223687488|NCT03071198|DRUG|adjuvant CT|CAPEOX protocol:Oxaliplatin 130mg/m2 ivgtt 2-6h dl;(Capecitabine 1000mg/m2 2 times a day lasts for 14 days Repeat every 3 weeks
223687489|NCT03658707|OTHER|questionnaire|Shoulder questionnaire
223687490|NCT01231308|PROCEDURE|Roux-en-Y-Gastric Bypass|Standard laparoscopic gastric bypass. Preoperative preparation will include antibiotic prophylaxis given less than 60 minutes prior to making the first incision. Under general anesthesia with endotracheal intubation, a laparoscopic gastric bypass will be performed in the usual fashion.
223775931|NCT04230382|DIAGNOSTIC_TEST|Diagnosis of diabetes (OGTT)|Blood sample will be collected for glucose, HbA1c and magnesium. Standard OGTT will be conducted with 75g of glucose (repeated, if disgnostic).
223775932|NCT06105307|BEHAVIORAL|RN-SLEEP|RN-SLEEP is a training program delivered via mobile application and designed to help improve the sleep of nurses who engage in shift work. RN-SLEEP aims to include training on strategies for sleeping while working shift work, basics of sleep science and physiology, behavior change components (i.e., goal setting), and components of cognitive behavioral therapy for insomnia (i.e., relaxation).
223687491|NCT01231308|BEHAVIORAL|Intensive lifestyle modification and Optimal medical Therapy|Very low calorie diet consisting of 5 feedings: 2 liquid meal replacements, 2 low-calorie snacks, and 1 small meal of known caloric content. After 10% weight loss is achieved, the subjects will received individualized nutrition sessions beginning bi-weekly but extending time intervals as the weight loss progresses.
223687492|NCT05035641|DRUG|AND017|Orally, 3 times per week in Period 1 and randomize to TIW or QW group at the same dose in Period 2
223687493|NCT05035641|DRUG|Placebo|Orally, 3 times per week
223687494|NCT02343133|BIOLOGICAL|HemaMax|
223687495|NCT02343133|DRUG|Placebo|
223687496|NCT00234390|DRUG|Pulmicort (budesonide) pMDI|
223687497|NCT02783677|PROCEDURE|Percutaneous balloon angioplasty|
223687498|NCT02464917|DEVICE|Device: simple facemask to administer supplemental oxygen|
223687499|NCT02147028|RADIATION|Hippocampal sparing whole brain radiotherapy|30 Gy in 10 fractions hippocampal sparing whole brain radiotherapy will be administered by Helical Tomotherapy, IMRT, or VMAT
223687500|NCT02147028|RADIATION|Conventional whole brain radiotherapy|30 Gy in 10 fractions conventional whole brain radiotherapy will be administered
223687501|NCT05910177|DRUG|Karelizumab combined with etoposide and cisplatin|Karelizumab：200 mg，ivgtt，D1，q3w； Cisplatin：75 mg/m2，ivgtt，D1，q3w； Etoposide：100 mg/m2，ivgtt，D1\~3，q3w
223687502|NCT05730634|DRUG|Atorvastatin 40 Mg Oral Tablet|Atorvastatin 40mg once daily for three months
223687503|NCT02239224|BIOLOGICAL|Placebo|Concentrate for solution for infusion
223687504|NCT02239224|BIOLOGICAL|ATYR1940|Concentrate for solution for infusion
223687505|NCT03718871|BEHAVIORAL|HIV testing at traditional healer practices|HIV 1/2 antigen-antibody POC test (Oraquick©) will be administered to those participants who agree to test. Pre-test counseling will be performed before results are delivered. Clients with positive tests will be provided with detailed contact information for the MUST ISS clinic, and given specific instructions to present to the clinic as soon as possible for confirmatory testing and linkage to care.
223687506|NCT02395510|DRUG|Vortioxetine|Vortioxetine 5-20mg
223687507|NCT00073073|DRUG|Exemestane|exemestane 25 mg by mouth (PO) every day for two years
223687508|NCT00073073|DIETARY_SUPPLEMENT|Calcium carbonate|calcium carbonate 1200 mg PO every day x 2 years
223687509|NCT00073073|DIETARY_SUPPLEMENT|Vitamin D|Vitamin D 400 international units PO every day x 2 years
223687510|NCT05291026|OTHER|mobile phone-based health information|health education and follow-up messaging, randomly assigned to each participant in the intervention arm using a randomization software, delivered once daily, as short message service (sms)
223687511|NCT05337436|BIOLOGICAL|Lymphatic drainage|Biological determination in plasma:
223687512|NCT05337436|BIOLOGICAL|Total and ionized magnesium|Total and ionized magnesium
223687513|NCT05337436|BIOLOGICAL|Total and ionized calcium|Total and ionized calcium
223687514|NCT00101712|DRUG|vildagliptin|
223687515|NCT00101712|DRUG|Vildagliptin Placebo|
223687516|NCT03183778|DRUG|Patiromer|Patiromer dosing will be determined based on fasting potassium concentrations measured at the end of each week, factoring in both the absolute concentration, as well as the rate of change. The baseline dose of patiromer will correspond to the study by Weir et al. (2015); 8.4-g once per day for participants with a baseline serum potassium of greater than or equal to 5.1 mEq/L.
223687517|NCT03183778|DIETARY_SUPPLEMENT|Research Diet Menu|During the study, participants will be asked to consume only the foods provided in the research diet
223687518|NCT01512056|DRUG|AdimFlu-S|All enrolled participants will be divided into 3 groups: participants refused to receive vaccination, those receive either one (week 0) or one more booster vaccination (week 0 and week 3). Each dose of vaccine contains 15μg antigen of each virus strain suggested by WHO (A/California/7/2009 (H1N1);A/Perth/16/2009 (H3N2);B/Brisbane/60/2008).
223687519|NCT03031236|BEHAVIORAL|Psychosocial stimulation, Cognitive behavioral therapy and positive parenting practice|The mothers of intervention (ECD+HN) group will receive fortnightly group sessions for 12 months that will include combined messages on a) psychosocial stimulation, b) positive parenting to prevent child maltreatment and c) cognitive behavioural therapy (CBT) for positive thinking, d) health and nutrition messages and e) 15 micronutrient sprinkle supplement.(90 sachets of over 6 month-period)
223687520|NCT02248415|OTHER|No pump|In the no pump group blood cardioplegia was delivered using the arterial line pressure, created by the arterial centrifugal pump of the cardiopulmonary bypass system. Blood cardioplegia flow depended on the difference between arterial line pressure and aortic root pressure.
223687521|NCT02248415|OTHER|Pump|In the pump group blood cardioplegia was delivered using a roller pump. The blood cardioplegia flow was given at 200 mL/min.
223687522|NCT02248415|OTHER|Blood sample collection: after induction of anaesthesia (T0)|The following biomarkers were analysed: TnT-hs, H-FABP, NT-pro-BNP and CRP.
223687523|NCT02248415|OTHER|Blood sample collection: after arrival at the ICU (T1)|The following biomarkers were analysed: TnT-hs, H-FABP, NT-pro-BNP and CRP.
223687524|NCT02248415|OTHER|Blood sample collection: 4 hours in ICU (T2)|The following biomarkers were analysed: TnT-hs, H-FABP, NT-pro-BNP and CRP.
223687525|NCT02248415|OTHER|Blood sample collection: the first postoperative day (T3)|The following biomarkers were analysed: TnT-hs, H-FABP, NT-pro-BNP and CRP.
223687526|NCT04732169|DRUG|Active study drug ( oral CBD)|CBD in single dose syringes
223687527|NCT04732169|DRUG|matching placebo|Placebo made with sesame oil flavored with strawberry flavoring in single dose syringes
223687528|NCT02921360|DRUG|acetylsalicylic acid|
223687529|NCT01670318|DEVICE|platinum chromium everolimus-eluting stent (PROMUS Element by Boston Scientific, Massachusetts)|
223687530|NCT04758910|DEVICE|High Flow Oxygen Therapy|A 30-minute spontaneous breathing trial using high flow oxygen therapy via tracheostomy.
223687531|NCT04758910|DEVICE|T-piece|A 30-minute spontaneous breathing trial using T-piece via tracheostomy.
223687532|NCT00000656|DRUG|Zidovudine|
223687533|NCT00000656|DRUG|Didanosine|
223687534|NCT00272428|BEHAVIORAL|ascorbic acid, vitamin E, beta carotene, selenium, zinc|
223687535|NCT02929173|OTHER|Allceram|Pressed E-max coping veneered with E-max veneering system
223687536|NCT02929173|OTHER|hybrid crown|pressed Bio HPP coping veneered with visolign veneering system
223687537|NCT00721123|DRUG|Tocilizumab|Tocilizumab (myeloma receptor antibody \[MRA\]) was supplied in sterile solution of 20 mg TCZ/mL for aseptic preparation of infusion bags for IV administration.
223687538|NCT00182871|DRUG|testosterone|
223687539|NCT05041946|DRUG|Methylphenidate|Given PO
223687540|NCT05041946|OTHER|Placebo (Sugar Pill)|Given PO
223687541|NCT01941043|DRUG|CERC-301|
223687542|NCT01941043|OTHER|Placebo|
223687543|NCT05201742|OTHER|Inspiratory muscle training|Threshold inspiratory muscle training was performed for 6 weeks with device.
223687544|NCT05201742|OTHER|Incentive Spirometry|Incentive spirometry was performed for 6 weeks with device.
223687545|NCT04014023|DRUG|DWP16001|DWP16001 tablets
223687546|NCT04014023|DRUG|Placebo|DWP16001 placebo-matching tablets
223687547|NCT00905827|BEHAVIORAL|CAMS|Collaborative assessment management in suicidality
223687548|NCT06086691|OTHER|Strength Training with Caffeine|"The intervention protocol consists of 5 types of strength training exercises. The following exercises will be performed for the strength training group:~1. bench press (3 sets of 10 reps)~2. biceps curl (3 sets of 10 reps)~3. triceps pushdown (3 sets of 10 reps)~4. leg press (3 sets of 10 reps)~5. leg extension (3 sets of 10 reps)~Strength training would be performed in 3 sets of 10 repetitions with 2 minutes of rest between each exercise. This protocol will be performed in a 30-40-minute session. 10-15 minutes of light warm-up activities will be performed before the start of each exercise session. The intervention sessions would be carried out with a 3-5-day gap between the two intervention sessions."
223775933|NCT06105307|BEHAVIORAL|Healthy Habit - Educational Control|Healthy habit app (i.e., exercise tracking) to act as a control arm for the RN-SLEEP intervention
223775934|NCT04955626|BIOLOGICAL|BNT162b2|Intramuscular Injection
223687549|NCT06086691|OTHER|Endurance Training with Caffeine|"The intervention protocol consists of 3 types of endurance training exercises. The following exercises will be performed by this group:~1. Cycling (15 min)~2. Running (20 min)~3. Rowing (10 min)~The intervention sessions would be carried out with a 3-5-day gap between the two intervention sessions."
223687550|NCT00509392|DEVICE|Seg. RF Ablation & ClosureFAST catheter|Seg. RF Ablation \& ClosureFAST catheter
223687551|NCT00509392|DEVICE|Endovenous Laser|laser catheter
223687552|NCT03619343|PROCEDURE|ETOIMS(Electrical Twitch Obtaining Intramuscular Stimulation)|When the abdominal wound is closed, the operator performs needle insertion at 14 sites near the incision site under the guidance of ultrasonography. When the needle is in the abdominal muscle, the operator performs muscle stimulation for about 10 seconds per needle insertion.
223775935|NCT04955626|OTHER|Placebo|Intramuscular Injection
223775936|NCT04955626|BIOLOGICAL|BNT162b2 OMI|Intramuscular Injection
223775937|NCT04955626|BIOLOGICAL|Combination BNT162b2 and BNT162b2 OMI|"30-µg (15-µg each) or 60-µg (30-µg each)~Site prepared dosing suspension from 1 vial each of diluted BNT162b2 and BNT162b2 OMI~Intramuscular Injection"
223775938|NCT04955626|BIOLOGICAL|Combination (Bivalent) BNT162b2 and BNT162b2 OMI|"30-µg (15-µg each) or 60-µg (30-µg each)~Preformulated bivalent mixture (no dilution required) presented in a single vial~Intramuscular Injection"
223687553|NCT00372203|PROCEDURE|Endobronchial Ultrasound Guided Transthoracic Needle Biopsy|Endobronchial Ultrasound Guided Transthoracic Needle Biopsy of mediastinal lymph nodes at the time of the mediastinoscopy.
223687554|NCT02210273|DEVICE|Solace Bladder Control (Vesair) Balloon|Subjects may undergo treatment every 12 months until study completion.
223687555|NCT02210273|DEVICE|Solace Sham Treatment|Sham treatment that resembles treatment with the Solace Bladder Control (Vesair) Balloon
223687556|NCT05574166|DRUG|SP-8356|SP-8356 demonstrates anti-atherosclerotic and anti-ischaemic activity as a novel CD147 inhibitor.
223687557|NCT05574166|DRUG|Placebo|Placebo for SP-8356 powder
223687558|NCT02330484|BEHAVIORAL|Give incentives to patients based on their own HbA1c improvement|Give incentives to patients based on their own HbA1c improvement
223687559|NCT02330484|BEHAVIORAL|Give incentives to physician based on their patient's HbA1c improvement|Give incentives to physician based on their patient's HbA1c improvement
223687560|NCT01279473|DRUG|Nilotinib|
223687561|NCT04951440|DRUG|Nitrate ketone oxazine|Intervention group: 30min intravenous point. Drop qiu was given 1400 mg of injected sichuan nitrone I bed, and the drug was given 100 mL at day F Set 12 h, and at odds with another 7 days, that is, about 14 times in total.
223687562|NCT04689815|DRUG|Oral Arsenic Trioxide Formulation|Eligible subjects with NPM1 MRD positivity will receive oral arsenic trioxide (oral-As2O3) (Arsenol ®) (5-10mg per day, from days 1-7 per cycle), ascorbic acid (1g per day, from days 1 - 7 per cycle) plus azacitidine (75mg/m2 per day subcutaneously, from days 1 to 3 per cycle). Each cycle of oral-As2O3 plus azacitidine will be given once every 28 days. The total duration of treatment is 12 months (12 cycles). Treatment will be day-care and outpatient based. Reduction in the dosage and duration of oral-As2O3 is required if the subject is experiencing adverse events (AEs). In case of grade 3 or above toxicity, the dosage of oral-As2O3 will be reduced to 5mg per day.
223687563|NCT05959200|DEVICE|Serafilcon A toric contact lenses|Silicone hydrogel contact lenses for the optical correction of refractive ametropia (myopia or hyperopia with astigmatism)
223687564|NCT05959200|DEVICE|Senofilcon A toric contact lenses|Silicone hydrogel contact lenses for the optical correction of refractive ametropia (myopia or hyperopia with astigmatism)
223687565|NCT05959200|DEVICE|CLEAR CARE|Hydrogen peroxide-based contact lens cleaning and disinfecting solution
223775939|NCT00281840|BIOLOGICAL|bevacizumab|Bevacizumab IV over 30-90 minutes once every 2 weeks for up to 1 year. Bevacizumab, which stops 8 weeks before surgery, may restart 4 weeks after surgery and continue for 9 months in the absence of disease progression or unacceptable toxicity.
223775940|NCT00281840|DRUG|docetaxel|docetaxel IV over 1 hour once a week for 8 weeks
223687566|NCT03954041|DRUG|BIIB093|Administered as specified in the treatment arm.
223687567|NCT03954041|DRUG|Placebo|Administered as specified in the treatment arm.
223687568|NCT06110572|DRUG|Carboplatin|Given by IV
223687569|NCT06110572|BIOLOGICAL|Atezolizumab|Given by IV
223687570|NCT06110572|DRUG|Etoposide|Given by IV
223687571|NCT06110572|RADIATION|Total Body Irradiation|Undergo Total Body Irradiation
223687572|NCT06110572|RADIATION|Hypofractionated Radiation Therapy|Undergo Hypofractionated Radiation Therapy
223687573|NCT06110572|PROCEDURE|Magnetic Resonance Imaging|Undergo Magnetic Resonance Imaging
223687574|NCT06343389|DIAGNOSTIC_TEST|serum creatinine|to detect patients with Acute kidney injury
223687575|NCT03054454|PROCEDURE|Podiatry|Podiatry treatments and care from the multidisciplinary team.
223687576|NCT03024879|DRUG|Erythromycin|
223687577|NCT03024879|DRUG|Saline|
223687578|NCT04958772|BIOLOGICAL|Filgrastim Megalabs|Filgrastim Megalabs 5 μg/Kg/day, subcutaneous single dose
223775941|NCT00281840|PROCEDURE|conventional surgery|8-10 weeks after the completion of chemoradiotherapy, patients may undergo neck dissection
223775942|NCT00281840|RADIATION|radiation therapy|radiotherapy once daily, 5 days a week, for 8 weeks
223687579|NCT04958772|BIOLOGICAL|Granulokine|Granulokine 5 μg/Kg/day, subcutaneous single dose
223687580|NCT05324722|OTHER|pragmatic posterior capsular stretch|pragmatic posterior stretch is used to increase the length of the posterior capsule
223687581|NCT05324722|OTHER|cross body stretch|crossbody stretch performed by an individual
223687582|NCT05926414|DRUG|Enavogliflozin|treated with Envlo tab. 0.3mg
223687583|NCT05926414|DRUG|Enavogliflozin|Envlomet SR Tablet 0.3/1,000mg
223687584|NCT02218255|DEVICE|Eeva™ results|
223687585|NCT02600065|OTHER|Blood draw and MRI|The study is observational. The treatment-plan of the underlying disease remained unchanged. Blood draw and MRI from patients at several time points during and after radio(chemo)therapy.
223687586|NCT02837068|DEVICE|Wheelchair handrail compensator|Patients were treated by wheelchair handrail compensator for six times per week during the four-weeks treatment, with each treatment lasting at least 60 minutes, and follow up by eight weeks. The handrail compensator would help the paralysis upper limb kept the shoulder joint stretch forward, the elbow joint extend, the forearm in pronation, the wrist in flection and the fingers extend.
223687587|NCT02837068|DEVICE|Ordinary wheelchair|Patients were treated by ordinary wheelchair for six times per week during the four-weeks treatment, with each treatment lasting at least 60 minutes, and follow up by eight weeks.The ordinary handrail could prevent the disable arm from sinking, but could not help the upper limp keep a normal position.
223687588|NCT05857943|DEVICE|AEYE-DS Software|Eligible participants will undergo the following procedures: Photographic imaging of each eye using a funduscopy camera device. Images obtained will be sent to the AEYE-DS software for analysis. -Additional photographic and OCT images will be obtained using a second funduscopy/OCT camera device. Images obtained will be sent to a professional reading center for analysis. -All study subjects will have their pupils dilated using dilation drops.
223687589|NCT02547324|RADIATION|Slump sitting|Patients are asked to sit slumped on the chair as much as possible without leaning forwards, and place you hands below your thighs.
223687590|NCT02547324|RADIATION|Forward bending|Patients are asked to stand with both feet placed together, hands behind their heads, and bend forward in this position as much as possible without falling
223687591|NCT04837092|DRUG|FR104|FR104 treatment administration at day 0, day 14 then every 28 days until month 12
223687592|NCT03868124|COMBINATION_PRODUCT|G2-TR intraocular implant containing travoprost|Provided in Arm/Group descriptions
223687593|NCT03868124|DRUG|Sham surgery + active-comparator eye drops|Sham surgery plus postoperative active-comparator eye drops (Timolol Maleate ophthalmic solution, 0.5%)
223687594|NCT04106908|BIOLOGICAL|Eqwilate|Eqwilate® is a new generation, albumin-free, high-purity, double virus-inactivated, freezedried concentrate of VWF and FVIII
223687595|NCT04177355|BIOLOGICAL|BG505 SOSIP.664 gp140|Administered by IM injection
223687596|NCT04177355|BIOLOGICAL|Placebo|Administered by IM injection
223687597|NCT04177355|BIOLOGICAL|3M-052-AF|Administered by IM injection
223687598|NCT04177355|BIOLOGICAL|CpG 1018|Administered by IM injection
223687599|NCT04177355|BIOLOGICAL|GLA-LSQ|Administered by IM injection
223687600|NCT04177355|BIOLOGICAL|Alum (Aluminum Hydroxide Suspension)|Administered by IM injection
223687601|NCT04177355|BIOLOGICAL|Trimer 4571|Administered by IM injection
223687602|NCT04986579|DEVICE|Paxman Scalp Cooling System|Cap attached to coolant lines connected to a refrigeration unit placed on scalp
223687603|NCT04986579|DRUG|Eribulin|Intravenous Infusion
223687604|NCT04986579|DRUG|Sacituzumab govitecan|Intravenous Infusion
223687605|NCT04986579|DRUG|Trastuzumab deruxtecan|Intravenous Infusion
223687606|NCT05802173|DRUG|TDM-105795, 0.0025%|The assigned drug will be applied once daily for 16 weeks, with application to the scalp focusing on the regions that are bald and thinning.
223687607|NCT05802173|DRUG|TDM-105795, 0.02%|The assigned drug will be applied once daily for 16 weeks, with application to the scalp focusing on the regions that are bald and thinning.
223687608|NCT05802173|DRUG|TDM-105795 topical vehicle solution|The assigned placebo will be applied once daily for 16 weeks, with application to the scalp focusing on the regions that are bald and thinning.
223687609|NCT05559333|PROCEDURE|class I restoration placement|zirconomer, glass carbomer, glass ionomer and composite resin class I restorations were placed.
223687610|NCT01165333|DRUG|Cilengitide dose escalation|"Cilengitide will be administered intravenously over 60 minutes, twice a week, at a given dose.~The Cilengitide dose (mg/m²/infusion)levels are as follows :~* 240~* 480~* 720~* 1200~* 1800"
223687611|NCT01165333|DRUG|Cilengitide|Patients will be treated at the recommended dose in order to confirm the recommended cilengitide dose and to carry out the exploratory investigations
223687612|NCT01165333|RADIATION|Concomitant radiotherapy|1.8 Gy per fraction for a total of 54 Gy over 6 weeks, from monday to friday of the first cycle. The radiation will imperatively begin between 3 and 7hours after the end of Cilengitide infusion.
223687613|NCT01165333|BIOLOGICAL|Pharmacokinetic|A pharmacokinetic assessment for Cilengitide will be carried for all patients. The pharmacokinetic (PK) samples will be drawn during day 1 and day 2 of the first cycle of treatment.
223687614|NCT01165333|BIOLOGICAL|Pharmacogenetic|For every patient 1 blood sample will be taken before study treatment. These blood samples can be made at any hour of the day, and does not require to be taken on an empty stomach. DNA will be extracted in the Laboratory of Pharmacology.Constitutional polymorphisms of genes will be measured before the treatment initiation.
223687615|NCT01165333|BIOLOGICAL|Exploratory investigation|Evaluate the metabolic impact of the treatment with dynamic MRI (diffusion, perfusion, spectro), and with FDG-PETand sestamibi SPECT.
223687616|NCT05793515|DIAGNOSTIC_TEST|whole genome sequencing|Whole genome sequencing will be performed in patients whose test was negative for the targeted resequencing and/or clinical exome sequencing.
223687617|NCT05099393|DIETARY_SUPPLEMENT|Non Nutritive Sweeteners|"The 2 arms will participate in 3 periods and each of these periods will correspond to the intake of either sucralose, AceK or a placebo.~The order will be defined randomly. There will be 3 periods and each period will last 4 weeks. 7 to 14 days of break will be respected between each period."
223687618|NCT02448186|BEHAVIORAL|ESTEEM|10-session cognitive behavioral treatment
223687619|NCT01632917|DRUG|ATX-101 - U.S.|US ATX-101, 10 mg/mL, one dosing session in the submental area
223687620|NCT01632917|DRUG|ATX-101 - EU|EU ATX-101, 10 mg/mL, one dosing session in the submental area
223687621|NCT04120285|BEHAVIORAL|remote internet-based cognitive behavior therapy (eCBT)|Provide access to online psychotherapy program to participants in rural WV areas at no expense to them.
223687622|NCT06218069|DRUG|Sasanlimab|6 mL of the study drug will be administered subcutaneous injection in the abdominal fat fold. If SC injections in the abdominal location are not possible, SC injections can be administered in a distributed manner in the thighs. SC injections in the upper extremities (eg, deltoid, upper and lower arm) are not permitted. Any observed abnormality at the injection site (e.g. erythema, induration, ecchymosis, injection site pain, injection site pruritus) will be monitored and judged by the investigator to determine whether a corresponding AE should be reported.
223687623|NCT06218069|RADIATION|non-ablative radiotherapy|Patients will receive a total dose of 24Gy irradiation to the tumor, fractionated in 3 doses of 8Gy, on three consecutive days and starting on the day of first sasanlimab administration.
223687624|NCT06218069|DRUG|[89Zr]Zr-crefmirlimab berdoxam|Prior to sasanlimab injection and prior to surgery, \[89Zr\]Zr-crefmirlimab berdoxam (1.5 mg protein dose labelled with activity dose 37 MBq Zirconium-89) will be administered via an intravenous catheter. After 21-27 hours after injection patient will undergo a whole-body PETscan te detect CD8+ T-cell infiltration.
223687625|NCT05255653|DRUG|Olaparib|300 mg twice daily for one year
223687626|NCT05255653|RADIATION|Pelvic external beam radiotherapy|45.0-48.6 Gy; 1.8-2.0 Gy per fraction, 5 fractions a week
223687627|NCT05255653|DRUG|Chemotherapy|Preferably concurrent and adjuvant according to the PORTEC-3 schedule: two cycles of intravenous cisplatin 50mg/m² in the first and fourth week of the pelvic external beam radiotherapy followed by four cycles of intravenous carboplatin AUC 5 and paclitaxel 175 mg/m² at 21-day intervals.
223687628|NCT05255653|DRUG|Durvalumab|1500 mg intravenous once every 4 weeks for in total 1 year (13 cycles) starting within the first week of radiotherapy,
223687629|NCT05255653|DRUG|Medroxyprogesterone Acetate|Oral medroxyprogesterone acetate for two years
223687630|NCT05255653|DRUG|Megestrol Acetate|Oral medroxyprogesterone acetate for two years
223687631|NCT05255653|RADIATION|Vaginal brachytherapy|Vaginal brachytherapy is to be considered in patients with documented cervical stromal involvement and/or substantial LVSI. Brachytherapy is given with a vaginal cylinder or vaginal ovoids or ring applicator, according to the center's standard technique. When using a cylinder, the active length will ideally be 2-3 cm, with the reference isodose covering the proximal 2.5-3 cm of the vagina. High-dose-rate (HDR) and pulse-dose-rate (PDR) schedules are permitted, which deliver an EQD2 equivalent dose of 10-14 Gy at 5 mm from the vaginal mucosa (to obtain a cumulative EDQ2 of 60 Gy at 5 mm).
223687632|NCT05255653|OTHER|Observation|No adjuvant therapy
223687633|NCT00433511|BIOLOGICAL|Bevacizumab|Given IV
223687634|NCT00433511|DRUG|Cyclophosphamide|Given IV
223687635|NCT00433511|DRUG|Doxorubicin Hydrochloride|Given IV
223687636|NCT00433511|OTHER|Laboratory Biomarker Analysis|Correlative studies
223687637|NCT00433511|DRUG|Paclitaxel|Given IV
223687638|NCT00433511|OTHER|Placebo Administration|Given IV
223687639|NCT00433511|OTHER|Quality-of-Life Assessment|Ancillary studies (closed as of 5/28/10)
223687640|NCT05192122|OTHER|Discontinue maintenance therapy SOC|Continue maintenance therapy SOC
223687641|NCT03920618|DRUG|Entecavir|Patients would receive treatment of oral entecavir (ETV) 0.5 mg once per day.
223687642|NCT03920618|DRUG|Tenofovir Disoproxil Fumarate|Patients would receive treatment of oral tenofovir disoproxil fumarate (TDF) 300 mg once per day.
223687643|NCT03920618|DRUG|Tenofovir Alafenamide|Patients would receive treatment of oral tenofovir alafenamide (TAF) 25 mg once per day.
223687644|NCT05534087|DRUG|mFOLFIRINOX-FOLFIRI intensified chemotherapy|"(1) Modified FOLFIRINOX (mFOLFIRINOX) regimen: 6 cycles every 2 weeks~* Oxaliplatin 85mg/m2 IV infusion over 120 min D1~* Leucovorin 400mg/m2 IV (concurrently with oxaliplatin)~* Irinotecan 150mg/m2 IV infusion over 60-90 min D1~* 5-fluorouracil 2,400mg/m2 IV infusion continuously over 46-48h D1-2"
223687645|NCT05534087|DRUG|FOLFOX or CAPOX adjuvant chemotherapy|"1. FOLFOX regimen: 6 cycles every 2 weeks~   * Oxaliplatin 85mg/m2 IV infusion over 120 min D1~  * Leucovorin 400mg/m2 IV infusion over 120 min (concurrently with oxaliplatin)~  * 5-fluorouracil 400mg/m2 IV bolus D1~  * 5-fluorouracil 2,400mg/m2 IV infusion continuously over 46-48h D1-2 or~2. CAPOX regimen: 4 cycles every 3 weeks~   * Oxaliplatin 130mg/m2 IV infusion over 120 min D1~  * Capecitabine 1,000mg/m2 PO bid D1-14"
223687646|NCT04474132|DEVICE|toxoplasma ICT IgG-IgM BK|a point-of-care device, using blood from finger stick to measure the presence or absence of anti Toxoplasma gondii antibody
223687647|NCT04912011|DRUG|Canrenoate Potassium|Intervention: 200 mg of Canrenoate potassium in 100 ml 0,9% NaCl, intravenously twice a day for 7 days.
223687648|NCT04912011|DRUG|Normal Saline|Placebo: 100 ml 0,9% NaCl, intravenously twice a day for 7 days.
223687649|NCT03370614|OTHER|IBS Group|Participants will receive approximately 2 months of dietary and nutritional counseling.
223687650|NCT03370614|OTHER|Healthy Control Group|Participants will not receive any dietary or nutritional counseling.
223687651|NCT06053463|DEVICE|Daily disposable multifocal soft contact lens|Daily disposable multifocal soft contact lens that will be worn for 1 month.
223687652|NCT03703050|DRUG|Nivolumab cohort 1|Induction: nivolumab 3 mg/kg (maximal unitary dose: 240 mg) iv Q2W until CR Evaluation of response as defined below, including biopsy in case of residual masses at Week 24 Maintenance: nivolumab 3 mg/kg (maximal unitary dose: 240 mg) Q4W Total duration of treatment (induction + maintenance) = 24 months
223687653|NCT03703050|DRUG|Nivolumab cohort 2|Induction: nivolumab 3 mg/kg iv Q2W for 4 doses (Wk0, Wk2, Wk4 and Wk6) Maintenance: nivolumab 3 mg/kg Q4W, for 25 doses, starting at Week 8 (14 days after the last induction dose) Total duration of treatment (induction + maintenance) = 24 months
223687654|NCT06003712|BEHAVIORAL|Mindfulness|Participants will engage in a 10-15 minute mindfulness exercise three times weekly for one month. This mindfulness exercise utilizes guided attention on the breath through an instructional video, aiming to cultivate calmness and alleviate stress.
223687655|NCT06262464|BEHAVIORAL|Prevention|A cognitive-behavioural prevention programme.
223687656|NCT04931212|PROCEDURE|FETO with Smart-TO balloon|Fetal endoscopic tracheal occlusion using the Smart-TO balloon Unplug procedure by peripheral course around the MR scanner
223687657|NCT06028347|BIOLOGICAL|sa-mRNA vaccine Dose 1|self-amplifying mRNA vaccine
223687658|NCT06028347|BIOLOGICAL|sa-mRNA vaccine Dose 2|self-amplifying mRNA vaccine
223687659|NCT06028347|BIOLOGICAL|sa-mRNA vaccine Dose 3|self-amplifying mRNA vaccine
223687660|NCT06028347|BIOLOGICAL|Placebo|Saline for injection
223687661|NCT06042257|DRUG|Guanfacine Hydrochloride Immediate Release|0.5 mg capsules
223687662|NCT06042257|DRUG|Placebo|Matching placebo capsule
223687663|NCT04902053|DIAGNOSTIC_TEST|Subjects previously implanted with INSPIRIS RESILIA Model 11500A and are undergoing planned valve-in-valve treatment.|Designed to capture Adverse Event information and valve measurement data from dysfunctional INSPIRIS RESILIA aortic valves before and after Valve-in-valve (ViV) treatment.
223687664|NCT06581796|OTHER|pepsinogen-1|association between pepsinogen 1 serum level with hyperemesis gravidarum
223687665|NCT06583239|OTHER|Engagement Navigator Service (ENS)|ENS will be a centralized service, staffed by dedicated professional to (1) receive and organize referrals, (2) complete ongoing specialized training in engagement science and evidence-based strategies, (3) provide unbiased support when participants' and/or families' relationships with a CSC program are poor, (4) re-engage participants in CSC or actively connect them with other services if preferred, and (5) continue contact with those who refuse treatment in case they reconsider.
223687666|NCT04953052|DRUG|Imatinib Mesylate|An isotonic sterile solution of imatinib.
223687667|NCT04953052|DRUG|Placebo|An isotonic sterile solution
223687668|NCT02629484|OTHER|Focused cardiac ultrasound|focused cardiac ultrasound is a goal-focused transthoracic echocardiography examination of the heart, aimed to improve the diagnostic accuracy of clinical assessment
223687669|NCT03844607|DEVICE|Active Transcranial Direct Current Stimulation (tDCS)|Cognitive training concurrent with 2 mAmps of anodal stimulation applied to the left frontal cortex for 20 minutes.
223687670|NCT03844607|DEVICE|Sham Transcranial Direct Current Stimulation (tDCS)|Cognitive training concurrent with sham tDCS (30 secs ramp up/ramp down of current at beginning of session).
223687671|NCT02806973|DRUG|Nasal Glucagon|Administered intranasally.
223687672|NCT04540575|BEHAVIORAL|NICU Acquires MOM|Mother receives 1) hospital-grade electric smart breast pump for home use at no charge to the mother while the infant is in the NICU and the mother continues to pump; 2) free pickup of expressed MOM from home to transport to NICU 2-3 times per week during weekdays as needed; 3) receives payment for opportunity costs of pumping and handling milk at $24.00/day for each day that the mother pumps during her infant's NICU stay
223687673|NCT04540575|BEHAVIORAL|Mother Provides MOM|Mother receives standard Rush NICU lactation care
223687674|NCT02840240|DRUG|Gabapentin enacarbil|600 mg BID 1 day pre-op and 2 hours before surgery, 6 hours after surgery, 600 mg BID 3 days post-operative
223687675|NCT02840240|DRUG|Placebo|600 mg BID taken 1 day pre-op and 2 hours before surgery, 6 hours after surgery, 600 mg 3 days post-operative
223687676|NCT03606044|DEVICE|3D-models|"The study radiologist will generate a patient-specific virtual 3D model of the participant's body from their pre-operational medical scans (CT, and MRI if available) using regulated commercial medical image analysis software, specifically Osirix MD 9.0 (Pixmeo, Geneva, Switzerland).(Rosset et al. 2004)~The CRFw checks that the medical scan segmentation is accurate and validates the virtual 3D model.~The surgeon checks that the medical scan segmentation is accurate and validates the virtual 3D model.~The surgeon uses all available medical scan data, and the virtual 3D model as an adjunct, to assess the patient anatomy and plan the operation accordingly"
223687677|NCT06427759|PROCEDURE|arm aesthetic surgery|liposuction of arms brachioplasty of arms
223687678|NCT03900442|DRUG|PTX-100|Doses of 500 to 2000 mg/m2 will be administered.
223687679|NCT05940311|PROCEDURE|Blood sampling in addition to the blood normally required for their clinical management|Patients will undergo blood sampling in addition to the blood normally required for their clinical management. The study aims to collect 50 blood samples (one to 4) from 20 patients undergoing treatment in the adjuvant or advanced (metastatic) setting, as per standard of care. The first blood sample (T1) will be carried out immediately before the treatment, the subsequent blood samples (T2-T4) will coincide with the periodic radiographic re-evaluations, typically at months 3 and 6 (M3 and M6, T2 and T3), and at progression/recurrence, if and when recorded.
223687680|NCT05940311|PROCEDURE|Blood plasma and circulating tumor DNA (ctDNA)|Blood drawing by venepuncture (elbow) in K2EDTA vacutainers to obtain blood plasma.The patients will otherwise receive the most appropriate treatment for their condition. The following data will be collected and pseudo-anonymised: demographic data (age and gender), histopathology including primary and metastatic sites, BRAF status, medical imaging, previous therapies assigned if any
223687681|NCT00585559|DRUG|Placebos for acetaminophen and N-acetylcysteine|Placebos for acetaminophen and N-acetylcysteine
223687682|NCT00585559|DRUG|APAP 1 gm every 6 hours and N-acetylcysteine placebo|Acetaminophen 1 gm every 6 hours and N-acetylcysteine placebo
223687683|NCT00585559|DRUG|NAC IV infusion at 0.5 gm hourly and APAP placebo|N-acetylcysteine IV infusion at 0.5 gm hourly and acetaminophen placebo
223687684|NCT00585559|DRUG|APAP 1 gm q6 hours, plus NAC IV infusion at 0.5 gm hourly|Acetaminophen 1 gm every 6 hours, plus N-acetylcysteine IV infusion at 0.5 gm hourly
223687685|NCT00585559|DRUG|APAP 1.5 gm q6 hours, plus NAC IV infusion at 0.5 gm hourly|Acetaminophen 1.5 gm every 6 hours, plus N-acetylcysteine IV infusion at 0.5 gm hourly
223687686|NCT04209426|DEVICE|THA with SYMBOL CUP DMR HA|
223687687|NCT04209426|DEVICE|THA with SYMBOL CUP DM CEM|
223687688|NCT05008185|PROCEDURE|Regenerative Peripheral Nerve Interface (RPNI) surgery|Surgeons will perform neuroma resection and RPNI creation using a free muscle graft from the brachioradialis muscle harvested through a small separate incision
223687689|NCT05008185|PROCEDURE|Traction Neurectomy|Surgeons will perform neuroma resection and traction neurectomy,
223687690|NCT01135108|DRUG|Placebo|Placebo IV Infusion
223687691|NCT01135108|DRUG|KAI-1678|KAI-1678 IV Infusion
223687692|NCT03844477|PROCEDURE|single-injection QLB(quadratus lumborum block)|"Inject 0.4ml/kg 0.5% ropivacaine between quadratus lumborum and psoas major without continuous local infusion~Device: Ultrasound Scanner The curved (C1-5) probe of Ultrasound Scanner is used for scan~Device: PAJUNK StimuLong Drug: single dose ropivacaine 0.4ml/kg 0.5% ropivacaine given immediately after the correct position of the tip of the needle has been verified."
223687693|NCT03844477|PROCEDURE|Placebo control|"Inject 0.4ml/kg saline between quadratus lumborum and psoas major without continuous local infusion~Device: Ultrasound Scanner The curved (C1-5) probe of Ultrasound Scanner is used for scan~Device: PAJUNK StimuLong Drug: single dose 0.4ml/kg 0.9% NS. given immediately after the correct position of the tip of the needle has been verified."
223687694|NCT06533527|DRUG|Semaglutide|GLP1 medication
223687695|NCT06533527|DRUG|Tirzepatide|GLP1/GIP medication
223687696|NCT06533527|DRUG|Liraglutide|GLP1 medication
223687697|NCT06533527|DRUG|Dulaglutide|GLP1 Medication
223687698|NCT03682809|DRUG|Systane Complete|Systane Complete is an artificial tear indicated for patients who have evaporative, aqueous deficient, or mixed dry eye.
223687699|NCT05211687|OTHER|Smart-home for freezing of gait|"A projector, Kinect camera and computer are located 2 meters from the walking area. Participants walk nine times back and forth on the walking track, in each of three walking conditions:~1. Baseline: participants walk in a comfortable pace. The walking track consist a rectangle created by a white light projected on the floor. Based on in this walking condition, step width and cadence are calculated to determine the individual parameters of the cueing.~2. Light-stripes: The walking area consist of 4-5 white light-stripes. Space between the stripes is 110% of the participant step length. Participants are instructed to walk over the stripes.~3. Metronome: The walking track consist of a rectangle created by a white light projected on the floor, and in addition metronome beats are delivered by the computer. Beats frequency are 90% of the cadence. Participants are instructed to match their steps to the metronome beats.~Each walking condition up to 90 seconds."
223775943|NCT01167946|DRUG|methylprednisolone sodium succinate|Group A will receive pulse treatment for 3 consecutive days once every 2 weeks for 24 weeks. The daily dose of each pulse treatment will consist of methylprednisolone sodium succinate 15mg/kg of ideal body weight, given orally in 200 ml of fresh orange juice.
223775944|NCT01167946|DRUG|methylprednisolone sodium succinate|Group B will receive 2 consecutive daily pulses every 3 weeks for 24 weeks. The daily dose of each pulse treatment will consist of methylprednisolone sodium succinate 15mg/kg of ideal body weight, given orally in 200 ml of fresh orange juice.
223775945|NCT01167946|DRUG|methylprednisolone sodium succinate|Group C will receive 3 consecutive daily pulses every 3 weeks for 24 weeks. The daily dose of each pulse treatment will consist of methylprednisolone sodium succinate 15mg/kg of ideal body weight, given orally in 200 ml of fresh orange juice.
223775946|NCT00006411|OTHER|corneas assigned by donor age group|A web-based computer program was used to select and assign a cornea by donor age group from those available at the eye bank that met the study eligibility criteria. The program randomly selected a cornea based on a two-level minimization procedure which attempted first to balance for each surgeon the number of corneas from donors \>=66 and \<66 years old and then, when possible, to balance among age subgroups of 10-35, 36-50, 51-65, 66-70, and 71-75 years. The assignment was made without regard to recipient age or any other subject characteristics.
223775947|NCT03717337|PROCEDURE|Single visit pulp regeneration|Access cavity, disinfection, preparing and injecting platelet rich plasma, and restoring the tooth all done in one visit.
223687700|NCT04758000|DRUG|Metformin Hydrochloride|"Metformin will be administrated according with patients body mass index (BMI).~Patients between 14 and 18 years old or with BMI ≤ 20: 500 mg two times a day Patients older than 18 years or with BMI \> 20: 850 mg two times a day.~In all cases, metformin will be administrated for 3 years maximum, unless there is a progression disease or if toxicity is verified."
223687701|NCT05835973|OTHER|Sleep activity|"Actinography : Patient will wear actinometers on the wrist for 1 year continuously. In the study, MotionWatch 8 actimeters will be used, a class 1 medical device with CE mark (EN ISO 13485:2016 standard).~Ancillary study :~DREEM 3 headband : a subgroup of patients will wear the headband during 2 nights every 3 months."
223687702|NCT05835973|OTHER|Questionnaires|"The PSQI, EPWORTH, FACIT-F, ISI, and ICSD-3 questionnaires will be completed by patients every 3 months during their follow-up consultation according to the usual management.~The questionnaire by Horne and Ostberg will be completed by the patients only during the inclusion visit."
223687703|NCT02755688|PROCEDURE|Thoracoscopic Surgical ablation|Thoracoscopic approach to isolate pulmonary veins, ganglionic plexi ablation and left atrial appendage exclusion
223687704|NCT02755688|PROCEDURE|Catheter ablation|Ablation using contact force technology to isolate pulmonary veins and create linear lesions.
223687705|NCT03535571|DIETARY_SUPPLEMENT|Salmon Protein Hydrolysate|4g of salmon protein hydrolysate per serving.
223687706|NCT05244642|DRUG|Penpulimab|A humanized monoclonal immunoglobulin.
223775948|NCT03717337|PROCEDURE|Two visit pulp regeneration|first visit : access, disinfection and placing calcium hydroxide as intracanal medicament second visit: re opening of tooth, preparing and injecting platelet rich plasma and restoring the tooth.
223775949|NCT06139952|DRUG|Atorvastatin 80mg|Atorvastatin 80mg taken Once before coronary angiography
223775950|NCT06139952|DRUG|N-acetyl cysteine|200mg 3 times daily 2 days before coronary angiography
223775951|NCT06139952|OTHER|Normal Saline|adequate hydration using Normal Saline (1ml/kg/hr)
223775952|NCT03221413|DEVICE|transcranial alternating current stimulation (tACS)|
223775953|NCT01079234|DRUG|insulin degludec|Injected subcutaneously (under the skin) once daily
223775954|NCT01079234|DRUG|insulin glargine|Insulin glargine injected subcutaneously (under the skin) once daily
223775955|NCT01079234|DRUG|insulin aspart|At least three daily doses at meal-time
223775956|NCT02501889|BEHAVIORAL|Walnut-rich weight loss diet|Composition of prescribed diets will be based on individual preferences, with the goal of reduced energy intake and increased energy expenditure. During the 6-month intervention, study subjects will participate in individualized counseling and group sessions, with in-person, telephone, email and text message contacts to provide support and behavioral guidance and strategies. Walnuts will be provided to participants. The overall content of the intervention consists of key elements of cognitive-behavioral therapy for obesity. The physical activity component emphasizes planned aerobic exercise, increased physical activity in the lifestyle, and strength training.
223775957|NCT02501889|BEHAVIORAL|Standard weight loss diet|Composition of prescribed diets will be based on individual preferences, with the goal of reduced energy intake and increased energy expenditure. During the 6-month intervention, study subjects will participate in individualized counseling and group sessions, with in-person, telephone, email and text message contacts to provide support and behavioral guidance and strategies. The overall content of the intervention consists of key elements of cognitive-behavioral therapy for obesity. The physical activity component emphasizes planned aerobic exercise, increased physical activity in the lifestyle, and strength training.
223775958|NCT06404996|DEVICE|Smart-phone Voiding Diary|Smart-phone Voiding Diary
223775959|NCT06404996|DIAGNOSTIC_TEST|Paper voiding diary|Conventional Paper voiding diary
223775960|NCT01037790|DRUG|PD-0332991|Given orally, 125 mg QD on a 21-day
223687707|NCT05244642|DRUG|Investigator's choice of Chemotherapy|Participants will receive one of the following chemotherapies, including but not limited to DHAP (cisplatin 100mg/m2 D1, high dose cytarabine 2 mg/m2 q12h D2, dexamethasone 40mg D1-4, Q3W); ESHAP (etoposide 40 mg/m2 D1-4, cisplatin 25 mg/m2 D1-4, high dose cytarabine 2 mg/m2 D5, methylprednisolone 500mg D1-4, Q3W); DICE (dexamethasone 10mg/m2 D1-4, ifosfamide 1.0g/m2 D1-4, cisplatin 25mg/m2 D1-4, etoposide 60 mg/m2 D1-4, Q3W); ICE (ifosfamide 5 mg/m2 D2, carboplatin AUC 5 D2, etoposide 100 mg/m2 D1-3, Q3W); IGEV (ifosfamide 2 mg/m2 D1-4, gemcitabine 800 mg/m2 D1, D4, vinorelbine 20mg/m2 D1, prednisone 100 mg D1-4, Q3W); GVD (gemcitabine 1g/m2 D1, D8, vinorelbine 20 mg/m2 D1, D8, liposome doxorubicin 15 mg/m2 D1, D8, Q3W); MINE (etoposide 65mg/m2 D1-3, ifosfamide 1.33g/m2 D1-3, mitoxantrone 8mg/m2 d1, Q3W); GemOx (gemcitabine 800mg/m2 D1, D8, oxaliplatin 85mg/m2 D1, Q3W); GemOx (gemcitabine 1000mg/m2 D1, oxaliplatin 100mg/m2d1, Q2W).
223687708|NCT05163873|PROCEDURE|Extra-peritoneal|Surgery procedure: a non-mesh prophylactic surgical technique to prevent PH
223687709|NCT02661711|DRUG|Aflibercept|"2mg of 40mg/ml of Eylea Solution administered via intravitreal injection every four weeks for three months (loading dose), followed by a treat and extend protocol up to 12 months. Extension from monthly to 6, 8, 10 and 12 week follow up will occur where there is no reduction in macula oedema compared with the previous visit.~Number of cycles; minimum of 5 injections and maximum of 13 injections per study eye."
223687710|NCT01060345|DRUG|Polyphenon E|three 200mg capsules (600mg total dose of the study drug) with food (within one hour of eating a substantial meal) daily for a minimum of 4 weeks, or until the day before surgery
223687711|NCT02808572|BIOLOGICAL|Plasma osteoprotegerin level|dosage of plasma osteoprotegerin
223687712|NCT02808572|BIOLOGICAL|Plasma fibroblast growth factor 23 level|dosage of plasma fibroblast growth factor 23
223687713|NCT02808572|PROCEDURE|Vascular calcification score|measurement of vascular calcification score by multidetection computerized tomography
223687714|NCT01464983|DRUG|Acetylsalicylic acid (Aspirin, BAYE4465)|Acetylsalicylic acid 500 mg orally, single dose, 1 tablet; in addition, 1 Placebo tablet of Acetylsalicylic acid, and 2 Placebo tablets of Ibuprofen
223687715|NCT01464983|DRUG|Acetylsalicylic acid (Aspirin, BAYE4465)|Acetylsalicylic acid 2 x 500 mg orally, single dose, 2 tablets; in addition, 2 Placebo tablets of Ibuprofen
223687716|NCT01464983|DRUG|Ibuprofen|Ibuprofen 200 mg orally, single dose, 1 tablet; in addition, 1 Placebo tablet of Ibuprofen, and 2 Placebo tablets of Acetylsalicylic Acid
223687717|NCT01464983|DRUG|Ibuprofen|Ibuprofen 2 x 200 mg orally, single dose, 2 tablets; in addition, 2 Placebo tablets of Acetylsalicylic Acid
223687718|NCT01464983|DRUG|Placebo|2 Placebo tablets of Acetylsalicylic Acid, and 2 Placebo tablets of Ibuprofen, orally, single dose
223687719|NCT03355664|DRUG|ACT|Artemether-lumefantrine (20/120 mg) as a fixed dose combination twice daily for 3 days according to weight plus low dose primaquine at hour 24
223687720|NCT03355664|DRUG|TACT|Artemether-lumefantrine (20/120 mg) as a fixed dose combination twice daily for 3 days according to weight plus Amodiaquine (150mg) twice daily for 3 days according to weight plus low dose primaquine at hour 24
223687721|NCT01242397|DEVICE|CRT pacing|The chronic effect of CRT pacing on the degree of MR in pts with severe-to-moderate or severe functional MR. The treatment being studied is CRT pacing therapy with standard of care LV lead placement. Patients will be randomized to CRT pacing ON vs. OFF and followed for a total of up to 8 months. This includes two 3-month crossover periods for each pacing modality (CRT ON and CRT OFF) and a 6-week washout period between these periods.
223687722|NCT03280927|DRUG|Jublia®|Jublia® topical solution
223775961|NCT02534610|DRUG|Etoricoxib|120 mg etoricoxib PO administered 1 h preoperative for group A; group B received 120 mg etoricoxib PO at the end of the surgery.
223687725|NCT03671590|DRUG|TG-1701|Oral daily dose
223687726|NCT03671590|DRUG|Umbralisib|Oral Daily Dose
223687727|NCT03671590|BIOLOGICAL|Ublituximab|IV infusion
223775962|NCT02534610|DRUG|Placebo|Group A received 1 sham pill PO at the end of the surgery; group B received 1 sham pill PO 1 h preoperative and group C received sham pill PO 1 h preoperative and 1 sham pill PO at the end of the surgery.
223687728|NCT02034136|DIETARY_SUPPLEMENT|Ginsenoside|3.0 g/ d for 28 days
223687729|NCT02034136|DIETARY_SUPPLEMENT|Dietary fiber fill|3g/day, 28days
223687730|NCT03792984|DIETARY_SUPPLEMENT|Vitamin D3|Vitamin D3 (Cholecalciferol) (6000 IU/daily). PO for 8 weeks.
223687731|NCT03792984|DIETARY_SUPPLEMENT|Calcium Carbonate|Calcium carbonate (1000 mg/daily). PO for 8 weeks.
223687732|NCT03792984|DRUG|Metformin|Metformin (1500 mg/daily; the metformin dose was increased stepwise, starting with 500 mg once daily for the 1st week, 500 mg twice daily in the 2nd week, followed by 500 mg 3 times daily from the 3rd week onward). PO for 8 weeks.
223687733|NCT03792984|DRUG|Placebo|PO for 8 weeks.
223687734|NCT01232218|OTHER|Standard education/exercises for hemiplegic shoulder pain|Each participant will receive standard education for safe positioning and movement of the painful hemiplegic shoulder. Participants will also be provided with standard stretching and strengthening exercises by and experienced Occupational Therapist who will grade the level of exercise to suit their needs. Intervention will take place 3x/week for 1 hour.
223687735|NCT01232218|OTHER|Three dimensional Scapular-Humeral Mobilizations|Each participant will receive standard education for safe positioning and movement of the painful hemiplegic shoulder. Participants will also be provided with stretching and strengthening exercises by and experienced Occupational Therapist who will grade the level of exercise to suit their needs. Intervention will take place 3x/week for 1 hour. Participants in this group will receive an additional scapular humeral mobilization while simultaneously performing the standard stretching/strengthening exercise protocol.
223687736|NCT06497231|OTHER|Beautifil II LS|Beautifil II LS is a low shrinkage bioactive giomer resin composite.
223687737|NCT06497231|OTHER|Nanohybrid resin composite material|Nanohybrid resin composite is a type of restorative material that features nano-sized fillers as a main component.
223687738|NCT00276042|DRUG|Faropenem Medoxomil|
223687739|NCT00084773|BIOLOGICAL|cetuximab|
223687740|NCT00084773|DRUG|fluorouracil|
223687741|NCT00084773|PROCEDURE|neoadjuvant therapy|
223687742|NCT00084773|RADIATION|radiation therapy|
223687743|NCT05276648|DIAGNOSTIC_TEST|CAM ICU test|CAM ICU for delirium
223687744|NCT05276648|DIAGNOSTIC_TEST|MOCA test|MOCA for cognitif disfonction
223687745|NCT05276648|DIAGNOSTIC_TEST|brief pain test|BRİEF PAİN for chronic pain
223687746|NCT05276648|DIAGNOSTIC_TEST|VAS scale|VAS scale for acute pain
223687747|NCT00218101|DRUG|Buprenorphine|
223687748|NCT01337687|DRUG|Intranasal Oxytocin|Oxytocin administered intranasally twice a day via 1 12 unit puff to each nostril, totaling 48 IU a day.
223687749|NCT01337687|DRUG|Placebo|Saline will be administered intranasally twice a day via 1 puff per nostril, totaling 48 IU a day.
223687750|NCT02577276|DEVICE|Tele-motion rehabilitation system|Tele-motion rehabilitation system: Interventions include functional therapeutic exercise and real-time feedback. Clinicians remotely monitor subjects' motor performance using Microsoft Kinect 3D sensor tracking system in their home to record their upper limb and trunk movements as they participate in a variety of functional tasks and motor activities, which are directed by their interaction with a monitor screen in their home using uniquely adapted software to integrate key rehabilitation intervention principles.
223687751|NCT01158664|DEVICE|0.6 mm tread pitch implant|0.6 mm tread pitch implant will be used
223687752|NCT01158664|DEVICE|0.1 mm tread pitch implant|0.1 mm tread pitch implant will be used
223687753|NCT05345041|BEHAVIORAL|Keep it Movin'|Individual participants in churches randomized to the intervention arm will participate in the Keep it Movin' multi-component PA education program, as well as be encouraged by their church and study interventionist to participate in the church-wide walking program. Individuals enrolled in Keep It Movin' will attend weekly 90-minute sessions for 24 weeks. All sessions will include the structured physical activity component from the LIFE study intervention, with the following components, which were added to address needs of the target community: functional education, social support and problem-solving. To increase the functional gains seen in the LIFE pilot study and add content addressing self-management and PA with multiple chronic conditions (MCCs), the number of sessions in the proposed trial has been increased from 16 to 24 weeks.
223687754|NCT05345041|BEHAVIORAL|Go 4 Life Self Guided Education|Individual participants in churches randomized to the comparator arm will receive the church-wide walking program and the Go4Life Your Everyday Guide to Exercise and Physical Activity which was developed by the National Institutes of Health National Institute on Aging to promote physical activity in older adults. This includes an evidence-based exercise guide and motivational tips to help older adults start and sustain an exercise program. The Go4Life guide will add individual level education and encouragement to the interpersonal and community levels of intervention provided by the church-wide walking program.
223687755|NCT00696475|DRUG|Diazoxide choline|
223687756|NCT00696475|DRUG|Diazoxide choline|
223687757|NCT00696475|DRUG|Diazoxide choline|
223687758|NCT00696475|DRUG|Placebo|
223687759|NCT01751802|DRUG|Ecopipam|Antagonist of the dopamine D1 receptor
223687760|NCT01751802|DRUG|Placebo|Placebo for Ecopipam
223687761|NCT06477328|PROCEDURE|Telemedicine|Video calls were made with the telemedicine group.
223687762|NCT05461807|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Retrospective cohort analysis using United States Optum De-Identified Electronic Health Records data
223687763|NCT05461807|DRUG|Apixaban|Retrospective cohort analysis using United States Optum De-Identified Electronic Health Records data
223687764|NCT06352333|PROCEDURE|supraclavicular ultrasound guided brachial plexus block|two approaches of ultrasound guided supraclavicular brachial plexus block in upper limb surgery : the cornerpocket supraclavicular brachial plexus block and parasagittal supraclavicular brachial plexus block
223687765|NCT05312047|PROCEDURE|Pelvic organ prolapse surgery|Vaginal surgery of any compartment for pelvic organ prolapse
223687766|NCT01484938|DEVICE|OPTI-FREE PureMoist|Commercially marketed multi-purpose contact lens solution for cleaning, rinsing, disinfecting/storing, and reinserting contact lenses
223687767|NCT01326325|DRUG|Ketamine|Drip continues of ketamine in intravenous injection included posology enters 0,5mg/kg /day and 2mg/kg/day during 4 days
223775963|NCT04300400|OTHER|Delphi questionnaire|Statements on OAB topics, rated along their level of appropriateness on a scale from 1 to 9. Multiple rounds are organised to reach consensus on a topic.
223687768|NCT01326325|DRUG|NaCl|Drip continues of NaCl 0,9% in intravenous injection during 4 days
223687769|NCT05868889|DRUG|Trabectedin and PLD|The main treatment observed in this study is trabectedin in combination with PLD in elderly patients with platinum-sensitive relapsed ovarian cancer, according to the SmPC.
223775964|NCT04412135|OTHER|spirituality|Patients will take three questionnaires (FACIT-Sp, Euroqol 5 dimensions and ESAS)
223775965|NCT01312961|DRUG|Dupilumab|Solution for injection, one subcutaneous injection.
223687770|NCT00071266|DRUG|Niacin Extended Release and Lovastatin Tablets|
223687771|NCT03857152|DIAGNOSTIC_TEST|Contrast enhanced spectral mammography (CESM)|"Contrast enhanced spectral mammography (CESM) will be undertaken in addition to routine practice.~CESM is a specialist mammography test that aims to 'highlight' areas of concern within the breast in more detail than a standard mammogram.~The difference between CESM and a standard mammogram (x-ray of the breast) is the use of a special dye (called contrast medium) that is injected into the veins before the mammogram images are taken. The contrast enhanced images give more detailed information to the breast radiologists (expert doctors trained to analyse breast imaging)."
223687772|NCT01580371|DRUG|CKD-581|CKD-581 qd for Day 1, 8 and 15 every 28days/Cycle
223687773|NCT03518671|BEHAVIORAL|cognitive behavioral therapy, face to face|self-limited cognitive behavioral therapy delivered weekly for 6 weeks via face-face delivery method
223687774|NCT03518671|BEHAVIORAL|cognitive behavioral therapy, telemedicine|self-limited cognitive behavioral therapy delivered weekly for 6 weeks via tablet-based telemedicine platform
223687775|NCT01403233|DIETARY_SUPPLEMENT|cogniVida 50mg/day|2 capsules 25 mg (total 50 mg) cogniVida™ once a day
223687776|NCT01403233|DIETARY_SUPPLEMENT|cogniVida100mg/day|4 capsules 25 mg (total 100 mg) cogniVida™ once a day
223687777|NCT01403233|DIETARY_SUPPLEMENT|Rebaudioside-A 303.7mg/day|4 capsules 75.92 mg (total 303.68 mg) rebaudioside A once a day
223687778|NCT03373799|OTHER|Video-Based Rehabilitation Program|In both groups, a program consisting of exercises used in conservative treatment of rotator cuff tears was performed. A video record was made by the physiotherapist to a patient where each exercise was described in detail and the patient correctly performed the exercises according to the verbal and visual commands of the physiotherapist. This video record watched by the patients who come to the clinic and patients were asked to do the exercises in the video. Patients did the exercises under control of the physiotherapist in the clinic.
223687779|NCT03373799|OTHER|Physiotherapist-Supervised Rehabilitation Program|In both groups, a program consisting of exercises used in conservative treatment of rotator cuff tears was performed. Program was carried out by teaching the same exercises individually by the physiotherapist.
223687780|NCT06301243|OTHER|Inactivity|Low physical activity level prior to the exercise intervention.
223687781|NCT00192686|PROCEDURE|culture a.m. Kamme-Lindberg|
223687782|NCT04503291|PROCEDURE|Metal stent placement|Non-covered biliary metal stents are placed by endoscopy. The distal ends of metal stents are located above the major ampulla in the common bile duct or below the major ampulla in the duodenum.
223687783|NCT01858636|DEVICE|Angio-Seal VIP 6 French (6F) and 8 French (8F) devices|These devices are used for the vascular closure procedure
223687784|NCT02139800|PROCEDURE|Sustained Inflation|The first sustained inflation will use inflation pressure of 20 cm H20 for 15 seconds
223687785|NCT02139800|PROCEDURE|Standard of Care|Newborn Resuscitation Program (NRP) Guidelines using a standard PEEP/CPAP of 5-7 cm H2O as compared to the Sustained Inflation intervention
223687786|NCT05480774|DRUG|KRG hard capsule|Each subject was given orally 2 KRG hard capsules/day for 12 weeks
223687787|NCT05480774|DRUG|Placebo hard capsule|Each subject was given orally 2 placebo hard capsules/day for 12 weeks
223687788|NCT05751616|OTHER|Laminate veneers with speed sintering|Zirconia specimens will be sintered using speed sintering cycle in a conventional furnace according to the manufacturer instructions.
223687789|NCT05751616|OTHER|Laminate veneers with conventional sintering|Zirconia specimens will be sintered using conventional sintering cycle in a conventional furnace according to the manufacturer instructions.
223687790|NCT00842452|DRUG|topotecan hydrochloride|Patients receive oral topotecan hydrochloride on days 1, 8, and 15. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
223687791|NCT00842452|OTHER|pharmacological study|Patients treated at the maximum tolerated dose undergo blood sample collection periodically on day 1 of course 1 for pharmacokinetic studies.
223687792|NCT05977478|DEVICE|SPECTRA IMDx™|In this study, SPECTRA IMDxTM system will be used to capture the Raman spectra to correlate to histopathology results and mass spectrometry profiling results.
223687793|NCT02526329|BIOLOGICAL|donor regulatory T lymphocytes|Given IV
223687794|NCT02526329|OTHER|laboratory biomarker analysis|Correlative studies
223687795|NCT03000270|DEVICE|Impella unloading prior to PPCI|Impella unloading prior to PPCI
223775966|NCT01312961|DRUG|Placebo (for Dupilumab)|Solution for injection, one subcutaneous injection.
223687796|NCT05578001|DRUG|Pilocarpine Ophthalmic|1 drop of Pilocarpine 1%
223687797|NCT02958384|BIOLOGICAL|Anti-LeY-CAR-transduced T cells|The first 3 enrolled patients will receive autologous-derived LeY-targeted CAR-T cells on day 1, 2 and 3 with respective 10%, 30% and 60% of the total expected dosage after receiving lymphodepleting chemotherapy. If the 3 patients don't display severe toxicity,the next patients enrolled will get infused in 2 days with respective 40% and 60% total dosage.
223687798|NCT03420027|OTHER|questionnaire to be filled in by investigators|A simple seven-item questionnaire will be filled in by the investigator before performing urgent tracheal intubation. This intubation, which will be performed as done in routine care, does not constitute a study specific intervention
223687799|NCT04246736|BEHAVIORAL|Bädda för Kvalitet|"A group-administered preventive programme focusing on beneficial strategies for sleep and recuperation, in relation to work related stress and shift work. The intervention was based on knowledge from previous research on sleep, stress and work hours, as well as on cognitive behavioural therapy (CBT) techniques for sleep and stress management, modified for shift workers. Participants were encouraged to discuss and reflect on personal habits related to sleep and recovery. As homework between sessions, the participants were encouraged to try possibly beneficial strategies for sleep and recuperation. All participants got written material covering the content of the session, during each sessions. In addition, an adapted version of a biomathematical model (ArturNurse) was used to give participants an estimation of expected sleep lengths and fatigue levels together with tips of possible strategies to optimise sleep in relation to different shifts."
223687800|NCT03709329|DEVICE|Robot Assisted Gait Therapy|The robot-assisted gait treatment will receive 18 treatments per patient for 1 week, 3 times a week, and 6 weeks for 30 minutes a day.
223687801|NCT03709329|DEVICE|Conventional Gait Therapy|The conventional gait therapy group receives a total of 18 classical gait training sessions once a day for 30 minutes and three times a week for 6 weeks. Classical gait training consisted of exercise training based on neurophysiological theories such as Bobath, restraint of rigid and cooperative movements by therapists, exercise training in sitting or standing posture, Gait training and balance training, weight training of the paralyzed lower limb.
223687802|NCT02586402|DRUG|pegol-Sihematide|
223687803|NCT02586402|DRUG|Epoetin Alfa|
223687804|NCT03784287|DRUG|AX 250|Chimeric fusion of recombinant human alpha-N-acetylglucosaminidase and truncated human insulin-like growth factor 2 (rhNAGLU-IGF2)
223687805|NCT01085500|BEHAVIORAL|Mastery Learning TEP Curriculum|A simulation-based educational curriculum
223687806|NCT01085500|PROCEDURE|Current Practice|The current practice of learning how to perform the TEP repair in the operating room is under direct supervision of the staff surgeon without any simulation pre-training.
223687807|NCT00480974|OTHER|Clinical follow up and laboratory analysis|Clinical follow up and laboratory analysis
223687808|NCT06516601|OTHER|no intervention|observational study, the patients received corticosteroids according to the physician on duty
223687809|NCT01513369|DRUG|ferric carboxymaltose|Dose:according to SmPC Duration: 12 weeks; Frequency: at week 1 and again at week 5 (if again indicated according to principal inclusion criteria); Application: intravenous
223687810|NCT01513369|DRUG|NaCl (0,9%)|Duration: 12 weeks; Frequency: at week 1 and again at week 5 (if again indicated according to principal inclusion criteria); Application: intravenous
223687811|NCT01227564|BIOLOGICAL|ACC-001 3 μg/ QS-21 50 μg|ACC-001 3 μg/ QS-21 50 μg IM on day 1, month 1, month 3, month 6, month 12, and month 18
223687812|NCT01227564|BIOLOGICAL|ACC-001 10 μg/ QS-21 50 μg|ACC-001 10 μg/ QS-21 50 μg IM on day 1, month 1, month 3, month 6, month 12, and month 18
223687813|NCT01227564|OTHER|Placebo- Phosphate buffered saline (PBS)|Phosphate buffered saline IM on day 1, month 1, month 3, month 6, month 12, and month 18
223687814|NCT04616742|DRUG|[14C]SHR6390|Patients will receive single dose of orally \[14C\]SHR6390 on Day 1.
223687815|NCT04697381|BIOLOGICAL|somatropin - GH naïve pediatric cohort|somatropin 0.245 mg/kg/week
223687816|NCT04697381|BIOLOGICAL|somatropin - GH treated cohort|somatropin 0.084 mg/kg/week
223687817|NCT04697381|BIOLOGICAL|somatropin - adult cohort|somatropin 0.084 mg/kg/week
223687818|NCT00230477|DRUG|Hepsera|
223687819|NCT00230477|DRUG|Hepsera and lamivudine|
223687820|NCT01057901|DRUG|Flibanserin|Flibanserin 100mg administered at bedtime for 24 weeks
223687821|NCT01057901|DRUG|Placebo|This is the matched placebo which will be administered two tablets daily at bedtime.
223687822|NCT02687659|DEVICE|TEMIS system|Wearing TEMIS system over the day during one week
223687823|NCT06309407|DEVICE|Hand Dosimeters|Participants were assigned to wear hand dosimeters in addition to the standard chest dosimeter worn by all participants
223687824|NCT06309407|DEVICE|Standard Practice|Participants only wore standard chest dosimeters
223687825|NCT04812080|DEVICE|EXPLORER PET/CT|FDG PET Scans on the total body EXPLORER PET/CT scanner
223687826|NCT02799979|DEVICE|3D right ventricular imaging echocardiographic|Echocardiographic data (3D right ventricular imaging echocardiographic) will be collected at baseline and after 6months.
223687827|NCT00890188|DRUG|THALIDOMIDE and UFUR|T: Thalidomide (50): 150 mg/d ((1# tid) U: UFUR(100) 300 mg/d (1# tid) 28 days for one cycle
223687828|NCT02096575|OTHER|Nitrous oxide administration|"All participants will receive 800 mg of oral ibuprofen 30 minutes pre-operatively. The NO group will get two placebo pills and the standard care group will get one 5/325 mg Vicodin, and 1 mg of Ativan 30 minutes before the procedure. The standard care group will get oxygen intraoperatively.~NO or oxygen will be administered via a scented nasal mask to blind patients to the intervention.~All patients will get local anesthesia via a standardized PCB."
223687829|NCT02862600|DRUG|Perhexiline|Period 1 (Weeks 1-8) and Period 2 (Weeks 9-16): dose titrated to two different plasma levels of perhexiline
223775967|NCT01312961|DRUG|Fluticasone/Salmeterol combination therapy|Oral inhalation twice daily.
223775968|NCT01312961|DRUG|Fluticasone monotherapy|Oral inhalation twice daily.
223687830|NCT02862600|DEVICE|Use of bioanalytical assay to monitor plasma levels of perhexiline|The bioanalytical assay is the device under investigation. It will be used to monitor plasma levels of perhexiline. The data obtained from this analysis will be used to guide dose adjustments of perhexiline.
223687831|NCT05463627|DRUG|Metformin|All participants among the three groups were treated with metformin
223687832|NCT03825471|PROCEDURE|electrotherapy|Cranial electrotherapy stimulation
223687833|NCT03825471|DRUG|Opioid Anesthetics|consumption of opioids during general anesthesia
223687834|NCT03825471|PROCEDURE|colon cancer surgery|laparoscopic colon cancer surgery
223687835|NCT05990621|BIOLOGICAL|Anti-CD70 CAR-T cells|0.6×106/Kg ～ 5.0×106/Kg; cells will be infused intravenously.
223687836|NCT04859114|BEHAVIORAL|Format of outcome data presentation|Outcome data is provided to participants as either text-only, a static pictograph, or an iterative pictograph.
223687837|NCT04859114|BEHAVIORAL|Displayed chance of survival|In the outcome data provided to participants, they view either a 30% or 60% chance of survival.
223687838|NCT05501262|DEVICE|Cryoablation|Image (ultrasound and fluoroscopic guided) cryoablation will be performed of the Morton's neuroma after nerve block.
223687839|NCT05501262|PROCEDURE|Nerve block|Ultrasound and fluoroscopic guided nerve block.
223687840|NCT02503345|DRUG|ALLN-177 low dose|ALLN-177 1,500 units (1 capsule)/meal PO 3 times per day
223687841|NCT02503345|DRUG|ALLN-177 mid dose|ALLN-177 3,000 units (2 capsules)/meal PO 3 times per day
223687842|NCT02503345|DRUG|ALLN-177 high dose|ALLN-177 7,500 units (5 capsules)/meal PO 3 times per day
223687843|NCT02503345|DRUG|Placebo|Placebo: 1, 2 or 5 capsules with meals PO 3 times per day
223687844|NCT03809923|DRUG|lidocaine and dexmedetomidine infusion|Patients received IV bolus infusion of lidocaine (2%) 1.5 mg/kg and dexmedetomidine 0.5 µg/kg diluted with normal saline to 20 ml in the LD group respectively, over 10 minutes before induction of anesthesia, followed by a continuous IV infusion at rate of lidocaine 1.5 mg/kg and dexmedetomidine 0.4 µg/kg made up to 20 mL every hour until 30 min before the end of operation, respectively.
223687845|NCT03809923|DRUG|Saline infusion|Patients received 20 ml normal saline and 20 ml normal saline in the CON group respectively, over 10 minutes before induction of anesthesia, followed by a continuous IV infusion 20 ml normal saline and 20 ml normal saline every hour until 30 min before the end of surgery
223687846|NCT03809923|DRUG|Lidocaine infusion|patients received an IV bolus infusion of lidocaine (2%) 1.5 mg/kg made to 20ml with normal saline and 20ml normal saline respectively, over 10 minutes before induction of anesthesia, followed by a continuous IV infusion of lidocaine 1.5 mg/kg made up to 20ml and 20ml normal saline every hour until 30 min before the end of operation, respectively.
223687847|NCT03809923|DRUG|Dexmedetomidine infusion|Patients received IV bolus infusion of dexmedetomidine 0.5 μg/kg made to 20ml with normal saline and 20ml normal saline respectively, over 10 minutes before induction of anesthesia, followed by a continuous IV infusion of dexmedetomidine 0.4μg/kg made up to 20ml and 20ml normal saline every houruntil 30 min before the end of operation, respectively.
223687848|NCT02906462|OTHER|Early consideration of vulnerability|One day training with the provision of vulnerability criteria inciting an early reflection of the level of therapeutic engagement; sheets available on the internet computer support collegial reflection and traceability of decisions to limit and stop treatments, incorporating the provisions of law known Leonetti
223687849|NCT02906462|OTHER|Usual practices|the centres applies their usual practices
223687850|NCT04223648|DRUG|tremelimumab/durvalumab, ipilimumab/nivolumab and nivolumab monotherapy|"Subjects will receive 1 cycle of tremelimumab/durvalumab~* Subjects will undergo resection to obtain tumor for generation of autologous tumor infiltrating lymphocytes (TIL) cultures and blood draw to obtain peripheral blood mononuclear cell (PBMC)s~* TIL and PBMC will undergo immunoselection based on binding to an anti-programmed cell death 1 (PD-1) antibody and then will be expanded ex vivo.~Subjects will receive 3 cycles of ipilimumab/nivolumab~• Subjects will undergo staging with computer tomography (CT) chest/abdomen/pelvis and brain magnetic resonance imaging (MRI) or CT scan.~subjects with stable disease will continue with nivolumab monotherapy; Subjects with progressive disease will proceed to cell therapy."
223687851|NCT03826576|BEHAVIORAL|Multicomponent intervention|"The multicomponent intervention will be consist of:~1. Training of the restaurant staff (waiters and cookers) about Mediterranean and Healthy Diet and food allergens,~2. Nutritional and food allergen analysis of the menu of the restaurant~3. Improvement of the menu to follow the Mediterranian diet standards (AMED criteria), the nutritional quality of the menu and the adaptations of the menu for food allergies and food intolerances~4. Marketing campaign about healthy and food allergen adapted menus in the restaurants"
223687852|NCT03245229|DRUG|Aprocitentan|Capsule for oral administration
223687853|NCT03245229|DRUG|Rosuvastatin|Tablet for oral administration
223687854|NCT02378025|BEHAVIORAL|Yoga Group|A 10-week yoga course designed to treat pain.
223687855|NCT02378025|BEHAVIORAL|Pain Management Wellness Group|A 10-week behavioral therapy course designed to treat pain.
223687856|NCT04291378|RADIATION|Proton versus photon radiation therapy|The intervention is proton radiation therapy versus photon radiation therapy
223687857|NCT03750422|DEVICE|Picoway|1064/532nm picosecond laser
223687858|NCT03750422|OTHER|Stratacel|a self-drying, bacteriostatic, transparent silicone gel with anti-inflammatory properties
223687859|NCT03750422|OTHER|Aquasonic|clear ultrasound gel
223687860|NCT05151627|PROCEDURE|KINESIO TAPING|Kinesio taping The patient is in a supine position with full knee flexion. Prior to application, the skin surface was cleaned. This technique involved the use of two Y-cut strips and two I-cut strips.
223687861|NCT05151627|DEVICE|CONVENTIONAL PHYSICAL THERAPY|"Transcutaneous Electrical Nerve Stimulation TENS device settings, such as the frequency of 32-50 Hz, pulse width of 80 ms, and symmetrical biphasic waveform. The surface electrodes were placed on the medial and lateral superior borders of the patella, as well as the medial and lateral inferior borders of the patella.~Exercise therapy program The total duration of each exercise session was about 50 minutes, including warm-up-10 minutes, resistance exercise-20 minutes, balance and stability exercise-10 minutes, lower-limb stretching exercise-5 minutes, and cool-down exercise-5 minutes. The same assigned physical therapist supervised all of the sessions."
223687862|NCT02495103|DRUG|Vandetanib|PHASE I: Vandetanib by mouth (PO) daily at 300mg in combination with escalating doses of metformin.
223687863|NCT02495103|DRUG|Metformin|Phase I: Metformin starting dose 250mg by mouth (PO) daily in combination with Vandetanib
223687864|NCT02495103|DRUG|Vandetanib/Metformin|Phase II: Vandetanib and metformin by mouth (PO) daily at determined maximum tolerated dose (MTD).
223687865|NCT01807832|OTHER|capsaicin challenge|
223687866|NCT04186091|PROCEDURE|correlation between baseline perfusion index and decrease in systolic blood pressure post spinal induction|correlation between baseline perfusion index and decrease in systolic blood pressure post spinal induction
223687867|NCT02187770|DEVICE|IMED-4|Non invasive recording electrode used to assess lung fluid
223687868|NCT00633867|DEVICE|McGrath|Tracheal intubation, using Mcgrath video-laryngoscope
223687869|NCT00633867|DEVICE|Tracheal intubation using Macintosh Laryngoscope|Tracheal intubation using Macintosh Laryngoscope
223687870|NCT01654796|DEVICE|Low Field Magnetic Stimulation (LFMS)|The LFMS devices produces a unique magnetic field that may help alleviate symptoms of depression.
223687871|NCT01654796|DEVICE|Sham LFMS|Sham LFMS looks and sounds like the active treatment but does not produce any magnetic stimulation.
223687872|NCT04452929|DRUG|Erenumab|Subcutaneous injection of 140 mg erenumab.
223687873|NCT04452929|DRUG|Placebo|Subcutaneous injection of saline placebo.
223687874|NCT04452929|DRUG|Calcitonin gene-related peptide|Intravenous infusion of 1.5ug/min calcitonin gene-related peptide over 20 minutes.
223687875|NCT04452929|DRUG|Cilostazol|Oral intake of 200 mg cilostazol.
223687876|NCT04971330|DIAGNOSTIC_TEST|Access HCV|"All samples were tested with both reference anti-HCV assay and Access anti-HCV assay according to respective instructions for use (IFU) or study guide, as applicable, to determine non-reactive (NR), initial reactivity, and repeat reactivity. Reference assay was Abbott Architect anti-HCV assay. For blood donors, Abbott PRISM HCV was used as reference.~For the specificity cohorts (blood donor and hospitalized patient samples), all HCV Ab positive results will have supplemental confirmation testing with HCV Immunoblot for final HCV Ab status"
223687877|NCT00649415|DRUG|piroxicam|piroxicam 40 mg capsule QD for up to the first 3 days of the menstrual cycle
223687878|NCT00649415|DRUG|valdecoxib|valdecoxib 40 mg capsule twice a day (BID), taken as required, on the first day of treatment in the menstrual cycle followed by oral valdecoxib 40 mg once a day (QD) for up to the first 3 days of the menstural cycle
223687879|NCT01497145|DRUG|KRN321|
223687880|NCT02615925|OTHER|Psychiatry Consultation|Psychiatry Consultation
223687881|NCT04610164|DRUG|Tranexamic acid|Prior to surgery, the patient will receive 1 gram of IV TXA
223687882|NCT03486704|BEHAVIORAL|Face to Face VRRS and telerehabilitation|"Face to Face cognitive training using VRRS plus telerehabilitation. Participants will receive 12 sessions of an individualized Face to Face cognitive training using VRRS over 4 weeks followed by 36 sessions of home-based VRRS cognitive training, three sessions for week.~Cognitive training will initially be tailored to the patient's baseline characteristics. The exercise program will be charged by therapist on the patient's computer before the beginning of the at-home treatment. Each patient's performed session will be reviewed by the therapist.~The group will receive a kit home-based (a tablet home, access to a daily individualized cognitive training program)."
223687883|NCT03486704|BEHAVIORAL|Usual rehabilitation program|The usual rehabilitation group will receive 12 sessions of face-to-face usual cognitive training program.
223687884|NCT03486704|BEHAVIORAL|FTF VRRS plus unstructured CS|"Face to Face cognitive training using VRRS plus at-home unstructured cognitive stimulation.~Participants will receive 12 sessions of an individualized Face to Face (FTF) cognitive training using VRRS over 4 weeks followed by 36 sessions of home-based unstructured cognitive stimulation (CS), three sessions for week."
223775969|NCT01312961|DRUG|Albuterol|Oral inhalation as needed.
223775970|NCT01312961|DRUG|Levalbuterol|Oral inhalation as needed.
223687885|NCT03486704|BEHAVIORAL|Face to Face VRRS plus active tDCS and telerehabilitation|"Participants will receive 12 sessions of an individualized Face to Face cognitive training using VRRS combined with active (anodal) tDCS applied to the left dorsolateral prefrontal cortex over 4 weeks followed by 36 sessions of home-based VRRS cognitive training, three sessions for week.~Face to Face VRRS cognitive training will initially be tailored to the patient's baseline characteristics.~The exercise program will be charged by therapist on the patient's computer before the beginning of the at-home treatment. Each patient's performed session will be reviewed by the therapist.The group will receive a kit home-based (a tablet home, access to a daily individualized cognitive training program)."
223687886|NCT03486704|BEHAVIORAL|Face to Face VRRS plus placebo tDCS and telerehabilitation|"Participants will receive 12 sessions of an individualized Face to Face cognitive training using VRRS combined with placebo tDCS applied to the dorsolateral prefrontal cortex of the left hemisphere over 4 weeks followed by 36 sessions of home-based VRRS cognitive training, three sessions for week.~Face to Face VRRS cognitive training will initially be tailored to the patient's baseline characteristics.~The exercise program will be charged by therapist on the patient's computer before the beginning of the at-home treatment. Each patient's performed session will be reviewed by the therapist.The group will receive a kit home-based (a tablet home, access to a daily individualized cognitive training program)."
223687887|NCT04276454|DEVICE|Flexitouch Plus system|A single treatment for external lymphedema using the FDA-approved Flexitouch Plus device.
223687888|NCT00745576|DRUG|SAM-531|
223687889|NCT02599805|DEVICE|Natrox™ Oxygen Delivery System (ODS)|Natrox™ ODS will be applied to the subject's diabetic ulcer and attached to the active Natrox™ Oxygen Generator using the tubing provided or regular dressing will be used. The Natrox™ oxygen delivery system (ODS) is a device designed to overcome a number of problems associated with previous methods of oxygen therapy by delivering continuous oxygen to the ulcer bed through a dressing.
223687890|NCT00772070|BIOLOGICAL|A/C/Y/W-135, Meningococcal Polysaccharide Vaccine (Menomune®)|0.05 mL, Subcutaneous
223687891|NCT00772070|BIOLOGICAL|A/C/Y/W-135, Meningococcal Polysaccharide Vaccine (Menomune®)|0.05 mL, Subcutaneous
223687892|NCT02663583|BEHAVIORAL|Symptom Questionnaires|"Intensity-Modulated Proton Therapy or( IMPT) Group: Symptom questionnaires about symptoms of cancer and how they affect life at work and at home, diet, and speech completed at baseline, every week during IMPT, at 3 months, and at 6 months.~TransOral Robotic Surgery (TORS) Group: Symptom questionnaires about symptoms of cancer and how they affect life at work and at home, diet, and speech completed at baseline, after TORS, at 3 months, and at 6 months."
223687893|NCT02663583|BEHAVIORAL|Dysphagia Inventory Questionnaire|"Intensity-Modulated Proton Therapy or( IMPT) Group: Dysphagia Inventory questionnaire about how difficult it is to swallow completed at baseline, every week during IMPT, at 3 months, and at 6 months.~TransOral Robotic Surgery (TORS) Group: Dysphagia Inventory questionnaire about how difficult it is to swallow completed at baseline, after TORS, at 3 months, and at 6 months."
223687894|NCT02663583|BEHAVIORAL|Activity Bands|Activity bands given to participant at baseline. Participant wears the band 24 hours a day for 1 week leading up to all study visits.
223687895|NCT03785743|PROCEDURE|TLPD Surgery|TLPD
223687896|NCT03785743|PROCEDURE|OPD Surgery|OPD
223687897|NCT04735718|DEVICE|Cerviron|"Cerviron® ovules is a class IIb medical device used as adjuvant treatment in cervical lesions of mechanical origin. It favors the healing and re-epithelialization processes and reduces the proliferation of endogenous pathogens.~Moreover, it provides a strong hemostatic effect, as shown in multiple studies. Moreover, it contains collagen with nutritive, hydrating, healing and trophic effect. Collagen is structurally and functionally a key protein of the extracellular matrix which is also involved in forming the scars during the healing of conjunctive tissues, due to its chemotactic role. Many collagen bandages were developed to improve the repair of the wound, especially of non-infected, chronic, idle cutaneous ulcerations."
223687898|NCT04327479|DIAGNOSTIC_TEST|Assessment of cardiovascular diseases and cardiovascular risk factors|At inclusion, patients will be screened for pre-existing cardiovascular diseases and cardiovascular risk factors, as well as medication.
223687899|NCT01692873|PROCEDURE|suspected pancreatic tumor|Realization of pancreatic surgery to obtain tumor biopsy and blood samples to realize biomarkers analyses.
223687900|NCT01309308|PROCEDURE|sweeping the membranes|The cervical length will be measured and the patient will be examined to determine the Bishop score. Later the the membranes will be swept.
223687901|NCT01309308|OTHER|No sweeping group|Cervical length will be measured by transvaginal USG and the patient will be examined to determine the Bishop score.
223687902|NCT01949285|DEVICE|Transcutaneous Electrical Spinal Cord Stimulation|A prototype device that non-invasively delivers electrical stimulation to the spinal cord will be used to assess and rehabilitate spared spinal cord function.
223687903|NCT01017575|DRUG|Daclatasvir|Tablets, Oral, 10 mg, daily, 24-48 weeks
223687904|NCT01017575|DRUG|Daclatasvir|Tablets, Oral, 60 mg, daily, 24-48 weeks
223687905|NCT01017575|DRUG|Placebo|Tablets, Oral, 0 mg, daily, 48 weeks
223687906|NCT01017575|DRUG|Peginterferon alfa-2a|Syringe, Subcutaneous, 180µg, weekly, 24-48 weeks
223687907|NCT01017575|DRUG|Ribavirin|Tablets, Oral, 600 to 1000 mg based on weight, daily, 24-48 weeks
223687908|NCT06438146|DRUG|Liraglutide|"Dosing regimen: In this study protocol, liraglutide dosing will be implemented as follows: Liraglutide will be started at a dose of 0.6 mg per day. Participants will be taught to use the injection pen and will be observed giving the first injection. The dose will then be increased by 0.6 mg each week to a maximum dosage of 3.0 mg per day at the end of 4 weeks.~This corresponds to the following dosing schedule:~Week 1: 0.6 mg per day for one week Week 2: 1.2 mg per day for one week Week 3: 1.8 mg per day for one week Week 4: 2.4 mg per day for one week Week 5-12: 3.0 mg per day for 8 weeks Week 13-24: No drug administration"
223687909|NCT04401644|DIAGNOSTIC_TEST|Novel laser inferometry test for CORONA virus|detection of virus particles by light absorbtion patterns.
223687910|NCT05445934|DRUG|FB2001|FB2001 for injection will be reconstituted with 100 mL of normal saline prior to intravenous infusion. FB2001 will be administered by IV infusion over approximately 60 minutes.
223687911|NCT05445934|DRUG|FB2001 placebo|Placebo will be reconstituted with 100 mL of normal saline prior to intravenous infusion. Placebo will be administered by IV infusion over approximately 60 minutes.
223687912|NCT02854410|DIETARY_SUPPLEMENT|Sodium nitrate|Dietary intake:Sodium nitrate 0.5mmol/kgbodyweight,bid
223687913|NCT02854410|DIETARY_SUPPLEMENT|sodium chloride|Dietary intake:sodium chloride 0.5mmol/kgbodyweight,bid
223687914|NCT04586361|COMBINATION_PRODUCT|RegenLab PRP|PRP preparations also improved functional outcome scores compared to hyaluronic acid and placebo in patients affected by knee osteoarthritis (OA). Based on previous studys, we can conclude that the PRP treatment is a safe and efficacious procedure which can provide functional benefit.
223687915|NCT04586361|COMBINATION_PRODUCT|hyaluronic acid|Few studies investigated the effects of HA+PRP combined treatment for knee osteoarthritis (OA). Numerous studies demonstrated the efficacy of HA injection therapy in knee OA for a clinical point of view, reducing the pain and improving the quality of life.
223687916|NCT04586361|OTHER|normal saline|In this study, we compare introperative PRP/PRP+HA/normal saline in ACL reconstruction patient.
223687917|NCT04485429|DRUG|Methylprednisolone|Methylprednisolone 0.5 mg/kg every 12 hours intravenously for the first 14 days; followed by 0.5 mg/kg/day from day 15 to day 21; followed by 0.25mg/kg/day from day 22 to day 25; followed by 0.125 mg/kg/day, from day 26 to day 28 of treatment.
223687918|NCT04485429|DRUG|Heparin|Enoxaparin 1 mg/kg subcutaneously every 12 hours (if creatinine clearance greater than 40ml/min) or Unfractionated heparin dosed to target activated partial thromboplastin time (aPTT) between 1.5 - 2.0 times the normal value (if creatinine clearance less or equal to 40ml/min). The treatment period with full-dose heparin will be 7 days. After 7 days of full-dose heparin, patients will continue using prophylactic dose of heparin, according to the standard treatment routine.
223687919|NCT02399618|DRUG|Fecal Microbiota Transplantation|Fecal microbiota transplant from healthy, unrelated donor via freeze-dried capsule
223687920|NCT03777735|PROCEDURE|human bone graft screw|All patients undergo surgical treatment of osteochondral defects in the knee joint with human bone graft screws.
223687921|NCT04373668|BEHAVIORAL|Hypnotic Medication Review|A training programme focused providing guidance on the review and withdrawal process of hypnotic drugs.
223687922|NCT04373668|BEHAVIORAL|Structured Sleep Hygiene|Training module on the principle of good sleep hygiene
223687923|NCT04373668|BEHAVIORAL|Night Time Care Activities Programme|Training and support package to assist in the development of a personalised night time care plan and support the implementation and dissemination of information within the care home environment
223687924|NCT04271280|OTHER|Non-interventional|This is a non-interventional study.
223687925|NCT02201511|DRUG|3 mg PF-06412562 MR tablets_Fasted|A single modified release tablet with 3 mg PF-06412562 administered after an overnight fast
223687926|NCT02201511|DRUG|2 x 15 mg PF-06412562 MR tablets_Fasted|Two 15 mg PF-06412562 modified release tablets administered after an overnight fast
223687927|NCT02201511|DRUG|2 x 15 mg PF-06412562 MR tablets_Fed|Two 15 mg PF-06412562 modified release tablets administered after a high fat breakfast
223687928|NCT02201511|DRUG|10 mg PF-06412562 IR tablets|a single immediate release tablet of 10 mg PF-06412562 after an overnight fast
223687929|NCT01668927|DRUG|Proton Pump Inhibitor|
223687930|NCT01668927|DRUG|Bismuth|
223687931|NCT01668927|DRUG|Metronidazole|
223687932|NCT01668927|DRUG|Tetracycline|
223687933|NCT01668927|DRUG|Furazolidone|
223775971|NCT04139785|OTHER|Moodbuster|"Moodbuster intervention comprises three elements: (1) a web-based interface providing the patients access to CBT therapies, (2) a web-based portal for the trial co-ordinator and researchers, where they can view participation, amend modules and send login codes, (3) a mobile phone component which enables daily EMA monitoring of mood state, cognitions, activities, social interaction, and sleep.~The mobile application will be used to capture EMA data."
223775972|NCT03333746|OTHER|Laboratory Biomarker Analysis|Correlative studies
223775973|NCT03333746|DRUG|Lenalidomide|Given PO
223775974|NCT03333746|BIOLOGICAL|Nivolumab|Given IV
223775975|NCT03333746|OTHER|Pharmacological Study|Correlative studies
223775976|NCT03511482|DEVICE|myAsthma Application|myAsthma Application is a Multi facetted online self management tool developed by my mhealth Ltd, which is an online interface for patient to feedback symptoms and (Quality of Life) QoL score. The app consists of an online action /self management plan, Patient education videos, medication diary, Peak Flow diary, Inhaler technique videos, mindfulness videos as well as weather and Pollution forecasters.
223687934|NCT01668927|DRUG|Amoxicillin|
223775977|NCT03511482|DEVICE|Lloyds Pharmacy Online Doctor|"Online Doctor is part of Expert Health Ltd a doctor-led initiative providing safe and reliable remote online healthcare to adults in the UK. Their patient-centred model of healthcare allows patients to tailor care around their schedule and increases healthcare access for harder-to-reach patient groups.~As the first ever online healthcare organisation to register with the government regulator of healthcare - and having received outstanding feedback from the Care Quality Commission about the high level of safe, effective, caring, responsive and well led care provided by the service - They pride themselves on their pioneer status and work constantly to expand the boundaries of personalised healthcare."
223775978|NCT02709070|PROCEDURE|resection|hepatectomy for HCC
223775979|NCT02709070|PROCEDURE|highly-purified CTL|hepatectomy first, followed by highly-purified CTL treatment
223775980|NCT04003727|DEVICE|Mcgrath Mac Videolaryngoscope|Patient's laryngoscopy will be done using McGrath Mac video laryngoscope
223775981|NCT02279810|BEHAVIORAL|survey|Survey
223775982|NCT02510157|DRUG|Dexamethasone|active comparator
223687935|NCT05834413|DRUG|chemotherapy plus TCM 1&ICIs plusTCM2 placebo|"In China,TCM herbs are given on the basis of the TCM syndrome differentiation as diagnosed by the TCM herbal specialist. Prescriptions formulated into granules origin from Professor Liu Jia-xiang and Xu Ling. Package of granules is made into two types with functions such as tonifying the stomach and nourishing the blood recipe, benefiting Qi Yin and detoxification and resolving masses recipe. The herbal treatment is adapted to the syndromes.~Chemotherapy：Vincristine/paclitaxel/docetaxel/pemetrexed/gemcitabine plus cisplatin/carboplatin：administrated for patients with NSCLC requiring post-operative adjuvant therapy.~ICIs：Nivolumab/Pembrolizumab/Durvalumab/Atezolizumab/ Camrelizumab/Dupilumab/Sintilimab/Tislelizumab：administrated for patients with NSCLC requiring post-operative adjuvant therapy."
223687936|NCT05834413|DRUG|chemotherapy plus TCM 1placebo &ICIs plus TCM2 placebo|"Chemotherapy：Vincristine/paclitaxel/docetaxel/pemetrexed/gemcitabine plus cisplatin/carboplatin：administrated for patients with NSCLC requiring post-operative adjuvant therapy.~ICIs：Nivolumab/Pembrolizumab/Durvalumab/Atezolizumab/ Camrelizumab/Dupilumab/Sintilimab/Tislelizumab：administrated for patients with NSCLC requiring post-operative adjuvant therapy."
223687937|NCT00295971|BIOLOGICAL|anti-thymocyte globulin|
223775983|NCT02510157|DRUG|Normal Saline|placebo controlled intervention
223775984|NCT02510157|DRUG|sugammadex|sugammadex is administered in both groups to reverse deep neuromuscular blockade at the end of surgery
223775985|NCT01929356|PROCEDURE|Chest physiotherapy|20 minutes of chest physiotherapy by physiotherapist
223775986|NCT06431620|DRUG|Recombinant Human Thyroid Stimulating Hormone|recombinant human thyrotropin (rhTSH) injection: 0.9mg/1.0mL/piece; intramuscular injection; once a day for two consecutive days.
223775987|NCT04051892|DEVICE|FixNip™ NRI|The FixNip™ NRI is an implantable hypodermic, silicone implant specially designed for nipple areola definition
223687938|NCT00295971|BIOLOGICAL|therapeutic allogeneic lymphocytes|
223687939|NCT00295971|DRUG|fludarabine phosphate|
223687940|NCT00295971|DRUG|thiotepa|
223775988|NCT03119103|DEVICE|Functional Bed Sheet|All participants sleep on the functional bed sheet that is placed under a normal bed sheet. The device collects pressure sensor information and informs on body position, respiration rate, and respiration patterns.
223775989|NCT06176027|DRUG|Azacytidine plus CAOLD regimen|Patients were treated by Azacytidine(75 mg/m2 on days 1-7) plus CAOLD regimen (cyclophosphamide 400mg/m2 qd d1; cytarabine 30mg/m2 qd d1-d4; vindesine 2mg/m2 qd d1; pegaspargase 2500iu/m2 qd d2; dexamethasone 7.5mg/m2 qd d1-d5)
223775990|NCT06414109|BEHAVIORAL|BREATHE-Migraine|"The BREATHE-Migraine intervention was adapted from the research-supported curriculum, Learning to BREATHE (Broderick, 2021), based on qualitative feedback from adolescents with migraine, their parents, and pediatric headache providers. BREATHE-Migraine includes experiential and didactic exercises designed to address emotion regulation and the stress of living with frequent migraine."
223687941|NCT00295971|PROCEDURE|allogeneic bone marrow transplantation|
223687942|NCT00295971|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
223687943|NCT00295971|PROCEDURE|in vitro-treated peripheral blood stem cell transplantation|
223687944|NCT00295971|RADIATION|total-body irradiation|
223687945|NCT05223335|DRUG|Clopidogrel|75 mg/day
223687946|NCT05223335|DRUG|Prasugrel|60 mg bolus then 10 mg daily
223687947|NCT05223335|DRUG|Tricagrelor|180 mg bolus then 90 mg twice daily
223687948|NCT04853381|OTHER|dietary treatment (low FODMAP)|The aim of the study will be explained to the patients and the dietary treatment that will be recommended if they participate in the study will be told that they should be followed for 4 weeks. In addition, it will be notified that surveys will be conducted at the beginning and end of the 4-week period.
223687949|NCT04853381|OTHER|dietary treatment (gluten free)|The aim of the study will be explained to the patients and the dietary treatment that will be recommended if they participate in the study will be told that they should be followed for 4 weeks. In addition, it will be notified that surveys will be conducted at the beginning and end of the 4-week period.
223687950|NCT04853381|OTHER|dietary treatment (low FODMAP+gluten free)|The aim of the study will be explained to the patients and the dietary treatment that will be recommended if they participate in the study will be told that they should be followed for 4 weeks. In addition, it will be notified that surveys will be conducted at the beginning and end of the 4-week period.
223775991|NCT04278417|BIOLOGICAL|Brolucizumab 6 mg|3 x q6w loading injections, followed by q12w maintenance through Week 90
223775992|NCT04278417|PROCEDURE|Panretinal photocoagulation laser|initial treatment in 1-4 sessions up to Week 12, followed with additional PRP treatment as needed
223775993|NCT02390583|BEHAVIORAL|CBT treatment of internet dependence|CBT treatment of internet dependence
223775994|NCT02390583|BEHAVIORAL|CBT treatment of sleep disorders|CBT treatment of sleep disorders
223775995|NCT06969027|DRUG|JS207|JS207 (10 mg/kg or 15 mg/kg, IV, d1)
223687951|NCT04853381|OTHER|dietary treatment (Traditional diet recommendations)|The aim of the study will be explained to the patients and the dietary treatment that will be recommended if they participate in the study will be told that they should be followed for 4 weeks. In addition, it will be notified that surveys will be conducted at the beginning and end of the 4-week period.
223687952|NCT02312921|OTHER|PREDICT|Allied dental personnel provide screening and preventive services in community settings and case managers serve as patient navigators to arrange referrals of children who need dentist services. The intervention is paired with a compensation system for high performance (pay-for-performance) with efficient performance monitoring. PREDICT focuses on: 1) identifying eligible children and gaining caregiver consent for services in community settings (e.g., schools); 2) providing risk-based preventive and caries stabilization services efficiently at these settings; 3) providing curative care in dental clinics; and 4) incentivizing local delivery teams to meet performance benchmarks.
223687953|NCT01851915|BEHAVIORAL|Cognitive Behavioral Therapy|14 sessions psychological treatment for depression
223687954|NCT01851915|BEHAVIORAL|Interpersonal Psychotherapy (IPT)|14 sessions psychological treatment for depression
223687955|NCT05554523|DEVICE|Photoacoustic imaging|Photoacoustic imaging
223687956|NCT02449720|DRUG|Ropivacaine|Intraperitoneal instillation and infusion
223687957|NCT02449720|DRUG|0.9% Saline|Intraperitoneal instillation and infusion
223687958|NCT01253707|DRUG|AMG 337|AMG 337 is a small molecule inhibitor of c-Met which is a receptor tyrosine kinase expressed on the surface of epithelial cells.
223687959|NCT00003173|BIOLOGICAL|filgrastim|
223687960|NCT00003173|DRUG|thiotepa|
223687961|NCT00003173|PROCEDURE|autologous bone marrow transplantation|
223687962|NCT00003173|PROCEDURE|peripheral blood stem cell transplantation|
223775996|NCT06969027|DRUG|Pemetrexed injection|Pemetrexed (500 mg/m2 IV, D1)
223775997|NCT06969027|DRUG|Platinum|Platinum (carboplatin AUC 5, D1 or cisplatin 75 mg/m2, D1)
223687963|NCT02653404|OTHER|IGRA test (QTF-GIT)|blood sample for QFT-GIT will be taken together with other routine blood samples
223775998|NCT06969027|DRUG|Paclitaxel|Paclitaxel (175 mg/m2 IV, D1)
223775999|NCT00628602|DEVICE|BION|"30 patients operated will be randomized into 2 equal groups, a BION Therapy Group (Rx group) and a Control Group (Control group)."
223776000|NCT01973985|OTHER|Pleural Manometry|Intrapleural pressure will be monitored with the use of an electronic pleural manometer (Mirador Biomedical CompassTM Thoracentesis Assist Device).
223776001|NCT01973985|OTHER|Thoracic ultrasonography|"Thoracic ultrasound scan will be done before drainage of pleural effusion - all participants.~Thoracic ultrasound scans will also be done during drainage of pleural effusion and the results will be recorded after every 100mL of pleural fluid drained - all participants.~Thoracic ultrasound scan will be done after drainage of pleural effusion - all participants.~Thoracic ultrasound scan will also be be done during clinic follow-up as part of routine clinical care - all participants."
223776002|NCT01973985|PROCEDURE|Pleural aspiration catheter OR chest drain (standard care)|Insertion of pleural aspiration catheter OR intercostal chest drain under ultrasound guidance - all participants (standard care).
223687964|NCT04572555|OTHER|Heat Treatment|Thermoforming was applied to the lower abdomen by the subjects themselves when the dysmenorrhea pain was at its peak.
223687965|NCT01232205|DIETARY_SUPPLEMENT|micronutrient antioxidant|Supplementation with milk enriched with vitamin and mineral, such as Cu, Zn, Mn, Fe, carotene, vitamin B6, B12, C, E, selenium, and calcium
223687966|NCT01232205|DIETARY_SUPPLEMENT|Control|supplementation with milk
223687967|NCT02945787|BEHAVIORAL|Spanish-Language Version of the Stop Smoking for Good|Participants in the first arm will receive the Spanish-language version of the Stop Smoking for Good (SS-SP) intervention distributed over 18 months.
223687968|NCT02945787|BEHAVIORAL|NCI-Produced Spanish-language Self-help Booklet|Participants in the second arm will receive a single, credible, NCI-produced Spanish-language self-help booklet.
223687969|NCT03811275|BEHAVIORAL|Virtual Reality (A) then Task (B)|Participants will use their intact arm to perform virtual reality tasks while perceiving a reflected virtual image of their paretic arm.
223687970|NCT03811275|BEHAVIORAL|Task (B) then Virtual Reality (A)|Participants will use their paretic arm to perform real tasks in a structured environment, with a practice and feedback schedule organized by a physical or occupational therapist, or graduate student.
223687971|NCT04898205|OTHER|Treadmill Exercise|The cardiopulmonary rehabilitation protocol utilizes progressive treadmill exercise with alternating increases in intensity and incline with no more than 0.5 Met increase per session.
223687972|NCT04898205|OTHER|Concentrated Oxygen|Supplemental oxygen from a concentrator (6 liters per minute) will be provided via nasal cannula regardless of oxygen saturation.
223687973|NCT04898205|OTHER|Concentrated Air|Room air will be delivered through an concentrator provided via nasal cannula.
223687974|NCT03266198|OTHER|No intervention|No intervention
223687975|NCT05923619|PROCEDURE|Total pulpotomy|Total pulpotomy procedures explained in arm descriptions.
223687976|NCT05923619|PROCEDURE|Root canal treatment|Root canal treatment procedures explained in arm descriptions.
223687977|NCT01718795|DEVICE|Bag-valve mask or laryngeal tube ventilation|"Interventions are either Bag-valve mask (BVM) or Laryngeal tube (LT) ventilation during CPR"
223687978|NCT01030783|DRUG|tivozanib (AV-951)|Tivozanib: 1.5 mg orally once daily. Subjects will receive 1.5 mg tivozanib once daily beginning on Day 1 for 3 weeks followed by 1 week off treatment. One cycle will be defined as 4 weeks of treatment. Cycles will be repeated every 4 weeks.
223687979|NCT01030783|DRUG|Sorafenib|Sorafenib: 400 mg orally twice daily. Subjects will receive 400 mg (2 x 200 mg tablets) sorafenib twice daily continuously, beginning on Day 1. One cycle will be defined as 4 weeks of treatment. Cycles will be repeated every 4 weeks.
223687980|NCT02966886|PROCEDURE|Eccentric Reaming|"Pre-operative CT imaging and surgical planning software based on pre-operative CT scans will be used in each case to determine the degree of eccentric (high side) anterior reaming to within \< 10 degrees of neutral glenoid version."
223687981|NCT02966886|PROCEDURE|Augmented Glenoid Component Implantation|Patients will undergo standard glenoid preparation and implantation of a posteriorly augmented glenoid component. The degree of posterior augment will be based on pre-operative CT scan assessment and templating software with the goal of correcting glenoid retroversion to within 10 degrees of neutral version.
223687982|NCT02966886|PROCEDURE|Posterior Glenoid Bone Grafting|Patient will undergo a total shoulder arthroplasty as per standard technique. Glenoid version will be restored to within 10 degrees of neutral with a posterior glenoid bone graft. The bone graft will be harvested from the humeral head and fixed to the posterior glenoid with mini-fragment screws.
223687983|NCT06102746|DRUG|Sintilimab，Surufatinib|Based on the standard EP regimen, the combination of surufatinib (anti-angiogenic therapy) and sintilimab (PD-1 inhibitor) were used among patients with advanced gastric neuroendocrine carcinoma.
223687984|NCT01857583|DRUG|15mg DU-176b|
223687985|NCT01857583|DRUG|30mg DU-176b|
223687986|NCT01857583|DRUG|Fondaparinux|
223687987|NCT06640335|OTHER|Co-ingestion|Subjects co-ingest both (300 g mashed potatoes) and (200 g baby round spinach supplemented with canola oil) in the same time.
223687988|NCT06640335|OTHER|0 min preload|Subjects consume 200 g baby round spinach supplemented with canola oil first, then directly consume 300 g of mashed potatoes.
223687989|NCT06640335|OTHER|5 min preload|Subjects consume 200 g baby round spinach supplemented with canola oil first, wait 5 minutes, then consume 300 g of mashed potatoes.
223687990|NCT06640335|OTHER|10 min preload|Subjects consume 200 g baby round spinach supplemented with canola oil first, wait 10 minutes, then consume 300 g of mashed potatoes.
223687991|NCT06640335|OTHER|15 min preload|Subjects consume 200 g baby round spinach supplemented with canola oil first, wait 15 minutes, then consume 300 g of mashed potatoes.
223687992|NCT06640335|OTHER|20 min preload|Subjects consume 200 g baby round spinach supplemented with canola oil first, wait 20 minutes, then consume 300 g of mashed potatoes.
223687993|NCT06640335|OTHER|Spinach only / 10 min preload|Subjects consume 200 g baby round spinach WITHOUT canola oil first, wait 10 minutes, then consume 300 g of mashed potatoes.
223687994|NCT06640335|OTHER|Canola oil only / 10 min preload|Subjects consume 20 g of canola oil first, wait 10 minutes, then consume 300 g of mashed potatoes.
223687995|NCT03971513|PROCEDURE|Trans abdominal plane|"Trans abdominal plane block is performed with ultra sound guidance.~1. \- The high frequency probe is placed right to the umbilicus, and slips laterally to the side to block. It allows showing the three belts of larges muscles of abdomen (External Oblicum, internal oblicum, and transversal of the abdomen).~2. \- When the needle is visualised in the plan separating the muscle internal oblicum and transversal of the abdomen, 20 ml of ropivacaïne 5mg/ml are injected after aspiration test. If in doubt, hydro localisation car be realised."
223687996|NCT01510457|DRUG|Milnacipran|Total target dose of 200 mg/day. Subjects will titrate-up according to the following schedule: 25 mg/d (2 pills, 2 days), 50mg mg/d (4 pills, 2 days), 100mg/d (2 pills, 3 days), 150 mg/d (3 pills, 4 days), and steady state is reached once the study participant ingests 200 mg/d(4 pills). The steady state is maintained for 44 days (approx. 6 weeks). If intolerable side effects occur, the dose may be reduced to last tolerable does, a minimum of 100 mg/day at the discretion of the PI. Subjects unable to tolerate 100 mg/day will be discontinued from the study. A 2-week down-titration will be used.
223687997|NCT01510457|DRUG|Placebo|Subjects will receive identical placebo pills and dosing schedule as that of participants receiving active study medication.
223687998|NCT02824861|BEHAVIORAL|Bemobile|
223687999|NCT00134537|DEVICE|Interspinous process and dynamic stabilization|Interspinous process and dynamic stabilization
223688000|NCT00134537|DEVICE|Conservative Care|Medication, exercise and spinal injections
223688001|NCT01187719|DRUG|phenytoin|phenytoin 184 mg (2 tablets of 92mg) OD at onset of labour and continue for seven days
223688002|NCT04163679|PROCEDURE|Vaginal Preparation|"One sponge stick will be inserted into the vagina, where it will stay during the scrubbing of thighs and genitals.~One sponge will be used to scrub the right inner thigh from mid-thigh to right labia majora. This sponge will then be discarded.~A second sponge will be used to scrub the left inner thigh from mid-thigh to left labia majora. This sponge will then be discarded.~A third sponge will be used to scrub the mons pubs, labia majora and minor, perineum and rectum in that order then will be discarded. This will be repeated with a fourth sponge.~The existing sponge stick in the vagina will be rotated in the vagina twice then removed. This will be discarded.~A second sponge stick will be inserted in the vagina, rotated twice then removed. As it is removed from the vagina, the perineum and rectum will be swabbed with the stick in that order then discarded. This will be repeated using a third sponge stick."
223688003|NCT04235465|OTHER|Dynamic Gait Index|The Dynamic Gait Index (DGI) measures functionality and dynamic balance in walking and stair climbing. The DGI consists of 8 items including normal gait on flat ground, gait with speed changes, gait with horizontal head movements, gait with vertical head movements, gait and pivot turn, gait and step over an obstacle, gait around obstacles and steps up and downstairs. The performance on each item is rated on a 4-point scale ranging from 0 (severe disorder) to 3 (independent walking). The total score is 24.
223688004|NCT00458536|BIOLOGICAL|Dendritic Cell Tumor Fusion Vaccine|3 vaccinations at three week intervals
223688005|NCT00458536|DRUG|Granulocyte Macrophage Colony Stimulating Factor (GM-CSF)|Combined with the vaccine in the remaining subjects after the first 6 are enrolled.
223688006|NCT01676363|DRUG|Diflunisal|Open-label diflunisal 500 mg twice daily for 4 weeks
223688007|NCT06003998|DRUG|Irinotecan|2 weekly IP irinotecan (max 12 cycles), dose 75 mg flat dose
223688008|NCT06003998|DRUG|FOLFOX regimen|FOLFOX-4 regimens consist of 85 mg/m2 oxaliplatin plus 200 mg/m2 LV and 5-FU 400 mg/m2 bolus on day 1 followed by 1600 mg/m2 5-FU as a 46-h infusion
223688009|NCT06003998|DRUG|Bevacizumab|Bevacizumab according to standard of care
223776003|NCT01973985|PROCEDURE|Talc slurry pleurodesis via chest drain (standard care)|Talc slurry pleurodesis via intercostal chest drain where/when clinically indicated as part of routine clinical care participants with intercostal chest drain only (standard care).
223776004|NCT00850031|DEVICE|AcuFocus Corneal Inlay|Inlay implanted in cornea for improvement of near vision
223776005|NCT03422120|OTHER|Natural Killer Cell Activity Assay|Subjects had a blood test to measure NK cell activity (NKA) at different time points
223688010|NCT02811354|DRUG|AZD9291|oral administration as a single daily dose of 80 mg
223688011|NCT05117632|DRUG|ALTO-100 PO tablet|one tablet twice daily
223688012|NCT06333756|OTHER|Cross education|Cross education training of the biceps brachii (12 rep./set, 3sets, 60%MVIC,180°/s, eccentric contraction)
223688013|NCT00538525|DRUG|Doxorubicin, Docetaxel, Cisplatin|Doxorubicin, Docetaxel, Cisplatin
223688014|NCT04894916|OTHER|My Diabetes Care Mobile (MDC-m)|My Diabetes Care (MDC) is a multi-faceted patient portal intervention for mobile devices that is designed to help patients better understand their diabetes health data as well as promote and support self-management. MDC uses infographics to facilitate patients' understanding of their diabetes health data (e.g., HbA1c, LDL), incorporates motivational strategies and access to an online patient support community, and provides literacy level-appropriate and tailored diabetes self-care information.
223688015|NCT05821634|BEHAVIORAL|Personalized intervention condition: Cognitive behavioral therapy skills|An 11-session cognitive behavioral therapy (CBT) skills based intervention will be delivered to participants randomized to the personalized intervention. Influential constructs will be identified using the person specific digital phenotyping model, targeted using CBT skills, and tracked across sessions.
223776006|NCT02166983|OTHER|computer-assisted cognitive training|Complete Lumosity cognitive exercises
223776007|NCT02166983|OTHER|cognitive intervention|Complete Active Journaling cognitive exercises
223776008|NCT02166983|PROCEDURE|mind-body intervention procedure|Complete relaxation exercises
223776009|NCT02166983|OTHER|memory intervention|Complete compensatory strategies
223688016|NCT05821634|BEHAVIORAL|Therapeutic control condition: Cognitive behavioral therapy skills|Participants randomized to this condition will receive an 11-session CBT skills based treatment targeting a non-personalized construct selected from the person-specific digital phenotyping model.
223776010|NCT02166983|OTHER|questionnaire administration|Ancillary studies
223776011|NCT03342664|DEVICE|Artemis + Medical Management|Subject will receive best MM in addition to the MIS procedure with Artemis.
223776012|NCT03342664|OTHER|Best Medical Management Alone (MM)|Subject will receive best MM for ICH as determined by stroke physician following AHA/ESO guidelines.
223776013|NCT04898231|DRUG|Infliximab|Infliximab will be administered as a single IV dose of 10 mg/kg over 2 hours.
223688017|NCT05821634|BEHAVIORAL|Tracking control condition: Supportive counseling|Participants randomized to this condition will receive 11 supportive counseling sessions that are non-directive in nature (providing support and validation for non-acute weekly stressors). Participants will continue digital phenotyping, controlling for the effect of counseling and digital phenotyping.
223776014|NCT04898231|DRUG|Anakinra|Anakinra will be administered at a dose of 8 mg/kg/day IV or SQ with 100 mg every 6 hours as the max dose. This is discontinued with a taper during the hospitalization over 2-4 days once a patient is stable with significantly improved clinical course and laboratory profile.
223776015|NCT04898231|DRUG|Methylprednisolone|Methylprednisilone (steroids) will be administered as 2 mg/kg IV or orally divided every 12 hours. At the time of hospital discharge the patient will be given a steroid taper that will take at least 3 weeks to complete.
223776016|NCT03282552|DEVICE|Nasal Cannula High Flow Oxygen|Nasal Cannula High Flow Oxygenation will be implemented at these study groups . (1st study group, and 2nd study group)
223776017|NCT00205712|DRUG|Ketamine|Ketamine without dexmedetomidine
223688018|NCT02776267|DEVICE|Angiolite stent|Following index PCI, patients will be followed via scheduled clinic and/or phone contact at 1-, 3-, 6-, 12- and 24-month. Patient will be randomized to undergo a scheduled repeat coronary angiogram and OCT evaluation at either at 3- or 6-month post index PCI.
223688019|NCT04631484|DRUG|Cytoflavin ((Inosine + Nicotinamide + Riboflavin + Succinic Acid)|20 ml (2 ampoules, 10 ml each) dissolved in 200 ml of 0.9% sodium chloride, intravenously 2 times a day with an interval of 12 ± 2 hours, for 10 days.
223688020|NCT04631484|DRUG|Placebo|20 ml of 0.9% sodium chloride (2 ampoules of 10 ml each), added to 200 ml of 0.9% sodium chloride, intravenously 2 times a day with an interval of 12 ± 2 hours, for 10 days
223688021|NCT06420466|BEHAVIORAL|Time-restricted Feeding|Controlling the eating time to 6 hours per day, but not being prescriptive about the quantity and content of dietary intake.
223688022|NCT06566521|PROCEDURE|thoracic paravertebral block|After surgery and before extubation, the patient was positioned in an upper lateral position on the affected side. For patients in the TPVB group, an ultrasound high-frequency linear array probe was used to perform a mid-sagittal scan at the T8-9 spinous process interspace on the affected side. The probe was moved to visualize the T8-9 transverse process and pleura. Using the out-of-plane needling technique, the needle was inserted between the costotransverse ligament and the pleura in the paravertebral space adjacent to the thoracic vertebra. After confirmation of no blood or cerebrospinal fluid return, 30 mL of 0.5% ropivacaine hydrochloride was injected. Under ultrasound guidance, the spread of the medication and downdraft of the pleura could be observed.
223688023|NCT04397887|PROCEDURE|micro-surgical varicocelectomy|Sub-inguinal micro-surgical varicocelectomy
223688024|NCT02789579|DRUG|levofloxacin|There are 50 patients in the group,each patient receives levofloxacin 0.5g, qd, po 7 days before Minimally invasive upper tract lithotomy.All patients in all groups, 30 minutes before surgery, are given preventive medication cefuroxime 1.5g ivgtt, and continue using 1.5g q12h ivgtt until postoperative 48 hours.
223688025|NCT02789579|DRUG|Nitrofurantoin|There are 50 patients in the group,each patient receives nitrofurantoin 0.1g, qd, po 7 days before Minimally invasive upper tract lithotomy.All patients in all groups, 30 minutes before surgery, are given preventive medication cefuroxime 1.5g ivgtt, and continue using 1.5g q12h ivgtt until postoperative 48 hours.
223688026|NCT02789579|DRUG|cefuroxime|There are 150 patients in the group, 30 minutes before surgery, each patient is given preventive medication cefuroxime 1.5g ivgtt, and continue using 1.5g q12h ivgtt until postoperative 48 hours.
223688027|NCT06986460|DEVICE|MagPro X100/R30 stimulator, Cool-B70 coil|1Hz rTMS delivered to the right DLPFC
223688028|NCT06987773|DRUG|RLF-OD032 100 mg/mL oral suspension|Sapropterin dihydrochloride
223688029|NCT06987773|DRUG|Kuvan 100 MG Powder for Oral Solution|Sapropterin dihydrochloride
223688030|NCT06816836|PROCEDURE|Bed Side ultrasound guided muscle mass estimation of lower extremity|Bed Side ultrasound guided muscle mass estimation of psoas major, rectus femoris, vastus intermedius and tibialis anterior.
223688031|NCT06666049|DIAGNOSTIC_TEST|Gastric Ultrasound|Gastric Ultrasound
223688032|NCT06589778|DRUG|SHR-A2102|SHR-A2102: injection, 80mg/ bottle, intravenous drip
223688033|NCT06589778|DRUG|Adebelimab (SHR-1316)|Adebelimab (SHR-1316): injection, 600mg(12mL)/ bottle, intravenous drip
223688034|NCT06589778|DRUG|SHR-8068|SHR-8068: injection, 50mg（10mL）/ bottle, intravenous drip
223776018|NCT00205712|DRUG|Dexmedetomidine|Ketamine plus dexmedetomidine
223776019|NCT01479803|PROCEDURE|Puncture with fine needle aspiration under endoscopic ultrasonographic control|Puncture of the pancreatic solid mass with fine needle aspiration under endoscopic ultrasonographic control Passage in the same pancreatic mass of first EchoTip HD Procore then EchoTip 22 Gauge or vice versa according to the randomization
223776020|NCT00112203|DRUG|Itopride|
223688035|NCT06666504|OTHER|Combined Retrospective and Prospective Data Analysis|Collection of both retrospective and prospective data all ready available for participant
223688036|NCT06993857|OTHER|Neuromuscular taping applied with no tension|Neuromuscular taping applied with no tension over the anterior surface of the forearm before performing an exercise protocol to observe immediate changes in pain pressure, muscle oxygenation and grip strength
223688037|NCT06993857|OTHER|Neuromuscular taping applied with distal-to-proximal tension|Neuromuscular taping applied with distal-to-proximal tension over the anterior surface of the forearm before performing an exercise protocol to observe immediate changes in pain pressure, muscle oxygenation and grip strength
223688038|NCT06993857|OTHER|Neuromuscular taping applied with proximal-to-distal tension|Neuromuscular taping applied with proximal-to-distal tension over the anterior surface of the forearm before performing an exercise protocol to observe immediate changes in pain pressure, muscle oxygenation and grip strength
223688039|NCT06993571|DEVICE|Active-tACS|30 seconds of closed-loop tACS at 2-4 mA, with 6 alternating phase alignments and 1-3 repetitions. Phase alignment is adjusted to the patient's tremor frequency and rhythm in real time. Administered using the neuroConn LOOPIT device and 2 electrodes placed on the cerebellum and jaw, with an area of 5x5 and 5x7 respectively. The stimulation begins with a 3-second ramp-up and ends with a 3-second ramp-down.
223688040|NCT06993571|DEVICE|Sham-tACS|30 seconds of tACS at 0 mA and 1-3 repetitions. Administered using the neuroConn LOOPIT device and 2 electrodes placed on the cerebellum and jaw, with an area of 5x5 and 5x7 respectively. The sham protocol begins with a 3-second ramp-up and ends with a 3-second ramp-down.
223776021|NCT00006095|DRUG|irinotecan hydrochloride|
223776022|NCT00006095|DRUG|vincristine sulfate|
223776023|NCT05638373|OTHER|One shade universal composite|A resin composite with new smart chromatic technology and chameleon effect. It has the ability to match the new lighter shade of the bleached teeth unlike the conventional composite
223688041|NCT06993571|DEVICE|Unlocked-tACS|30 seconds of open-loop tACS at 2-4 mA, with no phase alignments and 1-3 repetitions. Administered using the neuroConn LOOPIT device and 2 electrodes placed on the cerebellum and jaw, with an area of 5x5 and 5x7 respectively. The stimulation begins with a 3-second ramp-up and ends with a 3-second ramp-down.
223688042|NCT06994533|PROCEDURE|methods on bone reconstrucion after chest wall tumor resection|Selecting appropriate implants for chest wall bone reconstruction
223688043|NCT06995313|BEHAVIORAL|Biofeedback training|This is an audio-luminous stimulation on the micro perimeter that teaches the brain to use a different fixation locus on the retinal other than the fovea and develops visual attention to the surrounding retinal areas. 20 minutes exercises for stimulation are performed on the micro perimeter, once a week, for 5 weeks.
223688044|NCT06995209|DIETARY_SUPPLEMENT|Placebo|20 g, \~74 Kcal, 97% flavored maltodextrin, similar in color, flavor, taste, and energy as PWS
223688045|NCT06995209|DIETARY_SUPPLEMENT|Pre-workout Supplement|20 g, \~73 Kcal, 200 mg caffeine, 3.3 g creatine monohydrate, 3.2 g β-alanine, 6 g citrulline malate, and 5 g branched chained amino acid (BCAA)
223688046|NCT05824741|BEHAVIORAL|Infant Cardiovascular Health (CVH) Promotion|The pilot infant CVH intervention will be delivered by Nurse-Family Partnership (NFP) staff starting no later than 1 month postpartum and lasting up to 6 months postpartum. The visit schedule will be consistent with the NFP visit structure to deliver intervention content at regularly scheduled visits that are typically 60 minutes long. This pilot study will include an enhanced version of the NFP standard care plan delivered by trained nurses to promote cardiovascular health by targeting soothing, feeding, sleep, and physical activity behaviors during infancy. The intervention delivered by trained visiting nurses will include behavior change strategies (e.g., goal setting, problem solving barriers). This pilot study will also examine the feasibility and acceptability of a digital device (infant foot worn actigraphy) during this same time period.
223688047|NCT06277791|DRUG|Adebrelimab|Adebrelimab：20mg/kg, ivdrip, D1，Q3W
223688048|NCT06622070|DRUG|SPY002-072|Experimental
223688049|NCT06622070|OTHER|Placebo|Placebo
223688050|NCT06685588|DRUG|5-FU (fluorouracil)|Topical 5-FU (fluorouracil) pretreatment prior to dovonex
223688051|NCT06685588|DRUG|Calcipotriol|Calcipotriol pre-treatment prior to PDT
223688052|NCT06682247|DRUG|Chidamide, Tucidinostat; PD-1/PD-L1 inhibitor or double antibodies; Bevacizumab or tyrosine kinase inhibitors|Chidamide, Tucidinostat; PD-1/PD-L1 inhibitor or double antibodies; Bevacizumab or tyrosine kinase inhibitors
223776024|NCT05638373|OTHER|Nanohybrid resin composite|A conventional resin composite with multiple shades
223776025|NCT01331694|DRUG|fluticasone/salmeterol combination (FSC) 250/50mcg|patients initiating treatment with fluticasone/salmeterol combination (FSC) 250/50mcg
223688053|NCT06683703|DRUG|Utidelone combined with Bevacizumab|The initial dose was Utidelone 30mg/m2/d,D1-D5,Q3W+ Bevacizumab 15mg/kg/Q3w. If dose adjustment was required due to DLT events, Utidelone was reduced by up to one dose (to 25mg/m2/d), while the dose of Bevacizumab remained unchanged (15mg/kg).
223688054|NCT06683703|DRUG|Utidelone|Utidelone injection, 30mg/m2/d, D1-D5 for 5 consecutive days, every 21 days as a treatment cycle
223688055|NCT06683703|DRUG|Utidelone combined with Bevacizumab|In the combination group, the dose of Utidelone was determined according to the safety run-in period, 30 mg/m2/d or 25mg/m2/d, D1-D5,Q3W; The dose of Bevacizumab was 15 mg/kg/3W.
223688056|NCT06683703|DRUG|Utidelone combined with Bevacizumab|The dose of Utidelone was 30 mg/m2/d or 25mg/m2/d, D1-D5,Q3W; The dose of Bevacizumab was 15 mg/kg/3w.
223688057|NCT05952271|OTHER|Hospitalization|Population of patients hospitalized for Herpes Zoster (ICD9-CM 053.xx)
223688058|NCT06878495|OTHER|Discontinuation of 5-ASA|Discontinuation of 5-ASA from the time of study enrollment.
223688059|NCT04996498|DRUG|Oxytocin|intrauterine Instillation of oxytocin in distention media used during Hysteroscopic Myomectomy
223688060|NCT04996498|OTHER|sterile bacteriostatic water ampule|a placebo drug similar in shape to oxytocin ampules
223688061|NCT03287635|DRUG|Corticotropin 80Unit/Ml Repository Injection|H.P. Acthar Gel (repository corticotropin injection) is an adrenocorticotropic hormone (ACTH) analogue used for: Treatment during an exacerbation or as maintenance therapy in selected cases of systemic lupus erythematosus.
223688062|NCT06715696|DEVICE|"HANBIO Gauze (Sterilized, 1% Collagen)"|"After tissue resection in a standard procedure for gynecological surgery, direct application of HANBIO Gauze to cover the bleeding site/area which identified during dissection."
223688063|NCT05401019|DRUG|Pramipexole|Oral medication, once a day during 16 weeks
223688064|NCT05401019|DRUG|Risperidone|Oral medication, once a day during 16 weeks
223688065|NCT06893185|OTHER|Dry cupping therapy|Dry cupping therapy will perform on the skin areas containing the EX-B2, A-shi, and GB21 acupuncture points every 3 days for 2 weeks.
223688066|NCT06893185|OTHER|Electroacupuncture|Electroacupuncture therapy will be performed five times a week for 2 weeks. The acupoints are the Huatuojiaji (EX-B2), A-shi, and Jianjing (GB21).
223688067|NCT06118892|DEVICE|MISHA Knee System|The MISHA Knee System is an extra-capsular knee implant intended to reduce loads on the medial knee. The implant consists of an absorber located between bases fixed with locking screws to the medial cortices of the distal femur and proximal tibia. The implant shares the load with the medial knee joint and articulating ball-and-sockets allow the device to accommodate the natural motions of the knee.
223688068|NCT06742710|DRUG|Liraglutide and metformin|Liraglutide 3.0 mg or maximum tolerable dose/day × 12 weeks and metformin 1500 mg/day until pregnancy.
223688069|NCT06742710|DRUG|Metformin|Metformin 1500 mg/day until pregnancy
223688070|NCT05329584|DEVICE|InSpace Subacromial Tissue Spacer|Rotator Cuff Tear Treatment
223688071|NCT06748170|OTHER|ChatGPT|OpenAI's ChatGPT language model with chat interface.
223688072|NCT06754917|BEHAVIORAL|Face-Forward-Web|This is a self-administered web-based mind-body intervention that consists of 5 30-minute video sessions disseminating tailored relaxation, mindfulness, and cognitive-behavioral skills for COP. Ultimately, the Face-Forward-Web program aims to increase patients' physical and emotional functioning and decrease pain intensity and maladaptive coping behaviors.
223688073|NCT06809894|PROCEDURE|Application of an action protocol for the management of delirium through the use of non-pharmacological interventions|The interventions carried out stand out for being non-pharmacological, this avoiding the use of drugs and polypharmacy in elderly patients, avoiding the appearance of clinical complications derived from the side effects that the use of these substances can lead to in the patient. In addition, it also encourages the education of health professionals and nurses' families or caregivers in the management of delirium.
223688074|NCT06809894|OTHER|Tradicional management of delirium|The use of the pharmacological treatment and the mechanical patients restrain were de base of the traditional treatment in deliriums patient in the University hospital of Igualada, because of the less knowledge of the professionals and non-existence protocol of non-pharmacological interventions to management the delirium.
223688075|NCT00323869|DRUG|Bevacizumab|Murine humanized anti-vascular endothelial growth factor A (VEGF-A) monoclonal antibody
223688076|NCT00323869|DRUG|Gemcitabine|Nucleoside analog
223688077|NCT00323869|DRUG|Carboplatin|Alkylating agent
223688078|NCT00000506|DRUG|fenfluramine|
223688079|NCT00000506|DRUG|phentermine|
223688080|NCT04840030|BEHAVIORAL|Multimodal intervention (MM-int)|"1. Cognitive intervention objective: To enhance cognitive functioning and incorporate daily habits and routines that are cognitively stimulating~2. Socio-emotional intervention objective: • Promote socio-emotional skills associated with awareness, communication and regulation of emotions in late life.~3. Nutritional intervention objective: To improve eating habits of participants to be based on the Mediterranean Dietary pattern by an educational program~4. Physical activity intervention objective: To improve aerobic capacity y, decrease the risk of falls, and improve static and dynamic balance.~5. Risk factors and comorbidities monitoring intervention: quarterly scheduled visits for a cardiovascular risk factors check-up and review active medication"
223688081|NCT06894992|DRUG|Tegoprazan|Tegoprazan 50 mg tab PO OD in 2 weeks
223688082|NCT06894992|DRUG|Lansoprazole|Lansoprazole 30 mg tab PO OD in 2 weeks
223688083|NCT06770517|BEHAVIORAL|Exposure therapy|The exposure therapy will be given by the mental health care nurses (MHN) working in primary care centres. In addition, there will be eight sessions spread over 12 weeks. The first session will be 60 minutes long and the rest will be 30 minutes long.
223688084|NCT06770517|BEHAVIORAL|Usual Care|The Usual Care group will receive care based on the general practitioners guidelines for anxiety disorders in the primary care center. This will entail possible medication, e-learning or psycho-education, problem solving therapy or a referral to a mental health institution.
223776026|NCT01331694|DRUG|tiotropium|patients initiating treatment with tiotropium
223776027|NCT01331694|DRUG|ipratropium bromide alone or in fixed dose combination with albuterol|patients initiating treatment with ipratropium/albuterol
223688085|NCT06577870|PROCEDURE|Hospitalization in intensive care or continuing care unit|Hospitalization in intensive care or continuing care unit for medical reasons or surgery, conscious or unconscious under mechanical ventilation. Resuscitation patients are then cared for in a continuing care unit.
223688086|NCT00921245|DRUG|Darifenacin (Emselex, BAY79-4998)|Patients in daily clinical treatment receiving Emselex according to local drug information
223688087|NCT04981834|OTHER|Quality-of-Life Assessment|Ancillary studies
223688088|NCT04981834|OTHER|Questionnaire Administration|Ancillary studies
223688089|NCT04981834|PROCEDURE|Radical Prostatectomy|Undergo RARP
223688090|NCT04981834|PROCEDURE|Vesicopexy|Undergo vesicopexy
223688091|NCT05331248|BEHAVIORAL|Leaders in Action: Household Treatment|The Household Treatment (HT) followed a door-to-door delivery approach: CHVs, in coordination with the local Women Emergency Center (CEM), offered 8 treatment sessions to households in the targeted sample. The sessions took place over a period of 1 to 2 months at the residences of the female participants. This intervention was subject to a second-stage randomization to include edutainment videos in its implementation for the HT only treatment arm. In 31 randomly selected HT villages, all targeted households watched the edutainment component as part of the HT program, and in the other 31 HT villages, only 50% of the targeted households were randomly assigned to watch the edutainment component.
223688092|NCT05331248|BEHAVIORAL|Leaders in Action: Group Treatment|The group-based approach (Group Treatment, or GT) entailed 4 workshops involving various activities and group discussions. The group sessions directed at men had a slightly different curriculum than those directed at women, and always had at least one male CHV in the room facilitating the session. GT sessions took place over one month in each community in village community centers, schools, churches, or other communal spaces where village residents would often gather, and lasted for approximately two hours. The edutainment component was screened in every GT workshop.
223688093|NCT07052344|OTHER|Preload condition|Participants will consume a fixed compulsory preload meal of Campbell's Tomato soup (\~300 grams) 30 minutes after the baseline assessments. Fifteen minutes after consuming the preload meal, participants will receive the ad libitum test meal, consisting of a pre-weighed serving of Stouffer's Macaroni and Cheese (\~700 g).The pre-load condition will be completed at only one of two visits. Participation will be up to 2 weeks with the visits separated by up to 2 weeks. Duration for the pre-load condition visit will be up to 6 hours
223688094|NCT07052344|OTHER|Ad-libitum control condition|Participants will only consume the ad libitum test meal, which consists of a pre-weighted serving of Stouffer's Macaroni and Cheese (\~700 g). The ad-libitum meal will be consumed at both visits. Participation will be up to 2 weeks with the visits separated by up to 2 weeks. The ad-libitum control condition visit will take up to 2 hours.
223688095|NCT05694338|OTHER|Frailty survey|Frailty survey using the Clinical Risk Analysis Index (RAI-C).
223688096|NCT02502162|DRUG|LDN|
223688097|NCT02502162|DRUG|Placebo|Sugar pill
223688098|NCT06362226|DRUG|Steroid/Antibiotic (Maxitrol)|Group one subjects receive topical maxitrol ophthalmic ointment twice daily for two weeks
223688099|NCT06362226|DRUG|5-FU/Kenalog|Group two undergoes treatment with a subcutaneous injection of a 5-fluorouracil (5-FU) and Kenalog (triamcinolone) combination (80/20 ratio, 0.3-0.5 mL per session) administered in four sessions, spaced two weeks apart, starting within 48 hours of hospital presentation
223688100|NCT07126912|DEVICE|Alcarisa (hyaluronic acid filler)|A single injection of Alcarisa filler with a maximum dose of 2 to 4 cc , was administered in the zygomaticomalar area, and if deemed appropriate by the physician, also in the anteromedial cheek and submalar areas on each side of the face.
223776028|NCT01856816|OTHER|Meal Pattern Treatment A|"In treatment A, subjects consumed 100% of salad vegetables and canola oil in the first meal and 0% in the second. Additional protein-rich chef's salad ingredients were distributed equally between meals."
223776029|NCT01856816|OTHER|Meal Pattern Treatment B|"In treatment B, subjects consumed 50% of salad vegetables and canola oil in the first meal and 50% in the second. Additional protein-rich chef's salad ingredients were distributed equally between meals."
223776030|NCT01856816|OTHER|Meal Pattern Treatment C|"In treatment C, subjects consumed 75% of vegetables and oil in the first meal and 25% in the second. Additional protein-rich chef's salad ingredients were distributed equally between meals."
223776031|NCT00178191|OTHER|Bladder diary|3-day bladder diary
223776032|NCT00178191|OTHER|Questionnaires|Incontinence Quality of Life questionnaires
223776033|NCT00178191|PROCEDURE|Urodynamics|Urodynamics
223776034|NCT00178191|OTHER|Pad weight|Pad weight
223776035|NCT05321394|DRUG|Sotrovimab|Single intravenous infusion of sotrovimab 500 mg (500 mg/8 mL), administered in 100 mL prefilled 0.9% sodium chloride injection infusion solution over 1/2 hour.
223776036|NCT05321394|DRUG|Tixagevimab Cilgavimab|"2 subsequent injections:~1. tixagevimab 300mg/3mL (100mg/mL)~2. cilgavimab 300mg/3mL (100mg/mL)"
223776037|NCT05321394|DRUG|Nirmatrelvir Ritonavir|300 mg nirmatrelvir (two 150 mg tablets) with 100 mg ritonavir (one 100 mg tablet) with all three tablets taken together twice daily for 5 days
223776038|NCT03275558|DRUG|Axitinib 1 MG|"Pharmaceutical composition of Axitinib 5MG +Sunitinib 5MG + Pazopanib 5MG in the liquid form of a nasal spray NST-4-G.~Subjects take a nasal spray BID at a single dose in each nostril (approximately at the same time of day) for 7 weeks or unacceptable toxicity or other adverse events."
223776039|NCT03275558|DRUG|Sunitinib 5 MG|Pharmaceutical composition of Axitinib 5MG +Sunitinib 5MG + Pazopanib 5MG in the liquid form of a nasal spray NST-4-G.
223776040|NCT03275558|DRUG|Pazopanib 5 MG|Pharmaceutical composition of Axitinib 5MG +Sunitinib 5MG + Pazopanib 5MG in the liquid form of a nasal spray NST-4-G.
223776041|NCT02582099|DRUG|Gentamicin nasal irrigation|Nasal wash with gentamicin solution
223776042|NCT02582099|DRUG|Normal saline nasal irrigation|Nasal wash with normal saline solution
223776043|NCT02269462|DRUG|Efavirenz|600 mg once daily in combination with other drugs (e.g. tenofovir and emtricitabine)
223776044|NCT02269462|DRUG|Nevirapine|200 mg twice daily in combination with other drugs (e.g. tenofovir and emtricitabine)
223776045|NCT05996861|BEHAVIORAL|ICU sleep protocol|"Adjusting sound intensity, as well as reducing noise: efforts will be made to minimize staff conversation volume during the night.~Earplugs will be offered, along with the provision of eye masks for lucid patients, and thermal comfort adjustments will be made, such as providing blankets and/or adjusting room temperature.~Dimming of lights starting from 10 PM. Reduced circulation of external services between 11 PM and 6 AM, and rationalization of sample collections and/or patient transfers between beds during the 11 PM to 6 AM interval.~Optimization of analgesics for better pain control; optimization of medication use during wakefulness when clinically feasible; adjustment of intervals for capillary blood glucose measurement; maintaining and/or resuming the use of chronic sleep medications. If the patient has been unable to sleep, a hypnotic medication will be offered.~Other considerations include suggesting ventilatory support measures for selected patients."
223776046|NCT03430752|OTHER|questionnaires|Participants were asked to respond to the questionnaires including the Chinese version of the Paediatric Quality of Life Inventory 4.0 Generic Core Scale (PedsQL 4.0), the Chinese version of the Center for Epidemiological Studies Depression Scale for Children (CES-DC), the Chinese version of Rosenberg self-esteem scale, the Chinese version of the Herth Hope Index (HHI) and the Chinese version of Resilience Scale for Children (RS10).
223776047|NCT03619421|DIETARY_SUPPLEMENT|Zinc supplement|25 mg
223776048|NCT05566340|PROCEDURE|mitral valve repair|Repair of mitral valve concomitant to aortic valve replacement.
223776049|NCT01749891|DRUG|ALG 1001|Patients who will receive three, monthly intravitreal injections of 1.5mg, 2.5mg ,or 4.0 /50μl of ALG-1001 in 0.05cc in isotonic saline solution.
223776050|NCT02845661|DRUG|Dexmedetomidine|a bolus of dexmedetomidine was administered intravenously 15 min after spinal anesthesia,and the initial dose in group 1 was started from 0.9 µg/kg
223776051|NCT02845661|DRUG|Dexmedetomidine|a bolus of dexmedetomidine was administered intravenously 15 min after spinal anesthesia,and the initial dose in group 2 was started from 1.0 µg/kg
223776052|NCT02845661|DRUG|Dexmedetomidine|a bolus of dexmedetomidine was administered intravenously 15 min after spinal anesthesia,and the initial dose in group 3 was started from 1.1 µg/kg
223776053|NCT02136875|DRUG|Double dose of Salmeterol + Fluticasone Propionate|
223776054|NCT02136875|BEHAVIORAL|Self-management education on the use of a self-administered prescription for exacerbation.|Patients will be instructed to start treatment within 48 hours of experiencing an acute exacerbation of COPD and/or after starting their self-administered prescription.
223688101|NCT06934161|PROCEDURE|dynamic computer-guided Corticotomy|corticotomy cuts were made guided by a dynamic navigation system, ensuring accuracy and reducing the risk of injuries
223688102|NCT06934161|PROCEDURE|static computer-guided Corticotomy|corticotomy cuts were made guided by a static system (using reticulated surgical template), ensuring accuracy and reducing the risk of injuries
223688103|NCT06934161|DIAGNOSTIC_TEST|smartphone-based thermography|a Mini2 Infrared Smartphone Camera (Hangzhou HIKMICRO Sensing Technology Co., China) was initially calibrated with the surrounding ambient temperature. The calibration phase was essential as it enabled the device's algorithm to have a reference point based on the surrounding conditions and eliminate any bias caused by varying environmental temperatures. Then, pre-operative temperatures of attached gingiva and alveolar mucosa surfaces were recorded. The measurements were registered by distinguishing, for both arches, the temperature corresponding to soft tissues from incisor region (from central incisor to homolateral canine), premolar region (first and second premolars), and molar region (first and second molars).
223688104|NCT00071578|BEHAVIORAL|Group Psychotherapy-Negative Emotion Focus|20 weekly sessions, 2 hours, group format
223688105|NCT00071578|BEHAVIORAL|Group Psychotherapy- Self-Esteem Focus|20 weekly sessions, 2 hours, group format
223688106|NCT02294773|PROCEDURE|Intrauterine Insemination|Intrauterine insemination is either performed on the day the home ovulation predictor kit first turns positive or the day after the first positive.
223688107|NCT02294773|DRUG|Clomiphene|Patient is to take clomiphene citrate during cycle days 3-7.
223688108|NCT02294773|DRUG|Letrozole|Patient is to take letrozole during cycle days 3-7.
223688109|NCT03052764|BIOLOGICAL|onabotulinumtoxinA|OnabotulinumtoxinA (BOTOX®) injection into the bladder.
223688110|NCT03052764|DRUG|Placebo (saline)|Placebo (saline) injection into the bladder.
223688111|NCT06166602|DRUG|PENG block with 0.25% bupivacaine.|Peng block will be applied to the same side as the surgery, using 0.25% bupivacaine at the same concentration in different volumes.
223688112|NCT04314154|OTHER|Monitoring PROM @ PREM data on participating patients|"125 patients (ages 18-55) admitted to SHALVATA mental health center and their clinicians will be recruited to participate in a prospective longitudinal assessment. Each will include PREMs, PROMs clinician rated outcomes and assessment of the degree to which clinical indicators (reflected processes of clinical guidelines) were carried out. The assessments will take place at admission, discharge and every 3 months for up for 9 months. The design is a repeated measures design with evaluating the interaction effect between assessed levels of indicators (between subject effect) and level of change in the PREMs, PROMs clinician along the research trajectory (within subject effect)."
223688113|NCT04822649|DIAGNOSTIC_TEST|Adenosine stress echocardiography with the evaluation of coronary artery blood flow|"The color Doppler flow of distal left anterior descending artery will be examined from the modified apical four-chamber view in the anterior interventricular groove.~In regard to body composition analysis, Using InBody S10, impedance is measured in 6 frequency bands (1 kilohertz (kHz), 5 kHz, 50 kHz, 250 kHz, 500 kHz, 1000 kHz) for each of 5 parts (right plate, left arm, torso, right leg, left leg). Reactance is measured in 3 frequency bands (5 kHz, 50 kHz, 250 kHz for each of 5 parts (right arm, left arm, torso, right leg, left leg).~By treadmill exercise test with modified Bruce protocol or bicycle ergometer for patients with orthopedic problems, maximal oxygen consumption (VO2 max) will be measured using the exhalation gas analysis."
223688114|NCT06517108|PROCEDURE|Chuna therapy|"The chuna therapy group will receive chuna therapy based on the degree of displacement of the lumbar, ilium, sacrum, and cervical vertebrae. The type of weight or treatment is selected based on the clinical judgment of the Korean medicine practitioner (HVLA: high-velocity low-amplitude thrust, drop table manipulation, muscle energy techniques, myofascial release, etc.). The area and number of treatments performed are recorded separately. Thermotherapy is applied as an adjuvant treatment.~The treatment will be administered between MCD 8 and MCD 28, twice a week during the 1st and 2nd cycle. The number of treatments can be adjusted depending on the patient's menstrual cycle and degree of displacement."
223688115|NCT06517108|PROCEDURE|Physical therapy|"The physical therapy group will receive transcutaneous electrical nerve stimulation (TENS) for about 10 to 15 minutes, and the area and number of times it was administered will be recorded. Thermotherapy is applied as an adjuvant treatment, and the area and number of times it is applied are recorded separately.~The treatment will be administered between MCD 8 and MCD 28, twice a week during the 1st and 2nd cycle. The number of treatments can be adjusted depending on the patient's menstrual cycle and degree of displacement."
223688116|NCT01339026|DRUG|Prasugrel|Day 1 loading 60mg Day 2 to 7 10mg o.d. Day 8 to 30 days 10mg od
223688117|NCT01339026|DRUG|Plavix|Clopidogrel (Plavix) Day 1 Loading 600mg Day 2 to 7 day: 150mg o.d. Day 8 to 30 days: 75mg o.d.
223688118|NCT02069288|DRUG|Fludrocortisone|50 µg of fludrocortisone per os
223688119|NCT02069288|DRUG|Placebo|1 tablet of placebo per os
223688120|NCT04823416|PROCEDURE|Resection|Left hemicolectomy
223688121|NCT04823416|PROCEDURE|Stoma|Colostomy
223688122|NCT01530347|DEVICE|Easy Check|Collection of paired measurements of capillary blood glucose using reference method and data generated by the non invasive study device. Samples will be obtained at specific time points during 4 hours: at fasting, and after consuming standard liquid meal at 60, 120, 180 and 240 minutes.
223688123|NCT03470974|BEHAVIORAL|Self-titration strategy|The self-titration strategy allows patients or medical professionals to adjust their medicine (additional, maintain, or decrease dose) depending on a bespoke plan. The bespoke plan for hypertensive patients involves setting target blood pressure, self-monitoring blood pressure, recording blood pressure readings and constructing a medication titration schedule. Each medication titration step is conducted based on the average home BP measurement readings.
223688124|NCT00606944|BEHAVIORAL|fast-track rehabilitation|fast-track rehabilitation with early ambulation and diet after elective colorectal resection
223688125|NCT02808091|DRUG|GIFOX-Bortezomib|GIFOX-Bortezomib will be given every 21 days for 4 cycles
223688126|NCT02808091|DRUG|GIFOX-Bortezomib|GIFOX-Bortezomib will be given every 21 days for a total of 6 cycles.
223688127|NCT02808091|RADIATION|IMRT|a minimum of 50 Gy of IMRT to tumor bed and neck (5 weeks)
223688128|NCT04827121|PROCEDURE|Fascial iliac compartment block|Patients will recieve supra-inguinal approach of fascial iliac compartment block under ultrasound guidance with 30 ml of 0.5 percent ropivacaine.
223688129|NCT04827121|PROCEDURE|Quadratus lumborum block|Patients will recieve transmuscular approach of quadratus lumborum block under ultrasound guidance with 30 ml of 0.5 percent ropivacaine.
223688130|NCT01386112|DRUG|EUR-1100|Active oral medication
223688131|NCT01386112|DRUG|placebo|matching placebo
223688132|NCT06083935|DRUG|Daflon|Daflon; two film coated tablets 500 mg daily
223688133|NCT06083935|DRUG|Combined oral contraceptive|Yassmin ® film-coated tablets 3 mg of drospirenone and 0.03 mg of ethinyl estradiol once daily daily
223688134|NCT06083935|DRUG|Metformin|Glucophage ® 500 tablets twice daily
223688135|NCT00964132|DRUG|NRX194204|Once Daily, Oral
223688136|NCT04123665|DRUG|Stannous fluoride|In this arm, participants will apply a full ribbon of dentifrice ( 0.454% w/w stannous fluoride) to the bristles of a study toothbrush and brush their teeth in their usual manner for one timed minute twice daily (morning and evening) and record on their study diary completed brushings.
223688137|NCT04123665|DRUG|Sodium monofluorophosphate|In this arm, participants will apply a full ribbon of negative control dentifrice (1000 ppm fluoride as SMFP to the bristles of a study toothbrush and brush their teeth in their usual manner for one timed minute twice daily (morning and evening) and record on their study diary completed brushings.
223688138|NCT03073967|DRUG|Pritelivir|100 mg oral tablets
223688139|NCT03073967|DRUG|Investigator's choice|Foscarnet iv, 40 mg/kg BW tid or 60mg/kg bid or Cidofovir iv, 5 mg/kg BW given once weekly or Cidofovir 1% or 3%, topically applied 2 to 4 times daily or Imiquimod 5%, Solution for iv infusion or topical application
223688140|NCT06544057|BEHAVIORAL|CBT-MI|CBT-MI combines elements from Cognitive Behavioural Therapy and Motivational Interviewing in treating nicotine addiction, delivered remotely via Zoom by trained 'layperson coaches'
223688141|NCT06559540|RADIATION|Hypofractionated radiation|External beam photon therapy with IMRT or VMAT to the breast/chestwall and regional lymph nodes, including supraclavicular, infraclavicular, axillary, and internal mammary nodes,
223688142|NCT06559540|RADIATION|Ultra-hypofractionated breast/chest wall and regional nodal radiation|External beam photon therapy with IMRT or VMAT to the breast/chestwall and regional lymph nodes, including supraclavicular, infraclavicular, axillary, and internal mammary nodes
223688143|NCT04057989|DRUG|ketamine|
223688144|NCT02698995|DRUG|Dexamethasone|One hour before surgery the patients received single shot VIB block with the mixture according to the group allocation
223688145|NCT02698995|DRUG|Ropivacaine|One hour before surgery the patients received single shot VIB block with the mixture according to the group allocation
223688146|NCT02698995|DRUG|Paracetamol|After the block regression, at the first analgetic request the patients received the same analgesia protocol
223688147|NCT02698995|DRUG|Morphine|After the block regression, at the first analgetic request the patients received the same analgesia protocol
223688148|NCT02698995|DRUG|Lidocaine|One hour before surgery the patients received single shot VIB block with the mixture according to the group allocation
223688149|NCT00206076|DRUG|mycophenolate mofetil|mycophenolate mofetil and half their baseline dose of calcineurin inhibitor
223688150|NCT00206076|DRUG|mycophenolate mofetil|mycophenolate mofetil monotherapy
223688151|NCT05847712|OTHER|Simulated work in the heat|Participants perform a continuous moderate-intensity work bout (metabolic rate of \~200 W/m2) until core temperature reaches 38.0°C (equivalent to a 1°C increase in body core temperature above resting levels), which is immediately followed by intermittent work using a 3:1 work-rest allocation, starting with a 15 min rest break followed by a 45 min work bout for a total work duration of \~240 min. The work protocol is performed in the morning of day 1, and repeated in a post-lunch work period (i.e., afternoon of day 1) and on the morning of the next day (i.e., morning of day 2).
223688152|NCT01960387|DRUG|Clofarabine|Clofarabine will be administered as a 1-hour (range: 1 hour minimum to 2 hours maximum) intravenous infusion at a dose of 40mg/m2 daily on days 1 through 5.
223688153|NCT01960387|DRUG|Cytarabine|Cytarabine at a dose of 1g/m2 daily will be given as a 2-hour intravenous infusion, starting 3 hours after the completion of clofarabine administration on days 1 through 5.
223688154|NCT00198796|BIOLOGICAL|H10407|The primary objective of the proposed clinical investigation is to validate a dose for ETEC H10407 that will cause diarrhea in 50% or more of subjects without causing high output diarrhea
223688155|NCT05493618|DRUG|Pembrolizumab|Pembrolizumab 200 mg IV q3 weeks until unacceptable toxicity or disease progression for up to 2 years (35 cycles).
223688156|NCT05493618|DRUG|Belantamab mafodotin|Belantamab 2.5 mg/kg IV q3 weeks until unacceptable toxicity or disease progression for up to 2 years (35 cycles).
223688157|NCT05493618|DRUG|Dexamethasone|Dexamethasone 40 mg IV q3 weeks (20 mg if patient \>75) until unacceptable toxicity or disease progression for up to 2 years (35 cycles).
223688158|NCT03431311|BIOLOGICAL|Adoptive Cell Therapy (ACT)|T cell receptor based therapy of metastatic colorectal cancer with mRNA-engineered T cells targeting mutant transforming growth factor beta receptor type II (TGFβII)
223688159|NCT05369260|OTHER|Telerehabilitation-based cervical and scapular stabilization exercises|Telerehabilitation based cervical and scapular stabilization exercises will be applied via videoconference method for 8 weeks, one day a week , 45-60 minutes for each session.
223688160|NCT05369260|OTHER|Telerehabilitation-based cervical and core stabilization exercises|Telerehabilitation based cervical and core stabilization exercises will be applied via videoconference method for 8 weeks, one day a week , 45-60 minutes for each session.
223688161|NCT00847119|BIOLOGICAL|Bevacizumab|Bevacizumab 4 cycles each 15 days, the first 10 mg/kg and the rest of cycles with 5 mg/kg.
223688162|NCT00847119|DRUG|capecitabine (Xeloda)|Capecitabine 900 mg/m2 two times a day concomitant during radiotherapy period
223688163|NCT00847119|RADIATION|Rectal Radiotherapy|Radiotherapy in rectum 45 Gy starting on Bevacizumab 2nd cycle during 5 weeks, 1.8 Gy per day, 5 days at week.
223688164|NCT01082380|DRUG|PF-02341066|oral suspension, single 250 mg dose of PF 02341066 containing approximately 100 µCi of \[14C\]PF 02341066
223688165|NCT01496768|DIETARY_SUPPLEMENT|Leucine|7,2 g/day during 3 months
223688166|NCT01496768|DIETARY_SUPPLEMENT|Alanine|7,2 g/day during 3 months
223688167|NCT03409068|PROCEDURE|C2-C4 compartment anesthetic block|C2-C4 compartment anesthetic block is performed by injecting levobupivacaine 0.375% 20 mL between the posterior face of the middle scalenus muscle, the anterior face of the posterior scalene muscle and the lower plane of the sternoscleidomastoid muscle.
223688168|NCT03409068|PROCEDURE|Costagliola block|Costagliola block is performed by injected by injecting levobupivacaine 0.375% 20 mL along the anterior and the posterior border of sternocleidomastoid muscle
223688169|NCT06130007|DRUG|Three-Week Treatment Regimen with Trastuzumab in Combination with Docetaxel and Platinum Triple Therapy|Three-Week Treatment Regimen with Trastuzumab in Combination with Docetaxel and Platinum Triple Therapy
223688170|NCT01875003|DRUG|Lebrikizumab|Lebrikizumab will be administered as SC injection at high or low dose Q4W.
223688171|NCT01875003|DRUG|Placebo|Lebrikizumab matching placebo will be administered as SC injection Q4W.
223688172|NCT01875003|DRUG|Standard of Care|Participants will continue to receive ICS therapy (total daily dose of 500-2000 mcg fluticasone propionate DPI or equivalent) along with at least one second controller medications (e.g. long-acting beta agonists \[LABAs\], leukotriene receptor antagonists (LTRAs), long-acting muscarinic antagonists (LAMAs), or theophylline) as standard of care.
223688173|NCT00276081|DRUG|Gabapentin, Estrogen and placebo administration|
223688174|NCT05041517|BEHAVIORAL|BOLT + PTC|BOLT is a Brief Online Training (BOLT) for Measurement-Based Care (MBC). Participants in the BOLT condition were subsequently randomized into varying amounts of post-training consultation (PTC).
223688175|NCT06314620|DRUG|Heparin saline lock|Participants with intercostal chest catheter who underwent normal saline flushing with heparin saline lock
223688176|NCT06314620|OTHER|Without heparin saline lock|Participants with intercostal chest catheter who underwent normal saline flushing without heparin saline lock
223688177|NCT04729946|DEVICE|Pure-Vu Cleansing Device|The Pure-Vu device attaches to the colonoscope and provides colonic cleansing during urgent colonoscopy without the need for a bowel preparation
223688178|NCT00750880|DRUG|tocilizumab [RoActemra/Actemra]|8mg/kg iv (60 minute infusion)
223688179|NCT06207435|BEHAVIORAL|Transportation|Eligible patients are contacted and offered free transportation to and from their upcoming appointment.
223688180|NCT05456919|OTHER|SFQ28 Questionnaire|SFQ28 Questionnaire
223688181|NCT05950958|OTHER|Multimodal therapy for prevention of delirium|Multimodal therapy for prevention of delirium
223688182|NCT04883957|DRUG|BGB-11417|Film-coated tablets administered orally as specified in the treatment arm.
223688183|NCT02687178|DRUG|Canrenone 50 vs canrenone 100 mg|
223688184|NCT04638192|DEVICE|tACS|A pair of 25 cm2 rubber electrodes enclosed in saline-soaked sponges and affixed to the head with rubber bands.
223688185|NCT00455910|DRUG|Thalidomide|
223776055|NCT02136875|DRUG|Self-administered prescription|"An Acute Exacerbation of COPD (AECOPD) is defined as a sustained worsening of dyspnea, cough or sputum production leading to an increase in the use of maintenance medication and/or supplementation with additional medication. In addition, exacerbations should be defined as either purulent or non-purulent.~Standing prescriptions for exacerbation:~1\) Purulent exacerbation - Antibiotic: Avelox 400 mg daily for 5 days. 2a) Mild to moderate exacerbation - Combination therapy (SFP - Advair) to be increased as follows: If regular treatment is Advair 250/50 BID then dose should be increased to Advair 500/100 BID for 10 days; if regular treatment is Advair 500/50 BID then increase to Advair 1000/100 BID for 10 days.~2b) Severe exacerbation - Prednisone (oral): 40 mg once daily for 7-10 days"
223776056|NCT01652716|DRUG|Exenatide once weekly suspension|Exenatide suspension 2 mg weekly subcutaneous injection
223776057|NCT01652716|DRUG|Exenatide twice daily|5 mcg twice daily for 4 weeks followed by 10 mcg twice daily for 24 weeks
223776058|NCT01482780|DEVICE|PICSO|PICSO (pressure controlled intermittent coronary sinus occlusion) will be used in the pre ECC period. The procedure of PICSO will be performed in analogy to retrograde cardioplegia.
223776059|NCT01045304|DRUG|Iniparib|"Pharmaceutical form: solution for infusion~Route of administration: intravenous"
223776060|NCT01045304|DRUG|Gemcitabine|"Pharmaceutical form: solution for infusion~Route of administration: intravenous"
223776061|NCT01045304|DRUG|Carboplatin|"Pharmaceutical form: solution for infusion~Route of administration: intravenous"
223776062|NCT01337297|DEVICE|transcranial Direct Current Stimulation|transcranial Direct Current Stimulation (tDCS) will be applied by electrodes (5 x 7 cm2), with intensity of 2 mA, during 20 min, with cathode over the left dorsolateral prefrontal cortex (F3 site) and anode placed in the contralateral dorsolateral prefrontal cortex (F4 site).
223776063|NCT02143570|DRUG|Darifenacin|Darifenacin will be prescribed in a starting dose of 7.5mg, once daily. This dose may be increased to 15mg a day in cases with refractory symptoms.
223776064|NCT02143570|PROCEDURE|Physiotherapy|All patients will received a tailored pelvic floor exercise programme as part of the standard of care of overactive bladder at the study centre. This intervention will be mainly comprised of biofeedback stimulation techniques.
223776065|NCT03541694|BIOLOGICAL|Stamaril®|Routine vaccination with Stamaril yellow fever vaccine
223776066|NCT02778204|DRUG|Maraviroc|8 mg/kg oral solution as a single dose.
223776067|NCT02778204|DRUG|Maraviroc|8 mg/kg oral solution given twice daily.
223776068|NCT00676442|DRUG|PN400|naproxen/esomeprazole
223776069|NCT02499393|DRUG|Magnesium Sulfate|intravenous infusion of magnesium sulphate
223776070|NCT00594256|DRUG|Sodium Oxybate|Patients will undergo a one-week evaluation period, which will include a taper and discontinuation of any currently prescribed sedative/hypnotics, as well as baseline diagnostic, psychopathology, neurocognitive and polysomnographic measurements (see below for details). Hypnotic taper may be extended or abbreviated, depending on clinical judgment. Patients will then begin a 4-week trial of adjunctive Xyrem (sodium oxybate). Patients will begin at 4.5 g/night (in divided doses of 2.25 g, with 1st dose at bedtime and then 2nd dose four hours later). Dosage will increase by 1.5 g/day every week, until a dose of 9 g nightly is reached, or a patient cannot tolerate further dose escalations. Medication will be administered in divided dosage for the duration of the study. A three-week taper (by 3 g/day weekly) of sodium oxybate will follow the four-week trial of sodium oxybate.
223776071|NCT03982329|DEVICE|navigated repetitive transcranial magnetic stimulation|
223776072|NCT03982329|PROCEDURE|physical therapy|
223776073|NCT02923518|OTHER|Questionnaire|Observational study without any intervention described under intervention type
223776074|NCT02066012|OTHER|dysmetabolic iron overload syndrome|
223776075|NCT04160260|DRUG|Omadacycline|Omadacycline: PO Tablets
223776076|NCT01445392|BIOLOGICAL|Multicycle SS1P|Assigned dose level of SS1(dsFv)PE38 on days 1, 3 \&amp; 5 of a 21 day cycle for 2 cycles
223776077|NCT01445392|DRUG|Pemetrexed|500 mg/m\^2 on day 1 of each 21 day cycle until disease progression
223776078|NCT01445392|DRUG|Cisplatin|75 mg/m\^2 on day 1 of each 21 day cycle until disease progression
223776079|NCT01445392|BIOLOGICAL|Single cycle SS1P|Patients 1 - 3 of single cycle cohort. 45 mcg/kg of SS1(dsFv)PE38 on 4 or 5 days (depending on dose level) of cycle 1 only.
223776080|NCT06046638|DRUG|Cyclopofol|Induction of anesthesia followed by continuous infusion through out surgery. The anesthetic drug regimen will be adjusted according to the changes of blood pressure.
223776081|NCT06046638|DRUG|Propofol|Induction of anesthesia followed by continuous infusion through out surgery. The anesthetic drug regimen will be adjusted according to the changes of blood pressure.
223776082|NCT03198611|DIAGNOSTIC_TEST|Echocardiography|Usual echocardiographic studies in patients suffering septic shock
223688186|NCT04360863|OTHER|Telephone survey|Participants will be asked to respond to a survey regarding their knowledge about the relationship between smoking and COVID-19, their smoking behaviors and readiness to quit during the pandemic.
223688187|NCT01257802|DRUG|depot leuprolide acetate 3.75 mg|Monthly depot leuprolide acetate 3.75 mg vs placebo during cyclophosphamide administration. First dose of study drug given at least 10 days before following dose of cyclophosphamide if cyclophosphamide is given in biweekly or monthly boluses
223688188|NCT01257802|DRUG|Placebo|Monthly placebo during cyclophosphamide administration. First dose of study drug given at least 10 days before following dose of cyclophosphamide if cyclophosphamide is given in biweekly or monthly boluses
223688189|NCT02794740|DRUG|X0002|External Spray
223688190|NCT02794740|DRUG|Placebo|External Spray
223688191|NCT05464173|DRUG|Chidamide|10-30mg biw
223688192|NCT05464173|DRUG|Abemaciclib|150mg or 100mg bid
223688193|NCT05464173|DRUG|endocrinotherapy（doctor's choice）|According to the drug insert
223688194|NCT02964507|DRUG|GSK525762|GSK525762 will be administered.
223688195|NCT02964507|DRUG|Placebo|Placebo will be administered.
223688196|NCT02964507|DRUG|Fulvestrant|Fulvestrant will be administered.
223688197|NCT06059209|DIETARY_SUPPLEMENT|Enfamil NeuroPro|FDA Infant formula
223688198|NCT06059209|DIETARY_SUPPLEMENT|Enfamil Infant|FDA Infant formula
223688199|NCT05979779|DRUG|HU6|HU6 is being evaluated for its efficacy in improving liver fat content in subjects with Nonalcoholic Steatohepatitis (NASH)
223688200|NCT05979779|OTHER|Placebo|Placebo
223688201|NCT06524895|OTHER|Medical Reiki|Reiki is a form of energy therapy involving the facilitation of healing through the manipulation of biofields utilizing light touch. It is a process of targeting the energy fields around the patient's body is believed to stimulate the patient's natural ability to heal itself.
223688202|NCT06524895|OTHER|Sham Reiki|Sham Reiki involves a non-Reiki healer who mimics the treatment of a Reiki healer. Sham Reiki providers will be medical students who are not interested and without prior knowledge or experience with Reiki Medicine.The medical students will not have any prior experience in Reiki healing or associated energy healing modalities. It is better for this project if the medical student has no interest so there is true placebo effect being monitored.
223688203|NCT05786196|DEVICE|Ab-interno canaloplasty utilizing the iTrack Advance device|360 degree microcatheterization and viscodilation of Schlemm's canal
223688204|NCT05786196|DEVICE|Ab-interno canaloplasty utilizing the OMNI Surgical System|360 degree microcatheterization and viscodilation of Schlemm's canal
223688205|NCT03874494|DRUG|Brexpiprazole|Brexpiprazole 2-4 mg/day
223688206|NCT03874494|DRUG|Aripiprazole|Aripiprazole 10-20 mg/day
223688207|NCT02610569|DEVICE|standard endoscopy|standard endoscopy will be either colonoscopy or rectosigmoidoscopy
223688208|NCT02610569|DEVICE|PillCamCOLON (C2)|PillCamCOLON (C2) is a colon video-capsule
223688209|NCT05227547|OTHER|Thoracic resection surgery|Patients undergoing thoracic resection surgery (pneumonectomy, lobectomy, segmentectomy) for cancer or suspected cancer, including smokers (active or ex-smokers) and non-smokers, with COPD and without COPD, and non-smoking patients.
223688210|NCT06490445|DRUG|Medical Cannabis|Syqe cartridge containing medical cannabis (Bedrocan®) administered using Fixed-dose Syqe Inhaler.
223688211|NCT06490445|DRUG|Placebo|Placebo administered using Fixed-dose Syqe Inhaler.
223688212|NCT06144840|DRUG|Dersimelagon|MT-7117
223688213|NCT06144840|DRUG|Placebo|Placebo
223688214|NCT05585320|DRUG|IMM-1-104 Monotherapy (Treatment Group A)|Once-daily, oral IMM-1-104 dose administered in 28-day cycles until treatment discontinuation criteria are met
223688215|NCT05585320|DRUG|IMM-1-104 + modified Gemcitabine/nab-Paclitaxel (Treatment Group B)|"Once-daily, oral IMM-1-104 dose administered in 28-day cycles in combination with intravenous infusions of gemcitabine and nab-paclitaxel until treatment discontinuation criteria are met.~Gemcitabine will be administered at a dose of 1000 mg/m\^2 nab-Paclitaxel will be administered at a dose of 125 mg/m\^2"
223688216|NCT05585320|DRUG|IMM-1-104 + modified FOLFIRINOX (Treatment Group C)|"Once-daily, oral IMM-1-104 dose administered in 28-day cycles in combination with intravenous infusions of modified FOLFIRNOX until treatment discontinuation criteria are met.~FOLFIRINOX will be administered as follows:~Folinic Acid will be administered at 400 mg/m\^2 Fluorouracil will be administered at 2400 mg/m\^2 Irinotecan will be administered at 150 mg/m\^2 Oxaliplatin will be administered at 85 mg/m\^2"
223688217|NCT05585320|DRUG|IMM-1-104 + dabrafenib (Treatment Group D)|Once-daily, oral IMM-1-104 dose administered in 28-day cycles in combination with twice daily oral dose of dabrafenib until treatment discontinuation criteria are met. Dabrafenib will be administered at a dose of 150mg daily (75mg twice daily).
223688218|NCT05585320|DRUG|IMM-1-104 + pembrolizumab (Treatment Group E)|Once-daily, oral IMM-1-104 dose administered in 28-day cycles in combination with intravenous infusions of pembrolizumab in sequence or concurrently depending on the enrolled cohort (two sub cohorts) until treatment discontinuation criteria are met. Pembrolizumab will be administered at a dose of 400mg.
223688219|NCT06647420|BEHAVIORAL|Sedative Music|The participants will come twice in person and listen to 9 minutes of sedative music.
223688220|NCT06647420|BEHAVIORAL|Stimulative Music|The participants will come twice in person and listen to 9 minutes of stimulative music.
223688221|NCT05734430|GENETIC|Genetic profiling|Whole exome sequencing
223688222|NCT05734430|OTHER|Retrospective tissue procurement|Collection of archived fixed-formalin, paraffin-embedded (FFPE) primary appendix tumor tissues that were previously removed
223688223|NCT03392324|DEVICE|PRIMA|Implantation of PRIMA device
223688224|NCT04781530|DEVICE|BioFire FilmArray Respiratory Panel 2.1 plus (RP2.1plus)|BioFire FilmArray Respiratory Panel 2.1 plus (RP2.1plus): Nasopharyngeal swab
223688225|NCT06363695|BEHAVIORAL|SafeCare Kenya|Adapted from SafeCare, this is a strengths-based program for parents with children ages 18 months through age 5, teaching parents skills and knowledge in three areas: 1) parent-child interactions, 2) child health, and 3) home safety.
223688226|NCT06363695|OTHER|Care as Usual by Community Health Volunteers|Community Health Volunteers support families with children up to age 5 around the physical health needs of family members, including delivering key health messages (e.g., importance of immunizations); treating minor injuries and illnesses; identifying/treating/referring common childhood illnesses (e.g., diarrhea, malaria); conducting home visits to evaluate the home environment and discuss improvements; and encouraging care at home and appropriate health seeking behaviors. These support services are not highly structured but rather tailored to the needs of each family.
223688227|NCT05788796|BEHAVIORAL|Band-aid application|"Before starting the study, cotton and band-aids will be provided to the women in the application group by the researchers.~• Pregnant women in the application group will be asked to take a hazelnut-sized cotton ball before going to bed, put it in the middle of the navel and close it diagonally with a band-aid."
223688228|NCT02495233|DRUG|Gilteritinib|oral
223688229|NCT02495233|DRUG|Erlotinib|oral
223688230|NCT04232553|DRUG|Mirikizumab|Administered IV
223688231|NCT04232553|DRUG|Mirikizumab|Administered SC
223688232|NCT05915182|COMBINATION_PRODUCT|Budesonide Glycopyrronium bromide Formoterol fumarate pressurized Metered Dose Inhaler|Participants with moderate to severe Chronic Obstructive Pulmonary Disease
223688233|NCT03880461|BEHAVIORAL|Lifestyle Intervention|Behavioral lifestyle intervention
223688234|NCT06416670|OTHER|Skilled nursing facility care at home|Skilled nursing facility care at home delivers a range of advanced rehabilitation services in patients' homes, enabling care at home despite requiring intensive rehabilitative care. Our approach blends personalized, high-level professional care with innovative technology applications to ensure adequate rehabilitation.
223688235|NCT03828318|OTHER|Patient Activation Booklet and nursing support for patients with LARS|The LARS Patient-Centered Program will consist of an educational booklet and nursing support made available only to patients randomized to the intervention group.
223688236|NCT01875224|DRUG|Belatacept|
223688237|NCT01875224|DRUG|Tacrolimus|Standard administration of tacrolimus
223688238|NCT01873703|DRUG|pracinostat|Histone deacetylase inhibitor (HDACi)
223688239|NCT01873703|DRUG|Placebo|Placebo
223688240|NCT01873703|DRUG|Azacitidine|Active comparator 75 mg/m2 Azacitidine for 7 days of each 28 day cycle, via subcutaneous (SC) injection or intravenous infusion if SC injections are intolerable
223688241|NCT00672204|BIOLOGICAL|Allogeneic islets of Langerhans transplant|Up to 3 intraportal infusions of cadaveric pancreatic islets of Langerhans. Each infusion to contain at least 5,000 islet equivalents/kg body weight.
223688242|NCT00672204|DRUG|Raptiva|Treatment Day -1 pretransplant to Treatment Day 90 after tx.: 1.0 mg/kg/wk SQ; Treatment Day 91 to Treatment Day 365: 0.5 mg/kg/wk SQ;
223688243|NCT00672204|DRUG|Sirolimus|Initial dose 0.1 mg/kg PO on day -2, followed by 0.05 mg/kg daily, whole blood 24-hour trough adjusted to target 3-15 ng/ml as tolerated
223688244|NCT00672204|DRUG|anti-thymocyte globulin|2.0 mg/kg on days -2, and -1 IV
223688245|NCT03325751|DIAGNOSTIC_TEST|Visual field testing|Standard Automated Perimetry using a perimeter is one of the most commonly used techniques for measuring perceived visual ability of a subject. For a given eye, it provides quantitative measurements of visual function represented as a 2D spatial visual field map. It is of great clinical importance for diagnosing and monitoring glaucoma and detecting neurological conditions.
223688246|NCT02848053|OTHER|no intervention|
223688247|NCT01503112|OTHER|No intervention, observational study|
223688248|NCT04134403|DRUG|STASIS|Hydrocortisone sodium succinate, 50 mg, every 6 hours, 7 days or until ICU discharge Thiamine, 200 mg, every 12 hours, 4 days or until ICU discharge Ascorbic acid, 1,500 mg, every 6 hours, 4 days or until ICU discharge
223688249|NCT01295268|OTHER|Emu Oil|Subjects will apply a specified amount of emu oil daily to area.
223688250|NCT01295268|OTHER|Inert oil|A specified amount of inert oil will be applied daily to area.
223688251|NCT02652767|BIOLOGICAL|GS010|"Both eyes of each participant will receive standard antiseptic preparation, administration of topical local ocular anesthetic agents and will undergo pupillary dilation. Administration of an intra-ocular pressure lowering agent will precede treatment for every participant.~GS010-treated Eyes: GS010 is a recombinant adeno-associated viral vector serotype 2 (rAAV2/2) containing the wild-type ND4 gene (rAAV2/2-ND4). Participants will receive a single dose of GS010 in one of their randomly selected eyes, via intravitreal injection containing 9E10 viral genomes in 90μL balanced salt solution (BSS) plus 0.001% Pluronic F68®."
223688252|NCT02652767|DEVICE|Sham Intravitreal Injection|"Both eyes of each participant will receive standard antiseptic preparation, administration of topical local ocular anesthetic agents and will undergo pupillary dilation. Administration of an intra-ocular pressure lowering agent will precede treatment for every participant.~Sham-treated Eyes: One eye of each participant will undergo sham injection. Sham intravitreal injection will be performed by applying pressure to the eye at the location of a typical intravitreal injection procedure using the blunt end of a syringe without a needle."
223688253|NCT01973530|PROCEDURE|adductor canal block|Continuous adductor canal block and single shot posterior tibial nerve block under ultrasound guidance and using nerve stimulating needle (bolus: 0.5% Ropivacaine 10-15ml with dexamethasone 4mg ;with single shot posterior tibial nerve block (8-10ml 0.5% ropivacaine)
223688254|NCT01973530|PROCEDURE|femoral nerve block|Femoral nerve catheter inserted under ultrasound guidance using nerve stimulating needle administering ropivacaine bolus 10-15ml and infusing 0.2% ropivacaine at 4-6ml/h; plus a single shot posterior tibial nerve block under ultrasound guidance and use of nerve stimulating needle
223688255|NCT06391801|BEHAVIORAL|Neuroathletic training|Specific Neuroathletic training exercises were performed to improve balance ability of post stroke patients
223688256|NCT06391801|BEHAVIORAL|Traditional movement therapy in outpatient rehabilitation|Traditional movement therapy in outpatient rehabilitation
223688257|NCT04118933|DRUG|JS001|JS001 240mg, Q3W
223688258|NCT03862040|DRUG|Cefiderocol|Administered intravenously, at a dosage determined based on renal function.
223688259|NCT03862040|DRUG|Standard of Care Antibiotic|Standard of care antibiotic treatment for pneumonia
223688260|NCT06002685|BEHAVIORAL|Attachment and Biobehavioral Catch-Up|The ABC program consists of 10 one-hour home-based sessions delivered by a trained parent coach. Each session includes the mother and her child together and addresses a specific topic. Principal intervention activities include a discussion of basic attachment principles, guided practice of new parenting behaviors, and a review of video clips from previous sessions to help reinforce parenting targets. The parent coach promotes (a) nurturance, especially in response to distress; (b) following the child's lead with delight; and (c) avoiding frightening caregiving behavior. As specified by the ABC protocol, any/all other family members will be invited to observe or participate in each ABC session Each full-time ABC parent coach will serve 8 to 10 families at a time (i.e., complete 8-10 hourly ABC visits per week).
223776083|NCT03968952|OTHER|SMARThealth Pregnancy|Education and Training package on high-risk pregnancies and the associated long-term cardiometabolic risks; An mHealth platform providing mobile decision support to Community Health Workers.
223776084|NCT01999010|DEVICE|MHT|MHT and visualizer contains mood information about the patient themselves, which allows for self management of the mood disorder. Self-management interventions promote early recognition of mood episodes, medication adherence and self-management skills which have shown to improve outcomes in depression. MHT encourages patients to take an active role by engaging in mood journaling, while making this information available in explorable form to the patient and his / her team of clinicians.
223776086|NCT03877393|COMBINATION_PRODUCT|Probiotic supplementation + gluten-free diet|The probiotic and gluten-free diet group (PRO-GFD) will receive one capsule containing the probiotic mixture powder (Sanprobi Stress; Sanprobi sp. z o.o., sp.k., Szczecin, Poland) in the amount of 3 × 10\^9 colony forming units (CFU) per day divided in two equal doses, comprising two bacteria strains: Lactobacillus helveticusRosell®-52, Bifidobacterium longumRosell®-175, and excipients: potato starch, magnesium stearate, and the capsule shell of hydroxypropyl methylcellulose. The participants will be asked to consume supplements before breakfast. The group will follow the elimination diet containing no gluten.
223776087|NCT03877393|COMBINATION_PRODUCT|Placebo supplementation + gluten-free diet|The placebo and gluten-free diet group (PLA-GFD) will receive one capsule containing only the excipients, i.e. maize starch, maltodextrins, and the capsule shell. The participants will be asked to consume supplements before breakfast. The group will follow the elimination diet containing no gluten.
223688261|NCT06002685|OTHER|Home-Based Book-of-the-Week|The HBOW program is an active control condition developed by PI Berlin. It consists of 10 English/Spanish developmentally appropriate books hand-delivered weekly to the mothers. During each of the 10 weeks, a trained RA will visit each HBOW mother to drop off the book and to ask briefly about the mother's and child's well-being (using a standard set of questions). Thus, this condition will parallel the intervention condition in duration (number of weeks) and structure, although it will be less intensive in terms of participant contact time per visit.
223688262|NCT04148729|DRUG|ESP block|Ultrasound guided ESP block will perform with 15 ml bupivacaine+ 5 ml lidocaine at the T10 level bilaterally. 0.1 microgram morphine (IV) and diclofenac sodium 75 mg intramuscularly will perform for postoperative analgesia.
223688263|NCT04148729|DRUG|Control Group|In this group Ultrasound guided ESP block will not perform. Postoperative analgesia will provide with 0.1 microgram morphine (IV) and diclofenac sodium 75 mg intramuscularly.
223688264|NCT02039440|OTHER|Blood draw|One-time blood draw
223688265|NCT03872011|DRUG|Vitamin C,thiamine,hydrocortisone|"Vitamin C (2g) will be diluted in 100ml 0.9%NACL and administered ivd every 6 hours for 5 days or until participant is discharged from the ICU.~Thiamine(200mg) will be diluted in 100ml 0.9%NACL and administered ivd every 12 hours for 5 days or until participant is discharged from the ICU. Hydrocortisone was administered 200 mg/d as a continuous infusion for 5 days or until participant is discharged from the ICU."
223688266|NCT03872011|DRUG|Placebo|Normal saline (0.9% NaCl solution) volume to match all components
223688267|NCT05064839|PROCEDURE|Bony scintigraphy|Bony scintigraphy (99mTc-Hydromethylene diphosphonate) will be performed in all patients with hypertrophy of the left ventricle
223688268|NCT01115803|DRUG|LY2584702|Supplied as 25 milligrams (mg) and 100 mg capsules, administered orally for two 28-day cycles.
223688269|NCT01115803|DRUG|Erlotinib|"Supplied as 25 mg, 100 mg, or 150 mg tablets, administered orally, daily for two 28-day cycles.~Starting dose is 150mg. Doses may be decreased in 50mg increments if necessary due to toxicity."
223776088|NCT03877393|COMBINATION_PRODUCT|Probiotic supplementation + gluten-containing diet|The probiotic and gluten-containing diet group (PRO-GD) will receive one capsule containing the probiotic mixture powder (Sanprobi Stress; Sanprobi sp. z o.o., sp.k., Szczecin, Poland) in the amount of 3 × 10\^9 colony forming units (CFU) per day divided in two equal doses comprising two bacteria strains: Lactobacillus helveticusRosell®-52, Bifidobacterium longumRosell®-175 and excipients: potato starch, magnesium stearate, and the capsule shell of hydroxypropyl methylcellulose. The participants will be asked to consume supplements before breakfast. The group will stay with their current diet.
223776089|NCT03877393|COMBINATION_PRODUCT|Placebo supplementation + gluten-containing diet|The placebo and gluten-containing diet group (PLA-GD) will receive one capsule containing only the excipients, i.e. maize starch, maltodextrins, and the capsule shell. The participants will be asked to consume supplements before breakfast. The group will stay with their current diet.
223776090|NCT02268981|DEVICE|Oxymizer® compared to CNC|Oxygen Saturation measurement for 12 h with CNC
223776091|NCT02268981|DEVICE|Oxymizer® compared to CNC|Oxygen Saturation measurement for 12 h with Oxymizer®
223776092|NCT02268981|DEVICE|Oxymizer® compared to CNC|Saturation measurement for 12 h with Oxymizer® by reduced flow rate (-1l/min)
223688270|NCT01115803|DRUG|Everolimus|Supplied as 5 mg or 10 mg tablets, administered orally, daily for two 28-day cycles.
223688271|NCT02885168|DRUG|Recombinant Activated Protein C|24 μg/kg/h during 96 hours - intravenous injection
223688272|NCT02885168|DEVICE|Near-infrared spectroscopy (NIRS)|After baseline measurement, cuff is blown up to obtain a muscular saturation at 40% and then deflated. Reactive hyperthermia is measured. It is considered as an index for endothelial function.
223688273|NCT02885168|DRUG|Phenylephrine|"Continuous administration of phenylephrine with electric syringe with increasing dosing levels: 0.0; 0.02; 0.05; 0.1; 0.2; 0.5; 0.75; 1.00; 1.50; 3.00; 4.50; 6.00; 9.00 et 12 µg/kg/min. Each level is maintained for 5 minutes. Administration of phenylephrine is stopped progressively with the same schema.~Arterial tension through an invasive approach is measured during the test."
223688274|NCT02885168|BIOLOGICAL|Blood sample|Analysis of inflammation and cellular adhesion markers and free radicals
223688275|NCT01407042|PROCEDURE|mobile-bearing unicondylar knee arthroplasty|mobile-bearing unicondylar knee arthroplasty
223688276|NCT03764488|DRUG|Tofersen|Administered as specified in the treatment arm.
223688277|NCT03764488|DRUG|99mTc-MAG3-BIIB067|Administered as specified in the treatment arm.
223688278|NCT04489238|OTHER|Risk Factor Questionnaire|Participants, both cases and controls, will complete the CYOC risk factor questionnaire, preferably at the time of first visit
223688279|NCT03877081|BIOLOGICAL|Probiotics|Administration of oral probiotics with 2 doses a day
223688280|NCT03877081|OTHER|Placebo|Administration of oral placebo with 2 doses a day
223688281|NCT02565927|DEVICE|Traditional airway stent|process airway stenting
223688282|NCT02565927|DRUG|Iodine-125 seeds|process intraluminal brachytherapy
223688283|NCT00000188|DRUG|Selegiline|
223776093|NCT01900470|BEHAVIORAL|CHW Goal Support|IMPaCT CHWs will perform the following functions, depending on the needs of the participants: 1) Deconstructing Distal Goals into Proximal Goals: IMPaCT CHWs will help patients to deconstruct collaborative distal clinical goals into patient driven proximal goals and develop strategies for achieving each proximal goal.2) Creating Roadmaps: Roadmaps are individualized strategies for achieving each proximal goal identified by patients. 3) IMPaCT Partners conduct weekly follow-up with patients through either telephone or home visit in order to support the achievement of proximal goals. As part of these followup encounters, CHWs ask patients to measure their chronic disease control during their weekly followup calls/visits. 4) Group: CHWs and their Project Manager run a group session for patients in the IMPaCT arm. This group meets weekly and is a forum for patients to discuss common issues around chronic disease management and form a social support network.
223776094|NCT03811730|DIAGNOSTIC_TEST|Transesophageal echocardiography|Eligible patients would be conducted both Transesophageal echocardiography and Transthoracic echocardiography to offer independent results
223688284|NCT03475875|DEVICE|senofilcon A TEST Lens|senofilcon A with new UV blocker investigational process
223688285|NCT03475875|DEVICE|senofilcon A CONTROL Lens|senofilcon A with new UV blocker standard process
223688286|NCT06154681|OTHER|World Digital Detox Family Program|The Self-Help World Digital Detox Family Program spans four weeks and offers a structured approach to tackle the rising issues associated with the overuse of screens, social media, and digital devices within families. This intervention provides practical tools and strategies to be implemented on a weekly basis.
223688287|NCT01642407|DRUG|Sildenafil|Body weight \> 20 kg: 20 mg TID (60 mg/day) Body weight ≤ 20 kg: 10 mg TID (30 mg/day) Treatment duration: 16 weeks in Part 1, until until sildenafil obtained marketing approval in Part 2
223688288|NCT05019976|RADIATION|Radiation - Dose Level 0|"Dose Per Fraction (Each Radiation Treatment): 3.2Gy to 2.4Gy (minimal dose) depending on what study doctor prescribes~Total Dose of Radiation for Treatment Period: 44.8Gy to 33.6Gy (minimal dose) depending on what study doctor prescribes~Total Number of Radiation Treatments: 14"
223688289|NCT05019976|RADIATION|Radiation - Dose Level 1|"Dose Per Fraction (Each Radiation Treatment): 4.2Gy to 3.2Gy (minimal dose) depending on what study doctor prescribes~Total Dose of Radiation for Treatment Period: 42Gy to 32Gy (minimal dose) depending on what study doctor prescribes~Total Number of Radiation Treatments: 10"
223688290|NCT05019976|RADIATION|Radiation - Dose Level 2|"Dose Per Fraction (Each Radiation Treatment): 5.2Gy to 4.2Gy (minimal dose) depending on what study doctor prescribes~Total Dose of Radiation for Treatment Period: 39.2Gy to 29.4Gy (minimal dose) depending on what study doctor prescribes~Total Number of Radiation Treatments: 7"
223688291|NCT05019976|RADIATION|Radiation - Dose Level 3|"Dose Per Fraction (Each Radiation Treatment): 6.8Gy to 5.4Gy (minimal dose) depending on what study doctor prescribes~Total Dose of Radiation for Treatment Period: 34Gy to 27Gy (minimal dose) depending on what study doctor prescribes~Total Number of Radiation Treatments: 5"
223688292|NCT05019976|RADIATION|Radiation - Dose Level 4|"Dose Per Fraction (Each Radiation Treatment): 10Gy to 7.8Gy (minimal dose) depending on what study doctor prescribes~Total Dose of Radiation for Treatment Period: 30Gy to 23.4Gy (minimal dose) depending on what study doctor prescribes~Total Number of Radiation Treatments: 3"
223688293|NCT00721903|PROCEDURE|Ultrasound Scan|10 female volunteers with normal breast who will be studied to refine imaging techniques and for comparison with patients. To the degree possible, the volunteer group will be age-matched to patients with symptoms, initially 30 to 70 years of age.
223688294|NCT00721903|PROCEDURE|Mammography and Ultrasound|To determine how well from ultrasound scans, changes in malignant masses can be measured, and to whether the use of a dye visible by ultrasound will be useful in evaluating different therapies for breast cancer.
223688295|NCT04025710|DEVICE|BIOMONITOR III and BIOMONITOR IIIm|"* Insertion of BIOMONITOR III or BIOMONITOR IIIm~* three scheduled in-office follow-ups~* 48-hour Holter ECG"
223688296|NCT02523612|PROCEDURE|Biopsy|
223688297|NCT02523612|PROCEDURE|Blood sample|
223688298|NCT02431247|DRUG|Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide FDC|A tablet containing DRV 800 mg, COBI 150 mg, FTC 200 mg and TAF) 10 mg will be administered once daily.
223688299|NCT02431247|DRUG|DRV/COBI FDC|A tablet containing DRV 800 mg and COBI 150 mg will be administered once daily.
223688300|NCT02431247|DRUG|FTC/TDF FDC|A tablet containing FTC 200 mg and TDF 300 mg will be administered once daily.
223688301|NCT02431247|DRUG|D/C/F/TAF FDC - Matching Placebo|Matching placebo of D/C/F/TAF FDC will be administered once daily.
223688302|NCT02431247|DRUG|FTC/TDF FDC Matching Placebo|Matching placebo of FTC/TDF FDC will be administered once daily.
223688303|NCT02431247|DRUG|DRV/COBI FDC Matching Placebo|Matching placebo of DRV/COBI FDC will be administered once daily.
223688304|NCT03695874|OTHER|Phase 1 : fill out 1 scale|"Patients will be asked to complete questionnaires.~Group 1: the purpose is to simplify a 75 items scale by a statistical analysis of the data collected from 400 patients. The statistical purification will allow to finalize an abbreviated scale (20-25 items).~Doctors specialized in Hereditary Haemorrhagic Telangiectasia may suggest that patients enter the study. After submission of the information notice and collection of their non-opposition, patients will have the choice to fill out the paper version or the electronic version of the scale and questionnaires."
223688305|NCT03695874|OTHER|Phase 2 : fill out 1 scale and 4 questionnaires|"Patients will be asked to complete questionnaires.~Group 2: the purpose is to validate the abbreviated scale by a statistical analysis of the data collected from 200 patients. The statistical validation will allow to check the consistency and correlation of the abbreviated scale with other scales: a general Quality Of Life scale (SF36), an anxiety and depression scale (HAD), a social support scale (SSQ6) and a scale of regulation emotional (CERQ) and to test and re-test to check fidelity of the abbreviated scale.~Doctors specialized in Hereditary Haemorrhagic Telangiectasia may suggest that patients enter the study. After submission of the information notice and collection of their non-opposition, patients will have the choice to fill out the paper version or the electronic version of the scale and questionnaires."
223688306|NCT01396330|BEHAVIORAL|stress|3 professional safe drive training courses each lasting 30 minutes
223688307|NCT00005093|DRUG|gemcitabine hydrochloride|
223688308|NCT00005093|DRUG|tacedinaline|
223688309|NCT02091674|DEVICE|Hyaluronic acid|Injected gel
223688310|NCT04448054|OTHER|MRI|"Case 1: Routine care protocol not requiring injection~* Realization of the non-injected MRI protocol adapted to the indication~* \+ Addition of a 3D bFFE-Xd sequence (+ 2 min) The protocol will last the examination time usually provided by the current treatment according to the indication + 2 min of complementary sequence Case 2: Routine treatment protocol requiring an injection~* Realization of the injected MRI protocol adapted to the indication~* Before gadolinium injection:~* Addition of a 3D bFFE-Xd sequence (+ 2 min) before injection~* After gadolinium injection:~* Option 1: if olfaction disorder, addition of DCE perfusion sequence (T1-WI) which will be the 1st post injection sequence (+ 4 min 30)~* FABIR 0.9 3D sequence (+ 4 min)~* 3D sequence T1 TSE 0.7 (+ 2 min 30)~* FLAIR HR coronal sequence (+ 3 min 30)~* Option 2: if hearing / balance disorder, adding 3D FLAIR labyrinth sequence (+ 6min) which will be the 1st post injection sequence"
223688311|NCT00769665|OTHER|Systane Ultra|Re-wetting ocular eye drop
223688312|NCT00769665|OTHER|Sensitive Eyes Rewetting Drops|Re-wetting ocular eye drop
223688313|NCT06276985|DEVICE|low intensity pulsed ultrasound and iPRF|iPRF and LIPUS has been found to speed up OTM by stimulating the RANK/RANKL/OPG system to initiate osteoclast formation.
223688314|NCT03029130|DEVICE|Catheter extension|Foley transurethral catheter placed to allow continuous drainage of urine.
223688315|NCT01690338|DRUG|Vecuronium Bromide|Administrative protocol of Vecuronium Bromide is determined by each caregiver's clinical experience.
223688316|NCT01690338|DRUG|Rocuronium|Administrative protocol of rocuronium is determined by each caregiver's clinical experience.
223688317|NCT01690338|DRUG|Cisatracurium|Administrative protocol of cisatracurium is determined by each caregiver's clinical experience
223688318|NCT02855515|PROCEDURE|Short-time diagnostic anaesthesia|Patients will undergo a short-time general anaesthesia in order to diagnose Obstructive Sleep Apnoea when relaxed.
223688319|NCT01562873|DRUG|Ruxolitinib|
223688320|NCT00097851|DRUG|docetaxel|
223688321|NCT00097851|DRUG|PI-88|
223688322|NCT02918981|BEHAVIORAL|Resistance Exercise|Participants will perform unilateral leg extension exercise immediately prior to ingestion of the experimental beverage
223688323|NCT02918981|DIETARY_SUPPLEMENT|14 g Whey protein|
223776095|NCT00236938|DRUG|Venofer and stable erythropoietin (EPO) regimen|Fixed dose of erythropoietin (EPO) and Venofer (300mg) administered intravenous infusion over 1.5 hours on Days 1 and 15, and Venofer (400mg) administered intravenous infusion over 2.5 hours on Day 29.
223688324|NCT02918981|DIETARY_SUPPLEMENT|6.6 g Whey protein + 1.25 g leucine|
223688325|NCT02918981|DIETARY_SUPPLEMENT|4 g Whey protein + 1.25 g leucine + 2.6 g Whey peptides|
223688326|NCT02918981|DIETARY_SUPPLEMENT|6.6 g Whey protein + 1.25 g leucine + 0.8 g Citrulline|
223688327|NCT02918981|OTHER|Water control|
223688328|NCT01657929|BIOLOGICAL|H5-VLP + GLA-AF|H5-VLP antigen and GLA-AF adjuvant. 2 injections at Days 0, and 21.
223688329|NCT01657929|BIOLOGICAL|H5-VLP alone|H5-VLP antigen alone. 2 injections at Days 0, and 21.
223688330|NCT01657929|BIOLOGICAL|H5-VLP + Alhydrogel(R)|H5-VLP antigen and Alhydrogel(R) adjuvant. 2 injections at Days 0, and 21.
223688331|NCT01657929|BIOLOGICAL|Licensed H5N1 vaccine|Licensed H5N1 vaccine. 2 injections given on Days 0 and 21.
223688332|NCT03696927|DEVICE|Active Powered Prosthesis (APEX) for Spinal Cord Injury|The Active Powered Prosthesis (APEX) is a proof-of-concept shoulder-elbow-wrist device intended to provide non-invasive active powered robotic assistive movement to upper extremities. Focus group participants will control the APEX device on a test manikin and provide feedback on the device design and function.
223688333|NCT02942576|DRUG|Edoxaban|Edoxaban 60 mg once-daily or 30 mg once-daily in selected subjects.
223688334|NCT02942576|DRUG|VKA-Based Regimen|Dosed at International Normalised Ratio (INR) levels, which is a test of how long it takes for blood to clot. Standard of Care treatment in Canada, Italy, Poland, Hungary, Czech Republic, United Kingdom (UK), Taiwan and Korea.
223776096|NCT00236938|DRUG|stable erythropoietin (EPO) regimen|Stable erythropoietin (EPO) dose and no supplemental iron.
223776097|NCT06236035|DEVICE|Analgesia nociception index|a device to assess patient's pain during surgery
223776098|NCT00059904|BIOLOGICAL|aldesleukin|
223776099|NCT00059904|BIOLOGICAL|rituximab|
223688335|NCT02942576|DRUG|VKA-Based Regimen|Dosed at INR levels. Standard of Care treatment in Germany, Belgium, and the Netherlands.
223688336|NCT02942576|DRUG|VKA-Based Regimen|Dosed at INR levels. Standard of Care treatment in France.
223688337|NCT02942576|DRUG|VKA-Based Regimen|Dosed at INR levels. Standard of Care treatment in Spain.
223688338|NCT01631955|DRUG|Ciprobay|Ciprobay (250mg, bid, oral)
223688339|NCT04188171|PROCEDURE|Polidocanol foam sclerotherapy|"* Preparation of the foam is done according to the Tessari technique (2 disposable 20ml syringe, a three-way tap, reusable extender adapted to intravenous needle).~* Sclerosant applied according to the Blanchard technique through a disposable transparent anoscope (patient in knee-chest position).~* In each session, treatment can be performed on more than one hemorrhoidal cushion. The maximum dose per treatment session is 20ml (mixture of 4ml of polidocanol 3% with 16ml of air).~* During the intervention period the participants are observed at 3-week intervals. The required number of sessions (maximum of 3) is determined by clinical and anoscopic evaluation.~* After the intervention period, a one-year follow-up is scheduled with medical appointments performed every 3 months."
223688340|NCT00938964|DRUG|Lidocaine|Lidocaine versus placebo infusion for 48 hours
223688341|NCT00938964|DRUG|Placebo|Lidocaine versus placebo infusion for 48 hours
223688342|NCT00746447|DRUG|mesalamine granules|3.0g mesalamine in the morning, 0.5g placebo at lunch, 0.5g placebo in the evening;
223688343|NCT00746447|DRUG|mesalamine granules|1.5g mesalamine and 1.5g placebo in the morning, 0.5g placebo at lunch, 0.5g placebo in the evening;
223688344|NCT00746447|DRUG|mesalamine granules|0.5g mesalamine and 2.5g placebo in the morning, 0.5g mesalamine at lunch, 0.5g mesalamine in the evening
223688345|NCT01765803|DRUG|Mellaril|Subjects will undergo a physical exam including an electrocardiogram (EKG) and have blood drawn before treatment. A single 50 gm dose of thioridazine (Mellaril) will be given to eligible subjects. A second blood draw will occur at 24 hours post-treatment.
223688346|NCT05656989|OTHER|Periodontal clinical measurements and GCF sampling|Periodontal clinical parameters measurements probing depth (PD), clinical attachment loss (CAL), the dichotomous recording (present/absent) of bleeding on probing (BOP), gingival index (GI) and plaque index (PI) were recorded at six sites (mesio-buccal, mid-buccal, disto-buccal, mesio-lingual, mid-lingual, and disto-lingual) per tooth, except the third molars using a manual periodontal probe. A sterile paper strip was gently placed into the gingival sulcus/periodontal pocket until mild resistance was sensed and left in place for 30 seconds.
223688347|NCT02646202|PROCEDURE|Sclerotherapy|Injection of varices
223688348|NCT02646202|PROCEDURE|Band ligation|endoscopic banding of varices
223688349|NCT02646202|PROCEDURE|Scleroligation|intra variceal endoscopic sclerotherapy combined with band ligation.
223688350|NCT02986880|DRUG|Botulinum toxin A|
223688351|NCT02986880|PROCEDURE|Placebo|Injection of sodium chloride (NaCl) 9/1000
223688352|NCT01043900|PROCEDURE|repetitive transcranial magnetic stimulation (rTMS)|30 daily sessions: each with 40 trains of 5 seconds at 10Hz, with a 25 second inter-train interval, at an intensity of 110% of motor threshold. Site: Right Dorsolateral Prefrontal Cortex
223688353|NCT04109898|DEVICE|Supraglottic airway device (I-gel) insertion|Modified I-gel insertion technique believed to be easier and non traumatic in anaesthetised patients.
223688354|NCT04230720|DRUG|Systane Complete|1 drop 4 times a day for 14 days
223688355|NCT03523000|OTHER|Continuous intrathecal prognostic infusion test|The patient is infused with solution through the percutaneous intrathecal catheter at a rate of 0.5-1.0 ml/hr for approximately 14-18 hours
223688356|NCT03523000|DRUG|Bupivacaine|Bupivacaine 0.625 mg/ml and fentanyl 1 mcg/ml continuous infusion at a rate of 0.5-1.0 ml/hr for approximately 14-18 hours
223688357|NCT03523000|DRUG|Fentanyl|Bupivacaine 0.625 mg/ml and fentanyl 1 mcg/ml continuous infusion at a rate of 0.5-1.0 ml/hr for approximately 14-18 hours
223688358|NCT03523000|DRUG|Placebo|Intrathecal infusion of normal saline at a rate of 0.5-1.0 ml/hr for approximately 14-18 hours
223688359|NCT03523000|DEVICE|Intrathecal Drug Delivery System (IDDS)|40-mL IDDS containing a solution of fentanyl 50 mcg/mL with bupivacaine 30 mg/mL
223688360|NCT03141645|OTHER|Fluid loading|Patients in the preoperative intravenous fluid loading group (group F) will receive ringer lactate solution 10ml/kg in 15 minutes before starting operation.
223688361|NCT03141645|DRUG|Ondansetron|Patients in the ondansetron group (group O) will receive an 8 mg of intravenous ondansetron in 15 minutes before finishing operation
223688362|NCT04143529|BEHAVIORAL|Personalized acceptance-based mindfulness exercise|The mindfulness intervention will be a video-flash found at http://www.pixelthoughts.co. In this exercise patients are asked to write down a concern or worry, and watch it get put into perspective within a 60 seconds time frame.
223688363|NCT04143529|BEHAVIORAL|Brief educational pamphlet|The control condition will be educational information on pain and stress that patients will read over within 60 seconds
223688364|NCT06415851|DRUG|mFOLFOX6 regimen + bevacizumab + PD-1 monoclonal antibody|This study is a single-arm intervention study. All subjects in this study will be treated with this study protocol, that is, after mFOLFOX6 protocol and bevacizumab induction therapy, combined with slulimumab treatment.
223776100|NCT01218997|DRUG|Medisorb naltrexone 380 mg|Administered via intramuscular (IM) injection once every 4 weeks for up to 1 year.
223776101|NCT01218997|DRUG|Oral naltrexone 50 mg|Tablet taken orally once daily for up to 1 year
223776102|NCT04232163|BEHAVIORAL|Arm Boot Camp|The intervention involves a combination of daily homework based upper limb exercises and feedback from an activity monitor to motivate use of the affected upper limb. Participants will be supported through virtual sessions with a therapist.
223688365|NCT04631302|BEHAVIORAL|Be Mindful|"Be mindful is an online course run by the Mental Health Foundation and Wellmind Media. It was developed together with British mindfulness instructors and offers access to its course materials and instructional videos through a website (http://www.bemindfulonline.com).~The course consists of 11 sessions led by two mindfulness teachers, one female, one male. Using a variety of media (videos, assignments, audio tracks and e-mails), participants are taught to use formal as well as informal mindfulness techniques. The course lasts 4 weeks. For each week, participants are asked to do a daily formal mediation practice (up to 30 minutes but it varies from week to week) and one or two informal exercises."
223688366|NCT04631302|BEHAVIORAL|Light exercise course|"The control condition involves light physical exercises aimed at increasing mobility, reducing stiffness, improving circulation, and avoiding pain or repetitive strain injuries that may result from sedentary or repetitive tasks common in office environments. The exercises will include simple whole-body slightly aerobic exercises such as rotation of limbs and stretching. The course was developed by Dr Julieta Galante, a public health doctor, together with an expert in body posture re-education and body techniques.~The course is designed to match with the mindfulness intervention condition in duration and media (length of videos, amount of written instructions). It also replicates the encouraged use of short breaks (of seconds or minutes) throughout the workday to focus on wellbeing, as occurs in mindfulness."
223688367|NCT05193357|DEVICE|home-based intermittent pneumatic compression (IPC) device|During the intervention, two programmed modes were used. The first mode, which mimics the MLD massage technique, begins with the inflation of the proximal chamber. After reaching the target pressure, the next chamber consecutively inflates while the initially inflated proximal chamber deflates. The inflation time of each chamber is 3 seconds with holding time of 1 second. The deflation and resting time of each chamber is 7 seconds (pressure setting: 40-60 mmHg). After 30 minutes of the first mode, the second mode, which is the conventional mode of sequential inflation from distal to proximal chambers while sustaining the pressure of the previously inflated chambers, was applied for 30 minutes (pressure setting: 80-100 mmHg, inflation time of each chamber: 6 seconds, holding time: 1 second, deflation time of each chamber: 7 seconds). Participants were instructed to use the IPC device with that 1-hour cycle twice a day for four weeks.
223688368|NCT05120843|BEHAVIORAL|Care coordination and motivational interviewing|Interventionist will engage participants in care planning, health education, health care navigation, screening for unmet health needs or social needs, and motivational interviewing. The final intervention is expected to be six months in duration. However during this single-arm open testing phase, some participants may receive only key components of the intervention in order to assess feasibility, reach, adoption, and fidelity of those components.
223688369|NCT03358537|DIETARY_SUPPLEMENT|Clear Liquid Diet|Clear liquid diet was compared with low-residue diet, in combination with Poliethylene Glycol in each group
223688370|NCT03358537|DIETARY_SUPPLEMENT|Low-residue Diet|Clear liquid diet was compared with low-residue diet, in combination with Poliethylene Glycol in each group
223688371|NCT02869984|DRUG|Ramosetron|
223688372|NCT01177332|OTHER|exercise|2 hours cycling exercise at 50 % of maximal power output
223688373|NCT00194675|DRUG|Dutasteride|Dutasteride 0.5 mg orally daily
223688374|NCT00194675|DRUG|Testosterone gel|Testosterone gel 7.5 g daily topical
223688375|NCT00194675|DRUG|Placebo dutasteride|placebo dutasteride orally daily
223688376|NCT00704808|PROCEDURE|Primary surgical treatment|Primary surgery for tumor resection.
223688377|NCT00704808|RADIATION|Radiotherapy|Radiotherapy is given with concomitant temozolomide. Dosing according to European Summary of Product Characteristics.
223688378|NCT00704808|DRUG|Temozolomide|Temozolomide is first given with concomitant radiotherapy, and then as monotherapy (adjuvant chemotherapy). Dosing according to European Summary of Product Characteristics.
223688379|NCT05590221|BIOLOGICAL|Relmacabtagene Autoleucel|A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells
223688380|NCT05590221|DRUG|Fludarabine|Administered according to package insert
223688381|NCT05590221|DRUG|Cyclophosphamide|Administered according to package insert
223688382|NCT01285960|DEVICE|ExAblate Treatment UF V2|Treatment with the ExAblate UF V2 system. Patients may have up to two ExAblate treatments within a two-week period.
223688383|NCT03714737|BIOLOGICAL|experimental vaccine|bivalent meningococcal serogroups A and C tetanus toxoid conjugate vaccine(OLYMVAX Biological Co., LTD)
223688384|NCT03714737|BIOLOGICAL|Positive control vaccine 1|bivalent meningococcal serogroups A and C tetanus toxoid conjugate vaccine(WALVAX Biological Co., LTD)
223688385|NCT03714737|BIOLOGICAL|Positive control vaccine 2|bivalent meningococcal serogroups A and C tetanus toxoid conjugate vaccine(Royal (Wuxi) Biological Co., LTD)
223688386|NCT00433264|PROCEDURE|peritoneal dialysis|individualised
223688387|NCT02515032|DIETARY_SUPPLEMENT|Nutrifriend Cachexia|2 daily for 12 weeks
223688388|NCT02515032|DIETARY_SUPPLEMENT|Isocaloric placebo|2 daily for 12 weeks
223688389|NCT02172053|OTHER|Compensatory Workplace Exercise (CWE) - Comparative Group|The comparative group will receive warming up and stretching and light resisted exercise with elastic bands. The exercise will realize three times per week, 20 minutes for day in total 60 minutes per week. With warming up for 5 minutes and 15 minutes of the specific training . The exercise will realize in 3 series with 10 repetitions and rest 30 seconds between series.
223688390|NCT02172053|OTHER|Individual Resistance Exercise (IRE) - Intervention Group|Intervention group will receive warming up and stretching, and a specific resistance training with increase progress load. The exercise will realize three times per week, 20 minutes for day in total 60 minutes per week. With warming up and stretching for 5 minutes and 15 minutes of the specific training. The exercise will realize in 3 series with 10 repetitions and rest 30 seconds between series.
223688391|NCT02516735|DEVICE|I-scan with magnification|
223688392|NCT02516735|DEVICE|Standard endoscopy|
223688393|NCT00586196|DRUG|donepezil|5 mg each day for 30 days
223688394|NCT00586196|DRUG|Placebo|Encapsulated cornstarch One capsule daily for 30 days
223688395|NCT04664244|COMBINATION_PRODUCT|Combination of nimotuzumab and radiotherapy|Patients will undergo targeted radiotherapy no more than 8 weeks, and concurrent nimotuzumab 200 mg intravenous injection every one week till the ending of radiotherapy. Then patients undergo a maintaining therapy with nimotuzumab 200 mg intravenous injection every two weeks up to one year or till the disease progresses.
223688396|NCT04910373|OTHER|Experimental Extensively Hydrolyzed Formula|experimental powder formula
223688397|NCT04910373|OTHER|Placebo Extensively Hydrolyzed Formula|placebo powder formula
223688398|NCT05969418|DIAGNOSTIC_TEST|Diagnostic test: using artificial intelligence to evaluate the changes OCT and OCTA parameter|Diagnostic test: using artificial intelligence to evaluate the changes OCT and OCTA parameter before and after ANTI-VEGF treatment
223688399|NCT06409403|DEVICE|clinical application of robotic technique|effect of various surgical technique on clinical efficacy of TME
223688400|NCT04368273|DRUG|PD-1 antibody|a new treatment drug combined radical radiotherapy concurrent chemotharpy
223688401|NCT05344638|DRUG|AGS (Experimental)|tid
223688402|NCT05344638|DRUG|AGU (Active Comparator)|tid
223688403|NCT03690323|PROCEDURE|Radiofrequency ablation (RFA)|RFA involves the implantation of electrodes directly into the tumor, with the use of intra-operative ultrasound. The electrodes produce a high frequency alternating current, which leads to frictional heating and thus tissue destruction by thermal coagulation and protein denaturation.
223688404|NCT03690323|DRUG|FOLFIRINOX|Oxaliplatin 85mg/m2 given as 2-hour IV infusion, followed by leucovorin 400mg/m2 given as 2-hour IV infusion with addition of irinotecan 180mg/m2 given as 90-minute IV infusion. Followed by fluorouracil 400mg/m2 IV bolus, followed by continuous IV infusion of 2400mg/m2 during 46-hour. Every 2 weeks.
223688405|NCT03690323|DRUG|Nab-paclitaxel plus Gemcitabine|Nab-paclitaxel 125mg/m2 given as 30-40-minute IV infusion, followed by gemcitabine 1000mg/m2 IV infusion. On day 1, 8 and 15 every 4 weeks.
223688406|NCT03690323|DRUG|Gemcitabine|Gemcitabine 1000mg/m2 given as 30-minute IV infusion. On day 1, 8 and 15 every 4 weeks.
223688407|NCT03804034|DEVICE|Block of resin|
223688408|NCT03804034|DEVICE|Buccal tube, Bracket and 0.0017 × 0.025 in titanium molybdenum alloy wire|
223688409|NCT03832075|DIAGNOSTIC_TEST|Berg Balance Scale|Berg Balance Scale is 14 item scale for detecting balance disorder.
223688410|NCT03832075|DIAGNOSTIC_TEST|Timed Up and Go Test|Timed Up and Go Test assesses mobility, balance, walking ability, and fall risk in older adults.
223688411|NCT03832075|DIAGNOSTIC_TEST|Korebalance Balance System|"Korebalance Balance System evaluates the balance and stability using objective neuro-sensory balance assessment. Static Test requires standing steady \& balancing on the platform, keeping the crosshairs of cursor in the center of the test pattern. The Score indicates the deviation of user's center of gravity from the center of the pattern. Dynamic Test offers a moving cursor that the user follows. Four patterns are offered: Circle, Square, Infinity and Random. Each pattern is available in three dimensions: Small, Medium and Large; five speeds; Clockwise and Counterclockwise directions."
223688412|NCT06265779|BEHAVIORAL|Comprehensive rehabilitation therapy|"Including： Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training.~Pulmonary function training, including standing training, cough training, and diaphragm muscle training."
223688413|NCT06265779|DEVICE|Intermittent Oro-esophageal Tube Feeding|All patients are given enteral nutritional support with Intermittent Oro-esophageal Tube according to the following procedure: Before each feeding, inside and outside of the tube was cleaned with water. During feeding, the patient should maintain a semi-reclining or sitting position with mouth opened, and the tube was inserted slowly and smoothly into the upper part of the esophagus by medical staffs while the appropriate depth of intubation was checked with the calibration markings on the tube wall. The distance from the incisors to the head part of the tube should be between 22-25 cm. However, the specific depth should be evaluated based on patients' feedback and adjusted accordingly. After insertion, the tail part of the tube should be put into a container full of water and the absence of continuous bubbles indicated a successful intubation. Then, the feeding was to be conducted three times per day with 50 ml per minute and 400-600ml for each feeding.
223688414|NCT06265779|DEVICE|Transcranial direct current stimulation|In this study, transcranial direct current stimulation is performed using a battery-powered constant current stimulator. This device delivers the current through two electrodes immersed in saline solution. Specifically, a 50mm\*50mm anodal electrode pad is placed at the center of the healthy side swallowing sensory-motor cortex of the patient. According to the positioning method of the international 10-20 electrode system, the swallowing sensory-motor cortex of the left brain is located at the midpoint between C3 and T3, while that of the right brain is located at the midpoint between C4 and T4. The cathode is placed on the opposite shoulder, using a current of 1mA, once a day, for 20 minutes each time, and 5 days a week. The instruments used for placebo patients will not have any actual effect.
223776103|NCT05322317|OTHER|ADVANCE-PC training via ECHO|To assess the feasibility of using a technology-based platform to deliver the ADVANCE-PC program to multiple primary care clinics. This model will be based on the ECHO program, a tele-mentoring program which uses communications technology to provide facilitated education, case review, and peer-to-peer problem solving remotely. Our working hypothesis is that the use of ECHO will be efficient (allowing several clinicians and teams to be supported simultaneously while creating a community of practice), feasible (that clinicians will enroll and share experiences via mentoring, guidance, feedback, and didactic education), and have the potential to impact patients as clinicians perceptions shift to favor ACP, their skills increase, and they are able to integrate ACP for patients with dementia into their clinic.
223776104|NCT04589585|DEVICE|DiVeRt|DiVeRt - Vascular Reconstruction Device and Delivery System
223776105|NCT01815671|PROCEDURE|colonoscopy in the lateral horizontal position|colonoscopy in the lateral horizontal position with tilt down
223776106|NCT03819231|DRUG|Oxytocin|A single 40 IU dose of Pitocin (oxytocin, USP; concentration = 10 IU/1 mL; PAR Pharmaceuticals, NY, USA) will be self-administered to each participant. Each 40 IU dose will be transferred into four, 1 ml intranasal atomizers and will be administered in four sprays to each nostril over the course of 15 minutes.
223688415|NCT03810404|DIETARY_SUPPLEMENT|Sodium bicarbonate supplementation|"Interventions:~The experimental procedure for each athlete included an acute SB supplementation in a different-dose regimen in order to assess whether the dose affects the actual physical and exercise capacity (doses: 0.15-, 0.25-, 0.35- and 0.50 g/kgFFM (0.12-, 0.20-, 0.28- and 0.40 g/kgBM), respectively). SB (Alkala, SANUM, Poland) will be administered as dissolved form in a 750 ml of fluid (water + fruit juice). On testing days the SB will be taken before physical and exercise capacity tests session.~Between the SB and PLA or a PLA and SB treatments, a minimum 7-day washout period will be introduced."
223688416|NCT03810404|DIETARY_SUPPLEMENT|Placebo treatment|"Interventions:~The experimental procedure for each athlete will be included an PLA supplementation. Placebo will be administered in a form of 750 ml of fluid (water + fruit juice). On testing days the PLA will be taken before physical and exercise capacity tests session.~Between the PLA and SB or a SB and PLA treatments, a minimum 7-day washout period will be introduced."
223688417|NCT05320302|DRUG|[11C]-Lu AF88370|PET ligand in a single intravenous bolus injection
223688418|NCT06278220|DEVICE|placido-based topographer (wavelight allegro topolyzer vario) and scheimpflug -based (Oculus Pentacam )|"An informed written consent will be obtained from all patients that will be included in this study. Patients in this study will undergo pentacam and topolyzer examination to asses corneal high order aberrations before LASIK procedure.~Patients will be assigned to undergo LASIK. Follow up pentacam and topolyzer examination will be done 3 months after LASIK."
223688419|NCT01476644|OTHER|Clinical evaluation|Biomicroscopy (look at front of eye), ophthalmoscopy (look at back of eye), visual acuity, visual fields, intraocular pressure, spectral domain optical coherence tomography, Pelli-Robson and the Spaeth-Richman Contrast Sensitivity tests
223688420|NCT01476644|OTHER|Performance based measures|Compressed Assessment of Ability Related to Vision (CAARV) items include: 1) computerized motion detection; 2) recognizing facial expressions; 3) reading street signs; and 4) finding objects in a room
223688421|NCT01476644|OTHER|Subjective measures of vision-related quality of life|National Eye Institute Visual Functioning Questionnaire 25 (NEI-VFQ-25) includes a series of questions pertaining to vision or feelings about a vision condition and the Modified Glaucoma Symptom Scale (MGSS) includes a series of questions pertaining to eye comfort.
223688422|NCT04186481|DEVICE|MINITAC Ti 2.0 suture anchor|The MINITAC◊ Ti 2.0 Suture Anchor is intended to provide secure reattachment of soft tissue to bone in the foot and ankle as well as elbow, wrist and hand.
223688423|NCT02922491|DIETARY_SUPPLEMENT|vitamin E|daily intake of vitamin E
223688424|NCT02922491|DIETARY_SUPPLEMENT|starch|daily intake of starch (control)
223688425|NCT04661969|PROCEDURE|Surgery|(group 1) In-bloc excision and primary closure (group 2), Resection plus Vacuum assisted closure (VAC) and split thickness skin graft (STSG) (group 3) and In-bloc excision and microsurgical reconstruction (group 4).
223688426|NCT04410770|BEHAVIORAL|Mood tracker ratings|The participant rates his/her emotional distress several times a week using a specially developed smart phone app. The participant receives support call to ensure that self-ratings are being completed.
223688427|NCT01477203|DRUG|Escitalopram|2-4 weeks, 5-10mg, max 20mg
223688428|NCT01486485|DRUG|heparinized saline priming group|
223776107|NCT03819231|BEHAVIORAL|Mindfulness|Participants will be instructed to listen to and practice a 20-minute guided mediation each day for 7 days prior to the experimental session. The guided mindfulness practices will include body scan and seated stillness meditations.
223776108|NCT03819231|DRUG|Saline Solution|A single 40mL doses of sterile saline (0.9% provided by USC pharmacy) will be transferred into four, 1 ml intranasal atomizers and will be self-administered in four sprays to each nostril over the course of 15 minutes.
223776109|NCT03819231|BEHAVIORAL|Sham mindfulness|The mindfulness sham group will be required to listen to 20-minutes of Tedtalk podcasts each day that match the attention and time of the mindfulness group. Participants will be instructed to listen to two 10-minutes segments per day in succession between lab visits while in a seated posture.
223776110|NCT00965848|DRUG|Doripenem|Doripenem 500 mg will be administered as 1 or 4 hours intravenous infusion, after every 8 hours up to maximum of 14 days.
223688429|NCT01486485|DRUG|nafamostat infusion after heparinized saline priming|
223688430|NCT00238511|DRUG|SPM 927|
223688431|NCT00468039|DRUG|vildagliptin + metformin|
223688432|NCT03862716|DRUG|IDegLira|Dose is titrated to achieve fasting normoglycemia
223688433|NCT03862716|DRUG|insulin degludec|In those who need additional insulin or who cannot tolerate IDegLira, insulin degludec will be used. Dose is titrated to achieve fasting normoglycemia.
223688434|NCT03862716|DRUG|Metformin|Dose is titrated to 2000 mg per day or maximal tolerated dose
223688435|NCT03862716|BEHAVIORAL|Lifestyle Therapy|Lifestyle intervention includes individualized dietary and exercise advice targeting at least 5% weight loss with frequent visits and coaching for goal reinforcement, behavior modification and problem-solving
223688436|NCT05550610|BEHAVIORAL|Mindfulness Based Attention Training (MBAT) and Yoga|Mindfulness-Based Attention Training (MBAT) was delivered in 4, 2-hour sessions over 4 weeks. Participants also completed 15 minutes of group mindfulness practice 6 days/week and received information on embedded practice during the duty day. Yoga was delivered 6 days/week, 30 minutes per day during warm-up (15 min) and cool-down (15 min) as part of Army physical readiness training.
223688437|NCT00095628|DRUG|ispinesib|Given IV
223688438|NCT00095628|OTHER|laboratory biomarker analysis|Correlative studies
223688439|NCT00095628|OTHER|pharmacological study|Correlative studies
223688440|NCT02851186|DEVICE|Acupuncture|
223688441|NCT02851186|DEVICE|Sham acupuncture|
223688442|NCT04980573|OTHER|Aromatherapy|The aromatherapy intervention consists of inhaling a fragrant oil extracted from citrus peels, plant resins, and leaves.
223688443|NCT04980573|OTHER|Placebo|The placebo intervention consists of inhaling an oil extracted from inert plant matter.
223688444|NCT05497635|DRUG|STSA-1002 Injection|Intravenous injection
223688445|NCT05497635|DRUG|Placebo|Intravenous injection
223688446|NCT01480128|PROCEDURE|Single-port|Single-port laparoscopic colon resection
223688447|NCT01480128|PROCEDURE|Multi-port|Multi-port laparoscopic colon resection
223688448|NCT02280473|DRUG|Refresh Optive® Gel Drops|Refresh Optive® Gel Drops; 1-2 drops in each eye as needed at least 2 times daily for 30 days.
223688449|NCT02280473|DRUG|REFRESH LIQUIGEL®|REFRESH LIQUIGEL®; 1-2 drops in each eye as needed at least 2 times daily for 30 days.
223688450|NCT05242523|OTHER|Bergamot scent|The scent of bergamot is fruity and citrusy, with floral hints and spice notes.
223688451|NCT05242523|OTHER|Natural wood scent|Wood notes tend to be rich and warm, often forming the base of a scent due to their aromatic weight.
223688452|NCT06275581|DEVICE|Ketac Universal Aplicap Glass Ionomer Restorative (3M) (test group)|Ketac Universal Aplicap Glass Ionomer Restorative (test group) was applied in one cavity of the patient, randomized allocated, in a stress bearing Class II restoration when the isthmus was less than half of the intercuspal distance and with at least one occlusal contact on enamel of the restored tooth. This material does not require a cavity conditioning step prior to restoration placement.
223688453|NCT06275581|DEVICE|Ketac Molar Quick Aplicap Glass Ionomer Restorative (control group)|Ketac Molar Quick Aplicap Glass Ionomer Restorative (control group) was applied in the other cavity of the patient,randomized allocated, in a stress bearing Class II restoration when the isthmus was less than half of the intercuspal distance and with at least one occlusal contact on enamel of the restored tooth.
223688454|NCT04235803|OTHER|Telemedicine follow-up|A telemedicine follow-up form based in REDCap that collects information from the patient including: history, photographs, vision measurement, and questions.
223688455|NCT00939757|DRUG|mirabegron|oral tablet
223688456|NCT05927324|BEHAVIORAL|CAVEAT|Brief psychotherapy with mothers of infants and young children, to which infants and young children attend many but not all sessions with mother
223688457|NCT01469104|OTHER|3 day fast|Subjects will fast for 72 hours
223688458|NCT01469104|OTHER|3 day CHO-free diet|Subjects will receive a carbohydrate-free diet for 72 hours
223688459|NCT05529940|DRUG|Folfirinox|The primary aim of this trial was to investigate whether six cycles of preoperative mFOLFIRINOX followed by six cycles of postoperative mFOLFIRINOX improved the overall survival rate by intention-to-treat compared to surgery followed by 12 cycles of postoperative mFOLFIRINOX.
223688460|NCT03461510|PROCEDURE|Hyperglycemic clamp|Subjects with T2D will receive IV Dextrose infusion to maintain plasma glucose at \~250 mg/dL during fMRI.
223688461|NCT03461510|PROCEDURE|Hyperinsulinemic Euglycemic clamp|Subjects with T2D will receive IV Dextrose and Insulin infusion to maintain plasma glucose at approximately 90 mg/dL during fMRI.
223688462|NCT05011903|BEHAVIORAL|Cross-tailored Dynamic Feedback|Dynamic, technology-delivered weekly feedback on weekend diary self-reports of first-year college student behavior related to alcohol use and related sexual behaviors.
223688463|NCT05011903|BEHAVIORAL|Personalized Feedback Intervention|Technology-delivered personalized feedback on first-year college student behavior related to alcohol use and related sexual behaviors.
223688464|NCT05011903|BEHAVIORAL|Dynamic Feedback on General Health Behaviors|Dynamic, technology-delivered weekly feedback on weekend diary self-reports of first-year college student behavior related to general health behaviors.
223776111|NCT03390907|DEVICE|Hybrid APC|Following standard EMR Hybrid Argon Plasma Coagulation (APC) of the base and edges of the polypectomy site to fulgurate any potential microscopic residual disease.
223776112|NCT04284696|DIETARY_SUPPLEMENT|Pregnan-C-Gum(R) chewing gum|"Using a chewing gum with 150mg vitamin C (per piece/gum) for 14 days ad libitum"
223776113|NCT04284696|DIETARY_SUPPLEMENT|Placebo chewing gum|"Using a chewing gum without vitamin C (per piece/gum) for 14 days ad libitum"
223776114|NCT00788866|DIETARY_SUPPLEMENT|Pomegranate Juice|8 oz of pomegranate juice daily vs placebo juice identical in all respects except pomegranate
223688465|NCT01858311|DIETARY_SUPPLEMENT|Tocotrienol Capsules|Vitamin E TCT capsules- 400mg to 800mg per day (2 in the morning and 2 in the evening)
223688466|NCT01858311|OTHER|Placebo Vehicle|Placebo capsules per day (2 in the morning and 2 in the evening)
223688467|NCT04598464|OTHER|Home based exercise|The home-based training program included posture and stretching exercises, strengthening exercises, balance training, and a walking regimen 3 days per week for 3 months.
223688468|NCT03583515|BEHAVIORAL|Alcohol-Specific Personalized Normative Feedback|Participants will receive personalized normative feedback about drinking.
223688469|NCT03583515|BEHAVIORAL|Social Media Personalized Normative Feedback|Participants will receive personalized normative feedback about social media use.
223688470|NCT00749554|DEVICE|Disc biacuplasty|The lesion duration will be 15 minutes with a ramp rate of 2°C per minute and a peak set temperature of 45°C (Temperature in posterior annulus of disc reaches 65°C).
223688471|NCT00749554|DEVICE|Sham biacuplasty|Probes not inserted into disc, no RF electricity applied.
223776115|NCT00788866|DIETARY_SUPPLEMENT|Placebo|Juice that matches the makeup of pomegranate in regards to sugar, vitamin C, etc. The only difference is that it lacks pomegranate juice.
223776116|NCT02791815|DRUG|Midazolam|Single oral dose of 7.5 mg midazolam (tablet)
223776117|NCT02791815|DRUG|Selexipag|Oral administration of selexipag (200 µg film-coated tablet) for 12 consecutive days (with a titration scheme from 400 to 1600 μg b.i.d. )
223776118|NCT05108181|OTHER|Muscle typology + exercise training|Exercise training: Participants perform 9 weeks of strength training at 60% of their 1RM.
223776119|NCT05108181|OTHER|Muscle typology + training frequency|Training frequency: leg A and arm A of the participants train 3 times per week, leg B and arm B train 2 times per week.
223688472|NCT01432509|OTHER|Prediabetes screening and prospective follow-up over 5 years|"The study period per patient is 5 years. The planned schedule of the study is as follows :~* Enrollment at visit V0 of subjects at high metabolic risk, based on a biological value (within the past 2 months) of moderate fasting hyperglycaemia (blood glucose ≥ 1,10 g/l and \< 1,26 g/l) or fasting blood glucose ≥ 1 g/l and \< 1,10 g/l with HbA1c ≥ 6,5%.~* First biological sample (B0) within 1 month following V0 (measuring fasting blood glucose + glycated hemoglobin HbA1c + lipid profile + creatinemia + liver function; and establishment of a biological sample collection to identify biomarkers).~* Annual follow-up for five years consisting in one blood sample (B1 to B5) measuring the same parameters as V0 + biological sample collection, and questionnaire on major health events or health events related to study procedures.~* End of study phone call"
223688473|NCT01484054|DEVICE|etafilcon A with print and PVP for dark eyes (EAPVPDE)|A daily disposable contact lens
223688474|NCT01484054|DEVICE|etafilcon A control lens (EADE)|A marketed daily disposable contact lens
223688475|NCT06380829|OTHER|Questionnaire|Self-Care Assessment Scale for Children with CP aged 3-6 years - Parent Form (SPÇÖS-EF): A draft scale named SPÇÖS-EF was prepared by the researchers, using the literature, to determine the self-care status of children with cerebral palsy aged 3-6.
223688476|NCT04496310|PROCEDURE|Telemedicine|Telemedicine versus usual care (face to face visit)
223688477|NCT06138288|BEHAVIORAL|acupressure|The acupressure points to be used in the research are located on the inner side of the lower leg, 4 fingers above the ankle and on the spleen meridian behind the tibia (SP6), which was previously effective in reducing pain, and located three fingers above the wrist (in the middle of the 2nd metacarpal bone, on the dorsum of the hand, adjacent The points determined as P6 (located between the metacarpal bones) and LI4 located in the space between the thumb and index finger (between the 1st and 2nd metacarpal bones of the hand, in the middle of the 2nd metacarpal bone on the radial side) were applied by a certified researcher to women in the acupressure group. will be done
223688478|NCT00938223|BIOLOGICAL|4-peptide and 12-peptide melanoma vaccines|"Each vaccination will be administered over a 6-week period (days 1, 8, 15, 29, 36, 43). Patients will be randomized into one of two groups, Group A or Group B.~Group A will receive 4 class I MHC-restricted synthetic melanoma peptides (1 each restricted by HLA-A1, -A3, and two restricted by HLA-A2) and a tetanus helper peptide.~Group B will receive the 12 class I MHC-restricted synthetic melanoma peptides (4 each restricted to HLA-A1, -A2, and -A3) and a tetanus helper peptide.~All vaccines will contain GM-CSF-in-adjuvant and will be administered intradermally and subcutaneously. Concurrent with the first three of these vaccinations, each patient will also receive an additional set of 3 identical vaccinations in a distal site, the response to which will be evaluated at the draining lymph node. This node will be harvested using lymphatic mapping and sentinel node biopsy methods and will be referred to as the sentinel immunized node (SIN)."
223688479|NCT05360368|DRUG|HLX07|A Recombinant Humanized Anti-EGFR Monoclonal Antibody, HLX07 will be administered as a single intravenous (IV) infusion on Day 1 in each 3-week cycle
223688480|NCT03551483|DEVICE|ArtontheBrain|The ArtontheBrain intervention has three activities focused on a user selected artwork. The activities promote an in-depth analysis of the artwork and are organized into three activity categories; learn, play, and mingle. In 'learn', the options are to read and/or listen to the curatorial description of the artwork. In 'play', the options are to engage in a word search game, to engage in a visual puzzle game, or to engage in a storytelling game whereby a reminiscence or imaged story can be written. In 'mingle' the options involve social communications about the artwork that include seeing what other comments and seeing how the artwork has been rated by others. The mingle option permits the user to engage only with a select circle of users or to engage with a group of public users.
223688481|NCT03551483|DEVICE|Seniors Online Victoria|The active control group will use a freely available website, which is updated daily with online games for seniors through an organization called Seniors Online Victoria (https://www.seniorsonline.vic.gov.au/services-information/games).
223688482|NCT00002398|DRUG|Levocarnitine|
223688483|NCT00002398|DRUG|Adefovir dipivoxil|
223688484|NCT00411931|DRUG|Multihance|0.5M administered as a single injection
223688485|NCT05357547|DRUG|Buspirone 20mg|Buspirone tablets in opaque capsule. Used as probe for 5HT1A agonism
223688486|NCT05357547|DRUG|Placebo comparator|Lactose-sucrose tablets in opaque capsule
223688487|NCT00296803|DRUG|clopidogrel|
223688488|NCT06025929|OTHER|Maitland's mobilization technique|Maitland's mobilization technique was performed on the patients with its all components, such as 1. Distraction 2. Anteroposterior glides 3. Posteroanterior glides 4. Medial glides and 5. Lateral glides.
223776120|NCT00882011|OTHER|Latest generation chemotherapies for T-LBL + transplant|"1. Standard doses of one of the following chemotherapies:~   * Holzer~  * LSA2-L2 modified~  * Stanford regimen~  * Hyper CVAD~  * Sequential treatments analogous to the ones above mentioned (e.g.: GIMEMA LAL094, others)~  * Intensive chemotherapy, ALL-type, MRD oriented (NILG-TLL Clinical Trial)~2. Autologous transplant or allogeneic transplant or mini-allogeneic transplant"
223688489|NCT06025929|OTHER|Mulligan's mobilization techniques|Mulligan's mobilization technique was performed on the patients with its all components using a therapeutic belt, such as 1. Medial mobilization with movement (MWM) for Knee flexion 2. Medial mobilization with movement (MWM) for Knee extension 3. Lateral mobilization with movement (MWM) for Knee flexion 4. Lateral mobilization with movement (MWM) for Knee extension.
223776121|NCT00813761|DEVICE|O2Optix contact lens|control contact lens to be worn daily for approximately 7 months for entire length of study.
223688490|NCT06025929|OTHER|Interferential Therapy (IFT)|Interferential Therapy was performed on the patients with the following parameters: career frequency 4000Hz; waveform: rectangular; sweep time: 1 second rise and fall and 5 second stay; Treatment duration: 10 minutes; sweep frequency: 10 to 130 Hz. The current intensity was adjusted until the subject reported feeling a strong tingling sensation without causing muscle contraction. A aquatic gel was applied before straping the electopads over treatment area for smooth electrical conduction.
223688491|NCT02818491|DRUG|Placebo|Normal saline 0.9% in 2 mls
223776122|NCT00813761|DEVICE|Proclear contact lens|control contact lens to be worn for entire length of study.
223688492|NCT02818491|DRUG|Dexamethasone 1 mg|Dexamethasone 1 mg in 2 mls
223688493|NCT02818491|DRUG|Dexamethasone 2 mg|Dexamethasone 2 mg in 2 mls
223688494|NCT02818491|DRUG|Dexamethasone 3 mg|Dexamethasone 3 mg in 2 mls
223688495|NCT02818491|DRUG|Dexamethasone 4 mg|Dexamethasone 4 mg in 2 mls
223688496|NCT02818491|DRUG|Ropivacaine 0.5%|Ropivacaine 0.5% 20 mls
223688497|NCT02761291|DRUG|Gemcitabine|Gemcitabine will be administrated 600\~1250 mg/m\^2 intravenously according to the body surface area at day 1 and day 8 in a 28 day-treatment cycle. The treatment cycle of 28 days will be repeated maximum 6 times. The first dose level of gemcitabine will be started at 800 mg/m\^2. If no subject suffered the dose limit toxicity, 1000 mg/m\^2 and even 1250 mg/m\^2 will be started by order. If subjects suffered the dose limit toxicity in 800 mg/m\^2, the 600 mg/m\^2 will be started.
223688498|NCT02761291|DRUG|Valproic acid|Valproic acid will be administrated orally by the fixed dose 12.5 mg/kg/day according to instructions from day 1 to day 14 in one treatment cycle. The treatment cycle of 28 days will be repeated maximum 6 times.
223688499|NCT02761291|DRUG|Valganciclovir|Valganciclovir will be administrated orally by the fixed dose 1350 mg/day (creatinine clearance rate ≥ 60 mL/min) or 900 mg/day (creatinine clearance rate ≥ 40 mL/min and \< 60 mL/min) from day 9 to day 15 in one treatment cycle. The treatment cycle of 28 days will be repeated maximum 6 times.
223688500|NCT01604759|DEVICE|Polarized Reflectance Spectroscopy System|Fiber optic probe designed to measure polarized reflectance spectroscopy will be used to gather data from all study participants.
223688501|NCT06110520|DEVICE|Violet Light Lamp|Medical grade lamps with Violet LEDs enabled
223688502|NCT06110520|DEVICE|White Light Lamp|Standard bedside lamp with standard 4000K LED light bulb.
223688503|NCT02732080|DEVICE|deferred coronary stenting|Final coronary stenting will be performed when coronary auto regulation was recovered (approximately 30 minutes after establishment of TIMI III flow şn the infarct related artery)
223688504|NCT02732080|DEVICE|immediate stenting|Stent implantation will be performed immediately after balloon angioplasty (or thrombectomy or wire crossing) as it is performed in daily routine.
223688505|NCT04639115|DRUG|Ozanimod|Ozanimod
223688506|NCT04720261|DRUG|Caplacizumab|Analyse of ADAMTS13 activity in patients with aTTP treated with Caplacizumab in order to help adapting the treatment with caplacizumab in TTP patients
223688507|NCT02942589|OTHER|Meal portion size|
223776123|NCT00813761|DEVICE|ReNu MultiPlus Multi-Purpose Solution|lens solution for overnight lens disinfection
223688508|NCT04616027|DRUG|PF-06882961 20 mg|PF-06882961 20 mg single oral dose provided in tablet form administered in a fed state on Day 1
223688509|NCT03020290|DEVICE|Endovascular treatment for PAD during medical care (SuperA stent (Abbott))|Long femoropopliteal stenting with SuperA devices during medical care. The endovascular treatment for PAD will be done during the usual medical treatment of patient. The intervention is not carried out within the framework of the research protocol
223688510|NCT06134609|BEHAVIORAL|Sexual intercourse|Sexual intercourse without barrier contraceptive at the evening/night after the embryo transfer
223688511|NCT00468767|DRUG|Vernakalant Injection 20 mg/mL|
223688512|NCT01195077|OTHER|seaweed, spirulina, seaweed + spirulina|"Arm 1: Seaweed. Ten capsules of .5 grams per capsule for a total of 10 grams per day.~Arm 2: Spirulina: Ten capsules of .5 grams per capsule for a total of 10 grams per day.~Arm 3: Seaweed: (2.5 grams) plus Spirulina (2.5 grams). Ten capsules of .5 grams per capsule for a total of 10 grams per day.~Spirulina: Ten capsules of .5 grams per capsule for a total of 10 grams per day."
223688513|NCT04290390|DRUG|Segesterone Acetate and Ethinyl Estradiol|Contraceptive Vaginal System
223688514|NCT04290390|DRUG|Rifampin|CYP3A inducer
223776124|NCT00813761|DEVICE|Clear Care Cleaning and Disinfecting Solution|lens solution for overnight lens disinfection
223776125|NCT03756766|DIAGNOSTIC_TEST|RSV point of care testing|Patients will have 2 nasopharyngeal swabs, a nasal swab, a stool and urine taken at baseline/ enrolment and the RSV positive ARTI group will have samples repeated at 6-8weeks.
223688515|NCT04290390|DRUG|Itraconazole|CYP3A inhibitor
223688516|NCT00318227|PROCEDURE|Blood Transfusion|Blood transfusion will be administered when the transfusion trigger is met.
223688517|NCT04490031|DRUG|Ketamine Hydrochloride|patient in Ketamine group will be given Ketamine as sedative agent
223688518|NCT01400685|DRUG|Lenalidomide|Lenalidomide will be dose escalated until the maximum tolerated dose is reached. The starting dose is 2.5mg, followed by 5mg, followed by 10mg.
223688519|NCT01400685|DRUG|Bendamustine|90 mg/m\^2 IV days 1-2 of each cycle for 6 cycles
223688520|NCT01400685|DRUG|Rituximab|375 mg/m\^2 IV day 1 (cycle 1), 500 mg/m\^2 day 1 (cycles 2-6)
223688521|NCT01987531|OTHER|left ventricular epicardial pacing lead|
223688522|NCT05658666|BEHAVIORAL|Video feedback intervention (in Dutch: Video Interventie Ouderenzorg)|The video feedback trainer assesses the interaction between the person with dementia and the caregiver and acquires agreement from the caregiver on the goals of the intervention. Caregivers are trained during several feedback sessions using personal video footage of interaction between the person with dementia and the caregiver. The feedback focuses on basic interaction and attunement principles, and the team feeling competent. Recording starts with a nondemanding situation, enabling the caregiver to become aware of the principles they already apply and to learn how these principles can be used in more demanding situations. Subsequently, video footage is recorded in 1 to 3 situations, depending on the progress, of increasing difficulty, with about 4 weeks between 2 recordings. After each recording, a 1-hour feedback session is held. The intervention concludes with separate, 30-minute sessions for the formal and informal caregivers evaluating the intervention.
223688523|NCT03737851|DRUG|elezanumab|solution for infusion
223688524|NCT03737851|DRUG|placebo|solution for infusion
223688525|NCT06011031|DEVICE|Novaloc attachment|Each patient will be restored with 4 implants retained maxillary overdenture with the assigned attachment
223688526|NCT06011031|DEVICE|Locator attachment|Each patient will be restored with 4 implants retained maxillary overdenture with the assigned attachment
223688527|NCT01328171|DRUG|FOLFOXIRI + Panitumumab|irinotecan 150 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5-FU 3000 mg/m² cont. inf. + panitumumab, iv, 6 mg/kg BW all on day 1 of each 2 weeks cycle until PD or resectability or to max. 12 cycles
223688528|NCT01328171|DRUG|FOLFOXIRI|irinotecan 165 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5-FU 3200 mg/m² cont. inf. all on day 1 of each 2 weeks cycle until PD or resectability or to max. 12 cycles
223688529|NCT04173793|DRUG|AK102|Administered by subcutaneous injection
223688530|NCT04173793|DRUG|Placebo|Administered by subcutaneous injection
223688531|NCT04173793|DRUG|Statins and/or Ezetimibe|Lipid-lowering therapies
223688532|NCT05675982|OTHER|CAR-T cells monitoring|monitoring of circulating DNA by blood sample
223688533|NCT02125773|BEHAVIORAL|Informed Risk Score|Subjects in the intervention arm will receive an estimate of their risk of HIV infection as estimated by the UCSD calculator. The risk of HIV infection will be based on the subject's responses to the self-reported sexual risk questionnaire and the risk of HIV infection in one year will be extrapolated based on continuation of the same risk behavior. The subjects will also be provided the calculated risk if they were to take PrEP. Subjects in the control arm will not be provided with the results of the risk calculators. Both arms will receive standard of care risk reduction education and information sheets about PrEP.
223688534|NCT04113031|BEHAVIORAL|Flywheel squats versus free weight high load squats for explosive actions in football|Over the course of the interventions, all players in all three groups will be instructed to adhere to their two-three weekly football practices and preseason matches of their team (\~one weekly match). The flywheel group performes squat resistance exercise in using a flywheel device, and the barbell free weight group performes squat resistance exercise using an Olympic barbell and weights.
223688535|NCT04408131|BIOLOGICAL|Blood sample|virological test
223688536|NCT04408131|BIOLOGICAL|Blood sample|serological test
223688537|NCT01110655|OTHER|Intravenous hypertonic Saline|Intravenous 100mL bolus of 3% saline
223688538|NCT01110655|OTHER|Oral hypertonic saline|Oral 100mL bolus of 3% saline
223688539|NCT04534803|DRUG|BCG Vaccine|.1 mL of reconstituted BCG vaccine given intradermally at baseline.
223688540|NCT04534803|OTHER|Placebo|.1 nL of diluent (saline) given intradermally at baseline
223688541|NCT03930160|OTHER|Logistic Organ Dysfunction System Score|Variables of logistic organ dysfunction system score, including: GCS; heart rate; systolic BP; blood urea; serum creatinine; urine output; leucocyte count; platelet count; PaO2/FiO2; serum bilirubin; prothrombin time.
223688542|NCT06256198|OTHER|measurement of serum lactate and procalcitonin and PCO2 gap|measurement of serum lactate, procalcitonin and PCO2 gap
223688543|NCT00410202|DRUG|Entecavir|Tablets, Oral, 1mg, once daily, 100 weeks
223688544|NCT00410202|DRUG|Tenofovir|Tablets, Oral, 300 mg, once daily
223688545|NCT00410202|DRUG|Adefovir|Tablets, Oral, 10mg, once daily, 100 weeks
223688546|NCT00410202|DRUG|Lamivudine|Tablets, Oral, 100mg, once daily, 100 weeks
223688547|NCT00773916|DRUG|Methylphenidate|Dose increments according to clinical evaluation, starting with 0,3 mg/kg of weight/day
223688548|NCT02653027|DRUG|Lumacaftor-ivacaftor|Subjects who are planning on starting the combination therapy (lumacaftor-ivacaftor) will participate in OGTTs before and after starting the medication.
223688549|NCT02653027|OTHER|OGTT|A subject is given an oral glucose load and insulin and glucose measurements are taken at specified time periods.
223688550|NCT05314088|BEHAVIORAL|RISE+|The intervention includes psychoeducational videos and written activities on topics such as coping strategies, cognitive appraisals, the responsibility model, and social connections, all integrated into the overarching process of resilience.
223688551|NCT05314088|BEHAVIORAL|Stress Reduction Control|Placebo Comparator: Stress Reduction Control Control participants will complete an attention-matched internet stress reduction paradigm, which includes an internet navigation protocol and placebo computer games.
223688552|NCT04426578|DRUG|Perhexiline|"All eligible and consented patients will be randomised to initiation of perhexiline 100mg once daily or identical placebo. After 4 days of treatment, a blood sample will be collected to determine plasma perhexiline concentrations: timing of the sample need not be trough in view of the long-acting nature of perhexiline. Depending on the blood results, patients might require as little as 50mg/week (slow metabolisers) or as much as 600mg/day (ultra-rapid metabolisers). The initial sample will be utilized primarily to detect presence of hydroxylated metabolite: patients in whom perhexiline is detected in the absence of metabolite will be designated slow metabolisers and will have their dosage reduced to 50 mg/week in the first instance. Repeat assay at 30 days will be utilized for individual finer dose titration based on dose adjustment table. Paired dosage adjustment in placebo-treated patients will be performed to avoid unblinding.~Compliance will be assessed by capsule count."
223688553|NCT04426578|OTHER|Placebo|"All eligible and consented patients will be randomised to initiation of perhexiline 100mg once daily or identical placebo. After 4 days of treatment, a blood sample will be collected to determine plasma perhexiline concentrations: timing of the sample need not be trough in view of the long-acting nature of perhexiline. Depending on the blood results, patients might require as little as 50mg/week (slow metabolisers) or as much as 600mg/day (ultra-rapid metabolisers). The initial sample will be utilized primarily to detect presence of hydroxylated metabolite: patients in whom perhexiline is detected in the absence of metabolite will be designated slow metabolisers and will have their dosage reduced to 50 mg/week in the first instance. Repeat assay at 30 days will be utilized for individual finer dose titration based on dose adjustment table. Paired dosage adjustment in placebo-treated patients will be performed to avoid unblinding.~Compliance will be assessed by capsule count."
223688554|NCT00184873|BEHAVIORAL|Health Counseling|
223688555|NCT00937391|DRUG|Gadopentetate dimeglumine (Magnevist, BAY86-6661)|For stage 1: Participants received an IV injection of 0.05 mmol/kg Body Weight (BW) (0.1 mL/kg BW) Magnevist. Upon completion of the MR imaging, the participants received another injection of 0.05 mmol/kg for a total cumulative dose of 0.1 mmol/kg BW (0.2 mL/kg BW). For stage 2: Participants received the optimal efficacious dose established in Stage 1 as a single IV injection of Magnevist Injection (0.1 mmol/kg BW (0.2 mL/kg BW)).
223688556|NCT04425824|DRUG|Toripalimab combine with Rituximab|"Toripalimab is a recombinant, humanized programmed death receptor-1 (PD-1) monoclonal antibody that binds to PD-1 and prevents binding of PD-1 with programmed death ligands 1 (PD-L1) and 2 (PD-L2).~Drug: Rituximab Rituximab is an antibody to CD20 molecules. One of the mechanisms of killing tumor cells is through antibody-dependent cell-mediated cytotoxicity (ADCC)."
223688557|NCT02884843|DEVICE|Intubation laryngeal Tube Suction|Intubation laryngeal Tube Suction
223688558|NCT02884843|DEVICE|AuraGain Laryngeal Mask|AuraGain Laryngeal Mask
223688559|NCT03613610|RADIATION|Radio-frequency ablation of genicular nerves|Ablation of the genicular nerves for pain relief in advanced knee osteoarthritis
223688560|NCT03824067|DIAGNOSTIC_TEST|Point of Care Early Infant Diagnosis|HIV testing where the blood sample is processed at either the facility itself or a nearby site that is closer to the facility than a laboratory. With POC EID, blood samples do not have to travel to the laboratory for processing.
223688561|NCT03824067|DIAGNOSTIC_TEST|Standard of Care Early Infant Diagnosis|Conventional laboratory based EID testing
223688562|NCT03702686|DEVICE|FEEDBACK System|Smart Nipple Shield and Monitor Unit
223688563|NCT02547285|OTHER|Shoes characteristics|A single parameter of shoe vary for each test (Different insole, heel height, stem length ...)
223688564|NCT02169193|RADIATION|99mTc-Rhenium Sulfide Nanocolloid|12 MBq of NanoCis added to 500 ml of enteral feeding
223688565|NCT06002243|DIAGNOSTIC_TEST|SPLASH echocardiography screening|Screening echocardiogram performed by a briefly trained health worker with images reviewed off site by an expert cardiologist or cardiac sonographer to determine screening outcome. Screening outcome may include: screen positive, screen negative or uninterpretable images.
223688566|NCT06115837|PROCEDURE|multivisceral resection|The prognostic factors were analyzed for pT4bN0M0 colorectal cancer after multivisceral resection
223688567|NCT02323932|BEHAVIORAL|Perception of correct intonation identification|The amount of change in the fundamental frequency that was required in order to identify a question
223688568|NCT03317132|BEHAVIORAL|IPS|One year of IPS Support
223688569|NCT04623385|COMBINATION_PRODUCT|Aerosolized 13 cis retinoic acid plus Inhalation Inhaled testosterone|"1. The infected patients will receive Aerosolized 13 cis retinoic acid in gradual in 2 divided doses increases froms 0.2 mg/kg/day to 4 mg/kg/day as inhaled 13 cis retinoic acid therapy for 14 days~2. The infected patients will be treated with a single dose of testosterone (0.1, 0.2, or 0.3 mg) by inhalation for 14 days"
223688570|NCT04623385|DRUG|The standard therapy|infected patients will receive the standard therapy for COVID-19 for 14 days
223688571|NCT05621915|DRUG|Nadroparin|Subcutaneous injection of nadroparin according to the ICU guidelines for thromboprophylaxis in ICU patients.
223688572|NCT03779360|DRUG|Erythromycin 4% topical gel formulation:|7 day pre-treatment with erythromycin and clindamycin applied twice daily on marked area on left (erythromycin) and right side (clindamycin) of the volar lower arm. Erythromycin is a bacteriostatic antibiotic that belongs to the macrolide group of antibiotics. Macrolides act as bacteriostatic by reversibly binding to the P site on the 50S subunit of bacterial ribosomes. A topical gel formulation with hyprolose and ethanol.
223688573|NCT03779360|DRUG|Clindamycin 1% lotion formulation:|7 day pre-treatment with erythromycin and clindamycin applied twice daily on marked area on left (erythromycin) and right side (clindamycin) of the volar lower arm. Clindamcin is a bacteriostatic antibiotic that belongs to the lincosamide group of antibiotics. Lincosamides act as bacteriostatic by reversibly binding to the P site on the 50S subunit of bacterial ribosomes. A topical lotion formulation with ethanol.
223688574|NCT03779360|DRUG|Prednisolone tablet (0.5mg/kg; parallel comparison):|2 day pre-treatment with prednisolone daily dose 0.5mg/kg (0.25mg/kg in the morning and 0.25mg/kg in the evening). Prednisolone tablet (0.5mg/kg; parallel comparison): Prednisolone is a synthetic corticosteroid with predominant glucocorticoid activity and as such it is widely used in the treatment for inflammatory and autoimmune diseases. Prednisolone exerts its effect by binding to cytoplasmic glucocorticoid receptors and subsequently activates glucocorticoid receptor mediated gene expression. This results in synthesis of certain anti-inflammatory proteins, while inhibiting the synthesis of certain inflammatory mediators.
223688575|NCT03779360|DRUG|Clobetasol propionate 0.05% topical formulation (crossover comparison):|"2 day pre-treatment with clobetasol propionate 0.05% topical formulation applied twice daily on marked area on left or right side of the volar lower arm.~Clobetasol propionate 0.05% topical formulation (crossover comparison):~Clobetasol propionate is a potent synthetic corticosteroid with anti-inflammatory, anti-pruritic, and vasoconstrictive properties. Clobetasol propionate exerts its effect by binding to cytoplasmic glucocorticoid receptors and subsequently activates glucocorticoid receptor mediated gene expression. This results in synthesis of certain anti-inflammatory proteins, while inhibiting the synthesis of certain inflammatory mediators. Specifically, clobetasol propionate appears to induce phospholipase A2 inhibitory proteins, thereby controlling the release of the inflammatory precursor arachidonic acid from membrane phospholipids by phospholipase A2."
223688576|NCT03779360|OTHER|Lipopolysaccharide|As TLR4 agonist, purified lipopolysaccharide prepared from Escherichia Coli: 113: H10:K negative (U.S. Standard Reference Endotoxin) will be used. This LPS batch is manufactured in the US by the National Institute of Health (NIH). Subjects will receive two intradermal doses of LPS in each forearm on day 0 (4 LPS injections in total, except for subjects 1-6 who receive none and subjects 25-27 will receive 2 LPS injections, only in the right arm). The dose per injection is 10 ng.
223688577|NCT03552458|DRUG|Lactobacillus Reuteri Oral Solution [BioGaia]|BioGaia Lactobacillus Reuteri drops
223688578|NCT03552458|DRUG|Placebos|Placebo will be identical in physical appearance and color to the study agent and will be made by the manufacturer
223688579|NCT02958189|BEHAVIORAL|Tweet4Wellness|A daily, behavior change theory-based intervention message is sent to a private, 25-person online Twitter-support group to prompt peer-to-peer discussion. Participants receive individual text messages to encourage group participation (e.g. 'thank you for participating' or 'please participate tomorrow'). Participants also receive weekly individual messages giving them daily step goals for the week based on their previous week's daily step average, recorded from Fitbit.
223688580|NCT02958189|BEHAVIORAL|Self-monitoring|A Fitbit is provided to the group which tracks participants' daily steps.
223688581|NCT01520454|DRUG|Saline|IV saline at 0.83 mL/kg/hr for six hours
223688582|NCT01520454|DRUG|Intralipid|Intralipid in either low-dose or high dose (10% vs. 20%) at 0.83 mL/kr/hr for six hours
223688583|NCT01520454|DIETARY_SUPPLEMENT|Water|Water by mouth
223688584|NCT01520454|DIETARY_SUPPLEMENT|oral fat|Soybean oil by mouth at 1.25 g/kg x 2 doses
223688585|NCT01520454|DRUG|Heparin|Heparin bolus of 1000 units followed by 800 u/hr, adjust per partial thromboplastin time (PTT), for 5.5 hours
223688586|NCT01351246|BEHAVIORAL|CBT Based Self-help Workbook + Counseling Telephone|"Over a period of 12 months parents work through 8 self-help booklets and additionally receive 14 counseling telephone calls. The intervention has a cognitive-behavioral foundation and is based on the therapy manual Therapy program for children with hyperactive and oppositional problem behavior THOP (Döpfner, Schürmann, \& Frölich, 2007) and the parent self-help book Wackelpeter and Trotzkopf: Help for parents of children with hyperkinetic and oppositional behavior (Döpfner, Schürmann, \& Lehmkuhl, 2006). Primary purpose of counseling telephone calls is to clarify contents of the booklets and support parents in managing their homework assignments accompanied with each booklet."
223688587|NCT04292392|OTHER|preop ACB, followed by Intra-articular block during TKA surgery|"Preoperative ACB (adductor canal block), followed by a local anesthetic injection during surgery, which is comprised of the following agents and amounts:~* Ropivacaine 5mg/ml (49.25ml)~* Epinephrine 1mg/ml (0.5ml)~* Ketorolac 30mg/ml (1ml)~* Clonidine 0.1mg/ml (0.8ml)~* Saline 48.45ml"
223688588|NCT04292392|OTHER|preop ACB+IPACK block|Preoperative ACB (adductor canal block) and IPACK (Interspace between the Popliteal Artery and the Capsule of the posterior Knee) block
223688589|NCT04292392|OTHER|preop ACB+IPACK block, followed by Intra-articular block during TKA surgery|"Preoperative ACB (adductor canal block) and IPACK (Interspace between the Popliteal Artery and the Capsule of the posterior Knee) block, followed by a local anesthetic injection during surgery, which is comprised of the following agents and amounts:~* Ropivacaine 5mg/ml (49.25ml)~* Epinephrine 1mg/ml (0.5ml)~* Ketorolac 30mg/ml (1ml)~* Clonidine 0.1mg/ml (0.8ml)~* Saline 48.45ml"
223688590|NCT00392821|DRUG|Sorafenib|Sorafenib
223688591|NCT00392821|DRUG|RAD001|RAD001
223688592|NCT04411524|DRUG|PD-1 antibody|Before neo-CRT: 2 cycles of PD-1 antibody After neo-CRT: 3 cycles of PD-1 antibody
223688593|NCT04411524|DRUG|Capecitabine|During neo-CRT: 625mg/m2 bid Monday-Friday per week
223688594|NCT04411524|DRUG|Irinotecan|During neo-CRT: 80mg/m2 qw (UGT1A1\*28 6/6) or 65mg/m2 qw (UGT1A1\*28 6/7)
223688595|NCT04411524|RADIATION|Neoadjuvant Radiotherapy|IMRT DT: 50Gy/25Fx
223688596|NCT01338142|OTHER|CCC|"600 mg (2 capsules of 300 mg) for oral use of 480 mg CCC (192 mg elemental calcium) intrinsically labeled with 15 mg 44Ca and 120 mg of inactive filler, sucrose.~1.5 mg of 42Ca labeled CaCl2 through IV injection"
223688597|NCT01338142|OTHER|ACC|600 mg (2 capsules of 300 mg) for oral use containing 600 mg ACC (192 mg elemental calcium) intrinsically labeled with 15 mg 44Ca 1.5 mg of 42Ca labeled CaCl2 through IV injection
223688598|NCT02812355|DRUG|Heparin|
223688599|NCT01854931|BEHAVIORAL|Tai Ji Quan|single aim intervention
223688600|NCT01753739|DRUG|Bepotastine besilate|Nasal spray administered in the morning and at night approximately 12 hours apart daily for 14 days
223688601|NCT01753739|DRUG|Placebo|Nasal spray administered in the morning and at night approximately 12 hours apart daily for 14 days
223688602|NCT00881478|OTHER|Nutrition counseling + portion control tool|Nutrition counseling with registered dietician in addition to teaching about how use of a portion control tool
223688603|NCT00881478|OTHER|Nutrition counseling|Nutrition counseling with registered dietician
223688604|NCT03759288|DRUG|Brazikumab low dose|Intravenous Brazikumab on Days 1, 29, and 57, followed by subcutaneous Brazikumab on Day 85 and every 4 weeks through Week 48
223688605|NCT03759288|DRUG|Brazikumab high dose|Intravenous Brazikumab on Days 1, 29, and 57, followed by subcutaneous Brazikumab on Day 85 and every 4 weeks through Week 48
223688606|NCT03759288|DRUG|Humira®|Administered subcutaneously on Day 1, Day 15, and Day 29 and every 2 weeks through Week 50.
223688607|NCT03759288|DRUG|Placebo|Intravenous placebo on Days 1, 29, 57 followed by subcutaneous placebo on Day 85 and every 4 weeks through Week 48
223688608|NCT01157156|DRUG|XRP0038 (NV1FGF)|"Pharmaceutical form:solution~Route of administration: intramuscular"
223688609|NCT00371501|DRUG|Rosuvastatin|10mg/day
223688610|NCT00371501|DRUG|placebo|one tablet/day
223688611|NCT00371501|DRUG|aspirin|80mg/day
223688612|NCT00371501|DRUG|placebo|placebo
223688613|NCT05462041|OTHER|DBD Donor Heart Transplantation|A technique of donor heart procurement.
223688614|NCT05462041|DEVICE|DCD Donor Heart Transplantation|A technique of donor heart procurement. The TransMedics' OCS Heart technology is the only portable system available for ex-vivo maintenance of the donor heart in a metabolically active and beating state. It is currently FDA approved for procurement and transport.
223688615|NCT02772679|BIOLOGICAL|PolyTregs+IL-2|PolyTregs will be infused into the patient in a single infusion. The first cohort will receive 3 x10\^6 cells. The second cohort will receive 20x10\^6 cells. Following the day 0 infusion of polyclonal Tregs, subjects will receive two 5-day courses of IL-2 (1 x 106 IU daily), the first on days 3-7 and the second on days 38-42. Administration of the second course of IL-2 may be delayed or withheld depending on threshold criteria for peripheral blood Treg frequencies and MMTT-stimulated C-peptide levels determined on day 28.
223688616|NCT03411837|BIOLOGICAL|Dupilumab|Biologic (monoclonal antibody)
223688617|NCT06324227|OTHER|multimodal music therapy|music therapy
223688618|NCT06324227|OTHER|no intervention|no intervention
223688619|NCT03194490|OTHER|combined intervention group|The combined intervention group received the cervical passive mobilization, stretching, and home program (Stretching and ROM exercise).Stretching, cervical passive mobilization, and range of motion: The manual therapy was conducted by a physical therapist who has licensed from the California Board of Physical Therapy. The cervical passive mobilization were selected by the physical therapist based on the participant's condition. Stretching techniques were performed in the combined intervention group for 30 seconds and repeated 3 times twice a week in the following order on the following muscles: anterior, middle and posterior scalene, upper fibers of trapezius, pectoralis minor and interspinous muscles .AROM Exercise were performed 10 repetitions 3-4 times daily. The ACROM exercise consisted of the subject placing fingers over the manubrium bone and placing chin on the fingers. The subject was then instructed to rotate to one side as far as possible and return to neutral.
223776126|NCT04315285|BEHAVIORAL|Treadmill gait training with verbal instruction|Each participant will receive 12 treatment with special verbal instruction which depends on participant's group. Each training session will last 60 minutes, including 5 minutes of warm-up stretching exercise, 40 minutes of treadmill training, and 15 minutes of over-ground gait and balance training. Throughout the 40 minutes of treadmill walking, the participants will walk on the level of 0% slope with a body-weight support system (LikorallTM 200, Liko, Sweden) used to protect the participants from falling; no actual weight support of the body will be provided. The frequency of intervention will be 2-3 days a week, spread across 4-6 weeks. The intervention protocols will be the same for all groups except the instruction provided to the participants in each group.
223776127|NCT03579199|DEVICE|exploration of abdominal cavity and liver using a NIR/ICG camera|exploration of abdominal cavity and liver using a NIR/ICG camera
223776128|NCT04530682|BIOLOGICAL|Biological samples|Serum and plasma samples. At baseline, 6, 12 and 24 months
223776129|NCT01328002|DRUG|Milnacipran|"Maximum tolerated dose (50, 75, or 100 mg/day tablets) was determined during the open label phase of the study.~Oral administration, twice daily dosing"
223776130|NCT01328002|DRUG|Placebo|matching placebo tablets daily
223776131|NCT02716844|OTHER|Exercise|Clinical Pilates exercise were given for 6 weeks, 3 days in a week
223776132|NCT06075602|DEVICE|Impact of current PCI techniques/ devices in complex coronary artery lesions|To evaluate the impact of current PCI techniques/devices, but also CABG strategies, in patients with complex coronary artery lesions
223776133|NCT00349492|DRUG|IP|irinotecan+cisplatin
223776134|NCT02125539|BEHAVIORAL|Navigating my Journey program|The online relapse prevention program called Navigating my Journey is designed for adolescents who are receiving outpatient treatment for substance abuse. Since the Navigating my Journey program will be available to adolescents 24/7, it is easy for them to access at their convenience. The program functions as an adjunct to treatment and is designed to complement and enhance the work the adolescent does with the counselor during counseling sessions. The core intervention is expected to last for 12 weeks.
223776135|NCT02125539|BEHAVIORAL|Attention Control|Client participants in the control group will receive their typical course of counseling and a link to online online health information in PDF form as an attention control.
223776136|NCT01767792|DRUG|Bevacizumab|"Treatment will be administered on an outpatient basis. Bevacizumab is administered by IV infusion at a dose of 10 mg/kg every 2 weeks for 24 weeks (induction therapy, see Schema). One cycle lasts 28 days and includes two infusions of bevacizumab. Clinical response will be assessed by audiology and MRI at weeks 12 and 24. Subjects with hearing decline at weeks 12 and 24 will be taken off of protocol. After week 24, patients with a clinical response or stable disease (together comprising clinical benefit) will transition to maintenance therapy with bevacizumab.~During the maintenance phase, subjects will be treated with open-label bevacizumab 5 mg/kg every 3 weeks for up to 72 weeks. Subjects will be followed with audiology and MRI scans every 12 weeks. The total time of the study will be 96 weeks (24 weeks induction + 72 weeks maintenance)."
223776137|NCT01208233|DRUG|PF-03049423|1 mg of PF-03049423 daily for 90 days
223776138|NCT01208233|DRUG|PF-03049423|3 mg of PF-03049423 daily for 90 days
223776139|NCT01208233|DRUG|PF-03049423|6 mg of PF-03049423 daily for 90 days
223776140|NCT01208233|OTHER|Placebo|Placebo of PF-03049423 daily for 90 days
223776141|NCT00674141|DRUG|Dexamethasone soduim phosphate|nasale administation of Dexamethasone in 20mg dose/day (in two divided doses) fpr sevem days of treatment
223776142|NCT02259491|OTHER|Manuka Honey Dressing|After surgical resection and reconstruction the skin graft donor site (thigh) and the free flap donor site will be dressed with Medihoney surgical dressings. More specifically, a dressing of appropriate size will be applied to the anterior thigh and covered with tegaderm. For the STSG recipient site a Medihoney dressing will cover the skin graft, followed by dry gauze, kerlex and a cast.
223776143|NCT05848635|DRUG|Hydromorphone Hydrochloride|Drug: Hydromorphone Hydrochloride Hydromorphone hydrochloride injection is used for perioperative lung tumor ablation
223776144|NCT05848635|DRUG|Morphine hydrochloride|Drug: Morphine Hydrochloride Morphine hydrochloride injection is used for perioperative lung tumor ablation
223776145|NCT01891734|OTHER|Problem Solving Therapy plus Moving Forward|All Veterans will receive a standard 6-session administration of Problem Solving Therapy (Nezu \& D'Zurilla, 1999). Session 1 will take place in-person during a scheduled appointment and will last for 1 hour. Subsequent sessions will take place over the telephone and will last for approximately 30 minutes. Participants in this arm will also receive the Moving Forward app for SmartPhones, which was adapted from Problem Solving Therapy to be used either as a standalone treatment or as an adjunct to other related therapies such as in-person Problem Solving Therapy or the Moving Forward website. The phone content matches Problem Solving Therapy. Benefits of the app include 24-hours accessibility of psychoeducational materials and worksheets.
223776146|NCT01891734|OTHER|Problem Solving Therapy|All Veterans will receive a standard 6-session administration of Problem Solving Therapy (Nezu \& D'Zurilla, 1999). Session 1 will take place in-person during a scheduled appointment and will last for 1 hour. Subsequent sessions will take place over the telephone and will last for approximately 30 minutes.
223776147|NCT01181895|DRUG|Vilanterol|Vilanterol inhalation powder inhaled orally once daily for 12 weeks
223776148|NCT01181895|DRUG|Salmeterol Inhalation Powder|Salmeterol inhalation powder inhaled orally twice daily for 12 weeks
223776149|NCT01181895|DRUG|Placebo Inhalation Powder NDPI|Placebo inhalation powder inhaled orally via Novel Dry Powder Inhaler
223776150|NCT01181895|DRUG|Placebo Inhalation Powder Diskus|Placebo inhalation powder inhaled orally twice daily for 12 weeks
223688620|NCT03194490|OTHER|The standard intervention|"The standard intervention group will receive cervical mobilization and home program (ROM exercises).~Cervical mobilization and range of motion: The manual therapy was conducted by a physical therapist who has experience in manual therapy and is licensed from the California Board of Physical Therapy. The manual therapy intervention will consist of Passive Accessory Intervertebral Movements (PAIVMs). The nature of PAIVMs techniques was selected by the physical therapist based on the participant's condition.~Active Cervical Range of Motion Exercises (ACROM) were performed 10 repetitions 3-4 times daily. Subjects were advised to maintain their usual activity within the limits of pain. The ACROM exercise consisted of the subject placing fingers over the manubrium bone and placing chin on the fingers. The subject was then instructed to rotate to one side as far as possible and return to neutral ."
223688621|NCT00477074|PROCEDURE|bronchoalveolar lavage, blood analysis|
223688622|NCT01214148|DEVICE|ORSIRO - Drug Eluting Coronary Stent|The coronary stent is delivered to the intended implantation location by means of the fast-exchange delivery system and then expanded to its final diameter by dilating the balloon. It remains in the vessel as a permanent implant.
223688623|NCT02975583|DRUG|Vorapaxar|2.08 mg oral tablet daily
223688624|NCT02975583|DRUG|Placebos|Placebo oral tablet daily
223776151|NCT05585333|DEVICE|MLS laser|Treatments were performed with MLS laser (Mphi laser, ASA Srl, Italy). MLS laser is a class IV NIR laser with two synchronized sources (laser diodes). The first one is a pulsed laser diode, emitting at 905 nm, with 25 W peak power. The second laser diode (808 nm) was operated in a continuous mode with power 1 W. Both of the laser beams were synchronized, the locked waves work within the range 1-2000 Hz.
223776152|NCT06294314|PROCEDURE|Fertilized ACL|Fertilized ACL is an acl reconstruction with Bone marrow aspirate, demineralized bone matrix, and an internal brace.
223776153|NCT05739500|OTHER||no intervention, just observation
223776154|NCT04929301|OTHER|Antenatal milk expression|Hand-expression of breast milk in pregnancy
223776155|NCT04929301|OTHER|Education handouts|Educational breastfeeding handouts
223688625|NCT05165745|BEHAVIORAL|Individualized Feedback|Participants taking PrEP will receive questionnaires regarding self-reported weekly PrEP adherence; they will then receive individualized text-message or email feedback based on their self-reported adherence.
223688626|NCT03833518|OTHER|Rehabilitation using motorized glove for stroke and spinal cord injury|Individuals with hand impairment due to stroke or spinal cord injury will wear a motorized glove (Gloreha Sinfonia), or exoskeleton, as part of a rehabilitation protocol to improve dexterity. For each exercise, participants will attempt to do the action, receiving assistance as necessary via powered motors that can move each finger through its passive range of motion based on the current and target position.
223688627|NCT03833518|OTHER|Functional MRI for stroke and spinal cord injury|All participants will undergo 3 functional MRI's (fMRI's), two at the beginning of the experiment to document brain activity related to movement intention and ability to sense movement. A third MRI will be performed after the rehabilitation is completed to document the change in brain activity related to movement intention and ability to sense movement.
223688628|NCT03833518|OTHER|Transcranial magnetic stimulation (TMS) for stroke and spinal cord injury|Stimulation of the nervous system may be performed using a magnetic stimulator. TMS of the central nervous system is optional. Whether or not a participant undergoes TMS will depend upon their consent, their eligibility for TMS (i.e. no seizure history), and their neurological response to TMS.
223776156|NCT00220818|DRUG|Lansoprazole|Lansoprazole 1.0 mg/kg/day suspension, orally, once daily for up to 5 days.
223776157|NCT00220818|DRUG|Lansoprazole|Lansoprazole 2.0 mg/kg/day suspension, orally, once daily for up to 5 days.
223776158|NCT04284189|OTHER|Transition model|Transition of follow-up care of childhood cancer survivors to adult care
223776159|NCT05845125|OTHER|Physiotherapy alone|Physiotherapy focusing on increasing the shoulder range of motion.
223688629|NCT04101201|DIETARY_SUPPLEMENT|µSmin® Plus|µSmin® Plus is a new Micronized Diosmin Formulation for oral administration. Diosmin is extremely well tolerated and safe to use. Diosmin is safe for most people when used short-term for up to 6 months. During the 8 weeks of the clinical investigation, the subject will administer 1 tablet of µSMIN® Plus (corresponding to 450 mg of micronized diosmin) or placebo per day.
223688630|NCT04101201|OTHER|Placebo|It will be supplied by the Sponsor in an amount enough for the duration of the study. The subject will administer 1 tablet per day
223688631|NCT04279288|DEVICE|Hilotherm mask|a cooling mask used to treat localized swelling and bleeding
223688632|NCT03793868|DRUG|Perampanel|Oral tablet
223688633|NCT03793868|OTHER|Placebo|Placebo (not drug)
223688634|NCT05547022|PROCEDURE|Endovascular revascularisation|Peripheral vascular angioplasty or stenting
223688635|NCT03934814|DRUG|TJ011133|TJ011133 will be administered weekly.
223688636|NCT03934814|DRUG|Pembrolizumab|Pembrolizumab will be administered every 3 weeks.
223688637|NCT03934814|DRUG|Rituximab|Rituximab will be administered weekly for 5 doses, then followed by monthly doses.
223688638|NCT03348384|RADIATION|[C-11]|Radiolabel
223688639|NCT03348384|DRUG|NOP-1A|Tracer
223688640|NCT03303703|OTHER|RENEwS|The intervention participants will meet with a trained interventionist for five 60-minute sessions as a group (two groups of five participants each). In the sessions time will be divided between didactic presentation of material, active practicing of techniques, group work focused on case studies, and worksheets for further practice at home. Topics covered within the intervention include emotional awareness, balancing emotional and physical wellbeing, selecting and implementing emotion regulation strategies (such as situation selections, mindfulness, engagement/avoidance, reappraisal, and emotional sharing), and emotional monitoring.
223688641|NCT04964284|BIOLOGICAL|rhTSH|rhTSH (0.9 mg) was administered intramuscularly (IM) once daily (qd) for 2 days. Twenty-four hours following the second dose of rhTSH
223688642|NCT04964284|RADIATION|Radioiodine (131I)|Patients were given an ablative dose of 131I (30 mCi±1.5 mCi).
223688643|NCT02648321|BEHAVIORAL|Motivational Interviewing|Motivational Interviewing is a patient-centered, tailored counselling intervention for exercise, through which patients' motives to change are identified. Personal ideas and ambivalence are explored. The discrepancies between the present behavior and the patient's own future goals are amplified. The patient's intrinsic motivation for change is increased through the process.
223688644|NCT02648321|BEHAVIORAL|Health Education|General education about healthy lifestyle and diet.
223688645|NCT03347708|BIOLOGICAL|IDCT|Discogenic Cells + Sodium Hyaluronate Vehicle
223688646|NCT03347708|DRUG|Saline Solution|Sodium Chloride Solution
223688647|NCT03347708|DRUG|Sodium Hyaluronate|Sodium Hyaluronate Vehicle
223688648|NCT03094039|PROCEDURE|Ventilatory support while attached to the cord|Infants will receive active resuscitative care (intubation and ventilation) using a specific designed platform for 120 seconds during delayed cord clamping. Then the cord will be clamped forgoing resuscitation care.
223688649|NCT03094039|PROCEDURE|Immediate cord clamping|Infants will receive immediate cord clamping, transferred to the resuscitation table, intubated and mechanical ventilated according to our current Congenital Diaphragm Hernia protocol.
223688650|NCT02707809|DRUG|Dexmedetomidine|Dexmedetomidine infusion
223688651|NCT03125291|BEHAVIORAL|Bridges 4-week Program|Participants receive 4, 2-hour sessions over a 6-week period.
223688652|NCT01818960|PROCEDURE|IRA-PCI|IRA only PCI at the time of Primary PCI
223688653|NCT01818960|PROCEDURE|SS-PCI|Same sitting multivessel PCI as an adjunct to primary PCI
223688654|NCT01574079|OTHER|Traditional Physical Therapy|Traditional physical therapy includes, but is not limited to, therapeutic exercise, functional mobility training, pre-gait and gait activities, electrotherapeutic modalities, and education.
223688655|NCT01574079|OTHER|Physical Therapy plus Mirror Therapy|The treatment group will receive traditional physical therapy intervention as described in the control group with the addition of mirror therapy. The participant will attempt to perform the flexion exercises with both lower extremities. The patient will be blinded to the affected lower extremity with a mirror, and will be looking at the image of the unaffected lower extremity superimposed on the affected lower extremity as he or she performs the activities.
223688656|NCT02865343|DEVICE|Non-invasive Ventilation(NIV)|The ventilator will be set in spontaneous mode with a ramp to reach a minimal pressure of 12 centimeters of water (cmH2O) during inspiration and 3 cmH2O during expiration.
223688657|NCT02865343|DEVICE|Sham Non-invasive ventilation(NIV)|The ventilator will be set in spontaneous mode with a ramp to reach a maximal pressure of 5 centimeters of water (cmH2O) during inspiration and 3 cmH2O during expiration.
223688658|NCT00924417|BEHAVIORAL|Routine Care|Parent given placebo intervention that entails brief information about what is routine care for intravenous line placement in the emergency department
223688659|NCT00924417|BEHAVIORAL|Distraction|"Parent given brief information about the cognitive behavioral technique known as distraction. Parent and child then given 3 distraction toys/tools to assist with peripheral intravenous line placement."
223688660|NCT06324929|BEHAVIORAL|CARRII Native Rapid Pilot Testing|The candidates that will be tested are: 1) Telephone-administered 30 day timeline follow-back of drinking, sex, and contraception, administered by phone at enrollment and monthly, which should increase awareness of AEP risk and motivation for alcohol and contraception behavior change, 2) Mailed pregnancy tests sent monthly to raise consciousness of pregnancy risk and to detect a new pregnancy early, which should increase motivation for contraception behavior change, 3) Automated, personalized digital safer sex and drink counting/reduction skills training, to improve drinking self-management skills and self-efficacy for drinking reduction and contraception use, 4) Fully automated text messages prompting usage of safer sex and drink reduction skills, which should increase self-efficacy for behavior change, and 5) access to an anonymized Community Message Board of Native women to discuss challenges in behavior change, which should increase perceived social support.
223688661|NCT03062410|OTHER|Electronic PRO in daily clinical practice|All patients diagnosed with mRCC initiating TKI anti-VEGF treatment (Sunitinib or Pazopanib) will be invited to complete the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 cancer specific questionnaire and the EQ-5D before each visit with the physician. Questionnaires completion will be done by patients on tablets and/or computer terminals via the CHES software (Computer-based Health Evaluation System) at hospital before consultation or at home via secured portal. Physician will immediately have access to a visual summary of HRQOL evaluation.
223688662|NCT04245371|DRUG|Lidocaine 1.8%|Topical Patch
223688663|NCT04245371|DRUG|Placebo|Matching Placebo Patch
223688664|NCT00028275|DRUG|Gamma Interferon 1b|
223688665|NCT01397812|DEVICE|BreathScanner 1.0|For the HeartsBreath test, breath is collected using BreathScanner 1.0 and sent to central laboratory for analysis for markers of transplant rejection.
223688666|NCT01397812|DEVICE|BreathLink|The BreathLink point-of-care system detects and quantifies the breath VOC's determined to be biomarkers during the development of the Heartsbreath test.
223688667|NCT04071587|DEVICE|Brain Computer Interface training|Training with RecoveriX system.
223688668|NCT04071587|BEHAVIORAL|Control|Standard physiotherapy and occupational therapy according to clinical routines.
223688669|NCT06187675|BEHAVIORAL|Nutrition and Exercise Lifestyle Intervention Program|Nutrition and Exercise components for pregnancy
223688670|NCT03391531|PROCEDURE|Bilateral subcostal TAP block|Echo-guided infiltration of a local anesthetic solution in the plane located between the transversus abdominis muscle and the rectus abdominis muscle
223688671|NCT03724175|DRUG|ursodiol (ursodeoxycholic acid, UDCA)|ursodiol (ursodeoxycholic acid, UDCA) 300 mg two times daily for 10 weeks for UC pouchitis patients
223688672|NCT04192370|DRUG|Cannabidiol 600mg|All subjects will receive 600mg of oral cannabidiol for 3 days in an open-label fashion. Cannabidiol will be provided using Epidiolex™ oral solution 100mg/mL, and the drug will be procured by the Brigham and Women's Hospital (BWH) Investigational Drug Services (IDS) pharmacy. The first dose will be administered at the BWH Center for Clinical Investigation, while doses 2 and 3 will be self-administrated at home. The CBD will be repacked in pre-drawn syringes for the subjects to self-administer at home.
223688673|NCT05128500|PROCEDURE|Total Shoulder Arthroplasty with Permedica's MIRAI|Total Shoulder Arthroplasty with Permedica's MIRAI Modular Shoulder Prosthesis System
223688674|NCT03640559|DRUG|Seroguard|
223688675|NCT03640559|DRUG|Placebos|
223688676|NCT01436162|DRUG|Antidepressant + SPD489 (Lisdexamfetamine dimesylate )|Antidepressant (either escitalopram oxalate, sertraline hydrochloride, venlafaxine hydrochloride extended release or duloxetine hydrochloride) oral, once daily + SPD489 (oral, 20, 30, 50 or 70 mg, once daily) for 8 weeks
223688677|NCT01436162|DRUG|Antidepressant + Placebo|Antidepressant (either escitalopram oxalate, sertraline hydrochloride, venlafaxine hydrochloride extended release or duloxetine hydrochloride) oral, once daily + Placebo (oral, once daily) for 8 weeks
223688678|NCT04157556|OTHER|Yo-Yo Intermittent Recovery Test Level 1|"The test is a standard test battery with progressively increasing speeds. After every 40-m run (2x20 m), active rest is performed by walking or jogging at a distance of 10 m (2x5 m). for 10 seconds. Participants are trying to adjust their speed according to incoming audio signals.The test is terminated when the participants can not reach the signal twice. The test ends in 10-20 minutes depending on the level of participants.~Reference Bangsbo, J., Iaia, F. M., \& Krustrup, P. (2008). The Yo-Yo intermittent recovery test. Sports medicine, 38(1), 37-51.~Krustrup, P., Mohr, M., Amstrup, T., Rysgaard, T., Johansen, J., Steensberg, A., ... \& Bangsbo, J. (2003). The yo-yo intermittent recovery test: physiological response, reliability, and validity. Medicine \& Science in Sports \& Exercise, 35(4), 697-705."
223688679|NCT04184258|BIOLOGICAL|Pooled mesenchymal stem cell|Pooled allogenic mesenchymal stem cell derived from olfactory mucosa
223688680|NCT04184258|OTHER|Standard treatment according to the Clinical protocols|Standard SLE treatment according to the Clinical protocols approved by the Ministry of healthcare of Republic of Belarus
223688681|NCT00946400|OTHER|Scoring 4Ts and Chong scale|Two physicians will independently score both the 4Ts and the Chong scale on all patients enrolled in this study.
223688682|NCT00946400|OTHER|Blood draw|Patient serum will be collected to perform Serotonin Release Assay testing to verify the presence of HIT.
223688683|NCT00805233|DRUG|combination ranibizumab + bromfenac|ranibizumab injection in study eye each month for 4 months then as needed each month for 8 months. Plus one drop of bromfenac in the study eye twice per day, each day, for 12 months.
223688684|NCT00805233|DRUG|ranibizumab injection alone|ranibizumab injection in study eye each month for 4 months then as needed each month for 8 months
223688685|NCT01825954|DEVICE|RINCE|The intervention uses the NeuroPoint device to deliver repeat applications of RINCE therapy stimulation. The sham uses the NeuroPoint device, but the RINCE therapy stimulation is not turned on.
223688686|NCT05270161|PROCEDURE|Tunnel technique|Intrasulcular incisions on the buccal surface were made using a n°15 C blade, preserving the integrity of the papillae. The incision was extended to the adjacent tooth on both sides of the multiple recessions. Dissection of the entire buccal aspect was performed as a partial-thickness flap using sharp tunnel elevators preserving the papillae. The flap was extended beyond the mucogingival junction and under each papilla allowing a tension-free flap mobilization in the coronal direction. The connective tissue graft was placed in the tunnel and was stabilized using absorbable suspensory sutures. The mobilized mucous flap was advanced coronally to the cemento enamel junction, and suspensory sutures were stitched.
223688687|NCT05270161|PROCEDURE|Laterally closed tunnel technique|Intrasulcular incisions on the buccal surface were made using a n°15 C blade, preserving the integrity of the papillae. The tunnel elevators were mobilized apically beyond the mucogingival line and extended medially and distally from the recession defect by undermining the facial surface of the interdental papillae. The insertion of muscles and fibers must be removed until a tension-free flap is obtained in the mesial, apical and distal directions. The preparation of the flap will be done carefully to avoid rupture of the papillae and perforation of the flap. As a result of this procedure, the mesial and distal margins of the flap must be brought together without tension to cover the exposed part of the root surface. The connective tissue graft was placed in the tunnel and was fixed mesially and distally at the inner aspect of the flap. Margins of the flap were pulled together over the graft and sutured with interrupted sutures.
223776160|NCT05845125|DRUG|Glenohumeral injection of 40mg (1cc) of Triamcinolone and 7cc of 0.5% Bupivacaine coupled with physiotherapy|"The patient will lie supine on the radiology table. Proper skin disinfection will be done with Soluprep x 3 and sterile draping will be applied. An anterior view of the shoulder will be obtained with the fluoroscopic C-arm. Location of the injection site will be obtained with a radio-opaque stylus. Proper local anesthesia will be performed using approximately 1cc of 0.5% Bupivacaine intradermal. A 22G 3.5 spinal needle will be placed in the glenohumeral joint under fluoroscopic guidance using the anterior approach. A small amount (1cc) of iodine-based contrast agent (Omnipaque) will be injected under live fluoroscopic imaging to confirm the intra-articular position of the needle in the glenohumeral joint. In the event of a known iodine contrast allergy, no contrast agent will be used. A combination of 40mg (1cc) of Triamcinolone and 7cc of 0.5% Bupivacaine will be injected into the glenohumeral joint."
223688688|NCT05270161|PROCEDURE|Free gingival graft|In the recipient area, a marginal horizontal linear incision will be made in the mucogingival junction with a n°15 C blade, creating a partial thickness flap, keeping the periosteum intact. The horizontal dimension of the receiving area will be determined according to the mesiodistal extension of the area without keratinized gingiva. All mobile soft tissues, including epithelium, connective tissue and muscle fibers will be removed from the donor area using scissors to ensure stability in the recipient area. The connective tissue graft will be obtained by the free gingival graft technique and will be sutured in the recipient area.
223688689|NCT05270161|PROCEDURE|Gingival graft - donor area|The connective tissue graft will be obtained by the free gingival graft technique for all groups (T1, T2, T3 and T4). The mold of the prepared receiving area will be performed using sterile aluminum foil. The mold will be transferred to the donor area on the palate and the edges of the mold delimited with a scalpel blade. Deeper incisions will be made on the edges with the scalpel perpendicular to the palate, aiming to obtain a graft approximately 1.5 mm thick. With the scalpel blade parallel, the graft will be removed (epithelium and connective graft) maintaining its uniform thickness. For T1 and T2, the free gingival graft will be de-epithelialized. In donor area, a hyaluronic acid gel and green tea will be applied by the participant 3 times a day for 7 days (gel group) or no material will be placed in the donor area and the clot will be kept in position by means of sutures (clot group).
223688690|NCT02828527|OTHER|Observational|
223776161|NCT05800054|DIETARY_SUPPLEMENT|Nutritional Support Team|Nutritionists formulate nutritional programs and manage them in a refined manner. On the basis of the patient's natural diet (food and homogenate meal), enteral nutritional preparations or parenteral nutritional supplements are given according to the patient's gastrointestinal obstruction, dietary structure, and food intake. Energy 30-35kcal/kg/d, protein 1.2-1.5g/kg/d. Enteral nutrition administration route: oral or tube feeding or ostomy, oral feeding is preferred; severe obstruction of eating or oral intake cannot meet the target nutrition, choose tube feeding or ostomy. When it is expected that enteral nutrition cannot meet 60% of the target energy requirement for 3 to 5 days, choose parenteral nutrition. The enteral nutritional preparation adopts the whole protein enteral nutritional preparation Nengquan, and/or the tumor nutritional preparation Ruineng, and/or whey protein powder.
223776162|NCT05800054|DRUG|Docetaxel|60-75 mg/m2, d1, at least 2 cycles in parallel with radiotherapy
223688691|NCT01834859|BEHAVIORAL|Multidisciplinary outpatient program|Diet (phase 1) and multidisciplinary lifestyle intervention (phase 2)
223776163|NCT05800054|DRUG|cisplatin|cisplatin 25mg/m2 d1-3, 21-28d/cycle. at least 2 cycles in parallel with radiotherapy
223776164|NCT05800054|RADIATION|Radiotherapy|image-guided intensity-modulated radiotherapy (IGRT) or intensity-modulated radiotherapy (IMRT); Irradiation targets include primary lesions, clinical targets, positive lymph nodes, and lymph node drainage areas. Dose splitting/prescription dose, 95% volume PGTV-T60-66Gy/30-35 times, PGTV-N 60-66Gy/30-35 times, PCTV-T 46-50Gy/23-25 times, PCTV-N46-50Gy/23-25 times.
223776165|NCT01751503|PROCEDURE|Interosseous route of TPTT|Anterior transposition of Posterior tibialis tendon (PTT) is the gold standard for surgical restoration of functional dorsiflexion of a permanently paralyzed foot. Two methods of rerouting the posterior tibialis tendon have been reported, one through the interosseous membrane i.e. Interosseous route and second subcutaneously around the medial side of tibia i.e. Extramembranous or circumtibial route. Both these techniques have been widely described in literature and are being extensively used in surgical management of foot drop. The selection of technique depends on surgeon choice and patient factors
223776166|NCT01751503|PROCEDURE|Extra membranous route of TPTT|Rerouting the posterior tibialis tendon subcutaneously around the medial side of tibia i.e. Extramembranous or circumtibial route (
223776167|NCT00879671|DIETARY_SUPPLEMENT|lutamax (leutein)|leutein 20 mg for 3 months, then lutein 10 mg
223776168|NCT00879671|DIETARY_SUPPLEMENT|placebo|Placebo capsules identical in taste and appearance
223688692|NCT01834859|BEHAVIORAL|Inpatient lifestyle program|Diet (phase 1) and lifestyle intervention (phase 2)
223688693|NCT01467245|PROCEDURE|Hypercapnia during thoracoscopy|keyhole surgery through the chest for repair of oesophageal atresia with tracheo-oesophageal fistula or congenital diaphragmatic hernia in neonates
223776169|NCT02995395|DEVICE|Mucosal Impedance Balloon catheter|"During the clinical endoscopy (a standard procedure that allows your doctor to look at the inside of your swallowing tube), the 2 mm catheter (tiny tube), called an Intraluminal Impedance Balloon, will be passed through the channel of the standard endoscope.~o The catheter (tiny tube) will be placed through the endoscope in your esophagus (swallowing tube) for two minutes, readings from the catheter will be recorded."
223776170|NCT02584309|DRUG|Dexrazoxane|
223776171|NCT02584309|DRUG|Doxorubicin|
223776172|NCT00061048|BIOLOGICAL|Alemtuzumab|Infusion of Campath-1H 3 mg on day # 1, 10 mg on day #2, and 30 mg day # 3 followed by maintenance Campath-1H 30 mg intravenously three times per week. Patients are eligible to receive a maximum of 12 weeks of maintenance Campath-1H treatment.
223688694|NCT01467245|PROCEDURE|Open surgery|open surgery for repair of oesophageal atresia with tracheo-oesophageal fistula or congenital diaphragmatic hernia in neonates
223688695|NCT06307431|BIOLOGICAL|Intismeran autogene|IM injection
223688696|NCT06307431|BIOLOGICAL|Pembrolizumab|IV infusion
223688697|NCT06307431|BIOLOGICAL|Placebo|IM injection
223688698|NCT02600754|BEHAVIORAL|IT-PST|5 sessions of problem-solving therapy by licensed mental health clinicians co-located in an aging-service agency (Meals on Wheels and More)
223688699|NCT02600754|BEHAVIORAL|IT-SCM|5 sessions of self-care management support by trained lay advisers co-located in an aging-service agency (Meals on Wheels and More)
223776173|NCT01114516|DRUG|Indomethacin and antibiotics (cefazolin or clindamycin)|q8hr dosing of po indomethacin 50mg X 24 hrs and q8 hr 1 g IV cefazolin or 600 mg IV clindamycin
223688700|NCT05362578|DEVICE|transcutaneous electrical accustimulation at treatment point.|The transcutaneous electrical accustimulator (TEA) device administers a mild electrical shock through the skin, similar to acupuncture at a location previously seen to provide benefit. The precise distinction between sham and experimental accustimulation is not described upon registration to reduce unblinding risk, to maintain scientific integrity.
223688701|NCT05362578|DEVICE|transcutaneous electrical accustimulation at sham point.|The transcutaneous electrical accustimulator (TEA) device administers a mild electrical shock through the skin, similar to acupuncture at a location which has not been shown to provide benefit. The precise distinction between sham and experimental accustimulation is not described upon registration to reduce unblinding risk, to maintain scientific integrity.
223688702|NCT05032859|DRUG|tapinarof cream, 1%|applied topically once daily
223688703|NCT05032859|DRUG|vehicle cream|applied topically once daily
223688704|NCT05694052|BEHAVIORAL|Multifaceted Intervention of environment control|Dynamic light therapy, auditory masking, and rationalization of ICU nocturnal patient activities.
223688705|NCT05364021|DRUG|LP352|LP352 administered three times daily, orally or through G-tube
223688706|NCT05364021|DRUG|Placebo|Matching placebo for LP352 administered three times daily, orally or through G-tube
223688707|NCT01931085|DRUG|Triclabendazole|Triclabendazole (10 mg/kg body-weight as a single dose).
223688708|NCT02747979|OTHER|hemodialysis only|hemodialysis treatment only
223688709|NCT02747979|OTHER|hemodialysis plus hemoperfusion(HA330)|combination of hemodialysis and hemoperfusion (HA330) treatment
223688710|NCT02747979|OTHER|hemodialysis plus hemoperfusion(HA130)|combination of hemodialysis and hemoperfusion (HA130) treatment
223688711|NCT01764802|OTHER|behavioral, psychological or informational intervention|Participate in enhanced standard care
223688712|NCT01764802|OTHER|behavioral, psychological or informational intervention|Participate in psychological intervention
223688713|NCT06080139|BEHAVIORAL|Refugee parenting education in a participatory community|"Parents will vote for one of the 5 previously studied refugee parenting curriculums: 1) Creating Opportunities Through Mentoring Parenting Involvement and Safe Space (COMPASS); 2) GenerationPMTO; 3) Happy Families; 4) Family Strengthening Intervention for Refugees (FSI-R).~Researchers will use a model of Learning by Observing and Pitching In (LOPI), to empower community members in the learning process. LOPI is a multicomponent way of organizing group learning that improves collaboration, alertness, and executive functions such as perspective-taking and self-regulation in addition to specific skills learning and has been used in many indigenous and indigenous-heritage communities of the Americas."
223776174|NCT00546143|DRUG|Omalizumab|
223776175|NCT00546143|DRUG|Omalizumab|
223776176|NCT00546143|DRUG|Omalizumab|
223688714|NCT01535664|OTHER|Withdrawal of dalfampridine-ER 10mg|"Withdrawal of dalfampridine-ER 10mg (7 days on study drug followed by withdrawal period of 10 days, followed by on study drug until study completion)~* On drug Day-7 (visit 1) through Day 1 (visit 2)~* Off drug Day 5±2 days (visit 3) through Day 11±2 days (visit 4)~* On drug Day 15±2 days (visit 5)"
223688715|NCT02787070|DRUG|PQ supervised|
223688716|NCT02787070|DRUG|PQ unsupervised|
223688717|NCT02283151|DIETARY_SUPPLEMENT|diet nutrition bar|The experimental group was given individual instructions on how to follow the VLCD (very low carbohydrate diet). Energy intake was restricted to less than 800kcal/day (3349kJ/d) (carbohydrate intake \< 20g/d). All daily meals were replaced as follows: a cup of soybean milk (200 mL) and a boiled egg at breakfast; a diet nutrition bar(Nutriease Health Technology Co., Ltd., Hangzhou, China), nonstarchy vegetables (\<200 kcal), and 50 g protein from meat at lunch and dinner. Supplementation of multivitamins and minerals was provided per day.
223688718|NCT02283151|OTHER|energy-restricted diet|The control group was given an energy-restricted diet (ER diet). Energy-restricted diet was designed in the traditional Chinese style with an initial target for a total energy intake of 1200 kcal/d (5021 kJ/d).
223688719|NCT00657826|DEVICE|ATS 3f® Aortic Bioprosthesis, Model 1000, 19mm|Isolated aortic valve replacement with a size 19mm valve
223688720|NCT01586273|DEVICE|MR-HIFU treatment for pain palliation of bone metastases|A treatment session with the Philips Sonalleve MR-HIFU device for bone pain palliation with high-intensity focused ultrasound.
223688721|NCT03456609|DRUG|shenqifuzheng injection|500ml shenqifuzheng daily（at day 1-14 and day22-36）through intravenous infusion.
223688722|NCT03456609|DRUG|Sodium Chloride Injection 0.9%|500ml sodium chloride（0.9%）daily（at day 1-14 and day22-36）through intravenous infusion.
223688723|NCT00700076|DRUG|Ketamine and Org 25935|Oral administration of Org 25935 16 mg and intravenous administration of ketamine (0.23 mg/kg bolus over 1 minute, followed by 0.58 mg/kg/hour x 30 minutes, followed by 0.29 mg/kg/hour x 69 minutes)
223776177|NCT06038682|DRUG|Argatroban Injection|Argatroban will be administered to the study subjects in this group in order to achieve anticoagulation.
223776178|NCT06038682|DRUG|Heparin|Heparin will be administered to the study subjects in this group in order to achieve anticoagulation.
223776179|NCT02755935|DEVICE|Cochlear Nucleus CI532|cochlear implantation
223776180|NCT03436472|DRUG|dexmedetomidine|low-dose dexmedetomidine infusion
223776181|NCT03436472|DRUG|placebo|normal saline infusion
223776182|NCT01092195|BIOLOGICAL|Gardasil|3 separate 0.5 ml intramuscular
223776183|NCT06347354|DRUG|Indocyanine green|Subdermal injection of 2,5 mg (1 cc) of ICG
223776184|NCT01866189|OTHER|PET and MRI|F-MISO PET followed by brain MRI (MRI-1)(diffusion, FLAIR, perfusion, TOF)
223776185|NCT01609556|DRUG|Mirvetuximab soravtansine|Mirvetuximab soravtansine IV infusion will be administered as per dose and schedule specified in the respective arms.
223776186|NCT03049059|DEVICE|Fractional Picosecond 1,064 nm laser|Fractional Picosecond 1,064 nm laser and daily application with 4% hydroquinone cream
223776187|NCT03049059|DRUG|4% hydroquinone cream|
223776188|NCT06573164|DRUG|Bacillus clausii tablets（Qipian®）|Take 4 tablets (0.3 mg each) orally three times daily.
223776189|NCT06573164|DRUG|conventional medication|Use conventional medication as needed based on the patient's condition.
223688724|NCT00700076|DRUG|Placebo and Ketamine|Oral administration of placebo and intravenous administration of ketamine (0.23 mg/kg bolus over 1 minute, followed by 0.58 mg/kg/hour x 30 minutes, followed by 0.29 mg/kg/hour x 69 minutes)
223688725|NCT01742247|OTHER|Physiogel|Application of moisturizer on laser-treated area
223688726|NCT01742247|OTHER|Moisturizer|Application of moisturizer on laser-treated area
223688727|NCT00247533|PROCEDURE|Digital subtraction angiography and 24-hour simultaneous recorder of electrocardiograph|
223688728|NCT01931202|DRUG|Escitalopram|Escitalopram is an antidepressant of the selective serotonin reuptake inhibitor (SSRI) class. It is FDA approved for the treatment of major depressive disorder (MDD) and generalized anxiety disorder (GAD) in adults and children over 12 years of age.
223688729|NCT01931202|DRUG|Placebo oral tablet|Inert substance or treatment which is designed to have no therapeutic value but resemble the active medication in this study
223688730|NCT03272984|PROCEDURE|ERAS group|ERAS is the name of a procedure. Patients in this group need receive the ERAS procedure instead of one drug.
223688731|NCT03272984|PROCEDURE|SC group|Patients were managed in accordance with SC programs during the perioperative period. SC programs were used daily in our center and were still routinely used in most of the other hospitals in China.
223688732|NCT02153710|BEHAVIORAL|Semantic Feature Analysis therapy|Control therapy; current standard of care therapy
223688733|NCT02153710|BEHAVIORAL|Phonomotor Therapy|Experimental therapy.
223688734|NCT00983398|DRUG|Carboplatin|Given IA
223688735|NCT00983398|DRUG|Mannitol|Given IA
223688736|NCT00983398|DRUG|Melphalan|Given IA
223688737|NCT00983398|OTHER|Quality-of-Life Assessment|Ancillary studies
223688738|NCT00983398|OTHER|Questionnaire Administration|Ancillary studies
223688739|NCT00983398|DRUG|Sodium Thiosulfate|Given IV
223688740|NCT05022875|DEVICE|Healthcare CEO app- for experimental app intervention|The app content was designed based on the results of previous qualitative and Delphi studies (Chiang et al., 2021; Chiang et al., 2020) and consists of 11 interfaces: CEO's profile, Health Tracking, CEO Knowledge Base, Barrier-free Communication, See Here: Diet and Exercise, Help Me, Detective!, CEO Chatroom, CEO's Secretary, Who's the Best CEO, SOS Calls, and Q\&A
223688741|NCT05022875|DEVICE|Healthcare CEO app-for control app intervention|consists of 2 interfaces: CEO's profile, Health Tracking.
223688742|NCT05748665|DRUG|Remimazolam besylate|Using remimazolam for induction of general anesthesia
223688743|NCT05748665|DRUG|etomidate|Using etomidate for induction of general anesthesia
223688744|NCT05333081|OTHER|Consumption of rice for evaluation of the glycemic index|The test of each food was carried out for a maximum time of 120 minutes, by carrying out repeated measurements of the glycaemia of all subjects at a distance of 0, 15, 30, 45, 60, 90 and 120 minutes from the administration of the sample in order to obtain a glycemic curve for each sample considered.
223688745|NCT05049733|DRUG|CBD 1mg/Kg|Participants will ingest soft gel tablets containing CBD 1mg/Kg
223688746|NCT05049733|DRUG|CBD 2mg/Kg|Participants will ingest soft gel tablets containing CBD 2mg/Kg
223688747|NCT05049733|DRUG|CBD 4mg/Kg|Participants will ingest soft gel tablets containing CBD 4mg/Kg
223776190|NCT05797805|DRUG|Tegavivint|"The first part is a phase 1 single-agent dose escalation, optimization, and expansion study of tegavivint in patients with advanced HCC after failure of at least one line of prior systemic therapy.~Tegavivint single agent dosing regimen: Tegavivint will be administered weekly on Days 1, 8, 15, and 22 of a 28-day cycle"
223688748|NCT05049733|DRUG|Placebo CBD|Participants will ingest soft gel tablets containing placebo for CBD
223776191|NCT05797805|DRUG|Lenvatinib|"In the second part of the study, the combination of tegavivint plus lenvatinib will be assessed with a limited dose escalation followed by a randomized dose optimization.~Tegavivint plus lenvatinib combination dosing regimen: Tegavivint will be administered weekly on Days 1, 8, and 15 and 22 of a 28-day cycle; lenvatinib 8 mg (patients \< 60 kg) or 12 mg (patients ≥ 60 kg) will be administered once daily on days 1-28 of a 28-day cycle ."
223776192|NCT05797805|DRUG|Cabozantinib|"In the second part of the study, the combination of tegavivint plus cabozantinib will be assessed with a limited dose escalation followed by a randomized dose optimization.~Tegavivint plus cabozantinib combination dosing regimen: Tegavivint will be administered weekly on Days 1, 8, and 15 and 22 of a 28-day cycle; cabozantinib 60 mg (patients with Child-Pugh A) or 40 mg (patients with Child-Pugh B) will be administered orally once daily on days 1 through 28 of each 28-day cycle"
223688749|NCT00193193|DRUG|Paclitaxel|
223688750|NCT00193193|DRUG|Estramustine|
223688751|NCT00193193|DRUG|Carboplatin|
223688752|NCT05538819|DRUG|Glimepiride|Glimepiride 1-4 mg/day
223688753|NCT06267001|DRUG|Atezolizumab|Atezolizumab will be administered IV.
223688754|NCT06267001|DRUG|Tiragolumab|Tiragolumab will be administered IV.
223688755|NCT06267001|DRUG|Placebo|Placebo will be administered IV.
223688756|NCT02145702|OTHER|Aerobic Exercise|Each exercise session will be conducted at the KUMC Exercise and Cardiovascular Health (REACH) Laboratory. Exercise sessions will include a warm-up period, exercise period and a cool down period. Exercise intervention individualized based on health of participant. Subject will be asked to completed two exercise sessions per week for 12 weeks.
223688757|NCT02145702|PROCEDURE|Standard Care Dialysis|12 weeks of standard of care.
223688758|NCT02186132|DRUG|Atropine 0.6 mg|Atropine 0.6 mg intravenous
223688759|NCT02186132|DRUG|Atropine 1.2 mg|Atropine 1.2 mg intravenous
223688760|NCT03894592|OTHER|Virtual reality|Trauma patients enrolled in the study will be offered Virtual Reality experieince per the protocol
223688761|NCT04468932|DEVICE|Repetitive transcranial magnetic stimulation (rTMS)|"Aim 1: To determine the clinical effects of rTMS targeting the cerebellum on postural instability in PSP. The hypothesis to be tested is that TMS augmentation of cerebellar inhibition will improve cerebellum-dependent balance symptoms of PSP for a period of time sufficient to improve rehabilitation outcomes. The investigators will measure a battery of objective posturography metrics and other measures of motor control, including sway and center of pressure changes to backward tilt and forward translation.~Aim 2: We will use functional near infrared spectroscopy (fNIRS) to examine changes in motor and premotor cortical activity after cerebellar rTMS. The hypothesis to be tested is that premotor and motor cortical activity will decrease after cerebellar rTMS compared to sham TMS, reflecting improved cerebellar inhibition of the motor cortex after the intervention."
223688762|NCT06429761|DRUG|Trastuzumab deruxtecan|IV infusion Trastuzumab deruxtecan will be administered at 5.4 mg/kg on day 1 of a 21 day cycle for 9 cycles.
223688763|NCT03041012|DRUG|Romidepsin|5mg/m2 romidepsin will be administered IV on days 10, 17, and 24 after initiating ART
223688764|NCT03041012|DRUG|3BNC117|30 mg/kg 3BNC117 will be administered IV on day 7 and 21 after initiating ART
223688765|NCT03041012|DRUG|Antiretrovirals|Combination antiretroviral therapy
223688766|NCT01770587|BEHAVIORAL|Behavioral Insomnia Treatment|
223688767|NCT06575946|DIAGNOSTIC_TEST|Vestibular Hypofunction Group|Demographic information form, vestibular tests, balance tests will be used in the evaluation. The demographic information form includes demographic information (name, surname, gender, smoking, alcohol use, etc.) and clinical conditions (past illnesses and/or surgeries, medications used, whether there is a history of falls, if any, frequency, whether they are afraid of heights and uncomfortable in the dark, etc.). The patients will be diagnosed with videonystagmography (VNG) after the decision of the ENT physician, and their hypofunction levels will be recorded. Vestibular and balance tests will be applied to the patients in the clinical setting. At the end of the study, it will be examined whether there is a relationship between the degree of vestibular hypofunction and the vestibular tests applied in the clinic.
223688768|NCT04059705|BEHAVIORAL|Dual-Task Training|The ThinkFIT intervention will involve two days per week participation in simultaneous cognitive and motor training activities, facilitated by the SMARTFit Multisensory FItness System.
223688769|NCT05545163|DEVICE|I-gel with standard insertion technique|"Standard I-gel insertion technique (grasping I-gel from integral bite block site and cuff facing towards chin and pressing down the manikin chin. I-gel introduced in patient's mouth in a direction towards hard palate. Then I-gel slided downwards and backwards along hard palate with a continuous but gentle push until a definitive resistance is felt)~Modified jaw thrust technique (grasping I-gel from integral bite block site and cuff facing towards chin and pressing down manikin chin. I-gel introduced in patient's mouth in a direction towards hard palate with gently advancing into oropharynx. Then after, I-gel left in oral cavity and both hands used to thrust jaw by lifting angle of mandible with little fingers and other fingers to stabilise jaw. And, at this point, both hand's thumbs used to apply balance force from I-gel stem head towards final placement position by looking at integral bite block mark at incisor teeth level)"
223688770|NCT05606874|OTHER|Pre-heating of flowable resin composite used as a pit and fissure sealant.|The occlusal fissures will be etched with a 37% phosphoric acid gel for 30 s. After rinsing the enamel with water for 30 s the enamel will be dried for 15 s with compressed air. After completing the fissure preparations a single coat of adhesive (3M ESPE ADPER ,USA) will be applied to the etched surface ,dried under gentle air flow for 2- 3 s and light cured for 20 s using a LED light curing unit with a 1000 mw output .Conventional resin fissure sealant (total etch), (UltraSeal XT®, Ultradent, USA) will be applied to the etched pits and fissures. After removing the rubber dam the occlusion will be checked the sealant will be adjusted with a composite finishing bur and polished with polishing points.
223776193|NCT06327126|PROCEDURE|two-session ERCP|early endoscopic drainage followed by endoscopic stone extraction
223776194|NCT06327126|PROCEDURE|single-session ERCP|directly endoscopic stone extraction
223776195|NCT02109588|BEHAVIORAL|A supervised physical exercise program|"Supervised physical conditioning program of three 55-60 minute sessions per week during whole pregnancy (from week 9 to 38). Each session consists of 25-30 minutes of cardiovascular exercise,10 minutes of specific exercises (strength and balance exercises), and 10 minutes of pelvic floor muscles training~Aerobic activity was prescribed at light to moderate intensity, aiming for 55-60% of heart rate reserve. All subjects wore a heart rate (HR) monitor (Polar FT7) during the training sessions to ensure that exercise intensity was light to moderate"
223776196|NCT02287415|DRUG|BIA 2-093|
223776197|NCT02287415|DRUG|Warfarin|
223688771|NCT05606874|OTHER|Conventional resin fissure sealant|The occlusal fissures will be etched with a 37% phosphoric acid gel for 30 s. After rinsing the enamel with water for 30 s the enamel will be dried for 15 s with compressed air. After completing the fissure preparations a single coat of adhesive (3M ESPE ADPER ,USA) will be applied to the etched surface ,dried under gentle air flow for 2- 3 s and light cured for 20 s using a LED light curing unit with a 1000 mw output .Conventional resin fissure sealant (total etch), (UltraSeal XT®, Ultradent, USA) will be applied to the etched pits and fissures. After removing the rubber dam the occlusion will be checked the sealant will be adjusted with a composite finishing bur and polished with polishing points.
223688772|NCT00655941|BEHAVIORAL|Dietary instruction|Weekly instruction by dieticians
223688773|NCT00655941|OTHER|Exercise|Supervised exercise in groups
223688774|NCT00025675|DRUG|gefitinib|
223688775|NCT01419262|DRUG|Vitamin D - Cholecalciferol 400 IU|One drop per day (liquid), 400 IU, 4 to 9 months depending on date of enrollment and date of follow-up
223688776|NCT01419262|DRUG|Vitamin D3 - Cholecalciferol 2000 IU|One drop per day (liquid), 2000 IU, 4 to 9 months depending on date of enrollment and date of follow-up
223688777|NCT01069185|PROCEDURE|Necessity endotracheal suctioning|Endotracheal suctioning depends on clinical manifestations
223688778|NCT01069185|PROCEDURE|Routine endotracheal suctioning|Endotracheal suctioning every two hours
223688779|NCT05745194|BEHAVIORAL|Promotion of adherence to the MedDiet|"Participants will be followed in six individual nutrition consultations with a duration of 30 to 60 minutes. The consultations will be focused on promoting the adherence to the MedDiet.~The nutritional intervention will be personalized to each individual ad libitum, without calories or macronutrients restriction and without the goal to promote weight change. The intervention will begin with an initial assessment of the dietary patterns of the participants in which the nutritionist will identify potential behavioural changes to promote adjustments in dietary habits and therefore adherence to the MedDiet.~The intervention will promote positive recommendations (behaviours recommended to follow) and negative recommendations (behaviours recommended to reduce or eliminate) (26), using the strategy and MedDiet definition proposed by Estruch et al. in the Primary Prevention of Cardiovascular Disease with a Mediterranean Diet study (3).~The participants will also maintain MDD TAU."
223688780|NCT06491329|OTHER|high-intensity interval training|high-intensity interval training ： 40-50 minutes, patients engage in power cycling with intervals of high-intensity exercise at 75%-100% of VO2peak for 30s-1min, followed by 30s-1min of passive recovery, totaling 15-25 cycles.
223688781|NCT06491329|OTHER|moderate-intensity interval training|40-50 minutes, involves power cycling with 8 minutes of moderate-intensity exercise at 40%-60% of VO2peak followed by 2 minutes of passive recovery, totaling 4 cycles.
223688782|NCT00033852|PROCEDURE|Massage Therapy|
223688783|NCT00474981|BEHAVIORAL|IMNCI|Implementation of IMNCI in the intervention sites
223688784|NCT06247527|BEHAVIORAL|Psychoeducation, Relaxation, PrOblem solving, Activation, Cognitive coping Therapy|This is a brief transdiagnostic psychological intervention based on the trauma-focused cognitive behavioral therapy (TF-CBT) designed for delivery by non-specialist providers to adolescents and youth with psychological distress
223688785|NCT06247527|BEHAVIORAL|Standard of care|Any intervention, including counseling, provided as a routine intervention at the HIV clinic selected as a control clinic
223688786|NCT01564446|OTHER|Participants will receive a internet based secure message confirming adherence to post-discharge medication regimen|Participants will receive a internet based secure message via My HealtheVet (MHV), The VA's online medical record and secure messaging portal. The message will specify post-discharge prescribed medications and inquire about adherence to these medications.
223688787|NCT01697098|DRUG|Dexamethasone 24 hours|
223688788|NCT01697098|DRUG|Dexamethasone 12|
223688789|NCT02211638|DRUG|Candesartan Cilexetil|Candesartan Cilexetil tablet
223688790|NCT03237195|OTHER|additional soft tissue in neck dissections|Evaluation of submission of additional soft tissue in neck dissections for head and neck squamous cell carcinomas
223688791|NCT04029155|DEVICE|Lung biopsy|Transbronchial Needle Aspiration performed via a ultra thin bronchoscope
223688792|NCT01260961|DIETARY_SUPPLEMENT|Placebo|The volunteers will start on the 200 mg daily of the placebo and will not increase their dose during the study.
223776198|NCT02746614|OTHER|Psychomotor Therapy|Psychomotor Therapy
223776199|NCT00265811|DRUG|Folfox|
223776200|NCT00265811|DRUG|Cetuximab|
223776201|NCT03211741|DRUG|Bevacizumab Injection [Avastin]|Bevacizumab 1.25mg/0.05 mL will be injected intravitreally using one 30-gauge x 1/2-inch injection needle vials are for single eye use only.
223776202|NCT02206126|BEHAVIORAL|Energy Restriction|The energy restriction group was instructed to follow an energy-restricted diet (-800 kcal/day).
223688793|NCT01260961|DIETARY_SUPPLEMENT|Docosahexanoic Acid|The volunteers will start on the 200 mg daily of the DHA capsule and will not increase their dose during the study.
223688794|NCT02775903|DRUG|Azacitidine|Administered by subcutaneous injection on Days 1 to 7 of each 4-week treatment cycle.
223688795|NCT02775903|BIOLOGICAL|Durvalumab|Administered by intravenous infusion on Day 1 of every 4-week treatment cycle.
223688796|NCT04041700|DEVICE|Osia 2 system|System includes the OSI200 implant surgically placed under the skin behind the ear, the BI300 implant osseointegrated in the bone and the external Osia 2 sound processor.
223688797|NCT06404346|DIAGNOSTIC_TEST|High Velocity Thrust|Group A Participants assigned to the HVT will receive manual therapy sessions consisting of specific manipulative techniques targeting the sacroiliac joint and surrounding structures. participant lying on your side or on your stomach, depending on which SI joint needs to be manipulated.The physiotherapist will stabilize body to isolate the specific SI joint that needs adjustment. This may involve holding certain parts of your body in place or using props like a belt or cushion.With precise control and speed, the physiotherapist will apply a sudden thrust to the targeted SI joint. This thrust aims to mobilize the joint and restore its normal function. This procedure will perform in 3 sessions per week for 2 weeks
223688798|NCT06404346|OTHER|Bowen therapy|participants will undergo sessions involving gentle, rolling movements over muscles, tendons, and ligaments in sacroiliac joint . participant lie comfortably on a treatment bed fully clothed, typically face down or on your side. The physiotherapist will perform a series of gentle, rolling movements with their fingers and thumbs over specific points on your body, including the lower back, hips, and buttocks. These moves are designed to stimulate the nervous system and promote relaxation and healing in the affected area.
223688799|NCT03173534|DEVICE|WATCHMAN|WATCHMAN Device is composed of a self-expanding nitinol structure with a porous membrane on the proximal face. The implant device is delivered to the Left Atrial Appendage by femoral venous access and transseptal puncture to enter the left atrium.
223688800|NCT03173534|DEVICE|TAVR|Transcatheter Aortic Valve Replacement
223688801|NCT05611125|OTHER|Telehealth Integrated Primary Care (TIPC)|The TIPC model of intervention incorporates video visits across research clinicians and patients' existing care clinicians for more synergized and accessible care provision for a given clinical indication. The first TIPC visit will center around the patient setting care goals for themselves and their caregiver with the help of a palliative care physician. The second TIPC visit will focus on assessing goal attainment and also close the care loop between their existing care team, a research-appointed palliative care team, and their involvement in our study.
223688802|NCT00188799|PROCEDURE|daily Xray volume imaging for planning radiotherapy|
223688803|NCT01284673|OTHER|in vitro characterization of the cord blood stem cell|The quantitative and qualitative, functional characterization will insist on cell populations which could potentially participate to neuronal regeneration. and assessment such characteristics in conditions of cryo-preservation, compared to fresh cell preparation
223688804|NCT04881656|OTHER|Help is in Your Hands|HIIYH is a set of 16 online educational modules for caregivers of children with social-communication delays or elevated likelihood of ASD.
223688805|NCT04588532|DRUG|BAM8-22|Bovine Adrenal Medulla will be applied to 2 previously determined area on the volar forearm (one alone and one in combination with doxepin)
223688806|NCT04588532|DRUG|Histamine|histamine will be applied to 2 previously determined area on the volar forearm (one alone and one in combination with doxepin)
223688807|NCT04588532|DRUG|Cowhage (Mucuna Pruriens)|cowhage spicules will be applied to 2 previously determined area on the volar forearm (one alone and one in combination with doxepin)
223688808|NCT04588532|DRUG|Doxepin|Doxepin cream (antihistamine) will be applied in 4 areas on the volar forearm
223688809|NCT03868982|DEVICE|Neurally adjusted ventilatory assist|NAVA uses the diaphragm activity to deliver mechanical ventilation
223688810|NCT02861378|DRUG|Phentolamine mesylate|Injection of 1ml at lidocaine injection site
223688811|NCT02861378|DRUG|Water|Injection of 1ml of physiologic saline water at injection site
223688812|NCT04104542|BEHAVIORAL|Mindfulness based stress reduction|on-line training on the website = www.palousemindfulness.com
223688813|NCT04104542|BEHAVIORAL|Healthy Lifestyle|Diet and Exercise
223776203|NCT06428201|DIAGNOSTIC_TEST|Control Group|The control group receives standard care, which includes routine medical management and general physical rehabilitation exercises. This involves regular consultations with healthcare providers and exercises aimed at maintaining mobility and physical function. The control group also follows a schedule of three 45-minute sessions per week for 12 weeks, ensuring a consistent comparison with the experimental group.
223776204|NCT06428201|COMBINATION_PRODUCT|Experimental Group|The experimental intervention involves tele-rehabilitation-based task-specific training to enhance cognitive functions in multiple sclerosis (MS) patients. This program includes cognitive exercises targeting memory, attention, executive function, and processing speed, conducted remotely via a tele-rehabilitation platform. Patients participate in three 45-minute sessions per week for 12 weeks. Each session is guided by a trained therapist, ensuring personalized support and real-time feedback.
223776205|NCT00951210|BIOLOGICAL|PLX-PAD|IM injection
223776206|NCT06534021|DRUG|IASO-782 injection|Each subject will be given only one dose of IASO-782. Subjects should avoid strenuous exercise within 48 h before administration and remain seated or semi-recumbent (except for necessary activities) for 4 h after administration. IASO-782 solution for injection or placebo was diluted in 0.9% sodium chloride injection (corresponding to the dose administered according to the body weight at baseline and the dose group) with a total volume of 250 mL, administered as a single intravenous drip at a drip rate recommended by the drug manual on the day of administration, The infusion time is about 90 minutes (± 15 minutes).
223776207|NCT06534021|DRUG|placebo|Each subject will be given one dose of placebo. Subjects should avoid strenuous exercise within 48 h before administration and remain seated or semi-recumbent (except for necessary activities) for 4 h after administration. IASO-782 solution for injection or placebo was diluted in 0.9% sodium chloride injection (corresponding to the dose administered according to the body weight at baseline and the dose group) with a total volume of 250 mL, administered as a single intravenous drip at a drip rate recommended by the drug manual on the day of administration, The infusion time is about 90 minutes (± 15 minutes).
223776208|NCT00810121|DRUG|ketoprofen 100 mg|100 mg b.i.d. for 5 days
223776209|NCT00810121|DRUG|ketoprofen|150 mg b.i.d. for 5 days
223776210|NCT03765957|BIOLOGICAL|Mesenchymal Stem Cells|After the subjects are screened and qualified, random number envelopes will be selected to group 12 subjects into group A, group B, group C and group D at a ratio of 1:1:1:1. The subjetcts of group A and B will be injected intravenously with 1.5x10E6/kg and 2.0x10E6/kg（according to the weight of subject）mesenchymal stem cells respectively at baseline and every 2 weeks, 4 times is a course of treatment. Subjects will be followed up for evaluation on 15 days, 30 days, 45 days, month 2, month 3 and month 6 after treatment. The subjetcts of group C and D will be injected intravenously with 2.5x10E6/kg and 3.0x10E6/kg （according to the weight of subject）mesenchymal stem cells respectively at baseline and every 4 weeks, 2 times is a course of treatment. Subjects will be followed up for evaluation on 15 days, 30 days, 45 days, month 2, month 3 and month 6 after treatment. Besides MSCs, moisturizers such as boric acid ointment will be given to all subjects.
223776211|NCT03966235|DRUG|Melatonin 3 mg|Melatonin was taken daily for 6 months.
223776212|NCT03966235|DRUG|Placebo|Placebo tablet was taken daily for 6 months.
223776213|NCT05781035|PROCEDURE|dexmedetomidine|patients will recieve moderate sedation by dexmedetomidine as study group
223776214|NCT05781035|PROCEDURE|general anesthesia|general anesthesia with neuromuscular blockade under controlled ventilation as control group.
223688814|NCT06259799|BEHAVIORAL|Smart Water Bottle|Participants in the intervention group will receive a bottle which measures participant fluid consumption. The bottle will be set to recommend 2.5L for male participants and 2.0L for female participants, consistent with fluid intake recommendations from the European Food Safety Authority for each sex. Participants will be prompted by the bottle (bottle will light up) when they are behind on fluid intake recommendations. Participants will use a validated urine color chart, 9 point Likert scale for thirst, and measure nude body mass on their own each morning. Participants will be informed that higher values for nude body mass and thirst, and lower values for nude body mass each morning may indicate they are less hydrated day-to-day.
223688815|NCT07129798|PROCEDURE|ILM flap with no endotamponade technique|Standard 3-port pars plana vitrectomy will be performed under either local anesthesia or general anesthesia. After core vitrectomy, posterior vitreous detachment induction will be done using vitrectomy cutter suction with the staining of intravitreal triamcinolone if necessary. This is followed by staining of the ILM with ILM blue dye. A half-moon shaped temporal ILM flap will be created, bridging the MH, using an end-gripping intraocular forceps. The posterior pole would be filled with perfluorocarbon (PFC) liquid and cohesive viscoelastic will be injected under the PFC to stabilize the ILM flap over the MH. Removal of PFC and search for peripheral retinal breaks will be done before removal of vitrectomy trocars and closure of sclerotomies wounds. Surgery will be combined with cataract removal (phacoemulsification) with intraocular lens implantation if patients have visually significant cataract. No specific post-operative posture will be required.
223688816|NCT03255447|DEVICE|Immunoadsorption|Fresenius Globaffin
223688817|NCT01815203|DRUG|Caffeine|Administration of one gelatin capsule containing 200-300 mg of caffeine with subsequent cognitive tasks and food test.
223688818|NCT01815203|DRUG|Placebo|Administration of placebo with subsequent cognitive tasks and food test.
223688819|NCT04571515|DRUG|MR-107A-01|Oral tablet
223688820|NCT04571515|DRUG|Placebo|Oral tablet
223688821|NCT06676631|BIOLOGICAL|NK 010 or NK042|NK010 is an allogeneic non-genetically modified NK cell infusion. NKX010 will be administered at a dose of 2.5 × 109 NK cells, 5.0 × 109 NK cells and 7.5 × 109 NK cells by a dose-escalation design and administered IV. N042 is an allogeneic genetic modification of NK cell. NKX042 will be administered at a dose of 6 × 108 NKR positive NK cells, 1.2 × 109 NKR positive NK cells and 2.4 × 109 NKR positive NK cells by a dose-escalation design and administered IV.
223688822|NCT06676631|DRUG|Rituximab|RTX dose of 1 g administered IV over 60 minutes at the first day of the treatment phase.
223776215|NCT00125554|DRUG|Metyrapone|
223688823|NCT05140382|DRUG|AZD4573|AZD4573 will be given intravenously
223688824|NCT06612424|DRUG|ANTERİOR QUADRATUS LUMBORUM BLOCK|In the Quadratus Lumborum block group, Participants will be placed in the lateral decubitus position. A convex ultrasound probe will be placed in sterile conditions along the midaxillary line, in the subcostal area above the iliac crest, to visualize the quadratus lumborum and psoas major muscles, as well as the L4 vertebral transverse process. Using an in-plane technique, a 22G, 100 mm peripheral block needle will be advanced anterior to the quadratus lumborum muscle and into the subfascial space between the quadratus lumborum and psoas major muscles. After confirming the correct location with hydrodissection, 20 mL of 0.25% bupivacaine will be injected slowly, observing the fascial displacement on ultrasound. The same procedure will be repeated on the contralateral side.
223688825|NCT06612424|DRUG|İNTRATECHAL MORPHİNE GROUP|In the intrathecal morphine group, 100 micrograms of morphine (0.1 mL) will be added to the 12 mg of intrathecally administered bupivacaine.
223688826|NCT07010770|OTHER|Web-Based Training (WBT)|A self-paced online training course that includes video demonstrations, self-guided modules, and clinical materials/resources.
223688827|NCT07010770|OTHER|Work Sample Review (WR)|Four months of weekly hour-long consultation that will include trainer-led reviews of work samples, focusing on the Impact Statement and Stuck Point Log.
223688828|NCT07010770|OTHER|Step down to fidelity self-monitoring|"After four months, and for participants who are classified as meeting early fidelity, for the next two months, therapists in self-monitored fidelity will no longer attend group consultation. Instead, they will assess their own fidelity through self-report surveys."
223688829|NCT07010770|OTHER|Step up to session audio review|"After four months, and for participants who are classified as meeting fidelity in progress, for the next two months, therapists will have their session audio recordings reviewed and rated for fidelity."
223688830|NCT07010770|OTHER|Standard Consultation (SC)|Four months of weekly hour-long group consultation
223688831|NCT07010770|OTHER|Standard Training (ST)|2-day instructor-led CPT workshop.
223688832|NCT07010770|OTHER|Continue in Standard Consultation|After four months, therapists will continue to attend weekly hour-long group consultation for another two months.
223688833|NCT00911742|DRUG|Tramadol Contramid OAD|1 Tramadol Contramid OAD 200 mg tablet as a single dose
223688834|NCT00911742|DRUG|Zytram|1 Zytram 200 mg tablet as a single dose
223688835|NCT06683755|DRUG|Nivolumab|Given by IV
223688836|NCT06683755|DRUG|Relatlimab|Given by IV
223688837|NCT06683755|DRUG|Ipilimumab|Given by IV
223688838|NCT06682325|OTHER|Multi-drug interaction|The clinical impact associated with the use of multiple drugs in liver transplant patients during their stay in ICU will be evaluated.
223688839|NCT06682052|OTHER|anti-stress ball|The women will be given a round, silicone, medium-sized and medium-hard anti-stress ball, and they will be told how to use the stress ball, and they will be asked to squeeze the anti-stress ball throughout the examination, allowing the patients to rest occasionally as they wish. The women will be told to count to 3 as they squeeze the anti-stress ball, then to relax the stress ball and repeat this process.
223688840|NCT03642327|BEHAVIORAL|Experimental: Maintenance of Certification (MOC)|MOC training will lead to more positive attitudes, comfort level and competence in addressing risk factors for Child Maltreatment.
223688841|NCT03642327|OTHER|Independent online training (IND)|IND refers to practitioners Independently doing the online training.
223688842|NCT06689800|BEHAVIORAL|Let's Get REAL|Family health communication tool
223688843|NCT06684717|BEHAVIORAL|Educational video intervention|A 3-minute educational video mainly about the benefits of Continuous positive airway pressure therapy in OSA patients. The video starts with basic knowledge about OSA and how it affects human health. What is a CPAP machine and how does it works? It was developed from consensus among expert opinions of Neurobehavioral specialists and sleep physicians.
223688844|NCT07024797|DRUG|ABBV-932|Oral Capsule
223688845|NCT07024797|DRUG|Placebo for ABBV-932|Oral Capsule
223688846|NCT06696183|DRUG|Gilteritinib (GILT)|80 mg
223688847|NCT06696183|DRUG|Venetoclax (VEN)|400 mg
223688848|NCT06696183|DRUG|Azacitidine (AZA)|75 mg/m²
223688849|NCT06994117|DRUG|Mezigdomide|Mezigdomide
223688850|NCT00529113|DRUG|Bardoxolone methyl|Bardoxolone methyl capsules (150 mg/day) for 21 days
223688851|NCT00529113|DRUG|Bardoxolone methyl|Bardoxolone methyl capsules (300 mg/day) for 21 days
223688852|NCT00529113|DRUG|Bardoxolone methyl|Bardoxolone methyl capsules (150 mg/day) for 28 days
223688853|NCT00529113|DRUG|Bardoxolone methyl|Bardoxolone methyl capsules (200 mg/day) for 28 days
223688854|NCT00529113|DRUG|Bardoxolone methyl|Bardoxolone methyl capsules (250 mg/day) for 28 days
223688855|NCT00529113|DRUG|Bardoxolone methyl|Bardoxlone methyl capsules (300 mg/day) x 28 days
223688856|NCT00529113|DRUG|Bardoxolone methyl|Bardoxolone methyl capsules (350 mg/day) x 28 days
223688857|NCT00529113|DRUG|Gemcitabine|1,000 mg/m2 administered as an intravenous infusion on days 1, 8, and 15
223688858|NCT00529113|DRUG|Placebo|Placebo capsules x 28 days
223688859|NCT00529113|DRUG|Bardoxolone methyl|Bardoxolone methyl maximum tolerated dose (as determined in the Phase 1 portion of the study)/day x 28 days
223688860|NCT04526899|BIOLOGICAL|BNT111|IV injection
223688861|NCT04526899|BIOLOGICAL|Cemiplimab|IV infusion
223776216|NCT04455386|DIAGNOSTIC_TEST|Stress radiography,Anterior drawer test,Stress ultrasound,Computed tomography, Magnetic resonance imaging,Arthroscopy|All patients suspected chronic ankle instability, will perform an anterior drawer test, stress ultrasound, computed tomography, magnetic resonance imaging of ankle. Patients with chronic ankle instability will be recommended to perform an arthroscopic repair if non-operative treatment failed.
223688862|NCT06683950|DRUG|Aflibercept 8mg|"Switching to intravitreal aflibercept 8mg in patients previously treated with faricimab or aflibercept 2mg.~The dosing schedule is as follows.~1. A single dose of 8mg aflibercept was administered to all patients~2. After treatment 1, follow-up observations were conducted at the same intervals as previous treatments. If complete fluid resolution (no evidence of SRF or IRF) is observed, an additional dose of 8mg aflibercept is administered, extending the dosing intervals by two weeks each time.~3. Up to three doses of 8mg aflibercept can be administered.~4. If, after the administration of 8mg aflibercept, follow-up observations reveal remaining SRF or IRF, the study concludes without additional dosing."
223688863|NCT06878391|PROCEDURE|Preemptive ultrasound-guided interscalene brachial plexus block and suprascapular nerve block and axillary nerve block|Preemptive ultrasound-guided interscalene brachial plexus block using ropivacaine, and suprascapular nerve block and axillary nerve block using ropivacaine or saline. Low fixed dose patient controlled analgesia (PCA) were done in the two group.
223688864|NCT06708039|OTHER|Mobile Instant Messaging Application based Self-management and Exercise Programme (SMEP)for Older Adults with Chronic Knee Pain.|The Mobile Instant Messaging Application based self-management and exercise programme (SMEP) consists of 10 short videos of self-management on chronic knee pain in older adults (5-10 minutes/video), 10 short videos of exercise interventions (5-10 minutes/video) and group discussions (10-20 minutes/session) with each video/session focusing on different content. A WhatsApp group that includes all participants in the intervention group will be created to deliver the three components of the program twice a week for five weeks. At the end of each session, they will be given the power point slides from the self-management video in Pdf format and an e-pamphlet of the exercise video. A total of 30-40 minutes will be allocated for each session to allow for socialization between the participants and researcher and also for a question and answer session.
223688865|NCT06707051|DRUG|Tranexamic Acid|Group A received Trannexamic Acid 500mg three times a day for 5 days
223688866|NCT06707051|DRUG|Calcium dobesilate (Doxium)|Group B recieved Cap.Calcium Dobesilate 500mg 3 times a day for 5 days
223688867|NCT05501366|DIETARY_SUPPLEMENT|Ketone Supplement|Four different exogenous ketone products at two serving sizes or a non-ketogenic placebo (one study product per test day). 1) Monoester of BHB (R)-1,3 butanediol (BHB Mono-ester), 2) diester of hexanoic acid (a ketogenic medium chain fatty acid) and (R)-1,3 butanediol (C6 Di-ester) 3) diester of AcAc and (R,S)-1,3 butanediol (AcAc Di-ester) \& 4) (R) -1,3 butanediol only (BDO). All products will be delivered in 2 different dosages 180mg/kg and 360mg/kg on separate testing days.
223776217|NCT01260441|OTHER|CPR Training using the Family and Friends CPR Anytime VSI Kit|Subjects will be trained using the American Heart Association's Family and Friends CPR Anytime Kit. Subjects will undergo training in-hospital and will be encouraged to take the kit home to share with their family members and friends.
223776218|NCT05747677|DRUG|HH-120 Nasal Spray|HH-120 nasal spray, 1 spray to each nostril of the participant each time,8-10 times per day, until the discharge of the SARS-CoV-2 infected patients or confirmed infection of the participant, whichever occurs first.
223776219|NCT04523129|DRUG|CyclASol topical ocular, eye drops|Cyclosporine A solution in vehicle
223776220|NCT04523129|DRUG|Vehicle topical ocular, eye drops|Vehicle
223776221|NCT07047131|BIOLOGICAL|GTO® (fully resorbable bone substitute)|Collagenated heterologous cortico-cancellous porcine bone mix + thermogelling copolymer with collagen (GTO®, OsteoBiol®, Tecnoss®)
223776222|NCT07047131|BIOLOGICAL|Apatos® (partially resorbable bone substitute)|Porcine cortical bone granules (Apatos Cortical®, OsteoBiol®, Tecnoss®) stabilized with TSV Gel®, a thermogelling copolymer with collagen.
223776223|NCT06722586|DRUG|Sirolimus|Sirolimus two pills (1mg) per day
223776224|NCT06722586|DRUG|Placebo|Placebo two pills per day
223776225|NCT07041814|DRUG|Oral estradiol valerate|Progynova is an oral hormone replacement therapy containing the active ingredient estradiol valerate, a synthetic ester of 17β-estradiol that, upon ingestion, is rapidly converted to bioidentical estradiol. Each film-coated tablet delivers either 1 mg or 2 mg of estradiol valerate, with inactive excipients including lactose monohydrate, maize starch, povidone, magnesium stearate, and hypromellose. In terms of pharmacokinetics, oral estradiol valerate undergoes first-pass metabolism in the liver, yielding a peak serum estradiol concentration within 4-8 hours of dosing and a biological half-life of approximately 20 hours. Progynova tablets are supplied in blister packs of 28 tablets, with recommended storage at room temperature (15-30 °C), protected from moisture and direct sunlight.
223688868|NCT05501366|BEHAVIORAL|Beverage Tolerability Questionnaire (BTQ) and satiety visual analogue scale|Beverage Tolerability Questionnaire (BTQ) and satiety visual analogue scale will be administered at beginning and end of testing day to tests palatability of supplement
223688869|NCT05501366|BIOLOGICAL|Blood Draw|IV cannula will be inserted at the start of each Test Day, and removed at the end of each Test Day, Blood samples will be collected according to the schedule in Figure 1. Cannula will be flushed with a small volume of saline after each sample to maintain patency. We will draw 504 mL of blood, which is about 2.1 cups throughout the 4-week intervention
223688870|NCT05501366|OTHER|Breath Reading|Participants will breathe into a commercially available handheld breath acetone analyzer according to the schedule. Participants will wear a fitted face mask attached to a metabolic cart for a 10-minute period every 60 minutes
223688871|NCT05501366|OTHER|Heart Rate Variability|Participants will wear a Bluetooth heart rate monitor chest strap throughout the test day.
223688872|NCT05501366|OTHER|CGM/CKM|Continuous Ketone Monitor will be applied at the start of Test Day 1. The sensor will be checked by the study team at each test day and will be removed and replaced by a fresh sensor at \~2- week intervals during the study. The sensor will be removed at the end of the final test day
223688873|NCT05501366|RADIATION|DXA|Lean Body Mass will be assessed once via DXA
223688874|NCT05501366|OTHER|Urine Analysis|Prior to consumption of the Study Product, participants will be asked to completely void bladder. And hydration status will be determined via urine specific gravity (USG) reporting \<1.025. Urine passed after the ingestion of the study product will be collected in a plastic container; participants will be asked to void their bladder and collect urine at the end of the test day. The volume produced will be recorded at the end of the study and aliquots will be frozen and stored for future analysis
223688875|NCT06704646|PROCEDURE|Curative intent surgery|Curative intent surgery means that surgeons intend to perform R0 resection.
223688876|NCT06656195|OTHER|glueus maximus strengthening|In week 1 SIJ Mobilization along with ,Single leg bridge ,alternating leg lifts ,clam Exercise,Prone hip extension with knee flexion. In week 2 SIJ Mobilization along with Side-squats,Star excursion exercise,Forward step-down.In week 3 SIJ Mobilization along with bilateral squat ,single leg squat ,split squat/lunge ,frontal step up ,lateral step up.In week 4 SIJ mobilization along with bilateral squat with a band and hip extension against resistance was done.Three times a week for 4 weeks In each session, a total of two sets of 12 repetitions each were carried out, with a 1 min rest time between sets.
223688877|NCT06656195|OTHER|hamstring stretching group|SIJ mobilization and Soft tissue mobilization along with Static Hamstrings stretching (3 sets, 15 repetitions with a holding time of 15 seconds ,3 times a week for 4 week) and Dynamic hamstrings stretching(3 set, 15 repetitions with a holding time of 1 second, 3 times a week for 4 weeks.
223688878|NCT01711372|DEVICE|Groundskeeper game for controls|The Groundskeeper game is a go/no go task that captures reaction time and movement using the accelerometers and touch capabilities of the Sifteo cubes.
223688879|NCT01711372|DEVICE|Groundskeeper game for ADHD|The Groundskeeper game is a go/no go task that captures reaction time and movement using the accelerometers and touch capabilities of the Sifteo cubes.
223688880|NCT06725901|DEVICE|Web-Based Application|The intervention involves the DIAGEN-IA platform, a diagnostic support tool designed to identify pediatric neurological diseases with a genetic basis. Using a Bayesian network model and integrating ontologies such as ORDO, HPO, and HOOM, DIAGEN-IA links phenotypic data entered by physicians to suggested diagnoses and tests. Pediatric neurologists will be trained to use the platform during a 12-month intervention. DIAGEN-IA allows clinicians to input clinical and diagnostic data, generating differential diagnoses and recommended tests, with results exportable in PDF for integration into medical records. Platform usage will be tracked, including login frequency, time spent, and evaluations performed.
223688881|NCT03893916|PROCEDURE|MEG - EEG HR|"MEG : Magnetoencephalography is the study of the magnetic fields produced by the electrical activity of the brain.~MEG signals are obtained while the patient is placed in a device specific to this technique. The latter comprises a recording chamber, recording sensors which are placed in a cryostat and an electronic measuring system. The magnetic fields are measured while the subject is placed in a shielded magnetic chamber protecting it from variations in the ambient magnetic field (displacement of metal masses, sector ...).~EEG HR: High Resolution EEG is defined as the recording of cerebral electrical activity with 128 electroencephalographic electrodes and with high temporal resolution usually followed by the use of source localization tools. The HR EEG is therefore derived from standard EEG techniques, but requires a higher number of electrodes and the use of source localization tools."
223688882|NCT06738173|DIAGNOSTIC_TEST|Gut microbiome testing|Gut microbiome testing for the characterization of the patient gut microbiome
223688883|NCT00385190|DRUG|HCV-796|
223688884|NCT06746441|DRUG|Psilocybin|"Psilocybin is a naturally occurring serotonergic psychedelic compound found in Psilocybe mushrooms. It is metabolized in the body into its active form, psilocin, which has a high affinity for serotonin 5-HT2A receptors. This enables psilocin to bypass the default serotonin pathway, producing antidepressant effects.~For this study:~Psilocybin will be administered orally in a dose of 5-6 grams per session. Each participant in the Psilocybin and Psilocybin-assisted CBT arms will receive two sessions spaced six weeks apart.~The therapy will be conducted in a controlled hospital setting with medical monitoring during the session to ensure safety until the hallucination phase subsides.~Psilocybin will be added to routine antidepressant medication."
223688885|NCT06746441|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|"Cognitive Behavioral Therapy (CBT) is a structured, time-limited psychotherapy aimed at alleviating symptoms of depression. It involves addressing negative thoughts and behavioral patterns through the following steps:~Identifying troubling life situations. Recognizing thoughts, emotions, and beliefs about those situations. Identifying negative or inaccurate thinking patterns. Restructuring those thoughts into positive and realistic perspectives.~In this study:~CBT will consist of 8-10 structured sessions, each lasting approximately 90 minutes.~Participants will attend therapy sessions twice weekly over a six-week period. The intervention will be delivered by trained psychotherapists in a controlled hospital setting.~Routine antidepressant medications will be continued alongside CBT."
223688886|NCT04430205|PROCEDURE|Adhesive restoration protocol|"The canal walls were etched with 37% orthophosphoric acid for 30 seconds with use of a microbrush.~The primer was applied on the wet canal walls, with a microbrush several times, after checking by drying the canal, that the appearance of the dentine was shiny and not opaque or chalky.~The next step was the application of bonding with a microbrush, blowing in the fracture line to make sure it is not loaded with bonding.~Flow composite was used to make it penetrate the fracture line with the help of a 0.06 mm k-file.~The canals were filled with dual composite parts more deeply, light cured at the canal entrance and pulp chamber; the following phase was the coronal restoration with a sandwich technique, covering the cusp with composite."
223688887|NCT07136870|DEVICE|Medical tape|The purpose of this exploratory study is to assess the adhesion to skin properties of test material samples over 24 hours to establish the peel-off measurement method at the new Essity study site. As the performance and safety of the tapes, WAFs and post-OPs in its intended use are not tested in the current study it is not considered a medical device study according to EU medical device regulation (MDR) 2017/745
223688888|NCT06034002|DRUG|INCA033989|INCA033989 will be administered at protocol defined dose.
223688889|NCT06034002|DRUG|Ruxolitinib|Rux will be administered according to Prescribing Information/SmPC.
223688890|NCT06916286|DEVICE|K-Lock|Surgical drain securement with a novel sutureless K-LOCK device
223688891|NCT06916286|OTHER|Suture|Surgical drain securement with traditional suture-based methods
223688892|NCT06912685|OTHER|Technology Enhanced Implementation Package|The Technology Enhanced Implementation Package for SafeCare delivery consists of protocol adaptations, evidence-informed guidelines, and digital health resources to improve SafeCare outcomes related to reach, quality, and equity.
223688893|NCT06912685|OTHER|SafeCare|SafeCare is an evidence-based home visiting parenting program with three modules focused on child health, home safety, and parent-child relationships. SafeCare sessions typically occur weekly over 18 weeks.
223688894|NCT07117708|OTHER|Early Surgical Consent|Surgical consent for possible cesarean delivery will be completed upon arrival to labor and delivery before induction of labor begins
223688895|NCT07117708|OTHER|Surgical Consent if Clinically Indicated|Surgical consent for possible cesarean delivery will be completed if it appears clinically indicated during a participant's induction of labor.
223688896|NCT07140718|BEHAVIORAL|Fundamental Adaptive Skills Training|The FAST intervention will be approximately 60 minutes in duration. The video component of FAST, animated using the Vyond software, will be presented via computer or projector. Pause points and brief interactive exercises will be added throughout the presentation to promote engagement and ensure comprehension of FAST material. The treatment will be sectioned into thirds: a physical health section focused on sleep hygiene and physical activity, an anxiety sensitivity section dispelling common AS myths, and a social health section. Each section will contain brief psychoeducation focused on dispelling common myths or promoting adaptive skills use.
223688897|NCT07140718|BEHAVIORAL|Relaxation and Mindfulness Training|The RMT intervention will be primarily psychoeducational and focused on explaining relaxation methods used in various psychological treatments such as progressive muscle relaxation, guided imagery, and mindfulness-focused breathing exercises. Interactive relaxation and mindfulness exercises and brief discussions following each relaxation component will be included to control for time spent on interactive exercises in the FAST condition. The intervention will take approximately 60 minutes. Tailored to control for the effects of general education, practice exercises, and time spent on the FAST intervention, RMT will be a stronger control in comparison to a waitlist or repeated contact condition. Like the FAST intervention, this program will also be digitalized to allow for ease-of-administration.
223688898|NCT06934577|OTHER|Standard optometric examination|Participants will see the optometrist at the Federally Qualified Health Center. The guidelines define usual care as: an in-person comprehensive eye examination with assessment of patient history, visual acuity, pupil examination, ocular motility and alignment, intraocular pressure, and biomicroscopy with additional tests, as appropriate. A glasses prescription will be given to the participant if needed. Participants will complete surveys at baseline before their eye exam and 6 weeks after the eye exam.
223688899|NCT06934577|OTHER|Technology enhanced eye disease detection protocol|Participants will receive a technology enhanced eye disease detection protocol from ophthalmic technicians that includes measurements of visual function such as visual acuity, refraction, intraocular pressure, pachymetry, external eye and fundus photography, and optical coherence tomography of the macula and retinal nerve fiber layer. The optometrist at the Federally. Qualified Health Center will then use a protocol to grade the testing and identify eye disease. The results of the grading will inform whether the person receives a brief appointment with the optometrist (no disease detected) or an in-depth appointment with the optometrist (disease detected). During the first visit, participants receive care navigation support to purchase low-cost glasses from an on-line retailer. When participants return for the optometrist exam, glasses will be fit. Participants will receive care navigation support to attend any recommended specialty follow-up appointments.
223688900|NCT04161456|DRUG|Apremilast|Apremilast twice daily 30 mg
223688901|NCT01994590|DRUG|Dovitinib|Starting dose will be 400 mg by mouth daily on Days 1-5, 8-12, 15-19, and 22-26 of each 28 day cycle.
223688902|NCT01994590|DRUG|Abiraterone Acetate|4 tablets (250 mg each) by mouth daily.
223688903|NCT01994590|DRUG|Prednisone|5 mg by mouth twice daily.
223688904|NCT05718050|DIAGNOSTIC_TEST|Mandibular flexure evaluation|A mandibular silicon impression was taken, and a vacuum molded thermoplastic stent with radiopaque fiducial markers (steel ball bearings) on the facial side of the canines and molars was fabricated for each patient. Two Cone Beam Computed Tomographs (CBCTs) were made per patient with their radiographic stent in the mouth at the OVD and MO positions at the University Advanced Digital Diagnostic Center. The CBCT examination was performed without any stitching procedure using a computed tomography (SCANORA 3DX; Dexis LLC) set up at 90 kV, 4 mA and a field of view (FOV) of 140 and 100 mm in height and width respectively, to decrease the radiation dose without affecting the quality of the examination.
223688905|NCT02237911|OTHER|Clinic-based outpatient exercise group|Subjects will participate in supervised sessions (clinic-based) of exercise followed by a home exercise program 2 times per week during 3 months. Each exercise session will last about 60 minutes. Treatment sessions will utilize a pragmatic approach and will include the exercises designed to increase muscular strength, low impact cardiovascular exercise, range of movement, and activity for daily living skills.
223688906|NCT02237911|OTHER|Community-based exercise group|Subjects will attend to exercise classes (community-based) 2 times per week during 3 months. The exercise classes last approximately 60 minutes. The group exercise classes consists of a variety of exercises designed to increase general muscular strength, low impact aerobic exercise, range of movement, and activity for daily living.
223776226|NCT07041814|DRUG|Transdermal 17β estradiol|Oestrogel® is a transdermal hormone replacement therapy containing 17β-estradiol in a hydroalcoholic gel formulation designed for topical application. Each pump actuation delivers 0.75 mg of estradiol in a 1.25 g dose of gel, which is formulated with excipients including ethanol, propylene glycol, carbomer, sodium hydroxide, and purified water to ensure consistent hormone release and skin penetration. Upon application to intact skin-typically the forearm or thigh-the gel allows for direct systemic absorption of estradiol, bypassing first-pass hepatic metabolism. Peak serum estradiol levels are generally reached within 6-12 hours post-application, with a half-life of approximately 10-20 hours, resulting in more physiological, steady- steady-state estradiol exposure compared to oral formulations. The gel is supplied in multi-dose pump bottles (150 g), each providing up to 120 actuations.
223688907|NCT02809326|BEHAVIORAL|17 week Exposure Therapy Control Arm|15 individual VR-assisted exposure therapy sessions and 14 psychoeducational group sessions conducted over a period of 17 weeks. After the Education session, treatment occurs three times a week during the Virtual Reality (VR) assisted Exposure phase, and then once a week during the Psychoeducational phase.The psychoeducational group therapy, will include topics such as: DSM-IV criteria of PTSD, prevalence of PTSD, risk factors for PTSD, biological and conditioning models of PTSD, PTSD comorbidity, pharmacological treatment of PTSD, the impact of substance abuse, impairment in interpersonal functioning among veterans with PTSD, and issues related to anger control problems and suggested coping strategies
223688908|NCT02809326|BEHAVIORAL|Trauma Management Therapy|TMT consists of 29 treatment sessions administered over a period of 17 weeks. After the Education session, treatment occurs three times a week during the Virtual Reality (VR) assisted Exposure phase, and then once a week during Social and Emotional Regulation (SER). Education and exposure are implemented individually while SER is administered in small group sessions (3-5 people). All exposure treatment sessions will terminate after a decline of 50% in the highest rating recorded. SER sessions will be 90 minutes. The treatment program as a whole results in approximately 43.5 hours of therapist contact for each patient.
223688909|NCT02809326|BEHAVIORAL|Intensive 3-Week Trauma Management Therapy|Intensive 3-Week Trauma Management Therapy consists of 29 treatment sessions administered over a period of 3 weeks. Individual VR-assisted exposure sessions and group sessions are conducted Monday-Friday with individual sessions conducted in the morning and Social and Emotional Regulation (SER) sessions conducted in the afternoon. Education and exposure are implemented individually while SER is administered in small group sessions (3-5 people). All exposure treatment sessions will terminate after a decline of 50% in the highest rating recorded. SER sessions will be 90 minutes. The treatment program as a whole results in approximately 43.5 hours of therapist contact for each patient.
223688910|NCT00053365|DRUG|irofulven|Given IV
223688911|NCT03708185|DIETARY_SUPPLEMENT|Beta-alanine|N/A: see arm description
223688912|NCT03708185|DIETARY_SUPPLEMENT|Placebo|N/A: see arm description
223688913|NCT01546012|DEVICE|HYABAK®|Hyaluronic Acid eye drops CE marked, packaged in multidose ABAK® container (preservative free)
223688914|NCT01546012|DEVICE|HYLO-COMOD®|Hyaluronic Acid eye drops CE marked, packaged in multidose COMOD® container (preservative free)
223688915|NCT05755737|DRUG|Ondansetron|Serotonin antagonists (5-HT3 antagonists) (Carbazole Derivative)
223688916|NCT05755737|DRUG|Placebo|Matching placebo identical in appearance.
223688917|NCT01583543|DRUG|Olaparib|400mg PO BID Continuous
223688918|NCT02260531|DRUG|Cabozantinib|
223688919|NCT02260531|DRUG|Trastuzumab|
223688920|NCT03234777|BEHAVIORAL|Whiteboard animation video|Developed via qualitative research with parents of children with acute gastroenteritis.
223688921|NCT03234777|BEHAVIORAL|Regular video|Developed by CDC
223688922|NCT00253500|BIOLOGICAL|pegfilgrastim|6 mg in a syringe
223688923|NCT00253500|DRUG|epirubicin hydrochloride|120 MG q 2 weeks for 4 cycles
223688924|NCT00253500|PROCEDURE|conventional surgery|to remove small piece of cancer
223688925|NCT04680676|DRUG|BI 730357|BI 730357
223688926|NCT04680676|DRUG|Placebo|Placebo
223688927|NCT00958789|DEVICE|Triathlon TS Knee System|Total knee replacement for revision cases
223688928|NCT05515172|OTHER|Mindfulness-based Intervention|"The intervention was designed by a volunteer multidisciplinary team expert in different mind-body medicine techniques (for example, medicine, psychology, thanatology, meditation, health, and wellness coaches, certified Qi Gong, and yoga instructors) and is made up of 3 components main: micropractices, cohesion and support groups, which will be implemented for a period of 12 weeks."
223688929|NCT04233463|DIETARY_SUPPLEMENT|Modulen|Crohn patients will be given Modulen, an oral polymeric diet enriched with TGF-beta 2, along with a tailored diet
223688930|NCT04233463|DRUG|Budesonide|Standard treatment for mild Crohn Disease patients
223688931|NCT00356733|DRUG|Erythropoietin administration|50 IU/kg/week EPO to a target haemoglobin level of 13.7 g/dL for men and 13.4 g/dL for women (group A) or to a target comparable to starting hemoglobin level (group B)
223688932|NCT04108442|BEHAVIORAL|Traditional|Surgeons (rather than individual subjects) will be randomized to traditional Postoperative follow-up modality groups. They will adhere to this form of postoperative follow-up for all of their surgical patients (subjects) for one month.
223688933|NCT04108442|BEHAVIORAL|Virtual|Surgeons (rather than individual subjects) will be randomized to virtual postoperative follow-up modality group. They will adhere to that form of postoperative follow-up for all of their surgical patients (subjects) for one month.
223688934|NCT04398251|DRUG|Febuxostat 40mg Tab|For the uric acid control group, except that lifestyle changes were the same as those in the uric acid non-drug control group, non-drug uric acid control group was given febuxostat to reduce uric acid synthesis. Febuxostat is taken at a dose of 40 mg three times a week.
223776227|NCT07044804|DEVICE|Active Group (Active Anodal tDCS to the left IFG or Cathodal tDCS to the left IFG)|Participants in the active tDCS group (Anodal tDCS or Cathodal tDCS) will receive stimulation set at 1 mA (milliampere), with a duration of 20 minutes per session. The stimulation will be administered in five consecutive sessions per day, five days a week, for two weeks, totaling 10 sessions, while participants will also undergo logopedic treatment for 20 minutes. The training protocol will consist of 10 minutes of training in motor planning and programming abilities and 10 minutes of training on the lexical, morphosyntactic, and functional aspects of language and communication.
223688935|NCT04398251|BEHAVIORAL|Non-drug control group|All patients in the group are advised to live regularly after operation, drink plenty of water, drink more than 2000ml every day, reduce the intake of high purine food and fructose-rich beverages, increase the intake of fresh vegetables, control weight and exercise regularly
223688936|NCT05753527|BEHAVIORAL|Progressive Relaxation Exercises|Deep abdominal breathing will be done three times and the breath will be given slowly. The fists will be clenched, keep the fists clenched in this way for 7-10 seconds, and then release them for 15-20 seconds. By opening the arms to the side and locking the elbows, the triceps muscle will be stretched and relaxed. The forehead muscles by raising the eyebrows The eyes will be closed and relaxed. The mouth will be opened and closed. The head will be stretched back and relaxed. The shoulders will be lifted and relaxed. Both hips will be tightened and relaxed by bringing them closer together. The thigh muscles will be tightened and relaxed.
223688937|NCT00877201|DRUG|CDR2|
223688938|NCT00168402|DRUG|Botulinum Toxin Type A|
223688939|NCT03007407|DRUG|durvalumab|Following three doses of hypofractionated palliative radiation (Days -2, -1, and Day 0 prior to Cycle 1), patients will receive durvalumab (1500 mg IV infusion) on Day 1 for 4 cycles (in combination with tremelimumab). Beginning with Cycle 5 through Cycle 12, patients will receive durvalumab alone (1500 mg/IV infusion) on Day 1 of each 28 day cycle.
223688940|NCT03007407|DRUG|Tremelimumab|Following three doses of hypofractionated palliative radiation (Days -2, -1, and Day 0 prior to Cycle 1), patients will receive tremelimumab (75 mg IV infusion) on Day 1 for 4 cycles (in combination with durvalumab).
223688941|NCT00850161|DRUG|aspart|Meal-time insulin. Administered subcutaneously based on routine clinical therapy.
223688942|NCT00850161|DRUG|Nasulin™|100 IU(2 puffs in each nostril)
223688943|NCT00198926|BEHAVIORAL|covert v overt nutrition labeling|
223688944|NCT00198926|BEHAVIORAL|varying meal nutrition manipulation|
223688945|NCT03939026|GENETIC|ALLO-501|ALLO-501 is an allogeneic CAR T cell therapy targeting CD19
223688946|NCT03939026|BIOLOGICAL|ALLO-647|ALLO-647 is a monoclonal antibody that recognizes a CD52 antigen
223688947|NCT03939026|DRUG|Fludarabine|Chemotherapy for lymphodepletion
223688948|NCT03939026|DRUG|Cyclophosphamide|Chemotherapy for lymphodepletion
223688949|NCT05237297|DRUG|Ilaprazole|Ilaprazole 10mg
223688950|NCT05237297|DRUG|Naproxen|Naproxen 500mg
223688951|NCT05237297|DRUG|Aceclofenac|Aceclofenac 100mg
223688952|NCT05237297|DRUG|Celecoxib|Celecoxib 200mg
223688953|NCT01536743|DRUG|PD0332991|"30 patients with recurrent ovarian epithelial carcinoma demonstrating Rb-proficiency and absent or low expression of p16 will be registered to receive PD0332991 once a day by mouth in the morning on an empty stomach.~PD0332991 will be administered daily for 3 weeks followed by 1 week off treatment (28 day cycle)."
223688954|NCT04833673|BEHAVIORAL|PMR: Progressive Muscle Relaxation|tensing and relaxing the body muscles accompanied with deep breathing
223688955|NCT04833673|BEHAVIORAL|BRT:Benson Relaxation Technique|relaxation using mental imagery and mediation
223688956|NCT02186431|DEVICE|senofilcon A|
223688957|NCT05096052|DRUG|Galactomannan|Precise chemistry based molecule that binds to galectin like receptors on the N terminal of S1 subunit of the Sars-CoV2 virus
223688958|NCT05096052|DRUG|PLACEBO|A blinded matching placebo containing inert chemistry not able to recognise and bind to the galectin like receptors on the N terminal of S1 subunit of the Sars-CoV2 virus
223688959|NCT03696173|OTHER|Non-Interventional|Non-Interventional
223688960|NCT03696173|OTHER|Non-Interventional|Non-Interventional
223688961|NCT04096742|DRUG|tretinoin 0.05% lotion (Altreno)|Altreno topical lotion
223688962|NCT04096742|OTHER|Vehicle|Lotion not containing active ingredient (tretinoin)
223776228|NCT07044804|DEVICE|Sham Group|For the sham condition, the same electrode placement will be used as in the anodal tDCS condition, but the current will be applied for 30 s and will be ramped down without the participant's awareness. Stimulation intensity will be set at 1 mA; the duration of stimulation will be 20 min and will be held five consecutive daily session per week for two weeks, for a total of 10 sessions. During the tDCS sessions participant will sit in a comfortable chair and a language training will be administered
223776229|NCT06743750|DIAGNOSTIC_TEST|RT-PCR in different respiratory tract samples|RT-PCR on saliva, orrobuccal swab and nasal swab will be performed. Nasopharyngeal swab will be performed independently of the study as standard of care.
223776230|NCT07052058|BIOLOGICAL|Tocilizumab|Single infusion tocilizumab, 8 mg/kg, diluted in 100 mL of normal saline
223776231|NCT07052058|DRUG|Normal Saline (0.9% NaCl)|Placebo, same volume as intervention
223776232|NCT07051616|BEHAVIORAL|Child laughter video|1 hour after the chemotherapy treatment was started, the video monitor was placed at a height where the patient could see comfortably while lying down and the video, which was checked and prepared beforehand, was turned on full screen. The appropriate volume was adjusted and the patient was allowed to watch the video for 10 minutes without any other intervention. The video was then stopped and the etagere was removed from in front of the patient. Chemotherapy was continued. At the 2nd hour of chemotherapy, the disinfected etagere and computer were placed in a position where the patient could see them comfortably and the 2nd video was started and the patient was allowed to watch the video for 10 minutes.
223776233|NCT07051824|DIETARY_SUPPLEMENT|Probiotic and Prebiotic|"This synbiotic intervention aims to minimize postoperative gastrointestinal symptoms in sleeve gastrectomy patients. The 5 g sachet contains:~* Partially hydrolyzed guar gum (PHGG; 4.9 g): Clinically shown to reduce diarrhea and improve stool consistency,~* Lactobacillus rhamnosus GG (LGG; 1×10⁹ CFU): Evidence-based for alleviating abdominal pain and bloating,~* Maltodextrin (0.1 g): Excipient for stability.~Administered daily in yogurt for 12 weeks post-surgery, this combination directly targets:~① Diarrhea and constipation (via PHGG's soluble fiber),~② Abdominal pain and bloating (via LGG's anti-inflammatory effects),~③ Overall GI symptom burden.~\*\*Distinctive features vs. other studies:~* Symptom-specific formulation: PHGG (high-dose fiber) + LGG (symptom-targeted probiotic) synergy,~* Surgical context: Optimized for rapid gastric transit post-sleeve gastrectomy,~* Delivery innovation: Yogurt matrix protects probiotics against surgical gut pH changes."
223776234|NCT07052227|DEVICE|Delfi blood flow restriction cuff|Leg press exercise with Delfi blood flow restriction cuff
223776235|NCT07052227|DEVICE|Fitcuffs|Leg press exercise with Fitcuff blood flow restriction cuff
223688963|NCT04450888|OTHER|The strategic use of messages in risk communication|The interventions in the EMT-OCSP study are strategic health messages delivered (gain-framed vs.loss-framed and long-term vs.short-term contexts) to individuals based on their calculated CVD-free life expectancy and potential interventional benefits.
223688964|NCT04523948|BEHAVIORAL|Behavioral and pharmacological support to reduce combustible tobacco use.|Behavioral and pharmacological support to reduce combustible tobacco use.
223688965|NCT02777736|DRUG|Methotrexate|i.v. or intrathecal CNS prophylaxis
223688966|NCT05419986|GENETIC|Blood collection|Molecular monitoring by measure of DNA methylation levels in blood samples collected by fingerstick blood drops, as opposed to veinous phlebotomy
223688967|NCT02961673|BIOLOGICAL|HU-014 Inj|Clostridium botulinum type A
223688968|NCT02961673|BIOLOGICAL|Botox Inj|Clostridium botulinum type A
223688969|NCT06033053|DEVICE|Real-time fMRI neurofeedback from Turbo Brain voyager (TBV) 3.2|The two groups will undergo the same paradigm while learning to modulate the vmPFC -amygdala pathway and the sham pathway.
223688970|NCT02330965|PROCEDURE|Blood Draw|Blood draws (65 mLs \[\~4 tablespoons\] per blood draw) at 4 time points: Prior to study medication initiation, and at +6, +12 and+24 months post treatment initiation.
223688971|NCT02330965|PROCEDURE|CSF collection by lumbar puncture (Optional)|For participants who volunteer to donate CSF samples: up to 25 mLs (\<2 tablespoons): prior to study medication initiation, and at month 24 post treatment initiation.
223688972|NCT06557070|OTHER|The Emotional Freedom Technique|Emotional freedom technique (EFT) is a method to help manage emotions and troubling thoughts and lower stress and anxiety. EFT is applying by tapping. To do EFT, you tap your fingertips on certain points on your hand, head, and torso which are used in acupuncture.
223688973|NCT06457919|DRUG|Tinengotinib|Tinengotinib will be administered daily for 28-day cycles. A flat dose of 10 mg PO once daily.
223688974|NCT06457919|DRUG|abiraterone acetate with prednisone|Abiraterone acetate 1000 mg PO QD in combination with prednisone 5 mg PO once or twice daily (QD or BID)
223776236|NCT07052227|OTHER|Control|Leg press exercise with no blood flow restriction cuff
223776237|NCT07051876|DEVICE|Mouthguard and Physiotherapy|The mouthguard and physiotherapy group will receive a custom-fitted mouthguard along with a physiotherapy program. The home-based physiotherapy exercises will include posture improvement routines, relaxation techniques, and targeted therapy for the muscles of the head, neck, and shoulders. These sessions will be performed daily at home for a duration of six weeks. Each participant will sign a consent form approved by the Ethics Committee of Saint Joseph University.
223776238|NCT07051876|DEVICE|Mouthguard Only|The mouthguard only group will receive a custom-fitted mouthguard, which will be fabricated by a qualified dentist. The mouthguard will be worn during sleep for 6 weeks. Participants will be instructed to clean the mouthguard daily and to store it in a cool, dry place.
223776239|NCT07051369|DIAGNOSTIC_TEST|Portal Hypertension diagnostics|his study aims to determine the frequency of portal hypertension among patients with cirrhotic liver using ultrasound.A cross-sectional study will be conducted at Sheikh Zaid Medical College and Hospital, Rahim Yar Khan,
223688975|NCT06457919|DRUG|Enzalutamide|Enzalutamide 160 mg PO QD
223688976|NCT05834296|BIOLOGICAL|ALZN002 (autologous DCs pulsed with E22W mutant peptide).|The cellular immunotherapy product consists of autologous dendritic cells (DCs) pulsed with a novel amyloid-beta peptide (Aβ1 42) containing a mutation at position 22 from glutamic acid to tryptophan (E22W). This mutation produces novel CD4+ T cell epitopes specific for the mutant E22W peptide that can facilitate an anti-Aβ1-42 antibody response. The activated E22W peptide specific CD4+ T cells license Aβ1-42-specific B cells to secrete anti Aβ1-42 antibodies, resulting in systemic reduction of amyloid and reduction or slowed accumulation of amyloid plaques in the brain.
223688977|NCT05834296|DRUG|Placebo|Saline
223688978|NCT06259084|DEVICE|Seedchrony|The seedchrony probe is coupled to the transfer catheter. When the transfer catheter is placed inside the uterus, the probe measures the biomarker concentraction in the fluid entering the catheter. The measurements last two minutes.
223688979|NCT06395688|DRUG|3ß-(4-methoxybenzyloxy)pregn-5-en-20-one|AEF0117 soft capsules of 1mg
223688980|NCT06395688|DRUG|Placebo|Placebo soft capsules (identical to active compound)
223688981|NCT00205829|DEVICE|battery-powered bion(R) microstimulator system|Stimulation on from initial activation and on.
223688982|NCT00216554|DRUG|risperidone|
223688983|NCT06293924|DIAGNOSTIC_TEST|Pericardiocentesis|"Enrolled patients will not undergo any invasive investigations outside of normal clinical practice. Patients with acute pericarditis and non-inflammatory pericardial effusion will undergo pericardiocentesis for diagnostic or therapeutic purposes.~Four ml of pericardial fluid will be collected: 2 ml for biochemical analysis in lithium heparin or serum-gel separator-associated tubes, and 2 ml for cellular analysis in K3 EDTA tubes."
223688984|NCT06293924|DIAGNOSTIC_TEST|Pericardiotomy|"During any type of cardiac surgery involving pericardiotomy, 4 ml of pericardial fluid will be collected and analyzed upon opening the pericardial sac of enrolled patients.~Four ml of pericardial fluid will be collected: 2 ml for biochemical analysis in lithium heparin or serum-gel separator-associated tubes, and 2 ml for cellular analysis in K3 EDTA tubes."
223688985|NCT06293924|DIAGNOSTIC_TEST|Cytofluorometry and Gene expression analysis|"A 30 ml sample of peripheral venous blood in K3 EDTA tubes will be collected by enrolled patients who participating in the translational substudy and stored with pericardial fluid samples.~Pericardial fluid cells by lineage and expression of inflammatory cytokines will be characterized through cytofluorometry and expression profile analysis of transcribed RNAs. Cytokine concentrations in peripheral blood and pericardial fluid will be analyzed by molecular assay. Peripheral blood mononucleated cells (PBMCs) and pericardial fluid cells will be cultured in vitro and exposed to the main therapies used during pericarditis, to verify the effects on gene expression and inflammatory molecules."
223688986|NCT04090723|BEHAVIORAL|CBI-CC with peer navigation|Computer delivered brief alcohol intervention enhanced with information of HIV infection, HIV risk, and comorbid mental health disorders
223688987|NCT06139796|DRUG|DRV/r FDC (120/20mg)|Initiation of DRV/r FDC (120/20mg) as part of antiretroviral therapy (ART) with an Optimized Background Therapy (OBT)
223688988|NCT03240731|BIOLOGICAL|bone marrow transplant|haploidentical bone marrow transplant
223688989|NCT05346250|BEHAVIORAL|Non-exercise control|12 month lifestyle education
223776240|NCT07051265|BEHAVIORAL|Transcutaneous Electrical Nerve Stimulation (TENS)|Participants received TENS therapy at two specific acupoints - Hegu (LI4) and Lieque (LU7). Surface electrodes were placed over the acupoints, and stimulation was delivered using a standard TENS device.
223776241|NCT07051265|BEHAVIORAL|Acupressure|The acupressure group placed the acupoint patches on the Hegu and Lieque points on both hands and pressed each acupoint with the index finger and thumb for 1 minute, 3 times a day, each time for about 4 minutes.
223776242|NCT07051499|DRUG|TAP Block Group|Bilateral ultrasound-guided TAP block with 0.25% levobupivacaine and 75 mcg clonidine per side, plus standard intraoperative intravenous analgesia (ketorolac, tramadol, ondansetron).
223688990|NCT05346250|BEHAVIORAL|Moderate intensity exercise|12 month moderate intensity exercise by brisk walk 30 min per day and more than 5 days per week.
223688991|NCT05346250|BEHAVIORAL|Vigorous intensity exercise|6 month vigorous intensity exercise on treadmill for 30 min per day and more than 5 days per week, and subsequent 6 month moderate exercise by brisk walk 30 min per day and more than 5 days per week.
223688992|NCT05669482|DRUG|avutometinib (VS-6766) and defactinib in combination with gemcitabine and nab-paclitaxel|The RP2D of avutometinib (VS-6766) and defactinib in combination with gemcitabine and nab-paclitaxel determined in Part A will be used in Part B dose expansion.
223688993|NCT05977439|DEVICE|fMRI-EEG-TMS|Participants will undergo a magnetic resonance imaging (MRI) scan with combined electroencephalography (EEG), and single-pulse transcranial magnetic stimulation (TMS) while completing cognitive flexibility (CF) and emotion recognition (CR) tasks.
223688994|NCT05977439|DEVICE|fNIRS-EEG-TMS|Participants brain activity will be measured using functional near-infrared spectroscopy (fNIRS) with combined electroencephalography (EEG), and single-pulse transcranial magnetic stimulation (TMS) while completing cognitive flexibility (CF) and emotion recognition (CR) tasks.
223688995|NCT05977439|DEVICE|fNIRS-EEG-rTMS Interleaved with CBT|Participants brain activity will be measured using functional near-infrared spectroscopy (fNIRS) with combined electroencephalography (EEG), and repetitive transcranial magnetic stimulation (rTMS). rTMS will be delivered via a MagVenture MagPro100 and Cool-B65 coil. The investigators will use a standard resting motor threshold (rMT) determination to determine the TMS dose. Treatment will be delivered at 120% of the motor threshold. The accelerated paradigm will consist 6 session a day for 5-6 days. Each rTMS session will be separated by 30 minutes of Cognitive Behavioral Therapy (CBT). rTMS treatment will be delivered at an individualized left DLPFC target based on each participant's individualized scans from prior neuroimaging sessions.
223688996|NCT03322891|OTHER|Educational Supplement|Participants will receive education about prostate cancer and treatments using models and props during a face-to-face interview. During the interview, participants will also be asked about medical terms and treatments regarding prostate cancer. The interview will last 45 to 60 minutes.
223688997|NCT03322891|OTHER|Standard Practice Education|Participants will receive traditional standard of care education regarding prostate cancer treatments and side effects provided by their physician.
223688998|NCT05693805|BEHAVIORAL|Tai Chi|The remote delivery Tai Chi protocol that will be developed in this study for Veterans with PTSD and pain will be adapted from a protocol that has been well-tested in previous trials All components of the program derive from the classical Yang-style Tai Chi 108 postures, which has been shown to be a moderate intensity exercise. Sessions will last 60 minutes, twice a week for 12 weeks. Experienced instructors will follow the Tai Chi protocol with rigorous quality control procedures. We will provide the patients with printed materials on the Tai Chi program, including Tai Chi principles, practice techniques, and safety precautions. Every session will include: warm up and a review of Tai Chi principles; breathing techniques; meditation with Tai Chi movement; and relaxation.
223776243|NCT07052149|OTHER|cervical muscle stabilization exercises|deep cervical muscle stabilization exercises, 15 minutes, 3 sessions per week for two months
223776244|NCT07052149|OTHER|Proprioceptive training|proprioceptive training, 15 minutes, 3 sessions per week for two months
223776245|NCT06738719|BIOLOGICAL|CT-P13 SC Auto-Injector|Subcutaneous(SC) Injection
223776246|NCT06738719|BIOLOGICAL|Placebo Auto-Injector|Subcutaneous(SC) Injection
223776247|NCT06926985|BIOLOGICAL|anti-CD19/BCMA CAR NK cells|Patients will receive Fludarabine and Cyclophosphamide on day -5, -4, and -3. Multiple doses of anti-CD19/ BCMA CAR NK cells will infused using the dose-escalation strategy.
223688999|NCT05693805|BEHAVIORAL|Wellness program|The Wellness intervention that will be developed for this study will consist of 60-minute sessions that meet twice a week for 12 weeks, and will be facilitated by doctoral level psychology staff and/or psychology trainees who will be supervised by staff. The Wellness intervention will be based on the VA Whole Health Program which helps individuals identify and achieve their personal health goals. The Whole Health Program include modules that address physical activity, personal development, healthy eating and drinking, stress management, relationships, personal surroundings, and spirituality. Using the SMART goals model, participants will set health and wellness goals each week. Discussions about ways to address potential barriers will be included in this condition.
223689000|NCT06121466|DRUG|Abdominal wall injections with lidocaine 2%|Injections will be administered for patient who are identified as having abdominal wall pain.
223776248|NCT03964454|BEHAVIORAL|WIC support + home-based individual support + Breastfeeding Incentives (SC+BFI)|Participants randomized into SC+BFI will receive the same services as the Standard Care Control (SC) group (standard breastfeeding services from Special Supplemental Nutrition Program for Women, Infants, and Children (WIC) plus monthly home visits that facilitate navigation to as-needed resources and referrals to services that support breastfeeding and problem solving) plus financial incentives (Breastfeeding Incentives, BFI) contingent on observed breastfeeding.
223689001|NCT05007717|BEHAVIORAL|Data-informed Stepped Care (DiSC)|"The DiSC intervention is comprised of a data-driven system to assign adolescents to care based on their health needs and the different levels of care for each assignment group.~The trajectory of services moves from a relative position of ALHIV autonomy to more intensive service provision. Intervention steps start with 1) multi-month refills or community treatment delivery (differentiated care); 2) a standard of care level for those with medical needs such as pregnancy or opportunistic infections or patient choice; 3) patient reminders/tracking and counseling and referral services for mental health needs; 4) case management of unsuppressed individuals, including enhanced counseling and case conference problem-solving"
223776249|NCT03964454|BEHAVIORAL|WIC support + home-based individual support (SC)|Participants randomized into SC will receive standard breastfeeding services from Special Supplemental Nutrition Program for Women, Infants, and Children (WIC) plus monthly home visits that facilitate navigation to as-needed resources and referrals to services that support breastfeeding and problem solving.
223776250|NCT05131100|DRUG|Somavert|As provided in real world practice
223776251|NCT04866394|RADIATION|SBRT|Patients will be planned with the aim of delivering 30 Gy in 5 fractions.
223776252|NCT00614029|DEVICE|Sumatriptan (via Intraject System)|0.5 mL of solution with 6 mg of sumatriptan (base) as the succinate salt
223776253|NCT01076400|DRUG|adavosertib|Adavosertib capsules are administered in sequentially rising dose levels twice daily for a total of nine doses on Days 1-5 of a 21-day cycle.
223776254|NCT01076400|DRUG|Topotecan|Topotecan is administered at a dosage of 0.75 mg/m\^2 by intravenous (IV) infusion over 30 minutes on Days 1-3.
223776255|NCT01076400|DRUG|Cisplatin|Cisplatin is administered at a dosage of 50 mg/m\^2 by IV infusion over 30 minutes on Day 1.
223776256|NCT01076400|DRUG|Placebo to adavosertib|Placebo to adavosertib capsules are administered in sequentially rising dose levels twice daily for a total of nine doses on Days 1-5 of a 21-day cycle.
223689003|NCT06387030|BIOLOGICAL|Blood sampling|3 tubes of blood for research purposes (maximum 9.6 mL for children weighing 5-12 kg, 16 mL between 12-20 kg, 24 mL between 20 and 30 kg, and 56 mL for those weighing over 30 kg) will be taken from the catheter necessary for general anaesthesia.
223689004|NCT06387030|BIOLOGICAL|Esophageal biopsies|4 additional esophageal biopsies will be taken during digestive endoscopy, in the pathological zone or in the lower third of the esophagus by default.
223776257|NCT03910335|DIAGNOSTIC_TEST|LSS Screen|Patients will fill out a questionnaire with 13 questions related to presence or absence of clinical symptoms of lumbar spinal stenosis (neurogenic claudication)
223776258|NCT03007316|PROCEDURE|VIP graft|surgical soft tissue grafting concomitant to implant placement
223776259|NCT03994861|DIAGNOSTIC_TEST|Assessment of disability and behavior (by questionnaires)|Assessment of disability and behavior (by questionnaires)
223689005|NCT06387030|BIOLOGICAL|Unstimulated saliva sampling|A esophageal brushing will be done during digestive endoscopy.
223689006|NCT06387030|BIOLOGICAL|Urine sampling|A urine sample will be collected during hospitalization for digestive endoscopy.
223689007|NCT06387030|BIOLOGICAL|Stool sampling|A stool sample will be collected during hospitalization for digestive endoscopy.
223689008|NCT03436563|BIOLOGICAL|Anti-PD-L1/TGFbetaRII Fusion Protein M7824|Given IV
223689009|NCT06070441|OTHER|Education|One-week, three sessions in alternate days, outpatient supervised education on how to perform the exercises at home
223689010|NCT06070441|DEVICE|Chatbot|12 week- intervention consisting of messages with an explanatory video of each exercise indicating how to do it and how many repetitions to perform
223689011|NCT06070441|OTHER|Home exercise, usual care|12 week- intervention. Printed sheets indicating how to exercises and how many repetitions to perform
223689012|NCT04449991|PROCEDURE|Repeat kidney biopsy|Intensification of immunosuppression if NIH AI \> 3
223776260|NCT00000435|DRUG|dnaJ peptide|dnaJP1 was taken in pill form at 25mg/day for 6 months
223776261|NCT00000435|DRUG|None-placebo|placebo was taken in pill form at 25mg/day for 6 months
223776262|NCT04612270|OTHER|Venous blood collection|Two venous blood collections in within one week. No drug-related intervention in-vivo.
223776263|NCT04368936|GENETIC|Isolated DNA, Real Time PCR|"We are isolated DNA from the blood sample. To determine the genotypes of the analyzed polymorphisms use real-time PCR using TaqMan essays.~When analyzing the KCC2 polymorphisms, the VIC dye gene corresponded to the C allele, and the FAM dye corresponded to the T allele, while at the TRPV1 gene polymorphism, the VIC dye corresponded to the C allele and the FAM dye to the G allele."
223776264|NCT00548769|DRUG|Formulation A|Formulation A will contain firategrast drug substance from native drug batch Irvine. Subjects will be administered three tablets of 300 milligrams with drug substance surface area of 2.1 square meter per gram. The tablets will be administered with 240 milliliters of water.
223776265|NCT00548769|DRUG|Formulation B|Formulation B will contain firategrast drug substance from native drug batch Tonbridge. Subjects will be administered three tablets of 300 milligrams with drug substance surface area of 2.6 square meter per gram. The tablets will be administered with 240 milliliters of water.
223689013|NCT05785429|DRUG|Colchicine 0.5 MG|Participant in the intervention group receive one tablet of 0.5mg colchicine per day for 12 weeks.
223689014|NCT05785429|DRUG|Placebo|Participants in the intervention group receive one tablet of placebo per day for 12 weeks.
223689015|NCT06313008|DRUG|Empagliflozin 10 MG|eligible subjects were randomly and equally assigned to the empagliflozin add-on group (empagliflozin 10 mg/ day).
223689016|NCT06313008|DRUG|Vildagliptin 50 MG|eligible subjects were randomly and equally assigned to vildagliptin add-on group (vildagliptin 50 mg/day as the initial dose).
223689017|NCT03335917|OTHER|Hypoxia|Participants will be exposed to hypoxia by reducing barometric pressure or by reducing oxygen concentration
223689018|NCT03335917|OTHER|Exercise|Graded cycling exercise to volitional fatigue
223689019|NCT00427960|BEHAVIORAL|Dietary advice|
223689020|NCT00427960|DRUG|rosuvastatin|rosuvastatin 5 mg
223689021|NCT00427960|DRUG|atorvastatin|atorvastatin 10 mg
223776266|NCT00548769|DRUG|Formulation C|Formulation C will contain firategrast drug substance from Tonbridge single pass micronized drug. Subjects will be administered three tablets of 300 milligrams with drug substance surface area of 3-4 square meter per gram. The tablets will be administered with 240 milliliters of water.
223776267|NCT00548769|DRUG|Formulation D|Formulation D will contain firategrast drug substance from Tonbridge with reduced tablet size. Subjects will be administered three tablets of 300 milligrams with drug substance surface area of 2.6 square meter per gram. The tablets will be administered with 240 milliliters of water.
223776268|NCT05751135|DEVICE|Focal muscle vibration|Focal muscle vibration will be provided by a longitudinal muscle vibrator on muscles of lower limb; hamstrings, quadriceps, illiopsoas, calf, gluteus maximus and medius. Each muscle will be targeted 3 times with 30 seconds time period and keeping 10 second interval.
223776269|NCT05751135|PROCEDURE|Stretching|Stretching of shortened lower extremity muscle
223776270|NCT05751135|PROCEDURE|Strengthening|Strengthening exercises for weak lower extremity muscles
223776271|NCT05751135|PROCEDURE|Positioning|Positioning of participant to maintain a good body posture
223776272|NCT03299140|BEHAVIORAL|Family Focused Therapy|
223776273|NCT04844164|DRUG|Cholecalciferol 15000 UNT/ML Oral Solution|A single dose (150,000 IU) of cholecalciferol aqueous solution per os
223776274|NCT04331366|DEVICE|GO2 PEEP MOUTHPIECE|The GO2 PEEP MOUTHPIECE has a bidirectional valve that delivers PEEP with each breath. Participants will be provided a G02 PEEP MOUTHPIECE to use underneath the oxygen face mask and will be instructed to breathe slowly and deeply through the mouthpiece for 15 minutes total. Metrics for primary and secondary endpoints will be recorded immediately prior to use and then at 5, 10 and 15 minutes of use and then 15 minutes after cessation of use.
223689022|NCT03935620|BEHAVIORAL|Enhanced Milieu teaching|"Enhanced Milieu Teaching (EMT) an evidence-based, naturalistic language intervention that has been optimized to address the specific language and communication deficits associated with DS. EMT is a parent-implemented intervention that involves home-visits during which clinicians teach parents to support their child learning language during typical parent-child interactions at home (play with toys, music, book reading, and snack time). Clinicians follow an evidence-based instructional framework called Teach-Model-Coach-Review to teach parents language support strategies."
223689023|NCT04804020|PROCEDURE|NC|The first ultrasound scan will be performed on the second to the fourth day of the menstrual cycle to identify any problem related to the patients' uterus or adnexa. The second ultrasound will be performed on the sixth day of the cycle. Daily ultrasound and serum estradiol and LH level evaluation will be performed when the mean diameter of the dominant follicle of ≥14 mm. LH surge initiation is defined as a concentration of 180% above the latest serum value available in that patient with a continued rise thereafter9 to a level of 20 IU/l or more10 detected by the ECLIA method (Roche Cobas® E 801, Roche Diagnostics, Germany). Embryo transfer will be scheduled by the time of the initiation of LH and embryo stages.
223689024|NCT04804020|PROCEDURE|mNC|The first ultrasound scan will be performed on the second to the fourth day of the menstrual cycle to identify any problem related to patients' uterus or adnexa. A second ultrasound scan will be performed on the sixth day of the cycle; if there is at least one follicle with a diameter of ≥12 mm, an ultrasound scan will be performed daily. When the dominant follicle's mean diameter is ≥16 mm, human chorionic gonadotropin (Ovitrelle® 250 μg; Merck, Kenilworth, NJ, USA) will be injected to trigger ovulation. Embryo transfer will be scheduled by the time of the hCG injection and embryo stages.
223689025|NCT04804020|PROCEDURE|AC|The endometrium is prepared using oral estradiol valerate (Valiera®; Laboratories Recalcine) 8 mg/day, ranging from the second or fourth menstruation day. The endometrial thickness will be monitored from day six onwards, and vaginal progesterone (Utrogestan®; Besins) 800 mg/day will be initiated when endometrial thickness reaches ≥7 mm. Estradiol exposure must be lasting for ≥9 days before progesterone administration. Embryo transfer will be scheduled by the time of the initiation of progesterone and embryo stages.
223689026|NCT01564771|OTHER|Non Intervention|This Is A Non Interventional Study
223689027|NCT02811601|PROCEDURE|PEAL surgery|Patients will undergo percutaneous externally-assembled laparoscopic surgery where one or more 3 mm instruments are added or substituted for conventional 5 or 10 mm trocars.
223689028|NCT03277079|DRUG|statin + ezetimibe|Combination of two drugs
223689029|NCT03277079|DRUG|statin + ezetimibe + Nutraceuticals|Combination of two grus plus nutraceuticals
223689030|NCT01011023|OTHER|Non application of nasogastric tube in the experimental group|Avoid the 5 post operative application of nasogastric tube in the experimental group vs the control group with the usual nasogastric tube
223689031|NCT04499547|BEHAVIORAL|YouTube-delivered aerobic and muscle-strengthening physical activity intervention|Participants in the intervention group will receive two YouTube-delivered videos each week, for 8 weeks. In detail, on Monday, participants will receive an aerobic-based physical activity video with information and a workout to complete and on Thursdays, the participants will receive a video with muscle-strengthening physical activity information and a workout to complete.
223689032|NCT01654861|DRUG|Gemcitabine, Intravenous and oral Ascorbic Acid (Vitamin C)|Weeks 1,2,3: IV Gemcitabine 1000 mg / m² over 30 minutes followed by HDIVC 1.2 g / kg: 1.2 g/kg over 90 minutes for a dose ≤90 g and over 120 minutes for a dose \>90g followed by 0.3 g / kg over 120 minutes; Week 4: no treatment.
223689033|NCT03137030|DRUG|GRT7014 - Abuse Deterrend Tablet|Single oral dose in one of the four cross-over trial periods and in the standard cross-over trial periods.
223689034|NCT03137030|DRUG|Norco 5Mg-325Mg Tablet|Single oral dose in one of the four cross-over trial periods and in the standard cross-over trial periods.
223689035|NCT02722096|DRUG|Axillary block anesthesia with Ropivacaine and Lidocaine|Axillary brachial plexus block anesthesia with injection of Ropivacaine and Lidocaine will be performed by anesthetist 30 to 45 minutes before surgery
223689036|NCT02722096|DRUG|Local anesthesia with Ropivacaine and Lidocaine|Local subcutaneous infiltration of Ropivacaine and Lidocaine will be performed by anesthetist at the beginning of surgery
223689037|NCT05390190|DEVICE|Non ablative radiofrequency|Device
223689038|NCT00842764|PROCEDURE|Holmium: YAG laser|Minimally Invasive Holmium:YAG laser Blepharoplasty
223689039|NCT06313879|OTHER|online education|Description of hydrocephalus disease, treatment methods and ventriculoperitoneal shunt care training will be given.
223689040|NCT02517970|BEHAVIORAL|Technology distraction|Infants will be fed with classical music playing in the background for one feeding and with a television show playing for the mother to watch during the other.
223776275|NCT05827367|DEVICE|Ultrasound|"The high-power pain threshold ultrasound (HPPTUS) In this technique, which be applied in continuous mode with intensity from t0.5 to 2 watt/cm to elicit pain threshold the US probe was kept motionless, and the intensity progressively increased until the maximum level of pain patient can endure was selected, it was maintained on this level for 3 to 4 seconds and then decreased to half intensity for 15 seconds the treatment process was repeated three times."
223776276|NCT05827367|OTHER|Myofascial release technique|Plantar fascia myofascial release Soluse muscle myofascial release Gastrocnmias muscle myofascial release
223776277|NCT05827367|OTHER|Strength and stretching|Plantar fascia stretching Interstice foot muscles strengthing
223776278|NCT05103761|OTHER|Study diet|A low carbohydrate diet (\<20g/day) is administered to achieve diet-induced ketosis.
223776279|NCT05103761|OTHER|Low glycemic index treatment diet|A diet matched with the study diet with added carbohydrates (40-60g/day) to avoid ketosis.
223776280|NCT03019536|DRUG|LY3303560 - IV|Administered IV
223776281|NCT03019536|DRUG|Placebo - IV|Administered IV
223776282|NCT03019536|DRUG|Florbetapir F 18|Administered IV during the Positron Emission Tomography (PET) scan performed during screening.
223776283|NCT03019536|DRUG|Flortaucipir F18|Administered IV during the PET scan performed during the study.
223776284|NCT00647920|BIOLOGICAL|adalimumab|40 mg adalimumab sc, every other week
223776285|NCT00647920|BIOLOGICAL|placebo|placebo sc, every other week
223776286|NCT05776485|OTHER|Progressive resistance training|Only the control group: 3 exercise bouts within the study period. Comparison between exercised and non-exercised leg.
223776287|NCT05776485|OTHER|Cross-sectional comparison between healthy and tendinopathic group|Comparison of primary and secondary outcomes.
223776288|NCT03894449|COMBINATION_PRODUCT|Prebiotic + Iron Forificant|A combination dosage of prebiotic (Inulin or GOS) and Iron Fortificant (FeSO4 or NaFeEDTA) will be given to the study subjects.
223776289|NCT06532448|DIAGNOSTIC_TEST|Single dose low-risk penicillin challenge|Initial screening to establish low risk allergy status followed by a single dose challenge using a standard penicillin dose. All challenges will be oral, conducted in a hospital setting and will be followed by a 1 hour monitoring period.
223776290|NCT03176160|OTHER|Palliative regimen consisting of LITT|Minimally invasive technique to necrotize intracranial lesions
223776291|NCT03223298|DRUG|Botulinum toxin type A|37.5 units injected into each masseter muscle and 12.5 units into each temporalis muscle
223776292|NCT03223298|DRUG|0.9% Sodium Chloride Injection|1cc syringe
223776293|NCT01653431|DEVICE|Transcranial direct current stimulation|
223689041|NCT03981302|OTHER|Family nursing conversations|"The intervention is based on the concept family systems nursing developed by Wright \& Maureen. Family nursing aims to change restricting beliefs and alleviate illness suffering. The Illness Beliefs model and Calgarymodels are essential components. The illness beliefs model illuminates the family's different beliefs about their problems. The Calgary models consist of the Calgary family assessment model and the Calgary intervention model and aim to support change and help the family to find new ways to handle the illness. The use of the components cannot be standardised but must be tailored to match the needs of the specific family. The family nursing conversations in this intervention will last 1,5 hour. Every family will be offered three family nursing conversations with roughly three weeks interval. If the family after three conversations express a need for follow-up, they will be offered the fourth conversation."
223689042|NCT03004196|DRUG|Probiotic Toothpaste|G.D Probiotic Toothpaste bacteriocin Lactic Acid Bacteria
223689043|NCT03004196|DRUG|Dr. Reddy's Clohex|0.20% Chlorhexidine Mouthwash
223689044|NCT03004196|OTHER|Control Group|No Probiotic toothpaste \& Chlorhexidine Mouthwash
223689045|NCT04406285|OTHER|Standard protocol Leukemia|"* Bicycle ergometer endurance training for 5 minutes, with resistance individually adjusted based on the patient´s feedback (from 70% of maximum heart rate);~* Resistance exercises for muscle groups: hip flexors, knee extensors and ankle plantar flexors (10 repetitions, 1 sets);~* Resistance training for arms, using 0,5 kg or 1,0 kg dumbbels (10 repetitions, 1 sets)."
223689046|NCT04406285|OTHER|Periodic Resistance Training Program Leukemia|"* Submaximal Ergometer tests with incremental load (from 85% of maximum heart rate or maximum effort related);~* 30-Second Chair Stand;~* Hand Grip Strength and submaximal arm effort using 0,5 kg or 1,0 kg dumbbels."
223689047|NCT04406285|OTHER|Standard protocol Lymphoma|"* Bicycle ergometer endurance training for 5 minutes, with resistance individually adjusted based on the patient´s feedback (from 70% of maximum heart rate);~* Resistance exercises for muscle groups: hip flexors, knee extensors and ankle plantar flexors (10 repetitions, 1 sets);~* Resistance training for arms, using 0,5 kg or 1,0 kg dumbbels (10 repetitions, 1 sets)."
223689048|NCT04406285|OTHER|Periodic Resistance Training Program Lymphoma|"* Submaximal Ergometer tests with incremental load (from 85% of maximum heart rate or maximum effort related);~* 30-Second Chair Stand;~* Hand Grip Strength and submaximal arm effort using 0,5 kg or 1,0 kg dumbbels."
223689049|NCT04383899|OTHER|Questionnaire|All patients testing positively for COVID-19, with completed questionnaires. As appropriate, the duration of the study will be at least the time to complete the questionnaire for non-hospitalized patients, and for those who are hospitalized, they will be followed until hospital discharge or death to ascertain outcome.
223689050|NCT03282565|OTHER|Functional Resistance Training with Brace|A brace will be strapped to the leg and apply resistance across the knee while subjects walk on a treadmill.
223689051|NCT03282565|OTHER|Control|A brace will be strapped to the leg and will not apply resistance across the knee while subjects walk on a treadmill.
223776294|NCT06074094|DRUG|Control Test|Lacteol fort 10 billion which contains culture medium and lactobacillus LS as active ingredients
223776295|NCT00182689|DRUG|sorafenib tosylate|Given orally
223776296|NCT00123227|DRUG|Rosiglitazone|
223776297|NCT01405391|DRUG|PM01183|PM01183 drug product (DP) is presented as a lyophilized powder for concentrate for solution for infusion with two strengths, 1 mg and 4 mg vials. Before use, the 1 mg and 4 mg vials should be reconstituted with 2 ml and 8 ml of water for injection respectively, to give a solution containing 0.5 mg/ml PM01183. For administration to patients as an i.v. infusion, reconstituted vials are diluted with glucose 50 mg/ml (5%) solution for infusion or sodium chloride 9 mg/ml (0.9%) solution for infusion.
223776298|NCT00664612|DEVICE|AirTraq|Laryngoscopy with AirTraq
223776299|NCT04054583|OTHER|Renovation of long-term residential care living spaces|Living spaces of the long term care facility will be renovated.
223776300|NCT02579642|DRUG|Ketamine|Low dose ketamine 0.2 mg/kg (or 0.5 mg/kg depending on results of interim analysis) administered with usual induction drugs for ECT
223776301|NCT02579642|DRUG|Placebo|Normal saline administered with usual induction drugs for ECT
223776302|NCT00201006|BEHAVIORAL|Face-to-face counseling|Biweekly group behavioral counseling sessions conducted in a face-to-face format
223776303|NCT00201006|BEHAVIORAL|Telephone counseling|Biweekly telephone counseling sessions conducted in a one-on-one format
223776304|NCT00201006|OTHER|Mail contact|Biweekly written newsletters with weight management advice delivered via U.S. mail
223776305|NCT05884060|OTHER|No intervention|No interventions
223776306|NCT04271930|BEHAVIORAL|Mindfulness Awareness Practices for Insomnia|MAP-I is a curriculum-based intervention that incorporates practice prior to bed, use of practice in the bed during night-time awakenings, and daily body scan.
223776307|NCT04271930|BEHAVIORAL|Sleep Health Information|A video SHE seminar will serve as active comparator for nonspecific treatment elements that pose rival explanations for the effectiveness of MAP-I.
223776308|NCT03946943|DRUG|Anlotinib|Once a day dosing of anlotinib alone for the first 7 days, Anlotinib ( 12mg, QD, PO, d1-14, 21 days per cycle), take once when limosis in the morning. If patients cannot suffer from AEs, they can get declined dosage.
223776309|NCT03946943|DRUG|Toripalimab|Toripalimab 240mg shall be administered via intravenous (IV) infusion, once every 21 days, on day 8 and day 29 of the first cycle, and days 1 and 22 of the following cycles.
223776310|NCT03946943|PROCEDURE|Blood Draw|Peripheral blood draws for correlative studies characterizing T-cells in peripheral blood will be performed at three timepoints: 1) pre-treatment, 2) on-treatment on cycle 3 day 1, and 3) off-study.
223776311|NCT03946943|PROCEDURE|Tumor Specimen Collection|Tumor specimen collection via core needle biopsy for correlative studies characterizing T-cells in tumor tissue will occur at three timepoints: 1) pre-treatment, 2) on-treatment on cycle 3 day 1, and 3) off-study.
223776312|NCT04194190|DRUG|Individual Patient TCR-Transduced PBL|
223776313|NCT05947448|DRUG|Azilsartan Medoxomil Potassium Tablet|Azilsartan Medoxomil Potassium Tablet，80mg，qd，lasts six month
223776314|NCT05947448|DRUG|Nifedipine Sustained -release Tablets|Nifedipine Sustained -release Tablets，qd，The maximum clinical dose，lasts six months；
223776315|NCT05947448|DRUG|Levoamlodipine Maleate Table|Levoamlodipine Maleate Table，qd，The maximum clinical dose，lasts six months；
223776316|NCT05306067|DIAGNOSTIC_TEST|LDH-based malaria rapid diagnostic test|Malaria testing using an LDH-based malaria rapid diagnostic test will be added to standard routine testing of suspected cases at health facilities
223776317|NCT05306067|DIAGNOSTIC_TEST|Malaria rapid diagnostic test|All pregnant women attending their first routine antenatal visit will be tested for malaria using routine malaria rapid diagnostic tests
223776318|NCT03339076|DEVICE|"M3 MINI CATHETER"|"Participants in the study are using either a foley catheter or Clean Intermittent Catheter devices to facilitate bladder drainage. The study is an alternative method of facilitating bladder drainage with the M3 Mini Catheter."
223776319|NCT03783351|GENETIC|CYP2C19 genotype testing|CYP2C19 genotype testing will be conducted in a designated central laboratory.
223776320|NCT01040871|DRUG|VELCADE|VELCADE intravenous on Days 1, 4, 8, and 11 of a 21 day (3 week) cycle for 6 cycles.
223776321|NCT01040871|DRUG|Rituximab|Rituximab intravenous on Day 1 of a 21 day (3 week) cycle for 6 cycles
223776322|NCT01040871|DRUG|Cyclophosphamide|Intravenous on Day 1 of a 21 day (3 week) cycle for 6 cycles
223689052|NCT03282565|OTHER|Functional Resistance Training with Elastic Band|An elastic band will be strapped to the leg and apply resistance across the knee while subjects walk on a treadmill.
223689053|NCT04768673|DRUG|CKD-393 formulation I|single, oral administration of 2 tablets under fed condition
223689054|NCT04768673|DRUG|CKD-393 formulation II|single, oral administration of 2 tablets under fed condition
223689055|NCT04768673|DRUG|D501, D759, H053|single, oral administration of 1 D501, 1 D759 and 2 H053 under fed condition
223689056|NCT00660283|DRUG|Temozolomide|"(Stage I Treatment) Postoperative concomitant limited-field radiation therapy with daily temozolomide (75 mg/m2) must begin between 14 and 28 days from surgery.~7\. (Stage II Treatment) temozolomide 150 mg/m2 to be given days 1-7 and 15-21 of a 28 day cycle to begin within 45 days of stop date of concomitant limited field radiation/daily temozolomide (Stage I treatment) up to a maximum of 12 cycles."
223776323|NCT01040871|DRUG|Doxorubicin|Intravenous on Day 1 of a 21 day (3 week) cycle for 6 cycles
223776324|NCT01040871|DRUG|Prednisone|Orally on Day 1 to Day 5 of a 21 day (3 week) cycle for 6 cycles
223689057|NCT05821673|PROCEDURE|Argon plasma pre-treated abutment insertion|abutments allocated to the test group were placed in an Argon plasma reactor (Diener Electronic GmbH, Jettingen, Germany) for decontamination and activation. In order to restrict any post-treatment contamination; abutments were inserted immediately after the end of the plasma process. The reactor was set at 75 W of power and -10 MPa of pressure for 12 min.
223689058|NCT05821673|PROCEDURE|abutment insertion|the abutments assigned to the control group were screwed onto the implants without receiving argon plasma pretreatment
223776325|NCT01040871|DRUG|Vincristine|Intravenous on Day 1 of a 21 day (3 week) cycle for 6 cycles
223776326|NCT04186962|OTHER|Behavioral: Simple cognitive task|"A memory reactivation cue followed by playing the computer game Tetris"
223776327|NCT05561686|DRUG|Pyrotinib|This study adopted a prospective, multicenter, observational design. From October 1, 2022, 100 patients with HER2-positive breast cancer scheduled to receive neoadjuvant therapy with pyrotinib were enrolled. The treatment regimen was determined according to the patient 's condition, physician' s treatment experience, evidence-based evidence and other factors to assess the clinical benefit (pCR, ORR) and safety of different neoadjuvant therapy modalities containing pyrotinib. Exploratory analysis was performed to investigate the correlation between the level of TMB and the pCR rate of neoadjuvant therapy in HER2-positive breast cancer patients, and the effect of pyrotinib on intestinal flora.
223776328|NCT03708341|DRUG|Melatonin 5 mg|Systematic daily administration of melatonin 5 mg during patient's ICU stay
223776329|NCT03708341|DRUG|Placebo Oral Tablet|Systematic daily administration of placebo during patient's ICU stay
223776330|NCT01273831|DRUG|atracurium|atracurium, Drop,0.5 mg/kg, one time, one day
223776331|NCT01273831|DRUG|cisatracurium|cisatracurium, drop,0.15mg/kg,one time, one day
223776332|NCT04175262|DRUG|sunitinib|Patients to receive sunitinib as second line therapy for mRCC
223776333|NCT05905185|DRUG|Tocotrienol-rich fraction vitamin E (TRF)|The 50 mg of vitamin E isomers in the TRF included 17.1 mg of α-tocopherol ,18.28 mg of α- tocotrienol, 2.02 mg of β-tocotrienol, 22.3 mg of γ-tocotrienol and 7.4 mg of δ-tocotrienol.
223776334|NCT05905185|DRUG|Placebo|50mg of Placebo
223776335|NCT05634681|RADIATION|Plan of the day|Several treatment plans are prepared and the appropriate plan is used at each treatment session.
223689059|NCT05350735|BEHAVIORAL|Intervention arm: SMS text reminders and medical card|This study arm will assess compliance with anti-rabies vaccine regimen by participants in the presence of SMS text reminders as compared to without the SMS reminder.
223689060|NCT01869725|DRUG|gallium Ga 68-edotreotide|Given IV
223689061|NCT01869725|PROCEDURE|positron emission tomography/computed tomography|Undergo gallium Ga 68-edotreotide PET/CT scan
223689062|NCT01869725|RADIATION|indium In 111 pentetreotide|Undergo indium In 111 pentetreotide contrast-enhanced CT or MRI scan
223689063|NCT01869725|PROCEDURE|computed tomography|Undergo indium In 111 pentetreotide contrast-enhanced CT scan
223689064|NCT01869725|PROCEDURE|contrast-enhanced magnetic resonance imaging|Undergo indium In 111 pentetreotide contrast-enhanced CT or MRI scan
223689065|NCT01143207|DRUG|Medroxyprogesterone acetate|Injectable hormonal contraceptive
223689066|NCT02235259|DRUG|XG-104|Comparison of XG-104 (3 concentrations) versus placebo eye drops efficacy
223689067|NCT02235259|DRUG|Placebo|
223689068|NCT01669564|OTHER|Will use HIT patient feedback to activate patients.|"After completing the FAST, GIMO patients seeing a participating provider will receive(or not receive)HIT patient feedback, based on their providers' study group assignment. Feedback for each PRI will be personalized based on the medical history, family history, and other PRI reported on the FAST. A discussion of potential treatment options will be presented along with possible general referral resources. The patient will be encouraged to discuss the PRI with his or her physician.~Patients will be provided with a list of resources, customized to their study-designated PRI, that includes ongoing programs available both in the community and GIMO to help them with behavior change and mental HRQoL."
223689069|NCT01669564|OTHER|Patients will not receive HIT patient feedback.|After completing the FAST (standard of care in GIMO) GIMO patients seeing a participating provider will receive (or not receive) HIT patient feedback, based on their providers' study group assignment.
223689070|NCT00123968|BIOLOGICAL|VRC-HIVDNA016-00-VP|1x10\^11 per unit vaccine administered intramuscularly via Bioinjector
223689071|NCT00123968|BIOLOGICAL|VRC-HIVADV014-00-VP|4 mg administered intramuscularly via injection
223689072|NCT00123968|BIOLOGICAL|VRC-DILUENT013-DIL-VP|Administered intramuscularly via Bioinjector
223689073|NCT00123968|BIOLOGICAL|VRC-HIVADV014-00-VP placebo|4 mg administered intramuscularly via injection
223689074|NCT04403490|BEHAVIORAL|HABIT-ILE|2 weeks HABIT-ILE
223689075|NCT04403490|BEHAVIORAL|Conventional intervention|2 weeks usual intervention (waitlist group)
223689076|NCT00281073|DEVICE|Intra-Cardiac Echocardiography guided Cardioversion|Intracardiac Echo and TEE
223689077|NCT00281073|DEVICE|Intracardiac Echo|Intracardiac Echo Viewmate
223689078|NCT00281073|DEVICE|ICE|ICE or TEE
223689079|NCT04163718|DRUG|Umbralisib|800 mg Umbralisib will be self-administered on an outpatient basis. Umbralisib will be taken orally once daily within 30 minutes of a meal until removal from study. This treatment will be administered in 4 week (28-day) cycles.
223689080|NCT01056328|DEVICE|SJM Irrigated Cardiac Ablation System|Irrigated ablation catheter
223689081|NCT01056328|DEVICE|FDA approved Open Irrigated RF Ablation System|Irrigated ablation catheter
223689082|NCT04457973|DEVICE|Active tDCS|tDCS with a constant current intensity of 2 milliampere (mA) will be applied for 20 minutes per session daily for 5 days via the Soterix 1x1 tDCS mini-CT Stimulator device with headgear and 5x7 cm saline-soaked surface sponge electrodes.
223689083|NCT04457973|DEVICE|Sham tDCS|The electrodes will be placed in the same positions as for active stimulation, but the stimulator will only deliver 2 mA current for 30 seconds.
223689084|NCT00187759|DRUG|cephalexin|
223689085|NCT02960997|DRUG|Sirolimus, 2%|
223776336|NCT05634681|RADIATION|Standard plan|One treatment plan
223689086|NCT02960997|DRUG|Vehicle|
223776337|NCT03042806|BEHAVIORAL|questionnaire|all the COPD patients will be ask to complete the questionnaire
223776338|NCT02106338|OTHER|Placebo|Placebo capsules have the same inert components as CRS3123; 2 subjects randomized in each cohorts recieve 200mg, 400mg; and 600mg, or 100mg are planned respectively given orally every 12 hours for 10 days
223689087|NCT05920928|RADIATION|Short course radiotherapy with concurrent capecitabine(825mg/m2)|Compared to conventional treatments, short-term radiotherapy has lower fraction numbers but higher radiation doses per fraction. capecitabine is given during treatment time (825mg/m2)
223689088|NCT05920928|RADIATION|Long course radiotherapy with concurrent capecitabine(825mg/m2)|Long-term radiation is administered in conjunction with concomitant capecitabine (825mg/m2)
223689089|NCT01639586|BEHAVIORAL|respite platform|Impact of the respite platform patient care on health profit
223689090|NCT01639586|BEHAVIORAL|Day care|Impact of the day care on health profit of patient
223689091|NCT01639586|BEHAVIORAL|No access to a respite structure|Control group without access to a respite structure
223689092|NCT00803218|DRUG|Fluticasone Propionate 0.005% Ointment-Reference Product|Small amount applied and evaluated over the course of one day
223689093|NCT00803218|DRUG|Fluticasone Propionate 0.005% Ointment-Test product|Small amount applied and evaluated over the course of one day
223689094|NCT01553032|DRUG|Erbitux®|400mg/m2 initial dose, followed by weekly doses of 250mg/m2 Treatment duration: 7-8 weeks
223689095|NCT01553032|RADIATION|Fractionated Radiotherapy|30-35 fractions of radiotherapy (6-7 weeks)
223689096|NCT00218725|BEHAVIORAL|Cognitive Therapy|The cognitive therapy intervention for suicide attempters has been designed to provide a brief, timely, flexible intervention that can be incorporated into general and psychiatric inpatient and outpatient services and applied to the population of patients who attempt suicide. A central feature of the intervention is the adaptation of cognitive therapy to the population of patients who attempt suicide. The focus of the intervention is the identification of core beliefs and key automatic thoughts that were elicited prior to and during the most recent suicide attempt. Once these beliefs and thoughts have been articulated, the counselor and patient develop more adaptive responses during an acute suicidal crisis.
223689097|NCT00218725|OTHER|Enriched Care|The Enriched Care condition will be used as the treatment comparison condition for this study. The Enriched Care condition consists of the usual care that patients may obtain in the community as well as the assessment and referral services provided by the case managers. Participation in the study does not restrict patients in any way in their access to other health care, and all patients in both conditions will be allowed to receive any additional mental health and substance abuse treatment in the community.
223689098|NCT00902733|OTHER|medical chart review|
223689099|NCT00902733|OTHER|questionnaire administration|
223689100|NCT00902733|PROCEDURE|fatigue assessment and management|
223689101|NCT00902733|PROCEDURE|psychosocial assessment and care|
223689102|NCT00902733|PROCEDURE|quality-of-life assessment|
223689103|NCT00003301|DRUG|irinotecan hydrochloride|
223689104|NCT02917473|BEHAVIORAL|In-person counseling|"In-person counseling~Sun protection"
223689105|NCT02917473|BEHAVIORAL|Written advice|Written advice
223689106|NCT02917473|BEHAVIORAL|Medical skin screening|Medical skin screening
223689107|NCT01218633|DRUG|saline infusion|saline infused at 30ml/hour
223689108|NCT01218633|DRUG|GLP-1-9,36 infusion|infused @ 1.2pmol/kg/min
223689109|NCT01218633|DRUG|Exendin-9,39 at low dose|infused at 30pmol/kg/min
223689110|NCT01218633|DRUG|Exendin-9,39 at high dose|infused @ 300pmol/kg/min
223689111|NCT04824365|DRUG|Sodium Pyruvate|Subjects will use a sodium pyruvate nasal spray 3x daily for 14 days.
223689112|NCT04824365|OTHER|Saline|Subjects will use a saline nasal spray 3x daily for 14 days.
223689113|NCT03395054|OTHER|cervical stabilization exercises|cervical stabilization exercises
223689114|NCT03395054|OTHER|conventional exercises|conventional exercises
223689115|NCT02983396|DEVICE|Diagnostic accuracy of Mini Relf Device|Evaluation of the Mini Relf Device when it is applied on daily basis at home and during coronary angioplasty at 60 second acute coronary occlusion angioplasty
223776339|NCT02106338|DRUG|CRS3123|CRS3123, a methionyl-tRNA synthetase inhibitor, formulated in 100 and 200 mg capsules; 8 subjects randomized in Cohorts A through C receive doses of 200 mg, 400 mg; and 600 mg or 100mg are planned respectively given orally every 12 hours for 10 days.
223689116|NCT01577654|DRUG|EC145|2.5 mg on Days 1,4,8,11 (Weeks 1 and 2 q3 weeks)
223689117|NCT01577654|DRUG|EC145 + Docetaxel|"EC145 2.5 mg on Days 1,4,8,11 (Weeks 1 and 2 q3 weeks) +~Docetaxel 75 mg/m2 IV Day 1 q 3 weeks"
223689118|NCT01577654|DRUG|Docetaxel|75 mg/m2 IV Day 1 q 3 weeks
223689119|NCT01577654|DRUG|EC20|During the screening period participants will receive a single intravenous administration of EC20 prior to SPECT imaging
223689120|NCT02193698|DRUG|Lenalidomide+Dexamethasone|Lenalidomide 25mg/day (day 1-21) Dexamethasone 20mg/day (day 2. 9, 16, 23)
223689121|NCT05931588|OTHER|Pilates excercises, streching and breathing|international group receive Pilates exercises, stretching and breathing two times a week (30 min per session) perform 3 to 5 reps of Pilates exercises under supervision
223689122|NCT05931588|OTHER|stretching and breathing|control group guided with stretching and breathing home based program both group till 8 week both groups
223689123|NCT01770652|DRUG|Deferiprone|Oral iron chelator
223689124|NCT00010127|BIOLOGICAL|therapeutic autologous dendritic cells|
223689125|NCT04565184|DRUG|Artesunate-amodiaquine combination|Artesunate-amodiaquine (Coarsucam®: Sanofi-Aventis, France) is co-packaged as artesunate 50 mg and amodiaquine hydrochloride USP equivalent to amodiaquine base of 153.1 mg. Each child shall be given one, two or three tablets depending on the weight.
223689126|NCT04565184|DRUG|Artemether, Lumefantrine Drug Combination|Artemether-lumefantrine (Coartem®: Novartis, Switzerland) is formulated as tablets and will be provided in blister packs. Each tablet contains 20 mg artemether and 120 mg lumefantrine. Every pack has a picture showing how the drug should be given and contains two blisters for each day with one, two or three tablets depending on the weight of the child
223689127|NCT03472066|OTHER|Previous conization|a group of women who have been conized,
223689128|NCT03472066|OTHER|no previous conization|group with asymptomatic patients on routine second trimester echography
223689129|NCT03463031|DRUG|GSP 301 NS|1 spray in each nostril twice daily for 14 days
223689130|NCT03463031|DRUG|GSP 301 Placebo NS|1 spray in each nostril twice daily for 14 days
223689131|NCT02171702|DRUG|BIBW 2992|
223689132|NCT00290212|DRUG|Natto capsules (food suppl.) cont. 360 microg. vit K2/day|
223689133|NCT00290212|DRUG|Placebo capsules|
223689134|NCT05547152|OTHER|massages|The experimental rehabilitation protocol includes massages
223689135|NCT05547152|OTHER|motor stimulation and stretching|motor stimulation and stretching
223689136|NCT05547152|OTHER|virtual reality|Patient watches an avatar of his face performing different movements on a screen, and will have to imagine performing these movements without actually doing them.
223689137|NCT03508271|OTHER|Non-Interventional|Non-Interventional
223689138|NCT02744469|OTHER|No intervention (observational study)|
223689139|NCT04348890|DRUG|Vamorolone 4% suspension for oral dosing|vamorolone 6 mg/kg/day orally once daily for 8 weeks.
223689140|NCT02131532|BEHAVIORAL|A brief psychological intervention|This intervention is based on the principle of cognitive-behavioral therapy
223689141|NCT04709939|OTHER|OPAT|Observation of patients who are discharged from the hospital on OPAT.
223689142|NCT04709939|OTHER|Focus Group|Focus group with infectious disease physicians who prescribe OPAT to patients but were not involved in the study.
223689143|NCT05572190|DRUG|ETR028, ETR029, [ETR028 + ETR029] or HCBT|Hydrocodone prodrugs
223689144|NCT01133561|DRUG|actozone A|pioglitazone 30 mg tablet , once daily dose for 10 weeks
223776340|NCT01353339|DRUG|Levofloxacin|500mg, PO, once daily for 3 months
223689145|NCT01133561|DRUG|actozone B|one tablet of vehicle without active ingredient pioglitazone
223689146|NCT00270829|DRUG|nesiritide|Drug given intrarenally or placebo
223689147|NCT02594540|DEVICE|Mechanical Peripheral Stimulation (GONDOLA)|
223689148|NCT02160353|DRUG|Abiraterone acetate, Prednisolone|
223689149|NCT06229782|DIAGNOSTIC_TEST|Orbital Doppler ultrasonography|During measurement, Doppler settings were adjusted to detect low flow and the smallest available Doppler gate was used for all ODUS examinations. The imaging probe position for ODUS was used transversely and axially, and mean values were recorded. ODUS 10-18 MHz linear probe was used.
223689150|NCT06229782|DIAGNOSTIC_TEST|Transcranial Doppler ultrasonography|"During the measurement, Doppler settings were adjusted to detect low flow, and the minor available Doppler gate was used for all TDUS examinations. For TDUS, a temporal window was used approximately 1 cm above the midpoint of the line joining the lateral palpebral fissure and the external auditory meatus.~Transcranial Doppler ultrasonography ( TDUS) 3-5 MHz convex array probe was used."
223689151|NCT06229782|DIAGNOSTIC_TEST|Computed Tomography Angiography|Cranial Computed Tomography Angiography
223689152|NCT02583243|BEHAVIORAL|MET/CBT based individualized counseling|Manualized counseling with the first four week being MET followed by 8 weeks of CBT
223689153|NCT02583243|DRUG|Buprenorphine|Target dose in stabilization is 16 mg of buprenorphine to be taken sublingually once daily.
223689154|NCT05049369|DEVICE|Polysomnography|Polysomnography is performed one time overnight
223689155|NCT03141073|DRUG|HMS5552|BID oral administration
223689156|NCT03141073|DRUG|Placebo|BID oral administration
223776341|NCT03604718|BIOLOGICAL|Beltavac® Polymerized with Alternaria alternata|Adminstration of Beltavac® Polymerized with Alternaria alternata according to the routine clinical practice
223689157|NCT00920231|DEVICE|initial system|The computer vision system is used to assist blind subject to navigate an extended path with multiple turns within a hospital setting.The initial prototype system would have been successfully tested for outdoor navigation and basic object recognition tasks.
223689158|NCT00920231|DEVICE|modified system|The problems associated with the initial system were identified and modified. This modified system was tested with a second separate group of subjects. The redesigned system is used to assist blind subject to navigate the same extended path with multiple turns within a hospital setting.
223689159|NCT06552247|DIAGNOSTIC_TEST|Fundus Picture AI testing|G-Risk AI algorithm will assess the optic disc centered fundus picture and determine whether or not there is a need for referrable based on a pre-determined threshold (\>=0.73)
223689160|NCT01013298|DEVICE|video-guided PCT|extubation and then re-intubation with the ETT-TVT, followed by video monitoring of the PCT procedure via the ETT-TVT
223776342|NCT03637998|BEHAVIORAL|Problem-solving Pain to Enhance Living Well (PROPEL)|PROPEL incorporates evidence-based, standard of care methods to promote physical activity among individuals with pain, and tools to improve knowledge, skills and confidence to cope with cLBP. The focus is self-management of cLBP. All eligible participants will then undergo baseline data collection, which entails completion of study questionnaires, quantitative sensory testing (QST) and venipuncture for collection of a blood specimen. Participants will be provided with the information to access the PROPEL intervention. All participants will be asked to complete questionnaires at 2, 4, 6, 8, and 10 weeks following baseline testing. At 12 weeks, participants will be scheduled for a final data collection visit, which will follow the same procedures as the baseline visit.
223689161|NCT04792515|DRUG|Camrelizumab combined with SOX/ or apatinib|"Camrelizumab: every 3 weeks (21 days) was given as one administration cycle. 200mg was given intravenously on the first day of each cycle. Dose adjustment is not allowed. Delayed administration is allowed.~Apatinib mesylate: 250mg, qd, stopped 28 days before surgery, and can be used by the investigator according to the patient's recovery 28 days after surgery.~Chemotherapy: The SOX regimen consisted of one cycle every 3 weeks (21 days).Dose adjustment is allowed. Delayed administration is allowed.~Oxaliplatin (OXA) : 130mg/m2, intravenous infusion, d1, infusion more than 2 hours.~Tigio Capsules (S-1) : Take orally after breakfast and dinner, twice daily, d1-14.~The dosing time window is ±3 days, but within 72 hours before each dosing, subjects must complete an examination that includes all clinical requirements to assess tolerance for continued dosing."
223689162|NCT02891811|DRUG|Carfilzomib|Induction treatment: Cycle 1 day 1+2: 20 mg/m2; days 8,9, 15 and 16: 27 mg/m2; Cycle 2: 27 mg/m2 on days 1,2,8,9,15 and 16; Cycle 3-9: 56 mg/m2 on days 1, 8 and 15; IV duration: 30-60 minutes; Maintenance treatment with carfilzomib (last tolerated dose on day 1 and 15 (± 7 days) of each cycle)
223689163|NCT02891811|DRUG|Thalidomide|100mg orally on days 1-28 in patients \<75 years of age at Cycle 1; 50mg p.o. on days 1-28 in patients ≥ 75 years of age at Cycle 1
223689164|NCT02891811|DRUG|Lenalidomide|25mg p.o. on days 1-21 of each cycle
223689165|NCT02891811|DRUG|Dexamethasone|40mg p.o. on days 1, 8, 15,22 (± 1 day ) in patients \<75 years of age at Cycle 1; 20mg p.o. on days 1, 8, 15, 22 (± 1 day) in patients ≥ 75 years of age at Cycle 1, given 4 hours-30 min prior to carfilzomib
223689166|NCT00154726|DRUG|Paclitaxel-HDFL|
223689167|NCT04095273|DRUG|Elimusertib (BAY1895344)|Study drugs will be administered as scheduled
223689168|NCT04095273|DRUG|Pembrolizumab (Keytruda®)|Study drugs will be administered as scheduled
223689169|NCT01137318|BEHAVIORAL|Cognitive remediation and Parent Training|Cognitive Intervention is CogMed Working Memory Training program, which is a 5-week, 5days/week computerized training program completed at home. The Parent Training is a 2.0 hour, weekly, group sessions that focus on behavioral management procedures.
223689170|NCT02233062|DIETARY_SUPPLEMENT|Exclusive Enteral Nutrition Therapy|
223689171|NCT02836353|DRUG|Somatostatin|Single dose of short acting Somatostatin (100mcg) pre Oral glucose tolerance test
223689172|NCT02836353|DRUG|Rifaximin|1 week course of 400mg three times daily (TDS) pre Oral glucose tolerance test
223689173|NCT03300531|BIOLOGICAL|Ultrasound-guided pure platelet-rich-plasma (P-PRP) injection|Blood will be drawn, and tendon will be penetrated with dry needle under ultrasound guidance. Pure platelet-rich plasma will be injected into the tendon.Once a week for three times.
223689174|NCT03300531|BIOLOGICAL|Ultrasound-guided platelet-rich-plasma (PRP) injection|Blood will be drawn, and tendon will be penetrated with dry needle under ultrasound guidance. Platelet-rich plasma will be injected into the tendon.Once a week for three times.
223776343|NCT06452459|OTHER|No interventinon|No intervention is anticipated. This is an observational study.
223689175|NCT03300531|DRUG|Ultrasound-guided Compound betamethasone injection|Tendon will be penetrated with dry needle under ultrasound guidance. Compound betamethasone will be injected into the tendon.Once a week for three times.
223689176|NCT04008823|OTHER|Retrospective and observational epidemiological study, by review of clinical histories,|Retrospective and observational epidemiological study, by review of clinical histories,
223689177|NCT05521724|PROCEDURE|exercise|resistance and strengthening exercises will be applied to a randomized patient group.
223689178|NCT03110731|BEHAVIORAL|Physical training|Physical training (2x / week) was performed for 12 weeks
223689179|NCT04779996|DIAGNOSTIC_TEST|Laboratory Samples|"1. After full vaccination with a Covid 19 vaccine, the following laboratory samples will be taken one time only, two weeks after full dose vaccination: i. Serologic rapid test (IgG, IgM) ii. Serum quantitative immunoglobulin levels iii. CD4 level iv. CD8 level~2. Laboratory samples will be taken at Hospital Auxilio Mutuo Laboratorio Clínico. Likewise, the Immuno Reference Lab might be used as an alternative.~3. Since monoclonal antibody therapy can induce hypogammaglobulinemia, we will measure gammaglobulin levels to correlate with antibody response to vaccine. Similarly, we will evaluate the CD4 and CD8 counts."
223689180|NCT01669096|BIOLOGICAL|GSK Biologicals' investigational TB vaccine GSK 692342|2 doses administered intramuscularly according to a 0, 1 month schedule (Day 0 and Day 30), in the deltoid region of the arm
223689181|NCT00146107|BEHAVIORAL|Diet|10 percent weight loss through diet and behavioral modification
223689182|NCT00146107|OTHER|Exercise|Multicomponent (resistance, aerobic, balance) exercise three times a week
223689183|NCT00146107|OTHER|Weight Loss and Exercise|10% weight loss through diet and exercise plus multicomponent exercise training three times a week
223689184|NCT02861131|DRUG|Sugammadex|At the end of the surgical procedure at a depth of neuromuscular blockade after the reappearance of T2 on the train-of-four, Sugammadex will be dosed once at 2 mg/kg through an intravenous line with brisk flow
223689185|NCT02861131|DRUG|Neostigmine|At the end of surgical procedure at a depth of neuromuscular blockade after the reappearance of T2 on the train-of-four, Neostigmine will be dosed once at 0.07 mg/kg to a maximum of 5 mg through an intravenous line with brisk flow. Glycopyrrolate will be administered with Neostigmine at a dose between 0.1 to 0.2 mg of Glycopyrrolate per 1.0 mg of Neostigmine administered.
223689186|NCT00027937|BIOLOGICAL|aldesleukin|
223689187|NCT00027937|BIOLOGICAL|filgrastim|
223689188|NCT00027937|BIOLOGICAL|sargramostim|
223689189|NCT00027937|DRUG|busulfan|
223689190|NCT00027937|DRUG|cyclophosphamide|
223689191|NCT00027937|DRUG|melphalan|
223689192|NCT00027937|DRUG|paclitaxel|
223689193|NCT00027937|DRUG|thiotepa|
223689194|NCT00027937|PROCEDURE|bone marrow ablation with stem cell support|
223689195|NCT00027937|PROCEDURE|in vitro-treated peripheral blood stem cell transplantation|
223689196|NCT00240695|DRUG|galantamine hydrobromide|
223689197|NCT02291744|PROCEDURE|resection of primary lesion|Oxaliplatin 130mg/m2 ivgtt d1 and capecitabine 1000mg/m2,bid,po,d1-d14,every three weeks for a cycle, and resection of primary lesion with metastatic colon cancer
223689198|NCT02291744|DRUG|XELOX|Oxaliplatin 130mg/m2 ivgtt d1 and capecitabine 1000mg/m2,bid,po,d1-d14,every three weeks for a cycle,
223689199|NCT03507062|OTHER|0.9% saline administration|Each patient will receive 0.9%saline based on attending physician decision
223689200|NCT03507062|OTHER|Ringer's lactate administration|Each patient will receive Ringer's lactate based on attending physician decision
223689201|NCT03507062|OTHER|Plasmalyte-like solution administration|Each patient will receive Plasmalyte-like solution based on attending physician decision
223689202|NCT02636842|DRUG|Aripiprazole Lauroxil|Intramuscular (IM) injection, single dose
223689203|NCT01169597|DRUG|prednisone|prednisone 12.5 mg daily po
223689204|NCT02494362|OTHER|Computer gaming hand exercise regimen.|Computer gaming hand exercise regimen using common objects of daily life. The hand exercises are coupled with commercially available computer games and will be performed 30 minutes,four times per week for 12 weeks.
223689205|NCT01466595|DRUG|Rifaximin|Participant were administered one 550 mg tablet of rifaximin to be taken orally two times a day for 4 weeks.
223689206|NCT01685346|BEHAVIORAL|biofeedback-mediated stress management (BFSM)|Therapist and study assistant meet with patient, attach sensors, record physiologic variables and train the patient in relaxation techniques including deep breathing, guided imagery, progressive muscle relaxation, autogenics. Patient is given a handheld thermometer to take home and practice self-regulation between visits, along with a recording sheet to indicate how often practice occurs.
223689207|NCT02606695|DEVICE|NuvaMap O.R.|Clinical imaging software used to assess intraoperative spinal alignment
223689208|NCT02606695|DEVICE|NuvaMap|Clinical imaging software used to assess spinal alignment
223689209|NCT01672229|DRUG|Bortezomib|If improvements are seen at any dose level and patients have no DLTs, they will stay at their dose level until the end of the study. This is to avoid any possible toxicity while the patient is benefiting from their current dosing of bortezomib. If the continuous improvement in GVHD stalls at any point, or the GVHD progresses after the original improvement, while the dose level is maintained, then the dose will be increased to the next dose level. Patients will remain enrolled until exacerbation of the GVHD on increasing dose schedule or closure of the study. Clinical activity will be monitored every other week after the initiation of bortezomib until the study closes.
223689210|NCT00562744|OTHER|Simulation|Use of high-fidelity patient simulator for training and assessment of PALS scenario performance
223689211|NCT04454164|BIOLOGICAL|PRP|platelet rich plasma
223689212|NCT04454164|DRUG|Saline|serum physiologic
223689213|NCT05258643|OTHER|Blood analysis|Venipuncture and collection of serum and whole blood
223689214|NCT00076973|DRUG|montelukast sodium|Duration of Treatment: 6 months
223689215|NCT00076973|DRUG|Comparator: placebo|Duration of Treatment: 6 months
223689216|NCT00057954|PROCEDURE|Extracorporeal Photopheresis|Day -7 to -4: Extracorporeal Photopheresis may be given as an outpatient therapy on two consecutive days any time between days -7 to -4. This must be performed on UVAR or XTS photopheresis machines (Therakos, Inc.) according to standard procedure as per manufacturer's guidelines.
223689217|NCT00057954|DRUG|Pentostatin|Day -3, -2: Pentostatin 4 mg/m²/d by continuous IV infusion (Total dose = 8 mg/m²)
223689218|NCT00057954|RADIATION|Total body irradiation (TBI)|Day -1: TBI 400 cGy total dose given in two 200cGy doses. Patients who have received TBI for a previous transplant or radiation as part of previous treatment for a lymphoid malignancy will receive only 200 cGy in 1 dose.
223689219|NCT00057954|PROCEDURE|Allogeneic bone marrow transplantation|Day 0: Infusion of unmanipulated allogeneic bone marrow or stem cells. Minimum cell dose of 2 x 106 CD34 cells/kg recipient and no more than 10 x 10\^6 CD34/kg
223689220|NCT00057954|DRUG|Cyclosporin (CSA)|Cyclosporin A or tacrolimus will be administered according to institutional GVHD prophylaxis protocols. Therapeutic levels will be maintained and patients will be switched to oral agents when they can tolerate
223689221|NCT00057954|DRUG|Mycophenolate mofetil (MMF)|At day 100 MMF will be introduced at a dose of 250 mg po BID and cyclosporine or tacrolimus will be tapered according to the discretion of the investigator. The dosage will be escalated to a maximum of 2 g/d at the discretion of the attending physician and will be tapered and discontinued at 12 months if there is no active cGVHD. Doses should be given on an empty stomach
223689222|NCT00057954|DRUG|Methotrexate (MTX)|"The dose of Methotrexate is based on the corrected ideal body weight for patients with \> 33% above ideal weight.~Day +1 MTX 15 mg/m² IV push; Day +3 MTX 10 mg/m² IV push (May be omitted if patient develops mouth sores.)"
223689223|NCT01244698|DRUG|Cefadroxil discontinued early|All patients will receive 24 hours of IV Cefazolin (1g IV every 8 hr), as is universal practice for clean breast surgery. The interventional group will then discontinue antibiotics. Clindamycin IV 600mg every 6 hours for 24 hours will be used in penicillin allergic patients.
223776344|NCT05361473|DEVICE|The NeoHilda Point of care method|This is a procedure that measures Lactate dehydrogenase in a fast and reliable way from only 10 microliter of blood. Using a small point of care card and a Smartphone for analysis.
223776345|NCT05361473|PROCEDURE|Traditional evaluation|Traditional way of evaluation
223776346|NCT02486224|DIETARY_SUPPLEMENT|Kona Deep|Subjects will receive Kona Deep post exercise
223776347|NCT02486224|DIETARY_SUPPLEMENT|Spring Water|Subjects will receive Spring Water post exercise
223776348|NCT02486224|DIETARY_SUPPLEMENT|Sports Drink|Subjects will receive Sports Drink post exercise
223776349|NCT00673049|DRUG|CP 751,871 (Figitumumab)|CP 751,871 (20 mg/kg) will be administered as an IV infusion on study Days 1 and 2 in Cycle 1, and every three weeks (from Day 1) (Cycle) thereafter.
223776350|NCT00673049|DRUG|Erlotinib|Erlotinib (one tablet of 150 mg/day PO).
223776351|NCT00673049|DRUG|Erlotinib|Erlotinib (one tablet of 150 mg/day PO). Erlotinib will be taken at least one hour before or two hours after the ingestion of food.
223776352|NCT05481021|OTHER|No intervention but assessing for burnout syndrome in all group|Using Maslach Burnout inventory to assess the presence of burnout and a self reporting questionnaire to identify possible stressors or associations
223776353|NCT02241226|BEHAVIORAL|Perfect Health Course|The Perfect Health course as taught at the Chopra Center for Wellbeing
223776354|NCT05680025|BEHAVIORAL|Physical exercise intervention|"The intervention group will have access to training videos through social networks (WhatsApp and YouTube) and infographics. The mobile phone of each of the participants will allow send dates of workshops, link for videos, messages reminding to perform exercise routines.~The training plan will be designed so the participants will achieve being physically active at the end of 6 months of intervention. Training will be planned to gradually, through 3 levels, increase the duration and intensity of exercises; they will have an important component of aerobic exercises and others for muscular strength. Each level of training will last two months; at each level the participants will be given 4 specific trainings and will be asked to perform two per week at level 1 and 2; and at the 3 level, 3 trainings per week.~The strategy for promoting physical exercise is based on the social cognitive theory, in which the bases of the transtheoretical model are found."
223776355|NCT05680025|BEHAVIORAL|Workshops|Six workshops to promote the performance of physical activity. The workshops will be held with groups of 15 participants. During them, the work will be to promote motivation to perform physical exercise, sharing information about the health benefits, benefits for control of the disease, together creating planning of measurable, realistic goals; reinforcing behavior when the desired advances are made, monitoring progress (using a monthly self-report of exercise performed). The participants will be motivated and congratulated each time for goals reached, self-sufficiency will be reinforced as well as greater evaluation of the advantages of performing exercise against the barriers or negative aspects perceived by the participants. These activities will be performed according to the level of exercise performed by the individuals (stage of change).
223776356|NCT03421925|PROCEDURE|Laparoscopic totally extraperitoneal procedure for inguinal hernia|Laparoscopic totally extraperitoneal procedure for inguinal hernia is a technique that is done by not entering the peritoneal cavity
223776357|NCT05522803|DEVICE|TMS followed by sham TMS|Transcranial Magnetic Stimulation followed by sham TMS
223776358|NCT05522803|DEVICE|Sham TMS followed by TMS|Sham Transcranial Magnetic Stimulation followed by TMS
223776359|NCT03844893|PROCEDURE|Mini bal|Mini-BAL is a minimally invasive technique frequently used in the investigator's local intensive care units (ICUs) to obtain alveolar fluid samples from mechanically ventilated patients. This is typically done for microbial analysis.
223776360|NCT02569697|OTHER|HEC Placebo gel|
223776361|NCT02569697|OTHER|Placebo Intravaginal Ring|
223776362|NCT02569697|OTHER|Placebo Vaginal Film|
223776363|NCT02569697|OTHER|Placebo Vaginal Insert|
223776364|NCT06489808|DRUG|Linperlisib|Linperlisib RP2D D1-14
223776365|NCT06489808|DRUG|Rituximab|rituximab 375 mg/m2 D0
223776366|NCT06489808|DRUG|Gemcitabine|gemcitabine per regimen dosage
223776367|NCT06489808|DRUG|Oxaliplatin|Oxaliplatin 130 mg/m2 D1
223776368|NCT06489808|DRUG|Ifosfamide|Ifosfamide 5g/m2 D2
223776369|NCT06489808|DRUG|Carboplatin|Carboplatin AUC=5mg/mL · min (maximum absolute dose/cycle = 800 mg)
223776370|NCT06489808|DRUG|Etoposide|Etoposide 100mg/m2 D1-3
223776371|NCT06489808|DRUG|Dexamethasone|Dexamethasone 40mg D1-4
223776372|NCT06489808|DRUG|Cisplatin|Cisplatin 100mg/m2 D1, continuous intravenous infusion
223776373|NCT06489808|DRUG|Ara-C|Ara-C 2g/m2 q12h D2
223776374|NCT06489808|DRUG|Vinorelbine|Vinorelbine 20mg/m2 D1
223776375|NCT06489808|DRUG|Mitoxantrone hydrochloride liposome|Mitoxantrone hydrochloride liposome 18mg/m2 D1
223776376|NCT00924950|DRUG|Taclonex Ointment and Hydrogel Patch|Each patient will have bilateral symmetrical psoriatic plaques. One plaque will be treated with Taclonex Ointment daily along with Hydrogel Patch daily. All treatment will be for 4 weeks.
223776377|NCT00924950|DRUG|Taclonex Ointment|Taclonex ointment daily for one psoriatic plaque.
223776378|NCT05793905|COMBINATION_PRODUCT|Buffered lidocaine in inferior alveolar nerve block injection|Buffered Lidocaine 2% with epinephrine 1.80000 mixed with 1.8% sodium bicarbonate in IANB injection in the treatment of bilateral primary mandibular molars
223776379|NCT05793905|DRUG|lidocaine 2% in inferior alveolar nerve block injection|Lidocaine 2% with epinephrine 1.80000 in IANB injection in the treatment of bilateral primary mandibular molars
223776380|NCT05089396|OTHER|Maxillary protraction|A petit facemask will be used for maxillary protraction along with a facemask splint (two acrylic bite blocks connected through a transpalatal arch) in the active comparator group. in the experimental group, two miniscrews will be inserted in the anterior region of the palate one on each side of the midline to provide skeletal anchorage for the facemask splint. in both groups, a force of 380 gm to 400 gm will be applied through the extra-oral elastics the will be attached to the facemask on one side and to the facemask splint on the other side.
223776381|NCT04028375|OTHER|No intervention|No intervention
223776382|NCT01511952|OTHER|Music Intervention|Applied by randomization-live at bassinet in the AM or PM Gato Box, Ocean Disc or parent-selected lullabies
223776383|NCT01511952|OTHER|Music|Remo Ocean disc Gato box Music therapist's or Parent's preferred lullaby or 'Twinkle'
223776384|NCT05507606|DRUG|Osimertinib|osimertinib 80mg/d
223689224|NCT01244698|DRUG|Cefadroxil until drain removal|All patients will receive 24 hours of IV Cefazolin, as is universal practice for clean breast surgery. The control group will receive oral outpatient Cefadroxil (500mg 2 times a day) until the final drain is removed. This is the normal postoperative regimen. In case of significant penicillin allergy (defined as a history of urticaria or anaphylaxis associated with penicillin) patients will receive Clindamycin 600mg IV every 6 hours for 24 hours followed by clindamycin 300mg IV every 6 hours.
223689225|NCT02410733|BIOLOGICAL|Lipo-MERIT|vaccination
223689226|NCT01957527|DEVICE|Peripheral arterial tonometry (EndoPAT)|
223689227|NCT01264016|DEVICE|Investigational Blood Glucose Monitoring System|Untrained subjects with diabetes performed Blood Glucose (BG) tests with subject's capillary fingerstick using the investigational Tradewind meter and investigational sensor. Study staff tested subject venous blood. All BG Results were compared to a reference laboratory glucose method. Subjects' success at performing basic tasks using only the User Guide were rated by study staff.
223689228|NCT02117414|DEVICE|MRI scan sequences of the head and chest regions|Non-diagnostic MRI scans
223689229|NCT02117414|OTHER|Waiting Period Visit|Waiting period time will equate to 1 hour
223689230|NCT03504579|OTHER|rt-fMRI neurofeedback|use of real time fMRI neurofeedback to achieve targeted brain changes
223689231|NCT00911378|PROCEDURE|Pressure support ventilation|These patients are weaned by gradual reduction of pressure support and extubated when they tolerate a pressure support of 7 cm of water for one hour.
223689232|NCT00911378|PROCEDURE|Spontaneous breathing trials|These patients are weaned by giving a T piece trial with 8 cm of water pressure support and extubated when they tolerate it for one hour.
223689233|NCT02182648|DRUG|etomidate|"1. intravenous injection midazolam 0.08 mg/kg, fentanyl 0.002 mg/kg, cisatracurium 0.15 mg/kg for induction of anesthesia.~2. infusion of etomidate at 2 minutes before anesthesia induction"
223689234|NCT02182648|DRUG|propofol|"1. intravenous injection midazolam 0.08 mg/kg, fentanyl 0.002 mg/kg, cisatracurium 0.15 mg/kg for induction of anesthesia.~2. infusion of propofol at 2 minutes before anesthesia induction"
223689235|NCT02182648|DRUG|sevoflurane|"1. intravenous injection midazolam 0.08 mg/kg, fentanyl 0.002 mg/kg, cisatracurium 0.15 mg/kg for induction of anesthesia.~2. inhale sevoflurane for anesthesia induction and maintenance"
223689236|NCT04665193|DIAGNOSTIC_TEST|Rapid Antigen Test|Antigen Technology Lab-based test and Point of care test
223689237|NCT03128645|DEVICE|Abdominal Corset|The patient's colonoscopy procedure in group 2 after randomization will be performed with the abdominal corset.
223689238|NCT02801344|DIETARY_SUPPLEMENT|Normal|test drink which contains low amount of amino acids (0.14 g/kg/day)
223689239|NCT02801344|DIETARY_SUPPLEMENT|Moderate|test drink which contains moderate amount of amino acids (0.40 g/kg/day)
223689240|NCT02801344|DIETARY_SUPPLEMENT|High|test drink which contains high amount of amino acids (1.03 g/kg/day)
223689241|NCT02801344|OTHER|Controlled-diet|the diet containing 0.8 g protein /kg/day
223689242|NCT00079534|BEHAVIORAL|Non-local/distant healing or prayer|
223689243|NCT00246688|DRUG|Sagopilone (BAY86-5302 , ZK219477)|10.5 mg lyophilized sagopilone per vial
223689244|NCT02359162|DRUG|Gemcitabine|gemcitabine :1250mg/m2 (ivdrip) on days 1
223689245|NCT02359162|DRUG|Oxaliplatin|oxaliplatin :85 mg/m2 (ivdrip) on day 1
223689246|NCT02359162|DRUG|Pegaspargase|pegaspargase : 2500 IU/m2 (intramuscular injection)
223689247|NCT02359162|DRUG|Etoposide|50 mg/m 2 /day 24 h continuous infusion on days 1-4
223689248|NCT02359162|DRUG|Vincristine|0.4 mg/m 2 /day 24 h continuous infusion on days 1-4
223689249|NCT02359162|DRUG|Doxorubicin|10 mg/m 2 /day 24 h continuous infusion on days 1-4
223689250|NCT02359162|DRUG|Cyclophosphamide|cyclophosphamide 750 mg/m2 /day over 15 min intravenously on day 5
223689251|NCT02359162|DRUG|Prednisone|60 mg/m 2 /day 60 mg/m 2 /day on days 1-5
223689252|NCT02359162|RADIATION|IMRT|IMRT is delivered using 6-8 MeV linear accelerator using intensity-modulated radiation treatment planning. The radiation dose is 50 grays (Gy) in 25 fractions.
223689253|NCT00417482|DRUG|risperidone|Risperidone open label flexible dose 0.25 to 3 mg daily for first 16 weeks; dose at 16 weeks then fixed for randomized trial
223689254|NCT04551144|DRUG|testosterone cypionate|intramuscular injection every 2 weeks. Dose will be titrated based on blood levels
223689255|NCT04551144|DRUG|Estradiol Valerate|intramuscular injection every week. Dose will be titrated based on blood levels
223689256|NCT05402020|DRUG|Tiotropium (Tio)|Tiotropium (Tio)
223689257|NCT05402020|DRUG|Inhaled corticosteroids (ICS)|Inhaled corticosteroids (ICS)
223689258|NCT05402020|DRUG|Olodaterol (Olo)|Olodaterol (Olo)
223689259|NCT05402020|DRUG|Long-acting β2-agonists (LABA)|Long-acting β2-agonists (LABA)
223689260|NCT06400979|DEVICE|Elequil aromatab|Aromatherapy impregnated tab utilized to dispense inhaled scent for the study
223689261|NCT05199727|DEVICE|LI-ESWT|Low intenisty shockwave therapy newly used for treatment of erectile dysfunction by applying 6 sessions on 3 weeks (2 sessions /week)
223689262|NCT05199727|DRUG|Tadalafil 20Mg Oral Tablet|Patients on this arm will allocate on on-demand tadalafil 20 mg for treatment of ED
223689263|NCT03403270|OTHER|ENCOURAGE App|Users will have an opportunity to engage with the app as described for the duration of the study period.
223689264|NCT05440071|DEVICE|JX- XFINE lead|Pacemaker subjects implanted with one JX - XFINE passive pacing lead
223689265|NCT05812079|DIAGNOSTIC_TEST|skin biopsy examined by ELISA technique|skin biopsy examined by ELISA technique
223689266|NCT05901792|OTHER|Virtual Reality Games|Six different Nintendo Wii Fit Plus games will be employed for six weeks, three days a week, for a total of 18 sessions ranging from 40 to 60 minutes. The games will be chosen from those that emphasize shifting the body's center of gravity. In addition, participants will be given basic correction exercises (derotation, deflexion, basic tension, and lateral flexion 3\*3) at the beginning of the study and instructed to practice them at home for six weeks.
223689267|NCT05901792|OTHER|Waiting List|As the control group, the cases on the waiting list will be evaluated. The control group will be given basic elements of corrective exercises (derotation, deflexion, basic tension, and lateral flexion 3\*3) at the start of the study and instructed to practice at home for six weeks.
223689268|NCT02545140|OTHER|No intervention|
223689269|NCT05468138|DRUG|SOX|"Drug: Tegafur-Gimeracil-Oteracil Potassium The dose of S-1 is according to body-surface area (BSA): patients with a BSA of less than 1.25 m2 received 80 mg daily; those with a BSA of 1.25 m2 or more but less than 1.5 m2 received 100 mg daily; and those with a BSA of 1.5 m2 or more received 120 mg daily. oxaliplatin 130mg/m2, intravenously, on day 1.~Drug: Oxaliplatin The dose of oxaliplatin is according to body-surface area (BSA): 130mg/m2, intravenously, on day 1."
223689270|NCT05468138|DRUG|XELOX|Drug: Capecitabine 1000mg/m2, orally, twice per day, from day 1 to day 14, Q3W. Drug: Oxaliplatin The dose of oxaliplatin is according to body-surface area (BSA): 130mg/m2, intravenously, on day 1.
223689271|NCT05468138|OTHER|Observation|follow up and Observation alone. Abdomen/chest CT scan will be performed every 6 months after surgery.
223689272|NCT05468138|DRUG|PD-1 antibody|Sintilimab at a dose of 200 mg every 3 weeks for 16 cycles or Nivolumab at a dose of 360 mg every 3 weeks for 16 cycles
223689273|NCT04706117|DEVICE|Self-retaining bicanalicular intubation stent|self-retaining bicanaliculs intubation setII(SRSII) which is the latest innovation in the field as these silicone stent segments traverse both canaliculi till the lacrimal sac. In which each end of this semicircular device has 2 stout angulated wings/flanges which pose no resistance while proceeding forward into the canaliculus, but once they get into open cavity (lacrimal sac), the flanges open up and give resistance to their removal against the common canalicular opening
223689274|NCT04536831|DRUG|Vitamin D|Vitamin D will be given to group A selected by Lottery method
223689275|NCT04536831|DRUG|Normal saline|Vitamin D will be given to group B slected by Lottery method
223689276|NCT02428985|DRUG|Riociguat (ADEMPAS, BAY63-2521)|The treatment of Riociguat should comply with the local product information
223689277|NCT01526122|DRUG|G0041(75/100mg)|G0041(75/100mg) 2 capsules(Clopidogrel 75mg \& Aspirin 100mg in 1 capsule), PO
223689278|NCT01526122|DRUG|Clopidogrel & Aspirin|Clopidogrel 75mg 2 tablets \& Aspirin 100mg 2 capsules, PO
223689279|NCT03739840|DRUG|Padsevonil|Padsevonil in different dosages.
223689280|NCT03739840|DRUG|Placebo|Placebo will be provided matching padsevonil.
223689281|NCT01545453|DRUG|lebrikizumab|subcutaneous dose every 4 weeks
223689282|NCT01545453|DRUG|lebrikizumab|subcutaneous dose every 4 weeks
223689283|NCT01545453|DRUG|lebrikizumab|subcutaneous dose every 4 weeks
223689284|NCT01545453|DRUG|placebo|subcutaneous dose every 4 weeks
223689285|NCT03411915|BIOLOGICAL|XmAb18087|monoclonal bispecific antibody
223689286|NCT02245204|DRUG|Chlorogenic acid|Chlorogenic acid for injection is polyphenols, micromolecular and un-endogenous substance. It might play the role of cancer treatment via balancing tumor micro-environmental immune status according to the stability and rationality of immunodeficiency and endogenous immune material expression around the tumor. Chlorogenic acid for injection is made from chlorogenic acid (purity≥98%) which is extracted from folium cortex eucommiae.Chlorogenic acid and its preparations have not been reported as chemical drug and marketed around the world.
223689287|NCT00147420|DRUG|Zhi Byed 11|
223689288|NCT04804007|DRUG|Etoposide|etoposide will be provided with prescription for etoposide 50mg orally daily for 21 days out of 28 day cycles. Cycles will be repeated every 4 weeks for a total of 3 cycles.
223689289|NCT03961373|PROCEDURE|Gastrectomy with D2 lymphadenectomy|Patients who are assigned to the neoadjuvant chemotherapy+ surgical D2 treatment group will undergo either subtotal or total gastrectomy, depending on the location of the primary tumour. Standardized D2-lymph node dissection is required with specific information about lymph node stations.
223689290|NCT03961373|PROCEDURE|Gastrectomy with D2plus lymphadenectomy|Patients who are assigned to the neoadjuvant chemotherapy + surgical D2+ extended lymphadenectomy treatment group will undergo either subtotal or total gastrectomy, depending on the location of the primary tumour. Standardized D2+ lymph node dissection plus resection of stations 8p, 12p, 13, 14v, 16a2/b1 is required with specific information about lymph node stations.
223689291|NCT00063193|DRUG|minocycline|
223689292|NCT00063193|DRUG|creatine|
223689293|NCT03531034|OTHER|Combined Exercise Training|The program consisted of 30 sessions of combined aerobic and resistance exercises training during 10 consecutive weeks. Each session lasted 45 minutes and consisted of 5 minutes warm-up, 20 minutes of resistance exercise and 20 minutes of aerobic exercise. The resistance training was performed in two sets of 15 repetitions in seven exercises of weight training (Based on 1 repetition maximum test - 1RM) for large muscle groups. The aerobic exercise was performed on a treadmill, at a speed of 5.5 km/h and intensity (imposed by treadmill inclination and heart rate) between ventilatory threshold 1 and 2 intensities. After 5 weeks of training, 1RM test was performed again to readjust the resistance load and aerobic intensity was readjusted by heart rate predicted in the incremental test.
223689294|NCT03560830|OTHER|2 submaximal exercise stress tests|
223689295|NCT01646060|DEVICE|CM-1500|Blood Volume Monitor
223689296|NCT01828515|DRUG|Vilazodone|Participants will be randomized to either vilazodone or placebo titrated as follows: 10 mg x 7 days, 20 mg x 7 days and 40 mg x 5 days.
223689297|NCT01828515|DRUG|Placebo|
223689298|NCT01828515|DRUG|Hydrocortisone|Participants receive 160 mg x 4 days after vilazodone or placebo pre-treatment
223689299|NCT01095471|BIOLOGICAL|PCV13|Immunisation with the 13-valent pneumococcal conjugate vaccine (PCV13) at approximately 40 months of age.
223689300|NCT02593201|DRUG|Extended antibiotics (cefazolin or ceftazidime)|To continue with the existing effective antibiotic therapy for one extra week
223689301|NCT02593201|DRUG|Usual antibiotics (cefazolin or ceftazidime)|Usual duration of effective antibiotic therapy therapy
223689302|NCT04246255|DRUG|Xylocaine 10% Oral|"50 ml of lidocaine solution maintained from xylocaine 10% oral that transferred to a bottle with a spray pump which pumps 0,1ml for each pump will be used for the experiment.~3 pumps of lidocaine will be administrated to 3M TegadermTM +Pad Film Dressing with Non-Adherent Pad and put onto the skin for 10 minutes that IV cannula planned to be inserted."
223689303|NCT04246255|DRUG|Placebo- Serum Fizyolojik Izotonik 0,9% 10 ml ampul|"50 ml of Serum physiologic in a bottle with a spray pump which pumps 0,1ml for each pump will be used for placebo.~3 pumps of placebo will be administrated to 3M TegadermTM +Pad Film Dressing with Non-Adherent Pad and put onto the skin for 10 minutes that IV cannula planned to be inserted."
223689304|NCT05993182|DRUG|Ephedrine 5mg|Patients received 5mg bolus dose of ephedrine Intravenous after the first hypotension \[ Base line time or starting point is first hypotension\]
223689305|NCT05993182|DRUG|Ephedrine 10mg|Patients received 10mg bolus dose of ephedrine Intravenous after the first hypotension \[ Base line time or starting point is first hypotension\]
223689306|NCT05993182|DRUG|Ephedrine 15mg|Patients received 15mg bolus dose of ephedrine Intravenous after the first hypotension \[ Base line time or starting point is first hypotension\]
223689307|NCT02992080|OTHER|miRNAs isolation from blood samples of patients and control|Blood sample collection in specific PAXGene tubes
223689308|NCT04309071|OTHER|Dietary intervention|Salivary insulin responses to a standardized mixed meal
223689309|NCT03970213|DRUG|Tranexamic Acid 100Mg/Ml Inj Vil 10Ml|IV TXA given during surgery
223689310|NCT03970213|DRUG|Normal Saline 0.9% Infusion Solution Bag|IV saline given during surgery
223689311|NCT00961766|DRUG|BG00010 (Neublastin)|Single dose, weight-based IV administration
223689312|NCT00961766|DRUG|Placebo|Single dose IV matched placebo
223689313|NCT01511393|OTHER|No treatment given|None. Non-interventional study.
223689314|NCT01058265|OTHER|Integrative|Integrative Medicine medical evaluation.
223689315|NCT01058265|OTHER|Standard|Standard general medical evaluation.
223689316|NCT04601922|OTHER|Semi-structured interview|The interview will have the audio recorded, and will explore the ideas of each participant around long term cardiovascular care pathways
223689317|NCT02594332|DRUG|Mepolizumab|100 mg SC every 4 weeks for 13 injections
223689318|NCT02594332|DRUG|Placebo|
223689319|NCT05802875|BEHAVIORAL|RASMUS Resilience Training|"RASMUS stands for Resilience through mindfulness, self-compassion and self-care and is a German-language 10-week group resilience program with one training unit per week. The main content of the RASMUS is based on seven resilience factors, i.e. acceptance, optimism, taking responsibility, solution orientation, future orientation, role clarity, and network orientation including the aspects of mindfulness, self-compassion, and self-care.~RASMUS has been tested and certified according to the German Prevention Standard. The Central Prevention Test Center has awarded the seal of approval for the areas of exercise, nutrition, stress management/relaxation, and addictive substance consumption. Accordingly, this training program has been certified as a prevention course that is recognized by the German statutory health insurance companies. Furthermore, RASMUS can and is already offered as a (group) online course."
223689320|NCT05802875|BEHAVIORAL|Progressive Muscle Relaxation|"Progressive Muscle Relaxation is a representative relaxation technique used in a wide scope of disorders. Developed by the American physician E.Jacobson in the late 1920s, it is based on the finding that anxiety states are usually accompanied by increased muscle tension, while in resting states the muscles are relaxed. By applying this technique, an individual learns how to relax several muscle groups in the body.~In the context of the current project, PMR is chosen as the active control condition because it is a broadly accepted and easy-to-implement relaxation exercise that can be offered as a (group) online course and does not include specific contents of RASMUS."
223689321|NCT02897765|BIOLOGICAL|NEO-PV-01|Personal cancer vaccine
223689322|NCT02897765|BIOLOGICAL|Nivolumab|monoclonal antibody against PD1
223689323|NCT02897765|OTHER|Adjuvant|immune adjuvant
223689324|NCT05633004|DEVICE|Vivio|Non-invasive estimation of Left-Ventricular End Diastolic Pressure (LVEDP)
223689325|NCT02869438|DRUG|Benralizumab|Benralizumab administered subcutaneously at Visit 1 (Day 0), Visit 8 (Day28 +/- 3 days) and Visit 9 (Day 56 +/- 3 days)
223689326|NCT02869438|OTHER|Placebo|Placebo administered subcutaneously at Visit 1 (Day 0), Visit 8 (Day28 +/- 3 days) and Visit 9 (Day 56 +/- 3 days)
223689327|NCT05344885|BEHAVIORAL|DPT-Standard|The parent training intervention includes 7 modules, recommended to be completed within 7- to 10-weeks period. Module's content includes videos and texts guiding the parent through the training process; interactive features, such as multiple-choice questions with direct feedback. Additional features embedded within the platform include downloadable materials, and a Q\&A section that contains frequently asked questions.
223689328|NCT05344885|BEHAVIORAL|DPT-Enhanced|DPT-Enhanced will include all the ingredients of DPT-Standard, but with additional features. The program itself is based on pre-defined decision rules that are either event or time based based on evidence based practice in promoting effective parental engagement. Each component includes a short learning phase, followed by a 1-2 week focusing phase. The focusing phase is designed to encourage and help parents to practice and acquire learned skills in their day-to-day lives, by making these skills more salient in their mind.
223776385|NCT05507606|DRUG|Bevacizumab Biosimilar IBI305|Bevacizumab, 7.5mg/kg d1; was discontinued after 2 years
223689329|NCT05220800|DRUG|Iron(III)isomaltoside|Weight-dependent dosage of iron(III)isomaltoside. See group descriptions
223689330|NCT05220800|DRUG|Placebo|Isoton saline infusion
223689331|NCT02343081|DRUG|Temozolomide|
223689332|NCT02343081|DRUG|Temozolomide|
223776386|NCT05507606|DRUG|Carboplatin|Carboplatin AUC5, d1; was stopped after 4 cycles
223776387|NCT05507606|DRUG|Pemetrexed|Pemetrexed, 500mg/m2, d1;Q3W/cycle; was discontinued after 2 years
223689333|NCT06637839|BEHAVIORAL|Moderate-Intensity Locomotor Training Program|The moderate-intensity program prescribes participants to exert 50-59% of their heart rate (HR) reserve, or a score of 13-15 on Borg's rating of perceived exertion (RPE) scale.
223776388|NCT03196921|DRUG|Encochleated Amphotericin B|lipid-crystal nanoparticle formulation of amphotericin B; oral
223776389|NCT04193202|DRUG|Gefapixant|Administered twice daily as an oral tablet of 45 mg
223776390|NCT04193202|DRUG|Placebo|Administered twice daily as a placebo oral tablet matching gefapixant
223776391|NCT04117828|DIETARY_SUPPLEMENT|Dates|Phoenix dactylifera, commonly known as date or date palm is a flowering plant species in the palm family, Arecaceae. Dates are the fruit of the date palm tree, which is grown in many tropical regions of the world. Dates provide a wide range of essential nutrients, and has certain protective effects on health of individuals.
223776392|NCT02595203|DRUG|[14C-pos 1]-Debio 1450 BES Solution|A solution containing Debio 1450 bis ethanolamine salt (BES) radiolabelled with carbon-14 (14C) at position 1
223776393|NCT02595203|DRUG|[14C-pos 25]-Debio 1450 BES Solution|A solution containing Debio 1450 BES radiolabelled with carbon-14 (14C) at position 25
223776394|NCT06432712|DRUG|Dexamethasone 4mg|2.5ml of Dexamethasone 4mg/ml will be administered via periapical infiltration with a 23 gauge needle to the experimental group.
223776395|NCT02979535|BIOLOGICAL|CYD Dengue Vaccine|0.5 mL, SC at Day 0, Months 6 and 12
223776396|NCT02979535|BIOLOGICAL|CYD Dengue Vaccine|0.5 mL, SC at Months 1, 7, and 13
223776397|NCT02979535|BIOLOGICAL|Human Papillomavirus Bivalent [Types 16 and 18] Vaccine, Recombinant|0.5 mL, IM at Day 0 and Month 6
223776398|NCT02979535|BIOLOGICAL|Human Papillomavirus Bivalent [Types 16 and 18] Vaccine, Recombinant|0.5 mL, IM at Day 0 and Month 6
223776399|NCT04269928|PROCEDURE|Endovascular chemical ablation of adrenal gland|Patients in this group will be treated with ablation of adrenal gland by endovascular injection of dehydrated alcohol
223776400|NCT01413451|DRUG|Amatuximab (MORab-009)|
223776401|NCT03749551|DIAGNOSTIC_TEST|cardiac magnetic resonance (CMR) post haemodialysis|patients will undergo a second CMR scan immediately after receiving haemodialysis (native CMR study)
223776402|NCT01335243|PROCEDURE|The Transforaminal Lumbar Interbody Fusion (TLIF) surgery|The TLIF surgery use a per-operating artificial substitute specific biomaterial: autologous osteoblasts punctured on iliac crest and put on a collagen support waxed with tri-calcium phosphate (which is osteoconductive) to perform a intervertebral body fusion.
223776403|NCT06636474|OTHER|patients with mental disorders|administration of standardized questionnaires and scales, upon entering the research, then annually, and finally upon leaving the research
223776404|NCT04795271|OTHER|Orthopedic intervention|"In each custom insole, modifications can be included in the following aspects according to the requirements of each participant :~1. Forefoot specifications: a) Retrocapital bar, b) Retrocapital support, c) Claw toe correction element, d) Pronating wedge, e) Supinator wedge, f) Metatarsal head pad, g) Selective perforations in the insole, h) Others.~2. Midfoot specifications: a) Internal arch, b) External arch, c) Full support, d) Excavations, e) Others.~3. Hindfoot specifications: a) Heel cup, b) Supinator wedge, c) Pronating wedge, d) Lifter, e) Cup, f) Others.~4. Insole type and lining material~5. Materials of the added corrections~6. Insole base: a) soft ethylene vinyl acetate (eva), b) semi-soft eva, c) hard eva, d) rubber, e) cuerolite."
223776405|NCT00843791|DRUG|placebo|treatment with placebo for 3 months
223776406|NCT00843791|DRUG|pioglitazone|treatment with 30mg daily for two weeks then 45mg every day with pioglitazone for three months
223776407|NCT04965779|DEVICE|Abdominal Binder|Women in the intervention group use an abdominal binder from postpartum hour 1 to 48, and will be checked every 6 hours. The abdominal circumference of the women is measured at the anterior superior iliac spine and umbilicus level with a tape measure before the application, and the binder size is adjusted to be 5% smaller (approximately 0.5-1 cm) than the measurement obtained.
223776408|NCT04965779|OTHER|Postpartum nursing care|Postpartum nursing care the follow-up protocol includes the evaluation and record between postpartum 1. and 48. hours of pain level, analgesic administration, follow-up of the puerperal bleeding, and uterine tone, measure of hemodynamic parameters measuring, hemoglobin level and hematocrit ratio, and assessment breastfeeding.
223776409|NCT05711069|OTHER|Core Stability Exercise Program|Core stability is an important component maximising efficient athletic function. Function is most often produced by the kinetic chain, the coordinate sequenced activation of body segments that places the distal segment in the optimum position at the optimum velocity with the optimum timing to produce the desired athletic task. Speed and power are critical performance factors in football. Football including jumping, kicking, tackling, turning, sprinting, changing pace, and sustaining forceful contractions to maintain balance and control of the ball against defensive pressure. İn the literature, no study has demonstrated the effectiveness of core stability exercise program in adolescent football players.
223776410|NCT05711069|OTHER|Routine Football Training Program|Core stability is an important component maximising efficient athletic function. Function is most often produced by the kinetic chain, the coordinate sequenced activation of body segments that places the distal segment in the optimum position at the optimum velocity with the optimum timing to produce the desired athletic task. Speed and power are critical performance factors in football. Football including jumping, kicking, tackling, turning, sprinting, changing pace, and sustaining forceful contractions to maintain balance and control of the ball against defensive pressure. İn the literature, no study has demonstrated the effectiveness of core stability exercise program in adolescent football players.
223776411|NCT01531959|DRUG|Midodrine|Patients will be randomized to blinded to 20 mg of midodrine
223689334|NCT06637839|BEHAVIORAL|High-Intensity Locomotor Training Program|The high-intensity program prescribes participants to exert at least 60% of their heart rate (HR) reserve, or a score of 16-18 on the RPE scale.
223689335|NCT06637839|BEHAVIORAL|High-Step Count Locomotor Training Program|The high step count program prescribes at least 600 steps per session, at less than 50% or HR reserve, or less than 13 RPE.
223689336|NCT02660398|PROCEDURE|Standardized NMBD Management|The intervention phase will introduce a standardized research protocol that spells out NMBD management, including how muscle relaxant should be administered and monitored, and how reversal with neostigmine should be done.
223689337|NCT05305027|BEHAVIORAL|Prompt diagnois pregnancy outcome|
223689338|NCT05613803|DRUG|Fish oil|6g of EPA and DHA in a 1.3:1 ratio as six Omacor capsules manufactured by Provona Biocare (Olso Norway), or generic equivalent, taken once daily, or in divided doses, with food.
223689339|NCT05613803|OTHER|Placebo|Six capsules containing palm oil and soybean oil on an 8:2 ratio taken once daily, or in divided doses, with food.
223689340|NCT00729287|DIETARY_SUPPLEMENT|selenium|Given orally
223689341|NCT00729287|OTHER|placebo|Given orally
223689342|NCT00952627|DIETARY_SUPPLEMENT|Pycnogenol|50 mg tablet, 200 mg/day, 4 tablets/day
223776412|NCT01531959|DRUG|Placebo|Patients will be randomized to blinded placebo control
223776413|NCT03837691|DEVICE|Placement of Snowshoe Suture Anchors|Snowshoe suture anchors from g-Cath EZ Delivery Catheters are placed in the stomach with the aid of a Transport, g-Lix and g-Prox device
223776414|NCT03837691|BEHAVIORAL|Moderate Intensity Diet & Exercise Program|After placement of the snowshoe suture anchors in the stomach, subjects are asked to follow a moderate intensity diet and exercise program
223689343|NCT00952627|DIETARY_SUPPLEMENT|Placebo|
223689344|NCT02613949|DEVICE|RINCE|The NeuroPoint device is used to deliver repeat applications of RINCE therapy
223689345|NCT04173234|OTHER|Aerobic Training|Aerobic training will be performed 3 days a week for 12 weeks at 60% of their maximum hearth rate with 50 minutes total duration consisting of 10 min warm up and 10 min cool down period to children in treatment group.
223689346|NCT04173234|OTHER|Home exercise program|Children will be given a home program including stretching, breathing, normal joint movement, body weight and mildly resistant exercises, and children will be asked to do these for 3 to 5 days a week.
223689347|NCT06392971|DRUG|Deep-sea fish oil|Starting from radiotherapy, the whole course of prophylactic oral deep-sea fish oil should be taken at the recommended dosage of 1g po bid according to the instructions (the administration method is to take it with the drug, remove the film on the drug surface, slowly swallow it in a supine position, and make the liquid fully contact with the esophageal mucosa). If no acute radioactive esophagus was assessed during the course of treatment, the patient was administered orally until the end of radiotherapy. If the patient developed radioactive esophagitis during the course of treatment, the relevant outcome measures were recorded and used as the endpoint event of the phase I study. The end point for patients without acute radiation esophagitis was at the completion of radiation therapy.
223689348|NCT06392971|OTHER|Placebo|Take a capsule made of food oil that looks like deep-sea fish oil at a dose of 1g po bid. Treatment is discontinued when patients develop acute radiation esophagitis.
223689349|NCT06568783|DRUG|[18F]-FAPI-74|\[18F\]-FAPI-74 7 mCi ± 20% administered intravenously.
223689350|NCT02738632|DRUG|Telmisartan/Amlodipine+Hydrochlorothiazide|"Treatment1:Telmisartan/Amlodipine 40/5mg 1 Tab.and Hydrochlorothiazide 12.5mg 1 Tab.QD~Treatment2: Telmisartan/Amlodipine 40/5mg 2 Tab.and Hydrochlorothiazide 25mg 1 Tab.QD"
223689351|NCT02738632|DRUG|Telmisartan/Amlodipine|"Treatment1:Telmisartan/Amlodipine 40/5mg 1 Tab.and Hydrochlorothiazide 12.5mg Placebo 1 Tab.QD~Treatment2: Telmisartan/Amlodipine 40/5mg 2 Tab.and Hydrochlorothiazide 25mg Placebo 1 Tab.QD"
223689352|NCT02738632|DRUG|Placebo for Hydrochlorothiazide|
223689353|NCT02169284|DRUG|Erlotinib Hydrochloride|Given PO
223689354|NCT02169284|OTHER|Laboratory Biomarker Analysis|Correlative studies
223689355|NCT02169284|OTHER|Pharmacological Study|Correlative studies
223689356|NCT02169284|OTHER|Placebo|Given PO
223689357|NCT02169284|OTHER|Quality-of-Life Assessment|Ancillary studies
223689358|NCT02169284|PROCEDURE|Therapeutic Conventional Surgery|Undergo TURBT or cystectomy
223689359|NCT03048916|OTHER|general swallowing therapy|including a session of oral exercises, tactile stimulation, compensatory techniques, swallowing maneuvers that are taught to the participants by a speech therapist.
223689360|NCT03048916|OTHER|NMES therapy|he NMES therapy with VitalStim therapeutic device will be done by one physician who is licensed practitioner and certified in use of the VitalStim device. The placement of 2-channel electrodes is depended on the dysphagic types and the findings on VFS.
223689361|NCT06195683|DRUG|Serplulimab|Serplulimab for 4.5mg/kg IV Q3W day 1,22,43,64
223689362|NCT00984568|BIOLOGICAL|Infliximab|Infliximab intravenous infusion at a dose of 5 mg/kg.
223689363|NCT00984568|DRUG|Prednisolone|Oral prednisolone 40 mg/day or 1 mg/kg/day depending upon participant response.
223689364|NCT00984568|DRUG|5-aminosalicylic acid|5-ASA administered orally at a dose of 2 g/day.
223689365|NCT00984568|DRUG|Azathioprine|AZA administered orally at a dose of 2.0-2.5 mg/kg/day.
223689366|NCT02415257|DRUG|Gentamicin|Intratympanic installation of gentamicin 2-4 times depending on the efficacy of vestibular deafferentation
223689367|NCT04482712|DRUG|Rapamycin|Daily administration of a dose of investigational drug for up to 4 weeks while hospitalized
223689368|NCT04482712|DRUG|Placebo|Administration of investigational drug placebo for up to 4 weeks while hospitalized
223689369|NCT01843088|DRUG|Mannitol cream|25% mannitol in PENcream (See above) (See above) This will be applied as needed to one side of the body (blinded assignment) over painful painful areas of legs following a 10 km run, on the day of the run and for five days afterwards.
223689370|NCT01843088|DRUG|Placebo Cream|This is the vehicle only cream (PENcream) (See above) This will be applied as needed to one side of the body (blinded assignment) over painful painful areas of legs following a 10 km run, on the day of the run and for five days afterwards.
223689371|NCT04857970|OTHER|Electronic HRQoL questionnaires with feedback to physicians|Use of the CHES software for HRQoL collection and graphical display of the patients' HRQoL scores to physicians
223689372|NCT04857970|OTHER|Paper-pencil HRQoL questionnaires w.o. feedback to physicians|Use of paper-pencil HRQoL questionnaires, the results of which are not presented to physicians
223689373|NCT01316354|OTHER|Bread types|Bread with 50 g available carbohydrate
223689374|NCT05059587|DRUG|MBA-P01|MBA-P01 will be injected into the Glabellar line.
223689375|NCT05059587|DRUG|BOTOX|Botox will be injected into the Glabellar line.
223689376|NCT01284582|BIOLOGICAL|ATH03|4 vaccinations
223689377|NCT06324760|DIETARY_SUPPLEMENT|Alpha-lipoic acid combined with B vitamins|The investigational product utilized in this research, Tiobec® 400 is a dietary supplement enriched with ALA, B vitamins, and vitamins E and C. T400 is designed to mitigate oxidative stress and support the optimal functioning of the nervous system
223689378|NCT05893355|BEHAVIORAL|Acupressure group|"Application to Acupressure Group~* Participants in this group will be interviewed for the first time at postpartum week 1, and for the second time between 4-6 weeks postpartum. The application will be explained and a voluntary consent form will be signed.~* Participant Information Form will be filled in by the researcher by face-to-face interview.~* The VAS, which will be applied to the puerperant women for the first time in the first week of the postpartum week and for the second time between the 4th-6th weeks, will be filled by the participant just before the application to evaluate the back pain.~* The VAS Evaluating Back Pain after the application will be filled in by the participant.~* The participant will be informed that the study has been completed."
223689379|NCT00185068|DRUG|Olmesartan medoxomil|
223689380|NCT00185068|DRUG|Olmesartan medoxomil/hydrochlorothiazide|
223689381|NCT00185068|DRUG|Hydrochlorothiazide|
223689382|NCT03816982|PROCEDURE|Single-injection bupivacaine HCl plus liposomal bupivacaine|Patients in the liposomal bupivacaine with added bupivacaine HCl ISB group will be given a single injection LB ISB in the preoperative area only by faculty who are part of the regional anesthesia division. The injectate will include liposomal bupivacaine 10ml (133mg) mixed with bupivacaine HCl 0.5% 10 ml.
223689383|NCT03816982|PROCEDURE|Single-injection bupivacaine HCl plus a subsequent bupivacaine CISB|Patients in the bupivacaine CISB group will undergo catheter placement with ultrasound guidance only by faculty who are part of the regional anesthesia division. A 20 mL single bolus ISB with 0.25% bupivacaine will be administered followed by catheter infusion of 0.125% bupivacaine at a rate of 5mL/hour postoperatively by the ON-Q pump
223689384|NCT00072631|DRUG|Tarceva (Trademark) (erlotinib HCl, OSI-774)|Intrapatient dose escalation of oral single agent daily erlotinib until intolerable rash
223689385|NCT05439642|OTHER|Evaluation of health related quality of life|Evaluation of health related quality of life of boys with hemophilia with the Canadian Haemophilia Outcomes-Kids' Life Assessment Tool and the Pediatric Inventory of Quality of Life
223689386|NCT02932683|DEVICE|MedNav|MedNav is a tablet based platform that uses auditory and visual cues to prompt people to perform the correct steps in neonatal resuscitation.
223776415|NCT06456294|BEHAVIORAL|MHC Outreach Intervention|Adult PC clinics are randomized to receive the MHC Outreach Intervention early (n=7 clinics) vs. delayed (n=7 clinics). In early intervention clinics, patients prescribed chronic opioid therapy, on a chronic opioid registry, and receiving their medication from the intervention clinic are sent emails and letters inviting them to schedule an MHC appointment. Clinical staff at the early intervention clinic are educated to encourage attendance. During MHC visits, MHC staff assess patients prescribed Chronic Opioid Therapy (COT), educate them about overdose, prescribe naloxone, and order guideline-concordant opioid monitoring.
223776416|NCT00145366|DRUG|Recombinant human thyrotropin (Thyrogen)|
223689387|NCT03439059|BEHAVIORAL|Reducing Sedentary Behaviour Group|Participants will be prompted to perform 10min of light physical activity (\>1.5 METS) 3x/day for 6 weeks
223689388|NCT05318482|BEHAVIORAL|Motivational group|In addition to the activities of the usual rehabilitation program, the PT will perform a daily motivational session of 15 minutes in a 1 patient: 1 physiotherapist modality. On that occasion, the patient will report the number of steps performed the previous day; the physiotherapist will check and promote the increase of 10% in the number of steps for the next day. If the patient fails to achieve the goal, the PT will analyze the reasons with the patient, in order to facilitate the achievement of the goal. The PT will advise on the time and place to perform physical activity and the patients will receive a diary to record his/her progress (number of steps and heart rate, Borg Fatigue and Borg Dyspnea before and after an exercise task). The PT will record all these evaluations on an excel database.
223689389|NCT05318482|OTHER|Control group|Besides the activities of the usual rehabilitation program, the patients of this group will be provided by the PT only with the generic recommendations of daily exercise during the in-hospital stay
223689390|NCT03647332|PROCEDURE|Cooled RFA treatment|cooled radiofrequency ablation
223689391|NCT03647332|DRUG|Steroid Drug|steroid injection
223689392|NCT03886662|DRUG|LB-100|"Phase Ib: Two escalating doses of LB-100 in two separate cohorts will be administered intravenously on days 1, 3 and 5 of a 21-day cycle over 120 minutes.~Phase 2: Safe dose of LB-100 as determined from phase Ib will be administered intravenously on days 1, 3 and 5 of a 21-day cycle over 120 minutes."
223689393|NCT05544370|BEHAVIORAL|Intensive high intensity intervallic training group|The intensive high intensity intervallic training group performs 6 sets of 60 seconds of work and 60 seconds of rest. During the first two weeks we work at an intensity of 80-85% of the reserve heart rate during the work phase and 50-55% of the reserve heart rate during the rest time. In weeks 3 and 4 the intensity in the work phase is increased by 5%, reaching from the fifth week onwards a work intensity of 95-95% of the reserve heart rate. The program duration is 8 weeks and the frequency of intervention is 2 sessions per week.
223689394|NCT05544370|BEHAVIORAL|Extensive high-intensity intervallic training|The extensive high-intensity intervallic training group performs 3 sets of 120 seconds of work and 120 seconds of rest at an intensity of 70-75% of the reserve heart rate during the work phase and an intensity of 50-55% of the reserve heart rate during the rest phase. In weeks 3 and 4 the intensity in the work phase is increased by 5%, reaching from the fifth week onwards a work intensity of 80-85% of the reserve heart rate. The program duration is 8 weeks and the frequency of intervention is 2 sessions per week.
223689395|NCT03800810|DRUG|Hyaluronic Acid|
223689396|NCT03800810|BIOLOGICAL|Umbilical Cord Mesenchymal Stem Cell|
223689397|NCT03800810|BIOLOGICAL|Recombinant Human Somatropin|
223689398|NCT03802695|BIOLOGICAL|OrcaGraft (Orca-Q)|engineered donor allograft
223689399|NCT04843059|OTHER|The resident memory T-cell infiltrate in perilesional vitiligo skin|"The 3 groups will receive a combination of narrowband UVB (Nb-UVB) 3 times a week and oral mini pulses of systemic steroids (5 mg of d medrol 16mg twice a week) for 24 weeks.~Three visits will be done (inclusion, Week 12 and 24) A skin biopsy will be done on lesional and peri-lesional area at baseline. Another skin biopsy will be taken after 24 weeks but only in perilesional area. A blood sample for assessing the circulating memory T cells and for checking the tolerance will be performed at baseline, then at W12 and W24."
224263344|NCT04461964|DEVICE|Machine-vision Image Guided Surgery (MvIGS) spine navigation system.|"The intended use of the MvIGS navigation system is to provide high quality intraoperative imaging with no radiation exposure. Use of the proprietary integrated surgical light with embedded tracking technology and Flash™ registration allows for continuous and direct visualization of the surgical field. The MvIGS system is exempt from IDE regulations as the device cleared Premarket Notification FDA-510(k) (K162375). The device includes:~* A single mobile cart with a boom arm and an integrated surgical light with embedded tracking technology (P/N 10-0001);~* Proprietary imaging software (P/N 60-0007); and,~* Kit of tacked surgical instruments including a spine reference clamp, awl tip, pedicle probe (P/N 11-0006)."
224263345|NCT02856308|DEVICE|Hairstetics hair implant device|
223689400|NCT03281460|DEVICE|laparoscopic myomectomy or hysterectomy with More-cell-Safe AMI bag morcellation|laparoscopic myomectomy or hysterectomy with More-cell-Safe AMI bag morcellation
223689401|NCT03281460|PROCEDURE|laparoscopic myomectomy or hysterectomy without any morcellation bag|laparoscopic myomectomy or hysterectomy without any morcellation bag
223689402|NCT05185115|DRUG|Oxygen|administration of oxygen at a flow rate of 3 liters per minute, via nasal cannula throughout the hospitalization.
223689403|NCT05185115|OTHER|no oxygen therapy|No oxygen therapy during hospitalization
223689404|NCT06293300|DRUG|BoNT A|Participants with TBI-associated photophobia will come one time in person to the clinic and receive 35 Units of BoNT-A injected in 7 forehead sites (0.1 cc in each location).
223689405|NCT06063772|DRUG|Clevidipine|The investigator will start the appropriate drug and titrate the drug in the pre-operative area until the mean arterial pressure is between 70 mmHg and 110 mmHg. The infusion will be titrated every 90 seconds to a maximum rate 32 mg/hr for clevidipine or the volume equivalent of placebo.
223689406|NCT06063772|DRUG|Lactated Ringers, Intravenous|The investigator will start the appropriate drug and titrate the drug in the pre-operative area until the mean arterial pressure is between 70 mmHg and 110 mmHg. The infusion will be titrated every 90s to a maximum rate 32mg/hr for clevidipine or the volume equivalent of placebo.
223689407|NCT04920799|DIETARY_SUPPLEMENT|Nitrate rich beetroot juice|Participants will drink nitrate rich beetroot juice (2.4 floz ; Beet It Sport Nitrate 400 concentrated beetroot shot; James White Drink, ltd) twice daily for two weeks.
223689408|NCT04920799|DIETARY_SUPPLEMENT|Nitrate depleted beetroot juice|Participants will drink nitrate depleted beetroot juice (2.4 floz ; Beet It placebo concentrated beetroot shot; James White Drink, ltd) twice daily for two weeks.
223689409|NCT03583073|BEHAVIORAL|Enhanced Referral/Linkage to Care|"The JJ worker reviews with the family psychoeducation material about the role of mental health care in emotional/behavioral problems. The JJ intake worker will contact the CSC program directly with the family for a warm hand-off. The CSC worker will speak with the parent and arrange for an intake evaluation. For families already receiving treatment, the CSC referral will be for consultation. Via phone, the CSC clinician will use a motivational interviewing style to encourage families to attend the appointment. Three and seven days after referral, the JJ worker will text the caregiver to see if the CSC appointment was kept. If not, the JJ worker will text the parent the CSC phone number and also ask permission to contact the CSC to assist the family in setting up another appointment."
223689410|NCT03583073|BEHAVIORAL|Standard Care|Referral to the Coordinated Specialty Care (CSC) clinic
223689411|NCT03690453|DRUG|Ivermectin|single dose of Ivermectin
223689412|NCT04555226|PROCEDURE|Lymph node dissection|Open/minimaly invasive pelvic and para-aortic lymph node dissection
223689413|NCT04555226|RADIATION|Standard chemoradiation±pembrolizumab|1\. A point/HCR-CTV D90≥80Gy(+20%).2. Extended-field EBRT: image-positive common iliac LN with SD≥10mm and/or image-positive PALN.3. Target doses for the image-positive nodes can range from 55 to 60Gy.4. Concurrent 5 cycles platinum-containing chemotherapy(Cisplatin 40mg/m2 q1w or Carboplatin AUC=2 q1w).5. CCRT will be completed in 56 days.6. The patients who received combined immunotherapy were treated with pembrolizumab (200mg, q3w, 3 cycles) during CCRT.7.After CCRT if the cervix biopsy shows residual tumor and/or imaging indicates that there are still positive LN with SD≥15mm in the pelvic and abdominal cavity, 3 cycles adjuvant chemotherapy (TAX 135mg/m2, DDP 50mg/m2, q3w or TAX 135mg/m2, CBP AUC=4, q3W) ± brachytherapy (if point A or HR-CTV D90 \< 96Gy) ± pembrolizumab(suitable for the patients who combined immunotherapy,200mg, q3w, 3 cycles) will be performed.8.Maintenance treatment with pembrolizumab (400mg, q6w) is optional for the combined immunotherapy patiants.
223689414|NCT04555226|RADIATION|Chemoradiation± pembrolizumab|1\. A point/HCR-CTV D90≥80Gy(+20%).2. Extended-field EBRT: image-positive common iliac LN with SD≥10mm and/or image-positive PALN.3. Target doses for the image-positive nodes can range from 55 to 60Gy.4. Concurrent 5 cycles platinum-containing chemotherapy(Cisplatin 40mg/m2 q1w or Carboplatin AUC=2 q1w).5. CCRT will be completed in 56 days.6. The patients who received combined immunotherapy were treated with pembrolizumab (200mg, q3w, 3 cycles) during CCRT.7.After CCRT if the cervix biopsy shows residual tumor and/or imaging indicates that there are still positive LN with SD≥15mm in the pelvic and abdominal cavity, 3 cycles adjuvant chemotherapy (TAX 135mg/m2, DDP 50mg/m2, q3w or TAX 135mg/m2, CBP AUC=4, q3W) ± brachytherapy (if point A or HR-CTV D90 \< 96Gy) ± pembrolizumab(suitable for the patients who combined immunotherapy,200mg, q3w, 3 cycles) will be performed.8.Maintenance treatment with pembrolizumab (400mg, q6w) is optional for the combined immunotherapy patiants.
223689415|NCT04967612|OTHER|Virtual implantation|Temporary placement of virtual optical lens in the crystalline lens plane.
223689416|NCT01367119|DRUG|Ketamine|Subjects were dosed with approximately 1.0 mg/kg, using ketamine as anesthetic.
223689417|NCT01367119|DRUG|methohexital|Subjects were dosed with approximately 1.0 mg/kg, using methohexital as anesthetic.
223776417|NCT01484470|BIOLOGICAL|StemEx|"For patients allocated to StemEx® arm:~* Day -20: Start small (or equal) portion expansion at processing site. (II) Conditioning Phase~* Day -6 to -1: Subject receives a RIC regimen containing Fludarabine, Cyclophosphamide and Total Body Irradiation (TBI) (III) Transplantation and Follow-up Phase~* Day 0: CBU unmanipulated portion transplantation (for StemEx® arm) or unmanipulated CBU transplantation.~* Day 1: StemEx® transplantation.~* Day 2 to 3 years: Post transplant follow-up."
223689418|NCT05515666|DIAGNOSTIC_TEST|Wearable electrocardiogram|All participants will have their ECG monitored at home using a wearable ECG, and then be hospitalized for coronary angiography and quantitative flow fraction to confirm the presence of coronary artery disease.
223689419|NCT00645684|PROCEDURE|Gastrointestinal Anastomosis|Gastrointestinal Anastomosis with synthetic, absorbable, coated suture material using two different suture-techniques
223776418|NCT03616756|BEHAVIORAL|Authentic Connections|Authentic Connections support groups for nurse leaders who are also mothers. Meetings occur once a week for one hour.
223776419|NCT03616756|BEHAVIORAL|Protected time|Participants have one hour per week protected time scheduled on their calendar to do with what they choose.
223776420|NCT01160965|DRUG|0.5% levobupivacaine|15mls of a 5mg/ml solution of the local anaesthetic levobupivacaine given via the epidural catheter.
223689420|NCT04570722|OTHER|Ipsilateral peripheral IV insertion|Patients with successful ipsilateral intravenous access will be provided a patient education sheet describing signs and symptoms that should be reported to the study team. All participants will be contacted by the study team at twelve week intervals for 12 months after their radiology encounter for completion of symptom assessments. If a subject reports new signs or symptoms of lymphedema during follow-up, a clinic appointment for volumetric measurements and thorough evaluation will occur
223689421|NCT06030310|OTHER|The developmental Exercise Programme of INPP|"The INPP school motor program consists of a series of developmental movements based on the normal movements of a child in their first year of life. Exercises must be performed as slow as possible and must be repeated for at least six weeks.~Once the children have performed a set of movements, a new set will be presented for practice in a more complex position.~The exercises are done on the floor and aid in developing:~Proper alignment of the head with the body, trunk stability. Balance and coordination. The ability to use both sides of the body and upper and lower parts independently.~Muscle tone in prone and supine position. Hand-eye coordination and visual skills"
223689422|NCT05860335|DRUG|Cisplatin/Nedaplatin, albumin paclitaxel|During induction chemotherapy, triplelimab JS001 was administered before cisplatin/Nedaplatin and albumin paclitaxel. JS001 Intravenous infusion of cisplatin/Nedaplatin was administered 60 minutes after the end of infusion and beginning on day 1 of each cycle 40mg/m 2, D1, D2 albumin paclitaxel 230 mg/m 2; Chemotherapeutic drugs are administered in accordance with the drug label and local prodrome and other standard protocols for prophylactic use, every 3 Once a week (Q3W) for 2 cycles
223689423|NCT04088604|DRUG|LY01610 ( Irinotecan hydrochloride liposome injection )|Part1-Dose Escalation and Part1-Dose Extension : subjects take LY01610;
223689424|NCT04088604|DRUG|LY01610 ( Irinotecan hydrochloride liposome injection ) with 5-Fu（Fluorouracil Injection）|Part2-Dose Escalation and Part2-Dose Extension : subjects take LY01610 with 5-Fu;
223689425|NCT04088604|DRUG|Irinotecan Hydrochloride Injection（CAMPTO®）|Irinotecan Hydrochloride Injection（CAMPTO®） pharmacokinetics comparative study
223689426|NCT02238171|DRUG|Atrovent® inhalets|
223689427|NCT06043284|DEVICE|Hyperbaric Oxygen Therapy|Subjects received 100% medical grade oxygen for 60 minutes at 2.0 ATA for 40 sessions in a hard-sided monoplace hyperbaric chamber
223689428|NCT03315182|BIOLOGICAL|rAAV9.CMV.hNAGLU|Adeno-associated virus serotype 9 carrying the human NAGLU gene under the control of a CMV enhancer/promoter (rAAV9.CMV.hNAGLU) will be delivered one-time through a venous catheter inserted into a peripheral limb vein.
223689429|NCT01578564|DRUG|SOR-C13|Intravenous solution for infusion, potential dose range 1.375 mg/kg to 6.12 mg/kg, dosing frequency 2 cycles with a cycle consisting of infusions on days 1-3 and days 8-10 followed by a 11 day off period
223689430|NCT04455243|DRUG|N-Acetyl cysteine|150 mg/kg every 12 hours for 14 days (oral/IV) Diluted in 200 ml diluent (D5%, NS)
223689431|NCT04455243|DRUG|Placebo|Matching placebo administered in the same schedule and volume as NAC
223689432|NCT00560378|DRUG|Tacrolimus ointment 0.1%|Topical
223689433|NCT02480985|OTHER|Pituitary function evaluation|"Pituitary function evaluation performed at hospital discharge, 6 and 12 months~* Thyroid-stimulating hormone, free T4 and T3~* Follicle stimulating hormone, luteinizing hormone, estradiol, bioavailable testosterone~* Adrenocorticotropic hormone stimulation test~* Glucagon test (growth hormone deficit)~Risk factors evaluation of pituitary dysfunction~* Demographic data~* Daily data (clinical exam, secondary brain injuries)~* Hormone levels on day 1, 3 and 7~* Biomarkers on day 1, 3 and 7~* Brain CT-Scan on day 1~* Pituitary MRI on day 7~Outcome measures at 6 and 12 months~* Neurological recovery (GOSe)~* Independent functioning (FIM)~* Quality of life (EQ-5D-5L)~* Life satisfaction (LISAT-11)~* Depression (PHQ-9)"
223689434|NCT00884533|DRUG|Rosi XR|Rosi XR
223689435|NCT00884533|OTHER|Placebo|Placebo
223689436|NCT00884533|DRUG|Moxifloxacin|400mg single dose
223689437|NCT06013982|BEHAVIORAL|Anxiety Reduction Bundle|"The Anxiety Reduction Bundle intervention comprises the following resources:~* Stroke Support Group~* Anxiety Reduction Sheet~* Understanding Anxiety Disorder sheet~* Your body's response to anxiety sheet~* Relaxation Tip sheet~* Breathing Tip sheet and video~* A sigh of Relief video"
223689438|NCT03180684|BIOLOGICAL|VGX-3100|One milliliter (1 mL) VGX-3100 injected IM and delivered by EP using CELLECTRA™ 2000 on Day 0, Week 4, Week 12 and Week 24.
224263346|NCT00896688|PROCEDURE|cervical medial branch blocks using the Quincke spinal needle|#25 gauge 1 and 1/2 inch long needle and #25 gauge 10cm long Quincke spinal needle will be used for placement.
223689439|NCT03180684|DRUG|Imiquimod 5% Cream|Participants applied imiquimod 5% cream to the vulvar lesion three times per week for 20 weeks.
224263347|NCT01910038|DRUG|corticoids+ tocilizumab 8mg/Kg/4 weeks|
224263348|NCT03498235|DRUG|Sevoflurane|In Team Sevoflurane,patients undergo sevoflurane.
224263349|NCT03498235|DRUG|Propofol|In Team Propofol ,anesthesia is maintained with propofol
224263350|NCT01449981|BEHAVIORAL|Integrated Twelve-Step Facilitation|The iTSF condition will include review of treatment goals and overall review of progress, coping skills, real life practices, emotions/mood management, how to make changes in one's social network and discussions about how 12-step meetings can be helpful in one's recovery efforts. In addition, speakers from 12-step fellowships such as Alcoholics Anonymous (AA) and Narcotics Anonymous (NA) will be invited to share their experiences and discuss myths and facts related to attendance at 12-step meetings as well as answer any questions participants have about these fellowships.
224263351|NCT01449981|BEHAVIORAL|Cognitive Behavioral Therapy|The CBT condition will include review of progress, coping skills, group exercises, real life practice, and emotions/mood management.
224263352|NCT04124315|OTHER|Accelerometry|Patients will be given accelerometers at this visit and informed on how to use them (e.g., wear on the ankle during waking hours, upright, etc).
224263353|NCT04124315|OTHER|Daynamica app|Participants will be asked to record location/activity on the app in order to characterize activity patterns both inside and outside of the hospital SET setting.
224263354|NCT00845637|DRUG|Eggplant extract|Dry eggplant extract in two 450mg capsules, twice a day (before the main meals) for fourteen days.
224263355|NCT00845637|DRUG|Placebo|Placebo in two 450mg capsules, twice a day (before the main meals) for fourteen days.
224263356|NCT04026815|OTHER|medical history, blood and urine tests|The study protocol consists of questionnaires (medical, socio-economic, dietary), comprehensive geriatric assessment, physical examination, anthropometric and blood pressure measurements and laboratory tests.
223689440|NCT03180684|DEVICE|CELLECTRA™ 2000|IM injection of VGX-3100 was followed by EP with the CELLECTRA™ 2000 device.
223689441|NCT04776239|DRUG|100 million Allogeneic Mesenchymal Human Stem Cells|1 single intravenous infusion
223689442|NCT04776239|OTHER|Placebo|Placebo delivered via peripheral intravenous infusion
223689443|NCT05809622|BEHAVIORAL|Elbow focused rehabilitation|"* Patient education~* Activity modification~* 2 days/week, 8 weeks in total~* Exercises for the wrist extensor tendon, especially the extensor carpi radialis brevis (EKRB) (stretching + strengthening)"
223689444|NCT05809622|BEHAVIORAL|Scapular and rotator cuff muscles strengthening|"* Patient education~* Activity modification~* 2 days/week, 8 weeks in total~* Exercises for the wrist extensor tendon, especially the extensor carpi radialis brevis (EKRB) (stretching + strengthening)~* Scapular stabilizer muscle + rotator cuff (RM) strengthening"
223689445|NCT06051448|BEHAVIORAL|Promoting Resilience in Stress Management (PRISM)|This program teaches the four pillars of resilience (stress management, goal setting, cognitive restructuring, and benefit-finding) in a one-on-one training program consisting of four 20-30 minute sessions occurring once weekly.
223689446|NCT06051448|BEHAVIORAL|Clinical-focused narrative (CFN)|This program consists of questions posed to adults with primary mitochondrial disease at regular mitochondrial medicine center visits. Specific topics will be discussed at each session. This consists four 20-30 minute sessions occurring once weekly.
223689447|NCT02675231|DRUG|Abemaciclib|Administered Orally
223689448|NCT02675231|DRUG|Trastuzumab|Administered IV
223689449|NCT02675231|DRUG|Fulvestrant|Administered IM
223689450|NCT02675231|DRUG|Standard of Care Single Agent Chemotherapy|Standard-of-care single-agent chemotherapy of physician's choice administered according to product label
223689451|NCT05468476|OTHER|No intervention|No intervention
223689452|NCT05919537|DRUG|HMBD-001|HMBD-001 is a humanized IgG1 anti-HER3 monoclonal antibody (mAb). It is administered IV weekly
223689453|NCT05919537|DRUG|Docetaxel|Docetaxel 75 mg/m\^2 IV once every 3 weeks
223689454|NCT05919537|DRUG|Nab-paclitaxel|Nab-paclitaxel 125 mg/m\^2 IV on days 1, 8, 15, every 4 weeks
223689455|NCT05919537|DRUG|Gemcitabine|Gemcitabine 1000 mg/m\^2 IV on days 1, 8, 15, every 4 weeks
223689456|NCT05133492|DEVICE|Endovascular Aneurysm Stabilization Treatment (EAST)|Endovascular procedure: an ipsilateral ilio-femoral aortogram to confirm suitability for placement of a 14F sheath will be performed. A baseline contrast aortogram will be performed to assess vessel patency and target location of the EAST delivery catheter. Occluding and Stabilizer balloons are inflated in preparation for Stabilizer Compound delivery within the AAA sac. A post-Stabilizer angiogram will re-assess vessel patency and aorta stability. Delivery catheter is removed and discarded. The entire procedure is approximately one hour.
223689457|NCT05279079|DIAGNOSTIC_TEST|Assessment of accuracy of microRNA and pancreatic enzyme markers in blood and/or urine in the detection and/or prediction of severity of drug-associated acute pancreatitis|Panel of microRNA and pancreatic enzyme biomarkers
223689458|NCT05351294|OTHER|Questionnaires|"All patients in Arm 2 will be seen and treated by one of three ROs with an interest in participating in this study, who will be trained by the PI to perform these visits reproducibly and with rigor. These will all be regular ROs, who like most ROs administer a mix of curative and PRT in their clinical practice; like most cancer centers, there are no ROs who formally subspecialize in PRT at our institution. Notably, patients in Arm 1 (control arm) will always have standard-of-care RO referral available for consideration of PRT if needed for symptom relief. However, patients in Arm 1 will be seen by other ROs without any specific training for this study. Any courses of PRT administered in either arm are at the discretion of the treating RO in terms of the timing, dose, fractionation, and treatment technique."
223689459|NCT05351294|COMBINATION_PRODUCT|Early Radiation Oncology Involvement Alongside Standard Oncologic Care|Early Radiation Oncology Involvement Alongside Standard Oncologic Care
223689460|NCT05014490|DRUG|Exib 120 mg etoricoxib film-coated tablets|Oral, COX-2 highly selective, non-steroidal anti-inflammatory generic drug
223689461|NCT05014490|DRUG|Arcoxia® 120 mg etoricoxib film-coated tablets|Oral, COX-2 highly selective, non-steroidal anti-inflammatory innovative drug
223689462|NCT05587673|DRUG|Methylprednisolone|High dose steroid injected directly into the inflamed bowel segment(s) via its arterial blood supply.
223689463|NCT04677413|RADIATION|Ultrafractionated radiotherapy for rectal cancer|To determine the toxicity of dose-escalated hypofractionated RT, in patients with locally advanced rectal cancer treated with RT, FOLFOX or CAPOX chemotherapy and selective omission of surgery.
223689464|NCT05078138|DRUG|Epoetin Alfa|Subcutaneous injection of Epoetin Alfa 3 times per week for 4 weeks
223689465|NCT04847622|DRUG|Remdesivir|treated with Remdesivir
223689466|NCT00210860|DRUG|topiramate|
223689467|NCT04722653|DRUG|NNC0194-0499|1 single dose administered subcutaneously (s.c. - under the skin)
223689468|NCT04722653|DRUG|Placebo (NNC0194-0499 )|1 single dose administered subcutaneously (s.c. - under the skin).
223689469|NCT05684939|BEHAVIORAL|Questionnaire (patient reported outcome)|Online self-administered questionnaire exploring substance use, pain, chemotherapy-induced peripheral neuropathy, health-related quality of life, anxiety, depression, social and material deprivation, patients and oncological charactericitcs, and intercurrent pathologies
223689470|NCT06190353|BEHAVIORAL|An internet-based self-help program with minimal telephone support utilizing Acceptance and Commitment Therapy for alleviating burnout among healthcare workers.|An eight module self help program
223689471|NCT00004076|DRUG|mureletecan|
223689472|NCT00246779|PROCEDURE|Modified ultrafiltration|
223689473|NCT03703596|DRUG|Anlotinib Hydrochloride|Anlotinib (12mg QD PO d1-14, 21 days per cycle)
223689474|NCT03703596|DRUG|Docetaxel|Docetaxel (75mg/m2 IV d1, 21 days per cycle)
223689475|NCT04094077|DRUG|AGuIX|2 IV injections (100 mg/Kg/injection) at day 4 and day 8 + Strereotactic Radiation from day 8 to day 15 as per standard practice.
223689476|NCT02896374|BEHAVIORAL|Theory of mind without visual cues|Theory of mind stimulation without visual reinforcement while performing EEG recordings
223689477|NCT02896374|BEHAVIORAL|Theory of mind without visual cues|Theory of mind stimulation with visual reinforcement while performing EEG recordings
223689478|NCT03143881|BEHAVIORAL|Education|Standardized information on the etiology of HF, mechanisms and side effects of medications prescribed, strategies for minimizing exacerbations, and warning signs of worsening clinical status will be discussed with the patient.
223689479|NCT05267821|DRUG|Anakinra|See information in arm/group descriptions
223689480|NCT05267821|DRUG|Placebo|See information in arm/group descriptions
223689481|NCT06324669|DIETARY_SUPPLEMENT|Ketone supplement|100 mL flavoured drink containing 0.3 g/kg ketone monoester ((R)-3-hydroxybutyl (R)-3-hydroxybutyrate; ΔG®, University of Oxford; https://www.deltagketones.com) consumed 30 min prior to a mixed meal tolerance test, on 2 occasions during test day
223689482|NCT06324669|DIETARY_SUPPLEMENT|Placebo supplement|Placebo with stevia and bitter agent to flavour match, consumed 30 min prior to a mixed meal tolerance test, on 2 occasions during test day
223689483|NCT06322264|DIAGNOSTIC_TEST|Measurement of variation in heart rate|The children will be given a portable device that will monitor their heart rate, enabling the recording of the rate of their pulse.
223689484|NCT05494320|DRUG|Folfox Protocol|Folfox: It includes the drugs leucovorin calcium (folinic acid), fluorouracil, and oxaliplatin.
223689485|NCT02264873|DRUG|Decitabine|Dose escalation starting at 5 mg, and increasing by 2.5 mg to a Dose Level of 12.5 mg qd x 3 days.
223689486|NCT06260761|PROCEDURE|MIPO|minimal invasive surgery with Volar locking plate fixation in isolated close fracture of distal radius under WALANT
223689487|NCT06260761|PROCEDURE|Conventional|standard surgery with Volar locking plate fixation in isolated close fracture of distal radius under WALANT
223689488|NCT00622076|PROCEDURE|postoperative catheterization|postoperative catheterization after anterior colporrhaphy for five days versus two days.
223689489|NCT00546221|BEHAVIORAL|Psychosocial support exercise programme|The experimental arm will experience 12 sessions of intervention, at a rate of three sessions a week for four weeks, exercising in groups of ten women. Each session will comprise: fifteen minutes of psychosocial and motivational support, run by a qualified rehabilitation psychologist and overseen by a qualified health psychologist; a half hour preferred intensity exercise session run by a qualified sports physiotherapist. Participants preferred intensity (chosen exertion level) will be established using the Borg RPE scale (Borg G 1998).
223689490|NCT00546221|BEHAVIORAL|Prescribed exercise|This group will experience 12 sessions of intervention, at a rate of three sessions a week for four weeks, exercising in groups of ten women. Each session will be an half hour exercise session, at a typically (GP) prescribed level, designed in accordance with national guidelines and run by a qualified sports physiotherapist.
223689491|NCT00833079|DRUG|Tacrolimus 0.1% manufactured by Taro|Treatment applied as a thin layer to target area twice daily for 14 days
223689492|NCT00833079|DRUG|Protopic - Tacrolimus 0.1%|Treatment applied as a thin layer to target area twice daily for 14 days
223689493|NCT00833079|DRUG|Tacrolimus Vehicle manufactured by Taro|Treatment applied as a thin layer to target area twice daily for 14 days
223689494|NCT02914821|BEHAVIORAL|Simulated tax via 3 cent per ounce price increase|For each of the 3 experimental conditions, investigators will increase the price of sugar-sweetened beverages by 3 cents per ounce. This price increase will be reflected in the price tag and described as a surcharge. In two of the arms (Pre-K and Childhood Healthy Eating), the beneficiary of the surcharge will be named.
223689495|NCT00600509|DRUG|Levetiracetam|
223689496|NCT04585139|DEVICE|Phase 1- Introduction to Dexcom G6 CGM|Examine whether non-adjunctive use of CGM improves glycemic control in adults with diabetes managed by intensive insulin therapy
223689497|NCT03370289|BIOLOGICAL|BLB-750 Vaccine (Qinghai RG strain)|BLB-750 Injection
223689498|NCT05501912|DRUG|ABM-1310|"Dose escalation starting dose will be based on a priming dose one level below the highest safe dose or two levels below the MTD that has been tested in US clinical trials.~Dose expansion will be initiated at the MTD or the optimal dose determined by the SMC as a fixed dose level."
223689499|NCT00248885|PROCEDURE|Regulating Mean Arterial Pressure during cardiopulmonary bypass|Patients were randomized to one of two groups. In the first group (Low) the goal was to maintain MAP between 50-60 mm Hg during CPB. In the second group (High), the goal was to maintain MAP between 80-100 mm Hg. In both groups, CPB flow was held constant at 1.6 L/min/M2 (cool) and 2.4 L/min/M2 (warm) and vasoactive drugs (nitroglycerin or phenylephrine) were used to maintain MAP in the desired range. MAP was controlled in this fashion from the onset of CPB through separation from CPB began.
223689500|NCT00922701|DRUG|L-carnitine|Instillation of glucose-based (1.5% weight/volume) peritoneal dialysis solution containing L-carnitine (0.25% weight/volume) for the nocturnal exchange. Patients were treated with the experimental peritoneal dialysis solution for 5 days.
223689501|NCT02503995|BEHAVIORAL|Physical Exercise Participation|
223689502|NCT06286371|PROCEDURE|Laparoscopic Endometriosis Surgery|Laparoscopic Excision of Deep Endometriotic Nodule related to pelvic pain
223689503|NCT02220998|DRUG|SOF/VEL|SOF/VEL (400/100 mg) FDC tablet administered orally once daily
223689504|NCT02220998|DRUG|SOF|SOF 400 mg tablet administered orally once daily
223689505|NCT02220998|DRUG|RBV|RBV tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
223776421|NCT01160965|DRUG|0.75% Ropivacaine|15mls of a 7.5mg/ml solution of the local anaesthetic ropivacaine given via the epidural catheter.
223689506|NCT00695201|DRUG|Floxuridine, Oxaliplatin, CPT-11|For patients on the 4-week cycle: On the first day of each cycle, the pump will be filled with FUDR and dexamethasone. The pump will be emptied of drugs after 2 weeks (on day 15 of each cycle) and filled with heparin (which is used to prevent blood from clotting) and saline. Whether the pump contains drug or heparin and saline, it will need to be emptied and refilled about every two weeks. We will inject either the drugs or the saline and heparin into the pump through the skin using a needle and syringe. In summary, 2 weeks of drug in the pump is followed by 2 weeks without drug in the pump. The systemic chemotherapy (Oxaliplatin/CPT-11) will be administered on the same day as the pump is filled and emptied, ie. Day 1 and Day 15 of each cycle.
223689507|NCT00695201|DRUG|Floxuridine, Oxaliplatin, CPT-11|For patients on the 5-week cycle: On the first day of each cycle, the pump will be filled with FUDR and dexamethasone. The pump will be emptied of drugs after 2 weeks (on day 15 of each cycle) and filled with heparin and saline. This is repeated on day 29 of each cycle). In summary, 2 weeks of drug in the pump are followed by 3 weeks without drug in the pump. The systemic chemotherapy (Oxaliplatin/CPT-11) will be administered on the same day that the pump is emptied and filled with heparin and saline, i.e. Day 15 and Day 29 of each cycle.
223689508|NCT05814601|DRUG|norepinephrine|norepinephrine at a concentration of 5 mcg/ml is preemptively administered
223689509|NCT04047927|DEVICE|EpiFinder|The EpiFinder is a sensing device intended to assist physicians performing placement of epidural needle analgesic and/or anesthesia injection in a safely and accurately manner. The device is a single use sterile device consisting of a probe (Stylet), an actuator (micro DC motor), IR sensor and Controller. The device is integrated to a standard LOR Syringe and an 18G Tuohy needle and enables to simultaneously work with the standard LOR technique.
223689510|NCT05034445|DIAGNOSTIC_TEST|Next generation sequencing|Extract DNA from sputum sample, minimum DNA amount should be over 50ng.
223689511|NCT05351398|DRUG|PDO group|Patients with stage III gastric cancer who need neoadjuvant chemotherapy before radical surgery are recruited. And they are treated with individualized neoadjuvant therapy under the guidance of a patient-derived organoid (PDO)-based drug sensitivity assay.
223689512|NCT05351398|DRUG|Traditional group|Patients with stage III gastric cancer who need neoadjuvant chemotherapy before radical surgery are recruited. In this group, patients are treated with the SOX regimen.
223689513|NCT00873860|OTHER|Placebo|Placebo matched to CAT-354 subcutaneous injection once every 2 weeks on Day 1, 15, 29, 43, 57, 71, and 85.
223689514|NCT00873860|BIOLOGICAL|CAT-354 150 mg|CAT-354 150 milligram (mg) subcutaneous injection once every 2 weeks on Day 1, 15, 29, 43, 57, 71, and 85.
223689515|NCT00873860|BIOLOGICAL|CAT-354 300 mg|CAT-354 300 mg subcutaneous injection once every 2 weeks on Day 1, 15, 29, 43, 57, 71, and 85.
223689516|NCT00873860|BIOLOGICAL|CAT-354 600 mg|CAT-354 600 mg subcutaneous injection once every 2 weeks on Day 1, 15, 29, 43, 57, 71, and 85.
223689517|NCT04344743|DEVICE|Cryoballoon ablation without contrast|Cryoballoon ablation without contrast
223689518|NCT00652691|BIOLOGICAL|filgrastim|
223689519|NCT00652691|DRUG|carboplatin|
223689520|NCT00652691|DRUG|cyclophosphamide|
223689521|NCT00652691|DRUG|topotecan hydrochloride|
223689522|NCT00652691|PROCEDURE|autologous hematopoietic stem cell transplantation|
223689523|NCT00652691|PROCEDURE|peripheral blood stem cell transplantation|
223689524|NCT02695212|DRUG|Apremilast|"Investigational Product: Apremilast~Doses: Period A:~10mg Per day, day #1, 10mg Twice Per day, day #2 10mg qAM, 20mg qHS day #3 20mg Twice per day, day #4 20mg qAM, 30 mg qHS day #5 30mg Twice per day, day #6~Period B:~30mg Twice per day, day #7 through week #24~Period C:~Week 28 (4 weeks off therapy), for final evaluation Mode of Administration: Oral"
223689525|NCT04562272|PROCEDURE|LV mechanical unloading by Impella-CP|The patients will receive Impella-CP for 36-48 hours. The pump speed and LV unloading will be guided by PCWP (Swan-Ganz catheter)
223689526|NCT00236951|DRUG|iron sucrose injection USP|
223689527|NCT00236951|DRUG|stable erythropoietin therapy|
223689528|NCT02436642|DEVICE|AVERT Plus System|
223689529|NCT02448342|DEVICE|Remote Dielectric Sensing (ReDS) Wearable System|The ReDS device provides noninvasive measurement of lung fluid content. It comprises a wearable vest with embedded sensors and a bedside console, with touch-screen display. A measurement reading is provided within 90sec. Results are shared with the treating physician via a secured web portal.
223689530|NCT02734420|DRUG|PapacarieMBlue and PDT|Initial periapical and interproximal radiographs Microbiological sample with otoscope curette to standardize volume of carious tissue; Application on PapacarieMBlue (addition of toluidine blue) for 5 minutes to potentiate effect of PDT; Removal of carious tissue around lateral walls of the cavity with non-cutting curette; No removal of carious tissue on pulp floor; Irradiation of dental tissue for one minute on a single point; Second microbiological sample of remaining dentin with curette; Clinical evaluation by inspection of texture of remaining dentin with exploratory probe; Restoration with glass ionomer cement (Ketac Molar EasyMIx 3M ESPE); Follow up;Radiographic control: periapical and interproximal radiographs at 3, 6 and 12 months.
223689531|NCT02734420|DRUG|Toluidine Blue O and PDT|Initial periapical and interproximal radiographs;Microbiological sample with otoscope curette to standardize volume of carious tissue;Application of Toluidine Blue O for 5 minutes to potentiate effect of PDT; Removal of carious tissue around lateral walls of the cavity with sharp curette; No removal of carious tissue on pulp floor;non-cutting curette; Irradiation of dental tissue for one minute on a single point;Second microbiological sample of remaining dentin with curette;Clinical evaluation by inspection of texture of remaining dentin with exploratory probe; Restoration with glass ionomer cement (Ketac Molar EasyMIx 3M ESPE);Follow up;Radiographic control: periapical and interproximal radiographs at 3, 6 and 12 months.
223689532|NCT02734420|DEVICE|Laser|
223689533|NCT00329940|DRUG|Letrozole|
223689534|NCT00079014|DRUG|triapine|Given IV
223689535|NCT00079014|DRUG|doxorubicin hydrochloride|Given IV
223689536|NCT00079014|OTHER|laboratory biomarker analysis|Correlative studies
223689537|NCT00079014|OTHER|pharmacological study|Correlative studies
223689538|NCT00081965|PROCEDURE|acupuncture therapy|
223689539|NCT00081965|PROCEDURE|hot flashes attenuation|
223689540|NCT00081965|PROCEDURE|management of therapy complications|
223776422|NCT04619316|DRUG|Trametinib 2 MG [Mekinist]|Monotherapy with Trametinib is given in patients with BRAF wildtype.
223689541|NCT03580304|BEHAVIORAL|Industrial work|Subjects perform simulated industrial work in lab setting. The industrial task exists of a physical component and a cognitive component. Physical load is measured by questionnaires and basic physiological measurements (e.g. heart rate). Mental fatigue will be determined by questionnaires and a cognitive stroop task before and after the trial.
223689542|NCT03580304|BEHAVIORAL|Physical load|The physical load of an industrial task will be simulated during this intervention. Physical load is measured by questionnaires and basic physiological measurements (e.g. heart rate). Before and after the trial, mental fatigue will be determined by questionnaires and a cognitive stroop task (10 min)
223689543|NCT03580304|BEHAVIORAL|Cognitive load|The cognitive load of an industrial task will be simulated in this intervention. Physical load is measured by questionnaires and basic physiological measurements (e.g. heart rate). Before and after the trial, mental fatigue will be determined by questionnaires and a cognitive stroop task (10 min)
223689544|NCT04800666|PROCEDURE|Stellate Ganglion Block|Patients underwent a stellate-ganglion block at the anterolateral aspect of the C6 vertebra. After local analgesia (lidocaine 2%), a 22-gauge Quincke needle was placed in the anterolateral aspect of the C6 vertebral body. When the needle contacted the bone, it was drawn back 1 mm. 5 mL of 0·5% ropivacaine was subsequently injected next to the stellate ganglion to produce a sympathetic block.The effect of the stellate-ganglion block on the sympathetic nervous system was confirmed by the presence of Horner's syndrome (ie, facial anhydrosis, enophthalmos, ptosis, swelling of the lower eyelid, miosis, and blood-shot conjunctiva), and an increase in the temperature of the right hand of at least 2°F from baseline.
223689545|NCT04800666|PROCEDURE|Facial Nerve Block|Operator touching the location of the mastoid, in the external auditory canal just below the front of the mastoid vertical needling.When touch the surface of the mastoid,adjust the needle across the front of the mastoid then slow needling about 1cm.The pin located below the stylomastoid foramen, and then injected drugs 5mL ( mecobalamin injection 1mg；lidocaine 60mg； dexamethasone 10mg )
223689546|NCT04800666|DRUG|Mecobalamin Tablets|oral Mecobalamin Tablets tid-8
223689547|NCT06515028|PROCEDURE|Group GA|Anesthesia induction will be performed preoxygenation with 3 minutes of 80% FiO2 , followed by intravenosus propofol 2-2.5 mg/kg and fentanyl 2 µg/kg. Rocuronium 0.6 mg/kg will be administered for neuromuscular blockade, followed by endotracheal intubation after 2 minutes of mask ventilation. Anesthesia maintenance will be achieved with inhalation of 2.5-3.3% sevoflurane with 50% oxygen and 50% air mixture, along with infusion of remifentanil at 0.1 micrograms/kg/min. ventilation will be performed using a volume-controlled.
223689548|NCT06515028|PROCEDURE|Group IB|infraclavicular brachial plexus block will be performed in supine position with the arm adducted and flexed at 90 degrees. A mixture consisting of 15 ml of 0.5% Bupivacaine, 15 ml of 2% Lidocaine, and 30 ml of saline solution will be prepared, with equal concentrations distributed into three different syringes of 20 milliliters each. The clavicular notch will be palpated, and an ultrasound linear probe covered with a sterile sheath will be positioned in the lateral sagittal plane over this area to visualize the median, lateral, and posterior cords of the brachial plexus surrounding the axillary artery. A special Stimuplex A 22G, 100 mm needle will be used for plexus anesthesia. local anesthetic injection will be sequentially performed around the posterior, median, and lateral cords under ultrasound guidance. After confirming sensory and motor block, the operation will be commenced.
223689549|NCT02041442|PROCEDURE|Electrical mapping of the urinary bladder|
223689550|NCT02633618|BIOLOGICAL|Analgecine|Extraction from rabbit skin extract through vaccinia virus inoculation inflammation as an antigen immune reaction.
223689551|NCT02633618|BIOLOGICAL|Neurotropin|a natural bio-product obtained from rabbit skin extract through vaccinia virus inoculation inflammation as an antigen immune reaction.
223689552|NCT01795378|BIOLOGICAL|donor natural killer cell infusion|"* Donor NK cells will be generated at the GCP laboratory at Asan Institute of Life Science by a team from Stem Cell Research Center, Korea Research Institute of Bioscience and Biotechnology.~* The patients will receive donor NK cell infusion (DNKI) around on days 6 and 9 (generated from the first collection), and around on days 13 and 20 (generated from the second collection).~* For DNKI to be given on days 6 and 9, a 3-patient cohort each will receive escalating dose of 2x10e7/kg, 5x10e7/kg, 1x10e8/kg, and 1-4 x10e8 cells.~* The dose of DNKI to be given on days 13 and 20 will be 1-4 x10e8/kg."
223689553|NCT02669654|OTHER|Day-care management of Severe Pneumonia|Day-care management of Severe Pneumonia
223689554|NCT06178705|BEHAVIORAL|Helpful Parenting Program Intervention|8-10 sessions with 60 minutes duration once in a week will be conducted with the parents in group and one-on-one setting. Helpful parenting program would be based on social learning theory, behavior modification and couple counseling. The program will be used as an intervention strategy with parents to built insight about their child's emotional \& behavioral issues. Different strategies to teach parenting skills will also be used as an intervention. Further more, this program will target parents' psychological distress and couples' problematic conflicts regarding parenting
223689555|NCT02898584|OTHER|BP Track|
223689556|NCT02985970|OTHER|questionnaire|The questionnaire will be send to all members of ČSARIM with the selected 4 controversial clinical scenarios in which the RSI should be used
223689557|NCT06070571|DRUG|Yarrow and moringa mixture|yarrow and moringa mixture nano particles loaded on buccal film
223689558|NCT00945854|OTHER|Wholegrain cereal diet|Thirty subjects with metabolic syndrome, after an initial run-in period of 4 weeks, during which they stabilise their own diet and other lifestyle habits, are assigned to a diet based on wholegrain cereals and foods with low glycemic index for a period of 12 weeks. Before and after the dietary treatment, a frequently samples intravenous glucose tolerance is carried out to measure the effects of the intervention on glucose and insulin metabolism. At beginning and at the end of intervention, the subjects consume also a standard test meal to evaluate the postprandial response of glucose, insulin, lipids, oxidative parameters and inflammatory molecules.
223689559|NCT00945854|OTHER|Refined cereal diet|Thirty subjects with metabolic syndrome, after an initial run-in period of 4 weeks, during which they stabilise their own diet and other lifestyle habits, are assigned to a diet based on refined cereals and foods with high glycemic index for a period of 12 weeks. Before and after the dietary treatment, a frequently samples intravenous glucose tolerance is carried out to measure the effects of the intervention on glucose and insulin metabolism. At beginning and at the end of intervention, the subjects consume also a standard test meal to evaluate the postprandial response of glucose, insulin, lipids, oxidative parameters and inflammatory molecules.
223689560|NCT05396703|PROCEDURE|TOETVA|Completed procedure.
224263357|NCT06512909|OTHER|Virtual Reality Glasses Application|A video containing relaxing nature images will be shown to a group via VR. Intramuscular injection will begin three minutes after the individual starts watching the video, and the procedure will be performed while continuing to watch the video.
224263358|NCT06512909|OTHER|Stress Ball Application|One group will be given a stress ball in the hand on the side where the intramuscular injection will be administered. Three minutes after the individual starts squeezing the ball, intramuscular injection will begin and the procedure will be performed while squeezing the ball.
224263359|NCT05806853|DRUG|68Ga-PSMA|Glu-NH-CO-NH-Lys-(Ahx)-\[68Ga(HBED-CC)\] (68Ga-PSMA)
223689561|NCT03039972|DIAGNOSTIC_TEST|No intervention|No intervention
223689562|NCT04149275|DRUG|Cabozantinib|Treatment with oral Cabozantinib once daily
223689563|NCT04149275|DRUG|Ipilimumab|IV administration of Ipilimumab on 21 day cycles
223689564|NCT04149275|DRUG|Nivolumab|IV administration of Nivolumab on 21 day cycles, followed by Nivolumab maintenance on 28 day cycles
223689565|NCT06278610|DIAGNOSTIC_TEST|PELVIC EXENTERATION|PELVIC EXENTERATION
223689566|NCT01613196|OTHER|Positron Emission Tomography with 18F-Fluoro-deoxy-glucose|"2 or 3 FDG-PET scans will be performed in all patients : at inclusion\*, end of treatment and 6 months after completion of treatment in cases of persistent uptake~\*except if already done in the last 15 days."
223689567|NCT04228575|BEHAVIORAL|Internet-delivered cognitive behaviour therapy|All clients will receive the Wellbeing Course developed at Macquarie University, Australia. The Wellbeing Course is a transdiagnostic Internet-delivered cognitive behaviour intervention targeting symptoms of depressive and anxiety disorders. It comprises 5 online lessons targeting: 1) symptom identification and the cognitive behavioural model; 2) thought monitoring and challenging; 3) de-arousal strategies and pleasant activity scheduling; 4) graduated exposure; and 5) relapse prevention. Materials are presented in a didactic (i.e., text-based with visual images) and case-enhanced learning format (i.e., educational stories demonstrate the application of skills) and include homework activities. Lessons are released gradually in a standardized order over 8 weeks. Phone calls will only be made if there is a significant clinical issue requiring therapist attention that cannot be addressed over email (e.g., sudden increase in symptoms). Therapists will spend \~15 mins. per week/per client.
223689568|NCT01064245|DRUG|high-dose methacholine challenge test|nebulized liquid inhalation, 0.0625 - 256 mg/mL, doubling doses
223689569|NCT01064245|OTHER|mannitol challenge test|inhaled powder, 0 - 635 mg, increments of 5,10, 20 and 40 mg
223689570|NCT04589312|BIOLOGICAL|Standard of care vaccines|Visit 1: Check tetanus immunisation status. Vaccination up to 25+ 6 weeks of pregnancy with Td; Visit 2: vaccination at least 4 weeks after visit 2 with either Tdap or Td (per randomisation and according to WHO guidance)
223689571|NCT04589312|BIOLOGICAL|Boostagen, (BioNet-Asia)|Visit 1: Check tetanus immunisation status. Vaccination up to 25+ 6 weeks of pregnancy with Td; Visit 2: vaccination at least 4 weeks after visit 2 with either Tdap or Td (per randomisation and according to WHO guidance);
223689572|NCT03927599|OTHER|Data Collection|Colleciton of data from medical records only
223689573|NCT04650646|OTHER|Exercise-related hypoglycaemia|Hypoglycaemia induced by intravenous insulin and exercise on a vertical cycle ergometer.
223689574|NCT04650646|OTHER|Hypoglycaemia under resting conditions|Hypoglycaemia induced by intravenous insulin during bed rest.
223689575|NCT03195842|OTHER|Recordable card|
224263360|NCT05806853|DRUG|68Ga-RM2|Bombesin receptor antagonist (68Ga-RM2)
224263361|NCT00472212|DEVICE|Spectacles|Hyperopic spectacle lenses
224263362|NCT00472212|DEVICE|Control|Plano (no power, control) spectacle lenses
224263363|NCT01798628|DRUG|Treatment A: abiraterone acetate|1000 mg (4 x 250 mg tablets) taken by mouth as a single dose administered after a high-fat meal
224263364|NCT01798628|DRUG|Treatment B: abiraterone acetate|1000 mg (4 x 250 mg tablets) taken by mouth as a single dose after a low-fat meal
224263365|NCT01798628|DRUG|Treatment C: abiraterone acetate|1000 mg (4 x 250 mg tablets) taken by mouth as a single dose administered in the fasted state
224263366|NCT02211924|DRUG|BI 44847|
224263367|NCT02211924|DRUG|Placebo|
224263368|NCT01395628|DRUG|in vitro sensitivity-directed chemotherapy|
223689576|NCT04421807|OTHER|Scapulatoracic stabilization exercises|Scapulatoracic stabilization exercises consisted of 3 phases; the warming phase which consists of mobility and stretching; exercise phase consisting of static, dynamic and functional phase; the cooling phase consisting of mobility and stretching. Scapulatoracic stabilization exercises additionally applied to CDT were performed 3 days a week for 8 weeks. These exercises were specially planned for the patients and applied gradually
223689577|NCT04421807|OTHER|Complex decongestive therapy (CDT)|In the treatment phase of CDT, manual lymph drainage, skin care, compression bandage, draining exercise were applied 5 days a week for 3 weeks. Compression socks, self-drainage, skin care and unloading exercises were applied for 5 weeks in the protection phase of CDT. Thus, patients were followed up with the CDT program for 8 weeks.
223689578|NCT04811573|DRUG|EU-sourced Otezla®|Test product
223689579|NCT04811573|DRUG|US-sourced Otezla®|Reference product 1
223689580|NCT04811573|DRUG|Japan-sourced Otezla®|Reference product 2
223689581|NCT03178695|OTHER|Autologous PRP injection into human ovarian tissue|Using FDA-approved equipment, blood plasma is received from participant, isolated/enriched into PRP, and infused into the ovaries under transvaginal ultrasound guidance.
223689582|NCT03551340|DIAGNOSTIC_TEST|Gastro-intestinal panel by PCR|The study will evaluate the change in medical management with the replacement of traditional stool investigations (microscopy and culture) by the new gastrointestinal multiplex PCR panels
223689583|NCT02914847|BEHAVIORAL|Functional Imagery Training (FIT)|Functional Imagery Training comprises of three elements: a) formulation of idiosyncratic drivers of self-harming behaviour and reasons for change; b) motivational interviewing combined with mental imagery techniques that enhance motivation to change the self-harm dysfunctional habit; c) formulation of goals for change (i.e. the goal is a desired behaviour alternative to self-harm) and practice of functional imagery to support goal achievement.
223689584|NCT06071936|DRUG|Adezunap (AP707)|Sublingual spray with maximum application of 16 actuations per day or a maximum daily dose of 17,6mg THC distributed over 4 daily intakes.
223689585|NCT06071936|DRUG|Placebo|Sublingual spray with maximum application of 16 actuations per day distributed over 4 daily intakes.
223689586|NCT01497327|DRUG|PSI-352938|PSI-352938 300mg once daily (QD) for seven days
223689587|NCT01497327|DRUG|PSI-7977|PSI-7977 400mg QD for seven days
223776423|NCT04619316|DRUG|Trametinib 2 MG [Mekinist] and Dabrafenib 75 MG (2-0-2) [Tafinlar]|Combination therapy is given in patients with BRAF V600E mutation.
223689588|NCT04461249|DRUG|Latanoprost 0.005% Ophthalmic Solution|Latanoprost eye drops was given to newly diagnosed primary open-angle glaucoma patients once by night and intraocular pressure fluctuation was measured using Goldmann applanation tonometer.
223689589|NCT04461249|DRUG|Travoprost 0.004% ophthalmic solution|Travoprost eye drops was given to newly diagnosed primary open-angle glaucoma patients once by night and intraocular pressure fluctuation was measured using Goldmann applanation tonometer.
223689590|NCT04461249|DRUG|Tafluprost Ophthalmic 0.0015% Ophthalmic Solution|Tafluprost eye drops was given to newly diagnosed primary open-angle glaucoma patients once by night and intraocular pressure fluctuation was measured using Goldmann applanation tonometer.
223776424|NCT02057757|DRUG|Nitazoxanide|"Participants 1 to 3 years old: 5 mL oral suspension (100 mg NTZ) every 12 hours for 5 days.~Participants 4 to 11 years old: 10 mL oral suspension (200 mg NTZ) every 12 hours for 5 days.~Participants 12 years and older: two 300-mg NTZ tablets orally twice daily for 5 days."
223776425|NCT02057757|DRUG|Placebo|"Participants 1 to 3 years old: 5 mL placebo oral suspension every 12 hours for 5 days.~Participants 4 to 11 years old: 10 mL placebo oral suspension every 12 hours for 5 days.~Participants 12 years and older: two placebo tablets orally twice daily for 5 days."
223776426|NCT03496285|RADIATION|Multimodal MRI with diffusion sequence for anorexia nervosa patient|Multimodal MRI with diffusion sequence, resting state, T2, T1 without gadolinium contrast
224263369|NCT01395628|OTHER|cell proliferation assay|
224263370|NCT01395628|OTHER|fluorescence activated cell sorting|
224263371|NCT01395628|OTHER|laboratory biomarker analysis|
224263372|NCT01395628|OTHER|microscopy|
224263373|NCT05059028|OTHER|Oxytocin massage AND music therapy|"Oxytocin massage: It is a massage that will accelerate the work of the parasympathetic nerves in order to transmit the oxytocin production stimulus to the posterior lobe of the brain. Massage the scapula from the cervical 7th to the 5th-6th spine, spinal (vertebral), 1-2 cm around the spine, both thumbs up and then 2-3 times down, in a small circular clockwise, downward and upward movements. It is a form of massage by pressing hard.~Music intervention: In order to decide on the type of music to be played to the mothers during breastfeeding, three samples (Pentatonic, Büzürk makam and classical music) selected by the researcher will be asked to the postpartum mother, and the music preferred by the mothers will be determined. It will be ensured that mothers listen to the music determined 5 minutes before the breastfeeding session for 7 days and continue breastfeeding while the same music is playing."
224263374|NCT06627361|DEVICE|PRO-FLEX PIVOT Foot evaluation|The subject will wear the PRO-FLEX PIVOT foot for 4 weeks, following which they will complete questionnaires and undergo a Time Up and Go test
224263375|NCT06627361|DEVICE|Class III ESAR Foot evaluation|The subject will wear his usual Class III ESAR Foot foot for 4 weeks, following which they will complete questionnaires and undergo a Time Up and Go test
224263376|NCT03098901|DIAGNOSTIC_TEST|Tc99m-labeled pyrophosphate scan|Intravenous injection of Tc99m-labeled pyrophosphate with consecutive whole body scan using gamma ray scanner for assessment of radioactive uptake in the heart. The results of the scan will be evaluated by a specialist in the field. The uptake will be graded using Perugini scale (0- no uptake, 1- uptake in heart less intense than in bones, 2-uptake in heart as intense as in bones, 3-uptake in heart more intense than in bones).
224263377|NCT02206893|BEHAVIORAL|Self-monitoring via Smartphone|
224263378|NCT02206893|BEHAVIORAL|Peer support via Smartphone|
224263379|NCT02206893|BEHAVIORAL|Professional support via Smartphone|
224263380|NCT02206893|BEHAVIORAL|Self-monitoring via Web (Static)|
224263381|NCT03270254|DEVICE|light activated dye photodynamic therapy (PDT)|light activated dye photodynamic therapy-PDT to periodontal pockets
224263382|NCT02061553|BEHAVIORAL|Motivation|Control condition in which participants receive a single session with education on the importance of self-confidence and motivation, followed by 8 weeks of daily SMS messages with self-selected motivational statements.
223689591|NCT04749511|BEHAVIORAL|Extrambulatory digital PROMs detection|The aim of the study is to investigate the validity of an alternative method of evaluating PROMs in which the questionnaire will be administered to the patient digitally (Google Forms) in an out-of-patient setting.
223689592|NCT02163122|PROCEDURE|Nasal Allergen Challenge|Cat allergen (FelD1) applied directly to the nasal tissues
223689593|NCT02163122|OTHER|Environmental Exposure Chamber|The mobile EEC (mEEC) is a movable facility, designed with clean-room technology, used to expose subjects to aeroallergens (in this trial, the allergen FelD1 from cats) at controlled, consistent airborne levels, similar to that experienced in subjects' daily lives.
223689594|NCT02163122|BIOLOGICAL|Cat allergen (FelD1)|
223689595|NCT02632643|BEHAVIORAL|Sensorimotor education with a view to obtaining an optimal FWS further to the relaxation of the masticatory, lingual and labial system. Learning of mandibular micro-movements in 5 directions.|
223689596|NCT04968379|DRUG|Ferric carboxymaltose|Intravenous
223689597|NCT01610271|DEVICE|Air Barrier System|ABS is a device that emits a stream of purified air over the surgical site creating a barrier that prevents the intrusion of bacteria.
223689598|NCT03860142|BEHAVIORAL|Archet scale|Parents will be asked to answer questions about their child's nutrition by using a new scale : Archet scale
223689599|NCT03660631|BEHAVIORAL|CVRS Intervention|"1. Evaluate gaps in therapy~2. Contact patients regularly by email, phone and/or text message~3. Assess and counsel for medication adherence, side effects, life-style behaviors~4. Develop an action plan and send recommendations to provider"
223689600|NCT06132399|DEVICE|META QUEST 3 virtual reality glasses|The RESET virtual reality software will be integrated into META QUEST 3 glasses (Meta Platforms, San Francisco, CA, US) by DYNAMICS.
223689601|NCT06132399|DEVICE|Nintendo Switch (Nintendo Co., Ltd, Kyoto, Japan)|This group will use the Nintendo Switch (Nintendo Co., Ltd, Kyoto, Japan) gaming system with the Sports package games.
223689602|NCT06132399|OTHER|Usual care|The UC intervention consists of 3 sessions/week of 90' of physical therapy and occupational therapy conducted by a physiotherapist and an occupational therapist.
223689603|NCT04878887|PROCEDURE|IP-DRA vs IP- PRA|Catetherization approach in plane : distal radial artery VS proximal radial artery
223689604|NCT00364130|DEVICE|Low magnitude mechanical stimulus|10 minute daily treatment sessions standing on the low magnitude mechanical stimulus device
223689605|NCT00364130|DEVICE|Placebo (inactive) low magnitude mechanical stimulus|10 minute daily treatments standing on a placebo version of a low magnitude mechanical stimulus device
223689606|NCT05751096|DEVICE|Low-intensity Focused Ultrasound (LIFU)|repeat pulse application of low intensity focused ultrasound using a single element transducer to a selected neurological target for neuromodulation.
223776427|NCT03496285|RADIATION|Multimodal MRI with diffusion sequence for obsessional compulsive disorder patient|Multimodal MRI with diffusion sequence, resting state, T2, T1 without gadolinium contrast
223776428|NCT03496285|RADIATION|Multimodal MRI with diffusion sequence for healthy volunteer|Multimodal MRI with diffusion sequence, resting state, T2, T1 without gadolinium contrast
223776429|NCT03614793|PROCEDURE|Cooled Radiofrequency Ablation of Medial Branch Nerves versus Facet Joint Injection of Corticosteroid for the Treatment of Lumbar Facet Syndrome|Radio frequency ablation (RFA) is a medical procedure in which heat is generated from high frequency electrical current in order to lesion (burn) nervous tissue.
224263383|NCT02061553|BEHAVIORAL|Intention|Implementation intentions are created collaboratively by participants and therapists in a single 2-hour session that uses principles of brief BA (the planning of rewarding activities). BA-based implementation intentions will then be delivered daily by text for 8 weeks.
223689607|NCT05751096|DEVICE|Sham Low-intensity focused ultrasound (LIFU)|Sham application of LIFU.
223776430|NCT00066196|BIOLOGICAL|MEDI--522|IV administration supplied in 10 mL vials containing 100 mg of MEDI-522 at a concentration of 10 mg/mL.
223776431|NCT00066196|BIOLOGICAL|Integrin + Dacarbazine|supplied in other formulations
223776432|NCT02082522|DRUG|Photodynamic therapy-Photofrin|Photodynamic therapy (PDT) involves the i.v. injection of Photofrin (2 mg/kg) followed by the illumination of the tumor using a fiber optic device during an endoscopic retrograde cholangiopancreatography (ERCP) or percutaneous transhepatic cholangiography (PTC). Two days after the injection, a laser light (180 J/cm(2)) will be applied to the tumor. A second light application will be given 96-120 hours after Photofrin injection if PDT could not initially be performed on all sides of the tumor. Post illumination, all patients will undergo stenting as part of standard medical care procedure. Up to 3 additional courses of PDT using a light dose of 120 J/cm(2) may be given at 3-month intervals.
224263384|NCT02061553|BEHAVIORAL|BA-Tech|Participants undergo a total of 8 sessions with a therapist. During these sessions, participants learn about the principles of BA (the translation of important life values into the planning of rewarding activities that support those values). The participants' values are explored and an activity schedule is created collaboratively by participants and therapists based on those values. Reminders to complete the scheduled activities will then be delivered by text once the schedule is made. Participants in this arm will also be monitoring their daily activities (and rating them based on enjoyment and perceived achievement) using a cell phone application.
224263385|NCT04481958|BEHAVIORAL|I-PROTECT|The I-PROTECT model is based on existing research and knowledge of experts in sport medicine, sport psychology and implementation science, with the involvement of end-users throughout the process. The interdisciplinary intervention includes exercises based on physical and psychological principles of effective injury prevention training, specifically tailored for youth handball players, and support for developing a continuous implementation strategy. The intervention is delivered through a mobile application (the I-PROTECT GO), including modules tailored for coaches, players, club administrators, and caregivers, respectively. Coaches are introduced to the intervention in a workshop, and they will conduct the exercises with their teams during handball practice. Due to pandemic restrictions, the mobile application could not be finalized, and only the module for coaches was available.
224263386|NCT03480763|BIOLOGICAL|V114|15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, 33F (2 mcg each), serotype 6B (4 mcg) and Merck Aluminum Phosphate Adjuvant (125 mcg) in each 0.5 mL dose
224263387|NCT03480763|BIOLOGICAL|Prevnar 13™|13-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F (2.2 mcg) and 6B (4.4 mcg) and aluminum phosphate adjuvant (125 mcg) in each 0.5 mL dose
223689608|NCT05777018|PROCEDURE|conventional recruitment maneuvers|"The recruitment maneuver will be performed at 3 predefined time points: 5 minutes after induction of GA (T2), 5 minutes after insufflation of the capnoperitoneum (T3), After the end of surgery and before recovery from anesthesia (T4).~by pressure controlled mode starting with an airway pressure of 15 cmH2O the subsquently changed ( decrease or increase) to provide targeted tidal volume according to each patient, maintaining end-tidal carbon dioxide between 35 to 45 mmHg with 5 cmH2O increments in PEEP until a peak pressure of 30 cmH2O will be achieved. Each PEEP level will be maintained for 5 s. The peak airway pressure will be maintained for 10 s or five breaths and subsequently reduced, followed by maintenance with the previous ventilator settings"
223689609|NCT05777018|PROCEDURE|ultrasound-guided recruitment maneuvers|"* Ultrasound guided maneuver will be performed at T2, T3 and T4.~* The recruitment maneuver will be performed under ultrasound guidance until no collapsed lung area is visible. The strategy to increase the airway pressure will be the same as that for the conventional maneuver, although the maximal pressure limit will be 40 cmH2O. The Recruitment maneuvers (RM) will be started searching the pressure level at which the consolidation pattern disappears and progressive lung re-aeration is observed and will be recorded for all patients (the lung's opening pressure).(14) Lung ultrasound examination will be performed every 5 cmH2O increments in PEEP to detect the lung's opening pressure."
223689610|NCT02809521|OTHER|Activity Liking|
223689611|NCT03207334|DRUG|Midostaurin|"Induction Phase: 50 mg orally twice daily beginning on day 7 and ending 48 hours prior to beginning the consolidation phase~Consolidation Phase: 50 mg orally twice daily beginning on Day 6 and ending 48 hours prior to either the start of the next cycle or beginning conditioning therapy for allogenic stem cell transplant."
223689612|NCT03207334|DRUG|Cytarabine|"Induction Phase: 3 g/m2 (patients 18-65 years old) or 1 g/m2 (patients \> 65 years old or those with co-morbidities precluding a higher dose) by vein over 3 hours every 12 hours on Days 1-6.~Consolidation Phase: 3 g/m2 (patients 18-65 years old) or 1 g/m2 (patients \> 65 years old or those with co-morbidities precluding a higher dose) by vein over 3 hours every 12 hours on Days 1, 3, and 5 of each cycle."
223689613|NCT03310320|DRUG|AZD0284 oral solution 2.5 mg/mL|AZD0284 oral solution 2.5 mg/mL, 100 mg twice daily for for 4 weeks
223689614|NCT03310320|DRUG|Placebo|Placebo for AZD0284 oral solution, twice daily for 4 weeks
223689615|NCT05129891|DRUG|Semaglutide D|Tablet given orally
223689616|NCT05129891|DRUG|Semaglutide G|Tablet given orally
223689617|NCT05129891|DRUG|Semaglutide H|Tablet given orally
223689618|NCT05129891|DRUG|Semaglutide I|Tablet given orally
223689619|NCT05129891|DRUG|NNC0385-0434 B|Tablet given orally
223689620|NCT05129891|DRUG|NNC0385-0434 C|Tablet given orally
223689621|NCT05129891|DRUG|NNC0385-0434 D|Tablet given orally
223689622|NCT05129891|DRUG|NNC0385-0434 E|Tablet given orally
223689623|NCT02789332|DRUG|PwO|paclitaxel 80 mg/m² iv weekly in combination with olaparib tablets 100 mg twice daily for 12 weeks (PwO) (65 patients)
223689624|NCT02789332|DRUG|PwCb|paclitaxel 80 mg/m² iv weekly in combination with carboplatin AUC 2 iv weekly for 12 weeks (PwCb) (37 patients)
223689625|NCT02789332|DRUG|EC|both Arms followed by 4 cycles of epirubicin 90 mg/m² and cyclophosphamide 600 mg/m² (EC) either every 3 or every 2 weeks followed by surgery.
223689626|NCT02789332|PROCEDURE|Surgery after neoadjuvant Therapy|In both study arms, treatment will be given until surgery, disease progression, unacceptable toxicity, or withdrawal of consent of the patients.
223689627|NCT02789332|OTHER|Stratification|Hormone-receptor status (HR+ vs HR-) Age \< 40 years vs \>= 40 years
223689628|NCT04526327|OTHER|exercise|the combination of aerobic and resistive exercise, three time a week
223689629|NCT05281601|DRUG|AZD7442|"IM Administration: AZD8895 and AZD1061 (comprising AZD7442), must both be administered separately to the participant in a sequential order.~IV Administration: AZD7442 is dosed by co-administration of AZD8895 and AZD1061 in a single IV infusion."
223776433|NCT02082522|PROCEDURE|Stenting procedure|As per standard medical procedures, stenting procedure consists in the placement of stents above the main tumors of the right and left hepatic bile ducts via endoscopic retrograde cholangiopancreatography (ERCP) or percutaneous transhepatic cholangiography (PTC) when the ERCP approach has been unsuccessful.
223689630|NCT00626054|DRUG|PEG solution in a single dose of 3 liters|Group 1 will receive the precolonoscopy PEG solution in a single dose of 3 liters in the evening preceding the test.
223689631|NCT00626054|DRUG|PEG solution|PEG solution: half the dose (1.5 liters) of the identical solution in the evening preceding the test and the other half (1.5 liters) on the morning of the test
223689632|NCT01954732|DRUG|metformin hydrochloride|Given PO
223689633|NCT01954732|OTHER|pharmacological study|Correlative studies
223689634|NCT00586846|DRUG|Cisplatin|Cisplatin 120 mg/m\^2
223689635|NCT00586846|DRUG|Doxorubicin|75mg/m\^2
223689636|NCT00586846|DRUG|Methotrexate|Methotrexate 12g/m\^2
223689637|NCT00519298|DRUG|SAM-531|dosage form : 0.5 mg and 5 mg capsules 3 different single doses : 1 mg, 3mg and 10 mg of SAM-531
223689638|NCT00519298|OTHER|placebo|placebo
223689639|NCT00519298|DRUG|Donepezil|dosage form: 5 mg encapsulated tablets one single dose of 5 mg.
223689640|NCT00715923|OTHER|Modified consent form|modified consent form used
223689641|NCT00715923|OTHER|Standard consent form|standard consent form used
223689642|NCT01571024|DRUG|BKM120|BKM120 40 mg, orally, once daily.
223689643|NCT01571024|DRUG|mFOLFOX6|mFOLFOX6 treatment will be as follows: Oxaliplatin: 85 mg/m2 IV, Leucovorin: 400 mg/m2 IV, 5FU bolus: 400 mg/m2 IV and 5FU infusion: 2400 mg/m2 IV.
223689644|NCT06288113|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
223689645|NCT06288113|PROCEDURE|Computed Tomography|Undergo PET/CT and SPECT/CT
223689646|NCT06288113|OTHER|Gallium Ga 68 Gozetotide|Given IV
223689647|NCT06288113|DRUG|Lutetium Lu 177 Vipivotide Tetraxetan|Given IV
223776434|NCT02082522|DRUG|Chemotherapy regimen|The regimen will comprise gemcitabine (1 000 mg/m(2)) followed by cisplatin (25 mg/m(2)), each administered on days 1 and 8 every 3 weeks (21 day-cycle) for four cycles. An additional 12 weeks of the same chemotherapy regimen may be administered if there is no disease progression or intolerable toxicity.
223776435|NCT02036905|OTHER|Cervical and thoracic mobilization|Described in arm description
223776436|NCT02036905|OTHER|cervical and thoracic manipulation|described in arm description
223776437|NCT00456092|DRUG|Apremilast|Capsules for oral administration
223776438|NCT00456092|DRUG|Placebo|Capsules for oral administration
223776439|NCT00191061|DRUG|duloxetine hydrochloride|
223776440|NCT01168999|OTHER|spinal manipulation|Spinal manipulation commonly used in the treatment of low back pain and known to be effective for some individuals experiencing low back pain
223776441|NCT01168999|OTHER|sham spinal manipulation|Sham spinal manipulation intended to mimic the studied spinal manipulation
223776442|NCT01168999|OTHER|Enhanced sham spinal manipulation|"Sham spinal manipulation intended to mimic the studied spinal manipulation and provided with the instructions, The manual therapy technique you will receive has been shown to significantly reduce low back pain in some people"
223689648|NCT06288113|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
223689649|NCT06288113|OTHER|Questionnaire Administration|Ancillary studies
223689650|NCT06288113|PROCEDURE|Single Photon Emission Computed Tomography|Undergo SPECT/CT
223689651|NCT01482351|BEHAVIORAL|CPAP adherence intervention|Critical factors were (1) OSA education, treatment expectations, and ways to minimize barriers and facilitate CPAP use; (2) promotion of a positive initial CPAP experience; (3) motivational interviewing to reinforce participants' health-related goals and CPAP self-efficacy; (4) anticipatory guidance and follow-up of common CPAP problems; and (5) social support by a study partner. Trained project staff provided the intervention by phone and face to face for a total of 12-14 hours over the 1 year project.
223689652|NCT01482351|BEHAVIORAL|Attention control intervention|This intervention, provided by phone and face to face by project staff, provided equal time and attention. Critical factors were (1) education about OSA and risks, (2) education about memory, and other health topics of interest to the participants; (3) motivational interviewing to reinforce participants' health-related goals; (4) building rapport, and (5) social support by a study partner.
223689653|NCT00144027|BEHAVIORAL|Antipsychotic medication adherence intervention|The medication adherence intervention will include using a computer to complete a brief set of questions related to medication adherence before mental health clinic visits.
223689654|NCT00107367|PROCEDURE|conventional surgery|
223776443|NCT01498926|DRUG|insulin detemir|Single dose containing mannitol as isotonic agent. Administered subcutaneously (s.c., under the skin)
223776444|NCT01498926|DRUG|insulin detemir|Single dose containing glycerol as isotonic agent. Administered subcutaneously (s.c., under the skin)
223689655|NCT00107367|RADIATION|intraoperative radiation therapy|
223689656|NCT06197399|PROCEDURE|Detethering Surgery|Detethering surgery, or cord untethering, is a conventional surgical approach for treating tethered cord syndrome (TCS). It involves releasing the spinal cord from its abnormal attachment. During the surgical procedure, once the tethered area is identified, careful microsurgical techniques are used to separate the spinal cord from the surrounding abnormal tissue. This operation aims to alleviate the symptoms of TCS by removing the cause of tension on the spinal cord.
223689657|NCT06197399|PROCEDURE|Spinal Column Shortening Surgery|"Spinal column shortening surgery is an innovative surgical approach that involves reducing the tension on the spinal cord by shortening the spinal column, effectively untethering the spinal cord indirectly. The procedure primarily involves the thoracolumbar region.The choice of this region for intervention offers several advantages: it is a safe distance from the previous detethering surgery area; it is closer to the conus medullaris of the spinal cord, ensuring better treatment effectiveness; and the impact on spinal mobility is minimal after internal fixation at this region. This technique is designed to alleviate TCS symptoms while minimizing the risk of postoperative cerebrospinal fluid (CSF) leakage, which is a common complication in direct untethering procedures for recurrent cases. All procedures will be conducted by trained and experienced neurosurgeons following standardized protocols."
223776445|NCT00927017|OTHER|Liquorice 66 g/day|Liquorice 66 g/day for two weeks
223776446|NCT00927017|OTHER|Liquorice 102 g/day|Liquorice 102 g/day for two weeks
223776447|NCT04575402|OTHER|Wearable Activity Monitor|Continuous monitoring of physical activity including step counts, sleep, heart rate, with consumer-based wearable activity monitor (Fitbit Charge HR4 or similar model)
223776448|NCT02571894|OTHER|Subclinical cardiotoxicity surveillance and treatment|Intervention arm receives cardiology assessment and intervention.
223776449|NCT03603964|DRUG|Guadecitabine|Guadecitabine
223776450|NCT04317586|DEVICE|Trident II Tritanium Acetabular Shell for Revision|A hemispherical acetabular shell indicated for cementless application in a previously failed total hip arthroplasty (THA)
223776451|NCT00563797|DRUG|Mecamylamine|mecamylamine 10mg/day for 12 weeks
223776452|NCT00563797|DRUG|Placebo|Placebo pill
223776453|NCT00136708|PROCEDURE|Neonatal Resuscitation|
223776454|NCT02341196|PROCEDURE|CEA|Patients in both groups received an intra-operative angiography
223776455|NCT02802553|DEVICE|Smart Goggle|Smart Goggle is a novel stereoscopic wearable multimodal intraoperative imaging and display systems entitled Integrated Imaging Goggles for assessment of SLNs. The prototype system offers real time stereoscopic fluorescence imaging along with in vivo handheld microscopy. The investigators have found that the system can detect fluorescent targets with as low as 1.2 picomoles ICG (60 nM concentration). The hand-held microscopy module has a resolution of 25 micron. The prototype system has 2 complementary metal-oxide-semiconductor (CMOS) imaging sensors housed on a printed circuit board (PCB) with imaging lenses and emission filters optimized for ICG dye. The light source provides concurrent excitation centered at 780 nm and white light illumination with OD6 level cut-off. The Smart Goggles is a non-invasive imaging system that does not require contact with patients.
224263388|NCT03480763|BIOLOGICAL|PNEUMOVAX™23|23-valent pneumococcal polysaccharide vaccine with serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, 33F (25 mcg each) in each 0.5 mL dose
224263389|NCT01631552|DRUG|Sacituzumab Govitecan-hziy (SG)|Administered via intravenous (IV) infusion
224263390|NCT05592574|OTHER|Blood sample|Blood samples required to performe IL-17 Dosage
224263391|NCT03608228|OTHER|Measuring electrical signals from the brain|If patients participate in this study, after the deep brain stimulator leads have been implanted, the researcher(s) will plan to measure electrical signals from the brain while patients perform hand movement tasks.
223776456|NCT02802553|OTHER|Cardio-Green|Indocyanine Green for Injection USP is a sterile, lyophilized green powder containing 25 mg of indocyanine green with no more than 5% sodium iodide. Indocyanine Green for Injection USP is dissolved using Sterile Water for Injection, and is to be administered intravenously.
223689658|NCT04624438|OTHER|Isometric training with electromyostimulation|"Each training session (18 in total) consisted of forty 4-s contractions separated by 20 s inter-contraction intervals. The exercise intensity was close-to-identical among the sessions (60 %MVC). The force intensity was determined individually during pretest where EMS was delivered at maximal tolerable dose. Electrical stimulation was 6.25-second long and was followed by a rest period of 20-second (duty cycle 15%). Stimulation characteristics were selected among the Compex commercially available strength programs. The stimulation intensity was monitored on-line and determined by the subject at the start of each EMS session according to his/her pain threshold to produce a force corresponding to at least 60% of the pretest MVC score."
223689659|NCT04624438|OTHER|Isometric training with voluntary activation|Each training session (18 in total) consisted of forty 4-s contractions separated by 20 s inter-contraction intervals. The exercise intensity was close-to-identical among the sessions (60 %MVC). Participants were required to reach the proscribed force level only through voluntary activation of QF. To attain the same contraction/rest ratio as in EMS, automated audible signals were delivered in accordance with the contraction-rest pattern produced by the muscle stimulation device. To ensure participants produced 60% of individual MVC during each contraction the force level was measured with a force transducer and real-time feedback was provided on a computer screen.
223689660|NCT04624438|OTHER|Isometric training with combination of electromyostimulation and voluntary activation|Each training session (18 in total) consisted of forty 4-s contractions separated by 20 s inter-contraction intervals. The exercise intensity was close-to-identical among the sessions (60 %MVC). The proscribed force level was reached by the simultaneous action of EMS and VOLUNTARY. Each contraction was 6.25-second long and was followed by a rest period of 20-second (duty cycle 15%). Electrical stimulation corresponded to 30% of MVC, while the remaining 30% was achieved through voluntary muscle activation. To ensure participants produced a force corresponding to 60% of MVC during each contraction the force level was measured with a force transducer and real-time feedback was provided on a computer screen.
223689661|NCT02521571|BEHAVIORAL|Resiliance Alliance|"The intervention is 6 months long \& is delivered through weekly sessions held in the participating child protective offices. The sessions follow a 4-week cycle with the participants changing each week of the cycle: (1) CPS alone, by units; (2) CPS/Supervisor units; (3) Child Protective Manager and CPS/Supervisor units; and (4) CPSs \& Supervisors/Managers separately.~Participating staff are introduced to a resilience-related topic or skill, and receive a brief didactic training on that topic. Staff then engage in a group activity, which is designed to help them apply the new topic or skill to the workplace. Each module wraps up with a relaxation or exercise to help staff transition back into their work responsibilities; the facilitator can pick among the selection provided based on their sense of what would be helpful for the group. Staff are also given handouts and activities to do during the week."
223689662|NCT02521571|BEHAVIORAL|Secondary traumatic stress training|"These trainings will take place in two parts (for a total of 3 hours) and include an overview of secondary traumatic stress and its impact on child welfare staff, and some strategies staff can use to protect themselves from STS - essentially a summary version of what the intervention group will receive over the 24 weeks of the intervention. The investigators consider this training to represent treatment as usual, as from our experience it is often how child welfare agencies address the issue of secondary traumatic stress among their staff."
223689663|NCT02474888|OTHER|blood specimen|blood specimen for serum rituximab level and serum anti-rituximab level at M1 and M3 after stop of induction rituximab treatment
223689664|NCT03813771|DRUG|Benepali|Benepali will be adminstered subcutaneously at a dose of 50mg weekly and discontinued at the primary endpoint (24 weeks).
223689665|NCT03813771|DRUG|Sulfasalazine|Sulfasalazine will be added at follow up visits (T2T care) if the subject fails to achieve low disease activity,administered orally at a dose of 1g twice daily.
223689666|NCT03813771|DRUG|Methotrexate|Methotrexate will be administered orally at a starting dose of 15mg weekly. It may be increased in line with T2T care (to a maximum of 25mg) over the 24 weeks.
223689667|NCT03813771|DRUG|Hydroxychloroquine|Hydroxychloroquine will be added at follow up visits (T2T care) if the subject fails to achieve low diseaseactivity, administered at a dose of 200mg daily.
223689668|NCT00636883|DRUG|Gemcitabine|GEMOX-Erlotinib consists of erlotinib 100 mg orally daily starting day 1, Gemcitabine 1000 mg/m2 in 10 mg/m2/min (100 minutes) infusion on day 1 followed on day 2 by oxaliplatin 100 mg/m2 in a 2-hour infusion. Treatment will be repeated every 2 weeks. Each two weeks is a cycle.If at end of 12 cycles response continues, will administer Gemox and erlotinib till achieve maximum response. Then start Erlotinib maintenance therapy.
223689669|NCT03954652|GENETIC|WGS-Diagnostic|Blood sampling, shot clinical characterization, WGS-based trio sequencing, NGS analysis and other omics analysis (transcriptomics, proteomics, metabolomics), functional cell biology studies (for example in fibroblast cultures), RNA-seq.
223689670|NCT04597918|DRUG|Faricimab|A 6-milligram (mg) dose of faricimab will be administered intravitreally (IVT) in the study eye once every 4 weeks (Q4W).
223689671|NCT00395538|DRUG|PTH 1-34|Given twice daily by subcutaneous
223689672|NCT02752555|OTHER|Antioxidant (l-cratinine) + modifiable lifestyle factors|All participants were subjected to the same three-month period treatment protocol, which included 1) antioxidant treatment with L-Carnitine (2g daily); 2) frequent ejaculation every 2 days; and 3) minimizing adverse lifestyle factors.
223689673|NCT05572554|OTHER|Foot Bath Group|The elderly were asked to soak their feet in the water in a marked plastic container with a depth of 10 centimeters and a temperature of 41-42°C for 20 minutes up to their ankles 50 minutes before normal sleeping hours every night for 8 weeks.
223776457|NCT02802553|DEVICE|SPY Elite Imaging system|Previously validated fluorescence detection system. Will be used to look at the same regions as the Smart Goggles to confirm sensitivity
223776458|NCT02802553|DEVICE|Quest near-infrared (NIR) Imaging system|Previously validated fluorescence detection system. Will be used to look at the same regions as the Smart Goggles to confirm sensitivity
223776459|NCT02802553|DEVICE|PDE Imaging system|Previously validated fluorescence detection system. Will be used to look at the same regions as the Smart Goggles to confirm sensitivity
223689674|NCT05511701|BEHAVIORAL|CHW Care Model|The CHW will measure the participant's blood pressure (BP) and along with other demographic variables, calculate the participant's absolute CVD risk score, using the mHealth (mobile health) app. If the participant's risk is \> 10%, they are asked to sign the informed consent. The CHW will electronically schedule an appointment at the PCC. The participant will receive a SMS appointment confirmation. S/he will have their cholesterol tested by nurses using a home POCT. Nurses will repeat POCT lipids and BP measurements at all PCC visits and other clinical information will be entered into the electronic decision support tool that will generate a guideline based treatment recommendation for the physician. CHWs will make up to four home visits or telephone calls to intervention participants over the 12 month study period to check on medication adherence, as well as to determine if the patient is in possession of the medication
223689675|NCT05511701|BEHAVIORAL|Usual Care Model|All study participants will be visited in their home by a CHW and a nurse for eligibility assessment, screening, and enrollment. The CHW will then measure the participant's blood pressure and the readings along with other demographic variables already collected, to calculate the participant's absolute CVD risk score. In the usual care arm the CHW will use the WHO paper-based non-lab CVD risk calculator and, if the participant's risk is \> 10%, they are asked to sign the informed consent and s/he will have their cholesterol tested by nurses using POCT during a home enrollment visit. The CHW will further verbally encourage her/him to schedule an appointment with a primary care physician at the PCC for evaluation. This is the usual care practice.
223689676|NCT06322329|OTHER|Dynamic MRI|Subjects receive a study-specific dynamic MRI scan. If the hypothesis of the study is confirmed, this examination can be used to inform future patients' treatment planning, replacing the use of 4D CT.
223689677|NCT06186479|DRUG|Aconite pain oil|Participants apply 6 ml oil topically 2 times per day (morning and evening) for 15 to 27 weeks on chemotherapy-free days as long as they receive chemotherapy.
223689678|NCT06186479|DRUG|Placebo|Participants apply 6 ml oil topically 2 times per day (morning and evening) for 15 to 27 weeks on chemotherapy-free days as long as they receive chemotherapy.
223689679|NCT04094103|DIETARY_SUPPLEMENT|Active strawberry powder|Participants will drink a strawberry beverage with active ingredients once a day during the 4-week intervention period.
223689680|NCT04094103|DIETARY_SUPPLEMENT|Placebo strawberry powder|Participants will drink a strawberry placebo beverage once a day during the 4-week intervention period.
223689681|NCT04094103|DIETARY_SUPPLEMENT|Mixed strawberry powder|Participants will drink a mixed strawberry beverage with active ingredients and placebo once a day during the 4-week intervention period.
223689682|NCT03160196|OTHER|Clinical Decision Support System|It is about a Clinical Decision Support System based on a diabetes mellitus clinical practice guideline.
223689683|NCT03160196|OTHER|Usual care based on clinical practice guideline|It is about usual care aligned with the diabetes guideline.
223689684|NCT06207981|DRUG|induction chemotherapy (mDCF)|"Induction chemotherapy consists of mDCF administered every 2 weeks:~* Docetaxel (40 mg/m², day 1),~* Cisplatin (40 mg/m², day 1)~* 5-FU (1200 mg/m²/day IV for 2 days)"
223689685|NCT06207981|DRUG|Concomitant chemotherapy (Capecitabin + Mitomycin-C)|Concomitant Chemotherapy consists of Mitomycin-C (10 mg/m2 intravenous infusion at D1 and D29) and Capecitabine (1650 mg/m²/day divided in two oral intakes 825 mg/m² twice a day, five days a week). Patients should be counseled to only take capecitabine on the days when radiotherapy is being given
223689686|NCT06207981|RADIATION|radiotherapy|"Radiotherapy consists of conformational intensity-modulated external irradiation with simultaneous integrated boost (IMRT-SIB) with 2 level of dose (30 sessions)~* 49.5 Gy (5 x 1.65 Gy/week) to the pelvis~* 60 Gy (5 x 2 Gy /week) to the primary tumor and initially involved nodes"
223689687|NCT00859027|DRUG|risedronate|35 mg/week by mouth
223689688|NCT00859027|DRUG|Placebo risedronate oral tablet|One tablet by mouth every week as directed
223689689|NCT05262231|BEHAVIORAL|Online Breastfeeding Education|Breastfeeding education will be announced with a poster on social media. At the same time, mothers will be informed about the training in the institution where the institution permission is obtained. Postpartum period 4-8. A single-blind randomization method will be used per week. Pre-test will be applied to the mothers in the experimental and control groups. After the pre-test, online breastfeeding training will be given to the experimental group. The training consists of a single session. It will take about 40-60 minutes. The content of the training includes the benefits of breastfeeding for the mother, baby and society, breast problems and solutions, causes and solutions of breast rejection, breastfeeding positions, etc. consists of topics. After the training experimental group, the post-test will be applied. At the same time, the post-test will be applied to the control group who did not receive the training.
223689690|NCT00285207|DRUG|placebo|5 days of 28 day cycle for 2 cycles
223689691|NCT00285207|DRUG|A007|5 days of 28 day cycle
223689692|NCT05175885|DEVICE|Ex vivo normothermic perfusion|Ex vivo normothermic perfusion (EVNP) of the renal graft with the Ark Kidney System
223689693|NCT05175885|DEVICE|Cold preservation|Static cold storage (SCS) or hypothermic machine perfusion (HMP) of the renal graft
223689694|NCT06809621|DRUG|NNC0471-0119 H|NNC0471-0119 H will be administered subcutaneously.
223689695|NCT06809621|DRUG|Insulin aspart|Insulin aspart will be administered subcutaneously.
223689696|NCT06809881|OTHER|olfactory testing, MRI acquisition, clinical assessment|
223689697|NCT07118592|DIETARY_SUPPLEMENT|Low Salt Diet|8 days of diet with low salt content will be given to the study participants
223689698|NCT07118592|DIETARY_SUPPLEMENT|High Salt Diet|8 days of diet with high salt content will be given to the study participants
223689699|NCT07118592|DIETARY_SUPPLEMENT|Saline Infusion|2 Liters of normal saline infusion (0.25 ml/kg/min over 2 hours) will be given to the study participants at the end of each study period
223689700|NCT01913587|DEVICE|Acupuncture|Acupuncture points are ST36, GB34 (bilateral), BL60 (bilateral), BL40 (bilateral), and 2 Back-su points (bilateral). Back-su points are selected as close as possible to pain region. Electroacupuncture will be performed at only 2 Back-su points (bilateral).
223689701|NCT01913587|PROCEDURE|Nerve block|Epidural nerve block uses the mixture (10ml) of dexamethasone (10 mg) and bupivacaine (10 mg) dissolved in saline solution. Medial branch block uses mepivacaine (10 mg).
223689702|NCT06575036|DRUG|Sugammadex|The starting dose of sugammadex will be 0.5mg/kg. When the dose for a patient was not effective, the dose for next patient will be increased by 0.5mg/kg. When the dose was effective, the dose for next patient will be decreased by 0.5mg/kg or maintained, with a 1:1 of allocation ratio.
223689703|NCT03620656|DIAGNOSTIC_TEST|FibriCheck|Photoplethysmography-based smartphone or smartwatch sensor to assess cardiac rhythm
223689704|NCT06666569|DEVICE|Use of the test for treatment optimization|Intervention cohort, where the clinician will have information on the test results to support decision making on treatment optimization. The randomization process will be by blocks and weighted to the ADL/IFX ratio of use of these treatments in the usual clinical practice of the participating hospitals, to guarantee a homogeneous distribution of the treatments in the groups at the beginning/end of the follow-up.
223689705|NCT06994078|DRUG|68Ga-NOTA-Nectin-4 antibody fragment|To perform integrated PET/MR or PET/CT visualization of patients with clinically suspected or confirmed urothelial carcinoma, breast cancer, lung carcinoma and other malignant tumors with high Nectin-4 expression and healthy volunteers, using specific positron imaging agents targeting Nectin-4 (taking \[68Ga\]Ga-NOTA-Nectin-4 antibody fragment as an example), to achieve the following purposes: Patients with malignant tumors: for diagnosis and staging of diseases, comparing with the gold standard pathological diagnosis, evaluating diagnostic efficacy, clarifying the presence or absence of lesions, and determining the location and nature of lesions; comparing with \[18F\]FDG PET for accurate staging, evaluating the tumor load, and helping to determine the therapeutic plan. Healthy volunteers: Pharmacokinetic analysis will be performed to clarify the distribution and metabolism of the drug in the body and its safety.
223689706|NCT06684444|BEHAVIORAL|firefighter Sleep Health Coaching Intervention (ffSHC)|This multi-component intervention is based on principles of cognitive behavioral therapy for insomnia. It includes telephone-based sleep health coaching to individuals, targeted training and sleep health education to fire service leaders, agency-level sleep health promotion, and facilitation strategies to internal facilitators.
223689707|NCT06684444|BEHAVIORAL|Control (Minimally Enhanced Usual Care)|The control arm is minimally enhanced usual care. Usual care interventions for sleep disturbance include any health or wellness interventions administered by the agency on the topic of sleep, including occupational health intervention, employee assistance programs, education, signage, and webinars. The type and dose of care will be assessed at each timepoint. Minimal enhancement is a referral to the agency's Employee Assistance Program and will address the ethical problem in the control condition of identifying but not treating a sleep disturbance.
223689708|NCT06683547|DIETARY_SUPPLEMENT|Ketone Monoester (KET)|Ketone monoester supplement (R)-3-hydroxybutyl (R)-3-hydroxybutyrate based on participants' body weight (0.36g/kg body weight). The ketone brand name: delta G Oxford Ketone Ester.
223689709|NCT06683547|DIETARY_SUPPLEMENT|Flavour matched placebo drink (CON)|\- Flavoured water (non-caloric bitter + citrus flavours)
223689710|NCT06683547|OTHER|Resistance Exercise|\- 5 sets of 10 repetitions of leg press and 3 sets of 12 repetitions of leg extension/leg curl 'supersets' (1 set of each back to back with no rest in between sets) at 95% of their 10-RM. Between-set rest intervals for the leg exercises will be 60 seconds.
223689711|NCT04067440|DIAGNOSTIC_TEST|Microbial Swab|Swabs will be taken from peritoneum and jejunum (intraoperatively), rectum, and stool
223689712|NCT06691724|OTHER|LLM-based transcription and reporting tool|"The LLM-based transcription and reporting tool works in three steps:~1. The conversation between patient and GP is transcribed to text with a speech-to-text LLM~2. The text is summarized according to the Subjective, Objective, Assessment, Plan (SOAP) rules~3. The SOAP summary is imported in the electronic health record of the GP"
223689713|NCT05063318|DRUG|Lurbinectedin alone|The dose of lurbinectedin during Parts A and B will be 3.2 mg/m² for all patients when administered without itraconazole.
224263392|NCT01876667|OTHER|Intervention (CPCRS) Group|CPCRS staff will order evidence-based lipid-lowering and/or antihypertensive medications, adjust doses, and order follow-up laboratory parameters, as necessary under pre-approved regional treatment protocols. Patients will be monitored for medication adherence and adverse effects. Patients receive dietary, exercise, and smoking cessation counseling verbally and through mailing of pre-printed Kaiser Permanente approved, patient education pamphlets, as necessary per the discretion of the clinical pharmacy specialist. Patients requiring more dietary counseling will be referred to dieticians, education classes, or other appropriate resources offered at KPCO. Primary care providers will be informed of all medication initiations or dosage adjustments.
224263393|NCT01876667|OTHER|Placebo|Usual Care
224263394|NCT04509167|BIOLOGICAL|Neoantigen Peptides|Patients will receive intradermal injection of individualized neoantigen peptides vaccine at a dose of \~500ug per peptide once a week for 8 weeks.
224263395|NCT04034277|OTHER|Lee Silverman Voice Therapy|LSVT LOUD® comprises maximum effort non-speech and speech drills. The non-speech drills include the production of 15 sustained 'ah' phonation at high volume and pitch glides (5 repetitions moving from modal pitch to high pitch and 15 repetitions moving from modal pitch and going down on production of sustained 'ah'). The speech drills utilize a hierarchy of speech tasks moving from single words through phrases and onto conversational speech to generalize
223689714|NCT05063318|DRUG|Lurbinectedin+Itraconazole co-administration|The dose of lurbinectedin when given in combination with itraconazole for the initial three patients in Part A will be 0.8 mg/m², and in Part B is susceptible to be adjusted properly if deemed necessary based on exposure and safety experience in Part A.
223689715|NCT07017387|BEHAVIORAL|Motivational interviewing based health education|Participants will receive three sessions of face-to-face health education using motivational interviewing techniques through home visits, along with an informational brochure.
223689716|NCT07017387|BEHAVIORAL|Health education|Participants will receive one face-to-face health education session and a brochure, followed by two reminder sessions via phone.
223689717|NCT07024706|DRUG|Acalabrutinib|Acalabrutinib is an orally available cBTKi that inhibits the activity of BTK and prevents the activation of the B-cell antigen receptor (BCR) signaling pathway.
223689718|NCT07024706|DRUG|Venetoclax|Venetoclax is an orally bioavailable inhibitor of the anti-apoptotic protein BCL-2
223689719|NCT05815576|BEHAVIORAL|Intrinsic foot muscle fatigue|"Electrostimulation will be delivered through electrodes placed on the abductor hallucis (NOT invasive).~The investigators plan 4 sets of 4 minutes of repeated contractions (electrostimulation + voluntary contraction)."
223689720|NCT06928298|BEHAVIORAL|RACS app|risk assessment questions, symbol matching task, voice tasks
223689721|NCT06941012|OTHER|Blood draw for the laboratory assessment|Participants' clinical histories will be reviewed at T0 (baseline) and T1 (24 months). They will also undergo a clinical assessment at T0 and T1. The assessments will be tailored based on whether the participant belongs to the PD or non-PD group, as outlined below: • MDS-UPDRS + H\&Y: Used to evaluate the neurological domain, applied to the PD group. • BERG: Used to assess balance and performance, applied to both PD and non-PD groups. • CIRS-G: Used to evaluate comorbidities, applied to both PD and non-PD groups. • PD-CRS: Used to assess cognitive function, applied to the PD group. • MMSE (temporal and spatial orientation only): Used to assess cognitive function, applied to both PD and non-PD groups. • PDQ-8: Used to evaluate quality of life, applied to the PD group. • PD-CFRS: Used for functional assessment, applied to the PD group. • GDS: Used to assess depression, applied to both PD and non-PD groups. Blood samples will be collected at T0 and T1, with 20 mL drawn per participant.
223689722|NCT00511212|DRUG|intravenous immunoglobulin|
223689723|NCT06949098|PROCEDURE|Local Tumor Resection|All enrolled patients will first undergo local tumor resection.
223689724|NCT06949098|RADIATION|Radiotherapy|"Pelvic field irradiation 45Gy in 25 fractions plus Local tumor bed boost 5.4Gy in 3 fractions.~For patients with positive surgical margins after local resection, a radiotherapy boost (pelvic field 45Gy/25 fractions + tumor bed local boost 14.4Gy/8 fractions) can be given."
223689725|NCT06949098|DRUG|Chemotherapy|Concurrent oral capecitabine 825 mg/m² twice daily with radiotherapy
223689726|NCT05498116|DRUG|Montelukast|10mg daily
223689727|NCT05498116|OTHER|Placebo|1 capsule daily
223689728|NCT07150572|PROCEDURE|surgery assisted rapid maxillary expansion|Under general anesthesia, the patients underwent a maxillary expansion procedure, during which the maxillary resistance sites were surgically released
223689729|NCT07149870|OTHER|Pain Management Team + Whole Health Coach (PMT-WHC)|"Whole Health Coaching (WHC) begins by completing a Personalized Health Inventory (PHI), where progress is evaluated within 8 dimensions of health and wellness. The PHI culminates in defining personal values and overall goals for health and wellness (i.e., What do you want your health for?). This is used to create goals for a Personal Health Plan. The Plan emphasizes self-management strategies to manage pain. After the Plan is developed, ongoing support is provided from the Coach through 8 coaching sessions over approximately 5 months."
223689730|NCT07149870|OTHER|Pain Management Team-Usual Care (PMT-UC)|Pain Management Team-Usual Care (PMT-UC) involves working with VA PMTs that includes working with PMTs comply with legislation requiring each medical center to have PMTs with expertise in pain, addiction, behavioral approaches, and rehabilitation approaches. PMTs will conduct multidisciplinary intakes (at least two provider types) with biopsychosocial assessments for all new patients. Follow-up care will be determined by the PMTs based on what is clinically indicated (with recommended minimum medication management follow ups at 1- 3- and 6-months for patients making medication changes).
223776460|NCT02802553|DEVICE|Gamma probe|Gold standard for fluorescence detection. The gamma probe and blue dyes will be used in conjunction to confirm presence of Sentinel Lymph Nodes (SLNs). The gamma probe provides non-imaging sensing data and the blue dyes provide visual signs for detection of SLNs.
223776461|NCT02802553|OTHER|Blue Dyes|Gold standard for fluorescence detection. The gamma probe and blue dyes will be used in conjunction to confirm presence of Sentinel Lymph Nodes (SLNs). The gamma probe provides non-imaging sensing data and the blue dyes provide visual signs for detection of SLNs.
223776462|NCT04151862|DEVICE|tight eye bandage|sterile eye pad made of 100% cotton
223776463|NCT04151862|DEVICE|Soflex Soft Contact Lens|Therapeutic contact lenses (TCL)
223776464|NCT02410681|DEVICE|Electromyographic recording of temporalis muscle activity during sleep|"Electromyographic recording of temporalis muscle activity during sleep. In total, 9 sleep recordings will be done at the home setting of each participant.~1. 3 recordings after the baseline visit~2. 3 recordings 6 weeks after the baseline visit~3. 3 recordings one year after the baseline visit"
223776465|NCT02410681|RADIATION|Vertical bitewing radiograph|An intraoral vertical bitewing radiograph will be performed with the assistance of individually modified plate positioning devices at each visit (in total 8 visits during the 2-year follow-up period).
223776466|NCT02410681|OTHER|Collection of biofilm sample|"Collection of peri-implant intrasulcular biofilm sample for DNA analysis of the biofilm composition. In total, samples will be collected three times:~1. At the baseline visit~2. Three months after the baseline visit~3. One year after the baseline visit"
223776467|NCT00192725|OTHER|rapid tryptophan depletion|Amino-acid mixture without tryptophan
224263396|NCT04034277|OTHER|Conventional Treatment|"speech rehabilitation protocol comprehend:~* Respiratory and phonatory exercises: exercises to increase diaphragmatic and respiratory functions, exercises to increase expiration time using natural expiration or sibilant, exercise to increase phonation time by pronouncing the vocal /a/, exercise to reduce oral stiffness.~* Articulation and prosody exercises: repetition or reading lists of possibly long and complex words that start with or contain consonants groups. Read aloud texts, sentences or words, making sure to articulate and pronounce the words well without diminishing or increasing the rhythm of speech, with the correct punctuation and intonation. If necessary, ask patients to hyperarticulate, accelerate or slow down, or exaggerate intonation."
223689731|NCT01659658|DRUG|IXAZOMIB|IXAZOMIB capsules
223689732|NCT01659658|DRUG|Dexamethasone|Dexamethasone tablets
223689733|NCT01659658|DRUG|Melphalan|Melphalan tablets
223689734|NCT01659658|DRUG|Cyclophosphamide|Cyclophosphamide tablets
223689735|NCT01659658|DRUG|Thalidomide|Thalidomide capsules
223689736|NCT01659658|DRUG|Lenalidomide|Lenalidomide capsules
223689737|NCT06227455|PROCEDURE|Maxillary alveolar ridge augmentation|The surgical procedure involves careful flap reflection, autogenous graft harvesting, and placement and fixation of the barriers over mixture of Autogenous graft and xenograft particles.
223689738|NCT00311662|DRUG|Tonabersat|Tablet 40mg daily for 12 weeks
223689739|NCT00311662|DRUG|Placebo|Tablet once daily for 12 weeks
223689740|NCT06166082|DEVICE|Active iTBS-DLPFC|Participants will receive 10 sessions per day of 1800 pulses per session, lasting for 5 days.
223689741|NCT06166082|DEVICE|Sham iTBS-DLPFC|The parameters in the sham arms are the same as the active stimulation groups. Stimulation was delivered by the same device as the active group fitted with a sham coil.
223689742|NCT05183815|OTHER|slow stroke massage and murrotal quran|murrotal quran and slow stroke massage
223689743|NCT01464892|BEHAVIORAL|Imagery Rescripting and Reprocessing Therapy|This intervention is comprised of 16 sessions (twice a week) of trauma-focused imagery rescripting
223689744|NCT01464892|BEHAVIORAL|STAIR + Imagery Rescripting|A two-phased treatment. Phase 1 is comprised of 8 (weekly) sessions of Skills Training in Affective and Interpersonal Skills (STAIR). Phase 2 consists of 16 sessions (twice weekly) of trauma-focused imagery rescripting.
223689745|NCT01319357|DRUG|Saxagliptin|orally 5 mg/d for 6 weeks
223689746|NCT01319357|DRUG|Placebo|orally for 6 weeks
223689747|NCT01083485|DRUG|Oxycodone/Naloxone PR 20/10mg or 10/5mg tablets|Oxycodone/Naloxone prolonged release 20/10mg or 10/5mg tabs twice a day (BID) for 2.5 days (total 5 dosages)or Oxycodone 20mg
223689748|NCT01083485|DRUG|Oxycodone|Oxycodone 20mg or 10mg BID for 2.5 days (total 5 dosages)
223689749|NCT04855929|DRUG|ANV419|ANV419 administered by intravenous (IV) infusion
223689750|NCT04855929|DRUG|Ipilimumab|Ipilimumab administered by intravenous (IV) infusion
223689751|NCT06201416|BIOLOGICAL|SBT777101|Experimental treatment
223689752|NCT02739165|DRUG|ART-123|380 U/kg/day by intravenous drip infusion in addition to standard of care steroid therapy
223689753|NCT02739165|DRUG|Placebo|Placebo by intravenous drip infusion in addition to standard of care steroid therapy
223689754|NCT02759978|OTHER|diagnostic workup|Our primary objective is to test whether the proportion of patients diagnosed correctly with the use of 18F-FDG-PET/CT, MD-CTA, and 18F-FDG-PET/MD-CTA added to the gold standard in current clinical practice, the modified Duke criteria by Li et al. 2000, is significantly higher as compared with the modified Duke criteria on itself. The gold standard is clinical judgement after clinical follow-up by a multidisciplinary team with medical specialists.
223689755|NCT04878627|DRUG|Cannabidiol|patients receive cannabidiol at various doses for 3 weeks
223689756|NCT04878627|DRUG|Placebo|patients receive placebo for 3 weeks
223689757|NCT00347841|DRUG|Bimatoprost 0.03%, Latanoprost|
223689758|NCT04237012|DRUG|Dextenza 0.4Mg Intracanalicular Insert|all patients will receive Intracanalicular dexamethasone, 0.4mg insert lower punctum and able to use over the counter artificial tears PRN at patient discretion
223689759|NCT04237012|OTHER|Over the counter Artificial tears|over the counter artificial tears PRN at patient discretion
223689760|NCT01225770|DIETARY_SUPPLEMENT|green tea|Gargling three times daily for 90 days
223689761|NCT04755244|DRUG|evorpacept|Fusion protein that blocks CD47-SIRPalpha pathway
223689762|NCT04755244|DRUG|venetoclax|BCL-2 inhibitor
223689763|NCT04755244|DRUG|azacitidine|Hypomethylating agent (HMA)
223689764|NCT02804529|DEVICE|Veress needle|
223689765|NCT05447039|DRUG|Montelukast Sodium Tablets|intervention group received standard cough therapy+ Montelukast 10 mg/day for 14 days
223689766|NCT00084838|BIOLOGICAL|filgrastim|
223689767|NCT00084838|DRUG|cisplatin|
223689768|NCT00084838|DRUG|cyclophosphamide|
223689769|NCT00084838|DRUG|cytarabine|
223689770|NCT00084838|DRUG|dexrazoxane hydrochloride|
223689771|NCT00084838|DRUG|doxorubicin hydrochloride|
223689772|NCT00084838|DRUG|etoposide|
223689773|NCT00084838|DRUG|leucovorin calcium|
223689774|NCT00084838|DRUG|methotrexate|
223689775|NCT00084838|DRUG|temozolomide|
223689776|NCT00084838|DRUG|therapeutic hydrocortisone|
223689777|NCT00084838|DRUG|vincristine sulfate|
223689778|NCT00084838|RADIATION|radiation therapy|
223689779|NCT00084838|DRUG|Dactinomycin|
223689780|NCT01654627|DEVICE|Regenecure AMCA GBR Dental Membrane|Patients will undergo Guided Bone Regeneration (GBR) procedure using the Regenecure AMCA GBR Membrane
223689781|NCT01654627|DEVICE|Geistlich Bio-Gide® collagen membrane|The Geistlich Bio-Gide® collagen membrane, a commercially available product, will be used in 10 patients.
223689782|NCT00017238|DRUG|KRN5500|Given IV
223689783|NCT00017238|OTHER|pharmacological study|Correlative studies
223689784|NCT05785104|OTHER|Myofascial release|Is Facilitation of mechanical and neurological adaptive capacity as integrated through the Myofascial system
223689785|NCT05785104|OTHER|Muscle energy technique|Is manual therapy procedure that involves alternating periods of resisted muscle contraction and assisted stretching
223689786|NCT00558727|DRUG|RH-1|1.5 mg/m2 to 12 mg/m2, depending on protocol cohort, administered via intravenous (IV) infusion over 3 hours once every 21 days.
223689787|NCT06045169|PROCEDURE|Post Isometric Relaxation|Post isometric relaxation with participants using 20% of their maximum voluntary contraction will be given to global muscles of core commonly involved in primary dysmenorrhea glutus maximus, Illiopsoas and pirifirmis. Post isometric contraction will be held for 6 to 10 seconds followed by 15 o 30 seconds stretch, rst time will be 5 seconds in between repetations and number of repetations will be 3-5.
223689788|NCT00122278|DRUG|Dexamethasone|Dexamethasone 10mg IV
223689789|NCT00122278|OTHER|Placebo|Placebo Dexamethasone 10mg IV
223689790|NCT01871857|DRUG|Hypertonic saline and epinephrine|
223689791|NCT01871857|DRUG|Normal saline and epinephrine|
223689792|NCT03480035|PROCEDURE|lightwand intubation|intubation using lightwand
223689793|NCT01728948|DRUG|Sorafenib (Nexavar, BAY43-9006)|treatment (including dose, duration, modification) decided by the investigator
223689794|NCT02653534|BEHAVIORAL|Kangaroo Mother Care|Promotion of, and support for lactation management and skin to skin care as soon as possible after birth by study ANM supported by study ASHA in addition to routine visits by government health workers
223689795|NCT03861611|DRUG|Ketorolac|Participants may be randomized to receive Ketorolac oral medication 10 mg, every 8 hours for 5 days as needed
223689796|NCT03861611|DRUG|Ibuprofen|Participants may be randomized to receive Ibuprofen oral medication 600 mg, every 8 hours for 5 days as needed
223689797|NCT03861611|DRUG|Diclofenac|Participants may be randomized to receive Diflofenac oral medication 50 mg, every 8 hours for 5 days as needed
223689798|NCT03861611|BEHAVIORAL|Educational Intervention|Research personnel will provide each patient with a 15-minute educational intervention. This will be based on National Institute of Arthritis and Musculoskeletal and Skin Diseases Handout on Health: Back Pain information
223689799|NCT06957080|DRUG|EYE103|EYE103 is a humanized antibody formulated for intravitreal administration
223689800|NCT06957080|DRUG|Ranibizumab|Ranibizumab is a commercially available anti-VEGF treatment formulated for intravitreal administration for use in patients with diabetic macular edema
223689801|NCT03878186|OTHER|Usual Care (UC)|Usual Care: single in-person psycho-educative session with information about HIV, transmission, natural history of the disease, importance of antiretroviral adherence. All the information is based on guidelines and information sheets from InfoVIHt
223689802|NCT03878186|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|Cognitive behavioral therapy (CBT): Usual Care + Cognitive-behavioral therapy program intervention (AppraHIV). This intervention involves 7 in-person weekly sessions based on Adjuvant Psychological Therapy centered in three areas: cognitive appraisal, affect and adherence and self-care, everyone with different techniques: cognitive techniques, diaphragmatic breathing, scheduling pleasurable activities, use of pillbox, solving problems, planning for the future, etc. The intervention was manualized (according to Template for Intervention Description and Replication TIDieR), piloted and validated.
223689803|NCT05067907|PROCEDURE|Early physiotherapy|"Respiratory physiotherapy included:~1. early and functional mobilization: passive and active mobilization, muscle strengthening, improving independence in activities of daily living (ADL), sitting out of bed, standing, walking;~2. patient positioning to achieve better ventilation/perfusion ratio and gas exchange;~3. airway clearance;~4. aerosol administration;~5. invasive mechanical ventilation weaning;~6. use of non-invasive mechanical ventilation (NIMV) and continuous positive airway pressure (CPAP);~7. tracheostomy management and weaning;~8. swallowing assessment;~9. management of oxygen delivery;~10. lung expansion;~11. patient assessment and functional scale administration."
223689804|NCT02969564|OTHER|scintigraphy 99mTc-MDP-SPECT/CT.|SPECT/CT will be performed for every patient in the frame of their clinical follow up
223689805|NCT02969564|OTHER|18F-NaF-PET/MR|a 18F-NaF-PET/MR will be performed, in the frame of this clinical study, to the patients to assess the difference of sensitivity of the 2 exams
223689806|NCT05023707|BIOLOGICAL|anti-FLT3 CAR-T|Single intravenous infusion of anti-FLT3 CAR-T cells
223689807|NCT03607422|DRUG|Placebo for Upadacitinib|Tablets taken orally once a day
223689808|NCT03607422|DRUG|Upadacitinib|Tablets taken orally once a day
223689809|NCT00261183|DRUG|Melatonin|
223689810|NCT05899062|OTHER|"Education with the telerehabilitation method. In addition, a Constipation Training Booklet will be sent via e-mail or WhatsApp"|"The patients in the control group will be given education about constipation, which lasts about 45-60 minutes, with the telerehabilitation method. In addition, a Constipation Training Booklet will be sent via e-mail or WhatsApp, related to the training content given to all patients and to reinforce the training. Definition of constipation in education, its causes, medications that cause constipation, risk factors, suggestions for prevention of constipation (such as regular defecation, not delaying defecation, best position for defecation, not straining for a long time), constipation treatment and the importance of individual management, healthy and balanced diet, nutrition Types, adequate fluid intake, benefits of exercise and appropriate exercise selection, abdominal massage, toilet training and individual methods of preventing constipation will be included."
223689811|NCT05899062|OTHER|Training and exercise practices with the telerehabilitation method.|The patients in this group will be given an exercise program in addition to all the practices in the control group. Training and exercise practices will be carried out with the telerehabilitation method. Exercise training, which will last 40-60 minutes, 3 days a week for 4 weeks, will consist of warm-up and breathing exercises, exercises for constipation and cooling movements. Patients will be asked to walk for at least 30 minutes, 2 days a week, on days without exercise training.
223689812|NCT02643329|DRUG|BF-Gliclazide Tablet 80mg|BF-Gliclazide Tablet is a generic product manufactured by Bright Future Pharmaceuticals Factory O/B Bright Future Pharmaceutical Laboratories Limited
223689813|NCT02643329|DRUG|Diamicron 80mg Tablet|Diamicron 80mg Tablet is manufactured by Les Laboratoires Servier Industrie, France
223689814|NCT00446589|DRUG|ibandronate|iv 1mg ibandronate monthly for one year
223689815|NCT00446589|DRUG|teriparatide|sc injection using a pen like device during every hemodialysis session (thrice a week)
223689816|NCT03252184|DEVICE|Low level laser therapy - 1|In the phase 1, the low level laser therapy will be performed with the Fluence device (HTM, Brasil) and the probe from the same manufacturer. For the interventions in groups G1, G2 and G3 (photobiomodulation) will be used, respectively, the energy doses of 18J, 36J and 54J. A 658nm wavelength with an output power of 10mW will be used. Group 4 intervention (placebo photobiomodulation) will be performed with the application of the device turned off. Each intervention will be performed in one day, with an interval of two days between each intervention. Photobiomodulation will be performed on the region of the radial and ulnar arteries of the left arm of each individual. The laser probe will be placed in direct contact with the skin.
223689817|NCT03252184|DEVICE|Low level laser therapy - 2|In the phase 2, the low level laser therapy will be performed with the Thor DD2 (London, UK) and the cluster probe from the same manufacturer. For the interventions in groups G1 and G2 (photobiomodulation) will be used, respectively, the energy doses of 30J and 60J. A 810nm wavelength and an output power of 200mW will be used. Group 3 intervention (placebo photobiomodulation) will be performed with the application of the device turned off. Each intervention will be performed in one day, with an interval of two days between each intervention. Photobiomodulation will be performed on the region of the radial and ulnar arteries of the left arm of each individual. The laser probe will be placed in direct contact with the skin.
223689818|NCT03252184|DEVICE|Low level laser therapy - 3|In the phase 3, the low level laser therapy will be performed with the Thor DD2 (London, UK) and the cluster probe from the same manufacturer. For the interventions in groups G1 and G2 (photobiomodulation) will be used, respectively, the energy doses of 30J and 60J. A 810nm wavelength and an output power of 200mW will be used. Each intervention will be performed in one day, with an interval of two days between each intervention. Photobiomodulation will be performed on the region of the radial and ulnar arteries of the left arm of each individual. The laser probe will be placed in direct contact with the skin.
223776468|NCT04908891|OTHER|Clinical Scapular protocol (ClinScaP)|the psychometric properties of two tests: Clinical Scapular protocol (ClinScaP) in PwMS and healthy controls.
223776469|NCT04908891|OTHER|the prevalence of trunk, scapula and upper limb impairments.|To investigate the prevalence of trunk, scapula and upper limb impairments in PwMS and stroke patients.
223776470|NCT04908891|OTHER|the interaction between trunk, scapula and upper limb impairments.|To investigate the interaction between trunk, scapula and upper limb impairments in PwMS and stroke patients.
223776471|NCT03495336|OTHER|coffee abstention phase|no coffee consumption for 2 weeks
223776472|NCT03495336|OTHER|LR Coffee consumption|for 4 weeks participants consumed only LR Turkish coffee
223776473|NCT03495336|OTHER|DR Coffee consumption|for 4 weeks participants consumed only DR Turkish coffee
223776474|NCT00651989|OTHER|optical coherence tomography foveal thickness measurement|In the same session in one randomly selected eye of each subject three consecutive measurements of foveal thickness were performed using both time-domain OCT and spectral-domain OCT.
224263397|NCT01111448|DRUG|Temsirolimus|25 mg/day 1; 8; 15; 22 of each 28-day cycle as intravenous infusion over 30 min
224263398|NCT05364177|DRUG|68Ga-Pentixather|After intravenous injection of 68Ga-pentixather, PET/CT scan will be performed.
224263399|NCT05364177|DRUG|68Ga-Pentixafor|After intravenous injection of 68Ga-pentixafor, PET/CT scan will be performed.
224263400|NCT01895764|DRUG|Adalimumab|adalimumab, subcutaneous injection, 40mg every 2 weeks, week 0 until week 26
224263401|NCT01895764|DRUG|Methotrexate|methotrexate, subcutaneous injection, 10mg per week, week -2 until week 26
224263402|NCT01647828|DRUG|OMP-59R5|OMP-59R5 administered intravenously
224263403|NCT01647828|DRUG|Gemcitabine|administered intravenously
224263404|NCT01647828|DRUG|Placebo|administered IV
224263405|NCT01647828|DRUG|Nab-Paclitaxel|administered intravenously
224263406|NCT01906372|DRUG|Adrenocorticotropic Hormone Gel|H.P. Acthar Gel 80 units will be self-administered subcutaneously twice weekly by the subject for a period of 6 months.
224263407|NCT03828708|OTHER|Iron in infant formula|Participants will receive the same low-iron (5 mg/L) infant formula. Infants in the standard iron group will add iron supplement to pre-made infant formula so the iron content will be 12 mg/L.
224263408|NCT06136039|PROCEDURE|Arm I (Sarcopenia)|Same as standard treatment
223689819|NCT05561179|PROCEDURE|Hyaluronic acid injection|"Patients with confirmed diagnosis of GERD will be treated with HA injections in the lower esophageal portion. HA + contrast will be injected in the 4 quadrants (4 cc/quadrant).~The response to the treatment will be measured by improvement in health-related quality of life index, pH monitoring, and endoluminal functional lumen imaging probe (EndoFLIP). In addition, the patients will be clinically assessed for reflux symptoms."
223689820|NCT05561179|PROCEDURE|Sodium chloride injection (control group)|"Patients with a confirmed diagnosis of GERD will be treated with sodium chloride injection in the lower esophageal portion. Sodium chloride + contrast will be injected in the 4 quadrants (4 cc/quadrant).~The response to the treatment will be measured by improvement in health-related quality of life index, pH monitoring, and endoluminal functional lumen imaging probe (EndoFLIP). In addition, the patients will be clinically assessed for reflux symptoms."
223689821|NCT01557894|OTHER|iSOFIE|Cognitive - Behavioral: Internet-administrated CBT for social phobia that contains 9 self-help text modules and exercises (i.e., behavioral experiments)
223689822|NCT05266274|DRUG|CD47 monoclonal antibody|patients who meet the criteria are selected, CD47 monoclonal antibody combined with azacitidine is used for the treatment of patients with recurrent AML after transplantation
223689823|NCT03015545|DEVICE|paretic leg-control|standing on the vibration platform, with no vibration signals delivered.
223689824|NCT03015545|DEVICE|paretic leg-WBV|standing on the vibration platform, with WBV at 30Hz, 1.5mm.
223689825|NCT03015545|DEVICE|non-paretic leg-control|standing on the vibration platform, with no vibration signals delivered.
223689826|NCT03015545|DEVICE|non-paretic leg-WBV|standing on the vibration platform, with WBV at 30Hz, 1.5mm.
223689827|NCT01938872|PROCEDURE|paclitaxel eluting balloon angioplasty in below-the-knee lesions|
223689828|NCT04960410|COMBINATION_PRODUCT|Types and exposure of different air pollutants|Types and exposure of different air pollutants in COPD patients' living and working environment
223689829|NCT02493582|BIOLOGICAL|Cytokine-Induced Killer Cells|CIKs are used with Apatinib to treat lung adenocarcinoma patients with wild-type EGFR
223689830|NCT02493582|DRUG|Apatinib|Advanced lung adenocarcinoma patients with wild-type EGFR take Apatinib 850mg qd by mouth.
223689831|NCT00543491|DRUG|MK0767|
223776475|NCT05940285|DIAGNOSTIC_TEST|Dynamic 99mTc-Tetrofosmin CZT-SPECT|Patients included in the study will undergo subsequently at 1-month after acute coronary syndrome Dynamic 99mTc-Tetrofosmin CZT-SPECT followed by FFR and IMR assessment
223689832|NCT05241431|DRUG|SGLT2 inhibitor|10 mg orally once daily in addition to standard medical treatment.
223689833|NCT05241431|DRUG|Placebo|Placebo tablets similar to active treatment.
223689834|NCT02584699|RADIATION|Stereotactic Ablative Radiotherapy (SABR)|Six Gy irradiation per fraction times 12 fractionations, resulting a total dose of 72Gy
223689835|NCT04741698|DRUG|Propranolol|Propranolol 2mg IV
223689836|NCT01242059|DIETARY_SUPPLEMENT|yellow pea protein|Served in a tomato soup
223689837|NCT01242059|OTHER|yellow pea fiber|Served in a tomato soup
223689838|NCT01242059|DIETARY_SUPPLEMENT|Control|Served in a tomato soup
223689839|NCT00295828|OTHER|Pegaptanib Sodium Injection/Panretinal Photocoagulation|Pegaptanib Sodium Injection is a single dose prefilled syringe and is formulated as a 3.47 mg/mL solution. Combined with an ocular laser procedure.
223689840|NCT00295828|PROCEDURE|Panretinal Photocoagulation (PRP)|Ocular Laser Procedure
223689841|NCT05509790|DRUG|LY3484356|Administered orally.
223689842|NCT01409395|DRUG|Metformin and nizatidine|Subjects will be given a single oral dose of 850 mg of metformin and a single oral dose of 600 mg of nizatidine
223689843|NCT01409395|DRUG|Metformin|Subjects will be given a single oral dose of 850 mg of metformin
223776476|NCT00363714|DRUG|AGN211745|100microgram single intravitreal injection
223776477|NCT00363714|DRUG|AGN211745|200microgram single intravitreal injection
223776478|NCT00363714|DRUG|AGN211745|400microgram single intravitreal injection
223689844|NCT04376879|OTHER|Data monitoring for 48h within the first 24 hours of admission for COVID-19|The admission variables and those constituting the predictive score (blood pressure, temperature, oxygenotherapy, biological analysis...) will be collected for 48 hours after enrolment (i.e within the first 24 hours of admission )
223689845|NCT01885871|DEVICE|Picosecond QS Nd:YAG Laser|Up to 2 laser treatments delivered 6 weeks apart
223689846|NCT00246896|BEHAVIORAL|care management|
223689847|NCT04215588|DEVICE|Hemostasis Management System Plus|Hemostasis Management System Plus (Medtronic, Minneapolis, MN) is a point of care device useful in the management of heparinization during bypass. It estimates the individual heparin dose response and calculates heparin concentration (IU/ml) in whole blood.
223689848|NCT04215588|DEVICE|Activated Coagulation Timer System Plus|The Activated Coagulation Timer System Plus device calculates the Activated Clotting Time (ACT) in seconds.
223689849|NCT06016192|BEHAVIORAL|Aerobic Exercise Training|Physical activity performed as controlled aerobic exercise training on ergometer
223689850|NCT06667765|DRUG|RPT1G|Dose formulation- Oral capsule
223689851|NCT06667765|DRUG|Placebo|Dose formulation- Oral capsule
223689852|NCT03213600|DEVICE|transcranial Direct Current Stimulation tDCS|75 participants will receive 20 minutes of active tDCS (1,5mA, 20 minutes stimulation over frontal (F3/F4) electrodes ); A group of 75 participants will receive 1,5mA 20 minutes of stimulation over parietal (CP3 CP4) electrodes. During this stimulation session and we will also measure your ability to perceive visual and auditory objects presented by a computer, while recording your brain activity using electroencephalography or EEG (a technique using electrodes that measures the electrical activity of your brain)
223689853|NCT00415376|DRUG|levetiracetam|
223689854|NCT00415376|PROCEDURE|quality-of-life assessment|
223689855|NCT02128828|DRUG|cenicriviroc|cenicriviroc given once daily for 24 weeks; number of pills dependent on recommended modifications based on patient's other antiretroviral medications and certain other medications anticipated to interact with cenicriviroc
223689856|NCT00791310|DRUG|Flucis|FDG injected i.v
223689857|NCT03960931|OTHER|Aquatic rehabilitation|Rehabilitation sessions using hydrophysiotherapy will occur in a pool of Grand Nancy Thermal, three times per week during 4 weeks, and each will last 45 min. They will begin with 10 min of warm-up, then 30 min of walking. Sessions will end cool-down during 5 min, which will be a reduction of intensity every 30 sec. Rehabilitation will be carried out by physiotherapist chosen for the study.
223689858|NCT03960931|OTHER|Land based physical activities|Rehabilitation sessions on treadmill will occur at Physical Medicine and Rehabilitation Regional Institute (IRR), on the University Hospital's site, three times per week during 4 weeks, and each will last 45 min. They will begin with 10 min of warm-up, then 30 min of walking, where intensity of effort can be modulated by speed and inclination of treadmill. Sessions will end cool-down during 5 min, which will be a reduction of intensity every 30 sec. Rehabilitation will be carried out by physiotherapist chosen for the study.
223689859|NCT03960931|OTHER|Conventional rehabilitation|Conventional rehabilitation sessions will occur in private practices in which patients receive their habitual care (same physiotherapist). This care will be guided by prescription delivered by the neurologist. This prescription suggests to work on active and passive upper and lower limb stretching, on hip and shoulder dissociation, and balance control management on unstable ground.
223689860|NCT02493387|OTHER|Exercise|The group-based exercise program consists of 60-minute sessions twice a week for 3 months, including central circulatory exercise performed on an ergometer cycle and muscle training, and one or two occasions of home-based exercise. The exercise program are designed after the patients requirements and with the intensity 13-17 on the Borg RPE 6-20 scale
223689861|NCT02493387|OTHER|Physical activity|The patients randomized PAP will receive a PAP prescription and a physical activity diary. The PAP and physical activity diary will be followed up at 6 and 12 weeks after the inclusion.
223689862|NCT02503007|DIETARY_SUPPLEMENT|Placebo|
223689863|NCT02503007|DIETARY_SUPPLEMENT|HMB-FA|
223689864|NCT00364754|DRUG|Tesmilifene (YMB 1002)|
223689865|NCT00090051|DRUG|Rituximab|Intravenous repeating dose
223689866|NCT00090051|DRUG|Fludarabine Phosphate|Intravenous repeating dose
223689867|NCT00090051|DRUG|Cyclophosphamide|Intravenous repeating dose
223689868|NCT04615897|PROCEDURE|new tecnology intervention|"The intervention consists of 16 sessions, performed with a frequency of twice a week, the final evaluation was made within three days after the end of the last treatment session. It is used for the motor task, the Fishing Under Zero exercise, included within the balance modality and the so-called Step Plus located in the aerobic exercise folder. Each subject carried out the training taking into account the following methodology: 3 cycles of the Fishing under zero exercise, one cycle of the Step Plus exercise and 3 cycles of the Fishing under zero exercise, the approximate duration of the task being about 30 minutes."
223689869|NCT05805488|DIETARY_SUPPLEMENT|Placebo sachet|consume 1 sachet per day
223689870|NCT05805488|DIETARY_SUPPLEMENT|TCI904 sachet|consume 1 sachet per day
223689871|NCT03228420|DEVICE|Senza HF10 Therapy|Senza 10kHz Spinal Cord Stimulation
223689872|NCT03228420|OTHER|CMM|Conventional Medical Management
223689873|NCT01904539|DRUG|obeticholic acid 10 mg|Single dose OCA 10mg in each arm
223776479|NCT00363714|DRUG|AGN211745|800microgram single intravitreal injection
223776480|NCT00363714|DRUG|AGN211745|1200microgram single intravitreal injection
223776481|NCT00363714|DRUG|AGN211745|1600microgram single intravitreal injection
223776482|NCT01480700|OTHER|Nutritional study|subjects consume 2 eggs per day during 4 months
223776483|NCT05106868|DEVICE|acupuncture|Acupuncture is a form of alternative medicine and a component of traditional Chinese medicine (TCM) in which thin needles are inserted into the acupoints on body to treat diseases.
223776484|NCT06175728|DEVICE|S-Press|Leg Strengthening Device that can be used in supine and seated positions
223776485|NCT06035926|OTHER|questionnaire|questionnaire
223776486|NCT04116554|DRUG|0.25% bupivacaine.|20 mL of 0.25% bupivacaine and the same procedure will be repeated on the other side
223776487|NCT04116554|DEVICE|0.9%saline|20 ml of 0.9%saline will be injected on each side
223776488|NCT03135223|BEHAVIORAL|Co-created intervention to promote physical activity|A working group of girls and researcher co-created a school-specific intervention to promote physical activity
223776489|NCT01542112|OTHER|PSactive model|"The model is designed to address the main issues that lie at the core of initiatives to manage patient expectations and improve patient satisfaction. It is a structured interventional set of activities, which gives the clinician an opportunity to meet patient expectations and improve patient satisfaction.~The interventional model is comprised of teachable-learnable interpersonal communicative steps occurring between the clinician and the patient which are: Gather information on the patient's expectations and perception of the hospitalization, respond, provide relevant information and document the intervention."
223776490|NCT01542112|OTHER|No treatment|Patients in this arm receive the usual routine in the department.
223776491|NCT04327934|DRUG|GnRH antagonist|GnRH antagonist up to 16 days.
223776492|NCT04327934|DRUG|GnRH antagonist + MethylTESTOSTERone 5 MG|GnRH antagonist + MethylTESTOSTERone 5 MG up to 5 days.
223776493|NCT06072066|DIETARY_SUPPLEMENT|Skin Barrier Oral Supplement|Supplment powder
223776494|NCT05294263|DRUG|Varenicline|Varenicline is a selective nACHr partial agonist of the 4 2 subtype and a full agonist of the 7 subtype
223776495|NCT05294263|DRUG|Placebo|Matching, inactive medication
223776496|NCT04416035|BIOLOGICAL|TRS003|TRS003 will be administered at 15 mg/kg by IV infusion on Day 1 of each cycle (every 3 weeks, Q3W). Each cycle is 3 weeks.
223776497|NCT04416035|BIOLOGICAL|China-approved Bevacizumab|China-approved bevacizumab will be administered at 15 mg/kg by IV infusion on Day 1 of each cycle (every 3 weeks, Q3W).Each cycle is 3 weeks.
223776498|NCT04416035|DRUG|Carboplatin|Carboplatin will be administered at an AUC 6 mg/mL/ min (the maximum dose capped at 900 mg) by IV infusion (over 15 - 30 minutes) Q3W on Day 1 of each cycle.
223776499|NCT04416035|DRUG|Paclitaxel|Paclitaxel will be administered at a dose of 200 mg/m\^2 by IV infusion (over 3 hours) Q3W on Day 1 of each cycle
223776500|NCT01223079|DRUG|r-hFSH|r-hFSH dose to be determined by the patient's primary doctor and adjusted according to their response
223776501|NCT01223079|DRUG|r-hFSH and r-hLH|Patients will begin r-hLH at 300IU/day when there are 2 follicles greater than or equal to 14mm.
223776502|NCT04886921|BEHAVIORAL|Abdominal muscle training|Participants will receive 12-week, 60 minutes, 36-session abdominal muscle training in the TRAM women. Aimed to evaluate the effects on abdominal muscle functions after 12 weeks abdominal muscle training in the TRAM women. Outcome measures were the clinical tests for trunk muscle strength, endurance and one-leg standing was also used to exam the abdominal muscle function.
223776503|NCT06573710|DEVICE|sonic activator|Polyamide EDDY tips 28mm long is inserted in the canal 2mm short of the working length operated at 6,000 Hz. Activation is done for three cycles each for 20sec. The tip is moved vertically in up and down motion, 1ml is used for each activation cycle followed by 2ml 17% EDTA20
223776504|NCT06573710|DEVICE|LASER activation|Diode laser 980nm is used to activate the irrigant using fiber optic tip of (200micrometer) and power of 1.5w continuous mode. The tip is placed 2 mm shorter than the working length. Laser irradiation is done for each canal for 20 secs repeated over three cycles for total time of 60 secs and 10 secs pauses between each cycle
223776505|NCT06573710|DEVICE|Ultrasonic activation|ED60tip is used with ultrasonic device operated on mode E and inserted in the canal 2mm short of the working. Activation is done for three cycles each for 20 sec. The tip is moved vertically in up and down motion,1ml is used for each activation cycle followed by 2ml 17% EDTA
223776506|NCT06573710|DEVICE|passive irrigation with Endodontic needle|Each canal is irrigated with side vented endodontic needle 30G Placed 2mm short of the working length with total time of 60 secs followed by 2ml 17% EDTA
223776507|NCT01116089|DRUG|Bramitob® administered by PARI LC® PLUS nebulizer|(tobramycin 300mg /4mL) solution administered by inhalation twice daily for 28 days
224263409|NCT06136039|PROCEDURE|Arm II(Normal)|Same as standard treatment
224263410|NCT06557954|DIAGNOSTIC_TEST|human PAX1 and JAM3 gene methylation assays (PAX1m/JAM3m)|PAX1m/JAM3m, with or without HPV testing and cytological pathology for cervical cancer screening
224263411|NCT01782053|BEHAVIORAL|Picture warning|Warning contains picture proposed for each text statement by FDA
224263412|NCT01782053|BEHAVIORAL|Control|
224263413|NCT05591105|DRUG|Control Group|At the end of surgery, they will continue receiving analgesia according the schedule and, addicionally, lidocaine (1 mg/kg/h) and Ketamine (0,15 mg/kg/h) for 90 minute as part of postoperative analgesia.
224263414|NCT05591105|DRUG|Placebo|At the end of surgery, they will continue receiving analgesia according the schedule.
224263415|NCT01503957|DEVICE|Nasya|Thixotropic nasal spray suspension, 2 sprays in each nostril
224263416|NCT01503957|DEVICE|Saline solution|Nasal spray, 2 sprays in each nostril
224263417|NCT03629054|DRUG|Empagliflozin, Metformin HCl, Linagliptin (fixed dose combination)|single dose
224263418|NCT03629054|DRUG|Empagliflozin|single dose
224263419|NCT03629054|DRUG|Linagliptin|single dose
224263420|NCT03629054|DRUG|Metformin HCl|single dose
224263421|NCT00851305|DEVICE|Endomicroscope (Pentax, Tokyo, Japan)|A Pentax EC3870K endomicroscope which can produce conventional white light endoscopic images and confocal images at the same time with a optical slice thickness of 7 μm, a lateral resolution of 0.7 μm, a scanning depth of 0 to 250 μm, a pixel density of 1024×512 pixels (at an image acquisition rate of 1.6 frames/second)，and a field of view of 475 μm×475 μm.
224263422|NCT00851305|DEVICE|Gastroscopes (Pentax, Tokyo, Japan)|Conventional white light gastroscopes (Pentax EG-2940 gastroscopes)
224263423|NCT01261949|DEVICE|Combined frontal and temporal rTMS|Experimental repetitive transcranial magnetic stimulation (Alpine Biomed Mag Pro Option): 1000 stimuli of 1Hz rTMS over the right DLPFC (110% motor threshold) followed by 1000 stimuli of 1 Hz rTMS over the left temporal cortex DLPFC (110% motor threshold)
224263424|NCT01261949|DEVICE|Temporal low frequency rTMS|Experimental repetitive transcranial magnetic stimulation (Alpine Biomed Mag Pro Option): 2000 stimuli of 1 Hz rTMS over the left temporal cortex (110% motor threshold)
223689874|NCT06097338|PROCEDURE|bariatric surgery (BS)|bariatric surgery (BS) is a very attractive choice for severely obese patients. After bariatric surgery, long-term weight loss (15%-25%) and diabetes remission can occur \[16\], as well as long-term mortality, cardiovascular events and tumor occurrence \[17\]. Regardless of the surgical procedure used for weight loss surgery, studies have shown that weight loss surgery can significantly reduce the liver NAFLD activity score (from 5 to 1), and 33.8% of patients have reduced liver fibrosis \[18\]. The follow-up results for a longer period of time (10 years) also indicate that weight loss surgery significantly reduces the occurrence of major adverse outcomes related to liver cirrhosis, liver cancer, liver transplantation, and liver related deaths
223689875|NCT05936125|OTHER|Annuloplasty Using Flexible Band|Tricuspid valve annuloplasty using a flexible band; (Polyethylene terephthalate band): (Dacron band)
223689876|NCT01173939|DRUG|Pravastatin|5 mg/day or 10 mg/day of pravastatin will be administered orally for 36 months, with a follow-up period of one month. If the target LDL-C level is not attained after one month of treatment, the steps will be taken to reduce the LDL-C to the target level of \<120 mg/dL (JASGL 2007 target level) as quickly as possible. (Maximum dose increase of pravastatin: 20 mg/day)
223689877|NCT01173939|DRUG|Rosuvastatin|5 mg/day or 10 mg/day of rosuvastatin will be administered orally for 36 months based on the LDL-C level of the subject, with a follow-up period of one month. If the target LDL-C level is not attained after one month of treatment, the steps will be taken to reduce the LDL-C to the target level of \<70 mg/dL as quickly as possible. (Maximum dose increase to rosuvastatin: 20 mg/day)
223689878|NCT03897504|PROCEDURE|feminizing genitoplasty using inner surface of the prepuce as pedicled tubularized flap|the prepuce of the females with congenital adrenal hyperplasia will be tubularized and used as pedicled flap in creating the new vagina, the urethra will be completed with the urogenital sinus, no mobilization either partial or complete urogenital mobilization will be needed in cases with low and intermediate confluence level (less than 30 mm), in case with high confluence (more than 30 mm) laparoscopic vaginal pullthrough will be attempted first then the same previously described technique will be applied, the depth of the confluence will be determined before starting surgery by doing genitograph under general anaesthesia, stent will be kept in the new vagina for 5 days and further scheduled calibrations and dilatations will be applied regularly with paying attention to urinary complications like incontinence and urethrovaginal fistula by doing urodynamics and micturating cystourethrogram if there is a complain.
223689879|NCT02428608|BIOLOGICAL|DWP-450 (Botulinum purified neurotoxin, Type A)|Botulinum toxin, Type A
223689880|NCT05650060|DRUG|Secukinumab|all patients with psoriasis who received secukinumab
223689881|NCT00091416|BIOLOGICAL|VRC-HIVADV014-00-VP|
223689882|NCT05346497|PROCEDURE|Bentall|Bentall procedure: include replacement of both aortic valve and root
223689883|NCT05346497|PROCEDURE|David|David procedure: include replacement of aortic root and aortic valvuloplasty
223689884|NCT05346497|PROCEDURE|ARR|Aortic root reconstruction: reconstruction instead of replacement of aortic root, without surgery of the valve. include sandwich procedure, adventitia invertion procedure, etc.
223689885|NCT03754673|DEVICE|MRI|MRI pulmonary with no contrast administration
223689886|NCT06247800|DEVICE|Virtual Reality Device|A virtual reality headset is a heads-up display that allows users to interact with simulated environment.
223689887|NCT06247800|OTHER|Without virtual reality|Patients undergoing intercostal chest drain without the use VR device
223689888|NCT05859685|OTHER|Experimental|"Manual therapy techniques:~* Talar dorsal sliding technique. Dorsal mobilization of the talus, with the patient in the supine position and ankle dorsiflexion, without pain or discomfort. The physiotherapist will exercise an anteroposterior mobilization of the talus, with a dorsal glide~* Mulligan movement mobilization technique: The patient will be in a standing position, with the ankle to be treated forward. You will be given an aid or support in the upper extremity to maintain stability."
223689889|NCT05859685|OTHER|Control|The patients included in the control group underwent the same techniques as those indicated for the experimental group, but without sliding or placing joint tension. The periodicity and times of administration will be the same
223689890|NCT03835104|DEVICE|CRP point-of-care testing|CRP point-of-care test using a fingerprick of blood and producing a result within 4 minutes, using the Afinion 2 (Abbott)
223689891|NCT05159284|DRUG|Hydrocortisone Ophthalmic|1 drop 4 times daily for 12 days, followed by twice daily for 2 days and stop, for a total of 14 days of treatment. Repeat on day 28: 1 drop 4 times daily for 12 days, followed by twice daily for 2 days and stop. Patients in the intervention arm will receive two 14-day cycles of hydrocortisone.
223689892|NCT05159284|DEVICE|MGD Rx EyeBag® eyelid warming device|Eyelid warming device used once daily for 10 minutes followed by lid massage for 12 weeks by patients in both control and intervention arm.
223689893|NCT05159284|DEVICE|Lephanet® lid wipes|Lid hygiene with Lephanet® lid wipes used twice daily for 3 weeks followed by once daily for 9 more weeks by patients in both control and intervention arm.
223776508|NCT01116089|DRUG|Bramitob® administered by PARI eFlow® rapid electronic nebulizer|(tobramycin 300mg /4mL) solution administered by inhalation twice daily for 28 days
223776509|NCT05371210|OTHER|SAIF|Participants interacted with SAIF system at least 2-3 times per week; each session took up to 20 minutes.
223689894|NCT05159284|DEVICE|Thealoz Duo® artificial tear with trehalose 3% and sodium hyaluronate 0.15%|Artificial tear supplementation with Thealoz Duo® 4 times daily for 12 weeks by patients in both control and intervention arm.
223689895|NCT02439983|DIETARY_SUPPLEMENT|Proprietary Nutritional Supplement|2 capsules taken by mouth with morning and evening meals.
223689896|NCT02439983|DIETARY_SUPPLEMENT|Placebo|2 capsules taken by mouth with morning and evening meals.
223689897|NCT03272230|BEHAVIORAL|ECOCAPTURE|45 minutes observational session for tracking goal directed behavior into a waiting room equipped with video and sensor-based data acquisition system
223776510|NCT01202838|DEVICE|Composite Implant|Subjects receiving composite implants
223776511|NCT03206021|DRUG|5 Azacytidine|Dose escalation of carboplatin combined with 5'azacytidine
223776512|NCT05864027|BEHAVIORAL|Peer-led Oral Health Recovery Group|"The interactive Oral Health Recovery group will be centered around the tailored materials previously developed, with topics such as it's never too late to make a change, oral health and whole health, taking care of your teeth, and going to the dentist."
223689898|NCT03272230|BEHAVIORAL|Cognitive and Behavioral experimental tasks|Cognitive and Behavioral experimental tasks to explore additional frontal cognitive and behavioral dimensions and functions
223689899|NCT03272230|DIAGNOSTIC_TEST|Neuropsychological assessment|STARKSTEIN APATHY SCALE (SAS) / DAS / MMSE / MADRS / EBI / MINI-SEA / FAB / HAD / MATTIS / HAYLING / STROOP / Verbal Span / Lexical verbal fluency / TMT / CDRS
223689900|NCT03272230|BEHAVIORAL|ICM_APATHY_TASKS|Apathy experimental task
223689901|NCT03272230|OTHER|MRI|T1 / T2 / rs-fMRI / MS-DWI
223689902|NCT03272230|BIOLOGICAL|Neurohormonal mechanisms|Hormonal dosage / Diabetic dosage / Ionogramme dosage / Inflammatory dosage / Hepatic dosage / Lipidic dosage / Thyroid dosage
223689903|NCT05356078|DRUG|Antidepressant|"Delirium event reported in the World Health Organization global database in subjects aged over 65 years taking antidepressants, comparative analysis by antidepressant class"
223689904|NCT03468985|DRUG|Cabozantinib|Given PO
223689905|NCT03468985|BIOLOGICAL|Ipilimumab|Given IV
223689906|NCT03468985|BIOLOGICAL|Nivolumab|Given IV
223689907|NCT03082482|BEHAVIORAL|Self-help materials|Self-help smoking cessation materials
223689908|NCT03082482|DRUG|nicotine patch|Participants who smoke \>10 cigarettes per day will receive 4 weeks of 21 mg, 2 weeks of 14 mg, and 2 weeks of 7 mg nicotine patches. Participants who smoke \<10 cigarettes per day will receive 6 weeks of 14 mg and 2 weeks of 7 mg nicotine patches.
223689909|NCT03082482|BEHAVIORAL|Counseling|Proactive phone counseling with a Certified Tobacco Treatment Counselor
223689910|NCT03082482|OTHER|Smartphone-delivered automated treatment|Tailored video clips, text and graphical messages delivered automatically each week to the participant.
223689911|NCT03094988|BEHAVIORAL|Cognitive and physical prehabilitation|Participants engage in cognitive and physical training daily for approximately 2-4 weeks prior to surgery.
223689912|NCT03094988|OTHER|Active attention control|Participants will be provided with personal health educational materials and access to the control version of cognitive training program.
223776513|NCT05864027|BEHAVIORAL|Educational Video about Oral Health|The video comparison will be pulled from Toothflix 2.0 Patient Education DVD Series, which are patient education videos developed by the American Dental Association.
223689913|NCT05894226|PROCEDURE|laparoscopic ventral mesh rectopexy|patients are treated by laparoscopic ventral mesh rectopexy for anterior rectocele
223689914|NCT03947996|OTHER|Stretching exercise|Stretching (30 minutes, 5 days per week, 8 weeks)
223689915|NCT03947996|OTHER|Walking exercise|Walking (30 minutes, 5 days per week, 8 weeks)
223689916|NCT05933447|DRUG|Rodatristat Ethyl|Oral, Tablet, 300 mg QD, 300 mg BID, 600 mg BID, 900 mg BID, 900 mg QD
223689917|NCT05933447|DRUG|Moxifloxacin|Oral, Tablet, 400 mg QD
223689918|NCT05933447|DRUG|Placebo for Rodatristat|Oral, Tablet, O mg QD, 0 mg BID
223689919|NCT05933447|DRUG|Placebo for Moxifloxacin|Oral, Tablet, 0 mg QD
223689920|NCT05312372|DRUG|Combination (S095033 + paclitaxel)|"Phase 1- dose escalation S095033 ; paclitaxel started at 80 mg/m²,(IV)~Phase 2 - S095033 at RP2D; paclitaxel started at 80 mg/m²,(IV)"
223689921|NCT03095833|OTHER|Odors|"Four odors are available: milk chocolate, dark chocolate, pineapple and apricot.~In addition, a neutral odor will be used clean air, a control odor transmitted during the task by the olfactometer in the same way as the other 4 odors, the only variant being that no odor will be deposited in the U-tube containing the smells. The images corresponding to the odors will be displayed after the odor has been proposed."
223689922|NCT03095833|OTHER|Visual stimulation|Concerning behavioral passes, the subjects will be in front of a computer screen on which the task will be presented. For fMRI passes, the visual stimulation of the participant is done by a mirror system placed about 10 cm from the participant's eyes, allowing him to watch a translucent screen on which the visual stimuli are projected. The latter have an intensity similar to that of television images, and therefore below the maximum permitted by labor legislation. The stimuli will be projected via a video projector located at the back of the imager.
223776514|NCT01132144|PROCEDURE|Endometrial injury|"Evaluate the position and size of the uterus by transabdominal ultrasonography, with the bladder comfortably full.~Identify the cervix with a disposable speculum. Open one sealed opaque envelope for allocation.~Endometrial injury:~* Slide the Pipelle de Cornier® (Laboratoires Prodimed, Neully-En-Thelle, France) gently through the cervix up to the uterine fundus. Transbadominal ultrasound might be used to confirm position.~* Draw back the piston to the end of the biopsy cannula until it locks creating a negative pressure.~* Sweep the uterine fundus slowly several times up to the internal orifice of the cervix, using regular to-and-fro movements while rotating the sampler to include the whole uterine cavity in the specimen, for 30 seconds or until participant ask for stopping."
223776515|NCT01132144|PROCEDURE|Control group|The investigator will dry the cervix with gauze and forceps for for 30 seconds or until participant ask for stopping.
223776516|NCT04611997|DRUG|Indocyanine Green|Indocyanine Green Tracer Using in Laparoscopic Gastrectomy with Lymph Node Dissection for Locally Advanced Gastric Cancer After Neoadjuvant
223776517|NCT00390390|DRUG|Lansoprazole|
223689923|NCT03095833|OTHER|Experimental Task|"The olfactory sensitivity and the olfactory identification capacities of the subjects will be evaluated using the ETOC test. Subjects will have to define his state of hunger/satiety thanks to a questionnaire of hunger. Finally, subjects should assess the hedonic nature of the odor and the edibility of the odor source. The task to be performed will be the same for the behavioral study as for the imaging study. The subject will receive instruction from the following three: indulge yourself, the subject must think of the desire to eat the food that will be presented to him in olfactory and visual form; Be natural, the subject must act as naturally as possible; Or hold back, the subject must distance themselves from their desire to eat and control themselves. In a second step, an odor will be presented for 5 seconds. This will be based on the subject's inspiration, then an image associated with the odor will be presented for two seconds."
223689924|NCT03095833|OTHER|Blood tests|Before and after the imaging examination, a blood sample will be taken by a medical imaging manipulator affiliated with the CERMEP whose actions will be remunerated in accordance with the usual hygiene and safety rules. The samples taken will then be annotated with the subject code and kept at the CERMEP. The volume of ghrelin sampling is 5 ml (10 ml for two samples). The volume of the leptin is 5 ml (ie 10 ml for two samples).
223689925|NCT03095833|OTHER|Questionnaires and test administered|The proposed questionnaires respond to all ethical aspects established by international and national standards to undertake studies on human subjects. Two types of questionnaires will be used in this experiment: Inclusion of the Subjects and Exploratory Tests.
223689926|NCT03095833|OTHER|fMRI|The purpose of the imaging part is to determine how high-level cognitive control (the setpoint) can affect the price of a food and the olfactory and visual perception of these foods in healthy subjects and Prader-Willi patients.
223689927|NCT03095833|OTHER|Odors 2|To modify the floral character of the wine used, the investigators will use the β-ionone odorant molecule (4 (2,6,6-trimethyl-1-cyclohexenyl) -3-buten-2-one (CAS number 14901-07-6) Purity ≥97.0% (Fluka) This molecule is commonly found in wines with a violet odor.
223689928|NCT03095833|OTHER|Images|The visual stimulation of the subject will be done by a system of mirrors placed about 10 cm from the subject's eyes allows him to look at a translucent screen behind the MRI scanner and on which the visual stimuli are projected.
223689929|NCT03095833|OTHER|Experimental Task fMRI|For each test the subjects will receive at the same time an image on the screen and a sample of wine (2 ml) delivered in the mouth of the subject thanks to the system of programmable pumps.
223689930|NCT03095833|OTHER|Genotyping for susceptibility to β-ionone|Sampling will be done by the subject himself by scratching and firmly pressing into the oral cavity, specifically at the cheeks and tongue for one minute, being careful not to touch the teeth and gums.
223689931|NCT03095833|OTHER|Experimental Task 2|The investigators will determine how perceptual judgments are modulated by cross-modal stimuli, as well as metacognitive judgments (how individuals judge their own sensory performance). In addition, they will determine how perceptual judgments are modified in the context of group decisions and how language influences performance.
223689932|NCT00085709|DRUG|gemtuzumab ozogamicin|Given IV, induction Arm1 6mg/m2 D4; post-consolidation 5mg/m2 3 doses \>/= 28 days apart
223689933|NCT00085709|OTHER|observation|No treatment given
223689934|NCT00085709|DRUG|Cytosine arabinoside|IV; induction Arms1/2 and reinduction 100 mg/m2/d days 1-7; consolidation 3gm/m2 q3hrs D1, 3, 5
223689935|NCT00085709|DRUG|Daunomycin|IV; induction Arm1 45mg/m2 D1-3; Arm2 and reinduction 60 mg/m2 D1-3;
223689936|NCT00535457|OTHER|Preoperative Magic Tricks|"Watching magic; Study patients will watch the anesthesiologist performing tricks (magic) before anesthesia induction."
223689937|NCT04393285|DRUG|Abemaciclib|Abemaciclib 150mg orally twice a day
223689938|NCT04393285|DRUG|Letrozole|Letrozole 2.5mg orally once a day
223689939|NCT01055522|DRUG|Arm 1: L19IL2 + Dacarbazine|"RD of L19IL2 determined in phase IIa. Induction Phase A: Intravenous (IV) infusion of L19IL2 on days 1, 3 and 5 of each 21-day cycle over 60 minutes via automated device (perfusor), for four consecutive 21-day cycles.~Induction Phase B: Intravenous (IV) infusion of L19IL2 on days 1, 8 and 15 of each 21-day cycle over 60 minutes via automated device (perfusor), for four consecutive 21-day cycles.~Maintenance: Intravenous (IV) infusion of L19IL2 on days 1, 8 and 15 of each 21-day cycle over 60 minutes via automated device (perfusor), for a maximum of 1 year after start of treatment.~DTIC 1,000mg/m2 every three weeks until disease progression, unacceptable toxicity, withdrawal of consent, or one year from initiation of therapy, whichever occurs first"
224263425|NCT04125407|OTHER|Sensorimotor foot orthoses|The interventional group will receive one customized pair of sensorimotor insoles and will be instructed for their using on a daily bases for the period of 3 months. The duration of using the insoles was established as 1 hour at the day after receiving the insoles. After that, the insoles' tolerance will be assessed based on the email correspondence and further adjustments of insole will be consulted with manufacturer if necessary. Recommended progression in time of using the insoles was established as +1 hour per each day (if possible) with no maximal limit. After 3 weeks, control examination will take place for the control of subjective effect of insoles. Consulting will be offered to the participants through the duration of research. Participants will not undergo any other supplementary treatment (physiotherapy, …) focusing on the flatfoot deformity.
224263426|NCT02482922|OTHER|Exercise & Dietary Supplement|
224263427|NCT02484807|OTHER|no intervention, only observation of different groups|
224263428|NCT03340545|OTHER|Custom Magnetic Resonance Elastography Device|Magnetic Resonance Elastography is an imaging method to measure mechanical properties of tissues.
224263429|NCT00137735|DRUG|Gabapentin|300mg tds
224263430|NCT00137735|OTHER|placebo|tds
224263431|NCT00624286|DRUG|Indacaterol 150 μg|Indacaterol was supplied in powder filled capsules together with a single-dose dry-powder inhaler (SDDPI) device.
224263432|NCT00624286|DRUG|Placebo to indacaterol|Placebo to indacaterol was supplied in powder filled capsules together with a single-dose dry-powder inhaler (SDDPI) device.
224263433|NCT05802563|DEVICE|fitness tracker|Study subjects will wear a Fitbit fitness tracker
224263434|NCT04143880|DRUG|Progesterone|intramuscular injection intranasal administration
224263435|NCT04143880|OTHER|saline|intramuscular injection intranasal administration
224263436|NCT03616691|DRUG|Atezolizumab|Stage I: The dose level of atezolizumab proposed to be tested in this study is 1200 mg administered by IV infusion every 3 weeks (q3w)
223776518|NCT00962429|DRUG|lipoic acid|Subjects will be started on a single daily dose of 600 mg of alpha lipoic acid or placebo for the first 4 weeks and then increased to 1200 mg for the remainder of the study.
223689940|NCT01055522|DRUG|Arm 3: Dacarbazine|Dacarbazine Dosage: 1,000 mg/m2 DTIC every three weeks until disease progression, unacceptable toxicity, withdrawal of consent, or for a maximum of 8 cycles, whichever occurs first.
223689941|NCT01055522|DRUG|ARM 2: L19IL2 + Dacarbazine|"RD of L19IL2 determined in phase IIa. Intravenous (IV) infusion of L19IL2 on days 1, 8 and 15 of each 21-day cycle over 60 minutes via automated device (perfusor), for for a maximum of 1 year after start of treatment.~DTIC 1,000mg/m2 every three weeks until disease progression, unacceptable toxicity, withdrawal of consent, or one year from initiation of therapy, whichever occurs first"
223689942|NCT00080275|DRUG|Niacin Extended-Release and simvastatin Tablets|
223689943|NCT04367233|OTHER|General anesthesia|General anesthesia with fentanyl, propofol and remifentanil.
223689944|NCT04367233|OTHER|Transverse abdominal block|Transverse abdominal block with ropivacaine 0,25% 0,2 ml/kg at the end of general anesthesia with fentanyl, propofol and remifentanil
223689945|NCT04367233|OTHER|Quadratus lumborum block|At the end of general anesthesia with fentanyl, propofol and remifentanil, patients will receive quadratus lumborum block with ropivacaine 0,25% 0,2 ml/kg
223689946|NCT04343820|PROCEDURE|Breast reconstruction|Breast reconstruction by prepectoral positioned implant after lipo-preparation of the wall.
223689947|NCT02718560|BEHAVIORAL|Writing|Writing exercise with or without cues for 1 hour per day for 4 days at week for 4 weeks
223689948|NCT02661451|DEVICE|SAPIEN 3 THV|
223689949|NCT02661451|BIOLOGICAL|Optimal Heart Failure Therapy|
223689950|NCT05922046|DEVICE|Leap Motion Controller on flat display|The LMC is a device with a Universal Serial Bus (USB) device capable of detecting the movement of hands and fingers. It is small in size and you need to connect the USB device to the computer and place your hands above the LMC. First, training will be carried out with the Leap Motion Controller instrument for 5 minutes, for a presentation and interaction with it, in the initial meeting. From the second meeting, the service protocol will be 16 sessions, this time being distributed as: first game lasting 7 minutes, second and third games lasting 6 minutes each and the last game lasting 8 minutes, totaling 27 minutes of intervention. Between games, about 2 minutes of rest was adopted. They were chosen through the website www.leapmotion.com¸ in order to relate them to the functional movements of the upper limbs in daily life tasks.
223689951|NCT06305624|DEVICE|Connections App|mobile application, a place where participants can find community and support to help them manage their ALD, learn liver health self-care, coping skills, and alcohol abstinence strategies.
223689952|NCT05947539|BEHAVIORAL|"Kisoboka Mukwano (It is possible, my love!) Intervention"|The intervention consists of 5 bi-weekly sessions each lasting 60 to 90 minutes. It uses motivational interviewing, peer navigation, and behavioral economics to promote strategies for economic strengthening, reductions in male partner alcohol use, coping with relationship conflict and stress, changing norms that reduce intimate partner violence and support engagement in HIV care and antiretroviral therapy (ART) adherence among adolescent girls and young women living with HIV, and, thereby, enhances future sustained viral suppression and benefits of treatment as prevention.
223689953|NCT05947539|BEHAVIORAL|Screening and Referral|Intimate partner violence screening, alcohol screening, and referral
223689954|NCT06443944|DRUG|Cretostimogene Grenadenorepvec|Engineered Oncolytic Adenovirus
223689955|NCT06443944|OTHER|n-dodecyl-B-D-maltoside|Transduction-enhancing agent
223689956|NCT05318417|DEVICE|The Cochlear™ Nucleus® Cochlear Implant (CI) System|"The Cochlear™ Nucleus® CI systems are designed to provide useful hearing. The system works by converting sound in the environment into electric pulses that stimulate the auditory nerve, allowing the brain to perceive sound. The Cochlear™ Nucleus® CI system has implanted and external components.~Implanted component:~The CI is surgically implanted under the skin behind the ear. It includes a receiver/stimulator to receive and decode the electrical signals from the sound processor and an electrode to deliver these signals to the cochlear.~External components:~The external components include a sound processor, and associated accessories and cables. The system is programmed by a Cochlear proprietary programming system, Custom Sound®."
223776519|NCT05966025|DRUG|Itopride|itopride will be taken by pateints one time per day by dose 100 mg
223776520|NCT05966025|DRUG|conventional therapy|will taken by patient in control group
223776521|NCT01970332|PROCEDURE|Revascularization Surgery|
223776522|NCT01970332|OTHER|Supervised exercise therapy|
223776523|NCT01842828|OTHER|Standard care plus electronic cigarettes|
223776524|NCT01842828|BEHAVIORAL|Standard care|
223776525|NCT05933915|OTHER|group-based laughter yoga|"Midwives in the intervention group of the research will apply 8 sessions of laughter yoga, 2 sessions a week. Laughter yoga will be practiced by researchers with leadership certification. Each session will take an average of 45 minutes. Laughter Yoga sessions will be held on the web through the Zoom program. Each session will consist of groups of 8 people."
223776526|NCT04133935|PROCEDURE|Laparoscopic Obturator Urethropexy|Suspending the periurethral vaginal tissue to the obturator internus fascia bilaterally via sutures, creating a support for the bladder neck compartment.
223776527|NCT04133935|PROCEDURE|Burch Urethropexy|Suspending the periurethral vaginal tissue to Cooper's ligament bilaterally via sutures, creating a support for the bladder neck compartment
223689957|NCT05898022|DRUG|Furosemide (plus potassium chloride)|Furosemide is a loop diuretic that inhibits the reabsorption of sodium and chloride in the proximal and distal tubules as well as the loop of Henle. Participants will receive 2 mg/kg enteral furosemide daily during treatment periods when they receive study drug. To prevent hypokalemia and hypochloremia associated with furosemide use, participants will also receive 1 mg/kg of potassium chloride enterally twice per day when receiving furosemide. Each patient will have 8 days of total exposure to furosemide over the 16-day N-of-1 trial.
223689958|NCT05898022|DRUG|Placebo (plus placebo electrolyte solution)|During treatment periods when participants receive placebo, they will receive a volume of sterile water equivalent to the study drug dose. Participants will also receive a placebo electrolyte solution equivalent to the volume of potassium chloride that would be given.
223689959|NCT06377696|OTHER|Best Practice|Receive SOC
223689960|NCT06377696|OTHER|Medical Device Usage and Evaluation|Wear wearable device
223689961|NCT06377696|DRUG|Metformin|Given PO
223689962|NCT06377696|OTHER|Neurocognitive Assessment|Undergo neurocognitive test
223689963|NCT06377696|OTHER|Questionnaire Administration|Ancillary studies
223689964|NCT06958276|OTHER|Ultrasound Guided Percutaneous Neuromodulation. Frequency of 10 Hz|The US-guided PNM intervention will be performed with the patient in the prone position, the shoulder to be treated flexed at 90 degrees, the humerus partially supported on the table, the elbow flexed at 90 degrees, and the musculature relaxed. Needles will be inserted near the perineurium of the axillary and suprascapular nerves. Prior to needle insertion, the skin will be cleaned with isopropyl alcohol and chlorhexidine. The PNM intervention will consist of applying a compensated asymmetric biphasic current, with a rectangular positive phase and a triangular negative phase, at a frequency of 10 Hz, pulse width of 240 μs, and the maximum tolerated intensity that elicits a painless maximal muscle contraction, following this protocol: 10 stimulations of 10 seconds each, with a 10-second rest between stimulations.
223689965|NCT06958276|OTHER|Ultrasound Guided Percutaneous Neuromodulación. Frequency of 1 Hz|Same intervention as previously described, with the only difference being that the frequency will be 1 Hz instead of 10 Hz.
223689966|NCT06959108|DRUG|Pucotenlimab|200mg every 3 weeks (21-day cycles) for a total of 3 cycles.
223689967|NCT06959108|DRUG|MRG003|2.3 mg/kg, every 3 weeks (21-day cycles) for a total of 3 cycles.
223689968|NCT05152875|OTHER|biological|fungal colonization by weekly cultures
223689969|NCT06796998|BIOLOGICAL|Epcoritamab|"Epcoritamab will be administered via subcutaneous (SC) injection using a step-up dosing schedule as follows:~* Cycle 1, Day 1: 0.16 mg~* Cycle 1, Day 8: 0.8 mg~* Cycle 1, Day 15: 3 mg~* Cycle 1, Day 22: 48 mg~* Cycles 2 to 3, Days 1, 8, 15 and 22: 48 mg~* Cycles 4 to 9, Days 1 and 15: 48 mg~* Cycles 10 to 12; Day 1: 48 mg"
223689970|NCT05716451|DEVICE|Device-assisted mobilisation with the sit/stand stabilizer Liana|Non-invasive device-assisted mobilisation with LIANA
223689971|NCT06797401|DRUG|RBD5044|RBD5044, active drug.
223689972|NCT06797401|DRUG|Placebo|Placebo that is identical in appearance and volume to the doses of active IMP.
223689973|NCT04974047|DRUG|Tislelizumab|Administered intravenously as specified in the treatment arm.
223689974|NCT03003117|BEHAVIORAL|Experimental: Intervention Program|"The home based educational component from the 3rd trimester of pregnancy to when the child is aged 24 months seeks to build knowledge, skills and social support (social cognitive theory, anticipatory guidance) to the parents regarding feeding practices (focussing on breastfeeding and complementary feeding), and lifestyle behaviors, consistent with the French Nutrition and Health Program (PNNS) guidelines (component 1). Fresh fruit and vegetable baskets, kitchen utensils and cooking devices are made available at a reduced price from the 3rd trimester of pregnancy to when the toddler is aged 24 m (component 2), along with the provision of follow-on formula, baby and family food vouchers from 6 to 24 m (component 3).~One home visit is scheduled during the 3rd trimester of pregnancy. Another visit will take place in the maternity ward after the child is born. Five further home visits will take place when the child is aged 3, 6, 12, 18 and 24 m."
223776528|NCT01639898|DRUG|Lenalidomide and dexamethasone|2 cycles of the lenalidomide-dexamethasone (Len-Dex) combination before radiation or intensive treatment
223776529|NCT01639898|DRUG|Lenalidomide and dexamethasone|9 cycles of the Len-Dex combination
223776530|NCT02998294|DEVICE|Respiratory Volume Monitor(RVM)|The purpose of this study was to determine the accuracy of one-time respiratory volume measured by RVM compared to the one-time respiratory volume measured by mechanical ventilation in post-operative ICU patients.
223776531|NCT02998294|DEVICE|artificial respirator|The purpose of this study was to determine the accuracy of one-time respiratory volume measured by RVM compared to the one-time respiratory volume measured by mechanical ventilation in post-operative ICU patients.
223776532|NCT01159301|DRUG|entinostat|Given orally (PO)
223776533|NCT01159301|DRUG|sorafenib tosylate|Given PO
223776534|NCT01159301|OTHER|pharmacological study|Correlative studies
223776535|NCT01159301|OTHER|laboratory biomarker analysis|Correlative studies
223776536|NCT03095417|BEHAVIORAL|Physical Exercise Intervention|In home exercise intervention.
223689975|NCT03003117|BEHAVIORAL|Active comparator: Usual Care|Usual Care reflects the standard treatment currently provided within the frame of the French health care system. One home visit is scheduled during the 3rd trimester of pregnancy. Another visit will take place in the maternity ward after the child is born. Five further home visits will take place when the child is aged 3, 6, 12, 18 and 24 m. If nutritional questions are raised by parents, dieticians will restrict their responses based on the food guides of the PNNS.
223689976|NCT05773742|DEVICE|Low-volume irrigation|Qufora IrriSedo MiniGo
223689977|NCT06736847|PROCEDURE|distal gastrectomy with D2 lymphadenectomy plus complete mesogastric excision (CME) in gastric cancer|distal gastrectomy with D2 lymphadenectomy plus complete mesogastric excision (CME) in gastric cancer
223689978|NCT05892653|DRUG|ABM-1310|"Dose Escalation Stage: Subjects will be given oral dosing of ABM-1310 twice daily (BID) for 28-day cycles of continuous administration until progressive disease (PD), unacceptable toxicity, or other withdrawal criteria are met as clinically observed.~Dose Expansion Stage: Subjects will begin to receive oral doses of ABM-1310, BID, for 28-day cycles at a fixed dose level (as determined at the dose escalation stage) until PD, unacceptable toxicity, or other withdrawal criteria are met as clinically observed."
223689979|NCT06431984|DIAGNOSTIC_TEST|prick test|self-sampling of capillary blood using the finger prick test method
223689980|NCT06005142|DIETARY_SUPPLEMENT|Eriomin|Pre-diabetic patients on oral biguanide (metformin) (1000 mg/day) will receive a 250 mg/day capsule of Eriomin for 12 weeks.
223689981|NCT06005142|DIETARY_SUPPLEMENT|Washout|After 12 weeks of treatment with the active component (Eriomin) or placebo, the participants will follow a washout for 2 weeks.
223689982|NCT06005142|DIETARY_SUPPLEMENT|Placebo|Pre-diabetic patients on oral biguanide (metformin) (1000 mg/day) will receive a 250 mg/day placebo capsule for 12 weeks.
223689983|NCT05237505|DEVICE|bi-level positive pressure non invasive ventilation|Participants randomized to the bi-level arm will be provided with an auto bi-level device that automatically delivers the required pressure. The settings in the auto bi-level will be minimum EPAP of 4 cmH2O, maximum IPAP of 24 cmH2O, and a range of pressure support between 6-10 cmH2O. For those participants who have been randomized to the bi-level group but have not successfully acclimated to the device with the automatic bi-level settings, we will conduct an in-lab titration of the bi-level therapy during the optional Overnight visit 2.
223689984|NCT05237505|DRUG|Oxygen gas|The dose of nocturnal oxygen in all participants in the oxygen therapy arm will be 2 liters/minute. Patients with daytime hypoxemia, measured as sustained desaturations below 89% during wake time and/or arterial blood PO2 ≤ 55 mmHg, will be excluded from this study (as specified in the exclusion criteria) for ethical reasons since withholding oxygen in hypoxemic patients would be at odds with standard of care.
223776537|NCT03095417|BEHAVIORAL|Cognitive Training Intervention|Online cognitive training modules.
223776538|NCT03095417|BEHAVIORAL|Stretching Control|In home stretching.
223776539|NCT03095417|BEHAVIORAL|Cognitive Control|Online control puzzles and games.
223776540|NCT03120975|OTHER|Computerized decision support and audit & feedback|"* suggestion of guideline concordant antimicrobial treatment based on indication entry in the computerized physician order entry system~* mandatory reevaluation of antimicrobial therapy therapy on calendar day 4 of treatment~* suggestion of standard antimicrobial treatment duration according to indication"
223776541|NCT03120975|OTHER|Audit & Feedback|\* regular (at least monthly) feedback of antibiotic use quality indicators (on the ward level)
223776542|NCT03120975|OTHER|Standard antibiotic stewardship|"* Infectious diseases consultation on demand~* Review of positive blood cultures~* Availability of a antibiotic use guidelines (on paper and as PDF)"
223776543|NCT04071873|DIAGNOSTIC_TEST|Point-of-care HIV testing|Participants will undergo an HIV 1/2 antibody point of care test (Oraquick) and receive pre- and post-test counselling.Participants with positive tests will be referred to the HIV clinic for Western Blot confirmation, and linkage to care.
223689985|NCT02549157|PROCEDURE|Pelvic Floor Muscle Training|
223689986|NCT00397943|BIOLOGICAL|GSK's candidate Mycobacterium tuberculosis vaccine 692342|Intramuscular injection, 2 doses at 0, 1 month
223689987|NCT00397943|BIOLOGICAL|Comparator vaccine with recombinant Mycobacterium tuberculosis antigen and adjuvant system|Intramuscular injection, 2 doses at 0, 1 month
223689988|NCT00397943|BIOLOGICAL|Comparator vaccine with recombinant Mycobacterium tuberculosis antigen and physiological saline|Intramuscular injection, 2 doses at 0, 1 month
223689989|NCT00397943|BIOLOGICAL|Control vaccine with the adjuvant system.|Intramuscular injection, 2 doses at 0, 1 month
223689990|NCT03718975|DEVICE|Successor of Phonak Audéo B90|Successor of the most recent Receiver in the canal (RIC) Hearing aid form Phonak which will be fitted to the participants individual Hearing loss.
223689991|NCT03718975|DEVICE|Phonak Audéo B90|The Phonak Audéo B90 is the most recent Receiver-in-the-canal Hearing aid from Phonak which will be fitted to the participants individual Hearing loss.
223689992|NCT06574165|BEHAVIORAL|Moderate Intensity Continuous Training|6-week structured exercise intervention. The intervention will include twice weekly, center-based, aerobic exercise consisting of continuous treadmill walking. Each center-based session will include 45 minutes of aerobic exercise in addition to balance and flexibility exercises to promote cool-down. During each exercise session, they will also be asked to wear a heart rate monitor to measure mean pulse during their exercise sessions.
223689993|NCT06430814|OTHER|No intervention|No intervention
223689994|NCT04521777|BEHAVIORAL|Exercise Intervention|Participate in an 8-week home-based strengthening and walking program
223689995|NCT04521777|OTHER|Physical Performance Testing|Complete a physical function test
223689996|NCT04521777|OTHER|Questionnaire Administration|Ancillary studies
223689997|NCT02314208|DRUG|Xenbilox|
223689998|NCT02314208|DIETARY_SUPPLEMENT|Resveratrol|
223689999|NCT02314208|DRUG|Tahor|
223690000|NCT05933395|DRUG|Fulvestrant|Fulvestrant will be administered intramuscularly into the buttocks in combination with one of the other interventions as outlined above.
223690001|NCT05933395|DRUG|Neratinib|Neratinib will be administered orally in tablet form once daily with food in combination with fulvestrant administration as outlined above.
223690002|NCT05933395|DRUG|Alpelisib|Alpelisib will be administered orally in tablet form once daily with food in combination with fulvestrant administration as outlined above.
223690003|NCT05933395|DRUG|Everolimus|Everolimus will be administered orally in tablet form once daily in combination with fulvestrant administration as outlined above.
223690004|NCT05933395|DRUG|Abemaciclib|Abemaciclib will be administered orally in tablet form twice daily in combination with fulvestrant administration as outlined above.
223690005|NCT05815524|OTHER|Physical activity training|training on treadmill
223690006|NCT05348564|BEHAVIORAL|Direct contact of family members for cascade screening of relevant variants|Study team members will directly contact potentially impacted family members to offer genetic testing of relevant variant.
223690007|NCT01896479|DRUG|Cabozantinib (XL184) 140 mg|
223690008|NCT01896479|DRUG|Cabozantinib (XL184) 60 mg|
223690009|NCT01896479|DRUG|Placebo tablet|
223690010|NCT01896479|DRUG|Placebo capsule|
223690011|NCT04874038|DRUG|Lidocaine 20mg/ml|Patients in the intervention group will receive an IV lidocaine infusion using a dosage regimen of 1.5 mg/kg bolus of a 2% lidocaine solution with induction of general anesthesia followed by a 2.0 mg/kg/hour infusion until the end of surgery (and up to 30 minutes into recovery room).
223690012|NCT04874038|DRUG|Placebo|Patients in the control group will receive a placebo bolus and infusion with normal saline (0.9% sodium chloride solution) until the end of surgery (and up to 30 minutes into recovery room).
223690013|NCT04464226|DRUG|Darolutamide (Nubeqa, BAY1841788)|Participants will continue receiving darolutamide treatment at the dose level and schedule of administration previously assigned in the feeder study.
223690014|NCT02232191|BIOLOGICAL|Pneumovax-23|
223690015|NCT06183502|BEHAVIORAL|Quantitative survey|Quantitative surveys will be conducted through Alchemer, a HIPPA-compliant online survey system previously used by our group in collaborative research with CDC and supported by the Emory University Center for AIDS Research (CFAR). Surveys will be optimized for participants to take them through a personal computer, mobile phone, tablet, or the SMART study app. For participants who do not have any of these devices or prefer not to take the survey from their device, each city will have a research space where participants can schedule a convenient time to take the survey on a computer or tablet that the study will provide for that purpose.
223690016|NCT06183502|PROCEDURE|HIV and STI testing|The research team has developed and validated procedures for self-collection of specimens for testing for STIs (syphilis, urethral, rectal, and pharyngeal gonorrhea/chlamydia) and HIV self-testing. All participants will be mailed self-collection kits to provide samples for STIs (urine, rectal swab, and pharyngeal swab for gonorrhea/chlamydia; dried blood spot (DBS) for syphilis testing) and HIV (HIV 4th generation testing on DBS specimens in a CLIA-certified laboratory). Participants will be asked to collect specimens for their STI and HIV testing (every 6 months) and return them to Molecular Testing Labs. For participants who prefer in-person procedures, they will meet study staff who will provide them with the STI and HIV self-collection kit and instructions and provide a room for participants to collect their specimens.
223690017|NCT06183502|BEHAVIORAL|Qualitative Assessment|Focus group discussions (n=up to 48 men for 3 qualitative assessments; total n=up to 144 men) as a part of the study consisting of 9 to 12 focus group discussions (FGD) with an average of 8 (range 3-10) participants in each (3 per city). These focus groups will be conducted once during the first year of the study. FGD will be conducted by a trained moderator using a semi-structured interview guide developed in collaboration with CDC scientists. For the FGD, in each city, there will be one FGD with men who have never used PrEP, one with men who are using PrEP and report no adherence issues, and one with men who are currently using PrEP or used PrEP previously and report sub-optimal adherence. In-Depth Interviews (IDIs) A series of 90 in-depth interviews (same n=up to 45 men for each of 3 qualitative assessments) will be conducted over 18 months: up to 45 IDIs each 6 months apart, with up to 15 IDIs per city each wave.
223776544|NCT04071873|BEHAVIORAL|HIV testing education|Participants will be provided with education on community based HIV resources.
223776545|NCT03103867|DEVICE|CGM augmented pump with PLGS ,|5 weeks treatment CGM augmented pump with PLGS compared with 5 weeks treatment with insulin pump with CGM , without integration
223690018|NCT05607797|OTHER|Epidemiological study|Sociodemographic data collection, treatments collection, physical assessment, clinical examination and physical and biological measurements, biological evaluation (blood and urine samples), CKD-specific clinical features collection, gout-specific clinical features collection, clinical characteristics specific to chronic diseases, questionnaires (Health Assessment Questionnaire (HAQ-II), EuroQol (EQ)-5D-5L, joint pain, state of health, diet and physical activity, access to care, addictions, pain scale (EVA), personal and family history)
223690019|NCT00488280|BEHAVIORAL|Locomotor Training|Task-specific practice of walking with assistance from trainers using body weight support and treadmill followed by training over ground, 5x/week, approximately 1.5 hours/day
223690020|NCT05432297|BEHAVIORAL|Preventive physical exercise|Daily physical activity depending on daily condition
223690021|NCT05481437|DRUG|Brentuximab Vedotin|Brentuximab Vedotin injection, 50 mg, once every 2 weeks
223690022|NCT03139604|DRUG|Itacitinib|Itacitinib at the protocol-defined dose administered orally once daily (QD) plus corticosteroids.
223690023|NCT03139604|DRUG|Placebo|Matching placebo tablets administered orally once daily (QD) plus corticosteroids.
223690024|NCT03139604|DRUG|Prednisone|Oral prednisone may be used to begin standard corticosteroid background treatment at the investigator's discretion, at a dose equivalent to methylprednisolone 2 mg/kg per day.
223690025|NCT03139604|DRUG|Methylprednisolone|Methylprednisolone 2 mg/kg IV daily (or prednisone equivalent) or at a dose appropriate for the severity of disease as background treatment.
223690026|NCT06635395|OTHER|Scale validity and reliability|The aim of this study is to adapt the Baltimore Orthopedic Subscapularis Score (BOSS) to Turkish society in patients with rotator cuff injury and to make its validity and reliability in Turkish. It has 5 questions. The patients will be sought to answer questionnaires during regular rehabilitation sessions.
223690027|NCT05912413|OTHER|there is no intervention|there is no intervention
223690028|NCT04950608|DRUG|Psilocybin|Oral, single administration, dosage 25 mg orally
223690029|NCT04950608|BEHAVIORAL|Psychotherapy|The treatment regimen consists of a single administration of psilocybin orally combined with a supportive psychotherapy including 2 preparation sessions and 2 integration sessions
223690030|NCT04142437|DRUG|larotrectinib(Vitrakvi, BAY2757556)|In the study, patients treated under local standard of care clinical practice; all decisions in terms of diagnostic procedures, treatments, management of the disease, and resource utilization are fully dependent on mutual agreement between the patient and the attending physician, without interference by the study initiator or study protocol
223690031|NCT05488483|DIAGNOSTIC_TEST|Multispectral Optoacoustic Tomography Imaging|Each participants will undergo MSOT imaging of the suspicious breast tumor detected with ultrasound imaging and any additional lesion present in either breast before undergoing ultrasound-guided breast biopsy as the standard of care. Melanoma participants with pathologically confirmed ITM will undergo MSOT imaging following physical exam and biopsy. Melanoma patients receiving immunotherapy will undergo MSOT imaging prior to and following immunotherapy.
223690032|NCT05343000|BEHAVIORAL|Home-based pulmonary rehabilitation (PR) system|Technology to facilitate remote health coaching through PAP management, sleep scheduling, sleep duration, diet, exercise, medication and more. The tablet and sensors upload the patient's activities, physiological data, and answers to the daily self-report questions to a secure website. This website also allows health coaches to view patient data via overview, weekly, daily, and trend reports. Health coaches call patients regularly to celebrate progress, assist with any issues, and set new goals.
223776546|NCT03103867|DEVICE|Insulin pump with CGM|5 weeks treatment continuous subcutaneous insulin infusion pump with CGM without data integration,
223776547|NCT01490060|DRUG|Fosaprepitant|150 mg administered intravenously, delivered in either single dose or two doses, on Day 1 for single dose and on Days 1 and 4 for two doses, varying between Cycle 1 or Cycle 2 depending upon randomization to arm.
223690033|NCT05945745|DRUG|Chemotherapy|different treatments based on the molecular analysis
223690034|NCT04709640|OTHER|Tailored Medication Management Intervention|This research study involved an initial 1.5 hour visit and 2-3 follow up home visits (each lasting 60 minutes). Participants received 2-3 home visits during which they received recommendations on strategies which will improve medication management. Level II occupational therapy fieldwork students made the recommendations, after approval from their supervising licensed OT. The OT fieldwork students provided assistance to the individual in implementing strategies, obtaining adaptive equipment at little or no cost to the individual.
223690035|NCT04223583|DRUG|Anlotinib Hydrochloride|The standard first-line chemotherapy regimen (adriamycin + ifosfamide) failed
223690036|NCT04349514|OTHER|Natural history|Longitudinal observation of neuroimaging, clinical, and blood markers.
223690037|NCT06180473|OTHER|questionnaire|PPQ, TTAQ PTCS
223690038|NCT06191380|BEHAVIORAL|PACE-MS|A single bout of cycling.
223690039|NCT01953640|OTHER|Laboratory Biomarker Analysis|Correlative studies
223690040|NCT01953640|OTHER|Quality-of-Life Assessment|Ancillary studies
223690041|NCT04418440|DIETARY_SUPPLEMENT|Souvenaid oral nutritional supplement (Nutricia)|Daily dose of a commercially available oral nutritional supplement based around the active compound recipe Fortasyn Connect, produced by Nutricia, Danone.
223690042|NCT04803877|DRUG|Regorafenib 40 MG|For subjects age 18 and older, Regorafenib will be administered as 80mg oral once daily on Cycle 1, Days 1-7 and then escalated to 120 mg once daily for Cycle 1, Days 8-21 if no Grade 2 or above regorafenib adverse events occur. For subsequent cycles, the highest tolerated dose will be taken once daily on days 1-21 of each 28-day cycle.
223690043|NCT04803877|DRUG|Regorafenib 20MG|For subjects younger than 18 years, Regorafenib will be administered as 60mg/m2/dose (rounded to the nearest 20mg, maximum dose of 80mg) once daily for Cycle 1, Days 8-21 if no Grade 2 or above regorafenib-related adverse events occur. For subsequent cycles, the highest tolerated dose will be taken once daily on days 1-21 of each 28-day cycle.
223690044|NCT04803877|DRUG|Nivolumab|"For subjects age 18 and older, Nivolumab will be administered at 480mg IV over 30 min every 28 days.~For subjects younger than 18 years, Nivolumab 3mg/kg (maximum dose 240mg) will be administered IV over 30 minutes on day 1 and 15 of each 28-day cycle."
223690045|NCT06219941|DRUG|AZD0901|Antibody-drug conjugate/Biologic
223690046|NCT06219941|DRUG|5-Fluorouracil|Chemotherapy agents
223690047|NCT06219941|DRUG|Leucovorin|Chemotherapy agents
223690048|NCT06219941|DRUG|l-leucovorin|Chemotherapy agents
223690049|NCT06219941|DRUG|Irinotecan|Chemotherapy agents
223690050|NCT06219941|DRUG|Nanoliposomal Irinotecan|Chemotherapy agents
223690051|NCT06219941|DRUG|Gemcitabine|Chemotherapy agents
223690052|NCT06262425|DEVICE|repetitive Transcranial Magnetic Stimulation over primary somatosensory cortex|It will be applyed a magnetic field over the Somatosensory cortex of the patient that pretends to hiperexcite the membrans of the neurons inthis area to enhance motor learning
223690053|NCT06262425|DEVICE|repetitive Transcranial Magnetic Stimulation over primary motor cortex|It will be applyed a magnetic field over the primary motor cortex of the patient that pretends to hiperexcite the membrans of the neurons inthis area to enhance motor learning
223690054|NCT06262425|DEVICE|sham repetitive Transcranial Magnetic Stimulation|It will be applied a sham stimulation with the same protocol that pretends to create the illusion of being stimulated
223690055|NCT02207465|RADIATION|Radiotherapy|
223690056|NCT02207465|DRUG|Abraxane|Dose varies within subtrial 1 to determine maximum dose. All patients in subtrial 2 receive 125mg Abraxane
223690057|NCT06079190|DRUG|GSK4527226|GSK4527226 will be administered.
223690058|NCT06079190|OTHER|Placebo|Placebo will be administered.
223690059|NCT06033924|BEHAVIORAL|Walking Program: Internet-based|Internet pages allow participants to see step-count goals, progress over time and access to walking tips for 12 weeks. Among participants who do not increase their step counts (\>15%), these non-responders will be rerandomized to received the combination of internet and telehealth or either along for an additional 12-weeks (total intervention time is 24-weeks). A follow-up phase of 12-weeks will be completed for a total participant duration of 36 weeks.
223690060|NCT06033924|BEHAVIORAL|Walking Program: Telehealth-based|Telehealth sessions allow participants review step-count goals, progress over time and access to walking tips with the study coordinator for 12 weeks. Among participants who do not increase their step counts (\>15%), these non-responders will be rerandomized to received the combination of internet and telehealth or either along for an additional 12-weeks (total intervention time is 24-weeks). A follow-up phase of 12-weeks will be completed for a total participant duration of 36 weeks.
223690061|NCT06505018|DEVICE|Cureety techcare|"Each week, patients complete a questionnaire via the Cureety platform, specifically designed for the drug class or specific treatment being administered. Based on their responses, the Cureety TechCare algorithm classifies patients into one of four risk categories: correct (green), compromised (yellow), state to be monitored (orange), or critical state (red). (Note: the color code is not visible to the patient).~The medical team uses the dashboard for daily patient monitoring and manages alerts related to the clinical classification of the patient's condition. The physician in charge of telemonitoring interprets the data, adjusts the treatment as needed, and provides supportive care during standard care consultations. Patients are also notified of alerts with tailored messages guiding them on the actions to take according to the category determined by the device."
223690062|NCT06537609|OTHER|De-escalation VS No De-escalation|"No de-escalation group: continue to receive the same antibiotic that was started initially (as long as it is confirmed to be effective based on the blood culture sensitivity result). De-escalation is only allowed within 7 days if patient is being discharged from hospital.~De-escalation group: switched to narrower spectrum antibiotic (based on spectrum scale specified in protocol)."
223690063|NCT06537609|OTHER|Oral beta-lactams VS non beta-lactams|"Beta-lactam antibiotic: This can be, but not limited to, amoxicillin, amoxicillin-clavulanate, cephalexin, cefadroxil, or cefixime.~Non beta-lactam antibiotic: This can be ciprofloxacin, moxifloxacin, levofloxacin or trimethoprim-sulfamethoxazole."
223690064|NCT06537609|OTHER|Central vascular catheter retention VS Central vascular catheter replacement|"Central vascular catheter replacement: the catheter will be changed by the treating team as soon as possible and within a maximum of 72 hours from blood culture finalization~Central vascular catheter retention: the catheter will not be changed and will be retained until it is non functional or no longer needed."
223690065|NCT06537609|OTHER|Cephalosporin VS Carbapenem for low risk AmpC organisms|"Cephalosporin (ceftriaxone) at standard doses~Carbapenem (Meropenem or Ertapenem) at standard doses"
223776548|NCT01490060|DRUG|Dexamethasone|Intravenous push (IVPB) daily for 5 days (12 mg on day 1, and 8 mg on days 2-5)
223776549|NCT01490060|DRUG|5HT3 receptor antagonist|5HT3 receptor antagonist as standard of care 30 minutes prior to chemotherapy
223690066|NCT06537609|OTHER|Routine follow-up blood culture VS No routine follow-up blood culture|"Routine follow-up blood culture: routine repeat blood collection 4 days from the index blood collection with positive bacteria.~No follow-up blood culture: no routine repeat blood collection 4 days from the index blood collection with positive bacteria"
223690067|NCT06327074|BEHAVIORAL|Engaged Approach to Lung Cancer Screening|"Sites randomized to use the EA-LCS materials will be given password-protected access to the program/toolkit web portal and encouraged to use any materials that fit the normal flow of clinic procedures. Materials available include both staff-facing and LCS candidate-facing materials.~Staff-facing materials include:~* Program website/manual/toolkit overview~* Implementation insights with experts video series~* Clinical placement placards~* Program and clinician communication tools~Candidate-facing materials include:~* Program welcome letter~* Maps and directions template~* Communication preferences~* Candidate letter templates (N=\~8)~* Program newsletter template and instructions~* Lung nodule size comparison chart"
223690068|NCT06833359|OTHER|Observation|The Cervical Disability Index will be taught individually online through the Google questionnaire.
223690069|NCT02007512|DRUG|Enzalutamide|160 mg/day administered as four 40mg soft gelatin capsules by mouth once daily with or without food.
223690070|NCT02007512|DRUG|exemestane|25mg (overencapsulated to match 50mg dose during the blinded portion of the study and one 25mg tablet after unblinding) by mouth once daily after food.
223690071|NCT02007512|DRUG|Placebo (for enzalutamide)|Sugar pill manufactured to mimic enzalutamide administered as four soft gelatin capsules by mouth once daily with or without food.
223690072|NCT02007512|DRUG|exemestane|50mg (two 25mg tablets overencapsulated as a single capsule during the blinded portion of the study and two 25mg tablets after unblinding) by mouth once daily after food.
223690073|NCT05407844|OTHER|Community Health Worker (CHW) based palliative care|Those in the intervention group will receive support from a dedicated CHW trained in motivational interviewing, components of palliative care communication, and social determinants of health.
223690074|NCT05417737|OTHER|Ozone therapy|Systemic and/or local ozone administration. Dosage, frequency, and duration of ozone treatment will depend on the treated symptom and clinical evolution. Usually planned 40 sessions.
223690075|NCT06328361|PROCEDURE|Nonoperative surveillance|Clinical and imaging surveillance with digital rectal examination and/or endoscopy, rectal MRI and body CT
223690076|NCT02379338|DRUG|[18F]Fluortriopride|All subjects will receive a \[18F\]Fluortriopride PET/CT scan
223690077|NCT05507008|DIETARY_SUPPLEMENT|Kenetik Ketone Drink|BHB supplementation
223690078|NCT06347159|DRUG|EDG-7500|Liquid suspension formulation of EDG-7500
223690079|NCT06347159|DRUG|EDG-7500|Solid oral formulation of EDG-7500
223690080|NCT06403514|OTHER|Psychological Skills Training (PST)|PST will include self-talk, imagery, goal-setting and arousal regulation (Biofeedback)
224263437|NCT03616691|DRUG|Bevacizumab|Stage II: Once radiologic progression confirmed from atezolizumab monotherapy (stage 1), 1200mg of atezolizumab would be administered with 15mg/kg of bevacizumab as combination therapy every 3 weeks.
224263438|NCT05237830|PROCEDURE|Use of Cell Salvage in revision of total hip arthroplasty|The effective use of the cell saver was defined as the ability to re-transfuse at least 125 mL of re-suspended red blood cells with a hematocrit of 60 %.
224263439|NCT03646175|DIETARY_SUPPLEMENT|Choline|Participants will consume 1000 mg (2x500 mg) of choline bitartrate (over-the-counter supplement) between 10PM and 12AM the evening before the scheduled testing session and arrive fasted to the laboratory. There will be 2 testing sessions separated by 1 week.
224263440|NCT03646175|DIETARY_SUPPLEMENT|Placebo|Participants will consume 1000 mg (2x500 mg) of placebo between 10PM and 12AM the evening before the scheduled testing session and arrive fasted to the laboratory. There will be 2 testing sessions separated by 1 week.
224263441|NCT04404725|DEVICE|comfilcon A|Subjects will be randomized to wear comfilcon A for one month.
224263442|NCT04404725|DEVICE|Samfilcon A|Subjects will be randomized to wear samfilcon A for one month.
224263443|NCT03456544|DRUG|Vancomycin|Patients who have vancomycin associated acute kidney injury will be in the Van-AKI group, and those who don't have vancomycin associated acute kidney injury will be in the none VAN-AKI group.
224263444|NCT05871463|BIOLOGICAL|MSC-derived exosomes|Patients will receive standard medication plus MSC-derived exosomes at a final dose of 40mg in three weeks. Standard medication includes: a) treatment of the underlying cause of cirrhosis such as drug treatment of hepatitis B and C. b) symptomatic treatment of port complications such as ascites, prevention of variceal bleeding, treatment and prevention of hepatic encephalopathy.
224263445|NCT02252016|DRUG|Grazoprevir + Elbasvir|FDC tablet containing grazoprevir 100 mg + elbasvir 50 mg taken once daily by mouth.
224263446|NCT02252016|DRUG|Placebo|Placebo tablets matching grazoprevir + elbasvir FDC tablets taken once daily by mouth.
224263447|NCT06212492|DRUG|NMBAs|Early and systematic use of NMBAs
224263448|NCT06212492|OTHER|Prone positioning|Early and systematic use of prone positioning
224263449|NCT00509990|DRUG|Pimecrolimus|Pimecrolimus cream 1 %
224263450|NCT00944190|BEHAVIORAL|Self-management intervention|Brief counseling technique, self-management,
224263451|NCT00944190|BEHAVIORAL|Education|Educational information about pain, fatigue, depression, and cognitive difficulties in multiple sclerosis.
224263452|NCT05351957|PROCEDURE|Dry needling|Only dry needling of the lower limbs will performed in all patients with acupunture needling
224263453|NCT01944072|OTHER|Aerobic exercise training intensity|
224263454|NCT06516354|DEVICE|Portable sleep apnea screening|Screening of stroke and TIA patients on the stroke inpatient unit using theSTOP BANG questionnaire and portable sleep testing (PST) during inpatient hospitalization, early interpretation of PST results by neurology with prescribed treatment upon discharge from hospital
224263455|NCT01190865|BIOLOGICAL|HP802-247|One dose of HP802-247 consisting off 260 mL containing keratinocytes and fibroblasts totaling 5.0 x 10.6 cells per mL, plus fibrin.
224263456|NCT02651506|PROCEDURE|Electromagnetic Navigation Bronchoscopy|• Participants randomized to the intervention arm will undergo biopsy using the superDimension®InReach™ System. Participants will undergo ENB guided biopsy under general anesthesia or local anesthesia. The procedure will be performed by a thoracic surgeon in the operating room or endoscopy suite. Following electromagnetic mapping, bronchoscopy and biopsy will be performed. Fiducial markings will be placed when necessary.
223690081|NCT06462547|DRUG|INZ-701|INZ-701 is a recombinant fusion protein that contains the extracellular domains of human ENPP1 coupled with an Fc fragment from an immunoglobulin gamma-1 (IgG1) antibody (rhENPP1-Fc).
223690082|NCT06848088|DRUG|Fianlimab+cemiplimab|No study drug administered in this observational study.
223690083|NCT04632953|OTHER|No Intervention|No Intervention
223690084|NCT01165632|PROCEDURE|biopsy|Correlative studies
223690085|NCT01165632|PROCEDURE|computed tomography|Undergo computed tomography
223690086|NCT01165632|PROCEDURE|therapeutic conventional surgery|Undergo stereotactic craniotomy
223690087|NCT01165632|RADIATION|radiation therapy treatment planning/simulation|Undergo radiation therapy treatment planning/simulation
223690088|NCT01165632|RADIATION|radiation therapy|Undergo radiation therapy
223690089|NCT01165632|PROCEDURE|magnetic resonance imaging|Undergo magnetic resonance imaging
223690090|NCT01165632|PROCEDURE|positron emission tomography|Undergo positron emission tomography
223690091|NCT01165632|DRUG|fluorine F 18 fluorodopa|Given IV
223690092|NCT04904575|PROCEDURE|Erector spinae plane block|"Procedure : After installing the sleeping patient and identifying the surgical level by the surgeon, the anesthetist will perform the erector spinae plane block. The anesthetist performs an ultrasound to view the spine and erector muscles and identifies the transverse processes of the vertebra involved in the surgery. Once the location has been made, the anesthetist injects the anesthetic product under ultrasound control between the erector muscle of the spine and its anterior fascia, the trajectory of the needle being thus visualized throughout the procedure. The anesthetist bilaterally injects 3ml/kg of solution with a maximum of 30ml injected.~Drug : Levobupivacaïne 2,5mg/ml."
223690093|NCT04904575|PROCEDURE|Erector spinae plane block|"Procedure : After installing the sleeping patient and identifying the surgical level by the surgeon, the anesthetist will perform the erector spinae plane block. The anesthetist performs an ultrasound to view the spine and erector muscles and identifies the transverse processes of the vertebra involved in the surgery. Once the location has been made, the anesthetist injects the anesthetic product under ultrasound control between the erector muscle of the spine and its anterior fascia, the trajectory of the needle being thus visualized throughout the procedure. The anesthetist bilaterally injects 3ml/kg of solution with a maximum of 30ml injected.~Drug : NaCL 0,9%."
223690094|NCT06427083|DRUG|Envlo Tablet|Enavogliflozin 0.3mg
223690095|NCT06427083|DRUG|Envolomet SR Tablet|Enavogliflozin 0.3mg/Metformin1,000mg
223690096|NCT06287918|DRUG|3HP-2827|3HP-2827 will be administered orally once daily in 28-day cycles.
223776550|NCT01490060|DRUG|Ifosfamide-based chemotherapy (AI)|Doxorubicin + Mesna + + Ifosfamide + Vincristine, chemotherapy cycles repeated every 3-4 weeks for up to 6 cycles. Chemotherapy drugs listed separately, individual dosages, etc.
223690097|NCT06347107|DEVICE|Robotic subretinal tPA injection|-The insertion of a 41G subretinal needle adjacent to a subretinal hemorrhage using the stabilizing (tremor-reducing) properties of a robotic instrument in order to slowly inject tPA and evaluate whether the needle can be held in place for up tot 3 minutes.
223776551|NCT01490060|DRUG|Doxorubicin|25 mg/m\^2/day IV continuous infusion for 72 hours on days 1, 2, and 3, completing infusion on day 4 (total dose: 75 mg/m\^2) as part of AI Chemotherapy.
223690098|NCT02477423|DRUG|Ampicillin|Ampicillin will be given as routine antibiotic coverage for those in the active arm, as the standard initial antibiotic used within the neonatal unit. It may also be used for patients who are not eligible for randomization.
223776552|NCT01490060|DRUG|Mesna|Prior to ifosfamide (Day 1) - 500 mg/m\^2 (20% of ifosfamide dose) given simultaneously with ifosfamide and then daily continuous infusion (Days 1-4 completing infusion on day 4) - 1,500 mg/m\^2/day (60% of daily ifosfamide dose) for a total of 6 gm/m\^2. The mesna infusion complete 24 hours after last dose of ifosfamide.
223776553|NCT01490060|DRUG|Ifosfamide|2.5 g/m\^2 IV bolus over 3 hours on days 1, 2, 3, 4 (total dose: 10 g/m\^2).
223776554|NCT01490060|DRUG|Vincristine|2 mg IV by rapid infusion (Day 1) may be given to participants with sarcomas of small cell histology.
223776555|NCT01405157|DRUG|methylprednisolone|constituted powder for oral suspension 4 mg/mL single dose at 16 mg
223690099|NCT02477423|DRUG|Gentamicins|Gentamicin will be given as routine antibiotic coverage for those in the active arm, as the standard initial antibiotic used within the neonatal unit. It may also be used for patients who are not eligible for randomization.
223690100|NCT02477423|DRUG|Placebo|Normal saline will be given as placebo for those in the placebo comparator group.
223690101|NCT06101784|DRUG|Avenanthramide|In each cohort 6 subjects will be assigned to the active treatment and 2 subjects will be assigned to the placebo.
223690102|NCT06101784|DRUG|Placebo|In each cohort 6 subjects will be assigned to the active treatment and 2 subjects will be assigned to the placebo.
223690103|NCT02397668|DEVICE|CorMatrix Cor TRICUSPID ECM Valve|CorMatrix Cor TRICUSPID ECM Valve to replace a diseased tricuspid valve, including tricuspid valve disease secondary to congenital heart disease.
223690104|NCT05190315|DRUG|Chlorpromazine|"Concurrent Phase: Oral chlorpromazine at 25 mg daily for the first 3 patients, then dose escalate to 50 mg if no dose limiting toxicity (DLT). Starting 7 days prior to radiation start.~Interim Phase: Chlorpromazine, 25 mg per day for first 3 subjects and then dose escalate to 50 mg per day if no DLT, will continue post radiation and prior to beginning adjuvant temozolomide.~Adjuvant Phase: Chlorpromazine, 25 mg per day for first 3 subjects and then dose escalate to 50 mg per day if no DLT, will be continued daily (7 days per week) concomitant with Temozolomide."
223776556|NCT01405157|DRUG|methylprednisolone|tablets 16 mg single dose
223776557|NCT01877421|DRUG|2 mg KSL-W|
223776558|NCT01877421|DRUG|4 mg KSL-W|
223690105|NCT05190315|DRUG|Temozolomide|"Concurrent Phase: Oral temozolomide at 75 mg/m2 per day concomitant with focal radiation and chlorpromazine. Temozolomide should be started on day 1 of radiation therapy, either at bedtime or morning as per patient preference.~Adjuvant Phase: Oral Temozolomide concomitant with Chlorpromazine, starting Temozolomide dose (Cycle 1) is 150 mg/m2 daily with a single dose escalation to 200 mg/m2 daily in subsequent cycles if no treatment-related adverse events \> grade 2 are noted. Temozolomide to be taken once daily for 5 consecutive days (1-5) of a 28 day cycle."
223690106|NCT05190315|RADIATION|Radiation Therapy|Concurrent Phase: Radiation therapy administered daily, M-F, to a total dose of 60 Gy in 2 Gy Fractions for a total of 30 fractions.
223690107|NCT04851184|DEVICE|Gaze stabilization Exercises using Virtual Reality Device|Participants will utilize a wireless virtual reality headset to perform their gaze stabilization exercises to better control the background and visual field as well as collect data related to speed, excursion, and duration of head movements.
223690108|NCT04851184|BEHAVIORAL|Gaze stabilization non-instrumented|Participants will perform gaze stabilization exercises in a non-instrumented manner. Subjects are instructed to focus on a letter on a piece of paper held at arm's length. They are instructed to move their head back and forth as quickly as they can while keeping the letter in focus. The total duration of the exercise (from 10 - 240 seconds) and background complexity (simple to complex moving) are increased gradually according to patient symptoms.
223690109|NCT05336045|PROCEDURE|trigger finger release|The A1 pulley and tendon sheath is divided in local anaestethic through a small incision in the palm
223690110|NCT03465423|PROCEDURE|Not applicable (measuring subject's effect site concentration of propofol during the induction of general anesthesia)|The patients of two cohort group will undergo general anesthesia in the same way and therefore there is no intervention in this study.
223690111|NCT04924179|DRUG|Tislelizumab plus Fruquintinib and SBRT|Fruquintinib:5mg ,qd,po, d1-d14, 21 days for a cycle;Tislelizumab Injection:200mg，IV,d1,21 days for a cycle;SBRT:8-10Gy×5F,qod,in 10 days.
223690112|NCT00625482|BIOLOGICAL|OPV|
223690113|NCT00625482|BIOLOGICAL|OPV plus BCG|
223690114|NCT00625482|BIOLOGICAL|OPV|
223690115|NCT00625482|BIOLOGICAL|OPV plus BCG|
223690116|NCT04205097|DRUG|Neostigmine + glycopyrate|maintaining of moderate neuromuscular block (train-of-four count 1-2) during surgery, reversal using neostigmine 50 ug/kg and glycopyrrolate 10 ug/kg
223690117|NCT04205097|DRUG|Sugammadex|maintaining of deep neuromuscular block (posttetanic count 1-2) during surgery, reversal using sugammadex 2-4 mg/kg
223776559|NCT01877421|DRUG|6 mg KSL-W|
223776560|NCT01877421|DRUG|10 mg KSL-W|
223776561|NCT01877421|DRUG|20 mg KSL-W|
223776562|NCT01877421|DRUG|30 mg KSL-W|
223690118|NCT06197425|DRUG|"FOLFIRI cures"|(Irinotecan 180 mg/m2, leucovorine 400mg/m2, 5FU bolus 400 mg/m2, 5FU continuous infusion 2400 mg/m2) every 14 days for 6 months or until disease progression on imaging
223690119|NCT06197425|DRUG|Trifluridine cures|Trifluridine tipiracil 35 mg/m2 bid during 5 days/w on week 1 and 2 every 4 weeks, for 6 months or until disease progression on imaging
223690120|NCT06197425|BIOLOGICAL|BIOLOGICAL ASSESSMENT|blood sample ACE markers
223690121|NCT06197425|OTHER|Questionnaires|Quality of life questionnaires (QLQ-C30 ; EQ-5D-5L ; GPAQ)
223690122|NCT06197425|OTHER|Thoracic-abdomino-pelvic scan or MRI|Thoracic-abdomino-pelvic scan or MRI
223690123|NCT03155360|OTHER|Non interventional study|Non interventional study
223690124|NCT02962947|DRUG|Propranolol|80 mgR propranolol once daily
223690125|NCT02962947|DRUG|Placebo|placebo once daily
223690126|NCT03355118|OTHER|General anaesthesia and major surgery|The effect of general anaesthesia and surgery on oxygen transport and how it relates to outcome
223776563|NCT01877421|DRUG|50 mg KSL-W|
223776564|NCT01877421|DRUG|75 mg KSL-W|
223776565|NCT01877421|DRUG|100 mg KSL-W|
223776566|NCT01877421|OTHER|Placebo|Cetylpyridinium chloride (CPC) as an additive, isomalt as a bulk sweetener, peppermint powder for flavoring, sucralose as an intense sweetener, colloidal silicon dioxide is a flow enhancer, magnesium stearate as a process aid, and the proprietary gum base formulation.
223690127|NCT04374968|DEVICE|Blood flood restriction cuff|Blood flow restriction cuffs will be used as an augment to physical therapy
223690128|NCT03899688|PROCEDURE|Maxillary sinus augmentation|Surgical technique for increasing the vertical bone height of the posterior maxilla an antrostomy of about 5 mm in height and 10 mm long will be prepared using a diamond insert mounted on a sonic-air surgical instrument. The Schneiderian membrane will be elevated and clinical measurements will be performed using an UNC 15 probe. The space obtained underneath the sinus mucosa will be filled with the xenograft and a resorbable collagen membrane will be placed to cover the antrostomy only at the randomly selected control sites.
223690129|NCT02902978|DRUG|E6130|
223690130|NCT02902978|DRUG|Placebo|E6130 matched placebo
223690131|NCT04816201|OTHER|Electroacupuncture|Electroacupuncture at Xuanji (CV21), Danzhong (CV27), Qihai (CV06), Guanyuan (CV04), and bilateral Liangmen (ST21) and Zusanli (ST36).
223690132|NCT01466140|OTHER|Writing down request for help|Patients in the intervention group could write down their request for help on a request card (with a maximum of 2 questions).
223690133|NCT00797368|OTHER|Manual Therapy and Exercise|Manual Therapy and Exercise
223690134|NCT00797368|OTHER|Home exercises|Home exercises
223690135|NCT05016284|OTHER|JW-100|Cosmetic CBD cream (JW-100)
223690136|NCT05016284|DRUG|Eucrisa|Topical EUCRISA®, Pfizer
223690137|NCT03986632|BEHAVIORAL|Tundra Gifts|Tundra Gifts is a home-focused intervention delivered by community health workers (CHW) that focuses on promoting healthy eating and an active lifestyle among 3-5 year olds through family and community partnerships. Primary caregivers will attend monthly interactive education session, receive a monthly gift basket that includes resources and supplies to support behavior change at home and receive ongoing social support through a Facebook site.
223690138|NCT05742906|DEVICE|Tricuspid valve replacement with the Cor TRICUSPID ECM Valve|Tricuspid valve replacement with the Cor TRICUSPID ECM Valve for the surgical management of tricuspid valve disease or dysfunction.
223690139|NCT02145507|DRUG|SOLX (Investigational)|SOLX is regulated as a drug but is not intended to provide a direct therapeutic benefit.
223690140|NCT02145507|DRUG|AS-3 (Control)|AS-3 solution is regulated as a drug but is not intended to provide a direct therapeutic benefit
223690141|NCT01182779|RADIATION|Carbon ion|"Arm A (carbon ion therapy):~Total dose to the PTV2 - 45 Gy E in 3 Gy E /d, 4-6 days a week, 15 fractions Total dose to the PTV1 - 63 Gy E ± 5%, further 5-7 fractions a 3 Gy E."
223690142|NCT01182779|RADIATION|Protons|"Arm B (proton therapy):~Total dose to the PTV2 - 50 to 56 Gy E in 2 Gy E /d, 4-6 days a week, 28 fractions Total dose to the PTV1 - 72 Gy E ± 5%, further 6-9 fractions a 2 Gy E."
223690143|NCT01490970|OTHER|Database|Database
223690144|NCT05173480|OTHER|Conventional rehabilitation|Exercise therapy through conventional rehabilitation training made by physiotherapists.
223690145|NCT05173480|DEVICE|Virtual Reality Rehabilitation System (VRRS)|Exercise therapy through a virtual reality rehabilitation system (VRRS).
223690146|NCT05173480|DEVICE|Virtual Reality Rehabilitation System (VRRS)|Exercise therapy through a virtual reality rehabilitation system (VRRS) with sensors not connected.
223776567|NCT04118621|DEVICE|chest ultrasound|detection of postoperative pulmonary complications after cardiothoracic surgery
223690147|NCT05648656|DRUG|TXA Nebulization|Nebulization with TXA 500mg/ 5mL 8 hourly for 2 days plus standard care of therapy
223690148|NCT05648656|OTHER|0.9% NS Nebulization|Nebulization with 0.9% normal saline (NS) 5mL 8 hourly for 2 days plus standard care of therapy
223690149|NCT01807702|DRUG|13C-Pyruvate 13C-lactate and dichloroacetate|Subjects will receive pyruvate and have blood,CO2, and buccal cell samples collected. The second visit the subjects will receive a dose of dichloroacetate before the pyruvate is given
223690150|NCT00702572|DRUG|Vorinostat, Bevacizumab, Carboplatin, Paclitaxel|This dose escalating phase will enroll sequential cohorts of 3-6 patients to be entered at the following dose levels: Level -1: Days 1-14, Vorinostat 100 mg po QD; Day 3, Bevacizumab 15 mg/kg; Carboplatin 6 AUC; Paclitaxel 175 mg/m2. Level 1: Days 1-14, Vorinostat 200 mg po QD days 1-14; Day 3, Bevacizumab 15 mg/kg; Carboplatin 6 AUC; Paclitaxel 200 mg/m2. Level 2: Days 1-14, Vorinostat 300 mg po QD days 1-14; Day 3, Bevacizumab 15 mg/kg; Carboplatin 6 AUC; Paclitaxel 200 mg/m2. Level 3: Days 1-14, Vorinostat 400 mg po QD days 1-14; Day 3, Bevacizumab 15 mg/kg; Carboplatin 6 AUC; Paclitaxel 200 mg/m2. Treatment cycles will be repeated every 3 weeks. The highest dose level which \<2 out of 5 patients experience dose limiting toxicity will be defined as the recommended phase II dose.
223690151|NCT00702572|DRUG|Vorinostat, Bevacizumab, Carboplatin, Paclitaxel|Once the recommended phase II dose has been established from Phase I, 12 additional patients will be treated to evaluate the toxicities and safety profile of the 4-drug regimen.
223690152|NCT05274685|PROCEDURE|haemodialysis|continuous venovenous hemodiafiltration (CVVHDF) at a prescribed dose of 30-35 mL/kg/h of effluent and with regional citrate anticoagulation
223690153|NCT03557827|DRUG|Photodynamic Therapy with indocyanine green and diode laser|mechanical debridement by periodontal curets plus Indocyanine green solution activated by diode laser. The diode laser is classified as a Class I medical device according to the Directive 93/42/EEC
223690154|NCT03557827|PROCEDURE|Mechanical debridement alone|Mechanical debridement by periodontal curets alone
223690155|NCT06274528|DRUG|Lemborexant 10 mg|Within FDA approved dose 10 mg; capsule; QD, 6 month duration
223690156|NCT06274528|DRUG|Lemborexant 20mg|20 mg; capsule; QD; 6 month duration
223690157|NCT06274528|DRUG|Placebo|0 mg; capsule; QD; 6 month duration
223690158|NCT05310188|DIAGNOSTIC_TEST|pseudocholinesterease|blood samples
223776568|NCT03022851|DEVICE|Occlutech AFR Device|Catheter-guided transeptal placement of an AFR device following balloon atrial septostomy (BAS) -procedure.
223690159|NCT03503071|PROCEDURE|Cytoreductive surgery and intraperitoneal chemotherapy|Cytoreductive surgery and intraperitoneal chemotherapy for colorectal cancer or pseudomyxoma peritonei. Either early postoperative intraperitoneal chemotherapy (EPIC) or hyperthermic intraperitoneal chemotherapy (HIPEC) is used for intraperitoneal chemotherapy.
223690160|NCT00900601|PROCEDURE|Arthrodesis to the sacroiliac joint and symphysis|"Standard surgical procedures will be used. When the patient has isolated pain in the symphysis isolated fixation will be performed. A 2x2 cm large bone block will be removed and replaced with spongy bone. For fixation the Matta-plate will be applied.~To the sacroiliac joint we use an anterior approach. A 2x1,5 cm large bone block will be removed and replaced with spongy bone from the iliac crest. For joint fixation we either use 2 plates or sacroiliac screws. The same procedure will be used on the other side in the cases with bilateral symptoms. Only one side will be operated at a time. After one year it will be decided if it's necessary to perform contralateral surgery."
223690161|NCT00608543|DRUG|Aripiprazole|varied dose (5, 10, 15 mg qd) for 6 wks
223690162|NCT00869427|DRUG|vitamin C|vitamin C 1g bid for 1 year
223690163|NCT00095680|DRUG|SCIO-469|two 30-mg capsules three times daily
223690164|NCT00095680|DRUG|SCIO-469 and bortezomib|The addition of bortezomib (treatment regimen or bolus) to monotherapy of SCIO-469 or bortezomib combination with SCIO-469 will be dependent upon clinical response or disease progression during the study
223690165|NCT05984368|DRUG|BG136|Subjects injected with BG136 in Part 1 and Part 2
223690166|NCT05984368|DRUG|Placebo|Subjects injected with Placebo in Part 1 and Part 2
223690167|NCT01076816|DRUG|dexmedetomidine|"dexmedetomidine will be given max 48h. In case analgosedation is still needed after stop of the dexmedetomidine infusion, the treatment is switched to conventional analgosedation regimens.~Additional drugs are given to every inadequately sedated patient (assessed by regular Comfort scoring). In case of oversedation or adverse drug events (hypotension, bradycardia), a downtitration (or stop) of the dexmedetomidine infusion is needed."
223690168|NCT01076816|PROCEDURE|Vital signs|systolic and diastolic blood pressure, heart rate, respiratory rate,oxygen saturation, temperature are assessed baseline and at least per hour reassessed after starting the dexmedetomidine.
223690169|NCT01076816|PROCEDURE|blood sampling|Blood sampling for pharmacokinetic modelling is limited to a maximum of 1,8 ml/kg (in line with the EMEA guidelines on maximum blood sampling in children). Pharmacokinetic parameters and influence of covariates on these parameters will be assessed by a population pharmacokinetic approach.
223690170|NCT05859555|OTHER|Thematic quality circles - Deprescription|Thematic quality circles on benzodiazepines and analogues with a pharmacist (practical cases)
223690171|NCT00366015|PROCEDURE|Robotic-assisted Coronary Surgical Revascularization|Robotic assistance of coronary artery bypass grafting using the DaVinci surgical robotic console
223690172|NCT00366015|PROCEDURE|PCI- Drug Eluting Stents|Drug eluting stents performed by cardiologist within the same operating theatre following robotic assisted coronary artery bypass surgery
223690173|NCT03026088|DRUG|Bisoprolol|Participants received Bisoprolol orally, once daily at a dose of 1.25 milligram (mg) up to Weeks 3, and then it was up-titrated to 2.5 mg up to Week 6, 3.75 mg up to Week 10, 5 mg up to Week 14, 7.5 mg up to Week 18 and 10 mg up to Week 26.
223690174|NCT03565965|BEHAVIORAL|Experimental training|"Each block of MP consists of 5 mental walking attempts with 10 imagined steps. Participants, seated comfortably, eyes closed, will be asked to imagine themselves walking as of a first-person perspective, without any overt physical movement, in four different conditions: habitual speed, as fast as possible, overcoming obstacles and memorizing a name of a specific medication.~Each block of PP consists of 5 physical walking attempts, with 10 steps. Participants will be asked to walk in 4 different conditions: habitual speed,as fast as possible, overcoming obstacles and memorizing a name of a specific medication."
223690175|NCT03565965|BEHAVIORAL|Control training|"Each block of MP consists of 5 mental walking attempts with 10 imagined steps. Participants, seated comfortably, eyes closed, will be asked to imagine themselves seated appreciating a beautiful landscape as of a first-person perspective, without any overt physical movement, in four different contexts: in a carriage, in a hot air balloon, in a boat and in a zepelin.~Each block of PP consists of 5 physical walking attempts, with 10 steps. Participants will be asked to walk in 4 different conditions: habitual speed,as fast as possible, overcoming obstacles and memorizing a name of a specific medication."
223690176|NCT04949971|BEHAVIORAL|High volume group|Thea High tidal volume of the exposed group was 10ml/kg ideal body weight
223690177|NCT01536288|DRUG|Rhodiola crenulata|Rhodiola crenulata:capsules, 800 mg daily for 7 days before ascent and 2 days during mountaineering
223690178|NCT01536288|DRUG|placebo|Placebo:capsules, 800 mg daily for 7 days before ascent and 2 days during mountaineering
223690179|NCT05162040|DEVICE|Use of PedaleoVR|"All participants must undergo an evaluation of their motor skills through the application of physical assessment metrics performed by the physician. The metrics are the Timed Up-and-Go Test (TUG) and the 6-minute walk test.~Next, they must perform a pedaling exercise on a bicycle or stationary pedaling station synchronizing the physical activity with the visual feedback from the virtual reality application. Two pedalling sets of 10 minutes each are performed, with 5 minutes of rest between sets. Finally, the participant is asked to rate the usability: System Usability Rating Scale (SUS), activity credibility (Credibility and Expectancy Questionnaire, CEQ) and intrinsic motivation (Intrinsic Motivation Inventory, IMI) of the virtual reality application."
223690180|NCT04174950|OTHER|Routine nursing care|routine perioperative nursing intervention, including intensive observation of vital signs, preoperative education, postoperative communication and instruction on diet. NPO after the dinner one day before operation. Patients are instructed to NPO 3 days after surgery and patients should stay on the bed for 3 days. Urinary catheter is always kept for 48 hours or more.
223690181|NCT04174950|OTHER|Perioperative Enhanced Recovery After Surgery (ERAS) Based Nursing Model|Establish ERAS nursing team and formulate ERAS nursing intervention. Nothing by mouth (NPO) 6 hours before operation and no water 4 hours before operation. Patients are given fluid food 24 hours after surgery. Urinary catheter is removed within 24 hours after surgery and encourage patient to mobile 24 hours after surgery. Give support to pain control and psychological support. Intensive observation of vital signs, preoperative education, postoperative communication and instruction on diet were also given to patients.
223690182|NCT01522885|DEVICE|KatGuide versus conventional method (forceps)|According to randomization Chest tubes are placed in the pleural cavity by using the KatGuide device.
223690183|NCT01522885|PROCEDURE|Chest tube insertion|The chest tube is placed in the pleural cavity by using a forceps (conventional method) or KatGuide
223690184|NCT03574480|BEHAVIORAL|Intervention (training in use of a Smartphone application)|The intervention group will be added a training for 3 months in use of a Smartphone application, designed to promote a healthy diet, increased physical acivity and decreased sedentary.
223690185|NCT03574480|BEHAVIORAL|Control (Advice on healthy diet and physical activity recommendations)|Advice on healthy diet and physical activity recommendations
223690186|NCT02769676|OTHER|3-week visit|The intervention will be an additional visit to the usual postpartum care provider at 3-weeks postpartum.
223690187|NCT02769676|OTHER|usual care|Participants in the usual care arm will receive no additional interventions.
223690188|NCT00003930|DRUG|cisplatin|
223690189|NCT00003930|DRUG|gemcitabine hydrochloride|
223690190|NCT00003930|DRUG|paclitaxel|
223690191|NCT00003930|PROCEDURE|conventional surgery|
223690192|NCT00003930|RADIATION|radiation therapy|
223690193|NCT00300118|DRUG|budesonide|9 mg
223690194|NCT00300118|DRUG|mesalazine|4.5 g
223690195|NCT05455762|OTHER|Exercise|The intervention consists of 8 week of combined resistance and aerobic exercise. Patients will exercise 6 days a week;3 days aerobic ones and 3 days resistance ones. The aerobic exercise include 20 minutes of walking divided into three parts. In the first five minute the patients walks slowly to warm up, in the next 10 minutes the patient will speedup to reach the intensity described by the physiotherapist. In the last 5 minutes the patient walks like the first five minutes. The middle 10 minutes may be increased or not based on patient's weekly report. The resistance training consists of 5 exercise; hip abduction, shoulder abduction, bridging, elbow flexion and knee extension. each of these exercises is done in 3 set of 10 repetition with one minute break between each set. Based on patients' weekly report a 0.5 kilogram weight might be added.
223690196|NCT01825603|DRUG|ADH-1|Given IV
223690197|NCT01825603|DRUG|Cisplatin|Given IV
223690198|NCT01825603|DRUG|Gemcitabine Hydrochloride|Given IV
223690199|NCT01825603|OTHER|Laboratory Biomarker Analysis|Correlative studies
223690200|NCT00033072|DRUG|Selegiline|
223690201|NCT03490968|BEHAVIORAL|Supervised Exercise|Subjects will have 3 visits per week for 12 weeks.
223690202|NCT03490968|BEHAVIORAL|Vascular Assessment|"Screen: Subjects will undergo a H\&P, ankle brachial index, ECG, CBC, CMP, lipid panel, HgA1C, and urinalysis. A urine pregnancy test will be performed on women of childbearing age.~Testing Visit 1: MRI, IV in common femoral vein with phlebotomy (60 cc total) before and after sphygmomanometric cuff occlusion of lower limb, 6-minute walk test, 4-meter walk speed test, walking impairment questionnaire, and muscle biopsy.~Supervised exercise and leg revascularization patients will return in 12 weeks and have the same study procedures as testing visit 1, plus an ankle brachial index, repeated."
223690203|NCT03416374|DRUG|Ixazomib|Ixazomib capsules
223690204|NCT03416374|DRUG|Bortezomib|Bortezomib injections
223690205|NCT03416374|DRUG|Carfilzomib|Carfilzomib intravenous infusions
223690206|NCT03416374|DRUG|Lenalidomide|Lenalidomide capsules
223690207|NCT03416374|DRUG|Dexamethasone|Dexamethasone tablets
223690208|NCT05156476|PROCEDURE|Genicular nerve block-iPACK group|Group 1: Genicular nerve block-iPACK group (performed by anaesthesiologist) Method: Ultrasound and nerve stimulation guided injection Drug: a total of 30 ml of ropivacaine 0,5% (150 mg) will be used
223690209|NCT05156476|PROCEDURE|Femoral triangle block-iPACK group|Group 2: Femoral triangle block-iPACK group (performed by anaesthesiologist) Method: Ultrasound and nerve stimulation guided injection Drug: a total of 30 ml of ropivacaine 0,5% (150 mg) will be used
223690210|NCT05156476|PROCEDURE|Local infiltration analgesia|Group 3: LIA (performed by surgeon) Method: Blind injection Drug: a total of 200ml of 0.2% ropivacaine will be used (400mg). Of this, 150ml of ropivacaine 0.2% will be mixed with 1mg of adrenaline.
223690211|NCT04327310|DRUG|Meplazumab for Injection|humanized mAb against CD147
223690212|NCT04327310|DRUG|Sterile normal saline (0.9%)|Sterile normal saline (0.9%)
223690213|NCT02147002|DIETARY_SUPPLEMENT|Gold omega 3|At the beginning and at the end of the observation period, besides the clinical test, some other tests will be carried out: echocardiography, pulse wave velocity (PWV), ambulatory blood pressure monitoring (ABPM). Blood will be collected for laboratory tests such as: lipid profile, uric acid, CRP, BUN, creatinine, morphology, Ca, P, Ca x P, ionogram, xanthine oxidase, MPC1,Omega-3 acids, resolvin and protectins - the metabolites of Omega-3 acids, creatinine excretion, MPC1 excretion and excretion of uric acid.The patients will be treated with Omega-3 acids as a Gold Omega 3 preparation (2x1 capsule where 1 capsule = 1000 mg) for 6 months.
223690214|NCT01052844|DRUG|Placebo|Placebo, given orally Ranitide 50 mg, IV, before chemotherapy (D1) Ondansetron 8 mg, IV, before chemotherapy (D1) Dexamethasone 10 mg, IV, before chemotherapy (D1) Dexamethasone 4 mg, PO, 2x/day (D2, D3)
223690215|NCT01052844|DRUG|Gabapentin|Gabapentin 300mg, orally Ranitide 50 mg, IV, before chemotherapy (D1) Ondansetron 8 mg, IV, before chemotherapy (D1) Dexamethasone 10 mg, IV, before chemotherapy (D1) Dexamethasone 4 mg, PO, 2x/day (D2, D3)
223690216|NCT02647840|BEHAVIORAL|voice therapy|voice therapy based on Estill Voice Model The study will provide primarily direct intervention, i.e. working directly on the voice with voice exercises based on the Estill model of voice. This will be structured and hierarchical. Participants will work through the content one-to-one with the voice specialist SLT at their level and pace, to suit their specific vocal needs, again reflecting current clinical practice. Participants may need fewer or more than four sessions to gain the required skills. Should patients need more than six session of voice therapy to recover their voice fully, final assessment for the study purposes will be taken at session 6, and voice therapy will continue as required.
223690217|NCT06175975|OTHER|The effect of placing the auricle position on the measurement values and comfort in measurements made with a tympanic membrane thermometer|The effect of placing the auricle position on the measurement values and comfort in measurements made with a tympanic membrane thermometer
223690218|NCT06081400|PROCEDURE|Cryoablation|Percutaneous imaging-guided cryoablation
223690219|NCT06081400|DRUG|Chemotherapy drug|"Either :~methotrexate 30mg/m² + vinblastine 6mg/m² (IV infusion) once/week for 6 months, then every other week from months 7 to 12, or vinorelbine 90mg/week (per os: 3x30mg, soft capsules) for 12 months."
223690220|NCT01222858|BEHAVIORAL|Diet and Activity Education|Education about behavioral modification of eating and activity habits for weight loss.
223690221|NCT01222858|BEHAVIORAL|Self-monitoring with Feedback|Participants self-monitor diet and activity behaviors, which are submitted via a website. Automated feedback on the self-monitoring record is provided to participants.
223690222|NCT01240876|DRUG|CEP-37247|0.5-, 1-, 3-, 6-, and 12-mg doses of CEP-37247 will be administered by the transforaminal epidural route.
223690223|NCT01240876|DRUG|Placebo|Matching placebo vials will be filled with the buffered solution for CEP-37247.
223690224|NCT00455767|DRUG|EPI-hNE4|I.V. injection of 1mg/kg Depelestat (EPI-hNE4) 3 times daily for 7 days
223690225|NCT00455767|DRUG|Placebo|Placebo
223690226|NCT04134702|OTHER|Acupuncture|Acupuncture and ear acupuncture using indwelling fixed needles, that will remained in situ several days after surgery until the patients will experience pain
223690227|NCT02005432|DRUG|Intravitreal Ranibizumabe|Intravitreal injection 0,05ml Ranibizumabe
223690228|NCT02005432|DRUG|panfotocoagulation (PASCAL)|
223690229|NCT02005432|DRUG|panfotocoagulation (PRP) single shoot (ETDRS)|
223690230|NCT00931736|DRUG|Isoniazid|The dosage of the medication is determined according to the weight of the subject. The dose is once per day, in pill format, for a total daily dose of 300mg if subject weighs ≥ 42 kg, otherwise 200 mg. Total duration of treatment is for 9 months.
223690231|NCT00931736|DRUG|Rifampin|The dosage of the medication is determined according to the weight of the subject. The dose is once per day, in pill format, for a total daily dose of 600 mg if the subject weighs ≥ 50 kg, 450 mg if the subject weighs ≥ 36 kg and \< 50 kg, otherwise 300 mg for those weighing \< 36 kg. Total duration of treatment is for 4 months.
223690232|NCT04378907|OTHER|ECIG Lab Session, 30 watts|During each session, participants will first complete a 10-puff product use bout, and then a 90-minute ad lib product use bout.
223690233|NCT00454701|DRUG|Alefacept exposure|Observational
223690234|NCT04953299|BEHAVIORAL|Functional Imagery training|Behavioural intervention focused upon motivation and reaching achievable goals.
223690235|NCT04953299|BEHAVIORAL|NHS 12 week weight loss programme|The plan is designed to help individuals lose weight at a safe rate of 0.5kg to 1kg (1lb to 2lb) each week by sticking to a daily calorie allowance and introducing exercise.
223690236|NCT01542073|DRUG|68Ga-BNOTA-PRGD2|Intravenous injection of one dosage of 111 MBq 68Ga-BNOTA-PRGD2. Tracer doses of 68Ga-BNOTA-PRGD2 will be used to image angiogenesis of myocardial infarction area by positron emission tomography / computed tomography (PET/CT)
223690237|NCT05922956|OTHER|Facial emotion recognition test|Facial emotion recognition test (TREF), questionnaires including self-administered questionnaires
223690238|NCT03583164|DRUG|Olorofim|30mg oral tablets
223690239|NCT02822391|OTHER|observation|
223690240|NCT02900001|PROCEDURE|early coronary angiography|Routine coronary angiography and revascularization if appropriate within 24 hours
223690241|NCT02900001|PROCEDURE|delayed coronary angiography|Routine coronary angiography and revascularization if appropriate after 72 hours
223690242|NCT03603054|OTHER|Active neck mobilization|The subjects, receive an active neck mobilization intervention.
223690243|NCT03603054|OTHER|Active Mobilization of the sciatic nerve|The subjects, receive an active sciatic nerve mobilization intervention.
223690244|NCT04659239|BIOLOGICAL|Inactivated SARS-CoV-2 Vaccine (Vero cell)|The inactivated SARS-CoV-2 vaccine (vero cell) was manufactured by IMBCAMS. Each dose of 0.5ml is for per person per time use.
223690245|NCT04659239|BIOLOGICAL|Placebo|The placebo was manufactured by IMBCAMS. Each dose of 0.5ml is for per person per time use.
223690246|NCT02764125|DRUG|Stalevo|levodopa/carbidopa/entacapone
223690247|NCT02764125|DRUG|levodopa MR|levodopa MR/carbidopa/ODM-104
223690248|NCT02144129|OTHER|active Whole Body Electromyostimulation|
223690249|NCT02144129|OTHER|Passive WB-EMS|
223690250|NCT02144129|DEVICE|WB-EMS application|
223690251|NCT04327960|DIAGNOSTIC_TEST|Cardiac troponin (cTn)|Cardiac troponin (cTn) will be measured with the Dimension RxL-HM analyzer .The one-step enzyme immunoassay is based on cTn specific monoclonal antibodies, performed on a separate module of the analyzer, assay-time is 17 minutes.
223690252|NCT01727843|DRUG|Tranexamic Acid|drug and placebo applied topically at end of surgery at hip site.
223690253|NCT01727843|OTHER|placebo|applied topically to surgical site in OR.
223690254|NCT05695300|DIETARY_SUPPLEMENT|BLM ORGANIC GOLD+|Participants in this arm need to be fed the assigned infant formula daily for three months, no other formula or breast milk
223690255|NCT05695300|DIETARY_SUPPLEMENT|BLM ORGANIC|Participants in this arm need to be fed the assigned infant formula daily for three months,no other formula or breast milk
223690256|NCT05695300|DIETARY_SUPPLEMENT|Breast milk|Participants in this arm need to be fed with breast milk daily for three months, no infant formula
223690257|NCT04661020|DRUG|CD19 CAR-T cells|Each subject receive CD19 CAR T-cells by intravenous infusion
223690258|NCT03537612|DRUG|Clonidine|Intrathecal Clonidine 1 mcg/kg (up to 75 mcg) immediatey post-op; 100 mcg capsule TID Post op day 1-5 (liquid version available if subject cannot swallow capsule)
223690259|NCT03537612|OTHER|Morphine|Intrathecal spinal morphine (5 mcg / kg) immediatey post-op; Placebo capsule TID Post op day 1-5 (liquid version available if subject cannot swallow capsule)
223690260|NCT03819426|BEHAVIORAL|Low Intensity Exercise Intervention|Those in the walking intervention will be instructed to take walks below a brisk pace (low intensity) to improve mood
223690261|NCT03819426|BEHAVIORAL|High Intensity Intervention|Instructed in high intensity interval training techniques and will be provided videos to follow for implementation of intervention at home that will include short bursts of high energy
223690262|NCT02797015|DRUG|RPC1063|Oral capsule daily
223690263|NCT03600298|OTHER|Simulation|Intervention phase: Study participants will be subjected to on-site simulation training focusing on communication, including CRM and non-technical skills in the PICU setting.
223690264|NCT01994928|DEVICE|Nose-mouth mask|Preoxygenation using a nose-mouth mask.
223690265|NCT01994928|DEVICE|High flow nasal cannula oxygen|Preoxygenation using high flow nasal cannula oxygen.
223690266|NCT01994928|PROCEDURE|Intubation|Intubation
223690267|NCT00559754|DRUG|bevacizumab [Avastin]|15mg/kg iv on day 1 of each 3 week cycle
223690268|NCT00559754|DRUG|Docetaxel|75mg/m2 iv on day 1 of each 3 week cycle
223776569|NCT04614428|BEHAVIORAL|RESILIENCE Program|"In addition to the standard care participants would normally receive (including exposure to any standard hospital avoidance programs), the 150 participants assigned to the RESILIENCE Program group will receive a combination of strategies designed to promote seasonal resilience.~This includes profiling of seasonal vulnerability; a 60-80 minute home visit by the RESILIENCE Nurse to assess physiological status, behavioural adaptations, environment, and modulating factors; a dedicated RESILIENCE Clinic with a dedicated RESILIENCE physician to develop a long-term plan to help promote/maintain seasonal resilience and; a structured follow-up over the next 12 months to monitor and adjust the participant's status and management from a seasonal perspective."
223776570|NCT01047683|DRUG|AMR101 (ethyl icosapentate) - 4 g/day|AMR101 (ethyl icosapentate) 4 capsules/day for 12 weeks (Weeks 1-12)
223690269|NCT00559754|DRUG|Standard chemotherapy|As prescribed
223690270|NCT06219694|DEVICE|Laser Acupuncture|Laser stimulation energy of 4.5 J for 30 seconds at each of the following acupoints: bilateral Cuanzhu (BL2), Fengchi (GB20), Taiyang (EX-HN5), Shuaigu (GB8), Hegu (LI4), Taichong (LR3) and midline Yintang (EX-HN3)
223690271|NCT06219694|DEVICE|Sham|"Sham treatment with no laser output, stimulate the same acupoints as laser acupuncture group as follows: 30 seconds at bilateral Cuanzhu (BL2), Fengchi (GB20), Taiyang (EX-HN5), Shuaigu (GB8), Hegu (LI4), Taichong (LR3) and midline Yintang (EX-HN3)~After \> 6 months followed up, the sham group received truely Laser stimulation energy of 4.5 J for 30 seconds at each of the following acupoints: bilateral Cuanzhu (BL2), Fengchi (GB20), Taiyang (EX-HN5), Shuaigu (GB8), Hegu (LI4), Taichong (LR3) and midline Yintang (EX-HN3), and followed up for another 3 months."
223690272|NCT05839483|DIAGNOSTIC_TEST|CXCR4|Participants diagnosed with PA will be asked to be scanned by 68Ga-PentixaFor PET imaging.
223690273|NCT00315146|DRUG|Pioglitazone|
223776571|NCT01047683|DRUG|AMR101 (ethyl icosapentate) - 2 g/day|AMR101 (ethyl icosapentate) 2 capsules/day with placebo 2 capsules/day for 12 weeks (Weeks 1-12)
223690274|NCT00315146|BEHAVIORAL|Resistance exercise training to maximize muscle power|
223776572|NCT01047683|DRUG|Placebo|Placebo 4 capsules/day for 12 weeks (Weeks 1-12)
223776573|NCT06396728|DIETARY_SUPPLEMENT|GI BIOTICS 100B UFC|Consumption of GI BIOTICS 100B UFC.
223690275|NCT00315146|BEHAVIORAL|Hypocaloric diet|
223690276|NCT00315146|DRUG|Placebo|
223690277|NCT02830061|OTHER|Interviews|Individual semi-structured interviews for 30-60 minutes using an interview schedule developed from an interpretative phenomenological analysis framework.
223690278|NCT04863547|OTHER|Data collection|Data collection
223690279|NCT02334631|DRUG|High Volume Simethicone|High volume simethicone is defined as 1125 mg simethicone in 750 ml of water (1.5 mg/ml).
223690280|NCT02334631|DRUG|Standard Volume Simethicone|Standard volume simethicone is defined as 300 mg simethicone in 200 ml of water (1.5 mg/ml).
223690281|NCT05179850|DIAGNOSTIC_TEST|Radiomic Algorithm|Different radiomic, machine learning, and deep learning strategies for radiomic features extraction, sorting features and model constriction.
223776574|NCT06396728|DIETARY_SUPPLEMENT|Placebo Consumption|Consumption of a placebo capsule.
223776575|NCT05497908|PROCEDURE|TAP block via lateral approach|TAP block via lateral approach
223776576|NCT05497908|PROCEDURE|TAP block via posterior approach|TAP block via posterior approach
223776577|NCT01831687|DRUG|Etodolac Extended Release Tablets USP 600mg|Etodolac Extended Release Tablets USP 600mg once a day
223776578|NCT01831687|DRUG|Etodolac Extended Release Tablets 600mg|Etodolac Extended Release Tablets 600mg once a day
223776579|NCT00922610|DRUG|methoxy polyethylene glycol-epoetin beta [Mircera]|sc every 2 weeks at a starting dose of 0.6micrograms/kg;subsequently every 4 weeks
223776580|NCT02755493|BEHAVIORAL|Sleep deprivation|
223776581|NCT02566837|PROCEDURE|Ultrasound|ultrasound imaging to guide the intramuscular injections of botulinum toxin : Ultrasound is used to identify the target muscle, and for guiding the insertion of the needle in the muscle. Once the needle is positioned, the botulinum toxin is injected
223776582|NCT02566837|PROCEDURE|electrical stimulation|electrical stimulation (reference technique currently recommended over muscle palpation and anatomical landmarks) to guide intramuscular injections of botulinum toxin. Intramuscular injection is carried out in register with the zone where is located the theoretically target muscle. Electrical stimulation (mediated by the tip of the needle) used to verify the correct position of the needle, and reposition it if necessary. Once the needle is correctly positioned, the botulinum toxin is injected.
223776583|NCT06216236|OTHER|Kinect intervention system combined with aerobic exercise training|A Kinect intervention system was used in the experimental group. The video displayed a skeletal simulation of the action. The participants could see their own actions and those of the teacher. After the video was completed, an accurate score for each action was displayed.
223776584|NCT06216236|OTHER|aerobic dance training|The control group used a video that did not show a skeletal simulation of the action and only saw the teachers movements.
223776585|NCT05410912|PROCEDURE|Great saphenous vein stripping and ambulatory phlebectomy|All patients included in the study were treated with great saphenous vein stripping and ambulatory phlebectomy.
223776586|NCT04627727|OTHER|low FODMAP diet|low FODMAP diet
223776587|NCT05500976|OTHER|Semi-controlled dietary intervention - Western|Participants will complete a 2-week washout prior to a 16-week randomized, crossover semi-controlled feeding study of mini-MED vs Western diet. Each diet intervention will last four weeks, with 500 kcal/day of target Western diet foods (eg, beef, potatoes, bread, sour cream) provided during each intervention and will be repeated twice.
223776588|NCT05500976|OTHER|Semi-controlled dietary intervention - MiniMed|Participants will complete a 2-week washout prior to a 16-week randomized, crossover semi-controlled feeding study of mini-MED vs Western diet. Each diet intervention will last four weeks, with 500 kcal/day of target Mediterranean foods (eg, oatmeal, salmon, nuts, basil, olive oil, fruits) provided during each intervention and will be repeated twice.
223776589|NCT06515860|DIAGNOSTIC_TEST|Liquid biopsy for MPNST development|Participants will be asked to complete a blood sample (liquid biopsy) at baseline (15 mL, approximately 1 tablespoon) and every 6 months (10 mL) for the five-year follow-up period.
223690282|NCT03325699|DEVICE|SMART4MD Health Application|"SMART4MD is a general health application which has been adapted specifically for people with mild dementia through a structured process. The application is intended to be used daily at home, mainly by the participants themselves, with the help of their informal carers. The application is optimized for tablet devices running on Android operating system (OS). Participants will be provided with a tablet with the SMART4MD health application.~The core functionalities of the application are based on reminders (medication, appointments with healthcare providers), brain supporting activities (clock, calendar, brain games, photos) and optional status and health information sharing with family and informal carers (including daily feeling status, specific health problems, and quality of life). An important feature of SMART4MD is its personalization facility: main users (PWD and informal carers) will be able to switch off/on various features and information sharing possibilities."
223690283|NCT00415350|DRUG|Azithromycin|Azithromycin Tablet 250 mg daily
223690284|NCT00415350|OTHER|Placebo|Placebo tablet 1 daily
223776590|NCT06073405|DEVICE|Colonic Polyp Measurement Assessment Via Artificial Intelligence|In this study, we collect colonoscopy video clips of polyps and, among the related clinical information, their estimated size using the gold standard technique, and we use them offline to evaluate the measurement performances of the novel virtual polyp sizing tool
223776591|NCT05305313|DRUG|Propofol|Propofol delivery will be controlled using automated closed loop anaesthesia delivery system which will control propofol delivery rate to consistent anaesthetic depth (BIS-50) feedback from the patient.
223776592|NCT05305313|DRUG|Propofol|Propofol delivery will be controlled using automated closed loop anaesthesia delivery system which will control propofol delivery rate to consistent anaesthetic depth (BIS-50) feedback from the patient.
223776596|NCT05038488|DRUG|MIB-626|Fifty participants will be randomized, stratified by sex, remdesivir use, and trial site, in a 3:2 ratio to receive either MIB-626 1.0 g orally or matching placebo twice daily for 14 days.
223690285|NCT00009061|DRUG|Ritonavir|
223690286|NCT00009061|DRUG|Abacavir sulfate|
223690287|NCT00009061|DRUG|Nelfinavir mesylate|
223776597|NCT05038488|DRUG|Placebo|Subjects will be randomized to receive either the placebo or 1000-mg MIB-626 twice daily orally.
223776598|NCT05038488|OTHER|Home Treatment|Participants, who are discharged from the hospital before the completion of the 14-day intervention period, will be provided sufficient study medication to take home with them so they can continue to take the medication twice daily for the remaining duration of the 14-day intervention period.
223690288|NCT00009061|DRUG|Lamivudine|
223776599|NCT02700230|PROCEDURE|Computed Tomography|Undergo CT scan
223776600|NCT02700230|OTHER|Laboratory Biomarker Analysis|Correlative studies
223776601|NCT02700230|BIOLOGICAL|Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter|Given intratumorally
223776602|NCT02700230|OTHER|Quality-of-Life Assessment|Ancillary studies
223776603|NCT02700230|PROCEDURE|Single Photon Emission Computed Tomography|Undergo SPECT imaging
223690289|NCT00009061|DRUG|GW433908|
223690290|NCT00214500|DRUG|migalastat HCl|
223690291|NCT05095831|DIAGNOSTIC_TEST|Pancreas EUS shear wave|"EUS Shear wave elastography (SWE) is a form of ultrasound elastography used in transabdominal ultrasonography. It measures tissue elasticity by generating shear waves inside the organ using the acoustic radiation force impulse (ARFI). The ultrasound machine monitors shear wave propagation and measures the velocity. The shear wave velocity, displayed in kilopascals \[kPa\] or meters per second. Also, the dispersion slope or ultrasound shear wave dispersion (SWD) will be recorded. It is the measure of viscosity \[(m/sec)/kHz\] using SWE.~A first endoscopist will perform EUS over pancreas tissue. Without any elastography assessment (strain ratio/histogram) , the endoscopist will take ten shear wave measurements of pancreas tissue elasticity by generating shear waves inside the pancreas using the ARFI."
223776604|NCT02700230|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223776605|NCT02700230|PROCEDURE|Ultrasound Imaging|Undergo ultrasound imaging
223776606|NCT02700230|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223776607|NCT02700230|PROCEDURE|Biopsy|Undergo tissue biopsy
223776608|NCT02700230|OTHER|Questionnaire Administration|Ancillary studies
223776609|NCT05505981|OTHER|Immediate PT|Patients will start PT immediately
223776610|NCT05505981|OTHER|Rest until pain resolves|Patients will wait to start PT until their pain resolves
223690292|NCT05095831|DIAGNOSTIC_TEST|Pancreas EUS-elastography and EUS-guided biopsy|"Pancreas EUS-elastography measures the pancreatic tissue stiffness through strain ratio (SR) and strain histogram (SH).~A second endoscopist blind to pancreas tissue shear wave findings will perform EUS-elastography with corresponding SR and SH measurements. The SR/SH will be measured and documented. Finally, a pancreas tissue biopsy will be performed. The impossibility of biopsy is an exclusion criterion (except in control patients). Due to ethical purposes, a biopsy will not be performed on patients from the control group."
223690293|NCT05160610|BEHAVIORAL|Multilevel intervention|Multilevel intervention based on AACTT theory
223690294|NCT03601000|DRUG|Yi-Zhi-An-Shen|Yi-Zhi-An-Shen Granules 5g given three times a day for up to 16 weeks.
223690295|NCT03601000|DRUG|Placebo|Placebo granules 5g given three times a day for up to 16 weeks.
223690296|NCT03149393|DRUG|Qizhi Weitong Granules|Patients in this group will take Qizhi Weitong Granules 2.5g,3 times/day,30 minutes before dinner for 8 weeks.
223776611|NCT05547464|BIOLOGICAL|BNT164a1|Multi-antigen ribonucleic acid (RNA) vaccine for active immunization against tuberculosis administered as intramuscular injection
223690297|NCT03149393|DRUG|Mosapride Citrate Tablets|Patients in this group will take mosapride citrate tablets 5mg,3 times/day,30 minutes before dinner for 8 weeks.
223690298|NCT04795986|PROCEDURE|HEARO Procedure|robotic access to the middle and inner ear in cochlear implantation
223690299|NCT03376048|PROCEDURE|Wound infiltration plus TAP|"1. TAP block: At the beginning of the main surgical procedure the surgeon will perform a TAP with ropivacaine infiltration, bilaterally in the anterior axillary line, between the costal margin and iliac crest in the intermuscular plane between the internal oblique and transversus abdominis muscles, the anesthesiologist under ultrasound guidance, the surgeon under laparoscopic guidance (two pops technique).~2. Wound infiltration : Wound infiltration of ropivacaine will be performed by the surgeon before skin incision."
223776612|NCT05547464|BIOLOGICAL|BNT164b1|Multi-antigen RNA vaccine for active immunization against tuberculosis administered as intramuscular injection
223776613|NCT05547464|OTHER|Placebo|Placebo
223776614|NCT00548782|OTHER|Paleolithic diet|diet
223690300|NCT03376048|PROCEDURE|Wound infiltration|Wound infiltration of ropivacaine will be performed by the surgeon before skin incision.
223690301|NCT03368248|OTHER|Survey|A survey was conducted among all professionals in neonatal resuscitation services : doctors (senior and intern), paramedics (managers, pediatric nurses, auxiliaries and nurses, psychomotor therapists) and psychologists. The survey was based on a questionnaire, which was offered to all professionals, both medical and non-medical. All questions were closed, and a free comment area was proposed at the end. The questionnaire was preceded by a comment recalling the objectives of the study, the voluntary and individual nature of participation, and insisted on respect for anonymity. It consisted of 49 questions, allowing 197 possible answers. For most questions, several answers could be chosen.
223690302|NCT00701376|OTHER|liver biopsy|Subjects undergoing laparoscopic gastric surgery will be evaluated for liver function by comparing liver tissue biopsied during surgery with tissue biopsied after 60% weight loss
223690303|NCT02537574|DRUG|NTX/BUP|Daily doses
223690304|NCT02537574|DRUG|NTX/PBO-B|Daily doses
223690305|NCT02537574|DRUG|PBO-N/PBO-B|Daily doses
223690306|NCT02663687|DRUG|Recombinant human C1 esterase inhibitor|Subjects will receive escalating doses I-IV as both IV and SC injections
223690307|NCT02663687|DRUG|Placebo|Subjects will receive matching placebo
223690308|NCT02663687|DRUG|SHP623|SHP623
223690309|NCT02663687|DRUG|Placebo|Placebo
223690310|NCT05774977|OTHER|Aviation Noise Only (AN)|The aviation noise (AN) night will expose subjects to a pre-programmed recording of aviation noise during sleep from 2300-0700.
223690311|NCT05774977|OTHER|Pink noise, 50 dBA only (BN50)|The BN50 night will consist of exposure to continuous pink noise throughout the sleep period at a level of 50 A-weighted decibels (dBA).
223690312|NCT05774977|OTHER|Aviation noise plus earplugs (AN+EP)|The AN + EP night will consist of the aviation noise (AN) exposure with the addition of wearing earplugs overnight.
223776615|NCT00548782|OTHER|ADA ( American Diabetes Association) recommended diet|diet
223835683|NCT06084429|OTHER|pre and post test (health educational intervention)|"The health education will be provided the following sessions.~Introduction to Global and Bangladesh Health, Health Information access (Validity), Critical Values (Vital signs, BMI, RBS etc.), Emergency Management (burn, chocking, knife cut, fainting etc.), Food (classification, healthy food, unhealthy, food label, salt intake) (NCDs from unhealthy diet), Smoking and Alcohol (NCD related, substance abuse, secondhand smoking), Physical activity (Benefits, sedentary lifestyle, NCD related), Women's health (menstruation, menstrual cycle, hygiene, STD, contraception), Hygiene (water, food, brushing, bath, toileting, healthy habits), Environmental Sanitation and Communicable disease (clean, effects on health), and Women's health and societal contribution"
223690313|NCT05774977|OTHER|Aviation noise plus white noise 40 dBA (AN+BN40)|The AN + BN40 night will consist of the aviation noise (AN) exposure with the addition of continuous pink noise throughout the sleep period at a level of 40 dBA.
223690314|NCT05774977|OTHER|Aviation noise plus white noise 50 dBA (AN+BN50)|The AN + BN50 night will consist of the aviation noise (AN) exposure with the addition of continuous pink noise throughout the sleep period at a level of 50 dBA.
223690315|NCT05774977|OTHER|Control Night (CTRL)|Control night (CTRL) without noise exposure and without earplugs.
223690316|NCT04807478|DRUG|Omegaven® (fish oil triglycerides) Injectable Emulsion|Dose, frequency and duration is a decision of the Investigator
223690317|NCT06556264|DRUG|Dupilumab|Dupilumab 300mg every 2 weeks for 24 weeks
223690318|NCT06556264|OTHER|Placebo|Placebo 300mg every 2 weeks for 24 weeks
223690319|NCT02297282|BEHAVIORAL|Behavioural Activation (BA)|Behavioural activation is a therapy, which has been shown to be quite effective in the treatment of depression. Originally a component of cognitive therapy, behavioural activation is the use of strategies such as activity scheduling, master/pleasure ratings, and graded task assignments to change one's perception of specific situations. It involves the use of activities to improve life situations or depressed mood.
223690320|NCT01424202|DEVICE|Mechanical Insufflation Exsufflation|"After passing the SBT and randomized to group B, before extubation, all patients were submitted to a treatment of MI-E (3 sessions) through the endotracheal tube with pressures set at 40 cm H2O for insufflation and -40 cm H2O for exsufflation pressure. An insufflation/exsufflation time ratio of 3secs/2 secs and a pause of 3 sec between each cycle was used. Eight cycles were applied in every session with an abdominal thrust timed to the exsufflation cycle.~On top of the standard medical therapy, during the first 48 hours post extubation, each patient received 3 daily treatments by means of a light-weight, elastic oronasal mask. Treatments (3 sessions each) were divided between morning, afternoon and night, making a total of 9 daily sessions.~The daily treatment frequency and its outcomes were recorded in a diary by the nursing staff. All MI-E treatments were administered by a trained respiratory therapist, ICU physician or nurse."
223690321|NCT02492581|DRUG|Nalmefene|No intervention on the use of Selincro. The physician will prescribe Selincro following its usual practice.
223690322|NCT04394182|RADIATION|Ultra-Low-dose radiotherapy|The total dose to be administered was 0.8 Gy in an only single session including both whole-lungs extended 1cm isometric in all directions.
223690323|NCT04394182|DEVICE|ventilatory support with oxygen therapy|Oxygen Therapy: Nasal Cannula (NC); Ventimask (VMK) or VMK with reservoir
223690324|NCT04394182|DRUG|Lopinavir/ritonavir|100/400 mg/12h; 7-10 days
223690325|NCT04394182|DRUG|Hydroxychloroquine|200 mg/12h
223690326|NCT04394182|DRUG|Azithromycin|500 mg/24h, 3 days
223690327|NCT04394182|DRUG|Piperacillin/tazobactam|4 g / 0.5 g administered every 6-8 hours through a vein (directly into the bloodstream), for 5-14 days. Adjustment to kidney function
223690328|NCT04394182|DRUG|Low molecular weight heparin|prophylactic doses
223690329|NCT04394182|DRUG|Corticosteroid injection|250mg x 3 boluses
223690330|NCT04394182|DRUG|Tocilizumab|600mg single dose
223690331|NCT05648071|DRUG|Sintilimab|The specific treatment regimen is as follows :Non-squamous NSCLC: Sintilimab (200 mg) plus Bevacizumab (7.5mg/kg) is started on the first day of each treatment cycle and administered every three weeks. Nedaplatin (80-100 mg/m2) (d2) +pemetrexed 500 mg/m2 (d2) Q3W is administered in this regimen for 4 cycles followed by sintilimab plus Bevacizumab until disease progression or intolerable toxicity.
223690332|NCT03220529|DEVICE|Brillouin Ocular Scanner|
223690333|NCT03595774|DIETARY_SUPPLEMENT|Beet root juice|Beet root juice
223690334|NCT00112697|DRUG|cisplatin|
223690335|NCT00112697|DRUG|docetaxel|
223690336|NCT00112697|DRUG|fluorouracil|
223690337|NCT00112697|RADIATION|radiation therapy|
223690338|NCT02891005|DEVICE|paclitaxel controlled release balloon catheter (VasoguardTM)|paclitaxel controlled release balloon catheter implantation for small vessel lesion
223690339|NCT02891005|DEVICE|common balloon catheter (Maverick2)|common balloon catheter implantation for small vessel lesion
223690340|NCT02770261|DRUG|DP-R208|DP-R208 + Candesartan 32mg placebo + Rosuvastatin 20mg placebo
223690341|NCT02770261|DRUG|Candesartan32mg|DP-R208 placebo + Candesartan 32mg + Rosuvastatin 20mg placebo
223690342|NCT02770261|DRUG|Rosuvastatin 20mg|DP-R208 placebo + Candesartan 32mg placebo + Rosuvastatin 20mg
223690343|NCT02770261|DRUG|DP-R208 Placebo|DP-R208 placebo + Candesartan 32mg placebo + Rosuvastatin 20mg
223690344|NCT02770261|DRUG|Candesartan32mg Placebo|DP-R208 placebo + Candesartan 32mg placebo + Rosuvastatin 20mg
223690345|NCT02770261|DRUG|Rosuvastatin 20mg Placebo|DP-R208 placebo + Candesartan 32mg + Rosuvastatin 20mg placebo
223690346|NCT03924531|BEHAVIORAL|Mindful Awareness Program|2-hour mindfulness training for 6 weeks.
223690347|NCT03924531|BEHAVIORAL|Health Promotion Program|Health Promotion Program
223690348|NCT00688727|BEHAVIORAL|CBT|CBT, up to 12 sessions.
223690349|NCT00688727|BEHAVIORAL|Standard Care|Routine review by neuropsychiatrist in outpatient clinic
223690350|NCT00117286|DRUG|Degarelix|Drug supplied as a powder to be dissolved in the solvent for solution for injection. Degarelix given by subcutaneous injection every 28 days until the end of the study.
223690351|NCT02351986|PROCEDURE|physical therapy|A 20 minutes ice pack cryotherapy applied for 4 consecutive days
223690352|NCT02351986|OTHER|ice pack|
223690353|NCT01272284|DEVICE|Altis® Single Incision Sling System (SIS)|The Altis® SIS is a permanently implantable synthetic sling for females placed at the mid-urethra to provide a scaffold for tissue in-growth and support for stress urinary incontinence.
223690354|NCT00048061|DRUG|Ibandronate [Bonviva/Boniva]|2.5mg po daily
223690355|NCT00048061|DRUG|Ibandronate [Bonviva/Boniva]|100mg po monthly on a single day
223690356|NCT00048061|DRUG|Ibandronate [Bonviva/Boniva]|100mg po monthly over 2 consecutive days
223690357|NCT00048061|DRUG|Ibandronate [Bonviva/Boniva]|150mg po monthly
223690358|NCT00048061|DIETARY_SUPPLEMENT|Calcium|500 mg/day
223690359|NCT00048061|DIETARY_SUPPLEMENT|Vitamin D|400 IU/day
223690360|NCT05102695|DIAGNOSTIC_TEST|Serum CRP , ferritine and d-dimer|Correlation between the results of the tests with outcome of the patient
223690361|NCT04152707|DEVICE|Splendor X|The Splendor X has two wavelengths in one system: Nd:YAG (1064nm) and Alexandrite (755nm).
223690362|NCT03555435|OTHER|Moving Forward On Your Own|Participants in this group will use the online program on their own for 6 weeks.
223690363|NCT03555435|BEHAVIORAL|Moving Forward with Peer Support|Participants in this group will use the online program on their own for 6 weeks with the support of a peer coach. Peer coaching sessions will consist of 6 15-20 minute sessions one time per week. Sessions will be guided by a Moving Forward Peer Support Manual.
223690364|NCT03555435|BEHAVIORAL|Wait|Participants in this group will wait 6 weeks.
223690365|NCT02758756|OTHER|Massage|Treatments will be on a massage table and last up to 75 minutes. We do not specify what will occur during the massage treatments. Instead we will follow the model of relying on the professional expertise of the therapist in combination with input from the client to determine what should happen in the session. We specify that energy healing techniques not be used, because that is our research comparison condition. We also specify that conversation between the massage therapist and the patient be kept to the minimum necessary to effectively provide the treatment. This is not meant to be talk therapy.
223690366|NCT02758756|OTHER|Reiki|Reiki treatments will be provided by Reiki Masters on a massage table and last up to 75 minutes. We will not specify what will occur during the Reiki treatments. Instead we will follow the model of relying on the professional expertise of the therapist in combination with input from the client to determine what should happen in the session. That being said, we will ask that two specific things be kept to a minimum. The first is that we ask that Swedish massage techniques not be used, because that is our research comparison condition. The second is that conversation between the massage therapist and the patient be kept to the minimum necessary to effectively provide the treatment. This is not meant to be talk therapy.
223835684|NCT05216666|PROCEDURE|Lateral approach|Total hip arthroplasty performed through a lateral surgical approach (Gammer)
223690367|NCT00348244|DRUG|Ketorolac, Prednisolone Acetate|
223690368|NCT05315856|BIOLOGICAL|either BNT162b2 or ChAdOx1 vaccine|Either BNT162b2 or ChAdOx1 was assigned to each participant by the Korean governmental policy, not allowing personal choice. Sixty participants were vaccinated with two doses of the ChAdOx1 (AstraZeneca) at 12-week intervals, and the remaining sixty were immunized with the BNT162b2 (Pfizer-BioNTech) vaccine at 3-week interval.
223690369|NCT03751228|DRUG|BMS-986165|Swish and expectorate after tasting
223690370|NCT03751228|DRUG|Active Pharmaceutical Ingredient|Swish and expectorate after tasting
223690371|NCT01323946|BIOLOGICAL|GSK Biologicals' investigational vaccine GSK1562902A|Three intramuscular injections
223690372|NCT03300310|OTHER|nursing visit|nursing visit at patient home
223690373|NCT03300310|OTHER|no nursing visit|the patient take his treatment without nursing visit
223690374|NCT00992927|PROCEDURE|Capsule-Preserving Intra-articular Hydraulic Distension|Capsule-Preserving Intra-articular Hydraulic Distension (CPIHD) infuses as much volume as possible during the distension without rupturing the capsule.
223690375|NCT00992927|PROCEDURE|Capsule-Rupturing Intra-articular Hydraulic Distension|Capsule-Rupturing Intra-articular Hydraulic Distension (CRIHD) infuses fluid into the joint space until the rupture of the capsule is observed.
223690376|NCT03543618|DEVICE|Sloped|Placement of implant with sloped design
223690377|NCT03543618|DEVICE|Control|Placement of implant with conventional design
223690378|NCT04005170|DRUG|Toripalimab|Patients received toripalimab 240 mg on days 1 and 22 during radiotherapy followed by a maintenance phase of toripalimab IV 240 mg every 3 weeks for up to 1 year.
223690379|NCT04005170|DRUG|Paclitaxel/Cisplatin|Patients received 5 cycles of paclitaxel/cisplatin (paclitaxel 50mg/m2 and cisplatin 25 mg/m2) on days 1, 8, 15, 22, 29 during radiotherapy.
223690380|NCT04005170|RADIATION|Intensity-modulated radiotherapy|All patients received external-beam radiation using intensity-modulated radiotherapy. The prescribed dose is 50.4 Gy in 28 fractions over 5-6 weeks.
223690381|NCT00666796|DRUG|Placebo ethanol|Matched placebo ethanol 0.4% in a total volume of 300 mL as an orange juice cocktail (consumed within 15 minutes) at 1 hour prior to assessment timepoint
223690382|NCT00666796|DRUG|Ethanol|Ethanol 0.7 g/kg in a total volume of 300 mL as an orange juice cocktail (consumed within 15 minutes) at 1 hour prior to assessment timepoint
223690383|NCT00666796|DRUG|Placebo|Matched placebo oral capsule with 8 oz of water 2 hours prior to assessment timepoint
223690384|NCT00666796|DRUG|Gabapentin|Gabapentin 500 mg oral capsule with 8 oz of water 2 hours prior to assessment timepoint
223690385|NCT00666796|DRUG|Ethanol|Ethanol 0.7 g/kg in a total volume of 300 mL as an orange juice cocktail (consumed within 15 minutes) at 1 hour prior to assessment timepoint
223690386|NCT00666796|DRUG|Placebo|Matched placebo oral capsule with 8 oz of water 2 hours prior to assessment timepoint
223690387|NCT00666796|DRUG|Gabapentin|Gabapentin 500 mg oral capsule with 8 oz of water 2 hours prior to assessment timepoint
223690388|NCT00666796|DRUG|Placebo ethanol|Matched placebo ethanol 0.4% in a total volume of 300 mL as an orange juice cocktail (consumed within 15 minutes) at 1 hour prior to assessment timepoint
223690389|NCT03871335|DIAGNOSTIC_TEST|Investigation of the work-related musculoskeletal disorders|Structured questionnaires will be used to determine the prevalence of the work-related musculoskeletal disorders and work-related factor. Photogrammetric method will be used to evaluate working posture.
223690390|NCT03585348|OTHER|Neuromuscular blocking agents|Neuromuscular blocking agent ED95 equivalent dose by provider
223690391|NCT03947203|BEHAVIORAL|Social media|Provided pamphlet and a private Facebook group where informational messages and content relating to oral health will be shared
223690392|NCT05288699|BEHAVIORAL|Aliento|Aliento is a culturally adapted, brief, personalized feedback intervention (PFI) to address alcohol misuse in the context of clinical anxiety delivered via a mobile application.
223690393|NCT02860455|DEVICE|RAD57 measurement (SpCO)|"SpCO measurement (Experimental)~Non invasive pulse CO-oximetry will be carried out by prehospital emergency nursing staff trained in the use of the Rad-57 pulse CO-oximeter (Masimo, Inc., Irvine, CA, USA), using the adult sized sensor (Sensor, Rev. B) placed on the 3rd or 4th digit, according to manufacturer recommendations. Nail polish will be removed if necessary. SpCO was expressed in total percentage of hemoglobin."
223690394|NCT02860455|DEVICE|CO-oximeter|"COHb measurement (Active Comparator)~Venous blood will be collected into EDTA treated tubes (Beckton Dickinson) prehospitally and sent to the toxicology laboratory for further carboxyhemoglobin testing. Blood carboxyhemoglobin will be analyzed by derivative spectrophotometry using an automated CO-oximeter (IL 682, Instrumentation Laboratory SpA V.le Monza 338-20128 Milan, Italy). Blood carboxyhemoglobin will be detected within a range of 0-100% and accuracy of 0.5% and reported as percentage of total haemoglobin."
223690395|NCT04354727|DRUG|APG-1252|infusion once weekly
223690396|NCT04354727|DRUG|Ruxolitinib|taken orally twice a day
223690397|NCT01926665|DRUG|Carfilzomib|Starting dose: 20/20 mg/m2 by vein on Days 1, 2, 15, and 16 of each 28 day cycle.
223690398|NCT01926665|DRUG|Dexamethasone|4 mg by vein or mouth prior to each Carfilzomib dose in Cycle 1 and 2 to prevent infusion reactions. After dexamethasone is stopped, it should be restarted and administered prior to subsequent doses for reactions.
223690399|NCT02549053|PROCEDURE|esophagus biopsies (pathologic and healthy zones)|Biopsies were realised in the distal third of esophagus : 4 for Barrett esophagus patients (2 in healthy zone, 2 in pathological zone).
223690400|NCT02549053|PROCEDURE|esophagus biopsies (healthy zones)|Biopsies were realised in the distal third of esophagus :2 for control patients in healthy zone
223690401|NCT03704987|DIAGNOSTIC_TEST|dual-energy X-ray absorptiometry|dual-energy X-ray absorptiometry
223690402|NCT01415895|DRUG|Naltrexone and Clonidine Combination|subjects will receive 1 study drug capsule by mouth twice daily for 3 weeks, followed by 1 capsule in the morning for 3 days.
223690403|NCT01415895|DRUG|placebo|subjects will receive 1 placebo capsule by mouth twice daily for 3 weeks, followed by 1 capsule in the morning for 3 days.
223690404|NCT01272661|BEHAVIORAL|Enhanced Curriculum|Brief health literacy focused modules on breastfeeding delivered in the home by Community Health Workers
223690405|NCT01272661|BEHAVIORAL|Enhanced Curriculum+Breastfeeding Doula|In the Doula Program, the Community Health Worker and mother will identify a support person (e.g. grandma, father, friend) who commits to learning about breastfeeding with the mother at home visits, and then helps her with breastfeeding postpartum.
223690406|NCT01272661|BEHAVIORAL|Enhanced Curriculum +Father Support|In the Father Support Program, mothers will give their partners father-friendly breastfeeding information and an invitation to a 3-week breastfeeding education group for fathers that includes a resource specialist or resource information for child support, re-entry and job services.
223835685|NCT05216666|PROCEDURE|Posterior approach|Total hip arthroplasty performed through a posterior surgical approach (Moore)
223690407|NCT05174845|DRUG|1L PEG + ASCORBIC ACID|"* 2-Day Split-Dosing: The patient has taken the product in the evening before the scheduled colonoscopy and mandatory additional clear fluid. The patient has taken the second dose with mandatory additional clear fluids on the morning of the colonoscopy.~* Same Day: The patient has taken the first dose of the product on the day of the colonoscopy and take mandatory additional clear fluid. After a 1-2 hour break, the patient has taken a second dose plus additional clear mandatory fluid."
223690408|NCT04033198|PROCEDURE|Appendectomy|patients diagnosed as acute appendicitis , appendectomy done
223690409|NCT05784961|DEVICE|tDCS|"tDCS will be delivered using this electrode montage: anode on the left dosolateral prefrontal cortex (L DLPFC) using F3 EEG landmark and cathode on the left temporoparietal junction (L TPJ) on the middle point between T3 and P3 EEG landmark.~The stimulation will be delivered at an intensity of 2 milliamps, for 20 minutes, five times a day, with 20 min inter sessions (it will be carried out on 5 consecutive days from Monday to Friday). Each processing day corresponds to a visit of V2, V3, V4, V5 and V6."
223690410|NCT01543373|DEVICE|Amphilimus Eluting Stent|Sirolimus formulated coronary eluting stent
223690411|NCT01543373|DEVICE|Bare Metal Stent|Bare metal coronary stent
223690412|NCT02193451|PROCEDURE|Urodynamics|Diagnostic test for urinary storage and voiding function
223690413|NCT02193451|PROCEDURE|Usual care|
223690414|NCT04710420|DEVICE|Endovascular therapy|Endovascular treatment for critical limb threatening Ischemia
223690415|NCT01243671|BIOLOGICAL|Adalimumab|
223690416|NCT03773211|DRUG|Renaparin|50 mL added at one occasion ex-vivo to machine perfusion solution to treat kidney at least 3 hours prior to transplantation
223690417|NCT03773211|DRUG|Placebo|50 mL added at one occasion ex-vivo to machine perfusion solution to treat kidney at least 3 hours prior to transplantation
223690418|NCT00312637|PROCEDURE|Magnetic Resonance Spectroscopy|
223690419|NCT02145988|DRUG|DLBS1033|Investigational drug or placebo will be given in addition to the standard therapy: aspirin at the dose of 80 mg, once daily, every day for twelve weeks of study period
223690420|NCT02145988|DRUG|Placebo|Investigational drug or placebo will be given in addition to the standard therapy: aspirin at the dose of 80 mg, once daily, every day for twelve weeks of study period
223690421|NCT05229978|OTHER|Showing an existing Dynamic Consent (computer interface) as prompt|An existing Dynamic Consent interface will be shown as a prompt halfway through the focus group sessions.
223690422|NCT04290780|OTHER|nosocomial infection/hospital acquired infection|"When there is suspicion of a community-acquired case (admission of an infected patient) or nosocomial case (infection of a patient already hospitalized), a case report form including demographic data, medical history, and clinical and biological data on the infectious episode will be completed for each case, either patient, caregivers or health care professionals, presenting clinical signs or symptoms compatible with SARS-CoV-2 infection. The suspected cases will undergo nasopharyngeal swab collection and detection of SARS-CoV-2 in nasopharyngeal swabs will be done by real-time RT-PCR assay.~Hygiene measures applied by the service will be collected using a questionnaire as well as recommendations of the learned societies within the country regarding the risk of infection by coronavirus. In addition, data characterizing the service and hospital will also be collected (specialty, number of beds, number of nurses, doctors, etc.)."
223690423|NCT03877731|PROCEDURE|isolated septal myectomy|
223690424|NCT03877731|PROCEDURE|septal myectomy + edge-to-edge mitral valve repair|
223690425|NCT03877731|PROCEDURE|septal myectomy + posterior leaflet sliding plasty|
223690426|NCT03877731|PROCEDURE|septal myectomy + secondary chordae transection|
223690427|NCT00856648|DEVICE|SmartPill ingestion and monitoring|The SmartPill device will be ingested and remotely monitored until it is excreted in a normal bowel movement.
223690428|NCT03408002|BEHAVIORAL|Psychological intervention|"The intervention aims to increase self-efficacy perception in managing pre-operative anxiety. The intervention is based on one single psychological consultation adopting the Four elements technique elaborated by Shapiro"
223690429|NCT03400644|DEVICE|Cervical collar|Cervical neck collar which is routinely made for post-laminoplasty patients
223690430|NCT00005110|DRUG|Salmeterol|
223690431|NCT00005110|DRUG|Albuterol|
223690432|NCT01033721|DRUG|Palomid 529|comparison of different dosages of drug
223776616|NCT05580718|BEHAVIORAL|MI-CBT|"* Education Common reactions following MI and general lifestyle advice on e.g., physical activity. The role of cardiac anxiety and avoidance behavior on quality of life and physical health. Brief training in self-observation.~* Goal setting Identifying life areas impaired by MI-related disability or symptom fear. Set health behavioral goals i.e., increased physical activity and gradually take steps towards them.~* Exposure therapy Exposure to physical sensations (e.g., palpitations due to physical activity) to reduce fear of these symptoms. Gradual exposure to avoided situations, activities and increase in physical activity.~* Relapse prevention Prevention of relapse into avoidance behaviors by identifying risk situations and conduct a plan forward on maintaining a healthy physically and active lifestyle."
223776617|NCT03698773|OTHER|Access to routine information|Access to routine pain-control information
223776618|NCT03698773|OTHER|Access to website|Access to informational website: thepainlesspush.com
223776619|NCT00908960|DRUG|Enoxaparin|
223776620|NCT05074433|DRUG|casirivimab+imdevimab|Co-administered sequentially subcutaneous (SC)
223690433|NCT04115644|DRUG|Ketorolac|Group 2 (ketorolac): will receive an injection of 3 cc 0.25% Marcaine without epinephrine and 2 cc ketorolac 30 mg/ml
223690434|NCT04115644|DRUG|Marcaine (placebo)|Group 1 (control): will receive an injection of 5 cc 0.25% Marcaine without epinephrine
223690435|NCT04115644|DRUG|Kenalog|Group 3 (kenalog): 4 cc 0.25% Marcaine without epinephrine and 1 cc triamcinolone.
223690436|NCT01840618|DEVICE|Nasal Continuous positive airway pressure (CPAP)|We will initiate treatment of OSA with CPAP for 3 months in PCOS adolescents with moderate to severe OSA. Compliance will be defined as the average number of hours for which CPAP was used per night over the 12-wk treatment period. Adherence with CPAP will be defined as CPAP use ≥4 hours daily. The primary outcome variable will be insulin sensitivity measured as change in GIR. Changes in cardio metabolic variables after CPAP treatment will be expressed as a percentage of the corresponding baseline values.
223690437|NCT00658580|DRUG|Cisplatin + etoposide|"Cisplatin 90 mg/m² day 1, every 3 weeks~Etoposide 100 mg/m² days 1-3, every 3 weeks"
223690438|NCT00658580|DRUG|Epirubicin + ifosfamide + etoposide|"Epirubicin 60 mg/m² day 1, every 3 weeks~Ifosfamide (+ uromitexan) 1.5 g/m² days 1-3, every 3 weeks~Etoposide 100 mg/m² days 1-3, every 3 weeks"
223690439|NCT05023876|OTHER|IASTM+respiratory Exercise|Instrument assisted soft tissue mobilization
223690440|NCT05023876|OTHER|Respiratory Exercise|Respiratory Exercise
223690441|NCT01601431|DEVICE|Cap Assisted Colonoscopy|Plastic transparent cap added to the distal end of the colonoscope which can increase adenoma detection rate
223690442|NCT01601431|DEVICE|Conventional colonoscopy|Regular colonoscopy as per standard clinical guidelines
223690443|NCT03526731|OTHER|ultrasound guided quadratus lumborum block|ultrasound guided quadratus lumborum block for post operative pain control after unilateral inguinal hernia repair.
223690444|NCT05958667|BEHAVIORAL|Quitxt text messaging or Chat|Mobile intervention using proven social cognitive, motivational interviewing, and brief intervention methods for promoting behavior change - blends bilingual text and social media messaging for smoking cessation tailored to the language and culture of young adult smokers in our vulnerable region of South Texas.
223690445|NCT05958667|OTHER|Usual care|Abbreviated text messaging with smoking cessation-related content and referral to the Texas Department of State Health Services (TDSHS) cessation program Yes Quit.
223776621|NCT05074433|DRUG|Placebo|Administered SC
223690446|NCT04092569|BEHAVIORAL|Pre-medical consultation structured diabetes self-care education programme|"The findings of integrative review revealed positive effects of DSME in improving glycemic control and promoting self-care among people with type 2 diabetes.~An evidence-based protocol is developed based on these findings to generate a DSME program for newly referred patients to SOPCs and before their first medical consultation to improve glycemic control and enhance self-care of people with type 2 diabetes in Hong Kong. The investigator will ensure that this study is conducted in compliance with ICH-GCP and in compliance with the Declaration of Helsinki."
223690447|NCT04806958|OTHER|PulsePoint notification|"The PulsePoint interface software monitors each 9-1-1 call on dispatch computers and is automatically triggered by particular conditions including call type (e.g. suspected cardiac arrest) and location type (public location). When triggered, the system pushes location data to all PulsePoint mobile application users within 400 meters of the emergency location.~When a mobile device running the PulsePoint Respond application receives the alert data from the PulsePoint system, the device alarms with auditory, tactile (vibration) and visual stimuli. The application presents a map showing the exact location of the suspected cardiac arrest and the closest public access defibrillator."
223690448|NCT00573248|DRUG|Nicotine|"21 mg nicotine patches for smokers for 2 days~7 mg nicotine patches for nonsmokers for 2 days"
223690449|NCT00573248|OTHER|Placebo|Placebo Patch
223690450|NCT02602392|BEHAVIORAL|Lungtropolis|A game-based website for children with asthma aged 5-10 to teach basic self-management skills and a comprehensive adjunct informational website for parents
223690451|NCT02602392|BEHAVIORAL|Asthma educational booklet|Text-based asthma education booklet for parents and children in PDF format
223690452|NCT06334887|DEVICE|Use of esTOCma|"Participants of the experimental group will use the esTOCma mobile app until completion, within a set period of 10 days.~EsTOCma is a a serious game with 10 missions where users have to free 10 characters who have been imprisoned by a monster called esTOCma, which metaphorically represents the stigma in OCD. With each mission, users will gain knowledge about OCD and free an imprisoned character until the tenth mission, when they will defeat the monster. This game has three modules: (1) Psychoeducation (missions 1-5), where general information about OCD, OCD treatments and where to seek help is provided; (2) Indirect Contact (missions 6 and 7), which consists of a series of audio-visual recordings in which OCD patients report their symptoms and the impact the disorder has had on their lives; and finally, (3) Cognitive Restructuring (missions 8-10), where common dysfunctional beliefs about OCD and OCD treatment are challenged."
223690453|NCT05790174|BEHAVIORAL|"ROS chubby and healthy - a multidisciplinary family-based weight-loss treatment program"|"The weight-loss treatment program ROS is family-based and delivered by a multidisciplinary team of physicians, nurses, dieticians, and psychologists. The treatment is based on an individualized tailored plan made together with the family. The plan consists of dietary changes, more physical activity, regular weight checks, and motivational conversations. The program includes options of cooking classes, group session with a psychologist and participation in structured physical activity called ROS sports twice a week. Follow up visits are scheduled every 2-3 months at the different health care professionals."
223690454|NCT05790174|BEHAVIORAL|Overweight Clinic for Children and Adolescents|The 'Overweight Clinic for Children and Adolescents' program at the municipal Health Center is based on the family-centered, multidisciplinary protocol developed by the Children's Obesity Clinic (TCOCT) at Holbæk Hospital. The intervention is individualized, informed by medical history and a structured questionnaire-based interview to identify behavioral and lifestyle changes needed to reduce the child's degree of overweight or obesity. The program consists of individual consultations every 6-8 weeks over approximately 12-18 months, with additional follow-up appointments as needed.
223690455|NCT05790174|BEHAVIORAL|Family Nutrition Guidance|"This treatment program is based on the Danish Health Authority's recommendations for lifestyle interventions. It follows a family-centered approach tailored to the family's everyday life and habits, focusing on sustainable changes in diet and physical activity. The program provides guidance on healthy eating, physical activity, and strategies for integrating these behaviors into daily routines.~The program included the entire family and began with school-based consultations delivered by health nurses during the first three months, followed by additional sessions at the municipal Health Center when needed. Families were offered 4-6 consultations within the first six months and follow-up sessions twice a year."
223690456|NCT05366205|DIETARY_SUPPLEMENT|Oral nutritional supplement|Enteral nutritional emulsion(TPF-T) will be given by oral intake,400ml per day, lasting for 7-10 days.
223690457|NCT05366205|BEHAVIORAL|Nutrition consultation|Nutritional treatment advice will be given
223690458|NCT03686826|PROCEDURE|Acquisition of MEP und SSEP|Acquisition of MEP und SSEP at two different time points within 1 to 30 days
223690459|NCT03536897|RADIATION|IORT|Intraoperative radiation therapy with INTRABEAM system to a dose of 20 Gy
223690460|NCT00506610|DRUG|T-62|
223690461|NCT01104220|OTHER|Weight loss|Bariatric surgery-induced weight loss to achieve \~20%-30% reduction in initial body weight
223690462|NCT05495087|DEVICE|IHT Treatment|IHT Treatment: IH exposure to 10% O2 for up to 5 min, interspersed with breathing room air recovery for up to 5 min, with up to 8 cycles/session, 3 sessions/week, for up to 12 weeks.
223690463|NCT05495087|OTHER|Sham-IHT Control|Sham-IHT Control: Exposure to 21% O2 for up to 5 min, interspersed with breathing room air recovery for up to 5 min, with up to 8 cycles/session, 3 sessions/week, for up to 12 weeks.
223690464|NCT02533791|BIOLOGICAL|4×10^10vp/1ml Ebola Zaire vaccine (Ad5-EBOV)|one dose, 4×10\^10vp/1ml per dose
223690465|NCT02533791|BIOLOGICAL|1.6×10^11vp/2ml Ebola Zaire vaccine (Ad5-EBOV)|two doses, 0.8×10\^11vp/1ml per dose, with one dose to each arm at the same time
223690466|NCT02533791|BIOLOGICAL|placebo|
223690467|NCT03260439|DRUG|Tramadol|Children receive 0.1% BPV non-adrenalinated 0.5% / kg on each side with tramadol 2mg / Kg (G1: GroupBT ). Postoperativ analgesia was assessed by: the modified OPS scale at waking (H0), 1st (H1), 2nd (H2), and 24th (H24) PO hour at home, by the number of analgesic The hospital and home, and by the time of the first demand analgesic.
223690468|NCT03260439|DRUG|Placebo|Children receive 0.1% BPV non-adrenalinated 0.5% / kg on each side with saline serum at the same volume (G2: Group B or control). Postoperativ analgesia was assessed by: the modified OPS scale at waking (H0), 1st (H1), 2nd (H2), and 24th (H24) PO hour at home, by the number of analgesic The hospital and home, and by the time of the first demand analgesic.
223690469|NCT02017171|DRUG|Allopurinol|
223776622|NCT05686304|BEHAVIORAL|Internet-based self-help money management program|The online money management program course will consist of 4 weekly modules, incorporating the key components of money management and the Model of Human Occupation (MOHO), including the concept of money management, money management skill, and risk of financial exploitation.
223776623|NCT06404177|DRUG|Dexketoprofen|An intravenous perfusion of eunantyum with an intramuscular isotonic saline
223776624|NCT06404177|DRUG|Piroxicam|intramuscular injection of piroxicam with a perfusion of isotonic saline intravenous
223776625|NCT04146480|DIAGNOSTIC_TEST|F18-NaF PET/CT|"The scan will be performed on the Discovery 690 Nuclear Medicine Camera. On the day of the scan, the patient will be admitted to the Office of Nuclear Medicine and will be admitted to administrative. Prior to the scan, the subject will undergo a brief interview by a physician or nurse and a 22 G Prefill will be installed on him, through which a 5 millikiric (mCi) of 18 F-NaF will be injected.~4\. An hour after the injection, the PET / CT scan, which will last about 10 minutes, during, the patient is required to lie down and breathe normally.~5\. Upon completion of the scan, will be released without any restrictions."
223776626|NCT02842268|DRUG|BAY987517|Test product dried for at least 15 minutes.Subjects to ride for 30 minutes on a stationary bicycle.(Formulation Number :Y73-161)
223776627|NCT03887091|OTHER|Postwire|Postwire© is a web-based, video platform
223776628|NCT02592473|DEVICE|Embozene Microspheres|Minimally invasive intra-arterial administration of particle embolics into prostate arteries under fluoroscopy and cone-beam CT imaging guidance.
223776629|NCT06344065|BIOLOGICAL|Diphtheria, tetanus and acellular pertussis (component) combined vaccine (adsorbed)|Three doses of basic immunization were administered at 3, 4, and 5 months of age, and one dose of booster immunization was administered at 18-24 months of age, for a total of four doses. The administration route for experimental vaccine is intramuscular injection of 0.5ml into the lateral deltoid muscle of the upper arm.
223776630|NCT06344065|BIOLOGICAL|Diphtheria, tetanus and acellular pertussis combined vaccine (adsorbed)|Three doses of basic immunization were administered at 3, 4, and 5 months of age, and one dose of booster immunization was administered at 18-24 months of age, for a total of four doses. The administration route for active control vaccine 1 is intramuscular injection of 0.5ml into the lateral deltoid muscle of the upper arm.
223776631|NCT06344065|BIOLOGICAL|Diphtheria, tetanus, pertussis (acellular, component), poliomyelitis (inactivated) vaccine (adsorbed) and Haemophilus influenzae type b conjugate vaccine|Three doses of basic immunization were administered at 3, 4, and 5 months of age, and one dose of booster immunization was administered at 18-24 months of age, for a total of four doses. The administration route for active control vaccine 2 is through intramuscular injection of 0.5ml into the anterolateral side of the thigh or the upper arm.
223776632|NCT01377974|DRUG|Miltefosine|1 Capsule of 50mg, taken orally 2 times a day for 28 days
223776633|NCT01377974|DRUG|Standard Treatment Meglumine antimoniate|20mgKg daily intravenous Meglumine antimoniate as oriented by the Brazilian Ministry of Health
223690470|NCT02017171|DRUG|Placebo|Inactive oral tablets identical in appearance to allopurinol tablets.
223690471|NCT06004687|DRUG|acetaminophen mannitol|Intravenous acetaminophen was administered 30 minutes before anesthesia
223690472|NCT06004687|DRUG|Normal saline|Intravenous acetaminophen was administered 30 minutes before anesthesia
223690473|NCT02981355|PROCEDURE|Microfracture treatment|Microfracture is performed by penetrating the subchondral bone beneath the cartilage lesion inducing a bleeding response.
223690474|NCT02981355|DEVICE|BST-CarGel|BST-CarGel is combined with fresh, autologous whole blood and applied to the lesion on the femoral condyle with a syringe following microfracture arthroscopic surgery.
223690475|NCT04972747|OTHER|skin care with sunflower oil|The application will be carried out twice a day during the maintenance hours of the service. In skin care applications, body baths are applied not more than three times a week, as it may cause hypothermia in preterm babies in the ward routine. In daily skin care, body cleaning with cotton, changing the fixation points such as orogastric probe, and changing the monitor probe locations are among the routine practices. In order to hydrate and moisturize the skin in preterm and term babies, baby oil in the service is used. Skin care applied in the service routine will be applied to the preterm babies included in the study, and only sunflower oil and coconut oil will be used as moisturizers.
223690476|NCT04609111|DRUG|No aspirin|1-month prasugrel monotherapy followed by clopidogrel monotherapy
223690477|NCT04609111|DRUG|1-month DAPT|1-month dual antiplatelet therapy comprising of aspirin and prasugrel followed by aspirin monotherapy
223776634|NCT01158924|DRUG|Intradiscal rhGDF-5|The API is recombinant human growth and differentiation factor-5 (rhGDF-5), a recombinant version of human GDF-5. GDF-5 is a member of the transforming growth factor-b (TGF-b) superfamily and the bone morphogenetic protein (BMP) subfamily, and is known to influence the growth and differentiation of various tissues, including the intervertebral disc. In vitro experiments have shown that rhGDF-5 can stimulate gene expression and synthesis of the extracellular matrix proteins type II collagen and aggrecan. In vivo experiments in rabbit models of disc degeneration have shown that intradiscal injections of rhGDF-5 can stimulate an increase in disc height and hydration.
223776635|NCT05796128|PROCEDURE|Nasal Intermittent Positive Pressure Ventilation (NIPPV)|In this group, infants will receive NIPPV during LISA procedure.
223776636|NCT05796128|PROCEDURE|Nasal continuous positive airway pressure (NCPAP)|In this group, infants will receive NCPAP during LISA procedure.
223776637|NCT01014507|DRUG|8 cycles BEACOPPesc plus oral contraceptive|
223776638|NCT01014507|DRUG|8 cycles BEACOPPesc plus Goserelin|
223776639|NCT03768739|PROCEDURE|Fiberoptic Endoscopic Evaluation of Swallowing|This procedure involves a flexible laryngoscope that contains a light source and video camera on the end through the open passages of your nose and to the back of the throat in order to visualize the swallowing mechanism.
223776640|NCT02857127|BEHAVIORAL|Walking program|To encourage people to exercise more through a behavioural and educational intervention during six months and other six months of follow up.
223776641|NCT05928442|DEVICE|in vitro diagnostic medical device|Collection of 2 saliva samples at inclusion.
223776642|NCT05928442|BEHAVIORAL|Completion of a self-questionnaire|Completion of a self-questionnaire on symptom and quality-of-life at inclusion.
223776643|NCT05928442|DEVICE|in vitro diagnostic medical device|Collection of 1 saliva sample at the follow-up visit.
223776644|NCT02233231|DRUG|Varenicline|Varenicline 2 mg x 1 day 7 to week 12
223776645|NCT02233231|DRUG|Placebo|similar tabl
223690478|NCT03169751|DEVICE|Brain Sentinel Monitoring and Alerting System|The Brain Sentinel Monitoring and Alerting System is indicated for use as an adjunct to seizure monitoring in adults in the home or healthcare facilities during periods of rest. The device is to be used on the belly of the biceps muscle to analyze surface electromyographs (sEMG) signals that may be associated with generalized tonic-clonic (GTC) seizures and to provide an alarm to alert caregivers of unilateral, appendicular, tonic extension that could be associated with a GTC seizure. The System records and stores sEMG data for subsequent review by a trained healthcare professional.
223690479|NCT03091777|DRUG|GDC-229|GDC-229 is a vaginal gel.
223690480|NCT03091777|DRUG|Metronidazole Vaginal Gel 0.75%|Metronidazole Vaginal Gel 0.75% is an FDA-approved drug
223690481|NCT03091777|DRUG|Placebo|Inactive arm of the study
223690482|NCT01415739|OTHER|laboratory biomarker analysis|Correlative studies
223690483|NCT02314143|DRUG|Dabrafenib|Dabrafenib will be provided as 50 mg and 75 mg capsules.
223690484|NCT02314143|DRUG|Trametinib|Trametinib study medication will be provided as 0.5 mg and 2.0 mg tablets.
223690485|NCT05991921|OTHER|Transcutaneous Electrical Nerve Stimulation (TENS)|"TENS application, postpartum 10-12. at hours and 14-16. It was applied twice for 30 minutes each. Researcher 1 programmed the TENS unit and was the only researcher who knew whether TENS was active or in placebo mode.~Two pairs of TENS electrodes were placed on the upper and lower border of the cesarean section incision line. A total of 4 electrodes were used in a sterile package for each participant. TENS stimulation was applied at a frequency of 100 Hz and was increased starting from 0 mA. The participant's stimulation was fixed at the mA level, where he felt optimal but did not feel discomfort.~The pretest data were applied to the participants who met the inclusion criteria and volunteered to participate in the study, by the researcher 2 in the patient rooms 10 hours after the cesarean section. Post-test data were obtained by the same investigator 16 hours after cesarean section."
223690486|NCT05991921|OTHER|Plasebo-Fake TENS|Participants in the placebo group 10-12 postpartum. at hours and 14-16. Two pairs of TENS electrodes were placed at the same time as the intervention group. TENS electrodes were attached to the participants in this group for 30 minutes, the device was operated but no electric current was applied.
223690487|NCT02818647|PROCEDURE|Tonsillectomy|Tonsillectomy is the name of the surgery where tonsils are removed via capsullary dissection. There are various techniques and its basically removing the tonsil from its tonsillary fossa and conducting hemostasis with various equipments.
223690488|NCT06523517|DRUG|Eliglustat Tartrate Capsules|The initial dose is 42 mg taken orally twice a day. After 2 weeks of treatment, if the blood trough concentration is less than 5 ng/mL, the dose will be increased to 84 mg taken orally twice daily.
223690489|NCT04934280|DIAGNOSTIC_TEST|sonohysterography|saline infusion transvaginally followed by 2D transvaginal ultrasound imaging
223690490|NCT02914145|DRUG|Dihydroartemisinin-piperaquine|Mass drug administration
223776646|NCT03795922|DRUG|MT10109L|MT10109L will be injected into the GL.
223776647|NCT03795922|DRUG|Placebo|Placebo will be injected into the GL.
223776648|NCT01611571|DRUG|Risedronate|weekly risedronate
223776649|NCT01611571|DRUG|Teriparatide|daily teriparatide
223776650|NCT01611571|DRUG|Placebo Teriparatide|daily placebo of teriparatide
223776651|NCT01611571|DRUG|placebo Risedronate|weekly placebo of Risedronic Acid
223690491|NCT02142114|DEVICE|Eye injection by 30 or 32 gauge needle|Consented patients receiving monthly bi-lateral injections of the same dose of ranibizumab will have one eye injected with a 30 gauge needle and the other eye injected with a 32 gauge needle. Bi-lateral injections may be performed on the same day or with one week of each other, depending on the subject preference and their normal injection regimen. On the first visit following enrollment in the study, the eye to receive the injection from the 30 or 32 gauge needle will be determined randomly. The other eye will be injected with the other needle size. When the patient returns for their next set of bi-lateral injections, the eyes receiving the 30 and 32 gauge needle injection will switch.
223776652|NCT00724451|BIOLOGICAL|Peginterferon alfa-2b|Peginterferon alfa-2b administered in accordance with approved labeling
223776653|NCT00724451|DRUG|Ribavirin|Ribavirin administered in accordance with approved labeling
223776654|NCT00724451|BIOLOGICAL|Peginterferon alfa-2a|Peginterferon alfa-2a administered in accordance with approved labeling
223776655|NCT04055194|DRUG|Tranexamic acid tablets|Pregnant women with symptomatic placenta previa with previous bleeding attacks will receive tranexamic acid tablets (500mg four times daily) till delivery.
223776656|NCT04055194|DRUG|Placebo oral tablet|Pregnant women with symptomatic placenta previa with previous bleeding attacks will receive placebo tablets four times daily till delivery.
223776657|NCT03992690|DEVICE|Brain-machine Interfaces, Visuo-tactile Feedback and Assisted Locomotion, or the WANR protocol|Training integrating virtual-reality avatar driven by a brain-machine interface, with tactile feedback through patient's forearms, and assisted locomotion, for neurorehabilitation of SCI patients.
223776658|NCT03992690|DEVICE|Training with traditional physiotherapy protocol|Stretching
223776659|NCT01470287|BIOLOGICAL|DTwP-HepB-Hib Vaccine|Open label, Single arm study to evaluate immunogenicity, safety and tolerability of a fully liquid pentavalent (DTwP-HepB-Hib) vaccine in infants of 6-8 weeks of age.
223776660|NCT03835260|DEVICE|Pivot Breath Sensor|The Pivot Breath Sensor measures the level of carbon monoxide in exhaled breath and displays the carbon monoxide value to the user.
223776661|NCT06158737|DRUG|JS010 injection|This study adopts a dose escalation design with six preset dose levels, namely 3mg, 30mg, 150mg, 300mg,600mg, 900mg, single subcutaneous injection. A total of 48 healthy subjects were enrolled in the experiment, 8 in each group.They were randomly assigned to receive JS010 injection and matching placebo in a ratio of 3:1. In accordance with the dose-escalation principle,Starting from the lowest initial dose, increasing to the higher dose and proceeding in sequence. Each subject can receive only one dose Level of single subcutaneous administration.
223776662|NCT06158737|DRUG|Placebo|This study adopts a dose escalation design with six preset dose levels, namely 3mg, 30mg, 150mg, 300mg,600mg, 900mg, single subcutaneous injection. A total of 48 healthy subjects were enrolled in the experiment, 8 in each group.They were randomly assigned to receive JS010 injection and matching placebo in a ratio of 3:1. In accordance with the dose-escalation principle,Starting from the lowest initial dose, increasing to the higher dose and proceeding in sequence. Each subject can receive only one dose Level of single subcutaneous administration.
223776663|NCT04083872|DRUG|Reference drug|D744 Cap. 1 Cap., single oral administration under fasting condition
223776664|NCT04083872|DRUG|Test drug|CKD-385 64 mg formulation I Tab. 1 Tab., single oral administration under fasting condition
223776665|NCT05194176|DEVICE|Virtual Reality|For all VR exercises a head mounted display (HMD), the PICO G2 4K (Barcelona, Spain) will be used. Together with SyncVRMedical (Utrecht, Netherlands) a VR dashboard has been created from which patients can chose the different exercises.
223776666|NCT00947622|DEVICE|Transcranial direct current stimulation|Transcranial Direct current stimulation
223776667|NCT01260922|DRUG|Donepezil Hydrochloride|10 mg Orally Disintegrating Tablet
223776668|NCT01260922|DRUG|Aricept®|10 mg Orally Disintegrating Tablet
223776669|NCT04701775|DIETARY_SUPPLEMENT|Only Lactobacillus rhamnosus GG strains|1x106 colony forming unit (CFU) Lactobacillus rhamnosus GG probiotic capsule
223776670|NCT04701775|COMBINATION_PRODUCT|Combined Lactobacillus acidophilus and Bifidobacterium animalis subsp.lactis strains|combination of Lactobacillus acidophilus 1x109 CFU and Bifidobacterium animalis subsp.lactis 1x109 CFU probiotic capsule
223776671|NCT04701775|OTHER|Placebo|Placebo probiotic capsule
223776672|NCT03652103|PROCEDURE|Ultrasound Guided Erector Spinae Plane Block Catheterisation|After receiving general anesthesia, patients will positioned prone. Before operation begins, ESP block catheter will be applied with ultrasound guidance to the same level as surgeon's incision.
223776673|NCT03652103|DRUG|Bupivacaine 0.25% Injectable Solution|Perineural Injection
223690492|NCT06271499|OTHER|Radial artery catheterization with USG|Radial artery catheterization with USG The catheterization was performed by two anesthesiologist with different experience (Junior practitoner who has the experience of 20-50, and the senior practitioner who has the experience of \>50 radial artery catheterizations). The side to be catheterized was determined by modifie Allen test which was first performed on the nondominant hand. After general anesthesia induction, a 45° angle was given to wirst of selected side with a support. After skin asepsis, radial artery was vizualized 2 centimeter (cm) above the wrist in short axis with the high-frequency linear USG probe. The radial artery puncture was performed while step by step monitoring the needle tip in short axis out-of-plane technique. Following the puncture, radial artery catheterized with a 3 French 8 cm catheter.
223690493|NCT06271499|OTHER|Radial artery catheterization with smart glasses integrated UGG|The catheterization was performed by two anesthesiologist with different experience (Junior practitoner who has the experience of 20-50, and the senior practitioner who has the experience of \>50 radial artery catheterizations). Before the study, as practitioners had no previous experience with smart glasses, they performed 5 catheterizations with smart glasses integrated USG on model. The side to be catheterized was determined by modifie Allen test which was first performed on the nondominant hand. After general anesthesia induction, a 45° angle was given to wirst of selected side with a support. After skin asepsis, radial artery was vizualized 2 centimeter (cm) above the wrist in short axis with smart glasses integrated high-frequency linear USG probe. The radial artery puncture was performed while step by step monitoring the needle tip in short axis out-of-plane technique. Following the puncture, radial artery catheterized with a 3 French 8 cm catheter.
223690494|NCT01936402|BEHAVIORAL|Education of chest compression depth|An American Heart Association Basic Life Support faculty educated each participant in Experimental group a standard 30-min lecture and hands- on practice for chest compression without ventilation using manikin on the floor according to 5-6cm or 6-7cm chest compression depth
223690495|NCT00708071|BIOLOGICAL|Fibrin Sealant with 4 IU/ml Thrombin, Vapor-Heated, Solvent Detergent Treated Containing Synthetic Aprotinin (FS VH S/D 4)|Each subject received fibrin sealant with 4 IU/mL thrombin, vapor heated, solvent detergent treated containing synthetic aprotinin (FS VH S/D 4 ) to one side of the face. The dosing volume to be applied is 0.02 mL/cm2 to 0.04 mL/cm2. The study product will be applied to the subcutaneous plane in both the neck and the face area. The product will be applied using the spray device provided by the sponsor. (The other side of the face will be treated using standard of care.)
223690496|NCT03096145|BEHAVIORAL|Telephone counseling 1 session|1 call coaching session for nonsmokers that will be piloted and adapted in this study
223690497|NCT03096145|BEHAVIORAL|Mobile texting|nonsmokers will receive 3-5 text messages for 4 weeks
223690498|NCT03096145|BEHAVIORAL|Health incentive|Smokers receive a $25 gift card if they call the quitline
223690499|NCT02710500|DRUG|rAAVrh74.MHCK7.DYSF.DV|Biological/Vaccine: rAAVrh74.MHCK7.DYSF.DV Recombinant adeno-associated virus carrying a dysferlin transgene under control of a muscle specific MHCK7 promoter.
223690500|NCT05540080|DEVICE|BTL-899|Treatment with applicators C4/C5 to the BTL-899 system.
223690501|NCT01766700|BEHAVIORAL|2 no calorie beverages per day|Weekly and monthly lifestyle weight loss/maintenance classes.
223690502|NCT01766700|BEHAVIORAL|2 water beverages per day|Weekly and monthly lifestyle weight loss/maintenance classes.
223690503|NCT01171170|DRUG|carboplatin paclitaxel bevacizumab|paclitaxel 200 mg/m2 d1 - carboplatin AUC 6 d1 - bevacizumab 15 mg/kg d1. Cycles every 3 weeks. Paclitaxel and carboplatin 4 cycles. Bevacizumab till progression
223690504|NCT01171170|DRUG|Standard treatment plus nitroglycerin|paclitaxel 200 mg/m2 d1 - carboplatin AUC 6 d1 - bevacizumab 15 mg/kg d1. Cycles every 3 weeks. Paclitaxel and carboplatin 4 cycles. Bevacizumab till progression. Plus nitroglycerin transdermal patches 25 mg per day from day -3 till +2 of First combination cycle till the last bevacizumab monotherapy cycle
223690505|NCT00686179|DRUG|AZD3480|Capsule, oral, single dose, 6 days
223690506|NCT00686179|DRUG|Moxifloxacin|Capsule(encapsulated), oral, single dose
223690507|NCT00686179|DRUG|PLACEBO|Capsule, oral, single dose
223690508|NCT03810820|DEVICE|mobile Cardiac Arrhythmia Diagnostics Service (m-CARDS)|A wearable cardiac monitoring device is provided to patients pre- and post-TAVI. The monitor transmits cardiac data in real time to the m-CARDs team. Cardiac abnormalities are reported to the clinical team who then assess the abnormality and intervene as clinically necessary.
223690509|NCT00069966|BIOLOGICAL|filgrastim|
223690510|NCT00069966|BIOLOGICAL|rituximab|
223776674|NCT02137200|PROCEDURE|Immediate pushing|Women in this arm will be instructed to initiate pushing as soon as complete cervical dilation is documented.
223776675|NCT02137200|PROCEDURE|Delayed pushing|Women assigned to delayed pushing will be instructed to wait for 60 minutes from complete cervical dilation before pushing. Women will be allowed to push earlier if they feel an irresistible urge to push, the fetal head is visible at the perineum, or the fetal heart tracing is non-reassuring.
223776676|NCT05867394|OTHER|Stress ball|Stress ball squeeze
223690511|NCT00069966|DRUG|cisplatin|
223690512|NCT00069966|DRUG|cytarabine|
223690513|NCT00069966|DRUG|methylprednisolone|
223690514|NCT00069966|DRUG|pixantrone dimaleate|
223690515|NCT00069966|PROCEDURE|autologous bone marrow transplantation|
223690516|NCT00069966|PROCEDURE|peripheral blood stem cell transplantation|
223776677|NCT05577897|OTHER|Education|"A separate room in Chest Diseases Clinic was used for the education of the patients in this group for a quiet environment and for the education not to be interrupted. The education of a patient lasted approximately 45 minutes. The education booklet COPD Guide on COPD management prepared in line with the literature was given to the patients by the researcher. After the content of the education was explained to the patients, 45-minute of education was given through face-to-face verbal presentation and demonstration method."
223776678|NCT04165291|BEHAVIORAL|F4C|Fathers for Change (F4C) focuses on: 1) the fathering role to facilitate engagement, 2) RF to understand self, partner and children and emotion regulation skills to reduce IPV and child maltreatment. F4C focuses on understanding of emotional experiences, how they impact thinking and behaviors related to partners, co-parents and children. F4C clients will meet individually with their F4C therapist for 50 minutes per week over 16 weeks.
223776679|NCT04165291|BEHAVIORAL|BIP|The Batterer Intervention Program (BIP) is a psychoeducational intervention that will be delivered in 50- minute individual weekly sessions over 16 weeks. The intervention focuses on the impact of violence on victims, power and control tactics, and societal influences supporting men's violence toward women. The intervention includes didactics and experiential exercises including role plays to teach anger management skills.
223690517|NCT05771792|OTHER|ECCENTRIC EXERCISE|Eccentric Exercise training group will perform 8 weeks of protocol with a total 24 sessions for 45 minutes (3 session per week). During each 45 minutes training session, subjects will complete the warmup for 10 minutes, Eccentric Exercise training for 25 minutes and cool down 10minutes. All players will perform each repetition in a slow, controlled manner, 10 repetition and 3 sets in first 4 week and 15 repetition and 3 sets in last 4 weeks of all exercises for 45 minutes. Eccentric exercise training protocol is as follow: Prone Hamstring Curl, Seated TheraBand Hamstring Curl, Exercise Ball (or glider) Bridge with Curl, Stiff-Legged Deadlift, Single Leg Deadlift, Nordic Hamstring Curl.
223690518|NCT05771792|OTHER|CONVENTIONAL EXERCISES PROGRAM|The participant of the Control Group will perform 8 weeks of protocol with a total 24 sessions for 45 minutes (3 session per week). During each 45 minutes training session, subjects will complete the warmup for 10 minutes, conventional training for 25 minutes and cool down 10minutes. All players will perform each repetition in a slow, controlled manner, 10 repetition and 3 sets in first 4 week and 15 repetition and 3 sets in last 4 weeks of all exercises for 45 minutes. The exercise will be as follow: Side Lunges, Split Squats, Calf Raises.
223690519|NCT02572193|PROCEDURE|POEM|To determine the feasibility of same-day discharge following a POEM procedure
223690520|NCT02701920|DEVICE|HeartLight hat|HeartLight hat will be worn for up to 1 hour.
223690521|NCT02701920|DEVICE|The HeartLight hat with in-built sensor|The HeartLight hat with in-built sensor will be worn.
223690522|NCT02701920|DEVICE|HeartLight|Electronic stethoscope will be used to estimate heart rate with HeartLight sensor/hat
223690523|NCT02701920|DEVICE|HeartLight device|HeartLight sensor/hat will be used with ECG/Pulse oximetry/electronic stethoscope
223690524|NCT02701920|OTHER|parental feedback|Questionnaire
223690525|NCT02701920|OTHER|healthcare provider feedback|Questionnaire
223690526|NCT04075110|DRUG|Montelukast 10mg|Montelukast is an orally dosed drug (available as a chewable tablet) which is FDA-approved for the treatment of chronic asthma and prophylaxis and the prevention of exercise-induced bronchoconstriction. It is also approved for the relief of symptoms of both seasonal and perennial allergic rhinitis.
223690527|NCT04075110|DRUG|Placebo|Placebo tablet once daily
223690528|NCT04884932|DEVICE|30 kHz stimulation (Myomed 932, Enraf-Nonius)|"A charge-balanced, symmetric, biphasic sinusoidal current without modulation will be delivered at a frequency of 30 kHz. The stimulation intensity will be defined as that sufficient to produce a strong but comfortable sensation, just below motor threshold, over the median nerve through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft,Netherlands)"
223690529|NCT04884932|DEVICE|Sham stimulation (Myomed 932, Enraf-Nonius)|Sham stimulation will be delivered at a frequency of 30 kHz only during the first 30 seconds.
223690530|NCT00808431|BEHAVIORAL|Lifestyle counseling|3 month skills building program emphasizing parent training, behavior modification training, nutrition education, and physical activity promotion
223776680|NCT03140891|DEVICE|NHFOV|NHFOV is used as the noninvasive mode after extubation
223776681|NCT03140891|DEVICE|NCPAP|NCPAP is used as the noninvasive mode after extubation
223776682|NCT02248922|DRUG|TIS or TIP|300mg nebulized Tobramycin (Tobramycin inhalation solution(TIS)) or TOBI Podhaler (Tobramycin inhalation powder(TIP), equivalent dry powder)
223776683|NCT02220010|DEVICE|Pancreatic stent|The plastic stent is introduced in the pancreatic duct by a duodenoscope
223776684|NCT04791800|DIAGNOSTIC_TEST|Malaria/CRP combination test|Testing with a malaria/CRP combination test, in parallel with a standard malaria RDT (to guide case management), preparation of thin/thick films for expert malaria microscopy, and collection of venous blood for subsequent CRP quantification.
223776685|NCT02351752|DRUG|Hydroxychloroquine Sulfate|Hydroxychloroquine Sulfate: 0.1 Tid(eGFR 30-59);0.2 Bid (eGFR\>60)
223776686|NCT03611634|OTHER|BIOLOGICAL COLLECTION FROM THE GUT MICROBIOTE|collection of saddles
223776687|NCT00544245|BEHAVIORAL|Self monitoring of estimated energy balance|Participant estimation of energy intake and energy expenditure
223776688|NCT02822794|DRUG|SOF/VEL|400/100 mg tablet administered orally once daily
223776689|NCT02822794|DRUG|RBV|Capsules administered orally in a divided daily dose according to package insert weight-based dosing recommendations (≤ 60 kg = 600 mg, \> 60 kg to ≤ 80 kg = 800 mg, and ≥ 80 kg = 1000 mg)
223776690|NCT00035906|DRUG|DEX PS DDS®|
223776691|NCT04603859|PROCEDURE|Elective induction of labor at 39 gestational weeks and 0 to 3 days|Elective induction of labor (eIOL) according to local policies
223776692|NCT00588913|BIOLOGICAL|aldesleukin|
223776693|NCT00588913|BIOLOGICAL|therapeutic autologous lymphocytes|
223690531|NCT05027893|DRUG|Moxifloxacin 400 mg Oral Tablet|All used film-coated tablets (400 mg moxifloxacin) were administered for the first five days postoperatively, once a day, after the lower third molar surgery.
223690532|NCT05027893|DRUG|Cefixime 400 mg Oral Tablet|All used film-coated tablets (400 mg cefixime) were administered for the first five days postoperatively, once a day, after the lower third molar surgery.
223690533|NCT05027893|OTHER|Placebo|All used film-coated placebo-tablets were administered for the first five days postoperatively, once a day, after the lower third molar surgery.
223690534|NCT00001431|DRUG|gemcitabine|
223690535|NCT00801918|DRUG|Denileukin Diftitox|Denileukin Diftitox: 18 mcg/kg/day: days 1-5 in cycles 1,2,3,4
223690536|NCT00801918|DRUG|Denileukin diftitox, ifosfamide, cyclophosphamide, etoposide|Denileukin Diftitox: 18 mcg/kg/day days 1-2 in cycles 5 and 6 Ifosfamide: 3000mg/m²/IV/d X 3 days + Mesna 3000 mg/m2/d X 3 days Carboplatin: 635mg/m2/d X 1 day Etoposide: 100mg/m2/d X 3 days
223690537|NCT04840576|OTHER|Regular waterproof sterile dressing.|Waterproof sterile dressing OPSITE Post-Op Visible, Smith \& Nephew, UK
223690538|NCT04840576|OTHER|Prophylactic Negative Pressure Dressing|Negative wound pressure dressing: PICO-7, Smith \& Nephew, UK
223690539|NCT04951232|DRUG|Cinepazide Maleate|The experimental group: guipiprazitel maleate injection (klingo): 320mg (4), dissolved in 500ml of normal saline, and injected in a medium vein at a rate of 100ml/h, once a day, and administered for 14 days.
223690540|NCT04951232|OTHER|Placebo|Placebo: 4 pieces, dissolved in normal saline 500ml, intravenous drip, the speed is 100ml / h, once a day, continuous administration for 14 days
223690541|NCT01778777|DEVICE|Universe Reverse Prosthesis|Implantation of an universe reverse prosthesis
223690542|NCT04526301|DEVICE|Tablo Hemodialysis System|Home hemodialysis treatments \~4 times a week.
223776694|NCT00588913|DRUG|zoledronic acid|
223776695|NCT01698697|DRUG|insulin aspart|Bolus 0.1 U/kg administered simultaneously with a continuous infusion of 0.029 U/kg/h via a programmed insulin pump. A total dose of 0.35 U/kg is delivered to the subject in the 12 hour infusion
223776696|NCT03732248|DRUG|Rapamycin|Immunosuppressive drug
223690543|NCT04984603|PROCEDURE|PLR in patients under VA-ECMO|After securing the VA-ECMO tubing, PLR is realized using an automatic bed elevation technique. The lower limbs are raised to a 45° angle while the patient's trunk is lowered in supine position
223690544|NCT01626638|PROCEDURE|Confocal Micro Endoscopy|
223776697|NCT03732248|DRUG|Placebo|Inert drug
223776698|NCT03626129|PROCEDURE|Oximetry guided deflation|"At the cath.lab. (Step 1) a hemostasis test is performed: oxymetry device on the thumb, compress a.ulnaris, evaluate if curve on device (=Patent hemostasis). If patent no further action. If not patent, air is deflated until a.radialis is patent (curve on device and no bleeding). If bleeding occurs before patency then re-inflate 1-2 ml. air until hemostasis (=no patent hemostasis). In patients with Patent hemostasis no action is taken in sixty minutes whereafter the TR-band is fully deflated (Step 2), and if bleeding then air is re-inflated until hemostasis and step 2 is repeated every 20 minutes until the TR-band is fully deflated with hemostasis. If no patent hemostasis at cath.lab. a hemostasis test is performed after 20 min. If patent hemostasis is achieved no action is taken in sixy minutes (as above). If still not patent then further action as in group A."
223776699|NCT04408443|DIETARY_SUPPLEMENT|Lactobacillus reuteri DSM 17938 + Vitamine D3|Lactobacillus reuteri DSM 17938 (10E8 CFU in 5 drops), Vitamin D3 (400 IU in 5 drops), sunflower oil, medium chain triglycerides, silicon dioxide
223776700|NCT04408443|DIETARY_SUPPLEMENT|Placebo|sunflower oil, medium chain triglycerides, silicon dioxide
224263457|NCT02651506|PROCEDURE|Transthoracic Needle Biopsy|• Patients randomized to the control arm (TTNB) will undergo lung biopsy using standard transthoracic needle biopsy technique. The procedure will be performed under local anesthesia with computed tomography guidance by an interventional radiologist. In this procedure, a CT-image is used to locate the area for biopsy. Once identified, the radiologist applies a local anesthetic and inserts an aspiration needle between the ribs, through normal lung tissue, leading into the biopsy area. The sampled lung tissue is then sent for pathological analysis.
224263458|NCT01045681|DRUG|Bendamustine, Velcade and Dexamethasone|Bendamustine : 70 mg/m2 iv on D1 and 8, for each cycle Velcade : 1.3 mg/m2 iv on D1, 8, 15 and 22, for each cycle Dexamethasone : 20 mg/day po on D1, 8, 15 and 22, given prior to Bendamustine and Velcade
223690545|NCT03005938|PROCEDURE|Spinal manipulation|"Spinal manipulation (SM) is a therapeutic intervention performed on spinal articulations in which force is applied to the spine. The selected joint is moved to its end range of motion, followed by application of an rapid impulse or thrust to achieve a gapping of the target joint.~SM is performed by an orthopedic medical doctor certified in Manual Therapy. After manual evaluation, high-velocity low-amplitude SM is carried out in all regions of the spine, including thoracic adjustments in the prone position, lumbar manipulation in lateral recumbent position, and cervical manipulation in sitting position."
223690546|NCT03005938|PROCEDURE|Imitation of the spinal manipulation|Imitation of the SM physically and visually resembles the act of SM. It comprises placing the patient in the same positions and performing the same movements as during SM but without applying the force in the end range of motion.
223690547|NCT02240173|DIETARY_SUPPLEMENT|Jobelyn|Jobelyn is a dietary supplement made from Sorghum bicolor
223690548|NCT02240173|DRUG|Haloperidol|Conventional drug normally used for psychotic problems
223690549|NCT07026279|DRUG|narmafotinib ascending doses|once daily capsules
223690550|NCT07026279|DRUG|narmafotinib dose comparison|once daily capsules
223690551|NCT04901286|BEHAVIORAL|Exercise Only|Cycling in a lab environment
223690552|NCT04901286|BEHAVIORAL|Exercise + Non-Immersive Virtual Reality|Cycling with an environment simulated by non-immersive virtual reality
223690553|NCT04901286|BEHAVIORAL|Exercise + Immersive Virtual Reality|Cycling with an environment simulated by immersive virtual reality
223690554|NCT06699732|BEHAVIORAL|Mindful Self Compassion Therapy|"Mindful Self-Compassion (MSC) therapy is an 8-week program blending mindfulness and self-compassion to improve emotional resilience and well-being.~Week 1: Introduction - Learn the basics of mindfulness, self-compassion, and reframing self-critical thoughts with kindness.~Week 2: Mindfulness - Practice observing thoughts and emotions without judgment to build self-awareness.~Week 3: Self-Kindness - Develop skills to treat yourself with warmth and care during difficult times.~Week 4: Common Humanity - Explore shared human experiences to reduce feelings of isolation.~Week 5: Working with Challenges - Learn strategies to respond compassionately to emotional pain.~Week 6: Growing Compassion - Deepen compassion for yourself and others through guided exercises.~Week 7: Resilience Building - Strengthen coping skills and foster emotional flexibility.~Week 8: Integration - Consolidate skills to maintain self-compassion in daily life."
223690555|NCT06878261|BIOLOGICAL|Tezepelumab|Tezepelumab subcutaneous injection
223690556|NCT06878261|OTHER|Placebo|Placebo subcutaneous injection
223690557|NCT07136103|DRUG|ABBV-277|• Intravenous (IV) infusion
223690558|NCT07136103|DRUG|Placebo|• Intravenous (IV) infusion
223690559|NCT05551052|DIAGNOSTIC_TEST|Next-Gen CRC Screening Test|The Next-Gen CRC Screening Test is a blood-based screening test for detection of CRC.
223690560|NCT07149662|DRUG|monoclonal CD-20 antibodies|Treatment with monoclonal CD-20 antibodies 6 months before or during pregnancy
223690561|NCT07149662|DRUG|No Drug|No medication
223690562|NCT07149662|DRUG|Other treatment|Any other immune modulating treatment
223690563|NCT07149519|DIETARY_SUPPLEMENT|probiotics - Lactobacillus spp|Group 1: Specific dietary guidance (low-FODMAP diet ) combined with placebo Group 2: Specific dietary guidance (low-FODMAP diet ) combined with probiotic Group 3: Control - Exclusive habitual diet After the 12-week period, we will evaluate the clinical improvement response of pelvic pain
223690564|NCT07150767|BIOLOGICAL|BioTTT001 injection|BioTTT001 is administered as a multiple Intratumoral injection. The dose groups to be infusion were 5.0×10\^10 viral particle (VP) ,2.0×10\^11 VP and 5×10\^11 VP based on the 3+3 dose escalation principle.
223690565|NCT07150923|OTHER|"Enhanced Standard of Care (Enhanced)"|"Enhanced Standard of Care (Enhanced) will include: Educational Materials and Outreach, Local Champions, Train the Trainer, Local Simulation Training, and SA Starter Packs."
223690566|NCT07150923|OTHER|"Enhanced Standard of Care (Enhanced-Plus)"|"Enhanced Standard of Care (Enhanced-Plus) will include: Educational Materials and Outreach, Local Champions, Train the Trainer, Local Simulation Training, SA Starter Packs, and three additional intensive external facilitation components."
223690567|NCT07150234|DEVICE|Acupuncture|The needles will be inserted in acupoints through adhesive pads. Needles will be lifted, thrusted and twirled gently for 3 times to achieve deqi sensation and manipulated every ten minutes.
223690568|NCT07150234|DEVICE|sham acupuncture|The needles will be inserted into the pad and reaching the skin. Needles will be lifted, thrusted and twirled gently for 3 times to simulate the effect of the needle tip penetrating the skin.
223690569|NCT07149337|OTHER|Oral phosphate load|Participants ingest an oral phosphate load containing 558 mg of phosphorus once.
223690570|NCT07149792|DIAGNOSTIC_TEST|Prescreen platform|Different biomarkers on PsO, PsA and paradoxical PsA
223690571|NCT07149792|BIOLOGICAL|biologics treatment|All psoriasis patients are receiving biologics treatment
223690572|NCT07150559|PROCEDURE|Arch-Clamping Technique under Mild Hypothermia|This procedure is performed under mild hypothermia. The branch arteries of the arch are reconstructed using the side arms of a Y-shaped graft, which allows bilateral antegrade cerebral perfusion (bACP) through the right axillary artery. A FET is deployed in the descending aorta and clamped together with the autologous aorta immediately, then distal perfusion is restored through the femoral artery. After the proximal procedures is completed, the distal anastomosis is performed in an end-to-end fashion. Finally, the main trunk of the Y-shaped graft is anastomosed to the proximal grafts.
223776701|NCT02648087|DEVICE|With and without SDB|Screening of sleep-disordered breathing (SDB)
223776702|NCT01950143|DIETARY_SUPPLEMENT|Standard broccoli soup|Volunteers will be required to consume one portion of broccoli soup per week as part of their normal diet for one year.
224263459|NCT06627621|PROCEDURE|Alveolar Ridge Reconstruction|scaffold guided alveolar bone regeneration
224263460|NCT04171115|DRUG|G03-52-01|G03-52-01 administered intramuscularly
224263461|NCT04171115|DRUG|Placebo|Placebo administered intramuscularly
223690573|NCT07150559|PROCEDURE|Arch-Clamping Technique under Moderate Hypothermia|This procedure is performed under moderate hypothermia. The branch arteries of the arch are reconstructed using the side arms of a Y-shaped graft, which allow bACP through the right axillary artery. A FET is deployed in the descending aorta and clamped together with the autologous aorta immediately, then distal perfusion is restored through the femoral artery. After the proximal procedures is completed, the distal anastomosis is performed in an end-to-end fashion. Finally, the main trunk of the Y-shaped graft is anastomosed to the proximal grafts.
223690574|NCT07150559|PROCEDURE|Total Arch Replacement combined Frozen Elephant Trunk Implantation using Bilateral Antegrade Cerebral Perfusion under Moderate Hypothermic Circulatory Arrest|This procedure is performed using bACP under MHCA, which involves FET deployment in the descending aorta followed by total arch replacement with a four-branched vascular graft. Deployment of the FET and suture of distal anastomosis are completed during bACP. MHCA is terminated and distal reperfusion is initiated once the distal anastomosis is completed, and the left carotid artery is reconstructed first (after which bACP is stopped, rewarming is started and the brain is perfused bilaterally). The root or valve procedures and some concomitant operations, if indicated, are performed during the cooling phase.
223690575|NCT07150429|OTHER|Verbal-Active Oral Hygiene Education with Negative Visual Aids|Verbal-Active Oral Hygiene Education with Visual Aid Variations
223690576|NCT07150429|OTHER|Verbal-Active Oral Hygiene Education (Control Group)|Control group
223690577|NCT07150429|OTHER|Verbal-Active Oral Hygiene Education with Positive Visual Aids|Verbal-Active Oral Hygiene Education with Visual Aid Variations
223690578|NCT07150299|DRUG|Mavacamten in clinical routine use|Clinical observation of mavacamten use
223690579|NCT07149532|OTHER|Biofeedback-based pelvic floor muscle training|Patients will receive the biofeedback-based pelvic floor muscle training (PFMT) alone.
223690580|NCT07149532|OTHER|Biofeedback-based pelvic floor muscle training (PFMT) with medical treatment|Patients will receive the biofeedback-based pelvic floor muscle training (PFMT) with medical treatment.
223690581|NCT07150936|BEHAVIORAL|stress ball application|Participants' demographic information will be collected interview using the Patient Information Form. Approximately 30 minutes before surgery, patients' systolic and diastolic blood pressure, heart rate, respiratory rate, and oxygen saturation will be measured and recorded. Pain severity will also be assessed using the VAS, and anxiety levels will be assessed using the VAS-A and Spielberger Trait Anxiety Scale. Intraoperative Period: All patients will be placed in the supine position on the operating room table. Patients in the intervention group will continue to use the stress ball for 15 minutes during the surgery, as per randomization. All patients will undergo a repeat 15-minute postoperative assessment of vital signs (systolic and diastolic blood pressure, heart rate, respiratory rate, oxygen saturation), pain with a VAS, and anxiety levels with a VAS-A. After the patients are taken to the clinic after the surgery, the same physiological measurements will repeated 10 mnt later
223690582|NCT04724395|OTHER|Hospitalization|Hospitalization in intensive care and non-intensive care units for COVID-19 followed by usual care
223690583|NCT04221412|DRUG|JNJ-53718678|JNJ-53718678 will be administered as directed by treating physician.
223690584|NCT06517810|DEVICE|QUELIMMUNE (SCD-PED)|QUELIMMUNE device used as part of clinical practice.
223690585|NCT03172910|DRUG|Ciraparantag|Ciraparantag (administered over 10 minutes)
223690586|NCT03172910|DRUG|Placebo|Saline for injection
223690587|NCT03172910|DRUG|Rivaroxaban|Rivaroxaban 20 mg given once per day (QD) in the morning
223690588|NCT06069726|DRUG|Atezolizumab|One dose of atezolizumab will be given prior to resection.
223690589|NCT04945330|DRUG|Larotrectinib (Vitrakvi, BAY2757556)|Follow clinical practice
223690590|NCT03062878|OTHER|Arterial blood pressure|Continuously monitored for 5-30 minutes via finger photoplesmography
223690591|NCT03062878|OTHER|Vascular Ultrasound|Assessment of carotid artery cross sectional area and intima-media thickness. Assessment of brachial artery diameter
223690592|NCT03062878|OTHER|Venous blood sample|Evaluation of oxidative stress via serum lipid hydroperoxide
223690593|NCT03062878|OTHER|Skin microcirculatory blood flow|Assessed non-invasively in the forearm skin via Laser Doppler flowmetry in response to locally delivered acetylcholine (ACh) and sodium nitroprusside (SNP) via iontophoresis.
223690594|NCT05307705|DRUG|LOXO-783|Oral
223690595|NCT05307705|DRUG|Fulvestrant|Intramuscular
223690596|NCT05307705|DRUG|Imlunestrant|Oral
223690597|NCT05307705|DRUG|Abemaciclib|Oral
223690598|NCT05307705|DRUG|Anastrozole, Exemestane, or Letrozole|Oral
223690599|NCT05307705|DRUG|Paclitaxel|Intravenous
223690600|NCT06565767|OTHER|cardiopulmonary resuscitation quality|variability in compression depth among different age groups, taking into account physical attributes, through an active learning approach and game-based learning framework
223690601|NCT05887648|BEHAVIORAL|SinDance|"One face-to-face briefing session (20 min) will be offered to participants in the SinDance group as part of promoting physical activity and safe exercise for older adults.~Participants will be asked to engage in SinDance 3 times a week for 6 weeks. Each session will last for about 30-40 mins, including 5 mins warm up exercise before the game and 5 mins cool down exercise afterwards.~All the game play sessions will be conducted in LB centres. Each participant will play the game individually.~To play the game, participants will dance to the dance moves shown on the screen (on the external monitor or the projected screen) and as they get each move right, they will be awarded points. The more accurate their moves are, the more points they get in the game.~During the gameplay, the participants will be instructed to stop and rest if they are tired. A RN/RA will be on site to observe the safety of exergaming and to help resolve technical issues as they arise."
223690602|NCT01350154|DRUG|Sildenafil|20 mg in gelatine capsules, oral, three times daily
223690603|NCT01350154|DRUG|Placebo|Lactose monohydrate oral in gelatine capsules, 3 times daily
223690604|NCT00032032|DRUG|carboplatin|
223690605|NCT00032032|DRUG|paclitaxel|
223690606|NCT00032032|RADIATION|radiation therapy|
223690607|NCT00538564|DRUG|tadalafil|10mg oral tablets taken 3 times a week for 2 months
223690608|NCT00538564|DRUG|placebo|Placebo tablets taken orally 3 times a week for 2 months
223690609|NCT04885946|OTHER|Fecal microbiota transplantion (FMT)|Single donor, fecal microbiota transplantion (FMT) from healthy human donors.
223690610|NCT04885946|OTHER|Placebo|Food coloring, water, glycerol
223690611|NCT02999399|OTHER|Brussel Sprouts|Subjects are given \~150 g of Brussels sprouts once daily for 7 consecutive days.
223690612|NCT02999399|DRUG|Deuterated Phenanthrene|Subjects are given 1 microgram of deuterated phenanthrene \[D10\]phe at baseline and after 7 days of Brussels sprout consumption. Urine is collected for 6 hours after each dose.
223690613|NCT02546115|DEVICE|tension night splint|this is the use of a commercially available tension night splint device, to be worn by the patient
223690614|NCT02546115|OTHER|standard practice - a structured rehabilitation programme|this is the standardised structured rehabilitation programme of home exercises given to patients, with supporting literature, and instructions on how to progress the regime themselves
223690615|NCT00729924|DRUG|Raltegravir|400mg orally every 12 hours for 7 days
223690616|NCT01199107|BEHAVIORAL|Prolonged Exposure|75-90 minute weekly psychotherapy sessions x 12 weeks, focused on gradually confronting distressing trauma-related memories and reminders
223690617|NCT01199107|BEHAVIORAL|Exercise|30 minutes of moderate-intensity treadmill exercise prior to the Prolonged Exposure
223690618|NCT01199107|BEHAVIORAL|Wellness Intervention|30 minutes of wellness education prior to Prolonged Exposure
223690619|NCT06199037|DRUG|SHR-1707|1 cohort of Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease patients will receive SHR-1707 injection
223690620|NCT06199037|DRUG|SHR-1707 placebo|1 cohort of Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease patients will receive SHR-1707 placebo injection
223690621|NCT04070144|DEVICE|IQ-Tip(tm) system|Physician performs therapeutic or diagnostic lumbar puncture using Injeq IQ-Tip(tm) system
223690622|NCT01638767|DRUG|Contraceptives, Oral|0.150 mg desogestrel and 0.030 mg ethinyl estradiol tablets, USP. One tablet per day at the same time each day, from the beginning of the menstrual cycle.
223690623|NCT01638767|DRUG|Contraceptive, Vaginal ring|etogestrel/ ethinyl estradiol slow release vaginal ring (11.4 mg/2.6 mg) to deliver 120 mcg etonogestrel/15 mcg ethinyl estradiol per day
223690624|NCT00400231|DRUG|Study drugs: Metformin and fenofibrate|145mg fenofibrate once/day and 2000mg/day of metformin for arm 3.
223690625|NCT00400231|DRUG|Study Drug: Metformin|2000mg/day
223690626|NCT00400231|DRUG|Study Drug: fenofibrate|145mg/day of fenofibrate
223690627|NCT00400231|DRUG|Metformin and Fenofibrate placebo|placebo metformin and fenofibrate
223690628|NCT02862899|DEVICE|Thermowire|
223690629|NCT02250859|DRUG|FMX101, Minocycline 4% foam|FMX101, Minocycline 4% foam to be applied twice daily for 16 consecutive days
223690630|NCT01330706|DRUG|Polihexanide|The investigators compared intraoperative antiseptic irrigation using 0.9% saline solution and 0.1% polihexanide.
223690631|NCT01847001|DRUG|Propranolol|Propranolol starting dose is 20mg b.i.d.; propranolol dose is up-titrated to 40mg b.i.d. to 80 mg daily with chemotherapy depending on tolerability. Tolerability is assessed every 2 weeks.
223690632|NCT01847001|OTHER|DOT imaging|(Non-experimental) During the baseline visit, you will undergo DOT evaluation of your tumor for determination of blood, fat, and water content in the affected and unaffected breast. DOT readings will be obtained at 4 additional time points: after paclitaxel week #3, before AC week #1, before AC week #3, and prior to surgery.
223690633|NCT01847001|DRUG|Paclitaxel|(Non-experimental) given as a one-hour intravenous infusion (IV) every week for a total of 12 weeks; the first dose of paclitaxel may be given over 90 minutes, per the discretion of your treating doctor. The dose will be given in 80 mg/m2 based on individual body surface area (BSA). This drug is given through a vein in the arm or a catheter (eg. Infusaport, Portacath).
223690634|NCT01847001|DRUG|Nab-paclitaxel|(Non-experimental) In the event paclitaxel is not available due to manufacturing and supply shortages, nab-paclitaxel will be substituted for paclitaxel. The dose is 100 mg/m2 IV infusion over 30 minutes weekly (or institutional standard). No premedications are given with nab-paclitaxel.
223690635|NCT01847001|DRUG|Trastuzumab|(Non-experimental) (only if HER2-positive): Trastuzumab is given as an IV infusion initially over 90 minutes for the first dose, then 30-60 minutes every 3 weeks in subsequent doses if well tolerated. To be given every 3 weeks with paclitaxel/propranolol.
223776703|NCT01950143|DIETARY_SUPPLEMENT|Beneforte broccoli soup|Volunteers will be required to consume one portion per week of a soup containing glucoraphanin-enriched broccoli (Beneforte®) as part of their normal diet for one year.
223690636|NCT01847001|DRUG|Pertuzumab|(Non-experimental) (only if HER2-positive): Pertuzumab is given as an IV infusion over 60 minutes on the first dose, then 30-60 minutes every 3 weeks if well tolerated. To be given every 3 weeks with paclitaxel/propranolol.
223690637|NCT01847001|DRUG|Doxorubicin|(Non-experimental) Doxorubicin will be given as a 510 minute intravenous infusion (IV) in a dose of 60 mg/m2; cyclophosphamide will be given as a 3060 minutes intravenous infusion (IV) in a dose of 600 mg/m2 based on BSA. This chemotherapy regimen will be given every 2 weeks for total of 8 weeks or 2 months.
223690638|NCT01847001|DRUG|Cyclophosphamide|(Non-experimental) Doxorubicin 60 mg/m2 IV over 5-10 minutes, Cyclophosphamide 600 mg/m2 IV infusion over 30-60 minutes. The first cycle should be initiated with 3 weeks after the last paclitaxel and/or trastuzumab/pertuzumab dose.
223690639|NCT01847001|PROCEDURE|Surgery|After you complete all chemotherapy plus propranolol treatment, you will then have surgery to remove the breast tumor if your doctor feels that it is medically appropriate (if you have had a good response to the treatment) - lumpectomy/mastectomy.
223776704|NCT01950143|DIETARY_SUPPLEMENT|Beneforte extra broccoli soup|Volunteers will be in which they will be required to consume one portion per week of a soup containing an other variety of glucoraphanin-enriched broccoli (Beneforte extra) as part of their normal diet for one year.
223776705|NCT03143244|DRUG|Dexmedetomidine group (D)|Patients received 1ug/kg dexmedetomidine in 50 ml saline over 10 min i.v 30 min before induction then 0.4 ug/kg/h dexmedetomidine (4ug/ml) and normal saline 0.1 ml/kg till end of surgery, using two syringe pumps one for dexmedetomidine and the other for saline
223776706|NCT03143244|DRUG|Ketorolac-Midazolam group (KM)|Patients received 0.5mg/kg ketolac in 50 ml saline over 10 min before induction and 25ug/kg midazolam in 50 ml saline over 10 min i.v 30 min before induction then 50ug/kg/h of ketolac and 40ug/kg/h midazolam till end of surgery in two separate syringe pumps.
223690640|NCT01847001|DRUG|Premedication|As premedication to prevent some of the side effects associated with paclitaxel, you will also receive dexamethasone (Decadron) in a dose of 10 mg, diphenhydramine (Benadryl) in doses of 2550 mg, and an H2 blocker (eg. ranitidine 50 mg or equivalent) 3060 minutes before each paclitaxel infusion. If no hypersensitivity reactions are experienced, dexamethasone may be reduced in increments of 2 mg per week per dose (until a minimum of 2 mg has been reached).
223690641|NCT01847001|DRUG|Anti-nausea therapy|In addition to doxorubicin, you will receive an anti-nausea therapy and dexamethasone about 3060 minutes before AC chemotherapy.
223690642|NCT01847001|DRUG|Pegfilgrastim|When you receive the AC chemotherapy, you will also receive treatment with a drug called pegfilgrastim (Neulasta). Neulasta is a commercially available drug. It stimulates the production of white blood cells and reduces the likelihood of developing a low white blood cell count and fever after chemotherapy. It will be given as an injection under the skin on the day after each chemotherapy treatment (day 2).
223690643|NCT05131360|BEHAVIORAL|Introduction Only|This is the placebo condition in which participants engage in one day of introductory mindfulness activities.
223690644|NCT05131360|BEHAVIORAL|Purpose Only|Participants engage in one day of introductory mindfulness activities followed up by 5 days of purpose-based mindfulness techniques.
223690645|NCT05131360|BEHAVIORAL|Connection Only|Participants engage in one day of introductory mindfulness activities followed up by 5 days of connection-based mindfulness techniques.
223690646|NCT05131360|BEHAVIORAL|Connection and Purpose|Participants engage in one day of introductory mindfulness activities followed up by 5 days of connection and purpose-based mindfulness techniques.
223690647|NCT05131360|BEHAVIORAL|Awareness Only|Participants engage in one day of introductory mindfulness activities followed up by 5 days of awareness-based mindfulness techniques.
223690648|NCT05131360|BEHAVIORAL|Awareness and Purpose|Participants engage in one day of introductory mindfulness activities followed up by 5 days of awareness and purpose-based mindfulness techniques.
223690649|NCT05131360|BEHAVIORAL|Awareness, Purpose, and Connection|Participants engage in one day of introductory mindfulness activities followed up by 5 days of awareness, connection, and purpose-based mindfulness techniques
223690650|NCT05131360|BEHAVIORAL|Awareness and Connection|Participants engage in one day of introductory mindfulness activities followed up by 5 days of awareness and connection-based mindfulness techniques.
223690651|NCT06403670|DRUG|Dexmedetomidine|Group DP received 0.5 mcg/kg of dexmedetomidine IV for 30 seconds, then dexmedetomidine infusion was started at 0.1-0.7 mcg/kg/h. Propofol 1 mg/kg was administered after waiting for 5 minutes for adequate sedation to develop due to dexmedetomidine's delayed onset of action.
223690652|NCT06403670|DRUG|Remifentanil|Group RP received remifentanil 0.1 mcg/kg intravenously for 30 seconds, then remifentanil infusion was started at 0.01-0.1 mcg/kg/min. After waiting 2 minutes to develop a sufficient sedation level, 1 mg/kg of propofol was given.
223690653|NCT04652232|OTHER|RV3466F lotion|"Code: RV3466F Formula: MF5354~Application modalities:~3 times per week, in the evening, on a dry scalp 10 sprays overall hair after having achieved hair rays in order that the product is in contact with the scalp. Then massage to promote penetration of the lotion. Don't rinse.~Shampoo should be avoided within the 2 hours after application"
223690654|NCT04652232|OTHER|Shampoo|"Associated neutral shampoo: Extra mild shampoo Ducray® Code: RD0057H Formula: VS4031~Application modalities:~as often as usual~For the treated group only : no shampoo within the 2 hours after lotion application"
223690655|NCT06220279|DRUG|Diclofenac|Each were monitored for pain within 24 hours
223690656|NCT01927341|DRUG|MEK162|Tablet for oral use, 45 mg (three 15 mg tablets), BID
223690657|NCT01927341|DRUG|Panitumumab|Intravenous infusion, 20mg/ml concentrate solution for infusion, Q2W (Days 1 and 15 of every cycle)
223690658|NCT02235519|DRUG|Azilsartan 40 mg.|Patients will take 40 mg of azilsartan during 12 weeks
223690659|NCT02235519|DRUG|Azilsartan 80 mg|Patients will take 80 mg of azilsartan during 12 weeks
223690660|NCT03250169|DRUG|Alemtuzumab|Licensed dose
223690661|NCT02022631|OTHER|Alternative summary of findings table format|Investigators will compare one SoF table with alternative formats (Table A) against one SoF table with the current formats (Table B). In both tables, the clinical question in terms of patients and setting, intervention, comparator, and outcomes informed by the tables, and the complementary information included as footnotes will be the same. The only differences between the current and alternative SoF table formats will be different methods to either show the same data in a different way or to provide complementary data to the one showed in the current format (i.e. supplementary data as risk difference).
223690662|NCT02022631|OTHER|Current summary of findings table format|Investigators will compare one SoF table with alternative formats (Table A) against one SoF table with the current formats (Table B). In both tables, the clinical question in terms of patients and setting, intervention, comparator, and outcomes informed by the tables, and the complementary information included as footnotes will be the same. The only differences between the current and alternative SoF table formats will be different methods to either show the same data in a different way or to provide complementary data to the one showed in the current format (i.e. supplementary data as risk difference).
223690663|NCT00411112|PROCEDURE|blue and isotopic detection of sentinel lymph nodes|
223690664|NCT05030324|DRUG|XC221 100 mg|Regardless of the group, all study subjects will receive the standard symptomatic therapy for influenza and other viral URIs, taking into account the latest clinical guidelines (the necessity of symptomatic therapy will be decided by the Investigator).
223690665|NCT05030324|DRUG|XC221 200 mg|Regardless of the group, all study subjects will receive the standard symptomatic therapy for influenza and other viral URIs, taking into account the latest clinical guidelines (the necessity of symptomatic therapy will be decided by the Investigator).
223690666|NCT05030324|DRUG|Placebo|Regardless of the group, all study subjects will receive the standard symptomatic therapy for influenza and other viral URIs, taking into account the latest clinical guidelines (the necessity of symptomatic therapy will be decided by the Investigator).
223690667|NCT04918576|DRUG|Tranexamic acid|3 grams of tranexamic acid (30mL of 100 mg/mL solution) diluted in 10 mL of normal saline
223690668|NCT04918576|DRUG|Normal Saline|40 mL topical of 0.9% normal saline
223690669|NCT00248131|DRUG|Octreotide acetate in microspheres|
223690670|NCT01397201|DRUG|Placebo|Placebo matching fluticasone propionate HFA MDI
223690671|NCT01397201|DRUG|BI 54903|BI 54903
223690672|NCT01397201|DRUG|Fluticasone propionate|Fluticasone propionate
223690673|NCT04209062|DEVICE|Medical device validation|The medical devices will both record electrical signals for comparison
223690674|NCT05064904|DRUG|never received RAAS blockers or received RAAS blockers before AKI.|"Enrollees who are not received renin-angiotensin-aldosterone blockers (RAAS) are randomly assigned to slow kidney function progression by adding RAAS blockers by receiving at least defined daily dose equal to Losartan 50mg or Captopril 25mg bid. The acute kidney disease (AKD) consultation should be transferred at least one time within 90 days after index hospital discharge after withdrawing from dialysis requiring AKI (AKI-D).~All enrolled patients are randomly referred to receive comprehensive multidiscipline consultation targeting a glycated hemoglobin level of less than 7.0%, systolic blood-pressure, target, \<130 mm Hg, low density lipid (LDL) less than 100mg/dL and control of hyperuricemia less than 7.2mg/deal in male as well as 6.1mg/dl in females. We suggest to adherence to low protein diet achieve the goal of hemoglobin more than 11g/L at 180 day after index discharge."
223690675|NCT00849537|DRUG|Triamcinolone|Injection of intravitreal Triamcinolone
223690676|NCT04691401|DEVICE|Artificial Intelligence System (CAD EYE, Fujifilm Co.)|A dedicated CNN-based AI system (CAD EYE, Fujifilm Co, Tokyo, Japan) has been recently developed. The Computer-aided diagnosis (CAD) CAD EYE system is a real-time computer-assisted image analysis that allows automatic polyp identification without modifications to the colonoscope or to the actual endoscopic procedure. When CAD EYE identifies a polyp, both a visual (a green blinking box surrounding the identified polyp, called the detection box) and an acoustic alarm pop up and attract the endoscopist attention. Around the endoscopic image a visual assist circle is shown and lights up in the direction where the suspicious polyp is detected.
223690677|NCT00000612|DRUG|estrogens, conjugated|
223690678|NCT00000612|BEHAVIORAL|diet, soy proteins|
223776707|NCT03143244|DRUG|Control group (Normal Saline) (C)|Patients received normal saline in two sets
223776708|NCT02035007|DEVICE|PiCCO Catheter (Pulsiocath 5F)|Measuring of PiCCO derived values
223776709|NCT03357458|BEHAVIORAL|Family Integrated Care|FICare is a dynamic psycho-educational intervention. The goal of FICare is a change in culture and practice that permits, encourages and supports parents in their parenting role while their infant is receiving health care in a Level II NICU. Underpinned by adult learning and change theories, FICare empowers parents to build their knowledge, skill and confidence so that the family is well-prepared to care for their infant long before discharge.
223776710|NCT06467318|DRUG|Paracetamol|Participants post mechanical pleurodesis on pneumothorax will be divided into two groups: Group A: patients taking classic pain management with NSAID. Group B: patients taking classic pain management without NSAID.
223690679|NCT00000612|BEHAVIORAL|dietary supplements|
223776711|NCT06467318|DRUG|NSAID, Paracetamol|Participants post mechanical pleurodesis on pneumothorax will be divided into two groups: Group A: patients taking classic pain management with NSAID. Group B: patients taking classic pain management without NSAID.
223835686|NCT01997502|DEVICE|Pulse CO-Oximetry Technology|"In addition to the standard pulse oximeter used for clinical care, up to six SpHb finger sensors will be applied to the patient. Additional sensors may also be applied to the forehead, neck, chest and ears.~Masimo FDA cleared pulse CO-Oximeter devices: Radical-7, Rad-87, Rad-57, Pronto, Pronto-7, for the noninvasive measurement of SpO2, PR, PI, PVI, SpCO, SpMet, and SpHb, total hemoglobin and respiratory rate.~No treatment decisions will be made based on the new technology and no extra medical procedures are required for the study."
223690680|NCT05272839|DIETARY_SUPPLEMENT|Hypoglycemic food group|A booklet with 4 common food products, clinically validated against diabetes, with instructions for use will be presented to the diabetic patient. The selected food products have been assessed as anti-diabetic for humans through at least one fair randomized comparative clinical trial, with a follow-up of several weeks or months. While continuing to take his/her standard medication if any, the patient will be encouraged to follow his/her preferences within the established list of foods and spices: he is expected to choose 2 plants from the list and to consume each of them every day during the whole duration of the trial (12weeks).
223690681|NCT05272839|DIETARY_SUPPLEMENT|Control group|The control group will receive only lifestyle and dietary recommendations.
223690682|NCT02380144|OTHER|Fresh orange fruit and pasteurized fruit juice|
223776712|NCT06165003|OTHER|Use of broselow tape|"In the research, the nurse is the decision maker in the selection of the catheters to be used in the procedures (peripheral intravenous catheter insertion, urinary catheter insertion, aspiration procedure, nasogastric/orogastric catheter insertion) for the patients in the control group.~In these procedures, the nurse's choices will be evaluated as control group data as routine clinical practice.~After the control group data is collected, Broselow tape will be used in the selection of catheters to be used in the procedures to be performed on the patients in the experimental group (peripheral intravenous catheter insertion, urinary catheter insertion, aspiration procedure, nasogastric/orogastric catheter insertion).~Our research will be conducted to examine the effect of nurses' use of Broselow tape in non-resuscitation applications and to minimize errors and application disruptions in procedures involving nurses."
223776713|NCT00764348|OTHER|no treatment|
223776714|NCT02005341|DEVICE|nanOSS|
223776715|NCT02005341|DEVICE|Autograft|
223776716|NCT02477384|PROCEDURE|8mm-TIPS|
223776717|NCT02477384|PROCEDURE|Endoscopic variceal ligation|
223776718|NCT02477384|DRUG|Propranolol|
223690683|NCT01245920|BIOLOGICAL|DFDBA + Bio-Gide Membrane|For patients in the FDBA + membrane group, a layer 4 mm thick of cancellous allograft bone (Puros Cancellous, Zimmer Dental inc., Carlsbad, CA) will be placed over the buccal bone in the area of the implant. A resorbable collagen membrane (Bio-Gide, 13 x 25 mm, Osteohealth, Shirley, NY) will be trimmed to extend 5 mm beyond the implant borders and to cover the implant head. Following membrane placement over the bone graft, the gingival flaps will be closed and sutured with 4-0 Vicryl (Ethicon Inc., Sommerville, NJ) with passive tension flap closure.
223690684|NCT01245920|OTHER|Non-FDBA|Patients in the non-FDBA group will have gingival flaps closed with the same suturing technique.
223690685|NCT04960800|OTHER|Specific exercises|Specific exercises which aims to contract the recti abdominis combined with functional exercises with the aim to contract all the layers of the anterior abdominal wall. Strengthening dosage will be applied with 3 sets, containing between 8 and 12 repetitions of maximal load.
223690686|NCT00283231|BEHAVIORAL|Paced Respiration|
223690687|NCT01413061|PROCEDURE|Subtalar Arthrodesis|
223690688|NCT02421029|DRUG|edetate calcium disodium|All subjects will receive a 250 mL 5% dextrose intravenous infusion over 1 hour that contains 1 gr of edetate calcium disodium
223690689|NCT05996627|DRUG|Belumosudil|Given PO
223690690|NCT05996627|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223690691|NCT05996627|OTHER|Electronic Health Record Review|Ancillary studies
223690692|NCT05996627|DRUG|Placebo Administration|Given PO
223690693|NCT01054326|OTHER|Exercises|
223690694|NCT00171743|DRUG|Cyclosporine microemulsion|
223690695|NCT01135602|DRUG|Topiramate|Topiramate 50-300 mg/day Orally Twice per day
223690696|NCT04648280|DRUG|Fostemsavir|fostemsavir in combination with optimized background therapy (OBT) in HIV-1 infected children and adolescents who are failing their current combination antiretroviral therapy (cART) and have dual- or triple-class ARV resistance
223690697|NCT05335278|DRUG|Nintedanib 150 milligrams [Ofev]|All patients will be given nintedanib 150 milligrams orally twice daily
223690698|NCT00215683|DRUG|Degarelix|Drug supplied as a powder to be dissolved in the solvent for solution for injection. Degarelix given by subcutaneous injection every 28 days until the end of the study.
223690699|NCT02858011|OTHER|Cash distribution during first 36 months|Three-monthly distribution of Cash (30,000 FCFA/trimester) to households that are beneficiary of the Jigisemejiri program.
223690700|NCT02858011|BEHAVIORAL|Accompanying information sessions on health, child nutrition, household economics and education during first 36 months|Large group gatherings of cash beneficiaries are organized in parallel to the cash distributions. During these meetings, local NGOs present and discuss a topic related to health, child nutrition, household economics or education.
223690701|NCT02858011|DIETARY_SUPPLEMENT|Preventive Nutrition Packages during last 12 months|Fortified flour supplements for children (Supercereal Plus)and pregnant/lactating mothers (super Cereal)
223690702|NCT02858011|OTHER|Cash distribution during the last 12 months|Three-monthly distribution of Cash (30,000 FCFA/trimester) to households that are beneficiary of the Jigisemejiri program.
223690703|NCT02858011|BEHAVIORAL|Accompanying information sessions on health, child nutrition, household economics and education during the last 12 months|Large group gatherings of cash beneficiaries are organized in parallel to the cash distributions. During these meetings, local NGOs present and discuss a topic related to health, child nutrition, household economics or education.
223690704|NCT02026284|OTHER|Questionnaire|A questionnaire was performed to gravid women who are to deliver, regarding theri anesthesia preferences.
223690705|NCT03539848|DEVICE|I-PAS Goggles|Portable, head-mounted display goggle system with integrated eye capture technology
223776719|NCT02477384|DEVICE|8mm ePTFE-covered stent|
223690706|NCT04356326|DRUG|Aspirin 150 mg|Treatment assigned by randomization will be prescribed immediately and continued throughout pregnancy up to 35 weeks + 6 days for both groups. The active or placebo will be dispensed by the centre's pharmacy. Treatment will be taken in the evening. A daily log is given to patients and must be completed every day.
223690707|NCT04356326|DRUG|Placebo|Treatment assigned by randomization will be prescribed immediately and continued throughout pregnancy up to 35 weeks + 6 days for both groups. The active or placebo will be dispensed by the centre's pharmacy. Treatment will be taken in the evening. A daily log is given to patients and must be completed every day.
223690708|NCT04233034|DEVICE|HCL|Hybrid Closed Loop therapy
223690709|NCT04233034|DRUG|verapamil 120mg tablet|verapamil tablet
223690710|NCT04233034|DEVICE|non-HCL|Usual diabetes care
223690711|NCT04233034|DRUG|placebo|placebo pill manufactured to mimic verapamil 120mg tablet
223776720|NCT01463605|DRUG|Nimotuzumab|Nimotuzumab 200mg,once per week,for 5 to 6 weeks
223776721|NCT03251703|PROCEDURE|Ultrasound-Guided Suprascapular Pulsed Radiofrequency .|The ultrasound-Guided Suprascapular Pulsed Radiofrequency was administered under operating room conditions while the patient was monitored in a sitting position.An ultrasound-guided 22 G 5-mm active-tip 100-mm radiofrequency needle (SC-K; Top Neuropole, Tokyo, Japan) was pushed forward towards the suprascapular notch until it passed the transverse scapular ligament using an in-plane approach.
223776722|NCT04636892|OTHER|MindMics earbud|Novel noninvasive wearable infrasound sensor
223690712|NCT04493333|DRUG|Vaginal Dehydroepiandrosterone|This is a vaginally administered suppository steroid indicated for the treatment of moderate to severe dyspareunia, a frequent symptom of vulvovaginal atrophy due to menopause or genitourinary syndrome of menopause.
223776723|NCT05460624|OTHER|Egg-containing breakfast|Involves participants eating six premade egg-containing breakfast meals per week for 12 weeks. Each meal contains 2 eggs to provide 12 eggs per week.
223690713|NCT04493333|COMBINATION_PRODUCT|Vaginal Polycarbophil Moisturizer|This is an FDA cleared, over-the-counter personal lubricant for vaginal application, intended to moisturize and lubricate, to enhance the ease and comfort of intimate sexual activity and supplement the body's natural lubrication. It is non-sterile, water-based, non-irritating, non-greasy, non-staining vaginal gel delivered as a long-lasting moisturizer for vaginal dryness.
223690714|NCT06472245|DRUG|OSE2101|OSE2101 is a peptidic cancer vaccine composed of nine epitopes restricted to HLA-A2 phenotype targeting the tumor associated antigens of P53, HER-2, CEA, MAGE-2 and MAGE-3, and one pan-HLA DR binding epitope (PADRE), all epitopes emulsified in Montanide ISA 51TM adjuvant.
223690715|NCT06472245|DRUG|Docetaxel|Docetaxel is an antineoplastic agent that acts by disrupting the microtubular network in cells that is essential for mitotic and interphase cellular functions.
223690716|NCT06472245|DEVICE|NGS HLAA2 assay|Amp-HLA-A-CDx Tedopi for amplification of human genomic DNA (gDNA), LFK-CDx Tedopi kit (library full kit) for library preparation, NGSengine-CDx Tedopi software for analysis of NGS data files.
223690717|NCT02791399|BEHAVIORAL|ISOP Intervention with the Nurse Care Manager|A Nurse Care Manager (NCM) will maintain a registry of enrolled patients, track opioid medication-related events from the medical record, and provide decision support to Primary Care Providers for issues related to prescription opioid safety. The NCM will also meet individually with enrolled participants in the intervention group to discuss strategies for preventing/reducing opioid side effects, preventing diversion, and providing rationale for screening for prescription opioid misuse.
223690718|NCT02135159|DRUG|TDM1|administration of the TDM1 by IV perfusion
223690719|NCT02135159|RADIATION|Brain Sequential RT|local RT
223690720|NCT06039410|DEVICE|ISO-101|ISO-101 is an experimental wearable class 1 medical device which when used is able to raise the blood pressure upon standing via controlled isometric muscular contractions
223690721|NCT05271162|DRUG|Empagliflozin 10 MG|Empagliflozin 10 mg q.d; p.o
223690722|NCT05271162|OTHER|Placebo|Placebo 1 tabl q.d; p.o
223690723|NCT01991106|BEHAVIORAL|High intensity interval training|Twelve weeks of 2-3 supervised training sessions each week.
223690724|NCT01991106|BEHAVIORAL|Moderate intensity continuous training|Twelve weeks of 2-3 supervised training sessions each week.
223690725|NCT01991106|DIETARY_SUPPLEMENT|Nutritional advice|healthy food choices, portion sizes and regular mealtimes
223690726|NCT06283524|DEVICE|Eye-Tracking|Eye-tracking technology and algorithms used to successfully capture and track eye movements using an electronic tablet and the embedded camera of the device.
223690727|NCT00451451|DRUG|BG00012|
223690728|NCT00451451|DRUG|Placebo|
223690729|NCT00451451|DRUG|Glatiramer Acetate|
223690730|NCT04603053|BEHAVIORAL|mHealth app|Participants will receive access to CBot-A app for 12 weeks.
223690731|NCT00462631|DEVICE|Paclitaxel Eluting Balloon|Paclitaxel eluting balloon
223690732|NCT00462631|DEVICE|paclitaxel eluting stent|paclitaxel eluting stent
223690733|NCT00462631|DEVICE|bare metal stent|bare metal stent
223690734|NCT04501939|DRUG|Cirmtuzumab|Cycle 1, Day 1 \& 15 - 600mg Cycle 2, Day 1 to Cycle 6, Day 1 - 600mg
223690735|NCT04501939|DRUG|Venetoclax|Venetoclax 400mg PO daily from cycle 1 day 1 for 6 cycles of 28 days.
223690736|NCT03320603|OTHER|Expert eCRF|An expert eCRF will be used to guide physicians during the management of patients treated with Vitamin K Agonist or Direct Oral Anticoagulant admitted in emergency units for severe bleeding.
223690737|NCT03320603|OTHER|Prothrombin Complex Concentrate|Prothrombin Complex Concentrate given as standard of care
223690738|NCT02013869|DEVICE|Flow-I, a modern anaesthetic machine without a bag/below/gas reservoir for compression of insufflation gas|Desflurane Dialed setting 18 % on the machine gas vaporized
223690739|NCT02013869|DEVICE|Asys, a anaesthetic machine with a bag/bellow for compression of gas to be insufflated|Desflurane dialed 18% on the machine gas vaporized
223690740|NCT01764425|DRUG|P7435|It is oral DGATI inhibitor with potential in dyslipidemia and T2DM
223690741|NCT06156540|OTHER|virtual reality glasses|Using virtual reality glasses, caregivers in the experimental group were shown 360-degree VR relaxing videos.
223690742|NCT04407260|DEVICE|Oxygen Hood|High-Flow Oxygen Hood with neck dam and intake and exhaust tubing incorporating a Bacterial/Viral HEPA filter and optional PEEP attachment.
223690743|NCT04824183|OTHER|Music intervention|Three WhatsApp sessions will be delivered before the surgery. In the first session, participants will describe their experience with the diagnosis of breast cancer and acceptance. In the second session, participants will be educated on anxiety before their surgery, how anxiety is being managed in the hospital and self-care strategies for anxiety like MI, how to report preoperative anxiety. The third session will include postoperative pain education. The pain education will include information about the type of pain to expect after surgery, medications, pain reporting and MI for pain management. Telephone session; on the day of surgery and at 24 and 48 hours after surgery, a reminder will be sent to the participants by WhatsApp group chat. Face-to-face; MI delivery will involve the delivery of the MP3 to participants and monitoring of their use for 30 minutes both on the day of surgery and 24 and 48 hours after surgery.
223690744|NCT06431373|DRUG|Brepocitinib PO QD|Brepocitinib PO QD
223690745|NCT06431373|DRUG|Placebo PO QD|Placebo PO QD
223690746|NCT02898155|OTHER|measure of access to primary care and of the Interface Between Primary ans Secondary Care|
223690747|NCT01002482|DEVICE|CGAO-based Glucose Control|"Use of a clinical computerized decision-support system named CGAOtm designed to achieve tight glucose control in various ICU settings, and fine-tuned to reduce glucose variability without increasing the incidence of severe hypoglycemia or nurse workload.~CGAOtm is based on explicit replicable recommendations following each blood glucose measurement for insulin rates and time to next measurement, and reminders, alerts, graphic tools, trends, and individual on-line data aimed at increasing confidence of the nursing staff in the computer protocol and giving care staff a method for controlling the process during the whole ICU stay, according to a human-in-the-loop approach.~The algorithm used in the CGAOtm software for the calculation of the recommended insulin rates derived from a PID (Proportional-integral-derivative) controller, a generic control loop feedback mechanism widely used in industrial control."
223690748|NCT01002482|DEVICE|Standard-Care Glucose Control|"Patients in the control group will receive conventional insulin therapy using the usual care protocol of each participating centre (already used in the centre before the beginning of the trial and targeting blood glucose levels inferior to 180 mg/dl)."
223690749|NCT02002611|DRUG|Lobeglitazone|
223690750|NCT02002611|DRUG|Warfarin|
223690751|NCT01865084|DRUG|Tadalafil|Administered orally
223690752|NCT01865084|DRUG|Placebo|
223690753|NCT01598675|OTHER|Same Belt Speeds|18 sessions of training (3X/week). 20 minutes/session on treadmill; 10 minutes/session overground 70-75%HRmax. Control-Dual-belted treadmill belts respond to encourage symmetric gait
223690754|NCT01598675|OTHER|Different Belt Speeds|18 sessions of training (3X/week). 20 minutes/session on treadmill; 10 minutes/session overground 70-75%HRmax. Treadmill belts of dual-belted treadmill respond either to amplify asymmetric gait or encourage symmetric gait.
223690755|NCT02469376|DRUG|[18F]-GP1|Radiopharmaceutical Product (Tracer) to visualize with Positron Emission Tomography a thrombus in humans.
223690756|NCT05073640|DRUG|Oxopurin|Subjects will receive two capsules per day.
223690757|NCT02619669|DRUG|TAK-228|Millennium has developed TAK-228, which is a novel, highly selective, orally bioavailable adenosine 5' triphosphate (ATP)-competitive inhibitor of the serine/threonine kinase referred to as the mechanistic target of rapamycin (mTOR). TAK-228 (formerly INK128 or MLN0128) targets 2 distinct multiprotein complexes, mTORC1 and mTORC2. TAK-228 selectively and potently inhibits mTOR kinase (IC50 = 1.1 nM), inhibits mTORC1/2 signaling, and prevents cellular proliferation.
223690758|NCT02619669|DRUG|Letrozole|An aromatase inhibitor that has a greater inhibitory effect on Ki67 (marker of cell proliferation).
223690759|NCT02289001|BEHAVIORAL|Education on SBAR worksheet|The intervention group will receive one hour of training in teamwork skills, distribution of roles and use of the SBAR worksheet before participating in the simulated scenario using a human patient simulator (HPS).
223690760|NCT00315159|PROCEDURE|Sentinel Node Biopsy|Inguinal sentinel node biopsy will be performed.
223690761|NCT00471016|BEHAVIORAL|Guided intervention|
223690762|NCT04351997|PROCEDURE|Cord clamping|Umbilical cord clamping after delivery.
223690763|NCT05272449|DEVICE|Sleep apnea diagnosis|Split-night
223690764|NCT00503516|DRUG|Megestrol acetate|1 sachet of powder containing 160 mg of megestrol acetate b.i.d. during 24 weeks
223690765|NCT00503516|DRUG|Placebo|1 sachet of 160 mg of placebo b.i.d.
223690766|NCT05132868|OTHER|Educational video and pamphlet|The primary intervention in this study is watching the video or reading the pamphlet in advance of the genetic counseling session, which overview the same information that we currently provide in-person/via telehealth during the genetic counseling session.
223690767|NCT05132868|OTHER|Traditional genetic counseling|Patients will receive traditional genetic counseling
223690768|NCT03319667|DRUG|Isatuximab SAR650984|"Pharmaceutical form: Solution for infusion~Route of administration: Intravenous (IV)"
223690769|NCT03319667|DRUG|Bortezomib|"Pharmaceutical form: Lyophilized powder for injection~Route of administration: Subcutaneous"
223690770|NCT03319667|DRUG|Lenalidomide|"Pharmaceutical form: Capsules~Route of administration: Oral"
223690771|NCT03319667|DRUG|Dexamethasone|"Pharmaceutical form: Tablets, ampoules or vials for injection~Route of administration: Oral/Intravenous"
223690772|NCT00796185|DRUG|Paliperidone ER|
223690773|NCT03732690|OTHER|Diet HP|"2000kcal for men 1800 kcal for women. Food boxes (HP pre-cooked meals and meat/chicken/fish portions, HP breads and snacks) will be provided to the participants throughout the study reaching 40-50% of their prescribed daily energy intake for 6 days per week. In total 932 kcal are provided through this food boxes (54g of carbohydrate, 101g of protein, 34,6g of fat). The rest of the daily food intake will be guided by a dietician with a list of recommended high protein foods.~Subjects are required to keep food diaries three days a week and will also have weekly contact with a dietician."
223690774|NCT03732690|OTHER|Diet LP|2000kcal for men 1800 kcal for women. Food boxes (LP pre-cooked meals, LP breads and snacks) will be provided to the participants throughout the study
223690775|NCT03294473|BEHAVIORAL|R/R - Autodialers|Investigators will send out flu vaccine reminder recall notices via autodialer message to the parents of children 6 months - 17 years of age who are due for the flu vaccine, per the records in the New York State Immunization Information System (NYSIIS).
223690776|NCT03294473|BEHAVIORAL|R/R - Texting|Investigators will send out flu vaccine reminder recall notices via text message to the parents of children 6 months - 17 years of age who are due for the flu vaccine, per the records in the New York State Immunization Information System (NYSIIS).
223690777|NCT03294473|BEHAVIORAL|R/R - mailed postcard|Investigators will send out flu vaccine reminder recall notices via mailed postcards to the parents of children 6 months - 17 years of age who are due for the flu vaccine, per the records in the New York State Immunization Information System (NYSIIS).
223690778|NCT05536479|PROCEDURE|Autogenous stored mineralized dentin graft (ASMDG)|"Autogenous stored mineralized dentin graft (ASMDG) particles will be prepared by immersing tooth particles in basic ethanol for 10 min for disinfection, then washed twice in saline and dried using sterile gauze.~The disinfected particles will then be stored at room temperature for 21 days in a sterile container. After 21 days, a second extraction will be performed followed by mixing the stored graft with a few drops of sterile saline to be packed in a socket after extraction"
223690779|NCT05536479|PROCEDURE|Autogenous fresh mineralized dentin graft (AFMDG)|Autogenous fresh mineralized dentin graft (AFMDG) particles will be prepared by immersing tooth particles in basic ethanol for 10 min for disinfection, then washed twice in saline and dried using sterile gauze.
223690780|NCT03693170|DRUG|encorafenib|300 mg administered orally once daily (QD)
223690781|NCT03693170|DRUG|Binimetinib|Binimetinib 45 mg administered orally twice daily (BID)
223690782|NCT03693170|DRUG|Cetuximab|"Standard of care for the 28 first weeks(\*) and then every 2 weeks (\*\*) :~(\*) 400 mg/m2 administered as a 120-min infusion on Cycle 1 Day 1, followed by 250 mg/m2 administered as a 60-min infusion once weekly (QW) for the first 28 weeks. (\*\*) 500 mg/m2 administered as a 120-min infusion twice weekly (Q2W) from Week 29 (Cycle 8 Day 1) onward.~Following implementation of an Urgent Safety Measure on 26 Mar 2020 due to the outbreak of COVID-19 pandemic, cetuximab infusions could be administered Q2W regardless of the cycle number, after investigator's evaluation of the benefit/risk ratio for the subject, with regards to COVID-19 pandemic."
223690783|NCT06710951|PROCEDURE|Change of normal concentration of povidone-iodine 5% to 1%|Normal concentration of povidone-iodine during anti-VEGF intravitreal injection was 5%. That concentration was utilized in the control group, and 1% in the experimental group.
223690784|NCT03964805|OTHER|20% oxygen|culture excusively at 20% O2 (Day 0 to Day 6)
223690785|NCT03964805|OTHER|5% oxygen|culture excusively at 5% O2 (Day 0 to Day 6)
223690786|NCT03964805|OTHER|20 % and 5 % oxygen|culture at 5% from Day 0 to Day 3, then at 20% from Day 3 to Day 6)
223690787|NCT00634400|DRUG|Candesartan|
223690788|NCT00634400|DRUG|Placebo|
223690789|NCT03432520|GENETIC|SPK-8011|Observational long-term safety follow-up study of participants previously treated with SPK-8011 in any Spark-sponsored SPK-8011 study
223835687|NCT01997502|OTHER|Blood draw|4mL arterial blood samples (up to 1 per hour), outside standard of care, are drawn throughout the surgical procedure and sent to UCDMC lab/Masimo lab for analysis.
223776724|NCT05460624|OTHER|Typical American-style breakfast excluding eggs|Involves participants eating six premade egg-excluding breakfast meals per week for 12 weeks. Breakfast meals are matched to the intervention egg-containing breakfast meals on total energy and saturated fat and to the 'What We Eat in America' on percent energy from macronutrients.
223776725|NCT00529828|PROCEDURE|Consumption of CLA enriched food|
223776726|NCT04111341|DRUG|TCM (Gan-Lu-Yin)GLY|TCM Gan-Lu-Yin 6g in the morning TCM Jia-Wei-Xiao-Yao-San, Ye-Jiao-Teng, Suan-Zao-Ren 8g in the evening for 12 weeks
223776727|NCT04111341|DRUG|PLACEBO|TCM Placebo 6g in the morning TCM Placebo 8g in the evening for 12 weeks
223776728|NCT04241939|BEHAVIORAL|Numberless BDS|Participants perform daily weighing using a numberless BDS with feedback from app (color codes, challenges), in conjunction with modified motivational interviewing (clinic visits and weekly telephone calls), and the standard adolescent weight loss program.
223776729|NCT04241939|BEHAVIORAL|Digital Scale|Participants perform daily weighing using a digital scale (number readout), in conjunction with standard adolescent weight loss program
223776730|NCT04241939|BEHAVIORAL|Modified Motivational Interviewing|Modified motivational interviewing (clinic visits and weekly telephone calls), and the standard adolescent weight loss program.
223690790|NCT03432520|GENETIC|SPK-8016|Observational long-term safety follow-up study of participants previously treated with SPK-8016 in any Spark-sponsored SPK-8016 study
223690791|NCT02486354|DRUG|icotinib|Patients were administered with oral icotinib (tablet form, 125 mg) three times daily within two days after enrollment until disease progression or unacceptable toxicity.
223690792|NCT02340507|OTHER|Rice and bread (high GI)|Rice is a high glycaemic index glutinous rice. Bread is a high glycaemic index white bread.
223690793|NCT02340507|OTHER|Rice and bread (low GI)|Rice is a low glycaemic index parboiled basmati rice. Bread is a low glycaemic index multigrain bread.
223690794|NCT03813797|DEVICE|Airseal®|Medical device set to the mode Airseal®, pressure adjustment between 5 and 7 mmHg
223690795|NCT03813797|DEVICE|Standard Insufflation|"Medical device set to the mode Standard Insufflation, pressure adjustment between 12 and 15 mmHg"
223690796|NCT03126877|DRUG|Mitomycin C|The surgical procedure includes a low dose, short duration mitomycin C (MMC) treatment on the exposed stromal bed of the non-dominant eye, before the unilateral implantation of the corneal inlay. This treatment is at a concentration of 0.2 mg/mL (0.02%) applied for 10 to 30 seconds on the stromal bed as well as the stromal side of the corneal flap or pocket.
223690797|NCT03126877|DEVICE|Raindrop Near Vision Inlay|The surgical procedure includes the unilateral implantation of the Raindrop Near Vision Inlay in the non-dominante eye for the improvement of uncorrected near vision.
223690798|NCT00941382|DRUG|Sibutramine-Metformin|sibutramine and metformin, 15 mg per day and 850 mg per day, respectively, in a single tablet, for 180 days
223690799|NCT00941382|DRUG|Sibutramine|15 mg per day for 180 days
223690800|NCT00941382|DRUG|Metformin|Metformin 850 mg per day for 180 days
223776731|NCT05515302|OTHER|Audio Clip|Selected Audio clips will be introduced to the study subjects during the Burns Dressing Changes. The Audio Clips will be selected as per subjects preference.
223776732|NCT05676242|DRUG|Jaktinib Hydrochloride Tablet|Orally administered, twice a day
223776733|NCT02708745|BEHAVIORAL|Intervention Survey|
223776734|NCT02708745|BEHAVIORAL|Placebo Survey|
223776735|NCT04170647|DRUG|Plasminogen Activators|standard dosage of 0.9 mg/kg or reduced dosage of 0.6 mg/kg, divided into a 15% bolus and an 85% venous infusion
223776736|NCT00647231|DRUG|HKT-500 Topical Patch|Treatment with Ketoprofen Topical Patch
223690801|NCT02525315|DEVICE|Transcranial magnetic stimulation: rTMS|4 sessions of 13 minutes, with 2 sessions a day, at 20Hz frequency and at an intensity of 80% of rest motor threshold will be delivered
223690802|NCT03447184|DRUG|Androgen priming|"Androgen priming: with a low dose of recombinant hCG, aromatase inhibitor, and a depot GnRHa for 8 weeks Stimulation: a standard rFSH stimulation with either 300 IU rFSH or 300 IU (rFSH + rLH) Blood sampling: 6 blood samples to measure FSH, LH, E2, testosterone, and AMH Ultrasound examination: to count all antral follicles, 2-10 mm in each ovary Follicular fluid: to analyze E2, androstenedione, testosterone, progesterone, inhibin B.~Granulosa cells: to analyze gene expression in cumulus and mural granulosa cells of Luteinising hormone receptor (LHR), 3β-hydroxy-steroid-dehydrogenase (3ßHSD), inhibin-Ba (INHB-A) receptor, androgen and FSH receptor"
223690803|NCT02922933|DRUG|entinostat|HDAC (histone deacetylase inhibitor)
223690804|NCT02922933|DIETARY_SUPPLEMENT|Omeprazole|Proton pump inhibitor
223690805|NCT02922933|DIETARY_SUPPLEMENT|Famotidine|Histamine-2 blocker
223690806|NCT01032902|DEVICE|In Vitro Diagnostic Device|For the detection of antibodies to HIV in serum, plasma, blood and oral fluid
223690807|NCT03037801|DEVICE|Intrapulmonary Percussive Ventilation (Percussionaire Corp, Sandpoint, Idaho)|IPV physiotherapy 3 times a day
223776737|NCT00647231|OTHER|Placebo Patch|Treatment with placebo patch
223776738|NCT06530316|DRUG|RET Inhibitor|RET inhibitors for neoadjuvant treatment
223776739|NCT06530316|PROCEDURE|Surgery|Operable patients receive surgery after neoadjuvant therapy
223776740|NCT04719585|DRUG|Duloxetine vs. Opioid|Prior to discharge, the drug is prescribed for a total of 6 weeks by dividing the duloxetine-administered group and the opioid-administering group, respectively. The administration period of duloxetine or opioid is 6 weeks. The follow-up periods for out-patient clinic are 2 weeks, 6 weeks, 3 months, 6 months, and 1 year after the TKA surgery. During the follow-up period, NSAIDs will be prescribed the same in both groups. As an additional rescue medication, 650 mg of acetaminophen will be allowed to use up to 2g per day.
223776741|NCT04870801|DRUG|Respirogen Micro-Oxygen|Enteral (rectal) delivery of Respirogen Micro-Oxygen
223690808|NCT03208595|DIAGNOSTIC_TEST|Endometrial sampling of a Typical Embryo transfer catheter|no intervention no additional change from unit protocol
223690809|NCT00185991|DRUG|gentamicin|"Daily gentamicin (5 mg/kg intravenously, then placebo doses IV after 8 and 16 hours).~Eight hour gentamicin (2 mg/kg intravenously, then 1.5 mg/kg IV after 8 and 16 hours)."
223690810|NCT05290545|OTHER|PBSCs|PBSCs harvest is performed from day 5 of G-CSF to obtain at least 7.0×10\^8 total nucleated cells/kg recipient ideal body weight.
223690811|NCT05290545|OTHER|Cord|The criteria for cord selection included the following: (1) ≥3 of 6 HLA loci , (2) blood type matches, (3) contained a minimum cell count of 0.3×10\^8 nucleated cells/kg and 0.15×10\^6 CD34-positive cells/kg before freezing. The third party UCB will be infused the day after infusion of PBSCs.
223690812|NCT05290545|OTHER|BMSCs|BMSCs of donor will be collected and infused at least 0.5×10\^8 total nucleated cells/kg recipient ideal body weight the day after PBSCs infusion.
223690813|NCT04414332|OTHER|Data collection only|This registry is to capture high quality patient safety and effectiveness data on use of the Angiovac device for 3 separate, but overlapping conditions; a) Iliofemoral and Caval DVT, b) Right heart masses, and c) PE. The goal will be achieved by capturing a concise set of immediate and short-term functional and clinical outcome data for all patients who have the angiovac catheter deployed into the vascular system.
223690814|NCT03402659|DRUG|neflamapimod|40 mg neflamapimod capsule
223690815|NCT03402659|OTHER|placebo|matching placebo capsule
223690816|NCT05419531|OTHER|prospective observational study - screening and follow up colonoscopy|Involves two visits and a colonoscopy. The first visit will be prior to the colonoscopy. 4-35 days after the colonoscopy, there will be a one time appointment to go over the results of the colonoscopy.
223690817|NCT02878824|OTHER|Ethnicity|"As mentioned by Goldberger and Veroff (1995) the concept of ethnicity is also associated with culture and is often used interchangeably with culture as well as with race. Ethnic differences are not necessarily inherited, but they are learned through constant exposure; however have strong genetic influences that explain consequent behavioural differences between different ethnic groups (Chudek \& Henrich, 2011). An individual's genetic makeup greatly affects their behaviours (Klahr \& Burt, 2014).~In this study, we look at exposure to different ethnicity as exemplified by comparison between two groups of typically-developing children from different ethnicity (Chinese children in Hong Kong and Filipino Children in Hong Kong)."
223690818|NCT02878824|OTHER|Environment|The living environment has been implicated to have an effect on a person's psychological functioning (Rutter, Picker, Murray \& Eaves, 2001) and eventually how behaviour is manifested. The proposed disparity or effects between urban and rural dwelling is built on research that looks at the restorative and calming features of the natural environment, as well as the chaotic organization of the living spaces in urban settings.
223690819|NCT01442038|DRUG|Ranolazine|"Subjects will receive ranolazine 500 milligrams (mg) twice daily for 7 days, followed by 1000 mg administered orally twice daily for the duration of the study.~Subjects receiving a moderate CYP3A4 inhibitor will receive ranolazine 500 mg or placebo administered orally twice a day for the duration of the concomitant therapy."
223690820|NCT01442038|DRUG|Placebo|"Subjects will receive one tablet of matching placebo twice daily for 7 days, followed by two tablets of matching placebo twice daily for the duration of the study.~Subjects receiving a moderate CYP3A4 inhibitor will receive ranolazine 500 mg or placebo administered orally twice a day for the duration of the concomitant therapy."
223690821|NCT00089284|DRUG|Rituxan|Patients receive motexafin gadolinium IV over 30-60 minutes on days 1-4 and 8-11. At least 1 hour after motexafin gadolinium administration, patients receive rituximab IV over 3-4 hours on days 1 and 8. After rituximab administration, patients receive indium In 111 ibritumomab tiuxetan IV over 10 minutes on day 1. Patients undergo gamma camera scanning on days 1, 2\*, 4\*, and 7 and dosimetry on days 2, 4, and 7. If safe biodistribution is demonstrated, patients receive yttrium Y 90 ibritumomab tiuxetan IV over 10 minutes (after rituximab administration) on day 8.
223690822|NCT00089284|DRUG|motexafin gadolinium|Patients receive motexafin gadolinium IV over 30-60 minutes on days 1-4 and 8-11. At least 1 hour after motexafin gadolinium administration, patients receive rituximab IV over 3-4 hours on days 1 and 8. After rituximab administration, patients receive indium In 111 ibritumomab tiuxetan IV over 10 minutes on day 1. Patients undergo gamma camera scanning on days 1, 2\*, 4\*, and 7 and dosimetry on days 2, 4, and 7. If safe biodistribution is demonstrated, patients receive yttrium Y 90 ibritumomab tiuxetan IV over 10 minutes (after rituximab administration) on day 8.
223690823|NCT00089284|DRUG|111Indium-Zevalin and 90Yttrium-Zevalin|Patients receive motexafin gadolinium IV over 30-60 minutes on days 1-4 and 8-11. At least 1 hour after motexafin gadolinium administration, patients receive rituximab IV over 3-4 hours on days 1 and 8. After rituximab administration, patients receive indium In 111 ibritumomab tiuxetan IV over 10 minutes on day 1. Patients undergo gamma camera scanning on days 1, 2\*, 4\*, and 7 and dosimetry on days 2, 4, and 7. If safe biodistribution is demonstrated, patients receive yttrium Y 90 ibritumomab tiuxetan IV over 10 minutes (after rituximab administration) on day 8.
223690824|NCT01658618|BIOLOGICAL|HP802-247|
223690825|NCT01043146|DRUG|COR-1|single intravenous administration of 10, 40, 80, 160 or 240 mg of COR-1
223690826|NCT01043146|DRUG|placebo|intravenous 0.9 % NaCl
223690827|NCT00215202|DRUG|Iressa (ZD1839)|
223776742|NCT01525082|DRUG|Capecitabine|Capecitabine by mouth twice daily on Days 1 to 14
223776743|NCT01525082|DRUG|Temozolomide|Temozolomide by mouth daily on Days 10 to 14
223690828|NCT03092024|OTHER|SPIN-HAND program|The internet-based SPIN-HAND program consists of 4 modules (1) Thumb Flexibility and Strength (3 exercises); (2) Finger Bending (3 exercises); (3) Finger Extension (3 exercises); and (4) Wrist Flexibility and Strength (2 exercises). The program includes sections on developing a personalized program, goal-setting strategies and examples, progress tracking, sharing goals and progress with friends and family, and patient stories of experiences with hand disability and hand exercises. Instructional videos demonstrate and explain how to perform each exercise properly with pictures to illustrate common mistakes. Separate versions of each exercise are available for patients with mild/moderate and more severe hand involvement.
223690829|NCT04360590|DEVICE|pressure support ventilation versus neurally adjusted ventilatory assist|All patients underwent three mechanical ventilation modes, lasting 1 hour each: pressure support mode, neurally adjusted ventilatory assist and again pressure support ventilation
223690830|NCT05391542|OTHER|aligning archwires|At the day of bonding, 0.016-inch archwire will be placed for the TuNT group. Eight weeks later it will be replaced by the 0.018-inch archwire for another eight weeks. While, for the CuNT group, 0.014-inch archwire will be placed at the day of bonding and eight weeks later it will be replaced by the 0.018-inch archwire for another eight weeks. Archwires will be tied to the bracket by elastomeric modules which will be changed every 4 weeks. A good-quality alginate impression for the lower arch should be taken pre-treatment and after 4, 8, 12 and 16 weeks and a stone study model is obtained. Periapical X-ray for the mandibular central incisors will be taken pre-treatment and after 16 weeks. The participants will be provided by a visual analog scale (0-10) to record their pain perception during the first week after each wire placement.
223690831|NCT01499069|DRUG|Oxybutinin, Fesoterodine, Solifenacin, Propiverin, Trospium|"Dosage and frequency can be adjusted according to the patients' symptoms based on the instruction for administration .~Duration; 3 or 6 months"
223690832|NCT02076633|DRUG|L19IL2+L19TNF|Patients will be treated with intratumoral injections of 10 MioIU L19IL2 and 312μg L19TNF once weekly for up to 4 weeks.
223690833|NCT04069572|DEVICE|Vibrotactile Stimulation|Application of VCR stimulation to the belly and back of patients with pelvic pain, functional abdominal pain, or low back pain or to the temporal region for patients with migraine.
223690834|NCT04069572|DEVICE|Sham Stimulation|Low-frequency sham of VCR stimulation
223690835|NCT03560310|DRUG|Ticagrelor 90mg twice daily and ASA 75-100 mg daily|Assess whether ticagrelor 90 mg twice daily and ASA 75-100 mg daily versus ASA 75-160 mg daily improves outcome after isolated coronary artery bypass grafting in patients with acute coronary syndrome
223690836|NCT03560310|DRUG|ASA 75-160 mg daily|Assess whether ticagrelor 90 mg twice daily and ASA 75-100 mg daily versus ASA 75-160 mg daily improves outcome after isolated coronary artery bypass grafting in patients with acute coronary syndrome
223690837|NCT06005974|DRUG|REC-4881|REC-4881 4mg capsules
223690838|NCT06142019|DEVICE|Controlled desaturation (hypoxemia)|Stable hypoxemia is created in healthy subjects by having them breathe hypoxic air mixtures
223690839|NCT06193434|DRUG|IBI356 for MAD|Receive IBI356 in a multiple dose.
223690840|NCT06193434|DRUG|Dupilumab for MAD|Active comparator
223690841|NCT06193434|DRUG|IBI356 for SAD|Receive IBI356 in a single dose.
223690842|NCT06193434|DRUG|Placebo for SAD|Receive placebo in a single dose.
223690843|NCT06193434|DRUG|Placebo for MAD|Receive placebo in a multiple dose.
223690844|NCT06358651|DRUG|Fasedienol Nasal Spray|Nasal spray delivered 20 minutes before the PSC
223690845|NCT06358651|DRUG|Placebo Nasal Spray|Nasal spray delivered 20 minutes before the PSC
223776744|NCT01525082|BIOLOGICAL|Bevacizumab|Bevacizumab IV over 30 to 90 minutes on Days 1 \& 15
223776745|NCT05623709|DEVICE|Positive airway pressure with continuous positive airway pressure or noninvasive ventilation|CPAP or NIV prescribed by the treating respirologist for long-term use at home
223776746|NCT00411307|DRUG|OROS hydromorphone HCI|
223776747|NCT05284045|OTHER|Detailed information|Subjects in this arm will receive usual information + detailed information on side effects
223776748|NCT02480621|DRUG|Liposomal Bupivacaine with Bupivacaine|Pain medications injected locally during surgery around affected ankle.
223835688|NCT03967405|DEVICE|MolecuLight PID|Hand-held, real-time fluorescence imaging device
223776749|NCT06276478|OTHER|AI-video|Video administration for the explanation of the dental procedures followed by verbal instructions.
223776750|NCT06276478|OTHER|Verbal instructions|Only verbal instructions will be administered for the explanation of the dental procedures
223776751|NCT03056690|DRUG|ASP0819|Oral capsule
223776752|NCT03056690|DRUG|Placebo|Oral capsule
223776753|NCT01294995|DIETARY_SUPPLEMENT|Tea-flavor Liquor|30 mL of Tea-flavor Liquor(45% alcohol content)
223776754|NCT01294995|DIETARY_SUPPLEMENT|Guizhou Meijiao Liquor|30 mL of Guizhou Meijiao Liquor (45% alcohol content)
223776755|NCT03360292|OTHER|Higher target range|Intervention is using a higher oxygen saturation target range than in routine practice
223776756|NCT05224947|OTHER|Infant Formula|Two infant formulas differing in composition
223776757|NCT02047617|DEVICE|the standard physiotherapy group|Mobilization and rehabilitation program is progressively introduced after clinical stabilization
223776758|NCT02047617|DEVICE|standing table group|The protocol involved a stepwise process to gradually raise the subject into a standing position on the standing table platform
223776759|NCT03895853|OTHER|Best Practice|Receive standard of care
223776760|NCT03895853|DIETARY_SUPPLEMENT|early metabolic resuscitation|Given Intravenous
223776761|NCT04313166|DRUG|Cu(II)ATSM|cooper-containing synthetic small molecule
223690846|NCT03646643|PROCEDURE|Standard Atrial fibrillation ablation|The AF ablation procedures should follow the sequence below: Diagnostic catheter placement Electrophysiology study; Transseptal puncture; Left atrial electro-anatomical mapping is required prior to an ablation procedure. Post ablation pacing procedure(s) and/or infusion of cardiac medications to localize triggers/ assess and localize pulmonary vein reconnections (e.g., Adenosine, Isoproterenol 2-20 mcg/min). Study procedure requirements are outlined below: Isolation of all pulmonary veins and Non-pulmonary vein trigger ablation for all patients. Linear ablation lines are only required to treat documented macro-reentry atrial tachycardias and limited to the following targets only: LA roof line, mitral valve isthmus line, LA floor line, right atrial carvotricuspid isthmus linear ablation.
223690847|NCT03646643|PROCEDURE|Coronary sinus to left atrium connection elimination|Distal coronary sinus pacing will be utilized to localize distal connections between the main coronary sinus body and the left atrium. Focal lesions will be applied to early left atrial activation sites, until no distal coronary sinus to left atrial connections are electrically manifest. If vein of marshall connections to the left atrium are present, differential pacing will be utilized to prove the lack of distal coronary sinus to left atrium connections.
223776762|NCT03973242|DEVICE|Dual focus with narrow band imaging|dual focus mode for imaging magnification + narrow band imaging for the enhancement of mucosal vascularity and irregularity
223776763|NCT06301165|DRUG|TPC induction chemotherapy|TPC induction chemotherapy regimen contains Polymeric micellar paclitaxel, which is a novel Cremophor EL-free, nanoparticle micellar formulation of paclitaxel, cisplatin and capecitabine. TPC induction chemotherapy regimen (polymeric micellar paclitaxel 200 mg/m2 D1, cisplatin 75 mg/m2 D1, capecitabine 1000 mg/m2/day D1-14, every 3 weeks for 3 cycles).
223776764|NCT06301165|DRUG|GP induction chemotherapy|GP induction chemotherapy regimen (gemcitabine 1000 mg/m2 D1/8, cisplatin 80 mg/m2 D1, every 3 weeks for 3 cycles)
223776765|NCT05215574|DRUG|NGM831|Drug: NGM831 NGM831 is given intravenously (IV) every 3 weeks in a 21 day cycle. Multiple dose levels will be evaluated.
223776766|NCT05215574|DRUG|NGM831 plus pembrolizumab (KEYTRUDA®)|"Drug: NGM831 NGM831 is given intravenously (IV) every 3 weeks in a 21day cycle. Multiple dose levels will be evaluated.~Drug: pembrolizumab (KEYTRUDA®) pembrolizumab (KEYTRUDA®) will be administered intravenously (IV) every 3 weeks in a 21day cycle."
223776767|NCT05215574|DRUG|NGM831 and NGM438 plus pembrolizumab (KEYTRUDA®)|"Drug: NGM831 NGM831 is given intravenously (IV) every 3 weeks in a 21-day cycle. Multiple dose levels will be evaluated.~Drug: NGM438 NGM438 is given intravenously (IV) every 3 weeks in a 21-day cycle. Multiple dose levels will be evaluated.~Drug: pembrolizumab (KEYTRUDA®) pembrolizumab (KEYTRUDA®) will be administered intravenously (IV) every 3 weeks in a 21-day cycle."
223776768|NCT05383170|DRUG|CyPep-1|Intratumoral injection
223776769|NCT05383170|DRUG|Pembrolizumab 25 MG/ML [KEYTRUDA®]|IV infusion
223776770|NCT04231630|OTHER|Prolacta|Will receive outpatient supplementation with donor human milk product added to mother's own milk
223776771|NCT02279303|BEHAVIORAL|Dietary Intervention|Participants will receive individualized anti-inflammatory dietary prescriptions with six monthly workshops (culinary demonstrations, recipes and meal planning) and behavior change cures reinforced through evidence- and theory-based patient navigation, motivational interviewing, and tailored newsletters personalized to individual readiness for change.
223776772|NCT02279303|BEHAVIORAL|Dietary Control|Control participants will receive minimal nutritional information at baseline, monthly American Cancer Society survivorship brochures, and two telephone calls prior to assessment appointments.
223776773|NCT06535906|OTHER|kinesio taping|The 5 cm wide Kinesio tape (Kinesio® Tex Gold™, Albuquerque, NM) applied to the participants has the ability to stretch up to 140% of its original length. Moreover, it provides comfortable use for 3 to 5 days thanks to its latex-free, cotton, hypoallergenic and porous features. The skin will be cleaned with alcohol before applying Kinesio tape. To prevent muscle tension, the physiotherapist will apply the kinesio tape inhibition technique to the wrist flexor muscles with light tension (15-25% of the current tension) from the end point to the origin. We will use this inhibition technique to prevent muscle spasm. Kinesio taping will be applied immediately after exercise
223690848|NCT04131556|DRUG|Maribavir|Participants in both part 1 and part 2 of the study will receive maribavir tablet or suspension orally depending upon the treatment sequence allocation for a total of 7 and 10 days respectively.
223690849|NCT06126744|BIOLOGICAL|MVR-C5252|MVR-C5252 is a genetically modified next generation oncolytic herpes simplex virus 1 (oHSV1) with an active domain of human IL-12 and Fab fragment of anti-PD-1 antibody. This is a Phase 1 open label study designed to determine the safety and tolerability of MVR-C5252. The dose-escalation portion of the study will be conducted in 4 stages to evaluate the safety of infusion and determination of the MTD/RP2D followed by efficacy assessment.
223690850|NCT06470867|BEHAVIORAL|VA S.A.V.E.|The intervention is called VA S.A.V.E. It is an online video-based training tailored to veterans and their close supports. It is free, brief (24 minutes), and includes three scripted role plays.
223690851|NCT06470867|BEHAVIORAL|Control training|"An attention control informational video containing information relevant to veterans' mental health but not including elements thought to be active ingredients in the intervention."
223690852|NCT04481009|DRUG|YH003|YH003 will be administered intravenously over 60 minutes every 21-day cycle.
223690853|NCT04481009|DRUG|Toripalimab|Toripalimab with fixed dose of 240 mg administered intravenously followed by YH003 administered intravenously every 21-day cycle.
223690854|NCT04481009|DRUG|Nab-paclitaxel|Nab-paclitaxel will be administered each 21-day cycle.
223690855|NCT04481009|DRUG|Gemcitabine|Gemcitabine will be administrated each 21-day cycle.
223776774|NCT06535906|OTHER|placebo kinesio taping|5 cm wide and 0.5 mm thick I-shaped Kinesio tape (Kinesio Tex® Gold) will be used. The tape will be applied in a plus-shaped, tension-free and technical sitting position. Kinesio taping will be applied immediately after exercise
223776775|NCT06535906|OTHER|manual lymph drainage|Participants will lie in a supine position with their knees bent. Manual lymphatic drainage will begin with abdominal lymph drainage followed by central lymph stimulation. Then, bilateral axillary lymph nodes will be stimulated and the fluid in the exercised arm will be directed to the axillary lymph nodes. While the patients are in the prone position, the axillary lymph nodes will be stimulated in the same way and each manual lymphatic drainage will be performed from the back to the axillary lymph node. Each treatment session will last approximately 30 minutes
223776776|NCT06535906|OTHER|placebo manual lymph drainage|Participants will lie in a supine position with their knees bent. It will only be moved in a stroking style with hand contact from the fingers towards the armpit.
223690856|NCT06092580|BIOLOGICAL|AWT020|Participants receiving AWT020 once every two weeks or longer at designated dose levels
223690857|NCT05498220|DRUG|Polatuzumab vedotin (PV)|1.8 mg/kg, intravenous, at day 1, in every 21 days
223690858|NCT05498220|DRUG|Rituximab|375 mg/m2 intravenous, at day 1 or day 2, in every 21 days
223690859|NCT05498220|DRUG|Hyaluronidase|1,400 mg/23,400 units sub-cutaneous, starts at cycle 2, in every 21 days
223690860|NCT05498220|DRUG|Gemcitabine|1,000 mg/m2 intravenous at day 1 and 8, in every 21 days
223690861|NCT05498220|DRUG|Cisplatin|75 mg/m2, intravenous, at day 1, in every 21 days
223690862|NCT05498220|DRUG|Dexamethasone|40 mg intravenous at day 1, Per oral days at days 2-4
223776777|NCT03239652|DEVICE|Taiwan ACE Beads|Similar with conventional Transcatheter Arterial chemo-embolization, radiologist use Taiwan ACE Beads instead of Gelfoam or polyvinyl alcohol.
223690863|NCT05498220|DRUG|GCSF|granulocyte-colony stimulating factor (GCSF )
223690864|NCT06377501|OTHER|Whole-food, plant-based diet|Subjects will be instructed to adopt a whole-food, plant-based diet for 8 weeks. They will attend weekly group cooking classes led by a RD and receive weekly health coaching sessions.
223690865|NCT05120544|BEHAVIORAL|EXTEND Plus|The EXTEND Plus approach builds patient self-management capacity by focusing on knowledge, self-efficacy, and goal setting (using an RN-delivered, module-based approach). All material is at an 8th grade reading level. Module topics include, but are not limited to, use of self-monitoring of blood glucose (SMBG), BP monitoring, developing a diet plan, medication adherence, hypoglycemia and hypotension self-management, and self-managing insulin. In addition, this intervention component addresses diet and activity self-management during each encounter.
223690866|NCT05120544|BEHAVIORAL|EXTEND|EXTEND patients self-manage using data they collect during the study, and continue to receive standard behavioral counseling from primary providers.
223690867|NCT05985161|DRUG|Selinexor|This phase II study will initially treat all patients, including adult patients, at the pediatric Selinexor RP2D of 35 mg/m2 (no maximum dose) once weekly using a liquid suspension .
223690868|NCT04882501|OTHER|QUEASEEase aromatherapy quick tab|Once patient complains of nausea above intervention will be administered for 5 minutes and nausea level reassessed.
223690869|NCT04882501|OTHER|Placebo product|Once patient complains of nausea above intervention will be administered for 5 minutes and nausea level reassessed.
223690870|NCT05700539|BEHAVIORAL|Internet-based cognitive behavioral therapy|A ten-week treatment based on cognitive behavioral therapy for ADHD, including two mandatory modules and at least four self-selected modules (out of ten available modules). The treatment consists of reading material and exercises to be completed each week.
223690871|NCT06580080|BEHAVIORAL|Are You Ready? (AYR)|"AYR is a group-based entertainment education (EE) intervention designed for sexually active youth who are at risk for or involved in the juvenile justice and/or child welfare systems. AYR is delivered in one, 2.5-hour (150-minute) session with a group of between 2 to 20 youth. The session includes screening a 40-minute video, Happy Birthday, Leonard and group-based discussions led by one to two facilitators. Discussions are guided by a participant workbook with journal prompts and handouts.~The session includes two modules; each module involves screening approximately 20 minutes of Happy Birthday, Leonard followed by a 40-minute group discussion. Module 1 includes topics related to contraception, condom use (with a condom demonstration), healthy communication, and stress management. Module 2 includes topics related to condom negotiation, communication styles, and intergenerational cycles."
223690872|NCT06580080|BEHAVIORAL|Social Media Awareness Shorts (SMAS)|SMAS is a virtually delivered, individual-based health program focused on social media use awareness. Participants are directed to a learning management platform that contains a pre-recorded, facilitated program. The program involves watching several short films and independently completing several activities related to social media use. The program does not include information related to the primary outcomes for this study.
223690873|NCT06788249|DRUG|Ketamine only|The primary study intervention involves the administration of intravenous ketamine (0.5 mg/kg) over a 40-minute infusion. Ketamine, an NMDA receptor antagonist, has shown rapid antidepressant effects in individuals with treatment-resistant depression.
223690874|NCT06104527|COMBINATION_PRODUCT|Standard protein enteral nutrition with enteral tracer|Enteral nutrition with standard (1.3 g/kg/d) protein provision, given via a nasogastric tube. An oral L-\[1-13C\]-phenylalanine tracer is given as co-intervention. Use of an enterally given tracer is necessary to determine indicator amino acid oxidation.
223690875|NCT06104527|COMBINATION_PRODUCT|High protein enteral nutrition with enteral tracer|Enteral nutrition with high (2.0 g/kg/d) protein provision, given via a nasogastric tube. An oral L-\[1-13C\]-phenylalanine tracer is given as co-intervention. Use of an enterally given tracer is necessary to determine indicator amino acid oxidation.
223690876|NCT00277797|DEVICE|Biowave Targeted Non-Invasive Electronic Pain Control Device|"This device is a non-invasive non-pharmacologic treatment for pain. It sends a premixed modulated envelope of two high frequency electronic wave forms (Feed Signals) between two electrodes."
223690877|NCT00277797|DEVICE|TENS (Transcutaneous Electrical Nerve Stimulation) device|This device features a bisourced, biphasic waveform. The combined constant voltage, constant-current waveform provides a strong stimulus that allows the clinician to prescribe a treatment program.
223690878|NCT03207893|BEHAVIORAL|GEM lifestyle modification & continuous glucose monitoring|Four treatment sessions of GEM lifestyle modification in 3 months and continuous glucose monitoring during the first 14 days of each of the 3 months.
223690879|NCT03207893|OTHER|Routine Care|Subject's current t2d treatment
223690880|NCT03497078|OTHER|Bone scintigraphy|Comparison of image quality between new collimator LEHRS (General Electric - GE Healthcare) vs Siemens LEHR on bone scintigraphy.
223690881|NCT06221917|OTHER|Face-to-face|FTF group are participants who will learn simple sutures physically present with the instructor in the same room.
223690882|NCT06221917|OTHER|Live-streaming|One general surgeon (FH) will teach the participants how to do simple sutures on a mannequin, starting by explaining, then doing a live-demo step-by-step of simple wound suturing. The instructor uses a GoPro Hero 8 device on her head which is connected to the internet and produced live-streaming video, which will then be watched by LS group.
223690883|NCT04060862|DRUG|Ipatasertib|Phase 1b: Ipatasertib, 300 mg starting dose administered orally once daily (PO QD) during an initial 5-7 day run-in period, then continued on Days 1-21 during the first cycle. Starting with Cycle 2, Day 1 ipatasertib will be taken orally once daily on Days 1-21 of each 28-day cycle. Phase 3: Ipatasertib, administered PO QD on Days 1-21 of each 28-day cycle at the dose confirmed in the Phase Ib portion.
223690884|NCT04060862|DRUG|Placebo|Phase 3: Matching placebo, administered PO QD on Days 1-21 of each 28-day cycle at the dose confirmed in the Phase Ib portion.
223690885|NCT04060862|DRUG|Palbociclib|Palbociclib, administered PO QD on Days 1-21 of each 28-day cycle.
223690886|NCT04060862|DRUG|Fulvestrant|Fulvestrant, 500 mg administered as two intramuscular injections of 250 mg each on Cycle 1 Days 1 and 15 and Day 1 of each subsequent 28-day cycle.
223690887|NCT05991388|DRUG|Odronextamab|CD20xCD3 bispecific antibody
223690888|NCT05991388|DRUG|Loncastuximab tesirine|CD-19-directed antibody-drug conjugate
223690889|NCT05991388|DRUG|Rituximab|Modified R-ICE chemotherapy
223690890|NCT05991388|DRUG|Ifosfamide|Modified R-ICE chemotherapy
223690891|NCT05991388|DRUG|Carboplatin|Modified R-ICE chemotherapy
223690892|NCT05991388|DRUG|Etoposide|Modified R-ICE chemotherapy
223690893|NCT05991388|DRUG|Etoposide Phosphate|Modified R-ICE (Treatment Arm II)
223690894|NCT05991388|DRUG|Dexamethasone|Modified R-ICE chemotherapy
223690895|NCT05991388|BIOLOGICAL|CAR T-cells (TBC)|Modified R-ICE chemotherapy
223690896|NCT02051413|DRUG|Venlafaxine extended release|antidepressant drug
223690897|NCT06504381|GENETIC|DB107-RRV|Given intracranially (IC) during resection and intravenously (IV) immediately following
223690898|NCT06504381|DRUG|DB107-FC|Given orally (PO)
223690899|NCT06504381|RADIATION|Radiation Therapy (RT)|Undergo RT
223690900|NCT06504381|DRUG|Temozolomide|Given PO
223690901|NCT06504381|PROCEDURE|Magnetic Resonance Imaging (MRI)|Undergo standard of care MRI
223690902|NCT06504381|PROCEDURE|Surgical resection|Undergo non-investigational tumor resection
223690903|NCT06245629|DRUG|Bortezomib-bendamustine-melphalan|The aim of this retrospective cohort study is to evaluate the efficacy and safety of the conditioning regimen BBM compared to HDM in the setting of relapsed multiple myeloma.
223690904|NCT03288454|DRUG|Ciraparantag|Ciraparantag (administered over 10 minutes)
223690905|NCT03288454|DRUG|Placebo|Saline for injection
223690906|NCT03288454|DRUG|Apixaban|Apixaban 10mg given twice daily (q12h)
223690907|NCT01678027|DRUG|Placebo|Lansoprazole placebo, amoxicillin placebo, and clarithromycin placebo, all twice a day for 1 week.
223690908|NCT01678027|DRUG|LAC triple therapy|Lansoprazole 30 mg, amoxicillin 1,000 mg, and clarithromycin 500 mg, all twice a day for 1 week.
223690909|NCT05005520|DRUG|DTRI-031|Investigational drug
223690910|NCT05005520|DRUG|Placebo|Matching placebo to DTRI-031
223690911|NCT03375710|DEVICE|Cordella™ Heart Failure System|"The Cordella™ Heart Failure System collects, records, and transmits physiologic data and communications from the patient at home to clinicians for assessment, patient communication, and patient-centered heart failure management. The system consists of the following components:~1. myCordella™ Patient Management Portal~2. myCordella™ Hub~3. myCordella™ Peripherals, including the Cordella™ Pulmonary Artery Sensor System (CorPASS)"
223776778|NCT02842567|DRUG|Hydroxytyrosol plus Vitamin E|This group will treated with 2 pills daily, each containing 3.75 mg of hydroxytyrosol plus 5 mg of Vitamin E, given orally for 16 weeks
223690912|NCT05558917|PROCEDURE|PECS BLOCK 2|With the patient supine, the linear probe will be placed in the sagittal plane slightly lateral to the hemiclavicular line ipsilateral to the surgical site. Once both muscle planes of interest have been identified, in-plane needle insertion will proceed in the cranio-caudal direction. The first local anesthetic administration with Ropivacaine 0.5% will be 20ml between small pectoralis and serratus anterior. Coming out with the needle, 10ml of Ropivacaine 0.5% will then be injected between large and small pectoral.
223690913|NCT05558917|PROCEDURE|ESP BLOCK|Positioning yourself behind the patient, lying on her side with the surgical hemilateral on top, you place the linear ultrasound probe in the sagittal plane and find the lateral margin of the transverse process. At this point, the blocking needle is inserted in the caudocranial direction and 25ml of Ropivacaine 0.5% is injected, taking care to visualize the anesthetic spread in the cranial direction.
223776779|NCT02842567|DRUG|Placebo|This group will treated with 2 identical placebo pills daily given orally for 16 weeks.
223776780|NCT02809495|OTHER|use of app in smartphone|
223776781|NCT03025620|DIETARY_SUPPLEMENT|Rapeseed oil|Active comparator arm : Dietary Supplement: rapeseed oil supplementation (10g per day) and margarine with a high level of alpha-linolenic acid (12.5g per day) during 42 days.
223776782|NCT03025620|DIETARY_SUPPLEMENT|Sunflower oil|Placebo comparator arm : Dietary Supplement: sunflower oil supplementation (10g per day) and margarine with a high level of inoleic acid (12.5g per day) during 42 days.
223690914|NCT00788398|PROCEDURE|Saline Solution|Irrigation with Saline
223690915|NCT00788398|PROCEDURE|Soap solution|Irrigation with Castile Soap Solution (80 ml per 3L bag of saline)
223690916|NCT00788398|PROCEDURE|Gravity Flow Irrigation|Gravity flow irrigation will be standardized across participating centers as 3L bags of normal saline (alone or with soap solution) suspended 6-8 feet above floor level using an I.V. pole. Irrigation tubing (measuring 1/4 - 3/8 inch inner diameter) will be connected to the 3L bag and secured with a stopcock (or compressive device) until ready for use.
223776783|NCT03732287|DEVICE|Cooling Anesthesia|Application of cooling anesthesia device prior to intravitreal injection
223776784|NCT05795933|DRUG|Vitamin D3|A single dose of intramuscular 200,000 IU vitamin D3 within 24 hours of admission
223776785|NCT06303765|OTHER|Practice Resource for Driving After Stroke (PReDAS)|"1. Provision of written copy of PReDAS for occupational therapist to review~2. 1:1 online training session to use the PReDAS (1 hour in length)"
223690917|NCT00788398|PROCEDURE|Low Pressure Irrigation|"Irrigation with the Stryker SurgiLav System. At the low pressure setting delivers 5.9 p.s.i. pressure. The high-flow irrigator tip will be held perpendicular to and 5cm above the wound.~Irrigation with the Zimmer PulsaVac. For low pressure delivery, the shower tip will be used at the low pressure setting which delivers a pressure of 5.8 p.s.i."
223690918|NCT00788398|PROCEDURE|High Pressure|"Irrigation with the Stryker SurgiLav System. For the high pressure delivery, the multi-orifice tip will be used at the high setting which delivers a pressure of 30 p.s.i.~Irrigation with the Zimmer PulsaVac System: For the high pressure delivery the shower tip will be used at the high pressure setting which delivers a pressure of 23 p.s.i."
223690919|NCT00048763|DRUG|Pletal|
223690920|NCT05542134|DIAGNOSTIC_TEST|P2Y12 Platelet Aggregation Inhibitor|Verify now PRU test
223690921|NCT00185653|PROCEDURE|Autologous followed by non-myeloablative allogeneic transplantation|
223690922|NCT04282512|OTHER|Sodium bicarbonate-rich mineral water|St-Yorre, a sodium bicarbonate-rich mineral water, is a commercial mineral water that contains 4368 mg/l sodium bicarbonate. The study intends to evaluate the effect on blood pressure of the sodium bicarbonate intake due to this mineral water consumption.
223690923|NCT00928798|DRUG|Rapamycin|Application of rapamycin 1 mg/ml oral solution to one predefined skin area on one facial half, twice daily 0,25 ml, during 6 months. The other facial half will be similarly treated with a placebo.
223690924|NCT00928798|DRUG|placebo|Application of placebo to one predefined skin area on one facial half, during 6 months. The other facial half will be similarly treated with rapamycin 1 mg/ml oral solution
223690925|NCT01165190|OTHER|pioglitazone|
223690926|NCT01266941|DRUG|Inhaled FF 200mcg/GW642444M 25mcg|All subjects are scheduled to receive FF 200mcg/GW642444M 25mcg once daily for 7 days. The dose for subjects with severe hepatic impairment may be adjusted to FF 100mcg/GW642444M 12.5mcg after review of the PK and safety data from the moderate and healthy matched control subjects.
223690927|NCT03599401|OTHER|Scaling and root planing|"Scaling and root planing was done by using ultrasonic scalers with high speed suction apparatus to prevent aerosol contamination.~."
223776786|NCT01242527|DRUG|placebo|4 capsules (1g) daily for 12 weeks
223776787|NCT01242527|DRUG|omefas|2 capsules (1g) + 2 placebo daily for 12 weeks
223776788|NCT01242527|DRUG|omefas|3 capsules (1g) + 1 placebo daily for 12 weeks
223776789|NCT01242527|DRUG|omefas|4 capsules (1g)daily for 12 weeks
223776790|NCT06222476|DRUG|Dorzagliatin|Dorzagliatin will be initiated and maintained at 75mg twice a day
223776791|NCT06222476|DRUG|Gliclazide|Gliclazide will be initiated and maintained at 30mg once a day
223776792|NCT04364997|DRUG|Desvenlafaxine Succinate Sustained-Release Tablet , Duloxetine Hydrochloride Enteric-coated Capsule Placebo|Desvenlafaxine Succinate Sustained-Release Tablet 50 mg+Duloxetine Hydrochloride Enteric-coated Capsule Placebo 60 mg orally once daily for 8 weeks.
223776793|NCT04364997|DRUG|Desvenlafaxine Succinate Sustained-Release Tablet Placebo, Duloxetine Hydrochloride Enteric-coated Capsule|Desvenlafaxine Succinate Sustained-Release Tablet Placebo 50mg +Duloxetine Hydrochloride Enteric-coated Capsule 60mg orally once daily for 8 weeks,
223776794|NCT04364997|DRUG|Duloxetine Hydrochloride Enteric-coated Capsule Placebo|Duloxetine Hydrochloride Enteric-coated Capsule Placebo 30 mg orally once daily for 1 week after 8-weeks treatment.
223776795|NCT04364997|DRUG|Duloxetine Hydrochloride Enteric-coated Capsule|Duloxetine Hydrochloride Enteric-coated Capsule 30mg orally once daily for 1 week after 8-weeks treatment.
223776796|NCT00004317|DRUG|Leucovorin calcium|See arm descriptions
223776797|NCT00004317|DRUG|Pyrimethamine|See arm descriptions
223776798|NCT00004317|DRUG|Spiramycin|Spiramycin is administered before the fetal diagnosis is made.
223776799|NCT00004317|DRUG|Sulfadiazine|See arm descriptions
223776800|NCT04584567|DRUG|Doxycyclin|daily (100mg)
223776801|NCT01251796|DRUG|ARQ 197 and Erlotinib|Orally twice daily administration of ARQ197 and orally once daily administration of erlotinib hydrochloride
223776802|NCT02141516|BIOLOGICAL|rMenB+OMV|2 doses of vaccine 2 months apart
223776803|NCT02141516|BIOLOGICAL|rMenB+OMV|2 doses of vaccine 2 months apart
223776804|NCT02141516|BIOLOGICAL|rMenB+OMV|2 doses of vaccine 2 months apart
223776805|NCT03884972|DRUG|Trabectedin|Given IV
223776806|NCT03884972|DRUG|Venetoclax|Given PO
223690928|NCT03671993|PROCEDURE|Electrical pudendal nerve stimulation|Four sacrococcygeal points were selected. Two 0.40Х100 mm needles were inserted perpendicularly to a depth of 80-90 mm 1 cm bilateral to the sacrococcygeal joint, to produce a sensation referred to the root of the penis (perineum) or the anus. Two needles of 0.40Х100 or 125mm were inserted obliquely toward the ischiorectal fossa to a depth of 90 to 110 mm about 1 cm bilateral to the tip of the coccyx, to produce a sensation referred to the root of the penis (or the perineum). Each two ipsilaterally needles were connected to one electrode from a G6805-2Multi-Purpose Health Device (Shanghai Medical Instruments High-Techno, Shanghai, China), with a frequency of 2.5 Hz and an intensity (45\~55 mA). EPNS was given for 60 min a time, 3 sessions per week for 6 weeks.
223690929|NCT03671993|PROCEDURE|Intravesical instillation|The patient should lie on a couch in a lithotomy position after urination. A catheter was passed through the urethra into the bladder and any residual urine should be drained. A mixture of the Cystistat (sodium hyaluronate, 50ml 40mg, Bioniche Teoranta, Ireland) solution and Lidocaine hydrochloride (40mg :20ml, Fangming Pharmacy company, Shangdong, China) is instilled through the catheter into the bladder. The catheter is then withdrawn leaving the mixture solution inside the bladder, retained for as long as possible, ideally at least 30 minutes. The instillation is once weekly for at 6 weeks.
223690930|NCT01159977|BEHAVIORAL|Facilitated small groups|1 hour sessions every 2 weeks for small groups of 9 participants, 19 sessions over 9 months.
223690931|NCT01159977|BEHAVIORAL|Unstructured time.|1 protected hour every 2 weeks for 9 months, without small group structure.
223776807|NCT04023006|DEVICE|Removable prostheses|Full dentures created by Additive manufacturing (Carbon Printers)
223776808|NCT03006406|DRUG|Long term GnRH-a (3.75mg)|patient in this group only receive GnRH-a 3.75 for pituitary down-regulation
223776809|NCT01979653|DRUG|dexmedetomidine alone or dexmedetomidine + midazolam|
223690932|NCT01159977|BEHAVIORAL|Usual practice|No protected time provided.
223776810|NCT06028061|PROCEDURE|Adjuvant-free Quadratus lumborum block|Patients are placed in the lateral decubitus position. The area where the block will be applied is disinfected with povidine iodine. A convex ultrasound probe is placed on the midaxillary line above the iliac crest. By visualizing the transverse process adjacent to the psoas major and quadratus lumborum muscles, using the in-plane technique, using a 22 gauge 80 mm peripheral block needle after negative aspiration into the anterior layer of the thoracolumbar fascia anterior to the quadratus lumborum muscle muscle, 0.5-1 ml of serum After observing hydrodissection with physiological, 20 ml of 0.25% bupivacaine is injected. The same is done to the opposite side.
223776811|NCT06028061|PROCEDURE|Quadratus lumborum block III with Adjuvant|The same block was applied to this group too, but a different local anesthetic mixture was used.Patients are placed in the lateral decubitus position. The area where the block will be applied is disinfected with povidine iodine. A convex ultrasound probe is placed on the midaxillary line above the iliac crest. By visualizing the transverse process adjacent to the psoas major and quadratus lumborum muscles, using the in-plane technique, using a 22 gauge 80 mm peripheral block needle after negative aspiration into the anterior layer of the thoracolumbar fascia anterior to the quadratus lumborum muscle muscle, 0.5-1 ml of serum After observing hydrodissection with physiological, 20 ml of 0.25% bupivacaine and 4mg dexamethasone is injected. The same is done to the opposite side.
223776812|NCT05283096|OTHER|Questionnaire|A questionnaire about beliefs on food and diet in rheumatic diseases, and if a diet was tried what effect it had on health and rheumatism
223776813|NCT01440946|DRUG|rFIXFc|Vials of rFIXFc were combined as needed, based on the actual labeled potency to achieve the participant's calculated dose. Partial vial use was allowed, in order to achieve the calculated dose.
223776814|NCT01440946|DRUG|FIX|Vials of prestudy FIX (provided by the participants) were combined as needed, based on the nominal labeled potency (e.g., 250 IU, 500 IU, and 1000 IU), to achieve the participant's calculated dose.
223776815|NCT00271336|DRUG|Pentoxifylline|
223776816|NCT06394128|DRUG|Cangpo Liujun Prescription|Based on the diagnostic criteria of spleen deficiency and dampness excess syndrome, Cangpo Liujun Prescription could be used to treat cancer-related fatigue in patients with advanced colorectal cancer undergoing second-line chemotherapy.
223776817|NCT05632809|DRUG|NKTR-255|Given by IV (vein)
223776818|NCT05632809|DRUG|Durvalumab|Given by IV (vein)
223776819|NCT04904523|DIAGNOSTIC_TEST|Diagnostic Test:Blood test|Drop of blood for RNA and metabolic analysis
223776820|NCT00078390|DRUG|S-3304|S-3304 will be administered at the tolerable dose BID along with chemo-irradiation
223776821|NCT00078390|OTHER|Chemo-irradiation|Standard of care chemo-irradiation
223776822|NCT00333606|BEHAVIORAL|Acupuncture|Body acupuncture of 1 specific point per trial session
223776823|NCT05249725|DRUG|Irsogladine Maleate|Orally administration of irsogladine maleate 4mg/day, for 8 weeks.
223776824|NCT05249725|DRUG|Hydrotalcite|Patients were given 1 g hydrotalcite every morning, afternoon and evening for 8 weeks.
223776825|NCT02052479|OTHER|Frequently Sampled Intravenous Glucose Tolerance Test (FSIVGTT)|
223776826|NCT02311049|RADIATION|Hypofractionation|
223776827|NCT01485601|BIOLOGICAL|MT10109|Single dose intramuscular injection MT10109 vs Botox®
223776828|NCT05552703|PROCEDURE|surgical evacuation of extradural hematoma|evacuation of extradural hematoma by craniotomy
223690933|NCT06252298|BIOLOGICAL|SCTC21C|SCTC21C is injected to the participants subcutaneously and is tentatively scheduled to be administered weekly for the first two cycles, once every 2weeks for cycle3-6, and once every 4 weeks thereafter until the occurrence of progressive disease
223690934|NCT04643821|DRUG|N-acetylcysteine, NAC, and calcitriol|iv administration of antioxidant and active vitamin D
223690935|NCT00176527|BIOLOGICAL|recombinant interferon alfa-2b|
223690936|NCT00176527|DRUG|docetaxel|
223690937|NCT00176527|DRUG|estramustine phosphate sodium|
223690938|NCT00176527|DRUG|isotretinoin|
223690939|NCT00176527|GENETIC|polyacrylamide gel electrophoresis|
223690940|NCT00176527|GENETIC|protein expression analysis|
223690941|NCT00176527|OTHER|immunohistochemistry staining method|
223690942|NCT05380310|DEVICE|"Active SMART ANGEL solution"|Nurse intervention according to the alert level + traditional monitoring
223776829|NCT06346561|DRUG|Dexmedetomidine|the reduction of controlled hypotension and the control of hemodynamic responses of the body
223690943|NCT05380310|DEVICE|"Inactive SMART ANGEL solution"|No alert + traditional monitoring + alert in case of imminent life threat
223690944|NCT01589328|OTHER|Early Palliative care integrated with usual oncologic care|"Drug: The interventions consisted of the following:~(1) Nursing assessment of pain and depression mood (2) Pain control based NCCN guideline (3) Depression control by psychoeducation and/or consultation of psychiatrist specialist (4) Patient education"
223690945|NCT01683227|BEHAVIORAL|Screening/motivational drug intervention|Screening and brief motivational intervention delivered in the ER to reduce drug use
223690946|NCT01683227|BEHAVIORAL|Motivational placebo intervention|Screening and brief motivational intervention delivered in the ER to reduce driving and traffic risk
223690947|NCT04185870|DIAGNOSTIC_TEST|3D scan|All participants will receive a 360 degrees 3D scan of their chest/pectus excavatum.
223690948|NCT04185870|DIAGNOSTIC_TEST|Standard photography|All participants will receive a the standard photographs and specialised recordings of the current work-up to document their chest/pectus excavatum.
223690949|NCT03383471|BIOLOGICAL|Invossa K Inj.|Invossa K Inj.
223690950|NCT03383471|DRUG|Placebo|Placebo control
223690951|NCT02380027|DEVICE|MRI|This will be a multi-parametric MRI of the prostate
223690952|NCT02380027|PROCEDURE|MRI-targeted biopsy|This will be a biopsy targeted to suspicious areas on the MRI
223690953|NCT02380027|PROCEDURE|TRUS-biopsy|This will be a standard 12 core trans-rectal prostate biopsy
223776830|NCT06346561|DRUG|Labetalol|the reduction of controlled hypotension and the control of hemodynamic responses of the body
223690954|NCT03300960|DRUG|Provera 10 mg.|One 10 mg tablet of MPA (Medroxyprogesterone acetate) is administered every 24 hours from the onset of Controlled Ovarian Stimulation (COS), until the day of triggering.
223690955|NCT03300960|DRUG|Ganirelix (GnRH antagonist)|One ampoule of Ganirelix (GnRH antagonist) a day once diameter of follicles are 14 mm diameter on average until triggering.
223690956|NCT03805607|DRUG|Ketorolac Tromethamine 30 MG/ML|Ketorolac 30 mg
223690957|NCT03805607|DRUG|Placebos|Normal Saline
223690958|NCT02803762|DRUG|Pacritinib|400 mg \[14C\]pacritinib (containing 100 μCi radioactivity) administered orally as a single dose following at least a 10-hour fast (not including water) on Day 1
223690959|NCT03512990|PROCEDURE|Bupivacaine - Superior Trunk Block|It will be performed the superior trunk approach with local anesthestic in patients and methylene blue in cadavers.
223690960|NCT02818231|OTHER|Brushing of the olfactory cleft|Non invasive sampling of olfactory cleft cells, by brushing under local anesthesia during fiberendoscopy Form: survey of acceptability
223690961|NCT05323110|DRUG|CBS001|Intravenously administered, humanised anti-LIGHT IgG monoclonal antibody.
223690962|NCT05323110|DRUG|Placebo|CBS001 matched placebo
223690963|NCT04014309|OTHER|Supportive and survivorship care program|Provision of routine systematic screening using distress thermometer and problem list with accompanying supportive care nurse service.
223776831|NCT00930358|DRUG|MEOPA|anaesthetic gaz inhalation
223776832|NCT00930358|DRUG|general anaesthesia|Anaesthetic intravenous route
223776833|NCT05795023|OTHER|NeuraLight|NeuraLight software-based platform
223776834|NCT05676385|DIETARY_SUPPLEMENT|First concept product (containing 50 grams of carbohydrates)|Fasted intake of First concept product (randomised)
223776835|NCT05676385|DIETARY_SUPPLEMENT|Second concept product (containing 50 grams of carbohydrates)|Fasted intake Second concept product (randomised)
223776836|NCT05676385|DIETARY_SUPPLEMENT|Reference product (containing 50 grams of carbohydrates)|Fasted intake of Reference product (randomised)
223776837|NCT00235989|DRUG|Interferon beta 1b (Betaseron, BAY86-5046)|250 mcg administered s.c.(subcutaneous) every other day
223690964|NCT04014309|OTHER|Usual care|Usual care
223690965|NCT04575454|OTHER|Multimodal evaluation of brain function : PET-MRI, electrophysiology, eye-tracking|"After 2 days of sedation withdrawal, each data should be collected within 3 days for organisation purposes :~1. After installation and movement management with standardized routine care protocol: 18Fluoro-Desoxy-Glucose's infusion for PET~2. Starting PET continuous acquisition~3. Morphological MRI sequences~4. MRI in Resting state N°1~5. MRI DTI acquisition~6. IRM in 2D-Arterial Spin Labelling~7. IRM in Resting state 2~8. End of PET continuous acquisition The day before or the day after PET-MR: standard 20 min EEG, somaesthetic evoked potentials, auditory evoked potentials, mismatch negativity, P300 oddball paradigm, local-global paradigm, P300 after music stimulation, EEG resting state for 10 min, CRS-R repeated before each examination (and at least 5 times for chronic patients), eye-tracking study of the environmental exploration."
223690966|NCT01722773|DEVICE|Bipap (Respironics, Inc)|Bipap every night pressure at 15/5 with heated humidifier
223690967|NCT00430430|PROCEDURE|High MUFA dietary portfolio|high monounsaturated fat background diet to dietary portfolio
223690968|NCT00430430|PROCEDURE|Low MUFA dietary portfolio|low monounsaturated fat background diet to dietary portfolio
223690969|NCT03865134|DIAGNOSTIC_TEST|Snellen Test|Visual acuity measurement
223690970|NCT03865134|DIAGNOSTIC_TEST|Autorefractometer|Refraction measurement
223690971|NCT03865134|DIAGNOSTIC_TEST|Titmus Stereo Fly Test|Stereopsis measurement
223690972|NCT03865134|DIAGNOSTIC_TEST|Optical Kohlerans Tomography|Retinal development measurement
223690973|NCT03865134|BEHAVIORAL|Investigation of Visual Motor Integration|Investigation of visual motor integration, motor coordination and visual perception by Beery- Buktenica Developmental Test of Visual Motor Integration.
223690974|NCT03865134|BEHAVIORAL|Peabody Developmental Motor Scales - II|Evaluation of motor development
223690975|NCT03865134|BEHAVIORAL|World Health Organization Quality of Life - BREF|Assesment of quality of life
223690976|NCT03865134|BEHAVIORAL|State - Trait Anxiety Inventory|Assesment of anxiety
223690977|NCT02180269|DRUG|JNJ-54861911 (25 mg)|Single oral dose of JNJ-54861911, 25 mg on Day 1.
223690978|NCT02180269|DRUG|JNJ-54861911 (50 mg)|Single oral dose of JNJ-54861911, 50 mg on Day 1.
223690979|NCT02180269|DRUG|JNJ-54861911 (100 mg)|Single oral dose of JNJ-54861911, 100 mg on Day 1.
223690980|NCT02180269|DRUG|Placebo|Single oral dose of placebo matched to JNJ-54861911 on Day 1.
223690981|NCT02922400|BEHAVIORAL|Social Cognition Assessment and Training|The study includes an assessment and treatment phase: The assessment phase will test the efficacy and feasibility of a battery of measures evaluating social cognition and behavior. Functional magnetic resonance imaging (fMRI) will also be used to investigate functional differences in regions of the brain associated with social cognition and differences in cognitive progressing. The treatment phase will assess the efficacy and feasibility of a strategy-based social skills treatment using a virtual reality platform.
223690982|NCT00150540|DRUG|Lanthanum carbonate|
223690983|NCT02545075|DRUG|Ipilimumab|
223690984|NCT02545075|DRUG|Dacarbazine|
223690985|NCT05272462|DRUG|Minoxidil|Minoxidil is an antihypertensive vasodilator medication commonly used for the treatment of high blood pressure and pattern hair loss.
223690986|NCT01737450|DRUG|BKM120|
223690987|NCT01279031|DEVICE|Abbott WHITESTAR Signature System with Ellips Transversal Ultrasound|Comparison of vision after cataract surgery based on two different types of equipment.
223690988|NCT01279031|DEVICE|Alcon Infiniti wiht the OZIL Torsional Handpiece|Comparision of vision after cataract surgery based on two different types of equipment.
223690989|NCT05232981|PROCEDURE|Ligation of the bilateral internal iliac arteries|"opening the posterior peritoneum overlying the bifurcation of the common iliac arteries. Then careful dissection of the internal iliac artery is carried out on each side and the anterior division of the internal iliac artery is ligated 4 cm below the bifurcation of the common iliac on both sides by single ligation procedure using Vicryl 1.0 .~Re-checking of the femoral pulsation of both sides is performed. Then, the placenta is removed manually in a piecemeal manner, any remaining bleeding points from the placental site are then controlled by hemostatic sutures ."
223690990|NCT05232981|PROCEDURE|Shehat's technique|"The three-step technique (Shehata's technique) entailed 3 steps, the first step is double bilateral ligation of uterine arteries before placental separation. Uterine artery ligation is made at 2 levels. First will be done at the isthmus and second will be done 1 cm above the cesarean incision. Regarding timing of ligation , we will apply the uterine artery ligation before placental separation to minimize blood loss at the attempt of placental separation.~Placenta is separated manually either totally or in piecemeal. If manual separation failed, placenta is removed by scissors.~Application of quadruple sutures is done at the lower uterine segment to compress and secure the neovascularization in the bed of placenta.~Insertion of triple way catheter is commenced from inside the uterine incision downwards using long artery forceps or uterine sound and the pulled by the assistant from below. The catheter balloon is inflated by 50 cc saline and left for 48 hours"
223690991|NCT00533923|DRUG|Cyclophosphamide; Fludarabine; Cyclosporin; CAMPATH-1H (Alemtuzumab); GM-CSF|intravenous
223690992|NCT00530101|DRUG|Doxorubicin|"This pilot study will select patients who are at increased likelihood to develop cardiotoxicity, due to borderline cardiac function at baseline, advanced age, or the anticipation of a high cumulative dose of administered doxorubicin. Patients who will receive radiation therapy to the left chest during chemotherapy (i.e., left breast cancer) will be excluded so as to eliminate possible cardiotoxic effects from radiation. CMR studies will be performed at no charge to the patient, supported by the sponsor of this study. CMR imaging will be subject to IRB approval, informed consent, and HIPAA regulations. Contrast-enhanced CMR will be obtained at three time points:~Patients will not undergo contrast-enhanced MR unless calculated GFR is equal to or greater than 60 mL/min/1.73 m2"
223776838|NCT00235989|DRUG|Interferon beta 1b (Betaseron, BAY86-5046)|250 mcg administered s.c. every other day (for patients having received 500 mcg before)
223776839|NCT00235989|DRUG|Interferon beta 1b (Betaseron, BAY86-5046)|500 mcg administered s.c. every other day
223776840|NCT00235989|DRUG|Interferon beta 1b (Betaseron, BAY86-5046)|500 mcg administered s.c. every other day (for patients having received 250 mcg before)
223690993|NCT04538573|DEVICE|Virtual Reality Distraction|Patients in this group will be offered to use Oculus Rift goggles while undergoing the burn treatments, dressing changes and hydrotherapy to reduce pain and anxiety during treatment. The goggles will display Dreamland, a virtual reality videogame created by our team to maximize fun, diminish difficulty, and motion sickness. The system will be available 5 minutes before treatment to the patient in order to ease acclimatation to the goggles until the end of the treatment session.
223690994|NCT04538573|DRUG|Standard Treatment|"Standard pharmacological care as per the unit's protocol will serve as the control for half of the duration of every treatment session. It consists of different analgesic and sedative medication used in combination in order to help patients go through the procedure. The unit's protocol includes drugs such as Morphine, Hydromorphone, Fentanyl, Clonidine, Ketamine, Midazolam and Acetaminophen.~Use of any co-interventions for pain or anxiety management (music, comforting, child life specialist or other) during this sequence will be documented."
223690995|NCT00261300|DRUG|Pantoprazole|Long term Pantoprozole trial
223690996|NCT01810432|DRUG|Evacetrapib|Administered orally
223690997|NCT01810432|OTHER|High-fat Meal|Administered orally, at breakfast.
223690998|NCT00736879|DRUG|Dapagliflozin|Tablets, Oral, Once Daily, Up to 24 weeks
223690999|NCT00736879|DRUG|Placebo|Tablets, Oral, Once Daily, Up to 24 weeks
223691000|NCT03090412|DRUG|HPPH|Given IV
223691001|NCT03090412|OTHER|Laboratory Biomarker Analysis|Correlative studies
223691002|NCT03090412|DRUG|Photodynamic Therapy|Undergo PDT
223691003|NCT03090412|OTHER|Quality-of-Life Assessment|Ancillary studies
223691004|NCT03090412|PROCEDURE|Therapeutic Conventional Surgery|Undergo standard of care surgery
223691005|NCT04476550|DRUG|Filgrastim|5 days of daily sub-cutaneous administration of 10mcg/kg filgrastim
223691006|NCT02360111|DRUG|Cyclophosphamide|
223691007|NCT00498056|BIOLOGICAL|VRC-HIVDNA016-00-VP|DNA vaccine administered intramuscularly
223691008|NCT00498056|BIOLOGICAL|VRC-HIVADV014-00-VP|Adenovirus vaccine administered intramuscularly
223776841|NCT04977843|PROCEDURE|EARLY BRONCHOALVEOLAR LAVAGE|E-BAL done with instillation of 100cc normal saline and sucked out
223691009|NCT00498056|BIOLOGICAL|VRC-HIVDNA016-00-VP placebo|DNA vaccine placebo administered intramuscularly
223691010|NCT00498056|BIOLOGICAL|VRC-HIVADV014-00-VP placebo|Adenovirus vaccine placebo administered intramuscularly
223691011|NCT01637987|PROCEDURE|Unassisted vein visualization|The traditional technique of vein visualization and palpation will be used to identify veins during the PIV insertion procedures. This involves the use of a tourniquet to facilitate venous pooling to see the vein and prevent vein rupture during cannulation. Nurse may use heat application to facilitate vein identification.
223691012|NCT01637987|PROCEDURE|Wee Sight® Transilluminator|The Wee Sight® Transilluminator (Philips Children's Medical Ventures, Monroeville, PA) is a hand held, non-heat producing, light emitting diode (Class 2), battery operated device. The device is held adjacent to or under the subject's extremity to visualize the venous anatomy superficial veins absorb light and appear as dark lines against the surrounding illuminated tissues. Vein visualization improves with dimmed room lighting and a thin subcutaneous tissue layer. Nurse will assess vascular anatomy using traditional techniques of visualization and palpation with tourniquet/heat application as needed, and add the Wee Sight to assist in vein identification.
223691013|NCT01637987|PROCEDURE|VeinViewer® (Christie Digital Systems, Cypress, CA)|VeinViewer near infrared light views hemoglobin up to 10 mm beneath skin. Hemoglobin absorbs the light while surrounding tissue scatters it providing a suitable contrast between the vein \& surrounding subcutaneous tissue. This data is captured, digitally processed by video camera, and projected back onto the skin as a visual image of venous anatomy. Nurse will assess vascular anatomy using traditional techniques of visualization and palpation with tourniquet/heat application as needed, and add the VeinViewer to assist in vein identification.
223691014|NCT03120442|DRUG|Propofol|target-controlled infusion starting for Cet 0.1 mcg/ml to achieve MOAA/S 3-4
223776842|NCT00983580|DRUG|Aspirin|Given PO
223776843|NCT00983580|DRUG|Eflornithine|Given PO
223776844|NCT00983580|OTHER|Laboratory Biomarker Analysis|Correlative study
223776845|NCT00983580|OTHER|Placebo|Given PO
223691015|NCT03120442|DRUG|Dexmedetomidine|Incremental titration of dexmedetomidine starting from 0.1 mcg/kg/hr to achieve MOAA/S 3-4
223691016|NCT03120442|DRUG|Fentanyl|0.25 mcg fo Fentanyl for anxiolysis
223691017|NCT05032248|DRUG|Tacrolimus ointment|oral gel
223691018|NCT00718302|DEVICE|Antiglide Plate|A plate is placed behind the broken ankle and secured with screws
223691019|NCT00718302|DEVICE|Lateral Plate|A metal plate is placed to the side of the broken ankle and is secured with screws
223691020|NCT00589901|DRUG|capecitabine and cyclophosphamide|"capecitabine 1000 mg/m2 oral Bid d1-14~cyclophosphamide 65 mg/m2 oral Qd d1-14"
223691021|NCT00657449|DRUG|valdecoxib|valdecoxib 80 mg (two 40 mg tablets) by mouth on Day 1 and valdecoxib 40 mg tablet once daily on Days 2-8
223691022|NCT00657449|DRUG|rofecoxib|rofecoxib 50 mg (two 25 mg capsules) by mouth once daily for 8 days
223691023|NCT00286507|PROCEDURE|Vitrectomy, post hyaloid detachment and gas injection with or without ILM peel.|Combined cataract surgery (phacoemulsification and intraocular lens implantation) and pars plana vitrectomy with postoperative intraocular tamponade with gas, with or without ILM peeling
223691024|NCT01698112|DIETARY_SUPPLEMENT|Flaxseed High Dose|26 gram flaxseed intervention
223691025|NCT01698112|DIETARY_SUPPLEMENT|Flaxseed Low Dose|13 grams flaxseed
223691026|NCT00089856|BIOLOGICAL|Immunotherapy with allogeneic prostate vaccine|Immunotherapy with allogeneic prostate vaccine
223691027|NCT00089856|DRUG|Chemotherapy (Taxotere and prednisone)|Chemotherapy (Taxotere and prednisone)
223691028|NCT02568137|BEHAVIORAL|Smart-phone based technology|
223691029|NCT04944095|OTHER|Change in SARS-CoV-2 Antibody Levels|Changes in plasma antibody levels over 12 months will be determine post-vaccination with one of the authorized SARS-CoV-2 vaccines.
223776846|NCT00983580|OTHER|Telephone-Based Intervention|Ancillary studies
223691030|NCT04704973|BEHAVIORAL|Transdiagnostic short-term psychotherapy|Focused clinical functional analysis, formulation of a valued life direction includings strategies to handle obstacles, and a summarizing exercise including relapse prevention.
223691031|NCT04104334|DRUG|Remifentanil infusion, desflurane titration and fluid infusion will be guided by NOL index, BIS index and Flotrac EV1000 system respectively|NOL index will guide the administration of remifentanil to keep the index between 5-25, and the desflurane will be titrated to keep a BIS index between 45 and 55. Cardiac output and stroke volume variation will be measured by the Flotrac EV1000 system. Patients will receive 250ml fluid challenges with a recommended solution as required, in order to achieve a maximal value of stroke volume
223691032|NCT04104334|DRUG|Remifentanil infusion and desflurane titration will be guided by anesthesia usual practices|Desflurane will be administered to keep MAC at 1, and remifentanil infusion rate will be adapted to the mean arterial blood pressure to keep it between 65 and 100, according to anesthesia usual practices
223691033|NCT02316912|DRUG|ATX2417|Randomised double blind parallel group ascending dose assessment
223691034|NCT02316912|DRUG|Placebo|Randomised double blind parallel group ascending dose assessment
223691035|NCT01940562|DRUG|eltrombopag|"Children ≥= 40 kg BW:~From day +1, start eltrombopag 100 mg/d. If primary end point not reached on day +14, then from day +15 - 150 mg/d. If primary end point not reached on day +28 then from day +29 - 200 mg/d (maximal dose).~Children 20-40 kg BW:~From day +1, start eltrombopag 50 mg/d. If primary end point not reached on day +14, then from day +15 - 75 mg/d. If primary end point not reached on day +28 then from day +29 - 100 mg/d.If primary end point not reached on day +42, then from day +43 and on - 150 mg/d (maximal dose).~Children \< 20 kg BW:~From day +1, start eltrombopag - 2 mg/kg/d. If primary end point not reached on day +14, then from day +15 - 3 mg/kg/d. If primary end point not reached on day +28 then from day +29 - 3.5 mg/kg (maximal dose).~If present dose not tolerated, return to last tolerated dose. Eltrombopag will be discontinued after platelet count has exceeded 50,000/microliter for 14 consecutive days without administration of platelets."
223691036|NCT01933217|DRUG|Methylphenidate|
223776847|NCT05321862|DRUG|[68Ga]Ga-PentixaFor|Tomography by Emission of Positons (PET) with the radiopharmaceutic \[68Ga\]Ga-PentixaFor
223776848|NCT01180712|DIETARY_SUPPLEMENT|Mirtoselect|"Male subjects (BMI \> 30) with type 2 diabetes controlling their diabetes by diet alone or impaired glucose tolerance.~Volunteers will be given either a total daily dose of 1.4 grams of concentrated blaeberry extract (mirtoselect provided by Indena S.p.A. (http://www.mirtoselect.info/) in a hard gelatin capsules or control capsules containing lactose administered thrice a day for 21 days."
223691037|NCT01933217|DRUG|Placebo|
223691038|NCT04757740|BIOLOGICAL|intra-articular Platelet rich fibrin and lidocaine|intra-articular injection of 3.5 ml of 1% lidocaine and PRF mixture.
223691039|NCT04757740|DRUG|methylprednisolone acetate and lidocaine|intra-articular injection of Mixture of 40 mg of methylprednisolone acetate(1 ml) and 1% lidocaine (2.5 ml). intra-articular steroid
223691040|NCT02706054|OTHER|saline|The patients received an IM injection of saline near the nerve root (periradicular)
223691041|NCT02706054|DRUG|Meloxicam|The patients received an IM injection of meloxicam near the nerve root (periradicular)
223691042|NCT01377571|BIOLOGICAL|Rotarix|2 doses of Rotarix vaccine, 106.5CID/dose, 1-month interval between doses
223691043|NCT03115073|DRUG|Candiplus|Administration of Candiplus
223691044|NCT03115073|DRUG|Clotrimazole|Administration of Clotrimazole
223691045|NCT03111173|DEVICE|Holter Device|MyECG E3.80 Holter Recorder
223776849|NCT05705622|OTHER|Oral mukositis nurse's education for patients|Education given to patients by nurses on the prevention, treatment and care of oral mucositis
223776850|NCT03306342|DEVICE|IOL implantation experimental|Implantation of trifocal IOL POD F GF consisting of hydrophobic material
223776851|NCT02199418|DRUG|Paclitaxel|
223776852|NCT02199418|DRUG|Cisplatin|
223776853|NCT04121325|DEVICE|Enterra|To measure validated and subjective pain scores among patients with an existing GES device, and who have a trial of new settings directed at abdominal pain and compare their pain scores to each patient baseline symptoms, done with their previous GES settings.
223776854|NCT00381420|DEVICE|drug-eluting stent|sirolimus-coated Bx VELOCITY Balloon-Expandable Stent
223776855|NCT00381420|DEVICE|bare-metal stent|un-coated Bx VELOCITY Stent
223776856|NCT02316717|BIOLOGICAL|IMM-124E|IMM-124E
223776857|NCT02316717|OTHER|Placebo|Matched placebo
223691046|NCT00876876|DRUG|Lixivaptan|Capsules containing 25, or 50 mg doses of oral lixivaptan to be administered BID or QD Lixivaptan will be administered for 12 weeks in the Open-Label Period which will be followed by a 4 week Randomized, Placebo-Controlled period.
223691047|NCT03189771|PROCEDURE|occlusal surface reduction|occlusal surface reduction after single visit root canal treatment
223691048|NCT03923738|DRUG|Tocilizumab|TCZ will be administered by IV infusion at two dose levels Q4W. The maximum dose of TCZ that will be administered is 800 mg. The dose of TCZ infusion will be calculated on the basis of body weight measured prior to each infusion.
223691049|NCT01822704|DEVICE|Low intensity whole body vibration|
223691050|NCT01822704|DEVICE|High intensity whole body vibration|
223691051|NCT01822704|BEHAVIORAL|Leg exercises|
223691052|NCT06386289|DEVICE|Cereglide 92|Aspiration of cerebral large vessels occlusions
223691053|NCT00004834|DRUG|imipramine|
223691054|NCT00004834|BEHAVIORAL|cognitive-behavioral therapy|
223691055|NCT02937428|BEHAVIORAL|Look away from the needle|Participant looks away from the needle during vaccination
223691056|NCT02937428|BEHAVIORAL|Look at the needle|Participant looks at the needle during vaccination
223776858|NCT01072201|DRUG|Triclosan and Fluoride|Brush twice daily
223776859|NCT01072201|DRUG|Fluoride|Brush twice daily
223776860|NCT03724825|DIAGNOSTIC_TEST|lipid profile: Total cholesterol (TC), triglycerides (TG), low density lipoprotein (LDL) and high density lipoprotein (HDL))|blood samples will be collected after 10 hours fasting
223691057|NCT05234658|BIOLOGICAL|PHITAH|Tissue Engineered Human Artificial Skin: Fibrin-Hyaluronic Acid
223691058|NCT05234658|BIOLOGICAL|PHIT|Human artificial skin created by tissue engineering: fibrin-agarose
223691059|NCT05234658|BIOLOGICAL|Skin Autograft|Skin Autograft
223691060|NCT00209768|DEVICE|Filter: NOE96E, ELD96E, NLF1E, TNA1E|
223691061|NCT01684020|BIOLOGICAL|ARTISS human fibrin sealant|
223691062|NCT03303014|DEVICE|5-0 Prolene, 5-0 Fast Absorbing Gut|The interventions are two types of sutures: 5-0 Prolene, 5-0 Fast Absorbing Gut.
223691063|NCT06087913|DRUG|TAF/EVG vaginal insert|vaginal insert applied daily for 3 days then every other day for 14 days
223691064|NCT06087913|DRUG|Matching Placebo vaginal insert|vaginal insert applied daily for 3 days then every other day for 14 days
223691065|NCT02164149|OTHER|Patients with primary colon cancer|CT scan two days after surgery
223691066|NCT00721266|DRUG|RO5083945|Administered iv, either weekly, every 2 weeks or every 3 weeks, at escalating doses (with a starting dose of 50mg weekly (Part 1)). Recommended dose administered iv, either weekly, every 2 weeks or every 3 weeks (Part 2).
223691067|NCT00486551|BEHAVIORAL|Anger control training|
223691068|NCT03246620|DRUG|Olanzapine oro-dispersible 5Mg Tab|Patient allocated to this arm will be given 5 mg olanzapine oro-dispersible tablet and an encapsulated placebo tablet
223691069|NCT03246620|DRUG|Haloperidol 2Mg encapsulated Tab|Patient allocated to this arm will be given 2 mg encapsulated haloperidol tablet and an oro-dispersible placebo tablet
223691070|NCT03246620|DRUG|Diazepam 2Mg encapsulated Tab|Patient allocated to this arm will be given 2 mg encapsulated diazepam tablet and an oro-dispersible placebo tablet
223691071|NCT04213521|OTHER|Multisensory balance exercise|Multisensory balance training describes a balance exercise incorporating individual sensory manipulation of vision, vestibular, proprioception and sensory integration.
223691072|NCT04213521|OTHER|Conventional balance exercise|such as static and dynamic standing balance without altered sensory inputs.
223691073|NCT05067673|OTHER|Dry needling|The dry needling will be performed using disposable stainless steel needles (AGU-PUNT needles of size 0.30x50mm or 0.30x60mm depending on the patient) that will be inserted perpendicularly at the point of major hyperalgesia using the Hong technique. The patient will be in the prone position with a pillow placed in the abdominal region. The area will be cleaned with an antiseptic and allowed to air dry for 3 minutes. After this time, the needle will be inserted at the point indicated by the evaluator before reaching the lumbar multifidus by means of echolocation. Once it is assured that it is in the right place, a total of 10 repetitions are performed. The needle will be removed by depositing it in a needle container and a compression will be removed in the treated area until hemostasis is achieved.
223691074|NCT05067673|OTHER|Placebo dry needling|Placebo dry needling will be performed with DongBang DB100 Acupuncture Needles which, upon contact with the patient, retract, hiding in the needle handle. The patient will be in the prone position with a pillow in the abdominal region. The area will be cleaned with an antiseptic and allowed to air dry for 3 minutes. At the point indicated by the evaluator, the placebo needle will be placed initially and the introduction of the needle and its location will be simulated with the ultrasound system. 10 repetitions will be performed. The needle will be removed by depositing it in a needle container and a compression will be made in the treated area.
223691075|NCT05104554|DIETARY_SUPPLEMENT|Iron and folic acid (IFA)|IFA: Weekly regimen of one tablet containing iron (60 mg) and folic acid (2800 μg)
223776861|NCT03724825|DIAGNOSTIC_TEST|Total testosterone|blood samples will be collected after 10 hours fasting
223776862|NCT03724825|DIAGNOSTIC_TEST|Adropin|blood samples will be collected after 10 hours fasting
223776863|NCT03724825|DIAGNOSTIC_TEST|Adiponectin|blood samples will be collected after 10 hours fasting
223691076|NCT05104554|DIETARY_SUPPLEMENT|Multiple Micronutrient Supplement (MMS)|MMS: Daily regimen of one multiple micronutrient tablet containing fifteen micronutrients in the United Nations International Multiple Micronutrient Preparation (UNIMMAP) preparation. Composition includes vitamin A (800 ug), vitamin D (5 ug), vitamin E (10 mg), vitamin C (70 mg), vitamin B1 (1.4 mg), vitamin B2 (1.4 mg), niacin (18 mg), vitamin B6 (1.9 mg), vitamin B12 (2.6 ug), folic acid (400 ug), iron (30 mg), zinc (15 mg), copper (2 mg), selenium (65 ug), and iodine (150 ug).
223691077|NCT03413943|OTHER|gaze training|Gaze training will consist of gaze tracking and then review of performance or the use of an implicit map to train an expert gaze pattern.
223691078|NCT04935437|OTHER|Supervised rehabilitation program.|The program includes aerobic exercise, strengthening exercises, physiotherapy, psychological support and dietary advice.
223691079|NCT06224543|DEVICE|SubtleGAD|SubtleGAD is an image processing software developed to enhance MR images acquired with low dose gadobutrol.
223691080|NCT06224543|DRUG|Gadobutrol|Gadavist is indicated for use with magnetic resonance imaging (MRI) in adult and pediatric patients including term neonates to detect and visualize areas with disrupted blood brain barrier and/or abnormal vascularity of the central nervous system.
223691081|NCT06556758|OTHER|stripping massage + conventional therapy|Stripping massage on rhomboid major and minor active trigger point in the direction of muscle fiber from origin to insertion of muscle. Frequency: 3 minutes for 3 times/week for 4 consecutive weeks. Conventional PT including Hot pack for 10 minutes + ischemic compression for 90 secs + CPA glides grade 3 kaltenborn mobilization on thoracic T1 to T4 (5 reps x 1 set) Frequency: 3 times/ week for 4 weeks
223691082|NCT06556758|OTHER|Conventional therapy|conventional therapy including Hot pack for 10 minutes + ischemic compression for 90 secs + CPA glides grade 3 kaltenborn mobilization on thoracic T1 to T4 (5 reps x 1 set ) Frequency : 3 times/ week for 4 weeks
223691083|NCT00147251|DRUG|FDA approved drugs to treat blood pressure and cholesterol|
223691084|NCT04437953|DRUG|Avatrombopag|"Patients will receive an initial dose of Avatrombopag 60 mg on Day 1. Starting on Day 2, the dose will be Avatrombopag 20 mg daily. Once a patient has reached a platelet target of \> 100,000/mcL patients can initiate systemic cancer therapy. Avatrombopag will be continued as maintenance (subscript m) and titrated weekly with a goal to maintain a platelet count of ≥ 100,000/mcL during administration of systemic cancer therapy. Duration of maintenance therapy will be at least 12 weeks (indicated by Week 1m, Week 2m, … 12m) starting from time of platelet correction and resumption of systemic cancer therapy. End of Treatment (EOT) is up to 15 weeks on study Week 12m."
223691085|NCT04804501|DEVICE|Blue Light Glasses|Participants will be randomized into an experimental group (blue light glasses) or a control group (no glasses). Participants will perform a computer reading task while either wearing, or not wearing the glasses.
223691086|NCT04804501|OTHER|Computer Reading Task|Participants will read on a computer until concussion symptoms increase by a score of 3 or more (reading task termination criteria). One or more points will be assigned for each increase in symptom severity, and one point will be assigned for each new symptom that appears.
223691087|NCT05732987|OTHER|Analysis of samples|DNA extraction from blood or saliva samples for the identification of gene variants by next generation sequencing;
223691088|NCT05732987|OTHER|Analysis of samples|RNA extraction from blood and skin samples for Nanostring analyses, quantitative RT-PCR or RNA sequencing.
223691089|NCT05732987|OTHER|Analysis of samples|Biobanked skin samples will be analyzed by immunostaining and imaging techniques to identify cell types in lesions and compare them to healthy skin.
223691090|NCT05732987|OTHER|Analysis of samples|Cells isolated from biobanked blood and skin samples will be cultured in vitro and proteins will be analyzed by ELISA (secreted proteins) and western blot (cell proteins).
223691091|NCT05536505|GENETIC|Adjuvant treatment for MRD positivity|The MRD positive group would receive icotinib as adjuvant treatment. When the peripheral blood MRD turned negative, the subjects entered the drug withdrawal observation period. When the MRD turned positive again, the subjects resumed icotinib treatment. If EGFR T790M mutation was found, researchers would resume medication and choose osimertinib therapy.
223691092|NCT01629706|DEVICE|Balafilcon A contact lens|Commercially marketed silicone hydrogel contact lens
223691093|NCT01629706|DEVICE|Habitual contact lenses|Commercially marketed silicone hydrogel contact lenses as prescribed by eye care practitioner, brand and power
223691094|NCT01629706|DEVICE|Renu multi-purpose solution|Commercially marketed solution for use in removing protein, cleaning, conditioning, and disinfecting contact lenses.
223691095|NCT01629706|DEVICE|ClearCare|Commercially marketed hydrogen peroxide system for cleaning and disinfecting contact lenses
223691096|NCT01629706|DEVICE|Habitual lens care|Lens care per habitual use
223776864|NCT03641352|DRUG|CKD-501 0.5mg|CKD-501 0.5mg, orally, 1 tablet once a dqy for 24weeks or 52weeks (if extension study) with D150 and D759
223776865|NCT03641352|DRUG|Placebo|Placebo, orally, 1 tablet once a dqy for 24weeks or 52weeks (if extension study) with D150 and D759. CKD-501 placebo will be changed to CKD-501 from extension study to EOS(end of study).
223835689|NCT05814861|DIAGNOSTIC_TEST|culture and PCR|"Stool samples will be cultured inTwo media :~A-Locke egg serum medium (LE) B- Jones' medium Then Molecular identification of Blastocystis hominis using polymerase chain reaction (PCR)."
223835690|NCT05421650|OTHER|CCRT|CCRT
223691097|NCT05324176|RADIATION|diaphragmatic ultrasound|diaphragmatic thickness will be measured on both sides during a deep breath in inspiration and during expiration.
223691098|NCT03376906|PROCEDURE|HIIE 1|In the HIIE 1 session, all the subjects performed 10 stimuli of 1 min at high intensity (92% of VO2Max) with passive recovery (without exercise) of 1 min.
223691099|NCT03376906|PROCEDURE|HIIE 3|In the HIIE 3 session, the subjects performed the same stimulus of the HIIE1, but with passive recovery of 3 min. Both protocols started with a warm-up of 5 min at 50% of the VO2Peak performed on a T2-100 GE Healthcare® treadmill (Lynn Medical, Wixon, Michigan, USA).
223691100|NCT03376906|PROCEDURE|Control|In the control session, participants remained seated for 30 min. During HIIE 1 and 2, HR and RPE were assessed immediately after stimulus intervals (ten measurements at each HIIE). In all sessions, the subjects remained in supine position to obtain hemodynamic measurements which were obtained before and at 10 min, 30 min and 60 min after the HIIE and control sessions.
223691101|NCT03003156|PROCEDURE|25 Hz magnetic seizure therapy|In addition to treatment as usual (TAU), participants were supposed to receive ten sessions of 25 Hz MST in four weeks, with three sessions per week in the first two weeks and two sessions per week in the following two weeks.
223691102|NCT03003156|PROCEDURE|50 Hz magnetic seizure therapy|In addition to treatment as usual (TAU), participants were supposed to receive ten sessions of 50 Hz MST in four weeks, with three sessions per week in the first two weeks and two sessions per week in the following two weeks.
223691103|NCT01429038|BIOLOGICAL|Mesenchymal Stem Cells|Third party MSC 1,5-3,010E6/kg. No HLA matching between MSC donor and the recipient or the liver/kidney donor. One infusion at day 3+/-2.
223691104|NCT04448782|DIAGNOSTIC_TEST|Asynchronies detection|Asycnhronies detection
223691105|NCT01151098|DRUG|Buprenorphine transdermal patch|Buprenorphine transdermal patch 5, 10 or 20 mcg/h applied for 7-day wear
223691106|NCT03771053|DRUG|Ezetimibe with simvastatin|ezetimibe 10mg with simvastatin 40mg everyday for 12 months after PCI
223691107|NCT03771053|DRUG|Simvastatin|simvastatin 40mg everyday for 12 months after PCI
223691108|NCT04988828|DEVICE|Whole body vibration|vertical vibration platform with the frequency of 30Hz, amplitude of 4mm. The intervention will last for 5 weeks, twice /week.
223691109|NCT00190944|DRUG|Teriparatide|
223691110|NCT00190944|DRUG|placebo|
223691111|NCT06329115|OTHER|Exercise training|Within the physical activity program, an aerobic training program will be applied to students for a total of 150 minutes per week for 8 weeks. Aerobic training includes moderate-intensity walking exercise. The concept of moderate walking will be explained to individuals at the beginning of the study. Maximal and submaximal heart rate calculations will be made with the formulas (220-age) / (220-age X 0.6) and this heart rate will be maintained throughout the training. Students will have a pedometer application installed on their phones and their step counts and exercise minute data will be recorded. At the same time, in order for students to use their respiratory functions properly during regular walking, diaphragmatic breathing and alternating nose breathing breathing exercises will be taught and they will be instructed to do them once a day with 5 repetitions.
223691112|NCT04384588|BIOLOGICAL|Convalescent Plasma from COVID-19 donors|Patients that will participate in this clinical trial will be treated with Convalescent Plasma from COVID-19 donors regardless of the arm where they will be included
223691113|NCT04686123|OTHER|Active Stretching or Self-stretching exercises|Pectoralis minor muscle was actively stretched under the supervision of a physiotherapist as follows: - 2 sets of 3-stretches/session/day, for 5 consecutive days a week, for 3 weeks
223691114|NCT04686123|OTHER|Active strengthening Or Self-Strengthening exercises|Lower trapezius muscle was strengthened under the supervision of a physiotherapist as follows: -2 sets of 5-rep./session/day, for 5 consecutive days in 1st week, progressed to 10 and 20 reps./session/day for 2 weeks and 3 weeks respectively.
223691115|NCT01880047|DRUG|Eltrombopag|Eltrombopag will be administered for 8 weeks or until the platelet count exceeds 150,000; at this point dosing will stop, subject will be considered a responder and the subject will eligible for entering Part 2 (the long term treatment part of the study. The dose at which the subject achieved the primary endpoint (\> 50,000 and increase by \> 20,000) will be considered the dose of response. Dose escalation will continue, despite satisfaction of the primary endpoint of study (\> 50,000 and \> 20,000 above baseline), unless the platelet count reaches the lower limit of normal range 150,000. Subjects will stop study medication if the platelet count is within the normal range, thereby minimizing any safety risk associated with elevated platelet count.
223691116|NCT01880047|DRUG|Placebo|
223691117|NCT00160589|DRUG|Levocetirizine|
223691118|NCT03210987|PROCEDURE|patient case presentation bedside|Patient case presentation in absence or presence of Patient at bedside.
223691119|NCT03210987|PROCEDURE|patient case presentation Outside-the-room|Patient case presentation Outside-the-room.
223691120|NCT01015144|DRUG|Tulip|Patients were divided into two groups: A, who were administered atorvastatin 40 mg daily for two months and 10 mg for next 4 months; and group B, 4 who were treated according to current guidelines without statin therapy.
223691121|NCT03533582|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223691122|NCT03533582|DRUG|Carboplatin|Given IV
223691123|NCT03533582|DRUG|Cisplatin|Given IV
223691124|NCT03533582|DRUG|Doxorubicin|Given IV
223691125|NCT03533582|DRUG|Etoposide|Given IV
223691126|NCT03533582|DRUG|Fluorouracil|Given IV
223691127|NCT03533582|DRUG|Gemcitabine|Given IV
223691128|NCT03533582|DRUG|Irinotecan|Given IV
223691129|NCT03533582|DRUG|Oxaliplatin|Given IV
223691130|NCT03533582|OTHER|Patient Observation|Undergo watchful waiting
223691131|NCT03533582|PROCEDURE|Resection|Undergo surgical resection
223691132|NCT03533582|DRUG|Sorafenib|Given PO
223691133|NCT03533582|DRUG|Vincristine Sulfate|Given IV
223691134|NCT01270854|OTHER|Plasmalyte A|Intravenous fluid
223691135|NCT01270854|OTHER|Normal Saline|Intravenous fluid
223691136|NCT05909527|BIOLOGICAL|CD7 CAR-T|A single infusion of autologous CD7 CAR-T cells administered intravenously
223691137|NCT00926068|DRUG|HO/03/03 10µg|
223691138|NCT00926068|DRUG|Placebo|
223691139|NCT03059433|OTHER|AVID Intervention|Advancement via Individual Determination (AVID) is a college preparatory program that participating high schools have available to students.
223691140|NCT04186936|DRUG|Combination Caplet with Loperamide HCl and Simethicone|Participants will receive combination caplet with loperamide HCl 2 mg and simethicone 125 mg as Test product A per assigned treatment sequence.
223691141|NCT04186936|DRUG|Loperamide HCl|Participants will receive loperamide HCl 2 mg tablet-lyophilizate orally as part of Reference product B per assigned treatment sequence.
223776866|NCT00581958|OTHER|Blood Samples|blood (approximately two 4 ml; equivalent to less than 2 tablespoon) and urine (a cup of urine) samples or testing a total of three times. Blood will be drawn and urine will be collected once before radiation treatment and twice after first radiation treatment.
223691142|NCT04186936|DRUG|Simethicone|Participants will receive Simethicone 40 mg capsule orally as part of Reference product B per assigned treatment sequence.
223691143|NCT01593722|DRUG|Diethylcarbamazine|single dose
223691144|NCT01593722|DRUG|Ivermectin|single dose
223691145|NCT04490824|DEVICE|KELEA Excellerated Water|Water with increased kinetic activity as assessed by published methods of the PI
223691146|NCT04490824|DEVICE|Water Without an Elevated Level of KELEA|Bottled water without an elevated level of KELEA, as shown by proprietary testing will be provided as a control.
223691147|NCT01489371|OTHER|Laboratory Biomarker Analysis|Correlative studies
223691148|NCT01489371|BIOLOGICAL|PEG-PEI-cholesterol Lipopolymer-encased IL-12 DNA Plasmid Vector GEN-1|Given IP
223691149|NCT01489371|DRUG|Pegylated Liposomal Doxorubicin Hydrochloride|Given IV
223691150|NCT03343067|DRUG|elagolix|Tablets
223691151|NCT03343067|DRUG|estradiol/norethindrone acetate (E2/NETA)|Capsules
223691152|NCT00434343|OTHER|Global Therapeutic Massage (GTM)|
223691153|NCT00434343|OTHER|Myofascial physical therapy (MPT)|Connective tissue manipulation to all body wall tissues of the abdominal wall, back, buttocks and thighs that clinically were found to contain connective tissue abnormalities and/or myofascial trigger point release to painful myofascial trigger points
223691154|NCT01285453|DRUG|vadimezan|
223691155|NCT01148797|DRUG|Canakinumab|
223691156|NCT05141825|RADIATION|proton and carbon ion radiotherapy|proton and carbon ion radiotherapy
223691157|NCT01554228|OTHER|Observation|Observational study to examine changes in cognition following bariatric surgery after one year.
223691158|NCT00346944|PROCEDURE|Removal of dental amalgam restorations|Removal of dental amalgam restorations by patient's own dentist. Fillings will be replaced with e.g. resin based filling material, metalloceramic restorations, and ceramic materials. Rubber dam will be used during removal of amalgam restorations.
223691159|NCT00116168|BIOLOGICAL|MEDI-528 0.3 mg/kg|MEDI-528 (0.3 mg/kg) administered as a single, subcutaneous (SC) dose
223691160|NCT00116168|BIOLOGICAL|MEDI-528 1 mg/kg|MEDI-528 (1 mg/kg) administered as a single, SC dose
223691161|NCT00116168|BIOLOGICAL|MEDI-528 3 mg/kg|MEDI-528 (3 mg/kg) administered as a single, SC dose
223691162|NCT00116168|BIOLOGICAL|MEDI-528 9 mg/kg|MEDI-528 (9 mg/kg) administered as a single, SC dose
223691163|NCT03110744|DRUG|Palbociclib|application on 21 consecutive days of a 28 days cycle
223691164|NCT06364306|PROCEDURE|Robotically-assisted ventral hernia repair (RVHR)|"3 8mm robotic trocars are placed intraabdominally and the DaVinci Xi-robotic system is docked. Adhesiolysis from any adherent structures to the abdominal wall is performed. Incision of the lateral verge of the retromuscular space and retromuscular dissection. Superior and inferior cross-over to the contralateral retromuscular space and dissection of the hernia sac.~Unilateral or bilateral transversus abdominis release (TAR) is performed, if necessary. Running suture with absorbable barbed suture of the posterior rectus sheath and peritoneum, as appropriate. Synthetic retromuscular mesh placement with a mesh-size as large as the prepared surface allows. Closure of the anterior rectus sheath with absorbable barbed running suture. Port extraction, skin closure. Dressing from xyphoid to pubis and 6 lateral dressings for blinding purposes."
223691165|NCT06364306|PROCEDURE|Open ventral hernia repair (OVHR)|Median laparotomy with a minimal length of the previous scar (in case of incisional hernia) and adhesiolysis is performed, where necessary, to liberate the abdominal wall and the ventral hernia from adhesions. Bilateral dissection of the posterior rectus sheath under visualisation and sparing of the epigastric vessels and neurovascular bundles. Closure of the posterior rectus sheath with a slowly-absorbable running suture. Indication for a uni- or bilateral TAR identical to the intervention group. Retromuscular synthetic mesh placement with a mesh-size as far as the prepared surface allows. Mesh fixation optional with either absorbable sutures to the posterior sheath or with glubran glue. Closure of the anterior rectus sheath with a slowly-absorbable running suture. Skin closure. Dressing from xyphoid to pubis and 6 lateral dressings for blinding purposes.
223691166|NCT01763671|DRUG|Docetaxel|75 mg/m² IV on day one of 21 days cycle Number of Cycles: until progression or unacceptable toxicity develops.
223691167|NCT01763671|DRUG|Paclitaxel|90 mg/m² IV on day 1, 8 and 15 of 28 days cycle Number of Cycles: until progression or unacceptable toxicity develops.
223691168|NCT01763671|DRUG|Bevacizumab|10 mg/kg IV on day 1 and 15 of 28 days cycle Number of Cycles: until progression or unacceptable toxicity develops.
223835691|NCT05421650|PROCEDURE|Surgical debulking of lymph nodes + CCRT|Surgical debulking of lymph nodes + CCRT
223835692|NCT04813146|OTHER|SLP|Synchronization of dietary intake with circadian rhythm of the body
223835693|NCT04813146|OTHER|SLP along with Physiotherapy|Synchronization of dietary intake along with Physiotherapy (aerobic, flexibility, resistance and balance exercises)
223776867|NCT03268967|BEHAVIORAL|Structured admission procedure|A structured ICU admission was inspired by principles of Crisis Resource Management and simulation training of ICU staff members. The Principles of Crisis Resource Management consisted of a treatment manual, a learning video, clear precise communication tool based on Identification-Situation-Background-Analysis-Recommendations (ISBAR) and Closed loop, actions cards, and ABCDE-evaluation of the patient including debriefing, and training in the simulation environment.
223776868|NCT00360334|DRUG|exenatide|subcutaneous injection, 5mcg or 10mcg, twice a day
223776869|NCT00360334|DRUG|insulin glargine|subcutaneous injection, titrated to target blood glucose level, once a day
223776870|NCT04814069|DRUG|Tislelizumab|Tislelizumab 200mg q3w
223776871|NCT03822728|DIAGNOSTIC_TEST|3D-DESS MRI (3 dimensional double echo steady state MRI)|3D-DESS MRI has been reported useful for the intra-parotid facial nerve imaging. It can provide information about the anatomical relationship between the tumor and the facial nerve in the parotid gland.
223691169|NCT04340297|DRUG|Tongjiang series prescription(Tongjiang granules, Jianpi Qinghua granules and Wenpi Qingwei granules)|According to the syndrome differentiation of TCM, Tongjiang granules are taken orally by patients with liver-stomach depression-heat syndrome, Jianpi Qinghua granules are taken orally by patients with spleen deficiency damp-heat syndrome, Wenpi Qingwei granules are taken orally by patients with cold-heat complicated syndrome, 1 bag per time, 3 times a day and 1 hour after a meal.
223776872|NCT05927233|DRUG|Methylprednisolone|30 ml Methylprednisolone (30mg/kg) with a maximum dose of 500 mg
223776873|NCT05927233|DRUG|Saline|30 ml Normal saline
223776874|NCT05493995|DRUG|Penpulimab|Penpulimab 200 mg administered intravenously every 3 weeks.
223691170|NCT04340297|DRUG|Acid inhibitors|In the 1-2 weeks, acid inhibitor (PPI) was reduced from the dose before entering the group to half of the dose, once a day, before going to bed; in the 3-4 weeks, acid inhibitor was changed from PPI to famotidine tablets, 20mg each time, before going to bed; in the 5-6 weeks, all acid inhibitors were stopped.
223776875|NCT05493995|DRUG|Anlotinib|12mg, continuous oral 2 weeks stop for 1 week, 21 days for a treatment cycle.
223776876|NCT05493995|DRUG|Nab paclitaxel|125mg/m\^2，administered intravenously on days 1 and 8 of every 21-day cycle.
223776877|NCT05493995|DRUG|Gemcitabine|1.0g/m\^2, administered intravenously on days 1 and 8 of every 21-day cycle.
223776878|NCT00003380|DRUG|etoposide|
223776879|NCT00003380|DRUG|pegylated liposomal doxorubicin hydrochloride|
223776880|NCT00863642|PROCEDURE|Laparoscopic cholecystectomy within 48 hours of admission|Patients are taken to the operating room for laparoscopic cholecystectomy within 48 hours of admission
223835694|NCT04813146|OTHER|Physiotherapy|Physiotherapy given only (aerobic, flexibility, resistance and balance exercises)
223691171|NCT04340297|DRUG|Placebo|Tongjiang granules placebo , Jianpi Qinghua granules placebo and Wenpi Qingwei granules placebo. The above three kinds of granulated placebo are respectively made of the simulation containing the low dose original prescription. Taking method is the same as Tongjiang series prescription.
223691172|NCT02788474|DRUG|nintedanib|
223691173|NCT02788474|DRUG|placebo|
223691174|NCT02317146|DRUG|Magnesium Sulfate|Magnesium sulfate is the drug used as prophylaxis to eclampsia in women with severe preeclampsia
223691175|NCT01206868|PROCEDURE|Fenestration|Fenestration of the peritoneum according to the length of the transplanted kidney
223691176|NCT01206868|PROCEDURE|Control|Standard kidney transplantation
223691177|NCT02670174|OTHER|Traditional training|
223691178|NCT02670174|OTHER|Separate kinetic chain training|
223691179|NCT02670174|OTHER|Integrated kinetic chain training|
223691180|NCT05005754|DIETARY_SUPPLEMENT|Probiotics|During the study period, subjects are instructed to take one capsule of probiotics daily for a total of 3 months. Aside from the probiotic supplement, all participants are instructed to continue their normal routine and not make any changes to their habitual diet or exercise habits.
223691181|NCT05005754|DIETARY_SUPPLEMENT|Placebo control|During the study period, subjects are instructed to take one capsule of placebo control daily for a total of 3 months. Aside from the probiotic supplement, all participants are instructed to continue their normal routine and not make any changes to their habitual diet or exercise habits.
223691182|NCT00773929|DRUG|TAK-593|"Tablets of TAK-593 investigational drug for oral administration, tablets in 2 strengths: 1 mg and 4 mg tablets.~Administration will initially be 4 mg, once a day and transition to 2 mg BID schedule dependant on safety"
223691183|NCT04094623|OTHER|Dialectical behavior therapy|15 patients in a group are treated by 2 psychotherapist by DBT including mindfulness skills, distress tolerance skills, emotional regulation skills and interpersonal effectiveness skills.
223691184|NCT04094623|OTHER|Social support group therapy|15 patients in a group are treated by 2 psychotherapist by SSGT.(Giving support to each other.)
223691185|NCT03057379|OTHER|Vaccine Reminder Recall|The investigators will be sending recall notices via phone call to 11-17 year olds who are eligible but lacking HPV vaccine doses recorded in the New York State Immunization Information System (NYSIIS). The investigators will be testing the effectiveness and cost effectiveness of up to 3 notices per dose with usual care (no intervention)
223691186|NCT04314310|DRUG|Tenoxicam|nonsteroidal anti-inflammatory drug (NSAID)
223691187|NCT04314310|DRUG|Placebo|equal volume of normal saline
223691188|NCT02175784|DRUG|ipragliflozin|oral
223691189|NCT02175784|DRUG|placebo|oral
223691190|NCT02737046|DRUG|Belinostat|Belinostat will be administered as 1,000 mg/m2 IV infusion over 30 minutes on Days 1- 5 every 21 days (Exception as per FDA-approved Package Insert: In patients known to be homozygous for the UGT1A1\*28 allele, the starting belinostat dose must be 750mg/m2) for up to 8 cycles.
223691191|NCT02737046|DRUG|Zidovudine|Zidovudine shall be administered in the outpatient setting as 300 mg tablets orally (PO), three times daily (TID) for 21 days on cycles 1 to 8, followed by maintenance therapy (+/- IFN-alfa) up to the end of Month 12.
223691192|NCT02737046|DRUG|Interferon-Alfa-2b|OPTIONAL: For subjects receiving interferon therapy at baseline, continue Interferon alfa-2b 5 million IU daily or pegylated interferon alfa-2b 1.5 μg/kg once weekly, subcutaneously (SQ) for up to 12 months.
223691193|NCT02737046|DRUG|Pegylated Interferon-Alfa-2b|OPTIONAL: For subjects receiving interferon therapy at baseline, continue Interferon alfa-2b 5 million IU daily or pegylated interferon alfa-2b 1.5 μg/kg once weekly, subcutaneously (SQ) for up to 12 months.
223776881|NCT00863642|PROCEDURE|Laparoscopic cholecystectomy after resolution of abdominal pain and laboratory values|Patients are taken to the operating room for laparoscopic cholecystectomy after resolution of abdominal pain and laboratory values
223776882|NCT05770466|DRUG|P1101 (Ropeginterferon alfa-2b)|"1. Name: P1101 (Ropeginterferon alfa-2b)~2. Dosage form: pre-filled syringe~3. Strength: A single dose of 250 mcg/0.5 mL~4. Dosage and administration: 250 mcg per subcutaneous injection~5. Mechanism of action (if known): Interferon work by binding to specific membrane receptors on the cell surface which in turn induce a complex sequence of intracellular events. These events include the induction of particular enzymes, suppression of cell proliferation, inhibition of virus replication in virus infected cells and immunomodulating activities.~6. Pharmacological category: Antineoplastic and immunomodulating agents/ Immunostimulants/ Cytokines"
223776883|NCT05770466|PROCEDURE|SOC|SOC includes infection prevention and control measures, supportive care, dexamethasone, and antiviral agents. The SOC is based on the Taiwan Centers for Disease Control (CDC) guidance and investigator's discretion.
223776884|NCT03098446|BEHAVIORAL|Prolonged sitting with exercise|Subjects will have a 2-day control period during which step count and diet will be controlled for and recreated for the other trial. Following this 2-day period, they will undergo the prolonged sitting trial with the acute bout of exercise on day 4. Day 5 will consist of the lipid tolerance test to determine the ability of the body to clear triglycerides.
223776885|NCT03098446|BEHAVIORAL|Prolonged sitting without exercise|Subjects will have a 2-day control period during which step count and diet will be controlled for and recreated for the other trial. Following this 2-day period, they will undergo the prolonged sitting trial, but will not be asked to complete an acute bout of exercise on day 4. Day 5 will consist of the lipid tolerance test to determine the ability of the body to clear triglycerides.
223776886|NCT00304785|DRUG|latanoprost 0.005%|
223776887|NCT00304785|DRUG|Fotil|
223776888|NCT00304785|DRUG|placebo|
223776889|NCT00964691|DRUG|Sulphadoxine-pyrimethamine|3 tablets of SP (500 mg sulfadoxine and 25 mg pyrimethamine per tablet) by mouth under supervision at enrolment, and 3 tablets of SP under supervision 4 to 12 weeks later in pregnancy (timing of second dose depends upon gestation at first dose)
223776890|NCT00964691|DRUG|Chloroquine prophylaxis|300 mg weekly by mouth from the enrolment date until delivery. Only the enrolment dose will be supervised.
223776891|NCT03200613|DRUG|Apixaban|2.5 mg orally twice daily
223776892|NCT03200613|DRUG|Low molecular weight heparin|Dalteparin 5000 units daily or Enoxaparin 40 mg subcutaneous daily
223776893|NCT00595582|DIETARY_SUPPLEMENT|curcumin + bioperine|Subjects who are currently in the primary Mild Cognitive Impairment study will be asked to be treated with 5.4 grams of curcumin + bioperine per day (900 mg pills, two pills 3x/day with meals) for 24 months concordant with the last two years of the primary longitudinal Mild Cognitive Impairment study.
223776894|NCT00169637|DRUG|rhGH|
223776895|NCT03612037|DIETARY_SUPPLEMENT|alpha lipoic acid|600 mg/day oral dose of alpha lipoic acid
223776896|NCT03612037|DIETARY_SUPPLEMENT|Cellulose|600mg/day oral dose of placebo cellulose
223776897|NCT03113591|PROCEDURE|Minimum invasive total hip arthroplasty|Minimum invasive total hip arthroplasty using the osteo introducer system
223776898|NCT03113591|PROCEDURE|Common total hip arthroplasty|Common total hip arthroplasty using common instruments
223776899|NCT04409041|DRUG|Low-Dose Naltrexone|Based on the promising evidence, we propose using low-dose naltrexone at a daily dose of 3mg to treat lichen planopilaris and frontal fibrosing alopecia. The patients would be continued on their other medications for these conditions. The study would be open-label, so all participants would receive the low-dose naltrexone. Patients would be seen at 0,3,6 and 12 months to monitor their progress.
223776900|NCT01978184|DRUG|gemcitabine|
223776901|NCT01978184|DRUG|abraxane|
223776902|NCT01978184|DRUG|hydroxychloroquine|
223776903|NCT01049659|BEHAVIORAL|Neuropsychological test|Bayley test (version III) which provides several scales of development. Children are assessed just one time at two year old
223776904|NCT04691466|PROCEDURE|Joint replacement|Routinely performed hip- or knee replacement
223776905|NCT03837496|OTHER|STRIDE|STRIDE is a brief, group-based, virtual (videoconference) cognitive-behavioral intervention. The intervention incorporates adherence problem-solving, cognitive restructuring, relaxation training, symptom management, coping skills training, and mindfulness techniques.
223776906|NCT03837496|OTHER|Medication Monitoring Control|Care provided as standard by the hospital and medication monitoring
223776907|NCT00448058|DRUG|GSK372475|daily administration during the 10-week treatment phase
223776908|NCT00448058|DRUG|venlafaxine|daily administration during the 10-week treatment phase
223776909|NCT00448058|DRUG|placebo|daily administration during the 10-week treatment phase
223776910|NCT03330535|BEHAVIORAL|Reminders once a week|Participants in this group will receive active oral hygiene reminders through text messaging once a week.
223776911|NCT03330535|BEHAVIORAL|Verbal oral hygiene instructions|Participants in this group will receive verbal oral hygiene instructions during their regular orthodontic visits every 4 weeks.
223776912|NCT03330535|BEHAVIORAL|Reminders three times a week|Participants in this group will receive active oral hygiene reminders through text messaging three times a week.
223776913|NCT03330535|BEHAVIORAL|Daily reminders|Participants in this group will receive active oral hygiene reminders through text messaging on a daily basis.
223776914|NCT04913428|OTHER|Interdigital exercise|Patient asked to sit in upright position interlocking their fingers with inhaling deeply bringing the arms up and exhaling through mouth while bring the arm down.
223776915|NCT04913428|OTHER|Blow-Bottle technique|For blow bottle 20cm of bottle filled with 10cm of water in which a tube of length 35- 40cm inserted with the inner diameter of ≥8mm(21).Patient is asked to form bubbles in bottle by exhaling in bottle performing Forced Expiratory Techniques.
223691194|NCT05619523|BEHAVIORAL|Developing Inclusive Youth (DIY)|Developing Inclusive Youth (DIY) is a web-based curriculum tool that serves as the intervention program. The animated and narrated tool displays eight peer social exclusion scenarios in a range of familiar everyday social contexts (such as the playground and school). Children enter their responses while watching the scenarios. Responses include making decisions about inclusion and exclusion, evaluating the actions as okay or not okay, attributing feelings to includers, excluders, and excluded characters, and selecting reasons that best match their justification for their decisions and evaluations. The program includes teacher-guided group discussions following use of the tool in which teachers facilitate discussions about children's interpretations of the scenarios, evaluations, reflections regarding their own experiences of exclusion, and solutions. Participants will view and discuss 8 scenarios and engage in a discussion for each one over the course of 8 weeks.
223691195|NCT06399198|PROCEDURE|Free gingival graft|After adequate local anesthesia is achieved, a horizontal incision will be placed at mucogingival junction level to prepare the recipient bed. A split-thickness flap will be raised without disturbing the periosteum. A free gingival graft will be obtained from the palate. The graft will be shaped and sutured to the recipient surface.
223691196|NCT00206310|DRUG|CRESTOR|
223691197|NCT05342532|DRUG|Amoxicillin|1 g
223776916|NCT01115426|DRUG|Ramipril or losartan|Ramipril (5 mg/day) was started soon after the enrollment and continued throughout the follow-up, having Losartan (50 mg/day) as alternative.
223776917|NCT05716711|OTHER|LAVENDER OIL|IT WILL BE APPLIED TO 60 PATIENTS, 20 IN EACH GROUP, WITH A COLOSTOMY
223776918|NCT01915368|BEHAVIORAL|Stroke Management Program (SMP)|Participants will have usual care, and in addition, be provided with periodic information about their progress in the area of mobility using specialized activity monitors
223691198|NCT05342532|DRUG|Omeprazole|40 mg. Patients were asked to take omeprazole one hour prior to food intake, while antibiotics were taken after meals.
223691199|NCT05342532|DRUG|Clarithromycin|500 mg twice daily
223691200|NCT00330798|DRUG|nepafenac 0.1%|Nepafenac 0.1% randomly assigned to one eye, with ketorolac 0.4% in the fellow eye for contralateral post-surgical use.
223691201|NCT00330798|OTHER|ketorolac 0.4%|Keterolac 0.4% randomly assigned to one eye, with nepafenac 0.1% in the fellow eye for contralateral post-surgical use.
223691202|NCT02057393|DRUG|Indocyanine green|Subjects receive 0.9ml of ICG subcutaneously about the primary melanoma. The ICG has an infrared signal that is detected with the SPY Elite system (Lifecell). The ICG travels through the lymphatics to the sentinel node.
223691203|NCT02057393|DRUG|Technetium99|Technetium99 is a standard, widely used radiopharmaceutical that is injected subcutaneoulsy about the primary melanoma site. Lymphoscintigraphy is performed to identify the draining nodal basin, and a gamma probe is used in the operating room to track the radioactive signal and find the sentinel node.
223691204|NCT02057393|DRUG|Methylene blue|Subjects receive 0.5-2ml of methylene blue subcutaneously about the primary melanoma at the time of surgery. The sentinel node should turn blue, which is visible with the naked eye.
223691205|NCT04337450|DRUG|Dolutegravir (DTG) and lamivudine (3TC)|Children randomised to the DTG/3TC arm will receive once daily DTG/3TC fixed dose combination dispersible or film-coated tablets dosed using WHO weight bands criteria
223691206|NCT04337450|DRUG|SOC|2 nucleos(t)ide reverse transcriptase inhibitor (NRTI) and a third (anchor) drug (either an integrase strand transfer inhibitor (INSTI), a protease inhibitor (PI) or a non- nucleoside reverse transcriptase inhibitor (NNRTI)
223691207|NCT05826782|BIOLOGICAL|Proxeed Plus 2*1 A arm|Proxeed plus 2 x daily sachets (2\*1) three mounths
223691208|NCT05826782|BIOLOGICAL|Placebo|Placebo 2 x daily sachets (2\*1) three mounths
223691209|NCT03978481|COMBINATION_PRODUCT|Helicobacter pylori eradication (combination therapy)|Antibiotic eradication therapy (triple or quadriple regimen)
223691210|NCT06434038|DRUG|Low Dose Regular insulin|Administered intranasally at 40 IU
223691211|NCT06434038|DRUG|High Dose Regular insulin|Administered Intranasally at 80 IU
223691212|NCT06434038|OTHER|0.9% Saline|Placebo control
223691213|NCT02284711|DEVICE|Bipolar electric energy|Coagulation during salpingectomy using conventional bipolar electric energy
223691214|NCT02284711|DEVICE|ultrasound energy|Coagulation during salpingectomy using UltraCision HARMONIC ACE® ultrasound energy
223691215|NCT04685226|DRUG|ICP-723|ICP-723 is a white, round, uncoated table
223691216|NCT06370325|PROCEDURE|VPOD Wireless Tens Unit|The VPOD unit will deliver NMES to participants in the Intervention Group.
223691217|NCT06370325|PROCEDURE|Physical Therapy|Physical therapy as per standard of care.
223691218|NCT06370325|DEVICE|Biodex|Used to assess strength, endurance, power, and range of motion.
223691219|NCT05942469|BEHAVIORAL|FOREST|"The skill sessions will include didactic content defining the skill, rationale for including the skill in FOREST, and research demonstrating that practice of the skill increases positive emotion. In addition, the group will practice the skill together and will discuss ways to practice the skill at work as well as outside of work. Throughout the month, PEAs will implement the FOREST skill of the month in other existing meetings, check-ins, and team outings.~Concurrently, a module in UCAN's learning management system (LMS) will become available. The LMS modules will contain skill-related content similar to what is taught in the skill sessions, including a thorough definition of the skill, examples of ways to utilize the skill, a review or summary of the skill, and several knowledge questions to check for comprehension. The LMS content may include text, audio, images, and video components."
223691220|NCT03415854|DRUG|Paricalcitol (Zemplar)|combination therapy
223691221|NCT05893797|DRUG|Insulin Lispro|As prescribed.
223776919|NCT01915368|BEHAVIORAL|Stroke Monitoring Program (SMonP)|Participants will have usual care, and in addition, be progressed according to customized protocols using feedback from specialized activity monitors
223776920|NCT01915368|BEHAVIORAL|Stroke Supplementary Program (SSP)|Participants will have usual care, and in addition, will receive the same as the Stroke Monitoring Group, and also receive one additional hour of daily (5 times per week) physical exercise
223776921|NCT00131781|BEHAVIORAL|Cognitive Therapy|
223776922|NCT00131781|BEHAVIORAL|Supportive Therapy|
223776923|NCT05075616|PROCEDURE|Percutaneous endoscopic gastrostomy|Percutaneous endoscopic gastrostomy (PEG) is a minimally-invasive endoscopic procedure that creates a passage from the patient's stomach to the abdominal wall via a feeding tube and provides a means of feeding if oral intake is not adequate.
223776924|NCT04891679|DRUG|Oral misoprostol solution (OMS)|"Based on the WHO labor induction recommendation, and for the purpose of achieving precise oral misoprostol dosage, one misoprostol tablet (200 mcg) was pulverized and dissolved into 200 ml water.90 Thus 1ml of solution had 1mcg of misoprostol. This misoprostol solution could be preserved at room temperature and remained active for 24 hours.~Hourly titrated oral misoprostol solution was given to group A as described by Wang X et al, 2016 as described below.~0 hour= 20ml~1. hour= 20ml~2. hour= 30ml~3. hour= 30ml~4. hour= 30ml~5. hour= 40ml 6.5 hour= 50ml 8.5 hour= 60ml 10.5 hour=60ml~Group B received 25 mcg (25 ml) oral misoprostol solution every 2 hours for a maximum of 12 doses or until the onset of regular uterine activity."
223776925|NCT02851238|OTHER|Driving Pressure Limited Ventilation|Positive end expiratory pressure is adjusted to minimize driving pressure, plateau pressure minus end expiratory pressure from 2 to 10 cmH2O during one-lung ventilation
223691222|NCT05893797|DEVICE|Tempo Smart Button|Attached to the Tempo Pen
223691223|NCT05893797|DEVICE|Dexcom G6 CGM|Continuous glucose monitor
223691224|NCT05893797|DEVICE|Glooko Research Medical App (RMA)|Installed on a study provided android phone.
223776926|NCT04002765|DIAGNOSTIC_TEST|pulmonary function tests|"1. Lung function tests (standard of care)~   1. Dynamic and static volumes (FVC, FEV1, TPC, RV)~  2. Lung diffusion capacity for CO (DLCO)~2. Chest Xrays~3. High resolution CT scanner (HRCT)"
223776927|NCT03362515|DRUG|Furosemide|furosemide
223691225|NCT01663168|DRUG|Rifabutin|
223691226|NCT02273739|DRUG|Enasidenib|Enasidenib tablets administered orally once a day in 28-day treatment cycles until disease progression or unacceptable toxicities.
223691227|NCT01291433|DRUG|Pentoxifylline placebo|Placebo for pentoxifylline 400 mg, 1 cp twice a day (7d/7)
223776928|NCT03362515|DRUG|Placebo|placebo
223776929|NCT05280119|DEVICE|EchOpen ultra-portable ultrasound device|Depending on the clinical picture, patients are examined to detect the presence or absence of pleural effusion, or intra-abdominal effusion, or to localize the basilic vein
223776930|NCT05280119|DEVICE|Ultrasound device routinely used in the department.|Patients who were first examined with the EchOpen ultra-portable ultrasound device, are secondarily examined with an ultrasound probe used routinely in the department.
223776931|NCT05280119|PROCEDURE|Standard ultrasound examination by an independent referent radiologist|In a case of discordance between the assessments made with echOpen and the usual ultrasound device, an independent referent radiologist will use a standard ultrasound machine to constitute the gold standard (GS) rating
223691228|NCT01291433|DRUG|Pentoxifylline|Pentoxifylline 400 mg: 1 cp twice a day (7d/7)
223691229|NCT01291433|DRUG|Tocopherol acetate|Tocopherol alpha-acetate, 500 mg: 1 capsule twice a day (7d/7)
223691230|NCT01291433|DRUG|Clodronic Acid|Clodronate disodium (clodronic acid) 800 mg: 2 cp per day, 5d/7 (from monday to friday)
223691231|NCT01291433|DRUG|Tocopherol placebo|Placebo for Tocopherol alpha-acetate, 500 mg: 1 capsule twice a day (7d/7)
223691232|NCT01291433|DRUG|Clodronate placebo|Placebo for clodronate disodium (clodronic acid) 800 mg: 2 cp per day, 5d/7 (from monday to friday)
223691233|NCT03038451|DRUG|S-NOR (s-amlodipine) 2,5 mg & 5 mg tablet|
223691234|NCT05208307|BIOLOGICAL|Belantamab Mafodotin|Given IV
223691235|NCT05208307|DRUG|Dexamethasone|Given PO
223691236|NCT05208307|DRUG|Pomalidomide|Given PO
223691237|NCT05967143|DEVICE|SIRT|Selective internal radiation therapy with SIR-Spheres Y90 resin microspheres.
223691238|NCT05185336|DIAGNOSTIC_TEST|ultrasound assessment|gastric volume assessment by ultrasound
223776932|NCT00555438|DRUG|fondaparinux 1.5 mg/day|Subcutaneous injection of fondaparinux 1.5 mg/l after major orthopaedic surgery
223776933|NCT04862091|DRUG|Abiraterone Acetate Tablets (I)|Abiraterone Acetate Tablets (I)
223776934|NCT04862091|DRUG|ZYTIGA®|ZYTIGA®
223776935|NCT04546854|BEHAVIORAL|Appeals|Written text motivating participants to take up the seasonal influenza vaccination
223776936|NCT03243734|DEVICE|trūFreeze® System spray cryotherapy|Subjects where trūFreeze® System spray cryotherapy is performed
223776937|NCT01431508|DRUG|Losartan 50 mg / HCTZ 12.5 mg|Losartan 50 mg / HCTZ 12.5 mg tablet once daily for 12 weeks
223776938|NCT03313596|DRUG|ADV-Tk|The first ADV-TK dose was administered during the operation; 1.0×10(12) viral particles of ADV-TK in 100 mL of 0.9% saline were injected into peritoneum tissues around the liver. The second and third ADV-TK dose was administered 60 days and 90 days after LT; 1.0×10(12) viral particles of ADV-TK in 100 mL of 0.9% saline were injected into the celiac artery (60 mL) and the superior mesenteric artery (40 mL) via femoral-artery puncture.
223776939|NCT03313596|PROCEDURE|LT|Orthotopic LT and subsequent immunosuppression therapy
223776940|NCT04897581|BEHAVIORAL|Brief Behavioral Therapy for Insomnia, BBTI|BBTI includes sleep hygiene, stimulus control, and sleep restriction, and is administered in three 50-minute sessions over telehealth by psychologic team.
223776941|NCT04897581|BEHAVIORAL|Physical Self-Regulation, PSR|PSR is conducted over telehealth and consists of three 50-minute sessions focused on jaw relaxation exercises, proprioceptive awareness training, and diaphragmatic breathing entrainment.
223776942|NCT00797615|BEHAVIORAL|Active intervention|12-week family-based weight gain intervention program focused on dietary intake and physical activity for 8-10 year old Hispanic girls and their parents (N=30 girl-parent dyads).
223776943|NCT00797615|BEHAVIORAL|Alternative Intervention|12-week alternative intervention addressing self-esteem, for 8-10 year old Hispanic girls and their parents (N=30 girl-parent dyads).
223776944|NCT00129259|BIOLOGICAL|Anti-CD3 mAb|Daily 14-day dose escalation course at study entry, with possible second course after 12-month interval
223776945|NCT00129259|OTHER|Diabetes Standard of Care Treatment|Receipt of intensive diabetes standard of care treatment/management under the care of a physician: dietary counseling, insulin dosing and multiple consultations during the course of the trial with the clinical diabetes management team.
223691239|NCT02721979|DRUG|Apalutamide|Given PO
223691240|NCT02721979|OTHER|Laboratory Biomarker Analysis|Correlative studies
223776946|NCT00129259|DIETARY_SUPPLEMENT|Iron supplementation|Immediately following randomization, all participants regardless of arm allocation begin iron supplementation with either ferrous sulfate or multivitamin with iron.
223776947|NCT03336008|OTHER|no intervention|No intervention but clinical assessement for all recruited subjects
223691241|NCT02721979|OTHER|Quality-of-Life Assessment|Ancillary studies
223691242|NCT02721979|OTHER|Questionnaire Administration|Ancillary studies
223776948|NCT06573021|DRUG|Near-infrared fluorescent cholangiography|For intra-operative fluorescent cholangiography, 2.5 mg indocyanine green (ICG, Pulsion Medical Inc., Irving, Tx) was administered intravenously 45-60 min prior to surgery, according to the recent guidelines from the International Society for Fluorescence Guided Surgery (ISFGS) and the latest consensus conference published in 2021.
223776949|NCT06573320|OTHER|physical exercise|physical exercise
223691243|NCT05808283|OTHER|preoperative anemia frequency|patients who applied to the outpatient clinic prospectively for 3 months
223691244|NCT02536833|DRUG|SM04690|
223691245|NCT02536833|DRUG|Placebo|
223691246|NCT00401895|DEVICE|TIPS created with 8 or 10 mm covered stent|creation of a shunt between hepatic vein and portal vein with PTFE-covered stents
223691247|NCT02764190|BEHAVIORAL|I-ACT with Check Yourself|
223691248|NCT04758845|DIETARY_SUPPLEMENT|Cocktail|Subjects will consume 2B CFU once daily containing .5B CFU DE111, .5B CFU MIT411, .5B CFU CGI314, and .5B CFU CSI08 for 45 days.
223691249|NCT04758845|DIETARY_SUPPLEMENT|CGI314|Subjects will consume 1B CFU of CGI314 once daily for 45 days.
223691250|NCT04758845|DIETARY_SUPPLEMENT|CSI08|Subjects will consume 1B CFU of CSI08 once daily for 45 days.
223691251|NCT04758845|DIETARY_SUPPLEMENT|MIT411|Subjects will consume 1B CFU of MIT411 once daily for 45 days.
223691252|NCT00569751|DEVICE|TAXUS™ Express2™ Paclitaxel-Eluting Coronary Stent System|Drug Eluting Stent used to treat de novo coronary artery lesions.
223691253|NCT01050478|DRUG|Paliperidone ER|paliperidone ER at 2 dosage levels (6 and 9 mg/day)
223691254|NCT01050478|DRUG|Benzodiazepine|Participants may receive the benzodiazepine lorazepam \[0-7.5 milligram (mg) per day\] as needed for sedation or rescue medication at the investigator's discretion.
223776950|NCT00023452|DRUG|RPT + INH once weekly for 3 months given by DOT|"Rifapentine (RPT) 900 mg once-weekly x 12 doses (3 months) for persons \> 50.0 kg. For persons \< 50.0 kg, the following doses will be given (Weight/Dose): 10.0-14.0 kg / 300 mg; 14.1-25.0 kg / 450 mg; 25.1-32.0 kg / 600 mg; 32.1-50.0 kg / 750 mg.~PLUS~Isoniazid (INH) 15 mg/kg (rounded up to nearest 50 or 100 mg; 900 mg max) once weekly x 12 doses if \> 12 years old. INH 25 mg/kg (round up to nearest 50 or 100 mg; 900 mg max) if 2-11 years old.~Therapy will be given by Directly Observed Therapy (DOT)."
223776951|NCT00023452|DRUG|Isoniazid (INH) daily for 9 months|Isoniazid (INH) 5 mg/kg (rounded up to nearest 50 or 100 mg; 300 mg max) daily x 270 doses (9 months) For children age 2 - 11, INH 10-15 mg/kg (round up to nearest 50 or 100 mg; 300 mg max) will be given.
223776952|NCT06573775|DEVICE|pulsed ultrasound|treatment of myofacial trigger points with therapeutic ultrasound
223776953|NCT06573775|OTHER|myofascial release|manual massage and range of motion exercises
223776954|NCT06573775|DEVICE|lidocaine phonophoresis|transdermal tranmission of lidocaine molecules via ultrasound
223776955|NCT05789875|OTHER|aDOT-CEI|For the design and development of the mobile health app, we have partnered with AiCure to use an existing HIPAA-compliant mobile health app. The app will record video of the participant taking their HIV medication in order to monitor the participant's medication adherence and track incentives for this behavior in real-time.
223776956|NCT06486545|DRUG|Irinotecan Hydrochloride Liposome Injection；Paclitaxel For Injection (Albumin Bound)|"Liposomal irinotecan, intravenous infusion 90min, d1:~Grade 1:50mg/m2； Grade 2:60mg/m2； Grade 3:70mg/m2；~Albumin-paclitaxel, 150mg/m2, intravenous infusion, d1~DLT was observed for 2 weeks (the first cycle). The same subject received only one dose of liposomal irinotecan during the study. If the patient volunteers and the investigator determines that the benefits of continuing the original regimen outweigh the risks, the subject may continue to receive treatment for metastatic disease. The drug was repeated every 2 weeks for up to 6 cycles, and the albumin paclitaxel or liposomal irinotecan were withdrawn according to the patient's adverse reactions and physical status, and the remaining single-agent maintenance therapy was performed. Until there is a possibility of surgery, disease progression, intolerable toxicity or the patient withdraws informed consent (whichever comes first)."
223776957|NCT06572202|BEHAVIORAL|Positive Psychology Intervention|The 14-session intervention program is designed to enhance various internal resiliency factors. It begins with an orientation to positive psychology and setting group guidelines. Cognitive resilience is developed through identifying personal and signature strengths, reappraising memories, and learning savoring techniques. Emotional resilience is strengthened by focusing on forgiveness, managing decision fatigue, and fostering positive communication. Spiritual resilience is cultivated through gratitude practices and exploring hope and optimism. Behavioral resilience is addressed by recognizing strengths in others and engaging in altruism. The final session integrates all these elements to promote lasting positive changes in engagement, relationships, meaning, and accomplishments. Mid-session feedback ensures the program's effectiveness and responsiveness to participants' needs.
223776958|NCT06574334|PROCEDURE|Proprioceptive exercise|"* The first session was included an orientation to the exercises and its purpose to geriatric participants in the first week. Also, pretest was done in the first session before implementing exercises to assess geriatric KOA pain and QOL, each session started by revision about what was given during the previous session and the objectives of the next session.~* The 2nd session about exercises.~* The 3rd session for repetition of exercises to ensure that the patient has learned it well in the second week.~* The 4th session after six weeks later (from wk. (3) to wk. (8) to make posttest after implementation session.~* The 5th session after two-month later (from wk. (9) to wk. (16) to do follow up test."
223776959|NCT04693663|PROCEDURE|Relex-Smile surgery|surgery using Relex-Smile
223776960|NCT06573593|DRUG|Tofacitinib|In the real-world settings, patients with AA treated with tofacitinib.
223776961|NCT06573593|DRUG|Baricitinib|In the real-world settings, patients with AA treated with Baricitinib.
223776962|NCT06573593|DRUG|Ruxolitinib|In the real-world settings, patients with AA treated with Ruxolitinib.
223776963|NCT06573593|DRUG|Upadacitinib|In the real-world settings, patients with AA treated with Upadacitinib.
223776964|NCT06573593|DRUG|Abrocitinib|In the real-world settings, patients with AA treated with Abrocitinib.
223776965|NCT06573593|DRUG|Ritlecitinib|In the real-world settings, patients with AA treated with Ritlecitinib.
223691255|NCT04507854|OTHER|Strength, range of motion and functional tests + Questionnaire|Patients undergoing instability surgery will perform amplitude, strength, functional tests and a questionnaire at 6 months of the operation. Then they will be contacted at 12, 18 and 24 months to find out if they have regained their performance level or if they have injured their shoulder again.
223691256|NCT04467996|DEVICE|Intrauterine balloon tamponade|Intrauterine balloon will be placed in the uterus for postpartum hemorrhage control.
223776966|NCT06572761|DRUG|Combination of antibiotics|Ceftriaxone : 1g/day parenteral clarithromycin 500 mg\*2/day orally metronidazole 500mg\*3/ day orally
223776967|NCT06572761|DEVICE|Emergency cerclage|Emergency cerclage
223776968|NCT06572761|DRUG|Vaginal progesterone|Vaginal progesterone
223776969|NCT02928328|DRUG|GABA oral solution|Oral mouth wash containing either GABA, lidocaine or distilled water will be used to decrease burning tongue pain produced by capsaicin
223776970|NCT02928328|DRUG|Intramuscular GABA|The effect of intramuscular injection of GABA or lorazepam will be compared with buffered isotonic saline
223691257|NCT01834482|DIETARY_SUPPLEMENT|Modified Atkins diet|Patients will receive the modified Atkins diet with a 20 gram per day carbohydrate limit and encouragement to consume plenty of fat and eat to satiety.
223691258|NCT01834482|DIETARY_SUPPLEMENT|KetoCal|Patients will receive a KetoCal 4:1 ratio (fat: carbohydrates and protein) liquid daily for the first month (if randomized to this arm of the study). They will also be started on the modified Atkins diet.
223691259|NCT01304784|DRUG|Cisplatin, Capecitabine, Trastuzumab and MM-111|Conventional chemotherapy
223691260|NCT01304784|DRUG|Lapatinib +/- Trastuzumab and MM-111|Conventional chemotherapy
223691261|NCT01304784|DRUG|Paclitaxel, Trastuzumab and MM-111|Conventional chemotherapy
223691262|NCT01304784|DRUG|Lapatinib, trastuzumab, paclitaxel, and MM-111|Conventional chemo
223691263|NCT01304784|DRUG|Docetaxel, trastuzumab and MM-111|Conventional chemotherapy
223691264|NCT02140775|BEHAVIORAL|Behavioral Activation Counseling|Behavioral Activation counseling is a manualized intervention adapted from a behavioral activation treatment for depression (BAT-D) and provides a basic foundation for behavior change. The individual sessions last one hour and are scheduled every two weeks. The counseling offers a brief, structured approach to identifying and scheduling activities in life areas to reduce avoidant behavior and increase activity level with the goal of achieving employment or enroll in training.
223776971|NCT02928328|DRUG|Pain modulation|The effect of GABA alone or in combination with lorazepam on muscle pain produced by intramuscular injection of glutamate will be assessed.
223776972|NCT02927691|DEVICE|EMST|
223776973|NCT02927691|BEHAVIORAL|smTAP|
223776974|NCT04990986|OTHER|Complex intervention|Will be co-developed during the study.
223776975|NCT05741918|DIAGNOSTIC_TEST|Fick's method|Cardiac output measurement by Fick method
223776976|NCT05741918|DIAGNOSTIC_TEST|Echocardiography|Cardiac output measurement by echocardiography
223776977|NCT06662708|DIAGNOSTIC_TEST|Accurate Prediction Artificial Intelligence Models|Diagnostic Test: Accurate Prediction Artificial Intelligence Models Post-operative pathology, precise pre-operative diagnosis (including benign and malignant, invasive, grading, subtypes) or 3D lesion modelling will be predicted based on the AI predictive model in response to the information provided
223776978|NCT06663254|DRUG|Hydroxyethyl starch 130/0.4|Individualized goal-directed administration of 6% Hydroxyethyl starch (HES) 130/0.4: After the induction of anesthesia, 200 ml trial fluid will be infused over 20 min. If stroke volume (SV) increases \&gt;10%, another 200 ml fluid will be given. After that, the use of trial fluid will be determined by the patients' Stroke Volume Variation (SVV). If the SVV exceeds 12%, 200 ml trial fluid will be given over 20 min; this will be repeated until SVV \&lt;12%. If the use of HES exceeds 30 ml/kg, sodium acetate Ringer will be replaced. In addition, patients will have a background infusion of sodium acetate Ringer's solution at 4 ml/kg/h to satisfy the maintenance fluid requirements during surgery.
223776979|NCT06663254|DRUG|Sodium acetate Ringer|"Individualized goal-directed administration of crystalloid alone: After the induction of anesthesia, 200 ml trial fluid will be infused over 20 min.~If stroke volume (SV) increases \&gt;10%, another 200 ml fluid will be given. After that, the use of trial fluid will be determined by the patients' Stroke Volume Variation (SVV). If the SVV exceeds 12%, 200 ml trial fluid will be given over 20 min; this will be repeated until SVV \&lt;12%. In addition, patients will have a background infusion of sodium acetate, the maintenance fluid requirement during surgery."
223776980|NCT06664008|DRUG|PPI (proton pump inhibitor)|It reduces stomach acid production and manage GERD symptoms
223776981|NCT06664008|DRUG|Probiotic|Live microorganisms, primarily bacteria and yeast, that are believed to provide health benefits when consumed in adequate.
223776982|NCT06664008|DRUG|Zinc|Zinc used a supplement due to its role in decreasing inflammation of the gastroesophageal reflux disease.
223776983|NCT06662838|OTHER|Ergonomics Awareness and First Aid Training Program|The ergonomic awareness and first aid training program includes training on possible situations that children of seasonal agricultural worker families may encounter in the field.
223776984|NCT06663085|DIETARY_SUPPLEMENT|Enteral feeding|intervention group received enteral feeding breastmilk during transfusion
223691265|NCT04356170|DRUG|Docetaxel|Docetaxel 75 mg/m² administered at D1 of each cure, every 3 weeks by intravenous infusion in 1 hour
223691266|NCT04356170|DRUG|Cisplatin|cisplatine 75 mg/m² administered at D1 of each cure, every 3 weeks by intravenous infusion in 1 hour
223776985|NCT06663215|OTHER|School Based Bullying Prevention Program|Three forms were administered to the adolescents: Personal Information Form, Bullying and Cyberbullying Scale for Adolescents (BCE-A) and Adolescent Future Expectations Scale. Adolescents were included in a school-based bullying prevention program the next day. One month later, the forms were administered again.
223691267|NCT04356170|DRUG|Fluoro Uracil|750 mg/m²/j administered continuously at D1 to D5 of each cure, every 3 weeks by intravenous infusion ( so 120 hours)
223776986|NCT02969928|PROCEDURE|Full-mouth ultrasonic debridement|Full-mouth ultrasonic debridement will be performed in order to treat diseased sites
223776987|NCT02969928|DRUG|Clarithromycin|Administration of Clarithromycin 500mg bid for 7 days
223776988|NCT02969928|DRUG|Amoxicillin|Administration of Amoxicillin 500mg tid for 7 days.
223776989|NCT02969928|DRUG|Metronidazole|Administration of Metronidazole 400mg tid for 7 days.
223776990|NCT02610699|OTHER|Conventional otoscope|The conventional analogue otoscope will be used to provide a two-dimensional view of the ear canal. Clinicians will use this for one month periods for a total of 3 months.
223776991|NCT02610699|OTHER|Smartphone otoscope|The smartphone otoscope is a pocket size smartphone attachment that uses technology and light source of a smartphone to capture reproducible images of the middle ear and tympanic membrane. Images and videos can be transmitted via real-time communication software from the device to another smartphone. Clinicians will use this for one month periods for a total of 3 months.
223776992|NCT06662578|OTHER|Traditional memory workshop|The participants received 8 weekly sessions of 60 minutes of neurocognitive stimulation, based on French memory workshops.
223776993|NCT06662578|OTHER|Equine assisted therapy memory workshops|The participants received 8 weekly sessions of 60 minutes, based on traditional memory workshops (French type of neurocognitive stimulation) with the mediation of a horse (example : working on associative memory by selecting which object is used for the horse between 2 presented objects).
223776994|NCT05318638|DEVICE|Soft robotic glove|The soft-robotic glove used in the study is the Carbonhand system (Bioservo Technologies, Sweden). It is a CE-marked medical device and it consists of a glove that supports finger flexion via sewn-in tendons and a control unit housing the actuators that pull on the tendons and the batteries. The grip support is activated by applying very light pressure on sensors in the fingertips of the glove, and de-activated by releasing the pressure on the sensors.
223776995|NCT07040332|OTHER||No intervention
223776996|NCT06884501|BEHAVIORAL|Latin dance, MIND diet, and Strength training|This will be a 6 month remote-delivered BAILAMOS™ dance program, MIND diet and strength training intervention.
223776997|NCT06884501|BEHAVIORAL|Latin dance and MIND Diet|This will be a 6 month remote-delivered BAILAMOS™ dance and MIND diet program.
223776998|NCT00321035|DEVICE|OculusGen Biodegradable Collagen Matrix Implant|
223776999|NCT07047872|PROCEDURE|Computer-Aided Diagnosis|Undergo CAD development for patient-specific external breast prosthesis model
223777000|NCT07047872|PROCEDURE|Prosthetics Intervention|Undergo measurements for external breast prosthesis
223777001|NCT07047872|PROCEDURE|Prosthetics Intervention|Undergo fitting for 3D-printed external breast prosthesis
223777002|NCT07047872|PROCEDURE|Prosthetics Intervention|Receive 3D-printed external breast prosthesis
223691268|NCT02225392|PROCEDURE|Bronchial thermoplasty|Bronchial thermoplasty (BT) will be performed using the Alair system (Boston Scientific, USA). Patients will undergo 3 bronchoscopy procedures with BT at least 3 weeks apart. Treatment sessions are designed to address different lobes of the lung with the right lower lobe treated during the first bronchoscopy, the left lower lobe treated during the second bronchoscopy, and both the right and left upper lobes treated in the third and final bronchoscopy. The right middle lobe and proximal airways including RC2 are left untreated.
223691269|NCT02225392|DEVICE|Alair system (Boston Scientific, USA)|The alair system consist of a controller and a bastket catheter.
223777003|NCT07047872|OTHER|Questionnaire Administration|Ancillary studies
223777004|NCT07048769|DRUG|Lidocaine|10cc of 1% lidocaine buffered with 1cc 8.4% sodium bicarbonate, injected at 4 and 8 o'clock paracervical positions.
223777005|NCT07048769|PROCEDURE|Sham paracervical block|A capped needle is pressed at 4 and 8 o'clock positions to mimic lidocaine block without injection.
223777006|NCT07051525|DRUG|Early antibiotic cessation alert|For all patients, antibiotics will be commenced at onset of fever. For those in the intervention arm an alert will fire in the electronic medical record once a patient is afebrile for 48-96 hours and clinically stable.
223777007|NCT07051759|PROCEDURE|Back contouring surgery|Back rolls are assessed, and the type of surgery is determined according to grade of back rolls.
223777008|NCT07051811|PROCEDURE|Intravascular Ultrasound Ablation Therapy|"The single-use intravascular ultrasound ablation catheter is used in conjunction with the ultrasound ablation device to remove renal sympathetic nerves.~Standardized medication regimen."
223777009|NCT07051811|PROCEDURE|Renal Artery Angiography|Only undergo renal artery angiography. Standardized medication regimen.
223777010|NCT07051278|DEVICE|Method Comparison|Quantifying the relationship using comparison measurement from the same sample between ABL90 FLEX PLUS and the predicate device within the reportable range for ctBil and FHbF in heparinized capillary whole blood samples in capillary measuring mode (C65).
223691270|NCT01244360|DIETARY_SUPPLEMENT|resveratrol|Subject will take resveratrol supplement for 4 weeks, with optional additional 4 week treatment period.
223691271|NCT01244360|OTHER|Placebo Comparator: Sugar Pill|Subject will take placebo for daily for 4 weeks, with optional additional 4 week treatment period.
223691272|NCT02123628|DRUG|duration of the antibiotic therapy|
223691273|NCT02436655|PROCEDURE|surgical aortic valve replacement|open heart aortic valve replacement
223777011|NCT07052110|OTHER|Digital storytelling|DST is an intervention that can potentially mitigate the psychological impact of traumatic experiences. People can usually find positive meaning in a traumatic experience by communicating their experience using narratives like storytelling. In particular, by externalising the traumatic experience in the form of a narrative, the individual can become an objective agent, distancing themselves from negative meanings attached to the experience. This lowers people's resistance to and defence against the experience, assisting them to explore alternative perspectives regarding the experience and to identify its positive aspects, which boost self-esteem. Likewise, storytelling engages different areas of the brain, including those responsible for visual, language, and hearing functions, to reorganise the disorganised traumatic experience into a coherent story, facilitating integration of the experience into existing memories.
223777012|NCT07052175|BEHAVIORAL|Standard Multidisciplinary Treatment|Comprehensive intervention including structured phases: initial assessment, detoxification, withdrawal management, psychological and psychiatric therapy, rehabilitation, and follow-up care. Delivered by a multidisciplinary team according to established clinical protocols.
223777013|NCT07052175|BEHAVIORAL|Digital Monitoring Tool|In addition to standard care, participants will use a mobile application that monitors clinical indicators, detects early signs of relapse risk, and provides personalized alerts and intervention prompts. The tool is designed to support both patients and clinicians in decision-making and therapeutic follow-up.
223777014|NCT07051382|DIAGNOSTIC_TEST|Transcranial Sonographic Examination (Cranial Ultrasound)|"No evidence of intracranial abnormalities such as intraventricular hemorrhage, germinal matrix hemorrhage, periventricular leukomalacia, hydrocephalus, or infarction.~Brain structures were assessed to be age-appropriate for gestational development."
223777015|NCT07051603|DRUG|SAL0140|In this part, SAL0140 tablets will be administered as a single or multiple oral dose.
223777016|NCT07051603|DRUG|SAL0140 placebo|In this part, SAL0140 placebo tablets will be administered as a single or multiple oral dose.
223777017|NCT07051395|DIAGNOSTIC_TEST|Road Traffic Accidents Patient|Coagulation Profiles And Injury Severity In Road Traffic Accidents Patients at Dera Ismail Khan
223691274|NCT04397627|PROCEDURE|Colorectal resection|All patients undergoing elective colorectal surgery with anastomosis will be included in a prospective database after written informed consent.
223777018|NCT07052643|OTHER|Image and data collection|Evaluation of the photographs by four independent raters
223777019|NCT07052123|DEVICE|MultiSense® Non-Invasive Hemodynamic Monitoring Device|The MultiSense® device is a wireless, non-invasive monitoring system designed to continuously measure blood pressure, microcirculation, central body temperature, and detect arrhythmias in ICU patients. It aims to reduce risks associated with invasive monitoring, improve patient comfort and mobility, and decrease alarm fatigue through intelligent alert algorithms.
223777020|NCT07051629|BIOLOGICAL|SIF001|SIF001 intravenous infusion every two weeks
223691275|NCT01172275|DRUG|N-Acetylcysteine|1 900mg tablet once a day for 1 week, then 1 900mg tablet twice a day for 1 week and then 1 900mg tablet three times a day for the remaining 10 weeks of the trial.
223691276|NCT01172275|OTHER|Placebo|1 900mg tablet once a day for 1 week, then 1 900mg tablet twice a day for 1 week and then 1 900mg tablet three times a day for the remaining 10 weeks of the trial. Children receiving placebo will be offered the active intervention after the double-blind portion of the trial.
223691277|NCT04470921|PROCEDURE|Opportunistic Salpingectomy|An opportunistic salpingectomy refers to removal of the fallopian tubes without the ovaries during (laparoscopic) interventions for benign (gynaecological) disease to reduce the number of ovarian cancer cases.
223691278|NCT06551103|BEHAVIORAL|Intervention group trained in line with the Health Promotion Model|A literature review was conducted by the researchers within the scope of Health Promotion Model and a educational material was prepared. With this educational material, the patients in the intervention group were trained in four sessions lasting 25 minutes each.
223691279|NCT00273507|DRUG|Carboplatin and Paclitaxel|
223691280|NCT02168426|PROCEDURE|Guardix|Applying 6g of guardix during abdominal surgery
223691281|NCT02168426|PROCEDURE|Seprafilm|Applying 1 sheet of seprafilm during abdominal surgery
223691282|NCT03973801|OTHER|Auricular acupuncture|National Acupuncture Detoxification Association (NADA) protocol for auricular acupressure will be initiated within 24 hours of delivery and continued until withdrawal symptoms measure 6 or less for 12 hours on the modified Finnegan score and/or the morning of expected discharge as in line with standard of care.
223691283|NCT03243266|DIAGNOSTIC_TEST|CBC/Diff Reference Interval|Results will not be used to manage patients
223691284|NCT01661816|BEHAVIORAL|interview|psychological, emotional, family and social parameters
223691285|NCT01865071|PROCEDURE|loop ileostomi|
223691286|NCT02325310|BIOLOGICAL|Combined measles-mumps-rubella (MMR) vaccine - PRIORIX®|One dose of 0.5 mL vaccine will be administered (intra-muscularly or subcutaneous) in post-partum (before the exit of the maternity) during visit V0. A second dose will be administered at week 8(+/-15 days) during visit V1.
223691287|NCT04596553|DIETARY_SUPPLEMENT|Essential Amino Acid|Immediately following the exercise intervention participants will consume their assigned essential amino acid supplement
223691288|NCT04596553|DIETARY_SUPPLEMENT|Collagen Peptide|Immediately following the exercise intervention participants will consume their assigned collagen peptide supplement
223691289|NCT04596553|DIETARY_SUPPLEMENT|Maltodextrin Placebo|Immediately following the exercise intervention participants will consume their assigned maltodextrin supplement
223691290|NCT05075057|BIOLOGICAL|Inactivated COVID-19 vaccine|three doses of inactivated COVID-19 vaccine
223691291|NCT05269251|DEVICE|Near Infrared Spectroscopy (NIRS)|After the brachial plexus block, the regional oxygen saturation (rSO2) was monitored for 30 minutes with the Regional Oximetry System (O3™, Masimo, Irvine, CA) and the radial artery diameter with ultrasound in the same period.
223691292|NCT02438527|BEHAVIORAL|Chart for CPR guidance|
223691293|NCT05218265|DIAGNOSTIC_TEST|routine laboratory tests|Complete blood count (CBC), coagulation profile, serum biochemical tests (including renal and liver function, and electrolytes), laboratory investigation to assess severity of COVID-19: lactate dehydrogenase (LDH), myocardial enzymes (CPK-MB), serum ferritin, D dimer and arterial blood gases analysis
223691294|NCT00812344|DRUG|AZD0837|Oral solution, dosing through the Loc-I-Gut catheter, single dose
223691295|NCT00812344|DRUG|Ketoconazole|tablets, orally, once daily for 3 days
223691296|NCT00812344|DRUG|ketoconazole|dissolved tablets, dosing through the Loc-I-Gut catheter, single dose
223691297|NCT01810588|DEVICE|CliniMACS® CD34 Reagent System|The stem cells from the haplo-identical donor will be purified by a procedure called CD34 selection before they are given to the subject. A special device called the CliniMACS® CD34 Reagent System, which is not FDA approved, will be used for this purpose. The manufacturer of the device, Miltenyi Biotec, is providing the researchers access to the device for use in this research study. Because the stem cells from the haplo-identical donor are treated using the CliniMACS CD34 selection device, they cells are considered investigational.
223691298|NCT01810588|DRUG|Fludarabine|Administer 30 mg/m2 /day intravenously x 5 days (Day -7 to Day -3) of a total dose of 150 mg/m2. Fludarabine will be dosed according to actual body weight.
223691299|NCT01810588|DRUG|Melphalan|Administer 70mg/m2/day intravenously x 2 days. Melphalan will be dosed according to actual body weight. Cryotherapy with ice chips will be administered to prevent mucositis
223691300|NCT01810588|DRUG|anti-thymocyte globulin (rabbit)|Administer 1.5 mg/kg/day intravenously x 3 days, total 4.5 mg/kg. ATG will be dosed according to actual body weight. The first dose will be infused over at least six hours, and subsequent doses over at least 4 hours. Pre-medications include acetaminophen 650 mg by mouth, diphenhydramine 25-50 mg by mouth or intravenously, and methylprednisolone 2 mg/kg (1 mg/ kg at the initiation and 1 mg/kg half-way through anti-thymocyte globulin administration).
223691301|NCT01810588|DRUG|Rituximab|Administer one dose of 375 mg/m2 prior to or upon admission for all patients not previously exposed to rituximab or who have not received rituximab in the six months prior to transplant.
223691302|NCT01810588|RADIATION|Total Body Irradiation|Patients at high risk of CNS relapse (e.g. ALL or Burkitt's lymphoma) or patients at high risk for graft rejection (i.e., donor-specific HLA antibodies, patients with severe aplastic anemia, or hemoglobinopathies) may receive 2 doses of TBI as part of the conditioning.
223691303|NCT01810588|DRUG|Mycophenolate Mofetil|Will be started on Day -2 and given at a dose of 1000 mg every 8 hours until Day 28. Mycophenolae Mofetil can be given orally or intravenously. Infection, toxicity, very low patient weight (\<50 kilograms) may prompt earlier discontinuation or adjustment of doses.
223691304|NCT01810588|DRUG|Tacrolimus|Administered 0.03/mg/kg/day intravenous continious infusion (CI) over 24 hours from 4pm Day -2 until engraftment or when subject is able to take orally, then tacrolimus approximately 0.09 mg/kg orally in 2 divided doses. Tacrolimus should be given at full dose to maintain levels of 5-15 ng/mL through Day 180, tapered by 20% every week thereafter. Infection, toxicity or other clinical circumstances may prompt earlier discontinuation or adjustment of doses. In the presence of Graft versus Host Disease, a clinical decision by the attending physician will determine if tacrolimus can be tapered or should be continued. Oral tacrolimus can be used when intravenous access for CI tacrolimus is unavailable.
223691305|NCT00730262|DRUG|TLN-4601|14 day continuous IV administration of TLN-4601 at 480 mg/m2/day followed by a 7-day recovery period
223777021|NCT07051629|DRUG|Placebo|Placebo
223777022|NCT07051889|PROCEDURE|Lower Trapezius Tendon Transfer|This procedure is performed arthroscopically. The lower trapezius tendon is harvested from the back of the shoulder blade. A donor tendon is then used to extend the lower trapezius tendon so that it can reach the top of the arm bone. The tendon graft is then attached to the top of the arm bone, while the other end remains attached to the lower trapezius tendon itself. Any additional concomitant procedures (e.g. debridement, biceps release…etc.) may be performed as well.
223777023|NCT07051889|PROCEDURE|Partial Rotator Cuff Repair|This procedure is performed arthroscopically. The massive rotator cuff tear will be repaired by securing the loose tendon ends to the bone with suture anchors. The surgeon may also conduct a debridement of the area to remove any broken-down cartilage and tissues. Finally, the biceps tendon in will be further inspected for any damage or inflammatory changes, and the tendon may be released at the discretion of the surgeon (known as a biceps tenodesis or tenotomy depending on technique).
223691306|NCT06477224|OTHER|Scooter Board Activities|Participants in this arm engage in scooter board activities designed to improve neck control and address dysphagia. These activities include moving the scooter board in various directions using their hands or feet, maneuvering through obstacle courses, and engaging in playful tasks that require reaching or turning, which can enhance neck muscle strength and stability.
223691307|NCT06477224|OTHER|Routine Physical Therapy|Participants in this arm receive traditional physical therapy interventions, which might include range-of-motion exercises, muscle strengthening, stretching exercises, and postural control activities. These exercises are aimed at improving overall motor function, with a focus on neck stability and control. Standard physical therapy equipment such as therapy balls, balance boards, and resistance bands may also be used.
223691308|NCT04650854|DRUG|Rozanolixizumab|Rozanolixizumab will be administered by subcutaneous infusion in dosage regimen 1 or 2.
223691309|NCT05072327|PROCEDURE|Mohs surgery|Mohs surgery of eyelid
223691310|NCT05072327|PROCEDURE|cryotherapy|cryotherapy of eyelid
223691311|NCT03986515|DRUG|apatinib plus SHR-1210|apatinib 250mg qd, 3-5 days later SHR-1210 200mg q3w
223691312|NCT05308290|OTHER|Blood pressure management according to cerebral autoregulation|Intraoperative blood pressure will be targeted based on limits of cerebral autoregulation.
223835695|NCT04894903|OTHER|Diabetes Care Gaps Patient Portal Intervention|The Diabetes Care Gaps Patient Portal Intervention is embedded within an existing patient web portal (My Health at Vanderbilt). The intervention (a) notifies patients when selected, clinically meaningful, evidence-based diabetes monitoring \& preventative care (e.g., annual urine microalbumin) are due and (b) allows patients to initiate orders for the care.
223691313|NCT05308290|OTHER|Blood pressure management according to usual care|Intraoperative blood pressure will be targeted based on usual care.
223691314|NCT04437368|DRUG|GT005|GT005 is a recombinant, non-replicating AAV2 expressing human complement factor I (CFI). GT005 was administered as a single time subretinal injection into the study eye of subjects allocated to one of the two GT005 doses.
223691315|NCT02068339|DRUG|Oltipraz 1 (90mg)|
223691316|NCT02068339|DRUG|Placebo|
223691317|NCT02068339|DRUG|Oltipraz 2 (120mg)|
223691318|NCT02025062|OTHER|CGA and geriatric follow-up|The CGA is a multidimensional assessment of general health status, using validated scales. It produces an inventory of problems which can then serve to develop an individualized geriatric intervention plan of care and follow-up
223691319|NCT01982331|BIOLOGICAL|LAIV H2N2|vaccine is delivered intranasally, .25 cc to each nostril at day 0 and day 28
223691320|NCT01982331|OTHER|Placebo|placebo delivered intranasally. .25cc to each nostril at day 0 and day 28
223691321|NCT00266773|BEHAVIORAL|Chronic pain therapeutic interactive voice response (TIVR) system|Therapeutic Interactive Voice Response as a daily self monitoring and relapse prevention tool with didactic reviews and practices of recorded skills and monthly feedback based on daily calls
223691322|NCT00121888|BEHAVIORAL|Prolonged Exposure Therapy|
223691323|NCT00121888|DRUG|Paroxetine-CR|
223691324|NCT01469117|OTHER|enteral formula|Complete feeding of study enteral formula, route and regimen prescribed by the physician
223691325|NCT03679585|OTHER|Internet-Based Intervention|Undergo Talking Pictures social media intervention
223691326|NCT03679585|OTHER|Quality-of-Life Assessment|Ancillary studies
223691327|NCT03679585|OTHER|Questionnaire Administration|Ancillary studies
223691328|NCT03181373|OTHER|Cognitive rehabilitation program|Rehabilitation
223691329|NCT04914507|DEVICE|Anterior Vertebral Body Tethering|Subject will receive anterior vertebral body tethering surgery.
223691330|NCT01091337|DRUG|Procaterol|"Procaterol(Meptin Air) MDI, 20 ug or 2 puffs every 20 minutes~\+ Hydrocortisone, 100 mg IV shall be given immediately at start of treatment"
223691331|NCT01091337|DRUG|Salbutamol|Salbutamol(Ventolin Inhaler) MDI, 40 ug or 4 puffs every 20 minutes + Hydrocortisone, 100 mg IV shall be given immediately at start of treatment
223691332|NCT01490788|DRUG|Treatment A|TNX-102 2.4 mg - 1 gelcap once under fasting conditions.
223691333|NCT01490788|DRUG|Treatment B|Cyclobenzaprine 5 mg, 1 tablet once under fasting conditions
223691334|NCT01490788|DRUG|Treatment C|TNX-102 2.4 mg, 1 gelcap once given under fed conditions.
223691335|NCT01247038|DEVICE|Metal on ceramic articulation|Metal on ceramic articulation against metal-on-metal articulation using the same Recap Acetabular cup
223691336|NCT01247038|DEVICE|Metal-on-Metal|Metal on Metal articulation
223691337|NCT01054807|DEVICE|Galyfilcon A Habitual Lens|Comparison of three soft contact lens designs.
223691338|NCT01054807|DEVICE|Galyfilcon A 8.7 BC (Investigational)|Comparison of three soft contact lens designs.
223691339|NCT01054807|DEVICE|Galyfilcon A 8.3 BC (Investigational)|Comparison of three soft contact lens designs
223691340|NCT01462786|DRUG|ATX-101|2 mg/cm2 ATX-101
223691341|NCT05321160|DRUG|Esketamine|0.25 mg/kg esketamine for induction and 0.25 mg/kg esketamine at the beginning of surgery
223691342|NCT05321160|DRUG|Sevoflurane|4% sevoflurane for induction and 2-4% sevoflurane for maintain
223691343|NCT05453266|PROCEDURE|Application of Tranexamic acid in arthroscopic irrigation solution|Application of Tranexamic acid in arthroscopic irrigation solution
223691344|NCT05453266|PROCEDURE|No application of Tranexamic acid in arthroscopic irrigation solution|No application of Tranexamic acid in arthroscopic irrigation solution
223777024|NCT07052487|PROCEDURE|Post-Isometric Relaxation (PIR)|A manual physiotherapy technique applied to the gluteus maximus, iliopsoas, piriformis, and hamstrings. Each session begins with 10 minutes of transcutaneous electrical nerve stimulation (TENS) and moist heat (hot-pack), followed by three cycles per muscle group of: a 10-second isometric contraction against the therapist's counterforce, 5-second relaxation, and 30-second passive stretch. Sessions are delivered thrice weekly for eight weeks (24 sessions total).
223691345|NCT01388920|DRUG|Tesamorelin|
223691346|NCT01388920|DRUG|Placebo|
223691347|NCT04529473|DIETARY_SUPPLEMENT|Eubacterium hallii|Eubacterium hallii, ≥ 1x10\^9 live bacterial cells (per capsule)
223691348|NCT04529473|OTHER|Placebo|Placebo capsules are identical to the active treatment
223691349|NCT05580510|DRUG|Sacubitril 49 MG / Valsartan 51 MG [Entresto] BID|"This group of patients will receive the conventional treatment of heart failure according to the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure and Sacubitril/Valsartan as an active comparator."
223777025|NCT07052487|PROCEDURE|Simple Stretching Exercises (SSE)|A set of four static stretches targeting the gluteus maximus, iliopsoas, piriformis, and hamstrings. Each session begins with 10 minutes of TENS and hot-pack application, followed by ten repetitions of each stretch held for 10 seconds. Sessions are delivered thrice weekly for eight weeks (24 sessions total).
223777026|NCT07051291|DIETARY_SUPPLEMENT|Instant Coffee Capsule|Participants received 1.7 grams of instant coffee in the form of three capsules. 200 mL of plain water was provided to participants to swallow the three capsules.
223777027|NCT07051291|DIETARY_SUPPLEMENT|Instant Coffee Beverage|Dissolved 1.7 grams of instant coffee in 200 mL of hot water to make a coffee beverage.
223777028|NCT07052253|DRUG|TT-00420 (tinengotinib)|oral
223777029|NCT07052253|DRUG|AK104|intravenous
223777030|NCT07052253|DRUG|AK112|intravenous
223691350|NCT05580510|DRUG|Empagliflozin 10 MG OD|"This group of patients will receive the conventional treatment of heart failure according to the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure and Empagliflozin as an experimental drug."
223691351|NCT00590629|DRUG|Niaspan|1500 mg Niaspan for 16 weeks
223691352|NCT00972855|DRUG|Bicalutamide|50 mg Tablet
223691353|NCT00972855|DRUG|Casodex®|50 mg Tablet
223691354|NCT02467335|DRUG|BMS-663068|BMS-663068
223691355|NCT00727831|DRUG|glucarpidase|
223691356|NCT00727831|DRUG|leucovorin calcium|
223691357|NCT00727831|DRUG|methotrexate|
223691358|NCT00727831|OTHER|laboratory biomarker analysis|
223691359|NCT00727831|PROCEDURE|quality-of-life assessment|
223691360|NCT00727831|RADIATION|radiation therapy|
223691361|NCT01280955|DRUG|Plerixafor|Matched sibling or Dual Cord donor subjects will receive plerixafor at 240 ug/kg subcutaneously every other day beginning at day +2 after transplant until day +21 or engraftment occurs.
223691362|NCT05246904|OTHER|Fitting algorithm|The best fitting algorithm will be selected by the audiologist (arm 1) or software.
223777031|NCT07052019|DEVICE|Virtual Reality Distraction|Children wear virtual reality glasses during restorative dental treatment to reduce pain and anxiety.
223691363|NCT04295655|OTHER|Global Exercise intervention|The program included 15 minutes of deep breathing exercises and 20-30 minutes of limb exercises. The exercises included global active range of motion (ROM) exercises and muscle strengthening like upper and lower limbs flexion-extension do single-leg stance, and sit to stand exercises
223691364|NCT04295655|OTHER|Functional Electrostimulation Group|"The program included a neuromuscular stimulation therapy on quadriceps accompanied by lower limb exercises. The intervention was performed following the protocol described by Valenza et al (2017).~Valenza MC, Torres-Sánchez I, López-López L, Cabrera-Martos I, Ortiz-Rubio A, Valenza-Demet G. Effects of home-based neuromuscular electrical stimulation in severe chronic obstructive pulmonary disease patients: a randomized controlled clinical trial. Eur J Phys Rehabil Med. 2018 Jun;54(3):323-332. doi: 10.23736/S1973-9087.17.04745-1. Epub 2017 Nov 16. PubMed PMID: 29144103."
223691365|NCT04295655|OTHER|Standard treatment|Patients received standard medical and pharmacological care that consisted in systemic steroids, inhaled bronchodilators, oxygen, and a regimen of oral prednisone or its equivalent in doses of 40 to 60 mg per day for the duration of therapy as well as anti-biotic therapy
223691366|NCT00904306|DIETARY_SUPPLEMENT|Sugar Pill|placebo oral tablet taken once per day
223691367|NCT00904306|DIETARY_SUPPLEMENT|chromium picolinate|1000 ug/day chromium picolinate for 6 months
223691368|NCT00904306|DIETARY_SUPPLEMENT|chromium picolinate|600 ug/day chromium picolinate
223691369|NCT01314157|OTHER|Isostretching|12 interventions (two times per week) for 45 minutes
223691370|NCT04105543|DRUG|CLR 131|CLR 131 is a radiopharmaceutical dosed intravenously over a period of approximately 30 minutes, dose will be based on total body surface area calculated from actual body weight and height
223691371|NCT04223232|DRUG|[14C]-MD1003|single oral dose of 100mg \[14C\]-MD1003
223691372|NCT04448873|DRUG|Sirolimus|After at least 2 years of remission of KHE, we compare guided discontinuation with maintenance treatment in pediatric patients with KHE.
223691373|NCT01145612|DRUG|Losartan|Losartán dosage: 12.5 mg /day for patients \< 50 Kg or 25 mg/day for patients \> 50 Kg (14 days). 50 mg/day from day 15 to the end of the study. Half of dose (25 mg/day) for patients \< 50 Kg
223691374|NCT01145612|DRUG|Atenolol|Atenolol dosage: 12.5 mg /day for patients \< 50 Kg or 25 mg/day for patients \> 50 Kg (14 days). 50 mg/day from day 15 to the end of the study. Half of dose (25 mg/day) for patients \< 50 Kg
223691375|NCT02393690|RADIATION|Iodine I-131|Given PO
223691376|NCT02393690|OTHER|Placebo Administration|Given PO
223691377|NCT02393690|DRUG|Selumetinib|Given PO
223691378|NCT06304038|DRUG|Flu Vaccine|Administration of quadrivalent split inactivated non-adjuvanted flu vaccine Fluarix Tetra
223691379|NCT05695534|OTHER|VR educational video|Patients will be educated with our specifically made VR video in the settings of our hospital to make patients more familliar with the spaces and to explain them the procedure.
223691380|NCT04842422|DRUG|Imiquimod 3.75% Cream|Imiquimod 3.75% Cream
223691381|NCT04907461|PROCEDURE|LAPTAP|Laparoscopic guided Transverse Abdominus Plane block
223691382|NCT04581759|DEVICE|RIPC device (IPC-906X)|Patients in the RIPC group will have five cycles of 5-min cuff inflation followed by 3-min deflation to the bilateral upper arm twice a day after Mechanical Thrombectomy.
223691383|NCT04581759|DRUG|foundational treatment|foundational treatment, including free radical elimination in the acute stage, blood pressure and blood glucose stabilization, and antiplatelet (aspirin or/and clopidogrel ) and lipid-lowering (statins) drugs
223691384|NCT05731531|DEVICE|ELECTROGASTROGRAPHY|Electrogastrography as a new tool to customize choice of Bariatric therapies by determining success or failure based on GMA and WLST results has not been studied. GMA measures the normal or depleted gastric ICCs and the WLST measures gastric capacity, objective measures that may be important to predict success of Bariatric procedures and thus to help with patient selection to maximize efficacy and minimize side effects.
223691385|NCT00438438|BEHAVIORAL|forced desynchrony protocol with sleep restriction|Subjects are scheduled to live on a non-24 hour day. This separates the sleep-wake schedule from the near-24 hour circadian rhythm. This allows assessment of how circadian rhythms and the length-of-time awake contribute to sleepiness, alertness, and cognitive performance.
223691386|NCT01674634|BIOLOGICAL|XIAFLEX / XIAPEX|injection (0.58 mg after reconstitution with sterile diluent \[0.3 mg/mL calcium chloride dihydrate in 0.9% sodium chloride\])
223691387|NCT04471597|DRUG|normal saline 0.9%|5ml of normal saline 0.9% topically 15 min will be installed topically around the ETT using ordinary syringe before the expected end of the surgery, this will be followed by manual ventilation using about the double tidal volume for 6-8 times or more to get air bubbles distributed within the upper airway to anesthetize the oropharynx and spread around ETT to the adjacent mucosal structures (laryngopharynx, larynx, and upper part of the trachea) then the cuff will be inflated to the previous pressure and the patient will be mechanically ventilated as usual.
223691388|NCT04471597|DRUG|Bupivacaine Hydrochloride|5 ml of bupivacaine 0.5% will be installed topically around the ETT using ordinary syringe before the expected end of the surgery, this will be followed by manual ventilation using about the double tidal volume for 6-8 times or more to get air bubbles distributed within the upper airway to anesthetize the oropharynx and spread around ETT to the adjacent mucosal structures (laryngopharynx, larynx, and upper part of the trachea) then the cuff will be inflated to the previous pressure and patient will be mechanically ventilated as usual.
223691389|NCT01473056|DRUG|JTK-853|Tablets, twice a day for 3 days
223691390|NCT01473056|DRUG|Dose 2 JTK-853|Tablets, twice a day for 3 days
223691391|NCT01473056|DRUG|Dose 3 JTK-853|Tablets, three times a day for 3 days
223691392|NCT01473056|DRUG|Dose 4 JTK-853|Tablets, twice a day for 3 days
223691393|NCT01473056|DRUG|Placebo|Tablets, twice a day or three times a day for 3 days
223691394|NCT01810211|OTHER|Horizontal Adduction Stretch and Pendulums|
223691395|NCT01810211|OTHER|Modified Sleeper Stretch and Pendulum|
223691396|NCT00935298|DRUG|Tacrolimus|The genotyping of gene CYP3A5 will be carried out in the 4-7days before renal transplantation. After transplantation, the patients will be treated by MMF, corticosteroids and tacrolimus at a dosage adapted to their genotype(CYP3A5\*1/\*1 type and CYP3A5\*1/\*3 type administer 0.15mg/kg/d，CYP3A5\*3/\*3 type administer 0.08mg/kg/d).
223691397|NCT00400530|DRUG|MK0217, alendronate sodium / Duration of Treatment: 1 Month|
223691398|NCT00400530|DRUG|Comparator: Alendronate-Teva / Duration of Treatment: 1 Month|
223691399|NCT06045650|OTHER|baseline serum oxytocin levels|Both cases and controls will be assessed for their baseline serum oxytocin levels
223691400|NCT06045650|OTHER|Emotional Sensitivity test|To assess the level of emotional sensitivity in the participant
223691401|NCT06045650|OTHER|Neuro-economical game|A game played to assess the trust-index of participants
223691402|NCT06045650|OTHER|Childhood Trauma Questionnaire|to assess childhood trauma score
223691403|NCT06045650|OTHER|Relationships Questionnaire|to assess attachment type
223691404|NCT06045650|OTHER|demographic questionnaire|To obtain basic data on demographics
223691405|NCT00543738|DRUG|MK0767|
223691406|NCT04430829|DIAGNOSTIC_TEST|Weight-Bearing CT arthrography|A 20ml mixture of 5ml 0.5% ropivacaine, 5ml preservative-free sterile saline, and 10ml of non-ionic iodinated contrast media (e.g. iohexol 240) will be instilled into the knee joint of each patient prior to WBCTa imaging of the knee (LineUp, CurveBeam, LLC).
223691407|NCT04430829|DIAGNOSTIC_TEST|Knee MRI|MRI will be acquired (in-plane 0.25mm x 0.25mm, and 1.00mm slab thickness/separation and In-plane 0.25mm x 0.25mm, and 2.00mm slab thickness/separation)
223691408|NCT01974154|OTHER|Cohort I|We will evaluate serum and lung ELF obtained by bronchoalveolar lavage, under previous protocols, from 159 individuals at baseline and at 0, 3, 6 and 12 months.
223691409|NCT01974154|OTHER|Cohort II|Quantify the cilia length on prepared slides from 67 cohort II samples of airway epithelium from biological samples were already obtained from subjects who were consented to participate in prior WCMC IRB approved protocols.
223691410|NCT01932073|DEVICE|Low-Level Laser Therapy|Low-Level Laser Therapy will be applied, twice a week, from the moment skin reactions become painful until skin reactions are no longer painful
223691411|NCT06852014|DIETARY_SUPPLEMENT|Dietary Supplement: Experimental Treatment with nutritional suplement A + nutritional suplement B|Intervention group will receive a nutritional formula A and, after 1-week washout period, will receive a nutritional formula B
223691412|NCT06852014|DIETARY_SUPPLEMENT|Dietary Supplement: Dietary Supplement: Experimental Treatment with nutritional suplement B + nutritional suplement A|Intervention group will receive a nutritional formula B and, after 1-week washout period, will receive a nutritional formula A
223691413|NCT02996734|PROCEDURE|curettage and resection|the investigators analyzed patients with giant cell tumor of bone who underwent curettage or resection with or without denosumab administration
223691414|NCT02761928|OTHER|Beighton score for hypermobility|The beighton score is a 9 point score of flexibility, used for patients with disorders of collagen.
223691415|NCT06515249|OTHER|Integrative medicine|Integrative medicine treatments including acupuncture, touch, movement, mind-body, as patient\&#39;s and staff\&#39;s choice
223691416|NCT06168227|DRUG|Disitamb Vedotin|RC48-ADC based therapy
223691417|NCT04990336|COMBINATION_PRODUCT|Dachaihu decoction compound|Dachaihu decoction compound includes Bupleurum, Rhubarb, Citrus aurantium, Scutellaria, Pinellia, White Peony, Jujube, Ginger.
223691418|NCT04990336|DRUG|Rhubarb single medicine|Rhubarb single medicine
223691419|NCT04990336|COMBINATION_PRODUCT|Regular therapies|Regular therapies, such as fluid therapy, for acute pancreatitis
223691420|NCT00089323|PROCEDURE|Bone Marrow Aspiration|
223691421|NCT03187756|DRUG|Cyclophosphamide|Shortened duration immunosuppression following nonmyeloablative peripheral blood stem cell transplant with high dose post transplantation cyclophosphamide in malignancies to engraft.
223691422|NCT02567552|DRUG|Subcutaneous progesterone|subcutaneous progesterone 25 mg/day
223691423|NCT02567552|DRUG|Intramuscular progesterone|intramuscular progesterone 50 mg/day
223777032|NCT07052019|BEHAVIORAL|Tell-Show-Do Technique|Conventional behavioral technique where the dentist tells, shows, and then performs the procedure to reduce anxiety and build cooperation.
223691424|NCT04167371|BEHAVIORAL|Biofeedback|Three sessions by biofeedback will be performed during the first 3 weeks of the intervention period. In each session patients will be taught to control abdominal and thoracic muscular activity by providing a visual display of the abdominal and thoracic perimeter; patients will be instructed to perform the same exercises before and after breakfast, lunch and dinner during the 4-week intervention period.
223691425|NCT04167371|DIETARY_SUPPLEMENT|Placebo|Three sessions will be performed during the first 3 weeks of the intervention period. In each session abdominal and thoracic perimeter will be recorded but not shown to the patient; patients will take a pill of placebo containing 0.5 g glucose and no specific instructions will be provided. Patients will be instructed to take a pill of placebo before breakfast, lunch and dinner during the 4-week intervention period.
223691426|NCT04299893|DRUG|Ozone|Ozone Group: Standard treatment + Ozone therapy (O3/O2) by rectal insufflation. O3/O2 concentration progressively increased from 10 to 30 μg/ml; 40 sessions in 16 weeks.
223691427|NCT04299893|DRUG|Oxygen|Control Group: Standard treatment + Oxygen (O2) by rectal insufflation. O3/O2 concentration = 0 μg/ml (only O2); 40 sessions in 16 weeks.
223835696|NCT06386653|DRUG|Diagnostic injection of [123I]I-DARPIN-Ec1|A single intravenous injection of \[123I\]I-DARPIN-Ec1
223691428|NCT01074047|DRUG|Azacitidine|75 mg/m\^2 subcutaneous (SC) daily for 7 days for 28 day cycles until disease progression or unacceptable toxicity
223691429|NCT01074047|DRUG|Conventional Care Regimen|"Physician pre-selects prior to randomization from one of the following:~* Intensive chemotherapy (cytarabine 100-200 mg/m\^2 continuous intravenous infusion for 7 days + anthracycline IV x 3 days) + Best Supportive Care; induction with up to 2 consolidation cycles~* Low-dose cytarabine 20 mg subcutaneous (SC) twice a day (BID) for 10 days, for 28 day cycles + BSC; until disease progression or unacceptable toxicity~* Best Supportive Care only; until study end"
223691430|NCT04619225|DEVICE|TetraGraph|FDA approved neuromuscular transmission monitor capable of measuring the depth of neuromuscular block in anesthetized patients who received neuromuscular blocking agents. TetraGraph uses EMG to measure the muscle action potentials that are generated in response to electrical neurostimulation via skin electrodes.
223691431|NCT03836976|OTHER|Auditory gamma sensory stimulation|"Gamma-conditioning stimulation will be~administered in 2 blocks of 3 min each. During each block, participants will be presented with a continuous~tone at the CF (500 or 1200 Hz) that will be amplitude modulated at 40 H"
223691432|NCT01996046|OTHER|FDG PET/CT scan|\[18F\] FDG PET/CT scan at 4 weeks after starting new hormonal therapy
223691433|NCT06743477|OTHER|Supergraft|This study is a prospective, single-center, single-arm clinical study, and it is planned to include 3-5 patients with Eastern Mediterranean major who have no HSCT indication and cannot undergo Eastern Mediterranean gene therapy. The diagnosis of Eastern Mediterranean major was determined by the genotype of Eastern Mediterranean and the clinical manifestations of patients, and patients who met the inclusion criteria were screened and enrolled and received super transplant therapy.
223835697|NCT06386653|DIAGNOSTIC_TEST|Whole-body planar scintigraphy with [123I]I-DARPIN-Ec1|Gamma camera-based whole-body planar scintigraphy imaging 2, 4, 6, and 24 hours after a single intravenous injection of \[123I\]I-DARPIN-Ec1
223691434|NCT07150507|OTHER|Session 1: Preparation Session|\*Meeting Patients \*Introducing the Content of Psychoeducation \*Emphasizing the Importance of Regular and Timely Attendance at Training \*Determining Training Dates \*Sharing Individuals' Experiences and Expectations
223691435|NCT07150507|OTHER|Session 2: Recognizing the Illness|\*What is Schizophrenia? \*What are its Symptoms? \*What Does Treatment Include?
223691436|NCT07150507|OTHER|Session 3: Treatment Evaluation|\*Things to Consider When Using Medication \*Side Effects of Medication \*Exacerbation of Schizophrenia \*Precursor Symptoms.
223691437|NCT07150507|OTHER|Session 4: What is anger?|\*What are the symptoms of anger? \*What are the methods for coping with anger?
223691438|NCT07150507|OTHER|Session 5: Communication|"\*What is communication? \*The importance of communication. \*Fundamentals of communication, working on I language. \*Ways to prevent communication difficulties."
223691439|NCT07150507|OTHER|Session 6: What is relaxation?|What is progressive relaxation? Introducing a relaxation CD
223691440|NCT07150507|OTHER|Session 7: Relaxation|Practicing the relaxation CD with patients
223691441|NCT07150507|OTHER|Session 8: Evaluation|\*Reinforcing what has been learned. \*Evaluating the program. \*Obtaining feedback
223835698|NCT06386653|DIAGNOSTIC_TEST|Whole-body SPECT with [123I]I-DARPIN-Ec1|Whole-body SPECT at 2, 4, and 6 hours after a single intravenous injection of \[123I\]I-DARPIN-Ec1
223835699|NCT04619368|OTHER|Follow up calls|The follow-up will consist in phone call with an intensive care doctor. These visits would be the opportunity to screen the complications after intensive-care with, find solutions to cure them or decrease their impact on patient's life to improve quality of life and prevent the post-traumatic syndrome disorder PTSD. A review would be sent to the patients' General Practitioners at the end of each visit.
223691442|NCT04378946|BEHAVIORAL|Intensive physical rehabilitation type training|Multiple reaching tasks aiming at increasing voluntary elbow range of motion
223691443|NCT04378946|DEVICE|Robotic system for supporting and monitoring arm motion|"Ergonomic double-joint horizontal manipulandum mounted on a rigid, movable arm (used to support UL movement during tasks).~An electromyogram (EMG) is used to monitor elbow extensor and flexor muscle activity.~A motion tracking device based on the Kinect II skeleton ( with Kalman filter to improve accuracy).~Simple Virtual Reality Reaching Game providing visual feedback with screen display of the subject's arm avatar and arm workspace for the VR training."
223691444|NCT04378946|DEVICE|Actigraph Activity Monitor|Used during and outside training sessions, this device is worned on the affected wrist that records activity (movements metrics) as a measure of upper extremity as well as heart rate
223691445|NCT04378946|DIAGNOSTIC_TEST|Magnetic resonance imaging (MRI)|Done once before treatment (PRE)
223691446|NCT04378946|DIAGNOSTIC_TEST|Montreal Spasticity Measure (MSM)|Used to identify the actual spatial threshold (ST) prior to every training session
223691447|NCT02946320|DEVICE|Predilatation with non-compliant balloon|Coronary artery stenosis is dilated before BVS implantation with the use of non-compliant balloon (standard procedure). Size and dilatation pressure is done according to OCT measurement of the coronary artery (distal segment / balloon diameter = 1:1)
223691448|NCT02946320|DEVICE|Predilatation with scoring balloon (Scoroflex)|Coronary artery stenosis is dilated before BVS implantation with the use of scoring balloon. Size and dilatation pressure is done according to OCT measurement of the coronary artery (distal segment / balloon diameter = 1:1)
223691449|NCT02946320|DEVICE|Predilatation with cutting balloon (Flextome)|Coronary artery stenosis is dilated before BVS implantation with the use of cutting balloon. Size and dilatation pressure is done according to OCT measurement of the coronary artery (distal segment / balloon diameter = 1:1)
223691450|NCT00604305|DEVICE|Acrysof|Monofocal IOL
223691451|NCT00604305|DEVICE|Acuity's AIOL|Accommodating IOL
223691452|NCT04766710|OTHER|Community-based ART delivery (CAD)|The frontline workers to implement the CAD model intervention will be people living with HIV recruited from the community who will plays roles as CAWs. The CAWs will receive intensive training, coaching, and mentoring from their respective ART clinics and implementing partners' field staff on ARV dispensing, drug storage, patient's vital sign assessment and recording, HIV education and counseling, medication adherence, referral systems, mental health, stigma and discrimination, and sexual and reproductive health of people living with HIV. To closely monitor the work of the CAWs, a respective ART clinic team, consisting of an ART counselor and a physician, will be tasked to conduct regular supervision along with the program team of the implementing partners to the community groups at least once a month in the first six months. After the six months, supervisory visits will be extended to once every two months.
223691453|NCT04766710|OTHER|ART multi-month dispensing (MMD)|The control arm participants will receive routine services under the MMD model based on standard community-based prevention, care, and support practices in Cambodia. The NCHADS has introduced MDD in all ART sites across the country. However, so far, not all ART sites currently operate the MMD. The MMD is designed to help ART service providers implement MMD for eligible patients-that is, patients whose condition is determined to be stable-which will reduce the need for frequent visits and providers' workload. Stable people living with HIV receive care and support from counselors and ARVs at the clinics every four to six months.
223691454|NCT03084731|DIETARY_SUPPLEMENT|Microbiota Directed Complementary Food (MDCF)|"For Study 1: Investigators will test 3 prototype MDCFs and the current RUSF standard of care for MAM to establish the effect size of each on MAZ repair in a 4 week twice daily intervention, with a 2 week post-intervention phase.~Study 2: From study 1 Investigators will select most efficacious MDCF and compare with 2 additional MDCF prototypes to establish the effect size of each on MAZ repair in a 4 week twice daily intervention, with a 2 week post-intervention phase.~Study 3: Investigators will select the lead MDCF from study 2 and examine the effects between the final MDCF versus current RUSF and also examine the impact dispensing of the lead MDCF once versus twice per day with a 4 week post-intervention period."
223691455|NCT00000842|DRUG|Nerve Growth Factor, Recombinant Human|
223691456|NCT03502083|DRUG|GLP-1 (7-36)Amide|IV infusion
223691457|NCT00045968|DRUG|Dendritic cell immunotherapy|Two intradermal (i.d.) injections of DCVax-L(treatment cohort) or autologous PBMC (placebo cohort) per treatment. Treatments will be given at days 0, 10, 20, and at weeks 8, 16, 32, 48, 72, 96 and 120.
223777033|NCT07051941|OTHER|Validation of a satisfaction questionnaire for robotic surgeon|"The primary endpoint is to validate a questionnaire to assess user satisfaction among expert surgeons utilizing various surgical robotic systems, including - but not limited to - the Da Vinci®, Hugo™ RAS, Versius®, and Toumai® platforms.~Based on these domains, an initial pool of items was generated; items were formulated as Likert-scale questions (5-point) and grouped into thematic sections.~The validation of the Questionnaire will be developed with a 2-step process.~1. Test for Content Validity and Face Validity: a pilot test will be performed with 5-10 surgeons from FPG to ensure content and face validity, item comprehension, and usability.~2. Validation from external users:"
223777034|NCT06797518|DRUG|Iptacopan|LNP023 oral capsule 200 mg b.i.d
223777035|NCT07051447|OTHER|PKRxHD|The precision approach will incorporate point of care testing of blood potassium concentration prior to each dialysis session and adjustment of the dialysate K prescription with a blood-dialysate K gradient minimization strategy (PKRxHD).
223777036|NCT07051447|PROCEDURE|Dialysis|Standard of care dialysis.
223777037|NCT07052383|BIOLOGICAL|DIT309 cell injection|3+3 dose escalation design： Dose Level 1: 4.0×10\^6/kg CAR+ T cells；Dose Level 2: 1.0×10\^7/kg CAR+ T cells；Dose Level 3: 2.0×10\^7/kg CAR+ T cells.
223777038|NCT07051460|OTHER|Baseline Condition (No Stimuli)|Participants underwent baseline evaluation using the Vertical Maddox Test with no auditory or oral proprioceptive stimulation. This phase was used to confirm the absence of spontaneous visual pseudo-scotomas and served as an internal control condition for each participant.
223777039|NCT07051460|OTHER|Auditory Stimulation only|Participants received bilateral auditory stimulation consisting of 500 Hz tones (500 ms duration, 50 dB) delivered through wireless headphones, without any accompanying oral stimuli. This condition was used to assess the isolated effect of sound on visual perception using the Vertical Maddox Test.
223777040|NCT07051460|OTHER|Auditory and Oral Proprioceptive Stimulation (OPS)|Participants received simultaneous auditory and oral proprioceptive stimuli while undergoing the Vertical Maddox Test. - Auditory: 500 Hz tones (500 ms, 50 dB) via headphones. - Oral Proprioceptive Stimuli (OPS): included Combined Oral Stimuli (e.g., tongue and lip self-administered positions) and Dental Stimuli (mechanical pressure or traction on central incisors using a calibrated probe). This condition aimed to assess whether OPS could modulate or eliminate sound-induced visual pseudo-scotomas.
223777041|NCT07051460|OTHER|Oral Proprioceptive Stimulation Only (OPS)|Participants received oral proprioceptive stimuli alone, without auditory input, during the Vertical Maddox Test. - Combined Oral Stimuli (COS): self-administered tongue/lip positions. - Dental Stimuli (DS): applied by the operator to central incisors. This condition was used to evaluate the independent effect of OPS on visual perception.
223691458|NCT06046885|DEVICE|Neuromuscular electrical stimulation|"As regards the electrodes position, one proximal electrode on the gastrocnemius, which will be located below the popliteal fossa (at least 5cm below it) for a better position on the muscle belly; and one distal electrode, located at least 10 cm from the calcaneus.~This protocol will last 20 minutes per session. The placement of the electrodes is as mentioned above, and the parameters to be used will be the following: a stimulation frequency between 35 and 80Hz, a pulse width between 150 and 200 µs, the intensity will be established individually using an intensity that generate a visible contraction of maximum intensity without generating pain. The duration of the contraction will be of 6 seconds with 30 seconds of rest."
223691459|NCT01801072|DRUG|Levetiracetam|Details covered in Arm Descriptions.
223691460|NCT01573351|DRUG|Asunaprevir|
223691461|NCT01573351|DRUG|Daclatasvir|
223691462|NCT01573351|DRUG|Peg-interferon Alfa-2a|
223691463|NCT01573351|DRUG|Ribavirin|
223691464|NCT06319638|BEHAVIORAL|Rehabilitation therapy|During the treatment, All the participants were provided with the rehabilitation therapy, which included routine rehabilitation, cognitive training, swallowing function training and nutrition support.
223691465|NCT06319638|PROCEDURE|Stellate ganglion block|Based on the invention above, the patients in the observation group were provided with Stellate ganglion block, using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate ganglion block . The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
223691466|NCT06319638|PROCEDURE|Placebo block|1 milliliter of normal saline will be used for injection. The percutaneous approach via the paratracheal route was used for Stellate ganglion block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
223691467|NCT06319638|DRUG|Lidocaine Hydrochloride|the patients in the observation group were provided with Stellate ganglion block, using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). Once a day, totally 10 days.
223691468|NCT05760105|OTHER|Patient Participation Form|A form that consists of revised osteoporosis knowledge test, osteoporosis self-efficacy scale, and osteoporosis health belief scale.
223691469|NCT00632073|DRUG|Vicriviroc|One tablet of vicriviroc maleate 30 mg once daily for 24 weeks (added to the subject's failing antiretroviral background regimen for 2 weeks, and then administered with optimized background therapy).
223691470|NCT05342610|OTHER|Distant reiki|Reiki; It is the transfer of energy to other people by the hands of the person who receives the theoretical training and attunement (initiation) from the reiki master, close or distant. When the hands are brought closer to the body in suitable positions or when the reiki practitioner visualizes the person in his/her thoughts, the energy flow starts spontaneously and the transferred energy is shaped according to the needs of the reiki recipient. The biggest advantage of Reiki; It is an easy and cost-effective method to ensure that the individual restores the balance between body, mind and spirit, has no side effects, has no negative effects on behavior and attitudes.
223691471|NCT02247531|DRUG|Lampalizumab|10 mg dose of lampalizumab administered intravitreally.
223691472|NCT02247531|OTHER|Sham Comparator|A sham injection is a procedure that mimics an intravitreal injection of lampalizumab.
223691473|NCT05931640|DEVICE|Virtual Reality|Virtual Reality Therapy that includes use of VR goggle, VR headset and play station if available. Virtual games like move-pro will be used for upper limb movements. A session of 12-45 minutes, twice weekly will be done. And scoring will be done with the help of additional tools.
223691474|NCT05931640|DEVICE|Plyometric Training|Plyometric therapy that includes 10 minutes of ball throwing, push-ups, jumping and hopping/skipping. At start intensity and speed is low, but will be increased gradually. Every score will be noted with the help of additional tools.
223691475|NCT00053573|BIOLOGICAL|Myozyme|20 mg/kg to 40 mg/kg qow
223691476|NCT03920748|OTHER|Group D|According to Cormack-Lehane (CL) Classification; laryngoscopic view grade 3-4 is defined as Group D
223691477|NCT03920748|OTHER|Group E|According to Cormack-Lehane (CL) Classification; laryngoscopic view grade 1-2 is defined as Group E
223691478|NCT03689673|OTHER|Data collection|
223691479|NCT04765215|BIOLOGICAL|CoronoVAC|SARS-CoV-2 IgM and IgG will be measured from blood samples between 3-6 weeks after the 2nd dose of vaccination
223691480|NCT00214643|DRUG|Fosmidomycin|30 mg/kg
223691481|NCT00214643|DRUG|clindamycin|10 mg/kg
223691482|NCT02423109|DEVICE|fanfilcon A|contact lens
223691483|NCT02423109|DEVICE|enfilcon A|contact lens
223691484|NCT06403215|OTHER|Chewing gum group|Women in this group chewed sugar-free and non-xylite gum for 15 minutes every two hours (2nd, 4th, and 6th) following the cesarean operation.
223691485|NCT06403215|OTHER|Fennel tea group|Women in this group started oral intake 6 hours after cesarean delivery and were allowed to drink 2 grams of fennel tea in the 6th, 8th, and 10th hours (a total of 6 grams of fennel tea).
223691486|NCT06403215|OTHER|Chewing gum+Fennel tea group|Women in this group both chewed sugar-free and non-xylite gum for 15 minutes every two hours (2nd, 4th, and 6th) following the cesarean operation and started oral intake 6 hours after cesarean delivery and were allowed to drink 2 grams of fennel tea in the 6th, 8th, and 10th hours (a total of 6 grams of fennel tea).
223691487|NCT06403215|OTHER|Control group|No intervention
223691488|NCT02919371|DRUG|Sunitinib|Oral therapy ( Anti-vascular endothelial growth factor Tyrosin Kinase Inhibitor): given as 50 mg daily from day 1 to day 28- cycle repeated every 42 days
223691489|NCT02919371|DRUG|Bevacizumab|Monoclonal antibody against vascular endothelial growth factor: given intravenously on day 29 of each sunitinib cycle
223691490|NCT04343300|OTHER|Pilates|Intervention of12 weeks of Pilates
223691491|NCT04343300|OTHER|exercise without Pilates|exercise without Pilates
223691492|NCT06269107|DRUG|IcoSema|IcoSema will be administered subcutaneously.
223691493|NCT06269107|DRUG|Insulin glargine|Insulin glargine will be administered subcutaneously.
223691494|NCT05775354|DIAGNOSTIC_TEST|Early diagnosis strategy|RED-CVD early diagnosis questionnaire, physical examination, laboratory testing, electrocardiography, echocardiography
223691495|NCT04763928|DRUG|Venetoclax+Decitabine|"Patients will receive treatment with a combination of decitabine and venetoclax as follows:~* Decitabine 20 mg/sqm intravenously on days 1 to 5 of 28-days courses~* Venetoclax 400 mg per day orally on days 1 to 28 of 28-days courses; a dose escalation period is provided at first cycle (ramp-up) in which VEN is administered as follows: 100 mg on day -2, 200 mg on day -1, and 400 mg on day 1, a dose that is continued subsequently, daily, for 28-day cycles.~In case of achievement of response, the treatment will be continued until disease progression or death by other causes."
223691496|NCT01229397|BIOLOGICAL|Inflexal V|vaccination with Inflexal V 0.25 mL administered twice, 4 weeks apart
223691497|NCT01229397|BIOLOGICAL|Inflexal V|Inflexal V 0.5 mL administrated once only
223691498|NCT00620789|DRUG|Escitalopram + CBT-I|"* Escitalopram, 10 mg daily for the duration of the study (6 months)~* CBT-I, four biweekly sessions during eight week Treatment phase."
223691499|NCT00620789|BEHAVIORAL|CBT-I plus placebo antidepressant medication|"* CBT-I, 4 biweekly sessions, eight week Treatment phase.~* Placebo,daily for duration of study(6 months)."
223691500|NCT00620789|DRUG|Escitalopram|"* Escitalopram, 10 mg daily for the duration of the study (6 months)~* SH, four biweekly sessions during eight week Treatment phase"
223691501|NCT01413412|PROCEDURE|Ventral hernia repair using full thickness skin graft|25 patients
223691502|NCT01413412|PROCEDURE|Ventral hernia repair using mesh|25 patients
223691503|NCT05722457|OTHER|external focus task focus in addition to physiotherapy and rehabilitation exercises|"The first study on the external focus was made in 1998 by Wulf, Ho ¨ß, \& Prinz, (1998). Focusing on the inside of the body while performing a movement is called internal (internal focus), focusing on the outside of the body is called external (external focus). Previous studies have shown that external focus is substantially more effective than internal focus in the performance of a movement."
223691504|NCT05722457|OTHER|internal focus task focus in addition to physiotherapy and rehabilitation exercises|"he first study on the external focus was made in 1998 by Wulf, Ho ¨ß, \& Prinz, (1998). Focusing on the inside of the body while performing a movement is called internal (internal focus), focusing on the outside of the body is called external (external focus). Previous studies have shown that external focus is substantially more effective than internal focus in the performance of a movement."
223691505|NCT05369676|DRUG|SSD8432 dose 1/Ritonavir|Cohort 1:SSD8432/ritonavir or placebo, on day 1 \~day5，BID；
223691506|NCT05369676|DRUG|SSD8432 dose 2/Ritonavir|Cohort 2:SSD8432/ritonavir or placebo, on day 1 \~day5，BID；
223691507|NCT03320226|DIETARY_SUPPLEMENT|Probiotic 10 (Nature's Bounty)|The Probiotic 10 (Nature's Bounty) that contains 20 billion live cultures of Lactobacillus plantarum 299v (Lp299v®), Lactobacillus bulgaricus Lb-87, Lactobacillus paracasei DSM 13434, Lactobacillus plantarum DSM 15312, Lactobacillus salivarius Ls-33, Lactobacillus brevis Lbr-35, Lactobacillus acidophilus La-14, Bifidobacterium lactis Bl-04, Lactobacillus paracasei Lpc-37, Lactobacillus casei Lc-11, which are under Lactobacillus and Bifidobacterium.
223691508|NCT04882046|OTHER|Blood collection|Blood samples (8ml) at three times of the study: at baseline, 3 hours and 6 hours after treatment
223691509|NCT04882046|OTHER|Data collection|collection of socio-demographic, clinical and biological data.
223835700|NCT06247826|PROCEDURE|Blood sampling|Blood samples (2\*10 mL on ethylenediaminetetraacetic acid (EDTA)) will be taken at time of disease progression and will be sent for central liquid biopsy ctDNA analysis.
223835701|NCT04925700|DIETARY_SUPPLEMENT|ProDentis Lozenge|1-2 ProDentis Lozenges per day
223835702|NCT04925700|OTHER|Placebo Lozenge|1-2 Placebo Lozenges per day
223777042|NCT07052162|DRUG|Single dose tafenoquine (10 mg/kg) given with water|Participants will receive single-dose TQ as 10 mg/kg taken with water and a low-fat meal (3 plain cracker biscuits; 2% fat). Food (low-fat meal) is taken with both regimens to attenuate any gastrointestinal adverse effects that are related to taking TQ on an empty stomach. Combinations of full or half-tablets will be swallowed whole or crushed lightly (tablets) or dissolved in boiled water (if dispersible tablets are available), as directly observed treatment. Children vomiting within the first 30 minutes of treatment will be withdrawn
223777043|NCT07052162|DRUG|Single dose tafenoquine (10 mg/kg) given with fat|Single-dose TQ as 10 mg/kg taken with 250 mL chocolate flavoured milk (9% fat) and a low-fat meal (3 plain cracker biscuits). Food (low-fat meal) is taken with both regimens to attenuate any gastrointestinal adverse effects that are related to taking TQ on an empty stomach. Combinations of full or half-tablets will be swallowed whole or crushed lightly (tablets) or dissolved in boiled water (if dispersible tablets are available), as directly observed treatment. Children vomiting within the first 30 minutes of treatment will be withdrawn
223777044|NCT07052617|DEVICE|Continuos renal replacement therapy|Different modalities of CRRT: continuous veno-venous hemofiltration; continuous veno-venous hemodialysis and continuous veno-venous hemodiafiltration Different doses of CRRT: low effluent dose (\<15 ml/kg/h); medium-low effluent dose (15-25 ml/kg/h); standard effluent dose (25-30 ml/kg/h); high effluent dose (\>30 ml/kg/h
223777045|NCT06575712|BEHAVIORAL|Step Up|A hybrid in-person and mHealth (mobile health) coping skills training and activity coaching intervention.
223777046|NCT06575712|OTHER|Usual Care Plus (UC+)|Usual medical care plus videos delivering educational content via an app.
223777047|NCT06576297|OTHER|Inspiratory Muscle Training (IMT)|IMT using a PrO2™ inspiratory training device will incorporate the Test of Incremental Respiratory Endurance (TIRE)9 technology to achieve an optimized exercise training regimen.
223777048|NCT06576297|OTHER|Standard of Care|Standard of Care Participants in the usual care group will be telephoned at 4 and 8 weeks, and AE/SAE will be reviewed.
223777049|NCT06830096|DRUG|10 mg glipizide ingestion|A single dose of 10 mg glipizide will be ingested
223777050|NCT05274022|OTHER|Standard of Care Physical Therapy Program|Standard of care will follow best practice. The subjects and their physical therapists will be provided with a standardized set of exercises and guidance on what to cover during skilled physical therapy visits. As part of the study, all patients will receive the same exercise program. Exercises will include lower extremity strengthening, balance, and mobility exercises with the use of modalities as needed
223777051|NCT05274022|OTHER|Speed Walking Intervention|The 4-6 week program will consist of a warm up of active stretching. Following the warm up, subjects will perform a 2 minute warm up followed by 1 minute of walking at their fastest comfortable speed followed by 2 minutes of active recovery where they will walk at a speed of their choosing for 4cycles and then a 2 minute cool down. The program will be performed 12 visits over 4-6 weeks.
223777052|NCT06786130|OTHER|observational study|This is an observational study in which participants complete PRO questionnaires via a web platform. No medical intervention or medication is involved.
223777053|NCT04804735|DEVICE|REV : local anesthesia and virtual reality|REV : local anesthesia and virtual reality in Implanted Venous Access Device (IVAD) procedure under local anesthesia
223777054|NCT04804735|DEVICE|MUS : local anesthesia and music therapy|MUS : local anesthesia and music therapy in Implanted Venous Access Device (IVAD) procedure under local anesthesia
223777055|NCT04621500|DRUG|cholecalciferol|Enrolled subjects will supplement with vitamin D3 at 4,000 IU daily for one year
223777056|NCT04621500|PROCEDURE|Standard of Care Prostate Biopsy - collection of 13th core for RNA-seq|RNA-seq analysis will be used to (a) identify changes in transcriptional profiles and biological pathways in the prostate between African American and Caucasian men and (b) compare Allostatic Load results to determine stress response and (c) identify changes in the molecular signature in relation to vitamin D levels
223777057|NCT04621500|PROCEDURE|Standard of Care Prostate Biopsies at baseline and after one year vitamin D3 supplementation|Pathology results of the prostate biopsies will be analyzed for changes in the (a) Gleason Score (b) the number of positive cores (0 to 12) and (c) the highest percentage of positive core involvement (0 to 100%).
223777058|NCT04621500|DIAGNOSTIC_TEST|Allostatic Load|"Diagnostic Test: Allostatic Load Measurements at baseline and after one year vitamin D3 supplementation Allostatic Load measurements to determine body stress compared at baseline and after one year of vitamin D3 supplementation. Also compared with RNA-seq results to determine stress response.~Other Names:~Bloodwork for HgbA1c, lipid profile, creatinine, albumin and vitamin D levels. Body measurements: Ht. Wt, BMI, waist and hip measurements for waist/hip ratio. Measurements of systolic and diastolic blood pressure and heart rate"
223777059|NCT01343160|DEVICE|GORE® VIABIL® Biliary Endoprosthesis|Deployment of GORE® VIABIL® Biliary Endoprosthesis to the area of stricture
223777060|NCT04577690|DRUG|Bupivacaine 0.25% with epinephrine 1:200000 by PECS block and wound infiltration|The anesthesiologist will administer bupivacaine 0.25% with epinephrine 1:200000 by PECS block after induction of anesthesia before surgical incision. The EP cardiologist will also administer bupivacaine 0.25% with epinephrine 1:200000 by infiltrating the wound after surgery is complete.
223691510|NCT05655052|DEVICE|Virtual Reality (VR) Group|"At the beginning of the study, the women who applied for the IUD procedure will be interviewed, and then the following procedures will be applied; Informed consent of all women will be obtained about the study.~* An introductory information form will be filled in for women in all three groups.~* While the Intervention Group 1 IUD is being applied, a nature video will be watched with Virtual Glasses.~* Distraction Cards will be shown while the Intervention Group 2 IUD is being administered.~* The Control Group will be given routine IUD application and care."
223691511|NCT05655052|DEVICE|Group using distraction cards|"At the beginning of the study, the women who applied for the IUD procedure will be interviewed, and then the following procedures will be applied; Informed consent of all women will be obtained about the study.~* An introductory information form will be filled in for women in all three groups.~* While the Intervention Group 1 IUD is being applied, a nature video will be watched with Virtual Glasses.~* Distraction Cards will be shown while the Intervention Group 2 IUD is being administered.~* The Control Group will be given routine IUD application and care."
223691512|NCT02976298|OTHER|transcranial magnetic stimulation|comparison of different conditions of transcranial magnetic stimulation
223691513|NCT04778072|DIETARY_SUPPLEMENT|Ferrous sulfate 14mg once daily|ACTIVE IRON™ (ferrous sulfate) 14 mg elemental iron once daily with matching placebo
223691514|NCT04778072|DIETARY_SUPPLEMENT|Ferrous sulfate 25mg once daily|ACTIVE IRON™ (ferrous sulfate) 25 mg elemental iron once daily with matching placebo
223691515|NCT04778072|DIETARY_SUPPLEMENT|Ferrous sulfate 25mg twice daily|ACTIVE IRON™ (ferrous sulfate) 25 mg elemental iron twice daily
223691516|NCT02729675|OTHER|Access Intervention|The 7 worksites in this arm received year-round, weekly mobile F\&V markets (Fresh To You - FTY) selling local and non-local fresh produce at or below local supermarket prices. The markets carried 50 to 70 different produce items and were held both indoors and outdoors depending on the weather and worksite preference. When held indoors, F\&V were sold in a cafeteria or other highly trafficked area. In good weather, the markets were held outside on the worksite property in a retrofitted a car trailer. Each market lasted two hours. On average, FTY prices were 15% to 25% lower than local retail supermarket prices. Signs, posters, email blasts and flyers advertised the markets. The FTY intervention at each worksite began with a Kick-Off event, which included the first FTY market. Each employee who attended the first market received a large, reusable shopping bag with the FTY logo on it and a freezer pack to keep F\&V fresh.
223691517|NCT02729675|BEHAVIORAL|Enhanced Intervention|The 7 worksites in this arm received the Access intervention described above as well as set of educational/behavioral interventions. At the Kick-Off, employees received the first month's newsletter and an educational digital video disk (DVD) in the reusable shopping bag. They also received a chef-run cooking demonstration/taste-testing along with recipes and information about the upcoming intervention activities. Intervention activities included two 6-week campaigns (Just Add Two and Choose Color, Choose Health); a 90 minute DVD with cooking demonstrations about preparing quick, healthy inexpensive meals and unusual F\&V; a two-page, full-color newsletter distributed monthly; Food demonstrations/tastings delivered once a month by chefs including an easy to prepare, F\&V-based recipe; a total of 12 recipe handouts that correlated with the monthly cooking demonstration; a Good to Go website; and a project bulletin board.
223691518|NCT02729675|BEHAVIORAL|Comparison Behavioral Intervention|Brown University contracted with the Greater Providence Young Men's Christian Association (YMCA) to provide a physical activity and stress reduction intervention at the 7 worksites in the comparison group. Two, six-week campaigns were developed jointly by the Brown study team and YMCA staff. These campaigns followed the same format as the enhanced intervention group campaigns and were provided during the same time periods as those at the enhanced intervention sites. Everyone who participated in the campaigns also received a free, 6-week membership to the YMCA.
223691519|NCT05807633|DEVICE|Novosyn®|Novosyn® for uterus closure in patients undergoing cesarian section
223691520|NCT04034082|DEVICE|Intermittent hypoxia therapy|Intermittent Hypoxic Therapy (further referred to as IHT). A typical IHT session consists of repeated short-term moderate hypoxia (down to 10 vol.% O2), interrupted by brief periods of reoxygenation. These periods of recovery could be either normoxic (21 vol.% O2, Hypoxia-Normoxia mode) or hyperoxic (30-35 vol.% O2, Hypoxia-Hyperoxia mode, further referred to as IHHT). The gas mixtures are supplied to a patient via facial mask.
223691521|NCT04034082|OTHER|Conventional phase 2 cardiac rehabilitation programme|The core components of a Phase 2 in-hospital cardiac rehabilitation program include: 1) patient assessment with medical control to promote clinical stabilization and optimization of pharmacologic treatment; 2) physical activity counselling; 3) prescription of an individualized exercise training; 4) diet/nutritional counselling; 5) weight control management; 6) Lipid management; 7) blood pressure monitoring and management; 8) smoking cessation; 9) vocational support; 10) psychosocial management..
223691522|NCT02330809|OTHER|Daily extra water intake|Amount of extra daily water intake to consume
223691523|NCT02330809|OTHER|Timing of daily extra water intake|Intervention-A: Timing of daily extra water intake specified Intervention-B: at any time during 24 hour period
223691524|NCT01404975|OTHER|Thoracic paravertebral block (PVB)|"We are planning to replace the standard intravenous opioid analgesia with a continuous paravertebral block using local anesthetic after trans-apical aortic valve replacement.~Anesthesia management will be standardized to minimize any impact that anesthetic type may have on neurological outcomes.~Adjuvant supplemental analgesia will be provided to both groups according to the standardized institutional guidelines."
223691525|NCT00132639|DRUG|Preoperative docetaxel-cisplatin combination chemotherapy|Preoperative docetaxel-cisplatin combination chemotherapy
223691526|NCT00132639|DRUG|Preoperative docetaxel monotherapy|Preoperative docetaxel monotherapy
223691527|NCT01251744|PROCEDURE|Blood sample|Blood sample at study entry, every two months during pregnancy, at pregnancy conclusion and one month after pregnancy conclusion.
223691528|NCT01251744|PROCEDURE|Cord blood sample|Cord blood sample taken at the time of delivery.
223691529|NCT01251744|PROCEDURE|Saliva swab|Saliva swab taken at study entry, every month during pregnancy, at pregnancy conclusion and one month after pregnancy conclusion.
223691530|NCT01251744|PROCEDURE|Urine sampling|Approximately 10 mL of urine will be sampled at study entry, every month during pregnancy, at pregnancy conclusion and one month after pregnancy conclusion.
223777061|NCT04577690|DRUG|Bupivacaine 0.25% with epinephrine 1:200000 by wound infiltration only|The EP cardiologist will administer Bupivacaine 0.25% with epinephrine 1:200000 by infiltrating the wound after surgery is complete.
223691531|NCT01251744|PROCEDURE|Vaginal swab|Vaginal swab taken at study entry, every month during pregnancy and one month after pregnancy conclusion.
223777062|NCT06922604|PROCEDURE|Biospecimen Collection|Undergo CSF and blood sample collection
223691532|NCT01670604|DRUG|6% HES 130/0.4 in NaCl 0.9% (Voluven, Fresenius Kabi, Bad Hom-bourg, Germany)|
223691533|NCT01670604|DRUG|Tetraspan, B. Braun, Melsungen, Germany|
223691534|NCT01299701|DRUG|ASA404|(5,6-dimethylxanthenone-4-acetic acid) DMXAA or DXAA
223691535|NCT00920101|DRUG|Atorvastatin|Subjects are advised to keep dietary habits according to the National Cholesterol Education Program (NCEP) from the run-in period throughout the study. The subjects are administered with 10mg/day for 3 months, if LDL-cholesterol levels does not decrease less than 80mg/dl, the dose is increased up to 20mg/day. If LDL-cholesterol levels decrease less than 60mg/dl, the dose is decreased down to 5mg/day or less.
223691536|NCT00920101|BEHAVIORAL|Lifestyle counseling|Subjects are advised to keep dietary habits according to the National Cholesterol Education Program (NCEP) from the run-in period throughout the study.
223691537|NCT01356979|PROCEDURE|Medical thoracoscopy|Performing medical thoracoscopy to diagnose pleural diseases after cytological and other investigational tests.
223691538|NCT01068652|DRUG|insulin detemir|Initial dose of 0.1 U/kg once daily, injected s.c. (under the skin).
223691539|NCT01068652|DRUG|insulin aspart|Pending evaluation of HbA1c every 3 months, insulin aspart was added to the insulin detemir treatment (up to three does daily, injected s.c. (under the skin)
223691540|NCT01068652|DRUG|biphasic insulin aspart 30|Initial dose of 0.1 U/kg once daily, injected s.c. (under the skin). Pending evaluation of HbA1c every 3 months, the dose will intensified up to 3 doses daily
223691541|NCT01068652|DRUG|metformin|1000-2000 mg/day in combination with insulin treatment
223691542|NCT05544981|DIETARY_SUPPLEMENT|Beetroot Juice|70 ml of beetroot juice containing \~5 mmol of inorganic nitrate
223691543|NCT05544981|DIETARY_SUPPLEMENT|Beetroot Juice|70 ml of beetroot juice which is nitrate-depleted
223691544|NCT06007859|OTHER|section orientation|The patient was placed in a decubitus supine head back extension position to fully expose the cervical thyroid examination site. The instrument was adjusted appropriately to achieve optimal imaging quality, the suspicious nodule was located in conventional ultrasound mode, the SWE option in VT mode was selected, and the patient was instructed to hold his/her breath to minimize the effect of respiration, and elastograms of the nodule in transverse and longitudinal sections were obtained.
223691545|NCT01997710|DEVICE|all-ceramic inlay-retained RBFDP|Rehabilitation of tooth loss with an all-ceramic inlay-retained RBFDP
223691546|NCT01997710|DEVICE|all-ceramic RBFDP|Rehabilitation of tooth loss with an all-ceramic RBFDP
223691547|NCT04158791|PROCEDURE|pars plana vitrectomy with epimacular membrane removal and internal limiting membrane peeling|25-gauge pars plana vitrectomy with a solution of 0.15% trypan blue, 0.025% brilliant blue G, 4% polyethylene glycol (MembraneBlue Dual) assisted ERM/ILM removal performed by a single surgeon (GV); no air-fluid exchange was performed during surgery. In phakic eyes, phacoemulsification with intraocular lens implantation was performed at the time of vitrectomy.
223691548|NCT06515522|OTHER|differential diagnosis|this is a retrospective observational study. no intervention has been or will be performed
223691549|NCT00953381|DRUG|5 mg ilaprazole|One 5-mg ilaprazole tablet (Livzon Pharm Group Inc., China) together with three placebo tablets and one placebo capsule in a package being taken orally each morning on an empty stomach for 4 weeks
223691550|NCT00953381|DRUG|10 mg ilaprazole|Two 5-mg ilaprazole tablets (Livzon Pharm Group Inc., China) together with two placebo tablets and one placebo capsule in a package being taken orally each morning on an empty stomach for 4 weeks
223691551|NCT00953381|DRUG|20 mg ilaprazole|Four 5-mg ilaprazole tablets together with one placebo capsule in a package being taken orally each morning on an empty stomach for 4 weeks
223691552|NCT00953381|DRUG|20 mg omeprazole|One 20-mg omeprazole capsule (AstraZeneca, Losec) together with four placebo tablets in a package being taken orally each morning on an empty stomach for 4 weeks
223691553|NCT04274387|BEHAVIORAL|Mindfulness-based Stress Reduction(MBSR)|A structural program focusing on the practice about attending to the current moment with non-judgmental attitude
223691554|NCT04268589|OTHER|virtual reality game|routine
223691555|NCT01567735|DRUG|TMC435|Type=exact number, unit=mg, number=150, form=capsule, route=oral use. TMC435 capsule is taken once daily for 12 weeks.
223777063|NCT06922604|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
223777064|NCT06922604|BIOLOGICAL|Glofitamab|Given IV
223777065|NCT06922604|PROCEDURE|Lumbar Puncture|Undergo lumbar puncture
223777066|NCT06922604|PROCEDURE|Magnetic Resonance Imaging|Undergo brain MRI
223777067|NCT06922604|BIOLOGICAL|Obinutuzumab|Given IV
223691556|NCT02824965|DRUG|Pembrolizumab|Pembrolizumab is a selective monoclonal antibody that blocks the interaction between PD1 and its ligands PDL1 and PDL2, resulting in infiltration of tumour specific CD8+ T-cells and ultimately leads to tumour rejection.
223691557|NCT02824965|BIOLOGICAL|CVA21|CAVATAK is an oncolytic Coxsackie virus that specifically infects and kills ICAM overexpressing tumour cells
223691558|NCT01374711|DRUG|GM-CSF|GM-CSF (4microgram/kg/day subcutaneously) on days 2, 4 and 6.
223691559|NCT01374711|DRUG|IFN-Y|IFN-Y (100 microgram/day, subcutaneously) on days 2, 4 and 6.
223777068|NCT06922604|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
223777069|NCT03645200|DRUG|Fluzoparib combined with Apatinib|"Fluzoparib :~40mg.bid, morning and evening each time, interval of 12 hours or so, the first oral administration 72 hours later~Apatinib :~250mg or 500mg take one day, 72 hours later, the continuous drug delivery phase (B-C1D1) was entered into the Fluzoparib, that is, the Fluzoparib capsule with 40mg.bid, every morning and evening, each time, interval of 12 hours, the Apatinib tablets daily with the Fluzoparib capsule with the same service, fixed doses of 250mg or 500mg, daily. Continuous drug delivery for 28 days for one cycle"
223691560|NCT01374711|OTHER|E.coli endotoxin|2 ng/kg E.coli reference endotoxin 11:H 10:K negative intravenously
223691561|NCT03282851|DRUG|MSB11456|Subjects will receive a single injection of MSB11456 on Day 1.
223691562|NCT03282851|DRUG|US-licensed Actemra|Subjects will receive a single injection of US-licensed actemra on Day 1.
223691563|NCT03282851|DRUG|EU-approved RoActemra|Subjects will receive a single injection of EU-approved RoActemra on Day 1.
223691564|NCT04019431|DIETARY_SUPPLEMENT|Whey protein, vegetable protein or animal protein|meal replacements or animal protein
223691565|NCT02694523|DRUG|risankizumab|Risankizumab administered by subcutaneous (SC) injection
223691566|NCT02694523|BIOLOGICAL|adalimumab|Adalimumab pre-filled syringe, administered by subcutaneous (SC) injection
223691567|NCT02694523|DRUG|placebo for risankizumab|Placebo risankizumab administered by subcutaneous (SC) injection
223691568|NCT02694523|BIOLOGICAL|placebo for adalimumab|Placebo for adalimumab pre-filled syringe, administered by subcutaneous (SC) injection
223691569|NCT04489732|BIOLOGICAL|Autologous bone-marrow derived, interferon gamma stimulated mesenchymal stromal cells|"Single dose, starting at~* Dose Level 0: 10 (8-12) x 10\^6 injected into one submandibular gland on Day 1~Sub-study for second injection after primary objectives met, 10 (8 - 12) x 10\^6 MSCs will be offered for injection into each participant's contralateral submandibular gland"
223691570|NCT04226534|OTHER|Maximal effort test|Performing a maximal effort test on the treadmill
223691571|NCT05289531|PROCEDURE|Rectal Resection Patients|Patients who have had low anterior resection of rectum was categorized for their quality of life related to surgery
223691572|NCT04774120|DRUG|Propofol|Propofol will be started at a rate of 15-20 mg/kg/hr in patients \>65 years and 20-25 mg/kg/hr in younger patients (\<65 years) until a suppression rate (SR) is achieved. If not, can be increased by 5 mg/kg/hr every 5 minutes up to 25 mg/kg/hr in the elderly group and 30 mg/kg/hr in the younger group or after 15 minutes have passed. When the SR appears, propofol infusion will be stopped. Then restarted at half of the initial rate. Maintenance of anesthesia will be guided by Sedline Monitor to maintain an alpha band present in the spectrogram and SEF95 between 8-12 Hz. BIS monitor will be covered. Both EEG signals (Sedline and BIS) will be registered simultaneously until the patient's extubation.
223691573|NCT03204461|DIAGNOSTIC_TEST|Oral glucose tolerance test (OGTT)|For the assessment of glucose metabolism, including beta-cell function and insulin sensitivity an 75g-OGTT was conducted.
223691574|NCT03204461|OTHER|1H-magnetic resonance spectroscopy|The amount of ectopic lipids in the liver, heart and the skeletal muscle was measured using 1H-magnetic resonance spectroscopy.
223691575|NCT03736694|BEHAVIORAL|Cognitive behavioural therapy for insomnia|CBTI involves habitual, belief and attitude alterations so as to eliminate factors preventing sleep (Morin, Savard, Ouellet, \& Daley, 2003). It is recommended by the American College of Physicians as the first-line therapy for insomnia (Qaseem, Kansagara, Forciea, Cooke, \& Denberg, 2016). CBTI workshops are a relatively novel and emerging way of delivery which involves a greater number of patients than group CBTI, increases availability and accessibility by concentrating the content into half or whole day and taking place in the community settings, and reduces diagnostic labeling and cost (Bonin, Beecham, Swift, Raikundalia, \& Brown, 2014; Swift, Stewart, Andiappan, Smith, Espie, \& Brown, 2012). Self-help CBTI involves independent learning of the provided materials via the Internet, video or audio recording, books and pamphlets (Bruin, Bogels, Oort, \& Meijer, 2015).
223777070|NCT06935435|OTHER|Pink Beans|Pink beans consumed for 2 weeks, at an amount of ½ cup/day for week 1 and 1 ½ cups/day for week 2.
223777071|NCT06935435|OTHER|Great Northern Beans|Great northern beans consumed for 2 weeks, at an amount of ½ cup/day for week 1 and 1 ½ cups/day for week 2.
223691576|NCT03736694|BEHAVIORAL|Sleep hygiene education|SHE, is commonly provided verbally or through leaflets during consultations (Espie, 2009), and is also included as a part of CBTI (Morin, Savard, Ouellet, \& Daley, 2003).
223691577|NCT06145906|PROCEDURE|Pulmonary vein isolation plus superior vena cava isolation|Pulmonary vein isolation plus superior vena cava isolation
223777072|NCT06935435|OTHER|Five-Bean Mixture|Five-bean mixture made of pinto, kidney, black, pink, and great northern beans consumed for 2 weeks, at an amount of ½ cup/day for week 1 and 1 ½ cups/day for week 2.
223777073|NCT06938672|DEVICE|Placebo Transcranial Direct Current Stimulation (tDCS)|Placebo Transcranial direct current stimulation (tDCS): Participants will experience a 20-minute session of placebo tDCS on two consecutive days.
223777074|NCT06938672|DEVICE|Active Transcranial Direct Current Stimulation (tDCS)|Active transcranial direct current stimulation (tDCS). Participants will experience a 20-minute session of active tDCS (1.2 mA) on two consecutive days.
223777075|NCT06940219|PROCEDURE|Delayed Sequence Induction|Delayed Sequence Induction - fractional dosing of Ketamin and Midazolam until a dissociative status is achieved. Dosing should follow the clinical effect. - start of preoxygenation with Bag-Valve-Mask Device or NIV when dissociative status is achieved for at least 3 minutes. - after completion of preoxygenation: neuromuscular blockade with Rocuronium - after application of Rocuronium: Intubation via standard of care. - should apnoea occur during preoxygenation, the continuation of ventilation via Bag-Valve-Mask or NIV is recommended, but not mandatory.
223777076|NCT06940219|PROCEDURE|Modified Rapid Sequence Induction|Modified Rapid Sequence Induction - Preoxygenation FiO2 100% with Bag-Valve-Mask-Device or NIV for at least 3 Minutes. - After completion of Preoxygeniation: application of Midazolam, Ketamin and Rocuronium. - The dosing of medication is determined in advance by the operating physician. - Ventilation via Bag-Valve-Mask-device or NIV after application of rocuronium is allowed. - After application of medication: Intubation via standard of care.
223777077|NCT06947135|DRUG|Morphine|Morphine (10 mg, 10 ml) is injected around the stellate ganglion using ultrasound guidance prior to coronary artery recanalization
223691578|NCT06145906|PROCEDURE|PVI, superior vena cava isolation, and linear ablation of linear ablations of the mitral isthmus, roofline and posterior wall line of the left atrium, and cavotricuspid isthmus|PVI, superior vena cava isolation, and linear ablation of linear ablations of the mitral isthmus, roofline and posterior wall line of the left atrium, and cavotricuspid isthmus
223691579|NCT04453228|OTHER|Classification statistics|We classified skiers in the two snow seasons by injury site, type of injury, cause of injury, etc
223691580|NCT01417936|DRUG|Sym004|Sym004 will be administered at the dose of 12 milligram per kilogram (mg/kg) as an intravenous infusion every week up to disease progression or withdrawal from treatment.
223691581|NCT04102670|DEVICE|Ultherapy|Subjects will be treated with Ultherapy, which is a microfocused ultrasound, on the lower face, neck, and chest.
223777078|NCT06947135|DRUG|saline placebo|Saline (10 ml) is injected around the stellate ganglion using ultrasound guidance prior to coronary artery recanalization
223777079|NCT03657641|BIOLOGICAL|Pembrolizumab|Given IV
223777080|NCT03657641|DRUG|Regorafenib|Given PO
223777081|NCT04204421|OTHER|Experience Sampling Method (ESM)|Experience Sampling Method (ESM) is a method for real time complaints assessment where people are asked to fill out a questionnaire 10 times per day at random moments. This will be done via a mobile phone application.
223777082|NCT05582941|OTHER|No intervention will be performed.|No intervention will be performed.
223777083|NCT00217789|PROCEDURE|Bronchoalveolar Lavage and Venipuncture|
223777084|NCT03129347|DRUG|Nalmefene|Comparing pharmacokinetics of intranasal nalmefene to intramuscular nalmefene
223777085|NCT05265468|OTHER|Jones Group (Strain Counterstrain)|No pain positioning technique with diaphragmatic breathing
223691582|NCT04102670|DEVICE|Xeomin|Vertical neckbands, also known as platysma bands, will be injected with Xeomin to relax the bands.
223691583|NCT04102670|DEVICE|Belotero Balance|Horizontal necklace lines will be filled using Beletero Balance.
223691584|NCT04102670|DEVICE|Dilute Radiesse|The chest area will be injected with dilute Radiesse to stimulate collagen.
223691585|NCT04102670|OTHER|Neocutis Micro Firm Face and Neck Cream|Neocutis Micro Firm Face and Neck Cream will be provided to subjects for topical use at home.
223691586|NCT00956956|DRUG|PF-04455242|3, 6, and 23 mg capsules administered orally Q6 hours for 7 days of dosing.
223691587|NCT00956956|DRUG|Placebo|Placebo administered orally Q6 hours for 7 days of dosing.
223691588|NCT05688007|DIAGNOSTIC_TEST|parathyroid hormone level|Serum level of parathyroid hormone
223691589|NCT05688007|DIAGNOSTIC_TEST|serum electrolytes|Serum levels of: magnesium, phosphorus, calcium, and albumin
223691590|NCT03470948|OTHER|Observe postoperative complications|The aim of this study is to confirm the utility of a 10-point Surgical Apgar Score to rate surgical outcomes in Whipples procedure in patients with pancreatic cancer.
223691591|NCT05059795|DRUG|Albumin + electrolyte solution|Type of resuscitation fluid, dose and use of inotrope
223691592|NCT05059795|DIAGNOSTIC_TEST|POCUS guided fluid resuscitation|Conventional goal directed therapy
223691593|NCT04965493|DRUG|Pirtobrutinib|Oral
223691594|NCT04965493|DRUG|Venetoclax|Oral
223691595|NCT04965493|DRUG|Rituximab|Intravenous (IV)
223691596|NCT04505540|OTHER|Bridge Clinic|Specialized addiction bridge clinic
223691597|NCT05952492|BEHAVIORAL|Stress Management Skills Training|Participants will attend group sessions with a trained facilitator held over videoconference. Sessions will each last 2 hours and be held once weekly for 10 weeks. Sessions will include stress management skills training and health education content.
223691598|NCT05295550|OTHER|Realibility|measurement of the thoracic kyphosis with flexicurve and Smartphone inclinometer app
223691599|NCT06158620|DRUG|intra-nasal ketorolac|Experimental group receiving intra-nasal ketorolac for management of post-operative pain following ureteroscopy for kidney stone, and associated ureter stent discomfort.
223691600|NCT06158620|DRUG|oral diclofenac|Control group to receive oral diclofenac, which is a comparable medication to intra-nasal ketorolac.
223691601|NCT05449366|DRUG|Intraperitoneal Paclitaxel Solution (Ml)|Weekly cycles of intraperitoneal paclitaxel monotherapy
223691602|NCT06631170|DRUG|Roflumilast Cream 0.15%|Roflumilast cream 0.15% is applied once daily for 4 weeks
223691603|NCT06631170|DRUG|Vehicle cream|Vehicle cream is applied once daily for 4 weeks
223691604|NCT04941781|DRUG|PIPE-307|"Each dose cohort will receive a single oral dose of PIPE-307. Doses to be tested in subsequent cohorts will be determined by the analysis of the exposure from PK data and the PET scans with \[11C\] PIPE-307.~Subjects will receive an intravenous dose of the radioligand \[11C\] PIPE-307 prior to PET imaging."
223777086|NCT05265468|OTHER|Lewit Group|Isometric muscular exercise acompained with stretching technique
223777087|NCT05265468|OTHER|Chaitow Group|Isometric muscular exercise acompained with stretching technique and diaphragmatic breathing
223777088|NCT05265468|OTHER|Placebo Group|No pain positioning of participants
223777089|NCT01043874|DRUG|Nilotinib|400 mg BID
223777090|NCT02818738|DRUG|Levamisole Hydrochloride|Dosage : 5, 10, 25 et 50 mg. Dosage form : oral tablets, coated and non dividable for taste-masking Posology : 2.5 mg/kg on alternate days maximum 150mg. Treatment duration : 6 months
223777091|NCT02818738|OTHER|Placebo|matching verum
223777092|NCT03850119|PROCEDURE|Nanofat injection|Lipoaspirate, harvested during the surgery, is centrifuged for 1 minute at 2000 rpm to discard infiltration fluid. The residual fat is passed back and forth between two 10cc syringes interlocked with Tulip connecting pieces (2.4, 1.4 and 1.2 diameter, each 10 passes for a total of 30 passes). This is injected intradermally before the intradermal sutures are placed. The donor site is always entirely sutured (both sides) by the same person.
223777093|NCT04134663|DRUG|vasoconstrictor and oxytocin treatment|intransal administration of vasoconstrictor and oxytocin
223777094|NCT04134663|DRUG|vasoconstrictor's placebo and oxytocin treatment|intransal administration of vasoconstrictor's placebo and oxytocin
223777095|NCT04134663|DRUG|vasoconstrictor and oxytocin's placebo treatment|intransal administration of vasoconstrictor and oxytocin's placebo
223777096|NCT03422003|RADIATION|Radiation Therapy|"For the conventional fractionation arm: Each fraction will consist of 200 cGy per day. Total dose = 5000 cGy to the chest wall and 4600-5000 cGy to the lymph nodes.~For the hypofractionation arm: Each fraction consists of 266 cGy per day. Total dose = 4256 cGy to the chest wall and 3990 cGy to the lymph nodes."
223777097|NCT04382118|OTHER|Data collection from routine medical records|Data collection from routine medical records (clinical and radiological data)
223777098|NCT01032694|DRUG|Azithromycin SR|Azithromycin SR, 2.0 g PO x 1 dose for treatment period
223777099|NCT01032694|DRUG|Amoxiclav|Amoxiclav 1000 x twice daily, 10 days duration
223777100|NCT01515085|PROCEDURE|laser interstitial thermal therapy|residual gliomas either after debulking or biopsy evaluated for intervention with laser ablation prior to onset of adjuvant therapy
223777101|NCT03574129|BEHAVIORAL|Adolescent Transition Package|Clinic level intervention composed of an adolescent transition package with tools to support health care workers to disclose HIV status to adolescents and to track transition to adult care.
223777102|NCT06535269|PROCEDURE|Monopolar Hemorroidecotmy|Hemorrhoidectomy with monopolar diathermy
223777103|NCT06535269|PROCEDURE|Caiman Hemorroidectomy|Hemorrhoidectomy with Caiman® bipolar energy
223777104|NCT04890340|DIAGNOSTIC_TEST|ARNA Breast|Women of the required age group, in case of suspicion of breast cancer, are sent to clarify the diagnosis for mammography or ultrasound of the mammary glands, or MRI. Based on the results of these studies, a biopsy is prescribed to make a final diagnosis. Before a biopsy to diagnose the presence / absence of breast cancer, patients do the blood sampling one time. The blood is processed in the Sponsor's laboratory. The test results are compared with the data obtained from the biopsy. The evaluation of the effectiveness of the method will be determined on the basis of the obtained data on the sensitivity and specificity of the test in relation to the reference method
223777105|NCT04514315|PROCEDURE|Minimally invasive cardiac valvular surgery|Minimally invasive valve surgery via right mini-thoracotomy.
223777106|NCT04514315|PROCEDURE|Conventional cardiac valvular surgery|Conventional valve surgery via full median sternotomy
223777107|NCT00648232|BEHAVIORAL|Voluntary brief HIV counseling and testing|Participants will receive 10 to 15 minutes of pretest counseling on the importance of HIV testing and on available services for people infected with HIV. After pretest counseling, participants will undergo a blood draw for HIV testing. Participants will receive test results and additional counseling 1 hour after the blood sample is drawn.
223777108|NCT00648232|BEHAVIORAL|Voluntary longer, more detailed HIV counseling and testing|Participants will receive 45 to 60 minutes of pretest counseling on general HIV/AIDS information and testing for HIV. After pretest counseling, participants will undergo a blood draw for HIV testing. Participants will receive test results and additional counseling 1 hour after the blood sample is drawn.
223691605|NCT05082532|OTHER|Interwoven supera stent (IW; Supera Veritas®; Abbott Vascular, Santa Clara, CA, USA) .|we here conduct a prospective study to evaluate the efficacy and safety of self- expandable nitinol stent especially interwoven supera stent (IW; Supera Veritas®; Abbott Vascular, Santa Clara, CA, USA) in femoropoliteal complex occlusive lesions.
223691606|NCT00085228|BIOLOGICAL|oblimersen sodium|
223691607|NCT00085228|DRUG|docetaxel|
223691608|NCT04095156|DIAGNOSTIC_TEST|In vitro assays.|Biochemical and flow-cytometry analysis of specimen collected.
223691609|NCT02091219|DRUG|Vitamin D|2400 IU/day by mouth for 16 weeks
223691610|NCT02091219|DRUG|25(OH)D3|20 micrograms/day by mouth for 16 weeks
223691611|NCT02808871|DRUG|Pirfenidone|Pirfenidone three times daily (2403 mg) for 52 weeks
223691612|NCT02808871|DRUG|Placebo|Placebo three times daily for 52 weeks
223691613|NCT06340854|DRUG|Insulin icodec|Insulin Icodec will be administered subcutaneously.
223691614|NCT06340854|DRUG|Insulin glargine|Insulin glargine will be administered subcutaneously.
223691615|NCT05164718|BEHAVIORAL|Supervised home-based exercise|150-300 minutes of moderate intensity activity (55-75% of maximum heart rate in sinus rhythm or RPE 12-13 on the Borg Scale) or 75-150 minutes of vigorous intensity activity (75-90% of maximum heart rate or 14-16 on the Borg Scale) per week, or an equivalent combination of both, according to current general recommendations, including also those with established CVD. To maximize the potential for improvements in cardiorespiratory fitness, we encourage that at least 40-60 minutes per week (i.e. 2 sessions á 20-30 minutes) should be of vigorous intensity.
223691616|NCT05164718|OTHER|Usual care|Standard management according to usual practice at the respective participating centers, including medical therapy as per guidelines. Prior to randomization all will be provided an ICM (Confirm RX™). The UC group will receive information about general PA recommendations as per guidelines at study enrollment. No further supervision is given.
223691617|NCT05748470|OTHER|SkinCeuticals A.G.E|Ultrasound therapy combined with SkinCeuticals A.G.E + conventional moisturizing and sunscreen.
223691618|NCT05748470|OTHER|standard cream|Ultrasound therapy combined with standard cream + conventional moisturizing and sunscreen
223691619|NCT05323656|DRUG|Setanaxib|Oral tablets, 400 mg per tablet
223691620|NCT05323656|BIOLOGICAL|Pembrolizumab|200 mg IV infusion
223691621|NCT05323656|DRUG|Placebo|Oral tablets
223777109|NCT00648232|BEHAVIORAL|Enhanced linkage to care|Participants will be provided with more detailed counseling on how to access HIV services, will be introduced to a specific HIV clinic, and will be given a list of other HIV services available in the area. After leaving the hospital, participants will receive reminder telephone calls 1 week before their scheduled visits at the HIV clinics.
223691622|NCT05323006|OTHER|scapular stabilization exercises|the effect of the scapular stabilization exercise on the clavicular motion on the adolescent girls
223691623|NCT00877474|DRUG|PM01183|Vials containing 0.2 mg of PM01183 as powder for concentrate for solution for infusion
223691624|NCT03895021|BEHAVIORAL|Pisando Fuerte|"Pisando Fuerte, a linguistically and culturally appropriate version for Spanish speakers of an evidence-based fall prevention program (Stepping On \[SO\])."
223691625|NCT02546635|DRUG|AX-024.HCl|AX-024.HCl will be administered as per the protocol defined frequency and dose level
223691626|NCT02546635|DRUG|AX-024.HCl|AX-024.HCl will be administered as per the protocol defined frequency and dose level
223691627|NCT03953183|OTHER|P3P-1mg|P3P-1mg (P3P product containing 1mg of nicotine.)
223691628|NCT03953183|OTHER|P3P-2mg|P3P-2mg (P3P product containing 2mg of nicotine.)
223691629|NCT00006324|DRUG|Ethinyl estradiol/levonorgestrel|
223691630|NCT00006324|DRUG|Medroxyprogesterone acetate|
223691631|NCT03824171|DRUG|Raloxifene 60mg/Cholecalciferol 800IU|Raloxifene 60mg/Cholecalciferol 800IU tablet
223691632|NCT03824171|DRUG|AD-102|AD-102 Raloxefene 45mg/Cholecalciferol 800IU tablet
223691633|NCT04508140|PROCEDURE|Hepatic Biopsy|In this trial a biopsy from the hepatic lesion to be injected will be mandatory on C1D1 and C2D1, prior to the BO-112 administration. On the same timepoints, a biopsy from a non-hepatic, non-injected lesion will be optional.
223691634|NCT04508140|DRUG|BO-112 with pembrolizumab|BO-112 was administered in the liver metastasis at the dose of 1mg (1.2 mL) in combination with intravenous pembrolizumab given at the fixed dose of 200 mg, every 3 weeks for up to 35 cycles (2 years). During the first cycle, BO-112 was administered on D1 and D8.
223691635|NCT02232334|OTHER|Global Osteopathic Manual Treatment|subtle manipulations of the body according to the methodology of osteopathic manual therapy will be the intervention on subjects in the study. The global treatments will take into consideration the past medical history of each subject as well as what is found on assessment. Focus is on the position, mobililty and quality of each subjects anatomy.
223691636|NCT02658058|OTHER|Landmark technique|The site of needle insertion will be determined via manual palpation. A line joining the superior aspect of the iliac crests posteriorly (Tuffier's line') will be used as a surface landmark for the L4 vertebral body. The midline will be established by palpation of the tips of the spinous processes, and the site of needle insertion will be marked on the patient's skin. The interspace that appears widest, based on manual palpation, will be chosen for the first attempt. If the first attempt is unsuccessful, further attempts can be made at the same interspace or another interspace.
223777110|NCT00648232|BEHAVIORAL|Routine referral to care|Participants will be provided with information on the importance of receiving HIV care and will be given a list of available HIV area services.
223777111|NCT05674695|DRUG|Ciclosporin|Any systemic drug used for atopic dermatitis in clinical practice
223777112|NCT04181554|OTHER|Measurement of postural stability|The postural stability will assess by using Biodex balance system.
223777113|NCT05740462|BEHAVIORAL|Recipes consumption|Participants will eat two recipes a day for 17 weeks
223777114|NCT05740462|BEHAVIORAL|Hydroponic unit|Participants will grow vitamin B12 biofortified plants for 17 weeks and consume (10 grams) of plant material for 11 weeks.
223777115|NCT01443962|OTHER|PEEP|applying PEEP 0 cmH2O during pneumoperitoneum continuously
223777116|NCT01443962|OTHER|ZEEP|applying PEEP 10 cmH2O during pneumoperitoneum continuously
223777117|NCT05064969|BEHAVIORAL|Blended intervention based in acceptance and commitment therapy|"Blended intervention includes completing 9 e-modules consist of written material, videos, and assignments (one e-module per week) that can be completed over 9 to 12 weeks AND 9 (to 12 ) coaching sessions (telephone call). Weekly coaching will be offered by a motivational coach based in Maastricht University.~After the post-intervention assessments, individuals will receive monthly calls from the motivational coach as booster sessions. Booster sessions will be received on monthly basis for a period of 6 months (one session per month) and until the last follow-up assessment. Communication with participants will take place online or via telephone."
223777118|NCT01737112|DRUG|99mTc-3PRGD2|For patients in suspicion of lung cancer, single intravenous bolus injection of nearly 11.1 MBq/kg body weight of 99mTc-3PRGD2 on day one of the treatment period, whole-body planar and thoracic SPECT/CT to determine the accumulation of 99mTc-3PRGD2 in the tumors and the other parts of the body.
223777119|NCT01130766|PROCEDURE|stereotactic radiosurgery (SRS)|Stereotactic radiosurgery using γ-rays from radioactive Cobalt-60 installed in Gamma Knife (Elekta Instruments, Stockholm, Sweden)
223777120|NCT01390012|DRUG|Dexamethasone tablet 6 mg|Dexamethasone tablet 6 mg
223777121|NCT01390012|DRUG|Dexamethasone injection 4 mg|Dexamethasone injection 4 mg
223777122|NCT06395350|DEVICE|Spire Health Monitor|Use of Health Monitor is Assessed
223777123|NCT05168774|DRUG|Elamipretide|Elamipretide is a tetra peptide with limited blood brain barrier penetration being developed for use in a variety of mitochondrial disorders, including FRDA, mitochondrial myopathy and Barth Syndrome.
223777124|NCT00966940|DRUG|Travoprost 0.004% ophthalmic solution (TRAVATAN)|One drop in the qualifying eye(s) each evening at 6:00 PM for 6 weeks, topical administration
223777125|NCT00966940|DRUG|Tafluprost 0.0015% ophthalmic solution|One drop in the qualifying eye(s) each evening at 6:00 PM for 6 weeks, topical administration
223777126|NCT06191926|DIAGNOSTIC_TEST|ultrasound|Shear-wave elastography and shear-wave dispersion ultrasound to evaluate the diagnostic performance of solid breast lesions for the diagnosis of breast cancer
223777127|NCT03719872|DIAGNOSTIC_TEST|Pre-Operative Transabdominal Ultrasound|Pre-Operative Transabdominal Ultrasound evaluation of the right upper quadrant of the abdomen. Examination with be performed with low frequency curvilinear transducer and high frequency linear transducer at 5 standardized locations along the right costal margin followed by a 10 second sweep along the costal margin from the xyphoid process to the mid-axillary line
223777128|NCT03719872|DIAGNOSTIC_TEST|Post-Operative Transabdominal Ultrasound|Post-Operative Transabdominal Ultrasound evaluation of the right upper quadrant of the abdomen. Examination with be performed with low frequency curvilinear transducer and high frequency linear transducer at 5 standardized locations along the right costal margin followed by a 10 second sweep along the costal margin from the xyphoid process to the mid-axillary line
223777129|NCT04536636|DRUG|Docohexanoic acid|Patients received 650 mg DHA/3 times/wk/post-HD session
223777130|NCT04536636|DRUG|Control-No drug|Patients received usual medical care with no DHA
223777131|NCT03151265|DEVICE|ThermaCare Low Back Heat Wrap|The ThermaCare Low Back Heat Wrap, is a continuous, low-level, direct heat therapy. It comes in the form of a heat-pack that is strapped to the low back. Heat is provided for approximately 8-hours.
223777132|NCT02833740|DEVICE|Click-MUAC prototype & regular MUAC tape|Screening of children using Click-MUAC and regular MUAC tape
223777133|NCT05625906|OTHER|Multi-media experiential training programme|"1. Webpage and mobile applications of training material on ACP, to be offered four weeks before the workshop~2. A three-hour multimedia workshop (8-10 nurses per group) including enhanced lectures and a role play encounter with standardised patients. Immediate feedback on their quality of decision support skills will be given. The workshops will be delivered by an experienced advance practice nurse with a palliative care specialty.~3. Writing a reflective journal after the role play with standardised patients"
223777134|NCT00004867|PROCEDURE|conventional surgery|
223777135|NCT00004867|PROCEDURE|positron emission tomography|
223777136|NCT00004867|PROCEDURE|radionuclide imaging|
223777137|NCT00004867|RADIATION|fludeoxyglucose F 18|
223777138|NCT00004867|DRUG|chemotherapy|
223777139|NCT00004867|RADIATION|Radiotherapy|
223777140|NCT02451748|OTHER|Lab Work|Lab work to measure IL-7 and IL-7R
223777141|NCT02451748|DRUG|Certolizumab pegol (CDP870, tradename Cimzia)(prefilled syringes at the dose of 200mg)|"Certolizumab pegol (CDP870, tradename Cimzia) or is provided in prefilled syringes at the dose of 200mg.~Patients received 2x200mg at weeks 0, 2 and 4. Additionally a maintenance dose of 200mg is given every 2 weeks. Treatment is performed through subcutaneous injection."
223777142|NCT02451748|DRUG|Certolizumab pegol (CDP870, tradename Cimzia)|"rtolizumab pegol (CDP870, tradename Cimzia) or is provided in prefilled syringes at the dose of 200mg.~Patients received 2x200mg at weeks 0, 2 and 4. Additionally a maintenance dose of 200mg is given every 2 weeks. Treatment is performed through subcutaneous injection."
223777143|NCT02451748|DRUG|Hydroxychloroquine|some patients are on 400mg/day of hydroxychloroquine.
223777144|NCT02451748|DRUG|Sulfasalazine|some patients are on 300 mg/day and some patients are on 1000 mg/day dose of sulfasalazine
223777145|NCT02451748|DRUG|Medrol|some patients are on 8mg/day of medrol
223777146|NCT02451748|DRUG|Prednisone|some patients are on 10mg /day, some patients are on 20 mg/day, some patients are on 2.5 mg/day, some patients are on 30 mg/day, and some patients are on 5 mg/day of prednisone
223777147|NCT02451748|DRUG|Triamcinolone|some patients are on Triamcinolone 40-80mg IM monthly (received 40mg dose 1 week before blood draw, off enbrel 50mg weekly and SSZ 1000mg bid for \~ 3 months) some patients are on Triamcinolone 40mg IM monthly
223777148|NCT02451748|DRUG|Naproxen|some patients are on 1000 mg/day of naproxen
223777149|NCT02451748|DRUG|Leflunomide|some patients are on 20mg/day of leflunomide
223777150|NCT02451748|DRUG|Methotrexate|some patients are on 20mg weekly, some patients are on 25mg weekly, some patients are on 17.5 mg, some patients are on 15 mg weekly, some patients are on 7.5 mg weekly, and some patients are on 15 mg weekly dose of methotrexate
223777151|NCT02451748|DRUG|humira|some patients are on Humira 40mg q2weeks
223777152|NCT06459609|DIETARY_SUPPLEMENT|protein supplementation|Protein supplementation takes the form of a powder sachet mixed with yoghurt or compote. It will be given twice a day, at the same time.
223777153|NCT00258986|PROCEDURE|Living donornephrectomy|
223777154|NCT01696630|DRUG|Xenon|
223777155|NCT01696630|DRUG|Desflurane|
223777156|NCT00173667|DRUG|Nifedipine 30 mg GITS|
223777157|NCT04877912|DIAGNOSTIC_TEST|MRI Abbreviated Scan|"All subjects will be receiving an MRI scan, up to 15 minutes long that includes an injection of contrast agent. This contrast agent will be injected into the arm and will help the doctors to read the MRI more effectively. If there is a lesion (abnormality) in the breast, the contrast agent will go to the lesion first and we will be able to see it better.~The examination table will then move subject into the magnet, which is a long tube with a diameter of about 3 feet. Subject will be asked to lie in the magnet for about 15 minutes. During the periods when we are taking pictures, we will ask subject to be as still as possible."
223777158|NCT04877912|DIAGNOSTIC_TEST|Abbreviated MRI Scan|"All subjects will be receiving an MRI scan, up to 15 minutes long that includes an injection of contrast agent. This contrast agent will be injected into the arm and will help the doctors to read the MRI more effectively. If there is a lesion (abnormality) in the breast, the contrast agent will go to the lesion first and we will be able to see it better.~The examination table will then move subject into the magnet, which is a long tube with a diameter of about 3 feet. Subject will be asked to lie in the magnet for about 15 minutes. During the periods when we are taking pictures, we will ask subject to be as still as possible."
223777159|NCT05838222|BEHAVIORAL|Solution Focused Intervention|A short term, goal focused, therapeutic approach which helps patients address problems contributing to health and mental health challenges
223777160|NCT05838222|OTHER|Treatment as Usual|The patient receives standardized care from primary care team without the SFBT intervention
223777161|NCT00750945|OTHER|Music and treadmill walking program|Treadmill with Music cueing training 3 days/wk, plus home music cueing 3 days/wk x 4 weeks
223777162|NCT00750945|OTHER|Treadmill walking program|Treadmill training 3 days/wk, plus home walking 3 days/wk x 4 weeks
223777163|NCT00750945|OTHER|Home program|Home walking program 6 days/wk x 4 weeks
223777164|NCT05600608|DIETARY_SUPPLEMENT|Oral Stimulant Drink|please see description of the drink in the arm/ group section
223777165|NCT02696850|DRUG|Budesonide|Participants will undergo 4-week treatment course that includes budesonide powder added to saline rinse.
223777166|NCT02696850|DRUG|Saline alone|Participants will undergo 4-week treatment course that includes lactose (placebo) powder added to saline rinse.
223777167|NCT05266911|BEHAVIORAL|high-intensity functional strength training|HIFST is an exercise program using an interval format: alternating periods of high intensity/'hard' exercise using everyday lower-extremity based strength-building movements (e.g., sit to stand) with periods of light/'easy' activity. High-intensity is individualized based on the use of a rating of perceived exertion (RPE) scale. The program includes a warm-up and cool-down and will be completed in participant's homes 3 days per week.
223777168|NCT05266911|BEHAVIORAL|Lower extremity stretching|Lower extremity stretching program to be completed by participants at home 3 days per week.
223777169|NCT06532695|OTHER|No intervention will be provided.|no intervention will be provided.
223777170|NCT01175824|DRUG|Insulin Lispro Low Mixture (LM)|Participant-dependent dose, administered subcutaneously for 24 weeks
223777171|NCT01175824|DRUG|Insulin Glargine|Participant-dependent dose, administered subcutaneously for 24 weeks
223777172|NCT01175824|DRUG|Prandial Insulin Lispro|Participant-dependent dose, administered subcutaneously for 24 weeks
223777173|NCT03455855|DEVICE|Jetstream System|including Atherectomy Console (Jetstream Console) and Atherectomy Catheter(Jetstream Catheter), intended for use in atherectomy of the peripheral vasculature and to break apart and remove atherosclerotic disease, debris, and thrombus from the SFA and/or PPA.
223777174|NCT04749264|BEHAVIORAL|Mindfulness meditation retreat|6 to 7-days mindfulness retreat (Vipassana/insight meditation). The retreats are held in silence and led by senior teachers with many years of experience in teaching meditation. The focus of the retreat is the practice of mindfulness meditation while sitting and walking. Retreats include focused attention and open monitoring mindfulness meditation practices. Each retreat has a similar practice schedule thus the amount and nature of formal practice is mostly the same.
223691637|NCT02658058|OTHER|Ultrasound-guided paramedian technique|The transducer will be applied in the parasagittal plane and the intervertebral levels will be identified by counting upwards from the sacrum (continuous hyperechoic line). The probe will then be angled obliquely to obtain a PSO view. The locations of the interlaminar spaces will be identified by visualizing the ligamentum flavum-dura mater complex and the posterior aspect of the vertebral body. The angulation at which the ligamentum flavum-dura mater complex and posterior vertebral body are best visualized will be considered the optimal angle for needle insertion and clearly communicated to the operator. The interlaminar space will be centered on the ultrasound screen and a skin marker will be used to make a mark on the patient's back at the middle of the ultrasound probe.
223691638|NCT02658058|OTHER|Ultrasound-guided midline technique|The transducer will be applied in the parasagittal plane, and after identification of the intervertebral levels, the probe will be rotated 90 degree to obtain the TM view. The transducer is moved in a cephalad-caudad direction between the spinous processes of L2 and L5 vertebra. The probe will be tilted slightly up and down to ensure a sufficient echogenic window at the selected intervertebral space. A skin marker will be used to make a mark on the patient's back at the middle of the ultrasound probe. The angle at which the ligamentum flavum-dura mater complex and the posterior aspect of the vertebral body are best visualized will be noted
223691639|NCT01100736|DRUG|Bosentan|Bosentan 125mg tablets, orally, twice daily for 7 days
223691640|NCT01100736|DRUG|Sitaxsentan|Sitaxsentan 100mg tablets, orally, once daily for 7 days
223691641|NCT01100736|DRUG|Placebo|Placebo tablets taken twice daily, orally, for 7 days (placebo arm) or once daily for 7 days (sitaxsentan arm)
223691642|NCT01100736|BIOLOGICAL|Endothelin-3|5 minute local intra-arterial infusion of endothelin-3 at a rate of rate of 60 pmol/min, during forearm blood flow studies
223777175|NCT04858737|BEHAVIORAL|e-predictD-Work intervention|The intervention is based on validated risk algorithms to predict depression and includes: 1) Mobile applications as main user's interface; 2) a DSS that helps worker participants to develop their own personalized plans to prevent (PPP) depression; 3) nine intervention modules (the core of the system) including activities to prevent depression, to be proposed by the DSS and chosen by the participants. The intervention is biopsychosocial and multi-component, including the following modules: physical exercise, improve sleep, expand relationships, solve problems, improve communication, assertiveness, decision making, manage thoughts and reduce work stress. Worker participants will implement the recommendations and the tool will monitor these actions, offering feedback to improve their PPP at 6 and 12 months.
223777176|NCT04858737|OTHER|Brief psychoeducational messages|The intervention consists of an App that weekly send short messages about stress and general health that will be extracted from brochures and websites of official agencies.
223691643|NCT04568824|OTHER|GraphoLearn reading intervention|This is an Edtech reading intervention
223691644|NCT04568824|OTHER|Vektor math control intervention|This is an Edtech math/cognition intervention
223777177|NCT02009618|DRUG|Rifaximin|Rifaximin tablet is given as 200 mg 3x2/daily, for 10 days.
223777178|NCT02009618|DRUG|placebo|
223777179|NCT03111225|DIAGNOSTIC_TEST|massage|a 15 minutes thoracic massage will be added to the regular physical therapy treatment
223777180|NCT02761564|OTHER|Red blood cell tranfusion|Red blood cell transfusion according to transfusion guidelines.
223691645|NCT03985384|DRUG|Semaglutide 2 MG/1.5 ML Subcutaneous Solution|Semaglutide 2 MG/1.5 ML Subcutaneous Solution
223691646|NCT03985384|DRUG|Placebo|Placebo 1.5 ml, pen-injector for SC injection.
223691647|NCT00880373|DRUG|Ibuprofen|Oral ibuprofen 800 mg three times daily for a total of 2400 mg per day for 4 days
223691648|NCT00880373|DRUG|Placebo|Matching placebo three times daily for 4 days
223691649|NCT00880373|DRUG|Diamorphine or Morphine|Diamorphine or Morphine by PCA
223691650|NCT01905410|DRUG|VVZ-149 Injection|VVZ-149 in water for injection
223691651|NCT01905410|DRUG|placebo|water for injection
223691652|NCT00068783|DRUG|imatinib mesylate|Given orally
223777181|NCT02761564|OTHER|ScvO2 measure|ScvO2 (oximetry) is measured at the distal lumen of the central venous catheter placed in the superior vena cava. Transfusion is performed if ScvO2 is inferior or equal to 65%.
223835703|NCT01227408|DRUG|doxorubicin, paclitaxel poliglumex, capecitabine, cyclophosphamide, methotrexate|doxorubicin 20mg/m2 weekly x 12 wks, cyclophosphamide 50 mg PO qd x 12 wks, methotrexate 2.5 mg PO bid d1,2 wkly x 12. One week later paclitaxel poliglumex 135mg/m2 IV every 3 wks plus capecitabine 825 mg/m2 PO bid x 14days x 4 cycles
223691653|NCT00068783|OTHER|laboratory biomarker analysis|Correlative studies
223691654|NCT06548165|DEVICE|Wearable|Participants will wear an electrode on the chest for the measurement of the heart rate variability, a sensor for temperature measurement, and a sensor for continuous blood glucose measurement. Food intake will be recorded via pictures. One mixed meal tolerance test will be performed as a reference for further analyses. Females have the option to use a device for intravaginal temperature measurement.
223691655|NCT01913132|DEVICE|Negative pressure wound therapy with PICO (Smith & Nephew)|Negative wound pressure therapy
223691656|NCT05661357|DRUG|Disitamab Vedotin Combined With Fruquintinib|Furquinotinib: 3mg, Qd, 28 days as a cycle. Vidicizumab: according to the instructions of Vidicizumab, d1, 2.5 mg/kg, intravenous drip (ivgtt)
223691657|NCT04150380|BIOLOGICAL|Lactobacillus rhamnosus GG (LGG; ATCC strain 53103; CRMTS #11272; PTS #3766)|See arm descriptions
223691658|NCT04150380|OTHER|Placebo|See arm descriptions
223691659|NCT05146154|DRUG|Imipenem/Cilastatin/Relebactam 1.25g|Imipenem/cilastatin/relebactam is a combination beta-lactam/beta-lactamase inhibitor antimicrobial marketed under the brand name Recarbrio and the approved dose is 1.25g Q6h in patients with normal renal function. The individual components of this agent must be administered together and cannot be separated. Therefore, this constitutes only one intervention. Each subject will receive at least 2 doses of study drug.
223691660|NCT01763242|OTHER|EMAN|See details on ESA Synchronization and Dosing in Detailed Description Above
223691661|NCT01298193|DRUG|Aprepitant|Efficacy phase (second cycle)
223691662|NCT00000977|BIOLOGICAL|gp160 Vaccine (MicroGeneSys)|
223691663|NCT02607839|BIOLOGICAL|glucose or normal saline|20% glucose solution or normal saline, intravenous infusion
223691664|NCT03445182|PROCEDURE|Local anaesthesia with conventional syringe|"Buccal infiltration in posterior maxillary region with traditional technique. A 27 gauge short needle is inserted in the mucobuccal fold above the tooth to be anesthetized.~Local anaesthetic infiltration speed 1ml/min. Drug: Local anaesthetic - Ubistesin - 4% Articaine with adrenaline 1: 200 000 1.7 mL"
223691665|NCT03445182|DEVICE|Local anaesthesia with conventional syringe + Dentalvibe|"Buccal infiltration in posterior maxillary region. The tip of the DentalVibe device is placed in the mucobuccal fold above the tooth to be anesthetized. The device is activated for 5 s. A 27 gauge short needle is inserted as close as possible to the inner side of the prong while the vibration is still on.~Local anaesthetic infiltration speed 1ml/min. After injection the needle is withdrawn and vibration continues for another 5 s.~Drug: Local anaesthetic - Ubistesin - 4% Articaine with adrenaline 1: 200 000 1.7 mL"
223691666|NCT03064581|BEHAVIORAL|Intervention|The educational session consisted of a one-hour small group discussion (5-10 people). Gender-specific community health educators facilitated sessions for Pacific Islander women and for their spouses/significant others that included an educational video and other materials (brochure, calendar, and resource list). The video emphasized the importance of Pap testing for Pacific Islander women, and showed men supporting their women to get tested. Women's sessions provided basic information on cervical cancer and pap testing, and ended with verbal commitments and target screening dates by women to get screened. The men's education sessions contained similar information, with supplemental information on how to provide support for their wives to get tested and exercises on showing their support.
223691667|NCT02925325|BEHAVIORAL|Music therapy|Music therapy (MT) treatment focuses on the use of 2 techniques of intervention: receptive MT and active MT. The work of receptive application is described as the use of prerecorded music or executed by the music therapist with effect on the patient, without the latter's active involvement in the psychotherapeutic process of musical creation. While the active application, both the music therapist and patient are involved in musical creation, for example, the use of voice, body and musical instruments (Muñoz, 2008). Contemplate their psychotherapeutic possibilities in 3 different dimensions of patient: body, emotional and social work, as explained above. Treatment with MT, as in cognitive behavioral therapy, includes breathing exercises, stress-relaxation techniques, psychoeducation, and exercises for the management of irrational thoughts and erratic behavior patterns (Dobson and Dozois, 2010).
223691668|NCT02925325|OTHER|Usual Treatment|It is the usual medical treatment that patients with major depressive disorder in remission but with residual symptom receives at the sponsor institution in a monthly basis.
223691669|NCT03624296|DEVICE|MRI 7T|MRI 7T
223691670|NCT03624296|OTHER|TEST EDSS|EDSS - Expanded Disability Status Scale
223691671|NCT03624296|OTHER|TEST MSFC|MSFC - Multiple Sclerosis Functional Composite
223691672|NCT04010539|DRUG|Gepotidacin|Gepotidacin will be administered as 3000 milligram (mg) oral dose (4 X 750 mg tablets) at the study site followed by 3000 mg oral dose (4 X 750 mg tablets) as an outpatient. Each dose should be taken after food consumption and with water.
223691673|NCT04010539|DRUG|Ceftriaxone|Ceftriaxone is available as sterile powder for reconstitution. It will be administered as one 500-mg IM dose at the study site.
223691674|NCT04010539|DRUG|Azithromycin|Azithromycin will be administered as 1000 mg oral dose (2 X 500 mg tablets) at the study site. Dose should be taken after food consumption and with water.
223691675|NCT03987776|BEHAVIORAL|Anti-inflammatory energy-restricted diet|During 6 months the participants will we asked to use recommended energy-reduced diet with anti-inflammatory properties, based on colorful vegetables and fruits, legumes, nuts, seeds, marine fish, whole-grain products, and daily use of olive oil, green/black tea, multiple spices and herbs.
223691676|NCT03987776|BEHAVIORAL|Control energy-restricted diet|During 6 months the participants of control group will be asked to use recommended energy-reduced diet based on standard obesity management (55-60% carbohydrates, 25% fat, 15-20% protein)
223691677|NCT00249288|DRUG|Folate|Folic acid taken as 2, 1mg capsule daily for 12 weeks
223691678|NCT00249288|DRUG|Placebo|Placebo taken as 2, 1mg capsule daily for 12 weeks
223691679|NCT01558193|DIETARY_SUPPLEMENT|Placebo|"Placebo for DHA of identical appearance - based on olive oil~Placebo for vitamins/minerals of identical appearance"
223691680|NCT01558193|DIETARY_SUPPLEMENT|Multi-vitamin/mineral|Each active tablet contained vitamins A (800µg); B1 (1.4mg); B2 (1.75mg); B6 (2mg); B12 (2.5mg); biotin 62.5 µg; folic acid 200 µg; niacin 20 mg; C (100mg); D (5µg); E (15mg); K (30µg); pantothenic acid (7.5 mg). In addition several minerals were administered: calcium (162mg); phosphorus (125mg); magnesium (100mg); potassium (40mg); chloride (36.3mg); iron (5mg); iodine (100µg); copper (500µg); manganese (2mg); chromium (40µg); molybdenum (50µg); selenium (30µg); zinc (5mg) as well as lutein (500 µg) . The placebo capsule was identical in color, size and appearance.
223691681|NCT01558193|DIETARY_SUPPLEMENT|Docosahexaenoic acid|22:6 (n-3) docosahexaenoic each capsule contained 224.2mg and three were taken per day
223691682|NCT01558193|DIETARY_SUPPLEMENT|DHA plus vitamins/minerals|The DHA and vitamin/mineral supplements are as above
223691683|NCT03059446|DRUG|Cenicriviroc|Cenicriviroc immediate release tablets
223691684|NCT05942105|PROCEDURE|Breast conservative surgery|Breast conservative surgery after non-palpable lesion localization
223691685|NCT02524210|DRUG|Dabigatran|dabigatran etexilate 150 mg/day (1 day)
223691686|NCT02524210|DRUG|Rabeprazole and Dabigatran|rabeprazole 20 mg / day for 5 days, then the 6th day concomitant rabeprazole 20 mg of dabigatran etexilate 150 mg;
223691687|NCT02524210|DRUG|Omeprazole and Dabigatran|omeprazole 20 mg / day for 5 days, then the sixth day concomitant omeprazole 20 mg and 150 mg dabigatran etexilate
223691688|NCT04737057|PROCEDURE|SDF|Apply this topical medication through : 1)Dry with a gentle flow of compressed air to decayed tooth surfaces. 2) Bend micro sponge brush to remove excess liquid before application apply SDF directly to only the affected tooth surface. 3) Apply the SDF material 4)Dry with a gentle flow of compressed air for at least one minute. and Remove excess SDF with gauze
223691689|NCT04737057|PROCEDURE|Hall technique|this technique is performed through :1) Orthodontic separator being stretched between two pieces of floss, then placed between the contact points of primary molars (for five days.) 2)The correct size of crown will not impinge on the teeth on either side, and a slight 'spring back' will be felt when the PMC is gently pushed up to (but not through) the contact points and the PMC has been filled with a Riva self-cure capsule cement, extruded cement is quickly wiped away and the child is asked to keep biting on the crown for two minutes, until the cement is set, to prevent 'spring back' of the PMC from the fully seated position
223691690|NCT04795622|DEVICE|Ultherapy treatment|Focused ultrasound energy delivered below the surface of the skin
223691691|NCT04795622|DEVICE|Untreated-control / delayed-treatment|Untreated-control, followed by Ultherapy treatment (focused ultrasound energy delivered below the surface of the skin)
223691692|NCT01155505|DRUG|Lenalidomide (CC-5013)|CC-5013 given PO daily on D1-D14 every 21 days and Paclitaxel administered IV over 1 hour on d1 and 8 every 21 days until tumor progression or unacceptable toxicity
223691693|NCT02195284|DEVICE|ELLIPTA|Dry powder inhaler (placebo) with two blister strips. One placebo strip containing lactose monohydrate and a second placebo strip containing lactose monohydrate blended with magnesium stearate
223691694|NCT02195284|DEVICE|DISKUS/ACCUHALER|Placebo inhaler with one blister strip containing lactose monohydrate.
223691695|NCT02195284|DEVICE|MDI|Placebo inhaler containing propellant (1,1,1, 2-Tetrafluoroethane)
223691696|NCT02195284|DEVICE|TURBUHALER|Placebo inhaler containing lactose monohydrate.
223691697|NCT03295526|PROCEDURE|Lymph nodes debulking surgery.|Radical hysterectomy and selective enlarged lymph node dissection
223691698|NCT05779735|DIAGNOSTIC_TEST|Transperineal ultrasound measurements of AOP|The angle of progression (AOP) defined as the angle between the pubic bone axis and the leading part of the fetal head
223691699|NCT00996723|DRUG|vandetanib and dasatinib|Two oral investigational agents (vandetanib \[VEGFR2, RET, and EGFR inhibitor\] and dasatinib \[bcr-abl, PDGFRA and B, src, lck, yes, and c-kit inhibitor\] will be administered during and after local RT, which is the only standard therapy for children with DIPG.
223691700|NCT04450459|DIAGNOSTIC_TEST|ergospirometer test|ergospirometric test will be done before cardiac catheterisation and invasive measurement of FFR
223691701|NCT00882492|BIOLOGICAL|GLP 1|This a continuous intravenous infusion of GLP-1 (7-36) amide infusion (1.5 pmol/kg/min)
223691702|NCT00882492|BIOLOGICAL|normal saline solution placebo|This is a continuous intravenous infusion of normal saline solution as placebo (1.5 pmol/kg/min) during cardiac surgery
223691703|NCT02347696|BEHAVIORAL|Control|Subjects will follow a diet based on INRAN guidelines without doing any physical activity.
223691704|NCT02347696|BEHAVIORAL|LGIMD|Subjects will follow a Low Glycemic Index Mediterranean Diet (LGIMD) without doing any physical activity.
223691705|NCT02347696|BEHAVIORAL|Endurance Activity (EA)|"Subject will follow a program of endurance activity as follows:~Frequency: 3 times/week Duration: 60 minutes~Intensity:~* weeks 1-4: 14.2 kcal\*kg-1\*week-1;~* weeks 5-8: 18.9 kcal\*kg-1\*week-1;~* weeks 9-12: 23.6 kcal\*kg-1\*week-1."
223691706|NCT02347696|BEHAVIORAL|EA+Resistance Training (RT)|"Subject will follow a program of endurance activity as follows:~Frequency: 3 times/week Duration: 60 minutes~Intensity (for Endurance activity):~* weeks 1-4: 14.2 kcal\*kg-1\*week-1;~* weeks 5-8: 18.9 kcal\*kg-1\*week-1;~* weeks 9-12: 23.6 kcal\*kg-1\*week-1.~Resistance activity:~Muscolation: Training of the bigger muscle groups (chest, shoulders, arms, abdomen, back, glutes and legs);~* Progression: increase of 1-2.5 kg\*week-1~* Training of all muscle groups in the same session"
223777182|NCT01579123|PROCEDURE|Angioplasty|With angioplasty, a catheter is guided to the portion of the artery that is narrowed or blocked off. A balloon that is attached to the end of the catheter will be inflated which dilates or expands the artery in the area where the narrowing or blockage is located. Based on the angiogram and extent of disease, the physician may place a stent (small mesh tube that is used to treat narrow or weak arteries in the body) during the angioplasty.
223777183|NCT01579123|PROCEDURE|Laser atherectomy|Laser atherectomy uses a catheter that emits high energy light (laser) to unblock the artery. The catheter is moved through the artery until it reaches the blockage. Laser energy is used to essentially vaporize the blockage inside the vessel.
223777184|NCT03574792|DRUG|Gabapentin|Given PO
223777185|NCT03574792|DRUG|Methadone|Given PO
223777186|NCT03574792|DRUG|Oxycodone|Given PO
223777187|NCT03574792|OTHER|Quality-of-Life Assessment|Ancillary studies
223777188|NCT03574792|OTHER|Questionnaire Administration|Ancillary studies
223777189|NCT03574792|DRUG|Venlafaxine|Given PO
223777190|NCT03574792|DRUG|Venlafaxine Hydrochloride Extended Release|Given PO
223777191|NCT06077396|PROCEDURE|radial artery cannulation|radial artery cannulation
223777192|NCT06388577|OTHER|Education|Participants in the intervention group (n = 36) will be administered the Epilepsy Education Programme based on Pender's Health Promotion Model by the researcher and will be given the education booklet developed by the researcher in line with the literature. The training topics of the intervention programme are: General information about epilepsy, seizure moment management, management of antiepileptic drug treatments, controlling the factors that may trigger seizures, and recommendations to parents about health promoting and protective behaviours. In the training, learning and teaching techniques such as presentation, video demonstration, question and answer sections, lecture and discussion will be applied. The training will last approximately one hour.
223777193|NCT01868581|DRUG|insulin degludec|Each subject will be allocated to 2 single injections of trial product on 2 separate dosing visits, administered subcutaneously (s.c., under the skin).
223777194|NCT01868581|DRUG|insulin degludec/insulin aspart|Each subject will be allocated to 2 single injections of trial product on 2 separate dosing visits, administered subcutaneously (s.c., under the skin).
223777195|NCT06182865|DRUG|Ga-68 Dolacga Injection|Ga-68 Dolacga will be administered via iv bolus injection followed by a whole-body PET/CT scan for liver reserve evaluation.
223691707|NCT02347696|BEHAVIORAL|LGIMD+EA|Subjects will follow a Low Glycemic Index Mediterranean Diet together with a program of endurance activity.
223777196|NCT05772793|DEVICE|Telerehabilitation|The home visual telerehabilitation path using the EyeFitness software consisted of performing one visual training session per day, 5 days a week (from Monday to Friday) for a total of 6 weeks.
223777197|NCT01519713|BIOLOGICAL|Meningococcal polysaccharide diphtheria toxoid conjugate|0.5 mL, Intramuscular
223777198|NCT03152747|DEVICE|ultrasound, b-scan|Some selected centres will participate in a substudy. In the substudy population, if the vitreous cortex is not visible on OCT both in the study eye and the fellow eye, or if the OCT is of poor quality and most likely will not allow definite diagnosis, a B-scan ophthalmic ultrasound will be performed by an experienced examiner. The presence or absence of a PVD in the ultrasound measurement will be recorded in the case report form (CRF). If ultrasonography was not performed, allocation to the groups is based on the staging of the reading centre. Otherwise ultrasonography will be used for final diagnosis and group allocation if the reading centre classifies the OCT as not decisive.
223777199|NCT01348451|DEVICE|surgical implantation|human spinal cord stem cell implantation in ALS patients
223777200|NCT01813799|DRUG|DA-9801 300mg|300mg of DA-9801 tablet is assigned at week 0 point and is taken for 8 continuous weeks, 3 times a day.
223777201|NCT01813799|DRUG|DA-9801 600mg|600mg of DA-9801 tablet is assigned at week 0 point and is taken for 8 continuous weeks, 3 times a day.
223777202|NCT01813799|DRUG|DA-9801 900mg|900mg of DA-9801 tablet is assigned at week 0 point and is taken for 8 continuous weeks, 3 times a day.
223691708|NCT02347696|BEHAVIORAL|LGIMD+EA/RT|Subjects will follow a Low Glycemic Index Mediterranean Diet together with a program of both endurance activity and resistance training.
223691709|NCT01440790|DIETARY_SUPPLEMENT|glucose bolus|50g anhydrous glucose dissolved in 300ml water consumed within 10min followed by a lunch (cheese sandwich, fruit and milk) at 4h.
223691710|NCT01440790|DIETARY_SUPPLEMENT|Glucose sipping|50g anhydrous glucose dissolved in 300ml water consumed at rate of 25ml per 15min followed by a lunch (cheese sandwich, fruit and milk) at 4h.
223777203|NCT01813799|DRUG|Placebo|Placebo is assigned at week 0 point and is taken for 8 continuous weeks, 3 times a day.
223777204|NCT00121771|BIOLOGICAL|FP9 CS|
223777205|NCT00121771|BIOLOGICAL|MVA CS|
223777206|NCT04820673|DRUG|Sarecycline|Clinicians will prescribe the sarecycline as per their own clinical judgment and standard practice.
223777207|NCT05975541|OTHER|Observational|No intervention will be carried out in this study. Patients from both groups will be monitored for 12 months through observations at time 0, time 6 months, and 12 months. Questionnaires, good clinical practice samples, and anthropometric measurements will be made to monitor changes in the two groups.
223777208|NCT01179594|DRUG|entecavir|0.5 mg orally daily, 24 weeks (weeks 12-36)
223777209|NCT01179594|DRUG|peginterferon alfa-2a [Pegasys]|180 mcg sc weekly, 48 weeks
223777210|NCT01179594|DRUG|peginterferon alfa-2a [Pegasys]|180 mcg sc weekly, 96 weeks
223777211|NCT01179594|DRUG|placebo|orally daily, 24 weeks (weeks 12-36)
223777212|NCT01042964|DRUG|revacept (PR-15)|single intravenous administration of revacept (PR-15), an inhibitor of platelet adhesion, in various strengths (10, 20, 40, 80, 160 mg) in healthy male volunteers.
223777213|NCT02123407|DRUG|Carbon Nanoparticles|Carbon Nanoparticles will be injected into the subserosa of stomach around the tumor.Gastrectomy with D2 dissection will be performed after the injection.
223777214|NCT02123407|PROCEDURE|Gastrectomy with D2 dissection|In the control arm,Gastrectomy with D2 dissection will be performed directly,without any coloring materials.
223777215|NCT00453765|DRUG|montelukast|montelukast, 8 weeks, once daily, 10 milligrams
223777216|NCT00453765|DRUG|placebo|placebo
223777217|NCT06018740|DIETARY_SUPPLEMENT|Daily Balance Gummy|Phenology Daily Balance Gummies 30 ct. Yuzu Tangerine Flavor. Product contains Vitamin D2, Vitamin K2, Vitamin B6, Vitamin B12, Biotin, Genistein, Saffron Extract, Organic Tapioca Syrup, Organic Cane Sugar, Water, Pectin, Citric Acid, Natural Flavors.
223777218|NCT03226067|DRUG|GKT137831|GKT137831 100mg capsules. To be taken as part of two dose arms which are 400mg twice daily or 400mg once daily.
223777219|NCT03226067|DRUG|Placebo oral capsule|Matching capsules.
223777220|NCT02237105|BEHAVIORAL|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy
223777221|NCT00699881|DRUG|cetuximab|cetuximab 400mg/m2 as initial dose, subsequently at 250mg/m2 weekly dose. CPT-11 180 mg/m2 CF 200 mg/m2 5Fu 400mg/m2 bolus, followed by 2.4g/m2 continuously intravenous infusion for 46 hours, days 1 and 15, every 4 weeks per cycle
223777222|NCT01264302|DRUG|Finasteride|Finasteride Tablets 5 mg
223777223|NCT05927402|OTHER|Laughter Therapy Based on Kolcaba Comfort Theory|The laughter yoga will be applied to experimanetal group. Every laughter yoga practice is 45 minutes long and is planned 3 times a week for a total of 6 sessions. Control group patients will take only routine nursing care.
223777224|NCT04358926|DEVICE|Hyperbaric oxygen therapy|8 sessions in 4 days of breathing 100% oxygen in 2.2 ATA. Each session is 60 minutes. 1 meter/minute compression/decompression
223777225|NCT01914432|DRUG|YH16410|
223777226|NCT01914432|DRUG|Rosuvastatin|
223777227|NCT01914432|DRUG|Telmisartan|
223777228|NCT01914432|DRUG|YH16410 placebo|
223777229|NCT01914432|DRUG|Rosuvastatin placebo|
223777230|NCT01914432|DRUG|Telmisartan placebo|
223777231|NCT00767000|DRUG|MK-0941|MK-0941 tablets three times daily
223777232|NCT00767000|DRUG|Comparator: Placebo|Matching placebo to MK-0941 three times daily
223777233|NCT00767000|BIOLOGICAL|Lantus|Lantus injection once daily
223777234|NCT00767000|DRUG|Metformin|Metformin ≥1500 mg/day at a stable dose for at least 6 weeks before Screening and for the duration of the study. The number of randomized participants who receive metformin will be capped at 70% of enrollment.
223777235|NCT05578404|DRUG|Cholecalciferol|Vit D is a fat-soluble vitamin, provided by sunlight and activated by kidneys and liver.
223777236|NCT05578404|DRUG|Placebo|matching placebo to Vit D
223777237|NCT06635239|OTHER|Co-creation and assessment|"1. MOOC co-creation: development of a MOOC initially structured into modules consisting of a variety of downloadable educational resources such as videos, audios, infographics, texts, etc., covering several units related to Person-Centered Care (Shared Decision-Making, strategies for managing the clinical encounter, Patient Decision Aids, etc.) and Digital Health Literacy (skills, tools, etc.). These resources will serve as the central focus of the educational intervention, and may undergo appropriate adjustments established during the co-creation sessions.~2. MOOC acceptability and effectiveness: evaluation of the MOOC in terms of effectiveness (level of Health Literacy, Digital Health Literacy, and knowledge acquired) and acceptability (usability, areas for improvement, etc.)"
223777238|NCT00335907|PROCEDURE|Fluid and Vasopressor Protocol|A Physician Ordered, Nurse Administered Fluid and Vasopressor Protocol
223777239|NCT03120104|OTHER|pelvic floor muscle exercise before stoma closure|pelvic floor muscle training for one month (2\~3 times a week, for 4 weeks) just one month before the stoma closure
223777240|NCT03120104|OTHER|pelvic floor muscle exercise after stoma closure|pelvic floor muscle training for one month (2\~3 times a week, for 4 weeks) just two weeks after the stoma closure
223777241|NCT03952247|DEVICE|Single Use Bronchoscopy for PDT|optical guidance of percutaneous tracheotomy is done by single use bronchoscopy
223777242|NCT03952247|DEVICE|Conventional Multi Use Bronchoscopy for PDT|optical guidance of percutaneous tracheotomy is done by conventional multi use bronchoscopy
223777243|NCT04789421|DEVICE|Clinical, dermoscopy and Reflective confocal microscopy evaluations|Adjunctive reflective confocal microscopy to dermoscopy and clinical dermatological evaluation.
223777244|NCT04789421|DEVICE|Clinical, dermoscopy evaluations|Dermoscopy and clinical dermatological evaluation only
223777245|NCT01444534|DEVICE|Dbees; diabetes mobile phone application|Participants randomized to the intervention group (G2) were asked to stop using their paper logbook and start using an electronic logbook on their computer and mobile phone using an application of Dbees. The Dbees software enables the mobile phone to be used as a small computer to record the blood glucose values, dose of insulin injection, daily carbohydrate intake, amount of physical activity, and blood pressure.
223777246|NCT01444534|DEVICE|control group|Participants in the control group (G1) continued using their paper logbook (usual care) and had no electronic logbook. Patients in the control group were requested not to use another mobile phone application instead of or besides their paper logbook.
223691711|NCT01440790|DIETARY_SUPPLEMENT|Glucose bolus plus 1g vitamin C|50g anhydrous glucose dissolved in 300ml water consumed within 10min with 1g vitamin C followed by a lunch (cheese sandwich, fruit and milk) at 4h.
223691712|NCT01440790|DIETARY_SUPPLEMENT|Glucose sipping plus 1g vitamin C|50g anhydrous glucose dissolved in 300ml water consumed at rate of 25ml per 15min. 1g vitamin C taken with first 25ml. Followed by a lunch (cheese sandwich, fruit and milk) at 4h.
223691713|NCT01642121|OTHER|laboratory biomarker analysis|Correlative studies
223691714|NCT02398409|BEHAVIORAL|ANSWERS - Acquiring New Skills While Enhancing Remaining Strengths|"Randomized trial to evaluate the efficacy of the telephone intervention Acquiring New Skills While Enhancing Remaining Strengthsin informal caregivers of Veterans with stroke and TBI."
223691715|NCT02398409|OTHER|Control|8 week telephone usual care with education with nurse case manager
223691716|NCT03799172|DRUG|Echinocandin treatment|Patients received echinocandins as a first-line therapy after candidemia diagnosis according to the standard of care
223691717|NCT03799172|DRUG|Triazole treatment|"Patients received triazoles as a first-line therapy after candidemia diagnosis according to the standard of care.~Candidemia was defined as at least one blood culture positive for Candida."
223691718|NCT03371771|BEHAVIORAL|Volunteer-delivered Behavioral Activation|Behavioral Activation as delivered by trained volunteers
223691719|NCT03371771|BEHAVIORAL|MSW-delivered Behavioral Activation|Behavioral Activation as delivered by trained MSWs
223691720|NCT00003567|BIOLOGICAL|filgrastim|Patients receive filgrastim (G-CSF) subcutaneously (SC) once daily on days 1-5 (or G-CSF twice daily alone for 4-5 days).
223691721|NCT00003567|BIOLOGICAL|sargramostim|Patients receive sargramostim (GM-CSF) subcutaneously (SC) once daily on days 1-5 (or G-CSF twice daily alone for 4-5 days).
223691722|NCT00003567|BIOLOGICAL|therapeutic autologous lymphocytes|
223691723|NCT00003567|DRUG|O6-benzylguanine|Patients receive O6-benzylguanine (BG) IV over 1 hour every 6 weeks for 5 courses. Four weeks after the completion of BG and carmustine, patients receive BG IV over 1 hour every 4 weeks for up to 5 courses, in the absence of hematologic toxicity. Patients with responding disease may continue to receive BG and temzolomide in the absence of disease progression or unacceptable toxicity.
223691724|NCT00003567|DRUG|carmustine|Patients receive carmustine IV over 1 hour every 6 weeks for 5 courses.Cohorts of 3-6 patients receive escalating numbers of CD34 stem cells targeted for retroviral infection and escalating doses of carmustine.
223691725|NCT00003567|DRUG|temozolomide|Four weeks after the completion of BG and carmustine, patients receive temozolomide IV over 1 hour every 4 weeks for up to 5 courses, in the absence of hematologic toxicity. Patients with responding disease may continue to receive BG and temzolomide in the absence of disease progression or unacceptable toxicity.
223691726|NCT00003567|PROCEDURE|in vitro-treated peripheral blood stem cell transplantation|Approximately 72 hours after the end of the first course of chemotherapy, patients receive reinfusion of retrovirally-transduced hematopoietic stem cells over 5-10 minutes. Cohorts of 3-6 patients receive escalating numbers of CD34 stem cells targeted for retroviral infection and escalating doses of carmustine.
223691727|NCT04921215|BEHAVIORAL|Morning bright light|All participants will receive phase advancing morning bright light.
223691728|NCT05381337|PROCEDURE|sideburns mini incision|The investigators present a new method to calculate the shortest incision for zygomatic fracture, and use this method to calculate the sideburns mini incision for the surgical treatment of zygomatic arch fracture.
223691729|NCT05381337|PROCEDURE|coronal scalp incision|Coronal scalp incisions were used as control group.
223691730|NCT00621803|DRUG|Probiotic Lactobacillus casei rhamnosus (Lcr35)|
223691731|NCT03309046|OTHER|REACH Individual Session|Individual telephone session with parent
223691732|NCT03309046|OTHER|Education Webinar|Videos with information on caregiving
223691733|NCT02354482|BEHAVIORAL|Patient Communication and Care Management|"Received the following Transitional Care strategies:~1. Helpful Health Care Contact OR Symptom Management~2. Post-discharge Care Consultation~3. Patient Goal/Preference Assessment~4. Plain Language Communication in Hospital~5. Plain Language Communication at Home~6. Transition Summary for Patients and Family Caregivers"
223691734|NCT02354482|BEHAVIORAL|Home-Based Trust, Plain Language, and Coordination|"Received the following Transitional Care Strategies:~1. Transition Team~2. Home visits~3. Plain Language Communication at Home~4. Promote Trust at Home~5. Referral to Community Services~6. Follow-up Appointment"
223691735|NCT02354482|BEHAVIORAL|Hospital-Based Trust, Plain Language, and Coordination|"Received the following Transitional Care Strategies:~1. Post-discharge care consultation~2. Identify High-Risk Patients and Intervene~3. Medication Reconciliation~4. Plain Language Communication in Hospital~5. Promote Trust in the Hospital~6. Transition Summary for Patients and Family Caregivers"
223691736|NCT02354482|BEHAVIORAL|Patient/Caregiver Assessment and Provider Information Exchange|"Received the following Transitional Care Strategies:~1. Patient Goal/Preference Assessment~2. Identify High-Risk Patients and Intervene~3. Timely Exchange of Critical Patient Information among Providers~4. Patient/Family Caregiver Transitional Care Needs Assessment"
223691737|NCT02354482|BEHAVIORAL|Assessment and Teach Back|"Received the following Transitional Care Strategies:~1. Post-discharge care consultation~2. Language Assessment~3. Teach Back for Information and Skills"
223777247|NCT05367453|DIETARY_SUPPLEMENT|Tropical juice with probiotics (B.coagulans)|Once a day during all the intervention phase, volunteers with lactose intolerance should allow the spore-forming ability of B. coagulans in order to digest lactase from dairy products through regular consumption of Tropical juice with probiotics (B.coagulans)
223777248|NCT05367453|OTHER|a Tropical juice with no probiotics|Once a day during all the intervention phase, volunteers with lactose intolerance should consume a Tropical juice with no probiotics
223691738|NCT02354482|OTHER|Standard of Care (Reference)|No specific Transitional Care Strategy
223691739|NCT00899509|OTHER|laboratory biomarker analysis|correlative studies
223691740|NCT00004229|BIOLOGICAL|recombinant human endostatin|
223691741|NCT05549427|OTHER|Ventilation|Ventilation in ICU
223691742|NCT00089674|DRUG|AMG 162|60 mg (1.0mL) administered subcutaneously at Day 1, Months 6, 12, 18, 24, 30
223691743|NCT00089674|DRUG|Placebo|60 mg (1.0mL) administered subcutaneously at Day 1, Months 6, 12, 18, 24, 30
223691744|NCT01584570|DRUG|0.5 mcg/kg IV infusion for 10 min, 1.0 mcg/kg IV infusion for 10 min|ECG monitoring for evaluation of QTc interval
223691745|NCT03279471|DRUG|Sertraline|Participants start at 12.5 mg and are increased by 12.5/day every two weeks for 14-16 weeks based on their tolerability to the medication. Dosing is capped at 125mg/day.
223691746|NCT03279471|BEHAVIORAL|CBT/BIACA|Participants receive 16 weeks of BIACA therapy.
223691747|NCT03279471|DRUG|Placebo|Participants are given a placebo capsule with an administration schedule matching that of the sertraline subjects.
223691748|NCT03095768|OTHER|Lifestyle Education and Cooking Demonstration|Participants will receive an interactive cooking demonstration as well as healthy lifestyle education
223691749|NCT03963401|DRUG|PF-06700841|Starting after the Week 16 visit, subjects receiving PF-06700841 10 mg once daily will start to randomly receive either the 60 mg QD dose or 30 mg QD dose until Week 52, as predetermined at randomization. All subjects will receive blinded dosing throughout the 52 weeks study treatment period in order to maintain the study blind.
223691750|NCT03963401|OTHER|Placebo|Starting after the Week 16 visit, subjects receiving placebo will start to randomly receive either the 60 mg QD dose or 30 mg QD dose until Week 52, as predetermined at randomization. All subjects will receive blinded dosing throughout the 52 weeks study treatment period in order to maintain the study blind.
223691751|NCT00652639|DRUG|Clonazepam|Tablets, 1 mg, single-dose
223691752|NCT00652639|DRUG|Klonopin|tablets, 1 mg, single-dose
223691753|NCT01022827|OTHER|massage|For the massage group, a physical therapist with 8 years of clinical experience in manual therapy provided the massage on the posterior deltoid, infraspinatus, and teres minor of the involved shoulder for 18 minutes \[about 6 minutes for each muscle and order was random\] two times a week for 4 weeks. The techniques of massage included petrissage for 3 minutes and rolling for 3 minutes of soft tissues
223691754|NCT05629000|PROCEDURE|Carotid revascularization|All patients received carotid revascularization surgery at Peking Union Medical College Hospital.
223691755|NCT05629000|DIAGNOSTIC_TEST|MRI-PWI|Multi-modal MRI before and after surgery.
223691756|NCT05629000|DIAGNOSTIC_TEST|CTA|CTA before and after surgery.
223691757|NCT05629000|DIAGNOSTIC_TEST|PET/MRI|PET/MRI before surgery.
223691758|NCT05629000|DIAGNOSTIC_TEST|Ultrasound|Ultrasound before and after surgery.
223691759|NCT02252276|PROCEDURE|Experimental (proprioception exercises, muscle strengthening, joint mobilization)|The experimental group performed a combined protocol of proprioception (the patient doing exercises standing on an unstable plane)exercises and muscle strengthening (The patient performed eccentric exercises to work the movement inversion of ankle), and joint mobilization techniques of the ankle joint two session per week, during four weeks
223691760|NCT02252276|PROCEDURE|Control (proprioception exercises, muscle strengthening)|The control group performed only proprioception exercises (the patient doing exercises standing on an unstable plane) and muscle strengthening (The patient performed eccentric exercises to work the movement inversion of ankle). Two sessión per week during four weeks
223691761|NCT01164384|DRUG|Baminercept|
223691762|NCT05025748|BEHAVIORAL|Behavioral Intervention|Complete questionnaires
223691763|NCT00225043|DRUG|Epinephrine/phenylephrine|
223777249|NCT05367453|OTHER|lactase tablet|lactase tablet
223777250|NCT05367453|OTHER|placebo tablet (cornstarch)|placebo tablet (cornstarch)
223691764|NCT02305043|OTHER|non-interventional|non-interventional
223691765|NCT03723200|OTHER|Fibrinogen and blood products|Fibrinogen and blood products
223777251|NCT05228613|BIOLOGICAL|SARS-CoV-2 protein subunit recombinant vaccine|candidate vaccine manufactured by PT. Bio Farma
223777252|NCT05228613|BIOLOGICAL|SARS-CoV-2 inactivated vaccine|active control manufactured by Sinovac Life Sciences Co.Ltd
223777253|NCT06137547|DEVICE|Hypotension prediction index (HPI)|The hypotension prediction index (HPI) is a value derived from the arterial pressure waveform. It was invented by Edwards Lifesciences through a machine-learning algorithm, and can be calculated with Acumen Hypotension Prediction Index software incorporated in HemoSphere advanced monitoring platform (EV1000). This value, ranging from 0 to 100, predicts the likelihood of a patient trending towards a hypotensive event, which is defined as mean arterial pressure below 65 mmHg for at least one minute.
223691766|NCT02622750|PROCEDURE|triple-branched stent graft|place the triple-branched stent graft into the aortic arch, descending aorta ,the left subclavian artery, the left common carotid artery, and the innominate artery.
223691767|NCT02622750|PROCEDURE|four-branched Dacron graft|"The stent elephant trunk was inserted into the true lumen of the distal aorta in a bound, compressed state after the distal aorta was transected between the origin of the left subclavian artery and the left carotid artery. The distal aorta incorporating the stent graft was firmly attached to the distal end of the four-branched Dacron graft using the open aortic procedure. After the anastomosis was completed, blood perfusion of the lower body was started via the perfusion limb of the four-branched Dacron graft."
223691768|NCT06822972|DRUG|Selinexor 40 mg|Patients will receive 40mg of oral SEL, weekly, beginning after they have completed step-up dosing and are 5 (± 2) days out from administration of the first full treatment dose of bispecific antibody therapy for 12 months or until disease progression.
223691769|NCT03640767|BEHAVIORAL|Message-based lifestyle intervention|Peripheral artery disease patients who have received revascularization in the past 6 months, are randomized into 2 groups. The total sample size will be 160. Both intervention and control groups will receive face-to-face lifestyle adherence counseling and booklets at baseline. The intervention group will receive 4 mobile phone messages per week for 24 weeks. The messages are motivational advice to support lifestyle behavioral modification in various stages of behavioral changes.
223691770|NCT03201627|DRUG|Lithium Carbonate|To observe whether lithium carbonate has protective role on the brain of Niemann-Pick disease C1
223691771|NCT01164540|DRUG|Rosuvastatin (AZD4522)|Oral dose (od) 20 mg
223691772|NCT01164540|DRUG|Placebo|Oral dose (od)
223691773|NCT05160987|DRUG|Remimazolam|Remimazolam will be diluted with 0.9% saline to ensure that the therapeutic drug and placebo are identical in appearance, and 50 ml syringes will serve as the containers for all intravenous drugs.
223691774|NCT05160987|DRUG|Midazolam|Midazolam will be diluted with 0.9% saline to ensure that the therapeutic drug and placebo are identical in appearance, and 50 ml syringes will serve as the containers for all intravenous drugs.
223691775|NCT03310827|BEHAVIORAL|Personalized Nutrition|Diet plan based on nutrition-related gene test results
223691776|NCT04491253|BEHAVIORAL|Social support for diabetes self-management|Four individualized intervention sessions, every two weeks with a duration of 40 minutes.
223691777|NCT00832390|DRUG|sitagliptin phosphate|Patients will receive sitagliptin with metformin for 24 weeks, given as oral tablets
223691778|NCT00667420|DRUG|panitumumab, epirubicin, oxaliplatin, xeloda|pilot study
223691779|NCT02985203|DRUG|Vinorelbine Oral|Oral vinorelbine plus cisplatin Followed by Metronomic oral Vinorelbine
223691780|NCT01554969|DRUG|capecitabine + ganetespib|"Capecitabine will be started on Day 1 of the concurrent chemo-radiation phase at the specified dose, and is given orally twice daily for the entire duration of radiation therapy.~Ganetespib will be started on Day 1 of radiation therapy and is administered as IV infusion over 1 hour on days 1, 8, 15 for cycle 1 and then on days 29 and 36 for cycle 2.~In all patients, ganetespib monotherapy will be given up to 2 weeks prior to start of concurrent chemoradiation. Sequential biopsies will be taken at baseline and prior to the start of concurrent chemoradiation. In the dose escalation part of the study, the starting does of ganetespib is 60mg/m² once weekly, and capecitabine at a dose of 825 mg/m² twice daily."
223691781|NCT00782327|DRUG|Losartan|Daily maximal doses of Losartan will be 50mg for subjects under 50kg of weight and 100mg if the weight is over 50kg
223691782|NCT00782327|DRUG|Placebo|Daily placebo capsule
223691783|NCT03362307|DEVICE|Low-Level Laser and Light-Emitting Diodes|Combination of Low-Level Laser and Light-Emitting Diodes were used after dental implant placement for enhancement of stability
223691784|NCT03362307|DEVICE|Dental implant placement|A dental implant with 4.8X 10 mm (Zimmer, USA) size was placed at the posterior of the mandible
223691785|NCT00002898|BIOLOGICAL|dactinomycin|
223691786|NCT00002898|DRUG|carboplatin|
223691787|NCT00002898|DRUG|cyclophosphamide|
223691788|NCT00002898|DRUG|epirubicin hydrochloride|
223691789|NCT00002898|DRUG|etoposide|
223777254|NCT03006666|BEHAVIORAL|CHW Training|"CHWs will be trained in DM concepts, motivational interviewing, brief action planning, and stages of behavior change. CHWs will participate in a 105- hour core competency training. CHWs will conduct mock telephone counseling calls with trained standardized patients to enhance skills, gain feedback and develop confidence in these techniques.~In addition to these training experiences, CHWs will have letter templates, motivational interviewing scripts, and protocols available for patient outreach to standardize and guide patient outreach .~The completion of the CHW training will be followed by a final examination of knowledge and evaluation of trial encounters with mock participants (consisting of research staff and advisory board members).~Individuals who do not pass will receive intensive remediation and be required to repeat the examination.~Community Health Worker Coaching Intervention."
223777255|NCT03006666|BEHAVIORAL|Data Only|The teams randomly allocated will not have access to Community Health Workers.
223691790|NCT00002898|DRUG|ifosfamide|
223691791|NCT00002898|DRUG|vincristine sulfate|
223691792|NCT00002898|PROCEDURE|adjuvant therapy|
223691793|NCT00002898|PROCEDURE|conventional surgery|
223691794|NCT00002898|PROCEDURE|neoadjuvant therapy|
223691795|NCT00002898|RADIATION|brachytherapy|
223691796|NCT00002898|RADIATION|radiation therapy|
223691797|NCT06468969|OTHER|Enhanced Follow-up|"Participants will receive comprehensive follow-up care starting from the 4th week post-surgery. Every 3 weeks, they will undergo a thorough assessment that includes:~Symptom Assessment Nutritional Assessment (using NRS 2002 and PG-SGA) Psychological Assessment (using DT, GAD-7, FCR-7, ISI, PHQ-9)"
223691798|NCT03937869|DRUG|Secnidazole|One dose
223691799|NCT04646772|PROCEDURE|Multivisceral resection|Multivisceral resection for locally advanced colon cancer.
223777256|NCT03893513|DEVICE|Transthoracic Electrical Bioimpedance|Non-invasive hemodynamic monitor
223777257|NCT03893513|DEVICE|Pulse Contour Analysis|Invasive hemodynamic monitor
223691800|NCT06288789|OTHER|Social Frailty Index|Social Frailty Index will be applied twice, one week apart.
223691801|NCT03144024|DEVICE|band implantation|
223691802|NCT03144024|DEVICE|rigid ring implantation|
223691803|NCT00062322|DRUG|cisplatin|
223691804|NCT00062322|DRUG|irinotecan hydrochloride|
223691805|NCT00062322|PROCEDURE|conventional surgery|
223691806|NCT00062322|PROCEDURE|neoadjuvant therapy|
223691807|NCT00062322|RADIATION|radiation therapy|
223691808|NCT04723758|DEVICE|GI Genius-assisted diagnostic colonoscopy|Participants will undergo diagnostic colonoscopy, which will be identical to the normal standard of care at the unit where they are undergoing their procedure, except that GI Genius will be turned on during the procedure.
223691809|NCT04723758|DIAGNOSTIC_TEST|Diagnostic Colonoscopy|Diagnostic colonoscopy will be performed as per the standard of care for the unit where the patient is having their procedure.
223691810|NCT06267976|DEVICE|ProSomnus RPMO2|The ProSomnus RPMO2 device is an intraoral reflectance pulse oximeter.
223691811|NCT05031598|OTHER|Long-term fasting according to the Buchinger Wilhelmi fasting program|the participants will undergo a fasting program that includes the daily intake of 250 kcal under medical supervision
223691812|NCT04493879|OTHER|Bioptron Light Therapy (BLT)|BLT for 30 days 10 minutes every day. The treatment points displayed were: one point in the right jugal mucosa, one point in the left jugal mucosa, one point in the lower lip 's inner mucosa, analgesics, anti-inflammatory treatment, and antimicrobial treatment for any new mouth infections)
223691813|NCT02961218|DRUG|ACZ885|Monthly doses of 4 mg/kg for subjects weighing ≤40 kg and 300 mg for all other subjects
223691814|NCT02961218|DRUG|Placebo|Monthly doses of placebo to match the administered dose of canakinumab s.c.
223691815|NCT01331941|DRUG|AMG 386 + Paclitaxel|15 mg/kg IV (in the vein) of AMG 386 weekly + 80 mg/m\^2 IV (in the vein) 3 weeks on/1 week off, optional beginning week 6 until progression, unacceptable toxicity, or withdrawal of consent.
223777258|NCT00633035|DRUG|esomeprazole 40 mg|esomeprazole 40 mg po given for 7 days
223777259|NCT00633035|DRUG|famotidine 20 mg|famotidine 20 mg intravenous bolus q12h for 7 days
223777260|NCT04496921|DIETARY_SUPPLEMENT|Vitamin K supplementation, dose #1|Vitamin K supplement : 2mg, once a day, for 6 months. Complete biochemical profile, weight and size (body mass index), drugs list, pulmonary function by spirometry (FEV, etc.). Food frequency questionnaire.
223691816|NCT01331941|DRUG|AMG 386|15 mg/kg IV (in the vein) weekly beginning week 1 day 1 until progression, unacceptable toxicity, or withdrawal of consent.
223691817|NCT01210573|DEVICE|adjustment of LVAD or pacemaker|"For patients without a device: Patients start at rest for 2 minutes and will wear a face mask and breathing parameters are recorded using the SHAPE-HF system (SHAPE Medical St. Paul, MN) that measures respiratory airflow and the constituent respiratory gases, oxygen and carbon dioxide.~For patients with a device: patients will be at rest and the adjustments of their device will be made by a study physician or device coordinator, done routinely in clinical practice. This will take up to 15 minutes and during this time; participants will wear a face mask and breathing parameters are recorded using the SHAPE-HF system (SHAPE Medical St. Paul, MN) that measures respiratory airflow and the constituent respiratory gases, oxygen and carbon dioxide."
223777261|NCT04496921|DIETARY_SUPPLEMENT|Vitamin K supplementation, dose #2|Vitamin K supplement : 7mg, twice a week, for 6 months. Complete biochemical profile, weight and size (body mass index), drugs list, pulmonary function by spirometry (FEV, etc.). Food frequency questionnaire.
223777262|NCT04928742|BEHAVIORAL|Group Cognitive Behavioural Therapy (CBT)|The 9-week group CBT intervention for PPD delivered via Zoom by two public health nurses. This intervention was developed by Dr. Van Lieshout (PI) at the Women's Health Concerns Clinic (WHCC) at St. Joseph's Healthcare Hamilton. It was designed to be brief, simple, and applicable to women in community settings. It consists of 9 weekly 2-hour sessions where core CBT skills are learned and practiced, and a new psychoeducational topic is introduced and discussed by women each week.
223777263|NCT04468295|PROCEDURE|Bonding|Bonding of upper and lower arches including 2nd maxillary molars with bracket prescription Roth 0.018 inch
223777264|NCT04468295|PROCEDURE|Leveling and alignment|Leveling and alignment till 0.016 x0.022 Ni Ti
223777265|NCT04468295|PROCEDURE|Extraction|Extraction of maxillary 1st premolars
223777266|NCT04468295|PROCEDURE|Retraction|En-masse retraction using 0.017x0.025 TMA T loop
223691818|NCT01715714|DRUG|Statin Recapture Therapy|Given 12h and 2h before CABG
223691819|NCT01715714|DRUG|Placebo|Given 12h and 2h before CABG.
223691820|NCT06135480|OTHER|subcision ,PRP or saline and microneedling|minimally invasive procedures
223691821|NCT01158703|DRUG|clopidogrel|clopidogrel 75mg daily by mouth daily for 12 months
223691822|NCT01158703|DRUG|sugar pill|sugar pill by mouth daily for 12 months
223691823|NCT01158703|DRUG|Aspirin|aspirin 81 mg daily by mouth for 12 months ( Standard of care in both arms)
223691824|NCT02639156|DIETARY_SUPPLEMENT|AYMES LONDON|AYMES LONDON is a powder, designed to be mixed with 75ml whole milk to make a dessert style ONS. When made-up, AYMES LONDON provides 303kcal (2.2kcal/ml) and 11.2g protein. It is not designed to be used as a sole source of nutrition. It is a Food for Special Medical Purposes (FSMP) and must therefore be used under medical supervision.
223777267|NCT04468295|PROCEDURE|Digital models|impression taking and digital scanning
223777268|NCT04468295|PROCEDURE|measurement|Assessment the rate of retraction for 6 months
223777269|NCT06573840|DEVICE|NeuroGlove|NeuroGlove is a non-invasive device that provides peripheral somatosensory stimulation to the hand. NeuroGlove provides sensory stimulation in the form of pneumatic puffs of air.
223777270|NCT06573268|DEVICE|robot surgery device|SPRA used da-Vinci SP system (SPRA) BABA used da-Vinci Xi system (BABA)
223777271|NCT01583725|PROCEDURE|Liquid meal responses|Subject ingests a meal-replacement shake and gut peptide levels are measured before and after intake.
223777272|NCT01583725|BEHAVIORAL|fMRI responses to food-cues|Subjects undergo a 40 min fMRI neuroimaging session while receiving auditory and visual food cues.
223777273|NCT03503968|DRUG|MDG1011|PRAME-T-Cell Receptor Gene Modified Autologous T Cells
223777274|NCT03503968|OTHER|Investigator Choice therapy|Any intervention/therapy chosen by the investigator
223691825|NCT02793466|DRUG|Durvalumab; MEDI4736|IV Infusion every 2 weeks for a maximum of 26
223691826|NCT02800759|DIETARY_SUPPLEMENT|JOINTRUS®|100% Fatty acid compound with 12.5% Cis-9-cetylmyristoleate
223777275|NCT00165282|BEHAVIORAL|Mindfulness training|Taught mindfulness meditation by mindfulness instructor (trained health care professional/RN) and audio c/d
223777276|NCT00165282|BEHAVIORAL|Nurse education|Meets with oncology nurse to have questions answered about medical treatments and side effects
223777277|NCT03750136|DRUG|Hypertonic saline|high dose furosemide with hypertonic saline 3x daily
223691827|NCT02800759|DIETARY_SUPPLEMENT|80% dose of JOINTRUS®|80% Fatty acid compound with 12.5% Cis-9-cetylmyristoleate
223691828|NCT02800759|DIETARY_SUPPLEMENT|62.4% dose of JOINTRUS®|62.4% Fatty acid compound with 12.5% Cis-9-cetylmyristoleate
223691829|NCT02800759|DIETARY_SUPPLEMENT|Starch 100%|0% Fatty acid compound with 12.5% Cis-9-cetylmyristoleate
223777278|NCT03750136|DRUG|Furosemide Injection|high dose furosemide
223777279|NCT02044081|DRUG|C16G2 Rinse|Active rinses are 1.6 mg/mL C16G2.
223777280|NCT02044081|DRUG|Placebo|Placebo is the vehicle without C16G2
223777281|NCT02044081|DRUG|C16G2 Gel|Active C16G2 Gel is 3.2 mg/mL
223777282|NCT02262429|OTHER|ONS QIP|Rapid comprehensive ONS, dietary consult, follow up phone calls
223777283|NCT02262429|OTHER|ONS Standard Feeding|Standard of care
223777284|NCT05924828|OTHER|no intervention|no intervention
223691830|NCT02876744|OTHER|ophthalmologic examination|ophthalmologic examination including optical coherent tomography with angiography module
223777285|NCT00506935|DRUG|GVG|5 grams GVG
223777286|NCT00506935|DRUG|placebo|placebo
223777287|NCT06145828|DEVICE|Cytokine Adsorption|During treatment with cytokine adsorption cartridge, the patient's blood is passed through these cartridges, which contain substances that can adsorb specific cytokines. Excess cytokines are captured and removed by these substances, and then the cleansed blood is returned to the patient's body.
223777288|NCT05009563|RADIATION|FDG-PET/CT|whole-body F-18-fluoro-deoxy-glucose positron emission tomography/computed tomography
223777289|NCT00550784|BIOLOGICAL|filgrastim|
223777290|NCT00550784|DRUG|cisplatin|
223777291|NCT00550784|DRUG|cyclophosphamide|
223777292|NCT00550784|DRUG|melphalan|
223777293|NCT00550784|DRUG|paclitaxel|
223777294|NCT00550784|DRUG|topotecan hydrochloride|
223777295|NCT00550784|GENETIC|TdT-mediated dUTP nick end labeling assay|
223777296|NCT00550784|GENETIC|gene expression analysis|
223777297|NCT00550784|OTHER|immunohistochemistry staining method|
223777298|NCT00550784|OTHER|pharmacological study|
223777299|NCT00550784|PROCEDURE|peripheral blood stem cell transplantation|
223691831|NCT05398926|BIOLOGICAL|COVID-19 Vaccine (Vero cell), Inactivated|The COVID-19 vaccine,inactivated was manufactured by Sinovac Research\& Development Co., Ltd.600SU inactivated SARS-CoV-2 CZ strain virus in 0.5 mL of aluminium hydroxide solution per injection.
223691832|NCT06550271|DRUG|Rapamycin|Rapamycin in 2 different dosage forms (compounded and generic)
223691833|NCT02606890|OTHER|MRI|Stroke patients routinely undergo MRI at Charite Campus Benjamin Franklin. Type of MRI stroke pattern is evaluated with regard to presence or detection of (new) atrial fibrillation.
223691834|NCT05050552|DEVICE|Masimo Radical-7 Pulse CO-Oximeter|The Masimo Radical-7 Pulse CO-Oximeter is a device for the measurement of pulse oximetry, oxygen reserve index (ORi), perfusion index (PI), and pleth variability index (PVI). The device is the product of a company called Masimo Inc, Irvine, CA, USA
223691835|NCT00591266|DRUG|Azilsartan Medoxomil and amlodipine|Azilsartan Medoxomil 40 mg, tablets, orally, once daily and amlodipine 5 mg, tablets, orally, once daily for up to 6 weeks.
223691836|NCT00591266|DRUG|Azilsartan Medoxomil and amlodipine|Azilsartan Medoxomil 80 mg, tablets, orally, once daily and amlodipine 5 mg, tablets, orally, once daily for up to 6 weeks.
223691837|NCT00591266|DRUG|Amlodipine|Azilsartan medoxomil placebo-matching tablets, orally, once daily and amlodipine 5 mg, tablets, orally, once daily for up to 6 weeks.
223691838|NCT03902106|DRUG|salbutamol|subjects ingest salbutamol
223691839|NCT03902106|OTHER|exercise|subjects undergo 6 weeks of endurance training (3 times weekly)
223691840|NCT03488927|BEHAVIORAL|Supporting Survivors and Self: An Intervention for Social Supports of Survivors of Partner Abuse and Sexual Aggression (SSS)|The SSS intervention consists of a two-hour session followed by a 90-minute booster session a month following the initial program session. The SSS intervention is delivered in groups of approximately 20 students facilitated by peer educators. The SSS intervention provides participants with specific information on the reasons why positive social reactions are important and negative social reactions can be harmful, examples of what to say and what not to say (including ways to promote healthy coping and discourage unhealthy coping, e.g., drinking to cope), opportunities for roleplay, and an emphasis on the importance of self-care and ways in which self-care can be balanced with the needs of IPV and SA victims.
223691841|NCT01234207|DEVICE|Standard, non-free-form, non-customized PAL spectacles|Control spectacles include several different PAL brands as selected by patients in the UC Berkeley Optometry Clinic and purchased in the Eyewear Center; after successful fitting and purchase, potential subjects were recruited for the trial.
223691842|NCT01234207|DEVICE|Individually customized free-form surfaced PAL spectacles|Test spectacles are Zeiss Individual, free-form surfaced, and customized using the iTerminal device to account for individual back vertex distance, wrap angle and pantoscopic tilt
223777300|NCT03019497|BEHAVIORAL|Specific Modules|Educational session about a specific related problem
223777301|NCT03019497|BEHAVIORAL|Cognitive behavioral therapy|PTSD of participants in both conditions will be addressed with cognitive-behavioral intervention strategies. These strategies are: (a) psychoeducation on PTSD, (b) anxiety management training, (c) restructuring irrational thoughts, (d) imaginative and / or in vivo exposure to memories and situations avoided, and (e) strategies for the prevention of relapse.
223777302|NCT02530619|DRUG|Alisertib|Given PO
223777303|NCT02530619|OTHER|Laboratory Biomarker Analysis|Correlative studies
223777304|NCT02530619|OTHER|Pharmacological Study|Correlative studies
223691843|NCT01135212|DRUG|Fimasartan 60mg|Fimasartan 60mg for mild to moderate hypertension. Take a tablet(filled in Doubleblind capsule) every morning.
223691844|NCT01135212|DRUG|Fimasartan 120mg|Fimasartan 120mg for mild to moderate hypertension. Take a tablet(filled in Doubleblind capsule) every morning.
223691845|NCT01135212|DRUG|Candesartan cilexetil|Candesartan 8mg for mild to moderate hypertension. Take a tablet(filled in Doubleblind capsule) every morning.
223691846|NCT01889524|OTHER|Mesh nebulizer|VMN (NIVO, Respironics®, Murrysville, Pennsylvania, USA) with an MMAD of 3.0 µm was placed in the elbow adapter at the mask. Inhalation was performed using diethilene triamine penta-acetic technetium (99mTc-DTPA) with radioactivity of 25 millicuries (Nobre et al., 2007). Both nebulizers were charged with 2.5 mg of salbutamol and 0.25 mg of ipratropium bromide and normal saline solution to complete a fill volume of 3 mL.
223691847|NCT01889524|OTHER|Jet nebulizer|"The JN (Misty Max, Air Life, Yorba Linda, USA) with a particle MMAD of 5 µm (according to the manufacturer information) was positioned in the circuit using a T piece placed between the circuit leak and the mask, and operated with oxygen flow at 8 L/min. Inhalation was performed using diethilene triamine penta-acetic technetium (99mTc-DTPA) with radioactivity of 25 millicuries (Nobre et al., 2007). Both nebulizers were charged with 2.5 mg of salbutamol and 0.25 mg of ipratropium bromide and normal saline solution to complete a fill volume of 3 mL."
223691848|NCT01889524|OTHER|Noninvasive ventilation-NIV|Bilevel positive airway pressure (BiPAP Synchrony, Respironics®, Murrysville, Pennsylvania, USA) was applied through face mask (Comfort Full 2, Respironics®, Murrysville, Pennsylvania, USA) attached with straps and pressure adjusted to12 cmH2O peak inspiratory pressure and 5 cmH2O of expiratory pressure at the beginning of the procedure. Patients were adapted to use NIV before starting measurements, pressures were titrated before reaching the established levels and just after this period masks were fitted using the straps. They were oriented to use a breathing pattern inspiring deeply and exhaling slowing to avoid ventilator-patient asynchrony.
223691849|NCT00901927|DRUG|Bendamustine|Starting dose 90 mg/m\^2 by vein over 30-60 minutes on Days 1 and 2 of each cycle.
223691850|NCT00901927|DRUG|Mitoxantrone|10 mg/m\^2 by vein over 15 minutes on Day 2 of each cycle.
223691851|NCT00901927|DRUG|Rituximab|375 mg/m\^2 by vein over several hours on Day 1 of each cycle.
223691852|NCT00062673|DRUG|Duloxetine|
223777305|NCT00000597|DRUG|antilymphocyte serum|
223691853|NCT00062673|DRUG|Placebo|
223777306|NCT00000597|DRUG|nandrolone|
223777307|NCT02109055|OTHER|Pilates|The exercise program will be held during the period of hospitalization for six days, often two to three sessions per day, totaling 12 sessions.
223777308|NCT02109055|OTHER|Conventional Physiotherapy|The conventional physiotherapy group will continue with the routine hospital consisting of respiratory physiotherapy, twice daily, six days.
223777309|NCT00259753|DRUG|Bevasiranib|
223777310|NCT02747940|DRUG|flunarizine and/or pregabalin|
223777311|NCT00189085|DRUG|simvastatin and ezetimibe|
223777312|NCT00110240|DRUG|vildagliptin|
223691854|NCT05237271|OTHER|Educational Materials on the Cardiovascular Disease in Type 2 Diabetes (CVD-T2D)|Educational Materials will detail the diagnostic tests in question. This CVD-T2D will provide a numerical risk score for the likelihood of patients with type 2 diabetes to have a cardiovascular event in the next 4 years.
223777313|NCT00997997|DRUG|Moxifloxacin (Avelox, BAY12-8039)|400 mg, intravenous / oral, once daily, treatment duration at the discretion of the attending physician who must consult the local product information
223691855|NCT05237271|OTHER|Educational Materials on the CVD-T2D and Bundled Metabolic Panel|Educational Materials will detail the diagnostic tests in question.his CVD-T2D will provide a numerical risk score for the likelihood of patients with type 2 diabetes to have a cardiovascular event in the next 4 years. The bundled metabolic scores will provide insight into the patient's current metabolic conditions.
223691856|NCT02049320|DRUG|Remifentanil|
223691857|NCT02942420|DRUG|Bucillamine|Thiol donor which results in a cysteine-bucillamine complex for removing excess cysteine from the urine
223691858|NCT05773703|DRUG|PSMA-Targeted [In-111]-Labeled Trillium Compound|Radiotracer
223691859|NCT05773703|DRUG|PTI-122|Cytoprotective agent
223691860|NCT00814151|OTHER|MicroPhage S. aureus / MSSA / MRSA Blood Culture Test (prototype)|"In vitro diagnostic: The MicroPhage Intervention was to perform the MicroPhage diagnostic test to detect S. aureus in the blood culture sample and determine MSSA or MRSA status at 4 and 5 hours of test incubation. The Intervention results were not made available to the patient or their physician."
223691861|NCT04121416|DRUG|Oxycodone 10mg|induction with 0.3mg/kg of oxycodone in general anesthesia
223691862|NCT04121416|DRUG|Sufentanil|induction with 0.3 µg/kg of Sufentanil in general anesthesia
223691863|NCT03913403|PROCEDURE|ECHO|Echocardiogram at baseline and 24 hours later
223691864|NCT03913403|PROCEDURE|Blood Draw|Blood Draw for Troponin Levels - 5ml at baseline and 24 hours later
223691865|NCT04490239|DRUG|Intranasal heparin sodium (porcine)|Intranasal heparin sodium
223777314|NCT03813303|DRUG|Midazolam|Administration of midazolam by anesthesiologist for sedation.
223777315|NCT03813303|DRUG|Fentanyl|Administration of fentanyl by anesthesiologist for sedation.
223777316|NCT03813303|DRUG|Propofol|Administration of propofol by anesthesiologist for sedation.
223691866|NCT02239627|DRUG|Epidural steroid|
223691867|NCT02239627|DRUG|Clonidine|
223777317|NCT05622773|OTHER|Mat use application|In the research, repeated measurements will be made by using mats and foot baths in a single group and the data will be recorded.
223691868|NCT05298306|DRUG|LAT8881|"In Part A, LAT8881 will be given as a single intravenous infusion at doses of 0.8, 1.2 and 1.8 mg/kg.~In Part B, a single intravenous infusion of LAT8881 will be given, the dose to be determined by the results in Part A"
223691869|NCT05298306|DRUG|Placebo|Matching placebo'given as a single intravenous infusion at all dose levels
223691870|NCT03412071|DRUG|Oral Tinidazole|Please see description under arms
223691871|NCT03412071|DRUG|Topical metronidazole|Please see description under arms
223691872|NCT03412071|DRUG|Topical Clindamycin|Please see description under arms
223691873|NCT03412071|DRUG|Topical Hydrogen Peroxide|Please see description under arms
223691874|NCT03625206|BEHAVIORAL|Cognitive bias modification training|These training sessions aim to modify a selective attention bias towards threat and a tendency to interpret ambiguous situations in threatening ways
223691875|NCT03625206|BEHAVIORAL|Control training|These exercises are matched to the task demands of the modules of cognitive bias modification training
223691876|NCT00410228|DRUG|AHT956|
223777318|NCT01699997|DRUG|Oxytocin|Intranasal spray with 40 IU of OXT
223777319|NCT01699997|DRUG|Placebo|Intranasal spray with placebo solution
223777320|NCT00334659|DRUG|apricitabine|
223777321|NCT01163682|DEVICE|Electro-acupuncture|Subjects will be placed in prone position and acupuncture sites will be cleaned with alcohol preparation. Stainless steel disposable acupuncture needle (diameter 0.25mm) will be inserted into the skin to appropriate depth needed to elicit de qi(approximately 3-4mm). Selected acupuncture points will be attached to2 leads connected to an electro-stimulator that generates 2 Hz of mixed pulsatile intervals for a total of 30 minutes. The acupuncturist will return two times during the treatment at 10 and 20 minutes with needles in situ to check on the patients and needles. Needles not attached to the electro-stimulator will be manipulated manually to elicit de qi one time during the treatment.
223777322|NCT01163682|DEVICE|Sham acupuncture|Will be utilizing a sham control that consists of collapsible acupuncture needle so that there is no penetration of skin. The sham needles will be place on 4 non specific body points. The electro-stimulator will be attached to the needles for 30 minutes but will not be turned on. The acupuncturist will return two times during the treatment at 10 and 20 minutes to check on the patient. The acupuncturist will touch the collapsible acupuncture needs to simulate the manipulation of the needles.
223777323|NCT00359762|DRUG|exenatide|subcutaneous injection (5mcg or 10mcg), twice a day
223777324|NCT00359762|DRUG|glimepiride|oral tablet (titrated to maximally tolerated dose), once daily
223777325|NCT02829034|DRUG|Ranolazine|Ranolazine 500mg by mouth twice per day and after two weeks increases to 1000mg by mouth twice per day and continue for a total of 26 weeks.
223691877|NCT02981810|DEVICE|Arthrocare® Corporation (ArthroCare Corporation, 7500 Rialto Boulevard Austin, Texas 78735) COBLATION electrode ReFlex Ultra 55*|The treatment was conducted using an Arthrocare® Corporation (ArthroCare Corporation, 7500 Rialto Boulevard Austin, Texas 78735) COBLATION electrode ReFlex Ultra 55\* for tonsillar tissue ablation at low temperatures with only one treatment. All the patients underwent tonsil channeling treatment with coblation, and 4-6 channels were done in each tonsil under local anesthesia, in the operating room. The patients were observed overnight.
223691878|NCT02981810|PROCEDURE|tonsillectomy|
223691879|NCT06370273|DRUG|Rivaroxaban|10mg once daily via oral ingestion
223691880|NCT06370273|DRUG|Apixaban|2.5mg twice daily via oral ingestion
223691881|NCT06370273|DRUG|Enoxaparin Injectable Solution|40mg once daily via subcutaneous injection
223691882|NCT06370273|DRUG|Tinzaparin Injectable Solution|4500 IU once daily via subcutaneous injection
223691883|NCT06370273|DRUG|Dalteparin Injectable Solution|5000 IU once daily via subcutaneous injection
223691884|NCT06370273|DRUG|Fondaparinux Injectable Product|2.5 mg once daily via subcutaneous injection
223691885|NCT04880005|BEHAVIORAL|Clinical decision support|"Based on the phenotyping and algorithms developed by the hospital specialists at Odense University Hospital and Holbæk Hospital in collaboration with GPs, the individual GPs and their patients will receive individualized recommendations on lifestyle interventions and pharmacological treatments.~The GPs will receive specific clinical decision support (CDS) recommendations on what drugs to prescribe to each patient based on the phenotyping in accordance with a clinical decision support tool (Cambio) and the updated guidelines at all times (Sparrow 2019). The treatment advice to the GPs will be adjusted annually based on treatment effect, re-phenotyping, and updated knowledge of the treatment of T2D. Furthermore, psychiatric, socioeconomic and/or cultural challenges and other determinants for frailty will be a part of the individualized intervention provided to patients by the GPs, again based on the specialist advice."
223691886|NCT04880005|BEHAVIORAL|Digital Lifestyle Coaching|As part of DICTA, the patients are offered a personal health coach (dietician, nurse, occupational therapist, or physiotherapist) through the complex eHealth intervention (Liva). Patients will receive personalized empathic, relation driven coaching on healthy lifestyle on the individual patient's preferences (e.g. increased physical activity, healthier diet, weight loss, smoking cessation, personal goal setting, tailored information, peer to peer support), including optimal pharmacological treatment (Komkova 2019). The collaborative eHealth tool will give health coaches access to patient registered outcome measurements (PRO), information. This forms the basis of the individual coaching and is partly supported by artificial intelligence (AI) to improve the coaching by the health coaches (Holzinger 2016).
223691887|NCT04880005|BEHAVIORAL|Integration to Standard Electronic Health Record|Data on physical activity, steps, diet goal fulfillment, smoking status etc., are being provided for GPs in a web-based solution integrated into the GPs' health record system. Integration with the GP system XMO (covering 52% of all Danish GPs) has been finalized.
223691888|NCT02935101|DRUG|Prednisolone|formulated for oral administration. encapsulated.
223691889|NCT02935101|DRUG|Placebo (for Prednisolone)|Sugar pill manufactured to mimic Prednisolon 10mg capsules
223691890|NCT01131767|DRUG|Naproxen Sodium & Pseudoephedrine HCl|Naproxen Sodium 220 mg and Pseudoephedrine Hydrochloride 120 mg Extended Release Tablets
223777326|NCT02829034|DRUG|Placebo|Placebo by mouth twice per day for a total of 26 weeks
223777327|NCT01141361|PROCEDURE|GPS recording(s) of walking capacity in PAD patients|Home-based GPS recording(s) of walking capacity in PAD patients. Two evaluations will be performed. The second evaluation will be performed six months after the initial assessment (test 1) and only for patients with GPS maximal walking distance below 2000 meters at test 1. It is expected that some patients at test 2 will have undergo surgery or endovascular treatment.
223777328|NCT05158062|BIOLOGICAL|pembrolizumab|pembrolizumab 200 mg every three weeks (Q3W)
223777329|NCT05158062|DRUG|olaparib|olaparib 300 mg twice daily (BID) during maintenance period
223777330|NCT05158062|BIOLOGICAL|bevacizumab|bevacizumab 15 mg/kg Q3W
223777331|NCT05158062|DRUG|carboplatin|carboplatin AUC=5 or 6 Q3W during treatment period
223777332|NCT05158062|DRUG|paclitaxel|paclitaxel 175 mg/m2 Q3W during treatment period
223777333|NCT05158062|DRUG|docetaxel|docetaxel 60 \~ 70 mg/m2 Q3W during treatment period
223777334|NCT02162628|DEVICE|Exair Prolapse Repair System|
223777335|NCT02162628|PROCEDURE|Total Native Tissue Repair|
223691891|NCT05733377|DIAGNOSTIC_TEST|Arrow Test|It consists of taking the widest measurement between the rope of a plumb bob on her upper and lower back.
223691892|NCT05733377|DIAGNOSTIC_TEST|Angle measurement by imaging device|First, three anatomical landmarks are located, and a sticker is placed on each of them: the 12th thoracic vertebra at its intersection with the midline descending from the axilla, the greater trochanter, and the anterior superior iliac spine. After this, the woman will be asked to stand in a normal position facing forward with her hands crossed over her shoulders, and a picture will be taken and pixelated with anything that could identify her. The angle formed by the three stickers will be measured with this image and the software.
223691893|NCT00006169|BEHAVIORAL|Behavioral Treatment|
223691894|NCT00397410|DEVICE|Hip protectors|
223691895|NCT05266027|DRUG|Nalbuphine Sebacate (Naldebain)|Nalbuphine Sebacate (Naldebain) 2mL/150mg would be intramuscularly injected during knee arthroplasty surgery.
223691896|NCT05266027|DRUG|Placebo medication|Placebo medication, Nalbuphine Sebacate not contained
223691897|NCT01016561|RADIATION|intracavitary balloon brachytherapy|
223691898|NCT01016561|RADIATION|external beam radiation therapy|
223691899|NCT01016561|RADIATION|intensity-modulated radiation therapy|
223691900|NCT01016561|RADIATION|radiation therapy treatment planning/simulation|
223691901|NCT01016561|RADIATION|3-dimensional conformal radiation therapy|
223691902|NCT01016561|DRUG|Cisplatin|
223691903|NCT00120354|PROCEDURE|Blood Testing|
223691904|NCT00120354|PROCEDURE|Percutaneous Liver Biopsy|
223691905|NCT00120354|PROCEDURE|Lamivudine Therapy|
223691906|NCT02676466|DIETARY_SUPPLEMENT|Omega-3 fish oil|The Omega-3 fish oil will be provided in 700 mg gelcaps. The starting dose will be 1.4 g/day of fish oil and continue until the 6 month visit. If the average of IL-6 measured at 3- and 6-month visits does not decrease by \>40% vs. baseline (average of screening visits 1 and 2), we increase the dose to 2.8 g/day.
223691907|NCT02676466|DRUG|Losartan|The Losartan will be provided in 25 mg and 50 mg capsules. The starting dose will be 25 mg/day, if tolerated, then stepped up to 50 mg/day. If there are no safety concerns, a continuation of 50 mg/day will be provided until the 6 month visit. If the average of IL-6 measured at 3- and 6-month visits does not decrease by \>40% vs. baseline (average of screening visits 1 and 2), an increase to the dose of 100 mg/day.
223777336|NCT02652780|BIOLOGICAL|GS010|"Both eyes of each participant will receive standard antiseptic preparation, administration of topical local ocular anesthetic agents and will undergo pupillary dilation. Administration of an intra-ocular pressure lowering agent will precede treatment for every participant.~GS010-treated Eyes: GS010 is a recombinant adeno-associated viral vector serotype 2 (rAAV2/2) containing the wild-type ND4 gene (rAAV2/2-ND4). Participants will receive a single dose of GS010 in one of their randomly selected eyes, via intravitreal injection containing 9E10 viral genomes in 90μL balanced salt solution (BSS) plus 0.001% Pluronic F68®."
223691908|NCT02676466|OTHER|Corn Oil (Fish oil Placebo)|The corn oil placebo gel caps will be identical in shape, color, taste and weight as the Omega-3 fish oil.
223691909|NCT02676466|OTHER|Cellulose Based (Losartan Placebo)|The placebo cellulose based capsules will be identical in shape, color, taste and weight as the losartan capsules.
223691910|NCT01119560|OTHER|Cytology Specimen Collection Procedure|Correlative studies
223691911|NCT01119560|OTHER|Laboratory Biomarker Analysis|Correlative studies
223691912|NCT01119560|OTHER|Questionnaire Administration|Ancillary studies
223691913|NCT01178073|DRUG|ambrisentan|ambrisentan (target dose: 10mg)
223691914|NCT01178073|DRUG|tadalafil|tadalafil (target dose: 40mg)
223691915|NCT01352468|OTHER|Multifaceted cognitive training|Four computerized training tasks
223691916|NCT01936077|DRUG|Recombinant LH (Luveris)|150 IU recombinant LH daily.
223691917|NCT04151342|DRUG|Cancer treatment with tyrosine kinase inhibitors (TKIs) or other molecularly targeted therapeutic agents.|Observing cancer patients who have received or are currently receiving tyrosine kinase inhibitors (TKIs) or other molecularly targeted therapies for their cancer treatment.
223691918|NCT04151342|OTHER|Patient-reported outcomes (PROs)|Prospectively enrolled participants will be provided with survey packets comprised of different PRO instruments at the initial/baseline visit, at 3 month follow up intervals and at the time when treatment/therapy is changed.
223691919|NCT01003444|PROCEDURE|Muscle biopsy|Collection of muscle biopsies of the vastus lateralis will be performed by a consulting specialist. The first muscle biopsy (Day 1, 2 hour) will be obtained from the vastus lateralis muscle of the non-dominant leg. The second biopsy (Day 1, 4 hour) will be obtained from the same vastus lateralis muscle on the same leg approximately 10 centimeters from the first muscle biopsy site.
223691920|NCT05684523|DRUG|Valerian-Hop Extract|herbal drug
223691921|NCT05684523|DRUG|Placebo|Placebo
223691922|NCT01721070|DRUG|Sufentanil NanoTab (SUF NT) 15 mcg|Period 1: One dose of SUF NT 15 mcg administered sublingually
223691923|NCT01721070|DRUG|Ketoconazole 400 mg, sufentanil NanoTab (SUF NT) 15 mcg|Period 2: Ketoconazole 400 mg administered daily for three days, SUF NT 15 mcg co-administered sublingually on the third day
223691924|NCT04302818|BEHAVIORAL|SKOLKONTAKT|N=21 participants are offered manualized and structured group training SKOLKONTAKT. The intervention includes 12 weeks, 3 sessions (50 minutes) per week.
223691925|NCT04302818|BEHAVIORAL|Social activity group|N=21 participants. The active comparison group includes 12 weeks, 3 sessions (50 minutes) per week. Sessions will include socially oriented activities such as board games, sports or baking as well as a recommended, general agenda.
223777337|NCT02652780|DEVICE|Sham Intravitreal Injection|"Both eyes of each participant will receive standard antiseptic preparation, administration of topical local ocular anesthetic agents and will undergo pupillary dilation. Administration of an intra-ocular pressure lowering agent will precede treatment for every participant.~Sham-treated Eyes: One eye of each participant will undergo sham injection. Sham Intravitreal injection will be performed by applying pressure to the eye at the location of a typical intravitreal injection procedure using the blunt end of a syringe without a needle."
223777338|NCT02011841|DRUG|Rifaximin|rifaximin 1200 mg/day orally for 6 months
223777339|NCT02011841|DRUG|Ciprofloxacin|ciprofloxacin 500 mg/day orally for 6 months
223691926|NCT02025517|OTHER|Cognitive Tasks.|The Experimental Group underwent treadmill gait training simultaneously to a protocol of cognitive tasks created specifically for this study, based on cognitive activities proposed in previous studies. The training sessions lasted 20 minutes. The first three minutes allowed subjects to familiarize themselves with the treadmill. From the 4th minute onward, the volunteer walked for 1 minute while performing cognitive tasks, and in the following minute, only walked. Thus, the 17 remaining minutes on the treadmill alternated between one minute of treadmill training combined with a cognitive task and the following minute only treadmill training. Treadmill gait speed was that reported by the patient as the fastest possible speed while maintaining a suitable comfort level.
223691927|NCT02250027|DRUG|HL301 300mg capsule|2 capsules at once, 3 times a day, for 7 days
223691928|NCT02250027|DRUG|Placebo|2 capsules at once, 3 times a day, for 7 days
223691929|NCT03497676|DRUG|Oral Cabotegravir (CAB)|30 mg tablets administered orally
223691930|NCT03497676|DRUG|Oral Rilpivirine (RPV)|25 mg tablets administered orally
223691931|NCT03497676|DRUG|Long-Acting Injectable Cabotegravir (CAB LA)|Administered by intramuscular (IM) injection
223691932|NCT03497676|DRUG|Long-Acting Injectable Rilpivirine (RPV LA)|Administered by intramuscular (IM) injection
223691933|NCT03497676|DRUG|Combination Antiretroviral Therapy (cART)|Participants will continue their pre-study cART regimen. The antiretroviral drugs in participants' cART regimens were not provided through the study.
223691934|NCT00934258|DRUG|rosuvastatin,fenofibrate|Rosuvastatin 10 mg once daily Rosuvastatin 5 mg + SFC fenofibrate 80 mg
223691935|NCT00934258|GENETIC|CYP2C9, UGT1A1, UGT1A3, OATP2, BCRP|All potential patients will be screened for the eligibility in a screening visit. Those who fill the inclusion criteria at screening will be invited for the registry study into different groups. The follow-up will take place at months 6, 12, 18, and every year thereafter for another 3 years, through clinical visiting, phone follow-up, or records from the NHIB Taiwan. At each clinical visit, vital signs, clinical endpoints, adverse events, concurrent medication information and laboratory specimens will be obtained as complete as possible. With phone or records from NHIB, only clinical endpoints will be recorded. If the primary care physician intends to treat the patient's lipid profile to the target, he/she can add, delete or adjust the LLT by his/her clinical judgement
223691936|NCT00589485|DEVICE|Simplex® Bone Cement|This arm will utilize Simplex® Bone Cement in total knee replacement.
223691937|NCT00589485|DEVICE|Cobalt™ Bone Cement|This arm utilizes Cobalt™ Bone Cement in total knee replacement.
223691938|NCT03927807|DRUG|Misoprostol|"This study will include 150 pregnant women who fulfill the inclusion criteria and will be subdivided in two groups.~Group1 will receive repetitive hourly dose of oral misoprostol solution equal to 10 microgram up to 12 doses or regular uterine activity.~Group2 will receive oral misoprostol solution every two hours as 20 microgram up to 6 doses or regular uterine activity."
223777340|NCT01411189|DRUG|Menthol|20 mL NPO-11 in prefilled syringe
223777341|NCT01172938|DRUG|Apremilast 20mg|Apremilast 20 mg twice daily, orally
223691939|NCT00687232|DRUG|AZD4818|Dry powder, inhalation, b.i.d, 10 + 1/2 days or 20 + 1/2 days
223691940|NCT00687232|DRUG|Placebo|
223691941|NCT03496571|DRUG|AK002|AK002 is a humanized non-fucosylated immunoglobulin G1 (IgG1) monoclonal antibody directed against Siglec-8, a member of the CD33-related family of sialic acid-binding, immunoglobulin-like lectins (Siglecs).
223691942|NCT03496571|OTHER|Placebo|Placebo
223691943|NCT00484718|DRUG|celecoxib|oral, 100 mg bid
223691944|NCT00484718|DRUG|Oxycodone|oral, 20 mg bid
223691945|NCT00484718|DRUG|placebo|oral bid
223777342|NCT01172938|DRUG|Apremilast 30mg|Apremilast 30 mg twice daily, orally
223777343|NCT01172938|DRUG|Placebo + 20 mg Apremilast|Placebo + 20 mg Apremilast
223777344|NCT01172938|DRUG|Placebo + 30 mg Apremilast|Placebo + 30 mg Apremilast
223777345|NCT00002408|DRUG|Crofelemer|
223777346|NCT00548821|DRUG|Cisplatin|
223777347|NCT04168749|COMBINATION_PRODUCT|Numeta G13|10 days
223777348|NCT00003498|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Non-Hodgkin's Lymphoma will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
223777349|NCT04188041|OTHER|TB Infection ECHO|A six-month virtual telementoring course regarding TB infection testing and treatment that incorporates didactics, case presentation, and discussion
223777350|NCT00038493|DRUG|Temozolomide and SCH66336|
223777351|NCT03396744|DEVICE|Light|Placebo light (50 Lux) during 1 week and then active bright light with glasses using a dosage escalation (inter- and intra-subject) of 7.5, 10, 15, 30 and 45 min
223777352|NCT02823925|DRUG|Pamidronate or Zoledronate|
223777353|NCT04823338|BEHAVIORAL|Conectar Jugando Online Program|Online play sessions with modern board and card games guided by the study researchers
223777354|NCT04575779|DRUG|Cyclosporin with a daily dose of 3 mg/kg/day intravenously over 2 h (short infusion) every 12 h|To determine whether administering CsA at a dailydose of 3 mg/kg/day intravenously(i.v.) in 2 hrs (short infusion) twice-daily will achieve C2 blood levels of at least 800 mg/l and whether it will be feasible and safe or not.
223777355|NCT06534138|BEHAVIORAL|Physical exercise|The CP-exercise group was categorized based on patients' self-reported daily exercise time into four levels: 15 minutes/day, 30 minutes/day, 45 minutes/day, and ≥60 minutes/day. Additionally, resistance exercise and endurance exercise were distinguished based on patients' self-reported exercise modalities, including swimming, jogging, brisk walking, practicing Tai Chi, and dumbbell training.
223777356|NCT05282004|DRUG|SOK583A1|SOK583A1 will be provided in a vial kit, with 40 mg/mL of aflibercept solution for IVT injection (2 mg/0.05 mL)
223691946|NCT06533397|PROCEDURE|Sinus floor elevation (SFE)|Patients rinse with 0.2% chlorhexidine solution for one minute before surgery. Under local anesthesia, a mucoperiosteal flap is raised from a midcrestal incision and two relieving incisions. Lateral window osteotomies are carried out using diamond burs. The Schneiderian membrane is carefully elevated and the synthetic bone graft material (Bond Apatite, Augma Biomaterials, Cesarea, Israel) (2-3 cm3) is packed in the defect with light force. The buccal flap is then mobilized to allow tension-free primary closure. The margins are stabilized with single interrupted sutures. Antibiotics (1 g amoxicillin-clavulanate twice a day for 5 days, or in case of side effects or known allergy to penicillin, 300 mg clindamycin 4 times a day for 4 days), anti-inflammatory drugs (50 mg diclofenac 3 times a day for 3 days), and chlorhexidine mouthwash (twice a day for 21 days from the first day after surgery) are prescribed. Suture removal takes place after 10 days.
223691947|NCT06533397|DIAGNOSTIC_TEST|preoperative cone beam computed tomography (CBCT)|A CBCT scan is performed before SFE surgery to evaluate the anatomy and pathologies of the maxillary sinus.
223691948|NCT06533397|DIAGNOSTIC_TEST|postoperative CBCT|A CBCT scan is performed following the 3- or 6-month-long healing period after SFE to evaluate the anatomy and healing of the augmented bone and the maxillary sinus.
223691949|NCT06533397|DIAGNOSTIC_TEST|bone core biopsy|At the time of dental implant placement, the first step of the implant bed preparation is performed using a trephine drill to harvest a bone core biopsy sample from the augmented bone. The biopsy sample is harvested from the implant bed, this way the patient is spared of excess surgical burden as this bone would be removed even if no biopsy sample was harvested during dental implant placement. The bone core biopsy samples are subjected to histomorphometric and microCT analysis.
223691950|NCT06533397|PROCEDURE|dental implant placement|Following the 3- or 6-month-long healing period following SFE, dental implants are placed non-submerged in the augmented bone under local anesthesia.
223691951|NCT06533397|PROCEDURE|fixed dental prosthesis (FDP) fabrication|3 months after dental implant placement, fixed dental prostheses are delivered on the dental implants.
223691952|NCT06533397|DEVICE|bone grafting|A synthetic bone graft material (Bond Apatite, Augma Biomaterials, Cesarea, Israel) is used during SFE.
223691953|NCT04684290|PROCEDURE|Alcohol Septal Ablation|Participants will be treated with alcohol septal ablation.
223691954|NCT04684290|PROCEDURE|Surgical Septal Myectomy|Participants will be treated with surgical septal myectomy.
223691955|NCT02636374|BEHAVIORAL|Guided Imagery|A fifteen minute recording of gentle music together with soft talking to guide relaxation.
223691956|NCT01226043|DRUG|Insulin Glargine|"* Pharmaceutical form: solution for injection~* Route of administration: subcutaneous"
223691957|NCT00769574|OTHER|Biological analysis of biomarkers|Biological analysis of biomarkers
223691958|NCT00769574|OTHER|Biological analysis of biomarkers|Biological analysis of biomarkers
223691959|NCT01110304|OTHER|Conservative treatment - brace|Patients selected for this treatment will wear a light brace for pain release and analgesics will be prescribed. They can move the elbow, the wrist and the fingers immediately. After two weeks, they will begin a training program to restore shoulder motion and strength, and they will be asked to take off the brace progressively. They are allowed to start working and sporting activities when they feel comfortable.
223691960|NCT01110304|DEVICE|Hook plate by Synthes|The patient is in a beach-chair position with injured arm slightly out of the table, on a bracket. The incision is longitudinal, from the distal third of the clavicle to the lateral border of the acromion. The deltoid is detached anteriorly to present the clavicle and the AC joint. The width of the hook depends on the depth of the acromion. The plate will always be 5 holes 3.5mm hook plate (Synthes®), left or right. The hook is inserted after visual reduction of the AC joint at the posterior border of the distal end of the clavicle, under the acromion. Reduction is then maintained by a davier and fixation with three 3,5mm cortical screws is achieved. After washing, deltoid is reinserted. CC ligaments are not directly repaired. Wound closure and bracing for two weeks.
223691961|NCT00596297|DRUG|bevacizumab|Intravitreal bevacizumab (1.5 mg; 0,06 ml) 1 day after baseline; pars plana vitrectomy 4 weeks after baseline
223691962|NCT00596297|PROCEDURE|pars plana vitrectomy|4 weeks after baseline
223691963|NCT00284596|PROCEDURE|High tibial osteotomy|HTO
223691964|NCT04152044|OTHER|Observation of different types of obesity and liver pathology in patients undergoing and oesophagectomy|Patinets undergoing surgery
223691965|NCT00666874|BEHAVIORAL|lifestyle changes|Detailed advice about how to achieve a reduction of weight of 10% or more through a low-energy Mediterranean-style diet and increased physical activity.
223691966|NCT00666874|BEHAVIORAL|Control - general information|General information about healthy food choices and exercise
223691967|NCT00355654|BIOLOGICAL|DT5aP-IPV-Hib 5-component Pertussis vaccine|0.5 mL, IM
223691968|NCT00355654|BIOLOGICAL|DT3aP-HBs-IPV|0.5 mL, IM
223691969|NCT02204007|DEVICE|3D imaging & surrogate bone model|3D imaging \& surrogate bone model to assist with acetabular shell placement. Different that standard of care preoperative imaging
223691970|NCT03052907|BEHAVIORAL|BSPAN|"1. Identify readiness assessment criteria (RAC) essential in determining a rural county's capacity to support comprehensive mammography and appropriate follow-up services.~2. Using the RAC, we will determine which of the five BSPAN1 counties have capacity to manage and sustain the Outreach \& Health Promotion and Delivery \& Navigation components of the program (High Capacity), and which have the capacity to manage and sustain only the Outreach \& Health Promotion component (Medium Capacity).~3. Expand BSPAN to 12 new rural and underserved counties according to RAC score and evaluate each county's ability to implement program components and increase comprehensive mammography and appropriate follow-up."
223691971|NCT00092690|DRUG|MK0653A, ezetimibe (+) simvastatin|
223691972|NCT00092690|DRUG|Comparator: atorvastatin|
223691973|NCT02341105|PROCEDURE|Catheter ablation|Pulmonary vein isolation by catheter ablation
223691974|NCT02341105|DRUG|Amiodarone|antiarrhythmic therapy using Amiodarone
223691975|NCT02477137|DEVICE|smartphone or tablet|Patients in the intervention group are given access to an application for a smartphone/tablet for daily reporting of symptoms, access to self-care advice and health-care professionals in real time.
223691976|NCT05345054|OTHER|no intervention|This study will not involve an intervention of any sort. Participants will either take a survey or undergo an interview, and those taking the survey will have clinical data captured.
223691977|NCT01514500|DRUG|somapacitan|Administered s.c. (subcutaneously, under the skin)
223691978|NCT01514500|DRUG|placebo (somapacitan)|Single or multiple placebo doses administered s.c. (subcutaneously, under the skin)
223691979|NCT00910988|DRUG|Olanzapine|olanzapine/Zyprexa
223691980|NCT00910988|DRUG|Ziprasidone|ziprasidone/Geodon
223691981|NCT00766883|BEHAVIORAL|Problem Solving Education|
223691982|NCT04722549|DIETARY_SUPPLEMENT|Placebo|Cellulose
223691983|NCT04722549|DIETARY_SUPPLEMENT|Butyrate|Sodium butyrate
223691984|NCT02578771|DRUG|ZuraPrep with 70% IPA|Apply topically
223691985|NCT02578771|DRUG|ZuraPrep without 70% IPA|Apply topically. 0% IPA
223691986|NCT02578771|DRUG|ChloraPrep CHG/IPA Teal Tint|Apply topically
223691987|NCT02578771|OTHER|Normal Saline|Apply topically
223691988|NCT05616806|BEHAVIORAL|iENDURE|"Two delivery modes: computer and text message. The intervention provides introductory strategies for managing physical and emotional distress associated with Long COVID through a computer-delivered session followed by 4-weeks of theoretically-informed text messages intended to promote distress tolerance (DT).~Computer - the initial intervention will be delivered online via the Qualtrics survey tool following informed consent. The intervention provides strategies to better tolerate emotional and physical discomfort to persist with behavioral goals. Text Message - The text message intervention will be delivered using Marigold Health (a HIPAA compliant platform for secure text messaging). Participants will receive daily text messages that focus on emphasizing adaptive strategies for tolerating physical and emotional discomfort in order to work toward behavioral goals. The text messages will be personalized and offer skills training (reminders of previously learned DT skills)."
223691989|NCT00494273|BEHAVIORAL|Cognitive Behavioral and Standard Care with Healthy Living|
223691990|NCT02671773|DRUG|Inhaled corticosteroid dose/type|
223691991|NCT05034133|DRUG|Durvalumab|Durvalumab (IV 1000mg on day 1) with chemotherapy (Etoposide and Cisplatin) for 6 cycles
223691992|NCT00526604|BEHAVIORAL|work related rehabilitation|"The workplace intervention includes two steps:~Evaluations of the work site: The occupational ergonomists task is to identify conditions at the work site, as for instance ergonomic, work demand and relations to the employer and colleagues.~Therapeutic Return to work: The occupational ergonomists will organize contacts and meetings between the employer and the patients and make a schedule for return to work. The therapeutic return-to-work-process will take place at the work place, with progressively more days at work and progressively increasing tasks."
223691993|NCT05350176|DIETARY_SUPPLEMENT|Probiotic|Probiotic capsules will be composed of 10 billion CFU of Lactobacillus plantarum.
223691994|NCT05350176|DIETARY_SUPPLEMENT|Placebo|Capsules containing dextrose (1 capsule per day)
223691995|NCT02701842|DEVICE|ImPACT Online/Paper Pencil Tests|
223691996|NCT02701842|DEVICE|ImPACT Online|
223691997|NCT01624051|OTHER|Standard dosing method arm: Cisplatin (chemotherapy) dosing based on body surface area|Cisplatin dosing calculated at the rate of 75 mg/m2
223691998|NCT01624051|OTHER|Experimental dosing method arm: Cisplatin (chemotherapy) dosing based on individual lean body mass|Cisplatin dosing calculated at the rate of 3.10 mg/kg lean body mass
223691999|NCT05618431|OTHER|NIPT|This research aims to develop and validate a new method for non-invasive prenatal testing
223692000|NCT05425589|PROCEDURE|Adjustable strabismus surgery|Our objective was to assess the long-term success of adjustable suture strabismus surgery in terms of postoperative alignment and complications.
223692001|NCT00003800|OTHER|immunohistochemistry staining method|
223692002|NCT00003800|OTHER|laboratory biomarker analysis|
223692003|NCT00003800|PROCEDURE|radionuclide imaging|
223692004|NCT03004443|DRUG|Infliximab|Infliximab will be administered intravenously (IV) as 5 mg/kg body weight over a 2 to 2.5 hour period.
223692005|NCT03004443|DRUG|Placebo|Saline solution will be administered intravenously over a 2 to 2.5 hour period.
223692006|NCT04176575|OTHER|Acupuncture|Acupuncture involves inserting thin needles into precise points on the body, known as acupuncture points, for therapeutic effect. Acupuncture will be provided by a licensed acupuncturist utilizing Dr. Tan's Balancing Method.
223692007|NCT00828854|DRUG|Entinostat|Entinostat 5 mg PO every week
223692008|NCT00828854|DRUG|Aromatase Inhibitor (AI) Therapy|AI therapy at labeled dose and schedule as prescribed in clinical practice. AI therapies include: Arimidex® (anastrozole) 1 mg/day by mouth (PO), Fermara® (letrozole) 2.5 mg/day PO , Aromasin® (exemestane) 25 mg/day PO.
223692009|NCT05774275|DRUG|Pegylated Liposomal Doxorubicin|In phase Ib: 37.5 mg/m2, 30 mg/m2, d1, q3w; In phase II: recommended phase 2 dose (RP2D), d1, q3w.
223692010|NCT05774275|DRUG|Doxorubicin|75mg/m2, d1, q3w Doxorubicin hydrochloride will be administered if subject is allergic to Doxil.
223692011|NCT05774275|DRUG|Anti-PD-1 monoclonal antibody|200 mg, d1, q3w
223692012|NCT05774275|RADIATION|Radiotherapy|BED=50-60Gy(α/β=10); Radiation dose depends on tumor characteristics and organs at risk.
223692013|NCT03476668|OTHER|MIRT|4-week multidisciplinary intensive rehabilitation treatment
223692014|NCT00137865|GENETIC|EGEN-001 (phIL-12-005/PPC)|
223692015|NCT06087146|OTHER|Sauerkraut (Brassica oleracea v. capitata)|The research material is a donation from the company Eko Bio Zrnje, Vrbovec, Croatia. It's grated pickle cabbage produced by fermentation in a saline solution (NaCl) in which the fermentation was stopped by pasteurization and was packed in glass 500g jars. The nutritional and microbiological composition was tested by the laboratories of the Faculty of Food and Biotechnology, as well as by the cultural laboratory approach confirmed the presence of bacteria that produce lactic acid (4.82·103 (±2.31) CFU/mL)
223692016|NCT05605431|DIAGNOSTIC_TEST|Polysomnography|over nightSleep study
223692017|NCT04253912|DRUG|VBP-245|2% Povidone-Iodine Gel
223692018|NCT04253912|DRUG|Placebo Gel (no Povidone-Iodine)|Placebo Gel (no Povidone-Iodine)
223692019|NCT05183893|DIETARY_SUPPLEMENT|L-citrulline|5 g of L-citruline + 5 g of additives
223692020|NCT05183893|DIETARY_SUPPLEMENT|Citrulline-malate|8g of citrulline-malate + 2 g of additives
223692021|NCT05183893|DIETARY_SUPPLEMENT|Placebo|10g of maltodextrine
223692022|NCT04630639|DEVICE|Sparkle|The Sparkle device is a single-use device intended to aid the diagnosis of sleep-disordered breathing; however, this study is intended only to validate the respiratory effort signal and does not assess diagnostic performance.
223692023|NCT00685555|BEHAVIORAL|Switch active lifestyles brought to you by MediaWise|The Switch™ Program is a unique community and family-based behavior change initiative that helps motivate children to change three critical health behaviors that are risk factors for childhood overweight and obesity.
223777357|NCT06571357|BEHAVIORAL|Pranic Healing|The Pranic Healing intervention will be applied according to the advanced protocol by Master Choa Kok Sui, involving seven key techniques: sensitizing the hands, scanning the aura, cleansing the aura, increasing receptivity, energizing with prana, stabilizing the projected prana, and releasing. The intervention will take place in three stages: 5 minutes before, during, and 5 minutes after venipuncture.
223692024|NCT00685555|BEHAVIORAL|Switch active lifestyles from MediaWise|1300 students (male and female) were recruited through two separate school districts in Lakeville, Minnesota and Cedar Rapids, Iowa. Informed consents went to all students who chose to participate. Demonstration and Control school were randomly selected. Baseline data was collected regarding physical activity, screen time, and nutrition, standard body measurements, and baseline data, and salivary cortisol levels were taken. Parent and teacher surveys were also conducted. After baseline selected demonstration sites and students were provided with information focused on improving healthy behaviors while the control sites served as matched comparison groups.
223692025|NCT01522729|DRUG|Fentanyl|Single-dose of intrathecal fentanyl \[25ug\] Duration of fentanyl : 3.5 hours
223692026|NCT01522729|DRUG|Placebo comparator|placebo \[NaCl\]
223692027|NCT03188627|BIOLOGICAL|Bronchial basal cells|Transplantation of autologous bronchial basal cells
223692028|NCT01841307|DRUG|Cromolyn Sodium|
223692029|NCT02644031|PROCEDURE|mtwo rotary system|post-treatment pain after using mtwo rotary system
223692030|NCT02644031|PROCEDURE|safe-sider rotary system|post-treatment pain after using safe-sider rotary system
223692031|NCT02644031|PROCEDURE|hand files|post-treatment pain after using hand files
223692032|NCT02103049|DRUG|Ezetimibe|Patients on standard immunosuppressive therapy with statin will be added ezetimibe for 6 months. Thereafter ezetimibe will be discontinued for three months. Biochemical parameters will be analysed at the time of enrolment, after 3 months, 6 months and 9 months.
223692033|NCT02015702|OTHER|One-on-one physician training|Physicians in the experimental arm were visited by a instructing physician at a computer while performing clinical duties who had observed others to identify best practices. Instructors watched subjects' work, looking for a specific tip that could be applied to the current work, then demonstrated the tip, and answered any questions the subject had about using or applying this new technique .
223692034|NCT02015702|OTHER|Usual training|Usual training included online e-modules, 12 hours of classroom time, practice in the EPIC Playground, user acceptability training classes,non-physician technical support on all of the floors, and a physician-only help line.
223692035|NCT01600508|OTHER|Videoconference stoma care|Stoma patients are randomized to videoconference stoma care or surgical outpatients clinic stoma care
223692036|NCT03425019|DEVICE|Soterix 1x1 tDCS mini-CT Stimulator device|Transcranial Direct Current Stimulation (tDCS) involves the application of weak direct electric current to the head in a noninvasive and painless manner. tDCS with a constant current intensity of 2 mA will be applied for 20 minutes per session daily for 2 weeks (Monday to Friday) via the Soterix 1x1 tDCS mini-CT Stimulator device. Participants will self-administer tDCS at their home or a private room for two weeks (Mondays-Fridays) under real-time supervision by the research staff.
223692037|NCT05116358|DEVICE|Phototherapy device|The active phototherapy device will emit light
223692038|NCT00294476|DRUG|IVIG|
223692039|NCT00294476|PROCEDURE|Biological Therapy|
223692040|NCT04095390|DRUG|Pyrotinib|400 mg
223692041|NCT04095390|DRUG|SHR6390|125mg
223692042|NCT04095390|DRUG|Letrozole|2.5mg
223777358|NCT05306106|OTHER|Glucose|Each subject will consume the reference product during visits V1 and V5. A venous catheter will be placed by a medical biology technician and a blood sample will be taken immediately after placement: this is the first sample at T = 0 min. Then, the subject will have a maximum of 10 minutes to consume the glucose solution. The technician will then take blood samples at T = 15, T = 30, T = 45, T = 60, T = 90 and T = 120 minutes.
223692043|NCT04095390|DRUG|Capecitabine|500mg
223692044|NCT05938179|DRUG|HS-10353 30mg oral capsules|HS-10353 30mg oral capsules
223692045|NCT05938179|DRUG|HS-10353 50mg oral capsules|HS-10353 50mg oral capsules
223692046|NCT05938179|DRUG|Placebo for HS-10353 30mg capsules|Placebo for HS-10353 30mg capsules
223692047|NCT05938179|DRUG|Placebo for HS-10353 50mg capsules|Placebo for HS-10353 50mg capsules
223692048|NCT02826850|PROCEDURE|Saphenous Nerve|Saphenous nerve neurotomy by radiofrequency, guided by ultrasound.
223692049|NCT02826850|PROCEDURE|Genicular nerves|Genicular nerves neurotomy by radiofrequency, guided by fluoroscopy
223692050|NCT05861310|DRUG|Metronidazole 1% Cream,Top|Cream that has an active ingredient in the form of metronidazole with a content of 1%. At the beginning of the study visit, anamnesis and examination of the skin status were carried out. Skin status includes examination of the degree of erythema with a Clinician Erythema Assessment Scale (CEA) score, examination of skin scrapings for demodex examination, dermoscopy examination, and TEWL (Transepidermal Water Loss) examination. Then the participants were given metronidazole 1% cream which was to be used twice a day in the morning and at night. Evaluation of the therapeutic response will be carried out on days 28 and days 56.
223692051|NCT05861310|DRUG|Placebo|Cream that has not medicine. At the beginning of the study visit, anamnesis and examination of the skin status were carried out. Skin status includes examination of the degree of erythema with a Clinician Erythema Assessment Scale (CEA) score, examination of skin scrapings for demodex examination, dermoscopy examination, and TEWL (Transepidermal Water Loss) examination. Then the research subjects were given Placebo cream (without the drug substance) which was to be used twice a day in the morning and at night. Evaluation of the therapeutic response will be carried out on days 28 and days 56.
223692052|NCT05736510|OTHER|Binaural sound|"When the pneumoperitoneum ends, the anesthesiologist puts headphones on the patient and plays the allocated file. In the experimental group, the allocated file is binaural sound with 40Hz beat. Thereafter, the target of PSI is to be between 40 and 50. If the Psi increases above 50, increase the propofol concentration by 0.5 mg/mL and record it. Train of four counts keep between 1 to 3 (moderate block). When the operation is ended, stop anesthetics administration, and, we reverse neuromuscular blocking using sugammadex (2mg/ kg). When the anesthesiologist starts waking the patient up, call the patient's name (unify into OOO, open your eyes.). The anesthesiologist lightly tap the patient's shoulder and avoid excessive sound or stimulation."
223692053|NCT05736510|OTHER|Control|"When the pneumoperitoneum ends, the anesthesiologist puts headphones on the patient and plays the allocated file. In the control group, the allocated file is silent. Thereafter, the target of PSI is to be between 40 and 50. If the Psi increases above 50, increase the propofol concentration by 0.5 mg/mL and record it. Train of four counts keep between 1 to 3 (moderate block). When the operation is ended, stop anesthetics administration, and, we reverse neuromuscular blocking using sugammadex (2mg/ kg). When the anesthesiologist starts waking the patient up, call the patient's name (unify into OOO, open your eyes.). The anesthesiologist lightly tap the patient's shoulder and avoid excessive sound or stimulation."
223692054|NCT02770833|OTHER|Fish and carbohydrats with low or high GI|
223692055|NCT02770833|OTHER|Veal and carbohydrats with low or high GI|
223692056|NCT00140634|BIOLOGICAL|Carticel (autologous cultured chondrocyte) implantation|Each Carticel vial of autologous cultured chondrocytes contains approximately 12 million cells implanted into the defect and secured with a periosteal flap.
223692057|NCT03508531|PROCEDURE|ESP Block|A high-frequency linear ultrasound transducer will be placed in a longitudinal parasagittal orientation 3 cm lateral to T9 spinous process. The erector spinae muscles will be identified superficial to the tip of T9 transverse process. The patient's skin will be anesthetized with 2% lidocaine. A 17-gauge 8-cm needle will be inserted using an in-plane superior-to-inferior approach to place the tip into the fascial plane on the deep (anterior) aspect of erector spinae muscle. The location of the needle tip will be confirmed by visible fluid spread lifting erector spinae muscle off the bony shadow of the transverse process. A total of 40 mL of bupivacaine/lidocaine mixture will be injected.
223692058|NCT03508531|PROCEDURE|OSTAP block|The bilateral OSTAP will be performed at the end of the surgery. A total of 40 ml local anesthetic mixture (Bupivacaine and lidocaine) will be injected bilaterally with interfascial plane between the external oblique and transversus abdominis muscles
223692059|NCT03508531|OTHER|Standard Pain Followup and Monitorization|Numeric Rating Scale (NRS) pain score will be recorded from 20th minute in recovery room followed by 1.-3.-6.-12.-18.-24.hours. Intravenous meperidine administration at 0.5 mg / kg rescue analgesia was determined in patients with a NSR score of 6 and over in the postoperative collection room. It is planned that the patient will continue to follow the hourly NRS score in ward. Intramuscular diclofenac will be administered in this period if NRS 6 and if it is over, intravenous 0.5 mg / kg meperidine will be administered if NRS score is 6 or more after 2 hours. Salvage analgesic needs and times will be noted in detail, and the use of rescue analgesics, as well as NRS scores at designated hours, will be kept in a statistical evaluation.
223692060|NCT01720212|DRUG|YM178|oral
223692061|NCT03602729|OTHER|Breastfeeding education|Breastfeeding education in three different forms: written/verbal/video
223777359|NCT05306106|OTHER|truffle match|"The products evaluated are pastries from the Mademoiselle Desserts range. The amounts consumed will be calculated for each of the pastries so that 50 g of carbohydrate is ingested per intake. Subjects may consume 200 mL of water after ingesting the pastries. During visits V2 to V4 and V6 to V8, the subject will consume successively the pastries which will have been assigned to him randomly and according to the randomization list.~During the visit : A venous catheter will be placed by a medical biology technician and a blood sample will be taken immediately after placement: this is the first sample at T = 0 min. Then, the subject will have a maximum of 10 minutes to consume 221.2 g of truffle match (contained 50 g of glucose). The technician will then take blood samples at T = 15, T = 30, T = 45, T = 60, T = 90 and T = 120 minutes."
223777360|NCT05306106|OTHER|hazelnut chocolate cookie|"The products evaluated are pastries from the Mademoiselle Desserts range. The amounts consumed will be calculated for each of the pastries so that 50 g of carbohydrate is ingested per intake. Subjects may consume 200 mL of water after ingesting the pastries. During visits V2 to V4 and V6 to V8, the subject will consume successively the pastries which will have been assigned to him randomly and according to the randomization list.~During the visit : A venous catheter will be placed by a medical biology technician and a blood sample will be taken immediately after placement: this is the first sample at T = 0 min. Then, the subject will have a maximum of 10 minutes to consume 142.8 g of hazelnut chocolate cookie (contained 50 g of glucose). The technician will then take blood samples at T = 15, T = 30, T = 45, T = 60, T = 90 and T = 120 minutes."
223777361|NCT05306106|OTHER|Paris Brest style eclair|"The products evaluated are pastries from the Mademoiselle Desserts range. The amounts consumed will be calculated for each of the pastries so that 50 g of carbohydrate is ingested per intake. Subjects may consume 200 mL of water after ingesting the pastries. During visits V2 to V4 and V6 to V8, the subject will consume successively the pastries which will have been assigned to him randomly and according to the randomization list.~During the visit : A venous catheter will be placed by a medical biology technician and a blood sample will be taken immediately after placement: this is the first sample at T = 0 min. Then, the subject will have a maximum of 10 minutes to consume 277.7 g of Paris Brest style eclair (contained 50 g of glucose). The technician will then take blood samples at T = 15, T = 30, T = 45, T = 60, T = 90 and T = 120 minutes."
223692062|NCT00191646|DRUG|Gemcitabine|"1000 mg/m\^2, Intravenously (IV), day 1 and day 8 every (q) 21 days x 6 cycles~If anything other than complete response in Paclitaxel arm patients, 1000 mg/m\^2, IV, day 1 and day 8 q 21 days until complete response, disease progression or unacceptable toxicity"
223692063|NCT00191646|DRUG|Paclitaxel|"175 mg/m\^2, IV, Day 1, q 21 days x 6 cycles~If complete response both Paclitaxel and Gemcitabine arms may elect to receive consolidation therapy, 135 mg/m\^2, IV, 3 hours q 28 days x 12 cycles (1 year)~If no complete response, then Gemcitabine arm patients may receive 175 mg/m\^2, IV, Day 1, q 21 days until complete response, disease progression or unacceptable toxicity"
223692064|NCT00191646|DRUG|Carboplatin|"Gemcitabine/Carboplatin AUC 5, IV, Day 1, q 21 days x 6 cycles~Paclitaxel/Carboplatin AUC 6, IV, Day 1, q 21 days x 6 cycles"
223692065|NCT00453518|DEVICE|FiberNet EPS used during SVG intervention.|The FiberNet EPS is indicated for use as a guide wire and embolic protection system to capture and remove embolic material produced while performing percutaneous transluminal interventional procedures in saphenous vein grafts.
223692066|NCT01501396|DRUG|Megestrol Acetate|
223692067|NCT01501396|DRUG|Mirtazapine|
223692068|NCT00322101|RADIATION|total-body irradiation|Radiation
223692069|NCT00322101|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Undergo allogeneic transplantation
223692070|NCT00322101|DRUG|cyclophosphamide|Given IV
223692071|NCT00322101|DRUG|mycophenolate mofetil|Given orally
223692072|NCT00322101|DRUG|busulfan|Given IV or orally
223692073|NCT00322101|DRUG|cyclosporine|Given IV or orally
223692074|NCT00322101|DRUG|fludarabine phosphate|Given IV
223692075|NCT00322101|PROCEDURE|peripheral blood stem cell transplantation|Undergo transplantation
223692076|NCT00322101|PROCEDURE|nonmyeloablative allogeneic hematopoietic stem cell transplantation|Undergo allogeneic transplantation
223692077|NCT00322101|OTHER|laboratory biomarker analysis|Correlative studies
223692078|NCT00322101|GENETIC|cytogenetic analysis|Correlative studies
223692079|NCT00322101|OTHER|flow cytometry|Correlative studies
223692080|NCT00322101|GENETIC|fluorescence in situ hybridization|Correlative studies
223692081|NCT00322101|OTHER|pharmacological study|Correlative studies
223692082|NCT00322101|GENETIC|polymorphism analysis|Correlative studies
223692083|NCT00322101|DRUG|tacrolimus|Given IV or orally
223692084|NCT00322101|DRUG|methotrexate|Given IV
223692085|NCT02666534|DRUG|lidocaine-prilocaine 5% cream application|The lesions were then cleansed with saline gauze, and a lidocaine-prilocaine 5% cream (EMLA®; Astra Pharmaceuticals, LP, Westborough, MA, USA) was applied to the treatment area for 30 min under occlusion
223692086|NCT02666534|DEVICE|2940-nm Er:YAG AFL pretreatment|After the anesthetic cream was removed, AFL was performed using a 2940-nm Er:YAG AFL (Joule; Sciton, Inc., Palo Alto, CA, USA) with a 500 µm ablation depth, level 1 coagulation, 22% treatment density, and a single pulse
223692087|NCT02666534|DRUG|methyl-aminolevulinate application|Immediately after the AFL, a 1-mm thick layer of methyl-aminolevulinate (16% Metvix® cream; PhotoCure ASA, Oslo, Norway) was applied to the lesion and to 5 mm of the surrounding healthy tissue. The area was covered with an occlusive dressing (Tegaderm; 3M, Co., Saint Paul, MN, USA) for 3 h, after which the remaining cream was removed with saline gauze, and the red fluorescence of porphyrins was visualized with Wood's light.
223692088|NCT02666534|DEVICE|Illuminating using red light-emitting diode lamps|Each treatment area was then separately illuminated using red light-emitting diode lamps (Aktilite CL128; Galderma S.A., Bruchsal, Germany) with peak emission at 632 nm and a total light dose of 37 J/cm2. Areas scheduled to receive MAL-PDT received the second treatment 7 days later. During the illumination, patients were asked to evaluate pain intensity using an 11-point visual analog scale.
223777362|NCT05306106|OTHER|hazelnut chocolate finger|"The products evaluated are pastries from the Mademoiselle Desserts range. The amounts consumed will be calculated for each of the pastries so that 50 g of carbohydrate is ingested per intake. Subjects may consume 200 mL of water after ingesting the pastries. During visits V2 to V4 and V6 to V8, the subject will consume successively the pastries which will have been assigned to him randomly and according to the randomization list.~During the visit : A venous catheter will be placed by a medical biology technician and a blood sample will be taken immediately after placement: this is the first sample at T = 0 min. Then, the subject will have a maximum of 10 minutes to consume 312.5 g of hazelnut chocolate finger (contained 50 g of glucose). The technician will then take blood samples at T = 15, T = 30, T = 45, T = 60, T = 90 and T = 120 minutes."
223777363|NCT05306106|OTHER|lemon finger|"The products evaluated are pastries from the Mademoiselle Desserts range. The amounts consumed will be calculated for each of the pastries so that 50 g of carbohydrate is ingested per intake. Subjects may consume 200 mL of water after ingesting the pastries. During visits V2 to V4 and V6 to V8, the subject will consume successively the pastries which will have been assigned to him randomly and according to the randomization list.~During the visit : A venous catheter will be placed by a medical biology technician and a blood sample will be taken immediately after placement: this is the first sample at T = 0 min. Then, the subject will have a maximum of 10 minutes to consume 263.1 g of lemon finger (contained 50 g of glucose). The technician will then take blood samples at T = 15, T = 30, T = 45, T = 60, T = 90 and T = 120 minutes."
223692089|NCT03579576|DRUG|sofosbuvir 400 mg/velpatasvir 100 mg (SOF/VEL) orally once daily for 12 weeks with or without weight-based ribavirin.|Direct Acting anti-HCV drugs given to all HCV infected participants at baseline.Those with Co-infections like HIV and or HBV will be given treatment as per national guidelines.
223692090|NCT00003099|DRUG|Fenretinide|Daily for 14-28 days.
223692091|NCT00003099|DRUG|Tamoxifen Citrate|Daily for 14-28 days.
223692092|NCT00003099|OTHER|Placebo|Daily for 14-28 days
223692093|NCT00723931|BIOLOGICAL|Peginterferon alfa-2b (SCH 54031)|Surveillance will be conducted after administration of peginterferon alfa-2b (administered according to the directions on the products' labeling). PegIntron Injection for surveillance is a weight-based dosing product administered at a dose of 0.5/1.0 ug/kg or 1.5 ug/kg. Administration of treatment is not part of this study.
223692094|NCT04142593|OTHER||
223692095|NCT04350606|BIOLOGICAL|PF-06462700|PF-06462700 is classified as an immunosuppressant/ immunosuppressive agent. It is the purified, concentrated, and sterile gamma globulin, primarily monomeric immunoglobulin G (IgG), from hyperimmune serum of horses that are immunized with human thymus lymphocytes.
223692096|NCT00328549|DRUG|Pegylated Interferon and Ribavirin|
223692097|NCT04483323|PROCEDURE|Erector Spinae Plane Block|"The patient will be placed in the lateral position. Following skin disinfection, counting down from the C7 spinous process and using ultrasound guidance, the level of T2 transverse process will be identified. A 2-5 MH2 curved array transducer (sono site Edge, Bothell, Will behington) will be positioned transversely to visualize the lateral tip of T2 transverse Process. A longitudinal parasagittal orientation will be obtained over the transverse process using a 22 - gauge 8 cm block needle (visioplex, Vygon , France) will be inserted in plane to US beam in a caudal to cranial direction to place the needle tip between the posterior fascia of the erector spinae muscle and the T2 transverse process.~Position of the needle tip in the ESP deep to the erector spinae muscle will be confirmed using hydrodissection with 0.5 - 1 ml of normal saline and visualization of the linear fluid spread deep to the erector spinae muscle following which 20 ml of 0.25% bupivacaine will be injected."
223692098|NCT04483323|PROCEDURE|Intraarticular Injection|Intraarticular injection of local anesthetic through the surgical port
223692099|NCT04948567|OTHER|split-dose of Magnesium Sulfate solution|purgative for bowel preparation
223692100|NCT04948567|OTHER|split-dose of PEG|purgative for bowel preparation
223692101|NCT03139097|DIAGNOSTIC_TEST|Quantra System|Diagnostic device to monitor coagulation properties of a whole blood sample at the point-of-care.
223692102|NCT06851195|DEVICE|lower limb neuromuscular electrical stimulation|The study adopts a quasi-experimental design with convenience sampling. Data collection will be done through structured questionnaires. Patients who meet the inclusion criteria will be referred by physicians, and before enrollment, a verbal introduction will be given explaining the study's purpose, the questionnaire, and the intervention procedure and duration. The experimental group will participate in both pulmonary rehabilitation exercises and an additional intervention of lower limb neuromuscular electrical stimulation, 30 minutes per session, three times per week, for eight weeks. The control group will only participate in pulmonary rehabilitation exercises. Based on Hill et al. (2018), neuromuscular electrical stimulation should continue for 4 to 8 weeks. Questionnaires will be administered before the intervention and at the 2nd, 4th, 6th, and 8th weeks post-intervention, including basic information, Modified Medical Research Council Dyspnea Scale, Manchester COPD Fatigue Scale,
223692103|NCT06851195|BEHAVIORAL|pulmonary rehabilitation exercises|The control group will only participate in pulmonary rehabilitation exercises
223692104|NCT03118973|PROCEDURE|Goff trans-pancreatic septotomy vs. Double wire technique|Goff trans-pancreatic septotomy vs. Double wire technique for achieving biliary access when biliary cannulation is challenging.
223692105|NCT05211284|DRUG|Saroglitazar Magnesium 4 mg|Subjects randomized to Saroglitazar Magnesium 4 mg arm will receive Saroglitazar Magnesium 4 mg treatment until the duration of treatment (24 weeks).
223692106|NCT05211284|DRUG|Placebo|Subjects randomized to Placebo arm will receive Placebo treatment until the duration of treatment (24 weeks).
223777364|NCT05306106|OTHER|elderflower madeleine|"The products evaluated are pastries from the Mademoiselle Desserts range. The amounts consumed will be calculated for each of the pastries so that 50 g of carbohydrate is ingested per intake. Subjects may consume 200 mL of water after ingesting the pastries. During visits V2 to V4 and V6 to V8, the subject will consume successively the pastries which will have been assigned to him randomly and according to the randomization list.~During the visit : A venous catheter will be placed by a medical biology technician and a blood sample will be taken immediately after placement: this is the first sample at T = 0 min. Then, the subject will have a maximum of 10 minutes to consume 294.1 g of elderflower madeleine (contained 50 g of glucose). The technician will then take blood samples at T = 15, T = 30, T = 45, T = 60, T = 90 and T = 120 minutes."
223777365|NCT02409485|BEHAVIORAL|Couples Skill-Training (CST)|Patients and partners each receive a workbook and 6 one-hour telephone sessions with a Masters level trained interventionist. Manual content is tailored based on role (patient or partner). Couples participate together via speaker phone for half the sessions and patients and partners receive separate (individual) intervention calls for the other half of the sessions.
223777366|NCT03297879|DRUG|Exenatide or metformin hydrochloride|Exenatide was administrated with 5 μg bid for 4 weeks and 10 μg bid for 8 weeks. Metformin hydrochloride was initiated at a dose of 500 mg bid for 2 weeks, and added to 2.0 g/day for 8 weeks.
223777367|NCT01079221|BEHAVIORAL|High intensity knee-extensor training|High intensity aerobic knee-extensor exercise training, 4x 3 minutes interval training at \< 90 % of peak power, 3 days/week for 6 weeks
223777368|NCT02323919|BEHAVIORAL|SystemCHANGE|consists of a series of five small-group (six to eight people) education sessions provided in three 1.5 -hour sessions once a week during the last three weeks of the CRP and in two sessions held at one and two months following completion of their CRP. An experienced cardiac nurse or exercise physiologist trained in the intervention protocol taught each of the sessions. In a series of structured activities, participants were taught to use behavior change strategies consistent with the respective intervention models. A series of three monthly booster calls were made during months four, five and six following the last intervention class and individuals were coached in the use of strategies consistent with the respective interventions.
223777369|NCT02323919|BEHAVIORAL|CHANGE+|consists of a series of five small-group (six to eight people) education sessions provided in three 1.5 -hour sessions once a week during the last three weeks of the CRP and in two sessions held at one and two months following completion of their CRP. An experienced cardiac nurse or exercise physiologist trained in the intervention protocol taught each of the sessions. In a series of structured activities, participants were taught to use behavior change strategies consistent with the respective intervention models. A series of three monthly booster calls were made during months four, five and six following the last intervention class and individuals were coached in the use of strategies consistent with the respective interventions.
223777370|NCT02323919|BEHAVIORAL|Usual Care|Participants will receive only the routine care provided to CRP patients. This care consists of assessment of exercise capacity, graduated exercise training (consisting of exercising three times a week at the cardiac rehabilitation center on treadmill or cycle, counseling about safe exercise {warm-up procedures, pulse taking, attending to body cues for exertion levels} and advisement to exercise on days between CRP sessions). At the end of the CRP, individuals are given an exercise prescription that includes their target heart rate and they are counseled to exercise at least 5 times a week for 30 minutes. This information is provided by the CRP personnel, usually in the form of individual informal conversations during exercise at the CRP.
223777371|NCT02804919|DEVICE|Fisher & Paykel Healthcare CPAP Device|Fisher \& Paykel Healthcare CPAP Device
223777372|NCT05163860|OTHER|Survey|Participants will complete an online survey.
223777373|NCT00889421|DRUG|Apremilast|oral dose of 30 mg BID for 6 months
223777374|NCT00013793|BEHAVIORAL|Motivational enhancement and ultrasound|
223777375|NCT01958918|DRUG|Ranibizumab|0.5 mg intravitreal injection
223777376|NCT01958918|DRUG|Aflibercept|2 mg intravitreal injection
223777377|NCT05787769|DRUG|P shot arm ( Autologous Platelet Rich Plasma)|Autologous Platelet Rich Plasma + placebo tab Each injection session will consist of a total of 10 mL PRP infused slowly over a 2-minute period; 5 mL each injected to the right and left corpus cavernosum
223777378|NCT05787769|DRUG|PDE5i arm|Patients will be treated by tadalafil 5 mg tablet daily in addition to four Tadalafil 5 mg tablet 3 hours before intercourse on demand in addition to placebo injection. Each injection session will consist of a total of 10 mL saline solution infused slowly over a 2-minute period; 5 mL each injected to the right and left corpus cavernosum.
223777379|NCT01625793|DRUG|Interferon-alpha|Hepatitis C patients who are eligible to receive IFN-alpha treatment and enrolled in this study will be treated with pegylated IFN-alfa-2b or pegylated IFN-alfa-2a plus ribavirin at a dose of 800-1,400 mg/d as determined by the treating gastroenterologist. All medication administration is for purely clinical indications as dictated by treating physicians. Any and all diagnostic or treatment issues related to potential treatment with IFN-alpha will be conducted by treating clinicians. Subjects will be randomized to start their clinical (non-research) treatment following completion of baseline assessments or to delay the start of their clinical (non-research) treatment by 7 weeks.
223777380|NCT01699594|DRUG|Mannitol|Indirect bronchoprovocation agent being compared to direct bronchoprovocation agent (methacholine)
223777381|NCT01699594|DRUG|Methacholine Chloride|Direct bronchoprovocation agent being compared to indirect bronchoprovocation agent (mannitol)
223777382|NCT04087057|OTHER|Interview|Participate in interview
223777383|NCT04087057|OTHER|Medical Chart Review|Patients' medical records are reviewed
223692107|NCT04992624|DRUG|Placebo|"Placebo drug will be taken similarly to the THC and CBD and be matched to keep the trial blinded.~In the event that 2.5 mg capsules of dronabinal capsules become unavailable, an equivalent product will be issued to participants and the comparator and placebo arms will be correspondingly adjusted to preserve blinding. If a participant's dose is not well-tolerated, the participant may initiate dose reductions with the study team.~Participants will be instructed to eat a meal or snack greater than one hour after taking study drug."
223692108|NCT04992624|DRUG|Cannabidiol (CBD)|"Epidiolex doses will be 0.37 milliliter (mL) for seven days of treatment and then 0.75 mL two times a day (b.i.d) for the remaining days of this treatment.~In the event that 2.5 mg capsules of dronabinal capsules become unavailable, an equivalent product will be issued to participants and the comparator and placebo arms will be correspondingly adjusted to preserve blinding. If a participant's dose is not well-tolerated, the participant may initiate dose reductions with the study team.~Participants will be instructed to eat a meal or snack greater than one hour after taking study drug."
223692109|NCT04992624|DRUG|Tetrahydrocannabinol (Marinol® or generic equivalent (e.g., dronabinol)|"Dronabinol Capsules doses will be 2.5 mg b.i.d. for seven days of treatment and then 5 mg b.i.d. for the remaining days of this treatment.~In the event that 2.5 mg capsules of dronabinal capsules become unavailable, an equivalent product will be issued to participants and the comparator and placebo arms will be correspondingly adjusted to preserve blinding. If a participant's dose is not well-tolerated, the participant may initiate dose reductions with the study team.~Participants will be instructed to eat a meal or snack greater than one hour after taking study drug."
223692110|NCT04898114|DRUG|Magnesium sulfate|Nebulized magnesium sulfate (4 ml of 6.4% solution) every 15 minutes
223692111|NCT04898114|DRUG|Sildenafil Citrate|Oral sildenafil citrate at an initial dose of 1 mg/kg, with incremental increases by 0.5 mg/kg every 6 hours till reaching a target dose of 2mg/kg every 6 hours.
223692112|NCT04898114|OTHER|Isotonic saline|Nebulized isotonic saline (4 ml) every 15 minutes
223692113|NCT03593161|BEHAVIORAL|Humor therapy|Clown visits
223692114|NCT06310044|OTHER|Root canal irrigant Commiphora Myrrh 50%|Root canal irrigant
223692115|NCT05597670|OTHER|traditional knee rehabilitation program|Patients in this group will receive a traditional therapeutic knee rehabilitation program in the form of mini-squatting exercise (up to 45 degree knee flexion measured by a universal goniometer) , strengthening of hip abductors and external rotators
223692116|NCT05597670|OTHER|proximal stabilization|the principles of proximal stability will be explained to patients before initiation of treatment and patients will be asked to comply with these principles during exercise. These principles include learning how to activate transversus abdominus by abdominal bracing without allowing pelvis tilting and ensure neutral spine and diaphragmatic breathing during exercise.
223692117|NCT05388396|OTHER|PIMS-TS diagnostic a treatment|PIMS-TS diagnostic a treatment
223692118|NCT03911843|DRUG|omega-3 supplementation|Supplementation with Ω-3, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) at a dose of 50-60 mg/kg/day for 12 months, currently underway or completed after 12 months of omega-3 administration, in 22/64 T1D children
223692119|NCT03911843|DRUG|Vitamin D supplementation|Cholecalciferol 1000 IU/die
223692120|NCT04449471|DRUG|Naproxen tablet|For this single intervention arm, each subject will receive a single 220-mg dose of naproxen sodium (Aleve), followed by urine collection for 24-hours.
223692121|NCT05456945|OTHER|acupressure application|Acupressure will be applied to the UB32 point
223692122|NCT05456945|DEVICE|Shotblocher|Shotblocher will be administered during injection
223692123|NCT02142985|DRUG|Sodium Chloride 0.9% Intravenous|vascular filling with 500 ml of crystalloid solution (sodium chloride 0.9%) over 30 minutes
223692124|NCT01907100|DRUG|Nintedanib|triple kinase inhibitor; 200mg starting dose
223692125|NCT01907100|DRUG|Pemetrexed|backbone chemo
223692126|NCT01907100|DRUG|Cisplatin|backbone chemo
223692127|NCT01907100|DRUG|Cisplatin|backbone chemo
223692128|NCT01907100|DRUG|Pemetrexed|backbone chemo
223692129|NCT01907100|DRUG|Placebo|Nintedanib matching placebo
223692130|NCT01048489|BEHAVIORAL|Health education in the high school|"(12- 13 years old): 1.Questionnaire and measuring of carbon monoxide in air. 2.Role Games.3.Build a machine that simulates a cigarette.~(13-14 years old):1.Questionnaire and measuring of carbon monoxide in air.2. Workshop dealing with current television series broadcast in Spain in which tobacco is constantly present.3.Workshop dedicated to make young people and their families stop smoking.A competition is performed between all the schools in order to reward the bookmark with the best motto asking any close person to stop smoking or thanking them for having quit.~(14-15 years old):1.Questionnaire and measuring of carbon monoxide in air. 2. Workshop to go into depth about tobacco effects,by searching in the internet, aiming for the creation of an anti-tobacco pressure group in social networks such like Facebook.3.Workshop to create an advertising campaign to encourage non-consumption by mobile messages,use of internet..coinciding with the international day without tobacco."
223692131|NCT02943902|BIOLOGICAL|Pneumococcal conjugate vaccine (PCV10 ) 1+1, 6 weeks|PCV10 1+1, 6 weeks \& 9 months
223692132|NCT02943902|BIOLOGICAL|Pneumococcal conjugate vaccine (PCV10 ) 1+1, 14 weeks|PCV10 1+1, 14 weeks \& 9 months
223692133|NCT02943902|BIOLOGICAL|Pneumococcal conjugate vaccine (PCV10 ) 2+1|PCV10 2+1, 6\&14 weeks \& 9 months
223692134|NCT02943902|BIOLOGICAL|Pneumococcal conjugate vaccine (PCV13 ) 1+1, 6 weeks|PCV13 1+1, 6 weeks \& 9 months
223692135|NCT02943902|BIOLOGICAL|Pneumococcal conjugate vaccine (PCV13 ) 1+1, 14 weeks|PCV13 1+1, 14 weeks \& 9 months
223692136|NCT02943902|BIOLOGICAL|Pneumococcal conjugate vaccine (PCV13 ) 2+1|PCV13 2+1, 6\&14 weeks \& 9 months
223692137|NCT03464695|DEVICE|O2matic|Continous measurement of SpO2 during an admission with COPD, and closed-loop control of oxygen-delivery to maintain SpO2 within a target interval.
223692138|NCT02859506|OTHER|Respiratory quotient|
223692139|NCT02859506|OTHER|Olfactory liking|
223692140|NCT02914587|DEVICE|ARTAS System|
223692141|NCT02914587|OTHER|Manual Implantation|
223692142|NCT01863810|DRUG|KW21052|1 Tablet contains 300mg of pregabalin. Oral, once a day, for 8 weeks.
223692143|NCT01863810|DRUG|Lyrica|1 Capsule contains 150mg of pregabalin. Oral, twice a day, for 8 weeks.
223692144|NCT01863810|DRUG|Lyrica (low dose)|1 Capsule contains 75mg of pregabalin. Oral, twice a day, for 1 week.
223692145|NCT01863810|DRUG|Placebo of KW21052|Oral,once a day, for 8 weeks
223692146|NCT01863810|DRUG|Placebo of Lyrica|Oral, twice a day, for 8 weeks.
223692147|NCT01466777|PROCEDURE|Traditional surgery type|Traditional laparoscopic surgery for endometrial cancer
223692148|NCT01466777|PROCEDURE|Robotic assisted laparoscopic surgery|Robotic assisted laparoscopic surgery for endometrial cancer
223692149|NCT05876260|BEHAVIORAL|Greek yogurt|Following 2 days of controlled diet, participants will consume greek yogurt following high-intensity interval exercise
223692150|NCT05876260|BEHAVIORAL|Carbohydrate-based study supplement|Following 2 days of controlled diet, participants will consume a carbohydrate-based study supplement following high-intensity interval exercise
223692151|NCT05876260|BEHAVIORAL|Exercise|Following 2 days of controlled diet, participants will perform high-intensity interval exercise following an overnight fast
223692152|NCT02820714|DRUG|BLI801 Laxative|BLI801 Laxative
223692153|NCT04738409|OTHER|Lifestyle intervention|The purpose of the research is to evaluate the potential of a multidimensional lifestyle program for PCOS girls. The primary aim is to verify the effectiveness of a 16-week AID intervention vs. HCD (combined with PA\&T), in terms of improvement in androgens level and immune-metabolic risk parameters
223692154|NCT04738409|OTHER|Effects of AIDiet intervention to improve diet quality, immuno-metabolic health in normal and overweight PCOS girls|The purpose of the intervention is to evaluate the effectiveness of the anti-inflammatory diet (AIDiet) among normal weight (N) and overweight/obese (Ov/Ob) women with PCOS.
223692155|NCT03192878|DRUG|Infliximab|infliximab biosimilar
223777384|NCT04087057|BEHAVIORAL|Questionnaire|Complete questionnaires
223777385|NCT00277264|DRUG|Tiotropium (Spiriva®)|
223777386|NCT03678948|DEVICE|Radiofrequency-Based Debridement|In this process, radiofrequency energy is used to excite the water molecules in a conductive medium, such as an electrolyte (saline) solution, to generate excited radicals within precisely focused plasma. The energized particles in the plasma have sufficient energy to break molecular bonds (16-18), excising or dissolving (i.e. ablating) soft tissue at relatively low temperatures (typically 40ºC to 70ºC).
223777387|NCT03678948|DEVICE|Mechanical Debridement|Arthroscopic chondroplasty used to remove loose and damaged cartilage which minimizes synovial irritation and mechanical impingement
223692156|NCT03901898|BEHAVIORAL|Training, audit, and reminders|Briefing and training for participating practices, baseline practice audit, addition of electronic prompts to patient records, GP-endorsed patient reminders (in person, phone and letter), and re-audit at 6 months.
223692157|NCT03901898|BEHAVIORAL|Intervention after 6 months (wait list)|After 6 months, practices receive the intervention: briefing and training for participating practices, baseline practice audit, addition of electronic prompts to patient records, GP-endorsed patient reminders (in person, phone and letter).
223692158|NCT01138839|DRUG|Dexamethasone|Pregnant women in the experimental group will receive 10-mg doses (2.5 cc) of dexamethasone sodium phosphate intravenously every 12 hours until delivery and 3 additional doses after delivery. Puerperal women will receive 3 10-mg doses after delivery.
223692159|NCT01138839|DRUG|sterile water|Pregnant women will receive 2.5 cc of sterile water every 12 hours until delivery and 3 additional doses after delivery. Puerperal women will receive 3 doses after delivery
223692160|NCT02059005|BEHAVIORAL|Specialized Community Disease Management|Specialized Community Disease Management is 90-day program that employs specialized teams including a trained clinical social worker and a peer-specialist community health worker who provide evidence-based telephone continuing care, home visits, and focus on patients' substance use following hospital discharge.
223692161|NCT02059005|BEHAVIORAL|Treatment As Usual|Treatment as Usual is a 90-day, post-discharge program that consists of medical monitoring by nurses and community health workers who have no special training in working with substance use disorder patients, and does not address substance use.
223692162|NCT02257853|OTHER|Stress reduction intervention|Gentle chair yoga and breath work
223692163|NCT06255210|DRUG|Gemcitabine+Cisplatin(GP); Cyclophosphamide+Etoposide+Cisplatin(CEP)|When the Ki67% index of the tumor is ≥ 25%, patients were treated with the GP regimen for induction chemotherapy; When the Ki67% index of the tumor is \< 25%, patients were treated with the CEP regimen for induction chemotherapy.
223692164|NCT00908011|DRUG|Ezetimibe|10mg/day ezetimibe in addition to ongoing rosuvastatin treatment (10mg/day)- tablet, orally, 10mg/day for 12 weeks
223692165|NCT00908011|DRUG|Rosuvastatin (standard care)|Increased dose of rosuvastatin to 20mg/day
223777388|NCT04078282|BEHAVIORAL|Intervention group|see above
223777389|NCT04598516|DIAGNOSTIC_TEST|serum creatinine assay|peak change in serum creatinine in a period of 5 days from baseline (day 0) will be determined
223777390|NCT01243450|DRUG|Tretinoin|Treatment of acne
223777391|NCT01243450|DRUG|placebo|treatment of acne
223777392|NCT02013765|DRUG|trastuzumab|Initial dose of 4 mg/kg i.v on Day 1, followed by weekly doses of 2 mg/kg i.v. beginning on Day 8 and continuing for up to 37 weeks.
223692166|NCT02103218|BEHAVIORAL|Education, activities, empowerment, racial pride building|Intervention focuses on information aimed toward reducing or preventing risky sex behaviors of minority adolescent females.
223692167|NCT02103218|BEHAVIORAL|General Health education, activities|Intervention focuses on information regarding general health knowledge and healthy behaviors (not including sex).
223777393|NCT00659269|DIETARY_SUPPLEMENT|Multivitamin (MV)|Multivitamins containing no more than 10 mg of pyridoxine and/or 10 micrograms of Vitamin B12 will be given to the patients on this arm.
223777394|NCT00659269|DIETARY_SUPPLEMENT|Multivitamin + Vitamin B12 + Vitamin B6|Multivitamin (containing no more than 10 mg of pyridoxine and/or 10 micrograms of Vitamin B12), plus Vitamin B6 tablets and Vitamin B12 injections
223777395|NCT00659269|DRUG|Chemotherapy|"Patients are treated per standard of care according to the choice of the treating physician with heavy metals (cisplatin, oxaliplatin), taxanes (paclitaxel, docetaxel), or vinca alkaloids (vincristine, vinorelbine)~Ranges of cumulative doses (in mg/m2) are:~paclitaxel, 700-960; docetaxel, 240-400; vincristine, 8-16; vinorelbine, 360-480; cisplatin, 240-400; oxaliplatin, 400-800; abraxane, 1200-1800"
223777396|NCT01158222|DRUG|sunitinib malate|Given orally
223777397|NCT00783536|DRUG|Etanercept + Methotrexate|
223777398|NCT00783536|DRUG|DMARDS|
223777399|NCT04723433|OTHER|Oxygen gas -Conservative|Oxygen administration will titrated to a oxyhemoglobin saturation (SpO2) between 90% and 94%.
223777400|NCT04723433|OTHER|Oxygen gas -Liberal|Oxygen administration will titrated to a oxyhemoglobin saturation (SpO2) higher than 96%.
223777401|NCT02359292|DRUG|CHF 5993 HS 200/6/25 pMDI|
223777402|NCT02359292|DRUG|CHF 5993 MS 100/6/25 pMDI|
223777403|NCT02359292|DRUG|CHF 5993 HS 200/6/25 pMDI + Charcoal Block|
223777404|NCT02359292|DRUG|CHF 5993 MS 100/6/25 pMDI + Charcoal Block|
223777405|NCT02359292|DRUG|Placebo pMDI|
223777406|NCT01598480|DRUG|Flamazine|Silver sulfadiazine cream
223777407|NCT01598480|DEVICE|BCT Antimicrobial Dressing|Activated carbon fiber impregnated with silver particles
223777408|NCT00718042|DEVICE|ABBOTT PRISM Chagas Assay and Chagas Confirmatory Assay|Test blood donor sample with ABBOTT PRISM Chagas assay. If results are reactive, donor sample will be tested with Chagas Confirmatory assay. Donors reactive with screening assay or positive with confirmatory assay will be deferred and asked to return for a follow-up blood draw.
223777409|NCT00718042|DEVICE|ABBOTT PRISM Chagas Assay and Chagas Confirmatory Assay|Test blood donor sample with investigational Chagas assay. If results are reactive, donor samples will be tested with Chagas confirmatory assay. Donors reactive with screening assay or positive with confirmatory assay will be deferred and asked to return for a follow-up blood draw.
223777410|NCT02443298|DRUG|placebo|Matching placebo for risankizumab
223777411|NCT02443298|DRUG|risankizumab|Monoclonal IgG antibody
223777412|NCT02960880|DRUG|Rivaroxaban (Xarelto, BAY597939)|15mg, 20mg
223777413|NCT02960880|DRUG|Phenprocoumon (branded and generics)|Individually adjusted dose
223777414|NCT05896592|DIAGNOSTIC_TEST|Invasive electrophysiological study|Invasive electrophysiological study consists in inserting two electrodes into the heart through femoral vein puncture into the right atrium and right ventricle. Then the following measurements are taken: SNRT- sinus rhythm recovery time, cSNRT- corrected sinus rhythm recovery time, Wenckebach point, AH and HV time and HRV-rhythm variability after SNRT measurement. The examination will be performed under general anesthesia.
223777415|NCT05896592|DIAGNOSTIC_TEST|Extracardiac vagal stimulation|"Extracardiac vagal stimulation consists in leading the electrode through the puncture of the femoral vein, successively to both internal jugular veins and stimulating the vagus nerve at the level of its cranial orifice and lower at the level of the angle of the mandible. Stimulation is performed using the Extra-Cardiac Autonomic NeuroStimulatorPachon.~Induction of a sinus pause or AV block during vagal stimulation is considered a positive test result. Absence of sinus pause and AV block during vagal stimulation indicates parasympathetic denervation of the heart. The examination is performed under general anesthesia."
223692168|NCT05334511|OTHER|Functional Electrical Stimulation|functional electrical stimulation with Frequency 20 pps with Pulse width of 300 msec.
223692169|NCT00739596|DRUG|Aliskiren Hydrochlorothiazide (HCTZ): 8 weeks|Aliskiren HCTZ (150/12.5 mg) for 1 week followed by forced titration to Aliskiren HCTZ (300/25 mg) for remaining 7 weeks
223692170|NCT00739596|DRUG|Amlodipine: 8 weeks|Amlodipine 5 mg for 1 week followed by forced titration to Amlodipine 10 mg for remaining 7 weeks
223692171|NCT00815724|BEHAVIORAL|Distributed Asthma Learning Initiative (DALI) distance learning program|Participants will take part in two Webinar teleconferences, have access to an interactive Web site, and receive a CD-ROM of study materials and a toolkit.
223692172|NCT00817284|DRUG|bevacizumab and Irinotecan and radiotherapy|"* Bevacizumab 10 mg/kg is administered on days 1 and 15.~* Irinotecan:~* Irinotecan 125 mg/m2 is administered on days 1 and 15 to patients NOT receiving enzyme-inducing antiepileptic drugs (EIAED).~* Irinotecan 340 mg/m2 is administered on days 1 and 15 to patients receiving EIAEDs.~* During concomitant chemoradiotherapy, bevacizumab and irinotecan are given in the same doses and schedules as before and after chemoradiotherapy.~Radiotherapy is delivered during 3rd and 4th cycle of chemotherapy and consists of fractionated focal irradiation at a dose of 2 Gy per fraction given once daily five days per week (Monday to Friday) over a period of six weeks for a total dose of 60 Gy."
223692173|NCT00817284|DRUG|Bevacizumab and Temozolomide and radiotherapy|"Bevacizumab 10 mg/kg is administered on days 1 and 15. Temozolomide dosing before start concomitant chemoradiotherapy: 150 mg/m2/day on days 1-5 during the first 28 days treatment cycle, then 200 mg/m2/day on the subsequent cycles until radiotherapy.~Temozolomide administered concomitantly with the radiotherapy: Temozolomide 75 mg/m2/day for 7 days per week is administered on each day of radiotherapy.~After completed chemoradiotherapy, temozolomide is dosed and administered as it was prior to start chemoradiotherapy, i.e. temozolomide 200 mg/m2/day on days 1-5 out of a 28 days schedule, taking into consideration any previous dose-reductions already made.~Radiotherapy is delivered during 3rd and 4th cycle of chemotherapy and consists of fractionated focal irradiation at a dose of 2 Gy per fraction given once daily five days per week (Monday to Friday) over a period of six weeks for a total dose of 60 Gy."
223692174|NCT04620655|DRUG|RD13-01 cell infusion|Universal CAR-T cells targeting CD7
223777416|NCT05896592|PROCEDURE|Cardioneuroablation|CNA consists in complete parasympathetic denervation of the heart or in its deep neuromodulation by destroying the postganglionic nerve fibers of the vagus nerve, located in the epicardium in the vicinity of the pulmonary veins to the left atrium and in the area of the interatrial septum. It consists in inserting the electrode into the left atrium through puncture of the femoral vein, and then the interatrial septum, and performing ablation in the vicinity of the pulmonary vein orifices and on the interatrial septum at the level of the mitral annulus. Then the electrode is withdrawn into the right atrium and subsequent applications are made in the area of the coronary sinus opening and the roof of the right atrium and the upper part of the interatrial septum. The procedure is performed under general anesthesia. In group 1, CNA will be performed 1 month after randomization. In group 2, CNA will be performed 4 months after randomization.
223777417|NCT05896592|PROCEDURE|Redo cardioneuroablation|It consists in re-performing the CNA if full parasympathetic parasympathetic denervation of the heart is not confirmed by ECVS.
223777418|NCT05896592|PROCEDURE|Implantation of the implantable loop recorder|Implantation of the implantable loop recorder consists in subcutaneous implantation of the ECG loop recorder in the sternum area.
223692175|NCT06131320|DIAGNOSTIC_TEST|PVSE Test|Completion of the PVSE test
223692176|NCT06131320|OTHER|Cerebral MRI|Cerebral MRI scan
223692177|NCT06201195|PROCEDURE|Adductor canal blockade|VAS, VAS move, incision place pain for up and down to patella, drain place pain, motor strenght for femoral nerve and siyatic nerve muscles, side effects, first analgesic requirement time, opioid requirement, other analgesics
223692178|NCT06201195|PROCEDURE|Distal adductor canala blockade and anterior cutaneus nerve blockade|VAS, VAS move, incision place pain for up and down to patella, drain place pain, motor strenght for femoral nerve and siyatic nerve muscles, side effects, first analgesic requirement time, opioid requirement, other analgesics
223692179|NCT06476964|PROCEDURE|skin biopsies|Additional punches of 3 mm from a skin lesion part of a skin biopsy performed as part of routine care, an additional (optional) biopsy of healthy skin
223692180|NCT04572802|PROCEDURE|Coronary angiography|Coronary angiography was performed in patients with coronary heart disease complicated with type 2 diabetes mellitus
223692181|NCT05992480|BIOLOGICAL|rVSVDG-ZEBOV-GP Ebola Virus Vaccine (ERVEBO)|It is an Ebola virus vaccine
223692182|NCT05597436|DRUG|Trehalose|Once weekly 0.75g/kg administration
223692183|NCT00644228|DRUG|Bortezomib|Given IV
223692184|NCT00644228|DRUG|Dexamethasone|Given PO
223692185|NCT00644228|OTHER|Laboratory Biomarker Analysis|Optional correlative studies
223692186|NCT00644228|DRUG|Lenalidomide|Given PO
223692187|NCT03475693|DRUG|Magnesium Oxide|400 mg Magnesium oxide tablet given once in the ED, and prescribed to take BID for 5 days total after discharge
223692188|NCT03475693|DRUG|Acetaminophen|500 mg tablets given once in the ED, and prescribed to take BID for 5 days total after discharge.
223692189|NCT03475693|DRUG|Zofran ODT 4 MG Disintegrating Oral Tablet|Given once in the Emergency department
223692190|NCT00760084|DRUG|Decitabine|Decitabine is administered at a dose of 20 mg/m² over a 1-hour intravenous infusion for 5 consecutive days every 4 weeks in patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML; ≥ 30% blasts).
223692191|NCT04054570|OTHER|No intervention|No Intervention
223692192|NCT05037968|DEVICE|MagnetOs Flex Matrix|Procedure: Instrumented Posterolateral Lumbar Fusion
223692193|NCT05037968|DEVICE|Trinity Elite|Procedure: Instrumented Posterolateral Lumbar Fusion
223692194|NCT00491426|DRUG|Ampicillin|Drug prescribed per routine medical care.
223692195|NCT00491426|DRUG|Metronidazole|Drug prescribed per routine medical care.
223692196|NCT00491426|DRUG|Piperacillin/Tazobactam|Drug prescribed per routine medical care.
223692197|NCT00491426|DRUG|Acyclovir|Drug prescribed per routine medical care.
223692198|NCT00491426|DRUG|Amphotericin B|Drug prescribed per routine medical care.
223692199|NCT00491426|DRUG|Ambisome|Drug prescribed per routine medical care.
223692200|NCT00491426|DRUG|Anidulafungin|Drug prescribed per routine medical care.
223692201|NCT00491426|DRUG|Caspofungin|Drug prescribed per routine medical care.
223692202|NCT06060821|OTHER|No intervention|No intervention
223692203|NCT00765024|DRUG|Ivermectin|single dose of 200 mcg/kg
223692204|NCT00765024|DRUG|ivermectin|two single dose of 200mcg/kg in 2 weeks
223692205|NCT00765024|DRUG|Albendazole|Albendazole 7 days
223692206|NCT01721707|DRUG|Latanoprost+Brinzolamide combination|1 drop in each eye, 1x/day, at 9PM
223692207|NCT01721707|DRUG|Latanoprost|1 drop in each eye, 1x/day, at 9PM
223692208|NCT06965621|DRUG|18F-metaFluorobenzylguanidine|PET Radiopharmaceutical to assess myocardial sympathetic innervation
223692209|NCT06965621|DRUG|Rubidium-82|PET Radiopharmaceutical to assess myocardial perfusion
223692210|NCT06799026|DRUG|Elranatamab|Bispecific T-cell engager antibody, 1.9 and 1.1 mL vials, via subcutaneous (under the skin) injection per protocol.
223692211|NCT06799026|BIOLOGICAL|GM-CSF|Granulocyte-Macrophage Colony-Stimulating Factor, via subcutaneous (under the skin) injection per protocol.
223692212|NCT06799026|BIOLOGICAL|DC/MM Fusion Vaccine|Dendritic Cell and tumor fusion vaccine, via subcutaneous (under the skin) injection per protocol.
223692213|NCT03381573|DRUG|Roflumilast|Roflumilast
223692214|NCT06148389|DRUG|STSA-1301 subcutaneous injection|Subjects will receive the administration dose on Day 0 following protocol requirements.
223692215|NCT06148389|DRUG|Placebo|Subjects will receive the administration dose on Day 0 following protocol requirements.
223692216|NCT02650427|DRUG|Sitagliptin|100mg or 200mg or 600mg, daily for 3 weeks ± 7 days
223692217|NCT05698810|OTHER|CE marked Medical Device MagnetoEncephaloGraphy (MEG) usability|tests
223692218|NCT05698810|OTHER|CE marked Medical Device Magnetic Resonance Imaging (MRI) usability|tests
223692219|NCT05698810|OTHER|CE marked Medical Device ElectroEncephaloGraphy (EEG) usability|tests
223692220|NCT05698810|OTHER|CE marked Medical Device ElectroCardioGraphy (ECG) usability|tests
223692221|NCT06403163|PROCEDURE|Transfusion|Transfusion of an hemostatic product
223692222|NCT05993767|DRUG|dolutegravir (DTG)/emtricitabine (FTC)/tenofovir alafenamide (TAF) regimen|Switch or start dolutegravir (DTG)/emtricitabine (FTC)/tenofovir alafenamide (TAF) regimen with a novel dose ratio for HIV treatment
223692223|NCT05993767|DRUG|Dolutegravir (DTG)/ Emtricitabine (FTC)/tenofovir alafenamide (TAF)|Single arm
223692224|NCT06553326|DEVICE|EndoStyle|The EndoStyle system is able to transform the style of the different video-processor images.
223692225|NCT04042298|OTHER|Arterial blood pressure|Measured using an automated non-invasive finger cuff that obtains beat-by-beat blood pressure measurements via finger photoplesmography. Briefly, changes in artery diameter are detected through infrared light in the finger cuff. (Finometer Pro, FMS, The Netherlands).
223692226|NCT04042298|OTHER|Skin microcirculatory blood flow|Assessed non-invasively in the forearm skin via Laser Doppler flowmetry in response to locally delivered acetylcholine and norepinepherine or phenylepherine via iontophoresis.
223692227|NCT04042298|OTHER|Brachial artery blood flow|A GE Ultrasound System will be used to non-invasively assess brachial artery blood flow prior to and following a standard flow mediated dilation protocol.
223692228|NCT04042298|OTHER|Venous blood draw|A venous blood sample from the antecubital vein or a vein in the back of the hand will be taken via venipuncure by a nurse or a certified phlebotomist at the beginning of the experimental visit. These blood samples will be analyzed for the presence of reactive oxygen species and inflammatory markers.
223692229|NCT05725499|DEVICE|Biostim-5 transcutaneous spinal stimulator|"Transcutaneous stimulation of the spinal cord. Mapping will be performed to determine sites for optimal modulation of blood pressure. During each mapping day, with participants in a supine or seated position, electrodes will be placed on the midline of one of the following spinous processes: C5/6, T7/8, T11/12, L1/2 and S1/2. Stimulation intensity will start at 5 mA and gradually increased in 5 mA increments up to 100 mA. The frequency will be 2 or 30 Hz. Profiles will be established to guide selection of optimal site locations for blood pressure modulation. The profile chosen will be used during training and testing.~During testing, stimulation will be applied using the selected profile in order to normalize SBP to the range of 110-120 mmHg and stabilize it within this range during a 30-min tilt test.~On each session during the 2-week training-period, stimulation will be applied for 30 minutes using the selected profile, while the participant remains in a seated position."
223692230|NCT05725499|DIAGNOSTIC_TEST|Tilt-table orthostatic stress testing|"While lying supine, participants will be strapped to a Hi-Low tilt-table bed. The bed will gradually be tilted to a 70 degrees tilt, during which time continuous hemodynamic measures will be recorded. This position will be maintained for 30 minutes.~During some of the sessions, the tilt test will be accompanied by spinal stimulation."
223692231|NCT05749770|OTHER|blood testing|blood testing for basal hormones and markers of inflammation
223692232|NCT02142803|BIOLOGICAL|Bevacizumab|Given IV
223692233|NCT02142803|OTHER|Laboratory Biomarker Analysis|Correlative studies
223692234|NCT02142803|OTHER|Pharmacological Study|Correlative studies
223692235|NCT02142803|DRUG|Sapanisertib|Given PO
223692236|NCT01298544|PROCEDURE|Blood draw|One 5mL blood draw for immunogenicity at least 3 years post completion of clinical study 0887X-101518.
223692237|NCT02900560|DRUG|CC-486|CC-486 Intervention will depend on cohort enrolled in. 100 mg tablet
223692238|NCT02900560|BIOLOGICAL|Pembrolizumab|Pembrolizumab 200 mg IV every 21 days
223692239|NCT04929379|DRUG|Fenofibrate|145 mg oral fenofibrate daily for 76 weeks. Dosage is decreased to 48 mg daily if iGFR is or is estimated to be below 30 ml/min/1.73 m2.
223692240|NCT04929379|OTHER|Placebo|Inactive tablets identical to fenofibrate
223692241|NCT05950503|RADIATION|Hepatic MRI|The patients will undergo hepatic MRI in pre-established timepoints
223692242|NCT06224673|DRUG|ARX788|Given IV
223692243|NCT06224673|PROCEDURE|Computed Tomography (CT)|Undergo CT or Positron Emission Tomography(PET)/CT
223692244|NCT06224673|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
223692245|NCT06224673|DRUG|Amiloride|Ophthalmologic drops given topically to participants for an eye toxicity substudy
223692246|NCT04050917|DEVICE|real stimulation|The smartwatch generates imperceptible vibratory stimulation.
223692247|NCT04050917|DEVICE|no stimulation|The smartwatch generates no stimulation.
223692248|NCT04321096|DRUG|Camostat Mesilate|Serine protease inhibitor that blocks TMPRSS-2 mediated cell entry of SARS-CoV-2
223692249|NCT04321096|DRUG|Placebo oral tablet|Placebo
223692250|NCT07119840|DRUG|Listerine Mouthwash Product|Participants in this group will receive Listerine mouthwash containing essential oils (menthol, thymol, eucalyptol, and methyl salicylate). They will be instructed to rinse once daily with 10 ml of the solution for 30 seconds after brushing, over a period of 4 weeks. The mouthwash will be dispensed in unlabelled bottles to maintain blinding. Standard oral hygiene instructions will be given.
223777419|NCT05896592|DIAGNOSTIC_TEST|Pacemaker check|It consists in evaluating the reliability of the PM system. And the assessment of pacing percentage and recorded arrhythmias. After successful cardioneuroablation in groups 1 and 2, 4 months after randomization, the PM will be programmed to the VVI 30/min mode and after 6 months to the OAO/OVO mode. In group 3 patients and in the case of unsuccessful cardioneuroablation, the pacemaker will be set to the optimal mode for the patient. During the PM control, a non-invasive electrophysiological study (NIEPS) is also performed, in which the SNRT, cSNRT, Wenckebach point and HRV after SNRT measurement are assessed. The procedure will be repeated at subsequent visits 1, 3, 4, 6, 9, 12, 15, 18 months after randomization.
223777420|NCT05896592|DIAGNOSTIC_TEST|Implantable loop recorder check|Assessment of arrhythmias recorded in the ILR. The procedure will be repeated at subsequent visits 3, 4, 6, 9, 12, 15, 18 months after randomization.
223692251|NCT07119840|DRUG|Chlorhexidine mouthwash|Participants in this group will receive Chlorhexidine mouthwash at a concentration of 0.12%. They will be instructed to rinse once daily with 10 ml of the solution for 30 seconds after brushing, over a period of 4 weeks. The mouthwash will be dispensed in unlabelled bottles to maintain blinding. Standard oral hygiene instructions will be given.
223692252|NCT06059547|DRUG|Nivolumab|Biological, monoclonal antibody
223692253|NCT06059547|DRUG|Visugromab (CTL-002)|Biological, monoclonal antibody
223692254|NCT06059547|DRUG|Placebo|Placebo (NaCl) for Visugromab (CTL-002)
223692255|NCT02718300|DRUG|Parsaclisib|Up to 3 oral once a day (QD) doses of parsaclisib. Doses will be taken once daily for 8 weeks, followed by once weekly dosing at the same dose level.
223692256|NCT02718300|DRUG|Parsaclisib|Two recommended oral QD doses of parsaclisib. Once daily doses of parsaclisib will be taken for 8 weeks, followed by once weekly dosing at the same dose level.
223692257|NCT02718300|DRUG|Ruxolitinib|The dose of ruxolitinib will be that which the subjects had been taking for at least 8 weeks before the first dose of parsaclisib.
223692258|NCT02718300|DRUG|Parsaclisib|20 mg oral QD dose of parsaclisib for 8 weeks. After 8 weeks patients will take either 20 mg once weekly or 5 mg once daily.
223777421|NCT05896592|DIAGNOSTIC_TEST|Holter ECG|24 hour ECG recording. The procedure will be repeated at subsequent visits 1, 3, 4, 6, 9, 12, 15, 18 months after randomization.
223777422|NCT05896592|DIAGNOSTIC_TEST|Anamnesis|Medical history assessing symptoms of bradycardia, MAS, paraMAS and complications of performed procedures. The procedure will be repeated at subsequent visits 1, 3, 4, 6, 9, 12, 15, 18 months after randomization.
223777423|NCT04779957|DRUG|Tocilizumab|Tocilizumab will be administered at 8 mg/kg before or immediately after graft nephrectomy.
223777424|NCT02464969|DRUG|Apixaban|Tablet or Solution
223692259|NCT02718300|DRUG|Parsaclisib|"2 dose strategies will be compared:~1. 5 mg parsaclisib beginning on Day 1 until end of treatment.~2. 20 mg oral QD dose of parsaclisib for 8 weeks; after 8 weeks patients will take 5 mg once daily."
223692260|NCT02452697|BIOLOGICAL|NK Cell enriched-DLI only|"The first NK cell-enriched DLI will be administered one to six months post transplant. The second NK cell-enriched DLI will be administered one to three months post the first infusion, in patients who have ≤ grade II aGVHD at the time of infusion and have not had unacceptable toxicities from the first infusion. Patients will continue on their stable dose of immunosuppressive agents started for therapy of acute GVHD before the NK cell-enriched DLI, and will not taper until at least 6 weeks following the each NK cell-enriched DLI (unless disease progression or patient toxicity from the agents requires earlier taper). The donor NK cells will be infused over 30 minutes intravenously.~If signs of GVHD occur after NK cell-enriched DLI, immunosuppressive agents may be started."
223692261|NCT02452697|BIOLOGICAL|NK-DLI + DUK-CPG-001|"DUK-CPG-001 was synthesized by Agilent Technologies (Boulder, CO) in 2013. Bulk DUK-CPG-001 has been resuspended in normal saline with a final concentration of 10 mg/mL, aliquoted into 0.75 mL (7.5 mg) per tube and stored at -20oC in the Investigational Chemotherapy Service pharmacy at Duke. DUK-CPG-001 will be thawed at room temperature right before use and injected intravenously right after NK cell-enriched DLI. The drug will be used within 4 hours of thawing.~On the day of NK cell-enriched DLI, for those patients who are randomized to receive DUK-CPG-001, 0.5 mL (5 mg) aliquots of DUK-CPG-001 will be dispensed to nurse. It will be thawed at room temperature right before use and injected intravenously right after NK cell-enriched DLI."
223692262|NCT02658097|DRUG|Pembrolizumab|200mg Pembrolizumab by IV infusion
223692263|NCT02658097|RADIATION|Single Fraction Radiation Therapy|8Gy radiation therapy will be given in a single fraction on the first day of treatment
223692264|NCT06813690|DEVICE|Cold Therapy with Axanova Cold Hot Pearls Maxi Pack|This intervention involves the application of the Axanova Cold Hot Pearls Maxi Pack, a cooling device designed to provide targeted cold therapy. The device will be used to cool both thighs for 20-minute sessions, three times per day, following a muscle soreness protocol. The cold therapy aims to reduce inflammation, swelling, and muscle pain associated with Delayed Onset Muscle Soreness (DOMS). The intervention begins immediately after completing the muscle soreness protocol in Group A, and 24 hours later in Group B. Participants will receive cooling treatment for a total of 72 hours, with temperature and duration carefully monitored to ensure effective cooling.
223692265|NCT06604624|DRUG|HD1916|HD1916，0.25mg/0.5mg/1.0mg/1.7mg/2.4mg，SC，once a week
223692266|NCT06604624|DRUG|semaglutide|semaglutide ，0.25mg/0.5mg/1.0mg/1.7mg/2.4mg，SC，once a week
223692267|NCT04169347|DRUG|Oxaliplatin|2 week cycles
223692268|NCT06216015|OTHER|Exercise training|"Participants will engage in combined training five times a week, with activities including 2 minutes of stationary marching and a set of 15 repetitions for squats, bilateral hip abduction, plantar flexion, floor abdominal exercises, and arm flexion with the knee close to the ground. Additionally, twice a week on non-consecutive days, volunteers partake in 20 minutes of aerobic walking.~The second program starts with a 2-minute stationary march, followed by 2 sets of 12 repetitions for free squats, hip abduction, plantar flexion, stiff-legged deadlifts, arm flexion with knee support, floor abdominal exercises, and concludes with 30 minutes of aerobic exercise.~The third program starts with a 2-minute stationary march, followed by 3 sets of 12 repetitions for free squats, hip abduction, plantar flexion, stiff-legged deadlifts, arm flexion, floor abdominal exercises, and includes thrice-weekly aerobic sessions lasting 30 minutes each."
223692269|NCT06216015|OTHER|Continue exercising|Following the 24-week training regimen, patients will have the option to decide whether they wish to continue their exercise training. This group will include individuals who choose to persist with their exercise routine.
223692270|NCT06216015|OTHER|Discontinue exercising|Following the 24-week training regimen, patients will have the option to decide whether they wish to continue their exercise training. This group will comprise individuals who opted not to continue their exercise routine.
223692271|NCT03315910|BEHAVIORAL|Motivational Interviewing (MI)|two counseling sessions
223692272|NCT03315910|DRUG|Nicotine Replacement Therapy (NRT)|receive 6 weeks of NRT patch with dosing dependent upon reported baseline cigarettes per day
223692273|NCT03315910|DRUG|Nicotine Lozenge|6 packs of NRT 2mg lozenge
223692274|NCT03315910|BEHAVIORAL|Message Framing|health communication literature and quitting messages
223692275|NCT03315910|OTHER|saliva sample|saliva samples from those reporting abstinence and analyze samples
223692276|NCT05079516|OTHER|Theta burst transcranial magnetic stimulation|Real or sham continuous theta burst TMS (cTBS) will be delivered to a location on the head, determined by randomized group assignment. cTBS consists of 600 low-intensity TMS pulses delivered over 40 seconds in a pattern of 50 Hz triplets delivered at 5 Hz.
223692277|NCT05419908|DRUG|Fezolinetant|Oral Capsule
223692278|NCT05419908|DRUG|Placebo|Oral Capsule
223692279|NCT06625801|DEVICE|IVUS|Intravascular Ultrasound
223692280|NCT05564091|DEVICE|Cataract surgery combined with ab-interno canaloplasty utililzing the iTrack Advance canaloplasty device|360 degree microcatheterization and viscodilation of Schlemm's canal
223692281|NCT05564091|PROCEDURE|Cataract surgery|Cataract surgery alone
223692282|NCT06683664|OTHER|Integrated health service delivery for very young adolescents|The proposed HPV-PASSREV intervention will aim to increase adolescent-centered access to HPV vaccination and other very young adolescent health services through an integrated, routine, community-based delivery model that incorporates household mobilization efforts with enhanced service delivery at the health facility and community levels.
223692283|NCT06619366|OTHER|coach-guided personalized depression risk communication|see information in arm description.
223692284|NCT06619366|OTHER|depression risk information|see information in arm description.
223692285|NCT06622889|OTHER|Multidomain Intervention Program|The intervention program aims to help older adults with subjective cognitive decline understand the aging process and adopt a positive attitude toward aging, highlighting age-related benefits. The sessions also provide emotion regulation techniques and stress-coping strategies to encourage proactive problem-solving and build confidence in handling challenges. By recalling positive life experiences, the program seeks to strengthen emotional connections, enhance the sense of belonging, and reconstruct a meaningful later life.
223777425|NCT02464969|DRUG|Standard of Care|Unfractionated heparin, low molecular weight heparin, and/or a vitamin K antagonist. For subjects under 2 years of age, standard of care will be limited to unfractionated heparin or low molecular weight heparin.
223777426|NCT04589065|DEVICE|Selective Cytopheretic Device|SCD therapy will take place for 4 hours on day 1, 3, and 5 while on hemodialysis treatment. Participants will be continue to be followed until 30 days after the last SCD treatment.
223777430|NCT01591746|DRUG|Botulinum Toxin Type A|
223777431|NCT01591746|DRUG|Placebo|5 mL 0.9% NaCl solution to mimic Botulinum Toxin Type A
223777432|NCT03539380|DRUG|TRx0237|Starting dose of TRx0237 16 mg/day (unless enrolled under earlier version of protocol and are on an established dose), with flexible dosing after 3 months (4-16 mg/day)
223777433|NCT06494735|BEHAVIORAL|MyMCT|Using the french version of the metagognitive bibliotherapy MyMCT
223777434|NCT03735420|DRUG|Xanthohumol|The xanthohumol supplement will be administered in a capsule. Participants in the experimental arm will consume the capsule once per day, with the first meal. The intervention will extend for 8 weeks.
223692286|NCT03098628|BIOLOGICAL|PCV Vaccine|PCV vaccination
223692287|NCT06693960|DIETARY_SUPPLEMENT|Oregano|Oil of oregano administered as a softgel (180 mg).
223692288|NCT06693960|DRUG|Drug cocktail|Oral drug cocktail consisting of caffeine (100 mg), dextromethorphan (30 mg), losartan (25 mg), midazolam syrup (2 mg), and omeprazole (20 mg).
223692289|NCT06694285|DIAGNOSTIC_TEST|Ultrasound evaluation|The subjects will constitute a cohort whose medical history, clinical, ultrasound and treatment data reported in the appropriate data collection form will be prospectively collected. Enrolled patients will undergo clinical and ultrasonographic evaluation in a manner not unlike routine clinical practice.
223692290|NCT06630039|OTHER|Scale validity and reliability|The aim of this study is to adapt the Short-Western Ontario Rotator Cuff Disability Index (SHORTWORC) to Turkish society in patients with rotator cuff injury and to make its validity and reliability in Turkish. It has 7 questions. The patients will be sought to answer questionnaires during regular rehabilitation sessions.
223692291|NCT05541250|BIOLOGICAL|Autologous Human Schwann Cell|A one-time dose of 1000 μl\* or 80 to 100 million ahSC prepared from segments of the sural nerve from the leg recovered from the participant.
223692292|NCT06683118|DEVICE|Rapamycin neurovascular Balloon Catheter|Drug-coated balloon for the symptomatic cerebral atherosclerotic stenosis
223692293|NCT06683118|DEVICE|Conventional Balloon|Conventional Balloon for the symptomatic cerebral atherosclerotic stenosis
223692294|NCT07050368|DRUG|Psilocybin|Capsule containing active ingredient, psilocybin
223692295|NCT07050368|DRUG|Placebo|Capsule with no active ingredients
223692296|NCT06736171|DEVICE|Robotic Exoskeleton|EksoNR, Ekso Bionics, San Rafael, CA, USA Atalante X, Wandercraft, Paris, France ReStore™, Lifeward Inc, Marlborough, MA
223692297|NCT06736171|OTHER|SOC|Standard of Care
223692298|NCT06287619|DRUG|Monoferric Injectable Product|Ferric derisomaltose will be prepared by an unblinded research pharmacist/delegated staff as per standard of care procedures. Specifically, 10 mL (containing 1000 mg ferric derisomaltose) will be diluted in 100 mL of sterile 0.9% sodium chloride solution and drawn up into blinded syringes and tubing. The 1000 mg doses of ferric derisomaltose will be administered by a bedside nurse over 60 minutes via an infusion pump through a dedicated IV.
223692299|NCT06287619|OTHER|0.9% sodium chloride solution|Patients in the control group will receive placebo, which will be 100 mL of sterile 0.9% sodium chloride solution and drawn up into blinded syringes and tubing according to good manufacturing practice (GMP).
223777435|NCT03735420|DRUG|Placebo oral capsule|The placebo (vehicle) will be administered in a capsule. Participants in the placebo arm will consume the capsule once per day, with the first meal.
223692300|NCT06933563|BIOLOGICAL|UCAR T-cell group|A single injection of UCAR T-cells, referred to as universal allogeneic anti-CD19/BCMA CAR T-cells
223692301|NCT06937944|BIOLOGICAL|Rcombinant botulinum toxin type A for injection（Eveotox)|Rcombinant botulinum toxin type A for injection（Eveotox)
223692302|NCT06937944|BIOLOGICAL|OnabotulinumtoxinA (Botox)|OnabotulinumtoxinA (Botox)
223692303|NCT06937944|BIOLOGICAL|Placebo|Placebo
223692304|NCT06941519|BEHAVIORAL|Telephonic Outreach|Higher Intensity (active telephonic outreach from a health navigator with follow-up contacts for up to 3 months)
223692305|NCT06941519|BEHAVIORAL|Virtual Outreach|Lower Intensity (outreach via text, email, and/or letter with materials that contain information about available local, state, and federal governmental benefits and services)
223692306|NCT07149545|DRUG|Arm A (Fentanyl + Midazolam)|Sedation protocol: Fentanyl infusion (0.1 mL/kg/h) initiated after surgical site disinfection; during ablation, fentanyl 2 mL and midazolam 0.5 mg were administered intravenously. Additional fentanyl or midazolam was given if needed.
223692307|NCT07149545|DRUG|Arm B (Flurbiprofen axetil + Fentanyl + Midazolam)|Sedation protocol: Fentanyl infusion (0.1 mL/kg/h) initiated after disinfection; flurbiprofen axetil (100 mg) administered intravenously after transseptal puncture; fentanyl 2 mL and midazolam 0.5 mg administered during ablation. Additional fentanyl was given if needed.
223777436|NCT04889092|OTHER|Blood Flow Restriction exercise|Exercise training will consist of blood flow restriction exercise. Specifically blood pressure cuff will be wrapped around the most proximal portion of the thigh and inflated to a pressure that is 80% of the pressure required to completely occlude femoral blood flow. With the cuff inflated the subject will perform a series of knee extension/flexion exercise protocol. This consists of 30 reps, 15 reps, 15 reps and 15 reps all separated by 1 minute of recovery. All reps will be performed at 30% of the subjects 1 repetition max. This will be preformed 20 times over 8 weeks.
223777437|NCT04889092|OTHER|Traditional resistance exercise|Traditional knee extension/flexion exercise will be performed. This will consist of a series of 13 reps, 12 reps, 12 reps with 1 minute recovery between each set. The resistance will be set at 60% of their 1 repetition max. This will be performed 20 times across 8 weeks.
223777438|NCT05234944|BEHAVIORAL|Type 1 Diabetes and Life|Brief behavioral intervention, delivered remotely by certified diabetes care and education specialists, targeting diabetes-specific health-related quality of life for people with type 1 diabetes across the lifespan and for their parents and partners.
223777439|NCT02877706|OTHER|no specific intervention|
223777440|NCT06126549|BEHAVIORAL|Building Better Caregivers|Peer-led, group intervention for caregivers focused on problem-solving
223777441|NCT06126549|BEHAVIORAL|Problem Solving Training|Clinician-led, one-to-one intervention for caregivers focused on problem-solving
223777442|NCT06126549|BEHAVIORAL|Usual Care|Usual discharge training and support offered to family caregivers of ABI patients
223777443|NCT02399085|DRUG|Tafasitamab|12 mg/kg
223777444|NCT02399085|DRUG|Lenalidomide|25 mg
223777445|NCT00833924|DEVICE|Zenith(R) Low Profile AAA Endovascular Graft|The Zenith(R) Low Profile AAA Endovascular Graft and ancillary components are indicated for the endovascular treatment of patients with abdominal aortic, aorto-iliac, or iliac aneurysms having morphology suitable for endovascular repair.
223777446|NCT02176733|DRUG|cyclosporine|
223777447|NCT01969071|DRUG|Levosimendan|The effects of levosimendan on renal function
223692308|NCT07149545|DRUG|Arm C (Fentanyl + Dexmedetomidine)|Sedation protocol: Fentanyl infusion (0.1 mL/kg/h) initiated after disinfection; dexmedetomidine continuous infusion (0.4 μg/kg/h) was administered throughout.
223692309|NCT07150364|OTHER|Square Stepping Exercise|5 days per week for 6 weeks. 30 minutes per session with appropriate rest interval in between.
223777448|NCT01969071|DRUG|Dobutamine|Standard Inotropic agent
223777449|NCT04245488|OTHER|taste test|rate intensity of sour solutions and fatty acid solutions
223777450|NCT00434096|DRUG|rimonabant (SR141716)|oral administration once daily
223777451|NCT00434096|DRUG|placebo|oral administration once daily
223692310|NCT07150364|OTHER|Wobble Board Exercise|5 days per week for 6 weeks. 30 minutes per session with appropriate rest interval in between.
223692311|NCT07150754|DRUG|Heart failure pharmacological treatments|Identify a positive signal for fall with one or more of the recommended pharmacological treatments for heart failure
223692312|NCT07149961|DIETARY_SUPPLEMENT|Curcumin plus Piperine|A loading dose of 2 capsules (each containing 390 mg curcumin + 20 mg piperine) is administered orally prior to PPCI, followed by maintenance of 1 capsule daily until day 28. Oral administration of standardized curcumin extract (390 mg) combined with piperine (20 mg), given twice daily for 28 days in addition to standard-of-care therapy for STEMI patients undergoing primary percutaneous coronary intervention (PPCI). The curcumin-piperine formulation is used to enhance bioavailability and anti-inflammatory effects, aiming to improve post-MI recovery and reduce oxidative stress.
223692313|NCT07149961|OTHER|Placebo capsules|A loading dose of 2 capsules (each containing saccarum lactic) is administered orally prior to PPCI, followed by maintenance of 1 capsule daily until day 28. Oral administration of standardized placebo capsule, given twice daily for 28 days in addition to standard-of-care therapy for STEMI patients undergoing primary percutaneous coronary intervention (PPCI).
223692314|NCT07149441|PROCEDURE|Fecal microbiota transplantation|Fecal microbiota transplantation (FMT) achieves the purpose of treating intestinal and extra-intestinal diseases by transplanting the functional microbes in the feces of healthy people into the patient's intestine through the upper or lower alimentary tract routes to rebuild the patient's intestinal microbiota.
223692315|NCT07149441|DRUG|infliximab|Intravenous infusion of infliximab once every 8 weeks.
223692316|NCT07150221|DEVICE|Vivacit-E Elevated Liners|Primary total hip arthroplasty
223777452|NCT04328493|DRUG|Chloroquine phosphate|"Each chloroquine tablet contains 250mg chloroquine phosphate (or 150mg chloroquine base). Chloroquine treatment for patient is weight-based dosing.~Chloroquine will be administered orally, as tablets. For unconscious patients chloroquine can be crushed and administered as a suspension via a nasogastric tube.~The total duration of treatment with Chloroquine will be 10 days"
223777453|NCT00902356|DRUG|AMG 167|Subjects will be randomized to receive 1 of 5 doses of AMG 167 or equivalent volume of placebo administered as a single dose. Postmenopausal women will receive AMG 167 in fixed doses of 21 mg, 70, 210, 350, or 700 mg SC (under the skin), or 70 mg or 350 mg IV (in the vein), while men will receive doses of 70 mg or 350 mg SC or IV.
223777454|NCT00902356|DRUG|Placebo|Subjects will be randomized to receive 1 of 5 doses of AMG 167 or equivalent volume of placebo administered as a single dose. Postmenopausal women will receive AMG 167 in fixed doses of 21 mg, 70, 210, 350, or 700 mg SC (under the skin), or 70 mg or 350 mg IV (in the vein), while men will receive doses of 70 mg or 350 mg SC or IV.
223777455|NCT04428632|DRUG|Berotralstat|One 150mg capsule administered orally once daily
223777456|NCT03104504|BEHAVIORAL|Suicide Risk Screening|Suicide risk screening will be implemented as the standard of care for all patients who present for treatment.
223777457|NCT03104504|BEHAVIORAL|Safety Planning|Suicide screen-positive patients who are to be discharged from the hospital will receive personalized safety planning by a mental health clinician or nurse that includes means restriction counseling as a step in the safety plan.
223777458|NCT03104504|BEHAVIORAL|Care transition facilitation|Include post-acute telephone phone call follow-up to foster engagement with outpatient care and problem solving within 24 hours of discharge
223777459|NCT03104504|BEHAVIORAL|A Lean Implementation Strategy|The Interventions will be implemented using Lean performance improvement strategies
223777460|NCT03036514|DEVICE|Sublingual sufentanil tablet system|Usage of a new patient-controlled SSTS in the postoperative phase after laminectomy or spinal fusion.
223692317|NCT07149701|DEVICE|Intervention|Treatment with intervention of catheter ablation or Implantable cardioverter defibrillator.
223692318|NCT07149935|OTHER|Rehabilitation Training|The rehabilitation training has two parts: the exercise training at home（5 times per week, as well as the Inspiratory muscle training(once per day) including Respiratory trainer exercise and abdominal breathing training.
223692319|NCT07149688|DEVICE|Comprehensive management program (pharmacologic treatment, lifestyle modification, health education, structured follow-up)|"Comprehensive management program (pharmacologic treatment, lifestyle modification, health education, structured follow-up)~Enhanced monitoring with 7-day ECG"
223692320|NCT07149467|DRUG|Ustekinumab (approximately 6 mg/kg)|"At Week 0:~≤55 kg: 260 mg administered by intravenous (IV) infusion.~\>55 kg and ≤85 kg: 390 mg administered by intravenous (IV) infusion.~\>85 kg: 520 mg administered by intravenous (IV) infusion.~From Week 8 onward (i.e., at Week 8 and then every 8 weeks up to Week 52 or the end of the follow-up period):~90 mg administered by subcutaneous (SC) injection."
223692321|NCT07149467|DRUG|Upadacitinib|"From Week 0 to Week 12: 45 mg once daily, administered orally.~From Week 13 through Week 52 or the end of the follow-up period: 30 mg once daily, administered orally."
223692322|NCT07149831|DRUG|Flotufolastat F-18 Injection|Single dose intravenous injection of Flotufolastat F-18 Injection . Serial whole-body PET scan will be obtain after injection, blood and urine collection after injection for the assessment of pharmacokinetics.
223692323|NCT07150949|RADIATION|Long-course radiotherapy|Long-course radiation: 50Gy/25Fx
223692324|NCT07150949|DRUG|Oxaliplatin|Oxaliplatin: 130mg/m2 d1 q3w
223692325|NCT07150949|DRUG|Capecitabine|Xeloda
223692326|NCT07150949|DRUG|Celecoxib|celecoxib 200 mg orally twice a day
223692327|NCT07150949|RADIATION|Short-course radiotherapy|Short-course radiotherapy: 25Gy/5Fx
223692328|NCT07150949|DRUG|Serplulimab|Serplulimab 300mg, d1, q3w
223692329|NCT07149649|DRUG|Magnesiocard|2.5 mmol film-coated tablets in addition to standard first line therapy
223692330|NCT07149649|DRUG|Magnesium Diasporal|4 mmol IV formulation in addition to standard first line therapy
223692331|NCT07149649|OTHER|Microcrystalline cellulose|Placebo film-coated tablets corresponding to Magnesiocard in addition to standard first line therapy
223692332|NCT07149649|OTHER|Isotonic saline solution 0.9%|Placebo for injection corresponding to Magnesium Diasporal in addition to standard first line therapy
223692333|NCT02136108|OTHER|OPENtext|Participants will receive 12 weeks of daily text messages sent from an automated system. The text messages will assist participants in managing their chronic pain.
223692334|NCT02136108|OTHER|OPENnav|Particpants will be linked with a RIPN PEER Navigator who will assisted them in managing their health care
223692335|NCT06337422|DRUG|Celecoxib 200 mg capsule|Celecoxib 200 mg capsule
223692336|NCT02454725|BEHAVIORAL|Social Network|Leaders of social networks will undergo small group training to develop skills to convey information effectively and deliver messages endorsing regular HIV testing to members of their social networks.
223692337|NCT02454725|BEHAVIORAL|Comparison|All participants will receive HIV counseling and rapid testing following the Wisconsin Department of Health guidelines. Sexually active men who receive a negative test result will be told that they should be HIV-tested every three to six months, unless they have a monogamous HIV negative partner
223692338|NCT05281016|BEHAVIORAL|Usual Care|"Participants will be offered standard care which consists of the following:~* Clinic consultation with physician and dietician,~* pamphlets on weight management principles."
223692339|NCT05281016|BEHAVIORAL|Online community LITE programme|"Participants will be invited to participate in the online community LITE programme. Participants will also receive basic sports equipment for the online programme.~The online community LITE programme will consist of 2 sessions a week for 4-5 months. Each session is 1 hour long. The programme will deliver 3 domains: physical activity, nutrition and behaviour. It consists of relatively unstructured sessions comprising of cooking and nutrition classes, games and sports and peer support."
223692340|NCT03906461|DEVICE|Radiofrequency Ablation|The Tacticath Contact Force Ablation Catheter, Sensor Enabled (TactiCath SE) is designed to facilitate electrophysiological mapping of the heart chambers and to transmit radiofrequency (RF) current to the catheter tip electrode for intracardiac ablation purposes.
223692341|NCT02872168|OTHER|Not intervention|None. there is no modification in the treatment of patients. A urine collection is carry out in patients during the day of their enrolment.
223692342|NCT05579691|BIOLOGICAL|CTI-1601|CTI-1601 is a recombinant fusion protein and is intended to deliver human frataxin, the protein deficient in Friedreich's ataxia
223692343|NCT05579691|OTHER|Placebo|Placebo Comparator
223692344|NCT06064266|OTHER|plant-based mild ketogenic controlled diet|Plant-based mild ketogenic diet (10-20EN% carbohydrates, 10-20EN% protein, and 60-70EN% fat), consisting of a daily breakfast, lunch, dinner, and snacks.
223692345|NCT06064266|OTHER|high-fat shake|The high-fat shake consists of unsweetened almond milk, sunflower oil, and plant sterols, resulting in a shake containing 885 kcal (1.5g protein, 97.3g fat, and 0.8g sugar).
223777461|NCT03036514|DRUG|Patient-controlled intravenous analgesia|Usage of classically used patient-controlled intravenous mophine-based postoperative analgesia after laminectomy or spinal fusion.
223692346|NCT06802172|BEHAVIORAL|Time-restricted eating|Participate in time-restricted eating plan
223692347|NCT06802172|OTHER|Questionnaire Administration|Complete questionnaire
223692348|NCT06802172|PROCEDURE|Biospecimen Collection|Undergo collection of blood and stool
223692349|NCT06802172|BEHAVIORAL|Health coaching|Receive nutrition counseling
223692350|NCT00660621|DRUG|Temozolomide and Bevacizumab|"Between 14 and 28 days after surgery, all subjects will begin a standard course of post-operative limited field radiation therapy to the tumor site and a surrounding margin with concomitant temozolomide at a daily dose of 75 mg/m2 (7 days/week).~No later than 45 days after date of completion of radiation therapy, all subjects will begin dose dense temozolomide at dose of 150 mg/m2 on Days 1-7 and 15-21 of a 28 day cycle with concomitant bevacizumab 10mg/kg administered intravenously every other week."
223692351|NCT00510874|BIOLOGICAL|Pumarix™|Two doses administered intramuscularly (IM), the first in the deltoid region of the non-dominant arm and the second in the deltoid region of the dominant arm.
223692352|NCT00510874|BIOLOGICAL|Pandemrix ™|Two doses administered intramuscularly (IM), the first in the deltoid region of the non-dominant arm and the second in the deltoid region of the dominant arm.
223777462|NCT02634658|OTHER|Muscle Ultrasound|Ultrasound will be performed using a linear-array transducer with standardized gain and varying depth based on the amount of overlying soft tissue and muscle size. The subjects will be examined in the supine position with extended limbs and relaxed muscles. We will perform bilateral scans of the biceps, anterior forearm, and anterior thigh at standardized sites. For muscle echogenicity measurements, we will scan the same muscles at the same points.
223692353|NCT03415100|BIOLOGICAL|CAR-NK cells targeting NKG2D ligands|The infusion of CAR-NK cells will be performed in the Third Affiliated Hospital of Guangzhou Medical University. Following infusion of CAR-NK cells, interleukin-2 (IL-2) will be injected subcutaneously into some patients to support the in vivo survival of CAR-NK cells. The subject will be observed for any side effects during this time and all the adverse events will be recorded.
223692354|NCT06309537|DIAGNOSTIC_TEST|chemoreflex evaluation|the ventilatory response to carbon dioxide and hypoxia will be assessed in study participants
223692355|NCT06418893|DRUG|Target control infusion propofol|target control infusion of propofol for target plasma concentration 2.5mcg/ml and BIS 40-60
223692356|NCT06418893|DRUG|Inhalational isoflurane|Inhalational Isoflurane at concentration 1-2%
223692357|NCT00085124|BIOLOGICAL|oblimersen sodium|Given IV
223692358|NCT00085124|DRUG|cytarabine|Given IV
223692359|NCT00085124|DRUG|daunorubicin hydrochloride|Given IV
223692360|NCT00085124|OTHER|laboratory biomarker analysis|Correlative studies
223692361|NCT00695578|DRUG|Biafine|Apply to wounds 3 times daily for 4 weeks: ingredients: purified water, liquid paraffin, glycol monostearate, stearic acid, propylene glycol, paraffin wax, squalene, avocado oil, trolamine sodium alginate, cetyl palmitate, methylparaben, sorbic acid, propyl paraben and fragrance.
223692362|NCT00695578|DRUG|Polysporin|over the counter Polysporin ointment 3 times daily for 4 weeks to wounds
223692363|NCT04308603|DIAGNOSTIC_TEST|NON-IMMUNE HYDROPS FETALIS diagnosis|Amniotic liquid of each selected patients will be tested by both technic to describe and detect etiological information. Each patient will be tested using the current procedure with a defined panel of genes as well as with the NGS procedure. The results of both procedures will be compared.
223692364|NCT00003742|DRUG|cisplatin|
223692365|NCT00003742|DRUG|irinotecan hydrochloride|
223692366|NCT00003742|DRUG|paclitaxel|
223692367|NCT06255184|BEHAVIORAL|Sernity intervention|Serenity Therapy is a holistic intervention that boosts psychological well-being and emotional balance through relaxation techniques, mindfulness, and guided imagery
223692368|NCT04375969|OTHER|whole body cryostimulation treatment|The WBC is apporved by National Ministry of Health. It uses cryochamber with low temperature -110 oC. The patient, minimally dressed (e.g., bathing suit, socks, clogs, headband, and surgical mask), remains 30sec at -60°C (vestibule) for body adaptation and, then, passes to the cryochamber, at -110°C and stay there 3 minutes.
223692369|NCT04375969|OTHER|Connection WBC treatment and HIIT training|WBC combination with Exercise HIIT according to Litlle protocol from 2011. This exercise protocol will be applied together with cryo-sessions
223692370|NCT04375969|OTHER|Control Group|This group willnot to change their daily habits . The measurements will be taken at baseline and at the end of the study
223692371|NCT04375969|OTHER|HIIT training group|This group will do the training program without cold exposure
223692372|NCT00420667|DRUG|Enoxaparin|
223692373|NCT01545258|OTHER|Exercise|Physiotherapy supervised exercise training. 60 minutes 3 times per week
223692374|NCT02310932|BEHAVIORAL|Healthy Living Intervention|"Patients in the intervention groups will receive integrated collaborative clinic care by their physicians, a nurse case manager and consulting psychiatrists. They will also participate in 12-month community-based Healthy Living groups, in which cognitive and behavioral strategies are used to target health promoting behaviors, such as increased activity, improved diet, adherence to medical regimens, as well as problem-solving skills, coping skills, and social support."
223692375|NCT03090841|BIOLOGICAL|Bio-specimen collected|
223692376|NCT06244017|DEVICE|EEG spectrogram|In the experimental group, the general anesthesia is guided by using the EEG spectrogram.
223692377|NCT06244017|DEVICE|Bispectral index|In the control group, the general anesthesia is guided by using the bispectral index
223692378|NCT04703387|DIAGNOSTIC_TEST|transthoracic echocardiography|Trans-mitral flow velocities (peak early diastolic E and peak late diastolic A) will be recorded with pulsed-wave Doppler, placing the sample volume at the mitral valve tips from the apical 4-chamber view; deceleration time of the E wave (DTE) will be measured. Peak early diastolic velocity will be obtained with tissue Doppler imaging (TDI), in the apical 4-chamber view, positioning the pulsed-wave Doppler sample volume at or 1 cm within the septal insertion sites of the mitral leaflets, so as to cover the longitudinal excursion of the mitral annulus in both systole and diastole. Then, the E/A ratio and the trans-mitral inflow E wave to mitral annular e' (E/e) will be calculated.Diaphragmatic thickness will be assessed in the zone of apposition of the diaphragm to the rib cage between the 8th and 10th intercostal spaces using a 3-12 MHz linear array probe , we will record changes in diaphragm vertical excursion using M-mode ultrasound.
223692379|NCT00886184|PROCEDURE|Hypothermia.|Induction of pre hospital therapeutic hypothermia.
223692380|NCT00886184|PROCEDURE|No early hypothermia|Induction of therapeutic hypothermia only once arrived at hospital.
223777463|NCT02634658|OTHER|Nerve Conduction Study|Nerve Conduction Studies will be performed using a Nicolet EDX using standard procedures. Repetitive stimulation of the median motor nerve are performed in all subjects. Bilateral sural, radial and median sensory nerves will be analyzed. We will only perform surface, not subdermal sensory recordings. The bilateral peroneal, tibial and median motor responses will be recorded over extensor digitorum brevis, abductor hallucis brevis, and abductor pollicis brevis muscles. The peroneal motor nerve will be stimulated at the fibular head and lateral popliteal fossa, recording from the tibialis anterior muscle. The compound motor action potential (CMAP) responses will be elicited from standard distal and proximal sites.
223692381|NCT02242188|DRUG|Iron|"Ferric pyrophosphate (powder preparation in sachets: Actiferol, SunActive Fe, Sequoia, Poland) in a single daily dose. Three doses will be used: 7 mg for infants up to 7 kg of body weight, 10 mg for infants from 7 to 10 kg of body weight, and 15 mg for those exceeding the weight of 10 kg. Caregivers will be instructed to administer the daily dose at the same time of a day, after mixing the content of the sachet with a little amount of breastmilk or milk formula.~The intervention will last from 4 months to 9 months of age."
223692382|NCT02242188|DIETARY_SUPPLEMENT|Placebo|Maltodextrin (packed in identical sachets as active products)
223692383|NCT03554616|OTHER|Chlorfenapyr LLIN|Dual active ingredient Long Lasting Insecticidal Net
223692384|NCT03554616|OTHER|pyriproxyfen LLIN|Dual active ingredient Long Lasting Insecticidal Net
223692385|NCT03554616|OTHER|Piperonyl butoxide LLIN|Combination insecticide and synergist Long Lasting Insecticidal Net
223692386|NCT03554616|OTHER|Standard LLIN|Standard Long Lasting Insecticidal Net with one insecticide
223692387|NCT04622735|COMBINATION_PRODUCT|nefopam hydrochloride 30mg / paracetamol 500mg X2|The first intake is taken right after randomization. Then on-demand period (5 days maximum) respecting a 6-hour interval between intakes, and up to 3 intakes per day.
223692388|NCT04622735|DRUG|Paracetamol 500 Mg Oral Tablet X2|The first intake is taken right after randomization. Then on-demand period (5 days maximum) respecting a 6-hour interval between intakes, and up to 3 intakes per day.
223692389|NCT04622735|DRUG|Nefopam HCl 30 MG Oral Tablet X2|The first intake is taken right after randomization. Then on-demand period (5 days maximum) respecting a 6-hour interval between intakes, and up to 3 intakes per day.
223692390|NCT03241069|OTHER|Reference position|patient is put in a 30 degree supine position during 5 minutes
223692391|NCT03241069|OTHER|sitting position|patient is put to a 90 degree sitting position during 1 to 2 minutes then the CO is measured
223692392|NCT03241069|OTHER|Valsalva maneuver|patients are asked to perform the Valsalva maneuver by executing a forced blow into a manometer for 30 seconds and the CO is calculated during this test.
223692393|NCT03241069|OTHER|a passive leg rising maneuver|we make a passive leg rising and we measure the cardiac output by BIOPAC system (45 degree passive leg rising was done for 1 to 2 minutes and CO was measured during the maneuver.)
223692394|NCT04282798|OTHER|Personalized Music Intervention|Participants will complete a series of questionnaires to identify participants' music preferences and participants' sensitivity to reward from musical engagement. The responses from the music preference questionnaires will be used to create a 1 hr playlist of songs by a member of the study team for the participant to be played daily for four weeks. After playlist is created and transmitted to MP3 device, participants will pick up the equipment and a compliance log will be given for the participant and participants' caregivers to confirm adherence to the protocol of daily listening. The platform will be Spotify, where the MP3 device given to participant at the start of the intervention will be preprogrammed with the participant's personal playlist on the platform. This trial is a supplementary treatment option for cognitive and neuropsychiatric assessments for AD, as such no alterations in the current treatment plans of any participant will be necessary.
223692395|NCT04073368|DIETARY_SUPPLEMENT|AXA1957|Amino acids, food study
223692396|NCT04073368|DIETARY_SUPPLEMENT|AXA1125|Amino acids, food study
223692397|NCT04073368|DIETARY_SUPPLEMENT|Placebo|Amino acids, food study
223692398|NCT05701488|DRUG|Durvalumab|Intravenous infusion
223692399|NCT05701488|DRUG|Tremelimumab|Intravenous infusion
223692400|NCT05701488|DEVICE|SIRT|SIR (Selective Internal Radiation) Sphere resin microspheres, radioactive particles delivered via injection into an artery.
223692401|NCT01135576|DIETARY_SUPPLEMENT|non-fortified fruit juices consumed as part of the usual diet|
223692402|NCT01135576|DIETARY_SUPPLEMENT|Iron fortified fruit juice|Consumption of micronized iron pyrophosphate supplemented fruit juices as part of the usual diet
223692403|NCT03051646|DRUG|Acetylsalicylic acid at 1st visit, then Placebo at 2nd visit|650 mg dose of acetylsalicylic acid is administered in a capsule one hour prior to exercise; Placebo oral capsule is administered one hour prior to exercise
223692404|NCT03051646|DRUG|Placebo at 1st visit, then Acetylsalicylic acid at 2nd visit|Placebo oral capsule is administered one hour prior to exercise; 650 mg dose of acetylsalicylic acid is administered in a capsule one hour prior to exercise
223692405|NCT00504985|BEHAVIORAL|Surveys|2 surveys, taking about 10-15 minutes each, during Emergency Center visit
223692406|NCT02682407|BIOLOGICAL|OMS721 (narsoplimab)|Biological: OMS721 (narsoplimab)
223692407|NCT03880604|PROCEDURE|Triple tourniquets|A number 1 polyglactin suture was tied around the cervix to occlude the uterine arteries, and polythene tourniquets were tied around the infundibulopelvic ligament to obstruct the ovarian vessels
223692408|NCT03880604|DRUG|TA|1-gram tranexamic acid (10 ml) in 100 ml saline infusion
223692409|NCT03880604|OTHER|placebo to TA|placebo to 1-gram tranexamic acid (10 ml) in 100 ml saline infusion
223692410|NCT06409351|BEHAVIORAL|Intervention group|Please refer to arm descriptions
223692411|NCT02796742|OTHER|Collecting samples from all patients presenting with SSTIs requiring drainage|The study will be conducted by microbiology laboratories. Before the start of the study, each participating laboratory will send an information letter to its corresponding emergency departments to increase vigilance of clinicians in collecting samples from all patients presenting with SSTIs; this will improve the level of inclusion. Each participating lab will also insure connection to local representation of the project for ethical clearance, collection of clinical data and SSTI specimen.
223692412|NCT00003548|DRUG|aminocamptothecin colloidal dispersion|
223692413|NCT01732731|OTHER|treadmill training|Home-based treadmill training will be administered to the children in the experimental group
223692414|NCT06345846|DEVICE|IFIOL|Implanted IFIOL
223692415|NCT06345846|DEVICE|SFIOL|Implanted SFIOL
223777464|NCT02634658|OTHER|Electromyography|EMG studies will be performed using standard precautions. Insertional activity, spontaneous activity, motor unit potential (MUP) morphology and recruitment/activation pattern will be recorded from some combination of the deltoid, triceps, biceps, first dorsal interosseous, abductor pollicis brevis, iliopsoas, vastus medialis, and tibialis anterior muscles. The specific muscles studied for each patient will vary according to the patient's level of consciousness and ability to activate the muscles either voluntarily or during spontaneous limb movement. If possible, we will try to examine 3 unilateral upper extremity and 3 unilateral lower extremity muscles. If a patient is not able to volitionally participate in EMG testing (by contracting their muscles on command), we will analyze insertional/spontaneous activity and potentially morphology/recruitment (e.g. stroking the sole of the foot to stimulate contraction of the tibialis anterior).
223777465|NCT04331080|DRUG|Granexin® gel 100 μM|Administered during the surgery, 24 hours post-surgery, and 48 hours post-surgery.
223777466|NCT04331080|DRUG|Granexin® gel 200 μM|Administered during the surgery, 24 hours post-surgery, and 48 hours post-surgery.
223777467|NCT04331080|DRUG|Vehicle gel|Administered during the surgery, 24 hours post-surgery, and 48 hours post-surgery.
223777468|NCT02344186|DRUG|Liraglutide|Crossover design - 24 weeks on active drug and 12 weeks daily placebo
223777469|NCT00491790|DRUG|Montelukast|Montelukast 4 mg rapid dissolving granules in sterile water given orally once
223777470|NCT00491790|OTHER|Sterile water|Sterile water
223777471|NCT02304237|DRUG|Vaginal progesterone|micronized progesterone 200mg/day till 36 weeks 6 days of gestation or premature rupture of membranes
223777472|NCT02304237|DRUG|Intramuscular progesterone|hydroxyprogesterone caproate 250mg/ml/week till 36 weeks 6 days of gestation or premature rupture of membranes
223777473|NCT03565406|DRUG|Mocetinostat Induction Phase + Ipilimumab + Nivolumab|"Treatment Cycle 1: Mocetinostat at a dose of 90 mg PO TIW; ipilimumab will be administered IV at a dose of 1 mg/kg and nivolumab will be administered IV at a dose of 3 mg/kg during the 12-week induction period. The induction phase will last for 2 treatment cycles.~Treatment Cycle 2: Mocetinostat at a dose of 70 mg PO TIW ipilimumab will be administered IV at a dose of 1 mg/kg and nivolumab will be administered IV at a dose of 3 mg/kg during the 12-week induction period. The induction phase will last for 2 treatment cycles."
223777474|NCT03565406|DRUG|Mocetinostat Maintenance Phase + Ipilimumab + Nivolumab|"De-escalation Phase 1: Mocetinostat will be administered 50 mg PO TIW during each 84-day treatment cycle. Ipilimumab will be administered IV at a dose of 1 mg/kg and nivolumab will be administered IV at a dose of 3 mg/kg~De-escalation Maintenance Phase 2: Mocetinostat will be administered 40 mg PO TIW during each 84-day treatment cycle. Ipilimumab will be administered IV at a dose of 0.3 mg/kg and nivolumab will be administered IV at a dose of 1 mg/kg during period"
223777475|NCT06377839|BIOLOGICAL|Advanced platelet-rich fibrin in the ekstraction socket|Advanced platelet-rich fibrin is a centrifuged fibrin matrix composed of concentrated growth factors, platelet cytokines, and blood cells, which possesses the ability to stimulate wound healing and tissue regeneration. Advanced platelet-rich fibrin is manufacturing from a blood sample.
223777476|NCT04574544|DRUG|Zinc Supplementation|The 25 supplemented children had received an oral zinc supplement per day for 14 days and had no dietary restrictions.
223777477|NCT04574544|BEHAVIORAL|Nutrition education of mothers|Nutritional information was delivered to each mother to facilitate a change in bad eating habits observed, improve knowledge, attitudes and skills of mothers on child nutrition. The anthropometric and biochemistry parameters of children were taken before and after the maternal nutrition education
223777478|NCT02533882|BEHAVIORAL|Movement to Music|
223777479|NCT02533882|BEHAVIORAL|Adapted Yoga|
223777480|NCT01385059|DRUG|axitinib|Given PO
223777481|NCT01385059|PROCEDURE|therapeutic conventional surgery|Undergo prostatectomy and pelvic lymph node dissection
223692416|NCT05310656|BEHAVIORAL|Mindfulness Based Empowerment Programme|Mindfulness Based Strengthening Program consists of 8 sessions, once a week. Each session has specific goals and objectives, and each session also has a separate theme along with its subject. The subject of the program sessions is as follows: 1st session; Getting to know, explaining the operation plan of the program, defining violence against women and its causes, 2nd session; Emotions and Perceptions, session 3; Being in the Body and Developing Self-Esteem; Session 4, Stress and Meeting Stress with Conscious Awareness; Session 5, The Case of Violence and the Meanings We Ascribe; Session 6, Aware Communication and Conflict Resolution; Session 7, Self-Care and Self-Compassion; Session 8 is Ending the Empowerment Program, Farewell, and a New Beginning. Each session is planned to last an average of 90-120 minutes. Mindfulness teachings and practices will be applied in the content of the program.
223692417|NCT03793218|DEVICE|Latera Device|"This study seeks to compare a gold standard functional rhinoplasty maneuver, the alar batten graft, to the LATERA implant"
223692418|NCT03793218|PROCEDURE|Alar Batten Graft|"This study seeks to compare a gold standard functional rhinoplasty maneuver, the alar batten graft, to the LATERA implant"
223692419|NCT04121988|DIAGNOSTIC_TEST|MRI|"1 mm slice thickness with deep learning based reconstruction algorithm applied to the following sequences:~* Coronal T2 weighted imaging~* Dynamic contrast enhanced T1 weighted imaging~* Coronal contrast enhanced T1 weighted imaging"
223777482|NCT01385059|OTHER|enzyme-linked immunosorbent assay|Correlative studies
223777483|NCT01385059|OTHER|laboratory biomarker analysis|Correlative studies
223777484|NCT04411043|BEHAVIORAL|Molecular caracterization|Prospective and retrospective study evaluating the epidemiological, clinical, molecular and therapeutic data of prolymphocytic leukemias T
223692420|NCT06377306|BEHAVIORAL|Effect of training loads and sport performance level on health and sport performance|Effect of training loads and sport performance level on health and sport performance
223692421|NCT04367129|DIAGNOSTIC_TEST|ECG|12 lead electrocardiogram
223692422|NCT02225509|PROCEDURE|FNA biopsy for thyroid nodule(s)|"The study is intended for patients for whom a FNA biopsy of thyroid nodule/nodules is medically indicated for the detection of thyroid cancer. FNA biopsy should preferably be carried out under ultrasound guidance. The FNA samples will be collected either from the remaining material of FNA or there will be dedicated FNA sample in order to ensure an adequate quantity of material for molecular analysis. The patients will also be invited to take part in the mutation study in a separate consent form.~The samples of enrolled patients will be sent to the Diaxonhit Genomics Laboratory and analysed using Diaxonhit technology after checking the quantity and quality of the samples. Enrolled patients whose samples are inadequate in terms of quantity or quality for the various molecular tests will not be considered for the study. If necessary, mutation analyses can be carried out anonymously by an independent French laboratory and under the supervision of Diaxonhit."
223692423|NCT05324618|DRUG|Tacrolimus|0.03% topical tacrolimus ointment applied on the affected areas twice daily for 4 months.
223692424|NCT05324618|DRUG|Hydrocortisone|1% hydrocortisone cream applied on the affected areas twice daily for 4 months.
223692425|NCT00493376|PROCEDURE|Cervical tissue biopsy analysis: Comet assay|Cervical tissue biopsy analysis: Comet assay
223692426|NCT00493376|PROCEDURE|Biopsy: Measurement of histone gamma H2AX phosphorylation|Biopsy: Measurement of histone gamma H2AX phosphorylation
223692427|NCT00493376|PROCEDURE|Biopsy: Immunohistochemistry: Ca9, Glut1, HIF-1 alpha|Biopsy: Immunohistochemistry: Ca9, Glut1, HIF-1 alpha
223692428|NCT00493376|PROCEDURE|Measurement of vascular perfusion: contrast enhanced MRI|contrast enhanced MRI
223692429|NCT05855070|DRUG|Intralesional treatment with Hyaluronic acid|Patients will receive intralesional treatment with Hyaluronic acid (0.8% highly purified sodium salt Hyaluronic acid16 mg/2 mL; Sinovial, IBSA, Lodi, Italy) weekly for 12 weeks.
223692430|NCT05855070|DRUG|Intralesional treatment with Verapamil|Patients will receive intralesional treatment with Verapamil (10 mg in 5 mL of normal saline water) weekly for 12 weeks.
223692431|NCT00994318|DRUG|FCM (Ferric carboxymaltose) high ferritin target|
223692432|NCT00994318|DRUG|FCM (Ferric carboxymaltose) low ferritin target|
223692433|NCT00994318|DRUG|Oral Iron (Ferrous sulphate)|
223692434|NCT02896244|OTHER|no intervention|
223692435|NCT02854176|PROCEDURE|Somatosensory electrical stimulation|
223692436|NCT02854176|PROCEDURE|Control|
223692437|NCT03024814|DRUG|Acetaminophen|"The first group will receive acetaminophen as the following~1. Loading dose: 20 mg/kg in the first 12-24 hours To be diluted in D5W up to 3-5 ml and to be infused over 15 minutes.~2. Maintenance dose: 7.5 mg/kg after 6 hrs from the loading dose and to be repeat every 6 hours for 3 days."
223692438|NCT03024814|DRUG|Dextrose 5|"The second group will receive placebo (D5W) as the following~1. Loading dose: 3-5 ml in the first 12-24 hours To be infused over 15 minutes.~2. Maintenance dose: 3-5 ml after 6 hrs from the loading dose and to be repeat every 6 hours for 3 days."
223692439|NCT04157621|DEVICE|Active taVNS|Patients will be masked to transcutaneous stimulation of the auricular branch of the vagus nerve at the tragus
223692440|NCT04157621|DEVICE|Sham Stimulation|Sham stimulation involves identical perceptual threshold finding and stimulation parameters as active stimulation, with the exception of stimulation target. Sham stimulation will be delivered to the left earlobe, a target believed to have little to no vagal nerve innervation.
223692441|NCT01943773|PROCEDURE|Functional Assessment|"Both arms of the study will undergo functional assessments at three points during the study progress.~BASELINE ASSESSMENT: On study entry, each participant will have a timed up-and-go, Mini Mental Status Exam, de Morton, Modified Physical Performance Test (MPPT), and a short physical performance battery performed.~ASSESSMENT OF INTERVENTION EFFECTIVENESS:~Immediately prior to the operation, all participants will undergo repeat testing. The difference in scores between the preoperative assessment and the initial assessment at enrollment will be compared in the control and intervention groups.~POST-OPERATIVE ASSESSMENT: Repeat testing will be performed 60 days following the operation."
223692442|NCT01943773|PROCEDURE|Prehabilitation|The intervention will consist of nine 45 minute long physical therapy sessions.
223692443|NCT04391413|DEVICE|Use of OCT to guide the angioplasty procedure|OCT will be performed and OCT data used to choose and/or modify procedural strategy. The OCT system used will be the Ilumien Optis system, and Dragonfly Optis probe.
223692444|NCT03960554|DRUG|Denosumab Inj 60 mg/ml|Treatment will be administered by study personnel as a subcutaneous injection every 6-months for one year.
223692445|NCT03960554|OTHER|Placebo|Placebo will be administered by study personnel as a subcutaneous injection every 6-months for one year.
223692446|NCT01454115|DRUG|BMS-708163 (Gamma-Secretase Inhibitor)|Oral Solution, Oral, 0.3 mg, Once daily, once
223692447|NCT01454115|DRUG|BMS-708163 (Gamma-Secretase Inhibitor)|Oral Solution, Oral, 1.5 mg, Once daily, once
223692448|NCT01454115|DRUG|BMS-708163 (Gamma-Secretase Inhibitor)|Oral Solution, Oral, 5.0 mg, Once daily, once
223692449|NCT01454115|DRUG|BMS-708163 (Gamma-Secretase Inhibitor)|Oral Solution, Oral, 15.0 mg, Once daily, once
223692450|NCT01454115|DRUG|BMS-708163 (Gamma-Secretase Inhibitor)|Oral Solution, Oral, 50 mg, Once daily, once
223692451|NCT01454115|DRUG|BMS-708163 (Gamma-Secretase Inhibitor)|Oral Solution, Oral, 100 mg, Once daily, once
223692452|NCT01454115|DRUG|BMS-708163 (Gamma-Secretase Inhibitor)|Oral Solution, Oral, 200 mg, Once daily, once
223692453|NCT01454115|DRUG|BMS-708163 (Gamma-Secretase Inhibitor)|Oral Solution, Oral, 400 mg, Once daily, once
223692454|NCT01454115|DRUG|BMS-708163 (Gamma-Secretase Inhibitor)|Capsule, Oral, 50 mg, Once daily, once
223692455|NCT01454115|DRUG|BMS-708163 (Gamma-Secretase Inhibitor)|Oral Solution, Oral, 800 mg, Once daily, once
223692456|NCT01454115|DRUG|Placebo matching BMS-708163|Oral Solution, Oral, 0 mg, Once daily, once
223692457|NCT01454115|DRUG|Placebo matching BMS-708163|Capsule, Oral, 0 mg, Once daily, once
223692458|NCT03432312|DRUG|Nicotine lozenge|Nicotine mint lozenge, 4 mg
223692459|NCT03432312|DRUG|Nicotine lozenge|NiQuitin mint lozenge, 4 mg
223692460|NCT02097043|DRUG|DA-7218|
223692461|NCT02097043|DRUG|Placebo|
223692462|NCT00138177|DRUG|oxaliplatin|Given IV
223692463|NCT00138177|DRUG|leucovorin calcium|Given IV
223692464|NCT00138177|DRUG|vorinostat|Given orally
223692465|NCT00138177|DRUG|fluorouracil|Given IV
223692466|NCT00735254|DEVICE|pulsed dye laser|patient will have scar treated with pulsed dye laser
223692467|NCT00735254|DEVICE|Affirm Laser|patient will have scar treated with Affirm laser
223692468|NCT00735254|DEVICE|combined PDL and Affirm Lasers|patient will have scar treated with Affirm and pulsed dye lasers
223692469|NCT00735254|OTHER|Placebo|patient will receive no treatment
223692470|NCT02835131|DRUG|Pasireotide|
223692471|NCT04147572|DRUG|Placebo Tiotropium inhalation powder type A|Placebo inhalation from inhaler A
223692472|NCT04147572|DRUG|Placebo Spiriva capsule|Placebo inhalation from HandiHaler
223692473|NCT04147572|DRUG|Placebo Tiotropium inhalation powder type B|Placebo inhalation from inhaler B
223692474|NCT04147572|DEVICE|Substudy Placebo Tiotropium Easyhaler|Substudy placebo inhalation
223692475|NCT04147572|DEVICE|Substudy Placebo Spiriva® via HandiHaler|Substudy placebo inhalation
223692476|NCT04176887|DRUG|Levetiracetam Injection|The levetiracetam dose is 20- 40 mg/kg by intravenous infusion over 15 minute, a rate of 2-5 mg/kg/minute diluted in 100 ml with 0.9% sodium chloride as a single dose.
223692477|NCT04176887|DRUG|Phenytoin Injection|Phenytoin dose is 20-40 mg/kg/min by intravenous infusion over 30 minute, diluted with 0.9% sodium chloride to a maximum concentration of 10 mg/ml.
223692478|NCT05053711|DEVICE|rTMS+rPMS_iTBS_M|Repetitive peripheral magnetic stimulation (rPMS) intermittent theta-burst stimulation pattern (iTBS) will intermittently give a 2 s train of iTBS every 10s repeated 2 times for a total of 40 times at median nerve on the affected hand(low pulse: 1200 pulses in total). Then following Repetitive transcranial magnetic stimulation (rTMS) will intermittently give a 2 s train of iTBS every 10s repeated 2 times for a total of 40 times on affected hemisphere(low pulse: 1200 pulses in total).
223692479|NCT05053711|DEVICE|rTMS+rPMS_cTBS_M|Repetitive peripheral magnetic stimulation (rPMS) continuous burst stimulation pattern (cTBS) will intermittently give a cTBS treatment consists of a continuous train of TBS for 40 seconds repeated for 2 times at median nerve on the affected hand(low pulse: 1200 pulses in total). Then following Repetitive transcranial magnetic stimulation (rTMS) will intermittently give a 2 s train of iTBS every 10s repeated 2 times for a total of 40 times on affected hemisphere(low pulse: 1200 pulses in total).
223777485|NCT05087043|DEVICE|Oral motor stimulation (OMS) and The supplemental nursing system (SNS)|OMS and an SNS were applied to preterm infants in the experimental group. Oral stimulation intervention provides assisted movement to activate muscle contraction and provides movement against resistance to build strength. The cheeks (internal and external), lips, gums, tongue, and palate were stimulated by finger-stroking following the protocol. OMS consisted of intra (oral region) and peri-oral stimulation (around the oral region). The OMS was administered three times a day by a nurse, from the day of initiation of oral feeding to the day of independent oral feeding 15 minutes before the feeding schedule. A bottle/container was filled with breast milk before the process and given to the baby via SNS while the baby was holding the mother's breast. The SNS consists of a syringe/container and a feeding catheter. One end of the feeding probe is inside the syringe/container, while the other end of it is fixed to the mother's nipple using plaster.
223777486|NCT02543346|DRUG|Cetirizine|Participants will receive either cetirizine (10mg tablet, orally) or a placebo (sugar pill) at one of the two treatment visits.
223777487|NCT02543346|OTHER|Placebo|Participants will receive either a placebo or cetirizine (10mg tablet, orally) at one of the two treatment visits
223777488|NCT02966067|DEVICE|Microneedle Device (Experimental)|Injection of 1.2ml of a standard local dental anaesthetic solution \[1.2ml of 2% lidocaine and 1:80,000 epinephrine (lidocaine 20 mg/ml, epinephrine 12.5 mμ/ml)\] at a rate of 1 mL/min.
223692480|NCT05053711|DEVICE|rTMS+sham rPMS_M|Repetitive peripheral magnetic stimulation (rPMS) sham burst stimulation pattern (sham TBS) will intermittently give a sham TBS treatment consists of a continuous train of TBS for 40 seconds at median nerve on the affected hand(almost no pulse: 1200 pulses in total). Then following Repetitive transcranial magnetic stimulation (rTMS) will intermittently give a sham TBS treatment consists of a continuous train of TBS for 40 seconds on affected hemisphere(almost no pulse: 1200 pulses in total).
223692481|NCT05053711|DEVICE|rTMS+rPMS_iTBS_U|Repetitive peripheral magnetic stimulation (rPMS) intermittent theta-burst stimulation pattern (iTBS) will intermittently give a 2 s train of iTBS every 10s repeated 2 times for a total of 40 times at ulnaris nerve on the affected hand(low pulse: 1200 pulses in total). Then following Repetitive transcranial magnetic stimulation (rTMS) will intermittently give a 2 s train of iTBS every 10s repeated 2 times for a total of 40 times on affected hemisphere(low pulse: 1200 pulses in total).
223692482|NCT05053711|DEVICE|rTMS+rPMS_cTBS_U|Repetitive peripheral magnetic stimulation (rPMS) continuous burst stimulation pattern (cTBS) will intermittently give a cTBS treatment consists of a continuous train of TBS for 40 seconds repeated for 2 times at ulnar nerve on the affected hand(low pulse: 1200 pulses in total). Then following Repetitive transcranial magnetic stimulation (rTMS) will intermittently give a 2 s train of iTBS every 10s repeated 2 times for a total of 40 times on affected hemisphere(low pulse: 1200 pulses in total).
223692483|NCT05053711|DEVICE|rTMS+sham rPMS_U|Repetitive peripheral magnetic stimulation (rPMS) sham burst stimulation pattern (sham TBS) will intermittently give a sham TBS treatment consists of a continuous train of TBS for 40 seconds at ulnar nerve on the affected hand(almost no pulse: 1200 pulses in total). Then following Repetitive transcranial magnetic stimulation (rTMS) will intermittently give a sham TBS treatment consists of a continuous train of TBS for 40 seconds on affected hemisphere(almost no pulse: 1200 pulses in total).
223692484|NCT05161195|DRUG|Ribociclib|Participants continue ribociclib as was administered in their parent study
223692485|NCT05161195|DRUG|Letrozole|Participants continue ribociclib in combination with letrozole as was administered in their parent study
223692486|NCT05161195|DRUG|Anastrozole|Participants continue ribociclib in combination with anastrozole as was administered in their parent study
223692487|NCT05161195|DRUG|Goserelin|Participants continue ribociclib in combination with goserelin as was administered in their parent study
223692488|NCT05161195|DRUG|Tamoxifen|Participants continue ribociclib in combination with tamoxifen as was administered in their parent study
223692489|NCT05161195|DRUG|Fulvestrant|All participants continue ribociclib in combination with fulvestrant as was administered in their parent study
223692490|NCT00316771|DRUG|P38 Inhibitor (4) 150mg|150mg po qd
223692491|NCT00316771|DRUG|P38 Inhibitor (4) 25mg|25mg po bid
223777489|NCT02966067|DEVICE|30-gauge Short Hypodermic Needle|Injection of 1.2ml of a standard local dental anaesthetic solution \[1.2ml of 2% lidocaine and 1:80,000 epinephrine (lidocaine 20 mg/ml, epinephrine 12.5 mμ/ml)\] at a rate of 1 mL/min.
223777490|NCT01767116|DRUG|ABT-450/r/ABT-267, ABT-333|Tablet; ABT-450 coformulated with ritonavir and ABT-267, ABT-333 tablet
223777491|NCT01767116|DRUG|Ribavirin|Capsule
223692492|NCT00316771|DRUG|P38 Inhibitor (4) 300mg|300mg po qd
223692493|NCT00316771|DRUG|P38 Inhibitor (4) 50mg|50mg po qd
223692494|NCT00316771|DRUG|P38 Inhibitor (4) 75mg|75mg po bid
223692495|NCT00316771|DRUG|Placebo|po bid
223692496|NCT00751621|BIOLOGICAL|IgPro20|
223692497|NCT04205994|DRUG|Tolcapone 200 MG|Tolcapone is a brain penetrant catechol-O-methyltransferase (COMT) inhibitor. It will be administered in randomized, double-blind, counterbalanced fashion with a placebo.
223692498|NCT04205994|OTHER|Functional Magnetic Resonance Imaging (fMRI)|FMRI provides an indirect and noninvasive measure of brain activity.
223692499|NCT01236014|DRUG|Eltrombopag|Eltrombopag \& standard of care
223692500|NCT01236014|DRUG|Romiplostim|Romiplostim \& standard of care
223692501|NCT01236014|DRUG|Placebo|Placebo \& standard of care
223692502|NCT00557427|DRUG|hypericum|250mg tablets twice daily for 8 weeks
223692503|NCT00557427|DRUG|fluoxetine|20mg - 40mg daily for 8 weeks
223692504|NCT01248481|DRUG|Acarbose (Glucobay, BAYG5421)|Adult female and male patients are scheduled to be treated with acarbose will be enrolled after the therapy decision has been made. Physicians should consult the full prescribing information for Glucobay® before enrolling patients and familiarize themselves with the safety information in the product package label.
223777492|NCT01767116|DRUG|Placebo for ribavirin|Capsule
223777493|NCT04508803|DRUG|HX008，Niraparib|Subjects received intravenous HX008 at a fixed dose of 200mg, administered every 3 weeks, and 200mg of Niraparib orally per day.Every 3 weeks is a cycle.
223777494|NCT04508803|DRUG|HX008，Niraparib|Subjects received intravenous HX008 at a fixed dose of 200mg, administered every 3 weeks, and 200mg of Niraparib orally per day.Every 3 weeks is a cycle.
223777495|NCT04508803|DRUG|HX008，Niraparib，Trastuzumab|Subjects received intravenous HX008 at a fixed dose of 200mg once every 3 weeks; 200mg Niraparib orally per day;Trastuzumab 8mg/kg in the first cycle and 6mg/kg after the first cycle intravenously once every 3 weeks; Every 3 weeks is a cycle.
223777496|NCT04508803|DRUG|HX008，Niraparib，Pyrrolitinib|"HER-2 negative subjects received intravenous HX008 at a fixed dose of 200mg, administered every 3 weeks, and 200mg of Neirapali orally per day. Every 3 weeks is a cycle.~Her-2 positive subjects received intravenous HX008 at a fixed dose of 200mg once every 3 weeks; 200mg Niraparib orally per day; Pyrrolitinib is taken orally at 400mg per day; Every 3 weeks is a cycle."
223777497|NCT04015193|PROCEDURE|Single-port thoracoscopic sympathicotomy (patient care)|Single-port thoracoscopic sympathicotomy will be performed as part of patient care, data will be collected of patients undergoing this procedure
223777498|NCT04345848|DRUG|Enoxaparin|Two different doses of anticoagulation
223692505|NCT00428129|DRUG|microplasmin|20mg with Trellis-8 15cm Treatment length 40mg with Trellis-8 30cm Treatment length
223692506|NCT00810524|DRUG|lamivudine|100mg, P.O.,QD, duration: until HBeAg seroconversion for more than 2years.
223692507|NCT00810524|DRUG|Telbivudine|600mg, P.O.,QD, duration: until HBeAg seroconversion for more than 2years.
223692508|NCT00810524|DRUG|Enticavir|0.5mg, P.O.,QD, duration: until HBeAg seroconversion for more than 2 years.
223692509|NCT00810524|DRUG|Adefovir Dipivoxil Tablets|10mg, P.O.,QD, duration: until HBeAg seroconversion for more than 2years.
223692510|NCT05880654|PROCEDURE|Scaling & root planning|Non Surgical periodontal therapy
223777499|NCT06568146|DIETARY_SUPPLEMENT|Multivitamin Supplement|: Participants will take 2 capsules of the multivitamin supplement daily with the first meal of the day in the morning.
223777500|NCT04834011|PROCEDURE|Laparoscopic right colonic resection with Complete Mesocolic Excision (CME)|
223777501|NCT04834011|RADIATION|3D CT angiography|
223777502|NCT00763542|BEHAVIORAL|CBT for SUD|CBT for SUD focuses on patient-motivation, self-control strategies and relapse-prevention.
223777503|NCT00763542|BEHAVIORAL|Structured writing therapy for PTSD|Patients progress through three stages, in which instructions for writing and feedback by therapists are successively aimed at achieving trauma processing, cognitive restructuring and social sharing of a traumatic event.
223777504|NCT00886093|DRUG|PF-04447943|35 mg tablet of PF-04447943 taken in the fed state in Period 1 followed a week later by administration of the same tablet and dose taken in the fasted state in Period 2
223777505|NCT00886093|DRUG|PF-04447943|35 mg tablet of PF-04447943 taken in the fasted state in Period 1 followed a week later by administration of the same tablet and dose in the fed state in Period 2.
223777506|NCT00355875|PROCEDURE|titration of oxygen during resuscitation|
223777507|NCT01403103|DIETARY_SUPPLEMENT|cholecalciferol|Given PO
223777508|NCT01403103|PROCEDURE|biopsy|Correlative studies
223777509|NCT01403103|GENETIC|protein expression analysis|Correlative studies
223777510|NCT01403103|OTHER|enzyme-linked immunosorbent assay|Correlative studies
223777511|NCT01403103|OTHER|laboratory biomarker analysis|Correlative studies
223777512|NCT01403103|GENETIC|reverse transcriptase-polymerase chain reaction|Correlative studies
223777513|NCT01132079|DRUG|cream treatment|
223777514|NCT01182077|DRUG|ASP015K|Oral
223692511|NCT05392517|OTHER|self-mobilization technique along with conventional therapy|"Group A will be treated with self-mobilization technique of thoracic spine with the frequency of 2 sets of 10 repetitions thrice per week for a total of six weeks and conventional treatment.~Self-mobilization technique will be comprised of self-mobilization technique using tennis balls and foam roller. The participant will be supine with knees in 90-degree flexion.~* Mobilization Technique 1: Cross your arms over your chest so that you are in slight flexion and then slowly begin to move your shoulders and head closer to the floor placing the mid back into extension over the balls joined to make mobilization device. Hold this position for 3 seconds and then return to the flexed position.~* Mobilization Technique 2: Lying lengthwise on the foam roller, clasp your hands together in front of you, above your chest with arms straight. Slowly move your arms above your head until you feel a good stretch. This exercise should be pain free. Hold stretch for 30- 60 seconds."
223777515|NCT01182077|DRUG|Midazolam|Oral
223777516|NCT02826889|DEVICE|Philips Intelivue MP70 monitor|Philips Intelivue MP70 monitor (Intellivue MP70, Philips medical Systems, Suresnes, France) -a radial arterial cannula is inserted and arterial pressure waveforms are monitored through Philips Intelivue MP70 monitor. In the monitor, PPVauto is displayed in real-time. It is based on automatic detection algorithms, kernel smoothing, and rank-order filters.
223777517|NCT02826889|DEVICE|Pleth Variability Index (PVI)|PVI is the measure of the dynamic changes in the Perfusion Index (PI) that occur during one or more complete respiratory cycles. A rainbow Pulse CO-Oximetry sensor is attached to the patient's finger and the PVI is displayed in real-time on the Root monitor.
223777518|NCT00967187|DRUG|bevirimat dimeglumine|Patients will be treated with MPC-4326 200mg monotherapy for 14 days. Once the Day 15 viral load results become available, patients, who achieve at least a 0.5 log10 reduction in viral load by Day 15 will have the option to continue on both MPC-4326 and an optimized background regimen (OBR) through Week 72.
223777519|NCT00967187|DRUG|bevirimat dimeglumine|Patients will be treated with MPC-4326, 300 mg monotherapy for 14 days. Once the Day 15 viral load results become available patients who achieve at least a 0.5 log10 reduction in viral load by Day 15 will have the option to continue on both MPC-4326 and an optimized background regimen (OBR) through Week 72.
223777520|NCT05090449|DRUG|Chlorthalidone (HIGROTON® 50)|Tablets with 50mg of Chlorthalidone, product de Sandoz, S.A. de C.V.
223777521|NCT05090449|DRUG|Losartan (COZZAR®)|Losartan potassium 100 mg tablet, a product of Schering-Plough, S.A. C.V.
223777522|NCT05090449|DRUG|A1+ A2 Co-administration of Chlorthalidone and Losartan|50mg chlorthalidone + 100 mg losartan potassium
223777523|NCT05090449|DRUG|Chlorthalidone + Losartan Fixed-Dose combination|Tablets with fixed combination of Chlorthalidone 25 mg and Losartan Potassium
223777524|NCT05030922|OTHER|Antiatherogenic diet|Participants instructed in antiatherogenic diet during pregnancy with frequent follow-ups to ensure compliance
223777525|NCT05712226|DEVICE|Sleepiz One+|In this study Sleepiz One+ will measure heart rate and respiration rate of a participant sitting or lying in different positions (right and left side, back, abdomen) on a bed. The recording will take around 35 minutes.
223777526|NCT06194903|DEVICE|isopropyl alcohol wipes|cellphones will be sanitised with isopropyl alcohol wipes and total bacterial load will be assessed immediately before sanitation, immediately after sanitation and 3 hours after sanitation.
223777527|NCT06194903|DEVICE|UVC box|cellphones will be sanitised in a UVC box and total bacterial load will be assessed immediately before sanitation, immediately after sanitation and 3 hours after sanitation.
223777528|NCT03933293|DRUG|AK102|450mg, Q4W, subcutaneous injection
223777529|NCT03933293|DRUG|Statins|Lipid-lowering therapies
223692512|NCT05392517|OTHER|conventional therapy|Group B will be treated with the conventional treatment (heating pad, ultrasound, thoracic strengthening exercises
223777530|NCT03933293|DRUG|Ezetimibe|Lipid-lowering therapies
223777531|NCT02264223|DIETARY_SUPPLEMENT|Fermented red clover isoflavones in aglycone form|Fermented isoflavones in aglycone form
223777532|NCT02264223|DIETARY_SUPPLEMENT|Unfermented glycosides (as aglycone equivalents)|Unfermented aglycone equivalents in glycoside form
223777533|NCT03755063|OTHER|Speech therapy apps|Speech therapy apps loaded on tablets
223777534|NCT00580905|DRUG|Adenosine|IV infusion of adenosine at a dose of 80 mcg/kg/min for 30 minutes.
223777535|NCT00580905|DRUG|Sodium Nitroprusside|To compare the effects of adenosine on increasing cytokines, sodium nitroprusside will be infused at 5 mcg/kg/min (a dose expected to produce similar systemic effects to adenosine)
223777536|NCT00580905|DRUG|Adenosine|"The local effects of adenosine or sodium nitroprusside will be studied in response to microinjection (intradermally) of both drugs. Two microdialysis catheters (CMA 100) will be inserted intradermally in the volar aspect of the forearm after numbing the area with local cold (ice applied in the study area). After 30 minutes,one catheter will be infused with sodium nitroprusside (2microliters/min of a 28 mM solution) and the other with adenosine (2mcl/min of a 100 microM solution) will then be started and continued for 60 minutes. Skin blood flow will be monitored throughout the study with the used of a skin laser Doppler fluxometer mounted adjacent to the area of the microdialysis probe.~A 2 mm skin biopsy punch will be performed 60 minutes after the end of the infusion."
223777537|NCT02233049|DRUG|Erlotinib|
223777538|NCT02233049|DRUG|Everolimus|
223777539|NCT02233049|DRUG|Dasatinib|
223777540|NCT00510666|DRUG|Saline|Saline infusion adjunct to morphine PCA pump
223692513|NCT05357638|BEHAVIORAL|High Intensity Interval Training (HIIT)|8 weeks of HIIT, 2x/week for about 30 minutes/session on a cycle ergometer
223692514|NCT05357638|BEHAVIORAL|Continuous Aerobic Training (CAT)|8 weeks of CAT, 2x/week for about 50 minutes/session on a cycle ergometer
223692515|NCT05357638|BEHAVIORAL|Movement Advice|Weekly step goal, monitored using an activity tracker, +3000 steps/day for 5 days/week, step goal is based on average step count in the 4 weeks of baseline prior to the intervention
223692516|NCT02791594|DRUG|Pembrolizumab|Patients were treated with pembrolizumab according to standard of care.
223692517|NCT05539716|DEVICE|PAP Therapy|Auto-PAP device (ResMed AirsenseTM Autoset) with a heated humidifier will be provided along with an appropriate mask and connecting hose for nightly use
223692518|NCT05539716|BEHAVIORAL|Lifestyle Counseling Intervention|Lifestyle intervention will include counseling on (a) education on nutrition and exercise; and (b) behavioral support for identifying lifestyle change strategies and problem-solving barriers to improve the regularity and duration of sleep. This will be conducted using brochures on weight loss and sleep hygiene
223692519|NCT02188225|PROCEDURE|acupuncture|12 sessions acupuncture during 12 weeks (3 sessions weekly), each session lasting 20 minutes
223692520|NCT02188225|DRUG|fluoxetine|10 mg/ daily
223692521|NCT01867112|BEHAVIORAL|Physical Activity|Physical activity either by individualized program or general guidelines
223692522|NCT05789381|PROCEDURE|Magnesium sulfate|This drug is commonly used on labor and delivery and in the postpartum period and is easily ordered through the electronic medical record and provided. This drug requires no specific storage for research study purposes as the drug is already being administered per standard of care and national and international guidelines. The only change is in the duration of therapy. This is NOT considered an off label use of the drug and does not require any form of exemption determination. Magnesium for severe preeclampsia is often given for anywhere from 12 to 24 hours postpartum depending on the clinical scenario, provider preference, and patient symptoms/adverse reactions to the medication.
223692523|NCT06399653|DEVICE|Cervical transcutaneous vagus nerve stimulation (active comparator)|Active nVNS produces low-voltage electrical signal that generates sensations on the skin on upper anterior cervical area (overlying carotid artery) and that stimulates the vagus nerve.
223692524|NCT06399653|DEVICE|Cervical transcutaneous vagus nerve stimulation (sham comparator)|Sham nVNS devices look identical to active devices and participants will undergo identical training for self-administration on upper anterior cervical area (overlying carotid artery). Sham devices do not stimulate the vagus nerve.
223692525|NCT06513312|DRUG|Lenacapavir Injection|Administered subcutaneously
223692526|NCT06513312|DRUG|Lenacapavir Tablet|Administered orally
223692527|NCT06513312|DRUG|Emtricitabine/tenofovir disoproxil fumarate (F/TDF)|Administered orally
223692528|NCT03780777|BEHAVIORAL|Home Hazard Removal|Removal of home barriers or hazards
223692529|NCT06010251|OTHER|tDCS and bodily illusions|"Participants will be required to perform (in person) 10 interventions over a time frame of 2-4 weeks. They can perform this everyday or for a minimum of 2-3 times per week over 4 weeks.~Two types of illusions will be used 15 min each, the rubber hand illusion and the walking illusion to target upper and lower limbs. These procedures will impact the body representation of the participants resulting in bodily illusions."
223692530|NCT04066959|BEHAVIORAL|Motivational Enhancement System (MES)|MES is a brief eHealth intervention delivered via an internet-based software application. MES is grounded in the Motivational Interviewing framework and the Information-Motivation-Behavioral Skills model of health behavior change. The goal of MES is to increase motivation to complete daily diabetes care tasks. MES consists of two 20-minute sessions that integrate psychoeducation with motivation-enhancing therapeutic exercises and behavioral goal setting.
223692531|NCT04066959|BEHAVIORAL|Question Prompt List (QPL)|A QPL is a list of questions related to the physical and psychosocial aspects of diabetes and treatment that youth may want to ask their physicians during a clinic visit. The theoretical foundation for the QPL resides in social-cognitive theory which posits that behavioral performance is a function of self-efficacy and behavioral expectations. Thus, the goal of a QPL is to increase self-efficacy and active participation in clinical care. QPL is completed within 14-days of a diabetes clinic visit and results in a personalized set of questions for youth to bring to their clinic visit.
223777541|NCT00510666|DRUG|Butorphanol tartrate|Butorphanol was delivered at a continuous infusion manner adjunct to morphine PCA pump
223692532|NCT04066959|BEHAVIORAL|Text Message Reminders (TXT)|TXT is a behavioral support strategy composed of one-way text message reminders to promote daily diabetes care task completion. TXT is supported by social cognitive theory which suggests that consistent task completion leads to perceptions of control and supports goal attainment. TXT may also foster a stronger relationship with diabetes care providers through greater communication and satisfaction. Youth will receive daily reminders to complete key diabetes care tasks.
223692533|NCT05780710|OTHER|Aktiia Optical Blood Pressure Monitoring (OBPM) device and antihypertensive drugs (monotherapy and bitherapy)|"The device under test is Aktiia Optical Blood Pressure Monitoring (OBPM) device and the comparator is the Aktiia cuff.~For study GROUP 1:~Study drugs are:~* Perindopril MEPHA (Angiotensin Converting Enzyme (ACE) inhibitors).~* Indapamide MEPHA (Diuretics).~* Amlodipine MEPHA (Calcium channel blockers). In each study treatment period, subjects in GROUP 1 will receive one of the following for each treatment period: monotherapy with Indapamide, bitherapy with Indapamide plus Perindopril, or bitherapy with Perindopril plus Amlodipine."
223692534|NCT05780710|OTHER|Aktiia Optical Blood Pressure Monitoring (OBPM) device and antihypertensive drugs (monotherapy)|"Study drugs:~* Perindopril MEPHA (Angiotensin Converting Enzyme (ACE) inhibitors).~* Indapamide MEPHA (Diuretics).~* Amlodipine MEPHA (Calcium channel blockers). In each study treatment period, subjects in GROUP 2 will receive one of the following monotherapies: Perindopril , Indapamide, or Amlodipine."
223692535|NCT05780710|OTHER|Aktiia Optical Blood Pressure Monitoring (OBPM) device and individualized antihypertensive treatment|"For study GROUP 3:~Subjects will be prescribed an individualized new antihypertensive treatment at their consultation with the Investigator at Visit 1."
223692536|NCT05314075|PROCEDURE|Upper Body Forced Air Warming device|Patients will have the Bair Hugger placed over the body
223692537|NCT05314075|PROCEDURE|Under Body Forced Air Warming device|Patients will have the Bair Hugger placed under the body
223692538|NCT02978924|DEVICE|tsDCS|20 min of treatment applied at the thoracic level (active electrode) with reference placed on the right shoulder
223692539|NCT05519241|DRUG|PLZ4-coated paclitaxel-loaded micelles (PPM)|PPM will be administrated weekly for 6 times through intravesical instillation into the bladder cavity
223692540|NCT06213545|DIAGNOSTIC_TEST|In-clinic interpretation|Reading patch test result at clinic
223692541|NCT06213545|DIAGNOSTIC_TEST|Photo interpretation|Reading patch test result by sending photo to clinic
223692542|NCT06273592|OTHER|Animal-based meal|Consuming a single plant-based meat or a single animal meat meal and measuring the meals impact on erectile function with the Rigiscan™ device.
223692543|NCT06273592|OTHER|Plant-based meat meal|Consuming a single plant-based meat or a single animal meat meal and measuring the meals impact on erectile function with the Rigiscan™ device.
223692544|NCT01764152|OTHER|nasopharyngeal sample|The nasopharyngeal sample will be used to find the types and subtypes of influenza virus and other respiratory viruses.
223692545|NCT05720702|DIETARY_SUPPLEMENT|homocysteine (Hcy) lowering supplements|NAFLD participants will take homocysteine (Hcy) lowering supplements daily for 12 weeks.
223692546|NCT05669365|BEHAVIORAL|Care Ecosystem|"Applying the principles of person-and-family centered and collaborative care to dementia, the Care Ecosystem (CE) offers proactive, protocol-guided phone- and web-based caregiver support, guidance, and care coordination that extends the reach of dementia primary and specialty care. Care is delivered primarily via the phone and web by unlicensed Care Team Navigators (CTNs), who are trained and supervised by a team of dementia specialists with nursing, social work, and pharmacy expertise. Care Protocols guide proactive, quality care that is documented in the electronic health record (EHR).~The CTN is an unlicensed, trained dementia care guide who served as the PWD's and caregiver's primary point of contact to the program under nurse supervision. Care team navigators respond to caregivers' immediate needs first, then screen for common problems and provide personalized support and standardized education using the care plan protocols."
223692547|NCT05135403|DEVICE|Defibrillation|External defibrillation from a wearable cardioverter defibrillator
223692548|NCT06562777|OTHER|Non-Interventional Study|Non-Interventional Study
223692549|NCT05781789|OTHER|Telehealth for preoperative evaluation|Conduct of preoperative evaluation remotely using Zoom application
223692550|NCT04723654|DEVICE|Wireless Wearable Vital Sign Monitor|Placement of wireless wearable vital sign monitors on patients limbs for up to 48 hours
223692551|NCT06223958|DRUG|OTX-TKI (axitinib implant)|Intravitreal Injection of OTX-TKI (axitinib implant)
223692552|NCT06223958|DRUG|Aflibercept|Injection of 2mg (0.05mL) of aflibercept
223692553|NCT04991103|DRUG|DaraVRD|"All patients with newly diagnosed multiple myeloma who was enrolled on the study will receive six cycles of combination quadruplet therapy (DaraVRD).~Six 28-day induction cycles of oral lenalidomide (25 mg daily on days 1-21), subcutaneous bortezomib (1.3 mg/m2 on days 1, 8, 15, 22), subcutaneous daratumumab (1800 mg on days 1, 8, 15, 22 of cycles 1-2 and days 1, 15 for cycles 3-6), and oral dexamethasone (40 mg on days 1, 8, 15, and 22)."
223692554|NCT04189835|DIAGNOSTIC_TEST|EBV DNA in whole blood and plasma|Consecutive measurements of EBV DNA in whole blood and plasma
223692555|NCT03165292|RADIATION|mIBG|Day 1 131I-mIBG course 1: about 444MBq/kg with in vivo whole-body dosimetry Day 15 131I-mIBG course 2: the target is to deliver a combined whole-body radiation dose of 4 Gy
223692556|NCT03165292|DRUG|Topotecan|Day 1-5 Topotecan 0.7 mg/m2 daily Day 15-19 Topotecan 0.7 mg/m2 daily
223692557|NCT03165292|DRUG|Thiotepa|Day 1-3 Thiotepa
223692558|NCT03165292|PROCEDURE|Autologous stem cell transplant|ASCT as soon as radiation level allows it in ARM A
223692559|NCT05754996|DRUG|Nifuroxazide|Nifuroxazide dosing : 200 mg capsule four times daily
223692560|NCT05754996|DRUG|Lactulose|Lactulose dosing: 30-60 mL PO TID with goal 2-3 semisoft stools
223692561|NCT05754996|DRUG|Rifaximin 550Mg Tab|Rifaximin 550 MG twice daily
223692562|NCT06494631|DEVICE|Xeltis Hemodialysis Access (aXess) graft|The aXess graft is a sterile, restorative biodegradable polymer-based vascular graft, consisting of a tubular structure with a 6mm inner diameter. It is comprised of a highly porous polymer matrix and an embedded electropolished nitinol reinforcement layer (Strain Relief System). The aXess graft is able to support both straight and loop configurations and may be implanted in the upper arm and forearm.
223692563|NCT04665180|DIAGNOSTIC_TEST|Primary knee arthroplasty|Patients who return to work after primary knee arthroplasty
223692564|NCT02310321|DRUG|Gilteritinib|Once-daily oral administration on 14 consecutive days in every cycle in each period.
223692565|NCT02310321|DRUG|Idarubicin|Induction period: Once-daily intravenous injection of 12 mg/m\^2 idarubicin on 3 consecutive days.
223692566|NCT02310321|DRUG|Cytarabine|"Induction period: Once-daily intravenous injection of 100 mg/m\^2 cytarabine on 7 consecutive days.~Consolidation period: Twice-daily intravenous injection of 1.5 g/m\^2 cytarabine on Days 1, 3, and 5."
223692567|NCT06307990|GENETIC|NGS sequencing|analysis of candidate genes for RTHs syndromes, transporters defects or gene involved in thyroid hormone metabolism. Whole exome sequencing (WES) in a minority of cases
223692568|NCT06307990|DIAGNOSTIC_TEST|serological tests|assessment of T4, T3 and other TH metabolites (LC-MS) in serum and dried blood spots
223692569|NCT03888924|DRUG|Bacille Calmette-Guerin vaccine|"One dose (0.1 mL) contains 50 μg of the semi-dry mass of BCG bacilli, i.e. from 150,000 to 600,000 of live BCG bacilli (Bacillus Calmette-Guerin), the Brazilian Moreau substrain.~One ampoule or vial with the powder contains: 0.5 mg (from 1.5 mln to 6 mln) of live BCG bacilli (Bacillus Calmette-Guerin), the Brazilian Moreau substrain.~Powder: monosodium glutamate. Solvent: isotonic solution of sodium chloride."
223692570|NCT03888924|DRUG|Placebo|isotonic solution of sodium chloride (2mL vials).
223692571|NCT02839278|BIOLOGICAL|Blood sample|
223692572|NCT06511895|DRUG|AZD4205|AZD4205 capsules administered at 150 mg or 75 mg orally, once daily, in 28-day cycle.
223692573|NCT06168058|DIAGNOSTIC_TEST|Transcatheter Venography|Venographic assessment of ovarian veins and internal iliac veins
223692574|NCT06168058|PROCEDURE|Bilateral ovarian vein embolization|Intervention will include sclerosis of pelvic varices and coil embolization of the bilateral ovarian veins.
223692575|NCT06584240|DRUG|Sequence 1|Single treatment, intramuscularly injected. The total injection 100-150U.
223692576|NCT06584240|DRUG|Sequence 2|Single treatment, intramuscularly injected. The total injection 200-250U.
223777542|NCT00510666|DRUG|Tramadol Hydrochloride|100mg tramadol was used preemptively to morphine PCA pump
223692577|NCT06584240|DRUG|Sequence 3|Single treatment, intramuscularly injected. The total injection 350-400U.
223692578|NCT06584240|DRUG|Sequence 4|Single treatment, intramuscularly injected. The total injection ≤400U.
223692579|NCT06584240|DRUG|Sequence 5|Single treatment, intramuscularly injected.
223692580|NCT03707431|BEHAVIORAL|Web-based CBT|The eight child modules include: 1) education about chronic pain, 2) recognizing stress and negative emotions, 3) deep breathing and relaxation, 4) implementing coping skills at school, 5) cognitive skills (e.g., reducing negative thoughts), 6) lifestyle interventions, 7) staying active (e.g., pleasant activity scheduling), 8) relapse prevention. The eight parent modules are: 1) education about chronic pain, 2) recognizing stress and negative emotions, 3) operant strategies I (using attention and praise to increase coping), 4) operant strategies II (using rewards to increase positive coping and reach school goals), 5) modeling, 6) lifestyle, 7) communication, 8) relapse prevention.
223692581|NCT03707431|BEHAVIORAL|Pain Education|The pain education website provides publicly available educational information about pancreatitis and abdominal pain. There is general information about pancreatitis from available web sources (e.g., National Pancreas Foundation) as well as information about chronic pain in childhood. The content does not include any instruction in the behavioral and cognitive skills taught within the WebMAP program.
223692582|NCT02656407|DEVICE|Ultrasound device|Ultrasensitive Doppler acquisition obtained with the Aixplorer ultrasound device
223692583|NCT03275181|DIAGNOSTIC_TEST|Transthoracic Echocardiography|Non-invasive assessment of left ventricle structure and function
223692584|NCT03275181|DIAGNOSTIC_TEST|Arterial blood pressure|Continuously monitored for 5-30 minutes via finger photoplethysmography
223692585|NCT03275181|DIAGNOSTIC_TEST|Submaximal Exercise|Incremental exercise test to 85% predicted maximal heart rate on a recumbent cycle ergometer
223777543|NCT00510666|DRUG|Saline|Preemptive saline as a control group to tramadol one
223692586|NCT04922723|DRUG|Daratumumab|Daratumumab will be administered by IV infusion to subjects in combination with current therapeutic strategies of surgical resection followed by a course of Temozolomide and radiation therapy.
223692587|NCT05650242|DRUG|BA1106|"In part A, after the observation period of DLT (28 days), intravenous (IV) once every 3 weeks (Q3W).~In Part B, intravenous (IV) once every 3 weeks (Q3W) or once every 2 weeks (Q2W)."
223692588|NCT01698905|DRUG|nilotinib|"Nilotinib was dosed by weight or body surface area.~Nilotinib 300 mg BID or 400 mg BID was be administered orally at approximately 12 hour intervals, and must not have been taken with food. The capsules were to be swallowed whole with water.~No food should have been consumed for at least 2 hours before the dose was taken and no additional food should have been consumed for at least one hour after the dose was taken. Patients were also allowed to enter this study on the same dose they were taking prior to study entry. Patients who required permanent dose reduction from their original starting dose were to be allowed to enter this study on the same dose only if the patient maintained this dose for a minimum of 6 months prior to study entry."
223692589|NCT05896748|DRUG|Cabotegravir - Injectable Suspension (CAB LA)|It is a sterile white to slightly pink suspension containing 200 mg/mL of CAB as free acid for administration by intramuscular (IM) injection. Each vial is for single-dose use containing a withdrawable volume of 2.0 mL, and does not require dilution prior to administration. CAB LA is composed of cabotegravir free acid, polysorbate 20, polyethylene glycol 3350, mannitol, and water for injection.
223692590|NCT05896748|DRUG|Rilpivirine - Injectable Suspension (RPV LA)|It is a sterile white suspension containing 300 mg/mL of RPV as the free base. The route of administration is by intramuscular (IM) injection. Each vial contains a nominal fill of 2.0 mL, and does not require dilution prior to administration. RPV LA requires refrigeration and must be protected from light. RPV LA is composed of RPV free base, poloxamer 338, sodium dihydrogen phosphate monohydrate, citric acid monohydrate, glucose monohydrate, sodium hydroxide, water for injection.
223692591|NCT05731986|DIAGNOSTIC_TEST|Orthostatic challenge|"Designed to invoke an orthostatic response. It begins with the participants lying supine on a specialized bed. The bed is then converted into a chair by raising the head of the bed by 90° and dropping the base of the bed by 90° from the knee.~This position will be maintained for 15 minutes, while hemodynamic measures are continuously recorded. Some of these sessions will be accompanied by spinal stimulation."
223692592|NCT05731986|DEVICE|Biostim-5 transcutaneous spinal stimulation - Mapping|Transcutaneous stimulation of the spinal cord. Two days of mapping will be performed to determine sites for modulation of blood pressure. During each day, with the participant in a supine or seated position, electrodes will be placed on the midline of one of the following spinous processes: C3/4, C5/6, C7/T1, T7/8, T11/12, L1/2 and S1/2. Stimulation intensity will start at 5 mA and gradually increase by 5 mA increments up to 100 mA. The frequency will be two or 30 Hz.
223692593|NCT05731986|DEVICE|"Biostim-5 transcutaneous spinal stimulation - Optimal testing"|Based on the mapping sessions, profiles will be established to guide the selection of an optimal site location for blood pressure modulation (within the range of 110-120 mmHg).
223692594|NCT05731986|DEVICE|"Biostim-5 transcutaneous spinal stimulation - Sham testing"|Based on the mapping sessions, a profile that does not elicit a significant blood pressure response, will be used for the sham stimulation.
223692595|NCT02445443|DEVICE|LEGION Hinge Knee System|All enrolled/treated subjects will receive the LEGION Hinge Knee System.
223692596|NCT04298723|DEVICE|Percutaneous closure of the LAA (Watchman / Watchman FLX)|LAA closure procedure will be done by experienced operators according to the local SOP. LAA closure will be performed under fluoroscopic and TEE guidance within conscious sedation or general anesthesia. Antibiotic single-shot prophylaxis should be administered peri-procedurally (i.e., cefazolin 2 g). The specific anatomy of the LAA is evaluated and an appropriately sized CE-marked device (Watchman or Watchman FLX) is deployed. LAA angiography and TEE imaging is performed to identify optimal positioning of the device and to exclude a relevant leak. Following device deployment, patients will receive a therapy according to the manufacturers IFU, currently Aspirin and clopidogrel for 3 months followed by single Aspirin up to 12 months. Alternatively, 3 months of NOAC followed by Aspirin monotherapy up to 12 months are possible.
223692597|NCT03207555|DRUG|Ibrutinib|420 mg by mouth once daily.
223692598|NCT05900206|DRUG|Trastuzumab deruxtecan|Experimental drug. Provided in 100mg vials. IV infusion.
223692599|NCT05900206|DRUG|Docetaxel|Active comparator. IV infusion.
223692600|NCT05900206|DRUG|Paclitaxel|Active comparator. IV infusion.
223692601|NCT05900206|DRUG|Carboplatin|Active comparator. IV infusion.
223692602|NCT05900206|DRUG|Trastuzumab|Active comparator. IV infusion.
223692603|NCT05900206|DRUG|Pertuzumab|Active comparator. IV infusion.
223692604|NCT05900206|DRUG|Ribociclib|Experimental drug. Tablets.
223692605|NCT05900206|DRUG|Letrozole|Experimental drug. Tablets.
223692606|NCT05900206|DRUG|Epirubicin|Active comparator. IV infusion.
223777544|NCT01975389|DRUG|bococizumab (PF-04950615)|150 mg, every 2 weeks, subcutaneous. The duration of the treatment period will depend upon reaching the targeted number of adjudicated and confirmed CV outcome events, approximately 3 to 4 years after the entry of first subject into the study.
223777545|NCT01975389|DRUG|Placebo|Placebo comparator, every 2 weeks, subcutaneous. The duration of the treatment period will depend upon reaching the targeted number of adjudicated and confirmed CV outcome events, approximately 3 to 4 years after the entry of first subject into the study.
223777546|NCT00874744|DRUG|Bevacizumab|1.25mg bevacizumab (0.05ml)
223777547|NCT00874744|DRUG|Triamcinolone acetonide|4.0 mg Triamcinolone acetonide injection
223692607|NCT05900206|DRUG|Cyclophosphamide|Active comparator. IV infusion.
223692608|NCT04107727|DRUG|Quizartinib|"Induction: oral quizartinib (dose defined in safety run-in phase) 14 days (8-21) (dose will be halved with strong CYP3A inhibitor), up to 2 cycles of 35 days.~Consolidation: oral quizartinib (dose defined in safety run-in phase) 14 days (6-19) (dose will be halved with strong CYP3A inhibitor), up to 4 cycles of 35 days.~Maintenance: oral quizartinib 60mg/day (dose will be halved with strong CYP3A inhibitor), up to 12 cycles of 28 days."
223692609|NCT04107727|DRUG|Placebo oral tablet|"Induction: oral placebo (dose defined in safety run-in phase) 14 days (8-21) (dose will be halved with strong CYP3A inhibitor), up to 2 cycles of 35 days.~Consolidation: oral placebo (dose defined in safety run-in phase) 14 days (6-19) (dose will be halved with strong CYP3A inhibitor), up to 4 cycles of 35 days.~Maintenance: oral placebo 60mg/day (dose will be halved with strong CYP3A inhibitor), up to 12 cycles of 28 days."
223777548|NCT06459557|PROCEDURE|cast|children with displaced distal radius fractures would be managed by a cast in the emergency room
223777549|NCT06459557|PROCEDURE|surgical reduction|anatomical reduction of pediatric displaced distal radius fractures under general anesthesia in the operating room
223692610|NCT04107727|DRUG|Cytarabine|"Induction: Cytarabine continuous IV infusion, 200 mg/m2 (days 1-7), up to 2 cycles of 35 days.~Consolidation: Cytarabine IV infusion, 1,5-3 g/m2 (days 1, 3, 5), up to 4 cycles of 35 days."
223692611|NCT04107727|DRUG|Idarubicin|Induction: Idarubicin IV infusion 12 mg/m2 (days 1-3), up to 2 cycles of 35 days.
223692612|NCT01106716|DRUG|Placebo|Placebo IV Infusion
223692613|NCT01106716|DRUG|KAI-1678|KAI-1678 IV Infusion
223692614|NCT01106716|DRUG|Lidocaine|Lidocaine
223692615|NCT05715333|BIOLOGICAL|CM326|CM326 Injection
223692616|NCT05715333|OTHER|Placebo|Subcutaneous injection
223692617|NCT02481453|DRUG|Rapamycin|Experimental: rapamycin oral solution, 2 mg/day during one year Comparator: placebo
223692618|NCT02481453|DRUG|Placebo|Comparator: placebo
223692619|NCT05304832|OTHER|Aqua-Plyometric Exercise|The aqua-plyometric training was conducted for 45 minutes, twice weekly, for 12 successive weeks. The training was geared toward the lower body and was conducted under close supervision of a licensed pediatric physical therapist in accordance with the safety performance guidelines defined by the American Academy of Pediatrics and the US National Strength and Conditioning Association.
223692620|NCT05304832|OTHER|Standard physical therapy|The program encompassed the standard exercises for patients with JIA (aerobic, weight-bearing, proprioceptive, flexibility, and strengthening exercises). The training was conducted for 40 minutes, two times a week for 12 successive weeks.
223692621|NCT04150406|DIETARY_SUPPLEMENT|Flexofytol|Curcuma extract
223692622|NCT04150406|OTHER|Placebo|placebo
223692623|NCT03784365|DRUG|One dose of Cefo-perazone Sulbactum|Antibiotic
223692624|NCT06327542|OTHER|Group Acupuncture|Acupuncture will be delivered in a group setting, in a common space with multiple reclining chairs. Acupuncture treatments will include a 10-15 minute diagnostic intake with the acupuncturist, followed by administration of acupuncture needles retained for 20-40 minutes. Acupuncture points will be selected based on a treatment manual developed for the study. All treatments will be administered using sterile, disposable, surgical stainless steel acupuncture needles.
223692625|NCT06327542|OTHER|Integrative Group Medical Visits|"IGMV sessions will be weekly for 90-120 minutes in a group meeting space. Sessions will start with a check-in where participants can share their emotions, thoughts, hopes, and fears related to their health and pain and provide updates since the last session. Group sessions will be led by a primary care provider and a health educator and will include psychosocial support, tools for pain self-management, and psychoeducation for pain management. Invited experts will provide information on educational topics, including neurobiology of pain, medication safety, and connections between mood and pain, as well as participatory activities such as therapeutic movement or mindfulness practice."
223692626|NCT01180166|DRUG|nimotuzumab|200 milligram (mg) of nimotuzumab per week during radiation period
223692627|NCT00282542|PROCEDURE|Hepatocyte Infusion|
223692628|NCT00381953|DRUG|Peginterferon alfa-2a|
223692629|NCT00381953|DRUG|Interferon alfa-2a|
223692630|NCT00381953|DRUG|Ribavirin|
223692631|NCT01729247|DEVICE|NIOX MINO® Instrument (09-1100)|
223692632|NCT04673981|DIAGNOSTIC_TEST|diagnostic tes for neuropathic pain|Thermotest and hot water, cold water (for the oral cavity), Von frey filament and the brush
223692633|NCT02425527|BEHAVIORAL|The rehabilitation gaming|The web-based cognitive training platform CogniFit includes about 33 mini games designed with the purpose of improving the user's cognitive abilities as brain exercises. For the purpose of the research, a selection of CogniFit mini games will be included in the intervention. The mini game tasks will be adapted to players' skills getting more difficult as the players progress. The game tasks are targeting different cognitive abilities such as memory, visual-spatial ability, attention, tracking and fast decision making.
223692634|NCT02425527|BEHAVIORAL|The entertaining gaming|The gameplay will consist of these main elements: 1) the player will be playing the main character of the game, 2) the character will be presented for the player from an isometric perspective, 3) the player will control the character by navigating in partly open-ended 3D environments in which the player must decide a direction and move towards it by avoiding obstacles; 4) the player will engage with real-time action events and act quickly by making strategic and tactical decisions; 5) the player must memorize locations, characters, dialogue and tasks; as well as 6) track, follow or aim at several objects simultaneously. Gaming requires also patience as participants can only make progress in games by trial and error.
223692635|NCT06366022|DEVICE|The tunnel technique for root coverage with CTG with inner side of the graft|Procedure: The tunnel technique for root coverage with CTG with inner side of the graft
223692636|NCT06366022|DEVICE|The tunnel technique for root coverage with CTG with outer side of the graft|The tunnel technique for root coverage with CTG with outer side of the graft
223692637|NCT00546468|PROCEDURE|laparoscopy assisted distal gastrectomy|under general endotracheal anesthesia, Five laparoscopic ports are made. Lymph node dissection and ligations of vessels are done in laparoscopic field. A 5-6cm small incision is made transversely in RUQ of the abdomen. Through the incisional window, stomach is taken out and resected. A Billroth I gastroduodenostomy using EEA stapler and GIA is performed. Abdomen is closed after hemostasis.
223692638|NCT00546468|PROCEDURE|Open distal gastrectomy|Open distal gastrectomy is performed under general endotracheal anesthesia. A long midline incision is made. omentectomy is skipped and D2 lymph node dissection is performed. Anastomosis is done in same manner as LADG. Abdomen is closed after hemostasis
223777550|NCT02130375|PROCEDURE|the IncontiLaseTM procedure|Utilizing laser (IncontiLaseTM) to treat the anterior vaginal wall area to intensify periurethral tissue and achieve urinary continence
223777551|NCT03299192|BEHAVIORAL|Tai Chi|Yang Style Tai Chi
223692639|NCT01669707|DRUG|Endostar -Continued Pumping into+GP|Gemcitabine(G):1000mg/m2 intravenous injection on d1,8 q3w; Cisplatin (P):75mg d1 q3w; Endostar:7.5 mg/m2 Continued Pumping into vein with saline,Each pump use 120 hours and the dosage is 7.5mg/m2\*5 ,on day 1 to day 14, discontinuancing for 7 days and 21 days is one cycle,Continued using 2-4cycles.
223692640|NCT01669707|DRUG|Endostar -injecting into +GP|Gemcitabine(G):1000mg/m2 intravenous injection on d1,8 q3w; Cisplatin (P):75mg iv on d1 q3w; Endostar:7.5 mg/m2 injecting into vein for 4 hours with saline on day 1 to day 14, discontinuancing for 7 days and 21 days is one cycle.Continued using 2-4cycles
223777552|NCT03299192|BEHAVIORAL|Health Education|Comprehensive Health Education relevant for Healthy Aging in Patients with Chronic Back Pain
223777553|NCT03299192|OTHER|Usual Medical Care|Medications, PT, Complementary and Integrative Health and other miscellaneous treatments as appropriate.
223777554|NCT00177437|BEHAVIORAL|home testing kit|
223692641|NCT00500305|PROCEDURE|Withhold standard INDO dose if BNP < 100 pg/ml|
223692642|NCT01393015|DEVICE|Automated settings on the oxygen delivery device|FreeO2 automatically adjusts the oxygen flow delivered to patients based on the SpO2 signal. Patients keep using the same device for duration of hospitalization.
223692643|NCT01393015|DEVICE|Manual settings with FreeO2 system in collection mode|Oxygen flow delivery is adjust by nurse and respiratory therapists. Standard medical treatment. Patients keep using the same device for duration of hospitalization.
223692644|NCT02594241|DRUG|Methyl-Prednisolone|Single-shot 125 mg infusion given immediately after induction of anesthesia.
223692645|NCT02594241|DRUG|Physiological saline|A single preoperative dosage 100 ml given intravenously as a 30 minute infusion, 2 hours before surgery
223692646|NCT05555758|DRUG|Adamgammadex Sodium|Aom0319 will be administered intravenously with water for injection.
223692647|NCT05555758|DRUG|0.9% Sodium Chloride Injection|0.9% Sodium Chloride will be administered intravenously.
223692648|NCT02325791|DRUG|Suptavumab 30 mg/kg|Participants received single dose of suptavumab 30 milligram per kilogram (mg/kg) intramuscularly (IM) on Day 1.
223692649|NCT02325791|DRUG|Placebo Matched to Suptavumab|Participants received 2 IM doses of placebo matched to suptavumab: the first dose on Day 1 and the second dose on Day 57.
223692650|NCT02325791|DRUG|Suptavumab 30 mg/kg- 1 Dose|Participants received single dose of suptavumab 30 mg/kg IM on Day 1 and single dose of placebo matched to suptavumab on Day 57.
223692651|NCT02325791|DRUG|Suptavumab 30 mg/kg - 2 Doses|Participants received 2 doses of suptavumab 30 mg/kg IM: the first dose on Day 1 and the second dose on Day 57.
223692652|NCT00752115|DRUG|sildenafil|50mg, day1,8 and 15 in each cycle
223692653|NCT00752115|DRUG|placebo|1 tab, day 1,8 and 15 in each cycle.
223692654|NCT00752115|DRUG|paclitaxel (taxol)|paclitaxel; 70mg/m2 div on day 1, 8 and 15, every 28 days
223692655|NCT00752115|DRUG|carboplatin (palaplatin)|carboplatin; AUC=6 on day 1, every 28 days
223692656|NCT06185127|DRUG|Dexmedetomidine|Dexmedetomidine solution of 1 μg/kg dissolved in 60 ml saline was administered over 15 minutes, followed by a maintenance dose of 0.5 μg/kg/h (continuous infusion).
223777555|NCT02212821|DRUG|Erythromycin|
223777556|NCT02212821|DRUG|Placebo|physiological saline
223777557|NCT03291613|OTHER|Pinpoint App|Tablet app with pain assessment and communication education, and pain assessment tool.
223777558|NCT02008500|OTHER|placebo mouthwash|15 ml placebo mouthwash prescribed and VAS score assessed at Baseline, 3 weeks, 6 weeks and 12 weeks
223777559|NCT02008500|OTHER|Herbal Mouthwash|15 ml Herbal mouthwash prescribed and VAS score assessed at Baseline, 3 weeks, 6 weeks and 12 weeks
223777560|NCT02008500|OTHER|Non Herbal Mouthwash|15 ml Non Herbal mouthwash prescribed and VAS score assessed at Baseline, 3 weeks, 6 weeks and 12 weeks
223692657|NCT06185127|DRUG|Ketamine|A bolus dose of 50 mg ketamine dissolved in 10 ml saline was given 15 minutes after Dexmedetomidine initiation.
223692658|NCT06185127|DRUG|Midazolam|Bolus doses of midazolam (5 mg midazolam dissolved in 10 ml saline; 2 ml of the solution or 1 mg midazolam per bolus, premedication dose of 2mg, induction dose of 2 mg) were administered at 20-minute intervals in between and titrated as needed to obtain the desired sedation depth. No more than 12 mg of midazolam were administered.
223692659|NCT06185127|DRUG|Fentanyl|Bolus doses of fentanyl (100 μg / 10 ml; 5 ml of the solution or 50 μg fentanyl per bolus, induction dose of 50μg) were administered at 20-minute intervals in between and titrated as needed to obtain the desired sedation depth. No more than 150 μg of fentanyl were administered.
223692660|NCT00679744|DRUG|Pyrimethamine|Pyrimethamine will be given PO once daily for 8 consecutive weeks.
223692661|NCT03070366|DRUG|Chemotherapy|"* cisplatin~* 5FU~* carboplatin~* cetuximab"
223692662|NCT03070366|RADIATION|Stereotactic radiotherapy|Stereotactic radiotherapy
223692663|NCT00985816|DIETARY_SUPPLEMENT|Lactobacillus Reuteri|L. reuteri DSM 17938 will be given at a dose of 1x108 colony forming units (CFU)/day
223692664|NCT00985816|DIETARY_SUPPLEMENT|Placebo|Placebo
223692665|NCT00398333|DIETARY_SUPPLEMENT|Eicosapentaenoic acid enriched nutritional supplement|Oral intake of nutritional supplementation: a maximum of 480 mL or a minimum of 240 mL daily during the first 3 months of the study.
223692666|NCT04895540|DIAGNOSTIC_TEST|ECG|All study subjects will undergo ECG recording.
223692667|NCT04895540|DIAGNOSTIC_TEST|Echocardiography|All study subjects will undergo transthoracic echocardiography
223777561|NCT01825408|DRUG|Doxycycline|Subjects with CRSwNP who are not allergic to doxycycline will receive Doxycycline 100mg BID for either 3 or 6 weeks duration.
223777562|NCT01825408|DRUG|Azithromycin|Subjects with CRS without Nasal Polyposis (CRSwNP)who are not allergic to azithromycin will be given Azithromycin 250mg daily for either 3 or 6 weeks duration.
223777563|NCT01825408|DRUG|Augmentin|If a subject in any of the study arms is allergic to the medication he/she is supposed to receive, he/she will be given Augmentin 875mg BID for either 3 or 6 weeks duration
223777564|NCT04796831|DRUG|Quizartinib dihydrochloride|Single oral dose of 60 mg quizartinib (2 x 30 mg tablets)
223692668|NCT04895540|DIAGNOSTIC_TEST|Cardiac MRI|All ACM patients and SCD survivors will undergo cardiac MRI testing.
223692669|NCT04895540|DIAGNOSTIC_TEST|Ambulatory ECG recording|All ACM patients and SCD survivors will undergo 24-hour ambulatory ECG recording
223777565|NCT04796831|DRUG|14C-Quizartinib solution for infusion|50 μg solution for infusion containing NMT 22.84 kBq 14C in 5 mL; administered once as a 15-minute infusion
223692670|NCT04895540|DIAGNOSTIC_TEST|Cardiac EP study|ACM patients and SCD survivors will undergo diagnostic cardiac Electrophysiology testing.
223692671|NCT04895540|GENETIC|All study subjects will undergo sample collection for genetic testing.|Blood samples and buccal swab will be collected from study subjects for genetic testing.
223692672|NCT03488823|DIETARY_SUPPLEMENT|with Flavanol|Patient will get twice daily drink rich on flavanols (400 mg) since one week before catheterization till one week after catheterization.
223692673|NCT03488823|DIETARY_SUPPLEMENT|without Flavanol|Patient will get twice daily drink without flavanols since one week before catheterization till one week after catheterization.
223692674|NCT05270421|DRUG|Furosemide 40 mg|Standard ESWL + Furosemide 40 mg
223777566|NCT06075680|PROCEDURE|Non-Surgical Periodontal Treatment|The primary goal of nonsurgical periodontal therapy is to control microbial periodontal infection by removing bacterial biofilm, calculus, and toxins from periodontally involved root surfaces. Performing a thorough periodontal debridement under local anesthesia will stop disease progression and result in improvement in the clinical signs and symptoms of active disease
223692675|NCT05270421|OTHER|Conventional Treatment|Standard ESWL
223692676|NCT04838197|OTHER|Questionnaires and Surveys|Quantitative questionnaires will measure and quantify the importance of the various factors (e.g., intensity of dependence, duration of care, health literacy, physical well-being, emotional well-being, social well-being, and financial well-being) that contribute to caregiver burden both preoperatively and postoperatively at 48 hours, 1 week, 2 weeks, and 1 month.
223692677|NCT04561674|OTHER|Implementation of web-based patient education|Web-Based Patient Education on Colostomy and Ileostomy (WBPECI) was developed in accordance with the principles of the ADDIE instructional design. The web-based education was designed in line with these learning objectives determined. The content of the website was developed in light of the opinions sought from five subject experts. The WBPECI content includes a total of 7 videos, 1 animation with sound, 1 forum and 1 consultation page
223692678|NCT01005043|RADIATION|heavy ion radiotherapy (C12)|"Desired target of Heavy ion radiotherapy is 60 to 66 Cobalt Gray Equivalent (GyE), whenever possible. It is applied through 1 - 3 isocenter treatment portals. Dose distributions are calculated and dose volume histograms (DVH) are generated. A α/β-ratio of 2 is used for biological plan optimization. Fractionation is planned to be equivalent to 6 x 3 GyE / week. Dosage to organs at risk is minimized. Treatment continues for 20 to 22 days or until one of the following criteria applies:~Other illness that prevents further administration of treatment, Patient or legal guardian decides to withdraw from the study, or changes in the patient's condition render the patient unacceptable for further treatment in the judgment of the investigator."
223692679|NCT00003046|BIOLOGICAL|Recombinant Interleukin-12|Intraperitoneal over 30 minutes once weekly for 4 weeks, repeats every 4 weeks for up to 6 courses
223692680|NCT00002178|DRUG|Ritonavir|
223692681|NCT00002178|DRUG|Nelfinavir mesylate|
223692682|NCT00002178|DRUG|Saquinavir|
223692683|NCT00002178|DRUG|Delavirdine mesylate|
223692684|NCT05060887|BIOLOGICAL|OVX836-003|One single administration intramuscularly at Day 1.
223692685|NCT05060887|BIOLOGICAL|Saline solution|One single administration intramuscularly at Day 1.
223692686|NCT04132245|BEHAVIORAL|behavioral intervention|Families were randomized to a 14-week family based obesity prevention intervention or a 14-week general health intervention
223692687|NCT04132245|BEHAVIORAL|Obesity prevention intervention trial|Families were randomized to a 14-week obesity prevention intervention or a 14-week general health intervention
223692688|NCT04895800|DIETARY_SUPPLEMENT|Phytovive|Bacopa monnieri bacosides, Kaempferia parviflora methoxy flavones, pomegranate peel polyphenols, and Moringa oleifera leaf saponins)
223692689|NCT04895800|DIETARY_SUPPLEMENT|Placebo|Natural Flavors \[Chocolate, Caramel, Vanilla Cream\], Silica, Inulin, Sucralose)
223692690|NCT04895800|DIETARY_SUPPLEMENT|Caffeine|Caffeine (Green tea caffeine extract (170 mg; to deliver 34 mg caffeine \[20% natural caf-feine\])
223692691|NCT01036061|DRUG|GSK618334 Low Dose|GSK618334 low dose
223692692|NCT01036061|DRUG|GSK618334 PET subjects|PET subjects
223692693|NCT01036061|DRUG|GSK618334 Medium Dose|Medium Dose
223692694|NCT01036061|DRUG|GSK618334 High Dose|GSK618334 High Dose
223692695|NCT02909179|OTHER|mCARE-II|mCARE-II is a package of interventions that provides guided client enumeration and follow-up support to community health workers, automated workflow scheduling, risk assessment, client prioritization and stratification and client-based demand generation messaging. These features are incorporated into a platform called OpenSRP, which integrates text message reminders, scheduling, and form submissions on the server side, and displays schedules and client lists on a tablet-based application for community health workers.
223692696|NCT03486431|RADIATION|Stereotactic Ablative Radiotherapy (SABR)|A minimum of thirty patients will be included for each dose level. An interval of at least 24 weeks from the first patient treatment to the next patient treatment at each dose level will be respected. In the meantime, more patients will be included in the previous dose level, in an effort to establish the secondary endpoints. In case 1-5 patients present with dose-limiting toxicity (DLT) at 6 months after SABR, thirty additional patients will be included at the same dose level. The maximal tolerated dose will be defined as the dose level below which at least 10 patients present with a dose-limiting toxicity at 6 months after SABR.
223692697|NCT01437878|DRUG|Iloprost|5ug dose of inhaled iloprost (20ug/mL solution) administered 6 to 9 times per day for 4 weeks
223692698|NCT01437878|DRUG|Placebo|matching placebo
223692699|NCT01194427|DRUG|Vorinostat and Tamoxifen|vorinostat 400 mg PO once daily and tamoxifen 20mg PO once daily for 14 days
223692700|NCT01070043|DRUG|Amlodipine 5mg/Valsartan 80 mg|Combination therapy of Amlodipine/Valsartan 5mg/80mg one dosage daily with one single tablet size for 8 weeks.
223692701|NCT01070043|DRUG|Valsartan|"For run-in period, Valsartan 80 mg daily in one dosage with one single tablet size for 4 weeks.~Monotherapy for double blind treatment period in one dosage (Valsartan 160mg) daily with one single tablet size for 8 weeks"
223692702|NCT05012436|DRUG|YHD1119 75mg|A single oral dose
223692703|NCT01323738|BEHAVIORAL|Psychoeducation|Psychoeducation group on stress and how it relates to alcohol use, 4 sessions a 45 minutes
223692704|NCT04965558|OTHER|No intervention|No intervention
223692705|NCT00473746|DRUG|Abiraterone acetate|The first cohort was a abiraterone acetate 250 mg/day orally (by mouth), once daily for 28-day treatment periods , if no dose limiting toxicity (DLT) was documented at this dose, the dose will be escalated to next dose levels 500, 750, and 1000 mg/day. The dose escalation will continue to a maximum of 1000mg/day until Maximum Tolerated Dose (MTD) and a recommended Phase II dose was established.
223692706|NCT00473746|DRUG|Abiraterone acetate|Abiraterone acetate 1000 mg daily under fasted conditions upto 10 cycles of therapy.
223692707|NCT00473746|DRUG|prednisone/prednisolone or dexamethasone|prednisone/prednisolone (5 mg twice daily) or dexamethasone (0.5 mg once daily) concurrent with abiraterone acetate
223692708|NCT00312403|PROCEDURE|Blood Sample|A single venous blood sample will be taken (10 ml).
223692709|NCT03832244|DIAGNOSTIC_TEST|Sub-mental ultrasonography|Sub-mental ultrasonography including tongue-base thickness, retropalatal distance and the distance between lingual arteries
223692710|NCT01129570|DRUG|Silybin|4 dose levels of siliphos: 2, 4, 8, and 12 grams daily in three divided doses. This study will follow a standard sequential Phase I dose escalation design.
223692711|NCT03729973|DRUG|Ketamine|Patients nebulized ketamine by compressor nebulizing for 15 minutes.
223692712|NCT03729973|DRUG|Magnesium Sulfate|Patients nebulized magnesium sulfate 250mg (3ml)plus 2ml normal saline by compressor nebulizing for 15 minutes.
223692713|NCT03729973|DRUG|Lidocaine|"In preparation room an I.V line was secured ,and standard monitoring was connected to patient.~Patients nebulized lidocaine 5ml by compressor nebulizing for 15 minutes."
223692714|NCT03729973|DRUG|Normal saline|"In preparation room an I.V line was secured ,and standard monitoring was connected to patient.~Patients nebulized by compressor nebulizing 5ml normal saline for 15 minutes."
223692715|NCT00188708|PROCEDURE|hypoxia measurement|transrectal oxygen measurement
223692716|NCT01435317|DEVICE|ANM T30 CR®-System|Stimulation for 4-6h/day for a time of 1 year
223692717|NCT06666400|BEHAVIORAL|LHMoms Intervention|The LHM arm (N=300) will receive a CBT+ Cardiovascular Health (CVH) Intervention to reduce CV risk. LHM employs a (CBT) + cardiovascular health (CVH) intervention delivered by doulas and integrating a healthy lifestyle intervention to reduce CV risk. The LHM intervention integrates the following key elements: (1) doula-led emergency detection in the first 7 days post-discharge; (2) home BP monitoring (HBPM); and (3) 12-sessions of the doula-delivered intervention to prevent PPD and reduce CV risk from 1 week to 6 months post-discharge, supported by (4) education through the Patient-Activated Learning System (PALS), a novel education platform used to engage low-literacy, racially marginalized individuals. LHM is based on the Thinking Healthy Programme (THP), an intervention originally designed to treat PPD in low and middle-income countries using community health workers.
223692718|NCT06666400|OTHER|No intervention|Standard doula care and the same number of telephone or video-delivered sessions and will last the same amount of time on general postpartum health topics not related to CV health or depression. Attention control participants will not receive doula-initiated outreach during the first 7 days.
223692719|NCT04405427|PROCEDURE|head acupoints acupuncture|The participants will undergo GV20, EX-HN-1, GV21, GV22, GV23, GV24, GV29, and GB13 head acupoints aupunture treatment 3 times/ 1 week for 4 weeks.
223692720|NCT04405427|PROCEDURE|body acupoints acupuncture|The participants will undergo HT7, PC6, SP6, ST36, KI3, and LR3 body acupoints acupunture treatment 3 time/1 week for 4 weeks.
223692721|NCT03893331|DEVICE|AcQMap System|To evaluate procedural and long-term outcomes when using the diagnostic AcQMap System as an imaging and mapping system for ablation of arrhythmias in accordance with the Instructions for Use (IFU).
223692722|NCT00983788|DRUG|Bezafibrate|3 x 200 mg/ day
223692723|NCT00983788|OTHER|Placebo|Placebo
223692724|NCT04732156|BIOLOGICAL|Blood sample|Measurement of PHI Index
223692725|NCT04732156|OTHER|Follow up questionnaire|3 years after inclusion
223692726|NCT04732156|DIAGNOSTIC_TEST|Human reading of prostate MR images (PI-RADSv2.1).|The PI-RADSv2.1 score will be compared to systematic and targeted biopsy findings (primary objective) and 3-year follow-up (secondary objective)
223692727|NCT05982210|OTHER|Breathing Exercises and Manual Therapy of the Muscle Diaphragm and Ribs Protocol|The intervention consists on applying a protocol based on five different exercises, compound by breathing exercises and manual therapy of the muscle diaphragm and the ribs, applied by a physiotherapist.
223692728|NCT03492411|OTHER|eHealth Breastfeeding Co-parenting Resource|The eHealth breastfeeding co-parenting resource was designed using a participatory model in partnership with the target population. It contains extensive information about breastfeeding and co-parenting. The topics include not only the importance of breastfeeding and technique but also information on how to manage common issues during breastfeeding establishment as well as over the child's first years, since breastfeeding is recommended to two years and beyond. Interactive learning elements, videos, and links to additional resources are included in the resources.
223692729|NCT04498494|DEVICE|ECG|12-lead ECG
223692730|NCT04145479|BEHAVIORAL|physical activity|exercise
223692731|NCT05994560|OTHER|With temporary occlusion|at the time of surgery the randomization table was consulted and if it was in the occlusion arm was performed
223692732|NCT03967678|DIETARY_SUPPLEMENT|Three portions per week (690g beef (raw weight)) for 5 weeks|Lunches served in Human Intervention Studies Unit
223692733|NCT01528215|DEVICE|OsseoSpeed EV|OsseoSpeed EV implants; Ø 3.6, 4.2, 4.8 mm in lengths of 9,11 and 13 mm
223692734|NCT01528215|DEVICE|OsseoSpeed TX|OsseoSpeed TX implants; Ø 3.5, 4.0 and 5.0 mm in lengths of 9,11 and 13 mm
223692735|NCT01043510|DRUG|insulin degludec|0.6 U/kg body weight injected subcutaneously (under the skin), once daily for 6 days
223692736|NCT01043510|DRUG|insulin detemir|0.6 U/kg body weight injected subcutaneously (under the skin), once daily for 6 days
223692737|NCT06264310|DRUG|Placebo|Matching placebo SC injection
223692738|NCT06264310|DRUG|R2R01|Pharmaceutical Form: sterile 2R vials containing 10 mg of R2R01 for SC injection.
223692739|NCT05245253|RADIATION|Positron Emission tomography|Patients will be tested with PET-examination at 3 weeks, 3 months and 1 year after the trauma
223692740|NCT04793061|OTHER|blood sample collection|Blood is samples from peripheral vein during routine care
223692741|NCT01231230|DRUG|fluticasone|220- mcg once
223692742|NCT01231230|DRUG|placebo inhalation|placebo inhalation once
223692743|NCT01231230|DRUG|Salmeterol|50 mcg salmeterol once
223692744|NCT01231230|DRUG|fluticasone/salmeterol|inhalation of 250 mcg of fluticasone combined with 50 mcg of salmeterol
223692745|NCT03722771|BEHAVIORAL|Inhalation|lavender oil inhalation in a separate room for 3 minutes prior to surgery
223692746|NCT03722771|OTHER|Anxiety Questionnaires 1|Modified Dental Anxiety Scale was used to describe the level of the dental anxiety.
223692747|NCT03722771|OTHER|Anxiety Questionnaires 2|State-Trait Anxiety Inventory-State Scale was used to distinguish the true anxiety level of the patients from the anxiety level for a particular situation.
223692748|NCT03722771|DIAGNOSTIC_TEST|Vital Signs 1|Changes in vital signs 1 - blood pressure - before, during and after the procedure were noted.
223692749|NCT03722771|DIAGNOSTIC_TEST|Vital Signs 2|Changes in vital signs 2 - respiratory rate - before, during and after the procedure were noted.
223692750|NCT03722771|DIAGNOSTIC_TEST|Vital Signs 3|Changes in vital signs 3 - heart rate - before, during and after the procedure were noted.
223692751|NCT03722771|DIAGNOSTIC_TEST|Vital Signs 4|Changes in vital signs 4 - saturation - before, during and after the procedure were noted.
223692752|NCT00042367|DRUG|Induction therapy (Regimen 1, Course 1, Cycle A1|"2-8 hrs: Cisplatin 3.5 mg/kg + mannitol 0.4 g/kg in D5 NS (1000 ml/m2) over 6 hrs at approximately 167ml/m2/hr. 8-12 hrs: D5 NS (665 ml/m2) + KCl (2 mEq/100 ml) +MgSO4 (0.5 mEq/100 ml) at approximately 167ml/m2/hr.~12-24 hrs: D5 NS + KCl (2 mEq/100 ml) + MgSO4 (0.5mEq/100 ml) at approximately 65 ml/m2/hr.~Days 2,3: 0 hrs: Mesna 6 mg/kg IV in 0.65 ml/kg of IVF over 15 min 15 min: Cyclophosphamide 30 mg/kg IV over 30 min 45 min: Post-chemotherapy hydration - D5 1/2 NS + KCl(1 mEq/100 ml) at approximately 130 ml/m2/hr for at least 24 hours.~3 hrs: Mesna 6 mg/kg IV in 0.65 ml/kg IVF over 15 min 6 hrs: Mesna 6 mg/kg IV in 0.65 ml/kg IVF over 15 min 9 hrs: Mesna 6 mg/kg IV in 0.65 ml/kg IVF over 15 min 12 hrs: Mesna 6 mg/kg IV in 0.65 ml/kg IVF over 15 min Day 4 G-CSF 5 µg/kg subcutaneously, daily until ANC ≥ 2000 on two consecutive days, post ANC nadir.~Day 8: Vincristine 0.05 mg/kg IV push (max dose = 2 mg) Day 15: Vincristine 0.05 mg/kg IV push (max dose = 2 mg)"
223692753|NCT00042367|DRUG|Regimen 1, Course 1, Cycle A2 (Days 22 - 42)|Drugs and doses are same as in Cycle A1. Cycle A2 begins following recovery from Cycle A1, but no sooner than day 21. Patients with delays in recovery beyond day 28 should have dose modifications
223692754|NCT00042367|DRUG|Cycle B|"Days 43 - 63) Etoposide, 1.7 mg/kg p.o. qd x 21 days. The dose will be diluted immediately prior to administration in juice flavored syrup to a final concentration of 0.4 Each dose should be aken 1 hour before or 2 hours after a meal.~Cycle B begins following recovery from Cycle A2; however, it begin no sooner than 21 days after the start of Cycle A2.~Monitor weekly CBC/diff/plt. If ANC \< 500/mm3 or platelets (unsupported) \< 50,000/mm3 then discontinue etoposide. A 25% reduction should be made for the next cycle of oral etoposide.~Interim Response Evaluation (Days 64 - 70) Interim Response Evaluation should be performed the week following the completion of Course 1."
223692755|NCT00042367|DRUG|Regimen 1, Course 2|6.3.3 Regimen 1, Course 2 Repeat systemic therapy as per Course 1 (Cycle A1, Cycle A2, and Cycle B) in patients with SD or better at the interim response evaluation (see Figure 2 for IT mafosfamide guidelines). Course 2 should not begin any sooner than 7 days after the completion of Course 1.
223692756|NCT00042367|DRUG|Intrathecal Mafosfamide|Regimen 1, Course 1 Mafosfamide, 14 mg, is given two times/week during Cycle A1 and Cycle A2 of Course 1, for 12 total doses during days 1-41. The first dose of Cycles A1 and A2 should be given, if possible, on the same day as the first I.V. cyclophosphamide dose and the second dose 3 to 4 days later. The assigned dose is given one time/week during Cycle B, Course 1 for 3 total doses during days 43 - 63.
223692757|NCT00042367|DRUG|Regimen 1 Course 2, IT mafosfamide|"Regimen 1, Course 2 The assigned dose is administered once with IV cyclophosphamide during each of Cycle A1 and Cycle A2, and day 1 of Cycle B for a total of 3 doses during Course 2.~Patients with an initially abnormal flow study, who show no evidence of obstructive hydrocephalus or compartmentalization on the repeat study, may begin intrathecal mafosfamide administration with the initiation of Regimen 1, Course 2. The frequency of intrathecal mafosfamide administration, for such patients, will be as outlined in Regimen 1, Course~1\."
223692758|NCT00042367|DRUG|Regimen 2, Course 1|"Cycle C1 (Days 1 - 21) Day 1: Prehydrate with D5W 1/2 NS + KCl 2 mEq/100 ml) at 2 times the hourly maintenance rate until the urine specific gravity is \< 1.012.~0 hrs: Mesna 6 mg/kg IV over 15 min. Dilute in 0.65 ml/kg IVF. 15 min: Vincristine 0.05 mg/kg IV push (Day 1 only)(max dose = 2 mg) 20 min: Cyclophosphamide 30 mg/kg IV over 30 min. 50 min: Post-chemotherapy hydration - D5 1/2 NS + KCl~(1 mEq/100 ml) at twice the hourly maintenance rate for at least 24 hours. 3 hrs: Mesna 6 mg/kg IV in 0.65 ml/kg IVF over 15 min 6 hrs: Mesna 6 mg/kg IV in 0.65 ml/kg IVF over 15 min 9 hrs: Mesna 6 mg/kg IV in 0.65 ml/kg IVF over 15 min 12 hrs: Mesna 6 mg/kg IV in 0.65 ml/kg IVF over 15 min Day 2: Repeat day 1, but omit vincristine. Day 3: G-CSF 5 µg/kg/day subcutaneously, daily, until ANC is \> 2000 on two consecutive days, post ANC nadir."
223692759|NCT00042367|DRUG|Regimen 2, Course, 1, Cycle C1|"Cycle C1, Weeks 2 and 3 Day 8: Vincristine 0.05 mg/kg IV push (max dose = 2 mg) Day 15: Vincristine 0.05 mg/kg IV push (max dose = 2 mg) Cycle C2 (Days 22-42) Drugs and doses are same as in Cycle C1. Cycle C2 begins following recovery from Cycle C1, but no sooner than day 21. Patients with delays in recovery beyond day 28 should have dose modificationsCycle D (Days 43 - 63) Etoposide 1.7 mg/kg, po qd x 21 days The dose will be diluted immediately prior to administration in juice or flavored syrup as per section 3.4.3. Each dose should be taken 1 hour before or 2 hours after a meal.~Cycle D should begin following recovery from Cycle C2; however, it should begin no sooner than 21 days after the start of Cycle C2."
223692760|NCT00042367|DRUG|Regimen 2, Course 2|Repeat Course 1 (Cycle C1, Cycle C2, and Cycle D) in patients with SD or better at the interim response evaluation. Chemotherapy should begin as soon as the patient has recovered from the toxicities of oral etoposide in cycle D, course 1. However, it should not begin any sooner than 7 days after the completion of Course 1.
223692761|NCT00042367|RADIATION|radiation therapy|"Conformal Irradiation Patients who are initially M0 with a CR, PR, or SD to Regimen 1 induction chemotherapy (with or without second surgery) will receive local irradiation using conformal techniques. Treatment will commence within 2 weeks of completing Regimen 1 or second surgery. Treatment planning and technique may involve 3D conformal,IMRT, or proton planning and delivery, provided the guidelines regarding volume, dose,and normal tissue restrictions are honored.~8.3.1 Fraction Size 180 cGy fractions will be used for all target volumes. 8.3.2 Fractionation Conventional fractionation will be used. Treatments will be given once daily, 5 days/week except for necessary interruptions secondary to medical or administrative reasons."
223692762|NCT03858231|DRUG|Norco 5Mg-325Mg Tablet|1 tablet up to 4 times per day for 7 days
223692763|NCT03858231|DRUG|Ibuprofen 600 mg|1 tablet up to 4 times per day for 7 days
223692764|NCT03858231|DRUG|Acetaminophen 325Mg Tab|1 tablet up to 4 times per day for 7 days
223692765|NCT05553951|BEHAVIORAL|Controlgroup|The control group and intervention group will receive daily text message reminders twice a week to take their medications and to rinse their nose.
223692766|NCT05553951|BEHAVIORAL|Intervention|Patients in the intervention group will receive systematic and structured nursing guidance regarding their adherence, which includes proper use of nasal irrigation once or twice daily, nasal steroid/drops, use of inhaled medications, follow-up of smoking status. The intervention group will receive guidance videos which have been prepared prior to the study and will be standard for the intervention group. Guidance videos will cover the correct use of nasal irrigation, inhalation steroid, and nasal steroid/drops.
223692767|NCT02130726|PROCEDURE|Minimally-invasive gastrectomy|Patients allocated to the 'Minimally-invasive gastrectomy' arm will receive total gastrectomy via laparoscopy.
223692768|NCT02130726|PROCEDURE|Open Gastrectomy|patients allocated to the 'Open gastrectomy' group will receive total gastrectomy via laparotomy
223692769|NCT00573365|DEVICE|Gentlewaves Select™ handheld high energy LED array|LED photomodulation within 5-10 minutes before and within 5-10 minutes after each radiation treatment
223692770|NCT00573365|RADIATION|Radiation|Weekly radiation treatment
223692771|NCT00573365|RADIATION|Radiation|Weekly radiation treatment
223692772|NCT01462227|DRUG|Naltrexone High Dose|Naltrexone 100mg for two administrations.
223692773|NCT01462227|DRUG|Naltrexone Low Dose|Naltrexone 50mg for two administrations.
223692774|NCT04165811|OTHER|Exercise treatment|A program consisting of aerobic dance based exercises and physical activity counseling accompanied by physiotherapists will be applied to the study group.
223692775|NCT04165811|OTHER|Counselling|Only physical activity counseling will be given to the subjects in this group.
223692776|NCT05045833|DRUG|SYN-020 Delayed Release Capsule|Oral administration (by mouth)
223692777|NCT06065423|OTHER|Manuel Lymphatic Drainage(MLD), Exercises|"MLD:It is a unique massage technique that uses specific hand movements to provide a gentle pumping effect on the skin.~Massage movements follow the direction of lymph flow and produce rapid results. The aim of this method is to achieve maximum skin tightening effect with minimum pressure.~Exercise, on the other hand, increases physical performance, improves body composition, and provides an increase in quality of life by providing acute and chronic reductions in fatigue. Both aerobic exercises and strengthening exercises have been found effective on physical performance. It shows that a mixed program consisting of components such as aerobics, strengthening, coordination and stretching can positively affect flexibility, pain and energy expenditure in breast cancer patients."
223692778|NCT00606827|DRUG|Sodium Bicarbonate|Patients in the sodium bicarbonate group (154 mEq/L) received 3 ml/kg for 1 hour before contrast medium, followed by an infusion of 1 ml/kg/h for 6 hours after the procedure
223692779|NCT00606827|DRUG|Isotonic Saline|Patients assigned to the isotonic saline group received 1 ml/kg/h 0.9% sodium chloride for 12 hours before and after the procedure
223692780|NCT02776371|DRUG|Modified non-clarithromycin triple therapy|H. pylori infected patients treated with 10 mg rabeprazole twice a day, and 1g amoxicillin, 500 mg tinidazole three times a day for 14 days.
223692781|NCT02776371|DRUG|Sequential therapy|H. pylori infected patients treated with 10 mg rabeprazole and 1 g amoxicillin, twice daily for 7 days, followed by 10 mg rabeprazole, 500 mg clarithromycin, and 500 mg tinidazole, twice daily for the next 7 days.
223692782|NCT03346044|DEVICE|Carpentier-Edwards SAV bioprostheses|Performance of these bioprostheses
223692783|NCT03346044|DEVICE|Medtronic Mosaic bioprostheses|
223692784|NCT03200665|DIAGNOSTIC_TEST|Ultrasound 35-36 (6 / 7 days weeks)|An obstetric ultrasound will be performed at 35-36 (6 / 7 days weeks) including biometric parameters and functional parameters of the fetus
223692785|NCT00018070|PROCEDURE|Angiography|
223692786|NCT00018070|PROCEDURE|Laser Treatment|
223692787|NCT00440778|DRUG|Abciximab|100% abciximab bolus dose (0.3 mg/kg) ic or iv vs standard bolus (0.25 mg/kg) ic or iv plus 12-hr infusion
223692788|NCT01500512|OTHER|Clinical Observation|Undergo observation
223692789|NCT03857906|DEVICE|Intra-Aortic Ballon Pump insertion|The IABP (Ultraflex IAB 7.5F, 2.5mm; Arrow International, Reading, PA) was inserted percutaneously through the right femoral artery in the previous 1 - 6 hours before the scheduled surgery. Positioning of the IABP was guided by radioscopy. The balloon size was based on the patient's height (30, 40 or 50 cc). Transesophageal echocardiography was used to confirm correct IABP placement before and after CABG
223692790|NCT00291538|DRUG|bortezomib|
223692791|NCT05753631|PROCEDURE|non surgical periodontal treatment|"scaling and root planning were applied for non-surgical periodontal treatment i-PRF application: Intravenous blood sample taken from the antecubital vein of the patients was collected in a 10 ml tube and centrifuged at 700 rpm for 3 minutes in a PRF centrifuge device. The PRF obtained from the upper liquid layer formed in the tube was injected subgingival into the deepest point of the pocket after SRP treatment.~Clinical periodontal measurements: plaque index, gingival index, probing depth, clinical attachment level, bleeding on probing, and gingival recession were calculated.~gingival crevicular fluid: Perio papers were placed in the deepest part of the sulcus and left for 30 seconds. After 30 seconds, the paper strips were placed in the periotron device and the volume was calculated."
223692792|NCT05403333|DRUG|utidelone|Utidelone Injection: 65 mg/m2/day, IV on day 1, 8, and 15 every 28 days
223692793|NCT01061983|DEVICE|Medtronic Activa Deep Brain Stimulation|In DBS, thin wires are used to carry electric current to the parts of the brain involved in OCD symptoms. These wires are implanted surgically and are attached to battery operated stimulators usually implanted in the chest. The study doctor will adjust the settings of the electrical stimulation to optimize treatment for each participant.
223692794|NCT03469050|DRUG|Rifaximin delayed released 400mg Tablet|Rifaximin delayed released
223692795|NCT03469050|OTHER|Placebo|Placebo BID + Placebo BID
223692796|NCT00413166|DRUG|All-Trans Retinoic Acid (ATRA)|Induction: 45 mg/m2 daily by mouth in 2 divided doses beginning day 1
223692797|NCT00413166|DRUG|Arsenic Trioxide (ATO)|Induction: 0.15 mg/kg daily IV beginning day 1
223692798|NCT00413166|DRUG|Idarubicin|"1. 12 mg/m2 one dose only (may be given on day 1 to 5 of induction)~2. If either ATRA or ATO are discontinued due to toxicity, idarubicin 12 mg/m2 x 2 doses will be administered once every 4 to 5 weeks (depending on the recovery of counts) until 28 weeks has elapsed from the Complete Recovery date."
223692799|NCT00413166|DRUG|Gemtuzumab Ozogamicin|Induction: 9 mg/m2 on day 1 of induction
223692800|NCT00979069|BEHAVIORAL|Aerobic group|12 weeks of aerobic exercise 3 times a week
223692801|NCT03139695|DIAGNOSTIC_TEST|Ultrasound|High resolution Ultrasound of the Diaphragm and Intercostal muscles
223692802|NCT04490811|OTHER|no intervention. observational cohort study|blood sampling is part of care
223692803|NCT04702854|DIAGNOSTIC_TEST|Ultrasound Biomicroscopy|Measure of cutaneous melanomas by ultrasound Biomicroscopy
223692804|NCT03965208|DRUG|Bivalirudin|titrated continuous infusion
223692805|NCT03965208|DRUG|Unfractionated heparin|titrated continuous infusion
223692806|NCT06169631|DEVICE|Gen0b|The ultrasound will be administered to the brain region of interest.
223692807|NCT03548233|BIOLOGICAL|bcg vaccine|live attenuated vaccine
223692808|NCT02271373|BEHAVIORAL|increasing time spent outdoors|The intervention group undertook interventions by increasing time spent outdoors. The interventions composed of performing two additional recess program lasting 30 minutes outside the classroom that encouraged children to go outside for outdoor activities during recess in both the morning and afternoon during school days within a intervention period of 1 school year.
223777567|NCT03709537|BEHAVIORAL|Mental Health Peer Workforce Support|"Supervisors and peer workers will participate in trainings covering effective peer services, trauma-informed effective peer supervision, and responsibilities of peer workers in a supervising relationship. A monthly Supervisors of Peer Workers meeting will support site change efforts. Sites will create an implementation team to work within their site to implement the training received.~Peer Workers will enroll in a peer mentoring program, where they serve as peer mentors matched with fellow peer mentors. Recovery International and the Los Angeles Department of Mental Health will encourage peer workers to attend Recovery International meetings. Emotional Health Association will refer Peer Workers and their Supervisors in the intervention group to self-help support groups that reduce stress and increase resiliency."
223777568|NCT03735862|BIOLOGICAL|Hepatic derived surgical matrix|Hiatal hernia repair with MIROMESH
223777569|NCT04749290|OTHER|Study Formula|Study infant formula for term infants containing OPO and CPP
223777570|NCT01514318|DEVICE|Revelation Hip Stem (Revelation)|Subjects who received the Revelation Hip Stem prior to 2002 and still maintain the original device.
223777571|NCT01725568|DEVICE|BioMonitor|Implantable cardiac monitor
223777572|NCT00648531|DRUG|Balsalazide Disodium Capsules 750 mg|3x750mg, single dose fasting
223777573|NCT00648531|DRUG|Colazal® Capsules 750 mg|3x750mg, single dose fasting
223777574|NCT00298831|DRUG|Sugammadex|At least 15 minutes after the intubation dose or the last maintenance dose of rocuronium, an intravenous single bolus dose of 4.0 mg/kg Org 25969 was administered.
223777575|NCT00298831|DRUG|Rocuronium|Each participant received an intravenous single bolus dose of 0.6 mg/kg rocuronium. If further neuromuscular block was required after endotracheal intubation, maintenance dose(s) of 0.15 mg/kg rocuronium was/were administered.
223777576|NCT00462956|DRUG|Tykerb|lapatinib 1500mg daily
223777577|NCT04122443|DRUG|Acetaminophen|Acetaminophen 650mg
223777578|NCT04122443|DRUG|Oxycodone|Oxycodone 10mg
223777579|NCT03998007|DEVICE|IRIS System|A QEEG based pain biomarker that scales with the patient reported NRS
223777580|NCT03553628|OTHER|Chlorhexidine, Propolis and Clove Oil mouthwash|Chlorhexidine Gluconate 0.12% with Propolis 1% and Clove Oil 1% mouthwash
223777581|NCT03553628|OTHER|Chlorhexidine mouthwash|Chlorhexidine HCL 0.12% mouthwash
223777582|NCT01659424|RADIATION|High Dose Rate Endorectal Brachytherapy (HDR-ERBT)|Combining pre-operative FOLFOX chemotherapy with HDR-ERBT (Radiation therapy) followed by surgery then additional FOLFOX chemotherapy to decrease the risk of distant metastasis and to maintain excellent locoregional control with decreased morbidity.
223777583|NCT02333916|OTHER|overfeeding + exercise pre-training|
223777584|NCT02333916|BEHAVIORAL|fitness training|
223777585|NCT02333916|OTHER|overfeeding + exercise post-training|
223777586|NCT03427385|DRUG|Ropivacaine 0.5%|The volume of local anesthetic Ropivacaine 0.5% will be determined by the response (success or failure of block, 30 minutes after local anesthetic injection) of the previous patient in that group. Block success is defined as an absence of ice sensation in the knee within 30 min of ropivacaine administration accompanied by tolerance to tetanic electrical stimulation (TES) at 60 mA(milliamp) for 5 seconds.
223777587|NCT01257594|DRUG|erlotinib|"For patients with no cytoreductive surgery planned, patients will receive single-agent erlotinib at a starting dose of 2000 mg on days 1 of every 7 days. For patients with cytoreductive surgery planned, patients will receive single-agent erlotinib at a starting dose of 2000 mg day 1 of every 7 days (+/- 2 days). One pre-operative dose of 2000 mg erlotinib will be administered in an open-label, unblinded manner, administered in the hospital on call to the operating room."
223777588|NCT01257594|PROCEDURE|Cytoreductive Surgery|Standard procedure
223777589|NCT03632291|BIOLOGICAL|UB-221|UB-221 (75 mg/ml)
224263462|NCT03157115|DEVICE|Kinocardiography|"This device records the electric and mechanic function of the heart. With electrodes and adequate electronics, ECG is recorded. 6 degrees of freedom accelerometers are also included in the device to measure the micro accelerations of the body at the body surface when the device is placed on the skin. Using physics principles and adequate calibration, those accelerations allow us to calculate parameters such as kinetics energies related to cardiac contractility.~During a standard echocardiography appointment for a patient suffering from a cardiovascular condition with/without heart failure, the cardiologist will monitor the heart of the patient with the Kino device (examination lasting a few minutes with the patient lying down on a bed). Data will be matched between the control group and the experimental group."
224263463|NCT00143364|DRUG|varenicline (CP-526,555)|
223692809|NCT01387373|DRUG|oxaliplatin, capecitabine, trastuzumab|Oxaliplatin intrahepatic capecitabine + trastuzumab systemic
223692810|NCT01753804|OTHER|Observational study|There is no medication or device tested in this study. This is an obversational study on the progression of the disease.
223692811|NCT00586066|DRUG|Memantine|Week 0: 5 mg memantine or placebo once a day (q.d.) Week 1: 5 mg memantine or placebo twice a day (b.i.d.) Week 2-3: 5 mg memantine or placebo once in the morning (q.a.m.)/10 mg once in the evening (q.p.m.) Week 4-12: 10mg Memantine or placebo b.i.d.
223692812|NCT00586066|DRUG|Placebo|Inactive comparator. Placebo-matching memantine tablet.
223777590|NCT06019416|BEHAVIORAL|culturally tailored mindfulness-positive psychological intervention|"This 3-week culturally tailored mindfulness-positive psychological intervention instructs techniques to enhance positive emotions and meditation exercise lasting approximately 30 minutes. The culturally tailored mindfulness-positive psychological intervention consists of four modules: 1) noticing positive events, 2) amplifying positive events, 3) gratitude, and 4) mindfulness and meditation. This 3-dimensional software includes gamification features, including a virtual living room, Japanese garden, art gallery, and meditation garden.~A private office and/or space was utilized to implement the culturally tailored mindfulness-positive psychological intervention for older Korean Americans/immigrants, provided by the recruitment sites such as non-profit organization and church. The private room at the sites had a desktop (or laptop) computer, a virtual reality device (Oculus Quest 2), a chair, and a desk."
223777591|NCT01867034|OTHER|Drug Eluting Stent|Comparison of two stents to see which results in best outcome.
223777592|NCT01867034|OTHER|Bare Metal Stent|
223777593|NCT04534842|DRUG|SYNB1618|15-day dose-ramp regimen (4 dose levels) of orally administered SYNB1618
223777594|NCT04534842|DRUG|SYNB1934|15-day dose-ramp regimen (4 dose levels) of orally administered SYNB1934
223692813|NCT03324672|PROCEDURE|TRIGGER|only TRIGGER point will be included for the manual therapy
223777595|NCT06142916|OTHER|Vırtual Realıty Traınıng On Mental Health Lıteracy And Stıgma|Nurses in the intervention group will be taken to a suitable room on the ward and virtual reality glasses will be worn. Mental health literacy training prepared by researchers by scanning the literature will be given using virtual reality glasses. Educational content; definition of mental health, definition of mental illness, definition and importance of mental health literacy, the most common mental illnesses in hospitals, Schizophrenia, Depression, Bipolar Disorder, Anxiety Disorders, Obsessive Compulsive Disorder (OCD), Post-Traumatic Stress Disorder (PTSD), Substance Use Disorder , Suicide-Self-Harm, Mental Health Literacy and Stigma, and where to find resources to obtain information about mental health. Information about the diagnostic criteria, risk factors, treatment methods, and what to pay attention to for the diseases discussed will be given. Animations will be prepared for each topic. The training is planned to last 45 minutes.
223777596|NCT06142916|OTHER|Classical Education|Nurses in the control group will be given mental health literacy training using the classical method using brochures. Educational content; definition of mental health, definition of mental illness, definition and importance of mental health literacy, the most common mental illnesses in hospitals, Schizophrenia, Depression, Bipolar Disorder, Anxiety Disorders, Obsessive Compulsive Disorder (OCD), Post-Traumatic Stress Disorder (PTSD), Substance Use Disorder , Suicide-Self-Harm, Mental Health Literacy and Stigma, and where to find resources to obtain information about mental health. Information about the diagnostic criteria, risk factors, treatment methods, and what to pay attention to for the diseases discussed will be given. The training is planned to last 45 minutes.
224263464|NCT00746421|DRUG|Quetiapine XR|oral doses, 200 mg, 300 mg, 400 mg
224263465|NCT00746421|DRUG|Placebo|200mg, 300mg or 400mg
224263466|NCT00570635|DRUG|XL820|XL820 capsules administered orally as a single agent at a dose of 800 mg daily
224263467|NCT00570635|DRUG|XL820|XL820 capsules administered orally as a single agent at a dose of 300 mg twice daily
224263468|NCT00108043|PROCEDURE|FES-evoked functional upright gait|
224263469|NCT05327777|DRUG|Oxycodone|Investigators provided set opioid prescriptions for 10 pills each patient.
224263470|NCT05327777|BEHAVIORAL|Zero Opioid Protocol|Investigators provided no opioid prescriptions at discharge and instead provided information on non-narcotic pain control.
223692814|NCT03324672|PROCEDURE|TRIGGER+CURETAPE|TRIGGER point will be included for the manual therapy with kinesio-taping
223692815|NCT00227773|DRUG|octreotide acetate|
223692816|NCT00227773|DRUG|vatalanib|
223692817|NCT00227773|PROCEDURE|anti-cytokine therapy|
223692818|NCT00227773|PROCEDURE|antiangiogenesis therapy|
223692819|NCT00227773|PROCEDURE|biological therapy|
223692820|NCT00227773|PROCEDURE|endocrine therapy|
223692821|NCT00227773|PROCEDURE|enzyme inhibitor therapy|
223692822|NCT00227773|PROCEDURE|growth factor antagonist therapy|
224263471|NCT02055547|DRUG|MK-8521 35μg|Single dose 35μg subcutaneous (SC) injection in a treatment period (Part 3, Panel H)
223692823|NCT00227773|PROCEDURE|hormone therapy|
223692824|NCT00227773|PROCEDURE|protein tyrosine kinase inhibitor therapy|
223692825|NCT00227773|PROCEDURE|somatostatin analogue therapy|
224263472|NCT02055547|DRUG|MK-8521 100μg|Single dose 100μg SC injection in a treatment period (Part 1, Panel A) and (Part 2, Panel D)
224263473|NCT02055547|DRUG|MK-8521 125μg|Single dose 125μg SC injection in a treatment period (Part 2, Panel E) and (Part 3, Panel H)
224263474|NCT02055547|DRUG|MK-8521 150μg|Single dose 150μg SC injection in a treatment period (Part 1, Panel B)
224263475|NCT02055547|DRUG|MK-8521 175μg|Single dose 175μg SC injection in a treatment period (Part 1, Panel B)
224263476|NCT02055547|DRUG|MK-8521 200μg|Single dose MK-8521 200μg SC injection in a treatment period (Part 1, Panel B)
224263477|NCT02055547|DRUG|MK-8521 300μg|Single dose 300μg SC injection in a treatment period (Part 1, Panel A)
224263478|NCT02055547|DRUG|MK-8521 50/72μg|MK-8521 50μg SC injection Days 1-5 and 72μg Days 6-10 (Part 2, Panel C)
224263479|NCT02055547|DRUG|MK-8521 72/125μg|MK-8521 72μg SC injection Days 1-7 and 125μg Days 8-14 (Part 2, Panel F)
224263480|NCT02055547|DRUG|MK-8521 100/150μg|MK-8521 100μg SC injection Days 1-5 and 150μg Days 6-10 SC in a treatment period (Part 2, Panel D)
224263481|NCT02055547|DRUG|MK-8521 125/150μg|MK-8521 SC 125μg SC injection Days 1-5 and 150μg Days 6-10 (Part 2, Panel E)
224263482|NCT02055547|DRUG|Placebo|Placebo to MK-8521 SC injection in a treatment period (Parts 1, 2, and 3)
224263483|NCT01822119|DEVICE|Baha Attract System|
224263484|NCT06596889|PROCEDURE|Successful airway management|"* Types of equipment: Traditional oral airways, new airways, etc.~* Professional experience of the airway management practitioner (in years).~* If advanced, type of airway complication (bleeding, dental damage, mucosal damage, etc.), number of attempts~will be recorded separately for each patient."
223692826|NCT01267656|DEVICE|Lubricating and Rewetting Drops|Instill 1-2 rewetting drops in each eye at least QID (4 times per day) for one week.
223692827|NCT01267656|DEVICE|AMO Blink Contacts Lubricant Eye Drops|Instill 1-2 rewetting drops in each eye at least QID (4 times per day) for one week.
223692828|NCT02173184|BIOLOGICAL|Gynevac|1 IM injection of Gynevac per week, for 4 weeks (five injections in total). Vaccination can take place in no less than 7 days intervals (+3 days).
223692829|NCT02173184|BIOLOGICAL|Placebo|1 IM injection of Placebo per week, for 4 weeks (five injections in total). Vaccination can take place in no less than 7 days intervals (+3 days).
223692830|NCT03235843|DEVICE|AAIR pacing|Rate adaptive pacing using a MV sensor.
223692831|NCT03235843|DEVICE|DDI-pacing|Rate adaptive pacing OFF
223692832|NCT05659056|DRUG|Pyrotinib, trastuzumab, paclitaxel-albumin|pyrotinib: 400mg orally daily; trastuzumab: 8mg/kg iv load followed by 6mg/kg iv 3-weekly for a total of 6 cycles; paclitaxel-albumin: 260mg/m2, every 3 week, a total of 6 cycles
223692833|NCT04398992|OTHER|observation|Data were collected by a designed form. Statistic software was used to analyze clinical data.
223692834|NCT01982058|OTHER|communication intervention|
223692835|NCT01982058|OTHER|counseling intervention|
223692836|NCT01982058|OTHER|nutrition intervention|
223692837|NCT01982058|OTHER|questionnaire administration|
223692838|NCT00013234|PROCEDURE|Teledermatology|
223692839|NCT05794971|DRUG|Regorafenib and DIBIRI|"Drug: Regorafenib Regorafenib will be given 3 weeks on/1 week off (initial dose: 80 mg od po.)~Drug: Irinotecan it will be mixed in eluting-beads and injected in the tumor.~Procedure: TACE Transcatheter arterial chemoembolization（TACE）is a minimally invasive procedure performed to decrease the tumor's blood supply.~Device: drug eluting-bead The eluting-bead,loaded with irinotecan (DEBIRI) to treat patients with hepatic metastases from colorectal cancer."
223692840|NCT05794971|DRUG|Regorafenib|Drug: Regorafenib Regorafenib will be given 3 weeks on/1 week off (initial dose: 80 mg od po.)
223692841|NCT04208464|DRUG|Baricitinib|4mg daily for 24 weeks from baseline
223692842|NCT04208464|DRUG|Baricitinib|4mg daily for 24 weeks starting after a 12-week treatment delay from baseline
223692843|NCT04407481|DRUG|Aminohippurate Sodium Inj 20%|Diagnostic aid/agent used to measure effective renal plasma flow (ERPF)
223692844|NCT04407481|DRUG|Iohexol Inj 300 milligrams per milliliter (MG/ML)|Diagnostic aid/agent used to measure glomerular filtration rate (GFR)
223692845|NCT04407481|RADIATION|PET/CT Scan|Imaging used to visualize the kidneys and quantify renal metabolic activity
223692846|NCT00130676|DRUG|Mifepristone|daily for 7 days
223692847|NCT00130676|DRUG|matching placebo|daily for 7 days
223692848|NCT06102915|DRUG|Rocuronium Bromide 10 MG/ML|Comparative
223692849|NCT06102915|DRUG|Nimbex 10 MG in 5 ML Injection|Comparative
223692850|NCT02730520|OTHER|Retrospective analysis of patient files|The results of the allergen skin tests will be encoded as the edema diameter. The allergenicity score (mean of the skin reactivities for each allergen) will be compared between each age groups. The impact of tabagism, gender, BMI and residential area on the allergic reactivity will also be assessed in the overall population and within each age group.
223692851|NCT03657862|DEVICE|application of 38% silver diamine fluoride solution|SDF solution was painted onto the surface of the carious lesion of the tooth
223692852|NCT03657862|OTHER|application of a placebo (tonic water)|tonic water was painted onto the surface of the carious lesion of the tooth
223692853|NCT02314390|BEHAVIORAL|Group-Mindfulness-Based Cognitive Therapy|The intervention consists of 8 weekly sessions of MBCT. Each session will be administered in a group and will last 2 1/2 hours.
223692854|NCT02314390|BEHAVIORAL|Individual-Mindfulness-Based Cognitive Therapy|The intervention consists of 8 weekly sessions of MBCT. Each session will be administered individually and will last 45 to 60 minutes.
223692855|NCT00992329|DRUG|ciprofloxacin|ciprofloxacin 200mg tablet (single dose)
223692856|NCT00252629|OTHER|Nasal CPAP treatment during sleep|After documenting sleep disordered breathing, GWS subject gets randomized to receive either a therapeutic nasal CPAP or a sham nasal CPAP treatment during sleep, GWS symptoms ( fatigue, pain, and cognitive dysfunction) were assessed by a baseline questionnaires and at 3 week period whether on sham or therapeutic CPAP. The change of symptoms in each group will be compared.
223692857|NCT00972088|DEVICE|capsule endoscopy|The disposable, ingestible PillCam® SB2 Capsule acquires the video images during natural propulsion through the digestive system. The Capsule transmits the acquired images via digital radio frequency communication channel to the Given® Data Recorder unit located outside the body.
223692858|NCT02595996|DRUG|Propranolol|escalating doses of propranolol from 1mg/kg/day to 2mg/kg/day to 3mg/kg/day
223692859|NCT01505647|BIOLOGICAL|Zoster Vaccine, Live (AMP)|One approximately 0.65-mL injection subcutaneously on Day 1
223692860|NCT01505647|BIOLOGICAL|Zoster Vaccine, Live|One approximately 0.65-mL injection subcutaneously on Day 1
223692861|NCT05904990|DEVICE|traditional exercise therapy only|50-minute program included a 10-minute warm-up phase (treadmill walking at a comfortable speed), 30 minutes of stretching exercises for (glutei, paraspinal muscles, hamstring, pectoralis, scalenus, intercostal muscles, and trapezius), and a 10-minute cool-down involving self-stretching and respiratory exercises
223692862|NCT05904990|DEVICE|HILT alongside traditional exercise therapy|YAG laser device (HIRO 3.0; ASA Laser, Arcugnano, Italy). This equipment delivers pulsed laser light at a wavelength of 1,064 nm, with a very high peak power of 3 kW and energy density ranging from 360 to 1,780 mJ/cm2. It operates with short pulse durations between 120 and 150 μs, at low frequencies of 10 to 40 Hz, and has a duty cycle of about 0.1%.
223692863|NCT01389271|DRUG|Ventavis inhaled (Iloprost, BAYQ6256)|Since this study is an observational, inhaled iloprost dosage and frequency for each patient will be prescribed by physicians as medically required.
223692864|NCT06554821|DRUG|Rosuvastatin|Participants will receive rosuvastatin (dose 1 or dose 2) orally as a single dose on Day 1 in Period 1 and Day 6 in Period 2.
223692865|NCT06554821|DRUG|Ticagrelor|Participants in each arm will receive ticagrelor 90 mg orally BID from Day 6 to Day 10.
223777597|NCT02960984|OTHER|Task Oriented rehabilitation and aerobic training|Participants in the experimental group will receive 1 hour treatment comprising 30' of aerobic training and 30' of task-oriented training focused on uppper limb rehabilitation for 3 times a week for 20 sessions.
223777598|NCT00139126|BEHAVIORAL|Fire safety education|Education on smoke alarm maintenance based on behavioral theories
223692866|NCT04620707|DEVICE|RGS based training and monitoring|The RGS treatment will consist in a variable number of sessions per week of RGS-based training. Each session consists of cognitive and motor training involving reaching, grasping, placing virtual objects. The duration of the training period will be variable. Patients will use the RGS@Clinic from admission to discharge, and will have the RGS@Home during the first 3 months of the outpatient stage after recruitment. After this period of time, the patient will be evaluated by clinicians and the RGS@Home system will be collected. The RGS-Wear will be kept by the patient also during the follow-up period, up to 1 year post-recruitment.
223692867|NCT04620707|BEHAVIORAL|Therapy as usual|The patients will follow treatment as usual, including conventional rehabilitation and physical therapy when corresponding. The exact treatment that the patients will receive will depend on the local medical guidelines.
223692868|NCT01138943|DRUG|Synthodont|"15 ml, tree times/day for 07 days~Arm: Chlorhexidine alcohol-base mouthrinse"
223692869|NCT01138943|DRUG|Soludent|"15ml of 01% Chlorhexidine non alcohol-based, 3 times a day for 7 days~Arm: Experimental: non alcohol chlorhexidine mouthrinse"
223692870|NCT06458595|DRUG|KH658|KH658 Ophthalmic Injection
223777599|NCT01236404|DRUG|Single Subcutaneous Dose (Part A) of PB1023 or Placebo (0.9% NaCl)|
223777600|NCT01236404|DRUG|Multiple (Four Weekly) Subcutaneous Injections (Part B) of PB1023 or Placebo (0.9% NaCl)|Once weekly injections for up to four weeks
223777601|NCT01651572|DRUG|Cisatracurium|"Cisatracurium (Nimbex):~* initial dose: 0.2 mg/kg~* maintaining dose: 0.1 mg/kg (repeated anytime TOF-count reaches 2 twitches)"
223777602|NCT01651572|DRUG|Rocuronium|"Rocuronium (Esmeron):~* initial dose: 0.6 mg/kg~* maintaining dose: 0.15 mg/kg (repeated anytime TOF-count reaches 2 twitches)"
223777603|NCT05388890|DRUG|MLD|Modified Liujunzi Decoction is provided by the chinese pharmacy of Peking University First Hospital , one dose per day, taken in twice, and the course of treatment is 6 months.
223777604|NCT05388890|DRUG|WFC|Chinese patent medicine, take according to the instructions, the course of treatment is 6 months.
223777605|NCT01974050|BEHAVIORAL|Text message surveillance|
223777606|NCT04231435|DRUG|Fedratinib|Oral
223777607|NCT04231435|DRUG|Digoxin|Oral
223777608|NCT04231435|DRUG|Rosuvastatin|Oral
223777609|NCT04231435|DRUG|Metformin|Oral
223777610|NCT00691210|DRUG|Vorinostat|"Dose escalation scheme (400 mg)~Vorinostat is used to treat cutaneous T-cell lymphoma (CTCL, a type of cancer) in people whose disease has not improved, has gotten worse, or has come back after taking other medications. Vorinostat is in a class of medications called histone deacetylase (HDAC) inhibitors. It works by killing or stopping the growth of cancer cells."
223777611|NCT00691210|DRUG|Niacinamide|"Dose escalation scheme (20, 40, 60, 80, 100 mg/kg rounded to 100 mg)~Niacinamide is a water soluble B-vitamin that has been evaluated for use in the treatment of pellagra, bullous pemphigoid, and as a radiation sensitizer in head and neck cancer."
223777612|NCT00691210|DRUG|Etoposide|"Dose escalation scheme (0, 25, 50, 100 mg/m2)~Etoposide is an anti-cancer (antineoplastic or cytotoxic) chemotherapy drug. This medication is classified as a plant alkaloid and topoisomerase II inhibitor."
223777613|NCT01222585|DRUG|Metronidazole|Metronidazole will be administered intravenously to premature infants as a 15 mg/kg loading dose followed by maintenance doses of 7.5 mg/kg every 12 hours for infants with \>=14 postnatal days and every 24 hours for infants \<14 postnatal days.
223777614|NCT01384058|DRUG|ezetimibe|ezetimibe 10 mg per day for six weeks
223777615|NCT01384058|DRUG|simvastatin|Simvastatin 20 mg per day for six weeks
223777616|NCT01384058|DRUG|Ezetimibe 10/Simvastatin 20|Ezetimibe 10mg/Simvastatin 20mg per day for six weeks
223777617|NCT03435094|DRUG|Binosto 70Mg Effervescent Tablet|Assess the effect of alendronate 70mg effervescent tablet on bone turnover markers and patient reported outcomes.
223777618|NCT03435094|DRUG|Fosamax 70Mg Tablet|Assess the effect of alendronate 70mg tablet on bone turnover markers and patient reported outcomes.
223777619|NCT01886794|DRUG|Postmenopausal, topical vaginal estrogen cream|Topical vaginal estrogen cream is commonly but not universally used to improve the health of vaginal tissue prior to surgery. This study will provide data regarding estrogen effects for post-menopausal women undergoing pelvic organ prolapse.
223777620|NCT01886794|DRUG|Placebo Comparator: Postmenopausal, topical placebo cream|Postmenopausal participants randomized to topical vaginal placebo for about one month's use prior to scheduled surgery.
223777621|NCT01306617|DRUG|ABT-450|tablets
223777622|NCT01306617|DRUG|ABT-333|tablets
223777623|NCT01306617|DRUG|ribavirin|tablets
223777624|NCT01306617|DRUG|ritonavir|capsules
223777625|NCT01494311|DRUG|Lidocaine/tetracaine patch|The lidocaine/tetracaine patch topical anesthetic patch contains 70 mg each of lidocaine and tetracaine. The central area of each patch consists of a Controlled Heat Assisted Drug Delivery pod which is designed to warm the skin to 26-34°C, theoretically enhancing drug absorption and allowing application just 20 minutes before percutaneous procedures. A active or placebo patch was placed on each patient's wrist in the region of the maximum radial artery pulsation. After 20 minutes, the patch was removed.
223777626|NCT01494311|DRUG|Placebo Patch|A placebo patch was placed on each patient's wrist in the region of the maximum radial artery pulsation. After 20 minutes, the patch was removed.
223777627|NCT01494311|DRUG|Subcutaneous injection of 0.5 ml Lidocain 1%|After removing the patch, a blinded investigator injected 0.5 ml of 1% lidocaine solution. Three minutes after injection, an attempt was made to cannulate the radial artery with a 20-gauge catheter.
223777628|NCT01494311|DRUG|Subcutaneous injection of saline|After removing the patch, a blinded investigator injected 0.5 ml saline solution. Three minutes after injection, an attempt was made to cannulate the radial artery with a 20-gauge catheter.
223777629|NCT01130740|BEHAVIORAL|Osteoarthritis Intervention|Primary care providers receive patient-specific osteoarthritis information and treatment recommendations two times (0 and 6 months); patients receive a 12-month intervention consisting of monthly phone calls focusing on exercise, weight management, and cognitive behavioral pain management.
223777630|NCT04688281|DEVICE|Medicurtain®|Medicurtain® 5ml prefilled syringe
223777631|NCT04688281|DEVICE|GUARDIX-SG®|GUARDIX-SG® 5ml prefilled syringe
223777632|NCT03049163|DRUG|vitrectomy under topical anesthesia [Proparacaine HCL (Alcaine®)]|to observe the anesthesia effect of topical anesthesia of 27-gauge vitrectomy for vitreous floaters
223777633|NCT05506020|PROCEDURE|indocyanine green (ICG) fluorescence cholangiography|indocyanine green (ICG) fluorescence cholangiography during operation
223777634|NCT00999349|DRUG|Silymarin (LEGALON)|Study group: Silymarin Capsule, 140 mg, 3 times a day + desferrioxamine injection 50 mg/kg, Placebo group:Placebo capsules Similar to Silymarin +desferrioxamine injection 50 mg/kg
223777635|NCT00999349|DRUG|Placebo|
223777636|NCT02780349|DEVICE|WIRION|Embolic Protection System
223777637|NCT00363987|DRUG|Ketosteril®|1 tablet Ketosteril/5kgBW/d
223777638|NCT00363987|OTHER|diabetic diet|Energy 30-35 Kcal/kg BW/d + protein 0.8 g/kg BW/d
223777639|NCT05063097|OTHER|urine test|The following illicit drugs will be evaluated for all consecutive patients by urine drug assay (NarcoCheck®, Kappa City Biotech SAS, Montluçon, France) within two hours of admission to the ICCU: i) cannabinoids (tetrahydrocannabinol \[THC\]), including cannabis and hashish; ii) cocaine and metabolites, including cocaine and crack; iii) amphetamines; iv) MDMA; and v) heroin and other opioids. In addition to the analysis of psychoactive drug use, the investigators will also use the NarcoCheck® urine drug assay to evaluate the associated use of the following psychostimulant drugs: barbiturates, benzodiazepines, tricyclic antidepressant drugs, methadone and buprenorphine.
223692871|NCT03534518|OTHER|BWS overground training|BWS will be provided with the goal to impose the maximal lower extremity weight bearing load without excessive knee flexion during stance phase and/ or toe dragging during the swing phase. The walking tasks will be roughly divided into different domains like skilled walking, balance, dual tasking, walking speed, walking endurance.
223692872|NCT03534518|OTHER|BWS treadmill training|Training will be conducted on a standard treadmill with an overhead BWS system that can provide active BWS. Participants are allowed to hold the rails but weight bearing is not allowed. BWS will be provided with the goal to impose the maximal lower extremity weight bearing load without excessive knee flexion during stance phase and/ or toe dragging during the swing phase. Main walking tasks will be endurance (walking long distances at preferred speed) and speed (walking at maximal possible speed).
223692873|NCT03911128|OTHER|Observational|Observational study - no intervention
223692874|NCT06965946|PROCEDURE|Intermittent Hypoxia-Hyperoxia Therapy (IHHT)|Participants receive 4 cycles per session of 5 minutes of hypoxia (13-15% O₂) followed by 2 minutes of hyperoxia (40% O₂) using a hypoxia generator (Olive OLV 10H). Sessions are delivered before each conventional physical therapy session, 3 times per week for 4 weeks (total 12 sessions). Participants are monitored for heart rate, blood pressure, and oxygen saturation throughout the intervention.
223692875|NCT06965946|PROCEDURE|Conventional Physical Therapy|Participants receive individualized conventional physical therapy for knee osteoarthritis based on current clinical practices in tertiary hospitals of Peshawar. Therapy is delivered 3 times per week for 4 weeks (total 12 sessions) and includes strength training, mobility exercises, and patient education.
223777640|NCT05063097|OTHER|Fagerström questionnaire|Tobacco consumption will also be evaluated for each patient using a Fagerström questionnaire.
223777641|NCT05063097|OTHER|Exhaled carbon monoxide (CO) measurement|Active smoking will also be systematically investigated in all patients using a standardized exhaled carbon monoxide (CO) measurement with a CO-Check Pro device (Bedfont Scientific Ltd, Kent, UK) on arrival, with a measure of \> 3 parts per million (ppm) signifying active smoking.
223777642|NCT01639079|BEHAVIORAL|Internet Smoking Cessation Web Site|Internet Stop Smoking site (TC5) with several intervention elements from which the participants may choose as many as they wish. The links (URLs) to register for the study are: English: www.stopsmoking.ucsf.edu Spanish: https://www.stopsmoking.ucsf.edu/es/intro/home.aspx
223777643|NCT01567189|BEHAVIORAL|Cardiac rehabilitation|"* Training sessions: 8 weeks of supervised physical training sessions. Stress intensity will be calculated from the peak heart rate reached during stress test: 60-70% during the first month and 70-85% during the second one. Patients will be advised to do at least 1 hour of outdoor exercise with the same intensity on the days when they do not attend hospital.~* Health education sessions and relaxation sessions: one per week.~* Smoking and diet checking: as recommended by doctor."
223777644|NCT01567189|BEHAVIORAL|Cardiac rehabilitation|The only difference in the hospital's program is that training sessions will be out of hospital with the same target heart rate that in this case will be controlled with pulsometer or Borg scale. The recommended frequency of sessions will be: at least 5 days a week with a minimum of 1 hour / day.
223777645|NCT03077165|DRUG|S42909 100 mg|50 mg Film-coated tablets per os administration, twice a day taken at the end of the morning and at evening meals.
223777646|NCT03077165|DRUG|S42909 200 mg|50 mg Film-coated tablets per os administration, twice a day taken at the end of the morning and at evening meals.
223692876|NCT06965946|PROCEDURE|Normoxic Air Placebo|Participants in the control group inhale normoxic air (19.8% O₂) using the same Olive OLV 10H hypoxia generator to maintain blinding. Each session consists of 4 cycles of 5 minutes of normoxia followed by 2 minutes of normoxia, simulating the timing of hypoxia-hyperoxia therapy. Sessions are administered prior to conventional physical therapy, 3 times per week for 4 weeks (total 12 sessions). Patients are monitored for vital signs throughout.
223692877|NCT05393401|DEVICE|VOP1k|Photoplethysmographic records
223692878|NCT05706779|DRUG|Encorafenib Oral Capsule + Cetuximab|Encorafenib: 4 capsules 75 mg/day (300 mg) , 7 days/7 during 6 weeks Cetuximab: 500mg/m2 intravenous route every 2 weeks (D1, D14, D28), for 3 cycles over 4 weeks.
223692879|NCT01055873|BIOLOGICAL|A single blood sample (30 mL)|A single blood sample (30 mL) was drawn during a hospital visit for clinical follow-up. Immunological assays were performed on fresh blood. Cells and plasma were stored and kept frozen for additional biological evaluations
223692880|NCT00177476|BEHAVIORAL|behavioral weight loss|
223692881|NCT00768937|DRUG|Sorafenib|All patients will receive Sorafenib (800 mg/day) p.o. beginning two weeks before the first TACE and every day thereafter until patient death or premature withdrawal from study.
223692882|NCT00768937|PROCEDURE|Transarterial chemoembolisation (TACE)|TACE will be carried out with doxorubicin (75 - 50 - 25 mg/m2, depending on serum bilirubin levels ≤ 1.5, 1.5 - 3, 3 - 5 mg/dL) : lipiodol (1:1) in a total volume of 20 mL; after administration of doxorubicin:lipiodol, additional embolisation will be carried out with bead block-endospheres. TACE will be repeated every 4 weeks for 3 cycles; additional cycles will be offered if clinically indicated (but no PEI or RF-ablation should be carried out after inclusion into the study)
223692883|NCT02750943|DRUG|Stannous Fluoride|Dentifrice containing 0.454% w/w stannous fluoride
223692884|NCT02750943|DRUG|Sodium Monofluorophosphate|Dentifrice containing 1000ppm fluoride as sodium monofluorophosphate
223692885|NCT01012076|BEHAVIORAL|Active Control vs Experimental Treatment|The parent education program involves 12 in-home training sessions (90 minutes each), is administered by trained graduate and postdoctoral students in developmental psychology or a related field, and follows a standardized treatment manual (Siller, 2005). The active control involves three 90 minute in-home training sessions. These training sessions will be administered by trained graduate students or a postdoctoral student in a developmental psychology or related field. The active control will follow a standardized treatment manual (Kasari, 2008). This treatment manual was based upon the teacher training workshops created by the Center on the Social and Emotional Foundations for Early Learning.
223692886|NCT00171054|DRUG|Valsartan 320 mg|Patients received 160 mg valsartan for 4 weeks. Patients were then up-titrated to receive either 320 mg valsartan for the following 8 weeks.
223692887|NCT00171054|DRUG|Amlodipine 10 mg|Patients received 5 mg amlodipine for four weeks. Patients were then up-titrated to receive 10 mg amlodipine for the following 8 weeks.
223692888|NCT00171054|DRUG|Hydrochlorothiazide|At Week 12, patients who did not meet target Blood Pressure for both Systolic Blood Pressure \< 140 mmHg and Diastolic Blood Pressure \< 90 mmHg were eligible to receive 12.5 mg open-label Hydrochlorothiazide for the following 26 weeks.
223692889|NCT03176875|OTHER|ALICALM (75% of daily caloric requirements)|PEN group will receive 75% of their daily dietary needs from a polymeric formula (Alicalm, Nutricia) and 25% of daily dietary needs (1 meal per day) from an antiinflammatory diet for CD (AID-CD) for 6 weeks.
223692890|NCT03176875|OTHER|ALICALM (100% of daily caloric requirements)|EEN group will receive 100% of their daily dietary needs from a polymeric formula (Alicalm, Nutricia) for 6 weeks.
223692891|NCT06971263|BEHAVIORAL|Consultation on both nutrition, and palliative care|The intervention on the nutrition and palliative care components will include open-ended consultations based on ESPEN practical guidelines on nutrition in cancer patients with one cancer center dietitian and one palliative care physician to discuss patient needs and required to improve their health consequences.
223692892|NCT06971263|BEHAVIORAL|Counselling on nutrition and healthy diet|The intervention on the nutrition and healthy diet components will include open-ended consultations based on ESPEN practical guidelines on nutrition in cancer patients with one cancer center dietitian to discuss patient dietary needs for improving their health consequences.
223692893|NCT05548010|OTHER|No intervention as this is an observational study|No intervention
223692894|NCT06297616|DRUG|LY3841136|Administered SC
223692895|NCT06297616|DRUG|LY3841136-Placebo|Administered SC
223692896|NCT06297616|DRUG|Tirzepatide|Administered SC
223692897|NCT06297616|DRUG|Tirzepatide-Placebo|Administered SC
223692898|NCT06522997|DRUG|BAY3283142|Tablet, intake orally once daily
223692899|NCT06522997|DRUG|Placebo|Matching with BAY3283142
223692900|NCT04799054|DRUG|TransCon TLR7/8 Agonist|TransCon TLR7/8 Agonist will be administered as an IT injection
223777647|NCT03077165|DRUG|S42909 400 mg|200 mg Film-coated tablets per os administration, twice a day taken at the end of the morning and at evening meals.
223692901|NCT04799054|DRUG|Pembrolizumab|Pembrolizumab will be administered IV
223692902|NCT03763318|BIOLOGICAL|EQ001|Itolizumab \[Bmab 600\])
223692903|NCT03763318|BIOLOGICAL|EQ001 Placebo|EQ001 Placebo
223692904|NCT04295486|DRUG|Aspirin|Non-enteric coated 81 mg Aspirin tablet.
223692905|NCT04025671|DEVICE|Nasal Spray Naloxone|Nasal spray naloxone device.
223692906|NCT04025671|DEVICE|Intramuscular Naloxone|A vial of simulated naloxone and syringe with attached needle.
223692907|NCT04025671|DEVICE|Improvised Nasal Atomizer|A naloxone bristoject dose and nasal atomizer device.
223692908|NCT03635788|DRUG|Standard of Care (SOC) Oral ART|SOC oral ART regimen must include at least 3 drugs with 2 or more drugs predicted to be fully active, including a boosted protease inhibitor (PI) and/or an integrase strand transfer inhibitor (INSTI)
223692909|NCT03635788|DRUG|Oral RPV|RPV 25 mg tablets
223692910|NCT03635788|DRUG|Oral CAB|CAB 30 mg tablets
223692911|NCT03635788|DRUG|RPV-LA Loading Dose|900 mg administered as one 3 mL (900 mg) intramuscular injection in the gluteal muscle
223692912|NCT03635788|DRUG|CAB-LA Loading Dose|600 mg administered as one 3 mL (600 mg) intramuscular injection in the gluteal muscle
223692913|NCT03635788|DRUG|RPV-LA Maintenance Dose|600 mg administered as one 2 mL (600 mg) intramuscular injection in the gluteal muscle
223692914|NCT03635788|DRUG|CAB-LA Maintenance Dose|400 mg administered as one 2 mL (400 mg) intramuscular injection in the gluteal muscle
223692915|NCT04669535|BIOLOGICAL|AXO-AAV-GM2 Starting Dose|1:1 ratio of AAVrh8-HEXA and AAVrh8-HEXB, administered via bilateral thalamic (BiTh) and dual intracisterna magna (ICM)/intrathecal (IT) administration into the cerebrospinal fluid (CSF).
223692916|NCT04669535|BIOLOGICAL|AXO-AAV-GM2 Low Dose|1:1 ratio of AAVrh8-HEXA and AAVrh8-HEXB, administered via bilateral thalamic (BiTh) and dual intracisterna magna (ICM)/intrathecal (IT) administration into the cerebrospinal fluid (CSF).
223692917|NCT04669535|BIOLOGICAL|AXO-AAV-GM2 Middle Dose|1:1 ratio of AAVrh8-HEXA and AAVrh8-HEXB, administered via bilateral thalamic (BiTh) and dual intracisterna magna (ICM)/intrathecal (IT) administration into the cerebrospinal fluid (CSF).
223692918|NCT04669535|BIOLOGICAL|AXO-AAV-GM2 High Dose|1:1 ratio of AAVrh8-HEXA and AAVrh8-HEXB, administered via bilateral thalamic (BiTh) and dual intracisterna magna (ICM)/intrathecal (IT) administration into the cerebrospinal fluid (CSF).
223777648|NCT03077165|DRUG|S42909 800 mg|200 mg Film-coated tablets per os administration,twice a day taken at the end of the morning and at evening meals.
223777649|NCT03077165|DRUG|S42909 1200 mg|200 mg Film-coated tablets per os administration, twice a day taken at the end of the morning and at evening meals.
223777650|NCT03077165|DRUG|Placebo Oral Tablet|Matching placebo tablets, per os administration, twice a day taken at the end of the morning and at evening meals.
223777651|NCT04028388|DRUG|Docetaxel in Parenteral Dosage Form|Treatment with IV docetaxel at 75 mg/m2 given as a one-hour infusion on day 1 every 21 days plus 5 mg oral prednisone twice daily
223777652|NCT04028388|DRUG|ModraDoc006/r|Treatment with twice daily once weekly (BIDW) ModraDoc006 (oral docetaxel) 10mg tablets in combination with ritonavir 100mg tablets
223777653|NCT01435668|BEHAVIORAL|Brief Motivational Intervention (BMI)|Patients receive an information leaflet plus a referral to a psychologiste. BMI is provided by the psychologist. BMI consists in a first face-to-face interview (35-45 minutes) plus a telephone interview, at 1 and 2 months. Minors' parents are also invited to attend the BMI session.
223692919|NCT06976450|OTHER|ChemoNurs Mobile Application Group|Participants in the mobile app group were oncology nurses employed at Hacettepe University Oncology Hospital who were provided access to CHEMONURS, a mobile chemotherapy drug guide application developed to support clinical decision-making and professional development. After completing a demographic form and baseline assessments using the Chemotherapy Practice Knowledge Scale and the Attitude Scale for Chemotherapy Practices, participants received a demo version of the app via a WhatsApp link. They were instructed to download the application onto their personal smartphones and use it freely over a six-month period during their routine clinical practice. No restrictions were placed on usage frequency to reflect real-world applicability; usage was monitored through embedded app analytics and nurse feedback. Daily reminders and follow-up communications were used to encourage continued engagement. Follow-up assessments of knowledge and attitudes were conducted at the 3rd and 6th months. U
223692920|NCT06976450|DEVICE|Personal Smartphone|Used by participants to access and interact with the CHEMONURS mobile application during the study period.
223692921|NCT06805032|OTHER|Observation of EMG and AMG readings|Simultaneous readings from electromyograph and acceleromyograph
223692922|NCT02004574|DRUG|Calcipotriol/betamethasone dipropionate gel|"All enrolled subjects will receive Xamiol® gel once daily for 8 weeks during the induction period and then will be assessed according to IGA at the end of 8-week induction period. Those subjects determined to be Responder by IGA will be randomized to one of the following three treatment groups and they will continue their therapy with randomized maintenance regimens for the duration of additional 8 weeks."
223692923|NCT01548586|DEVICE|Eldith DC stimulator ( Magstim Company Ltd. UK)|Anodal tDCS: Intensity of 2 mA , during 10 min Cathodal tDCS: Intensity of 2 mA , during 10 min Placebo type tDCS: Intensity of 0 mA during 10 min
223692924|NCT05450575|DRUG|Amosartan Q tablet|Amlodipine, Losartan, Rosuvastatin
223692925|NCT01213784|OTHER|all antidiabetic drugs will be appliable|We expect all participants to be set on insulin during the intervention, however all types of insulin and other antidiabetics can be used goal: Hba1c lower than 7,5%
223692926|NCT05776316|BEHAVIORAL|Integrated Harm Reduction Intervention (IHRI)|8-week program targeting areas rooted in the 8 principles of harm reduction. Includes weekly education lessons and informed referrals to social service organizations.
223692927|NCT00056589|DRUG|catridecacog|Single doses of rFXIII administered intravenously (IV) to two subjects in each of the five dose levels (2, 6, 20, 50 and 75 U/kg).
223692928|NCT02354157|OTHER|no intervention|no intervention
223692929|NCT04267757|PROCEDURE|rectovaginal fistula repair with Martius flap|rectovaginal fistula repair with Martius flap
223692930|NCT04382755|DRUG|Zilucoplan®|14 days of SC Zilucoplan® on top of standard of care + prophylactic antibiotics until 14 days after last Zilucoplan®
223692931|NCT04382755|DRUG|Placebo|standard of care treatment + 1 week of prophylactic antibiotics (or until hospital discharge, whichever comes first)
223692932|NCT03004144|OTHER|FLOAT|
223692933|NCT02624414|DEVICE|PillCam® COLON 2 Capsule Endoscopy|
223777654|NCT01435668|BEHAVIORAL|Simple written advice|Patients receive an information leaflet.
223777655|NCT05889858|OTHER|Data collection|Data collection
223777656|NCT01406691|DEVICE|Flashes|one hour of a sequence of light flashes (4000 lux, 3 msec, every 30 seconds); occurs during the hour immediately prior to desired waketime
223777657|NCT02747069|DEVICE|NICU electronic stethoscope|Assessment of heart rate using the electronic stethoscope for up to 10 minutes compared to ECG and pulse oximetry devices used to monitor neonates whilst on NICU
223777658|NCT02747069|DEVICE|Newborns <32 weeks and ECG|The three leads from the ECG device will be pre placed onto a plastic bag prior to delivery. The pre term infant (\<32 weeks) placed into the bag at the time of delivery and heart rate will be assessed for up to 30 minutes
223692934|NCT05114668|DRUG|EVT801|"Stage 1: Patients will be dosed orally with EVT801 capsules at the dose and schedule to which they are assigned.~Stage 2: Patients will be dosed orally with EVT801 capsules at the MTD / RP2D identified in Stage 1 of the study."
223692935|NCT06378125|DRUG|controlled-ileal-release nicotinic acid (SAD/ MAD/MD) single- and multiple-ascending dose (SAD/MAD) or multiple dose (MD)|A double-blind, randomised, placebo-controlled, single-ascending and multiple-ascending dose trial to evaluate the safety and pharmacokinetics of oral controlled-ileal-release nicotinic acid (CIR-NA) compared to immediate-release nicotinic acid and placebo in healthy subjects and subjects with prediabetes.
223692936|NCT06378125|DRUG|immediate-release nicotinic acid (SAD)|A double-blind, randomised, placebo-controlled, single-ascending and multiple-ascending dose trial to evaluate the safety and pharmacokinetics of oral controlled-ileal-release nicotinic acid (CIR-NA) compared to immediate-release nicotinic acid and placebo in healthy subjects and subjects with prediabetes.
223692937|NCT06378125|DRUG|Placebo controlled-ileal-release nicotinic acid (SAD/MAD)|A double-blind, randomised, placebo-controlled, single-ascending and multiple-ascending dose trial to evaluate the safety and pharmacokinetics of oral controlled-ileal-release nicotinic acid (CIR-NA) compared to immediate-release nicotinic acid and placebo in healthy subjects and subjects with prediabetes.
223692938|NCT06378125|DRUG|Placebo immediate-release nicotinic acid (SAD)|A double-blind, randomised, placebo-controlled, single-ascending and multiple-ascending dose trial to evaluate the safety and pharmacokinetics of oral controlled-ileal-release nicotinic acid (CIR-NA) compared to immediate-release nicotinic acid and placebo in healthy subjects and subjects with prediabetes.
223692939|NCT06016348|PROCEDURE|Endovascular treatment|This procedure is instrumental in restoring cerebral blood flow by addressing the clot-induced obstruction within brain-supplying blood vessels.
223692940|NCT04777357|DRUG|Cariprazine|Oral Capsule
223692941|NCT04777357|DRUG|Placebo|Oral Capsule
223692942|NCT03107533|OTHER|Video recording of clinical visit|For patients and parents that are considering scoliosis surgery, a video recording of the encounter will be obtained during their routine clinical visit to discuss surgery/options.
223692943|NCT05000138|DIAGNOSTIC_TEST|FDG PET/CT|Patients with suspected giant cell arteritis, of which FDG PET/CT is indicated for diagnosis of large vessel involvement, will have the small cranial arteries analyzed for involvement.
223692944|NCT04548154|OTHER|Proximal Resistance Training|Participants will be prescribed 5 categories of resistance exercises, and each category will have a series of exercises to select from. Two will target hip abduction, two will target trunk muscles, and one will target functional resistance training for the hip and trunk during walking-related tasks such as multi-directional resisted walking. Dosing will be based on guidelines for MS. Strengthening exercises will begin with 3 sets of 12-15 reps at 15 rep-max load (RM) and progress to 3 sets of 8-10 reps at 10-12 RM. Endurance exercises requiring a static hold will progress from 3 sets of 15-20 second holds to 30-second holds. Functional resistance will be dosed to improve muscular endurance: 3 sets of 15-20 reps based on form fatigue.
223692945|NCT05674708|OTHER|Fat intake|Four different sources of dietary fat
223777659|NCT03735394|DIAGNOSTIC_TEST|ultrasonic probe|apply the head of the ultrasonic probe on the keratinized tissue of the most protruded upper and lower central incisor in order to measure tissue thickness.
223777660|NCT02629406|OTHER|Hypoxia|Intermittent hypoxia which consist of five hypoxic periods (13% O2 inspired fraction of oxygen) each lasting 6 min, with five normoxic intervals of same duration
223777661|NCT03766321|BIOLOGICAL|Fecal microbiota transplantation|Fecal microbiota transplantation will be performed during two endoscopic procedures (baseline and at 6 months) by allogenic infusion of collected feces in the duodenum-jejunum.
223777662|NCT03766321|BIOLOGICAL|Placebo|patients will undergo endoscopic procedure with biopsy during sedation but without any kind of intervention
223777663|NCT00132444|DRUG|topical vaginal application of UC-781 gel|UC-781 gel (arms 1 and 2) or placebo (arm 3) applied vaginally twice daily for 14 days
224263485|NCT05510141|OTHER|Virtual reality gaming|Instead of nitrous oxide, which is the standard procedure, virtual reality gaming is applied to reach pain reduction in minor surgery procedures
224263486|NCT05510141|DRUG|Nitrous oxide|Standard procedure
224263487|NCT02294305|DRUG|Vortioxetine|
224263488|NCT02294305|DRUG|Placebo|
224263489|NCT04386577|DIETARY_SUPPLEMENT|Vitamin D3 (cholecalciferol)|Eligible participants were assigned by chance to one of four groups: (1) daily vitamin D3 and omega-3; (2) daily vitamin D3 and omega-3 placebo; (3) daily vitamin D placebo and omega-3; or (4) daily vitamin D placebo and omega-3 placebo. At baseline, year 2 and year 4 of the trial, a subcohort of 1,054 VITAL participants living within driving distance of Boston, Massachusetts received detailed in-clinic health assessments at the Clinical and Translational Science Center (CTSC) of Brigham and Women's Hospital. During CTSC visits, participants have a clinical exam, including measurement of height, weight, other anthropometrics, blood pressure, and physical performance. They also provide fasting blood and urine samples, and undergo 2-hour oral glucose tolerance testing, lung function testing (spirometry), electrocardiograms, bone mineral density testing, 2D-echocardiography, and assessments of thinking and mood.
224263490|NCT04386577|DRUG|fish oil|Eligible participants were assigned by chance to one of four groups: (1) daily vitamin D3 and omega-3; (2) daily vitamin D3 and omega-3 placebo; (3) daily vitamin D placebo and omega-3; or (4) daily vitamin D placebo and omega-3 placebo. At baseline, year 2 and year 4 of the trial, a subcohort of 1,054 VITAL participants living within driving distance of Boston, Massachusetts received detailed in-clinic health assessments at the Clinical and Translational Science Center (CTSC) of Brigham and Women's Hospital. During CTSC visits, participants have a clinical exam, including measurement of height, weight, other anthropometrics, blood pressure, and physical performance. They also provide fasting blood and urine samples, and undergo 2-hour oral glucose tolerance testing, lung function testing (spirometry), electrocardiograms, bone mineral density testing, 2D-echocardiography, and assessments of thinking and mood.
224263491|NCT02184715|OTHER|virtual reality system|The participants were randomly assigned to either Group A or Group B. Group A received rehabilitation treatment and additional virtual reality system for 1 month, followed by rehabilitation treatment for 1 month; by contrast, the participants in Group B received rehabilitation treatment for 1 month, followed by rehabilitation treatment and additional virtual reality system for 1 month.
224263492|NCT00932477|DRUG|Formulation 1: Carboxymethylcellulose Sodium, Glycerin and Polysorbate 80, based artificial tear|1 to 2 drops into each eye three times per day
223777664|NCT01994395|DEVICE|The Stride Management Assist (SMA) System|Participants will participate in 18 sessions of outpatient physical therapy + 3 sessions of testing for up to 8 weeks. Assessment (strength, flexibility, balance, sensation, endurance, transfers, gait. Treatment consists of 30 minutes high intensity gait training with device, 15 minutes functional mobility with device.
223777665|NCT01994395|OTHER|Impairment based therapy|Participants participate in 18 weeks of outpatient physical therapy + 3 assessment sessions. Assessment (strength, flexibility, balance, sensation, endurance, transfers, gait). Treatment will be divided into: 15 min balance training, 15 minutes functional mobility (transfers, strength or flexibility training) and 15 min high intensity gait training
223777666|NCT04948944|DEVICE|transcranial direct current stimulation|the tDCS stimulator delivers very low (2mAmp) current with surface electrodes to the skull
223692946|NCT04140097|OTHER|Prospective monitoring of a large variety of parameters|Patients will be recruited during an inpatient pulmonary rehabilitation program. This setting offers a unique opportunity to study the phenomenon of an acute exacerbation of the Chronic Obstructive Pulmonary Disease prior to the first visible clinical sign and further on to have a follow up of the underlying mechanisms. All COPD patients that are referred to the reference center for a rehabilitation program will be included after providing written informed consent. Prospectively, a wide range of measurements will be collected. If a patient develops an acute exacerbation there will be a comprehensive diagnostic assessment to differentiate between pulmonary, cardiac or cardio-pulmonary reasons for the exacerbation. The clinical diagnosis of an AECOPD will be made by a pulmonologist according to criteria of international guidelines within the first 24h of clinical symptoms suggestive of an exacerbation.
223692947|NCT03811002|RADIATION|3-Dimensional Conformal Radiation Therapy|Undergo 3D-CRT
223692948|NCT03811002|DRUG|Atezolizumab|Given IV
223692949|NCT03811002|PROCEDURE|Biospecimen Collection|Correlative studies
223692950|NCT03811002|DRUG|Carboplatin|Given IV
223692951|NCT03811002|DRUG|Cisplatin|Given IV
223692952|NCT03811002|DRUG|Etoposide|Given IV
223777667|NCT02939105|DEVICE|The ZELTIQ CoolSculpting System|The CoolSculpting device will be used to perform treatments.
223777668|NCT01626976|DRUG|PF-06282999|Solution, doses range from 20 to 200 mg, single dose
223692953|NCT03811002|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
223777669|NCT01626976|DRUG|Placebo|Solution, single dose
223777670|NCT01626976|DRUG|PF-06282999|Methylcellulose suspension, doses range 125 to 500 mg, single dose
223692954|NCT03811002|OTHER|Quality-of-Life Assessment|Ancillary studies
223692955|NCT03811002|OTHER|Questionnaire Administration|Ancillary studies
223692956|NCT04701684|DEVICE|Direct to Angio Suite (DTAS) Philips' CBCT triage|Stroke patients are diagnosed and treated (mechanical thrombectomy) in the same angio suite
223692957|NCT04701684|PROCEDURE|Conventional CT/MR triage|First a CT or MRI exam is acquired for triage. In case of an ischemic stroke the patient is then treated in an interventional suite.
223692958|NCT06407427|DEVICE|App for in-bed conditioning exercises|Participants will use an application (app) in facilitating in-bed conditioning exercises for hospitalized patients
223692959|NCT06407427|OTHER|Usual care|All participants will receive usual care in the post-operative setting.
223692960|NCT04191187|DRUG|Fludarabine|Fludarabine 30mg/m\^2/day will be administered over 30-60 minutes intravenous infusion on Days -6 through -2 for a total dose of 150 mg/m\^2
223692961|NCT04191187|DRUG|Melphalan|Melphalan 70 mg/m\^2 over 45 minutes will be administered Day -6. Melphalan dose will be calculated based on Actual Body Weight.
223692962|NCT04191187|RADIATION|Total Body Irradiation|Total Body Irradiation (TBI) will be delivered at a dose of 200 centigray units (cGy)
223692963|NCT06197685|BEHAVIORAL|The Kessler Foundation modified Story Memory Technique® (KF-mSMT®)|KF-mSMT is a memory retraining technique that consists of two-related skills: (1) imagery and (2) context/organization. The proposed KF-mSMT intervention includes 10 total sessions with 2 sessions per week for 5 weeks. Each session will last 45-60 minutes.
223692964|NCT06197685|BEHAVIORAL|Aerobic Exercise Training (AET) plus Virtual Reality (IDEAL)|The AET condition includes 12 weeks of supervised, progressive, moderate intensity cycle ergometry. The AET will include semi-immersive, interactive VR such the cycling speed on the bike will translate directly to perceived speed through the virtual environment.
223692965|NCT06197685|BEHAVIORAL|Stretching and Toning (S/T)|The S/T condition will include 12 weeks of supervised S/T activities that target the head/neck. shoulder, elbow/forearm, hand/wrist, trunk/hip, ankle/foot.
223692966|NCT01040078|BIOLOGICAL|7.5ug H1N1 Influenza vaccine|0.25 mL intramuscular injection into the deltoid region of the arm on Day 0 and day 21
223692967|NCT01040078|BIOLOGICAL|15ug H1N1 vaccine|0.5 mL intramuscular injection into the deltoid region of the arm on Day 0 and day 21
223692968|NCT01040078|BIOLOGICAL|seasonal influenza vaccine|0.5 mL intramuscular injection into the deltoid region of the arm on Day 0 and day 21
223692969|NCT01327911|BIOLOGICAL|NT-501 implant|Ciliary neurotrophic factor (CNTF) implant
223692970|NCT06417073|BEHAVIORAL|Face-To-Face Task-orianted Training|In this study, face-to-face task-oriented station training is provided by trained occupational therapists to elderly nursing home residents. Each session involves structured activities that simulate real-world challenges designed to improve cognitive and hand functions. These include exercises to enhance fine motor skills, hand strength, coordination, and cognitive tasks such as problem-solving and memory exercises.
223692971|NCT06417073|BEHAVIORAL|Tele-Rehabilitation Task-orianted Training|This intervention utilizes video-conferencing technology to deliver task-oriented training to elderly nursing home residents, focusing on cognitive and hand function improvements.
223692972|NCT06417073|BEHAVIORAL|Home-based Task-orianted Training|"Home-Based Task-Oriented Training Intervention Description:~This home-based intervention involves a series of task-oriented activities specifically designed to improve cognitive and hand functions for elderly residents in nursing homes. Participants carry out prescribed activities independently, based on detailed guides provided by occupational therapists. The activities are tailored to stimulate cognitive processes and enhance fine motor skills, including tasks like sorting, assembling, and manipulative exercises that replicate daily challenges. Each participant follows a structured program of daily 45-minute sessions for two weeks, with periodic remote check-ins by therapists to assess progress and adjust the difficulty of tasks as needed. This format allows participants to engage in rehabilitation at their own pace, within the comfort of their own living spaces, fostering greater autonomy and adherence to the intervention."
223692973|NCT00305825|BIOLOGICAL|bevacizumab|
223692974|NCT00305825|DRUG|letrozole|
223692975|NCT01352351|BEHAVIORAL|Breastfeeding promotion intervention|"* Breastfeeding counseling during monthly microcredit meetings~* Weekly cell phone messages about breastfeeding"
223692976|NCT02196571|OTHER|Structured Exercise|
223692977|NCT00657904|DRUG|Bicalutamide|150mg daily
223692978|NCT00657904|DRUG|Placebo|once daily
223692979|NCT04893837|DEVICE|Standard care plus infrascans|Hourly infrascans to detect expanding intracranial hematomas
223692980|NCT06649721|DRUG|bedaquiline|400 milligrams (mg) daily for 2 weeks(w), then 200mg three times a week for 22 weeks (w)
223692981|NCT06649721|DRUG|delamanid|"* for participants weighing up to 33.9 kilograms (kg): 50mg two times a day for 24w~* for participants weighing 34kg or above: 100mg two times a day for 8w, then 200mg daily for 16w"
223692982|NCT06649721|DRUG|linezolid|"* for participants weighing up to 33.9kg: 450mg daily;~* for participants weighing 34kg or above: 600mg daily; for 24w if a negative culture is obtained from sputum collected at 16w, or else for 36w"
223692983|NCT06649721|DRUG|Levofloxacin|"Only for participants with confirmed fluoroquinolone-susceptible TB or unknown fluoroquinolone susceptibility:~* for participants weighing up to 33.9kg: 500mg daily~* for participants weighing 34kg to 49.9kg: 750 daily~* for participants weighing 50kg or above: 1000mg daily for 24w if a negative culture is obtained from sputum collected at 16w, or else for 36w"
223692984|NCT06649721|DRUG|Clofazimine|"Only for participants with confirmed fluoroquinolone-resistant TB or unknown fluoroquinolone susceptibility:~100mg daily, for 24w if a negative culture is obtained from sputum collected at 16w, or else for 36w"
223692985|NCT06488924|DRUG|JR-446|IV infusion
223692986|NCT06225596|DRUG|BT8009|Participants will receive BT8009 on Days 1, 8, and 15 of every 21-day cycle.
223692987|NCT06225596|DRUG|BT8009|Participants will receive BT8009 on Days 1 and 8 of every 21-day cycle.
223692988|NCT06225596|DRUG|BT8009|Participants will receive BT8009 on days 1, 8 +/- 15 schedule of every 21-day cycle.
223692989|NCT06225596|DRUG|Pembrolizumab|Participants will receive Pembrolizumab on Day 1 of every 21-day cycle. Pembrolizumab infusion will be started 30 minutes following the completion of the BT8009 infusion.
223692990|NCT06225596|DRUG|Gemcitabine + cisplatin Or carboplatin|Participants will receive Gemcitabine on Days 1 and 8 of every 21-day cycle plus cisplatin Or carboplatin on Day 1 of every 21-day cycle.
223692991|NCT06225596|DRUG|Avelumab|After 4-6 cycles of Gemcitabine + Cisplatin or Carboplatin participants will receive maintenance Avelumab, if clinically indicated, on Days 1 and 15 each 28-day cycle.
223692992|NCT04107259|DIAGNOSTIC_TEST|Blood sample|Ten ml of venous blood was collected from all participants in the early morning after an overnight 12 hour fast by venipuncture of the antecubital vein into sterile tubes. Plasma and sera were separated immediately and were stored at -70 C until biochemical analyses.
223777671|NCT01626976|DRUG|Placebo|suspension, single dose
223777672|NCT01626976|DRUG|PF-06282999|Methylcellulose or simethicone suspension, doses range 200 to 500 mg, single dose
223777673|NCT01626976|DRUG|Placebo|suspension, single dose
223777674|NCT01626976|DRUG|PF-06282999|Methylcellulose or simethicone suspension, 500 mg dose, single dose
223777675|NCT01626976|DRUG|Placebo|suspension, single dose
223777676|NCT01626976|DRUG|PF-06282999|Simethicone or methylcellulose suspension, up to 1500 mg, single dose
223777677|NCT01626976|DRUG|Placebo|suspension, single dose
223777678|NCT01940705|OTHER|Hearing-Aid Informational Guide|Printed take-home guide on hearing aids
223692993|NCT01716325|OTHER|Self-management weight loss plan endorsement.|Self-management weight loss plan endorsement.
223692994|NCT01716325|OTHER|Conventional|Weight loss, comparator - no ICT support; conventional live workshops for weight loss
223692995|NCT05696860|DEVICE|Capnography Monitoring|Capnography monitoring
223692996|NCT06276530|OTHER|EOS imaging for musculoskeletal disorder|The patients will have a low radiation 2D/3D biplane imaging of the rib cage, and spine before and after surgery.
223692997|NCT06276530|OTHER|Movement analysis by an optoelectronic camera.|Movement analysis by an optoelectronic camera before and after surgery.
223692998|NCT06276530|OTHER|Stabilometric measurement by strength platform|Stabilometric measurement by strength platform before and after surgery.
223692999|NCT04068584|OTHER|Smart Angel|Patient issued with a tablet with the Smart Angel application to monitor clinical signs and symptoms
223693000|NCT05643560|DRUG|Damoctocog alfa pegol (Jivi, BAY94-9027)|Intervention is given as part of routine medical practice.
223693001|NCT06587750|BEHAVIORAL|Cognitive Multisensory Rehabilitation|CMR targets somatosensory and multisensory and cognitive functions through sensory discrimination exercises.
223693002|NCT04582916|DRUG|11C-MCI|Injected IV followed by PET scanning
223693003|NCT04582916|DRUG|11CPS13|Injected IV followed by PET scanning
223693004|NCT03552965|OTHER|Robust Radiotherapy planning|Investigator will plan Intensity-Modulated Radiation Therapy (IMRT) using calculations that minimize the dose of radiation to normal tissue
223693005|NCT03552965|OTHER|Margin-Based Radiotherapy planning|Investigator will plan Intensity-Modulated Radiation Therapy (IMRT) using calculations that introduce a margin to the target area
223693006|NCT05897398|OTHER|Data collection|Data collected at initiation, 6 months and 12 months of WEGOVY® treatment will be retrospectively extracted from the WEGOVY® ATU/AP2 eCRF.
223693007|NCT05897398|OTHER|Blood sampling|Blood sampling for routine care (max 15mL)
223693008|NCT05897398|OTHER|Questionnaires|"Completion of questionnaires for the entire cohort:~To assess hyperphagia and eating behaviour: BES, DEBQ and Hunger Score questionnaire To assess physical activity: short IPAQ To assess sleep behaviour: MCTQ To assess quality of life: EQ5D5L To assess digestive system disorders: GIQLI To assess anxiety and depression: HAD"
223693009|NCT06977152|DEVICE|Memory foam pillow|Patients in the memory foam pillow intervention group will have a memory foam pillow placed under their head and neck immediately after the initiation of mechanical ventilation support in the PICU.
223693010|NCT06977152|DEVICE|Fluidized Positioner|Patients in the fluidized positioner intervention group will have a fluidized positioner placed under their head and neck immediately after the initiation of mechanical ventilation support in the PICU.
223777679|NCT01940705|OTHER|Hearing-Aid DVD|Take-home DVD about hearing aids
223777680|NCT01940705|BEHAVIORAL|Teach-back Technique|Counseling/Educational session using the teach-back technique to review information about their hearing aids
223777681|NCT01940705|OTHER|Standard of Care|standard of care hearing-aid orientation as provided by clinical audiologist
223777682|NCT04420806|OTHER|HIT-exercise|13 months of high intensity endurance and resistance exercise, 3x 45 min/week - 3 months of COVID-19 induced exercise break
223777683|NCT04420806|OTHER|Sham intervention|Types of exercise (flexibility, relaxation) that did not affect the present outcomes
223777684|NCT00139997|DEVICE|Litebook treatment devices|Litebook LED phototherapy device used for 30 min before 8 am
223777685|NCT00139997|DEVICE|Inactivated negative ion generator|Equivalent exposure to inactivated negative ion generator
223777686|NCT03105050|OTHER|Access to bariatric surgery|All countries representatives will be interviewed on their Healthcare systems
223777687|NCT04751916|DIETARY_SUPPLEMENT|Essential Amino Acid Protein Supplement|Proprietary essential amino acid protein supplement
223777688|NCT04751916|DIETARY_SUPPLEMENT|Beneprotein®|Whey protein supplement
223777689|NCT02563041|DRUG|30% TSC|The patients were randomly assigned to have their catheter locked with either unfractionated sodium heparin 5000 U/mL or 30% trisodium citrate.
223777690|NCT02563041|DRUG|Heparin|The patients were randomly assigned to have their catheter locked with either unfractionated sodium heparin 5000 U/mL or 30% trisodium citrate.
223777691|NCT01632579|DRUG|LY3023703|Administered orally
223777692|NCT01632579|DRUG|Placebo|Administered orally
223777693|NCT01632579|DRUG|Celecoxib|Administered orally
223777694|NCT01164748|RADIATION|Lymphoscintigraphy|in all women a lymphoscintigraphy was done to investigate drainage patterns of a previous operated breast and axilla
223777695|NCT03779841|DRUG|AGN-151607|Injections were made into each 1 of 5 fat pads. The total injection volume into each fat pad was 1 mL. One-time treatment.
223777696|NCT03779841|DRUG|Placebo|Injections of placebo were made into each 1 of 5 fat pads. The total injection volume into each fat pad was 1 mL. One-time treatment.
223777697|NCT03841643|DEVICE|patient-specific implant|solid titanium implant that functions as a guiding template for harvesting, and as an implant for reconstruction of the cranial defect
223777698|NCT03841643|DEVICE|cement|norian cement for reconstruction of the cranial defect
223777699|NCT05163145|OTHER|TPN|early detection of comlications of prolonged TPN on neonatal liver
223777700|NCT00175474|PROCEDURE|knee surgery|
223777701|NCT02765945|OTHER|Supervised exercise program|Subjects were enrolled in a hospital-based wellness center where, after analysis of their medical history and previous levels of physical activity ands documentation of a normal exercise stress test, they chose individually tailored exercise programs
223777702|NCT02186964|PROCEDURE|tension free primary closure|tension free primary closure of the defects created by excision of the pilonidal sinus
223777703|NCT02186964|PROCEDURE|karydakis|the defect after excision of the pilonidal sinus is closed by Karydakis procedure
223777704|NCT02186964|PROCEDURE|Limberg flap|defect after excision of the pilonidal sinus is closed by Limberg flap procedure
223777705|NCT02788175|BIOLOGICAL|Entyvio (Vedolizumab)|A humanized monoclonal antibody that specifically binds to the alpha4beta7 integrin with MAdCAM-1, which in turn inhibits the migration of T-lymphocytes across the endothelium into GALT
223777706|NCT00162136|DRUG|Ixabepilone|Intravenous (IV) Infusion; 10, 20, 30, 35, 40 \& 45 mg/m2, once every 21 days (1 cycle), up to 9 cycles
223777707|NCT02886533|OTHER|Antithrombotic|Collection of clinical, biological data
223777708|NCT05012592|BEHAVIORAL|Health Awareness Program TO Reduce Malnutrition and Helminth Infestation among Primary School children|This interventional study period started from September 2021 up to September 2022 (13 months) by school nurses to implement HAPSC. After completing four to five months of the educational session the school nurse will collect midline follow-up data and the endline data will be collected at the end of the interventional study. In this period a total of nine months (except annual leave) will be considered an interventional education period. The intervention group will receive one educational session per week every month. School nurses will be assigned for each class to provide health education. Each session will be conducted for a maximum of 45 minutes. The community worker will be assigned to assist the school nurse and they will communicate with the child's parents about their child's healthy nutrition and good hygiene practice. The significance of healthy eating and hygiene behavior for the children will be shared with the child's parents or guardians properly.
223777709|NCT01187589|DEVICE|Pulsehaler|
223693013|NCT06810999|OTHER|From Fear to Purpose (Acceptance and Commitment Therapy)|The From Fear to Purpose ACT Protocol is based on Acceptance and Commitment Therapy (ACT) strategies, build around identifying and committing to personal values. The intervention will be group-based (90 minutes session).
223693014|NCT06810999|OTHER|Placebo|The placebo condition consists of a group-based attentional control intervention.
223693015|NCT06605027|OTHER|Therapeutic Ketogenic Diet|2 week induction to establish ketosis followed by 12 weeks therapeutic ketogenic diet
223693016|NCT06592378|DEVICE|Addinex|Medication dispensing system to control and monitor opioid use
223693017|NCT06592378|DEVICE|Standard Pill Bottle|Access and use of opioids in a standard pill bottle.
223693018|NCT06589154|DIAGNOSTIC_TEST|Multi-modal artificial intelligence model (BEAM)|Data from mpMRI and cfDNA analysis will be integrated and processed by deep learning. The model's output will be compared against the final pathological diagnosis from the prostate biopsy to evaluate its performance.
223777710|NCT01187589|DRUG|Nebulizer & Albuterol 0.5ml|Albuterol aerosolized by a nebulizer
223777711|NCT02678546|OTHER|Other|case review of diagnosed disease
223777712|NCT02977377|OTHER|Exercise therapy|Cases will take the treatment 1-hour, 3 days in a week for 8 weeks.
223777713|NCT02977377|OTHER|Whole body vibration|4 sets, 1 min application and 1min rest whole body vibration and after that exercises. Cases will take the treatment 1-hour, 3 days in a week for 8 weeks.
223777714|NCT02703935|BEHAVIORAL|health talk and adventure-based training|To develop an integrated programme for Hong Kong Chinese childhood cancer survivors, an advisory committee was set up which included an associate professor, an assistant professor and a research student at a local university, a pediatric oncologist and oncology nurse and one assistant professor of Sports and Recreation Management, ensuring the adequate 'dosage' of the intervention and the feasibility of implementing such programme for Hong Kong childhood cancer survivors.
223777715|NCT02703935|BEHAVIORAL|Placebo Control|They will be invited to attend leisure activities organized by a community centre in four different days during the study period. Activities will include cartoon film shows, handicraft workshops, chess games, health talks on the prevention of influenza and healthy diet, day visit to museums and theme parks and galleries
223777716|NCT03156231|DRUG|ACETAZOLAMIDE oral capsule|Administration of 125mg acetazolamide in the morning, 250mg in the evening, starting 24 hours before departure to 3200m
223777717|NCT03156231|DRUG|Placebo oral capsule|Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3200m
223777718|NCT05060224|DEVICE|EasyLaser: Low Level Laser therapy|
223777719|NCT02286882|DRUG|PF-06409577 or Placebo|PF-06409577or placebo will be administered as an extemporaneously prepared suspension once in each cohort
223777720|NCT03930745|OTHER|Placebo|Placebo vaginal inserts.
223777721|NCT03930745|DRUG|TOL-463|TOL-463 is a non-azole vaginal anti-infective drug candidate designed as a dual-indication therapy for BV and VVC.
223693019|NCT02394002|DRUG|Propofol|
223693020|NCT06817213|BEHAVIORAL|General education control|Participants will complete an online survey before reviewing education material for eosinophilic esophagitis, prior to patient's clinical physician's appointment (this appointment is a standard of care visit). Participants will complete a follow-up survey approximately 3 months after the clinic appointment.
223693021|NCT06817213|BEHAVIORAL|Decision support tool|Participants will complete an online survey before reviewing tailored educational materials for eosinophilic esophagitis prior to patient's clinical physician's appointment (this appointment is a standard of care visit). The intervention is a tailored, electronic decision support intervention with a patient-facing decision aid (DA) with three components-EoE knowledge/education, values clarifications, and communication. Tailored feedback from the patient will be given to the patient's provider prior to the visit to facilitate shared decision-making in the visit. Participants will complete a follow-up survey approximately 3 months after the clinic appointment.
223693022|NCT05132439|DRUG|Metformin ER|Oral medication typically used for Type 2 diabetes with presumed anti-inflammatory properties
223693023|NCT05132439|DRUG|placebo|Matched to active study drug
223693024|NCT05824364|OTHER|telerehabilitation|Telerehabilitation activites will be tested with the aim to provide 1) continuation of rehabilitative care, focused on physical training and patients'monitoring , and 2) information in the mid-term about study goals.
223693025|NCT05824364|OTHER|rehabilomic|blood withdrawal (10 ml of blood, two tubes of 5 ml for serum isolation): at the hospital admission at the Cardiac Rehabilitation Unit of IRCCS Fondazione Don Gnocchi of Milan (T0) and after the rehabilitative treatment (T1)
223693026|NCT06665932|PROCEDURE|Stereotactic radiotherapy|Stereotactic surgery is a minimally invasive form of surgical intervention that makes use of a three-dimensional coordinate system to locate small targets inside the body and to perform on them some action such as ablation, biopsy, lesion, injection, stimulation, implantation, radiosurgery, etc.
223693027|NCT06336928|OTHER|Non-Interventional Study|Non-interventional study
223693028|NCT06588049|DIETARY_SUPPLEMENT|Beet Root|Beet Root powder used as a mouth rinse in suspension with water
223693029|NCT06588049|OTHER|Water|Water used as a mouth rinse
223693030|NCT06068647|DIAGNOSTIC_TEST|Lung ultrasound, computed tomographic scan and patch-based cardio-respiratory evaluations|"Ultrasonographic findings will be obtained with machines supplied with clinical Units. Additionally, US scans as acquired with open research platform will also be gathered. For both scanners, ultrasonographic scans will be performed and videos will be recorded and stored in each landmark. Metal cutaneous landmarks will be positioned and left during computed tomographic (CT) scans, indicating the areas of ultrasonographic assessment.~Finally, on the same day of enrolment, a wearable system for measuring physiological signals, will be applied. Within the scope of this study, sensors will be applied to the upper chest. The following information will be collected by each sensor: electrocardiography, respiratory effort, respiratory flow, activity, position, and sound pressure level."
223693031|NCT05407753|DIETARY_SUPPLEMENT|Ketone ester|Subjects receive the ketone ester at the following timepoints: 25g before ultrarun, 12.5g every 30 min during race, 25g immediately after race, 25g before sleep, 3 x 25g on day after race.
223693032|NCT05407753|DIETARY_SUPPLEMENT|Placebo|Subjects receive a non-caloric taste-matched placebo (water with sucrose octaacetate)
223693033|NCT03316534|DRUG|Aspirin|Aspirin (100 mg once a day)
223693034|NCT02908893|BEHAVIORAL|In-app and push notification mobile messages|Short messages (100-250 characters) are to be delivered to a mobile app both by push notification (i.e., appearing on the phone dashboard like a text message if the user has allowed notifications from the app) and in-app messages (visible in the news feed of the wellness program app when the app is opened). Messages contain a short title (30 characters) and 2-3 lines of text in the body (30 characters each).
223693035|NCT06981507|DEVICE|MARPE (Miniscrew-Assisted Rapid Palatal Expansion)|MARPE (Miniscrew-Assisted Rapid Palatal Expansion) is an orthodontic expansion technique that uses a palatal expander anchored with miniscrews inserted into the palatal bone. The device applies lateral force to widen the maxilla skeletally in patients with transverse maxillary deficiency. In this study, all participants will receive MARPE treatment as part of their orthodontic management, and its potential effects on speech will be evaluated over time.
223693036|NCT03310879|DRUG|Abemaciclib|Abemaciclib is a cyclin-dependent kinase (CDK) inhibitor. CDK inhibitors work to stop cell growth.
223693037|NCT06991972|PROCEDURE|Needling + NBUVB|Participants in this arm will undergo needling using a sterile 30G (4mm) needle to manually puncture and implant melanocytes from perilesional pigmented skin into depigmented lesions. The procedure will be performed once every four weeks for a total of six sessions.
223693038|NCT06991972|PROCEDURE|Microneedling + NBUVB|Participants in this arm will undergo microneedling using a Dermapen device with 1.5 mm needles to create controlled micro-injuries in depigmented skin to enhance melanocyte migration and repigmentation. This procedure will be performed once every four weeks for six sessions.
223693039|NCT03120624|PROCEDURE|Biopsy|Undergo image-guided biopsy
223693040|NCT03120624|PROCEDURE|Computed Tomography|Undergo CT
223693041|NCT03120624|OTHER|Fluorine F 18 Tetrafluoroborate|Given IV
223693042|NCT03120624|OTHER|Pharmacological Study|Correlative studies
223693043|NCT03120624|PROCEDURE|Positron Emission Tomography|Undergo TFB-PET
223693044|NCT03120624|BIOLOGICAL|Recombinant Vesicular Stomatitis Virus-expressing Human Interferon Beta and Sodium-Iodide Symporter|Given IV
223693045|NCT03120624|DRUG|Ruxolitinib Phosphate|Given PO
223693046|NCT03120624|DRUG|Technetium Tc-99m Sodium Pertechnetate|Given IV
223693047|NCT03120624|PROCEDURE|Biospecimen Collection|Undergo mouth rinse, buccal swab, urine, and blood sample collection
223777722|NCT01693601|DRUG|Panobinostat|PO TIW QOW or PO TIW QW
223777723|NCT01693601|DRUG|Ruxolitinib|PO BID x 28 days
223777724|NCT05455567|DIAGNOSTIC_TEST|OCTA|Choriocapillary vessel density calculated with OCTA
223777725|NCT01364064|DRUG|TMZ|Comparing conventional adjuvant Temozolomide with dose intensive Temozolomide
223777726|NCT05820750|DEVICE|photodynamic therapy|root canal treatment of primary molars using photodynamic therapy
223693048|NCT06615609|BEHAVIORAL|Smart family doctor|"Based on health managers, participants were additionally provided Smart family doctor, which is an AI-assisted applications with personalized interactions. The content includes, but is not limited to: (1) General educational content, covering basic health knowledge on diseases, risk factors, and treatment methods; (2) Targeted health information, such as more specific guidance on blood pressure and blood sugar control, medication adherence, exercise, and smoking cessation; (3) Personalized disease management guidance, providing tailored reminders for patients regarding medication, diet, exercise, and medical visits. Patients can also directly report their latest self-measured blood pressure, blood lipid, blood sugar levels, and medication adherence to receive treatment and medication guidance from the 'Smart family doctor'."
223693049|NCT06615609|BEHAVIORAL|Health manager|Participants will received 3-hour health management guidance from a health manager once a week, including guidance on healthy lifestyle, medication treatment, and rehabilitation advice. The research team will provide participants with one smart band, requiring them to wear the band daily to collect health data during the 6-month study period.
223693050|NCT04523779|BEHAVIORAL|Brief Cognitive Behavioral Therapy|The proposed bCBT treatment for anxiety was specifically designed for use within VA PCMHI settings and uses a patient-centered approach to increase engagement while addressing the mental health needs of anxious Veterans. Emphasis was placed on maximizing intervention potency and minimizing intensity and duration to improve implementation value and alignment with VA PCMHI requirements. The intervention directly addresses challenges to delivery of CBT providing 1) a brief, practical model of care to address multiple anxiety conditions consistent with the PCMHI model (e.g. 4-6 sessions; measurement-based care), and 2) a clinically potent intervention that includes exposure-based skills.
223693051|NCT03393039|BEHAVIORAL|Negative Affect Task|fMRI stress task
223693052|NCT06673212|OTHER|Control Wheat Bread|Ingredients: Wheat Flour, Salt, Water, Allinson's Dried Active Yeast, Sugar
223693053|NCT06673212|OTHER|Berneray Bere barley bread|Ingredients: Berneray Bere Barley Flour, Salt, Water, Allinson's Dried Active Yeast, Sugar
223693054|NCT06673212|OTHER|Black Barley bread|Ingredients: Black Barley Flour, Salt, Water, Allinson's Dried Active Yeast, Sugar
223693055|NCT06994949|DEVICE|fCTOT cap|The fCTOT cap will be placed on the infant's head . After the MRI, fiber optics will be connected to the cap while donned on the infant and measurements will commence. After initial CSF diversion, a 0.5 cc volume of ICG solution will injected into the subcutaneous reservoir and measurements will be conducted using the fCTOT for 30 minutes. The fCTOT cap will be removed and NIRF planar imaging will be conducted to detect ICG in the subarachnoid space (SAS), draining cervical lymph nodes, along the spinal canal, and in the abdomen, where liver signals are expected. The infant will be transported back to the ICU where CSF diversion will continue and daily, 30 minutes NIRF imaging sessions may be conducted to detect ventricular flow into the SAS and liver clearance. Daily NIRF imaging will be performed in the neonatal intensive care unit (NICU) for as long as 7 days or until the ICG has cleared from the body from liver and/or CSF diversion.
223693056|NCT06994949|DEVICE|NIRF planar imaging|The fCTOT cap will be placed on the infant's head . After the MRI, fiber optics will be connected to the cap while donned on the infant and measurements will commence. After initial CSF diversion, a 0.5 cc volume of ICG solution will injected into the subcutaneous reservoir and measurements will be conducted using the fCTOT for 30 minutes. The fCTOT cap will be removed and NIRF planar imaging will be conducted to detect ICG in the SAS, draining cervical lymph nodes, along the spinal canal, and in the abdomen, where liver signals are expected. The infant will be transported back to the ICU where CSF diversion will continue and daily, 30 minutes NIRF imaging sessions may be conducted to detect ventricular flow into the SAS and liver clearance. Daily NIRF imaging will be performed in the NICU for as long as 7 days or until the ICG has cleared from the body from liver and/or CSF diversion.
223693057|NCT06994949|DRUG|ICG|The fCTOT cap will be placed on the infant's head . After the MRI, fiber optics will be connected to the cap while donned on the infant and measurements will commence. After initial CSF diversion, a 0.5 cc volume of ICG solution will injected into the subcutaneous reservoir and measurements will be conducted using the fCTOT for 30 minutes. The fCTOT cap will be removed and NIRF planar imaging will be conducted to detect ICG in the SAS, draining cervical lymph nodes, along the spinal canal, and in the abdomen, where liver signals are expected. The infant will be transported back to the ICU where CSF diversion will continue and daily, 30 minutes NIRF imaging sessions may be conducted to detect ventricular flow into the SAS and liver clearance. Daily NIRF imaging will be performed in the NICU for as long as 7 days or until the ICG has cleared from the body from liver and/or CSF diversion.
223693058|NCT06666582|DRUG|Paclitaxel and ramucirumab|Second-line treatment with paclitaxel/ramucirumab vs other regimens
223693059|NCT06666738|BEHAVIORAL|Structured antimicrobial review|The appropriateness of the documented indication, route of administration, expected duration and stop date of all antimicrobials will be reviewed within 48 hours of their prescription.
223693060|NCT06667622|DRUG|sodium glycididazole|Sodium glycididazole is intravenously infused at a dose of 800mg at 60 min before radiotherapy and used on Mondays, Wednesdays and Fridays during radiotherapy.
223693061|NCT06514651|DRUG|MAQ-001|MAQ-001 is an anti-PD-1 monoclonal antibody that inhibits T cell exhaustion through an alternative mechanism, independent of PD-1/PDL-1 blockade
223693062|NCT06514651|DRUG|Ipilimumab|Ipilimumab is a monoclonal antibody medication that works to activate the immune system by targeting CTLA-4, a protein receptor that downregulates the immune system
223693063|NCT06208852|OTHER|Virtual Navigator Program|For the intervention phase of the sub-study, 30 women with persistent PPD symptoms will be recruited to participate in the adapted virtual navigator program using rapid cycle testing over a 2-month period. These women will be enrolled and consented to receive virtual patient navigation for 2 months. Investigators will conduct rapid cycle testing in which we will evaluate satisfaction, feasibility, and target engagement of the intervention after every 10 participants in order to make rapid cycle changes prior to enrolling the next 10 participants. Women will communicate virtually with the PN by means of telephone, text messaging, Facetime, or other virtual modality of their choice. The Primary Navigator (PN) will meet with families at the beginning of the study to review results of depression screens and community mental health (MH) resources. The PN will partner with participants, engage them in the program, and provide ongoing communication with participants and MH clinicians.
223777727|NCT05820750|PROCEDURE|pulpectomy with metapex|root canal treatment using standard technique
223777728|NCT01587183|BEHAVIORAL|Educational material control|Participants will be given educational materials on starting a running program using a run/walk approach.
223693064|NCT02160483|OTHER|Functional magnetic resonance imaging|3 Tesla magnetic resonance imaging
223693065|NCT02943083|BEHAVIORAL|Relaxation Exercise|Groups receiving the intervention will be asked to engage in the relaxation protocol every day. Participants will be asked to continue practicing the relaxation protocol for the remainder of their pregnancy. Participants will be instructed to listen to the 7 minute guided muscle relaxation tape and engage in the 3 minute abdominal touch routine in the presence of the scent stick. Participants will be provided with a scent stick of their selected scent to take home. For the duration of the study, participants will be loaned standard headphones and an iPod Touch that contains only the guided progressive muscle relaxation audio recording to facilitate this at-home protocol.
223693066|NCT06287021|DEVICE|Jump System Traser® cup|Press-fit, cementless, 3D-printed, highly-porous trabecular titanium acetabular cup
223693067|NCT06287021|DEVICE|Jump System HAX-Pore® cup|Press-fit, cementless, hydroxyapatite/titanium plasma-sprayed acetabular cup
223693068|NCT02477696|DRUG|Acalabrutinib|Participants will receive oral acalabrutinib as stated in arm description.
223693069|NCT02477696|DRUG|Ibrutinib|Participants will receive oral ibrutinib as stated in arm description.
223693070|NCT07001930|DRUG|Epidiolex|Oral cannabidiol
223693071|NCT06147037|DRUG|FPI-2053|FPI-2053 is a bispecific antibody that targets EGFR and cMET
223693072|NCT06147037|DRUG|[111In]-FPI-2107|"\[111In\]-FPI-2107 is an imaging agent in which indium-111 is conjugated to FPI-2053.~Participants will have a fixed dose of \[111In\]-FPI-2107 followed by imaging scans (with or without pre-administration of FPI-2053)."
223693073|NCT06147037|DRUG|[225Ac]-FPI-2068|"\[225Ac\]-FPI-2068 is a radiopharmaceutical therapy in which an alpha emitter, actinium-225, is conjugated to FPI-2053.~Participants will be dosed through IV administration every 56 days for up to 3 cycles of the Treatment Period."
223693074|NCT06679075|PROCEDURE|Full pulpotomy using propolis and bioceramic putty|Full Pulpotomy for participants with mature adult molars diagnosed with irreversible pulpitis; using Propolis as a hemostatic agent and bioceramic putty as a dressing material
223693075|NCT06679075|PROCEDURE|Full pulpotomy using Propolis and MTA|Full Pulpotomy for participants with mature adult molars diagnosed with irreversible pulpitis; using Propolis as a hemostatic agent and MTA as a dressing material
223693076|NCT06679075|PROCEDURE|Full pulpotomy using sodium hypochlorite and bioceramic putty|Full Pulpotomy for participants with mature adult molars diagnosed with irreversible pulpitis; using sodium hypochlorite (NaOCl) as a hemostatic agent and bioceramic putty as a dressing material
223693077|NCT06679075|PROCEDURE|Full pulpotomy using sodium hypochlorite and MTA|Full Pulpotomy for participants with mature adult molars diagnosed with irreversible pulpitis; using sodium hypochlorite (NaOCl) as a hemostatic agent and MTA as a dressing material.
223693078|NCT07006324|BEHAVIORAL|The PEN-3 Intervention Model|The PEN-3 Model is a sociocultural model for planning and assessing participant behavior within the context a cultural phenomenon. It will be used to assess intervention impact on patient-clinical linkages in the Mississippi Delta. 3-4 home visits with appropriate interventions through a referral and support process.
223693079|NCT06617832|DRUG|Active drug for acute migraine treatment|Standard dose of Sumatriptan 100 mg, which is used as an acute treatment for episodic migraine
223693080|NCT06617832|DRUG|Placebo Oral Tablet|Inactive placebo pill (100 mg) looking like the active drug
223693081|NCT07130552|DEVICE|femoral triangle block and popliteal plexus block|Single dose bolus, 10 ml 5% bupivacaine will be used for FTB, 10 ml 5% bupivacaine will be used for PPB
223693082|NCT07130552|DEVICE|Femoral triangle block and distal iPACK|Single dose bolus, 10 ml 5% bupivacaine will be used for FTB, 10 ml 5% bupivacaine will be used for distal iPACK
223693083|NCT03971266|OTHER|Activity Monitor|Wear a Fitbit
223693084|NCT03971266|OTHER|Media Intervention|Complete smartphone based PRO diary
223693085|NCT06679842|DIAGNOSTIC_TEST|ascitis paracentesis|ascitis paracentesis
223693086|NCT04658472|DRUG|SAR445088 (IV)|Pharmaceutical form: Solution for Injection Route of Administration: Intravenous (IV)
223693087|NCT04658472|DRUG|SAR445088 (SC)|Pharmaceutical form: Solution for Injection Route of Administration: Subcutaneous (SC)
223693088|NCT06120777|DEVICE|INVSENSOR00069|Noninvasive pulse oximeter
223693089|NCT06114732|BEHAVIORAL|Walking exercise behaviour change intervention + TENS|"MOSAIC: Participants in this group receive two 60-minute individual video telehealth consultations (on weeks one \& two) and two 20-minute follow-up telephone calls (weeks six \& 12) delivered at a convenient time over the internet. All sessions are delivered by a trained senior/band 6 physiotherapist. All participants randomized to this arm are provided with a pedometer and a patient manual which include information on intermittent claudication (IC), risk factors, walking guidelines, goal setting, problem solving and action planning worksheets and a walking diary.~HF-TENS - TENS is a form of electrical stimulation that provides symptomatic pain relief that is used extensively within the health-care setting. It is a non-invasive modality; packaged in a small, portable unit that is easy to apply via small electrodes placed on the skin. Participants will be asked to use TENS during their everyday walking-based tasks, and any planned walking activity they undertake."
223693090|NCT06608212|DRUG|Finerenone (Kerendia, BAY948862)|Follow clinical practice/administration.
223693091|NCT06608212|DRUG|Others except finerenone|Follow clinical practice/administration. The non-use finerenone treatment strategy will require individuals to be free of finerenone use.
223693092|NCT06675812|OTHER|Information intervention|The participant will receive information on what treatment that is offered in their municipal, how the help-seeking process goes (where they can be anonymous etc), and tailored information regarding the barriers that the participant has stated preventing him or her for seeking help today.
223693093|NCT06685172|OTHER|f-ESWT|In the f-ESWT group, a total of 8 Hz, 0.28 mJ/mm2, and 2000 pulses were applied while in the r-ESWT group, a total of 8 Hz, 1.8 bar, and 2000 pulses were applied
223693094|NCT06685172|OTHER|r-ESWT|In the f-ESWT group, a total of 8 Hz, 0.28 mJ/mm2, and 2000 pulses were applied while in the r-ESWT group, a total of 8 Hz, 1.8 bar, and 2000 pulses were applied
223693095|NCT05642039|BEHAVIORAL|Mindfulness Course|Participants will attend a weekly 1.5-hour class over a 6-week period via Zoom. Participants will also be required to listen to guided practice audio recordings that are 12-20 minutes long and complete a weekly homework log detailing all audio recordings completed.
223693096|NCT05642039|BEHAVIORAL|HS Educational Course|Participants will meet for 10 -15 minutes once a week over a 6-week period. The course will be administered verbally or with the use of PowerPoint slides.
223693097|NCT04799535|PROCEDURE|Ultrasound|Undergo breast ultrasound
223693098|NCT06076005|OTHER|Advanced lung cancer patients' group|Evaluation of the demographic, clinical, histological and molecular characteristics of advanced lung cancer at the time of Diagnosis
223693099|NCT06470711|OTHER|Non-Interventional Study|Non-interventional study
223693100|NCT05530850|BEHAVIORAL|Holistic Corrective Exercise Program|A holistic approach corrective exercise program including corrective exercises and postural perception training,
223693101|NCT05530850|OTHER|Thoracic exercise program|Thoracic region focused exercise program
223693102|NCT06690814|OTHER|Ficus septica exudate (antiseptic plant exudates)|F. septica sap contains the antibacterial alkaloid ficuseptine which exhibits activivity agaisnt S. pyogenes and H. ducreyi, two pàthogens associated with cutaneous ulcer disease in Papau New Guinea. The sap has been tested using the Ames test for mutagenesis, and found to be non-mutagenic; testing was carried out by toxicology service provider Gentronix, UK (results available separately on request).
223693103|NCT06690814|OTHER|Pterocarpus indicus exudate|P. indicus sap exhibits antibacterial activivity agaisnt S. pyogenes, a pàthogen associated with cutaneous ulcer disease in Papau New Guinea. The sap has been tested using the Ames test for mutagenesis, and found to be non-mutagenic; testing was carried out by toxicology service provider Gentronix, UK (results available separately on request).
223693104|NCT06690814|OTHER|Curcuma longa aqueous extract|C. longa is a culinary herb that contains the antibatieral compound curcumin. Curcumin exhibits antibacterial activity agasint S. pyogenes and has profound effects on bacterial biofilms. This intervention uses a mulch of the rhizome that has been sqeeezed to produce a curcumin containing aqueous fluid.
223693105|NCT06690814|DRUG|Savlon antiseptic cream (cetrimide with chlorhexidine digluconate)|Common over the counter antiseptic cream
223693106|NCT06630026|OTHER|The aim of this study is to adapt the Dresden Falls Questionnaire scale (DREFAQ)scale to Turkish society in Parkinson patients and to make its validity and reliability in Turkish.|• The aim of this study is to adapt the Dresden Falls Questionnaire scale (DREFAQ)scale to Turkish society and to make its validity and reliability in Turkish. It has 5 questions. This study will be conducted with Parkinson patients. The patients will be sought to answer questionnaires during regular rehabilitation sessions.
223693107|NCT06686316|DEVICE|Device: Hypoxic Gas Mixture|The EG (Experimental Group) will undergo a 6-week intervention protocol of IHHE (Intermittent Hypoxia-Hyperoxia Exposure) using the MITOVIT® Hypoxic Training System (COMMIT GmbH, Salzgitter, Germany). They will breathe air with an oxygen concentration (FiO2) ranging from 10-14% for 5 minutes, followed by 3 minutes of rest in hyperoxia (FiO2 30-40%), for a total of 6 cycles. During the hypoxic phase, oxygen saturation will be maintained between 85-92%, while during the hyperoxic phase, it will be kept above 95%. This process is regulated by the device's AI. Participants will be asked to sit and breath normally in each exposure. An attendance checklist will be used to monitor compliance with the intervention
223693108|NCT06686316|OTHER|Sham Hypoxic-Hyperoxic exposure|The Sham Group (SG) will follow a single session protocol of 5 cycles of 6 minutes per session with an FiO2 of 21% using the MITOVIT® Hypoxic Training System (COMMIT GmbH, Salzgitter, Germany). Participants will be asked to sit and breath normally in each exposure. An attendance checklist will be used to monitor compliance with the placebo intervention.
223693109|NCT06698120|PROCEDURE|Awake prone positioning (APP)|"* APP are realized following the diagnosis of ACS~* Prone positioning or supine positioning are performed under supervision of a physician or a nurse~* Maximum session duration: 16 hours per day~* Sessions of prone positioning can be shortened, if necessary (30 minutes minimum), for better tolerance~* Tolerance of prone positioning is assessed by the physician in charge and sessions and may be stopped in case of poor tolerance"
223693110|NCT07025421|OTHER|Intervention Upright Bed positioning|Patient in receipt of the upright bed positioning will receive daily upright bed positioning time each day of mechanical ventilation following the time required by institutional protocol for ARDS - associated prone positioning
223693111|NCT06710639|BEHAVIORAL|Health Education Program|Instructions and recommendations will be provided in an informational leaflet to encourage an active and healthy lifestyle, promoting self-care and good health practices. This leaflet will include the new WHO guidelines recommending specific measures to reduce the risk of cognitive impairment.
223693112|NCT06710639|BEHAVIORAL|Cognitive Training Program|The cognitive training program (CT) focused on everyday cognition (EC) will be conducted individually. Each participant will receive a dossier specifically designed for the study.
223693113|NCT06884657|DRUG|mannitol|2.5 mg/kg Mannitol will be given intravenously
223693114|NCT06884657|OTHER|Saline|2.5 ml/kg saline will be given as plasebo
223693115|NCT06727773|DRUG|Memantine|memantine capsule
223693116|NCT06727773|DRUG|Placebo medication|placebo capsule
223777729|NCT01587183|BEHAVIORAL|Group running style B|Participants will attend a 4 hour group based training and 3, 2 hour follow up trainings.
223777730|NCT01587183|BEHAVIORAL|Group running style A|Participants will attend a 4 hour group based training and 3, 2 hour follow up trainings.
223777731|NCT01200381|OTHER|Quarterly remote follow ups and remote monitoring|Quarterly remote follow ups and remote monitoring
223777732|NCT01200381|OTHER|Quarterly remote follow ups + additional phone calls and remote monitoring|Quarterly remote follow ups + additional phone calls and remote monitoring
223777733|NCT01200381|OTHER|Quarterly in clinic follow ups and remote monitoring|Quarterly in clinic follow ups and remote monitoring
223777734|NCT03196765|DRUG|Sobetirome (NV1205)|Once a day oral dose of the study drug
223693117|NCT06727773|OTHER|Exercise Intervention|Exercise Intervention participants will concurrently engage in remotely delivered Get Real \& Heel, 3d/week. Intensity for aerobic and strength-training components will progress as tolerated under the direction of a trained exercise physiologist.
223693118|NCT06727773|OTHER|Exercise Control|Exercise control will have access to a library of pre-recorded Get Real \& Heel sessions.
223693119|NCT06885697|DEVICE|mesothelin expression testing|Assay done at screening to determine mesothelin expression levels
223693120|NCT06885697|BIOLOGICAL|TNhYP217 CAR T Cells|Variable doses, administered intravenously on Day 0
223693121|NCT06885697|DRUG|fludarabine|30 mg/m\^2 IV infusion administered followed by cyclophosphamide on days both are given. Daily x 4 doses on Day -7, -6, -5 and -4
223693122|NCT06885697|DRUG|cyclophosphamide|600 mg/m\^2 IV infusion. Daily x 3 doses on Day -6, -5, -4
223693123|NCT06093360|PROCEDURE|flapless surgery|Implant-supported restorations were unscrewed and modified if necessary (biofilm control). All the restorations were relocated at the end of each intervention session. After local anesthesia, a periodontal ultrasonic stainless-steel tip was used for supra- and sub-mucosal mechanical debridement. Next, a Columbia 4R/4L curette was used around the implant in a circular motion until a bone exposure of 2-3 mm was achieved. Mucosal curettage was simultaneously performed to remove the granulation tissue. After obtaining access to the implant surface, ultrasonic instrumentation was repeated and air polishing with an erythritol powder was applied submucosally with the aim of a periodontal probe. Hydrogen peroxide 3% was used to irrigate the implant surface for 2 minutes, followed by a rinse with saline. Oral hygiene instructions were given. Systemic antibiotics, when prescribed, were metronidazole or azithromycin
223693124|NCT06731504|DRUG|Abatacept|Abatacept is a monoclonal antibody that suppresses T-cell activation through costimulatory blockade. In 2021, abatacept was FDA approved to prevent acute GVHD following allogeneic HCT.
223693125|NCT07053969|DEVICE|Enamel Matrix Derivative|EMD is an FDA approved medical device used in periodontal procedures since 1996. It has been shown to enhance soft and hard tissue healing, increased root coverage and aid in periodontal regeneration. It's use as an adjunct during implant uncovering may increase peri-implant mucosal thickness.
223693126|NCT07056634|BEHAVIORAL|Active Nature Engagement|Participants in this group will walk at a comfortable pace for 30 minutes in an urban park, three times per week for four weeks. They will be guided to focus on their surroundings using a grounding exercise (e.g., noticing sights, sounds, and smells) and instructed not to use mobile phones or listen to music during the walk.
223693127|NCT07056634|BEHAVIORAL|Passive Nature Engagement|Participants in this group will sit quietly for 30 minutes in a designated spot within an urban park, three times per week for four weeks. They will engage in grounding exercises and draw aspects of the natural environment. Participants will be instructed not to use mobile phones or listen to music during the walk.
223693128|NCT07056634|BEHAVIORAL|Indoor Exercise|Participants will be asked to walk on a treadmill in an indoor room without windows for 30 minutes. The treadmill will be set to the speed that match the average pace in nature walk group (approximately 3 km/hr). The speed could be adjusted by the participant if needed, but kept within the range of 2.6 km/hr to 4.6 km/hr. Participants will be asked to not use their phones or listen to music.
223693129|NCT07069374|BEHAVIORAL|Wellness, Intervention Strategies and HIV Care (WISH)|A structured behavioral group program consisting of five weekly sessions, each approximately 60-90 minutes in length. The intervention is designed for individuals living with HIV who use substances and focuses on: managing stress, addressing barriers to care, and enhancing engagement with HIV-related health services. Sessions are delivered in a small-group format and facilitated by trained staff using a manualized curriculum.
223693130|NCT07069374|BEHAVIORAL|Movie Night Club - Attention and Time Matched Control|Weekly 90-minute group sessions over 5 weeks in which participants watch non-therapeutic, neutral-content movies in a group setting. Sessions are facilitated to control for social interaction and time spent in a structured group environment but do not include any therapeutic content.
223693131|NCT07098130|OTHER|US-guided PNM 100 Hz|a protocol of percutaneous neuromodulation of the median nerve consisting of 5 cycles of 5 seconds stimulation (100 Hz and 350 µs pulse width), followed by 55 seconds rest.
223693132|NCT07098130|OTHER|US-guided PNM 10 Hz|a protocol of percutaneous neuromodulation of the median nerve consisting of 10 cycles of 10 seconds stimulation (10 Hz and 250 µs pulse width), followed by 10 seconds rest.
223693133|NCT07089238|DIETARY_SUPPLEMENT|Citicoline|Oral
223693134|NCT07089238|DIETARY_SUPPLEMENT|Placebo|Oral
223693135|NCT03340896|DRUG|Docetaxel|Docetaxel 75 mg / m² administered on day 1 of each cycle every 3 weeks as an intravenous (IV) infusion of one hour followed by cisplatin 75 mg / m² administered on day 1 hour infusion followed by 5-FU, 750 mg / m² / day administered in continuous infusion from D1 to D5 (or 120 hours)
223693136|NCT03340896|DRUG|Cisplatin|Cisplatin: 75 mg/m² for experimental arm and 100mg/m² for comparator arm administered on day 1 of each cycle every 3 weeks as an intravenous (IV) infusion.
223693137|NCT03340896|DRUG|Fluorouracil|5-FU, 750 mg / m² / day administered in continuous infusion from D1 to D5 (or 120 hours)
223693138|NCT03340896|RADIATION|radiotherapy|Radiotherapy : 70Gy (2Gy/day) for 7 weeks.
223693139|NCT06878664|DRUG|177Lu-Dotatate (7.4 Gigabecquerel/cycle) during 30 min intravenous infusion every 16 weeks (q8w) x 4 cycles; 2) and 3) as in the experimental arm.|"Treatment with 177Lu-Dotatate (7.4 Gigabecquerel/cycle) during 30 min intravenous infusion every 16 weeks~177Lu-Dotatate, a radiopharmaceutical medicine which is an somatostatin analogue derived from octreotide that complexes via DOTA with non-carrier added (n.c.a) 177Lu radioconjugate.~177Lu-Dotatate will be supplied as a 370 MBq/mL solution for infusion. One mL of solution contains 370 MBq The total amount of radioactivity per single-dose vial is 7 400 MBq at the date and time of infusion. Given the fixed volumetric activity of 370 MBq/mL at the date and time of calibration, the volume of the solution in the vial ranges between 20.5 and 25.0 mL in order to provide the required amount of radioactivity at the date and time of infusion of lutetium (177Lu) oxodotreotide at the date and time of calibration."
223777735|NCT04663815|BEHAVIORAL|Animal-assisted activity|The intervention is an animal-assisted activity consisting of a visit to Villa Samson (a place on the campus of the hospital specifically intended for patients to meet pets), where the child will work with a therapy dog for 1 hour. Under supervision, the animal is stroked and combed by the child, they play games together, the child feeds the animal, etc.
224263493|NCT00932477|DRUG|Formulation 2: Carboxymethylcellulose Sodium, Glycerin and Polysorbate 80, based artificial tear|1 to 2 drops into each eye three times per day
223693140|NCT06878664|DRUG|177Lu-Dotatate (7.4 Gigabecquerel/cycle) during 30 min intravenous infusion every 8 weeks (q8w) x 4 cycles; 2) and 3) as in the experimental arm.|"Treatment with 177Lu-Dotatate (7.4 Gigabecquerel/cycle) during 30 min intravenous infusion every 8 weeks (q8w) x 4 cycles 177Lu-Dotatate, a radiopharmaceutical medicine which is an somatostatin analogue derived from octreotide that complexes via DOTA with non-carrier added (n.c.a) 177Lu radioconjugate.~Synonyms are:~177Lu-DOTA0-Tyr 3-Octreotate, 177Lu-DOTATE LUTATHERA, lutetium (177Lu) oxodotreotide 177Lu-Dotatate will be supplied as a 370 MBq/mL solution for infusion One mL of solution contains 370 MBq The total amount of radioactivity per single-dose vial is 7 400 MBq at the date and time of infusion. Given the fixed volumetric activity of 370 MBq/mL at the date and time of calibration, the volume of the solution in the vial ranges between 20.5 and 25.0 mL in order to provide the required amount of radioactivity at the date and time of infusion of lutetium (177Lu) oxodotreotide at the date and time of calibration."
223693141|NCT06878664|DRUG|Amino acid solution|Renal protection starting 30 minutes before RLT and lasting 4 hours (iv) amino acid solution of 14.4-20 g of lysine and 14.9-20.7 g of arginine in 1 to 2 liters of solution)
223693142|NCT06878664|DRUG|Lanreotide (Autogel formulation) or Octreotide LAR|Long-acting standard doses of SSA (Lanreotide autogel 120 mg subcutaneous (sc) or Octreotide LAR 30 mg im, starting 24h after RLT and every 4 weeks during RLT (q16w interval SSA administration should be adjusted to RLT administrations so that SSA is always given 24h after each RLT dose and at least 4 weeks prior to next RLT administration cycle) and q4w following last RLT administration until disease progression.
223693143|NCT07135843|BEHAVIORAL|Digital exercise program|KOKU is a digital adaptation of the evidence based Otago Exercise Program and Falls Management Exercise program, both designed to improve strength, balance, and reduce fall risk in older adults. KOKU includes 26 balance and strength exercises of varying difficulty. Each exercise is accompanied by written and audio instructions for safe performance and is demonstrated by a virtual trainer. Training sessions consist of three exercises suggested by the KOKU app, which participants are encouraged to perform for as many repetitions as possible until fatigue. Progression is guided by the participant's subjective assessment of effort and difficulty. Participants may choose to perform any exercise at any time, regardless of the app-suggested sequence. The KOKU app also provides reminders to exercise if no activity is detected for two days.
223693144|NCT07135843|BEHAVIORAL|Personal coaching for physical activity promotion|Personal coaching consists of three video calls conducted via the study tablet by staff trained in BCTs and motivational communication skills. Participants receive a low cost, wrist worn activity tracker during the initial home visit to support self-monitoring and provide feedback on PA behavior. The first virtual coaching session (week 2) focuses on goal setting and action planning, the second session (week 3) addresses identification and management of barriers, and the third session (week 12) serves as a booster to review and adjust activity goals for the post intervention period.
223693145|NCT06933212|OTHER|Mediterranean Diet with Extra Virgin Olive Oil|participants in this group will follow a Mediterranean Diet enriched with extra virgin olive oil
223693146|NCT06933212|OTHER|Mediterranean Diet with Walnuts|participants in this group will follow a Mediterranean Diet enriched with walnuts
223693147|NCT06933212|OTHER|Low-Fat Control Diet|participants in this group will follow a low-fat control diet as a comparison to the Mediterranean Diet groups
223693148|NCT07141836|PROCEDURE|Elastomeric chain|Elastic chain used to apply force that is capable of canine retraction. The chains were attached between canine bracket and molar band on the side that selected Randomly.
223693149|NCT07141836|PROCEDURE|Elastics|Elastics were used to bring a continuous force for maxillary canine retraction in orthodontic patients. Elastics were stretched between the canine bracket and the molar band to retract the canine distally
223693150|NCT07142603|OTHER|Metabolic response to protein source|Participants will be given a 350-400 kcal meal challenge containing 30% energy from animal protein. They will be given 10 minutes to consume the meal and meal response will be measured 240 minutes following the meal.
223693151|NCT07140796|BEHAVIORAL|Blood Flow Restriction Training|Participants perform squats with 15% of their body weight under blood flow restriction using a thigh cuff. Hip internal rotation is set at 15 degrees. The training is conducted twice a week for 4 weeks. Cuff pressure is estimated using a predictive formula based on thigh circumference and systolic blood pressure.
223693152|NCT07140796|DEVICE|Radial Extracorporeal Shockwave Therapy|Radial extracorporeal shockwave therapy (rESWT) is applied to the gluteus medius region prior to each exercise session. The protocol includes 2000 pulses per session, applied twice per week for 4 weeks, using a radial shockwave device.
223693153|NCT04679844|DEVICE|MagnetOs Easypack Putty|MagnetOs Easypack Putty used standalone in instrumented posterolateral fusion, 5cc-15c per spine level at the randomized assigned side.
223693154|NCT04679844|DEVICE|Demineralized Bone Matrix or Fibers mixed with local autograft bone|Demineralized Bone Matrix or Fibers (DBX or Grafton) mixed in a 1:1 vol% with local autologous bone graft used in instrumented posterolateral fusion, 5cc-15cc per level mixed with bone marrow aspirate/blood per spine level at the contralateral side.
223693155|NCT06954623|RADIATION|Radiation Therapy|proton beam radiation
224263494|NCT00932477|DRUG|Glycerin and Polysorbate 80 based artificial tear|1 to 2 drops into each eye three times per day
224263495|NCT02174926|PROCEDURE|Elective laparoscopic sigmoid resection|
224263496|NCT02174926|DIETARY_SUPPLEMENT|Conservative treatment|Written lifestyle guidance and fiber supplements
224263497|NCT01372930|DRUG|Etanercept|Etanercept 25mg in 1ml(subcutaneous injection)at 2h and 72h after PCI
224263498|NCT01372930|DRUG|saline|saline 1ml(subcutaneous injection) at 2h and 72h after PCI
224263499|NCT00756171|DRUG|colesevelam|2 times 3 625 mg tablets daily, 3 weeks
224263500|NCT00756171|DRUG|placebo|2 times 3 625mg tablets daily
224263501|NCT00205621|DEVICE|Positron Emission Tomography|
224263502|NCT00868998|DRUG|Gemcitabine, docetaxel, and capecitabine|Day 1-14: Capecitabine 600 mg/m2/day (maximum dose 2000 mg/m2/day total divided into BID PO doses) Day 4 and 11: Gemcitabine 600 mg/m2 IV over 60 mins Day 4 and 11: Docetaxel 30 mg/m2 IV over 60 mins preceded by 12 mg dexamethasone IV or PO or 4 mg if diabetic
224263503|NCT02047305|DEVICE|Radiofrequency Ablation|Patients with a histopathological diagnosis of moderate-grade intra-epithelial neoplasia (MGIN), high-grade intra-epithelial neoplasia (HGIN) and/or early flat-type SCCA of the esophagus, are treated with radiofrequency ablation, with repeat endoscopy and follow-up treatment at 3 month intervals.
223693156|NCT07149779|OTHER|Exercise|A total of 20 kickboxers between the ages of 20-26, healthy, and actively involved in this branch for at least 4 years participated in the study. The volunteers participating in the study were randomly divided into two groups as the study and control groups. The study group applied calisthenic strength exercises in addition to routine kickboxing technical training for 8 weeks and 3 days a week, while the control group continued only their weekly routine kickboxing training without applying any strength training. Static strength performance (grip-leg-back), dynamic strength performance (1RM bench press and 1RM barbel squat), 30-second push-ups and 30-second sit-ups tests were applied to the athletes participating in the study before and after the 8-week training.
223693157|NCT07149909|OTHER|Other (Conventional Therapy)|Participants received standard therapy including culture-guided antibiotics, tracheal lavage, and aspiration. Sputum samples were collected from the lower trachea for culture and sensitivity testing to guide antibiotic selection.
223693158|NCT07149909|PROCEDURE|Fiberoptic Bronchoscopy|Participants underwent fiberoptic bronchoscopy through the endotracheal tube for secretion clearance, sample collection, and alveolar lavage once daily for one week. Sterile sodium chloride solution with ambroxol hydrochloride was instilled, and antibiotics were administered immediately after lavage. Samples were cultured to guide antibiotic therapy.
223693159|NCT07150741|BEHAVIORAL|Exercise-Assisted Ergonomic Training|The program includes structured ergonomic and exercise activities designed to improve posture, reduce musculoskeletal pain, enhance sleep quality, and decrease anxiety levels among nursing students. Theoretical lectures cover ergonomics principles, postural assessment, body mechanics, and ergonomic risks in nursing. Practical sessions are delivered via video twice a week for 4 weeks, each lasting 30-40 minutes, including warm-up, stretching, strengthening, balance, and posture exercises. The intervention is supervised by an exercise specialist to ensure safety and proper technique.
223693160|NCT07149480|PROCEDURE|Underlay Tympanoplasty|Tympanoplasty performed using the underlay graft technique, where the graft is positioned beneath all three layers of the tympanic membrane remnant.
223693161|NCT07149480|PROCEDURE|Interlay Tympanoplasty|Tympanoplasty performed using the interlay graft technique, where the graft is positioned between the mucosal and fibrous layers of the tympanic membrane.
223693162|NCT07149493|DEVICE|Placebo nanofiber floss|Identical floss without probiotic coating, used under the same conditions.
223693163|NCT07149493|DEVICE|Probiotic nanofiber floss|Nanofiber floss infused with Ligilactobacillus salivarius (strain BCRC 14759), used twice daily for 14 days.
223693164|NCT07151027|PROCEDURE|sacroiliac joint injection|US-guided periarticular sacroiliac joint injection of a mixture of dexamethasone and lidocaine 2%
223693165|NCT07151027|PROCEDURE|sacroiliac joint injection|US-guided periarticular sacroiliac joint injection of a mixture of alcohol 30%, dexamethasone and lidocaine 2%
223693166|NCT07150468|OTHER|sampling blood|"Sampling~1. patient~   1. Peripheral blood samples in a volume of 25 cc will be collected before HCT and 2 weeks after HCT, and peripheral blood samples in a volume of 20 cc will be collected 4 weeks, 3 months, 6 months, and 12 months after HCT.~  2. If GVHD occurs, additional blood sample (20 cc) will be collected.~  3. In case of organ-specific GVHD including skin, gut, liver, muscle, etc., tissue samples from biopsy will be obtained for further analysis.~2. donor a. Peripheral blood samples in a volume of 20 cc will be collected before HCT"
223693167|NCT07150052|OTHER|Artifical intelligence in whatsapp|AI-based tool Tia Bete, designed to assist patients with T1DM in carbohydrate counting and insulin dose adjustment. The tool provides real-time recommendations based on personalized insulin-to-carbohydrate ratios, insulin sensitivity factors, and individualized glycemic goals.
223693168|NCT07150325|DEVICE|TIPr|TIPr is a second-generation device, which is originated from Pressing Evaluation and Training System (PETs), developed by NCKU Motion Analysis Lab. This 2nd generation device is a home-based training device, which equipped with single-axis force sensors and displayed visual feedback through a tablet advantages.
223693169|NCT07150325|DEVICE|Mirror Visual Feedback Device|A box with two compartments through a partition with two mirrors installed on each side, which is commonly applied in Mirror therapy.
223693170|NCT07150325|DEVICE|Mirror Visual Feedback Device(Blocked mirror)|Different from Mirror Visual Feedback Device in MVF group, the mirror was blocked by black curtain or paperboard.
223693171|NCT07150481|DRUG|IV Lidocaine infusion|2 mg/kg/h (the total dose of lidocaine per hour will be calculated and add to normal saline 0.9% to total volume 50 ml and infused by a rate 50 ml/h till the end of the procedure
223693172|NCT07150481|DRUG|IV normal saline|IV normal saline 0.9% , rate 50 ml/h
223693173|NCT07150104|DRUG|Belantamab mafodotin|Belantamab mafodotin will be administered.
223693174|NCT07150104|DRUG|Nirogacestat|Nirogacestat will be administered.
223777736|NCT04663815|OTHER|Control intervention|The control intervention reenacts a normal stay in the hospital, so the child spends one hour in the hospital room where the child can play, watch tv, etc.
223693175|NCT07150104|DRUG|Pomalidomide|Pomalidomide will be administered.
223693176|NCT07150104|DRUG|Dexamethasone|Dexamethasone will be administered.
223693177|NCT07149922|OTHER|Blood pressure was regulated within the normal target management range|Blood pressure monitoring was initiated immediately upon the patient's return to the intensive care unit (ICU) postoperatively, followed by randomization. Blood pressure management was guided by systolic blood pressure (SBP) measurements, with physicians encouraged to adjust therapy based on institutional protocols and clinical judgment. For SBP \<120 mmHg, intravenous crystalloid or colloid fluid resuscitation was prioritized. If the target blood pressure was not achieved, norepinephrine infusion was initiated at a minimum dose of 0.1 µg/kg/min and titrated up to a maximum of 0.5 µg/kg/min to maintain SBP between 120-160 mmHg (\<160 mmHg and \>120 mmHg). For SBP \>160 mmHg, intravenous or oral antihypertensive drugs were administered to reduce and maintain SBP within the 120-160 mmHg range. For SBP within the range of 120-160 mmHg, standard supportive care was provided.
223693178|NCT07149922|OTHER|Blood pressure was regulated within the elevated target management range|Blood pressure monitoring was initiated immediately upon the patient's return to the intensive care unit (ICU) postoperatively, followed by randomization. Blood pressure management was guided by systolic blood pressure (SBP) measurements, with physicians encouraged to adjust therapy based on institutional protocols and clinical judgment. For SBP \<160 mmHg, intravenous crystalloid or colloid fluid resuscitation was prioritized. If the target blood pressure was not achieved, norepinephrine infusion was initiated at a minimum dose of 0.1 µg/kg/min and titrated up to a maximum of 0.5 µg/kg/min to maintain SBP between 160-180 mmHg ( ≥160 mmHg and ≤120 mmHg). For SBP \>180 mmHg, intravenous or oral antihypertensive drugs were administered to reduce and maintain SBP within the 120-160 mmHg range. For SBP within the range of 160-180 mmHg, standard supportive care was provided.
223693179|NCT07150065|DRUG|Levofloxacin|Oral 200 mg levofloxacin tablet
223693180|NCT07150065|DRUG|ciprofloxacin|Oral 900-1,000 mg ciprofloxacin tablet
223693181|NCT07150533|DIETARY_SUPPLEMENT|Placebo Arm|Participants receive a placebo consisting of maltodextrin in capsule form, matched in appearance and taste to the active supplements.
223693182|NCT07150533|DIETARY_SUPPLEMENT|Green Tea Extract|Participants receive 500 mg of standardized green tea extract in capsule form.
223777737|NCT05334108|DRUG|Ecopipam|ecopipam HCl \~2mg/kg/day
223777738|NCT05334108|COMBINATION_PRODUCT|Cohort 1 Probe Substrate Cocktail|dextromethorphan, caffeine, omeprazole, and midazolam
223693183|NCT07150533|DIETARY_SUPPLEMENT|Ginger|Participants receive 1 g of ginger supplement in capsule form.
223693184|NCT07150533|DIETARY_SUPPLEMENT|Combined Supplement (Green Tea + Ginger)|Participants receive a combination of 500 mg green tea extract and 1 g ginger, both administered in capsule form.
223693185|NCT07150715|DRUG|Actinium Ac 225 Vipivotide Tetraxetan|Given IV
223693186|NCT07150715|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223693187|NCT07150715|OTHER|Gallium Ga 68 Gozetotide|Given IV
223693188|NCT07150715|DRUG|Lutetium Lu 177 Vipivotide Tetraxetan|Given IV
223693189|NCT07150715|PROCEDURE|PSMA PET-CT Scan|Undergo PSMA PET/CT scan
223693190|NCT07150715|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
223693191|NCT07151040|DRUG|TH9619|"Phase 1a - DOSE ESCALATION~Description:~Single arm dose escalation of TH9619 as monotherapy.~Phase 1b - DOSE EXPANSION~Description:~Single arm dose expansion of TH9619 as monotherapy in selected tumor types. The objectives and endpoints for the expansion cohort(s) will be defined in a protocol amendment, once data from Phase 1a are available."
223693192|NCT07150962|DRUG|HRS-9531 Tablet|HRS-9531 tablet.
223777739|NCT05334108|DRUG|Cohort 2 Probe Substrate|bupropion
223777740|NCT05334108|COMBINATION_PRODUCT|Cohort 3 Probe Substrate Cocktail|dabigatran, pitavastatin, rosuvastatin, atorvastatin, midazolam
223777741|NCT06328959|DEVICE|intermittent oro-esophageal tube feeding|The specific procedure was as follows: the infant was placed in a semi-recumbent or sitting position with the head fixed. Before each feeding, the infant's oral and nasal secretions were to be cleared. An intermittent oro-esophageal tube was appropriately lubricated with water on the head part. The professional medical staff held the tube and slowly inserted it through one side of the mouth into the upper part of the esophagus. The depth of insertion depended on the patient's age and height. After each feeding, the tube was immediately removed, and the patient was held upright for at least 30 minutes in case of reflux.
223693193|NCT07150676|OTHER|Long term follow-up|Long term follow-up as part of standard of care
223693194|NCT07150039|OTHER|Manual therapy intervention (Chaitow's myofascial diaphragm release)|Participants were given a myofascial release technique from a seated position, as described by Chaitow. With this technique, the athlete slightly bends his/her torso in order to relax the abdominal wall and breathes calmly and deeply (Figure 2). The therapist is behind the athlete holding his/her lower ribs, and during exhalation the therapist directs his hands caudally. This steady but gentle 'traction' is maintained throughout the breathing cycles for 4-5 minutes.
223693195|NCT07150039|OTHER|Sham Comparison|With this sham comparator technique, the therapist stood behind the athlete (who was sitting) touching the outside of the person's lower ribs without folding his or her fingers or applying any pressure. The athlete is verbally instructed, after fully exhaling the air in their lungs to take deep breaths opening his/her ribs as much as he/she can whistle the therapist's hands follow the movement (without applying any manual pressure or traction). The procedure here also lasted for 4-5 minutes
223693196|NCT07150897|OTHER|exercise for lower abdominal muscle wall|the exercise session will start with light walking for 5 minutes followed by, posture correction exercises from crock lying, supine, and sitting and standing positions (each exercise will be maintained for 5 seconds and then the woman relaxed for 10 seconds and repeated each exercise 10 times) to overcome the effect of poor pregnancy posture. Then, participants will perform first step of prone plank exercises which is a stable prone plank with attention to maintain a neutral position in the hip joints, pelvis and lumbar spine. The feet will be placed to match the width of the hip and forearm and acted as support points. The elbows place under the glenohumeral joints, and the arms support the body vertically to the surface. Second step of prone plank exercises will involve performing the unilateral stable prone plank which is the same as the stable prone plank but with the dominant leg in a fully extended position. Third step includes, prone bridge on a Swiss Ball with a diameter of 65
223693197|NCT07150988|DRUG|HSK44459 dose level 1|HSK44459 dose level 1 oral administration
223693198|NCT07150988|DRUG|HSK44459 dose level 2|HSK44459 dose level 2 orally administration
223693199|NCT07150988|DRUG|placebo|placebo oral adminisitration
223693200|NCT07150013|DRUG|Vorinostat (SAHA)|oral suspension
223693201|NCT07150013|DRUG|Placebo|placebo
223693202|NCT07149623|PROCEDURE|Experimental|sectioning and submitting fresh surgical specimens from the ileum mesentery
223693203|NCT07150858|OTHER|Erythropoietin and albumin PRF gel + implant placement|This group will be treated by transcrestal sinus lifting with erythropoietin and albumin PRF gel with simultaneous implant placement.
223693204|NCT07150858|OTHER|Albumin PRF gel +implant placement|This group (the Control group) will be treated with transcrestal sinus lifting using albumin PRF gel, with simultaneous implant placement.
223693205|NCT07150832|BEHAVIORAL|Improving Care, Accelerating Recovery & Education (ICARE)|I-CARE is a brief, digital intervention designed for adolescents who are boarding in a medical hospital awaiting transfer to a psychiatric inpatient unit. It consists of 7 tablet-based animated video modules and workbook exercises, facilitated by individuals who are not mental health professionals. All modules are grounded in evidence-based practices, such as cognitive-behavioral therapy and dialectical behavior therapy.
223693206|NCT07149363|DRUG|Durvalumab 50 MG/ML|Following surgical removal of their small-cell lung cancer, participants will receive a combination of 1500 mg durvalumab and cisplatin 75 mg/m2 or carboplatin AUC 5 on day 1, and etoposide 100 mg/m2 on days 1, 2, and 3, every 3 weeks for 4 cycles (a total of 12 weeks). Following the combination of chemotherapy and immunotherapy, participants will then receive 1500 mg durvalumab every 4 weeks for 9 cycles (a total of 36 weeks).
223693207|NCT07150780|PROCEDURE|Pre-operative instructions to eat and drink at liberty|Subjects will be instructed to eat and drink at liberty prior to their schedule elective cardiac catheterization.
223693208|NCT07150546|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
223693209|NCT07150546|DRUG|Lutetium Lu 177 Dotatate|Given IV
223693210|NCT07150546|PROCEDURE|Computed Tomography|Undergo CT and PET/CT
223693211|NCT07150546|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223693212|NCT07150546|RADIATION|Gallium Ga 68-DOTATATE|Undergo gallium Ga 68-DOTATATE PET/CT
223693213|NCT07150546|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
223693214|NCT07150546|OTHER|Questionnaire Administration|Ancillary studies
223693215|NCT07151001|DEVICE|No intervention|No intervention. Evaluate the automated DR screening software.
223693216|NCT07150286|DRUG|Levofloxacin-Based H. pylori Eradication Therapy|"This intervention consists of a 14-day levofloxacin-based triple therapy regimen for Helicobacter pylori eradication in ITP patients. The regimen follows current ACG guidelines and typically includes:~Levofloxacin - antibiotic targeting H. pylori~Amoxicillin - antibiotic used in combination for enhanced efficacy~Proton Pump Inhibitor (PPI) - to reduce stomach acid and improve antibiotic effectiveness~Patients will receive the full 14-day course, and platelet counts will be measured at baseline and four weeks post-therapy to assess hematological response. This intervention is unique to H. pylori-positive ITP patients in this study and is not administered to H. pylori-negative patients."
223693217|NCT07150650|DIAGNOSTIC_TEST|ICU-AW|The enrolled children receiving mechanical ventilation were grouped based on the occurrence of ICU-acquired weakness (ICU-AW) at the study endpoint.
223693218|NCT07149818|DRUG|Parsaclisib|parsaclisib 40mg qd
223693219|NCT07150130|OTHER|No Intervention: Observational Cohort|No Intervention: Observational Cohort
223777742|NCT06328959|DEVICE|gastric tube feeding|In PNG group, disposable gastric tubes were used for feeding to provide nutritional support. Each feeding was administered by a nurse using the infant's mother's breast milk through the tube. The amount of each feeding varied from 20 to 100 ml depending on the age of the infant, with feedings given every 2 to 3 hours, approximately 10 times per day. The duration of each feeding procedure ranged from 10 to 20 minutes. The total daily intake ranged from 200 to 1000 ml. Each tube was kept indwelling for 5 to 7 days. When the tube needed to be replaced, it was removed after the last feeding of a day and a new tube was to be inserted through the other nostril on the following morning to continue the nutritional support.
223777743|NCT02766491|OTHER|Strengthening and stretching|"Strengthening exercises will be performed 4 times a week for 10 weeks. Single leg heel raises will be the preferred exercise performed. The group of participants will have a wide range of strength and functional abilities, this will be accounted for with individualised programmes. The exercise load can be reduced by switching to bilateral heel raises, giving external support, reducing the range of motion or performing the heel raises while seated. Exercise load will be progressively increased by adding weight in the form of water bottles to a rucksack worn on the participant's back.~For the final six weeks of the intervention, stretching exercises of the calf muscles will be performed."
223777744|NCT02766491|OTHER|conventional stretching|"This group will perform seated biceps curls 4 times a week for 10 weeks, where extra load can be added progressively by holding water bottles in the hand.~For the final six weeks of the intervention, stretching exercises of the calf muscles will be performed."
223777745|NCT00002453|DRUG|Tenofovir disoproxil fumarate|
223777746|NCT04442516|OTHER|Questionnaire, sampling of blood, urine and saliva|We are following patients who are receiving Cisplatin as part of their cancer therapy.
223777747|NCT03705754|DEVICE|carbon black suspension colonic tattoo injection|Examine the SPOT syringe to verify that the pigment is fully suspended. A 23 or 25 G sclerotherapy needle is recommended for this procedure, attach the syringe and prime with SPOT. After injection catheter is primed, manoeuver with the endoscope for optimal injection position and inject tangentially, at a 30-40˚ angle to the mucosa and create a saline bleb to find the submucosal plane prior to injecting SPOT to reduce risk of intramural injection. Document both the depth of scope and anatomic location of each tattoo and the ink consumption as well. Place injection 2-3 cm distal (downstream) of the area of interest. Use 0.5-0.75 mL per injection site and no more than 8 mL per patient. Place SPOT tattoos in 3-4 quadrants around the lumen to increase likelihood of visualisation.
223777748|NCT02932631|OTHER|THERAPY CONTROL AND MOVEMENT OF INDUCTION|"Volunteers conventional physiotherapy group will stretching, strengthening and / or mobilization and functional training of the affected muscles with 3 sets of 10 repetitions for 60 minutes.~The restriction therapy group and induction motion the volunteers will wear a brace on the top healthy member to be restricted in each session during the exercises for this group for a period of 60 minutes, encouraging tasks involving activities of daily living and / or daily. In group practice mental, the volunteers listen to a CD that in the first two minutes, will promote progressive relaxation where imaginary in a calm and quiet place followed by 13 minutes of listening to the restriction therapy exercise protocol and motion induction. The association group practices and mental restriction therapy, volunteer listens to the CD for 15 minutes following the same procedures mentioned in group practice mental, followed by exercises functional activities for 45 minutes in the paretic limb."
223777749|NCT03265405|DRUG|Low dose prednisolone|An initial dose of 20 mg/day will be administered for 8 weeks, followed by 15 mg/day for 8 weeks, 10 mg/day for 4 weeks, and 5 mg/day for 4 weeks, after which the drug will be tapered over 2 weeks and discontinued.
223777750|NCT03265405|DRUG|Medium dose prednisolone|An initial dose of 40 mg/day will be administered for 4 weeks, followed by 30 mg/day for 4 weeks, 20 mg/day for 4 weeks, 15 mg/day for 4 weeks, 10 mg/day for 4 weeks, and 5 mg/day for 4 weeks, after which the drug will be tapered over 2 weeks and discontinued.
223777751|NCT03095989|BEHAVIORAL|Mindfulness|The structure of the protocol incorporates key features of Langer's mindfulness theory. Many of the tasks and exercises have demonstrated increased mindfulness in the general population and have been modified to incorporate ALS-specific exercises that make sense from patients and caregivers' points of view. The intervention provides easily understood multimedia (video and written) presentations of the framework of mindfulness and the aims of the planned tasks. The general structure of the protocol mixes different mindfulness elements; for every week there is a specific topic examined in depth. These topics are: Attention to variability; Positive and negative events; Unpredictability; Sense Making; and Novelty seeking / novelty producing. The overall duration of the protocol is 5 weeks.
223777752|NCT03545126|OTHER|13C6 Leucine|Recruited participants will be given 13C6-labeled leucine through intravenous infusion (4mg/kg/hr for 16hrs)
223693220|NCT07150819|BEHAVIORAL|Standard Nursing Care Protocol|The control group received standard perioperative nursing care in accordance with the Chinese Consensus and Clinical Guidelines for Enhanced Recovery After Surgery (2021 edition) and the Expert Consensus on Perioperative Nursing of Anorectal Diseases (2022 edition). Preoperative fasting included a 6-hour restriction on solid food and a 2-hour restriction on clear liquids. At 8:00 p.m. on the night before surgery, patients were instructed to orally ingest 500 mL of 10% glucose solution to supplement energy reserves. Fifteen minutes of structured health education was delivered preoperatively by the assigned nurse using 3D animations to explain the surgical process. Intraoperatively, an inflatable warming blanket was used to maintain the core temperature at 38°C, and all infusion fluids were pre-warmed to 37°C. For infection prophylaxis, 30 minutes before incision, patients received intravenous cefazolin (1 g for body mass index \[BMI\] \< 25 kg/m²; 2 g for BMI ≥ 25 kg/m²).
223777753|NCT03740217|DRUG|GKT137831|oral bioavailable small molecule that selectively inhibit NOX1 and NOX4
223777754|NCT01343706|DRUG|Placebo|Solution for oral administration
223777755|NCT01343706|DRUG|Placebo|Immediate release solid oral dosage (film-coated tablet)
223777756|NCT01343706|DRUG|BI 409306|Immediate release solid oral dosage (film-coated tablet)
223777757|NCT01343706|DRUG|BI 409306|solution for oral administration
223777758|NCT01713777|DRUG|"Lamotrigine Generic A"|
223777759|NCT01713777|DRUG|"Lamotrigine generic B"|
223777760|NCT05581693|DRUG|L04RD1|1 tablet of L04RD1
223777761|NCT05581693|DRUG|L04TD2|1 tablet of L04TD2
223777762|NCT05581693|DRUG|L04TD2|1 tablet of L04TD2
223777763|NCT05581693|DRUG|L04RD1|1 tablet of L04RD1
223693221|NCT07150819|BEHAVIORAL|MDC-based Pain Management|In accordance with the IASP Guidelines for Multidisciplinary Postoperative Pain Management (2023) and the Expert Consensus on Multidisciplinary Collaboration for Pain Management in China, a three-tier MDC framework was established;Surgeons were responsible for optimizing surgical procedures (e.g., using the tissue selecting technique for stapled hemorrhoidectomy) and administering a local injection of 5 mL 0.25% ropivacaine around the wound margin at the end of surgery. Anesthesiologists performed preoperative ASA physical status classification, monitored intraoperative vital signs, and configured postoperative patient-controlled analgesia (PCA) with sufentanil at 0.02 μg/kg/h.Compound Methylene Blue Nerve Block: A solution was prepared by mixing 2 mL of 1% methylene blue, 10 mL of 0.75% ropivacaine, and 8 mL of normal saline, yielding final concentrations of 0.02% methylene blue and 0.25% ropivacaine.
223693222|NCT07150871|OTHER|Patients diagnosed with syphilis|Collection of clinical data from patients aged ≥18 years with a microbiological and/or clinical diagnosis of syphilis, treated by the Infectious Diseases Department of the University Hospital of Alessandria from 2017 to 2025.
223693223|NCT05548738|DRUG|medthylprednisolone|a type of steroids injected in epidural space
223693224|NCT05548738|DRUG|prolotherapy|a type of hypertonic glucose
223693225|NCT02160782|DRUG|LUM001 (Maralixibat)|LUM001, also known as Maralixibat (MRX) will be administered orally Once Daily (OD). To be administered Twice Daily (BID) for patients who are eligible.
223693226|NCT02160782|DRUG|Placebo|Placebo will be administered orally once daily during randomized withdrawal period
223693227|NCT00309738|DRUG|pitavastatin|
223693228|NCT00309738|DRUG|simvastatin|
223693229|NCT05218239|BEHAVIORAL|Active Comparator: Routine education group|Behavior guidance on pelvic floor muscle function training , including Knack method education , and Kegel exercise and other pelvic floor muscle training methods were taught to postpartum women.
223693230|NCT05218239|BEHAVIORAL|Experimental: Global training group|Global training was added on the basis of control group. The 30min-training plan is divided into 9 sections, of which, groups 1 to 8, each group takes about 3 minutes, the ninth group is cool down section, including stretching for 5 minutes and foam axis stretching for 1 minute.
223693231|NCT01241084|DIETARY_SUPPLEMENT|Antileukotrienes + Lactobacillus reuteri|Montelukast (5mg/die) + 1000000000 CFU per day (5 drops) for 2 months
223693232|NCT01241084|DIETARY_SUPPLEMENT|Antileukotrienes + Placebo|Montelukast (5mg/die) + 5 drops of placebo daily for 2 months
223693233|NCT05979285|DEVICE|N1-Headache App (by Curelator)|Digital application allowing patients to monitor their migraines, and to identify triggers and/or protectors for their migraines.
223693234|NCT04645888|PROCEDURE|Impacted tooth surgery|Surgical extraction of İmpacted tooth
223693235|NCT00482027|BIOLOGICAL|tgAAC09|one or 2 doses of AAV-2 HIV vaccine (tgAAC09) at 3 dosage levels, dose escalation and dose optimization
223693236|NCT01104701|DRUG|exenatide once weekly|subcutaneous injection, 2 mg, once a week
223693237|NCT01104701|DRUG|exenatide once monthly suspension|subcutaneous injection, low dose, once a month
223693238|NCT01104701|DRUG|exenatide once monthly suspension|subcutaneous injection, medium dose, once a month
223693239|NCT01104701|DRUG|exenatide once monthly suspension|subcutaneous injection, high dose, once a month
223693240|NCT04926623|DEVICE|FreeStyle Libre 24 weeks|FreeStyle Libre flash sensor-based glucose monitoring system (FSGM; Abbott Diabetes Care, Witney, Oxon, UK)
223693241|NCT04926623|OTHER|SMBG (22 weeks) and blind CGM (2 weeks)|Self-Monitoring of Blood Glucose and Continuous Glucose Monitoring
223693242|NCT02883192|DRUG|Ondansetron|Zofran 4 mg.
223693243|NCT02883192|DRUG|Placebo|Placebo
223693244|NCT00437892|DRUG|atorvastatin|tablets, 40 mg day, 3 months
223693245|NCT00437892|DRUG|atorvastatin|tablets, 40 mg once daily
223693246|NCT00437892|BEHAVIORAL|diet|daily
223693247|NCT00437892|BEHAVIORAL|diet|daily diet
223693248|NCT05312073|OTHER|Biological samples|Blood samples Superficial skin Biopsy Collection of fallen squames Tapes - stripping
223693249|NCT05312073|OTHER|Skin biopsy|healthy skin from surgery interventions
223693250|NCT01329484|BEHAVIORAL|Reminiscence therapy|Personalized reminiscence therapy using a computerized system
223693251|NCT01329484|BEHAVIORAL|Cognitive training|Cognitive training using a computerized system
223693252|NCT01329484|OTHER|No treatment|Participants in the control group will receive neither of the 2 experimental interventions or any other similar interventions.
223693253|NCT04172896|PROCEDURE|Intraperitoneal Uterosacral Ligament Suspension|Vaginal intraperitoneal uterosacral ligament suspension performed by transfixing the ligament, intraperitoneally, in the intermediate portion (at the level of or above ischial spine plane) with three delayed absorbable 0 sutures, performed bilaterally (three sutures per side; six sutures total).
223693254|NCT04172896|PROCEDURE|Extraperitoneal Uterosacral Ligament Suspension|Vaginal extraperitoneal uterosacral ligament suspension performed by transfixing the ligament, extraperitoneally, in the intermediate portion (at the level of or above ischial spine plane) using a suture capturing device with two delayed absorbable 0 sutures, performed bilaterally (two sutures per side; four sutures total).
223693255|NCT03436836|DRUG|Nalbuphine|"Both groups received 8 ml solution for the peribulbar block, Patients of group N was received a mixture of 3 ml of 2% lidocaine, 4 ml of 0.5% bupivacaine with hyaluronidase (75IU)(16) and 4mg of nalbuphine in 1 ml normal saline. Patients of group C was received a mixture of 3 ml of 2% lidocaine, 4 ml of 0.5% bupivacaine with hyaluronidase (75 IU) and 1 ml normal saline. Nalbuphine (20mg amp.) was prepared in 0.9% sodium chloride in 5mL syringe.~If the block was inadequate after 10 minutes, a 2-4 ml supplementation of local anesthetics was given by the same technique and the patient was excluded from the study.~After adequate analgesia (loss of sensation to touch by a small cotton wool) and akinesia, the surgeon was allowed to start the surgery"
223693256|NCT03436836|DRUG|lidocaine, bupivacaine, hyaluronidase , saline|lidocaine, 0.5% bupivacaine, 1 ml hyaluronidase (75 IU) and 1 ml saline (total 8 ml).
223693257|NCT03436836|DRUG|lidocaine, bupivacaine , hyaluronidase|2% lidocaine, 4 ml of 0.5% bupivacaine with hyaluronidase (75IU)
223693258|NCT02413021|DRUG|Cytarabine|20 mg/m\^2 , SC, two times a day for 10 days every 30 days for 1 cycle
223693259|NCT02413021|DRUG|Deferasirox|20 mg/kg ,oral, per day
223693260|NCT04592107|DIAGNOSTIC_TEST|eGFR|estimated glomerular filtration rate
223693261|NCT03437512|DEVICE|Anodal tDCS|20 minutes of 2mA anodal stimulation.
223693262|NCT03437512|BEHAVIORAL|Fluency training|Speaking along with a metronome and/or speaking along with another person (choral speech) for 20 minutes
223693263|NCT03437512|DEVICE|Sham tDCS|For sham stimulation, current is ramped up and back down over 30 seconds.
223693264|NCT02583373|DRUG|CAL02 Low-dose|Two doses of CAL02 (low-dose) administered 2 times (24 hours apart) as i.v. infusion
223693265|NCT02583373|DRUG|CAL02 High-dose|Two doses of CAL02 (high-dose) administered 2 times (24 hours apart) as i.v. infusion
223693266|NCT02583373|DRUG|Placebo|Placebo administered administered 2 times (24 hours apart) as i.v. infusion
223693267|NCT06558539|DEVICE|Transcutaneous Tibial Nerve Stimulation(TTNS)|Participants in this group will discontinue all relevant medications (e.g., β3-adrenergic agonists, non-selective β-adrenergic agonists, or anticholinergic drugs) at least 14 days before signing the informed consent and will not use these medications during the study period. They will receive treatment solely with wearable transcutaneous tibial nerve stimulation.
223693268|NCT06558539|COMBINATION_PRODUCT|Combination Therapy|Participants in this group will continue their prescribed medication regimen, which may include β3-adrenergic agonists, non-selective β-adrenergic agonists, or anticholinergic drugs, with dosages and administration unchanged throughout the study. In addition to the standard medication therapy, participants will receive wearable transcutaneous tibial nerve stimulation using a wearable device
223693269|NCT06558539|DRUG|Standard Medication Therapy|Participants in this group will maintain their usual medication regimen, which may include β3-adrenergic agonists, non-selective β-adrenergic agonists, or anticholinergic drugs, with dosages and administration remaining consistent throughout the study. No additional interventions will be provided.
223693270|NCT01722123|OTHER|Hypothetical scenarios and related decisions|Patients are exposed to three hypothetical medical scenarios that require varying levels of decision making. We will be assessing how this experience alters their subsequent choice to forego life sustaining therapy.
223693271|NCT06331026|DRUG|PEG-rhGH with new preparation (T)|A single subcutaneous injection of PEG-rhGH with new preparation
223693272|NCT06331026|DRUG|PEG-rhGH with present preparation (R)|A single subcutaneous injection of PEG-rhGH with present preparation
223693273|NCT02414672|BEHAVIORAL|CareSTEPS|Caregivers receive a workbook and 6 one-hour telephone sessions with a trained interventionist.
223693274|NCT00263276|DRUG|dapagliflozin|Tablets, Oral, 2.5 mg, Once daily, 12 weeks.
223693275|NCT00263276|DRUG|dapagliflozin|Tablets, Oral, 5 mg, Once daily, 12 weeks.
223693276|NCT00263276|DRUG|dapagliflozin|Tablets, Oral, 10 mg, Once daily, 12 weeks.
223693277|NCT00263276|DRUG|dapagliflozin|Tablets, Oral, 20 mg, Once daily, 12 weeks.
223693278|NCT00263276|DRUG|dapagliflozin|Tablets, Oral, 50 mg, Once daily, 12 weeks.
223693279|NCT00263276|DRUG|placebo|Tablets, Oral, 0 mg, Once daily, 12 weeks.
223693280|NCT00263276|DRUG|metformin|Tablets, Oral, \>/= 1500 mg, Once daily, 12 weeks.
223693281|NCT02919098|BEHAVIORAL|Bystander, a game-based bystander intervention program|A game-based, high school age-appropriate program delivered by trained facilitators for sexual violence and harassment intervention
223693282|NCT02919098|BEHAVIORAL|Infection City, a game-based program about meningitis|A game-based, high school age-appropriate program delivered by trained facilitators to teach students about meningitis.
223693283|NCT00674973|DRUG|Erlotinib|Participants received erlotinib 150 mg tablet orally once daily.
223693284|NCT00674973|DRUG|Placebo|Participants received placebo matching to erlotinib 150 mg tablet orally once daily.
223777764|NCT01390558|PROCEDURE|custom orthotics|Orthotics are fabricated uniquely for each patient and use molds or casts of their foot as the template. They are fabricated by a licensed orthotist. There is no device or brand name other than custom orthotics.
223777765|NCT03261557|BEHAVIORAL|CBT + SST|"It will consist of 1 individual sessions and 15 weekly periodicity group sessions distributed in 3 modules: cognitive skills module, which includes the basic principles of CBT for psychosis; Social skills module, which includes the usual strategies in HHSS training; and problem solving module.~All patients will receive pharmacological treatment and will be followed up by their referral psychiatrist habitual."
223693285|NCT00763048|DRUG|Fluoride|Brush twice daily for 6 weeks
223693286|NCT00763048|DRUG|Fluoride, triclosan|Brush twice daily
223693287|NCT02602847|BIOLOGICAL|cccDNA assay on liver biopsy|cccDNA assay will be performed on liver biopsies at different times : During transplantation : Liver biopsy of explant and graft and virological biology Between M1 to M3 after transplantation : Liver biopsy between 1 to 3 months after transplantation M12 : Liver biopsy 12 months after transplantation
223693288|NCT04766827|DRUG|albumin-bound paclitaxel|Paclitaxel for injection (albumin-bound) uses human serum albumin as the carrier to avoid the use of organic solvents for intravenous injection of paclitaxel, reducing the incidence of allergic reactions, and reducing the toxicity of the drug.
223777766|NCT03261557|BEHAVIORAL|Psychoeducation, habits and healthy lifestyle|"Patients randomized to the control treatment will receive the same number of Individual and group sessions, with the same periodicity and format: 1 individual sessions and 15 weekly periodicity group sessions distributed in 3 modules: psychoeducation, habits and healthy lifestyle.~All patients will receive pharmacological treatment and will be followed up by their referral psychiatrist habitual."
223777767|NCT00928148|DRUG|SPD465|50 or 75 mg once daily for 7 days
223777768|NCT00928148|DRUG|Immediate Release Amphetamine Salt|25 mg once daily for 7 days
223693289|NCT02640040|DEVICE|llizarov external fixation device|llizarov external fixation device was applied to fix the tibia.
223693290|NCT02640040|DEVICE|intramedullary rod fixation|retrograde intramedullary rod was applied to stabilize the tibia.
223693291|NCT02640040|PROCEDURE|surgery|combined surgery for enrolled patients with CPT: sleeve resection of the pathological soft tissues, retrograde intramedullary rodding, packaged lilac bone autograft,and llizarov external fixation device installation.
223693292|NCT05318339|DRUG|Trastuzumab|"A loading dose of trastuzumab 8mg/kg IV over 90 minutes will be administrated on day 1 of week 1.~For all subsequent doses, trastuzumab 6mg/kg IV over 30 minutes will be administrated every three weeks.~Pyrotinib 400mg PO daily will be administrated at the same time."
223693293|NCT04105829|OTHER|Bond-a braid|Stainless steel lingual retainer application
223693294|NCT04105829|OTHER|EverStick-Ortho|Fiber reinforced lingual retainer
223693295|NCT04105829|OTHER|Ribbond|Fiber reinforced lingual retainer
223693296|NCT00954304|DRUG|HM30181AK 1mg|HM30181AK 1mg tablet
223693297|NCT00954304|DRUG|HM30181AK 5mg|HM30181AK 5mg tablet
223693298|NCT00954304|DRUG|HM30181AK 15mg|HM30181AK 15mg tablet
223693299|NCT00954304|DRUG|HM30181AK 60mg|HM30181AK 60mg tablet
223693300|NCT00954304|DRUG|Loperamide 2mg|Loperamide 2mg capsule
223693301|NCT05036369|DEVICE|Vibrant capsule|Vibrant capsule - Administered twice a week (Monday and Thursday).
223693302|NCT05036369|DEVICE|Placebo capsule|Placebo Capsule administered twice a week (Monday and Thursday)
223693303|NCT00051389|DRUG|Fosinopril|
223693304|NCT01039974|DRUG|GSK962040|"GSK962040. Planned doses per cohort as follows:~Cohort 1 planned dose = 10 mg; Cohort 2 to be determined based on data from Cohort 1"
223693305|NCT01039974|DRUG|Ketoconazole|400 mg
223693306|NCT03637023|BEHAVIORAL|Virtual Reality|Virtual Reality Based Rehabilitation including static balance, dynamic balance and walking
223693307|NCT03637023|BEHAVIORAL|Exercise Therapy|The conventional physical Therapy program includes parameters for improving strength, flexibility, transfers, posture, balance and coordination, and sensory stimulation. These activities consist of various types of exercises that focus on lower extremity movements.
223693308|NCT02599896|BIOLOGICAL|VRC-HIVMAB080-00-AB (VRC01LS)|VRC01LS is an Investigational Monoclonal Antibody targeted to the CD4 binding site of HIV-1.
223693309|NCT02599896|BIOLOGICAL|VRC-HIVMAB060-00-AB (VRC01)|VRC01 is an Investigational Monoclonal Antibody targeted to the CD4 binding site of HIV-1.
223693310|NCT03175757|DIETARY_SUPPLEMENT|Turmeric and Black Cumin Seed|Turmeric and Black Cumin Seed formulation
223693311|NCT03175757|DIETARY_SUPPLEMENT|Placebo|Placebo
223693312|NCT00115752|DRUG|Valdecoxib|
223693313|NCT00115752|DRUG|COX Inhibitor|
223693314|NCT00993902|PROCEDURE|Intrauterine insemination (single)|Single IUI after 36-38 hours of HCG
223693315|NCT00993902|PROCEDURE|Double intrauterine insemination|Double insemination after 18 and 40 hours of HCG administration.
223693316|NCT01956435|DEVICE|Excimer Light Treatment|Excimer light treatment will be performed on one leg of every subject as the intervention while the subjects other leg will serve as a control
223693317|NCT01397162|DRUG|Fluticasone propionate|Fluticasone propionate
223693318|NCT01397162|DRUG|Placebo|Placebo matching fluticasone propionate HFA MDI
223693319|NCT01397162|DRUG|BI 54903|BI 54903
223693320|NCT02715180|RADIATION|low dose chest computed tomography|All participants were evaluated 2 scout films during LDCT screenings. The first scout film was obtained while a participant was holding a comfortable expiration with the arms at down position, and the second scout film was obtained while a full inspiration with the arms at raised position. The axial images of LDCT were taken during participants' full inspiration. The radio-opaque marker was attached to the participants' skin where the lowest part of sternum was palpable, because the sternum moves according to the position of arms and respiration.
223693321|NCT00931879|DRUG|omega-3-ethyl esters|Lovaza (TM) (omega-3-ethyl esters) 1 gram Capsules are indicated as an adjunct to diet to reduce very high (\>500 mg/dL) triglyceride (TG) levels in adult patients.
223693322|NCT00931879|DRUG|Placebo|Subjects are males or non-pregnant, non-lactating females age 18-80 years. All subjects must have been diagnosed with type 2 diabetes mellitus a minimum of two years according to the current ADA criteria and triglyceride levels above 149 mg/dL. Subjects in this arm will be taking placebo for 6 months.
223693323|NCT05561569|PROCEDURE|Pars plana vitrectomy|23 gauge pars plana vitrectomy for managing primary retinal detachment.
223693324|NCT01483300|DRUG|lobaplatin|Gemcitabine 1000 mg/m2 d1, 8; Lobaplatin 30mg/m2 d1 q 3 weeks
223693325|NCT01483300|DRUG|cisplatin|Gemcitabine 1000 mg/m2 d1, 8; Cisplatin 25 mg/m2 d1-3 q 3 weeks
223693326|NCT00401531|BIOLOGICAL|DTaP-IPV-HB-PRP~T and Pneumococcal polysaccharide vaccines|0.5 mL, IM
223693327|NCT00401531|BIOLOGICAL|DTaP-HB-IPV and Pneumococcal polysaccharide vaccines|0.5 mL, IM
223693328|NCT01907997|DRUG|Systemic intravenous lidocaine infusion|In group L, intravenous lidocaine infusion(0.1mg/kg) for 10minutes after induction of anesthesia. After 10 minutes, lidocaine infusion continued at rate of 3mg/kg/hr during operation, and discontinued before move the patients to PACU.
223693329|NCT01907997|DRUG|normal saline infusion|In group C, the patients receive same volume of normal saline
223693330|NCT00287482|DRUG|Essiac|
223693331|NCT00750997|DRUG|hypertonic saline|patients in parent trial were randomized to 250cc 7.5% saline, 7.5%saline with 6%dextran or normal saline as control as the initial resuscitation fluid after injury with signs of either hemorrhagic shock or severe traumatic brain injury
223693332|NCT03454685|OTHER|without intervention type|Without intervention,this study is just an observational study.
223693333|NCT05374668|BEHAVIORAL|Video-based Yoga Exercises|They were trained face-to-face with social distancing and a maximum of three participants. They were observed while practicing and necessary alerts and corrections were made. Documents related to the videos for yoga exercises and posture exercises specially prepared for this study by the qualified physiotherapist (MD) were provided to the participants
223693334|NCT03215979|PROCEDURE|Platelet enriched plasma administration|It is a blinded administration of platelet enriched plasma in the temporal fascia used to cover the auricular reconstruction frame, during the second stage of the procedure. The use of platelet enriched plasma is focused to improve the integration rate of the full-thickness split skin graft
223693335|NCT03215979|PROCEDURE|Placebo Arm|5 ml of saline 0.9%will be applied in the temporal fascia as a placebo used to compare to the experimental group.
223693336|NCT04363177|BEHAVIORAL|Web-based psychosocial peer-to-peer support|"The evidence-based eHealth peer-to-peer psychosocial intervention Thinking Healthy, will be tested in this RCT. In line with the World Health Organization's mhGAP Intervention Guide (mhGAP-IG), Thinking Healthy is used to identify and manage perinatal mental health conditions (distress, symptoms of depression, and anxiety) in non-specialized psychosocial support setting."
223693337|NCT06058559|DIETARY_SUPPLEMENT|Sunflower lecithin|Lecithins are a group of essential phospholipids that are involved in a number of biological functions such as lipid-cholesterol transport, transmembrane signaling, and neurological function
223693338|NCT06058559|DIETARY_SUPPLEMENT|Olive oil|Extra virgin olive oil
223693339|NCT02560181|RADIATION|HDR brachytherapy|Whole gland salvage
223693340|NCT01050127|DRUG|ABT-436|See Arm Description for details.
223693341|NCT01050127|DRUG|Placebo|See Arm Description for details.
223693342|NCT06035055|DRUG|Ceftolozane/tazobactam|9g ceftolozane/tazobactam in 240 millilitres 0.9% sodium chloride IV infusion given over 24 hours for 10-14 days
223693343|NCT02772484|DEVICE|HS-1000|
223693344|NCT00869843|PROCEDURE|RF Ablation|
223693345|NCT05522387|DRUG|XPro1595|Each enrolled patient will be treated with 1.0 mg/kg of XPro1595 as a subcutaneous injection once a week for 55, or 74 weeks, for a total exposure to XPro1595 of up to 78 weeks (18 months), depending on their previous study.
223693346|NCT04007211|DEVICE|ABT13107|Dose: 3mL, maximum 10mL
223693347|NCT04007211|DEVICE|Hyalobarrier|Dose: 10mL
223693348|NCT03875118|BEHAVIORAL|The mouth-opening training with follow-up telephone calls program|Subjects in both groups received two 30-minute individual trainings on the mouth-opening exercises before discharge from the hospital. Subjects were instructed to practice the mouth-opening exercises three times a day, every day, for 12 weeks. Subjects in the intervention group received additional 6 follow-up phone calls (at 1, 2, 3, 4, 8 and 12-week after discharge) from the interventionist to enhance mouth-opening exercise adherence.
223693349|NCT03875118|BEHAVIORAL|The mouth-opening training without follow-up telephone calls program|Subjects in both groups received two 30-minute individual trainings on the mouth-opening exercises before discharge from the hospital. Subjects were instructed to practice the mouth-opening exercises three times a day, every day, for 12 weeks.
223693350|NCT03973073|COMBINATION_PRODUCT|CapulinTM|camouflage
223693351|NCT03973073|OTHER|topical applications and NB-UVB|combination therapy of vitiligo
223693352|NCT05970718|DRUG|REGN7544|Solution for single ascending Intravenous (IV) or Subcutaneous (SC) administration
223693353|NCT05970718|DRUG|Matching Placebo|Solution for single ascending IV or SC administration per the protocol
223693354|NCT04776031|DEVICE|R:GEN Laser System|Laser Treatment
223693355|NCT02778971|DRUG|[18F]Flutemetamol|amyloid PET imaging with \[18F\]Flutemetamol and subsequent modification of diagnosis and management
223693356|NCT06085794|PROCEDURE|Endoscopic combined intrarenal surgery|Combined complex stone clearance with mini-nephroscope and flexible URS
223693357|NCT06085794|PROCEDURE|Percutaneous nephrolithotomy|Clearance of renal stone with nephroscope in prone position
223693358|NCT00542568|BIOLOGICAL|EPODURE (dermal Biopump for erythropoietin)|Subjects will undergo similar study procedures and evaluations; however each dosage group will receive a different targeted dose of EPO delivered via EPODURE Biopump
223693359|NCT06515977|PROCEDURE|TXI (Group A)|Patients in Group A will undergo colonoscopy with TXI.
223693360|NCT06515977|PROCEDURE|TXI followed by WLI (Group B)|Patients in group B will first undergo colonoscopy with TXI and every polyp found should be removed. Then switch to WLI for a second withdrawal to detect lesions that were not observed the first time.
223693361|NCT06515977|PROCEDURE|WLI (Group C)|Patients in Group C will undergo colonoscopy with WLI.
223693362|NCT06515977|PROCEDURE|WLI followed by TXI (Group D)|Patients in group D will first undergo colonoscopy with WLI and every polyp found should be removed. Then switch to TXI for a second withdrawal to detect lesions that were not observed the first time.
223693363|NCT00408538|DRUG|UC-781 microbicide gel (0.1% and 0.25%)|
223693364|NCT00408538|DRUG|placebo|
223693365|NCT01423019|DIETARY_SUPPLEMENT|Advantra Z|Two capsules are taken twice daily, 20-30 minutes before breakfast and evening meals. Two capsules contain a total of 50 mg p-synephrine.
223693366|NCT01423019|DIETARY_SUPPLEMENT|Advantra Z + Naringin + Hesperiden|Two capsules are taken twice daily, 20-30 minutes before breakfast and evening meals. Two capsules contain a total of 50 mg p-synephrine, 600 mg naringin, and 100 mg hesperiden.
223693367|NCT01423019|OTHER|Sugar pill|Two capsules containing inert ingredients are taken twice daily, 20-30 minutes before breakfast and evening meals.
223693368|NCT03956056|BIOLOGICAL|Neoantigen Peptide Vaccine|• Each pool of vaccine study drug + poly IC:LC will be administered to one of the four limbs (A - Right Arm, B - Left Arm, C - Right Leg, D - Left Leg) by subcutaneous (SC) injection.
223693369|NCT03956056|DRUG|Poly ICLC|• Each pool of vaccine study drug + poly IC:LC will be administered to one of the four limbs (A - Right Arm, B - Left Arm, C - Right Leg, D - Left Leg) by subcutaneous (SC) injection.
223693370|NCT03956056|PROCEDURE|Blood for immune monitoring|-Baseline, day 1, day 22, day 50, day 78, week 25, and week 73
223693371|NCT01416844|BIOLOGICAL|anti-OX40|Patients with metastatic melanoma will be given 0.4 mg/kg anti-OX40 on days 1, 3 and 5 of a single treatment cycle.
223693372|NCT06391346|DIAGNOSTIC_TEST|MSOT|Non-invasive transcutaneous imaging of muscle components via infrared and near-infrared laser pulses
223693373|NCT03403374|DRUG|evolocumab|Administered by SC injection via autoinjector (AI)/pen
223693374|NCT02563977|DEVICE|2 year postop CT scan of the abdomen|CT scan of the abdomen (from the xiphoid process to the symphysis) performed approximately two years after performed DIEP flap breast reconstruction. No contrast used. Low dose of radiation.
223693375|NCT04875962|DRUG|UCB0599|Participants will receive an assigned dosage regimen of UCB0599 during the Treatment Period.
223693376|NCT04875962|DRUG|Placebo|Participants will receive an assigned dosage regimen of Placebo during the Treatment Period to maintain the blinding.
223693377|NCT03455127|OTHER|FSI ECD|Households will be visited by a trained community based lay worker on a weekly to biweekly basis to deliver the 15 module curriculum covering a range of topics from nutrition, water and sanitation, hygiene, early stimulation, conflict management, to good communication. The intervention seeks to promote healthy child development via active coaching to individual beneficiary households, delivering modules on a one on one basis and engaging all family members.
223693378|NCT00697359|DEVICE|Implantable loop recorder (ILR)|The ILR will be implanted subcutaneous following standard surgical procedure.
223693379|NCT05105230|DIAGNOSTIC_TEST|soluble programmed death 1biomarker|soluble programmed death 1biomarker
223693380|NCT00265551|DRUG|SCA-136 (200 mg)|
223693381|NCT00265551|DRUG|SCA-136 (400 mg)|
223693382|NCT00265551|DRUG|olanzapine (15 mg)|
223693383|NCT00265551|DRUG|placebo|
223693384|NCT01298531|DRUG|etanercept|etanercept 50 mg subcutaneous (SC) injections once weekly for 16 weeks.
223693385|NCT01298531|DRUG|etanercept|etanercept 50 mg subcutaneous (SC) injections once weekly for 8 weeks following the prior 8 weeks of placebo.
223693386|NCT01298531|DRUG|placebo|placebo subcutaneous (SC) injections once weekly for 8 weeks.
223693387|NCT03931824|OTHER|PRP|"A venous blood sample of 8.5 ml were obtained from patients. For the study group, the blood samples were mixed with 1.5 ml ACD-A or sodium citrate to achieve anticoagulation. Resulting material was then centrifugated for 5 minutes with RCF 1200 G speed to clump erythrocytes, and then centrifugated for 10 minutes in same speed to obtain thrombocyte concentrate. 2 ml's of the platelet rich plasma was injected to the shoulder of the subjects. For the sham injection group, same amount of blood was taken and they were given a of waiting time of same duration with the study group, with the resulting preparate being 2 ml's of 0,9% saline instead. PRP solutions were prepared with kits of Easy PRP(Neotec Biotechnology, Istanbul, Turkey).~Injections were done every two weeks, for a total of 3 times. 21 G injection needles with injection technique of posterior approach were used(18, 19). To provide blindness, all injections were done using injectors coated with non transparent tape."
223693388|NCT03931824|OTHER|Exercise|All of the patients were also informed about proper positioning and the standard care for the affected extremity. Their process of neurological rehabilitation was not changed, which was 5 days of the week, one session of 45 minutes a day. They were also given a program of standardized ROM exercises, which included passive and active motions.
223693389|NCT05548309|DEVICE|HFNC|High flow nasal cannula (HFNC) was inserted through specific medium/large nasal prongs . FiO2 was continuously measured by a dedicated system (AIRVO™ 2; Fisher \& Paykel Healthcare, Auckland, New Zealand) connected to the HFNC. Starting flow 35 L/min, temperature 31oc. The flow was titrated up to 60L/min with a target SpO2 of ≥94%.
223693390|NCT05548309|DEVICE|Oxygen face mask|Oxygen face mask was applied to patients postoperatively with starting flow 8L/min and titration of flow up to 10 L/min with target SpO2 of ≥94%
223693391|NCT02360995|DRUG|Triclosan/fluoride toothpaste|Brush whole mouth with Total toothpaste (sold in the US), using a Total 360 toothbrush, 2 times/day for 6 weeks (study duration).
223693392|NCT02360995|DRUG|stannous fluoride toothpaste|Brush whole mouth with Crest Pro-Health toothpaste using an Oral B Pro-Health toothbrush for 1 minute, 2 times/day for 6 weeks (study duration).
223693393|NCT02360995|DRUG|fluoride toothpaste|Brush whole mouth with Crest Cavity Protection toothpaste using an Oral B Indicator toothbrush for 1 minute, 2 times/day for 6 weeks (study duration).
223693394|NCT02360995|DRUG|Fluoride Mouthwash|Immediately after each toothbrushing rinse whole mouth with 20 ml of Crest fluoride Mouthrinse for 30 seconds each time.
223693395|NCT02360995|DRUG|cetylpyridinium chloride Mouthwash|Immediately after each toothbrushing rinse whole mouth with 20 ml of Crest Pro-Health Mouthrinse for 30 seconds each time.
223693396|NCT06557109|OTHER|Popular Music|A funky D mix version of a popular Turkish song
223693397|NCT04764487|DEVICE|KidneyPRO|Web-application for symptoms assessment
223693398|NCT04764487|OTHER|standard follow-up|usual follow-up
223693399|NCT00887406|DRUG|GSK961081 15mcg SD|Single dose delivered via solution for nebulisation
223777769|NCT00928148|DRUG|Placebo|Once daily for 7 days
223693400|NCT00887406|DRUG|GSK961081 3mcg SD|single dose delivered via nebulsier
223693401|NCT00887406|DRUG|GSK961081 50mcg SD|single dose delivered via solution for nebulisation
223693402|NCT00887406|DRUG|Placebo SD|single dose via nebuliser
223693403|NCT00887406|DRUG|GSK961081 100mcg SD|single dose delivered via solution for nebulisation
223693404|NCT00887406|DRUG|GSK961081 200mcg SD|single dose via nebuliser
223777770|NCT02490813|DIETARY_SUPPLEMENT|Treatment - Chinese Herbal Formula - X|Wu Mei (Fructus Pruni Mume), Ling Zhi (Gonoderma), Huang Bai (Cortex Phellodendron), and Zhi Su (Perilla frutescens).
223777771|NCT02490813|DIETARY_SUPPLEMENT|Placebo|Placebo will be starch with colorings
223777772|NCT03030833|DEVICE|Pulse Oximeter|Comparison of pulse oximetry to blood gas analyzer.
223777773|NCT00969852|DRUG|Sertraline|Multiple doses of 5, 25, and 50 mg Sertraline for 6 days each period.
223777774|NCT05095584|DIAGNOSTIC_TEST|3 meter backward walk test|validity and reliability of 3-meter backward walk test in lower limb amputation group
223693405|NCT00887406|DRUG|GSK961081 300mcg SD|single dose via nebuliser
223693406|NCT00887406|DRUG|GSK961081 100mcg RD|repeat dose via nebuliser
223693407|NCT00887406|DRUG|GSK961081 300mcg RD|repeat dose vai nebuliser
223693408|NCT00887406|DRUG|Placebo RD|repeat dose via nebuliser
223693409|NCT02611960|BIOLOGICAL|Pembrolizumab|IV infusion
223693410|NCT02611960|DRUG|Capecitabine|oral tablet
223693411|NCT02611960|DRUG|Gemcitabine|IV infusion
223693412|NCT02611960|DRUG|Docetaxel|IV infusion
223693413|NCT02395666|DRUG|DFMO|Subjects will receive twenty-seven (27) cycles of oral DFMO at a dose of 500 to 1000 mg/m2 BID on each day of a 28 day cycle.
223693414|NCT01851460|DEVICE|Cool-tip RF Ablation System|RFA therapy will be administered according to the instructions of the RFA device manufacturer. After infiltration of the skin (for percutaneous approach) with a local anesthetic, the needle probe will be directed into the lesion. For all methods, the needle placement is confirmed to be within the lesion by ultrasound or other imaging modality as appropriate. After confirming needle placement, the lesion will be heated to a target temperature of \>75 (Infinite)c for up to 15 minutes. The exposure time may be varied depending on the temperatures achieved. Depending on the size of the lesion to be ablated, multiple passes of the probe as well as multiple ablation cycles may be performed. Adequacy of ablation will be monitored by ultrasound throughout the procedure. Depending on the size of the lesions and the time required to complete the ablation, multiple lesions may be treated as staged procedures so as to improve safety.
223693415|NCT00805454|DRUG|OPC-34712|Single oral dose, 0.5 to 25 mg
223693416|NCT03570944|PROCEDURE|HRS, KRS|Elective HRS or KNR in adult patients, with any ERAS compliance
223693417|NCT05270122|DEVICE|Mechanical thrombectomy with ThrombX Retriever|Revascularization
223693418|NCT03470961|DRUG|Anti-Tlymphocyte Globulins|Induction therapy regimen in simultaneous pancreas kidney transplantation
223693419|NCT03470961|DRUG|Anti-Thymocyte Globulins|Induction therapy regimen in simultaneous pancreas kidney transplantation
223693420|NCT04123275|OTHER|No intervention wil be done. Patient characteristics and the standard care before and after withdrawal of life-sustaining treatment in all potential cDCD donors, will be studied. .|
223693421|NCT03269604|PROCEDURE|Prophylactic antibiotic during five days previous to the procedure|Prophylactic antibiotic during five days previous to the procedure.
223777775|NCT03213093|OTHER|Measure of cutaneous microcirculation|Measure of cutaneous microcirculation in response to a local application of pressure, to local heating and to the iontophoretic administration of acetylcholine
223693422|NCT03269604|PROCEDURE|Prophylactic antibiotic during three days previous to the procedure|Prophylactic antibiotic during three days previous to the procedure.
223693423|NCT03269604|PROCEDURE|Only a single dose of Prophylactic antibiotic|This group will receive a single dose of antibiotic 90 ± 20 minutes prior to the start of the surgical procedure (incision)
223693424|NCT05271461|RADIATION|Low level laser Therapy|Pin pointed application of low level laser on 15 acupuncture points each point 1 min time of application 15 min.
223693425|NCT05271461|OTHER|Circulatory exercises|"Active assisted or against mild resistance. Supine with leg up position 18degrees measured by the bed water balance in side rails.~If patient is not comfortable according to the modified Borg scale or contra indicated for the position then assume the supine position.~The subject will have A 3 min rest period to acclimatize themselves to each position.~The ankle pumping exercises consisted of simple repetitions of dorsiflexion 1 sec and planter- flexion for 1 sec with three different exercise intervals:~* repeated dorsiflexion and planter-flexion with no rest (no rest exercise).~* repeated dorsiflexion and planter-flexion with a 2 sec rest period (2 sec rest exercise).~* repeated dorsiflexion and planter-flexion with 4sec rest period (4sec rest exercise).~Subjects will have practiced ankle pumps before the exercise to get familiar and be educated about the procedure."
223693426|NCT05967000|OTHER|Preventive heart health and menopause programme|"This is a one-stop women's heart and menopausal service in a public hospital led by cardiologists and gynaecologists with a multidisciplinary team. Pre-existing speciality care and services are repackaged, and clinic workflows are reworked to provide more streamlined, convenient, and integrated care. Services encompass:~* Individualised risk assessment, screening, diagnosis, and treatment of CVD.~* Lifestyle education, adjustment, stress management, and counselling.~* Smoking cessation programs.~* Bone health screening, mammogram with access to our co-located gynaecologists and hormone replacement therapy.~* Virtual consults and health coaching."
223693427|NCT01409434|DRUG|Oral Glucose Tolerance Test|Administration of 75 gram oral glucose load and three plasma glucose measurements (including baseline).
223693428|NCT01727401|DRUG|Fondaparinux|Fondaparinux once daily sc injections at a dose of 2.5 mg if renal clearance of creatinine above 50 ml/min or Fondaparinux once daily sc injections 1.5 mg if renal clearance of creatinine between 20 and 50 ml/min
223777776|NCT03540342|PROCEDURE|One stop strategy group|Percutaneous coronary intervention (PCI) will be performed on the same operating table immediately after the endovascular aortic repair (EVAR)
223777777|NCT04917198|PROCEDURE|median sternotomy|median sternotomy
223777778|NCT03483623|OTHER|NATO WELP combination|Interface pressure will be measured using the XSensor X3 Pressure Mapping System. Transducers will be placed near both scapula. Measures will be obtained in upright (baseline) and supine positions on 4 randomly assigned litter mattress combinations. Constant TCPO2 measures, as well as peak pressures and total body surface area exposed to skin will be measured for the occiput, sacrum, both scapula, buttocks and heel areas. It will take about 20 minutes for each combination. The session is complete after all measures have been obtain for all litter/mattress combinations.
223777779|NCT03483623|OTHER|NATO FIS combination|Interface pressure will be measured using the XSensor X3 Pressure Mapping System. Transducers will be placed near both scapula. Measures will be obtained in upright (baseline) and supine positions on 4 randomly assigned litter mattress combinations. Constant TCPO2 measures, as well as peak pressures and total body surface area exposed to skin will be measured for the occiput, sacrum, both scapula, buttocks and heel areas. It will take about 20 minutes for each combination. The session is complete after all measures have been obtain for all litter/mattress combinations.
223777780|NCT03483623|OTHER|RAVEN WELP combination|Interface pressure will be measured using the XSensor X3 Pressure Mapping System. Transducers will be placed near both scapula. Measures will be obtained in upright (baseline) and supine positions on 4 randomly assigned litter mattress combinations. Constant TCPO2 measures, as well as peak pressures and total body surface area exposed to skin will be measured for the occiput, sacrum, both scapula, buttocks and heel areas. It will take about 20 minutes for each combination. The session is complete after all measures have been obtain for all litter/mattress combinations.
223777781|NCT03483623|OTHER|RAVEN FIS combination|Interface pressure will be measured using the XSensor X3 Pressure Mapping System. Transducers will be placed near both scapula. Measures will be obtained in upright (baseline) and supine positions on 4 randomly assigned litter mattress combinations. Constant TCPO2 measures, as well as peak pressures and total body surface area exposed to skin will be measured for the occiput, sacrum, both scapula, buttocks and heel areas. It will take about 20 minutes for each combination. The session is complete after all measures have been obtain for all litter/mattress combinations.
223777782|NCT04198610|PROCEDURE|Non surgical periodontal therapy|Procedure/Surgery: non surgical periodontal therapy and root planing (SRP) was performed in two to four appointments lasting approximately 60 minutes each under local anaesthesia (2% lignocaine hydrochloride with 1:2,00,000 adrenaline) using area specific Gracey periodontal curettes and an ultrasonic device. The treatment was concluded in 3 months. Within the duration of the study, all subjects received supportive therapy, which included professional plaque control and reinstruction of oral hygiene.
223777783|NCT00217906|BEHAVIORAL|A+ Asthma early intervention program|
223777784|NCT05014100|DRUG|Orelabrutinib tablet|Subjects received orelabrutinib150mg orally once daily for a 28-day cycle. Throughout the study period, all subjects continued treatment until one of the following conditions occurred: disease progression, intolerable toxicity, death, withdrawal of informed consent, or loss of follow-up
223777785|NCT05014100|DRUG|Lenalidomide|"Lenalidomide 25mg once daily for 21 days and rituximab 375mg/m2 for 7 days~Throughout the study period, all subjects continued treatment until one of the following conditions occurred: disease progression, intolerable toxicity, death, withdrawal of informed consent, or loss of follow-up"
223777786|NCT04471259|OTHER|Classification statistics|We classified patients by gender, age, recovery time,etc
223777787|NCT00523029|BEHAVIORAL|Chronic Disease Self-Management Program|Chronic disease self-management is a 6-week group program that teaches participants how to manage their chronic medical illness. Group leaders, also suffering from a chronic medical condition, will lead discussions based on the following topics: nutrition; exercise; appropriate use of medications; ways to communicate effectively with family, friends, and health care professionals; and how to make informed treatment decisions.
223777788|NCT04402333|PROCEDURE|Robotic Interval Debulking Surgery|Interval debulking surgery carried out in a minimally invasive manner using the Da Vinci Robot.
223777789|NCT06520748|OTHER|Hand rehabilitation program using the computerized glove|The patient extended finger to reach from grey to green to red colour and heard the beep providing knowledge of result (KR), whereas the increase of range of finger extension reached every session provides knowledge of performance (KP). As the patient's performance improved, the range of their finger's movement will also be increased due to the augmented feedback provided to the patient and the therapist through the glove software
223777790|NCT06520748|OTHER|Selected hand program|Distal key point of Bobath, approximation of affected arm, to control spasticity of wrist/ finger flexor (5 minutes). Dynamic splint to facilitate wrist and finger extension (10 repeat\*5 sets). Passive range of motion exercise (10 repeat\*5 sets) for each joint. Mud exercise (spherical, clyndrical , hook). Thera band exercises.
223777791|NCT00039767|DRUG|Lepirudin|
223777792|NCT02770391|DRUG|Leuprolide acetate|Leuprolide acetate, Intramuscular injection - 7.5 mg, one time dose on day (-28) ± 3
223777793|NCT02770391|DRUG|Apalutamide|Apalutamide, PO, 240 mg daily, starting day (-28) ± 3 until the day before radical prostatectomy. Apalutamide will be initiated the same day patients receive their leuprolide acetate injection.
223777794|NCT02770391|PROCEDURE|Radical prostatectomy|
223777795|NCT01295606|DRUG|Cefazolin|iv cefazolin (50mg/kg, 3 times a day) will be given as a routine prophylaxis treatment
223777796|NCT00578370|DRUG|Ciclosporin 0.5% (Formulation 01B)|Cutaneous emulsion 200µl once a day (26 days)
223777797|NCT00578370|DRUG|Ciclosporin 1.5% (Formulation 02B)|Cutaneous emulsion 200µl once a day (26 days)
223777798|NCT00578370|DRUG|0.1% betamethasone|Solution 200µl once a day (26 days)
223777799|NCT00578370|DRUG|0.005% calcipotriol|Solution 200µl once a day (26 days)
223777800|NCT00578370|DRUG|Formulation 00B|Cutaneous emulsion (Vehicle to Formulation 01B and Formulation 02B) 200µl once a day (26 days)
223777801|NCT01813500|OTHER|Blood and stool sample|Subjects are asked to provide a blood sample (6 to 10cc) and a stool sample. An additional blood sample will be requested if the subject has a flare.
223777802|NCT01640158|OTHER|Computerized Plasticity-based Adaptive Cognitive Training|Computerized plasticity-based adaptive cognitive training, up to 65 hours
223777803|NCT01640158|OTHER|Commercially available computerized training|Commercially available computerized training, up to 65 hours
223777804|NCT00720954|PROCEDURE|Ct-guided pleural needle biopsy|Biopsy of pleura
223777805|NCT00720954|PROCEDURE|Thoracoscopy|Biopsy of pleura
223777806|NCT02695238|PROCEDURE|Prophylactic Manual Rotation of persistent occipital posterior presentation|prophylactic manual rotation of persistent occipital posterior presentation on operative delivery will be performed in the experimental group
223777807|NCT03289962|DRUG|Autogene cevumeran|Autogene cevumeran will be administered by intravenous (IV) infusion, in 21-day cycles.
223777808|NCT03289962|DRUG|Atezolizumab|Atezolizumab will be administered by IV infusion on Day 1 of every 21-day cycle.
223777809|NCT05453474|GENETIC|Whole genome amplification|DNA is amplified by whole genome amplification
223777810|NCT05463224|DRUG|Lazertinib group|Lazertinib 240mg, Once, po, daily (1 cycle of 21 days)
223777811|NCT05870176|BEHAVIORAL|Enhanced Referral|The enhanced referral uses an electronic referral and patient decision aid to provide choices to 3 different physical activity programs.
223777812|NCT05870176|BEHAVIORAL|Standard Referral|"The standard referral period will serve as the usual care comparator. Patients will receive a paper referral and Fitbit monitor."
223777813|NCT04742595|BIOLOGICAL|SARS-CoV-2 Antigen-specific Cytotoxic T-lymphocytes|Given IV
223777814|NCT02087462|OTHER|Electroacupuncture (EA)|"Main acupoints: Da chang shu (BL25), Huan tiao (GB30), bilateral Jiaji point of attacked lumbar vertebra, Ashi points, modifying points according to different patterns.~Electroacupuncture: choose the dilatational wave, frequency is 2Hz/100Hz, electric current ranges from 0.1mA to 1.0mA, 30 mins per time.~Treatment frequency: 5 times per week in the first 2 weeks, 3 times per week in the 3rd and 4th week, 2 times per week in the 5th and 6th week.~Duration: 6 weeks."
223777815|NCT02087462|OTHER|Traction|An electric pelvis traction in supine position will be applied. The treatment frequency and duration are the same as EA.
223693429|NCT06056557|DEVICE|VARIPULSE™ catheter ablation|"Subjects will arrive to the electrophysiology laboratory for their ablation procedure and will undergo preparation for the procedure per standard protocol.~The purpose of an ablation procedure is to scar or destroy the heart tissue causing the atrial fibrillation. The current FDA approved ablation treatments commonly use freezing, radio frequency, or laser, delivered through a catheter that is threaded through blood vessels to the heart, as the energy source to destroy the abnormal tissue.~The BWI IRE VARIPULSE ablation system used in this study uses a type of energy source called pulse field.~Pulse field ablation applies ultra-rapid (less than 1 second) electrical fields to the heart muscle to destroy the abnormal tissue. This type of energy is thought to safer and more effective at treating atrial fibrillation.~● For a lesion set that cannot be performed using the VARIPULSE catheter technology, a conventional FDA-approved RF ablation"
223693430|NCT05777330|DIAGNOSTIC_TEST|Oral glucose tolerance test (OGTT)|"Longitudinal study using repeated OGTT, CGM and hyperglycemic clamp tests to evaluate glycemic variability, beta cell function and insulin action in individuals at moderate, high and very high risk of clinical onset of type 1 diabetes.~OGTT is performed every 6 months (every 3 months in case of dysglycemia) in all participants."
223693431|NCT05777330|DIAGNOSTIC_TEST|Hyperglycemic clamp test|"Longitudinal study using repeated OGTT, CGM and hyperglycemic clamp tests to evaluate glycemic variability, beta cell function and insulin action in individuals at moderate, high and very high risk of clinical onset of type 1 diabetes.~Clamp test is performed every 12 months in single autoantibody-positive participants and every 6 months in multiple autoantibody-positive participants. Clamp tests are not performed in participants aged between 5-11 years."
223693432|NCT05777330|DIAGNOSTIC_TEST|Continuous glucose monitoring|"Longitudinal study using repeated OGTT, CGM and hyperglycemic clamp tests to evaluate glycemic variability, beta cell function and insulin action in individuals at moderate, high and very high risk of clinical onset of type 1 diabetes.~A 10-day CGM recording is performed every 6 months (every 3 months in case of dysglycemia) in all participants."
223693433|NCT00841971|DRUG|Anidulafungin|200 mg IV loading dose followed by 100 mg qd for 21 days
223693434|NCT00841971|DRUG|Fluconazole|400 mg IV for 21 days
223693435|NCT02213042|DRUG|Lapatinib|Lapatinib is available as 250-mg orange tablets. Subjects randomized to the Lapatinib plus Trastuzumab arm received 1000 mg per day of Lapatinib, so wre instructed to take 4 x 250 mg tablets per day. Lapatinib was to be taken either 1 hour (or more) before a meal or 1 hour (or more) after a meal
223693436|NCT02213042|BIOLOGICAL|Trastuzumab|Trastuzumab is a sterile, white to pale yellow, preservative-free lyophilized powder for IV administration. Trastuzumab was administered on Day 1 of the start of Lapatinib or in conjunction with the first cycle of chemotherapy, as an 8 mg/kg loading dose. Subsequently, Trastuzumab was administered q3weekly as a 6 mg/kg maintenance dose. At the discretion of the investigator, weekly Trastuzumab could be given in either of the three treatment arms (loading dose 4mg/kg followed by weekly administration of 2mg/kg).
223693437|NCT02213042|DRUG|Aromatase Inhibitors (AIs)|Subjects who were hormone receptor-positive were required to receive an aromatase inhibitor as combination treatment; however the choice of the aromatase inhibitor selected for each patient was determined by the patients' investigator. The AIs the Investigator could choose from were anastrozole, exemestane, and letrozole and dosing was per product information.
223693438|NCT05860933|DRUG|LY3537982|Administered orally.
223693439|NCT05860933|DRUG|Itraconazole|Administered orally.
223693440|NCT05860933|DRUG|Carbamazepine|Administered orally.
223693441|NCT05314478|DEVICE|Continuous laryngoscopy during exercise test using the HALOS headgear|"The participant will undergo the CLE test following standard clinical practice.~The order of events of the aspects of the investigation related to the headgear will be:~1. The headgear is prepared for use.~2. The headgear is fitted onto the participant's head.~3. The endoscope is inserted into the participant.~4. The endoscope is fitted onto the headgear.~5. The CLE test is carried out.~6. The endoscope is removed from the headgear.~7. The endoscope is removed from the participant.~8. The headgear is removed from the participant.~9. The headgear is cleaned and stored."
223693442|NCT06437353|DRUG|Paclitaxel|"First-line chemotherapy regimen:~* Paclitaxel: 175 mg/m², intravenous infusion, on day 1.~* Carboplatin: AUC 5, intravenous infusion, on day 1.~* Surufatinib：250 mg once daily, taken continuously.~Maintenance Therapy Regimen:~* Surufatinib: 250 mg once daily, taken continuously.~* Olaparib: 300 mg twice daily."
223693443|NCT04629508|DRUG|itacitinib|itacitinb Immediate Release (IR) will be dosed orally twice a day
223693444|NCT05054036|DRUG|MoviPrep|Split-dose MoviPrep bowel preparation
223693445|NCT05054036|DRUG|Golytely|Split-dose GoLYTELY bowel preparation
223693446|NCT02646254|OTHER|blood cardioplegia|
223693447|NCT02646254|OTHER|del nido cardioplegia|
223693448|NCT00396747|DRUG|Infliximab, methylprednisolone, methotrexate|
223693449|NCT00396747|DRUG|Methotrexate|
223693450|NCT00396747|DRUG|Methotrexate + Methylprednisolone|
223693451|NCT00396747|DRUG|Methotrexate + Infliximab|
223693452|NCT04541160|DIAGNOSTIC_TEST|CR|Lung imaging evaluation performed with CR
223693453|NCT04541160|DIAGNOSTIC_TEST|ULDCT|Lung imaging evaluation performed with ULDCT
223693454|NCT04499976|DRUG|Isonicotinic Acid|Drug: Isonicotinic Acid then misoprostol Drug: Isonicotinic Acid 300mg total dose 900 mg per day for 3 days
223693455|NCT04499976|DRUG|Placebo|Drug: placebo then misoprostol Drug: Placebo placebo for 3 days
223693456|NCT04499976|DRUG|Misoprostol|Drug: Misoprostol Misoprosrol 800mcg will be given to all patients for induction of abortion
223693457|NCT01973543|BIOLOGICAL|VY-AADC01|Neurosurgical delivery of VY-AADC01 to the brain.
223693458|NCT03395925|DEVICE|Celon Pro Surge|bipolar coagulation electrode intended for tissue heating
223693459|NCT00378586|PROCEDURE|Rectal biopsy|Rectal biopsy.
223693460|NCT00378586|PROCEDURE|Measurement of inflammatory markers in the rectal mucosa|IL-6, TNF-alfa.
223693461|NCT00378586|PROCEDURE|Measurement of rectal lactic acid|Equilibrium dialysis.
223693462|NCT02030054|DRUG|Atorvastatin|Patients were randomly assigned to atorvastatin (40 mg day) for 30 days. After 1-week wash-out period to avoid any carryover effect, cross-over was performed, and patients were switched to the other drug which was continued for 30 days.
223693463|NCT02030054|DRUG|Rosuvastatin|Patients were randomly assigned to rosuvastatin (20 mg day) for 30 days. After 1-week wash-out period to avoid any carryover effect, cross-over was performed, and patients were switched to the other drug which was continued for 30 days.
223693464|NCT00708565|DRUG|iloprost|Baseline echo measurements, cardiac output, pulse oximetry will be taken. Subjects will then be given one dose of inhaled iloprost. Post-inhalation, the measurements will be repeated at rest and with exercise.
223693465|NCT02476422|DRUG|Diclofenac potassium|Single dose of diclofenac 50 mg soft gelatin capsule
223693466|NCT02476422|DRUG|Ibuprofen|Single dose of ibuprofen 400 mg tablet
223693467|NCT02476422|DRUG|Placebo to ibuprofen|Single dose of placebo to ibuprofen 400 mg tablet
223693468|NCT02476422|DRUG|Placebo to diclofenac potassium|Single dose of placebo to diclofenac potassium 50 mg soft gelatin capsule
223693469|NCT03205137|DRUG|subjects treated with telmisartan/hydrochlorothiazide|subjects treated with telmisartan/hydrochlorothiazide
223693470|NCT03205137|DRUG|Subjects treated with Telmisartan and amlodipine|Subjects treated with Telmisartan and amlodipine
223693471|NCT03205137|DRUG|subjects treated with Telmisartan+hydrochlorothiazide double-pill combination group|subjects treated with Telmisartan+hydrochlorothiazide double-pill combination group
223693472|NCT03205137|DRUG|subjects treated with telmisartan+amlodipine double pill|subjects treated with telmisartan+amlodipine double pill
223693473|NCT01310881|DRUG|NSI-189 Phosphate|Once daily oral administration
223693474|NCT02602899|PROCEDURE|PINS'Deep Brain Stimulator device|deep brain stimulation of the PINS'IPG function to anterior nucleus of the thalamus is off in a short time
223693475|NCT01288027|BIOLOGICAL|Alglucosidase Alfa|Alglucosidase alfa intravenous infusion 20 milligram per kilogram (mg/kg) every other week for 24 weeks.
223693476|NCT00760214|DRUG|Azilsartan medoxomil|Azilsartan medoxomil 20 mg, tablets, orally, once daily for two weeks; then increased to 40 mg, tablets, orally, once daily for up to 22 weeks.
223693477|NCT00760214|DRUG|Azilsartan medoxomil|Azilsartan medoxomil 20 mg, tablets, orally, once daily for two weeks; then increased to 80 mg, tablets, orally, once daily for up to 22 weeks.
223693478|NCT00760214|DRUG|Ramipril|Ramipril 2.5 mg, tablets, orally, once daily for two weeks; then increased to 10 mg, tablets, orally, once daily for up to 22 weeks.
223693479|NCT03126370|DRUG|TDF with a boosted protease inhibitor|"Participants who are already taking tenofovir disoproxil fumarate 300 mg (in the form of Viread or Truvada) in combination with either a ritonavir- or cobicistat-boosted protease inhibitor for HIV treatment will continue to take their prescribed treatment for 12 weeks after enrollment.~Other: Blood draws for tenofovir PK, renal function assessment"
223693480|NCT03126370|DRUG|TAF with a boosted protease inhibitor|"Participants will be switched from tenofovir disoproxil fumarate to tenofovir alafenamide 25 mg/emtricitabine 200 mg with a boosted protease inhibitor.~Other: Blood draws for tenofovir PK, renal function assessment"
223693481|NCT03126370|DRUG|TAF with a boosted protease inhibitor and LDV/SOF|"After taking tenofovir alafenamide/emtricitabine for 12 weeks, participants will then start taking ledipasvir 90 mg/sofosbuvir 400 mg (Harvoni) in combination with the tenofovir alafenamide 25 mg/emtricitabine 200 mg (Descovy) and a boosted protease inhibitor for 4 weeks. Subjects will then return to taking tenofovir alafenamide 25 mg/emtricitabine 200 mg (Descovy) and a boosted protease inhibitor for the final 12 weeks.~Other: Blood draws for tenofovir PK, renal function assessment"
223693482|NCT01134315|DRUG|Paricalcitol|
223693483|NCT01134315|DRUG|Calcitriol|
223693484|NCT03105804|OTHER|FT21039|An electronic cigarette
223693485|NCT03105804|OTHER|FT21041|An electronic cigarette
223693486|NCT03105804|OTHER|FT21044|An electronic cigarette
223693487|NCT03105804|OTHER|FT21042|An electronic cigarette
223693488|NCT01053949|DRUG|Pomalidomide|Pomalidomide 4 mg continuous daily oral route on 21 days per 28 days cycle. The proposed dose of dexamethasone is considered standard, 40mg/day once a week.
223693489|NCT01053949|DRUG|Pomalidomide|Pomalidomide 4 mg continuous daily oral route on 28 days of a 28 days cycle The proposed dose of dexamethasone is considered standard, 40mg/day once a week.
223693490|NCT05633225|OTHER|Submax exercise test on a bicycle ergometer|"To achieve exertion and not exhaustion, cycling will be stopped at 75% of the expected maximum heart rate (maximum heart rate of 220 beats per minute minus age) as a target value.~If the participant then indicated that they do not feel strained, the cycling will continue until the participant experienced an effort on Borg Rating of Perceived Exertion Scale scale of 15 (hard)."
223693491|NCT03161821|OTHER|Observational|
223777816|NCT02087462|DRUG|Voltaren|"Medication: 50 mg, twice per day~Treatment frequency: In the first 2 weeks, take medicine for continuous 5 days with a 2-day interval each week; in the 3rd and 4th week, take medicine every 2 days, totally 3 times each week; in the 5th and 6th week, take medicine every 3 days, totally 2 times each week.~Duration: 6 weeks."
223777817|NCT02087462|DRUG|Vitamin B1|"Medication: 10mg, twice per day.~Treatment frequency: In the first 2 weeks, take medicine for continuous 5 days with a 2-day interval each week; in the 3rd and 4th week, take medicine every 2 days, totally 3 times each week; in the 5th and 6th week, take medicine every 3 days, totally 2 times each week.~Duration: 6 weeks."
223777818|NCT04582552|DRUG|PARP inhibitors|Ovarian cancer patients with PARP inhibitors according to the NCCN guideline and their instructions.
223777819|NCT01612546|DRUG|cyclodextrin-based polymer-camptothecin CRLX101|Given IV
223777820|NCT01612546|OTHER|Laboratory biomarker analysis|Correlative studies
223777821|NCT01612546|OTHER|Pharmacological studies|Correlative studies
223777822|NCT05226650|OTHER|Regular meal pattern|6 meals every day
223777823|NCT05226650|OTHER|Irregular meal pattern|It consists of consuming a different number of meals every day (between 3 and 9).
223777824|NCT00234884|BIOLOGICAL|adalimumab|commercial adalimumab as prescribed by the rheumatologist in a normal clinical setting and in accordance with the Summary of Product Characteristics (SmPC)
223777825|NCT06534294|OTHER|reflexology|Reflex therapy was done for each patient for 30 minutes, first for the right foot and then for the left foot (15 minutes each) and breathing exercises in 3 stages
223777826|NCT06534294|OTHER|breathing exercise|breathing exercise done as 3 stages,stage one for 5 minutes, stage two for 10 minutes end stage ; Close eyes and focus your present feelings, Then Relax the whole body for 5 minutes.
223777827|NCT06534294|OTHER|standard care|standard medical care no other treatment
223777828|NCT02386202|OTHER|No intervention|No interventions
223777829|NCT00208377|DEVICE|DePuy ASR Hip System|A metal-on-metal bearing surface replacement system for use in resurfacing hip arthroplasty
223777830|NCT02276495|OTHER|ACB Control - 20 ml saline injection for ACB|Adductor Canal Block Control (20 ml saline injection)
223777831|NCT02276495|DRUG|ACB Study - 20 ml 0.5% Ropivacaine for Adductor Canal Block|Adductor Canal Block Study (20 ml 0.5% Ropivacaine)
223777832|NCT02276495|DRUG|Local infiltration - 100 mLs of a solution containing: Ropivacaine + Epinephrine + Ketorolac + Clonidine + 0.9% Normal saline|"100 mLs of a solution containing:~Ropivacaine 2 mg/mL (49.25 mL) + Epinephrine 1 mg/mL (0.5 mL) + Ketorolac 30mg/mL (1mL) + Clonidine 100 mcg/mL (0.8 mL) + 0.9% Normal saline (48.45 mL)"
223777833|NCT03541746|BIOLOGICAL|Platelet Rich Plasma|After hysteroscopic adhesiolysis, 30 patients will undergo once injection of 5ml PRP into the wall then lining the uterine cavity by 5ml platelet rich plasma gel. Finally, Foley balloon catheter will be inserted intrauterine then inflated and cutting its stem and to be left for two weeks.
223777834|NCT03541746|DEVICE|Intrauterine Foley's Catheter|After hysteroscopic adhesiolysis, 30 patients will undergo intrauterine insertion of one inflated Foley balloon catheter with cutting its stem only to be left for two weeks.
223777835|NCT05703529|BEHAVIORAL|Positive Psychotherapy|A 6-week group-based positive psychotherapy was conducted in this group. The themes of each week include positive introduction, three good things and positive reactions, gratitude, positive memory, identifying personal strengths and utilizing strengths.
223777836|NCT05703529|OTHER|Usual Care|Usual Care means treating as usual, including a regular home visit.
223777837|NCT01242904|DRUG|bimodal solution|200 mL of 30% glucose infused into the abdomen by the patient each morning for 6 weeks, added to the daytime dwell of approximately 2000 mL icodextrin that has been infused by the cycler
223777838|NCT01242904|DRUG|icodextrin|200 mL of icodextrin infused into the abdomen by the patient each morning for 6 weeks, added to the daytime dwell of approximately 2000 mL icodextrin that has been infused by the cycler
223777839|NCT01947504|BEHAVIORAL|education and support intervention|
223777840|NCT06117267|DEVICE|Anatase Spine Surgery Navigation System|Collect images with the probe touching the target position before screw implantation
223777841|NCT00612313|DRUG|Fluoxetine|Participants will take 10 to 40 mg per day of fluoxetine for 30 weeks.
223777842|NCT00612313|BEHAVIORAL|Relapse prevention cognitive behavioral therapy (CBT)|After the first 6 weeks of treatment with fluoxetine, some participants will be assigned to additionally receive relapse prevention CBT for the remaining 24 weeks of treatment. These participants will attend 10 to 12 CBT sessions, during which they will learn specific skills to reduce and prevent the occurrence of residual depressive symptoms.
223777843|NCT01745029|DEVICE|Motilis-3D-transit|
223777844|NCT00903838|DRUG|pardoprunox|1.5 to 12 mg/day
223777845|NCT00903838|DRUG|pramipexole|0.75-4.5 mg/day
223777846|NCT01016834|DEVICE|Sumavel DosePro|Needle free delivery system containing 0.5 mL of solution of 6 mg sumatriptan, subcutaneous administration
223777847|NCT01016834|DRUG|Sumatriptan|subcutaneous injection, 6 mg, per migraine attack, no more than two administrations within a 24 hr period
223693492|NCT04064385|DEVICE|FES Cycling|Stimulation parameters will be 450μs, 40Hz, and up to 140mA, these values will be changed if needed based on individual response. For example, stimulation to the gluteal muscles often may to be decreased to prevent autonomic dysreflexia. To receive correct stimulation parameters, stimulation intensity will be chosen to ensure a palpable muscle contraction and sensor tolerance. Each session will include a 2-minute warm-up and 2-minute cool-down of passive cycling. The unit automatically delivers enough stimulation to maintain a speed of 30 rotations per minute (rpm). Where this is not achieved, the leg cycle will assist the stimulated movement to maintain a speed of 30 rpm.
223693493|NCT06150755|PROCEDURE|implant supported overdenture by ball|overdenture supported by two implant with ball attachment
223693494|NCT06150755|PROCEDURE|implant supported overdenture by bar|overdenture supported by two implant splinted by intraoral welding titanuim bar
223693495|NCT01086423|BIOLOGICAL|Infanrix-IPV/Hib™|Intramuscular, three doses
223693496|NCT01086423|BIOLOGICAL|Infanrix Hib™|Intramuscular, three doses
223693497|NCT01086423|BIOLOGICAL|Poliorix™|Intramuscular, three doses
223693498|NCT01017471|PROCEDURE|Limited incision using PSU retractor|carpal tunnel release using limited incision with PSU retractor will be done by orthopaedic hand surgeons
223693499|NCT03843112|DRUG|Vivag Plus|Contains two lactobacilli strains; l. gasseri and l. rhamnosus
223693500|NCT03843112|DRUG|Placebo - Cap|Vaginal supplements
223693501|NCT02009007|DRUG|dopamine|continuous infusion during operation
223693502|NCT02009007|DRUG|phenylephrine|continuous infusion of phenylephrine during operation
223693503|NCT00749515|DRUG|Deferoxamine|After a 3-day washout period from all chelation, all patients have a 12 hour infusion of 50mg/kg of deferoxamine with urine collection and pre and post blood sampling to assess iron and Total Iron Binding Capacity (TIBC) by atomic absorption.
223693504|NCT00749515|DRUG|Deferasirox|After a 3-day washout period from all chelation, patients had a desferal challenge which was followed by a single dose of deferasirox, 35mg/kg orally with blood sampling taken pre-deferasirox and at intervals for 24 hours after the dose.
223693505|NCT00749515|RADIATION|HIDA|All patients had a HIDA scan to assess physiologic liver clearance capacity.
223693506|NCT05266534|DRUG|Terlipressin|the efficacy of intramyometrial Terlipressin injection on hemoglobin level and decreasing blood loss in women undergoing open myomectomy
223693507|NCT05266534|DRUG|Carbetocin|the efficacy of intramyometrial carbetocin injection on hemoglobin level and decreasing blood loss in women undergoing open myomectomy
223777848|NCT06653257|OTHER|Active surveillance|a non-operative management strategy aimed at avoiding unnecessary surgery in patients with thyroid nodules with a cytopathological diagnosis of Bethesda IV-VI, who do not present clinical or imaging characteristics suggesting malignancy and/or aggressiveness.
223693508|NCT05266534|DRUG|Saline|the efficacy of intramyometrial saline injection on hemoglobin level and decreasing blood loss in women undergoing open myomectomy
223693509|NCT01270542|DRUG|Avastin (bevacizumab)|single 0.05 mL intravitreal injection of bevacizumab 1.25 mg
223693510|NCT01270542|OTHER|Sham injection|Subject's eyes will be anesthetized but no injection will be performed.
223693511|NCT03432156|BIOLOGICAL|Autologous Tcm cells immunotherapy|Autologous Tcm cells immunotherapy is to collect patient's own immune cells in peripheral blood and then given back to the patient after amplified in vitro.
223693512|NCT02124486|PROCEDURE|Bariatric surgery|Participants randomised to the bariatric surgery arm of the trial will be referred to the surgery pathway according to NICE guidelines at Birmingham Heartlands Hospital (BHH), Heart of England NHS Foundation Trust.
223693513|NCT02124486|BEHAVIORAL|Dietetic intervention|Participants randomised to the dietetic arm will be given vouchers at baseline, 3, 6 and 9 months that exempt them from paying for consecutive and specified weeks of their local Weight Watchers.
223693514|NCT04594148|BEHAVIORAL|Weight-shift training|Weight-shift training will consist of a single session of 10x 2.5min of mediolateral weight-shifting in the VR Wasp Game. Including breaks, the session will approximately take 45min.
223693515|NCT05914922|OTHER|Educational Tool|20 MSK short case simulations were developed based on authentic patient experiences. Strategies to optimize learning of MSK conditions to prepare learners for real-world clinical encounters would be important for family medicine resident learners. To address this need, 20 case simulations of 15 minute duration were developed. This study will determine if an online educational tool may be impactful for determining competency of family medicine resident learners in developing skills and knowledge of 20 MSK conditions while also determining if the tool impacts patient care and satisfaction.
223693516|NCT00734123|DRUG|Simvastatin or Atorvastatin|Simvastatin 10-40 mg or Atorvastatin 20-40 mg will be prescribed according to LDL cholesterol reduction target.
223693517|NCT00734123|DRUG|Enalapril|Enalapril 10 mg/day will be prescribed as the initial treatment. Doses and adding drugs will be titrated accordingly
223693518|NCT00734123|DRUG|Aspirin or clopidogrel|Aspirin 100 mg or clopidogrel 75 mg/ per day
223693519|NCT00734123|DRUG|Rimonabant|"In both arms, we will follow the standard clinical care in terms of treatments, as far as obesity and diabetes mellitus is concerned.~Drugs will be prescribed as the standard clinical care"
223693520|NCT01572259|DRUG|Growth Hormone|
223693521|NCT01572259|OTHER|interruption of the traitment with growth hormone|
223693522|NCT01298973|DRUG|Viscoat|One group will receive Viscoat for incision closure
223693523|NCT01298973|DRUG|Saline|One group will receive Saline to irrigate the wound
223693524|NCT05276180|OTHER|Arm A) Multifactorial intervention strategy|"Implementation of the multifactorial intervention strategy will be supported by the following components:~1\) An implementation team at each intervention unit consisting of 5-6 HCWs is responsible for informing and engaging all HCWs at the unit. For implementing the various components of the strategy. They will have the role of planning regular workplace meetings. 2) One or two internal facilitators will be the link between the external facilitator and the care unit. The internal facilitator will give support with material, information and will be able to ask questions of the external facilitator.~3\) External facilitator will ensure that the implementation process works according to plan. The research team will present the results of SMET to the implementation team.~4\) The research group will be project leaders and support the external facilitators. They will provide workshops and will also be responsible for data collection."
223693525|NCT05276180|OTHER|Arm B) Single intervention strategy|No further interventions other than access to the Swedish guideline for patient handling and movement and the results from the SMET questionnaire will be presented to the manager. Arm B will be assigned an external facilitator who provides information, is present at the start-up meeting and will be the contact person during the study period. No further support will be given to the care units in arm B.
223693526|NCT05745532|BIOLOGICAL|β-globin restored autologous hematopoietic stem cells|β-globin-restored autologous hematopoietic stem cells modified with LentiHBBT87Q
223693527|NCT04234386|RADIATION|GammaPod Radiation|The basic design is a dose-escalation phase Ib study with 4 predefined dose levels. With this study treatment, participants will receive the dose level assigned treatment of radiation therapy before the lumpectomy surgery.
223693528|NCT03568890|DRUG|Rivaroxaban, dabigatran, apixaban, or edoxaban|Duration of treatment: 60 days
223693529|NCT03568890|DRUG|Clopidogrel -75 mg/day|Duration of treatment: 60 days
223693530|NCT03568890|DRUG|Low dose aspirin -80 to 125 mg/day-|Duration of treatment: 60 days
223693531|NCT03353389|OTHER|No AKI|Subjects will be allocated into this group if they did not acquire Acute Kidney Injury during admission.
223693532|NCT03353389|OTHER|CA-AKI|"CA-AKI is defined by any patient who developed AKI (as per definition below) within 48 hours of hospital admission.~Definition of AKI:~i. An increase in serum creatinine of 0.3 mg/dl (26.5 μmol/l) within 48 hours OR ii. An increase in serum creatinine to more or equal to 1.5 times baseline, which is known or presumed to have occurred within the prior 7 days~Definition for baseline creatinine:~i. The baseline creatinine level is defined as the creatinine level at or within 7 days before the hospital admission, OR ii. at the hospital admission OR iii. the lowest creatinine (excluding the post dialysis creatinine if dialysis is initiated) during the index hospitalisation for those whose baseline creatinine were unknown."
223693533|NCT03353389|OTHER|HA-AKI|"HA-AKI is defined by any patient who developed AKI (as per definition below) after 48 hours of hospital admission.~Definition of AKI:~i. An increase in serum creatinine of 0.3 mg/dl (26.5 μmol/l) within 48 hours OR ii. An increase in serum creatinine to more or equal to 1.5 times baseline, which is known or presumed to have occurred within the prior 7 days~Definition for baseline creatinine:~i. The baseline creatinine level is defined as the creatinine level at or within 7 days before the hospital admission, OR ii. at the hospital admission OR iii. the lowest creatinine (excluding the post dialysis creatinine if dialysis is initiated) during the index hospitalisation for those whose baseline creatinine were unknown."
223693534|NCT02779751|DRUG|Abemaciclib|Administered orally
223693535|NCT02779751|DRUG|Pembrolizumab|Administered IV
223693536|NCT02779751|DRUG|Anastrozole|Administered orally
223693537|NCT05497700|DRUG|Ephedrine|Bolus injection of 6 mg ephedrine to keep mean arterial blood pressure above 65 mm Hg
223693538|NCT05497700|DRUG|Norepinephrine|Bolus injection of either 6 mcg norepinephrine to keep mean arterial blood pressure above 65 mm Hg
223693539|NCT01755273|PROCEDURE|Pancreaticoduodenectomy with more distal enteral bypass|Patients undergoing pancreaticoduodenectomy, the enteral bypass (gastrojejunostomy/duodenojejunostomy is extra 100 cm away from standard bypass )
223693540|NCT03599635|DRUG|liposomal bupivacaine|Experimental
223693541|NCT03599635|DRUG|Bupivacaine|Active Comparator
223693542|NCT02129829|DRUG|Tenofovir disoproxil|Tenofovir disoproxil 245 mg once daily
223693543|NCT06019429|BEHAVIORAL|HiRO|"HiRO consists of weekly lessons. The lessons are aimed to promote social-emotional development. More specifically, lessons are designed to develop and enhance 1) trust, 2) collaboration, 3) respect, 4) self control, 5) resilience, 6) discipline, 7) joy. The annual program consists of four phases:~Phase 1 \& 3: Fundamental phase (6 weeks) Engaging with the values through movement. In these phases, group formation and establishing behavioral expectations are central. In the Fundamental phase, one value is addressed school-wide each week. The entire school starts with trust and ends with discipline.~Phase 2 \& 4: Theme weeks (12 lessons) A customized series of Experiential lessons for each class. Experiential learning is the guiding principle of the program, with a strong foundation based on the values upheld in judo. The learning cycle forms the basis for each experiential lesson within HiRO, and focusses on concrete experience, reflective observation, conceptualization, and practice."
223693544|NCT06019429|BEHAVIORAL|HiRO +judo|In the condition HiRO with judo, students receive the same treatment as offered in the HiRO condition. In addition, they receive physical judo classes that are designed to translate the above-mentioned values to the behavioral level.
223693545|NCT06019429|BEHAVIORAL|School as usual|Any amount of classes offered to promote social-emotional development
223693546|NCT01130103|DRUG|Paroxetine|Paroxetine (controlled release) 12.5-50 milligrams (mg) daily for 22 weeks
223693547|NCT01130103|BEHAVIORAL|Prolonged Exposure Therapy|Weekly for 10 weeks
223693548|NCT01727908|OTHER|Endoscopy with staining of the mucosa|Staining of the gastric mucosa with acetic acid and Indigocarmine
223693549|NCT01822678|DRUG|Eslicarbazepine Acetate|Eslicarbazepine Acetate, starting with 800 mg per day and up-titrated in 800 mg steps until 2400 mg (maximum dose) according to clinical response.
223693550|NCT01822678|DRUG|Eslicarbazepine Acetate|Eslicarbazepine Acetate, starting with 600 mg per day and up-titrated in 600 mg steps until 1800 mg (maximum dose) according to clinical response.
223693551|NCT01822678|DRUG|Placebo|Placebo
223693552|NCT01465191|DRUG|Morphine|Morphine will be given via spinal injection at doses of 50, 100, 150 micrograms as part of a spinal anesthetic for cesarean section
223693553|NCT02815488|DRUG|CHF6297 (Part 1 - SAD)|Single doses of CHF6297 at each period (for up to 3 periods per subject)
223693554|NCT02815488|DRUG|Placebo (Part 1 - SAD)|Single doses of placebo matching CHF6297 at each period (for up to 3 periods per subject)
223693555|NCT02815488|DRUG|CHF6297 (Part 2 - MAD)|Twice daily doses of CHF6297 for 7 days
223693556|NCT02815488|DRUG|Placebo (Part 2 - MAD)|Twice daily doses of placebo matching CHF6297 for 7 days
223693557|NCT02815488|DRUG|CHF6297 (Part 3)|Twice daily doses of CHF6297 for 14 days
223693558|NCT02815488|DRUG|Placebo (Part 3)|Twice daily doses of placebo matching CHF6297 for 14 days
223693559|NCT02815488|DRUG|CHF6297 (Part 4)|Twice daily doses of CHF6297 for 7 days
223693560|NCT02815488|DRUG|Placebo (Part 4)|Twice daily doses of placebo matching CHF6297 for 7 days
223693561|NCT00233428|PROCEDURE|Blood Draw|
223693562|NCT02089854|DRUG|Toremifene; Anastrozole|Toremifene 60mg PO. per day for premenopausal and perimenopausal patients; Anastrozole 1mg PO. per day for postmenopausal patients
223693563|NCT02992132|DRUG|Pimavanserin 34 mg|Pimavanserin 34 mg, tablet, taken as two 17 mg tablets, once daily by mouth
223693564|NCT02992132|DRUG|Pimavanserin 20 mg|Pimavanserin 20 mg, tablet, taken as two 10 mg tablets, once daily by mouth
223693565|NCT02992132|OTHER|Placebo|Placebo, taken as two tablets, once daily by mouth
223693566|NCT01509508|DRUG|Immediate ARV treatment initiation with TDF/FTC/EFV|"All HIV-infected adults will be offered ART regardless of their immunological and clinical staging.~The first line regimen proposed will be Atripla (R), a fixed dose combination containing tenofovir disoproxil (245 mg)/emtricitabine (200 mg)/efavirenz (600 mg)(FTC/TDF/EFV). The dosing will be 1 tablet OD."
223693567|NCT01509508|OTHER|South African recommendation guided ARV (TDF/FTC/EFV) initiation|"HIV-infected adult participants will be eligible for ART as per the South African guidelines (August 2011) if:~* CD4 count ≤ 350 cells/mm3 irrespective of clinical symptoms~* WHO clinical stage 3 or 4 irrespective of CD4 count~* MDR or XDR TB The first line regimen proposed will be Atripla (R), a fixes dose combination containing tenofovir disoproxil (245 mg)/emtricitabine (200 mg)/efavirenz (600 mg)(TDF/FTC/EFV). The dosing will be 1 tablet OD."
223693568|NCT05486741|OTHER|Optical cehernce tomography|OCT macula and disc
223693569|NCT05570201|OTHER|Control group|No intervention was applied to the women in the control group, only the questionnaires (pre-test, post-test) were filled out. Filling the questionnaires lasted 10-15 minutes on average in all groups
223693570|NCT00548106|DIETARY_SUPPLEMENT|partially hydrolyzed whey|Total infant feeding by study formula.
223693571|NCT00548106|DIETARY_SUPPLEMENT|Nan HA|Total infant diet by study formula.
223693572|NCT02231047|DIETARY_SUPPLEMENT|64N Nutraceutical|40 mg/kg/day of powdered 64N mixed in 12 ounces of a warm drink for 1 week (7 days)
223693573|NCT02231047|OTHER|No 64N Nutraceutical|12 ounce warm drink daily for 1 week (7 days)
223693574|NCT05240287|DIAGNOSTIC_TEST|Navicular Drop Test|The researchers will measure the distance between the navicular tuberosity and the ground with a caliper with non-weight bearing in sitting. After that, the distance between the ground and the navicular tuberosity will be measured in standing while weight-bearing. The researchers will evaluate both sides and record the value in mm. According to Navicular Drop Test, the difference between weighted and unweighted measurements is considered normal (neutral) if it is between 5 and 9 mm, pronation (pes planus) if it is 10 mm or more, and supination (pes cavus) if it is 4 mm or less. In our study, individuals with a difference of 10 mm or more in both feet will be included in the pes planus, and individuals with a difference between 5-9 mm will be included in the control group.
223693575|NCT05240287|DIAGNOSTIC_TEST|Foot Posture Index|The index consists of six items in which the foot is evaluated observationally. In the evaluation, the individual is asked to stand in a comfortable and relaxed position. The researcher observes the medial longitudinal arch structure, the structure of the talonavicular joint region, the degree of abduction/adduction in the forefoot relative to the hindfoot in the front part of the foot. In the back foot, inversion/eversion of the calcaneus, talus head position, and curvatures above and below the lateral malleolus are evaluated. The total score is reached by scoring each criterion between -2 and +2 values. 0; neutral position, (+) values; pronation (pes planus), (-) values indicate supination (pes cavus). Individuals with +6 to +12 points from this index will be included in our study.
223693576|NCT05240287|DIAGNOSTIC_TEST|Balance|Static and dynamic balance and stability limit values of individuals will be evaluated with the HUR Smart Balance (SME Inc, USA) balance measurement device. The device consists of a computer and a platform on which individuals can place their feet. For static balance measurement, individuals will be asked to place their feet on the marked places on the platform. The researchers will evaluate the balance in four different situations, 30 seconds each. In the first test, individuals keep the balance on firm ground with their eyes open. The second test performed on the firm ground with eyes closed, in the third test, on the soft ground with eyes open, and in the fourth test, on the soft ground with eyes closed. For dynamic balance, individuals will be asked to extend their body weight to the front, back, and sides with their feet in 4 different directions for 8 seconds.
223693577|NCT05240287|DIAGNOSTIC_TEST|Plantar Pressure Analysis|Plantar pressure analysis of individuals will be evaluated by measuring with the DIERS Pedoscan DICAM 3 v3.10.8 (2019) device. DIERS Pedoscan is a system integrated into the treadmill that measures the pressure distribution on the sole during stance. As a result of this evaluation, right-left and anterior-posterior weight transfer, left-right foot rotation, lateral mobility, the center of gravity movement, and swing area data will be recorded.
223693578|NCT05240287|DIAGNOSTIC_TEST|Gait Analysis|Gait analysis of individuals will be evaluated with the DIERS Leg Axis DICAM 3 v3.10.8 (2019) system. The system consists of a treadmill, computer, and cameras. Before the measurement, colored markers will be placed on the knee and ankle joints of the individual. For gait assessment, individuals will walk at their preferred comfortable walking speed. In the evaluation, joint angles, walking speed, step lengths are recorded. Evaluation time is approximately 5 minutes.
223693579|NCT00014404|DRUG|celecoxib|
223693580|NCT04838392|DEVICE|RIGHTEST Continuous Glucose Monitoring System|RIGHTEST Continuous Glucose Monitoring System
223693581|NCT00620464|DRUG|Radiopaque Implanon|Radiopaque rod for 3 years
223693582|NCT00620464|DRUG|Implanon (etonogestrel implant)|Implanon (etonogestrel implant) for 3 years
223693583|NCT03210181|OTHER|Superficial cervical plexus block|A nerve stimulator is used to guide the superficial cervical block. The nerve stimulator needle is first passed over the skin after aseptic preparation from the distal to proximal part of the posterior border of the sternocleidomastoid. Upon contraction of the levator scapulae, a mark is placed and the skin is infiltrated with 1 ml lidocaine 1%. A 22-G, 2.5 cm nerve stimulator needle is subsequently advanced through the skin by 0.5-1 cm depending on patient's weight while passing 5-8.5 mA current at 1 Hz. Then, the stimulating current is reduced to 0.5-0.6 mA while maintaining muscle contraction. At this point, 3-5 ml of the anesthetic mixture is injected.
223693584|NCT03210181|OTHER|Placebo|Patients will receive an equivalent volume of normal saline
223693585|NCT04190173|DRUG|Prucalopride|1-2 mg once daily enteral feeding for 5 consecutive days
223693586|NCT04190173|DRUG|Placebo|1/2-1 tablet once daily enteral feeding for 5 consecutive days
223693587|NCT06182280|BEHAVIORAL|PrEP4T|PrEP4T is an individualized TMSM-specific intervention adapted from The Fenway Model. PrEP4T consists of online one-on-one sessions between a peer and a participant using a strengths-based case management manualized curriculum. Peer navigators (PNs) share transmasculine community membership with participants and are trained to provide linkages. They use an individualized approach to navigate barriers, apply an assets-based frame to promote resiliencies, and pragmatically leverage these to improve biomedical HIV prevention outcomes. PNs utilize techniques from established behavior change models (e.g., Motivational Interviewing; Transtheoretical Model) in PrEP decision-making.
223693588|NCT06182280|BEHAVIORAL|LS4TM|LS4TM is a theory-based peer-delivered small group-based behavioral intervention to reduce HIV risk and address mental health-related effects of stigma for TMSM. Groups will be led by trained peer navigator staff and comprise no more than 10 participants per cohort.
223693589|NCT04082559|OTHER|Arm 1- Antibiotics treatment|Patients with active disease will be randomized and will receive a prescription antibiotic regimens
223693590|NCT04082559|OTHER|Arm 2- Antibiotics treatment|Patients with active disease will be randomized and will receive a prescription antibiotic regimens
223693591|NCT04082559|OTHER|Arm 1- Combination therapy (Antibiotics + diet)|Patients with active disease receiving a prescription for the antibiotic regimen defined as favorable in the antibiotics according to aim 1 , and randomized into one of two dietary interventions: Mediterranean diet (MED) or the specific carbohydrate diet (SCD).
223693592|NCT04082559|OTHER|Arm 2- Combination therapy (Antibiotics + diet)|Patients with active disease receiving a prescription for the antibiotic regimen defined as favorable in the antibiotics according to aim 1 , and randomized into one of two dietary interventions: Mediterranean diet (MED) or the specific carbohydrate diet (SCD).
223693593|NCT04082559|OTHER|Arm 1- Nutritional prevention|Patients in clinical remission will be recruited to a dietary prevention study
223693594|NCT04082559|OTHER|Arm 2- Nutritional prevention|Patients in clinical remission will be recruited to a dietary prevention study
223693595|NCT04082559|OTHER|Arm 3- Nutritional prevention|Patients in clinical remission will be recruited to a dietary prevention study
223693596|NCT01812590|BEHAVIORAL|Exercise|
223693597|NCT02207985|PROCEDURE|Allogeneic hematopoietic stem cell transplantation|
223693598|NCT00467610|DRUG|Panhematin|
223693599|NCT01369615|DRUG|Oxycodone hydrochloride controlled-release tablets|Oxycodone hydrochloride controlled-release tablets at strengths of 10, 15, 20, 30, or 40 mg (20 mg to 240 mg daily) every 12 hours.
223693600|NCT03557554|OTHER|Massage|A 20 minute massage protocol will be administered in a chair by a licensed massage therapist no more than 24 hours prior to each paclitaxel infusion.
223693601|NCT04263454|DRUG|Endotoxin, Escherichia Coli|Endotoxin is a purified lipopolysaccharide prepared from E. coli O:113 and vialed under good manufacturing practice guidelines.
223693602|NCT04263454|PROCEDURE|Magnetic Resonance Spectroscopy|MRI is a non-invasive imaging technique and does not utilize ionizing radiation.
223693603|NCT05093348|DEVICE|Click2Print artificial eye|Digitally designed and manufactured ocular prosthesis
223693604|NCT05093348|DEVICE|Hand-made artificial eye|Hand-made artificial eye
223693605|NCT00070655|DRUG|SR34006 (idraparinux sodium) Injection|
223693606|NCT00070655|DRUG|vitamin K antagonist (warfarin or acenocoumarol) tablets|
223693607|NCT05752981|DEVICE|multichannel time-resolved (tr) functional near infrared spectroscopy (fNIRS) (tr-fNIRS)|Participants will be monitored during surgery using the multichannel time-resolved (tr) functional near infrared spectroscopy (fNIRS) (tr-fNIRS). This study is observational in nature and no intervention will be applied based on the results of the tr-fNIRS device.
223693608|NCT01600118|DEVICE|Extracorporeal shockwave therapy|1000 impulses
223693609|NCT01600118|DEVICE|No extracorporeal shockwave|0 impulses, acoustic effect
223693610|NCT00752037|DRUG|lopinavir/ritonavir and raltegravir|lopinavir/ritonavir 400/100 mg po b.id. in combination with raltegravir 400 mg po b.i.d.
223693611|NCT05236153|DIAGNOSTIC_TEST|Electroanatomic substrate mapping|Participants will undergo a sinus rhythm RV substrate map using the HD Grid catheter (Abbott) and the Ensite X electroanatomic mapping system (Abbott) prior to TPVR.
223693612|NCT05591846|BEHAVIORAL|Face-to-face training|Face-to-face training
223693613|NCT05591846|BEHAVIORAL|web-based training|web-based training
223693614|NCT03815617|DIETARY_SUPPLEMENT|Zircombi|Twenty-five IBS patients (Rome IV criteria) (M:F= 8:17; age 48 yrs ± 11 SD) were enrolled and randomized to treatment or placebo in a a crossover randomized double-blind two-block placebo-controlled trial. Abdominal pain and bloating, intestinal habits, severity of disease, intestinal permeability, and intestinal microbiota were performed at the different time points.
223693615|NCT03815617|DIETARY_SUPPLEMENT|Placebo|Given as comparable packets. Same duration.
223693616|NCT03470571|DIAGNOSTIC_TEST|CMR|Outcome analysis of CMR features in suspected myocarditis patients
223693617|NCT03547986|DIAGNOSTIC_TEST|Duplex Ultrasound (DUS)|Occurrence of a flow-limiting dissection or residual stenosis will be assessed by standard angiography and Duplex Ultrasound
223693618|NCT03547986|DIAGNOSTIC_TEST|IVUS with Intraarterial pressure measurement (IAP) if needed|Occurrence of a flow-limiting dissection or residual stenosis will be assessed by standard angiography and Intra-vascular ultrasound associated to Intraarterial pressure measurement if needed
223693619|NCT04353414|PROCEDURE|Transmuscular Quadratus Lumborum Block|Transmuscular Quadratus Lumborum Block (TQLB) is a relatively new block that targets thoracic and lumbar nerves. The decrease in sensation means a decrease in pain. The TQL block will be preformed in addition to an incision-site injection (on hip), called pericapsular injection. The potential risks associated with the Transmuscular Quadratus Lumborum Block (TQLB) include nerve damage and infection at injection site. In addition, there can be temporary sensory and motor loss, depending on the dosage, site of injection and duration of the nerve block. However, the amount (30mL) used in this study meets FDA dosage-regulations for this medication.
223693620|NCT04353414|PROCEDURE|Pericapsular injection|Pericapsular injection (PCI) of 20 mL of 0.25% Bupivacaine HCL (numbing medication) into the incision-site (hip portal sites) to decrease sensation. The potential risks associated with the pericapsular injection include bleeding, infection at injection site and local anesthetic toxicity however, the likelihood is low due to the expertise of the surgeon preforming the injection and the sterile environment and good clinical practice from clinicians, which reduces the likelihood of infection.
223693621|NCT04353414|DRUG|Bupivacaine Hydrochloride|Bupivacaine used for this study is the standard of care for both TQLB and PCI. Pericapsular injection (PCI) contains 10 mL of 0.25% Bupivacaine HCL which will be injected through the anterolateral portal while the additional 10 mL will be injected through the mid-anterior portal.
223693622|NCT01712646|DRUG|Intranasal Oxytocin|
223777849|NCT06572176|BEHAVIORAL|With fluorescent concretization group|"Nurses were given the fluorescent lotion and asked to apply it all over their hands. The CE-certified test lotion is in gel form and is safety-approved. The lotion disperses particles the same size as bacteria on the skin. These particles settle on the skin, similar to the behavior of microorganisms, but disappear with hand washing under the influence of fluorescent light. They were then asked to wash their hands with 4 ml of soap. Two researchers marked the hand washing steps independently using the Hand Washing Skill Checklist. The duration of hand washing was recorded with a mobile stopwatch for each participant. Hand washing efficiency was evaluated using the Derma Litecheck device. UV rays were used after using the test lotion and drying the hands. Since any fluorescent material left on the hands would shine under UV light, it was possible to judge how well the hands were cleansed. The dirty spots were shown to the participants, and the reason for this was discussed."
223777850|NCT05446350|PROCEDURE|transcranial alternating current stimulation (tACS)|transcranial alternating current stimulation (tACS) used to manipulate how neural activity aligns to speech rhythm, leading to changes in speech perception
223777851|NCT05446350|PROCEDURE|electroencephalography (EEG)|analyse rhythmic electroencephalography responses that outlast the stimulation
223777852|NCT05446350|PROCEDURE|brain imaging (fMRI)|Using brain imaging (fMRI) to predict optimal stimulation protocols for individual participants
223777853|NCT05446350|PROCEDURE|electroencephalography (EEG) with neurofeedback|Using neurofeedback to teach participants to enhance their own neural entrainment
223693623|NCT03642743|OTHER|postoperative follow up appointment|Comparison of two and six week postoperative follow up versus a six week postoperative follow up alone
223693624|NCT02570841|DRUG|Topical High dose Capsaicin|Topical High dose Capsaicin exposure within an area of 3x3 cm for 60 minutes
223693625|NCT02570841|DRUG|Topical Placebo|Placebo exposure within an area of 3x3 cm for 60 minutes
223693626|NCT00986479|DRUG|AZD6765|Single IV infusion of 150 mg AZD6765.
223693627|NCT00986479|DRUG|Placebo to AZD6765|Single IV infusion of Placebo to AZD6765
223693628|NCT04672330|DRUG|Tislelizumab|Patients will receive 2-4 cycles of Tislelizumab (200mg per cycle) before surgery（radical nephroureterectomy, segmental ureteral resection, endoscopic ablation）
223693629|NCT02534818|DRUG|lower fluorescein sodium dosage 0.02ml/kg|fluorescein Sodium Dose of 0.02ml/kg on gastric intestinal metapalsia
223693630|NCT02534818|DRUG|conventional fluorescein sodium dosage 0.1ml/kg|fluorescein Sodium Dose of 0.1ml/kg on gastric intestinal metapalsia
223693631|NCT04332380|DRUG|Plasma|Day 1: CP-COVID19, 250 milliliters. Day 2: CP-COVID19, 250 milliliters.
223693632|NCT01225107|DIETARY_SUPPLEMENT|Cranberry Extract|500mg TID
223693633|NCT01225107|DRUG|Inert Placebo Capsule|Inert substance, 3 times per day in capsule form
223693634|NCT00237185|DRUG|Imatinib mesylate|Participants were randomized 1:1 to receive imatinib mesylate 400 mg/day or 600 mg/day. Upon unsatisfactory treatment effect on the starting dose of 400 mg/day or 600 mg/day imatinib mesylate, in the opinion of the treating physician, a dose increase up to 600 mg/day or 800 mg/day, was allowed provided that the participant continued to benefit from the treatment and in the absence of safety concerns.
223693635|NCT02947412|OTHER|laparoscopic sleeve gastrectomy|laparoscopic sleeve gastrectomy
223693636|NCT02761434|OTHER|Hypertonic Saline (3% NaCl)|0.1 ml of 3% NaCl per kg of body weight per minute
223693637|NCT02761434|OTHER|Isotonic Saline (0.9% NaCl)|0.1 ml of 0.9% NaCl per kg of body weight per minute
223693638|NCT02675712|OTHER|African drumming|Rhythmic beating or tapping of a variety of percussion instruments, which often occurs within a group setting
223693639|NCT00815243|PROCEDURE|Telemedicine consultation|Standard synchronous or asynchronous telemedicine consultations according recommendations and best practice models of ISfTeH
223693640|NCT00815243|PROCEDURE|Treatment plan|Treatment plan include diagnostic tests (physical examination, laboratory tests, xray, CT, MRI), medications and surgical treatment (debridements, osteosynthesis, arthroplasty, ORIF etc)
223693641|NCT05588271|OTHER|Exposures|This study is an observational study.Exposure factors is patients with pressure injury.
223693642|NCT06644612|PROCEDURE|Light Weight Mesh|Participants will undergo abdominal hernia repair using light-weighted polypropylene mesh. Standard post-operative care and antibiotic prophylaxis will be provided.
223693643|NCT06644612|PROCEDURE|Heavy Weight Mesh|Participants will undergo abdominal hernia repair using heavy-weighted polypropylene mesh. Standard post-operative care and antibiotic prophylaxis will be provided.
223693644|NCT02730338|BEHAVIORAL|High intensity aerobic and resistance training|
223693645|NCT02730338|BEHAVIORAL|Psychosocial support|
223693646|NCT00458068|DRUG|Oral administration of ferrous sulphate|
223693647|NCT06644118|BIOLOGICAL|OL-101 infusion|OL-101 infusion will be administered to patients via IV infusion at the assigned dose.
223693648|NCT02035475|DEVICE|Intuitive Vessel Sealer|Investigators intend to use this device unilaterally so the contralateral side can serve as an internal control.
223693649|NCT02159612|OTHER|MRI|MRI scan of muscles in the back and legs. Including T1, DIXON and STIR images.
223693650|NCT03828409|PROCEDURE|Short stitch|The rectus sheath are cleaned off the subcutaneous fats. Short stitch technique uses smaller needle and suture material. The suture is placed nearer to each other as compared to our conventional long stitch technique. It has inter-suture distance of 5mm and 5mm distance from rectus edge. The suture will be started at one end and sutured continuous until the other end. Hence, this technique is applied without tension.
223693651|NCT03828409|PROCEDURE|Long stitch|Long stitch uses a larger needle and suture material. The suture is placed 1cm from the linea alba and 1 cm from previous suture. This technique include mass closure sutures at the midline laparotomy
223693652|NCT05864170|BIOLOGICAL|β-globin restored autologous hematopoietic stem cells|β-globin-restored autologous hematopoietic stem cells modified with LentiHBBT87Q
223693653|NCT00178750|DEVICE|18G Tuohy epidural needle|
223693654|NCT00178750|DEVICE|CompuFlo® computerized syringe pump|
223693655|NCT01776047|DRUG|Exforge®|
223693656|NCT01776047|DRUG|G-0081|
223777854|NCT04176796|OTHER|Stratified Transplant Survival|"The transplant survival rate in the table of outcome statistics is stratified into two groups: (i) patients who received excellent donor organs and (ii) patients who received less than optimal donor organs.~Stratified transplant survival is computed from survival rates of transplant patients who received each quality category of organ.~excellent transplant survival = \[number of patients surviving after transplant with excellent organ\]/\[number of patients for whom excellent organ was accepted for transplant\] marginal transplant survival = \[number of patients surviving after transplant with marginal organ\]/\[number of patients for whom marginal organ was accepted for transplant\]"
223693657|NCT01231347|DRUG|AMG 479|AMG 479 12 mg/kg administered intravenously on days 1 and 15 of a 28 day cycle
223693658|NCT01231347|DRUG|Placebo|Placebo administered intravenously on days 1 and 15 of a 28 day cycle
223693659|NCT01231347|DRUG|AMG 479|AMG 479 20mg/kg administered intravenously on days 1 and 15 of a 28 day cycle
223693660|NCT01231347|DRUG|gemcitabine|gemcitabine 1000mg/m2 administered intravenously on days 1, 8 and 15 of a 28 day cycle
223693661|NCT01461278|DEVICE|iStent supra|Cataract surgery and implantation of one iStent supra
223693662|NCT01461278|PROCEDURE|Cataract surgery|Cataract surgery alone
223693663|NCT02085915|OTHER|strip Peri Screen|
223693664|NCT00326794|PROCEDURE|mobilisation (rehabilitation)|
223693665|NCT02322021|DRUG|E2609|Each participant will receive 2 tablets, which when combined will make up the required doses of E2609 or placebo, to be administered orally once per day (QD) with food.
223693666|NCT02322021|DRUG|Placebo|Each participant will receive 2 tablets, which when combined will make up the required doses of E2609 or placebo, to be administered orally once per day (QD) with food.
223693667|NCT06333821|BIOLOGICAL|Nimotuzumab|Nimotuzumab 400mg
223693668|NCT06333821|DRUG|Cisplatin|Cisplatin 40mg/m\^2
223693669|NCT06333821|RADIATION|External Beam Radiotherapy (EBRT)|External Beam Radiotherapy (EBRT)
223693670|NCT06333821|RADIATION|Brachytherapy|Brachytherapy
223693671|NCT06333821|DRUG|placebo for Nimotuzumab|placebo for Nimotuzumab 400mg
223693672|NCT01702571|DRUG|Trastuzumab Emtansine|Participants will receive trastuzumab emtansine 3.6 milligrams per kilogram (mg/kg) intravenously on Day 1 of a 3-week cycle every 3 weeks until unacceptable toxicity, withdrawal of consent, or disease progression.
223693673|NCT06327659|DEVICE|30 mL syringe manual thrombectomy catheter|30 mL syringe manual thrombectomy catheter
223693674|NCT06327659|DEVICE|50 mL syringe manual thrombectomy catheter|50 mL syringe manual thrombectomy catheter
223693675|NCT00232167|DRUG|Indiplon|
223693676|NCT00232167|DRUG|Sertraline|
223693677|NCT05030246|DRUG|Surufatinib/Toripalimab|Surufatinib 250mg will be taken orally once daily continuously through a 21-day cycle of study treatment. Toripalimab 240mg will be intravenously administered on Day 1 of each cycle.
223693678|NCT03356054|COMBINATION_PRODUCT|R-DHAP|3 cycles q 3 weeks
223693679|NCT03356054|DRUG|Brentuximab Vedotin|3 cycles q 3 weeks added to R-DHAP
223693680|NCT00406094|DRUG|montelukast|10mg
223693681|NCT00406094|DRUG|placebo|placebo
223693682|NCT00135733|DRUG|Amevive (Alefacept)|
223693683|NCT00135733|DRUG|Placebo|
223693684|NCT05355610|DRUG|Gentamicin|Intratympanic gentamicin and dexamethasone administered in two doses one week apart
223777855|NCT06655935|PROCEDURE|Ordinary Transcatheter ASD closure|deploying the Amplatzer delivery system of the Amplatzer™ Septal Occluders ASO inside the left atrial cavity over stiff wire into the pulmonary veins
223777856|NCT06655935|PROCEDURE|modified transcatheter ASD closure|deploying the Amplatzer delivery system of the Amplatzer™ Septal Occluders ASO over the multipurpose catheter inside the left atrial cavity which might help in the shortage of the duration \& the cost of the procedure with less complication rate
223693685|NCT05355610|DRUG|Dexamethasone|Intratympanic gentamicin and dexamethasone administered in two doses one week apart
223693686|NCT02185846|DRUG|DYNABAC 250 MG ENTERIC COATED TABLET|
223693687|NCT02185846|DRUG|DIRITHROMYCIN 500 MG ENTERIC COATED TABLET|
223693688|NCT01295229|PROCEDURE|laparoscopic Roux-en-Y gastric bypass (RYGB) procedure|The laparoscopic Roux-en-Y gastric bypass (RYGB) procedure is the most commonly performed bariatric procedure in the United States. Patients randomized to the surgical arm will undergo a standard laparoscopic proximal RYGB, as commonly practiced by GH surgeons, using a 90-cm alimentary limb, 50-cm biliopancreatic limb, antecolic/antegastric approach, and totally stapled technique.
223777857|NCT03802097|PROCEDURE|No use of antimicrobial prophylaxis|Do not use of prophylactic antimicrobial for the patients with undergoing totally laparoscopic distal gastrectomy with D1 or D1+ lymphadenectomy for the gastric cancer
223777858|NCT03802097|PROCEDURE|Use of antimicrobial prophylaxis|Use of prophylactic antimicrobial for the patients with undergoing totally laparoscopic distal gastrectomy with D1 or D1+ lymphadenectomy for the gastric cancer
223693689|NCT01295229|BEHAVIORAL|Lifestyle Intervention|The lifestyle intervention includes behavior-modification skills counseling combined with training in diet and exercise change. The focus of the exercise intervention is a gradual increase in brisk walking or other activities of similar moderate aerobic intensity. The exercise prescription will consist of at least 45 minutes of exercise, 5 days per week for 12 months. The diet intervention will be conducted by a research dietician with training in behavior modification, with supervision by Dr. Foster-Schubert. In week 1 the dietician will meet for a 60-minute individual session with participants at the FHCRC Prevention Center. Over the next 23 weeks the dietician will conduct one 30-minute group session per week.
223693690|NCT04180774|BIOLOGICAL|Tag-7 gene modified inactivated tumor cells|Patients received GMV once in three weeks subcutaneously in three points in the paravertebral region. One dose consisted of 10 million transfected and inactivated tumor cells. No dose reduction was allowed.
223693691|NCT02269046|OTHER|acupuncture and moxibustion|Warm needling acupuncture on Fenglong (ST40, bilateral), Zusanli (ST36, bilateral), Sanyinjiao (SP6, bilateral) and Cake-seperated moxibustion on Juque (RN14), Tianshu (ST25, bilateral), Pishu (BL20, bilateral), Xinshu (BL15, bilateral), Ganshu (BL18, bilateral), Shenshu (BL23, bilateral)
223693692|NCT02269046|DRUG|Simvastatin|10mg/d,p.o,12 weeks.
223693693|NCT02269046|OTHER|Therapeutic Lifestyle Change|"* Reduced intakes of saturated fats (\<7% of total calories) and cholesterol (\<200 mg per day)~* Therapeutic options for enhancing LDL lowering~* Weight reduction~* Increased physical activity"
223693694|NCT00861536|DRUG|ATG Fresenius|Day 0: 9 mg/kg bw bolus Days 1-4: 3 mg/kg bw/d
223693695|NCT00861536|DRUG|Thymoglobuline Genzyme|Day 0-3: 1.5 mg/kg bw/d
223693696|NCT00494455|DEVICE|continuous subcutaneous glucose monitoring|continuous subcutaneous glucose monitoring for 72h
223693697|NCT00494455|DEVICE|continuous subcutaneous glucose monitoring|continuous subcutaneous glucose monitoring for 72h
223693698|NCT04386031|DIAGNOSTIC_TEST|Throat culture for fungal pathogens|Throat culture for fungal pathogens will be taken before surgery, at post-operative day (POD) 3 and 2 weeks after the operation
223777859|NCT06098599|DRUG|Doxorubicin hydrochloride liposome injection|Doxorubicin hydrochloride liposome injection was administered intravenously for 90min (±3min) with an infusion pump on day 1 and day 29 of the trial. Doxorubicin hydrochloride liposome injection was diluted with 250mL 5% glucose injection.
223777860|NCT06664216|BEHAVIORAL|incorrect trocar placement marks.|Participants in the experimental group will perform trocar placements on laparoscopic models that have been pre-marked with incorrect insertion sites by previous participants. These marks simulate procedural steps or anatomical landmarks that are intentionally incorrect.
223777861|NCT06663891|OTHER|Functional MRI with EEG per MRI|"2 MRI examinations will be carried out on a Siemens Vida® MRI ( Siemens®, Erlangen, Germany) 3 Tesla. During this study, no MRI examination requires the injection of a contrast agent.~Different sequences, according to several acquisition modalities, will be performed during each MRI. The structural sequences (T1 and T2, MPRAGE) will highlight any lesions in the form of atrophies and/or vascular lesions in the participants, also subject to inter-individual differences. The examination will also involve a quantitative multiparametric acquisition with 8 modalities (R1, R2, Radial and Axial Diffusion in Diffusion Tensor, dispersion, orientation and density index of neurites by NODDI, the Macromolecular Proton Fraction, measurement of magnetic susceptibility and R2\*) to characterize tissue properties. Functional imaging (in resting state, during film viewing and performance of cognitive tasks in ASL, BOLD and multiband) will allow analysis of the primary endpoint - functional connectivity,"
223693699|NCT02516254|DIETARY_SUPPLEMENT|fortified bread|50 g of fortified bread + placebo daily
223693700|NCT02516254|DIETARY_SUPPLEMENT|supplement|vitamin D supplement+ plain bread
223693701|NCT02516254|DIETARY_SUPPLEMENT|placebo|plain bread+placebo
223693702|NCT04160728|OTHER|Work/ rest scenario|For every hour of work, the participants were asked to take 3-10 minutes break in the shade.
223693703|NCT04160728|OTHER|Hydration scenario|Participants were asked to consume at least 750ml of water or ice-slushies for every hour of work
223693704|NCT04160728|OTHER|Clothing scenario|Participants were asked to wear different types of clothing during the work shift i.e. ventilated garments, white breathable coveralls, clothing with water submerged parts
223693705|NCT04160728|OTHER|"E-carts scenario"|"Participants that were involved in manual labor by carrying heavy weights were provided with e-carts (automated carrying vehicles)"
223693706|NCT04160728|OTHER|Business as usual scenario|No interference with the usual work day of the participants
223693707|NCT04160728|OTHER|Sham evaluation|Participants were monitored during a usual day of work shift while sham measurements were recorded in order for them to get familiarized with the study environment
223693708|NCT02047227|DRUG|Pergoveris®|Pergoveris (follitropin alfa and lutropin alfa) was administered subcutaneously once daily with a starting dose of 300 International Unit (IU) recombinant human follicular stimulating hormone (rhFSH)/ 150 IU recombinant human luteinizing hormone (rhLH) after confirmation of down regulation up to 21 days. After follicle attained mean diameter of 17-18 millimeter (mm); 250 microgram (mcg) of r-hCG (Ovidrel) was administered once subcutaneously to trigger final follicular maturation as per site standard practice. The dose adjustment for r-hFSH was allowed in 75 IU increments while maintaining the 2:1 ratio of r hFSH to r-hLH in the Pergoveris group based on the subject's response per site standard clinical practice.
223693709|NCT02047227|DRUG|GONAL-f®|GONAL-f (r-hFSH) was self-administered subcutaneously once daily at a starting dose of 300 IU after confirmation of down regulation up to 21 days. After follicle attained mean diameter of 17-18 mm; 250 mcg of r-hCG was administered once subcutaneously to trigger final follicular maturation as per site standard practice. The dose adjustment for r-hFSH was allowed in 75 IU increments based on the subject's response per site standard clinical practice.
223693710|NCT02047227|DRUG|Recombinant human chorionic gonadotrophin (r-hCG)|On r-hCG day, 250 mcg of r-hCG was administered once subcutaneously
223693711|NCT05665179|BEHAVIORAL|Removing Barriers to Recovery|Experimental patients are provided no-cost legal services in-person at addiction treatment centers using an online platform
223693712|NCT04638673|DEVICE|Soterix taVNS model 0125-LTE Stimulator - Active-Active Group|Participants will receive active taVNS stimulation for weeks 1-4 of the stimulation portion of this study.
223693713|NCT04638673|DEVICE|Soterix taVNS model 0125-LTE Stimulator - Sham-Active Group|Participants will receive sham taVNS stimulation for weeks 1\&2 and active stimulation for weeks 3\&4 of the stimulation portion of this study.
223693714|NCT02466373|DRUG|Clonidine (Catapresan®) 0,150 mg/ml, ampoule 1 ml|clonidine intravenous
223693715|NCT01721473|OTHER|positron emission tomography scan|2-FA positron emission tomography scan
223693716|NCT01241773|DRUG|raltegravir|One 400 mg tablet twice daily for 7 days
223693717|NCT01241773|DRUG|TMC435 + raltegravir|Two 75 mg TMC435 capsules once daily and one 400 mg raltegravir tablet for 7 days
223693718|NCT01241773|DRUG|TMC435|Two 75 mg capsules once daily for 7 days
223693719|NCT01241773|DRUG|TMC435 + efavirenz|Two 75 mg TMC435 capsules + one 600 mg TMC278 tablet, once daily for 14 days
223693720|NCT01241773|DRUG|TMC435|Two 75 mg capsules once daily for 14 days
223693721|NCT01241773|DRUG|efavirenz|One 600 mg tablet once daily for 14 days
223693722|NCT01977937|DRUG|Gabapentin 250mg/5mL NDC:59762-5025-01|
223693723|NCT01977937|DRUG|Simple Syrup|
223693724|NCT00551044|DRUG|Bicalutamide|Bicalutamide 150mg once daily, oral administration, for 12 months
223693725|NCT01428362|DRUG|VI-1121|
223693726|NCT01428362|DRUG|Placebo|
223693727|NCT01094756|DIETARY_SUPPLEMENT|meal replacements, psychotherapy, dietary education|After the screening and scan days are completed, obese subjects will begin a lifestyle intervention program that includes dietary (low-calorie diet) and behavioral education topics. Treatment will be provided in individual weekly sessions. Each hour-long session will be led by a behavioral counselor or registered dietitian in the Weight Management Center at Washington University. The behavioral program will use cognitive-behavioral techniques to foster adherence to diet prescriptions and to build a supportive environment for the participant. The program will emphasize strategies of self-monitoring and goal-setting, and will include problem-solving, overcoming high-risk situations for unhealthy eating, relapse prevention, and strategies for long-term weight maintenance. Handouts will be provided for study subjects to allow them to record the setting and reaching of dietary goals, as well as summarize the key points of the educational content.
223693728|NCT05032430|BEHAVIORAL|CCC|A mix of mindfulness-based stress reduction, mindful eating, and mindful parenting strategies.
223693729|NCT05032430|BEHAVIORAL|Enhanced Usual Care|Consists of strategies meant to enhance health and well-being (e.g., health education, strategies to get more physical activity) but does not include mindfulness as an active ingredient.
223693730|NCT03144531|BEHAVIORAL|Sleep Intervention for Kids and Parents (SKIP)|Dyadic approach using self-efficacy theory to set goals, anticipate barriers, problem solve
223693731|NCT00915356|DRUG|AZD1305|Intravenous (iv) single infusion given intravenously until successful conversion of Atrial Fibrillation (AF) to Sinus Rhythm (SR) occur or for a maximum of 30 minutes
223693732|NCT00915356|DRUG|Placebo|iv single infusion given intravenously until successful conversion of Atrial Fibrillation (AF) to Sinus Rhythm (SR) occur or for a maximum of 30 minutes
223693733|NCT03031158|BEHAVIORAL|SFEX+H|Participants will receive an intervention consisting of heat to the low back, manual therapy to the hip (including movement of the hip by the therapist), hip-focused strengthening exercises and a trunk muscle training program including exercises for the abdominal and low back muscles. The intervention will be delivered twice weekly for 8 weeks.
223693734|NCT03031158|BEHAVIORAL|SFEX|Participants will receive an intervention consisting of heat to the low back, manual therapy to the hip (including movement of the hip by the therapist) and a trunk muscle training program including exercises for the abdominal and low back muscles. The intervention will be delivered twice weekly for 8 weeks.
223693735|NCT03267732|BIOLOGICAL|Pegilodecakin|Pegilodecakin Alone
223693736|NCT05276947|OTHER|position with peanut ball|The experimental group will be positioned with the peanut ball until the end of the active phase of labor.
223693737|NCT02073110|DEVICE|Percutaneous Optical Biopsy (OCT and DRS)|
223693738|NCT01302379|DRUG|Metformin|Week 1: 500 mg at dinner time Weeks 2-4: 1000 mg at dinner time Weeks 5+: 500 mg in morning; 1000 mg at dinner time
223693739|NCT01302379|DRUG|Placebo|Week 1: 1 pill at dinner time Weeks 2-4: 2 pills at dinner time Weeks 5+: 1 pill in morning; 2 pills at dinner time
223693740|NCT01302379|BEHAVIORAL|Lifestyle intervention|Telephone-based lifestyle intervention (dietary change and physical activity) for weight loss.
223693741|NCT01302379|BEHAVIORAL|Standard printed dietary guidelines|Set of standard health education materials provided to participants at single time point (immediately after randomization)
223693742|NCT01782833|OTHER|This is Non-interventional study|
223693743|NCT01438073|DRUG|kisspeptin 112-121|24-h continuous intravenous infusion of kisspeptin 112-121 (12.5-40 mcg/kg/h), single intravenous dose of kisspeptin 112-121 (0.313-13.19 mcg/kg)
223693744|NCT01438073|DRUG|GnRH|Single intravenous dose of GnRH (2.5-250 ng/kg)
223693745|NCT02715479|DRUG|Dolutegravir|Dolutegravir
223693746|NCT02715479|DRUG|BMS955176|BMS955176
223693747|NCT03221907|DRUG|GLA5PR GLARS-NF1|Pregabalin tablet
223693748|NCT03221907|DRUG|GLA5PR GLARS-NF1 placebo|tablet manufactured to mimic GLA5PR GLARS-NF1
223693749|NCT03221907|DRUG|Pregabalin|Pregabalin capsule
223693750|NCT03221907|DRUG|Pregabalin placebo|tablet manufactured to mimic pregabalin capsule
223693751|NCT00719095|DRUG|buprenorphine taper followed by naltrexone maintenance|direct comparison of 1-, 2- and 4-week durations of buprenorphine taper for treating prescription opioid abusers; those who successfully taper without resumption of illicit opioid use are subsequently transitioned to oral naltrexone therapy for the remainder of the 12-week trial; all participants receive a platform of intensive individual behavioral therapy and on-site urinalysis monitoring throughout the trial
223693752|NCT00719095|BEHAVIORAL|Behavioral therapy|
223693753|NCT03163810|DEVICE|Erchonia Verju Laser|The Erchonia Verju Laser is applied 2 times a week to the front and back of the waist, hips and upper abdomen for 30 minutes each time over 8 to 12 weeks.
223693754|NCT03163810|DEVICE|Erchonia EVRL Laser|The Erchonia EVRL Laser is applied under the right ribcage angled towards the liver for 10 minutes, one time per week over the same 8 to 12 weeks as the Verju Laser is administered.
223693755|NCT05511519|DRUG|ATI-450|Oral, small molecule MK2 inhibitor
223693756|NCT05511519|DRUG|Placebo Oral Tablet|Placebo tablet manufactured to match ATI-450 in appearance
223693757|NCT04069169|DRUG|Lidocaine|Intervention group (A) will receive P-IVLT in addition to the standard multimodal analgesia. P-IVLT will consist of 1 mg/kg bolus at start of anesthesia (T0), followed by 2 mg·kg-1·hr-1 infusion for 8 hours (T1), then continued at 1 mg·kg-1·hr-1 infusion thereafter and postoperatively until T0 + 48 hours (T2).
223693758|NCT04069169|DRUG|Saline Solution|Control group (B) will receive a placebo (0.9% sodium chloride also known as normal saline), made to mimic the intervention protocol described above, in addition to the standard multimodal analgesia.
223693759|NCT00945997|DRUG|misoprostol|mifepristone 200 mg followed by 200 µg misoprostol per vaginam 36- 48 hours later at 4 hourly intervals (with a maximum of 10 administrations in 48 hours) until the foetus was delivered.
223693760|NCT00945997|DRUG|misoprostol|mifepristone 200 mg followed by 400 µg misoprostol per vaginam 36- 48 hours later at 4 hourly intervals (with a maximum of 10 administrations in 48 hours) until the foetus was delivered.
223693761|NCT01782911|DIETARY_SUPPLEMENT|Resveratrol|The patients will take 2 g of resveratrol per day for 40 days.
223693762|NCT01782911|DIETARY_SUPPLEMENT|Placebo pills|The patients will take placebo for 40 days.
223693763|NCT03610451|BEHAVIORAL|Floatation-REST plus usual care|Individuals will receive Floatation-REST plus usual care. Floating creates an environment with minimal visual, auditory, tactile, proprioceptive, and thermal input to the brain. The float rooms are lightproof and soundproof. A high concentration Epsom salt water solution allows individuals to effortlessly float on their back while remaining completely still, reducing both proprioceptive and tactile input to the brain. The temperature of the water is calibrated to the temperature of the skin (\~94° F) and the temperature of the air is calibrated to the temperature of the water, making it difficult to discern the boundary between air and water, thus reducing thermal input to the brain while minimizing the need for thermoregulation of the skin.
223693764|NCT03610451|BEHAVIORAL|Usual care|Individuals will receive usual care on the inpatient unit of the Laureate Eating Disorders Program.
223693765|NCT05413031|DEVICE|relative motion splint|splint with ability to move the fingers
223693766|NCT05413031|DEVICE|static splint|splint with immobility of wrist, and fingers
223693767|NCT05836090|BEHAVIORAL|Family Spirit Strengths (FSS)|The FSS intervention consists of psychoeducational components that emphasize the importance of mental and emotional health as part of overall wellness, and seek to normalize experiences of stress, to de-stigmatize help-seeking, and to build hope. Core content focuses on awareness of the connections between thoughts, feelings, behaviors, and spirituality, and imparts related self-help skills. It also specifically builds in connection to culture, land and others as coping strategies. The FSS lessons were developed based on culturally adapting the Common Elements Treatment Approach (CETA).
223693768|NCT05836090|BEHAVIORAL|Family Spirit Nurture|The active control Family Spirit Nurture, is an evidence-based nutrition education curriculum that has been previously tested with Navajo communities which focuses on age-appropriate parental feeding practices, including snack routines, avoidance of sugar-sweetened beverages (SSB) and promotion of water consumption.
223693769|NCT03652376|DRUG|Benralizumab|Treatment with Benralizumab 30 mg s.c. every 4 weeks (three times)
223693770|NCT03164577|BEHAVIORAL|Drum-Assisted Recovery Therapy for Native Americans (DARTNA)|An intervention that utilizes AI/AN drumming as its core component of treatment.
223693771|NCT03164577|OTHER|Usual Care Plus|Participants randomized to usual care plus will participate in activities for approximately the same amount of time as DARTNA participants. They will engage in health and wellness education session once weekly for 6 weeks. They will also receive care for their alcohol and other drug use, This typically consists individual counseling, group therapy, and AI/AN traditional activities in their community.
223693772|NCT04866329|OTHER|Blood sample|Additional blood sampling at the end of ovarian stimulation monitoring (the eve of the oocyte pick-up)
223693773|NCT04866329|OTHER|Urine sample|Collection of the first urine in the morning on the day of the oocyte pick-up
223693774|NCT04866329|OTHER|Follicular fluid and granulosa cells sample|Collection of follicular fluid and granulosa cells during oocyte pick-up.
223693775|NCT00745173|DRUG|Premarin|
223693776|NCT03925064|OTHER|myocardial performance index|fetal right ventricular myocardial performance index measured with tissue doppler
223693777|NCT01858584|DRUG|Gastrotuss|"Gastrotuss baby: syrup based on alginate consisting of: magnesium alginate, simethicone, fructose, xanthan gum, honey, D-panthenol, fluid extracts of Althaea officinalis, Papaver rhoeas, zinc oxide, sodium bicarbonate, sodium hydroxide, p-hydroxybenzoate of methyl-sodium, sodium propyl p-hydroxybenzoate, natural flavors, erythrosine (E127), purified water.~dosage:~* Infants weighing \<5 kg in 2.5 ml 5-10 min after feeding. In case of regurgitation after administration, 1 ml additional~* Infants weighing\> 5 kg per 5 ml dose after the meal and the evening before putting the baby to sleep The administration should be maximum 3 times per day"
223693778|NCT01858584|DIETARY_SUPPLEMENT|thickened milk|Milk thickened (formulat AR): contains a special thickener derived from corn starch waxy, that maintains its fluidity into the bottle and thickens just inside the stomach of the child, and this makes it easy to use in breastfeeding , as it is usable with a common teat.
223693779|NCT00895856|OTHER|Evaluation of the functional capacity|An evaluation (questionnaire) was performed by the Katz Index of individuals in this group, including personal issues (sex and age) and different levels of functional independence for the elderly in their basic activities of daily living (ABVD's) such as: bathe, dress, use the bathroom for withdrawals, transfers perform, has control of the sphincters and the food itself. Subject themselves, if capable of responding to the issues of consistency index, did. The answers were given to the auxiliary nurse responsible for care to residents.
223693780|NCT00201331|DRUG|leucovorin+5-FU|
223693781|NCT02819518|BIOLOGICAL|Pembrolizumab|IV infusion
223693782|NCT02819518|DRUG|Nab-paclitaxel|IV infusion
223693783|NCT02819518|DRUG|Paclitaxel|IV infusion
223693784|NCT02819518|DRUG|Gemcitabine|IV infusion
223693785|NCT02819518|DRUG|Carboplatin|IV infusion
223693786|NCT02819518|DRUG|Normale Saline Solution|IV infusion
223693787|NCT00880165|DEVICE|Continuous positive airway pressure apparatus|Veterans randomized to both arms who are diagnosed with obstructive sleep apnea will be started on treatment with continuous positive airway pressure.
223693788|NCT05833334|BEHAVIORAL|Public health infographic (AIM 3)|Standard public health infographic about home air radon testing, plus information about requesting a free home air radon test kit
223693789|NCT05833334|BEHAVIORAL|Online health promotion intervention tailored by smoking status (AIM 3)|Online health promotion intervention with messaging about home air radon testing tailored by the participant's stated smoking status, plus information about requesting a free home air radon test kit
223693790|NCT05833334|BEHAVIORAL|Online health promotion intervention tailored by smoking status, plus reminder messages (AIM 3)|Online health promotion intervention with messaging about home air radon testing tailored by the participant's stated smoking status, plus information about requesting a free home air radon test kit, plus reminder messages about home air radon testing sent over two months
223693791|NCT05833334|BEHAVIORAL|Focus group with educational overview (AIM 1)|90-minute online focus group discussion about home air radon testing, plus an educational overview about home air radon testing using a standard public health infographic
223693792|NCT01473927|OTHER|Endoscopy|Only patients undergoing endoscopy for clinical reasons will be included in the study, i.e. no endoscopies will be performed solely for study reasons. For the purposes of our study, endoscopy serves to determine the degree of inflammation and no additional biopsies are taken. Blood for CRP and ficolin-2 analysis will be taken through the Venflon® installed for endoscopy.
223693793|NCT01473927|OTHER|Endoscopy|Only patients undergoing endoscopy for clinical reasons will be included in the study, i.e. no endoscopies will be performed solely for study reasons. For the purposes of our study, endoscopy serves to determine the degree of inflammation and no additional biopsies are taken. Blood for CRP and ficolin-2 analysis will be taken through the Venflon® installed for endoscopy.
223693794|NCT06252714|DEVICE|Defecation Posture Modification Device|Patients will be asked to use the defecation posture modification device with each bowel movement for two weeks.
223693795|NCT03010761|DRUG|escitalopram|antidepressant use for the betel-quid abstinence
223693796|NCT03010761|DRUG|Moclobemide|antidepressant use for the betel-quid abstinence
223693797|NCT03010761|DRUG|Placebo - Cap|Placebo - Cap
223693798|NCT02459652|DRUG|S-1|S-1 is administered orally at a dose of 40 mg/m2 twice daily on the day of irradiation (Monday through Friday) during radiation therapy.
223693799|NCT02459652|RADIATION|Radiation Therapy|Radiation therapy is delivered with \>6-megavolts (MV) photons, using a multiple field technique. A total dose of 50.4 Gy is delivered in 28 fractions over 5.5 weeks.
223693800|NCT05250752|DRUG|Dapagliflozin 10 MG [Farxiga]|Primary end-points are measure before (day 0), on treatment (day 1 and day 3) and after treatment (day 21)
223693801|NCT05899010|DRUG|Vaginal progesterone 600mg daily|If endometrial thickness (ETH) ≥7 mm and follicle dominance/ultrasound (US) signs of ovulation P levels are measured: if P ≤1.5 patients start LPS, else cycle is cancelled. If ETH \<7mm and no follicle dominance: estradiol dose is increased to 9mg/day and new US is performed up to 4 days after. If persistent thin endometrium after dose increase, cycle is cancelled. 24-48h pre ET, E2 and P are measured. in the morning, pre VMP dose, or at least 6h after last progesterone dose. If progesterone \<10ng/ml, additional 300mg daily oral micronized progesterone is administered on the day of the ET and maintained until 10 weeks pregnancy or up to menses or up to negative pregnancy test 10 days after ET. ET will be performed with available blastocysts 6 days after start of LPS. 3-5 days, after ET, a blood test for P measurement will be performed in the morning, before VMP dose, or at least 6h after last progesterone dose. 10 days after ET, the last P test will be done with pregnancy test.
223693802|NCT05899010|DRUG|Vaginal progesterone 800mg daily|If endometrial thickness (ETH) ≥7 mm and follicle dominance/ultrasound (US) signs of ovulation P levels are measured: if P ≤1.5 patients start LPS, else cycle is cancelled. If ETH \<7mm and no follicle dominance: estradiol dose is increased to 9mg/day and new US is performed up to 4 days after. If persistent thin endometrium after dose increase, cycle is cancelled. 24-48h pre ET, E2 and P are measured. in the morning, pre VMP dose, or at least 6h after last progesterone dose. If progesterone \<10ng/ml, additional 300mg daily oral micronized progesterone is administered on the day of the ET and maintained until 10 weeks pregnancy or up to menses or up to negative pregnancy test 10 days after ET. ET will be performed with available blastocysts 6 days after start of LPS. 3-5 days, after ET, a blood test for P measurement will be performed in the morning, before VMP dose, or at least 6h after last progesterone dose. 10 days after ET, the last P test will be done with pregnancy test.
223693803|NCT01184131|OTHER|Mentor Training|Four 2 hour sessions of Mentor Training
223693804|NCT05961644|DRUG|Cladribine Subcutaneous Injection|Cladribine subcutaneous injection, 10 mg daily, for 2-3 consecutive days (depending on individual dose)
223693805|NCT05961644|DRUG|0.9% Chloride Injection Sodium|0.9% sodium chloride injected subcutaneously, 10 ml daily, for 2-3 consecutive days
223693806|NCT00667602|BIOLOGICAL|MenACWY-CRM197 (two doses)|Two 0.5mL doses of MenACWY conjugate vaccine (MenACWY-CRM197) was administered by intramuscular injection.
223693807|NCT00667602|BIOLOGICAL|MenC|One 0.5mL dose of MenC vaccine was administered by intramuscular injection.
223693808|NCT00667602|BIOLOGICAL|PCV7|One 0.5mL dose of Pneumococcal 7-valent Conjugate Vaccine (PCV7) was administered by intramuscular injection.
223693809|NCT00667602|BIOLOGICAL|DTPa-IPV-HepB-Hib|One 0.5mL dose of Combined Diphtheria-Tetanus-acellular Pertussis, Hepatitis B, Inactivated Poliovirus and Haemophilus influenzae type b (DTPa-IPV-HepB-Hib) vaccine was administered by intramuscular injection.
223693810|NCT00667602|BIOLOGICAL|MenACWY-CRM197 (one dose)|One 0.5mL dose of MenACWY conjugate vaccine (MenACWY-CRM197) was administered by intramuscular injection.
223693811|NCT05221827|DIAGNOSTIC_TEST|C2i Test|The C2i-Test, a personalized molecular circulating tumor DNA (ctDNA) test, is an in vitro qualitative test that uses next generation sequencing (NGS)-based whole-genome sequencing (WGS) data for detecting molecular residual disease (MRD).
223693812|NCT06484673|DRUG|Bosentan Dispersible Tablets|1 tablet of 32 mg Bosentan
223693813|NCT06484673|DRUG|Tracleer Tablet for Oral Suspension|1 tablet of 32 mg Bosentan
223693814|NCT01594385|BIOLOGICAL|Seprafilm|"Two sheets of the Seprafilm material will be applied at each reoperation. Each sheet will be cut into 1x1 inch squares and applied to the following anatomic areas:~* Two Seprafilm pieces between the liver and the anterior abdominal wall~* Four pieces over the exposed bowel surfaces anteriorly~* Two slightly staggered pieces of Seprafilm in each colic gutter~* Two pieces in the pelvic area.~* If any of the above areas involve an anastomosis or bowel repair, then the Seprafilm should be placed at least 1 inch away from the anastomosis and/or bowel repair."
223693815|NCT00285467|DRUG|doxercalciferol|form of vitamin D that is already in active form.
223693816|NCT00285467|DRUG|Cholecalciferol|from of vitamin D that requires cells in the body to make active
223693817|NCT06336759|DEVICE|Restylane Defyne|Twenty (20) subjects with thin skin will be recruited and treated with Restylane Defyne.
223693818|NCT06336759|DEVICE|Restylane Lyft|Twenty (20) subjects with thick skin will be recruited and treated with Restylane Lyft.
223693819|NCT02698059|DEVICE|iNAP® Sleep Therapy System (iNAP)|The iNAP provides pressure gradient within the oral cavity to pull the tongue toward upper palate and the soft palate forward, which aims to maintain better upper airway patency near the pharynx to prevent sleep-disordered breathing.
223693820|NCT00052780|DRUG|O6-benzylguanine|Given IV
223693821|NCT00052780|DRUG|temozolomide|Given PO
223693822|NCT00052780|BIOLOGICAL|filgrastim|Given SC or IV
223777862|NCT06663800|OTHER|Ujjayi Paranayama|Inhale or breathe in slowly while taking a deep, prolonged breath through both nostrils. As you inhale, attempt to tighten your throat and feel the air in your throat. Air should not come into contact with the interior of the nose. When air enters the throat, an odd sound is made. Allow the breath to be loose and easy while you slightly tighten the back of your throat and hiss lightly as you breathe in and out. The sound isn't forced, but it should be loud enough for someone to hear you if they were close. Now close your right nostril and release the breath through your left. As you exhale, try making the sound HHHHHAAAA
223693823|NCT00052780|OTHER|pharmacological study|Correlative studies
223693824|NCT00052780|OTHER|laboratory biomarker analysis|Correlative studies
223693825|NCT06229639|DEVICE|Passy Muir Valve|
223693826|NCT06229639|DEVICE|Tracheostomy Plug|
223693827|NCT03827837|BIOLOGICAL|SHR-1210|SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody
223693828|NCT03827837|DRUG|Famitinib|a small-molecule multikinase inhibitor
223693829|NCT05578703|PROCEDURE|Fundic Ablation Sequentially in Combination with Endoscopic Sleeve Gastroplasty|Fundic mucosal ablation followed by endoscopic sleeve gastroplasty in the treatment of adults with obesity
223693830|NCT05578703|DEVICE|Fundic Mucosal Ablation with ERBE HybridAPC|Fundic mucosal ablation utilizing approved ERBE HybridAPC
223693831|NCT05578703|DEVICE|Apollo ESG|Using only Apollo ESG as approved per label
223777863|NCT06663800|OTHER|Standard Protocol|Control Group will perform Deep Breathing Adhering to a FITT model protocol, with a frequency of 5 days. Intensity set at 8 repetitions, duration range from 10 to 15 minutes
223777864|NCT06986707|OTHER|Strain counterstrain technique|"Group A: Conventional treatment will be given for 45 minutes (repeated 2 sets in each session)~* 1 day per week~* 4 weeks protocol"
223693832|NCT00503295|BIOLOGICAL|REOLYSIN®|REOLYSIN® is given intravenously at a dose of 3x10E10 TCID50 over 60 minutes on Days 1-5 of a 28 day cycle.
223693833|NCT02765685|DEVICE|brace ODRA (PROTEOR company)|Port of the orthosis ODRA during day during 12 months, Complement to their usual care. The subjects will have for instruction to wear the brace a minimum of 6 hours a day, 5 days a week, And to remove it during the rest periods in lengthened position.
223693834|NCT02765685|OTHER|Usual care|"The patients will benefit only from the coverage proposed usually, by their regular doctor and according to the notices of the medical and paramedical specialists taking care of this pathology (physiotherapists, orthopaedic osteopaths, sports medicine physician, surgeon, rheumatologists, rehabilitative doctors, etc.). In the absence of recommendations on the modalities of coverage of the gonarthrose and in front of diverse clinical habits, the usual said coverage can be at the same time medicinal (anti-inflammatory, painkilling, …), non-medicinal (physiotherapy, port of an orthosis, …), even surgical, according to the influencers."
223693835|NCT06561126|BEHAVIORAL|Participatory, Learning and Action Based Intervention|The total number of participants exposed to the intervention (adapted from the DMagic trial in Bangladesh) will be determined based on random selection from the community. A PLA-based intervention would be carried out to prepare the Diabetes Mellitus type II patients. The intervention would be carried out for a tentative time of 2 to 3 hours to educate the type II diabetes mellitus. The study participants would be evaluated after 18 months of the intervention. A structured, validated and literature-based assessment checklist will be devised to assess the effectiveness and feasibility of the intervention.
223693836|NCT05293964|DRUG|SIM0270|SIM0270 is an oral, selective estrogen receptor degrader (SERD)
223693837|NCT05293964|DRUG|Palbociclib|palbociclib is a selective inhibitor of cyclin D-cyclin-dependent kinase (CDK) 4/6
223693838|NCT05293964|DRUG|everolimus|Everolimus is an inhibitor of mTOR (mammalian target of rapamycin)
223693839|NCT05076071|GENETIC|NGS|Next Generation Sequencing
223693840|NCT06481631|BEHAVIORAL|The PEN-3 Intervention Model|The PEN-3 Model is a sociocultural model for planning and assessing participant behavior within the context a cultural phenomenon. It will be used to assess intervention impact on patient-clinical linkages in the Mississippi Delta.
223693841|NCT04989387|DRUG|INCA00186|INCA00186 will be administered every 2 weeks or 4 weeks as per protocol
223693842|NCT04989387|DRUG|Retifanlimab|Retifanlimab will be administered every 4 weeks as per protocol
223693843|NCT04989387|DRUG|INCB106385|INCB106385 will be administered orally once or twice a day.
223693844|NCT06352060|OTHER|No intervention or administration will be performed due to the observational nature of the study|Charts of patients enrolled in the study will be reviewed for an initial monitoring method and any changes in management.
223693845|NCT05433584|DRUG|Tirzepatide|Administered SC
223693846|NCT05433584|DRUG|Antihyperglycemic medication|As prescribed
223693847|NCT04187677|PROCEDURE|Sensory Training|The sensory training group includes sensory-oriented interventions and exercises unlike the other classical hand therapy group.
223693848|NCT04187677|OTHER|classical hand therapy|classical hand therapy
223693849|NCT02176343|DEVICE|AcrySof® IQ ReSTOR® +2.5 D Multifocal Toric IOL|Multifocal IOL with extended secondary focal point and astigmatism correction implanted for long-term use over the lifetime of the cataract patient
223693850|NCT00973349|BIOLOGICAL|MF59-eH1N1_f|8 arms consisting of different antigen combinations of A/H1N1 S-OIV and different percentages of MF59 adjuvant
223693851|NCT00504036|DEVICE|inflatable intra-gastric balloon|inflatable intra-gastric balloon
223693852|NCT04061473|DRUG|Sitagliptin 100mg|"2 tablets of sitagliptin 100 mg.~Standardized liquid meal Standardized liquid meal (200 ml) containing: 1,650 KJ, (394 kcal), carbohydrate 50%, protein 15%, fat 35% consisting of glucose (47.2 g + 2.8 g \[U-13C6\]-glucose), rapeseed oil (14.1 g), whey protein (15.2 g) and 1.5 g paracetamol."
223693853|NCT04061473|DRUG|Empagliflozin 25 MG|2 tablets of empagliflozin 25 mg.
223693854|NCT04061473|OTHER|Placebo tablet|"2 placebo tablets.~Standardized liquid meal Standardized liquid meal (200 ml) containing: 1,650 KJ, (394 kcal), carbohydrate 50%, protein 15%, fat 35% consisting of glucose (47.2 g + 2.8 g \[U-13C6\]-glucose), rapeseed oil (14.1 g), whey protein (15.2 g) and 1.5 g paracetamol."
223693855|NCT06134271|DRUG|Rezvilutamide|Rezvilutamide 240mg qd
223693856|NCT06134271|DRUG|Rezvilutamide plus abiraterone|Rezvilutamide 240mg qd plus abiraterone 1000mg + prednisone 5 mg qd
223693857|NCT06134271|DRUG|Continue previous treatment|Continue using the previous treatment regimen for treatment.
223693858|NCT00920205|DRUG|MPC-3100 (an Hsp90 inhibitor)|oral daily dose for 21 days in a 28-day cycle
223693859|NCT02301988|DRUG|Ipatasertib|Ipatasertib will be administered at a dose of 400 milligrams (mg) orally daily on Days 1-21 of each 28-day cycle for 3 cycles.
223693860|NCT02301988|DRUG|Paclitaxel|Paclitaxel will be administered at a dose of 80 milligrams per square meter (mg/m\^2) as IV infusion QW for 3 cycles.
223693861|NCT02301988|DRUG|Placebo|Participants will receive placebo (matching to ipatasertib) orally daily on Days 1-21 of each 28-day cycle for 3 cycles.
223693862|NCT06033716|OTHER|Measurement correlation variable|resilience and anxiety and depression
223693863|NCT04178473|PROCEDURE|total abdominal hysterectomy|total abdominal hysterectomy at time of sacrocolpopexy
223693864|NCT04178473|PROCEDURE|Subtotal abdominal hysterectomy|Subtotal abdominal hysterectomy at time of sacrocolpopexy
223693865|NCT05120661|OTHER|food product|a food product containing 50 gram carbohydrates
223693866|NCT04179851|DIAGNOSTIC_TEST|Thermal imaging of neck veins|Thermal imaging of neck veins
223693867|NCT03636737|OTHER|pathology associated|list of pathology associated to Pyoderma gangrenosum
223693868|NCT05262959|DRUG|Donafenib, PD-1|Eligible subjects will receive Donafenib combined with PD-1 and TACE. Donafenib will be taken orally twice a day, 0.1mg each time.PD-1 will be used intravenously every 3 weeks.
223693869|NCT05262959|PROCEDURE|TACE|TACE will be performed by the investigator based on the patient's tumor status.
223693870|NCT05368844|DEVICE|rTMS treatment using BrainsWay Model 104 system with H1-Coil|5 days of 10 daily sessions of rTMS treatment
223693871|NCT05368844|DEVICE|sham TMS using BrainsWay Model 104 system with H1-Coil|5 days of 10 daily sessions of sham iTBS treatment
223693872|NCT02904447|OTHER|x-ray and pedobar foot pressure mapping|
223693873|NCT06211335|DRUG|Losartan|Given PO
223693874|NCT06211335|BIOLOGICAL|Pembrolizumab|Given IV
223693875|NCT06211335|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
223693876|NCT05169567|DRUG|Abemaciclib|Administered orally.
223693877|NCT05169567|DRUG|Fulvestrant|Administered IM.
223693878|NCT05169567|DRUG|Placebo|Administered orally.
223693879|NCT01015131|RADIATION|18F-FLT-PET/CT Imaging|Participants receive the investigational radiotracer 18F-FLT intravenously and undergo Positron Emission Tomography (PET)/Computed Tomography (CT) scans at the following three times: prior to initiation of chemotherapy, at the end of the first cycle of treatment, and at the conclusion of chemotherapy.
223693880|NCT03980951|PROCEDURE|Dural Puncture Epidural Technique|three labor analgesia techniques
223693881|NCT03980951|PROCEDURE|Combined Spinal Epidural without intrathecal opioids|three labor analgesia techniques
223693882|NCT03980951|PROCEDURE|epidural|three labor analgesia techniques
223693883|NCT03671018|DRUG|Mosunetuzumab (IV)|Participants will receive intravenous (IV) mosunetuzumab.
223693884|NCT03671018|DRUG|Mosunetuzumab (SC)|Participants will receive subcutaneous (SC) mosunetuzumab.
223693885|NCT03671018|DRUG|Polatuzumab vedotin|Participants will receive IV polatuzumab vedotin.
223693886|NCT03671018|DRUG|Tocilizumab|Participants will receive IV tocilizumab as needed.
223693887|NCT03671018|DRUG|Rituximab|Participants will receive IV rituximab.
223693888|NCT05430022|BEHAVIORAL|Autism-adapted Group Cognitive Behavioral Therapy|The autism-adapted Group Cognitive Behavioral Therapy (CBT) was designed by the PI and research team in collaboration with autistic stakeholders (i.e., adults, parents, researchers). It is a 12-week group intervention (90 min) delivered on a weekly basis in an outpatient psychiatry clinic by licensed clinical psychologists and psychology trainees. Each group is comprised of 8-9 autistic adolescents (11-17 years old; middle and high school) with depression. The intervention targets adolescents' perception and understanding of self, including autistic identity, through a series of cognitive-behavioral approaches including psychoeducation, emotion regulation, cognitive distortions, cognitive restructuring, behavioral rehearsals, and weekly homework assignments.
223693889|NCT06587308|OTHER|Dorsal-Double-Layered 10% Circumferential Reduction (DD-10) Pressure Garment|During Phase IA, i.e., the first four weeks between Time 1 (Baseline) and Time 2 (Week 4), when participants are hospitalized in the rehabilitation department of the hospital. participants will need to wear the DD-10 pressure garment for 3 hours in the morning, 3 hours in the afternoon, and 8 hours at night daily. Additionally, all participants will need to attend an occupational therapy session for 30 minutes, 5 days a week. During Phase IB, i.e., the second four weeks between Time 2 (Week 4), and Time 3 (Week 8), when participants were being discharged from the hospital, they need to continually wearing the pressure garment according to same wearing schedule; however, the participants will not need to attend the occupational therapy session.
223693890|NCT06587308|OTHER|Single-Layered 10% Circumferential Reduction (S-10) Pressure Garment|During Phase IA, i.e., the first four weeks between Time 1 (Baseline) and Time 2 (Week 4), when participants are hospitalized in the rehabilitation department of the hospital. participants will need to wear the S-10 pressure garment for 3 hours in the morning, 3 hours in the afternoon, and 8 hours at night daily. Additionally, all participants will need to attend an occupational therapy session for 30 minutes, 5 days a week. During Phase IB, i.e., the second four weeks between Time 2 (Week 4), and Time 3 (Week 8), when participants were being discharged from the hospital, they need to continually wearing the pressure garment according to same wearing schedule; however, the participants will not need to attend the occupational therapy session.
223693891|NCT06587308|OTHER|Single-Layered No Circumferential Reduction (S-0) Pressure Garment|During Phase IA, i.e., the first four weeks between Time 1 (Baseline) and Time 2 (Week 4), when participants are hospitalized in the rehabilitation department of the hospital. participants will need to wear the S-0 pressure garment for 3 hours in the morning, 3 hours in the afternoon, and 8 hours at night daily. Additionally, all participants will need to attend an occupational therapy session for 30 minutes, 5 days a week. During Phase IB, i.e., the second four weeks between Time 2 (Week 4), and Time 3 (Week 8), when participants were being discharged from the hospital, they need to continually wearing the pressure garment according to same wearing schedule; however, the participants will not need to attend the occupational therapy session.
223777865|NCT06986707|OTHER|Graston technique|"GROUP B: Conventional treatment will be given for 45 minutes Before starting procedure, brisk walking or stretching is done for 4- 5 minutes~* Applying heat for 3-4 minutes to warm the area~* 40 seconds on right side~* 40 seconds on left side~* 1 day per week~* 4 weeks protocol After treatment, apply Ice for 2 minutes"
223777866|NCT03620851|OTHER|effect of age|effect of age on the efficiency of enhanced recovery program
223777867|NCT06663787|DRUG|Trastuzumab (Herceptin)|Continuing anti-HER2 treatment
223777868|NCT06663787|DIAGNOSTIC_TEST|SIgnatera|A personalized, tumor-informed test.
223777869|NCT06661837|OTHER|Clinical examination and mobile photo|Children were both clinically examined and a mobile photo was taken for assessment
223777870|NCT01736566|OTHER|Family History + Whole Genome Sequencing|"Doctors and their patients receive a Genome Report and a Family History report.~There are two sections of the Genome Report:~1. The General Genome Report, which include highly penetrant disease mutations, carrier status for recessive disease, and pharmacogenetic associations.~2. The Cardiac Risk Supplement, which contain genetic information found in the genome regarding cardiac diseases or a risk of cardiovascular diseases that can help with the care of the patient.~Extension Phase: Experimental: Family History + Whole Genome Sequencing~\*In the main study participants are randomized to either the Experimental or Other Arm, in the Extension phase of the study all participants are in the Experimental Arm."
223693892|NCT06677866|BEHAVIORAL|Cognitive behavioral therapy|"Cooperative Group Therapy (CGT) is a cognitive-behavioral group therapy based on the theoretical and practical principles of the Cooperative Parent-Mediated Therapy model \[Valeri et al., 2020\].~The goal of CGT is to promote the following core skills: Pragmatics, Executive Functions, and Cooperative Interactions. The CGT program consists of 15 sessions over a total duration of 6 months: 12 group therapy sessions with adolescents and 3 sessions with their parents. Each session focuses on a specific topic and lasts between 90 and 120 minutes.~The CGT therapist is a psychotherapist with a cognitive-behavioral orientation who utilizes evidence.-based strategies to enhance pragmatic, socio-conversational skills, cognitive flexibility, emotional regulation, and cooperative interactions. The CGT intervention is conducted by two cognitive-behavioral psychotherapists specialized respectively in the treatment of FXS and ASD."
223693893|NCT06677866|OTHER|Waiting List|The Waiting List (WL) is a control group in which participants who do not receive the experimental treatment are placed on a waiting list to receive the intervention after the active treatment group has completed it. In the case of the WL, the CGT intervention is carried out after at least 6 months to allow the patients in the first group to complete the treatment cycle. This approach enables a comparison between a group of treated patients and a group of patients who have not yet been treated, while still allowing the latter to access the treatment at a later stage.
223693894|NCT06680245|DRUG|Mitomycin c|Patients needing Ahmed valve implants to control intraocular pressures will be eligible. Eligible patients who consent will be randomized to receive either mitomycin-C or no intervention during implant surgery. Screening visits occur one week before surgery to assess eligibility and take baseline measurements (visual acuity, IOP, anterior chamber reaction). On surgery day, patients register at SJHH King Campus and undergo randomization. IOP is measured using a tonopen in the OR. An experienced glaucoma specialist performs the surgery, injecting 0.2 mg/ml mitomycin-C into the sclera for the experimental group, while the control group receives no intervention. The area is irrigated with 40mL balanced salt solution before implant insertion. Post-operative care includes topical antibiotics and steroids for six weeks, with follow-ups at 1 and 2 weeks, and 1, 3, 6, and 12 months to monitor visual acuity, IOP, anterior chamber reaction, complications, and additional glaucoma medications.
223693895|NCT04504812|DRUG|Duloxetine|Duloxetine is a drug that is used to improve pain and function in people with knee osteoarthritis (KOA). Duloxetine is approved by the Food and Drug Administration (FDA) for the treatment of depression, anxiety disorder, fibromyalgia, and joint pain. It will be titrated up from 20 or 30mg according to a schedule provided by a study provider.
223693896|NCT04504812|COMBINATION_PRODUCT|Intra-Articular Injection|Intra-Articular Injection is an injection of 3-6 milliliter (mL) hyaluronic acid (HA) mixed with 1 milliliter (mL) depo methylprednisolone (a steroid) and 2 mL 0.5% bupivacaine (an anesthetic) into the knee.
223693897|NCT04504812|PROCEDURE|Nerve Procedure with long acting blocks|People assigned to receive this will have 1 milliliter (mL) of a long-acting local anesthetic (a.k.a. liposomal bupivacaine or EXPAREL) and steroid injected into the knee.
223693898|NCT04504812|PROCEDURE|Nerve Procedure with nerve ablation|People assigned to receive this will have heat applied to destroy the nerve signaling pain in the knee. Steroid will be administered after the procedure to reduce the risk of neuritis.
223777871|NCT01736566|OTHER|Family History Only|Doctors and their patients receive a Family History report.
223777872|NCT02539875|BEHAVIORAL|AWARD and brief leaflet/ Referral leaflet and active referral/ Smoking cessation booklet and general advices|Use AWARD and brief leaflet/ Referral leaflet and active referral/ Smoking cessation booklet and general advices interventions to achieve smoking abstinence
223777873|NCT06621121|OTHER|Tenecteplase|The enrolled patients received treatment with tenecteplase (rhTNK-tPA) at a dosage of 0.25 mg/kg, up to a maximum of 25 mg, based on their clinical condition and the preferences expressed by the patients and their families.
223777874|NCT06621121|OTHER|Alteplase|The enrolled patients received treatment with alteplase (rtPA) at a dosage of 0.9 mg/kg, up to a maximum of 90 mg, based on their clinical condition and the preferences expressed by the patients and their families.
223777875|NCT06325995|RADIATION|Conventional radiation therapy|66-74 Gy in 33-37 daily fractions of 2 Gy to the prostate bed in the absence of disease progression or unacceptable toxicity.
223777876|NCT06325995|RADIATION|Hypofractionated radiation therapy|57.5-65 Gy in 23-26 daily fractions of 2.5 Gy to the prostate bed in the absence of disease progression or unacceptable toxicity.
223777877|NCT07023679|DRUG|Morphine|Morphine (10 mg, 10 ml) is injected around the stellate ganglion using ultrasound guidance prior to coronary artery recanalization
223777878|NCT07023679|DRUG|saline placebo|Saline (10 ml) is injected around the stellate ganglion using ultrasound guidance prior to coronary artery recanalization
223777879|NCT07029347|DEVICE|Strength of the dominant and non-dominant hip muscles using hydraulic pusj pull dynamometer|fleksor, ekstensor, abductor, adductor, internal rotasi, eksternal rotasi
223777880|NCT07029347|DEVICE|Static balance parameters using stabilometry|Center of Pressure (COP) range sway, velocity sway, dan weight distribution
223777881|NCT03403634|DRUG|Celecoxib|Given PO
223777882|NCT03403634|OTHER|Laboratory Biomarker Analysis|Correlative studies
223777883|NCT03403634|BIOLOGICAL|Recombinant Interferon Alfa-2b|Given IV
223777884|NCT03403634|DRUG|Rintatolimod|Given IV
223777885|NCT01997775|DRUG|METFORMIN|Participants enrolled in this study will be treated with either chemotherapy (Cisplatin 75mg/m2 plus Pemetrexed 500mg/m2 on D1) for 4 cycles or targeted therapy (Gefitinib 250mg/d) till disease progression according to physicians' decision. For participants with plasma IL-6 \> 2.0 pg/mL after 2 cycles of chemotherapy or targeted therapy, Metformin 500mg orally qd will be given on Day 1 of cycle 3. If patient could tolerate it well, metformin will be titrated to 500mg bid in the following week (Cycle 3 D8) and 500mg tid in the 3rd week (Cycle 3 D15). For patients receiving chemotherapy, metformin will be used for total 12 weeks and plasma IL-6 level will be checked at the end of metformin treatment. For patients receiving targeted therapy, metformin will be used till disease progression and plasma IL-6 level will be measured after use of metformin for 12 weeks.
223777886|NCT07032961|OTHER|Collect epidemiological, diagnostic, and follow-up data after MCG examination.|MCG System: GICE-1000 Manufacturer: Guangzhou Side Medical Technology Co., Ltd.
223777887|NCT00568308|DRUG|PI-88|160mg subcutaneous injection
223777888|NCT00568308|DRUG|placebo|matched placebo
223777889|NCT04160299|BEHAVIORAL|Dance-based exergaming|Dance sessions
223777890|NCT07042464|PROCEDURE|Modified poco-poco exercises|Participants performed modified poco-poco exercises three times weekly for 12 weeks
223777891|NCT07042763|PROCEDURE|Cutaneous Suture|Subciliary incision followed by closure using skin sutures only. The skin was closed with 5-0 nylon using subdermal interrupted sutures. No closure of the periosteal plane was performed.
223777892|NCT07042763|PROCEDURE|Periosteal Suture|Subciliary incision followed by closure of both the periosteum and skin layers. The periosteum was closed with absorbable 4-0 Vicryl sutures, and the skin was closed with 5-0 nylon using subdermal sutures.
223777893|NCT07042256|RADIATION|Low-field MR-informed adaptive marker-less SBRT for definitive treatment of localized prostate cancer in patients with bilateral hip prostheses|Low-field MR-informed adaptive marker-less SBRT
223777894|NCT06820697|BEHAVIORAL|Low HIVST kit subsidy|"The two study groups are the high and low subsidy groups. The high subsidy group will start off with a 90% subsidy while the low subsidy group will start off with a 50% subsidy. Both study groups will experience decreasing subsidies at each phase of the study."
223777895|NCT06820697|BEHAVIORAL|High HIVST kit subsidy|"The two study groups are the high and low subsidy groups. The high subsidy group will start off with a 90% subsidy while the low subsidy group will start off with a 50% subsidy. Both study groups will experience decreasing subsidies at each phase of the study."
223777896|NCT07046520|BEHAVIORAL|High intensity interval training|HIIT protocol was performed three times per week over a 10-week period, totaling 30 sessions. HIIT sessions included: (1) a standardized warm-up of five minutes of continuous jogging at 50%MAS, followed by five minutes of dynamic mobility and activation drills such as high-knee skips, high-knee running, and butt kicks. (2) a HIIT training session, consisted of four series of 15-second runs at 90-105% of the maximal aerobic speed (MAS) interspersed with 15 seconds of active recovery and (3) a cool-down of five minutes of static stretching.
223693899|NCT04504812|BEHAVIORAL|Pain Coping Skills Training|Participants will be provided with a written manual that includes login information for the pain coping skills training website. The participants will be expected to log into the system weekly, work through the modules, and participate in skills practice. This intervention will be conducted in combination with best practices and duloxetine.
223693900|NCT04504812|OTHER|Best Practices|Best Practices can include topical or oral nonsteroidal anti-inflammatory drugs (NSAIDs), acetaminophen; physical therapy that may include aquatherapy; integrative treatments such as acupuncture, yoga, or a structured exercise program; and other non-invasive treatments.
223693901|NCT06698575|DRUG|ABI-1179|Once daily tablet dosing (SAD), or weekly tablet dosing over 29 days (MAD)
223693902|NCT06698575|DRUG|ABI-1179 Placebo|Once daily tablet dosing (SAD), or weekly tablet dosing over 29 days (MAD)
223693903|NCT04104893|DRUG|Pembrolizumab|Pembrolizumab is a programmed death receptor-1 (PD 1)-blocking antibody. Pembrolizumab is a humanized monoclonal IgG4 kappa antibody with an approximate molecular weight of 149 kDa. Pembrolizumab is produced in recombinant Chinese hamster ovary (CHO) cells.
223777897|NCT07042685|DRUG|Fruquintinib Combined With Chemotherapy|The intervention in this trial involves administering a combination of 5FU-based chemotherapy and fruquintinib to patients with locally advanced unresectable or metastatic colorectal cancer. Patients receive either the FOLFIRI or mFOLFOX6 regimen, both of which include 5-fluorouracil (5FU), leucovorin (LV), and either irinotecan (FOLFIRI) or oxaliplatin (mFOLFOX6). Fruquintinib is given orally once daily for 21 days in each 28-day cycle. The initial dose of fruquintinib is 4 mg daily for the first three patients to assess safety; if no dose-limiting toxicities are observed, the dose is increased to 5 mg daily for subsequent participants. Treatment continues until disease progression, unacceptable toxicity, or patient withdrawal. After six months, patients with stable disease or better transition to a maintenance phase with 5FU and fruquintinib alone.
223777898|NCT06889740|OTHER|NMNH|Reduced Nicotinamide Mononucleotide
223777899|NCT06889740|OTHER|Placebo|Starch powder
223777900|NCT07045883|DRUG|Vitamin D Supplementation+ standard treatment|The experimental group was tested for 25(OH)D concentration after enrollment, and the experimental group was divided into vitamin D deficiency group and vitamin D normal group. In the vitamin D-deficient group, participants will receive standard treatment plus oral vitamin D3 supplementation (800 IU daily for 4 weeks), whereas the vitamin D normal group will receive standard treatment alone
223777901|NCT07045883|OTHER|standard treatment|The experimental group was tested for 25(OH)D concentration after enrollment, and the experimental group was divided into vitamin D deficiency group and vitamin D normal group. The vitamin D normal group will receive standard treatment alone
223777902|NCT07051681|OTHER|Individualized Medical Nutrition Therapy|Pregnant women with GDM received individualized nutrition therapy during pregnancy. No intervention was applied to the control group.
223777903|NCT06749288|DIETARY_SUPPLEMENT|Radicle Revive Placebo Control Form 4.1|Participants will use their Placebo Control Form 1 as directed for a period of 6 weeks.
223777904|NCT06749288|DIETARY_SUPPLEMENT|Radicle Revive Active Study Product 4.1 Usage|Participants will use their Radicle Revive Active Study Product 1.1 as directed for a period of 6 weeks.
223777905|NCT06911619|DIETARY_SUPPLEMENT|Dietary management|The intervention consists of a personalized dietary management with a nutritional follow-up pending transplantation. Teleconsultation appointments are scheduled with the dietician for dietary coaching and a re-evaluation of the nutritional strategy every month. Follow-up visits in person, carried out by the dietitian at the 3rd and 6th month waiting for transplant and are coupled with the usual consultations with the referring hepatologist. The visits allow the realization of LFI (Liver Frailty Index), the collection of interrelated events and the reassessment of hepatic disease as well as the re-evaluation of the nutritional strategy (CNO, enteral or parenteral nutrition)
223777906|NCT06911619|OTHER|No dietary management|The patient will be followed up by his reference hepatologist every 3 months. Follow-up visits at 3 months and 6 months waiting for liver transplantation will be performed by Clinical Research assistant on the same day as the follow-up consultation with his hepatologist with the completion of the Liver Frailty Index test and the collection of intercurrent events and the reassessment of liver disease.
223777907|NCT04560504|OTHER|Control Group|Leisure activities
223777908|NCT04560504|OTHER|Oculomotor Training Group|Eye movement training
223777909|NCT00126048|DRUG|Atorvastatin|40mg tablet
223777910|NCT00126048|DRUG|Placebo|Placebo tablet
223777911|NCT01197222|DEVICE|EndoClear Lens Cleaning Device|EndoClear Lens Cleaning Device is used during a laparoscopic abdominal surgery.
223777912|NCT01973127|OTHER|Verum rTMS|rTMS on the right dorsolateral prefrontal cortex. TMS procedure: The resting motor threshold (RMT) will be defined in each subject as the minimal stimulation intensity evoking an MEP of ≥ 0.05 mV in 50% of the trials in the muscle of the right thumb (M. abductor pollicis brevis). TMS will be conducted in the form of 'conventional rTMS', whereby 30 trains of 10 Hz pulses with a duration of 5 seconds and an inter-train interval of 25 seconds are applied to the righ dorsolateral prefrontal cortex (50 pulses per train, 6000 pulses per session). Used equipment: Magstim Rapid 2 device.
223777913|NCT01973127|OTHER|Sham rTMS|TMS procedure: The resting motor threshold (RMT) will be defined in each subject as the minimal stimulation intensity evoking an MEP of ≥ 0.05 mV in 50% of the trials in the muscle of the right thumb (M. abductor pollicis brevis). Like in verum TMS coil will be placed on the skull, but no magnetic field will be pulsed. Used equipment: Magstim Rapid 2 device.
223777914|NCT05738395|DIAGNOSTIC_TEST|Questions|Questions
223777915|NCT01337089|DRUG|Nabiximols|
223777916|NCT05601479|DRUG|Acetyl-L-carnitine|At the beginning of the first chemotherapy of the oxaliplatin regimen, Acetyl-L-carnitine 500mg will be given orally three times daily for 24 weeks. If subjects discontinue oxaliplatin-containing chemotherapy for various reasons (e.g., allergy to oxaliplatin), they will continue taking acetyl-L-carnitine until 24 weeks (unless acetyl-L-carnitine intolerance or other conditions interfere with medication).
223777917|NCT02341716|PROCEDURE|WA|Walk advice with Nordic Poles and best medical treatment
223693904|NCT03307057|BEHAVIORAL|Social Communication Growth Charts (SCGC)|The Social Communication Growth Charts (SCGC) is a web-based tool that parents can access to teach them the social communication milestones that are developing from 6 to 24 months of age. The SCGC has an explore function with hundreds of video clips illustrating 80 social communication milestones and a support video that has narration explaining how the parent in the video is supporting the child's development. The SCGC also has a charting function that parents can use by answering questions about their child's social communication milestones and then view charts in 5 developmental domains. Parents in the SCGC condition are also invited to a bi-weekly online Guided Tour to join other parents in a group meeting, like a book club, as they go through the SCGC.
223693905|NCT03307057|BEHAVIORAL|Parent-Implemented (P-I) Condition|"The Parent-Implemented (P-I) condition is based on the Early Social Interaction (ESI) model, which is an evidence-based parent-implemented intervention involving active and productive engagement for 5 hours per day, 5 days per week for toddlers with ASD. ESI teaches parents how to support their child's social communication, language, play and behaviors in everyday routines, activities, and places.~Weekly home sessions with a family navigator include:~1. developing the visit agenda~2. intervention implementation including: guided/caregiver practice, feedback and problem solving~3. planning for parent implementation between sessions~Families can also access the Autism Navigator How-To Guide for Families (a self-guided, web-based course), the Online Guided Tour for the How-To Guide (an online group to engage families), and have the opportunity to interact with other families who suspect their child has autism through audio or video conferencing or typed chat."
223693906|NCT03307057|BEHAVIORAL|Clinician-Implemented (C-I) Condition|The Clinician-Implemented (C-I) condition is based on the core principles of empirically-supported naturalistic developmental behavioral interventions (NDBI) for infants and toddlers with or at-risk for ASD, including Early Start Denver Model (ESDM), Project ImPACT (Improving Parents As Communication Teachers), Pivotal Response Treatment (PRT), and Early Social Interaction (ESI). The goal of C-I NDBI is to use naturalistic, developmental, and behavioral strategies with infants at-risk for ASD to improve social-communication, which includes eye contact, gesture use, intentional vocalizations, and language. Parents are not actively involved in C-I NDBI intervention sessions, though they may observe and the clinician will be given information about current social-communication targets.
223777918|NCT02341716|PROCEDURE|SET|Walk advice with Nordic Poles, best medical treatment and hospital-based supervised exercise therapy
223777919|NCT02341716|PROCEDURE|HET|Walk advice with Nordic Poles, best medical treatment and home-based supervised exercise therapy
223693907|NCT03307057|BEHAVIORAL|Usual Care|Care as recommended and provided by the child's pediatrician or other health care providers in the community.
223777920|NCT01311830|BEHAVIORAL|Telephone Counseling|
223777921|NCT01311830|BEHAVIORAL|Written Materials|
223777922|NCT05025293|DRUG|Zoledronic Acid 5Mg/Bag 100Ml Inj|100ml Zoledronic acid (5mg/100ml) administered intravenously
223777923|NCT05025293|DRUG|sodium chloride|100ml NaCl 9mg/ml administered intravenously
223777924|NCT06168708|PROCEDURE|Transurethral resection of the prostate (TURP)|TURP with addition of gentamicin on irrigation fluid to reduce infectious complications
223777925|NCT06168708|DRUG|Gentamicin|gentamicin 80 mg (2ml) /3L of irrigation solution (the first 9 Liters during resection and the first 6 Liters during post-operative irrigation)
223777926|NCT06168708|DRUG|normal saline|normal saline (2 ml) on the irrigation solution (placebo)
223777927|NCT03077282|DRUG|Prasaprohyai|Prasaprohyai 95% ethanolic extract capsules will take three times a day before meals
223693908|NCT03727607|DRUG|Desflurane|Desflurane vs TIVA, bariatric surgery. Postoperative nausea and pain
223693909|NCT06682156|DRUG|Carfilzomib|carfilzomib C1: 20mg/m2，D1-2; 27mg/m2，D8-9; 36mg/m2，D15-16 C2 and subsequent cycles: 36mg/m2。
223693910|NCT06698601|DIETARY_SUPPLEMENT|blueberry-rich diet|"The study participants follow a diet rich in blueberries for 12 weeks based on the nutritional therapy and the integrative medical concept taught during their inpatient stay at the clinic for internal and integrative medicine in Bamberg.~Participants will drink approximately 35g of a powder made from wild, freeze-dried blueberries containing 780mg of anthocyanines stirred in a glas of water every morning for a period of 12 weeks."
223693911|NCT06698601|OTHER|Control diet|"The study participants will focus on the nutritional therapy and the integrative medical concept taught during their inpatient stay at the clinic for internal and integrative medicine in Bamberg.~Participants will receive no additional blueberry treatment."
223693912|NCT06699888|OTHER|cervicothoracic manipulation group|"The participant lay prone with the head firmly into the head piece Palpation of the upper cervico-thoracic segment observed the side of the restriction.~The participants head was rotated to the contralateral side of the restriction. The practitioner's hand contacted the forehead and the other hand's thumb contacted the spinous process of the restricted side.~A low amplitude, high velocity thrust towards the axilla was applied, on the spinous process in PA direction.~Experimental group also received following exercises Chin tuck Strengthening Shoulder Retractors. Stretching SCM Pectoralis Stretch 3 × 10 repetitions, 3 times a week for 2 weeks"
223693913|NCT06699888|OTHER|forward head correction exercises traditional group|Chin tuck Strengthening Shoulder Retractors. Stretching SCM Pectoralis Stretch 3 × 10 repetitions, 3 times a week for 2 weeks.
223693914|NCT06878066|DRUG|thrombolysis therapy|All treatment and monitoring routines are according to the hospitals' standard operating procedures (SOP), and both drugs (Alteplase (ALP) and Tenecteplase (TNK)) are approved drugs for the indication AIS with similar efficacy and safety profile. SIFT is designed to test the hypothesis that intravenous thrombolysis (IVT) (tenecteplase 0.25 mg/kg or alteplase 0.9 mg/kg intravenously) is efficient and safe in acute ischemic stroke patients (AIS) with recent ingestion (last 48 hours) of an Factor Xa (FXa) inhibitor who otherwise are eligible for IVT.
223693915|NCT06708221|DEVICE|Real-Time Image Guided Radio Therapy (IGRT)|Real-time image guided radiation therapy (IGRT) methods image the cancerous tumour in real-time, enabling the treatment beam to focus its destructive energy on the patient's cancer, not their healthy tissue.
223693916|NCT06707831|OTHER|Teleassessment|Children underwent assessments on two occasions: one in face-to-face within a clinical setting, and the other through teleassessment using video conferencing. This video conference session was recorded to be later reviewed and scored by two separate raters.
223693917|NCT06709274|DRUG|Osimertinib|80mg daily, for EGFR-positive patients
223693918|NCT06709274|DRUG|Alectinib|600mg BID, for ALK-rearranged patients
223693919|NCT06709274|DRUG|TORIPALIMAB INJECTION (JS001 ) combine with chemotherapy|Toripalimab 240mg + Platinum-based chemotherapy (Q3W for 4 cycles), followed by Toripalimab maintenance therapy (240mg Q3W for one year), for EGFR/ALK wildtype patients
223693920|NCT06709924|OTHER|EXERCISE TRAINING WITHOUT MEDICATION|After ingesting the capsular sensor, the participants were request to perform exercise packages and monitor the change of signal transmission rate and shift of intraabdominal pressure level.
223693921|NCT06708767|DRUG|Contrast Media|IV contrast media administration
223693922|NCT06708767|DRUG|Placebo|Saline
223693923|NCT06709352|OTHER|non|non
223693924|NCT07131332|BEHAVIORAL|Mindful eating group|Behavioral group intervention involving 8, 2-hour long sessions
223693925|NCT06714396|DRUG|QRL-101|Single doses of QRL-101 will be orally administered. The dose levels may change subject to available nonclinical, clinical, safety, and PK data.
223693926|NCT06714396|OTHER|Placebo|Single doses of compartor placebo will be orally administered. The dose levels may change subject to available nonclinical, clinical, safety, and PK data.
223693927|NCT06702423|BEHAVIORAL|AI-based chatbot|A tailored Japanese HPV vaccination chatbot.
223693928|NCT06702423|BEHAVIORAL|Leaflet|A publicly accessible HPV vaccination leaflet prepared by the Ministry of Health, Labour, and Welfare.
223693929|NCT07039292|BEHAVIORAL|Harm Reduction (E-cigarette switching)|Participants will be assigned to receive an e-cigarette and try to switch completely from smoking to using the e-cigarette
223693930|NCT07039292|BEHAVIORAL|Standard of Care|Participants will be assigned to receive tobacco treatment referrals and the opportunity to re-enroll in the Tobacco Treatment Program
223693931|NCT07030543|BEHAVIORAL|Individualized Dietary Plan (IDP) for Type 2 Diabetes|This study evaluates the feasibility of an Individualized Dietary Plan (IDP), a structured, patient-tailored nutrition intervention designed to improve glycemic control and lipid profiles in adults with Type 2 Diabetes Mellitus (T2DM).
223693932|NCT07030543|BEHAVIORAL|Usual care|Standard dietary advice as per the current clinical practice.
223693933|NCT06709508|OTHER|Examination group|This study differs from other clinical studies because the participants of this study consisted of patients undergoing single-member implant-supported restoration treatment at the Department of Prosthodontics, Afyonkarahisar Health Sciences University.
223693934|NCT06708715|DEVICE|PEACE Patch|A topical patch that incorporates a sensory pattern of vibrotactile haptic technology.
223693935|NCT06708715|DEVICE|Topical Sham Patch|Sham Patch that does not include vibrotactile haptic technology
223693936|NCT07041853|DIETARY_SUPPLEMENT|KSM-66 Ashwagandha|Root extract ashwagandha, KSM-66
223693937|NCT07041853|DIETARY_SUPPLEMENT|Placebo|Organic chickpea flour
223693938|NCT06710743|OTHER|Glucose solution Day 1, Day 8, and Day 15|Glucodin powder diluted with water
223693939|NCT06710743|OTHER|Food (cereal). Ten different cereals served once each|Variety of cooked or flake cereal
223693940|NCT06708065|DEVICE|Armeo Power robot restores upper limb motor function.|"ArmeoPower is a robotic rehabilitation device developed by Hocoma, designed to assist patients with impaired upper limb motor functions following conditions such as stroke or neurological injuries. The device features an exoskeleton that supports and tracks movements of the arm and hand, utilizing motor-assisted motion based on the principle of adaptive support, which adjusts assistance levels according to the patient's capabilities. ArmeoPower integrates interactive exercises, often in the form of engaging games, to enhance patient motivation and maintain focus during therapy sessions. It also collects and tracks performance data, enabling clinicians to evaluate progress over time. This device is widely used in rehabilitation centers and hospitals to improve muscle control, strength, and range of motion in patients recovering from severe motor impairments."
223693941|NCT06708065|BEHAVIORAL|A Home Exercise Program|A Home Exercise Program (HEP) is a personalized set of exercises designed to support recovery and enhance functional abilities outside of clinical therapy sessions. For patients with hemiplegia due to cerebral infarction, the program typically includes range of motion (ROM) exercises to maintain joint flexibility and prevent stiffness, as well as strengthening exercises using resistance bands or light weights to improve muscle function. Balance and postural control exercises, such as weight shifting or standing on one leg, help enhance stability and reduce fall risks. Functional training focuses on practicing daily movements like reaching, grasping, or transferring between positions, while fine motor skill tasks aim to restore hand functionality. The program may also incorporate low-impact aerobic exercises, such as walking or seated cycling, to boost cardiovascular health, along with relaxation and breathing techniques to reduce stress and improve overall well-being. These exercises a
223693942|NCT06708065|BEHAVIORAL|Occupational therapy activities|Occupational therapy activities are designed to help individuals regain independence in daily life by addressing functional abilities, motor skills, and cognitive functions. For patients with hemiplegia due to cerebral infarction, these activities often include practicing Activities of Daily Living (ADLs) such as dressing, grooming, bathing, and feeding, as well as more complex tasks like cooking and managing finances. Fine motor skills development is emphasized through exercises involving tasks like buttoning, tying shoelaces, or handling small objects, sometimes using adaptive tools. Additionally, functional mobility training focuses on teaching safe movement strategies, such as transferring between surfaces or navigating stairs, and may include wheelchair mobility or energy conservation techniques. These activities are tailored to the patient's needs to enhance their ability to perform meaningful and necessary daily tasks independently.
223777928|NCT04959045|OTHER|intervention group (Flipped Teaching Method Group)|"Students will be given skill training with the Flipped Teaching method, which consists of outside and in-class applications.~Out-of-Class Practice: A Learning Management System-Web-Based Distance Education System will be created for the Flipped Teaching method. Theoretical course topics and skill training videos will be uploaded to the system 7 days before the course day. Students will be able to watch the video tutorials in the number and frequency they want until the day of the lesson. At the end of the lesson, the mini-exam will be uploaded to the system.~In-class practice: The researcher will come to the lesson prepared for classroom activities such as question and answer. Theoretical lectures and skill demonstrations will not be made by the researcher. The researcher will only guide the students. Then, the students will be provided to perform the skill under the guidance of the researcher in the clinical skills laboratory."
223777929|NCT06373094|DRUG|Donepezil Dihydroxynaphthalate for Injection|HHT201 will be injected into the muscle of gluteus.
223777930|NCT01627249|DRUG|2.0 mg intravitreal aflibercept|Intravitreal injection of 2.0 mg aflibercept at baseline and up to every 4 weeks using defined retreatment criteria.
223777931|NCT01627249|DRUG|1.25 mg intravitreal bevacizumab|Intravitreal injection of 1.25 mg bevacizumab at baseline and up to every 4 weeks using defined retreatment criteria.
223693943|NCT06708494|BEHAVIORAL|video decision aids|The video includes an introduction to geriatric frailty (3 minutes) and ACP (5 minutes). ACP includes three levels of medical care: life-prolonging care, limited care, and comfort care.
223693944|NCT03367013|DIETARY_SUPPLEMENT|Bovine Lactoferrin|Intervention includes a daily dose of 200 mg/kg bovine lactoferrin in breast/donor human milk or formula milk until 34 weeks corrected gestation or for a minimum of 2 weeks, whichever is longer, or until discharge home or transfer, if earlier.
223693945|NCT03367013|OTHER|No Bovine Lactoferrin added|Control includes daily study feed with no bovine lactoferrin added in breast/donor human milk or formula milk until 34 weeks corrected gestation or for a minimum of 2 weeks, whichever is longer, or until discharge home or transfer, if earlier.
223693946|NCT06722183|DRUG|Futibatinib orally administered|Futibatinib will be administered 20mg orally, once daily, continously
223693947|NCT06722183|DRUG|Tislelizumab (i.v. 200mg)|Tislelizumab (i.v. 200mg) will be administered on day 1 and day 22 of a 6-week cycle
223777932|NCT01627249|DRUG|0.3 mg intravitreal ranibizumab|Intravitreal injection of 0.3 mg ranibizumab (Lucentis™) at baseline and up to every 4 weeks using defined retreatment criteria.
223777933|NCT00736242|BIOLOGICAL|PEG-IFN alfa-2b|Peginterferon alfa-2b administered subcutaneously at a dose 1.5 ug/kg/week, according to the European Medicines Agency (EMEA)-approved labeling
223777934|NCT00736242|DRUG|RBV|Ribavirin administered at a dose of 800-1200 mg/day (on a weight-basis) according to the EMEA-approved labeling
223777935|NCT04981587|PROCEDURE|Strength exercise|Strength exercise protocol for upper and lower limbs, using weights and elastic bands
223777936|NCT04981587|OTHER|Usual treatment|The usual treatment is based on activities to enhance brain functions: attention, memory, executive functions, language and orientation.
223777937|NCT01346657|DRUG|Nifidipine & LipoCol|The effect of LipoCol Forte® capsules on the pharmacokinetics of nifedipine after administering single-dose combination in healthy subjects.
223777938|NCT06478147|DIETARY_SUPPLEMENT|Oral Nutritional Supplement|Commercially available Oral Nutritional Supplement alone consumed 90 minutes prior to an ad libitum breakfast
223777939|NCT06478147|DIETARY_SUPPLEMENT|Oral Nutritional Supplement + Whey Protein Hydrolysate|Whey Protein Hydrolysate dissolved in an Oral Nutritional Supplement consumed 90 minutes prior to an ad libitum breakfast
223777940|NCT06478147|DIETARY_SUPPLEMENT|Whey Protein Hydrolysate + still water|Whey Protein Hydrolysate dissolved in still water consumed 90 minutes prior to an ad libitum breakfast
223693948|NCT04721847|OTHER|Pain Neuroscience Education|In first part educational content will be designed to be given in group of patients in six sessions by PNE booklet. The six sessions are 1.5 hours long (9 hours) and will be given at a frequency of 1 session per week. Final session will be given to solve doubts, and to provide additional information to the educational program. Book for additional material will be delivered to participants.
223693949|NCT04721847|OTHER|Conventional Physical therapy|Control group will be treated by Conventional Physical therapy like TENS, stretching and strengthening exercises. Intervention will be initiated with warm up period (joint mobility exercises) for the duration of 5 mins and ended up with cool down period (relaxing exercises i.e. deep breathing) for the duration of 5 mins.
223693950|NCT06886256|DEVICE|Polar H10 Heart Rate Monitor|Wearable sensors to capture movement-based data during physical therapy session. The Polar H10 Heart Rate Monitor measures heart rate and will transfer the data to the mHealth app.
223693951|NCT06886256|DEVICE|Empatica EmbracePlus|Wearable sensors to capture movement-based data during physical therapy session. The Empatica EmbracePlus measures physiological parameters and will transfer the data to the mHealth app.
223693952|NCT06886256|DEVICE|Apple Watch Ultra 2|Wearable sensors to capture movement-based data during physical therapy session. The Apple Watch Ultra 2 measures heart rate, will transfer the data to the mHealth app, and will provide an alert when the heart rate is too high or too low.
223777941|NCT01509573|BEHAVIORAL|Family Strengthening Intervention in Rwanda (FSI-R)|"Core components of the FSI-R are derived from the FBPI theoretical framework, and were chosen to address key risk factors identified in qualitative data. The FSI-R holds separate preliminary meetings with caregivers and children to prepare for a larger family meeting. In these modules, the interventionist helps caregivers and children prioritize concerns or key messages that they most want to share with the other party. Role play and discussions are used to impart improved parenting and communication skills. In the family meetings, children and caregivers share their concerns with one another and develop a shared family narrative, which integrates past events into a singular story with shared goals and a future orientation. These family modules also discuss the services and supports (formal and non-formal resources) that the family can engage with in order to achieve their shared goals.~8-12 weeks for 1-2 hours per week, depending on each family's pace and coverage of the material."
223777942|NCT03196648|OTHER|Gingival health formulation in an accelerating device|The intervention is a gingival health formulation for soft tissue maintenance, oral malodor and gentle teeth whitening to be used with the GLO Science Device
223777943|NCT03196648|OTHER|Gingival health formulation on a toothbrush|The intervention is a gingival health formulation for soft tissue maintenance, oral malodor and gentle teeth whitening to be used on a toothbrush together with toothpaste.
223777944|NCT03196648|OTHER|OTC fluoride toothpaste|OTC anti-cavity toothpaste containing fluoride and sodium monofluorophosphate.
223777945|NCT05058911|BEHAVIORAL|Internet-delivered exposure-based cognitive behavior therapy|The primary treatment component is exposure to stimuli (situations and activities) that give rise to pain, distress, and unwanted emotional responses. The treatment proceeds in accordance with functional analysis. Exercises are tailored for the patient so that, for example, individuals whose main coping strategy is to be overly active (i.e., persistence behavior) are encouraged to sit down and observe pain and other aversive bodily sensations as they arise. The protocol also includes regular exercises where the participant is encouraged to observe and name physical sensations without acting on them.
223777946|NCT05058911|BEHAVIORAL|Internet-delivered traditional cognitive behavior therapy|This treatment is based on components typical of T-CBT for FM, such as relaxation, activity planning or pacing, cognitive restructuring techniques and stress management strategies.
223777947|NCT04489095|DIAGNOSTIC_TEST|Electrophysiology Study|After informed consent is obtained, patient will undergo TAVR as per usual standard of care. Using the same femoral vein access as is used standard for a portion of the TAVR procedure, an EPS will be performed during the TAVR procedure, immediately before and after valve implantation. The patient will recover on a general telemetry floor as per usual care, and the next day will undergo another EPS. This is not uncommonly done clinically for some patients after TAVR. At that point, based on the baseline EKG, intra-procedure findings, and EPS findings, the patient will either have a pacemaker implanted, a 30-day event monitor ordered, or neither of the above.
223777948|NCT06634563|OTHER|mindfulness meditation|the patients will receive mindfulness meditation in the form of Attention-focusing technique (body scan, directing attention throughout the body in a relaxed, supine state) guided by audiotapes. Relaxing every part of the body by guided audiotape from head to toes and Sitting meditation (systematically directing attention to breath) guided by audiotapes. Relaxing deep rhythmic breathing with concentration on every breath.
223777949|NCT06634563|OTHER|cognitive behavioral training|Training sessions will include three cognitive training tasks each of them target a particular core cognitive capability and are grouped into three categories by target domain: memory (working memory), attention (selective attention), and problem solving (logical reasoning) through these games (organic order and fuse clues for logical reasoning training, lost in migration, trouble brewing, assist ants and train of thought for attention training and memory match and memory match one drive for working memory training).
223777950|NCT03103282|DEVICE|PuraStat®|Synthetic haemostatic material
223777951|NCT02528201|DRUG|Celecoxib 200 milligrams|Celecoxib 200 milligrams once a day
223777952|NCT02528201|DRUG|Celecoxib 400 milligrams|Celecoxib 400 milligrams once a day
223777953|NCT02528201|DRUG|diclofenac 50 milligrams|diclofenac 50 milligrams three times a day
223777954|NCT04231656|DEVICE|CLEARSIGHT and NICCOMO measurements in sequence A|Starting from 0° position, shift to position +20°, then tilt to -20°, and finally back to the 0° position.
223777955|NCT04231656|DEVICE|CLEARSIGHT and NICCOMO measurements in sequence B|Starting from 0° position, shift to position -20°, then tilt to +20°, and finally back to the 0° position and collect the last group of figures.
223777956|NCT01076595|DRUG|Interferon beta-1b (Betaseron, BAY86-5046)|Betaferon 250 microgram
223777957|NCT01438632|DEVICE|jet injection device|Rapid-acting insulin analogue aspart (Novorapid®) administration by means of a jet injector or a conventional insulin pen in the subcutaneous tissue. Dosage of insulin will be determined by the normal dosage of insulin used by the patient before breakfast.
223777958|NCT06105489|PROCEDURE|Lateral Sinus Lift using tunnel flap technique|"The surgical procedure will involve the following steps:~* A single vertical anterior incision will be made, at least 10 mm mesially to the expected outline of the bony window.~* A full-thickness flap will be carefully elevated to expose the lateral wall of the maxillary sinus.~* A trap door will be created in the lateral wall of the maxillary sinus using either a dedicated piezosurgical insert or a straight handpiece with a 3mm round diamond bur.~* The door will be removed.~* The sinus membrane will be gently elevated using various-shaped curettes until it becomes completely detached from the lateral, inferior, and medial walls of the sinus.~* The maxillary sinus will be filled with a heterologous bone graft with a well-documented efficacy.~* The flaps will be meticulously sutured."
223693953|NCT06707467|OTHER|occlusal splint|nineteen patients diagnosed with internal temporomandibular derangement will receive occlusal splint therapy, a treatment method with proven effectiveness.
223693954|NCT06707467|OTHER|occlusal splints combined with rocabado exercise|Nineteen patients diagnosed with internal temporomandibular derangement will be provided with Rocabado exercises in addition to the proven-effective treatment method of occlusal splint therapy. This approach aims to evaluate whether Rocabado exercises have a positive effect on the treatment process.
223693955|NCT06707467|OTHER|occlusal splint combined with posture exercise|Nineteen patients diagnosed with internal temporomandibular derangement will be provided with posture exercises in addition to the proven-effective treatment method of occlusal splint therapy. This approach aims to evaluate whether posture exercises have a positive effect on the treatment process.
223693956|NCT06707363|PROCEDURE|orthopedic surgery|Surgeries involving major interventions on the musculoskeletal system, such as joint replacement surgeries or fracture repairs.
223693957|NCT07043088|PROCEDURE|Membrane sweeping|Serial membrane sweeping from gestational age 39+5-40+2 with 2-3 days interval and a maximum og three times.
223693958|NCT06709365|PROCEDURE|Tibiotalar calcaneal fusion by hindfoot|Hindfoot nail for ankle fusion
223777959|NCT06105489|PROCEDURE|Lateral Sinus Lift using crestal incision flap|"The surgical procedure will involve the following steps:~* A horizontal incision is made on the top of the alveolar ridge, along with two additional releasing incisions in the mesial and distal regions.~* A full-thickness flap will be carefully elevated to expose the lateral wall of the maxillary sinus.~* A trap door will be created in the lateral wall of the maxillary sinus using either a dedicated piezosurgical insert or a straight handpiece with a 3mm round diamond bur.~* The door will be removed.~* The sinus membrane will be gently elevated using various-shaped curettes until it becomes completely detached from the lateral, inferior, and medial walls of the sinus.~* The maxillary sinus will be filled with a heterologous bone graft with a well-documented efficacy.~* The flaps will be meticulously sutured."
223693959|NCT06708975|OTHER|Insulin therapy phonophoresis|Insulin therapy phonophoresis is the use of ultrasound to deliver drugs through patients skin, Insulin therapy will be used to determine its effect on wound healing in patients with chronic diabetes mellites because in addition to its systemic impact, numerous reports suggest that applying insulin topically causes localized effects. Many trials and case reports have been released reporting positive effects of topical insulin for many diseases such as dermatological compromises, ophthalmological diseases and others
223693960|NCT06708975|OTHER|Hyperpolarized light therapy and Standard wound cleaning and dressing.|Hyperpolarized light therapy safely accelerates wound healing by stimulating blood circulation, reducing inflammation and relieving muscle spasms.
223693961|NCT03944746|OTHER|Education Curriculum|Different educational curriculums were applied to each cohort
223693962|NCT02981940|DRUG|Abemaciclib|Abemaciclib capsule
223693963|NCT02981940|PROCEDURE|Surgery|Surgery
223693966|NCT06897566|DIAGNOSTIC_TEST|Fasting lipid profile|Recruited patients will be requested to provide data from their most recent fasting lipid profile
223693967|NCT06765941|DEVICE|Probe-based near-infrared parathyroid autofluorescence detection system|The surgeon will use the PTeye as an intraoperative tool to identify whether a suspect tissue is parathyroid or not during the surgery. The surgeon will first take five baseline NIRAF measurements on the thyroid gland (or neck muscle, if thyroid is absent), to establish a reference point for subsequent measurements, using the disposable sterile fiber probe that is connected to the PTeye console, as per device functionality requirements. The subsequent step involves touching the target tissue in the neck with the fiber optic probe, after which the PTeye will indicate to the surgeon whether the tissue is parathyroid or not. Parameters displayed on the PTeye console - Baseline values, Detection Intensity, Parathyroid Detection Ratio - will be recorded for each patient in the study arm. PTeye indicates that a tissue is parathyroid if the 'Parathyroid Detection Ratio' is greater than 1.2. The rest of the surgical procedure will follow the standard protocol.
223693968|NCT06765941|PROCEDURE|Surgeons naked eyes for parathyroid glands identification|The surgeons will not use the probe-based near-infrared parathyroid autofluorescence detection system and will proceed with the procedure as usual, relying on their surgical experience to identify parathyroid glands. At the end of the procedure, the thyroid specimen will be evaluated visually to search for inadvertently resected parathyroid glands. If this is the case, these parathyroid glands will be reimplanted in the sternocleidomastoid muscle, following standard protocol.
223777960|NCT01335711|DRUG|ChronVac-C + SOC|"IMP: I.m. administration of 500 μg plasmid DNA vaccine CHRONVAC-C (solution for injection) administered i.m. in combination with electroporation using MedPulser® DDS on 2 occasions with 4 weeks in between followed by standard of care (SOC) initiation after 14 - 42 days.~SOC: Peg-IFN-α-2a (180 μg per week) and Ribavirin (1000 mg/day for subjects with a BW of \< 75 kg and 1200 mg/day for subjects with a BW of \> 75 kg)"
223777961|NCT01335711|DRUG|SOC|SOC: Peg-IFN-α-2a (180 μg per week) and Ribavirin (1000 mg/day for subjects with a BW of \< 75 kg and 1200 mg/day for subjects with a BW of \> 75 kg)
223777962|NCT05004623|DEVICE|Sentinel Lymph Node Biopsy|Detection of sentinel lymph nodes by indocyanine green (ICG) fluorescent dye technique, using a prototype of the Easy Light device.
223777963|NCT02039505|DRUG|Vedolizumab|Vedolizumab intravenous infusion
223777964|NCT02039505|DRUG|Vedolizumab placebo|Vedolizumab placebo
223777965|NCT03263377|DIETARY_SUPPLEMENT|The school feeding intervention|The baseline study will be conducted using a cluster randomized study design in which schools represent clusters. Seven schools will be randomly selected from each of 7 Upazilas out of 10 that have been selected for intervention. The school feeding intervention consists of a daily snack in the form of a fortified biscuit that provides 300 kcal per single 75 gm packet (approximately 15% of daily calorie requirements), and a range of micronutrients contributing to about 75% of the daily requirement of vitamin A, folate, iron, iodine, zinc and magnesium.
223777966|NCT01320410|DRUG|ISM®|
223777967|NCT02376452|DRUG|Raltitrexed|2mg/m2 iv gtt, d1
223777968|NCT02376452|DRUG|Irinotecan|180 mg/m2 iv gtt, d1
223777969|NCT02376452|DRUG|5-fluorouracil|5-FU 400mg/m2 iv, 2400mg/m2 civ 46h
223777970|NCT02376452|DRUG|Leucovorin|400mg/m2 iv gtt,d1
223777971|NCT02832895|OTHER|Transcranial doppler examination|Assessment of frontal bone window for transcranial doppler
223777972|NCT00059683|PROCEDURE|cervical cerclage|Cerclage is a circumferential stitch of non-absorbable suture placed around the cervix
223777973|NCT06534801|DRUG|Oxycodone will be administered intravenously in the group 1|Oxycodone will be administered intravenously 30min before the end of surgery, and Dixon sequential method will be used for the study
223777974|NCT03822169|DIETARY_SUPPLEMENT|Choline added as a phospholipid|A shake with 3000 mg choline added as a phospholipid
223777975|NCT03822169|DIETARY_SUPPLEMENT|Choline added as a salt|A shake with 3000 mg choline added as a salt
223777976|NCT03752281|OTHER|Investigation of health and activity|During a six months multidisciplinary investigation of health status, activity and working ability for individuals receiving long-term social assistance, the health and activity status as well as function will be described using established questionnaires and the International Classification of Functioning
223777977|NCT04007952|PROCEDURE|Anterior Gastropexy|Two permanent sutures will be introduced into the abdomen and placed along the lesser curvature of the stomach. A suture passer will be used to grasp the ends of the sutures to externalize them at separate fascial punctures. At time of abdominal desufflation, the sutures will be tied and the incision closed per individual surgeon practice.
223777978|NCT03311074|GENETIC|Strimvelis|Strimvelis is a gene therapy that aims to restore ADA function in hematopoietic cell lineages and prevent the immunological manifestations. Strimvelis is a cluster of differentiation (CD) 34+ cell enriched dispersion of human bone marrow derived hematopoietic stem cells for infusion which have been transduced with a retroviral vector containing the human ADA gene.
223777979|NCT05078645|DEVICE|Maya|The Maya is a cover which can be placed over the end of the patients bed. The Maya aims to reduce light and sound nuisances and enhance patients' privacy
223777980|NCT05979792|DRUG|CAR-T Therapy|CAR-T cell infusion
223777981|NCT00679991|DRUG|PRT-201|Applied topically to AVF during surgery
223777982|NCT00679991|DRUG|PRT-201|Dose escalation study. Drug/placebo administered at the time of fistula creation
223777983|NCT04014660|DIETARY_SUPPLEMENT|Probiotic|The probiotic product consists of two different bacterial strains, L.plantarum Heal 9 and L.paracasei 8700:2
223777984|NCT04014660|DIETARY_SUPPLEMENT|Placebo|The placebo supplement consists of corn starch only.
223777985|NCT05259449|BEHAVIORAL|Nutritional education program|The education intervention will consist of individual nutritional counselling. The nutritional education program will be conducted every 2 weeks for 12 consecutive weeks, with 20-min counselling sessions by an experienced nutritionist. Participants will be provided with an introduction (in an easy-to-understand manner) regarding the association between T2DM, gut microbiome and dietary habits. Firstly, the diet of the patient should be analysed, to determine which aspects can be improved, such as, total calories intake, amount and types of carbohydrates (highlighting the relevance of fibre), etc. Moreover, some suggestions about the combination of foods and culinary technical in order to manage the glycaemic index of foods will be provided. Finally, those pattern of the Mediterranean diet and some qualitative aspects and aids (as the size of the plat or avoid having the food platter on the table) will be taught the patients.
223777986|NCT05259449|OTHER|The High-Intensity Interval Training (HIIT)|3 sessions per week in a cycle ergometer, with 1-2 days off between sessions, during a total of 12 weeks under the supervision of a personal trainer. HIIT program will consist of 3-5 series of 1 min duration at 90-130% of its maximum power (determined in the first training session), with 90 seconds of rest between sets (estimated total time of the session: 10 minutes). Depending on the number of training session, the load and the series will increase up to 40% more than the maximum load.
223777987|NCT05259449|OTHER|The Moderate-Intensity Continuous Training (MICT)|3 sessions per week in a cycle ergometer, with 1-2 days off between sessions, during a total of 12 weeks under the supervision of a personal trainer. MICT program will consist of sessions of approximately ˜45 min of moderate aerobic exercise (at the intensity at which the maximal fat oxidation was achieved in the laboratory test) in cycle ergometer.
223777988|NCT04409756|OTHER|shoulder rating questionnaire|to investigate reliability of turkish version of shoulder rating questionnaire
223777989|NCT00633984|BEHAVIORAL|Cognitive Behavioral Group Therapy (CBGT)|The patient will then receive 12 weekly sessions of Cognitive Behavioral Therapy lasting approximately two and a half hours each. During these sessions, patients will receive information on the nature of social phobia and a model of treatment and will receive weekly training in how to become more comfortable with social situations, with the goal of achieving confidence in social interactions. As part of this training, the therapist will practice social interactions with the patient, who will also be asked to practice what they have learned outside of the therapists' office.
223777990|NCT00633984|DRUG|D-Cycloserine|For the third, fourth, fifth, sixth, and seventh sessions of the twelve-session program of Cognitive Behavioral Therapy, the patient will be asked to arrive one hour early to take one of the study pill, a 50mg pill of d-cycloserine. A physician will be available in the unlikely event that a patient begins to experience side effects. Before the treatment starts, before the eighth session, and one week after the final session patients will have a separate visit in which their levels of symptoms assessed with measures of mood, anxiety, and avoidance.
223777991|NCT00633984|DRUG|Placebo|For the third, fourth, fifth, sixth, and seventh sessions of the twelve-session program of Cognitive Behavioral Therapy, the patient will be asked to arrive one hour early to take one of the study pill, a placebo. A physician will be available in the unlikely event that a patient begins to experience side effects. Before the treatment starts, before the eighth session, and one week after the final session patients will have a separate visit in which their levels of symptoms assessed with measures of mood, anxiety, and avoidance.
223777992|NCT05368597|PROCEDURE|PCI in native vessel or in bypass graft|Native vessel PCI,which choose native coronary artery as the target vessel, while the bypass graft PCI choose graft vessel as the target vessel.
223777993|NCT03524391|BEHAVIORAL|Counselling based on yoga|Counseling sessions were given as one-on-one and group to patients based on yoga philosophy and therapy.
223777994|NCT03524391|DRUG|Chemotherapy|Usual Care group had standard chemotherapy regimens
223777995|NCT00003545|DRUG|nelarabine|
223777996|NCT02496884|DRUG|DS-5565|DS-5565 7.5 mg tablet for oral use
223777997|NCT02496884|DRUG|Placebo|Placebo tablet for oral use to match DS-5565 7.5 mg tablet
223777998|NCT00618020|DEVICE|CiTop(tm) Guidewire|CiTop(tm)6 Guidewire
223777999|NCT01577134|BEHAVIORAL|Social-cognitive resource intervention|Intervention group that receives a behavior change technique intervention to increase volitional strategies and physical activity.
223778000|NCT01577134|BEHAVIORAL|Social-cognitive resource intervention|Active control group that receives a behavior change technique intervention to increase volitional strategies and volunteering.
223778001|NCT01577134|BEHAVIORAL|no intervention|Passive control group that receives no intervention until the 8.5 months follow-up. Subsequently, they receive the information by mail the active groups received within the intervention.
223778002|NCT05434897|DRUG|AK3280 Cream|Active Substance: AK3280, Pharmaceutical Form:Cream, Route of Administration: External use
223778003|NCT05434897|DRUG|Placebo cream|Active Substance: Placebo, Pharmaceutical Form: Cream, Route of Administration: External use
223778004|NCT04692246|OTHER|Plant-based oral rinse|Oral rinse enriched with plant-based essential oils.
223778005|NCT04692246|OTHER|Placebo oral rinse|Oral rinse with the exact characteristics in terms of colour and odour of the plant-based one, but without the essential oils aimed to test in this study
223778006|NCT03980847|DRUG|Alendronate 20 mg|The Alendronate 20 mg combined with nanocrystalline hydroxyapatite as a synthetic bone substitute for socket preservation after tooth extraction
223778007|NCT03980847|PROCEDURE|Nanocrystal hydroxyapatite|Postextraction Sockets Preserved With Nanocrystal hydroxyapatite as a synthetic bone substitute alone as a bone graft
223778008|NCT00097591|DRUG|Prasugrel|Administered orally
223778009|NCT00097591|DRUG|Clopidogrel|Administered orally
223778010|NCT03318575|DEVICE|autoRIC|Automated Remote Ischemic Conditioning
223778011|NCT03318575|DEVICE|autoRIC Sham|Automated Remote Ischemic Conditioning Sham
223778012|NCT02061462|PROCEDURE|EVLP-DCD Group|Events: application of an open lung protective ventilatory strategy (recruitment manoeuvre, low volume-low frequency ventilation-high PEEP) to the DCD donors; procurement of lungs and cold storage on ice; reconditioning/evaluation by EVLP to assess suitability for transplantation; cold storage on ice; transplantation. Endpoints of suitability: oxygenation, respiratory mechanics, pulmonary vascular resistance, chest X-ray, fibrobronchoscopy
223778013|NCT06372730|OTHER|Ventilation/Perfusion Single Photon Emission Computed Tomography (V/Q SPECT/CT)|All patients will undergo a V/Q SPECT/CT scan at inclusion.
223778014|NCT02798848|DEVICE|Tablet computer|iPad
223778015|NCT03722875|DRUG|SHR-1210|SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody.
223778016|NCT03722875|DRUG|apatinib|Apatinib is a selective VEGFR2 inhibitor
223778017|NCT01586442|DRUG|Eplerenone|Eplerenone 25mg once daily titrated to 50 mg once daily for 4 months
223778018|NCT01586442|DRUG|Spironolactone|Spironolactone 12,5mg daily titrated to 25mg once daily for 16 weeks
223693969|NCT06782139|DRUG|Enavogliflozin|Patients who are enrolled in the study will undergo adenosine stress tests assessing coronary flow velocity reserve and body composition analysis on the day of registration. Within 2 weeks, cardiopulmonary exercise tests will be performed with exhalation gas analysis. After completing the baseline cardiopulmonary exercise capacity evaluation, patients will be assigned to either the enavogliflozin or placebo group and monitored for adverse effects within one month. Patients without significant adverse effects will continue the assigned treatment, and at 12 weeks, they will undergo re-evaluation of coronary flow velocity reserve, body composition analysis, and cardiopulmonary exercise capacity. Adverse events will be monitored from the date of enrollment through the final evaluation.
223693970|NCT06782139|DRUG|Placebo|Patients who are enrolled in the study will undergo adenosine stress tests assessing coronary flow velocity reserve and body composition analysis on the day of registration. Within 2 weeks, cardiopulmonary exercise tests will be performed with exhalation gas analysis. After completing the baseline cardiopulmonary exercise capacity evaluation, patients will be assigned to either the enavogliflozin or placebo group and monitored for adverse effects within one month. Patients without significant adverse effects will continue the assigned treatment, and at 12 weeks, they will undergo re-evaluation of coronary flow velocity reserve, body composition analysis, and cardiopulmonary exercise capacity. Adverse events will be monitored from the date of enrollment through the final evaluation.
223693971|NCT07069660|BEHAVIORAL|COMPASS|The data from the baseline assessment will be used to develop an environmental modification intervention plan. Environmental modifications will be installed before discharge if possible. Problem areas addressed are participant specific (tailored), but the process to identify and address the target area is systematic. All participants will receive identical intervention components. The standardized components include assessment, identification of problematic activities (and environmental barriers), identification of solutions for each problem, implementation of solution set selected by the participant, training, and active practice of daily activities in one's own home and community.
223693972|NCT07069660|BEHAVIORAL|Education Program|The control group will experience the same effects of time and attention in the home but no effect on the outcome of interest.
223693973|NCT06900127|BEHAVIORAL|Safe Swaddling|newborns will be wrapped with the safe wrapping method.
223693974|NCT04268615|OTHER|Covert Saccades and Virtual Reality|During this intervention, patients will undergo head impulse testing while wearing virtual reality Headsets. During the head impulse tests the visual information will be modified in order to create a conflict between head rotation and rotation of the visual scene. Recording of head and eye movement will be done during these head impulses in order to verify if visual information modifies compensatory eye movements during head impulses.
223693975|NCT04268615|OTHER|Actives versus passives Head Impulses|Patients will undergo classic passive head rotation as well as active head rotation in order to compare latencies of covert saccades in both conditions.
223693976|NCT04268615|OTHER|Visually guided saccades|Patients as well as healthy control subjects will undergo testing of visually guided saccades in different conditions (step, gap, overlap) in order to compare latencies of covert saccades between both groups.
223693977|NCT05069259|OTHER|Stool sample collection|collection for measuring calprotectin levels
223693978|NCT07068438|DEVICE|Pulse electric field ablation system|Bronchial rheoplasty (BR) is a staged procedure wherein pulsed electric fields are delivered to the right lung in the first treatment visit, and then the left lung is treated approximately 1 month later.
223693979|NCT07068438|DEVICE|Sham Procedure|Staged sham procedure: the catheter is inserted into the right lung, but energy is not delivered; then the same steps are performed in the left lung approximately 1 month later (no energy is delivered to the patient).
223693980|NCT04876729|BEHAVIORAL|Otago Exercise Program|Otago Exercise program implemented including education on fall risk reduction, instruction on strength and balance exercises and walking program. Perform a home safety assessment and provide recommendations to reduce trip hazards. CHRs will engage local housing authority services to complete the modifications (such as grab bar installation). CHRs will complete approximately 10 home visits during 12 months with reassessment at 3, 6, and 12 months.
223693981|NCT06900712|BEHAVIORAL|PATH-SS|"This single-session intervention includes the following components:~* Providing the PATH-SS rationale.~* A review of life events (PATH of life: negative and positive).~* A verbal narrative of the sexual assault (revisiting and processing as is done in imaginal exposure)~* Reminiscence and processing of a major positive life event, and real-life practice to enact what was taught. In positive reminiscence, clients vividly remember the positive event providing details and focus on positive emotions. The therapist will encourage savoring of the experience and encourage facial expression of the positive emotions, so that clients do not dampen, avoid, or minimize the experience. This is particularly relevant with depression.~* Summary of content, integration and consolidation of learning, application of new learning and resilience in real life as next steps."
223693982|NCT07075185|DRUG|KLN-1010|Given at specified dose one time
223693983|NCT06571708|DRUG|Gemcitabine|Gemcitabine 1000 mg/m\^2 IV
223693984|NCT06571708|DRUG|Cisplatin|Cisplatin 70 mg/m\^2 IV or renally-dosed split-dose cisplatin 35 m/m\^2 IV
223693985|NCT06571708|DRUG|Cemiplimab|Cemiplimab 350mg IV
223693986|NCT06571708|DRUG|Fianlimab|Fianlimab 1600mg IV
223693987|NCT03894137|DIETARY_SUPPLEMENT|Grains of Paradise (Aframomum Melegueta)|This is a randomized, double blind, crossover design testing the effect of grains of paradise on resting energy metabolism
223693988|NCT06886152|PROCEDURE|Transcutaneous Spinal Cord Stimulation|A portable transcutaneous spine stimulator (Digitimer ®, USA) will supply biphasic stimulation superficial to the thoracolumbar spine.
223693989|NCT06886152|OTHER|Sham|A portable transcutaneous spine stimulator (Digitimer ®, USA) will be applied superficially with no electrical current.
223693990|NCT07081815|DEVICE|JOCOAT(TM) APN-3003|10 mL of JOCOAT(TM) APN-3003 is applied at the end of surgery
223693991|NCT06665373|BEHAVIORAL|Modified Atkins Diet|The Atkins diet is a low-carb eating plan that focuses on balancing protein, fat, and carbohydrates.
223693992|NCT06665373|BEHAVIORAL|Fitness Program|12 weeks of two weekly supervised exercise sessions combined with an individualized home exercise program based on physical capabilities and available equipment.
223693993|NCT03148275|OTHER|Questionnaire Administration|Ancillary studies
223778019|NCT05928221|DEVICE|Thrombectomy|removal of fresh soft emboli and thrombi from the vessels of the venous system
223693994|NCT03148275|DRUG|Trametinib|Given PO
223693995|NCT07087197|DRUG|SKB107 for injection|177Lu-DOTA-IBA is a Radionuclide conjugated drugs (RDC) targeting bone.
223693996|NCT06928766|DRUG|Eszopiclone 3 mg|Both eszopiclone and lemborexant taken together at bedtime for one night
223693997|NCT06928766|DRUG|Placebo|Placebo sugar pills that looks like the eszopiclone and lemborexant capsules taken at bedtime for one night.
223693998|NCT06928766|DRUG|Lemborexant 10mg|Both eszopiclone and lemborexant taken together at bedtime for one night
223778020|NCT04177524|DEVICE|Background Mode|The LifeSaver app tracks the date, time, and global positioning system (GPS) location of each trip that the participant takes in a moving vehicle, along with a list of apps used during the trip, but does not contain any anti-distracted driving features.
223778021|NCT04177524|DEVICE|Manual Mode|"In addition to the features in the Background Mode, the LifeSaver app locks the participants' phone while they are in a moving vehicle unless they actively press an Emergency Unlock or Passenger Unlock button."
223693999|NCT07078435|PROCEDURE|surgery (any volume) and / or pharmaceuticals treatment initiated or planned or only dynamic observation, in accordance with current clinical guidelines|The surgery is performed on both arms as part of the current / recommended treatment. But during this surgery, an extension of the samples is performed. In both arms, the surgeons take samples of the endometrium, peritoneum and peritoneal lavage. For patients with endometriosis, the lesion is also sampled.
223694000|NCT07078435|BIOLOGICAL|Blood test|Before surgery, the patient will need a blood test at the recommendation of the anaesthetist. This allows us to see the level of oestrogen and progesterone in the blood.
223694001|NCT07078435|BIOLOGICAL|Stool samples|Before the surgery, the patient will take a stool sample.
223694002|NCT07078435|BIOLOGICAL|Stool samples|After 1 year's follow-up, the patient will take a stool sample.
223694003|NCT06234930|DEVICE|Audiovisual stimulation VR system|Delivery of synchronized auditory and visual stimuli at varying frequencies via a VR headset.
223694004|NCT05098938|DRUG|Acyclovir 50mg buccal/topical tablet, BAYM008894/UI1614773|Oral (upper gum area), 50mg, 1 tablet.
223694005|NCT05098938|DRUG|Placebo|Oral (upper gum area), 1 table.
223694006|NCT06223750|OTHER|population-based screening for chronic kidney disease|Randomized controlled trial that uses an integrated health platform for eligibility and outcome assessments
223694007|NCT06902805|DRUG|OnabotulinumtoxinA|intra-articular injection
223694008|NCT06902805|DRUG|Normal saline (placebo)|intra-articular injection
223694009|NCT07090395|DEVICE|EVO Sleep and Snore Device|ProSomnus EVO Sleep and Snore Device mandibular advancement device
223694010|NCT07091539|OTHER|Fruit/vegetable vouchers|The intervention is $80 of fruit/vegetable vouchers (EatSF Veggies4Vouchers) per month x 6 months
223694011|NCT06903091|PROCEDURE|SMS|Usual follow-up
223694012|NCT07132541|DRUG|Pancreatic parenchymal injection of N-butyl-2-cyanoacrylate(Histoacryl®)|"This procedure is integrated into the standard pancreaticoduodenectomy.~Injection of Histoacryl® (n-butyl-2-cyanoacrylate) mixed with Lipiodol® (1:1 ratio) into the pancreatic parenchyma circumferentially (3, 6, 9, and 12 o'clock positions) around the main pancreatic duct (MPD) orifice, extending 5-8 mm deep and 5-10 mm laterally from the future anastomotic line, avoiding the main pancreatic duct and vessels. Total volume injected typically ranges from 0.2 ml to 0.6 ml.~Follow with standard duct-to-mucosa pancreaticojejunostomy:~* Tying down the posterior duct-to-mucosa sutures.~* Placing and tying the anterior duct-to-mucosa sutures.~* Tying down the posterior outer layer sutures.~* Placing the anterior outer layer sutures. Meticulously avoid glue contact with sutures/mucosa~Reconstruction: Complete the hepaticojejunostomy and duodenojejunostomy (or gastrojejunostomy)."
223694013|NCT06419816|OTHER|"Physician-managed WellCheck use"|"Physician-managed WellCheck use"
223694014|NCT06419816|OTHER|"self-managed WellCheck use"|"self-managed WellCheck use"
223694015|NCT07112521|DEVICE|active tDCS|The anodal electrode will be placed over the left DLPFC (F3), and the cathodal electrode will be placed over the right supraorbital area (FP2). The current will be gradually ramped up to 2mA over 30 seconds, held constant at 2mA for 29 minutes, and then gradually ramped down to 0mA over the final 30 seconds.
223694016|NCT07112521|DEVICE|sham tDCS|The anodal electrode will be placed over the left DLPFC (F3), and the cathodal electrode will be placed over the right supraorbital area (FP2). The current will be initially ramped up to 2mA over 30 seconds and immediately ramped back down to 0mA.
223694017|NCT05797246|DRUG|Bevacizumab|10 mg/kg IV every three weeks for 3 cycles and then every 6 weeks for a total treatment course of 11 cycles for approximately 1 year total.
223694018|NCT07115966|BEHAVIORAL|Computerized decision support by best practice alert (BPA)|"The antimicrobial stewardship intervention encourages prescribers by a simple alert to follow guidelines for reviewing antimicrobial prescriptions after a set timeframe for potential de-escalation to targeted therapy or discontinuation of the antibiotics, as recommended by national and international guidelines.~An automated simple BPA will trigger after an antibiotic prescription with therapeutic indication (72 hours) or surgical prophylaxis (24 hours, reminding prescribers to reassess treatment for possible de-escalation, adaption to targeted therapy, or cessation.~If ignored, the prescription remains unchanged, but the alert will continue until addressed. Prescribers must select reasons for not changing the prescription, such as pending microbiology results. The control group corresponds to the inpatient wards not yet receiving the BPA, where antibiotics are managed according to standard-of-care."
223694019|NCT07118904|OTHER|Rapid weight loss through dehydration|Dehydration will be induced by exposing athletes to sauna heat with an average temperature of 70-80°C. The participants will undergo consecutive 15 minute sessions in sauna with 5 minute breaks until 3% weight loss is achieved. No liquids or food will be consumed between sessions.
223694020|NCT07116759|DEVICE|Real-time head stabilization with robotic platform|A robotic platform will use data from motion-detection cameras to position a person's head in real time. This procedure is non-invasive.
223694021|NCT00182702|DRUG|ixabepilone|Given IV
223694022|NCT00182702|OTHER|laboratory biomarker analysis|Correlative studies
223694023|NCT06934460|DEVICE|Composite resin|Direct composite resin restoration after application of an adhesive system
223694024|NCT06934460|DEVICE|lithium disilicate endocrown|Lithium disilicate endocrown in conjunction with Immediate Dentin Sealing
223694025|NCT06933771|OTHER|LAVENDER ESSENCE GROUP|Parents stood on the left side, easily visible to the child. The sole routine method used to reduce pain in the blood collection unit of the hospital in which the study was conducted is the presence of parents during the procedure. In this study, all children in both intervention and control groups were accompanied by their parents. Afterwards, the researcher explained to the children in the intervention group and their parents how to apply the lavender essence and what kind of a plant lavender is, and showed the bottle of essential oil to be used during the procedure. A 5x5 cm sponge with 2 drops of almond oil that contains 1% lavender essence was located on the shoulder of the children to smell for 5 minutes.
223694026|NCT06933771|OTHER|CONTROL GROUP|Parents stood on the left side, easily visible to the child. The sole routine method used to reduce pain in the blood collection unit of the hospital in which the study was conducted is the presence of parents during the procedure. In this study, all children in both intervention and control groups were accompanied by their parents. Routine nursıng care provıed.
223694027|NCT06933615|OTHER|Training prepared with mobile application|The m-BAFY program will be loaded onto the mobile phones of patients in the mobile application group. Each patient will be informed on how to use the mobile program. In addition, a short training will be given on how to use the application. With this application, the symptoms and vital signs recorded by the patients will be monitored and individual feedback will be provided. Information on the management of the disease prepared in line with the guidelines is included.
223694028|NCT06933966|OTHER|observation alone|Patient will not received post-operative chemotherapy. There will be only surveillance until progression.
223694029|NCT06934941|DRUG|NM-101|NM-101 IV versus placebo
223694030|NCT06934941|DRUG|Placebo|Placebo
223694031|NCT06933914|DRUG|MY008211A tablets|Participants will receive MY008211A at a dose of 400 mg orally b.i.d
223694032|NCT06933992|DEVICE|Chocolate PTA Balloon Catheter|The Chocolate PTA balloon catheter is a nitinol-constrained percutaneous transluminal angioplasty balloon designed to minimize vessel trauma during treatment of peripheral arterial lesions. The device is used according to its standard indications and instructions for use in patients with symptomatic peripheral artery disease.
223694033|NCT06933654|PROCEDURE|IOL implantation surgery for aphkic eye|Aphakic eyes underwent secondary intraocular lens (IOL) implantation using one of two techniques. In Group A, an iris-claw IOL (Artisan aphakia IOL, Ophtec BV, The Netherlands) was implanted and fixated to the mid-peripheral iris via enclavation. In Group B, a posterior chamber foldable PMMA IOL was fixated to the iris using transscleral sutures passed through eyelets in the haptics. All procedures were performed under peribulbar anesthesia using standard aseptic technique, and postoperative management included topical antibiotics and corticosteroids.
223694034|NCT01828320|BEHAVIORAL|Cognitive Behavior Therapy for Insomnia, Interpersonal and Social Rhythms Therapy, Chronotherapy|
223694035|NCT01828320|BEHAVIORAL|Psychoeducation|
223694036|NCT07143591|OTHER|Not found|No intervention
223694037|NCT06937892|BEHAVIORAL|Transdiagnostic metacognitive therapy|A single, generic treatment protocol focusing on metacognitions.
223694038|NCT06937892|BEHAVIORAL|Disorder-specific cognitive-behavioral therapy|Disorder-specific treatment protocols focusing on cognitions and/or behaviors.
223694039|NCT06946576|DEVICE|Fetoscopic Endoluminal Tracheal Occlusion (FETO) Procedure|FETO procedure involves insertion of a balloon into the fetal trachea under IV sedation with local anesthesia or combined spinal-epidural anesthesia. Balloon removal will take place up to 7 weeks after insertion.
223694040|NCT06933758|DIAGNOSTIC_TEST|Determine COPD prevalence utilizing spirometry along with CT scans and symptom assessments in the THCI lung cancer screening populatio|Demonstrate utility of LDCT in COPD characterization Determine exacerbation risk and symptom burden in this patient population Determine the severity of COPD identified through this process Describe phenotypic characteristics including imaging analysis of THCI population Determine the suitability and acceptance of patients to participate in COPD clinical trials Determine the incidence of comorbid lung (ILA, bronchiectasis, pulmonary artery enlargement) and non-lung problems (cardiac and aortic calcifications, osteopenia/osteoporosis and for gut abnormalities) identified by LDCT in a patient population at risk for lung cancer and/or COPD Determine the correlation between clinical measurements and imaging biomarkers
223694041|NCT07141849|BEHAVIORAL|Power Resistance Training|Participants will receive a total of twenty-four 45-minutes in-person training sessions, twice per week using three sets of eight repetitions per set. During training participants will be allowed 1-minute rests between sets. Exercises will include six upper-body exercises and five lower-body exercises.
223694042|NCT07141849|BEHAVIORAL|Periodized Resistance Training|Participants will receive three weeks of hypertrophy training to increase muscle size followed by six weeks of strength training, and then three weeks of power training twice per week for a total of twenty-four 45-minutes in-person training sessions. During training participants will be allowed 1-minute rests between sets. Exercises will include six upper-body exercises and five lower-body exercises.
223694043|NCT07125677|DEVICE|I-gel first|After general anesthesia, I-gel is inserted first, the maximum sealing pressure is measured, and then it is removed. Subsequently, I-gel plus is inserted, and the same procedure is repeated.
223694044|NCT07125677|DEVICE|I-gel plus first|After general anesthesia, I-gel plus is inserted first, the maximum sealing pressure is measured, and then it is removed. Subsequently, I-gel is inserted, and the same procedure is repeated.
223694045|NCT02576431|DRUG|BAY2757556 (Larotrectinib, Vitrakvi)|Larotrectinib will be administered orally as capsule or liquid solution at a dose of 100 mg twice daily in continuing 28-days cycles.
223694046|NCT07150000|DIAGNOSTIC_TEST|Ex Vivo Assay|Ex vivo assay with patient's PBMCs. Cytokine quantification (e.g. TNFα, IL-1β). HCI with single-cell analysis (\>100 features/cell). Data preprocessing and normalization to transfer for machine learning.
223694047|NCT07150624|DRUG|Experimental Group|Receiving 930mg of polyene phosphatidylcholine injection one day before the operation,twice a day. And 930mg of polyene phosphatidylcholine injection,twice a day, combined with 100mg of magnesium isoglycyrrhizinate injection once a day，from the 1st to the 5th day after the operation.
223694048|NCT07150624|DRUG|control group|Receiving 100mg of magnesium isoglycyrrhizinate injection once a day，from the 1st to the 5th day after the operation.
223694049|NCT07150182|OTHER|The Integrated Shared Decision-making Program|The Integrated Shared Decision-making Program
223694050|NCT07150637|DIAGNOSTIC_TEST|ICU-AW|The enrolled children receiving mechanical ventilation were grouped based on the occurrence of ICU-acquired weakness (ICU-AW) at the study endpoint.
223694051|NCT07150208|DRUG|Bevacizumab (Bev)|Bevacizumab is a drug that targets vascular endothelial growth factor (VEGF) and inhibits tumor angiogenesis, thereby inhibiting tumor growth and spread. In the treatment of breast cancer, Bevacizumab can be used in combination with chemotherapy to improve treatment outcomes and extend patients' progression-free survival and overall survival.
223694052|NCT07150208|DRUG|Trastuzumab Deruxtecan (T-DXd)|"Trastuzumab deruxtecan (T-DXd) is an antibody-drug conjugate (ADC) composed of an anti-HER2 monoclonal antibody (trastuzumab), a cleavable linker, and a topoisomerase I inhibitor (an exatecan derivative). It targets and binds to HER2-positive tumor cells, internalizes, and releases cytotoxic drugs to induce DNA damage and apoptosis. It also has a bystander effect that can kill neighboring tumor cells with low HER2 expression, enhancing anti-tumor activity. T-DXd has shown significant efficacy in HER2-positive advanced breast cancer, with key clinical trials (such as DESTINY-Breast03) confirming that its progression-free survival (PFS) and overall survival (OS) are superior to traditional second-line treatments, with a median PFS reaching 28.8 months. Additionally, for HER2-low-expressing (IHC 1+ or 2+/ISH-) metastatic breast cancer (in the DESTINY-Breast04 study), T-DXd can extend PFS and OS, becoming the first targeted therapy to alter the survival outcomes of such patients."
223694053|NCT07150169|DEVICE|Active TMS disruption|Active TMS disruption delivered to the personalized target
223778022|NCT04177524|DEVICE|Auto-Detect Mode|"In addition to the features in Manual Mode, the LifeSaver app's Passenger Unlock feature can only be used if the app, via the smartphone's camera, confirms that the participant is not the driver of the vehicle."
223778023|NCT02841423|PROCEDURE|neuropsychological test battery|
223694054|NCT07150169|DEVICE|Sham TMS disruption|Sham TMS disruption delivered to the personalized target
223694055|NCT07150091|DRUG|Belantamab mafodotin|Belantamab mafodotin will be administered.
223694056|NCT07150091|DRUG|Nirogacestat|Nirogacestat will be administered.
223694057|NCT07150091|DRUG|Lenalidomide|Lenalidomide will be administered.
223694058|NCT07150091|DRUG|Dexamethasone|Dexamethasone will be administered.
223694059|NCT07150312|BEHAVIORAL|HIIT|"A 12-week home-based HIIT exercise plan (running). Duration: Each session consists of 10 x 1-minute high-intensity bouts interspersed with 10 x 1-minute recovery periods. Adding the 3-minute warmup and 3-minute cool-down, each session totals approximately 26 minutes. This protocol is followed for 12 weeks.~Intensity: High-intensity bouts are performed at 80-90% of HRmax (RPE 15-18). Recovery periods are at 40-50% of HRmax (RPE 11-13). Warm-up and cool-down are at 50% HRmax (RPE 11-13).~Modality: Running, jogging, or brisk walking, either on a treadmill or outdoors.~Supervision: The first three sessions are supervised in a laboratory setting. Subsequent sessions are unsupervised and performed at home with heart rate monitoring and remote data tracking via Polar Flow for Coach."
223778024|NCT00898911|OTHER|matrix-assisted laser desorption/ionization time of flight mass spectrometry|
223778025|NCT01409694|DRUG|Memantine|Memantine is administered to all participants according to the usual strategy, with upward titration of 5 mg per week during the first three weeks to reduce the risk of side effects. The final dosage is 20 mg per day, with no subsequent modification of dosage or specialty during the trial.
223778026|NCT01409694|DRUG|Vitamin D|Subjects receive Vitamin D supplementation (cholecalciferol 100,000 IU, drinking solution, 2 mL vial) at a rate of 1 drinking vial of 100,000 IU cholecalciferol every month. In brief, the total dose is 600,000 IU over the duration of the study starting with one vial at the time of inclusion, then at week(W) 4, W8, W12, W16 and W20. The dose of vitamin D supplementation will not be adjusted except in case of an adverse event such as hypercalcemia. In this case, vitamin D supplementation is stopped and the participant is released prematurely from the study.
223778027|NCT01409694|DRUG|Vitamin D placebo|Subjects receive Vitamin D placebo (drinking solution, 2mL vial) at a rate of 1 drinking vial every month. In brief, the subjects start with one vial at the time of inclusion, then at week(W)4, W8, W12, W16 and W20. The placebo drinking solution contains all the excipients present in the Vitamin D vial.
223778028|NCT06573788|BEHAVIORAL|Internet + wearble device multimodal prehabilitation|Use the Prehabilitation Learning Platform to learn what to do and follow along with the videos for follow up exercises
223778029|NCT06573788|BEHAVIORAL|traditional multimodal prehabilitation|The researchers used a prehabilitation manual to explain to subjects what they needed to do, and the patients went home and practiced on their own, recording the exercises daily
223778030|NCT06068816|DIETARY_SUPPLEMENT|Nutrient-dense drink|a nutrient-dense drink developed by FrieslandCampina in line with the European Society for Clinical Nutrition and Metabolism guidelines for the dietary management of older malnourished patients
223778031|NCT03561779|DRUG|YYD302 2ml|YYD302 2ml
223778032|NCT03561779|DRUG|Active comparator: Synovian Inj.|Active comparator: Synovian Inj.
223778033|NCT00055328|BEHAVIORAL|Problem-Solving Treatment for Primary Care|
223778034|NCT02406144|DRUG|MLN9708|
223778035|NCT02406144|DRUG|Lenalidomide|
223778036|NCT02406144|DRUG|Dexamethasone|
223778037|NCT04134897|DRUG|Capecitabine|2000 mg/m2, bid, per os, days 1-14, 4 cycles
223778038|NCT04134897|DRUG|Oxaliplatin|130 mg/m2 iv day 1, 4 cycles
223778039|NCT04134897|DRUG|Capecitabine|825 mg/m2, bid, per os, only on days of radiation (Monday through Friday)
223778040|NCT04134897|RADIATION|Radiotherapy|Pelvic radiotherapy dose: 44 Gy on regional nodes, 50 Gy on primary tumor
223778041|NCT04134897|PROCEDURE|Rectal cancer surgery|Laparoscopic or open total mesorectal excision
223778042|NCT04134897|RADIATION|Radiotherapy|Pelvic radiotherapy dose: 25 Gy in 5 Gy fractions
223778043|NCT04221516|DRUG|Camrelizumab|Camrelizumab 200mg every 21 days (3 weeks) for up to 18 cycles, from 4 to 12 weeks after the completion of radiotherapy.
223778044|NCT05219201|DEVICE|partial-body cryotherapy chamber session|"The cryotherapy procedure consisted of a 2-3 min stay in the cryotherapy chamber:~* at -30°C for sham cryotherapy session~* at -120°C for cryotherapy intervention session. For Inpatients, cryotherapy session will be performed daily, late in the afternoon, excluding saturdays and sundays, during 3 weeks. (15 sessions) For outpatient, cryotherapy session will occured late in the afternoon each day care (15 sessions)."
223778045|NCT05953194|BEHAVIORAL|Exposure to counter-marketing messages|Counter-marketing messages about sugary drinks that incorporate principles of effective counter-marketing campaigns, including describing industry manipulation of consumers, appealing to emotions (especially anger), describing health consequences, and criticizing the industry for demographic targeting. Messages include text adapted from prior counter-marketing campaigns. Participants will view a total of 4 messages developed for this arm.
223778046|NCT05953194|BEHAVIORAL|Exposure to traditional health messages|Traditional health messages focused on the health consequences of sugar-sweetened beverage consumption, using text adapted from prior sugary drink campaigns. Participants will view a total of 4 messages developed for this arm.
223778047|NCT05953194|BEHAVIORAL|Exposure to control (neutral) messages|Control messages approximately matched to the intervention messages on length, but discussing a neutral topic unrelated to sugary drinks (safe driving). Participants will view a total of 4 messages developed for this arm.
223778048|NCT03322306|GENETIC|Genechip screening kit|10 ml blood for genetic screening by specific genetic screening kit
223778049|NCT02585739|GENETIC|blood sample|
223778050|NCT06129292|BEHAVIORAL|EFT group|"Procedure 1: Preliminary tests will be carried out and then the 1st EFT session will be held.~2nd Procedure: After 10 days, the first final tests will be performed and then the second EFT session will be held."
223778051|NCT06560268|DRUG|Sevoflurane; In our study, the effects of sevoflurane in different FGFs administered in children undergoing strabismus surgery on EA and anesthetic agent consumption will be investigated.|Low-flow anaesthesia is generally adminstered as nitrogen wash-out, a period of higher flow rate in combination with a high vaporizer setting for initial saturation, and subsequent reduction of fresh gas flow and adjustment of the vaporizer to maintain the desired end-tidal anesthetic agent concentration (Etaa).In the initial wash-in phase, the vaporizer setting is adjusted to 6% for desflurane and 2.5-3% for sevoflurane, with FGF=4 L/min, until the Etaa concentration is 1-1.3 MAC. In another method, the vaporizer setting is adjusted to 12-18% for desflurane and 6-8% for sevoflurane, with FGA=1 L/min. Reducing the FGF during the wash-in period prevents unnecessary depth of anesthesia and reduces the consumption of inhalational anesthetics. In LFA using minimal FGF (250-500 mL/min), if the vaporizer is turned off 10-15 min before the end of the operation and the FGF is not changed, the inhaled anesthetic agent concentration gradually and slowly decreases to zero.
223778052|NCT06573736|DIAGNOSTIC_TEST|Stockholm3|Stockholm3 combines protein markers tPSA, fPSA, KLK2, PSP94 and GDF15, genetic markers and clinical data to estimate risk for clinically significant prostate cancer.
223694060|NCT07150312|BEHAVIORAL|MICT|"A 12-week home-based MICT exercise plan (running). Duration: Each session consists of 20 minutes of continuous exercise. Including the 3-minute warm-up and 3-minute cool-down, each session totals 26 minutes. This protocol is followed for 12 weeks.~Intensity: Exercise is performed at 64-76% of HRmax (RPE 12-14). Warm-up and cool-down are at 50% HRmax (RPE 11-13).~Modality: Running, jogging, or brisk walking, either on a treadmill or outdoors.~Supervision: The first three sessions are supervised in a laboratory setting. Subsequent sessions are unsupervised and performed at home with heart rate monitoring and remote data tracking via Polar Flow for Coach."
223694061|NCT07150026|DRUG|Vorinostat (SAHA)|oral suspension
223694062|NCT07150026|DRUG|Placebo|placebo
223694063|NCT07150416|DRUG|Recombinant Human Ad-p53 Injection|A replication-deficient recombinant human type 5 adenovirus vector encoding the human wild-type p53 tumor suppressor gene. For this study, it will be administered via nebulized inhalation.
223694064|NCT04180085|DRUG|Belatacept Injection|9 injections of belatacept at 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months 11 months and 12 months post graft
223694065|NCT07149896|DEVICE|Collagen Scaffold (Colla-Plug)|The collagen cartilage scaffold(COLTRIX® CartiRegen) used in this study consist of an injection needle, a syringe, and a collagen gel prefilled in a syringe. The collagen gel contains phosphate buffer and type Ⅰ collagen which the telopeptides are removed.. After the product is implanted in the body, it forms a degradable three-dimensional scaffold to provide an environment for cells to adhere, proliferate, migrate, differentiate and secrete, thereby promoting cartilage repair. At present, it has been commercially applied to clinical repair of knee cartilage defect.
223694066|NCT07149896|PROCEDURE|microfracture|Microfracture to repair cartilage defect is a minimally invasive procedure that is usually done arthroscopically. The doctor first cleans the damaged cartilage area, and then uses a special microfracture cone to drill vertically in the subchondral bone plate, forming multiple tiny holes, allowing mesenchymal stem cells and growth factors in the bone marrow to overflow, forming a blood clot rich in repair components, and finally stimulating fibrocartilage regeneration to fill the defect area.
223694067|NCT07149987|PROCEDURE|All implant placements were performed exclusively in the maxillary region (upper jaw) to ensure a controlled comparison within the same anatomical area|All implant placements were performed exclusively in the maxillary region (upper jaw) to ensure a controlled comparison within the same anatomical area. The implants used in this study were C-Tech® implants (C-Tech Implant, Italy) with the following dimensions: Diameter: 3.8 mm Length: 11 mm . Cone-Beam Computed Tomography (CBCT): To assess bone quality, quantity, and anatomical structures . Digital Intraoral Scans Heron Scanner (USA) to obtain detailed gingival contours, occlusion, and existing teeth. The scan data was exported as an STL file for digital planning. Easy Check Implant Stability Measuring System is used for implant stability measurement, the tapping rod was gently placed in slight contact with the healing abutment, avoiding any axial or lateral pressure, and aligned within 0°-30° relative to the abutment's occlusal surface. If the angle exceeded 30°, the device issued an alert and prevented measurement, ensuring consistent alignment
223694068|NCT07149883|OTHER|Complete blood count|Complete blood count
223694069|NCT07149883|DEVICE|ECHO|device that used to evaluate the cardiac function
223694070|NCT07149805|PROCEDURE|open surgery or interventional treatment|open surgery or interventional treatment
223694071|NCT07149454|DRUG|Recombinant Human Anti-Tetanus Toxin Monoclonal Antibody Injection|intramuscular injection
223694072|NCT07149454|DRUG|Human Tetanus Immunoglobulin|intramuscular injection
223694073|NCT07149454|DRUG|Placebo|intramuscular injection
223694074|NCT07150728|BEHAVIORAL|dignity therapy|"Dignity therapists use the Dignity Psychotherapy Question Protocol to guide patients through life's most important issues, providing them with the opportunity to participate in and discuss the things they would like their families to remember them for. During the process, dignity therapists use audio recording to fully record, transcribe, and edit the interview material, creating a valuable record that the patient wishes to preserve. The edited document is then returned to the patient, who then gives it to their family members."
223694075|NCT07150728|BEHAVIORAL|Hospice palliative care|Participants regularly receive hospice care
223694076|NCT07150377|DRUG|First-line Cohort|Iparomlimab and Tuvonralimab: 7.5 mg/kg, IV, Q3W Lenvatinib: 12 mg (for body weight ≥60 kg) or 8 mg (for body weight ≤60 kg), po, qd
223694077|NCT07150377|DRUG|Second-line Cohort|Iparomlimab and Tuvonralimab: 7.5 mg/kg, IV, Q3W Lenvatinib: 12 mg (for body weight ≥60 kg) or 8 mg (for body weight ≤60 kg), po, qd
223694078|NCT07150689|PROCEDURE|Rigid bronchoscopy|Participants will undergo rigid bronchoscopy under general anesthesia using an age-appropriate rigid bronchoscope. The airway will be systematically inspected. Any identified foreign body will be removed using appropriate retrieval devices (optical forceps, retrieval basket, suction). Post-removal, the airway will be re-examined to confirm clearance and detect trauma.
223694079|NCT07150689|PROCEDURE|Flexible scope|Participants will undergo flexible fiberoptic bronchoscopy under sedation or general anesthesia. The bronchoscope will be inserted transorally or transnasally. The airway will be inspected, and foreign body retrieval attempted using retrieval baskets, forceps, or cryoprobe
223694080|NCT07150689|PROCEDURE|Combined Flexible-Rigid Bronchoscopy|Initial flexible bronchoscopy will be performed to locate the foreign body and inspect distal airways, followed by rigid bronchoscopy for definitive removal.
223694081|NCT07150689|PROCEDURE|Imaging-Guided Bronchoscopy|Participants will undergo pre-procedure high-resolution CT or virtual bronchoscopy. Based on imaging, either rigid or flexible bronchoscopy will be performed, targeting the suspected location to reduce procedure time.
223694082|NCT07149740|DEVICE|OCT|A10900 is an optical coherence tomography device
223694083|NCT06275620|BIOLOGICAL|AGTC-501 (high dose and standard corticosteroid regimen)|Adeno-associated virus vector expressing a human RPGR gene
223778053|NCT06573918|DIAGNOSTIC_TEST|EMG-based assessment of paratonia|EMG-assessed paratonia was analyzed and compared to assess motor response efficiency in three groups of healthy young adults with different levels of physical activity: professional athletes engaged in closed and open skills sports, amateurs, and sedentary individuals. To analyze EMG-assessed paratonia, two surface electrodes were attached to the biceps and triceps brachii muscles during passive flexion-extension movements of the elbow while the participant remained in a state of maximum relaxation. Any EMG activity detected during these movements was attributed to an inability to relax, thereby reflecting their degree of paratonia.
223778054|NCT06573398|COMBINATION_PRODUCT|SBRT with Sequential AG regimen +Tislelizumab+Thymalfasin|Stereotactic body radiation therapy (SBRT): 30 \~ 40 Gy/5f, Week 1, Day 1 \~ Day 5, 6-8 Gy/time, once a day; 3 weeks as a cycle, for 4 cycles Tislelizumab: 200 mg, i.v., single infusion, 21 days as a cycle for 4 cycles, on Day 1 of each treatment cycle; Thymalfasin: 4.8 mg, subcutaneous injection, twice a week, on Day 1 and Day 4 of each week during Weeks 1 \~ 13; Albumin-bound paclitaxel: 125 mg/m2, i.v., on Day 1 and Day 8 of each treatment cycle; Gemcitabine: 1000mg/m2, i.v., on Day 1 and Day 8 of each treatment cycle; After 4 cycles of preoperative neoadjuvant therapy, radical surgery will be evaluated by the MDT team within 2-4 weeks after completion of chemotherapy + immunotherapy.
223778055|NCT04635046|PROCEDURE|Transfer or extirpation of the peroneus longs tendon|Tendon transfer or extirpation of peroneus longus or brevis tendon, ligamental reconstruction +/- calcaneal osteotomy
223778056|NCT02972697|RADIATION|11C-acetate ligand|
223778057|NCT02972697|RADIATION|FDG ligand|
223778058|NCT02543541|BEHAVIORAL|Structured palliative care|Supportive care for the patient and caregiver will be provided by the outpatient palliative care team which includes clinicians with specialized palliative care training, social workers, spiritual care specialists and mental health clinical nurse specialist.
223778059|NCT02543541|BEHAVIORAL|Standard supportive care|Supportive care for the patient and caregiver will be provided by the treating oncologist.
223778060|NCT01911533|PROCEDURE|extracorporeal removal of CO2 (ECCO2-R)|To promote a better gas-exchange, the patient with ARDS will be mechanically ventilated. This can be aggressive and harmful for the lungs. With the use of an extra-corporeal CO2-remover, CO2 can be removed so that the mechanical ventilation setting will be less aggressive and will decrease lesions in the lung. The veno-venous extracorporeal CO2-remover pumps blood from a vein via a catheter through an oxygenator (gas exchanger that adds oxygen to the blood and extracts carbon dioxide from the blood) and back into a vein.
223778061|NCT01911533|PROCEDURE|No extracorporeal CO2-removal|Patients are their own control group.
223778062|NCT00734526|DRUG|Temozolomide|"Groups 1 \& 2: 75 mg/m\^2 Once Daily by Mouth During Radiation; 4 Weeks after Completion of Radiation, 150-200 mg/m\^2 Once Daily by Mouth Days 1-5 of 1st 28-Day Cycle, then 75 mg/m\^2 Once Daily by Mouth Days 1-5 for Subsequent 28-Day Cycles.~Groups 3 \& 4: 75 mg/m\^2 Once Daily by Mouth During Radiation; 4 Weeks after Completion of Radiation, 75-100 mg/m\^2 Once Daily by Mouth Days 1-21 every 28-Day Cycle."
223778063|NCT00734526|RADIATION|Radiation|Total of 60 Gy delivered over 30 Days (approximately 6 weeks).
223778064|NCT00734526|DRUG|Sorafenib|"Group 1: 4 Weeks after Completion of Radiation, 400 mg Twice Daily by Mouth.~Group 2: 200 mg Twice Daily by Mouth during Radiation; 4 Weeks after Completion of Radiation, 400 mg Twice Daily by Mouth.~Group 3: 200 mg Twice Daily by Mouth during Radiation; 4 Weeks after Completion of Radiation, 200 mg Twice Daily by Mouth.~Group 4: 400 mg Twice Daily by Mouth during Radiation; 4 Weeks after Completion of Radiation, 400 mg Twice Daily by Mouth."
223778065|NCT02640794|DRUG|Clopidogrel|Clopidogrel therapy will start within 24 hrs before the TAVI procedure in cases where a transfemoral approach is used and within 24 hrs after the TAVI procedure in cases where a transapical approach is used. The initial dose of clopidogrel will be of 300 mg followed by 75 mg/die. The duration of clopidogrel treatment will be of 3 months.
223778066|NCT02640794|DRUG|Aspirin|Aspirin/acetylsalicylic acid (80-325 mg/d). Aspirin/acetylsalicylic acid therapy will start at least 24 hrs before the TAVI procedure and continued for at least 6 months.
223778067|NCT04962971|DIETARY_SUPPLEMENT|X|exocyan
223778068|NCT04962971|DIETARY_SUPPLEMENT|Y|exocyan
223778069|NCT04962971|DIETARY_SUPPLEMENT|Z|exocyan
223778070|NCT06204393|OTHER|Thyroid metabolic index|"The following indicators were collected from these patients: hyperthyroidism symptoms, signs, hyperthyroidism complications, psychological evaluation results, other complications，blood routine, liver and kidney function, thyroid function (FT3, FT4, TSH), thyroid-related antibodies, glucose and lipid metabolism (FBG, HbA1c, TC, TG, HDL-C, LDL-C), thyroid ultrasound and hyperthyroidism medication.~Psychological evaluations (using the 7-item Generalized Anxiety Disorder Questionnaire, GAD-7, and the Patient Health Questionnaire 9, PHQ-9) and interventions."
223778071|NCT06103981|OTHER|Acute Liver Injury|To evaluate the impact of acute liver injury in patients with pneumonia on hospital stay and outcome.
223778072|NCT00188097|BEHAVIORAL|Diagnosis of variceal bleeding and dits control in cirrhosis|
223778073|NCT00009737|DRUG|5-Fluorouracil|425mg/m2 iv daily from day 1 to day 5 every 28 days.
223778074|NCT00009737|DRUG|Leucovorin|20mg/m2 iv daily from day 1 to day 5 every 28 days.
223778075|NCT00009737|DRUG|Capecitabine [Xeloda]|1250mg/m2 po bid on days 1-14 every 21 days.
223778076|NCT01097226|OTHER|Apple extract delivering 70 mg epicatechin|Delivered as a flavoured water based beverage
223778077|NCT01097226|OTHER|Apple extract delivering 140 mg epicatechin|Delivered as a flavoured water based beverage
223778078|NCT01097226|OTHER|Apple granules delivering 70 mg epicatechin|Delivered as a puree
223778079|NCT01097226|OTHER|Water delivering no epicatechin|Delivered as flavoured water
223778080|NCT04840095|DRUG|Ketones|Sports supplement that is administered mid-scan.
223778081|NCT04840095|DRUG|Glucose|Supplement is administered mid-scan.
223778082|NCT01807585|DEVICE|VenaSeal SCS|Non-tumescent, non-thermal, non-sclerosant procedure that uses a proprietary medical adhesive delivered endovenously to close the vein.
223778083|NCT01807585|DEVICE|ClosureFast Radiofrequency Ablation (RFA)|Radiofrequency thermal ablation of the GSV using the Covidien ClosureFast system.
223778084|NCT01807585|DEVICE|Roll-in (VenaSeal SCS)|Non-tumescent, non-thermal, non-sclerosant procedure that uses a proprietary medical adhesive delivered endovenously to close the vein.
223778085|NCT04459611|BIOLOGICAL|sintilimab|200 mg by IV infusion every 3 weeks (Q3W), given on cycle day 1.
223778086|NCT04459611|DRUG|pemetrexed|500 mg/m\^2 by IV infusion Q3W, given on cycle day 1.
223778087|NCT04459611|DRUG|Carboplatin|AUC 5 mg/mL/min by IV infusion Q3W, given on cycle day 1.
223778088|NCT04459611|DRUG|albumin-bound paclitaxel|260 mg/m\^2 by IV infusion Q3W, given on cycle day 1.
223778089|NCT00204191|DRUG|tacrolimus|
223778090|NCT03021759|BEHAVIORAL|Active choice|Statin options are framed to physicians as an active choice to prescribe or not prescribe a statin
223778091|NCT03021759|BEHAVIORAL|Social comparison feedback|Statin prescribing rates are communicated to physicians and along with how their performance compares to their peers
223778092|NCT04031339|PROCEDURE|Standard treatment|e.g., surgery, radioiodine therapy, systemic treatments (multikinase inhibitors), surveillance
223778093|NCT03109834|DIETARY_SUPPLEMENT|Meal replacement (MR)|"MR-WL group followed an energy-restricted diet with a balanced variety of nutrient-dense food of approximately 1200 kcal/d and was advised to replace two meals, i.e. breakfast and dinner, every day with two MR shakes, soups or bars and to prepare their own lunch during 3-month weight loss phase (phase 1).~During 3-month weight stabilization phase (phase 2) MR-S group (MR group during weight stabilization phase) were encouraged to consume a self-directed well-balanced variety of nutrient-dense foods without meal intervention. MR counted to food choice option. The MR-S group was instructed to continue the implemented nutrition advice of weight loss phase.~Duration: 6 months (phase 1 and phase 2: baseline I - 6.month)"
223778094|NCT03109834|OTHER|Control (C)|"During 3-month weight loss phase (phase 1) C-WL group followed an energy-restricted diet with a balanced variety of nutrient-dense food of approximately 1200 kcal/d without MR for weight control.~During 3-month weight stabilization (phase 2) phase C-S group (C group during weight stabilization phase) were encouraged to consume a self-directed well-balanced variety of nutrient-dense foods without meal intervention. MR counted to food choice option. The C-S group was instructed to continue the implemented nutrition advice of weight loss phase.~Duration: 6 months (phase 1 and phase 2: baseline I - 6.month)"
223778095|NCT03109834|DIETARY_SUPPLEMENT|Verum|"Verum: Specific micronutrient composition with omega-3 fatty acids (capsules)~Verum group followed an energy-restricted diet with a balanced variety of nutrient-dense food of approximately 1500 kcal/d and was advised to consume 3 verum-capsules twice a day (with breakfast and dinner) with 200 ml water during 6-month weight loss maintenance phase (phase 3).~Duration: 6 months (6.month / baseline II - 12.month)"
223778096|NCT03109834|OTHER|Placebo|"Placebo group followed an energy-restricted diet with a balanced variety of nutrient-dense food of approximately 1500 kcal/d and was advised to consume 3 placebo-capsules twice a day (with breakfast and dinner) with 200 ml water during 6-month weight loss maintenance phase.~Placebo contains no micronutrients and omega-3 fatty acids.~Duration: 6 months (6.month / baseline II - 12.month)"
223778097|NCT02815111|DRUG|Ketamine|Receive an analgesic regimen that involves Ketamine infusions
223778098|NCT02815111|DRUG|Lidocaine|Receive an analgesic regimen that involves Lidocaine infusions
223778099|NCT02815111|DRUG|Acetaminophen|May be administered Acetaminophen rectally, by mouth, or intravenously in patients not suitable for either of the other methods of administration
223778100|NCT02815111|DRUG|Neurontin|May be given Neurontin by mouth as an approved medication for pain control
223778101|NCT05417711|DEVICE|Transcutaneous Vagus Nerve Stimulation Paired with Tailor-Made Notched Music Therapy|The pulse frequency of vagus nerve stimulation is 25 Hz, the pulse width is 200 US, and the intensity is 1-10 mA. Tailor-made notched music is produced by filtering a frequency band of 1/2 octave width centered at the individual tinnitus frequency. When two sides of tinnitus frequencies are different, each side of music are filtered respectively, according to the different tinnitus frequency. When only have unilateral tinnitus or bilateral tinnitus in the same central frequency, both sides of music are filtered with the same tinnitus frequency. The tVNS and TMNM begin at the same time during treatment.
223778102|NCT05417711|DEVICE|Tailor-made Notched Music Training|Tailor-made notched music is produced by filtering a frequency band of 1/2 octave width centered at the individual tinnitus frequency. When two sides of tinnitus frequencies are different, each side of music are filtered respectively, according to the different tinnitus frequency. When only have unilateral tinnitus or bilateral tinnitus in the same central frequency, both sides of music are filtered with the same tinnitus frequency. At the beginning of TMNMT, 10 seconds sham vagus nerve stimulation is output, whose parameters are as same as experimental group.
223778103|NCT02504645|DRUG|IPP-201101|
223778104|NCT02504645|DRUG|Placebo|
223778105|NCT02504645|OTHER|Standard of Care|
223778106|NCT00710333|DRUG|Avotermin|10 patients undergoing surgical revision of bilateral keloids will be dosed with 500ng Juvista/100µL per cm of wound margin to one ear lobe and placebo to the other and followed up for three months after dosing to assess the local and systemic tolerability.
223778107|NCT00710333|DRUG|placebo|placebo
223778108|NCT01394861|DEVICE|ESD using Master Slave Robotic System|Endoscopic submucosal dissection of early gastric cancer or broad sessile polyp using Master Slave Robotic System
223778109|NCT00991601|PROCEDURE|FNAC (fine needle aspiration cytology)|UL guided biopsy
223778110|NCT02445079|OTHER|This is an observational study only|Observational study only
223778111|NCT05153018|OTHER|Blood collection|a 4-mL blood sample collected in a dry tube
223778112|NCT04049994|DRUG|Uro-Vaxom|Uro-Vaxom® (OM Pharma SA, Meyrin, Switzerland) is a lyophilized lysate of 18 E. coli strains.
223778113|NCT04049994|DRUG|Placebo oral tablet|Placebo oral tablet
223778114|NCT03211936|PROCEDURE|PEEP TITRATED|After titrated peep levels, we choice this level of peep for de group (peep titrated)
223778115|NCT03211936|DEVICE|Use ultrasound|We make a lung ultrasound after we setup a different level of PEEP
223778116|NCT03211936|DEVICE|Impedance tomography|We use the impedance tomography to titrate peep levels, and acquire dates of collapse, hyperdistension and compliance.
223778117|NCT03211936|OTHER|Best PEEP for less collapse|After titrated PEEP levels we setup the best PEEP the according of tomography impedance
223778118|NCT03211936|OTHER|PEEP 4|We set the peep level after titrated peep = 4 cmH20.
223778119|NCT05029648|OTHER|Cohort|Cohort
223778120|NCT01033747|DRUG|Deferasirox|10 mg/kg or 30 mg/kg orally daily
223778121|NCT01033747|DRUG|Deferasirox|5 mg/kg or 30 mg/kg orally daily
223778122|NCT02805192|DEVICE|Size Measurement by a Smart phone App|
223778123|NCT02306915|DRUG|lipegfilgrastim|lipegfilgrastim 30 μg/kg, 60 μg/kg, 100 μg/kg
223778124|NCT02956629|DRUG|Uprifosbuvir|Participants take 3 tablets each containing 150 mg uprifosbuvir q.d. by mouth.
223778125|NCT02956629|DRUG|Ruzasvir|Participants take 3 capsules each containing 60 mg RZR q.d. by mouth.
223778126|NCT02956629|DRUG|Ribavirin|RBV 200 mg capsules will be taken according to package instructions for a maximum of 16 weeks for any GT that meets virologic futility rules on uprifosbuvir + RZR alone.
223778127|NCT00221936|BEHAVIORAL|Self-administration or nurse administered medication|
223778128|NCT01754558|PROCEDURE|Ajust system|The use of Ajust system for stress incontinence
223778129|NCT01754558|PROCEDURE|TVT/TVT-O|sling surgery
223778130|NCT02881281|OTHER|educational program for Development of problem-solving skills|
223778131|NCT02881281|OTHER|no education program|no education program
223778132|NCT01410838|OTHER|Broth|200 mL of sodium chloride containing broth, consumed three times per day
223778133|NCT01410838|OTHER|Broth|200 mL of MSG containing broth consumed three times per day
223778134|NCT00701389|DRUG|telcagepant potassium|Single oral dose of 2 x 300 mg capsules.
223778135|NCT00701389|DRUG|sumatriptan|single oral dose of 100 mg sumatriptan
223778136|NCT00701389|DRUG|sumatriptan placebo|single oral dose
223778137|NCT00701389|DRUG|telcagepant potassium placebo|single oral dose of 2 MK-0974 placebo capsules
223778138|NCT04564352|DIETARY_SUPPLEMENT|Adansonia digitata|Juice of AD fruit
223778139|NCT03324061|DRUG|Fulvestrant for Injectable Suspension|Test drug is administered as a single 5mL intramuscular injection in the right or left dorsogluteal muscle area
223778140|NCT03324061|DRUG|Faslodex (Reference)|Reference drug is administered as two 5mL intramuscular injections, one in each of the right and left dorsogluteal muscle areas
223778141|NCT00165724|DRUG|Donepezil Hydrochloride|
223778142|NCT04808609|DEVICE|Lumme mobile phone application|Lumme mobile phone app provides smoking cessation support and tracks smoking behaviors
223778143|NCT04808609|BEHAVIORAL|Standard of Care|Smoking cessation counseling and nicotine replacement therapy
223778144|NCT02202135|DRUG|Ceftaroline fosamil|IV ceftaroline 600mg every 8 hours
223778145|NCT02202135|DRUG|Vancomycin|IV vancomycin 15mg/kg every 12 hours
223778146|NCT02202135|DRUG|Aztreonam|IV aztreonam 1 g every 8 hours
223778147|NCT01554046|DRUG|Methylphenidate- Ritalin IR (Immediate Release)|"Duration of treatment- 4 weeks. Dosage- up to 3 times/day.~* Ages 6-12, up to 25Kg - 35mg maximum per day.~* Ages 6-12, above 25Kg - 50mg maximum per day.~* Ages 12-65, above 25Kg - 80mg maximum per day."
223778148|NCT03649126|BEHAVIORAL|Implementation tools|Implementation tools developed by experts in order to increase the use of SSR in pathology
223778149|NCT06238505|OTHER|Virtual|application will be made with virtual reality device
223778150|NCT06238505|OTHER|biodex|application will be made with biodex device
223694084|NCT06275620|BIOLOGICAL|AGTC-501 (low dose and standard corticosteroid regimen)|Adeno-associated virus vector expressing a human RPGR gene
223694085|NCT06275620|BIOLOGICAL|AGTC-501 (high dose and modified corticosteroid regimen)|Adeno-associated virus vector expressing a human RPGR gene
223694086|NCT03424473|DRUG|Tucatinib|
223694087|NCT02286557|DRUG|Methelphenidate|All participants will undergo 4 weeks of treatment with Methelphenidate and 4 weeks of placebo
223694088|NCT02286557|DRUG|Placebo|
223694089|NCT05165225|DRUG|Pyrotinib + epirubicin and cyclophosphamide followed by docetaxel treatment|Drug: Pyrotinib pyrotinib 320mg orally daily Drug: Epirubicin epirubicin 90mg/m\^2 d1 iv Q3W for 4 cycles Drug: Cyclophosphamide cyclophosphamide 600mg/m\^2 d1 iv Q3W for 4 cycles Drug: Docetaxel docetaxel 100mg/m\^2 d1 iv Q3W for 4 cycles
223694090|NCT06103370|BEHAVIORAL|Peer-educator-based network|The intervention is a social network-based method of dispersing HIV knowledge, HIV self-testing (HIVST) kits, and naloxone in social networks of people who inject drugs (PWID). It targets index participants (peers) to receive training on HIVST, peer education, and linkage to syringe service programs (SSPs) for HIV services.
223694091|NCT01632046|DRUG|lactate and bicarbonate buffered dialysis solutions|Either PD-solution will be applied. Number of cycles and glucose concentration will be varied according to clinical needs. Sleep Safe system will be used and connected to Sleep Safe Cyclers in patient on CCPD.
223694092|NCT00585390|DIETARY_SUPPLEMENT|Omega-3 Fatty Acids|"* Essential omega-3 fatty acid replacement therapy with Eicosapentaenoic acid at 3.2 grams~* Docosahexaenoic acid fish oil concentrate at 1.6 grams"
223694093|NCT00585390|OTHER|Olive oil placebo|Olive oil capsules, 8 capsules per day
223694094|NCT00585390|DIETARY_SUPPLEMENT|EPA fish oil concentrate; DHA fish oil concentrate|3.2 grams for EPA 1.6 grams for DHA
223694095|NCT00585390|DRUG|Placebo|Olive oil capsule
223694096|NCT01501331|DEVICE|CRTD or ICD (Energen)|RRT measurement by cardiac resynchronization therapy devices and implantable cardioverter defibrillators
223694097|NCT05251311|BEHAVIORAL|Social Risk Screening Tool|"Investigators will use an adapted version of the evidence-based WE CARE screening tool, which assesses need in the 5 domains most frequently requested by our patient population: housing, transportation, child care, food security, and household heat and electricity. This tool was selected as it is evidence-based, takes fewer than 5 minutes to complete, is written at a 3rd grade reading level, and allows for differentiation between social risk and caregiver desire for assistance, as well as areas of emergency need."
223694098|NCT05251311|OTHER|Electronic Resource Map|All participants will receive access to an electronic, geographically searchable resource map hosted on Aunt Bertha
223694099|NCT05251311|BEHAVIORAL|Resource Menu|Participants randomized to this experimental arm will receive a social resource menu tool, which assess desire for social resources.
223694100|NCT02886689|DRUG|TNF-alpha antagonist and other biotherapy|
223694101|NCT06332248|DIETARY_SUPPLEMENT|Magnesium|The dietary supplement magnesium (375 mg) was given daily for up to 3 months (oral intake).
223694102|NCT06332248|DIETARY_SUPPLEMENT|Placebo|Placebo tablet, oral intake once a day for up to three months.
223694103|NCT00664469|DRUG|ezetimibe|ezetimibe 10 mg/day over a 6-week course of treatment.
223694104|NCT00664469|DRUG|Comparator: Simvastatin 20, 40 and 80 mg|Simvastatin 20, 40 and 80 mg; actual statin regimen for 6 weeks followed by another 6 weeks if at goal or statin dose can be doubled.
223694105|NCT00664469|DRUG|Comparator: Atorvastatin|Atorvastatin 20, 40 \& 80 mg; actual statin regimen for 6 weeks followed by another 6 weeks if at goal or statin dose can be doubled.
223694106|NCT00664469|DRUG|Comparator: Rosuvastatin|Rosuvastatin 10, 20 \& 40 mg; actual statin regimen for 6 weeks followed by another 6 weeks if at goal or statin dose can be doubled.
223694107|NCT01436916|DRUG|oral cholecalciferol + life style counselling|oral cholecalciferol 600000 units loading then 60000 units fortnightly for 6months
223694108|NCT01436916|DRUG|placebo + life style counselling|Will provide placebo 10 sachets loading and then single sachet fortnightly for 6 months
223694109|NCT04925271|DEVICE|X-Tack|The mucosal or submucosal defect is closed with X-Tack.
223694110|NCT04925271|DEVICE|Overstitch|The mucosal or submucosal defect is closed with Overstitch.
223778151|NCT01993719|DRUG|Aldesleukin|720,000 IU/kg intravenous (IV) every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 4 days (maximum 12 doses).
223778152|NCT01993719|DRUG|Fludarabine|25 mg/m\^2/day intravenous piggy-back (IVPB) daily for 5 days
223778153|NCT01993719|DRUG|Fludarabine|30 mg/kg/day intravenous piggy-back (IVPB) daily for 3 days.
223778154|NCT01993719|DRUG|Cyclophosphamide|60 mg/kg/day X 2 days intravenous (IV)
223778155|NCT01993719|DRUG|Cyclophosphamide|Days -5 to -3 (low-dose arm):30 mg/kg IV over 60 minutes for 2 days
223778156|NCT01993719|DRUG|Cyclophosphamide|Days -5 to -3 (low-dose arm): 300 mg/m\^2 IV over 60 minutes.
223778157|NCT01993719|BIOLOGICAL|Young TIL|Day 0: Cells will be infused intravenously (IV)
223778158|NCT01993719|DRUG|Pembrolizumab|2 mg/kg intravenous (IV) on Days -2, 21 (+/- 2 days), 42 (+/- 2 days), and 63 (+/- 2 days).
223778159|NCT02256111|DRUG|Enzalutamide|
223778160|NCT02256111|DRUG|Androgen deprivation therapy|
223778161|NCT02256111|BEHAVIORAL|Supervised exercise training|
223778162|NCT00600964|DRUG|GX15-070MS|A 60-minute or 3-hour IV infusion every 2-3 weeks.
223778163|NCT00600964|DRUG|GX15-070MS|GX15-070MS at various doses and schedules
223778164|NCT02591394|BEHAVIORAL|STEP Clinic|Patients will visit with STEP clinic staff (including a stroke nurse practitioner or stroke doctor) to receive personalized goals, stroke education (including diet and exercise), instructions to self-monitor using blood pressure cuff, and prescription medications Patient will be scheduled for additional clinic follow-up or be contacted for telephone follow-up for management of your blood pressure. Questionnaires will be administered to determine medication adherence and persistence (following instructions for prescribed medication), disability, depression, cognition, self-efficacy, and sleep apnea. The care plan determined by the STEP clinic will be shared with the patient's primary care provider.
223778165|NCT02591394|BEHAVIORAL|Usual Care|"Patients will complete questionnaires related to medical history and health behaviors prior to initial visit.~After being seen by the stroke neurologist, patients may be scheduled to return to the stroke clinic according the doctor's recommendations.~Recommendations for blood pressure and risk factor monitoring will be sent to primary care providers."
223778166|NCT03663075|BEHAVIORAL|Group information (GI)|The group education consists of four information sessions discussing myths and myths around menopause, physiology, local estrogen deficiency symptoms, women's cardiovascular health, stress-related ill health, mental health, relationships, sexuality, lust and possible treatment options. In addition, conversations about insight into obstacles and resources, coping strategies and behavioral changes will be included.
223778167|NCT03663075|BEHAVIORAL|Structured person-centered support (PCS)|The individually structured person-centered support comprises of five meetings consisting of dialogue on symptoms of stress-related ill health, physiology and coping strategies.
223778168|NCT02148094|DRUG|Truvada|The demonstration project will use a prospective cohort design, enrolling individuals and following them up at multiple intervals over the course of 16 months. Study participants will be asked to take one tablet of Truvada daily, as HIV Pre-Exposure Prophylaxis, over this period. They will be asked to attend 7 regular visits at the project sites over the course of the project. In between visits, they will receive peer educator home visits every other day, as part of regular DMSC (Kolkata) and Ashodaya (Mysore/Mandya) outreach prevention activities. We plan to enroll 2000 female sex workers equally split between the two sites.
223778169|NCT06175494|BIOLOGICAL|Recombinant COVID-19 (XBB) Trimer Protein Vaccine (Sf9 Cell)|boost with Recombinant COVID-19 (XBB) Trimer Protein Vaccine (Sf9 Cell)
223778170|NCT06175494|BIOLOGICAL|Recombinant COVID-19 Variant Vaccine (Sf9 Cell)|boost with Recombinant COVID-19 Variant Vaccine (Sf9 Cell)
223778171|NCT06175494|BIOLOGICAL|Placebo|boost with saline
223778172|NCT05331742|DRUG|Vaccine|patients who have received vaccine against coronavirus disease infection
223778173|NCT05296616|BEHAVIORAL|Mindfulness Based Stress Reduction Intervention|Mindfulness Based Stress Reduction intervention is a manualized course that includes meditation, relaxing movement, and breathing. A certified MBSR instructor will teach the courses in a group-based format for 90 minute sessions, once per week for eight weeks.
223778174|NCT04177693|DIETARY_SUPPLEMENT|Epigallocatechin gallate (EGCG)|800 mg (4 capsules) of EGCG (green tea extract), taken orally on a daily basis for up to 2 months
223778175|NCT04177693|DRUG|Clomiphene Citrate|100 mg for 5 days
223778176|NCT04177693|DRUG|Letrozole|5 mg for 5 days
223778177|NCT04840745|DRUG|CKD-841 A-1 3.75mg|Single injection, subcutaneous injection
223778178|NCT04840745|DRUG|CKD-841 A-1 1.88mg|Single injection, subcutaneous injection
223778179|NCT04840745|DRUG|CKD-841 D 2.92mg|Single injection, subcutaneous injection
223778180|NCT04840745|DRUG|Leuplin Inj. 3.75 mg|Single injection, subcutaneous injection
223778181|NCT02436382|OTHER|change in temperature|increase in ambient room temperature
223778182|NCT05826821|DRUG|Pirfenidone|Intervention drug
223778183|NCT01931839|DRUG|Lumacaftor Plus Ivacaftor Combination|Fixed dose combination tablet, oral use
223778184|NCT01931839|DRUG|Ivacaftor|Film-coated tablet, oral use
223778185|NCT00970086|DRUG|Bupivacain/levobupivacaine|"Caudal block: Identification of the epidural space with a loss of resistance technique. Administration of Bupivacain 1ml/kg 0.125%.~Transversus abdominal plane block: Identification of the anatomical structures by the ultrasound technique, administration of 0.4ml/kg levobupivacaine 0.25%."
223778186|NCT02259530|BEHAVIORAL|Integrated Psychotherapeutic Intervention|Evidence-based standard tools for the treatment of PTSD and comorbid khat dependence: Community Reinforcement Approach, Relapse Prevention, Narrative Exposure Therapy
223778187|NCT04382326|BIOLOGICAL|20-valent pneumococcal conjugate vaccine|20-valent pneumococcal conjugate vaccine
223778188|NCT04382326|BIOLOGICAL|13-valent pneumococcal conjugate vaccine|13-valent pneumococcal conjugate vaccine
223778189|NCT01070875|DRUG|Variation of heparin dose|Study subjects will be randomized to receive unfractionated heparin 5000 U subcutaneous two times a day.
223778190|NCT01070875|DRUG|Variation of heparin dose|Study subjects will be randomized to receive heparin 5000 U subcutaneous three times a day.
223778191|NCT03923127|OTHER|Elan and HealthDot|Patients with elective surgery will wear two devices (HealthDot and Elan) after surgery in hospital and after discharge at home for up to 2 weeks (HealthDot) or 3 weeks (Elan).
223778192|NCT01679535|BEHAVIORAL|nutrition and hygiene education|Monthly education sessions about child feeding and hygiene for mothers of young children, conducted by local Kenyan community health workers
223778193|NCT01326520|DIETARY_SUPPLEMENT|milk phospholipid|The patients will consume daily 250 mL of a dairy product, which is enriched with 3 g of milk phospholipids.
223778194|NCT01326520|DIETARY_SUPPLEMENT|diary product|The patients will consume daily 250 mL of a common dairy product.
223778195|NCT02919852|PROCEDURE|laparoscopic retrovesical colpopectinopexia|Laparoscopic correction of pelvic organ prolapse using a mesh in retrovesical space with pectineal ligament fixation.
223778196|NCT01771276|DEVICE|g-Cath Suture Anchor Delivery Catheter|Evaluate changes in emptying, hormones, satiety and weight loss with use of the g-Cath Suture Anchor Delivery Catheter in maximizing g-Cath Suture Anchor placement to as high as 25 anchors.
223778197|NCT01569334|BIOLOGICAL|blood samples|
223778198|NCT00277017|DRUG|5-Flourouracil, Interferon-a, IL-2 and Thalidomide|"Patients will receive oral dosages of Thalidomide at 200mg/day to start, with dosage gradually increasing up to a max of 1200mg/day. This will be taken in combination with:5-fluorouracil, given by continuous IV infusion over 24 hours (Day 1) every week for 4 weeks.~Interferon-α, given subcutaneously on Day 1, 3 and 5 of every week for 4 weeks. Interleukin-2, given by continuous IV infusion Days 2-5, every week for 4 weeks.~Treatment will be followed by 2 weeks of rest then repeated."
223778199|NCT01316627|BEHAVIORAL|Crooked Mirror Externalization Therapy|After subjects complete the pre-treatment assessments, the study therapist will meet with participants to design their treatment program. Treatment will be conducted every day for 15 days, Monday through Friday, for 90-minute sessions. In addition, as a part of therapy, subjects will complete homework assignments daily. Intensive CBT for BDD is done in the form of Exposure and Response Prevention (ERP) with either the mirror retraining method or the crooked mirror externalization therapy. This involves prolonged and repeated exposures to images of the perceived defects, and prevention of ritualistic behavior (e.g., camouflaging with cosmetics, skin-picking, etc.).
223778200|NCT01316627|BEHAVIORAL|Mirror Retraining Method|After subjects complete the pre-treatment assessments, the study therapist will meet with participants to design their treatment program. Treatment will be conducted every day for 15 days, Monday through Friday, for 90-minute sessions. In addition, as a part of therapy, subjects will complete homework assignments daily. Intensive CBT for BDD is done in the form of Exposure and Response Prevention (ERP) with either the mirror retraining method or the crooked mirror externalization therapy. This involves prolonged and repeated exposures to images of the perceived defects, and prevention of ritualistic behavior (e.g., camouflaging with cosmetics, skin-picking, etc.).
223778201|NCT04978246|BEHAVIORAL|Neuropsychometric Test|Participants' global cognitive skills were measured by the Montreal Cognitive Assessment Test (MoCA), the Clock Drawing Test and memory functions, the Öktem Verbal Memory Processes Test (Ö-SBST), the attention functions by the Digit Span Forward and Digit Span Backwards Test, the executive functions by Categorical Fluency, Phonemic Fluency, the Stroop Test, Trail Making Test A and B, visuospatial skills were evaluated with the Rey-Osterrieth Complex Figure Test (ROCF), and behavioral symptoms were evaluated with the Neuropsychiatric Inventory (NPI).
223778202|NCT00690547|OTHER|muscle activation|activation of the muscle quadriceps femoris
223778203|NCT01538875|DRUG|Hydralazine|Patients with an hypertensive crisis during pregnancy will receive 5mg IV every 15 minutes until high blood pressure is controlled (Maximum number of doses: 3).
223778204|NCT01538875|DRUG|Labetalol|Patients with an hypertensive crisis during pregnancy will receive 20 mg of Labetalol IV. After 15 minutes if the crisis continue, 40 mg IV. After 15 minutes if the crisis continue, 80 mg IV. Then, if the crisis continue, 80 mg IV every 15 minutes (maximum dose: 300 mg IV in total).
223778205|NCT00847574|BEHAVIORAL|Moderate-fat|35% of calories from fat
223778206|NCT00847574|BEHAVIORAL|Lower-fat|20% of calories from fat
223778207|NCT05109910|PROCEDURE|Pelvic lymph node dissection|Bilateral extended pelvic lymph node dissection
223778208|NCT03571061|PROCEDURE|whole colon water immersion and sigmoid water immersion|we chose water immersion method instead of the triaditional method of carbon dioxide (CO2) insufflation.
223778209|NCT01762761|DRUG|eltrombopag|TPO-R agonist
223778210|NCT01762761|DRUG|placebo|placebo
223778211|NCT03017508|DRUG|BHV-0223|35mg of sublingual riluzole before performing an anxiety provoking speech task. Participants will then be clinically assessed every hour for 3 hours.
223778212|NCT03017508|DRUG|Placebo|a sublingual tablet identical to the active drug will be given before performing an anxiety provoking speech task. Participants will then be clinically assessed every hour for three hours.
223778213|NCT05319314|DRUG|GCC19CART|Single infusion of Chimeric Antigen Receptor (CAR) transduced autologous T cells administered intravenously (i.v.)
223778214|NCT04704414|DEVICE|Exophthalmos measurement|Exophthalmos measurement with iPhone 11 vs Artec Space Spider 3D Scanner vs Hertel Exophthalmometer.
223778215|NCT01793857|OTHER|Data collection|Paper questionnaire
223778216|NCT06425393|DIAGNOSTIC_TEST|Urea beath test (UBT)|H. pylori infection will be tested using a 13C-urea breath test Kit for all enrolled family members, following the manufacturer's instructions. The sensitivity and specificity of the assay are both over 95%, according to the manufacturer's introduction.
223778217|NCT01557946|DRUG|citalopram|citalopram 20-40 mg daily
223778218|NCT03296189|DRUG|Levobupivacaine|intraluminal injection post procedure for pain relief: alkalinised high concentration 10 mls
223778219|NCT03296189|DRUG|Dexamethasone Sodium Phosphate|intraluminal injection post procedure for pain relief: alkalinised high concentration 10 mls levobupivicaine and 2mls dexamethasone
223778220|NCT03296189|DRUG|Placebos|10 mls normal saline
223778221|NCT04652193|PROCEDURE|Recovery profile from general anesthesia|It includes the phases during recovery from general anesthesia: Time to spontaneous ventilation, Laryngeal Mask Airway (LMA) removal time, open eyes, and Post-Anesthesia Care Unit (PACU) discharge.
223778222|NCT04591834|OTHER|Observational|An observational study in subjects with the severe form of MPS II.
223778223|NCT06533124|DEVICE|The ultrasonic cardiac output monitor 1A system (USCOM Ltd., Sydney, Australia) is a non-invasive Doppler stroke volume (SV) technique derived from echocardiography.|In the USCOM + ultrafiltration group, cardiac output was monitored using a non-invasive ultrasonic cardiac output monitor, which employed transaortic or transpulmonary Doppler flow tracing and estimated the valve area using a patient's height to estimate their cardiac output. The monitored parameters include, SV index (SVI), SV variation (SVV), cardiac output (CO), cardiac index (CI), inotropy (INO), systemic vascular resistance index (SVRI), systemic vascular resistance (SVR), flow time corrected (FTC) and velocity time integral (VTI) .
223778224|NCT01422759|DRUG|Spironolactone|50-100 mg PO BID (X 12 weeks)
223778225|NCT02639884|DEVICE|SedLine EEG|
223778226|NCT02639884|DEVICE|RRa monitoring|
223778227|NCT02352493|DRUG|ALN-CC5|Single or multiple doses of ALN-CC5 by subcutaneous (sc) injection
223778228|NCT02352493|DRUG|Sterile Normal Saline (0.9% NaCl)|calculated volume to match active comparator
223778229|NCT03188640|PROCEDURE|Laparoscopic gastric-bypass surgery|Female participants with BMI \>30, between age 18-50, will be operated with laparoscopic gastric bypass surgery by an experienced gastric bypass surgeon.
223778230|NCT06017284|DRUG|Thalidomide|Thalidomide 100 mg/day, once a day, orally intake at night.
223778231|NCT06017284|DRUG|Nab paclitaxel|nab-paclitaxel (120 mg per square meter of body-surface area) on days 1, 8, and 15 every 4 weeks.
223778232|NCT06017284|DRUG|Gemcitabine|gemcitabine (1000 mg per square meter) on days 1, 8, and 15 every 4 weeks.
223778233|NCT06017284|DRUG|Placebo|Placebo, 100 mg/day, once a day, orally intake at night.
223778234|NCT06061458|DIAGNOSTIC_TEST|speech auditory brainstem response|A diagnostic objective test to evaluate the speech process in hearing impaired children
223778235|NCT02652728|DRUG|Enalapril Orodispersible Minitablet|Weight-dependent dose titration and long-term treatment scheme with enalapril ODMTs of 0.25 mg and 1 mg strength
223778236|NCT05571943|DRUG|Difamilast|Difamilast Ointment 1%
223778237|NCT00145431|DRUG|torcetrapib/atorvastatin|
223778238|NCT00145431|DRUG|atorvastatin|
223778239|NCT00145431|DRUG|fenofibrate|
223778240|NCT01465334|DRUG|Ofatumumab|
223778241|NCT01465334|DRUG|High-Dose Methylprednisolone|
223778242|NCT01465334|DRUG|Alemtuzumab|
223778243|NCT03395795|DEVICE|NAVA|"The study has 3 phases:~1. Phase 1:~   The patient is connected to the SERVOi® ventilator in classic VNI mode, which is parameterized according to the patient's needs and then maintained for 30min for measurements.~2. Phase 2:~   Switch to NAVA mode (1h).~  * Definition of NAVA parameters: The positive expiratory pressure will not be modified. The NAVA level (the proportionality factor that converts the EADi (microV) to the pressure level in cmH2O was first adjusted according to the actual assisted pressure in the patient in the normal VNI mode.~  * NAVA period: The ventilatory pressure, as well as the EADI is recorded continuously for 30min after a NAVA adaptation period of about 30min.~3. Phase 3:~The patient returns to classic VNI mode with Phase 1 ventilatory settings for a 30 minute recording."
223778244|NCT00572572|DRUG|Aprepitant|Subjects will be randomized to receive aprepitant 125mg PO day 3 then 80mg on days 4-7 on either cycle 1 or cycle 2.
223778245|NCT00572572|DRUG|Placebo|Subjects will be randomized to receive placebo on days 3-7 on either cycle 1 or cycle 2.
223778246|NCT06071000|BEHAVIORAL|Neuro-developmental stimulation (Neuro-vývojová stimulace).|Neuro-developmental stimulation is exercise based intervention program that is focused on repeating reflex movements and thus inhibiting reflexive response.
223778247|NCT01831089|DRUG|PM01183 + paclitaxel +/- bevacizumab|"PM01183: 1 mg and 4 mg vials. Powder for concentrate for solution for infusion~paclitaxel: 6 mg/ml concentrate for solution for infusion~bevacizumab: 25 mg/ml concentrate for solution for infusion~Once a recommended dose is defined for the PM01183 and weekly paclitaxel combination, the feasibility of adding bevacizumab to this combination will be explored in a prospectively selected cohort of patients"
223778248|NCT02723617|OTHER|MED 0.5|Participants will be fed a Mediterranean diet providing 0.5 oz. per day of lean beef.
223778249|NCT02723617|OTHER|MED 2.5|Participants will be fed a Mediterranean diet providing 2.5 oz. per day of lean beef.
223778250|NCT02723617|OTHER|MED 5.5|Participants will be fed a Mediterranean diet providing 5.5 oz. per day of lean beef.
223778251|NCT02723617|OTHER|AAD 2.5|Participants will be fed an average American diet providing 2.5 oz. per day of lean beef.
223778252|NCT02579291|OTHER|Dry needling|Once the most painful spot is located within a palpable spastic taut band, the overlying skin is cleaned with alcohol. The needle will be inserted, penetrating the skin about 15-20mm, until the first local twitch response is obtained. Once the first local twitch response is obtained, the needle will be moved up and down (4 to 5 mm. vertical motions with no rotation) in the muscle at approximately 1Hz for 25-30 seconds.
223694111|NCT00426231|BEHAVIORAL|Navigation by a health worker|Help provided by health worker to navigate medication access programs
223694112|NCT00426231|BEHAVIORAL|Information control|Information about medication access programs provided to the participant and their healthcare provider
223694113|NCT00000862|DRUG|Zidovudine|
223694114|NCT01795638|DRUG|Sodium chloride|
223694115|NCT01795638|DRUG|Placebo|sterile water, 0.4 ml/kg every 6 hours on days of life 7-35.
223694116|NCT01799031|OTHER|internet-based intervention|Receive access to the WISE web-based educational intervention
223694117|NCT01799031|PROCEDURE|management of therapy complications|Receive standard of care
223694118|NCT01799031|OTHER|educational intervention|Receive access to the WISE web-based educational intervention
223694119|NCT01799031|OTHER|questionnaire administration|Ancillary studies
223694120|NCT01799031|PROCEDURE|quality-of-life assessment|Ancillary studies
223694121|NCT06008158|RADIATION|Accelerated Partial Breast Irradiation|Undergo APBI
223694122|NCT01655680|DRUG|ABT-126|ABT-126 Middle Dose
223694123|NCT01655680|DRUG|ABT-126|ABT-126 Low Dose
223694124|NCT01655680|DRUG|ABT-126|ABT-126 High Dose
223694125|NCT01655680|DRUG|Placebo|Placebo
223694126|NCT00032942|DRUG|Lofexidine|
223694127|NCT02831374|DRUG|Local anesthesia|The surgical extraction under local anesthesia (2% Lignocaine and 1:100000 Adrenaline) procedure was the same in all patients.
223694128|NCT02831374|PROCEDURE|surgical extraction of impacted third molar|After achieving Local anesthesia using 2% lignocaine hydrochloride with 1:100,000 epinephrine, standard Terrence Ward's incision was placed to raise a full thickness mucoperiosteal flap. Disto-buccal bone was carefully exposed and bone surrounding the buccal aspect of impacted tooth was performed using surgical bur under copious irrigation with 0.9% saline. Tooth was elevated using Coupland elevator and if required situations tooth was sectioned with surgical bur to facilitate its removal. The socket was checked for any tooth or bony debris. The bony margins smoothened using a file and irrigated with 0.9% saline.
223694129|NCT02831374|BIOLOGICAL|Preparation of PRP gel|Before surgery, 10 milliliter of venous blood was collected from the anticubital fossa of the patients forearm and stored into sterile tubes containing anticoagulant (0.5 milliliter citrate phosphate dextrose) from each patient in the experimental group using routine venipuncture procedure. The whole blood is then centrifuged at 1,200 rotations per minute for ten minutes. The supernatant layer obtained was platelet poor plasma and buffy coat was collected in a new sterile tube and centrifuged again at 1,000 rotations per minute for 10 min. The upper half of the supernatant is removed and the lower half is mixed carefully to get platelet rich plasma. Five drops of mixture of 10 % CaCl2 and 1000 Units bovine thrombin to 2 milliliter Platelet rich plasma to obtain the gel form.
223694130|NCT02831374|PROCEDURE|Placing platelet Rich plasma and suturing|Subsequently, platelet rich plasma gel was placed into the extraction sockets of patients in the group A and wound closure was done using simple interrupted 3.0 black silk sutures.
223694131|NCT02831374|PROCEDURE|Suturing|Wound closure was done using simple interrupted 3.0 black silk sutures.
223694132|NCT02831374|DRUG|Postoperative medication|Patients were advised regular post extraction and prescribed 500 milligram of paracetemol postoperatively (1 tablet every 6 hours for 2 days).
223694133|NCT03054753|BEHAVIORAL|Abduction brace wearing time analysis|To evaluate the patient´s abduction brace wearing time a sensor = Orthotimer® (Rollerwerk, 72336 Balingen, Germany, www.orthotimer.com) is implanted in the abduction brace. The sensor measures the body temperature of the patient. Through that the wearing time can be evaluated.
223694134|NCT05432141|BIOLOGICAL|sIPV vaccine /DTaP vaccine|All subjects received 3 doses of sIPV vaccines and 3 doses of DTaP vaccines. Subjects recommended intramuscular injection. The best site for intramuscular injection is the anterolateral middle thigh for infants and the deltoid muscle for children.
223694135|NCT05432141|BIOLOGICAL|sIPV vaccine /Hepatitis A inactivated vaccine /MMR vaccine|All subjects will receive 1 dose of sIPV and 2 doses of hepatitis A inactivated vaccine/or 1 dose of attenuated hepatitis A vaccine and 1 dose of MMR vaccine.Subjects recommended intramuscular injection. The best site for intramuscular injection is the anterolateral middle thigh for infants and the deltoid muscle for children.
223694136|NCT01892215|PROCEDURE|Cephalad-caudad expansion|Blunt expansion of the uterine incision by the physician separating the fingers in a cephalad-caudad direction.
223694137|NCT01892215|PROCEDURE|Transversal expansion|Blunt expansion of the uterine incision by the physician separating the fingers in a transversal direction.
223694138|NCT06154538|DRUG|Cadonilimab|PD-1/CTLA-4 bi-specific antibody
223694139|NCT06154538|DRUG|FOLFOX regimen|FOLFOX chemotherapy
223694140|NCT04138069|OTHER|PLB+Aerobic Bicycling|"Combination of Breathing control and Purse lips breathing technique for 5 minutes at the start of session.~Purse lips breathing with aerobic bicycling for 8 minutes"
223694141|NCT04138069|OTHER|Aerobic Bicycling|"Breathing control for 5 minutes at the start of session.~Aerobic bicycling for 8 minutes"
223694142|NCT00894023|DRUG|Intracoronary bolus wtih ClearWay™RX catheter|Intracoronary bolus with Clearway catheter
223694143|NCT00894023|DRUG|IV abciximab|IV abciximab + infusion
223694144|NCT00011973|DRUG|fenretinide|
223694145|NCT05504473|DEVICE|NEURO-BLINK Device|The NEURO-BLINK is a class IIa medical device that intends to restore the blink function in patients with facial palsy through the application of transcutaneous electrical stimulation.
223694146|NCT00820352|DRUG|bosentan|4 weeks of oral bosentan 62,5 mg b.i.d., followed by 8 weeks of 125 mg b.i.d.
223694147|NCT00820352|DRUG|placebo|placebo twice a day for 12 weeks
223694148|NCT00293215|DRUG|111-Indium-CMD-193|111-In-CMD-193 (3-7 mCi) was administered as an IV infusion over 60 (± 5) minutes.
223778253|NCT02579291|OTHER|Bobath|Patients will receive different neuromodulatory interventions based on the Bobath concept with the aim to decrease spasticity on the lower extremity
223778254|NCT03494257|DRUG|Brinzolamide-Brimonidine fixed combination|Simbrinza 0.2%-1% Ophthalmic Suspension
223778255|NCT00725166|OTHER|Skeletal muscle aging|"W1 - Blood test~* Maximal voluntary contraction of quadriceps~* Hydrostatic weighing~W2 - Maximal metabolic test using a cycloergometer~W3 - Muscular biopsy"
223778256|NCT05413538|BEHAVIORAL|Mindfulness training|The intervention recordings will teach the basic concepts of mindfulness through simple guided meditations with content supported by science. Each recording has the same format that included (1) a daily theme, (2) a meditation exercise echoing the theme, (3) a suggested exercise for practice, and (4) an invitation for participants to give a short response to their meditation experience at the end of the recording.
223778257|NCT01058200|DEVICE|iCup|new vacuum extractor: sterile disposable plastic cup
223778258|NCT01058200|DEVICE|reference cup|reference cup of the obstetrical ward: metallic cup
223778259|NCT00422539|DRUG|70% trichloroacetic acid|
223778260|NCT00664144|DRUG|Rasburicase (SR29142)|
223778261|NCT04954365|DRUG|Rescue Post-Operative Nausea and Vomiting (PONV) treatment according to the standard of care (SOC)|Rescue Post-Operative Nausea and Vomiting (PONV) treatment
223778262|NCT04954365|DRUG|Amisulpride|Rescue Post-Operative Nausea and Vomiting (PONV) treatment with Amisulpride
223778263|NCT04344821|DIETARY_SUPPLEMENT|Curves Calcium|"Dietary Supplement: Curves Calcium~Curves Essential Bio-Available Calcium (providing 800 mg/d of calcium \[as calcium citrate malate and calcium citrate\], 400 IU of Vitamin D, 300 mg/d of magnesium, 4 mg/d of zinc, 2 mg/d of copper, 2 mg/d of manganese, 198 mg/d of potassium, 100 mg/d of trace mineral complex, and 2 mg/d of boron)"
223778264|NCT04344821|DIETARY_SUPPLEMENT|Placebo|Dextrose Placebo
223778265|NCT03522662|DRUG|GSK1070806|Single 10mg/kg infusion on Day 0
223778266|NCT02185352|DRUG|BEEP regimen|Bevacizumab 15mg/kg IVF on D1, Etoposide 70 mg/m2 IVF QD, D2-4, Cisplatin 70 mg/m2 IVF on D2, repeat every 3 weeks, for 3 cycles
223778267|NCT06266221|DRUG|Prednisone 20 Mg|Oral corticosteriods
223778268|NCT06266221|DRUG|Oral Placebo|Oral placebo
223778269|NCT06266221|DRUG|Methylprednisolone 120 Mg|IV corticosteriods
223778270|NCT06266221|DRUG|IV Placebo|IV placebo
223778271|NCT04499157|DRUG|MEMOPTIC|Patients will receive their usual treatment of glaucoma adding 1 tablet of MEMOPTIC per day during 2 years of following
223778272|NCT04499157|DRUG|usual treatment of glaucoma|Patients will receive only their usual treatment of glaucoma.
223778273|NCT00652457|DRUG|Memantine|10 mg BID x 3 months
223778274|NCT05410574|BEHAVIORAL|Family-based Behavioral Weight Loss Treatment|The treatment includes: 1) the Traffic Light Eating Plan; 2) the Traffic Light Activity Program, 3) a variety of behavioral change strategies e.g., stimulus control, self-monitoring, planning, goal setting and 4) facilitation of support in the family and peer environments to optimize the durability and generalizability of health habits across multiple social and environmental contexts
223778275|NCT01547572|PROCEDURE|The study group will get a video and leaflet on enhanced recovery|The study group will get a video and leaflet
223778276|NCT01547572|PROCEDURE|The control group will receive a leaflet only|The control group will receive a leaflet only
223778277|NCT01748435|DRUG|Qutenza|Single treatment with Qutenza
223778278|NCT01952912|PROCEDURE|PkEP|
223778279|NCT01952912|PROCEDURE|OP|
223778280|NCT03401970|BEHAVIORAL|Acellular carbohydrate diet|Participants will be asked to consume 2,000 - 2,500 kcals, thereof 45 energy percent (E%) carbohydrate (up to 5 E% added sugar), 30 E% fat (10-12 E% saturated fatty acids and 7-10 E% polyunsaturated fatty acids) and 17 E% protein. They will use an original online/smartphone application that provides choices of meals/food combinations/recipes corresponding to their prescribed macronutrient profile and dietary pattern. Participants are asked to complete 3-day dietary records every 14 days throughout the study, and to report any deviations from the planned interventions.
223778281|NCT03401970|BEHAVIORAL|Cellular carbohydrate diet|Participants will be asked to consume 2,000 - 2,500 kcals, thereof 45 energy percent (E%) carbohydrate (up to 1 E% added sugar), 38 E% fat (10-12 E% saturated fatty acids and 7-10 E% polyunsaturated fatty acids) and 17 E% protein. They will use an original online/smartphone application that provides choices of meals/food combinations/recipes corresponding to their prescribed macronutrient profile and dietary pattern. Participants are asked to complete 3-day dietary records every 14 days throughout the study, and to report any deviations from the planned interventions.
223778282|NCT03401970|BEHAVIORAL|Low-carbohydrate high-fat diet|Participants will be asked to consume 2,000 - 2,500 kcals, thereof 10 energy percent (E%) carbohydrate (up to 1 E% added sugar), 73 E% fat (30 E% saturated fatty acids and 7-10 E% polyunsaturated fatty acids) and 17 E% protein. They will use an original online/smartphone application that provides choices of meals/food combinations/recipes corresponding to their prescribed macronutrient profile and dietary pattern. Participants are asked to complete 3-day dietary records every 14 days throughout the study, and to report any deviations from the planned interventions.
223778283|NCT05954897|DRUG|Lenvatinib, Tislelizumab Combined with RALOX Regimen HAIC|RALOX Regimen of Hepatic Arterial Infusion Chemotherapy (HAIC) Combine Lenvatinib and Tislelizumab
223778284|NCT01597687|PROCEDURE|Blood collection|1 blood sample will be collected from each subject.
223778285|NCT01597687|OTHER|Data collection|Quality of Life and HE questionnaires.
223778286|NCT01197040|DRUG|Prednisone|1 mg/kg/day for 4 weeks. Then, the dose will be progressively tapered if the remission will be achieved. For patients who exhibit incomplete remission at this time, high dose steroid will be continued for 4 weeks again before the tapering.
223778287|NCT01197040|DRUG|acid mycophenolic (Myfortic)|patients will receive prednisone 0.5 mg/kg/day combined with mycophenolic acid (MyforticR) 1440 mg/day. The management of steroid therapy will be identical in both groups, while MyforticR will be continued for six months
223778288|NCT03891212|BEHAVIORAL|Placed in prone position for at least 16 consecutive hours a day.|Patients assigned to the prone group had to be turned within the first hour following randomization. They were placed in prone position for at least 16 consecutive hours. Patients assigned to the control group had to be turned within the first hour following randomization. They were placed in supine position for at least 16 consecutive hours.
223778289|NCT05515055|OTHER|Blood test|1 blood sample extra to standard of care is taken
223778290|NCT05779267|DRUG|NRX-101|D-cycloserine/lurasidone fixed dose combination
223778291|NCT05786677|OTHER|Physiotherapy protocol|"the physiotherapy protocol which will include: 4. Exercise in the form of: d. Breathing exercise e. Aerobic exercise (walking on treadmill with a speed of 3 miles per hour and 0% inclination) f. Bridging exercise 5. Manual techniques in the form of:~1. Suboccipital release~2. Diaphragm release~3. Clavi-pectoral myofascial release 6. Home Routine~c. Hot tub bath for 30 minutes d. Breathing exercise"
223778292|NCT05786677|DRUG|Selective serotonin reuptake inhibitors (SSRI)|Selective serotonin reuptake inhibitors (SSRIs)
223778293|NCT01329601|BEHAVIORAL|StaCog, stage specific cognitive Intervention|StaCog intervention to improve cognitive performance and activities of daily living in AD and MCI
223778294|NCT01329601|BEHAVIORAL|booklet based training|Home based training of episodic memory using paper-pencil exercizes
223778295|NCT02897544|BEHAVIORAL|Individualized Manualized Health Education Intervention|
223778296|NCT00620308|DRUG|CD-NP|One of two dosage levels (20 ng/kg/min and another level to be finalized) as a continuous intravenous infusion for four hours
223778297|NCT00620308|DRUG|Placebo|Dextrose 5% in water (the vehicle)
223778298|NCT02114892|DRUG|Resveratrol|Resveratrol capsules of 500 mg three times per day before meals with a total dosis of 1500 mg per day.
223778299|NCT02114892|DRUG|Placebo|Calcined magnesia capsules, 500 mg, three times per day before meals with a total dose per day of 1500 mg
223778300|NCT01392352|DRUG|Pazopanib|2 x 400mg pazopanib tablets taken once daily for 12 weeks
223778301|NCT00418392|PROCEDURE|Simple aspiration with minocycline pleurodesis|Intrapleural instillation of 300mg minocycline within 5 min after simple aspiration
223778302|NCT00418392|PROCEDURE|simple aspiration|Simple aspiration for primary spontaneous pneumothorax by pigtail catheter
223694149|NCT00293215|DRUG|CMD-193|CMD-193 was administered as an IV infusion over 60 (± 5) minutes.
223778303|NCT06387563|PROCEDURE|Abdominal activation using pressure biofeedback|"PBF assisted abdominal muscle activation training (30 min, 3x /week /4 weeks) Progressive Muscle Relaxation for 5 min Pressure biofeedback assisted abdominal muscle activation training. Frequency: 25 min; 10 sec hold, 15 sec relax, 10 reps Progression criteria in training: Maintaining 3 - 5 mmHg pressure on PBF dial while performing abdominal muscle activation.~Exercises for Group For biofeedback assisted abdominal muscle activation training these exercises will be performed:~1. Supine abdominal muscle activation (45° Hip knee flexion)~2. Both hip and knee 90° flexion~3. One side hip and knee 90° flexion with other fully extended~4. One side hip and knee 90° flexion with other fully extended + heel 12 cm raised~5. Both legs fully extended with heel 12 cm raised~6. Partial curl ups~7. Prone lying abdominal muscle activation~8. Prone leg raises~9. Prone upper back extension simple~10. Prone reciprocal UE/LE exercises"
223694150|NCT01229371|BIOLOGICAL|Inflexal V influenza vaccine (CSL HA Antigen) 2010|Inflexal V influenza vaccine (surface antigen, inactivated, virosome, using CSL HA Antigen) 2010/2011, with intramuscular administration, containing per 0.5 mL dose: 15 μg HA antigen of A/California/7/2009 (H1N1)-like virus; 15 μg HA antigen of A/Perth/16/2009 (H3N2)-like virus; 15 μg HA antigen of B/Brisbane/60/2008-like virus
223694151|NCT01229371|BIOLOGICAL|Inflexal V influenza vaccine (AdImmune HA antigen) 2010/2011|Inflexal V influenza vaccine (surface antigen, inactivated, virosome, using AdImmune HA antigen) 2010/2011 with intramuscular administration, containing per 0.5 mL dose: 15 μg HA antigen of A/California/7/2009 (H1N1)-like virus; 15 μg HA antigen of A/Perth/16/2009 (H3N2)-like virus; 15 μg HA antigen of B/Brisbane/60/2008-like virus
223778304|NCT06387563|PROCEDURE|Abdominal activation using SEMG biofeedback|"SEMG-BF assisted abdominal muscle activation training (30 min, 3x/ week/ 4 weeks) Progressive Muscle Relaxation for 5 min Surface EMG-BF assisted abdominal muscle activation training. Frequency: 25 min; 10 sec hold, 15 sec relax, 10 reps Maintaining minimal volumetric contraction of abdominal muscle activation (as per person) on SEMG device with abdominal muscle activation for set frequency~Exercises for Group B For biofeedback assisted abdominal muscle activation training these exercises will be performed:~1. Supine abdominal muscle activation (45° Hip knee flexion)~2. Both hip and knee 90° flexion~3. One side hip and knee 90° flexion with other fully extended~4. One side hip and knee 90° flexion with other fully extended + heel 12 cm raised~5. Both legs fully extended with heel 12 cm raised~6. Partial curl ups~7. Prone lying abdominal muscle activation~8. Prone leg raises~9. Prone upper back extension simple~10. Prone reciprocal UE/LE exercises"
223778305|NCT02872064|DRUG|Verteporfin|Verteporfin (which is marketed under the brand name Visudyne) is the photosensitizer. Verteporfin is a benzoporphyrin derivative which is clinically active when formulated with liposomes. By itself the clinically recommended dose of Verteporfin is not cytotoxic. It produces cytotoxic agents only when activated by light in the presence of oxygen. When energy absorbed by the porphyrin is transferred to oxygen, highly reactive short lived singlet oxygen is generated. Singlet oxygen causes damage to biological structures, leading to local vascular occlusion, cell damage and cell death.
223778306|NCT05307224|DEVICE|Mandala|Experimental group will paint mandala for 30 minutes/day in the evenings for six consecutive days. Six pre-selected mandalas were planned to be printed separately on A4 paper. Each patient will be given a new mandala each day. Additionally, At the beginning of the study, the experimental group will be given six colors (yellow, blue, green, red, purple, brown).
223778307|NCT02769091|DRUG|TEV-45478|80 mg (2x40mg) tablets once daily for up to 24 weeks
223778308|NCT02769091|DRUG|Placebo|
223778309|NCT06101693|DIAGNOSTIC_TEST|Plasma biomarker levels|"This study will investigate the diagnostic utility and performance of:~1. Alternative cut-offs for NT-proBNP to identify HF(pEF) in people with suspected HF and obesity, in whom~2. Novel candidate biomarkers to identify HF(pEF) in people with suspected HF and obesity.~3. Novel candidate biomarkers to identify HF(pEF) in people with suspected HF and NT-proBNP \<125 ng/L~4. The prevalence of HF in people with suspected HF and low NT-proBNP \<125 ng/L).~The diagnosis of heart failure will be determined according to international guidelines, when there are symptoms and/or signs of HF in association with objective evidence of cardiac structural and/or functional abnormalities consistent with the presence of LV diastolic dysfunction/raised LV filling pressures. Non-invasive testing with rest and diastolic stress echocardiography will be used to evaluate for evidence of raised filling pressures, in order to make the study procedures applicable to usual clinical practice."
223778310|NCT03060941|BEHAVIORAL|Physical activity education|Participants will be given educational materials on how to increase physical activity levels.
223778311|NCT03060941|BEHAVIORAL|Facility access|Participants will receive at 6 month membership to a local fitness facility.
223778312|NCT03060941|BEHAVIORAL|Supervised exercise sessions|Participants will attend weekly supervised exercise sessions with an exercise interventionist.
223778313|NCT03060941|BEHAVIORAL|Self-monitoring (Fitbit)|Participants will be given a Fitbit to monitor their physical activity levels.
223778314|NCT03060941|BEHAVIORAL|Active living counseling|Participants will attend 12 biweekly educational sessions about how to increase their physical activity levels.
223778315|NCT01787526|DRUG|ferric carboxymaltose|1 g intravenously per infusion
223778316|NCT01787526|DRUG|oral iron|oral tablets of 100mg iron over 8 weeks, total dose 10g
223778317|NCT03175653|OTHER|Oxycodone Pill A|Prescription for oxycodone pills for post-Cesarean delivery pain control after hospital discharge. Oxycodone is an opioid.
223778318|NCT03175653|OTHER|Oxycodone Pill B|Prescription for oxycodone pills for post-Cesarean delivery pain control after hospital discharge. Oxycodone is an opioid.
223778319|NCT00592995|DRUG|Creatine monohydrate|10 to 30 grams daily
223778320|NCT00592995|DRUG|Placebo|10 to 30 grams daily
223778321|NCT05916508|DRUG|0.454% stannous fluoride|Brush two times daily
223778322|NCT05916508|DRUG|0.76% sodium monofluorophosphate|Brush two times daily
223778323|NCT05916508|DRUG|0.454% stannous fluoride AM and 0.76% sodium monofluorophosphate PM|Brush two times daily
223778324|NCT05394623|DIAGNOSTIC_TEST|HDV-Ab (IgG), HDV-RNA, RNA genotype|Anti-HDV was evaluated semiquantitatively by means of end-point dilutions. Quantitative HDV-RNA was performed by means of LightCycler 2.0. Genotyping of HDV was performed by direct sequencing of the delta antigen region.
223778325|NCT06475157|OTHER|No intervention|No intervention is applied.
223778326|NCT02116465|DRUG|Levodopa Carbidopa immediate release tablets|oral administration
223778327|NCT02084953|DRUG|BMS-791325|
223778328|NCT02084953|DRUG|Moxifloxacin|
223778329|NCT02084953|DRUG|Placebo matching BMS-791325|
223778330|NCT00585754|DRUG|Guanfacine|1.5mg BID
223778331|NCT00585754|DRUG|Placebo|placebo
223778332|NCT03427372|BEHAVIORAL|anxiety scale, depression scale|post spinal puncture headache and backache will be assess by using visual analogue scale, anxiety will assess by beck anxiety scale, depression mood will assess by beck depression scale
223778333|NCT03525834|DRUG|Everolimus|Everolimus 2.5 mg and 5 mg tablets with dosage regimen of 10 mg orally once daily.
223778334|NCT00902616|DIETARY_SUPPLEMENT|L-arginine|3gm TDS for three months
223778335|NCT00902616|DIETARY_SUPPLEMENT|Placebo Lactose powder|3gm TDS for 3 months
223778336|NCT03608800|BEHAVIORAL|Intermittent fasting|The intervention of two nonconsecutive days of 75% energy restriction per week for 8 weeks
223778337|NCT01795001|OTHER|No intervention|
223778338|NCT03176394|DEVICE|BLASTX Gel|Foley Catheter lubricated with BLASTX Gel
223778339|NCT03176394|DEVICE|McKesson Jelly|Foley Catheter lubricated with McKesson Jelly
223778340|NCT00908440|BEHAVIORAL|Decision Aid|25 page booklet informing patients about PTSD symptoms and treatment options
223778341|NCT05810922|OTHER|arbutus berry|consumption of 50 g arbutus berry/day or 200 g arbutus berry/day for 14 days
223778342|NCT01828242|BEHAVIORAL|Empowerment model to improve dietary intake|Empowerment model using specific guidelines to improve dietary intake
223778343|NCT01828242|OTHER|Control group following conventional approach|Control group following conventional approach
223778344|NCT03955484|DIAGNOSTIC_TEST|Urinary Glycosaminoglycan|Urine will be collected from patients before and after one month of medical treatment (alpha-blocker). After being centrifuged at 5000 g for 10 minutes, urine will be stored at -80 ° C. At the end of the study, urinary glycosaminoglycan levels will be studied by spectrophotometric method.
223778345|NCT01984398|DRUG|12.5 mg Androxal Formulation A|Single dose of 12.5 mg Androxal formulation A
223778346|NCT01984398|DRUG|12.5 mg Androxal Formulation B|Single dose of 12.5 mg Androxal Formulation B
223778347|NCT01984398|DRUG|25 mg Androxal Formulation A|Single dose of 25 mg Androxal formulation A
223778348|NCT01984398|DRUG|25 mg Androxal Formulation B|Single dose of 25 mg Androxal formulation B
223778349|NCT03834194|BEHAVIORAL|Lottery + Monthly Weight|"Lottery for daily self-weighing.~Incentives for gaining weight within a recommended (by Institute of Medicine) on a monthly basis."
223778350|NCT03834194|BEHAVIORAL|Lottery + Overall Weight + Exercise|"Lottery for daily self-weighing.~Incentives for gaining weight within a recommended (by Institute of Medicine) by the end of the study.~Incentives for meeting an exercise goal of 150 minutes of moderate physical activity per week, as recommended by the American College of Obstetricians and Gynecologists."
223778351|NCT03834194|BEHAVIORAL|Lottery + Overall Weight|"Lottery for daily self-weighing.~Incentives for gaining weight within a recommended (by Institute of Medicine) by the end of the study."
223778352|NCT03834194|BEHAVIORAL|Loss + Overall Weight|"Certain loss for not engaging in daily self-weighing.~Incentives for gaining weight within a recommended (by Institute of Medicine) by the end of the study."
223778353|NCT03834194|BEHAVIORAL|Loss + Overall Weight + Exercise|"Certain loss for not engaging in daily self-weighing.~Incentives for gaining weight within a recommended (by Institute of Medicine) by the end of the study.~Incentives for meeting an exercise goal of 150 minutes of moderate physical activity per week, as recommended by the American College of Obstetricians and Gynecologists."
223778354|NCT03834194|BEHAVIORAL|Lottery + Monthly Weight + Exercise|"Lottery for daily self-weighing.~Incentives for gaining weight within a recommended (by Institute of Medicine) on a monthly basis.~Incentives for meeting an exercise goal of 150 minutes of moderate physical activity per week, as recommended by the American College of Obstetricians and Gynecologists."
223778355|NCT03834194|BEHAVIORAL|Loss + Monthly Weight|"Certain loss for not engaging in daily self-weighing.~Incentives for gaining weight within a recommended (by Institute of Medicine) on a monthly basis."
223778356|NCT03834194|BEHAVIORAL|Loss + Monthly Weight + Exercise|"Certain loss for not engaging in daily self-weighing.~Incentives for gaining weight within a recommended (by Institute of Medicine) on a monthly basis.~Incentives for meeting an exercise goal of 150 minutes of moderate physical activity per week, as recommended by the American College of Obstetricians and Gynecologists."
223778357|NCT01751568|DRUG|Raltegravir|Chewable raltegravir tablets, initially dosed at 12 mg/kg (up to a maximum of 800 mg) orally twice daily.
223778358|NCT02660944|DRUG|RSLV-132|RNase-Fc fusion protein
223778359|NCT02660944|DRUG|Placebo|Saline placebo
223778360|NCT03586999|DRUG|Nivolumab|Nivolumab injection is to be administered as an IV infusion.
223778361|NCT03586999|DRUG|Etoposide|Dosage calculations will be based on the patient's body surface area (BSA) at baseline, recommend using the Mosteller formula and administered through IV. Dose adjustments at the beginning of each cycle do not need to be made unless there has been a \>10% weight gain or loss. Patients receive six 21-day cycles of the medications.
223778362|NCT03586999|DRUG|Prednisolone|Dosage calculations will be based on the patient's body surface area (BSA) at baseline, recommend using the Mosteller formula and administered through IV. Dose adjustments at the beginning of each cycle do not need to be made unless there has been a \>10% weight gain or loss. Patients receive six 21-day cycles of the medications.
223778363|NCT03586999|DRUG|Oncovin|Dosage calculations will be based on the patient's body surface area (BSA) at baseline, recommend using the Mosteller formula and administered through IV. Dose adjustments at the beginning of each cycle do not need to be made unless there has been a \>10% weight gain or loss. Patients receive six 21-day cycles of the medications.
223778364|NCT03586999|DRUG|Cyclophosphamide|Dosage calculations will be based on the patient's body surface area (BSA) at baseline, recommend using the Mosteller formula and administered through IV. Dose adjustments at the beginning of each cycle do not need to be made unless there has been a \>10% weight gain or loss. Patients receive six 21-day cycles of the medications.
223778365|NCT03586999|DRUG|Hydroxydaunorubicin|Dosage calculations will be based on the patient's body surface area (BSA) at baseline, recommend using the Mosteller formula and administered through IV. Dose adjustments at the beginning of each cycle do not need to be made unless there has been a \>10% weight gain or loss. Patients receive six 21-day cycles of the medications.
223778366|NCT04096560|DRUG|TAK-994|TAK-994 tablets.
223778367|NCT04096560|DRUG|Placebo|TAK-994 placebo-matching tablets.
223778368|NCT01485861|DRUG|Abiraterone|Orally once daily
223778369|NCT01485861|DRUG|Apitolisib|Orally once daily
223778370|NCT01485861|DRUG|Ipatasertib|Orally once daily
223778371|NCT01485861|DRUG|Placebo|Orally once daily
223778372|NCT01485861|DRUG|Prednisone|Orally bid
223778373|NCT01485861|DRUG|Prednisolone|Orally bid
223778374|NCT01229436|DRUG|Xiapex|Xiapex 0.58 mg in diluent, 0.25 ml for MP joints and 0.20 ml for PIP joints, injection to cord over joint using either 26 or 27 gauge needle, maximum 3 injections with 30 days interval between injections to any single site, maximum 5 injections in this protocol
223778375|NCT03515148|PROCEDURE|Cryotherapy and eccentric exercise|12 weeks, 5 days/week, once a day, 2 exercise, 3 sets/execise, 15 repetition/set of eccentric exercise of foot plantar flexors First exercise with knee in extension, second exercise with knee in flexion. Previously subjects should cold their leg in ice water during sexteen minutes at a temperature of 8ºC (+/-2ºC)
223778376|NCT03515148|PROCEDURE|Vibration and eccentric exercise|12 weeks, 5 days/week, once a day, 2 exercise, 3 sets/execise, 15 repetition/set of eccentric exercise of foot plantar flexors First exercise with knee in extension, second exercise with knee in flexion.During the exercise subjects will be subjected to vibration. Vibrations parameters: Frequency: 35Hz, Amplitude: 4 milimeters, Force: 3,9G
223778377|NCT05167344|BEHAVIORAL|Healthy Relationships Program-Enhanced|The Healthy Relationships Program-Enhanced (HRP-E) is a small group mental health promotion and healthy relationship program designed for vulnerable, at-risk youth. It is a trauma-informed, 16-session manualized program.
223778378|NCT04242316|BEHAVIORAL|Mirror Therapy|Patients performed customized bimanual upper limb exercises with graded level of difficulty based on the patient's individual levels of upper limb functioning according to the 7 levels of the FTHUE and each level consisted of 5 standardized table-top tasks. The patients practiced the movements with the unaffected hand (including the shoulder, elbow, wrist, and hand). While watching the reflection of the unaffected hand in the mirror, the patient was then asked to moving the affected hand at the same time to synchronize the movement with the reflection of the unaffected hand. If the patient was unable to move the hand, a therapist would passively assist the movement of the affected hand so as to synchronize it with the reflection of the unaffected hand.
223778379|NCT04242316|BEHAVIORAL|Bilateral arm training|Patients performed customized bimanual upper limb exercises with graded level of difficulty based on the patient's individual levels of upper limb functioning according to the 7 levels of the FTHUE and each level consisted of 5 standardized table-top tasks, but without a mirror. The patients can take a direct view of their paretic hand.
223778380|NCT02928341|OTHER|Improved water supply|
223778381|NCT00024518|DRUG|30,000 units hrINF-alpha|
223778382|NCT00024518|DRUG|5,000 hrINF-alpha|
223778383|NCT00024518|OTHER|Placebo|placebo was prepared as saline alone with 6mg human serum albumin (HSA).
223778384|NCT05279261|PROCEDURE|The axillary approach|The approach enters from the axilla through the interval between the latissimus dorsi and subscapularis to expose the anteroinferior glenoid, neck and lateral border of the scapula with entire rotator cuff sparing and fix the fracture with screws or plates.
223778385|NCT04590391|DEVICE|Visual and Auditory Breathing-swallowing Coordinated Training device|This device has a structure in which a band wrapped around the chest detects the respiratory phase from changes in the lung volume, and the connected device lights a signal and sounds a sound.
223778386|NCT00466323|BEHAVIORAL|Family Member Provider Outreach|Family Member Provider Outreach is a brief recovery oriented model. THe FMPO meets with the consumer for 2-3 sessions and with the family for 2-3 sessions with the consumer's permission.
223778387|NCT00466323|BEHAVIORAL|Enhanced treatment as usual (e-TAU)|Enhanced treatment as usual. In this condition, the consumer is given a list of family services available including the family intervention team.
223778388|NCT02266381|PROCEDURE|US-guided renal access|Patients undergo MPCNL using only US-guided renal access.
223778389|NCT02266381|PROCEDURE|Fluoroscopy-guided renal access|Patients undergo MPCNL using only fluoroscopy-guided renal access.
223778390|NCT02266381|PROCEDURE|US combined with fluoroscopy-guided renal access|Patients undergo MPCNL using US combined with fluoroscopy-guided renal access
223778391|NCT03269591|DEVICE|Pulsed electromagnetic field|EASY Qs portable (by ASA, Italy)
223778392|NCT03269591|DRUG|diclofenac tablets|drugs
223778393|NCT03269591|DIAGNOSTIC_TEST|Visual analogue scale|a graphic rating scale
223778394|NCT03269591|DIAGNOSTIC_TEST|Progesterone blood level|blood test
223778395|NCT03269591|DIAGNOSTIC_TEST|Menstrual symptom questionnaire|questionnaire
223778396|NCT06043414|DEVICE|triclosan-coated barbed suture|STRATAFIX™ Symmetric PDS™ (Johnson \& Johnson) triclosan-coated polydioxanone barbed suture caliber 0 or 1 will be the standardized suture used for abdominal fascial closure in patients randomized to the treatment group. STRATAFIX™ Symmetric PDS™ is an FDA approved sterile, synthetic, absorbable, barbed triclosan-coated polydioxanone suture. Its indications for use include soft tissue approximation where absorbable suture is appropriate.
223778397|NCT06043414|DEVICE|triclosan-coated non-barbed suture|PDS™ Plus (Johnson \& Johnson) non-barbed triclosan-coated polydioxanone suture in either 0 or 1 caliber will be used for abdominal fascial closure in patients randomized to the control group. PDS™ Plus is an FDA approved sterile, synthetic, absorbable, triclosan-coated surgical monofilament suture prepared from the polyester, poly(p-dioxanone). Its indications for use include soft tissue approximation where absorbable suture is appropriate.
223778398|NCT06043414|DEVICE|Non-coated non-barbed suture|PDS™ II (Johnson \& Johnson) non-barbed non-coated polydioxanone suture in either 0 or 1 caliber will be used for abdominal fascial closure in patients randomized to the control group. PDS™ II is a FDA approved sterile, synthetic, absorbable, surgical monofilament suture prepared from the polyester, polyester, poly(p-dioxanone) indicated for use in soft tissue approximation where absorbable suture is appropriate.
223778399|NCT00648869|DRUG|metformin tablet, metformin gum|500 mg, 250 mg
223778400|NCT02983955|DEVICE|UPnRIDE Powered Wheelchair|The UPnRIDE Powered Wheelchair device is a product which changes people position from sitting to standing and standing to sitting. The product provides indoor and outdoor mobility.
223778401|NCT05051241|DRUG|GFH018|Subjects will receive GFH018 orally at different dose levels following twice daily, 14-day on/14-day off regimen. Other dose regimens, eg 7d-on/7d-off will also be considered to be explored when the safety/tolerability is confirmed.
223778402|NCT06368128|BEHAVIORAL|Indoor Rock Climbing Exercise Training Program|Training will occur 2-3 days per week for 60 minutes; ratings of perceived exertion between 3-7 on a scale of 0-10 will be targeted for the desired intensity throughout the program. Minutes of rock climbing will also be monitored to develop the progression strategy.
223778403|NCT01384539|DRUG|Cholecalciferol|
223778404|NCT01384539|DRUG|Calcitriol|
223778405|NCT00004926|DIETARY_SUPPLEMENT|vitamin D3 analogue ILX23-7553|
223778406|NCT00889122|BEHAVIORAL|Exergame (DDR)|Use of an active videogame vs. pedometers given to entire families to promote physical activity.
223778407|NCT04856319|PROCEDURE|Dental implant placement|Insertion of not more than two dental implants at the same area
223778408|NCT04856319|DRUG|Antibiotic prophylaxis|Per-os 2g amoxicillin+clavulanic acid will be administered one hour prior to the surgery
223778409|NCT04856319|OTHER|Placebo|Per-os placebo (inert polysaccharide) will be administered one hour prior to the surgery
223778410|NCT01714024|DEVICE|Zimmer Trabecular Metal Test Cylinder|For all subjects 2 titanium and 2 trabecular 2.9-3.0 mm x 5 mm test cylinders will be implanted in alveolar bone. One of each type will be removed at 2 weeks. The remaining two will be removed at 4 weeks.
223778411|NCT01714024|DEVICE|Zimmer Titanium Test Cylinder|For all subjects 2 titanium and 2 trabecular 2.9-3.0 mm x 5 mm test cylinders will be implanted in alveolar bone. One of each type will be removed at 2 weeks. The remaining two will be removed at 4 weeks.
223778412|NCT01645709|DRUG|Verapamil|
223778413|NCT01645709|DRUG|Placebo|
223778414|NCT02572271|PROCEDURE|Rubins Mastopexy|The surgical technique described by Rubin is performed. No other intervention.
223778415|NCT02572271|PROCEDURE|LOPOSAM|The surgical technique LOPOSAM is performed. No other intervention.
223778416|NCT06460194|DRUG|Botuinum toxin|Injection of botulinum toxin in the palm of the hand
223778417|NCT04972500|DIETARY_SUPPLEMENT|Nutricia Pre-op, 400 milliliters, per os|After 10 hours of fasting participants will receive per os 400 milliliters of Nutricia Pre-op
223778418|NCT01921972|DRUG|Galantamine CR|24 mg/day with dose-titration over twelve weeks
223778419|NCT01921972|DRUG|Memantine|memantine 10 mg b.i.d. with a dose titration of sixteen weeks
223778420|NCT01921972|DRUG|Placebo|Placebo will be similar in appearance to Memantine
223778421|NCT01048138|DRUG|Biperiden Lactate|5mg IV(in the vein)every 6 hours for 10 days
223778422|NCT01048138|DRUG|Placebo|5mg IV(in the vein)every 6 hours for 10 days
223778423|NCT00614211|PROCEDURE|Total Abdominal Radical Hysterectomy|In a radical hysterectomy the uterus, the upper one to two centimetres of the vagina and the soft tissues around the cervix are excised.
223778424|NCT00614211|PROCEDURE|Total Laparoscopic or Robotic Radical Hysterectomy|In a radical hysterectomy the uterus, the upper one to two centimetres of the vagina and the soft tissues around the cervix are excised.
223778425|NCT01731171|DIETARY_SUPPLEMENT|Probiotic Supplement|Probiotic Supplement 1 tablet by mouth daily
223778426|NCT01731171|DIETARY_SUPPLEMENT|Inert Compound|Probiotic identical placebo 1 tablet by mouth daily
223778427|NCT05247944|PROCEDURE|Fenestrated and branched endovascular aortic repair (F-BEVAR)|Fenestrated and branched endovascular aortic repair (F-BEVAR)
223778428|NCT05247944|PROCEDURE|Open repair|Open surgery for complex abdominal aortic aneurysm
223778429|NCT01446848|DIETARY_SUPPLEMENT|iron supplement|325 mg tablets by mouth once a day for 1 week, then twice a day for 1 week, then three times daily for the remainder of the 3-month study period.
223778430|NCT04123639|PROCEDURE|PTA|Percutaneous transluminal angioplasty
223778431|NCT06535698|DIETARY_SUPPLEMENT|Perelel Health Hormonal Balance Support|The supplement contains Myo-inositol (1000 mcg), Metabolic balance blend (200 mcg) including Berberine HCl, Alpha lipoic acid, DIM (33'-Diindolylmethane), and D-chiro-inositol (25 mg). Other ingredients include Vegetable cellulose (capsule), plant cellulose, and L-leucine.
223778432|NCT01607034|DRUG|Dexpramipexole|150 mg single dose
223778433|NCT03290716|OTHER|SS|Replace regular salt with market available potassium-enriched salt substitute in kitchens of nursing homes.
223778434|NCT03290716|OTHER|SSSC|A stepwise approach to reduce salt used in the kitchen of nursing homes by controlling the supply of salt.
223778435|NCT00826085|DRUG|ThermoDox in combination with Microwave Hyperthermia (heat)|"ThermoDox is a 30 minute intravenous infusion followed by hyperthermia within 60 minutes of infusion completion.~Hyperthermia is a therapy used to heat tumors for 60 minutes. Using heat energy, the tumor is heated to a certain temperature. The heat can damage cancer cells at levels that are usually safe for normal cells and can be used to attack cancer in four major ways: 1) heat damages or weakens the cells of the tumor; 2) heat increase blood flow through the weakened tumor; 3) increased blood flow raises oxygen levels in tumors; and 4) when the body senses fever it can stimulate the nature immune system.~All patients will receive up to six ThermoDox/hyperthermia treatments at 21-day intervals."
223778436|NCT01736852|DEVICE|CRB|Labor induction using the CRB
223778437|NCT01736852|DRUG|Pitocin|Labor induction using Pitocin
223778438|NCT01180075|DRUG|tenofovir/emtricitabine/efavirenz (TDF/FTC/EFV)|Patients receiving this drug for clinical care at standard dosages will be enrolled.
223778439|NCT01180075|DRUG|tenofovir/emtricitabine (TDF/FTC)|Patients receiving this drug for clinical care at standard dosages will be enrolled.
223778440|NCT01180075|DRUG|Atazanavir (ATV)|Patients receiving this drug for clinical care at 300mg with 100mg ritonavir daily will be enrolled.
223778441|NCT01180075|DRUG|Ritonavir|Patients receiving this drug for clinical care at 100mg daily with 300mg atazanavir will be enrolled.
223778442|NCT01180075|PROCEDURE|Phlebotomy|Multiple blood draws will be performed in the study, and vary depending on the group.
223778443|NCT03653429|DRUG|Tranexamic Acid|administered prior to surgical incision
223778444|NCT03653429|DRUG|Normal saline|administered prior to surgical incision
223778445|NCT00881725|DRUG|Metformin|500mg tablets t.i.d. for 4-12 weeks prior to Radical Prostatectomy
223778446|NCT06317792|OTHER|online exergaming-based physiotherapy programs|The online exergaming-based physiotherapy programs focus on training in shoulder, hip, and knee ROM balance, weight-bearing, strength, weight shifting, and walking based on RF in machine learning to the features selection in patients with PIGD. The training tasks consist of a set of 10 pieces of training (20 min per session, five sessions every week, for 8 weeks). Five exergaming programs were used for training, designed to incorporate an appropriate level of challenge to match the ability and fitness of patients with PD.
223778447|NCT01018849|DIETARY_SUPPLEMENT|Cholecalciferol|cholecalciferol 150,000 IU by mouth every 2 months for 1 year
223778448|NCT01018849|DIETARY_SUPPLEMENT|Placebo|placebo by mouth every 2 months for 1 year
223778449|NCT04265079|OTHER|Additional weight at hand|Added weight of an inactive hand orthosis (300 gram)
223778450|NCT00490425|DRUG|Lactobacillus rhamnosus strain GG ATCC 53103 (LGG, 1010 cfu)|
223778451|NCT00403546|DRUG|Ziprasidone 80-160 mg/d|Participants will be instructed to take one study capsule of ziprasidone orally twice daily (80 mg/d). After the first week, the study drug will be increased to two capsules twice daily (160 mg/d).
223778452|NCT00403546|DRUG|Placebo|Participants will be instructed to take one study capsule of matching placebo orally twice daily. After the first week, the matching placebo will be increased to two capsules twice daily.
223778453|NCT00403546|DRUG|Ziprasidone 160 mg/d|Participants will be taking open-label ziprasidone 80 mg orally twice daily for a total dose of 160 mg/d from at least 3 weeks before randomization to end of study 8 weeks after randomization.
223778454|NCT04492046|OTHER|Manual Lymph Drainage|Manual lymph drainage is an effective therapeutic method used in the conservative treatment of lipedema. The application was performed on both lower extremities for 45 minutes.
223778455|NCT04492046|OTHER|Bandaging|Multilayered compression bandaging techniques have an assisting role in the further reduction of the volume of the limb and enhance the continuous pump mechanism via the active involvement of muscle pumps. All patients received bandages following Manual lymph drainage application.
223778456|NCT06364566|RADIATION|Neoadjuvant chemradiotherapy|Patients receiving neoadjuvant chemradiotherapy cause tumor shrinkage
223778457|NCT06364566|PROCEDURE|Minimally invasive esophagectomy|The patient underwent minimally invasive esophagectomy to remove residual tumors and surrounding lymph nodes
223778458|NCT02449824|OTHER|magnetic resonance imaging|early MRI
223778459|NCT02893722|DRUG|atosiban|give drugs 30 minutes before the start of the embryo transfer,and intravenous infusion in total dose of 37.5 mg is set in certain infusion rate, and complete the infusion in 3 hours.
223778460|NCT02893722|DRUG|0.9% saline|give drugs 30 minutes before the start of the embryo transfer,and intravenous infusion is set in the same rate with experimental group, complete the infusion in 3 hours.
223778461|NCT00948831|BIOLOGICAL|Osteocel Plus|biologic
223778462|NCT02233712|BIOLOGICAL|G17DT|
223778463|NCT02358486|DEVICE|Acupuncture|"1. Acupuncture rationale 1a) Style of acupuncture: body acupuncture (in accordance with meridian theory)~2. Needling details 2a) Number of needle insertions per subject per session: 13 2b) Acupoints: Basic points - Large Intestine(LI)4, Stomach(ST)36, Liver(LR)3, Pericardium(PC)3, Spleen(SP)4, Stomach(ST)34, Conception Vessel(CV)12, 2c) Depth: 5 \~ 30mm 2d) Response sought: 'De qi' sensation; 2e) Needle stimulation: Manipulation 2f) Retention time: 15 minutes 2g) Needle type: 0.2 X 40 mm, sterilized stainless steel needle, Dongbang Inc., Korea"
223778464|NCT02358486|DEVICE|Sham acupuncture|The participants in sham acupuncture group are given sham acupuncture treatment at the same acupoints in the same times and method as acupuncture arm. The sham device would be a Streitberger device.
223778465|NCT04886141|BEHAVIORAL|Virtual Reality Headset|To determine if virtual reality headsets can reduce a patients pain level instead of using the standard Nitrous. This may provide a alternate to patients who cannot receive nitrous if pain or anxiety can be reduced effectively.
223778466|NCT01547650|OTHER|Calculated CVP by using cardiac echogram|Before and after the correction of plasma volume
223778467|NCT05185024|DIETARY_SUPPLEMENT|Ferrous Sulfate Capsules|Once daily dose of one Ferrous Sulfate Capsule for 12 weeks in total.
223778468|NCT05185024|DIETARY_SUPPLEMENT|>Your< Iron Forte Capsules|Once daily dose of one \>Your\< Iron Forte Capsule for 12 weeks in total.
223778469|NCT05185024|DIETARY_SUPPLEMENT|>Your< Iron Forte Liquid|Once daily dose of 5 ml of \>Your\< Iron Forte Liquid for 12 weeks in total.
223778470|NCT05185024|OTHER|Blank Capsules|Once daily dose of one Blank Capsule (excipients only) for 12 weeks in total.
223778471|NCT05185024|OTHER|Blank Liquid|Once daily dose of 5 ml of Blank Liquid (excipients only) for 12 weeks in total.
223778472|NCT01369628|DRUG|Atacicept|"1. Regimen 1: Atacicept 25 mg weekly for 12 weeks~2. Regimen 2: Atacicept 75 mg weekly for 12 weeks~3. Regimen 3: Atacicept 150 mg weekly for 12 weeks"
223778473|NCT04408963|BIOLOGICAL|VRC-HIVMAB0102-00-AB|The VRC-HIVMAB0102-00-AB (CAP256V2LS) broadly neutralizing monoclonal antibody (bNAb) targets the V1V2 region of the HIV-1 envelope, is human in origin, and contains two amino acid modifications within the C-terminus of the heavy chain constant region designed to improve antibody half-life in vivo.
223778474|NCT00002684|DRUG|cisplatin|
223778475|NCT00002684|DRUG|ifosfamide|
223778476|NCT00002684|DRUG|paclitaxel|
223778477|NCT04868201|DEVICE|0-anxiety|0-anxiety is a self-guided app-based utilizing virtual reality establish in cognitive behavior therapy treatment.
223778478|NCT02604589|DRUG|hydromorphone hydrochloride|Patient-controlled narcotic analgesia pump
223778479|NCT02604589|PROCEDURE|Infusion catheter placement|Placement of continuous infusion catheter and elastomeric pump into extrathoracic paraspinous space
223778480|NCT02604589|DRUG|bupivicaine 0.25%|Low Dose analgesia
223778481|NCT02604589|DRUG|bupivicaine 0.5%|High dose analgesia
223778482|NCT03908684|DEVICE|Ultrasound Imaging|Ultrasound Spectroscopy assess changes in five different ultrasound spectroscopic parameters over different times during treatment with radiotherapy as predictors of tumour shrinkage and pathologic complete response. Ultrasound parameters investigated will include mid-band fit (related to image intensity),spectroscopic slope (backscatter versus frequency), spectroscopic intercept, histogram fit size and shape parameters which can be used as estimates of scatterer size and concentration.
223778483|NCT04901559|PROCEDURE|Graft type at ACLR|The choice of graft at primary ACL Reconstruction
223778484|NCT00793910|DRUG|Gabapentin|Gabapentin 300 mg taken by mouth thrice daily for 7 days
223778485|NCT00793910|DRUG|placebo|placebo (sugar pill) taken by mouth thrice daily for 7 days
223778486|NCT01700946|DRUG|dexamethasone|given intravenously or orally
223778487|NCT01700946|DRUG|vincristine sulfate|given intravenously
223778488|NCT01700946|BIOLOGICAL|rituximab|given intravenously
223778489|NCT01700946|DRUG|clofarabine|given intravenously
223778490|NCT01700946|DRUG|cyclophosphamide|given intravenously
223778491|NCT01700946|DRUG|etoposide|given intravenously
223778492|NCT01700946|BIOLOGICAL|aldesleukin|given subcutaneously
223778493|NCT01700946|DRUG|pegaspargase|given intravenously
223778494|NCT01700946|DRUG|methotrexate|given intrathecally or intravenously
223778495|NCT01700946|DRUG|mercaptopurine|given orally
223778496|NCT01700946|DRUG|cytarabine|given intrathecally or intravenously
223778497|NCT01700946|DRUG|mitoxantrone|given intravenously
223778498|NCT01700946|DRUG|teniposide|given intravenously
223778499|NCT01700946|DRUG|vinblastine|given intravenously
223778500|NCT01700946|BIOLOGICAL|natural killer cell infusion|undergo allogeneic natural killer cell infusion
223778501|NCT01700946|OTHER|laboratory biomarker analysis|correlative studies
223778502|NCT01700946|DRUG|therapeutic hydrocortisone|given intrathecally
223778503|NCT01700946|PROCEDURE|allogeneic hematopoietic stem cell transplantation|undergo allogeneic HSCT
223778504|NCT01700946|DEVICE|CliniMACS|The mechanism of action of the CliniMACS Cell Selection System is based on magnetic-activated cell sorting (MACS). The CliniMACS device is a powerful tool for the isolation of many cell types from heterogeneous cell mixtures, (e.g. apheresis products). These can then be separated in a magnetic field using an immunomagnetic label specific for the cell type of interest, such as CD3+ human T cells.
223694152|NCT06570395|PROCEDURE|Osteopathic Manipulative Treatment|"Osteopathic Manipulative Therapy (OMT) is a hands-on approach to treating conditions that affect all areas of the body. Physicians trained in OMT (Doctors of Osteopathic Medicine or DO) use OMT to correct structural imbalances in the body, relieve pain, and improve circulation. It is not only used as a treatment modality, but also to diagnose and prevent disease and improve overall functioning. There are over 40 OMT techniques that all involve gentle manipulation of the muscles, soft tissues, and joints in several ways to optimize alignment, improve blood flow, restore balance, and improve range of motion (Osteopathic Manipulative Therapy \& OMT. Cleveland Clinic)."
223694153|NCT03012568|DEVICE|SJM Implantable cardiac devices|SJM implantable devices undergoing MRI scan
223694154|NCT01859143|BIOLOGICAL|Trivalent Influenza Vaccine|A single dose of 10\^(7.0 ± 0.5) FFU of trivalent influenza vaccine will be administered as intranasal spray on Day 1.
223694155|NCT01859143|OTHER|Placebo|A single dose of placebo matched to trivalent influenza vaccine will be administered as intranasal spray on Day 1.
223694156|NCT02126358|DRUG|Gemigliptin and/or Rosuvastatin|
223694157|NCT01146275|RADIATION|Radiologial breast examination|MRI of breast, mammography and ultrasound of breast
223694158|NCT03036306|DRUG|SCX-001|Nefopam cream formulation
223694159|NCT03036306|OTHER|Placebo|Cream formulation without Nefopam
223694160|NCT05780697|PROCEDURE|Surgery of Drainage of septic hip arthritis|Surgery for septic hip arthritis by anterior or lateral approach and inspection of femoral head
223694161|NCT03677908|OTHER|ElectroEncephaloGraphy|Density ElectroEncephaloGraphy analysis
223694162|NCT01303354|PROCEDURE|Lumbar Transforaminal Epidural Steroid Injection|
223694163|NCT00982124|DRUG|Zoledronic Acid|Each patient is to receive an initial dose of zoledronic acid of 0.0125 mg per kg body weight, then subsequent doses of zoledronic acid at a dose of 0.025 mg per kg body weight once every 12 to 13 weeks for 104 weeks (total of 8 doses).
223694164|NCT03895242|BEHAVIORAL|Group 1:Supine-Prone|After the infants were treated and fed, supine position was first given and waited for 60 minutes to stabilise (no data was collected during this time). After 61 minutes, it was allowed to stay in supine position for 2 hours. From the 61st minute, heart rate and oxygen saturation were evaluated in each infant in the supine positions at intervals of 15 min over a period of 120 min. At the end of two hours, the infant was given the prone position after the routine requirements such as diaper replacement were completed. Infants were waiting for 60 minutes to stabilize after the prone position (no data was collected during this time). From the 61st minute, heart rate and oxygen saturation were evaluated in each infant in the prone positions at intervals of 15 min over a period of 120 min.
223694165|NCT03895242|BEHAVIORAL|Group 2:Prone-Supine|After the infants were treated and fed, prone position was first given and waited for 60 minutes to stabilise (no data was collected during this time). After 61 minutes, it was allowed to stay in prone position for 2 hours. From the 61st minute, heart rate and oxygen saturation were evaluated in each infant in the prone positions at intervals of 15 min over a period of 120 min. At the end of two hours, the infant was given the supine position after the routine requirements such as diaper replacement were completed. Infants were waiting for 60 minutes to stabilize after the supine position (no data was collected during this time). From the 61st minute, heart rate and oxygen saturation were evaluated in each infant in the prone positions at intervals of 15 min over a period of 120 min.
223694166|NCT01031381|DRUG|RAD001|RAD001 10mg is taken orally (by mouth) once daily on a continuous basis. RAD001 is provided in tablet form and should be taken with a big glass of water on an empty stomach or after a low-fat meal.
223694167|NCT01031381|DRUG|bevacizumab|bevacizumab will be administered intravenously (IV) once every 14 days.
223694168|NCT00537992|PROCEDURE|combined surgery|UV-filter IOL (transparent IOL group) or a blue light-filter IOL (yellow IOL group) combined with a vitreoretinal procedure
223694169|NCT00179543|BEHAVIORAL|Relaxation response|
223694170|NCT06556524|BEHAVIORAL|observation|Behavioral observation and trauma measurement in live mannequin application
223694171|NCT00111982|BIOLOGICAL|Liatermin|Liatermin
223694172|NCT05482542|OTHER|Autologous hematopoietic stem cell transplantation|Autologous hematopoietic stem cell transplantation
223694173|NCT05482542|DRUG|Cyclophosphamide/ATG|Cyclophosphamide/ATG
223694174|NCT05482542|DRUG|Cyclophosphamide/Rituximab|Cyclophosphamide/Rituximab
223694175|NCT05927701|OTHER|Group comparaison|Questionnaires
223694176|NCT06301217|OTHER|There is no intervention|There is no intervention
223694177|NCT01604915|PROCEDURE|Caudal block|After inhalation induction of general anesthesia, caudal block was applied. Patients were randomly assigned in two groups. Normal saline 0.02mL/Kg added to ropivacaine 0.15% 1.5ml/kg was administered to Group R.
223694178|NCT01604915|PROCEDURE|Caudal block|After inhalation induction of general anesthesia, caudal block was applied. Patients were randomly assigned in two groups. Dexamethasone 0.1mg/kg added to ropivacaine 0.15% 1.5ml/kg to Group DR.
223694179|NCT05044091|DRUG|PARP inhibitor|Ovarian/fallopian tube/primary peritoneal cancer patients with PARP inhibitors according to the NCCN guideline and their instructions
223694180|NCT03533101|DRUG|Tocilizumab|IL-6 receptor antibody pre-transplant administration to avoid cytokine release syndrome
223694181|NCT03584100|DEVICE|Tourniquet 8000|Pneumatic tourniquet with appropriate upper extremity cuff, pressure sensing, and ability to set device at 40 mmHg of pressure
223694182|NCT00122109|BEHAVIORAL|12 sessions Anger Management Therapy.|Anger Management Treatment (AMT), a 12-session manual-driven cognitive-behavioral intervention developed and found efficacious for anger management treatment with substance abuse veterans and has been applied to the PTSD population. AMT is highly structured with both psychoeducational and psychotherapy components. AMT is aimed at reducing anger affect and aggression through increasing anger management skills.
223694183|NCT03153956|DEVICE|Calibrated AposTherapy®|a biomechanical device including 2 hemispheric biomechanical elements attached to a platform in a form of a shoe. the biomechanical device is calibrated to each patient by a physiotherapist specialized with the treatment methodology.
223694184|NCT03153956|DEVICE|Non-Calibrated Sham Apos Therapy Device|The comparator group will receive a non-calibrated sham device.
223778505|NCT00001402|DEVICE|PET scan|
223778506|NCT05013892|RADIATION|NTS-WBRT (normal tissue sparing whole brain radiation therapy)|Radiation
223778507|NCT05013892|DRUG|Memantine|Capsule, taken orally
223694185|NCT06556784|BEHAVIORAL|12-week at-home immersive virtual reality exergame|12-week training of at least 150 minutes per week at-home immersive virtual reality exergame playing with a set device of Meta Quest 2 and maintaining regular eating and working habits without making significant changes.
223694186|NCT02224092|DIETARY_SUPPLEMENT|multivitamin multimineral with phytonutrient supplementation|"The multivitamin multimineral with phytonutrient product consists of four tablets per dose, two Vitamin tablets, a Mineral tablet, and a Phytonutrient tablet. The placebo for this trial will be formulated to match the shape and color of all multivitamin multimineral with phytonutrient product tablets, e.g., a Vitamin Placebo, a Mineral Placebo and a Phytonutrient Placebo."
223694187|NCT06352996|OTHER|Three-Dimensional Assessment of Maxillary Canine Retraction with Power Arm|A nickel titanium closed coil spring will be stretched from the mini-implant to the power arm will be used for canine retraction.
223694188|NCT06352996|OTHER|Three-Dimensional Assessment of Maxillary Canine Retraction without Power Arm|A nickel titanium closed coil spring will be stretched from the mini-implant to the canine bracket will be used for canine retraction.
223694189|NCT00002665|DRUG|asparaginase|10,000 units/d IV or IM 15 - 24
223694190|NCT00002665|DRUG|cyclophosphamide|con: 650 mg/m2 IV 1, 15, 29 maint: 650 mg/m2 IV 1
223694191|NCT00002665|DRUG|cytarabine|cons: 75 mg/m2/d IV Push 2 - 5, 9 - 12, 6 - 19, 23 - 26
223694192|NCT00002665|DRUG|daunorubicin hydrochloride|ind: 60 mg/m2 IV 22 and 23
223694193|NCT00002665|DRUG|dexamethasone|main: 10 mg/m2/day PO 1 - 28
223694194|NCT00002665|DRUG|doxorubicin hydrochloride|main: 25 mg/m2 IV 1, 8, 15, and 22
223694195|NCT00002665|DRUG|etoposide|60 mg/kg based on ideal body weight day -3
223694196|NCT00002665|DRUG|leucovorin calcium|5 mg q 6 hours for 4 doses, PO 1, 3, 8, 11 after each methotrexate if WBC \< 3,000 /μl
223694197|NCT00002665|DRUG|mercaptopurine|con: 60 mg/m2 PO 1 - 28
223694198|NCT00002665|DRUG|methotrexate|10 mg/m2 IT or IV, d 2, 9, 16, and 23; Maximum 15 mg/admin
223694199|NCT00002665|DRUG|prednisone|"ind: 60 mg/m2/d PO 1 - 21\*, 22 - 28 Patients will receive full dose through day 8 and then tapered to zero between Day 29 and 42.~ind2: 60 mg/m2/d PO through day 42"
223694200|NCT00002665|DRUG|thioguanine|main: 60 mg/m2/day PO 1 - 14
223694201|NCT00002665|DRUG|vincristine sulfate|ind: 1.4 mg/m2 2 mg max, IV 1, 8, 15, and 22 ind2: 1.4 mg/m2 2 mg max IV 29 and 36 main: 1.5 mg/m2 2 mg max, IV 1, 8, 15, and 22
223694202|NCT00002665|PROCEDURE|allogeneic bone marrow transplantation|day 0
223694203|NCT00002665|RADIATION|radiation therapy|day -7 through day -4 total dose of radiation is 1,320 cGy.
223694204|NCT04396665|BEHAVIORAL|Precam|6 months Web-App intervention related with: diet, physical activity, self-care and breast cacner risk prevention
223778508|NCT05996887|OTHER|standard care protcol|All patients will receive antiemetics as haloperidol 2 mg and dexamethasone 8 mg and ondansetron 8 mg in addition to standard care protocol.
223778509|NCT05996887|OTHER|enhanced recovery protocol|All patients will receive antiemetics as haloperidol 2 mg and dexamethasone 8 mg and ondansetron 8 mg in addition to following the recommendation of ERAS society guidelines.
223778510|NCT05826236|DEVICE|Periarticular compression|Periarticular knee compression using a sphygmomanometer.
223778511|NCT02308202|DRUG|doxazosin|
223778512|NCT02308202|DRUG|Perindopril|
223778513|NCT02308202|DRUG|Placebo|
223694205|NCT00121264|DRUG|sorafenib tosylate|Given orally
223694206|NCT00121264|DRUG|tanespimycin|Given IV
223694207|NCT00121264|OTHER|laboratory biomarker analysis|Correlative studies
223694208|NCT00121264|OTHER|pharmacological study|Correlative studies
223694209|NCT00121264|PROCEDURE|magnetic resonance imaging|Correlative studies
223694210|NCT01395862|DRUG|Salmeterol and Fluticasone|
223694211|NCT02015585|PROCEDURE|interocclusal appliance|Patients will be submitted to the treatment with interocclusal appliances 30 days before the replacement of their complete dentures.
223694212|NCT02015585|PROCEDURE|Relining of the complete dentures|Patients will be submitted to the relining of their old dentures 30 days before the replacement of their complete dentures.
223694213|NCT02015585|PROCEDURE|Complete denture rehabilitation|All patients will be rehabilitated with new complete dentures in the study
223694214|NCT02126371|DRUG|LEO32731|
223694215|NCT03714802|PROCEDURE|Szabo T-Stenting Technique|2-stent strategy was performed using modified T-stenting with Szabo technique in bifurcation lesions. First, stent was implanted in the side branch with Szabo technique. Then, stent was implanted in the main branch. Finally, kissing balloon inflation was performed.
223694216|NCT03714802|PROCEDURE|T-Stenting Technique|2-stent strategy was performed using traditional T-stenting technique in bifurcation lesions. First, stent was implanted in the side branch with angiographic guidance. Then, stent was implanted in the main branch. Finally, kissing balloon inflation was performed.
223694217|NCT03918889|DRUG|Dexmedetomidine Injectable Product|dexmedetomidine infusion at 0.5 µg•kg-1 for 10 min before tracheotomy then adjusted to 0.3µg•kg-1•h-1
223694218|NCT03918889|DRUG|Midazolam injection|midazolam infusion at 0.05 mg•kg-1 ten minutes before tracheotomy then adjusted to 0.02mg•kg-1•h-1
223694219|NCT00267189|DRUG|Everolimus|1.5 mg bid adjusted in order to achieve a trough level between 3 and 8 ng/mL while in combination with CNI and between 6 and 12 ng/mL after CNI discontinuation
223694220|NCT00267189|DRUG|Calcineurin inhibitors (CNI)|
223694221|NCT00267189|DRUG|Mycophenolate acid (MPA)/ Azathioprine (AZA)|
223694222|NCT00267189|DRUG|Steroids|
223694223|NCT04674579|DEVICE|MRI|magnetic resonance imaging
223694224|NCT04240470|PROCEDURE|Thrombectomy|Participants will receive endovascular treatment (mechanical thrombectomy) alone without using IV rt-PA.
223694225|NCT02116218|PROCEDURE|acupuncture|Acupuncture in the Hegu (LI4), Shousanli (LI10), Zusanli (ST36), Yanlinquan (GB34), Taichong (LV3) and Ouch point. Needles would be correctly inserted and manually stimulated until the 'De Qi' sensation is elicited. The needles would stay in place for 15 minutes.
223694226|NCT02116218|PROCEDURE|Vaccaria seed|We put Vaccaria seeds near the acupoints without acupressure as an intervention in control group.
223694227|NCT01556880|BEHAVIORAL|Short Message Service (SMS)|A computer-based text message database was created. Messages prompted subjects to get rid of smoking and eating out, to persevere with the quit smoking attempt with the emphasis on the peer pressure on the smoking cessation by the smoking ban in restaurants. They encouraged them to overcome the barriers of healthy eating diet and physical activity with a block of text messages.
223694228|NCT03458962|GENETIC|Genetic Enrollees|Identification of new genetic diagnoses in children with multiple congenital anomalies, developmental delay, autism, seizures, intellectual disabilities, neurodegenerative disorders and metabolic illness. Samples and data will be stored in a pediatric biorepository. A subset of samples will undergo genetic/genomic analysis.
223694229|NCT02737280|DEVICE|Airvo (TM, Fisher & Paykel Healthcare) - High flow oxygen therapy|High flow nasal cannula therapy with Airvo (TM, Fisher \& Paykel Healthcare) device
223694230|NCT02737280|DEVICE|MedKit Finland - Usual oxygen therapy|Oxygen therapy with normal nasal cannula (for example MedKit Finland) 0-2 l/min
223694231|NCT01031602|BEHAVIORAL|Surveys|Surveys -- Female Sexual Function Index (FSFI), the Hospital Anxiety and Depression Scale (HADS), and a demographic questionnaire completed at time of clinic appointment, taking about 20 minutes.
223694232|NCT00145171|DRUG|apomorphine HCl injection|
223694233|NCT02080910|BEHAVIORAL|Psychoeducation|
223694234|NCT03617354|PROCEDURE|Total Laparoscopic Hysterectomy|The trainee gynaecologists are undertaking a training program in performing Total Laparoscopic Hysterectomy
223694235|NCT00745940|BEHAVIORAL|MBCT for TBI|Subjects will participate in a 10-week Mindfulness-Based Cognitive Therapy Program led by two trained facilitators. Weekly one-and-a-half hour group sessions will guide subjects through exercises such as meditation, awareness, and breathing techniques aimed at developing skills to help with tension, stress, anxiety and depression. Subjects will be encouraged to practice skills at home and in daily life.
223694236|NCT06025305|DIAGNOSTIC_TEST|Intravascular imaging test|Coronary artery disease patients first underwent CCTA and then intravascular imaging test within 3 months
223694237|NCT01287078|DRUG|Cyclosporine Inhalation Solution|sterile, clear, colorless, preservative-free solution of cyclosporine (USP) in propylene glycol developed specifically for administration by oral inhalation.
223694238|NCT02907580|BEHAVIORAL|Local educational information|Participants in this arm receive educational information regarding influenza vaccination based on local educational information.
223694239|NCT02907580|BEHAVIORAL|National educational information|Participants in this arm receive educational information regarding influenza vaccination based on national educational information.
223694240|NCT01578330|DRUG|Fingolimod|Fingolimod 0.5mg orally once a day without food.
223778514|NCT01168934|DRUG|crizotinib|Treatment A: Intravenous dose of 50 mg crizotinib will be administered as directed.
223778515|NCT01168934|DRUG|crizotinib|Treatment B: Oral dose of 250 mg crizotinib as 1 × 50-mg Immediate Release Tablet and 2 × 100-mg Immediate Release Tablets will be administered in the fasted state as directed.
223778516|NCT01504438|DEVICE|Salto-Talaris Total Ankle Replacement|Salto-Talaris Total ankle replacement surgery
223778517|NCT01504438|DEVICE|STAR Total Ankle Replacement|STAR Total Ankle Replacement
223694241|NCT04088643|DEVICE|transcranial alternating current stimulation|The alternating current is administered through medical grade conductive pads that are produced specifically for the Nexalin technology. The pads are places on the forehead and behind each ear, and are connected to the Nexalin device with thin cables. Intervention will be implemented with a tACS device with 4Hz frequency and a peak-to-peak amplitude of 15mA, 30 one-hour sessions in 3 weeks (21 days).
223694242|NCT04088643|DEVICE|sham stimulation|Electrodes will also be put on patient's forehead and behind each ear. The sham stimulator has the exactly same appearance with the true stimulator. Participants and operators cannot determine whether the stimulator is true based on its appearance or patients' feelings. However, when the device is started, no current flows through the electrodes. Participants in this controlled group will also receive sham stimulations with 30 one-hour sessions in 21 days.
223694243|NCT05464550|BEHAVIORAL|Eye tracker|Eye movements on a screen are captured with an eye tracker during a repeated measures before/after a directed autobiographical recall.
223694244|NCT06210464|OTHER||Trial have no Intervention measures.
223694245|NCT04537260|BEHAVIORAL|Educational Video|Those in the intervention arm were asked to watch the 3-minute educational video prior to the knowledge questionnaire and meeting their provider (midwife or obstetrician). The video shown to these participants is linked here: https://youtu.be/Pc9tcIV4Dm8.
223694246|NCT02297243|DEVICE|Sinopsys Lacrimal Stent|The Sinopsys Lacrimal Stent is indicated for use to create a transcaruncular ethmoid sinus access.
223694247|NCT04923815|DEVICE|THERMOCOOL SMARTTOUCH® Diagnostic/Ablation Deflectable Tip Catheter|THERMOCOOL SMARTTOUCH® catheter is a pressure catheter irrigated with cold saline, contact force sensing catheter. When used with Carto ®3 system, this catheter can provide a real time measurement for contact force. The magnitude and direction of the contact force can be displayed visually in the form of vector arrow on the top of catheter in Carto®3 system. It can be used for electrophysiological mapping and ablation of the heart.
223694248|NCT04865640|DIAGNOSTIC_TEST|Noninterventional and noninvasive|The ADI At-Home CPM (Cardiopulmonary Management) System is intended for adults undergoing monitoring for cardiopulmonary conditions under the direction of a licensed medical professional to measure, record, and periodically transmit physiological data.
223694249|NCT03342014|DEVICE|Ultrasound|3DPD and UAD acquisitions (10 min)
223694250|NCT03342014|BIOLOGICAL|Blood sample collection|A blood sampling (20 mL) is collected for biomarker analysis (PAPP-A and PlGF) and biological collection.
223694251|NCT03459261|DIAGNOSTIC_TEST|blood sample on admission (ADD), first postoperative day (POD1) and fourth postoperative day (POD4)|Laboratory analyses of peripheral venous blood on admission (blood sample ADD), 24 hours after surgery (blood sample POD1) and fourth-day after surgery (blood sample POD4) included biochemical analysis, complete blood count, C-reactive protein (CPR), procalcitonin (PCT), albumin/protein level, prothrombin time and international normalized ratio (INR) (only on admission) and for determination of cytokines: tumor necrosis factor alpha (TFN-α), interleukin-6 (IL-6), interleukin-10 (IL-10).
223694252|NCT04376892|OTHER|Quality of life measurement|Quality of life measurement by St. George Respiratory questionnaire
223694253|NCT02672228|DEVICE|MalariaSense device|All participants enrolled in the study will be assessed for malaria using the intervention device called MalariaSense technology
223694254|NCT01632137|DRUG|Rebamipide 2% ophthalmic suspension|Instill one drop into each eye 4 times a day for 4 weeks.
223694255|NCT01632137|DRUG|Placebo (vehicle)|Instill one drop into each eye 4 times a day for 4 weeks.
223694256|NCT05473884|DEVICE|lesion preparation devices|successful recanalization of femoropopliteal artery occlusion and then followed by lesion preparation devices and plain old balloon angioplasty
223694257|NCT05473884|DEVICE|conventional balloon|Lumen gain is achieved by plain old balloon angioplasty under working inflation pressure.
223694258|NCT04647071|DIETARY_SUPPLEMENT|Garlic and onion concentrate|Garlic extract concentrate (equivalent to 2 garlic cloves) and onion extract concentrate (equivalent to 1 onion).
223694259|NCT04647071|DIETARY_SUPPLEMENT|Control|Microcrystalline cellulose
223694260|NCT03830385|DRUG|PaclitaxelPaclitaxel (Albumin Bound),Bleomycin combined with Cisplatin or Carboplatin|All patients enrolled in the study will accept Paclitaxel (Albumin Bound),Bleomycin combined with Cisplatin or Carboplatin as their firstline chemotherapy
223694261|NCT02155569|PROCEDURE|Extraperitoneal Cesarean|Pfannenstiel incision, paravesical approach to lower uterine segment extraperitoneally and Kerr incision for uterine entry
223694262|NCT02155569|PROCEDURE|Transperitoneal Cesarean|Pfannenstiel-Kerr technique for laparatomy and uterine entry
223694263|NCT04648709|DIAGNOSTIC_TEST|ELISPOT|measure of immune response by ELISPOT
223694264|NCT04648709|DIAGNOSTIC_TEST|QUANTIFERON|measure of immune response by QUANTIFERON
223694265|NCT06058403|DIETARY_SUPPLEMENT|20g whey protein drink ingestion|Ingestion of a 300 mL drink containing 20g whey protein
223694266|NCT06058403|DIETARY_SUPPLEMENT|20g native canola protein drink ingestion|Ingestion of a 300 mL drink containing 20g native canola protein
223694267|NCT06058403|DIETARY_SUPPLEMENT|20g processed canola protein #1 drink ingestion|Ingestion of a 300 mL drink containing 20g processed canola protein #1
223694268|NCT06058403|DIETARY_SUPPLEMENT|20g processed canola protein #2 drink ingestion|Ingestion of a 300 mL drink containing 20g processed canola protein #2
223778518|NCT02087800|BEHAVIORAL|F phase lab session|F phase sessions will occur three to seven days post the onset of menses. It will include blood draws, an acute stressor and completion of questionnaires.
223778519|NCT02087800|BEHAVIORAL|L phase lab session|L phase sessions will occur six to ten days prior to the onset of the next expected menses. It will include blood draws, an acute stressor and completion of questionnaires.
223778520|NCT02211989|DRUG|BI 14332 CL|
223778521|NCT02211989|DRUG|Placebo|
223778522|NCT03686774|DRUG|Memantine|"Women provide written informed consent prior to their participation in the study, during their Anesthesiology visit. After baseline assessments (15 days before surgery: Day 0 - 15) of pain intensity, cognitive, quality of life and quality of sleep questionnaires, participants will be randomized in two parallel groups: memantine (n=75) or usual care (n=75). Memantine will be given orally for four weeks starting two weeks before surgery. Endpoints will be assessed 15 days (Day 0 + 15), 3 months (Day 0 + 3 months), 6 months (Day 0 + 6 months) et 12 months (Day 0 + 12 months) post-mastectomy. In order to maintain a good compliance and to verify that women do not develop adverse events, patients will be called once a week by phone. A booklet for monitoring will be completed daily by the patient for 3 months from the day of surgery."
223778523|NCT03686774|OTHER|no memantine|"Concerning the comparator group, patients will be followed in the same way as those in the memantine group except that they will not receive the study treatment"
223778524|NCT02958644|DIETARY_SUPPLEMENT|Synbiotics|12g / day synbiotics (fructo-oligosaccharide and probiotics) supplemented orally for 90 days
223778525|NCT02958644|DIETARY_SUPPLEMENT|Placebo|12g / day placebo (polydextrose) supplemented orally for 90 days
223778526|NCT03503942|BEHAVIORAL|Lifestyle modification|Participants in the treatment arm will receive structured, locally tailored, group-based lifestyle interventions that consist of a core intervention phase (3 months) and a maintenance phase (33 months). The core intervention phase will consist of twice weekly group sessions on nutrition, exercise and goal-setting within the first 6 weeks followed by 6 weeks of self-directed lifestyle modification. During the maintenance phase, the participants will receive monthly short message service (SMS) on health tips as well as 6 monthly telephone calls from program coordinators.
223778527|NCT03503942|DRUG|Metformin|Metformin will be will be prescribed to treatment group participants at highest risk of diabetes conversion (i.e.IFG + IGT or IFG + HbA1c ≥6.0%) after at least 6 months of lifestyle interventions at a starting dose of 250 mg twice a day followed by up-titration to 500 mg twice a day after 3 months if the participants do not experience any gastrointestinal side effects.
223778528|NCT03503942|OTHER|Financial incentives|Participants will be given cash incentives if they meet the weight loss target, which is pre-defined as 5% of baseline weight, at the 3rd, 6th, 12th, 18th, 24th, 30th and 36th month of study period.
223778529|NCT00811083|DRUG|DMSA - dimercaptosuccinic acid|dose of 10 mg/kg bodyweight 3 doses/day, for 3 days, followed by 11 days off
223778530|NCT00352729|DEVICE|ACell dressing|dressing
223778531|NCT00780091|OTHER|classical monitoring strategy|intensive on-site monitoring, consistently with the pharmaceutical industry practices
223778532|NCT00780091|OTHER|optimized monitoring strategy|optimized on-site monitoring, depending on patient's risk
223778533|NCT04163276|DIAGNOSTIC_TEST|18F FDG PET exam|All patients have received 18F-FDG PET/CT in nuclear medicine
223778534|NCT02754167|BIOLOGICAL|PRS-080#022-DP|Hepcidin antagonism to mobilize iron and to treat anemia
223778535|NCT02754167|BIOLOGICAL|PRS-080-Placebo#001|Placebo comparator
223778536|NCT01070810|DRUG|D5W|Dextrose 5%
223778537|NCT01070810|DRUG|Thiamine|Thiamine 200mg in 50ml D5W
223778538|NCT00418171|DRUG|Ziprasidone|
223778539|NCT00418171|DRUG|Olanzapine|
223778540|NCT01260233|OTHER|Smoking cessation program|"Smoking cessation program includes:~* brief smoking cessation counselling by preadmission nurse (less than 5 minutes)~* smoking cessation brochures~* referral to the Smokers' Helpline telephone advice line, run by the Canadian Cancer Society~* free transdermal nicotine replacement therapy for 6 weeks Smokers of 10 cigarettes per day or more receive 4 weeks of nicoderm 21mg/day, 1 week of 14mg/day and 1 week of 7mg/day Smokers of less than 10 cigarettes per day receive 4 weeks of nicoderm 14mg/day and 2 weeks of 7mg/day"
223778541|NCT04498936|DRUG|Sofosbuvir and Ledipasvir|Evaluate the efficacy of Sofosbuvir/Ledipasvir in treatment of COVID-19
223778542|NCT04498936|DRUG|Nitazoxanide|Evaluate the efficacy of Nitazoxanide in treatment of COVID-19
223778543|NCT02418546|BEHAVIORAL|In-Person Nutritional Counseling by a Registered Dietitian|
223778544|NCT02418546|BEHAVIORAL|Nutritional counseling using an e-Health Application|
223778545|NCT01032967|PROCEDURE|Esophagectomy|The patients will receive standard open esophagectomy with two-field lymphadenectomy
223778546|NCT01032967|RADIATION|Definitive chemoradiation|3-weekly cycles of cisplatin and 5-fluorouracil chemotherapy and radical radiotherapy delivered in a three-dimensional conformal mode (total of 50-60 Gy given in 25-30 fractions) will be given over a period 5-6 weeks.
223778547|NCT00893490|DEVICE|Ahmed Glaucoma Valve (AGV)|AGV implantation
223778548|NCT00893490|DRUG|Mitomycin C (MMC)|3 minute MMC application
223778549|NCT00893490|PROCEDURE|amniotic membrane coverage|single layer coverage of amniotic membrane
223778550|NCT05378711|DRUG|Fluoxetine|Children will receive a placebo or fluoxetine at different times dependent upon random assignment to a treatment schedule.
223778551|NCT01927445|OTHER|quality improvement toolkit|educational and informatics-based interventions, including brief guideline summary, decision support and audit and feedback
223778552|NCT05156723|BIOLOGICAL|Subunit recombinant vaccine for the prevention of coronavirus infection|solution for intramuscular injection, 0.5 ml
223778553|NCT05156723|BIOLOGICAL|Placebo|solution for intramuscular injection, 0.5 ml
223778554|NCT05002101|DIETARY_SUPPLEMENT|zinc|The zinc syrup was prepared with a concentration of 7 mg zinc in each 5 ml solution. Accordingly, children with weight more than 10 kg were asked to take 5 ml syrup daily, while children with weight less than 10 kg were asked to take 2.5 ml daily.
223778555|NCT05002101|DRUG|Placebo|Children with weight more than 10 kg were asked to take 5 ml syrup daily, while children with weight less than 10 kg were asked to take 2.5 ml daily.
223778556|NCT04192097|OTHER|Professionalism curriculum|"One year training program including ten two-hours sessions about~* Knowing yourself~* Interaction with patients and their families~* Teamwork and organization with colleagues"
223778557|NCT04823845|DRUG|Topical Adapalene Gel 0.1%|applying Adapalene Gel 0.1% to plantar warts topically
223778558|NCT02801045|BEHAVIORAL|art therapy|"Patient's creativity is stimulated by visual arts materials and various art therapy techniques including punctual use of music, poetry and body expression. The intervention, based on the investigators previous experience, is founded on:~* humanistic phenomenological focus~* transpersonal therapeutic bound~* transdisciplinarity in the artistic approach~* integrative-relational specialized counseling of the grief, loss and trauma aspects."
223778559|NCT02048956|OTHER|Hydrotherapy intervention|Participants randomized to the exercise programme received a training in a swimming pool focused on dance therapy.
223778560|NCT02048956|OTHER|Control group|Standard exercises of hydrotherapy
223778561|NCT04304690|OTHER|blood sample|2 blood samples at T0 and 3 months
223778562|NCT05239091|DRUG|Dextrose solution|A total of 3 doses of dextrose prolotherapy will be administered with an interval of 2 weeks.
223778563|NCT05239091|DRUG|Lidocain|A total of 3 doses of lidocaine will be administered with an interval of 2 weeks.
223778564|NCT05409417|DRUG|Experimental drug|Tilelizumab combined with XELOX and bevacizumab or tislelizumab combined with FOLFOX and cetuximab
223778565|NCT00285753|BEHAVIORAL|support groups|cognitive behavioral intervention with psychoeducation
223778566|NCT00378417|BIOLOGICAL|7-valent pneumococcal-CRM197 conjugate vaccine|
223778567|NCT00378417|BIOLOGICAL|7-valent pneumococcal-OMPC conjugate vaccine|
223778568|NCT03321981|DRUG|Zenocutuzumab|full length immunoglobulin gamma-1 (IgG1) bispecific antibody targeting Human Epidermal Growth Factor Receptor (HER)2 and HER3
223778569|NCT03321981|DRUG|Trastuzumab|humanised IgG1 monoclonal antibody
223778570|NCT03321981|DRUG|Vinorelbine|antineoplastic drug of vinca alkaloid family
223778571|NCT03321981|DRUG|Endocrine therapy|same endocrine therapy is administered as the last line of endocrine therapy
223778572|NCT01339650|DRUG|ABT-767|ABT-767 once or twice daily for a 28 day cycle
223778573|NCT03424876|DRUG|Imatinib 400mg|exposure 400 mg/day or 600mg/day,
223778574|NCT03424876|DRUG|Sunitinib 37.5Mg Oral Capsule|exposure 37.5 mg/day, continuous taking, or 50 mg/day (4/2)
223778575|NCT05927129|DRUG|Antidepressant|Patients will receive standardized treatment with antidepressant, and their treatment efficacy will be assessed by a blinded psychological assessor using validated rating scales. The assessment will be conducted monthly, and evaluations will be tracked for a period of three months.
223778576|NCT05927129|OTHER|Psychotherapy IPT|The participants will receive standardized IPT treatment for 12 weeks. Patients will receive standardized treatment, and their treatment efficacy will be assessed by a blinded psychological assessor using validated rating scales. The assessment will be conducted monthly, and evaluations will be tracked for a period of three months.
223778577|NCT05927129|OTHER|The combination of antidepressant and IPT|The participants will receive standardized IPT treatment for 12 weeks. Also，long-term antidepressant will be administered in accordance with clinical guidelines. Patients will receive standardized treatment, and their treatment efficacy will be assessed by a blinded psychological assessor using validated rating scales. The assessment will be conducted monthly, and evaluations will be tracked for a period of three months.
223778578|NCT04076228|DRUG|Pembrolizumab|pembrolizumab is a PD-1 inhibitor. Treatment and follow up will be performed at Kiang Wu Hospital in their clinical oncology center. Clinically pathological related information will be recorded.
223778579|NCT02628119|PROCEDURE|Intra-procedural access flow|"Intra-procedure access flow technique:~Room temperature saline is injected into the vascular access blood stream during angioplasty via ReoCath(tm) 6 French antegrade or retrograde flow catheters. When the saline is injected into the access, an injection thermistor located close to the proximal end of the catheter records the temperature of the injected saline. A second thermistor located close to the distal tip of the catheter then records the thermodilution within the access and the HVT100 endovascular flow meter calculates and displays intragraft blood flow in ml/min."
223778580|NCT02628119|PROCEDURE|Standard Angioplasty|Intervention based on 2 Dimensional fluoroscopy views
223778581|NCT05720832|OTHER|WINGS-IP1 Smartphone Application|"The technology-based SSIP (WINGS) offers disease-related information and builds up social inner circles between patients, their friends, and family members while facilitating to organize, perform, and enjoy activities and content."
223778582|NCT04689737|DRUG|Doravirine|Participants will be told to take one tablet of doravirine (Pifeltro, MDS) once daily, with or without food, approximately at the day time that they usually finish the hemodialysis sessions. The rest of their antiretroviral regimen and concomitant medications will remain unchanged
223778583|NCT05061446|DRUG|Etrasimod|Etrasimod tablet by mouth, once daily for 12 weeks
223778584|NCT05061446|DRUG|Etrasimod|Etrasimod tablet by mouth, once daily for 12 weeks
223778585|NCT05061446|DRUG|Placebo|Etrasimod matching placebo tablet by mouth, once daily up to 12 weeks
223778586|NCT03880578|DRUG|Levothyroxine Sodium|thyroid hormone replacement
223778587|NCT04934670|DRUG|T-Guard|T-Guard will be administered intravenously inpatient over 4 hours every 2 calendar days on Days 0, 2, 4, and 6, at a dose of 4mg/m2 Body Surface Area (BSA).
223778588|NCT04934670|DRUG|Ruxolitinib|Ruxolitinib will be administered orally twice a day starting on Day 0 through Day 56, at a dose of 10mg. Ruxolitinib taper can be initiated starting on Day 56 for participants responding to treatment, tapering will be done according to institutional practices.
223778589|NCT05447988|DEVICE|Breast Tissue Expander|tissue expander based breast reconstruction
223778590|NCT04240821|DRUG|Theophylline ER|Oral theophylline
223778591|NCT06435871|BEHAVIORAL|Expanded Prostate Cancer Index Composite and Decision Regret Scale|This comprehensive instrument measures urinary, sexual, and bowel symptoms in men treated for prostate cancer. It can provide a detailed view of the patient's quality of life post-treatment.
223778592|NCT01544712|PROCEDURE|core decompression with autologous bone marrow implantation|core biopsy with injection of 40 ml concentrated autologous bone marrow.
223778593|NCT01544712|PROCEDURE|core decompression of the femoral head|core biopsy with injection of 40 ml saline solution in place of bone marrow.
223778594|NCT00420680|DRUG|Sugammadex|Sugammadex, 2.0 mg/kg given as a reversal agent at reappearance of T2 after 0.6 mg/kg rocuronium
223778595|NCT00420680|DRUG|Sugammadex|Sugammadex, 4.0 mg/kg given as a reversal agent at reappearance of T2 after 0.6 mg/kg rocuronium.
223778596|NCT00420680|DRUG|Placebo|Placebo given at reappearance of T2 after 0.6 mg/kg rocuronium
223778597|NCT04519229|BEHAVIORAL|Child-Parent Psychotherapy|Relationship-based trauma focused psychotherapy for Children 0-6 years old and their caregivers. The objective is to decrease symptoms of post-traumatic tress and re-establish a secure attachment for the child and good caregiving from the caregiver/s.
223778598|NCT01852890|DRUG|Ascorbate|Intravenous infusion of high-dose ascorbate
223778599|NCT01852890|DRUG|Gemcitabine|Intravenous chemotherapeutic
223778600|NCT01852890|RADIATION|Radiation therapy|
223778601|NCT02015377|OTHER|High sugar versus low sugar meals|Participants visit our lab for two 8-hour periods with a minimum of two weeks washout in between. In one visit they receive high sugar low fiber meals, in the other they receive low sugar, high fiber meals. The order of meals is randomized
223778602|NCT03653754|DIAGNOSTIC_TEST|Measurement of growth and body composition|Growth (height and body weight), and body composition were measured. For the body composition, Inbody 770 and Inbody S10 were used.
223778603|NCT00861341|DRUG|Aspirin|81 mg
223778604|NCT00861341|DRUG|Pioglitazone|30mg Pioglitazone x1
223778605|NCT03011216|BEHAVIORAL|Adaptive emotional cognitive control training|Is supposed to train ability to continuously update emotional material in working memory.
223778606|NCT03011216|BEHAVIORAL|Adaptive non-emotional feature match task|Does not train updating of working memory content; may train reaction time speed, visual search, or concentration abilities.
223778607|NCT01835782|DRUG|L-Serine|
223778608|NCT01384435|DRUG|KPS-0373|
223778609|NCT01384435|DRUG|KPS-0373|
223778610|NCT01384435|DRUG|KPS-0373|
223778611|NCT01384435|DRUG|KPS-0373|
223778612|NCT01384435|DRUG|Placebo|
223778613|NCT00797953|DRUG|T89|A two-herb botanical drug product in 62.5mg capsule formulation. It is to be used as 125mg or 187.5mg twice daily.
223778614|NCT04015661|DRUG|Nab-paclitaxel|induction chemotherapy with nab-paclitaxel and nedaplatin followed by concurrent chemoradiotherapy
223778615|NCT01916304|DRUG|Levothyroxine sodium new formulation|Levothyroxine tablets
223778616|NCT01863472|DEVICE|HeartLight(TM) Laser Balloon|With the HeartLight(TM) Laser Balloon pulmonary vein isolation is done endoscopically guided
223778617|NCT01863472|DEVICE|irrigated radiofrequency current ablation|The irrigated radiofrequency current ablation is used for pulmonary vein isolation
223778618|NCT05457309|PROCEDURE|malignant fungating wounds care regimen|1\) Preliminary construction of regimen: The researchers summarized the literatures and guidelines about malignant fungating wounds care, and then formed a preliminary draft of the regimen.2) Expert consultation: Experts in malignant fungating wound care, breast cancer and rehabilitation were consulted by email, and the researchers revised the protocol according to the experts' comments, and the final draft was determined after multiple rounds of consultation with experts. 3) Pre-experiment: The researchers investigated the enrolled patients to assess the feasibility of the protocol, and adjusted the content based on the feedback.4) Final Determining: including health records establishment, the intervention time, implementers, location, method and frequency. A wound care team was formed, interventions were carried out in terms of somatic care, wound home care, psychological support, and rehabilitation guidance, and the enrolled patients would be regularly followed by the researchers.
223778619|NCT05793385|OTHER|operative intervention|all patients were operated after being admitted to surgical ward for acute abdomen
223778620|NCT03639480|DRUG|Amlodipine 10mg+Valsartan 160mg+Atorvastatin 40mg|Amlodipine 10mg+Valsartan 160mg+Atorvastatin 40mg
223778621|NCT03639480|DRUG|Amlodipine 10mg+Valsartan 160mg|Amlodipine 10mg+Valsartan 160mg
223778622|NCT03639480|DRUG|Valsartan 160mg+Atorvastatin 40mg|Valsartan 160mg+Atorvastatin 40mg
223778623|NCT04908813|DRUG|HLX22|IV Q3W D1
223778624|NCT04908813|DRUG|Placebo|IV Q3W D1
223778625|NCT04908813|DRUG|Trastuzumab|IV Q3W D1
223778626|NCT04908813|DRUG|Oxaliplatin|IV Q3W D1
223778627|NCT04908813|DRUG|Capecitabine|PO Q3W D1-D14
223778628|NCT03149328|OTHER|Educational Support|In the intervention group, clinicians will be provided with PRO feedback for use in their clinical practice. They will also receive educational support on how to use PRO data at point of care.
223778629|NCT00396734|DRUG|Provigil (Modafinil)|Increase from 100mg to 400mg during 1 month of treatment
223778630|NCT00396734|DRUG|Topamax (Topiramate)|Increase from 25mg to 200mg in one month (double every week)
223778631|NCT01507428|DRUG|18F-Fluoromisonidazole|Undergo FMISO PET/CT (Correlative studies)
223778632|NCT01507428|DRUG|Carboplatin|Given IV
223778633|NCT01507428|PROCEDURE|Computed Tomography|Undergo FDG PET/CT
223778634|NCT01507428|PROCEDURE|Computed Tomography|Undergo FMISO PET/CT (Correlative studies)
223778635|NCT01507428|RADIATION|External Beam Radiation Therapy|Undergo radiotherapy
223778636|NCT01507428|DRUG|Fludeoxyglucose F-18|Undergo FDG PET/CT
223778637|NCT01507428|RADIATION|Image-Guided Adaptive Radiation Therapy|Undergo individualized adaptive radiotherapy
223778638|NCT01507428|OTHER|Laboratory Biomarker Analysis|Correlative studies
223778639|NCT01507428|DRUG|Paclitaxel|Given IV
223778640|NCT01507428|PROCEDURE|Positron Emission Tomography|Undergo FDG PET/CT
223778641|NCT01507428|PROCEDURE|Positron Emission Tomography|Undergo FMISO PET/CT (Correlative studies)
223778642|NCT02114970|OTHER|Randomized- paper consent|
223778643|NCT02114970|OTHER|Randomized- Tablet-delivered consent|
223778644|NCT02114970|OTHER|Focus Group- paper and tablet consent|
223778645|NCT02069561|DIETARY_SUPPLEMENT|Eicosapentaenoic Acid|Twenty patients with long-standing ulcerative colitis undergoing the usual colonoscopic surveillance + biopsy sampling will be recruited. At entry six extra biopsy samples will be collected from the colon. We will also collect blood (for serum, plasma and red cells isolation), urine and stools. Subjects will then receive 2 g/day of Eicosapentaenoic Acid (ALFA ™, SLA Pharma AG, Switzerland) as a supplement for 90 days. At the end of the study each subject will undergo sigmoidoscopy for the collection of 6 biopsies. Blood, urine and stools will be obtained prior to the procedure.
223778646|NCT05053282|OTHER|endurance running exercise|regular competitive or non-competitive running of medium and/or high intensity with the duration at least 20 minutes per session
223778647|NCT02758236|OTHER|No Intervention|No Intervention
223778648|NCT06573138|DRUG|Selinexor, anti-PD-1 antibody plus Golidocitinib|Selinexor, 40mg, qw, po; anti-PD1 antibody, 200mg, d1, i.v. (21d cycle); Golidocitinib, Dose 1, 150mg, qod, po; Dose2, 150mg, qd, po.
223778649|NCT05635747|DEVICE|Relizorb Enzyme Cartridge|Tube feeds run across device to digest fats.
223778650|NCT02741947|DRUG|Levodopa Benserazide Madopar|Madopar 100+25mg and 200+50mg, tablet, tid e qid, for four weeks
223778651|NCT02741947|DRUG|Levodopa Benserazide Teva Italia|Levodopa benserazide Teva 100+25mg and 200+50mg, tablet, tid e qid, for four weeks
223778652|NCT04620434|DEVICE|Video laryngoscopic view|The glottic view on the screen of the video laryngoscope during laryngoscopy with a C-MAC video laryngoscope, which installed with Macintosh blade.
223778653|NCT04620434|DEVICE|Direct laryngoscopic view|The glottic view evaluated by the anesthesiologist who performing tracheal intubation, by direct laryngoscopy with C-MAC installed with Macintosh blade.
223778654|NCT01606982|DRUG|MDV3100|oral
223778655|NCT04689113|BEHAVIORAL|Incontinence Health Belief Development Program|After the applied interventions, it is desired to develop kegel exercise behavior in women.
223778656|NCT05943301|BEHAVIORAL|Self-hypnosis/self-care|Learning phase of self-hypnosis/self-care
223778657|NCT06532539|DRUG|Paclitaxel and Cisplatin|"Paclitaxel and Cisplatin Paclitaxel: 135 mg/m², intravenous infusion, Day 1, every 3 weeks (Q3W). Cisplatin: 75 mg/m², intravenous infusion, Days 1-3, every 3 weeks (Q3W). Duration: 6-8 cycles, until disease progression or intolerable adverse effects as judged by the investigator.~Alternative: If contraindicated for cisplatin, or if there is an allergy to paclitaxel and/or cisplatin, alternative drugs such as different types of paclitaxel or carboplatin can be used."
223778658|NCT06532539|DRUG|Cadonilimab|Cadonilimab: 5-10 mg/kg, intravenous infusion, Day 1, every 3 weeks (Q3W). Duration: Continuous administration until disease progression, death, intolerable toxicity, subject's voluntary withdrawal, investigator's decision for withdrawal, or a maximum of 24 months.
223778659|NCT06532539|RADIATION|Radiotherapy|"Site Selection: Original site, lymph nodes, lung metastasis, bone metastasis, adrenal metastasis, brain metastasis, and other relatively isolated, well-vascularized lesions. Select at least one suitable lesion for radiotherapy based on the impact of the recurrent or metastatic lesion on the body, prioritizing lesions that cause symptoms, are life-threatening, or are expected to cause symptoms.All tumor lesions will be irradiated, which can be done in phases.~Dosage and Fractionation: Conventional or hypofractionated radiotherapy, with a biologically effective dose (BED) of ≥ 72 Gy. Dose adjustments can be made for brain metastases.~Timing: After completing relevant baseline examinations, radiotherapy can be implemented generally after 2-6 cycles of systemic therapy, or after the first cycle for small, solitary metastatic lesions.~echnique: IMRT, TOMO, SBRT, 3D-BT, interstitial implantation therapy, or proton therapy."
223778660|NCT00818441|DRUG|Dacomitinib (PF-00299804)|Dacomitinib (PF-00299804) at 45 mg daily or 30 mg daily by continuous oral dosing, to be escalated in tolerating patients to 45mg after at least 8 weeks of therapy (30 patients in Cohort A started at the lower dose).
223778661|NCT00818441|DRUG|Dacomitinib (PF-00299804)|In Cohort B, patients getting Dacomitinib for first line therapy started at 30 mg, but those who had prior anti-cancer therapy started at 45 mg.
223778662|NCT03856229|DRUG|Conventional steroid regimen|Subjects will receive the conventional steroid regimen with prednisolone or equivalent (with methylprednisolone): Day 1 to 5: 40 mg orally every 12 h; Day 6 to 10: 40 orally every 24 hours; and Day 11 to 21: 20 mg orally every 24 h.
223778663|NCT03856229|DRUG|Shortened steroid regimen|"* Subjects with Moderate PCP. Prednisolone (or equivalent with methylprednisolone) 40 mg orally every 12 h (Day 1 to 5);40 mg orally every 24 hours (Day 6 to 8).~* Subjects with severe PCP. Prednisolone (or equivalent with methylprednisolone) 40 mg orally every 12 h (Day 1 to 5),40 mg orally every 24 hours (Day 6 to 10); and 20 mg orally every 24 h (Day 11 to 14)."
223778664|NCT00228449|DRUG|peginesatide|
223778665|NCT05889936|BEHAVIORAL|Lev|Lev includes three sessions using psychoeducation, motivational interviewing, and applied behavioral analyses. Lev also include two homework assignments. The second session can be repeated if needed. Lev-s and Lev are described in two manuals.
223778666|NCT00522210|DRUG|Detemir|Patients will discontinue their usual bedtime dose of intermediate acting insulin and replace this with the same unit dose of detemir at supper time. The detemir will not be mixed with the rapid acting insulin and will be given as a separate injection. The patient's morning dose of intermediate acting insulin will be decreased by 20% to adjust for the longer duration of action of detemir. Doses of rapid acting insulin will remain the same at breakfast and at supper.
223778667|NCT00522210|OTHER|Novolin NPH or Humulin N|Patients will continue on their usual insulin regimen of insulin three times per day. Intermediate and rapid acting insulin at breakfast, rapid acting insulin at supper, and intermediate acting insulin at bedtime.
223778668|NCT00974428|DIETARY_SUPPLEMENT|Wobenzym® N|4 tablets TID, 6 weeks
223778669|NCT00974428|DIETARY_SUPPLEMENT|Placebo|4 tablets TID
223778670|NCT04292301|DEVICE|STrategically Acquired Gradient Echo (STAGE)|The STAGE package uses conventional 3D gradient echo MR, its magnitude and phase, collected at set parameters which allow for the reconstruction of multiple MR datasets which results in decreased acquisition time, equivalency to conventional MR, and the decrease in scan time allows for a higher standard of wealth within the data acquired.
223778671|NCT05494879|BEHAVIORAL|microkinesitherapy treatment|"The therapeutic session of microkinesitherapy included a seeking of body scares both taking into account somatic dysfunctions as well as psychosomatic disorders. According to the creators of the method, Grosjean and Benini Everything that happens with us in a toxic level, either physically or emotionally, are stored by the brain which keeps memories and generates links that may harm the function of the cells generating a vast array of symptoms and dysfunctions."
223778672|NCT04446663|DRUG|Toripalimab|Toripalimab 240mg ivdrip, every 3 weeks for 6 cycles, with 3 cycles combined with induction chemotherapy, 3 cycles combined with concurrent chemoradiotherapy
223778673|NCT04446663|DRUG|Albumin-bound Paclitaxel|Albumin-bound Paclitaxel 260 mg/m2, d1 of every cycle, every 3 weeks for 3 cycles before radiotherapy
223778674|NCT04446663|DRUG|Cisplatin|Induction cisplatin 80mg/m2, every 3 weeks for 3 cycles before radiotherapy Concurrent cisplatin 100mg/m2, every 3 weeks for 2 cycles during radiotherapy
223778675|NCT04446663|RADIATION|intensity-modulated radiotherapy|Definitive IMRT of ≥66 Gy will be given .
223778676|NCT04159831|DRUG|LTI-01|single-chain urokinase plasminogen activator, scuPA
223778677|NCT04159831|DRUG|Placebo|normal saline
223778678|NCT05676411|DRUG|Benzoyl Peroxide Topical|Topical benzoyl peroxide cream will be applied to the shoulder skin twice a day for 2 days leading up to and in the morning of surgery.
223778679|NCT05676411|PROCEDURE|Electrocautery surgical skin incision|The skin incision will be made entirely using electrocautery at the beginning of shoulder replacement.
223778680|NCT01003418|BIOLOGICAL|GSK2340272A GSK Biologicals' investigational influenza pandemic vaccine|Two doses; intramuscular administration
223778681|NCT01003418|BIOLOGICAL|Infanrix™-IPV/Hib|Routine infant immunisation vaccine, three doses administered intramuscularly
223778682|NCT01003418|BIOLOGICAL|Prevenar|Routine infant immunisation vaccine, three doses administered intramuscularly
223778683|NCT03357042|OTHER|Aerobic exercise and balance retraining|Aerobic and balance exercises that gradually progress in intensity over the course of 8 weeks.
223778684|NCT03357042|OTHER|Standard of care|Normal concussion treatment; physical and cognitive rest
223778685|NCT01418300|DRUG|sequential versus triple|sequential: lansoprazole 30mg bid+amoxicillin 100mg bid for first five day lansoprazole 30mg bid+clarithromycin 500mg bid+metronidazole 500mg for 5day conventional tripe lansoprazole 30mg bid+clarithromycin 500mg bid+amoxicillin 1000mg bid
223778686|NCT02798198|OTHER|T2DM|T2DM without DKD
223778687|NCT00019682|BIOLOGICAL|Aldesleukin|Given IV
223778688|NCT00019682|BIOLOGICAL|gp100 Antigen|Given SC
223778689|NCT00019682|DRUG|Montanide ISA 51 VG|Given SC
223778690|NCT00019682|OTHER|Quality-of-Life Assessment|Ancillary studies
223778691|NCT00019682|OTHER|Questionnaire Administration|Ancillary studies
223778692|NCT00019682|OTHER|Laboratory Biomarker Analysis|Correlative studies
223778693|NCT05360524|PROCEDURE|Laminectomy alone versus laminectomy and fusion|"laminectomy only with expected less operative time, blood loss and restriction of neck motion (compared to laminectomy with fusion). Instrumented fusions also entail the risks of screw misplacement, pseudoarthrosis, distal junction kyphosis, and adjacent segment pathology.~Multi-level laminectomy compromises the posterior tension band and increases the mobility of the neck, resulting in post laminectomy kyphosis and potential dynamic injury to the spinal cord . In contrast, spinal instrumentation and fusion helps to eliminate movement at the treated levels and reduce spinal cord tension with less incidence of kyphosis."
223778694|NCT04309435|BEHAVIORAL|Self-esteem intervention|See relevant study arm for description
223778695|NCT04309435|BEHAVIORAL|Self-stigma intervention|See relevant study arm for description
223778696|NCT04309435|BEHAVIORAL|Jumping to conclusions intervention|See relevant study arm for description
223778697|NCT04309435|BEHAVIORAL|Control procedure (assessment only)|See relevant study arms for description
223778698|NCT03813615|BEHAVIORAL|treadmill walking (Proof-of-Concept)|Individualized, progressive aerobic training consisting of treadmill walking for a total of 150 mins/wk delivered over 5 sessions/wk following a linear dosing schedule for a minimum of 2 weeks. All aerobic training treatment will be implemented and may be monitored using TeleEx. Participants may also perform up to two aerobic training sessions per week in an unsupervised home-based setting. Patients will be provided with Appendix J - Unsupervised Home-Based Exercise Recording Form and Appendix K - Unsupervised Home-Based Exercise Instructions to record their sessions. General physical activity as well as exercise performed outside of the structured treatment sessions will be evaluated via continuous monitoring using MSK approved telemedicine / wireless technology. setting.
223778699|NCT03813615|BEHAVIORAL|treadmill walking Dose-Finding / Escalation|Six doses of aerobic training ( 90mins/wk, 150 mins/wk, 225 mins/wk, 300 mins/wk \& 450mins/wk) delivered following either a standard linear (i.e., each dose of exercise is performed at the same intensity \& duration) or non-linear (i.e., exercise dose is continually altered \& progressed in conjunction with appropriate rest/recovery sessions across the entire intervention period) dosing schedule 3 to 6 times weekly (over a 7-day period) for a minimum 2 weeks. Aerobic training treatment will be implemented \& may be monitored using TeleEx. Patients may also perform up to three aerobic training sessions per week in an unsupervised home-based setting. Patients will be provided a plan for their unsupervised session(s) verbally or via Portal Secure Messaging (PSM), as appropriate.
223778700|NCT05755373|OTHER|No treatment given|No treatment given
223778701|NCT01912248|OTHER|strength training|strength training, lower limb.
223778702|NCT06663410|DEVICE|SPG block with the use of the Tx360 device|A SPG block was performed using the Tx360 nasal applicator according to the manufacturer's instructions bilaterally, injecting 0.3cc of lidocaine 2% into each nostril.
224263504|NCT06034483|OTHER|Pelvic floor exercise training|"* Pelvic floor muscle contraction will be verified with vaginal palpation and a progressive pelvic floor muscle training program will be given.~* In the pelvic floor muscle training program:~* Fast and slow pelvic floor muscle contractions will be taught,~* Training will begin with 3 sets of exercises per day, exercise compliance of individuals will be monitored in the controls to be made every 2 weeks, and the number of exercise sets will be increased by one set.~* 1 set of exercises: It will include 10 fast + 10 continuous (frequent-(3-10 sec) hold-release) contractions.~* Individuals will be tracked with exercise diaries.~* At the end of the 8th week, post-intervention evaluations will be made again.~* The exercise program will be completed with a total of 6 sets of exercises per day (60 fast and 60 slow per day)."
223694269|NCT04585373|OTHER|kinesio-taping with conventional therapy 24 hours|"standardized therapeutic KT application along with conventional therapy (hot pack ,strengthening and stretching exercises) quadriceps tapping: In the supine position, the Y shape tape will be applied from the middle of the thigh to the upper edge of the patella, Then, the tape will anchored to the inner and outer aspect of the patella with 25% muscle tension and the distal end of the strips are positioned on the tibial tubercle without any tension.~McConnell Patellar tapping technique:~The patient will be positioned in long sitting position; affected knee joint exposed. As per McConnell patellar taping technique, tape will applied from superior and lateral patellar borders, maximally pulling it medially. A second strip can be used for reinforcement, but it should not cover the popliteal fossa."
223694270|NCT04585373|OTHER|kinesio-taping with conventional therapy 48 hours|"standardized therapeutic KT application along with conventional therapy (hot pack ,strengthening and stretching exercises) quadriceps tapping: In the supine position, the Y shape tape will be applied from the middle of the thigh to the upper edge of the patella, Then, the tape will anchored to the inner and outer aspect of the patella with 25% muscle tension and the distal end of the strips are positioned on the tibial tubercle without any tension.~McConnell Patellar tapping technique:~The patient will be positioned in long sitting position; position; affected knee joint exposed. As per McConnell patellar taping technique, tape will applied from superior and lateral patellar borders, maximally pulling it medially. A second strip can be used for reinforcement, but it should not cover the popliteal fossa."
223694271|NCT04585373|OTHER|kinesio-taping with conventional therapy 72 hours|"standardized therapeutic KT application along with conventional therapy (hot pack ,strengthening and stretching exercises) quadriceps tapping: In the supine position, the Y shape tape will be applied from the middle of the thigh to the upper edge of the patella, Then, the tape will anchored to the inner and outer aspect of the patella with 25% muscle tension and the distal end of the strips are positioned on the tibial tubercle without any tension.~McConnell Patellar tapping technique:~The patient will be positioned in long sitting position; affected knee joint exposed. As per McConnell patellar taping technique, tape will applied from superior and lateral patellar borders, maximally pulling it medially. A second strip can be used for reinforcement, but it should not cover the popliteal fossa."
223694272|NCT02002390|DRUG|Fingolimod|A sphingosine-1-phosphate receptor regulator
223694273|NCT03114488|DEVICE|tDCS|Transcranial electrical stimulator
223694274|NCT03075046|DEVICE|Blue LED 405 nm|It will be applied a 405 nm blue Tonderm LED with a power of 1.66 W / m2, in a closed room by a physiotherapist for 30 minutes. The apparatus shall be supported on a tripod, statically, externally, 5 cm away from the vulva and vagina region, with the patient naked, in gynecological stretcher and lithotomy position. The protocol will consist of only one session.
223694275|NCT03075046|OTHER|Questionnaire of anamnesis|The participants will answer the anamnesis Questionnaire that will be applied by the physiotherapist
223694276|NCT01225887|DRUG|Nintedanib|Given PO
223694277|NCT01669928|DRUG|Anti-hypertensive Medication -|"Patients will be taking their routine blood pressure lowering medication prescribed by their GP, different patients will be using different blood pressure lowering medication.~Dosing regimen either in the morning (between 06.00 and 11.00) or in the evening (between 18.00 and 23.00)."
223694278|NCT06136247|DIAGNOSTIC_TEST|Neurocognitive battery|The Penn Computerized Neurobehavioral Battery (CNB) consists of a series of cognitive tasks, measuring accuracy and speed of performance in major cognitive domains, including executive functions (i.e., abstraction, sustained attention, working memory), episodic memory (i.e., verbal, facial, and spatial memory), complex cognitive processing (i.e., language reasoning, nonverbal reasoning, spatial processing), social cognition (i.e., emotion identification, emotion intensity differentiation, age differentiation) and processing speed (i.e., sensorimotor and motor).
223694279|NCT06136247|DIAGNOSTIC_TEST|fNIRS|Functional near-infrared spectroscopy (fNIRS) is a noninvasive optical imaging technique that measures changes in oxygenated and deoxygenated hemoglobin (Hb) concentrations within the brain by means of their characteristic absorption spectra of the wavelengths range of 700-1000 nm \[35,36\].
223694280|NCT00925990|DRUG|ribavirin|200 mg capsules, either 1000 or 1200 mg taken twice daily for up to 24 weeks
223694281|NCT00925990|DRUG|CTS-1027|5 and 10 mg tablets, 15 mg taken twice daily, for up to 24 weeks
223694282|NCT00925990|DRUG|Placebo for ribavirin|Capsules identical to ribavirin in appearance containing inactive ingredients
223694283|NCT06637215|PROCEDURE|laparoscopic colorectal day surgery|laparoscopic colorectal day surgery in patients with colorectal tumor who are generally in good health and have sufficient organ functions
223778703|NCT06663150|BEHAVIORAL|health intervention with a socio-community approach|"The intervention consists of five components, including education, cognitive stimulation, physical activity, nutrition, and socio-community aspects. The duration of the intervention will be 6 months and will be conducted in either in-person or virtual format, individually or in groups, depending on the nature of each component. Mode of Delivery:~The intervention will be offered in both in-person and synchronous virtual formats. Participants who are unable to attend in person or who face difficulties doing so on any occasion will have the option to join the sessions through a real-time videoconferencing platform. In both modalities, the professionals in charge will supervise and guide the activities, ensuring proper execution and adherence to the study's objectives. The research team will maintain a detailed record of attendance and participation using the RedCap platform for appropriate tracking."
223778704|NCT06661980|DRUG|Dexmedetomidine Injectable Solution|Dexmedetomidine 200 mcg/ 2 mL IV.
223778705|NCT06661980|OTHER|Placebo|Normal Saline IV.
223778706|NCT06664060|DRUG|osteoimplant|30 lower third molars will be selected and prescribed preoperative treatment with two units of Osteoimplant Complex® 5 days prior to surgery and postoperative treatment with one unit of Osteoimplant® for 8 weeks from the time of surgery. Both nutritional supplements will be administered every 24 hours.
223778707|NCT06664060|DRUG|Placebo|30 lower wisdom teeth will be selected and prescribed placebo, both preoperatively 5 days prior to surgery and postoperatively for 8 weeks from the time of surgery.
223778708|NCT06664580|OTHER|Metabolic Bariatric Surgery Procedures|Observational analysis of various metabolic bariatric surgeries, including LSG, RYGB, and OAGB, focusing on long-term outcomes related to weight maintenance, nutritional health, and patient satisfaction.
223778709|NCT06662903|PROCEDURE|Cranioplasty with Titanium mesh|Cranioplasty using titanium mesh
223778710|NCT06662903|PROCEDURE|Cranioplasty with bone cement|Cranioplasty using bone cement
223778711|NCT06663839|DRUG|Biological NILK-2301|Treatments will be administered every two weeks in 28-day cycles for up to 12 months until disease progression, unacceptable toxicity, or Investigator/patient decision to withdraw study consent. Should evidence emerge showing that treatment beyond one year may prolong benefit in responding patients, the protocol will be amended to ensure that these responding patients may continue with the study treatment beyond 12 months until disease progression.
223778712|NCT07052539|OTHER|High protein and sodium meal|Meal with 1g/kg protein content and 3900mg sodium
223778713|NCT07052500|DIETARY_SUPPLEMENT|Seed Cycling|Daily consumption of 1 tablespoon each of flax and pumpkin seeds during the follicular phase and 1 tablespoon each of sunflower and sesame seeds during the luteal phase
223778714|NCT07052448|DRUG|sequential radiotherapy after the combination of transcatheter arterial chemoembolization (TACE) combined with lenvatinib and anti-PD-1 antibodies|sequential radiotherapy after the combination of transcatheter arterial chemoembolization (TACE) combined with lenvatinib and anti-PD-1 antibodies
223778715|NCT07052357|BEHAVIORAL|Intern Health Study behavioral change mobile notification|The study's mobile app will be used to deliver push notifications. The notifications appear on the participant's phone lock screen. The notifications include 3 categories: mood notifications, activity notifications, sleep notifications. Mood notifications aim to increase the participant's mood. Activity notifications aim to increase the participant's physical activity. Sleep notifications aim to increase the participant's sleep duration. All notifications are categorized as one of five therapeutic approaches: 1) CBT-Behavioral, 2) CBT-Cognitive, 3) Distanced Self-Talk, 4) Mindfulness, 5) Motivational Interviewing.
223778716|NCT07052396|DRUG|Dupilumab|This study will not administer any treatment, only observe the treatment as prescribed in real world clinical practice.
223778717|NCT07051174|DIAGNOSTIC_TEST|MIMS|This study is an extension follow up study conducted in continuation of the prior MIMS® study (see: STUDY ID: MMS EEU-1), in which the long-term (i.e., 28, 36, 42 months) clinical outcomes of Minimally Invasive Micro Sclerostomy System \[MIMS® System\] \[CE Marked device\] are evaluated.
223778718|NCT07051564|BIOLOGICAL|CNK-UT009 cell injection|CNK-UT009 cell injection
223778719|NCT07051421|PROCEDURE|EARLY WARNING SCORE|In the RECO-EWS scoring system we designed; 0-7 low risk, 7-10 medium risk, ≥10 high risk, postoperative stay findings of high-risk patients and, if necessary, new cut-off values are determined for each parameter in the scoring system according to the analysis results.
223694284|NCT06637215|PROCEDURE|traditional laparoscopic colorectal surgery|traditional laparoscopic colorectal surgery in patients with colorectal tumor who are generally in good health and have sufficient organ functions
223778720|NCT07051720|DEVICE|Bilateral implantation of CT ASPHINA 409M|Patients will be implanted with CT ASPHINA 409M during catarct surgery. The CT Asphina 409M has been commercially available for several years and is widely used in clinical practice. Designed with aberration-neutral optical properties, it could improve contrast sensitivity and visual quality. This monofocal aspheric IOL features four-point plate haptics and a one-piece design made from hydrophilic acrylic material with hydrophobic surface properties. It also has an overall diameter of 11 mm and a 6 mm optical diameter. The lens has a sharp posterior optic edge to minimize posterior capsule opacification. It is ideally suited as a comparative referent lens to new EDOF IOLs.
223694285|NCT00835159|DRUG|Rivastigmine Patch|Rivastigmine Patch 4.6 mg/24 hours: 5 cm2 size containing 9 mg rivastigmine applied to upper back preoperatively for a period of 24 hours
223694286|NCT00835159|OTHER|Placebo Patch|A 2x2 gauze and a Tegaderm dressing applied to upper back within 3 hours of surgery for a period of 24 hours.
223694287|NCT04058418|OTHER|Survey Administration|Completion of a short survey.
223694288|NCT00662454|DRUG|ethinyl estradiol / levonorgestrel|Take one tablet daily of 20 mcg ethinyl estradiol/100 mcg levonorgestrel for 21 days plus 7 days of placebo tablets, repeat for two months total duration.
223694289|NCT00662454|DRUG|ethinyl estradiol / levonorgestrel|Take one tablet daily of 20 mcg ethinyl estradiol/100 mcg levonorgestrel for 21 days plus 7 days of placebo tablets, repeat for two months total duration.
223694290|NCT05484908|OTHER|DPMAS+LPE|Patients will receive treatment of double plasma molecular adsorption system (DPMAS) and low volume plasma exchange (LPE) for three times in two weeks. The volume of plasma adsorption in DPMAS is 5000\~6000 millilitre. The volume of fresh frozen plasma used in LPE is 1000 millilitre.
223694291|NCT05484908|OTHER|PE|Patients will receive treatment of plasma exchange (PE) for three times in two weeks. The volume of fresh frozen plasma used in PE is 2000 millilitre.
223694292|NCT05484908|OTHER|Comprehensive internal medical treatment|Patients will receive comprehensive internal medical treatment.
223694293|NCT02595138|DRUG|Zoledronic acid|
223694294|NCT00737438|DRUG|epirubicin, cisplatin, capecitabine, bevacizumab, docetaxel and irinotecan|"Patients with FDG avid locally advanced but resectable gastric or GEJ adenocarcinoma will receive preoperative therapy with epirubicin, cisplatin, capecitabine (ECX), and bevacizumab. Each cycle of therapy is 21 days. Near the completion of cycle 1 of therapy (eg during week 3, target days 18-21), patients will undergo a second FDG-PET/CT scan. Note, patients will hold capecitabine for 48 hours prior to the FDG-PET/CT scan.~Patients with a good metabolic response (eg. \> 35% reduction in FDG uptake at the primary tumor on the week 3 PET scan as compared with baseline FDG uptake) will continue ECX for 2 additional cycles (cycle 2 and 3).~Cycle 2 will be administered with bevacizumab and cycle 3 will be administered without bevacizumab. Patients will then proceed to surgery approximately 4-6 weeks following the completion of cycle 3. There is a 10-12 week time interval (eg. 70-84 days) between the last bevacizumab treatment and surgery."
223694295|NCT01460316|BIOLOGICAL|Bood sampling for biochemicals and genetic analysis|There will be one blood sampling for the nutritionnal, metabolic and genetic parameters studied in the protocol
223694296|NCT03751644|OTHER|Electrical stimulation|Patients with systemic autoimmune myopathies will receive peripheral electrical stimulation in thigh muscles
223694297|NCT00277446|DRUG|Soy isoflavones|
223694298|NCT06438939|OTHER|Biopsy for diagnostical purposes|Incisional biopsy is the current golden standard for OPMD/OSCC diagnosis. Yet, the site it shall be performed is choosen by clinician at naked eyes. We will compare and study the results of performing the common golden standard biopsy site when guided by NBI.
223694299|NCT00917111|DRUG|Nasal CO2|Four times a day for 14 days
223694300|NCT00917111|DRUG|Inactive Placebo Gas|Placebo
223694301|NCT03861650|OTHER|Bone Marrow Aspirate Concentrate|A rich MSCs prepration made by centrifugation and concentration of aspirated bone marrow
223694302|NCT03861650|OTHER|Saline|Physiological saline is added in control group to act as placebo
223694303|NCT04986644|DEVICE|Hioxifilcon A standard hydrogel contact lens with Hyaluronic Acid (HA)|Daily disposable contact lens wear for 1 week
223694304|NCT00431678|DRUG|Avelox (Moxifloxacin, BAY12-8039)|Sequential intravenous/oral (400/400 mg once daily for 7 to 14 days) of Avelox (Moxifloxacin, BAY12-8039)
223694305|NCT00431678|DRUG|Levofloxacin + Ceftriaxone|Intravenous combination therapy of levofloxacin 500 mg twice daily and ceftriaxone (2 g once a day) followed by oral levofloxacin (500 mg twice a day for 7 to 14 days).
223694306|NCT01982565|DEVICE|NOx dressing|The NOx dressing should be changed at least every 2 days.
223694307|NCT01982565|OTHER|Standard of Care|The clinician/podiatrist is free to use whichever treatment they would choose to use on the patient in their current clinical practice.
223694308|NCT00011557|DEVICE|Assistance in Voiding|
223694309|NCT04855864|OTHER|Follow-up of BCR TKA|Pre- and postoperative follow-up of patients treated with the BCR design by measuring PROMs, and clinical- and radiographic evaluation
223778721|NCT07051720|DEVICE|Bilateral implantation of TECNIS Eyhance ICB00|Patients will be implanted with TECNIS Eyhance ICB00 during catarct surgery. TECNIS Eyhance ICB00 is a one-piece, posterior chamber lens with an overall diameter of 13.0 mm and an optic diameter of 6.0 mm. The lens has a spherical posterior surface and a modified aspheric anterior surface that offers a smooth and continuous change in power from the periphery to the center of the lens, without a demarcation zone.
223778722|NCT07051720|DEVICE|Bilateral implantation of AcrySof® IQ Vivity®|Patients will be implanted with AcrySof® IQ Vivity® during catarct surgery. The AcrySof® IQ Vivity® is a single-piece, hydrophobic acrylic IOL that utilizes non-diffractive wavefront-shaping technology (X-wave™) on its anterior surface to achieve an extended range of vision. Its aspheric anterior surface features a 2.2 mm central zone composed of two smooth transition elements: the first forms a slightly elevated plateau (\~1 µm) that stretches the wavefront, while the second shifts the wavefront to create a negative extended focal range. Together, these elements could create advanced and delayed wavefronts resulting in a continuous extended focal range instead of multiple focal points, while optimizing light transmission. This UV-absorbing and blue light filtering foldable IOL has a refractive index of 1.55 at 35 °C, an optic diameter of 6 mm and an overall length of 13 mm. The lens is available in spherical powers ranging from +10.0 to +30.0 diopters.
223778723|NCT07051720|DEVICE|Bilateral implantation of LuxSmart™|Patients will be implanted with LuxSmart™ during catarct surgery. The LuxSmart™ intraocular lens is a single-piece, acrylic hydrophobic and aspheric IOL with an overall diameter of 11 mm, an optical diameter of 6 mm, and a 4-point fixation haptic design. This non-diffractive IOL utilizes a technology known as Pure Refractive Optics (PRO), incorporating a 2.0 mm central EDOF zone that combines fourth- and sixth-order spherical aberrations of opposite signs designed to improve perceived depth of focus. The paracentral region, on the other hand, is a transition zone meant to gradually decrease the optic vergence from the center to the monofocal periphery. It has also a 360° continuous square edge on the posterior surface to prevent epithelial lens cells migration and posterior capsule opacification.
223694310|NCT04855864|OTHER|Follow-up of BCS TKA|Pre- and postoperative follow-up of patients treated with the BCS design by measuring PROMs, and clinical- and radiographic evaluation
223694311|NCT04855864|OTHER|Follow-up of PS TKA|Pre- and postoperative follow-up of patients treated with the PS design by measuring PROMs, and clinical- and radiographic evaluation
223694312|NCT03036605|DRUG|Bupivacaine|%0.5 bupivacaine
223694313|NCT03036605|DRUG|Dexamethasone|8 mg Dexamethasone
223694314|NCT03743974|PROCEDURE|arthroscopic shoulder surgery of rotary cuff (ISB)|ISB were performed in the same manner by one of the two anesthesiologists in our team: (i) patients were monitored, after sedation with sublingual midazolam (0.1 mg/kg) + a single bolus of intravenous (IV) ketamine (0.2 mg/kg); (ii) ultrasound-guidance was carried out using a Kontron® or General Electric® ultrasound machine; (iii) neurostimulation was performed with a Stimuplex HNS® 12 set at 0.1 ms, 1 Hz and 1 mA stimulation, in sentinel mode, with the aim of securing the approach of the needle; (iv) a single perineural injection was performed with a 50 mm Vygon® needle containing a mixture of 100 mg levobupivacaine (20 mL, 0.5%) and clonidine (1 µg/kg patient) as is the local common protocol and in the absence of contraindications.
223694315|NCT03743974|PROCEDURE|arthroscopic shoulder surgery of rotary cuff (CSB)|SCB were performed in the same manner by one of the two anesthesiologists in our team: (i) patients were monitored, after sedation with sublingual midazolam (0.1 mg/kg) + a single bolus of intravenous (IV) ketamine (0.2 mg/kg); (ii) ultrasound-guidance was carried out using a Kontron® or General Electric® ultrasound machine; (iii) neurostimulation was performed with a Stimuplex HNS® 12 set at 0.1 ms, 1 Hz and 1 mA stimulation, in sentinel mode, with the aim of securing the approach of the needle; (iv) a single perineural injection was performed with a 50 mm Vygon® needle containing a mixture of 100 mg levobupivacaine (20 mL, 0.5%) and clonidine (1 µg/kg patient) as is the local common protocol and in the absence of contraindications.
223694316|NCT04926077|DEVICE|DreamKit|The DreamKit device is a single-use device intended to aid the diagnosis of sleep-disordered breathing; however, this study is intended only to validate the respiratory effort signal and does not assess diagnostic performance.
223694317|NCT01038193|OTHER|Cognitive assessment|Cognitive and functional assessments at 2-4 weeks, 3 months and 12 months.
223694318|NCT05736783|OTHER|plyometric exercises|"1. st week Wall touches 3x30 s Split squat jumps 2x40 Lateral cone jumps 2x30 Cone hops with 180 turn 4conesx10~2. nd week Wall touches 4x30 s Split squat jumps 2x40 Lateral cone jumps 2x30 Cone hops with 180 turn 4 cones x 30~3. rd week Wall touches 5x30 s Split squat jumps 2x60 Lateral cone jumps 2x50 Cone hops with 180 turn 4 cones x 30~4. th week Wall touches 5x30 s Split squat jumps 2x60 Lateral cone jumps 2x50 Cone hops with 180 turn 4 cones x 30 Drop jump 45.72 cm 45.72 cm (20)~5. th week Wall touches 5x30 s Split squat jumps 2x60 Lateral cone jumps 2x50 Cone hops with 180 turn 4 cones x 30 Drop jump 45.72 cm 45.72 cm (30)~6. th week Wall touches 6x30 s Split squat jumps 2x70 Lateral cone jumps 2x60 Cone hops with 180 turn 4 cones x 40 Drop jump 45.72 cm (40)"
223694319|NCT05736783|OTHER|strenghtening of quadriceps and hamstring|1st to 3rd week l 4th to 6th week Squat 2x12 3x8 l 3x10 4x6 Knee extension 3x12 3x8 l 2x10 2x6 Nordic hamstring 3x3 3x3 l 3x4 3x4
223778724|NCT07051720|DEVICE|Bilateral implantation of Eyecryl SERT|Patients will be implanted with Eyecryl SERT during catarct surgery. EyeCryl-SERT (Biotech) is a new advanced monofocal, single-piece hydrophobic IOL with an aspheric surface, continuous vision from distance to intermediate, spectacle independence for intermediate vision, an extended range of vision: \>1.75 D at spectacle plane with visual acuity 0.2 LogMAR or better, an intermediate vision up to 57 cm and a design for fast neural adaptation.
223778725|NCT07051720|DEVICE|Bilateral implantation of RayOne EMV|Patients will be implanted with RayOne EMV during catarct surgery. RayOne EMV (Rayner) is a new EDOF lens that has recently emerged in the market. It is a truly non-diffractive, single-piece hydrophilic IOL which does not use light splitting technology like many IOLs which increase depth of focus, resulting in low levels of dysphotopsia, similar to standard monofocal lenses. RayOne EMV is the only patented aspheric IOL that induces controlled positive spherical aberration. Compared to a lens with zero spherical aberration, the carefully controlled positive spherical aberration induced by RayOne EMV spreads light along the visual axis, elongating the focal range from far into intermediate with up to 1.5 D of depth of focus (per lens on the spectacle plane).
223778726|NCT07051694|DEVICE|taVNS|Transcutaneous Auricular Vagus Nerve Stimulation
223778727|NCT07051694|DEVICE|sham-taVNS|sham transcutaneous auricular vagus nerve stimulation
223778728|NCT07051200|BEHAVIORAL|Peer Support Services Recovery|A program of mental health recovery through one-on-one and small group meetings with a PSS and RCOs for individuals recently discharged from an acute care psychiatric facility.
223778729|NCT07051512|DRUG|dexmedetomidine 4μg|patients received (0.5% hyperbaric bupivacaine 12.5 mg + dexmedetomidine 4μg)
223778730|NCT07051512|DRUG|dexmedetomidine 8 μg|patients received (0.5% hyperbaric bupivacaine 12.5 mg + dexmedetomidine 8 μg)
223778731|NCT07051512|DRUG|dexmedetomidine 10 μg|patients received (0.5% hyperbaric bupivacaine 12.5 mg + dexmedetomidine 10 μg).
223778732|NCT07051213|DIAGNOSTIC_TEST|Whole exome sequencing|Whole exome sequencing using Illumina short read sequencing
223778733|NCT07051213|DIAGNOSTIC_TEST|Whole genome Sequencing|Whole genome sequencing using Illumina short read sequencing
223778734|NCT07051343|OTHER|designed artificial intelligence Chatbot education about electronic fetal monitoring|effect of using designed artificial intelligence Chatbot about electronic fetal monitoring on maternity nursing students' performance
223778735|NCT07051343|OTHER|traditional teaching method|the traditional learning method (online meeting).
223778736|NCT07052422|DRUG|Venetoclax (VEN)|Venetoclax (VEN) was administered at 400mg/day on days -10 to -4.
223778737|NCT07052422|DRUG|Decitabine (DAC)|"Decitabine (DAC) was administered at 20mg/m2/day on days~-10 to -8."
223778738|NCT07052422|DRUG|Busulfan (Bu)|"Busulfan (Bu) was administered at 3.2 mg/kg/day on days~-5 to -4."
223778739|NCT07052422|DRUG|Fludarabine (Flu)|Fludarabine (Flu) was administered at 30mg/m2/day on days -5 to -2.
223778740|NCT07052422|DRUG|Fludarabine (Flu)|Fludarabine (Flu) was administered at 30mg/m2/day on days -6 to -2.
223778741|NCT07051551|DEVICE|tooth restoration|restoration of class ııı cavities
223778742|NCT07051551|DEVICE|tooth restoration|restoration of class ııı cavities
223778743|NCT07052136|DRUG|Levetiracetam|Patients were treated with intravenous levetiracetam (LEV) 20 mg/kg over 15 minutes, followed by 60 mg/kg/day in two divided doses over 24 hours.
223778744|NCT07052136|DRUG|Valproic acid|Patients received intravenous valproic acid at 15 mg/kg over 15 minutes, followed by 20 mg/kg/day in two divided doses over 24 hours.
223778745|NCT01639209|PROCEDURE|Vitrectomy|Pars plana vitrectomy plus laser/cryotherapy
223778746|NCT01639209|PROCEDURE|Pneumatic retinopexy|Pneumatic retinopexy plus laser/cryotherapy
223778747|NCT02184468|OTHER|Simultaneously dispatch of firefighters and/or police in case of OHCA|In case of OHCA, firefighters and/or police trained in CPR and equipped with AEDs will be dispatched in parallel with EMS in nine counties in Sweden.
223778748|NCT04577144|OTHER|Online survey only|There are no interventions planned for this study. This is an observational study only.
223778749|NCT02177344|DRUG|Low dose of Ipratropium bromide|One puff, 4 times daily by oral inhalation
223778750|NCT02177344|DRUG|High dose of Ipratropium bromide|One puff, 4 times daily by oral inhalation
223778751|NCT02177344|DRUG|Atrovent|Two puffs, 4 times daily by oral inhalation
223778752|NCT02177344|DRUG|Placebo|
223778753|NCT05710523|BEHAVIORAL|I-ACE training|"The I-ACE training encompasses a training on the non-pharmacological therapies' methodology and a training on awareness of body language which favors a passage from implicit to explicit knowledge. It allows the reading of the subjective relational experience of the care situation by the professional caregiver and a comparison of shared readings of the situation itself by the group of colleagues, and with the residents. Participants will follow:~Two sessions, each lasting 4 hours, on theoretical introduction to the non-pharmacological therapies' methodology; Ten monthly supervisions, each lasting one and half hours, on discussion of clinical cases and implementation of the non-pharmacological therapies with person with dementia.~Ten monthly supervisions, each lasting two hours, on theatrical exercises guided by an expert actor, with the help of a psychologist-psychotherapist who promotes understanding and awareness of self-reading in the relationship with the other."
223778754|NCT05710523|OTHER|Standard non-pharmacological therapies (NPT) training|"The standard NPT training encompasses a training on the non-pharmacological therapies' methodology. Participants will follow:~Two sessions, each lasting 4 hours, on theoretical introduction to the non-pharmacological therapies' methodology; Ten monthly supervisions, each lasting one and half hours, on discussion of clinical cases and implementation of the non-pharmacological therapies with person with dementia."
223778755|NCT03787368|DRUG|BAY1213790|Single intravenous infusion of BAY1213790 (Two different doses)
223778756|NCT03787368|DRUG|0.9% sodium chloride solution|Single intravenous infusion of Placebo (0.9% sodium chloride solution)
223778757|NCT02256501|BIOLOGICAL|Mono Nuclear Cell (MNC) transplantation|Intracoronary administration of autologous bone marrow derived mononuclear cells
223778758|NCT00434720|DEVICE|GlideScope Specific Stylet|
223778759|NCT00824681|BEHAVIORAL|Sound Of Family Together (S.O.F.T.) Music Program|Audio compact disk containing songs, music, special messages, poems from children of adults with major burns
223778760|NCT00824681|OTHER|Non-Therapy Related Activities (NTRA)|NTRA includes non-directed activities e.g. reading books/magazines, watching TV/movie in family lounge off the BICU, playing with toys, listening to music CDs/radio.
223694320|NCT01682668|PROCEDURE|Bilateral subthalamic stimulation|
223694321|NCT06146881|DRUG|Diquafosol sodium 3%|Diquafosol sodium 3% 4 times a day for 4 weeks before cataract surgery and 21 days after surgery
223694322|NCT06146881|DRUG|Sodium hyaluronate 0.1%|Sodium hyaluronate 0.1% 4 times a day for 4 weeks before cataract surgery and 21 days after surgery
223694323|NCT05113095|BIOLOGICAL|Darvadstrocel|Darvadstrocel injection
223694324|NCT04045301|BIOLOGICAL|Omalizumab 16mg/kg|Participants will receive omalizumab 16 mg/kg monthly doses for 12 weeks, followed by omalizumab 8 mg/kg monthly for 4 weeks and then omalizumab 4 mg/kg monthly for 4 weeks, for a total of 20 weeks including a taper period.
223778761|NCT05507268|OTHER|no intervention|no intervention
223778762|NCT02447731|DEVICE|"Induction of sound waves in lungs by sonic oscillator"|A device called sonic oscillator will add sonic waves to the inhaled gases while the subjects are going through 3 tests measuring the variations made in pulmonary functions induced by sound waves.
223694325|NCT04045301|BIOLOGICAL|Omalizumab 8mg/kg|Participants will receive omalizumab 8 mg/kg monthly doses for 12 weeks, followed by omalizumab 4 mg/kg monthly for 4 weeks and then omalizumab 2 mg/kg monthly for 4 weeks, for a total of 20 weeks including a taper period.
223694326|NCT04045301|BIOLOGICAL|Placebo|Participants will receive placebo for 8 weeks prior to the initiation of oral immunotherapy and 12 weeks after for a total of 20 weeks including a taper period.
223694327|NCT04045301|OTHER|Multi-food oral immunotherapy (OIT)|Multi-food oral immunotherapy will be conducted to a mix of three foods. It will be started 8 weeks after study drug with an initial food escalation. Participants will undergo biweekly increase until they tolerate a maintenance dose of 1500 mg (500 mg per food) of food protein.
223694328|NCT02234986|DRUG|ENMD-2076|250 mg oral dose, once daily (QD) for 28 day cycles
223694329|NCT04872218|DRUG|Abatacept|24 week treatment of IV abatacept following recommended dosages from the monograph
223694330|NCT04872218|DRUG|Placebo|24 week treatment of IV placebo following recommended dosages from the abatacept monograph
223694331|NCT04872218|OTHER|Peanut oral immunotherapy|Peanut oral immunotherapy, following a patient-driven protocol, starting 24 to 72h after the first administration of abatacept or placebo.
223694332|NCT06155643|DEVICE|Eko Sensora|The exam involves placing the stethoscope in the aortic, pulmonic, tricuspid, and mitral areas for 15-30 seconds until a green light is displayed indicating that useful sound has been recorded. The recording is then uploaded by the device using wi-fi to the AI program for analysis. It does not carry patient identifiers. The device then indicates whether a clinically significant heart murmur was heard, and if so in which recording.
223694333|NCT04007198|DRUG|EQ001|Itolizumab \[Bmab 600\]
223694334|NCT04007198|DRUG|EQ001 Placebo|EQ001 Placebo
223694335|NCT05712369|OTHER|Blood sampling|"Before the anti-CD20 monoclonal antibodies treatment (e.g. Rituximab/Ofatumumab) and after 6, 9 and 12, 24 months from the first infusion the following blood samples will be collected for the analysis of lymphocyte subpopulations:~* 50/100 mL of blood (20 mL for pediatric patients) for Peripheral Blood Mononuclear Cells (PBMCs) isolation.~* 8 mL of blood (both adult and pediatric) to obtain serum. Serum will be obtained by standard centrifugation and PBMC will be isolated by Ficoll-Paque® density gradient centrifugation, according to manufacturer's instruction."
223694336|NCT04950166|DRUG|pegsitacianine|An intraoperative nanoparticle-based fluorescence imaging agent comprised of micelles covalently conjugated to indocyanine green (ICG).
223778763|NCT00812292|DRUG|TMC278|
223778764|NCT02283528|DEVICE|Stryker Hybrid|Place Hybrid arch bars
223778765|NCT02283528|DEVICE|Erich|Control group is Erich arch bars
223694337|NCT06197347|BEHAVIORAL|Web-based nursing intervention : Ch@ngeons Ensemble|"The web-based nursing intervention, named Ch@ngeons Ensemble, was designed to increase physical activity and quality of life among older adults living with CHD. The intervention will be multicomponent, including educational content, videos, forums, goal planning, an electronic physical activity journal, and virtual written interactions with a nurse. An initial in-person meeting with the nurse will be provided to foster the older adult's commitment to the intervention and help build a relationship of trust. Throughout the intervention, the nurse will asynchronously provide counseling, feedback, and encouragement, and attempt to promote quality of life, knowledge, motivation, and self-efficacy among the older adults."
223778766|NCT03136068|DRUG|Digoxin|Trans-abdominal injection
223778767|NCT03136068|DRUG|Placebo|Trans-abdominal injection
223778768|NCT03189914|DRUG|RX-3117|RX-3117 will be administered orally in combination with Abraxane.
223778769|NCT03505658|BEHAVIORAL|Education and Behavior|Involves 6-weeks of education related to healthy behaviors, nutrition, and exercise.
223778770|NCT01429545|DRUG|Atosiban|Atosiban was given as a bolus (6.7 mg. IV) over 1 min then an infusion of 18 mg/hr for 3 hrs followed by 6 mg/hr for 48 hrs.
223694338|NCT06414096|DRUG|Follicle Stimulating Hormone|Pulsatile FSH administration via a portable pump.
223694339|NCT00063375|BEHAVIORAL|Computer Based Cognitive Behavioral Therapy|
223694340|NCT05920915|OTHER|non-interventional clinical research|This study is a non-invasive clinical trial designed to observe the effect of applying cold to the neck area to effect of venous cannulation pain
223694341|NCT04165642|OTHER|Laser ballon ablation for Pulmonary vein isolation|The patients indicated to AF ablation procedure will be treated with laser balloon ablation without verification of electrical isolation of pulmonary veins using implantable loop recorder and/or Holter monitoring
223694342|NCT03660488|DRUG|Cefixime 400 milligram Oral Capsule [Suprax]|The intervention group will receive Cefixime 400mg, one tablet twice per day, for ten consecutive days
223694343|NCT03660488|DRUG|Benzathine Penicillin G|The control group will receive Benzathine Penicillin G 2.4 Million Units intramuscularly for treatment of syphilis. Penicillin is the indicated treatment for syphilis infection
223694344|NCT00857415|DRUG|florbetapir F 18|Single i.v. bolus injection of 370MBq (10 mCi) followed by saline flush, 50 minutes prior to imaging, 10 minute image duration
223694345|NCT03785288|RADIATION|HDR vaginal brachytherapy|HDR vaginal brachytherapy 7 Gy in 3 fractions or HDR vaginal brachytherapy 4 Gy in 6 fractions
223694346|NCT04766073|PROCEDURE|Niche prevention suture|This group will have the uterus sutured in two layers using a new technique.
223694347|NCT05436223|DRUG|Human CD19Targeted T Cells Injection|A single dose of predetermined level CAR-positive T cells will be infused.
223694348|NCT00554112|BEHAVIORAL|Exercise|Exercise
223694349|NCT01284530|DRUG|TPM XR|Equivalent TDD in XR form, QD, Day 1-14
223694350|NCT03024697|PROCEDURE|Pectoral Plane Block|
223694351|NCT03024697|PROCEDURE|Local Anaesthetic Wound Infusion Catheter|Levobupivicaine 0.1% @10ml/hr via a wound infusion catheter
223778771|NCT01429545|DRUG|Atosiban and nifedipine|This group were given simultaneously as follows:Atosiban was given as a bolus (6.7 mg. IV) over 1 min then an infusion of 18 mg/hr for 3 hrs followed by 6 mg/hr for 48 hrs.Nifedipine was given in the dose of 10 mg orally every 15 min till uterine quiescence was achieved (\<4 contractions/hr). Maximum dose was 40 mg in the first hour then maintenance dose of 10 mg every 4-6 h for 48 hrs was given.
223694352|NCT04623307|DIAGNOSTIC_TEST|Non-contact DCS-Speckle multi-parameter imaging|The protocol consists of 2-min resting, 6-min stationary state and 2-min resting, with monitoring data continuously by the DCS-Speckle.
223694353|NCT03839082|OTHER|Usual Care then FitBit|Usual care is a visit (15-20 mins) every 6-12 months. Usual care includes a Fibroscan (FDA 510(k) device).
223694354|NCT03839082|OTHER|FitBit then Usual Care|Intervention is tailored physical activity and nutritional counseling. Step counts are monitored by a FitBit Zip. A Fibroscan (FDA 510(k) device) is done.
223694355|NCT00764504|DEVICE|Reverse Shoulder Prosthesis|For subjects with rotator cuff arthropathy and no previous shoulder device implanted.
223694356|NCT00764504|DEVICE|Reverse Shoulder Prosthesis|For subjects with rotator cuff arthropathy and a failed hemi or total shoulder implant.
223694357|NCT01200862|DRUG|Investigational new drug company code: BGS649|
223694358|NCT01200862|DRUG|Placebo|
223694359|NCT05397132|GENETIC|Blood draw|Patients will provide a blood draw for research and repository
223778772|NCT03047447|BEHAVIORAL|Dietary Ketosis: Regulator of Obesity and Metabolic Syndrome|30 adults previously diagnosed with MetS randomly prescribed to one of three groups: a sustained ketogenic diet with no exercise, the participant's normal diet with no exercise, or participant's normal diet with 3-5 days per week of exercise for 30 minutes
223778773|NCT00432380|BIOLOGICAL|Rotarix™|oral doses
223778774|NCT00432380|BIOLOGICAL|Placebo|oral dose
223694360|NCT05542186|PROCEDURE|Kinesiotaping|Biomechanical correction for discogenic low back pain using kinesiotaping
223694361|NCT02034071|DRUG|DCCR|
223694362|NCT02034071|DRUG|Placebo|
223694363|NCT00005928|DRUG|Ramipril|
223778775|NCT03019952|BEHAVIORAL|Care Coordination Visit|This is a longitudinal study. Adolescents or young adults with autism will participate in this study. Participants will be required to complete a baseline of assessment measures at enrollment and then monthly assessments (described in the study procedures below) during the first (approximately) 10-15 minutes of each visit with the t-CARE coordinator. The remainder of the visit will focus on care coordination and clinical treatment goals.
223778776|NCT04634201|DIETARY_SUPPLEMENT|Oral probiotics (L. reuteri)|administration of probiotic containing tablets twice daily after tooth brushing for 3 months
223778777|NCT04634201|DIETARY_SUPPLEMENT|Placebo|administration of a placebo twice daily after tooth brushing for 3 months
223778778|NCT01134874|BEHAVIORAL|Standard weight loss intervention|In-person weight loss sessions, dietary intake prescription of 1200-1500 kcal per day, exercise progressing to 300 minutes per week.
223778779|NCT01134874|BEHAVIORAL|Standard weight loss intervention plus technology|In-person weight loss sessions, dietary intake prescription of 1200-1500 kcal per day, exercise progressing to 300 minutes per week, plus technology to provide real-time feedback on energy expenditure, plus a website to log dietary intake.
223778780|NCT01134874|BEHAVIORAL|Technology only|One intervention telephone call per month, dietary intake prescription of 1200-1500 kcal per day, exercise progressing to 300 minutes per week, plus technology to provide real-time feedback on energy expenditure, plus a website to log dietary intake.
223694364|NCT01385007|BEHAVIORAL|Preventing Aggression in Veterans with Dementia (PAVeD)|PAVeD-Telephone consists of three components: pain-management strategies, improvement of patient-collateral communication skills, and behavioral activation through increased pleasant activity planning. The intervention will be primarily geared toward the caregiver; but patients may be involved in some modules, depending on their dementia severity and willingness. The goal of the sessions is to prevent aggression in veterans with dementia. The sessions will include didactics, skill-building, and discussion. Participants will also be provided a copy of the book, Pain Management for Older Adults: A Self-help Guide, as an additional resource for optional reading on the topics covered in the intervention. The intervention is proposed to include six to eight sessions of weekly treatments, lasting 30 minutes to 45 minutes, specifically developed to address the recognition and management of pain in persons with dementia.
223694365|NCT05749211|DRUG|Huaier granule|Oral administration, 20 g once, 3 times a day, continued until progression or intolerance of toxicity
223694366|NCT02687373|BIOLOGICAL|PfSPZ Vaccine|Aseptic, purified, cryopreserved, radiation-attenuated Plasmodium falciparum sporozoites
223694367|NCT02687373|OTHER|Normal Saline|0.9% Sodium chloride
223694368|NCT02914015|PROCEDURE|Continous QLB (quadratus lumborum block)|Inject local anesthetics in between quadratus lumborum and psoas major muscle with catheter insertion and continuous local infusion
223694369|NCT02914015|DEVICE|Philip CX50 Ultrasound Scanner|The curved (C1-5) probe of Philip CX 50 Ultrasound Scanner is used for scan
223778781|NCT04367168|DRUG|Colchicine|Colchicine 1mg, 1 ½ pill in day 1 and ½ pill BID during 10 days in both mild and severe COVID-19
223778782|NCT04367168|DRUG|Placebo oral tablet|Placebo, 1 ½ pill in day 1 and ½ pill BID during 10 days in both mild and severe COVID-19
223694370|NCT02914015|DRUG|Ropivacaine|"* 0.6ml/kg 0.5% ropivacaine with 1:200,000 adrenaline given immediately after the correct position of the tip of the needle has been verified.~* followed with 0.2% ropivacaine infusion at a rate of 0.125ml/kg/h given through the catheter inserted in between the quadratus lumborum muscle and psoas major muscle."
223694371|NCT02914015|DRUG|Morphine given as IPCA|Bolus: 1-2mg, lock time: 10min, 1h limitation: 5-10mg. without background infusion.
223694372|NCT04148833|DRUG|LDE-Paclitaxel|LDE-Paclitaxel at the dose of 175 mg/m2 IV each 21 days for 6 weeks
223694373|NCT04148833|DRUG|LDE-Placebo|LDE-Placebo at the dose of 175 mg/m2 IV each 21 days for 6 weeks
223694374|NCT05423054|OTHER|Abdominal massage|"* Patients will be positioned on their back while their knees will be flexed.~* Each patient will receive a 15-minute abdominal massage intervention half an hour before enteral feeding twice per day and the interval between two massages is 2 hours for consecutive 3 days.~* The PR will be standed on the right side of the patient during the massage practice.~* The abdominal massage technique will be delivered to each patient in four consecutive strokes including stroking, effleurage, kneading and vibration."
223694375|NCT05090462|DEVICE|PICO dressing|Negative Pressure Wound Therapy device
223694376|NCT01726660|DEVICE|IMT Robotic Arm therapy|Interactive Motion Technologies (IMT) planar and wrist robots for robotic arm therapy
223694377|NCT03773445|DIAGNOSTIC_TEST|Golimumab trough levels|Golimumab trough levels taken immediately before the administration of the next subcutaneous dose of golimumab
223694378|NCT03773445|DIAGNOSTIC_TEST|Antibodies to golimumab|Antibodies to golimumab taken immediately before the administration of the next subcutaneous dose of golimumab
223694379|NCT03773445|DIAGNOSTIC_TEST|Histology|Histology of colonic biopsies using the Geboes Index
223694380|NCT03773445|DIAGNOSTIC_TEST|Colonoscopy|Colonoscopy to evaluate the endoscopic activity by a Mayo endoscopic subscore
223694381|NCT03792243|PROCEDURE|Complication|Readmission, reoperation
223694382|NCT05961878|DIETARY_SUPPLEMENT|mediterranean diet with adequate protein intake|balanced mediterranean diet with 1.1 g/kg die protein intake
223694383|NCT05789108|DIAGNOSTIC_TEST|Blood sample and Ultrasound examination|"The ultrasound examination is a non-invasive procedure with no risks, adverse reactions, or discomforts associated with the examination. The study blood samples are mostly obtained at the same time as clinical blood sample collection in order to avoid unnecessary complications.~The inclusion and ultrasound examiniation is performed by the patient responsible physician at the Emergency Department. Blood samples during the study period are performed by trained study staff."
223694384|NCT05716503|DEVICE|Negative Pressure Wound Therapy (NPWT)|Patients Will Receive negative pressure wound therapy dressings before skin grafting to prepare the wound bed and after skin grafting.
223694385|NCT05716503|OTHER|Ordinary dressings with antibiotic ointment and gauze|Patients will Receive once daily dressing with antibiotic ointment and gauze before and after skin grafting.
223694386|NCT06346808|DRUG|Oncolytic virus Plus Anti-PD1 and Chemotherapy|Oncolytic virus，Camrelizumab ，AG（Gemcitabine +Capecitabine ）
223694387|NCT04231318|DRUG|Cingal|Single intra-articular injection of Cingal into the knee.
223694388|NCT04231318|DRUG|Triamcinolone Hexacetonide (TH)|Single intra-articular injection of TH into the knee.
223694389|NCT04231318|DRUG|Placebo|Single intra-articular injection Placebo (0.9% Saline) into the knee.
223694390|NCT00337350|DRUG|rosiglitazone|Rosiglitazone 4mg, one capsule per day for eight weeks
223694391|NCT00337350|DRUG|placebo|matched placebo for rosiglitazone 4mg/day
223694392|NCT00846287|DRUG|Hyperpolarized Helium-3|Patients will be required to breath in individual 1 liter bags of gas while in an MRI to produce lung images. These bags of gas are each made up of 333mL of Helium-3 gas and 667mL of Nitrogen. The first three bags will be administered with a break between each of five to ten minutes. Then the intervention (drug or placebo) will be administered and an hour will pass. Then three additional bags will be administered, again with five to ten minutes between each bag.
223694393|NCT00846287|DRUG|Placebo|Subject will inhale a placebo (nebulized saline) with no drug.
223694394|NCT00846287|DRUG|Aformoterol|Subjects will receive the drug arformoterol prior to scanning
223694395|NCT02852772|BEHAVIORAL|Cognitive function tests|
223694396|NCT01967758|BIOLOGICAL|Cohort 1|Four doses of IV ADU-623 at a dose of 3 x 10\^7cfu
223694397|NCT01967758|BIOLOGICAL|Cohort 2|Four doses of IV ADU-623 at a dose of 3 x 10\^8cfu
223694398|NCT01967758|BIOLOGICAL|Cohort 3|Four doses of IV ADU-623 at a dose of 3 x 10\^9cfu
223694399|NCT01967758|DRUG|Antibiotics|A 3-day course of oral amoxicillin (500 mg three times per day) or trimethoprim/sulfamethoxazole in penicillin-allergic patients (160 mg trimethoprim / 800mg sulfamethoxazole at 12 hour intervals) will be initiated for each patient 3 days following each dose of ADU-623. Patients will receive a 7-day course of antibiotics starting at the end of treatment visit.
223694400|NCT02240290|DRUG|tozadenant tablet|Active substance: tozadenant Pharmaceutical form: Tablet Concentration: 240 mg Route of Administration: Oral administration
223694401|NCT02240290|DRUG|C14-tozadenant capsule|Active substance: C14-tozadenant Pharmaceutical form: Capsule Concentration: 74 kBq (2 μCi) Route of administration: Oral administration
223694402|NCT00557401|DRUG|XP19986 SR3, 20 mg QD|XP19986 Sustained Release (SR) 20 mg tablet taken orally, once daily (QD) for approximately 32 days with titration and taper periods.
223694403|NCT00557401|DRUG|XP19986 SR3, 40 mg QD|XP19986 Sustained Release (SR) 40 mg tablet taken orally, once daily (QD) for approximately 32 days with titration and taper periods.
223694404|NCT00557401|DRUG|XP19986 SR3, 60 mg QD|XP19986 Sustained Release (SR) 60 mg tablet taken orally, once daily (QD) for approximately 32 days with titration and taper periods.
223694405|NCT00557401|DRUG|XP19986 SR3, 30 mg BID|XP19986 Sustained Release (SR) 30 mg tablet taken orally, twice daily (BID) for approximately 32 days with titration and taper periods.
223694406|NCT00557401|DRUG|Placebo|Placebo tablet taken orally for approximately 32 days with titration and taper periods.
223694407|NCT05274139|DRUG|HD-MTX-Ara-C regimen|"HD-MTX-Ara-C regimen high-does metrotrexate 3.5g/m2 d1 ivgtt 6h,cytarabine~1g/m2 bid d2-3.Continued use to the end of chemotherapy .Every 21 days for one cycle and four cycles are required. Efficacy was evaluated every two cycles"
223778783|NCT05385016|BEHAVIORAL|Cooking Skills|This session will consist of a hands-on cooking demonstration in a demo kitchen. Skills addressed in this portion of the session will include proper kitchen utensil and appliance use, measuring dry and wet ingredients, following/reading a recipe, preparing ingredients, cooking a meal, etc. The participant will follow a visual recipe that provides a breakdown of each skill needed to complete each step of the recipe. Additionally, during the cooking session investigators will address nutrition topics related to food/kitchen safety, basic nutrition education (i.e., portion sizes, food groups, reading food labels, meal planning etc.) in a discussion format.
223778784|NCT05385016|BEHAVIORAL|Physical Activity|This session will consist of a group functional fitness class. Each session will include a warm-up (\~5 min) moderate-to-vigorous intensity aerobic and resistance exercise (\~20 min) and cool-down/stretching (\~5 min). Exercises may be accompanied by music and will include walking/jogging, dancing, imitating animal movements, vertical/horizontal jumps, squats, hurdles, walking on balance beam etc. Thera-Band, kettle bells, free weights, and medicine balls will be used during strength exercises for major muscle groups. These sessions will be led by certified personal trainers with experience in adaptive physical activity.
223778785|NCT02627677|DRUG|Ponatinib 30 mg QD|Ponatinib 30 mg, taken orally once daily.
223778786|NCT02627677|DRUG|Ponatinib 15 mg QD|Ponatinib 15 mg, taken orally once daily.
223778787|NCT02627677|DRUG|Nilotinib 400 mg BID|Nilotinib 400 mg, taken orally twice daily.
223778788|NCT05148000|BIOLOGICAL|QM1114-DP|QM1114-DP
223778789|NCT02092948|RADIATION|[124I] PSCA-Minibody PET/CT imaging of the whole body|Whole body Imaging
223778790|NCT03818373|PROCEDURE|polysomnography|Sleep examination strictly non-invasive with skin sensors. This exploration would allow for the detection of respiratory sleep disorders and consider of appropriate management for patients.
223778791|NCT02842775|OTHER|balance perturbation training|perturbation training on the split-belt balance perturbance treadmill,
223778792|NCT03434717|OTHER|Individualised rehabilitation|Patients will get access/support to individualised rehabilitation based on their needs identified through the distress thermometer
223778793|NCT03434717|OTHER|Care as usual|Patients will get care as usual
223778794|NCT02044510|DRUG|Mirabegron|Mirabegron 25mg PO daily for 2 weeks, with dose increase to Mirabegron 50mg PO daily for the remaining 8 weeks.
223778795|NCT02044510|DRUG|Placebo|Matched placebo capsules to the intervention arm
223778796|NCT03971617|DRUG|Hydrogen|each hydrogen tablet contains 80mg magnesium
223778797|NCT03971617|DRUG|Placebo oral tablet|matching placebo tablet
223778798|NCT05242679|OTHER|Myofascial release technique along with conventional physiotherapy exercises|Myofascial release technique was performed using a tennis ball along with conventional physiotherapy exercises.
223694408|NCT05274139|DRUG|FTD regimen|FTD regimen(fotemustine, temozolomide and dexamethasone),fotemustine 100mg/m2 d1 ivgtt,temozolomide 150mg/m2 d1-5 po,dexamethasone 40mg d1-5 ivgtt.Continued use to the end of chemotherapy .Every 28 days for one cycle and four cycles are required. Efficacy was evaluated every two cycles
223778799|NCT05242679|OTHER|Conventional physiotherapy exercises|Conventional physiotherapy exercises were performed including the range of motion/flexibility exercises, strength training, postural control, functional exercises, and gait training.
223778800|NCT03491735|OTHER|collection of data from patient files|recording of patient data and its input into an excel sheet from which statistics will be derived
223778801|NCT06155981|OTHER|Coke Zero|Coca-Cola Zero Sugar drink will be given.
223778802|NCT06155981|OTHER|Coke|Coca-Cola drink will be given.
223694409|NCT05524246|DRUG|Pravastatin|Participants will receive pravastatin orally once daily through the first 35 days after bone marrow transplant.
223694410|NCT04005989|BIOLOGICAL|Stromal Cells Injection|Adipose stromal cell
223694411|NCT02057627|BEHAVIORAL|Perinatal Dyadic Psychotherapy|8-session mother-infant psychotherapy (Perinatal Dyadic Psychotherapy) delivered by nurse-interventionists in participant's homes over 3 months
223778803|NCT02453789|DRUG|Alginate oligosaccharide|Inhalation of dry powder for inhalation (DPI)
223778804|NCT02453789|DRUG|Placebo|
223778805|NCT05020483|DRUG|FEIBA|Administered via the central line catheter after termination of cardiopulmonary bypass if bleeding related to poor clotting develops; in addition, according to conventional protocol blood products will be transfused simultaneously. Three small doses, 5 mg/kg each, will be available.
223694412|NCT02057627|BEHAVIORAL|Placebo Comparator|Standard care plus depression monitoring by phone
223778806|NCT05020483|DRUG|Placebo|Contains no active ingredient and administered via the central line catheter after termination of cardiopulmonary bypass if bleeding related to poor clotting develops; in addition, according to conventional protocol blood products will be transfused simultaneously.
223778807|NCT02998242|DRUG|Apatinib|
223778808|NCT02998242|RADIATION|SBRT to symptomatic bony metastatic bony site(s)|
223778809|NCT00581945|DRUG|Canakinumab|The dose of canakinumab (ACZ885) administered was individualized, based on the subject's weight pre-dose, and was administered via intravenous infusion.
223778810|NCT00581945|DRUG|Placebo|Matching placebo to ACZ885 administered via intravenous infusion.
223778811|NCT02621983|BEHAVIORAL|Aerobic Exercise|Subjects with a diagnosis of SCZ will complete aerobic exercises consisting of spin classes 3 times a week on a stationary bicycle ergometer. Exercise time will progress from an initial 20 minutes per session to a maximum of 45 minutes by increasing 5 minutes each week for 12 weeks.
223778812|NCT02621983|BEHAVIORAL|Balance and Stretching|Subjects with a diagnosis of SCZ will complete a balance and stretching program consisting of progressive whole body stretching and toning exercises. Exercise time will progress from an initial 20 minutes per session to a maximum of 45 minutes by increasing 5 minutes each week for 12 weeks.
223778813|NCT04576169|PROCEDURE|Arthroscopic Debridement|Wrist arthroscopy can be performed with or without irrigation. In the debridement arm, a central or radial TFCC tear found during arthroscopy is debrided with a shaver. Portals are closed either with sutures or with medical tape. Immediate mobilization of the wrist is allowed after the operation. Participants are provided with instructions for home exercises, and they are advised to commence the exercises two weeks post-operation.
223778814|NCT04576169|PROCEDURE|Placebo surgery|Diagnostic wrist arthroscopy can be performed with or without irrigation. A central or radial TFCC tear found during wrist arthroscopy is left untouched and no other operative interventions are done. Portals are closed either with sutures or with medical tape. The procedure is performed in general or regional anesthesia in operating room. Participants are not able to see to the operation area or monitor. They will listen to music with noise-cancelling headphones throughout the operation. The operative time will be matched, with the surgeon simulating a debridement procedure. Immediate mobilization of the wrist is allowed after the operation. Participants are provided with instructions for home exercises, and they are advised to commence the exercises two weeks post-operation.
223778815|NCT04576169|PROCEDURE|Arthroscopic or Open Repair|An ulnar TFCC tear found during wrist arthroscopy is sutured to the capsule or fovea with one of the separately defined methods choosed by the treating hand surgeon. The procedure is performed in general or regional anesthesia in operating room. Wounds are closed and standardized post-operative treatment is started after six weeks.
223778816|NCT04576169|PROCEDURE|Physiotherapy|An ulnar TFCC tear found during wrist arthroscopy is left untouched and no other operative interventions are done. Portals are closed with sutures or medical tape. The procedure is performed in general or regional anesthesia in operating room. Physiotherapy exercises of wrist and DRUJ stabilizers is started after two weeks.
223778817|NCT02387021|PROCEDURE|Continuous femoral nerve block|
223778818|NCT02387021|PROCEDURE|Continuous adductor canal block|
223778819|NCT02387021|PROCEDURE|infragluteal Sciatic nerve block|
223778820|NCT02387021|DRUG|Ropivacaine 0.2%|
223778821|NCT02387021|DRUG|Saline|
223778822|NCT00587587|DEVICE|Apligraf|Application at Day 0, potential re-application at Week 4
223778823|NCT00587587|OTHER|Standard dressing regimen|A primary nonadherent dressing, dry gauze dressing and bolster gauze dressing if necessary
223778824|NCT05430516|OTHER|No intervention|No intervention
223778825|NCT04362358|BEHAVIORAL|Online cognitive behavioral therapy (CBT)|7 sessions of Cognitive Behavioural Therapy (CBT) online + possibility to contact the psychological hotline
223778826|NCT04362358|BEHAVIORAL|Online bibliotherapy programme|online bibliotherapy programme on the Ma Santé website Also with explanatory sheets and tools to improve stress management and the possibility of contacting the Psychological Hotline
223778827|NCT00875394|DRUG|sitagliptin phosphate|sitagliptin 100 mg Once a day (QD) for 24 weeks
223778828|NCT00875394|DRUG|Comparator: metformin|metformin 850 mg Twice a day (BID) for 24 weeks
223778829|NCT00875394|DRUG|Comparator: metformin|metformin 500 mg Three times a day (TID) to 850 mg Twice a day (BID), for 24 weeks
223778830|NCT00875394|DRUG|Comparator: Antidiabetic Standard of Care|Patient can take any oral antidiabetic drug (other than metformin)
223694413|NCT05671328|OTHER|Biological examinations performed on blood and BAL|Direct examination and culture of BAL Galactomannan in serum and BAL Serum 1,3 beta D glucans Aspergillus PCR in BAL
223694414|NCT02406950|DRUG|Sitagliptin|The brachial FMD before and after IR injury will be assessed. After randomization, study medication will be treated. In 2 hours later, the brachial FMD before and after IR injury will be assessed again. All volunteers had a wash-out period of 7 days. Seven days later, the subjects returned to crossover study medication (ie, sitagliptin or placebo), and the protocol described above was repeated.
223694415|NCT05587218|BEHAVIORAL|Self-production|After participants learn L2 lexical items via hearing or observing them paired with L1 translations, they are prompted to produce them themselves
223694416|NCT01638819|BIOLOGICAL|Autologous Cord Blood Stem Cells|One infusion of 60 ml syringe of study product
223694417|NCT01638819|BIOLOGICAL|Placebo|Saline
223694418|NCT00813033|OTHER|patient decision aid for endoscopy|patient decision aid will be administered at the point of decision making
223694419|NCT02795793|DRUG|Non-operative management group (NOM)|With intravenous Piperacillin with Tazobactam (Tazocin)
223694420|NCT02795793|PROCEDURE|Appendectomy group (Operative management, OM)|
223694421|NCT01008631|DRUG|Sodium thiosulfate|6g of Sodium Thiosulfate are applicated in a short infusion over a time of 5 min
223694422|NCT01942473|DEVICE|Automated FiO2 Control|Infants will be ventilated with or without automated FiO2-Control in a randomized sequence.
223694423|NCT04483167|DRUG|99mTccAbVCAM1-5 injection|intravenous injection of 99mTccAbVCAM1-5 with dose increase
223694424|NCT03538431|DRUG|Buspirone|Buspirone is an atypical anxiolytic medication.
223694425|NCT05078502|DIETARY_SUPPLEMENT|Vitamin D3|One capsule of vitamin D3(40000IU) weekly for 8 weeks
223694426|NCT01061632|PROCEDURE|High intensity motor control exercise (deadlift)|12 treatment sessions over a 8 week period is planned for the high intensity motor control exercise.
223694427|NCT01061632|PROCEDURE|Low intensity motor control exercise|12 sessions of low intensity motor control exercises over 8 weeks
223694428|NCT00377000|DRUG|clindamycin 1% / benzoyl peroxide 5% gel pump|
223694429|NCT00377000|DRUG|clindamycin 1% / benzoyl peroxide 5% tube|
223694430|NCT06518902|DRUG|mesenchymal stem cells (umbilical cord) injection|Patients receive mesenchymal stem cells (umbilical cord) injection once or once a week for three consecutive weeks
223694431|NCT00135070|DRUG|Detemir|
223694432|NCT04025281|OTHER|Extra Virgin Olive Oil|Participants will consume a meal prepared with 50 mL extra virgin olive oil. The meals will be prepared and provided to the study participants in the cafeteria of Griffin Hospital, where the Prevention Research Center is located. With the exception of the type of olive oil used in the meals, the meal plan will be comparable in all the intervention phases for the same individual.
223694433|NCT04025281|OTHER|Refined Olive Oil|Participants will consume a meal prepared with 50 mL refined olive oil in the cafeteria of Griffin Hospital. With the exception of the olive oil used, the meal plan will be comparable in each the intervention phases for the same individual.
223694434|NCT05708027|PROCEDURE|Thoracoscopic surgical ablation|Thoracoscopic surgical ablation is a minimally invasive procedure used to treat atrial fibrillation by creation Box Lesion Set using Radio Frequency Energy. Pulmonary veins isolation was performed using ablation clamps, whereas isolation of the posterior left atrium (box) was performed using a clamping Medtronic or a linear nonclamping AtriCure device.
223694435|NCT03359239|DRUG|Atezolizumab|1200 mg administered by IV infusion every 3 weeks (21 \[+/-2\] days) for up to 12 months in the adjuvant setting and up to 24 months in the metastatic setting.
223694436|NCT03359239|BIOLOGICAL|PGV001|"PGV001: up to ten total doses of PGV001with helper peptides. The product is prepared within the ISMMS . The product consists of two independent preparations of patient specific long peptides mixed with poly-ICLC.~A dose of PGV001 consists of the following:~Up to ten synthetic peptides - 100μg (0.01 mL, 10 mg/mL) per peptide. One tetanus helper peptide - 100μg (0.01 mL, 10 mg/mL)"
223694437|NCT03359239|DRUG|Poly ICLC|1.4 mg (0.7 mL, 2 mg/mL)
223694438|NCT03359239|DRUG|Normal saline|0.19 mL
223694439|NCT03327454|BIOLOGICAL|Benepali|Administered as specified in the treatment arm.
223694440|NCT00642720|DRUG|Pegvisomant|if the addition of 40 mg pegvisomant weekly will improve the quality of life of acromegaly patients compared to placebo weekly
223694441|NCT02861989|OTHER|qualitative study|
223694442|NCT02320318|DRUG|Ibodutant 10 mg|Oral tablet, once daily.
223694443|NCT02320318|DRUG|Placebo|Oral tablet (identical in appearance and weight to ibodutant tablet), once daily.
223694444|NCT00287651|PROCEDURE|Pulsatile IV Insulin|Intravenous Insulin is provided in a pulsed manner based upon weekly physician orders the amount of insulin provided is dependent on patients level of insulin resistance.
223694445|NCT00287651|PROCEDURE|Effects of Pulsatile IV Insulin on Diabetic Retinopathy|Control Patients are not given pulsatile intravenous insulin therapy during the study.
223694446|NCT00287651|PROCEDURE|Effects of Pulsatile IV Insulin on Diabetic Retinopathy|Intravenous Insulin is provided in a pulsed manner based upon weekly physician orders the amount of insulin provided is dependent on patients level of insulin resistance.
223694447|NCT03258138|BEHAVIORAL|Health and wellness learning sessions|The health and wellness learning sessions provide a platform for concepts from a variety of health behaviour theories and CBT to be combined with evidence- and practice-based recommendations for healthy lifestyles. They provide the basis for participants' development of an individualized action plan. The sessions will last one hour and participants will receive them in a group setting, 18 times throughout the duration of the program. Specifically, the sessions will be delivered during weeks: 1-8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48.
223694448|NCT03258138|BEHAVIORAL|Brainstorming group sessions|The brainstorming group sessions allow for facilitated discussions where individuals explore barriers and facilitators to achieving their goals and provide an interpersonal component to the program through the building of social interactions. Participants will also receive help in finding community programs to support healthy lifestyles. These sessions will last one hour and participants will receive them in a group setting, 30 times throughout the duration of the program. Specifically, these sessions will be delivered during weeks: 9-11, 13-15, 17-19, 21-23, 25-27, 29-31, 33-35, 37-39, 41-43, 45-47.
223694449|NCT03258138|BEHAVIORAL|Individual sessions with a multidisciplinary health team|Monthly individual sessions with a family physician trained in medical CBT, a dietician and a physical therapist help individuals tailor their action plans and recommendations to their particular circumstances and provide supports based on their needs. The initial session will last 3 hours and occur at baseline. The follow-up sessions will last 1 hour.
223694450|NCT03258138|BEHAVIORAL|Health goal development|Participants in both arms will develop health goals. Several components of these goals will be measured throughout the study, including the stage of change, self-efficacy and actual goal achievement. In the more intensive program arm, participants will develop health goals and learn about how to meet those goals through the group and individual sessions. In the less intensive program arm, participants will receive support in developing health goals from a research assistant trained in theories of health behaviour and in goal setting at baseline, 3 months, 6 months, 9 months and 12 months. The initial goal setting session will be provided within a time period of 2 hours, and the follow-up sessions will be provided within one hour time periods.
223694451|NCT03258138|BEHAVIORAL|Physical activity and nutrition journals|Participants in both arm will be asked to maintain a physical activity journal and a nutrition journal for a week each every three months. These journals help participants reflect on current behaviours and areas for change.
223694452|NCT05182099|DIAGNOSTIC_TEST|Liver MRI|Gd-EOB-DTPA enhanced MRI consists of T2-weighted image (T2WI), diffusion weighted image (DWI) and precontrast T1-weighted image (T1WI), dynamic T1WI (arterial, portal and transitional phases), and hepatobiliary phase.
223694453|NCT02325661|OTHER|cognitive interviewing|"For the individual cognitive interviews we are using the two techniques to think aloud and the verbal probing. To think aloud means, that the patients are asked to express precisely what comes to their mind when reading the single questions. This means, the interviewer is interested in the line of thoughts, which arise when reading the question. Thereby, the problems which appear in the usually covert process of answering a question should be revealed. In a second step, we are using the verbal probing technique to identify possible misunderstandings of the questions or difficulties with single phrases. The interviewer asks further questions that target the patients' interpretation."
223694454|NCT03191240|DRUG|Vasopressins|Administer additional vasopressin 40 IU IV for 2 times during cardiopulmonary resuscitation
223694455|NCT03191240|DRUG|Normal saline|Placebo
223694456|NCT02968511|BIOLOGICAL|fecal microbiota transplant|Fecal microbiota transplant for the treatment of severe, complicated C. difficile infection
223694457|NCT04644536|DEVICE|Bone graft substitute|Orthopaedic or Spine bony defects
223694458|NCT01213550|DRUG|Chlorhexidine gluconate|
223694459|NCT01213550|DRUG|Placebo mouthrinse|
223694460|NCT00124488|DEVICE|Tomotherapy Treatment Planning|
223694461|NCT03219918|DEVICE|EndoRings II Distal Attachment|Colonoscopy cap
223694462|NCT00151853|DRUG|PPSB-SD|
223778831|NCT04684797|BEHAVIORAL|Virtual T-maze task|Patients will have to perform the virtual T-maze task, which is known to elicit reward positivity. During this task, the patients will see a virtual T-maze on a computer screen and have to choose at every junction whether they go right or left. Depending on the direction they choose, they either get positive or negative feedback (reward or no reward). This feedback is chosen completely at random, on a 50% reward/50% no reward basis.
223778832|NCT02278497|OTHER|ASSESSMENT OF CORONARY FLOW RESERVE BY PET-H215O AND FFR|
223694463|NCT01498835|DRUG|Sunitinib|"Patients will receive Sunitinib daily for 2 weeks prior to and then concurrently with irradiation as neoadjuvant treatment. Radiotherapy will be given as intensity modulated radiation therapy with a total dose of 50.4Gy in 28 fractions to each patient (5 1/2 weeks).~Sunitinib will be given in two dose levels. The first dose level will be 25mg Sunitinib per os daily. The second dose level will be 37.5mg sunitinib per os daily. A dose modification schedule according to a 3+3 design will be applied for patient accrual."
223778833|NCT01693224|DEVICE|"Alere Determine lateral-flow urine lipoarabinomannan assay"|"lateral-flow (point-of-care) urine test to detect the lipoarabinomannan (LAM) component of the M. tuberculosis antigen in the urine of TB suspects, in vitro.~Manufacturer: Alere"
223778834|NCT01693224|DEVICE|"Alere Clearview ELISA urine LAM assay"|"ELISA-based urine test to detect the lipoarabinomannan component of the M. tuberculosis antigen in the urine of TB suspects, in vitro.~Manufacturer: Alere."
223778835|NCT01693224|DEVICE|Cepheid Xpert MTB/Rif assay|
223778836|NCT04494919|DEVICE|Ultrafine Endoscope|The reversal of the normal colonoscope (CV-260SL; Olympus, Tokyo, Japan) along the guidewire to replace the UFE (GIF-XP260NS; Olympus, Tokyo, Japan).
223778837|NCT01933334|DRUG|Pirfenidone|Pirfenidone will be administered orally at a dose of 267 mg one oral capsule TID (801 mg/day) for 1 or 2 weeks followed by two 267 mg oral capsules TID (1602 mg/day) for 1 or 2 weeks (titration period) and then three 267 mg oral capsules TID (2403 mg/day) for 12 weeks (maintenance period).
223778838|NCT00927745|DEVICE|AutoFlow mode on Evita 4 Dräger ventilators|Activation of AutoFlow mode during assist-controlled ventilation
223778839|NCT00927745|DEVICE|Evita 4 Dräger ventilators|Assist-controlled ventilation without activation of AutoFlow mode
223778840|NCT02048761|DRUG|Placebo gel|After debridement, a single dose of the placebo gel was applied into the periodontal pockets with a syringe and a blunt canula
223778841|NCT02048761|DRUG|1 % Metformin gel|After debridement, 1% Metformin gel gel was applied into the periodontal pockets with a syringe and a blunt canula.
223694464|NCT01216124|DRUG|docetaxel oxaliplatin|"docetaxel 75mg/m2 D1 oxaliplatin 130mg/m2 D2~1 cycle=21 days DO\*6"
223694465|NCT01743456|OTHER|Targeted intra-operative depth of anaesthesia|The intervention group receives isoflurane at a concentration that results in a BIS value between 40-60 intra-operatively.
223694466|NCT02557659|DEVICE|Zenith Low Profile AAA Endovascular Graft|Treatment of patients with abdominal aortic, aorto-iliac, or iliac aneurysms having morphology suitable for endovascular repair
223694467|NCT03518931|DIAGNOSTIC_TEST|Fitness testing|The intervention in this study was measuring cardiorespiratory fitness and muscular strength and providing normative data to subjects.
223694468|NCT00417573|DRUG|IV Gamunex 10%|
223694469|NCT00402272|DEVICE|XIENCE V® Everolimus Eluting Coronary Stent|Drug eluting stent implantation stent in the treatment of coronary artery disease.
223694470|NCT01785407|DIETARY_SUPPLEMENT|Iron Supplement (Ferrous Sulfate Dried)|Iron supplements of varying concentration will be administered to the four groups in the study. Iron bioavailability from the supplements will be assessed.
223778842|NCT00585897|BEHAVIORAL|discontinuation of sugar sweetened beverages|Individual sessions which utilize motivational interviewing to assist participants to eliminate sugar sweetened beverages from their diet.
223778843|NCT03454594|DEVICE|low level laser hemotherapy|semiconductor laser therapeutic instrument irradiate the circulating blood in the vessels of left hand acupoint and the mucosal tissue in the nasal cavity
223778844|NCT05027191|DIAGNOSTIC_TEST|Neutrophil Gelatinase-Associated Lipocalin (NGAL)|The evaluation of inhalational anesthetics (desflurane and sevoflurane) on NGAL levels in laparoscopic cholecystectomy patients.
223778845|NCT05027191|DRUG|Desflurane|Desflurane
223778846|NCT05027191|DRUG|Sevoflurane|Sevoflurane
223778847|NCT06635460|OTHER|Motivational interviewing|This programme has been developed from the literature and structured according to expert opinion. It will consist of a total of 8 online sessions. The duration of the motivational interviewing sessions will be limited to 30-45 minutes, in line with the literature.
223694471|NCT03911154|DEVICE|Philips SmartSleep Technology--Continuous Fixed Interval modality|"During the 4 nights of sleep restriction (5 hours time in bed), subjects will have one of the following SmartSleep stimulation modalities each night in a randomized order. All subjects will receive all 4 stimulation modalities:~1. Continuous Fixed Interval~2. Block~3. In-Phase Adjustable~4. Sham: No auditory stimulation while wearing the SmartSleep headband"
223778848|NCT06635460|OTHER|Social media-based patient monitoring|Blood glucose results, lowest and highest values, and reasons will be included in the content of the patient follow-up, which will be conducted at intervals on the WhatsApp platform. There will be a total of 10 follow-ups. Although the duration of the written dialog will vary among adolescents, it will be limited to an average of 2-10 minutes.
223778849|NCT02999308|OTHER|Observe the patient's condition and then change the regimen|The patients will be assessed every 3 months and the treatment regimen will be modified by the result of assessment.
223778850|NCT00119444|PROCEDURE|Periacetabular osteotomy|osteotomy of the pelvis to increase acetabular coverage
223778851|NCT06635421|OTHER|Model of care delivery for long-acting injectable ART|This study is assessing a novel model of care delivery, i.e. pharmacist administered long-acting cabotegravir + rilpivirine (CAB+RPV LA). In phase 2 and 3, no medication will be provided by the study. The decision to initiate CAB+RPV LA will be at the discretion of the patient and their provider in accordance with both standard of care and local prescribing practices. This will occur independent of study participation. The study intervention is the model of care for CAB+RPV LA administration. The models of care being studied include (1) pharmacist administered CAB+RPV LA in MetroHealth satellite pharmacy setting (novel model of care); (2) nurse administered CAB+RPV LA in the Infectious Diseases clinic at MetroHealth main campus (current standard of care).
223778852|NCT00030550|DRUG|thalidomide|
223778853|NCT03229551|DRUG|Xylitol|Topical 5% Xylitol (wt/vol) diluted in saline nasal irrigant. Topical corticosteroid and antibiotic as directed by bacterial DNA sequencing results will be diluted in this irrigant and administered concurrently.
223778854|NCT03229551|DRUG|Saline|Saline as a standard-of-care nasal irrigant. Topical corticosteroid and antibiotic as directed by bacterial DNA sequencing results will be diluted in this irrigant and administered concurrently.
223778855|NCT05237622|DEVICE|High Flow|Standard HighFlow therapy after weaning from continuous positive airway pressure therapy will be applied on different flow levels. Starting with a flow level of 8l/min, the flow-rates will be changed every 30 minutes subsequently from 8-6-4-2-4-6-8 l/min. Meanwhile, data on lung volume changes will be measured using electrical impedance tomography.
223778856|NCT05668182|PROCEDURE|TRUMATCH Graft Cage|TRUMATCH Graft Cage for surgical repair of segmental long bone defect
223778857|NCT03788889|DRUG|Ketamine|Ketamine infusion
223778858|NCT03788889|DRUG|Phenobarbital|Phenobarbital intravenous injection
223778859|NCT03788889|DRUG|Lorazepam|Standard of Care
223778860|NCT03788889|DRUG|Placebo A|Placebo injection
223778861|NCT03788889|DRUG|Placebo B|Placebo infusion
223778862|NCT02032901|DRUG|Daclatasvir|
223778863|NCT02032901|DRUG|Sofosbuvir|
223778864|NCT00444158|DRUG|MOA-728|
223694472|NCT03911154|DEVICE|Philips SmartSleep Technology--Block modality|"During the 4 nights of sleep restriction (5 hours time in bed), subjects will have one of the following SmartSleep stimulation modalities each night in a randomized order. All subjects will receive all 4 stimulation modalities:~1. Continuous Fixed Interval~2. Block~3. In-Phase Adjustable~4. Sham: No auditory stimulation while wearing the SmartSleep headband"
223778865|NCT01722331|DRUG|Tildrakizumab 200 mg|Two tildrakizumab 100 mg/mL pre-filled syringes (PFS)
223778866|NCT01722331|DRUG|Tildrakizumab 100 mg|Tildrakizumab 100 mg/mL PFS
223778867|NCT01722331|DRUG|Matching Placebo|Matching placebo to tildrakizumab PFS
223778868|NCT04485403|DRUG|Ibuprofen|800 mg/day ( 2 x 400mg) for 3 weeks in women with a bodyweight \<70 kg, and a dose of 1200 mg/day (3x400mg) in women weighing\> 70kg. The effects of treatment will be compared on the basis of changes in the hormonal profile and inflammatory markers, as well as the clinical assessment of the patient.
223778869|NCT04419636|DRUG|Lu AG06466|capsules, orally
223778870|NCT02799433|BEHAVIORAL|Usual services + HAP|The HAP process includes child care center providers completing a self-assessment(s), setting improvement goals, receiving technical assistance materials, attending topic-specific workshops, improving best practices, re-self-assessment and qualification for a HAP award.
223778871|NCT02799433|BEHAVIORAL|Usual services|Control condition
223778872|NCT05739747|OTHER|Questionnaire|"All patients should complete the following questionnaires:~On the day of surgery:~* Patient registration.~* Complete medical history.~* Gendolcat scale (including the Spanish version of the SF-12 scale).~* Spanish version of the catastrophizing scale."
223778873|NCT05739747|OTHER|Questionnaire|The investigators should complete a questionnaire during the surgical procedure specifying the anesthetic technique used, drugs and doses used and record any incident during the surgical procedure
223778874|NCT05739747|OTHER|Questionnaire|The investigators should complete a questionnaire 24 hours after surgery to assess the possible presence of postoperative pain as well as the intensity and need for rescue analgesia.
223694473|NCT03911154|DEVICE|Philips SmartSleep Technology--In-Phase Adjustable modality|"During the 4 nights of sleep restriction (5 hours time in bed), subjects will have one of the following SmartSleep stimulation modalities each night in a randomized order. All subjects will receive all 4 stimulation modalities:~1. Continuous Fixed Interval~2. Block~3. In-Phase Adjustable~4. Sham: No auditory stimulation while wearing the SmartSleep headband"
223694474|NCT05560035|DRUG|Lidocaine|Intravenous bolus of 1.5 mg/kg of lidocaine followed by a continuous infusion of 3.0 mg/kg for the frst hour, 1.5 mg/kg for the second hour, 0.7 mg/kg for the next 22h.
223694475|NCT05560035|OTHER|Normal saline (NS)|Patients are received equal volumes of saline intravenously until the end of the surgery
223694476|NCT00023244|DRUG|Basiliximab|Administered as a bolus intravenous injection. The first dose is given pre-operatively, the second dose is given on post-transplant day four. Dosage is determined by individual weight.
223778875|NCT05739747|OTHER|Questionnaire via telephone call|At 3 months, patients will be called and a structured questionnaire will be completed to assess the presence of chronic postoperative pain.
223694477|NCT00023244|DRUG|Cyclosporine|Participants receiving cyclosporine microemulsion formula (in lieu of tacrolimus) will have the dose adjusted to maintain a whole blood trough Abbott TDx assay monoclonal level of 175-400 ng/mL (or an equivalent high pressure liquid chromatography (HPLC) level) for the first 2 weeks after transplant. The dose will subsequently be tapered to maintain a trough level of 175-300 ng/mL from week 3 to month 3, and 50-250 ng/mL from month 3 through the end of the study at month 36 (year 3).
223694478|NCT00023244|DRUG|Tacrolimus|Participants receiving tacrolimus (in lieu of Cyclosporine) will have the dose adjusted to maintain a whole blood trough level between 10 and 15 ng/mL for the first 4weeks after transplant. Trough levels will be maintained between 5 and 10 ng/mL thereafter throughout the duration of the study.
223778876|NCT05739747|OTHER|Physical examination|Those women who, after the telephone call, are considered to have chronic post-surgical pain will undergo a physical examination to confirm it. The type of pain and its intensity will also be evaluated. The impact on their daily physical activity and quality of life will be evaluated by means of a questionnaire.
223778877|NCT01194115|DRUG|cephalexin & metronidazole|cephalexin at 500 mg per oral every 8 hours for a total of 6 doses
223778878|NCT01194115|DRUG|placebo|placebo representing standard of care
223778879|NCT03931577|DIAGNOSTIC_TEST|C-reactive protein rapid testing|Continuous (workshop and monthly web-based training) disease-focused intervention with the provision of CRP rapid testing in the primary care practices.
223778880|NCT03931577|PROCEDURE|Communication skill enhancement|Continuous (on-site and monthly online training) illness-focused intervention (enhancement of communication skills to optimise doctor-patient consultations and share decision making with the aid of patient-centred leaflets) in the primary care practices.
223778881|NCT02505932|PROCEDURE|Arthroscopic Latarjet procedure|arthroscopic approach (set Depuy-Mitek, Raynham, MA)
223778882|NCT02505932|PROCEDURE|Mini-open Latarjet procedure|mini-open approach (set Arthrex, Naples, FL)
223778883|NCT03669003|BIOLOGICAL|Gelfoam slurry|Approximately 1-2cc of Gelfoam slurry will be used to lace the needle track.
223778884|NCT03669003|PROCEDURE|CT-guided percutaneous lung biopsy|Biopsy of a lung nodule under CT guidance.
223778885|NCT04564833|DRUG|Low Dose RBT-1|intravenous administration
223778886|NCT04564833|DRUG|High Dose RBT-1|intravenous administration
223778887|NCT04564833|DRUG|Placebo|intravenous administration
223778888|NCT02672904|DEVICE|CO2 laser|surgical removal of carcinoma from the vocal cords with CO2 laser
223778889|NCT02672904|DEVICE|KTP laser|surgical removal of carcinoma from the vocal cords with KTP laser
223778890|NCT06063629|PROCEDURE|Subcutaneous drain|The drain will be inserted into subcutaneous layer of the surgical wound. Redivac drain will be used in this study.
223778891|NCT06063629|PROCEDURE|No drain|No drain will be inserted into patients allocated to this group
223778892|NCT01998373|BEHAVIORAL|training leaflet and oral training|The intervention consisted of training leaflet and oral training. All of the patients were new cases and were divided into 2 groups. All patients were treated with routine medication, no addition medication for two groups were done, the case group attended the workshops and were trained In addition to medical therapy, continuing education and training workshop. The result of the effect of workshop was also filling out a questionnaire before and after training. Finally, two groups with statistical analysis were compared.
223778893|NCT00709163|DRUG|Nesiritide|The patient will be given an initial bolus of 1mcg/kg and then placed on a continuous infusion of 0.01mcg/kg/min. Three hours after the start of the infusion the patient will be rebolused with 1mcg/kg and increase the continuous infusion to 0.015mcg/kg/min. This will occur again at 6 hours after the start with an increase in the continuous infusion rate to 0.02mcg/kg/min. Patients will continue on the study drug for a total of 24 hours.
223778894|NCT00709163|DRUG|5% Dextrose|The patient will be given an initial bolus of 1mcg/kg and then placed on a continuous infusion of 0.01mcg/kg/min. Three hours after the start of the infusion the patient will be rebolused with 1mcg/kg and increase the continuous infusion to 0.015mcg/kg/min. This will occur again at 6 hours after the start with an increase in the continuous infusion rate to 0.02mcg/kg/min. Patients will continue on the study drug for a total of 24 hours.
223778895|NCT01686711|DRUG|AD-4833 15 mg|
223778896|NCT01686711|DRUG|AD-4833 30 mg|
223778897|NCT01686711|DRUG|Placebo|
223778898|NCT02855060|DEVICE|Pelvic Binder|
223778899|NCT03826277|OTHER|Melanostop peel|"Melanostop peel treatments containing 20% azelaic acid, 10% resorcinol, 6% phytic acid, 3% tranexamic acid. (4 treatments, performed at 2-week intervals), in combination with home care products (twice daily):~* a facial tonic and cream containing brightening ingredients: vitamin C, niacinamide, alpha arbutin, kojic acid,~* sunscreen protection cream with SPF 50, protecting against UVA, UVB, HEV and IR"
223778900|NCT03697291|DEVICE|PS wire|The wiring connection used to convey ECG signal from inside the body
223778901|NCT01054729|DRUG|Sofosbuvir|Sofosbuvir tablet(s) administered orally once daily
223778902|NCT01054729|DRUG|Placebo|Placebo to match sofosbuvir administered orally once daily
223778903|NCT01054729|DRUG|PEG|Pegylated interferon alfa-2a (PEG) 180 μg was administered once weekly by subcutaneous injection.
223778904|NCT01054729|DRUG|RBV|Ribavirin (RBV) tablets were administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg).
223694479|NCT00023244|DRUG|Sirolimus|Participants take daily (orally, either as tablets or as liquid) starting on postoperative day 1 at a dose of 6 mg/m2 and will be adjusted to maintain a trough level of 10-20 ng/mL throughout the study.
223694480|NCT00023244|DRUG|Methylprednisolone|Administered at 10 mg/kg intravenously perioperatively and on postoperative day 1.
223694481|NCT00023244|DRUG|Prednisone|Administered orally beginning on Post-Op Day 2 and maintained for all participants until day 180. Randomization will determine whether patients will maintain this treatment following day 180.
223694482|NCT00023244|DRUG|Bactrim|All subjects will receive TMP SMX (Bactrim), pneumocystis jiroveci (carinii) prophylaxis, beginning on postoperative day 1 and continuing for 6 months following transplant. Dosage: 10 mg/kg taken orally three times weekly (maximum dose 160 mg).
223778905|NCT05978882|PROCEDURE|Laparoscopic sentinel navigation surgery using fluorescence|If the frozen biopsy of sentinel lymph nodes are all negative using fluorescence, stomach-preserving surgery is performed
223778906|NCT02199457|DEVICE|SVSS and reference devices|Blood pressure will be measured with standard mercury manometer
223778907|NCT02199457|DEVICE|SVSS and reference devices|Body temperature taken with infrared thermometer
223694483|NCT03368703|DEVICE|Anodal transcranial direct-current-stimulation|2mA / 20min Anodal and Sham tDCS over dominant M1. Anodal tDCS consists of 30s of ramp up followed by 20min of stimulation and 30s of ramp down.
223778908|NCT02199457|DEVICE|SVSS and reference devices|Pulse rate and Sp02 measured with a reference pulse oximter. The pulse oximeter is just clipped to the end of the finger.
223778909|NCT02199457|DEVICE|SVSS and reference devices|Measurement of respiration rate
223778910|NCT00935103|BEHAVIORAL|Psychoeducation|
223778911|NCT02563158|PROCEDURE|non-occlusion technique|Hepatectomy is carried out without hepatic inflow control. (non-occlusion technique)
223694484|NCT03368703|DEVICE|Sham transcranial direct-current-stimulation|"Sham tDCS consists of only 30s of ramp up followed by 30s of ramp down and no further stimulation.~Participants therefore have the same feeling for both modalities : slight itching due to the induced current at the beginning of the protocol (during around 30s) allowing no differentiation by the participant between the anodal or sham sessions."
223694485|NCT00225446|DEVICE|MicronTracker|MicronTracker is a Third Generation Optic Repositioning System in orthognatic surgery.
223694486|NCT05300633|BEHAVIORAL|Group-Based Community Reinforcement Approach and Family Training-Early Psychosis Intervention (CRAFT-EPI)|Behavioral therapy adapted for families of young people experiencing early psychosis delivered via telemedicine to groups following an individual orientation. Group session topics include self-care, communication, functional analysis, positive reinforcement, treatment engagement, natural consequences, and problem solving. A happiness scale will be completed at each session. Will be provided in the context of an early psychosis intervention program that provides coordinated specialty care to 16- to 29-year-olds experiencing any diagnosis that can manifest as early psychosis.
223694487|NCT00390598|DRUG|PEG (solution given 4 L)|
223694488|NCT00390598|DRUG|senna glycoside 36 mg and PEG (solution given 2 L)|
223694489|NCT00136331|BIOLOGICAL|Pandemic influenza vaccine|
223778912|NCT01057212|DRUG|ixabepilone|Ixabepilone will be administered intravenously, 16 mg/m2, once weekly for 3 of 4 weeks on a 28-day schedule, to the first six patients enrolled. Ixabepilone will be administered intravenously, 20mg/m2, once weekly for 3 of 4 weeks on a 28-day schedule, to the remaining 40 patients enrolled.
223694490|NCT03875820|DRUG|VS-6766|"VS-6766 will be supplied as 0.8mg hypromellose (HPMC) capsules for oral administration. The capsule fill consists of VS-6766 and the inactive ingredients mannitol and magnesium stearate.~VS-6766 will be administered on a twice weekly (Monday and Thursday or Tuesday and Friday) schedule for 3 weeks followed by 1 week off in every 4 week cycle, under fasting conditions (approximately 1 hour prior or 2 hours after a meal). The starting dose, based on the previous Phase I trial will be 3.2 mg given orally as a single daily dose. This can be escalated to a maximum of 4mg (as per dose escalation rules in the protocol)."
223694491|NCT03875820|DRUG|Defactinib|"Defactinib is formulated as a white to off-white oval tablet for oral administration and supplied in single unit dose strength of 200 mg in 120 cc (HDPE) bottles. In addition to Defactinib, formulation components include microcrystalline cellulose, lactose monohydrate, sodium starch glycolate, and magnesium stearate.~Patients will receive Defactinib orally immediately after a meal twice daily (approximately every 12 hours) for 3 weeks followed by 1 week off in every 4 week cycle. The starting dose will be 200mg. This can be escalated to a maximum of 400mg (as per dose escalation rules in the protocol)."
223694492|NCT01699932|DRUG|Glimepiride+metformin (Amaryl M®) - HOE4900|"Pharmaceutical form:tablet~Route of administration: oral"
223778913|NCT01057212|DRUG|bevacizumab|Bevacizumab will be administered intravenously, 10 mg/kg, every two weeks.
223778914|NCT03272191|PROCEDURE|Liposuction and stem cell implantation|The adipose tissue specimen will be collected mainly from the patient's abdomen using a liposuction cannula. The adipose tissue may be collected from other areas if necessary The adipose tissue is transferred to the laboratory for separation of the adipose tissue-derived stem cells, which are then transferred to an injection/infusion catheter for delivery into the akinetic myocardial scar in the region of a previous infarct
223778915|NCT04233814|DRUG|Caveolin-1-Scaffolding-Protein-Derived Peptide (LTI-03)|LTI-03, a Caveolin-1 scaffold protein-derived 7-amino acid peptide to be administered as a dry powder by inhalation through a dry powder inhaler.
223778916|NCT04233814|DRUG|Placebo|Matching placebo is micronized lactose powder administered by inhalation through a dry powder inhaler.
223778917|NCT01925183|DRUG|Pegylated interferon alpha-2a|180mcg once weekly; subcutaneous injection
223694493|NCT01370668|BEHAVIORAL|Functional remediation|"The functional remediation program is composed of 21 weekly sessions of 90 minutes, each aimed at improving the following cognitive domains: attention, memory and executive functions and psychosocial functioning.~The program will be performed in an 12- to 15-patient group conducted by 2 experienced neuropsychologists with previous experience with bipolar patients and specific training on patients' group management."
223694494|NCT01370668|BEHAVIORAL|Psychoeducation|Group psychoeducation is a tested and manualized intervention consisting of 21 weekly sessions of 90 minutes aimed at improving 4 main issues: illness awareness, treatment adherence, early detection of prodromal symptoms and recurrences, and lifestyle regularity.
223694495|NCT01370668|BEHAVIORAL|Treatment as usual|The patients will not receive any add-on psychosocial intervention. All patients will keep on receiving standard psychiatric treatment.
223694496|NCT02595359|DRUG|Moxifloxacin|Moxifloxacin intracameral
223694497|NCT00362037|DRUG|Irbesartan (Aprovel)|Aprovel (150 \& 300mg) \& CoAprovel (300/12.5mg hydrochlorothiazide one per day per os.
223694498|NCT01580358|DRUG|Shen-Mai San|Shen mai san is composed of three herb medicines, Ginseng radis, Liriope spicata, and Schizandrae fructus and was manufactured into concentrated herbal extract and packed with 0.5g per capsule and labeled by Sun-Ten pharmaceutical company in Taiwan with good manufacturing practice (GMP).
223694499|NCT01580358|DRUG|Starch|It was packed in granules with 0.5gm starch. Patients took eight granules three times per day for four weeks.
223694500|NCT00187031|DRUG|Topotecan, Filgrastim (G-CSF), Pegfilgrastim|See detailed description section for additional details.
223694501|NCT02101203|DRUG|Placebo|
223694502|NCT02101203|DRUG|0.5 mgTestosterone + 10 mg Buspirone|"A total of 28 doses will be provided. Subjects are required to take a minimum of 8 doses over the 8-week treatment period (1 dose/week). The other 20 doses may be taken as desired (ie, on demand) throughout the 8-week treatment period; dosing is permitted every 2 days (ie, on alternate days)."
223694503|NCT05835531|DEVICE|Catheters comparation|Assessment of incidence of complications associated with midline catheters
223694504|NCT06202456|DRUG|Huazhi Rougan granule|Huazhi Rougan granule
223694505|NCT05691907|DEVICE|THE therapy|"THE therapy consisting of:~* Heating Pad~* Interferential Therapy"
223694506|NCT05691907|PROCEDURE|Directional Preference Exercises|Directional Preference Exercises consisting of Mckenzie's extension protocol
223694507|NCT05691907|PROCEDURE|Motor Control Exercises|Motor Control Exercises consisting of External limb loading extension protocol
223694508|NCT05116007|DRUG|AK112|IV infusion
223694509|NCT05116007|DRUG|Etoposide|Etoposide intravenous infusion was administered at a dose of 100 mg/m\^2 on Days 1, 2, and 3 of each 21-day cycle during the induction phase (Cycles 1-4).
223694510|NCT05116007|DRUG|Carboplatin|Carboplatin intravenous infusion to achieve an initial target AUC of 5 mg/mL/min was administered on Day 1 of each 21-day cycle during the induction phase (Cycles 1-4)
223694511|NCT01209923|DEVICE|BC1|Body composition measures taken twice at the same visit for BIA, DEXA, and hydrostatic weighing.
223694512|NCT00046748|DRUG|Omalizumab|
223694513|NCT05716399|DEVICE|Transcutaneous electric stimulation pretreatment|Within 30 minutes before spinal anesthesia or 30 minutes after hypotension, TEAS (density wave 10/50Hz, one side of Neiguan and Quchi points connected to two electrodes on the same wire on the electroacupuncture instrument) was continuously performed on both sides of Neiguan and Quchi points, and the current intensity was only as high as the patient could comfortably tolerate (the electrical stimulation intensity was 2-3 times of the sensory threshold, for example, if the electrical stimulation intensity was 5 mA, 10-15 mA was used for stimulation), Record the specific value of current. FTEAS group pastes electrode piece, turns on the power, but there is no current output.
223694514|NCT05716399|DEVICE|Transcutaneous acupoint electrical stimulation treatment|Transcutaneous acupoint electrical stimulation treatment
223694515|NCT05716399|DEVICE|Transcutaneous acupoint pseudo electric stimulation|Transcutaneous acupoint pseudo electric stimulation
223778918|NCT01925183|DRUG|Ribavirin|600mg two times daily (BID) (e.g. 3x200mg at 6am, 3x200mg at 6pm) in patients ≥75kg body weight; 2x200mg at 6am and 3x200mg at 6pm in patients \<75kg; orally
223778919|NCT01925183|DRUG|Boceprevir|800mg three times daily (TID) (e.g. 4x200mg at 6am, 4x200mg at 2pm, 4x200mg at 10pm); orally
223778920|NCT03736525|BEHAVIORAL|Design For Wellness (DWELL)|Design for wellness is an online Facebook intervention. During 3 months intervention period, participants in the intervention group will be exposed to contents on their newsfeed (posts on Facebook wall), and also be expected and encouraged to create new content themselves. The contents will be interactive and involve different modes of delivery, as audio and video, to reinforce active learning. Participants will be part of DWELL Facebook group community and will be empowered to read and control cues in the environment, by developing skills to enhance their self-efficacy.
223778921|NCT03736525|BEHAVIORAL|Wait list control group|Wait list control group will get no intervention during the study period. Participants will answer questionnaires pre, mid and post intervention. A delayed form of the intervention will be available to them after the close of the study.
223778922|NCT01046110|DRUG|insulin degludec|Injected under the skin once daily for 26 weeks. The doses will be individually adjusted.
223778923|NCT01046110|DRUG|sitagliptin|Sitagliptin tablets administered orally once a day at the same time every day for 26 weeks
223778924|NCT02362880|RADIATION|Florbetaben|single dose of Florbetaben followed by PET scan
223778925|NCT02753751|OTHER|AKI Alert|"Provider's will receive a pop-up alert in the electronic health record until AKI is documented in the problem list or AKI resolves."
223694516|NCT05266716|BEHAVIORAL|Affect Methamphetamine Treatment Program|"Components of the treatment services include: contingency management (CM; monetary incentives for drug tests negative for stimulants), the digital behavioral therapy curriculum (based on CBT) delivered via the Affect app on smartphones, weekly one-on-one telemedicine (TM) with clinical personnel and group therapy, and referral to psychiatrist for medication support, as needed. The program incrementally builds skills and beliefs to develop personally meaningful strategies to combat cravings, using such techniques as regular app-promoted deep breathing exercises, daily exercise, and help in making and sticking to a relapse prevention plan. Counseling sessions are arranged via text sent by the Team Care advocate and also presented to the participant via the app as a reminder. Individual and group therapy sessions occur over Zoom, which is integrated into the app.~Contingency Management (CM). CM utilizes monetary incentives and rewards to promote behavior change."
223694517|NCT05400915|DRUG|Variltinib, Paclitaxel|Varlitinib will be administered orally to the study participants at doses 300mg, BID in combination with the weekly intravenous infusion of Paclitaxel for 3 weeks with a rest period of 1 week.
223694518|NCT01761864|BEHAVIORAL|academic detailing intervention|
223694519|NCT00562250|DRUG|Dapagliflozin|Tablets, Oral, 20 mg, once daily, single dose
223694520|NCT00562250|DRUG|Glimepiride|Tablets, Oral, 4 mg, once daily, single dose
223694521|NCT00562250|DRUG|Dapagliflozin + Glimepiride|Tablets, Oral, Dapagliflozin 20 mg + Glimepiride 4 mg, once daily, single dose
223694522|NCT00723216|DRUG|enoxaparin|20 mg twice a day
223694523|NCT00723216|OTHER|Physical prophylaxis|
223694524|NCT02095067|DEVICE|Video consultation|
223694525|NCT02526173|PROCEDURE|RALP using full nerve sparing technique|RALP using full nerve sparing technique
223694526|NCT02526173|OTHER|dHACM Application|2x12 sheet of dHACM applied to the neurovascular bundle
223694527|NCT05466448|DRUG|RZL-012|concentration of injected formulation 50 mg/mL RZL-012 of 7.5 mg/0.15 mL/injection point that results in a maximum total dose/volume of 240±30 mg/4.8±0.6 mL RZL-012
223694528|NCT02279238|PROCEDURE|cardiac rehabilitation|"It is a cross over study in which the participants are assigned for two test simultaneously with washout time of 6 hrs . 5th POD patients are randomly assigned to either 6 minute walk test or 3 minute ramp walk test as first test with 6 hours of rest \[Washout time\] in between the two test.~6 MWT : The patient is instructed to walk for a period of 6 minute on a 30 meters Hallway with its extent being demarcated by the placement of 2 cones at the extremes of the Hall.~3 MRWT : The patient is instructed to walk for a period of 3 minute on a Ramp with an elevation of 30 degree and length of 20 meters with its extent being demarcated by the placement of 2 cones at the extremes of the ramp.~The data of \[HR, SPO2, PSG RPE scale, Distance walked, BP\] the participants are collected before, during and after the completion of each lap \[according to American Thoracic Society \[ATS\] protocol\]."
223694529|NCT01952782|DRUG|Kisspeptin 112-121|Subjects will receive up to 10 IV doses of kisspeptin 112-121
223694530|NCT01952782|DRUG|Naloxone|Subjects will receive one IV dose of naloxone followed by an IV infusion of naloxone.
223694531|NCT01952782|DRUG|GnRH|Subjects will receive up to 10 doses of IV GnRH
223778926|NCT02176889|DIETARY_SUPPLEMENT|Lactospore|Bacillus coagulans MTCC 5856
223778927|NCT02176889|OTHER|Placebo|
223694532|NCT04112888|COMBINATION_PRODUCT|Collagen|Patients will receive 3 to 5 collagen infiltrations in the scar once per week. Patients with episiotomy will receive 3 collagen infiltrations while patients who underwent a cesarean section will receive 5 collagen infiltrations. The infiltration will be done by tunneling technique, that is, it will be applied along the scar, placing the needle almost tangential to the entire length of the area, then it will be injected and at the same time the needle will be removed. Infiltrations will be carried out intradermally, previously performing asepsis in the area to be infiltrated. 2 ml syringes will be used to infiltrate the episiotomy scars (we will use 1 vial of 2 ml ) and 5 ml for cesarean scars (2 vials of 2 ml ) and sterile needles of 30G, 13mm.
223694533|NCT04112888|PROCEDURE|Rehabilitation sessions|Patients will receive the conventional treatment of 8 rehabilitation sessions with massage therapy techniques, muscle stretches and fascial work. The rehabilitation sessions will always be carried out by the same physiotherapist specialized in pelvic floor. There will be two sessions per week for four weeks. The sessions will last 45 minutes.
223694534|NCT00575250|BEHAVIORAL|Osteoporosis Prevention and Self-Management Course|Four weekly education sessions of 2 1/2 hours duration, in a group session facilitated by a community nurse and trained lay leader.
223694535|NCT00575250|BEHAVIORAL|Introductory education session on osteoporosis|Introductory education session, 1 x 2 1/2 hours in a group session facilitated by a community nurse and trained lay person.
223694536|NCT02966041|DRUG|Ondansetron|Ondansetron/Zofran is an antiemetic drug used to prevent and treat nausea and vomiting.
223694537|NCT02966041|DRUG|Saline|Normal saline is salt water and is acting as a placebo in this study. A placebo is an inactive substance that looks identical to the test drug, but it contains no therapeutic ingredient.
223694538|NCT01278160|DRUG|biphasic insulin aspart 30|Administered subcutaneously (under the skin), twice daily with a dosage of 2/3 and 1/3 total daily dose before breakfast and before dinner, in combination with metformin.
223694539|NCT01278160|DRUG|biphasic insulin aspart 30|Administered subcutaneously (under the skin), twice daily with a split dosage of 1/2 and 1/2 total daily dose before breakfast and before dinner, in combination with metformin.
223694540|NCT01278160|DRUG|metformin|Tablets 500 mg administered orally with meals. Pre-trial dose and regimen unchanged
223694541|NCT03171051|DEVICE|950 nm LED Device|Device to be used in aesthetic and cosmetic procedures which consists of a console and an applicator belt that delivers the treatment LED to the subject's skin.
223694542|NCT03171051|DEVICE|1050nm Diode Laser Device|FDA approved laser device that has been shown to reduce fat in the flanks by heating the fat cells and causing them to burst. The contents of the cells are then cleared naturally by the body.
223694543|NCT00497276|PROCEDURE|placement of popliteal catheter|Bolus naropin 7,5 mg/ml 30 ml; infusion bupivacaine 2,5 mg/ml 5-10 ml/h
223694544|NCT03882931|OTHER|Theta Burst Transcranial Magnetic Stimulation|Theta Bursts are short bursts of stimulation at high frequencies, which are applied 5 times per second
223694545|NCT03882931|OTHER|Focused Ultrasound|Low intensity focused ultrasound is sound energy stimulation at a low intensity of 1-30 W/cm2
223694546|NCT03882931|OTHER|Sham|The investigators will simulate theta bursts pulses similar to the Theta Burst Transcranial Magnetic Stimulation groups but without stimulation.
223694547|NCT02245178|PROCEDURE|Lung spirometry|measurement of pulmonary function pre- and post-bronchodilator
223694548|NCT02245178|OTHER|CT scan analysis|Analysis of existing year 25 thoracic CT scans for lung and intrathoracic vascular structure
223694549|NCT01483807|BEHAVIORAL|Sound Production Treatment - Blocked|Sound Production Treatment is a treatment for acquired apraxia of speech. Combines therapist modeling, simultaneous production, articulatory instruction, feedback and repeated practice. SPT-Blocked entailed practicing all treatment targets blocked by target. SPT-Random entailed practicing all treatment targets in a non predictable, random order.
223694550|NCT01483807|BEHAVIORAL|Sound Production Treatment - Random|A treatment for acquired apraxia of speech. Combines therapist modeling, simultaneous production, articulatory instruction, feedback and repeated practice. SPT-Random entailed practicing treatment targets in a non predictable order. SPT-Blocked entailed practicing treatment targets blocked by target.
223778928|NCT04880551|RADIATION|Fluoroscopy|In this study the patient will be exposed to radiation during the fluoroscopy for lungs. There is a small chance of alopecia. There is a rare chance that the patients skin may turn red or be damaged.
223694551|NCT00806338|DRUG|Trodusquemine (MSI-1436)|A single dose of Trodusquemine (MSI-1436) will be administered every 72 hours on Days 0, 3, 6, 9, 12, 15, 18 and 21. Doses are 3mg/m2 in cohort 1, 6mg/m2 in cohort 2 and 10mg/m2 in cohort 3.
223694552|NCT00806338|DRUG|Placebo|
223694553|NCT01502280|DRUG|5-Aminolevulinic acid (ALA)|Following informed consent, within 3 hours prior to surgery, patient will orally ingest \[or be given via Nasogastric (NG), Orogastric (OG), or Gastric tube (G-tube)\] either (1) 5-ALA/Gliolan® mixed with sterile water (20mg/kg)
223694554|NCT01502280|DRUG|Placebo - ascorbic acid|Within 3 hours prior to surgery, patient will orally ingest \[or be given via Nasogastric (NG), Orogastric (OG), or Gastric tube (G-tube)\] 1.5 Gm. placebo - ascorbic acid in 50 ml sterile water.
223694555|NCT02872571|DRUG|Intramuscular Islet Autograft|Intramuscular Islet Autograft After Extensive Pancreatectomy
223694556|NCT01900639|BEHAVIORAL|change time of intake of aspirin|
223778929|NCT03149094|BEHAVIORAL|CBSM-SMI|The intervention group will receive Cognitive Behavioral Stress Management (CBSM) for Individuals Living with HIV via mHealth through smartphones and tablets.
223778930|NCT03149094|BEHAVIORAL|CBSM-SMI control|this group will receive the LifeSum app.
223778931|NCT01086657|BIOLOGICAL|VRC-AVIDNA036-00-VP|H5 DNA Vaccine
223778932|NCT01086657|BIOLOGICAL|Monovalent Influenza Subunit Virion (Inactive H5N1) Vaccine|Inactive H5N1 Vaccine
223778933|NCT04992260|BIOLOGICAL|Inactivated COVID-19 Vaccine|The inactivated COVID-19 vaccine was manufactured by Sinovac Research\& Development Co., Ltd..600SU Inactivated SARS-COV-2 virus in 0·5 mL of aluminium hydroxide solution per injection
223778934|NCT04992260|BIOLOGICAL|Controlled vaccine|The placebo was manufactured by Sinovac Research\& Development Co., Ltd.The composition is aluminium hydroxide,The appearance of the placebo is consistent with the vaccine, which is a milky-white suspension.
223778935|NCT00583726|BEHAVIORAL|motivational interviewing|telephone counseling
223778936|NCT00583726|BEHAVIORAL|written materials only|dietary guidance materials and pedometers
223778937|NCT04023695|DRUG|Corticosteroid with lidocaine with epinephrine|Trigger finger injection
223778938|NCT04023695|DRUG|Corticosteroid with normal saline|Trigger finger injection
223778939|NCT05043337|BEHAVIORAL|Maternal voice|"The recordings were made in a quiet and separate consultation room. For infants in the maternal voice group, mothers were recorded what they wanted to say to their baby and read an independently published children's book, Xiao Qi's yellow persimmon which describes how mothers with premature babies care for their infants. After reviewing the quality of the recordings, the maternal voice recordings were edited for 13 minutes using a sound organizer. Respiration, heart rate, oxygen saturation, and Neonatal Infant Pain Scale (NIPS) were measured and recorded 3 minutes before, during, 1 minute, 3 minutes, and 10 minutes after the puncture."
223778940|NCT05043337|BEHAVIORAL|Lullaby|The Brahms Lullaby recordings are compiled for 13 minutes. Measuring with the Respiration, heart rate, oxygen saturation, and neonatal infant pain scale (NIPS ) were recorded 3 minutes before, during, 1st, 3rd, and 10th minutes after the heel lance puncture.
223778941|NCT05043337|BEHAVIORAL|Maternal voice combined with lullaby|"The recordings were made in a quiet and separate consultation room. For infants in the  Maternal voice combined with lullaby group,  mothers were recorded what they wanted to say to their baby and read an independently published children's book-Xiao Qi's yellow persimmon , and giving mother listening to the Brahms Lullaby at the same time, the maternal voice recordings were edited for 13 minutes using a sound organizer. Measuring with the Respiration, heart rate, oxygen saturation, and neonatal infant pain scale (NIPS ) were recorded 3 minutes before, during, 1st, 3rd, and 10th minutes after the heel lance puncture."
223778942|NCT00002026|DRUG|Acyclovir|
223778943|NCT02011438|BEHAVIORAL|UTalk|Prevention intervention delivered in group format adapted from IPT-AST, for adolescents who experience peer victimization and who are at risk for developing social anxiety and depression.
223778944|NCT02574975|DRUG|methacholine|Methacholine,inhaled cumulative dosage 2.5mg
223778945|NCT02574975|DRUG|adenosine monophosphate|Adenosine monophosphate ,inhaled cumulative dosage 40mg
223778946|NCT02574975|DRUG|leukotriene D4|Leukotriene D4,inhaled cumulative dosage 2.4 μg
223778947|NCT02574975|DEVICE|Astograph Jupiter-21 airway reaction testing apparatus|Methacholine bronchial provocation test was performed by using Astograph Jupiter-21 airway reaction testing apparatus
223778948|NCT02574975|DRUG|budesonide /formoterol|budesonide 160μg and formoterol 4.5ug,1 inhalation ,twice daily ,for three months in all participants (80 Anticipated)
223694557|NCT06392802|DEVICE|Rehabilitation treatment using Muvity|The users have the support of the telerehabilitation system Muvity
223694558|NCT06191835|BEHAVIORAL|myCare Start|The service consists of 2 times 10-minutes semi-structured pharmaceutical interventions between community pharmacist and patient, tailored to the patient's needs, positioned as partner, during the first 6 weeks after treatment initiation.
223694559|NCT06322979|PROCEDURE|Mineral trioxide aggregate|Apexification treatment was done with mineral trioxide aggregate
223694560|NCT06322979|PROCEDURE|Premixed Bioceramic Putty|Apexification treatment was done with Premixed Bioceramic Putty (Well-Root™ PT)
223694561|NCT05530031|PROCEDURE|trabeculotomy ( angle glaucoma surgery )|a scleral flap is raised at the selected site with UBM and a cutdown in shlemm's canal is performed, a metal trabeculotome is used to cannulate and tear through a section of the inner wall of SC and trabeculum into the AC. Closure of the scleral flap and conjunctiva with 10/0 nylon. Viscoelastic is used to dilate the schlemm's canal, form the anterior chamber and decrease the risk of hyphema.
223778949|NCT02216331|DRUG|TMC207|"This is a two group, 2 period study design with both groups in the first period receiving TMC207 alone, followed by one group in the second period receiving TMC207 in the presence of dosing with rifapentine and the other group receiving TMC207 in the presence of dosing with rifampicin. All treatments details specified under Arms description."
223694562|NCT01634763|DRUG|LDK378|
223694563|NCT03167905|DEVICE|Epidural delivery system|Epidural delivery system for maintenance of labour epidural analgesia using 0.1% ropivacaine (amide local anaesthetic) with 2mcg/ml fentanyl (opioid) as maintenance solution.
223694564|NCT03167905|DRUG|Entonox|Entonox will be given upon request in non-epidural group.
223778950|NCT02216331|DRUG|rifapentine|
223778951|NCT02216331|DRUG|rifampicin|
223778952|NCT02302729|DIETARY_SUPPLEMENT|Micronutrients|Nutrient Quantity Nutrient Quantity Zinc 9 mg Copper 0.3 mg Iron 12.5 mg Vitamin D3 5 mg Folic Acid 160 mcg Vitamin E 5 mg Iodine 90 mcg Calcium 200 mg Vitamin A 250 mg Phosphorus 150 mg Vitamin C 40 mg Magnesium 40 mg Vitamin B12 0.9 mcg Selenium 17 mcg Thiamine 0.5 mg Manganese 0.17 mg Niacin 0.5 mg Biotin 8 mg Riboflavin 6 mg Vitamin B5 1.8 mg Vitamin B6 0.5 mg
223778953|NCT02302729|BEHAVIORAL|Responsive feeding|"Strategy~Mother ensures that feeding area is set up with infant and mother able to see one another.~Mother mirrors the infant's facial expressions to attract the infant's attention.~Mother interprets infant's behavior with a positive voice, Oh, you like the spinach. Mother extends infant's behavior by saying, Oh the cereal is all gone and doing a consistent hand signal Mother models eating, makes positive comments in a nurturing tone. Mother offers finger food or use of utensil"
223778954|NCT02302729|DIETARY_SUPPLEMENT|Placebo|Riboflavin Vitamin B2
223778955|NCT04080973|DIAGNOSTIC_TEST|CT scan|non contrast spiral CT of the urinary tract including the bony structures of the spine and pelvis
223778956|NCT04080973|DIAGNOSTIC_TEST|24 hour urine collection|24 hours collection of urine and measurement of the concentration of calcium, phosphorous, uric acid, oxalate and citrate
223694565|NCT03167905|DRUG|Meperidine|Intramuscular pethidine (75mg/1.5ml) will be given upon request in non-epidural group.
223694566|NCT03167905|DRUG|Ultiva|Intravenous patient controlled remifentanil (20-40mcg/ml) is only given when the patient rejects or cannot receive pethidine and entonox in non-epidural group..
223694567|NCT03167905|DRUG|Fentanyl|Epidural delivery system for maintenance of labour epidural analgesia using 0.1% ropivacaine (amide local anaesthetic) with 2mcg/ml fentanyl (opioid) as maintenance solution.
223694568|NCT03167905|DRUG|Ropivacaine|Epidural delivery system for maintenance of labour epidural analgesia using 0.1% ropivacaine (amide local anaesthetic) with 2mcg/ml fentanyl (opioid) as maintenance solution.
223694569|NCT00625066|OTHER|biologic sample preservation procedure|
223694570|NCT00625066|OTHER|cytology specimen collection procedure|
223694571|NCT00625066|OTHER|medical chart review|
223694572|NCT00625066|OTHER|questionnaire administration|
223694573|NCT00625066|OTHER|survey administration|
223694574|NCT00625066|PROCEDURE|biopsy|
223778957|NCT01734668|DEVICE|In Vitro Diagnostic device to aid in diagnosis|
223694575|NCT00625066|PROCEDURE|evaluation of cancer risk factors|
223694576|NCT00625066|PROCEDURE|screening colonoscopy|
223694577|NCT05965726|DRUG|Paxlovid 25 day dosing|nirmatrelvir 300mg and ritonavir 100mg taken bid for 30 days
223694578|NCT05965726|DRUG|Paxlovid 15 day dosing|nirmatrelvir 300mg and ritonavir 100mg taken bid for 15 days then ritonavir 100mg taken bid plus nirmatrelvir matching placebo bid for 15 days
223694579|NCT05965726|DRUG|Control|ritonavir 100mg taken bid plus nirmatrelvir matching placebo bid for 30 days
223694580|NCT05035511|DEVICE|tDCS|Active-tDCS over 10 sessions in 2 weeks (once per day, for 10 consecutive working days), while performing the executive function training tasks. Also, participants will complete an online cognitive training program while they receive active tDCS stimulation for 10 training sessions. The training session will last for 20 minutes and the online cognitive training program is comprised of 5 exercises targeting at information processing speed and executive function capacities. Each exercise lasts for approximately 4 minutes, totaling approximately 20 minutes.
223694581|NCT03602820|BIOLOGICAL|AAV2-hRPE65v2|
223778958|NCT02491320|OTHER|Pre-treatment acupuncture|Acupuncture treatment will start on day 3-5 after a spontaneous period or after a withdrawal bleeding following progestin. They will receive acupuncture treatment three times a week. Each treatment session lasts for 30 minutes and can be separated by an interval of 1-3 days, with a maximum of 48 treatment sessions during 16 weeks.
223778959|NCT02491320|DRUG|Letrozole|Starting from 2.5mg daily from day 3-5 for 5 days after a spontaneous period or after a withdrawal bleeding following progestin, one time per day.Participants are treated for up to 4 cycles.
223778960|NCT01462994|OTHER|Blood will be withdrawn at baseline and in intervals of 3 months for a total period of 2 years|
223778961|NCT03408158|PROCEDURE|same type infusion of main HPA antigen|Compare the differences of platelet count between participants with same type infusion of main HPA antigen and not
223778962|NCT03039673|DRUG|Riluzole|"All patients will be treated with Riluzole for a period of three months prior to final inclusion and randomization. Riluzole treatment will continue throughout the 18 months of follow-up planned for in this protocol.~Riluzole treatment is part of routine care for patients with ALS."
223778963|NCT03039673|DRUG|IL-2|"The dose of IL-2 to be used in this study will be 2.0 million IU/day.~Each treatment course will last 5 days (i.e. 1 sub-cutaneous injection per day for 5 consecutive days). The 5-day course will be repeated every 4-weeks over an 18-month treatment period.~In case of intolerance, a flexible dose-reduction schedule is available."
223778964|NCT03039673|DRUG|5% glucose water solution|"The placebo consists of 5% glucose water solution, which is the matrix with which low-dose IL-2 injections are prepared in the experimental arm. Placebo injections are prepared in exactly the same manner as IL-2 injections, just without the IL-2.~Each treatment course will last 5 days (i.e. 1 sub-cutaneous injection per day for 5 consecutive days). The 5-day course will be repeated every 4-weeks over an 18-month treatment period."
223778965|NCT01134900|OTHER|Pharmacy Dashboard Review and Intervention|Clinical pharmacist reviews patients on dashboard and makes intervention with providing team when necessary.
223778966|NCT03497325|DRUG|autologus platelet rich plasma|55 participant unergoing prelabor primary CS will receive intramyometrial injection of PRP after closure of uterine incision
223778967|NCT03497325|DRUG|placebo|55 participant unergoing prelabor primary CS will receive intramyometrial injection of normal saline after closure of uterine incision
223694582|NCT03007901|BEHAVIORAL|Mindful Climate Action|Educational and Behavioral Training Curriculum: An article describing our proposed program was recently published in Sustainability (1) and is summarized here. Experienced instructors from the UW Integrative Medicine Mindfulness Program will teach the 8-week program. Classes will meet weekly for 2½ hours, with a 6 hour weekend retreat. Twenty to 45 minutes of daily home practice will be guided by audio recordings leading participants through body scan, sitting meditations, breath awareness, and mindful movement. Each of the 2½ hour weekly classes includes topics (\~30 min) relating to climate change, energy use, and carbon footprint.
223694583|NCT02780609|DRUG|Selinexor|Selinexor will be given orally 2 to 3 hours prior to high dose-melphalan IV infusion. Phase I: Dose escalation beginning with 40 mg to determine the recommended Phase II dose (RPh2D). Phase II: Treatment at RPh2D.
223694584|NCT02780609|DRUG|Melphalan|Melphalan 100 mg/m\^2 IV over 30-45 minutes.
223778968|NCT01881451|DRUG|18F-EF5 PET/CT scan|Patients will undergo an investigations 18F-EF5 PET/CT scan.
223778969|NCT01881451|PROCEDURE|Optional biopsy|Patients who choose to participate, will undergo a tissue biopsy.
223778970|NCT04601155|DEVICE|AlloSure|AlloSure is an analytically validated targeted next-generation sequencing (NGS) assay that uses single-nucleotide polymorphisms (SNPs) to measure the fraction of dd-cfDNA in transplant patients without the need for genotyping either the donor or the recipient.8
223778971|NCT00162851|DRUG|alemtuzumab|
223694585|NCT02780609|DRUG|Dexamethasone|Dexamethasone 20 mg PO (or IV) daily (on days -3, -2 and -1).
223694586|NCT02780609|PROCEDURE|Autologous Hematopoietic Cell Transplantation (HCT)|Participant's own stem cells are collected from their blood, frozen, then given back to them after chemotherapy.
223694587|NCT02780609|DRUG|Fosaprepitant|Fosaprepitant at 150 mg IV on days -3 and -2.
223694588|NCT02898116|DRUG|Ensartinib|Ensartinib was administered orally once daily at a dose of 200 mg during the Run-in Period. During combination therapy, the ensartinib starting dose was to be 200 mg. Based on observed toxicity at the starting dose level, the ensartinib dose may have been escalated to the recommended single-agent dose (225 mg) or de-escalated to the minimum effective dose (150 mg).
223694589|NCT02898116|DRUG|Durvalumab|During combination therapy, durvalumab was to be administered as an IV infusion over 60 (± 5) minutes every 4 weeks at a dose of 1500 mg.
223694590|NCT02312271|OTHER|enteral formula|standard tube feeding formulas
223694591|NCT02745210|DIAGNOSTIC_TEST|13C magnetic resonance spectroscopy|acquisition of 13C MR spectroscopy in the brain
223694592|NCT03381105|DIAGNOSTIC_TEST|PSA and Stockholm3|The new Stockholm3 test and traditional PSA test
223778972|NCT04834323|PROCEDURE|distal mesogastric fixation after sleeve gastrectomy|Investigators performed traditional laparoscopic sleeve gastrectomy then we fixed the greater omentum \& mesocolon that were cut during gastrectomy to the remaining gstric pouch along the new greater curvature as high as possible along the stable line then we plicated the remaining staple line till angle of His. (the greater omentum \& mesocolon not reach this part of staple line) , so the remaining gastric pouch remained tension free and was returned to original position and this may prevent the axial gastric rotation
223778973|NCT06047769|OTHER|Board Games|Participants will receive cognitive training in board games including Ludo, Chutes \& Ladder and Chess with both single and multiplayer modes. After 1 week of training, participants will receive intervention of 1 hour per day, three days a week for 8 weeks completing a total of 1440 minutes. With this technique, we will target the cognitive process of information processing, speed and executive function of the patient.
223694593|NCT02891161|DRUG|durvalumab|1500 mg Q4 weekly
223694594|NCT02891161|RADIATION|Radiation Therapy|64.8 Gy, 36 daily fractions on weekdays over about 7 weeks
223694595|NCT04755283|BIOLOGICAL|Abelacimab|Abelacimab provided as liquid in vial (150 mg/mL)
223694596|NCT04755283|DRUG|Rivaroxaban|Rivaroxaban 15 mg and 20 mg provided as commercially available film-coated tablets
223694597|NCT03309150|DRUG|Berzosertib|Participants received intravenous infusion of Berzosertib at a dose of 126 milligrams (mg) on Days 1, 8 and 15 until disease progression or unacceptable toxicity occurred.
223694598|NCT04401605|OTHER|Fermented Food-supplemented Diet|Fermented foods include Kimchi, Sauerkraut, Yoghurt, Kefir and more.
223694599|NCT04401605|OTHER|Regular Diet|No change in diet.
223694600|NCT06785428|DIETARY_SUPPLEMENT|Amino Acid Intake|Amino acid intakes will vary between 0.2 to 2.8 g/kg/d.
223694601|NCT00883584|DRUG|IMD-1041|Capsule 4 x 100mg BID (30 minutes after breakfast/dinner) 12 weeks
223694602|NCT00883584|DRUG|Placebo|Capsule 4 x 100mg BID (30 minutes after breakfast/dinner) 12 weeks
223694603|NCT04352231|DIETARY_SUPPLEMENT|High Fiber Diet Intervention|Plant-based diet with a targeted quantity of 35 g of dietary fiber per day, from a variety of fiber types. Each meal will be balanced to provide all essential nutrients and portions will be of adequate size to ensure participants are satiated. Participants on both diet interventions will be given multivitamin supplements in order to ensure they are receiving essential vitamins and minerals.
223694604|NCT04352231|DIETARY_SUPPLEMENT|Low Fiber Diet Intervention|Animal based diet (meat, dairy) with a targeted quantity of 10 g of dietary fiber per day. Each meal will be balanced to provide all essential nutrients and portions will be of adequate size to ensure participants are satiated. Participants on both diet interventions will be given multivitamin supplements in order to ensure they are receiving essential vitamins and minerals.
223694605|NCT04457219|DEVICE|Haemostatic Dressing|A Hemostatic Dressing is applied at the radial access site, following a transradial angiographic procedure. This is a mineral-based dressing with a hydrophilic polymer that works independently of the clotting cascade to seal the site, by accelerating topical hemostasis.
223694606|NCT04457219|DEVICE|Conventional Dressing|A Conventional Absorbent Dressing is applied at the radial access site, following the transradial angiographic procedure.
223694607|NCT04457219|DEVICE|120 Minutes External Compression|A radial compression device is applied at the radial access site to achieve patent hemostasis. The device remains in situ for 2 hours. Prolonged time of compression may be required.
223694608|NCT04457219|DEVICE|60 Minutes External Compression|A radial compression device is applied at the radial access site to achieve patent hemostasis. The device remains in situ for 1 hour. Prolonged time of compression may be required.
223694609|NCT02123043|BEHAVIORAL|Motor learning-based training|The motor learning-based training will focus on some of the core concepts in the field of motor learning. The key concepts will include variable practice with respect to speed, feedback (both intrinsic and extrinsic but focusing on extrinsic), feedback focusing on three main variables (wheeling pattern, speed of hand when contacting push rim, push angle), sequential learning (specifically relating to wheeling pattern), and mental imagery (during the rest breaks).
223694610|NCT02123043|BEHAVIORAL|Practice wheeling|The practice wheeling will consist of the same amount of wheeling exposure compared to the motor learning-based training group, however no feedback regarding an individuals's wheeling will be provided. Participants randomized to this group will wheel for two 5-minute trials/ visit for 6 visits for a total of 60 minutes of wheeling exposure.
223694611|NCT00990938|DRUG|IMO-2125|IMO 2125 is a synthetic DNA-based agonist of Toll-like receptor 9, which is expressed in humans in plasmacytoid dendritic cells and B cells of the immune system.
223694612|NCT00990938|DRUG|Saline|Subcutaneous injection once per week for four weeks
223694613|NCT05568407|DRUG|Avelumab|As used in real world practice
223694614|NCT01571297|DRUG|RM-131|Double blind RM-131 will be studied with various doses and regimens from 10 to 100 μg for 35 days.
223694615|NCT01571297|DRUG|Placebo|Placebo given subcutaneously for 35 days
223694616|NCT05726734|DRUG|Vonoprazan|potassium-competitive acid blocker
223694617|NCT05726734|DRUG|Amoxicillin, Metronidazole|Antibiotics for H. pylori eradication
223778974|NCT06055088|OTHER|Hand and foot exercise|"The exercise group will participate in home-based hand and foot exercises for 8 weeks. The exercise program will start the week the first neuropathy symptom appears and continue for 8 weeks. The exercises, which will last for 8 weeks, will be performed 3 times a day and at least 3 times a week.~Patients in the massage ball group will be given a massage ball to be used in exercises. Patients in the stress ball group will be given a stress ball to be used in exercises."
223778975|NCT03698682|DRUG|Levofloxacin 500mg|One tablet per day for 7 days.
223778976|NCT00826501|PROCEDURE|Endoscopic cyst-gastrostomy|After passing a small camera into the stomach the pseudocyst will be punctured and drained into the stomach by stent placement.
223778977|NCT00826501|PROCEDURE|Surgical cyst-gastrostomy|After making an incision in the abdomen the pseudocyst contents will be emptied and the pseudocyst will be sutured to the stomach.
223778978|NCT03197220|OTHER|fish|300 gr/week fish
223778979|NCT03197220|OTHER|walnut|18 walnut per week
223778980|NCT03197220|OTHER|fish-walnut|150 gr fish and 9 walnut per week
223778981|NCT05156229|BIOLOGICAL|CDK-003|CDK-003 administered subcutaneously
224263505|NCT06034483|OTHER|Patient/individual education|"In the individual/patient information training, training will be given on menopause, sexual health, pelvic floor health and lifestyle. This training will cover more specifically the following topics:~* Explaining menopause and menopausal symptoms~* Defining the Genitourinary Syndrome of Menopause (MGS)~* The effect of MGS on sexual function cycle and sexual function,~* Conservative recommendations on MGS management~* Explaining pelvic floor anatomy and function and recommendations for pelvic floor health.~The training will take approximately 1 hour and the training will be repeated at the end of the 1st month."
223694618|NCT05726734|DRUG|Bismuth Potassium Citrate|Gastric mucosal protective drug with anti-H. pylori effect
223694619|NCT05726734|DRUG|Esomeprazole|Proton pump inhibitor
223694620|NCT02370446|OTHER|personalized medication log|
223694621|NCT02370446|OTHER|standard of care|
223694622|NCT02370446|BEHAVIORAL|questionnaires|
223694623|NCT02370446|BEHAVIORAL|Cognitive Interview|
223694624|NCT00415571|DRUG|Fispemifene (once daily for 8 weeks)|
223694625|NCT04150029|DRUG|MBG453|Solution for intravenous infusion
223694626|NCT04150029|DRUG|Venetoclax|Tablet for oral administration
223694627|NCT04150029|DRUG|Azacitidine|Solution for subcutaneous injection or intravenous infusion
223778982|NCT04239534|DEVICE|Convergence Of Epicardial And Endocardial RF Ablation|The epicardial lesion pattern will be created using the EPi-Sense®-AF Guided Coagulation System with VisiTrax®. Epicardial linear lesions will be created endoscopically using the EPi-Sense-AF Guided Coagulation System with VisiTrax throughout the posterior left atrium and along the pericardial reflections from a trans-diaphragmatic or sub-xyphoid access without any chest incisions. An endocardial ablation catheter will be used to ablate endocardially to connect lesions at the reflections, complete the isolation of the pulmonary veins and create a cavotricuspid lesion to prevent typical atrial flutter. Once the study lesion pattern has been created by coagulating cardiac tissue using the EPi- Sense-AF Guided Coagulation System and the endocardial ablation catheter, the pulmonary veins must be evaluated for entrance and/or exit block to confirm isolation.
223778983|NCT00575588|DRUG|Metformin|open-label metformin
223778984|NCT00575588|DRUG|Sulphonylurea|Glipizide 5-20 mg capsules (titrated to optimal effect or highest tolerable dose during 18 weeks)
223778985|NCT00575588|DRUG|Saxagliptin|Saxagliptin 5 mg tablets
223778986|NCT00003945|DRUG|cisplatin|
223778987|NCT00003945|DRUG|topotecan hydrochloride|
223694628|NCT05629013|BEHAVIORAL|After-Action Review|After-action reviews, or debriefs, are a relatively simple, inexpensive, and quick, tool to improve learning, performance, and the effectiveness of teams and individuals. After-action reviews are active self-learning processes wherein participants reflect on specific performance episode to actively engage in self-discovery and improve learning in a non-punitive/non-judgmental manner to result in enhanced performance. This proposal aims to apply the team effectiveness intervention of the after-action review (AAR) to the services intervention of the Child and Family Team (CFT) meetings currently used in the CWS.
223694629|NCT05353647|BIOLOGICAL|Autologous CD34+ HSC cells transduced with the lentiviral vector containing a shRNA targeting BCL11a|A single infusion of autologous CD34+ HSC cells transduced with the lentiviral vector containing a shRNA targeting BCL11a
223694630|NCT04407611|BEHAVIORAL|Online modality|Return of BRCA results directly online or return of printed BRCA results if participant cannot access online or chooses not to
223694631|NCT04407611|BEHAVIORAL|Genetic counselor follow-up|Optional genetic counselor follow-up over the telephone
223694632|NCT06517784|OTHER|No treatment given|No treatment given
223694633|NCT03422601|DIAGNOSTIC_TEST|Immunoscore test|To identify patients with high risk (IS 0-1) of relapse or death under oxaliplatin-based adjuvant therapy.
223694634|NCT04095195|RADIATION|MRCP|"Subjects fulfilling the radiological follow-up criteria will be submitted to MRCP or EUS according to the pancreatologist's prescription"
223694635|NCT04095195|PROCEDURE|Endoultrasonography|"Subjects fulfilling the radiological follow-up criteria will be submitted to MRCP or EUS according to the pancreatologist's prescription"
223694636|NCT01187680|DEVICE|Spraygel|
223778988|NCT03528330|DEVICE|Rehabilitation with dental implant with internal hexagon connection|"All patients will receive an implant with internal hexagon connection. All implants will be10 mm in length and 3.75 mm in diameter. Implants will be inserted slightly subcrestal. Bone levels will be measured using a calibrated probe.~Torque insertion will be assed using W\&H machine Once inserted, implants will be connected to smart pegs to test primary stability.~A periapical x-ray will be done after the operation. Thereafter, a specific coping for digital impression will be connected to the implant and a digital impression will be taken. Aim of this procedure will be to produce a screw retained definitive zirconia prosthesis to be adapted at the time of second surgery"
223694637|NCT01187680|DEVICE|Control|Good surgical technique, no adhesion barrier
223694638|NCT05597020|DRUG|Daridorexant|Daridorexant is available as oral film-coated tablets at a strength of 50 mg.
223694639|NCT05597020|DRUG|Placebo|Placebo matching daridorexant is provided as identical-looking oral tablets, formulated with the same inactive ingredients (excipients) as the active tablets.
223694640|NCT05411614|DEVICE|AtriCure EPi-Sense-AF Guided Coagulation System +/- Atriclip|Minimally-invasive epicardial ablation +/- left atrial appendage exclusion using an epicardial clip, combined with endocardial radiofrequency catheter ablation
223694641|NCT05411614|DEVICE|Endocardial Catheter Ablation|Standard percutaneous endocardial catheter ablation of atrial fibrillation
223694642|NCT05495633|OTHER|Collection and evaluation of clinical (CROMs) and patient-reported outcomes (PROMs)|"The study uses a web-based German-language registry database called heartbeat ONE by heartbeat medical solutions GmbH (Berlin, Germany) that provides both clinical reported outcome measures (CROMs) and patient-reported outcome measures (PROMs). PROMs are investigated by validated questionnaires: IPSS/QoL, ICIQ-MLUTS, MSHQ, ICIQ-MLUTSsex, QoR-15GE, PROMIS Global Health 10, ICIQ-S, NRS, and by home urine flow measurement (iUFlow) as well as by self-designed questionnaires to assess patients´ preferences and expectations for Rezum and for surgical therapy of the prostate, satisfaction with the Rezum therapy, side effects of the Rezum therapy, (re)medication to treat BPO and LUTS, and reoperations after Rezum therapy."
223694643|NCT05495633|OTHER|Analysis of uroflowmetry data by Kesem Health iUFlow medical uroflowmetry device|If patients have a smartphone with app function (Android or Apple), they will be provided with a certified and approved home uroflowmetry medical device (iUFlow from Kesem Health) at study entry. This should enable patients to measure their urine flow conveniently from home and thus be independent of the medical consultation (automated home bladder monitoring solution). iUFlowTM is marketed by Kesem Health Pty Ltd, 5A Hartnett Cl, Mulgrave VIC 3170, Australia. The Device is FDA and CE approved and is approved to be used in the EU and Switzerland. Every time a patient is using the device urine flow measurement data and additional voluntary parameters entered by the patient (micturition protocol, drinking protocol) will be sent to the study database.
223694644|NCT04162600|BIOLOGICAL|ChAdOx2 RabG|Single dose of ChAdOx2 RabG at different concentrations: 5 x 10\^9 vp, 2.5 x 10\^10 vp, 5 x 10\^10 vp
223694645|NCT04162600|BIOLOGICAL|Inactivated Rabies Vaccine|A complete pre-exposure prophylactic course of an existing rabies vaccine, ≥2.5 international units.
223694646|NCT04162600|BIOLOGICAL|ChAdOx2 RabG|Single dose of ChAdOx2 RabG at different concentrations: 5 x 10\^9 vp, 2.5 x 10\^10 vp, 5 x 10\^10 vp
223694647|NCT04162600|BIOLOGICAL|ChAdOx2 RabG|Single dose of ChAdOx2 RabG at different concentrations: 5 x 10\^9 vp, 2.5 x 10\^10 vp, 5 x 10\^10 vp.
223694648|NCT04162600|BIOLOGICAL|Inactivated Rabies Vaccine|A complete pre-exposure prophylactic course of an existing rabies vaccine, ≥2.5 international units.
223694649|NCT04162600|BIOLOGICAL|Inactivated Rabies Vaccine|A complete pre-exposure prophylactic course of an existing rabies vaccine, ≥2.5 international units.
223694650|NCT05725668|BEHAVIORAL|dual-task tai ji quan|dual-task tai ji quan training
223694651|NCT05725668|BEHAVIORAL|standard tai ji quan|standard tai ji quan training
223694652|NCT05725668|BEHAVIORAL|stretching|stretching exercise
223778989|NCT03528330|DEVICE|Rehabilitation with dental implant with conical connection|"All patients will receive an implant with conical connection. All implants will be10 mm in length and 3.75 mm in diameter. Implants will be inserted slightly subcrestal. Bone levels will be measured using a calibrated probe.~Torque insertion will be assed using W\&H machine Once inserted, implants will be connected to smart pegs to test primary stability.~A periapical x-ray will be done after the operation. Thereafter, a specific coping for digital impression will be connected to the implant and a digital impression will be taken. Aim of this procedure will be to produce a screw retained definitive zirconia prosthesis to be adapted at the time of second surgery"
223778990|NCT05212636|DEVICE|Repetitive transcranial magnetic stimulation (rTMS)|A total of 12 sessions of rTMS (5 sessions per week for 2 weeks, follow by 1 session per week for next 2 weeks) .
223778991|NCT00501449|BEHAVIORAL|Questionnaire|Mailed packets including cover letter describing purpose of study, study questionnaire, and return envelope.
223778992|NCT06026566|DRUG|Dos of Afentanil 20|the dosage of Afentanil is 20 ng/ml for TCI
223778993|NCT06026566|DRUG|Dos of Afentanil 30|the dosage of Afentanil is 30 ng/ml for TCI
223778994|NCT06026566|DRUG|Dos of Afentanil 40|the dosage of Afentanil is 40 ng/ml for TCI
223694653|NCT05532475|DIAGNOSTIC_TEST|measurement of vitreous level of tumor necrosis factor alpha|measurement of vitreous level of tumor necrosis factor alpha using ELISA technique
223694654|NCT03029702|DRUG|Insulin|Insulin will be used for GDM treatment
223694655|NCT03029702|DRUG|Glyburide|Glyburide will be used for GDM treatment
223694656|NCT03029702|DRUG|Metformin|Metformin will be used for GDM treatment
223694657|NCT02741388|DRUG|selinexor|
223694658|NCT02741388|DRUG|Rituximab|
223694659|NCT02741388|DRUG|Dexamethasone|
223694660|NCT02741388|DRUG|Oxaliplatin|
223694661|NCT02741388|DRUG|Cisplatin|
223694662|NCT02741388|DRUG|Cytarabine|
223694663|NCT02741388|DRUG|Gemcitabine|
223694664|NCT00777218|DRUG|propranolol|standard pediatric doses, based on body weight
223694665|NCT00777218|DRUG|zonisamide|standard pediatric dosages, based on body weight
223694666|NCT00777218|DRUG|topiramate|standard pediatric dosages, based on body weight
223694667|NCT04208568|PROCEDURE|Laparoscopic cholecystectomy|Four ports laparoscopic cholecystectomy under general anaesthesia
223778995|NCT06026566|DRUG|Dos of Afentanil 50|the dosage of Afentanil is 50 ng/ml for TCI
223778996|NCT06026566|DRUG|Dos of Afentanil 60|the dosage of Afentanil is 60 ng/ml for TCI
223694668|NCT02819661|DEVICE|SOMNOTOUCH RESP|Ventilatory effort recorder
223694669|NCT02819661|PROCEDURE|Caesarean section|Cesarean delivery is defined as the delivery of a fetus through surgical incisions made through the abdominal wall (laparotomy) and the uterine wall (hysterotomy).
223694670|NCT02819661|DRUG|Spinal anesthesia with intrathecal morphine|is a form of regional anaesthesia involving injection of a local anaesthetic into the subarachnoid space
223694671|NCT06091787|DRUG|Ursodeoxycholic acid|Tablet Ursodeoxycholic acid 450mg per orally twice daily from Post operative day 1 to post operative day 10.
223694672|NCT06091787|OTHER|Standard Medical Treatment|Standard Medical Treatment
223694673|NCT00040261|DRUG|Memantine HCL|
223694674|NCT04081038|DIAGNOSTIC_TEST|Brush biopsy|Brush biopsy will be performed by dentists and dental hygienists
223694675|NCT06404775|DRUG|mastalgia-oil, tamoxifen placebo|external mastalgia-oil 1 ml/d per breast plus oral tamoxifen placebo 10mg/d for 3 consecutive menstrual cycles
223694676|NCT06404775|DRUG|mastalgia-oil placebo, tamoxifen|oral tamoxifen 10mg/d plus external mastalgia-oil placebo 1 ml/d per breast for 3 consecutive menstrual cycles
223694677|NCT06666946|DEVICE|Electroacupuncture|Hwato brand disposable acupuncture needles (size 0.30 × 40 mm), and SDZ-V EA apparatuses will be used. Participants in the EA group will receive acupuncture at bilateral ST36 and GB34. After sterilisation, sterile adhesive pads will be placed on bilateral ST36 and GB34, and acupuncture needles will be inserted through the adhesive pads approximately 20 to 30 mm into the skin. Following needle insertion, manual manipulation of needles will be performed on all needles to reach de qi (a composite of sensations including soreness, numbness, distention, heaviness, and other sensations). Then, paired electrodes from the EA apparatus will be attached transversely to the needle handles at bilateral ST36 and GB34. EA stimulation lasted for 30 minutes with a continuous wave of 10 Hz and a current intensity of 0.5 to 1 mA (preferably with the skin around the acupoints shivering mildly without pain). Participants will receive 6 treatment sessions once daily for 6 consecutive days.
223694678|NCT06666946|DEVICE|Sham electroacupuncture|Non-insertive placebo needles (size 0.30 × 30 mm), and SDZ-V EA apparatuses will be used. Participants in the sham EA group will receive sham EA with a non-insertive placebo needle on sham acupoints. The sham ST36 point is located at 1 cun (≈20 mm) lateral to ST36, and the sham GB34 point is located at 1 cun (≈20mm) lateral to GB 34. Procedures, electrode placements, and other treatment settings will be the same as in the EA group but with no skin penetration, electricity output, or de qi.
223694679|NCT04468321|DEVICE|Apple Watch|Participants will be assigned to the Apple Watch arm to assess the impact of individual use of the Apple Watch on patient-reported and clinical utilization outcomes using Hugo.
223694680|NCT04468321|DEVICE|Withings Move|Participants will be assigned to the Withings Move arm to assess the impact of individual use of the Withings Move on patient-reported and clinical utilization outcomes using Hugo.
223694681|NCT02597153|DRUG|Mitoxantrone HCL Liposome Injection|
223694682|NCT04737135|OTHER|Non intervention|Patients without intervention
223694683|NCT06512545|OTHER|second allogeneic stem cell transplantation|"1. Change another donor if possible~2. Conditioning regimen: fludarabine (30mg/m2/day, days -6 to -2 )/cyclophosphamide (1g/m2/day, days -5 to -4)/rabbit antithymocyte globulin (1.5mg/kg/day, days -4 to -2)~3. GVHD prophylaxis: cyclosporine A (concentration 150-250ng/ml), mycophenolate mofetil (0.5g bid -3d to neutrophil engraftment)+anti CD25 monoAb (20mg, +1d, +8d, +15d)"
223694684|NCT06306144|BEHAVIORAL|Psychoeducation|Arm 1 : Psychoeducation aims to inform patients about post-stroke cognitive impairment, teach them coping strategies to compensate for these difficulties, provide information on symptom recognition and management, and offer emotional and psychological support to help them meet the challenges associated with these potential cognitive impairments.
223694685|NCT06306144|BEHAVIORAL|Computerised Cognitive Stimulation|Arm 2 :Patients will participate in a 6-week cognitive stimulation telerehabilitation intervention, that will consist of two 45-minute sessions per week. Each week they will participate in a 45-minute on-line session with a rehabilitation clinician and later in the week will complete 45 minutes of on-line exercises set by the rehabilitation clinician
223694686|NCT06306144|BEHAVIORAL|Usual Care|Arm 3 : No specific care.
223694687|NCT04956250|OTHER|Traffic Calming Curbs|Temporary curb extensions, placed at intersections.
223694688|NCT04956250|OTHER|In-Street Pedestrian Sign|Yield sign placed in middle of road at intersection.
223694689|NCT00550251|DEVICE|Acupressure Wrist Bands (Sea-Bands)|Elasticated wrist bands with active bead pressing on Pericardium 6 acupressure points bilaterally.
223694690|NCT00550251|DEVICE|Placebo wristbands|Elasticated wrist bands without active bead.
223694691|NCT05644496|DRUG|Bupivacaine-Meloxicam 400 Mg-12 Mg/14 mL Injectable Solution, Extended Release|Instillation of the drug into the knee joint capsule and surrounding tissues after placing the knee prosthesis and before close of the surgical wound
223694692|NCT03237871|BEHAVIORAL|Text-message survey and informational text messages|Participants will complete a text-messaged survey each week for 5 weeks assessing economic and sexual risk behaviors. Participants will also receive 3 informational text messages each week for 5 weeks on HIV prevention and economic empowerment.
223694693|NCT05072886|DRUG|AT193|Topical applied to affected areas daily
223694694|NCT01334242|DRUG|Schedule A|Dosing 1 hour before breakfast
223694695|NCT01334242|DRUG|Schedule B|Dosing 0.5 hour before breakfast
223694696|NCT01334242|DRUG|Schedule C|Dosing immediately before breakfast
223694697|NCT01334242|DRUG|Schedule D|Dosing immediately before lunch
223694698|NCT01334242|DRUG|Schedule E|Split dose, dosing 1 hour before breakfast and dinner
223694699|NCT03959228|DRUG|keto-analogs|The patients that will be included in the experimental arm will have additional keto-analogs (1 pill/5 kg).
223694700|NCT05595382|BEHAVIORAL|Emotional Appeal|Participants will be presented with a short vignette about a child undergoing cancer treatment and needing a bone marrow transplant in order to survive cancer.
223694701|NCT05595382|BEHAVIORAL|Rational Appeal|Participants will be presented with data regarding the importance of considering race/ethnicity when looking for a bone marrow transplant donor and the likelihood of finding a match based on the patient's racial/ethnic background.
223694702|NCT06656312|DEVICE|Use ASUS EndoAim as an assistant software to perform colonoscopy|Use ASUS EndoAim as an assistant software to perform colonoscopy
223694703|NCT00043121|DRUG|oxaliplatin|Given IV
223694704|NCT00043121|DRUG|leucovorin calcium|Given IV
223694705|NCT00043121|DRUG|fluorouracil|Given IV
223694706|NCT00043121|DRUG|capecitabine|Given orally
223778997|NCT06026566|DRUG|Dos of Afentanil 70|the dosage of Afentanil is 70 ng/ml for TCI
223778998|NCT06026566|DRUG|Dos of Afentanil 80|the dosage of Afentanil is 80 ng/ml for TCI
223694707|NCT00043121|OTHER|pharmacological study|Correlative studies
223694708|NCT06663917|OTHER|Experimental frequency allocation table (FAT) - 438 Hz|"The modified cochlear implant program (experimental FAT) changes which frequencies are presented to the cochlear implant. The experimental FAT frequency of 438 Hz will be loaded onto the subjects processor via the CI Select Mobile App. Subjects will use the experimental FAT for one month."
223694709|NCT06663917|OTHER|Standard FAT - 188 Hz|All subjects will retain one program with the standard 188 Hz FAT. Subjects will use the standard FAT for one month.
223778999|NCT06026566|DRUG|Dos of Afentanil 90|the dosage of Afentanil is 90 ng/ml for TCI
223779000|NCT06026566|DRUG|Dos of Afentanil 100|the dosage of Afentanil is 100 ng/ml for TCI
223779001|NCT05885347|OTHER|360 videos|Caregivers will receive 2h session of 360 videos about caring and medication errors. Then Caregivers will be recorded performed the task worked in 360 videos instantly after the education and after 6 months.
223779002|NCT05885347|OTHER|VR|Caregivers will receive 2h session of VR about caring and medication errors. Then Caregivers will be recorded performed the task worked inVR instantly after the education and after 6 months.
223779003|NCT05885347|OTHER|AR|Caregivers will receive 2h session of AR videos about caring and medication errors. Then Caregivers will be recorded performed the task worked in AR videos instantly after the education and after 6 months.
223779004|NCT05885347|OTHER|Control group|Caregivers will follow the routine and then will be recorded performing their labour as a caregiver after 6 months.
223779005|NCT03459417|PROCEDURE|intrathecal morphine+LA|Lumbar puncture will be performed in the sitting position. A 25 gauge (pencil point, Braun, Melsungen, Germany) spinal needle will be introduced into the subarachnoid space at the L3-L4 lumber level midline approach with the needle orifice cephalad. Cerebrospinal fluid will be aspirated and the ready mixture will be injected to subarachnoid space over the period of 15 s, with barbotage. patients will receive intrathecal LA 15 mg (3 mL) (hyperbaric bupivacaine 0.5%) intrathecal with 0.5 mg preservative free morphine + magnesium sulfate 100 mg.
223779006|NCT03459417|PROCEDURE|intrathecal morphine+LA+ Mg sulp. 50|Lumbar puncture will be performed in the sitting position. A 25 gauge (pencil point, Braun, Melsungen, Germany) spinal needle will be introduced into the subarachnoid space at the L3-L4 lumber level midline approach with the needle orifice cephalad. Cerebrospinal fluid will be aspirated and the ready mixture will be injected to subarachnoid space over the period of 15 s, with barbotage.patients will receive intrathecal 15 mg (3 mL) of hyperbaric bupivacaine 0.5% intrathecal +0.5 mg preservative free morphine + magnesium sulphate 50 mg.
223779007|NCT03459417|PROCEDURE|intrathecal morphine+LA+ Mg sulp. 100|Lumbar puncture will be performed in the sitting position. A 25 gauge (pencil point, Braun, Melsungen, Germany) spinal needle will be introduced into the subarachnoid space at the L3-L4 lumber level midline approach with the needle orifice cephalad. Cerebrospinal fluid will be aspirated and the ready mixture will be injected to subarachnoid space over the period of 15 s, with barbotage.patients will receive intrathecal 15 mg (3 mL) of hyperbaric bupivacaine 0.5% intrathecal with 0.5 mg preservative free morphine + magnesium sulphate 100 mg.
223779008|NCT02664428|DIETARY_SUPPLEMENT|PreBIOil|A daily dose of about 90 gram will be given for 8 weeks
223694710|NCT06825494|DRUG|LM-108 injection+Penpulimab+ Oxaliplatin+Capecitabine|"LM-108 injection is a monoclonal antibody that selectively clears regulatory T cells that infiltrate tumor sites.~Penpulimab is a novel and differentiated programmed cell death protein 1 (PD-1) monoclonal antibody.~Oxaliplatin is a third-generation platinum drug. Capecitabine is a fluoropyrimidine."
223694711|NCT06825494|DRUG|Tislelizumab+Oxaliplatin+Capecitabine|"Tislelizumab is a humanized monoclonal antibody against Programmed cell death -Ligand-1(PD-1).~Oxaliplatin is a third-generation platinum drug. Capecitabine is a fluoropyrimidine."
223694712|NCT06825494|DRUG|LM-108 injection 10mg/kg +penpulimab|"LM-108injection is a monoclonal antibody that selectively clears regulatory T cells that infiltrate tumor sites.~Penpulimab is a novel and differentiated programmed cell death protein 1 (PD-1) monoclonal antibody."
223694713|NCT06825494|DRUG|LM-108 injection 600mg + penpulimab|"LM-108 injection is a monoclonal antibody that selectively clears regulatory T cells that infiltrate tumor sites.~Penpulimab is a novel and differentiated programmed cell death protein 1 (PD-1) monoclonal antibody."
223694714|NCT02422940|DRUG|dalfampridine-ER 7.5 mg|
223694715|NCT02422940|DRUG|dalfampridine-ER 10 mg|
223694716|NCT06486558|DRUG|HU6 450 mg Tablet|new 450 mg tablet test formulation
223694717|NCT06486558|DRUG|HU6 150 mg Capsules x 3 (Total dose = 450 mg)|150 mg capsule reference formulation (3 x 150 mg).
223694718|NCT06145659|BEHAVIORAL|Preschool and Me|Utilizes patient navigation services and a medical-educational care plan to support linkages between medical and educational systems
223694719|NCT06585982|DIETARY_SUPPLEMENT|Treatment|RILLUS is a synbiotic produced by Kalbe Farma
223694720|NCT06585982|DIETARY_SUPPLEMENT|Control|Placebo produced by Kalbe Farma
223694721|NCT06591286|DEVICE|RT-CGM|This group of patients will wear RT-CGM for blood glucose monitoring for three months.
223694722|NCT06591286|DEVICE|SMBG|This group of patients will use a a fingertip glucose meter for blood glucose monitoring for three months, and the monitoring frequency was not less than 4 times per week.
223694723|NCT02942329|DRUG|apatinib|Apatinib was administered 250mg or 375mg orally daily. For gastric cancer patients, the dose would be 250mg or 375mg daily. For hepatocellular carcinoma patients, the dose would be 250mg daily.
223694724|NCT02942329|DRUG|SHR-1210|SHR-1210 was administered 200mg (3mg/kg for underweight patients) iv every 2 weeks.
223694725|NCT02445391|DRUG|Capecitabine|Given PO
223694726|NCT02445391|DRUG|Carboplatin|Given IV
223694727|NCT02445391|DRUG|Cisplatin|Given IV
223694728|NCT00560885|DEVICE|AtriCure Bipolar System|Surgical bipolar radiofrequency ablation using the AtriCure Bipolar System
223694729|NCT01993784|DRUG|nimotuzumab|
223694730|NCT02216825|DIETARY_SUPPLEMENT|Delayed release capsule, L. reuteri NCIMB 30242, escalated dose|
223694731|NCT02216825|DIETARY_SUPPLEMENT|Standard vegetarian capsule, L. reuteri NCIMB 30242, escalated dose|
223694732|NCT06608368|DRUG|Test Dentifrice (Sensodyne Repair and Protect Original Mint)|Dentifrice containing 5% w/w NovaMin (Calcium Sodium Phosphosilicate) and 1040 ppm fluoride as sodium fluoride.
223694733|NCT06608368|DRUG|Positive Control Dentifrice (Sensodyne Fresh Mint)|Dentifrice containing 5% w/w KNO3 and 1150 ppm fluoride as sodium fluoride.
223694734|NCT06608368|DRUG|Reference Dentifrice (Crest Cavity Protection Regular)|Dentifrice containing 1100 ppm fluoride as sodium fluoride.
223694735|NCT03722173|DRUG|Itraconazole|Oral solution
223694736|NCT03722173|DRUG|BI 894416|Tablet
223694737|NCT01176344|DRUG|Vitamin D|50,000 IU (1.25 mg) cholecalciferol capsules once monthly for 2 years
223694738|NCT01176344|DRUG|Placebo|Inert placebo capsules once monthly for 2 years.
223694739|NCT05928871|DRUG|Misoprostol 200mcg Tab|60 women: will receive preoperative 600 microgram of misoprostol ( 3 tablets ) rectally after spinal anaesthesia and urinary catheterization and postoperative placebo (3 tablets). (as per WHO dose recommendation)
223694740|NCT05928871|DRUG|Misoprostol Pill|"60 women: will receive preoperative placebo 3 tablets and postoperative 600 microgram of misoprostol  3 tablets at operating theatre (as per WHO dose recommendation)."
223694741|NCT00982696|BIOLOGICAL|Opioid Growth Factor|250ug per kilogram weekly IV infusions
223694742|NCT05024045|DRUG|LOXO-338|Oral
223694743|NCT05024045|DRUG|Pirtobrutinib|Oral
223694744|NCT06676709|BIOLOGICAL|IMMUNEPOTENT-CRP (I-CRP)|IMMUNEPOTENT-CRP (I-CRP), a bovine dialyzable leukocyte extract (DLE) obtained from disrupted spleen cells, is a mixture of low-molecular-weight peptides (\<12 kDa) that exhibit non-specific immunomodulatory properties.
223779009|NCT02664428|DIETARY_SUPPLEMENT|Control|A daily dose of about 90 gram will be given for 8 weeks
223779010|NCT06332794|DEVICE|KOKU4PD|Exercise at home using the KOKU app for 4 weeks.
223779011|NCT05604729|DRUG|Botulinum toxin type A|Botulinum Neurotoxin type A
223779012|NCT05604729|DRUG|Placebo|Saline solution
223779013|NCT02691858|DRUG|Hydrocortisone|10 mg/kg with Resuscitation before attempting pneumatic reduction, single dose with Resuscitation before attempting reduction
223779014|NCT02691858|DRUG|Saline|100 ml with Resuscitation before attempting pneumatic reduction, single dose with Resuscitation before attempting reduction
223779015|NCT04979221|DRUG|Cyproheptadine|Cyproheptadine 8mg three times a day during 10 days
223779016|NCT02139163|OTHER|Cohort Study|
223779017|NCT00141960|DRUG|Famotidine|
223779018|NCT03937375|BEHAVIORAL|High PEEP|Use of high levels of PEEP combined with recruitment maneuvers and low tidal volume ventilation during general anesthesia
223779019|NCT03937375|BEHAVIORAL|Low PEEP|Use of low levels of PEEP without recruitment maneuvers and low tidal volume ventilation during general anesthesia
223779020|NCT05634265|BEHAVIORAL|Vijana-SMART|The Vijana-SMART intervention is a facilitated peer group, delivered through WhatsApp. Intervention messages were developed based on findings from formative interviews and social support theory, which posits that individuals experience social support through informational, instrumental, companionship and emotional forms. Groups will have approximately 25 members and will be facilitated by a study team member, by sending weekly scheduled messages, answering participant questions, and encouraging group discussion. Intervention messages were designed based on guidance from formative interviews; topics include ART adherence, medication side effects, nutritional practices, depression, social support, HIV status disclosure, stigma, positive prevention, substance use, and contraception.
223779021|NCT01946061|DRUG|S-1 plus oxaliplatin|Patients will receive adjuvant chemotherapy of eight 3-week cycles of oral S-1 (70 mg/m2/day on days 1 to 14 of each cycle) plus intravenous oxaliplatin (130 mg/m2 on day 1 of each cycle) for 6 months after D2 gastrectomy.
223779022|NCT03701477|BEHAVIORAL|Trans-diagnostic cognitive-behavioral therapy|10 therapeutic sessions hold in groups of 5-10 individuals. Details about each session: Session 1: Establishing rapport, psychoeducation; Session 2: Relaxation, hierarchy development; Session 3: Identifying automatic negative thoughts, guided imaginary; Session 4: Cognitive restructuring; Session 5: Problem solving skills training, distraction; Session 6: Exposure-based procedures, cognitive restructuring; Session 7-9: Advanced cognitive restructuring, stress management, assertiveness skills training, preparation for termination phase; Session 10: Relapse prevention, termination
223779023|NCT03701477|BEHAVIORAL|General relaxation/stress management therapeutic session|Patients will attend a 3-hour meeting in which basic techniques of relaxation and stress management will be discussed.
223779024|NCT01369290|DRUG|Venlafaxine|75 to 375 mg/day for 6 weeks. If no response at 6 weeks, reassignment to one of the other treatment groups for a further 6 to 12 weeks in phase II.
223779025|NCT01369290|DRUG|bupropion|150 to 300 mg daily for 6 weeks. If no response at 6 weeks, reassignment to one of the other treatment groups for a further 6 to 12 weeks in phase II.
223779026|NCT01369290|DRUG|escitalopram|10 to 30 mg daily for 6 weeks. If no response at 6 weeks, reassignment to one of the other treatment groups for a further 6 to 12 weeks in phase II.
223779027|NCT01369290|OTHER|Psychotherapy|Once weekly CBT psychotherapy session for 12 weeks. If no response at 12 weeks, reassignment to one of the other treatment groups for a further 6 weeks in phase II.
223779028|NCT01369290|DRUG|Duloxetine|30 to 60 mg daily for 6 weeks. If no response at 6 weeks, reassignment to one of the other treatment groups for a further 6 to 12 weeks in phase II.
223779029|NCT00614939|DRUG|Saxagliptin|2.5 mg once daily oral dose
223779030|NCT00614939|DRUG|Placebo|Placebo
223779031|NCT01506245|BEHAVIORAL|Family-based behavioral therapy|The intervention consist of a 6-month family-based behavioural therapy either in group (1 session/week, with a dietician and a psychologist) or in individual setting (with a paediatrician or a dietician in alternance 1x/month). Both therapies include exercise training twice per week (60 minutes each). Parents, or at at least the mother, must participate to the behavioral treatment.
223779032|NCT00840970|DEVICE|non-coated Intranasal Splint|placement of non-coated intranasal splint following FESS
223779033|NCT00840970|DEVICE|Sinexus Intranasal Splint|placement of Sinexus Intranasal Splint placed following FESS
223779034|NCT03901248|OTHER|No Intervention|Observational study
223779035|NCT00000463|DRUG|lovastatin|
223694745|NCT06676709|BIOLOGICAL|Placebo Comparator|The placebo was prepared from a lyophilized corn starch extract and was provided in an identical appearance and presentation to IMMUNEPOTENT-CRP (I-CRP).
223694746|NCT06671002|DRUG|NSAID|"Once randomized to this group the surgical team will elect to prescribe 1 of the following treatment options for post-discharge pain:~* Ibuprofen 10 milligrams(mg)/kilogram (kg) (maximum 600mg) by mouth every 6 hours around the clock for 2 days, then as needed for pain thereafter (40 doses)~* Celecoxib 6mg/kg (maximum 400mg) by mouth once then 3 mg/kg (maximum 200mg) every 12 hours around the clock for 2 days, then as needed for pain thereafter (40 doses)"
223779036|NCT00000463|DRUG|cholestyramine|
223694747|NCT06671002|DRUG|Opioid|"Once randomized to this group the surgical team will elect to prescribe for 1 of the following treatment options to be given post procedure for post-discharge pain:~* Oxycodone 0.1 mg/kg (maximum 5 mg) by mouth every 4 to 6 hours as needed for pain, number 10 doses.~* Hydromorphone 0.04 mg/kg (maximum mg) by mouth 4 to 6 hours as needed, number 10 doses"
223694748|NCT06671002|DRUG|Acetaminophen|Participants will receive 15mg/kg up to 1000mg by mouth every 6 hours around the clock for the first 2 days after discharge from surgery then as needed thereafter (40 doses)
223694749|NCT06671002|DRUG|Ibuprofen|Ibuprofen 10mg/kg (maximum 600 mg) by mouth every 6 hours around the clock for 2 days after discharge from surgery then as needed thereafter (40 doses)
223779037|NCT00000463|DRUG|warfarin|
223779038|NCT06262087|BEHAVIORAL|Change of direction training|The experimental group is implemented FIFA 11+ program combined with COD training
223779039|NCT06262087|BEHAVIORAL|FIFA 11+ program|The experimental group is implemented FIFA 11+ program.
223779040|NCT03663114|DRUG|Lenvatinib|Lenvatinib capsule
223779041|NCT00003863|GENETIC|comparative genomic hybridization|
223779042|NCT00003863|GENETIC|cytogenetic analysis|
223779043|NCT00003863|GENETIC|fluorescence in situ hybridization|
223779044|NCT00003863|GENETIC|gene rearrangement analysis|
223779045|NCT00824109|DEVICE|Second Generation Anti-Microbial bifurcated vascular graft (InterGard)|treatment of patients with aorto-iliac occlusion,stenosis, or aneurysm
223779046|NCT05702957|DRUG|letrozole 2.5mg-7.5mg|Tab letrozole 2.5 mg-7.5mg per day for 5 days started from 2nd day of menses.
223779047|NCT05702957|DRUG|Clomiphene Citrate 50mg-150mg|Tab clomiphene citrate 50-150mg per day for 5 days started from 2nd day of menses.
223779048|NCT03650205|DRUG|Ivabradine|Ivabradine capsule
223779049|NCT03650205|DRUG|Placebo|Placebo oral capsule.
223779050|NCT04620317|DIETARY_SUPPLEMENT|Synbiotic|10 billion (B) colony forming unit (CFU) of Lactobacillus plantarum LP01, Bifidobacterium lactis BB12, and inulin oligofructose
223779051|NCT04620317|DIETARY_SUPPLEMENT|Placebo|Non-active ingredients - Maltodextrins
223779052|NCT00504829|DRUG|LCP-AtorFen|40mg atorvastatin combined with 100mg fenofibrate in a tablet for once daily treatment of dyslipidemia and mixed dyslipidemia
223779053|NCT00504829|DRUG|atorvastatin|dyslipidemia and mixed dyslipidemia
223779054|NCT00504829|DRUG|fenofibrate|dyslipidemia and mixed dyslipidemia
223779055|NCT04939259|DEVICE|New Music Program|A mini behind-the-ear hearing aid that amplifies sounds and directs them into the ear. The music program within the hearing aid will provide amplification specifically tuned for listening to music.
223779056|NCT04939259|DEVICE|Standard Listening Program|A mini receiver-in-the-ear hearing aid that amplifies sounds and directs them into the ear. The standard listening program within the hearing aid will provide amplification specifically tuned for listening to speech and daily general sounds in the environment.
223779057|NCT01771003|DEVICE|CellAegis' autoRIC™ Device|Patients in the active group will have the autoRIC device (like a blood pressure cuff) inflated and deflated to a pressure of 200 mmHg in four 5 minute cycles with intervening 5 minutes of reperfusion with the cuff deflated between cycles
223779058|NCT03959501|DRUG|Dapagliflozin 10 mg|Dapagliflozin 10mg daily for 24 weeks
223779059|NCT03959501|DRUG|Sitagliptin 100mg|Sitagliptin 100mg daily for 24 weeks
223779060|NCT01854827|DRUG|Intravenous immunoglobulin (IVIG)|All participants will receive the same dose of IVIG at the same intervals in an open-label fashion as long as the subject does not have any increased risk for toxicity for any IVIG infusion. IVIG will be initiated on day 3 (up to day 5) after HPE surgery (HPE is day 0) at a dose of 1 gm/kg body weight by slow intravenous infusion over at least 4 hours. The same dose (1 gm/kg) and duration of infusion will be repeated on day 30 and day 60 after HPE.
223779061|NCT02688634|DRUG|Amoxicillin|Amoxicillin will be given as: 7 days, 20mg/kg orally every 6 hours to a maximum of 1.8g/day for a 7-day period.
223779062|NCT01850160|DRUG|GROUP A: Valsartan plus Chlorthalidone|Combination therapy of Valsartan plus Chlorthalidone: Valsartan 80 mg / Chlorthalidone 12,5 mg. Once daily during 12 weeks. If the goals of blood Pressure are uncontrolled at week 6, the dose will be increase to Valsartan 160 mg / Chlorthalidone 25 mg once daily.
223779063|NCT01850160|DRUG|GROUP B: Valsartan|GROUP B: Treatment monotherapy: Valsartan 80 mg once daily during 12 weeks. If the goals of blood Pressure are uncontrolled at week 6, the dose will be increase to Valsartan 160 mg once daily.
223779064|NCT01850160|DRUG|GROUP C: Chlorthalidone|GROUP C: Treatment monotherapy: Chlorthalidone 12,5 mg once daily during 12 weeks. If the goals of blood pressure are uncontrolled at week 6, the dose will be increase to Chlorthalidone 25 mg once daily.
223779065|NCT00687258|DEVICE|VitabranE ViE|Polysulfone dialyser with vitamin E alpha-tocopherol
223779066|NCT01991834|PROCEDURE|gynecologic laparoscopy|Gynecological laparoscopy without opening hollow viscera.
223779067|NCT01991834|DRUG|Cefazolin|Intravenous administration of 1 g of cefazolin
223779068|NCT01991834|DRUG|Placebo|Intravenous administration of saline sterile solution
223779069|NCT03789539|BIOLOGICAL|LD Universal Influenza Vaccine Uniflu|low dose Universal Influenza Vaccine Uniflu
223779070|NCT03789539|BIOLOGICAL|HD Universal Influenza Vaccine Uniflu|High dose Universal Influenza Vaccine Uniflu
223779071|NCT03789539|BIOLOGICAL|Placebo|Placebo saline
223779072|NCT03038373|PROCEDURE|Laparoscopic Sleeve Gastrectomy|Laparoscopic Sleeve Gastrectomy will be conducted based on standard protocol.
223779073|NCT05709730|DIAGNOSTIC_TEST|HPV genotyping|"HPV genotyping of samples classified that were positive for other HPV"
223779074|NCT02571452|BEHAVIORAL|Brief Behavioral Treatment for Insomnia|Participants will receive 4 weeks of Brief Behavioral Treatment for Insomnia (BBTI). BBTI consists of two in-person sessions, with the two other sessions conducted via telephone. BBTI emphasizes behavioral elements of insomnia treatment. Treatment begins with sleep education and discussion of the biological rhythms that influence sleep cycles. Next, a series of interventions are employed that are derived from sleep restriction and stimulus control techniques.
223779075|NCT02571452|BEHAVIORAL|Progressive Muscle Relaxation|Participants will receive 4 weeks of progressive muscle relaxation training (PMRT). PMRT consists of two in-person and two phone sessions. Treatment begins with training on muscle tensing and relaxing, and advances to progressively more efficient tensing-relaxing and passive relaxation exercises. Sessions are employed that teach techniques and problem-solve barriers to the use of PMRT.
223779076|NCT05581446|DIAGNOSTIC_TEST|Visual Analogue Scale|pain type severity determination and quality of life assessment
223779077|NCT05117606|DEVICE|LYNG by Ably Medical|Comparing LYNG to traditional, standard equipment for heart rate, respiration, movement, and blood pressure.
223779078|NCT06535672|OTHER|kamishibai education|Patients in the intervention group will be given Kamishibai diabetes education.
223779079|NCT06535672|OTHER|routine education|Patients in the control group will be given routine diabetes education.
223779080|NCT06095414|DIAGNOSTIC_TEST|MRI|MRI based assessment of tumor microenvironment in breast cancer mass
223779081|NCT01714219|PROCEDURE|Posterior reconstruction|
223779082|NCT00499187|PROCEDURE|Blood Draws|A single whole blood sample was collected for genomic analysis.
223779083|NCT02268773|DRUG|Asasantin®|
223779084|NCT02268773|DRUG|Acetylsalicylic acid low dose|
223694750|NCT06678698|DEVICE|Panel Effective Photobiomodulation Therapy|"Photobiomodulation therapy is the use of low-power light in biological tissues through a non-ionizing source of light (600 to 1.100 nm), with variable power between 1 and 500 mW and therapeutic goals.~This group will receive photobiomodulation from a whole-body panel of low intensity LEDs"
223694751|NCT06678698|DEVICE|Sham Panel Photobiomodulation Therapy|Use of common red lamp to perform the sham photobiomodulation for the panel group
223694752|NCT06678698|DEVICE|Modified ILIB Sham Photobiomodulation Therapy|ILIB Therapy device turned off for the sham ILIB therapy
223694753|NCT06678698|DEVICE|Modified ILIB Photobiomodulation Therapy|Common laser used in ILIB mode for modified ILIB therapy
223694754|NCT06871046|DRUG|Esflurbiprofen Topical System (EFTS)|One EFTS is applied to the injured area over 7 days
223694755|NCT06680115|DRUG|Sintilimab|Induction chemotherapy stage: Sintilimab combined with GP regimen chemotherapy; Adjuvant chemotherapy stage: Sintilimab combined with Capecitabine
223694756|NCT03306862|DIETARY_SUPPLEMENT|Whole yellow pea soup|Soup containing whole yellow peas
223694757|NCT03306862|DIETARY_SUPPLEMENT|Split yellow pea soup|Soup containing split yellow peas
223694758|NCT03306862|DIETARY_SUPPLEMENT|Potato soup|Soup containing potatoes
223694759|NCT06624449|BEHAVIORAL|Cold debriefing|Manipulation (experimental): The researcher assigned a cold debriefing (after one-day post-simulation) for undergraduate nursing students in the intervention group.
223694760|NCT06624449|BEHAVIORAL|Hot Debriefing|The control group received a hot debriefing (immediately after the simulation).
223694761|NCT06682169|DRUG|Rovadicitinib|Rovadicitinib is an inhibitor of Janus associated kinases (JAK) family and Rho associated kinases (ROCK). It can inhibit the sustained abnormal activation of the Janus kinase (JAK) signal transducer and activator of transcription (JAK-STAT) pathway and also inhibit Rho associated kinase 2 (ROCK2). The JAK 1-JAK 2 signaling pathway is a key step in causing inflammation and tissue damage in acute and chronic graft-versus-host disease.
223694762|NCT06682169|DRUG|Imatinib|Imatinib tyrosine kinase inhibitor is a small molecule protein kinase inhibitor that has the ability to block one or more protein kinases. Clinically used for the treatment of chronic myeloid leukemia and malignant gastrointestinal stromal tumors.
223694763|NCT06682169|DRUG|Methotrexate|Methotrexate is an organic compound, mainly used as an anti folate anti-tumor drug. It inhibits the synthesis of tumor cells by inhibiting dihydrofolate reductase, thereby inhibiting the growth and reproduction of tumor cells.
223694764|NCT06682169|DRUG|Mycophenolate mofetil|Metoprolol ester is an organic compound mainly used as an immunosuppressant
223694765|NCT06682169|DRUG|Rituximab|Rituximab activates antibody dependent cell-mediated phagocytosis and complement dependent cytotoxicity by binding to cluster of differentiation 20 (CD20) antigen, clearing malignant B cells expressing CD20 and achieving therapeutic goals.
223694766|NCT06688851|DIAGNOSTIC_TEST|Preoperative Cone Beam Computed Tomography (CBCT) scan|A CBCT scan is performed before the surgical intervention.
223694767|NCT06688851|PROCEDURE|Cystostomy|Under local anesthesia, a full-thickness flap is prepared and cystostomy is performed.
223694768|NCT06688851|DIAGNOSTIC_TEST|Histology to confirm the initial diagnosis|A sample of the cyst lining is sent for histologic diagnosis.
223694769|NCT06688851|DEVICE|Patient Specific Implant|The PSI is fixed on the surface of the bone using osteosynthesis screws.
223694770|NCT06688851|PROCEDURE|Cyst decompression|The PSI enables the discharge of the cystic liquid into the oral cavity. The resulting decrease in cystic pressure induces bone healing. Patients are recalled monthly for controls and panoramic X-rays are performed to monitor the decompression.
223779085|NCT02268773|DRUG|Acetylsalicylic acid high dose|
224263506|NCT01483820|DRUG|TPI 287|Subjects will receive six cycles of intravenous (IV) TPI 287 at a dose of 125 mg/m2 on Days 1, 8 and 15 of a 21-day cycle.
224263507|NCT00867360|DRUG|Mifepristone (RU-486)|
224263508|NCT00867360|DRUG|Placebo|Placebo medication
224263509|NCT04673825|OTHER|Patient initiated care + telemonitoring|See arm/group descriptions.
224263510|NCT02763488|DEVICE|DelfiPTS tourniquet system|
224263511|NCT02763488|OTHER|Standard physical therapy|
224263512|NCT03493178|DIETARY_SUPPLEMENT|Glycine|Dietary Supplement: glycine will be supplemented in the active arm for 12-weeks
224263513|NCT03493178|DIETARY_SUPPLEMENT|N-acetylcysteine (NAC)|Dietary Supplement: NAC will be supplemented in the active arm for 12-weeks
224263514|NCT03493178|DIETARY_SUPPLEMENT|Alanine|Dietary Supplement: Alanine will be supplemented in the placebo arm for 12-weeks
224263515|NCT04840927|DRUG|E7386|Regimen A: 40 milligram (mg) IR Oral Tablet.
224263516|NCT06651476|DRUG|oxytocin|Oxytocin 10 IU will be administered over 30 minutes by intravenous infusion and repeated 30 minutes after the end of the first infusion.
224263517|NCT06651476|DRUG|placebo|A placebo will be administered over 30 minutes by intravenous infusion and repeated 30 minutes after the end of the first infusion.
224263518|NCT00013390|PROCEDURE|Tinnitus Masking|"Tinnitus Masking is a widely-used method for providing relief of tinnitus. The central premise of Tinnitus Masking involves the use of wearable ear-level devices (hearing aids, maskers, or combination instruments) that deliver sound to a patient's ear(s). The primary purpose of the sound presentation is to produce a sense of relief from the annoyance caused by the tinnitus sound. The relief is accomplished by either obscuring, or covering up (masking) the tinnitus sound, or by changing the sound of the tinnitus in some way, usually by reducing its loudness (Vernon, Meikle)."
224263519|NCT00013390|PROCEDURE|Tinnitus Retraining Therapy|"Tinnitus Retraining Therapy (TRT) was derived from a purely psychological approach for facilitating tinnitus habituation (Hallam et al). The current method is based on neurophysiological principles, and aims at retraining brain regions that are involved in processing the tinnitus signal, without attempting to suppress generation of the signal (Jastreboff). The retraining involves a systematic effort aimed at decreasing both the detectability of tinnitus and the transmission of the tinnitus signal to emotional centers of the brain. Habituation of tinnitus thus purportedly occurs at two levels: habituation of emotional reactions to the tinnitus and habituation of tinnitus perception. Habituation is achieved by utilizing directive counseling, along with the use of low-level broadband noise to reduce the detectability of tinnitus for patients with normal or near-normal hearing. When hearing loss is a significant problem to the patient, appropriate hearing aids are fitted."
224263520|NCT05377164|BEHAVIORAL|food choices|Analysis of lymphocytes isolated from the peripheral blood of participants who had been on vegetarian, ketogenic or normal mixed diet for at least one year will be performed.
224263521|NCT02336308|DRUG|Ketamine|
224263522|NCT02336308|DRUG|Placebo, Normal Saline|
224263523|NCT02363764|PROCEDURE|Nasal swab|"Will be obtained by the physiotherapist in:~* Expectorating CF patients~* Non-expectorating CF patients~* Bronchoscopy CF patients"
224263524|NCT02363764|PROCEDURE|Cough swab|"Will be obtained by the physiotherapist in:~* Expectorating CF patients~* Non-expectorating CF patients~* Bronchoscopy CF patients"
224263525|NCT02363764|PROCEDURE|Spontaneous expectorated sputum|"Will be obtained by the physiotherapist in:~\- Expectorating CF patients"
224263526|NCT02363764|PROCEDURE|Induced sputum|"Will be obtained by the physiotherapist in:~* Non-expectorating CF patients~* Bronchoscopy CF patients"
224263527|NCT02363764|PROCEDURE|Bronchoalveolar lavage|"Will be obtained by the pulmonologist in:~\- Bronchoscopy CF patients"
223694771|NCT06688851|DIAGNOSTIC_TEST|CBCT|Post-operative CBCT is performed six months after cystostomy to assess whether the cyst volume has been sufficiently reduced for enucleation, minimizing the risk of damage to anatomical landmarks.
223694772|NCT06688851|PROCEDURE|Enucleation|Under local anesthesia a full-thickness flap is raised and the PSI is removed by unscrewing the osteosynthesis screws. The wall of the cyst is completely enucleated and the flap is sutured.
223694773|NCT06688851|DIAGNOSTIC_TEST|Histology performed on the entire lining of the cyst|The residual cyst wall is sent for histopathologic examination.
223694774|NCT06934707|BEHAVIORAL|Three meals a day|This group will follow a dietary prescription consisting of three meals per day. The total energy value will be distributed in accordance with the macronutrient recommendations for type 1 diabetes (T1D), as follows: 45% of energy from total carbohydrates, prioritizing those with a low glycemic index; up to 30% from total fats, with unsaturated fats being the primary source; and 25% of energy from proteins. Caloric distribution will be divided into 30% for breakfast, 40% for lunch, and 30% for dinner, with 14 g of fiber per 1000 kcal distributed across the three meals. Furthermore, the gram amounts of the macronutrient in each meal will be apportioned such that 15-20% of the total carbohydrate intake, 7-10% of the total protein intake, and 10% of the total fat intake.Participants will also be instructed to maintain their habitual physical activity level.
223694775|NCT06934707|BEHAVIORAL|Six meals a day|This group will follow a dietary prescription consisting of six meals per day. The total energy value will be distributed in accordance with the macronutrient recommendations for type 1 diabetes (T1D), as follows: 45% of energy from total carbohydrates, prioritizing those with a low glycemic index; up to 30% from total fats, with unsaturated fats being the primary source; and 25% of energy from proteins. Caloric distribution will be divided into 20% for breakfast, 10% morning snack, 30% for lunch, 10% afternoon snack, 25% for dinner and 5% bedtime snack, with 14 g of fiber per 1000 kcal distributed across the three meals. Furthermore, the gram amounts of the macronutrient in each meal will be apportioned such that 5-10% of the total carbohydrate intake, 2-7% of the total protein intake, and 2-8% of the total fat intake.Participants will also be instructed to maintain their habitual physical activity level.
223694776|NCT04021563|DRUG|SR419|Ascending single and multiple doses of SR419 orally
223694777|NCT04021563|DRUG|Placebo|Ascending single and multiple doses of placebo orally
223694778|NCT06686238|DEVICE|MITOVIT® Hypoxic Training System|The EG (Experimental Group) will undergo a single session of IHHE (Intermittent Hypoxia-Hyperoxia Exposure) session using the MITOVIT® Hypoxic Training System (COMMIT GmbH, Salzgitter, Germany). They will breathe air with an oxygen concentration (FiO2) ranging from 10-14% for 5 minutes, followed by 3 minutes of rest in hyperoxia (FiO2 30-40%), for a total of 6 cycles. During the hypoxic phase, oxygen saturation will be maintained between 85-92%, while during the hyperoxic phase, it will be kept above 95%. This process is regulated by the device's AI. Participants will be asked to sit and breath normally in each exposure. An attendance checklist will be used to monitor compliance with the intervention
223694779|NCT06686238|DEVICE|Sham MITOVIT® Hypoxic Training System|The Sham Group (SG) will follow a single session protocol of 5 cycles of 6 minutes per session with an FiO2 of 21% using the MITOVIT® Hypoxic Training System (COMMIT GmbH, Salzgitter, Germany). Participants will be asked to sit and breath normally in each exposure. An attendance checklist will be used to monitor compliance with the placebo intervention.
223694780|NCT06696586|DRUG|Fentanyl infusion|will received lidocaine with dose 250 mg and fentanyl infusion in dose of 200 µg in rate 10ml /hr using 50ml syringe pump.
223694781|NCT06696586|DRUG|Fentanyl Injection|will receive lidocaine 250 mg in addition to fentanyl injection in dose 100 µg by shots
223694782|NCT06620042|DRUG|Ketamine|Open-label Ketamine
223694783|NCT06620042|OTHER|Functional magnetic resonance imaging (fMRI)|Functional magnetic resonance imaging (fMRI) of the brain
223694784|NCT06709560|OTHER|Moderate Intensity Continuous Exercise|Participants perform a continuous cycling exercise session on a reclined ergometer at moderate intensity (50% HRR)
223694785|NCT06709560|OTHER|Vigorous Intensity Continuous Exercise|Participants perform a continuous cycling exercise session on a reclined ergometer, at a vigorous intensity (80% HRR).
223694786|NCT06709560|OTHER|Moderate Intensity Continuous Exercise Matched for Blood Pressure|Participants perform a cycling session where exercise intensity is adjusted to match the systolic blood pressure levels attained during the first visit at moderate intensity (50% HRR).
223694787|NCT06709560|OTHER|Vigorous Intensity Continuous Exercise Matched for Blood Pressure|Participants perform a different cycling session where exercise intensity is adjusted to match the systolic blood pressure levels attained during the first visit at vigorous intensity (80% HRR).
223694788|NCT06706765|BEHAVIORAL|Behavioral Treatment|Behavioral cough suppression therapy delivered in a group setting via telehealth.
223694789|NCT06710431|DRUG|AFA-281|AFA-281
223694790|NCT06709326|DIAGNOSTIC_TEST|Apheresis|Isolate tumor cells, immune cells, exosomes and cell free DNA from the blood by a clinically used method of whole blood volume filtration, apheresis, and subsequent separation of blood components using novel techniques, such as acoustophoresis and other experimental protocols.
223694791|NCT06709326|OTHER|Androgen deprivation therapy|Apheresis will be performed before initiation of systemic therapy (androgen deprivation therapy) and 4 weeks after. Androgen deprivation therapy is treatment as per clinical routine and not part of the protocol.
223694792|NCT06709326|DIAGNOSTIC_TEST|Anti androgen therapy|Apheresis will be performed before initiation of systemic therapy (anti androgen therapy). Anti androgen therapy is treatment as per clinical routine and not part of the protocol.
223779086|NCT03888573|OTHER|Stretching protocol|Patients within Stretch Group will receive stretching protocols to the cervical musculature at the side of symptoms. Traction Group will be treated with traction from 15-degree flexion, 30-degree lateral bending, and 15-degree rotation toward the painful side.
223779087|NCT03807362|DRUG|CC-11050|CC-11050 is a novel anti-inflammatory compound with potential to treat a variety of chronic inflammatory conditions.
223694793|NCT06710600|DRUG|Single oral dose of selected medicines, respectively|amiodarone (Amiodaron Arcana) 200mg, diclofenac (Diclobene) 100mg, hydrochlorothiazide (HCT G.L) 25mg, pantoprazole (Pantoloc) 40mg, voriconazole (Voriconazol Aristo®) 200mg
223694794|NCT06710600|RADIATION|UVA and UVB radiation|The skin of the inner arm will be exposed to five fixed incremental doses of UVA and UVB. Each dose will be applied to a circular area on the inner forearm of 1 cm diameter for both UVA and UVB.
223694795|NCT06710600|DRUG|Single oral dose of selected medicines, respectively|"acetylsalicylic acid (ASS Genericon) 500mg, doxycycline (Doxybene) 200mg, enalapril (Enalapril ratiopharm) 10mg, furosemide (Lasix) 40mg, verapamil (Verapabene) 80mg"
223694796|NCT06707285|DEVICE|MRI|1.5T siemens
223779088|NCT00749151|BEHAVIORAL|telephone counseling|First time callers to telephone help line agreed to one year follow-up on smoking cessation.
223694797|NCT06709638|OTHER|Placebo Comparator|Placebo Comparator
223694798|NCT06709638|DRUG|Zhilong Huoxue Tongyu capsule|Zhilong Huoxue Tongyu capsule
223779089|NCT02816671|DEVICE|Surgical Stapler|Patients in whom the MicroCutter stapler was used during a thoracic surgical procedure.
223779090|NCT02515019|DEVICE|Bispectral index Monitoring|In group SevoBIS, the sevoflurane concentration was titrated to maintain a target BIS value between 40 and 60.
223779091|NCT01142258|DRUG|Trazodone|Trazodone tablets, 50 mg, 10pm (before bedtime) for 14 days.
223779092|NCT01142258|DRUG|Placebo|Inactive or inert pill which will be used as a comparator
223779093|NCT00501605|DRUG|AZD2171|
223779094|NCT03380923|BEHAVIORAL|Moderate Intensity|Exercise prescription intensity is moderate
223779095|NCT03380923|BEHAVIORAL|High Intensity|Exercise prescription intensity is high
223779096|NCT04143347|OTHER|No Intervention|
223694799|NCT06706947|PROCEDURE|Lymphaticovenous Anastomosis|"Lymphaticovenous Anastomosis (LVA) is an emerging super-microsurgical procedure pioneered by Professor Xie Qingping and his team, a group of Chinese microsurgery experts. This technique has been published in the official journal of the American Society of Plastic Surgeons (ASPS), confirming its effectiveness in improving the drainage function of the brain and reducing lymphatic pressure in deep brain tissues. By establishing an anastomosis between lymphatic vessels and veins in the neck, the surgery enhances the drainage of cerebrospinal fluid, alleviating the accumulation of toxins and waste within the brain, thereby easing the symptoms of Alzheimer's disease. Due to its significant contribution to the field of microsurgery, this innovative surgery has been selected as one of the Top Seven Advances in Microsurgery for 2022."
223694800|NCT06708650|RADIATION|Combination of SFRT, PD-L1 inhibitor, and Anti-VEGF|Patients received intravenous PD-1 inhibitor 200mg(Camrelizumab, Tislelizumab, or Sintilimab) plus oral Apatinib 250 mg or Lenvatinib 12mg (for bodyweight ≥60 kg) or 8 mg/kg (for bodyweight \<60 kg) daily, and additional SFRT for primary liver tumor. PD-1 inhibitor is administered for 2 years or until disease progression or intolerance. Anti-VEGFR is continued until disease progression or intolerance. SFRT implementation plan is as follows: The GTV consists of 2-5 sub-target volumes, which are cylindrical shapes with a diameter of 1.6cm, a height of 2cm, and an interval of 3-5cm. The total volume of the GTV is about 8-20cc, and the distance between the GTV and the OARs is greater than 2cm. The prescribed dosage for each course of radiotherapy is 24 Gy in 3 daily fractions (8Gy x 3F), with a 3-week interval between courses (Q3W). The total courses of radiotherapy shall not be less than 2 (depending on the efficacy and cumulative dose of OARs).
223694801|NCT06708858|DRUG|Surufatinib|200mg，qd，po
223694802|NCT06708858|DRUG|Gemcitabine|1000mg/ m2, IV，d1，8，q3w
223694803|NCT06708858|DRUG|Cisplatin|25mg/m2，IV，d1，8，q3w
223779097|NCT00534352|DRUG|TMC125; darunavir; ritonavir|TMC125 400mg once daily for 4 weeks; Darunavir-800mg once daily for 48 weeks; Ritonavir-100mg once daily for 48 weeks
223779098|NCT03450551|DEVICE|Twin Block, Herbst, Frog distalising appliance|To study which of the three orthodontic appliances does achieve the best clinical progress, produce least discomfort to the patient, minimize the time taken for completion of treatment and maximize compliance.
223779099|NCT04594512|OTHER|Fresh corneal lenticule and autologous serum in advanced keratoconus using ReLex Smile surgery|A 19-year-old female patient with keratoconus and chronic hydrops cornea referred to the cornea department of our clinic with thin cornea and hydrops in chronic stage and minimal dry eye symptoms. Minimum corneal pachymetry in the right eye was 378 µm as measured by optical coherence tomography(AS-OCT-Zeiss). Atlas corneal topography showed steep K-values 82.60 ax.37 and flat K 75.15 D ax 127 with -7.45 corneal astigmatism. Her best corrected visual acuity was 0.0.5 in right eye and 1.0 in the left eye. Slit lamp examination showed intense punctate epitheliopathy (Figure 1), tear film break-up time (TBUT) was measured as 7-8 sec and Schirmer test was 10 mm in right eye, and the other eye examinations were determined normally
223779100|NCT06003855|BEHAVIORAL|Supervised exercise therapy|Subjects will be enrolled in a 12-week intervention program of either modified supervised exercise therapy or standard supervised exercise therapy. The program will be 3 sessions/week for 12 weeks. Each session will consist of 50 minutes plus 5 minutes warm up and cool down.
223694804|NCT06708858|DRUG|Durvalumab|1500mg，IV，d1，q3w
223694805|NCT06708858|DRUG|Pembrolizumab|200mg，IV，d1，q3w
223694806|NCT06705062|DRUG|reduced-dose PTCy|Patients receiving reduced dose of PTCy at 35mg.kg on day +3 and +4 together with tacrolimus starting from day+5 and single dose of anti-thymoglobin (ATG) 2.5mg/kg at 72 hours after documentation of neutrophil engraftment.
223779101|NCT03208738|BEHAVIORAL|VetChange|VetChange is a self-management mobile application designed to to concurrently reduce both alcohol misuse and PTSD symptoms.
223779102|NCT03208738|BEHAVIORAL|web-based drinking assessment and feedback tool (AFT)|Program will administer a comprehensive assessment of drinking and consequences of drinking, and will provide normative feedback and highlight negative consequences of drinking.
223779103|NCT01720095|DRUG|Niaspan|
223779104|NCT03858075|DRUG|BLU-782|oral capsules
223694807|NCT06705062|DRUG|Standard dose PTCY|Patients receiving standard dose PTCy at 50mg/kg on day +3 and +4 with tacrolimus starting from day +5 and single dose of anti-thymoglobin at 2.5mg/kg 72 hours after documentation of neutrophil engraftment.
223779105|NCT03858075|DRUG|Placebo|oral capsules
223779106|NCT03858075|DRUG|BLU-782 taken with food|oral capsules
223694808|NCT06708923|PROCEDURE|Intervention Name: Acupuncture Therapy Before and After Embryo Transfer Description: The intervention involves acupuncture therapy performed at two key time points during the IVF cycle: 25 minutes be|"Acupuncture Therapy Before and After Embryo Transfer~This intervention consists of acupuncture sessions designed to support implantation and improve pregnancy outcomes during frozen embryo transfer (FET) cycles.~Procedure:~Acupuncture is performed using sterile, single-use needles by certified practitioners trained in reproductive health.~Sessions occur at two critical time points:~Before Embryo Transfer: A 25-minute session targeting acupoints such as Baihui (DU20), Guanyuan (CV4), and Sanyinjiao (SP6) to enhance endometrial receptivity and reduce stress.~After Embryo Transfer: A second 25-minute session targeting acupoints such as Zusanli (ST36) and Taichong (LR3) to promote implantation and relaxation.~Purpose:~Improve uterine blood flow and receptivity. Regulate hormonal balance to optimize the implantation environment. Reduce psychological stress associated with IVF procedures. This intervention is compared retrospectively to standard IVF protocols without acupuncture to asses"
223694809|NCT06707350|DEVICE|Remote ischemic preconditioning (RIPC)|8 cycles of 5-minute inflation and 5-minute deflation on 2 upper and lower limbs with a blood pressure cuff
223694810|NCT06707350|DEVICE|sham condition (control group)|8 cycles of 5-minute inflation to a pressure of 20 mm Hg followed by 5-minute cuff deflation.
223694811|NCT06707064|BEHAVIORAL|SFEE Diet Management Intervention|"A structured diet management program designed to improve glycemic control, dietary adherence, and maternal outcomes. It includes:~Self-empowerment: Goal-setting, dietary planning, and evaluation. Family empowerment: Emotional support and supervision. Environmental empowerment: Peer group interaction and education via WeChat groups and in-person meetings."
223694812|NCT06707064|BEHAVIORAL|Standard Dietary Advice|Routine nursing care, including dietary education, exercise planning, and self-monitoring for gestational diabetes management.
223694813|NCT04275635|DEVICE|Orthokeratology lenses|Orthokeratology lenses
223694814|NCT05001542|OTHER|Educational moral injury video|Educational video that addresses the identification of moral injury and distress in frontline healthcare workers during COVID-19; offers available interventions at the levels of individual, team and organization
223694815|NCT06030622|DRUG|Gemcitabine and C3 (Metformin, Simvastatin, and Digoxin)|Combination treatment of Metformin, Simvastatin and Digoxin with Gemcitabine (Arm 1)
223694816|NCT06030622|DRUG|C3 (Metformin, Simvastatin, and Digoxin) only|C3 only (Metformin, Simvastatin, and Digoxin) if patients decline Gemcitabine (Arm 2).
223694817|NCT06884410|DEVICE|MRI|Multiparametric renal MRI on 1.5T scanners
223694818|NCT04868045|DRUG|Thyrotropin Releasing Hormone (TRH)|TRH administration will be given as a 200-mcg single IV bolus on Day 1 and Day 5.
223694819|NCT04868045|DRUG|levothyroxine|"Patients maintenance dose of levothyroxine will be taken throughout the study. On Day~1 and Day 5, the levothyroxine will be taken after the TRH test is complete. On Days 2- 4, the levothyroxine will be taken in the morning."
223694820|NCT04868045|OTHER|Hypothyroidism QOL questionnaire|Administer standardized Hypothyroidism QOL questionnaire.
223694821|NCT05108636|OTHER|Therapeutic Touch|Therapeutic touch; It is a low-cost, non-contra-indications, easy-to-apply and non-invasive form of complementary therapy that can be applied anywhere and at any time (Vanaki et al., 2016). Therapeutic touch was developed by Krieger in 1975 as a nursing intervention to help and even heal the patient by balancing the patient's energy field (Marta et al., 2010). The basic assumption of therapeutic touch is that people have energy fields and these energy fields interact with the environment (Hanley, 2008). Therapeutic touch aims to harmonize, renew and heal the flow of the human energy field by removing the blockages of a person's biofield (Mueller et al., 2019). Unlike other touch-based methods such as massage therapy, therapeutic touch does not require the practitioner to physically touch the patient. Instead, the practitioner uses their hands to focus their energy and intent to help the recipient (Hanley, 2008).
223694822|NCT05108636|OTHER|Music Rest|The use of music in the treatment of diseases has been seen in many civilizations since ancient times. In ancient Greek and Roman communities, individuals resorted to music to get rid of their humanitarian problems, while in Ancient Egypt, music was used to give strength to patients during birth (Kor \& Adar, 2016). In today's studies, it has been determined that music positively affects the physiological parameters, nutrition, hospital stay and sleep of the patients (O'Toole et al., 2017; Van Der Heijden et al., 2016). It is important that the sound level is within the appropriate limits while listening to music to the patients. The American Academy of Pediatrics recommends a sound level between 45dB- a maximum of 65dB (ACOG - AAP, 2012). The World Health Organization recommends a sound level of 35 dB during the day and 30 dB at night (Berglund et al., 2000).
223694823|NCT04539899|OTHER|VR+|Use of a virtual reality helmet during IUD insertion
223694824|NCT06706921|DRUG|18F-Fluciclovine PET/CT Scan|In this prospective study, an 18F-Fluciclovine PET/CT will be additionally obtained at baseline (pre-LuPSMA RLT), and after the 2nd, 4th, 6th LuPSMA RLT cycles.18F-Fluciclovine PET/CT will be acquired within 7 days from the PSMA PET.
223694825|NCT06709794|BEHAVIORAL|Informational flyer|In addition to a standard eligibility notice informing participants of their eligibility for marketplace coverage, they receive an informational flyer describing what Covered California is, the availability of financial assistance, and information on benefit design and private insurance terminology, such as deductibles and copays
223694826|NCT06709794|BEHAVIORAL|Modified eligibility notice with plan information|a modified eligibility notice that includes information on the pre-selected lowest-cost silver health insurance plan with a personalized quote for their net premium amount in addition to the informational flyer and instead of a standard eligibility notice
223694827|NCT06708871|PROCEDURE|Thermal ablation|Thermal ablation is a minimally invasive procedure used to treat primary hyperparathyroidism, a condition where one or more of the parathyroid glands produce excessive amounts of parathyroid hormone (PTH). The treatment involves using heat to destroy the overactive parathyroid tissue. This can be done through various methods such as radiofrequency ablation (RFA) and microwave ablation(MWA).
223694828|NCT06708871|PROCEDURE|Parathyroidectomy|Parathyroidectomy is a surgical procedure to remove one or more of the parathyroid glands in cases of hyperparathyroidism.
223779107|NCT00618215|BEHAVIORAL|peer group educational implementation strategy|"Delivery CPG~Education session IQual group~Online training website (individual feed back)~Reminder (flow chart), individual feed back record form~Feed back by email~Registration in practice"
224263528|NCT02363764|OTHER|Questionnaire|Completing questionnaire on acceptability of different sampling methods by patients \>6 years of age
223694829|NCT06708013|BIOLOGICAL|Transcranial Magnetic Stimulation|Transcranial Magnetic Stimulation Transcranial Magnetic Stimulation (TMS) is a noninvasive procedure that uses magnetic fields to stimulate nerve cells in the brain. It\&#39;s primarily used to treat depression, especially in patients who haven\&#39;t responded well to traditional treatments like medications or psychotherapy. The most common target is the dorsolateral prefrontal cortex, a region often underactive in people with depression. The magnetic pulses stimulate or inhibit brain activity in the targeted area. This is believed to help reset or correct patterns of neural activity associated with depression and other psychiatric disorders. TMS represents an alternative for those struggling with depression, offering a non-invasive approach with relatively few side effects and significant potential benefits
223694830|NCT06728891|OTHER|In addition to routine diagnosis and treatment, no additional intervention measures were taken.|This study does not impose any intervention on the patients
223694831|NCT04711187|DRUG|AT-527 Formulation 1|AT-527 Formulation 1 (R07496998)
223694832|NCT04711187|OTHER|Placebo Comparator|Placebo Comparator
223694833|NCT04711187|DRUG|AT-527 Formulation 2|AT-527 Formulation 2 (R07496998)
223694834|NCT06708273|OTHER|Constraint induced movement therapy|Constraint the sound side and encourage movement of the burned side
223694835|NCT06708273|OTHER|Positioning - stretching|Position hand in functional hand position - stretching against deformity position
223694836|NCT06708273|OTHER|constraint induced movement therapy|constraining sound hand to enforce patient to use affected burned dominant hand
223694837|NCT06733636|OTHER|Sudoku Puzzles|Sudoku puzzles of consistent and regular difficulty
223694838|NCT06733636|OTHER|ScentCare (Olfactory Training Device)|ScentCare is a smell training device with eight encapsulated scents housed in separate compartments and is contained using a charcoal filter, which will be dispersed in the base of our device to prevent smell contamination in the user's environment. The outer casing contains an opening that can be manually rotated to line up with the casing on each scent. This is facilitated by a rod in the center of the device, which serves as the axis of rotation. By pressing the capsule, the desired scent is released through a hole in the casing, similar to the mechanism of a pen. The user presses the compartment back downwards into the casing when done. The ScentCare mobile application offers clear instructions for at-home smell training and testing, with features like scent randomization to prevent users from getting accustomed to a specific order. It provides detailed guidance on device use and allows users to schedule sessions and receive daily reminders, ensuring a structured training regimen.
223694839|NCT06633692|OTHER|Head down tilt (HDT)|In the head-down tilt intervention, a participant is positioned on a tilt table, initially in supine position and afterwards with their head inclined downward at a specific angle. This position causes a shift of body fluids towards the head, mimicking the fluid redistribution observed in microgravity conditions in space.
223694840|NCT06602960|BEHAVIORAL|Accurate Sleep Data Feedback|Participants will receive accurate feedback about their sleep data.
223694841|NCT06602960|BEHAVIORAL|Inflated Sleep Data Feedback|Participants will receive inflated feedback about their sleep data, suggesting better sleep quality than detected by Fitbit (actual sleep hours +10%).
223694842|NCT06602960|BEHAVIORAL|Deflated Sleep Data Feedback|Participants will receive deflated feedback about their sleep data, suggesting poorer sleep quality than detected by Fitbit (actual sleep hours -10%).
223694843|NCT06602960|BEHAVIORAL|Accurate Sleep Data Feedback + Sleep-related Educational Information|Participants will receive accurate feedback about their sleep data along with sleep-related educational information.
223694844|NCT06878560|BIOLOGICAL|10 GE Xenokidney|Porcine-derived kidney containing intentional genomic alterations for xenotransplantation
223694845|NCT05889416|OTHER|Audit and feedback through a quality registry|Centres answer CR process and structure variables through the SWEDEHEART registry every six months for three years. Feedback will be accessible online and through annual reports, enabling comparisons with own prior and other centres´ results.
223694846|NCT05889416|OTHER|Implementation support|On-site support to implement guidelines on secondary prevention applying practice facilitation - a multifaceted approach carried out by CR experts who enable personnel at intervention centres to address and overcome challenges in implementing guidelines.
223694847|NCT04938349|BEHAVIORAL|Dual task perturbation training|Participants will play six cognitive games targeting working memory, executive functioning, visuomotor reactions, and language fluency provided in standing. Following which they will receive 12 slips without performing cognitive task (Single task training) at the highest intensity and 12 slips during standing while performing a cognitive task (dual task). Also, they will then undergo 12 dual task walking trials (at self-selected speed) followed by 12 walking slips.
223694848|NCT07057414|DRUG|GMDTC for injection|GMDTC for Injection with a specification of 0.5g/vial, and administered by intravenous infusion. According to the drug preparation SOP , Using 0.9% physiological saline to achieve the required concentration for each dose group (e.g., The initial dose group: 2 g reconstituted in 500 mL, with each 1 g reconstituted in 250 mL, resulting in a 4 mg/mL concentration.). All infusion-related reactions must be documented. Drug preparation must be performed by an non-blind investigator independent of the study to maintain blinding integrity for other study personnel.
223694849|NCT07057414|OTHER|0.9% Sodium Chloride Injection(0.9% NaCl)|0.9% Sodium Chloride Injection with a specification of 250mL/bag, and administered by intravenous infusion. The infusion should be strictly adhering to the assigned dosage. All infusion-related reactions must be documented. Drug preparation must be performed by an non-blind investigator independent of the study to maintain blinding integrity for other study personnel.
223694850|NCT06759701|DRUG|Tirzepatide|Participants will perform weekly self-injection of tirzepatide as standard of care, following manufacturer instructions
223694851|NCT06875960|DRUG|BMS-986165|Specified dose on specified days
223779108|NCT04002674|DRUG|Placebo oral capsule|"Thirty (30) patients in arm 1 will receive the matching placebo (sugar pill) one (1) capsule orally (without food) once daily for 6 months (180 days)."
223694852|NCT06883526|BIOLOGICAL|ZG005 for Injection|intravenous infusion
223694853|NCT06883526|DRUG|Gecacitinib Hydrochloride Tablets|Oral
223694854|NCT06749197|DEVICE|Rehacom|Home-based cognitive training program
223779109|NCT04002674|DRUG|Nilotinib Oral Capsule|Thirty (30) patients in arm 2 will receive the 200 mg of Nilotinib one (1) capsule orally (without food) once daily for 6 months (180 days).
224263529|NCT00351039|DRUG|Bevacizumab|Treatment Regimen Item 1: Bevacizumab 10 mg/Kg I. V. Day 1 and Day 15. Repeat cycles every 28 days.
223779110|NCT02354638|BEHAVIORAL|Tobacco users|Various tobacco cessation interventions in the form of one to one counseling, focus group discussions, role plays, games etc. will be used in the tobacco users.
223779111|NCT02354638|DRUG|Pharmacotherapy|"Pharmacotherapy will also be prescribed as per the need assessment consisting of:~Nicotine Chewing Gums:~Dose: 2 mg/4 mg, 10-15 pieces per day with maximum dose of 24 pieces/day depending on cravings.Total Duration: 12 weeks Duration of treatment: Higher dose for 4-6 weeks, with weaning till 2-3 months~Nicotine Transdermal patches:~Dose: 7 mg/10 mg/14 mg/21 mg -for 24-hours use. Total Duration: 12 weeks Duration of treatment: Higher strength patch for 2 weeks and depending on cravings will be gradually decreased till 4 weeks"
223779112|NCT00027430|DRUG|TheraDerm|
223779113|NCT04394728|DRUG|Trabectedin|1.3 mg/m2 with a top-dose of 2.6 mg per cycle, via a central venous catheter as a 24-hour infusion every 21 days.All patients received premedication with dexamethasone 20 mg i.v. 30 min before administration of trabectedin.
223779114|NCT01144104|BEHAVIORAL|Public Service Announcement|
223779115|NCT01144104|BEHAVIORAL|Interactive Multi-Media Computer Program|
223779116|NCT01144104|BEHAVIORAL|Sleep Hygiene Video|
223779117|NCT05337878|DRUG|Placebo|Pelacarsen-matching placebo administered by SC injection.
223779118|NCT05337878|DRUG|Pelacarsen|Pelacarsen administered by SC injection.
223779119|NCT02091999|DRUG|enfortumab vedotin|intravenous (IV) infusion
223779120|NCT02651623|DRUG|Sertraline|Multiple doses of sertraline for 14 days
223779121|NCT02651623|DRUG|Moxifloxacin|A single dose of 400 mg Moxifloxacin
223779122|NCT02651623|DRUG|Drug - Placebo|Placebo administered for 14 days
223779123|NCT01006811|DIETARY_SUPPLEMENT|modified Atkins diet|"Modified Atkins Diet administration~1. Carbohydrates intake restricted to 10 grams/ day. (Carbohydrate values of various food items will be explained in detail, and exchange lists provided. Four 2.5 grams carbohydrate exchange items will be allowed in a day.)~2. Fats (e.g. cream, butter, oils, ghee) encouraged.~3. Proteins (cheese, fish, eggs, chicken, soya products) unrestricted.~4. Clear carbohydrate-fluids not restricted.~5. Calcium and multivitamin supplementation will be provided."
223779124|NCT01006811|OTHER|modified Atkins diet|"Modified Atkins Diet administration~1. Carbohydrates intake restricted to 10 grams/ day. (Carbohydrate values of various food items will be explained in detail, and exchange lists provided. Four 2.5 grams carbohydrate exchange items will be allowed in a day.)~2. Fats (e.g. cream, butter, oils, ghee) encouraged.~3. Proteins (cheese, fish, eggs, chicken, soya products) unrestricted.~4. Clear carbohydrate-fluids not restricted.~5. Calcium and multivitamin supplementation will be provided."
223779125|NCT01061749|BIOLOGICAL|Cixutumumab|Given IV
223779126|NCT01061749|OTHER|Laboratory Biomarker Analysis|Correlative studies
223779127|NCT01061749|OTHER|Pharmacological Study|Correlative studies
223779128|NCT01061749|DRUG|Selumetinib|Given PO
223779129|NCT01260987|DRUG|Conventional photodynamic therapy|Photodynamic therapy using methyl-aminolevulinate and red light (37 J/cm2)
223779130|NCT01260987|DRUG|Fractional CO2 laser assisted PDT|Pretreatment with fractional CO2 laser before methyl-aminolevulinate PDT
223694855|NCT06776211|BEHAVIORAL|Virtual Reality Simulation|"Virtual reality simulation application:~The video content to be used in the virtual reality-based application was created by researchers from the Ministry of Health of the Republic of Turkey, General Directorate of Public Health, Neonatal Resuscitation Programme (NRP) Practitioner Certified Training Programme. The duration of the video was planned not to exceed 10 minutes in order not to reduce the interest and attention span."
223694856|NCT06776211|BEHAVIORAL|Low-Reality Simulation|Low reality simulation application: The low reality simulation application to be used will use a neonatal model as a teaching aid, with human anatomy and functional features designed to simulate neonatal resuscitation applications.
223779131|NCT05592210|OTHER|Questionnaires|Participants will be asked to fill out the the Demographic Information Sheet, Karitane parenting confidence scale, Parental Stressor Scale: Neonatal Intensive Care Unit (PSS:NICU) and Dyadic Coping Inventory.
223779132|NCT02341248|OTHER|Exclusive Enteral Nutrition (EEN)|8 week standard course of treatment with EEN
223779133|NCT04426058|DRUG|CMP|Cluneal nerve Block 0.25% bupivacaine 20ml Pericapsular Nerve group block 0.25% Bupivacaine 20ml Lateral femoral cutaneous Block 0.25% bupivacaine 10ml
223779134|NCT04426058|DRUG|Fascia Illica|Fascia iliaca block suprainguinal technique 0.25% bupivacaine 50ml
223779135|NCT06003725|BEHAVIORAL|Culturally Adapted Adolescent Substance Use Treatment|The Cannabis Youth Treatment Series (CYT) (MET/CBT12 model) aims to reduce alcohol and cannabis use.
223779136|NCT00188526|DEVICE|lung biopsy|
223779137|NCT01734226|DIETARY_SUPPLEMENT|Prunus Mume Extract|Prunus Mume Extract (3.94g/day)
223779138|NCT01734226|DIETARY_SUPPLEMENT|Placebo|Placebo (3.94g/day)
223779139|NCT03259711|DRUG|Hormonal therapies L02 in the ATC classification|Hormonal therapies L02 in the ATC classification
223779140|NCT00485875|DRUG|Atomoxetine Hydrochloride|
223779141|NCT01131481|DEVICE|Intraocular lens|
223779142|NCT06019858|OTHER|Vitamin Energy Shot|"Vitamin Energy® shot is a naturally-caffeinated functional energy shot that contains:~Vitamin B3 Vitamin B6 Vitamin B12 Natural Caffeine (green tea extract) L-Carnitine Tartrate Potassium Sorbate Taurine Sucralose"
223779143|NCT05613439|PROCEDURE|Day-surgery|Standard surgical procedure but with planned discharge on day of surgery
223779144|NCT05613439|PROCEDURE|High-risk patient|Standard fast-track procedure but with additional perioperative measures dependent on risk-profile.
223779145|NCT05613439|PROCEDURE|Main Group|Standard fast-track procedure according to usual standard of care and discharge when fulfilling functional discharge criteria
223779146|NCT00343187|DRUG|ACZONE (dapsone) Gel, 5%|
223779147|NCT00343187|DRUG|Vehicle Control|
223779148|NCT02782481|DRUG|ND0612|
223779149|NCT02782481|DRUG|Placebo|
223779150|NCT03174340|BEHAVIORAL|Exercise|Once per week, participants will be enrolled in supervised group exercise intervention. They will be encouraged in walking 45 minutes per day
223779151|NCT05505708|DRUG|hydroxyethyl starch in sodium chloride injection Brand Name: Voluven|"(6% hydroxyethyl starch 130/0.4 in 0.9% sodium chloride injection) is a clear to slightly opalescent, colorless to slightly yellow, sterile, non-pyrogenic, isotonic solution for intravenous administration using sterile equipment.~Each 100 mL of the solution contains: 6 g of Hydroxyethyl Starch 130/0.4 and 900 mg of Sodium Chloride USP in Water for Injection USP.~In addition, sodium hydroxide, USP, or Hydrochloric acid, USP, has been added to adjust the final pH so the final solution pH is 4.0 to 5.5."
223779152|NCT05505708|DRUG|saline solution|Within each 100 mL of 0.9% sodium chloride Injection USP, there is 15.4 mEq of sodium ions and 15.4 mEq of chloride ions. Additionally, the osmolarity is 308 mOsmol/liter, and it has a pH range of 4.5 to 7
223779153|NCT04068675|BEHAVIORAL|Group pre-operative counseling|Enrolled patients will participate in a group pre-operative counseling session on the online conferencing platform BlueJeans® prior to their surgery. The sessions will not replace any portion of the pre-operative standard counseling and is designed to review and re-enforce the counseling already provided. The sessions will not review or discuss the specifics of any one individual's cancer or surgery. Rather the counseling session will focus on the universal instructions provided to all patients undergoing major surgery for a known or suspected gynecologic malignancy. The sessions will be led by a physician on a weekly basis with a minimal of three (3) enrolled patients per session and last approximately one (1) hour.
223779154|NCT00151359|DEVICE|SoleSensor|
223779155|NCT00710502|PROCEDURE|Transvaginal NOTES cholecystectomy|Under general anesthesia, patients will undergo Transvaginal NOTES cholecystectomy
223779156|NCT00710502|PROCEDURE|Laparoscopic cholecystectomy|Under general anesthesia, patients will undergo standard Laparoscopic cholecystectomy
223779157|NCT05145920|BEHAVIORAL|HabitE (effective parenting habit) program (in Brazilian Portuguese)|Parents who enroll in the program will receive a series of 5 videos (\~ 7 minutes each), 1 video at a time, generally every 3 days. Parents will also receive daily written texts, which include implementation tips and an assessment of a target (transition) behavior.
223779158|NCT04788147|DEVICE|RMRS IDE Device|Participants will be injected with FDG at the studied dose and will undergo imaging sessions using the RMRS IDE device and a third-party Positron Emission Tomography (PET)/CT imaging device.
223779159|NCT05349669|DRUG|Jafron use during CPB|Use of filter Jafron during CPB
223779160|NCT01141296|DRUG|fenofibrate|fenofibrate 200 mg PO daily for 1 year
223779161|NCT01141296|DRUG|placebo|Placebo pill identical to active drug will be given PO once a day for 1 year
223779162|NCT04010110|DIAGNOSTIC_TEST|visual field testing (10-2), spectral domain ocular coherence tomography and Fundus auto-fluorescence|The diagnosis of toxic retinopathy was based on the positivity of at least two objective tests to confirm the subjective findings. The presence or absence of toxicity was recorded.
223779163|NCT05086458|DIETARY_SUPPLEMENT|probiotics|probiotics blend of Bifidobacterium longum, Lactobacillus acidophilus, Enterococcus faecalis
223779164|NCT05035979|DRUG|BaidI Quzhi granule|Put each bag of medicine in one day into the same container, pour in about 50ml of warm water, stir until the granules are basically dissolved, add some boiled water to dilute, and take it twice.
223779165|NCT05035979|DRUG|Ju Yin cream|Take JY cream 5g evenly applied to the face, negative ion spray at the same time acupoint massage along the meridian, apply 10min, clean the face with water, 3 times a week.
223779166|NCT05035979|DRUG|Baidi Quzhi placebo granule|Put each bag of medicine in one day into the same container, pour in about 50ml of warm water, stir until the granules are basically dissolved, add some boiled water to dilute, and take it twice.
223694857|NCT06776315|DEVICE|Resistive threshold inspiratory muscle training device|"In the other arm of the study, respiratory muscle training is performed in addition to the standard pulmonary rehabilitation program. Respiratory muscle strengthening training is performed with a resistive thereshold inspiratory muscle strengthening device. The exercise is performed at an intensity of 30% of the maximum inspiratory pressure determined by mouth pressure measurement. The exercise is performed in 7 sets, with 2 minutes of work and 1 minute break for a total of 21 minutes."
223694858|NCT06776315|PROCEDURE|Standard pulmonary rehabilitation programme|Patients are asked to perform thoracic, diaphragmatic breathing, and lower basal breathing exercises with 10 repetitions. Then, strengthening exercises are performed on the major muscle groups of the upper and lower extremities. In accordance with the resistance training program in the ATS/ERS guidelines for pulmonary rehabilitation, two to four sets of 6-12 repetitions are performed with intensities ranging from 50% to 85% of one maximum repetition, two to three times a week. During the exercises, the patient is questioned about their fatigue and dyspnea levels using the Borg scale, and breaks are given when necessary. The aerobic exercise program is performed as a 12-week, 3-day-a-week self-walking exercise. The walking program is performed in the form of walking on flat ground at 60% workload, based on the data obtained from the 6-minute walking test result (land-based walking).
223694859|NCT06776315|GENETIC|No intervention|Peripheral blood samples will be taken once from the participants in the control group and no other intervention will be performed.
223694860|NCT06775769|PROCEDURE|Sclerotherapy|Laparoscopic ethanol sclerotherapy of endometrioma
223694861|NCT06775769|PROCEDURE|Routine Care|Routine surgical management of endometrioma
223694862|NCT07070427|OTHER|Exercise|Cognitive-based balance exercises.
223694863|NCT06927856|BEHAVIORAL|Test-to-PrEP|Participants, called Egos, will come once to the clinic throughout the duration of the study, for up to 1 hour. During the visit, participants will receive up to 4 Test-to-PrEP Packs, which include an HIV self-test kit and HIV prevention education materials and a brief (approximately 15 minutes) training. The training includes instructions on how to initiate conversations related to HIV, HIV testing, and HIV prevention, as well as proper handling of the HIV self-test kit. Participants are asked to distribute the Test-to-PrEP Packs to Social Network Contacts (peers), called Alters.
223694864|NCT06927856|BEHAVIORAL|Access by Referral|Participants, called Egos, will receive up to 4 Access by Referral Cards once. Participants will receive a brief (approximately 15 minutes) training. The training includes instructions on how to initiate conversations related to HIV, HIV testing, and HIV prevention, as well as proper handling of the HIV self-test kit. Participants are asked to distribute the Access by Referral Cards to Social Network Contacts (peers), also called Alters. The Referral Card can be used to order a Test-to-PrEP Pack, including the HIV self-test and HIV prevention education material, that will be mailed to an address of the Alter's choice.
223694865|NCT07076004|BEHAVIORAL|Medically Tailored Grocery Plus Nutrition Counseling Group|Weekly delivery of medically tailored groceries plus 8 remote nutritional counselling sessions.
223694866|NCT07076004|BEHAVIORAL|Experimental: Medically Tailored Grocery Group|Weekly delivery of medically tailored groceries.
223694867|NCT07076004|BEHAVIORAL|Standard of Care Group with Delayed Medically Tailored Grocery Delivery|Option to pick up fresh produce weekly from participating clinics. Medically tailored grocery delivery will be available for 6 months beginning at the end of the study.
223694868|NCT05176418|DRUG|low dose Nicotine|IV nicotine infused over different delivery rates
223694869|NCT05176418|DRUG|high dose Nicotine|IV Nicotine infused over different delivery rates
223694870|NCT06906120|BEHAVIORAL|Virtual Reality-Based Operating Room Education|"For the Intervention Group:~Written informed consent will be obtained one day before surgery when patients visit the anesthesia clinic.~Subsequently, the Patient Introduction Form, State-Trait Anxiety Inventory (STAI-I, STAI-II), and Surgical Fear Scale will be completed, and electrodermal activity data and physiological parameters will be recorded for 5 minutes.~Participants will watch a 3D training video created by the researcher using Meta Quest 3 virtual reality headsets. This video will provide an introduction to the operating room environment and related procedures.~After the video, physiological parameters will be recorded again, and STAI-I and the Surgical Fear Scale will be completed.~On the day of the surgery, after the patients are admitted and necessary preparations are made, STAI-I and the Surgical Fear Scale will be completed again, and physiological parameters will be recorded.~Electrodermal activity data will be recorded 15-20 minutes before anesthesia is administ"
223694871|NCT06073132|DRUG|AC-203|The investigational product is formulated as 1% topical ointment
223694872|NCT06073132|DRUG|Vehicle|Vehicle-only control study medication is the same formulation as investigational product without active ingredient
223694873|NCT02179658|DRUG|OPT-80|oral
223694874|NCT02179658|DRUG|vancomycin|oral
223694875|NCT05500248|BEHAVIORAL|Leave In Situ|"Polyps will be left in situ if diminutive (≤5 mm) in size, located in the rectum or sigma and optically diagnosed by the endoscopist using the system to be hyperplastic with high confidence, otherwise resected and sent to pathology.~This behaviour is recommended by guidelines if the endoscopist is expert in optical diagnosis. In this case the endoscopists will be experts and they will also be helped by the CADx system that has shown to exceed the thresholds requested for use in clinical practice in previous trials."
223694876|NCT05500248|BEHAVIORAL|Standard|All identified polyps will be removed and sent to pathology.
223694877|NCT07103993|OTHER|Low meal condition|Participants will consume a standardized meal (500 grams) with a low nutrient modification one time at one visit. Participants will attend one visit per week for 3 weeks. Each is visit separated by one week and each visit will take approximately 6 hours
223694878|NCT07103993|OTHER|Moderate meal condition|Participants will consume a standardized meal (500 grams) with a moderate nutrient modification one time at one visit. Participants will attend one visit per week for 3 weeks. Each is visit separated by one week and each visit will take approximately 6 hours.
223694879|NCT07103993|OTHER|High meal condition|Participants will consume a standardized meal (500 grams) with a high nutrient modification one time at one visit. Participants will attend one visit per week for 3 weeks. Each is visit separated by one week and each visit will take approximately 6 hours.
223694880|NCT07103993|OTHER|Ad-libitum control condition|The ad-libitum meal consists of 600-700 g of a standardized control meal one time at all visits. Participants will attend one visit per week for 3 weeks. Each visit is separated by one week and each visit will take approximately 6 hours.
223694881|NCT06811493|PROCEDURE|bilateral thoracic erector spinae plane block combined with general anesthesia in laparoscopic bariatric surgery in obese patients|using the in-plane approach, in caudal -to- cephalad direction, through the interfascial plane between the Erector Spinae and the underlying transverse process under strict aseptic precautions until the tip is deep to erector spinae muscle. the block will be performed bilaterally by injecting 60 mL of 0.25% bupivacaine (15 mL into each of four site) into the fascial plane between the deep surface of the Erector Spinae muscle and the bilateral transverse processes of the thoracic vertebrae 5 and 10 (at the most lateral part of the transverse process)
223694882|NCT06923345|COMBINATION_PRODUCT|Reduced CTV|"Long-course radiotherapy with selective CTV reduction (lower to S2/S3 level) + CAPOX + PD-1 inhibitor.~After treatment, patients will undergo TME surgery or a watch-and-wait approach, depending on response."
223694883|NCT06923345|COMBINATION_PRODUCT|Conventional CTV|"Long-course radiotherapy with conventional CTV irradiation + CAPOX + PD-1 inhibitor.~After treatment, patients will undergo TME surgery or a watch-and-wait approach, depending on response."
223694884|NCT07103772|DIETARY_SUPPLEMENT|Ananá|"The supplement consists of a box containing 14 sachets of the product for 14 days of treatment. Patients should preferably consume the supplement in the morning.~The Ananá's Nutraceutical Group will receive the real supplement for consumption over 14 days, while the Ananá's Placebo Group will receive a placebo supplement for comparison at the end of the trial."
223694885|NCT06933680|PROCEDURE|Sphenopalatine Ganglion Block|"To perform an SPG block, the ultrasound linear probe is placed parallel to the zygomatic bone, facing anteriorly, to obtain an image that includes the ramus of the maxilla and mandible and the pterygoid process of the sphenoid bone.~A 23-gauge, 50 mm needle is inserted just behind the posterior orbital rim and advanced in an antero-caudal direction over the zygomatic arch. When the needle reaches the pterygopalatine fossa at approximately 5 cm, aspiration is performed to check for blood. If no blood is seen, 4 mL of 0.5% bupivacaine is injected.~The procedure is performed on both sides"
223694886|NCT06933680|PROCEDURE|Sham Block|"To perform a Sham block, the ultrasound linear probe is placed parallel to the zygomatic bone, facing anteriorly, to obtain an image that includes the ramus of the maxilla and mandible and the pterygoid process of the sphenoid bone.~A 23-gauge, 50 mm needle is inserted just behind the posterior orbital rim and advanced in an antero-caudal direction over the zygomatic arch. When the needle reaches the pterygopalatine fossa at approximately 5 cm, aspiration is performed to check for blood. If no blood is seen, 4 mL of %0,9 NaCl is injected.~The procedure is performed on both sides."
223694887|NCT06933394|DRUG|Arsenic trioxide|Patients will receive 9 cycles of chemotherapy. ATO dosing: Arsenic trioxide（ATO） is administered 0.18mg/kg per day over eight hours IV daily for ten days. Patients will receive ATO alone on days 1-2 and combined with conventional induction chemotherapy on days 3-10.
223694888|NCT06933394|DRUG|MAPK inhibitors|"The dosage of MAPK inhibitors is adjusted based on the specific drug. For example, Trametinib is used as follows: Trametinib will be administered daily from Cycle 5 until the end of induction chemotherapy. Patients start at Dose Level I; if no hematologic toxicity or severe drug-related complications occur after 1 cycle, the dose is escalated to the next level, otherwise, it is maintained. Dose Level I: 0.016 mg/kg/day (\<6 years) or 0.012 mg/kg/day (\>6 years), po. qd. Dose Level II: 0.024 mg/kg/day (\<6 years) or 0.018 mg/kg/day (\>6 years), po. qd. Dose Level III: 0.032 mg/kg/day (\<6 years) or 0.025 mg/kg/day (\>6 years), po. qd.~The dosages of other MAPK inhibitors should be modified according to their respective recommended therapeutic guidelines."
223694889|NCT06933394|DRUG|Chemotherapy|"The conventional chemotherapy regimens are as follows:~Cycles 1, 2, 4, and 6 follow the CAV regimen (cyclophosphamide(1.2g/m2.d, d3-d4), pirarubicin(25mg/m2.d,d3-d5), vincristine(0.022mg/kg.d or 0.67mg/m2.d，d3-d5)).~Cycles 3, 5, and 7 follow the PVP regimen (cisplatin(50mg/m2.d, d3-d6), etoposide(200mg/ m2.d, d3-d5)).~Cycles 8 and 9 follow the CT regimen (cyclophosphamide(1.2g/m2.d, d3-d4), topotecan(2mg/m2.d, d3-d5))."
223779167|NCT05035979|DRUG|Ju Yin placebo cream|Take JY placebo cream 5g evenly applied to the face, negative ion spray at the same time acupoint massage along the meridian, apply 10min, clean the face with water, 3 times a week.
223779168|NCT01603550|OTHER|Sleep Deprivation|Sleep Deprivation
223694890|NCT06934304|OTHER|new preoperative handout|A new preoperative handout for robotic sacrocolpopexy was designed at a lower reading level and providing more perioperative details
223694891|NCT06934304|OTHER|old preoperative handout|The old or standard preoperative handout for robotic sacrocolpopexy
223779169|NCT01603550|OTHER|Energy Restriction|Energy Restriction
223779170|NCT05036187|BEHAVIORAL|Behavioral Weight Loss Intervention|Rx Weight Loss: PRIDE is a fully automated online behavioral obesity treatment that is tailored for sexual minority women and involves viewing 12 online video lessons delivered each week, self-monitoring body weight, calorie intake, and physical activity levels, and receiving personalized automated weekly feedback on progress toward goals.
223779171|NCT05036187|BEHAVIORAL|Minority Stress Intervention|The Minority Stress Intervention is designed to help sexual minority women cope with stress and stigma (e.g., due to weight, sexual orientation, gender). In this program, participants watch online video lessons that teach cognitive and behavioral strategies for coping with minority stress so that it may have less of an influence on participants' weight and well-being.
224263530|NCT00351039|DRUG|Erlotinib|Treatment Regimen Item 2: Erlotinib 150mg Per Orally (PO) Once Daily (QD) for 7 days starting day 2 and day 15. Repeat cycles every 28 days.
224263531|NCT00351039|DRUG|Pemetrexed|Treatment Regimen Item 3: Premetrexed 500mg/m2 I.V. Day 1 and Day 15. Repeat cycles every 28 days.
224263532|NCT00834353|DRUG|ATT|
224263533|NCT03033810|DEVICE|Fractional flow reserve and instantaneous wave-free ratio|"1. To explain discrepancies between FFR and iFR using demographic, morphological, genetic and functional indices.~2. The development of software for the automatic detection of the lowest point of microvascular resistance."
224263534|NCT03045536|DEVICE|MML (Fa. ESKA/Orthodynamics)|Classification of complications according to MSTS
224263535|NCT01159899|PROCEDURE|Transplantation of Bone Marrow Stem Cells Activated in Knee Arthrosis|Transplantation of Activated Bone Marrow Stem Cells in Knee Arthrosis, under arthroscopy, in one-step procedure
223694892|NCT06934824|PROCEDURE|Sixty patients with early gastric cancer in stage T1bN0-1M0 were divided into Group A-N0 and Group B-N + according to the presence or absence of lymph node metastasis. When the enrolled patients und|"Patients in group A-No lymph node metastasis, who underwent simple Double-Endoscopic Combined with local full-thickness resection.~Patients in group B-imaging examination showed lymph node metastasis. patients were randomly divided into Group N + a and Group N + b.~Group N + a: Local full-thickness gastric wall and lymph nodes dissection on D1 or D1 + were performed with Double-Endoscopic Group N + b: Traditional standard surgical gastrectomy and D1 or D1 + lymph nodes dissection was performed ."
223694893|NCT06934811|DRUG|Ciprofol|Continuous intravenous infusion (0.05-0.3 mg/kg/h), adjusted hourly based on the RASS score (target range: -3 to 0).
223694894|NCT06934811|DRUG|Midazolam|Continuous intravenous infusion (0.02-0.1 mg/kg/h), adjusted hourly based on the RASS score (target range: -3 to 0).
223694895|NCT06933407|DIAGNOSTIC_TEST|Strain Elastography|Strain elastography (SE) is a parametric imaging modality that assesses tissue deformation in response to externally applied pressure, providing qualitative and semi-quantitative information on tissue elasticity and mechanical properties. Unlike conventional 2D ultrasound, SE enables the objective evaluation of paraurethral tissue stiffness, which may play a role in the pathophysiology of stress urinary incontinence (SUI). SE will be performed on three predefined paraurethral regions to assess pelvic floor elasticity and biomechanical characteristics. A standardized protocol will be implemented to ensure high reproducibility, with controlled probe compression and precisely defined regions of interest. SE may improve the diagnostic accuracy and therapeutic decision-making for SUI by identifying differences in tissue compliance among affected women.
223694896|NCT06934551|DEVICE|obturator|conventionally constructed and polished obturator
223694897|NCT06934486|DEVICE|TissuePatch Sealant Film|Sealant film
223694898|NCT06933836|DEVICE|DSLT enables newly diagnosed patients to remain well controlled and off medications|DSLT enables newly diagnosed patients to remain well controlled and off medications
223694899|NCT06933849|BEHAVIORAL|Structured case management|When a Bluestone Accountable Care Organization registers in an emergency department, a Bluestone chronic care manager contacts emergency department clinicians by phone and fax to provide up-to-date clinical and discharge support information.
223694900|NCT06933264|DIETARY_SUPPLEMENT|Exclusion diet|Experimental Group: Patients will receive modifications to their pharmacological and will be assigned to an intervention consisting of an exclusion diet in conjunc-tion with supplemental enteral nutrition. This nutritional strategy will involve a progressive increase in the caloric intake derived from the diet, coupled with a corresponding reduction in supplemental enteral nutrition.
223694901|NCT06933303|DEVICE|Distraction with kaleidoscope|During the intervention measurement, the pediatric patient will be distracted by the use of a kaleidoscope during the procedure. Distraction by use of the kaleidoscope will be initiated at the start of the procedure (dressing change) and the kaleidoscope will be offered until at least a minute after the procedure is completed. Removal of the dressing will be started when the child seems distracted as indicated by response with a smile or laughter, or a verbal response
223694902|NCT06933147|BEHAVIORAL|Constraint-Induced Movement Therapy (CIMT)|This intervention involved constraining the unaffected upper limb for 6 hours per day and performing 3-hour intermittent daily sessions of functional task practice with the affected limb for 12 weeks, 5 days per week. Exercises included stretching, grasping, dexterity tasks, and functional activities like self-feeding and button pressing. The program used shaping techniques to increase task difficulty and improve motor recovery. A home exercise program was also prescribed for daily practice.
223694903|NCT06933147|BEHAVIORAL|Resistance Training (RT)|This intervention consisted of structured progressive resistance exercises targeting the affected upper limb muscles (shoulder, elbow, wrist) using weight cuffs (½-1 kg). Sessions were 60 minutes/day, 5 days/week, for 12 weeks. Intensity progressed from 50% to 70% of 1-repetition maximum (1RM) based on individual capacity. Exercises were performed in 3 sets of 8 repetitions for each muscle group, with 2-minute rest intervals. A home program included additional wrist and hand strengthening tasks.
223694904|NCT06934005|DEVICE|Baseplate type A|Type A: Acrylate tested for 35 days behind one ear
223694905|NCT06934005|DEVICE|Baseplate type C|Type C: Hydrocolloid tested for 35 days behind the other ear
223694906|NCT07140653|OTHER|Femto arcs|Femtosecond laser-assisted arcuate corneal relaxing incisions (AK) will be performed to correct astigmatism.
223694907|NCT07140653|DEVICE|Light Adjustable Lens (LAL)|The LAL is intended to replace the natural lens at time of lens removal.
223694908|NCT06934096|DEVICE|Ultrasound Pulsed Doppler Imaging System|Ultrasound pulsed doppler system accompanied with the abdominal curvilinear probe will be used for the purpose of collecting the data for the endpoints.
223694909|NCT07149766|OTHER|Breast crawling|"The newborn will be placed on the mother's abdomen for no more than 60 minutes, during which breast crawling and suckling behaviors will be observed. Throughout this period, the researcher will maintain active communication with the mother, providing information on the importance of breastfeeding.~The mother will be gently guided to support the baby when necessary, without interfering with the baby's natural instincts. The newborn's heart rate, respiratory rate, and body temperature will be recorded at birth and at the 60th minute."
223694910|NCT07150975|DRUG|GZR18|Administered SC
223694911|NCT07150975|DRUG|Semaglutide(Wegovy® )|Administered SC
223694912|NCT03803683|DEVICE|mLab App|The mLab App is a web application that uses an image processing algorithm to interpret the results of the OraQuick® In-Home HIV Test.
223694913|NCT03803683|BEHAVIORAL|HIV Prevention Information|Youth randomized to the standard of care will be sent an email with links to mobile-optimized online prevention information, including PrEP and HIV testing information that is found on the Centers for Disease Control and Prevention (CDC) website.
223694914|NCT03803683|DEVICE|HIV Home Tests|Youth randomized into this arm will receive OraQuick® In-Home HIV Test.
223694915|NCT00492050|DRUG|Bortezomib|1.6 mg/m\^2 IV Weekly on Days 1, 8, 15 and 22.
223694916|NCT00492050|DRUG|Rituximab|375 mg/m\^2 IV on Day 8 and 22.
223694917|NCT00492050|DRUG|Valacyclovir|500 mg orally daily (or acyclovir 200 mg orally twice daily)
223779172|NCT05036187|BEHAVIORAL|Negative Body Image Intervention|The Negative Body Image Intervention is designed to help participants improve their body image. In this program, participants will watch online video lessons that provide education on queer women's body image and teach cognitive and behavioral strategies for improving your body image (regardless of your weight) to reduce its influence on your health.
223694918|NCT04125277|OTHER|FES-PET scan, and possibly one additional visit for an FDG-PET|One visit to either the UMCG or Amsterdam UMC-location VUMC is required for the FES-PET scan, and possibly one additional visit for an FDG-PET. A FES- or FDG-PET scan plus low dose CT will each induce an extra radiation burden of about 6.1 mSv (210 MBq injected for an average patient of 70 kilogram body weight).
223694919|NCT05766501|DRUG|DOR/ISL|FDC tablet of 100 mg doravirine (DOR)/0.25 mg islatravir (ISL) taken once daily
223694920|NCT00239902|DRUG|FTY720|
223694921|NCT02037958|DEVICE|Laryngeal Mask Airway-Supreme|Patients who receive the LMA-S
223694922|NCT02037958|DEVICE|Endotracheal Tube|Patients who receive endotracheal intubation
223694923|NCT04954287|BIOLOGICAL|CVXGA1 low dose|see arm/group description
223694924|NCT04954287|BIOLOGICAL|CVXGA1 high dose|see arm/group description
223694925|NCT02947555|OTHER|Non interventional|
223694926|NCT05693116|PROCEDURE|Rhinectomy|Surgery will be performed according to extension of the tumour, i.e. local resection limited to the vestibule, partial rhinectomy, total rhinectomy, extended total rhinectomy
223694927|NCT05594654|OTHER|Smart Phone Application|"Breathe is an app that can be used by people with asthma to promote collaborative self-management. It is a platform that empowers patients to self-manage their condition. Breathe helps patients detect when they might be exacerbating or adequately controlled based on symptoms entered by the user into the application. The application then feeds these symptoms through a rules-based algorithm that identifies the early onset of an exacerbation, based on the user's zone of control or action plan. It also stores the patient's self-management action plan and gives them relevant instructions when it sees that their symptoms are getting better or worse. These instructions are delivered through a chatbot that provides information, support, and education to the patient through a friendly, human-like text message conversation."
223694928|NCT02207023|BEHAVIORAL|Healthy Lifestyle Training Program|Study participants in the Healthy Lifestyle Training Program will each receive 7 lifestyle coaching telephone-sessions (30-60 minutes) with a trained lifestyle coach over a 6 month period. The lifestyle coaches will work on a 1:1 basis with each participant to encourage healthy lifestyles.
223694929|NCT02932215|DRUG|lorcaserin|Open label
223694930|NCT02932215|OTHER|Fitbit Charge HR|This is actually not an intervention- it is a tool to measure activity and sleep; all participants will be receiving one to collect data
223694931|NCT05289427|PROCEDURE|ultrasound guided triple injection peri-sartorius block|Patients will receive ultrasound guided triple injection peri-sartorius block preoperatively before surgical incision
223694932|NCT05289427|PROCEDURE|Femoral Nerve Block|Patients will receive femoral nerve block (FNB) before surgical incision
223694933|NCT04625816|DEVICE|whole body tilt device (Spine Balance 3D)|The symmetry of the deep muscle was evaluated using a whole body tilt device (Spine Balance 3D, Cyber Medic Co., Ltd., Korea). Spine Balance 3D can evaluate the maintenance strength and maximum strength of the core muscles, and perform a personalized core muscle training program based on the evaluated results.
223694934|NCT04046198|OTHER|Educational program|The Professional Values Education Program was developed in accordance with the Professional Values Model. For nurses in the intervention group program continued for three months. Group training was given before. Then, three individual interviews were conducted. After the post test was applied to the control group, group training was performed.
223694935|NCT04231890|OTHER|IPI monitoring|Patients in this arm will have IPI monitoring
223694936|NCT02828969|OTHER|Phone call or physical consultation|
223694937|NCT05191563|DRUG|HCP1904-1|Take it once per period.
223694938|NCT05191563|DRUG|RLD2006|Take it once per period.
223694939|NCT05191563|DRUG|RLD2001-2|Take it once per period.
223694940|NCT02400177|BEHAVIORAL|emotion regulation training|This is a workshop for parents that help them to understand how to deal with emotions generally and specifically with their ASD children's emotion
223779173|NCT05036187|BEHAVIORAL|Social Support Intervention|The Social Support Intervention provides online opportunities for participants to receive more social support as they work toward their weight loss goals. Participants receive education on the importance of social support for weight management, they can earn badges for completing program milestones, and they gain access to a private online forum to get support and advice from other participants.
223694941|NCT05830773|OTHER|Resonance Breathing Exercises|This intervention uses the Camera Heart Rate Variability (CHRV) smartphone application, a resonance breathing app that is available for download to iPhones and Android devices. The CHRV app uses Photoplethysmography (PPG) technology to measure heart rate. PPG is a noninvasive technology that uses a light source (the phone's flashlight) and a photodetector (the phone's camera lens) at the surface of one's skin to measure the volumetric variations of blood circulation. The app also has a timer (to allow the participant to see how long they use the app in each session). The iPhone version of the app also has a breathing pacer (a bar that moves up and down to show the participant when to inhale and exhale). Participants are instructed to initiate a resonance breathing session for at least 5 minutes every day and whenever they experience cravings, feel like they are going to relapse, feel anxious or stressed, or just want to feel calm.
223694942|NCT03400995|DRUG|AK0529|A solution containing 300 mg radiolabelled AK0529.
223694943|NCT01297556|BEHAVIORAL|Cognitive Behavior Therapy(CBT)|Cognitive Behavior Therapy(CBT) for 6 weeks.
223779174|NCT05101252|DEVICE|senofilcon A C3|TEST Lens
223779175|NCT05101252|DEVICE|Dailies Total 1 Multifocal Contact Lenses|CONTROL Lens
223779176|NCT01144338|DRUG|Exenatide Once Weekly|Subcutaneous injection, 2 mg, administered once weekly.
223779177|NCT01144338|DRUG|Placebo|Subcutaneous injection, matching volume of placebo, administered once weekly.
223779178|NCT00079105|BIOLOGICAL|bleomycin sulfate|Treatment
223779179|NCT00079105|DRUG|cyclophosphamide|Treatment
223694944|NCT04359667|DRUG|Tocilizumab 20 MG/ML Intravenous Solution [ACTEMRA]|1 - 8 mg per kg of body weight once, maximal 800 mg per dose (can be repeated once more after 12 hours, per clinician's assessment)
223694945|NCT01817244|OTHER|care management|6-month care management
223694946|NCT02652832|DEVICE|non invasive brain stimulation|non invasive brain stimulation
223694947|NCT05578248|DIAGNOSTIC_TEST|Magnetic Resonance Imaging (MRI)|Non-invasive imaging technology that produces three-dimensional detailed anatomical images
223694948|NCT05578248|PROCEDURE|ACL reconstruction|Surgical procedure to repair damaged or severed anterior cruciate ligament in the knee
223694949|NCT00414271|DRUG|Docetaxel|Docetaxel 60 mg/m2 IV on day 1
223694950|NCT00414271|DRUG|Capecitabine|Capecitabine 900 mg/m2 PO two times per day from day 1 to day 14 every 3 weeks for 2 cycles.
223694951|NCT00518687|BIOLOGICAL|V710|0.5-mL single injection of V710 (60 µg)
223694952|NCT00518687|BIOLOGICAL|Placebo|0.5-mL single injection of matching placebo
223694953|NCT04027543|COMBINATION_PRODUCT|Neoadjuvant chemoradiotherapy|In most patients, the chemotherapy regimens before surgery were consisted of cisplatin combined with either fluorouracil or taxanes.
223694954|NCT04027543|PROCEDURE|Oesophagectomy|Various surgical oesophagectomy methods were used, such as Ivor Lewis, transthoracic, three-hole, transhiatal, and left transthoracic,and the appropriate surgical approach for each patient was chosen according to the tumour location, size, and depth.
223694955|NCT04027543|DRUG|Neoadjuvant chemotherapy|In most patients, the chemotherapy regimens before surgery were consisted of cisplatin combined with either fluorouracil or taxanes.
223694956|NCT04970784|OTHER|Activities of Daily Living (ADL) questionnaire (The Katz index )|"For patients cared for by the geriatric sector, questionnaire will be filled in at admission D0 and by phone at D30, for the classic emergency patients questionnaire will be submitted by phone the day following the consultation D1, and D30."
223694957|NCT05108922|DRUG|Donanemab|Participants received 700 milligram (mg) donanemab administered by intravenous (IV) infusion every 4 weeks (Q4W) for first three doses and then 1400 mg IV Q4W.
223694958|NCT05108922|DRUG|Aducanumab|Participants received aducanumab administered by IV infusion per US label (prescribing information/routine clinical practice).
223779180|NCT00079105|DRUG|etoposide|Treatment
223779181|NCT00079105|DRUG|mitoxantrone hydrochloride|Treatment
223779182|NCT00079105|DRUG|prednisolone|Treatment
223779183|NCT00079105|DRUG|procarbazine hydrochloride|Treatment
223779184|NCT00079105|DRUG|vinblastine sulfate|Treatment
223694959|NCT05765396|DEVICE|imPulse™ Systems (Una and TOR) infrasound-to-ultrasound e-stethoscope|The imPulse™ Systems are an every/anywhere-point-of-care cardiopulmonary functional state assessment platform designed to capture normal and abnormal, audible and inaudible cardiopulmonary sounds, rhythms and patterns, via a real-time, intelligent, full-spectrum phonocardiogram obtained from direct to skin coupling or through a layer of clothing.
223694960|NCT00001624|DRUG|Insulin|
223694961|NCT05663567|BEHAVIORAL|solution oriented approach|Implementing a solution-focused approach to support breastfeeding
223694962|NCT01814384|DEVICE|prosthesis GMK ® without the ancillary MyKnee ® LBS|
223694963|NCT01814384|DEVICE|Matched patient cutting blocks MyKnee ® LBS|
223694964|NCT06378931|OTHER|Quality of life progression after parathyroidectomy|Study the progression of quality of life.
223694965|NCT02095223|DEVICE|Electromyographic Biofeedback|Electromyographic biofeedback is a device that enables a patient or clinician to measure the intensity of a muscle contraction using electrodes placed on the skin over a muscle of interest. In this study, participants in the electromyographic biofeedback supplemented exercise will also be instructed on correct setup and use of the electromyographic biofeedback unit. These instructions will focus on correct placement of the electromyographic recording electrodes over quadriceps muscle as well as correct tuning of the feedback threshold for each exercise to maximize the benefit of the intervention. Electromyographic biofeedback will be used during all exercises throughout the course of the study for this group.
223694966|NCT02095223|BEHAVIORAL|Traditional Exercise|All participants will be asked to complete 3 set of 10 repetitions of isometric quadriceps contractions with a 15 second hold time, supine straight leg raises, body weight squatting, and body weight lunges daily. Participants will be required to complete the single limb exercises on the previously injured limb only.
223694967|NCT05565131|DEVICE|Guided placement with PYTHEAS® ODYSSEE|Pre-surgery, the surgeon generates a 3D model of the spine from a preoperative CT scan During the perforation and insertion of the implant, the system indicates the orientation of the pedicle path and the current orientation of the instruments (perforation tool) with the orientation sensor (inertial sensor). The system also displays the position of the entry point of the planned pedicle path on the views.
223694968|NCT02339285|DEVICE|tACS (alpha)|
223694969|NCT02339285|DEVICE|tACS (gamma)|
223694970|NCT03714971|BEHAVIORAL|WhatsApp embedded in smoking cessation service|The routine service delivery was ongoing as the intervention was conducted. In addition to the routine procedures in service delivery described above, WhatsApp messages were sent according to the plan.
223694971|NCT00282412|BIOLOGICAL|Hematopoietic Stem Cell Transplantation|Allogeneic Hematopoietic Stem Cell Transplantation
223694972|NCT00282412|DRUG|Fludarabine|inhibits DNA synthesis or repair
223694973|NCT00282412|DRUG|Cyclophosphamide|Causes prevention of cell division by forming adducts with DNA
223694974|NCT00282412|DRUG|Campath 1H|humanized monoclonal antibody against CD52 antigen
223694975|NCT00282412|DRUG|GCSF|Hematopoietic growth factor
223694976|NCT00282412|DRUG|Cyclosporins|immune suppressive drug
223694977|NCT00282412|DRUG|Mycophenolate Mofetil|immune suppressive drug
223694978|NCT03024619|OTHER|Pain and Urinary pH|assess the correlation between urinary pH and Interstitial Cystitis (IC) pain, with emphasis placed on exploring the type and severity of pain
223779185|NCT04819685|DRUG|KANG FU PEN|FU PEN: anti-radiation spray (liquid dressing) treatment which is a protective irrigation solution against rays
223779186|NCT05441059|DRUG|Mepolizumab 100 MG|Treatment with mepolizumab for severe asthma
223779187|NCT05622591|DRUG|ELU001|Folic-acid functionalized C'Dot-Drug-Conjugate (FA-CDC)
223694979|NCT03211338|BIOLOGICAL|Culture with progesterone|Progesterone, a steroid hormone will be cultured with placental IMC cells or peripheral blood CD14+ monocyte cells
223694980|NCT03211338|BIOLOGICAL|Culture without progesterone|Culture of placental IMC cells or peripheral blood CD14+ monocyte cells without progesterone
223694981|NCT03211338|BIOLOGICAL|Culture with growth factors|Culture of placental IMC cells with growth hormones only and analysis
223694982|NCT06706856|DIAGNOSTIC_TEST|MR exam|Participants will undergo an advanced magnetic resonance (MR) examination of the abdomen and liver.
223694983|NCT06706856|DIAGNOSTIC_TEST|US exam|Participants will undergo an abdominal ultrasound (US) examination using a full-size US system. Some participants may undergo a point-of-care abdominal US exam with a handheld US system, if possible.
223694984|NCT06706856|OTHER|Blood draw|Participants will undergo a blood draw of approximately 25 mL volume.
223779188|NCT02067013|DRUG|Ranibizumab|Subjects in the Ranibizumab arm will receive an injection of drug within 2 weeks prior to their surgery.
223779189|NCT02067013|OTHER|No Ranibizumab|Subjects in the control arm will NOT receive an injection of drug within 2 weeks prior to their surgery.
223779190|NCT02188823|BEHAVIORAL|Low carbohydrate diet|
223694985|NCT06706856|OTHER|Physical measurements|Participants will have their height, weight and waist circumference measured. Vital signs including respiratory frequency, heart rate, temperature, and blood pressure will be measured.
223694986|NCT06706856|OTHER|Questionnaires|Participants will be asked to fill out questionnaires to collect information about their prescribed medications, demographics, medical and surgical histories, prior laboratory results, physical activity and lifestyle measures, and potential alcohol intake (AUDIT questionnaire).
223694987|NCT03763864|OTHER|Skin Biopsy|Skin Biopsy
223694988|NCT00537238|DRUG|pregabalin|300, 450, 600 mg/day administered orally, BID until seizure control/improvement or intolerable side effects
223694989|NCT00537238|DRUG|levetiracetam|1000, 2000, 3000 mg/day administered orally, BID until seizure control/improvement or intolerable side effects
223694990|NCT01315912|DRUG|Letrozole|2.5 mg /day for 5 days
223694991|NCT03804008|DRUG|Ultrasound-guided corticosteroid injection|A 21-gauge, 40 mm needle is connected to a 2.5 cm3 syringe filled with 1 ml Triamcinolonhexacetonid 20mg/ml + 1 ml Lidocain 10 mg7ml. The skin is cleansed with Chlorhexidine alcohol 0.5 %. The needle is inserted with a medial approach under ultrasound-guidance aligned to the long axis of the ultrasound transducer. The injection is placed anterior to the plantar fascia insertion on the calcaneal bone in the region of maximal fascia thickness. Participants are asked to start performing the exercise as soon as they feel ready but not before 24 hours after the injection. Furthermore, they are asked not to progress the method used to achieve 8RM when they start to do the exercise after the injection until Week 3 of the exercise programme. If standing on both feet was sufficient to achieve 8RM at baseline, the participant must not perform the exercise single-legged or to wear a backpack with weights after the injection regardless of any pain reduction afforded by the injection.
224263536|NCT00842309|DRUG|d-cycloserine|100mg of d-cycloserine in pill form administered 1 hour before behavior therapy sessions once a week for 8 weeks.
224263537|NCT00842309|DRUG|Placebo|Placebo in pill form administered 1 hour before behavior therapy sessions once a week for 8 weeks.
224263538|NCT00427154|DRUG|rosiglitazone|Tablets, 4 mg once or twice daily.
224263539|NCT00427154|DRUG|inhaled human insulin|Treat-to-target dose titration scheme, inhalation.
224263540|NCT00427154|DRUG|metformin|Tablets, 2000 mg/day.
224263541|NCT00427154|DRUG|glimepiride|Tablets, 8 mg/day.
224263542|NCT02997345|OTHER|There is no intervention associated with this study.|There is no intervention associated with this study.
224263543|NCT00893945|DRUG|DC/AAT|Autologous dendritic cells that have been co-cultured with autologous apoptotic tumor (AAT) specimens.
224263544|NCT00893945|DRUG|DC/AAT-Flu|Intradermal injection of Autologous dendritic cell vaccine (DC/AAT-Flu) after co-culture with flu-infected AAT
224263545|NCT00893945|DRUG|DC/KLH|Intradermal injection of Autologous dendritic cell vaccine (DC/KLH) which have been co-cultured with Keyhole pimpit hemocyanin (KLH) as a positive control.
224263546|NCT00000205|DRUG|Buprenorphine|
224263547|NCT03646409|OTHER|Venous thromboembolic event, arterial thromboembolic event, bleeding events|Whether or not venous or arterial thromboembolic and bleeding events occur in patients with esophageal cancer receiving neoadjuvant chemotherapy
224263548|NCT01376596|BEHAVIORAL|Cognitive-Behavioral Therapy based intervention immediately|This intervention will include: i) Psychoeducation on social anxiety disorder; ii) Cognitive Restructuring: Identify negative thoughts that occur before, during, or after anxiety-provoking situations; Evaluate the accuracy of their thoughts in the light of data derived from Socratic questioning or as a result of so-called behavioral experiments; and derive rational alternative thoughts based on the acquired information; iii) Exposure component, which focuses on the collection of information that will allow patients to revise their judgments about the degree of risk to which they are exposed in feared situations, challenge their dysfunctional beliefs about the self relative to the illness and their self-efficacy (social status related), and iv) Use of Thought Records to identify, explore and dispute negative thoughts about dysfunctional self-identity and core beliefs related to the onset and presence of diagnosis of schizophrenia.
223694992|NCT03804008|OTHER|Heavy-slow resistance training|Participants will be asked to complete a heel raise standing with the forefoot on a step. The toes are maximally dorsi flexed by placing a towel underneath them. The participant is instructed to perform a heel raise to maximal plantar flexion in the ankle joint and afterwards to lower the heel to maximal dorsiflexion. Supporting oneself for balance by placing the hands on a wall or a rail is allowed. Participants are instructed in performing the exercise with a load as heavy as possible but no higher than 8RM and for as many sets as possible every other day.
223694993|NCT03804008|OTHER|Fundamental advice and a silicone heel cup|Participants receive brief information about pathology, risk factors and advice on how to decrease activities that lead to symptom flares and slowly increase their activity level based on their symptoms. They also receive a leaflet that includes the same information as the research assistants will deliver orally after inclusion and a silicone heel cup.
223694994|NCT03438318|DRUG|CMP-001|CMP-001 will be administered as per the dose and schedule specified in the respective arms.
223694995|NCT03438318|DRUG|Atezolizumab|Atezolizumab will be administered as per the approved label and according to the schedule specified in the respective arms.
223694996|NCT03438318|RADIATION|Radiation Therapy|Radiation therapy will be administered using either 3-dimensional (3D) conformal radiotherapy or intensity-modulated radiation therapy (IMRT) to non-target node or metastatic lesion as per the dose and schedule specified in the respective arms.
223694997|NCT00004347|BEHAVIORAL|diet|
223694998|NCT03538678|OTHER|Kwit smartphone app|Kwit smarphone app
223694999|NCT03791827|DRUG|Corticosteroid|corticosteroid is given to patients orally or methylprednisone is given to patients through i.v.
223695000|NCT03791827|DRUG|Hydroxychloroquine|Hydroxychloroquine is recommended as the basic therapy for lupus nephritis
223695001|NCT03791827|DRUG|Cyclophosphamide|The typical therapy for cyclophosphamide is either 500 to 750mg/m2 once every month for 6 doses or 8 to 12 mg/kg/d for two consecutive days every two weeks for 6 to 8 doses through i.v.
223695002|NCT03791827|DRUG|Mycophenolate Mofetil|The recommended dose of mycophenolate mofetil is 20 to 30mg/kg/d
223695003|NCT03791827|DRUG|Azathioprine|The recommended dose of azathioprine is 1.5 to 2mg/kg/d
223695004|NCT03791827|DRUG|Tacrolimus|The recommended dose of tacrolimus is 0.05 to 0.15mg/kg/d, Q12h
223695005|NCT03791827|DRUG|Cyclosporine A|The recommended initial dose of cyclosporine A is 4 to 6mg/kg/d, Q12h
223695006|NCT03791827|DRUG|Rituximab|The recommended dose of rituximab is 375mg/m2 once a week for 2 to 4 doses
223695007|NCT00446342|DRUG|SNS-032 Injection|"Stage 1: Escalating doses of SNS-032 on days 1, 8 and 15 per 28 day cycle~Stage 2: Same as stage 1 except SNS-032 administered at the maximum tolerated dose established in stage 1"
223695008|NCT00006363|DRUG|cytarabine|Given IV
223695009|NCT00006363|DRUG|daunorubicin hydrochloride|Given IV
223695010|NCT00006363|DRUG|etoposide|Given IV
223695011|NCT00006363|DRUG|valspodar|Given IV
223695012|NCT00006363|BIOLOGICAL|filgrastim|Given SC
223695013|NCT00006363|DRUG|busulfan|Given orally
223695014|NCT00006363|PROCEDURE|autologous hematopoietic stem cell transplantation|Undergo autologous PBSCT
223695015|NCT00006363|PROCEDURE|peripheral blood stem cell transplantation|Undergo autologous PBSCT
223779191|NCT00813930|BEHAVIORAL|INTERxVENT lifestyle modification program|It is a lifestyle behavior modification program which helps Type 2 diabetics manage diabetes better and reduce cardiovascular risk factors. The program involves up to 12 telephone mentor/coaching sessions with a certified health professional.
223779192|NCT04796610|BEHAVIORAL|Mopati|The intervention will provide training to health care providers on how to guide unsuppressed HIV patients in the selection of treatment partners. The Mopati program will provide education to patients and their treatment partners about HIV treatment and how treatment partners can support patients in treatment adherence.
223779193|NCT02401672|DEVICE|Transcranial magnetic stimulation|Transcranial magnetic stimulation (TMS) is a noninvasive (and relatively painless) brain stimulation technology that can focally stimulate the brain of an awake individual. A localized pulsed magnetic field transmitted through a TMS coil is able to focally stimulate the cortex by depolarizing superficial neurons inducing electrical currents in the brain. If TMS pulses are delivered repetitively and rhythmically, the process is called repetitive TMS (rTMS).
223779194|NCT05187455|DRUG|Sugammadex|Each patient received a single dose administration of sugammadex 2mg/kg at reappearance of the second twitch of the train-of-four (TOF).
223695016|NCT00006363|BIOLOGICAL|aldesleukin|Given SC
223695017|NCT00006363|OTHER|clinical observation|Undergo clinical observation
223695018|NCT00006363|OTHER|pharmacological study|Correlative studies
223695019|NCT02047149|DRUG|Zileuton (Zyflo®) Dasatinib (Sprycel®)|To determine the maximum dose of zileuton/dasatinib in subjects with CML
223695020|NCT02047149|DRUG|Dosing with Zileuton/Dasatinib in CML|Three dose levels of daily zileuton will be studied in conjunction with dasatinib to define the MTD
223695021|NCT02047149|DRUG|Daily dosing of Zileuton/Dasatinib|Three dose levels of daily zileuton will be studied in conjunction with dasatinib to define the MTD
223695022|NCT02047149|DRUG|Daily dosing with Zileuton/Dasatinib for CML|Three dose levels of daily zileuton will be studied in conjunction with dasatinib to define the MTD
223695023|NCT05454904|BEHAVIORAL|Low fat diet|The low fat diet group will be counseled to consume a dietary pattern with fat restriction including food intake based in the following criteria: 1) \<3 teaspoons/day of olive or Canola oil and \<3 units/week of avocado, 2) removal of visible fat from meats before cooking or from cooked dishes before intake, 3) ≤1 serving per week fat-rich meats, hamburger, commercial ground meat, sausage, cured ham, bacon and salami, 4) daily consumption of low fat dairy products, 5) ≤1 serving/week of butter, margarine, lard, mayonnaise, milk cream, or milk- based ice cream, 6) ≤1 time/week intake of fatty fish or seafood, 7) ≤1 serving per week of commercial sweets or industrial bakery products (not homemade), and 8) ≤1 time/week consumption of nuts (including peanuts), potato chips, French fries, or commercial snacks. This intervention arm will be supplemented with powdered low fat milk (3 kgs/month) for daily use.
223779195|NCT02443038|OTHER|Yoga|"16 bi-weekly 50-60 minute yoga classes, followed by daily, 10 minute home exercise poses and 5 minute relaxation, the control group will practice 5 minutes relaxation, each day between classes.~The first of 3 classes is the 8-10 member advisory board, the second and third classes with 10-15 participants in each workshop will be held in other counties. There will be 2-3 months between the first set of classes and second and third set of classes to refine methods and conduct enrollment and testing for the subsequent groups."
223779196|NCT00003326|DRUG|paclitaxel|
223695024|NCT05454904|BEHAVIORAL|Mediterranean diet|The Mediterranean diet group will receive dietary recommendations as follows: 1) use of olive oil (\>3 teaspoons/day), 2) Canola oil as second fat source for cooking and dressing or \>3 units/week of avocado; 3) ≥3 daily servings of vegetables (at least one of them as fresh vegetables in a salad), 4) ≥2 daily servings of fresh fruits; 5) ≥2 weekly servings of legumes; 6) \>2 weekly servings of fresh, canned or frozen fish (at least one serving of oily fish)/seafood; 7) ≥2 weekly servings of nuts/seeds; 8) 4-8 servings/week of white meats (poultry or turkey without skin) instead of 9) fatty or processed meats (\<1 serving/week), 10) ≥2 daily servings of whole grains, 11) ≥1 daily/serving of low fat and fermented dairy products, 12) \<1 daily/serving of whole fat dairy products, 13) ≤1 daily/serving of sugary snacks, drinks or juices and \<4 teaspoons/daily of sugar, and 14) moderate (1-2 drinks/day) wine consumption with meals.
223695025|NCT05454904|BEHAVIORAL|Mediterranean diet plus psychological well-being support|This group will be subjected to the same Mediterranean diet pattern indicated previously as well as to a psychological well-being intervention that will include a variety of components/activities, embracing values, purpose, self-acceptance, character strengths, emotional regulation, dealing with negativity, goal-setting, mindfulness, savoring, gratitude, autonomy, relationships, social interactions, and prosocial behavior.
223695026|NCT03250429|PROCEDURE|Sinus surgery|Standard Clinical Sinus Surgery
223695027|NCT05803629|DIAGNOSTIC_TEST|68Ga-FAPI|Intravenous injection of one dosage of 74-148 MBq(2-4 mCi) 68Ga-FAPI.
223695028|NCT05803629|DIAGNOSTIC_TEST|18F-FDG|Intravenous injection of one dosage of 7.4MBq/kg(0.2mCi/kg) 18F-FDG. 18F-FDG PET/CT is performed within one week from 68Ga-FAPI PET/CT scan.
223695029|NCT00610623|DRUG|azithromycin|300 mg/day, IV from day 1 to 20
223695030|NCT00610623|DRUG|placebo|once per day, IV from day 1 to 20
223695031|NCT06174064|DEVICE|Broadband Light treatment|While shielding the eyes, multiple passes of broadband light will be applied to the upper cheeks and eyelids after applying topical lidocaine.
223695032|NCT06174064|DEVICE|Sham broadband light treatment|The light will be occluded on the usual BBL device so that no treatment is delivered but the preparation and procedure will otherwise be the same.
223695033|NCT02746068|DRUG|AXS-02|
223695034|NCT02746068|DRUG|Placebo|
223695035|NCT01690026|BEHAVIORAL|Motivation interviewing based brief intervention|
223695036|NCT01690026|BEHAVIORAL|Standard Intervention|
223695037|NCT02889692|DRUG|YiQiFang|"Prescriptions formulated into TCM granules origin from Professor Liu Jia-xiang in Longhua hospital. Package of granules is made into three types with functions such as benefiting Qi, benefiting Yin and detoxication recipe.~YiQiFang: Patients with Qi deficiency syndrome are administered two packages of each benefiting Qi and detoxication recipe, four packages, twice a day, until progression or unacceptable."
223695038|NCT02889692|DRUG|YangYinFang|"Prescriptions formulated into TCM granules origin from Professor Liu Jia-xiang in Longhua hospital. Package of granules is made into three types with functions such as benefiting Qi, benefiting Yin and detoxication recipe.~YangYinFang: Patients with Yin deficiency syndrome are administered two packages of each benefiting Yin and detoxication recipe, four packages, twice a day, until progression or unacceptable."
223695039|NCT02889692|DRUG|YiQiYangYinFang|"Prescriptions formulated into TCM granules origin from Professor Liu Jia-xiang in Longhua hospital. Package of granules is made into three types with functions such as benefiting Qi, benefiting Yin and detoxication recipe.~YiQiYangYinFang: Patients with Qi and Yin deficiency syndrome are administered one package of each benefiting Qi and benefiting Yin and two packages of detoxication recipe, four packages, twice a day, until progression or unacceptable."
223695040|NCT02889692|DRUG|placebo granules|Oral granules, which the taste and smell are similar to experimental TCM granules, has no therapeutic effect, four packages, twice a day, until progression or unacceptable.
223695041|NCT02889692|DRUG|Erlotinib®|"Erlotinib®,tarceva, 150 mg oral once a day until progression or unacceptable toxicity develops."
223695042|NCT02889692|DRUG|Gefitinib®|"Gefitinib®,Iressa, 250 mg oral once a day until progression or unacceptable toxicity develops."
223695043|NCT02889692|DRUG|Icotinib®|"Icotinib®,Conmana 125 mg oral three times a day until progression or unacceptable toxicity develops."
223695044|NCT02580903|RADIATION|Radiology|Only a small subsample will require CT and right heart catherisation
223695045|NCT00473473|DRUG|Potassium Dichromate (Homeopathy)|twice daily with an interval of 12 hours, for a period of up to 14 days
223695046|NCT00473473|DRUG|Placebo homeopathic remedy|identical to treatment without active component
223695047|NCT00729755|DIETARY_SUPPLEMENT|Creatine monohydrate|In addition to 10-20mg escitalopram, the subjects will be given total 3 gram of creatine (500mg/capsule) a day in first week and then, 5 gram a day in the rest of the weeks.
223695048|NCT00729755|DIETARY_SUPPLEMENT|Placebo|In addition to 10-20mg escitalopram, the subjects will be given total 6 capsules of placebo (equal quantities to those of creatine group) a day in first week and then, 10 capsules a day in the rest of the weeks.
223695049|NCT04687384|PROCEDURE|Robotic-assisted colectomy|Robotic-assisted colectomy performed by usage of da Vinci Xi robotic technology
223695050|NCT04687384|PROCEDURE|Conventional laparoscopic colectomy|Conventional laparoscopic colectomy
223695051|NCT02437513|DEVICE|NewBreez|Intralaryngeal prosthesis to protect the airways
223695052|NCT04163497|DEVICE|ICU Diaries|To explore the effects of providing an ICU Diary in the symptoms of anxiety, depression and PTSD within patients who were hospitalized in the unit.
223695053|NCT03956134|DRUG|Tapentadol Test Product 1|Tapentadol tablet containing 116 mg of tapentadol hydrochloride; Tapentadol Test Product 1 contains different amounts of excipients than Tapentadol Test Product 2
223695054|NCT03956134|DRUG|Tapentadol Test Product 2|Tapentadol tablet containing 116 mg of tapentadol hydrochloride; Tapentadol Test Product 2 contains different amounts of excipients than Tapentadol Test Product 1
223695055|NCT03956134|DRUG|Tapentadol Prolonged-release Reference Product|Tapentadol PR tablet containing 116 mg of tapentadol hydrochloride
223695056|NCT06496464|BEHAVIORAL|Intervention|"Phase 1 MASTER Coach Development Workshop (weeks 1) PE teachers participated in a 6-hour theory and practical teacher education workshop to a research team (JY) member, including 4h of reading relevant papers and books regarding the game-based approach (GBA) .~Phase 2 Eight weeks of teaching mentoring (weeks 2-7) This 8-week phase involved coaches implementing MASTER elements (e.g. 10-minute stretching before a sports game, teachers will give 1-2 sentences of praise during the game for individual students who make a reasonable effort) in their regular training sessions.~Phase 3 3 weeks peer assessed teaching/discussions (weeks 8-10) The mentor prepared and implement a 2-h training session designed to highlight important aspects of the MASTER framework and games-based coaching practices."
223695057|NCT03998878|BEHAVIORAL|Low-Carbohydrate Diet|Participants will be instructed to follow a low-carbohydrate diet.
223695058|NCT03998878|BEHAVIORAL|Intermittent Energy Restriction|Participants will be instructed to follow intermittent energy restriction.
223695059|NCT03998878|BEHAVIORAL|Hunger Training|Participants will be instructed to follow Hunger Training.
223695060|NCT04937855|OTHER|no intervention|no intervention
223695061|NCT02219347|DRUG|DMARD cessation|Complete cessation of non-biologic DMARD therapy (single or combination of methotrexate, sulphasalazine and/or hydroxychloroquine)
223695062|NCT00004868|DRUG|semaxanib|
223695063|NCT01613365|DRUG|Chlorhexidine Gluconate|Oropharyngeal and nasopharyngeal decontamination with Chlorhexidine Gluconate
223695064|NCT01613365|DRUG|Placebo|Oropharyngeal and nasopharyngeal decontamination with placebo
223695065|NCT06130917|OTHER|Multisystem Exercise|"Proprioception: Seated ankle ball. Single leg stance with support and with extension of knees. Single leg stance (hip extension) with support and with extension' of knees.~Muscle strengthening: Seated alternate double knee lifts with weights, chair stands. Seated alternate kicks with weigh. Hip extension standing with support with weights.~Balance Training Seated alternate weight shifts. Seated calf and toe raise. Heel raise with support.. Crossover with support Reaction time Seated alternate touches to front. Seated alternate touches to back. Seated alternate touches to side. Seated alternate touches to 3 steps (forward, side, backward)."
223695066|NCT06130917|OTHER|Conventional Treatment|"ROM exercises Passive ROM exercise of hip. Passive ROM exercise of knee. Passive ROM exercise of ankle Muscle strengthening Seated alternate double knee lifts with weights. chair stands. Seated alternate kicks with weigh. Hip extension standing with support with weights.~Balance Seated alternate weight shifts. Seated calf and toe raise. Heel raise with support. Crossover with support Stretching exercises Stretching exercise of hamstring. Stretching exercise of quadriceps. Stretching exercise of calf muscle"
223695067|NCT03802812|DEVICE|Thin bronchoscope and VBN|targeted washing at more adjacent TB lesion using thin bronchoscope and virtual bronchoscopic navigation system
223695068|NCT01677546|DEVICE|CSII+BC+CL|Insulin pump bolus calculator wirelessly communicated with blood glucose meter (Contour Link)
223695069|NCT01677546|DEVICE|CSII+BC|Insulin pump bolus calculator without wireless communication with blood glucose meter (Contour Link)
223695070|NCT03852004|OTHER|ostheopathy|standardized osteopathic treatment
223695071|NCT03852004|OTHER|simulated osteopathic treatment|standardized simulated osteopathic treatment
223695072|NCT00422097|DRUG|Ixabepilone, 5 mg/d|Ixabepilone, 5 mg, administered orally once daily on Days 1 through 5 every 21 days. Dose increased by 5 mg for each subsequent treatment group until disease progression, unacceptable toxicity, or participant refusal. No dose escalation within each treatment group. On all dosing days in Cycle 1, participants must fast at least 4 hours before and 4 hours after treatment.
223695073|NCT00422097|DRUG|Ixabepilone, 10 mg/d|Ixabepilone, 10 mg, administered orally once daily on Days 1 through 5 every 21 days. Dose increased by 5 mg for each subsequent treatment group until disease progression, unacceptable toxicity, or participant refusal. No dose escalation within each treatment group. On all dosing days in Cycle 1, participants must fast at least 4 hours before and 4 hours after treatment.
223695074|NCT00422097|DRUG|Ixabepilone, 15 mg/d|Ixabepilone, 15 mg, administered orally once daily on Days 1 through 5 every 21 days. Dose increased by 5 mg for each subsequent treatment group until disease progression, unacceptable toxicity, or participant refusal. No dose escalation within each treatment group. On all dosing days in Cycle 1, participants must fast at least 4 hours before and 4 hours after treatment.
223695075|NCT00422097|DRUG|Ixabepilone, 20 mg/d|Ixabepilone, 20 mg, administered orally once daily on Days 1 through 5 every 21 days. Dose increased by 5 mg for each subsequent treatment group until disease progression, unacceptable toxicity, or participant refusal. No dose escalation within each treatment group. On all dosing days in Cycle 1, participants must fast at least 4 hours before and 4 hours after treatment.
223695076|NCT00422097|DRUG|Ixabepilone, 25 mg/d|Ixabepilone, 25 mg, administered orally once daily on Days 1 through 5 every 21 days. Dose increased by 5 mg for each subsequent treatment group until disease progression, unacceptable toxicity, or participant refusal. No dose escalation within each treatment group. On all dosing days in Cycle 1, participants must fast at least 4 hours before and 4 hours after treatment.
223695077|NCT00422097|DRUG|Ixabepilone, 30 mg/d|Ixabepilone, 30 mg, administered orally once daily on Days 1 through 5 every 21 days. Dose increased by 5 mg for each subsequent treatment group until disease progression, unacceptable toxicity, or participant refusal. No dose escalation within each treatment group. On all dosing days in Cycle 1, participants must fast at least 4 hours before and 4 hours after treatment.
223695078|NCT00422097|DRUG|Ixabepilone, 25 mg, with famotidine|Participants crossed over from Cycle 1 to receive famotidine, 40 mg, in an oral dose given 2 hours before ixabepilone, 25 mg, on Day 1 of Cycle 2 only.
223695079|NCT00422097|DRUG|Ixabepilone, 25 mg, with food|Participants consume a low-fat meal starting 30 minutes before dose administration on Day 1 of Cycle 2. Food consumed within 30 minutes. Administration of the total oral dose should not exceed more than 10 minutes from start to finish.
223695080|NCT00736957|DRUG|Tramadol Hydrochloride (HCL) plus Acetaminophen (JNS013)|Tramadol hydrochloride 37.5 milligram (mg) plus acetaminophen 325 mg (JNS013) one or two tablets will be given orally four times daily (maximum dose is 8 tablets per day) for 4 weeks during treatment period 1 (restrictions on concomitant treatments will be established) and for 48 weeks during treatment period 2 (permitting modifications to the concomitant drugs/therapies). The dosing interval will be of at least 4 hours.
223695081|NCT00462540|DRUG|Formoterol Fumurate inhalation solution 20 mcg|
223695082|NCT00462540|DRUG|Ipratropium bromide 18 mcg and albuterol sulfate 103 mcg|
223695083|NCT02547948|BIOLOGICAL|CD19-targeting CAR T Cells infusion|CD19-targeting 2nd generation CAR t cells infusion for refractory B cell lymphoma
223695084|NCT01368978|DEVICE|InsuPatch|device which apply local heating at 38.5 degrees Celsius to the vicinity of the subcutaneous insulin infusion insertion site.
223695085|NCT02680509|PROCEDURE|Sympathicotomy R3|sympathicotomy R3 consists of transecting the sympathetic chain at the third costal level, cranial of the ganglia, leaving the ganglia themselves untouched
223695086|NCT04171154|BEHAVIORAL|Expectation|writing task
223695087|NCT04171154|BEHAVIORAL|Acceptance|listening
223695088|NCT00484627|PROCEDURE|Use of creatine monohydrate (a dietary supplement)|
223695089|NCT00484627|BEHAVIORAL|Progressive resistance exercise training|
223695090|NCT06199778|BEHAVIORAL|Rehabilitation therapy|"1. Acupuncture: Regular acupuncture treatment that can prevent muscle atrophy, improve circulation, and have a stimulating effect.~2. Exercise therapy: Training that focused on limb movements or joint mobilization to prevent muscle contracture, reduce joint mobility, improve spasms, and promote blood circulation.~3. Others: Regular turning, back patting, and position changes performed by caregivers."
223779197|NCT00701051|BEHAVIORAL|Aerobic exercise training|24 weeks of aerobic exercise training: 3 times per week, 60 minutes per session, at 70% of maximal aerobic capacity
223779198|NCT00701051|BEHAVIORAL|Detraining (cessation of exercise)|Cessation of exercise for 2 weeks
223779199|NCT04513600|DIAGNOSTIC_TEST|Cardiac MRI|Lab work: Hs- Troponin, Serum N-terminal-proBNP CMR: Native T1, Native T2, extracellular volume, strain and strain rate.
223779200|NCT00643955|OTHER|muscle strength|muscle strength
223779201|NCT04777461|OTHER|Survey on patient's perspectives on the development of an structured education programme for PCOS|The outcome of this survey will help with developing curriculum for the structured education programme.
223779202|NCT04777461|OTHER|Pre-pilot questionnaire|The questionnaire is aimed to capture the knowledge and expectations of the participants from taking part in the educational sessions.
223779203|NCT04777461|OTHER|Piloting the structured education programme for PCOS|Piloting the education program through 2 educational group sessions
223779204|NCT04777461|OTHER|Post-pilot questionnaire|The questionnaire aimed to capture participant's satisfactions and knowledge gained by taking part in the pilot study
223779205|NCT04777461|OTHER|cognitive outcomes outcome evaluation form|This aimed to capture skills developed, knowledge gained and changes in participants behaviour and perceptions by taking part in the pilot study.
223779206|NCT01275924|DEVICE|Tightrope Syndesmosis Repair Kit|Tightrope Syndesmosis Repair Kit
223779207|NCT01275924|DEVICE|Syndesmotic screw|Quadricortical syndesmotic screw
223779208|NCT01151241|PROCEDURE|Elbow arthroscopy with infraclavicular nerve block and continuous local anesthetic infusion to day 3 post op.|Patients undergoing elbow arthroscopy surgery will receive standard anesthesia/analgesia, including infraclavicular nerve block and general anesthesia for surgery followed by infraclavicular catheter infusion of local anesthetic until day 3 after surgery.
223779209|NCT01151241|OTHER|Early Discharge|Patients will be discharged home on the first day after surgery, with infraclavicular catheter infusion of local anesthetic in place.
223779210|NCT01151241|OTHER|Normal Discharge|Patients will remain in hospital and be discharged per current discharge criteria, once the infraclavicular catheter has been removed on day 3 post op. Typical discharge occurs on day 3 or 4 post op.
223779211|NCT06202885|DRUG|Immunotherapy|Immunotherapy
223779212|NCT02059148|DRUG|LY2835219|Administered orally.
223779213|NCT01340339|DEVICE|Phototherapy|Fluorescent reverse phototherapy (7 white lights 5cm below the base of acrylic cot), with spectral irradiance of 8-12microwatts/cm2/nm; daily; until bilirubin reaches level that indicates suspension of therapy
223779214|NCT01340339|DEVICE|Phototherapy|super LED reverse phototherapy (17 bulbs arranged in 42 x 31 cm in blue base acrylic cot), with spectral irradiance of 8-12microwatts/cm2/nm; daily; until bilirubin reaches level that indicates suspension of therapy
223779215|NCT02073968|DRUG|Carboplatin|Given IV
223779216|NCT02073968|PROCEDURE|Computed Tomography|Undergo PET-adjusted IMRT
223779217|NCT02073968|RADIATION|Intensity-Modulated Radiation Therapy|Undergo PET-adjusted IMRT
223779218|NCT02073968|DRUG|Paclitaxel|Given IV
223779219|NCT02073968|PROCEDURE|Positron Emission Tomography|Undergo PET-adjusted IMRT
223779220|NCT02073968|RADIATION|Proton Beam Radiation Therapy|Undergo proton beam radiation therapy
223779221|NCT05663398|DRUG|Darfen 400, 400 mg ibuprofen coated tablets (512 mg ibuprofen sodium dihydrate)|Oral, a nonsteroidal anti-inflammatory drug
223779222|NCT05663398|DRUG|Nurofen® Forte Express, 400 mg ibuprofen coated tablets (512 mg ibuprofen sodium dihydrate)|Oral, a nonsteroidal anti-inflammatory drug
223779223|NCT00638547|DRUG|IRT Laronidase|"Laronidase belongs to a class of drugs called enzyme replacement therapies or ERT that provides people with sufficient quantities of an important enzyme that they cannot create on their own. The main ingredient in laronidase is a protein that is identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. Laronidase replaces the missing enzyme alpha-L-iduronidase and restores sufficient enzyme activity to break down GAG buildup.~Subjects will receive an infusion of Laronidase into his/her spinal fluid approximately 12 weeks before, 2 weeks before, 100 days after and 6 months after transplant. This procedure is done by lumbar puncture"
223779224|NCT01722591|DEVICE|Cardiapex device|Cardiapex percutaneous transapical access and closure system
223779225|NCT03639155|DRUG|vadadustat reference tablets|oral tablet
223779226|NCT03639155|DRUG|vadadustat test tablets|oral tablet
223779227|NCT01320163|DEVICE|i-gel airway (Intersurgical Ltd., Wokingham, England)|supra-glottic airway device
223779228|NCT01320163|DEVICE|Laryngeal Mask Airway|supra-glottic airway device
223779229|NCT01061294|PROCEDURE|Advanced CustomVue™ iLASIK procedure|
223779230|NCT01061294|DEVICE|WaveScan WaveFront® System, STAR S4 IR™ Excimer Laser System and IntraLase™ FS System|
223779231|NCT04641468|PROCEDURE|DCB|OCT technical guidance: if B-type or C-type dissection can be seen, Oct should be used for further evaluation, and des treatment should be conducted if necessary
223779232|NCT02157558|DRUG|Fexofenadine|All subjects will receive 180 mg fexofenadine
223779233|NCT02157558|DRUG|Telotristat etiprate|All subjects will receive 500 mg (2 X 250 mg tablets) telotristat etiprate tablets three times daily
223779234|NCT05372198|DRUG|Chohort 1: Surufatinib|Surufatinib 300mg, qd, every 3 weeks as a cycle
223779235|NCT05372198|DRUG|Chohort 2: Immunotherapy|Refer to the instructions for the use of immunotherapy, every 3 weeks as a cycle
223779236|NCT05372198|DRUG|Chohort 2: Surufatinib|Surufatinib 250mg, qd, every 3 weeks as a cycle
223779237|NCT05831852|OTHER|no intervention|no intervention
223779238|NCT05797779|PROCEDURE|Skin biopsy|Punch biopsy of the skin
223695091|NCT06199778|DEVICE|Intermittent Oro-esophageal Tube Feeding|Based on this, the patients in the observation group were given nutrition support with Intermittent Oro-esophageal Tube Feeding (Medical Device No. 20010234, developed by the Swallowing Disorders Research Institute of Zhengzhou University). The entire feeding process strictly followed the standard procedure of Intermittent Oro-esophageal Tube Feeding(18). During the feeding process, patients were maintained in a semi-recumbent position with their head elevated, facilitating the placement of the tube into the oral cavity along one side, with the chin brought close to the manubrium sterni.
223695092|NCT06199778|DEVICE|Nasogastric tube feeding|The patients in the control group were provided nutrition support with Nasogastric tube feeding, while the feeding process strictly followed the relevant guideline. During the treatment, the patients remained in a continuous state of tube indwelling, receiving feeding every 2-3 hours with a maximum feeding volume of 200ml, of which the contents were consistent with the observation group. The entire feeding process was conducted by trained nursing staff. Besides, the tube was replaced by a new one every 5-7 days.
223695093|NCT06199778|DRUG|Reserpine|Reserpine was administered to patients to nourish their nerves, with frequency based on their condition.
223695094|NCT06199778|DRUG|Levofloxacin|The levofloxacin was administered to patients as antibiotic treatment, with frequency based on their condition.
223695095|NCT03728530|OTHER|Deep Breathing exercises|"In pursed lip exercise subject was guided to inhale through nose with mouth closed and exhale through pressed lips (pursed lips).~In Diaphragmatic breathing subject was instructed to place his one hand below the rib cage and the other hand on chest. The patient inhaled slowly so that stomach moves out against the hand. Tighten the stomach muscle while exhaling through pursed lip.~In powered breathing subject was to inhale and exhale forcefully with some movements like subject was instructed to inhale forcefully while moving his hands upward and exhale forcefully while moving hands downward.~These three exercise techniques were advised to each subject of experimental group. They have to practice these exercises 3-4 times a day with 10 repetitions each. These exercises can be performed in sitting position or in supine lying position. Subject can adopt any position in which he feels comfortable."
223695096|NCT01554020|DIETARY_SUPPLEMENT|Blood Sugar Take Care|One 1200 mg soft gel capsule administered 3X/day for duration of study
223695097|NCT01554020|DIETARY_SUPPLEMENT|Placebo|One 1200 mg soft-gel capsule administered 3X/day for duration of study
223695098|NCT01381484|DRUG|10% Argireline|10% Argireline (La jolie gel®, Pacific health care, Thailand) were instructed to apply the gel over the face and periorbital area twice daily for a period of 3 months.
223695099|NCT06170892|OTHER|Kangaroo method|The newborns were placed in the kangaroo position in a single session, and the variables were identified before, during and after the application of the technique.
223695100|NCT00331864|DRUG|Ranibizumab|
223695101|NCT01092507|BIOLOGICAL|Japanese encephalitis chimeric virus vaccine (JE-CV)|0.5 mL, Subcutaneous
223695102|NCT01092507|BIOLOGICAL|Japanese encephalitis live vaccine (SA14-14-2 vaccine) (CD.JEVAX®)|0.5 mL, Subcutaneous
223695103|NCT04839146|BIOLOGICAL|ABNCoV2 Vaccine|SARS-CoV-2 vaccine
223695104|NCT01238185|DRUG|acetylsalicylic acid|
223695105|NCT01238185|GENETIC|gene expression analysis|
223695106|NCT01238185|GENETIC|protein expression analysis|
223695107|NCT01238185|OTHER|laboratory biomarker analysis|
223695108|NCT01238185|OTHER|questionnaire administration|
223695109|NCT01238185|PROCEDURE|biopsy|
223695110|NCT03798847|DEVICE|Journey II XR TKA|Journey II XR Total Knee System
223695111|NCT03872323|PROCEDURE|Endovascular treatment|The arteries injuries are repaired by endovascular treatment.
223695112|NCT03872323|PROCEDURE|Open surgery|The arteries injuries are repaired by open surgical operation.
223695113|NCT06192784|PROCEDURE|DEB-TACE|transcatheter arterial chemoembolization with doxorubicin embedded eluting beads- was performed every 3 weeks through the tumor feeding arteries.
223695114|NCT06192784|DRUG|Lenvatinib plus pucotenlimab|lenvatinib (8mg, qd) plus pucotenlimab (200mg, q3w)
223695115|NCT05593133|OTHER|Pnf exercises|"PNF techniques will comprise of Warm up, Rhythmic stabilization, Hold Relax, Contract Relax and light exercises and performed on three muscle groups ( Hamstring, Quad and Calf).~20 participants will be followed up with the therapist regularly twice a week for 30 minutes session each for a duration of 8 weeks."
223695116|NCT05593133|OTHER|Gait training exercises|gait Training exercises comprised of one foot balancing, leg raises, heel raises, tight-rope walking. 20 participants will be followed up with the therapist regularly twice a week for 30 minutes session each for a duration of 8 weeks.
223695117|NCT03030807|DIAGNOSTIC_TEST|Right heart catheterization (in case of suspected PH)|
223695118|NCT00016159|BIOLOGICAL|filgrastim|
223695119|NCT00016159|BIOLOGICAL|lintuzumab|
223695120|NCT00016159|DRUG|arsenic trioxide|
223695121|NCT00016159|DRUG|idarubicin|
223695122|NCT00016159|DRUG|tretinoin|
223695123|NCT04429048|DEVICE|Acupressure elastic band (Sea-Band)|The PC6 acupressure was done via Sea-Band in persistent compressive state for 3 minutes per time and three times a day , then at least 5 days in one week for 6 weeks continuously except modern routine standard therapy
223695124|NCT04429048|DEVICE|General elastic band (no bud)|general elastic band was put over bilateral PC6 acupoints
223779239|NCT00345579|BIOLOGICAL|GSK Biologicals' Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine combined 792014|3-dose intramuscular injection
223779240|NCT00345579|BIOLOGICAL|ActHIB|3-dose intramuscular injection
223779241|NCT00345579|BIOLOGICAL|Pediarix/Infanrix Penta|3-dose intramuscular injection
223779242|NCT05393310|OTHER|post isometric relaxation|The therapist will apply Post isometric relaxation ensure that foot will not actually move and only a static muscle contraction apply and held for 20 seconds. This will be followed by 2-3 second of relaxation, and then the foot passively stretched to dorsiflexion up to the palpated barrier and/or tolerance to stretch. This will continue until no further gains achieved 2 sets of 5 repetitions a day for 3 days a week for 4 weeks
223779243|NCT05393310|OTHER|MWM group|MWM group will receive inferior tibiofibular, talocrural, or cubometatarsal MWM 2-8 treatment sessions over 4 weeks.
223695125|NCT03189485|DRUG|the radiotracer 18F-AV-1451|Subjects will receive a single IV bolus injection target dose of approximately 370 MBq (10 mCi ± 20%) of 18F-AV-1451 At approximately 75 minutes post dose, scanning will begin. An approximately 30-minute acquisition (six 5 minute intervals) will be performed
223695126|NCT05264415|BEHAVIORAL|Families OverComing Under Stress (FOCUS) for Early Childhood (FOCUS-EC)|Trauma-informed, family-centered, skill-building preventive intervention for families with preschool-aged children.
223695127|NCT05264415|OTHER|Parenting Education Website|A website providing parenting education resources in four primary domains relevant for families with preschool-aged children (parenting, child development, transitions, and self-care).
223695128|NCT05208606|BEHAVIORAL|Wawokiya Health Advocate|"Study visits 1 and 2 will follow the same broad procedures. Subsequent visits will be structured around needs. WHAs will cover multiple domains of assessment utilizing a visit guide.~Visit 1: Specific topics covered in this visit will include; 1) an explanation of palliative care, study, and WHA role and 2) mapping of providers/family/caregivers The WHA will arrange dates and times for future visits.~Visit 2: Occurs 1 week after the first visit. WHAs will begin to assess patient needs utilizing a needs assessment tool. Specific topics covered will include: 1) Documentation of disease history 2) Needs assessment screen~Following Visits: After visit 2, activities will be based on needs assessed. Activities may entail: 1) Review of palliative care and WHA role, 2) Assessment of needs, 3) Addressing needs 3) Exploring goals of care.~We anticipate patients will receive an average of 2-3 WHA visits per month. Investigators will hold regular supervisory meetings with the WHA."
223695129|NCT04487522|PROCEDURE|Open retromuscular ventral hernia repair|With the subject under general anesthesia, a single incision is made in the abdomen. The retrorectus space is developed for mesh placement to repair the defect. The repair technique will be per the surgeon's standard of care.
223695130|NCT04487522|PROCEDURE|Laparoscopic retromuscular ventral hernia repair|With the subject under general anesthesia, several small incisions are made in the abdomen. Ports are placed, the abdomen is insufflated, and laparoscopic instruments as well as a laparoscope are inserted to complete the repair. The retrorectus space is developed for mesh placement to repair the defect. The repair technique will be per the surgeon's standard of care.
223695131|NCT04487522|DEVICE|Robotic-assisted retromuscular ventral hernia repair|With the patient under general anesthesia, several small incisions are made in the abdomen. Ports are placed, the abdomen is insufflated, and the da Vinci Robotic Surgical System (Intuitive) is docked to the subject and used to complete the procedure. The retrorectus space is developed for mesh placement to repair the defect. The repair technique will be per the surgeon's standard of care.
223695132|NCT04799327|DRUG|SHR20004|SHR20004：low dose
223695133|NCT04799327|DRUG|SHR20004|SHR20004: medium dose
223695134|NCT04799327|DRUG|SHR20004|SHR20004: high dose
223695135|NCT04799327|DRUG|placebo|Placebo
223695136|NCT00173888|DRUG|Docetaxel, Cisplatin|docetaxel 36mg/m2 IF 30 mins on day 1,8,15 cisplatin 75mg/m2 IF 2 hrs on day 15
223695137|NCT00173888|DRUG|Gemcitabine, Cisplatin|gemcitabine 1000mg/m2 IF 30mins on D 1,8,15, cisplatin 75mg/m2 IF 2 hrs on day 15
223695138|NCT03225742|DIAGNOSTIC_TEST|to measure the residual volume after catheterization|after first micturition to measure the residual volume in bladder
223695139|NCT05061966|BEHAVIORAL|immi|The intervention has four main content areas: 1) gender identity (the gender guide), 2) sexual orientation (the queerness guide), 3)stress and coping (the stress guide), and 4) internalized stigma (the internalized stigma guide).
223695140|NCT05061966|BEHAVIORAL|Control|The control will have access to resources on the website, but will not receive any engagement reminders, matching the conditions present in real world contexts in which web-based resource lists are available.
223695141|NCT01562158|PROCEDURE|standard therapy|Standard treatment of bleeding
223695142|NCT01562158|DRUG|activated recombinant human factor VII|Two days repeated treatment regimen - low dose administered i.v. (into the vein)
223779244|NCT03758898|OTHER|Treatment|Chest physiotherapy and mobilization were applied twice a day, 8 times in total.
223779245|NCT03758898|OTHER|Group 2|Only mobilization was applied twice a day, 8 times in total.
223779246|NCT01579344|DRUG|Radioiodine therapy|Radioiodine therapy with NaI131
223695143|NCT01562158|DRUG|activated recombinant human factor VII|Two days repeated treatment regimen - medium dose administered i.v. (into the vein)
223695144|NCT01562158|DRUG|activated recombinant human factor VII|Two days repeated treatment regimen - high dose administered i.v. (into the vein)
223695145|NCT01562158|DRUG|placebo|Placebo
223695146|NCT02685514|DEVICE|HIFU Graves|The HIFU treatment technique will be applied to the recruited participants
223695147|NCT04384783|DRUG|growth hormone|growth hormone was adjuvanted 2IU/d from previous menstrual period for about six weeks.
223695148|NCT05324137|DRUG|CM326|CM326 injection
223695149|NCT05324137|OTHER|Placebo|Placebo
223695150|NCT06569251|DRUG|Dexamethasone 12 mg QD|Administration of dexamethasone to the mother as an inducer of fetal lung maturity. shortened scheme
223695151|NCT06569251|DRUG|Dexamethasone 6 mg BID|Administration of dexamethasone to the mother as an inducer of fetal lung maturity. standard Scheme
223695152|NCT01554085|DRUG|ALS-002158|ALS-002158
223695153|NCT01554085|DRUG|Placebo|placebo
223695154|NCT01442454|OTHER|chronic pancreatitis|No intervention, subjects followed through surgery
223695155|NCT04148690|OTHER|Group antenatal care (GANC)|Group antenatal care (GANC) is a service delivery model where women with pregnancies of similar gestational age are brought together for antenatal care (ANC), incorporating information sharing and peer support.
223695156|NCT04148690|OTHER|Standard antenatal care|Routine antenatal care as recommended by th Ministry of Health of Tanzania
223695157|NCT04402918|DIAGNOSTIC_TEST|biological samples day of delivery|mother samples: serology, viremia, nasopharyngeal swab, vaginal swab, placenta swab, piece of placenta newborn: serology, viremia, nasopharyngeal aspiration
223695158|NCT05630755|DRUG|DOR/ISL|DOR/ISL 100 mg/0.25 mg oral tablets once daily
223695159|NCT05630755|DRUG|BIC/FTC/TAF|BIC/FTC/TAF 50 mg/200 mg/25 mg oral tablets once daily
223695160|NCT05630755|DRUG|Placebo to BIC/FTC/TAF|0 mg oral tablets once daily
223695161|NCT05630755|DRUG|Placebo to DOR/ISL|0 mg oral tablets once daily
223695162|NCT00975520|OTHER|Observation|Patients will be observed after surgery until recurrence when they will be offered radiation therapy
223695163|NCT00975520|RADIATION|Radiation Therapy|Patients randomised to the Investigational treatment arm, will receive adjuvant curative post-operative radiation therapy aiming to reduce the rate of local recurrence. The recommended dose prescribed is 48 Gy in 20 fractions over 4 weeks.
223695164|NCT05718726|OTHER|Questionnaire, interview or observation study|Questionnaire administered by telephone
223695165|NCT04644003|DRUG|STP1|STP1 is a combination of two drugs, a phosphodiesterase (PDE) inhibitor and an NKCC1 inhibitor
223695166|NCT04644003|DRUG|Placebo|Placebo medication (capsule and tablet) identical in appearance to active medication
223695167|NCT03424668|BEHAVIORAL|diet|lifestyle factors
223695168|NCT00261079|DRUG|Fexofenadine|
223695169|NCT03699683|OTHER|Combined aerobic and resistance training program|
223695170|NCT05962749|OTHER|Assessment|3 meter backward walk test (3MBWT), 10 meter walk test (10MWT), Selective Control Assessment of the Lower Extremities (SCALE), Trunk Control Measurement Scale (TCMS), Pediatric Balance Scale (PBS), Functional Independence Measure for Children (WeeFIM), Modified Ashworth Scale (MAS)
223695171|NCT06529965|BEHAVIORAL|covivio|Participants will receive access to the digital health intervention covivio in addition to TAU.
223695172|NCT03304821|DRUG|GM-CSF|Participants will self-administer 500 μg/day of GM-CSF, subcutaneously, three times per week (Monday, Wednesday, Friday) for three weeks. After three months the participants will receive a second administration of 500 μg/day of subcutaneous GM-CSF, three times per week for another 3 weeks and then will be followed for another 3 months.
223695173|NCT03304821|DRUG|Placebo|Participants will self-administer 500 μg/day of a placebo, subcutaneously, three times per week (Monday, Wednesday, Friday) for three weeks. After three months the participants will receive a second administration of 500 μg/day of a placebo administered subcutaneously, three times per week for another 3 weeks and then will be followed for another 3 months.
223695174|NCT01815983|OTHER|Videolaryngoscopy review.|Review of video recordings.
223695175|NCT05500599|DRUG|Fentanyl Citrate|Intravenous Formulation of Fentanyl Citrate and Midazolam Administered Orally for Premedication
223779247|NCT01415661|OTHER|cricoid pressure|The current study test by direct visual evidence the occlusion of esophageal entrance during application CP. The closure of the lumen was further demonstrated by the inability to introduce a GT into the esophagus during CP.
223779248|NCT00185029|PROCEDURE|Ferumoxtran-10 enhanced MRI (MRL)|
223779249|NCT06065696|PROCEDURE|Early mobilization|Patients who received early mobilization in postoperative period
223779250|NCT06065696|PROCEDURE|No early mobilization|Patients who did not receive early mobilization in postoperative period
223779251|NCT02235766|OTHER|Echocardiographic assessment|
223779252|NCT06534736|PROCEDURE|Electrotherapy and physical agents|It will comprise of hot pack for 10 minutes, Tens for 10 minutes.
223779253|NCT06534736|PROCEDURE|Post Facilitation Stretch|Participants will be instructed to maintain the contraction for 6 to 10 seconds and then relax the muscles as quickly as possible.The stretch will be held for 15 seconds in an attempt to lengthen the shortened facscial structures.The muscles which will be targeted are Levator Scapular Upper Trapezius Sternocleidomastoid scalene Pectoralis Muscles
223779254|NCT06534736|PROCEDURE|Scapular Stabilization Exercise|Scapular Stabilization exercises protocol will consist of scapular wall slide exercise, scapular retraction, wall Ball Circle exercises, scapula squeeze, wall press ups. Exercise program 3 sets of 5 - 10 repetition for 10 seconds hold a 20 second break between each sets. The intervention will be applied 2 weeks 3 times a week and 30 min per session. Post Facilitation stretch of the targeted muscles also will be carried out during the sessions
223779255|NCT03054844|DRUG|Lidocaine|Lidocaine will be administered before administration of midazolam.
223779256|NCT03054844|DRUG|Lidocaine and midazolam (PREMIX)|Lidocaine will be administered as a mixture with midazolam.
223779257|NCT03054844|DRUG|Midazolam|Midazolam will be administered either after lidocaine, or as a mixture with lidocaine.
223779258|NCT02673697|DEVICE|Perceval valve|Sutureless Aortic Biological Valve
223779259|NCT02673697|DEVICE|other stented biological valve|Any biological stented valves available on the market (Edwards, Medtronic, St.Jude, LivaNova, Labcor)
223779260|NCT02580526|PROCEDURE|V-E mask ventilation for one minute|"V-E approach maintains mouth open, creates larger oral cavity and allow positive pressure generated during inspiration to push forwards submandibular region.~When apnea occurs after anesthesia induction subjects will be ventilated with one of the two techniques randomly, either two-handed C-E facemask ventilation technique or with V-E technique. Ventilation will be carried out using pressure mode ventilation at respiratory rate of 10 breaths per minute. Subject will start with one technique and then cross over to the other technique."
223779261|NCT02580526|PROCEDURE|C-E mask ventilation for one minute|"Using C-E technique, the operator's fingers pressure mouth closed and push posteriorily the soft tissue of submandibular region.~When apnea occurs after anesthesia induction subjects will be ventilated with one of the two techniques randomly, either two-handed C-E facemask ventilation technique or with V-E technique . Ventilation will be carried out using pressure mode ventilation at respiratory rate of 10 breaths per minute. Subject will start with one technique and then cross over to the other technique."
223695176|NCT01265251|DEVICE|Computerized neuropsychological test|Computerized neuropsychological test battery.
223695177|NCT01265251|OTHER|Conventional neuropsychological test|Conventional neuropsychological test (paper and pen)
223695178|NCT05015530|DEVICE|Healsea® Chronic, hypertonic seawater-based nasal spray supplemented with natural Symbiofilm® extract|Healsea® Chronic nasal spray will be administered twice daily (1 puff, 1-2 sec) in each nostril during 30 days
223695179|NCT04735536|DRUG|CT1812|Active Treatment- CT1812 at a dose of 300mg
223695180|NCT04735536|OTHER|Placebo|Placebo Comparator
223695181|NCT04968847|DEVICE|FemaSeed Localized Directional Insemination|Subjects undergoing FemaSeed Artificial Insemination
223695182|NCT00560469|OTHER|Administration of 70% deuterated water|Subjects will drink 70% deuterated water daily for 8 weeks.
223695183|NCT02923427|DEVICE|Laryngeal mask Supreme Evaluation|Evaluation of clinical performance in terms of Insertion, ventilation and complications
223695184|NCT02923427|DEVICE|i-gel Evaluation|Evaluation of clinical performance in terms of Insertion,ventilation and complications
223695185|NCT01910571|DRUG|P7435|
223695186|NCT01910571|OTHER|Placebo|
223695187|NCT01681797|DEVICE|Fluorescence angiography (Fluobeam™ imaging system developed by Fluoptics company)|Fluorescence angiography after intravenous injection of Infracyanine® (indocyanine green)
223695188|NCT01325623|DEVICE|Model 106 VNS Therapy System|The VNS Therapy System is an adjunctive therapy for the treatment of epilepsy. VNS Therapy is available as a scheduled stimulation, this is cyclic stimulation between programmable On- and Off- times (e.g., a 30-second burst every 5 minutes). VNS Therapy is also available as on-demand stimulation, that is, when a magnet is introduced briefly over the implanted device (Magnet Mode). The AspireSR VNS Therapy System includes a new feature, Automatic Magnet Mode or AutoStim. In addition to Normal Mode and Magnet Mode, AspireSR uses a Seizure Detection Algorithm to identify a potential seizure onset based on associated heart rate increases known as ictal tachycardia. The purpose is to deliver stimulation at or near the onset of a seizure.
223695189|NCT00728052|DRUG|GSK598809|GSK598809 capsules will be available with dose strengths of 5 milligrams and 25 milligrams, administered orally with water.
223695190|NCT00728052|DRUG|Placebo|Placebo capsules will be administered orally with water.
223695191|NCT00145600|DRUG|12 Week Stanford V Chemotherapy|12 weeks of Stanford V chemotherapy plus low-dose, involved-field RT in children
223779262|NCT00437489|DRUG|Inhaled Human Insulin (Exubera)|Initial dose (mg) as per weight based formula = 0.05 x body weight (kg) TID
223779263|NCT00437489|DRUG|Inhaled Human Insulin (Exubera)|Initial dose of 1mg TID of inhaled human insulin
223695192|NCT00145600|DRUG|4 cycles of VAMP chemotherapy|4 cycles of VAMP chemotherapy alone in patients who achieve a complete response after 2 cycles of VAMP chemotherapy. For patients that do not achieve a complete response after 2 cycles of VAMP, they will receive low low-dose involved field radiotherapy at the end of all chemotherapy.
223695193|NCT00145600|DRUG|2 alternating cycles of VAMP/COP chemotherapy|2 alternating cycles of VAMP/COP chemotherapy (total 4 cycles of chemotherapy) plus low-dose, involved-field RT.
223695194|NCT00145600|DRUG|3 alternating cycles of VAMP/COP chemotherapy|3 alternating cycles of VAMP/COP chemotherapy (total 6 cycles of chemotherapy) plus low-dose, involved-field RT
223695195|NCT03257176|BEHAVIORAL|Stepping Stones and Creating Futures|21 session intervention, comprising of 10 Stepping Stones sessions focused on gender, relationships and communication. 11 Creating Futures sessions focused on livelihoods.
223695196|NCT06025643|OTHER|TENS - Cervical stimulation group|TENS will be applied bilaterally through self-adhesive electrodes in the cervicothoracic ganglionic region, located between the C7 and T4 vertebral processes.
223695197|NCT06025643|OTHER|TENS - Plus cervical stimulation group|TENS will be applied bilaterally in the cervicothoracic ganglionic region, located between the C7 and T4 vertebral processes, on the earlobe, on the wrists and ankles simultaneously.
223695198|NCT06025643|OTHER|TENS - Renal stimulation group|TENS will be applied through self-adhesive electrodes in the abdomen (anatomical region corresponding to the kidneys) and dorsal region at the level of the 10th thoracic vertebra.
223695199|NCT05377203|DRUG|Quadruple combination of half doses therapy→Dual combination of standard dose therapy|"Quadruple combination of half doses therapy: a single capsule containing quadruple combination of half doses of blood pressure medicines (amlodipine besylate tablet 2.5mg, amlodipine besylate tablet simulator 2.5mg, irbesartan tablets 75mg, irbesartan tablets simulator 75mg, metoprolol succinate sustained-release tablets 23.75mg, indapamide tablets 1.25mg), take orally, one capsule once a day.~Dual combination of standard dose therapy: a single capsule containing dual combination of standard dose of blood pressure medicines (amlodipine besylate tablets 2.5mg×2, irbesartan tablets 75mg×2, metoprolol succinate sustained-release tablets simulator 23.75mg, indapamide tablets simulator 1.25mg), take orally, one capsule once a day."
223695200|NCT05377203|DRUG|Dual combination of standard dose therapy→ Quadruple combination of half doses therapy|"Dual combination of standard dose therapy: a single capsule containing dual combination of standard dose of blood pressure medicines (amlodipine besylate tablets 2.5mg×2, irbesartan tablets 75mg×2, metoprolol succinate sustained-release tablets simulator 23.75mg, indapamide tablets simulator 1.25mg), take orally, one capsule once a day.~Quadruple combination of half doses therapy: a single capsule containing quadruple combination of half doses of blood pressure medicines (amlodipine besylate tablet 2.5mg, amlodipine besylate tablet simulator 2.5mg, irbesartan tablets 75mg, irbesartan tablets simulator 75mg, metoprolol succinate sustained-release tablets 23.75mg, indapamide tablets 1.25mg), take orally, one capsule once a day."
223695201|NCT04465162|OTHER|Radiation Therapy|Undergo radiation therapy
223695202|NCT01539642|DRUG|Sufentanil NanoTab PCA System/15 mcg|15 mcg Sufentanil NanoTab dosed sublingually every 20 minutes as needed for pain for up to 48 hours. Patient may elect to remain in study for up to 72 hours.
223695203|NCT01539642|DRUG|Placebo Sufentanil NanoTab PCA System|Placebo NanoTab dosed sublingually every 20 minutes as needed for pain for up to 48 hours. Patient may elect to remain in study for up to 72 hours.
223695204|NCT03098355|BIOLOGICAL|4SCAR19/22 T cells|CD19/CD22-targeted 4th Generation CAR-T Cell (4SCAR19/22)
223695205|NCT03098355|DRUG|Interleukin-2|Interleukin-2 of 250,000iu/m\^2 every other day for 2 weeks and then rest for 2 weeks for up to 6 months.
223695206|NCT01969643|DRUG|ladiratuzumab vedotin|LV will be given into the vein (IV; intravenously)
223695207|NCT01969643|DRUG|Trastuzumab|Trastuzumab will be given by IV every 3 weeks at a dose of 6 mg/kg (the first dose will be 8 mg/kg)
223695208|NCT02518412|OTHER|tDCS|Transcranial Direct Current Stimulation (tDCS) is a non-invasive treatment method, using a low Direct current stimulation to increase excitability and thus stimulate plasticity and cognitive functions.
223695209|NCT02518412|OTHER|Placebo tDCS|Half of the patients will receive Placebo tDCS. The procedure is the same as for active tDCS, but the in the Placebo tDCS the stimulation is non-active / sham.
223695210|NCT00898378|GENETIC|gene expression analysis|gene expression analysis
223695211|NCT00898378|GENETIC|polymerase chain reaction|polymerase chain reaction
223695212|NCT00898378|GENETIC|polymorphism analysis|polymorphism analysis
223695213|NCT00898378|GENETIC|protein expression analysis|protein expression analysis
223695214|NCT00898378|GENETIC|proteomic profiling|proteomic profiling
223695215|NCT00898378|OTHER|gas chromatography|gas chromatography
223695216|NCT00898378|OTHER|laboratory biomarker analysis|laboratory biomarker analysis
223695217|NCT00898378|OTHER|liquid chromatography|liquid chromatography
223695218|NCT00898378|OTHER|mass spectrometry|mass spectrometry
223695219|NCT00898378|OTHER|questionnaire administration|questionnaire administration
223695220|NCT03031535|DRUG|Intranasal octreotide acetate|Intranasal spray of octreotide acetate
223695221|NCT03031535|DRUG|Subcutaneous octreotide acetate|Subcutaneous injectable solution of octreotide acetate
223779264|NCT04136106|DRUG|IL-2|IL-2 is a medicine which can use in autoimmune disease, infection or cancer with different dose. Low-dose IL-2 preferentially used in autoimmune disease, such as SLE. Our enrolled SLE patients will divided into two groups depend on whether use IL-2 or not, combined with corticosteroid and immunosuppressor.
223779265|NCT03009110|DEVICE|Prophylactic NPWT|The Prevena NPWT system is a small, lightweight, portable suction device consisting of an electric motor-driven vacuum pump connected to a proprietary foam and adhesive dressing. It is supplied as a pump with a sterile dressing kit and two batteries. Different dressing sizes are available for transverse and vertical incisions ranging from 13 to 20 cm and more. The pump maintains negative pressure of -125 mmHg to the wound surface. The device is placed after skin closure.
223695222|NCT03031535|DIAGNOSTIC_TEST|Growth hormone-releasing hormone|Part of the well established GHRH/Arginine challenge to detect GH deficiency.
223695223|NCT03031535|DIAGNOSTIC_TEST|Arginine hydrochloride|Part of the well established GHRH/Arginine challenge to detect GH deficiency.
223695224|NCT00426998|DRUG|Verteporfin|
223695225|NCT00426998|DRUG|Bevacizumab|
223695226|NCT01384071|DEVICE|Unstable shoes (MBT)|Wearing unstable (MBT) shoes during 6 weeks
223695227|NCT01384071|DEVICE|Sham intervention (Adidas shoes)|Normal stable shoes (Adidas Bigroar2)
223695228|NCT04758078|OTHER|Inhaled corticosteroids|Budesonide 2 mL = 1000 microgram will be given within 6 hours of birth and the second dose will be given after 12 hours
223695229|NCT04758078|OTHER|Placebo|Nebulized 0.9% saline will be given four times per day
223779266|NCT03009110|DEVICE|Standard Dressing|Standard wound dressing is routine postoperative wound dressing consisting of layers of gauze and adhesive tape.
223779267|NCT01428323|DEVICE|Vented and Unvented Jet Nebulizer|Nebulizers used with 500mg aminoglycosides in 4ml until One minute after the sputerring point.
223695230|NCT03644680|DIAGNOSTIC_TEST|Nasal Provocation with Birch Extract|Nasal spray containing birch extract from Allergopharma
223695231|NCT03644680|OTHER|Nasal Provocation with NaCl 0.9%|Nasal spray containing sterile sodium chloride 0.9%
223695232|NCT00635791|DRUG|Sorafenib|Given by mouth
223695233|NCT00635791|DRUG|Vorinostat|Given by mouth
223695234|NCT05648760|BEHAVIORAL|Simulation training|Participants randomized to the simulation condition received simulation training based on a standard training of how to communicate bad news to patients
223695235|NCT05622370|DRUG|Brivaracetam tablets (50mg/ tablet, BRIVIACT®, UCB)|"Brivaracetam tablets (trade name: Briviact) Specification: 50mg/ piece Batch number: 34244 Content: 100.0% Date of purchase: September 2022~According to the random table, take test preparation A(T1) once (1 tablet/time) or test preparation B(T2) once (2 tablets/time) or reference preparation (R) twice (1 tablet/time, with an interval of 12 hours, before taking the medicine for the first time) on an empty stomach.~Expiry date: April 2025 Storage conditions: sealed, stored at 20-25℃, allowing short-term temperature deviation of 15-30℃ Manufacturer: Union Chimique Belge Pharm, UCB Provider: Taizhou Overseas Pharmaceuticals Co.,Ltd."
223695236|NCT05622370|DRUG|Brivaracetam sustained-release tablets 100mg|"Brivaracetam sustained-release tablets Specification: 100mg/ tablet Batch number: 22081201 Content: 102.5% Date of production: August 12, 2022 Expiry date: August 11th, 2024. Storage conditions: sealed and stored at 10-30℃ Manufacturer: Overseas Pharmaceuticals, Ltd. Provider: Taizhou Overseas Pharmaceuticals Co.,Ltd.~According to the random table, take test preparation A(T1) once (1 tablet/time) or test preparation B(T2) once (2 tablets/time) or reference preparation (R) twice (1 tablet/time, with an interval of 12 hours, before taking the medicine for the first time) on an empty stomach."
223779268|NCT05491733|DRUG|APX001|Low-load oral tablet
223779269|NCT05491733|DRUG|APX001A|High-load oral tablet
223779270|NCT02388321|DRUG|Ketamine|intranasal sub-dissociative dose ketamine for the treatment of moderate to severe pain in pediatric patients in the emergency department.
223779271|NCT02388321|DRUG|Fentanyl|intranasal fentanyl for the treatment of moderate to severe pain in pediatric patients in the emergency department.
223779272|NCT02029924|DRUG|BioChaperone insulin lispro|Single dose of 0.2 U/Kg body weight injected subcutaneously (under the skin)
223779273|NCT02029924|DRUG|Humalog®|Single dose of 0.2 /Kg body weight injected subcutaneously (under the skin)
223779274|NCT03893448|BIOLOGICAL|V114|V114 15-valent pneumococcal conjugate vaccine containing 13 serotypes present in Prevnar 13® (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) and 2 unique serotypes (22F and 33F) in each 0.5 mL intramuscular administration.
223779275|NCT03893448|BIOLOGICAL|Prevnar 13™|Prevnar 13™ 13-valent pneumococcal conjugate vaccine containing 13 serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) in each 0.5 mL IM administration.
223779276|NCT03893448|BIOLOGICAL|RotaTeq™|A total of 3 RotaTeq™ 2 mL oral dosings at \~2, \~4, and \~6 months of age.
223779277|NCT03893448|BIOLOGICAL|Pentacel™|A total of 3 Pentacel™ 0.5 mL IM dosings at \~2, \~4, and \~6 months of age.
223779278|NCT03893448|BIOLOGICAL|RECOMBIVAX HB™|A total of 3 RECOMBIVAX HB™ 0.5 mL IM dosings at \~2, \~4, and \~6 months of age.
223779279|NCT03893448|BIOLOGICAL|VAQTA™|One VAQTA™ 0.5 mL IM dosing at 12 to 15 months of age.
223779280|NCT03893448|BIOLOGICAL|MMR II™|One MMR II™ 0.5 mL subcutaneous (SC) dosing at 12 to 15 months of age.
223779281|NCT03893448|BIOLOGICAL|VARIVAX™|One VARIVAX™ 0.5 mL SC dosing at 12 to 15 months of age.
223779282|NCT03893448|BIOLOGICAL|HIBERIX™|One HIBERIX™ 0.5 mL IM dosing at Visit 5.
223779283|NCT04170127|PROCEDURE|Irradiation of implants with 635nm laser|Irradiation of implants with 635nm laser
223779284|NCT04345146|COMBINATION_PRODUCT|FSRT combined with Bevacizumab|"Bevacizumab: Patients will receive Bevacizumab (7.5mg/kg, q3w, IV) before and after FSRT.~Fractionated stereotactic radiotherapy(FSRT): 40 Gy/10 fractions or 30 Gy/5 fractions for GTV will be delivered to brain metastases."
223779285|NCT03821428|PROCEDURE|Acupuncture|Needling of P6 and CV24 points
223779286|NCT03821428|PROCEDURE|Placebo|Application of placebo acupuncture needles to the areas, where the acupoints are situated
223779287|NCT02573987|DRUG|Oxygen/nitrous oxide equimolar mix|an experimental strategy inhalation by means of a breathing mask diffusing MEOPA
223779288|NCT02573987|DRUG|Lidocaine|standard strategy by local injection anesthesia of lidocaine
223779289|NCT02175446|DRUG|Bevacizumab and eribulin|"In this study, Bevacizumab and Eribulin are considered to be the investigational study drugs. Bevacizumab is provided as 25 mg/ml concentrate for infusion. Vials contain 100 mg of Bevacizumab in 4 ml and/or 400 mg in 16 ml. Eribulin is provided as vials containing 1 mg/2 mL Eribulin as a 500 µg/mL solution in ethanol/water"
223779290|NCT03632161|DRUG|Dexmedetomidine|isobaric bupivacaine 0.5% (0.3ml/kg) and dexmedetomidine (1 mcg/kg)
223779291|NCT03632161|DRUG|Bupivacaine|isobaric bupivacaine 0.5% (0.3ml/kg)
223779292|NCT05205603|DRUG|Infliximab|Infliximab, 5mg/kg at week 0,2,6 and schedule administration at every 8 weeks
223779293|NCT05205603|DRUG|Vedolizumab|Vedolizumab, 300mg at week 0,2,6 and schedule administration at every 8 weeks
223779294|NCT05205603|DRUG|Mesalazine|Mesalazine, 4-6g/d, systemic and/or topical administration
223779295|NCT04592367|PROCEDURE|Patient age at time of procedure of reconstruction of ACL|Primary reconstruction of ACL with no other concomitant ligament reconstructions. Treatment of cartilage og meniscal injury may be a part of the procedure
223779296|NCT01063205|DRUG|Placebo|Placebo administration will be started on day 2 and stopped on day 5. Methylsulonylmethane (MSM) will serve as a placebo for MA.
223779297|NCT01063205|DRUG|N-acetylcysteine|Study medication (NAC 1800 mg) will be started on day 2 and stopped on day 5.
223779298|NCT01063205|DRUG|N-acetylcysteine|Study medication (NAC 3600 mg) will be started on day 2 and stopped on day 5.
223779299|NCT01286818|BIOLOGICAL|Ramucirumab (IMC-1121B)|Ramucirumab (IMC-1121B): Intravenous (IV) infusions, 8 milligrams per kilogram (mg/kg) every 2 weeks
223779300|NCT01286818|DRUG|Irinotecan|IV Infusion, 180 milligrams per square meter (mg/m²) every 2 weeks
223779301|NCT01286818|DRUG|levofolinate|IV infusion, 200 mg/m² every 2 weeks
223779302|NCT01286818|DRUG|5-Fluorouracil (5-FU)|400 mg/m² bolus followed by a 2400 mg/m² continuous infusion, every 2 weeks
223779303|NCT01551862|PROCEDURE|body contouring surgery of back, abdomen and thighs|simultaneous body contouring surgery of back, abdomen and thighs
223779304|NCT05284994|DRUG|TQ-B3525 Tablets, Osimertinib Mesylate Tablets|TQ-B3525 is a novel α/δ dual inhibitor PI3K kinase inhibitor. Osimertinib mesylate is a third-generation epidermal growth factor receptor inhibitor.
223779305|NCT00583492|BIOLOGICAL|Ad5-yCD/mutTKSR39rep-ADP|Ad5-yCD/mutTKSR39rep-ADP (1 x 10\^12 vp) on day 1 Plus Radiation - 40 x 2 Gy for a total dose of 80 Gy or 44 x 1.8 Gy for a total dose of 79.2 Gy Plus 2 week course (weekdays only) of 5-FC and vGCV prodrug therapy
223779306|NCT00583492|RADIATION|IMRT|40 x 2 Gy for a total dose of 80 Gy or 44 x 1.8 Gy for a total dose of 79.2 Gy
223695237|NCT05622370|DRUG|Brivaracetam sustained-release tablets 50mg|"Brivaracetam sustained-release tablets Specification: 50mg/ piece Batch number: 22082501 Content: 100.0% Date of production: September 02, 2022 Expiry date: August 24th, 2024. Storage conditions: sealed and stored at 10-30℃ Manufacturer: Overseas Pharmaceuticals, Ltd. Provider: Taizhou Overseas Pharmaceuticals Co.,Ltd.~According to the random table, take test preparation A(T1) once (1 tablet/time) or test preparation B(T2) once (2 tablets/time) or reference preparation (R) twice (1 tablet/time, with an interval of 12 hours, before taking the medicine for the first time) on an empty stomach."
223695238|NCT01729260|DRUG|Mebendazole|The mebendazole will be given by mouth three times every day on a 28 day cycle. it's in the form of 500 mg chewable tablets, to be taken with meals.
223695239|NCT02675101|OTHER|Whole Nuts|Participants will be advised on maintaining an iso-caloric diet. Aside consuming nuts, the remaining composition of the prescribed diet will be based on individual preferences. During the 6-month intervention, study subjects will meet with study staff every 2-3 weeks to weigh in, pick up food supplies and complete a questionnaire on compliance. All participants will have contact with the project coordinator/study dietitian a minimum of every 1-2 weeks either in-person, telephone, email and text message contacts for support, behavioral guidance and strategies. Both walnuts and almonds will be provided to participants in the whole nut study arm.
223695240|NCT02675101|OTHER|Olestra: Fat Free Pringles|Participants will be advised on maintaining an iso-caloric diet. Aside consuming fat free potato crisps, the remaining composition of the prescribed diet will be based on individual preferences. During the 6-month intervention, study subjects will meet with study staff every 2-3 weeks to weigh in, pick up food supplies and complete a questionnaire on compliance. All participants will have contact with the project coordinator/study dietitian a minimum of every 1-2 weeks either in-person, telephone, email and text message contacts for support, behavioral guidance and strategies. Fat Free Pringles will be provided to participants in the olestra study arm.
223695241|NCT02675101|OTHER|Vegetable Oil: Original Pringles|Participants will be advised on maintaining an iso-caloric diet. Aside consuming potato crisps, the remaining composition of the prescribed diet will be based on individual preferences. During the 6-month intervention, study subjects will meet with study staff every 2-3 weeks to weigh in, pick up food supplies and complete a questionnaire on compliance. All participants will have contact with the project coordinator/study dietitian a minimum of every 1-2 weeks either in-person, telephone, email and text message contacts for support, behavioral guidance and strategies. Original Pringles will be provided to participants in the vegetable oil study arm.
223695242|NCT02753218|DRUG|Midazolam|
223695243|NCT02753218|DRUG|LEO 32731|
223695244|NCT05152563|DRUG|AK002|Lirentelimab (AK002) is a humanized non-fucosylated immunoglobulin G1(IgG1) monoclonal antibody directed against Siglec-8
223695245|NCT05152563|OTHER|Placebo|Placebo
223695246|NCT00761579|DRUG|Paliperidone|Paliperidone oral tablet was administered once daily at a starting dose of either 3 milligram (mg), 6 mg or 9 mg for 48 weeks, wherein recommended dose was 6 mg and dose range was 3 to 12 mg per day.
223695247|NCT03253458|DEVICE|Confocal Laser Endomicroscopy|Transperineal confocal laser endomicroscopy or optical coherence tomography measurements. Probe will be placed guided by ultrasound, similar procedure as transperineal template guided mapping biopsies.
223779307|NCT05658692|DEVICE|protective ventilation|Patients with moderate to severe ARDS received ventilation treatment according to predicted body weight(PBW) and controlled plateau pressure.
223779308|NCT05658692|BEHAVIORAL|prone position ventilation|patients with moderate to severe ARDS who don't have contraindications were given prone ventilation for over 12 hours.
223779309|NCT05658692|DRUG|glucocorticoid therapy|"Dexamethasone: Patients received intravenous dexamethasone 20 mg daily from days 1 to 5, reduced to 10 mg daily from days 6 to 10.~Hydrocortisone：For septic ARDS patients, 50 mg of hydrocortisone was given as an intravenous bolus every 6 hours for 7 days; For patients with COVID-19-related ARDS, The corticosteroid field randomized participants to a fixed 7-day period of intravenous hydrocortisone (50 mg or 100 mg every 6 hours)."
223779310|NCT05658692|OTHER|restrictive fluid resuscitation|"1. without other organ dysfunction patients: Minimize fluid was given;~2. other ARDS patients: In the resuscitation phase, controlled fluid replacement combined with vasoactive drugs was given; multiple measures were taken, like lactate and so on, to utilizedto guide fluid resuscitation therapy; diuretics or diuretics in combination with albumin to achieve fluid balance."
223779311|NCT05658692|BIOLOGICAL|Thymosin Alpha|People received thymosin Alpha subcutaneous injections, twice a week.
223779312|NCT05658692|DRUG|Muscle relaxant therapy|Deep sedation combined with intermittent bolus injection of muscle relaxant or deep sedation combined with continuous infusion of muscle relaxant
223779313|NCT05658692|OTHER|Integrated Chinese and Western Medicine Treatment|"1. ventilation;~2. conventional western medicine treatment；~3. Chinese herbal medicine（Determining medication based on syndrome differentiation）"
223779314|NCT05658692|DRUG|statin therapy|"1. Simvastatin: 80mg qd po for not more than 28days;~2. Rosuvastatin: 20mg qd po (40mg for the first time) for 28days or 3 days after transfer out of the ICU, or the patient died."
223779315|NCT05658692|COMBINATION_PRODUCT|anti-infective treatment|"According to Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021."
223779316|NCT05658692|DEVICE|Extracorporeal Membrane Oxygenation（ECMO）|"1. For severe ARDS patients with refractory hypoxemia within 7 days of onset;~2. (Inspiratory oxygen concentration) ≥ 0.80, tidal volume 6ml/kg (PBW), positive end-expiratory pressure \[PEEP\] ≥ 10 cmH2O;~3. V-V Model."
223779317|NCT05658692|GENETIC|stem cell therapy|A single injection of bone marrow stem cells, doses of 1, 5, 10\*106 cells/kg was taken according to the previous clinical studies.
223779318|NCT05658692|DRUG|Sedative analgesia/muscle relaxant therapy|Deep sedation combined with intermittent bolus injection of muscle relaxant or deep sedation combined with continuous infusion of muscle relaxant
223779319|NCT05658692|DRUG|inotropes therapy|"According to Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021."
223779320|NCT05658692|DRUG|Vasoactive drug therapy|"According to Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021."
223779321|NCT04260581|DRUG|Determination of drug effects through amantadine cessation|Patients will discontinue amantadine, which has been taken since beginning of diagnosis.
223779322|NCT03789422|DRUG|association of levocetirizine and tranexamic acid|levocetirizine 10 mg/day + tranexamic acid 2 g/day
223779323|NCT03789422|DRUG|Levocetirizine only|levocetirizine 20 mg/day
223779324|NCT04287933|DEVICE|Drain insertion|insertion of a drain
223779325|NCT04994626|DRUG|Ibrutinib Combined With Rituximab|"Drug: ibrutinib ibrutinib 560mg administered orally once daily. Other Name: Imbruvica~Drug: rituximab rituximab 375mg/m² administered intravenously (IV)"
223779326|NCT03753126|RADIATION|4-dimensional volume-rendered computed tomography|
223779327|NCT04616651|BEHAVIORAL|Online Survey|Participants respond to online survey questions either before or after using the Chatbot O2O intervention.
223779328|NCT04616651|BEHAVIORAL|Chatbot prototype|An online, automated, menu-based agent in which all responses are pre-programmed to be consistent with the existing O2O program. The chat-like responses help guide the participant through a process with the goal of developing a list of questions for their upcoming appointment with a cancer clinician. The session is meant to be completed in one sitting and estimated to take about 45 minutes to complete (including the pre- or post-intervention survey); however, if a participant stops in the middle, they may go back and complete the Chatbot session (or survey).
223779329|NCT04616651|BEHAVIORAL|Open to Options (O2O) Program|Evidence-based program developed by Cancer Support Community that helps patients actively engage in their treatment decision process by preparing them for their upcoming appointments.
223779330|NCT03299595|OTHER|printed questionnaire|For each eligible participant, a full history will be obtained according to a questionnaire followed by thorough clinical examination.
223779331|NCT05005546|BEHAVIORAL|Yoga|Yoga will be applied to mothers in the yoga group
223779332|NCT05005546|BEHAVIORAL|Laughter Yoga|Laughter Yoga will be applied to mothers in the yoga group
223779333|NCT01448759|OTHER|blood sampling|Other: Blood sampling 10mL of peripherical blood will be collected specially for the study. It's an additional blood sampling compare to the normal follow up of the patient.
223779334|NCT00187798|DRUG|Metformin HCl|Subjects will be given a single oral dose in tablet form containing 850 mg of metformin
223779335|NCT01789944|BEHAVIORAL|Behavioral: Family-based behavioral intervention|This behavioral treatment includes behavioral skills training and accountability, including food and activity self-monitoring, goal setting, and home environment change
223695248|NCT04840173|BEHAVIORAL|Music|During attendance at a one hour, 6-week psychosocial classroom or virtual training, caregivers will learn to use singing and other music-based interventions, implementing them each week before the informational session.
223695249|NCT03611010|DRUG|Atorvastatin injection|statin (i.e., 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor) for injection
223695250|NCT00905216|DRUG|heparin sodium - Bergamo|5.000 UI/mL
223695251|NCT00905216|DRUG|heparin sodium - APP|5.000 USP
223695252|NCT03517124|OTHER|Ceramic tooth restoration|Dental restorations
223695253|NCT00111878|DRUG|MEDI-534|
223695254|NCT04870034|DRUG|Binimetinib|Given PO
223695255|NCT04870034|DRUG|Palbociclib|Given PO
223695256|NCT04870034|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
223779336|NCT03604250|DIETARY_SUPPLEMENT|Lifestyle plus prebiotic supplement|Research participants will be asked to wear health monitoring devices, including a continuous glucose and heart-rate monitors. They may be prompted to perform lifestyle modifications aimed at better understanding their health parameters, based on the results obtained from the wearable devices and other tests. During the last 3 weeks of the study, research participants may be asked to take a personalized prebiotic supplement, up to once/day.
223779337|NCT00487201|PROCEDURE|endoscopic balloon dilatation|
223779338|NCT00487201|PROCEDURE|plastic stent placement|
223779339|NCT00984841|OTHER|Tailored letter|
223779340|NCT02323724|GENETIC|BRAF V600E mutation by pyrosequencing technique|
223779341|NCT01494285|DRUG|ARK-E021 5%|Topically applied once daily at bedtime
223779342|NCT01494285|DRUG|ARK-E021 10%|Topically applied once daily at bedtime
223779343|NCT01494285|DRUG|Placebo|Topically applied once daily at bedtime
223779344|NCT04111497|DRUG|Glasdegib|Given PO
223779345|NCT06141642|DEVICE|Self-adaptive serious game|A self-adaptive serious game in immersive virtual reality using the device MetaQuest 1 or 2
223779346|NCT06141642|DEVICE|Non-adaptive serious game|A non-adaptive serious game in immersive virtual reality using the device MetaQuest 1 or 2
223779347|NCT06133582|BEHAVIORAL|Internet Based Psychodynamic Psychotherapy|"This is a 10-week intervention, delivered on a website called 'Iterapi' which was developed in Sweden. The programme involves creative and interactive web-based content- worksheets, audio, video, expressive writing exercises. Additionally, each participant is assigned a Therapeutic Support Worker (TSW). The TSW logs into the platform and views the questionnaires and other data provided by the participants that they are supporting. Each week, the TSW sends each of their participants a reflective message in response to the data they have provided when interacting with the programme over the last week. The participant can reply to this message.~The principal objective of the iPDT intervention is to reduce depressive symptoms through the promotion of emotional awareness and emotional experience. The intervention is an affect-focused therapy and draws on Malan's Triangle of Conflict (Malan, 1995)."
223779348|NCT04534829|PROCEDURE|Fluoroscopic-guided Radiofrequency Ablation|Radiofrequency ablation of the posterior SIJ complex under fluoroscopic-guidance
223779349|NCT04534829|PROCEDURE|Ultrasound-guided Radiofrequency Ablation|Radiofrequency ablation of the posterior SIJ complex under ultrasound-guidance
223779350|NCT02012374|BEHAVIORAL|Intensive Language Action Therapy|
223779351|NCT00817089|DRUG|Placebo Oral Tablet|Placebo pill
223779352|NCT00817089|DRUG|Naltrexone|50 mg of naltrexone prior to challenge session
223779353|NCT03783923|DRUG|Deflazacort|Deflazacort tablet will be administered as per the dose and schedule specified in the arm.
223779354|NCT01592708|OTHER|Antiemetic anesthesia protocol|Intervention group consisted of patients undergoing maxillary osteotomy who received an antiemetic protocol designed to provide multimodal antiemetic therapy which have been shown to help prevent and/or treat postoperative nausea, combined with the elimination of anesthetic factors that may contribute to postoperative nausea and vomiting.
223779355|NCT05281692|DIAGNOSTIC_TEST|Enhanced Preservation Media (EPM-IX)|EPM-IX is a clinical specimen collection medium that inactivates pathogens, preserves nucleic acids, and integrates DNA/RNA purification. EPM-IX eliminates the need for additional extraction reagents or kits and purifies DNA/ RNA from the entire sample to enable optimal test performance.
223779356|NCT04897516|DRUG|Short regimen of benznidazole|Benznidazole, under the brand name Abarax (100 mg tablet), 300 mg divided into three daily doses (100 mg every 08 hours) for 2 weeks.
223779357|NCT04897516|DRUG|Short treatment with benznidazole|Benznidazole, under the brand name Abarax (100 mg tablet), 300 mg divided into three daily doses (100 mg every 08 hours) for 4 weeks.
223779358|NCT04897516|DRUG|Standard treatment with benznidazole|Benznidazole, 300 mg divided into three daily doses (100 mg every 08 hours), orally for 8 weeks
223779359|NCT03397901|PROCEDURE|Transverse colostomy|Transverse double-cavity colostomy
223779360|NCT04257370|DEVICE|Kerecis™ Omega3 Wound|Kerecis™ Omega3 Wound is decellularised, intact fish skin from North Atlantic cod fish. Kerecis™ Omega3 Wound is FDA approved and EU cleared for the treatment of diabetic ulcers, chronic vascular ulcers, venous ulcers, trauma wounds (including abrasions, lacerations, and skin tears), acute surgical wounds (including debridement, amputation, and donor sites), surgical wounds (dehiscence or failed healing after surgery), imminent failure of STSG, and post-injection necrosis.
223779361|NCT04257370|OTHER|Standard of care|Standard of care wound treatment as defined by the local site, including debridement of the wound, standard wound dressing, and proper offloading of the wound site.
223779362|NCT00032292|DRUG|Visilizumab|
223779363|NCT00127959|DRUG|tenofovir|
223779364|NCT00127959|DRUG|emtricitabine|
223779365|NCT00127959|DRUG|zidovudine|
223779366|NCT00127959|DRUG|efavirenz|
223779367|NCT05397522|OTHER|Supervised Exercise by a physiotherapist via face to face|The exercises are performed by the participants under the supervision of a physiotherapist via face-to-face.
223695257|NCT00877110|DRUG|cyclophosphamide, vincristine, topotecan ,allogeneic NK cells & 3F8|Patients will receive combination chemotherapy with intravenous (IV) cyclophosphamide 70mg/kg/day (for patients with body weight\<70kg) or 2100mg/m2/day (for patients with body weight ≥70kg) for two days, IV vincristine 0.067mg/kg or 2mg/m2/day (lower of the two doses to be chosen; maximum 2mg) for one day, and IV topotecan 2.4 mg/m2/day for 3 days during their first cycle. If receiving a second and/or third cycle, the only chemotherapy patients will receive is cyclophosphamide at 50 mg/kg/day for 2 days. On Day 0, patients will receive a single dose of allogeneic NK cells isolated from a HLA-haploidentical related donor. On day +3, the patient will start daily infusion of 3F8 for 5 days. The treatment schedule may require minor adjustment by ±1 day as clinically indicated (e.g. due to PDH closure for holidays or due to inclement weather).
223695258|NCT05080127|COMBINATION_PRODUCT|application of the allergenic food|a small amount of the allergenic fresh food will be placed on the forearm using a patch test sticker for 15 minutes. the skin reaction will be measured.
223695259|NCT00359918|DRUG|fibrinolysis|Primary PCI
223695260|NCT00359918|PROCEDURE|Primary PCI|Primary PCI
223695261|NCT02474680|GENETIC|Pharmacogenetic testing|Psychotropic genotyping panel
223695262|NCT03570879|DEVICE|Power morcellation|Power morcellation of surgical specimens after laparoscopic myomectomy.
223695263|NCT03570879|PROCEDURE|Transvaginal extraction|Transvaginal extraction of surgical specimens after laparoscopic myomectomy.
223695264|NCT00950911|DRUG|amg 162|120 mg SC injection of denosumab Q4W until the subject has access to commercially available product or for up to 2 years, which ever comes first.
223695265|NCT03136731|DIAGNOSTIC_TEST|Celiac disease antibody screening|Observational parameters
223695266|NCT04416308|DIAGNOSTIC_TEST|NG test|rapid diagnosis Covid 19
223695267|NCT04416308|DIAGNOSTIC_TEST|Blood test|sample
223695268|NCT04416308|BEHAVIORAL|Self-questionnary|behavioral survey
223695269|NCT01742936|DEVICE|CoaguChek|Hand held coagulation monitor.
223695270|NCT01742936|OTHER|Hospital Laboratory|Coagulation testing done by hospital laboratory.
223695271|NCT02600351|DRUG|LDV/SOF|90/400 mg FDC tablet administered orally once daily
223695272|NCT02600351|DRUG|RBV|Tablets administered orally in a divided daily dose according to weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
223695273|NCT02063880|OTHER|Urgent ART|Children will be started on HAART \<48 hours after enrollment.
223695274|NCT02063880|OTHER|Early ART|Children will be started on ART after stabilization 7-14 days after enrollment.
223695275|NCT06412575|PROCEDURE|JNT Guided OGT-overlap Oesophagojejunostomy|In the JNT group, the Joint Nasogastric Tube (JNT) was put into the oesophageallumen from the nose, to guide the cutting of a small enterotomy on the posterior oesophageal stump.
223695276|NCT06412575|PROCEDURE|TNT Guided OGT-overlap Oesophagojejunostomy|In the TNT group, the Traditional Decompression Nasogastric Tube (TNT) was put into the oesophageallumen from the nose, to guide the cutting of a small enterotomy on the posterior oesophageal stump.
223695277|NCT05123911|OTHER|Investigational Shampoo|Parent/LAR will bathe the child participant with the investigational shampoo at least 3 times a week for up to 28 days.
223695278|NCT05123911|OTHER|Investigational Conditioner|Parent/LAR will bathe the child participant with the investigational conditioner at least 3 times a week for up to 28 days.
223695279|NCT05123911|OTHER|Investigational Combing Cream|Parent/LAR will apply investigational combining cream to wet and previously moistened hair at least 3 times a week for up to 28 days.
223695280|NCT00567593|DRUG|Rosiglitazone|8mg tablet once a day for 14 days
223695281|NCT03530566|OTHER|PnK® Method|A multidisciplinary program of weight loss based on diet (initially very low ketogenic diet), physical activity and emotional support
223695282|NCT03530566|OTHER|standard diet|standard low calorie diet for weight loss
223695283|NCT01621503|DEVICE|NT-530P|intraocular pressure and central corneal thickness measurement
223695284|NCT01813110|DRUG|4 g prescription omega-3 concentrate|4 g/d prescription omega-3 fatty acid concentrate taken orally for 8-12 weeks
223695285|NCT01813110|DRUG|Placebo|olive oil
223779368|NCT05397522|OTHER|Supervised Exercise by a physiotherapist via video conference|The exercises are performed by the participants under the supervision of a physiotherapist via video conference.
223779369|NCT05705102|OTHER|Coronary intervention|Coronary intervention will be done immediately in patients with OMI (even STEMI criteria are negative), instead of waiting for \<24h.
223779370|NCT03373591|DRUG|Liposomal Bupivacaine TAP block|Infiltration of the transverse abdominis peritoneum by a local anesthetic under laparoscopic visualization.
223779371|NCT03373591|DRUG|Bupivacaine TAP block|Infiltration of the transverse abdominis peritoneum by a local anesthetic under laparoscopic visualization.
224263549|NCT01376596|BEHAVIORAL|Wait list|The group receiving treatment as usual (TAU) will be put on a wait list to receive the CBT intervention at the end of the experimental group, the one receiving the intervention immediately
223695286|NCT00003678|DRUG|tamoxifen citrate|
223695287|NCT00003678|PROCEDURE|adjuvant therapy|
223695288|NCT00289484|DRUG|Omega-3 Polyunsaturated Fatty Acids|
223695289|NCT04087213|DEVICE|HemoCare™ Hemodialysis System|The HemoCare™ Hemodialysis System is intended for hemodialysis treatment, including short daily and nocturnal hemodialysis, of renal failure patients. The HemoCare™ Hemodialysis System is intended for use in chronic dialysis facilities, self-care dialysis facilities, or the home setting. All treatments must be prescribed by a physician and administered by a trained operator. Treatments must be performed under the supervision or assistance of a medical professional or a care partner who has been trained and deemed competent in the use of the device by the prescribing physician.
223695290|NCT04708600|BEHAVIORAL|Pitch Elevation Therapy|"Goal: mean fundamental frequency of 180Hz (range 140 and 300Hz); Doses and duration: 5 one hour sessions (5h), 5 weeks~Content:~* auditory discrimination of lower and higher tones~* pitch glides~* pitch glides using straw phonation and resonance tube phonation~* practice of higher pitch voice (target: 180Hz) in isolated vowels - syllables - mono and bisyllabic words -phrases - sentences and texts - conversation (generalization to spontaneous speech)"
223695291|NCT04708600|BEHAVIORAL|Articulation Resonance Therapy|"Goal: increase in lipspreading, forward tongue carriage, larynx elevation, forward resonance, precise articulation; 5 sessions Doses and duration: 5 one hour sessions (5h), 5 weeks~Content:~* auditory and visual discrimination of forward vs backed tongue carriage and lip spreading vs lip rounding)~* practice of technique on isolated vowels -syllables -mono and bisyllabic words - phrases - sentences and texts - conversation (generalization to spontaneous speech)~* practising larynx elevation through the twang technique, isolated vowels -syllables -mono and bisyllabic words - phrases - sentences and texts - conversation (generalization to spontaneous speech)~* forward resonance, focusing on oral forward resonance rather than chest resonance, isolated vowels -syllables -mono and bisyllabic words - phrases - sentences and texts - conversation (generalization to spontaneous speech)~* clear, precise articulation and cork exercise"
223695292|NCT04708600|BEHAVIORAL|Sham therapy|"Goal: active sham treatment, 4 sessions Doses and duration: 4 one hour and 15 minutes sessions (5h), 4 weeks~Content:~* providing information about vocal function, vocal surgery, vocal hygiene, transgender health care~* discussing communication aspects and patterns, possible exercise contexts, communication partners, expectations of voice modification, conversational subjects~* active intervention on nonverbal communication (Kinesics, gestures and sign language, facial expression, haptics, proxemics, occulsics, and physical appearance)~* practising costo abdominal breathing patterns"
223695293|NCT02712255|BEHAVIORAL|Individual Planning|"CONTENT: The planning materials and forms have sections: (a) information on the importance of planning, including examples of how planning works and what it affects, (b) instructions of what should be included in a good plan (the when, where, and how components), (c) formulating action and coping plans.~Action plans (referring to when, when, and how the individual will act) as well as coping plans (referring to how to overcome potential difficulties, risky situations or temptations to not engage in physical activity). Each participant will form their plans individually, without consulting the dyadic partner, but discussing the plans with the experimenter."
224263550|NCT01444053|DEVICE|No Intervention|No Intervention
224263551|NCT04752605|BEHAVIORAL|Finnish ENGAGE together|Early childhood education workers play games with children during day care. The games (e.g. ball games, puzzles, Simon says) target children's executive functions and self-regulatory skills, e.g. inhibition, attention, and emotion regulation. The first phase of the intervention (6 weeks) includes play sessions (15 minutes each day) for all children as well as a parents' evening to encourage playing at home. In the second phase (8 weeks), more individualized small group play sessions (3 times a week, 30 minutes at once) are arranged for the children that show difficulties in self-regulation after the first phase. Also, a parents' group including 6 group sessions and 2 phone calls is arranged for their parents in this phase. The participating parents are asked to play the games for 20 minutes each day with their children. During the group meetings, the parents share their experiences of playing at home and receive support and guidance from 2 health care professionals.
224263552|NCT02597374|DEVICE|EEG|A 45 mn EEG will be performed in each participants during action and action observation of each hand.
224263553|NCT05271890|PROCEDURE|Immediate non-surgical periodontal treatment and oral hygiene instructions|
224263554|NCT04054258|DEVICE|App support Programme (ASP) group|All subjects will continue their usual care with prescribed medical treatments, ED nursing advice, and follow-ups as indicated. In addition to the above usual care, bi-weekly 20 minutes telephone follow ups will be provided by a trained research nurse (B) up to 3 months. Patients can ask related health problems if any. The nurse will address their problem by providing advices or refer them to the ED follow up clinic if the problems cannot be solved by the nurse.
224263555|NCT03858933|DEVICE|eBrainFit Platform|Alpha/Theta regulation with eyes open
224263556|NCT03858933|DEVICE|eBrainFit Platform|Amygdala regulation with eyes open
224263557|NCT05326880|DEVICE|Ceramic Dental Implant|The ceramic implant will be placed in healed extraction sockets in the premolar-to-premolar area in the mandible and maxilla for single tooth replacement followed by prosthetic loading with definitive prosthesis after 6 months healing time. Type 4 surgery will be performed as defined by the ITI Consensus Statements for Implant Placement in Extraction Sockets: healed sites, typically around 16 weeks after tooth was extracted or after tooth was lost to allow complete healing of the ridge as well as soft- and hard tissue maturation. Both SG and CG receive routine treatment, only the choice of the implant material is defined by the study protocol.
224263558|NCT05326880|DEVICE|Titanium Dental Implant|The titanium implant will be placed in healed extraction sockets in the premolar-to-premolar area in the mandible and maxilla for single tooth replacement followed by prosthetic loading with definitive prosthesis after 6 months healing time. Type 4 surgery will be performed as defined by the ITI Consensus Statements for Implant Placement in Extraction Sockets: healed sites, typically around 16 weeks after tooth was extracted or after tooth was lost to allow complete healing of the ridge as well as soft- and hard tissue maturation. Both SG and CG receive routine treatment, only the choice of the implant material is defined by the study protocol.
224263559|NCT03218787|DEVICE|XIENCE|Subjects who received XIENCE family stent systems will be included.
223695294|NCT02712255|BEHAVIORAL|Dyadic Planning|"CONTENT: The planning materials and forms have sections: (a) information on the importance of planning, including examples of how planning works and what it affects, (b) instructions of what should be included in a good plan (the when, where, and how components), (c) formulating action and coping plans.~Action plans (referring to when, when, and how the individual will act) as well as coping plans (referring to how to overcome potential difficulties, risky situations or temptations to not engage in physical activity). Both partners in the dyad jointly form one plan. This jointly developed plan is discussed with the experimenter.~The plan focuses on physical activity of only one person in the dyad: the patient."
223695295|NCT02712255|BEHAVIORAL|Collaborative Planning|"CONTENT: The planning materials and forms have sections: (a) information on the importance of planning, including examples of how planning works and what it affects, (b) instructions of what should be included in a good plan (the when, where, and how components), (c) formulating action and coping plans.~Action plans (referring to when, when, and how the individual will act) as well as coping plans (referring to how to overcome potential difficulties, risky situations or temptations to not engage in physical activity). Both partners in the dyad jointly form one plan. This jointly developed plan is discussed with the experimenter.~The plan focuses on physical activity of both persons within the dyad (the patient and the partner) and include some plans for joint physical activity."
223695296|NCT02712255|BEHAVIORAL|Education|CONTENT: The education materials address physical activity and healthy nutrition guidelines for age groups and chronic disease. Participants receive a set of educational materials about types of physical activity (PA), PA intensity, exercise calorie expenditure, strength and endurance training, stretching, and general nutrition guidelines in terms of meal composition, and nutrients, meal frequency. The materials exclude any planning statements. The education is delivered by the experimenter to a patient-partner dyad and discusses individual guidelines for both dyadic partners.
223695297|NCT00438451|DRUG|Levetiracetam|LEV 250 mg capusles: week 1 and 2 0-0-1, week 3 and 4 1-0-1, week 5: 1-0-2, week 6: 2-0-2. Patients may take 2 to 12 per day (500 - 3000 mg)during maintenance.
223695298|NCT00438451|DRUG|Carbamazepine|CBZ 100 mg capusles: week 1 and 2: 0-0-1, week 3 and 4: 1-0-1, week 5: 1-0-2, week 6: 2-0-2. Patients may take 2 to 12 per day (200 - 1200 mg) during maintenance depending on tolerance and efficacy.
223695299|NCT00438451|DRUG|Lamotrigine|LTG 25 mg encapsulated: week 1 and 2: 0-0-1, week 3 and 4: 1-0-1, week 5: 1-0-2, week 6: 2-0-2. Patients may take 2 to 12 caps. per day (50 - 300 mg)during maintenance depending on tolerance and efficacy.
223695300|NCT04672720|DRUG|L-carnitine 1000 Mg|Prescription 3mg l-carnitine (L-carnitine® tablet 1000 mg, Karen Pharmaceutical Company, Iran) daily from day 2 of the previous menstrual cycle until pregnancy test day (approximately 8 weeks).
223695301|NCT00540319|BEHAVIORAL|HIP|"The Health in Pregnancy (HIP) computer program provides tailored, interactive Video Doctor counseling about behavioral risks, educational worksheets for the patients, and a cueing sheet for providers."
223695302|NCT04433533|DRUG|Rosuvastatin 20|Patients who are eligible for all of the criteria and who do not qualify as exclusion criteria should be enrolled in the study and randomly enrolled in a 1: 1 dose of Rosuvastatin 20mg Monotherapy.
223695303|NCT04433533|DRUG|Rosuvamibe 10/10|Patients who are eligible for all of the criteria and who do not qualify as exclusion criteria should be enrolled in the study and randomly enrolled in a 1: 1 dose of rosuvastatin10mg/ezetimibe 10mg combination Therapy
223695304|NCT05702866|DIAGNOSTIC_TEST|Transcutaneous oximetry|Comparison of the TcpO2 values recorded during dynamic maneuver with the estimated rate of compression of the subclavian and axillary vessels determined on dynamic angiography.
223695305|NCT00689598|DRUG|Spironolactone|25 mg po qd 25 mg po bid
223695306|NCT00689598|DRUG|Placebo|Spironolactone 25 mg po qd
223695307|NCT01739114|PROCEDURE|"IPPV group"|"Infants randomized into the IPPV group will receive mask IPPV with an initial PIP of 20 cmH2O and PEEP of 5 cm H2O, and a ventilation rate of 40-60 inflations/min until spontaneously breathing, at which time CPAP will be provided."
223695308|NCT01739114|PROCEDURE|SI group|"Infants randomized into the SI group will receive two initial sustained inflations with a PIP of 20 cmH2O. After the two initial SIs infants will receive PEEP of 5 cm H2O and then CPAP if breathing spontaneously or, if found to have apnea or laboured breathing, mask IPPV with a PIP of 20 cmH2O and PEEP of 5 cmH2O at a rate of 40 to 60 bpm until spontaneously breathing, at which time CPAP will be provided"
223695309|NCT06038981|DRUG|Administration of 1g tranexamic acid intravenous bolus, after anesthesia was introduced|"The systemic use of tranexamic acid (TXA) has been shown to be effective in many types of surgery, reducing the incidence of post-operative bleeding and thereby reducing the rate of reoperation.~To evaluate if TXA systemic administration reduces postoperative blood loss in bariatric surgeries (sleeve gastrectomy operation)"
223695310|NCT02413372|DRUG|BMS-986036|
223695311|NCT02413372|DRUG|BMS-986036|
223695312|NCT02413372|DRUG|Placebo|
223695313|NCT01550471|DRUG|Alvesco/Omnaris, QVAR/Beconase, Placebo/Placebo|Alvesco Inhalation Aerosol 80 BID and Omnaris Nasal Spray 200 mcg QD QVAR Inhalation Aerosol 40 mcg BID and Beconase AQ Nasal Spray 168 mcg BID Placebo Nasal Spray QD/Placebo Inhalation Aerosol BID
223695314|NCT01550471|DRUG|Alvesco/Omnaris, Placebo/Placebo, QVAR/Beconase|Alvesco Inhalation Aerosol 80 BID and Omnaris Nasal Spray 200 mcg QD, Placebo Nasal Spray QD and Placebo Inhalation Aerosol BID, QVAR Inhalation Aerosol 40 mcg BID and Beconase AQ Nasal Spray 168 mcg BID
223695315|NCT01550471|DRUG|QVAR/Beconase, Alvesco/Omnaris, Placebo/Placebo|QVAR Inhalation Aerosol 40 mcg BID and Beconase AQ Nasal Spray 168 mcg BID, Alvesco Inhalation Aerosol 80 BID and Omnaris Nasal Spray 200 mcg QD, Placebo Nasal Spray QD/Placebo Inhalation Aerosol BID
223695316|NCT01550471|DRUG|QVAR/Beconase, Placebo/Placebo, Alvesco/Omnaris|QVAR Inhalation Aerosol 40 mcg BID and Beconase AQ Nasal Spray 168 mcg BID, Placebo Nasal Spray QD and Placebo Inhalation Aerosol BID, Alvesco Inhalation Aerosol 80 BID and Omnaris Nasal Spray 200 mcg QD
223695317|NCT01550471|DRUG|Placebo/Placebo, Alvesco/Omnaris, QVAR/Beconase|Placebo Nasal Spray QD and Placebo Inhalation Aerosol BID, Alvesco Inhalation Aerosol 80 BID and Omnaris Nasal Spray 200 mcg QD, QVAR Inhalation Aerosol 40 mcg BID and Beconase AQ Nasal Spray 168 mcg BID
223695318|NCT01550471|DRUG|Placebo/Placebo, QVAR/Beconase, Alvesco/Omnaris|Placebo Nasal Spray QD and Placebo Inhalation Aerosol BID, QVAR Inhalation Aerosol 40 mcg BID and Beconase AQ Nasal Spray 168 mcg BID, Alvesco Inhalation Aerosol 80 BID and Omnaris Nasal Spray 200 mcg QD
223695319|NCT00795925|DRUG|propiverine hydrochloride|"coated tablets containing 5 mg~consecutive dose escalation of 5 mg, 10 mg or 15 mg propiverine b.i.d."
223695320|NCT04379544|OTHER|Observation only|There is no intervention. This study is purely observational. This study simply follows COVID-19 patients who get CPUS based on their clinician deeming it necessary.
223695321|NCT02556203|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|10mg OD (once-daily)
223695322|NCT02556203|DRUG|Acetylsalicylic Acid (ASA)|75-100mg OD
223695323|NCT02556203|DRUG|Clopidogrel|75mg OD
223695324|NCT02556203|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|In case of NOAF, 20/15 mg OD (once-daily)
223695325|NCT02556203|DRUG|Vitamin K antagonist (VKA)|In case of NOAF, Open-label VKA therapy to target international normalized ratio (INR) 2-3, according to guidelines
223695326|NCT05631665|OTHER|Survey results before and after laser treatment|Determination of sexual activity rates as points with a questionnaire before and after laser treatment for patients with postmenopausal sexual function problems.
223695327|NCT02404467|DEVICE|TF TAVI|Follow-up Observation of patients having received a TF-TAVI
223695328|NCT05092854|OTHER|PR Lotion - AMP Human Performance|"Sodium Bicarbonate Topical Solution. For use of the PR Lotion solution, consumers are instructed to apply the lotion to areas of the body that have been identified as most likely to use during their activity (i.e. calves and thighs for runners, shoulders and forearms for swimmers, etc.). Moreover, the product can be applied up to 2 hours prior to beginning a workout or event with one use supporting a 4-6 hour workout. AMP Human has also verified the safety of their product as being well tolerated in consumers \>2 years of age unless there is a known allergy to an ingredient on the label. Moreover, to the company's knowledge no side effects have been reported per the SAFETY Section at https://amphuman.com/pages/faq.~Other Names:~NDC Code: 72358-101-01 NDC Code: 72358-101-02 NDC Code: 72358-101-03"
223695329|NCT05092854|OTHER|Placebo Lotion|Placebo Topical Solution. Lotion will be created by the AMP Human Performance company and will include all ingredients similar to the PR Lotion product except for the exclusion of sodium bicarbonate.
223695330|NCT05092854|OTHER|AminoVital - Rapid Recovery|AminoVITAL Rapid Recovery is a commercially available supplement that is not currently regulated by the FDA but does complete both internal quality control and third-party testing for all of their products. AminoVITAL Rapid Recovery has been certified by the Banned Substance Control Group (BSCG; https://www.bscg.org/certified-drug- free-supplements/?AminoVITAL) and has been certified to be free of 496+ drugs including WADA Prohibited Substances as well as prescription, over the counter, and illicit drugs not banned in sport. AminoVITAL Rapid Recovery is safe to consume multiple times within a single day and has been found most effective when taken within 30 minutes of cessation of exercise. No known side effects are associated with the ingestion of aminoVITAL Rapid Recovery; however, side effects of amino acid toxicity include gastrointestinal distress, nausea and headache.
223695331|NCT05092854|OTHER|Placebo Supplement|Supplement will be created by the aminoVITAL company and will include all ingredients similar to the commercially available Rapid Recovery product except for the exclusion of the amino acid blend.
223695332|NCT00452855|PROCEDURE|Sevoflurane-remifentanil anaesthesia|
223695333|NCT04587271|DIETARY_SUPPLEMENT|Moringa oleifera (high dose)|Mothers will receive 20 grams of moringa leaf powder in porridge consumed daily for three months.
223695334|NCT04587271|DIETARY_SUPPLEMENT|Moringa oleifera (low dose)|Children will receive 5-10 grams of moringa leaf powder in porridge consumed daily for three months.
223695335|NCT04587271|DIETARY_SUPPLEMENT|Placebo|Mothers and children will receive porridge with placebo.
223779372|NCT01990053|BEHAVIORAL|Beating the Blues|The BtB program guides patients through a series of 8 fully automated online lessons intended to help them identify and change problematic patterns of thinking and behavior that maintain depression. Support will be provided by licensed professional therapists over the phone or via email.
223779373|NCT03735550|DEVICE|Contact thermographic breast examination device|A class 2a medical device being an active non-invasive multiple-use thermographic contact tester that uses a technology of passive liquid crystal matrices placed in the head of the device that records a thermographic image of breast glands with application of these matrices to the examined organ. The examination is non-invasive.
223779374|NCT01785602|DRUG|QAW039|Capsules
223779375|NCT01785602|DRUG|Placebo|Capsules
223779376|NCT01172548|DRUG|imatinib mesylate|
223779377|NCT06155617|OTHER|Upper Extremity Rehabilitation|Pain management, ROM, Edema Management, Desensitization, Strengthening, Functional Tasks
223779378|NCT06023784|PROCEDURE|left bundle branch area pacing|Left bundle branch area pacing(LBBAP) is a novel physiological pacing form for ventricular pacing. In patients received LBBAP, the pacing lead will be placed at left bundle branch area to achieve narrow paced QRS duration.
223779379|NCT06023784|PROCEDURE|right ventricular pacing|Right ventricular pacing is the traditional pacing modality for ventricular pacing. The pacing lead was placed in the apex or septum of right ventricle.
223779380|NCT02749903|DRUG|enzalutamide|oral
223779381|NCT04266457|OTHER|No Intervention|No Intervention
223695336|NCT06407271|DEVICE|CAD/CAM custom ZrO2 healing abutment|Application of custom, zirconium-dioxide healing abutment, fabricated with computer aided design and manufacturing, following immediate implantation.
223695337|NCT06407271|DEVICE|Cylindrical ZrO2 healing abutment|Application of cylindrical, zirconium-dioxide healing abutment following immediate implantation.
223695338|NCT00739999|DRUG|Atorvastatin|6-10 years Tanner Stage 1 will be administered 5-mg daily dose of an atorvastatin pediatric tablet formulation. Dose may be doubled if subjects have not attained target LDL (\<3.35 mmol/L) after 4-week treatment.
223695339|NCT00739999|DRUG|Atorvastatin|10-17 years Tanner Stage 2 will be administered 10-mg daily dose of atorvastatin tablet formulation. Dose may be doubled if subjects have not attained target LDL (\<3.35 mmol/L) after 4-week treatment.
223695340|NCT05906979|OTHER|PAHOLA (digital health assistant)|Pahola is the Pan American Health Organization's new digital health specialist on alcohol use. Programmed with the latest information and research, she can help you make healthier decisions related to your alcohol consumption. Pahola is free to use and can easily be accessed from the privacy of your own home by making use of the online app.
223695341|NCT05906979|OTHER|Standard information on alcohol use and health|A brochure on alcohol use and health as produced by the Pan American Health Organization will be provided to participants.
223695342|NCT01310504|PROCEDURE|SonoSite Ultrasound|Will be moulaged to resemble a peritoneal dialysis patient. Paramedics will scan the abdomen and determine it there's fluid within.
223695343|NCT01310504|PROCEDURE|SonoSite Ultrasound|Paramedics will scan the abdomen and determine it there's fluid within.
223695344|NCT02586051|DRUG|Obinutuzumab|Obinutuzumab 1000 milligrams (mg) IV infusion.
223695345|NCT02586051|DRUG|Intravenous Immunoglobulin|High dose (2 grams per kilogram \[g/kg\]) IVIG (maximum 140 grams).
223695346|NCT05546918|OTHER|survey, interviews and focus groups|"The 2 groups of participants will be invited to:~* complete an anonymous online survey~* participate in individual semi-structured interviews and 2 focus groups"
223695347|NCT00093782|DRUG|temsirolimus|Given IV
223695348|NCT00093782|OTHER|laboratory biomarker analysis|Correlative studies
223695349|NCT02563990|PROCEDURE|High Pressure Injection|Adductor canal block performed at greater than 20 psi injection pressure
223695350|NCT02563990|PROCEDURE|Low Pressure Injection|Adductor canal block performed at less than 15 psi injection pressure
223695351|NCT02010827|BIOLOGICAL|isoglycemic intravenous glucose infusion and Glucagon infusion, day C|Infusion of 0.8ng/kg/min glucagon from time 0-25min
223695352|NCT02010827|BIOLOGICAL|Oral glucose tolerance test, day A|
223695353|NCT02010827|BIOLOGICAL|intravenous iv glucose infusion, day B|
223695354|NCT01490554|PROCEDURE|autologous fibroblasts grafts|Autologous cultured fibroblasts will be grafted in facial skin
223695355|NCT01995630|DEVICE|AMO Tecnis ZA9003|
223695356|NCT01995630|DEVICE|AMO Sensar AR40e|
223695357|NCT00395772|DRUG|Xarelto (Rivaroxaban, BAY59-7939)|BAY59-7939 20 mg once daily (od) for 12 weeks
223695358|NCT00395772|DRUG|Xarelto (Rivaroxaban, BAY59-7939)|BAY59-7939 30 mg od for 12 weeks
223695359|NCT00395772|DRUG|Xarelto (Rivaroxaban, BAY59-7939)|BAY59-7939 40 mg od for 12 weeks
223695360|NCT00395772|DRUG|(LMW) Heparin + Vitamin K Antagonist|Low Molecular Weight (LMW) Heparin + Vitamin K Antagonist (VKA) for 5 days, then VKA only for the rest of 12 weeks
223695361|NCT02180165|DRUG|Posaconazole|300 mg posaconazole twice on Day 1, either by oral tablet or IV solution; followed by 300 mg once daily for up to 84 days
223695362|NCT02180165|DRUG|Voriconazole|300 mg voriconazole oral tablet (or 6 mg/kg IV solution) twice on Day 1, followed by 200 mg oral tablet (or 4 mg/kg IV solution) twice daily for up to 84 days
223695363|NCT00826761|DIETARY_SUPPLEMENT|probiotic|One capsule per meal test (high dose or low dose)
223695364|NCT00826761|DIETARY_SUPPLEMENT|placebo|1 capsuel every morning
223695365|NCT06392607|DEVICE|Euclid orthokeratology (standard coating)|Lens with the current coating
223695366|NCT06392607|DEVICE|Euclid orthokeratology (enhanced coating)|Lens with the enhanced coating
223695367|NCT01568788|BIOLOGICAL|Inactivated Influenza Vaccine|200 subjects were randomly assigned (60 children, 100 adults and 40 elders) to receive Inactivated Influenza Vaccine (Split virion) of Hualan Biologicals, 15ug HA/strain/0.5ml/syringe, one dose regime
223695368|NCT01568788|BIOLOGICAL|Inactivated Influenza Vaccine of Pasteur|200 subjects (60 children, 100 adults and 40 elders) were randomly assigned to receive the Inactivated Influenza Vaccine of Sanofi Pasteur, 15ug HA/strain/0.5 ml/syringe, one dose regime,
223779382|NCT04040972|OTHER|Compassion Focussed Therapy|Group compassion focussed therapy. One session every week for 10 weeks. Each session lasts 2.5 hours with two breaks during this time.
223695369|NCT01568788|BIOLOGICAL|Inactivated Influenza Vaccine of GSK|200 subjects (60 children, 100 adults and 40 elders) were randomly assigned to receive Inactivated Influenza Vaccine (Split virion) of GSK, 15ug HA/strain/0.5ml/syringe, one dose regime
223695370|NCT01884623|DRUG|Cetuximab|
223695371|NCT01884623|DRUG|Methotrexate|
223695372|NCT01008397|DRUG|AHIST NDC#58407-012-01|Oral tablet containing chlorpheniramine tannate 12mg.
223695373|NCT05246397|DRUG|Sugammadex administration|Sugammadex will be given in 50 mg increments every five minutes for reversal of neuromuscular blockade until reaching a train-of-four ratio of 0.9
223695374|NCT00921128|DRUG|Muscimol|
223695375|NCT02775604|BEHAVIORAL|Video based/Therapists' rating of comprehensive-home-fall-hazard-checklist (vt-CHFHC)|The participant will use GoPro technology and follow standardized instructions to inspect each room of their house. They will navigate through their home wearing the GoPro camera, recording images about their home and their usual activities and use a talk-aloud approach to describe what they are doing and seeing. The evaluator will provide no feedback during the assessments.
223695376|NCT02775604|BEHAVIORAL|Paper based/Patient self-rating of comprehensive-home-fall-hazard-checklist (pp-CHFHC)|A paper version of CHFHC and other self-reported documents will be completed by the participants in their homes based on standardized verbal instruction provided by the research staff.
223695377|NCT05790083|OTHER|Body Lotion and Intensive Care|Body Lotion, applied twice daily on whole body, for 3 months. Intensive Care, applied as needed on affected body areas.
223695378|NCT03222011|PROCEDURE|Standard (single) endoscopic stricture dilatation|single endoscopic stricture dilatation
223695379|NCT03222011|PROCEDURE|Intensive endoscopic stricture dilatation|3 endoscopic dilatations 3 weeks apart and possible needle knife strictureplasty
223695380|NCT00051454|BIOLOGICAL|HIV DNA plasmid vaccine plus recombinant fowlpox vector|
223695381|NCT02943460|DRUG|Cilofexor|Tablet(s) administered orally once daily with food
223695382|NCT02943460|DRUG|Placebo to match cilofexor|Tablet(s) administered orally once daily with food
223695383|NCT05631600|BIOLOGICAL|Manuka honey|The honey was applied with special designed cannula. The dosage is not exactly define so we inject the amount of honey until until the excess of the material was observed in the sulcus.
223695384|NCT01176331|PROCEDURE|20 and 23 gauge pars plana vitrectomy|
223695385|NCT02161029|DEVICE|Flexible drill biopsy instrument|Biopsies taken with the new drill biopsy instrument for flexible endoscopy
223695386|NCT02161029|DEVICE|conventional biopsy instrument|Biopsies taken with conventional biopsy forceps for flexible endoscopic instruments
223695387|NCT05400863|BEHAVIORAL|avoid sugary and NNS drinks plus start Metformin|Subjects will receive education and counseling to avoid all sweetened drinks (drink water only). Participants will be asked to consume minimum of 3 drinks/day
223695388|NCT05400863|BEHAVIORAL|avoid sugary drinks (allowed water and drinks sweetened with NNS) plus start Metformin|Subjects will avoid drinks sweetened with sugar (can have diet drinks sweetened with NNS). Participants will be asked to consume minimum of 3 drinks/day
223695389|NCT03057509|DRUG|Ga-68-DOTA-TOC|Ga-68-DOTA-TOC is a imaging radiotracer that is used for positron emission tomography imaging of a variety of the neuroendocrine tumors. This radiotracer in the body binds to several subtypes of the somatostatin receptor and accumulates in the tissue with high expression of these receptors. Therefore neuroendocrine tumors that express somatostatin receptors can be imaged using this radiotracer.
223695390|NCT03057509|DEVICE|Siemens PET/MR scanner|Positron emission tomography-magnetic resonance (PET/MR) is a hybrid imaging technology that incorporates magnetic resonance imaging (MRI) soft tissue morphological imaging and positron emission tomography (PET) functional imaging. The Siemens PET/MR system (Biograph mMR) received a CE mark and FDA approval for clinical diagnostic imaging.
223695391|NCT03057509|OTHER|Standard Siemens Software|The Siemens PET/MR scanner are equipped with a standard clinical visualization software with the advanced application tools based on the Siemens image interpretation engine called syngo.via. This software allows for visualization and interpretation of the image data-sets in the clinical environment.
223695392|NCT03057509|DRUG|LAR Octreotide|LAR octreotide is a man-made protein that is similar to a hormone in the body called somatostatin. LAR Octreotide lowers many substances in the body such as insulin and glucagon, growth hormone, and chemicals that affect digestion. LAR octreotide is used to treat a variety of clinical conditions but most importantly to reduce flushing episodes and watery diarrhea caused by cancerous tumors such as neuroendocrine tumors.
223695393|NCT01385631|DRUG|Ezetimibe|100 patients with ST elevation myocardial infarction are randomized 1:1 to either placebo or Ezetimibe 10 mg per day in addition to treatment with Atorvastatin 80 mg in both arms.
223779383|NCT06142201|DRUG|JT001|oral administration
223695394|NCT01385631|DRUG|Placebo|100 patients with ST elevation myocardial infarction are randomized 1:1 to either placebo or Ezetimibe 10 mg per day in addition to treatment with Atorvastatin 80 mg in both arms.
223695395|NCT03875768|BEHAVIORAL|Tracking plus coaching|Participants will track their nutrition intake every day for six months using a study app and receive tailored feedback via text message based on their nutritional intake and adherence to the DASH dietary pattern. If necessary, they will receive responsive coaching from a Nourish registered dietitian in order to increase adherence to the DASH dietary pattern and their engagement with the intervention.
223695396|NCT03761667|OTHER|Endoscopy using Narrow band imaging|Inspection of resection margin of SSA/P for the evaluation of complete resection or the presence of remnant lesion using NBI method
223695397|NCT01967433|DRUG|Diphenhydramine|
223695398|NCT01967433|DRUG|Placebo|
223695399|NCT01925274|DRUG|PF-05212384|30 minute IV infusion of PF-05212384 on days 2, 9, 16 and 23 of each cycle. Intra-patient dose escalation will commence with 110mg and will increase depending on tolerability.
223695400|NCT01925274|DRUG|irinotecan|90 minutes IV infusion of irinotecan 180mg/m\^2 on days 1 and 15 of each cycle
223695401|NCT01925274|DRUG|Cetuximab|120 minute IV infusion of cetuximab 400mg/m\^2 on cycle 1 day 1; 60 minute IV infusion of cetuximab on days 8, 15, and 22 of each cycle, and on day 1 of each cycle after cycle 1
223695402|NCT01925274|DRUG|Irinotecan|90 minutes IV infusion of Irinotecan 180mg/m\^2 on days 1 and 15 of each cycle
223695403|NCT03563287|DRUG|cocktail of nine CYP probe drugs|"Two equally loaded capsules containing:~Melatonin (2.0 mg) Nicotine (1.0 mg) Bupropion (37.5 mg) Repaglinide (0.25 mg) Losartan (12.5 mg) Omeprazole (10 mg) Chlorzoxazone (62.5 mg) Midazolam (1.85 mg) Dextromethorphan (30 mg) as an oral solution was administered separately after the capsules."
223695404|NCT02690883|DRUG|Exenatide|Exenatide (Astrazeneca ) 5 μg(initial dose)/10ug(maintenance dose) Subcutaneous injection Bid
223695405|NCT02690883|DRUG|Lispro|Lispro (Eli Lilly), the dosage is initiated according to the previous treatment plan and weight of the patients, distribute the dosage to 1:1:1 before 3 meals, titration following PPG \<10.0mmol/L.
223695406|NCT01902238|PROCEDURE|EUS-guided ethanol-lipiodol mixture ablation|By using 3D-volumetric analysis, the optimal volume of ethanol/lipiodol (1:1 mixture) is calculated by computer estimation of areas on each axial image, using EUS software permitting volume calculation. After calculating optimal ethanol volume by 3D volumetric analysis, we advance the needle into the tumor and inject estimated volume of ethanol, typically 1 to 1.5 ml.
223695407|NCT05555771|BEHAVIORAL|Counterpressure Maneuvers|Movements that can aid in delaying or preventing syncope by recruiting skeletal muscle pumping (via compression of major veins by contracting muscle to eject blood through cardiovascular circuit) and increased sympathetic drive (via sustaining an isometric muscle contraction). In this trial, we will be evaluating three commonly recommended maneuvers of arm tensing, squatting, and leg crossing with arm tensing. Maneuvers should be held for 1-2 minutes, or until symptoms subside.
223695408|NCT05555771|BEHAVIORAL|Usual Care|Participants will engage in behavioural interventions and avoidance measures that are commonly recommended as a part of usual care for recurrent syncope. This primarily includes recommendations such as staying hydrated, increasing salt intake, avoiding warm temperatures, avoiding standing for long periods of time, and engaging in regular physical activity. Some patients may be prescribed medication (Midodrine, Fludrocortisone), or other assistive interventions (e.g., compression stockings) at the discretion of their physician.
223695409|NCT00723398|DIETARY_SUPPLEMENT|Lovaza 4gm oral|Dietary supplement; Take 4 mg oral capsules daily
223779384|NCT05813054|DIETARY_SUPPLEMENT|HA matrix ingredient|1 capsule/day
223779385|NCT05813054|DIETARY_SUPPLEMENT|Placebo|1 capsule/day
223779386|NCT05210920|OTHER|Nail polish application|After application of nail polish as described, participants will have bacterial swabs collected from the under the fingernail and from the nail bed of the three assigned fingers on their dominant hand, both before and after scrubbing with a chlorhexidine surgical scrubbing brush.
223779387|NCT04341922|BEHAVIORAL|Internet-delivered cognitive behavior therapy (ICBT) for dysfunctional worry related to the Covid-19 pandemic|The intervention focuses on 1) teaching participants how to discriminate between functional and dysfunctional worry (what are solvable problems vs. what is worry, i.e. unsolvable thoughts?) 2) providing participants with skills to solve functional worry topics (e.g. set time and make a workable plan to be prepared for possible negative outcomes \[e.g. becoming unemployed\]), 3) helping participants to reduce unhelpful behaviors that may reinforce worry (e.g., limit excessive news consumption, refrain from assurance seeking behaviors), 4) providing participants with skills to approach dysfunctional worry (e.g., not engage in worrisome thoughts, just leave them), and 5) increase the behavioral repertoire (take walks, engage in activities that promote health without putting oneself at risk to become infected).
223779388|NCT03345459|OTHER|ICare Prevent (internet-based treatment for depression in college students)|ICare Prevent (internet-based treatment for depression in college students): 7 weekly sessions and 1 booster session. Each session requires about 30-45 minutes to complete. All sessions are accessed online, and it is a guided treatment (i.e., each patient provided an eCoach).
223779389|NCT02041429|DRUG|Ruxolitinib|
223779390|NCT02041429|DRUG|Paclitaxel|
223779391|NCT06504017|PROCEDURE|COG-TB: Cognitive Fusion guided prostate targeted Biopsy|Cognitive Fusion guided targeted Biopsy 4 cores under cognitive fusion ultrasound
223779392|NCT06504017|PROCEDURE|FUS-TB: MRI-TRUS Fusion guided prostate targeted Biopsy|MRI-TRUS Fusion guided targeted Biopsy 4 cores under cognitive fusion ultrasound
223779393|NCT02445235|OTHER|Patient Reported Outcome Survey Tool|Patient Reported Outcome Survey Tool
223779394|NCT03508557|BEHAVIORAL|Advance care planning tools|Structured conversations between patients/substitute decision-maker and clinician based on education about advance care planning using locally relevant booklet/website, values clarification tool for patient engagement, clinician use of the Serious Illness Conversation Guide
223779395|NCT01988818|DEVICE|Mepilex® Border Post-Op|wound dressing with Mepilex® Border Post-Op with Safetac®Technology, self-adherent soft silicone surgical dressing
223695410|NCT00723398|DRUG|Raloxifene 60 Mg Oral Tablet|60 mg orally every day for two years
223695411|NCT00723398|DRUG|Raloxifene 30 Mg Oral Tablet|30 mg orally daily for two years
223695412|NCT00723398|DRUG|Lovaza 4gm & Raloxifene 30mg|Lovaza 4gm and Raloxifene 30 Mg orally once per day for 2 years
223695413|NCT00436774|PROCEDURE|assessment of therapy complications|
223695414|NCT00436774|PROCEDURE|quality-of-life assessment|
223695415|NCT03283111|BIOLOGICAL|autologous stem cell transplantation|autologous stem cell transplantation
223695416|NCT00011661|BEHAVIORAL|Education on behaviors to reduce lead exposure|
223695417|NCT05532787|OTHER|Application of acute chest pain risk stratification scores (HEART and EDACS)|Collection of data elements for the HEART Pathway and EDACS-ADP assessments and calculation of scores to risk stratify patients into low risk or high risk
223695418|NCT01543971|DRUG|TXA127|TXA127 : 300mcg/kg per day for 5 days, injection
223695419|NCT01543971|DRUG|Neupogen (filgrastim)|Neupogen : 10mcg/kg per day for 5 days, injection
223695420|NCT00777205|BEHAVIORAL|Telephone-based peer support|Patients received a) a peer-support manual that outlines self-management and recovery principles and provides peer discussion topics and b) access to a specialized telephone platform that permits free calls to their partners, ready access to mental health staff for back-up and advice on being effective partners, and recorded tips on depression management. They were asked to call their peer partner at least once a week for 24 weeks.
223779396|NCT01988818|DEVICE|standard wound dressing|standard wound dressing after hip-knee or spinal surgery
223779397|NCT06151249|COMBINATION_PRODUCT|Meritup oral solution|chemotherapy + Meritup
223779398|NCT01920815|OTHER|No interventions|
223695421|NCT00777205|BEHAVIORAL|Enhanced Usual Care|Patients received their usual mental health care plus a copy of the Depression Helpbook by Wayne Katon and bi-weekly study mailings with depression management tips.
223695422|NCT04298372|DRUG|Lenalidomide 25mg|"As single arm study, patients will be treated as follows:~* Lenalidomide : D1\~D21 daily oral administration, starting dose 15mg, with an increase of 5mg every cycle, if tolerated, up to 25mg.~* Dexamethasone : D1\~D4 daily oral administration or intravenous injection, 40mg(or 20mg for age for age ≥ 65 years old) Patients will be treated every 4 weeks as one cycle, and up to 12 cycles of treatment will be conducted."
223695423|NCT00630474|DRUG|xylometazoline|xylometazoline (0.1 % solution, 3 drops, 0.15 mg) in each nostril
223695424|NCT04835519|BIOLOGICAL|chimeric antigen receptor T cell|Subjects will be pretreated with chemotherapy prior to infusion of CAR T cells: about 5 days before cells transfusion, the patients who planned to reinfuse CAR T cells were treated with fluorodarabine 30 mg/m\^2( body surface area) and cyclophosphamide 250 mg/m\^2( body surface area) for 3 days. Then this study will be using the Bayesian optimal interval phase I/II (Boin12) trial design. The protocol preset 2 dose levels: Dose 1 (DL-1) was 5×10\^5 (±20%) CAR T cells/kg, and dose 2 (DL-2) was 1×10\^6 (±20%) CAR T cells/kg. If the above dose cannot be met, subjects can still enter the study upon investigator consideration but require documentation of dosing. The lowest dose is 1×10\^5 CAR T cells/kg (±20%), and the highest dose is 1×10\^6 CAR T cells/kg (±20%). If the dose is out of the range mentioned above, entry into the trial will not be considered.
223779399|NCT01418209|DRUG|Low-dose 17-ß-estradiol with progesterone taper|Low-dose 17-ß-estradiol oral (by mouth), 0.5 mg once per day for 8 (eight) weeks. 17-ß-estradiol is approved by the US Food and Drug Administration (FDA) and is indicated for the treatment of menopausal symptoms. ß is the Greek symbol for beta; the symbol and the word are used interchangeably. The 8 week estradiol treatment is followed by 14 days (2 weeks) of progesterone taper (as medroxy-progesterone 10 mg/day).
223695425|NCT00100178|DRUG|Mycophenolate mofeteil (MMF)|
223695426|NCT00100178|DRUG|Daclizumab (DZB)|
223695427|NCT00100178|DRUG|Placebo control for Mycophenolate mofeteil (MMF)|Placebo pills taken orally
223695428|NCT00100178|DRUG|Placebo control for Daclizumab (DZB)|saline intravenous infusions
223779400|NCT01418209|DRUG|Venlafaxine XR|Venlafaxine oral (by mouth) 37.5 mg once per day for 1 (one) week, then 75 mg once per day for 7 (seven) weeks. Venlafaxine XR should not be taken while also taking monoamine oxidase inhibitors (MAOIs). Venlafaxine XR is approved by the US Food and Drug Administration (FDA) for treatment of depression, generalized anxiety disorder, social anxiety disorder, and panic disorder, and is available by prescription. Venlafaxine XR is not FDA-approved for the treatment of hot flashes, although prior studies have indicated that it is useful for treating hot flashes and vasomotor symptoms. After the 8-week venlafaxine XR study treatment period, women will receive a tapering dose of venlafaxine XR 37.5 mg once per day for 14 days (2 weeks).
223779401|NCT01418209|DRUG|Placebo|The placebo is an inactive pill that looks like the active medication.
223779402|NCT00101101|DRUG|Cyclophosphamide|Participants receive conventional chemotherapy comprising 6 courses of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) OR 3 courses of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with high-dose methotrexate and cytarabine (hyper-CVAD) for patients who have relapsed after CHOP.
223779403|NCT00101101|DRUG|Doxorubicin|Participants receive conventional chemotherapy comprising 6 courses of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) OR 3 courses of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with high-dose methotrexate and cytarabine (hyper-CVAD) for patients who have relapsed after CHOP.
223779404|NCT00101101|DRUG|Vincristine|Participants receive conventional chemotherapy comprising 6 courses of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) OR 3 courses of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with high-dose methotrexate and cytarabine (hyper-CVAD) for patients who have relapsed after CHOP.
223779405|NCT00101101|DRUG|Prednisone|Participants receive conventional chemotherapy comprising 6 courses of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) OR 3 courses of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with high-dose methotrexate and cytarabine (hyper-CVAD) for patients who have relapsed after CHOP.
223779406|NCT00101101|DRUG|Dexamethasone|Participants receive conventional chemotherapy comprising 6 courses of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) OR 3 courses of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with high-dose methotrexate and cytarabine (hyper-CVAD) for patients who have relapsed after CHOP.
223779407|NCT00101101|BIOLOGICAL|Autologous Tumor Cell-Based Vaccine|Participants receive vaccine comprising autologous tumor cells and GM.CD40L intradermally on day 1 and low-dose interleukin-2 (IL-2) subcutaneously twice daily on days 1-14. Treatment repeats every 28 days for 4 courses. Patients who have stable or responding disease at 12 months receive 4 additional courses of booster vaccine and low-dose IL-2 as above.
223779408|NCT00101101|DRUG|IL-2|Participants receive vaccine comprising autologous tumor cells and GM.CD40L intradermally on day 1 and low-dose interleukin-2 (IL-2) subcutaneously twice daily on days 1-14. Treatment repeats every 28 days for 4 courses. Patients who have stable or responding disease at 12 months receive 4 additional courses of booster vaccine and low-dose IL-2 as above.
223779409|NCT04710251|DEVICE|Speedometer|We will measure and monitor the withdrawal time of colonoscopy with a speedometer.
223779410|NCT00658112|DRUG|Benzoyl Peroxide|Benzoyl peroxide 5% gel. Applied once daily to face, minimum amount usable to cover area. Every day for six weeks.
223779411|NCT01027169|DRUG|safinamide|single dose of 50mg safinamide on Day 1
223779412|NCT01027169|DRUG|safinamide|single dose of 50mg safinamide on Day 1
223779413|NCT01027169|DRUG|safinamide|single dose of 50mg safinamide on Day 1
223779414|NCT04618055|DEVICE|NiTiDent Tuah Porous NiTi Dental Implants|A newly developed NiTiDent Tuah porous NiTi cylindrical bone level dental implant measuring 4.5 mm in diameter and 10 mm in length and an abutment system of different heights and angulations produced by Nitium Technology Sdn Bhd.
223779415|NCT04618055|DEVICE|Control Dental Implant Systems|A market approved bone level dental implant systems measuring 4.5 mm in diameter and 10 mm in length and an abutment system of different heights and angulations
223779416|NCT01603875|BIOLOGICAL|New Chromatographically Purified Vero-cell Rabies vaccine(new CPRV).|new CPRV 0.1 ml intradermal route and 0.5 ml intramuscular route are the experimental intervention
223779417|NCT02734316|OTHER|endoscopic procedure|Evaluation of adverse events in patients on DOACs undergoing GI endoscopy
223779418|NCT01690390|DRUG|Icotinib of routine dose|Icotinib of routine dose: 125 mg is administered orally three times per day.
223779419|NCT01690390|DRUG|Icotinib of high dose|Icotinib: 250 mg is administered orally three times per day.
223779420|NCT03109678|DEVICE|Crossover Ambu Aura-i™ / Rüsch Super Safety Silk™|After unsuccessful blind intubation in the Ambu Aura-i™ / Rüsch Super Safety Silk™ group: crossover design using the Ambu Aura-i™ mask in combination with the LMA ETT™ tracheal tube
223695429|NCT00783965|DRUG|tazarotene|Applied to the skin
223695430|NCT00783965|OTHER|placebo|Applied to the skin
223695431|NCT03388515|BIOLOGICAL|SSS11|IV infusion for 60 min.
223695432|NCT03388515|OTHER|placebo|IV infusion for 60 min.
223695433|NCT02477839|DRUG|Lacosamide|Active Substance: Lacosamide Pharmaceutical Form: Syrup Concentration: 10 mg/mL Route of Administration: oral
223695434|NCT02477839|OTHER|Placebo|Active Substance: Placebo Pharmaceutical Form: Syrup Concentration: N/A Route of Administration: oral
223695435|NCT04137029|DRUG|Formoterol|The participants will receive inhalation of formoterol 12 micrograms
223695436|NCT04137029|DRUG|Tiotropium Bromide|The participants will receive inhalation of tiotropium bromide 18 mkg once
223695437|NCT04137029|DIAGNOSTIC_TEST|metacholine test|The participants will receive inhalation of metacholine once
223695438|NCT02626767|OTHER|Novel high-intensity interval exercise training|Please see information already included in the 'intervention' arm description.
223695439|NCT03610282|DRUG|IV Methylphenidate|Subjects will receive a bolus of IV methylphenidate during propofol infusion at one of the study visits.
223695440|NCT03610282|DRUG|Propofol|Subjects will received propofol for up to 100 minutes.
223695441|NCT01439568|DRUG|LY2510924|Administered subcutaneous injection
223695442|NCT01439568|DRUG|Carboplatin|Administered intravenously
223695443|NCT01439568|DRUG|Etoposide|Administered intravenously
223695444|NCT01354067|BEHAVIORAL|Control group|The control group receives standardized patient education four times, once every two weeks, during the eight week intervention period. Each session will last 60 minutes, consisting of information regarding anatomy, physiology, causes and mechanisms of COPD, drugs, nutrition, aids and energy saving procedures. The information is the same as for the intervention group, given at separate occasions.
223695445|NCT01354067|BEHAVIORAL|High-repetitive single limb training|The high-repetitive single limb exercise regime consists of three sessions per week during eight weeks of exercise training, giving a total number of 24 sessions at each location (Umeå and Huddinge University hospitals). The exercise sessions are supervised and conducted by a physical therapist using a group format, six to eight participants in each group. Each session will span for 60 minutes, duration of the major components are: 10 min warm-up followed by 40 minutes of single limb training and 10min cool-down. In addition this experimental group also receives four sessions of patient education once every two week.
223695446|NCT05734300|PROCEDURE|Combined Endoscopic Laparoscopic Surgery (CELS)|"The main surgical advantage in this procedure is the ability to view the colon intra- and extraluminal simultaneously. The laparoscopic approach enables manipulation and mobilization of the colon, while the endoscopic view secures that the resection is complete and not overlapping the ileac valve or creating stenosis.~Compared to the traditional oncological colon resection, the CELS resection is a minimally invasive procedure - organ sparing procedure leading to a reduced surgical stress response."
223695447|NCT05734300|PROCEDURE|Standard resection|In this study standard resection of the colon will be performed according to complete mesocolic excision (CME) principles.
223695448|NCT01676727|DEVICE|CoreValve aortic valve|Implantation of CoreValve aortic valve via direct aortic approach
223695449|NCT06428682|DRUG|Tranexamic acid|Experimental group will receive TXA intraoperatively (15mg/kg IV, once at beginning of case then re dose at 4hrs if operation goes longer) at the time of their surgery.
223695450|NCT06428682|DRUG|Placebo|Control group will receive same volume equivalent of saline intravenously at the time of their surgery.
223695451|NCT00000631|BIOLOGICAL|HIVAC-1e|
223695452|NCT00000631|BIOLOGICAL|gp160 Vaccine (MicroGeneSys)|
223695453|NCT06202417|DRUG|Fruquintinib|an oral tyrosine kinase inhibitor (TKI)
223695454|NCT02138422|BIOLOGICAL|Xilonix|
223695455|NCT02138422|BIOLOGICAL|Placebo|
223695456|NCT00544999|DRUG|cytarabine|
223695457|NCT00544999|DRUG|daunorubicin hydrochloride|
223695458|NCT00544999|DRUG|everolimus|
223695459|NCT00544999|OTHER|laboratory biomarker analysis|
223695460|NCT00544999|OTHER|pharmacological study|
223695461|NCT03248843|DRUG|KN035|Four cohorts dosed at 1.0 mg/kg, 2.5 mg/kg, 5.0 mg/kg, and 10 mg/kg weekly. All cohorts are administered by subcutaneous injection (SC).
223695462|NCT03668769|OTHER|Internet Mobile Technology|Use Quitting Schedule mobile smartphone app
223695463|NCT03668769|OTHER|Interview|Ancillary studies
223695464|NCT03668769|OTHER|Questionnaire Administration|Ancillary studies
223695465|NCT03668769|BEHAVIORAL|Smoking Cessation Intervention|Participate in individual smoking cessation program
223779421|NCT03109678|DEVICE|Crossover Ambu Aura-i™ / LMA ETT™|After unsuccessful blind intubation in the Ambu Aura-i™ / LMA ETT group: crossover design using the Ambu Aura-i™ mask in combination with the Rüsch Super Safety Silk™ tracheal tube
223779422|NCT03109678|DEVICE|Crossover FASTRACH™ / Rüsch Super Safety Silk™|After unsuccessful blind intubation in the FASTRACH™ / Rüsch Super Safety Silk™ group: crossover design using the FASTRACH™ mask in combination with the LMA ETT™ tube
223779423|NCT03109678|DEVICE|Crossover FASTRACH™ / LMA ETT™|After unsuccessful blind intubation in the FASTRACH™ / LMA ETT™ group: crossover design using the FASTRACH™ mask in combination with the Rüsch Super Safety Silk™ tube
223695466|NCT03707054|DIAGNOSTIC_TEST|Study Arm|Measurements of optic nerve diameter, serum and urine osmolarity, serum vasopressin
223695467|NCT03053271|DRUG|ATR-101|During the 4-week randomized withdrawal period, subjects will be dosed for 4 weeks at the same dose level being used at the completion of the open-label dose-escalation period.
223695468|NCT03053271|DRUG|Placebo|During the 4-week randomized withdrawal period, subjects will be dosed for 4 weeks with placebo that matches the same ATR-101 dose level being used at the completion of the open-label dose-escalation period.
223695469|NCT03781544|DRUG|Tramadol|A single i.v. infusion of Tramadol (dose: 400mg/100ml) will be administered to the participants (treatment arm).
223695470|NCT03781544|DRUG|Paracetamol|A single i.v. infusion of Paracetamol (dose: 1g/100ml) will be administered to the participants (control arm).
223695471|NCT03781544|DRUG|Diclofenac|A single i.v. infusion of Diclofenac (dose: 75mg/100ml) will be administered to the participants (treatment arm).
223695472|NCT00580970|DRUG|lovastatin|The HMG-coA reductase inhibitor used in this study will be lovastatin. Dosage: 20 mg/d PO with evening meal. Patients on a higher dose of lovastatin at the time of study entry may continue at that dose level; for patients switching to lovastatin, the dose will be at the discretion of the prescribing physician, but must be at least 20 mg/day.Schedule: begin on the first day of external beam radiation therapy (external beam alone or external beam followed by brachytherapy) or on the day of brachytherapy (brachytherapy alone or brachytherapy followed by external beam radiotherapy) and continue for 12 months. Patients or their third party payers will be expected to cover the cost of the drug.
223695473|NCT02018068|OTHER|Remote control|When pain or sensory and motor block evaluation exceed the thresholds, the patient enters the data in the PCA (patient Control Analgesia) pump. The investigator is alerted by SMS on his smartphone and makes the necessary programming changes by remote control on the Micrel Care TM site. Systematic assessments via the PCA pump are scheduled for 9:00, 13:00 and 19:00 every day during 48 to 72 hours. The patient can alert his physician through his PCA pump of any additional requests (pain, motor blockade, numbness). The anesthesiologist receives an SMS alert and can make any necessary programming changes to the pump via the remote control.
223695474|NCT02018068|OTHER|At bedside care|When pain or sensory and motor block evaluation exceed the thresholds, the nurse contacts the physician and she will be able to modify the pump settings according to the anesthesiologist prescription. The delay between the call of the patient and the programming changes, the duration of the procedure are reported. Systematic evaluations via the PCA (Patient Control Analgesia) pump are done when the patient arrives in this surgical ward and at 9:00, 13:00 and 19:00 every day for 48 to 72 hours.Throughout the study, if necessary, the nurse or referring physician performs the programming changes directly on the PCA pump and notes the delay in treatment. All the reasons and the duration of any bedside visit are reported.
223695475|NCT04749875|OTHER|blood sample|sampling of blood for research during routine care
223695476|NCT03712631|PROCEDURE|tunneling technique bone augmentation|horizontal ridge augmentation using mixture of xenograft,autogenous bone
223695477|NCT02414451|DRUG|Propranolol|Week 1: 40 mg propranolol (1 capsule, nightly) Week 2: 80 mg propranolol (2 40mg capsules, morning \& night) Weeks 3 - 8: 100 mg propranolol (3 capsules, 40 mg/morning, 20mg/afternoon, \& 40mg/night) Week 9: 60 mg propranolol (2 capsules, 40 mg/morning \& 20mg/night) Week 10: 20 mg propranolol (1 capsule, nightly) Week 11: no capsules
223695478|NCT02414451|DRUG|Placebo|"Placebo will be administered via lactose-filled oral capsule(s) daily for a period of 10 weeks. The schedule of placebo administration will be as follows:~Week 1: 1 capsule, nightly Week 2: 2 capsules, morning \& night Weeks 3 - 8: 3 capsules, morning, afternoon, \& night Week 9: 2 capsules, morning \& night Week 10: 1 capsule, nightly Week 11: no capsules"
223695479|NCT00600444|PROCEDURE|Venae sectio|surgical preparation of the cephalic vene to insert a totally implantable access port.
223695480|NCT00600444|PROCEDURE|Punction of V. subclavia|radiological punction of the v. subclavia with Seldinger technique to implant a totally implantable access port
223695481|NCT02045173|OTHER|Apneascan TM|Autoscoring algorithms with automatical detection of sleep apnea by the Apneascan TM
223695482|NCT02045173|DEVICE|Polysomnography/polygraphy|1 night polysomnography/polygraphy
223695483|NCT02331875|DRUG|IPH2201|The first 6 patients will receive IPH2201, IV, at a dose of 4 mg/kg q2w x 4. Subsequent patients will be treated at a dose of 10 mg/kg q2w x 4.
223695484|NCT02331875|PROCEDURE|Standard Surgery|After the end of treatment with IPH2201, according to standard recommendations in the relevant country .
223695485|NCT02331875|RADIATION|Postsurgical Adjuvant Therapy|After the standard surgery, according to standard recommendations in the relevant country
223695486|NCT04137224|BIOLOGICAL|IgPro20|Human normal immunoglobulin for subcutaneous administration
223695487|NCT04137224|BIOLOGICAL|IgPro10|Human normal immunoglobulin for intravenous administration
223695488|NCT02276404|BEHAVIORAL|relaxation training|"The relaxation sessions comprise an introduction in 3 relaxation techniques conducted by a mind-body therapist: Body Scan, mindfulness meditation and imagination. Patients also receive a CD with different relaxation exercises and the instruction to exercise daily at home for at least 15 minutes."
223695489|NCT02276404|OTHER|acupuncture|The acupuncture treatment comprises needling of 6 standardized acupoints: Pericardium 6, Stomach 36, Large intestine 4, Spleen/Pancreas 10, Dumai 20, Liver 3, Shenmen. Additional points can be chosen individual.
223695490|NCT02892032|BEHAVIORAL|Attention Modification Training|Subjects are taught to disengage attention from a certain stimuli
223695491|NCT02892032|BEHAVIORAL|No Attention Modification Training|Subjects are exposed to two stimuli, but attention is not manipulated in any way
223695492|NCT00414921|DRUG|clonidine|Clonidine is FDA-approved for the treatment of hypertension in adults
223695493|NCT00414921|DRUG|methylphenidate|Methylphenidate is known to safely and effectively treat many ADHD symptoms.
223695494|NCT00414921|OTHER|placebo|inactive substance
223695495|NCT02423837|DRUG|Rituximab, bendamustine|
223695496|NCT01826721|OTHER|Transplant Medication Information Teaching Tool|Online e-learning tool for post-transplant medication education.
223695497|NCT02439879|DRUG|Alpha lipoic acid|Alpha lipoic acid 1800 mg PO divided in 3 doses for 4 weeks . If total symptoms score decreased \>3 points patients received alpha lipoic acid 600 mg PO each day or no treatment for 16 weeks.
223695498|NCT00004637|DRUG|Vitamin E|
223779424|NCT01971346|DRUG|etanercept|100 mg Etanercept injections per week (2 separate single-use pre-filled 50 mg subcutaneous injections taken on two separate days) for 3 months
223779425|NCT04737538|OTHER|Experimental Dentrifrice|Toothpaste containing sodium bicarbonate, sodium hyaluronate and sodium fluoride
223779426|NCT04737538|OTHER|Positive control dentifrice|Dentifrice containing 67% w/w sodium bicarbonate and 0.221% w/w sodium fluoride
223779427|NCT04737538|OTHER|Negative control dentifrice|Dentifrice containing 1100ppm fluoride as sodium fluoride (Crest Cavity Protection)
223779428|NCT03492697|DRUG|PF-06882961 Immediate Release Tablet|Immediate Release Tablet
223779429|NCT03492697|DRUG|PF-06882961 Controlled Release Tablet (long)|Controlled Release tablet (long)
223779430|NCT03492697|DRUG|PF-06882961 Controlled Release Tablet (short)|Controlled Release tablet (short)
223779431|NCT03492697|DRUG|PF-06882961 Immediate Release Solution|PF-06882961 Immediate Release solution
223779432|NCT01544972|DRUG|Oral paracetamol|Patients will receive oral paracetamol 15 mg/kg per dose every 6 hours.
223779433|NCT01544972|DRUG|Oral ibuprofen|Patients will receive oral ibuprofen at an initial dose of 10 mg/kg, followed by 5 mg/kg at 24 and 48 h.
223779434|NCT01719692|DRUG|Rituximab|
223779435|NCT05641740|DEVICE|Single-session of Radiofrequency|"The experimental group continue with their usual conservative and pharmacological treatment and will receive a single-session of monopolar dielectric capacitive radiofrequency in their hands. An Biotronic Advance Develops® (ABD-S25v) with a carrier wave frequency of 800-900 KHz of 850 KHz will be used. Patients will be placed in a seated position, with the forearms supinated and resting on a wooden table. An almond oil conductor will be applied to the hands. The application will be carried out with a circular head of 5 cm2 and for a total of 10 minutes on each of the palms of the hands.~They will be evaluated at baseline and post-session."
223779436|NCT05641740|DEVICE|Control Placebo single-session of Radiofrequency|"The control placebo group continue with their usual conservative and pharmacological treatment and will receive a placebo single-session of radiofrequency. This group will follow the same protocol and treatment time, but they will receive a placebo treatment (the device remains in paused mode), so that radiofrequency will not be applied.~They will be evaluated at baseline and post-session."
223779437|NCT03538340|PROCEDURE|Thoracic Epidural|The control arm will receive standard of care pain management which includes a Thoracic Patient Controlled Epidural
223779438|NCT03538340|PROCEDURE|Intercostal Cryoanalgesia|The study arm will receive standard of care pain management which includes a Thoracic Epidural plus Intraoperative Intercostal Cryoanalgesia
223779439|NCT06232733|BEHAVIORAL|Healthy Lifestyles Project e-intervention|Virtual lifestyle behaviour change support.
223779440|NCT00338195|BEHAVIORAL|Individualized caffeine cessation instructions|Intervention is described in the protocol
223779441|NCT00602303|DRUG|Torsemide|
223779442|NCT02284997|DEVICE|MGDRx® EyeBag|Class 1 Medical Device, registered with the Medicines and Healthcare products Regulatory Agency. UK Patent: GB2421687B. The EyeBag is made of silk and 100% brushed black cotton and filled with flax / linseed. When heated, this device is intended to warm the eyelids. This melts the meibum and clears the meibum obstruction of the MGs.
223779443|NCT02460198|BIOLOGICAL|Pembrolizumab|IV infusion
223779444|NCT01338116|OTHER|antibiotic treatment of by TREAT/PCR|Management by TREAT/PCR. The data available at the time of patient recruitment will be entered into TREAT. TREAT will provide advice for the empirical antibiotic treatment and unless the caring physician can justify a deviation from this recommendation, TREAT's recommendation will be implemented (yes or no antibiotic treatment and type of antibiotic). TREAT will also recommend whether a blood sample for PCR should be obtained. Blood will be collected aseptically and the test will be performed once daily between 1000AM-1700PM (results available daily at 1700 PM). PCR results and a PCR-revised TREAT recommendation will be reported to the patient's physician in charge and treatment will be revised accordingly. On day 2, when results of blood cultures and other cultures become available TREAT will be re-consulted and will issue a new recommendation based on the full microbiological investigation (negative and positive results).
223779445|NCT00748943|OTHER|Chlorine Dioxide|Experimental mouthwash (ClO2 Fresh®) contained 0.16% sodium chlorite (NaClO2)
223779446|NCT00536367|OTHER|No intervention - observational study only|
223779447|NCT04382612|DEVICE|HARPOON Beating Heart Mitral Valve Repair System (MVRS)|Repair of the chordae tendinae in the mitral valve.
223779448|NCT00841126|DRUG|Magnesium iron hydroxycarbonate|500 mg tablets, administered orally: initial dosage 500 or 1000 mg (total daily dose 1500 or 3000 mg) depending on serum phosphate concentration, titrated to a maximum DAILY dose of 9000 mg). The total daily dose should be divided and taken with meals. Any SINGLE dose should not exceed 3000 mg.
223779449|NCT00841126|DRUG|Lanthanum carbonate|750 mg chewable tablets, administered orally: initial dosage 750 mg up to 3-times daily (total daily dose 2250 mg), titrated to a maximum SINGLE dose of 1500 mg (DAILY dose 3750 mg). The total daily dose should be divided and taken with meals.
223779450|NCT00841126|DRUG|Placebo|0 mg (500 mg-size) tablets, administered orally: The total daily dose should be divided and taken with meals. Any SINGLE dose should not exceed 6 tablets.
223779451|NCT04666441|DRUG|REGN10933+REGN10987 combination therapy|Administered IV or SC single dose
223779452|NCT04666441|DRUG|Placebo|Administered IV or SC single dose to match
223779453|NCT03969771|BEHAVIORAL|Mindfulness-Based Stress Reduction (MBSR)|The MBSR program was developed by the University of Massachusetts Medical School.
223779454|NCT06364826|DRUG|Sintilimab, bevacizumab, gemcitabine|This is a prospective, single-center, single-arm, phase II clinical study. The study was intended to include patients with locoregionally advanced nasopharyngeal cancer identified by histology or cytology, who signed informed consent and met the screening criteria to enter the study. Patients will receive induction therapy (sintilimab + bevacizumab + gemcitabine, Q3W, 3 cycles) followed by IMRT+ Sintilimab. Consolidation therapy with sintilimab continued after radiotherapy until disease progression, intolerable toxicity, death, or the subject's decision to withdraw from the study, with a total treatment period of no more than 12 cycles.
223779455|NCT06364826|RADIATION|IMRT|IMRT
223779456|NCT00090012|DRUG|Olanzapine|
223779457|NCT00090012|DRUG|Quetiapine|
223779458|NCT04917679|DRUG|Eltrombopag plus diacerein|In the combination group, eltrombopag will be administered orally at an initial dose of 75mg daily for 14 days, and diacerein will be given orally at an initial dose of 50mg bid concomitantly for 14 days (D1-D14). During treatment period, treating physicians will modify the dosage of trial treatment to maintain participants' platelet count at the range of 50 - 150 × 10\^9/L as follows: (1) if platelet count is less than 150 × 10\^9/L, continue the original treatment (eltrombopag 75mg daily plus diacerein 50mg bid); (2) if platelet count is between 150 × 10\^9/L to 250 × 10\^9/L, the treatment will be modified to eltrombopag 50mg daily plus diacerein 50mg bid; (3) if platelet count is over 250 × 10\^9/L, original treatment (both eltrombopag and diacerein) need to be stopped, and platelet count should be reexamined every other day, and the treatment (eltrombopag 50mg daily plus diacerein 50mg bid ) will be restarted until platelet count is below 100 × 10\^9/L.
223779459|NCT04917679|DRUG|Eltrombopag|In the monotherapy group, eltrombopag also will be administered orally at an initial dose of 75mg daily for 14 days (D1-D14), and the individualized dosage could be modified by treating physicians to maintain participants' platelet count between 50 × 10\^9/L to 150 × 10\^9/L.
223779460|NCT05252559|PROCEDURE|ultrafiltration|In cardiac surgery patients, ultrafiltration is usually applied to reduce free water and concentrate all blood components before weaning from cardiopulmonary bypass
223779461|NCT05252559|DIAGNOSTIC_TEST|maximal clot firmness in EXTEM assay of ROTEM test|before and after applying ultrafiltration, arterial blood sample underwent EXTEM and FIBTEM assays of rotational thromboelastometry
223779462|NCT03285477|DRUG|Placebo|Vehicle Ointment was used in participants with Clinically typical AK on the face or scalp.
223779463|NCT03285477|DRUG|KX2-391 Ointment 1%|The experimental drug, KX2-391 Ointment 1% was used in participants with Clinically typical AK on the face or scalp.
223779464|NCT04090814|DEVICE|HeatTens (HV-F311-E)|(1) 2\~108 Hertz (modulation program inside); (2) 100 microseconds (pulse duration)
223779465|NCT05829408|BEHAVIORAL|KOPPeling|KOPPeling lasts ten to twelve weeks and will be administered by health care professionals.
224263560|NCT03218787|DRUG|DAPT|"3-month clear subjects who receive 3-month DAPT without interruption of either aspirin and/or P2Y12 receptor inhibitor for \> 7 consecutive days.~Subject who are 3-month clear will discontinue P2Y12 inhibitor after 3-month visit, but continue taking aspirin through 12-month follow-up. Subjects who are not eligible for early P2Y12 inhibitor discontinuation will be treated per site standard of care."
224263561|NCT00246662|DRUG|Vosaroxin|All patients receive vosaroxin Injection
224263562|NCT04276064|DEVICE|Auditory closed-loop stimulation: slow oscillation boosting|Auditory-closed loop stimulation: slow oscillation boosting
224263563|NCT04276064|DEVICE|Auditory closed-loop stimulation: slow oscillation disruption|Auditory closed-loop stimulation: slow oscillation disruption
224263564|NCT04276064|DEVICE|Sham stimulation|Sham stimulation
223779466|NCT03899870|PROCEDURE|Rectal resection|Patients underwent anterior or low anterior resection. Patients with tumors in the lower third of the rectum where anal sphincters could not be preserved underwent abdominoperineal resection. In majority of the cases, inferior mesenteric artery (IMA) was ligated caudal to the origin of the left colic artery. For the tumors of the upper rectum, partial excision of the mesorectum was performed up to the minimum of 5 cm from the inferior aspect of the tumor. For the tumors of the middle and low rectum a total mesorectum excision was done with the minimum distal mucosal margin of 1 to 2 cm. Ileostomy was performed in cases where colon was poorly prepared, anastomotic leak test was positive or colonel anastomosis was made. In most of the cases, open surgery was performed. Laparoscopic surgery was performed in selected cases. Wide local excision was performed in selected cases with T1 tumors without locoregional lymphadenopathy.
223779467|NCT03899870|DRUG|Neoadjuvant therapy|Patients with locally advanced disease (T3, T4) or lymph nodal positive disease were offered neoadjuvant therapy. In the neoadjuvant therapy, we used 45 Gy in 25 fractions with concurrent 5-fluorouracil \[5-FU\] and patients were operated 8 to 10 weeks after neoadjuvant therapy. In some cases, especially the elderly patients with multiple co-morbidities, we used short-course pelvic radiation therapy which included 25 Gy in 5 fractions over 1 week.
223779468|NCT03899870|DRUG|Adjuvant therapy|Patients with locally advanced disease (T3, T4) or lymph nodal positive disease were offered adjuvant therapy. In most of the cases, FOLFOX (leucovorin, 5-FU, oxaliplatin) regimen was used and for elderly patients who could not tolerated this regimen, we used oral capecitabine.
223695499|NCT05342402|OTHER|Somatosensory Rehabilitation Program|Somatosensory rehabilitation program includes minimizing contact with the painful zone of the vulva and uses tactile stimulation at a tolerated distance from the vulva. Each participant will also receive advice on resuming sexual activities with vaginal penetration.
223695500|NCT05342402|OTHER|Educational Pain Management Program|Educational Pain Management Program includes education on decreasing irritative contacts with the vulva and relaxation techniques. Each participant will also receive advice on resuming sexual activities with vaginal penetration.
223695501|NCT02098824|DRUG|Galantamine|Single administration of capsule containing 16 mg of Galantamine
223695502|NCT02098824|DRUG|Methylphenidate|Single administration of capsule containing 10 mg of Methylphenidate
223695503|NCT02098824|DRUG|Placebo|Single administration of capsule containing placebo
223779469|NCT02769143|OTHER|Whole-Body Vibration|Will be performed six months of WBV exercises
223779470|NCT02769143|OTHER|Pilates|Will be performed six months of Pilates exercises
223779471|NCT06169917|BEHAVIORAL|Paced Resonance Frequency Breathing|Participants are required to pace their breathing to their pre-determined individual resonance frequency.
223779472|NCT06169917|BEHAVIORAL|Paced Breathing at Natural Frequency|Participants are required to pace their breathing to their pre-determined individual breathing frequency at rest.
223695504|NCT04965051|DRUG|insulin degludec/insulin aspart (IDegAsp)|To evaluate the efficacy and safety of the IDegAsp in T1DM
223695505|NCT04965051|DRUG|basal insulin plus pre-prandial insulin|To evaluate the efficacy and safety of basal insulin plus pre-prandial insulin in T1DM
223695506|NCT03425513|DIAGNOSTIC_TEST|Hepatitis B serology|A serum specimen will be taken and assessed for hepatitis B serology (HBsAg and anti-HBc antibodies).
223779473|NCT06169917|OTHER|Heat Stimulations|Participants will undergo a heat stimulation procedure on their left and right foot (the order of which is counterbalanced across participants). During this procedure, there are 10 blocks, with an inter-stimulus interval of 30 seconds between two blocks. During a block, six 6-second heat stimulations (48 degrees) are given. Between the stimulations, the temperature quickly returns to baseline (32 degrees).
223779474|NCT05857046|DRUG|Melatonin 10 MG|Patients received extended-release melatonin 10 mg PO every 12 hours for 7 days and then every 24 hours for 83 days
223695507|NCT03425513|OTHER|Questionnaire|Participants will be asked to fill in a questionnaire regarding demographic characteristics, known viral hepatitis status and risk factors for HBV infection.
223695508|NCT06638268|PROCEDURE|Acute TAVI|TAVI must be performed as soon as possible and within 12 hours of admission to the heart center.
223695509|NCT06638268|OTHER|Stabilization and subacute TAVI|Patients are stabilized according to target parameters. Treatment may include vasopressor, mechanical ventilation, renal replacement therapy, and blood transfusion. TAVI is then performed no earlier than 72 hours of admission to heart center.
223695510|NCT00566501|DRUG|Donepezil|Donepezil SR 23 mg once daily orally.
223695511|NCT04558281|DRUG|Active ropivacaine 0.3% erector spinae plane perineural administration|Ropivacaine 0.3% administration via an erector spinae plane perineural catheter
223695512|NCT04558281|DRUG|Placebo erector spinae plane perineural administration|Normal saline administration via an erector spinae plane perineural catheter
223695513|NCT05111808|DEVICE|Methylene blue fluorescence|IV administration of methylene blue, detection with deep infrared camera and light source
223695514|NCT03583723|RADIATION|Radiotherapy Group|Patients will be immobilized with customized devices. Either four-dimensional CT or slow CT images using a multislice CT scanner will be acquired to evaluate internal target motion. Initially, gross tumor volume (GTV) will be determined in the maximum intensity projection on the initial size of the tumor and involved lymph nodal sites defined as PET-positive nodes and/or a node diameter greater than 1 cm, clinical target volume (CTV) will be defined as equal to the GTV plus node-positive stations and hilar stations, and planning target volume (PTV) will be created equal to the CTV plus a 0.5-cm safety margin. Treatment will be performed with a linear accelerator in a photon regimen, with a 6-to 15-megavolt (MV) nominal energy and three-dimensional (3D) conformal technique.
223695515|NCT00679055|DRUG|MK-0736|MK-0736; 7mg once daily, orally at approximately the same time each morning for 12 weeks.
223695516|NCT00679055|DRUG|Comparator: placebo (unspecified)|Matching Placebo once daily, orally at approximately the same time each morning for 12 weeks.
223695517|NCT03711201|BEHAVIORAL|Group IORE|This group will undergo the IORE procedure before surgery (operation). On the day of surgery, the patient will be brought to the operating room by the anesthesiologist. Hemodynamic data (blood pressure, pulse rate, respiratory rate, SpO2) will be measured at the service, preop unit and operating room. The anxiety level in the operating room will be measured by the ST-STAI scale.
223695518|NCT01368432|DRUG|Escitalopram|Escitalopram 10 mg or 20 mg daily for 12 weeks by mouth
223695519|NCT01368432|DRUG|Placebo|Sugar pill placebo
223695520|NCT05955053|OTHER|Midwifery care applied in line with Midwife-Pregnant cooperation|Pregnant women who apply to the obstetrics clinic will be informed about the research by the doctor and the pregnant woman whose labor has started will be sent to the delivery room. The researcher will be welcomed by the midwife from the first time the pregnant woman arrives in labor (delivery room), and firstly she will be informed about the purpose of the research and an informative consent form and a pregnant identification form will be filled in that she agrees to participate in the research. During labor and labor, the research midwife (HYY) will be with a pregnant woman until she gives birth and care will be given according to the items in the midwifery care checklist prepared based on the partnership model. After giving birth to a pregnant woman and applying the scales, another pregnant woman will be transferred and care will be given in the same way according to the midwifery care model checklist.
223695521|NCT00744276|DRUG|danazol|danazol applied topically once per day for 4 treatment cycles
223695522|NCT00744276|DRUG|Placebo|placebo topically applied once daily for 4 treatment cycles
223695523|NCT04348110|DIETARY_SUPPLEMENT|Placebo tablets|consume 2 tablets per day for 8 weeks
223695524|NCT04348110|DIETARY_SUPPLEMENT|Blueberry Chewable Tablets|consume 2 tablets per day for 8 weeks
223695525|NCT00535366|DRUG|Tiotropium|Oral inhalation by HandiHaler® device
223695526|NCT00535366|DRUG|Salmeterol|Oral inhalation from Diskus®
223695527|NCT00535366|DRUG|Fluticasone|Oral inhalation from metered dose inhaler (MDI)
223779475|NCT05857046|OTHER|Placebo|Patients received placebo every 12 hours for 7 days and then every 24 hours for 83 days
223695528|NCT00535366|DRUG|Ciclesonide low|Oral inhalation from MDI
223695529|NCT00535366|DRUG|Ciclesonide high|Oral inhalation from MDI
223695530|NCT00535366|DRUG|Placebo|Oral inhalation from MDI
223695531|NCT02080858|DRUG|Ticagrelor + Apixaban + ASA|
223695532|NCT02080858|DRUG|Ticagrelor + Apixaban|
223695533|NCT04462510|PROCEDURE|Block/Local infiltration|One group received ILI/IHG Block and the other group received local anesthetic infiltration for pain relief
223695534|NCT01008150|DRUG|Paclitaxel|
223695535|NCT01008150|DRUG|Trastuzumab|
223695536|NCT01008150|DRUG|Neratinib|
223695537|NCT01008150|DRUG|Doxorubicin|
223695538|NCT01008150|DRUG|Cyclophosphamide|
223695539|NCT00251355|DRUG|Gemcitabine|Gemcitabine, IV bolus administered weekly (weeks 1-6) at least 4 hours before that day's radiation therapy.
223695540|NCT00251355|DRUG|5-Fluorouracil|5-FU via continuous IV infusion.
223695541|NCT00251355|PROCEDURE|Radiation Therapy|External Beam Radiotherapy (weeks 1-6), Monday through Friday.
223695542|NCT03564028|OTHER|energy conservation technique|During the session of stair climbing, patients will perform a break at least of 5 seconds every 3 steps.
223695543|NCT03564028|OTHER|control session|Patients will realize one session of stair climbing at their own pace
223779476|NCT01267123|PROCEDURE|Trendelenburg position|The patient will be placed in the Trendelenburg position with a 15 degree angle of inclination
223779477|NCT01267123|PROCEDURE|Standard care|The patient will be placed in the standard horizontal position
223695544|NCT01741090|BIOLOGICAL|mesenchymal stem cell injection|Hepatic artery catheterization and mesenchymal stem cell injection will be used in alcoholic liver cirrhosis. And before and 1 month after injection, change of liver cirrhosis and portal hypertension will be evaluated.
223695545|NCT00969904|DRUG|N-acetylcysteine|600 mg TID for 12 weeks
223695546|NCT00969904|DRUG|placebo|placebo tablet TID for 12 weeks
223695547|NCT06218212|DIETARY_SUPPLEMENT|Renastart formula|"* Renastart formula is an artificial formula is made by Vitaflo USA, Nestle Health Science Company.~* Renastart formula preparation: Adding one level scoop of Renastart to 30 ml water.~* Renastart formula will be used with breast milk, standard infant formula, standard pediatric infant feed and/ or mixed with diet.~* Renastart formula dosage will be adjusted to be 1/4 Renastart and 3/4 breast milk, standard infant formula or standard pediatric infant daily caloric feed ratio.~* Readjusting dosage ratio according to serum electrolytes levels especially potassium."
223695548|NCT06218212|DRUG|calcium carbonate (phosphorus binder) with / or sodium polystyrene sulfonate (potassium binder) with dosage 0.5-1mg/kg/day orally.|calcium carbonate (phosphorus binder) in dosage of 45-65 mg/kg/day orally with / or sodium polystyrene sulfonate (potassium binder) in dosage of 0.5-1mg/kg/day orally.
223695549|NCT00139061|DRUG|Torcetrapib/Atorvastatin|
223695550|NCT00139061|DRUG|Fenofibrate|
223695551|NCT01225796|DRUG|Sodium bicarbonate|Sodium bicarbonate 650mg by mouth three times daily for 6 months.
223695552|NCT03767101|BEHAVIORAL|Cognitive behavioral therapy|In all three treatment arms, licensed therapists/trainee therapists perform a cognitive behavior therapy (CBT) under conditions of the German health care system. All treatments are based on individualized treatment plans for each patient. Therapists are supervized by an CBT expert therapist in the outpatient treatment center. On average every forth session is supervized. The total duration of treatment is variable, oriented on patients symptoms and treatment goals.
223695553|NCT05391451|PROCEDURE|efficacy of quadratus lumborum block in post-operative analgesia in kidney transplant surgery|no premedication for anxiolytic purposes before surgery. Cimetidin 200mg can be administrated for Mendelson syndrome prevention. After general anesthesia induction, echo-guided quadratus lumborum block is performed by applying 20ml of levobupivacaine
223695554|NCT05391451|PROCEDURE|general anesthesia|general anesthesia is the current technique for kidney transplant surgery. The protocol involves the combination of several drugs: Propofol, Remifentanil, Ketamin, Atracurium or Cisatracurium. Curarization monitoring is systematic.
223695555|NCT00762216|DEVICE|AcrySof® Toric intraocular lens|Implantation of the AcrySof Toric intraocular lens (IOL) into the eye following cataract extraction surgery
223695556|NCT02027038|DEVICE|Pelvic belt application|
223695557|NCT01408797|PROCEDURE|donor specific transfusion|before transplantation,200mL of donor whole blood will be transfused to the recipient
223695558|NCT01408797|DRUG|MMF, Bortezomib|MMF and Bortezomib will be administered after donor specific transfusion
223695559|NCT01408797|PROCEDURE|drugs added according to the immuno condition of the recipients|drugs (corticosteroid, MMF and/or CNI) will be added according to the recipients immuno event and donor specific antibody
223695560|NCT00661973|DRUG|budesonide|inhaled budesonide (turbohaler) 400 micrograms twice a day for 4 weeks
223695561|NCT05668975|DEVICE|Inspiratory Muscle Training|A mechanical pressure threshold loading device (POWERbreathe, POWERbreathe International Ltd, UK) will be used for the training.
223695562|NCT03845543|DEVICE|Luminor-14 Paclitaxel eluting balloon|Patients will be treated with the Luminor-14 paclitaxel eluting balloon
224263565|NCT01129258|DRUG|PF-04991532|Subjects will be dosed wtih PF-04991532 for 14 days. The tentative dosing schedule is 30, 100, 300, 1000, and 1500 mg QD, and 150 and 500 mg BID). Doses shown may be adjusted upwards or downwards and may be adjusted to include intermediate doses. All doses will be administered as tablets (10, 50, and 150 mg strengths). In each cohort 9 subjects will receive PF-04991532 and 3 will receive placebo.
224263566|NCT01129258|DRUG|Placebo|Placebo to match PF-04991532 will be provided. Subjects will be dosed for 14 days. In each cohort 9 subjects will receive PF-04991532 and 3 will receive placebo.
224263567|NCT03653299|DEVICE|Placebo or Active Phototherapy (MR4)|Phototherapy, placebo or active, will applied in 9 different points of anterior muscle of the thigh, 6 different points of posterior muscle of the thigh and 2 different points of the gastrocnemius muscle, bilaterally. Once a week during for 4 weeks, before the tests, the phototherapy programs (1, 2, 3 and 4) order will depend of the group randomized. The 10 subjects will do the three-dimensional gait analysis, muscle activity during gait, evaluation of mobility, static and functional balance, and mobility tests.
224263568|NCT03076437|COMBINATION_PRODUCT|Drugs and Anti-CD19-CAR transduced T cells|"Drug: Fludarabine On days -4 through -2, Fludarabine 30mg/m2 IV will be infused over 30 minutes. Drug: Cyclophosphamide On days -4 through -2, Cyclophosphamide 300mg/m2 IV will be infused over 60 minutes followed by fludarabine.~Biological: Anti-CD19-CAR transduced T cells Modified cells will be infused IV over 30 minutes (1-3 days after the last dose of fludarabine)."
224263569|NCT02264977|DEVICE|GORE® TAG® Thoracic Branch Endoprosthesis|
223695563|NCT03873610|BEHAVIORAL|Stress and Symptom Management Program 1|The Stress and Symptom Management Program 1 introduces and reinforces stress and symptom management for adolescents with NF. The program consists of 8 weekly 45 minute sessions, delivered through videoconferencing.
223695564|NCT03873610|BEHAVIORAL|Stress and Symptom Management Program 2|The Stress and Symptom Management Program 2 introduces and reinforces stress and symptom management for adolescents with NF. The program consists of 8 weekly 45 minute sessions, delivered through videoconferencing.
223695565|NCT05816031|DIETARY_SUPPLEMENT|Ketogenic diet|Ketogenic diet administrated to obese patients planned for right laparoscopic adrenalectomy
224263570|NCT03573544|DRUG|OBI-888|For the dose-escalation phase, OBI-888 will be given weekly at the dose levels of 5, 10, and 20 mg/kg.
224263571|NCT03573544|DRUG|OBI-888|For the dose-expansion phase, OBI-888 will be given weekly at 20 mg/kg dose level.
224263572|NCT03573544|DEVICE|Globo H IHC Assay|This assay will be used to identify eligible patients who may clinically benefit from the OBI-888 treatment, defined by Globo H expression.
224263573|NCT00246792|BEHAVIORAL|Group treatment|
224263574|NCT02736019|DRUG|Celecoxib|Women will receive oral Celecoxib 200mg 2 hours before the procedure
224263575|NCT02736019|DRUG|Tramadol|Women will receive oral Tramadol 100 mg 2 hours before the procedure
224263576|NCT02736019|DRUG|Placebo 1|Women will receive an oral placebo similar to Tramadol 2 hours before the procedure.
224263577|NCT02736019|DRUG|Placebo 2|Women will receive an oral placebo similar to celecoxib 2 hours before the procedure
224263578|NCT04443998|DEVICE|Bone reducion forceps|Repositioning forceps provide a more accurate anatomical reduction and higher pre-compression can be achieved compared to IMF or manual reduction
224263579|NCT01345539|RADIATION|Stereotactic Radiosurgery (SRS)|Dose and fractionation will be dependent on the lesion location and lesion size, the exact fractionation and dose is at the discretion of the treating physician. A minimum of 48 hours must be used in between SRS treatments at each site. Patients may have SRS everyday or multiple SRS sessions in one day as long as the minimum time for each treatment site is met.
224263580|NCT01345539|DRUG|Chemotherapy|Chemotherapy choice of agents is at the discretion of the treating medical oncologist.
224263581|NCT03856580|BEHAVIORAL|Alternative long-acting PrEP injection strategies|"Participants in the two intervention groups will complete injection procedures (e.g., self-injection, injection by healthcare providers at drop-in clinics) to determine if this could facilitate improved adherence to an inert version of long-acting cabotegravir injections"
224263582|NCT03856580|BEHAVIORAL|mHealth adherence app|"Participants in the two experimental arms will be given a smartphone application, designed to facilitate adherence (this app will be developed during earlier phases of the study using in-depth interviews and design session groups)"
224263583|NCT03769532|DRUG|Pembrolizumab|Pembrolizumab (IMP): 200mg i.v. (fixed dose), every 3 weeks (Q3W), 8 doses
224263584|NCT03769532|DRUG|Azacitidine|Azacitidine (SOC): 75 mg/m2 s.c., day 1-7 every 4 weeks (Q4W), 6 cycles
224263585|NCT03463460|OTHER|Laboratory Biomarker Analysis|Correlative studies
224263586|NCT03463460|BIOLOGICAL|Pembrolizumab|Given IV
224263587|NCT03463460|DRUG|Sunitinib Malate|Given PO
224263588|NCT02389595|OTHER|HIV positive subjects|This group will provide a blood sample.
224263589|NCT02389595|OTHER|Non-infected control subjects|This group will be de-identified blood samples from a commercial source.
224263590|NCT06973265|DEVICE|TENS|After the surgery, 2 TENS electrodes will be placed on the inner part of the upper arm of the patient's arm on the side where surgery was performed, and the frequency will be 100 Hz, the pulse duration will be 100 µs and the amplitude will be adjusted so as not to cause muscle contraction, and a 20-minute TENS application will be performed.
224263591|NCT06200363|DRUG|T3011|T3011 will be administered intravenously on D1, 4, 8, 11, 15, 18 of each 28-day cycle.
224263592|NCT06200363|DRUG|Regorafenib|Regorafenib will be administered orally once daily for the first 21 days of each 28-day cycle according to NCCN and CSCO guidance.
224263593|NCT05683561|BIOLOGICAL|CoronaVac|D0; intramuscular injection
224263594|NCT05683561|BIOLOGICAL|SCTV01E|D0; intramuscular injection
223695566|NCT01327456|BEHAVIORAL|Self-Management Intervention|patients will participate in a 1-on-1 interactive intervention, delivered by a trained research assistant targeting self-management skills (e.g. inhaler use, use of an action plan), smoking cessation, and exercise/pulmonary rehabilitation. All participants will return 2-4 weeks after the intervention for a follow-up assessment of inhaler technique use, COPD-related knowledge, and time spent in self-management.
223695567|NCT00117195|DEVICE|Automated Neuropsychological Assessment Matrix|"This study will evaluate a profile of neurophysiologic tests for potentially predictive signs of PD or PS in individuals with PD or PS, those who may be at risk for PD or PS and in a population of individuals without parkinsonian symptoms or any other neurologic conditions.~In addition, the study will evaluate serum samples for changes in proteins or metabolites that may be indicators of early changes associated with Parkinson's disease or parkinsonian syndrome."
223695568|NCT03686514|BIOLOGICAL|FLUARIX QUADRIVALENT|The FDA-approved, quadrivalent seasonal influenza vaccine that will be administered contains four distinct strains, two influenza A viruses and two influenza B viruses.
223695569|NCT01400815|DRUG|X-22 Smoking Cessation Product|"The X-22 Smoking Cessation Product is a tobacco-based (botanical) medical product consisting of very low nicotine (VLN) cigarettes.~Subjects will be allowed to smoke as much as desired throughout the 6-week treatment period."
223695570|NCT01400815|DRUG|Active Control Cigarettes|"The Active Control cigarette is identical to the X-22 cigarette except for the tobacco, which has a nicotine content similar to that of a conventional light cigarette.~Subjects will be allowed to smoke as much as desired throughout the 6-week treatment period."
223695571|NCT05010408|OTHER|Flavored carbonated soft drink (CSD) at different sweetness levels|Beverage
223695572|NCT01192373|OTHER|Metabolic substrate modulation|for high circulation free fatty acids: Heparin (250IE/hour) + intralipid (20%, 62 ml/hour).
223695573|NCT01192373|OTHER|metabolic substrate modulation|low circulating free acids: hyperinsulinaemic euglycemic clamp (0,8 mUkg/min) with venous blood glucose at 4,5-6,5 mM.
223695574|NCT04856202|BEHAVIORAL|Advance Care Planning interview|The facilitator will clarify the patients' preferences, asking specific questions regarding personal goals, including religious and cultural beliefs. The facilitator will discuss life supporting treatments that might be applicable to the patient and encourage the patient to weigh up personal benefits and burdens. Treatments may include: invasive therapy (such as chemotherapy or dialysis), hospitalization, resuscitation, ventilation, artificial nutrition or hydration and administration of antibiotics. The patient will also be encouraged to identify specific situations that are likely to improve or diminish his or her quality of life. The facilitator will assist the patient in documenting their wishes, including the assignment of a health care proxy.
223695575|NCT04242173|DRUG|Cemiplimab-Rwlc|Cemiplimab-rwlc will be administered as a flat dose of 350 mg IV over approximately 30 minutes every 21 days (+/- 3 days)
223695576|NCT02193581|DEVICE|MDS|Patients with a suspicious lesion, referred for a biopsy is tested using MDS.
223695577|NCT00805948|DEVICE|Talent Thoracic Stent Graft System|endovascular repair of descending thoracic aortic aneurysms using the Talent Thoracic Stent Graft System.
223695578|NCT01123850|DEVICE|Copios|Bone Void Filler
223695579|NCT03509610|OTHER|Diet|Macronutrient composition (specifically type and/or amount of carbohydrate) is manipulated
223695580|NCT04627662|BEHAVIORAL|Tele-STELLA|Tele-STELLA (Support via TEchnology: Living and Learning with Advancing Alzheimer's disease and related dementias) is a multicomponent videoconference-based intervention designed to facilitate effective management of behavioral and psychological symptoms common to the later stages of dementia.
223695581|NCT05135247|OTHER|Exercise|3 different types of training or control
223695582|NCT03805906|PROCEDURE|L5 Dorsal ramus block|Ultrasound-guided L5 dorsal ramus block
223695583|NCT04429243|DEVICE|GORE® VIABAHN® Stent Graft|On Day 1, participants will receive the GORE® VIABAHN® Stent Graft.
223695584|NCT03739671|DIETARY_SUPPLEMENT|Vitamin D|Group will receive 5000 units of vitamin D daily
223695585|NCT03739671|DIETARY_SUPPLEMENT|No Vitamin D|No vitamin D supplementation
223695586|NCT00482261|DRUG|Lenalidomide|15mg daily, days 1-21 of a 28 day cycle for 4 cycles. Patients who get stable disease or better will then receive 15mg on days 1-21 from cycle 5 onwards
223695587|NCT00482261|DRUG|dexamethasone|20mg day 1-4, 9-12, 17-20 for 4 cycles. Patients who get stable disease or better will then get dexamethasone 20mg on days 1-4 of a 28 day cycle, from cycle 5 onwards
223695588|NCT00482261|DRUG|aspirin|100mg/day
223695589|NCT06514976|DRUG|Cytoflavin|Cytoflavin solution for infusions. 20-40 ml/day (10 ml with the interval of 8-12 hours for 10 days; the single dose is increased up to 20 ml in case of the severe form of the disease) by intravenous drop infusion in dilution per 100-200 ml of 0.9% sodium chloride solution for 10 days; rate of administration: 3-4 ml/min
223695590|NCT00775476|DRUG|N-acetylcysteine|Capsules of NAC, each containing 600 mg of NAC between dosages of 2.4 g to 4.8 g daily
223695591|NCT00775476|DRUG|Placebo|placebo (sugar) twice daily, daily dosage will match that of NAC that was tolerated between daily dosages of 2.4 g and 4.8 g during the open-label titration phase.
223695592|NCT04783597|DIAGNOSTIC_TEST|Arterial Stiffness and Wave Reflection|Arterial stiffness and wave refection, a non-invasive test, will be collected and combined with standard clinical markers (blood biomarkers, ultrasound imaging) as well as medical and psychosocial questionnaires in order to test a comprehensive, multi-marker approach for pre-eclampsia prediction in high risk pregnant women.
224263595|NCT01189747|BIOLOGICAL|onabotulinumtoxinA|24 units onabotulinumtoxinA (botulinum toxin Type A) total dose injected into bilateral Crow's Feet Line areas on Day 1
224263596|NCT01189747|DRUG|normal saline|Injected into bilateral Crow's Feet Line areas on Day 1
224263597|NCT07130877|DIETARY_SUPPLEMENT|WHO F100|WHO F1OO
224263598|NCT07130877|DIETARY_SUPPLEMENT|WHO RECIPE BASED F100|Recipe-made formula will be given after initial stabilization, starting from 150 kcal per kg per day to a maximum of 220 kcal per kg per day at 4-hourly intervals, and intakes and vitals will be monitored.
224263599|NCT04469959|DRUG|L-Dopa|"Generic 25/100mg carbidopa/levodopa (Sinemet)capsules will be administered in this study. Participants will begin randomized double blinded 3- week trial of Levodopa. Dose titration starting at 150 mg /daily to maximum of 450 mg daily three times a day for three weeks.~After one week of taper participants will enter step 2 phase of study where carbidopa/levodopa matched placebo will be administered for 3 weeks afterwards dose will be slowly tapered over next 7 days."
223695593|NCT01289457|DRUG|Clofarabine|"Phase I: 15 mg/m2 by vein (IV) daily for 5 days of a 28 day cycle.~Phase II: Clofarabine (dose selected based on Phase I portion) by vein over approximately 1 hour daily for 5 days (days 1-5) for a 28 day cycle."
223695594|NCT01289457|DRUG|Idarubicin|10 mg/m2 by vein over approximately 30 minutes daily for 3 days (days 1-3) of a 28 day cycle.
223695595|NCT01289457|DRUG|Cytarabine|1 g/m2 by vein over approximately 2 hours daily for 5 days (days 1-5) for a 28 day cycle.
223695596|NCT01289457|DRUG|Fludarabine|30 mg/m2 by vein over approximately 30 minutes daily for 5 days (days 1-5).
224263600|NCT04469959|DRUG|Placebo|Step 1 (3 weeks) Carbidopa/levodopa-matched placebo capsules 3 times. Followed by 1 week of taper. Step2(3 weeks):150-450mg carbidopa/levodopa 3 times daily for three weeks .Followed by 1 week of taper.
224263601|NCT07125664|BIOLOGICAL|alpha1-proteinase inhibitor, produced from the plasma of human donors (Prolastin 1000 mg, powder and solvent for solution for infusion)|IV Prolastin administered once at 120 mg per kilogram of body weight
224263602|NCT07125664|DRUG|Placebo|\+ IV administration of 0.9% sodium chloride
224263603|NCT01248728|DIETARY_SUPPLEMENT|Omega-3 Fatty Acids|Children will be administered 3.75ml of the liquid formulation of Nutra Sea HP (containing 1.5 gr of EPA+DHA). The starting dose will be 1.875ml (0.75 gr of EPA+DHA) and the dose will be doubled on week 2. The parents may choose to give this as a single dose or split it to two doses if stomach upset occurs. This formulation is double distilled and has very little fishy taste, which will make it more palatable for children and will make creating a matching placebo a simpler process.
224263604|NCT01248728|DIETARY_SUPPLEMENT|Placebo|Children will be administered 3.75ml of the liquid formulation of Placebo. The starting dose will be 1.875ml and the dose will be doubled on week 2. The parents may choose to give this as a single dose or split it to two doses if stomach upset occurs. This formulation is double distilled and has very little fishy taste, which will make it more palatable for children and will make creating a matching placebo a simpler process.
224263605|NCT07130656|DIAGNOSTIC_TEST|Diagnosis of SSI|Diagnosis of SSI by manual system in colorectal surgery procedures enrolled in the SSI surveillance programme.
224263606|NCT03047564|DEVICE|Coated Total Knee Arthroplasty|Implantation of a coated Total Knee Arthroplasty
224263607|NCT03047564|DEVICE|Standard Total Knee Arthroplasty|Implantation of a Standard Total Knee Arthroplasty
224263608|NCT04681534|DEVICE|AlphaDBS System|AlphaDBS can be programmed with two different types of stimulation: conventional DBS and adaptive DBS, that automatically adjusts the energy delivered to patient using a biosignal, local field potential (LFP), in a close loop configuration.
224263609|NCT01513434|PROCEDURE|transtibial technique|Femoral tunnel was made via tibial tunnel in anterior cruciate ligament reconstruction.
224263610|NCT01513434|PROCEDURE|Transportal technique|Femoral tunnel was made via anteromedial portal in anterior cruciate ligament reconstruction.
224263611|NCT01513434|PROCEDURE|anterior cruciate ligament reconstruction|femoral and tibial tunneling graft fixation on the femoral side with endobutton and on the tibial side with post-tie and interference screw
224263612|NCT02377778|DRUG|Propofol|Propofol intravenous infusion for introduction and maintance of anaesthesia at doses 3-5mg depending on the total time needed for completion of oocyte retrieval
224263613|NCT02377778|DRUG|Thiopental|Patients will receive thiopental in addition to fentanyl for introduction and maintanance of anaesthesia at doses 7mg. IF required patients will receive a repeat dose of 1-3mg of thiopental depending on the totla time needed to complete oocyte retrieval
224263614|NCT02368639|DEVICE|Fisher & Paykel Healthcare PAP Device|The device is a modified version of the Fisher \& Paykel Icon continuous positive airway pressure (CPAP) device, which is a fully released product in New Zealand.
224263615|NCT00147498|DRUG|CP-690,550|Oral tablets administered at a dose of 5 mg BID for 6 weeks
224263616|NCT00147498|DRUG|CP-690,550|Oral tablets administered at a dose of 15 mg BID for 6 weeks
224263617|NCT00147498|DRUG|CP-690,550|30 mg BID for 6 weeks
224263618|NCT00147498|OTHER|Placebo|Placebo tablets
223695597|NCT03786614|OTHER|Discontinuation of serotonergic antidepressants|Discontinuation of serotonergic antidepressants and possibly shift to other antidepressant categories that were proven to be effective in treating depression such as pramipexole, bupropion, quetiapine, lurasidone, brexpipazole. Additionally, subjects will have access to other treatment measures of treating treatment resistant depression.
223695598|NCT03786614|OTHER|Continuation of serotonergic medications|Continuation of serotonergic medications which is the standard care of treatment. Additionally, subjects will have access to other treatment measures of treating treatment resistant depression.
223695599|NCT06084598|DRUG|BMS-986446|Specified dose on specified days
223695600|NCT06084598|OTHER|Placebo|Specified dose on specified days
223695601|NCT02267642|BIOLOGICAL|AbGn-168H|monoclonal antibody
223695602|NCT00596180|DRUG|HBOT|total body exposure to greater than atmospheric pressure oxygen
223695603|NCT00005851|DRUG|fludarabine phosphate|Given IV
223695604|NCT00005851|RADIATION|total-body irradiation|Undergo TBI
223695605|NCT00005851|PROCEDURE|nonmyeloablative allogeneic hematopoietic stem cell transplantation|Undergo nonmyeloablative allogeneic PBSC transplantation
223695606|NCT00005851|DRUG|cyclosporine|Given PO or IV
223695607|NCT00005851|DRUG|mycophenolate mofetil|Given PO or IV
223695608|NCT00005851|PROCEDURE|peripheral blood stem cell transplantation|Undergo nonmyeloablative allogeneic PBSC transplantation
223695609|NCT00005851|BIOLOGICAL|therapeutic allogeneic lymphocytes|Undergo DLI
223695610|NCT00005851|OTHER|laboratory biomarker analysis|Correlative studies
223695611|NCT05715801|PROCEDURE|hyperbaric oxygen therapy|The hyperbaric oxygen group was given 60 minutes of pure oxygen under 2ATA (Atmosphere Absolute, ATA) and 5 minutes of rest in between.
223695612|NCT05715801|PROCEDURE|conventional oxygen therapy|Conventional oxygen therapy group breathed 27% oxygen at 1.03 ATA for 60 minutes. (The chamber pressure was increased to 1.2ATA with circulating air noise for the first 5 minutes of the experiment, then reduced to 1.03 ATA for the next 5 minutes.)
223695613|NCT02686281|DRUG|GMC-252-L-Lysine|
223695614|NCT02686281|OTHER|Placebo|
223695615|NCT03206255|PROCEDURE|3 doses of HPV 16/18 bivalent vaccine|Participants have received 60μg of HPV 16/18 bivalent vaccine according to the standard 3-dose schedule (0,1,6 months)
223695616|NCT03206255|PROCEDURE|2 doses of HPV 16/18 bivalent vaccine|Participants have received 60μg of HPV 16/18 bivalent vaccine according to an alternative 2-dose schedule (0,6 months)
223695617|NCT01627171|DRUG|Bisacodyl 10mg|Given at the start of the bowel preparation the day before colonoscopy
223695618|NCT01627171|DRUG|Polyethelene Glycol|280g reconstituted in 4 liters of water
223695619|NCT01627171|DRUG|Picosulfate sodium|Two sachets, Each sachet has 10mg dose
223695620|NCT00179127|DRUG|glargine|0.3u/kg of glargine, subcutaneously, once
223695621|NCT00179127|DRUG|saline|0.3u/kg of saline, subcutaneously, once
223695622|NCT00129818|DRUG|Famciclovir|
223695623|NCT04707352|DRUG|Dapagliflozin|All eligible subjects will receive Dapagliflozin 10 mg each day. The study treatment will be provided for the duration of the trial from baseline (Day 1) through last visit (Day 180).
223695624|NCT03491943|PROCEDURE|ultrasound-assisted midline approach|A preprocedural ultrasound scanning will be done, and skin marking will be made. The needle entry point and insertion angle will be determined based on ultrasound scanning. Spinal anesthesia will be performed via midline approach.
223695625|NCT03491943|PROCEDURE|ultrasound-assisted paramedian approach|A preprocedural ultrasound scanning will be done, and skin marking will be made. The needle entry point and insertion angle will be determined based on ultrasound scanning. Spinal anesthesia will be performed via paramedian approach.
223695626|NCT03216031|BEHAVIORAL|Gardening programme|3 groups with up to 10 patients and 2-4 students/staff members each should meet once per week for about 1 hour to engage in gardening activities at the falls prevention growing site. Each participant will attend the programme 8 times.
223695627|NCT04692740|DRUG|Chlorambucil, Oral, 2 Mg|Eligible patients will be treated with Chlorambucil 6 mg/m2 daily p.o. for 42 consecutive days (weeks 1-6). After restaging, responder patients (complete or partial response) and those with stable disease will receive Chlorambucil 6 mg/m2 daily p.o for 14 consecutive days every 28 days until disease progression or unbearable toxicity, patient refusal or medical decision. Patients' clinical data will be collected pseudo-anonymously and a sequential identification code number will be assigned to each patient enrolled in the study.
223695628|NCT03522753|DEVICE|Metal skin staples|Routine closure methods/material for surgical wounds
223695629|NCT03522753|DEVICE|Nylon sutures|Routine closure methods/material for surgical wounds
223695630|NCT04255797|BEHAVIORAL|baby massage|The steps are as follows:1. Monitor the physiological indicators before massage, 2. Assist premature babies to lie on prone, take off their clothes and diapers, and then apply the baby's massage oil to the hands of both parents to warm them. 3. In the incubator, slight pressure touch the baby's body with warm palms and fingers.
223695631|NCT00381381|DRUG|Donepezil|2.5mg once daily for the first 7 days, 5mg once daily for the next 3 weeks, after then the dose can be increased 10mg once daily under the investigator's decision.
223695632|NCT03364907|OTHER|HIPEC with flushing afterwards|flushing with saline fluid after HIPEC
223695633|NCT03364907|OTHER|HIPEC without flushing afterwards|NO flushing with saline fluid after HIPEC
223695634|NCT00711074|DRUG|AZD5672|single dose 200mg aqueous solution
223695635|NCT02746003|OTHER|Managed Aquifer Recharge water|Rain water will be recharged through slow sand filter and recharge wells into the confined underground aquifer and the surrounding community will abstract the water for drinking and cooking purposes
223695636|NCT05062278|DRUG|Vinblastine|Single-dose of intravenous vinblastine at 6mg/m2 (maximum 10mg).
223779478|NCT06249100|PROCEDURE|flexible mini percutaneous nephrolithotomy|In Group A (flexible mini-PCNL cases), a puncture will be done under fluoroscopic guidance medial to the posterior axillary line using an 18-gauge puncture needle. The puncture will be directed horizontally or with a slight upward inclination towards the lower or middle calyx. After a successful puncture, a 0.035 Fr Super Stiff guidewire will be inserted. Tract dilatation with amplatz dilator followed by access sheath insertion. Stone disintegration will be done with the flexible mini-nephroscopy (WiScope Digital Endoscope System by OTU Medical, California, USA) which has a shaft length of 38 cm, distal tip diameter is 15.3 F tapering to 10 F, working channel inner diameter is 6.6 F, and the angle of deflection of the distal tip is 210 degrees.
223779479|NCT06249100|PROCEDURE|Retrograde intrarenal surgery|n Group B, Flexible ureteroscopy will be used with a ureteral access sheath and laser fragmentation of renal stones will be done
223779480|NCT00385970|DRUG|Tegafur-uracil (UFT)|From within 9 weeks after surgery, 300 mg/m2, PO from day 1 to day 28 of each 35 day cycle. Number of Cycles: 5
223779481|NCT00385970|DRUG|Calcium folinate (LV)|From within 9 weeks after surgery, 75 mg, PO from day 1 to day 28 of each 35 day cycle. Number of Cycles: 5
223779482|NCT00385970|DRUG|Krestin (PSK)|From within 9 weeks after surgery to 12 months after surgery, 3 g/day, PO every day
223779483|NCT03154710|DEVICE|MOOVCARE|web-mediated follow up
223779484|NCT01294618|DRUG|Nilotinib,Novartis,300 mg twice a day +Pegylated interferon 2a,Roche, 45 microg weekly starting Month 2-Month 12 or beyond according to investigator choice.|Combination of both treatments active by different means on the leukemic cells, in order to enhance the response rates of CP CML patients since diagnosis.
223779485|NCT06652035|DIETARY_SUPPLEMENT|Quevir® (Quercetin Phytosome®)|500 mg Quevir® (Quercetin Phytosome®) tablet
223779486|NCT06652035|DIETARY_SUPPLEMENT|Bactoblis®|Probiotic Streptococcus Salivarius K12 (ATCC BAA-1024)
223779487|NCT00424905|DRUG|Bacillus clausii|2 Enterogermina vials/day for 12 to 17 days (i.e. during the 5 to 10-days antibiotic treatment and for 7 days thereafter.
223779488|NCT00836875|DRUG|Voriconazole|"All subjects will receive voriconazole for a minimum of 6 weeks and a maximum of 12 weeks. All subjects must receive intravenous (IV) voriconazole for the first week of therapy.~Group 1: Subjects 2 to 11 years old and subjects 12 to 14 years old with low body weight (\<50 kg) will receive 9 mg/kg IV every 12 hours (q12h) on day 1, then 8 mg/kg IV q12h starting day 2. If there is a significant clinical improvement after the first week of IV therapy, subjects may be switched to the step-down oral regimen (9 mg/kg PO q12h with a maximum dose of 350 mg PO q12h) at the discretion of the investigator.~Group 2: Subjects 12 to 17 years old (excluding 12-14-year-olds weighing \<50 kg) will receive 6 mg/kg IV q12h on day 1, then 4 mg/kg IV q12h starting day 2. Similar to Group 1, subjects may be switched to the step-down oral regimen (200 mg PO q12h) at the discretion of the investigator. Oral voriconazole can be administered as tablet or oral suspension."
223779489|NCT00273403|BEHAVIORAL|Maintenance in Care Services|
223779490|NCT00273403|BEHAVIORAL|Access to Care Services|
223779491|NCT06662851|DIAGNOSTIC_TEST|UDFF|Ultrasound-Derived Fat Fraction (UDFF) is a quantitative ultrasound technique used to assess hepatic steatosis by measuring the amount of fat in the liver tissue. UDFF estimates fat content using specific ultrasound parameters, namely the attenuation coefficient (AC) and backscatter coefficient (BSC). The AC measures the rate at which ultrasound waves weaken as they pass through the liver, which correlates with fat content, while the BSC quantifies the amount of reflected ultrasound signal, providing additional insights into liver tissue characteristics.
223695637|NCT05062278|DRUG|Hydroxyurea capsules|Oral hydroxyurea at a dose of 50mg/kg/day until the administration of induction chemotherapy.
223695638|NCT04516044|BEHAVIORAL|Video games|See arm description
223779492|NCT06664190|DIAGNOSTIC_TEST|Advanced sequences, such as arterial spin labeling (ASL) and diffusion-weighted imaging (DWI)|Advanced sequences, such as arterial spin labeling (ASL) and diffusion-weighted imaging (DWI)
223779493|NCT06662721|DRUG|Baricitinib 4 MG|The patients received Baricitinib for 48 weeks. The method is to take Baricitinib 4mg every day for a period of 48 weeks. All the patients will be followed up prospectively for 48 weeks.
223779494|NCT06664476|BEHAVIORAL|PortCare Professional Training Program|The intervention is a targeted educational program to enhance oncology nurses' skills in managing Port-A-Catheters for chemotherapy patients. It includes a preparatory phase to assess baseline knowledge and practices, followed by an implementation phase with theoretical and practical training. Theoretical sessions cover device basics and care guidelines, while practical sessions provide hands-on training on procedures like catheter insertion, flushing, and removal. This program aims to improve patient safety, reduce complications, and boost nurses' confidence in Port-A-Catheter care.
223779495|NCT06663228|DIAGNOSTIC_TEST|MMS|miniature mass spectrometry with AI assistance
223695639|NCT04256889|DEVICE|nfant(R) feeding system|Use of nfant(R) technology feeding system as an adjunct to visual assessment and cue-based feedings for infants born less than 30 weeks GA
223695640|NCT00160966|DRUG|Ciclosporin and Mycophenolate-mofetil|according to the Giessen protocol
223695641|NCT00160966|DRUG|Tacrolimus and Mycophenolate-mofetil|according to Giessen protocol
223695642|NCT00160966|DRUG|Tacrolimus and Mycophenolate-mofetil with change from Mycophenolate-mofetil to Everolimus|according to Giessen protocol
223695643|NCT02135939|BEHAVIORAL|Diet|Whole foods plant based vegan diet vs the American Heart Association-recommended diet
223695644|NCT00817583|DRUG|docetaxel, cisplatin, fluorouracil|"neoadjuvant chemotherapy:docetaxel 75 mg/m2 on day 1; cisplatin 75 mg/m2 on day 1; continuous fluorouracil infusion at 500 mg/m2/d on days 1 through 5.~concurrent chemotherapy:cisplatin 40 mg/m2 weekly"
223695645|NCT00817583|RADIATION|3D-CRT (three-dimensional conformal radiation therapy) or IMRT (intensity-modulated radiation therapy)|
223695646|NCT03616171|BEHAVIORAL|SLEEP-Extend intervention|"1. One education session (5-10 minutes) consisting of strategies for sleep hygiene which is the routine for going to sleep~2. Instructions on extending time in bed by at least one hour but can be up to 2 hours total per night for 4 weeks which can be accomplished by either going to bed earlier or staying in bed later"
223695647|NCT03616171|OTHER|Control|Control group will receive 1. One educational session (5-10 minutes) consisting of safety practices used for an urban environment (a safety brochure and safety information will be given and reviewed with the subject)
223779496|NCT06664723|DEVICE|high tone external muscle stimulation|Device HiToP®: Parameters of (HTEMS), Voltage: 230-V Pulse widths: ≤350 mA. Electrical Frequency: Frequencies continuously scanned from 4096 Hz to 31768 Hz, allowing for a much higher power of up to 5000 m W. Intensity: the electrical stimulation will be adjusted to a pleasant level that will not produce any pain or discomfortable paraesthesia, Duration 30 minutes per session. Electrodes will be placed around ulcer. It will be introduced 3 times per week, for 8 weeks Prior to intervention, skin sensation will be assessed using warm water in a test-tube (temperature), pin prick (pain) and cotton wool (light touch) to ascertain the skin sensitivity
223779497|NCT06664723|OTHER|Standard medical treatment (SMT)|The Standard care of diabetic foot ulcers includes good glycemic control, adequate nutrition, off-loading (via bed rest or casts), local care (moist dressings and topical management), lessening of edema, surgical debridement of devitalized wound tissue and antibiotic therapy.
223779498|NCT05747118|BEHAVIORAL|Physical training|A 12 week supervised training intervention with 1 hour physical training two times a week.
223779499|NCT04286594|DRUG|CBD|Participants will receive CBD solution during the open-label phase of the trial.
223779500|NCT06444789|DEVICE|connected smartwatch|The smartwatch is worn by the patient and data are sent automatically to a server that detects if there are signs of RBD.
223779501|NCT06587347|DRUG|Tirofiban Hydrochloride|Tirofiban will use a loading dose, 0.4 μg/kg/min × 30 minutes, then 0.1μg/kg/min infusion until 24 hours after Intravenous thrombolytic therapy, or use a loading dose, 25 μg/kg, administrated within 3 minutes, then 0.15μg/kg/min infusion until 24 hours after Intravenous thrombolytic therapy.
223779502|NCT06587347|DRUG|Standard medical treatment (SMT)|Patients will receive standard antiplatelet therapy.
223779503|NCT05943860|DIETARY_SUPPLEMENT|Pantovigar® vegan|Oral application of 1 capsule three times a day (morning, noon, evening) for 6 months
223779504|NCT06669013|DRUG|dinutuximab beta|Chemotherapy + Immunotherapy (dinutuximab beta)
223779505|NCT05551364|DEVICE|ATLAS 2030 exoskeleton|"Individualized Rehabilitation Treatment with the ATLAS 2030 Exoskeleton consists of the following phases:~1. Telephone contact phase (1 session)~2. Inclusion Phase (1 session)~3. Signing of informed consent (1 session)~4. Initial Evaluation Phase (1 session)~5. Treatment Phase (1st part) (7 sessions)~6. Monthly Evaluation Phase (1 session)~7. Treatment Phase (2nd part) (7 sessions)~8. Monthly Evaluation Phase (1 session)~9. Treatment Phase (3rd part) (7 sessions)~10. Final Evaluation Phase and results (2 sessions)"
223695648|NCT01147172|DEVICE|Elevess|Injectable gel, 0.5mL or 1.0mL material supplied in a 1.0mL pre-filled sterile glass syringe with two 30 gauge needles
223695649|NCT02787551|DRUG|Insulin glargine/lixisenatide fixed ratio combination|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
223695650|NCT02787551|DRUG|liraglutide|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
223695651|NCT02787551|DRUG|exenatide|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
223695652|NCT02787551|DRUG|exenatide extended-release|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
223695653|NCT02787551|DRUG|albiglutide|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
223779506|NCT05654324|OTHER|pelvic floor muscle exercises|Before the pelvic floor exercises are taught to all women participating in the study, a brief informational training about the function and structure of the pelvic floor and pelvis will be given using visuals. The application protocol will be given by experienced specialist physiotherapists who have received special training on pelvic floor muscle training. In this study, the training protocol described by Mørkved et al and Bø et al will be used. An exercise series will consist of slow and fast muscle contractions of the pelvic floor muscles. The exercise series will include 10 reps of maximum pelvic floor muscle contraction held for 6 seconds followed by three rapid muscle contractions. A 10-second rest period will be given between each exercise series. A total of 5 minutes, 4 repetitions of pelvic floor muscle contraction series will be applied, including the rest period.
223779507|NCT00109564|DRUG|ispronicline (nicotinic acetylcholine receptor agonist)|
223695654|NCT02787551|DRUG|dulaglutide|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
223695655|NCT02787551|DRUG|Background therapy: Oral Anti-diabetic Drug (Metformin, Pioglitazone, SGLT2 inhibitor)|Pharmaceutical form: tablet Route of administration: oral If previously taken, doses to remain stable through the study.
223695656|NCT00892658|DRUG|Sorafenib|Patients will receive sorafenib alone (following the dose escalation scheme) for one week, followed by 2 weeks of concurrent administration of sorafenib with conformal radiation therapy (6 fractions over two weeks). Sorafenib administration will continue for four weeks following completion of radiation. At three months following radiation, when liver toxicity is assessed, full dose sorafenib (400mg PO BID) will then be initiated and continued until disease progression or serious toxicity occurs, to a maximum time of 12 months.
223695657|NCT00590798|BEHAVIORAL|Walking|Patient will walk within 30 minutes of vascular closure system procedure
223695658|NCT02998216|PROCEDURE|Bilateral sacrospinous fixation|Bilateral sacrospinous vaginal suspension
223695659|NCT04149873|PROCEDURE|MIE|MIE
223695660|NCT04890431|DRUG|Oxygen|oxygen treatment (5 L/minute for 30 minutes by nasal cannula, twice/day)
223695661|NCT04890431|DRUG|Placebo|ambient air not enriched with oxygen (5 L/minute for 30 minutes by nasal cannula, twice/day)
223695662|NCT03995836|DEVICE|CPAP|Decision of CPAP treatment is according to clinical guidelines
223695663|NCT03995836|PROCEDURE|Bariatric Surgery|All patients.
223695664|NCT00725504|DRUG|Intravenous lidocaine|Intravenous lidocaine administered up to 5 µg/ml.
223695665|NCT02386969|DEVICE|active rTMS then sham rTMS|A first period during which the patient will have 1 session of active rTMS every 3 weeks for 3 months A 2nd period during which the patient will have 1 session of sham rTMS every 3 weeks for 3 months
223779508|NCT06898749|OTHER|canine mediation|"Animal mediation consists of bringing an animal into contact with a specific audience to improve the mental or physical health of a person. The dog and beneficiaries interact through various activities, in which the animal participates, offered during the sessions. The dog plays a particularly important role as a mediator through the bonds it forms with the human, as well as a non-judgmental partner in interaction.~The canine educator will be accompanied by a healthcare professional during interventions. The sessions are organized based on the expertise and suggestions of both professions (canine educator and psychomotor therapist).~The canine educator will be a state-certified professional educator with a specialization in animal mediation.~The dog used is trained by the educator, with two types of learning being worked on: emotions and commands on cue."
223779509|NCT06898749|OTHER|standard psychomotor therapy|standard sessions of psychomotor therapy
223779510|NCT06765863|DIETARY_SUPPLEMENT|Human Milk Fortifier|"Human milk fortifier added to expressed human milk (mother's own milk or pasteurized donor human milk) per feed per manufacturer's instructions for a minimum of 21 days (in-facility provision only)~* Clinical feeding guideline including targets for initiation and advancement of breast milk feeding~* Provision of guideline-driven standard of care \[facility-based lactation support/feeding counseling + KMC + WASH package (referred to as facility-based FSP+) and breast pumps\]"
223779511|NCT06765863|OTHER|Volume targets|"* Clinical feeding guideline including targets for initiation and advancement of breast milk feeding~* Provision of guideline-driven standard of care \[facility-based lactation support/feeding counseling + KMC + WASH package (referred to as facility-based FSP+) and breast pumps\]"
223779512|NCT05069831|DRUG|Abrocitinib|Abrocitinib daily for 4 months
223695666|NCT02386969|DEVICE|sham rTMS then active rTMS|A first period during which the patient will have 1 session of sham rTMS every 3 weeks for 3 months A 2nd period during which the patient will have 1 session of active rTMS every 3 weeks for 3 months
223779513|NCT06618352|OTHER|Simulated indoor overheating exposure|Young adults exposed to a multi-day extreme heat event
223779514|NCT05955560|DEVICE|PureWick Male External Catheter|The PureWick™ Male External Catheter (MEC) is intended for non-invasive urine output management in male patients. It is a single-use, non-sterile device. The PureWick™ Male External Catheter is a commercially available device which is Class I, 510(K) exempt.
223779515|NCT05955560|DEVICE|Sage PrimoFit|The PrimoFit External Urine Management for the Male Anatomy is indicated for the non-invasive external collection of urine for adult patients with male anatomy who require urine management. It is a single-use, non-sterile device. The Sage PrimoFit is a commercially available device which is Class I, 510(K) exempt.
223779516|NCT06866054|DRUG|SPSIPB block|A high-frequency linear US probe (11-12 MHz, Vivid Q) will be covered with a sterile sheath, and an 80 mm block needle (Braun 360°) will be used. The procedure will be performed with the patient in the lateral decubitus position. After the scapula is shifted slightly laterally, the US probe is placed sagittal at the upper corner of the spina scapula, and the serratus posterior superior muscle is visualized with the third rib. The in-plane technique will be used. The block needle will be advanced in the craniocaudal direction to enter between the serratus posterior superior and the third rib. The block location will be confirmed by injecting 5 ml of saline between the rib and the muscle. After the block location is confirmed, 30 ml of 0.25% concentration bupivacaine will be used.
223779517|NCT06866054|DRUG|Postoperative analgesia management|Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. A patient-controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol including 10 mcg bolus without infusion dose, 10 min lockout time, and 4-hour limit. If the NRS score is ≥ 4, 0.5 mg kg-1 iv meperidine will be administered as a rescue analgesic. Postoperative patient evaluation will be performed by an anesthesiologist blinded to the procedure.
223779518|NCT06230367|BEHAVIORAL|Sexual health advocacy for guys|5 month HIV prevention program delivered via text messaging
223779519|NCT06230367|BEHAVIORAL|Healthy lifestyle control|5 month control group program delivered via text messaging
223779520|NCT03586479|BEHAVIORAL|Interactive storybook reading|Children will be taught 30 words prior to, during, and after reading a commercially available storybook by an adult.
223779521|NCT00756509|DRUG|Nilotinib|800 mg/d orally
223779522|NCT06405230|BIOLOGICAL|Pembrolizumab|Pembrolizumab will be administered.
223779523|NCT06405230|BIOLOGICAL|Dostarlimab|Dostarlimab will be administered.
223779524|NCT06405230|DRUG|Pemetrexed+ (carboplatin or cisplatin)|PBCD consisting of pemetrexed+ (carboplatin or cisplatin) will be administered.
223779525|NCT05089656|GENETIC|OAV101|Gene therapy
223779526|NCT05089656|PROCEDURE|Sham control|The sham procedure will consist of a small needle prick on the lower back at the location where the LP injection is normally made. The needle will break the skin, but no needle insertion for lumbar puncture will occur.
223779527|NCT06304337|DEVICE|New oropharyngeal airway group|Oropharyngeal airwayIt is composed of nasal plug, bite mouth, oropharyngeal passage, oxygen supply tube, rope and optional accessories carbon dioxide gas catheter and carbon dioxide collection tube.For patients undergoing endoscopic surgery/examination to prevent airway obstruction caused by backtongue fall, establish oropharyngeal airway for patients, and provide nasal oxygen at the same time, JK model can monitor oropharyngeal end-expiratory carbon dioxide collection.
223695667|NCT06061731|DRUG|low-frequency acupoint electrical stimulation|In order to determine the efficacy of low-frequency acupoint electrical stimulation and electroacupuncture to improve thumb to finger action after stroke
223695668|NCT06202690|PROCEDURE|Single-port robotic-assisted thoracic surgery|"All patients : 145 patients Single-port anatomical pulmonary resection(segmentectomy, lobectomy) with a complete mediastinal lymph node dissection will be performed using the SP robotic system.~A 4-cm single incision will be made below the subcostal margin. A chest tube will be inserted in same incision."
223779528|NCT05147103|DEVICE|Low-Intensity Focused Ultrasound|LIFU application using various durations, responses of neuromodulation recorded using TMS and EMG.
223779529|NCT06939816|DRUG|Vonafexor low dose|Oral tablets
223779530|NCT06939816|DRUG|Vonafexor high dose|Oral tablets
223779531|NCT06663033|PROCEDURE|colorectal surgery|surgery for colorectal cancer
223779532|NCT04832763|PROCEDURE|Biospecimen Collection|Undergo collection of blood sample
223779533|NCT04832763|OTHER|Medical Chart Review|Review of medical charts
223779534|NCT04832763|OTHER|Physical Performance Testing|Undergo physical function testing
223779535|NCT04832763|OTHER|Quality-of-Life Assessment|Ancillary studies
223779536|NCT04832763|OTHER|Questionnaire Administration|Complete questionnaire
223779537|NCT06295549|BIOLOGICAL|LUCAR-G39P cells product|LUCAR-G39P cells product Prior to infusion of the LUCAR-G39P, subjects will receive a conditioning premedication regimen consisting of cyclophosphamide and fludarabine
223779538|NCT05102890|OTHER|ESOGER|For patients in the intervention group, ESOGER will be administered by phone by a member of the clinic team prior to their virtual or in-persons consultation with their primary care provider. ESOGER is already available on an online platform for data entry. Based on feedback our team obtained from interviews with current users of ESOGER, administration of the tool is expected to take between 5 and 10 minutes. A report summarizing the health and social status of the patient along with flagged potential vulnerabilities will be generated automatically by the online ESOGER platform. This report will then be uploaded to the patient's electronic chart by a member of the clinic and made available for the primary care provider at the time of the consultation.
223779539|NCT03059108|PROCEDURE|Early Loading|The procedure in this group will consist on placing implant-supported restorations over the implants placed 4 weeks earlier. The device (dental implant) is of the same type in both groups.
223779540|NCT03059108|PROCEDURE|Conventional Loading|The procedure in this group will consist on placing implant-supported restorations over the implants placed 8 weeks earlier. The device (dental implant) is of the same type in both groups.
223779541|NCT01918995|DRUG|Regadenoson|Intravenous (IV)
223779542|NCT01918995|DRUG|Placebo|Intravenous (IV)
223779543|NCT05382416|BEHAVIORAL|SHARE! Peer Toolkit Training|The SHARE! Peer Toolkit training is designed to improve the performance of peer workers in their provision of peer support. The training covers each of the 12 tools in the Peer Toolkit, which are taught through brief presentations followed by group discussions and interactive exercises to help people competently use each of the tools. Training sessions are typically two hours each, three times per week for 10 weeks.
223779544|NCT02023385|DEVICE|BTL-9000 LLLT|Irradiation of adipocyte cells within the fat layer with BTL-9000 LLLT for the release of fat and lipids from these cells
223779545|NCT02023385|DEVICE|sham BTL-9000 LLLT|Irradiation of adipocyte cells within the fat layer with sham BTL-9000 LLLT for the release of fat and lipids from these cells
223779546|NCT02459067|BIOLOGICAL|ImmuniCell®|Autologous γδ T Lymphocytes
223779547|NCT06272916|DRUG|Aminophylline , magnesium sulphate and placebo|Comparison of the Effect of Aminophylline, Magnesium Sulphate and Placebo in Prevention of Post Dural Puncture Headache in Parturient Undergoing Caesarean Section
223779548|NCT05115162|OTHER|Exercise|The exercises consist of flexibility, strengthening exercises for the trunk and extremities, and walking indoors.The walking program was applied for at least 30 minutes. Eight different exercises were given for the trunk and extremities and these exercises were applied 3 times a week, 2 sets, each set with 10 repetitions.
223779549|NCT05177809|OTHER|Clinical rating scale to measure ataxia disease severity and progression|SARA is a clinical scale developed by Schmitz-Hübsch et al which assesses a range of different impairments in cerebellar ataxia. The scale is made up of 8 items related to gait, stance, sitting, speech, finger-chase test, nose-finger test, fast alternating movements and heel-shin test.
223779550|NCT00206674|DRUG|Sargramostim (Leukine)|6µg/kg SARGRAMOSTIM subcutaneous daily for 8 weeks
223779551|NCT00206674|DRUG|Placebo|Sterile liquid solution, inactive excipient only subcutaneous daily for 8 weeks
223779552|NCT05413187|DRUG|Medical Grade Cannabis oil|MGC, 30% CBD and 1.5% Δ9-THC
223779553|NCT05413187|DRUG|Placebos|Olive oil and Chlorophyl
223779554|NCT06111092|OTHER|Design Thinking|Participants attend the DT session through all the stages that include emphasize, define, ideate, prototype and test.
223779555|NCT06111092|OTHER|Focus Groups|Participants attend the FG that includes the introduction. discussion, and reflection.
223779556|NCT06321718|PROCEDURE|PENG + LFCN block versus S-FICB|1\. Group (A) will receive PENG + LFCN block:
223779557|NCT00483522|BEHAVIORAL|Self-management telephone counseling|Subjects are contacted 7 times in year 1 after discharge from hospital rehabilitation unit and 4 times in year 2. Telephone counseling based on a self-management/problem-solving model is conducted by a research care manager.
223695669|NCT06202690|PROCEDURE|Single-port video-assisted thoracoscopic surgery|"All patients : 145 patients Single-port anatomical pulmonary resection(segmentectomy, lobectomy) with a complete mediastinal lymph node dissection will be performed using the VATS.~A 4-cm single incision will be made at 5th intercostal space. A chest tube will be inserted in same incision."
223779558|NCT00726531|BEHAVIORAL|Otago Exercise Programme|Home based exercise programme (OEP) This exercise programme consists of a 30 minute programme of leg muscle strengthening and balance retraining exercises progressing in difficulty to be performed at home at least three times per week, and a walking plan to be undertaken at least two times per week for 24 weeks. . Trained peer mentors will contact and visit the patients at their home to start the exercise programme with them and will follow-up with up to three more home visits / exercise sessions as the participants require
223695670|NCT05685654|DEVICE|Norbert Device|The Norbert Device (ND) is a contactless, noninvasive device that provides measurements of body temperature, oxygen saturation (SpO2), and pulse rate.
223695671|NCT02001181|DRUG|Tofacitinib ointment 20mg/g|Tofacitinib ointment 20mg/g twice daily (BID) for 4 weeks
223695672|NCT02001181|DRUG|Placebo ointment (Vehicle)|Placebo ointment (vehicle) twice daily (BID) for 4 weeks
223695673|NCT01842815|DEVICE|755 nm alexandrite laser|755 nm alexandrite laser for the treatment of unwanted, non cosmetic, tattoos.
223695674|NCT00292318|BEHAVIORAL|Biofeedback Therapy for Fecal Incontinence: A Randomized Control Study|Patients who have more than one episode per week of fecal incontinence would be enrolled and randomized into either the control group (medical counseling and exercises) or study group (biofeedback therapy, medical counseling, and sphincter exercises) for seven sessions to assist with their medical problem.
223695675|NCT00292318|BEHAVIORAL|control group|Medical counseling and ano-sphinctal exercises.
223695676|NCT05226273|OTHER|no intervention|no intervention
223695677|NCT04017247|DRUG|Oxytocin|Intermittent oxytocin Infusion
223695678|NCT04017247|DRUG|Oxytocin|Continous oxytocin Infusion for 16 hours
223695679|NCT04461288|BEHAVIORAL|Social media-based education, counseling, and support|This six-month intervention is culturally-tailored to sexual and gender minority cigarette smokers. The intervention is group-based and includes daily posts and weekly live sessions during the initial three months. Posts and group sessions focus on tobacco use education, developing a quit plan, as well as managing stress, negative thinking, social support, exercise, as techniques to support cessation.
223695680|NCT04461288|OTHER|Nicotine replacement therapies (NRT)|"Participants will have access to up to six months of nicotine patch therapy. Participants will start on either 21, 14, or 7 mg patches based on manufacturers recommendations based on smoking behaviors.~In addition to nicotine patch, participants will have access to a choice of 2 mg. nicotine lozenges or nicotine gum as an adjunct to patch treatment. Participants will be encouraged to use up to 5 pieces daily to address situational urges and cravings for a cigarette."
223695681|NCT04461288|OTHER|Gamification|Gaming elements designed to encourage participation in the program and behavior change.
223695682|NCT04560790|DRUG|BD111 Adult single group Dose|3-6 Participants will receive a single group dose administered via corneal injection in the study eye.
223695683|NCT05255029|DEVICE|POD T 49P implantation experimental|The investigational lens will be implanted within the capsular bag after removal of the natural crystalline lens following phacoemulsification and alignment the toric axis of investigational lens to the intend axis which was calculated by the Toric calculator software. When enroll the test lenses into both eyes, the lens is implanted first to the eye with more advanced cataract. If both eyes have a similar degree of cataract, perform the surgery first for the right eye. The timing of surgery the investigational lens into the fellow eye will be determined after the investigator and the investigator (hereinafter referred to as the investigator) have confirmed the safety of the previously operated eye.
223695684|NCT00013468|PROCEDURE|Tinnitus|
223695685|NCT05080907|OTHER|Observational|Subjects for observational study Various conditions \& healthy subjects
223695686|NCT00771316|DRUG|MK0826 (ertapenem)|A single dose of 1.0g IV infused over a 30 minute interval at hour 0
223695687|NCT00771316|DRUG|Comparator: meropenem|500 mg IV infused over a 30 minute interval at hours 0, 8, and 16 for at least 4 days
223695688|NCT02526901|OTHER|No intervention|
223695689|NCT02055807|OTHER|PEEP and recruitment maneuvers|
223695690|NCT02055807|OTHER|ZEEP (no PEEP nor recruitment maneuver)|
223695691|NCT02027376|DRUG|LDE225|
223779559|NCT00726531|BEHAVIORAL|Fame|Community based exercise programme (FaME) FaME includes and extends the OEP. It will comprise one hour PSI delivered group exercise class in a local community centre for a maximum of 15 participants, and two 30 minute home exercise sessions (based on the extended OEP) per week for 24 weeks. Participants will also be advised to walk at least twice per week for up to 30 minutes at a moderate pace.
223779560|NCT00726531|OTHER|Treatment As Usual|Treatment as usual by the general practitioner
223779561|NCT00734305|DRUG|MM-121|Dose escalation Frequency - once weekly
223695692|NCT02027376|DRUG|Docetaxel|
223695693|NCT04148820|DRUG|Aspirin, Atorvastatin, Perindopril|Cardiovascular drugs will be administered all together every day at the same time
223695694|NCT05475613|PROCEDURE|Downstaging procedures containing immunotherapy|Anti-PD-1 inhibitor will be given every 3-4 weeks intravenously according to the manufacturer's instruction. Other combination regimens, such as locoregional therapies or targeted therapies will be given to patients according to the protocol decided by the multidisciplinary team of Centers.
223695695|NCT05475613|PROCEDURE|Liver transplantation|Patients with successful downstaging therapy at the end of the observation phase will enroll and undergo liver transplantation unless major medical or oncological contraindications should occur during the waiting phase.
223695696|NCT05616715|DEVICE|Peek device|Participants with gummy smile will be recruited from the Dental Clinic of Instituto Universitário Egas Moniz
223695697|NCT05616715|OTHER|Crown lengthening/gingivectomy|Participante with gummy smile will be recruited from the Dental Clinic of Instituto Universitário Egas Moniz
223695698|NCT00540098|DRUG|paroxetine + aerobic exercise|paroxetine, 40 mg once daily + regular aerobic exercise
223695699|NCT00540098|DRUG|Paroxetine + relaxation|paroxetine, 40 mg once daily + regular relaxation training
223695700|NCT00540098|DRUG|Placebo + aerobic exercise|placebo pill once daily + regular aerobic exercise
223695701|NCT00540098|DRUG|Placebo + relaxation|placebo pill once daily + regular relaxation training
223695702|NCT03442283|DIETARY_SUPPLEMENT|Vitamin mineral supplementation|supplementation with a vitamin or mineral: vitamin A, β-carotene, B1, B2, B3 (niacin), B6, B10 (folic acid), C, D and E, calcium, iron, zinc, magnesium and selenium. Also, multivitamins, antioxidants, B-complex and the combination of calcium and vitamin D.
223695703|NCT04539145|DEVICE|Chocolate PTA Balloon|Chocolate PTA Balloon
223695704|NCT04539145|DEVICE|conventional balloon angioplasty|conventional bal-loon angioplasty
223695705|NCT03540043|DRUG|Administration of Placebo|Botanical Drug Phase 2 clinical study
223695706|NCT03540043|DRUG|Administration of PUR0110 (Thykamine) 0.05%|Botanical Drug Phase 2 clinical study
223695707|NCT03540043|DRUG|Administration of PUR0110 (Thykamine) 0.1%|Botanical Drug Phase 2 clinical study
223695708|NCT03540043|DRUG|Administration of PUR0110 (Thykamine) 0.25%|Botanical Drug Phase 2 clinical study
223695709|NCT02815774|DRUG|SP2086|all subjects were given SP2086 50mg only one time.
223695710|NCT05449522|DIETARY_SUPPLEMENT|Vitamin D|High dose of vitamin D with 576,000 IU on the 3rd post-trauma day and 432,000 IU on the 10th post-trauma day (1,008,000 IU in total) is given orally or enterally via a feeding tube
223695711|NCT05449522|DIETARY_SUPPLEMENT|Placebo|Medium-chain triglyceride (MCT)
223695712|NCT02186366|OTHER|Abdominal Massage Therapy|Abdominal Massage Therapy , 30 minutes, three times one week for 6 weeks. If the subjects have recovered in the treatment of 6 weeks, we can end treatment early.
223695713|NCT02186366|DRUG|Buspirone|Buspirone by mouth 5mg three times per day for 6week. If the subjects have recovered in the treatment of 6 weeks, we can end treatment early.
223695714|NCT04169100|DRUG|Prednisone|We propose to test whether QT prolongation is reversible with moderate doses of prednisone in patients with QT interval greater than 500 msec.
223695715|NCT03606395|DRUG|NV-5138|single ascending dose
223695716|NCT03606395|DRUG|Placebos|Placebo liquid solution to mimic NV-5138
223695717|NCT03979430|OTHER|Home spirometry|Patients will receive a tablet and a spirometer for daily home spirometry. Each patient is supposed to do the home spirometry at the same time every morning. The spirometer and the tablet are connected via Bluetooth. Data will be transferred to a webpage, which team members have access to. Alerts will be automatically send to team members, if the FVC-value decreases about 5% or more within three consecutive days or if the patient does not do the measurement on three consecutive days. Study period is one year. Patients will also conduct a survey to measure health related quality of life (K-BILD). This questionnaire, as well as a phone interview to record changes in medication and condition will be conducted at baseline and every 4 weeks. At baseline and after 3, 6, 9, and 12 months, patients will conduct a 6 minutes walking test, lung function test, blood will be drawn for biomarker analysis, and sputum, nasal swab, and urine samples will be collected and analyzed.
223695718|NCT03280095|DRUG|co-codamol 15mg/500mg capsule|
223695719|NCT03280095|DRUG|co-codamol 30mg/500mg tablet|
223695720|NCT05589272|OTHER|Active tDCS|cognitive training + active-tDCS tDCS twice a day (two 13 minute sessions per day, each 2mA / 25cm² = 0.08 current density; anode on left dorsolateral prefrontal cortex F3, cathode on right dorsolateral prefrontal cortex F4) for five consecutive days.
223695721|NCT05589272|OTHER|Sham tDCS|cognitive training + sham-tDCS tDCS twice a day (two 13 minute sessions per day, each 2mA / 25cm² = 0.08 current density; anode on left dorsolateral prefrontal cortex F3, cathode on right dorsolateral prefrontal cortex F4) for five consecutive days.
223695722|NCT04568993|PROCEDURE|Proximal phalangeal level|Injection of methyl prednisone and lidocaine in the tendon sheet at the level of the proximal phalanx
223695723|NCT04568993|DRUG|Volar to the MCP-joint|Injection of methyl prednisone and lidocaine in the tendon sheet volar to the MCP-joint
223695724|NCT00843726|RADIATION|Arm 1 stereotactic body radiation therapy|Patients undergo 1 high-dose fraction
223695725|NCT00843726|RADIATION|Arm II stereotactic body radiation therapy|Patients undergo 3 high-dose fractions
223695726|NCT01863238|OTHER|Ophthalmologic examinations|Subjects will undergo an ophthalmologic examination at study entry (Day 1) and every 6 months thereafter for 2 years (Months 6, 12, 18, and 24). Subjects who discontinue treatment with commercially-available ivacaftor for any reason and are willing to continue participation in the study will complete the study.
223695727|NCT01863238|DRUG|Ivacaftor Exposed|
223695728|NCT01498328|DRUG|Bevacizumab|A vascular endothelial growth factor (VEGF)-specific humanized monoclonal antibody angiogenesis inhibitor. Infusions of 10 mg/kg of bevacizumab will begin on day 1 and will be administered every two weeks until progression of disease or intolerance during the treatment period.
223695729|NCT01498328|DRUG|Rindopepimut (CDX-110) with GM-CSF|Rindopepimut/GM-CSF will initially be given three times, two weeks apart, followed by monthly injections until tumor progression or intolerance. Each dose will be 0.8 mL containing approximately 500 mcg CDX-110 and 150 mcg GM-CSF.
223695730|NCT01498328|DRUG|KLH|KLH will initially be given three times, two weeks apart, followed by monthly injections until tumor progression or intolerance. Each dose will be 0.8 mL containing approximately 100 mcg of KLH.
223695731|NCT04595604|PROCEDURE|Trimodal rehabilitation + ERAS|Prehabilitation will cover a range preoperative education and exercises (weekly) on diet, physical activity (daily walking), respiratory training (forced deep inspiration with spirometer device), as well as anxiolytic group psychotherapy.
223695732|NCT04595604|PROCEDURE|ERAS + nutritional prehabilitation|Enhanced Recovery Program, including preoperative 4 weeks nutritional supplementation.
223779562|NCT06197139|DRUG|[177Lu]Lu-XT117|\[177Lu\]Lu-XT117 is a radiopharmaceutical therapy in which an beta emitter, Lu-177, is conjugated to XT117. Patients will receive \[177Lu\]Lu-XT117 administration at an interval of 6 weeks between each dose.
223779563|NCT00512759|DRUG|Goal-directed preload and afterload decrement|Early goal-directed preload and afterload decrement with a target systolic blood pressure (RR) of 90-110 mmHg for the entire hospitalization using sublingual nitrates (Nitroglycerin Streuli®) or nitrospray (Corangin Nitrospray®) transdermal nitrates (Nitroderm TTS 10®), ACE-inhibitors (Triatec®) and/or ARB (Atacand®).
223779564|NCT04790253|RADIATION|Prophylactic cranial irradiation|Prophylactic cranial irradiation (PCI) is a technique used to combat the occurrence of metastasis to the brain in highly aggressive cancers that commonly metastasize to brain, most notably small-cell lung cancer.
223695733|NCT05603663|GENETIC|Informing study subjects about their high CVD polygenic risk score|During a visit, the family physician will announce the value of the subject's polygenic risk for CVD (either at the start or end of the trial, depending on the group) and discuss what it means, calculate the subject's overall risk for CVD using the Kardiokompass tool, advise the subject on weight loss and physical activity, and, if necessary, commence preventive treatment. Between visits, a mobile application will be utilized to collect data about the subjects' level of physical activity and body weight as well as to send reminders to the subjects every two weeks regarding exercise and healthy lifestyle choices.
223695734|NCT02134197|DRUG|Lupartumab Amadotin (BAY1129980)|Starting dose is 0.15mg/kg intravenous (I.V.) administration every 21 days.
223695735|NCT03161132|DRUG|Olaparib|Combination of continous olaparib 300mg for oral administration plus Pegylated Liposomal Doxorubicin (PLD), followed by maintenance treatment further described.
223695736|NCT03161132|DRUG|Pegylated Liposomal Doxorubicin|PLD 40mg/m2 every 28 days intravenous
223695737|NCT01880216|DRUG|Bemiparin sodium|subcutaneous application daily for 7±2 days
223695738|NCT01880216|DRUG|Enoxaparin sodium|subcutaneous for 7±2 days
223695739|NCT00406718|BEHAVIORAL|Med-eMonitor|Participants will use the Med-eMonitor™ device, which is an electronic device that holds up to one month's supply of up to five medications. It is capable of cueing the taking of medication, warning patients when they are taking the wrong medication or taking it at the wrong time, recording side effect complaints, and through modem hookup promptly alerting treatment staff of failures to take medication as prescribed.
223695740|NCT00406718|BEHAVIORAL|PharmCAT|Pharm CAT is a psychosocial intervention using environmental supports such as signs, alarms, checklists, and special medication containers to cue and sequence adaptive behavior in the patient's home environment. This treatment specifically targets adherence to medication, medication education, and orientation for patients with schizophrenia. Participants will receive weekly home visits from a case manager.
223695741|NCT00406718|BEHAVIORAL|Treatment as Usual|Participants receiving standard treatment will keep the Med-eMonitor™ device in their homes throughout the study but will not use its medication reminder function.
223695742|NCT05916560|DRUG|LY3437943|Administered SC.
223695743|NCT03577613|PROCEDURE|Open radical hysterectomy|
223695744|NCT03577613|PROCEDURE|laparoscopic radical hysterectomy|
223695745|NCT03577613|PROCEDURE|Robotically assisted radical hysterectomy|
223695746|NCT06518642|DEVICE|Sooma tDCS portable device - active stimulation|Treatment followed common tDCS protocol upon considering safety and tolerability, comprising five consecutive sessions in five days of 30-minute 2 mA tDCS. We utilized the Soterix Medical tDCS device (Soterix Medical, New York, NY, USA, Model 1x1 tDCS-CT) in the research lab and the Sooma Oy device (Sooma Depression Therapy Comfort, Helsinki, Finland) for patient self-administration.Sooma provided two of their portable tDCS devices for a brief period, including one customized sham device.Due to the limited availability of the Sooma devices, participants were randomly allocated to either the Sooma or. Due to the limited availability of the Sooma devices, participants were randomly allocated to either the Sooma or the Soterix device based on availability during their initial session. A current of 2 mA was applied with the anode positioned left DLPFC, corresponding to area F3 in the international 10-20 system. The cathode (reference electrode) was applied at the right dPLFC, F4.
223695747|NCT06518642|DEVICE|Sooma tDCS portable device - sham stimulation|Sooma provided two of their portable tDCS devices for a brief period, including one customized sham device for effective blinding, distinguishable only by serial number and managed by an external data manager following the randomization sequence.To ensure blinding to the participant and their caregiver, at the beginning of the stimulation sessions, participants receiving both the active and sham stimulation would experience a ramp-up in current from 0 to 2 mA, and then the current would ramp down to 0 mA for participants receiving sham stimulation. Participants were told that they may experience sensations such as tingling, headache, or mild burning during the first 30-60 seconds of the stimulation session but that they may subside afterwards as they got used to it. In other words, participants would not be able to tell if diminishing of side effects were due to habituation (active tDCS) or ramping down of current (sham tDCS).
223695748|NCT06933576|DEVICE|DSOC EyeMAX 11Fr|digital single-operator cholangioscopy using the new EyeMAX™ 11Fr (Micro-Tech Endoscopy, Nanjing, China)
223695749|NCT06930898|BEHAVIORAL|Gamified Mammoverse Platform|A gamified, metaverse-based platform delivering breast health education through story-based tasks, interactive challenges, points, rewards, badges, and virtual incentives.
223695750|NCT06930898|BEHAVIORAL|Standard Mammoverse Platform|A non-gamified version of the Mammoverse platform that provides the same breast health educational content.
223695751|NCT04567823|DIETARY_SUPPLEMENT|Smoothie with microalgae|Smoothie with microalgae I: Chlorella pyrenoidosa, Smoothie with microalgae II: Nannochloropsis salina, Smoothie without microalgae
223695752|NCT01897714|DRUG|Melflufen|
223695753|NCT01897714|DRUG|Dexamethasone|
223695754|NCT03905408|DRUG|50 mL of 50% Glucose|1st dose
223695755|NCT03905408|DRUG|100 mL of 50% Glucose|2nd dose
223695756|NCT03905408|DRUG|150 mL of 50% Glucose|3rd dose
223695757|NCT03905408|DRUG|200 mL of 50% Glucose|4th dose
223695758|NCT06129162|DEVICE|Conventional Syringe|Dental local anesthesia injection is given by conventional syringe by two injection methods inferior alveolar nerve block and buccal infiltration.
223695759|NCT06129162|DEVICE|STA Single Tooth Anesthesia® System.|Dental local anesthesia injection is given by STA device by two injection methods inferior alveolar nerve block and buccal infiltration.
223695760|NCT06129162|DEVICE|Star Pen anesthesia device.|Dental local anesthesia injection is given by Star Pen anesthesia device by two injection methods inferior alveolar nerve block and buccal infiltration.
223695761|NCT06556836|DEVICE|Doppler color and M-Mode ultrasound|A diagnostic test intervention using color Doppler and M-Mode ultrasound will be conducted to localize the catheter within the epidural space and compared with epidurography.
223695762|NCT06556836|DEVICE|Epidurography|An epidurography is an imaging procedure used to visualize the epidural space of the spine. The process involves inserting an epidural catheter, through which a contrast dye is injected. Fluoroscopy or X-rays are then used to capture real-time images of the contrast flow, helping to ensure the catheter's correct placement and to detect any localization anomalies. In this study, the epidurography will be performed in the radiology department by a radiologist and a pain management interventionist.
223779565|NCT06127420|OTHER|coronary physiological indices|Resting distal coronary to aortic pressure ratio, Fractional flow reserve, Resting full-cycle ratio, Coronary Flow Reserve, Microvascular resistance
223779566|NCT01071395|DRUG|Amantadine|Amantadine hydrochloride 300mg daily in three divided doses
223779567|NCT01071395|DRUG|Placebo|Sugar pill given 3 times daily
223695763|NCT05938842|BEHAVIORAL|Online DBT-Mindfulness Intervention|"The whole intervention exists of 10 sessions, one session a week for at least one hour and a half. The session 1 is tailored to address specific issues to people with MS, whereas the sessions 2 to 7 are based on DBT and mindfulness contents, and in sessions 7 to 10 introduced some contents of ACT. The program is based in teaching two different sets what and how (Linehan, 1993). The first skill what, teaches patients to simply observe; in a second level, to describe, which implies the ability to put the name to what one has observed; and in the third, what skill patients learn to fully participate in their actions in the current moment and without self-consciousness (Soler et al., 2012). In the other hand, the skills of how are related to how observe, how to describe and how to participate. Moreover, some mindfulness skills such as Observing the breath, Half-smiling, Awareness are practice introduced as homework tasks."
223695764|NCT05938842|BEHAVIORAL|Online psychoeducational intervention|The active control group intervention will be based on a psycho-educational framework and will involve MS-related topics (Oz \& Oz, 2020). The psychoeducational intervention will be conducted by a psychologist with experience in working with pwMS through group videoconference and will follow similar format as the DBT-Mindfulness intervention, except for the homework tasks. The participants will receive information about different aspects related to the disease (e.g., disease progression, disease-symptoms, stress management, nutrition, sleep hygiene, physical activity, social relationships). The content of the sessions of the psychoeducation program was created based on the current literature about MS. Similar psychoeducational programs were used in other studies before (Oz \& Oz, 2020; Dowd et al., 2015).
223695765|NCT03102333|DEVICE|Variable-rate Feedback Infusion mode|The PCA regimen consisted of fentanyl 20 μg/kg and Ramosetron Hcl 0.3 mg (total volume including saline: 100 ml) and was programmed to deliver 1 ml /h as a background infusion and a bolus of 1.5 ml on-demand, with a 15 min lockout time. It can increment or decrement rate(0.2ml/hr) by press bolus button during a 48 h period
223779568|NCT01539291|DRUG|Idelalisib|Idelalisib tablet(s) administered orally twice daily
223779569|NCT02365051|BEHAVIORAL|Care of Persons with Dementia in their Environments|In-home visits by occupational therapist and advanced practice nurse.
223779570|NCT00738842|DRUG|AZD6140|Oral tablets taken bid for 5 days
223779571|NCT00738842|DRUG|Placebo to match AZD6140|Oral tablets taken bid for 5 days
223779572|NCT05422118|DIAGNOSTIC_TEST|ascitic fluid calprotectin|ascitic fluid calprotectin
223779573|NCT01698060|BIOLOGICAL|ND1.1|
223779574|NCT01946711|DRUG|Budesonide|Inhalation
223779575|NCT01946711|DRUG|Budesonide|Nasal spray
223779576|NCT02239510|DRUG|Senna|1 capsule (50 mg) Senna daily for 12 weeks
223779577|NCT02239510|DRUG|Linzess|1 capsule (145 mcg) of Linzess once daily for 12 weeks
223779578|NCT04987918|DIAGNOSTIC_TEST|Applied Biosystems TaqPath COVID- 19 Combo Kit|Reverse Transcriptase Polymerase Chain Reaction (RT-PCR)
223779579|NCT02607579|DRUG|Exparel|
223779580|NCT02607579|DRUG|Ropivacaine|
223779581|NCT02398097|BIOLOGICAL|Agripal|2011/2012 influenza season standard dose trivalent subunit inactivated intramuscular vaccine, single dose
223779582|NCT02398097|BIOLOGICAL|IDflu9μg|2011/2012 influenza season reduced-content intradermal split vaccine, single dose
223779583|NCT02398097|BIOLOGICAL|IDflu15μg|2011/2012 influenza season standard-content intradermal split vaccine, single dose
223779584|NCT06398353|OTHER|Real acupuncture|Real acupuncture twice a week for two weeks
223779585|NCT06398353|OTHER|Sham acupuncture|Sham acupuncture twice a week for two weeks
223779586|NCT01787604|PROCEDURE|Aortic Root Reimplantation Procedure|Modified Florida Sleeve.
223779587|NCT01787604|PROCEDURE|Aortic Valve Reimplantation Procedure|David I
223779588|NCT03773744|DRUG|Ad-MAGEA3|Adenovirus vaccine expressing Melanoma-associated antigen 3 (MAGEA3), a tumor antigen
223779589|NCT03773744|DRUG|MG1-MAGEA3|MG1 Maraba oncolytic virus expressing Melanoma-associated antigen 3 (MAGEA3), a tumor antigen
223779590|NCT03773744|DRUG|Pembrolizumab|monoclonal antibody; checkpoint inhibitor of PD1
223779591|NCT03773744|DRUG|Cyclophosphamide|low-dose chemotherapy
223779592|NCT06326801|OTHER|Resistive Diaphragmatic breathing exercise|"1. Resistive Diaphragmatic breathing exercise~2. Pursed lips breathing exercise~3. Conventional stroke physiotherapy"
223779593|NCT06326801|OTHER|Diaphragmatic breathing exercise|"1. Diaphragmatic breathing exercise~2. Pursed lips breathing exercise~3. Conventional stroke physiotherapy"
223779594|NCT06326801|OTHER|Conventional stroke physiotherapy|Conventional stroke physiotherapy
223779595|NCT06300008|DRUG|cetylated fatty acid|use approximately 3 cm long of cream per each side of knee, then apply on the operated knee until completely absorb
223779596|NCT06300008|DRUG|Placebo|use approximately 3 cm long of cream per each side of knee, then apply on the operated knee until completely absorb
223779597|NCT02239718|PROCEDURE|2-unit cantilevered resin bonded bridge|Use one tooth as abutment tooth to replace one adjacent missing tooth
223779598|NCT02239718|PROCEDURE|3-unit fixed movable resin bonded bridge|Use teeth from both side of the missing tooth space to replace a tooth. The prosthesis is cast in two piece and connected with a fixed-movable joint (semi-precision, allow degree of movement).
223779599|NCT01198080|BIOLOGICAL|CD133+ cells|bone marrow derived CD133+ cells injection with core compression
223695766|NCT03102333|DEVICE|Constant-rate Infusion mode|The PCA regimen consisted of fentanyl 20 μg/kg and Ramosetron Hcl 0.3 mg (total volume including saline: 100 ml) and was programmed to deliver 1 ml /h as a background infusion and a bolus of 1.5 ml on-demand, with a 15 min lockout time during a 48 h period
223695767|NCT00423722|DRUG|Saline|1,000 ml of normal saline (0.9% sodium chloride) parenterally over 4 hours daily.
223695768|NCT00423722|DRUG|Saline|100 ml of normal saline (0.9% sodium chloride) parenterally over 4 hours daily.
223695769|NCT05922111|DEVICE|cervical ripening balloon for one hour|The cervical ripening balloon will be left in place for one hour and after balloon removal the induction of labor will proceed at the discretion of the attending physician at labor and delivery room
223695770|NCT05922111|DEVICE|cervical ripening balloon for twelve hours|The cervical ripening balloon will be left in place for for twelve hours and after balloon removal the induction of labor will proceed at the discretion of the attending physician at labor and delivery room
223695771|NCT06354062|BEHAVIORAL|Talent management intervention program|Talent management intervention program
223695772|NCT00293527|DRUG|Interferon Alpha-2b|
223695773|NCT04205708|DIAGNOSTIC_TEST|Tuberculosis test|Tuberculosis (TB) test: A blood sample is collected for lab testing to determine if you have tuberculosis (QuantiFeron test). Alternatively, the test is done by injecting a small amount of fluid (called tuberculin) into the skin on the lower part of the arm. A person given the tuberculin skin test must return within 48 to 72 hours to have a trained health care worker look for a reaction on the arm.
223695774|NCT04205708|DIAGNOSTIC_TEST|Chest X-ray|Chest X ray: non-invasive medical test that helps physicians diagnose and treat medical conditions of the lungs and chest. The Chest X-ray will be done to check for abnormalities on the lungs. The test is non-invasive.
223695775|NCT04205708|DIAGNOSTIC_TEST|Pulmonary Function Test|A pulmonary function test (PFT, spirometry) is a breathing test that measures how much air your lungs can hold as well as how hard and fast you can blow air out of your lungs. The test is not invasive and involves blowing into a machine.
223695776|NCT06204978|DIETARY_SUPPLEMENT|short-chain fructo-oligosaccharides (dose 1)|10 g / day at breakfast during 7 days (Day 8 - Day 14)
223695777|NCT06204978|DIETARY_SUPPLEMENT|short-chain fructo-oligosaccharides (dose 2)|20 g / day at breakfast during 7 days (Day 8 - Day 14)
223695778|NCT06204978|OTHER|Baseline|0 g / day of short-chain fructo-oligosaccharides during 7 days (Day 1 - Day 7)
223695779|NCT05578079|OTHER|Music|"Intervention-1 group will listen to the classical music that the Arts of Fugue by Bach."
223695780|NCT05578079|OTHER|Music|Intervention-2 group will listen to lullaby.
223695781|NCT02604056|BEHAVIORAL|Audit + Feedback|Online Audit + Feedback practice reports detailing prescribing performance for this class of medication for each prescriber in the nursing home. (Details: http://www.hqontario.ca/Quality-Improvement/Practice-Reports/Primary-Care)
223695782|NCT02604056|BEHAVIORAL|Audit + Feedback + Educational Outreach|"The Educational Outreach program will be delivered by academic detailers, health professionals (often nurses or pharmacists) who have received specific intensive training to support prescribing providers in a particular environment, in this case long-term care homes, to make the best or appropriate clinical decisions as possible. It is defined as: an innovative method of service-oriented educational outreach for front-line clinicians. It combines the interactive, one-on-one communication approach of industry detailers with the evidence-based, non-commercial information of academia. The Educational Outreach will be delivered in addition to online Audit + Feedback practice reports, which detail prescribing performance for this class of medication for each prescriber in the nursing home."
223695783|NCT03507231|BEHAVIORAL|Email Message|Participants will randomly receive an e-mail message about the availability of free flu vaccines.
223695784|NCT03507231|BEHAVIORAL|Incentive for Vaccination|$5 gift card offered for vaccination
223695785|NCT03507231|BEHAVIORAL|Incentive for completing a short survey|$5 gift card offered for completing s short survey after one gets vaccinated
223695786|NCT02746172|DEVICE|Cochlear implant with in-situ audiometry|
223695787|NCT05509270|BEHAVIORAL|Letter|Mailed letter about flu vaccination
223695788|NCT05509270|BEHAVIORAL|Patient portal|Patient portal message about flu vaccination
223695789|NCT05509270|BEHAVIORAL|SMS|SMS about flu vaccination
223695790|NCT00881101|DRUG|Liposomal paclitaxel|All Patients will receive liposomal paclitaxel (starting at a dose of 190mg/m2,3h,ivgtt,at d1)each cycle for 1 cycle.
223695791|NCT02223312|BIOLOGICAL|TAPA-pulsed DC vaccine|A cycle of low-dose cyclophosphamide (100mg/day) by mouth for 5 days starting seven 7 days prior to the DC vaccine cycle to reduce Treg activity. Low-dose cyclophosphamide will be taken every 14 days for six 6 cycles. A total of 6 vaccines containing 1 x 10\^7 TAPA-pulsed DC will be administered SQ every 14 days. The DC vaccine is given on Day 1 of the DCV cycle plus low-dose GM-CSF 50mcg/day SQ x 5 days (Day 1 to Day 4). GM-CSF is administered for 5 days to increase monocyte production and dendritic cell precursors to optimize immune responses.
223695792|NCT04901546|OTHER|Patient's own saliva|Infants with esophageal atresia will be given their own saliva
223695793|NCT00683085|BIOLOGICAL|HLA-A*02:01-restricted VEGFR1-derived peptide vaccination|VEGFR1-derived HLA-A\*02:01-restricted peptide (VEGFR1-A2-770; TLFWLLLTL)was vaccinated twice weekly for 8 weeks (total 16 doses) combined with conventional dose (1,000 mg/m\^2 body surface area) of gemcitabine 6 doses for advanced stage pancreatic cancer to confirm the feasibility and efficacy of this type of peptide.
223779600|NCT03778736|OTHER|Cumulase denudation|Testing the effect of cumulase for women with poor oocyte yield due to poor ovarian reserve
223779601|NCT03859323|DRUG|SHP681|Participants will receive SC injection of SHP681 in the abdomen.
223779602|NCT03859323|OTHER|Placebo|Participants will receive SC injection of placebo matched to SHP681 in the abdomen.
223779603|NCT04286035|DRUG|Bupivacaine Injection|Femoral nerve block with 20 ml %0.375 bupivacaine
223779604|NCT04286035|DRUG|Bupivacaine Injection|Adductor canal block with 20 ml %0.375 bupivacaine
223779605|NCT02343341|BEHAVIORAL|Preschool Health Promotion Education Program|
223779606|NCT00822510|BEHAVIORAL|Telephone Interpersonal Counseling|Telephone delivered 8 week education and counseling intervention based on interpersonal psychotherapy.
223779607|NCT00822510|BEHAVIORAL|Telephone delivered education only|Telephone delivered 8 week educational intervention on prostate cancer health, side effects, physical activity, diet, smoking cessation
223779608|NCT01979926|DRUG|Combination of Broussonetia spp and Lonicera spp|600 mg/ day or 1200 mg/ day for 7 days
223779609|NCT00698529|BEHAVIORAL|Face-to-face training|NGOs will receive the POL intervention through face-to-face training. Staff will receive 2-day training on the POL intervention and individualized telephone follow-up consultations concerning POL implementation.
223779610|NCT00698529|BEHAVIORAL|Distance training|NGOs will receive the POL intervention through Web-based training. Staff will receive training delivered entirely by means of a Web-based, distance learning curriculum and through individualized telephone follow-up consultations concerning POL implementation.
223779611|NCT00698529|BEHAVIORAL|Popular Opinion Leader (POL)|POL is a community-level HIV intervention that recruits and trains opinion leaders in the community to promote safe sex behaviors through risk-reduction conversations with peers.
223779612|NCT02751281|PROCEDURE|Pneumatic percutaneous nephrolithotomy|Pneumatic percutaneous nephrolithotomy is type of surgery that we use pneumatic lithotripter to treat kidney stone
223695794|NCT02876627|BEHAVIORAL|Exercise training|twelve-week aerobic exercise training program consisted of three sessions per week, each session lasting 30 to 60 minutes 50 to 75 percent of their maximum heart rate reserve
223695795|NCT00704912|DRUG|Orlistat/Meal Replacement/Lifestyle Modification|Orlistat will be given at 60 mg three times per day (1 tablet 3 times a day) before meals, i.e., breakfast, lunch, and dinner.
223695796|NCT00704912|DRUG|Loestrin 1/20|Patients will be started on a low dose containing OCP for a continuous 4 month period.
223695797|NCT00704912|DRUG|Combination of treatments|Medications will be administered as described for the other 2 arms.
223695798|NCT01842022|DIETARY_SUPPLEMENT|Isomaltulose|Isomaltulose sweetened meal will be given to each of four groups who differ in their glucose tolerance
223695799|NCT01842022|DIETARY_SUPPLEMENT|Sucrose|Sucrose sweetened meal will be given to each of four groups who differ in their glucose tolerance
223695800|NCT01842022|DIETARY_SUPPLEMENT|Glucose|Glucose sweetened meal will be given to each of four groups who differ in their glucose tolerance
223695801|NCT01846104|BIOLOGICAL|50-μg booster dose RVEc|Subjects will be recruited from the 10 subjects who received three 50-μg doses of RVEc during the Phase 1 trial. Subjects will receive a single booster dose only and will be followed for 6 months after vaccination.
223695802|NCT03094403|DRUG|Azelaic Acid 15% topical gel|Gel
223695803|NCT03094403|DRUG|Finacea® (azelaic acid) Gel, 15%|Gel
223695804|NCT03094403|DRUG|Placebo|Gel
223695805|NCT01262131|DEVICE|magnetic therapy protocol A|Application of magnetic fields using the Resonator device Protocol A
223695806|NCT01262131|DEVICE|magnetic therapy Protocol B|Application of magnetic fields using the Resonator device Protocol B
223695807|NCT01262131|DEVICE|placebo therapy|Application of inactive magnetic fields using the Resonator device
223695808|NCT02930330|BEHAVIORAL|INT|"* 5 min warm-up (40% Pmax\*)~* 30 min high intensity interval training (1 min 100% Pmax, 1 min 20% Pmax, in alternating sequence)~* 10 min cool-down (30% Pmax)~Pmax\*: Maximal power output (Watt) achieved at the end of an incremental exercise test."
223695809|NCT02930330|BEHAVIORAL|CONT|"* 5 min warm-up (40% Pmax\*)~* 30 min moderate intensity continuous training (60% Pmax)~* 10 min cool-down (30% Pmax)~Pmax\*: Maximal power output (Watt) achieved at the end of an incremental exercise test."
223695810|NCT05265416|PROCEDURE|Piezosurgery|Three vertical incisions will be made (3-mm depth and 8-10 mm length) after anesthesia. The cuts will be performed mesial and distal the upper canine as well as at an equal distance from the upper canine and 2nd premolar.
223695811|NCT05265416|OTHER|Low-level laser therapy|GaALAs diode laser (wavelength: 810 nm and exposure time of 10 seconds\\point) will be applied around the upper canine in 10 sites from buccal and palatal.
223695812|NCT05265416|DEVICE|Traditional treatment|The canine retraction in this group will be performed in conventional method. Closed nickel-titanium coil springs applying 150 g of force per side will be used for retraction of the upper canine.
223695813|NCT02983565|DEVICE|Intelligent oxygen therapy system (iO2Ts)|
223695814|NCT05210673|OTHER|ERAS|Preoperative: Preoperative explanation of ERAS. Preoperative medical optimization. Smoking cessation 4-8 weeks before surgery. Nutritional status assessment. Preoperative fasting: 2hours for Clear fluids and water, 6hours for Semi-solid foods and 8 hours for Solid food. Preoperative carbohydrate loading. Pre-anesthetic medication: Avoid long active sedatives. Thromboembolic prophylaxis and Compression stockings Intraoperative: Antimicrobial prophylaxis and skin preparation. Epidural analgesia. Prevention of intraoperative hypothermia. Intraoperative fluid management. Minimize incision. Drain strategy Postoperative: Nasogastric intubation. Early oral intake. Early mobilization. Prevention of postoperative ileus through. Prevention of postoperative nausea and vomiting. Multimodal opioid sparing analgesia. Discharge criteria: Patients have resumed adequate oral intake and normal bowel function, Effective oral pain management and No other clinical or biochemical concerns
223695815|NCT05210673|OTHER|Non ERAS pathway|standard preoperative preparation intraoperative: combined general and epidural anesthesia postoperative standard care
223695816|NCT00851630|DRUG|Fixed dose combination zidovudine/lamivudine/abacavir|All subjects will receive fixed dose combination zidovudine(300 mg) / lamivudine (150 mg) / abacavir (300 mg) by mouth twice daily. Medications will be provided as long as deemed beneficial by the site investigator and study subject for up to two years. Toxicity substitutions are allowed per protocol.
223695817|NCT02260440|DRUG|Pembrolizumab|Pembrolizumab will be given at 200 mg every 21 days
223695818|NCT02260440|DRUG|Azacitidine|Azacitidine will be given at 100 mg daily subcutaneous injection on days 1-5 every 21 days.
223779613|NCT02751281|PROCEDURE|Ultra-sonic percutaneous nephrolithotomy|Ultra-sonic percutaneous nephrolithotomy is type of surgery that we use ultra-sonic lithotripter to treat kidney stone
223779614|NCT00206648|DRUG|Betaferon/Betaseron|Betaseron 250 µg SC every other day
223779615|NCT00206648|DRUG|Betaferon/Betaseron|Avonex 30 µg IM once per week
223779616|NCT04777565|OTHER|Robotic surgery|Cochlear implant surgery with HEARO procedure
223779617|NCT01895504|DEVICE|ColoAssist|Screening colonoscopy with the test instrument
223779618|NCT01895504|DEVICE|MEI|Colonoscopy with Olympus colonoscopes and MEI guidance
223779619|NCT04474184|PROCEDURE|Biospecimen Collection|Receive vaginal kit for biospecimen collection
223779620|NCT04474184|BEHAVIORAL|Focus Group|Attend focus group
223779621|NCT04474184|OTHER|Survey Administration|Ancillary studies
223779622|NCT02959060|DRUG|BMS-986177|Single dose of BMS-986177 and multiple doses of Rifampin
223695819|NCT03940287|OTHER|Muscle Energy Technique|"Muscle energy technique will be given in two different position. For anterior in- nominate rotation and posterior in- nominate rotation patient position will be in supine lying position.~For weakened muscle,piriformis application the patient should be side-lying position, close to the edge of the table, affected side uppermost, both legs flexed at hip and knee.~The therapists stand facing the patient at hip level,then patient should be close enough to the edge of the table for the therapist to stabilize the pelvis against his trunk. The angle of hip flexion should not exceed 60°, and then places one hand on the contralateral ASIS to prevent pelvic motion, while the other hand is placed against the lateral flexed knee as this is pushed into resisted abduction to contract piriformis.~Isometric contraction should be hold for 3-5 second and that particular method will be repeated for 7-10 times."
223695820|NCT03940287|OTHER|Kinesiotape application|"Kinesiotaping will be applied to piriformis muscle and Sacroiliac joint (SIJ). This tape will be applied in I shape to both sides of the spine from sacrum to Anterior Superior Iliac Spine. For SIJ taping same 5 cm KT tape will be used, it will be applied from below posterior sacroiliac spine to opposite side. Here patient should be in standing position.~For Piriformis application patient will be in side lying position where the affected leg will be placed uppermost with hip in flexion, adduction, and internal rotation , then the application will be performed. The base of the tape will be placed over contralateral part of sacrum and then make a Y strip with no tension will be attached over the greater trochanter of femur."
223695821|NCT03940287|OTHER|Conventional physiotherapy|Hydro-collator pack will be used superior to the affected area for at-least 15 minute to reduce the stiffness. Hydocollator pack will be wrap twice with a thick towel and then it will be placed to the affected part.
223695822|NCT03464578|PROCEDURE|Therapy of proximal humeral fractures (irrespective conservative or operative)|
223779623|NCT02959060|DRUG|Rifampin|Single dose of BMS-986177 and multiple doses of Rifampin
223779624|NCT00359112|DRUG|metformin|
223779625|NCT00359112|DRUG|sulphonylurea|
223779626|NCT00359112|DRUG|Avandamet|
223779627|NCT04916639|DEVICE|Device: Physiomer undiluted seawater nasal spray|"In this study, subjects are asked to adhere to the following dosage during the 3 weeks of the study:~* Nasal wash four times every day~* These washes are to be carried out in each nostril~* By continuously pressing the spray for 3 seconds in each nostril~* Subjects are recommended to distribute the 4 nasal washes as follows:~  * 1st : morning~ * 2nd : midday~ * 3rd : afternoon~ * 4th : evening Subjects will be instructed to maintain daily nasal wash over the 3 weeks study period even in case of earlier nasal symptoms resolution, in order to assess the impact of nasal wash on viral load and other symptoms."
223779628|NCT05820724|DIAGNOSTIC_TEST|PSMA PET scan|Subjects will undergo DCFPyL PET/CT imaging and mpMRI imaging prior to the prostate biopsy. The decision for biopsy targets will be made based on the combination of the findings of mpMRI and PSMA scans. The intervention includes a mpMRI, a PSMA PET scan, and a prostate biopsy.
223779629|NCT05820724|OTHER|No PSMA PET|Subjects will undergo mpMRI imaging prior to the prostate biopsy. These subjects do not undergo a PSMA PET scan prior to the prostate biopsy. The decision for biopsy targets will be made based on the findings of mpMRI. The intervention includes a mpMRI and a prostate biopsy.
223779630|NCT05820724|DRUG|18F- DCFPyl Injection|DCFPyL is a PSMA imaging ligand that was developed to enhance the detection of small lesions in the prostate or other pelvic areas. 18F- DCFPyl Injection will be administered prior to the PSMA PET/CT via an in-dwelling catheter placed in an antecubital vein or an equivalent venous access under the direct supervision of study personnel.
223779631|NCT05117645|DIAGNOSTIC_TEST|Computed tomography|All patients will be examined by multislice CT scanner,Light speed 5X GE 8 detector elements scanner or GE Revolution Evo 128 multidetector elements scanner (GE Healthcare, Chicago, Illinois, United state) or Toshibe Alexion 16 detector elements scanner (Aplio 500, Toshiba Medical Systems, Otawara-shi, Tochigi 324-8550, Japan). Axial scanns will be done commences at 1 cm above the diaphragm and ending at lesser trochanters then coronal and sagittal reconstruction images will be exposed.
223779632|NCT03794089|BEHAVIORAL|Brief anxiety intervention|Modular anxiety intervention, tailored for Veterans, with emphasis on adaptive coping skills
223779633|NCT03794089|BEHAVIORAL|Usual PC-MHI care|Anxiety treatment with mental health provider in local primary care clinic
223779634|NCT03985423|DRUG|Emapalumab-Lzsg|Patients were administered Emapalumab-Lzsg by intravenous (i.v.) infusion over a period of 1 to 2 hours, at an initial dose of 6 mg/kg and continued at 3 mg/kg, every 3 days for the first 2 weeks (Study Day \[SD\] 15), and then twice-a-week. If the treating physician deemed appropriate, the dose of emapalumab could be increased (up to 10 mg/kg), guided by clinical and laboratory response.
223779635|NCT02754635|OTHER|Induction of labour|Induction of labour
223779636|NCT02754635|OTHER|Expectant management|Expectant management
223779637|NCT02562755|BIOLOGICAL|Pexastimogene Devacirepvec (Pexa Vec)|Pexa-Vec is a vaccinia virus based oncolytic immunotherapy designed to stimulate the immune system following infection and replication within tumor cells.
223779638|NCT02562755|DRUG|Sorafenib|"Sorafenib belongs to the pharmacotherapeutic group of antineoplastic agents, protein kinase inhibitors, ATC code: L01XE05.~Sorafenib is a multi-kinase inhibitor which has demonstrated both anti-proliferative and anti-angiogenic properties in vitro and in vivo.~Sorafenib is approved for the treatment of advanced HCC and is the Standard Of Care for this disease."
223779639|NCT02034578|DRUG|Apixaban|
223779640|NCT06264440|DRUG|BIIB122|Administered as specified in the treatment arm.
223779641|NCT06264440|DRUG|Rabeprazole|Administered as specified in the treatment arm.
223779642|NCT01822860|DRUG|Chlorthalidone 12.5 mg|
223779643|NCT01822860|DRUG|Hydrochlorothiazide 25 mg|
223779644|NCT01822860|DRUG|Placebo|
223779645|NCT03419169|DEVICE|Light load BFR resistance training|A novel training light load resistance training modality.
223779646|NCT03419169|PROCEDURE|Heavy load resistance training|A common form of resistance training used for rehabilitation within the National Health Service.
223779647|NCT02405715|DRUG|Oxytocin nasal spray or placebo|
223779648|NCT03873649|OTHER|Bronchoscopy with lavage|"Bronchoscopy will be performed according to standard clinical procedures. Bronchoscopy will be performed under conscious sedation with continuous cardiopulmonary monitoring and the subject's upper airway will be anesthetized with topical lidocaine. The bronchoscope will be passed through the naris or mouth to the upper airway and then into the lower airway. 360cc of sterile saline will be instilled into 2 sub-segments by instilling and aspirating 3 aliquots of 60cc sequentially into each sub-segment.~Venipuncture to obtain peripheral blood mononuclear cells (PBMCs) for the proposed assays.~Cells collected will be analyzed for various T-cell subsets and gene expression to help determine the type of immune response."
223779649|NCT03049124|BEHAVIORAL|Exercise|Participants will engage in supervised exercise 3 times per week for 60-75 minutes/session for 12 weeks. Sessions will include a warm-up (aerobic activity less than \< 60% of heart rate reserve), aerobic training (30 minutes of exercise at 60-75% of heart rate reserve, using cycle ergometers/treadmills), strength training (8 exercises; upper body, lower body, and core), and a cool-down (aerobic activity less than \< 60% of heart rate reserve) component.
223779650|NCT01045447|DRUG|insulin degludec/insulin aspart|Treat-to-target dose titration scheme, injected subcutaneously (under the skin) once daily with main meal. Dose was individually adjusted.
223779651|NCT01045447|DRUG|insulin glargine|Treat-to-target dose titration scheme, injected subcutaneously (under the skin) once daily. Dose was individually adjusted.
223779652|NCT03157986|OTHER|Balance Training on a vibration platform|n=24 patients with severe chronic obstructive pulmonary disease. Exercises will be performed on a side-alternating Vibration platform (Galileo) at frequencies between 15 to 26 Hertz.
223779653|NCT03157986|OTHER|Conventional Balance training|n=24 patients with COPD, Exercises will be performed on a Balance pad
223779654|NCT04133610|DIAGNOSTIC_TEST|Self-sampling using digene HC2 DNA Collection Device|All women will undergo a clinician-collected cervical swab and self-collected cervicovaginal swab.
223779655|NCT04133610|DIAGNOSTIC_TEST|Self-sampling using Evalyn Brush|All women will undergo a clinician-collected cervical swab and self-collected cervicovaginal swab.
223779656|NCT05372445|BEHAVIORAL|Non-intensive intervention|"After an evaluation of 7 day initial food-recall, subjects will receive counseling in order to improve their dietary habits, according to the American Diabetes Association 2019 Guidelines. The goals of this intervention are (i) achieve a caloric restriction of 500 kcal from their habitual energy intake, (ii) prioritize natural, minimally processed foods with a low glycemic index and glycemic load, (iii) eat lean protein sources, both from plant and animal origin and (iv) gradual increments of fiber intake, to achieve at least the minimum recommendations for the general population.~The frequency of the follow-up appointments will be every 4 weeks, alternating between a clinical control and nutritional one. Therefore, the planned nutritional follow-up frequency will be every 2 months. In these appointments, the objective will be to achieve the mentioned energy intake reduction of 500 kcal, aiming to the nutritional goals previously mentioned, with the aid of the food-recalls."
223779657|NCT05372445|BEHAVIORAL|Intensive intervention|"People will have virtual education with food and nutrition coaching workshops, as well as weekly meetings in small groups as a support and follow-up groups. The frequency of the face-to-face follow-up appointments will be every 3 weeks.~The nutritional intervention will emphasize the consumption of mainly minimally processed food from plant origin. A vitamin b12 supplement per week will be provided. This intervention group will have 2 stages. First stage will have a duration of 3 months setting the nutritional bases going to a plant-based diet with basic considerations regarding fiber intake reducing meat consumption, and incorporating protein from vegetable sources, among other considerations. Second stage will progress to higher levels of fiber and others nutritional requeriments in order to intensify the nutritional plant-based intervention."
223779658|NCT01659918|DRUG|Montelukast|
223779659|NCT01659918|DRUG|Singulair|
223779660|NCT03935386|PROCEDURE|Standard Multi-layered Compression dressing|Compression therapy with a multi-layered compression dressing for the treatment of venous leg ulceration
223779661|NCT03935386|PROCEDURE|Standard Multi-layered Compression dressing with a cryopreserved skin allograft (TheraSkin)|Application of a cryopreserved skin allograft (TheraSkin) beneath compression therapy with a multi-layered compression dressing.
223779662|NCT06535685|DRUG|Romiplostim|Enrolled patients will be given Romiplostim (20 µg/kg subcutaneously once a week) for a minimum of 3 months.
223779663|NCT02181530|OTHER|No Intervention|No treatment (intervention) is being administered as part of this study.
223779664|NCT00826891|DRUG|Cisplatin Combined With Topotecan|"Patients must have specific minimum neutrophil and platelet counts before administration of Hycamtin. The dose of Hycamtin is 0.75 mg/m2 by intravenous infusion over 30 minutes daily on days 1, 2, and 3; followed by cisplatin 50 mg/m2 by intravenous infusion on day 1 repeated every 21 days (a 21-day course).~Dosage adjustments for subsequent courses of Hycamtin in combination with cisplatin are specific for each drug.~Dose levels for cisplatin Initial dose 0 = 50 mg/m2 Dose reduction level -1 = 37.5 mg/m2 Dose reduction level -2 = 25 mg/m2~Dose levels for topotecan Initial dose 0 = 0.75 mg/m2 Dose reduction level -1 = 0.60 mg/m2 Dose reduction level -2 = 0.45 mg/m2"
223779665|NCT00374530|DRUG|PGE2|
223779666|NCT03845257|DIAGNOSTIC_TEST|Blood sampling, FeNO, bronchoalveolar lavage, bronchoscopic tissue sampling|Blood sampling (eosinophil count; eosinophilia is defined as \>300/µl (or \>150/µl during oral glucocorticosteroid treatment); FeNO: Measurement of fractional nitric oxide (NO) concentration in exhaled breath; Bronchoscopy: BAL: total leukocyte counts and leukocyte differential counts including eosinophils, PSB sampling: eosinophil count/100 cells, endobrochial biopsy: tissue eosinophil count/100 cells.
223779667|NCT05006170|DRUG|DTG DT 20 mg|Give 2 tabs of MYLTEGA DT (10mg) PO once daily
223779668|NCT05006170|DRUG|DTG DT 25 mg|Give 2.5 tabs of MYLTEGA DT (10mg) PO once daily
223779669|NCT00803465|DRUG|Fluticasone Propionate 0.05% Cream-Reference Product|Small amount applied and evaluated over the course of two days
223779670|NCT00803465|DRUG|Fluticasone Propionate 0.05% Cream-Test product|Small amount applied and evaluated over the course of two days
223779671|NCT00332748|DRUG|Oral Taxane|
223779672|NCT01141894|OTHER|Goal directed haemodynamic treatment|Treatment by fluids and Dobutamine to attain fixed haemodynamic goal
223779673|NCT01141894|OTHER|Routine fluid treatment|Protocol guided fluid treatment used in the clinical routine
223779674|NCT02279758|DRUG|Metformin|
223779675|NCT02357212|PROCEDURE|coronary angiography|invasive procedure performed to determine coronary anatomy
223779676|NCT02357212|PROCEDURE|adenosine stress test|non-invasive procedure to determine area of cardiac ischemia
223779677|NCT03574168|BIOLOGICAL|CD19-CAR-T Cells|T cells purified from the PBMC of subjects or subjects' relatives which depends on their conditions, transduced with 4-1BB/CD3-ζ lentiviral vector, expanded in vitro for future administration.
223779678|NCT01184066|BEHAVIORAL|ACTS Intervention|ACTS (Attitudes, Communication, Treatment, Support) Intervention is a onetime intensive 45 minute intervention delivered by a black breast cancer survivor and utilizing video, graphics, teaching tools, and supportive testimony to encourage chemotherapy adherence.
223779679|NCT01184066|BEHAVIORAL|Usual Care|Usual Care will consist of standard therapy education by a registered nurse in the treatment center. Education and support from clinicians are offered as needed throughout the course of cancer treatment at all participating medical oncology clinics.
223779680|NCT00129987|BEHAVIORAL|Self management education|
223779681|NCT02684422|OTHER|Intervention N/A. Observational study|There are no interventions to the subjects other than collection of an expectorated sputum since this is an observational study; There are no study groups.See details per detailed study description.
223779682|NCT03257982|PROCEDURE|BCI-FES hand therapy|BCI-FES rehabilitation therapy of the upper limb
223779683|NCT03721380|BEHAVIORAL|Treatment as usual|Patients receive some HIV risk education for the enrollment; after that, health education is delivered irregularly (1-2 times a month or none), based on the patient's needs. During MMT treatment, the participant receives monthly random urine testing for opiate use and HIV testing as needed. Monthly meetings between the patient and physician are expected to occur however, there is no structure to these sessions and content is considered to be quite variable.
223779684|NCT01017406|DEVICE|PSU heel cushion and plantar fascia specific stretching exercise|"* Wear heel cushion during daily activity~* Plantar fascia stretching exercise 3 times per day"
223779685|NCT01244048|DIETARY_SUPPLEMENT|n3 long chain polyunsaturated fatty acids|Group 1 (placebo) Group 2 (0.8 g n3 LC-PUFA/d in 125 g yoghurt) Group 3 (3 g n3 LC-PUFA/d in 200 g yoghurt)
223779686|NCT01735539|DIETARY_SUPPLEMENT|15g EAA bolus|Oral; in aqueous solution
223779687|NCT01735539|DIETARY_SUPPLEMENT|4 x 3.75g Mixed EAA Pulses|Oral; in aqueous solution
223779688|NCT01735539|DIETARY_SUPPLEMENT|15g EAA Bolus supplemented with 3g Arginine|Oral; in aqueous solution
223695823|NCT03484377|DEVICE|Anodal tDCS|The experimental condition will use a constant current of 2mA for 20 minutes, delivered via gradual increase and decrease over 10 seconds at the onset and offset of stimulation (current ramps), respectively.
223695824|NCT03484377|DEVICE|Sham tDCS|The anodal electrode will be placed over the supreorbital ridge. The current will be delivered only in the first 10 seconds, after which the stimulation will cease but with the electrodes still in place throughout the session. The session will last for 20 minutes.
223695825|NCT02349061|DRUG|Ustekinumab IV|Weight-range based dosing of approximately 6 mg/kg of ustekinumab intravenously at Week 0.
223695826|NCT02349061|DRUG|Placebo Infusion|Placebo intravenously at Week 0.
223695827|NCT02349061|DRUG|Placebo SC|Placebo subcutaneously at Weeks 8 and 16.
223695828|NCT02349061|DRUG|Ustekinumab SC|Ustekinumab 90 mg subcutaneously every 8 weeks up to Week 40 and up to Week 104 in study extension (for eligible participants)
223695829|NCT02349061|OTHER|Concomitant Medication|Concomitant treatment (mycophenolate, azathioprine/6-mercaptopurine, methotrexate, hydroxychloroquine and/or chloroquine, oral corticosteroids, NSAIDs, antihypertensive medications, and topical medications) through Week 48, as well as through the study extension although tapering of corticosteroids is encouraged beyond Week 48.
223695830|NCT05500157|PROCEDURE|aspiration sclerotherapy versus laparoscopic fenestration|See arm description
223695831|NCT00398411|DRUG|moxifloxacin|400 mg p.o. per day
223695832|NCT00398411|DRUG|placebo|one tablet per day p.o.
223695833|NCT02772107|DRUG|Temozolomide|Temozolomide is a nonclassic oral alkylating agent. Temozolomide will be given alone as maintenance therapy in patients who have achieved study entry hematologic criteria and who do not have progressive disease or severe toxicity. During temozolomide maintenance therapy, patients will receive temozolomide at 150mg/m2/d for 5 days of a 28-day cycle orally daily. Temozolomide maintenance therapy will continue until progressive disease or irreversible toxicity occurs.
223695834|NCT02772107|DRUG|first-line chemotherapy|first-line chemotherapy must be platinum-based: cisplatin(75mg/m2 for d1) or carboplatin（AUC 5 for d1) combined with etoposide（100mg/m2 for d1-d3）
223695835|NCT02772107|RADIATION|Prophylactic cranial irradiation|Prophylactic cranial irradiation was allowed if necessary
223695836|NCT02772107|RADIATION|thoracic radiotherapy|thoracic radiotherapy was allowed if necessary
223695837|NCT03691155|OTHER|The Crohn's Diet|All recruited participants will be educated on the Crohn's Diet and instructed to adhere to the study diet for 14 days.
223779689|NCT05234294|OTHER|Survey|We will investigate symptoms through monthly surveys.
223779690|NCT00033254|RADIATION|radiation therapy|Undergo conventional radiation therapy
223779691|NCT00033254|DRUG|thalidomide|Given orally
223779692|NCT00033254|PROCEDURE|quality-of-life assessment|Ancillary studies
223779693|NCT06467045|OTHER|Pediatric patients who received sedation for magnetic resonance imaging|Pediatric patients who underwent MRI under sedation will be prospectively observed. All non-intubated patients under the age of 16 will be included in the study. The demographic data, comorbidities, and medications of the patients, the procedures performed, the anesthetic drugs used, the expertise duration of the anesthesiologist, and the adverse effects encountered will be recorded.
223779694|NCT03114254|DRUG|Cabazitaxel|"Six cycles of chemotherapy comprising:~Cabazitaxel 25mg/m2 to be repeated at intervals of 21 days."
223779695|NCT02609243|BEHAVIORAL|dietary consulting|dietary consulting implies specific dietary advice based on pre-interventional self-report regarding food intake; consulting focuses on nutrient content, calory intake, weight loss; with regard to randomisation consulting intensity and content varies
223779696|NCT01577706|DRUG|Alprazolam|Alprazolam, gel-capsule, 1mg, single-dose, 1-day
223779697|NCT01577706|DRUG|Dextroamphetamine|Dextroamphetamine, gel-capsule, 20mg, single-dose, 1-day
223779698|NCT01577706|OTHER|Placebo|Placebo, gel-capsule, single-dose, 1-day
223779699|NCT03859843|COMBINATION_PRODUCT|PRP|Ten mL of venous blood will be drawn in a syringe fill with 1.5 mL of anticoagulant solution (anticoagulant citrate dextrose solution formula A, Baxter, Deerfield, IL). The blood will be centrifuged at 160 g for 10 minutes. After the first spin, the lower red blood cell portion will be discarded, and the supernatant will be centrifuged at 400 g for 10 minutes. The resulting pellet of platelets will be mixed with 1.5 mL of supernatant, which make 1.5 mL of PRP. One mL of 3% calcium chloride will be added to the PRP to induce platelet activation.
223779700|NCT03859843|OTHER|Chemical peeling (Salycilic acid)|SA is a 2-hydroxybenzoic acid (from willow tree) used for superficial peeling due to its strong keratolytic and comedo- lytic properties. It promotes shedding of epidermal cells and due to its lipophilic properties can penetrate comedones and pores to prevent clogging and neutralize bacteria. It promotes desquamation of the upper lipophilic layers of the stratum corneum.19 These chemical properties explain its popularity and success in acne patients.It also has well- documented anti-inflammatory properties.
223779701|NCT03859843|OTHER|Chemical peeling (Jessener's solution)|is a superficial peeling agent used as adjuvant therapy for acne. it is generally proposed to break of the hydrogen bonds of keratin (keratolysis), disruption of cell membranes (cell death) and is bactericidal.
223779702|NCT01952340|DIETARY_SUPPLEMENT|Flaxseed|Milled flaxseed
223779703|NCT01952340|DIETARY_SUPPLEMENT|Placebo|Wheat germ/wheat bran and mixed dietary oils
223779704|NCT02732535|PROCEDURE|sleeve gastrectomy , roux-en-y gastric bypass|laparoscopic sleeve gastrectomy or laparoscopic gastric bypass
223779705|NCT04372966|DEVICE|Total hip arthroplasty|Corail Total hip arthroplasty system, Depuy. Exeter and Contemporary acetabular components, Stryker.
223779706|NCT02980367|OTHER|Non-Surgical Management (Rehabilitation)|Routine ACL rehabilitation protocols used at the participating site will be followed. As part of the site selection process, documentary evidence of the use of or willingness to adopt a rehabilitation protocol that reflects the guidelines of the mandatory aims/goals set for the study rehabilitation intervention will be required.
223779707|NCT02980367|PROCEDURE|Surgical Management (Reconstruction)|All surgical reconstructions will be patella tendon or hamstrings tendon depending on the surgeon's preference. All other care will be routine, including immediate post-operative care.
223779708|NCT01893242|DRUG|Aleglitazar|Aleglitazar 150 mcg oral doses, once a day for approximately 3 years
223695838|NCT02883959|OTHER|music therapy|Music therapy will be delivered through headphones during nursing procedures (toilet and/or surgical dressings): from initiation up to 30 minutes after the end of procedure.
223779709|NCT01893242|DRUG|Placebo|Matching placebo to aleglitazar, once a day for approximately 3 years
223779710|NCT00264615|DRUG|lamotrigine extended-release|
223779711|NCT00116805|DRUG|TDF|300 mg tablet administered orally once daily
223779712|NCT00116805|DRUG|ADV|10 mg tablet administered orally once daily
223779713|NCT00116805|DRUG|TDF placebo|Tablet administered orally once daily
223779714|NCT00116805|DRUG|ADV placebo|Tablet administered orally once daily
223779715|NCT00116805|DRUG|FTC/TDF|200/300 mg fixed-dose combination (FDC) tablet administered orally once daily
223779716|NCT01782131|DRUG|Posaconazole|POS IV: Day 1: 300 mg BID Day 2-84: 300 mg QD POS oral: Day 1: 300 mg BID Day 2-84: 300 mg QD
223779717|NCT01782131|DRUG|Voriconazole|VOR IV: Day 1: 6 mg/kg per body weight administered BID Day 2-84: 4 mg/kg per body weight administered BID VOR oral: Day 1: 300 mg BID Day 2-84: 200 mg BID
223779718|NCT01782131|DRUG|Placebo|Matching placebo received for Posaconazole (IV and oral) or Voriconazole (oral)
223779719|NCT04256551|OTHER|Heali mobile application + Registered Dietitian|The Heali mobile application is a dietary resource validated by RD's which uses AI and ML to scan menus and barcodes to provide individuals with information regarding nutritive content and applicability to one's diet using an overall food score and traffic light system. Users have the ability to choose a number of therapeutic diets including LFD, SCD, GERD, and Lectin Free to name a few, but for this study, the app will be isolated to only the LFD. RDs employed by Heali provide real-time messaging to users. For this study, participants will be given access via cell phone login and password (names will not be used). Participant usage information will be de-identified and automatically sent to excel for study authors to perform statistical analysis.
223779720|NCT04256551|OTHER|Heali mobile application|The Heali mobile application is a dietary resource validated by RD's which uses AI and ML to scan menus and barcodes to provide individuals with information regarding nutritive content and applicability to one's diet using an overall food score and traffic light system. Users have the ability to choose a number of therapeutic diets including LFD, SCD, GERD, and Lectin Free to name a few, but for this study, the app will be isolated to only the LFD. For this study, participants will be given access via cell phone login and password (names will not be used). Participant usage information will be de-identified and automatically sent to excel for study authors to perform statistical analysis.
223779721|NCT04256551|OTHER|Standard Dietary Education|An educational guide to the implementation of the elimination and reintroduction phases of the diet, a suitable/unsuitable food guide, 19 substitutes for unsuitable foods, a guide of example meals (i.e., breakfast-6 recipes, lunch-8 recipes, dinner-12 recipes, and snacks/beverages-13 recipes), and tips for reading labels and eating a balanced diet while following the LFD. The website is located at http://www.myginutrition.com/news.html and operated by the University of Michigan Health System.
223779722|NCT04444154|BEHAVIORAL|Control group|oral hygiene advice given orally in the chair during the bonding appointment and at each check-up appointment.
223779723|NCT04444154|BEHAVIORAL|Group with active participation|oral hygiene advice given orally in the chair during the bonding appointment and at each check-up appointment with a demonstration of brushing methods in the sink with active participation (use of plate developer and then the Oral B electric toothbrush with special orthodontic head) during the bonding appointment as well than at each check-up appointment.
223779724|NCT04444154|BEHAVIORAL|Group with video and quizz|oral hygiene advice given orally in the chair during the bonding appointment and at each check-up appointment with have an additional appointment between the device bonding appointment and the first check-up. This is a 15-minute session dedicated to teaching oral hygiene. This session will include watching of an educational video followed by a quiz, as well as the application of the methods taught in the sink (using plate developer and the Oral B electric toothbrush with special orthodontic head).
223779725|NCT03506516|DIETARY_SUPPLEMENT|Mixing alcohol|Alcoholic beverages, different types
223779726|NCT03506516|DIETARY_SUPPLEMENT|Single type alcohol|Alcoholic beverages, different types
223779727|NCT06025955|PROCEDURE|minimally invasive non- surgical therapy|hand and ultrasonic instrumentation will be done
223779728|NCT06025955|PROCEDURE|open flap debridement|flap surgery will be done
223779729|NCT01772433|DIETARY_SUPPLEMENT|Olive oil|Phonophoresis with Olive oil for 10 day, daily
223779730|NCT01772433|DRUG|Phonophoresis gel|Phonophoresis with base gel for 10 days, daily
223779731|NCT02794493|DRUG|Traditional Chinese Medicine Formula LC09|
223779732|NCT02794493|OTHER|Placebo|
223779733|NCT00919243|DRUG|prednisone|1 mg/kg/day with a maximum dose of 60 mg/day given orally
223779734|NCT00919243|DRUG|allopurinol|allopurinol, the dose of allopurinol is adjusted by patients' renal function, and with a maximum dose of 300mg/day.
223779735|NCT00796718|RADIATION|Standard radiotherapy|Administered as prescribed according to normal clinical practice.
223779736|NCT00796718|DRUG|Capecitabine [Xeloda]|825 milligrams per meter square (mg/m\^2) orally twice daily for 5 weeks.
223779737|NCT03266588|DRUG|Rimegepant|75 mg oral tablet
223779738|NCT03239379|DRUG|BNZ132-1-40|Injectable peptide antagonist of IL-2, IL-9 and IL-15
223779739|NCT03239379|DRUG|Placebo|Normal Saline
223779740|NCT00393926|DEVICE|TheraDrive Assistive Device|
223779741|NCT00393926|PROCEDURE|Rote Therapy versus Fun Therapy|
223779742|NCT04785404|PROCEDURE|primary skin closure|skin will be stitched after stoma reversal to heal by primary intention
223779743|NCT03711981|PROCEDURE|TAP Block|
223779744|NCT04608474|DRUG|Evolocumab|Two different but equivalent drug dosing strategies are available. A 420mg monthly subcutaneous injection using an on-body infuser (Repatha Pushtronex system) or a 140mg subcutaneous injection once every two weeks using a prefilled auto-injector (Repatha SureClick). The choice of dosing strategy will be based on patient preference.
223779745|NCT04608474|DRUG|Statins (Cardiovascular Agents)|Previously prescribed statin therapy.
223779746|NCT00814372|DRUG|MBX-102|capsule
223779747|NCT00814372|DRUG|Placebo|matching placebo
223779748|NCT00814372|DRUG|Actos|over-encapsulated to match MBX-102 and placebo
223779749|NCT00814372|DRUG|Metformin|greater than or equal to 1500 mg/kg day
223779750|NCT01220011|PROCEDURE|Fetoscopic laser surgery|Fetoscopic laser surgery
223779751|NCT06373822|DIAGNOSTIC_TEST|Circulating-mirna|A single blood sample (1 tube of 10 ml) on the day of the patient's visit to the service de Gynécologie of the CUSL.
223779752|NCT02001480|DEVICE|12 lead Holter|12 lead Holter measurements will be performed for 7 days
223779753|NCT02001480|DEVICE|CGM Continuous Glucose Monitoring|CGM will be performed continously for 7 days
223779754|NCT06170008|DEVICE|Physical microstructure-modified transparent silicone film sheet|The main component of the physical microstructure-modified transparent silicone film sheet is transparent silicone rubber, which has a three-dimensional microstructure on its trauma contact surface through physical mechanics treatment, which can provide effective mechanical stimulation for trauma healing. And after testing, the silicone film sheet is breathable, light-permeable, non-toxic and non-allergenic. It is expected to significantly reduce the number of dressing changes, reduce the damage to the wound and the painful stimulation to the patient during dressing changes, and promote the healing of the wound to a certain extent, thus improving the quality of wound repair and saving medical costs.
223779755|NCT06170008|DEVICE|Decellularized pig skin|Decellularized pig skin is an allogeneic trauma covering from pigs and is a commonly used trauma covering for second-degree burn wounds. It adheres to clean superficial wounds, creates a temporary barrier to the wound, reduces wound exudation, limits loss of body components, improves microcirculatory stasis, provides a microenvironment suitable for wound healing, protects inter-ecological tissue, promotes repair and regeneration, and reduces pain. Its disadvantages are: soft structure, difficult to fix the trauma; opaque, unable to observe the trauma; pigskin needs to be stored under suitable temperature and humidity, and has a limited time. When used, decellularized pig skin is directly covered on conventionally treated second-degree burn wounds.
223779756|NCT06170008|DEVICE|Vaseline gauze|Vaseline gauze is the most commonly used conventional dressing for the implant area, which is mainly made of skimmed cotton gauze impregnated with petroleum jelly and paraffin oil, which has a lubricating effect and can promote the growth of granulation and wound healing. However, its moisturizing time is relatively short and requires frequent dressing changes; moreover, petroleum jelly gauze often adheres to the wound surface severely, which may cause bleeding and new epidermal damage during dressing changes and affect the wound healing; the wound surface is constantly oozing blood and fluid, and the dressing cannot be effectively isolated from the outside world after wetting, which increases the chance of infection. Vaseline gauze is applied directly to the post-operative skin grafting wound.
223779757|NCT05659290|DRUG|Fruquintinib alternating with Bevacizumab plus Capecitabine|Maintenance therapy with Fruquintinib 5mg, orally, once daily, d1-14, 2 weeks on/ 1 week off, q3w, followed by Bevacizumab 7.5 mg/kg, iv.gtt,d1,q3w + Capecitabine 850 mg/m2, orally, twice daily, d1-14, q3w; every 6 weeks as a treatment cycle; until unacceptable toxicity, withdrawal of informed consent, death, or other criteria for ending the study (whichever occurs earlier).
223779758|NCT05659290|DRUG|Bevacizumab plus Capecitabine|Maintenance therapy with Bevacizumab 7.5 mg/kg, iv.gtt,d1,q3w + Capecitabine 850 mg/m2, orally, twice daily, d1-14, q3w; every 3 weeks as a treatment cycle; until unacceptable toxicity, withdrawal of informed consent, death, or other criteria for ending the study (whichever occurs earlier).
223779759|NCT04247854|DIETARY_SUPPLEMENT|Bacillus subtilis probiotic|Bacillus probiotic which contains one confidential ingredient of Bacillus subtilis spores (2 x 1010 CFU/g). Over 5 days of interventional period, the patient receives one tablet (250 mg; 5 x 109 CFU) of probiotic per day.
223779760|NCT04247854|OTHER|Placebo|Over 5 days of interventional period, the patient receives 1 placebo tablet per day
223779761|NCT00317772|DRUG|Topotecan|"Phase I Starting Dose: 2 mg/m\^2 by vein Weekly Over 30 Minutes on Days 1, 8, and 15.~Phase II: MTD dose from Phase I by vein weekly on Days 1, 8, and 15."
223779762|NCT00317772|DRUG|Gefitinib|"Phase I: 250 mg by mouth daily for 28 Days.~Phase II: 250 mg by mouth daily for 28 Days."
223779763|NCT04167397|OTHER|Collaborative learning|Participants will be allocated to either single, dyad, triad or tetrad practice during initials skills training on an ultrasound simulator. Afterwards their competencies will be assessed with an individual transfer test on another simulator.
223779764|NCT02359669|BEHAVIORAL|StimuLearn Intervention|"* StimuLearn apps~* Cognitive questionnaires"
223779765|NCT02359669|BEHAVIORAL|Without StimuLearn intervention|Cognitive Questionnaires
223779766|NCT00244244|DRUG|arimoclomol|
223779767|NCT02007486|OTHER|Cardiopulmonary Exercise Testing|Symptom-limited incremental exercise testing (10 watts/min) on an electronically braked cycle ergometer
223779768|NCT00171587|DRUG|PTK787/ZK 222584 (vatalanib)|
223779769|NCT03041415|BEHAVIORAL|ALED Alone Physical Activity Program|• 12-week class focused on teaching self-regulatory skills to increase regular PA
223779770|NCT03041415|BEHAVIORAL|ALED + Our Voice PA Program|"* 12-week class focused on teaching self-regulatory skills to increase regular PA~* Neighborhood assessment, consensus-building, \& advocacy program in which participants are taught skills to promote neighborhood-level changes in support of regular Physical activity"
223779771|NCT00137332|DRUG|GAP-486 (ZP-123)|
223779772|NCT00137332|DRUG|0.9% Sodium Chloride, USP|
223779773|NCT00389714|DEVICE|dental restoration|
223779774|NCT03269032|OTHER|American Diet|"According to National Health and Nutritional Examination Survey (NHANES) data, the nutritional composition of the baseline typical American diet is 50%Carbohydrates, 15% Protein, 35% Fat, \>11% Saturated Fatty Acids, \<12% Monounsaturated Fatty Acids, and \>8% Polyunsaturated Fatty Acids.~Participants will receive 3 meals and 1 snack for each day during the study period."
223779775|NCT03269032|OTHER|Mediterranean-style Diet|"The nutritional composition of the baseline typical Mediterranean-style diet is 46% Carbohydrates/Alcohol (red wine will be included in the Mediterranean diet only), 17% Protein, 32% Fat, \<7% Saturated Fatty Acids, \>18% Monounsaturated Fatty Acids and \<5% Polyunsaturated Fatty Acids.~Participants will receive 3 meals and 1 snack for each day during the study period."
223779776|NCT01169870|DRUG|Genexol-PM|Treatment is given in the outpatient setting. Patients receive treatment every 3 weeks up to 6 cycles.
223779777|NCT01169870|DRUG|Paclitaxel|
223779778|NCT00788554|PROCEDURE|Lichtenstein procedure|open surgical procedure for inguinal hernia correction
223779779|NCT00788554|PROCEDURE|TEP|Total Exta Peritoneal procedure for inguinal hernia correction
223779780|NCT06191705|DIAGNOSTIC_TEST|QuickDASH|Participants will be administered Urdu version of QuickDASH to collect data regarding Disabilities of Arm, Shoulder \& Hand twice with a time interval of 72 hours to determine validity and reliability.
223779781|NCT02385955|PROCEDURE|Myeloablative double unit cord blood transplantation|Two myeloablative conditioning regimens will be used in this study: (1) total body irradation (TBI, 12Gy), followed by cyclophosphamide (60 mg/kg/day on day -3 and -2) and cytarabine (3 g/m2 every 12 hours on day -5 and -4), or (2) thiotepa (5 mg/kg/day on day -7 and -6), busulfan (3.2 mg/kg/day on day -5, -4, and -3), and fludarabine (50 mg/m2/day on day -5, -4, and -3).
223779782|NCT00797784|DRUG|etanercept(Enbrel®)|etanercept(Enbrel®) 50mgs subcutaneous (SC) injections twice weekly for 20 weeks
223779783|NCT05433558|OTHER|Neuropsychological Rehabilitation|Neuropsychological Rehabilitation
223779784|NCT01138124|DRUG|Gabapentin prescriptions|The exposure of interest is gabapentin use as defined by prescriptions recorded by the GPRD general practitioner (British National Formulary codes). Data on prescriptions for gabapentin will be extracted for each case and control from entry into the study cohort up to the index date (the exposure window). Gabapentin exposure will be parameterized as follows: (1) Ever versus never exposed; (2) Number of prescriptions; (3) Duration of exposure; and (4) Cumulative dose. These parameterizations will also be examined with a 2 year lag time from the index date, limiting the exposure window from entry into the study cohort up to 2 years prior to the index date.
223779785|NCT00954213|BEHAVIORAL|DIR/Floortime parent intervention|Parent will be trained to observe their autistic child's cues, follow their child's lead and techniques to enhance his/her development.
223779786|NCT04011059|BIOLOGICAL|Wharton's jelly-derived mesenchymal cells|Revascularization surgery, placement of an extracellular matrix patch with WJ-MSCs cultured on the epicardial surface and injection of WJ-MSC around the infarcted zone.
223779787|NCT01075321|DRUG|everolimus|Given orally
223779788|NCT01075321|DRUG|lenalidomide|Given orally
223779789|NCT01075321|OTHER|laboratory biomarker analysis|Correlative studies
223779790|NCT01075321|GENETIC|polymorphism analysis|Correlative studies
223779791|NCT01075321|OTHER|immunohistochemistry staining method|Optional correlative studies
223779792|NCT01075321|GENETIC|microarray analysis|Optional correlative studies
223779793|NCT01075321|GENETIC|fluorescence in situ hybridization|Optional correlative studies
223779794|NCT02311595|PROCEDURE|reduced port laparoscopic distal gastrectomy|
223779795|NCT00969891|OTHER|PK-PD analysis|The danish medicines agency regards new knowledge in pharmacokinetics and pharmacodynamics as an intervention.
223779796|NCT03502343|DRUG|Modified Gemcitabine plus nab-Paclitaxel Combination Chemotherapy|"All patients will receive slow (over 30-40 minutes) intravenous administration of nab-paclitaxel (125 mg/m2) on days 1 and 15, and gemcitabine (1000 mg/m2) on days 1, 8, and 15 of a 28- day cycle (every 4 weeks). Treatment will discontinue if disease progression or intolerable toxicity is observed, if the patient withdraws from the study, or at the physician's discretion.~Dose reduction of the chemotherapeutic agent and/or delay of administration is allowed if serious treatment-related AEs occur, according to specified guideline in study protocol (Level 1: 100% -\> 80%; Level 2: 80% -\> 60%). If dose reduction is needed more than Level 2, the patient will be dropped from the trial."
223779797|NCT02423473|PROCEDURE|Connective tissue graft|Periodontal surgical technique to treat gingival recessions
223779798|NCT02423473|PROCEDURE|Composite resin restoration (Filtek Supreme - 3M)|Restorative procedure do treat tooth structure loss
223779799|NCT03112772|OTHER|Puros® Allograft|It is a type of bone grafting materials used for enhancing bone formation
223779800|NCT03112772|OTHER|CopiOs® Cancellous Particulate|It is a type of bone grafting materials used for enhancing bone formation
223779801|NCT05570526|DIETARY_SUPPLEMENT|Melatonin|Puritan's Pride ® Melatonin 5mg tablets orally once daily.
223779802|NCT05570526|OTHER|Placebo|Placebo tablet once daily.
223779803|NCT00262834|DRUG|vorinostat|Given orally, conventional surgery to follow.
223779804|NCT00262834|OTHER|conventional surgery|Undergo conventional surgery
223779805|NCT02893215|OTHER|Screening for silent AF with Zenicor thumb-ECG|Each patient has a device for 14 days, which monitorizes their heart rhythm. They send the ecg four times daily.
223779806|NCT06535282|OTHER|surgery|Surgical treatment of conductive hearing loss with tinnitus
223779807|NCT05230329|PROCEDURE|right sided hemicolectomy, laparoscopy|Comparison of CME
223779808|NCT01800877|DRUG|Vasopressors|
223779809|NCT04901611|BEHAVIORAL|Parental touch|Parental touch in the form of stroking at 3cm/s for 10 seconds on the posterior lower limb where the heel lance will be/has been administered
223779810|NCT02779179|PROCEDURE|Periodontal treatment|"* Mechanical debridement (scaling, root planning, subgingival curettage)~* Antimicrobial therapy (systematically administered: amoxicillin or clindamycin).~* Antiseptic mouthrinses, gel or dentifrice~* Oral hygiene instructions (to educate and motivate patients to control the accumulation of plaque and calculus)"
223779811|NCT05801601|BEHAVIORAL|Many Ways of Being, an innovative sexual health promotion program focused on addressing rigid gender norms and promoting healthy relationships|The Many Ways of Being program is a gender-synchronous program informed by Equimundo's existing single-gender Manhood 2.0 and Sisterhood 2.0 programs. The curriculum is designed to shift unequal gender attitudes and behaviors and provide skill-building on maintaining healthy relationships, making healthy and informed decisions around sex, and avoiding risky sexual behaviors.
223779812|NCT05801601|BEHAVIORAL|A career readiness program|Youth enrolled in the control condition will receive a career readiness curriculum, either International Youth Foundation's Passport to Success, LAYC's Next Generation program or LAYC's Career Readiness Curriculum, depending on the site and implementation period. These programs equip young people with a range of professional, employment readiness, and practical skills that will help them stay in school and acquire the education, professional skills, employment
223779813|NCT00003457|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|Adults with a persistent or recurrent brain tumor will receive Antineoplaston therapy (Atengenal + Astugenal).
223779814|NCT00052065|DRUG|TLK286|
223779815|NCT06110312|BEHAVIORAL|NavCare-EU|NavCare-EU is a person- and family-centered intervention in which navigators collaborate with older persons and their close family caregivers across the continuum of supportive, palliative, and end-of-life care,. NavCare-EU is based on the existing and successfully tested Nav-CARE intervention from Canada. Navigators focus on connecting clients to social supports, both formal and informal, advocating for clients in meeting their quality-of-life goals, resourcing by identifying needs and negotiating access to meeting those needs, and engaging clients in what is most meaningful to them. Navigators are selected, trained, and mentored volunteers or professionals. NavCare-EU is based on the existing and successfully tested Nav-CARE(c) intervention from Canada.
223779816|NCT01664845|DRUG|metformin|metformin 500mg tid
223779817|NCT01664845|DRUG|pegylated-IFN|pegasys 180 mcg qw
223779818|NCT01664845|DRUG|ribavirin|ribavirin 800-1200 mg qd according to BW
223779819|NCT00836823|DRUG|Alfuzosin|Alfuzosin 10mg once daily for 12 months
223779820|NCT04563858|DIAGNOSTIC_TEST|Validation|Assessment of Polish version of the 4AT
223779821|NCT02525133|DRUG|XaraColl|Surgical implantation of 3 bupivacaine collagen implants
223779822|NCT02525133|OTHER|Placebo|Plain collagen implant (vehicle)
223779823|NCT04073043|BEHAVIORAL|Telephone Coaching|Access to Telephone Coaching for a period of 12 weeks
223779824|NCT04997174|DRUG|Celecoxib|Patients in ERAS group received celecoxib
223779825|NCT01075074|PROCEDURE|Transversus abdominis plane block|A regional block performed in the transversus abdominis plane of the abdomen, used to provide anesthesia and analgesia for the abdominal region.
223695839|NCT05343442|PROCEDURE|Percutaneous tracheostomy|"Guidewire dilating forceps (Grigges') technique was the method which has been applied during our work. Proper positioning: patient's neck was extended as much as possible by placing a rolled towel between the shoulder blades, the patient's neck and the bed were maintained in neutral position. The operative site was sterilized before draping with 10% povidone iodine solution. Lidocaine 2% was used as local anesthetic prior to beginning the intervention.~Transverse (1 cm) skin incision was made midway between the cricoid cartilage and the suprasternal notch, i.e., opposite the 2nd - 3rd or 3rd - 4th tracheal rings. Blunt dissection of subcutaneous fat and pre-tracheal tissue with mosquito clamp in a vertical direction was done till the tracheal rings were palpable."
223779826|NCT03876067|DRUG|Ozone|"Our procedures for O3T application in CBP surgery conform to international guidelines of the ''Madrid Declaration on Ozone Therapy'' 32 . M-O3T will be carried out as follows:~50mL of blood drawn by vacuum from the patient central catheter into a sterile blood transfusion bag in which 10 mL of 3.8% Na citrate solution (Galenica Senese Industries, Siena, Italy) as an anticoagulant will be previously added so that the blood/citrate volume ratio was 9:1. After blood withdrawal, the bag will momentarily disconnected leaving the venous access open by a saline infusion 33 . A corresponding volume (50 mL) of gas was immediately added with an O3 concentration of 20-50 micrograms/mL gas. Ozone was produced by Medozon compact generator (Herrmann Apparatebau GmbH, Germany).~At this point, the hyper-oxygenated ozonated blood will be mixed with the cold cardioplegia (Thomsons cardioplegia) this amount of ozonated blood will be added to each 500 ml of cardioplegic solution"
223779827|NCT03876067|DRUG|Cardioplegic Solutions|in which in which only cold blood cardioplegia
223779828|NCT00873795|DRUG|aripiprazole , sertraline|In this ten weeks,double-blind,placebo-control,randomized,fixed dose study, study,subjects were randomly assigned to treatment with aripiprazole 2.5mg/day plus sertraline 50mg/day or sertraline 50mg/day plus placebo.
223779829|NCT05331352|BEHAVIORAL|Semi-structured interviews|Interview
223779830|NCT05331352|BEHAVIORAL|Projective methode|Rorschach + thematic aperception test
223779831|NCT05331352|BEHAVIORAL|Selfreported|RSQ - PBI - RFQ - QSCPGS - SSQ6 - ÉCHELLES DE CUNGI - STAI - PCL-S - IES-R
223779832|NCT01258114|OTHER|SPA treatment (ST)|"Drug: spa treatment soon after randomization :~Spa treatment of 18 days. Spa treatment : the most adapted to the concerned pathology and common to all of spa resorts (mineral water drinking, bath with automatic air (bubble bathing), mud body wrapping, manual massages, water exercises ;~* nutritional counseling (french nutritional recommendations booklet) ;~* caloric restriction and physical training on demand (non mandatory)."
223779833|NCT01258114|OTHER|Non SPA treatment (NST)|"Drug: General practitioner (GP) counselling After randomisation Verbal and/or written advice based on the French national guidelines for a healthy life style brochure (given to the patient by the GP at baseline)"
223779834|NCT03358225|PROCEDURE|anterior cervical discectomy and fusion|The patients undergoing anterior cervical discectomy and fusion sugery
223779835|NCT03358225|PROCEDURE|cervical artificial disc replacement|The patients undergoing cervical artificial disc replacement surgery
223779836|NCT03358225|PROCEDURE|hybrid surgery|The patients undergoing 1-level C-ADR plus 1-level ACDF surgery
223779837|NCT04265755|DRUG|Erenumab|Erenumab 70 mg or 140 mg packed in a SureClick® Autoinjector Pen (AI).
223779838|NCT04779801|BEHAVIORAL|Attachment-Based Family Therapy|16 weeks of Attachment-Based Family Therapy treatment.
223779839|NCT03464227|DRUG|UCB0107|"* Pharmaceutical form: solution for infusion~* Route of administration: intravenous use"
223779840|NCT03464227|OTHER|Placebo|"* Pharmaceutical form: intravenous infusion~* Route of administration: intravenous use"
223779841|NCT03753438|PROCEDURE|Intragstric Ballooning|Intragstric Ballooning will be put.
223779842|NCT05785780|BEHAVIORAL|Targeted CRC Screening Toolkit|Strategies in the toolkit include but are not limited to: identification of patient and practice-level barriers, routine tailored patient reminders, provider reminders, \& clinic staff feedback.
223779843|NCT02624973|DRUG|Neoadjuvant tamoxifen + goserelin (premenopausal women)|
223779844|NCT02624973|DRUG|Neoadjuvant letrozole (postmenopausal women)|
223779845|NCT02624973|DRUG|Neoadjuvant endocrine therapy + palbociclib (if lack of response to endocrine therapy alone)|
223779846|NCT02624973|DRUG|Neoadjuvant docetaxel + cyclophosphamide|
223779847|NCT02624973|DRUG|Neoadjuvant docetaxel|
223779848|NCT02624973|DRUG|Neoadjuvant docetaxel + trastuzumab + pertuzumab|
223779849|NCT02624973|DRUG|Neoadjuvant docetaxel + cyclophosphamide + trastuzumab + pertuzumab|
223779850|NCT02624973|DRUG|Neoadjuvant olaparib|
223779851|NCT02624973|DRUG|Neoadjuvant cyclophosphamide (after 10 weeks of olaparib alone)|
223779852|NCT02624973|PROCEDURE|Breast conserving surgery or mastectomy + SNB/axillary dissection|After response to neoadjuvant treatment
223779853|NCT02624973|RADIATION|Postoperative radiotherapy breast/chest wall + regional lymph nodes|
223779854|NCT02624973|DRUG|Adjuvant trastuzumab|
223779855|NCT02624973|DRUG|Adjuvant letrozole (postmenopausal women)|
223779856|NCT02624973|DRUG|Adjuvant tamoxifen + goserelin (premenopausal women)|
223779857|NCT02624973|DRUG|Adjuvant palbociclib (if palbociclib given neoadjuvant)|
223779858|NCT02624973|DRUG|Adjuvant Epirubicin+ Cyclophosphamide|
223779859|NCT04659980|DEVICE|hilotherapy|continuous cooling of hands and feet at a constant temperature
223779860|NCT04659980|DEVICE|frozen gloves|cooling of hands and feet using frozen gloves
223779861|NCT05794269|OTHER|TQoR-15 questionnaire|The TQoR-15 questionnaire (Turkish version) consists of 15 questions concerning five domains (the patient's feelings, comfort, pain, dependence on the health care team and psychological well-being). Two to three minutes are required to complete all the questions. If the patient is not able to read the questionnaire himself, a third person can ask the patient the questions orally. Each item is scored from 0 to 10 and the total score is the sum of the score obtained for each item, i.e. a score from 0 to 150.
223779862|NCT01347190|BIOLOGICAL|CR002 Liquid API|A single nominal dose of CR002 (three different dose groups) will be inhaled as an aerosol mist produced by an I-neb Adaptive Aerosol Delivery (AAD) System.
223779863|NCT01347190|BIOLOGICAL|Placebo|A single nominal dose of Placebo will be inhaled as an aerosol mist produced by an I-neb Adaptive Aerosol Delivery (AAD) System.
223779864|NCT00934999|PROCEDURE|Burch urethropexy|Patients will undergo a Burch modified Tanagho procedure (in which the anterior vagina is suspended to Cooper's ligament bilaterally using two non-absorbable sutures).
223779865|NCT00934999|PROCEDURE|Synthetic mid-urethral sling (TVT)|Patients will undergo a polypropylene mid urethral sling as described by the manufacture (Align, Bard Urological, Covington, GA).
223779866|NCT03448367|DEVICE|FreeStyle Libre Flash Glucose Monitoring System|Subjects will utilize capillary SMBG for managing diabetes for 6 months (control phase) followed by diabetes management using FreeStyle Libre for 6 months (intervention phase).
223779867|NCT01575561|DRUG|Lurasidone|Lurasidone 20-80 mg taken orally once daily
223779868|NCT03769441|DRUG|Ferric carboxymaltose|Four intravenous dosages of ferric(III) carboxymaltose
223779869|NCT03769441|DRUG|Sodium chloride|Four intravenous dosages of sodiumchloride
223779870|NCT05480605|BEHAVIORAL|Occupational Therapy|Children with autism will receive 6 - 8 weeks of regularly scheduled occupational therapy at Nationwide Children's Hospital outpatient centers. The intervention consists of one-hour weekly sessions with a licensed occupational therapist.
223779871|NCT01166932|DRUG|Amoxycillin/clavulanic acid|100mg/Kg/day/10 days.
223779872|NCT01166932|DRUG|ceftriaxone/oxacillin|75 mg/Kg/day/10 days.
223779873|NCT00005619|GENETIC|polymerase chain reaction|
223779874|NCT00005619|OTHER|flow cytometry|
223779875|NCT00005619|OTHER|immunohistochemistry staining method|
223779876|NCT02182284|DRUG|low dose BI 201335 NA soft gelatine capsule (SGC)|
223779877|NCT02182284|DRUG|high dose BI 201335 NA soft gelatine capsule (SGC)|
223779878|NCT02182284|DRUG|low dose BI 201335 NA powder in bottle (PIB)|
223779879|NCT02182284|DRUG|high dose BI 201335 NA powder in bottle (PIB)|
223779880|NCT05665218|DIAGNOSTIC_TEST|right heart catheterization|Right heart catheterization (RHC) is an invasive hemodynamic procedure that allows direct measurement of right-sided cardiac pressures, calculation of cardiac output and pulmonary vascular resistance. It is the gold standard for the diagnosis of pulmonary arterial hypertension. Right heart catheterization is commonly performed by accessing the internal jugular vein (echo-guided access). Swan Ganz catheter with a dedicated thermistor is used to perform RHC; it is advanced through the right heart chambers to measure right atrial, right ventricle, pulmonary artery and pulmonary arterial wedge pressures. Cardiac output is measured using Fick direct, Fick indirect and thermodilution methods.
223779881|NCT03354000|BEHAVIORAL|Take-home online training|We randomized patients to receive a link to access the online tutorial on their own. Participants in the take-home arm were given a paper handout with a link to the training materials and an outline of the steps for accessing the training curriculum.
223695840|NCT03854201|BEHAVIORAL|Personalized Exercise Counseling (PEC)|At the first counseling appointment, PEC-participants answer the physical activity (PA) questionnaire, perform fitness tests and discuss with their exercise instructor. The target is a personalized short-term PA plan including where and when the PA/exercise takes place and what is the mode. Participants may choose instructed group-exercise sessions provided by the municipal sports/leisure sector or exercising alone as preferred. The exercise instructors utilize the fitness test results and feedback data of the research accelerometers by the UKK Institute to guide the participants. The PEC includes 2 more face-to-face sessions and 4-6 phone calls by the instructors aimed at checking the realization of exercise plans and discussing the outcomes provided by the interactive accelerometer.
223695841|NCT01937754|DIETARY_SUPPLEMENT|Nitric Oxide supplement|Lozenge consisting of beetroot and 75 mg caffeine
223695842|NCT01937754|DIETARY_SUPPLEMENT|Placebo|Same form factor and flavor as test lozenge but contains no active ingredients
223695843|NCT05138211|DEVICE|Exoskeleton assisted gait on a treadmill|"The experimental protocol is divided in three sessions. During all of them, the patient will walk on a treadmill for 6 minutes while wearing a safety harness and the robotic exoskeleton in the paretic leg.~1. \- Training session: The patient will wear the robotic exoskeleton to familiarize with the action of the device.~2. \- Ramp Velocity Session: the session will be divided into five trials: (a) Pre, the patient will not wear the device; (b) Free, the patient will wear the robot but it is mechanically decoupled so it will enable the free knee movement; (c) Active, the robot will assist the gait until 75% maximum gait velocity ; (d) MaxActive, the robot will assist the gait until maximum gait velocity ; and (e) Post, the patient will repeat the Pre condition. Velocity will increase from comfortable velocity to the maximum and then come back to the comfortable one.~3. \- Random Velocity session: the session will be divided into the same trials than the Ramp Velocity Session."
223695844|NCT05457426|PROCEDURE|robotic right hemicolectomy with CME|The distribution of trocars was placed according to the position of Intuitive Surgical Inc. for robotic colectomy. The robot was set to come and dock from theright shoulder of the patient. Three robotic 8-mm trocars (R1, R2 and R3) and two 12-mm trocars (camera and assistant port) were used for the robotic procedure. One working arm carrying a monopolar cautery hook for dissection was located in the left upper quadrant port (R1). The other two working arms carried bipolar forceps in the suprapubic port (R3), and Cadiere's fenestrated forceps in the right lower quadrant port (R2) that was used to keep the superior mesenteric axis in traction. After gentle cephalad traction on the transversemesocolon with the grasp in R2, the assistant grasped the ileocecal valve through the assistant port to put the ileocolic vascular pedicle on tension and the ileocolic vessels were identified and lifted up with R3.
223695845|NCT06556498|PROCEDURE|Proflor group|evaluate the surgical outcomes of patients underwent to laparoscopic inguinal hernia repair with Proflor mesh.
223695846|NCT06556498|PROCEDURE|Progrip group|evaluate the surgical outcomes of patients underwent to laparoscopic inguinal hernia repair with Progrip mesh.
223695847|NCT00342940|BIOLOGICAL|influenza surface antigen inactivated vaccine|
223695848|NCT03228264|DEVICE|teleSLT|The teleSLT intervention consists of a daily training session with a tablet computer at the patients' home. The teleSLT application that will be used for this study was developed within a multidisciplinary team of speech and language therapists, neurologists and computer engineers that have transferred well-established SLT exercises to a tablet computer. The investigators call this application Bern Aphasia App (BAA). During the four weeks the training time with the BAA differs between the two arms. The experimental group trains for 96 minutes per day (80% of two hours) and the control group for 24 minutes per day (20% of two hours).
223695849|NCT03228264|DEVICE|teleCT|For the cognitive training the investigators will use two custom-made versions of popular commercial casual puzzle video games: Flow Free (Big Duck Games LCC) and Bejeweled (PopCap Games). The video games are also delivered on tablet-computers. Again, during the four weeks the training time differs between the two arms. The experimental group trains for 24 minutes and the control group for 96 minutes per day.
223695850|NCT05993039|DRUG|Isoflurane Inhalant Product|1.5-2%
223779882|NCT03354000|BEHAVIORAL|In-person online training|For participants randomized to the in-person training arm, a trained research assistant prompted participants to log into the learning platform and guided them in accessing the training materials for portal features that were of interest to them. The staff member provided further explanation or clarification if participants had questions about the training material.
223779883|NCT05942508|DRUG|TQB2450 Injection + Anlotinib Hydrochloride Capsules|Anlotinib Hydrochloride Capsules: multi-target receptor tyrosine kinase inhibitor; TQB2450 injection: programmed cell death protein 1 (PD-1) human monoclonal antibody
223779884|NCT03272100|PROCEDURE|flap|after flap incision , the sinus cavity was opened and then the membrane raised up
223695851|NCT05993039|DRUG|Sevoflurane inhalant product|1-2% adults 0.6-1.5% Children
223695852|NCT05993039|DRUG|Propofol injection|1mg/kg-mcg/kg/min adults 100-200mcg/kg/min children
223695853|NCT05993039|DRUG|Remifentanil Injection|0.05-2ug/kg/min adults and children
223695854|NCT03095443|OTHER|Music Therapy - Personalized Playlist|Participant receives personalized playlist.
223695855|NCT03095443|OTHER|Music Therapy - Standard Playlist|Participant receives a standard low beats per minute playlist.
223695856|NCT03095443|OTHER|Attention Control|Participant receives an audio-book.
223695857|NCT06077448|DEVICE|MRI|imaging modality
223695858|NCT00694915|BIOLOGICAL|Mycobacterium w|Immunomodulator
223695859|NCT00694915|BIOLOGICAL|BCG (Bacillus Calmette-Guerin)|Immunotherapeutic agent
223695860|NCT03621774|BEHAVIORAL|Mobile-assisted CBT-informed Skills Training|mCBTn combines the CBT-informed components that target defeatist attitudes from Cognitive Behavioral Social Skills Training (CBSST) group skills training and mobile smartphone interventions from our prior clinical trials research.
223695861|NCT03621774|BEHAVIORAL|Supportive Contact|The SC intervention will provide the same amount of group and mobile device contact as the mCBTn condition. Participants will be carrying a phone but will not have access to the CBT-informed app. Group contact sessions will be semi-structured and consist of trouble-shooting device use and check-in about symptoms and potential crisis management, followed by a flexible discussion involving psychoeducation, instructions for accessing community crisis lines and related community resources, empathy, and non-directive reinforcement of health, coping, and symptom management behaviors that grow out of group discussions, with only minimal group leader guidance.
223695862|NCT01334892|DRUG|Cyclosporine Inhalation Solution|Cyclosporin for inhalation twice daily
223695863|NCT00526045|DRUG|AUY922 2 mg/m2|
223779885|NCT02545712|OTHER|Exposure to ethanol|The drug source(s) and amount administered daily are noted.
223779886|NCT02545712|OTHER|Exposure to propylene glycol|The drug source(s) and amount administered daily are noted.
223695864|NCT04012918|DRUG|Capecitabine plus aromatase inhibitor|Capecitabine 625 mg/m2 bid PO for 14 days to be repeated every 21 days until progression in combination with aromatase inhibitor if postmenopausal, addition of LHRH agonist will be added if premenopausal.
223695865|NCT04012918|DRUG|A.I.|aromatase inhibitors ( letrozole 2.5 mg PO per day or Anastrozole 1 mg PO per day or aromasin 25 mg PO per day) if post-menopausal, if premenopausal leutnising hormone releasing hormone (LHRH) agonist will be added to the aromatase inhibitor
223695866|NCT01297998|DRUG|gemcitabine , cisplatin|Dose of gemcitabine and cisplatin and treatment schedule
223695867|NCT03061097|BIOLOGICAL|Autologous fecal microbiota transplant (Auto-FMP Enema)|FMT is the process by which processed donor microbiota material is transplanted into recipients. The aim is to reconstitute the normal intestinal microbial flora in recipients. In this study, the fecal microbiota preparation will be made from the participant's own stool and processed into an auto-FMP enema formulation.
223695868|NCT03061097|OTHER|Placebo Enema Preparation|The placebo enema preparation will be identical in appearance but will not contain human feces to prevent unmasking of the trial arms.
223695869|NCT02469207|OTHER|Removal of tissue post-mortem|
223695870|NCT05410015|OTHER|Normal clinical treatment without intervention|Normal clinical treatment without intervention
223695871|NCT05712876|DRUG|CK-0045|Interleukin-22 agonist
223695872|NCT05712876|DRUG|Placebo|Matching placebo
223695873|NCT04877743|OTHER|None (Observational study)|The main data sources for the study will be participants and their medical records. Vaccination details will be verified by a vaccination card, batch/lot number, and/or using a regional vaccination register. Participants will report all study outcomes using the study app, web portal, or call centre. Participants can also select a proxy to communicate on their behalf: a caregiver, family member, or other trusted individual. Participants will be asked for an emergency contact in case of death or incapacity.
223695874|NCT00004920|DRUG|cisplatin|
223695875|NCT00004920|DRUG|raltitrexed|
223695876|NCT02616419|DEVICE|Buzzy® device|Just before the needle-related procedure, the Buzzy®, combining an ice pack and vibration integrated to a plastic bee, will be applied 5 cm above the needle insertion site and will be maintained in place throughout the painful procedure.
223695877|NCT02616419|DRUG|Maxilene® (Lidocaine liposomal 4%)|Maxilene® topical anaesthetic cream will be applied 30 minutes before the needle-related procedure at the insertion site.
223695878|NCT03180697|DIAGNOSTIC_TEST|APT MR Imaging|Patients who will receive target therapy( Bevacizumab) for recurrent malignant gliomas will obtain routine sequences, Gd- enhanced MR imaging and APT MR imaging will be performed before and after target therapy. We will observe the change of tumor after target therapy using APT imaging. We will compare the change of tumor between Gd-enhanced and APT Imaging before and after therapy.
223695879|NCT02436252|DRUG|DSP-7888|3.5-10.5 mg/body,Id every 2-4 weeks
223695880|NCT00335920|DRUG|Dexamethasone-dihydrogenphosphate (4mg/ml)|
223695881|NCT03911713|DRUG|VX-561|VX-561 tablets for oral administration.
223695882|NCT03911713|DRUG|IVA|150-mg film-coated tablet for oral administration.
223695883|NCT03911713|DRUG|Placebo|Placebo matched to IVA.
223695884|NCT03911713|DRUG|Placebo|Placebos matched to VX-561.
223695885|NCT00612183|DRUG|bendamustine hydrochloride|bendamustine hydrochloride is administered by 60-min drip infusion at 120 mg/m2/day for 2 consecutive days, and the course is then observed for 19 days. This is one cycle and administration is repeated for 3 - 6 cycles. From the second cycle, the dose is reduced or administration is discontinued as required based on adverse events observed in the previous cycle or observation of the course.
223695886|NCT01614600|DEVICE|Nelfilcon A contact lenses|Commercially marketed hydrogel contact lenses for daily wear, daily disposable use
223695887|NCT03484637|OTHER|Lifestyle-medicine intervention|
223695888|NCT01030068|BEHAVIORAL|Yoga|Yoga twice weekly
223695889|NCT01030068|BEHAVIORAL|Wellness|Health and wellness classes twice weekly
223695890|NCT01030068|OTHER|Smoking cessation therapy|Smoking cessation therapy
223695891|NCT03855956|OTHER|KB174|KB174 is a novel mixture of oligosaccharides.
223695892|NCT03855956|OTHER|Maltodextrin|Maltodextrin is a commercially available easily digestible polysaccharide.
223695893|NCT03926871|OTHER|Ergonomic Training|The ergonomic training consisted of an educational program in Ergonomics with a duration of 60 (sixty) minutes divided into a theoretical exposition and videos of the occupational tasks performed by the workers themselves. Theoretical lecture covered topics such as ergonomics, human anatomy, worker health, prevention measures to minimize the risks of musculoskeletal diseases. A better way of performing the work to protect the musculoskeletal system was demonstrated.
223695894|NCT05472324|DRUG|TQC2731 injection|TQC2731 is a humanized monoclonal antibody based on human thymic stromal lymphopoietin (TSLP) sequence.
223695895|NCT05472324|DRUG|Placebo|The drug is a placebo Comparator.
223695896|NCT01230723|DEVICE|Everolimus-Eluting-Stent|due randomization everolimus-eluting-stent will be implanted
223695897|NCT01230723|DEVICE|Zotarolimus-Eluting-Stent|due randomization zotarolimus-eluting-stent will be implanted
223695898|NCT00141388|DRUG|Pregabalin|
223695899|NCT01391754|BEHAVIORAL|SafeCare|Behavioral home based family preservation. Weekly visits X six months.
223695900|NCT01391754|OTHER|In vivo coached quality control|Live observation of practice with expert coaching, feedback and fidelity monitoring
223695901|NCT01391754|BEHAVIORAL|Services As Usual|Home based services not using the SafeCare model
223695902|NCT01391754|OTHER|Uncoached|No in vivo coached quality control or fidelity monitoring
223695903|NCT02457481|DEVICE|Embryo Culture medium|Two step sequential embryo culture medium system
223695904|NCT03347188|DRUG|Fremanezumab|Fremanezumab will be administered per dose and schedule specified in the arm.
223695905|NCT03347188|DRUG|Placebo|Placebo matching to fremanezumab will be administered per schedule specified in the arm.
223695906|NCT01874743|DRUG|Rosuvastatin 20 mg/day|All patients must take 20mg/day of rosavastatin during 3 months
223695907|NCT03368612|OTHER|Electronic evaluation system|spirometry, plethysmography, cardiopulmonary exercise test
223695908|NCT03368612|OTHER|Electronic evaluation system|AirGo recording
223695909|NCT06393543|OTHER|No intervention, only registration|No intervention, only registration
223779887|NCT02545712|OTHER|Exposure to benzyl alcohol|The drug source(s) and amount administered daily are noted.
223779888|NCT02545712|OTHER|Exposure to acesulfam potassium|The drug source(s) and amount administered daily are noted.
223779889|NCT02545712|OTHER|Exposure to aspartame|The drug source(s) and amount administered daily are noted.
223779890|NCT02545712|OTHER|Exposure to glycerol|The drug source(s) and amount administered daily are noted.
223695910|NCT02954627|DIETARY_SUPPLEMENT|Dietary Supplement: Intensive dietary intervention|Participants receive a hypo-caloric formula diet containing 800 to 1,000 kcal/day. The formula diet consists of ready-to-use meal bars and powders to mix with water to make shakes, soups, or porridge. The weight loss programme consists of an 8-week period with full meal replacement by a standard liquid energy intake protocol. To facilitate compliance with the programme, participants will be scheduled for weekly facility-based group sessions with 6-8 participants led by a dietician. The recommendations for daily nutrient intake will be met.
223779891|NCT02545712|OTHER|Exposure to sorbitol|The drug source(s) and amount administered daily are noted.
223779892|NCT02545712|OTHER|Exposure to methyl-p-hydroxybenzoate|The drug source(s) and amount administered daily are noted.
223779893|NCT02545712|OTHER|Exposure to propanyl-p-hydroxybenzoate|The drug source(s) and amount administered daily are noted.
223779894|NCT02545712|OTHER|Exposure to polysorbate-80|The drug source(s) and amount administered daily are noted.
223779895|NCT05792553|DEVICE|bonded tongue tamers|Enamel surface will be treated initially with 37% phosphoric acid for 30 seconds then tongue tamers will be bonded to the palatal/lingual surface of upper and lower central incisors
223779896|NCT05792553|DEVICE|customized bonded spurs|Composite restoration will be used to fabricate the customized bonded spurs with sharp ends and 3 mm in length.
223779897|NCT05792553|DEVICE|conventional fixed palatal spurs|conventional fixed palatal spurs will be fabricated by taking impression after band selection, then the spurs appliance will be fabricated from 0.9 mm stainless steel wire and soldered to the bands bilaterally.
223779898|NCT02250885|DRUG|Selinexor|Selective Inhibitor fo Nuclear Export (SINE)
223779899|NCT02378142|DRUG|Pazopanib|
223779900|NCT01992536|BIOLOGICAL|MenABCWY+OMV|"Vaccine contains rMenB (50 µg per antigen) with 25 µg of OMV (a full dose) plus the fully lyophilized MenACWY vaccine"
223779901|NCT01992536|BIOLOGICAL|MenABCWY+¼OMV|Vaccine contains rMenB (50 µg per antigen) with 6.25 µg OMV (1/4 dose) plus the fully lyophilized MenACWY vaccine
223779902|NCT01992536|BIOLOGICAL|Placebo|Saline solution for injection (0.5mL)
223695911|NCT05413070|BEHAVIORAL|Multimodal approach to QI for Low-Value Care|Up to 4 brief educational components in existing quality meetings Informational email/newsletter Individualized performance feedback reports Educational resources for patients
223779903|NCT00229008|DRUG|ceftobiprole plus placebo|ceftobiprole 500 mg every 8 hours as a 120 minute intravenous infusion and placebo administered every 12 hours as a 60-minute intravenous infusion for 7 to 14 days
223779904|NCT00229008|DRUG|linezolid plus ceftazidime|linezolid 600 mg every 12 hours as a 60-minute intravenous infusion plus ceftazidime 2 g every 8 hours as a 120-minute intravenous infusion for 7 to 14 days
223779905|NCT03907501|DIETARY_SUPPLEMENT|Synbiotic|an herbal prebiotic plus probiotic
223779906|NCT03907501|DIETARY_SUPPLEMENT|Probiotic|Triphala alone
223779907|NCT03907501|DIETARY_SUPPLEMENT|Placebo|Inert capsule
223779908|NCT05778214|DEVICE|Interventional Robotic System|Cerebral angiography was performed by using the interventional robotic system
223779909|NCT00995449|BIOLOGICAL|KB003|KB003 IV x5 doses
223779910|NCT00995449|OTHER|Placebo Comparator|Placebo IV x5 doses
223779911|NCT04861649|BIOLOGICAL|fecal microbiota transplantation|"The nasointestinal tube was placed and the fecal bacteria of healthy people were transplanted with liquid fecal bacteria (three transplants per course of treatment).~200ml of bacterial liquid was transplanted for each course, containing 40g of bacterial volume, transplanted consecutively for 3 times, once a day)"
223779912|NCT02065466|DRUG|nab-paclitaxel|
223779913|NCT02065466|DRUG|Temozolomide|
223779914|NCT02065466|DRUG|Bevacizumab|
223779915|NCT02421991|BEHAVIORAL|Telephone Delivered Intervention|
223779916|NCT00406029|DRUG|Preladenant|1 mg BID capsules
223779917|NCT00406029|DRUG|Preladenant|2 mg BID capsules
223779918|NCT00406029|DRUG|Preladenant|5 mg BID capsules
223779919|NCT00406029|DRUG|Preladenant|10 mg BID capsules
223779920|NCT00406029|DRUG|Placebo|BID capsules
223779921|NCT00406029|DRUG|L-dopa|Participants must receive L-dopa as part of their usual ongoing treatment for Parkinson's Disease. L-dopa is often administered concomitantly with a dopa decarboxylase inhibitor (e.g., carbidopa).
223779922|NCT00406029|DRUG|Other Parkinson's Disease treatments|Participants may also receive other drugs as part of their usual ongoing treatment for Parkinson's Disease, such as dopamine agonists (e.g., pramipexole) and/or the catechol-O-methyl transferase (COMT) inhibitor entacapone.
223779923|NCT00120393|DRUG|atazanavir/ritonavir +2 NRTIs (immediate Switch Group)|Capsules, Oral, ATV 300mg/RTV 100mg + 2 NRTIs, QD, 48 weeks.
223695912|NCT02186873|DRUG|Placebo|Participants will receive matching placebo.
223695913|NCT02186873|DRUG|Golimumab|Participants will receive 2mg/kg of intravenous infusions of golimumab .
223695914|NCT01681017|BEHAVIORAL|HBB/ENC Training and Equipment|See the detailed description section
223695915|NCT01681017|OTHER|HBB/ENC supplies|Staffs associated with participating facilities receive HBB/ENC training and use related equipment.
223695916|NCT01680965|DRUG|Ofatumumab|"Phase I: test an escalating dose of ofatumumab at cohorts of 300 mg, 700 mg, and 1000 mg given on day 0 and 14 of study.~Phase II: Ofatumumab MTD on day 0 and 14; patients will be followed for total of 24 months (months 1, 3, 6, 12 after therapy, then at 18 and 24 months following therapy)"
223695917|NCT02343107|BEHAVIORAL|e-coaching|connexion to a website and interaction with an automatizes system which delivers tailored recommendations over a 4 month period.
223695918|NCT05285800|DRUG|0.5% Hyperbaric Bupivacaine|In both groups 0.5% Hyperbaric Bupivacaine is given intrathecally and then saddle group is advised to stay in sitting position for next 5minutes so that drug can block only lower segments of nerves, Lumber 5th to Sacral dermatomes level. The spinal group is advised to take supine position immediately so that drug distribution be uniform uptill T10 level of spinal dermatome. Then outcomes regarding haemodynamic status and vasopressor usage are recorded
223695919|NCT01519232|RADIATION|Liver Irradiation|Patients already scheduled to undergo radiation treatment
223695920|NCT02537028|DRUG|MSC2364447C|Subjects will be administered with MSC2364447C 25 milligrams orally once daily for 4 weeks.
223695921|NCT02537028|DRUG|MSC2364447C|Subjects will be administered with MSC2364447C 75 milligrams orally once daily for 4 weeks.
223695922|NCT02537028|DRUG|Placebo|Subjects will be administered with placebo matching to MSC2364447C orally once daily for 4 weeks.
223695923|NCT04750603|DRUG|Fluticasone furoate (FF)/Vilanterol (VI)|Patients with a positive exercise challenge test were allocated to a single administration of salbutamol (400 µg) and 22 to FF/VI (92/22 µg) in a double blind, double dummy method to assess the short-term effect on exercise induced complaints
223695924|NCT04750603|DRUG|Salbutamol|Patients with a positive exercise challenge test were allocated to a single administration of salbutamol (400 µg) and 22 to FF/VI (92/22 µg) in a double blind, double dummy method to assess the short-term effect on exercise induced complaints.
223695925|NCT00241085|DRUG|valsartan|
223695926|NCT06435728|DIAGNOSTIC_TEST|AccuIMR and AccuFFR|AccuFFR and AccuIMR were obtained by reviewing coronary angiography at the time of primary PCI
223695927|NCT05663229|DEVICE|Ankle foot orthosis|We evaluate the difference of with or without ankle foot orthosis
223695928|NCT00107783|DRUG|Nitisinone (NTBC)|Treatment
223779924|NCT00120393|DRUG|LPV/r +2 NRTIs (Delayed/optional Switch Group)|Capsules, Oral, LPV 400mg/RTV 100mg +2 NRTIs, BID, 24 weeks then option to switch to ATV arm or stay until 48 weeks.
223779925|NCT00910481|DEVICE|Intra-Aortic Balloon Pump|Elective IABP insertion before PCI
223779926|NCT02139501|DRUG|Recombinant Human Thrombopoietin (rhTPO)|rhTPO was given intravenously at a dose of300Units/kg ,daily for 14 consecutive days;at a dose of 300Units/kg ,one times every other day for 7 times; or at a dose of 300Units/kg ,daily for 7 consecutive days
223779927|NCT00879294|DEVICE|Motion sickness wristband|No drugs are involved.
223779928|NCT00879294|DIETARY_SUPPLEMENT|Chewing Gum|Patients will be asked to chew gum for 20 minutes, four times daily.
223779929|NCT00058305|DRUG|bryostatin 1|Given IV
223779930|NCT00058305|DRUG|vincristine sulfate|Given IV
223779931|NCT00058305|OTHER|laboratory biomarker analysis|Correlative studies
223779932|NCT01263743|BEHAVIORAL|Relaxation Response|The Relaxation Response is a type of relaxation. The goal of the Relaxation Response is to consciously elicit a reaction opposite in direction to the stress response.
223779933|NCT01263743|BEHAVIORAL|Relaxation Response|Relaxation Response is a type of relaxation. This is a technique that elicits a state that is opposite to the stress response.
223779934|NCT01219738|DRUG|Budesonide 360ug|A single inhaled dose of 360ug budesonide from a DPI.
223779935|NCT01219738|DRUG|Budesonide 720ug|A single inhaled dose of 720ug budesonide from a DPI.
223779936|NCT01219738|DRUG|Budesonide 1440ug|A single dose of 1440ug of the budesonide from DPI.
223779937|NCT01219738|DRUG|Budesonide720ug 4 times|720ug of budesonide will be inhaled by the subjects 4 times, separated by 30 minutes.
223779938|NCT01219738|DRUG|Placebo|A single inhaled dose of placebo from a DPI.
223779939|NCT04944823|OTHER|Clinical follow-up for 24 months|Sampling and clinical follow-up for 24 months
223779940|NCT05590091|OTHER|Parenteral nutrition;Enteral nutrition|The intelligent nutrition management system was used to carry out standardized nutrition management of patients after hematopoietic stem cell transplantation
223779941|NCT04897048|PROCEDURE|Incremental exercise test (IET)|Incremental cardio pulmonary exercise test until exhaustion
223779942|NCT04897048|PROCEDURE|Constant work rate exercise test (CWRET)|constant (on 75% Wmax) cardio pulmonary exercise test until exhaustion
223779943|NCT06126562|DRUG|Lanifibranor|Lanifibranor is a pan-peroxisome proliferator-activated receptor (PPAR) agonist.
223779944|NCT01799174|PROCEDURE|UVA-1 Phototherapy|
223779945|NCT01799174|PROCEDURE|Placebo|
223695929|NCT04200560|OTHER|Rhythmic Handgrip Exercise|60 minute rhythmic handgrip exercise
223695930|NCT04200560|OTHER|Chronic Exercise Training|Handgrip exercise training consisting of three 60-minute training sessions per week for eight weeks.
223695931|NCT02367131|DRUG|JARDIANCE®|JARDIANCE®
223695932|NCT01114152|DRUG|AZD9742|IV Formulation
223695933|NCT01114152|DRUG|Placebo|IV Formulation
223695934|NCT02725034|DEVICE|Standard endoscopy|
223695935|NCT02725034|DEVICE|High definition endoscopy with Optic Enhancement|
223695936|NCT02187705|DRUG|Telmisartan tablets|All patients were treated with different doses of telmisartan for 14 days
223695937|NCT00290277|BIOLOGICAL|HPV-16/18 L1/AS04|
223695938|NCT00418639|DRUG|Nitazoxanide|
223695939|NCT02841189|DEVICE|King Vision video Laryngoscope|The King Vision video laryngoscope (Ambu) will be used for tracheal intubation.
223695940|NCT05816720|DRUG|Lutetium-177 DOTATATE|Intravenous administration
223695941|NCT05877768|DIAGNOSTIC_TEST|Photon Counting Detector Coronary Computed Tomography Angiography|Clinically indicated Photon Counting Detector Coronary Computed Tomography Angiography for the suspicion of coronary artery disease or the progression thereof.
223779946|NCT03862118|OTHER|PRP|platelet rich plasma will be delivered by intradermal method using mestherapy needle.
223779947|NCT05761691|PROCEDURE|Dental treatment|Children treated for ECC under general (DGA) and local anesthesia (LA).
223779948|NCT01709227|DRUG|Furosemide|Patients randomized to the furosemide arm will be given 1 mg/kg intravenously every 6 hours for 2 doses and then as directed by CICU attending to augment urine output. Patients within this arm who have urine output \<1 ml/kg/hr over 16 hours after the first dose of Lasix will be considered poor responders. These patients may be started on PD if clinically indicated. Those who show good response (urine output \>1 ml/kg/hr over subsequent 16 hours) will continue furosemide as needed to augment urine output. If they subsequently develop oliguria or fluid overload unresponsive to diuretic therapy, these patients may later be started on PD at discretion of CICU attending with consultation of nephrology service.
223779949|NCT01709227|PROCEDURE|Peritoneal Dialysis|Patients within the PD arm will begin PD with a standardized dialysis plan of 10ml/kg of 1.5% Dianeal™ with 1 hours cycles (5 minute fill, 45 minute dwell and 10 minute drain). Further PD management and discontinuation will be directed by CICU attending and Nephrology service.
223779950|NCT00426478|DRUG|Valsartan plus Hydrochlorothiazide (80mg/12.5mg)|
223779951|NCT00426478|DRUG|Amlodipine (5mg)|
223779952|NCT06533709|DIAGNOSTIC_TEST|Radio-score|A score based on the LASSO regression model predicting the R0 resection of the primary debulking surgery of advanced ovarian cancer.
223779953|NCT04695691|DEVICE|Cutera Laser System|Subjects will receive laser treatments
223779954|NCT06270121|BEHAVIORAL|Living-lab digital intervention group|Older adults will receive individualized daily health feedback via the mobile applications, which will be shared with caregivers. They will also receive support for health emergency by the platform sending automatic emergency push alarm to community and family caregivers.
223779955|NCT05748639|OTHER|Mobile health application|Participants randomized to receive the QG-A (Experimental) intervention will receive monthly appointments with a medical provider, access to naltrexone, and weekly and bi-weekly appointments with a licensed clinical counselor through an integrated digital health application.
223779956|NCT05748639|OTHER|Medical Management|Participants randomized to receive the MM (Control) intervention will receive monthly appointments with a medical provider and access to naltrexone.
223779957|NCT00559897|OTHER|3'-deoxy-3'-[18F]FLT|Patient should receive the dose of zoledronic acid within 48 hours of the first FLT PET scan. The second FLT PET scan will be done 6-8 days after the dose of zoledronic acid.
223779958|NCT00559897|PROCEDURE|Single photon emission computed tomography|Patient should receive the dose of zoledronic acid within 48 hours of the first FLT PET scan. The second FLT PET scan will be done 6-8 days after the dose of zoledronic acid.
223779959|NCT03669081|DRUG|Ketorolac|Ketorolac was administered intravenously: 30 mg in the operating room, and 15 mg every 6 hours for 7 doses post-operatively.
223779960|NCT03669081|DRUG|Pregabalin|Pregabalin was administered orally: 75 mg 30 minutes prior to operation.
223779961|NCT03669081|DRUG|Placebo oral capsule|Placebo oral capsule was administered orally 30 minutes prior to operation.
223779962|NCT03669081|DRUG|Saline|Saline was administered intravenously: once in the operating room, and every 6 hours for 7 doses post-operatively.
223779963|NCT00389324|BIOLOGICAL|Immune Globulin Intravenous (Human)|This trial was an open-label, single-sequence, study. The enrolled subjects received IGIV-C via two routes of administration (IV for 4 -5 weeks and SC for 24 weeks) in order to compare the PK variables, safety and tolerability of SC administration of IGIV-C. Certain subjects required IV IGIV-C dosing during a Run-in Phase (3 - 4 months) for steady-state conditions prior to the IV phase. Subjects received two IV infusions of IGIV (between 200 - 600 mg based on the subject's previous IgG dosing regimen, 3 to 4 weeks apart) until a steady-state was reached at which time PK profiling was performed. Subjects began weekly SC administration (1.37 times the weekly equivalency of each subject's monthly IV dose) 1 week following last IV dose and followed for a period of six months.
223779964|NCT04455919|OTHER|Wait-list group|The wait-list group benefit from a 8-week yoga program after the interventional group
223779965|NCT04455919|OTHER|Yoga group|During 8 weeks, the intervention group attended weekly yoga sessions and had to practice poses at home
223779966|NCT06071039|COMBINATION_PRODUCT|3D spacer Fabric Based Mattress|For the patients in the intervention group, the 3D spacer fabric-based mattress was used instead of the operating room theater mattress. The pressure level of the patients was monitored throughout the surgery.
223779967|NCT03749226|DRUG|Aztreonam lysine|nebulization
223779968|NCT03749226|DEVICE|Aerogen Solo|Aerogen's vibrating mesh technology, available within the Aerogen® Solo has been adopted for use of conventional mechanical ventilation. Aerogen Solo utilizes active vibrating mesh technology, where energy applied to the vibrational element, causes vibration of each of the 1000 funnel shaped apertures within the mesh. The mesh acts as a micropump drawing liquid through the holes producing a low velocity aerosol optimized for targeted drug delivery to the lungs. According our study (Rodriguez A et al , Expert Opin Drug Deliv. 2017 Dec;14(12):1447-1453) Aeroneb Solo showed an excellent aerosol delivery profile for Aztreonam lysine (AZLI) in an in vitro model of MV with short drug delivery time.
223779969|NCT03749226|DEVICE|CombiHaler|The inhalation chamber CombiHaler™ spacer for mechanical ventilation and critical care (ICU) allows using both a vibrating mesh nebulizer such as Aeroneb ™, and a pMDI. It saves 50% of the nebulized drug when used in invasive ventilation. The inhalation chamber CombiHaler® is integrated on a circuit of a breathing device in invasive ventilation in particular for connexion of an Aeroneb® Pro or an Aeroneb® Solo. According our study (Rodriguez A et al , Expert Opin Drug Deliv. 2017 Dec;14(12):1447-1453) a better aerosol delivery performance (30%) was obtained using the Conbihaler spacer.
223779970|NCT02779218|PROCEDURE|Paired Associative Stimulation|Patient with Paired Associative Stimulation only
223779971|NCT02779218|PROCEDURE|Paired Associative Stimulation + Motor Imagery exercises|Patient with Paired Associative Stimulation + Motor Imagery exercises
223779972|NCT02779218|PROCEDURE|Placebo Paired Associative Stimulation + Motor Imagery exercises|Patient with placebo Paired Associative Stimulation + Motor Imagery exercises
223779973|NCT00477711|DRUG|cetuximab, cisplatin, capecitabine|Product 1: Cetuximab(Erbitux®) Dosing schedule: 400mg/m2 initial dose and then 250mg/m2 ,weekly dose Mode of administration: intravenously Product 2: capecitabine Dosing schedule: 1000mg/m2 bid, days 1-14, every 3 weeks Mode of administration: orally Product 3: cisplatin Dosing schedule: 80mg/m2, day 1 of every 3 weeks Mode of administration: intravenously
223779974|NCT03751904|DEVICE|AcoustiCare|Electronic stethoscope
223779975|NCT03089424|DEVICE|Placebo PBMT|The PBMT treatments will be performed using the Multi Radiance Medical™ Super Pulsed Laser MR4™ console (Solon, OH, USA), with the LS50 (emitter with an area of 20 cm2) and SE25 (emitter with an area of 4 cm2) cluster probes as emitters. Nine sites will be irradiated at patient's lumbar region: 3 central sites, using the SE25 (without any dose, 0 J); and 6 sites in the same direction, but laterally (both sides, 3 at a side), using the LS50 (without any dose, 0 J). Patients will be treated during 12 sessions over a period of four weeks (three sessions/week). At each treatment session, patients will receive a total dose of 0 J. At the end of the 12 treatment sessions, patients will receive a total dose of 0 J.
223779976|NCT03089424|DEVICE|PBMT active|The PBMT treatments will be performed using the Multi Radiance Medical™ Super Pulsed Laser MR4™ console (Solon, OH, USA), with the LS50 (emitter with an area of 20 cm2) and SE25 (emitter with an area of 4 cm2) cluster probes as emitters. Nine sites will be irradiated at patient's lumbar region: 3 central sites, using the SE25 (3000 Hz of frequency, 3 minutes of irradiation per site, 24.75 J per site, a totalizing 74.25 J irradiated from SE25); and 6 sites in the same direction, but laterally (both sides, 3 at a side), using the LS50 (1000 Hz of frequency, 3 minutes of irradiation per site, 24.30 J per site, a total of 145.80 J irradiated from LS50). Patients will be treated during 12 sessions over a period of four weeks (three sessions/week). At each treatment session, patients will receive a total dose of 220.05 J. At the end of the 12 treatment sessions, patients will receive a total dose of 2640.60 J.
223779977|NCT06535178|BEHAVIORAL|Sleep Regularity Group|Maintained consistent sleep onset time (±30 min self-selected sleep time) for 12-weeks.
223779978|NCT04353297|OTHER|EEG-based BCI system for (hand) Motor Imagery training|The Promotoer is an all-in-one BCI-supported motor imagery (MI) training station, equipped with a computer, a commercial wireless Electroencephalography (EEG)/ Electromyography (EMG) system, a screen for therapist feedback (EEG and EMG activity monitoring) and screen for the real-time ecological feedback to patient - a custom software program that provides a for (personalized) visual representation of the patient's own hands. As such, this software allows the therapists to create an artificial reproduction of a given patient's hand/forearm by adjusting a digitally created image in shape, size, skin colour and orientation to match as much as possible the real patient hand/forearm. Training consists of the MI tasks only of the affected hand, grasping or finger extension in separate runs. The trial length will include a constant baseline period of 4 sec and a task period of maximally 10 sec for BCI intervention group. Each training session will consist of 4 runs (20 trials each).
223779979|NCT04353297|OTHER|Motor Imagery training|Training consists of MI tasks only of the affected hand, grasping or finger extension in separate runs. MI training will be delivered without BCI support (ie., the Promotoer system will not provide real-time feedback of MI performance; hand/forearm visual representation will remain standstill) with a dose/setting regimen equivalent to EXP intervention. The trial length will include a constant baseline period of 4 sec and a task period of maximally 4 sec. Each training session will consist of 4 runs (20 trials each).
223779980|NCT05759091|BEHAVIORAL|cognitive defusion techniques|"Defusing from your delusions helps to lessen their negative impact on your behaviour. So defusion is a vital step towards being able to act flexibly, in accordance with core values, instead of being dictated to by inflexible rules, reasons, judgments etc. There are numerous exercises in ACT Companion with a focus on identifying unhelpful thoughts which would benefit from defusion, or building defusion skills, most of which are found in the open up section of the app. Some of these are reading and writing exercises, and some are guided meditation audio recordings.~ACT Companion defusion exercises~1. Letting go~2. Not good enough~3. Thought defusion~4. Observing your thoughts~5. Labelling thoughts and feelings~6. I am having the thought that.....~7. milk.milk.milk exercise~8. silly voice exercise, passenger on the bus, tug of war with a monster"
223779981|NCT04020510|DRUG|onaBoNT-A|Intradetrusor onabotulinumtoxinA in either the standard number of injections or a reduced number of injections
223779982|NCT05046938|BEHAVIORAL|Motivational İnterviewing|Students with food addiction will be provided with motivational interviews about food addiction in 5 sessions, each of which varies between 6-8 groups.
223779983|NCT02317575|BIOLOGICAL|LY900014|Administered SC
223779984|NCT02317575|BIOLOGICAL|Insulin Lispro|Administered SC
223779985|NCT03957122|DEVICE|repetitive transcranial magnetic stimulation|"Stimulation of the temporoparietal junction with repetitive transcranial magnetic stimulation~* 2000 pulses~* intensity of 110% resting motor threshold~* 10 sessions (daily from Monday to Friday)~* positioning of coil according to EEG position CP5/CP6"
223779986|NCT00130884|DRUG|levosimendan|
223779987|NCT03813329|DIETARY_SUPPLEMENT|Modified Sodium Bicarbonate|4 progressively larger doses (110 mg·kg-1 - 200 mg·kg-1) of sodium bicarbonate
223779988|NCT03813329|DIETARY_SUPPLEMENT|Acute Sodium Bicarbonate|3 progressively larger doses of calcium carbonate followed by one acute dose of sodium bicarbonate (300 mg/kg)
223779989|NCT03813329|DIETARY_SUPPLEMENT|Calcium carbonate (placebo)|4 progressively larger doses (110 mg·kg-1 - 200 mg·kg-1) of calcium carbonate
223779990|NCT05951322|DEVICE|Shockwave therapy|Radial extracorporeal shock wave device, it is serial number (1107394), medispec and connected to electrical supply 115/220 A C frequency.
223779991|NCT05951322|DEVICE|Phonophoresis|Pagani ultrasound apparatus 200 cosistts of multi frequency head(1 and 3 MHz), surface area 4 cm², continuous and pulsed mode, main voltages: 100-240-VAC.50/60Hz.
223779992|NCT05719974|OTHER|rehabilitation protocol|Current conventional protocols were based mainly on biological tissue healing time frames. These protocols emphasize pain reduction, full passive knee extension, quadriceps strength training, immediate motion, immediate par¬tial weight bearing (only if there is a correct gait pattern without any complications), and functional exercises The criterion-based rehabilitation protocol is relatively new. It was developed and recommended in 2016 by the Royal Dutch Society for Physical Therapy (KNGF), aiming to assure a more patient-tailored rehabilitation and to maximize the speed of a patient's progress. It's a three phases protocol with a criterion-based progression.
223695942|NCT04045275|BEHAVIORAL|Calm|"Calm provides daily, 10-minute, guided meditations grounded in mindfulness-based stress reduction (MBSR) and Vipassana meditation. Calm also offers Sleep Stories, developed using techniques from Cognitive Behavioral Therapy and Relaxation Technique. Clam also includes behavioral components to reinforce sustained practice."
223695943|NCT03820180|DRUG|Test Product|2 inhalations of Test and Reference product in each study period
223779993|NCT03220191|DRUG|Palbociclib|palbociclib tablet formulation
223779994|NCT03220191|DRUG|Rabeprazole|rabeprazole as PPI
223779995|NCT03912857|DRUG|Camrelizumab|"Experimental: test group Drug:Camrelizumab(SHR-1210) 200mg, once every 2 weeks, each 4 weeks is 1cycle.~Apatinib :250 mg or 375 mg, qd"
223779996|NCT05590702|DRUG|First line therapy|"Patient with CLL or SLL requiring a therapeutic strategy according to iwCLL criteria or investigator evaluation will be identified in MCM (multidisciplinary collegial meeting).~Patients will be treated and managed according to the decision of their physicians and the related MDM. No treatment plan is recommended in the setting of this non-interventional study."
223779997|NCT04612361|OTHER|insommnia severity index questionnaire|insomnia severity index questionnaire and scoring system
223779998|NCT05712291|PROCEDURE|Total knee arthroplasty using the active robotic surgical system|Total knee arthroplasty using the active robotic surgical system TSolution One TCAT, and system for planning TPlan
223779999|NCT05712291|DEVICE|TSolution One TCAT, and system for planning TPlan|the active robotic surgical system TSolution One TCAT, and system for planning TPlan
223780000|NCT05712291|PROCEDURE|total knee arthroplasty using the standard manual technic|total knee arthroplasty using the standard manual technic
223780001|NCT02602301|DRUG|Oxytocin|different oxytocin diluents and effect on fetal bilirubin\&sodium levels.
223695944|NCT03820180|DRUG|Reference Product|2 inhalations of Test and Reference product in each study period
223695945|NCT01291953|PROCEDURE|Screening|Determination of the arterial pulse and if it is arrhythmic, accomplishment of an ECG
223695946|NCT01291953|PROCEDURE|Control|Determination of the arterial pulse and if it is arrhythmic, accomplishment of an ECG
223780002|NCT02026700|DEVICE|bariederm cream|patients are asked to apply twice a day a barrier cream on their hands for 3 weeks only
223695947|NCT01051466|DRUG|Duloxetine|60 milligrams (mg) administered orally daily for 8 weeks then 60-120 mg if non remitter or 60 mg if remitter for 4 additional weeks
223780003|NCT00089440|DRUG|Aripiprazole|
223780004|NCT02667158|OTHER|Survey to Eval Relation between Shopping and Misuse, Abuse|A Survey Study to Evaluate the Relation Between Doctor/Pharmacy Shopping and Outcomes Suggestive of Misuse, Abuse and/or Diversion
223780005|NCT02169687|DEVICE|HIFU|High Intensity focalized Ultrasounds
223780006|NCT04378075|DRUG|Vatiquinone|Vatiquinone will be administered per the treatment arm description.
223695948|NCT01286727|DRUG|BB3|intravenous drug
223695949|NCT05626582|PROCEDURE|pain delivery - learning only|Experimental pain paradigm delivered (capsaicin cream combined with heat) that is short-term and painful but not harmful. Applied to skin just during the Day 1 learning period.
223695950|NCT05626582|PROCEDURE|pain delivery - learning and retention|Experimental pain paradigm delivered (capsaicin cream combined with heat) that is short-term and painful but not harmful. Applied to skin during the Day 1 learning period and again during the Day 2 retention period.
223780007|NCT04378075|OTHER|Placebo|Vatiquinone-matching placebo will be administered per the treatment arm description
223780008|NCT06573957|DRUG|Dexmedetomidine|Patient in experimental arms will received intravenous dexmedetomidine at a dose of 0.5 µg/kg body weight 10 minutes before general anesthesia induction
223780009|NCT06573957|DRUG|Lidocain|Patient in experimental arms will receive intravenous lidocaine at 1.5 mg/kg body weight in a 5cc syringe 90 seconds before intubation
223780010|NCT06635993|DIAGNOSTIC_TEST|68Ga-Pentixafor PET/CT|The patients had a normal diet with no special preparation before 68Ga-Pentixafor PET/CT imaging. The dosage of intravenously injected 68Ga-Pentixafor was calculated based on the patient\&#39;s weight (1.85 MBq \[0.05mCi\]/kg). Local PET/CT scanning of the upper abdomen was performed on a hybrid PET/CT scanner at 10 minutes after the injection of the intravenous tracer, respectively.
223780011|NCT06634667|DRUG|third-generation EGFR-TKI combined with anlotinib|third-generation EGFR-TKI combined with anlotinib as maintenance therapy following 4 to 6 cycles of chemotherapy and immunotherapy until progressive disease.
223780012|NCT01709019|BIOLOGICAL|Low dose RSV-F Vaccine with Adjuvant (Day 0); Seasonal TIV (Day 0 & Day 28)|0.5mL IM injections
223780013|NCT01709019|BIOLOGICAL|Low dose RSV-F Vaccine without Adjuvant (Day 0); Seasonal TIV (Day 0 & day 28)|0.5mL IM injections
223780014|NCT01709019|BIOLOGICAL|High dose RSV-F Vaccine with Adjuvant (Day 0); Seasonal TIV (Day 0 & Day 28)|0.5mL IM injections
223780015|NCT01709019|BIOLOGICAL|High dose RSV-F Vaccine without Adjuvant (Day 0); Seasonal TIV (Day 0 & Day 28)|0.5mL IM injections
223780016|NCT01709019|BIOLOGICAL|Placebo (Day 0 & Day 28); Seasonal TIV (Day 0)|0.5mL IM Injections
223695951|NCT03974360|DRUG|AMG 334|100 subjects with persistent post-traumatic headache will be allocated to receive monthly subcutaneous injections of 140 mg erenumab at three time points (week 0, week 4, week 8)
223695952|NCT02231918|DRUG|MIRAPEX® - low|
223695953|NCT02231918|DRUG|MIRAPEX® - medium|
223695954|NCT02231918|DRUG|MIRAPEX® - high|
223695955|NCT04045548|DRUG|Dinoprostone|1 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia \& Upjohn, Puurs, Belgium) inserted by the study nurse 6 hours before IUD insertion.
223695956|NCT04045548|DRUG|Placebo|one tablet of placebo inserted by the study nurse 6 hours before IUD insertion.
223695957|NCT01568515|PROCEDURE|Electronic Message|Students enrolled in the intervention group received 7 electronic contacts over a 7-month period. Specifically, participants received 4 electronic education messages, 2 electronic reminder/education messages, as well as 1 baseline and 1 final assessment contacts. Up to 4 reminder contacts were used if surveys were not completed for both intervention and control group participants. Control group participants will receive 2 contacts throughout the study, 1 at baseline and 1 at their final assessment. Up to 4 reminder contacts were used if surveys were not completed. Intervention \& control groups were compared longitudinally for 7 months on the differences in HPV vaccine utilization and adherence, knowledge and attitudes about HPV, and the HPV vaccine (parallel design).
223695958|NCT00234273|PROCEDURE|Rehabilitation programme in Adapted Physical Activity (APA)|
223695959|NCT00234273|BEHAVIORAL|Therapeutic education primarily focused on dietary|
223780017|NCT06384677|OTHER|M-Tapa Block|M-TAPA block was performed bilaterally with 20 mL of 0.2% bupivacaine under ultrasound guidance at the end of surgery
223780018|NCT05134805|PROCEDURE|Bipolar hemiarthroplasty , proximal femoral nail|"* Removal of head of femur , greater trochanter , and lesser trochanter and use bioplar hemiarthroplasty (BHA).~* Intra-medullary fixation of intertrchanteric femoral fracture by proximal femoral nail (PFN) Fixation of the fracture by using intramedullary nail(proximal femoral nail)."
223780019|NCT03284268|GENETIC|VCN-01|VCN-01 intravitreal injection
223780020|NCT02843568|OTHER|Laboratory Biomarker Analysis|Correlative studies
223780021|NCT02843568|RADIATION|Standard fractionation|60-66y Gy delivered in 1.8-2.0 Gy fractions over 30-36 treatments
223780022|NCT02843568|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|40-60 Gy delivered in 5-20 Gy fractions over 3-8 treatments
223780023|NCT02843568|PROCEDURE|Four Dimensional Computed Tomographic Imaging (4DCT)|Subjects undergo a total of 7 research-ordered four dimensional computed tomographic imaging (4DCT) scans: 1 at simulation, and 2 scans at each of the 3 post-radiation therapy time points (3, 6, and 12 months). 4DCT determines lung tissue elasticity and for standard of care radiation treatment planning.
223780024|NCT05824884|BEHAVIORAL|Visual Feedback|Visual progress feedback and words of positive affirmation will be presented triggered by checkpoints set in the VR-height-exposure.
223780025|NCT05824884|BEHAVIORAL|Self-efficacy enhancement:|specific instructions regarding the retrieval of mastery experiences during exposure will be given (modified version of the procedure used in Raeder et al. 2019).
223780026|NCT05824884|BEHAVIORAL|placebo intervention|specific instructions regarding the retrieval of the exposure session will be given without an emphasis on personal mastery experience (modified version of the procedure used in Raeder et al. 2019).
223780027|NCT05824884|BEHAVIORAL|No visual feedback|Participants can not trigger any checkpoints during VR and therefore not receive any progress feedback or positive affirmation.
223780028|NCT01218724|DRUG|Losartan Potassium and Hydrochlorothiazide Tablets|
223780029|NCT00088218|DRUG|Clofarabine|1-hour IV infusion 30 mg/m\^2 daily times 5 days (Days 1-5)
223780030|NCT00088218|DRUG|Ara-C|20 mg/m\^2 subcutaneously daily times 14 days (Days 1-14). On Days 1 to 5 of each course, clofarabine will precede injection of ara-C by approximately 4 hours (+/- 1 hour).
223780031|NCT02395354|DEVICE|Placing a self-expanding metallic stent|"* Income on short stay unit (SSU) post-procedure~* Light sedation by the endoscopist vs anesthetist by center~* Fully covered self-expanding metal stents Tae Woong Medical® type; prosthesis size at the endoscopist discretion~* Clips can be placed at the distal end of the prosthesis according to the endoscopist.~* Prosthesis removal time in 4 weeks."
223780032|NCT02395354|DEVICE|A balloon dilatation|"* Income on short stay unit (SSU) post-procedure~* Light sedation by the endoscopist vs anesthetist by center.~* Pneumatic ball type CRE Boston cientific®; balloon diameter at the endoscopist discretion~* Up to 2 expansion will be made with a minimum interval between 15-30 days between each expansion~* It shall be deemed failure to expansion if required\> 2 expansions."
223780033|NCT01231698|DRUG|esmolol|Strict heart rate control: esmolol at any dose to maintain heart rate between 95 and 80 bpm.
223780034|NCT01231698|OTHER|control|standard treatment without strict heart rate control
223780035|NCT01546493|RADIATION|MRI|MRI scan. 3.0 Tesla MRI scans of both hips using Tip(T1-rho) and ultra-short echo time (UTE) sequences.
223780036|NCT01546493|RADIATION|qCT|Quantitative computed tomography(QCT) scans using a CT phantom
223780037|NCT01546493|OTHER|Motion Analysis|3D motion analysis to assess hip function.
223780038|NCT01546493|RADIATION|PET-MRI|Positron emission tomography combined with magnetic resonance imaging (PET-MRI) is a technology that will help us examine bone and cartilage at the molecular level.
223780039|NCT02313142|BEHAVIORAL|Leg exercises|
223780040|NCT05841745|DEVICE|Robotically-Assisted Percutaneous Coronary Intervention with CorPath GRX System|The CorPath GRX System is intended for use in the remote delivery and manipulation of guidewires and rapid exchange catheters, and remote manipulation of guide catheters during percutaneous coronary and vascular procedures. The CorPath GRX System is composed of two units; the first is a bedside unit which consists of the extended robotic arm, robotic drive, and single-use loading cassette, and the second is the remote workstation, which consists of the interventional cockpit and the control console. A key innovation of the CorPath GRX System is the software-based automation of common maneuvers, called technIQ automated movements with the potential to increase procedural success, reduce procedure time, and generally increase user comfort with robotic assistance during PCI.
223780041|NCT06247176|BEHAVIORAL|Sensory Habituation Protocol|"The first session continues with the Mock MRI, which lasts 10 minutes. Participant's comfort level in VR will be evaluated.~At the pre-exposure visit, participants complete an MRI scan on a 3 Tesla MRI, which takes approximately 1 hour \& 15 minutes. It consists of structural \& functional MRI scans. Structural scans require the participant to stay still with eyes closed. Functional scans will require the participant to lie with eyes closed or watch and listen to sensory stimulation.~VR exposure will occur across 3 1-hour sessions at most. Participants will be asked to complete a sensory habituation protocol, in which they will watch and listen to sensory stimuli in VR for an increasing amount of time. Between the sensory stimuli, the participant will watch a self-selected video.~Finally, the subject will be asked to do a post-exposure MRI visit, which is the same as the pre-exposure visit."
223780042|NCT04011150|DEVICE|Epidural infusion pump|Epidural delivery system for maintenance of labour epidural analgesia using 0.1% ropivacaine (amide local anaesthetic) with 2mcg/ml fentanyl (opioid) as maintenance solution.
223780043|NCT04011150|DRUG|Ropivacaine|Epidural delivery system for maintenance of labour epidural analgesia using 0.1% ropivacaine (amide local anaesthetic) with 2mcg/ml fentanyl (opioid) as maintenance solution.
223780044|NCT04011150|DRUG|Fentanyl|Epidural delivery system for maintenance of labour epidural analgesia using 0.1% ropivacaine (amide local anaesthetic) with 2mcg/ml fentanyl (opioid) as maintenance solution.
223780045|NCT05961202|DRUG|Hydroxychloroquine|Hydroxychloroquine 200mg qd
223780046|NCT05961202|DRUG|Prednisolone|Prednisolone 20mg qd
223780047|NCT03477890|DIAGNOSTIC_TEST|Stratified medicine involving a diagnostic intervention|"Adjunctive tests of coronary artery lesion severity (fractional flow reserve) and function at the time of invasive coronary angiography. Diagnostic groups: stable coronary syndromes in patients with obstructive coronary artery disease (mis-classified by non-invasive CTCA) or no-obstructive coronary disease including the following sub-groups (coronary artery vasospasm, microvascular spasm, impaired vasorelaxation due to (1) endothelial dysfunction and/or (2) non-endothelial dysfunction, or unaffected (normal test results).~Medical management is linked to contemporary clinical guidelines for the management of patients with stable coronary artery disease (European Society of Cardiology (2013), Scottish Intercollegiate Guideline Network (SIGN), 2017)."
223780048|NCT03477890|DIAGNOSTIC_TEST|Stratified medicine involving a diagnostic intervention|"Adjunctive tests of coronary artery lesion severity (fractional flow reserve) and function at the time of invasive coronary angiography. Diagnostic groups: stable coronary syndromes in patients with obstructive coronary artery disease (mis-classified by non-invasive CTCA) or non-obstructive coronary disease including the following sub-groups (coronary artery vasospasm, microvascular spasm, impaired vasorelaxation due to (1) endothelial dysfunction and/or (2) non-endothelial dysfunction, or unaffected (normal test results).~Medical management is linked to contemporary clinical guidelines for the management of patients with stable coronary artery disease (European Society of Cardiology (2013), Scottish Intercollegiate Guideline Network (SIGN), 2017)."
223780049|NCT04452461|DRUG|mFOLFIRINOX|mFOLFIRINOX, including: Oxaliplatin 85 mg/m2 IV over 2 hours, Leucovorin 400mg/m2 IV over 2 hours, Irinotecan at 150 mg/m2 IV over 90 min, 5-Fluoruracil continuous infusion of 2400 mg/m2 IV over 46h.
223780050|NCT04452461|DRUG|Gemcitabine / Nab-paclitaxel|Both drugs are administered once weekly for three weeks (days 1, 8, 15) followed by a week of rest (28-day cycle) for 3 cycles prior to imaging. Gemcitabine: 1000 mg/m2 intravenous infusion over 30 to 40 minutes. Nab-paclitaxel: 125 mg/m2 intravenous infusion over 30 to 40 minutes.
223780051|NCT03594448|PROCEDURE|Specimen Collection|Undergo collection of blood samples
223780052|NCT03594448|PROCEDURE|Serial Liquid Biopsy|Undergo serial liquid biopsy
223780053|NCT03698955|OTHER|Plant-based diet|Weekly instructions will be given to the participants in the intervention group about following the vegan diet.
223780054|NCT03698955|OTHER|Mediterranean Diet|Weekly instructions will be given to the participants in the intervention group about following the Mediterranean diet.
223780055|NCT06299202|DIAGNOSTIC_TEST|Diagnostic test|"* Inclusion visit (V1) Initial baseline CESM (V2) 15 days after inclusion~* First chemotherapy treatment (V3) 28 days after V2.~* Unilateral follow-up CESM (V4) 4 to 6 weeks after the first course of chemotherapy.~* Surgery (V5):~  3 to 6 weeks later at the end of the complete treatment with primary chemotherapy~* End of research visit (V6) It corresponds to the histological analysis on the surgical specimen after the complete treatment with neoadjuvant or primary chemotherapy."
223780056|NCT06538532|OTHER|Zamzam water|Zamzam water
223780057|NCT00309998|BIOLOGICAL|bevacizumab|
223780058|NCT00309998|DRUG|vinorelbine tartrate|
223780059|NCT05905965|DRUG|Empagliflozin 20 mg|Patients receiving empagliflozin 20 mg daily - experimental arm
223780060|NCT05905965|DRUG|Empagliflozin 10 mg|Patients receiving empagliflozin 10 mg daily - control arm
223780061|NCT05960682|OTHER|Questionnaire|Patients will complete the French version of the Brief Index of Sexual Functioning for Men (BISFM) paper questionnaire. The BISFM is a self-administered questionnaire. It has 22 questions, grouped into 7 domains allowing a qualitative and quantitative evaluation of the sexual experience: D1 (desire), D2 (excitement), D3 (frequency of activity), D4 (receptivity), D5 (pleasure, orgasm ), D6 (relationship satisfaction), D7 (problems affecting sexuality).
223695960|NCT02970916|DRUG|FOLFIRI+aflibercept|"Aflibercept: 4 mg/kg administered intravenous infusion on day 1~FOLFIRI regimen immediately after aflibercept:~Irinotecan:180 mg/m2 intravenous infusion, folinic acid (dl racemic): 400 mg/m2 intravenous infusion, followed by 5-fluorouracil (5-FU): 400 mg/m2 intravenous bolus, followed by 5-FU: 2400 mg/m2 continuous intravenous infusion over 46 hours.~\* folinic acid: 400 mg/m² (racémic) or 200 mg/m² (L-form)"
223780062|NCT05875584|DIAGNOSTIC_TEST|rbcDNA test|fecal immunochemical test
223780063|NCT06635512|OTHER|The Effect of Stress Ball Application After Transurethral Resection of the Prostate on Patients' Recovery Quality and Hospital Discharge Time|The effect of the stress ball applied after surgery on patients' recovery quality will be evaluated.
223780064|NCT06635265|DEVICE|Target Stimulation (HGN, AC, GG, Strap muscles)|Simulation of a combination of: HGN, AC, GG or strap muscles
223780065|NCT06635174|OTHER|Dextrose|we are using 2ml of 50% dextrose
223780066|NCT06635174|OTHER|normal water|patient will receive 2ml of normal water
223695961|NCT00772473|OTHER|subjects personal triptan|Subjects will treat 1 migraine attack with their usual triptan
223780067|NCT04079933|OTHER|Oral tobacco-derived nicotine product (OTDN)|
223695962|NCT05391529|BEHAVIORAL|Interview|Semi structured patient interview via telephone
223695963|NCT03562910|OTHER|HelpSteps application|Mobile or tablet-based tool that screens for social needs and refers to local agency based on needs and proximity.
223695964|NCT03419520|BEHAVIORAL|Nutritional counseling|Schoolchildren, parents and teachers from intervention schools, will regularly receive nutrition and healthy lifestyle guidelines performed by nutritionists. Moreover, workshops aimed to reinforce the healthy habits will also be held along the study.
223695965|NCT02536651|PROCEDURE|Ankle surgery|Plastic or orthopedic surgery of the ankle
223695966|NCT00072657|BEHAVIORAL|Cognitive Behavioral Therapy|The CBT intervention will have three phases: 1) education on the nature of the adjustment process in chronic illness, 2) coping skill development, and 3) generalization and application of skills to everyday situations. Participants in the CBT group will attend 12 weekly group sessions of about 2 hours each.
223695967|NCT00072657|BEHAVIORAL|Tai Chi Chih|Participants in the TCC group will learn to perform 18 movements under the guidance of an expert TCC teacher. TCC participants will have 50- to 60-minute biweekly sessions during the 12-week study.
223695968|NCT00072657|BEHAVIORAL|Health Education Seminar|Control group participants will attend weekly group educational sessions; these sessions will provide general knowledge about arthritis health and illness, and they will include lectures, demonstrations, and question-and-answer sessions with experts in rheumatology, sleep science, and behavioral medicine.
223695969|NCT05341687|OTHER|No applicable|No applicable
223695970|NCT05686954|OTHER|CSO LOW|Participants are provided a breakfast shake and a snack daily that delivers 10% of the participant's estimated energy needs as cottonseed oil for 28 days.
223695971|NCT05686954|OTHER|CSO MID|Participants are provided a breakfast shake and a snack daily that delivers 20% of the participant's estimated energy needs as cottonseed oil for 28 days.
223695972|NCT05686954|OTHER|CSO HIGH|Participants are provided a breakfast shake and a snack daily that delivers 30% of the participant's estimated energy needs as cottonseed oil for 28 days.
223695973|NCT05686954|OTHER|CONTROL|Participants are provided a breakfast shake and a snack daily that delivers 10% of the participant's estimated energy needs as a mixture of oils that match the average American fat intake for 28 days.
223695974|NCT03498066|DRUG|Beta-blockers withdrawal|withdrawal of all type of betablockers
223695975|NCT03498066|DRUG|Continuation of the Betablockers (βB) treatment|Use Betablockers treatment
223695976|NCT02284542|PROCEDURE|Awake|Upon approximate lead positioning, the patient is brought to a conscious sedated state while maintaining local anesthetic. Stimulation of the spinal cord through the paddle lead is accomplished with an external pulse generator, while communicating with the patient regarding paresthesia coverage of painful regions.
223695977|NCT02284542|PROCEDURE|Non-Awake|"The patient is maintained under general anesthesia for the full duration of the implant. Upon approximate lead positioning, bilateral EMG of myotomes overlapping dermatomal regions of pain are monitored. Stimulation is delivered through the lead by an external pulse generator in order to elicit compound muscle action potentials (CMAPs) in the target regions. Lead placement is targeted to have symmetric CMAPs (i.e. physiologic midline) and adequate coverage of the painful regions as described by Falowski et al.~(Falowski et al., 2011)."
223695978|NCT04140838|BEHAVIORAL|Acceptance and Commitment Therapy (ACT)|Group treatment protocol of 8 weekly 90 minute sessions. Session 1: Presentation of the general concept of ACT therapy. Session 2: Value analysis I. Session 3: Value analysis II. Session 4: Value analysis III. Session 5: Values and feelings. Session 6: Taking a direction. Session 7: Dare and change. Session 8: Ready to act with ACT.
223695979|NCT04140838|BEHAVIORAL|Behavioral Activation Therapy for Depression (BATD)|"Group treatment protocol of 8 weekly 90 minute sessions. Session 1: Collection of information regarding areas of activity and interaction contexts.~Session 2: Identification of information related to depressive behaviours. Session 3 Obtaining complementary information regarding the characteristics of the history of patient interactions and any contexts.~Session 4: Explanation of the hypotheses of problematic behaviour, its maintenance and change throughout the intervention.~Session 5: Once the 10 target activities have been identified, a record is made to track and their progress weekly.~Session 6: Discussion of what was obtained from the records in general and of the satisfaction obtained, and explanation of the contexts and reinforcers.~Session 7: Psycho-education Session 8: New behaviours, the goals achieved and the maintenance of the weekly activity are inquired about."
223695980|NCT04140838|OTHER|Treatment as Usual (TAU)|Standard pharmacological treatment usually provided to patients suffering chronic pain and mild-moderate depression.
223695981|NCT02020187|OTHER|Exercise on a cycle-ergometer|Home training on an ergometer-cycle 30 minutes every other day or at least three times a week. Subject will exercise in a pulse interval corresponding to 70% of their maximal VO2.
223695982|NCT02479269|OTHER|Aerobic exercise|Aerobic exercise for 8 weeks
223695983|NCT03996759|DIAGNOSTIC_TEST|Laboratory diagnostic medicine|Metabolomic profiling and laboratory diagnosis including blood routine examination, liver function, renal function, myocardial enzyme, coagulation, arterial blood gas analysis, C-reactive protein, procalcitonin, B-type natriuretic peptide, myoglobin, lipopolysaccharide, cytokines (TNF-α, IL-1β, IL-6, etc.), immune cell markers (CD3+, CD4+, CD8+, etc.), and stool routine as well as intestinal microecology analysis.
223695984|NCT06203379|OTHER|Neuromuscular Exercise Training|Neuromuscular Exercise Training
223695985|NCT06203379|OTHER|control exercise|Exercise Training
223695986|NCT04425356|BEHAVIORAL|LifeXT Program|The intervention involves participation in and completion of the 4-month LIFEXT program, including: A baseline 15-20 minute health assessment administered online, a 50 minute introductory, one-on-one telephonic coaching session, four 50 minute one-on-one telephonic coaching sessions, optional coaching session follow-up activities (such as videos, practice exercises, and reading materials), and a post-intervention 15-20 minute health assessment administered online.
223695987|NCT03234673|DRUG|Tacrolimus ointment|3 sessions of fractional CO2 laser one month apart Patients will start treatment Tarolimus ointment twice daily for 3 months.
223695988|NCT03234673|DRUG|calcipotriol ointment|3 sessions of fractional CO2 laser one month apart Patients will start treatment Calcipotriol ointment twice daily for 3 months.
223695989|NCT03234673|DRUG|NB-UVB|3 sessions of fractional CO2 laser one month apart Patients will start treatment NB-UVB phototherapy twice weekly for 3 months
223695990|NCT00555685|DRUG|NaCl 7,5% (Hypertonic Saline Solution)|Patients in the intervention arm will receive 100ml of NaCl 7,5, twice daily during 3 days
223695991|NCT00555685|DRUG|NaCl 0,9%|Patients in the placebo arm will receive 100ml of NaCl 0,9% twice daily during 3 days
223695992|NCT06556693|DEVICE|Dual Channel Stimulation|implant of dual channel stimulation device
223695993|NCT03898843|OTHER|Animal assisted therapy|Patients of AAT group will leave their hospital bedroom to go in the session room, where they will meet a dog, who has come with his veterinary student master. Animal assisted therapy session will last at most 20 minutes, in which the patient is going to interact with the dog, pet him, play with him, etc.
223695994|NCT03898843|BIOLOGICAL|Nasal swab sampling|All patients will have nasal swab sampling at inclusion and 7 days after AAT session or sham session in order to screen multidrug resistant bacteria
223695995|NCT03898843|BEHAVIORAL|STAI-Y and POMS Questionnaires|Before and after AAT or sham session, patients will answer State-Trait Anxiety Inventory Y (STAI-Y), Profile of Mood States (POMS) questionnaires.
223695996|NCT03898843|PROCEDURE|physiological parameters measure|Before and after AAT or sham session, blood pressure, heart rate dans respiratory rate will be measured.
223695997|NCT03898843|OTHER|Visual Analog Scale (VAS)|Before and after AAT or sham session, pain will be evaluated thanks to VAS
223695998|NCT03898843|BEHAVIORAL|Impact of Event Scale - Revised (IES-R)|Patients will answer IES-R questionnaire 3 months after AAT or sham session
223695999|NCT03898843|BEHAVIORAL|satisfaction questionnaire|Patients of the AAT group will answer satisfaction questionnaire at the end of the AAT session and 3 months after AAT
223696000|NCT03898843|BIOLOGICAL|Rectal swab sampling|All patients will have rectal swab sampling at inclusion and 7 days after AAT session or sham session in order to screen multidrug resistant bacteria
223696001|NCT00137631|BEHAVIORAL|Many Men, Many Voices (3MV)|Small-group, 6-session HIV prevention intervention for Black MSM.
223696002|NCT00994929|BIOLOGICAL|Neumega (Oprelvekin, Interleukin 11, IL-11)|25 microgram/kg IL-11 by subcutaneous injection once daily for four days, followed by DDAVP 0.3 microgram/kg by intravenous infusion over 30 minutes on day 4, 30 minutes after IL-11.
223780068|NCT00851214|DEVICE|NexfinHD Monitor|Finger cuff device (NexfinHD Monitor, BMEYE, Amsterdam) that can measure hemodynamics on a beat to beat basis and that can be easily applied to acutely ill individuals.
223780069|NCT00023829|DRUG|bicalutamide|
223780070|NCT00023829|DRUG|flutamide|
223780071|NCT00023829|DRUG|releasing hormone agonist therapy|
223696003|NCT04202471|DEVICE|Chlorhexidine Cloth|2% chlorhexidine gluconate cloth
223696004|NCT03468829|BIOLOGICAL|ALX-0171 Dose 1|Oral inhalation of ALX-0171 Dose 1 once daily for a maximum of 14 days
223696005|NCT03468829|BIOLOGICAL|ALX-0171 Dose 2|Oral inhalation of ALX-0171 Dose 2 once daily for a maximum of 14 days
223696006|NCT03468829|BIOLOGICAL|Placebo|Oral inhalation of Placebo once daily for a maximum of 14 days
223696007|NCT00351000|DRUG|Ziprasidone|
223696008|NCT03813667|BEHAVIORAL|Intervention FamPALcare|"The FamPALcare intervention includes all standard care information on R-ALD home care plus 2 weeks of EOLPC coaching by community nurses experienced in EOLPC. The nurse uses the Conversation Ready pamphlet to guide discussion of EOL preferences. The nurse will: (1) support the patient and family in making decisions about EOL care options based on their preferences; (2) discuss options for EOL care when the patient's R-ALD symptoms become severe; (3) encourage completion of the advance directive forms at next physician appointment. The nurse will use teach-back processes to ensure that FamPALcare discussions are clear."
223780072|NCT00023829|PROCEDURE|adjuvant therapy|
223780073|NCT00023829|RADIATION|radiation therapy|
223780074|NCT04504045|DRUG|Metformin|500 mg tablet
223780075|NCT04504045|DRUG|Caffeine|As part of a 6-drug cocktail caffeine 100 mg tablet will be administered as a single dose before the initiation of metformin treatment and 3 weeks and 12 weeks after. The drug will be used as a probe to assess CYP1A2 activity.
223696009|NCT05136352|PROCEDURE|adductor canal block|loco-regional anesthesia using adductor canal block
223780076|NCT04504045|DRUG|Efavirenz|As part of a 6-drug cocktail efavirenz 50 mg coated tablet will be administered as a single dose before the initiation of metformin treatment and 3 weeks and 12 weeks after. The drug will be used as a probe to assess CYP2B6 activity.
223780077|NCT04504045|DRUG|Losartan|As part of a 6-drug cocktail losartan 12.5 mg coated tablet will be administered as a single dose before the initiation of metformin treatment and 3 weeks and 12 weeks after. The drug will be used as a probe to assess CYP2C9 activity.
223780078|NCT04504045|DRUG|Omeprazol|As part of a 6-drug cocktail Omeprazol 10 mg enteric-coated tablet will be administered as a single dose before the initiation of metformin treatment and 3 weeks and 12 weeks after. The drug will be used as a probe to assess CYP2C19 activity.
223780079|NCT04504045|DRUG|Metoprolol|As part of a 6-drug cocktail metoprolol 12.5 mg release tablet will be administered as a single dose before the initiation of metformin treatment and 3 weeks and 12 weeks after. The drug will be used as a probe to assess CYP2D6 activity.
223780080|NCT04504045|DRUG|Midazolam|As part of a 6-drug cocktail midazolam 2 mg oral solution will be administered as a single dose before the initiation of metformin treatment and 3 weeks and 12 weeks after. The drug will be used as a probe to assess CYP3A4 activity.
223780081|NCT05813743|DIAGNOSTIC_TEST|3 dimensional ultrasound|Detect the accuracy of 3D ultrasonography in prenatal detection of bladder wall involvement in abnormally invasive placenta (AIP) at 3rd trimester of pregnancy .
223780082|NCT01717573|PROCEDURE|Deferred stenting|
223780083|NCT01717573|PROCEDURE|Conventional treatment|
223780084|NCT04151810|DRUG|CDP1|"Single dose part:~Cohort 1:400 mg/m2; Cohort 2: 500 mg/m2; Cohort 3: 750 mg/m2;~Multi-dose Part:~Starting dose: Cohort 1:400 mg/m2; Cohort 2/3: 500 mg/m2; Maintenance dose: Cohort 1:250 mg/m2, QW; Cohort 2/3: 500 mg/m2, Q2W;"
223780085|NCT04151810|DRUG|CDP1|Starting dose: 400 mg/m2; Maintenance dose: 250 mg/m2,QW;
223780086|NCT04151810|DRUG|TIP chemotherapy|Paclitaxel: 175 mg/m2 in day 1, Q3W; Ifosfamide: 1200 mg/m2 in day 1, day 2 and day 3, Q3W; Cisplatin: 25 mg/m2 in day 1, day 2 and day 3, Q3W; Participants received TIP chemotherapy up to 6 cycles (21 days per cycle).
223696010|NCT05136352|PROCEDURE|iPACK block|loco-regional anesthesia using infiltration between the popliteal artery and the capsule of the posterior knee
223780087|NCT06041477|DRUG|Oxaliplatin,calcium folinic acid, levofolinic acid, 5-FU|Hepatic arterial infusion chemotherapy with (oxaliplatin 135mg/m2 over 3hrs, calcium folinic acid 400mg/m2 or levofolinic acid 200mg/ m2 over 1.5hrs, 5-FU 400mg/m2 over 2hrs, 5-FU 2400mg/m2 over 46hrs,every 4 weeks)
223780088|NCT06041477|DRUG|Concurrent Lenvatinib|Lenvatinib 8mg/day combined with the HAIC from the first cycle
223780089|NCT06041477|DRUG|Concurrent PD-1 antibody|PD-1 antibody which is approved by authorities for HCC treatment combined with the HAIC from the first cycle (dosage and frequency according to instructions)
223780090|NCT06041477|DRUG|Sequential Lenvatinib|Lenvatinib 8mg/day combined with the HAIC from the third cycle for those patients who do not achieve complete response (CR)
223696011|NCT02601599|BEHAVIORAL|Motivational interviewing|"The medical student will deliver a brief (approximately 15 minute) consultation with the patient that is based on principles of social cognitive theory and motivational interviewing. The goals of this consultation will be to enhance the patient's motivation and self-efficacy regarding quitting, and collaboratively elicit a plan to stay quit after discharge. Patients will be offered the opportunity to receive a consultation from the attending physician to determine eligibility for pharmacotherapy (via a chart sticker).~Each student will counsel 1-3 smokers each over the 8-month academic period, with student training and intervention staggered over this time. Students will also re-contact the smoker at 1-week post-discharge via telephone or personal follow-up, to provide further support."
223696012|NCT02829255|OTHER|altitude exposure|altitude exposure
223696013|NCT00100061|DRUG|Cranberry juice|liquid juice taken daily
223696014|NCT00100061|DIETARY_SUPPLEMENT|Cranberry Juice|Taken orally
223696015|NCT00100061|DIETARY_SUPPLEMENT|Placebo cranberry juice|Placebo comparitor
223696016|NCT05511194|OTHER|Enhanced Recovery After Surgery therapeutic protocol|Feeding and early ambulation, double short IV antibiotic regimen.
223696017|NCT05511194|OTHER|Conventional management|Delayed feeding and ambulation, triple short IV antibiotic regimen.
223696018|NCT01228864|PROCEDURE|quality of life|survey
223696019|NCT01228864|PROCEDURE|Quality of life|
223696020|NCT05149599|DRUG|Saccharomyces cerevisiae|Saccharomyces cerevisiae, which is a pro-biotic, was given in capsule form, 500mg twice daily for 1 month
223696021|NCT06558084|DRUG|CDK4/6 Inhibitor|CDK4/6 inhibitor in first and second lines
223696022|NCT01565720|DRUG|Isavuconazole|oral
223696023|NCT01565720|DRUG|Placebo|oral
223696024|NCT01565720|DRUG|Moxifloxacin|oral
223696025|NCT02469740|DRUG|Ticagrelor|Patients that are randomly selected to receive ticagrelor during the first phase of the study will receive the dose of 90 mg BD orally. This will be continued for 4 weeks before the endothelial function test will be performed. If the patients are assigned in the 2nd phase of the study, they will receive 90 mg BD orally for 5 weeks (4 weeks plus a 1 week washout period).
223696026|NCT02469740|DRUG|Clopidogrel|Patients that are randomly selected to receive ticagrelor during the first phase of the study will receive the dose of 75 mg OD orally. This will be continued for 4 weeks before the endothelial function test will be performed. If the patients are assigned in the 2nd phase of the study, they will receive 75 mg OD orally for 5 weeks (4 weeks plus a 1 week washout period).
223696027|NCT02299882|DRUG|Vancomycin|Patient will be randomized to either vancomycin or no vancomycin. This treatment will take place prior to the closure of the incision from back surgery.
223696028|NCT01340547|DRUG|palifosfamide-tris|palifosfamide-tris IV infusion of 150 mg/m2 on Days 1, 2 and 3 every three weeks (21 day cycle)
223696029|NCT01340547|DRUG|Normal Saline|0.9% Normal Saline 250 ml IV infusion on Cycle 1 Day -1
223696030|NCT05351502|DRUG|Nitric Oxide 25,000 ppm|Intratumoral injection of 25,000 gNO
223696031|NCT05351502|DRUG|Nitric Oxide 50,000 ppm|Intratumoral injection of 50000 gNO
223696032|NCT05351502|DRUG|Nitric Oxide 100,000 ppm|Intratumoral injection of 100,000 gNO
223696033|NCT05351502|DRUG|Nitric Oxide selected dose|Intratumoral injection of selected does on gNO
223696034|NCT01542333|GENETIC|gene expression analysis|
223696035|NCT01542333|GENETIC|proteomic profiling|
223696036|NCT01542333|GENETIC|reverse transcriptase-polymerase chain reaction|
223696037|NCT01542333|GENETIC|western blotting|
223696038|NCT01542333|OTHER|immunohistochemistry staining method|
223696039|NCT01542333|OTHER|laboratory biomarker analysis|
223696040|NCT01542333|PROCEDURE|spectroscopy|
223696041|NCT01871142|DRUG|Placebo|100 mL
223696042|NCT01871142|DRUG|Aes-103|Single dose of 1000mg Aes-103 dissolved in 100 mL of Tropicana Pure Premium Orange Juice
223696043|NCT01871142|DRUG|Aes-103|Single dose of 3000mg Aes-103 dissolved in 100 mL of Tropicana Pure Premium Orange Juice
223696044|NCT03179527|DRUG|Anti-Platelet Drugs|Including aspirin and clopidogrel, etc
223696045|NCT03179527|DRUG|Lipid Regulating Drugs|Mainly including statins
223696046|NCT03179527|DRUG|Coronary Vasodilator|Mainly including nitrates
223696047|NCT03179527|DRUG|Shuanghe Decoction|Mainly including Ginseng, Poria, Calamus, Cyperus, Salvia miltiorrhiza, Radix Polygalae etc.
223696048|NCT02754557|OTHER|Breath-Focused Meditation|"Participants will attend two breath-focused meditation sessions per week for three weeks. During the breath focus task, participants are asked to alternatively focus their breathing (1.5 minutes of breathing and 15 seconds of rest). Participants will be asked to attend to the changing patterns of physical sensations as the breath moves in and out of your body. Focus your awareness on any sensations you may experience (e.g., your abdominal wall rising). Follow the sensations as you breathe in and all the way through until your breath leaves your body."
223696049|NCT02754557|DEVICE|Physiological Feedback|Participants will receive breath feedback, via dynamic velocity estimates from a respiration belt, which allows an analog of breath to be felt as vibration on their wrist via a tactile transducer on a table. The transducer is tuned to produce low frequencies so there is more vibration and less of an audible component than a regular speaker would produce.
223696050|NCT05267288|DRUG|afatinib|afatinib 40mg oral, bevacizumab 15mg/kg iv, every 21days, until progression disease, untolerated toxicities, or patient death.
223780091|NCT06041477|DRUG|Sequential PD-1 antibody|PD-1 antibody which is approved by authorities for HCC treatment combined with the HAIC from the third cycle for those patients who do not achieve complete response (CR) (dosage and frequency according to instructions)
223780092|NCT06087939|DEVICE|Mechanical ventilation|Mechanical ventilation (MV) is a life support technique that is routinely used in the intensive care units (ICUs) for patients with life-threatening conditions.
223696051|NCT06402630|DRUG|STS01|Participants are block randomised to be treated with 0.25%, 0.5%, 1.0%, 2% STS-01 or a matching placebo control topically once daily for 6 months with a 2-month follow up.
223696052|NCT06402630|DRUG|Placebo|Participants are block randomised to be treated with 0.25%, 0.5%, 1.0%, 2% STS-01 or a matching placebo control topically once daily for 6 months with a 2-month follow up.
223696053|NCT00997061|DRUG|HYCAMTIN|Observing patients on HYCAMTIN and other drugs for SCLC.
223696054|NCT05672121|DRUG|KH631|KH631: AAV vector containing a coding sequence for an anti-VEGF protein
223696055|NCT00002895|DRUG|chemotherapy|
223696056|NCT01237821|DRUG|BenzaClin|Topical, 1% Clindamycin/5% Benzoyl Peroxide, BID, 12 weeks
223696057|NCT01237821|DRUG|Effaclar|Topical, Bid, 12 weeks
223696058|NCT04920981|OTHER|atezolizumab|observational
223696059|NCT05644769|OTHER|Determine the presence of Human sequence Ang-(1-12) on no medication|Determine the presence of the human sequence of Ang-(1-12) in the plasma of ten normal male and female hypertensive patients on no medication.
223696060|NCT05644769|DRUG|Human sequence Ang-(1-12) on Lisinopril 40mg every day|Determine the presence of the human sequence of Ang-(1-12) in the plasma of 10 normal male and female hypertensive patients after four weeks on Lisinopril 40 mg every day.
223696061|NCT03534934|DIAGNOSTIC_TEST|Vital signs|"Heart rate, respirations, blood pressure, temperature, oxygen saturation~arterial oxygen saturation (SaO2), height and weight"
223696062|NCT03534934|DIAGNOSTIC_TEST|Urine Pregnancy Test|Urine pregnancy test done on woman of childbearing potential.
223696063|NCT03534934|OTHER|Questionnaires|Subject Questionnaire Calcium Intake Questionnaire Home and Work Activities Survey
223696064|NCT03534934|DIAGNOSTIC_TEST|Blood Test|Blood test for vitamin D level, Hemoglobin A1c, and creatinine level
223696065|NCT03534934|DIAGNOSTIC_TEST|Duel-energy X-ray absorptiometry scan|Bone density measurement
223696066|NCT03534934|DIAGNOSTIC_TEST|Multi-detector computed tomography|Hip and ankle CT scan
223696067|NCT03534934|DIAGNOSTIC_TEST|Dual-energy X-ray absorptiometry scan|Vertebral fracture assessment
223696068|NCT06187662|BEHAVIORAL|Checklist|This intervention consists of a checklist to guide blood culture decisions, that a clinician in a site randomized to Arm A will be asked to consult and complete prior to ordering or not ordering a blood culture; as the relevant clinical scenario occurs. Meaning, if a clinician in Arm A is faced with a scenario in which it is customary or usual care to consider a blood culture, the clinician will be asked to first review this checklist. The checklist is not a binding or absolute process - the clinician should use both the checklist and typical clinical judgment to decide if the blood culture test is needed or not. The checklist is based on prototypes used in the completed parent study, BrighT STAR and the earlier preliminary studies at Johns Hopkins.
223696069|NCT06187662|BEHAVIORAL|Targeted Messaging|This intervention consists of targeted messaging and education that the primary study team will create and ask the Arm B sites to deliver to the PICU clinicians, which focuses on the importance of diagnostic stewardship and the current evidence for the benefit/low risk nature of the stewardship program to date.
223696070|NCT06048536|DRUG|MR-130A-01 Transdermal patch|MR-130A-01 transdermal patch, containing 2.43 mg Norelgestromin, will be worn 28 days per cycle with no patch free period.
223696071|NCT06048536|DRUG|MR-130A-01 Transdermal patch|MR-130A-01 transdermal patch, containing 3.64 mg Norelgestromin, will be worn 28 days per cycle with no patch free period.
223696072|NCT06048536|DRUG|MR-130A-01 Transdermal patch|MR-130A-01 transdermal patch containing 4.86 mg Norelgestromin, will be worn 28 days per cycle with no patch free period
223696073|NCT06048536|DRUG|MR-130A-01 Transdermal patch|MR-130A-01 Transdermal patch MR-130A-01 transdermal patch containing 4.86 mg Norelgestromin, will be worn 21 days with a 7-day patch free period.
223696074|NCT05436275|BIOLOGICAL|CM310|300 mg every two weeks
223696075|NCT05436275|BIOLOGICAL|Placebo|once every two weeks
223696076|NCT04910256|DRUG|Huatuo Zaizao Pills|Patients take 8g of HuaTuo Zaizao pill three times a day. Treatment lasts for 12 weeks.
223696077|NCT04910256|OTHER|Basic treatment|"It accordance with the Guidelines for diagnosis and treatment of ischemic stroke in China,and the drug and dosage will be formulated by the researchers according to the clinical situation."
223696078|NCT02722486|DEVICE|Vestibular Rehabilitation/Balance Belt|With this device, a subject stands on a force platform on the ground, which measures his/her center of pressure. Additionally, there is laptop displaying the video-based exercise programs and a camera that senses the subject's linear sway, roll, and pitch. Information about the subject's position is transmitted via Bluetooth technology to a non-invasive vibrotactile belt which fits comfortably around the subject's waist, over his/her clothing. Using the Sensory Kinetics software, the subject will play a series of games projected on the laptop screen, which prompt him/her to sway in various directions while keeping both feet planted on the force platform.
223696079|NCT02722486|OTHER|Standard Vestibular Rehabilitation|This is the standard three-month vestibular rehabilitation therapy that patients are routinely referred to at Boston Children's Hospital.
223696080|NCT05804474|OTHER|Observational study|Observational study
223696081|NCT01427322|DRUG|Lapatinib|given orally 2-4 hours before first fraction of radiation therapy
223696082|NCT01427322|RADIATION|Radiation therapy|Standard radiation therapy
223780093|NCT05595291|OTHER|investigation of the factors affecting walking characteristics|In order to investigate the factors affecting walking characteristics, 2-minute walking test, 10-point VAS (overall prosthesis satisfaction level, socket comfort and satisfaction level, knee joint satisfaction level, prosthetic foot satisfaction level, pain level in amputated extremity) and locomotor capacity index will be applied.
223780094|NCT02618993|PROCEDURE|Realization of the V3 block in maxillofacial surgeries|bilateral mandibular block in maxillofacial surgeries
223780095|NCT01459796|DRUG|Rilonacept|Rilonacept 160 mg loading dose followed by Rilonacept 80 mg/2 mL injections qw for 52 weeks.
223780096|NCT01459796|DRUG|Placebo|Placebo loading dose followed by placebo injections (2 mL) qw for 52 weeks.
223780097|NCT01459796|DRUG|Allopurinol|Allopurinol 50 or 100 mg, orally daily for 52 weeks as background treatment.
223780098|NCT01002599|DEVICE|Boussignac TM CPAP|Post-operative patients will be fitted with a Boussignac TM CPAP mask immediately after extubation and oxygenation and pulmonary function will be measured over a 24 hour period.
223780099|NCT01002599|DEVICE|Venturi Face Mask|Post-operative patients will be fitted with a Venturi face mask immediately after extubation and oxygenation and pulmonary function will be measured over a 24 hour period.
223780100|NCT05283291|BEHAVIORAL|Directed Imagery Technique|"The sound recording will include a soothing light background music for approximately 30 minutes.~Imagination will be practiced, starting with the patient's focusing his/her attention on his/her breath, relaxation, and relaxation with the suggestions given in the recording with the accompaniment of relaxing music."
223780101|NCT02399267|PROCEDURE|Once daily screening|RTs will screen invasively ventilated patients between approximately 06:00 - 08:00 hours daily. To pass the 'readiness to wean screen' and undergo an SBT, specific criteria must be met.
223780102|NCT02399267|PROCEDURE|Twice daily screening|In the 'at least twice daily' screening arm patients will be screened at a minimum between approximately 6:00-8:00 hours and 13:00-15:00 hours daily. To pass the 'readiness to wean screen' and undergo an SBT, specific criteria must be met.
223780103|NCT02399267|PROCEDURE|PS SBTs|Patients are assigned a SBT technique. All SBTs for these patients must be conducted on PS =\< 8 cm H2O with PEEP =\< 5 cm H2O.
223780104|NCT02399267|PROCEDURE|T-piece SBTs|Patients are assigned a SBT technique. All SBTs for these patients must be conducted with T-piece.
223780105|NCT00413413|DRUG|Valsartan/amlodipine 80/5 mg|1 valsartan/amlodipine 80/5 mg tablet, 1 placebo capsule to match valsartan once daily
223696083|NCT01420653|DRUG|Maxigesic 325|Maxigesic USA (acetaminophen 325 mg + ibuprofen 97.5mg), three tablets four times a day with food for 48 hours
223696084|NCT01420653|DRUG|Acetaminophen|Acetaminophen 325 mg, 3 tablets four times a day, with food for 48 hours
223696085|NCT01420653|DRUG|Ibuprofen|Ibuprofen 97.5mg, three tablets four times a day, with food for 48 hours.
223696086|NCT01420653|DRUG|Placebo|placebo, three tablets four times a day, with food for 48 hours
223696087|NCT00167557|DRUG|Pegylated Interferon|180mcg SC weekly starting 30 days post transplant
223696088|NCT00167557|DRUG|Ribavirin|goal dose 13mg/kg starting 120 days post transplant for a minimum of 48 wks
223696089|NCT00167557|PROCEDURE|Liver Biopsy|Liver biopsies performed at 9 points in time from time of liver transplant
223696090|NCT04860427|DEVICE|trapezoidal condylar plate|trapezoidal condylar plate open reduction and fixation
223696091|NCT04860427|DEVICE|two miniplates|two miniplates open reduction and fixation
223696092|NCT03183011|OTHER|MRI|Cardiac MRI
223696093|NCT00598702|DRUG|IV Acetaminophen|Target is 1 to 7 days of therapy with intravenous (IV) Acetaminophen (IV APAP) at a dose of 40 to 75 mg/kg body weight/day administered as an IV infusion (or by syringe pump) over 15 minutes and given every 4 to 6 hours as a scheduled dose
223696094|NCT01749774|BEHAVIORAL|Physical activity counseling|
223696095|NCT01556737|DIETARY_SUPPLEMENT|High daidzein supplement|8 weeks exposure to the supplement, daily 100 mg of isoflavones
223696096|NCT01556737|DIETARY_SUPPLEMENT|High genistein supplement|8 weeks exposure to the supplement, daily 100 mg of isoflavones
223696097|NCT04920422|OTHER|No intervention|Retrospective analysis using database without any intervention assigned in the study.
223696098|NCT01387399|PROCEDURE|Cisplatin administered intraoperatively as hyperthermic intraperitoneal chemoperfusion|"Classical 3+3 dose escalation study of cisplatin administered as HIPEC (60mg/m², 80mg/m² and 100mg/m²)"
223696099|NCT03287583|BEHAVIORAL|SBIRT for Gambing|The SBIRT intervention uses a brief gambling screening assessment to determine whether or not a participant is at risk for problem gambling. This is followed by a structured short brief intervention to assist people in better understanding their risk for gambling and what they can do to limit that risk.
223696100|NCT03287583|OTHER|Enhanced Control|Participants randomized to the enhanced control condition will receive a handout with gambling resources.
223696101|NCT01444352|BIOLOGICAL|Pneumococcal vaccine Formulation 1|0.5 mL, Intramuscular (Low dose)
223696102|NCT01444352|BIOLOGICAL|Pneumococcal vaccine Formulation 2|0.5 mL, Intramuscular (Middle dose)
223696103|NCT01444352|BIOLOGICAL|Pneumococcal vaccine Formulation 3|0.5 mL, Intramuscular (High dose)
223696104|NCT01444352|BIOLOGICAL|Placebo|0.5 mL, Intramuscular
223696105|NCT05919004|DIAGNOSTIC_TEST|App-based spirometer|App-based spirometer to perform serial spirometry to assess lung function variatione
223696106|NCT00354471|PROCEDURE|Uterine Artery Embolization|
223696107|NCT05385185|DRUG|Camrelizumab or envafolimab|combine Camrelizumab or envafolimab with Recombinant human vascular endostatin
223696108|NCT02106910|DEVICE|Cytosponge|The Cytosponge is a simple, non-endoscopic device developed for endoscopic screening of subjects at risk for Barrett's esophagus (BE) by investigators at the University of Cambridge in the U.K. The Cytosponge is an ingestible gelatin capsule enclosing a compressed spherical polyurethane mesh sponge of 3 cm diameter, the center of which is attached to a string (Astralen, braided synthetic non-absorbable suture) (Figure 1). The capsule and string are swallowed with water. The string is held at the mouth without tension by means of a 7 cm cardboard tab attached to the string, and esophageal peristalsis and gravity move the capsule into the stomach. After 5 to 7 minutes (during which the gelatin capsule dissolves and the sponge is liberated), the sponge is withdrawn by gentle traction on the string and as it does so, collects cells from the lining of the esophagus. The sponge is placed in fixative for 48 hours, then the cells are pelleted, and processed into paraffin blocks
223696109|NCT02521766|DEVICE|Harmoni Modular Intraocular Lens|Two-component system consisting of a base and a separate optic that allows for an intraoperative exchange of the optic only without direct manipulation of the capsular bag
223780106|NCT00413413|DRUG|Valsartan 80 mg|1 valsartan 80 mg capsule, 1 placebo tablet to match valsartan/amlodipine 80/5 mg once daily
223780107|NCT00413413|DRUG|Valsartan 160 mg|1 valsartan 160 mg capsule, 1 placebo tablet to match valsartan/amlodipine 80/5 mg once daily
223696110|NCT02521766|DEVICE|Commercially Available Intraocular Lens|IOL per investigator's standard of care
223696111|NCT02521766|PROCEDURE|Optic exchange|Removal of one optic and replacement with another for the purpose of improving refractive outcomes
223696112|NCT00696683|OTHER|None, this is an observational study|
223696113|NCT02607007|OTHER|2% M.F. Milk|
223696114|NCT02607007|OTHER|White Bread|
223696115|NCT02607007|OTHER|Strawberry Jam|
223696116|NCT02607007|OTHER|31% M.F. Cheddar Cheese|
223696117|NCT02607007|OTHER|2% M.F. Plain Greek yogurt|
223696118|NCT02607007|OTHER|Soy Beverage|
223696119|NCT02607007|OTHER|Water|
223780108|NCT00541762|DIETARY_SUPPLEMENT|Fat perfusion to the small intestine|"1. Triglycerides, long chain fatty acids, medium chain fatty acids perfused to the small intestine~2. Orlistat perfused to the small intestine~3. DEXLOX as CCK-1 receptor antagonist"
223780109|NCT03789526|PROCEDURE|ultrasound guidance|ultrasound guidance of tendon injection
223696120|NCT01675427|OTHER|Interleukin 28B testing|Blood sampling for ILB28 genotyping
223780110|NCT03207750|BIOLOGICAL|Rotarix|Two doses administered orally according to a 0, 2 month schedule as per the immunization schedule for HRV vaccine administration in the US.
223780111|NCT03207750|BIOLOGICAL|Pediarix|Three doses administered intramuscularly according to a 0, 2, 4 month schedule.
223780112|NCT03207750|BIOLOGICAL|Hiberix|Three doses administered intramuscularly according to a 0, 2, 4 month schedule.
223780113|NCT03207750|BIOLOGICAL|Prevenar 13|Three doses administered intramuscularly according to a 0, 2, 4 month schedule.
223780114|NCT05859347|DEVICE|Repetitive Transcranial Magnetic Stimulation|rTMS is a non-invasive neuromodulatory technique that applies alternating magnetic fields to the scalp to induce electric currents in localized cortical tissue. The intervention (LF or HF rTMS) will be administered daily 5 days/week for 4 weeks, using the MagVenture MMC-140 circular coil, with the brain regions targeted as the bilateral prefrontal cortex and the insula.
223780115|NCT05447169|DIAGNOSTIC_TEST|EBV antibodies test|ELISA test of VCA-IgA，EBNA1-IgA，EA-IgA， Zta-IgA ，Rta-IgG and BNLF 2b in nasopharyngeal brushing and plasma
223780116|NCT05447169|DIAGNOSTIC_TEST|EBV DNA test|quantitative polymerase chain reaction, CRISPR-associated protein 12a and target sequencing of EBV DNA in nasopharyngeal brushing and plasma
223696121|NCT05997758|OTHER|SEEG stimulation|Electrodes already implanted in patient's anterior insula will be stimulated below the patient-specific threshold at which a seizure was induced. This stimulations will coincide with certain trials in the adaptation task.
223696122|NCT05997758|BEHAVIORAL|Adaptation task|Participants will perform a task that requires them to learn and correctly respond to outliers of two sorts; inconsequential outliers, which require no action, and outliers that are relevant to the course of stimuli and outcomes in future trials, requiring adaptive action.
223696123|NCT04343729|DRUG|Methylprednisolone Sodium Succinate|injectable solution at a dose of 0.5mg/kg
223696124|NCT04343729|DRUG|Placebo solution|injectable saline solution
223696125|NCT05068024|DRUG|FWD1509 MsOH|FWD1509 MsOH is administered orally once daily. The starting dose is 10 mg/day for dose-escalation phase, and the dose level to be investigated in the expansion study will depend on the emerging data. For dose-extension phase, the recommended Phase 2 dose will be administered.
223780117|NCT02462395|DEVICE|tDCS|"Sponge-electrodes (5 x 7 cm) will be postioned at Fz (anode) and over the spinous process of C7 (cathode). Stimulation intensity will be set to 2 mA.~A first group of CCH patients will have to apply the neurostimulation outside of an attack every day for 20 minutes during 4 weeks. A second group will use the tDCS device everyday for 8 weeks.~Adherence to the treatment will be evaluated by monitoring the time during which the device is switched on via an in-built software."
223780118|NCT01650389|BIOLOGICAL|MVA85A|
223780119|NCT01650389|BIOLOGICAL|Candin|
223780120|NCT01650389|BIOLOGICAL|BCG Vaccine SSI|"All infants who test negative by HIV PCR will receive BCG vaccination at 8 weeks of age.~Infants who test positive by HIV PCR will not receive BCG vaccination."
223780121|NCT04498650|DRUG|PQ912|PQ912 50 mg tablets and 150 mg tablets
223780122|NCT04498650|DRUG|Placebo|Placebo tablets to mimic PQ912 50 mg and 150 mg tablets
223780123|NCT00744536|DRUG|Lenalidomide and melphalan|Lenalidomide (Revlimid) 10 mg po daily for 21d/28 Melphalan (Melphalan) 2 mg po daily for 21d/28
223780124|NCT03129893|DEVICE|Cuffed tracheal tubes|Cuffed tracheal tube with an anatomically designed high volume - low pressure tube cuff, with a recommendation chart for tube size selection available for pediatric anesthesia
223780125|NCT03509935|OTHER|Intervention Ultrasound Group|"Protocol:~* US 4 pulmonary quadrants in each hemithorax: anterior and lateral, upper and lower regions (figure 1)~* US inferior vena cava, collaborative index or distensibility according to the patient's conditions, in spontaneous or controlled ventilation, respectively.~* Cardiac US: subjective evaluation of contractility in normal, discreetly reduced or severely reduced."
223780126|NCT02520635|DRUG|supra-early TEMODAL® chemotherapy|
223780127|NCT02520635|DRUG|standard TEMODAL® chemotherapy|
223780128|NCT02520635|RADIATION|Radiotherapy 60Gy|
223780129|NCT03931434|DIETARY_SUPPLEMENT|Aged Garlic Extract (AGE)|2400mg of Aged Garlic Extract (AGE)
223780130|NCT03931434|DIETARY_SUPPLEMENT|Placebo|Placebo
223780131|NCT01784705|DEVICE|Transcranial bright light therapy|The bright light treatment was given transcranially via ear canals by using bright light device. The bright light was produced using two light-emitting diodes (LEDs). The bright light was transmitted into both ear canals by an optical fibre. Daily 12 minutes TBL was taken at home during forenoon.
223780132|NCT01784705|DEVICE|Transcranial placebo treatment|The placebo treatment was given transcranially via ear canals by placebo device. Daily 12 minutes placebo treatment was taken at home during forenoon.
223780133|NCT01902849|OTHER|blood sampling for IL measurement|"Blood sampling to determine interleukins IL6 , IL10 plasma levels are drawn at the following moments:~* T0- before the induction of anesthesia (venous cannula insertion time)~* T1- after induction but before starting surgery~  * In the group I (TIVA -TCI) when the plasma concentration of propofol is 3-3.5 ng/ml~ * In group II (ISOFLURANE) when concentration of isoflurane in exhaled air (Et Isoflurane) is between 0.3-0.5%~* T2, T3- at 2 and 24 hours after surgery"
223780134|NCT04674059|OTHER|patient survey|A questionnaire will be delivered by the health care providers at Ndera Hospital, Kigali, Rwanda or CHUK, Hospital, Kigali, Rwanda. The questions will explore the patient's clinical characteristics, the current treatment and their experience with the mental health care system.
223696126|NCT01291654|DRUG|Paracetamol|po Paracetamol 15 mg/kg every 6 hours x 3 days
223696127|NCT01291654|DRUG|NSAID|IV indomethacin 2 mg/kg/dose for three doses at 12 hour intervals; or IV Ibuprofen 10 mg/kg infused over 15 minutes, followed by two doses of 5mg/kg each at 24 hour intervals (total of 3 doses).
223696128|NCT01291654|DRUG|D5W|Since the paracetamol is given q 6 hours, in order to maintain blinding of the clinical staff, a placebo (D5W) must be given intermittently between the doses of NSAID such that each infant will receive drug every 6 hours.
223696129|NCT00002121|DRUG|Diethylhomospermine|
223696130|NCT01524757|DRUG|Pantoprazole|pantoprazole 40mg 1dd1; 12 months
223696131|NCT04322981|BEHAVIORAL|Pharmacist-Led care|Rapid testing in a community pharmacy, with rapid linkage to care and treatment that is pharmacist-led
223696132|NCT04322981|BEHAVIORAL|Standard of Care (Hepatology)|Rapid testing in a community pharmacy, with standard of care referral to academic hepatology
223696133|NCT00700570|DRUG|bevacizumab [Avastin]|5mg/kg iv on day 1 of each 2 week cycle.
223696134|NCT00700570|DRUG|capecitabine [Xeloda]|1000mg/m2 iv on days 1-5 and 8-12 of each 2 week cycle
223696135|NCT00700570|DRUG|oxaliplatin|85mg/m2 iv on day 1 of each 2 week cycle
223696136|NCT04040270|BEHAVIORAL|Live drama+DVD+Worksheets|"Interactive live drama was proposed to enhance memories of the audience of health promotion programmes.~The interactive live drama and DVD conveyed educational information on healthy living habits (including physical activity and healthy eating) as well as the importance and suggested methods to enhance family well-being. Students were encouraged to share the information on healthy living habits and watched the DVD with their parents.~Worksheets were given to all students and encouraged to finish the worksheets with their parents."
223696137|NCT04040270|BEHAVIORAL|DVD+Worksheets|"The DVD conveyed educational information on healthy living habits (including physical activity and healthy eating) as well as the importance and suggested methods to enhance family well-being. Students were encouraged to share the information on healthy living habits and watched the DVD with their parents.~Worksheets were given to all students and encouraged to finish the worksheets with their parents."
223696138|NCT05895071|DRUG|5%potassium hydroxide|. In group-A 30 patients were given topical 5% potassium hydroxide solution on affected area once at night for upto 4 weeks
223696139|NCT05895071|DRUG|Liquid nitrogen|in group-B 30 patients treated with cotton bud method of cryotherapy with liquid nitrogen once every two weeks. Patients were reassessed at every two weeks. The treatment carried out upto 12 weeks or until complete recovery from warts.
223696140|NCT01796756|OTHER|Handover program|
223696141|NCT05734573|BEHAVIORAL|Family-based treatment|FBT is carried out by a family therapist who has received FBT training. The duration of FBT is commonly 6-12 months, in most cases comprising 10-20 sessions. At the beginning of treatment, there are weekly sessions; later in treatment, the sessions are less frequent. The patient and their family meet their psychiatrist every four to six weeks, and the family therapist also takes part in these meetings. The treatment is implemented in accordance with the FBT treatment manual.
223696142|NCT01316471|BEHAVIORAL|Online Behavioral Intervention|The online behavioral intervention is travel-themed and participants visit 8 destinations (1 per week) designed to take 30 min each to complete. The destinations serve as an online analog for the weekly sessions used when delivering behavioral interventions face-to-face. The 8 child destinations include: 1) education about chronic pain, 2) recognizing stress and negative emotions, 3) relaxation and distraction skills, 4) school, 5) cognitive skills, 6) sleep hygiene and lifestyle, 7) staying active, and 8) relapse prevention. The eight parent destinations include: 1) education about chronic pain, 2) recognizing stress and negative emotions, 3) operant strategies I, 4) operant strategies II, 5) modeling, 6) sleep hygiene and lifestyle, 7) communication, and 8) relapse prevention.
223696143|NCT01316471|OTHER|Education: Online Patient Education|The purpose of the online patient education group is to control for time, attention, and computer usage. Children and parents will be provided with access to a modified version of the study website that will provide links to information from publicly available educational websites about pediatric chronic pain management. Children and parents will log onto the web program weekly at the same interval as the Online Behavioral Intervention group. Children and parents will be asked to view 3 links each week and then report a few details pertaining to the content of what they viewed.
223696144|NCT04708379|BEHAVIORAL|Lifestyle intervention|Nutrition and physical activity education.
223696145|NCT00611533|DRUG|atomoxetine|Subjects will receive ATX 40mg/d x 1 week, then 80mg/d x 5 weeks followed by a 4-week wash out period that is followed by an additional 6 weeks of treatment in the alternate condition. The 4-week washout period include a 4-day taper in the first week.
223696146|NCT00611533|DRUG|placebo|Subjects will receive placebo equivalent for 6 weeks followed by a 4-week wash out period that is followed by an additional 6 weeks of treatment in the alternate condition. The 4-week washout period include a 4-day taper in the first week.
223696147|NCT01431131|PROCEDURE|Intrasocket graft|Intrasocket mineralized cancellous allograft
223780135|NCT00761839|BEHAVIORAL|After-care summary|"The wound care NP will measure the wound and assess adherence to the following self-management activities: visiting the wound care clinic as scheduled; offloading; applying dressings; obtaining assistance at home; and participating in social activities. This information will be entered into a computer database on a VA computer that will generate a summary chart showing the relationship between adherence and wound healing. The generated after-care summary will be discussed with the patient and used to set self-management goals."
223696148|NCT01431131|PROCEDURE|Intrasocket plus facial overlay graft|Intrasocket mineralized cancellous allograft plus a facial overlay graft of bovine xenograft
223696149|NCT00968318|PROCEDURE|Excision of strip of deep fascia|operative technique to excise deep fascia.
223696150|NCT04899427|DRUG|orelabrutinib|Orelabrutinib will be given as 150mg per day orally, until progression of the disease (PD), unacceptable toxicity, or patient/investigator discretion.
223696151|NCT04899427|DRUG|Sintilimab|Sintilimab 200mg intravenous infusion d1, every 21 days for 1 cycle. The medicine will be given until progression of the disease (PD), unacceptable toxicity, or patient/investigator discretion.
223696152|NCT04899427|DRUG|Tislelizumab|Tislelizumab 200mg intravenous infusion d1, every 21 days for 1 cycle. The medicine will be given until progression of the disease (PD), unacceptable toxicity, or patient/investigator discretion.
223696153|NCT04666675|DRUG|Upadacitinib|Oral; Tablet
223696154|NCT04666675|DRUG|Placebo for Upadacitinib|Oral; Tablet
223696155|NCT01787422|OTHER|Traditional versus Telemedicine office visit|
223696156|NCT00152360|DRUG|Orlistat|See Detailed Description.
223696157|NCT01978418|DRUG|salbutamol|Medication given once as a dose of 4 puffs at 30-60 minutes of age
223696158|NCT01978418|DRUG|Placebo|Placebo given once as a dose of four puffs at 30-60 minutes of age
223696159|NCT00400738|DRUG|Saquinavir, lopinavir, ritonavir|arm 1 = LPV/RTV 400/100 mg BID + SQV 1000 mg BID arm 2 = LPV/RTV 400/100 mg BID + SQV 600 mg BID arm 3 = LPV/RTV 266/66 mg BID + SQV 1000 mg BID arm 4 = LPV/RTV 266/66 mg BID + SQV 600 mg BID
223696160|NCT01359007|DRUG|Irinotecan, Oxaliplatin, Leucovorin, 5-FU|5-FU 2400 mg/m2 IV continuous infusion for 46-48 hours Days 1-3 for 2 weeks 5-FU 400 mg/m2 IV Bolus Day 1 Oxaliplatin 85 mg/m2 IV over 120min +/-30 min. Day 1 Irinotecan 180 mg/m2 IV to run over 90 min +/- 30 min Day 1 Leucovorin (Before bolus 5-FU) 400 mg/m2 IV over 120 min. +/- 30 Day 1 May give oxaliplatin and leucovorin concurrently
223696161|NCT01892267|DEVICE|PEG-J placement|PEG-J placement
223696162|NCT06534749|DEVICE|ultrasound|Ultrasound screening: by (SonoScape A6, Yizhe Building, Yuquan, Road Shenzhen, 518051, China). General-purpose diagnostic abdominal ultrasound equipment was used, with a 7.5-MHz linear-type probe. Screenings will be performed by radiologist with appropriate practice. The ultrasound examination will take 10 min for each patient. The recordings will consist of two bilateral renal images will be obtained and one transverse and longitudinal images. The urinary bladder will be observed with the patient in a supine position, and images will be recorded when abnormalities will be identified. The following will be investigated by ultrasound: number, size (including differences between sides), and location of the kidneys; pelvic dilatation; echogenicity, and other findings indicating cysts or tumours. Shape and wall thickening of the urinary bladder, as well as ureter dilatation, will be also examined
223780136|NCT00761839|BEHAVIORAL|Control group|Patients in the control group will receive usual counseling for self-management.
223780137|NCT03634579|DEVICE|MRI Guided Focal Laser Interstitial Thermal Ablation|"The procedure is done under general anesthesia. Laser fiber placement will be performed by one of two approaches (Trans gluteal or trans rectal) based on the target location within the prostate gland. When the needle position is deemed satisfactory, a 1.5-cm-active tip diode laser fiber will be introduced within an internally cooled catheter through the introducing sheath.~The catheter tip location will be confirmed on Turbo Spin-Echo (TSE) T2-weighted images in the axial and sagittal oblique planes.The introducer sheath will be withdrawn to allow contact of the active laser tip with the lesion. A laser test dose will be done at 9 Watts for about 30 seconds to confirm the site of fiber placement with the subsequent delivery of full dose ablation at 12-27 Watts. Ablation duration is determined based on real time feedback of response using real time temperature and damage estimate maps."
223780138|NCT04880941|BEHAVIORAL|Progressive Relaxation Exercise|In the progressive relaxation technique, the tension and anxiety in skeletal muscles are relatively relieved.
223780139|NCT02817789|DRUG|Ticagrelor alone|180 mg loading dose before intervention and 90 mg twice daily during 30 days after the procedure
223780140|NCT02817789|DRUG|Combination lysine acetylsalicylate - clopidogrel|75 mg before and 75 mg daily after the procedure of lysine acetylsalicylate and 300mg loading dose before and 75 mg of clopidogrel daily after the procedure
223696163|NCT03702517|DEVICE|lateral stair walking exercise|15 minutes of lateral stair walking exercise
223696164|NCT03702517|DEVICE|traditional physiotherapy|strengthening exercise, balance training and gait training
223696165|NCT05551208|DRUG|fluzopanib and bevacizumab|fluzopanib and bevacizumab were used for maintenance treatment
223696166|NCT06173934|DRUG|insulin injection 15 minutes before meals|Adjust insulin injection time to observe blood glucose spectrum
223696167|NCT06173934|DRUG|Insulin injection 15 minutes after eating|Adjust insulin injection time to observe blood glucose spectrum
223696168|NCT04138004|DRUG|polyethylene glycol in combination with lubiprostone|2-litre polyethylene glycol split-dose in combination with one 24 mcg tablet of lubiprostone
223696169|NCT04138004|DRUG|polyethylene glycol alone|4-litre polyethylene glycol split-dose
223696170|NCT01825525|DEVICE|Exposure to ScopeGuide|The 2 minute protocol exposure to the electromagnetic field of the ScopeGuide device.
223696171|NCT00135564|BIOLOGICAL|MenC-TT|
223696172|NCT00135564|BIOLOGICAL|Hib-MenC-TT|
223696173|NCT04256226|PROCEDURE|Tumor excision|Excision of GIST
223696174|NCT02540616|DEVICE|Transcranial Electrical Stimulation|A form of external neuromodulation using electrodes on the surface of the head. We will be using the TCT tDCS device (www.trans.cranial.com) or devices constructed by our research group or collaborators.
223696175|NCT00922233|DRUG|levonorgestrel|oral contraceptive pills
223696176|NCT00001966|DRUG|Mind-body therapy|
223696177|NCT01461980|BIOLOGICAL|rLP2086 + MCV4 + Tdap|At visit 1, group 1 will receive MCV4 + Tdap vaccines concomitantly with an injection of rLP2086. At visits 3 and 5 (Months 2 and 6), group 1 will receive an injection of rLP2086.
223696178|NCT01461980|BIOLOGICAL|MCV4 + Tdap + saline|At visit 1, group 2 will receive MCV4 + Tdap vaccines concomitantly with an injection of saline. At visits 3 and 5 (months 2 and 6), this group will receive a saline injection only.
223696179|NCT01461980|BIOLOGICAL|rLP2086 + saline|At visit 1, group 3 will receive 2 injections of saline concomitantly with an injection of rLP2086. At visits 3 and 5 (Months 2 and 6), group 3 will receive an injection of rLP2086. Subjects randomized to this group will receive MCV4 and Tdap following their final visit blood draw (Visit 6).
223696180|NCT06029738|BEHAVIORAL|Metacognitive Training for Obsessive-Compulsive Disorder (MCT-OCD)|MCT-OCD is a group education for OCD patients.
223696181|NCT02785315|BEHAVIORAL|rehabilitation & remediation approach|The rehabilitation \& remediation approach group will receive 12 weekly 90-minute combined cognition interventions in a group. The first half of each session will be cognitive training which focus on teaching various cognitive strategies to enhance the attention, memory, processing speed, and executive functions. The second half of the session will apply rehabilitation intervention by discussing everyday situations with memory problem and specific strategies related to real-life situations. Investigators will also include one individual session in the 12 group sessions.
223696182|NCT02785315|BEHAVIORAL|remediation approach|The remediation approach will receive 12 weekly 90-minute cognitive training which focus on teaching various cognitive strategies and their applications to enhance the attention, memory, processing speed, and executive functions.
223696183|NCT00808678|DRUG|ABT-143|once, see arm description for more information
223696184|NCT00808678|DRUG|ABT-335|once, see arm description for more information
223696185|NCT00808678|DRUG|rosuvastatin|once, see arm description for more detail
223696186|NCT02364921|DEVICE|Two multilayer compression bandage|"Usual clinical practice in venous ulcer in wound care in assessing, cleaning, desinfection, debridement and topical treatment.~Compression therapy: a multilayer compression bandage with two layers, suitable for the treatment of venous leg ulcers and to reduce edema chronic venous be used. Apply one two seven days"
223696187|NCT02364921|DEVICE|Crepe bandage|Crepe bandage: Usual clinical practice in venous ulcer in wound care. crepe bandage apply one to seven days
223696188|NCT06228274|DEVICE|ARTHRUM 2.5%|ARTHRUM 2.5%
223696189|NCT03731845|GENETIC|Blood sample for genetic test|Patients will be genotyped for single nucleotide polymorphism previously found to be associated with age at natural menopause
223696190|NCT03731845|BIOLOGICAL|Blood sample for hormonal measurement|at each visit : 2x7ml. At the end of the study hormonal measurements (AMH, P4, LH, FSH, E25)
223696191|NCT03731845|OTHER|Ovarian ultrasound scan|Ovarian ultrasound scan at follow up visits (Y1,Y1.5, Y2.5 Y3.5 Y4.5 Y5.5)
223696192|NCT01933958|DRUG|Regorafenib (Stivarga, BAY73-4506)|The usual dosage is 160 mg of Regorafenib/ STIVARGA taken orally after meal once daily for 3 weeks on therapy followed by 1 week off therapy to comprise a cycle of 4 weeks.
223780141|NCT02905526|BEHAVIORAL|Contraceptive instant messages|Contraceptive Instant messages
223780142|NCT02905526|OTHER|Mobile phone app|Mobile phone app
223780143|NCT02297152|DEVICE|FLIP HOLE|The subjects had to use the masturbator aid at least five times per week for six weeks, during a minimum of five minutes without never overcoming half daily hour and during intercourse. The device Flip Hole is a masturbation aid made from Thermoplastic Elastomer (a silicone like substance) that the user inserts their penis in to for stimulation.
223780144|NCT01897584|OTHER|inverse IE|in only one group changes of I:E ratio would be applied
223780145|NCT05983653|PROCEDURE|arthrocentesis without PRP|150 ml arthrocentesis without PRP
223780146|NCT05983653|PROCEDURE|arthrocentesis with PRP|150 ml arthrocentesis with PRP
223780147|NCT03727204|PROCEDURE|On-pump cardiac surgery|All participants will undergo on-pump cardiac surgery
223780148|NCT00877448|BIOLOGICAL|Adjuvanted Multimeric-001 250 Mcg|
223780149|NCT00877448|BIOLOGICAL|Multimeric-001 250 Mcg|
223780150|NCT00877448|BIOLOGICAL|Phosphate Buffered saline|
223780151|NCT00877448|BIOLOGICAL|Adjuvanted PBS|
223780152|NCT00877448|BIOLOGICAL|Adjuvanted Multimeric-001 500 Mcg|
223780153|NCT00877448|BIOLOGICAL|Multimeric-001 500 Mcg|
223780154|NCT00877448|BIOLOGICAL|Multimeric-001 125 Mcg|
223780155|NCT00592449|BEHAVIORAL|Cognitive behavioral therapy (CBT) for insomnia|During CBT, participants will learn how to change their sleeping habits and reduce arousal and alertness while trying to sleep. Participants will attend 8 weekly CBT sessions with a psychologist.
223780156|NCT00592449|BEHAVIORAL|Behavioral desensitization treatment for insomnia|The behavioral desensitization treatment is designed to decondition states of arousal that interfere with sleep. Participants will attend 8 weekly behavioral desensitization treatment sessions with a psychologist.
223780157|NCT03673436|PROCEDURE|Lumbar spinal fusion|The patient got a instrumented fusion of a maximum of 3 adjacent vertebrae
223780158|NCT00907270|DIETARY_SUPPLEMENT|Cholecalciferol|Cholecalciferol: 4,000 IU/day and 400 IU/day
223780159|NCT03321019|DRUG|Capsaicin|Participants will inhale aerosolized capsaicin with the goal of this inducing cough and an urge-to-cough.
223780160|NCT03321019|DEVICE|Resistive respiratory loads|Participants will breath through a mouthpiece. Every 3-5 breaths in, a respiratory load will be applied. Participants will be asked to rate the magnitude of the load.
223780161|NCT03321019|OTHER|Event-related evoked potential using electroencephalography (EEG).|The study team will use EEG time-locked to a respiratory occlusion to measure the brain's response to respiratory sensation.
223780162|NCT03321019|PROCEDURE|Fluoroscopic swallow evaluation|Participants will swallow various consistencies of barium under fluoroscopy (moving-picture x-ray) in order to assess swallowing safety and efficiency.
223780163|NCT01961869|OTHER|Fast release BRB confection|Fast release BRB confection includes lyophilized black raspberry powder, corn syrup, and sugar. All ingredients are generally regarded as safe (GRAS) food ingredients
223780164|NCT01961869|OTHER|Intermed release BRB confection|Intermediate release BRB confection includes lyophilized black raspberry powder, corn syrup, sugar, and pectin. All ingredients are generally regarded as safe (GRAS) food ingredients
223780165|NCT01961869|OTHER|Prolong release BRB confection|Prolonged release BRB confection includes lyophilized black raspberry powder, corn syrup, corn starch, and sugar. All ingredients are generally regarded as safe (GRAS) food ingredients.
223780166|NCT04481347|DEVICE|Sleep EEG recording using a DREEM® headband|Sleep EEG recording using a Dreem® headband (Rythm, Paris, France), an EEG recording device adapted to sleep conditions and completely non-invasive
223780167|NCT04481347|OTHER|Montreal Cognitive Assessment (MoCA)|Neuropsychological assessment using the The Montreal Cognitive Assessment (MoCA) questionnaire to detect postoperative cognitive dysfunction
223780168|NCT04481347|DEVICE|Intraoperative EEG recording using a Sedline® monitoring|Intraoperative brain function monitoring using a Sedline® module (Masimo corporation) to evaluate the state of the brain under anesthesia
223780169|NCT01899976|DEVICE|X-Suit NIR Covered Biliary Stent|
223780170|NCT03380039|GENETIC|CAR-BCMA T cells|"Single dose of CAR-BCMA T cells will be infused, and classic 3+3 dose escalation will be applied."
223780171|NCT03380039|DRUG|Fludarabine|Fludarabine is used for lymphodepletion.
223696193|NCT03491306|OTHER|PEEK|PEEK has been successfully used over the last years in the medical ﬁeld, and orthopedics, speciﬁcally. which presents high bio compatibility, good mechanical properties, high temperature resistance, and chemical stability due to a 4 GPa modulus of elasticity, it is as elastic as bone and can reduce stresses transferred to the abutment teeth.Additional advantages of this polymer material are elimination of allergic reactions and metallic taste, high polishing qualities, low plaque afﬁnity, and good wear resistance, it has only recently been used in dentistry.
223696194|NCT03491306|OTHER|Breflex|"In the recent time thermoplastic materials become quite popular in clinical practice such as nylon and acetal resins. since the 1950, poly-amide resin (nylons) provide improved esthetics and reduction of rotational forces on the abutment teeth due to their low elastic modulus(3).~The major disadvantage of a nylon removable denture is the inability for a reline procedure and the lack of occlusal rests as well as rigid frameworks, that could lead to occlusal instability and sinking, especially in Kennedy class I and II cases. On the other hand, acetal resins present adequate mechanical strength to form a frame-work more rigid than nylon with retentive clasps, connectors, and supportive elements; however, the acetal resin material lacks natural translucency and vitality."
223696195|NCT04102943|DRUG|tacrolimus tablet|"* Orally, twice a day in the morning and night~* After first dose 0.1mg/kg, check the blood concentration of tacrolimus at each visit and adjust the dose to acheive the blood concentration maintaining at 7\~12ng/ml for 0 to 3months and then at 5\~8ng/ml for 3 to 6months of study treatment."
223696196|NCT04102943|DRUG|tacrolimus capsules|"* Orally, twice a day in the morning and night~* After first dose 0.1mg/kg, check the blood concentration of tacrolimus at each visit and adjust the dose to acheive the blood concentration maintaining at 7\~12ng/ml for 0 to 3months and then at 5\~8ng/ml for 3 to 6months of study treatment."
223696197|NCT05117333|OTHER|Reminder (information letter)|Reminders
223696198|NCT05769309|PROCEDURE|Erector spinae block|After induction, the patients will be administered bilateral Erector spinae block with 20 ml of 0.25 % bupivacaine
223696199|NCT05769309|DRUG|Fentanyl|fentanyl boluses of 0.5-to-1 µg/kg titrated according to haemodynamic parameters.
223696200|NCT02655978|OTHER|Magnetic Resonance Imaging|
223696201|NCT01341197|OTHER|Fecal immunochemical test, guaiac fecal occult-blood test, and Helicobacter pylori stool antigen test|
223696202|NCT02540226|DRUG|Intravenous tranexamic acid|
223696203|NCT02540226|DRUG|Topical tranexamic acid|
223696204|NCT02540226|DRUG|Intravenous saline|
223696205|NCT02540226|DRUG|Topical saline|
223696206|NCT00109200|DRUG|Xolair (omalizumab)|
223696207|NCT03416907|BEHAVIORAL|Original consent form|Participants will review the full-length, original consent form for the clinical trial.
223696208|NCT03416907|BEHAVIORAL|Shortened consent form|Participants will review a shortened consent form for the clinical trial, which includes only material indicated as important by 2/3 of participants from a previous study.
223696209|NCT03416907|BEHAVIORAL|Reordered, shortened consent form|Participants will review a reordered, shortened consent form. This form is based on the shortened consent form, but the sections are reordered based on a previous study, such that sentences previously rated as more likely to impact a participant's decision is more likely to be presented first (except for an initial introductory section).
223696210|NCT03416907|BEHAVIORAL|Shortened consent form with a highlights box|Participants will review a shortened consent form with a highlights box, where the highlights box includes the 10 sentences rates as most likely to impact a participant's decision from a previous study.
223696211|NCT03416907|BEHAVIORAL|Interactive, shortened consent form|Participants will review an interactive, shortened consent form, where hyperlinks to different sections of the consent form are provided. The landing page includes the introductory section.
223696212|NCT03177057|BEHAVIORAL|Compliance Monitoring|Record behavior
223696213|NCT03177057|OTHER|Health Telemonitoring|Receive health monitoring text messages
223696214|NCT03177057|OTHER|Questionnaire Administration|Ancillary studies
223696215|NCT01425788|BIOLOGICAL|Osiris Phleum pratense|
223696216|NCT01425788|BIOLOGICAL|Osiris Phleum pratense|
223696217|NCT01425788|BIOLOGICAL|Osiris Phleum pratense|
223696218|NCT01701921|DRUG|Pregabalin 75mg|Pregabalin 75mg by mouth one hour before surgery
223696219|NCT01701921|DRUG|pregabalin 150 mg|pregabalin 150mg by mouth one hour before surgery
223696220|NCT01701921|DRUG|Placebo|Sugar pill designed to mimic pregabalin capsule, by mouth one hour before surgery
223780172|NCT03380039|DRUG|Cyclophosphamide|Cyclophosphamide is used for lymphodepletion.
223780173|NCT00338026|DRUG|ECO-4601|Continuous IV infusion for 14 days with 7 days recovery (21 day cycle)
223780174|NCT05154903|DRUG|Citicoline 500 MG|Citicoline will be administered in continuous iv infusion in a dose of 2000 mg per day for the first week following AIS then by oral route for the next 5 weeks.
223780175|NCT01070290|DRUG|ARQ 197|120 mg capsule administered twice daily
223780176|NCT01070290|DRUG|Oxaliplatin, capecitabine or irinotecan|Investigator's choice or oxaliplatin, capecitabine or irinotecan
223780177|NCT06429306|DRUG|Dexycu|5ul dexamethasone, concentration: 103.4 μg/μl, equivalent to 517μg dexamethasone
223780178|NCT06429306|DRUG|Placebo|Acetyl triethyl citrate
223780179|NCT01533610|PROCEDURE|Stellate ganglion block|Local anesthesia applied to the stellate ganglion in the neck
223780180|NCT02036099|OTHER|Driving in Mild Dementia Decision Tool|
223780181|NCT04341038|DRUG|Tacrolimus|the necessary dose to obtain blood levels of 8-10 ng / ml
223780182|NCT04341038|DRUG|Methylprednisolone|120mg of methylprednisolone daily for 3 consecutive days
223780183|NCT06155786|DEVICE|transcranial direct current stimulation (tDCS) active stimulator|In tDCS the electrical current is applied directly between electrodes mounted on the head which can can de-or hyperpolarizes resting membrane potential and thereby modulate cortical excitability
223780184|NCT06155786|DEVICE|transcranial random noise stimulation (tRNS)|Here, an alternating electrical current is applied at a mix of frequencies it is called transcranial random noise stimulation (tRNS), which can be delivered in low (between 0.1-100 Hz) or high (between 101-640 Hz) frequency stimulation
223780185|NCT06155786|DEVICE|transcranial direct current stimulation (tDCS) sham stimulator|Here a sham electrical current is applied directly between electrodes mounted on the head which can can de-or hyperpolarizes resting membrane potential and thereby modulate cortical excitability
223780186|NCT00296556|DRUG|Rivenprost (drug)|
223780187|NCT02283502|DEVICE|MRgHIFU system|Magnetic resonance-guided high-intensity focused ultrasound (MRgHIFU) system for the noninvasive treatment of uterine fibroids
223780188|NCT06359405|BEHAVIORAL|drug safety simulation|"The intervention's purpose is to develop a simulation program to increase nursing students' crisis management skills regarding medication safety. This simulation program will provide students with the opportunity to develop skills in recognizing, evaluating, and effectively intervening in medication errors in real-world scenarios.~The simulation program will include interactive case scenarios, virtual patients, and simulation sessions led by an instructor providing feedback to students. Also, medicine Learning materials covering preventing, recognizing, and correcting errors will also be provided."
223780189|NCT05668793|DIAGNOSTIC_TEST|GNB4 and Riplet Gene Methylation Combined Detection Kit (Fluorescent PCR Method)|Blood samples from participants in the group were collected and methylation tests were performed according to the kit instructions.
223780190|NCT04645212|BIOLOGICAL|ADVM-022|Long term follow-up of subjects that received ADVM-022
223780191|NCT06377735|PROCEDURE|BAI-BACE|Bronchial arterial infusion, bronchial arterial chemoembolization (BACE-BAI) procedure was performed as follows: Bronchial arteriography was performed to find tumor-feeding artery. After the catheter had been inserted into the tumor-feeding artery, paclitaxel (300 mg) was infused slowly at least 30 min. BAI (bronchial arterial infusion) chemotherapy was followed by BACE (Drug-eluting beads bronchial arterial chemoembolization); the CalliSpheres loaded with cis-platinum (30 mg) were infused into the tumor-feeding arteries until stasis or near-stasis of blood flow in the vessel was observed.
223780192|NCT01085175|DRUG|LMI 1195|Single bolus intravenous injection of LMI 1195
223780193|NCT02672371|DEVICE|Active eMNS|Each session will consist of right eMNS stimulation that will last 20-minutes. The frequency of stimulation will be random assigned using random frequency interval. The electrodes that will be used will be standard transcutaneous electrodes. The electrodes will be placed on the wrist.
223780194|NCT02672371|DEVICE|Sham eMNS|Each session of sham eMNS will be the same as active, except the device will be turned off. Similar parameters will be used (for 20 minutes and same electrode placement), except no stimulation will be delivered.
223780195|NCT01443442|DRUG|bepotastine besilate, 1.5%|Topical ocular aqueous formulation, oen drop per instillation, twice per day for 14 days
223780196|NCT01443442|DRUG|Loteprednol etabonate|Topical ocular aqueous formulation, one drop per instillation, four times per day for 14 days
223780197|NCT02317159|DRUG|Imatinib|400mg imatinib qd PO
223780198|NCT04150575|DRUG|HLX10+Albumin-Bound Paclitaxel|HLX10: 4.5 mg/kg/3w+Albumin-bound paclitaxel: 260 mg/m2/3w.Albumin-bound paclitaxel may be used for up to 6 cycles, and HLX10 for up to 2 years.
223780199|NCT06354153|OTHER|Polarity Management Training Program|60 first-line nurse managers received a training program involving theoretical and practical sessions
223780200|NCT02466308|DEVICE|SAM Ultrasound Diathermy Device|
223780201|NCT01578551|DRUG|Paclitaxel|200 mg/m² IV over 3 hours, day 1 of each cycle. Paclitaxel + Carboplatin + Bevacizumab will be administered once every 21 days (Day 1) for up to 6 cycles. If subject has complete response, partial response, stable disease, or unacceptable toxicity. Bevacizumab with Metformin (Arm A) or Bevacizumab alone (Arm B) may continue as maintenance therapy.
223780202|NCT01578551|DRUG|Carboplatin|"Carboplatin is administered at AUC= 6 mg/ml X min IV over 15-30 minutes, immediately following Paclitaxel infusion every 21 days~Paclitaxel + Carboplatin + Bevacizumab will be administered once every 21 days (Day 1) for up to 6 cycles. If subject has complete response, partial response, stable disease, or unacceptable toxicity. Bevacizumab with Metformin (Arm A) or Bevacizumab alone (Arm B) may continue as maintenance therapy"
223780203|NCT01578551|DRUG|Bevacizumab|All patients will receive the drug at 15 mg/kg every 21 days, given immediately after completion of chemotherapy, starting with Cycle 1. After induction chemotherapy is completed (4 cycles), bevacizumab will continue at 15 mg/kg every 21 days until PD (provided neither PD nor toxicity requiring discontinuation has occurred) measured from date of first dose of bevacizumab.
223780204|NCT01578551|DRUG|Metformin|1000 mg twice daily with food.
223780205|NCT05458349|DEVICE|acellular dermis|
223780206|NCT00996567|DRUG|Cetuximab (Erbitux)|Patients will be treated with standard chemotherapy (4-6 cycles), combined with weekly administration of Cetuximab (Erbitux) until disease progression.
223780207|NCT00766415|DRUG|AZD1981|Oral tablet, twice daily, 4 weeks treatment
223780208|NCT00766415|DRUG|Placebo|Placebo
223780209|NCT02430077|DRUG|Obeticholic Acid|Capsules of obeticholic acid (OCA) or an identical placebo in the dose of 25 mg/day for a period of 4 months .
223780210|NCT02430077|DRUG|Placebo|Identical to Obeticholic Acid - placebo drug
223696221|NCT05559398|DRUG|Glenzocimab|"Glenzocimab (ACT-017, Acticor Biotech) is formulated for IV administration as a sterile product with 20 mM sodium citrate and 130 mM sodium chloride buffer at pH of 5.0.~It is supplied for clinical trial use in vials containing 50 mL of the drug product at a concentration of 10 mg/mL.~Each vial contains 500 mg of glenzocimab. Two vials (2x500 mg) of glenzocimab should be administered concomitantly for eligible patients for a total daily dose of 1g.~Glenzocimab is intended to be administered as an IV infusion over 6 hrs, with 1/4 of the dose administered by a 15-minute bolus and 3/4 of the dose administered by 5h45min-slow infusion."
223696222|NCT05559398|DRUG|Placebo|Placebo of glenzocimab is 0.9%NaCl (Acticor Biotech) for IV administration. It is supplied for clinical trial use in vials of 50 mL. Two vials of placebo of glenzocimab should be administered concomitantly for eligible patients.
223696223|NCT00436241|DRUG|Oxaliplatin|85mg/m2 iv on day 1 of each 2 week cycle
223696224|NCT00436241|DRUG|capecitabine [Xeloda]|1000mg/m2 po bid on days 1-10 of each 2 week cycle
223696225|NCT05712434|OTHER|Long Intervention|Each unit will start with iodine protocol, which uses 10% povidone-iodine for disinfection during Foley insertion, for 2 months. After the designated duration of protocol (determined by the results of randomization), each unit will than switched to CHG protocol for 4 months, in which 2% aqueous chlorhexidine solution are used instead of iodine solution. Subsequently, in the final 6-month phase of study, each unit will than switched to CHG plus protocol, in which 0.05% CHG impregnated gel will be used alongside 2% CHG solution during Foley insertion.
223696226|NCT05712434|OTHER|Mid-length Intervention|Each unit will start with iodine protocol, which uses 10% povidone-iodine for disinfection during Foley insertion, for 4 months. After the designated duration of protocol (determined by the results of randomization), each unit will than switched to CHG protocol for 4 months, in which 2% aqueous chlorhexidine solution are used instead of iodine solution. Subsequently, in the final 4-month phase of study, each unit will than switched to CHG plus protocol, in which 0.05% CHG impregnated gel will be used alongside 2% CHG solution during Foley insertion.
223696227|NCT05712434|OTHER|Short Intervention|Each unit will start with iodine protocol, which uses 10% povidone-iodine for disinfection during Foley insertion, for 6 months. After the designated duration of protocol (determined by the results of randomization), each unit will than switched to CHG protocol for 4 months, in which 2% aqueous chlorhexidine solution are used instead of iodine solution. Subsequently, in the final 2-month phase of study, each unit will than switched to CHG plus protocol, in which 0.05% CHG impregnated gel will be used alongside 2% CHG solution during Foley insertion.
223696228|NCT02268955|DRUG|IV Ibuprofen|Intravenous ibuprofen will be administered for treatment of pain in adults presenting to the ED with biliary colic
223696229|NCT02268955|DRUG|Saline|Saline will be administered to the placebo group
223696230|NCT00631696|DRUG|Pregabalin|pregabalin 600 mg given twice a day
223696231|NCT00631696|DRUG|Placebo|Placebo
223696232|NCT00691067|DRUG|mifepristone|200 mg po per day x 6 weeks
223696233|NCT00691067|DRUG|Placebos|placebo
223696234|NCT04726670|OTHER|Evaluation of postoperative pain|"A participant voluntary consent form was obtained from each patient. Ninety patients were numerically coded in computer environment by someone who was not included in the study for randomization (www.random.org).~A single clinician performed retreatment on each of the 90 teeth during a single visit."
223696235|NCT01400165|DRUG|Trazodone|each subject will be taken 1 tablet of Trazodone 150mg of each group (brand/generic)
223696236|NCT01400165|DRUG|Quetiapine|each subject will be taken 1 tablet of Quetiapine 100mg of each group (brand/generic)
223696237|NCT01400165|DRUG|Pindolol|each subject will be taken 1 tablet of Pindolol 10mg of each group (brand/generic)
223696238|NCT01400165|PROCEDURE|Blood Collection|Blood Samples will be collected at a predefined time-frame to study the plasma level of each medication.
223696239|NCT00630370|DRUG|Placebo|2 Placebo tablets, TID, orally, 58 days
223696240|NCT00630370|DRUG|20 mg ATI 7505|1 ATI 20mg and 1 placebo tablet, TID, orally, 58 days
223696241|NCT00630370|DRUG|40 mg ATI 7505|1 ATI 40mg and 1 placebo tablet, TID, orally, 58 days
223696242|NCT00630370|DRUG|80 mg ATI 7505|2 ATI 40mg tablets, TID, orally, 58 days
223696243|NCT06421116|PROCEDURE|Synovial ultrasound-guided biopsy Intestinal biopsy|Patients will undergo biopsies if needed for standard-of-care follow-up and after clinical indication.
223696244|NCT01292785|DRUG|Hormones|"FtM will receive~* 1000mg testosterone undecanoate every 12 weeks (Nebido® 4ml i.m.), or alternatively 50mg testosterone transdermally (Testogel® 5g-bag per day) and~* if menstruation still occurs, additionally either lynestrenol Orgametril® (2-3 tablets/day) or in some cases 0.075mg desogestrel (Cerazette®, 1 tablet/day).~MtF will receive~* 50mg cyproterone acetate daily (Androcur®)~* estradiol 100µg transdermal therapeutic system (TTS) twice a week (Estradot®, Estramon®), especially if subjects age is \> 40 years, or p.o. estradiol 2x2mg (Estrofem®) if subjects age is \< 40 years; alternatively estradiol 0,75-1,5mg (1-2 hubs) transdermally (Estrogel-Gel®) and~* 2,5mg alpha-5-reductase-inhibitor every 2nd day (Finasterid Actavis/ Arcana/ Aurobindo®) in case of extensive hair loss."
223696245|NCT00559936|DRUG|Topical Avastin 1%|Avastin (bevacizumab) 1%
223696246|NCT04693455|DRUG|ZD03|ZD03 capsule
223696247|NCT04693455|OTHER|Placebo|placebo capsule
223696248|NCT02016430|BEHAVIORAL|MeLT Dietary intervention|Mediterranean diet containing food with low TMAO content.
223696249|NCT02016430|BEHAVIORAL|TLC Dietary intervention|Standard American Heart Association (AHA) recommendations for dietary counseling.
223696250|NCT02016430|BEHAVIORAL|MeLT dietary intervention with TMAO|Mediterranean diet containing food with low TMAO content with TMAO levels provided to the subject for guidance.
223696251|NCT01938573|DRUG|Cisplatin|Given IV
223696252|NCT01938573|DRUG|Gemcitabine Hydrochloride|Given IV
223696253|NCT01938573|DRUG|Sirolimus|Given PO
223696254|NCT01938573|PROCEDURE|Cystectomy|Undergo cystectomy when appropriate
223696255|NCT01649609|DRUG|Tacrolimus|Reduction of standard immunosuppression - The standard of care immunosuppression treatment commonly used for renal transplant patients
223696256|NCT01649609|DRUG|Mycophenolate acid|Myfortic or CellCept - The standard of care immunosuppression treatment most commonly used for renal transplant patients
223696257|NCT01649609|DRUG|Sirolimus|mTOR Substitution - Replacing tacrolimus (a calcineurin inhibitor) with sirolimus (an mTOR inhibitor) along with reduction of mycophenolic acid
223696258|NCT04814862|BEHAVIORAL|3 validated questionnaires (ADHD-RS, SRS, BRIEF) for the diagnosis of neurodevelopmental disorders|Completion of three validated questionnaires for the diagnosis of neurodevelopmental disorders
223696259|NCT00484809|DRUG|Enbrel (Etanercept)|
223696260|NCT01028885|PROCEDURE|radiation therapy treatment planning/simulation|
223696261|NCT01028885|PROCEDURE|intensity-modulated radiation therapy|
223696262|NCT01028885|PROCEDURE|image-guided radiation therapy|
223696263|NCT01028885|PROCEDURE|magnetic resonance imaging|
223696264|NCT01028885|PROCEDURE|computed tomography|
223696265|NCT04470271|OTHER|Patients with hepatitis C lost follow up|Patients with chronic HCV who were lost of follow up will be contacted by phone or email. At least 3 phone calls will be made on three different days. In case the patient is not contacted it will be considered lost of follow-up
223696266|NCT02697487|OTHER|No treatment|This is an observational study with no intervention.
223696267|NCT03500575|DEVICE|photopheresis|• Treated group will receive ECP with Therakos online system. Each session consists in 1 treatment for 2 consecutive days. First session stars within 72 hours after transplantation followed by a session weekly for 3 time and 2 sessions for the next 2 months (6 sessions = 12 treatment)
223696268|NCT06319131|PROCEDURE|TIPS|Using the transjugular approach, TIPS was created under local anesthesia. The first branch of the left or right portal vein (PV) was punctured by RUPS-100 set guided by digital subtraction angiography. After successful access into PV, direct portography was performed and all visible varices and/or concurrent spontaneous portosystemic shunts (SPSS) were embolized with coils and n-butyl cyanoacrylate. A polytetrafluoroethylene-covered stent (Viatorr Endoprosthesis, GORE and Associates, Flagstaff, Arizona, USA) with a diameter of 8 mm was implanted and fully dilated.
223696269|NCT06319131|DRUG|Nadroparin|Nadroparin calcium will be subcutaneously injected with the dose of 85IU/kg q12h
223696270|NCT03938467|DRUG|Antiseptic Cleanser|Contains 0.05% Chlorhexidine gluconate in sterile water for irrigation. The mechanical action of the Irrisept system removes bacteria and debris without harming underlying tissues. Irrisept has demonstrated broad spectrum bactericidal activity against antibiotic-resistant strains. Its contents are wrapped in two sequential sterilization wraps which repel water blood, and saline, making it effective against both air and water borne bacteria.
223696271|NCT06495866|RADIATION|ultrasound|Ultrasound finding of entheseal sites of upper \& lower limbs of all groups and scoring according to enthesitis scoring system
223696272|NCT00398827|DRUG|Dexmedetomidine|
223696273|NCT00398827|DRUG|Placebo|
223696274|NCT05550844|RADIATION|Chest HRCT|A chest HRCT to identify emphysema
223696275|NCT05550844|GENETIC|blood analysis|If emphysema is identified, a blood analysis will be performed to exclude known causes of emphysema (Alpha-1 antitrypsin deficiency, PTPN6 mutation)
223696276|NCT05550844|OTHER|Lung function tests|Lung function tests will be performed in accordance with ATS/ERS technical standard
223696277|NCT05012657|DEVICE|Point Partial|The Point Partial partial finger prosthetic system consists of 1-4 ratcheting mechanical partial digits and mounting brackets
223696278|NCT04247776|COMBINATION_PRODUCT|Prehab|Exercise: functional exercises, walking, Fitbit goals Nutrition: handout, supplements (protein, vitamins, minerals) Stress reduction: deep breathing
223696279|NCT04247776|OTHER|ERAS|Enhanced Recovery After Surgery guidelines are applied.
223696280|NCT04247776|BEHAVIORAL|Fitbit|Fitbit is worn to monitor step counts.
223696281|NCT03420859|DIAGNOSTIC_TEST|qPCR for abnormal vaginal microbiota|qPCR for A.vaginae and/or G.vaginalis as developed in the pilot study (Hum Reprod. 2016 Apr;31(4):795-803. doi: 10.1093/humrep/dew026. Epub 2016 Feb 23.)
223696282|NCT02605785|DRUG|F-18 AV 1451|Tau PET scan
223696283|NCT00815269|DRUG|Halothane|Induction: 2-4% halothane pluses 3-5 L/min oxygen Maintenance: different doses from 0.5% to 3% with 1-2 L/min oxygen
223696284|NCT00815269|DRUG|Isoflurane|Induction: 2-5% isoflurane pluses 3-5 L/min oxygen Maintenance: different doses from 1% to 4% with 1-2 L/min oxygen
223696285|NCT00815269|DRUG|Sevoflurane|Induction: 3-8% sevoflurane pluses 3-5 L/min oxygen Maintenance: different doses from 1% to 4% with 1-2 L/min oxygen
223696286|NCT00815269|DRUG|Desflurane|Induction: 2-8% desflurane pluses 3-5 L/min oxygen Maintenance: different doses from 1% to 4% with 1-2 L/min oxygen
223696287|NCT00815269|DRUG|Enflurane|Induction: 2-5% enflurane pluses 3-5 L/min oxygen Maintenance: different doses from 1% to 4% with 1-2 L/min oxygen
223696288|NCT05783986|OTHER|randomly divided|500 patients of our hospital were randomly divided into testing group and internal validation group, and 100 patients in collabrative hospital were external validation group.
223696289|NCT04255927|DRUG|Coated Vicryl plus|Vicryl plus (Coated Polyglactin 910 with Triclosan)
223696290|NCT04255927|DRUG|Coated vicryl|Vicryl (Coated Polyglactin 910 without Triclosan)
223696291|NCT04805944|DRUG|Dolutegravir|Dolutegravir treated patients will be included and samples (blood for pharmacokinetic, pharmacogenetic et metabolite profiling, stools for microbiota profiling) drawn at follow-up.
223780211|NCT02752048|DRUG|TAS-205|2 groups: Low dose group, High dose group. Oral administration for 24 weeks, bis in die (BID) after meal
223780212|NCT02752048|DRUG|Placebo|1 group: Placebo group. Oral administration for 24 weeks, BID after meal
223780213|NCT01312467|DRUG|metformin hydrochloride|
223780214|NCT01947803|DRUG|Paliperidone Palmitate|Paliperidone Palmitate is injected with a dose of 150 mg eq. on Day 1 and 100 mg eq. on Day 8 in the deltoid muscle, followed by a monthly flexible dose range of 75 - 150 mg eq. for injection, based on patients' tolerability and/or efficacy. Monthly doses can be administered in either the deltoid or gluteal muscle alternatively. All the antipsychotics should be discontinued prior to the first dose of study drug. Other antipsychotics are prohibited across this study.
223780215|NCT04739748|DIAGNOSTIC_TEST|complete blood picture|Measure the red blood cell distribution width (RDW), the neutrophil-lymphocyte ratio (NLR).
223780216|NCT05729022|DEVICE|Ultrasound microendoscopic technique|Ultrasound-guided microendoscopic lumbar transforaminal epidural steroid injection
223780217|NCT05729022|RADIATION|Fluoroscopy|Fluoroscopy-guided lumbar transforaminal epidural steroid injection.
223780218|NCT03361410|DIETARY_SUPPLEMENT|Grape Powder|36 g of grape powder to be taken twice/day (total of 72 g/day) for 12 months
223780219|NCT03361410|DIETARY_SUPPLEMENT|Placebo Powder|36 g of placebo powder to be taken twice/day (total of 72 g/day) for 12 months
223780220|NCT04401228|OTHER|predict admission of covid-19 patients to ICU and death with routine and quickly avalaible clinical, biological and radiological variables?|"patients were questioned about their usual medication (Sartan, angiotensin-converting enzyme inhibitors, nonsteroidal anti-inflammatory drug, immunosuppressive drugs), their health condition (diabetes, hypertension, tobacco use, mental status). The Body mass index was computed.~Age, gender, caucasian/african, weight, body mass index, number of days with symptoms before hospitalization, asthenia, pyrexia, dyspnea, chest pain, digestive sign, anosmia, ageusia, confusion, Travel or contact \< one month, cigarette consumption ,hypertension, diabetes, mental status, angiotensin-converting-enzyme inhibitors, Sartan, non-steroidal anti-inflammatory drugs, immunosuppressive drugs, SpO2,Thoracic Computerized Tomography : % of lung injury, Thoracic Computerized Tomography : density of lung injury, blood type, white blood cells, neutrophils, lymphocytes, blood platelets, fibrinogen, ferritin, triglycerides, LDH, troponin, CRP. The dates of admission to ICU and death were recorded"
223780221|NCT00199745|DRUG|atorvastatin|
223780222|NCT00132769|DRUG|MK-0873|MK-0873 1.25 mg twice daily for 12 weeks
223780223|NCT00132769|DRUG|Comparator: Placebo|Matching placebo to MK-0873 1.25 mg twice daily for 12 weeks
223780224|NCT04452344|DRUG|opioid-containing analgesic|hydrocodone/ acetaminophen combination product
223780225|NCT04452344|DRUG|two over-the-counter analgesics|combination of over-the-counter analgesics (ibuprofen/acetaminophen)
223780226|NCT06105476|OTHER|Alcohol|Test drink with 12 g alcohol (30 g vodka 40%) in water
223780227|NCT06105476|OTHER|Alcohol+protein|Test drink with 12 g alcohol (30 g vodka 40%) and 25 g whey protein in water
223780228|NCT06105476|OTHER|Alcohol+retinol|Test drink with 12 g alcohol (30 g vodka 40%) and 1000 μg retinol in water
223780229|NCT06105476|OTHER|Retinol|Test drink with 1000 μg retinol in water
223780230|NCT06572735|OTHER|QoL surveys|2 quality of life surveys (OV28 and ELD14) will be completed by patients every 3 months during a 12-month period
223780231|NCT06572735|OTHER|Geriatric assessment (G-CODE)|A geriatric assessment (G-CODE) will be performed by the research staff every 3 months during a 12-month period
223780232|NCT06572735|BIOLOGICAL|Blood sampling|A supplementary volume of blood will be collected from a routine blood sample (8 mL) at 3 different time points : one at inclusion, one 6 and 12 months after the beginning of PARP inhibitors treatment. Genetic lab test will be performed to assess whether there is a specific genetic signature for PARP inhibitors toxicity.
223780233|NCT06572319|DRUG|Disitamab Vedotin(RC48) Plus Tratuzumab|Disitamab Vedotin: 2.5mg/kg，ivgtt，D1, every 2 weeks for a treatment cycle. Tratuzumab: RP2D，ivgtt，D1, every 2 weeks for a treatment cycle.
223780234|NCT05314153|DRUG|Brexanolone|Brexanolone injection is an Federal Drug Administration (FDA)-approved drug to treat postpartum depression. It is administered via continuous intravenous infusion over a 60-hour time period.
223780235|NCT02710526|DRUG|CAM2038|Long-Acting Subcutaneous Injectable Depot of Buprenorphine
223780236|NCT04091841|DRUG|protein supplement|Three sachet of protein supplement to be mixed in with water used daily.
223780237|NCT04091841|OTHER|Carbo Mass|Three sachet of Carbo Mass supplement to be mixed in with water used daily.
223780238|NCT00497926|BIOLOGICAL|Enriched Hematopoietic Stem Cell Infusion|Enriched Hematopoietic Stem Cell Infusion
223780239|NCT00249145|DRUG|risperidone|
223780240|NCT03481946|DRUG|BAY1093884|0.3 mg/kg given intravenously
223780241|NCT03481946|DRUG|BAY1093884|1 mg/kg given intravenously
223780242|NCT01577394|OTHER|oculomotor measurements|"The variability is indicated by the coefficient of variation (i.e. standard-error/mean) of saccades latencies in the gap paradigm.~Mean reflexive saccades latency Percentage of express saccades"
223780243|NCT05820022|OTHER|Research Barriers Scale|This scale was prepared after a detailed literature review and sent to five physiatrists for review and feedback. It consists of 21 items with Likert-type responses and two open-ended questions. It is designed to measure the barriers that individuals or groups face in conducting research. The scale includes a list of potential barriers and asks respondents to rate the extent to which they experience each barrier. Examples of barriers that may be included in such a scale could include lack of funding, limited access to resources or equipment, time constraints, difficulty finding participants or accessing data, institutional or administrative hurdles, and so on.
223780244|NCT06420635|BEHAVIORAL|Interdisciplinary intervention program on maternal self-efficacy and the motor development of premature children|The experimental group will receive an intervention about maternal self-efficacy and motor stimulation strategies for premature children applied by mothers. There will be two face-to-face meetings: the first with a theoretical session on motor development, a practical workshop on stimulation skills using a baby simulator and strengthening of maternal self-efficacy. The second meeting seeks for mothers to reflect on self-efficacy and carry out practical simulation of strategies with their children. At home (for four weeks), self-efficacy will be strengthened through 4 strategies twice a week, for 8 sessions. Mothers will put into practice with the baby the 10 stimulation strategies explained in the face-to-face sessions, must complete 14 sessions per week, 2 times a day, for a total of 56 sessions. The initial measurement will be carried out before the intervention, the second at 4 weeks and the third at 8 weeks after the intervention began.
223780245|NCT06420635|BEHAVIORAL|Traditional kangaroo program|The control group will receive the conventional family-centered care plan, including kangaroo position, exclusive breastfeeding, and outpatient follow-up. The traditional intervention for the control group is based on the Kangaroo Mother Method (KMC) program, proposed according to technical guidelines, which promotes skin-to-skin contact between mother and premature baby. In periodic outpatient consultations, clinical assessments are carried out focused on optimal growth (goal 15-20g/kg/day), neurological and psychomotor development, and timely detection of pathologies that require specialized care according to findings. Compliance with the vaccination schedule and medical indications, and assurance of breastfeeding, are monitored. The frequency of check-ups is daily initially, then weekly until 40 weeks and then monthly. The approach includes early stimulation and follow-up until 12 months of corrected age.
223780246|NCT03407352|BEHAVIORAL|Active Video Game Play|60 minutes of active video game play at a moderate intensity
223780247|NCT03407352|BEHAVIORAL|Passive Video Game Play|60 minutes of passive video game play
223780248|NCT00233025|DRUG|Duloxetine|
223780249|NCT00233025|DRUG|Placebo|
223780250|NCT02939222|DEVICE|Implant placement|Routine implant placement in the ideal three dimensional implant position
223780251|NCT06341244|DEVICE|Air Stacking Technique|To perform the air stacking technique, an air manual breathing unit (AMBU) was used, attached to a unidirectional valve and nasal/oral mask. For each AMBU manual compression (three in the total), the patient was instructed to breathe in deeply and hold the air inside the lungs.
223780252|NCT06531707|DRUG|Ibuprofen + Loratadine fixed dose|Suspension 8,000 mg / 100 mg / 100 mL, 5 mL twice a day
223780253|NCT06531707|DRUG|Ibuprofen|Suspension 2,000 mg / 100 mL, 20 mL twice a day
223780254|NCT06531707|DRUG|Loratadine|Suspension 1 mg / 1 mL, 5 mL twice a day
223780255|NCT02670629|PROCEDURE|Partial reduction with overriding position|The patient was subjected to an alignment instead of an anatomic reduction; this means that the fracture was left in an overriding position, after this, the patient was placed in a short arm cast for 6 weeks.
223780256|NCT02670629|PROCEDURE|Closed anatomic reduction|The patient was subjected to an anatomic reduction; this means that the fracture was completely reduced, after this, the patient was placed in a short arm cast for 6 weeks.
223780257|NCT04095858|DRUG|Efprezimod alfa|IV infusion: 480 mg at Day -1, 240 mg at Day 14, 240 mg at Day 28.
223780258|NCT04095858|DRUG|Placebo|IV infusion, 100 ml at Day -1, Day 14, and Day 28.
223780259|NCT04095858|DRUG|Methotrexate|IV, 15 mg/m\^2/dose at Day 1, then 10 mg/m2/dose at Day 3, 6, 11.
223780260|NCT04095858|DRUG|Tacrolimus|Begin on day -3. IV \[0.03 mg/kg/day\] or PO \[0.045 mg/kg/dose\] dosing is permitted
223780261|NCT05360238|BIOLOGICAL|MB-106|T-cells derived from autologous leukapheresis that are genetically modified.
223780262|NCT01344460|DRUG|Gadobutrol (Gadovist, BAY86-4875)|a single bolus injection of approx. 0.1mmol/kg
223780263|NCT03145272|DRUG|Oxycodone|A single weight-adjusted oxycodone dose of 0.1 mg/kg is administered as per standard clinical dosing guidelines
223780264|NCT02455908|DRUG|Proleukin®|
223780265|NCT00755586|PROCEDURE|Mononuclear cell injection: 4 * 10e8 cells|350 ml bone marrow will be aspirated from the posterior iliac crest under general anesthesia in combination with a muscle tendon transposition surgery. Next, the patients will receive a bone marrow derived mononuclear cell injection of 4 \* 10e8 cells in the m. biceps brachii.
223696292|NCT04805944|DRUG|Bictegravir|Bictegravir treated patients will be included and samples (blood for pharmacokinetic, pharmacogenetic and metabolite profiling, stools for microbiota profiling) drawn at follow-up.
223696293|NCT04805944|DRUG|Dolutegravir|Patient having discontinued dolutegravir will be included and samples (blood for pharmacogenetic and metabolite profiling, stools for microbiota profiling) drawn at follow-up.
223696294|NCT04805944|DRUG|Dolutegravir|Patients starting dolutegravir will be included and sampled both before (blood for pharmacogenetic and metabolite profiling, stools for microbiota profiling) and after (blood for pharmacokinetic and metabolite profiling, stools for microbiota profiling) the start of dolutegravir
223696295|NCT04805944|DRUG|Bictegravir|Patients starting bictegravir will be included and sampled both before (blood for pharmacogenetic and metabolite profiling, stools for microbiota profiling) and after (blood for pharmacokinetic and metabolite profiling, stools for microbiota profiling) the start of bictegravir
223696296|NCT02649114|BEHAVIORAL|Cognitive-Behavioural Therapy|
223696297|NCT02649114|BEHAVIORAL|Compassion-Focused Therapy|
223696298|NCT04640181|DRUG|Enoxaparin|Subcutaneous enoxaparin While hospitalized only.
223696299|NCT04640181|DRUG|Rivaroxaban|Oral rivaroxaban While hospitalized and through discharge for a total of 28 days.
223696300|NCT05693844|BIOLOGICAL|Pan-T booster co-expressing MSLN CAR T cell|Starting Dose: 1×10\^6 cells/kg
223696301|NCT05693844|DRUG|Albumin-bound paclitaxel|Administered intravenously at dose of 100-200mg/m2 on day -5
223696302|NCT05693844|DRUG|Cyclophosphamide|Administered intravenously at a total dose of 15-30mg/kg on day -3 and day -2
223696303|NCT05693844|DRUG|Fludarabine|Administered intravenously at dose of 30mg/m2/d on day -3 and day -2
223696304|NCT04708119|PROCEDURE|The follicular tissues were also excised after tooth extraction.|The follicular tissues were also excised after tooth extraction. Soft tissue samples taken during surgical removal of ILTM were evaluated in the department of pathology.
223696305|NCT03467607|PROCEDURE|tidal volume ventilation|low tidal volume ventilation
223696306|NCT05235243|OTHER|Online therapeutic intervention for maladaptive daydreaming based on mindfulness and self-monitoring|An 8-weeks internet-based self-guided intervention program, accompanied by e-mail. The content of the intervention and training modules comprised texts, illustrations, explanatory video and audio lectures, as well as interactive worksheets embedded in each week's lesson. Typically, a lesson started with a textual description of its target and duration. Then, participants received a summary of what had been taught thus far, and finally, a novel technique or skill was introduced. Each lesson required about 60 minutes to complete. Users had open access to web pages of previous lessons. Upon completion of each lesson, participants received a list of home assignments to practice during the following week. Our internet-based program featured a notification and download center containing the program's materials and pertinent messages from the researchers.
223780266|NCT00755586|PROCEDURE|Mononuclear cell injection: 8 * 10e8 cells|650 ml bone marrow will be aspirated from the posterior iliac crest under general anesthesia in combination with a muscle tendon transposition surgery. Next, the patients will receive a bone marrow derived mononuclear cell injection of 8 \* 10e8 cells in the m. biceps brachii.
223780267|NCT00755586|PROCEDURE|No mononuclear cell injection|Patients will receive a muscle tendon transposition surgery without bone marrow aspiration or mononuclear cell injection.
223780268|NCT05690958|OTHER|Survey|Filling in a survey
223780269|NCT03772405|DRUG|Nascum Plus|nasal application of nascum plus
223780270|NCT03772405|OTHER|ACC|4 hours challenge to grass pollen in the allergen challenge chamber (ACC)
223780271|NCT01455649|DRUG|Everolimus|Group will switch calcineurin inhibitor to everolimus within 1 day (overnight).
223780272|NCT01455649|DRUG|calcineurin inhibitor|Group will maintain their initial immunosuppression therapy with calcineurin inhibitor
223780273|NCT06532045|DEVICE|Transcutaneous electrical nerve stimulation|TENS applied for 30 min for each time, five times a week, for 2 weeks and deep breathing relaxation exercise given to the intervention group twice a day (10min/exercise) for two weeks.
223780274|NCT04090944|PROCEDURE|the fiberoptic laryngoscope (KARL STORZ 11301BN1, Germany) for confirmation of LMA position|-The position of LMA will be assessed by another anesthetist (blinded assessor) using the fiberoptic laryngoscope (KARL STORZ 11301BN1, Germany) per the grading licensed by Aoyama et al.
223780275|NCT02376413|PROCEDURE|Breast surgery|Traditional breast-conserving surgery, oncoplastic breast-conserving surgery or modified radical mastectomy
223780276|NCT02376413|DRUG|Chemotherapy or endocrine therapy or Trastuzumab therapy|
223780277|NCT02376413|RADIATION|Radiation therapy|
223780278|NCT02440152|DEVICE|Suzhou Sceneray® DBS System|We plan to use the SceneRay 1242 (SceneRay, SuZhou, China) electrode with a diameter of 1.27 mm and 4 contacts. The SceneRay 1242 electrode combined with the SceneRay 1181 implantable pulse generator has the advantage of adaptive coverage area for the Ventral Capsule/Ventral Striatum, enabling simultaneous implantation in the nucleus accumbens (NAc; 2 ventral contacts) and the anterior limb of the internal capsule (ALIC; 2 dorsal contacts) with independently programmed parameters such as frequency, amplitude, and voltage; and remote and wireless programing, which allows for convenient and prompt adjustments in emergency situations. The contact length is 3.0 mm and the spacings between the ventral and dorsal contacts are 2 mm, 4 mm, and 4 mm, respectively, spanning a total length of 22.5 mm (3 + 2 + 3 + 4 + 3 + 4 + 3 mm, with 0.5 mm projecting from the electrode tip).
223780279|NCT00560833|DRUG|esmirtazapine|
223780280|NCT00560833|DRUG|Placebo|
223780281|NCT04702074|DRUG|Traditional Chinese medicine granules|"Bu Fei Jian Pi Hua Tan granule for syndrome of the lung and spleen qi deficiency and unclean phlegm dampness.~Yi Qi Yang Yin Qing Fei granule for syndrome of qi and yin deficiency and unclean phlegm heat.~Traditional Chinese medicine granules will be administered twice daily for 2 months."
223780282|NCT04702074|DRUG|Traditional Chinese medicine granules placebo|"Bu Fei Jian Pi Hua Tan granule placebo for syndrome of the lung and spleen qi deficiency and unclean phlegm dampness.~Yi Qi Yang Yin Qing Fei granule placebo for Syndrome of qi and yin deficiency and unclean phlegm heat.~Traditional Chinese medicine granules placebo will be administered twice daily for 2 months.~The appearance, weight, color and odor of the preparation are the same as those of experimental group.~The granule placebo consists of dextrin, bitter and 5% of the Traditional Chinese medicine granules ."
223780283|NCT01287442|PROCEDURE|Trabeculectomy|A scleral flap is created. The aqueous humor is so guided under the conjunctiva to lower IOP.
223780284|NCT01702129|DRUG|anti-EGFR immunoliposomes loaded with doxorubicin|All patients were treated with anti-EGFR immunoliposomes Different dose levels (5, 10, 20, 30, 40, 50 and 60 mg doxorubicin/m2), at least 3 patients per dose level, treatment was given every 4 weeks
223780285|NCT04596566|OTHER|Therapeutic diet Intervention|The CD-TDI will incorporate global principles of the Mediterranean Diet (MD) refined to inform specific food choices based on our pilot data results and published literature reported mechanisms of mitigating inflammation in IBD. Patient compliance will be measured in three ways: 1) Mediterranean diet score checklists completed every 3 weeks at the face-to-face visits; 2) goal attainment scores captured weekly to identify the goals set, and the goals attained 47; and 3) fatty acids profiled from red blood cells to identify if fat intake reflects CD-TDI fat recommendations: 35% total calories from fat, 15% from MUFA, 13% from SFA and 6% from PUFA with a 8 n6:n:3 ratio of 8:1
223780286|NCT05987267|OTHER|multidisciplinary precision care|The experimental group received precision nursing based on a multidisciplinary collaborative team in addition to standard treatment and care
223696307|NCT05235243|OTHER|Online therapeutic intervention for maladaptive daydreaming based on mindfulness|An 8-weeks internet-based self-guided intervention program, accompanied by e-mail. The content of the intervention and training modules comprised texts, illustrations, explanatory video and audio lectures, as well as interactive worksheets embedded in each week's lesson. Typically, a lesson started with a textual description of its target and duration. Then, participants received a summary of what had been taught thus far, and finally, a novel technique or skill was introduced. Each lesson required about 60 minutes to complete. Users had open access to web pages of previous lessons. Upon completion of each lesson, participants received a list of home assignments to practice during the following week. Our internet-based program featured a notification and download center containing the program's materials and pertinent messages from the researchers.
223696308|NCT03578757|BEHAVIORAL|21-day residential program|"Both groups will benefit of a 21-day residential program at the thermal spa resort combining corrections of eating disorders (and a negative energy balance of 500 kcal/day), physical activity (2h30 per day, minimum), thermal spa treatment (2h per day, minimum), and health education (1h30 per day, minimum: cooking, nutrition and physical activity classes…). Physical activity will be diverse (endurance, strength, circuit training) and personalized to the target of each participant.~The intervention group will benefit from psychological interventions based on validated approaches of stress (3 x 1h30 per week). Participants will attend psychological sessions by group of less than 10 individuals. Individual meeting with the psychologist will occur at least twice: at the beginning of the residential program and at the end.~After the spa residential program, participants will undergo a one-year at-home follow-up."
223696309|NCT06523283|OTHER|Natural Landscape Pictures Accompanied by Music|after data collection tools filled by participants , they will watch the video one time in hospital bed while breastfeeding , second time in their home while researchers is there and they will also receive the video link so they will contunie to watch video 8 more time. in total 10 sessions will be completed.
223696310|NCT00289367|DRUG|Triiodothyronine|0.8 mcg/kg bolus loading dose followed by a six hour infusion of 0.8 mcg/kg/6hr.
223696311|NCT00289367|DRUG|triiodothyronine|IV formulation - Triostat, 0.8 mcg/kg bolus loading dose followed by a six hour infusion of 0.8 mcg/kg/6hr.
223696312|NCT00570414|DEVICE|Laryngeal mask airway|Airway management by the use of the flexible, reinforced laryngeal mask airway
223696313|NCT00570414|DEVICE|Endotracheal tube|Airway management by the use of endotracheal tube
223696314|NCT01199731|DRUG|GSK2248761 100 mg once daily|1 100mg capsule OAD plus matching placebo
223696315|NCT01199731|DRUG|GSK2248761 200 mg once daily|2 100mg capsules OAD
223696316|NCT01199731|DRUG|Etravirine|2 100mg tablets twice daily
223696317|NCT05120609|DEVICE|Parkinson's Application|The application delivers at-home, tailored allied health exercises (physiotherapy, speech and language therapy, and occupational therapy) for the gait, speech, and manual dexterity symptoms associated with Parkinson's disease.
223696318|NCT05120609|DEVICE|Digital Placebo Application|The application is designed to provide a method of capturing outcome measures without providing access to the therapy exercises.
223696319|NCT04648254|DRUG|Q702|The study drug Q702 will be administered once daily by mouth on Days 1 through 7 and Days 15 through 21 of every treatment cycle.
223696320|NCT04466176|DRUG|Test Product|2 inhalations of Test and Reference product in each study period
223696321|NCT04466176|DRUG|Reference Product|2 inhalations of Test and Reference product in each study period
223696322|NCT04753307|DIAGNOSTIC_TEST|Laboratory measurements|Inflammatory and cardiac biomarkers will be measured before surgery, and on the first, second, third and fifth postoperative day
223696323|NCT00662688|DRUG|daltéparine|
223696324|NCT00662688|DRUG|Chemotherapy at the investigator's discretion|
223696325|NCT03964766|DEVICE|Rotary instrumentation|using pedo rotary files in cleaning and shaping the root canals of infected primary molars
223696326|NCT03964766|DEVICE|Hand instrumentation|using conventional hand files in cleaning and shaping the root canals of infected primary molars
223696327|NCT04072562|DRUG|AZD7594|"Treatment A: The study drug is a nebulizer suspension with strength 2.8 mg/mL using 2 mL in the device. The study drug is administered via oral inhalation.~Treatment B: The study drug is a nebulizer suspension with strength 6.3 mg/mL using 2 mL in the device. The study drug was administered via oral inhalation.~Treatment C: The study drug is an inhalation powder. The study drug was administered via oral inhalation."
223696328|NCT05693766|DRUG|Capecitabine|2000 mg taken by mouth twice daily for 7 days on, 7 days off
223696329|NCT05693766|OTHER|Endocrine-therapy|Endocrine therapy administered
223696330|NCT05693766|OTHER|MammoPrint ® and BluePrint assays|Archival tissue will be analyzed using the MammoPrint ® and BluePrint assays
223696331|NCT04374071|DRUG|Methylprednisolone|IV methylprednisolone 0.5 to 1 mg/kg/day in 2 divided doses for 3 days
223696332|NCT03750370|DEVICE|Doppler ultrasound|Colored Doppler Sonography is well established to illustrate microvascularity and therefore perfusion of the testis. The arterial flow velocities (peak systolic velocity \[PSV\] and end diastolic velocity \[EDV\]) and the resistance indices against this flow (resistive index \[RI\] and pulsatility index \[PI\]) in the testis can be measured with this technique.
223696333|NCT03295461|PROCEDURE|SRP+ 10% Emblica officinalis irrigation|
223696334|NCT03295461|PROCEDURE|SRP + 0.2% Chlorhexidine irrigation)|
223696335|NCT03295461|PROCEDURE|SRP + 0.9% Saline irrigation|
223696336|NCT03295461|PROCEDURE|SRP +10% E. officinalis gel application.|
223696337|NCT03295461|PROCEDURE|SRP+ placebo gel application.|
223696338|NCT00558779|PROCEDURE|OBCAB (Off Pump Coronary Artery Bypass Grafting)|OPCAB with sparing of aortic manipulation (eg, no aortic cannulation for cardiopulmonary bypass, no aortic cross-clamp, no side-clamping of the aorta). Graft anastomosis to the central circulation with y-grafts on the arteria thoracica interna or on the aorta with help of the Heart-string-system (Guidant)
223696339|NCT00558779|PROCEDURE|CABG (coronary artery bypass grafting)|conventional CABG with cardiopulmonary bypass
223696340|NCT01456390|DEVICE|iStent and iStent supra|Implantation of two iStent devices and one iStent supra device
223696341|NCT03843827|DEVICE|Laryngeal Mask Airway|The aim of this study is to compare between cLMA and I gel regarding insertion success rate, the time of insertion, leaking pressure, assessment of position by fiber optic, hemodynamic, Spo2 for each device during insertion and maintenance of general anaesthesia and postoperative complications in obese patients
223696342|NCT03843827|DEVICE|I gel Airway|I gel is a new type of laryngeal mask and doesn't have an inflatable cuff. Because of its thermoplastic elastomer structure, it exactly adapts to the supraglottic tissue by binding with body temperature, thus minimising air leakage
223696343|NCT06123663|BIOLOGICAL|TTVA|Intramuscular injection, 1 dose of 0.5ml inoculated on Day 0
223696344|NCT06123663|BIOLOGICAL|TT|Intramuscular injection, 1 dose of 0.5ml inoculated on Day 0
223696345|NCT05438641|DRUG|BZDP-Sparing Protocol|BZDP-Sparing group includes subjects primarily treated with a non-BZDP agent (e.g., Alpha-2 agonists and/or anticonvulsants). Rescue with BZDP-based treatment allowed if there is symptomatic breakthrough- as measured by CIWA \> 15.
223696346|NCT05438641|DRUG|BZDP-Based Protocol|Patients in this arm will received active treatment based on conventional BZDP-based protocol; additional BZDP are permitted for patients who are still symptomatic, based on CIWA-Protocol.
223696347|NCT00943124|DRUG|MK0524B (ER niacin (+) laropiprant (+) simvastatin)|Single dose of MK0524B (ER niacin 900 mg/ laropiprant 20 mg/ simvastatin 20 mg) in one of two treatment periods.
223696348|NCT00943124|DRUG|MK0524A (ER niacin + laropiprant)|Single dose of MK0524A (ER niacin 1000 mg/ laropiprant 20 mg) in one of two treatment periods.
223696349|NCT00943124|DRUG|Simvastatin|Single dose simvastatin (Zocor™) 20 mg in one of two treatment periods.
223696350|NCT02923258|DRUG|Docetaxel|20mg/m2/w
223696351|NCT02923258|DRUG|Cisplatin|100mg/m2/q3w
223696352|NCT02923258|RADIATION|IMRT|a total dose of 60Gy in 30fractions over 6 weeks
223696353|NCT03649867|OTHER|Semi-structured interviews|Each participant will attend a 30-45 minute semi-structured interview conducted by the CI
223696354|NCT03242538|BEHAVIORAL|Pelvic Exercise|Hip extension and external hip rotation exercises are completed prior to daily external beam radiation treatment.
223696355|NCT03706131|OTHER|cervical mobilisation|manual therapy
223696356|NCT02724150|DRUG|Omeprazole High dose|High regimen of Proton Pump Inhibitors in treatment of bleeding ulcer 80 mg loading dose then 8 mg/h iv for 3 days
223696357|NCT02724150|DRUG|Omeprazole Low dose|low regimen of Proton Pump Inhibitors in treatment bleeding ulcer 80 mg loading dose then 40 mg two times per day for 3 days
223696358|NCT02640469|OTHER|Chlorhexidine with water rinse|"This procedure will be followed for both the right and left hands and arms:~scrub each side of finger, in between fingers and back and front of hands for 2 minutes, followed by scrubbing of arms, keeping hands higher than arms at all times, wash each side of the arms from wrist to elbow for 1 minute"
223696359|NCT02640469|OTHER|Chlorhexidine without water rinse|Scrub each side of finger, in between fingers and back and front of hands for 2 minutes, proceed to scrub the arms, keeping the hand higher than the arm at all times, wash each side of the arms from wrist to elbow for 1 minute, and repeat the process on the other arm.
223696360|NCT02640469|OTHER|Chlorhexidine + sterillium hand rub|Scrub each side of finger, in between fingers and back and front of hands for 2 minutes, Scrub each side of finger, in between fingers and back and front of hands for 2 minutes, proceed to scrub the arms, keeping the hand higher than the arm at all times, wash each side of the arms from wrist to elbow for 1 minute, and repeat the process on the other arm. Rinse hands and arms by passing through water in one direction, dry hands, and rub 5 mL of alcohol into the palm of the hands, forearms and elbows. Ensure that the whole skin area on both arms is covered.
223696361|NCT03071159|DEVICE|FreeStyle Flash Libre glucose monitoring system|glucose monitoring system with sensors
223696362|NCT00200551|DRUG|Cyclosporin, mycophenolate mofetil, antilymphocyte serum and corticoids.|
223696363|NCT00200551|DRUG|Cyclosporin, mycophenolate mofetil, antilymphocyte serum without corticoids.|
223696364|NCT02448810|BIOLOGICAL|BAX69 + infusional 5-FU/LV|"Study Part 1: Safety Run-in~* Administered weekly as part of a 4 week treatment cycle~* Intravenous injection"
223696365|NCT02448810|BIOLOGICAL|BAX69 + panitumumab|"Study Part 1: Safety Run-in~* Administered weekly as part of a 4 week treatment cycle~* Intravenous injection"
223780287|NCT01085318|DRUG|Rebif|44 mcg tiw
223780288|NCT01224041|DRUG|Tacrolimus|oral
223780289|NCT00175136|DEVICE|Maxim TKA|Operation with Total Knee Arthroplasty and either an I-beam stem or a wedge stem of the tibial component.
223780290|NCT01381055|DRUG|Pentoxifylline|Patients with cutaneous leishmaniasis treated with pentavalent antimony/Meglumine antimoniate 20mg/kg/day during 20 days and pentoxifylline pills 400mg three times a day during 20 days.
223780291|NCT01381055|DRUG|Placebo|Patients with cutaneous leishmaniasis treated with pentavalent antimony/metilglucamine 20mg/kg/day during 20 days and placebo pills three times a day during 20 days.
223780292|NCT04141293|PROCEDURE|alveolar recruitment|Alveolar recruitment is a procedure to re-expand collapsed lung regions with the transient increment in transpulmonary pressure.
223780293|NCT05436574|OTHER|Dance therapy|Before/after study to measure the effects of the dance therapy activity on the quality of life of the elderly population housed in the establishments of UNIVI group.
223696366|NCT02448810|BIOLOGICAL|BAX69 + 5-FU/LV|"Study Part 2: Administered weekly as part of a 4 week treatment cycle~•Intravenous injection"
223696367|NCT02448810|BIOLOGICAL|BAX69 + panitumumab|"Study Part 2: Administered weekly as part of a 4 week treatment cycle~•Intravenous injection"
223696368|NCT02448810|DRUG|Standard of Care|"* Investigator's choice~* Dose according to drug label"
223696369|NCT02448810|BIOLOGICAL|Standard of Care|"* Investigator's choice~* Dose according to drug label~* Choice includes panitumumab in KRAS \&NRAS wt group only"
223696370|NCT02185755|OTHER|Internet-Based Glucose Monitoring System|
223780294|NCT02206529|BEHAVIORAL|Social Network Engagement+Std Treatment|
223780295|NCT02206529|BEHAVIORAL|Standard Treatment|Standard Treatment = family-based behavioral pediatric obesity treatment, as per protocol outlined in FOCUS trial (Family Overweight: Comparing Use of Strategies; NCT00746629)
223780296|NCT00898677|DRUG|rizatriptan benzoate|single dose administration of 5mg rizatriptan (by Mouth) p.o.
223780297|NCT00898677|DRUG|rizatriptan benzoate|single dose administration of 10 mg rizatriptan p.o.
223780298|NCT00898677|DRUG|Comparator: sumatriptan|single dose administration of sumatriptan 100 p.o.
223780299|NCT00898677|DRUG|Comparator: Placebo|placebo to rizatriptan
223780300|NCT02157740|DEVICE|Residents of nursing homes with telemedicine after implementation of telemedicine|
223780301|NCT04064281|OTHER|the healthy Cantonese diet|After a 1-week run-in period, the intervention group will eat the healthy Cantonese diet for 4 consecutive weeks. Free meals will be provided 3 times a day (breakfast, lunch, dinner). The actually intake of every meal for all subjects will be recorded to estimate their nutrients intake. All subjects will be advised to avoid eating other food, but they should inform researchers of what they eat if they eat food that we will not provide.
223696371|NCT02185755|DRUG|Normal Medication Positive Control|
223696372|NCT06045104|DIETARY_SUPPLEMENT|Wheat Soy Blend Plus Plus (WSB++) with nutrition counselling|Wheat Soy Blend Plus Plus (WSB++) with nutrition counselling
223696373|NCT06045104|DIETARY_SUPPLEMENT|15 Micro Nutrient Powder (15 MNP) with improved nutrition counselling|15 Micro Nutrient Powder (15 MNP) with improved nutrition counselling
223696374|NCT00730197|DRUG|Albuterol Sulfate Extended-Release Tablets 8 mg|8mg, single dose fed
223696375|NCT00730197|DRUG|VoSpire® ER Tablets 8 mg|8mg, single dose fed
223696376|NCT05368090|PROCEDURE|EUS-RFA of left adrenal tumour in PA with AVS-verified left lateralisation|Patients will fast, receive prophylactic antibiotics and conscious sedation prior to the endoscopic procedure.The procedure is performed with a standard linear echo-endoscope with a 3.7 mm or larger working channel. The left adrenal is identified from the fundus of the stomach. Color-Doppler is used to map adrenal vascularity. Ultrasound contrast is used to demarcate the border of the tumour. EUS-guided fine needle tissue sampling from tumour tissue is performed. The RFA ablation catheter is water-cooled and stable temperature is maintained at 70-75 degrees celsius until formation of heat bubbles can be seen on EUS. If necessary, the procedure is repeated after moving the probe until the whole adenoma volume is ablated. Ultrasound contrast medium is used after the procedure to ensure that the target for the ablation is non vascularized, before termination. The patients will be observed at the postoperative unit a few hours, and further in the ward for 24h
223696377|NCT05368090|PROCEDURE|"EUS-RFA of left adrenal tumour in PA, debulking group"|Patients will fast, receive prophylactic antibiotics and conscious sedation prior to the endoscopic procedure.The procedure is performed with a standard linear echo-endoscope with a 3.7 mm or larger working channel. The left adrenal is identified from the fundus of the stomach. Color-Doppler is used to map adrenal vascularity. Ultrasound contrast is used to demarcate the border of the tumour. EUS-guided fine needle tissue sampling from tumour tissue is performed. The RFA ablation catheter is water-cooled and stable temperature is maintained at 70-75 degrees celsius until formation of heat bubbles can be seen on EUS. If necessary, the procedure is repeated after moving the probe until the whole adenoma volume is ablated. Ultrasound contrast medium is used after the procedure to ensure that the target for the ablation is non vascularized, before termination. The patients will be observed at the postoperative unit a few hours, and further in the ward for 24h
223696378|NCT05368090|PROCEDURE|EUS-RFA of left adrenal tumour in MACS with AVS-verified left lateralisation|Patients will fast, receive prophylactic antibiotics and conscious sedation prior to the endoscopic procedure.The procedure is performed with a standard linear echo-endoscope with a 3.7 mm or larger working channel. The left adrenal is identified from the fundus of the stomach. Color-Doppler is used to map adrenal vascularity. Ultrasound contrast is used to demarcate the border of the tumour. EUS-guided fine needle tissue sampling from tumour tissue is performed. The RFA ablation catheter is water-cooled and stable temperature is maintained at 70-75 degrees celsius until formation of heat bubbles can be seen on EUS. If necessary, the procedure is repeated after moving the probe until the whole adenoma volume is ablated. Ultrasound contrast medium is used after the procedure to ensure that the target for the ablation is non vascularized, before termination. The patients will be observed at the postoperative unit a few hours, and further in the ward for 24h
223696379|NCT05368090|PROCEDURE|"EUS-RFA of left adrenal tumour in MACS with bilateral overproduction, debulking group"|Patients will fast, receive prophylactic antibiotics and conscious sedation prior to the endoscopic procedure.The procedure is performed with a standard linear echo-endoscope with a 3.7 mm or larger working channel. The left adrenal is identified from the fundus of the stomach. Color-Doppler is used to map adrenal vascularity. Ultrasound contrast is used to demarcate the border of the tumour. EUS-guided fine needle tissue sampling from tumour tissue is performed. The RFA ablation catheter is water-cooled and stable temperature is maintained at 70-75 degrees celsius until formation of heat bubbles can be seen on EUS. If necessary, the procedure is repeated after moving the probe until the whole adenoma volume is ablated. Ultrasound contrast medium is used after the procedure to ensure that the target for the ablation is non vascularized, before termination. The patients will be observed at the postoperative unit a few hours, and further in the ward for 24h
223696380|NCT05708586|BEHAVIORAL|Control|This is the control condition and anxiety is addressed in a standard way of having the care taker calm the child during the intervention.
223696381|NCT05708586|DEVICE|Virtual Reality (VR)|The child who is undergoing a procedure uses VR as a distraction during the intervention
223696382|NCT00920634|DRUG|Follitropin beta|For subcutaneous or intramuscular injection, the usual dosage is 50 IU of follitropin beta (recombinant) once daily for 7 days. The dosage should be adjusted subsequently while monitoring the development of follicles (dose increase by 25 IU every 7 days if the response of the ovaries is poor) and, after confirming presence of follicles of 18 mm or larger in mean diameter by the ultrasonic tomography, ovulation is induced by the administration of a human chorionic gonadotropin preparation.
223696383|NCT02255578|DEVICE|Endobarrier treatment in PCOS|the effect of an EndoBarrier device on fertility and metabolic parameters in obese insulin resistant (IR) PCOS women
223696384|NCT02255578|DRUG|clomiphene citrate treatment|
223696385|NCT05205967|OTHER|MCED|Multi-cancer early detection (MCED) test
223696386|NCT05205967|OTHER|SOC|Standard of care cancer screening
223696387|NCT00470847|DRUG|Lapatinib|Orally twice daily
223696388|NCT00470847|PROCEDURE|Whole Brain Radiation|15 treatments over a period of 3 weeks
223696389|NCT00470847|DRUG|Herceptin|Herceptin 4mg/kg loading dose then 2 mg/kg IV once weekly, then once every three weeks after cycle 3.
223696390|NCT05504395|DRUG|CSTI-500|Single 10 mg capsule
223696391|NCT05584332|BIOLOGICAL|Quadrivalent Human Papillomavirus (Types 6, 11, 16, and 18) Recombinant Vaccine (Hansenula Polymorpha)|0.5 ml injection in 3 dosing regimen
223696392|NCT05584332|BIOLOGICAL|Placebo|0.5 ml injection in 3 dosing regimen
223696393|NCT03071146|DEVICE|Bard® LifeStent® 5F Vascular Stent System|The LifeStent® Vascular Stent is a peripheral stent intended to improve luminal diameter in the treatment of symptomatic de-novo or restenotic lesions up to 240 mm in length in the native superficial femoral artery (SFA) and popliteal artery with reference vessel diameters ranging from 4.0 - 6.5 mm.
223696394|NCT01355029|BEHAVIORAL|Stroke Caregiver Education and Support Program|4 week program offered weekly over a 4 week period. Each session is a 2 hour small group guided discussion on the topic area facilitated by 2 trained facilitators. The topics are: Program Introduction, sharing Caregiving Stories and an introduction to Self Management; Community Connections; Session 3 and 4 are chosen by the participants during session 1 from 6 possible options: Communication in your relationship; Cognition, Memory and Personhood; Dealing with your Emotions; Managing your Stress; Changing roles in your relationships and How to be Caregiver Smart?
223696395|NCT00595777|BEHAVIORAL|EPAT© Educational Package|The EPAT package consists of an education programme, which deals with the known common barriers to effective pain control and the bedside pain tool. The pain tool is uniquely incorporated into the vital signs chart to enable a systematic approach to cancer pain assessment and review. EPAT consists of 2 steps: step 1 is a colour-coded pain assessment on the bedside vital signs chart. Patients with moderate or severe pain on step 1 will progress to to step 2, which helps to identify the aetiology of the pain, screening for opioid side effects and is linked via flags to simple management plans. The intervention will be delivered to the clusters randomised to the intervention, after collection of baseline data (pre-intervention data) on 50 patients.
223696396|NCT04304157|DRUG|Dexmedetomidine|Dexmedetomidine (DEX) a potent α 2 agonist that have unique analgesic, anxiolytic and sedative profile has been called upon as attractive adjunct in general as well as regional anesthesia with enticing results. Several studies have pursued DEX median effective dose (ED50) in different settings e.g., co induction agent with Propofol, in laryngeal muscle insertion and with local anesthetic to enhance the quality of spinal anesthesia
223696397|NCT01719978|DRUG|3.6mL 2% Mepivacaine with 1:100,000 epinephrine|Local anesthetic with vasoconstrictor
223696398|NCT01719978|PROCEDURE|Lower Third Molar Extraction|Lower Third Molar Extraction with LA + hyaluronidase (or placebo)
223696399|NCT01719978|DRUG|Hyaluronidase|75RTU Hyaluronidase administration concomitant to the local anesthetic
223696400|NCT01719978|DRUG|Placebo|1mL 0.9% saline administration concomitant to the local anesthetic
223696401|NCT05653726|OTHER|Telemonitoring follow-up using medical devices and telematic consultations|Home telemonitoring of blood pressure, heart rate and peripheral oxygen saturation on a daily basis during 12 months
223696402|NCT03783247|PROCEDURE|Pericapsular nerve group block|The regional block was performed with the patient in the supine position. A curvilinear low-frequency ultrasound probe (2-5MHz) was initially placed in a transverse plane over the AIIS and then aligned with the pubic ramus by rotating the probe counterclockwise approximately 45 degrees (Figs. 2, 3). In this view, the IPE, the iliopsoas muscle and tendon, the femoral artery, and pectineus muscle were observed. A 22-gauge, 80-mm needle was inserted from lateral to medial in an in-plane approach to place the tip in the musculofascial plane between the psoas tendon anteriorly and the pubic ramus posteriorly. Following negative aspiration, the local anesthetic solution (20ml of bupivacaine 0.25%) was injected in 5-mL increments while observing for adequate fluid spread in this plane for a total volume of 30 mL
223696403|NCT03783247|PROCEDURE|Fascia Iliaca BLock|In supine position, a high frequency linear probe will be placed in the inguinal crease. Scan starting laterally from the femoral artery and nerve in inguinal crease to identify the sartorius muscle, tracing the muscle until it's origin to anterior superior iliac spine. The shadow of the bony of iliac crest \& iliacus muscle will be seen, the end point of the injection is deep to the fascia iliaca and above the iliacus muscle in the lateral part of the iliacus muscle. After negative aspiration, 30 mL of 0.25 % of bupivacaine will be injected under the fascial plane incrementally, aspirating every 5 ml.
223696404|NCT04172662|BEHAVIORAL|Facilitated Music Listening|The patient gets a preparatory session with the music therapist one day before the invasive procedure, where individual assessment is made based on a biopsychosocial approach. Sequences of facilitated Music listening is provided during the pre-, peri and postoperative phase, and a closing dialog performed postoperatively. Patient-preferred music is chosen from a limited set of playlists provided on the app The Music Star.
223696405|NCT02592811|PROCEDURE|ERCP|Common bile duct cannulation with a cannulation catheter
223696406|NCT02592811|PROCEDURE|Endoscopic Sphincterotomy|Endoscopic large sphincterotomy
223696407|NCT02592811|DEVICE|Large Balloon Dilatation of Oddi Sphincter|Large Balloon Dilatation : with the HERCULES, Cook 12, 15, 18 or 20 mm of diameter (adapted to stone diameter)
223696408|NCT02592811|PROCEDURE|Stone extraction|After dilatation, extraction of stones is done with dormia basket or extraction balloon and if not possible a mechanical lithotripsy is performed
223696409|NCT03150667|DRUG|Ticagrelor|Ticagrelor in patients with CKD presenting with ACS.
223696410|NCT03150667|DRUG|Clopidogrel|Clopidogrel in patients with CKD presenting with ACS.
223780302|NCT04064281|OTHER|the typical Cantonese diet|After a 1-week run-in period, the control group will still eat the typical Cantonese diet for 4 consecutive weeks. Free meals will be provided 3 times a day (breakfast, lunch, dinner). The actually intake of every meal for all subjects will be recorded to estimate their nutrients intake. All subjects will be advised to avoid eating other food, but they should inform researchers of what they eat if they eat food that we will not provide.
223780303|NCT05024812|DRUG|fruquintinib＋toripalimab + SOX|phase Ib: fruquintinib (dose finding): L1: 3 mg/d，L2: 4 mg/d，L3: 5 mg/d, qd po, D1-14, Q3W toripalimab: 240mg, I.V., D1, Q3W; S-1: 40-60mg bid, D1-14, Q3W; Oxaliplatin: 130mg/m\^2, ivgtt 2h, D1,Q3W. phase II: fruquintinib: RP2D toripalimab: 240mg, I.V., D1, Q3W; S-1: 40-60mg bid, D1-14, Q3W; Oxaliplatin: 130mg/m\^2, ivgtt 2h, D1,Q3W.
223696411|NCT03568084|OTHER|MEFAP|multicomponent physical activity program (MEFAP) with 12 weekly sessions of an hour and a half which includes 1) briefing 2) exercises for improving aerobic resistance, muscle strength, proprioception-balance and flexibility and 3) delivery of exercise chart to do at home (two times per week).
223696412|NCT03568084|OTHER|control usual practice|Individuals allocated to this arm, will be look after as usual in their health Centers.
223696413|NCT06387160|DRUG|as per institutional protocol|This is an observational study. Treatment will be given to the patients as per institutional protocol
223780304|NCT06165705|DEVICE|CureSight|dichoptic therapy with anaglyph goggles and eye tracking
223780305|NCT00373243|DRUG|GW406381|GW406381 will be available as 10 mg hard gelatin capsules. Subjects will receive two capsules of 10 mg to make 20 mg dose.
223780306|NCT01142245|DRUG|Oral esomeprazole|• Oral Esomeprazole 40mg on Day 1, 2 and Day 3 q12h
223780307|NCT01142245|DRUG|Intravenous Esomeprazole|"Esomeprazole IV 80mg loading bolus~* Esomeprazole intravenous infusion 8mg/hr for 72 hours"
223696414|NCT00974766|DRUG|Glucocorticoids|Prednisolone 0.5 mg/kg/day for 2 weeks; then 0.5 mg/kg/day for alternate days for eight weeks. Then taper by 5 mg every 2 weeks and discontinue
223696415|NCT00974766|DRUG|Glucocorticoids|Prednisolone 0.75 mg/kg/day for 6 weeks; then 0.5 mg/kg/day for 6 weeks. Then taper by 5 mg every 6 weeks and discontinue
223780308|NCT02199691|BIOLOGICAL|Meningococcal Polysaccharide (Serogroups A, C, Y, and W135) Tetanus Toxoid Conjugate Vaccine|0.5 milliliter (mL), Intramuscular (IM)
223780309|NCT02199691|BIOLOGICAL|Meningococcal (Groups A, C, Y and W135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine|0.5 mL, IM
223780310|NCT02199691|BIOLOGICAL|Adacel®: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed|0.5 mL, IM
223780311|NCT02199691|BIOLOGICAL|GARDASIL®: Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant|0.5 mL, IM
223780312|NCT02199691|BIOLOGICAL|Meningococcal Polysaccharide (Serogroups A, C, Y, and W135) Tetanus Toxoid Conjugate Vaccine|0.5 mL, Intramuscular (IM)
223780313|NCT02199691|BIOLOGICAL|Adacel®: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed|0.5 mL, IM
223780314|NCT02199691|BIOLOGICAL|GARDASIL®: Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant|0.5 mL, IM
223780315|NCT06573216|DEVICE|Wrist Ambulatory Blood Pressure Monitor|Comparing blood pressure measured by wrist blood pressure monitor with mercury sphygmomanometer .
223780316|NCT05433883|PROCEDURE|sleep surgery|Thirty severe OSA patients (AHI\>30, treatment group) receive comprehensive upper airway surgery with/without bariatric surgery and repeat postoperative assessment in polysomnography and aforementioned examinations 1 year later.
223780317|NCT06664268|BIOLOGICAL|Plasma rich in growth factors (PRGF-Endoret)|Plasma Rich Fibrin (PRF) is a newer modality in regenerative medicine derived from the patient's own blood. PRF does not use anticoagulants during processing, leading to a natural fibrin matrix that supports prolonged release of growth factors and cytokines .This matrix has been shown to enhance wound healing and improve scar texture and appearance .
223780318|NCT06664268|DEVICE|Fractional CO2 laser assisted PDT|Fractional CO2 laser therapy is a well-established technique for scar treatment, including postburn scars. This technology utilizes laser energy to create microthermal zones in the skin, which stimulates collagen production and skin remodeling while minimizing damage to surrounding tissues .
223780319|NCT06661109|OTHER|Intervention (Kinesio Taping) group|No randomized study was found investigating the effect of kinesio taping on comfort levels in women having a cesarean delivery.
223780320|NCT06664372|PROCEDURE|Trans fontanelle US Guided VP Shunt|Insertion of proximal VP shunt catheter by trans fontanelle US
223780321|NCT03360500|OTHER|EXERCISE PROTOCOL + CRYOTHERAPY|"Protocol: The therapeutic exercise protocol was designed according to the recommendations and guidelines of evidence-based practices and specific randomized clinical trials of physical exercise intervention for Knee osteoarthritis.~The suggested parameters for an adequate prescription of physical exercises include the type, application method, intensity, duration, minimum number of sessions and frequency of exercises.~Cryotherapy: Crushed ice inside two plastic bags. The positioning of the plastic bags will cover the entire knee surface (Anterior, lateral and posterior region). After the positioning of the ice bags, they will be fixed with an elastic bandage (compression). To protect the skin against frost bites, all the knee surface will be covered with a moistened operative field."
223780322|NCT03360500|OTHER|EXERCISE PROTOCOL|"Protocol: The therapeutic exercise protocol was designed according to the recommendations and guidelines of evidence-based practices and specific randomized clinical trials of physical exercise intervention for Knee osteoarthritis.~The suggested parameters for an adequate prescription of physical exercises include the type, application method, intensity, duration, minimum number of sessions and frequency of exercises."
223780323|NCT03360500|OTHER|EXERCISE PROTOCOL + PLACEBO|"Protocol: The therapeutic exercise protocol was designed according to the recommendations and guidelines of evidence-based practices and specific randomized clinical trials of physical exercise intervention for Knee osteoarthritis.~The suggested parameters for an adequate prescription of physical exercises include the type, application method, intensity, duration, minimum number of sessions and frequency of exercises.~Placebo: Sand inside two plastic bags. The positioning of the plastic bags will cover the entire knee surface (Anterior, lateral and posterior region). After the positioning of the sandbags, they will be fixed with an elastic bandage (compression). All the knee surface will be covered with a moistened operative field."
223780324|NCT06620237|DEVICE|Implantation of the Solia CSP S pacing lead for LBBAP|Left bundle branch area pacing using a Solia CSP S lead
223780325|NCT04274738|DRUG|Mavorixafor|Mavorixafor capsules will be administered per dose and schedule specified in the arm.
223780326|NCT04274738|DRUG|Ibrutinib|Ibrutinib capsules will be administered per dose and schedule specified in the arm.
223780327|NCT03823651|BEHAVIORAL|Interval training|Patients will be asked to complete up to 3 x 30-minute structured high intensity interval training aerobic exercise sessions/week. For the first session, patients will come to the Duke Center for Living for in person evaluation and training. After the initial training session in person, a subsequent training session will take place at the patient's home via iPad/iPhone videoconference using a device provided to the patient to provide additional support and the opportunity to answer questions. Subsequent sessions will be done independently by patients, but study staff will be available via iPad/iPhone if questions arise.
223780328|NCT03823651|BEHAVIORAL|Psychiatric consult|Subjects who score below threshold on the PHQ2/PHQ9, PC-PTSD/PCL-5, PROMIS-Depression and/or PROMIS-Anxiety assessments will be referred to a psychiatrist for follow up.
223696416|NCT03497793|OTHER|SNUBY|Following written informed consent, mother will be issued with an appropriate sized SNUBY® for her use only. The infant will be placed in skin-to-skin in SNUBY®, infant chest to mother's chest whilst the mother is seated on a reclining chair, allowing the infant to be further stabilised by gravity. Monitor wires, IV lines and/or ventilation tube will be secured using the ties on the SNUBY®. The infant's temperature, pulse and SaO2 will be recorded prior to skin-to-skin, repeated as required for the infant's clinical condition or at 30min intervals for the duration of skin-to-skin. Maternal and infant behaviour will be recorded, including spontaneous breastfeeding. The time taken to put the infant into skin-to-skin care, time in skin-to-skin care and time to return to cot will be recorded.
223696417|NCT03194503|DEVICE|VL Coaching training using C-MAC video laryngoscope|"Each neonatology attending providers will receive a video laryngoscopy coaching training using a C-MAC video laryngoscope and an intubation training manikin available at each site by a site leader. During the training, site leader will act as a trainee confederate, and each neonatology attending provider will be trained to coach a trainee utilizing video images from C-MAC video laryngoscope and a cognitive aid with standardized language in a laminated card. This training part typically takes approximately 15-30 minutes including consenting process.~Each site leader will be trained by PI or PI's designee using remote simulation. In this remote simulation, each site leader will coach an actor at the Children's Hospital of Philadelphia (CHOP) using a profile video image and C-MAC video laryngoscopy image through CHOP approved video conferencing software. A standardized language will be taught to each site leader with a cognitive aid (laminated card)."
223696418|NCT03961074|OTHER|Iron deficiency anemia in Chinese pregnant women|Iron deficiency anemia exists in Chinese pregnant women during pregnancy
223696419|NCT01180530|DEVICE|NovoPen Echo®|Prescribed insulin treatment delivered by NovoPen Echo®
223696420|NCT06198764|DRUG|Colistimethate sodium for injection|Colistimethate Sodium for Injection is the Prodrug of Polymyxin E, which is hydrolyzed into Polymyxin E after entering the human body to play a bactericidal role.Polymyxin selectively acts on gram-negative aerobic bacteria with hydrophobic outer membrane, leading to cell death by destroying the cell membrane.
223696421|NCT06198764|DRUG|Meropenem for Injection|Meropenem is a broad-spectrum carbapenem antibiotic that inhibits the synthesis of bacterial cell walls by penetrating the cell wall and reaching its target, the penicillin-binding protein, to ultimately produce antibacterial effects.
223696422|NCT06198764|DRUG|Coly Mycin M Injectable Product|Coly Mycin M is the originally marketed colistimethate sodium for injection.
223696423|NCT01082731|DRUG|Artemether-Lumefantrine|4 tablets containing 20 mg of artemether plus 120 mg of lumefantrine per tablet twice daily for three days as 2 doses 8 hours apart on the 1st day and then 2 doses 12 hours apart on the 2nd and 3rd days, administered with a fatty meal
223696424|NCT01082731|DRUG|Mefloquine- Artesunate|Tablets of 100 mg artesunate and 220 mg mefloquine (fixed dose combination), given once daily for 3 days.
223696425|NCT00462371|DEVICE|Insulin pump (CSII)|
223696426|NCT04957355|DEVICE|Neuromuscular electrical stimulation (NMES) or Functional electrical stimulation (FES)|"Stance and Walk-Perturbation Training Protocol ActiveStep and Surefooted Protocol: Perturbation training protocol with and without FES Participants will be asked to perform a postural disturbance protocol in the stance position and walk in the form of 7 slips and 7 trips with two retention trials after the training using the ActiveStep treadmill system while fitted in a safety harness. All perturbations will be delivered at each participant's comfortable walking speed. Similar slip and trip training in walking will be conducted on the surefooted platform with and without FES.~Gait Training Protocol and Surefooted protocol Participants will be asked to perform a 10m walking test (walking for a distance of 45 feet) in a laboratory environment six times (three times with and without FES) and in an outdoor environment located in the parking lot of the Applied Health Science building (1919 W. Taylor St., Chicago, IL)"
223696427|NCT02003339|OTHER|Additional RMIs|
223696428|NCT02841527|PROCEDURE|Gastric Band|Surgical intervention in which a band is inserted around the top of the stomach to reduce its size.
223696429|NCT02841527|PROCEDURE|Gastric Bypass|Surgical intervention where a small pouch is made in the top of the stomach and a loop of bowel connected to this pouch to bypass the rest of the stomach.
223696430|NCT02841527|PROCEDURE|Sleeve Gastrectomy|Surgical intervention which reduces the size of the stomach by about 75%, creating a narrow tube. It is done by stapling down the stomach and removing the remainder of the stomach.
223696431|NCT02905656|BEHAVIORAL|Brief Advice|Psychoeducation
223696432|NCT02905656|BEHAVIORAL|Motivational Interviewing|Guides participants toward choosing to make a change in their behavior with a collaborative conversation.
223696433|NCT02905656|BEHAVIORAL|Rate Reduction|Reducing the number of cigarettes consumed.
223696434|NCT02905656|DRUG|Pharmacological|Nicotine Replacement Therapy in the form of gum.
223696435|NCT02905656|BEHAVIORAL|MI+RR|Combination of reducing the number of cigarettes consumed while guiding the participant to make a change in their behavior.
223696436|NCT00066144|DRUG|Cimicifuga racemosa|
223696437|NCT00066144|DRUG|Trifolium pratense|
223696438|NCT00066144|DRUG|Black cohosh|
223696439|NCT00066144|DRUG|Red clover|
223696440|NCT00844818|BEHAVIORAL|Telephone Quitline Enrollment|The intervention included a brief motivational interview (MI), enrollment in the proactive state quitline, and follow-up faxes to the pediatric, OB, and PCP providers with tailored treatment messages.
223696441|NCT02997267|PROCEDURE|Closure of the ileostomy|Surgical closure of the protective ileostomy (reconnection of intestinal loops)
223696442|NCT02119091|DRUG|Moxifloxacin|
223696443|NCT00116662|DRUG|Resiquimod|
223696444|NCT02273518|DRUG|Asasantin ER, new formulation I|
223696445|NCT02273518|DRUG|Asasantin ER, new formulation II|
223696446|NCT02273518|DRUG|Asasantin ER, present commercial formulation|
223696447|NCT05569811|DRUG|Patritumab deruxtecan|HER3-DXd will be administered as Lyo-DP, a sterile lyophilized powder in a dose of 5.6 mg/kg
223696448|NCT05569811|DRUG|Chemotherapy|Anthracycline/taxane-based neoadjuvant regimen recommended by the NCCN or local guidelines. i.e. EC or AC (epirubicin 90 mg/m2 or doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2 every 14 or 21 days) followed by weekly paclitaxel 80mg/m2 during 12 weeks
223696449|NCT05569811|DRUG|Letrozole|Letrozole and LHRH will be used following SmPC specifications, according to standard therapy and clinical studies
223696450|NCT00678340|DEVICE|WACA and PVI|Wide area circumferential ablation (WACA) in the pulmonary vein antrum with subsequent pulmonary vein isolation (PVI) with a single tip irrigated catheter.
223696451|NCT00678340|DEVICE|PVAC|Circumferential ablation with a circular ablation catheter (Ablation Frontiers) to electrical silence.
223696452|NCT02759354|OTHER|Blood Sample|Blood sample at approx. 4 years of age
223696453|NCT04805827|DRUG|Gabapentin|1 tablet contains 600 mg Gabapentin
223696454|NCT04805827|DRUG|Neurontin|2 capsule contains 2\*300 = 600 mg Gabapentin
223696455|NCT04234139|PROCEDURE|liver transplant|solid organ transplant
223696456|NCT01912963|DRUG|Pertuzumab|
223780329|NCT03823651|BEHAVIORAL|Nutrition/diet evaluation|PG-SGA, ASA24, food group tracking Assessments and Vit D, Vit A, albumin, prealbumin, lipids, A1c levels will be used to provide weekly feedback for one month
223696457|NCT01912963|DRUG|Trastuzumab|
223696458|NCT01912963|DRUG|eribulin|
223696459|NCT02313324|DEVICE|Extracorporeal shock wave therapy (ESWT)|The patients received 2000 shots of extracorporeal shock wave therapy in the coccyx area per session for four sessions (one session a week for 4 consecutive weeks). The frequency used was 5 Hz and the pressure was 3-4 bar.
223696460|NCT02313324|DEVICE|SWD combined IFC|The shortwave diathermy (SWD) was the inductive mode with a coil at a frequency of approximately 27.12 MHz. The shortwave diathermy applicator was placed over the sacrococcygeal area. The treatment duration was 20 minutes. After completing the SWD treatments, the patients received the interferential current (IFC) treatment. IFC provides deeper electrical stimulation. The electrical current was applied to the gluteal area using four electrodes from 2 channels of the stimulator. The four electrodes were set on the gluteal area. The carrier frequency, typically 4000 Hz and 4100 Hz and designed to interfere with each other, resulted in a beat frequency of 100 Hz within the treated area. The treatment duration was 20 minutes. The protocol was set as 3 times per week for a period of 4 weeks.
223696461|NCT04167722|PROCEDURE|Robotic Radical Prostatectomy|Routine NHS Radical Prostatectomy
223696462|NCT03005171|DRUG|Bupivacaine|Thoracic epidural bupivacaine infusion
223696463|NCT03005171|DRUG|Lidocaine|Intravenous lidocaine infusion
223696464|NCT05348135|OTHER|functional strength training|children in this group received FST. Each training session started with 10 minutes dynamic warm-up period and ended with 5 minutes cool down in the form of muscle stretching and aerobics. The warm up was followed by gait training in addition to 4 functional lower limb exercises; sit to stand exercise, forward/ lateral step-up exercise, half knee rise exercise, and bridging exercise.
223696465|NCT05348135|OTHER|cognitive training|Children in this group received cognitive training by RehaCom cognitive rehabilitation software. Training was applied for four cognitive domains of function; attention / concentration, figural memory, reaction behavior and logical reasoning.
223780330|NCT03823651|BEHAVIORAL|Referral to Social Worker|Subjects who score below threshold on the PROMIS-Emotional Support and/or PROMIS-Social Isolation assessments will be referred to a social worker for follow up
223780331|NCT06261697|OTHER|A web based survey|An online based questionnaire includes three screens, the first includes the consent form, the second includes the demographic data , and the third page includes questionnaires
223780332|NCT00428610|DRUG|LY573636-sodium|LY573636 dose is dependent on participant's height, weight, and gender and is adjusted to target a specific maximum concentration (Cmax) based on participant laboratory parameters. LY573636 is administered every 28 days until disease progression or other criteria for participant discontinuation are met.
223696466|NCT05348135|OTHER|conventional physical therapy|including reinforcement of normal motor development, reflex inhibiting patterns, balance exercises, stretching exercises and gait training
223696467|NCT03462069|DRUG|Sotagliflozin (SAR439954)|"Pharmaceutical form: tablet~Route of administration: oral"
223696468|NCT03462069|DRUG|Placebo|"Pharmaceutical form: tablet~Route of administration: oral"
223696469|NCT03462069|DRUG|Empagliflozin|"Pharmaceutical form: capsule~Route of administration: oral"
223696470|NCT03462069|DRUG|Placebo|"Pharmaceutical form: capsule~Route of administration: oral"
223696471|NCT00478374|DRUG|Sorafenib|Sorafenib 400mg bid
223696472|NCT00478374|PROCEDURE|Transarterial chemoembolisation with doxorubicin|Transarterial chemoembolisation (TACE)
223696473|NCT04856891|DRUG|AK002|Lirentelimab (AK002) is a humanized non-fucosylated immunoglobulin G1(IgG1) monoclonal antibody directed against Siglec-8.
223696474|NCT04856891|OTHER|Placebo|Placebo
223696475|NCT00390234|DRUG|ziv-aflibercept|Given IV
223696476|NCT05697744|DIAGNOSTIC_TEST|Vidiac Score|Vidiac score is a scoring system created according to the visibility of laryngeal structures under videolarnyngoscopy in patients with expected difficult intubation.
223696477|NCT00792831|DRUG|ITF2357|Histone-Deacetylase Inhibitor
223696478|NCT01384279|DRUG|metformin, topiramate|metformin 250 mg/d is gradually increased to 1000 mg/d over four weeks, and topiramate 50 mg/d is gradually increased to 200 mg/d over four weeks
223696479|NCT01181648|BEHAVIORAL|questionnaire and semi-structured interviews|Survivors will be asked to complete a brief, self-administered, paper-based survey to assess quality of life, mental health and employment status following completion of therapy. Second, in a subset of 20 survivors of HPV+ oropharynx cancer, we will conduct in-depth, semi-structured, face-to-face interviews addressing the psychosocial impact of the HPV diagnosis. A follow up letter will be sent to participants who do not return their completed study questionnaires.
223696480|NCT00229151|BEHAVIORAL|Sleep deprivation and sleep phase advancement|Total sleep deprivation from 0800 to 1700 next day, and three day sleep phase advancement following sleep deprivation.
223696481|NCT00229151|OTHER|usual treatment|Treatment as usual in the psychiatric ward. Patients in this group will be offered treatment with sleep deprivation and sleep phase advancement after five weeks if they still meet inclusion criteria
223696482|NCT02715973|DIETARY_SUPPLEMENT|Nutritional Supplement|Energy dense supplement appox. 2 kcal/mL, prepared from locally available, affordable, socially acceptable food items - milk, sugar, edible coconut oil, egg and custard powder as base) in addition to standard nutritional counseling by a trained dietician as per the recommended daily allowance according to gender and age.
223780333|NCT03977844|OTHER|Technical Assistance|"TA for Individual Programs TA uses experts to train program staff via webinars and site visits, using the same toolkits as CEP, in a train the trainer approach. TA provides a series of webinars and as needed site visits, focused in the example of depression care on team support for assessment, treatment support as appropriate with medication and/or psychotherapy, case management and educational resources and access to intervention toolkits. It also includes webinars and training toolkits for agencies on domains of social risk factors for health (financial security and housing security) as well as disaster preparedness and recovery."
223696483|NCT02715973|DIETARY_SUPPLEMENT|Standard Nutritional Treatment|Standard nutritional counseling by a trained dietician as per the recommended daily allowance according to gender and age
223696484|NCT05663268|BIOLOGICAL|Infliximab-dyyb biosimilar|Remsima for subcutaneous injection is a biosimilar monoclonal antibody of infliximab-dyyb that inhibits the activity of tumour necrosis factor (TNF)-alpha.
223696485|NCT06025851|DRUG|Anti-human CCL24 monoclonal antibody (CM-101)|Intravenous Infusion of Anti-human CCL24 monoclonal antibody (CM-101)
223696486|NCT06025851|DRUG|Placebo|Placebo Comparator
223696487|NCT03111966|OTHER|Spanish cohort with HCV treated in real practice with Elbasvir/Grazoprevir|Spanish cohort with HCV treated in real practice with Elbasvir/Grazoprevir
223696488|NCT00537784|BIOLOGICAL|Autologous platelets|Local injection 10mL, about 2.5 x 10E10 platelets.
223696489|NCT00537784|BIOLOGICAL|no injection|
223696490|NCT06023524|DEVICE|Laser Acupuncture and Standard Medication|Laser Acupuncture: using RJ laser Nogier E program, with 4672Hz, 785 nm and power 70 mW. Dose 4 Joule at the acupuncture body points and 1 Joule at the ear points
223696491|NCT06023524|DEVICE|Sham Laser Acupuncture and Standard Medication|Laser Acupuncture: using RJ laser Nogier E program, with 4672Hz, 785 nm and power 70 mW. The laser is turned on but not activated
223696492|NCT03625934|BIOLOGICAL|VVX001|5 s.c. injections of 20 micrograms of VVX001 four weeks apart
223696493|NCT03625934|BIOLOGICAL|Placebo|5 s.c. injections of matching Placebo four weeks apart
223696494|NCT05895864|DRUG|utidelone injection|utidelone monotherapy in patients with recurrent or metastatic urothelial carcinoma by utidelone
223696495|NCT03857035|OTHER|Piezosurgery group|Piezosurgery technique will be examined about impacted third molar surgery.
223696496|NCT04406610|BIOLOGICAL|GD2 CAR-T immunotherapy|Antigen-specific T cell therapy
223696497|NCT04542044|OTHER|management strategy of outpatient with mild to moderate SARS-CoV-2 pneumonia|Data collected with a cohorte of SARS-CoV-2 pneumonia in an outpatient basis
223696498|NCT04920682|DRUG|Reversal of moderate neuromuscular blockade|Neostigmine 60 mcg/kg when TOF (Train-of-Four) = 3 and saline when TOF (T4 / T1)\> 0.4
223696499|NCT04920682|DRUG|Reversal of superficial neuromuscular blockade|Neostigmine 30 mcg/kg when TOF (T4 / T1)\> 0.4
223696500|NCT04920682|DRUG|Two-step reversal|Neostigmine 30 mcg/kg when TOF = 3 and neostigmine 30 mcg/kg when TOF (T4 / T1)\> 0.4
223696501|NCT04920682|DRUG|Placebo|0.9% saline solution (SF) when TOF = 3 and when TOF (T4 / T1)\> 0.4
223696502|NCT06359431|DEVICE|Novel Smart Speculum|"The examiner will lubricate the intended speculum with a water-based lubricant then insert through the vagina. Immediately after the first speculum is inserted, and before the examiner attempts to expand the blades to visualize the cervix, the participant's comfort will be assessed using a modified version of the 0-10 Universal Pain Assessment Tool, which shows a series of faces ranging from happy face at 0, or no pain, to a crying face at 10, which represents worst pain possible. Her response will be recorded immediately.~Then the examiner will open the speculum adequately to visualise the cervix. At this point, the visual analogue scale will be given to the participant and told to indicate again the level of pain following manipulation of the speculum, using a scale of 0 (no pain) to 10 (the worst pain imaginable). Her response will be recorded immediately."
223696503|NCT06359431|DEVICE|Standard speculum|"he examiner will lubricate the intended speculum with a water-based lubricant then insert through the vagina. Immediately after the first speculum is inserted, and before the examiner attempts to expand the blades to visualize the cervix, the participant's comfort will be assessed using a modified version of the 0-10 Universal Pain Assessment Tool, which shows a series of faces ranging from happy face at 0, or no pain, to a crying face at 10, which represents worst pain possible. Her response will be recorded immediately.~Then the examiner will open the speculum adequately to visualise the cervix. At this point, the visual analogue scale will be given to the participant and told to indicate again the level of pain following manipulation of the speculum, using a scale of 0 (no pain) to 10 (the worst pain imaginable). Her response will be recorded immediately."
223696504|NCT00706810|DRUG|Hydroxyurea|Hydroxyurea inhibits DNA synthesis by inhibition of ribonucleotide diphosphate reductase and is a well-known drug used for the treatment of a number of tumor types including head and neck tumors and chronic myelogenous leukemia. It has also been used as an adjuvant for antiretroviral treatment for patients with HIV and as a treatment for polycythemia vera, essential thrombocythemia and sickle cell disease.
223696505|NCT00706810|DRUG|Verapamil|Verapamil is another commonly used medication. It is used for the treatment of angina, hypertension, supraventricular arrhythmias, and migraine prophylaxis. Dosing with standard verapamil is 80-120 mg pox three times a day but the sustained release form can be given 120-480mg once or twice each day.
223696506|NCT00603421|OTHER|24 hour phone line|24 hour phone line is available as soon as the patient himself feels necessary. This phone line is supported by professionals of mental health, all specialised in borderline personality disorder
223696507|NCT00603421|OTHER|treatment as usual|Treatment as usual
223696508|NCT03112590|BIOLOGICAL|Interferon-gamma (IFN-γ)|Phase 1: IFN-γ 50 or 75 mcg/m\^2 SQ x 3 days/week for 12 weeks. Phase 2: IFN-γ at Recommended Phase II Dose (RP2D) subcutaneously (SQ) x 3 days/week, for 12 weeks.
223696509|NCT03112590|DRUG|Paclitaxel|Phase 1 and Phase 2: Paclitaxel 80 mg/m\^2/week, for 12 weeks.
223696510|NCT03112590|DRUG|Trastuzumab|Phase 1 and Phase 2: Trastuzumab 8 mg/kg intravenous (IV) loading dose on cycle 1/day 1 (C1D1), followed by 6 mg/kg on subsequent cycles every 3 weeks, for 12 weeks.
223696511|NCT03112590|OTHER|Pertuzumab|Phase 1 and Phase 2: Pertuzumab 840 mg IV loading dose on C1D1, followed by 420 mg on subsequent cycles every 3 weeks, for 12 weeks.
223696512|NCT03112590|PROCEDURE|Post Therapy Surgery|Phase 2: Participants will be assessed for surgery following the fourth cycle of study therapy (or earlier if study treatment is cancelled due to unmanageable side effects).
223696513|NCT01444131|DRUG|Varenicline, Nicotine Patch|active nicotine patches added to varenicline.
223696514|NCT01444131|DRUG|Varenicline and Placebo Patch|placebo nicotine patches added to varenicline.
223696515|NCT01837732|OTHER|Relational Touch|"Relational touch 15 mn  relational touch, hand touch (neck, face and head)"
223696516|NCT01837732|OTHER|Relational:|Relational: 10 mn verbal patient's centered exchanges
223696517|NCT06296212|DRUG|TAD® 600 mg/4 mL powder and solvent for solution for injection|TAD® 600 mg/4 mL powder and solvent for solution for injection, 1 vial powder (glutathione sodium salt 646 mg) + 1 solvent ampoule (4 mL water for injection) reconstituted solution in 50 mL of 0.9% sodium chloride solution) administered intravenously (with an infusion rate of 10 mL/min), 2 times a day (with a dosing interval of 8 hours ± 30 minutes) for 5 consecutive days (Day 1, Day 2, Day 3, Day 4 and Day 5). Doses will be administered at the same time of the day (every 24 hours ± 30 minutes).
223696518|NCT06296212|DRUG|Saline solution 0.9% of sodium chloride|Placebo (50 mL of 0.9% sodium chloride solution) administered intravenously (with an infusion rate of 10 mL/min), 2 times a day (with a dosing interval of 8 hours ± 30 minutes) for 5 consecutive days (Day 1, Day 2, Day 3, Day 4 and Day 5). Doses will be administered at the same time of the day (every 24 hours ± 30 minutes).
223696519|NCT05156073|OTHER|Educational Materials|"1. Patient care partner cohort:~   a. mailing of an educational brochure introducing deprescribing to patients with mild cognitive impairment or dementia and/or MCC and MCC care partners.~2. Primary care physician cohort:~   1. education on deprescribing through a 15-45-minute presentation~  2. one-page weekly tip sheets on options for deprescribing in specific clinical situations and suggested language for deprescribing conversations."
223696520|NCT05569473|PROCEDURE|TEST GROUP: VCMX + OFD, CONTROL GROUP : OFD ONLY|A full-thickness mucoperiosteal flap will be raised, no bone recontouring would be performed, Thorough debridement of the surgical site would be performed. For the test group, VCMX would be placed according to the dimensions of the intrabony defect after open flap debridement (OFD). For the control group, OFD will be done and After this, flaps would be approximated and sutured at the original position with a monofilament suture material using interrupted sutures.
223696521|NCT05446181|BEHAVIORAL|Perioperative delirium|Perioperative delirium
223696522|NCT05446181|PROCEDURE|Hip surgery|Orthopedic hip joint surgery under spinal anesthesia
223696523|NCT05266898|BIOLOGICAL|Human papillomavirus 9-valent vaccine, recombinant|Subunit vaccine against 9 genotypes of human papillomavirus (6, 11, 16, 18, 31, 33, 45, 52, 58)
223696524|NCT05266898|BIOLOGICAL|human papillomavirus vaccine, recombinant|Subunit vaccine against four (6, 11, 16, 18) or nine (6, 11, 16, 18, 31, 33, 45, 52, 58) genotypes of human papillomavirus. Administered as part of participant's clinical care prior to study enrollment (intervention not delivered as part of study design).
223696525|NCT01512290|OTHER|Theta Burst Transcranial Magnetic Stimulation|This rTMS paradigm consists of 5 pulses at 50Hz repeated at 5Hz for 60 seconds with a total of 900 pulses per treatment
223696526|NCT02734433|DRUG|Pexidartinib|
223696527|NCT05879835|DEVICE|KiteLock 4% Sterile Catheter Lock Solution|KiteLock™ is a clear, colorless, and sterile 4% (40 mg/ml) tetrasodium EDTA solution that contains no preservatives, latex, antibiotics, or ethanol and is nonpyrogenic. Tetrasodium salt of EDTA has been shown to disrupt in vivo and ex vivo-generated biofilms by destabilizing the structural integrity of micro-organisms at the cellular level.
223696528|NCT05879835|DEVICE|Heparin Lock Solution|Nonpyrogenic, hypertonic preparation of heparin sodium injection, USP with sodium chloride in water for injection.
223696529|NCT05860803|DEVICE|LungTrainers|A training device that provides a variable resistance against which users breathe out. Users breathe through a plastic mouthpiece that is connected to an acrylic cylinder via rubber tubing. The mouthpiece has several small holes of various diameters and up to three stainless steel weights (half-weight increments) can be inserted into the acrylic tube. With each breath-out, the user exhales against the resistance provided by the weight inserts, and each inspiration (i.e., breath-in) is unresisted. During each resisted exhalation, the weight inserts are 'lifted' within the acrylic tube depending on the level of expiratory pressure generated by the participant.
223696530|NCT05860803|BEHAVIORAL|LungTrainers Pulmonary Rehabilitation regime|Series of different exercises using the LungTrainers device 3-5 days per week for approximately 10 weeks. Exercises complete in one long session (20-30 minutes) or be broken down into multiple shorter sessions (e.g., 3 x 10 minutes). A health coach will be assigned to guide participants through the LT-PR program.
223696531|NCT03861702|DRUG|FOLFOX regimen|FOLFOX (Oxaliplatin, Leucovorin, 5-Fluorouracil)
223696532|NCT03861702|DRUG|Liposomal Irinotecan|Liposomal Irinotecan
223696533|NCT00267618|BEHAVIORAL|FHP Pain|Evidence-based psychological and behavioural Intervention
223696534|NCT05897099|BEHAVIORAL|Comprehensive Tele-harm Reduction|Comprehensive Tele-Harm Reduction is on-demand services including low-barrier access to PrEP, medications for substance use disorder and hepatitis C treatment. It includes mobile phlebotomy, peer harm reduction counseling, medication management, telehealth mental health/substance use disorder services-- all delivered via an syringe services program.
223696535|NCT05897099|BEHAVIORAL|Off-site Linkage to HIV Prevention|The community engagement team is comprised of peers and social workers and provides the wraparound support needed.The team will assist participants in scheduling appointments at community health clinics. The community engagement team provides active clinic referral- that is, a member of the team will accompany patients to the first clinic visit.
223696536|NCT04911257|DEVICE|Cervical or Lumbar Spinal fusion|This is a prospective, multi-center study of subjects who will undergo spinal fusion surgery utilizing certain Stryker Interbody Systems.
223696537|NCT03805646|OTHER|Mobile Phone-based Triage Tool|The proposed intervention is a mobile phone-administered survey. Participants that have been admitted to participating hospitals for treatment of injury will be contacted by mobile phone approximately two weeks after discharge. A seven-question survey will be administered over the phone to each participant. Cross-validation with a separately administered in-person physical exam will be performed to assess the survey tool's prediction of who needs further care for treatment of their injury.
223696538|NCT06236243|DIETARY_SUPPLEMENT|Korean Red Ginseng Extract Powder 120 mg/tablet|Participants will take 2 tablets 2 times daily (preferably after breakfast and after dinner) for 12 weeks.
223696539|NCT06236243|DIETARY_SUPPLEMENT|Korean Red Ginseng Extract Powder 500 mg/tablet|Participants will take 2 tablets 2 times daily (preferably after breakfast and after dinner) for 12 weeks.
223696540|NCT06236243|DIETARY_SUPPLEMENT|Placebo|Participants will take 2 tablets 2 times daily (preferably after breakfast and after dinner) for 12 weeks.
223696541|NCT05473897|DEVICE|Catalyst Cryohelmet|The Catalyst Cryohelmet will be used to provide head and neck cooling. It comes in three sizes based on head circumference. Once informed consent is obtained then the patient's head will be measured to provide the correct helmet size. The Cold Packs will be stored in the emergency department freezer and applied to the helmet once the helmet is ready to be applied. The Cryohelmet will be washed between uses. The Catalyst Cryohelmet is registered with the FDA as D344812. It is a Class I (minimal risk) device not requiring pre-marketing or regulatory processes.
223696542|NCT06575309|BIOLOGICAL|Blood test|The procedures added as part of this research are 6 blood samples, the volumes of which do not exceed the volume authorized in the order of February 17, 2021, i.e. 27mL.
223696543|NCT03193190|DRUG|Nab-Paclitaxel|Nab-Paclitaxel will be administered as per the schedule specified in the respective arm.
223696544|NCT03193190|DRUG|Gemcitabine|Gemcitabine will be administered as per the schedule specified in the respective arm.
223696545|NCT03193190|DRUG|Oxaliplatin|Oxaliplatin will be administered as per the schedule specified in the respective arm.
223696546|NCT03193190|DRUG|Leucovorin|Leucovorin will be administered as per the schedule specified in the respective arm.
223696547|NCT03193190|DRUG|Fluorouracil|Fluorouracil will be administered as per the schedule specified in the respective arm.
223696548|NCT03193190|DRUG|Atezolizumab|Atezolizumab will be administered as per the schedule specified in the respective arm.
223696549|NCT03193190|DRUG|Cobimetinib|Cobimetinib will be administered as per the schedule specified in the respective arm.
223696550|NCT03193190|DRUG|PEGPH20|PEGPH20 will be administered as per the schedule specified in the respective arm.
223696551|NCT03193190|DRUG|BL-8040|BL-8040 will be administered as per the schedule specified in the respective arm.
223696552|NCT03193190|DRUG|Selicrelumab|Selicrelumab will be administered as per the schedule specified in the respective arm.
223696553|NCT03193190|DRUG|Bevacizumab|Bevacizumab will be administered as per the schedule specified in the respective arm.
223696554|NCT03193190|DRUG|RO6874281|RO6874281 will be administered as per the schedule specified in the respective arm
223696555|NCT03193190|DRUG|AB928|AB928 will be administered as per the schedule specified in the respective arm.
223696556|NCT03193190|DRUG|Tiragolumab|Tiragolumab will be administered as per the schedule specified in the respective arm.
223696557|NCT03193190|DRUG|Tocilizumab|Tocilizumab will be administered as per the schedule specified in the respective arm.
223696558|NCT03493516|DIAGNOSTIC_TEST|PET scan quantifying sympathetic denervation using [18F]-LMI1195|A cardiac PET scan will be obtained to quantify the percentage of the left ventricle that is denervated and has reduced uptake of the sympathetic nerve tracer \[18F\]-LMI1195
223696559|NCT05979727|DRUG|RE02|Low, medium or high dose of RE02
223696560|NCT05979727|DRUG|Manitol|Placebo Comparator
223696561|NCT04552925|OTHER|Rehabilitation|Exercises and rehabilitation for massive rotator cuff tears
223696562|NCT05521906|BEHAVIORAL|Promoting Resilient Youth with Strong Hearts and Minds (PRYSHM)|The intervention focuses on psycho-education (provision of accurate information about LGBTQIA2S+ people, education about the effects of alcohol), fostering positive identity development for LGBTQIA2S+ youth (e.g., fostering pride in identity, exposure to positive adult role models), teaching of alcohol use and sexual refusal skills, correction of inaccurate social norms about alcohol use and dating violence, teaching assertive communication skills, teaching emotion coping skills, mindfulness and grounding skills, and teaching bystander intervention skills related to dating/sexual violence and alcohol use..
223696563|NCT02458456|OTHER|Isometric resistance training|Isometric exercise using a hand dynamometer.
223696564|NCT06656208|OTHER|Pubic symphysis manipulation|Manipulation was applied in the crook lying position with 5 repetitions hold for 10 sec and ask the patient to apply max. Contraction in Abduction and then relax. Whereas, the therapist applies a rapid stretch to a new barrier and is held for 10 seconds.
223696565|NCT06656208|OTHER|Traditional sacroiliac treatment|Mobilization was applied in prone lying position on sacroiliac joint, 30 Oscillations per set for 15 seconds, 3 sets on effected side.
223696567|NCT06207604|PROCEDURE|Open sinus lifting without bone grafting and simultaneous implant placement|no bone graft will be used after open sinus lifting
223696568|NCT06207604|PROCEDURE|Open sinus lifting with bone grafting and simultaneous implant placement|bone graft will be packed palatally after open sinus elevation and before implant placement, then implant placement will took place followed by packing of bone grafts
223696569|NCT04272853|OTHER|Interview|Compilation of the interview concerning: demographic data, sports practice, habits on sleep, sexual habits, perception of the relationship between sexual habits and sleep, perception of the relationship between sexual habits and sports practice.
223696570|NCT01542671|BEHAVIORAL|Intervention|"* Lifestyle Counselor meetings at baseline, 6 months, and 12 months~* Structured eating plan~* Tailored nutritional and exercise tips. Weekly: months 1-12, biweekly: months 13-18, and monthly: months 19-24.~* Monthly Motivational phone calls with Lifestyle Counselor for the first year~* 4 informational DVDs over the two year period~* Feedback on submitted food and exercise journals"
223696571|NCT01542671|BEHAVIORAL|Control|"* Lifestyle Counselor meetings at baseline, 6 months, and 12 months~* Structured eating plan~* 5 informational NIDDK mailings over the two year period"
223780334|NCT03977844|OTHER|Community Engagement and Planning|CEP for Coalitions CEP creates multi-sector networks to collaborate in evidence-based and community-prioritized toolkits or intervention materials. CEP supports a series of biweekly to monthly meetings to develop network and individual program capacity, prepare stakeholders as co-leads, and create a written training plan following CPPR principles \[48, 64\]. CEP councils consider local context, i.e., cultural assets and stakeholder input. Disaster preparedness and public health sectors will be encouraged to offer education/resources on social determinants and disasters within CEP training plans. CEP will be supported by a Learning Collaborative, meeting 2-3 times, using activities such as project examples, tabletop exercises and self-assessment to identify gaps and formulate goals for improvement.
223696572|NCT06623721|DEVICE|Movement-evoked transcutaneous auricular Vagus nerve stimulation|"Intervention requires wearing of an inertial measurement unit (IMU) sensor on an affected upper limb together with a transcutaneous auricular Vagus nerve (taVNS) stimulator on an outer ear on the contralateral side.~Intervention involves IMU measurement-evoked initiation of taVNS during conventional neurorehabilitation therapy that is defined by the patient\&amp;#39;s doctor and therapist. Typically this is around 60 minutes/day of 50-300 repetitive upper limb movements targeting specific deficits such as flexor synergies and/or wrist, triceps or shoulder activation.~taVNS intensity is calibrated at the start of every neurorehabilitation session by the patient to the maximal comfortable level with instructions to avoid pain or any serious discomfort. Patient is always accompanied by a therapist trained in the use of taVNS and the device is easy to immediately remove should any discomfort occur."
223696573|NCT06682065|OTHER|Telemedicine for contraceptive counseling (TECC)|WhatsApp algorithmic chatbot that screens preferences and medical eligibility to recommend two methods, informs about all methods, allows choice out of all methods, produce summary to substitute for clinical record
223696574|NCT06682065|OTHER|Standard Care|In-personcontraceptive counseling with a nurese according to clinical standard of care
223696575|NCT06334276|OTHER|Drowning|"Drowning is defined by the WHO in 2002 as the process of experiencing respiratory impairment from submersion or immersion in liquid"
223696576|NCT06709313|DRUG|Chromium|Participants in the experimental group will receive oral chromium supplementation, the dosage of which is determined based on previous studies(200 mcg daily) taking into account safety and efficacy considerations. The supplementation will commence for 45 days following the injection.
223696577|NCT06708585|OTHER|progressive relaxation exercises and training|Considering the high incidence of cesarean section and the prevalence of anxiety and fear as psychological symptoms, providing comfort and pain support to women is of great importance. Therefore, the effect of progressive relaxation exercise and education before cesarean section surgery on care outcomes will be determined.
223696578|NCT06707779|OTHER|PNF with electrical stimulation|"Group A receive PNF including combination of isotonic and rhythmic stabilization on trunk with electrical stimulation Participants perform three sets10 repetitions at maximal resistance The resting interval of 30 seconds and 60 seconds will be provided after the completion of 10 repetitions for each pattern and between sets respectively.~In total all PNF exercise will be held for 30 to 45 minutes. 'BURST' TENS (acupuncture-like TENS), characterized by discontinuous stimulation at low frequencies (1-4 Hz), with wave durations of 100-400 ms and high intensities, inducing weak muscle twitches for 10 minutes."
223696579|NCT06707779|OTHER|PNF without electrical stimulation|"Group B receive PNF including combination of isotonic and rhythmic stabilization on trunk without electrical stimulation. Participants perform three sets of 10 repetitions at maximal resistance will be provided by the same physiotherapist.~The resting interval of 30 seconds and 60 seconds will be provided after the completion of 10 repetitions for each pattern and between sets respectively.~In total all PNF exercise will be held for 30 to 45 minutes."
223696580|NCT06709729|DEVICE|Insulin pump with closed-loop system|Device: Usage of Insulin pump t:slim X2 with Control-IQ technology or MiniMed 780G with Smartguard technology in previous users of AndroidAPS
223696581|NCT06879249|DEVICE|critical ultrasonography|In the CUGP group, attending physicians utilized a designed fluid management strategy guided by ultrasonographic evaluation of the inner diameter of IVC, ejection fraction (EF) value and passive leg raising-induced changes in VTI (ΔVTI). This ultrasonographic assessment was performed by a team of trained critical ultrasonography physicians at enrollment, 1 hour, 3 hours, 6 hours, 12 hours, 24 hours, 48 hours, and 72 hours thereafter, respectively. Additionally, patients did not preclude the concurrent use of conventional hemodynamic monitoring methods. At each of these time points, attending physicians would make comprehensive decisions on fluid management based on the results of ultrasonographic evaluation, along with other monitoring methods. The researcher recorded the basis of decisions, disposal strategy and outcomes.
223696582|NCT06877923|DIETARY_SUPPLEMENT|Elemental 028 Extra|Elemental 028 Extra formulations. Both powder and liquid versions will be used
223696583|NCT00814788|DRUG|Bicalutamide|50 mg oral tablet daily
223696584|NCT00814788|DRUG|Everolimus|10 mg oral capsule daily
223696585|NCT00775216|BEHAVIORAL|"Behavioral counseling plus telephone helpline"|A trained behavioral counselor will place phone calls to Phase 2 intervention participants. These calls will be used to provide tailored physical activity advice and to extend our partnership with the Metro Nashville Parks and Recreation Department, directing participants to community centers close to their homes or workplaces where they can access a variety of physical activities (e.g., indoor pools, walking tracks, fitness centers, greenways, etc) using a newly developed electronic database. Following an orientation to the Metro Parks services which will be held at either Hadley Regional Park or Coleman Regional Park, participants will be directed to the Metro Parks facility most convenient to them.
223696586|NCT00195572|DRUG|Isovorin|
223696587|NCT00195572|DRUG|TS-1|
223696588|NCT00960739|DRUG|Topotecan hydrochloride|The topotecan hydrochloride is administered intravenously over five days to dose of 0.7 mg/ m²/day from day 1 to day 5 (first cycle), then from day 21 to day 25 (second cycle)
223696589|NCT00960739|PROCEDURE|Autologous hematopoietic stem cell transplantation|Hematopoietic stem cells are reinjected 10 days after the second injection of 131-iodine MIBG
223696590|NCT00960739|RADIATION|iobenguane I 131|444 MBq / kg of 131-iodine MIBG is administered on day 1 with activity
223696591|NCT00960739|RADIATION|total-body irradiation|the dose of total-body irradiation of 4 Gy is reached during the first cycle, the second cycle is canceled (131-iodine MIBG and Topotecan)
223696592|NCT00413400|DRUG|Etanercept|50 mg one syringe sc 2X per week for three months followed by 50 mg one syringe sc 1X per week for three months
223696593|NCT00413400|DRUG|Placebo|50 mg one syringe sc 2x per week for three months followed by 50 mg one syringe sc 1X per week for three months
223696594|NCT02505178|OTHER|Problem Solving Therapy|PST is a minimally invasive treatment. The five sessions of CM implemented PST will involve psychotherapy also known as talk therapy between the CM's and study participants in a group setting. Psychogeriatric interdisciplinary staff (CM's) i.e. psychiatric nurses, social workers who have been previously trained in PST will function in the roles of facilitator, cofacilitator and scribe. The roles can be shared amongst the professionals to build capacity in each role or maintained over time if so desired. Sessions will be approximately one-and-a-half to two hours in length and conducted at the Cherry Hill Mall library in London.
223696595|NCT02387177|BEHAVIORAL|Stress Management Group 1|Subjects will attend group stress management sessions via Skype once weekly for 8 weeks and learn stress/NF symptoms managements techniques.
223696596|NCT02387177|BEHAVIORAL|Stress Management Group 2|Subjects will attend group stress management sessions via Skype once weekly for 8 weeks and learn stress/NF symptoms managements techniques.
223696597|NCT02504996|DRUG|Paracetamol|1 g paracetamol via intravenous route in 100 ml normal saline
223696598|NCT02504996|DRUG|morphine|0.1 mg/kg morphine via intravenous route in 100 ml normal saline
223696599|NCT02504996|DRUG|Placebo|Intravenous 100 ml normal saline
223696600|NCT01149837|DEVICE|InnoLIA HTLV I/II Score line immunoassay|This intervention consists of testing a residual serum or plasma sample from a blood donation or donor follow-up sample using the InnoLIA HTLV I/II Score line immunoassay
223696601|NCT00891462|DRUG|Aclidinium bromide|Aclidinium bromide 200 μg, oral inhalation twice per day for 12 weeks of treatment
223696602|NCT00891462|DRUG|Aclidinium bromide|Aclidinium bromide 400 μg, oral inhalation twice per day for 12 weeks of treatment
223696603|NCT00891462|DRUG|Placebo|Dose-matched placebo, oral inhalation twice per day for 12 weeks of treatment
223696604|NCT04710134|BIOLOGICAL|Reslizumab|Reslizumab 3,4, or 5 mg/kg IV q4 weeks
223696605|NCT00970073|BIOLOGICAL|Thymoglobulin 3mg total|1.5 mg/kg induction on Day 0 and 1.5 mg/kg induction on Day 2 (total of 3 mg/kg)
223696606|NCT00970073|BIOLOGICAL|Thymoglobulin 4.5mg total|1.5 mg/kg induction on Days 0, 2 and 4 (total 4.5 mg/kg)
223696607|NCT00970073|DRUG|Mycophenolate mofetil|1000 mg PO/IV BID for up to 6 months
223696608|NCT00970073|DRUG|tacrolimus 3-8|Trough concentration between 3 ng/mL and 8 ng/mL starting on Day 10 and continuing beyond Day 180
223696609|NCT00970073|DRUG|tacrolimus 8-12|Trough concentration between 8 ng/mL and 12 ng/mL on Days 0-10; between 6 ng/mL and 12 ng/mL on Days 10-30; between 6 ng/mL and 10 ng/mL Days 31-60; between 5 ng/mL and 8 ng/mL Days 61-179; and between 3 ng/mL and 8 ng/mL beyond Day 180.
223696610|NCT01786655|DRUG|Neosaxitoxin in saline|NeoSTX will be administered in sequential dose cohorts. Each subject receives one injection with bupivacaine 0.2% alone on one side (control). On the other side they receive NeoSTX in saline (test). Subjects receive NeoSTX in saline in subsequent dose escalation levels: 5 mcg, 10 mcg, 15 mcg, 20 mcg, 30 mcg, and 40 mcg of NeoSTX.
223696611|NCT01786655|DRUG|NeoSTX + bupivacaine 0.2%|NeoSTX will be administered in sequential dose cohorts. Each subject receives one injection with bupivacaine 0.2% on one side (control). On the other side they receive NeoSTX with 0.2% bupivacaine. Subjects receive NeoSTX in 0.2% bupivacaine in subsequent dose escalation levels: 5 mcg, 10 mcg, 15 mcg, 20 mcg, 30 mcg, and 40 mcg of NeoSTX.
223696612|NCT01786655|DRUG|NeoSTX + bupivacaine 0.2% + epinephrine 5mcg/ml|Each subject receives one injection with bupivacaine 0.2% on one side (control). On the other side they receive NeoSTX in 0.2% bupivacaine with epinephrine 5 mcg/ml. Subjects receive NeoSTX in 0.2% bupivacaine with epinephrine 5 mcg/ml in doses of 10 mcg or 30 mcg of NeoSTX.
223696613|NCT01786655|OTHER|Saline placebo|Each subject receives one injection with bupivacaine 0.2% alone on one side. On the other side they receive saline placebo.
223696614|NCT01757262|DRUG|90 mg Ticagrelor|Morning and Evening dose for 5 days
223696615|NCT01757262|DRUG|75mg Clopidogrel|Morning dose for 5 days
223696616|NCT03063242|DRUG|Sargramostim|Study participants (n=5 per project) will receive subcutaneous injection of sargramostim (6 ug/kg) daily until maximal mDC levels are achieved, as determined by a dose response curve.
223696617|NCT03063242|BIOLOGICAL|Blood samples|Blood samples will be drawn at baseline and during each subsequent visit
223696618|NCT05948787|BEHAVIORAL|Psychosocial intervention|A structured sessions for families that promotes improving communication, bonding, and improved parenting techniques in managing stress within the family setting.
223696619|NCT01254097|DIETARY_SUPPLEMENT|Probiotic|Probiotic capsule, 2 capsules twice daily
223780335|NCT03977844|OTHER|Community Resources (CR)|The CR app will primarily provide informational resources and referral information relevant to the local community. We will identify resources for depression, social determinants and disaster preparedness and response within each community during planning with local stakeholders.
223780336|NCT03977844|OTHER|Community Resources + eBT|"The CR+eCBT app consists of the functionality of the CR app along with an interactive component to support CBT-informed coping with mood and stressors at the individual level. This component was developed previously by our group using participatory methods with community partners and includes interactive support to enhance social support networks, support cognitive restructuring (framed through partnered input as Catch it, Check it, Change it), and encourage pleasant activities \[65\]. Participants will receive text message notifications (with frequency set by participants, up to several times per day) and can either reply back to messages to explore content or click a link in the message to access the interactive mobile app."
223780337|NCT06503120|BEHAVIORAL|Mediterranean-diet intervention group|Dietitian-guided Nutritionist Education Process
223780338|NCT06503120|BEHAVIORAL|Standard care|A 10-minute talk on the epidemiology of MASLD and balanced diet, resembling routine clinical practice.
223780339|NCT03609060|DRUG|Dexamethasone|Dexamethasone 10 mg/12h, IV over 30 minutes, D1 to D3 concomitant to induction and post remission chemotherapy in elderly patients with AML Induction
223780340|NCT05350449|BEHAVIORAL|Loving-kindness Meditation|Loving-kindness meditation is a type of mindfulness practice where the focus is on love/compassion and kindness for self and others. The guided meditation will be provided via recording device. The intervention is 4 week long.
223780341|NCT06081660|BEHAVIORAL|ACP-I Plan|ACP-I Plan consisting of education, counseling, decisional support, and patient navigation
223780342|NCT04624698|DEVICE|iStent Inject Implantation|Subjects will be implanted with the iStent Injection Micro-Bypass device
223780343|NCT05424419|PROCEDURE|Brace therapy|A Chêneau-type brace was made to be worn as a full-time brace or during daytime only (double-brace group), whereas the nighttime brace was produced according to the Charleston approach.
223780344|NCT05577429|OTHER|Low-moderate intensity exercise under normoxia|The participant will perform the exercise interventions consisting of cycling at the 90% lactate threshold at normoxia (fraction oxygen: 20.9%) for 60 minutes on separate days (5-7 days). Immediately after exercise oral glucose tolerance test (OGTT) and 24-hour glucose concentration will be monitored continuously. Pre, post and post-24 h circulatory markers will be determined.
223780345|NCT05577429|OTHER|Low-moderate intensity exercise under moderate hypoxia|The participant will perform the exercise interventions consisting of cycling at the 90% lactate threshold at normoxia (fraction oxygen: 16.5%) for 60 minutes on separate days (5-7 days). Immediately after exercise oral glucose tolerance test (OGTT) and 24-hour glucose concentration will be monitored continuously. Pre, post and post-24 h circulatory markers will be determined.
223780346|NCT05577429|OTHER|Low-moderate intensity exercise under high hypoxia|The participant will perform the exercise interventions consisting of cycling at the 90% lactate threshold at normoxia (fraction oxygen: 14.8%) for 60 minutes on separate days (5-7 days). Immediately after exercise oral glucose tolerance test (OGTT) and 24-hour glucose concentration will be monitored continuously. Pre, post and post-24 h circulatory markers will be determined.
223780347|NCT01404312|DRUG|Rifapentine (RPT)|"RPT dosing was be based on participants' weight:~Participants who weighed 30 kg to less than 35 kg received 300 mg once daily (administered as two 150-mg tablets).~Participants who weighed 35 kg to less than 45 kg received 450 mg once daily (administered as three 150-mg tablets).~Participants who weighed greater than 45 kg received 600 mg once daily (administered as four 150-mg tablets)."
223780348|NCT01404312|DRUG|Isoniazid (INH)|Participants received one 300-mg tablet or three 100-mg tablets of INH once daily.
223780349|NCT01404312|DIETARY_SUPPLEMENT|Pyridoxine (Vitamin B6)|"Participants received 25 mg or 50 mg of pyridoxine, based on the current local, national, or international dosing guidelines.~Participants who received 25 mg of pyridoxine took one 25-mg tablet once daily with INH.~Participants who received 50 mg of pyridoxine took two 25-mg tablets once daily with INH."
223780350|NCT00584688|DRUG|quetiapine|quetiapine dosage will be titrated to subject tolerance beginning at 50 mg every 24 hours upwards to 400 mg every 24 hours.
223780351|NCT04477980|OTHER|Disease outcome (mortality)|Mortality rate between the two groups
223780352|NCT05704959|DIAGNOSTIC_TEST|povidone iodine|Reference measurements were made simultaneously with two separate calibrated pulse oximeter devices from the index, middle and ring fingers of both hands of the participants. One layer of 10% povidone iodine was applied to the index finger, two layers to the middle finger, and three layers to the ring finger of one hand of the participant's choice. Two pulse oximetry measurements were made with the fingers of the other hand, immediately after the application of povidone-iodine and three minutes later, and it was noted on the data collection form.
223780353|NCT02965560|DIAGNOSTIC_TEST|plasma suPAR, PGE2 measurement. Other biomarkers were just recorded from clinical laboratory.|
223696620|NCT04864301|PROCEDURE|Tumescent Stretching Measurement Technique|"The Tumescent Stretching Measurement Technique (TSMT) group (N=12) will be administered an intracorporal injection (ICI) of 20 microgram Alprostadil. Hegar 7 dilator will be introduced through the corporotomy until reaching a bone stopping point. The tumescent penis will stretched maximally, and the proximally inserted dilator measured externally to the coronal sulcus."
223696621|NCT03431766|DEVICE|placebo gel|On control group A once the dental implants are inserted on both mandible or maxilla of the patient placebo (group A) would be applied on the internal surface of the implants on all the surgical or prosthetic phases of the study.
223696622|NCT03431766|DEVICE|0.20% chlorhexidine gel|On test group B once the dental implants are inserted on both mandible or maxilla of the patient a 0.20% chlorhexidine gel would be applied on the internal surface of the implants on all the surgical or prosthetic phases of the study.
223696623|NCT05040048|OTHER|Clinical, biological and imaging assessment|
223696624|NCT04672395|BIOLOGICAL|CpG 1018/Alum-adjuvanted SCB-2019 vaccine|Group 1: Participants will receive 1 intramuscular (IM) injection of 30 microgram (ug) SCB-2019 with CpG1018/Alum adjuvant on Day 1 and on Day 22
223696625|NCT04672395|BIOLOGICAL|Placebo; 0.9% saline|Group 2: Participants will receive 1 IM injection of SCB-2019-matching placebo on Day 1 and on Day 22
223696626|NCT04672395|BIOLOGICAL|SCB-2019 vaccine|Participants will receive 1 IM injection of 30 microgram (ug) SCB-2019 with CpG 1018/alum adjuvant
223696627|NCT04672395|BIOLOGICAL|SCB-2019 vaccine for Placebo|Participants will receive 2 IM injection of 30 microgram (ug) SCB-2019 with CpG 1018/alum adjuvant, 21 days apart
223696628|NCT00121381|DRUG|Pimecrolimus plus topical corticosteroid (TCS)|Pimecrolimus 1 % cream plus topical corticosteroid (TCS) twice daily
223696629|NCT00121381|DRUG|Pimecrolimus vehicle (Placebo) plus topical corticosteroid (TCS)|twice daily administration
223696630|NCT03545100|OTHER|motor control therapy|scapular muscle progressive resistive exercise(PRE)
223696631|NCT03545100|OTHER|regular physical therapy|transcutaneous electrical nerve stimulation(TENS), shoulder joint ROM, scapular muscle PRE
223696632|NCT02474381|BIOLOGICAL|EPCs plus PTA|Intra-arterial infusion of autologous CD133+ cells on diabetic subjects with PAD,plus angioplasty
223696633|NCT02474381|DEVICE|Single PTA|Angioplasty of arteries below tibial plateau level only
223696634|NCT01595672|DEVICE|AN69 hemofilter|An AN69 hemofilter (1.6 m2 surface area, 35-KD limit; Baxter Healthcare Corp. Deerfield, IL, USA) will be used for EHCVVH.
223696635|NCT01595672|OTHER|conventional treatments|Patients receive conventional treatments recommended by guidelines only.
223696636|NCT03029442|DRUG|Denosumab (Prolia)|In clinical trials, denosumab (Amgen Inc., Thousand Oaks, CA), has been shown to be more potent in reducing osteoclastosis and function than bisphosphonates. The dose of denosumab chosen for our protocol in patients after acute SCI will be the same dose that has been shown to be efficacious to treat postmenopausal osteoporosis (60 mg SQ q 6 months).
223696637|NCT03029442|OTHER|Placebo (normal saline)|Identical Denosumab volume of normal saline
223696638|NCT04382391|DEVICE|gammaCore® Sapphire (non-invasive vagus nerve stimulator)|"Administer gammaCore® Sapphire daily, prophylactically, for three treatments (morning, mid-day and night, one hour before bed), each treatment consisting of two 2-minute doses/stimulations, one on each side of the neck. This would be a total of 6 treatments (2 doses x 3 times per day) of stimulation.~For acute respiratory distress or shortness of breath (SOB), administer one treatment consisting of two 2-minute stimulations, on the neck. If respiratory distress or shortness of breath persists 20 minutes after the start of the first treatment, administer a second treatment."
223696639|NCT04382391|OTHER|Standard of care therapies|Will receive standard of care therapies for the treatment of CoViD-19 infection and symptoms
223696640|NCT03124446|BEHAVIORAL|Mindfulness-Based College|MB-College is an 8-week, 9-session curriculum providing systematic and intensive training in mindfulness meditation practices, applied to health behaviors relevant to college students. The curriculum is based on the manualized and standardized Mindfulness-Based Stress Reduction. The course builds a foundation of mindfulness self-regulation skills, including attention control, self-awareness and emotion regulation. It then directs those skills towards participants' relationships with health-related factors particularly salient in college undergraduates, including physical activity, diet, alcohol consumption, sleep, stress, social relationships, cognitive performance, and emotion regulation. Health behavior goal setting, and support for behavior change are integrated in the curriculum.
223696641|NCT03124446|BEHAVIORAL|Enhanced Usual Care Control|Participants in the enhanced usual care control group were spoken with by trained study staff, and as part of the enhanced usual care, were offered a referral to the study's psychiatrist and University counseling resources, if anxiety, depression, or suicidal ideation levels at baseline or follow-up reached clinical levels on the Beck Anxiety Inventory or the Revised Centers for Epidemiologic Studies Depression (CESD-R) scale. Participants in the control group were eligible to take the MB-College program during the following university term.
223696642|NCT04601402|DRUG|GEN-001|The capsules taken by mouth once a daily. Each capsule will contain ≥ 1x10\^11 colony-forming units (CFU)
223696643|NCT04601402|DRUG|Avelumab|800 mg given by intravenous (IV) infusion once every 2 weeks
223696644|NCT03531125|PROCEDURE|Endoscopic Ultrasound|Endoscopic ultrasound for tumour biopsy collection
223696645|NCT03531125|PROCEDURE|Pancreaticoduodenectomy|Surgery to remove pancreatic tumour
223696646|NCT00257608|DRUG|bevacizumab|Intravenous repeating dose
223696647|NCT00257608|DRUG|placebo|Oral repeating dose
223696648|NCT00257608|DRUG|erlotinib HCl|Oral repeating dose
223696649|NCT05207254|DIAGNOSTIC_TEST|Ultrasonic test|Ultrasonic test to the patient's head, neck and jaw area.
223696650|NCT05390931|BEHAVIORAL|6-session motivational interviews|A total of 6 motivational interviews will be held once a month. Motivational interviews will be conducted individually.
223696651|NCT05390931|OTHER|Health education structured according to the health belief model|After the participants enrolled in the study, the patients in the study group will be given a health education structured according to the health belief model at the first interview.
223696652|NCT05390931|OTHER|Training booklet prepared by the researchers on healthy lifestyle behavior changes|After the participants enrolled in the study and take health education, a training booklet prepared by the researchers on healthy lifestyle behavior changes will be given to the participants.
223696653|NCT05390931|OTHER|6 month follow-up|Follow-ups will be made 3 times in total, on the basis of pre-test, intermediate follow-up test (3 months), and post-test (6 months).
223696654|NCT01197664|DRUG|paricalcitol|Given PO
223696655|NCT01197664|RADIATION|radiation therapy|Undergo radiotherapy
223696656|NCT01197664|OTHER|laboratory biomarker analysis|Correlative studies
223696657|NCT01197664|DRUG|fluorouracil|Given PO
223696658|NCT02515448|DRUG|gentamicin|
223696659|NCT00000337|DRUG|Selegiline|
223696660|NCT02171065|DEVICE|sham|
223696661|NCT02171065|DEVICE|ABSORB BVS|
223696662|NCT05015439|DRUG|Cannabidiol|The study intervention will be supplied as a softgel capsule containing cannabidiol.
223696663|NCT05015439|DRUG|Placebo|The study intervention will be supplied as a softgel capsule containing inert filler.
223696664|NCT00562029|PROCEDURE|Duodenal-jejunal Bypass|Patient has undergone a duodenal bypass and bypass of 60cm of proximal jejunum
223696665|NCT05414877|DRUG|Ephedrine|vasopressor
223696666|NCT05414877|DRUG|Phenylephrine|vasopressor
223696667|NCT05414877|DRUG|Norepinephrine|vasopressor
223696668|NCT06558513|DRUG|XNW5004 tablets|XNW5004 an EZH2 inhibitor, BID, administered in continuous
223696669|NCT03245684|DIAGNOSTIC_TEST|assessment of inflammatory response during PSV|assessment cytokines level in BAL and plasma
223696670|NCT03134404|OTHER|No Intervention|No Intervention is required for this study
223696671|NCT06169046|DRUG|Clenbuterol|tablets
223696672|NCT06169046|DRUG|Placebo|tablets
223696673|NCT01435278|DEVICE|Glucosanol|2 tablets taken 3 times a day.
223696674|NCT00066638|DRUG|Romidepsin|Given IV
223696675|NCT00066638|OTHER|Laboratory Biomarker Analysis|Correlative studies
223696676|NCT03968770|DIETARY_SUPPLEMENT|Experimental group|Probiotic (Lactobacillus casei) once daily taken by 6 weeks.
223696677|NCT03968770|DIETARY_SUPPLEMENT|Control group|Placebo of Probiotic once daily taken by 6 weeks.
223696678|NCT03968770|OTHER|Usual medical care|NSAIDs, once daily taken and promotion of a healthy lifestyle by 6 weeks.
223696679|NCT04672343|OTHER|Data collection|from D0 to hospital discharge
223696680|NCT04672343|OTHER|Querying the INSEE database|Vital status at 3 months and 12 months
223696681|NCT01121653|DRUG|Magnogene ® (magnesium)|evaluate on pain scores (neuropathic pain questionnaire and pain numeric scale) and on quality of life, the effect of oral magnesium intake on patients with neuropathic pain comparing with patients receiving placebo,. The study drug will be taken during 4 weeks.
223696682|NCT05863338|BEHAVIORAL|NURSING FOLLOW-UP BY PHONE|The training was carried out in the form of individual training and as a single session.The training,which lasted about 30 minutes,was carried out in the training room of the polyclinic with the support of Barco vision.In the training session,lecture,question-answer methods were used and at the end of the training session,a booklet containing the training content was given to the patients.The researcher phoned the patients once a week for 24 weeks,conveyed how they were doing,whether there was anything they wanted to ask or learn,and provided counseling to the patients in line with their needs.The next week's plan was also determined in the phone calls made in the following weeks.Patient follow-ups as stated were continued for 24 weeks.At the 12th and 24th weeks of the telephone nursing follow-up, the patients filled out the scales again.
223696683|NCT03332290|BEHAVIORAL|sport practice|the intervention was a training course lasting 10 days. It included 10 days of sports practice. For divers, diving was carried out using air at a maximum depth of 40-meters, with a maximum of one dives a day. For the multisport group (the non-divers), the course included kayaking, mountain climbing or hiking with a maximum of two activities a day.
223696684|NCT01705990|BIOLOGICAL|SeV-G(NP) (0.2mL, 2x10^7 CIU)|Delivered intranasally by drops
223696685|NCT01705990|BIOLOGICAL|SeV-G(NP) (0.2mL, 2x10^8 CIU)|Delivered intranasally by drops
223696686|NCT01705990|BIOLOGICAL|Ad35-GRIN (0.5mL)|(1x10\^10 vp) Delivered intramuscularly by standard syringe and needle injection
223696687|NCT04663373|OTHER|Step counting|Patients are given a physical activity tracker (wrist band) that they are asked to wear for two weeks after discharge from percutaneous coronary intervention.
223696688|NCT02598960|DRUG|BMS-986156|
223696689|NCT02598960|DRUG|Nivolumab|
223696690|NCT04258514|PROCEDURE|Virtual Reality during vasectomy|Virtual Reality
223696691|NCT04258514|PROCEDURE|Standard Vasectomy|No Virtual Reality
223696692|NCT04512417|DRUG|Camrelizumab+Radiotherapy|The combined treatment group received radiotherapy for recurring or metastatic lesions: at least one or more lesions were irradiated, stereotactic body radiotherapy (SBRT, 8Gy/time, 3-5 times) or conventional radiotherapy (parts not suitable for SBRT, total Dose 30Gy or more); start immunotherapy within 8 weeks after radiotherapy.Until PD or toxicity is intolerable or up to 24 months.
223696693|NCT04512417|DRUG|Camrelizumab|Camrelizumab,200mg,Q3W,Until PD or toxicity is intolerable or up to 24 months.
223696694|NCT05557435|OTHER|breast milk odor|"The intervention of the experimental group was to stimulate the odor of breast milk. The researchers informed the mothers of premature infants in advance on the day before the experiment, and collected the breast milk samples in the morning before eating on the day of the experiment (excluding the influence of the odor of breast milk by diet). The researchers took a clean cotton ball so that the breast milk was completely absorbed by the cotton ball, and placed the cotton ball that absorbed breast milk at a distance of 5cm next to the mouth and nose of the premature infant, so that the premature infant could receive the smell of breast milk.~The intervention of the control group was to stimulate the smell of distilled water."
223696695|NCT05557435|OTHER|Placebo|Placebo
223696696|NCT02007993|OTHER|PDT|"A single session of PDT will be performed with the Chimiolux® photosensitizer at a concentration of 0.005% applied over the middle and posterior thirds of the dorsum of the tongue.~Nine points will be irradiated, the device will be previously calibrated with a wavelength of 660 nm, power of 100 mW, energy of 9 joules for 90 seconds per point in Groups 2 and 4 and 12 joules for 120 second per point in Groups 3 and 5"
223696697|NCT02007993|OTHER|Tongue Scraper|The pacient will scrap the tongue 10 times.
223696698|NCT03816488|DRUG|Metformin|Metformin (usual dose) administered 2 h before surgery
223696699|NCT03816488|DRUG|Salsalate|Salsalate 1.5 g administered 2 h before surgery
223696700|NCT03137342|BEHAVIORAL|Pepped on PrEP Package|A counseling and problem-solving adherence intervention with a Behavioral Activation approach to re-engage participants in safe but pleasurable activities in life and addresses stimulant abuse as well as associated factors, including depression, as barriers to optimal PrEP adherence.
223696701|NCT04680091|DRUG|Pyrotinib Maleate|single oral dose, 400 mg, fed.
223696702|NCT04680091|DRUG|Efavirenz|single oral dose, 600 mg, fasted, at bedtime.
223696703|NCT06311825|OTHER|Horticultural Therapy|"One week before horticultural therapy (HT) interventions, face-to-face interviews will be held with the individuals in the experimental group and the forms will be filled in as a pretest.~HT will be applied to the experimental group. The application period was determined as a total of 6 weeks with 50-minute sessions twice a week.~Before starting the HT sessions, area preparations will be made and a safe therapeutic garden will be established.~Medicinal and aromatic plants will be selected that can grow in Turkey, are not harmful to human health, are fragrant and colorful in order to stimulate the senses, and according to air temperature and physical conditions.~HT sessions will consist of gardening activities (group meeting, introduction of plants and cultivation).~After HT interventions, the forms will be filled as a post test. The forms will be filled again 4 weeks after the end of the interventions for follow-up."
223696704|NCT04394611|OTHER|Obstetric ultrasound- doppler examination|Obstetric ultrasound- doppler examination and fetal- maternal assessment Tin (Sn), manganese (Mn), Vanadium (V), Magnesium (Mg), cobalt (Co), nickel (Ni), arsenic (As), chromium (Cr), cadmium (Cd), lead (Pb), mercury (Hg), antimony (Sb), aluminum (Al), zinc (Zn), copper (Cu), selenyum (Se), iron (Fe), vitamin D, vitamin A, vitamin B12 and folate concentrations measurements
223696705|NCT04099407|DRUG|Pirfenidone|Treatment consist of 600 mg tablets of a prolonged-released formulation of Pirfenidone. Patients are instructed to take medication orally, every 12 h, after breakfast and dinner.
223696706|NCT04099407|OTHER|Standard of care|All participants will require to adhere to a standard of care including nutritional support, quarterly medical evaluation to review lab results and adjust medications, bi-annual Fibrotest, FibroScan and liver ultrasound, and annual upper-gastrointestinal endoscopy.
223696707|NCT00232973|DRUG|ICXP007|
223696708|NCT00250055|PROCEDURE|Colposcopy, Spectroscopy, and Biopsy|During the colposcopy or LEEP (Loop Electrical Excision Procedure) procedure, or during pelvic exams before surgery after the doctor applies 3% acetic acid to the cervix, the doctor then positions the colposcope to take pictures of the patient's cervix. Digital pictures are taken of the patient's cervix under white light using a colposcopy imaging system. These pictures are annotated by the doctor during the appointment to mark the spectroscopy sites.
223696709|NCT02874157|BIOLOGICAL|blood draw|
223696710|NCT05282329|DEVICE|Transcranial alternating Current Stimulation (tACS)-active|Transcranial alternating current stimulation (tACS) employs a weak electric current for non-invasive brain stimulation with a sine-wave waveform, targeting brain oscillations in a frequency-specific manner. daily tACS sessions were scheduled in a 5-day sequence for four consecutive weeks, and each session lasted 20minutes. Participants were administered 2 mA alternating current delivered with gamma frequency, delivered over the temporal lobe.
223696711|NCT05282329|DEVICE|Transcranial Alternating Current Stimulation (tACS)-sham|Transcranial alternating current stimulation (tACS) employs a weak electric current for non-invasive brain stimulation with a sine-wave waveform, targeting brain oscillations in a frequency-specific manner. Controls received sham stimulations with the same protocol.
223696712|NCT00004075|DRUG|tanespimycin|
223696713|NCT02829632|BEHAVIORAL|Group Sessions|Participants will receive a 3-session behavioral lifestyle program for a healthful lifestyle and weight loss.
223696714|NCT02829632|BEHAVIORAL|Feedback|Participants will receive up to 4 daily feedback messages based on progress in attaining target behavior. The feedback messages will be delivered on a variable ratio schedule and tailored to data in subjects' dietary recordings.
223696715|NCT02829632|BEHAVIORAL|Self-monitoring|Participants will receive an one-time how to self-monitor using the smartphone session.
223696716|NCT05900271|DEVICE|rTMS|10 Hz repetitive-transcranial-magnetic-stimulation
223696717|NCT05900271|DEVICE|iTBS|neuronavigated intermittent theta burst transcranial-magnetic-stimulation
223696718|NCT03832777|DEVICE|Repetitive Transcranial Magnetic Stimulation|Subjects will receive both active and placebo rTMS, in a crossover modality.
223696719|NCT02138500|DRUG|PF-06372865|Single, oral dose administration of 10 mg PF-06372865 using tablet formulation.
223696720|NCT02138500|DRUG|PF-06372865|Single, oral dose administration of TBD dose PF-06372865 using tablet/extemprep formulation.
223696721|NCT02138500|DRUG|PF-06372865|Single, oral dose administration of TBD dose PF-06372865 using tablet/extemprep formulation.
223696722|NCT01634009|DIETARY_SUPPLEMENT|Soy-based RUTF (in double blind design)|Soy-based RUTF will be given in double blind manner
223696723|NCT04281303|PROCEDURE|Endoscopic vertical gastroplasty|endoscopic vertical gastroplasty + lifestyle modification
223696724|NCT02793921|BEHAVIORAL|Moderate-Intensity Aerobic Exercise Intervention|The intervention is moderate-intensity aerobic exercise. Walking on a motorized treadmill will be the encouraged mode of exercise; however participants may use other equipment or home exercise. Participants will begin by exercising 10-15 minutes for 3 days/week during the first 2 weeks and gradually increase the duration for the following 4 weeks until they reach 40-50 minutes per session/3 days per week. This level is then maintained for the remainder of the 6 months. The rate of increase will be tailored based on baseline cardiorespiratory fitness and response to exercise. All sessions start and end with a vital sign check (in-person) and 5-10 minutes warm-up/cool-down. Trained exercise physiologists will supervise all exercise sessions and closely monitor adherence, intensity, and safety when sessions are completed in-person, or through regular communication when home-based exercise is warranted (due to COVID-19).
223696725|NCT04423783|BEHAVIORAL|7-day exposure therapy via self-developed app according to (Haberkamp et al., submitted)|Confrontation with spiders via gamified app
223696726|NCT04423783|BEHAVIORAL|Therapist-guided one-session online exposure therapy according to (Öst, 1989)|Massed exposure therapy over the course of one single session, applied in a remote-online context
223696727|NCT00646919|PROCEDURE|Nose swab|
223696728|NCT03851471|DRUG|Jiu-wei-zhen-xiao Granule|Patients will be treated for 12 weeks, with oral administration of 5g once of Jiu-wei-zhen-xiao Granule,three times a day, based on the conventional treatment for HCC, such as antiviral treatment, supportive treatment or symptomatic treatment.
223696729|NCT01570556|OTHER|Antibiotic treatment|In patients with positive urinary culture, seven days of antibiotics will be given orally according to the bacteriogram sensitivity.
223780354|NCT06349902|BEHAVIORAL|Re-Link|The HCV nurse will attempt to contact the PWDU HCV via phone call and text. If unable to connect with a client via phone, an alert is added to the client's chart in the electronic medical record. When the client presents to the CBSUTP for their regular substance use follow up appointment, the chart alert is flagged by the administrative team and the client is connected with the HCV nurse via telemedicine. Clients who are connected to the HCV team are considered re-linked. The HCV nurse will provide an HCV intake as per program guidelines. Clients who would prefer to pursue treatment elsewhere will be supported with a referral to their family doctor or an alternative HCV program in the community. Clients who choose to be treated at the CBSUTP will receive a HCV consultation, DAA treatment and follow-up from the HCV clinical team onsite as per existing program guidelines.
223780355|NCT00354705|BEHAVIORAL|Questionnaire|Two questionnaires taking 30 minutes to complete.
223696730|NCT02609009|OTHER|Spinal Manipulation Therapy|Intervention will consist of Diversified type adjustments. Patients will be assigned to the nearest participating chiropractic clinic and will have a complete standardized examination on their first visit. Patient will then receive a maximum of 12 treatments (3x per week for a period of 4 weeks).
223696731|NCT02609009|OTHER|Usual Medical Care|Usual interventions generally consist in the administration of medications (NSAIDs or ibuprofen), physical therapy or exercises. If recommended, physical therapy will be provided by the hospital physical therapy services. Physical therapy might include treatments such as massage, different electrotherapy, postural repositioning, exercises, etc
223696732|NCT02538328|DEVICE|Harmonic scapel|different surgical devices used in the obesity surgery
223696733|NCT02538328|DEVICE|Ligasure|Bipolar vessel sealing system used in obesity surgery
223696734|NCT02572362|OTHER|No intervention in this retrospective study|No Intervention in this retrospective Analysis. All patients included did receive Radiation therapy Independent of this study
223696735|NCT03734575|DEVICE|ClariCore System|The user will perform a standard trans-perineal biopsy and collect a number of biopsy cores as per standard practice.
223696736|NCT03376100|PROCEDURE|Ultrasound guided nerve blocks|Ultrasound guided nerve blocks of the radial and median nerves
223696737|NCT03376100|PROCEDURE|Hematoma Block|Conventional local anesthetic method using hematoma block
223696738|NCT04858256|DRUG|Pacritinib|Pacritinib will be dosed at 200mg twice daily.
223780356|NCT04120506|DRUG|VPRIV|Safety, pharmacokinetics, and efficacy of rapid intravenous infusion of velaglucerase alfa (VPRIV) in adult patients with type 1 Gaucher disease
223780357|NCT00880932|BEHAVIORAL|Electronic Alert|
223780358|NCT05684016|OTHER|NeuroQuant|Reliably defines the volume of those parts of the brain that are important for memory and thinking.
223780359|NCT05684016|OTHER|Automated Neuropsychological Assessment Matrices|This is like an IQ test.
223780360|NCT05684016|OTHER|EDSS|Extended Disability Status Score
223780361|NCT05684016|OTHER|Physical Examination|Physical Examination
223780362|NCT00711685|PROCEDURE|coronary artery bypass grafting via midline sternotomy|
223780363|NCT04419493|DRUG|Alteplase (from modified manufacturing process)|Alteplase, TPA-05
223780364|NCT04419493|DRUG|Alteplase (from current manufacturing process)|Alteplase, TPA-02
223780365|NCT04419493|DRUG|Heparin-Natrium-5000-ratiopharm (unfractionated heparin)|Heparin-Natrium-5000-ratiopharm (unfractionated heparin)
223780366|NCT00524134|DRUG|Carvedilol-CR|Week 1: 20mg capsule once daily Week 2-3: 40mg capsule once daily Week 4-15: 80mg once daily Week 16: tapering (40mg/day x 4d, then 20mg/day x 3d), unless the patient wishes to continue receiving the medication.
223780367|NCT03347500|OTHER|use of patient-derived biological samples|We will use biological samples that are routinely collected as waste material from patients undergoing prosthetic surgery at IRCCS Istituto Ortopedico Galeazzi. Peripheral blood will be also collected from patients during the pre-surgery visit and during the post-surgery hospitalization coinciding with routine blood sample collection.
223780368|NCT01283789|DRUG|Lapatinib and RAD-001|"Lapatinib will be taken orally as a once-daily dose of 1250 mg (five 250 mg tablets) continuously from study day 1 until progression of disease. Patients will take the tablet at bedtime, at the same time each day, in a fasting state.~Everolimus will be taken orally as a once-daily dose of 5 mg (one 5 mg tablet) from study day 1 until progression of disease. Patients will take the tablet at the same time each morning."
223780369|NCT04576208|DRUG|TAK-788|TAK-788 capsules
223780370|NCT04576208|DRUG|Antidiarrheal prophylaxis|Antidiarrheal prophylaxis includes loperamide tablet administered as per routine clinical practice.
223780371|NCT06086912|DRUG|HR17031|Receive a single dose of HR17031 at every period (First period：abdomen. Second period. upper arm. Third period: thigh).
223780372|NCT06086912|DRUG|HR17031|Receive a single dose of HR17031 at every period (First period：upper arm. Second period: thigh. Third period: abdomen).
223780373|NCT06086912|DRUG|HR17031|Receive a single dose of HR17031 at every period (First period：thigh. Second period: abdomen. Third period: upper arm).
223780374|NCT00587873|DRUG|Methotrexate|MTX 6mg/m2 given IV bolus, followed by 24mg/m2 given in 24hrs continuous infusion
223780375|NCT00587873|DRUG|Leucovorin calcium|5 mg orally at 12 hours after the end of MTX infusion then every 12 hrs for a total of 3 doses.
223780376|NCT00587873|DRUG|6-Thioguanine|6-TG 300 mg/m2 PO as a single oral dose
223780377|NCT00053833|DRUG|irinotecan|
223780378|NCT05081414|BEHAVIORAL|Program for Teaching Self-Care in HF (PEAC-IC)|As described previously
223780379|NCT05556408|DRUG|Succinylcholine|1.5mg/kg was given intravenously
223780380|NCT06201182|DRUG|FMT via rectal enema|50 grams of FMT via rectal enema
223780381|NCT06201182|DRUG|FMT capsules|FMT capsules given twice daily for 2 consecutive days
223780382|NCT06201182|DRUG|Placebo via rectal enema|Placebo via rectal enema
223780383|NCT06201182|DRUG|Placebo capsules|Placebo capsules given twice daily for 2 consecutive days
223780384|NCT00270543|DRUG|Taxotere, Fluorouracil, Leucovorin|
223780385|NCT03399734|DRUG|Perampanel|Single oral dose of 1 x 4-mg perampanel tablet
223780386|NCT03399734|DRUG|Perampanel|Single 4-mg dose of perampanel fine granules
223780387|NCT00005854|DRUG|cyclophosphamide|
223780388|NCT00005854|DRUG|cyclosporine|
223780389|NCT00005854|DRUG|methotrexate|
223780390|NCT00005854|PROCEDURE|allogeneic bone marrow transplantation|
223780391|NCT00005854|PROCEDURE|in vitro-treated bone marrow transplantation|
223780392|NCT00005854|RADIATION|radiation therapy|
223696739|NCT04437849|DEVICE|Home Telemonitoring System|Home Telemonitoring System (HTS) The HTS consists of an App that daily collects measurements of weight, blood pressure, heart rate and symptoms (checklist of symptoms questions). The HTS processes the data and generates and sends an alert to the physicians if a risk situation occurs (measurements are outside of normal ranges). The App has also an educational functionality that allows learning about lifestyle, self-care and healthy habits for HF patients. For this purpose, the application: a) has a section that answers frequent questions, b) has a question and answer game about HF, and c) sends educational messages to the patients every day.
223696740|NCT05250089|OTHER|Simulation|Each simulation will focus on a trauma case deemed to be complex, that is to say one involving difficult decision-making. Each simulation session lasts approximately thirty minutes. It includes a time to complete the questionnaires necessary for carrying out the study, before and / or after the simulated practice depending on the type of questionnaire, a brief briefing on the simulation scenario, and the time for the simulated practice.
223780393|NCT05637463|OTHER|No intervention|no intervention was made
223780394|NCT00404339|BIOLOGICAL|mutant p53 peptide pulsed dendritic cell vaccine|
223780395|NCT00404339|BIOLOGICAL|tetanus toxoid helper peptide|
223780396|NCT00404339|PROCEDURE|adjuvant therapy|
223780397|NCT04553952|OTHER|Measurement of gingival display|"All individuals were instructed to sit on a dental chair and the measurements were made by using a millimetric ruler. Next, the patients were grouped according to Liebart's classification by gingival display at maximum smile as follows:~Class 1.Excessive gingival display (Gummy smile): ≥ 3mm gingival display Class 2.High smile line: 0-2 mm of gingival display Class 3. Average smile line: Dental papilla is visible. Class 4. Low smile line: Gingival margin, dental papilla is not visible at all."
223780398|NCT01954706|OTHER|Structured Exercise|Structured and supervised aerobic and resistance training 2 times per week
223696741|NCT03068598|DEVICE|PulseOn watch/Suunto Spartan Ultra watch|The Watch (PulseOn or Suunto Spartan Ultra) and a smartphone will be given to the patient after discharge. After a brief training on how to use the sleep tracker, patient will monitor his sleep with watch during the five nights following the discharge. All data will be transmitted directly to the smartphone. Each morning, the patient will complete a questionnaire to assess the quality of his sleep and on day 5, during a standart follow up visit, he will complete a questionnaire evaluating the acceptability of the sleep recording device.
223696742|NCT05305339|OTHER|Placental and Umbilical cord biopsy|After delivery of the placenta, two tissue fragments, 1st piece about 1x1 cm from the central zone of the maternal surface of the placenta and 2nd piece about 1 x 1 cm from mid segment of umbilical cord will be cut. Each of both samples will be divided and fixed in either a 10% formalin for light microscopic examination or glutaraldehyde 2.5% for Electron microscopic examination. Paraffin-embedded placental tissue sections (4 μm thick) will be used for histological (stained with hematoxylin and eosin) and immunohistochemical examination using primary antibody markers for telocytes CD117, CD34, vimentin, SMA (smooth muscle actin), and the new telocyte marker TMEM16a (DOG-1).
223696743|NCT03238742|DRUG|Xuebijing Injection|100ml Xuebijing Injection every 12 hours for 5 days
223696744|NCT03238742|DRUG|normal saline|200ml normal saline every 12 hours for 5 days
223696745|NCT05788900|BIOLOGICAL|Heparin|intravenous Heparin
223696746|NCT00145704|DRUG|bisphosphonate therapy (risedronate)|Bisphosphonate therapy given to patients with growth hormone deficiency
223696747|NCT00145704|DIETARY_SUPPLEMENT|Vitamin D supplement|Vitamin D given to patients with growth hormone deficiency
223696748|NCT00145704|DIETARY_SUPPLEMENT|Calcium|calcium supplement given to patients with growth hormone deficiency
223696749|NCT02525276|BEHAVIORAL|exercise|The exercise intervention will conduct the following training program 4 days/week for 6 months: endurance training consisting of supervised training on a bike ergometer for 20 min at 70% of maximal heart rate (HR) the first week, increased by 5 min each week until reaching 40 min. Then the intensity will be increased to 80% of max HR over the next month and recalculated every month.
223696750|NCT02525276|DRUG|Hormone treatment|"Continually estradiol and gestagens - tablets and patches or cyclic estradiol and gestagens - tablets or patches.~Including:~Drospirenon, Norethisteronacetat, Medroxyprogesteronacetat"
223696751|NCT03265665|BEHAVIORAL|ACTION Intervention|The intervention is based on the Women's Lifestyle Physical Activity Program, a culturally sensitive lifestyle physical activity intervention for African American (AA) women. There are 2 phases to the intervention: Adoptive (24 weeks) and Maintenance (12 weeks). 3 motivational/reminder texts will be made each week during the adoption phase. 5 Group sessions(adoptive): Participants will be given individualized step goals, watch a short DVD featuring AA women demonstrating skills and sharing experiences of engaging in walking. 1 Group session (maintenance): watch a short DVD featuring AA women demonstrating skills and sharing experiences of engaging in walking, reinforce barriers and facilitators to walking. An interventionist will lead a discussion on role-modeling and encouraging problem solving. Each intervention group will have 10 women with 1 interventionist. Data will be collected at 3 time points: baseline, 24-weeks and 36-weeks.
223696752|NCT03265665|OTHER|Enhanced usual care|"Participants will attend 1 two hour asthma education/physical activity session at community location near them. Participants will review basic asthma topics in a didactic session and will include exercising with asthma and exercise-induced asthma. Participants will be given Fitbit and provided instructions on how to use it. Participants may receive 2 newsletters with information on asthma and reminder texts regarding data collection visits.~Data will be collected at 3 time points: baseline, 24-weeks and 36-weeks."
223696753|NCT04269590|BEHAVIORAL|Dual Task (DT) training|Participants will practice the Swipe Slide Pattern (SSP) task in combination with a secondary task, i.e. counting red or green lights. On day 1, participants perform 2 runs of the SSP-task (only one pattern), each lasting approx. 10 min, within an MR scanner. During each run, 9 trials of 30s are performed, alternated with rest periods of 14s. Instructions are provided before each trial (i.e. view of the pattern in combination with instruction to count red or green lights, 4s), as well as an answer option (i.e. participants have to indicate how many red or green lights they counted by circling a number from zero to nine, 6s). For the following 4 days, participants will continue practice of the SSP-task at home. During the at-home-sessions, participants will perform 9 trials of 12 patterns each, alternated with rest periods of 14s. Instruction and answers are also included. During at home practice, the same pattern as during scans is included, in combination with 2 new patterns.
223696754|NCT04269590|BEHAVIORAL|Single Task (ST) training|Participants will practice the Swipe Slide Pattern (SSP) task without the presence of a secondary task. On day 1, participants perform two runs of the SSP-task (only one pattern), each lasting approx. 10 min, within an MR scanner. During each run, nine trials of 30s are performed, alternated with rest periods of 14s. In addition, instructions are provided before each trial (i.e. view of the pattern, 4s), as well as an answer option (i.e. participants have circle a random number from zero to nine, 6s). For the following four days (day 2-5), participants will continue practice of the SSP-task at home. During the at-home-sessions, participants will perform nine trials of 12 patterns each, alternated with rest periods of 14s. Instruction are also included. During at home practice, the same pattern as during scans is included, in combination with two new patterns.
223696755|NCT00729599|DRUG|Cetylpyridinium chloride|Cetylpyridinium chloride during 21 consecutive days.
223696756|NCT00199069|DRUG|Asparaginase|
223696757|NCT00199069|DRUG|Vincristine|
223696758|NCT00199069|DRUG|Daunorubicin, Adriamycin|
223696759|NCT00199069|DRUG|Cyclophosphamide|
223696760|NCT00199069|DRUG|Ifosfamide|
223696761|NCT00199069|DRUG|Cytarabine|
223696762|NCT00199069|DRUG|Mitoxantrone|
223696763|NCT00199069|DRUG|Methotrexate|
223696764|NCT00199069|DRUG|6-Mercaptopurine|
223696765|NCT00199069|DRUG|6-Thioguanine|
223696766|NCT00199069|DRUG|VM26|
223696767|NCT00199069|DRUG|Dexamethasone / Prednisolone|
223696768|NCT00199069|PROCEDURE|CNS Irradiation|
223696769|NCT00199069|PROCEDURE|Mediastinal Irradiation|
223696770|NCT00199069|PROCEDURE|Stem Cell Transplantation|
223696771|NCT01303328|DRUG|C1|Local application of the experimental gel or placebo gel.
223696772|NCT05231044|DRUG|KX01 ointment 1%|The experimental drug, KX01 Ointment 1% is used in participants with Clinically typical AK on the face or scalp.
223696773|NCT05231044|DRUG|Placebo|Vehicle Ointment is used in participants with Clinically typical AK on the face or scalp.
223696774|NCT06076954|BEHAVIORAL|CoolMinds|CoolMinds consists of 11 adolescent sessions and 9 parent sessions to be completed simultaneously during a 14-week treatment period. The main components comprise psychoeducation, cognitive restructuring, exposure therapy, and relapse prevention. The parent program also comprises information on how to handle school absenteeism for parents and teachers or pedagogues. The intervention is mainly transdiagnostic within the anxiety disorders but also includes diagnosis specific modules and content allowing for more personalized treatment. The treatment is delivered via a telephone app but can also be accessed via computer.
223696775|NCT04754243|DRUG|Gonadotropin|Giving patients gonadotropins and antagonist cetrotide
223696776|NCT04754243|DRUG|Standard protocol in IUI|Giving patients gonadotropins without antagonist cetrotide
223696777|NCT00110903|DRUG|Etanercept Liquid|
223696778|NCT01193660|BIOLOGICAL|Umbilical Cord Blood Infusion|The subjects will be undertaken allogeneic umbilical cord blood infusion (total nucleated cells \> 3x10\^7/kg) intravenously under non-myeloablative immunosuppression (maintaining blood level of cyclosporine as 100-200ng/mL for 1 month).
223696779|NCT01193660|DRUG|Erythropoietin Injection|Erythropoietin will be given as the schedule of twice a week for 4 weeks with the dosage of 500 IU/kg for 2 times intravenously and 250 IU/kg subcutaneously for 6 times.
223696780|NCT01193660|OTHER|Active Rehabilitation|All subjects should participate in active rehabilitation. They received two physical and occupational therapy sessions per day. Post discharge, each participant continued to receive rehabilitation therapy at least 3 days per week for additional 5 months.
223696781|NCT01193660|OTHER|Placebo Umbilical Cord Blood|Placebo Umbilical Cord Blood will be given except the Experimental arm. Placebo Umbilical Cord Blood was made using peripheral blood. Participants and Investigators maintained as blind.
223696782|NCT01193660|OTHER|Placebo Erythropoietin|Placebo Erythropoietin containing Normal Saline
223696783|NCT04156477|DIETARY_SUPPLEMENT|Ketone ester|Intake of weight adjusted drink of a ketone ester
223696784|NCT04156477|DIETARY_SUPPLEMENT|Glucose|Isocaloric and - volumetric taste adjusted drink
223696785|NCT04156477|DIETARY_SUPPLEMENT|Tap water|Isovolumetric taste adjusted tap water (placebo)
223696786|NCT02537782|DEVICE|Cardiac resynchronisation therapy|
223696787|NCT02537782|OTHER|Echocardiography|
223696788|NCT02537782|OTHER|Magnetic Resonance Imaging|
223696789|NCT02537782|OTHER|Positron Emission Tomography|
223696790|NCT06115785|BEHAVIORAL|Cognitive Stimulation Therapy|Cognitive Stimulation Therapy CST consists of 14 sessions, each session with different themes. The materials used in therapy will differ according to the characteristics of each theme. For example; In the theme of physical games, one of the individuals will be selected by voting, and each individual will be asked to choose a song suitable for the theme and introduce himself/herself to the music accompaniment. Then, a small table game will be prepared with the rackets and ball used for table tennis, and individuals will be able to play a round of table tennis with the researcher and their groupmates. Sessions 10 min. introductory part, 25 min. activity section and in progress10 min. 45 minutes in total, including the ending.
223696791|NCT01593189|BEHAVIORAL|KITS Program|This is a 4-month psychosocial intervention for children with developmental disabilities and behavior problems who are entering kindergarten and their caregivers. The intervention begins in the summer before kindergarten. The KITS intervention consists of: (a) child school readiness play groups to facilitate the development of self-regulatory, social, and early literacy skills (2 times per week in summer, 1 times per week in the fall); and (b) a bi-monthly psychoeducational support group to promote parent involvement in the child's early literacy and schooling and the use of effective parenting techniques
223696792|NCT05883423|OTHER|FPCMP-Old Age|"1. Exercise program：The main purpose of the exercise program is to improve cardiorespiratory endurance, upper and lower limb muscle strength and endurance, body flexibility, sense of balance and coordination. The exercise program is carried out with a suspension training system, which can improve core muscle strength, improve physical fitness, activate more core and stabilizing muscle groups, increase joint stability, and strengthen ligaments.~2. Health integrated nursing management courses (nutrition, psychosocial, drug and other health management activities involved)"
223696793|NCT00195273|DRUG|sirolimus|15 mg loading dose, followed by 5 mg/day to achieve target trough levels of 10-15 ng/mL at months 1-6, then 8-12 ng/mL at months 7-12
223696794|NCT00195273|DRUG|cyclosporine|Initial dose of 10 mg/kg/day, then twice daily to achieve target trough levels of 300-400 ng/mL at weeks 0-4; 200-300 ng/mL at months 1-2; 150-250 ng/mL at months 2-3; 100-200 ng/mL at months 3-6; 75-150 ng/mL months 6-12
223696795|NCT00195273|DRUG|mycophenolate mofetil|1 g twice daily; may be reduced to 750 mg BID for adverse events, or to 500 mg BID for persisting adverse events
223696796|NCT00195273|DRUG|corticosteroids|As per center practice. By day 8 prednisolone tapered to 20 mg/day; by day 30 to 15 mg/day; by day 60 to 10 mg/day; after 4 to 6 months to 5-7.5 mg/day
223696797|NCT00195273|DRUG|daclizumab|IV: 1 mg/kg to a maximum of 100 mg/dose. 5 doses at 2, 4, 6, and 8 weeks after transplantation
223696798|NCT00244062|BEHAVIORAL|counseling|
223696799|NCT00595465|BIOLOGICAL|Japanese Encephalitis purified inactivated vaccine|IC51 6 mcg i.m. injection on Day 0 and Day 28
223696800|NCT02595970|DRUG|Secukinumab|weekly sub cutaneous injections of 300 mg during the first month and then monthly until week 52 plus extension until 03/11/2016.
223696801|NCT04996381|DIAGNOSTIC_TEST|Scanning Chest X-rays and performing AI algorithms on images|Chest X-Rays; AI CNNs; Results
223696802|NCT00315536|DRUG|Administration of remifentanil and glycopyrrolate|2 mg, intravenius use
223696803|NCT04879225|BEHAVIORAL|Tobacco e-liquids|Marketplace includes tobacco flavored e-liquids
223696804|NCT04879225|BEHAVIORAL|Menthol and Tobacco e-liquids|Marketplace includes menthol and tobacco flavored e-liquids
223696805|NCT04879225|BEHAVIORAL|Mint, Menthol and Tobacco e-liquids|Marketplace includes mint, menthol and tobacco flavored e-liquids
223696806|NCT04879225|BEHAVIORAL|All e-liquid flavors|Marketplace includes fruit, dessert, mint, menthol and tobacco flavored e-liquids
223696807|NCT03388385|DRUG|Sodium Chloride 0.9% Intravenous Solution|Physiologic saline infusion will be infused in day 1.
223696808|NCT03388385|DRUG|Ferinject|Ferric carboxymaltose will be infused in day 2.
223696809|NCT02116231|DRUG|Concurrent chemotherapy with cisplatin|Three cycles of weekly Cisplatin 100 mg/m2 starting on the first day of IMRT
223696810|NCT02116231|RADIATION|Intensity modulated radiotherapy|Intensity modulated radiotherapy is a technique of radiotherapy.
223696811|NCT05059171|DEVICE|OneSahpe single file|The rotary motion of OneShape single file
223696812|NCT05059171|DEVICE|WaveOne Gold single file|reciprocation motions of WaveOne Gold single file
223696813|NCT01854203|DRUG|Inductive chemotherapy + concurrent cisplatin and IMRT|Patients receive Gemcitabine (800mg/m2 on day 1,8) and cisplatin (80mg/m2 on day 1)of a 21 day cycle, patients received four cycles chemotherapy before the radiotherapy, then receive radical radiotherapy with IMRT and cisplatin (30mg/m2，on day 1) repeated every week for 6 cycles during radiotherapy.
223696814|NCT01854203|DRUG|Inductive chemotherapy + IMRT|Patients receive Gemcitabine (800mg/m2 on day 1,8) and cisplatin (80mg/m2 on day 1)of a 21 day cycle, patients received four cycles chemotherapy before the radiotherapy, then receive radical radiotherapy with IMRT.
223696815|NCT00806975|DEVICE|KwikPen® and FlexPen®|The treatment is changed to twice a day injection of the same unit of Novo Rapid 30 Mix injection FlexPen® or Humalog Mix 25 injection KwikPen®for 3 months, after which the final assessment is made.
223696816|NCT05129670|DEVICE|Calcite chewing gum|The calcite chewing gum is administered as two pieces of gum in a single dose, 30 minutes following the consumption of a refluxogenic meal.
223696817|NCT05129670|DEVICE|Unmatched Placebo chewing gum|The placebo chewing gum is administered as two pieces of gum in a single dose, 30 minutes following the consumption of a refluxogenic meal.
223696818|NCT03257696|DIAGNOSTIC_TEST|Close-ended questionnaire|"Yes/no questionnaire used in order to identify reliable respondent and unreliable respondent"
223696819|NCT06357312|DEVICE|hip trochanteric nail|hip trochanteric nail with and without distal interlocking screw
223696820|NCT02138773|DRUG|Tamsulosin formulation-A|oral
223696821|NCT02138773|DRUG|Tamsulosin formulation-B|oral
223696822|NCT02572388|BIOLOGICAL|R21|
223696823|NCT02572388|BIOLOGICAL|Matrix-M1|
223696824|NCT01973569|DRUG|denosumab|denosumab administered subcutaneously
223696825|NCT01973569|DRUG|placebo|placebo administered subcutaneously to match denosumab
223696826|NCT00161473|DRUG|prazosin|"Participants taking prazosin. Prazosin was administered as 1 or 2 mg capsules. Doses were initiated at 1 mg at bedtime. Titration based on tolerability was conducted up to a dose of 2 mg in the morning plus 4mg at bedtime.~Duration was 8 weeks."
223696827|NCT00161473|DRUG|placebo (inert substance)|Placebo is an inert substance used as a standard comparator in clinical pharmacologic trials. Duration is 8 weeks.
223696828|NCT01446107|OTHER|placement of fissure sealant|placement of resin-based fissure sealant at baseline without replacement
223780399|NCT01954706|OTHER|Usual Care|Subjects will be counseled on American Cancer Society and American College of Sports Medicine physical activity and nutritional guidelines at the initiation of the study. Study participants will be contacted by a physician or nurse on weeks 2, 6, 10, and 14 to provide support and encouragement to patients.
223780400|NCT03119766|DRUG|Kolofort|Oral administration
223780401|NCT03119766|DRUG|Placebo|Oral administration
223780402|NCT05377398|BEHAVIORAL|Digital individual-level intervention (Bit Habit)|"All participants in the intervention group receive access to the BitHabit app for the 1-year intervention period. The BitHabit app was designed in the StopDia project, and it aims to help its users to adopt healthier lifestyles and habits.The content and approach of the app is based on habit formation theories and the Self-Determination Theory. The app provides an extensive library of suggested lifestyle habits that was created according to lifestyle guidelines and recommendations. The habits are related to diet, physical activity, sleep, positive mood, stress management, smoking, and alcohol consumption. Users of the app select these habits from the library to their shopping basket to complete in their everyday life. The app also allows the users to report and monitor their performance and progress."
223696829|NCT01446107|OTHER|fluoride varnish|topical applications of a 5% sodium fluoride (NaF) varnish onto tooth surface every 6 months
223696830|NCT01446107|OTHER|silver fluoride|topical applications of a 38% silver diamine fluoride (SDF) solution onto tooth surface every year
223696831|NCT01446107|OTHER|placebo control|application of water onto tooth surface every year
223696832|NCT00810108|DRUG|lopinavir/ritonavir (Kaletra®) tablets|The subject will bring their own prescription of lopinavir/ritonavir. The patient will take a witnessed dose of lopinavir/ritonavir with an 6 ounce glass of cool water (if taken whole) or mixed in 4 ounces of Jell-O brand pudding (if crushed).
223696833|NCT05089162|PROCEDURE|Clinical examination centered on congestion|Clinical examination centered on congestion (including the EVEREST, ASCEND and Ambrosy scores) will be performed during day hospitalization or consultation
223696834|NCT05089162|PROCEDURE|Cardiac, pulmonary, peritoneal, jugular and renal Doppler ultrasounds|Cardiac, pulmonary, peritoneal, jugular and renal Doppler ultrasounds and liver elastography will be performed during day hospitalization or consultation/ peritoneal, jugular and renal Doppler ultrasounds are optional
223696835|NCT05089162|PROCEDURE|Blood sample retrieved for biological assessment and biobanking|Blood sample retrieved for biological assessment and biobanking will be performed during day hospitalization or consultation
223696836|NCT05089162|OTHER|Telephone follow-up|Telephone follow-up will be performed 3, 12 and 24 months after day hospitalization or consultation
223696837|NCT05089162|BEHAVIORAL|Kansas City Cardiomyopathy Questionnaire (KCCQ)|Questionnaire centered on patient's quality of life at discharge and 3, 12 and 24 months after discharge
223696838|NCT06432231|OTHER|Low glycemic index diet treatment|This study was a non-randomized, single centre, pre/post-intervention study. A low glycemic index diet was prescribed by a dietician for 3 months. LGID treatment consisted of 10% (40-60 g) low glycaemic index (glycaemic index \<50) carbohydrate, 20-30% protein and 60-70% lipid
223696839|NCT01526772|PROCEDURE|Endoscopy|Transoral endoscopy versus transoral endoscopy
223696840|NCT06270329|OTHER|Neuromuscular training program|"Hotpack application TENS (transcutaneous electrical stimulation) Warm-up phase: bicycle ergometer (ten minutes)~Exercise phase:~core stabilization and postural control exercises postural orientation exercises lower extremity strengthening exercises functional exercises (balance and proprioception exercises using a balance board) Cool-down Phase"
223696841|NCT06270329|OTHER|conventional physical therapy program|Hotpack application TENS (transcutaneous electrical stimulation) Conventional physical therapy exercises (straight leg raises, knee flexor and extensor strengthening, hip muscle strengthening)
223696842|NCT00794781|DRUG|E6201|E6201 Part A (Dose Escalation): Intravenous (IV) infusion administered over 30 minutes once weekly for 3 weeks (Days 1, 8, and 15). The first 3 to 6 subjects of the first cohort will receive 20 mg/m\^2/week for a cycle of 3 weeks followed by a 1-week rest period. Subsequent dose escalations may increase at increments of 100% until two Grade 2 toxicities or 1 dose-limiting toxicity (DLT) are observed in a dose group. Thereafter, doses will be increased in increments of 50% or less until the maximum tolerated dose (MTD) is determined. Part B (MTD Expansion): After the MTD is determined in Part A, 15 additional subjects will continue to receive cycles at the MTD.
223696843|NCT04355507|DIAGNOSTIC_TEST|Chest computed tomography (CT)|Chest computed tomography (CT) examination
223696844|NCT04355507|DIAGNOSTIC_TEST|Reverse-transcription polymerase chain reaction (RT-PCR)|Identification of viral RNA by reverse-transcription polymerase chain reaction
223696845|NCT00632840|DRUG|Atorvastatin and fenofibrate|atorvastatin (40mg/day) fenofibrate (200mg/day)
223696846|NCT03714620|DRUG|Ketamine|Ketamine 0.15 mg/kg vs. 0.3 mg/kg IVPB over 15 minutes
223696847|NCT00949273|PROCEDURE|cylindrical abdominoperineal resection|Extended abdominoperineal resection with human acellular dermal matrix reconstruction of the pelvic floor for rectal cancer
223696848|NCT00508222|DRUG|Kaletra Tablets|Kaletra 800/200 OD
223696849|NCT06119035|OTHER|Single dose of 75 grams glucose in 200ml water|Consume single dose of 75 grams glucose in 200ml water
223696850|NCT04781504|BEHAVIORAL|Exercise|intervention groups will complete supervised virtual exercise sessions for 12 weeks using the platform preferred by the patient (Zoom care, Zoom business, Google duo, google meet, FaceTime, join.me, WhatsApp Call, etc). The appointment will be scheduled and conducted 2 days per week. The first class will be conducted on-site to teach the patient how to take vitals and to do an in-person exercise session
223780403|NCT05377398|BEHAVIORAL|Group-based healthy lifestyle and green power intervention|The group-based healthy lifestyle intervention is based on the Supportive Environment Theory (SET). The intervention is implemented in accordance with DiClemente and Prochaska's Stages-of-Change Model which is often used as framework for lifestyle change as well as Shazer and Berg's Solution Focused Brief Therapy. We expect participants to increase knowledge about healthy lifestyle choices and notice the beneficial effect of exercise, healthy diet and staying in nature. The intervention includes 12 to 16 hours of group activities during a period of 8 weeks. Interventions comprehend guided activities in nature, related to healthy relationship to food and exercise, as well as reflecting on shared experiences. In addition to group meetings, participants have access to material for mental well-being on an electronic learning environment.
223780404|NCT05377398|BEHAVIORAL|Individual-level healthy lifestyle intervention|The individual-level healthy lifestyle intervention follows the principles and theoretical background of the group-based intervention, but the intervention is carried out entirely on the electronic learning environment. The participants complete activities and exercises independently or with a friend in their own time.
223780405|NCT05377398|BEHAVIORAL|Mini-intervention for substance use|The mini-intervention for substance use follows the principle of the ASSIST-linked brief intervention created by WHO. This brief intervention is a phone-call lasting 3 to 15 minutes and given to the participant according to their risk score calculated with the ASSIST questionnaire which is included in the baseline survey. The intervention includes presenting the participant with their test score and associated health problems related to their level of risk. Especially in primary health care context, brief intervention according to the ASSIST score has been found to be successful in moderating risk for substance use. The intervention is not intended as a stand-alone treatment and in cases where high risk substance use is detected, the professional should encourage the participant to seek specialized drug and alcohol assessment and treatment.
223780406|NCT04711564|OTHER|Olive oil-based intravenous fat emulsions|Parenteral nutrition planned according to the requirements of the patients is given for ten days.
223780407|NCT04711564|OTHER|Soybean-based intravenous fat emulsions|Parenteral nutrition planned according to the requirements of the patients is given for ten days.
223780408|NCT03137511|OTHER|Taking photographs of suspicious lesions with his smartphone and sending them to the dermatologist|Taking photographs of suspicious lesions with his smartphone and sending them to the dermatologist
223780409|NCT03405987|DIAGNOSTIC_TEST|Strain analysis by CMR|Strain analysis by CMR will be performed
223780410|NCT00737087|DEVICE|Delta Xtend Reverse Total Shoulder|Orthopaedic implant for total shoulder replacement
223780411|NCT06082180|PROCEDURE|prophylactic central neck dissection|prophylactic central neck dissection was performed for the ipsilateral lesion
223780412|NCT01156753|DRUG|CDX-011|CDX-011 (1.88 mg/kg) administered as an intravenous infusion on Day 1 of each 21 day cycle.
223780413|NCT01156753|DRUG|"Investigator's Choice chemotherapy"|Any of the following single-agent chemotherapy may be given at the discretion of the investigator, with a cycle length not to exceed four weeks: Capecitabine, Vinorelbine, Gemcitabine, Docetaxel, Paclitaxel, Albumin-bound paclitaxel, Doxorubicin HCL, Liposomal doxorubicin, Ixabepilone and Eribulin.
223780414|NCT02516618|DRUG|Fasinumab|
223780415|NCT02516618|DRUG|Placebo|
223780416|NCT03525353|OTHER|Endoscopic retrograde cholangiopancreatography - No Intervention have been used other than standard of care|No intervention has been used and this is an observational study
223780417|NCT04489446|DRUG|Sildenafil|Patients allocated to this arm will receive Sildenafil 25mg every 8 hours orally for up to seven consecutive days.
223780418|NCT04489446|DRUG|Placebo|Patients allocated to this arm will receive a matching placebo similar to Sildenafil pills used in the intervention arm. Placebos will be delivered orally every 8 hours for up to seven consecutive days.
223696851|NCT00579592|DRUG|Campath-1H, rituximab, myfortic|Campath-1H 30mg IV x 2 doses, rituximab 375mg/m2 IV x 1 dose, myfortic 720mg bid, cyclosporine po bid (target trough 200ng/ml) x 10-20 days
223696852|NCT05038670|DEVICE|Total Knee Replacement|Participant will undergo total knee replacement performed via anterior parapatellar approach with either PERSONA PS or JOURNEY II BCS
223696853|NCT05143450|OTHER|Manual Pressure|In the experimental group manual pressure will be applied to the injection site with the thumb for 10 seconds to the infants by the researcher before the procedure. Manual pressure reduces pain within the framework of the gate control theory. According to the gate control theory, when pressure is applied to an area, a fiber transmits the feeling of pressure instead of pain and ultimately the pain sensation is alleviated.
223696854|NCT03115047|DRUG|Dexmedetomidine Injection|0.35 mcg/kg intravenous in 2 minutes if shivering 5 minutes after delivery
223696855|NCT03115047|DRUG|Meperidine Injection|0.35 mg/kg intravenous in 2 minutes if shivering 5 minutes after delivery
223696856|NCT02431338|PROCEDURE|Remote ischemic conditioning|Intermittent arm ischemia through four cycles of alternating 5-minute inflation followed by 5-minute deflation of a blood pressure cuff placed around the upper arm.
223696857|NCT02484183|DEVICE|bubble continuous positive airway pressure (CPAP)|This study will use an Airsep® oxygen concentrator and a Fisher \& Paykel Bubble CPAP (bCPAP) system to deliver bCPAP. The Airsep® machine is connected to the Fischer \& Paykel Bubble CPAP system and the CPAP delivers pressure and oxygen to the patient with appropriately sized masks and tubing. The Fischer \& Paykel Bubble CPAP system can deliver up to 10 centimeters (cm) water (H20) pressure. Since an oxygen concentrator is being used as the flow driver of this bubble CPAP system patients receiving CPAP will therefore also be receiving 6-8 liters per minute (LPM) of concentrated oxygen flow. Per manufacturer specifications the Airsep oxygen concentrator delivers 90-97% fractional inspired oxygen concentration at the 6-8 LPM flows required to generate 4-10 cm H20 pressure.
223696858|NCT05014217|BEHAVIORAL|Mentalization-based Treatment|An empirically-validated intervention for personality disorders based on the attachment theory and on knowledge from developmental psychology and cognitive neuroscience (Bateman and Fonagy, 2004). Patients assist psychoeducative group meetings beforehand, along with a pretreatment of four to six individual meetings (over four to eight weeks), followed by bi-weekly individual follow-ups and weekly group follow-ups. The treatment lasts two years. Patients have an assessment meeting with their individual therapist and one of the group therapists at the end of each session. Psychiatric follow-up appointments are on an as-needed basis and every patient has a treatment contract with specific and measurable treatment objectives.
223780419|NCT00857324|DRUG|Vorinostat|"Patients will start induction treatment with a standard dose of MP and escalating doses of Vorinostat:~* Melphalan 0.18 mg/Kg for 4 days; Prednisone 1.5 mg/Kg for 4 days. Each cycle will be repeated every 28 days for a total of 6 courses~* In the first part of the study, the standard oral MP will be combined with escalating doses of Vorinostat.~Level -1 Vorinostat = 100 mg daily on days 1-21 Melphalan = 0.18 mg/kg on days 1 - 4 Prednisone = 1.5 mg/kg on days 1 - 4~Level 0 Vorinostat = 200 mg daily on days 1-21 Melphalan = 0.18 mg/kg on days 1 - 4 Prednisone = 1.5 mg/kg on days 1 - 4~Level +1 Vorinostat = 300 mg daily on days 1-21 Melphalan = 0.18 mg/kg on days 1 - 4 Prednisone = 1.5 mg/kg on days 1 - 4~Level +2 Vorinostat = 400 mg daily on days 1-21 Melphalan = 0.18 mg/kg on days 1 - 4 Prednisone = 1.5 mg/kg on days 1 - 4"
223780420|NCT06457542|OTHER|Active Release Technique|Active Release Therapy, which involves instructing the patient to sit and then positioning their shoulder in 90-degree abduction. The therapist will provide assistance to the patient's arm and then examine the supraspinous fossa by applying pressure with a finger. The patient will be instructed to gradually bring the arm towards the body as the therapist manipulates the muscle plane. This procedure should be repeated for a duration of 10 minutes, 3 times per week, over a duration of four weeks.
223780421|NCT06457542|OTHER|Soft Tissue Mobilization|Soft Tissue Mobilization (STM) targeting the subscapularis muscle. The participants will be placed in a position where their upper arm bone (humerus) is raised at a 45° angle, with the elbow bent at a 90° angle. Additionally, the humerus will be rotated outward to a position that is normally around 20° to 25° of external rotation. The subscapularis muscle remained examined by touch in the armpit area to locate regions of limited mobility due to myofascial limitations, trigger points or tense bands. The identified limitations remained addressed with STM, which included applying prolonged manual pressure and slow deep stroke to the subscapularis myofascial. This treatment was performed for a period of 7 minutes, three times a week, over a period of four weeks.
223780422|NCT06471101|DIAGNOSTIC_TEST|clusters|clustering
223780423|NCT03750396|PROCEDURE|Surgical resection|Surgical resection for their metastatic lesions will be performed. Achievement of tumor-free margin is not mandatory.
223780424|NCT03750396|RADIATION|Stereotactic body radiotherapy|Deliver appropriate metastasis directed radiotherapy while minimizing exposure of surrounding normal tissues. Total radiation dose and fractions are various according to metastatic lesions (57\~97.5Gy/6\~10 Fraction).
223780425|NCT03750396|PROCEDURE|Radiofrequency ablation|RFA is a localized thermal treatment technique designed to induce tumor destruction by heating the tumor tissue to temperatures that exceed 60℃. The alternating current of radiofrequency waves passing down from an uninsulated electrode tip into the surrounding tissues generates changes in the direction of ions and creates ionic agitation and frictional heating. This tissue heating then drives extracellular and intracellular water out of the tissue, resulting in tissue destruction by coagulative necrosis.
223780426|NCT01073618|DRUG|voriconazole IV|6 mg/kg iv q 12 hours (loading) then maintenance
223780427|NCT06300645|PROCEDURE|SPLATT|split tibialis anterior tendon transfer to peroneus brevis total tibialis anterior tendon transfer to lateral cuneiform
223780428|NCT02812810|DEVICE|active rTMS|
223780429|NCT02812810|DEVICE|sham rTMS|
223780430|NCT01144312|DRUG|Fentanyl|an initial intravenous bolus of fentanyl 100 μg and infusion of fentanyl at variable rates ranging from 250 to 400 μg/hr
223780431|NCT00999479|DRUG|Norethindrone acetate and ethinyl estradiol tablets, USP|"Loestrin® 24 Fe provides a dosage regimen consisting of 24 white progestogen-estrogen contraceptive tablets and 4 brown ferrous fumarate (placebo) tablets.~Each white tablet contains 1 mg norethindrone acetate and 20 mcg ethinyl estradiol. Each white tablet also contains the following inactive ingredients: acacia, lactose, magnesium stearate, starch, confectioner's sugar, and talc."
223780432|NCT00999479|DRUG|ferrous fumarate (placebo) tablets|Loestrin® 24 Fe provides a dosage regimen consisting of 24 white progestogen-estrogen contraceptive tablets and 4 brown ferrous fumarate (placebo) tablets. Each brown tablet contains ferrous fumarate, microcrystalline cellulose, magnesium stearate, povidone, sodium starch glycolate, and compressible sugar. The ferrous fumarate tablets do not serve any therapeutic purpose.
223780433|NCT03932565|BIOLOGICAL|CAR-T therapy for nectin4-positive malignant solid tumor|The Intravenous minimally invasive surgery combined with intratumoral injection of Nectin4/FAP-targeted the fourth-generation CAR-T cells (expressing IL7 and CCL19, or IL12) are used to treat Nectin4-positive advanced malignant solid tumors, maximally eliminating residual cancer cells and preventing recurrence.
223780434|NCT00547560|DRUG|GSI-953|Oral capsule, 10- and 50-mg, either once a day for 14 days or twice a day for 14 days, depending on cohort assignment.
223696859|NCT05014217|BEHAVIORAL|Dialectical Behavior Therapy-inspired Treatment|A psychotherapy developed by M. Linehan for patients with borderline personality disorder that combines cognitive behavioral therapy techniques (emotional regulation, practical exercises) with Buddhist meditation principles (stress tolerance, acceptance, open-mindedness) (Linehan, M. M. \& Dimeff, L., 2001). As opposed to Linehan's model, individual meetings are bi-weekly, no emergency phone service is offered, the mindful meditation module is reorganized into life habits modules, and every module includes mindfulness exercises. Patients assist psychoeducative group meetings beforehand, along with a pre-treatment of 4-6 individual meetings (over 4-8 weeks), followed by bi-weekly individual follow-ups and weekly group follow-ups. The treatment lasts one year, but can be extended to two years for eligible patients who are interested. Psychiatric follow-up appointments are on an as-needed basis. Every every patient has a treatment contract with specific and measurable treatment objectives.
223696860|NCT00547196|BIOLOGICAL|filgrastim|
223696861|NCT00547196|DRUG|Busulfan|
223696862|NCT00547196|DRUG|Cyclophosphamide|
223696863|NCT00547196|DRUG|Cyclosporine|
223696864|NCT00547196|DRUG|Fludarabine phosphate|
223696865|NCT00547196|DRUG|Melphalan|
223696866|NCT00547196|DRUG|Mycophenolate Mofetil|
223780435|NCT03796455|DIETARY_SUPPLEMENT|Capsule + Powder supplementation|For Fish oil and Placebo oil, treatment will be provided in capsules.Each group will receive dose distributed to 3 capsules per day. Participants will be instructed to take all capsules with morning meal. . For HMB and a placebo powder, product will be delivered as powder taken with water or non-carbonated beverage (like juice). Product will be provided in 2 sachets/day. One sachet should be consumed with breakfast and the other prior to bedtime (approx. 10pm).
223780436|NCT03796455|OTHER|stable tracer infusion|labeled amino acids L-Phenylalanine (ring-13C6), L-Tyrosine (ring-D4), and tau-Methylhistidine will be infused as a single injection. Subsequently, the catheter will be used for arterialized venous blood samples (3 ml) drawn multiple through the day
223780437|NCT01834365|OTHER|Structured education|Formatted education about hypertension
223780438|NCT01834365|OTHER|Checklist|
223780439|NCT01834365|OTHER|Without structure education with checklist|
223780440|NCT05924919|PROCEDURE|Whole-body Passive Heat Therapy (HT)|The whole-body passive heat therapy (HT) intervention will consist of an acute bout of infrared sauna for 25 minutes at 60°C. Participants will lie supine on a memory foam pad.
223780441|NCT05924919|PROCEDURE|Thermoneutral Control (CON)|Participants will remain in a room temperature environment (22°C) underneath the infrared domes for 25 minutes.
223780442|NCT03717532|PROCEDURE|Placebo|Patients will be receiving blood flow restriction therapy with a pressure cuff set to a placebo pressure setting.
223780443|NCT03717532|PROCEDURE|Personalized Tourniquet System for Blood Flow Restriction|Patients will be receiving blood flow restriction therapy with a pressure cuff
223780444|NCT04139811|OTHER|Pars Plana Vitrectomy|vitrectomy with and without ILM peeling
223780445|NCT05494398|DRUG|N-acetylcysteine|12 week administration of N-Acetylcysteine to target restricted repetitive behavior severity.
223780446|NCT00382343|DRUG|Sulfamethoxazole/trimethoprim|Sulfamethoxazole/trimethoprim prophylaxis
223780447|NCT06137391|PROCEDURE|Vital Pulp Therapy|The pulp is accessed after caries removal then the inflamed part of the pulp is excavated. After haemostasis is achieved, a pulpootmy medicament is used to coronally seal the remaining pulp tissue. In partial pulpotomy only part of the pulp chamber is excavated while in full pulpotomy the whole pulp chamber is excavated.
223780448|NCT04081207|BEHAVIORAL|AAC for Language Recovery (AAC-LaRc)|iPads will be programmed with a personalized communication application (app) and a structured 4-step intervention will be employed to instruct patients how to cue themselves during anomic events via pictures, text, or speak buttons.
223780449|NCT00326235|DRUG|Buspirone|
223780450|NCT02233829|DRUG|Brain Dopamine Reactivity|IV methylphenidate, used under IND #124, 912 is injected into the subject s bloodstream to be used in conjunction with PET imaging to show displacement of \[11C\]raclopride.
223780451|NCT02233829|RADIATION|Brain Dopamine Receptor|The radiotracer \[11C\] raclopride is used for imaging dopamine receptors and dopamine release.
223780452|NCT01648777|DEVICE|L bupivacaine|"L-bupivacain solution CHIROCAINE® 5mg/ml, flakon de 20 ml): for the intravenous bolus of 10 ml~o (CHIROCAINE®1.25mg/ml, 200 mL/unit, 400 ml in the accufusor infused at 8ml/h during 48h00: for infusion during 48h00"
223780453|NCT01648777|DRUG|placebo|"* Isotonic NaCl solution (9°/00) solution: for the intravenous bolus of 10 ml~* Isotonic NaCl solution (9°/00) solution, 400 ml in the accufusor infused at 8ml/h during 48h00: for infusion during 48h00"
223696867|NCT00547196|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
223696868|NCT00547196|PROCEDURE|umbilical cord blood transplantation|
223696869|NCT00547196|RADIATION|total-body irradiation|
223696870|NCT00547196|RADIATION|Fractionated total body irradiation|
223696871|NCT02486302|DRUG|Etanercept|Etanercept shall be used according to clinical practice and in line with the summary of product characteristics.
223696872|NCT02727413|PROCEDURE|Blood sample collection|Drawing of 10 ml blood at inclusion, at the time of CPB connection, 60 min under CPB, at the time of CPB disconnection, 6, 24 and 48 hours post-surgery
223696873|NCT02727413|OTHER|Assessment of signs of organ dysfunction|Assessment of signs of organ dysfunction based on medical data prior to surgery, 24 and 48 hours post-surgery, and at the time of ICU discharge
223696874|NCT01924988|DEVICE|Prostatic Embolization with Embosphere Micropsheres|"Each patient will have a selective internal iliac arteriogram, and as necessary, an arteriogram of the anterior division of the internal iliac artery performed to identify the prostatic arterial supply. This typically arises from the inferior vesicle artery (also known as the prostatic artery), but may have supply from the superior vesicle, the internal pudendal or obturator branches as well.~The prostatic arteries will be selected using standard micro-catheter technique. Embolization of the prostate will be performed with 300 to 500 um sized TAGM (Embosphere® Microspheres, Merit Medical, South Jordan, UT). The embolization endpoint will be absence of the normal blush of the prostate on post embolization angiography and stasis of flow in the prostate arteries."
223696875|NCT01297075|BEHAVIORAL|Outreach visits|The 16 facilitators in the project attend an educational programme designed to provide them with the necessary skills and tools for the task. The facilitators visit general practice clinics from March 2011 until the end of 2012. Each clinic is offered three visits. The facilitator is to act as a change agent who motivates and helps the clinic team in the process of defining common goals, and choosing the appropriate means for achieving them.
223696876|NCT01006460|DRUG|Rhodiola rosea, L|3 Capsules twice a day
223696877|NCT01006460|DRUG|Rhodiola rosea, L., Eleutherococcus senticosus, Schisandra chinensis|3 capsules twice a day
223696878|NCT01006460|DRUG|Panax ginseng|3 capsules twice a day
223696879|NCT01006460|DRUG|Placebo - dark brown sugar|3 capsules twice a day
223696880|NCT02860377|PROCEDURE|recorded maternal voice|"A voice recording will be performed before the operation. At a preoperative visit or preoperative clinic, informed consent was obtained before the recording. On a calm environment, the mother was asked to speak following sentences.~ OO (first name of child), wake up\~. Let's go home with mommy. OO, wake up\~. Open your eyes. Take a deep breath. ~At the end of surgery, the recorded maternal voice was delivered to the child every 15 seconds until he/she wakes up."
223696881|NCT02860377|PROCEDURE|recorded stranger's voice|"A voice recording will be performed before the operation. On a calm environment, a blinded female investigator was asked to speak following sentences.~ OO (first name of child), wake up\~. Let's go home with mommy. OO, wake up\~. Open your eyes. Take a deep breath. "
223696882|NCT05296733|DRUG|BI 456906|BI 456906
223696883|NCT00190970|DRUG|Ruboxistaurin|
223696884|NCT00630643|BIOLOGICAL|NI-0401 (anti-CD3 mAB)|0.05 mg up to 10 mg
223696885|NCT00630643|DRUG|Placebo|Placebo
223696886|NCT05958732|OTHER|Somato-sensorial exercises therapy|It includes exercises, which is already mentioned in the arm description.
223696887|NCT05958732|OTHER|Conventional Therapy|It Includes routine exercises for the stroke patient the detail is already given in the arm description.
223696888|NCT04903665|DEVICE|Multi-cancer early detection test|Blood collection and multi-cancer early detection testing
223696889|NCT06333301|OTHER|Surveys|Group will complete several surveys
223696890|NCT05642078|BIOLOGICAL|Investigational Vaccine(0.25ml/vial)|Subjects were vaccinated with a dose of low-dose Investigational vaccine on day 0 and day 28 respectively.The site of inoculation for infants aged 6-11 months is the anterolateral thigh, and the site of inoculation for infants aged 12-35 months is the lateral deltoid muscle of the upper arm.
223696891|NCT05642078|BIOLOGICAL|Investigational Vaccine(0.5ml/vial)|Subjects were vaccinated with a dose of high-dose Investigational vaccine on day 0 and day 28 respectively.The site of inoculation for infants aged 6-11 months is the anterolateral thigh, and the site of inoculation for infants aged 12-35 months is the lateral deltoid muscle of the upper arm.
223696892|NCT05642078|BIOLOGICAL|Active compared Vaccine|Subjects were vaccinated with a dose of active compared vaccine on day 0 and day 28 respectively.The site of inoculation for infants aged 6-11 months is the anterolateral thigh, and the site of inoculation for infants aged 12-35 months is the lateral deltoid muscle of the upper arm.
223696893|NCT04171765|DRUG|Placebo|Participants will receive subcutaneous (SC) placebo matched to BFKB8488A.
223696894|NCT04171765|DRUG|BFKB8488A|Participants will receive subcutaneous (SC) BFKB8488A.
223696895|NCT00480285|PROCEDURE|Laparoscopic Nissen Fundoplication|
223696896|NCT00480285|PROCEDURE|Laparoscopic anterior partial fundoplication|
223696897|NCT00809354|DRUG|NSAID|IV doses of placebo (to match tanezumab) every 8 weeks (through Week 48) plus oral naproxen 500 mg BID for 56 weeks or oral celecoxib 100 mg BID for 56 weeks
223696898|NCT00809354|BIOLOGICAL|tanezumab|IV tanezumab 5 mg every 8 weeks (through Week 48) and oral placebo for NSAID BID from Weeks 2 through 56
223696899|NCT00809354|BIOLOGICAL|tanezumab|IV tanezumab 10 mg every 8 weeks (through Week 56) and oral placebo for NSAID BID from Weeks 2 through 56
223696900|NCT00809354|BIOLOGICAL|tanezumab|IV tanezumab 5 mg every 8 weeks (through Week 48)
223696901|NCT00809354|DRUG|NSAID|Oral naproxen 500 mg BID for 56 weeks or oral celecoxib 100 mg BID for 56 weeks
223696902|NCT00809354|BIOLOGICAL|tanezumab|IV tanezumab 10 mg every 8 weeks (through Week 48)
223696903|NCT00809354|DRUG|NSAID|Oral naproxen 500 mg BID for 56 weeks or oral celecoxib 100 mg BID for 56 weeks
223696904|NCT03028103|DRUG|Tazemetostat|Tazemetostat is a selective oral small molecule inhibitor of EZH2
223696905|NCT03028103|DRUG|Fluconazole|200mg will be orally administered QD for 4 days in order to determine CYP3A4 inhibition when administered concomitantly with tazemetostat
223696906|NCT03028103|DRUG|Omeprazole|Using omeprazole as a probe substrate, 20mg will be orally administered for a total of 5 days in order to determine the potential of tazemetostat to inhibit or induce CYP2C19. Omeprazole is also being used to determine the effect of increased gastric pH on metabolism of tazemetostat.
223696907|NCT03028103|DRUG|Repaglinide|Using repaglinide as a probe substrate, 25mg will be orally administered for a total of 2 days in order to determine the potential of tazemetostat to inhibit or induce CYP2C8.
223696908|NCT04558580|DRUG|Rufinamide|Rufinamide
223696909|NCT04537039|DIAGNOSTIC_TEST|Frailty screening for people over 65 living at home.|The home care services will carry out the SEGA-A test.
223696910|NCT03970642|OTHER|Video directly observed therapy|The intervention group will receive individualized text reminders on their phone prior to each dose of their depression medicine. They will be requested to use the VDOT smartphone app to make a video recording of each medication dose ingested during the 3 month study period following their first visit. The app will automatically upload the video to a HIPAA compliant server. Research staff will regularly monitor videos using a password protected website and document each medication dose.
223696911|NCT01489397|DEVICE|Confocol laser endomicroscopy|Confocal laser endomicroscopy was applied at suspected lesion and normal mucosa followed by biopsy for pathology.
223696912|NCT02736994|DRUG|PIP toothbrush cleaner® (Chrisal, Lommel, Belgium).|Probiotic
223696913|NCT02736994|DRUG|Corega Tabs Anti-bacteria®|Cleansing tablet -Corega Tabs Anti-bacteria® (GlaxoSmithKline Consumer Healthcare SA, Genval, Belgium)
223696914|NCT02736994|OTHER|Water|Water
223696915|NCT00002451|DRUG|Indinavir sulfate|
223696916|NCT00002451|DRUG|Ritonavir|
223696917|NCT00002451|DRUG|Lamivudine|
223696918|NCT00002451|DRUG|Stavudine|
223696919|NCT05978778|DEVICE|wii sports game|wii sports is a collection five sports game stimulation,which have been designed to demonstrate the motion sensing capabilities of wii remote
223696920|NCT05978778|OTHER|pre-hand writing skills|pre-hand writing skills
223696921|NCT00448838|BIOLOGICAL|Cetuximab|Cetuximab: an initial loading dose of 400 mg/m2 will be given followed by 250 mg/m2 administered weekly. Cetuximab will be given first followed by gemcitabine on the weeks the patient receives cytotoxic chemotherapy on day 1. Cetuximab will be given as a single agent on Day 8. The treatment will be given on two-week cycles.
223696922|NCT00448838|DRUG|Gemcitabine Hydrochloride|Gemcitabine 1000 mg/m2 IV day 1. The treatment will be given on two-week cycles.
223696923|NCT00448838|DRUG|Oxaliplatin|Oxaliplatin 100 mg/m2 IV day 2. The treatment will be given on two-week cycles.
223696924|NCT05543889|OTHER|Educational package|Online learning package that will discuss the van Herick technique, grading, accuracy and information and discusses the current guidelines for primary angle closure suspect referral.
223696925|NCT02544178|RADIATION|brain radiotherapy|effect of cerebral radiotherapy on neurocognitive state
223696926|NCT02904889|BEHAVIORAL|Stay Active at Home|Stay Active at Home' aims to change the behaviour of community nurses and domestic support workers by offering them an intensive training programme. Subsequently, professionals are expected to deliver goal-oriented, holistic and person-centred services focusing on supporting older adults to maintain, gain or restore their competences to engage in physical and daily activities so that they can manage their everyday life as independently as possible.
223696927|NCT02904889|OTHER|Usual care|Homecare professionals will get no training and their clients will receive usual homecare.
223696928|NCT03458975|RADIATION|MRI|Magnetic Resonance Imaging
223696929|NCT03458975|RADIATION|Perfusion CT scan|Perfusion Computerized tomography scan
223696930|NCT03458975|OTHER|Contrast enhanced ultrasound|Contrast enhanced ultrasound
223696931|NCT03458975|DRUG|Sonoporation|Gaseous microbubbles (Sonovue) combinated with Ultrasounds
223696932|NCT02787382|DEVICE|echocardiographic examination|"Patients will undergo echocardiography (us) starting at the time of the first referral and every 3-4 weeks until delivery and at the 2-7th day birth. Cardiac scans of fifty pregnant women the healthy women from the group will serve as controls at the 2-7th day birth. Cardiac scans of fifty pregnant women and the healthy women from the group will serve as controls~EXPECTED RESULTS Subtle myocardial deformation abnormalities are expected to be commonly found in fetuses and infants with CMV infection."
223696933|NCT04894695|DIAGNOSTIC_TEST|biomarkers detection in different groups|Biomarkers of urine exosomes in different groups were identified by sequencing technology，then biomarkers were validated using urine samples of different groups
223696934|NCT01480089|DRUG|Intraperitoneal Ropivacaine (AIR)|Ropivacaine 2 mg/kg per lean body mass up to no more than 200mg total dose will be atomized and delivered into the peritoneal cavity at the completion of surgery.
223696935|NCT01480089|DRUG|Atomized Intraperitoneal Saline (AIS)|Atomized saline will be administered to the peritoneal cavity at the completion of surgery.
223696936|NCT06317376|OTHER|MICT with Aerobic exercise on treadmill|MICT 3 session per week with Aerobic exercise on treadmill for 30 minute with moderate intensity.
223696937|NCT06317376|OTHER|standard hospital protocol|standard hospital protocol
223696938|NCT03427112|DEVICE|Xin1 Humerus System|"Retrospective assessment of the surgical handling and performance of the X-ray-based tracking and navigation system Xin1 Humerus system evaluated from 10 proximal humerus plate fixations"
223696939|NCT03434574|DIETARY_SUPPLEMENT|Placebo|Identical formulation as the treatment consisting of colored maltodextrin using artificial colors.
223696940|NCT03434574|DIETARY_SUPPLEMENT|Aronia extract|Powdered extract obtained from aronia berries (Aronia melanocarpa).
223696941|NCT02781779|DEVICE|Silverlon®|Silverlon wound dressings
223696942|NCT02781779|DEVICE|AQUACEL® AG|AQUACEL® AG wound dressings
223696943|NCT04589455|DIETARY_SUPPLEMENT|Hennep extract|Hennep extract from Becanex containing 70 mg CBD
223696944|NCT05801133|DRUG|Pirfenidone|200 mg TID in the first week, 300 mg TID in the second week, and maintenance treatment of 400 mg TID from the third week until 3 months
223696945|NCT04743076|PROCEDURE|Endovascular treatment|Endovascular treatment
223696946|NCT04743076|OTHER|Standard medical treatment|Standard medical treatment
223696947|NCT00365144|BIOLOGICAL|bevacizumab|
223696948|NCT00365144|DRUG|erlotinib hydrochloride|
223696949|NCT00365144|OTHER|laboratory biomarker analysis|
223696950|NCT05720260|DRUG|Goserelin|Hormone therapy
223696951|NCT05720260|DRUG|Fulvestrant|Hormone therapy
223696952|NCT05720260|DRUG|Capivasertib|AKT inhibitor
223696953|NCT05720260|DRUG|Durvalumab|immunotherapy
223696954|NCT01492569|PROCEDURE|electroacupuncture therapy|Undergo TAPS at sham point
223696955|NCT01492569|OTHER|questionnaire administration|Ancillary studies
223696956|NCT01492569|PROCEDURE|electroacupuncture therapy|Undergo TAPS
223696957|NCT04937361|OTHER|rectal swab|collection of rectal swabs
223696958|NCT05107427|DRUG|MRx0518|MRx0518 is a live biotherapeutic product consisting of a lyophilised formulation of a proprietary strain of bacterium. The study dosing regimen is one capsule two times per day for the duration of the treatment period.
223696959|NCT05107427|BIOLOGICAL|Avelumab 20 mg/mL Intravenous Solution (IV)|"Avelumab is an IV administered monoclonal antibody that blocks the interaction of programmed death ligand-1 (PD-L1) with its receptors PD-1 and B7.1 on T cells and antigen-presenting cells, and has been shown to activate adaptive and innate immune functions.~The study dosing regimen is 800 mg (four 20mL vials of 20mg/mL solution) for IV infusion once every two weeks"
223696960|NCT05401968|BEHAVIORAL|Osteoporosis patient education|During osteoporosis patient education the participants get knowledge about e.g. osteoporosis, medication, and diet, and they participate in physical exercises. Though, differences between municipalities exist. The participants meet in groups and face-to-face.
223696961|NCT02678273|OTHER|Intervention group|"The Family Medicine Clinic will be the patient centred medical home to manage their complex care needs. A common electronic record will be created for information sharing between care partners. The Integrated Clinical Care Service will provide inpatient care for admitted residents, with emphasis on comprehensive discharge planning and hand-over of care. Patients at high risk of destabilization will receive an early review in outpatient clinic. Home or bed bound residents will be managed by SGH Home Care. The Care Closer to Home comprises a case manager and nursing aides to put in place health, personal and social services e.g. medication management, home help services. The Senior Activity Centre will encourage the elderly to remain integrated in society through community outreach programmes and social recreational activities. A community virtual ward will connect these care providers and weekly meetings to discuss care plans for the frail and sick residents~."
223696962|NCT00275964|DRUG|TMN-1|
223696963|NCT04373174|DEVICE|Regional oximetry probe|Regional oximetry probe will be placed in the frontal area of the head
223696964|NCT04373174|PROCEDURE|Thoracic Epidural block|Thoracic epidural block will be applied to the patients before the operation begins
223696965|NCT03198078|DRUG|Brexpiprazole (OPC-34712)|Once-daily, tablets
223696966|NCT03198078|DRUG|Aripiprazole|Once-daily, tablets
223696967|NCT03198078|DRUG|Placebo|Once-daily, tablets
223696968|NCT01784848|PROCEDURE|Laparoscopic Roux-en-Y gastric bypass (LRYGB)|Laparoscopic Roux-en-Y gastric bypass (LRYGB)is the one of the techniques of bariatric surgery
223696969|NCT01784848|OTHER|Clinical treatment|Medical treatment aiming the control of risk factors for cardiovascular diseases (including adequate control of blood pressure), psychological assistance and dietetic advice for body weight reduction.
223696970|NCT02607930|DRUG|ABC/DTG/3TC|600/50/300 milligrams (mg) tablets administered orally, once daily
223696971|NCT02607930|DRUG|B/F/TAF|50/200/25 mg tablets administered orally, once daily, without regard to food
223696972|NCT02607930|DRUG|ABC/DTG/3TC Placebo|Tablets administered orally, once daily
223696973|NCT02607930|DRUG|B/F/TAF Placebo|Tablets administered orally, once daily
223696974|NCT06134908|BEHAVIORAL|Multifaceted Intervention|The multicomponent intervention elements include education for clinicians and patients as well as a shared decision-making program among clinicians and patients. A shared decision-making booklet and a mobile application will be used to promote osteoporosis management and fracture practice.
223696975|NCT01622803|PROCEDURE|parallel stent|bilateral parallel stent insertion (right and left side)
223696976|NCT01622803|DEVICE|Y-stent (BONASTENT M-Hilar)|Bilateral Y-stent insertion (stent in stent type)
223696977|NCT02777619|DRUG|0.0ng/ml Dexmedetomidine|Dexmedetomidine target plasma concentration is 0.0ng/ml
223696978|NCT02777619|DRUG|0.4ng/ml Dexmedetomidine|Dexmedetomidine target plasma concentration is 0.4ng/ml
223696979|NCT02777619|DRUG|0.6ng/ml Dexmedetomidine|Dexmedetomidine target plasma concentration is 0.6ng/ml
223696980|NCT02777619|DRUG|0.8ng/ml Dexmedetomidine|Dexmedetomidine target plasma concentration is 0.8ng/ml
223696981|NCT02777619|DRUG|Propofol|
223696982|NCT00111488|DEVICE|Flex 4 and Generator|
223696983|NCT01924507|DEVICE|CPAP|CPAP - continuous positive air pressure in patients with sleep apnea
223696984|NCT05850065|OTHER|Hu-Friedy 212 clamp|Hu-Friedy 212 clamp is normally used for the retraction with rubber-dam
223780454|NCT02602574|OTHER|heparinized peripheral venous blood and urine sample.|All patients will be taken heparinized peripheral venous blood and urine sample
223780455|NCT02897947|PROCEDURE|Surgery for lumbar spinal stenosis in Norway|
223780456|NCT02897947|PROCEDURE|Surgery for lumbar spinal stenosis in Sweden|Surgery for neurogenic claudication due to lumbar spinal stenosis in Sweden
223696985|NCT05850065|OTHER|dental floss using the simple knot tie method|Dental floss using the simple knot tie method is normally used for the retraction with rubber-dam
223696986|NCT05850065|OTHER|Coltene B4 clamp|Coltene B4 clamp is normally used for the retraction with rubber-dam
223696987|NCT04452032|PROCEDURE|Dental avulsion|Before radiotherapy, each subject undergoes a dental evaluation and if it is necessary, dental avulsions if their long-term survival is compromised (see in section 6.1.2) and if they are located in an area at risk to receive more than 40 Gy, so to develop osteoradionecrosis of the jaw. The avulsions should be performed as far as possible from the start of radiotherapy (RT) namely at least 2 weeks before irradiation to allow mucosal healing.
223696988|NCT04452032|RADIATION|Radiotherapy|"Radiotherapy:~All Subjects will be treated by simultaneous integrated boost (SIB) intensity modulated radiotherapy (IMRT) / volumetric modulated arc therapy (VMAT)."
223696989|NCT06198283|OTHER|Low Level LASER Therapy with Pressure Garment|This group will be treated by low level laser therapy with pressure garment (8-10hrs a day) by Laplace' s Law method because it is more accurate since the range of pressures that can be delivered to a particular range of body circumferences varies depending on the fabric used and its particular tension- extension profile, the method is difficult to utilize manually and till present there is no available design tool to aid in its application. Pressure garments generate an increase in subdermal pressures in the range 9- 90 mmHg depending on the anatomical site. Garments over soft tissues generate pressures ranging from 9 to 33 mmHg. Over bony prominences the pressures range from 47 to 90 mmHg. 25mmHg pressure will be provided by garments and garments will be replaced in every 2 months
223696990|NCT06198283|OTHER|Low Level LASER Therapy without Pressure Garment|This group will receive low level LASER therapy (422-800nm) without pressure garment only for the duration of 6 weeks (3 days in a week with 20-30 minutes per session).
223696991|NCT00860444|BEHAVIORAL|Basic Educational and Counseling Program|Participants will receive one session of brief patient-centered physician counseling, along with educational handouts and nurse-assisted guidance with goal-setting.
223696992|NCT00860444|BEHAVIORAL|Comprehensive Educational and Counseling Program|Participants will receive one session of brief patient-centered physician counseling, along with educational handouts and nurse-assisted guidance with goal-setting. They will also receive 12 months of telephone counseling and a monthly newsletter.
223696993|NCT01050543|DRUG|sugammadex|sugammadex 2.0 mg/kg, single intravenous bolus dose administered within 10 seconds into a fast flowing venous infusion
223780457|NCT02897947|PROCEDURE|Surgery for lumbar spinal stenosis in Denmark|Surgery for neurogenic claudication due to lumbar spinal stenosis in Denmark
223696994|NCT01050543|DRUG|neostigmine|neostigmine 50 mcg/kg (total dose not to exceed 5.0 mg) combined with glycopyrrolate 10 mcg/kg, single intravenous bolus dose administered within 10 seconds into a fast flowing venous infusion
223696995|NCT04091009|DRUG|Buprenorphine|"Participants will be randomly assigned to be maintained on their daily dose of buprenorphine or to have their buprenorphine reduced to 16mg on the day before surgery.~Participants in the reduced group will then be prescribed 8mg buprenorphine daily from the day of surgery until transitioned back to their regular dose of buprenorphine when postoperative surgical pain has subsided"
223696996|NCT04091009|DRUG|Buprenorphine/naloxone|"Participants will be randomly assigned to be maintained on their daily dose of buprenorphine/naloxone or to have their buprenorphine/naloxone reduced to 16mg on the day before surgery.~Participants in the reduced group will then be prescribed 8mg buprenorphine daily from the day of surgery until transitioned back to their regular dose of buprenorphine when postoperative surgical pain has subsided"
223696997|NCT05432375|DRUG|Tinostamustine|infusion given over 60 minutes
223696998|NCT00476359|DRUG|Lopinavir/r plus saquinavir|lopinavir/ritonavir 230/57.5 mg/m2 orally twice daily and saquinavir 50 mg/kg orally twice daily
223696999|NCT05486754|BEHAVIORAL|Cognitive behavioral stress management|Participants will receive in-person weekly stress management group sessions (3-8 participants) for two hours per week for ten weeks total. Each session will consist of a half hour of relaxation training and one and a half hours of stress management skill training, including coping effectiveness training, anger management, assertiveness training, and stress awareness.
223697000|NCT05486754|BEHAVIORAL|Psychoeducational Control|Participants will receive one four-hour seminar in-person groups (3-8 participants) of educational information related to prostate cancer and abbreviated psychological information provided in cognitive behavioral stress management.
223697001|NCT04130984|DEVICE|EZ-IO|The insertion site locates at 1 cm medial tibial tuberosity. EZ-IO (U.S. Teleflex® Corporation) will be used with an adult 15G needle. Pull out the needle when having a sense of frustration, withdraw the bone marrow with the syringe, bolus 20 mL of normal saline to open intramedullary path and begin drug resuscitation at the same time. The retention time of IO route should be less than 24 h, and venous access should be established after winning rescue time as soon as possible to continue treatment.
223697002|NCT06364475|BEHAVIORAL|16:8 Time-Restricted Intermittent Fasting Group|Participants total daily energy expenditures were calculated using the Harris-Benedict formula. This group have a feeding window 8 hours and eating plan of 400 kcal lower than the total daily energy requirement and with similar macronutrient content (50% carbohydrates, 25% fat and 25% protein). Participants in the time-restricted eating group were allowed to drink calorie-free. They were expected to follow their diet for two months during the study.
223697003|NCT06364475|BEHAVIORAL|Energy-Restricted Six-Meal Group|Participants total daily energy expenditures were calculated using the Harris-Benedict formula. This group have an eating plan three meals and three snacks of 400 kcal lower than the total daily energy requirement and with similar macronutrient content (50% carbohydrates, 25% fat and 25% protein). They were expected to follow their diet for two months during the study.
223697004|NCT05661123|OTHER|Complete decongestive therapy|"1. Education.~2. Skin care .~3. Pneumatic compression device .~4. Manual lymph draining .~5. Multilayer short stretch compression bandages.~6. Exercises."
223697005|NCT04056351|DIAGNOSTIC_TEST|Post-Operative (OP) Computer Tomography (CT)|Post-OP CT of the treated shoulder
223697006|NCT04056351|OTHER|Questionnaires on patient activity and comorbidities|"* Shoulder activity scale (Marx)~* Parker Mobility Scale~* Barthel index~* Charlson Comorbidity Score"
223697007|NCT04056351|OTHER|Grip strength measurement|Grip strength will be measured using a CE marked hydraulic hand dynamometer device.
223697008|NCT04056351|OTHER|Non-invasive shoulder activity tracking usinig wearable sensors|Post-OP activity will be assessed via wearable CE-marked accelerometer sensors.
223697009|NCT01782547|BEHAVIORAL|Telehealth Intervention|Monthly videoconference with diabetes nurse educator; Monthly videoconference with social worker; Diabetes action plan;
223697010|NCT01782547|OTHER|Usual Care|Standard diabetes care- typically a visit with a diabetes health care provider every 3 months and referrals to a dietitian or mental health specialist as deemed appropriate; Study participation reminder cards twice per month
223697011|NCT03913546|PROCEDURE|Spinal manipulative therapy|Participants in the actual spinal manipulative therapy group will be assessed through the activator basic method protocol. SMT will be performed with an Activator IV (Activator Methods International, Phoenix, AZ) setting the force at level 3 for the low thoracic spine (T7-T12), and level 4 for the lumbar spine and pelvis.
223697012|NCT03913546|OTHER|Sham spinal manipulative therapy|Participants in the sham SMT group will undergo a protocol identical to the actual one, with the exception that a sham mechanical thrust (force set at level 0) will be delivered to the targeted areas. In the force level 0 no excursion of the stylus occurs, but the instrument produces the same clicking sound as in the actual SMT condition
223697013|NCT00366977|BEHAVIORAL|Multi-session telephone counseling|
223697014|NCT00366977|DRUG|NRT patches|
223697015|NCT04004546|BEHAVIORAL|Health literacy-based intervention|Participants in the intervention group will receive a: i) 30-min video about medication adherence, ii) medication adherence booklet, and iii) 2-week telephone call by a nurse.
223697016|NCT01504568|OTHER|Treatment|Adults: ≥40 kg:250mg every eight hours Children: \<40kg: 20mg/kg/day divided in three doses (up to 250mg) every eight hours Suspension form 250mg/ml
223697017|NCT00003254|DRUG|ethynyluracil|10mg/m2/dose, PO, Days 1-28, q 5wk
223697018|NCT00003254|DRUG|fluorouracil|1.0mg/m2/dose, PO, Days 1-28 BID, q 5wk
223697019|NCT01146990|DRUG|ASQ-3, Bayley III, Neurologic exam|Developmental Scales of infant development - Children born to mothers who participated in the 17P-ES-003 study will be enrolled in this study and evaluated using the ASQ-3. Those meeting protocol criteria based on ASQ-3, will be evaluated using the Bayley III and have a neurologic examination.
223697020|NCT03525093|BEHAVIORAL|Hypnosis|"5 session of group hypnosis, each 90 minutes, to reduce subjective levels of stress, improve coping with stress. Additional audiotapes of hypnosis sessions as homework.~Participants receive a health education booklet on improving coping with stress."
223697021|NCT03525093|BEHAVIORAL|Health education|Participants receive a health education booklet on improving coping with stress.
223697022|NCT02325986|DRUG|fluorouracil|cisplatin 25mg/m2 on day 1, fluorouracil 1176mg/m2 on day 1-3，repeated weekly for 4 weeks concurrently with IMRT radiotherapy (60Gy/28fr)
223697023|NCT02325986|DRUG|Cisplatin|cisplatin 25mg/m2 on day 1, fluorouracil 1176mg/m2 on day 1-3，repeated weekly for 4 weeks concurrently with IMRT radiotherapy (60Gy/28fr)
223697024|NCT02325986|RADIATION|Intensity-modulated radiation therapy|cisplatin 25mg/m2 on day 1, fluorouracil 1176mg/m2 on day 1-3，repeated weekly for 4 weeks concurrently with IMRT radiotherapy (60Gy/28fr)
223697025|NCT04478981|OTHER|No intervention|This concerns a natural history study; no interventions will be used
223697026|NCT00570765|DRUG|Placebo|Matching placebo tablets were administered orally once daily.
223697027|NCT00570765|DRUG|Obeticholic Acid (OCA)|Starting dose of 10 or 50 mg administered orally once daily, followed by dose titration planned from 10 mg to 25 mg to 50 mg once daily, which could be modified for safety and tolerability issues or to achieve adequate therapeutic response.
223697028|NCT03272516|BEHAVIORAL|Mindfulness based cognitive therapy (MBCT)|Mindfulness Based Cognitive Therapy (MBCT). This group receives 8 weeks of MBCT in addition to usual treatment (TAU). The MBCT consists of weekly group sessions of 2,5 hours, where participants receive cognitive therapy as well as mindfulness meditation. This group is also assigned homework, according to the MBCT protocol.
223697029|NCT03272516|OTHER|Treatment as usual (TAU)|Usual treatment prescribed by each physician, specifically interview therapy, cognitive therapy, antidepressants and/or anxiolytics as well as a mixture of all of the above.
223697030|NCT04234607|DRUG|TQB2450|TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.
223697031|NCT04234607|DRUG|Anlotinib|a multi-target receptor tyrosine kinase inhibitor
223697032|NCT04234607|DRUG|Etoposide|Etoposide is a cell cycle-specific antitumor drug
223697033|NCT04234607|DRUG|Carboplatin|Carboplatin is cell cycle nonspecific antitumor drug
223697034|NCT04234607|DRUG|TQB2450（blank）|Subjects administrated TQB2450 (blank) intravenously (IV) on Day 1 of each 21-day
223697035|NCT04234607|DRUG|Anlotinib（blank)|Subjects administrated anlotinib (blank) in fasting conditions, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21)
223697036|NCT04329442|DRUG|Emtricitabine / Tenofovir Disoproxil Oral Tablet|30 day supply of 200mg tablets
223697037|NCT04784039|DIAGNOSTIC_TEST|Transesophageal echocardiography|Patients randomized to the TEE group will be scheduled for cardioversion with prior TEE
223697038|NCT04784039|DIAGNOSTIC_TEST|D-Dimer analysis|Patients randomized to the DD-group will be scheduled for cardioversion with prior D-Dimer analysis. In case of positive D-Dimer results, TEE will be performed prior to cardioversion
223697039|NCT01129674|DRUG|LY2140023|Administered orally, twice daily for 104 weeks
223697040|NCT01129674|DRUG|Olanzapine|Tablets or capsules, given orally, consistent with approved labeling and local practice for 104 weeks
223697041|NCT01129674|DRUG|Aripiprazole|Tablets or capsules, given orally, consistent with approved labeling and local practice for 104 weeks
223697042|NCT01129674|DRUG|Risperidone|Tablets or capsules, given orally, consistent with approved labeling and local practice for 104 weeks
223697043|NCT01129674|DRUG|Quetiapine|Tablets or capsules, given orally, consistent with approved labeling and local practice for 104 weeks
223697044|NCT01298310|DRUG|Xylocaine|1 mg/mL solution for injection
223697045|NCT01298310|DRUG|Xylocaine|10 mg/mL solution for injection
223697046|NCT01298310|DRUG|Placebo|solution for injection
223697047|NCT04877106|DRUG|Sitagliptin Phosphate/metformin Hydrochloride Tablets(JANUMET®,50mg/850mg)|The subjects randomly received single oral administration of Sitagliptin Phosphate/metformin Hydrochloride Tablets (JANUMET®, 50mg/850mg)
223697048|NCT04877106|DRUG|Sitagliptin Phosphate/metformin Hydrochloride Tablets (50mg/850mg)|The subjects randomly received single oral administration of Sitagliptin Phosphate/metformin Hydrochloride Tablets (50mg/850mg)
223697049|NCT00234234|DRUG|Adalimumab|
223697050|NCT05371678|OTHER|Therapeutic motor control interventions|Treatment duration will be 8 weeks, two sessions a week. Each session will take approximately 60 minutes. This intervention includes education, dietary advices, core stabilization exercises and pelvic floor muscle training with surface Electromyographic-Biofeedback. In the education will be taught to the child and their parents in the first session. Dietary advices will be given by specialist dietitian. Core stabilization exercises will be performed 2 days a week with a physiotherapist and the session will be approximately 50 minutes. Diaphragmatic breathing will be taught to children in breathing exercises. The pelvic floor muscles exercises will be do by surface Electromyographic-Biofeedback. The Electromyographic-Biofeedback teaches the child how to relax the external anal sphincters with visual and auditory feedback techniques.The child will learn to relax the pelvic floor muscles during defecation by monitoring the recorded electromyographic activity.
223697051|NCT05371678|OTHER|Conventional treatment|Treatment duration will be 8 weeks. This intervention includes education, dietary advices and laxative therapy. In the education will be taught to the child and their parents in the first session. Dietary advices will be given by specialist dietitian. Laxative therapy will be adjusted at different doses according to the child's age and weight. Laxative therapy will be administered to children by a specialist doctor.
223697052|NCT03711266|BEHAVIORAL|PE-PC|PE-PC treatment will follow the PE-PC manual and patient workbook. Treatment content for PE-PC is drawn from the PE model and condensed so as to deliver the most efficacious components of PE. PE-PC consists of four, 30-minute appointments scheduled approximately once a week over 4-6 weeks
223697053|NCT03366779|DEVICE|6mm annular closure device|6MM Barricaid annular closure device implantation following standard lumbar discectomy
223697054|NCT03935412|PROCEDURE|Erector Spinae Plane Block|Erector Spinae Plane Block
223697055|NCT02977130|BEHAVIORAL|Map group|diabetes shared care plus conversation map intervention
223697056|NCT02977130|BEHAVIORAL|Control group|diabetes shared care
223697057|NCT00057876|DRUG|Gemcitabine|"Induction: Patients receive the first cycle of gemcitabine 1000 mg/m\^2 intravenously once per week for 6 weeks followed by 1 week rest.~Consolidation: Following the week of rest, treatment resume with gemcitabine 1000 mg/m\^2 administered intravenously once per week for 3 weeks, followed by 1 week rest, for 5 (4-week) cycles."
223697058|NCT00057876|RADIATION|radiation therapy|"Induction: Patients receive gemcitabine 600 mg/m\^2 intravenous infusion over 30-60 minutes once a week for 6 weeks while receiving radiation therapy. The first gemcitabine dose is given on the first day of radiation therapy (prior to radiation), then weekly thereafter. All patients on Arm B receive radiation therapy Monday through Friday (no radiation on Saturday or Sunday), weeks 1-6, with once/week gemcitabine. The radiation dose per fraction is 180 cGy prescribed to the isocenter. The total dose of radiation is 5040 cGy given in 28 fractions over 5 1/2 weeks.~Consolidation: Additional cycles of gemcitabine begin approximately 4 weeks after completion of radiation therapy."
223697059|NCT04418284|OTHER|survey|online survey
223697060|NCT03580148|DRUG|Cortisone|Patients randomized to receive this study intervention will undergo one ultrasound guided 80mg Depo Medrol GHJ injection
223780458|NCT04376996|DIAGNOSTIC_TEST|NO intervention planned due to the observational study design - only a diagnostic testing|Only a diagnostic tests are planned: SARS-CoV-2 RNA in nasopharyngeal samples and anti-SARS-CoV-2 antibodies in blood
223780459|NCT03455075|DRUG|Dimethandrolone-Undecanoate|Single doses of DMAU in castor oil/benzyl benzoate administered in 100 mg capsules.
223780460|NCT03455075|DRUG|Levonorgestrel 0.03 MG|Single doses of LNG administered in 30 mcg capsules.
223780461|NCT03455075|DRUG|Placebo oral capsule|Placebo capsules that look like DMAU and LNG capsules but with no active ingredients.
223697061|NCT03580148|BIOLOGICAL|Bone Marrow Aspirate|Patients randomized to receive this study intervention will have, under sterile conditions and after injection of local anesthetic, 10 mls of bone marrow aspirate taken from the posterior superior iliac spine and injected under ultrasound guidance to the glenohumeral joint
223697062|NCT00935051|OTHER|Picture + MMPs and TIMP1 at week 0 and week 4|Sample of wound fluid will be collected using a non traumatic procedure at week 0 and week 4. This will allow to assess the level of MMP9, MMP13, MMP1 and TIMP1. A numeric photograph of the wound will be taken at week 0, week 4 and week 12 in order to assess wound area.
223697063|NCT02409810|DRUG|Dexmedetomidine|Prior to the burn dressing changes PCA-DEX patients will receive a bolus of dexmedetomidine (Precedex®) 0.25 mcg/kg administered over 10 minutes by nursing staff, followed by a continuous infusion of Precedex® at 0.4 mcg/kg/hr via a standard infusion pump (LifeCare PCA). Patients will self-medicate as needed for anxiety self-management by self-administering a bolus of Precedex® 0.1 mcg/kg. This dosage is within the FDA-approved package insert parameters. Heart rate, blood pressure and oxygen saturation will be closely monitored by a staff RN already trained to provide care in the procedure room. 1 hour prior to- and after completion of the burn dressing change each day using a 100-mm visual analog scale. Patients will both rate their satisfaction with PCA-DEX for anxiety management after each completion of the burn dressing change.
223697064|NCT04633356|DEVICE|EUS-portal pressure gradient measurement (PPGM)|EUS-guided PPGM is performed under conscious sedation. An OGD would be performed to evaluate for findings consistent with portal hypertension such as varices and portal hypertensive gastropathy. The linear array echoendoscope is passed from the mouth into the stomach and duodenum, as with a standard exam. Under endoscopic ultrasound guidance, a 25 gauge EUS needle (Echotip, Cook Medical, USA) primed with heparin 100 USP/ml is then placed across the stomach or duodenal wall and through the liver parenchyma into the portal vein. A pressure measurement is then obtained from the compact pressure transducer attached to the handle of the needle. Three separate measurements are made with re-priming of heparin (less than 0.5 ml). The process is repeated for the hepatic vein. The EUS - PPG is calculated by subtracting the average of the three hepatic vein pressure measurements from the average of the 3 direct portal vein pressure measurements.
223697065|NCT04040244|OTHER|Exhaled Breath Collection|Exhaled breath condensate (EBC) and exhaled breath volatiles (EBV) samples will be obtained over 5-10 minutes using a one-time use R-tube apparatus.
223697066|NCT04040244|OTHER|Blood sample|Blood samples collected simultaneously with routine standard of care blood draws.
223697067|NCT00003307|DRUG|amifostine trihydrate|
223697068|NCT00003307|RADIATION|radiation therapy|
223697069|NCT00480883|DRUG|meglumine antimoniate, allopurinol|first drug in injectable, second is in tablet form.
223697070|NCT00480883|DRUG|meglumine antimoniate|injectable 20 mg/kg/day/intramuscular for 21 days.
223697071|NCT00480883|DRUG|meglumine antimoniate, allopurinol|injectable meglumine antimoniate 10 mg/kg/day/intramuscular for 21 days plus tablet allopurinol 300mg/4times a day for 21 days.
223697072|NCT04798456|BEHAVIORAL|Coma scales|CRS-R and GOSE
223697073|NCT04798456|DIAGNOSTIC_TEST|Imaging, electrophysiology, body signals, and brain stimulation|MRI, fMRI, EEG, TMS-EEG, Olfaction, Respiration, EKG
223697074|NCT04798456|BEHAVIORAL|Questionnaires|several questionnaires and an interview with the caregiver
223697075|NCT00437320|DRUG|Metvix Cream 160 mg/g|Participants were treated with topical administration of Metvix cream.
223697076|NCT00437320|DRUG|Metvix Vehicle Group|Participants were treated with topical administration of Metvix Vehicle cream.
223697077|NCT01995643|DIETARY_SUPPLEMENT|Active Capsule|GSE Capsule
223697078|NCT01995643|DIETARY_SUPPLEMENT|Placebo Capsule|Placebo Capsule
223697079|NCT05705414|DRUG|Valine|A medical food intended for use under medical supervision
223697080|NCT05705414|DRUG|EEA|A medical food intended for use under medical supervision
223697081|NCT04721951|PROCEDURE|Endovascular Aortic Repair using Carbon Dioxide Angiography|Endovascular Aortic Repair using Carbon Dioxide Angiography
223697082|NCT03036904|DRUG|Venetoclax|Venetoclax will be administered orally on days 3-12 in cycle 1, and days 1-10 with all subsequent cycles except dose level -1. If dose level -1 is required, venetoclax will be administered on days 3-7 in cycle 1 and 1-5 with subsequent cycles.
223697083|NCT03036904|DRUG|Rituximab|Rituximab will be administered as an IV infusion at 375 mg/m2 on day 1 of each cycle of DA-EPOCH-R, immediately prior to the start of chemotherapy. Oral pre-medication 650 mg of acetaminophen and 50-100 mg diphenhydramine hydrochloride will be administered 30 to 60 minutes prior to starting each infusion of rituximab. The first rituximab infusion should be started at 50 mg/hr, and increased in 50-mg/hr increments every 30 minutes to a maximum rate of 400 mg/hr. If this rate of escalation is well tolerated the second and subsequent infusions can begin at a rate of 100 mg/hr and increase in 100 mg/hr increments every 30 minutes to a maximum of 400 mg/hr. CAUTION: DO NOT ADMINISTER AS AN INTRAVENOUS PUSH OR BOLUS.
223697084|NCT03036904|DRUG|Etoposide|Etoposide will be obtained from commercial supply, and will be given for a total of 6 cycles for all patients. The drug will be given by IV route.
223697085|NCT03036904|DRUG|Vincristine Sulfate|Vincristine Sulfate will be obtained from commercial supply, and will be given for a total of 6 cycles for all patients. The drug will be given by IV route.
223697086|NCT03036904|DRUG|Cyclophosphamide|Cyclophosphamide will be obtained from commercial supply, and will be given for a total of 6 cycles for all patients. The drug will be given by IV route.
223697087|NCT03036904|DRUG|Prednisone|Prednisone will be obtained from commercial supply, and will be given for a total of 6 cycles for all patients. Prednisone will be given orally.
223697088|NCT03036904|DRUG|Doxorubicin Hydrochloride|Doxorubicin Hydrochloride will be obtained from commercial supply, and will be given for a total of 6 cycles for all patients. The drug will be given by IV route.
223697089|NCT02617888|RADIATION|CCTA ~ BREAST SHIELDS|Breast shield placement (randomized) among women.
223697090|NCT01522807|DRUG|PF-05190457|100 mg single oral dose of PF-05190457 is administered as a suspension in the fasted state
223697091|NCT01522807|DRUG|PF-05190457|100 mg single oral dose of PF-05190457 is administered as a short-duration osmotic capsule in the fasted state
223780462|NCT02081794|OTHER|Tailored education intervention|Receive 2 minute video-assisted intervention on the risk and prevention of falls with tailored hand-outs depending on participant answers about fall risks
223780463|NCT02081794|OTHER|Standard fall care|Patient are given a generic handout on falling and receive standard care by nurses comprising of a fall risk assessment and verbal education
223780464|NCT02912533|DRUG|JR-131|
223780465|NCT00907569|RADIATION|Hypofractionated Chest Radiotherapy|Hypofractionated chest radiotherapy regimen of 58 Gy delivered in 25 fractions in 5 weeks.
223780466|NCT03846843|DRUG|OCR-002 IR Oral Tablet|OCR-002 3 gram immediate release (IR) tablet for oral administration
223780467|NCT03846843|DRUG|OCR-002 Oral Solution|OCR-002 5 gram solution for oral administration
223780468|NCT03846843|DRUG|OCR-002 IV Solution|OCR-002 5 gram solution for intravenous (IV ) administration
223780469|NCT02577705|BEHAVIORAL|Self Empowerment Groups|The Self Empowerment Groups (SEG) curriculum draws key components from the S.E.L.F. tool within Sanctuary, focusing the four domains: creating personal, emotional, moral and physical safety (S), processing and managing emotions (E), recognizing loss and letting go (L), and developing goals for a sense of future (F). S.E.L.F. establishes a common language that all people who have experienced adversity can use to organize their lives and work towards building stable foundations to support their goals and invest in their potential.
223780470|NCT02577705|BEHAVIORAL|Financial Empowerment|The Financial Empowerment curriculum developed for this study consisted of interactive exercises, worksheets, and journal assignments that fostered understanding and practice of banking, building credit and debt management, making the most of one's money, and setting financial goals for oneself and one's family. Content focused on identifying and harnessing the internal and external resources that participants can leverage to begin taking steps towards financial self-sufficiency.
223780471|NCT02577705|BEHAVIORAL|Matched Savings|Participants were assisted with opening a savings accounts at a local non-profit federal credit union (with 1:1 matches of up to twenty dollars per month) over the course of 12 months.
223780472|NCT04596163|PROCEDURE|Transversus thoracis muscle plane block|After general anaesthesia, transversus thoracis plane (TTP) block, a kind of regional block will be performed near both sides of the sternum under ultrasound guidance using either levobupivacaine or normal saline to both groups of patients. The end point for injection is the fluid spread along the plane just superficial to the transversus thoracis muscle, together with the downward displacement of the pleura.
223780473|NCT06043921|OTHER|No intervention|There is no intervention associated with this observational study.
223780474|NCT06532110|OTHER|Endoscopy/Colonoscopy|Esophagogastroduodenoscopy and colonoscopy with video recording and biopsy collection
223780475|NCT04497441|OTHER|Electronic Survey questionnaire|"This Cross sectional study utilizes an electronic google form to get responses from netizens of Al Qassim province of Saudi Arabia regarding the perception of COVID-19 information and information sources. All the questions in the survey are compulsory answerable questions. The settings in the google form are set so that a single respondent can limit the survey response to single time. The Survey Questionnaire contained following sections:~Section I: Minimum required personal details Section II: 10 Questions regarding the source of COVID-19 information Section III: 6 Questions regarding perception of the COVID-19 information~The very first part of the Questionnaires seeks responders' consent for giving responses to the survey questions. participation Section II \& III contained all closed ended questions. The Google form link is shared to the netizens of Al Qassim province across relevant Social media platforms."
223780476|NCT04558957|DEVICE|FLEBOGRIF|The catheter is a device dedicated to mechano-chemical ablation of insufficient veins of the superficial system.
223780477|NCT02677545|DRUG|Ticagrelor|
223780478|NCT02677545|DRUG|Clopidogrel|
223780479|NCT02677545|DRUG|Aspirin|
223780480|NCT00982020|DRUG|Olanzapine|2.5 milligrams (mg) to 20 mg given orally, daily for 52 weeks
223780481|NCT00982020|BEHAVIORAL|Standard behavioral weight intervention|One time counseling and basic counseling information on healthy eating and exercise habits at randomization visit only.
223780482|NCT00982020|BEHAVIORAL|Intense behavioral weight intervention|Counseling provided at randomization and at all subsequent study visits by appropriately trained individual regarding healthy lifestyle habits. Participants also provided with simple tools to help enable healthy eating and exercise habits.
223780483|NCT01384344|OTHER|observational|Observation during a physical exercise
223780484|NCT01229345|DRUG|Breakfast & exercise|1859 kJ breakfast vs fast, exercise at 60% maximum aerobic capacity to expend 1859 kJ.
223780485|NCT01786356|DEVICE|HOYA iMics Y-60H|same-day bilateral cataract surgery with implantation of intraocular lens HOYA iMics Y-60H in one eye
223780486|NCT01786356|OTHER|B&L MI60|same-day bilateral cataract surgery with implantation of intraocular lens B\&L MI60 in one eye
223780487|NCT02800707|OTHER|Sucralose|Sweetner
223780488|NCT02800707|OTHER|Stevia|Sweetner
223780489|NCT06257147|BEHAVIORAL|multifaceted antibiotic stewardship intervention|Group 3 wards will receive a multifaceted antibiotic stewardship intervention. Physician education will be provided as in Group 1. All consecutive patients fulfilling inclusion and exclusion criteria for study eligibility will be assessed by an Antibiotic Stewardship team. A trained nurse will first assess the patients for clinical and host criteria to determine eligibility for short-course antibiotic therapy. The antibiotic susceptibility test results and the prescribed antibiotics treatment will be reviewed. An Infectious Diseases physician will subsequently make written recommendations for the duration and choice of antibiotic therapy, and provide an appointment within 2 weeks after hospital discharge to review patients' clinical condition when indicated.
223780490|NCT00949247|BIOLOGICAL|bevacizumab|Bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. After 6 courses, treatment modifications may apply according to response.
223780491|NCT00949247|BIOLOGICAL|trastuzumab|Trastuzumab IV over 30-90 minutes on days 1, 8, and 15. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. After 6 courses, treatment modifications may apply according to response.
223780492|NCT00949247|DRUG|carboplatin|Carboplatin IV over 30-90 minutes on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. After 6 courses, treatment modifications may apply according to response.
223780493|NCT00949247|DRUG|docetaxel|Docetaxel IV over 30-90 minutes on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. After 6 courses, treatment modifications may apply according to response.
223780494|NCT00949247|OTHER|laboratory biomarker analysis|Tumor tissue and bone marrow samples may be collected for further laboratory analysis.
223780495|NCT02199847|DRUG|Pharmaton® Caplets|
223780496|NCT02199847|DRUG|Placebo|
223780497|NCT00466193|DRUG|zolpidem tartrate sublingual tablet|3.5 milligram zolpidem tartrate sublingual tablet taken as needed following a middle-of-the-night awakening over the 28-night study period. Participants placed the study drug under the tongue and allowed it to dissolve there for about 2 minutes, then swallowed after dissolved.
223780498|NCT00466193|DRUG|Placebo|Placebo sublingual tablet taken as needed following a middle-of-the-night awakening over the 28-night study period. Participants placed the study drug under the tongue and allowed it to dissolve there for about 2 minutes, then swallowed after dissolved.
223780499|NCT02671487|BEHAVIORAL|Mind-Body Skills Groups|Mind-Body Skills groups consist of small groups of about 8-10 participants who learn and practice meditation, guided imagery, breathing techniques, autogenic training, biofeedback, genograms, and self-expression through words, drawings, and movement.
223780500|NCT05934344|OTHER|Action observation training|The activities proposed will be based on items from the FMA scale (Voluntary movement within synergies, voluntary movement mixing synergies, voluntary movement with little or no synergy, grip, coordination/speed, passive joint movement), and the exercises for the lower limbs will be designed by the authors of the study, based on Vivifrail (32), a multicomponent physical training program for the prevention of deconditioning and falls in older adults. These exercises will be progressive each week, focusing on strengthening, balance, and functional exercises to improve gait. The sessions will last between 20 and 30 minutes, with a frequency of three days per week. The intervention will last for 5 weeks.
223780501|NCT02246998|DRUG|STB|150/150/200/300 mg fixed dose combination (FDC) tablet administered orally once daily with food
223780502|NCT02246998|DRUG|TVD|200/300 mg FDC tablet administered orally once daily with food
223780503|NCT02246998|DRUG|ATR|600/200/300 mg FDC tablet administered orally once daily on an empty stomach at bedtime
223780504|NCT02246998|DRUG|RTV|100 mg tablet administered orally once daily with food
223780505|NCT02246998|DRUG|ATV|300 mg capsule administered orally once daily with food
223780506|NCT02246998|DRUG|ABC/3TC|600/300 mg FDC tablet administered orally once daily with food
223780507|NCT02246998|DRUG|Iohexol|1500 mg solution administered intravenously at baseline, and at Weeks 4, 8, 16, and 24
223780508|NCT02270346|DEVICE|Inspiratory muscle training|"Treatment group received inspiratory muscle training using threshold loading device (POWERbreathe Classic, IMT Technologies Ltd. Birmingham, England) at 40% of maximal inspiratory pressure (MIP).~The MIP was measured at supervised session each week, and 40% of measured MIP value was the new training workload.~The treatment group trained for 30 min-per/day, 7 days/week, for 6 weeks. Six sessions at home and 1 session were performed at department."
223780509|NCT02270346|DEVICE|Sham inspiratory muscle training|"Control group received sham inspiratory muscle training using threshold loading device (POWERbreathe Classic IMT Technologies Ltd. Birmingham, England) at fixed workload, 5% of MIP.~The control group trained for 30 min-per/day, 7 days/week, for 6 weeks. Six sessions at home and 1 session were performed at department."
223780510|NCT05881044|OTHER|Psychiatric interview|"1. Psychiatric interview which include personal identification, present history, past history and family history~2. Complete physical and Neurological Examination.~3. Mini Neuropsychiatric Interview scale. (MINI): to diagnosis psychiatric disorders~4. Symptom checklist 90(SCL 90)~5. Quality of life questionnaire.~6. Hamilton Depression scale.~7. Hamilton Anxiety scale.~8. Socioeconomic scale (A.El.Gilany,A.El.Wehady,and M.EL.Wasify)"
223780511|NCT00164801|DRUG|Baclofen, Diltiazem|
223780512|NCT05093517|DRUG|REMD-477|A biologic glucagon receptor agonist to which randomized subjects are assigned 2:1
223780513|NCT05093517|DRUG|Placebo Subcutaneous injection|Placebo for REMD-477 to which subjects will be randomized 1:2.
223780514|NCT04088097|BEHAVIORAL|Cognitive-Behavioral Therapy for Adolescent Binge/Loss-of-Control Eating|Cognitive-behavioral therapy (CBT) developed for adolescents with binge eating or loss-of-control eating.
223780515|NCT04088097|OTHER|Control Condition|Educational and informational materials on adolescent health and nutrition.
223697092|NCT01522807|DRUG|PF-05190457|100 mg single oral dose of PF-05190457 is administered as a long-duration osmotic capsule in the fasted state
223697093|NCT01522807|DRUG|PF-05190457|100 mg single oral dose of PF-05190457 is administered as a short-duration osmotic capsule in the fed state
223697094|NCT01522807|DRUG|PF-05190457|100 mg single oral dose of PF-05190457 is administered as a suspension in the fasted state
223697095|NCT01522807|DRUG|PF-05190457|100 mg single oral dose of PF-05190457 is administered as a short-duration osmotic capsule in the fasted state
223697096|NCT01522807|DRUG|PF-05190457|100 mg single oral dose of PF-05190457 is administered as a long-duration osmotic capsule in the fasted state
223697097|NCT01522807|DRUG|PF-05190457|100 mg single oral dose of PF-05190457 is administered as a long-duration osmotic capsule in the fed state
223697098|NCT02148107|DRUG|BI 691751|BI 691751 Dose 1
223697099|NCT02148107|DRUG|BI 691751|BI 691751 Dose 2
223697100|NCT02148107|DRUG|BI 691751|BI 691751 Dose 3
223697101|NCT02148107|DRUG|BI 691751|BI 691751 Dose 4
223697102|NCT02148107|DRUG|BI 691751|BI 691751 Dose 5
223697103|NCT02148107|DRUG|BI 691751|BI 691751 Dose 6
223697104|NCT02148107|DRUG|Placebo|Placebo
223697105|NCT00079768|DRUG|Alemtuzumab (Campath)|
223697106|NCT02302534|DEVICE|MRI|MRI
223697107|NCT01649804|DRUG|tocilizumab [RoActemra/Actemra]|8 mg/kg intravenously every 4 weeks for 104 weeks
223697108|NCT01799577|PROCEDURE|Laparoscopic surgery|Two methods will be compare
223697109|NCT00037960|PROCEDURE|Constrained Induced Therapy|
223697110|NCT02883647|DRUG|Entecavir or Tenofovir|Patients in retreatment group receive nucleos(t)ide analogs therapy (Entecavir 0.5mg/d or Tenofovir 300mg/d) again
223697111|NCT06254378|PROCEDURE|Sinus lifting with allograft|Participants will receive sinus lifting and allograft with immediate implant in premolar-molar area.
223697112|NCT06254378|OTHER|Sinus lifting without graft|Participants will receive sinus lifting with immediate implant in premolar-molar area without graft
223697113|NCT03378375|OTHER|nutritional assessement|
223697114|NCT03275792|DRUG|D5-0.9%NS|Admission for intravascular volume expansion
223697115|NCT03275792|DRUG|Routine home oral rehydration|Routine oral fluids as is given at home to all children with acute diarrheal disease
223697116|NCT02456103|DRUG|Ataluren|Ataluren will be provided as a vanilla-flavored powder to be mixed with water or milk.
223697117|NCT01975961|DRUG|Crestor 20mg(Rosuvastatin 20mg), Micardis 80mg(Telmisartan 80mg) , FDC|For co-administration, Crestor 1 tablet and Micardis 1 tablet. For FDC administration, FDC 1 tablet.
223697118|NCT03495037|BEHAVIORAL|Real World Strategy Training|The key features of the protocol are: i. Participants are actively engaged in selecting their treatment goals. The research clinician will work with the participants to identify five specific, measurable real-world goals using a standardized semi-structured interview, the Canadian Occupational Performance Measure. Three of these will be training goals, two will not be trained but evaluated post-intervention for evidence of generalization and transfer to non-trained tasks; ii. A global problem solving approach is used (Goal- Plan- Do- Check). Participants are guided by the trainer to apply this strategy to their goals.
223697119|NCT03495037|BEHAVIORAL|Psychosocial Education|The active comparator uses an information-based format and is designed to engage participants without providing any specific training techniques or strategies. During weekly sessions, participants will receive factual information on brain structure and function, age-related cognitive changes, and general brain health issues and will spend time doing non-specific cognitive exercises including crossword and Sodoku puzzles. Homework will consist of reading assignments related to the session topics.
223697120|NCT03003611|PROCEDURE|hypnose sedation|Patient will be anesthetized with an hypnose sedation and a complement with light anesthesia
223697121|NCT03003611|PROCEDURE|general anesthesia|Patient will be anesthetized with a classical general anesthesia
223697122|NCT03292211|BEHAVIORAL|early mobilization|early out-of-bed activities including supine to sit training, sit on the edge of bed without supporting, standing with hand supporting, stepping while standing etc.within three days after stroke while being monitored by medical equipment.
223697123|NCT03292211|BEHAVIORAL|early standard intervention|Conventional early in-bed activities within three days after stroke
223697124|NCT03149510|BEHAVIORAL|Mobile Application|Participants will use the mobile application daily to assess heart failure symptoms.
223697125|NCT01336296|DRUG|mycophenolic acid|Comparing mycophenolic acid 720mg orally twice daily starting 2 weeks prior to transplant to mycophenolic acid 720mg orally twice daily starting day of transplant.
223697126|NCT03480867|DRUG|Temozolomide|Experimental: Registered one arm study Seven days of pre-operative Radiation+Temozolomide followed by surgery plus TMZ, as adjuvant component.for six cycles.
223697127|NCT03480867|RADIATION|Pre-Operative Radiation|Radiation is given with Temozolomide for 7 days before surgery
223697128|NCT02209831|DEVICE|BIBR 796 BS|single dose
223697129|NCT02209831|DRUG|Pantoprazole|5 days
223697130|NCT02575131|OTHER|whole wheat bread yeast basis|
223697131|NCT02575131|OTHER|Oatmeal|
223697132|NCT02575131|OTHER|Cheerios|
223697133|NCT02575131|OTHER|whole wheat sourdough bread|
223697134|NCT02575131|OTHER|standard breakfast|
223697135|NCT01066403|DRUG|Pergolide|"0,3 mg pergolide (the first two days begin with 0,05mg, then increase of dose of 0,1mg every 3 days for a maximum of 0,3mg/d, taken orally 3x 0,1mg/day). Then stable dose of 0,3mg for one week.. Subsequently slow (for 8 days) reduction of dosage of 0,1mg every 3 days for 6 days then 0,05mg every day for the last two days.~Placebo group is identical in appearance and number of placebo capsules, in the same starting and maintenance scheme as for the pergolide group."
223697136|NCT04108676|DRUG|Fluzoparib|PARP inhibitor
223697137|NCT04108676|DRUG|Omeprazole|proton pump inhibitor
223697138|NCT04504773|BEHAVIORAL|Virtual Reality Exposure Therapy|Participants will receive a single session of virtual reality exposure therapy that targets the participant's specific phobia stimuli.
223697139|NCT03775031|DEVICE|Fractional Laser and Chemical Peel|Fractional 1927 nm Laser, Fractional 1550 nm Laser, and 25% TCA (trichloroacetic acid) peel
223697140|NCT04228393|DRUG|6-mercaptopurine|6-mercaptopurine was administered orally to patients once daily.
223697141|NCT04228393|PROCEDURE|Standard treatment|The initial dose is 50mg/m2. The dose was adjusted according to white blood cells.
223697142|NCT04228393|PROCEDURE|Individualized treatment|The initial dose is determined according to the genotypes of patients combined with Clinical Pharmacogenetics Implementation Consortium (CPIC). The dose was adjusted according to white blood cells, genotypes and the concentrations of 6-TGN in red blood cells.
223697143|NCT04462185|DIAGNOSTIC_TEST|A genomic and transcriptomic landscape analysis|A genomic and transcriptomic landscape analysis will be developed to identify and characterize the transcriptome of benign versus malignant by using RNA sequencing, and to profile cfDNA in blood samples collected from patients with pulmonary nodules.
223697144|NCT03332550|PROCEDURE|Laparoscopic lavage|Operation with laparoscopic lavage for perforated diverticulitis Hinchey 3
223697145|NCT03332550|PROCEDURE|Colon resection|Operation with colon resection for perforated diverticulitis Hinchey 4
223697146|NCT00602173|DRUG|Cilostazol|
223697147|NCT04493580|BEHAVIORAL|iDBT|Electronic DBT sessions designed to mirror in-person DBT.
223697148|NCT04493580|BEHAVIORAL|In-Person DBT|In-person DBT
223697149|NCT02028871|DRUG|Intranasal Insulin|
223697150|NCT02028871|DRUG|Placebo|
223697151|NCT05140850|BIOLOGICAL|neuroimaging examination,neuro-cognitive test,blood pressure,blood sample|neuroimaging will be perform,neuro-cognitive will be tested,blood pressure will be monitored,blood samples will be tested
223697152|NCT02801305|DRUG|Diltiazem Gel 2%|This a topical agent which will be applied on digital ulcers by scleroderma patients.
223697153|NCT02801305|DRUG|Nitroglycerin Ointment 2%|This a topical agent which will be applied on digital ulcers by scleroderma patients.
223697154|NCT02801305|DRUG|Vaseline|This is used as the topical placebo agent.
223697155|NCT02907268|DRUG|onabotulinumtoxinA|OnabotulinumtoxinA (Botox; Allergan) was approved by the FDA in 2002. Intervention administered by study nurse. Intradermal administered in a regular 1 cm2 grid across the cheeks and forehead. Intramuscular administered as per normal practice.
223697156|NCT02907268|DRUG|abobotulinumtoxinA|AbobotulinumtoxinA (Dysport; Galderma) was approved by the FDA in 2009. Intervention administered by study nurse. Intradermal administered in a regular 1 cm2 grid across the cheeks and forehead. Intramuscular administered as per normal practice.
223697157|NCT00125684|DRUG|morphine|
223697158|NCT03258177|OTHER|Virtual Visit|Participants will be given information about how to enroll in virtual care. Participants will use their own camera-enabled device with internet connection to see and speak to the medical professional in real-time and complete the virtual follow-up visit.
223697159|NCT01687036|DEVICE|Cryoablation|Cryoablation of Atrial Fibrillation Using a Novel Cryoablation System
223697160|NCT00457366|DRUG|Quetiapine|Quetiapine 300mg PO/Initial dose and repeat dose at 2 hours if deemed clinically necessary up to a maximum dose of Quetiapine 600mg PO QD
223697161|NCT00457366|DRUG|Haloperidol|given in combination with Lorazepam 2 mg IM, Cogentin 2 mg IM; repeated at 2 hours as deemed clinically necessary
223697162|NCT00457366|DRUG|Lorazepam|given in combination with Haloperidol 5mg IM and cogentin 2mg IM; repeated at 2 hours as deemed clinically necessary.
223697163|NCT00457366|DRUG|Cogentin|given in combination with haloperidol 5mg IM, and Lorazepam 2mg IM; repeated at 2 hours as deemed clinically necessary.
223697164|NCT00823342|DRUG|CLEVUDINE + TENOFOVIR PLACEBO|30 MG
223697165|NCT00823342|DRUG|CLEVUDINE IN ASSOCIATION TENOFOVIR|TENOFOVIR 300 mg qd in association with CLEVUDINE 30 mg qd
223697166|NCT00823342|DRUG|TENOFOVIR + CLEVUDINE PLACEBO|TENOFOVIR 300 mg qd + CLEVUDINE Placebo
223697167|NCT06143774|DRUG|TRX-920 Oral Gel (10 mg and 30 mg)|"TRX-920 Oral Gel will be administered orally at a week (BIW) in an 8-week cycle. No food should be taken 2 hours before and 1 hour after taking TRX-920. The dose escalation/de-escalation rules will be based on definitions of dose-limiting toxicity (DLT) and will be monitored during the first treatment cycle (i.e., the first 4 weeks post the first dose).~The starting dose will be 1 mg and the dosing frequency is twice every week (BIW). Subjects will be assigned to a dose level in sequential cohorts based on the order of their enrollment. The dose escalation will follow a 3+3 design and doses escalate from approximately 1 mg BIW, 2 mg BIW, 4 mg BIW, 8 mg BIW, and 16mg BIW and the doses for subsequent cohorts will be determined by Safety Review Committee (SRC). Dose escalation will be stopped till the maximum tolerated dose (MTD) is reached or identified."
223697168|NCT01916967|DRUG|Desloratadine|Desloratadine 5 mg tablets, given orally, once daily in the evening for 2 weeks
223697169|NCT01916967|DRUG|Placebo|Placebo tablets, given orally, once daily in the evening for 2 weeks
223697170|NCT05323578|OTHER|Survey|Prevalence of safe caffeine consumption among anesthetists
223697171|NCT03456440|DIAGNOSTIC_TEST|MRI|MRI scan of the patients liver with DWI and acquisition of ADC value.
223780516|NCT04344067|DEVICE|Far Infrared Therapy|The WSTM TY101 FIR emitter (WS Far Infrared Medical Technology Co., Ltd., Taipei, Taiwan) was used to conduct FIR therapy in this study. The electrified ceramic plates of the emitter generated electromagnetic waves with wavelengths in the range between 3 and 25 μm (a peak between 5 to 6 μm). The irradiating power density is 10 and 20 milliwatt (mw) /cm2 when the top radiator was set at a distance of 30 and 20 cm above the skin surface respectively.
223780517|NCT05966441|DIETARY_SUPPLEMENT|Curcumin|"The safety of curcumin has been widely demonstrated, and curcumin has a variety of potential pharmaceutical applications. Curcumin exhibits antioxidant, anti-inflammatory and anticancer properties and has been described as neuroprotective against neurological disorders.~Many of curcumin's pharmacological benefits arise from its antioxidant or anti-inflammatory properties. Curcumin appears to have significant potential for treatment of diseases that result from oxidative stress.~Curcumin is provided in soft gelatin capsules each capsule contains 1 g of curcumin and patient is asked to take 2 capsules daily"
223780518|NCT05966441|DRUG|Paclitaxel|"Paclitaxel (PTX), the most widely used anticancer drug, is applied for the treatment of various types of malignant diseases. Mechanisms of PTX action represent several ways in which PTX affects cellular processes resulting in programmed cell death. PTX is frequently used as the first-line treatment drug in breast cancer Paclitaxel dose in adjuvant therapy after doxorubicin and cyclophosphamide every 3 weeks 175mg/m2 IV or Weekly 80 mg/m2 IV..~Paclitaxel dose in neoadjuvant therapy every 3 weeks 175 mg/m2 IV."
223780519|NCT01151670|DRUG|pioglitazone|Pioglitazone 22.5 mg daily before, during and after radiation therapy.
223780520|NCT01151670|DRUG|Pioglitazone|Pioglitazone 45 mg by mouth daily before, during and after radiation therapy
223780521|NCT00856401|DRUG|PTH1-84 in parent study|daily injection of rhPTH(1-84); 25, 50 75, or 100mcg in parent study. In ADD-ON study, there is no intervention, only testing.
223780522|NCT00004179|BIOLOGICAL|rituximab|
223780523|NCT00004179|DRUG|CHOP regimen|
223780524|NCT00004179|DRUG|cyclophosphamide|
223780525|NCT00004179|DRUG|doxorubicin hydrochloride|
223780526|NCT00004179|DRUG|prednisone|
223780527|NCT00004179|DRUG|vincristine sulfate|
223780528|NCT01343082|DRUG|DE-111 ophthalmic solution|
223780529|NCT02554773|DRUG|Fitusiran (SAR439774)|Pharmaceutical form: solution for injection Route of administration : subcutaneous (sc)
223780530|NCT01854554|RADIATION|IMPT|IMPT treatments delivered as once daily fractions, 5 days per week Monday - Friday for 30 treatments.
223780531|NCT01854554|RADIATION|IMRT|IMRT treatments delivered as once daily fractions, 5 days per week Monday - Friday for 30 treatments.
223780532|NCT01854554|BEHAVIORAL|Cognitive Tests|Cognitive tests given at baseline, 4 months, then every 2 months for 2 years.
223780533|NCT01854554|BEHAVIORAL|Questionnaires|Questionnaires about quality of life and symptoms given at baseline, 4 months, then every 2 months for 2 years.
223780534|NCT02819726|BIOLOGICAL|SAIT101|1,000 mg i.v. of SAIT101 on Day 1 and 15. 1,000 mg i.v. of SAIT101 on week 24 and 26 for eligible patients.
223780535|NCT02819726|BIOLOGICAL|MabThera|1,000 mg i.v. of MabThera® on Day 1 and 15. 1,000 mg i.v. of MabThera® on week 24 and 26 for eligible patients.
223780536|NCT02819726|BIOLOGICAL|Rituxan|1,000 mg i.v. of Rituxan® on Day 1 and 15. 1,000 mg i.v. of Rituxan® on week 24 and 26 for eligible patients.
223780537|NCT03499158|OTHER|nerve conduction study|nerve conduction study
223780538|NCT01518205|DEVICE|LDL-apheresis|"The patient of the Arm LDL-apheresis in addition to standard therapy, will undergo a cycle of LDL-apheresis.~LDL-apheresis will be performed with B.Braun Avitum H.E.L.P. System. Apheretic treatment scheme: 10 apheretic sessions carried out as follows: the first 2 with a 3 day distance (i.e. 2 treatments in one week), successively 1 session per week (every 7 days).~To perform the treatment, the forearm surface veins will be punctured by means of 17 Ga needles, as an alternative a two-ways CVC will be used."
223780539|NCT01902017|DRUG|Ketotifen|5 mg PO bid
223780540|NCT01902017|DRUG|Placebo|5 mg placebo PO bid
223780541|NCT01982916|DRUG|AGR tablet|
223780542|NCT01982916|DRUG|Placebo (for AGR tablet and/or Active Comparator)|
223780543|NCT01982916|DRUG|Active Comparator|
223780544|NCT02546245|BEHAVIORAL|Heroes of Knowledge|Participants will play their assigned game(s) on a tablet computer for 1-1.5 hours, 2-3 times per week for 2-4 weeks (to accumulate 6-8 hours of gameplay).
223780545|NCT02546245|BEHAVIORAL|Attention/Time Control Game|Participants will play their assigned game(s) on a tablet computer for 1-1.5 hours, 2-3 times per week for 2-4 weeks (to accumulate 6-8 hours of gameplay).
223780546|NCT05516199|BEHAVIORAL|Antenatal breastmilk expression|Stimulation of the breast by hand/handexpression of breastmilk during pregnancy from week 34
223780547|NCT05516199|BEHAVIORAL|Breastfeeding consultation|60 min standardized breastfeeding consultation with a trained midwife, with focus on practical breastfeeding skills
223780548|NCT02613481|DRUG|Poly-L-Lactic Acid (Sculptra) injection|1 vial of of poly-l-lactic acid (Sculptra) reconstituted in the usual sterile fashion with 7cc of sterile water and 2cc of Lidocaine without epinephrine. The contents of the vial will be injected as deemed appropriate by the certified injector and agreed upon by the study subject.
223780549|NCT03270761|OTHER||
223780550|NCT00058890|DRUG|Gabapentin|Under code, the study drug was started at 100 mg by mouth 3 times a day for 3 days, to be increased, if necessary and in the absence of side effects, by 300 mg every 3 days to a maximum of 2,400 mg daily in divided doses.
223780551|NCT00058890|DRUG|Placebo|
223780552|NCT01100463|DRUG|Cream|Twice daily lotion to prevent HFS
223780553|NCT01100463|DRUG|0.1% Uracil Cream|Twice daily lotion to prevent HFS
223780554|NCT05170698|PROCEDURE|Coaltion excision and arthroereisis|Both done to treat rigid flat foot with talocalcaneal coalition. Talocalcaneal coalition excision and management of rigid pes planovalgus in adolescent
223780555|NCT05170698|PROCEDURE|Coalition excision and corrective osteotomies|Both done to treat rigid flat foot with talocalcaneal coalition. Talocalcaneal coalition excision and management of rigid pes planovalgus in adolescent
223697172|NCT00397566|DRUG|HIV Integrase Inhibitor (BMS-707035)|
223697173|NCT03439943|DRUG|Lixisenatide|Patients randomized in the Lixisenatide group will receive 10μg/day for 14 days and then 20μg/day administered by once-daily subcutaneous injections during 12 months. If patients are unable to tolerable the dose of 20μg/day, this dose can be reduced to 10μg/day
223697174|NCT03439943|DRUG|placebo|Patients randomized in the placebo group will receive the corresponding placebo administered subcutaneously (once daily subcutaneous injection).
223697175|NCT04654884|OTHER|Auricular acupuncture (AA)|The add-on treatment will be administered at the treatment sessions with their caregiver (i.e. registered nurse, psychologist, curator), and at each session the participants receive 5 sterile stainless needles in each outer ear. The needling is standardised according to the NADA-protocol. The needles will remain in the outer ears for approximately 45 minutes, and will be removed by the care giver.
223697176|NCT01590992|BEHAVIORAL|Exposure-based psychotherapy for somatic symptoms|Application of different types of exposure-based psychotherapeutic interventions (behavioral therapy), adapted for subjects with somatic symptoms (Somatoform Disorders/Functional Somatic Syndromes)
223697177|NCT01590992|BEHAVIORAL|Relaxation therapy|Progressive muscle relaxation (Jacobson)
223697178|NCT03701737|OTHER|questionnaires|"* VAS on the feeling of hunger~* Evaluation of food wanting by the Finlayson test~* PREFQUEST Questionnaire~* 24-hour food recall~* Stunkard Questionnaire~* Measurement of daytime sleepiness by Epworth score"
223697179|NCT03701737|DEVICE|wrist actimeter|Actimeter delivery: it is worn on the wrist for 7 days, 24 hours a day.
223697180|NCT03701737|BIOLOGICAL|Blood samples|2 dry tubes of 7 ml of blood collected at each visit for plasma assays (ghrelin, leptin, FGF 21, amino acids including tryptophan, insulin resistance)
223697181|NCT02198872|OTHER|Exercise, Aerobic (Water based)|Patients of this group will be submitted to an aerobic water based physical training
223697182|NCT02198872|OTHER|Land Group|Patients of this group perform physical training on bicycle.
223697183|NCT00284622|PROCEDURE|Arthroscopy|HTO with pre-scope
223697184|NCT03458663|DEVICE|Prevena™ og ACTIV.A.C™ Therapy System.|A vacuum assisted (negative pressure) system, Prevena ™ and ACTIV.A.C ™ therapy system have been developed to maintain drainage on closed incisions. The system also works by altering the cytokine profile locally so that it functions anti-inflammatory, by increasing local growth factors and promoting angiogenesis19. Negative pressure wound management (NPWM) such as Prevena ™ and ACTIV.AC ™ is a widely used tool with many different variations, but the evidence of effect remains sparse and more studies are required20. We believe that in a dry and closed incision such as the one after BCL surgery, in an area exposed to stretching during healing, it must be an advantage of maintaining drainage, reducing the anti-inflammatory response and increasing angiogenesis.
223697185|NCT01551537|OTHER|Cervarix data collection|Safety monitoring: recording of all AEs during the study period using diary cards, follow-up visit or telephone contact.
223697186|NCT01551537|OTHER|Data Collection|All adverse events will be recorded by diary card, follow-up visit or telephone contact.
223697187|NCT02462174|DRUG|Ketamine|0.5 mg/ kg ketamine with bupivacaine by caudal route after anesthesia and before start of surgery.
223697188|NCT02462174|DRUG|Ketamine|0.5 mg/ kg ketamine with bupivacaine will be sprayed around the spermatic cord before wound closure.
223697189|NCT02462174|DRUG|Bupivacaine|1 ml/kg bupivacaine 0.25% (maximum volume = 20 ml) by caudal route
223697190|NCT02462174|DRUG|Bupivacaine|0.3 ml/kg bupivacaine 0.25% will be sprayed around the spermatic cord before wound closure
223697191|NCT00976170|DRUG|GC33(RO5137382)|IV administration at 6 escalating dose levels.
223697192|NCT00976170|DRUG|Sorafenib|Oral administration at 400mg twice daily or 400mg once daily
223697193|NCT04243785|DRUG|BTX-A51|Orally administered capsules available in strengths of 0.5 mg, 1.0 mg, 2.0 mg and 7 mg.
223697194|NCT04243785|DRUG|Azacitidine|Azacitidine will be administered IV or SC 75 mg/m2 QD on Days 1-7 of each 28-day cycle.
223697195|NCT05144204|BEHAVIORAL|Low FODMAP diet|Low FODMAP diet instruction to irritable bowel syndrome patients.
223697196|NCT00568685|DRUG|Atomoxetine Hydrochloride|Patients receive 0.2 mg/kg/day atomoxetine administered orally in two divided doses for the duration of the 6-week acute treatment period
223780556|NCT02773979|DRUG|Chloroquine|Administered as 600mg PO, day 1, 300mg PO days 8, 15, 22.
223697197|NCT00568685|DRUG|Atomoxetine hydrochloride|Patients receive 0.5 mg/kg/day atomoxetine administered orally in two divided doses for the duration of the 6-week acute treatment period
223697198|NCT00568685|DRUG|Atomoxetine hydrochloride|"Patients initially receive atomoxetine 0.5 mg/kg/day administered orally in two divided doses for approximately 7 days. Patients will then receive atomoxetine 0.8 mg/kg/day administered orally in two divided doses for approximately 7 days.~Patients will receive atomoxetine 1.2 mg/kg/day administered orally in two divided doses for the remainder of the study, lasting approximately 28 days"
223697199|NCT00845780|DRUG|withdrawal or continuation of amiodarone therapy|withdrawal or continuation of amiodarone therapy after at least 6 months sinus rhythm maintenance on amiodarone therapy
223697200|NCT02171572|DRUG|Dabigatran etexilate low|
223697201|NCT02171572|DRUG|Dabigatran etexilate high|
223697202|NCT05025254|OTHER|Neurocognitive testing|"We are assessing several cognitive domains and have made minor adaptations (reducing the total number of trials or lengthening response windows) to several standard neuropsychology tests including measures of executive function, working memory, visuospatial function, declarative memory, reward processing, response inhibition.~Overall, the tests we use follow a standard set-up: participants are shown stimuli on the screen and are asked to provide a response using either a keyboard or a mouse, based on a specific set of instructions. We always provide a detailed set of on-screen instructions and a practice phase. In some cases, information about performance is provided in the form of points, in other cases, none is provided."
223697203|NCT00753779|DRUG|colesevelam HCl tablets, and simvastatin tablets|colesevelam HCl tablets, 6/day simvastatin tablet, 1/day
223697204|NCT00753779|DRUG|simvastatin tablets and colesevelam HCl placebo|simvastatin tablet, 1/day; Welchol placebo tablets, 6/day
223697205|NCT04810663|RADIATION|Radiotherapy|Adjuvant Radiotherapy in operated gastric cancer
223697206|NCT02957565|BEHAVIORAL|Baseline Questionnaires|Participant completes 5 questionnaires during an already-scheduled office visit. Questionnaires ask about symptoms, physical and emotional health, and trust in the medical profession. These questionnaires should take about 17 minutes to complete.
223697207|NCT02957565|OTHER|Videos|Participant watches 2 short videos that show actors playing doctor and patient roles, discussing different cancer-related symptom treatment options. Each video is about 4 minutes long and discusses the same content, but setting of each video is different.
223697208|NCT02957565|BEHAVIORAL|Assessment Questionnaires|"After viewing first video, participant completes assessment questionnaire to evaluate their opinion of the physicians behavior. These questionnaires should take about 5 minutes to complete.~After viewing second video, participant completes the same 3 assessment questionnaires. Participant also completes 2 additional questionnaires asking which physician participant would prefer as a primary physician and the satisfaction with health information technology use in their care."
223697209|NCT05530785|COMBINATION_PRODUCT|radiotherapy combined with sintilimab and bevacizumab biosimilar|After signing informed consent, patients received sintilimab 200 mg intravenously on the first day of each cycle, Q3W; Bevacizumab biosimilar 7.5mg/kg was administered intravenously on the first day of each cycle, Q3W; Concurrent radiotherapy (single dose 3-8Gy, times 3-10, total dose 20-50Gy; The duration of radiotherapy was completed between the first administration of sintilimab and the second administration of bevacizumab, but it should be noted that the interval between before and after the administration of sintilimab and bevacizumab was at least 3 days.
223697210|NCT05462470|PROCEDURE|Repeat Liver Surgery|repeat liver surgery included not only hepatectomy, but also ablative treatment, including radiofrequency ablation (RFA) and microwave ablation (MWA)
223697211|NCT05462470|PROCEDURE|Non-Repeat Liver Surgery|Systemic palliative chemotherapy
223697212|NCT02554188|BIOLOGICAL|Seasonal influenza (flu) vaccine|"Seasonal influenza (flu) vaccine~* Fluzone Quadrivalent Vaccine (Sanofi Pasteur), for participants ages 50 - 64 years old~* Fluzone High-Dose (Sanofi Pasteur), for participants ages 65 years and older"
223697213|NCT02554188|OTHER|Diet|A 5-day low calorie fasting-mimicking diet
223697214|NCT02526836|PROCEDURE|Conventional Surgery|removal of the tumor with no ligation of the vessel centrally or removal of the whole mesocolon
223697215|NCT02526836|PROCEDURE|Complete mesocolic excision with central vascular ligation|excision of the whole mesocolon plus ligation of the supplying blood vessel centrally
223697216|NCT00069433|PROCEDURE|Social skills and symptom management training|
223697217|NCT00441454|DEVICE|Transobturator Tension-free vaginal tape (TVT-O)|tension-free vaginal tape (TVT)
223697218|NCT00441454|DEVICE|Retropubic Tension-free vaginal tape (TVT)|Retropubic Tension-free vaginal tape (TVT)
223697219|NCT00074438|DRUG|methotrexate|Oral or parenteral repeating dose
223697220|NCT00074438|DRUG|rituximab|Intravenous repeating dose
223697221|NCT00074438|DRUG|corticosteroids|Intravenous repeating dose
223697222|NCT00074438|DRUG|placebo|Intravenous repeating dose
223697223|NCT02210468|DEVICE|APIC-CF, 4 cc|
223697224|NCT02210468|DEVICE|APIC-CF, 2 cc|
223697225|NCT02210468|OTHER|Placebo Comparator: Saline|Placebo Comparator: Saline
223697226|NCT05693727|DIAGNOSTIC_TEST|pleural markers|Pleural Fluid Adenosine Deaminase,Lactate Dehydrogenase, interferonY, Tumor Necrosis Factor,and Interleukins{2,12,18}
223697227|NCT02038452|DRUG|Depo-Medrone|Steroid Injection
223697228|NCT02038452|DEVICE|Wrist Splint|Simple wrist splint
223697229|NCT02617784|DRUG|Oseltamivir|Oseltamivir will be given as marketed oral suspension, 30 mg after HD or CAPD treatment.
223697230|NCT00859183|DRUG|Sirolimus|cumulative loading dose of 8 mg of oral sirolimus two days prior to and the day of repeat intervention followed by maintenance therapy of 2 mg/day for 7 days
223697231|NCT00859183|DRUG|Sirolimus|cumulative loading dose of 24 mg of oral sirolimus two days prior to and the day of repeat intervention followed by maintenance therapy of 2 mg/day for 7 days
223697232|NCT00859183|DRUG|Placebo|Placebo oral
223697233|NCT04084327|OTHER|stastical analysis|1-Clinical examination data-Complete Blood Count (CBC).Bone Marrow Aspiration (BMA)-Bone Marrow Biopsy (BMB). (if available)-Immunophenotyping results (IPT).Cytogenetic results
223697234|NCT06090591|OTHER|SGLT-2 inh therapy, CIED implantation, thromboaspiration,|long-term follow up and observation of patients treated in Cardiology department in the tertiary center and University hospital
223697235|NCT02366858|PROCEDURE|19 gauge|Evaluate the ability to perform molecular marker or immunohistochemistry studies on tissue procured with a 19 gauge needle
223697236|NCT02366858|PROCEDURE|22 gauge|Evaluate the ability to perform molecular marker or immunohistochemistry studies on tissue procured with a 22 gauge needle
223697237|NCT05689944|BEHAVIORAL|Dance-therapy|"This session will take place once a week between weeks 1 and 15 of the protocol.~* 5 mn of welcome and presentation of the upcoming session~* 5 mn of self-evaluation of the pain as well as of the thymia and the fatigue before the beginning of the session (Visual numerical scales: VNS)~* 15 mn of body warm-up with taught contemporary dance exercises~* 15 mn of creative research based on dance improvisation on a given theme~* 15 mn of sharing for the elaboration of a choreography~* At the end of the session, 5mn of self-evaluation of the pain, the thymia, the fatigue and the level of appreciation of the session (VNS).~After the session, the patient will be asked to think about the next session if he/she wishes (e.g. think of a choreography, remember what was done etc. ....) in order to encourage the commitment to care. These sessions will be based on contemporary dance and dance improvisation techniques."
223697238|NCT05689944|BEHAVIORAL|Art-therapy|"This session will take place once a week between weeks 1 and 15 of the protocol.~* 5 mn of welcome and presentation of the upcoming session~* 5 mn of self-evaluation of the pain as well as of the thymia and the fatigue before the beginning of the session (Visual numerical scales: VNS)~* 10 mn of discovery of a new technique (acrylic painting or collage).~* 35 mn of practice in a project fixed beforehand~* At the end of the session, 5mn of self-evaluation of the pain, the thymia, the fatigue and the level of appreciation of the session (VNS).~After the session, the patient will be asked to think about the next session (e.g. collecting plants for collage....) in order to encourage commitment to the treatment. The sessions will be based on acrylic painting or collage techniques."
223697239|NCT05689944|BEHAVIORAL|Yoga|"This session will take place once a week between weeks 1 and 15 of the protocol.~* 5 mn welcome~* 5 mn of self-evaluation of the pain as well as of the thymia and the fatigue before the beginning of the session (Visual numerical scales: VNS)~* 50 mn of Vinyasa type yoga (warm-up, breathing, balance, strength and flexibility, relaxation)~* 5 mn of closing of the session~* At the end of the session, 5mn of self-evaluation of the pain thanks, the thymia, the fatigue and the level of appreciation of the session (VNS).~These sessions engage the body without entering into a therapy protocol turned towards art as in the two previous interventions."
223697240|NCT05063890|PROCEDURE|Muscle Specific Post Isometric Relaxation MET|3-5 reps of Post Isometric Relaxation MET targeted at muscles of the neck prone to get short
223697241|NCT05063890|PROCEDURE|Movement Specific Post Isometric Relaxation MET|3-5 reps of Post Isometric Relaxation MET targeted at specific movements of the cervical spine
223697242|NCT05063890|PROCEDURE|unilateral postero-anterior glide|3 sets of unilateral posteroanterior glide (10-15 oscillations) at the involved segment
223697243|NCT05063890|PROCEDURE|Heating and TENS|Heating and TENS for 10 minutes
223697244|NCT04307914|RADIATION|External beam radiotherapy|The current standard of care for patients with uncomplicated painful bone metastases is palliative locoregional external beam radiotherapy, often in combination with systemic therapy and analgesics.
223780557|NCT02773979|BIOLOGICAL|PfSPZ (NF54) Challenge|Cryopreserved Plasmodium falciparum (Pf) fully infectious sporozoites (SPZ) that have been developed to be used to infect volunteers in controlled human malaria infection (CHMI) to assess the efficacy of antimalarial drugs and vaccines. The PfSPZ (NF54) Challenge contains a laboratory malaria strain isolated from a Dutch traveler to Africa.
223780558|NCT02773979|OTHER|Placebo|Placebo
223780559|NCT00844194|DRUG|Duloxetine 60 mg QD|given to (1) all patients week 2-6; (2) all responders of both arms week 7-12
223780560|NCT00844194|DRUG|Duloxetine 60 mg QD|given to (1) all patients week 2-6; (2) all responders of both arms week 7-12
223780561|NCT00844194|DRUG|Duloxetine 30 mg QD|given to (1) all patients for one week as taper in; (2) all patients for taper down (responder for 2 weeks)
223780562|NCT00844194|DRUG|Duloxetine 30 mg QD|given to (1) all patients for one week as taper in; (2) all patients for taper down (responder for 2 weeks)
223780563|NCT00844194|DRUG|Duloxetine 90 mg QD|given to non-responders of both arms from day of notice that 120 mg is not tolerated to week 12 as 60 mg+30 mg Duloxetine QD
223780564|NCT00844194|DRUG|Duloxetine 90 mg QD|given to non-responders of both arms from day of notice that 120 mg is not tolerated to week 12 as 60 mg+30 mg Duloxetine QD
223780565|NCT00844194|DRUG|Duloxetine 60 mg QD|given to (1) all patients week 2-6; (2) all non-responders of both arms for first week of taper down
223780566|NCT00844194|DRUG|Duloxetine 60 mg QD|given to (1) all patients week 2-6; (2) all non-responders of both arms for first week of taper down
223780567|NCT00844194|DRUG|Duloxetine 120 mg QD|given to non-responders of both arms from week 7-12 as 2x60 mg Duloxetine QD, if tolerated
223780568|NCT00844194|DRUG|Duloxetine 30 mg QD|given to (1) all patients for one week as taper in; (2) all patients for taper down (non-responder for the second week of taper down)
223780569|NCT00844194|DRUG|Duloxetine 30 mg QD|given to (1) all patients for one week as taper in; (2) all patients for taper down (non-responder for the second week of taper down)
223780570|NCT00844194|DRUG|Duloxetine 120 mg QD|given to non-responders of both arms from week 7-12 as 2x60 mg Duloxetine QD, if tolerated
223780571|NCT02879461|PROCEDURE|LUMBAR DESCOMPRESSION|ATRODESIS AND DESCOMPRESSIO OFF VERTEBRAL CANAL
223780572|NCT00803023|DRUG|Sodium Oxybate|4.5 grams per night taken in two equally divided doses
223780573|NCT00803023|DRUG|Sodium Oxybate & 6 Tablets|4.5 grams taken as a combination of liquid and 6 Placebo tablets in two equally divided doses per night
223780574|NCT00803023|DRUG|Sodium Oxybate & 8 Tablets|6 grams taken as a combination of liquid and 8 Placebo tablets in two equally divided doses per night
223780575|NCT00803023|DRUG|Sodium Oxybate Oral Solution (6 grams)|6 grams per night taken in two equally divided doses
223780576|NCT02647658|BEHAVIORAL|Guideline Based Care plus Psychologically Informed Physical Therapy|PCP care is enhanced with a prompt referral to physical therapy (PT) that includes psychologically informed coaching directed towards education and reduced fear of movement
223780577|NCT02647658|BEHAVIORAL|Guideline Based Care (GBC)|Management decisions are made between PCPs and patients with the guidance of best evidence but with no specific directives
223697245|NCT04307914|PROCEDURE|MR-HIFU|MR-HIFU is a non-invasive treatment modality that delivers acoustic energy to heat tissue to ablative temperatures of more than 60°C. The combination of focused ultrasound with magnetic resonance imaging (MRI) enables physicians to perform localized tumor tissue ablation, with real-time temperature monitoring using magnetic resonance (MR) thermometry.
223697246|NCT06356090|BEHAVIORAL|Supportive Parenting for Anxious Childhood Emotions (SPACE)|SPACE is a parent-based treatment (parent-stand-alone treatment) for parents of youth with anxiety symptoms or OCD. The manualized treatment protocol contains 12 sessions, in which parents are taught to reduce family accommodation (FA) and to increase supportive responses to their child.
223697247|NCT00959712|BEHAVIORAL|ECA Interaction|The technology uses a computer character (Embodied Conversational Agent (ECA)) that simulates face-to-face conversation. The ECA talks to the patient and the patient responds by tapping a touch-screen.
223697248|NCT04964843|DRUG|N-acetylcysteine|N-acetylcysteine is an FDA approved medication that is used to treat acetaminophen overdose.
223697249|NCT04964843|DRUG|Placebo|Placebo
223697250|NCT02637336|DEVICE|Acupuncture|Acupuncture in point 6 of the pericardium channel (neiguan) bilaterally
223697251|NCT02637336|DEVICE|Aerobic exercise|aerobic exercise of moderate intensity
223697252|NCT02637336|DEVICE|Aromatherapy|inhalation of eucalyptus essential oil
223697253|NCT04940208|OTHER|Pain and neuropsychological questionnaires|Patient-reported outcomes, listed in the Secondary Outcome Measure Section
223697254|NCT04940208|DIAGNOSTIC_TEST|Quantitative Sensory testing|Summation pain threshold test and Heat pain threshold skin test
223697255|NCT03130491|PROCEDURE|Transcatheter Aortic Valve Replacement (TAVR)|placement of a filter to capture and remove embolic material from entering the cerebral vascular circulation during aortic valve replacement
223697256|NCT03130491|DEVICE|EMBLOK filter|Embolic Filter Protection System During TAVR
223697257|NCT04326959|BIOLOGICAL|Umbilical Cord-Mesenchymal Stem Cells and Conditioned Medium|Injection of Allogeneic Umbilical Cord Mesenchymal Stem Cells 2 million cell/cm3 in Nacl 1 cc/million cell and booster with Conditioned Medium 1 cc/cm3 in 3 weeks later. All treatment via intralesional injection. The maximum size of the keloid is 15 cm.
223697258|NCT04326959|BIOLOGICAL|Conditioned Medium|Injection of Conditioned Medium 1 cc/cm3 and booster with Conditioned Medium 1 cc/cm3 in 3 weeks later. All treatment via intralesional injection. The maximum size of the keloid is 15 cm.
223697259|NCT04326959|BIOLOGICAL|Triamcinolone Acetonide|Injection of Triamcinolone Acetonide 40 mg/cc/cm3 and booster in 3 weeks later. All treatment via intralesional injection. The maximum size of the keloid is 15 cm.
223697260|NCT04515927|DRUG|JS002|Biological: JS002 Administered by subcutaneous injection
223697261|NCT03589781|DIETARY_SUPPLEMENT|Mikei Red Reishi Essence EX|Dosage is 490 mg per capsule, 3 capsules twice a day with food or water. Total of 6 capsules per day.
223697262|NCT03589781|DIETARY_SUPPLEMENT|Placebo|Matching placebo. Consume 3 capsules twice a day with food or water. Total of 6 capsules per day.
223697263|NCT05689697|DIETARY_SUPPLEMENT|PanTrek|administration of exogenouse keton body
223697264|NCT02864719|OTHER|Energy Conservation+Problem Solving Therapy|The intervention was delivered by telephone. Each EC+PST intervention session was planned to last approximately 45 minutes and occur twice a week for up to 4 weeks. Sessions terminated when the participants identified and solved two fatigue-related problems of their choice or had participated in the intervention for eight sessions. A Participant Workbook was used throughout the intervention. During eight intervention sessions, participants identified two fatigue-related problems and solutions for them, implemented the solution plans, and reviewed the implementations.
223697265|NCT03956381|DEVICE|Primary Total Hip Replacement with Trinity cup and TriFit TS stem via posterolateral surgical approach.|The participant will undergo surgery using the hip prostheses and surgical approach used by their surgeon Investigator. A patient specific femoral guide, generated by the OPS™ plan preoperatively, will be used during the surgical step of femoral neck resection. These are not study specific procedures as the OPS™ system is already in use by the surgeon Investigator in their standard of practice.
223697266|NCT03956381|DEVICE|Primary Total Hip Replacement with Trinity cup and MetaFix stem via direct anterior surgical approach|The participant will undergo surgery using the hip prostheses and surgical approach used by their surgeon Investigator. A patient specific femoral guide, generated by the OPS™ plan preoperatively, will be used during the surgical step of femoral neck resection. These are not study specific procedures as the OPS™ system is already in use by the surgeon Investigator in their standard of practice.
223697267|NCT04336410|DRUG|INO-4800|INO-4800 will be administered ID on Day 0, Week 4 and at the optional Booster Dose Visit.
223697268|NCT04336410|DEVICE|CELLECTRA® 2000|EP using the CELLECTRA® 2000 device will be administered following ID delivery of INO-4800 on Day 0, Week 4 and at the optional Booster Dose Visit.
223697269|NCT02290327|DRUG|Pantoprazole|Proton pump inhibitor
223697270|NCT02290327|DRUG|Placebo|50 ml of 0.9% normal saline
223697271|NCT05268107|DRUG|Dupilumab|"Patients will be treated with dupilumab for 4 months (standard FDA-approved dosing of 600 mg subcutaneously at baseline/week 0, followed by 300 mg every 2 weeks).~Skin biopsies will be assessed at baseline (lesional and non-lesional), week 2 (lesional), and week 16 (lesional). In addition, blood will be obtained at baseline and week 16."
223697272|NCT02434367|BEHAVIORAL|Walk With Ease Arm A|Walk With Ease is the Arthritis Foundation's evidence-based walking intervention to help with fatigue and pain. The interention is a self directed program that helps guide participants in a safe and comfortable paced walking program with an ultimate goal of walking for 30 minutes per day, five days per week.
223697273|NCT06298890|DEVICE|Artificial tears (sodium hyaluronate 0.2%)|Patients randomised into Ist study group will use artificial tears 7 days before the cataract surgery 4 times a day and they will continue to use them after surgery for 3 months.
223697274|NCT01369160|BEHAVIORAL|Quality of Life measures|measuring QOL with different therapies
223780578|NCT01542528|BEHAVIORAL|IBBS|Combination of computer-presented brain exercises with a physical education curriculum designed to enhance sustained attention, inhibitory control and other executive capacities. Groups of 10 students incorporating the Good Behavior Game. Two-hour sessions four days a week: classroom with computers (45-60 mins) plus sports activities in the gymnasium (45-60 mins) extending over a total 15 weeks (60 sessions).
223780579|NCT01267071|DRUG|A|GSK962040 (50 mg, SD, oral)
223697275|NCT05199493|DRUG|Angiotensin II|Patients with Delta-renin \>= 3.7 micro-unit/mL are at high risk for AKI. Patients who have a high delta-renin and a postoperative hypotension requiring vasopressors ad will be randomized. After randomization patients will receive intravenous infusion with the investigational drug.
223697276|NCT05199493|DRUG|Control|Patients with Delta-renin \>= 3.7 micro-unit/mL are at high risk for AKI. Patients who have a high delta-renin and a postoperative hypotension requiring vasopressors ad will be randomized. After randomization patients will receive intravenous infusion with placebo
223697277|NCT01841177|DRUG|Milrinone|Milrinone is a potent selective phosphodiesterase (PDE) type III inhibitor which stimulates myocardial function (inotropy), causes peripheral vasodilatation (afterload reduction) and improves myocardial relaxation (lusitropy).
223697278|NCT05215990|DRUG|MetFORMIN 500 Mg Oral Tablet|studying about acid-fast bacillus sputum conversion ratio from positive to negative of pulmonary tuberculosis patients receive metformin with pulmonary tuberculosis standard treatment group in second week, second, fifth, and sixth month.
223697279|NCT05215990|DRUG|Placebo|studying about acid-fast bacillus sputum conversion ratio from positive to negative of pulmonary tuberculosis patients receive placebo drug with pulmonary tuberculosis standard treatment group in second week, second, fifth, and sixth month.
223697280|NCT03986151|PROCEDURE|Coronary angiography +/- percutaneous coronary intervention|Comparison of the conventional radial approach with the distal radial approach (anatomical snuffbox)
223697281|NCT03325088|PROCEDURE|Bronchial endoscopy|Bronchial endoscopy will be performed after clinical examination and pulmonary function tests
223697282|NCT03325088|PROCEDURE|Bronchial biopsies|5 biopsies will be done and analysed at the end of recruiting to assess monomeric GTP Rac1 protein expression and activity on bronchial biopsies
223697283|NCT03325088|PROCEDURE|Bronchial alveolar enema|For participants who had signed ancillary research consent
223697284|NCT01739673|OTHER|Ultraviolet-A and riboflavin|
223697285|NCT00017017|DRUG|paclitaxel poliglumex|
223697286|NCT01798680|DIETARY_SUPPLEMENT|Vitamin D3 (cholecalciferol)|Supplements containing 50,000 IU of vitamin D3 (cholecalciferol) taken orally once per week for 4 weeks (weeks 0, 1, 2, 3) followed by 2,000 IU of vitamin D3 (cholecalciferol) supplements taken orally once per day starting at 4 weeks until study discharge at 12 months
223697287|NCT01798680|OTHER|Placebo|Placebo pills taken once weekly for 4 weeks (weeks 0, 1, 2, 3) followed by placebo pills taken orally once per day starting at 4 weeks until study discharge at 12 months
223697288|NCT00126607|BIOLOGICAL|trastuzumab|Given IV
223697289|NCT00126607|OTHER|laboratory biomarker analysis|Correlative studies
223697290|NCT04206007|BIOLOGICAL|UMC119-06|Cohort 1: Low does of UMC119-06 Cohort 2: Medium does of UMC119- 06 Cohort 3: High does of UMC119-06
223697291|NCT06207838|DEVICE|MiniMed 780G system|The MiniMed™ 780G system automatically adjust insulin delivery to patient needs for an easier way to stabilise glucose levels. It features an advance level of automation for diabetes management, known as SmartGuard™ technology. If patient glucose levels are trending high, it gives patient more insulin. Technology is CE marked.
223697292|NCT00614328|DRUG|Naltrexone, Baclofen, Placebo and Behavior Therapy|Naltrexone 50mg/day for 12 weeks Baclofen 10mg tid = 30mg/day for 12 weeks Behavior Therapy 9 sessions
223697293|NCT00957112|PROCEDURE|acupuncture therapy|Patients undergo therapist-acupuncture with or without self-acupuncture
223697294|NCT00957112|PROCEDURE|standard follow-up care|Patients receive standard care
223697295|NCT00703196|DIETARY_SUPPLEMENT|folic acid|Given orally once daily
223697296|NCT00703196|OTHER|placebo|Given orally once daily
223697297|NCT05043558|DRUG|beprostaglandin sodium|beprostaglandin sodium
223697298|NCT03405610|BEHAVIORAL|The Toolkit for Optimal Recovery after Injury|The Toolkit for Optimal Recovery after Injury (ToR) is a skills based mind body program that was designed to prevent the development of chronic pain and disability following an acute musculoskeletal injury (e.g., fracture). The program has 4 sessions and it is delivered via live video. Patients learn myth about recovery after injury, false and real pain alarms, the fear avoidance model and how to prevent the disability spiral, mindfulness based exercises and activity pacing.
223697299|NCT06008028|DRUG|BR1015|One tablet administered alone
223780580|NCT01267071|DRUG|B|14C GSK962040 (100 μg, SD, iv)
223780581|NCT03073616|DEVICE|Lung ultrasound|Lung ultrasound and chest RX
223780582|NCT01597206|DEVICE|Removable partial denture (Chrome Cobalt Distal extension)|For Group A: a distal extension removable denture will be constructed for patients with a reduced posterior dental arch
223780583|NCT01597206|OTHER|A reduced posterior dental arch|For Group B: Patients with a reduced posterior dental arch will not be provided with a removable denture and will be compared to patients in Group A
223697300|NCT06008028|DRUG|BR1015-1|One tablet administered alone
223697301|NCT06008028|DRUG|BR1015-2|One tablet administered alone
223697302|NCT01962831|DRUG|Dinoprostone|
223697303|NCT01962831|DEVICE|Single balloon foley catheter|
223697304|NCT02499978|DRUG|Darunavir/Cobicistat|Fixed dose combination medication
223697305|NCT02499978|DRUG|Dolutegravir|single tablet medication
223780584|NCT01910844|DRUG|Cisplatin|25 mg/m² I.V. from day 1 to day 3 - total dose = 75 mg/m² every 3 weeks
223780585|NCT01910844|DRUG|Cyclophosphamide|Metronomic cyclophosphamide per os 150 mg from day 1 to day 14 - total dose 2100 mg every 3 weeks
223697306|NCT06147453|DEVICE|Aerobika OPEP device|16 week twice daily use of the Aerobika OPEP device
223697307|NCT00160173|DRUG|Estrogel|
223697308|NCT00160173|OTHER|Placebo|
223697309|NCT05635071|DRUG|Nintedanib 100 MG [Ofev]|Nintedanib 100mg bid \*15 days orally after hysteroscopic surgery
223697310|NCT05635071|DRUG|Nintedanib 150 MG [Ofev]|Nintedanib 150mg bid \*15 days orally after hysteroscopic surgery
223697311|NCT04595240|DIAGNOSTIC_TEST|semen analysis|semen analysis
223697312|NCT02969551|DEVICE|Manometry and possibly DISE|A Manometry is performed on all patients. After it in some Patient DISE is followed
223780586|NCT00659165|DRUG|Insulin Detemir|Subjects will be given a dose of detemir equivalent to their current long acting insulin regimen. Study insulin will be injected subcutaneously at 8 AM and 8 PM for at least 3 weeks.
223780587|NCT00659165|DRUG|Insulin Glargine|Subjects will be given a dose of glargine equivalent to their current long acting insulin regimen. Study insulin will be injected subcutaneously at 8 AM and 8 PM for at least 3 weeks.
223780588|NCT05490667|DRUG|Anlotinib|Anlotinib combined with chemotherapy for desmoid tumors
223780589|NCT04077008|PROCEDURE|unilateral drainage of Bilaterally Obstructed Kidneys|drainage of obsructed kidneys by PCN or jj
223780590|NCT04077008|PROCEDURE|bilateral drainage of Bilaterally Obstructed Kidneys|drainage of obsructed kidneys by PCN or jj
223780591|NCT02239458|DRUG|Saxagliptin|
223780592|NCT00125216|BEHAVIORAL|Response Elaboration Training|Therapist modeling, reinforcement and forward-chaining are used to stimulate verbal descriptions of pictures
223780593|NCT04478097|DRUG|CKD-330 Tab. and D086 Tab.|1T
223780594|NCT04478097|DRUG|CKD-333 Tab.|1T
223697313|NCT02069132|DRUG|Warfarin|warfarin treatment will be determined by treating physicians according to in-hospital guidelines, blindly to genotype assessment.
223697314|NCT00756015|OTHER|Early Motion Protocol|Early range of motion group: Shoulder pendulum exercises will be allowed from the time of surgery. Immediate range of motion of the elbow, forearm, wrist and hand. At the first postoperative visit, PROM of the shoulder will be permitted under therapist direction. Patients will avoid IR and behind the back stretching. At 6 weeks, AAROM and AROM will be advanced as tolerated. Capsular stretching will be advanced until full range of motion is achieved. Strengthening activities of the rotator cuff, deltoid and scapular stabilizers will be permitted at 3 months post surgery.
223697315|NCT00756015|OTHER|Immobilization|Immobilization group: 6 weeks of sling shoulder immobilization. Immediate range of motion of the elbow, forearm, wrist and hand. At 6 weeks, PROM and stretching of the shoulder allowed under therapist direction. At 12 weeks, AAROM and AROM exercises will be initiated and capsular stretching advanced until full ROM achieved. Strengthening activities of the rotator cuff, deltoid and scapular stabilizers will be permitted at 4 months post surgery.
223697316|NCT01464944|DRUG|Acetylsalicylic acid (Aspirin, BAYE4465)|Acetylsalicylic acid 500 mg orally, single dose, 1 tablet; in addition, 1 Placebo tablet of Acetylsalicylic acid, and 2 Placebo tablets of Paracetamol
223697317|NCT01464944|DRUG|Acetylsalicylic acid (Aspirin, BAYE4465)|Acetylsalicylic acid 2 x 500 mg orally, single dose, 2 tablets; in addition, 2 Placebo tablets of Paracetamol
223697318|NCT01464944|DRUG|Paracetamol|Paracetamol 500 mg orally, single dose, 1 tablet; in addition, 1 Placebo tablet of Paracetamol, and 2 Placebo tablets of Acetylsalicylic Acid
223697319|NCT01464944|DRUG|Paracetamol|Paracetamol 2 x 500 mg orally, single dose, 2 tablets; in addition, 2 Placebo tablets of Acetylsalicylic Acid
223697320|NCT01464944|DRUG|Placebo|2 Placebo tablets of Acetylsalicylic Acid, and 2 Placebo tablets of Paracetamol, orally, single dose
223697321|NCT02080637|DRUG|Ambrisentan|Once daily oral dosing
223697322|NCT02080637|OTHER|Placebo|
223697323|NCT02091973|DRUG|Everolimus|Everolimus dosing to target tough level 6-10 mg/ml
223697324|NCT02091973|DRUG|Tacrolimus|Tacrolimus dosing to target tough level 5-10 ng/ml
223697325|NCT01090973|DRUG|LBH589|"The LBH589 capsule(s) should be swallowed by mouth with a glass of water (8 ounces noncarbonated) in the morning. The daily dose of LBH589 should be taken at approximately the same time each day. Patients should avoid eating grapefruit, Seville (sour) orange or drinking grapefruit juice or Seville orange juice during the study.~After 2 cycles of treatment, if patients do not demonstrate a partial response or complete response (all of the tumor is gone) to the therapy they will be removed from the study. If patients do obtain a partial (the tumor(s) have decreased in size or number but there are still tumors present) or complete response then treatment will continue until their disease progresses."
223697326|NCT05239260|DIAGNOSTIC_TEST|CMR|CMR
223697327|NCT03648827|DRUG|Ataluren|Ataluren will be administered as per the dose and schedule specified in the arm.
223697328|NCT03401736|DEVICE|Mechanical Ventilation|Whether midazolam and dexmedetomidine have an effect on the diversity of intestinal microbiota or not is still unknown，especially the patient who requires the mechanical ventilation.
223697329|NCT03401736|DRUG|Midazolam|The impact of Midazolam on the diversity of intestinal microbiota.
223697330|NCT03401736|DRUG|Dexmedetomidine|The impact of dexmedetomidine on the diversity of intestinal microbiota.
223697331|NCT04252365|DRUG|Sintilimab|Given i.v.
223697332|NCT04252365|DRUG|Pembrolizumab|Given i.v.
223697333|NCT02854150|GENETIC|characterization of variants in new genes using high throughput sequencing either on a panel of targeted genes or on exome in families.|
223697334|NCT03132012|BEHAVIORAL|Indoor tanning intervention|6 Web-based modules that focus on preventing skin cancer through sun protection and indoor tanning reduction using the Theory of Planned Behavior and Prospect Theory
223697335|NCT03132012|BEHAVIORAL|Standard of care control|One website with content similar to those available in dermatology offices on skin cancer prevention
223697336|NCT02054377|OTHER|Tai chi|"Tai Chi, a Chinese form of mindful exercise, may help alleviate CF symptoms, encourage active self-management and provide a practical way to relieve and manage stress for patients and carers. It involves gentle physical exercises, combined with breathing techniques and mindful awareness.~It will be taught by qualified instructors either face to face in the participant's home or over videoconferencing technology e.g. Skype.~A DVD of the Tai Chi was developed in Phase 1 which was successful for teaching adults, and will be used here, along with a child-friendly DVD. This will be filmed with and aimed at children aged 6-18. Teaching support materials, incorporating child-specific guidance such as animal-based Tai Chi movements, will be prepared for use in conjunction with the DVD."
223697337|NCT03835910|BEHAVIORAL|Social Incentives and Gamification to Promote Exercise|The intervention will provide social incentives and gamification to promote physical activity.
223697338|NCT03835910|PROCEDURE|Corticosteroid Injection given in A-B order|The study will compare corticosteroid injections with lidocaine to lidocaine only in a crossover design. These participants will receive the medication in A-B order.
223697339|NCT03835910|BEHAVIORAL|No Social Incentive applied|No social incentive will be applied
223697340|NCT03835910|PROCEDURE|Corticosteroid Injection given in B-A order|The study will compare corticosteroid injections with lidocaine to lidocaine only in a crossover design. These participants will receive the medication in B-A order.
223697341|NCT04317976|OTHER|paralaryngeal pressure|cricoid pressure with paralaryngeal pressure by fingertips applied under ultrasound guidance
223697342|NCT04317976|OTHER|cricoid pressure|cricoid pressure by fingertips applied under ultrasound guidance
223697343|NCT03109054|DIAGNOSTIC_TEST|State-Trait Anxiety Inventory Test|All patients will take a State-Trait Anxiety Inventory Test. After the test patients will enroll low or high anxiety level.
223697344|NCT03848104|OTHER|bone and joint infection treated with cefoxitin|the patients had cefoxitin in combination in continuous parenteral administration to treat their bone / joint infection
223697345|NCT01626495|BIOLOGICAL|CART-19|Day 0: 10% of total dose Day 1: 30% of total dose if patient is stable (no significant toxicity) from prior dose.
223697346|NCT01149811|DRUG|Fipamezole ODT|Subjects will receive fipamezole ODT 15 mg three times daily for 1 week followed by fipamezole ODT 30 mg three times daily for 1 week, followed by a 2-week washout period. Beginning at Visit 5, subjects will receive fipamezole ODT 30 mg three times daily for 2 weeks.
223780595|NCT01764334|DEVICE|Fractional flow reserve|"Guidewire-based coronary pressure measurement of myocardial FFR can identify obstructive coronary lesions in patients with stable coronary disease, and potentially, medically stabilized patients with recent MI. The FFR index is measured by a conventional coronary wire (0.014) with a pressure sensor on its distal tip during coronary hyperemia induced by intravenous or intracoronary adenosine. The potential diagnostic and prognostic benefit of guidewire-based coronary pressure measurement to inform the management and treatment of patients with recent acute NSTEMI will be assessed."
223780596|NCT06460623|OTHER|external mobilization|two 5-minute sessions of external manipulation per week over a 5-week period.
223780597|NCT06460623|OTHER|rectal coccygeal mobilization|consisted of two 5-minute sessions of external manipulation per week over a 5-week period.
223780598|NCT03736200|OTHER|Exergaming group|Neurorehabilitation - 4-week-long intervention, targeted postural instability and mobility using at-limit intensity sensori and visuomotor agility training. (1/day)
223780599|NCT03736200|OTHER|Physiotherapy|Physiotherapy 4-week-long.
223780600|NCT03736200|OTHER|Exergaming group 2/day|Neurorehabilitation - 4-week-long intervention, targeted postural instability and mobility using at-limit intensity sensori and visuomotor agility training. (2/day)
223780601|NCT05036148|OTHER|Data analysis|MH registry data will be screened for MH positive diagnosis
223780602|NCT00618657|DRUG|Carboplatin|Given IV
223780603|NCT00618657|DRUG|paclitaxel albumin-stabilized nanoparticle formulation|Given IV
223780604|NCT00618657|DRUG|bevacizumab|Given IV
223780605|NCT00618657|DRUG|trastuzumab|Given IV
223780606|NCT00618657|PROCEDURE|magnetic resonance imaging|Optional correlative studies
223780607|NCT00618657|PROCEDURE|therapeutic conventional surgery|Post-chemotherapy surgery for patients with a response or stable disease must take place no sooner than 21 days after last dose of Herceptin; and 40 days after last dose of bevacizumab to allow for normalization of blood counts
223780608|NCT03890341|DRUG|Drospirenone/Ethinylestradiol|A single oral dose of drospirenone/ethinylestradiol 3 mg/0.02 mg (OC) tablets will be administered on Days 1, 13 and 19.
223780609|NCT03890341|DRUG|Midazolam|Midazolam 2 mg will be administered orally on Days 1, 13 and 19.
223780610|NCT03890341|DRUG|JNJ-64530440|A single oral dose of JNJ-64530440 2,000 mg will be administered on Day 6 and once daily on Days 13 to 22.
223780611|NCT01190241|DRUG|desatinib or sunitinib or erlotinib or everolimus or lapatinib or sorafenib|The drug will be selected based on ex vivo test on the tumor tissue. The patients will be treated with the selected drug until disease progression.
223780612|NCT02125058|PROCEDURE|Transcutaneous sutures|Conventional excision followed by subcutaneous sutrues and transcutaneous sutures
223780613|NCT02125058|PROCEDURE|Intracutaneous sutures|Conventional excision followed by subcutaneous sutrues and intracutaneous sutures
223780614|NCT03956303|DRUG|Chirocaine %0.5|Levobupivacaine 8 mg Chirocaine (% 0.5) +20 mcg fentanyl
223780615|NCT03956303|DRUG|Chirocaine Heavy 40|Chirocaine (%0.75) + Dextrose 40 mg+20 mcg fentanyl
223780616|NCT03956303|DRUG|Chirocaine Heavy 60|Chirocaine (%0.75) + Dextrose 60 mg+20 mcg fentanyl
223780617|NCT03956303|DRUG|Chirocaine Heavy 80|Chirocaine (%0.75) + Dextrose 80 mg+20 mcg fentanyl
223780618|NCT05140278|DRUG|Argesun 60mg (1 step parenteral artesunate)|Each vial of powder contains 60mg artesunate. Each ampoule of 6 ml solvent contains: sodium bicarbonate 8.4mg/ml; arginine 20mg/ml.
223780619|NCT05140278|DRUG|Artesun 60mg (2-step parenteral artesunate)|Each vial of powder contains 60 mg artesunate. Each ampoule of 1 ml solvent contains 50 mg sodium bicarbonate. Each ampoule of 5 ml diluent contains 45 mg sodium chloride.
223780620|NCT03984266|DIAGNOSTIC_TEST|NGS panel|A next-generation-sequencing panel, which contains a group of genes that specifically cause disease, for mutational analysis in newborns.
223780621|NCT04718246|OTHER|Dental Implants Placed In hyperlipidemia patients|"A preoperative cone beam CT (CBCT) will be performed for each patient prior to the surgery.~Surgical phase (T0):~After local anesthetics, all osteotomies will be prepared by the same operator, using a drilling speed of 1200 rpm, under copious irrigation with normal saline.~* Penetration of cortical bone will be achieved with no. 6 round burs.~* The osteotomies will be widened, using a drill 1 mm larger than the final drill provided by the manufacturer. The final size of the control osteotomies were same diameter of the implant.~* Periotest® will measure initial implant stability. Implant site exposure will take place 6 months following the implant placement. Insertion of the healing collars in order to obtain adequate soft tissue form for 1-2 weeks"
223780622|NCT01790750|DEVICE|PES first, then FFES|A 5-minute Pocket echocardiography system scan (PES) scan will be performed to detect PDA on neonates. This scan will be followed by a Full Featured Echocardiography System Scan (FFES) and scan results will be compared.
223780623|NCT01921348|DEVICE|acupressure pellets|The treatment group will have acupressure pellets placed in pre-determined acupressure point on the ear that relates to rhinitis.
223780624|NCT01921348|DEVICE|acupressure pellets|The sham group will have acupressure pellets placed in a pre-determined non-specific acupressure point on the ear that is not related to rhinitis.
223780625|NCT01129310|DRUG|Irinotecan-Capecitabine-Oxaliplatin|Irinotecan-160mg/m2 IV infusion over 60-90 min on Day 1 Capecitabine-1900mg/m2 daily PO in divided doses (=950mg/m2 BID) on days 2-15 Oxaliplatin- 100mg/m2 IV infusion over 2 hours Day 1
223780626|NCT04273958|DEVICE|Virtual reality helmet|During a painful procedure, the patient will watch a virtual world in a virtual reality helmet, while wearing a noise-canceling headset with soothing music.
223780627|NCT04273958|DEVICE|Computer screen|During a painful procedure, the patient will watch the same virtual world, while wearing a noise-canceling headset with the same soothing music.
223780628|NCT04462796|DIETARY_SUPPLEMENT|Magnesium Citrate|Magnesium Citrate 200 mg daily
223780629|NCT00452634|DRUG|Irinotecan|Irinotecan 65mg/m2/iv over 90min on day 1 and 8, repeat Q 3weeks. until disease progression, unacceptable toxicity or patients' refusal.
223780630|NCT00452634|DRUG|Cisplatin|Cisplatin 30mg/m2/iv over 30min on day 1 and 8, repeat Q 3weeks. until disease progression, unacceptable toxicity or patients' refusal.
223780631|NCT00452634|DRUG|Simvastatin|simvastatin 40mg/QD, PO, daily, every 3 weeks
223780632|NCT01177111|OTHER|Sunflower seed oil|Locally manufactured refined sunflower seed oil will be provided to pregnant women late in pregnancy and community workers will promote its daily use during massage of newborns during the first month of life
223780633|NCT01177111|OTHER|Mustard seed oil|Locally manufactured mustard seed oil will be provided to pregnant women late in pregnancy and community workers will promote its daily use during massage of newborns during the first month of life
223780634|NCT05286918|PROCEDURE|The intervention (CRP-guided) group|"The attending doctor will use the CRP level to inform their decision to continue antibiotics around 3 hours from blood taking. These doctors will be provided pre-study training on CRP interpretation.~Every day from randomization, serum CRP testing will be encouraged to take. Once CRP has declined to \<5mg/dL and the patient has remained afebrile for past 48 hours, antibiotic treatment will be reviewed for discontinuation. Otherwise, antibiotic treatment will be continued. A switch on the administration route, or a change of antibiotics due to adverse effect, allergy, or suggestion from culture result, is permitted according to in-patient physician's decisions. CRP will continue to be monitored daily upon discharge from that hospital (up to 28 days)."
223697347|NCT01149811|DRUG|Fipamezole ODT Cohort 2|Subjects will receive fipamezole ODT 30 mg three times daily for 2 weeks, followed by a 2-week washout period. Beginning at Visit 5, subjects will receive fipamezole ODT 15 mg three times daily for 1 week followed by fipamezole ODT 30 mg three times daily for 1 week.
223697348|NCT04324931|OTHER|Biomechanical corrections|Biomechanical corrections is to be done to correct the varus deformity of knee joint and for pain management.
223697349|NCT04324931|OTHER|Conventional Physiotherapy|Conventional therapy includes Hydrocollatoral pack for 20 minutes, Interferential therapy for 15 minutes beat frequency 100 Hz, Sweep frequency 150 Hz and exercise program of 3 sessions for 20 minutes on alternative days for 3 weeks for management of knee osteoarthritis.
223697350|NCT03949985|OTHER|Tests of biological hemostatic profile associated with contraceptives|Tests of biological hemostatic profile associated with contraceptives will be done before and after having stopped an estrogenic contraceptive (group 1) and during the non-use of an estrogenic contraceptive (group 2)
223697351|NCT04290312|OTHER|Mastiha oil|After overnight fasting, the authorized study staff inserted a plastic cannula in an arm vein of the volunteers in order to minimize discomfort during consecutive blood sampling. A blood sample was collected on time point 0h and then the volunteers consumed 1mL of MO. The dose selection was based on the study of Papada et al. (2017) who administered healthy volunteers with 10g of Mastiha (containing \~10% MO). Afterwards blood samples were collected on time points 0.5h, 1h, 2h, 4h, 6h and 24h after MO intake, and were centrifuged at 3000rpm for 10 minutes at 4◦C for plasma and serum isolation. All samples were stored at -80◦C until further analysis.
223697352|NCT01451580|DRUG|Lipo-Dox|
223697353|NCT03298373|DRUG|Placebo|Placebo capsules that look like the 11β-MNTDC capsules but with no active ingredients.
223697354|NCT03298373|DRUG|11β-methyl-nortestosterone-dodecylcarbonate|11β-MNTDC doses in castor oil/benzyl benzoate capsules (100 mg each) administered in 200 mg or 400 mg doses orally.
223780635|NCT06149260|DRUG|Semaglutide Pen Injector|Inject semaglutide subcutaneously once weekly, on the same day each week, at any time of day, in a dose increasing mode: the initial dose of 0.25mg QW (once a week), increased to 0.5mg QW after 4 weeks, and then maintained 0.5mg until the end of treatment in total 24 weeks.
223780636|NCT00793416|DEVICE|Shunt flow detection|Shunt flow detection based upon ShuntCheck results compared to radionuclide test results
223697355|NCT02808377|OTHER|Surgical Pelvic Organ Pessary|In participants randomized to intervention, the SPOP will be placed at the completion of surgery, following routine placement of IDC and prior to placement of vaginal pack. The SPOP is available in 4 sizes and the surgeon will select the appropriate size so that the SPOP rests snugly without undue tension inside the hymeneal remnant. The SPOP is sutured in place with 2/0 Vicryl to prevent dislodgement at the level of the hymen.
223697356|NCT04171284|DRUG|SCT-I10|200 mg, Q3W, maximum treatment up to six cycles
223697357|NCT04171284|DRUG|Docetaxel|70-75mg per square meters of body surface area, Q3W, maximum treatment up to six cycles
223697358|NCT04171284|DRUG|Placebo|200 mg, Q3W, maximum treatment up to six cycles
223697359|NCT02368704|OTHER|No intervention|
223697360|NCT00650234|DRUG|Metformin Hydrochloride ER Tablets 500 mg|500mg, single dose fasting
223697361|NCT00650234|DRUG|Glucophage® XR Tablets 500 mg|500mg, single dose fasting
223697362|NCT05625893|RADIATION|PBT and atezolizumab/bevacizumab|"Atezolizumab 1200 mg and bevacizumab 15 mg/Kg is administered IV infusion every 3 weeks.~Proton beam therapy 30 - 50 Gy/5 fractions to portal vein tumor thrombosis with or without main primary tumor after 1 week (+/- 7 days) of 2nd cycle of atezolizumab and bevacizumab~The follow-up phase begins when the decision to discontinue study is made. The follow-up phase is defined as the day after the end of study treatment until the day the subject dies."
223697363|NCT03084510|DEVICE|Lotus Edge™ Valve System|"• The Lotus Edge™ Valve System consisting of two main components:~* a bioprosthetic bovine pericardial aortic valve, and~* a delivery system Device sizes include 23 mm, 25 mm and 27 mm diameter."
223697364|NCT00384254|BEHAVIORAL|5 A|Dental providers are trained to provide Ask, Advise, Assess, Assist and Arrange to all tobacco using patients. Written materials are provided, including information on local cessation resources, pharmacotherapy and tobacco quitlines.
223697365|NCT00384254|BEHAVIORAL|3 A|Providers are trained to provide Ask, Advise and Arrange intervention to all tobacco using patients. Written materials, prescription for NRT and a Fax-to-Quit referral are provided.
223697366|NCT05969431|DIAGNOSTIC_TEST|measurement of cortisol level|We will measure the cortisol level from the hair sample of the father at three time points. Furthermore the father will answer questionnaires at three time points and the paternal sensitivity is measured once.
223697367|NCT02660931|OTHER|AKI Risk Notification|When a patient's calculated acute kidney injury risk exceeds the threshold value, the electronic medical record will notify the provider of the risk and that appropriate screening (BMP including serum creatinine) may be indicated.
223697368|NCT03572751|DIAGNOSTIC_TEST|Bed-, wrist- and ECG-sensor monitoring|Bed-, wrist- and ECG-sensor monitoring
223697369|NCT03126903|DEVICE|KeraKlear Non-Penetrating Keratoprosthesis|The KeraKlear is a flexible non-penetrating artificial cornea designed to be implanted through small corneal incisions in subjects with corneal opacity.
223697370|NCT03643159|COMBINATION_PRODUCT|Abilify MyCite - Digital Medicine System|The Abilify MyCite system is a drug-device combination product comprised of aripiprazole (an atypical antipsychotic) tablets embedded with a sensor that communicates with a patch (wearable sensor) and a medical software application with collected information (ingestion, mood, activity, rest) tracked and summarized for participants, healthcare providers, and potential caregivers. Abilify MyCite is intended to track drug ingestion and is indicated for the treatment of adults with schizophrenia (SCH), bipolar 1 disorder (BP1) (acute treatment of adults with manic and mixed episodes or maintenance treatment of adults), and adjunctive treatment of adults with major depressive disorder (MDD).
223697371|NCT03643159|DRUG|Aripiprazole or other oral antipsychotics|For the treatment of adults with SCH, BP1 (acute treatment of adults with manic and mixed episodes or maintenance treatment of adults), and adjunctive treatment of adults with MDD.
223697372|NCT01828879|DRUG|Tacrolimus|Tacrolimus ointment, 0.1 percent will be applied twice daily, in adult population for 4 weeks or until 1 week after the affected areas defined for treatment at baseline are completely cleared, whichever is first.
223697373|NCT01056731|DRUG|Aliskiren and HCTZ|Aliskiren 150 mg and 300 mg Hydrochlorothiazide 12.5 mg and 25 mg
223697374|NCT03504670|PROCEDURE|Early Amniotomy|This intervention involves using an amniotomy hook to rupture the membranes during a sterile vaginal exam. This intervention will be performed prior to the cervix being dilated 4cm.
223697375|NCT03504670|PROCEDURE|Late Amniotomy|This intervention involves using an amniotomy hook to rupture the membranes during a sterile vaginal exam. This intervention will be performed once the cervix is at least 4cm dilated.
223697376|NCT00000663|DRUG|CD4-IgG|
223697377|NCT00000432|BEHAVIORAL|Education about disease prevention|
223697378|NCT02520661|BEHAVIORAL|Care Transitions Intervention|The Care Transitions Intervention uses coaches, in this case paramedics, to support patients being discharged home by transferring skills to activate patients.
223697379|NCT02165371|BEHAVIORAL|Sinovuyo Caring Families Programme|"Goal of the program is reduction in child behavior problems in high-risk South African families. Program will be delivered to caregivers responsible for the wellbeing of the child.~Program activities will be delivered over 12 weekly group sessions with additional individualized in-home sessions. The groups (n = 15 participants per group) will meet weekly with community facilitators (n = 2 per group). Parenting skills will be developed during the sessions through role-plays, group-discussion, storytelling, and home practice activities.~The program is manualized in isiXhosa."
223780637|NCT00816634|DRUG|Capecitabine plus cisplatin(XP) versus capecitabine plus paclitaxel(XT)|"3.2 Overview of Study Design This study is a prospective, randomized, phase II study comparing response rate between patients with XP chemotherapy versus XG chemotherapy for patients with metastatic squamous cell carcinoma.~Chemotherapy regimen (XP):~D1- D14 Capecitabine 1000 mg/m2 bid p.o. D1 Cisplatin 75 mg/m2 + NS 150mL MIV over 1hr every 3 weeks~Chemotherapy regimen (XT):~D1- D14 Capecitabine 1000 mg/m2 bid p.o. D1, D8 Genexol (Paclitaxel) 80 mg/m2 + D5W 500mL MIV over 3hrs every 3 weeks"
223697380|NCT05770583|PROCEDURE|Titration of fraction of inspired oxygen (FiO2) guided by ORI and oxygen saturation|"* FiO2 will be titrated by reducing 10% if Ori\>0.01 and oxygen saturation ≥ 98% until Ori is 0.00.~* FiO2 will not be changed if Ori is 0.00 and %95\<oxygen saturation≤%98~* FiO2 will be increased by 10% if oxygen saturation \<95 or PaO2\<60 mmHg"
223697381|NCT05770583|PROCEDURE|SpO2 (oxygen saturation)|Fraction of inspired oxygen (FiO2) is titrated guided by oxygen saturation in that range; %95\<oxygen saturation≤%98
223697382|NCT05420792|BEHAVIORAL|Peplau Interpersonal Relations based IPSRT will be applied to the intervention group|IPSRT based on peplau Interpersonal Relations theory will be applied to the intervention group. First of all, information about the study will be given. An informed consent form will be filled and a history will be taken from the patient. With the Life Events Chart, past attacks and life events, interpersonal relations will be compared. Interpersonal Circle will be made to better understand the individual and relationships. A Joint Study Plan, which summarizes the disease history, life events, and interpersonal circle, will be created and presented to the patient in summary form. The patient will be given psychoeducation about his illness, drugs and social rhythms. A Social Rhythm Metric (SRM) will be created and monitored throughout therapy to assess their daily routine. Early warning signs of impending attacks will be discussed, managing symptoms, situations that may disrupt social rhythm will be determined (travel, vacation, moving, changing job)
223697383|NCT00121095|DRUG|Samarium Sm-153 lexidronam + Docetaxel|1 mCi/kg Sm153 + 75 mg/m2 docetaxel
223697384|NCT01480648|DRUG|BI 144807 Placebo|Placebo that represents BI drug
223697385|NCT01480648|DRUG|BI 144807|single dose (low to high dose)
223697386|NCT04017000|DIAGNOSTIC_TEST|Bladder Shape Test|Capturing images of bladder under natural filling conditions images are analysed at a later date for shape change.
223697387|NCT04017000|OTHER|Calibration images|Capturing images of bladder under artificial filling conditions during Urodynamic assessment images are analysed at a later date to inform shape change technology.
223697388|NCT02561624|BEHAVIORAL|Behaviour change communication via text message|
223780638|NCT04561570|DEVICE|Vivity ACRYSOF IQ IOL Group|Subjects that were implanted with the Vivity ACRYSOF IQ extended depth of focus IntaOcular Lens
223780639|NCT04561570|DEVICE|ACRYSOF IQ IOL Control Group|Subject that were implanted with the ACRYSOF IQ Monofocal IntaOcular Lens
223780640|NCT03326999|DRUG|Obturator nerve regional block|Obturator nerve regional block involves the injection of a local anesthetic called bupivacaine into the upper thigh.
223780641|NCT03326999|DRUG|Adductor canal regional block|Adductor canal regional block, which involves injecting numbing medication in the thigh region for pain control.
223697389|NCT05508997|DEVICE|respiratory parameters on mechanical ventilator (PEEP)|"The 3rd \& 4th phases of operation in the group (A) and (B): Each patient received one single session inside the Operation Room (OR) as one shot of the treatment procedure. Arterial Blood Gases (ABGs) were obtained to measure:~1. Oxygenation by PaO2/FiO2 ratio with constant FiO2 = 100% (oxygen) through the procedure time as a primary outcome.~2. Secondary outcome.~   * Ventilation by PaCO2 value from ABGs.~  * Static compliance (Cstat) was measured as the amount of recruitment of alveoli in the lung.~  * Blood pressure (systolic/diastolic) one of the hemodynamics measurements was measured pre/post the procedure in the two groups."
223697390|NCT00384527|DRUG|Nitazoxanide|One nitazoxanide 500 mg tablet twice daily plus one vancomycin-placebo capsule four times daily for 10 days.
223697391|NCT00384527|DRUG|Vancomycin|One vancomycin 125 mg capsule four times daily plus one nitazoxanide-placebo twice daily for 10 days.
223697392|NCT00560768|DEVICE|Ovatio VR 6250 or DR6550|"The study requires the implantation of locally approved material:~* A right ventricular defibrillation lead~* In case of use of a dual chamber ICD a right atrial pacing lead~* A single chamber or dual chamber ICD manufactured by SORIN Group. At begin of the study this will be OVATIO VR model 6250 and OVATIO DR model 6550. Any new devices of same type manufactured by SORIN Group which will become locally approved during the conduction of the trial can be used in the study.~Holter recording will be performed with a market approved recording system allowing high resolution ECG recording compatible with the analysis software for TVar."
223697393|NCT00005673|DRUG|Capravirine|
223697394|NCT02402829|PROCEDURE|Peripheral Vein Blood draw|Drawing blood through a peripheral vein in the arm.
223697395|NCT06072248|DRUG|Meropenem|all patients in both groups receive meropenam and put on the ventilators for 2 weeks
223697396|NCT06072248|PROCEDURE|bronchoscopy|Only patients of group B had three times bronchoscopy according to our protocol one at the end of first 5 days, second bronchoscopy at the end of the second 5 days and last one at the end of the studied period
223697397|NCT06072248|DEVICE|ventilator|ventilator
223697398|NCT04612439|DEVICE|VABB Elite 10G|If the biopsy device is a vacuum-assisted Elite 10G needle, insert the needle groove into the mass and rotate to cut the biopsy tissue one circle
223697399|NCT04612439|DEVICE|BARD 14G CNB|If the biopsy device is a BARD 14G hollow core needle, insert the needle to the edge of the mass and pull the trigger in different directions to eject the needle to retrieve the material
223697400|NCT05933824|DRUG|LP-98 injection|Part A is administration is by subcutaneous LP98/placebo,Part B is administration is by intravenous drip LP98/placebo
223697401|NCT00302263|DRUG|Metobes-compound|
223697402|NCT01132274|PROCEDURE|Radiofrequency catheter ablation|Conventional radiofrequency catheter ablation through fluoroscopic guidance of supraventricular arrhythmias.
223697403|NCT01132274|PROCEDURE|Radiofrequency catheter ablation|Radiofrequency catheter ablation through the non-fluoroscopic EnSite NavX mapping system (St.Jude Medical, St Paul, MN, USA) guidance.
223780642|NCT03326999|DRUG|Saline|Saline as placebo comparator
223780643|NCT00681317|DRUG|AZD6280|oral
223697404|NCT03325270|DIETARY_SUPPLEMENT|labeled ferrous fumarate|labeled iron as Ferrous Fumarate
223697405|NCT03325270|DIETARY_SUPPLEMENT|labeled ferrous fumarate + prebiotics|labeled iron as Ferrous Fumarate + galacto-oligosaccharides
223697406|NCT03325270|DIETARY_SUPPLEMENT|labeled ferrous sulfate + prebiotics|labeled iron as Ferrous Sulfate + galacto-oligosaccharides
223697407|NCT03170856|OTHER|Sub-maximal exercise|Subjects will participate in aerobic exercise 5 days a week. This includes walking, biking, jogging and running. While participating in these activities, they will be wearing their Polar Wrist Unit and Heart Rate Monitor to help subjects track their exercise intensity. They will exercise for 20 minutes 5times a week at 60% of their maximum heart rate or 80% of their symptom limited heart rate.
223697408|NCT03676335|DRUG|CsA eye gel|The CsA eye gel of 0.3 g: 0.15 mg, 0.3 g: 0.3 mg
223697409|NCT03676335|DRUG|CsA for eye emulsion|The CsA for eye emulsion of 0.4 ml: 0.2 mg
223697410|NCT03676335|DRUG|Hypromellose Eye Drops|Hypromellose Eye Drops of 15ml：75mg, 3 times daily, 1-2 drop
223697411|NCT00072176|DRUG|temsirolimus|Given IV
223697412|NCT00072176|OTHER|laboratory biomarker analysis|Correlative studies
223697413|NCT03521219|DRUG|Apatinib|Apatinib 500mg, once a day, oral of each 28 day cycle. Number of cycle: until progression or unacceptable toxicity develops.
223697414|NCT04863235|BEHAVIORAL|Control Group|Eight week behavioural change program aimed to increase physical activity plus information on general health topics among individuals with prediabetes.
223697415|NCT04863235|BEHAVIORAL|Intervention Group|Eight week behavioural change program plus a self-compassion intervention aimed to increase physical activity among individuals with prediabetes.
223697416|NCT06557187|RADIATION|ippocampus-Avoidance Whole-Brain Radiation Therapy With Simultaneous Integrated Boost|hippocampus-Avoidance Whole-Brain Radiation Therapy With Simultaneous Integrated Boost
223697417|NCT05281211|DIETARY_SUPPLEMENT|Nutrition|6 weeks nutrition implementation in the form of branched chain amino acids and immune-system boosters twice daily for 4 weeks and once daily for 2 weeks
223697418|NCT05281211|BEHAVIORAL|Exercise|6 weeks exercise 30 minutes' walk/day or 2000 extra steps daily
223697419|NCT02292342|DIETARY_SUPPLEMENT|Water|Control
223697420|NCT02292342|DIETARY_SUPPLEMENT|Epicatechin 0.1 mg/kg|EC 0.1 mg/kg
223697421|NCT02292342|DIETARY_SUPPLEMENT|Epicatechin 0.5 mg/kg|EC 0.5
223697422|NCT02292342|DIETARY_SUPPLEMENT|Epicatechin 1.0 mg/kg|EC 1.0
223697423|NCT06184867|BEHAVIORAL|Relational Agent (RA)|Consists of a clinical letter and engagement with genetic education and uptake of genetic testing for hereditary cancer risk among cancer survivors.
223697424|NCT06184867|BEHAVIORAL|Enhanced Usual Care (EUC)|Consists of a clinical letter and recommendation for genetic testing for hereditary cancer risk among cancer survivors.
223697425|NCT03806491|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|Study therapists will follow the 2014 CBT-I in Veterans manual developed by leading researchers in the behavioral sleep medicine field. Intervention components include (1) sleep hygiene: limiting naps; avoiding caffeine, tobacco, alcohol, and rich/heavy foods before bedtime; exercising; establishing a bedtime routine; and creating a comfortable sleep environment; (2) sleep restriction: limiting time in bed in order to improve sleep efficiency, or the percentage of time in bed that is actually spent sleeping; time in bed will be titrated each week based on sleep efficiency; (3) stimulus control: strengthening association between bedroom and sleep to decrease conditioned arousal; (4) relaxation: diaphragmatic breathing, progressive muscle relaxation, and visual imagery to reduce arousal; and (5) cognitive therapy: identifying and challenging thoughts that interfere with sleep.
223697426|NCT03806491|BEHAVIORAL|Sleep Hygiene|Study therapists will review a one-page handout on sleep hygiene with all participants. This is the only intervention that participants assigned to the sleep hygiene condition will receive. This is consistent with what may be expected as standard care in a doctor's visit with a primary care physician.
223697427|NCT03806491|BEHAVIORAL|Alcohol Use Disorder Treatment as Usual|CBT-based groups for Alcohol Use Disorder will focus on the acquisition of skills needed to cope effectively with urges and cravings to drink and manage high-risk situations.
223697428|NCT05588778|BEHAVIORAL|BAILAMOS™ @home/en casa|The BAILAMOS™ dance program and dance manual. BAILAMOS™ originally encompassed four dance styles: Merengue, Cha Cha Cha, Bachata, and Salsa. These four styles of Latin dance are generally considered the most popular in terms of recognition and preference. We have added two styles to appeal to the largely Mexican-origin Latinos in Chicago (i.e., Cumbia and Samba). The dances were jointly choreographed by the PI and Mr. Mendez, a professional dance instructor and owner of The Dance Academy of Salsa and http://www.salsachicago.com/. The PI and dance instructor co-developed the extensive manual is used by program instructors and includes background information on the authors, an introduction describing the goals of the program, and descriptions of the various styles of dance. The manual also has photos and descriptions of each dance broken down into its component parts.
223780644|NCT03032120|DIETARY_SUPPLEMENT|Orange juice|Lean and obese subjects drank one single dose (5 mL/kg body weight) of fresh-squeezed orange juice (FOJ) and processed orange juice (POJ) followed by an ad libitum breakfast. A washout period of seven days among each beverage (FOJ, POJ and control) was applied.
223780645|NCT03032120|DIETARY_SUPPLEMENT|Control|Lean and obese subjects drank one single dose (5 mL/kg body weight) of an energy and sugars-matched orange-flavored drink (control), followed by an ad libitum breakfast. A washout period of seven days among each beverage (FOJ, POJ and control) was applied.
223780646|NCT02063646|DIETARY_SUPPLEMENT|Polyphenol-rich extract|Two groups, each of 102 volunteers, are studied. For 24 weeks, one group of volunteers will consume the active product (polyphenol-rich extract) while the other one will consume the placebo product.
223780647|NCT02063646|DIETARY_SUPPLEMENT|Placebo|"The placebo is a capsule with same appearance and organoleptic properties as the active product, containing no active component.~Two groups, each of 102 volunteers, are studied. For 24 weeks, one group of volunteers will consume the active product (polyphenol-rich extract) while the other one will consume the placebo product."
223780648|NCT04295941|DRUG|TraZODone Hydrochloride 300 MG|Oral administration of Trazodone once-a-day.
223780649|NCT01053923|OTHER|Magnetic Resonance Imaging (MRI)|This study involves three imaging sessions (Magnetic Nuclear Resonance -MRI), with one session before radiation therapy and two sessions during radiation therapy (one at 3 weeks of RT; the other during the last week of RT). Each imaging session will last for approximately 45 to 60 minutes.
223697429|NCT05588778|BEHAVIORAL|¡En Forma y Fuerte! @home/en casa|The ¡En Forma y Fuerte! Program. ¡En Forma y Fuerte! is designed to be delivered in Spanish by bilingual, bicultural, qualified exercise instructors. Instructors are required to have an exercise instructor/specialist certification through a national organization such as the American College of Sports Medicine, American Council on Exercise, or Aerobics and Fitness Association of America, or to have an undergraduate degree in an exercise science related field. The 8 hour training uses both didactic and hands-on role modeling for delivering both the exercise and health education components of the program. Instructors in the online version will also participate in a 60 minute training designed for this new version of the program. We have previously developed an asynchronous, online instructor training for the customary program and will translate it to Spanish for this proposal.
223697430|NCT03955380|DRUG|Contraloid|Oral administration of capsules, drug substance or placebo without any exipients.
223697431|NCT06863571|DRUG|PPA Intervention|"Participants in this group will receive a pharmacological cocktail (PPA) for five days in addition to standard medical treatment for acute ischemic stroke. The regimen includes terazosin or urapidil, and propranolol or esmolol, with individualized blood pressure management. The specific protocol is as follows:~* Terazosin (no less than 1 mg orally or via nasogastric tube, nightly) or Urapidil (100 mg in 30 mL saline, IV infusion at no less than 2 mL/h)~* Propranolol (10 mg orally or via nasogastric tube, three times daily) or Esmolol (1 g in 40 mL saline, IV infusion at no less than 2 mL/h; use for no more than 48 hours. Beyond 48 hours, switch to Propranolol)"
223697432|NCT02887859|BIOLOGICAL|Human Acellular Vessel (HAV)|Patients will be implanted with a Human Acellular Vessel (HAV) as a femoro-popliteal bypass conduit using standard vascular surgical techniques
223697433|NCT05608759|BEHAVIORAL|Multimodal prehabilitation|4 weeks of an supervised, pre-operative exercise prescription augmented by a wearable fitness device.
223697434|NCT03555032|DRUG|Talimogene laherparepvec (T-VEC)|One dose of 1 x 106 PFU/mL. Two doses of 1 x 108 PFU/mL. Given by intra-tumoural (i.t.) injection.
223697435|NCT00252395|DEVICE|PDA-based Electronic Prescribing Software|
223697436|NCT03449875|DEVICE|TREOVANCE® Stent-Graft with Navitel® Delivery System|Endovascular repair of abdominal aortic aneurysms.
223697437|NCT04796545|DEVICE|SING IMT(TM) System, model NG SI IMT 3X|The SING IMT 3X implant is a visual prosthetic implantable device, which, when combined with the optics of the cornea, constitutes a telephoto system for improvement of visual acuity in patients with bilateral, end-stage age-related macular degeneration.
223697438|NCT03616275|OTHER|HRV biofeedback|HRV biofeedback protocol is modified from Lehrer's HRV biofeedback manual (2000), which had been successfully used to improve functioning and quality of life for patients with asthma and COPD. A noninvasive biofeedback system with a NeXus-10 with BioTrace+ (Mind Media B.V., Netherlands) and laptop computer will be used for biofeedback intervention. The intervention protocol is including paced breathing in resonant frequency, abdominal breathing and pursed-lip breathing, and visual biofeedback. The designed intervention protocol will include 8 once-a-week, individual, 20-min in hospital training sessions and twice-a-day, 20-min home self-practices.
223697439|NCT02053051|DEVICE|ABC4D|Advanced Bolus Calculator for Type 1 Diabetes (ABC4D) to calculate pre-meal insulin boluses
223697440|NCT02053051|DEVICE|Standard bolus calculator|
223697441|NCT04571814|BEHAVIORAL|Psycho-social, computerized intervention targeting error sensitivity|"A psycho-social, computerized intervention for parents and children targeting error sensitivity. This intervention will be based on the constructs in the Child Error Sensitivity Index, as well as other constructs, that relate to the error-related negativity - for example, perfectionism, fear of evaluation from others, and over-valuation of the negative consequences of errors. The parent version of the intervention will include these same basic concepts, but will also target parenting style and provide psychoeducation on the negative impact of over-reacting to children's mistakes.~The parent version will also include examples of how to model appropriate reactivity to mistakes, and provide video vignettes and examples of both critical and adaptive parenting reactions to mistakes."
223697442|NCT02467400|DRUG|Atenolol|beta blocker
223697443|NCT02467400|DRUG|Nebivolol|beta blocker
223697444|NCT02467400|DRUG|Propranolol|beta blocker
223697445|NCT02467400|DRUG|placebo|placebo
223697446|NCT04847856|BEHAVIORAL|Diabetic care Information, education, and communication intervention will be delivered by relevant and trained health animators working in chronic care clinic.|The training sessions and the IEC materials were adapted from John Hopkins University studies on self-care for diabetic patients.
223697447|NCT04929574|DIAGNOSTIC_TEST|Echocardiogram and Hematological Analysis|Echocardiogram and Hematological Analysis
223697448|NCT00378339|DEVICE|gold berlocks|
223697449|NCT00282074|PROCEDURE|laparoscopic bilateral hernia repair|
223697450|NCT05005910|DRUG|Vonoprazan|Vonoprazan 20 mg oral every 12 hours (total 72 hours)
223697451|NCT05005910|DRUG|PPIs IV infusion|Pantoprazole 80 mg IV loading then 8 mg/hr
223697452|NCT03531983|PROCEDURE|fixation of tochentric fractures by gamma nail|• Thirty patients with recent traumatic extracapsular proximal femoral fractures were treated using a short gamma nail of third-generation assembly
223697453|NCT00292214|DRUG|Paracetamol (acetaminophen)|
223697454|NCT02084212|OTHER|Microperimetry|
223780650|NCT05983601|DEVICE|Transcranial Direct Current Stimulation|The anode electrode will be placed at the midline of the Cz according to international 10-20 EEG system, and the cathode electrode will be placed at the midline of forehead. In this way, both hemisphere of motor cortex can be stimulated which is used as protocol in various balance studies (Siedel-Marzi and Ragert, 2020b; Saruco et al., 2017). Participants will continue their training with tDCS (2mA) for 20 minutes. This application will continue three times a week for four weeks. In the end of the study, participants will be asked to guess which group they were in (active or sham).
223780651|NCT05662501|DEVICE|Pleioflow-RF|Subjects who are going to undergo scheduled cardiac surgery and are prone to developing renal insufficiency, will receive the Pleioflow-RF device in conjunction with IABP during CPB. Subjects will be followed until 30-days post-intervention.
223780652|NCT05718765|BEHAVIORAL|PACES intervention|"The exercise perception intervention program is divided into three stage, and every four weeks is a stage. The theme of the first stage is to make the patient have the intention to exercise. The theme of the second stage is to provide effective support for the patient, so that the patient can take the initiative to start exercise. The theme of the third stage is to enable patients to keep exercising.~The exercise intervention is a 12-week progressive intradialytic combined cycling exercise which proceed in the first HD 2 hours for safety. Each session consisted of a 5-minute warm-up, cool-down and 30-minute cycling at a Rating of Perceived Exertion (RPE) of 12-14. The machine has two exercise types including aerobic exercise and resistance exercise. Every four weeks is divided into a stage. And the time of aerobic exercise and resistance exercise were personally adjusted per stage to maintain the personalized target RPE."
223780653|NCT05718765|OTHER|Usual care with sham intervention|Patients in the control group received usual care and were advised to do sham exercise such as stretch legs and arms about 15 minutes during the first 2 hemodialysis hours.
223780654|NCT03963895|DRUG|AB002 Dose 1|AB002 (E-WE thrombin) 1.5 mcg/kg administered on Day 1 as a single intravenous infusion
223780655|NCT03963895|DRUG|AB002 Dose 2|AB002 (E-WE thrombin) 3.0 mcg/kg administered on Day 1 as a single intravenous infusion
223780656|NCT03963895|DRUG|placebo|placebo administered on Day 1 as a single intravenous infusion
223780657|NCT04831736|DRUG|Ketamine|Ketamine at a dose of 0.6 mg/kg will be administered intravenously (IV) while the participant is recovering in the PACU. The study drug will be administered over at least 30 minutes at one time point and will be administered after subject has been deemed to be stable (hemodynamically stable, awake) by the study team on POD 0.
223780658|NCT04831736|DRUG|Placebo|Matching equal dose of saline placebo will be administered intravenously while the participant is recovering in the PACU.
223780659|NCT05205135|BEHAVIORAL|SHARE Programme|"SHARE is Singapore's first 'Hospital-to-Home' programme to screen, identify and provide targeted interventions for caregivers at-risk of caregiver burden. Our interventions include psychosocial and emotional preparation of caregivers' mental resilience, and long-term engagement initiatives to connect caregivers into an integrated network of peers and community support services, delivered by programme facilitators and care support nurses.~Key stakeholders essential for the success of share include ward nurses and clinicians who refer caregivers to SHARE and community partners and hospital leaders.~This study seeks to recruit all of these individuals to better understand their experience of SHARE and the facilitators and barriers to its successful rollout to better evaluate the feasibility of SHARE in the hospital to home setting."
223780660|NCT00871481|BIOLOGICAL|ipilimumab|Given IV
223780661|NCT00871481|DRUG|cyclophosphamide|Given IV
223780662|NCT00871481|PROCEDURE|biopsy|Optional correlative studies
223780663|NCT00871481|BIOLOGICAL|aldesleukin|Given SC
223780664|NCT00871481|OTHER|immunohistochemistry staining method|Correlative studies
223780665|NCT00871481|GENETIC|polymerase chain reaction|Correlative studies
223780666|NCT00871481|OTHER|immunoenzyme technique|Correlative studies
223780667|NCT00871481|BIOLOGICAL|therapeutic cytotoxic T lymphocytes|Given IV
223780668|NCT03136601|OTHER|PTNS maintenance|The intervention is the timing of PTNS for maintenance (monthly treatment versus as patient needs)
223780669|NCT00387218|BEHAVIORAL|Exercise, Physical therapy|
223780670|NCT03424746|DRUG|disodium EDTA|Open-label study of TACT-formula, EDTA-based chelation therapy + commercially available TACT oral multi vitamins, delivering 40-50 infusions over 1 year.
223780671|NCT04815603|DRUG|BGE-117|Active Treatment
223780672|NCT04815603|OTHER|Placebo|Placebo
223780673|NCT02250404|OTHER|cytology specimen collection procedure|Correlative studies
223780674|NCT02250404|OTHER|laboratory biomarker analysis|Correlative studies
223780675|NCT04598282|DEVICE|Prokera Slim|Placement of an Adjunctive Cryopreserved Amniotic Membrane Treatment.
223780676|NCT04598282|OTHER|Standard of Care|Standard of care includes epithelial debridement of all dendrites via Weck-Cel Cellulose sponge, topical prophylactic antibiotics (e.g., Ocuflox QID for one week) and oral acyclovir (400 mg 5x/day for 10 days for primary cases but tapered to 2x/day for 3 months for recurrent cases based on investigator's discretion).
223780677|NCT01081587|PROCEDURE|Access to a Computerized Clinical Decision Support System (CCDDS)|Automatic CCDSS will alert physician for each case of malnourished using an algorithm based on age, sex, weight and size of each hospitalized children.
223780678|NCT01081587|BEHAVIORAL|Education of Healthcare workers|Education of the hospital staff to evidence-based practices in malnutrition care will be proposed in the experimental arm. Specific training will be targeted on participants according to their function.
223780679|NCT01081587|OTHER|Local assistance by a dietician|Assistance will be conducted locally by a local dietician. Periodic multidisciplinary meetings will be attended by the hospital staff belonging to the intervention arm, including the analysis of clinical incidents related to nutrition care.
223780680|NCT01319006|DRUG|GSK1278863A|100mg (x90=13um), oral tablet, single-dose with 7 day wash-out
223780681|NCT01319006|DRUG|GSK1278863A|100mg (x90=29um), oral tablet, single-dose with 7 day wash-out
223780682|NCT01319006|DRUG|GSK1278863A|100mg (x90=41um), oral tablet, single-dose with 7 day wash-out
223780683|NCT00649012|DRUG|Pioglitazone HCl Tablets 45 mg|45mg, single dose fed
223780684|NCT00649012|DRUG|Actos® Tablets 45 mg|45mg, single dose fed
223780685|NCT06534866|OTHER|Traditional Physical Therapy|"1. TENS+cold pack (For 10 mins on plantar ascpect of foot)~2. Stretching exercises (5 repetition 2 sets/day) Standing calf stretch Seated plantar fascia stretch Plantar fascia massage Achilles stretch Frozen can roll Towel stretch"
223697455|NCT01628705|OTHER|Nutritional intervention|"The subjects were undergoing nutritional intervention was reduced by 500 kcal per day of habitual caloric intake.~The proportion of daily intake of macronutrient in the moderate-fat diet was: 30% fat (saturated fat \<7%, monounsaturated 10-15% and polyunsaturated 10%, respectively to total calories), 15% of protein, and 55% of carbohydrates. The dietary cholesterol was less than 200 mg/day, fiber intake was increased to 25 grams per day (50% soluble fiber)."
223697456|NCT01628705|DIETARY_SUPPLEMENT|Green tea|The patients drank secha green tea. Subjects of the INT group were instructed on how to prepare the green tea infusion. Each cup was prepared using 3g of dried green tea in 300ml of hot water (temperature 80°C)for 4 min. It was drunk fresh and without sugar. The treatment consisted of 2 cup/day of green tea, one in the morning and one at night. The amount of epigallocathechin-3-gallate was 498mg/day.
223697457|NCT06323187|DIAGNOSTIC_TEST|Cervical Sampling|Each participant will provide a sample of fluid or mucus collected from the uterine endocervix.
223697458|NCT05928260|DEVICE|Medtronic Guardian Connect Sensor 3|This is a real-time CGMS which transmits all the blood glucose readings into the application downloaded in a device continuously and also gives alarms and alerts to the person.
223697459|NCT05928260|DEVICE|Abott Freestyle Libre Sensor|This system is an is-CGMS in which the participant gets his blood glucose only when the device is scanned.
223697460|NCT05928260|OTHER|Self blood Glucose monitoring by a glucometer|In this all patients will check their blood glucose using a needle prick and glucometer at pre-specified intervals.
223697461|NCT06291974|DIAGNOSTIC_TEST|electromyography|"Surface Electromyography (SEMG) is a measurement of the electrical activity in muscles as a byproduct of contraction.~It is the summation of action potentials from the muscle fibers under the electrodes placed on the skin"
223697462|NCT01920555|DRUG|Ketamine|Dose of Ketamine will be 0.1 mg/kg - one single infusion
223697463|NCT01920555|DRUG|Ketamine|Dose of Ketamine will be 0.2 mg/kg - one single infusion
223697464|NCT01920555|DRUG|Ketamine|Dose of Ketamine will be 0.5 mg/kg - one single infusion
223697465|NCT01920555|DRUG|Ketamine|Dose of Ketamine will be 1.0 mg/kg - one single infusion
223697466|NCT01920555|DRUG|Placebo Midazolam|Dose of Midazolam (active placebo) will be 0.045 mg/kg - one single infusion
223697467|NCT05997771|OTHER|Personal Nutrition Advisor|The study intervention will be the use of the PNA data analysis tool during remote nutritional counselling sessions delivered by certified dietitians, also referred to as PNA-assisted remote nutritional counselling.
223780686|NCT06534866|OTHER|Kinesiotaping|In the first step, after the metatarsophalangeal joints is dorsiflexed, the first strap will be adhered firmly to the posterior heel at its proximal end. The other end of the strap is cut into four slices of equal width. Each slice is applied with a 50% stretch (50% tensile strain) and attached to the plantar forefoot. In the second step, another strap is applied with gentle compression across the bases of the four slices beneath the foot and wrapped around the rearfoot
223780687|NCT04475601|DRUG|Enzalutamide Pill|The once daily dose will be given only during hospitalization and stop if starting invasive mechanical ventilation or at discharge from hospital
223780688|NCT01168050|DRUG|Nilotinib|Nilotinib 400 mg twice per day
223780689|NCT05298085|DRUG|Oxytocin nasal spray|Study treatment will be administered intranasally daily for 12 weeks. The daily dose of OT will be adapted according to age at the beginning of the study
223780690|NCT05298085|DRUG|Placebo|Study treatment will be administered intranasally daily for 12 weeks.
223780691|NCT00795600|DRUG|insulin detemir|Insulin detemir once daily plus insulin aspart at mealtime
223780692|NCT00795600|DRUG|insulin NPH|Insulin NPH once daily plus insulin aspart at mealtime
223780693|NCT01690650|DRUG|Oxygen|Oxygen exposure (100% oxygen) for 5 minutes, then 25 minutes with room air. Repeated twice. Continuously monitoring of the cerebral oxygen saturation (NIRS).5 replacements of sensor for reproducibility.
223780694|NCT04218019|DEVICE|TTFields|The NovoTTF-200 A device used in this trial delivers very low intensity, alternating electric fields to the tumor site through the scalp. These fields are known as Tumor Treating Fields or TTFields.
223780695|NCT04890002|DEVICE|Far-infrared emitting pyjamas|Clothing made in far infrared (FIR) - based textiles could be a sustainable way for alleviating sleep problems with many advantages. Firstly, the proposed far infrared textiles are made of man-made profiled fibers without the addition of chemicals such as ceramic additives or other related coatings.
223780696|NCT04890002|DEVICE|Sham-pyjamas|The sham-pyjamas are made of pure cotton fibres and man-made fibres without the far-infrared emitting function.
223780697|NCT04425226|DRUG|Pembrolizumab Injection [Keytruda]|Pembrolizumab (Keytruda, MSD China) is a recombinant anti-human PD-1 monoclonal antibody.
223780698|NCT04425226|DRUG|Lenvatinib Oral Product|Lenvatinib (Lenvima, Eisai China) is a novel angiogenesis inhibitor which targets vascular endothelial growth factor 1-3, fibroblast growth factor receptor 1-4, platelet-derived growth factor receptor β, RET and KIT
223780699|NCT00081588|DRUG|TMC114|600/100 mg tablets of TMC114/rtv BID for 144 weeks or until commercial available
223780700|NCT03936244|DEVICE|Transurethral Resection of the Prostate (TURP)|Randomized allocation to M-TURP or PK-TURP
223780701|NCT01973790|DRUG|Z-338|100mg TID
223780702|NCT00975234|PROCEDURE|Intra-lesion injection of autologous skeletal myoblasts|Intra-lesion injection
223780703|NCT00975234|PROCEDURE|Revascularisation|Revascularisation surgery
223780704|NCT05260710|BEHAVIORAL|Telemedicine Intervention|"Tele-Critical Care: 1) establishing a diagnosis 2) guiding the therapeutic approach and 3) performing clinical follow-up. Physicians will discuss all patients in the unit, bed by bed, evaluating the specific clinical situation of each hospitalized patient, according to the protocol developed by the study.The proposal is to maintain horizontal care (the patient is monitored from the 1st day of hospitalization until discharge) for all patients in the unit.~\+~Continuing education activities: video classes and discussions of complex cases."
223780705|NCT03450031|OTHER|NAC (no drug/no device)|Nasal allergen challenge (NAC) with mixed grass pollen: a bolus NAC with mixed grass pollen will be conducted
223697468|NCT06708052|BEHAVIORAL|voodoo flossing|"The voodoo flossing intervention used the standard voodoo flossing, wrapping a voodoo flossing (lime green Sanctband Comprefloss™, 2 × 3.5 m; PENTEL, Shah Alam, Malaysia) made of natural rubber tightly around the ankle on the affected side. It was started at the fifth metatarsal and wrapped horizontally around the metatarsals twice, in a figure eight to the medial malleolus, over the Achilles tendon and the lateral malleolus three times, and around the medial malleolus again, before being passed twice from the medial mal-leolus over the Achilles tendon to the lateral malleolus, forming an end knot"
223697469|NCT06708052|BEHAVIORAL|Control group|The control group did not use voodoo flossing.
223697470|NCT06434818|COMBINATION_PRODUCT|EDITOR (CBOT with olfactory stimulants, OFC tasks & remote monitoring of treatment compliance)|EDITOR includes a user-friendly cloud portal synced with the main device, providing a comprehensive training program for the orbitofrontal cortex (OFC). The main device stimulates the orbitofrontal cortex intensely, preventing habituation to smells and improving adaptability. This enhances neurobehavioral plasticity, benefiting Substance Use Disorder (SUD) outcomes. The device also features a 60% beta-caryophyllene scent for addressing issues like Alcohol Use Disorder and stimulant use disorders. With ten digital enhancements, it enables remote treatment and data collection, seamlessly transmitting information to healthcare providers through a secure, HIPAA-compliant portal.
223697471|NCT06434818|COMBINATION_PRODUCT|CBOT with olfactory stimulants & OFC tasks|The CBOT with proprietary odorant molecules is designed to stimulate olfactory neural activity over long periods of time combined with orbitofrontal cortex (OFC) dependent olfactory tasks.
223697472|NCT06434818|COMBINATION_PRODUCT|CBOT Sham|CBOT Sham uses artificially scented compressed room air instead of olfactory stimulants and has control cognitive olfactory tasks
223697473|NCT06130527|PROCEDURE|Nicardipine|Following the intubation, the infusion was initiated by using an infusion device (Orchestra Base Primea, Fresenius Kabi) with an i.v. dose of 1.0 µg/kg/min iv in Group N. The targeted MAP was determined as 50-65 mmHg and drug doses were increased until the targeted MAP was achieved In Group N. Nicardipine infusion will be increased by titration in groups with MAP above 65 mm/Hg for more than 5 minutes.
224263619|NCT06209983|PROCEDURE|ERAS|"1. Preoperative preparation: shorten the fasting time, take a small amount of sugar water two hours before the surgery, and reduce excessive bowel preparation.~2. Intraoperative care: multi-model analgesia (mainly epidural analgesia), sleep depth monitoring, warm air blanket to avoid hypothermia.~3. Postoperative care: focus on pain relief methods (such as oral analgesics, patient-controlled epidural analgesia), early postoperative feeding (try drinking water on the first day after surgery, liquid diet on the second day, and soft diet on the third day), early removal of invasive tubes such as nasogastric tubes, intravenous catheters, and urinary catheters, and medication to prevent postoperative nausea and vomiting."
223697474|NCT06130527|PROCEDURE|Remifentanil|Infusion was administered i.v. using an infusion device (Orchestra Base Primea, Fresenius Kabi). In Group R, the dose will start at 0.05 µg/kg/min following intubation. The target MAP was determined as 50-65 mmHg and drug doses will be increased until the target MAP is reached. HR more than 120 seconds and less than 45 beats/min will be considered as bradycardia and the remifentanil dose will be reduced. If response is unsatisfactory, 0.5 mg Atropine i.v. will be implemented. Nicardipine and Remifentanil infusions in groups will be increased by titration if MAP rises above 65 mm/Hg for more than 5 minutes.
223697475|NCT04625790|DEVICE|Repetitive transcranial magnetic stimulation|"Transcranial Magnetic Stimulation(TMS) has been used for diagnostic and therapeutic purposes in the treatment of many neurological and psychiatric diseases such as stroke, multiple sclerosis, myelopathy, amyotrophic lateral sclerosis, movement disorders, epilepsy, and depression. It is a way to stimulate the targeted areas in the cerebral cortex without invasive methods. The application of TMS in the aphasia usually consists of repetitive stimulations, in order to activate or deactivate the target area.~In this study, 10 sessions of 1-Hz low frequency rTMS for 20 minutes will be applied to the inferior frontal gyrus of the right frontal lobe."
223697476|NCT04625790|OTHER|Speech therapy|Speech therapy will be given to each patient by the same therapist, and the treatment will last 10 days, 60 minutes a day. It will consist of exercises to improve the articulation and comprehension.
223697477|NCT01088737|DRUG|Imiquimod|Imiquimod 5% cream is applied once daily. Each patient will begin with the application 3x/week. After two weeks of treatment the inflammation response to imiquimod will be assessed. If no or only minor inflammation is detectable in the treatment area, the dosing schedule will be increased to 5x/week. After four weeks of treatment the inflammation response will be assessed again. If still no or only minor inflammation is detectable, application will be extended to daily use.
223697478|NCT04738851|OTHER|Therapy Mirror task|"The protocol has 3 conditions:~* A virtual TM task (TMV~* A classic TM task (TMC)~* A control task (TC)~The order of the 3 conditions will then be randomized to avoid potential biases linked to the sequence of conditions."
223697479|NCT06374771|DRUG|Melatonin 10 MG|10 mg of Melatonin will be given orally pre and post-operative
223697480|NCT06374771|DRUG|Vitamin C|1 gm of Vitamin C will be given orally pre and post-operative
223697481|NCT01896336|DRUG|Zolpidem Hemitartrate|"Patz - 5mg sublingual zolpidem hemitartrate~1 QD~Stilnox - 10mg oral zolpidem hemitartrate~1 QD"
223697482|NCT01858376|DIETARY_SUPPLEMENT|Capros dietary supplement|Study participants will have 2 to 3 baseline blood draws, 3 blood draws while taking Capros supplements and 2 wash out blood draws after finishing 12 weeks of Capros supplementation. Participants will attend 7 to 8 study visits (depending on number of baseline visits needed) and at each visit participants will have their blood drawn as well as height, weight, blood pressure, and pulse measured.
223697483|NCT05320185|DEVICE|RuiXin-CoronaryAI software|RuiXin-CoronaryAI, based on Computed Tomography Angiography (CTA) and was independently designed by RaysightMed Inc., which has been already authorized by National Medical Products Administration (NMPA).
223697484|NCT03150160|DRUG|brinzolamide 1%/brimonidine 0.2% fixed combination|One drop applied topically to the affected eye(s) in the morning and evening
223697485|NCT03150160|DRUG|Placebo|One drop applied topically to the affected eye(s) in the morning and evening
223697486|NCT03150160|DRUG|travoprost 0.004% ophthalmic solution|One drop applied topically to the affected eye(s) in the evening
223697487|NCT06516484|DRUG|Romiplostim|Enrolled patients were given roprostin (20 µg/kg subcutaneously once weekly) for at least 3 months, with discontinuation of roprostin for platelet counts ≥50 x 10\^9/L and continuation of roprostin for platelet counts \<50 x 10\^9/L. Responders were continued to 6 months. Responders continue to use the drug until 6 months.
223697488|NCT03725215|BEHAVIORAL|Split-Belt Treadmill Training|One session of 6 x 5 min with 1 min intervals.
223697489|NCT02562833|DEVICE|Self-Management and exercise|Self-Management and exercise It is a 3 months intervention where the participants were enrolled two times per week, 90 minutes each session, first 30 minutes were allocated for the self-management component and the remaining 60 minutes for the exercise component. Additionally,participants received glucosamine and chondroitin sulfate supplement.
223697490|NCT02562833|DEVICE|Educational|This group received an educational book with information about OA features, treatment modalities and exercise education with illustration. Additionally, a monthly educational session each with one hour and a half duration, in total 3, where joint protections strategies, OA self-management and exercise contents were transmitted. Additionally,participants received glucosamine and chondroitin sulfate supplement.
223697491|NCT04507100|BEHAVIORAL|World Health Organization Health Promoting Schools|"Healthy eating: regulation and monitoring of food sold in school cafeterias, healthy eating behavior change campaign, provision of healthy breakfasts.~Physical activity: hourly active breaks during classes, quality physical education, active recess, and extra-curricular leisure activities and tournaments.~Healthy hydration: access to water fountains and regular monitoring of water safety, regulation and monitoring of beverages sold in the school, and social marketing campaign promoting drinking plain water.~Other cross-sectional activities: Referral of children identified as living with underweight, overweight, or obesity, training for school directors, teachers and parents, establishment of school objectives to become a health promoting school, monitoring progress, and publicly acknowledging school progress in becoming a health promoting school."
223697492|NCT01475409|BIOLOGICAL|QuantiFERON-TB Gold In-Tube (QFT-GIT)|Patients were randomized to undergo, on the same day, TST and QFT-GIT by means of a randomization list to generate the order by which the 2 tests had to be executed. QFT-GIT was repeated after 3 and 6 months since TNF antagonist onset
223697493|NCT04036734|DIAGNOSTIC_TEST|Longitudinal|Longitudinal orientation of ultrasound to long axis of vein to guide access needle
223697494|NCT04036734|DIAGNOSTIC_TEST|Transverse|Transverse orientation of ultrasound to long axis of vein to guide access needle
223697495|NCT02708901|DIETARY_SUPPLEMENT|Vivomixx®|Two packets (900 billions bacteria) per os (P.O.) daily x 1 month and one packet (450 billions bacteria) P.O. daily x 5 months
223697496|NCT02708901|DIETARY_SUPPLEMENT|Placebo|Two packets (4,4 grams of maltose and silicon dioxide x 2) P.O. daily x 1 month and one packet (4,4 grams of maltose and silicon dioxide) P.O. daily x 5 months
223697497|NCT03836703|DRUG|Feroglobin single daily use|Feroglobin single daily use ( IRON FUM\&POLYSAC#1/FA/MV NO.18 162 Mg-115.2 Mg (106 Mg Iron)-1 Mg ORAL CAPSULE ) to prevent iron deficiency anemia during pregnancy from 14 weeks gestation going on.
223697498|NCT03836703|DRUG|Feroglobin twice daily dose|Feroglobin twice daily dose ( IRON FUM\&POLYSAC#1/FA/MV NO.18 162 Mg-115.2 Mg (106 Mg Iron)-1 Mg ORAL CAPSULE ) to prevent iron deficiency anemia during pregnancy from 14 weeks gestation going on.
223697499|NCT03878238|DIETARY_SUPPLEMENT|Probiotic Bths-003|Probiotic with maltodextrin as a carrier.
223697500|NCT03878238|OTHER|Placebo|Placebo with maltodextrin base.
223697501|NCT02910362|DEVICE|Alcon phacoemulsification equipment|cataract surgery with Alcon phacoemulsification equipment.
223697502|NCT02910362|DEVICE|AMO phacoemulsification equipment|cataract surgery with AMO phacoemulsification equipment.
223697503|NCT01886716|BEHAVIORAL|Anxiety Attention Training|Anxiety Attention Training will preferentially direct participants' attention away from reminders of anxiety.
223697504|NCT01886716|BEHAVIORAL|Alcohol Attention Training|Alcohol Attention Training will preferentially direct participants' attention away from reminders of alcohol.
223697505|NCT01886716|BEHAVIORAL|Control Training|Placebo Anxiety Training and Placebo Alcohol Training will not preferentially direct participants' attention away from reminders of anxiety or alcohol.
223780706|NCT06534476|OTHER|Education|"Patients who agreed to participate in the study and met the inclusion criteria were interviewed face to face before the HD session and their verbal and written permissions were obtained by reading the voluntary consent form. The researcher interviewed the patients one-on-one and provided information about the purpose of the study and the training program. Then, scale forms were applied to the patients. In order not to interrupt the training and not to distract the patients in this group, a separate room in the Dialysis Unit was used during the training. The education booklet Living with Hemodialysis on hemodialysis management prepared in line with the literature was given to the patients by the researcher. The training of a patient lasted an average of 40-50 minutes. During and at the end of the training, the patients' questions were answered in the training room."
223780707|NCT00000218|DRUG|Carbamazepine|
223780708|NCT00406575|DRUG|Placebo|Placebo was the diluent used for preparation of the 100 µg/kg/day dose of active study medication.
223780709|NCT00406575|DRUG|Recombinant human relaxin (rhRlx)|Recombinant human relaxin (rhRlx) diluted for continuous IV infusion.
223780710|NCT03251469|DRUG|Tranexamic Acid 15mg/kg , iv, Single Dose|Tranexamic Acid 15mg/kg , administered intravenously, preoperatively, in a single dose
223780711|NCT03251469|DRUG|Normal Saline, 100mg, iv, Singe dose|Normal Saline, 100mg, administered intravenously, preoperatively in single dose
223780712|NCT03391648|OTHER|Observation|Observation only
223780713|NCT05575947|DEVICE|da Vinci Surgical System|da Vinci Surgical System
223780714|NCT05575947|PROCEDURE|laparoscopic bariatric surgery|laparoscopic bariatric surgery
223780715|NCT00993720|DRUG|Liraglutide|after optimal treatment on insulin alone 10 patients with type 1 diabetes are treated for four weeks with Liraglutide : in the first week at 0.6 mg sc and after one week optitration to the recommended 1.2 mg sc pr day.
223780716|NCT00993720|DRUG|Liraglutide|after optimal treatment with insulin alone, 10 type 1 diabetic patients are treated with Liraglutide at a dose of 0.6 mg sc. After one week the dose is optitreted to the recommended 1.2 mg sc pr. day.
223780717|NCT00993720|OTHER|continuous insulin therapy|after optimal treatment with insulin, patients continue on insulin for four weeks
223780718|NCT01114646|DEVICE|Cemented Hip Hemiarthroplasty|The cemented femoral prosthesis is a VerSys LD/Fx, Zimmer, Warsaw, IN.
223780719|NCT01114646|DEVICE|VerSys Beaded FullCoat, Zimmer|The press-fit component is a VerSys Beaded FullCoat, Zimmer, Warsaw, IN,
223780720|NCT03398538|OTHER|Offloading|Patient will be offloaded in a diabetic camboot after treatment, or total contact cast if patient cannot be fit with diabetic offloading boot
223780721|NCT03398538|OTHER|Additional (outer) Dressing Application|Application of outer a moisture retentive dressing, and a multi-layer compression dressing.
223697506|NCT04953429|BEHAVIORAL|workload|Mental needs, physical needs, time needs, self performance, effort, frustration, technical autonomy, decision-making autonomy and work needs of nursing work
223697507|NCT05596942|DIETARY_SUPPLEMENT|Albumin Channa Striata Extract|This study is a randomized controlled trial of 42 patients at the ICU of Dr. Moewardi General Hospital. The control group received 20 grams of human albumin on the first day and the study group received 15 grams of Channa striata extract daily for two days. Subsequently, eNOS, NLR and PLR are measured before and three days after treatment, and the examiners compare the three markers statistically.
223697508|NCT05688449|DRUG|Bupivacaine-fentanyl|A 20 ml bolus of 2 mcg/ml fentanyl + 0.125% bupivacaine solution will be administered to the bupivacaine group via the epidural catheter, and 5ml/hour infusion will be started.
223697509|NCT05688449|DRUG|Saline|A 20 ml bolus of saline will be administered to the saline group via the epidural catheter, and 5ml/hour infusion will be started.
223697510|NCT03559673|DRUG|Lacosamide|Patients will start on the individual Lacosamide (LCM) dose that they had reached at the completion of the previous monotherapy study. LCM will be administered orally twice daily in 2 divided doses.
223780722|NCT03398538|OTHER|Mirragen Wound Matrix Dressing|Application of Mirragen to wound site along with standard of care treatment
223780723|NCT03398538|OTHER|Fibracol Wound Dressing|Application of Fibracol Alginate along with standard of care treatment
223780724|NCT02326402|DEVICE|TandemHeart or LifeSPARC System|Percutaneous insertion of TandemHeart or LifeSPARC System
223697511|NCT01232231|DRUG|pharmacological decolonization treatment|Chlorhexidine gluconate 4% body scrub and 2% shampoo daily PLUS mupirocin 2%, fusidic acid 2%, or chlorhexidine gluconate 0.2% intranasally bid PLUS trimethoprim-sulfamethoxazole 160/800mg po bid or doxycycline 100mg po bid all for 7 days
223697512|NCT01232231|BEHAVIORAL|Education|No pharmacological decolonization treatment but given education regarding personal hygiene and environmental cleaning
223697513|NCT03326726|DRUG|2% CHG|Chlorhexidine Gluconate
223697514|NCT00785928|BIOLOGICAL|LY2127399|Administered SC every 4 weeks over a 24-week period (Weeks 0, 4, 8, 12, 16, and 20).
223697515|NCT00785928|DRUG|Placebo|Administered subcutaneously (SC) every 4 weeks over a 24-week period (Weeks 0, 4, 8, 12, 16, and 20).
223780725|NCT03811067|PROCEDURE|Transversus abdominis plane block|Transversus abdominis plane block will be performed bilaterally after the surgery.
223780726|NCT03811067|PROCEDURE|Rectus sheath block|Rectus sheath block will be performed bilaterally after the surgery.
223780727|NCT05734846|DEVICE|Control Lenses (control fitting approach)|Daily wear multifocal lenses for 1 week
223780728|NCT05734846|DEVICE|Test Lenses (test fitting approach)|Daily wear multifocal lenses for 1 week
223780729|NCT01381172|DEVICE|Optimizer System|The OPTIMIZER System delivers non-excitatory cardiac contractility modulating (CCM) electrical signals to the heart muscle. Treatment group subjects receive five non-contiguous one-hour periods of CCM signals per day.
223780730|NCT01381172|OTHER|No intervention: Optimal medical therapy|The control group receives optimal medical therapy only.
223780731|NCT01666002|DEVICE|Laser Treatment (Pulsed Nd:YAG 1064 nm Laser)|0.65 Millisecond Pulsed Nd:YAG 1064 nm Laser
223780732|NCT03178357|OTHER|Cardiac rehabilitation + standard therapy|Patients with HCM subjected to cardiological rehabilitation
223780733|NCT03178357|OTHER|Standard therapy|Standard treatment according to current guidelines and outpatient visits with psychological and / or psychoeducational counseling
223780734|NCT03317704|BEHAVIORAL|Speed endurance training|Speed endurance training
223697516|NCT06441669|DRUG|Letermovir|Patients will be given Letermovir with a recommended dose from +1 day to +100 days after UCBT.
223697517|NCT03349931|DIAGNOSTIC_TEST|DNA extraction and detection of Aspergillus fumigatus in serum samples|Performances diagnostic test of the real-time PCR ADEMTECH kit of DNA extraction and detection of Aspergillus fumigatus in serum samples in patients at high-risk for invasive aspergillosis (IA).
223697518|NCT00689780|DRUG|AZD1940|Oral solution Multiple ascending dose given orally once daily at day 1-12
223697519|NCT00689780|DRUG|Midazolam|Oral solution given orally once daily on day -1 and day 14
223697520|NCT04051281|BEHAVIORAL|Letter|Letters sent to GPs in relevant practices (prescribing data is by practice, so the practice is the unit of randomization)
223780735|NCT03346668|DRUG|Topical gabapentin|topical gabapentin 6% solution
223780736|NCT06178666|BIOLOGICAL|BCG|Three dose levels of intradermal BCG
223780737|NCT04346758|PROCEDURE|lumbar plexus block|Patients undergoing orthopedic procedures of the lower extremeties are going to be studied. A modified Shamrock approach of the lumbar plexus is going to be used for postoperative analgesia, using an ultrasound-guided technique combined to a nerve stimulatior. The technique is going to be assessed as for accuracy, and safety.
223780738|NCT04155931|OTHER|body temperature measurement|Postoperative analgesic and antiemetic requirements, nausea and vomiting were observed in the recovery room at 6, 12 and 24 hours
223780739|NCT05883306|DRUG|[14C]LXI-15028|\[14C\]LXI-15028
223780740|NCT04421144|PROCEDURE|orthognathic surgery|patients with maxillofacial disharmony will undergo orthognathic surgery using CAD/CAM Cutting Guides and Customized Titanium Plates.
223780741|NCT00001112|DRUG|Zidovudine|
223780742|NCT00001112|DRUG|Interferon gamma-1b|
223697521|NCT00037622|DRUG|ACH-126, 443 (beta-L-Fd4C)|
223697522|NCT03683160|OTHER|Cognitive Augmented Mobility Program|CAMP will combine education, one-on-one cognitive strategy training, and a cardiovascular and strength-training program conducted within a group setting. It will be run as a group of up to 6 participants, facilitated by a physiotherapist and a physiotherapy assistant or kinesiologist. It consists of 2 phases with a total of 19 sessions: Intervention Preparation (3 sessions), Active Intervention (16 sessions), and Follow-Up (1 session).
223780743|NCT00486343|DRUG|Zileuton CR|Zileuton CR tablets 2x600mg BID for 24 weeks
223780744|NCT00486343|DRUG|Placebo|Placebo tablets 2x600mg BID for 24 weeks
223697523|NCT03676998|DEVICE|Measurement of diaphragm function|A bilateral magnetic stimulation induces a non voluntary diaphragm contraction and a drop in airway pressure that is measured.
223697524|NCT04612582|DRUG|Thalidomide|Bortezomib (d 1, 8, 15, 22, 1.3mg /m2, subcutaneous injection); thalidomide (d 1-28 50-100mg, oral); dexamethason (d 1, 2, 8, 9, 15, 16, 22, 23, 20mg, oral/intravenous injection) as a course of treatment, the patients will complete six courses of treatment after entering the group, and the total observation time is one year after the end of treatment.
223697525|NCT04612582|DRUG|Cyclophosphamide|Bortezomib (d 1, 8, 15, 22,1.3mg / m2, subcutaneous injection); cyclophosphamide (d 1, 2,900mg / m2, intravenous drip); dexamethason (d 1, 2, 8, 9,15, 16, 22, 23, 20mg, oral/intravenous injection) as a course of treatment, patients will complete six courses of treatment after entering the group, the overall observation time is one year after the end of treatment.
223697526|NCT00813020|DRUG|semaglutide|Comparison of different formulations of the drug, semaglutide: Formulation 1 administered in equimolar doses
223780745|NCT05036629|DEVICE|MRI Protocol|"Eye-tracker Eyelink (eye movements) BIOPAC : (electrodermal resistance) INVIVO Precess : breathing, arterial pressure, pulse,~* NIRS Oxymon artinis medical system~* tES (transcranial electrical stimulation, Neuroelectrics)"
223780746|NCT02706158|DIETARY_SUPPLEMENT|1500 mg Calcium and 1200 IU Vitamin D for 2 months|1500 mg Calcium and 1200 IU Vitamin D for 2 months
223697527|NCT00813020|DRUG|semaglutide|Comparison of different formulations of the drug, semaglutide: Formulation 2 administered in equimolar doses
223780747|NCT02706158|BEHAVIORAL|balanced diet|participants will get a balanced diet according to pregnancy stage
223780748|NCT05219240|OTHER|20Lighter Program|Visceral Adiposity-Focused Anti-Obesity Telehealth Program
223780749|NCT00905580|DRUG|Pregabalin|Pregabalin 150 mg orally
223780750|NCT00905580|DRUG|Vitamin Complex (placebo)|Vitamin Complex 150 mg orally
223780751|NCT02159482|DRUG|Interferon Alfa-2a|
223780752|NCT01233817|OTHER|Progressive strength training|the systematic increase in resistance weights
223780753|NCT01857544|DRUG|Aflibercept|Monthly 2.0mg Aflibercept Intravitreal Injection
223780754|NCT04121104|OTHER|SCS is switched off|Spinal cord stimulator is switched off for 12 hours
223780755|NCT04121104|OTHER|SCS is switched on|Spinal cord stimulator is on
223780756|NCT05224791|PROCEDURE|Roux-en-Y Gastric Bypass|The RYGB connects a limb of the intestine to a much smaller stomach pouch, which prevents the bile from entering the upper part of the stomach and esophagus, thereby effectively bypassing the remaining stomach and first segment of the small intestine.
223780757|NCT05224791|PROCEDURE|Sleeve Gastrectomy|"The SG is a restrictive procedure in which a partial left gastrectomy of the fundus and body of the stomach is performed in order to create a long tubular sleeve along the lesser curvature. The weight loss and resolution of comorbidities are attributed not only to the restrictive nature of the procedure but also to restriction by the pylorus, decreased ghrelin, increased satiety, increased gastric emptying, and faster small bowel transit times with a component of malabsorption"
223780758|NCT00135954|DRUG|Cyclophosphamide and steroids|comparison of difference in time of start of therapy
223780759|NCT01513304|PROCEDURE|Manual therapy|
223780760|NCT04485962|BIOLOGICAL|Fibroblasts and keratinocytes|"Autologous cultured fibroblasts and keratinocytes~For PR: The name  fibroblasts and keratinocytes is exactly the name of the cell product registered by our ministry of health. There is no trade or international name."
223780761|NCT02999555|PROCEDURE|Ovum pickup|Ovum pickup or Egg retrieval, that is performed not for the purpose of the study, but for the purpose of well known in vitro fertilization indications
223780762|NCT00370162|DRUG|lactoserum|
223697528|NCT00813020|DRUG|semaglutide|Comparison of different formulations of the drug, semaglutide: Formulation 3 administered in equimolar doses
223697529|NCT01385761|DEVICE|Laryngeal Mask Airway|Each child will be randomized to either receiving the LMA or air-Q ILA-SP as their supraglottic airway device for primary airway maintenance.
223697530|NCT01385761|DEVICE|air-QTM Intubating Laryngeal Airway|Each child will be randomized to either receiving the LMA or air-Q ILA-SP as their supraglottic airway device for primary airway maintenance.
223697531|NCT04348643|BIOLOGICAL|CEA CAR-T cells|CEA-CAR-T cells will be administered intravenously.
223697532|NCT00232089|DRUG|Tegaserod|
223697533|NCT04256096|DEVICE|Thrombectomy|Endovascular treatment of large vessel occlusion (mechanical thrombectomy) with stent-retriever and/or thromboaspiration (neurointerventionalist choice)
223697534|NCT02670720|DRUG|avoralstat|
223697535|NCT00643773|DIETARY_SUPPLEMENT|Leucine|capsules are 0.5g, subjects take 5 capsules with every main meal for 6 months In total this is 15 capsules per day
223697536|NCT00643773|DIETARY_SUPPLEMENT|Wheat flour|Wheat flour
223697537|NCT03180593|DRUG|Valsartan 80 mg|Compare office and 24-hour Blood Pressure Control and regression of Left Ventricular Hypertrophy
223697538|NCT04238416|DRUG|Branched chain amino acid|Intravenous branched chain amino acids will be given for 3 days to patients in experimental arm
223697539|NCT04238416|DRUG|Lactulose|Oral lactulose will be given to patients in both arms
223697540|NCT05883683|OTHER|Molecular Profiling & drug testing in tumor organoids and PDXs|Molecular profiling of native tumor will be performed and analyzed by using a self-designed panel. Tumor organoids will be cultured from fresh tumor tissues and patient-derived xenografts model will be established using the tumor organoids. Drugs will be tested in the two models. And the recommendation will be communicated to the clinicians.
223697541|NCT05870293|BEHAVIORAL|nurse coaching|2 sessions of nurse coaching including the Walt Disney method will be applied to the participants.
223780763|NCT03221582|DRUG|EBR/GZR|Elbasvir and Grazoprevir (EBR/GZR) tablet by mouth, once daily.
223780764|NCT05524194|DRUG|Intravenous Infusion|Dose-limiting toxicity (DLT) are assessed during the first 3 weeks (21 days) after initial administration. Then, the intended dosing frequency is every 2 weeks (Q2W).
223780765|NCT02484794|BEHAVIORAL|Standard Outpatient Treatment|Standard treatment offered by the Nova Scotia Health Authority Eating Disorder Outpatient Program varies in intensity but involves therapy groups (e.g., goal setting and skill building groups), individual contact, and meal experiences. Minimal participation in the program consists of a weekly nutritional counselling group (Nutri-Logical) and one supervised meal a week. In the nutritional counselling group, patients keep a food journal (self-monitor), set eating goals, receive feedback from a psychologist and dietitian, and share experiences with the group.
223780766|NCT02484794|BEHAVIORAL|Smartphone App|The smartphone app is a mobile eating disorder self-monitoring tool that incorporates discrete reminders, positive feedback, social support, summative feedback, coping skill suggestions, and linking patients with their treating clinicians (psychologist and dietician). The app is CBT-based and was designed as an alternative to paper food records for use in clinical treatment.
223780767|NCT00475059|DRUG|cimetidine arrow|patients who received cimétidine
223780768|NCT06360835|PROCEDURE|total hip arthroplasty|
223780769|NCT01858662|PROCEDURE|Metastases Resection ( multiple steep surgery possible)|Metastases resection will be process by surgery, after a randomized chemotherapy (FOLFOX or FOLFIRI) + Target therapy (Cetuximab). The surgery will allow to compare the pathological response on the resected metastases by the chemotherapy + target therapy type.
223780770|NCT01858662|DRUG|5-Fluorouracile|5-FU bolus 400 mg/m2, IV bolus every 2 weeks 5-FU continuous infusion 2400 mg/m2, 46-hour cont. IV infusion every 2 weeks
223780771|NCT01858662|DRUG|leucovorin L|Leucovorin L (levoleucovorin) 200 mg/m2 (or folinic acid 400 mg/m²) in 250 ml glucose 5%, 2-hour IV infusion
223780772|NCT01858662|DRUG|Oxaliplatin|Oxaliplatin 85 mg/m² in 150 ml NaCl 0.9%, 2-hour IV infusion every 2 weeks
223780773|NCT01858662|DRUG|Irinotecan|Irinotecan 180 mg/m² in 150 ml NaCl 0.9%, 1.30-hour IV infusion every 2 weeks
223780774|NCT01858662|DRUG|Cetuximab|Cetuximab 400 mg/m² in 100 ml NaCl 0.9% 2-hour IV infusion for 1rst cycle and after the 1rst cycle 250 mg/m² in 100 ml NaCl 0.9% 1-hour IV infusion
223780775|NCT00005776|DRUG|Inhaled nitric oxide|Inhaled Nitric oxide at a concentration of 20 ppm
223780776|NCT00005776|DRUG|Placebo|100% Oxygen
223780777|NCT04223453|DIAGNOSTIC_TEST|BIA and DXA|Patients with acute pneumonia measured simultaneously with DXA-scan and BIA-impedance
223780778|NCT01248884|BIOLOGICAL|Infanrix hexa™|3 doses, intramuscular into left thigh
223780779|NCT01248884|BIOLOGICAL|Prevenar 13®|3 co-administered doses, intramuscular into right thigh
223780780|NCT01248884|BIOLOGICAL|GSK217744|3 doses, intramuscular into left thigh
223780781|NCT06507267|OTHER|Pain and Clinical Reflections in Pelvic Congestion Syndrome|Pain and Clinical Reflections in Pelvic Congestion Syndrome
223780782|NCT03110289|OTHER|superdonor FMT|"Fecal microbiota transplantation (FMT) is the transfer of feces from a healthy superdonor to the patient."
223780783|NCT03110289|OTHER|autologous FMT|Fecal microbiota transplantation (FMT) with feces from the patient him/herself
223780784|NCT02511431|DRUG|Lonafarnib|prenylation inhibitor to be administered daily at doses of 50 mg, 75 mg or 100 mg.
223780785|NCT02511431|DRUG|Ritonavir|FDA approved drug for use of boosting other drugs. Will be used to boost Lonafarnib as they both use the same cytochrome P450 system. Will be administered at 100 mg daily.
223780786|NCT02511431|OTHER|Placebo|Placebo
223780787|NCT03074422|PROCEDURE|Hypnosis|Hypnosis session performed by a board certified senior anesthesiologist during the frame fixation on the patient's head.
223697542|NCT05818098|DEVICE|Intravascular Lithotripsy System of Shanghai MicroPort Rhythm|The Intravascular Lithotripsy System is a single-use, sterile, disposable balloon angioplasty catheter that contains a series of unfocused, electrohydraulic lithotripsy emitters, which convert electrical energy into transient acoustic circumferential pressure pulses that disrupt both superficial and deep calcium within vascular plaque.
223697543|NCT05735353|BEHAVIORAL|High-Speed Circuit Resistance Training|three times per week; 45 minutes per session; 12-weeks
223697544|NCT05735353|BEHAVIORAL|High-Speed Multidirectional Yoga|two times per week; 60 minutes per session; 12-weeks
223697545|NCT01473043|DRUG|Axitinib|5mg twice daily \[BD\] daily dosing until progression or prohibitive toxicity Dose titration by 2 levels upwards (7mg and 10mg) and downwards (3mg and 2mg) allowed per protocol
223780788|NCT05996354|DEVICE|Concave Supra-arch Branched stent-graft system|To evaluate the efficacy and safety of the Concave Supra-arch Branched stent-graft system for endovascular treatment of aortic arch diseases.
223697546|NCT04547790|DIETARY_SUPPLEMENT|Psyllium|One level scoop (12.5mL) of 5.1g of psyllium fiber twice a day with 8 ounces water
223697547|NCT04547790|DIETARY_SUPPLEMENT|Wheat Dextrin|One level scoop (12.5 mL) of 1.7g wheat dextrin fiber twice a day with 8 ounces water
223697548|NCT05034718|OTHER|PIBIS clinical decision support|The intervention is the presence of the PIBIS physician alert and powerform, which is clinical decision support for the treating provider if a patient meets inclusion criteria for Pittsburgh Infant Brain Injury Score (PIBIS) calculation.
223697549|NCT05034718|OTHER|Standard of care|Standard of care, absent the PIBIS powerform and alert for providers.
223697550|NCT03387683|DRUG|dapagliflozin|dapagliflozin 10mg
223697551|NCT03387683|DRUG|placebo|placebo to match dapagliflozin
223697552|NCT06557694|OTHER|Data collection|Data collected included maternal demographics, medication during pregnancy, the gestational week when COVID-19 was diagnosed, antenatal diseases occurring after COVID-19 detection during pregnancy, intrauterine growth retardation (IUGR), small for gestational age (SGA), fetal distress, intrauterine fetal demise (IUFD), intrapartum complications, gestational age (GA) at delivery, mode of delivery, postpartum hemorrhage (PPH), admission to the maternal ICU, birth weight, admission to the NICU, and the indication for NICU hospitalization Pregnancy outcomes included mode of delivery, gestational age at delivery, pre-eclampsia, and postpartum hemorrhage (defined as an estimated blood loss of 1,000 mL or greater).
223780789|NCT03713762|DRUG|peribulbar block 1 lidocaine/bupivacaine|Peribulbar block: 100 mg of lidocaine 5% and 15 mg of bupivacaine 0.5% for a total volume of the anesthetic mixture of 5 ml.
223780790|NCT03713762|DRUG|peribulbar block 2 lidocaine/bupivacaine/fentanyl|Peribulbar block: 100 mg of lidocaine 5%, 15 mg of 0.5% bupivacaine and 50 mcg of fentanyl citrate for a total volume of the anesthetic mixture of 6 ml.
223780791|NCT04479618|DEVICE|Usual Practice|A saline soaked piece of gauze, conformed to the size of the open ulcer area, will be placed over the ulcer and held in place with a wrap of stretch gauze. Ulcers will be rinsed with saline at daily dressing changes, which will be conducted by the patient after they master the procedure.
223780792|NCT04479618|DEVICE|Improvised dressing|A piece of a new food-grade plastic bag, cut slightly larger than the ulcer, will be placed over the ulcer, sealed at the edges with an emollient to create an occlusive dressing. The dressing will be gently conformed to the ulcer contours to eliminate dead space, and a slit will be cut in the center to allow excess fluid to escape into a clean absorbent material placed over the slit. The device will be held in place with a wrap of stretch gauze. Ulcers will be rinsed with saline at daily dressing changes, which will be conducted by the patient after they master the procedure.
223780793|NCT04479618|DEVICE|Advanced dressing|A piece of polymeric membrane dressing, cut to extend at least 0.5cm beyond the open ulcer edges, will be placed over the ulcer and held in place with a wrap of stretch gauze. The approximate wound edges will be marked on the back of the dressing. Dressing changes will consist only of removing the dressing when the saturation level, visible through the wound backing, reaches the mark indicating the dressing edges and applying a new cut dressing. Changes will be conducted by the patient after they master the procedure.
223780794|NCT01140035|OTHER|Administration of continuous insulin infusion for glycemic control in brain dead donors|As per protocol
223780795|NCT04984044|DIETARY_SUPPLEMENT|Vitamin D3|"Dietary supplement:Vitamin D3~1 capsule of Vitamin D3 (40,000IU) weekly for 8 weeks with antidiabetic drug"
223780796|NCT04984044|DIETARY_SUPPLEMENT|Placebo|1 capsule weekly for 8 weeks with antidiabetic drug
223780797|NCT05843942|OTHER|Questionnaire|A food frequency questionnaire that was designed to assess folate, iron, and vitamin B12 intake will be administered. Furthermore a 24-hour recall food record will be administered and a complete blood count will be collected. Food frequency questionnaire data will be compared to recall food records and blood count data.
223780798|NCT01202773|DRUG|LY2127399|Administered Subcutaneously (SC)
223780799|NCT01202773|DRUG|Placebo Q4W|Administered SC
223780800|NCT01202773|DRUG|Placebo Q2W|Administered SC
223697553|NCT01646073|BIOLOGICAL|Adalimumab|adalimumab eow
223697554|NCT01646073|BIOLOGICAL|placebo|placebo
223697555|NCT03722069|OTHER|Low sodium diet|Patients received low sodium diet (3g of sodium chloride/day) and a limit of fluid intake of 1000 ml/day.
223697556|NCT03722069|OTHER|Normal sodium diet|Patients received normal sodium diet (7g of sodium chloride/day) and a limit of fluid intake of 1000 ml/day.
223780801|NCT03649022|DEVICE|Catheter ablation|Ventricular Tachycardia ablation, that will be performed per clinical practice, by using EnSite Precision mapping system with the Flexability catheter (St.Jude, now Abbott)
223780802|NCT00389662|DEVICE|"Wearing the Nike Free shoe"|
223780803|NCT04423965|DRUG|mFOLFOXIRI|irinotecan 165 mg/m² IV day 1+ oxaliplatin 85 mg/m² IV day 1 + leucovorin 400 mg/m² day 1, fluorouracil 1200mg/m²/day \*2 days (total 2400 mg/m² over 48 hours) continuous infusion starting on day 1 of each 2 weeks cycle
223780804|NCT04423965|COMBINATION_PRODUCT|Chemoradiotherapy|Capecitabine based chemoradiotherapy
223697557|NCT01387620|DRUG|Hyaluronic Acid and hydroxypropylmethylcellulose|Hyaluronic Acid 1.6% was used to performed phacoemulsification in one eye and hydroxypropylmethylcellulose 2% was used in the fellow eye.
223697558|NCT05111704|OTHER|Balance Body Tape|The intervention group received a three-week treatment with Balance Body Tape (BBT) (product by Babota AB), the control group received no treatment. A questionnaire regarding pain, including a Numeric Rating Scale (NRS) measuring pain intensity, and a Photographic posture analysis measurement (PPAM) of habitual sitting posture were accomplished before and after the intervention for both groups.
223697559|NCT03634644|DRUG|Omega 3 fatty acid|Omega 3 fatty acid,mainly composed of EPA and DHA.
223697560|NCT03634644|DRUG|Placebo oral capsule|mainly composed of corn oil
223697561|NCT02047383|OTHER|Respiratory infection|An assessment of the patients included in the study will be conducted
223697562|NCT02437383|DRUG|Propranolol ER|Capsules given orally according to schedule at Visit 1, Visit 2, Visit 3, and Visit 4.
223697563|NCT02437383|DRUG|Placebo|Gelatin capsules with a microcrystalline cellulose filler manufactured to mimic propranolol ER 60 mg capsules
223697564|NCT02722369|DRUG|Gemcitabine|Chemotherapy
223697565|NCT02722369|DRUG|Carboplatin|Chemotherapy
223697566|NCT02722369|DRUG|Etoposide|Chemotherapy
223697567|NCT02722369|DRUG|Hydroxychloroquine|Maintenance Agent
223697568|NCT00053937|DRUG|pirfenidone|
223697569|NCT04336358|OTHER|Telemedicine|Telemedicine consultation online
223697570|NCT00643396|RADIATION|thoracic radiotherapy|
223697571|NCT04882384|PROCEDURE|Pericapsular Nerve Group Block|This will be a peripheral nerve block.
223780805|NCT04098627|BEHAVIORAL|Laughter Therapy|Once weekly 30-minute long group laughter therapy session for 8 weeks
223780806|NCT00114374|DRUG|Escitalopram|
223780807|NCT01775891|DRUG|pilsicainide|The dose of pilsicainide will be 50mg tid PO. Pilsicainide will be started on the night of the ablation for a duration of at least 3 months. Physicians were encouraged to stop the drugs following the 3 months treatment if possible.
223780808|NCT01775891|DRUG|other class IC antiarrhythmic drug|Other class IC antiarrhythmic drug that they had been taking before catheter ablation will be administrated.(flecainide 100mg bid PO or propafenone 225mg tid) Antiarrhythmic drug will be started on the night of the ablation for a duration of at least 3 months. Physicians were encouraged to stop the drugs following the 3 months treatment if possible.
223780809|NCT01060228|DRUG|paliperidone ER|1 tablet of 500 mg once daily on Day 1 and Day 15
223780810|NCT01060228|DRUG|divalproex sodium ER|2 tablets of 500 mg once daily from Days 5 through 18
223697572|NCT01501370|DRUG|Vorinostat|Vorinostat orally at the dose of 400 mg/day on days 1-7 and 15- 21 on a 28-day cycle
223697573|NCT01501370|DRUG|Lenalidomide|Lenalidomide orally at the dose of 25 mg/day for 21 days every 28 days
223697574|NCT01501370|DRUG|Dexamethasone|Dexamethasone orally at the dose of 40 mg day 1,8, 15, 22 every 28 days.
223697575|NCT01501370|DRUG|Lenalidomide|Lenalidomide orally at the dose of 25 mg/day for 21 days every 28 days
223697576|NCT01501370|DRUG|Dexamethasone|Dexamethasone orally at the dose of 40 mg day 1,8, 15, 22 every 28 days.
223697577|NCT03135626|DRUG|Biodentine|
223697578|NCT03135626|DRUG|ProRoot (Aggregate)|
223697579|NCT03135626|DRUG|MTA Plus|
223697580|NCT03135626|DRUG|Ferric Sulfate 20 % Dental Gel|
223697581|NCT06378580|DRUG|Surufatinib combine immune checkpoint inhibitor|"Before drug use demographics, blood markers, pathology information# and enhanced CT features.~Chemotherapy regimens that were combined with surufatinib included AG or FOLFIRINOX regimens. The AG regimen consisted of nab-paclitaxel (125 mg/m2) followed by gemcitabine (1000 mg/m2) on days 1 and 8 every 3 weeks. The FOLFIRINOX regimen included oxalip"
223780811|NCT02811029|BEHAVIORAL|measurement of phonology|measurement of phonology will be assess using BILO-3, EDA, VS and VL tests
223780812|NCT04629794|PROCEDURE|Posterolateral Lumbar Fusion with Demineralized Bone Fibers|Posterolateral Lumbar Fusion with Demimeralized Bone Fibers
223780813|NCT04629794|PROCEDURE|Posterolateral Lumbar Fusion with Bone Morphogenic Protein|Posterolateral Lumbar Fusion with Bone Morphogenic Protein
223780814|NCT02334800|DRUG|Palbociclib 75 mg Capsule|Single oral 75 mg dose of palbociclib followed by serial PK sampling up to 192 hours post-dose (up to 120 hours post-dose for the healthy volunteer cohort).
223780815|NCT06113042|BEHAVIORAL|Health talks, learning packs|All participants can join the health talks and receive the learning packs.
223780816|NCT06113042|BEHAVIORAL|Lifestyle modification programme|"In Group 1: The programme includes both knowledge and activity/practicum sessions for children and parents. It will be carried out in district community hubs.~Group 2: The programme focuses on the knowledge sessions for parents. It will be carried out in schools.~Group 3: The programme focuses on the activity/practicum sessions for children and parents. It will be carried out in district community hubs."
223697582|NCT06378580|DRUG|AG/FOLFIRINOX|"Before drug use demographics, blood markers, pathology information# and enhanced CT features.~The AG regimen consisted of nab-paclitaxel (125 mg/m2) followed by gemcitabine (1000 mg/m2) on days 1 and 8 every 3 weeks. The FOLFIRINOX regimen included oxaliplatin (85 mg/m2), irinotecan (180 mg/m2), leucovorin (400 mg/m2), and 5-fluorouracil (400 mg/m2 bolus, 2400 mg/m2 continuous intravenous infusion for 46 hours) every 14 days. Both the AG and FOLFIRINOX regimens required completion of 6 cycles or until disease progression or unacceptable toxicity."
223697583|NCT04558944|DEVICE|Extracorporal Shock Wave Therapy|Acoustic high amplitude waves with Energy Flux Density of 0.15mJ/mm 2 and 512 pulses per session. A total of two sessions per week during a 4-week period.
223697584|NCT06426719|PROCEDURE|Alveolar ridge wideninig via applying osseodensification protocol using densah burs|alveolar ridge expansion using densah burs in horizontally deficient maxillary alveolar ridges prior to dental implants insertion
223697585|NCT06426719|PROCEDURE|Alveolar ridge widening via hand osteotomes|Alveolar ridge expansion using hand driven osteotomes in horizontally deficient maxillary alveolar ridges prior to dental Implant insertion
223697586|NCT01108120|DRUG|continuous intra-femoral thrombolysis group|Firstly, 20 0000 u urokinase is injected to the diseased foot via catheter. Then, continuous injection of urokinase via femoral artery by a artery mini-pump (100 ml 0.9% sodium chloride + 100 0000 unit urokinase at a rate of 4 ml per hour) is taken for 7 - 9 days.
223697587|NCT01108120|DRUG|Conventional therapy group|All patients receive an intravenous injection of prostaglandin E1 20 ug per day during hospitalization period.
223697588|NCT03948607|OTHER|Electroencephalography during sustained attention task.|"The Continuous Temporal Expectancy Task (CTET) (O'Connell et al., 2009) is a very demanding discrimination task with sustained attention. It consists of the presentation on a computer screen of a visual pattern resembling a checkerboard that changes orientation at regular intervals of time. In this task the subject must respond (pressing a response button) to the appearance of rare target stimuli that have a longer duration (1120 ms) than non-target stimuli (800 ms).~SART (Sustained Attention to Response Task) (Robertson et al., 1997) is a task of inhibition (Go / No-Go task) to evaluate the capacities of sustained attention. It consists in the successive and random presentation on a computer screen of the numbers from 1 to 9. In this task the subject must respond, by pressing a response button, to the appearance of all the numbers (very non-target stimuli frequent), with the exception of the number 3."
223697589|NCT03292575|DRUG|Anticoagulants|
223780817|NCT06113042|BEHAVIORAL|School healthy environment evaluation|Evaluation on school healthy environment will be carried out in Group 1 and Group 2 to enhance the schools to provide a healthy school environment to children.
223697590|NCT05143541|DEVICE|AEON Endostapler|Surgery with AEON Endostapler
223697591|NCT04423510|PROCEDURE|Crystallized phenol treatment|
223697592|NCT02899845|OTHER|postural task|
223697593|NCT02899845|OTHER|walk task|
223697594|NCT06206642|DIAGNOSTIC_TEST|PET/CT|Low-dose CT images were first collected during scanning. The tube voltage was 120kilovolt, the tube current was 50-220Milliampere and the layer thickness was 3.75mm.
223697595|NCT05133232|DEVICE|SynPhNe physio-neuro platform|"The SynPhNe device training protocol lasting approximately 60 mins:~1. Preparation for setup (\~5 mins)~2. Instruction video led warm up with active single and multi-joint movements - (\~20 mins): • Wrist extension and flexion• Fingers extension and flexion• Arm pronation and supination• Open grasp and close grasp • Open pinch and close pinch• Pronate and close grasp/ supinate and open grasp~3. Rest break - (\~5 mins)~4. Video led task practice as per the tasks below (any 4 tasks only) - (\~30 mins) • Grasp, lift and transfer water bottle using cylindrical grasp• Grasp lift and transfer pen using pinch grip• Flip pages of a book using lateral pinch grip• Use chopsticks to lift, transfer and place a small object• grasp doorknob and turn clockwise/anticlockwise, spoon scoop to pick up macaroni, open/ close a cylindrical jar, put object in pouch while holding it open and close it, fold/crease/tear a A4 size paper or fold handkerchief, reach a basket at different heights with an object."
223697596|NCT04210583|DEVICE|Vulvovaginal Treatment|"Device model(s) - Venus Fiore™ Device settings and programming internal applicator - 42°C - 45°C Temperature output via automatic temperature control (ATC) (optional treatment).~Duration of exposure and frequency of exposure with internal applicator - one treatment for 12-15 minutes at 12 months (optional treatment).~Device settings and programming external mons pubis and labia applicators - 10-35% output (optional treatment).~Duration of exposure and frequency of exposure external applicators - one treament for 15 minutes for the mons pubis, 10 minutes for labia at 12 months (optional treatment)."
223697597|NCT02410551|DRUG|Pacritinib|200 mg by mouth twice a day for 60 days.
223697598|NCT02410551|DRUG|Busulfan|Busulfan AUC of 4000 microMol-min per day providing that pharmacokinetic can be done, otherwise Busulfan dose given as a fixed dose of 100 mg/m2 daily for four days.
223697599|NCT02410551|BEHAVIORAL|Questionnaires|Questionnaires completed at baseline, 1, 3, 6, and 12 months after transplant.
223697600|NCT02410551|BEHAVIORAL|Phone Calls|Phone calls made by study staff to participant on second and third week of each month.
223697601|NCT02410551|PROCEDURE|Allogeneic Stem Cell Transplantation|Allogeneic stem cell transplantation (Allo TP) 60 days after starting Pacritinib but not more than 180 days.
223780818|NCT03826420|BEHAVIORAL|SCF Supervision with Secure Confinement Sanctioning|Parolees assigned to this group will, in the face of a violation, be given a sanction that involves secure confinement.
223780819|NCT03826420|BEHAVIORAL|SCF Supervision with Work Release Sanctioning|Parolees assigned to this group will, in the face of a violation, be given a sanction that involves work-release.
223697602|NCT02410551|DRUG|Fludarabine|Fludarabine taken along with Busulfan as per standard of care as preparative regimen for allogeneic stem cell transplantation (Allo TP).
223697603|NCT01792271|OTHER|Inhaled 7% HS (NaCl) home treatment|Administering inhaled 7% NaCl for two weeks of home treatment vs. a placebo of 0.12% NaCL during a separate home treatment period, and assessing the effects of each primarily by MCC study.
223697604|NCT01739309|DRUG|Abemaciclib|Administered orally
223697605|NCT02103712|OTHER|Qualitative|
223780820|NCT03826420|BEHAVIORAL|SCF Supervision with GPS Supervision Sanctioning|Parolees assigned to this group will, in the face of a violation, be given a sanction that involves GPS supervision.
223697606|NCT06362070|DEVICE|DaVinci® Surgical System|Assisted-robotic radical Gastrectomy
223697607|NCT06362070|DEVICE|Hugo™ RAS System|Assisted-robotic radical Gastrectomy
223697608|NCT06362070|DEVICE|Versius® Robotic Surgery System|Assisted-robotic radical Gastrectomy
223697609|NCT05426772|OTHER|exercise and kinesiotaping|"Exercise: Aerobic exercise will be performed on the treadmill for 20 minutes with a maximum heart rate of 55%-65% and a perceived exertion of less than 3. The Moxy muscle oxygen monitor will take measurements over the quadriceps femoris muscle at this time.~Kinesiotaping: After 3 days, the same participants will be called for kinesiotaping application. The application will be applied to the quadriceps femoris muscle with the facilitation technique by a physiotherapist who has a kinesio taping training certificate."
223697610|NCT00881673|DRUG|AL38583 Ophthalmic Solution|Topical ophthalmic
223697611|NCT00881673|DRUG|Maxidex|Topical ophthalmic
223697612|NCT00881673|DRUG|Vehicle|AL38583 Vehicle
223697613|NCT00929123|PROCEDURE|neural mobilization|manual therapy technique known to directly stress the median nerve
223697614|NCT00929123|PROCEDURE|sham neural mobilization|sham technique mimicking the neural mobilization which is not specific to the median nerve
223697615|NCT00929123|OTHER|healthy controls|People without carpal tunnel syndrome for comparison
223780821|NCT03139656|BEHAVIORAL|Values Clarification|This intervention will incorporate elements from several widely established self-regulatory strategies aimed at enhancing the motivational aspects of goal pursuit, including mental contrasting (Oettingen, 2000), self-reflection (Koestner et al., 2002), self-affirmation (Schmeichel and Vohs, 2009), and the values clarification components of Acceptance and Commitment Therapy (ACT; Hayes, Strosahl, \& Wilson, 1999). Participants will be prompted to enter their selected health goal and will then be instructed to identify personal values that might be practiced in pursuit of this goal. Participants will write about these values for several minutes, after which they will be instructed to select a short phrase or image that conjures up for them the reasons they choose to engage in their goal. Participants will be asked to type the phrase into a textbox and will have the option of receiving a confidential print-out of their chosen phrase at the end of the study visit.
223780822|NCT03139656|BEHAVIORAL|Planning|"Participants in this condition will be guided to create detailed implementation intentions, or if-then planning statements (Gollwitzer \& Sheeran, 2006), specifying when, how, and where they will engage in their selected health goal. Participants will be provided with a detailed rationale adapted from earlier research on implementation intentions (e.g., Webb et al., 2010). Participants will be guided to generate a plan indicating when, where, and how they will enact their goal-based behavior over the next week. They will also be prompted to identify 3 obstacles they are likely to encounter during the pursuit of each goal, and to specify in an if-then format what specific actions they will take to overcome each obstacle (following the procedures and sample if-then responses of Koestner et al., 2002). They will be asked to rehearse each if-then statement to themselves before the end of the visit."
223697616|NCT01495975|OTHER|Diabetes Transitions Tool Kit|Access to a remote glucose monitoring and a web-based patient-provider communication portal, the Diabetes Transitions Toolkit (DTTK), for the month after discharge.
223697617|NCT00239304|DRUG|Gefitinib|
223697618|NCT00239304|DRUG|Cisplatin|
223697619|NCT00239304|PROCEDURE|Radiotherapy|
223697620|NCT01954160|DEVICE|Symplicity Renal Denervation|Renal denervation
223697621|NCT05627297|OTHER|CEUS and CEMRI|contrast-enhanced ultrasound and contrast-enhanced MRI examination
223697622|NCT05447897|OTHER|Qualitative Group Interviews|One time interview, 60-90 minutes
223697623|NCT05447897|OTHER|Stakeholder advisory group|The team will meet with the stakeholder advisory group four times for 1-2 hours each
223697624|NCT02083081|BEHAVIORAL|Community level intervention|Community intervention plus individual counseling
223697625|NCT03661710|OTHER|Investigating Adherence to Standard of Care Medication and Cardiac Rehabilitation|Information from health care insurance providers on how many patients adhered to prescribed medication and how many underwent cardiac rehabilitation and how adherence influenced cardiovascular outcome will be retrieved
223697626|NCT00496223|DRUG|Sunitinib|Sunitinib will be given PO once daily on days 1-14 of each 21 day cycle. The exact dose of sunitinib will be determined during the Phase I part of the trial.
223697627|NCT00496223|DRUG|Dacarbazine|Dacarbazine will be given at 1000 mg/m2 on day 1 of every 21 day cycle.
223697628|NCT01360281|OTHER|Neuromuscular Electrical Stimulation|
223697629|NCT01360281|OTHER|ECR|Resisted exercises
223697630|NCT00520832|DEVICE|Microcurrent|20 minutes of sub-threshold microcurrent 2 hours before bedtime per day for 21 days.
223697631|NCT00520832|DEVICE|Microcurrent|Participants will receive a device identical to the active device used in the experimental condition, but which produces no current.
223697632|NCT05005078|DRUG|WST-057|WST-057 topical solution
223697633|NCT05005078|DRUG|Placebo|WST-057 Matching placebo
223697634|NCT04190667|DIAGNOSTIC_TEST|Genomic testing|A multi-panel testing of 36 genes would be given for these patients in their peripheral blood and tumor tissues. These 36 genes include: BRCA1, BRCA2, ABRAXAS1(FAM175A）, ATM, ATR, BAP1, BARD1, BRIP1, C11ORF30（EMSY）, CDK12, CHEK1, CHEK2, FANCA, FANCC, FANCD2, FANCI, FANCL, MRE11A, NBN, PALB2, PPP2R2A, PTEN, RAD50, RAD51B, RAD51C, RAD51D, RAD54B, RAD54, MLH1, MSH2, MSH6, PMS2, EPCAM, STK11, TP53, CDH1. The study would select 150 patients with pathogenic or likely pathogenic mutations in BRCA1/2 and 150 patients without these mutations to further explore the HRD status.
223697635|NCT06352983|PROCEDURE|Fixed dental prosthesis|Fixed dentals prosthesis made out of high translucent zirconium dioxide with or without a porcelain veneer.
223697636|NCT02276326|DIETARY_SUPPLEMENT|VSL#3 sachets|4 sachets a day for 4 months
223697637|NCT03459482|OTHER|Food Elimination Diet|Subjects asked to participate in a food elimination diet, either True or Sham to evaluate the effects on their IBS symptoms
223697638|NCT02378675|OTHER|Blood draw|During the routine blood sampling, a 10ml plasma sample as well as a 10ml serum sample will be obtained, spinned and stored at -80°C until the final assessment of adipocytokines.
223697639|NCT04375618|DRUG|RhEGF|The EGF impregnated membrane will be placed upon the recession site and will be stabilized by suturing it to the lingual papillae using 4-0 absorbable sutures. The flap will be coronally advanced as far as possible to cover the membrane and will be sutured to the buccal interdental papillae with 4-0 absorbable sutures (Trulenetm, Healthium Medtech Pvt Ltd, Bangalore, India). Standard recall and maintenance regimen will be followed and subjects will be encouraged to report to the department on a monthly basis.
223697640|NCT04375618|DRUG|Plain Collagen|A collagen membrane without FGF-2 will be used.
223697641|NCT03775291|DIAGNOSTIC_TEST|Simultaneous assessment of sleep apnea by polysomnogram and wearable device|Characterization of sleep apnea by lab-based polysomnogram
223697642|NCT01104155|DRUG|eribulin mesylate + erlotinib|21-day Regimen: Eribulin mesylate given at a dose of 2 mg/m2 as a 2-5 min intravenous (IV) bolus on Day 1 and 150 mg of erlotinib given orally once daily, one hour before or two hours after the ingestion of food, on Days 2-16 of a 21-day cycle.
223697643|NCT01104155|DRUG|eribulin mesylate + erlotinib|28-day Regimen: Eribulin mesylate given at a dose of 1.4 mg/m2 as a 2-5 min IV bolus on Days 1 and 8, and 150 mg of erlotinib given orally once daily, one hour before or two hours after the ingestion of food, on Days 15-28 of a 28-day cycle.
223697644|NCT00975637|DRUG|70 mg SC|70 mg SC
223697645|NCT00975637|DRUG|210 mg SC|210 mg SC
223697646|NCT00975637|DRUG|140 mg SC|140 mg SC
223697647|NCT00975637|DRUG|280 mg SC|280 mg SC
223697648|NCT00975637|DRUG|Placebo|Placebo SC
223697649|NCT01484132|PROCEDURE|Restoration of dental caries with dental composite|Dental Restoration (bisphenol A diglycidyl ether methacrylate based composite)
223697650|NCT05091671|OTHER|Free From Pain Exercise Programme Variation 1|Includes the initial 45-minute consultation + the exercise booklet + the 12 reasons to exercise leaflets + the 12 metaphor leaflets.
223697651|NCT05091671|OTHER|Free From Pain Exercise Programme Variation 2|Includes the initial 45-minute consultation + the exercise booklet + the 12 reasons to exercise leaflets + the 12 metaphor leaflets, and the 12 Zoom online sessions.
223697652|NCT00000671|DRUG|Zidovudine|
223697653|NCT00000671|DRUG|Didanosine|
223697654|NCT01199900|DRUG|PF-04171327|25 mg extemporaneous preparation of oral solution predosed 8 hours prior to Oral Glucose Tolerance Test (OGTT)
223697655|NCT01199900|DRUG|PF-04171327|25 mg extemporaneous preparation of oral solution predosed 12 hours prior to Oral Glucose Tolerance Test (OGTT)
223697656|NCT01199900|DRUG|Prednisone|5 mg tablet predosed at 8 hours prior to Oral Glucose Tolerance Test (OGTT)
223697657|NCT01199900|DRUG|PF-04171327|3 mg extemporaneous preparation of oral solution predosed at time selected from Part 1 prior to Oral Glucose Tolerance Test (OGTT)
223697658|NCT01199900|DRUG|PF-04171327|10 mg extemporaneous preparation of oral solution predosed at time selected from Part 1 prior to Oral Glucose Tolerance Test (OGTT)
223697659|NCT01199900|DRUG|Prednisone|5 mg tablet predosed at 8 hours prior to Oral Glucose Tolerance Test (OGTT)
223697660|NCT01199900|DRUG|Prednisone|5 mg tablets predosed at 8 hours prior to Oral Glucose Tolerance Test (OGTT)
223697661|NCT05319769|PROCEDURE|Atrial fibrillation ablation|Pulmonary vein isolation
223697662|NCT02276365|DRUG|BI 10773|
223697663|NCT02276365|DRUG|Pioglitazone|
223697664|NCT04807140|DRUG|Toripalimab, nab-paclitaxel, carboplatin|"Patients receive Toripalimab IV on day 1, nab-paclitaxel IV on day 1 and carboplatin IV on day 1.~Treatment repeats every 21 days for up to 2-4 courses in the absence of disease progression or unacceptable toxicity."
223697665|NCT04807140|DRUG|Toripalimab|"Patients receive Toripalimab IV on day 1.~Treatment repeats every 21 days for up to 2-4 courses in the absence of disease progression or unacceptable toxicity."
223697666|NCT04807140|PROCEDURE|Surgical resection|Surgical therapy will be at the discretion of the treating surgeon per standard of care.
223697667|NCT00186329|DRUG|Natrecor, a recombinant form of B-type Natriuretic Peptide, made by Scios, Inc. vs. placebo|
223697668|NCT02354183|BEHAVIORAL|DBT Skills Training|Based on Linehan's (1993) manualized DBT approach, the brief DBT skills training group covers will cover five skills: wise mind, TIP skills, distraction, mindfulness of the current emotion, and opposite to emotion action.
223697669|NCT02207673|PROCEDURE|Tailoring of the resection based on biomarker in aEcoG during epilepsy surgery|
223697670|NCT02193477|DEVICE|TEAS|Electric stimulation was given through electrode attached to specific acupoints for 30mins before general anesthesia induction,1th day and 2nd day after surgery.
223697671|NCT02193477|DEVICE|Sham TEAS|Electric stimulation was given through electrode attached to non-acupoints for 30mins before general anesthesia induction,1th day and 2nd day after surgery.
223697672|NCT02196207|DRUG|Eloctate Prophylaxis|Prevention Trial, Arm A: Eloctate (65 IU/kg) will be administered weekly by intravenous infusion for up to 48 weeks in previously untreated children with severe hemophilia A beginning before the first bleed.
223697673|NCT02196207|DRUG|Emicizumab Prophylaxis|Prevention Trial, Arm B: Emicizumab (1.5 mg/kg) will be administered weekly by subcutaneous injection for up to 48 weeks in previously untreated children with severe hemophilia A.
223697674|NCT02196207|DRUG|Eloctate ITI plus Emicizumab|Eradication Trial, Arm A: Eloctate (100 IU/kg) ITI every other day by intravenous infusion plus Emicizumab (1.5 mg/kg) weekly by subcutaneous injection will be administered for up to 48 weeks as immune tolerance in children and adults with severe hemophilia A and high-titer inhibitors.
223697675|NCT02196207|DRUG|Eloctate ITI|Eradication Trial, Arm A: Eloctate (100 IU/kg) ITI every other day by intravenous infusion will be administered for up to 48 weeks as immune tolerance in children and adults with severe hemophilia A and high-titer inhibitors.
223697676|NCT01934972|OTHER|CR + DCS (D-cycloserine)|CR + DCS
223697677|NCT01934972|OTHER|CR + placebo|CR + placebo
223697678|NCT06286358|DIAGNOSTIC_TEST|Kinocardiography|Technology Measuring Cardiac Mechanical Activity Via Accelerometers and Gyroscopes
223697679|NCT03131453|DRUG|CNP520 50mg|50 mg capsule
223697680|NCT03131453|DRUG|CNP520 15mg|15 mg capsule
223697681|NCT03131453|OTHER|Matching placebo|Matching placebo for 15 and 50 mg capsules
223697682|NCT03864770|DEVICE|Extracorporeal shock wave therapy|Extracorporeal shock wave therapy is a mechanical sound wave that generates energy by extremely high-frequency vibration to compress the medium. Low-energy extracorporeal shock waves can be used for cell regeneration and pain control therapy; medium-high energy can be used to treat patients with poor bone healing; high-energy can be used to lithotrite. In recent years, extracorporeal shock waves have been applied on the musculoskeletal diseases, such as: epicondylitis, plantar fasciitis, chronic pelvic pain, chronic heel pain syndrome, lymphedema, burns, pressure sores, calcific tendinitis and myofascial pain syndrome. This treatment is a non-invasive and safe treatment.
223697683|NCT03864770|PROCEDURE|General physical therapy|The general physical therapies such as: thermotherapy, straight leg raise (SLR), transcutaneous electrical nerve stimulation (TENS) for treatment on calf muscle.
223697684|NCT00950495|DEVICE|Mandibular Advancement Device (MAD)|This oral appliance keeps the mandible and the tongue in a protruded position. This results in an upper respiratory tract widening and/or reduced collapsibility of the upper airway, thereby preventing the upper airway collapse during sleep.
223697685|NCT00950495|DEVICE|nasal CPAP|The CPAP machine delivers a stream of compressed air via a hose to a nose mask, splinting the airway (keeping it open under air pressure) so that unobstructed breathing becomes possible, reducing and/or preventing apneas and hypopneas
223697686|NCT00950495|DEVICE|placebo|as a placebo, a thin (\< 1 mm), hard acrylic-resin palatal splint with only a partial palatal coverage was used
223697687|NCT03975062|DRUG|dabigatran etexilate|150 mg twice daily (BID)
223697688|NCT00006223|BIOLOGICAL|recombinant flt3 ligand|
223697689|NCT01945112|DEVICE|Paper Tape|Applied to blister prone areas of the foot
223697690|NCT02770170|DRUG|BI 655064 dose 1|
223697691|NCT02770170|DRUG|BI 655064 dose 2|
223697692|NCT02770170|DRUG|BI 655064 dose 3|
223697693|NCT02770170|DRUG|Placebo|
223697694|NCT04840732|BEHAVIORAL|VR training program|Use VR software to make a training education program.
223697695|NCT04840732|BEHAVIORAL|usual care|Chemotherapy training as usual care (for training chemotherapy skill).
223697696|NCT04205253|DIAGNOSTIC_TEST|Ultrasonography imaging|This study aimed to evaluate the tongue areas and compare the tongue areas before the implementation of rigid direct laryngoscope and after the rigid direct laryngoscope.
223697697|NCT04768725|BEHAVIORAL|Dietary intervention combined with physical-cognitive exergaming|Intermittent Fasting (IF) \[self-selected diet with 25-75% of estimated baseline energy requirements for 2 days/week (fast day) along with ad libitum for 5 days/week (feed day)\] combined with physical-cognitive exercise \[60-70% of heart rate maximum for aerobic and 60-70% of 1 repetition maximum, 8-12 repetitions/set, 3 sets of each exercise for resistance exercise; memory, attention, and executive function for cognition\], 60 minutes per session, 3 sessions per week for 12 weeks (36 sessions)\].
223697698|NCT04768725|BEHAVIORAL|Dietary intervention|Intermittent Fasting (IF) \[self-selected diet with 25-75% of estimated baseline energy requirements for 2 days/week (fast day) along with ad libitum for 5 days/week (feed day)\].
223697699|NCT04768725|BEHAVIORAL|Physical-cognitive intervention|Physical-cognitive exercise \[60-70% of heart rate maximum for aerobic and 60-70% of 1 repetition maximum, 8-12 repetitions/set, 3 sets of each exercise for resistance exercise; memory, attention, and executive function for cognition\], 60 minutes per session, 3 sessions per week for 12 weeks (36 sessions)\].
223697700|NCT04020328|DRUG|Leflunomide 20 mg+prednisone 0.5mg/kg/d|Leflunomide plus low dose glucocorticoids to have the immunosuppressive therapy to those progressive IgA nephropathy with eGFR\<50ml/min
223697701|NCT02988154|OTHER|Simulation training|Simulation training (computer simulation of the procedure, followed by simulation on a dead animal model).
223697702|NCT02988154|OTHER|''See one, do one'' approach|The participants watch an experienced surgeon perform the EVD placement, after which the participants attempt to perform the procedure independantly on the skull model.
223697703|NCT00445978|DRUG|Sapropterin Dihydrochloride|Subjects will receive oral, once-daily (for 2.5, 5, 10mg/kg/day doses) or twice-daily (for the 20 mg/kg/day dose) sapropterin dihydrochloride during a 16-week dose escalation phase, with dose levels increasing within subjects every 4 weeks as follows: 2.5, 5, 10, and 20 mg/kg/day. Dosing was with 100 mg tablets and rounded to the nearest whole tablet. Each dose was taken within 1 hour after the morning meal. Subjects may continue in an optional extension phase at the highest tolerated dose for up to a total of 2 years.
223697704|NCT01483768|PROCEDURE|Sleeve gastrectomy for morbid obesity|Sleeve gastrectomy or longitudinal gastrectomy for morbid obesity: is a partial gastrectomy without interruption of the gastric continuity. This procedure includes the resection of the great curvature of the stomach, the fundus , except the lesser curvature and the antrum.
223697705|NCT02497300|DRUG|Spironolactone|
223697706|NCT02497300|DRUG|Amiloride|
223697707|NCT02378623|DRUG|Apixaban|Patients who meet the study eligibility criteria and consent for enrollment will be randomized in a 1:1 ratio to intervention with apixaban or control group with placebo. The randomization will be performed by a computer generated block randomization protocol. Randomization will be stratified according to pre-existing CIED (≥6 months) vs. new implantation (\<6 months from date of implant), in order to ensure at least 25% of patients have longstanding lead placement.
223697708|NCT02378623|DRUG|Placebo|Patients who meet the study eligibility criteria and consent for enrollment will be randomized in a 1:1 ratio to intervention with apixaban or control group with placebo. The randomization will be performed by a computer generated block randomization protocol. Randomization will be stratified according to pre-existing CIED (≥6 months) vs. new implantation (\<6 months from date of implant), in order to ensure at least 25% of patients have longstanding lead placement.
223697709|NCT00087165|BIOLOGICAL|GTI-2040|
223697710|NCT00087165|DRUG|docetaxel|
223697711|NCT00087165|DRUG|prednisone|
223697712|NCT05913648|OTHER|Tool Translation|The Data Collection procedure will be done in two phases. The first phase will revolve around the translation of the instrument. Firstly the tool will be translated into Urdu with the help of two professional translators and then it will be back-translated into English to cross-check the clarity of the text. The translation will focus more on the context and understanding of the text rather than literal word-to-word meanings. The translation will be done according to the WHO guidelines. The Urdu version of MENQOL will be used to assess content validity on menopausal women.
223697713|NCT02670434|DRUG|NK-104-CR|NK-104-CR 8 mg daily for 52 weeks
223697714|NCT02670434|DRUG|Placebo|Placebo daily for 12 weeks
223697715|NCT02670434|DRUG|Livalo|Livalo® IR daily from week 12 to week 52
223697716|NCT05306431|DRUG|Polyhexamethylene biguanide|Polyhexamethylene biguanide (PHMB), is a disinfectant solution having a broad spectrum of antimicrobial activity and is investigated as an endodontic irrigant
223697717|NCT05306431|DRUG|Sodium Hypochlorite|A number of irrigant solution has thus been proposed to serve the purpose, the most popular being sodium hypochlorite (NaOCl) because of its excellent antimicrobial activity but also the ability to dissolve organic matter
223697718|NCT05078242|DEVICE|EaseVRx|Participants will experience 7 sessions of the EaseVRx device for chronic pain.
223697719|NCT01822496|RADIATION|Radiation Therapy|30 once-daily 2 Gy fractions over 6 weeks totaling 60 Gy of intensity-modulated radiation therapy (IMRT) or 3-dimensional conformal radiation therapy (3D-CRT).
223697720|NCT01822496|DRUG|Carboplatin|"Concurrent: AUC=2, IV, days 1, 8, 14, 22, 29, and 36 of radiation therapy. For patients receiving either erlotinib or crizotinib, carboplatin will begin 2 weeks after erlotinib or crizotinib, as applicable.~Consolidation: 4-6 weeks after completion of RT, AUC=6, IV, days 1 and 22."
223697721|NCT01822496|DRUG|Cisplatin|50 mg/m2, IV (intravenous), on days 1 and 8 of two 4-week cycles concurrent with radiation therapy. For patients receiving either erlotinib or crizotinib, cisplatin will begin 2 weeks after the completion of erlotinib or crizotinib, as applicable.
223780823|NCT03139656|BEHAVIORAL|Combined|"Participants in this condition will complete abbreviated versions of both the values clarification and planning procedures, as detailed above. Participants will be prompted to identify 2 obstacles (as opposed to 3) they might encounter during the pursuit of each goal. For each of the obstacles they identify with respect to each of their target goals, they will be prompted to form an additional implementation intention in the form: When \[I encounter the specified obstacle\], I will do \[X\] and remember \[values-based statement or image identified during values clarification exercise\]. They will be asked to rehearse these if-then statements to themselves before the end of the visit."
223697722|NCT01822496|DRUG|Crizotinib|250 mg, orally, twice daily for four 3-week cycles (12 weeks in total)
223780824|NCT00001180|DRUG|Ovine Corticotropin-Releasing Hormone (oCRH)|
223697723|NCT01822496|DRUG|Erlotinib|150 mg, orally, once daily for four 3-week cycles (12 weeks in total)
223697724|NCT01822496|DRUG|Etoposide|50 mg/m2, IV, on days 1 and 8 of two 4-week cycles concurrent with radiation therapy. For patients receiving either erlotinib or crizotinib, etoposide will begin 2 weeks after the completion of erlotinib or crizotinib, as applicable.
223697725|NCT01822496|DRUG|Paclitaxel|"Concurrent: 45 mg/m2, IV, days 1, 8, 14, 22, 29, and 36 of radiation therapy. For patients receiving either erlotinib or crizotinib, carboplatin will begin 2 weeks after erlotinib or crizotinib, as applicable.~Consolidation: 4-6 weeks after completion of RT, 200 mg/m2, IV, days 1 and 22."
223780825|NCT03678012|DRUG|Ferumoxytol/Hydrogen peroxide|1.5% Ferumoxytol / 3% Hydrogen Peroxide (H2O2) 1:1 ratio. Each subject will use this product during one of three treatment periods in the crossover study design.
223780826|NCT03678012|DRUG|Hydrogen Peroxide|Sham Solution / 3% Hydrogen Peroxide (H2O2) 1:1 ratio. Each subject will use this product during one of three treatment periods in the crossover study design.
223697726|NCT05843955|OTHER|Questionnaire|Nutritional status, physical activity levels, anthropometric measurements, and biochemical parameters of individuals were examined. A food consumption frequency questionnaire was administered.
223697727|NCT03267251|OTHER|Vacteens Web app for mobile devices|The Web app provides parents of young adolescent girls (ages 11-14) accurate information about HPV Vaccination, and a number of tools to aid informed decision making.
223697728|NCT03267251|OTHER|Standard Usual and Customary HPV Information - CDC pamphlet|The usual communication about HPV Vaccination in clinics is for parents to be issued the CDC pamphlet on HPV Vaccination.
223780827|NCT03678012|DRUG|Water|Sham solution (water; negative control). Each subject will use this product during one of three treatment periods in the crossover study design.
223697729|NCT03946488|DEVICE|Functional electrical stimulation|Functional electrical stimulation of finger's muscles in order to open the hand
223697730|NCT02902068|DEVICE|NICaS Bio Impedance|"Hemodynamic monitoring will be carried out using non invasive NICaS cardiac impedance by the use of two electrodes stickers which are pasted on the wrists for about 6 minutes.~Monitoring will be done with women lying down or sitting up half an hour preoperatively (in the woman's surgery waiting room) intraoperatively, and postoperatively in the PACU.~Preoperative data will be compared to intraoperative and postoperative data, and will be analyzed in order to evaluate the dynamic cardiac output changes in women undergoing cesarean sections."
223697731|NCT00304239|COMBINATION_PRODUCT|Metvix-PDT|Metvix 160 mg/g Cream was applied for 3 hours with occlusive dressing, and illumination with non-coherent red light using the Aktilite CL128 lamp, with a total light dose 37 Joule/square centimeter (J/cm²). All eligible lesions on the participant were treated twice with an interval of 1 week between treatments.
223697732|NCT00304239|COMBINATION_PRODUCT|Vehicle-PDT|Vehicle Cream was applied for 3 hours with occlusive dressing, and illumination with non-coherent red light using the Aktilite CL128 lamp, with a total light dose 37 J/cm². All eligible lesions on the participant were treated twice with an interval of 1 week between treatments.
223697733|NCT05227378|BIOLOGICAL|neoantigen tumor vaccine with or without PD-1/L1|personalized neoantigen tumor vaccine with or without PD-1/L1
223697734|NCT06047925|PROCEDURE|3D printed crown|Reduction will be performed on the occlusal surface using a flame stone or a wheel stone, to perform occlusal clearance by 1 mm. Reduction will be performed by 1 mm on the mesial, distal, buccal and lingual surfaces of the tooth. Impression for the preparation will be taken using putty and light poly vinyl siloxane material. Temporary crown will be placed above the preparation as temporisation.The impression will be sent to the lab .The preparation will be optically scanned in the lab and the restoration will be digitally designed using computer designing software.The crown will be printed using 3D printer using hybrid resin(micro-filled hybrid material) material.The 3d printed crown is cemented with resin cement.
223697735|NCT06047925|PROCEDURE|stanless steel crown|The occlusal surface of the tooth should be reduced by about 1.5 mm, maintaining its occlusal contour or until the tooth is out of occlusion with adequate room to fit a crown.Proximally, tooth reduction will be made through the mesial and distal contact areas, then roundation of line angles to avoid the creation of ledges or steps.The crown selection will be done by trial and error or by measuring the mesiodistal dimension of the tooth space with dividers. It can also be helpful to measure the dimension of the contralateral tooth. A correctly fitting crown should snap or click at try in.
223697736|NCT00244517|DRUG|TTE measurements under anesthesia with sevoflurane, isoflurane, desflurane, and remifentanyl|TTE measurements were performed during remifentanil 2 ng/ml TCI end-organ concentration, 1 MAC of either anesthetic gas under spontaneous ventilation and 1 MAC of either anesthetic under IPPV
223697737|NCT00244517|DRUG|Sevoflurane, Isoflurane, Desflurane|1 MAC
223697738|NCT04867057|DRUG|Trichomylin for SAD|Healthy subjects meeting eligibility criteria were randomized to each dose cohort (up to four dose ascending cohorts) to receive either Trichomylin or Placebo. The study drug (Trichomylin or Placebo) will be administered orally as a single dose.
223697739|NCT04867057|DRUG|Placebo for SAD|Healthy subjects meeting eligibility criteria were randomized to each dose cohort (up to four dose ascending cohorts) to receive either Trichomylin or Placebo. The study drug (Trichomylin or Placebo) will be administered orally as a single dose.
223697740|NCT04867057|DRUG|Trichomylin for MAD|Healthy subjects meeting eligibility criteria were randomized to each dose cohort (up to three cohorts) to receive either Trichomylin or Placebo. The study drug (Trichomylin or Placebo) will be administered daily oral doses for a total of 9 days.
223697741|NCT04867057|DRUG|Placebo for MAD|Healthy subjects meeting eligibility criteria were randomized to each dose cohort (up to three cohorts) to receive either Trichomylin or Placebo. The study drug (Trichomylin or Placebo) will be administered daily oral doses for a total of 9 days.
223697742|NCT04956926|DRUG|JS201|JS201 is administered intravenously Q3W at the corresponding dose.
223697743|NCT01960673|DEVICE|LMA proseal|It would be used to observe the leak pressure at 30,45,60 degree of the head and neck position and the condition between the vocal cord and peri-laryngeal region. The cuff pressure would be kept at 30 cm H20.
223697744|NCT01960673|DEVICE|igel LMA|It would be used to observe the leak pressure at 30,45,60 degree of the head and neck position and the condition between the vocal cord and peri-laryngeal region.
223697745|NCT01960673|DEVICE|air Q LMA|It would be used to observe the leak pressure at 30,45,60 degree of the head and neck position and the condition between the vocal cord and peri-laryngeal region. The cuff pressure would be kept at 30 cm H20.
223780828|NCT00968110|DRUG|omalizumab|Dosing table established for omalizumab
223780829|NCT05002322|OTHER|Systems Analysis and Improvement Approach|"Intensive phase: district MOH supervisors receive a one-week training on SAIA-HTN. The nine-month intervention wave will be mentored by INS study personnel who will accompany and support district MOH supervisors as they implement at the facility level. Over the first week of each iterative cycle, facility teams populate and interpret the HCAT, develop process maps, define one to two micro-interventions and indicators to monitor these modifications. Facility teams receive two mentorship visits by district supervisors and study personnel for the first month, followed by monthly visits throughout intensive implementation.~Sustainment phase (depending on implementation wave allocation): district supervisors will independently lead implementation, with financial support for travel to clinics and to hold meetings, but without intensive support from study personnel."
223780830|NCT01430130|DEVICE|embrace device|Adhesive bandage/dressing intended to minimize scar formation.
223780831|NCT02703844|DEVICE|Caloric Vestibular Stimulation|Stimulation of the vestibular nerves
223780832|NCT02703844|DEVICE|Sham Caloric Vestibular Stimulation|Sham stimulation of the vestibular nerves
223780833|NCT03704818|DRUG|Dapagliflozin 5mg|Dapagliflozin treatment taken daily for 4-weeks.
223780834|NCT03704818|DRUG|Placebo Oral Tablet|Placebo treatment taken daily for 4-weeks.
223780835|NCT03905057|DEVICE|Dornier Aries 2 (with active applicator)|Active ESWT: 5000 shockwaves per session. 2 ESWT sessions per week, 12 sessions in total.
223780836|NCT03905057|DEVICE|Dornier Aries 2 (with sham applicator)|Sham ESWT - No shockwave administered
223780837|NCT02752412|DRUG|Insulin glargine/Lixisenatide (HOE901/AVE0010)|"Pharmaceutical form: solution~Route of administration: subcutaneous"
223780838|NCT02752412|DRUG|Insulin glargine U100 (HOE901)|"Pharmaceutical form: solution~Route of administration: subcutaneous"
223780839|NCT02752412|DRUG|Metformin|"Pharmaceutical form: tablet~Route of administration: oral"
223780840|NCT00801684|DRUG|Placebo|Supplied as an empty size-2 capsule and administered as a single dose via C2S inhaler.
223780841|NCT00801684|DRUG|TrIP-2D|Trospium inhalation powder containing 100 mcg TrCl (trospium chloride), supplied as dry powder in size-2 capsules and administered as a single dose via C2S inhaler.
223780842|NCT00801684|DRUG|TrIP-2SS|Trospium inhalation powder containing 100 mcg TrCl (trospium chloride), supplied as dry powder in size-2 capsules and administered as a single dose via C2S inhaler.
223780843|NCT00801684|DRUG|TrIP-2D|Trospium inhalation powder containing 400 mcg TrCl (trospium chloride), supplied as dry powder in size-2 capsules and administered as a single dose via C2S inhaler.
223780844|NCT00801684|DRUG|TrIP-2SS + Foradil|Trospium inhalation powder containing 100 mcg TrCl (trospium chloride), plus foradil (12 mcg formoterol fumarate) supplied as dry powder in size-2 capsules and administered as a single dose via C2S inhaler.
223780845|NCT05481112|DRUG|Extended-Release Buprenorphine Injection|Extended-release buprenorphine (XR-B, Sublocade) is manufactured by Indivior. XR-B consists of a depot injectable formulation in polymeric solution to the abdomen and releases buprenorphine over 28-days (4-weeks) by diffusion as the polymer biodegrades.
223780846|NCT02828111|DRUG|Patidegib|
223780847|NCT02828111|DRUG|Vehicle gel|
223780848|NCT00965224|BIOLOGICAL|dendritic cell vaccination (active specific immunotherapy)|
223780849|NCT02289131|PROCEDURE|Tooth Brushing Protocol|A 2-minute tooth brushing protocol, followed by a mouthwash rinse and application of moisturizer for a total of approximately 15 minutes.
223780850|NCT03173196|DEVICE|Non-invasive Multispectral Sonography|We measure both groups wirh the non-invasive multispectral sonography for 3 and for 30 minutes.
223780851|NCT01184014|DRUG|NPH insulin plus Complete Insulin Orders|NPH dosed per study-specific algorithm which incorporates total daily dosage of steroid to determine NPH dose. Complete insulin orders include background, meal-time and correction factor.
223780852|NCT01184014|DRUG|Complete Insulin Orders|3-part insulin which includes background, meal-time and correction factor
223780853|NCT05409924|DRUG|ATR-258|Single Ascending Dose
223780854|NCT05409924|DRUG|ATR-258|Multiple Ascending Dose
223780855|NCT05409924|DRUG|ATR-258|Repeat Dose
223780856|NCT01686087|BEHAVIORAL|Monthly Booster Sessions of EX/RP|45 minute EXRP booster sessions each month
223780857|NCT01686087|PROCEDURE|Visits with MD and independent evaluators|All patients will be followed carefully and evaluated by their study doctor and an independent evaluator to assess their symptoms.
223780858|NCT03125668|BEHAVIORAL|Educational Program|At the hospitalization, patients receive the educational program with Power Point®Slides, booklets and orientation about the use of warfarin.
223780859|NCT03125668|BEHAVIORAL|Telephone follow-up|"After hospital discharge they receive a telephone follow-up (five calls for six months: 1st call in one week and the others calls month by month until six months).~During the telephone calls the researcher talk with the patient about the topics that were approach in the educational intervention and motivate the patient to follow the recommendations for they have a successful treatment."
223697746|NCT01960673|DEVICE|ambu LMA|It would be used to observe the leak pressure at 30,45,60 degree of the head and neck position and the condition between the vocal cord and peri-laryngeal region. The cuff pressure would be kept at 30 cm H20.
223697747|NCT05280210|OTHER|PTC drug screening|PTC is an in vitro tumor model, which serves as a structural and functional unit recapitulating the original tumors in genotype, phenotype, and drug response. PTC will be used in drug screening.
223697748|NCT02979197|DRUG|OE 10 mg amlodipine besylate tablet|
223697749|NCT02979197|DRUG|OE 200 mg celecoxib capsule|
223697750|NCT02979197|DRUG|Matched placebo for OE amlodipine besylate tablet|
223697751|NCT02979197|DRUG|Matched placebo for OE celecoxib capsule|
223697752|NCT04876144|DEVICE|Kogito|"Users of the Kogito app progress throught the deep self-help intervention in a sequence of 5 modules. The base of the Kogito app is in the cognitive-behavioral therapy (CBT), relaxation techniques and peer support.~Module~1. Introduction to the CBT (psychoeducation) and deep breathing relaxation plus perinatal peer support videos. Emotional tracking.~2. Behavioral activization, relaxation techniques, CBT diary, psychoeducation on anxiety and depression, peer support.~3. CBT - vicious circle, progressive muscle relaxation, peer support content~4. Cognitive distortions, relaxation in imagination, peer support content~5. Cognitive restructuring, mindfulness relaxation, peer support content.~Progress in the Kogito app is conditional on the completion of various CBT tasks"
223697753|NCT01819376|OTHER|Facebook Status Update|
223697754|NCT00177996|DRUG|sertraline hydrochloride|The study was a double-blind study in which subjects diagnosed with major depression complicated by lifetime panic spectrum symptomatology were randomized to either high (but still within the standards of normal clinical practice) or low dose titration schedules of sertraline. The doses and titration schedules used in this study are consistent with recommended FDA guidelines.
223697755|NCT05060484|BIOLOGICAL|SCT1000|HPV vaccine
223697756|NCT05060484|BIOLOGICAL|Gardasil®9|HPV vaccine
223697757|NCT05060484|BIOLOGICAL|Gardasil®|HPV vaccine
223697758|NCT05060484|OTHER|placebo|adjuvent
223697759|NCT01407744|OTHER|laboratory biomarker analysis|Correlative studies
223697760|NCT04086875|BEHAVIORAL|Focus Group|Participate in focus group
223697761|NCT04086875|OTHER|Text Message|Receive text messages
223697762|NCT04086875|OTHER|Best Practice|Receive usual care
223697763|NCT04086875|OTHER|Questionnaire Administration|Ancillary studies
223697764|NCT03438383|DEVICE|Bi-PAP|The Bi-PAP system combines inspiratory support-IPAP (inspiratory positive airway pressure) with expiratory support-EPAP (expiratory positive airway pressure) and has been used, with good results, in a number of different clinical conditions such as COPD, respiratory failure due to neuromuscular disease, cardiogenic pulmonary edema and immediately post-operatively with pro-phylactic purpose.
223697765|NCT03438383|DEVICE|Sham Bi-PAP|"Sham Bi-PAP was created by introducing a hole at the connection of the mask with the spiral tube of the conventional Bi-PAP system. By doing so, the applied pressure by sham Bi-PAP was constant and equal to 2 cm H2O."
223697766|NCT06557174|DRUG|IMC-002|intravenous injection: Weekly administered for a period of first 4 weeks, then rest for 20 weeks. After the administration of the testing drug, if the subject's symptoms get worsen, a rescue therapy need to be adopted as based on Investigator's judgement, the testing drug injection should be discontinued.
223697767|NCT06557174|DRUG|mycophenolate mofetil， MMF|daily oral 0.2g
223697768|NCT04627025|DRUG|apraglutide|Apraglutide is a peptide analogue of GLP-2 under development for treatment of SBS-IF, which acts as a full agonist at the GLP-2 receptor with in vitro potency and selectivity comparable with native GLP-2.
223697769|NCT02766465|DRUG|Busulfan|"A:~Busulfan dose will be 3.2 mg/kg administered as a single daily dose IV on days -8 through -5 with dosing adjusted using targeted pharmacokinetics."
223697770|NCT02766465|DRUG|Fludarabine|"A:~Fludarabine dose will be 35 mg/m\^2/day administered IV on days -7 through -3 (total fludarabine dose is 175 mg/m\^2).~C:~Fludarabine 30mg/m2 IV dose will be given on Days -8, -7, -6, -5, -4"
223697771|NCT02766465|DRUG|r-ATG|"A:~r-ATG will be administered IV on day -6 at 0.5mg/kg, on day -5 at 1 mg/kg and on days -4, -3 and -2 at 1.5mg/kg (total r-ATG dose is 6 mg/kg)."
223697772|NCT02766465|PROCEDURE|Hematopoietic Cell Transplant|"A,B,C:~Day 0 is the day of transplantation."
223697773|NCT02766465|DRUG|Tacrolimus|"A:~Tacrolimus commences on day -3 and extends through day +180 after transplantation with doses adjusted to maintain appropriate levels according to institutional guidelines.~C:~Tacrolimus at therapeutic doses through Day 180, then taper per institutional guidelines"
223697774|NCT02766465|DRUG|Methotrexate|"A:~Methotrexate will be administered intravenously on day+1 at 15mg/m\^2, day+3 at 10mg/m\^2, day+6 at 10mg/m\^2, and day+11 at 10mg/m\^2.~C:~Methotrexate IV 7.5 mg/m2 dose will be given on Days +1, 3, +6 following transplant"
223697775|NCT02766465|PROCEDURE|Standard of Care|Continue to receive standard of care treatment per patient's SCD physician.
223697776|NCT02766465|DRUG|Alemtuzumab|"B:~Alemtuzumab 0.03 mg/kg IV dose will be given on Day -7, Alemtuzumab 0.1 mg/kg IV dose will be given on Day -6, Alemtuzumab 0.3 mg/kg IV dose will be given on Day -5,-4,-3~C:~Alemtuzumab test dose 3 mg IV once 24 hours prior to 1st dose of Alemtuzumab Alemtuzumab 10 mg IV, 15 mg IV, 20 mg IV given on Days -22 through Day -18. Alemtuzumab doses may be administered between Days -22 and -18 but are required to be on three consecutive days."
223697777|NCT02766465|DRUG|Total Body Irradiation (TBI)|Total Body Irradiation 300 cGY on Day -2
223697778|NCT02766465|DRUG|Sirolimus|Sirolimus at therapeutic doses through day 180, then taper per institutional guidelines if donor CD3+ \>50%
223697779|NCT02766465|DRUG|Melphalan|"C:~Melphalan 140 mg/m2 IV dose will be given on Day -3"
223697780|NCT02766465|DRUG|G-CSF|G-CSF 5 μg/kg/day continue until neutrophil engraftment.
223697781|NCT05986760|BEHAVIORAL|SPARK|Functional Motor training
223697782|NCT01631812|DRUG|SPM 962|SPM 962 transdermal patch once a daily up to 36.0 mg/day
223697783|NCT03469388|DIAGNOSTIC_TEST|Pulse wave analyses; central blood presaure parameters|Pulse wave analyses; central blood presaure parameters
223697784|NCT02496065|DRUG|BLZ-100|
223780860|NCT03125668|BEHAVIORAL|Face to face counseling|They receive two face to face counseling (1st meeting in three months and the 2nd meeting in six months after hospital discharge). In the face to face counseling the researcher collect the data about anxiety and depression again, health-related quality of life and adverse events related to oral anticoagulation therapy.
223780861|NCT03327480|OTHER|orthosis|Group 1: neoprebe CMC orthosis Group2: thermoplastic CMC orthosis
223780862|NCT00016289|BIOLOGICAL|recombinant interleukin-12|Given intraperitoneally
223697785|NCT06522412|DIETARY_SUPPLEMENT|JING SI HERBAL TEA LIQUID PACKETS|JING SI HERBAL TEA LIQUID PACKETS contains: eight herbal ingredients, primarily including dwarf lilyturf, houttuynia, balloon flower, siegesbeckia, licorice, mugwort, perilla leaf, and chrysanthemum. These eight Taiwanese native herbs are known for their abilities to moisturize, disperse cold, relieve lung congestion, dissolve phlegm, remove dampness, and clear heat.
223780863|NCT05110885|OTHER|Questionnaire|A questionnaire prepared by the researchers will be presented to the group.
223780864|NCT04574622|DEVICE|radial Extracorporeal Shockwave Therapy|rESWT was given on gastrocnemius muscles with the subject lying on prone position. No anesthesia was required.
223780865|NCT02030691|DEVICE|Nasal continuous airway positive pressure (nCPAP)|
223780866|NCT02030691|DEVICE|Nasal high frequency percussive ventilation (nHFPV)|
223780867|NCT00916877|RADIATION|Prophylactic Cranial Irradiation|Prophylactic Cranial Irradiation
223780868|NCT04177511|DEVICE|Transcutaneous Auricular Vagus Nerve Stimulation|"Transcutaneous Auricular Vagus Nerve Stimulation has an eartip connected to an external stimulator. The device used in this study is the TENS Eco Plus commercialized by Schwa Medico and European Compliance (CE) marked.~The electrode is positioned in the cymba concha of the left ear."
223780869|NCT01428960|DIETARY_SUPPLEMENT|Palm Mid Fraction, Shea Butter, High Oleic Sunflower Oil|Acute effect of sn-1 and sn-3 palmitic acid-rich or stearic acid-rich fats on postprandial lipemia, haemostatic and inflammatory markers, gut hormone concentrations, satiety, and insulinemic response in human volunteers ; 6 wk each with 2 week wash out in between
223780870|NCT03815071|DRUG|Ips-nsc cells|Total dose of ips-nsc cells will be administered at day0.
223697786|NCT06522412|DIETARY_SUPPLEMENT|JING SI HERBAL TANG HENG POWDER DRINK|JING SI HERBAL TANG HENG POWDER DRINK contains: Based on the eight herbal ingredients of Jingsi Herbal Drink Concentrate, this drink additionally includes pumpkin powder and bitter melon extract powder. (Ingredients: siegesbeckia, Jingsi complex herbal powder (dextrin fiber, herbal extracts (mugwort, siegesbeckia, dwarf lilyturf, houttuynia, balloon flower, licorice, perilla leaf, chrysanthemum)), pumpkin powder, bitter melon extract powder (bitter melon extract (containing bitter melon peptides), maltodextrin), black pepper, chromium nicotinate complex (chromium nicotinate, sodium chloride)).
223697787|NCT02281565|BEHAVIORAL|survey|Survey about Knowledge, Attitude and Practice About Blood Donation
223697788|NCT05910814|BEHAVIORAL|Sleep Deprivation (SD)|Participants in the sleep deprivation group will spend a night awake, under the supervision of an investigator, at Croix-Rousse Hospital. The investigator will provide a list of activities to maintain the participant awake.
223697789|NCT05910814|BEHAVIORAL|Normal Night (Night)|Participants in the normal night group will spend one night sleeping in their own home.
223697790|NCT05910814|BEHAVIORAL|Physical Exercise (HIIE)|"Participants in the physical exercise group (i.e. IM+HIIE, PP+HIIE, SD+PP+HIIE) will start with a 2-minute warm-up on an ergometer cycle.~After the warm-up, they will perform 3 minutes of exercise at a workload customized to their maximal aerobic power (MAP) corresponding to 80 % their MAP and then rest actively for 2 minutes at 40 % of MAP. This cycle of 5 minutes will be repeated 3 times in row, resulting in a total of 17 minutes of physical exercise including the warm-up."
223697791|NCT05910814|BEHAVIORAL|Rest control|Participants will watch a documentary during an equivalent time as the physical exercise (i.e. 17 minutes).
223697792|NCT05910814|BEHAVIORAL|Motor imagery|On the bimanual finger tapping task composed of 8 elements, the participant will be required to repeat the motor sequence mentally using MI (mental rehearsal of movement) during twelve blocks of 30 seconds. Participant will imagine performing the sequence as fast and accurately as possible without overt movement.
223697793|NCT05910814|BEHAVIORAL|Physical Practice (PP)|Participants will practice a bimanual sequential finger tapping task composed of 8 movements. Participant will be required to perform the sequence as fast and as accurately as possible during blocs of 30 s (i.e. twelve blocs during training).
223697794|NCT00224848|BEHAVIORAL|Palm-Pilot Intervention|"Both groups received guideline dissemination, patient activation materials, continuing education (CE) and feedback based on baseline chart audit. The intervention included academic detailing (AD) and a hand-held computerized decision support tool that provided patient-specific, ATPIII-based risk stratification and treatment recommendations. CE sessions offered information relevant to ATPIII and JNC7 and focused on the evidence base. AD offerings focused on strategies to apply concepts to practice and were specific to the randomized arm. Investigators visited each practice at baseline to educate physicians about the guideline and evidence supporting prevention of CVD, and to provide training on use of the Palm tool. Visits were conducted as lunch and learn sessions. The tool was a modified version of NHLBI's PDA decision support program and indicates specific drug therapies and dosages needed to achieve cholesterol reduction and prints documentation. A user's manual was developed."
223697795|NCT05890742|DRUG|Sintilimab|In ARM Phase Ib Control group, Sintilimab will be used twice, q3w.
223697796|NCT05890742|DRUG|IBI310&Sintilimab|In ARM Phase Ib\&III Experimental group，IBI310\&Sintilimab will be used in first cycle, Sintilimab will be used in second cycle(q3w). Radical surgery after neoadjuvant therapy.
223697797|NCT05890742|PROCEDURE|Radical surgery|In ARM Phase Ib\&III Experimental group, Phase Ib Control group, subjects will receive radical surgery after neoadjuvant therapy. In ARM Phase III Control group,subjects will receive radical surgery without neoadjuvant therapy
223697798|NCT05781373|PROCEDURE|Peep individualization|Intraoperative Peep individualization in order to achieve the lowest driving pressure
223697799|NCT00914680|PROCEDURE|magnetic seizure therapy|antidepressant treatment with MST
223697800|NCT03513523|DIETARY_SUPPLEMENT|Group 1 NRPT|Two capsules of NRPT and two placebo will be taken once daily in the morning for 26 weeks. Each NRPT capsule will contain 125 mg NR and 25 mg PT.
223697801|NCT03513523|DIETARY_SUPPLEMENT|Group 2 NRPT|Four capsules of NRPT will be taken once daily in the morning for 26 weeks. Each NRPT capsule will contain 125 mg NR and 25 mg PT.
223697802|NCT03513523|OTHER|Group 3 Placebo|Four placebo capsules will be taken once daily in the morning for 26 weeks.
223697803|NCT00715455|DRUG|REG1|ii. The REG1 anticoagulation system consists of a drug (RB006) and antidote (RB007). The drug (RB006) is administered via IV bolus to achieve anticoagulation. The antidote (RB007) is administered as an IV bolus dose at approximately 10% the total reversal dose followed by the remaining dose several hours later to counteract RB006 induced anticoagulation.
223697804|NCT00715455|DRUG|REG1|ii. The REG1 anticoagulation system consists of a drug (RB006) and antidote (RB007). The drug (RB006) is administered via IV bolus to achieve anticoagulation. The antidote (RB007) is administered as an IV bolus dose at 100% of the total reversal dose to counteract RB006 induced anticoagulation.
223697805|NCT00715455|DRUG|Unfractionated Heparin|Heparin will be administered per standard of care at sites
223697806|NCT02435069|DRUG|Dose Response - NS and USP Glycerin - First Intervention|This trial used a repeated measures, single subjects alternating treatments A-B-C-B'-C'-B1' withdrawal design in which all subjects were tested under all conditions and each subject acted as his or her own control. The subjects were randomly assigned to either normal saline or USP glycerin to control for order effects. Baseline data A served as the control and was obtained pre-operatively. The B-C arm evaluated dose-response relationship and was used to identify the minimum dosing volume and frequency of ACE administration of NS and USP Glycerin necessary to promote fecal continence. When the optimal dose as identified, the child continued on that dose for 2 weeks to insure treatment stability and effectiveness.
223780871|NCT03251846|DEVICE|Pops! One personalized mobile platform|Enrolled subjects will be given a POPS! Device (meter, lancet/test strips, and software app) to use for 6 months. Primary outcomes will be measured at baseline and 6-month follow-up.
223780872|NCT04487977|OTHER|Survey|Answering a survey on airway management in COVID-19 patients
223780873|NCT02736084|BEHAVIORAL|Positive Psychology|The Positive Psychology intervention consists of 7 exercises that will be completed by the participant with the guidance of a trainer.
223780874|NCT01323439|DEVICE|Axium™ MicroFX™ PGLA COILS|Axium™ MicroFX™ PGLA COILS to treat aneurysms
223780875|NCT02765932|PROCEDURE|Dummy Movements|The placebo group will be asked to perform the same touch technique and count backwards from 50 while removing petals from a flower. Patients will also perform these techniques before rehab and sleep.
223780876|NCT02765932|PROCEDURE|Psychosensory Therapy|The research assistant will administer one of the several psychosensory touch techniques prior to surgery. This will involve the touching of upper arms, palms, and a visualization process. This will last no longer than 10 minutes. These techniques will also be performed by the patients prior to any rehab sessions and before going to sleep. The patients will be asked to perform these touch techniques with the eyes closed and imaging having no pain. The patients will also be asked to keep a record of all medications.
223780877|NCT05491473|DEVICE|Closed incisional negative pressure wound therapy (iNPWT) system|The closed incisional negative pressure wound therapy (iNPWT) system (PREVENA Incision Management System, KCI, an Acelity company, San Antonio, Texas, USA)
223780878|NCT01168817|DRUG|BAY60-4552 plus Vardenafil|Treatment with 3 tablets once daily for 4 weeks (Vardenafil 10 mg plus BAY60-4552 1.0 mg)
223780879|NCT01168817|DRUG|Vardenafil|Treatment with 3 tablets once daily for 4 weeks (Vardenafil 20 mg)
223780880|NCT01168817|DRUG|Placebo|Treatment with 3 tablets once daily for 4 weeks (Placebo)
223780881|NCT05695859|DRUG|99mTc-DARPinG3 SPECT/CT|One single injection of 99mTc-DARPinG3, followed by gamma camera imaging 4 hours after injection
223780882|NCT05391282|OTHER|ultrasound assessment|Transfontanel ultrasound assessment before and after prone positioning
223697807|NCT02435069|DRUG|Effectiveness - NS and USP Glycerin - Second Intervention|To prevent statistical bias from subject loss due to treatment failure, each child was randomized to a second treatment sequence once they have achieved continence with minimal side effects on optimal dosing The second phase B'-C'-B1' of the study compared the two regimens at optimal dose and administration frequency. This phase was used to confirm the effectiveness of NS and USP Glycerin at optimal dosing on continence and assess side effects.
223697808|NCT03516825|OTHER|Musical Neglect Training|MNT uses musical exercises which are structured in pitch, time and tempo, and musical equipment (tone bars, keyboards, drums) configures to focus attention to the neglect visual field.
223697809|NCT02682771|DEVICE|Bilevel positive airway pressure|The use of positive airway pressure airway seeking in the prevention or treatment of hypoxic respiratory failure, improved arterial oxygenation, restoration or maintenance of lung volume reduction and atelectasis, decrease the work of breathing, decreased dyspnea index and increased residual volume
223697810|NCT02682771|DEVICE|PowerBreathe|Exercises with inspiratory load has the aim to trainning inspiratory muscle in strength and endurance, thus, could help to prevent postoperative complications.
223697811|NCT02682771|PROCEDURE|Conventional Respiratory Physiotherapy (CRP)|CRP consisted of diaphragmatic respiratory exercises, deep inhalation exercises, inhalations fragmented two to three times and respiratory exercises associated with shoulder flexion movements and extension of the upper limbs. One series of 10 repetitions was carried out for each exercise. Walking sessions and preventive exercises for deep vein thrombosis were carried out
223697812|NCT01528033|DEVICE|Vacuum Assisted Closure®|"Vacuum Assisted Closure® (V.A.C.®) Therapy within a maximum study treatment time of 42 days.~VAC® Therapy Systems used within the trial are ActiV.A.C.®, InfoV.A.C.®, V.A.C. Freedom®, V.A.C. Via® and VAC Ulta®. All used systems are equally eligible for the treatment of subcutaneous abdominal wounds and should be used according to availability and local preferences within the trial site.~Systems differ regarding user surface and display and processing of data. For the treatment of subcutaneous abdominal wounds the V.A.C.® Granufoam Dressing (size medium and big) is recommended."
223697813|NCT01528033|OTHER|Standard conventional wound therapy|Standard conventional wound therapy (SCWT) according to institutional clinical standards within a maximum study treatment time of 42 days
223697814|NCT04143893|DEVICE|Mechanical circulatory support|Patients with cardiogenic shock who underwent MCS
223697815|NCT04143893|DRUG|Optimal medical treatment|Patients with cardiogenic shock who received optimal medical treatment including vasopressor
223780883|NCT01705457|DRUG|Dietary Supplement: vitamin A|"25000 IU/day vitamin A for 6 months~1 Cap/Day~1 cap placebo/day for 6 month"
223780884|NCT01705457|DRUG|placebo|
223780885|NCT01056224|DRUG|Remifentanil|A single bolus dose of Remifentanil will be administered at the time of skull pin insertion
223780886|NCT03647514|DRUG|Abraxane|Tailored neoadjuvant chemotherapy with 4 cycles of PX(weekly Abraxane 125mg/m2, Q3week Xeloda 1250mg/m2, 21day/cycle) is planned for early breast cancer patients(stage of T2-4N0-3M0) who are eligible for primary systemic therapy.
223697816|NCT02297048|DIETARY_SUPPLEMENT|Potassium depletion|Healthy subjects will be submitted twice at 15-30 day interval, to a low potassium diet (20mmol/day)
223697817|NCT04143087|DRUG|withdrawal TKIs or halve TKIs|Stop TKIs or treated by half TKIs
223780887|NCT03647514|DRUG|Xeloda|Tailored neoadjuvant chemotherapy with 4 cycles of PX(weekly Abraxane 125mg/m2, Q3week Xeloda 1250mg/m2, 21day/cycle) is planned for early breast cancer patients(stage of T2-4N0-3M0) who are eligible for primary systemic therapy.
223780888|NCT02501304|DEVICE|ReVENT Sleep Apnea System|The ReVENT Sleep Apnea System consists of minimally invasive biocompatible devices that are placed into the tongue base and palate of patients with obstructive sleep apnea
223780889|NCT06089304|DEVICE|Percutaneous coronary intervention|Percutaneous coronary intervention (PCI) is a catheter-based technique performed under fluoroscopic guidance to treat coronary artery disease and restore blood flow to the myocardium. During PCI, coronary vessel patency is generally achieved with drug-eluting stents, which are metallic scaffolds coated with a polymer that carry and gradually release an antiproliferative drug. In the present study, all participants underwent PCI with implantation of a thin-strut, cobalt-chromium, durable-fluorinated polymer, everolimus-eluting stent (XIENCE, Abbott), and received a course of dual antiplatelet therapy (DAPT) ranging from 28 to 365 days after PCI.
223780890|NCT02667912|PROCEDURE|Distal renal denervation|Percutaneous endovascular intervention when catheter-based electrode (Symplicity Flex; Medtronic, Inc.) is used for stepwise radiofrequency energy delivery to segmental branches of the renal artery in a number of points distributed along the length and circumference of the vessels in order to ablate renal nerve plexus
223780891|NCT02667912|PROCEDURE|Conventional renal denervation|Percutaneous endovascular intervention when catheter-based electrode (Symplicity Flex; Medtronic, Inc.) is used for stepwise radiofrequency energy delivery to the main trunk of the renal artery in a number of points equally distributed along its length and circumference in order to ablate renal nerve plexus
223780892|NCT01354821|PROCEDURE|Endovascular aortic repair|Insertion via bilateral femoral access, stent-graft deployment under fluoroscopic guidance, complementary stenting of visceral arteries, control angiogram
223780893|NCT01354821|PROCEDURE|Open surgical repair|Conventional therapy in France with the national database of the M.O.H.
223780894|NCT06104735|PROCEDURE|Synaptic Pairing Interval|Optimize interstimulus pairing between brain and spinal cord stimulation.
223780895|NCT06104735|PROCEDURE|Frequency|Compare 2 Hz continuous to intermittent theta burst frequency
223780896|NCT06104735|PROCEDURE|Bouts|Compare effects of 1, 2, or 4 bouts of SCAP
223780897|NCT06104735|PROCEDURE|Spacing|Compare 6 versus 12 minutes of rest in between bouts of SCAP
223780898|NCT06104735|PROCEDURE|Exercise|Task-oriented hand exercises
223780899|NCT06104735|PROCEDURE|SCAP plus Exercise|Compare interleaved versus serial bouts of SCAP and exercise.
223780900|NCT04036916|OTHER|Virtual Reality Sensorimotor Training|Games/activities specifically developed to train the sensorimotor system in headset virtual reality + strengthening of the neck
223780901|NCT04836260|DRUG|SARS-CoV-2 convalescent plasma|Included patients will receive at least one unit of convalescent plasma with NTAB titer ≥1:160 at maximum 3-7 days after diagnosis by RT-PCR or symptom onset. A second unit of plasma from a different donor can be proposed 24h after the first unit if immunocompromised and/or the patient received less than 3-5ml/kg of plasma volume. Additional units can be exceptionnally infused, at the investigator discretion.
223780902|NCT04443218|DEVICE|Edwards PASCAL Transcatheter Valve Repair System|The Edwards PASCAL Valve Repair System is indicated for the percutaneous reconstruction of an insufficient mitral valve.
223780903|NCT05917730|BEHAVIORAL|Emotional Regulation and Interpersonal Abilities group Therapy (MERITA)|"Therapy sessions Block 1. Recognition and verbalization of emotions: Session 1: Presentation, framing, and beginning of identification and denomination of emotions. Session 2: Recognition and differentiation of emotions. Session 3 and 4: Effects of traumatic experiences.~Block 2. Learning to manage emotions: Session 5: Managing unpleasant emotions, coping Abilities in body, mind, and behavior. Session 6: New coping skills, self-esteem. Session 7: New coping skills, self-care. Session 8: Skills for clear communication. Session 9: Assertiveness and reciprocity. Session 10: Save card and the good relations game/negotiation skills. Session 11: Social skills and confidence recovery. Session 12: Consolidation and farewell."
223780904|NCT01234506|DIETARY_SUPPLEMENT|secoisolariciresinol diglucoside|SDG supplementation as a packet of 0.8g/day of BeneFlax containing 300 mg SDG for 24 weeks
223780905|NCT02543359|BEHAVIORAL|Training Models of PCIT|Agency participants are trained in one of three training model strategies: Train the Trainer Model (TTT), Learning Collaborative (LC), or Web-Supported Self Study (SS).One third of participating agencies will be randomized to the Train the Trainer training model.One third of participating agencies will be randomized to the Learning Collaborative training model.One third of participating agencies will be randomized to the Web-Supported Self Study.
223780906|NCT02543359|BEHAVIORAL|Training Models of PCIT|One-third of administrators are trained in the Learning Collaborative training model. One-third of administrators will be trained to usual treatment (none). One-third of administrators will be trained to usual treatment (none).
223697818|NCT01242683|BEHAVIORAL|Vivamos Activos Fair Oaks Program|"Comparison of Case-management vs. Case-management plus Home Visits vs. Usual Primary Care.~Case-management: Five 60 minute individual and 15 90 minute group sessions devoted to behavioral strategies to facilitate weight loss conducted by a health educator.~Home-visits: Seven home visits provided by a community health worker to provide life-style/environmental support for behavior change to facilitate weight loss.~Usual primary care: Usual care provided at health center that is available to participants in all three study arms."
223697819|NCT02800902|DRUG|placebo|Oral prophylaxis followed by placement of placebo gel
223697820|NCT02800902|DRUG|Rosuvastatin|Oral prophylaxis followed by placement of rosuvastatin gel
223697821|NCT02800902|DRUG|Atorvastatin|Oral prophylaxis followed by placement of atorvastatin gel
223697822|NCT03588871|OTHER|Dental bleaching with PaintOn Plus VivaStyle|Procedure of tooth bleaching using products with 6% hydrogen peroxide or its equivalent, specifically the PaintOn Plus Vivastyle 6% HP (Ivoclar Vivadent)
223697823|NCT03588871|OTHER|Dental Bleaching impact in quality of life with PaintOn Plus Vivastyle|Evaluation of oral quality of life after dental bleaching treatment with PaintOn Plus Vivastyle 6% HP (Ivoclar Vivadent) using an oral quality of life measuring questionnaire, specifically the Oral Health Impact Profile-14
223697824|NCT03588871|OTHER|Dental bleaching with Opalescence GO|Procedure of tooth bleaching using products with 6% hydrogen peroxide or its equivalent, specifically the Opalescence GO 6% HP (Ultradent)
223697825|NCT03588871|OTHER|Dental Bleaching impact in quality of life with Opalescence GO|Evaluation of oral quality of life after dental bleaching treatment with Opalescence GO 6% HP (Ultradent) using an oral quality of life measuring questionnaire, specifically the Oral Health Impact Profile-14
223697826|NCT03588871|OTHER|Dental bleaching with Opalescence PF|Procedure of tooth bleaching using products with 6% hydrogen peroxide or its equivalent, specifically the Opalescence PF 16% CP (Ultradent)
223697827|NCT03588871|OTHER|Dental Bleaching impact in quality of life with Opalescence PF|Evaluation of oral quality of life after dental bleaching treatment with Opalescence PF 16% CP (Ultradent) using an oral quality of life measuring questionnaire, specifically the Oral Health Impact Profile-14
223697828|NCT04407052|DRUG|Double trigger|Final follicular maturation is triggered by the coadministration of GnRH-agonist (Triptorelin acetate, decapeptyl 0.2 mg, Slough, United Kingdom) and 10000 IU of HCG, 40 and 34 h prior to oocyte retrieval, respectively
223697829|NCT04407052|DRUG|HCG trigger|Final follicular maturation is triggered by a dose of 10000 IU of HCG 36 h prior to oocyte retrieval
223697830|NCT00808561|OTHER|Group 1: Alternative Fistula|Performing other autogenous AV fistulas which include various options such as brachiocephalic AV fistula, basilic or brachial vein transpositions or a variety of other strategies to maintain a primary access. The advantage would be to maintain an autogenous all venous access with less risk of infection and thrombosis.
223697831|NCT00808561|OTHER|Group 2: Forearm AV Graft|a) ePTFE (polytetrafluoroethylene) bridge AV graft typically anastomosed in the proximal forearm to the radial or brachial artery and to an antecubital vein. The advantages include a quick maturation of 2-3 weeks, excellent flow rates and high technical success rates. Although secondary patency rates approach 80% at one year postoperatively, disadvantages include a more involved surgical procedure, a lower primary patency than a well functioning AV fistula, and higher revision and infection rates.4, 5
223697832|NCT02994134|BEHAVIORAL|Moderate intensity exercise.|Moderate intensity aerobic exercise intervention (delivered at 55-64% age-predicted maximal heart rate), 4 times per week for 4 weeks.
223697833|NCT02994134|BEHAVIORAL|High intensity exercise.|High intensity aerobic exercise intervention (delivered at 65-90% age-predicted maximal heart rate), 4 times per week for 4 weeks.
223697834|NCT04459624|PROCEDURE|Erector Spina Plane Block|Group E (ESP block) will be applied 20 ml of % 0.25 bupivacaine between the erector spina muscle and transverse process at the 8th thoracic level. The blocks will be administered under general anesthesia in lateral position by the same anesthesiologist.
223780907|NCT02543359|BEHAVIORAL|Parent-Child Interaction Therapy (PCIT) Treatment|Parent-Child Interaction Therapy (PCIT), a parent coaching evidence-based protocol is given to each family from clinicians and supervisors in each training model.
223697835|NCT04459624|PROCEDURE|Quadratus Lumborum Block 2|Group Q (QLB2 block) lumbar interfacial triangle (LIFT) will be applied 20 ml of % 0.25 bupivacaine. The blocks will be administered under general anesthesia in lateral position by the same anesthesiologist.
223697836|NCT06151431|DRUG|Alpha-Agonist|The maternal systolic blood pressure was consistently maintained above 80% of the preoperative baseline value from the initiation of spinal anesthesia until fetal delivery.
223697837|NCT06151431|DRUG|α-adrenergic receptor agonist|The maternal systolic blood pressure was consistently maintained above 90% of the preoperative baseline value from the initiation of spinal anesthesia until fetal delivery.
223697838|NCT00194909|DRUG|sildenafil (Viagra)|
223697839|NCT00590889|DEVICE|Artificial Mechanical Heart Valve|Both arms used market released mechanical heart valves in accordance with approved labeling
223697840|NCT05303077|DIETARY_SUPPLEMENT|Nutribén Innova® 1|Infants are fed solely with infant formula supplemented with an inactive probiotic and omega 3 fatty acids over the first 6 months of their life, from then on the infants are fed with the study formula and the usual supplementary food, recommended to the baby's
223697841|NCT05303077|DIETARY_SUPPLEMENT|Nutribén®|Infants are fed solely with infant formula over the first 6 months of their life, from then on the infants are fed with the study formula and the usual supplementary food, recommended to the baby's age.
223697842|NCT05303077|DIETARY_SUPPLEMENT|Breastfeed|Infants are breastfeeding solely over the first 6 months of their life, from then on the infants are fed as recommended by their caregiver, as if they are not participating in a research study.
223697843|NCT06520670|DIAGNOSTIC_TEST|Urinary galectin-3 binding protein|Investigate urinary galectin-3 binding protein (G3BP) as a biomarker for lupus nephritis and indicator for disease activity.
223697844|NCT01854996|DRUG|PF-05089771|450mg
223697845|NCT01854996|DRUG|PF-05089771|450mg
223697846|NCT01854996|DRUG|PF-05089771|450mg
223697847|NCT04021420|DEVICE|SONOCLOUD|"The SonoCloud System is an active implantable medical. The SonoCloud is indicated to locally and transiently increase the permeability of the blood brain barrier to facilitate the passage of substances into the cerebral parenchyma.~The SonoCloud System consists of :~1. an implantable ultrasound transducer,~2. a needle connection device,~3. an external radiofrequency generator, and~4. an ultrasound resonator. The SonoCloud® is designed to be fixed to the skull. The device is placed in a burr hole or in place of a bone flap and ultrasound energy is delivered directly to the brain tissue, without traversing the skull bone. The device is activated by connecting the implant to the external generator system using the transdermal needle. Once connected to the external generator, the implant delivers low-intensity pulsed UltraSound (US) for duration of 120-270 seconds. A total of 3 US dose levels will be evaluated (0.78, 0.9 and 1.03 MPa)."
223697848|NCT04021420|DRUG|Nivolumab Injection|Nivolumab (flat dose: 240mg, 30 minutes infusion)
223697849|NCT02643173|OTHER|Volatile anesthetics|
223697850|NCT02643173|OTHER|Intravenous anesthetics|
223697851|NCT02436681|DEVICE|MIROMESH|
223697852|NCT05350306|DEVICE|Chincup|Patients will receive an individual fabricated bonded bite block and occipital chincup. A 400-500g/side retroactive force will be applied in the direction of the condyles. Patients or panthers will be instructed to wear the appliance /14-16/ hours a day.
223697853|NCT05350306|OTHER|Control group|The changes in condyle-mandibular volumes and superficial areas and relative positions of the condyles and glenoid fossa will be calculated after 16 months of observation.
223697854|NCT01498601|OTHER|Enhanced oral care protocol|"* Changing mouth suction equipment every 24 hours~* Mouth assessment every 2-4 hours~* Cleansing mouth with toothbrush every 12 hours~* Cleansing oral mucosa with oral rinse solution every 2-4 hours~* Moisturize mouth/lips with swab and standard mouth moisturizer every 4 hours~* Suction mouth and throat as needed~* Head of the bed elevated to a minimum of 30° during oral care"
223697855|NCT01879514|DRUG|Chinese Herb Prescription Granule plus prednisone|Chinese Herb Prescription Granule includes ZiBuGanShen Granule and BuShenTongLuo Granule
223697856|NCT01879514|DRUG|Placebo|Placebo includes placebo of ZiBuGanShen Granule and placebo of BuShenTongLuo Granule
223697857|NCT02030938|DEVICE|SERI® Surgical Scaffold|Standard revision augmentation (with or without implant exchange) with the adjunctive use of SERI® Surgical Scaffold placed intra- or extra-capsularly.
223697858|NCT00819299|DEVICE|AcuFocus Corneal Inlay ACI 7000PDT|corneal inlay
223697859|NCT00752544|DRUG|TMC435350|
223697860|NCT00805701|DRUG|avodart|0.5 avodart once daily for 13 weeks
223697861|NCT00805701|DRUG|Placebo|placebo
223697862|NCT02571036|DRUG|DCC-2618|50 mg formulated tablets
223697863|NCT02571036|DRUG|DCC-2618|10 mg and 50 mg formulated tablets
223697864|NCT01599832|DRUG|pazopanib hydrochloride|Given PO
223697865|NCT01599832|OTHER|laboratory biomarker analysis|Correlative studies
223697866|NCT01599832|PROCEDURE|dynamic contrast-enhanced magnetic resonance imaging|Undergo dynamic contrast-enhanced magnetic resonance imaging
223697867|NCT01599832|OTHER|pharmacogenomic studies|Correlative studies
223697868|NCT05293015|OTHER|NP-Supported Multidisciplinary Diabetes Management|NP establishes files to evaluate and manage patients before hospital and visits patients after hospitalization. Then set blood glucose control goals with endocrinology and orthopedic doctors together, initiates consultation with endocrinologists for patients with postoperative hyperglycemia, and is responsible for post-hospital follow-up.
223697869|NCT01936727|PROCEDURE|cataract surgery|
223697870|NCT00046514|DRUG|ABI-007|
223697871|NCT03169686|BEHAVIORAL|Cognitive and Behavioral Intervention|Participants who allocate to the intervention group will receive regular smoking cessation related information by professional team.
223780908|NCT02063503|OTHER|physiotherapy|every group receives 2 treatments every week during 9 consecutive weeks
223780909|NCT01248650|DRUG|nalfurafine hydrochloride|
223780910|NCT00000123|DEVICE|Polymethyl Methacrylate-Silicone Contact Lenses|
223780911|NCT00000123|DEVICE|Polymethyl Methacrylate Contact Lenses|
223780912|NCT00650468|DRUG|tacrolimus|Oral
223780913|NCT00650468|DRUG|CellCept|IV or Oral
223780914|NCT00650468|DRUG|steroids (methylprednisone or prednisone)|IV or Oral
223780915|NCT03584594|DIAGNOSTIC_TEST|Presepsin measurement|Presepsin measurements are performed with PathFast immunoassay analytical system on the ICU, bedside method. (Mitsubishi Chemical, Japan).
223780916|NCT03249623|DEVICE|Beacon Caresystem|The core of the system is a set of physiological models including pulmonary gas exchange, acid-base chemistry, lung mechanics, and respiratory drive. The Beacon Caresystem tunes these models to the individual patient such that they describe accurately current measurements. Once tuned, the models are used by the system to simulate the effects of changing ventilator settings. The results of these simulations are then used calculate the clinical benefit of changing ventilator settings by balancing the competing goals of mechanical ventilation.
223780917|NCT04725994|DRUG|IDX-1197+XELOX|The dose levels will be escalated following a 3+3 dose escalation scheme.
223780918|NCT04725994|DRUG|IDX-1197+Irinotecan|The dose levels will be escalated following a 3+3 dose escalation scheme.
223780919|NCT00042328|DRUG|Valacyclovir|
223780920|NCT01701375|DRUG|PD 0332991|• PD 0332991 will be given orally days 1,2,3
223780921|NCT06214585|PROCEDURE|Intermittent heat and cold versus heat-only therapy|for the experimental group, a cyclical method of alternating heat and cold application will be used on the lumbosacral and lower abdominal area of the laboring women. The process involves applying a hot pack with a temperature range of 38-40°C on their lower abdomen and low back for 30 minutes during contractions and a relaxing period using a 2-litre rubber hot water bag. Subsequently, reusable ice packs typically contain water, covered with a towel and with a temperature range of 0-5°C will be applied to the same areas for 10 minutes. After a 30-minute interval, the heat application will be reapplied, and this alternating heat and cold cycle will be repeated throughout the first stage of the laboring process.
223780922|NCT06214585|PROCEDURE|Heat- only Therapy|hot water bag will be used to provide heat to the lower back of primigravida women during the first stage of labor. The water in the bag will be maintained at a temperature of 40-42ºC. The application of heat will last for 20 minutes, and it will be repeated every hour until the cervix is fully dilated.
223780923|NCT04847050|BIOLOGICAL|Messenger ribonucleic acid (mRNA)-1273 Vaccine|A rapid response, proprietary messenger RNA (mRNA)-based vaccine platform. 100 mcg administered intramuscular (IM) on Day 1 and 29 for vaccine naive cohorts.
223780924|NCT04847050|BIOLOGICAL|Messenger ribonucleic acid (mRNA)-1273 Vaccine Booster|A rapid response, proprietary messenger RNA (mRNA)-based vaccine platform. 100 mcg administered intramuscular (IM) on Day 1 for vaccine booster cohorts. Participants may receive up to 3 booster injections on study.
223780925|NCT04847050|DIAGNOSTIC_TEST|ECG|Baseline (-28 days/Day 1); and Day 29 (+/- 3 days).
223697872|NCT05882188|PROCEDURE|Oil-based contrast|oil-based contrast fluid, Lipiodol Ultra Fluid. Lipiodol is a solution of iodinated ethyl esters of fatty acids of poppyseed oil. Equivalent to 480 mg iodine per ml. The maximum dosage is 15ml. Lipiodol is produced by Guerbet, France. Lipiodol is FDA approved and registered as contrast agent for HSG.
223697873|NCT05882188|PROCEDURE|ExEm Foam|ExEm Foam which is created by mixing 5ml ExEm-gel and 5ml of purified water. ExEm-gel contains hydroxyethylcellulose and glycerol. The ExEm Foam is distributed by IQ Medical Ventures, the Netherlands. ExEm Foam is FDA approved, CE marked and registered as contrast agent for HyFoSy.
223697874|NCT00399620|PROCEDURE|Gingival crevicular fluid samples (this procedure is added to the subject usual medical follow-up).|
223697875|NCT03813823|BEHAVIORAL|Fear tasks|All participants will be exposed to 5 fear tasks involving spiders, with increasing fear intensity.
223697876|NCT05186285|DRUG|CM338|CM338 : a humanized monoclonal antibody.
223780926|NCT04847050|OTHER|Antibiotics|Use of prophylactic antibiotics is recommended according to institutional standards.
223780927|NCT04847050|OTHER|Anti-viral agents|Use of prophylactic antiviral agents is recommended according to institutional standards.
223780928|NCT04847050|OTHER|Anti-fungal agent|Use of prophylactic antifungal agents is recommended according to institutional standards.
223780929|NCT04847050|OTHER|Anti-emetics|Use of prophylactic anti-emetics is recommended according to institutional standards.
223780930|NCT05811104|DEVICE|Sequential bilateral theta burst stimulation|Three sessions of active or sham bilateral TBS will be delivered daily for 10 days in 2 weeks (no session on weekend) with a total of 30 sessions for each patient. Daily low intensity (90% resting motor threshold) bilateral sequential continousTBS ( cTBI) will be applied first on the right DLPFC (1800 pulses) and then intermittent TBS (iTBS)on the left DLPFC (1800 pulses) with an intersession interval of 60 minutes. We will adopt 1800 pulse per session based on the previous studies. Patients will receive a stimulation of 3600 pulses a session, 10,800 pulses a day and 108,000 pulses in total. After the study, sham group will receive active stimulation following the same protocol
223780931|NCT02187016|DEVICE|AirFloss + BreathRx|Manual Toothbrush used twice daily, 1 minute. Interproximal cleaning plus Rinse used once daily.
223780932|NCT02187016|DEVICE|AirFloss + Listerine|Manual Toothbrush used twice daily, 1 minute. Interproximal cleaning plus Rinse used once daily.
223697877|NCT05186285|DRUG|Placebo|Placebo.
223697878|NCT05517993|DRUG|Gui-Lu-Er-Xian-Jiao-Wan|Gui-Lu-Er-Xian-Jiao-Wan (GLEXJW) is an ancient CHM formula, mainly originating from processed tortoise shells, antlers, Ginseng, and wolfberry.
223697879|NCT02359344|DRUG|CNV1014802|
223697880|NCT02359344|DRUG|Placebo|
223697881|NCT00334607|BIOLOGICAL|2-dose oral live attenuated G1P[8] human rotavirus vaccine|
223780933|NCT02187016|DEVICE|Dental Floss|Manual Toothbrush used twice daily, 1 minute. Interproximal cleaning used once daily.
223780934|NCT02187016|DEVICE|Manual Toothbrush|Manual Toothbrush used twice daily, 1 minute.
223780935|NCT02468843|DEVICE|Biphasic DBS stimulation|"The following protocol will be followed for each subject. In between, baseline and novel stimulation settings there will be a 30-minute washout period with DBS in the off state.~1. Current best/optimized DBS setting (considered baseline)~2. DBS off for 30 minutes~3. Biphasic pulse stimulation mode (immediate assessment)~4. Biphasic pulse stimulation mode (assessment at 1h)~5. Biphasic pulse stimulation mode (assessment at 2h)"
223780936|NCT02468843|OTHER|Unified Dystonia Rating Scale|Neurologist use the UDRS to determine the severity and duration of dystonia on 14 body areas.
223780937|NCT02468843|OTHER|Burke-Fahn- Marsden scale|Neurologist use the BFMDRS to rate the severity of dystonia in 9 regions of the body.
223780938|NCT05266326|OTHER|Western medicine conventional treatment +Bloodletting puncture|All acupoints are positioned according to the WHO standard acupuncture point locations in the Western Pacific Region. Operation: The patient is placed in a reasonable position, the acupuncture site is exposed, and the operator uses pushing, rubbing, squeezing and butterfly on or around the acupuncture site to collect blood at the acupuncture site before pricking, and then disinfects the acupuncture site with 75% ethanol. If more bleeding occurs, press with sterile dry cotton balls to stop the bleeding. The treatment was performed once daily for 7 days.
223780939|NCT05266326|OTHER|Western medicine conventional treatment|The patients in both groups were given conventional comprehensive treatment such as improving cerebral circulation, neuroprotection, antiplatelet aggregation, lipid regulation and symptomatic management after admission. Patients with hypertension, hyperglycaemia, hyperlipidaemia and coronary atherosclerotic heart disease were given individualised symptomatic treatment and advised to stop smoking, drinking alcohol and other adverse lifestyles as far as possible.
223780940|NCT04424368|DEVICE|The remote monitoring system|Usage of remote monitoring system
223780941|NCT06280300|OTHER|health services intervention|Health services intervention
223780942|NCT04331327|DRUG|allogenic lyophilized growth factors|Prior to usage, reconstitution of the product was done using 1-ml saline and 1-ml lignocaine followed by gentle vial rubbing for 3 minutes. Then, the mixture was kept at ambient temperature for 5 minutes to ensure complete protein re-hydration.
223780943|NCT05286905|DEVICE|Osteosynthesis cephalomedullary nail|Osteosynthesis of reverse oblique peritrochanteric fractures with cephalomedullary nail
223780944|NCT05286905|DEVICE|Osteosynthesis proximal femur locking plate|Osteosynthesis of reverse oblique peritrochanteric fractures with proximal femur locking plate
223780945|NCT03117335|DRUG|Placebos|"Drug 1:~Placebo(Sodium Chloride Injection),7.5mg/m2 on d1-d14 in each 21-day cycle（stop interventing until the disease progress）~Drug 2:~Vinorelbine-Cisplatin:~Vinorelbine, 25mg/m2, iv, on d1 and d8 in each 21-day cycle (no more than 4 cycles); Cisplatin,75mg/m2, iv, on d1 in each 21-day cycle(no more than 4 cycles)"
223780946|NCT03117335|DRUG|Sulijia|"Drug 1:~Sulijia(Recombinant Endostatin Injection) Sulijia, 7.5mg/m2 on d1-d14 in each 21-day cycle（stop interventing until the disease progress）~Drug 2:~Vinorelbine-Cisplatin:~Vinorelbine, 25mg/m2, iv, on d1 and d8 in each 21-day cycle (no more than 4 cycles); Cisplatin,75mg/m2, iv, on d1 in each 21-day cycle(no more than 4 cycles)"
223780947|NCT06391996|DRUG|After exclusion of relevant contraindications, participants received subcutaneous ustekinumab/secukinumab therapy.|During the treatment period, participants received either ustekinumab at weeks 0, 4, 16, and every 12 weeks thereafter until week 48, or secukinumab at weeks 0, 1, 2, 3, and 4, and every 4 weeks thereafter until week 48. The dose of ustekinumab/secukinumab was referenced to the dose used for moderate to severe plaque psoriasis. The single dose of ustekinumab was 45 mg for adult subjects weighing ≤ 100 kg, and 90 mg for subjects weighing \> 100 kg. The ustekinumab dosage for pediatric participants was 0.75 mg/kg for participants weighing \< 60 kg; 45 mg for pediatric participants weighing 60 kg to 100 kg; and 90 mg for pediatric participants weighing \> 100 kg. The secukinumab dosage was 300mg for adult humans. Pediatric participants received a dose based on their weight category ( \<50 kg, ≥50 kg): participants weighing \< 50 kg received 75 mg, those weighing ≥ 50 kg received 150 mg.
223697882|NCT03954132|DRUG|Spiolto® Respimat®|Chronic Obstructive Pulmonary Disease (COPD) patients who were symptomatic (dyspneic) despite Long-acting beta2 adrenoceptor agonist/Inhalative Corticosteroids (LABA/ICS) maintenance treatment were switched to Spiolto® Respimat® inhaler by their attending physician in an real-world setting.
223697883|NCT03954132|DRUG|Triple-Therapy (LAMA/LABA/ICS)|Chronic Obstructive Pulmonary Disease (COPD) patients who were symptomatic (dyspneic) despite Long-acting beta2 adrenoceptor agonist/Inhalative Corticosteroids (LABA/ICS) maintenance treatment were switched to any triple therapy Long-acting muscarinic antagonist + Long-acting beta2 adrenoceptor agonist + Inhalative Corticosteroids (LAMA + LABA + ICS) by their attending physician in an real-world setting.
223780948|NCT04112849|DIAGNOSTIC_TEST|Measurement of S3 heart sound|S3 heart sound to be measured by Nanowear Congestive Heart Failure Management System device.
223780949|NCT02113020|DRUG|TAK-233|Oral administration of TAK-233
223780950|NCT02113020|DRUG|Placebo|Oral admininstration of Placebo
223780951|NCT05319418|BEHAVIORAL|Daily Blood Pressure Monitoring|Patients are provided standard off-the-shelf blood pressure monitors and take their BP vitals daily. Patients report their daily BP through phone or online. BP data is viewed online by physicians who use their independent medical judgement for any changes in medical management.
223780952|NCT01884298|DRUG|remifentanil(Ultiva)|remifentanil (TCI, Ce 3 ng /ml)for intra-operative analgesia
223780953|NCT01884298|DRUG|epidural infusing 2% lidocaine|epidural infusing 2% lidocaine 4ml bolus followed by 6-18ml/hr for intra-operative analgesia
223780954|NCT06097052|DEVICE|Hypotension Predictive Index|Introduction of Hypotension Predictive index and transition from a reactive to a proactive approach of intraoperative hypotension treatment.
223780955|NCT00931021|DRUG|Varenicline (Chantix)|2 mg
223780956|NCT00931021|DRUG|Nicotine Patch|21 mg
223780957|NCT01420796|OTHER|Swallowing exercise|"Patients will perform oral motor exercises for swallowing muscles for five weeks, four days a week.~This exercises aim to increase strength and range of motion of mouth, larynx and pharynx structures. All patients will make sustained vowel phonation of /a/, pushing plosive phonemes /pa/, /ta/, /ka/ in a forceful manner, suction of wet gauze, swallowing with tongue hold and modified supraglottic maneuver, in ten repetitions, ascending and descending gliding phonation of vowel /a/ and /u/, five repetitions of each vowel, and tongue rotation in oral vestibule, 3 series of 5 repetitions to each side."
223780958|NCT01420796|OTHER|Breathing Exercises|Patients will perform expiratory muscle training. Initial load will be 30% of maximal expiratory pressure which will increase until 75%. This load will be keep until end of training. Patients will made the exercises for 30 minutes with three minutes of training and two of rest.
223780959|NCT01420796|OTHER|Swallowing and breathing exercises|For five weeks, patients will perform swallowing and breathing exercises that follow: expiratory muscle training and sustained vowel phonation of /a/, pushing plosive phonemes /pa/, /ta/, /ka/ in a forceful manner, suction of wet gauze, swallowing with tongue hold and modified supraglottic maneuver, in ten repetitions, ascending and descending gliding phonation of vowel /a/ and /u/, five repetitions of each vowel, and tongue rotation in oral vestibule, 3 series of 5 repetitions to each side.
223780960|NCT00961974|BEHAVIORAL|Care Ambassador Intervention|Care Ambassador provides additional monthly outreach (by phone or e-mail) to families between clinic visits.
223780961|NCT00961974|BEHAVIORAL|Psychoeducational Intervention|"A psychoeducational intervention module is reviewed with the family by the Care Ambassador at each clinic visit. The intervention focuses on incorporating intensive therapy into the daily routine of the child through positive family support for blood glucose monitoring and healthy eating. The intervention modules review positive family communication, realistic expectations, ways to avoid perfectionism and maintain family involvement, prevention of hypoglycemia, avoidance of diabetes-specific family conflict, and approaches to reducing diabetes burnout."
223780962|NCT03178734|DEVICE|Foley Catheter vs Self-Contained Valved Catheter|This study aims to compare UTI rates and patient satisfaction between an indwelling Foley catheter group (established SOC); and a relatively (FDA-approved) new valved addition to the Foley catheter which requires no drainage bag.
223780963|NCT02534974|DEVICE|NOSTEN|
223780964|NCT03000894|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia (CBT-I)|This CBT-I is a 4 sessions 60-90 minutes group-based therapy administered by a nurse therapist. Each session has 6-8 participants.
223780965|NCT04884126|PROCEDURE|dental implant placement|The time of dental implant surgery
223780966|NCT03835377|OTHER|Iron-biofortified beans|Iron-biofortified beans (Phaseolus vulgaris L MIB465)
223780967|NCT03835377|OTHER|Control beans|Control beans (Phaseolus vulgaris L Jamapa variety), identical in color and size
223780968|NCT01517451|RADIATION|Radiation Therapy|7.25 Gy every other day fractions to a total dose of 36.25 Gy (total of 5 fractions)
223780969|NCT01517451|DRUG|Androgen Deprivation Therapy (ADT)|Androgen deprivation therapy (ADT) for 4 months total, greater than or equal to 1 month prior to SBRT.
223780970|NCT02961140|OTHER|Cardiac Output Maximization|According to Frank-Starling law, the investigator will administer Voluven 6% 250 mL every 5 minute until stroke volume maximized (stabilized for 20 minutes), and maintain cardiac index and stroke volume variation during the whole operation.
223780971|NCT02961140|OTHER|Cardiac Output Normalization|The investigator will administer intravenous fluids to keep cardiac index (CI) ≥ 2.2, and maintain CI and stroke volume variation during the whole operation.
223780972|NCT00022516|DRUG|Cyclophosphamide|50 mg/day orally continuously for 1 year
223780973|NCT00022516|DRUG|Methotrexate|2.5 mg twice/day orally days 1 and 2 of every week for 1 year
223780974|NCT02323464|PROCEDURE|Surgery for colorectal cancer|Includes open and minimally invasive surgery for colon- and rectal cancer
223780975|NCT02323464|OTHER|No Interventions|This is a control group from the population. They are not scheduled for surgery
223780976|NCT04090307|BEHAVIORAL|TLC Group Prenatal Care|TLC will start in the late first trimester or early second trimester and run for \~6-10 sessions. Groups of 2-10 consented women, with two or more GDM risk factors, will meet under the supervision of an obstetric provider (nurse practitioner or MD) and co-facilitator (health educator, nutritionist, or nurse) for two-hour sessions. A major focus of TLC will be education, and much of each visit will be spent on pregnancy, exercise/nutrition education, and behavioral health.
223780977|NCT06294509|DEVICE|in-house developed transcutaneous auricular Vagus Nerve Stimulation device|taVNS in this study involves short electric pulses (0.25 ms) delivered to the ear's skin to activate the auricular branch of the Vagus. The pulses are current-controlled to ensure stability and delivered in a bipolar fashion to prevent skin irritation. Before each session, taVNS is calibrated for each participant. Starting at 0.1 mA, the intensity is increased stepwise until a comfortable maximum (typically 1.5-2.5 mA) is reached. Stimuli are delivered in short trains lasting 0.5 seconds each, with 13 pulses (0.25ms each) per train. Participants receive a maximum of 150 stimuli per session, totaling a maximum of 75 seconds of cumulative stimulation. Participants adapt their movements over up to six sessions across two weeks. The robotic task facilitates accurate movement tracking and provides interactive real-time feedback.
223780978|NCT03259035|DRUG|Folfox Protocol|6 cycles of q2weekly FOLFOX, or
223780979|NCT03259035|DRUG|Capox|4 cycles of q3weekly CAPOX
223780980|NCT05844878|BEHAVIORAL|Cognitive behavioral therapy (CBT) by using Distraction technique.|"Distraction: The distraction in this arm will be done by hearing of soft music; the name of music that will be used is relaxing piano music and water sounds 24/7 - ideal for stress relief. This music will be used in both the reception room and in the dental room treatment from the time-point that patient enters the reception room, and continues into the dental treatment room until the end of dental treatment when the patient exits the dental treatment room"
223780981|NCT05844878|BEHAVIORAL|Mindfulness technique by using of relaxation breathing with muscle relaxation|"The mindfulness technique consist of combination of 2 procedures:~1. Relaxation breathing: this will be done during the course of dental treatment by asking the patient to do the following Gently breathe in - hold - and let go. This procedure will be applied at the first moment when the patient sits on the dental chair before any dental treatment is done and the patient is asked to repeat this twice, each for a duration of 10 seconds. This procedure will be repeated twice; at zero time and after an interval of 16 minutes of dental treatment that extend for a 30-minute duration for each patient.~2. Muscle relaxation: this will be done by asking the patient during dental treatment to do the following Hands - gently clench - hold - and let go. This procedure will be applied after 8 minutes from starting dental treatment, and ask the patient to do it twice for about 10 seconds. This procedure will be repeated twice; at 8 minutes and at 24 minutes of dental treatment."
223780982|NCT04184076|BEHAVIORAL|Time-restricted feeding (TRF) with dietary counseling|"1. Subjects will be instructed to administer time-restricted feeding.~2. Subjects have to compete a 3-d food record, including 2 regular day and 1 holiday. At baseline, a dietitian will provide 15 min of instruction to each participant on how to complete the food records. Subjects will be asked to measure the volume of foods consumed with household measures. The timing of food intake will be also recorded. Food records will be collected each week during the experiment and will be reviewed by the dietitian for accuracy and completeness. A database for food content will be used to calculate the total daily intake of energy, fat, protein, carbohydrate, cholesterol, and fiber. All subjects will be asked to maintain their level of physical activity throughout the entire trial.~3. Blood withdraw will be performed prior to the first consumption of food and analyze some biochemistry data."
223780983|NCT06395597|DIAGNOSTIC_TEST|Nine Hole Peg Test|3 attempts of each subtest of the Nine Hole Peg Test performed according to the Czech Extended Version of Manual for the Nine Hole Peg Test; questionnaire
223780984|NCT04543929|BEHAVIORAL|exercise|partially supervised and home-based exercise activity
223780985|NCT01304836|DRUG|Advagraf|oral
223780986|NCT01304836|DRUG|Mycophenolate Mofetil|oral
223697884|NCT05250128|PROCEDURE|Catheterization|Right heart catheterization, using the Swan-Ganz standard technique, to measure mean pulmonary arterial pressure, pulmonary capillary wedge pressure, cardiac output and pulmonary vascular resistance
223697885|NCT03344354|DEVICE|Biogel|Sterile surgical gloves used during surgical procedures.
223697886|NCT03344354|DEVICE|Ansell|Sterile surgical gloves used during surgical procedures.
223697887|NCT03344354|DEVICE|Cardinal|Sterile surgical gloves used during surgical procedures.
223697888|NCT03344354|DEVICE|Medline|Sterile surgical gloves used during surgical procedures.
223697889|NCT05354154|PROCEDURE|endotracheal intubation|Consenting healthy patients of either sex will be endotracheally intubated under controlled environment
223697890|NCT06119724|PROCEDURE|Bipolar enbloc resection of bladder tumor|Enbloc retrival of bladder tumor entoto using cystoscopy using bipolar
223697891|NCT06119724|PROCEDURE|Thulium laser enbloc resection of bladder tumor|Enbloc retrival of bladder tumor entoto using cystoscopy using thulium laser
223697892|NCT02035501|DRUG|L-Tyrosine|
223697893|NCT02035501|DRUG|Placebo|
223697894|NCT00200096|PROCEDURE|Acupuncture and questionnaires|"Acupuncture once weekly for six weeks Brief Fatigue Inventory, Hospital Anxiety and Depression Scale, Functional Assessment of Cancer Treatment scale. Patients will repeat the BFI and FACT-G at seven and eight weeks after randomization, approximately one and two weeks after their final treatment. HADS will be repeated at week seven. At the end of the study, patients will be asked to state whether they were thought they on true or placebo acupuncture and why.~On the day of the final session of acupuncture treatment (approximately day 35), blood samples will be collected and tested for hemoglobin, thyroid function tests, as described in pretreatment evaluation. The results will be designated posttreatment values. Actigraphic monitoring will be conducted in week seven. Patients will be asked to wear the device for seven days just like during baseline evaluation."
223697895|NCT00200096|PROCEDURE|placebo acupuncture|"During the placebo phase, placebo acupuncture needles (68) will be applied a few mm away from the points. The placebo acupuncture needle is a blunt tipped needle that moves up inside its handle. However, the needle does not penetrate the skin and instead moves upward inside the handle. Needles will be applied after sterile swabbing of the skin and kept in place for 20 minutes in both group.Patients in the placebo group will be offered true acupuncture after receipt of the week seven and eight fatigue diaries.~Patients will complete the BFI, HADS and FACT-G at baseline, approximately two weeks before randomization and their first treatment. The BFI and FACT-G will be repeated after seven days, that is, one week before randomization. The use of repeat measurement decreases intrapatient variability and hence increases the precision of the baseline measure."
223697896|NCT00662220|DRUG|ribavirin|25-29 mg/kg/day
223697897|NCT00662220|DRUG|ribavirin|12-15 mg/kg/day
223697898|NCT06560619|BEHAVIORAL|MENTOR|Participants will attend a group-based, 8-week online program (a total of 40 hours) via Zoom videoconferencing. The program is split into three wellness sections (Mindfulness, Exercise, and Nutrition) and eight other sections (self-care skills, core values, outdoor time in nature, rest/relaxation, contribution to others, arts and leisure, relationships, and spiritual practice). Participants will access all assessment and intervention tools on any mobile device (phone, tablet, laptop, desktop) using a password-protected identification (ID) to log in via their devices. Health coaches can create intake flows to collect health data and track analytics. Participants can see their goals, upcoming intervention sessions, and activities through the study application (app). Features of the study app include goal setting, where participants record their goals, zoom videoconferencing links for online classes and coaching sessions, and the ability to share materials with participants.
223697899|NCT03374631|DEVICE|active anodal tDCS|active anodal tDCS with behavioral tasks and self-report measures to assess paranoid ideation
223697900|NCT03374631|DEVICE|sham tDCS|sham tDCS with behavioral tasks and self-report measures to assess paranoid ideation
223697901|NCT00514566|DEVICE|Suture for midline abdominal closure|closure with Polyamide or Polydioxanone
223697902|NCT03107663|DRUG|⁸⁹Zr-Df-IAB22M2C Infusion|A single dose of 3.0 (±20%) mCi of ⁸⁹Zr-Df-IAB22M2C (with 0.2 mg, 0.5 mg, 1.0mg, 1.5 mg, 5.0 mg, or 10.0 mg of protein) will be administered intravenously over 5-10 minutes.
223697903|NCT03512899|PROCEDURE|Right internal jugular access.|Implantation using percutaneous puncture.
223697904|NCT03512899|PROCEDURE|Left internal jugular access.|Implantation using percutaneous puncture.
223697905|NCT03512899|PROCEDURE|Right axillary vein access.|Implantation using percutaneous puncture.
223697906|NCT03512899|PROCEDURE|Left axillary vein access.|Implantation using percutaneous puncture.
223697907|NCT03980431|DIAGNOSTIC_TEST|FBY PET Examination|A single dose of 0.10 mCi/kg FBY will be intravenously injected and PET examination will carry out 30 minutes later.
223697908|NCT02869997|DEVICE|Aspect BIS XP (A-2000) Bispectral Index Patient Monitor|
223697909|NCT01902433|PROCEDURE|Astym|
223697910|NCT00065208|BEHAVIORAL|Reiki|Energy therapy - 8 biweekly sessions of 30 minutes
223697911|NCT00065208|BEHAVIORAL|Pretend Reiki|Touch from untrained pretend practitioners. 8 biweekly sessions of 30 minutes
223780987|NCT01304836|DRUG|Simulect|IV
223780988|NCT01304836|DRUG|Corticosteroids|IV \& oral
223780989|NCT05872139|DIETARY_SUPPLEMENT|Placebo|Gelatin capsules
223780990|NCT05872139|DIETARY_SUPPLEMENT|Mitoquinone Mesylate|MitoQ was given once (single dose, 80 mg)
223780991|NCT04413604|OTHER|Young children's milk (1-<3)|young children's milk containing protein, energy and fat and micronutrients, in accordance with global and local nutritional recommendations for ages 1-3.
223780992|NCT02094989|OTHER|posture dependence of VCG-ECG-transformation|
223780993|NCT04182425|OTHER|Infant formula|Healthy full-term infants fed on an infant formula marketed on the French market
223780994|NCT03895060|DEVICE|autogenous ring blockls with GBR covered by collagen membrane|"* A crestal incision is made using No. 15 blade extending over the anterior maxilla, an anterior vertical releasing incision is made and a full mucoperiosteum flaps elevated to provide access to the alveolar ridge and the lateral aspect of the maxilla~* Autogenous onlay ring blocks is taken by a trephine bur from the chin area and then fixed by screws to the deficient maxillary alveolar height.~* Equally autogenous and xenograft bone particles is packed around the screw to fill the defect area completely.~* The collagen membrane is fixed to the alveolar ridge by bone tacks and the mixture of autogenous and xenograft bone is then packed.~* The flap will then be closed using interrupted 4/0 resorbable sutures."
223780995|NCT05759598|OTHER|Rehabilitation protocol + guided spontaneous breathing exercises|Standard integrated metabolic rehabilitation protocol + guided spontaneous breathing exercises
223780996|NCT05759598|OTHER|Rehabilitation protocol + specific respiratory muscle training program|Standard integrated metabolic rehabilitation protocol + specific respiratory muscle training program according to the protocol recently proposed by Spengler et al. (Wuthrich et al., 2015; Schaer et al., 2018), adapted according to the baseline characteristics of the respiratory function of the subjects
223780997|NCT05758662|DIAGNOSTIC_TEST|18F-sodium fluoride Positron Emission Tomography (18F-NaF PET), Cardiac Computed Tomography (CT), Transthoracic Echocardiography (TTE)|Patients undergo a hybrid 18F-NaF-PET CT scan and TTE at five years after TAVI
223780998|NCT00899223|OTHER|biologic sample preservation procedure|
223780999|NCT00324623|BIOLOGICAL|Melan-A VLP vaccine, IMP321 adjuvant|
223781000|NCT00324623|BIOLOGICAL|adoptive immunotherapy|
223781001|NCT00324623|BIOLOGICAL|therapeutic autologous lymphocytes|
223781002|NCT00324623|DRUG|cyclophosphamide|
223781003|NCT00324623|DRUG|fludarabine phosphate|
223781004|NCT06341218|OTHER|Pediatric Cardiopulmonary Resuscitation Training Based On Team Resource Management|"The sociodemographic information form, Pediatric CPR knowledge level and teamwork attitudes pretest were administered to the healthcare teams just before the training intervention.~The intervention group received a 3-hour training intervention on technical/non-technical skills for CRM-Based Pediatric CPR Training To measure pediatric CPR team performance, 5 different scenarios were prepared by the researcher by INACLS standards. One day after the training intervention, simulation application including pediatric cardiac arrest scenarios was applied to all CPR teams in the intervention(5 groups) and control(5 groups) groups. The scenario content was based on a 5-year-old male patient diagnosed with Pneumonia+Septic Shock.~Pediatric CPR skill levels of the healthcare teams were evaluated during the simulation practice. Immediately after the simulation, the post-intervention post-test of Pediatric CPR knowledge level and team attitudes of the healthcare teams was performed."
223781005|NCT02332486|DRUG|Qingxuan Decoction|In Qingxuan Decoction, there are a bag of Chinese honeylocust spine，Glehnia littoralis and Smilax china L,and two bags of Silktree albizia bark, Kadsura interior,Cortex dictamni, Lilium brownii var, Silkworm larva,Forsythia suspensa and Rhizoma polygonati preparata, and three bags of viridulumArisaema erubescens and Poria cocos Wolf. All drugs are made by Jiangyin Tianjiang company in China.
223781006|NCT00439959|DRUG|GSK625433/placebo|
223781007|NCT02266238|DEVICE|DSA guided percutaneous balloon dilatation|Under the guidance of DSA, balloon is introduced into the stenosis area, proper pressure is given to achieve balloon dilatation to expand the narrow AVF lumen.
223781008|NCT02266238|DEVICE|Ultrasound guided percutaneous balloon dilatation|Under the guidance of ultrasound, balloon is introduced into the stenosis area, proper pressure is given to achieve balloon dilatation to expand the narrow AVF lumen.
223781009|NCT02266238|PROCEDURE|Surgical reconstruction|Direct surgery to reconstruction the AVF lumen.
223781010|NCT02921412|DEVICE|fanfilcon A|contact lens
223781011|NCT00451581|PROCEDURE|Endoscopic papillary balloon dilation-5 minutes|
223781012|NCT00451581|PROCEDURE|Endoscopic papillary balloon dilation-1 minute|
223781013|NCT06522451|OTHER|conventional physical therapy|Only conventional physical therapy (CPT) will be administered to this group. These regular workouts will include dynamic and static stretching, walking-specific functional exercises, passive mobilizations for pain-free mobility, balance modulation, and gait training. At baseline, the functional state of both groups will be evaluated. Treatment sessions will run for a total of 12 weeks, five days a week, for 45 minutes each. They will consist of four to six repeated exercises, six times on average, and use BSID-4 once the trial is over.
223781014|NCT06522451|OTHER|Conventional physical therapy along with cuevas medek exercises|In addition to regular physical therapy, this group will get Cuevas Medak exercises including head and trunk control (by stabilizing limb) and standing to sitting transition. For a duration of 12 weeks, five days a week, and 45 minutes, each session will be held. At the baseline, the functional state of both groups will be evaluated.
223781015|NCT02806739|DIETARY_SUPPLEMENT|Soy Group (Soy Protein + Isoflavones)|Women in the intervention group are asked to eat a combination of soy foods that contain about 25 grams of protein and 60-75 milligrams of isoflavones per day, from the 16th gestational week to birth. A registered dietitian will instruct them to incorporate the soy foods into their daily diet.
223781016|NCT02806739|DIETARY_SUPPLEMENT|Control Group (Minimize Soy Intake)|Women in the control group will be instructed by the dietitian how to avoid soy supplements and minimize soy intake.
223781017|NCT06336070|BEHAVIORAL|HIIT program (8 weeks)|Metabolic Power Training: A High Intensity Interval Training (HIIT) intervention, 3 times per week (30 min session) during 8 weeks with professional supervision and intensities adapted and modified during the intervention period.
223781018|NCT06336070|BEHAVIORAL|MPI program (8 weeks)|Muscle Power Intervention (MPI), 2 times per week (45 min session) during 8 weeks with professional supervision and intensities adapted and modified during the intervention period.
223697912|NCT00065208|BEHAVIORAL|Rest / Guided Imagery|4 weekly sessions of 30 supine rest listening to soft music. One session of Guided Imagery followed at visit 9. Listen to CDs twice a day 3 days prior to and 2 days following surgery (affect only post surgery outcomes)
223697913|NCT05097612|DEVICE|Placebo LiftSuit Exoskeleton|The LiftSuit is a soft passive wearable device that is designed to support the hip and back muscles during forward leaning and lifting. It exerts it function through Elastic Energy Storages (EES). In this condition the EES are removed from the device to create a placebo device.
223697914|NCT05097612|DEVICE|LiftSuit Exoskeleton (low support level)|The LiftSuit is a soft passive wearable device that is designed to support the hip and back muscles during forward leaning and lifting. It exerts it function through Elastic Energy Storages (EES). EES of different three different levels of stiffness (low, medium, high stiffness) will be used.
223697915|NCT05097612|DEVICE|LiftSuit Exoskeleton (medium support level)|The LiftSuit is a soft passive wearable device that is designed to support the hip and back muscles during forward leaning and lifting. It exerts it function through Elastic Energy Storages (EES). EES of different three different levels of stiffness (low, medium, high stiffness) will be used.
223697916|NCT05097612|DEVICE|LiftSuit Exoskeleton (high support level)|The LiftSuit is a soft passive wearable device that is designed to support the hip and back muscles during forward leaning and lifting. It exerts it function through Elastic Energy Storages (EES). EES of different three different levels of stiffness (low, medium, high stiffness) will be used.
223697917|NCT04489459|DRUG|Colistin|Intravenous colistin 9 MIU IV infusion over 2 hours loading dose followed by maintenance dose 4.5 MIU IV infusion over 2 hours q12 h
223697918|NCT04489459|DRUG|Meropenem|Intravenous meropenem 2 g IV infusion over 30 minutes q8 h
223697919|NCT04489459|DRUG|Tigecycline|Intravenous Tigecycline 100 mg IV infusion over 1 hour loading dose followed by maintenance dose 50 mg IV infusion over 1 hour q12
223697920|NCT05500547|OTHER|"US Public Health Service USPSH criteria for assessment of success of resin composite restorations"|"US Public Health Service USPSH criteria for color match, marginal adaptation, surface texture, retention, recurrent caries and others after 1, 3, 6 and 9 months."
223697921|NCT00163111|DRUG|VFENDÂ® I.V., Oral|
223697922|NCT00163111|DRUG|Conventional amphotericin B|
223697923|NCT00163111|DRUG|Diflucan IV, oral|
223781019|NCT01528228|DEVICE|TENS Treatment with functional or disabled unit|TENS treatment will be standardized and will consist of 20 minute sessions three times per day at the manufacturer's recommended settings for both functional and disabled TENS units.
223697924|NCT02812173|DEVICE|suprapubic tube ex 2 day|balloon catheter for suprapubic bladder-drainage, suprapubic tube removal on the second day after the surgery
223697925|NCT02812173|DEVICE|suprapubic tube ex 5 day|balloon catheter for suprapubic bladder-drainage, suprapubic tube removal on the fifth day after the surgery
223697926|NCT02812173|DEVICE|transurethral catheter ex 5 day|transurethral catheter withdrawal removal on the fifth day after the surgery
223697927|NCT03788629|OTHER|Talocrural joint MWM mobilization|There were two groups for this study. In addition to Bobath Concept, talocrural joint mobilization was performed.
223697928|NCT03788629|OTHER|Subtalar joint MWM mobilization|There were two groups for this study. In addition to treatment of control group, subtalar joint mobilization was performed.
223697929|NCT05126680|OTHER|Supervised exercise therapy: intermittent treadmill walking exercise and moderate intensity functional training|Subjects will perform a 12-week supervised exercise therapy program based on intermittent treadmill walking exercise (15-30 min.) and moderate intensity functional training (MIFT) (15 min.). In intermittent treadmill walking exercise, the speed and incline of treadmill will be adjusted that patients achieve moderate claudication pain in the time interval between 3 and 5 min. In MIFT, subjects must complete in 15 min. the highest number of repetitions / rounds possible (AMRAP) to a circuit composed of 6 global functional exercises from which they performed 10 repetitions with a rating of perceived exertion (RPE) of 5-7 on a 1 to 10 scale in each exercise.
223781020|NCT02255110|DRUG|TH-302|TH-302 will be administered at a dose of 300 milligram per square meter (mg/m\^2) by intravenous infusion over 30 minutes on Days 1 and 8 of every 21-day cycle until the evidence of significant treatment-related toxicity or progressive disease.
223781021|NCT02255110|DRUG|Doxorubicin|Doxorubicin will be administered at a dose of 75 mg/m\^2 by intravenous injection (over at least 5 minutes) or by intravenous infusion over 6-96 hours on Day 1 of every 21-day cycle starting 2 to 4 hours after completion of TH-302 administration until the evidence of significant treatment-related toxicity or progressive disease.
223781022|NCT02579993|PROCEDURE|Pannus and conjunctival dissection|A complete conjunctival peritomy is performed and the fibrovascular pannus and conjunctiva invading the cornea is dissected from the cornea and limbus.
223781023|NCT02579993|PROCEDURE|Human cultivated limbal stem cell transplantation|The amniotic membrane graft cultured with the human limbal stem cell transplantation is placed in the limbic and corneal surface and fixed with fibrin glue. The amniotic membrane is placed with the stroma in contact with the graft and it is sutured.
223781024|NCT06531759|DRUG|Fentanyl|Fentanyl soaked nasal packs.
223781025|NCT02803710|OTHER|Microbiological study|
223781026|NCT02137629|DRUG|Vidaza®|The recommended starting dose for the first treatment for all patients regardless of baseline hematology values is Vidaza® 75mg/m2 subcutaneous(SC) injection or intravenous (IV) infusion, daily for 7 days.
223781027|NCT06381908|OTHER|Calorie-restriction with low carbohydrate|Calorie-restriction and low carbohydrate availability
223781028|NCT06381908|OTHER|Calorie-restriction with moderate carbohydrate|Calorie-restriction and moderate carbohydrate availability
223781029|NCT00766376|DEVICE|Erbium laser|Erbium laser treatment. Each subject will undergo up to 6 treatment sessions
223781030|NCT02207829|DRUG|Umeclidinium|Umeclidinium 62.5 mcg once daily in the morning via nDPI
223781031|NCT02207829|DRUG|Umeclidinium matching placebo|Umeclidinium matching placebo once daily in the morning via nDPI
223781032|NCT02207829|DRUG|Tiotropium|Tiotropium 18 mcg once daily in the morning via HANDIHALER inhaler
223781033|NCT02207829|DRUG|Tiotropium matching placebo|Tiotropium matching placebo once daily in the morning via HANDIHALER inhaler
223781034|NCT01583972|DIETARY_SUPPLEMENT|retinyl palmitate|50,000 IU vitamin A in oil given within 48 h of birth from single-dose capsule
223781035|NCT01583972|DIETARY_SUPPLEMENT|Placebo|edible oil used as diluent for vitamin A given within 48 h of birth from single-dose capsule identical in appearance to vitamin A capsule
223781036|NCT03876327|PROCEDURE|fecal microbial transplantation|Fecal microbiota transplantation (FMT) is a technique in which intestinal microbiota are transferred from a healthy donor to the patient, with as primary goal to introduce - or restore - a stable and 'healthy' microbial community in the gut.
223781037|NCT06057415|PROCEDURE|HAPTOS (Handling Adapted to Postnatal age with Tactile-kinaesthetic and Oral sensorimotor Stimulation|Tactile-kinaesthetic and Oral sensorimotor Stimulation
223781038|NCT06398704|OTHER|Standart of care|No additional intervention was made. An evaluation was made.
223781039|NCT01342562|DRUG|spinal anesthesia|0.4% bupivacaine(normal saline 0.3ml with dexmedetomidine 3 mcg)
223781040|NCT01342562|DRUG|spinal anesthesia|0.4% bupivacaine(normal saline 0.3 ml with 0.5% bupivacaine 1.2 ml)
223781041|NCT01800903|DEVICE|ZN-D catheter|ZN-D catheter is a catheter, similar to the CE-marked SpeediCath, but with a newly developed coating.
223781042|NCT01800903|DEVICE|ZN-C catheter|ZN-C catheter is a catheter, similar to the CE-marked SpeediCath, but with a newly developed coating.
223781043|NCT01800903|DEVICE|SpeediCath catheter|The Speedicath cathere is CE-marked and commercially available.
223781044|NCT03061539|DRUG|Nivolumab & Ipilimumab|"Combination Therapy: Cohort 1: Nivolumab 1 mg/kg + ipilimumab 3 mg/kg every 3 weeks for a maximum of 4 cycles . Cohort 2 : Nivolumab 3mg/kg + ipilimumab 1mg/kg every 3 weeks for a maximum of 4 cycles.~Treatment free gap after last combination dose : Cohort 1: 6 weeks; Cohort 2: 3 weeks~Monotherapy: 480 mg flat dose of nivolumab every 4 weeks for up to 10 cycles, or until progression, unacceptable toxicity or withdrawal of consent"
223781045|NCT02384603|OTHER|Global postural reeducation|
223781046|NCT02384603|OTHER|Segmental muscle stretching exercises|
223781047|NCT02384603|OTHER|Cognitive behavioral therapy|
223781048|NCT00261924|DEVICE|Transfusion of Pathogen Inactivated Platelets stored for 6-7 days|pathogen inactivation of platelets for transfusion
223781049|NCT03943810|OTHER|No intervention|There is no intervention
223781050|NCT00222937|BEHAVIORAL|Lessac-Madsen Resonant Voice Therapy|Patients receive 8 sessions of therapy over a course of 4 weeks, with one double session per week.
223781051|NCT00222937|BEHAVIORAL|Casper-Based Confidential Flow Therapy|Patients receive 8 sessions of therapy over a course of 4 weeks, with one double session per week.
223781052|NCT05584501|OTHER|Care Navigator|The Dental Team will have a Care Navigator as an added resource to assist with offering, implementing, and counseling for HIV testing; providing PrEP education and linkage; and providing linkage and re-linkage to HIV care.
223781053|NCT05584501|OTHER|Health Information Supported Ending the HIV Epidemic (ETE) Activities in Dental Setting|Dental Teams will receive a Best Practice Alert (BPA) when they have a patient who should be offered HIV testing. Dental Teams will also be notified when they have a patient known to be HIV positive but out of HIV care.
223781054|NCT03461627|DRUG|Salmeterol Xinafoate and Fluticasone Propinate Powder|50ug/250ug 1 puff twice a day for 4 weeks
223781055|NCT03461627|DRUG|Seretide|50ug/250ug 1 puff twice a day for 4 weeks
223781056|NCT00228527|DRUG|Esomeprazole (Nexium)|
223781057|NCT03218111|OTHER|MR Imaging|All subjects will undergo six sessions of MR imaging over a 10-12 hour period
223781058|NCT03218111|OTHER|CT-guidance|All subjects will be injected, intrathecally using CT-guidance, with an MRI contrast.
223781059|NCT00907920|OTHER|laboratory biomarker analysis|Correlative studies
223781060|NCT05896358|BEHAVIORAL|ketogenic diet|a low calorie ketogenic diet
223781061|NCT00000252|DRUG|0% N2O|
223781062|NCT00000252|DRUG|10% N2O|
223781063|NCT00000252|DRUG|20% N2O|
223781064|NCT00000252|DRUG|30% N2O|
223781065|NCT00000252|DRUG|40% N2O|
223781066|NCT05580731|DIAGNOSTIC_TEST|Diagnostic test: 5 different Rapid diagnostic test and Reference tests|Diagnostic test: 5 different Rapid diagnostic test and Reference tests
223781067|NCT03058406|DRUG|Eribulin mesylate|Participants will receive 1.4 milligrams per square meter (mg/m2) administered as an intravenous (IV) infusion (over 2 to 5 minutes) on Days 1 and 8 of each 3-week cycle and beyond.
223697930|NCT05126680|OTHER|Supervised exercise therapy: intermittent treadmill walking exercise|Subjects will perform a 12-week supervised exercise therapy program based on intermittent treadmill walking exercise (30-45 min.). In intermittent treadmill walking exercise, the speed and incline of treadmill will be adjusted that patients achieve moderate claudication pain in the time interval between 3 and 5 min.
223697931|NCT02883166|DRUG|abiraterone|integested with a continental breakfast
223697932|NCT03838146|BEHAVIORAL|Types of Exercise|moderate intensity exercise
223697933|NCT00834678|DRUG|bendamustine|100 or 120 mg/m2 IV on days 1 and 2
223697934|NCT00834678|DRUG|erlotinib|100 or 150 mg po on days 5 - 21 of each 28 day cycle
223697935|NCT00834678|DRUG|Maintenance erlotinib|150 mg po daily (days 1 - 28 of 28 day cycle)
223697936|NCT02876094|DRUG|celecoxib|dose-response
223697937|NCT04107779|OTHER|Switch from UB of Combustible Cigarette to JUUL 5% Virginia Tobacco ENDS|JUUL 5%, ENDS for 6-days in confinement
223697938|NCT04107779|OTHER|Switch from UB of Combustible Cigarette to JUUL 3% Virginia Tobacco ENDS|JUUL 3%, ENDS for 6-days in confinement
223697939|NCT04107779|OTHER|Switch from UB of Combustible Cigarette to JUUL 5% Mint ENDS|JUUL 5%, ENDS for 6-days in confinement
223697940|NCT04107779|OTHER|Switch from UB of Combustible Cigarette to JUUL 3% Mint ENDS|JUUL 3%, ENDS for 6-days in confinement
223697941|NCT04107779|OTHER|Switch from UB of Combustible Cigarette to JUUL 5% Menthol ENDS|JUUL 5%, ENDS for 6-days in confinement
223697942|NCT04107779|OTHER|Switch from UB of Combustible Cigarette to JUUL 3% Menthol ENDS|JUUL 3%, ENDS for 6-days in confinement
223697943|NCT04107779|OTHER|Switch from UB of Combustible Cigarette to JUUL 5% Mango ENDS|JUUL 5%, ENDS for 6-days in confinement
223697944|NCT04107779|OTHER|Switch from UB of Combustible Cigarette to JUUL 3% Mango ENDS|JUUL 3%, ENDS for 6-days in confinement
223697945|NCT04107779|OTHER|Switch to Dual-use of JUUL 5% and UB of Combustible Cigarette|Combination use of JUUL 5% (Virginia Tobacco, Mint, Menthol or Mango flavored) and usual brand combustible cigarettes for 6-days in confinement
223697946|NCT04107779|OTHER|Tobacco/Nicotine Abstention|No smoking for 6-days in confinement.
223697947|NCT04107779|OTHER|Usual Brand of cigarettes|Continue smoking UB for 6-days in confinement.
223697948|NCT01739361|DRUG|Acetaminophen|
223697949|NCT01739361|DRUG|placebo|
223781068|NCT02541240|OTHER|Resilience Curriculum|The Resilience Curriculum consists of 4 modules, with one 2-hour module presented each week.
223781069|NCT00001100|DRUG|ganciclovir|
223697950|NCT05396807|DEVICE|AI|The aim of using AI software to support physicians in choosing the most effective treatment.
223697951|NCT02370277|OTHER|Cytology Specimen Collection Procedure|Undergo collection of stool samples
223697952|NCT02370277|OTHER|Laboratory Biomarker Analysis|Correlative studies
223781070|NCT01127438|DRUG|fospropofol disodium Subgroup 1 Lower Dose|Dose of Initial IV (Titration) Bolus 6.5mg/kg) (administered to Subgroup 1, Weight \< 60 kg and Age \< 65 years and ASAI and II)
223781071|NCT01127438|DRUG|fospropofol disodium Subgroup 1 Approved Dose|(Dose of Initial IV (Titration) Bolus 385mg) (Administered to Subgroup 1, Weight \<60 kg and Age \<65 years and ASAI and II)
223781072|NCT01127438|DRUG|fospropofol disodium Subgroup 2 Lower Dose|Dose of Initial IV (Titration) Bolus 4.875 mg/kg) (administered to Subgroup 2, Weight \< 60 kg and Age \>/=65 years and ASA 3 or 4
223697953|NCT02370277|OTHER|Questionnaire Administration|Ancillary studies
223697954|NCT03237078|DIETARY_SUPPLEMENT|Lactobacillus plantarum PS128|Each PS 128 capsule contains 300 mg of probiotics. PS128 will be provided 300 mg twice, in the morning and in the afternoon, daily.
223697955|NCT00067574|BEHAVIORAL|Structured treatment interruption|
223697956|NCT05660681|DRUG|glycerin 0.7%/PEG 400 0.3%|Eye drop with active agents from the OTC Monograph.
223697957|NCT05660681|DRUG|polyethylene glycol 400 0.4%/propylene glycol 0.3%|Eye drop with active agents from the OTC Monograph.
223697958|NCT01904565|RADIATION|Hyperthermia and Proton Beam|"1. Local hyperthermia,once a week for 5 to 7 weeks to a temperature of 41.5 to 42.5 degree Centigrade~2. Proton beam therapy, 5 days a week at 1.8 - 2.0 GyE per fraction to a dose of 55 - 60 GyE (preoperative) or 72 - 76 GyE (for radical. Patients who have good response at 5 weeks of treatment would be considered for preoperative treatment, while those with unsatisfactory response that could be taken up for at least R0 resection would be treated to a radical dose."
223697959|NCT05738629|DRUG|Pluripotent Stem Cell-derived Mesenchymal Stem Cell Exosome (PSC-MSC-Exo) Eye Drops|Participants will receive artificial tears for 2 weeks to get the normalized baseline, followed by PSC-MSC-Exo eye drops 0.125 ml/single eye/one time, four times a day for 12 weeks. The follow-up visit will be 12 weeks since the administration of PSC-MSC-Exo eye drops.
223697960|NCT04660253|BEHAVIORAL|LTP Plus Dads|
223697961|NCT00302198|BEHAVIORAL|ALS Registry|
223697962|NCT04128774|DRUG|Dexamethasone|The case group receives dexamethasone based on the clinical indication.
223697963|NCT04502979|BEHAVIORAL|Responsive Feeding Training|Families will receive 4 monthly 1-hour sessions: (1) Signing with infants; (2) infant communication and responsive feeding; (3) nutrition, portion sizes, and neophobia; and, (4) infant intentionality.
223697964|NCT02815410|DRUG|levetiracetam|Patients in this group are with newly diagnosed glioblastoma patients who are supposed to be treated with concurrent chemoradiotherapy (CCRT) and adjuvant chemotherapy with temozolomide (TMZ). Patients ( intervention Group) will be given levetiracetam (LEV) from the beginning of treatment till after the adjuvant chemotherapy with TMZ is over.
223697965|NCT03049527|BEHAVIORAL|Education, Incentives and Feedback|The study participants will receive additional educational activities, including low-literacy fact sheets on liquid intake guidelines, cards with instructions on how to self-monitor urine color and volume, and flyers and posters placed throughout the worksite. All consenting study participants will be offered incentives to start the work day hydrated and then to maintain or improve their hydration status over the work shift. Participants who do not meet hydration goals will receive additional coaching and feedback on ways to improve hydration.Feedback will also be provided to all groups about their productivity level to help participants recognize the connection between improved health and function.
223697966|NCT02856698|DRUG|Midazolam|Dose use according to the product technical sheet
223697967|NCT02856698|DRUG|Morphine|Dose use according to the product technical sheet
223697968|NCT04794088|DRUG|Imatinib Mesylate intravenous solution|A 25ml volume of IMP will be administered over 2-hours as an intravenous infusion. This corresponds to a dose of 200mg imatinib (100mg/h).
223697969|NCT04794088|DRUG|Placebo|A 25ml volume of IMP will be administered over 2-hours as an intravenous infusion. This corresponds to a dose of 25ml placebo (12.5ml/h).
223781073|NCT01127438|DRUG|fospropofol disodium Subgroup 2 Approved Dose|(Dose of Initial IV (Titration) Bolus 297.5mg) (Administered to Subgroup 2, Weight \<60 kg and Age \>/=65 years and ASA 3 or 4
223781074|NCT01127438|DRUG|fospropofol disodium Subgroup 3 Lower Dose|(Dose of Initial IV (Titration) Bolus 3.9mg/kg) (Administered to Subgroup 3, Weight \>/= 60 kg and Age \>/= 65 years and ASA 3 or 4
223781075|NCT01127438|DRUG|fospropofol disodium Subgroup 3 Approved Dose|Dose of Initial IV (Titration) Bolus 4.875 mg/kg) (Administered to Subgroup 3, Weight \>/= 60 kg and Age \>/= 65 years and ASA 3 or 4
223697970|NCT03318900|BIOLOGICAL|Aldesleukin|Given IV
223697971|NCT03318900|DRUG|CD8-Positive T-Lymphocyte|Given IV
223697972|NCT03318900|DRUG|Cyclophosphamide|Given IV
223697973|NCT03318900|PROCEDURE|Leukapheresis|Undergo leukapheresis
223697974|NCT03318900|BIOLOGICAL|Utomilumab|Given IV
223697975|NCT00002078|DRUG|Interferon alfa-n3|
223697976|NCT03158987|OTHER|Medical record review|Review of medical records of patients diagnosed for the first time as HIV seropositivity
223697977|NCT02422173|DEVICE|Anodal transcranial direct current stimulation|The active electrode is placed on the affected hemisphere
223697978|NCT02422173|DEVICE|Cathodal transcranial direct current stimulation|The active electrode is placed on the unaffected hemisphere
223697979|NCT02422173|DEVICE|Bilateral transcranial direct current stimulation|The cathode and anode is positioned as active electrodes on the unaffected and affected hemisphere,respectively.
223697980|NCT02422173|DEVICE|Sham transcranial direct current stimulation|Placebo stimulation, with emission current by only 30 seconds
223697981|NCT01658852|DRUG|metronidazole|
223697982|NCT01658852|DRUG|Placebo|
223697983|NCT02443519|BEHAVIORAL|MBCT for Migraine|8 75-90 minute individual sessions of the manualized Mindfulness-based Cognitive Therapy plus a manual and homework
223697984|NCT04155489|PROCEDURE|blood transfusion|In the restrictive blood transfusion group, if the hemoglobin value is less than 8 g /dL or if there are suspected symptoms of anemia such as dizziness or chest pain, headache, low on energy, blood transfusion is started. in the liberal transfusion group, If the hemoglobin value is less than 10 g /dL, blood transfusions begin.
223697985|NCT06309186|OTHER|Evaluation of midwifes' burnout|Burnout evaluated by questionnaires
223697986|NCT04022434|DIETARY_SUPPLEMENT|Placedo|Subjects will mix the placebo in the beverage of their choice and consume this approximately 20 minutes before meals or snacks, in according with the dosing guidelines set for them by the dietitian.
223697987|NCT04022434|DIETARY_SUPPLEMENT|Alanine|Subjects will mix the alanine in the beverage of their choice and consume this approximately 20 minutes before meals or snacks, in according with the dosing guidelines set for them by the dietitian.
223697988|NCT00932737|DRUG|Placebo|1-5 tablets per episode
223697989|NCT00932737|DRUG|HBB 20 mg|Active drug, one to five tablets per episode
223697990|NCT01812772|DEVICE|Double J-stent with a long tether|Patients will receive a double-J stent placement with a long tether following ureteroscopy.
223697991|NCT01812772|DEVICE|Double J-stent without a long tether|Patients will receive a double-J stent placement without a long tether following ureteroscopy.
223697992|NCT06450158|DEVICE|Robot (Amadeo)-assisted Training|"Amadeo® is an FDA Class I Exempt hand/finger robot that has the capacity to precisely measure hand/finger functions.~To use Amadeo, a participant will be seated in a chair. The height of the robot arm support will be adjusted to achieve a comfortable position for the participant. One of the participant's arms will be will be placed on the robot arm support. Magnetic finger tips will then be attached to fingers and thumb. After this, fingers and thumb will be connected to the robot finger sliders. To use Amadeo, the movement range and maximal force of each finger will be configured according to the finger's capability. The following four types of function assessments will be performed with Amadeo: Force, range of motion, tone, and spasticity. Each session will last approximately one hour."
223697993|NCT04126551|OTHER|Methylation status|Participants will be recruited, and muscle biopsies will be obtained for methylation analyses and measuring mitochondrial function
223697994|NCT01042574|DRUG|Clevidipine butyrate|Cleviprex will be administered according to current package insert instructions, with a starting dose of 2.0mg/hr for 1.5 minutes and thereafter titrated to lower blood pressure to a target goal of 110 mmHG to 140mmHG.
223697995|NCT04864418|DRUG|AST-021p|3 priming immunization (2weeks x3) in 4 cohort groups (1.2mg, 2.4mg, 3.6mg and 4.8mg AST-021p) if possible, 3 boosting immunization (4weeks x 3) in cohort groups after priming immunization
223697996|NCT01689636|DRUG|Tc 99m EC20|
223697997|NCT00775073|DRUG|Everolimus, Bevacizumab|Everolimus 5 mg tablet per day orally. Bevazicumab 5 mg per kg intravenous every 2 weeks.
223697998|NCT04736342|OTHER|PALI questionaire|Survey comprised of a series of multiple choice questions
223697999|NCT02216760|DEVICE|Ripple Mapping guided VT ablation|RM will be used to guide identification of conduction channels and hence substrate guided ablation
223698000|NCT02216760|DEVICE|Conventional VT ablation|Substrate guided ablation using conventional methods (pace-mapping, LAVA/late potential abolition, scar border zone ablation)
223698001|NCT05888454|OTHER|Integrative Group Program|The integrative group program consists of 6 in-person sessions directed by a health coach and occurring every other week, and 6 asynchronous educative sessions during a period of 12 weeks.
223698002|NCT05888454|OTHER|Conventional treatment for T2DM|Conventional medical treatment for T2DM
223698003|NCT01881373|OTHER|CHL program|Multiple component environmentally focused program designed with community engagement.
223698004|NCT01881373|OTHER|Delayed Optimized CHL program|CHL programs with fewer component and shorter duration.
223698005|NCT01398553|DEVICE|Armeo Spring|30min Armeo Spring + 15min task oriented therapy over 6 weeks Frequency: 3 x/week
223698006|NCT01398553|OTHER|conventional physiotherapy|30min occupational therapy(15min ADL-training, 15min repetitive training) + 15min task oriented therapy over 6 weeks Frequency: 3x/week
223698007|NCT02681601|DIETARY_SUPPLEMENT|Nutrawell Powder|"The NutraWell nutrition powder will be provided by and distributed from New Health Nutraceuticals (Irvine, California - USA). Nutrawell is manufactured New Health Enterprises, Inc. The supplement sample will be stored at room temperature in the UCLA Center for Human Nutrition research unit.~OmegaRich Contains high concentration and high purity of natural omega-3 polyunsaturated fatty acids: Eicosapenatenoic acid (EPA) and docosahexaenoic acid (DHA) from deep water fish.~Enriched with natural vitamin E: d- tocopherol Triglyceride form (TG-form) of the raw fish oil ingredients. Each fish oil capsule contains 55% EPA and DHA with 330 mg EPA and 220 mg DHA."
223698008|NCT02681601|OTHER|Diet Only|Subjects will be evaluated by a registered dietitian and randomized to diet prescription (55% carbohydrate, 30% fat and 15% protein)
223698009|NCT02681601|DIETARY_SUPPLEMENT|OmegaRich fish oil supplement|"OmegaRich is manufactured New Health Enterprises, Inc. The supplement sample will be stored at room temperature in the UCLA Center for Human Nutrition research unit.~OmegaRich Contains: high concentration and high purity of natural omega-3 polyunsaturated fatty acids: Eicosapenatenoic acid (EPA) and docosahexaenoic acid (DHA) from deep water fish.~Enriched with natural vitamin E: d- tocopherol Triglyceride form (TG-form) of the raw fish oil ingredients. Each fish oil capsule contains 55% EPA and DHA with 330 mg EPA and 220 mg DHA."
223698010|NCT05325060|DEVICE|Electromagnetically navigated total knee arthroplasty|The navigated group had surgery using the iNav portable EM navigation system (Zimmer GmbH, Winterthur, Switzerland and Medtronic, Minneapolis, MN, USA) and the definitive implant used was NexGen LPS implant (Zimmer Inc, Warsaw, IN, USA), a fixed-bearing bicruciate-sacrificing total condylar implant using traditional instrumentation with no patellar resurfacing
223698011|NCT05325060|DEVICE|Conventional total knee arthroplasty|The conventional group received surgery using conventional instrumentation and jigs from the implant manufacturer (Zimmer Inc, Warsaw, IN, USA) and the definitive implant used was NexGen LPS implant (Zimmer Inc, Warsaw, IN, USA), a fixed-bearing bicruciate-sacrificing total condylar implant using traditional instrumentation with no patellar resurfacing
223698012|NCT00772304|DRUG|Olopatadine 0.6% / Azelastine 137 mcg|single dose; 2 sprays per nostril
223698013|NCT01628172|DEVICE|Biosense Webster Celcius Thermacool catheter|catheter-based sympathetic renal denervation
223698014|NCT04110587|BIOLOGICAL|Hyaluronic Acid|1 mL Hyaluronic Acid Injection (20 mg/mL, 7000 KDa) at the end of arthroscopy .
223698015|NCT04110587|PROCEDURE|Temporomandibular Joint Arthroscopy|Lysis and Lavage
223698016|NCT04110587|DRUG|Antibiotic therapy|Amoxicillin / Clavulanic Acid, 1g I.V. (Intraoperative); as well as Amoxicillin / clavulanic acid, 500/125 mg / 8h / 5 days by mouth (Post-operative).
223698017|NCT04110587|DRUG|corticosteroid|Dexamethasone, 4 mg I.V. (Intraoperative)
223698018|NCT04110587|DRUG|Antiinflammatories|Diclofenac 100 mg / 12h / 5 days by mouth (Post-operatively).
223698019|NCT04110587|DRUG|Analgesics|Metamizol 575 mg / 8h by mouth (Post-operatively)
223698020|NCT04110587|OTHER|Exercise program|Home exercise program
223698021|NCT04112459|OTHER|prolonged mechanical ventilation|No intervention will be applied in this study
223698022|NCT02906332|DRUG|Pembrolizumab|Pembrolizumab 200 mg IV every 3 weeks x 2 cycles. This is followed by followed by pembrolizumab 200 mg IV every 3 weeks for 2 additional cycles.
223698023|NCT02906332|DRUG|Lenalidomide|Lenalidomide 25 mg po daily x 14 days once weekly for a 21-day cycle x 2 cycles. This is followed by lenalidomide 25 mg po daily x 14 days for a 21-day cycle x 2 cycles for 2 additional cycles.
223698024|NCT02906332|DRUG|Dexamethasone|Dexamethasone 40 mg po once weekly for a 21-day cycle x 2 cycles only.
223698025|NCT02384161|OTHER|Isometric exercise Intermittent|Intermittent isometric exercise is characterized by an interval muscle contraction (one period and another relaxed contracted period) in which there is no generation of voltage change in the length of the muscle fiber.
223698026|NCT02949700|DRUG|Metformin|Metformin will be administered orally twice daily during treatment with chemo-radiation for head and neck squamous cell carcinoma. This will occur 7 to 11 days prior to chemotherapy and radiation.
223698027|NCT06273631|OTHER|diverse carbohydrate diet|"Carbohydrate provides 45\~55% of total dietary energy, protein 15\~20%, and fat 25 \~35%. Among them, 45\~50% of carbohydrate supply sources are refined grains, 45\~50% of carbohydrate supply sources are whole grains or beans.~The total energy is divided into 3 meals per day. The breakfast provides 25\~30% of total energy, lunch 30\~40%，and dinner 30\~35%."
223698028|NCT06273631|OTHER|middle carbohydrate diet|"Carbohydrate provides 45\~55% of total dietary energy, protein 15\~20%, and fat 25 \~35%. Among them, 90\~95% of carbohydrate supply sources are refined grains.~The total energy is divided into 3 meals per day. The breakfast provides 25\~30% of total energy, lunch 30\~40%，and dinner 30\~35%."
223698029|NCT01403311|DRUG|5-Aminolevuline Acid|5-Aminolevuline Acid (ALA) at 30 mg/kg given orally 4 hours before surgery
223698030|NCT04831606|PROCEDURE|debridement|Cleaning of the wound area
223698031|NCT04831606|DEVICE|Offloading|Offloading performed with a standard brace to the calf (Optima Diab, from Molliter).
223698032|NCT04831606|DEVICE|Advanced dressing|Protect the wound with Advanced dressing
223698033|NCT04831606|DEVICE|Blue Light Photobiomodulation|2 minutes irradiation of blue light performed with EmoLED device
223698034|NCT04399226|DRUG|Dexmedetomidine|Group D received 1mg/kg dexmedetomidine+0.5mg/kg propofol intravenous (iv) bolus, 0.5 μg/kg/h dexmedetomidine+ 0.5 mg/kg/h propfol infusion. Group K received 0.125 mL/kg bolus, 0.125 mL/kg/h ketamine+ propofol = ketofol infusion (ketofol was prepared with 4 mg propofol+2 mg ketamine).
223698035|NCT03629210|DRUG|OZURDEX|OZURDEX® (DEX implant, 0.7 mg) is a micro-ionized and non-preserved dexamethasone within a cylindrically-shaped 0.45 mm diameter x 6.5 mm length biodegradable Poly D, L-lactate-co-glycolic acid pellet allowing for sustained delivery dexamethasone into the vitreous cavity and retina following intravitreal injection. Health Canada has granted approval for use of DEX implant in the treatment of ME following central retinal vein occlusion, non-infectious uveitis affecting the posterior segment and pseudophakic DME in adult patients. (OZURDEX® Canadian Product Monograph, April 14, 2015). DEX implant will be provided as investigational treatment by Allergan Inc., Markham, ON, Canada.
223698036|NCT03629210|BIOLOGICAL|Eylea|EYLEA® (AFL 2.0 mg intravitreal injections) is an anti-VEGF treatment. AFL (2.0 mg) has received approval from Health Canada for the treatment of DME. Health Canada has also granted approval for AFL (2.0 mg) in the treatment of age-related macular degeneration, and ME secondary to retinal vein occlusion.
223698037|NCT02929914|PROCEDURE|Local anesthesia and rubber dam isolation|Local anesthesia was performed. Tooth was isolated using a rubber dam isolation in order to collect the dentin samples.
223698038|NCT02929914|PROCEDURE|Incomplete caries removal and microbiological samples collection|Partial carious tissue was removed with conventional dentinal curette and collection of dentin with a spoon (1#) was performed.
223698039|NCT02929914|PROCEDURE|Dentin washed with sodium 0.9% saline|The remaining dentin was dipped in sodium 0.9% saline for 2min.
223698040|NCT02929914|PROCEDURE|Antimicrobial Photodynamic Therapy|The remaining dentin was disinfected with aPDT for 2 min.
223698041|NCT02929914|PROCEDURE|Microbiological samples collection and Indirect pulp treatment|A new dentin collection was performed after this treatment at another site of the cavity. Then teeth were conventionally restored using the following materials: calcium hydroxide lining material and resin (Z350,3M).
223698042|NCT01522508|PROCEDURE|tetanic stimulation|as test stimulus a painful tetanic stimulation is used
223698043|NCT02966769|OTHER|Overall survival|Compare overall survival between both groups.
223698044|NCT04637113|OTHER|This is a non-interventional study|This is a non-interventional study.
223698045|NCT03191279|PROCEDURE|First aid|Open airway (head tilt, chin lift), recovery position, staunch of bleeding, prevention of hypothermia, cooling of burn, CPR
223698046|NCT04934475|DRUG|Isatuximab|Treatment with Isa-KRD during induction and consolidation , with Lenalidomide (Revlimid) or Iberdomide + Isatuximab during maintenance phase
223698047|NCT04934475|PROCEDURE|ASCT|ASCT for ams B, C and D during consolidation
223698048|NCT04985370|OTHER|Pain neuroscience education|Three sessions of pain neuroscience education based on explaining patients: characteristics of acute versus chronic pain, function of acute pain, how acute pain is originated within the nervous system, how acute pain progress to chronic pain, and factors that contribute to central sensitization (e.g., emotions, stress, disease and pain beliefs, behaviors regarding pain...). All the explanations will be conducted using easy-understandable examples and metaphors.
223698049|NCT04985370|OTHER|Exercise|Progressive resistance exercise program based on isometric, concentric, eccentric, and pliometric contractions.
223698050|NCT03451942|DRUG|FLOT regimen chemotherapy|FLOT regimen chemotherapy
223698051|NCT03451942|PROCEDURE|D2 gastric and imaging metastases resection|After received 4 cycles FLOT regimen chemotherapy , D2 gastric resection and imaging metastases resection was performed. Then continue 4 cycles of FLOT regimen chemotherapy (Chemotherapy begins within 4-6 weeks after surgery)
223698052|NCT06281288|BEHAVIORAL|Cognitive-Behavioral Therapy|Cognitive behavioral therapy
223698053|NCT06281288|OTHER|Exercise Training|Moderate intensity (\~63% maximum heart rate; HRmax) aerobic (\~25 min) and resistance (\~25 min) activities
223698054|NCT04879277|BIOLOGICAL|Blood samples|Plasmatic cytokine and plasmatic CRP assay will be realised using luminex in both arms. IL2, IL10,INF gamma, IL, IL6, ILB, TNF alpha will be analysed.
223698055|NCT04399837|DRUG|Spesolimab|Solution for injection
223698056|NCT04399837|DRUG|Placebo|Solution for injection
223698057|NCT03239158|DEVICE|Cancer ablation|Tumors bigger than 2 cm are fit for ablation therapy, percutaneously under CT scan or ultrasound.
223698058|NCT03239158|DRUG|Life information rehabilitation therapy|Each treatment: one bottle solution each day, consecutive 3 months, oral administration
223698059|NCT05361785|BIOLOGICAL|FMT|FMT from healthy donor or placebo
223781076|NCT06533306|PROCEDURE|Surgery for cryptorchidism.|Patients previously operated on for cryptorchidism.
223781077|NCT00165438|PROCEDURE|Pulmonary Function Tests|Tests include; total lung capacity, vital capacity, functional residual capacity, forced vital capacity, forced expiratory volume in 1 second, carbon monoxide diffusing capacity, pulse oximetry before and after a 6 minute walk and Pulmonary Status and Dyspnea Questionnaire
223781078|NCT00165438|PROCEDURE|CAT Scan|Obtained at different time points during the study depending upon standard of care chemotherapy treatment
223781079|NCT03421613|DRUG|3VM1001|Self treatment 3 times daily for 10 days
223781080|NCT03421613|OTHER|Placebo|Cream without investigational drug. Self treatment 3 times daily for 10 days
223781081|NCT03453333|PROCEDURE|3D laparoscope|For laparoscopic camera system, a 10-mm ENDOEYE FLEX 3D Deflectable Videoscope (Olympus Corp., Germany) was used in the 3D group.
223781082|NCT03453333|PROCEDURE|2D laparoscope|For laparoscopic camera system, a 10-mm 30º IDEAL EYES Laparoscope (Stryker, Kalamazoo, MI, USA) camera was used in the 2D group.
223781083|NCT03041610|BEHAVIORAL|Walking intervention|The intervention will be delivered over a six-month period and will consist of: (1) an individualized pedometer-based walking program with weekly step goals, (2) regular visits to the clinic including face-to-face session with the physician, and (3) regular telephone calls with the research nurse in between the face-to-face contacts.
223781084|NCT03600285|DEVICE|TB1-K|Use of TB1-K for preservation and transport of donated kidneys
223781085|NCT00771680|DRUG|insulin detemir|Start dose and frequency at the discretion of the physician following clinical practice
223781086|NCT00771680|DRUG|biphasic insulin aspart 30|Start dose and frequency at the discretion of the physician following clinical practice
223781087|NCT00771680|DRUG|insulin aspart|Start dose and frequency at the discretion of the physician following clinical practice
223781088|NCT03283670|DRUG|Nitrous Oxide 25%|Nitrous oxide, an odorless, colorless gas typically used as an induction agent for general anesthesia or for dental sedation, is a known N-methyl-D-aspartate (NMDA) antagonist. It will be given at a concentration of 25% nitrous oxide/50% oxygen/25% nitrogen.
223781089|NCT03283670|DRUG|Nitrous Oxide 50%|Nitrous oxide, an odorless, colorless gas typically used as an induction agent for general anesthesia or for dental sedation, is a known N-methyl-D-aspartate (NMDA) antagonist. It will be given at a concentration of 50% nitrous oxide/50% oxygen.
223781090|NCT03283670|DRUG|Placebo Gas|Placebo gas given at 50% nitrogen \[inert\]/50% oxygen.
223781091|NCT06275100|OTHER|Prehabilitation|"Participants will be exposed to exercise and psychoeducation. Aerobic exercise will be on a cycle ergometer tailored to their capability and will aim for a low to moderate intensity.The patients will be exercised using the intermittent protocol of alternating 1 minute moderate and 1 minute low intensity aerobic exercise. This duration can be gradually increased during subsequent sessions depending on the patient's ability. Aerobic exercise will be conducted 2- 3 times per week depending on patient's ability.~In addition, participants are expected to do strength and inspiratory muscle training in their own time.~The psychoeducation booklet and audio are designed with input from in-house clinical psychologist. The aim of the booklet is to explain the emotions they may feel whilst being in hospital, symptoms of anxiety, suggest how to manage anxiety, behavioural strategies that may help and signposting if they require further support."
223781092|NCT00987298|DEVICE|Visceral fat mass measurement|Total body DXA measurement, Abdominal CT scan
223781093|NCT01081977|PROCEDURE|Early Cord Clamping|Early Umbilical Cord Clamping (Clamping of Umbilical Cord within 30 seconds of shoulder delivery of neonate)
223781094|NCT01081977|PROCEDURE|Delayed Cord Clamping|Delayed Umbilical Cord Clamping (Clamping Umbilical Cord after 2 minutes of shoulder delivery of neonate
223781095|NCT03626181|DEVICE|Theta Burst Stimulation ( Transcranial Magnetic Stimulation)|"Participants will receive bilateral TBS, 5 times daily (15 minutes between), over 5 consecutive days (25 sessions total). In each session they will receive intermittent TBS (iTBS) over left dorsolateral prefrontal cortex (DLPFC), followed by continuous TBS (cTBS) over right DLPFC. Stimulation sites will be targeted with the Localite neuronavigation system and Visor2 software, and according to Talairach coordinates in relation to individual MRIs. Intensity will be standardized at 120% of RMT.~The MagPro stimulator will deliver iTBS over left DLPFC with 1620 pulses in 54 triplet bursts (5Hz) with train duration of 2 seconds, and intertrain interval of 8 seconds. cTBS over right DLPFC will consist of 1620 pulses in 54 triplet bursts, train duration of 2 seconds, with no intertrain interval."
223781096|NCT00411021|PROCEDURE|Pipelle (Endometrial Sampling)|
223781097|NCT05052970|DRUG|Mitoxantrone Hydrochloride Liposome injection|Mitoxantrone Hydrochloride Liposome injection will be administered by an intravenous infusion on day 1 of each 28-day cycle
223698060|NCT01638364|DRUG|alcoholic beverage|An appropriate amount of 95% USP ethyl alcohol will be mixed in orange juice and tonic water to obtain a drink equivalent to 3-5 standard drinks. The beverage will be consumed over a period of 15 minutes.
223698061|NCT01638364|DRUG|non-alcoholic beverage|This beverage will be a mixture of orange juice and tonic water. The beverage will be consumed over a period of 15 minutes.
223698062|NCT01122433|DEVICE|Endotracheal intubation using the C-MAC video laryngoscope|Using the C-MAC video laryngoscope for endotracheal intubation after failed direct laryngoscopy
223698063|NCT01532973|DRUG|Elbasvir|Elbasvir was administered orally by tablet(s)
223698064|NCT01532973|DRUG|Placebo|Dose-matched placebo tablets were administered orally.
223698065|NCT06441955|DRUG|Ritonavir-Boosted Nirmatrelvir (Paxlovid)|"Participant Selection and Baseline Data Collection: 6 months~* Longitudinal Observation and Intervention Implementation: 24 months~* Data Analysis and Findings Dissemination: 6 months Evaluate methodological advantages and limitations of an international pharmacosurveillance system based on electronic health records (EHRs). Adverse outcome; Electronic health record; Health informatics; Medication adherence; Pharmacoepidemiology; Pharmacosurveillance; Risk assessment."
223698066|NCT06441955|DIAGNOSTIC_TEST|Physiological Evaluation|Common Medical laboratory work-up, Cancer screening test, Biomarkers, tissue biopsy, blood specimen, diagnostic imagining, Sensitivity and Specificity, HIV PCR, Viral load ( antigen), CD4- T cell count, while implementation of social mediators of prevention, promotion studies and conceptual models and quality of care.
223781098|NCT05052970|DRUG|Bortezomib for Injection|Bortezomib (1.3 mg/m\^2) will be administered by an intravenous injection or subcutaneously on day 1,4,8,11of each 28-day cycle
223781099|NCT05052970|DRUG|Dexamethasone Acetate Tablets|Dexamethasone (20 mg/d) will be taken orally on day 1,2,4,5,8,9,11,12 of each 28-day cycle
223781100|NCT00125632|PROCEDURE|Eccentric Viewing Training for Reading|
223781101|NCT01475526|OTHER|El Valor de Nuestra Salud Store Intervention|Changes to physical and social environment of grocery stores through implementation of the El Valor de Nuestra Salud intervention.
223781102|NCT03890302|DRUG|FB704A|Administered by IV infusion
223781103|NCT03890302|DRUG|Placebo|Identical in appearance and same excipients as FB704A, but without active compound. Administered by IV infusion
223781104|NCT06446635|DEVICE|Semiflex Dome Catheter System|"Abces: In patients that present with a perianal abscess/sinus the semiflex dome catheter is inserted under general anesthesia. A small cut is made to drain and irrigate the septic sinus.~Fistula: Under general anesthesia the seton is removed, the internal opening is excised and the internal opening is closed with a 2-0 Vicryl cross stitch.~Both: Before surgery, the length of the tract is measured on MRI or CT. A Semiflex Catheter with the appropriate length and a diameter is selected. If during surgery appears that this is not the appropriate size, a different size catheter can be used. The catheter is fixed on a Renasys Adhesive gel patch (Smith and Nephew). The catheter is connected with a tubing system to a vacuum pomp with an average vacuum pressure of 80 cm H2O. The tube will be taped on the patient. After every 2-3 days the catheter will be exchanged by a 3-6 mm shorter catheter."
223781105|NCT00852397|DRUG|Apixaban|Apixaban 2.5 mg tablet BID for 24 weeks
223781106|NCT00852397|DRUG|Apixaban|Apixaban 5.0 mg tablet BID for 24 weeks
223781107|NCT00852397|OTHER|Placebo|Placebo tablet for 24 weeks
223781108|NCT03860896|DRUG|GB004|GB0004 high dose
223781109|NCT03860896|DRUG|Placebo|Placebo
223781110|NCT03860896|DRUG|GB004|GB004 low dose
223781111|NCT02479984|PROCEDURE|Staging Laparoscopy|"Resectable pancreatobiliary cancer confirmed by radiologic studies (CT scan, MRI, PET-CT) and no evidence of distant metastasis.~Staging laparoscopy will perform through 2 ports and a 30˚ laparoscope is inserted into the peritoneal cavity. Examining the whole abdominal wall, including the parietal and visceral peritonea, we will observe the liver surface from the dome area to the inferior surface and hepatoduodenal ligament in order to find metastatic nodules. Laparoscopic ultrasound (US) will be used to overcome in inspecting the posterior part of the liver. After complete laparoscopic examination, peritoneal lavage will be performed through the laparoscopic port."
223781112|NCT02479984|DEVICE|Laparoscopic ultrasound|
223781113|NCT05039905|DRUG|99mTc-MSA-ICG|Intratumoral injection of 99mTechnetium-manosylated albumin-indocyanine green to lung cancer patients
224263620|NCT06209983|PROCEDURE|Conventional care|"1. Preoperative preparation: overnight fasting preparation, bowel preparation.~2. Intraoperative care: traditional pain care (intravenous analgesics), sleep depth monitoring, warm air blanket, central venous pressure and body water monitoring indicators, traditional muscle tension relaxation treatment and the use of health insurance antagonist drugs (Neostigmine).~3. Postoperative care: patient-controlled intravenous drip for postoperative pain relief, oral feeing (rice porridge) on the postoperative day 5, and according to the progression of patient condition, step by step to removal of invasive tubes such as nasogastric tubes, intravenous catheters, and urinary catheters."
223698067|NCT06441955|BIOLOGICAL|Moderna COVID-19 Vaccine|Single dose, 0.25 mL If previously vaccinated, ≥2 months after receipt of the last previous dose of COVID-19 vaccine
223698068|NCT06441955|BEHAVIORAL|Biopsychological|Diagnosis of developmental milestones is considered a missing element in care measurement or a determining factor in disease signs and symptoms in chronic care management. Cognitive mapping, variations of survey, assessments, cancer counseling, leading to the realization that adherence requires a whole-person approach to delivering high-quality and cost-effective care. the project aims to offer opportunities to individuals from diverse backgrounds, including those underrepresented in biomedical research, in an inclusive environment in which all trainees can contribute. The proposed training activities are designed to improve the research skills of the participants and encourage them to pursue further training and careers in biomedical and/or social/behavioral research.
223698069|NCT06441955|BEHAVIORAL|Behavioral (e.g., Psychotherapy, Lifestyle Counseling)|Diagnosis of developmental milestones is considered a missing element in care measurement or a determining factor in disease signs and symptoms in chronic care management. Cognitive mapping, variations of survey, assessments, cancer counseling, leading to the realization that adherence requires a whole-person approach to delivering high-quality and cost-effective care. the project aims to offer opportunities to individuals from diverse backgrounds, including those underrepresented in biomedical research, in an inclusive environment in which all trainees can contribute. The proposed training activities are designed to improve the research skills of the participants and encourage them to pursue further training and careers in biomedical and/or social/behavioral research.
223698070|NCT06441955|GENETIC|Genetic (including gene transfer, stem cell and recombinant DNA)|Full genome sequencing, complete genome sequencing, or entire genome sequencing, is the process of determining the entirety, or nearly the entirety, of the DNA sequence of an organism's genome at a single time to address the intersection of genomics and health disparities, recognizing that genetic variations can contribute to health disparities in several ways. Understanding these genetic contributions to health disparities is crucial for developing targeted interventions and personalized healthcare strategies that can help address these disparities. genetics, epidemiology, public health, and social sciences, the study aims to shed light on the complex interplay between genomics and health equity. To evaluate cellular errors and the effects of myocardial DNA, you may need to consider tests such as DNA sequence.
223698071|NCT06441955|COMBINATION_PRODUCT|Multidisciplinary approach|The aim of utilizes psychology-applied science and science in nursing frameworks to address health disparities and promote health and wellness across the health span to improve patient population outcomes, evaluate cost-effectiveness, and patient health literacy competencies. The experimental framework of a compilation of the bio-psychosocial model, Eric Erickson developmental stages, AI/AML, and cognitive learning theories address system decision making factors, for sound decision making and behavioral change cognitive behavioral therapies protocol segmentation demographic and urban areas affected by social-economic access to healthcare and related ethical stance of United States healthcare policy developmental outlines. Biology plays a role in the content of development stages, and the great debate of nurture vs. nature sets the foundation for addressing the psychosocial approach to healthcare integration as an applied science model for strengthening primary services and improving
223698072|NCT06223737|DIAGNOSTIC_TEST|EOS x-ray|After marking the anatomical landmarks where later on skin markers will be placed, radiopaque markers are attached for the radiographic examination with the EOS system. Images are taken from the positions standing and sitting
223698073|NCT06223737|DIAGNOSTIC_TEST|Motion capture|"The used marker set is the IfB marker set (List et al. 2013), consisting of 40 skin markers on the lower extremities, 7 on the pelvis, 24 on the trunk and 6 on the upper extremities. For the later musculoskeletal modelling the IfB marker set is extended with 7 additional markers on the spinal thoracic processes. All markers will be placed by skilled operators.~The test procedure consists of six trials, namely a standing trial in an anatomic upright position and a calibration motion as well as four basic motion tasks to define functional estimated joint axis, respectively centers (each performed twice).~Tasks: standing, maximal flexion-extension, lateral bending, axial rotation, lifting, holding load, walking, step up, sitting and sit-to-stand"
223698074|NCT04266769|DEVICE|LightForce Orthodontic System|The LightForce Orthodontic System is a a digital treatment planning platform and patient-specific 3D printed polycrystalline alumina brackets for the treatment of malocclusion
223698075|NCT02628769|DRUG|Solithromycin|
223698076|NCT02628769|DRUG|Placebo|
223698077|NCT02374086|BEHAVIORAL|Exercise training|
223698078|NCT04417543|DRUG|Memantine Hydrochloride|Memantine is a low-affinity voltage-dependent uncompetitive antagonist of the NMDA-type glutamate receptor .Memantine hydrochloride tablet was started at the dose of 5 mg once daily orally, and the same dose was given for 3months and dose is titrated to 10 mg once daily orally for the remaining 3months. Placebo was given once daily orally for6months. Patients were instructed to take the study medication at the same time every day.
223698079|NCT04417543|DRUG|Placebo|Placebo was given once daily orally for6months. Patients were instructed to take the study medication at the same time every day.
223698080|NCT02906371|DRUG|Tocilizumab|Patients with ≥ 40% blasts in the bone marrow at pre-infusion will be enrolled in the early tocilizumab cohort and will follow early CRS treatment algorithm.
223698081|NCT02906371|DRUG|Tocilizumab|Patients with ˂ 40% blasts in the bone marrow at pre-infusion (\~ Day -5 to -1) will follow the standard CRS Rx algorithm
223698082|NCT02906371|BIOLOGICAL|CART 19|CART-19 cells transduced with a lentiviral vector to express either anti-CD19ζ scFv TCRζ:41BB, administered by i.v. injection using an intra-patient dose escalation approach: 10% on day 0, 30% on day 1 with a total dose goal of \~1.5 x107 - 5 x109 (\~3x105 - 1x108/kg) T cells.
223698083|NCT00990873|GENETIC|gene expression analysis|
223698084|NCT00990873|GENETIC|microarray analysis|
223698085|NCT00990873|GENETIC|reverse transcriptase-polymerase chain reaction|
223698086|NCT00990873|OTHER|laboratory biomarker analysis|
223698087|NCT02024555|DRUG|Levofloxacin|
223698088|NCT02024555|DRUG|Ethambutol|
223698089|NCT02024555|DRUG|Azithromycin|
223698090|NCT02024555|DRUG|Rifampin|
223698091|NCT02024555|DRUG|Placebo|This will serve as a placebo to the antibiotics used in antimycobacterial therapy.
223698093|NCT01397669|PROCEDURE|Colon biopsy, lymph node biopsy, lumbar puncture, Leukapheresis, Brain MRI/MRS/DTI|"Eligible subjects will undergo a flexible sigmoidoscopy/biopsy and Brain MRI/MRS/DTI at Chulalongkorn University Hospital.~Lumbar puncture, lymph node biopsy, and leukapheresis will be done at TRCARC or IHRI."
223698094|NCT03950791|BEHAVIORAL|Pain Catastrophizing Class|A 2-hour class that will be delivered by a clinical psychologist to participant cohorts. Didactic content includes psychoeducation about opioid use, the risk for misuse, and opioid reduction education materials. It will also include mind-body science as it relates to pain and PC. Participants learn how to identify catastrophizing in the moment, and how to self-treat it. During the class, participants acquire skills and develop a plan to apply the learned skills to decrease physiological hyperarousal within the context of PC. Participants also acquire skills that improve the regulation of cognition and emotion, including PC reframing and thought restructuring, and develop a plan for implementing these skills in daily life. Finally, participants develop a plan to use behaviors that modulate attention and counteract helplessness.
223698095|NCT03950791|BEHAVIORAL|Health Education|Education about improving lifestyle factors to improve participants' overall health.
223698096|NCT06458855|PROCEDURE|Post radical prostatectomy nerve restoration procedure (PRP-NR)|A somatic to autonomic nerve grafting procedure which will use a nerve graft of ilioinguinal nerve harvested from the inguinal canal to perform a bilateral end to side junction between the dorsal penile nerve and the penile corpora cavernosa
223698097|NCT05076565|DEVICE|Airbag Belt Fall Protection System|Both versions of Airbags features different number of IMU sensors. Participant's will be randomly assigned one of the two versions. The algorithms developed in this project will help the researcher to identify the optimal performance (sensitivity and specificity values for detecting falls). Based on this information the research team will be able to choose a version for home/community deployment portion of the study. Based on the performance of the airbags in detecting true positives (falls) and true negatives (non-falls) accurately one of the airbags will be used in community deployment phase of the study.
223698098|NCT02719327|DRUG|icosapent ethyl (IPE)|Participants will be randomized in a 1:1 ratio to receive icosapent ethyl 4 g daily vs. matching gel cap placebo
223698099|NCT02719327|OTHER|gel cap placebo|Participants will be randomized in a 1:1 ratio to receive icosapent ethyl 4 g daily vs. matching gel cap placebo
223698100|NCT03350620|DRUG|NVK-002 Concentration 1|Study medication will be administered, once daily (QD)
223698101|NCT03350620|DRUG|NVK-002 Concentration 2|Study medication will be administered, once daily (QD)
223698102|NCT03350620|DRUG|Placebo|Vehicle (placebo) will be administered, once daily (QD)
224263621|NCT03281135|OTHER|HPV testing|Clusters randomly allocated to this arm of the study will be sensitized to be showed up in nearby health posts for self sampling with Evalyn brush for HPV testing.
223698103|NCT06509334|DRUG|JYB1904|Participants will receive JYB1904 at week0 and receive placebo at week4,8,12
223698104|NCT06509334|DRUG|JYB1904|Participants will receive JYB1904 at week0,8 and receive placebo at week4,12
223698105|NCT06509334|DRUG|Omalizumab|Participants will receive Omalizumab every 4 weeks for 12 weeks
223698106|NCT01645722|PROCEDURE|Procedure/Surgery: Enriched Fat grafting|Fat grafting is a minimally invasive clinical procedure that has been widely used by plastic surgeons within reconstructive surgery for many years. Fat tissue to be used for grafting is harvested (usually from abdomen or thighs) in the operating room. The fat tissue is then sterilely centrifuged and allowed to decant before separating the fluid and oil layers from the fat tissue fraction. The aspirated fat is then injected into the amputation stump.In this study, we will concentrate the adipose stromal cells (ASCs) in the fat graft material to assess whether this modification will increase fat graft retention over time. The volume retention in areas treated with ASC concentrated fat grafts will be compared with regions treated with standard fat grafts in the same patient.
223698107|NCT03733340|DRUG|Imipenem|Imipenem: A wide-spectre antibiotic from the carbapenem group Other name: Imipenem-cilastatin
223698108|NCT00586131|DRUG|ammonium chloride or sodium citrate/citric acid|Dose dictated by changes in pH
223698109|NCT00586131|DRUG|Sodium citrate/citratic acid|dictated by pH
224263622|NCT01139970|OTHER|Laboratory Biomarker Analysis|Correlative studies
224263623|NCT01139970|OTHER|Pharmacological Study|Correlative studies
224263624|NCT01139970|DRUG|Temozolomide|Given PO
224263625|NCT01139970|DRUG|Veliparib|Given PO
224263626|NCT01838681|DRUG|Placebo|Once daily, tablets, orally
224263627|NCT01838681|DRUG|Brexpiprazole|1, 2, or 3 mg/day, once daily dose, tablets, orally. Uptitration in weekly steps from 1 mg/day
223781114|NCT06662643|PROCEDURE|Delayed transanal pull-through anastomosis|Laparoscopic surgery is recommended. A standard 5-port method is used to create pneumoperitoneum after placing the trocar. The sigmoid colon and upper rectal mesentery are dissected along Toldt's fascia. Autonomic nerves should be preserved, and high ligation of the inferior mesenteric vessels with lymph node dissection is recommended. TME: Using a posterior-to-anterior approach, the mesorectal plane is dissected down to the pelvic floor, cutting the Waldeyer's fascia to enter the intersphincteric space, where sharp dissection is carried out toward the levator ani muscle hiatus. The dissection endpoint is the dentate line, where the proximal colon is exteriorized by at least 2 cm and sutured to the anal canal with 6-8 stitches, without a protective ileostomy.Two to four weeks after the first surgery, after the colon has adhered well to the surrounding tissue, the exteriorized colon is excised (under epidural or spinal anesthesia, trimming the exteriorized colon to form the anus).
223781115|NCT06662643|PROCEDURE|Direct Anastomosis Plus Prophylactic Ileostomy|ISR is categorized into partial ISR (PISR), subtotal ISR, and total ISR (TISR). Correspondingly, the anastomosis site after coloanal anastomosis is located below the levator ani hiatus (PISR, near the dentate line; subtotal-ISR and TISR, below the dentate line).The dissection steps are the same as in the first stage of the Staged Turnbull-Cutait Pull-through Anastomosis group (TME and intersphincteric space dissection).The bowel is transected at least 1 cm below the tumor, leaving a larger segment of healthy tissue on the non-tumor side while ensuring that no more than 1/3 of the dentate line is resected to avoid impairing fecal control.Anastomosis is performed using absorbable sutures under direct visualization. A protective ileostomy is created 25-30 cm from the ileocecal valve.3 to 6 months after surgery, the ileostomy is reversed. Prior to closure, digital rectal examination, defecography, MRI, colonoscopy, and other evaluation must perform.
223781116|NCT06663514|OTHER|SupporTive Care At Home|"Home-based medical care is based on a specialized home-based medical team approach, including following:~Specialized Home-Based Medical Team Approach Initial Assessment and Education Initial Home Visits and Education Multidisciplinary Team Meeting Regular Assessment After the Initial Visit"
223781117|NCT06664229|BEHAVIORAL|Fall and dementia prevention exercise|"The fall and dementia prevention exercise is designed as a combination of balancing and cognitive exercise and games that is conducted as a group activity. The session will be provided three times per week for six weeks for a pilot test and three times per week for 12 weeks for a main comparison study.~The fall prevention exercise involves the pressure mat based balancing exercise such as side stepping, heel or toe standing, and quarter squat. The safety bar will be placed around the mat, so that older adults with instability can hold while they follow the movements.~The cognitive exercise will concise of multiple types of cognitive tasks to train memory, numeric processing, spatial perception, and logical thinking. For example, memory task such as memorizing the series of positions on the screen and use the mat to point the positions in the right order.~At the end, older adults play games in which they use balancing movements and cognitive tasks to gain scores for their team."
223698110|NCT04012125|DEVICE|flexible thoracolumbar brace|Subjects would wear the flexible thoracolumbar brace over 18 hours a day
223698111|NCT04000230|BEHAVIORAL|TCIT|"TCIT consists of the following:~* CDI Teach Session: Teachers will participate in two training workshops in Child-Directed Interaction (CDI) skills. Specifically, teachers will learn to use positive attention skills and active ignoring.~* CDI Coaching: Teachers will receive 90 minutes of CDI coaching in the classroom once or twice weekly for 6 total coaching sessions over a period of 4-6 weeks. The coach will observe the class and coach the teacher live using a microphone and bug-in-the-ear device.~* TDI Teach Session: Teachers will complete two training workshops in Teacher Directed Interaction (TDI) skills, which focus on increasing compliance and reducing disruptive behavior. Teachers will learn to present developmentally appropriate, direct, and clear instructions and consistent positive and negative consequences.~* TDI Coaching: Teachers will receive six 90-minute TDI coaching sessions once or twice weekly for 4-6 weeks."
223698112|NCT04000230|BEHAVIORAL|Booster|Teachers in the Intervention group will receive additional booster sessions during the second half of the school year. Booster sessions consist of coaching teachers in CDI and TDI skills. Teachers receive 4-8 booster sessions.
223698113|NCT01479504|DRUG|nedaplatin and docetaxel|"neoadjuvant chemotherapy: nedaplatin 80mg/m2+docetaxel 65 mg/m2/day,every 21 days for 2 cycles before radiotherapy~concurrent chemotherapy: nedaplatin 40mg/m2,weekly,for 6 cycles during radiotherapy"
223698114|NCT01479504|DRUG|cisplatin and docetaxel|"neoadjuvant chemotherapy: cisplatin 80mg/m2+docetaxel 65 mg/m2/day,every 21 days for 2 cycles before radiotherapy~concurrent chemotherapy: cisplatin 40mg/m2,weekly,for 6 cycles during radiotherapy"
223698115|NCT01479504|DRUG|nedaplatin and docetaxel|"neoadjuvant chemotherapy: nedaplatin 80mg/m2+docetaxel 65 mg/m2/day,every 21 days for 2 cycles before radiotherapy~concurrent chemotherapy: nedaplatin 40mg/m2,weekly,for 6 cycles during radiotherapy"
223781118|NCT06663059|DRUG|Adebrelimab combined with albumin-bound paclitaxel and cisplatin 2 cycle|"Each treatment cycle is 3 weeks long (Q3W), with a total of 2 cycles. Adebrelimab: 1200 mg once on Day 1, administered intravenously, Q3W. Albumin-bound Paclitaxel: 130 mg/m² on Day 1 and Day 8, administered intravenously, Q3W.~Cisplatin: 75 mg/m² on Day 1, administered intravenously, Q3W.~Drug infusion should follow this sequence:~Adebrelimab → Albumin-bound Paclitaxel → Cisplatin, with a minimum interval of 30 minutes between each infusion."
223698116|NCT01479504|DRUG|cisplatin and docetaxel|"neoadjuvant chemotherapy: cisplatin 80mg/m2+docetaxel 65 mg/m2/day,every 21 days for 2 cycles before radiotherapy~concurrent chemotherapy: cisplatin 40mg/m2,weekly,for 6 cycles during radiotherapy"
223698117|NCT01470859|DRUG|pramipexole|tablets, 0.375mg-4.5mg/day divided by 3 times according to the optimal improvement of motor dysfunction in PD patients. duration is 1 year.
223698118|NCT01470859|DRUG|Sinemet CR|tablet of Sinemet CR, dosage of levodopa ranging from 200mg-600mg/day divided by 2 or 3 times, Duration is 1 year
223698119|NCT05816096|COMBINATION_PRODUCT|Hall technique|The child will be placed to them SSC on one of their HSPM affected teeth. Pain during treatment will be assessed using the FLACC scale and satisfaction the child and parent will be evaluated using likert scale after the treatment immediately and after one month and evaluate the success restoration adapted from Innes et al. after 3\_6\_9\_12 month.
224263628|NCT01838681|DRUG|ADT|Duloxetine, escitalopram, fluoxetine, paroxetine IR, sertraline, venlafaxine XR; dosing according to label
224263629|NCT00246922|DRUG|Roflumilast|
224263630|NCT05816564|BEHAVIORAL|Attention Bias Modification (ABM) for depression|"Both groups will be asked to engage in mindfulness activities but only one group will receive the train-positive ABM task. The control group will receive a sham task that is not programmed to train attention towards positive stimuli."
224263631|NCT05816564|BEHAVIORAL|Sham Attention Bias Modification (ABM)|The sham intervention will be given to the control group (but they will still receive mindfulness exercises).
224263632|NCT00298415|DRUG|Paclitaxel + Carboplatin|Paclitaxel 90 mg/m² D1, D8, D15 (D1=D29, 4 cycles) Carboplatin AUC 6 D1 (D1=D29, 4 cycles)
224263633|NCT00298415|DRUG|Monotherapy (gemcitabine or vinorelbine)|Gemcitabine 1150 mg/m² D1 and D8 (D1=D22, 5 cycles) Vinorelbine 30 mg/m² D1 and D8 (D1=22, 5 cycles)
224263634|NCT04964973|DEVICE|Control|Post-surgical physiotherapeutic activity.
224263635|NCT04964973|DEVICE|Experimental|Post-surgical physiotherapeutic activity with the application of the technique
224263636|NCT04964973|DEVICE|Placebo|Post-surgical physiotherapeutic activity with the application of the non-activated technique
223698120|NCT05816096|COMBINATION_PRODUCT|ART|The child will be restored to them one of their HSPM affected teeth by GIC. Pain during treatment will be assessed using the FLACC scale and satisfaction the child and parent will be evaluated using likert scale after the treatment immediately and after one month and evaluate the success restoration adapted from Innes et al. after 3\_6\_9\_12 month.
223698121|NCT03051854|BEHAVIORAL|Interaction Competencies with children - for teachers|Core training components include teacher-student interaction, maltreatment prevention, effective discipline strategies, identifying and supporting burdened students and implementation of the training materials into the school setting.
223698122|NCT01066000|DRUG|methoxy polyethylene glycol-epoetin beta [Mircera]|initial doses of either 120 micrograms or 200 micrograms or 360 micrograms, once monthly
223698123|NCT02706678|DRUG|Tacrolimus sustained-release capsule|Oral
223698124|NCT06019507|BIOLOGICAL|TCD601|Investigational Product
223698125|NCT06019507|BIOLOGICAL|Cyclophosphamide|Conditioning Regimen
223698126|NCT06019507|DRUG|TAC|Immunosuppression Therapy
223698127|NCT06019507|DRUG|MMF|Immunosuppression Therapy
223698128|NCT06019507|DRUG|Corticosteroids|Immunosuppression Therapy
223698129|NCT04926376|DEVICE|Eye90 Microspheres|Y90 glass microspheres
223698130|NCT03979131|COMBINATION_PRODUCT|Avelumab addition to perioperative chemotherapy in GC and GEJC|Avelumab addition to perioperative chemotherapy in GC and GEJC. Peri-operatory treatment consisting of four cycles (each cycle is 14 days) of neoadjuvant chemotherapy (docetaxel, oxaliplatin and fluorouracil/leucovorin) plus avelumab previous to surgery. Surgery is recommended to be scheduled 4 to 6 weeks after the last dose. Afterwards (4 to 10 weeks after surgery), four cycles of adjuvant therapy with the same schema, followed by avelumab up to one year. There will be be a follow-up of 5 years.
223698131|NCT02812407|DEVICE|Mucosal Impedance|"During the clinical endoscopy, the 2.13 mm catheter will be passed through the channel of the standard endoscope this is called an Intraluminal Impedance. The Intraluminal impedance (made by Sandhill Scientific) has not been approved by the Food and Drug Administration (FDA) but it is considered to be minimal risk related to using it. The catheter gives the investigators a reading at each level.~* The catheter will be placed on the esophageal mucosa 5 cm above the gastroesophageal junction (where the stomach and esophagus meet) for 5 second~* At 10 cm above the gastroesophageal junction the catheter will be placed for 5 seconds~* And at 20 cm"
223698132|NCT06654791|DRUG|[14C] SIM0270 Oral Preparation|Use according to the prescribed protocol
223698133|NCT06016907|BEHAVIORAL|Internet-delivered cognitive behavioral therapy (ICBT)|Cognitive behavioral therapy (CBT) delivered through an internet platform with therapist support.
223698134|NCT06016907|BEHAVIORAL|In-person cognitive behavioral therapy (CBT)|Cognitive behavioral therapy (CBT) delivered in-person at a clinic by a therapist.
223698135|NCT04981067|OTHER|Maintain the concentration of ropivacaine as same as those used in the previous participant|Maintain the same concentration of ropivacaine used in the previous participant with an 89% chance through a random assignment
223698136|NCT04981067|OTHER|Decrease the ropivacaine concentration by 0.05% from the concentration used in the previous participant|Decrease ropivacaine concentration by 0.05% from the concentration used in the previous participant with an 11% chance through a random assignment
223698137|NCT04981067|OTHER|Increase the ropivacaine concentration by 0.05% from the concentration used in the previous participant|Increase ropivacaine concentration by 0.05% from the concentration used in the previous participant.
223698138|NCT00757107|DEVICE|Taperloc Microplasty|primary total hip arthroplasty
223698139|NCT00757107|DEVICE|Taperloc standard|primary total hip arthroplasty
223698140|NCT02948283|OTHER|Laboratory Biomarker Analysis|Correlative studies
223698141|NCT02948283|DRUG|Metformin Hydrochloride|Given PO
223698142|NCT02948283|OTHER|Pharmacological Study|Correlative studies
223698143|NCT02948283|DRUG|Ritonavir|Given PO
223698144|NCT02948283|OTHER|Quality-of-Life|Ancillary studies
223698145|NCT02948283|OTHER|Questionnaire|Ancillary studies
223698146|NCT06708247|PROCEDURE|Standard Peri-implant Reconstructive Surgery|This intervention involves standard peri-implant reconstructive surgery without the additional step of electrolytic cleaning. The procedure includes mechanical debridement of the implant surface to remove biofilm, followed by bone grafting using autogenous bone harvested from the tuberosity and coverage with a resorbable collagen membrane for bone regeneration and stabilization of the implant.
223698147|NCT06708247|PROCEDURE|Electrolytic Cleaning with Peri-implant Reconstructive Surgery|This intervention involves peri-implant reconstructive surgery with an added step of electrolytic cleaning for enhanced implant surface decontamination. The procedure starts with mechanical debridement of the implant surface, followed by the use of an electrolytic cleaning device to remove biofilm and contaminants without damaging the implant surface. This is then followed by bone grafting using autogenous tuberosity bone and coverage with a resorbable collagen membrane to promote bone regeneration and implant stability.
223698148|NCT05268055|OTHER|"Sign Here training intervention"|Training film to educate healthcare providers to competently and sensitively interact with Deaf patients in healthcare settings.
223698149|NCT05268055|OTHER|Intervention as usual|"Communicating with People Who Are Deaf or Hard of Hearing in Hospital Settings (https://archive.ada.gov/hospcombrprt.pdf)"
223698150|NCT06842004|OTHER|Participatory action|The reality of audiovisual fiction in Spain and professionals' perceptions of how motherhood is portrayed will be explored. Through participatory action, participants will share their experiences and knowledge to identify areas for improvement in the representation of reproductive processes. The result will be a manual of good practices for fiction production, aimed at promoting more inclusive, realistic and stereotype-free representations, in order to improve both public perception and professional training in the audiovisual field.
223698151|NCT02208700|OTHER|Oxepa|Therapeutic nutrition with EPA, GLA\< and antioxidants
223781119|NCT06663059|DRUG|Adebrelimab combined with albumin-bound paclitaxel and cisplatin 4 cycle|"Each treatment cycle is 3 weeks long (Q3W), with a total of 4 cycles. Adebrelimab: 1200 mg once on Day 1, administered intravenously, Q3W. Albumin-bound Paclitaxel: 130 mg/m² on Day 1 and Day 8, administered intravenously, Q3W.~Cisplatin: 75 mg/m² on Day 1, administered intravenously, Q3W.~Drug infusion should follow this sequence:~Adebrelimab → Albumin-bound Paclitaxel → Cisplatin, with a minimum interval of 30 minutes between each infusion."
223781120|NCT06662877|DRUG|Albumin-bound Paclitaxel + Tegafur Gimeracil Oteracil (S-1) + Anlotinib|Albumin-bound Paclitaxel, 125mg/m2,iv.drip,d1,d8,Q3W +Tegafur Gimeracil Oteracil (S-1) 40-60mg,p.o,bid,d1-d14,Q3W+Anlotinib 10mg,p.o,d1-d14,Q3W
223781121|NCT06662877|DRUG|Oxaliplatin + Leucovorin + Fluorouracil (FOLFOX regimen)|Oxaliplatin 85 mg/m2,d1,iv.drip,Q2W + Leucovorin 400mg/m2,d1,iv.drip,Q2W+ Fluorouracil 2400 mg/m2 civ46h, Q2W
223781122|NCT06325098|DIAGNOSTIC_TEST|Anti-nephrin antibodies|Assessment of anti-nephrin antibodies on serum samples and in vitro study of permeabilizing effect on 3D organ-on-a-chip models and STED microscopy on healthy human kidneys.
223781123|NCT06325098|DIAGNOSTIC_TEST|u-RPC cultures|Urine sample collection for u-RPC cultures
223781124|NCT02932397|DRUG|Intravenous dose of 0.5 mg/kg of propofol|
223781125|NCT02932397|DRUG|Intravenous dose of 0.05 mL/kg of saline solution|
223781126|NCT06618599|PROCEDURE|Mid-transverse process to pleura block combined with erector spinae block|The probe will be placed vertically 3 cm lateral to the T5 spinous process and the transverse process will be identified. The needle will be introduced in an in-plane fashion until the tip lay deep in the erector spinae muscle. One milliliter of normal saline will be injected to confirm the correct needle tip position by visualizing the spread under the erector spinae muscle. 20 mL of 0.25% bupivacaine will be injected .The needle will be directed aiming for the midpoint between the transverse process and pleura from cephalad to caudad. One milliliter of normal saline will be given to confirm the position of the needle tip, then a total of 20 ml of 0.25% ropivacaine will be injected
223781127|NCT06618599|PROCEDURE|paravertebral block|the transducer will be positioned laterally 3 cm to the midline at T5 spinous process, defining the spinous process, pleura, transverse process, the paravertebral (PV) space, and superior costotransverse ligament. The trapezius, rhomboid major, and erector spinae muscles will be recognized as superficial to the hyperechoic transverse process shadow. However, when the rhomboid major muscle disappeared, this indicated that we will be at the 7th thoracic vertebra's level. Local infiltration using 2-3 mL of 2.0% lignocaine will be done. A spinal 22-gauge needle will be injected at the cephalic side of the transducer using an in-plane technique, and the needle directed towards the costotransverse ligament (CTL). The passage of the needle through the CTL will be associated with a pop, informing that the superior costotransverse ligament will be passed. Following a 3 mL testing dose of normal saline containing epinephrine (1:200,000), 30 mL bupivacaine 0.25% injected.
223781128|NCT05932290|DRUG|Elranatamab|BCMA-CD3 bispecific antibody
223781129|NCT05932290|DRUG|Standard of care|Standard of care
223781130|NCT01850004|DRUG|Dasatinib|
223781131|NCT05309382|DIAGNOSTIC_TEST|Prospera|Monthly testing and results provided
223698152|NCT02208700|OTHER|Jevity 1.5|Complete balanced nutrition with a unique fiber blend
223698153|NCT06656923|DIAGNOSTIC_TEST|Biopsies|Analyze previous biopsies to quantify changes induced by Poly-L-Lactic Acid in Adipose Tissue
223698154|NCT04949685|PROCEDURE|plantar plate repair|surgical repair via dorsal approach of lesser metatarsophalangeal joint general anesthesia
223698155|NCT04266249|DRUG|Docetaxel|Given IV
223698156|NCT04266249|PROCEDURE|Lumpectomy|Undergo lumpectomy
223698157|NCT04266249|PROCEDURE|Mastectomy|Undergo mastectomy
223698158|NCT04266249|DRUG|Nab-paclitaxel|Given IV
223698159|NCT04266249|DRUG|Paclitaxel|Given IV
223698160|NCT04266249|BIOLOGICAL|Pertuzumab|Given IV
223698161|NCT04266249|RADIATION|Radiation Therapy|Undergo radiation therapy
223698162|NCT04266249|BIOLOGICAL|Trastuzumab|Given IV
223698163|NCT04266249|BIOLOGICAL|Trastuzumab Emtansine|Given IV
223698164|NCT05469685|DRUG|Vonoprazan|Potassium-competitive acid blocker
223698165|NCT05469685|DRUG|Amoxicillin|Antibiotic for H. pylori eradication
223698166|NCT05209178|DIAGNOSTIC_TEST|Collection of nasal and oropharyngeal specimen for COVID19 antigen test|Regarding two independent sampling procedures from the anterior part of the nose and the oropharynx, participants are randomized to either perform the sampling by themselves with written instructions or having the procedure performed by trained personnel. The specimen is meant for a rapid antigen test for COVID-19 infection.
223698167|NCT06434298|BEHAVIORAL|Choose to Move|As described under study arm description
223698168|NCT03262402|PROCEDURE|Basic periodontal treatment|Basic periodontal treatment consists of scaling and root planing performed with manual curettes or ultrasonic instruments.
223698169|NCT01793831|PROCEDURE|FMT|Standard FMT
223698170|NCT06665802|BEHAVIORAL|Questionnaire|Questionnaire completion
223698171|NCT06612853|OTHER|Sleep Quality Scale (SQS)|"For the pilot testing, each patient will complete the pre-final version of the SQS.~The patients involved in the field study will have to fill in the SQS twice before treatment, one week apart, to assess reproducibility of the scale and a third time at 3 months after treatment (surgical or conservative) to assess the responsiveness of the scale."
223698172|NCT06612853|OTHER|Pittsburgh Sleep Quality Index (PSQI)|The patients involved in the field test will have to fill in the PSQI twice before treatment, one week apart, to assess reproducibility of the scale and a third time at 3 months after treatment (surgical or conservative) to assess the responsiveness of the scale.
223698173|NCT04330183|DRUG|Ketamine|0.3mg/kg of ketamine
223698174|NCT04330183|DRUG|Normal Saline|3cc of normal saline
223781132|NCT06369740|OTHER|Case scenarios - questionnaire|Participants fill in a questionnaire on the current care of hemophilia A and envisioned use scenarios of a point-of-care diagnostic device for hemophilia A.
223781133|NCT06369740|OTHER|Case scenarios - Focus groups|Participants partake in focus groups on the current care for hemophilia A, the envisioned use scenarios of point-of-care diagnostic device for hemophilia A and desired features of such a diagnostic device.
223698175|NCT05184478|DRUG|Medicinal cannabis (MC): THC 10mg/mL : CBD 15mg/mL, manufactured by Cann Group Ltd.|"Each 1mL contains 10mg tetrahydrocannabinol (THC),15 mg cannabidiol (CBD), and 0.004mL peppermint oil in medium chain triglyceride (MCT) oil.~All participants will start at 0.1 mL per day, and will gradually increase in 0.1mL increments until day 21 when a dose of 0.5mL (participants weighing \<50kg) or 1mL (participants weighing ≥50kg) is reached. At day 29, an assessment of treatment response will be conducted. Participants who meet criteria for a treatment response will remain on the same dose for the remainder of the treatment period. Participants who do not meet criteria for a treatment response will gradually increase the dose in 0.1mL increments until day 49 when a daily dose of 1mL (participants weighing \<50kg) or 2mL (participants ≥50kg) is reached."
223698176|NCT05184478|DRUG|Placebo|"The placebo contains MCT oil and peppermint flavoring solution, which is indistinguishable from the active medication in appearance, smell and taste.~The dose will be matched for volume to the medicinal cannabis, and will follow the same dosing schedule as the medicinal cannabis treatment phase."
223698177|NCT06482307|DIAGNOSTIC_TEST|[18F]-olaparib PET scan|The IMP investigated is \[18F\]Olaparib, a radiolabelled PARP inhibitor suitable for PET imaging.
223698178|NCT02367989|DIETARY_SUPPLEMENT|0g barley β-glucan no fibre|Food containing no barley β-glucan and no additional fibre
223781134|NCT06369740|OTHER|Use scenarios - Usability test|Participants are asked to perform basic tasks with the mock-ups with minimal instructions, they will also be given a graphic of the user interface (GUI).
223781135|NCT06369740|OTHER|Use scenarios - interview|The participants will be interviewed and asked for their opinions and experiences with the mock-ups.
223781136|NCT01284400|OTHER|Home-based disease management|Symptom monitoring, comprehensive advice, and counseling at home by nurses, as well as telephone follow-up by nurses
223781137|NCT06508554|OTHER|Haptonomy|5\. With the energy work, we will move on to the stage of harmonizing the intuitive and heart energy fields. It will be ensured that the mother's communication with her baby has a spiritual dimension as well as a physical one. 6. Then the stage of touching and communicating with the baby will begin. The hands of the researcher and the pregnant woman will be placed on the pregnant woman's uterus. Then, the pregnant woman will be the first to call her baby. This call to the baby will be repeated 2-3 times. 7. The pregnant woman and her uterus will be touched and exercises will be performed to adapt to the fetus. The aim is to increase the emotional awareness of the pregnant woman and to enable her to play intrauterine games with her baby (such as calling the baby, shaking her belly, moving the baby to the touched area with the mother's voice). Haptonomy will be completed with a deep relaxation exercise that will support the heart-uterus connection accompanied by breathing exercises.
223781138|NCT00925158|PROCEDURE|Dissector Assisted Malar Elevation|Malar dissector - Surgical instrument for video endoscopic rhytidoplasty.
223781139|NCT00146952|DEVICE|Vibrotactile feedback|
223698179|NCT02367989|DIETARY_SUPPLEMENT|2g barley β-glucan|Food containing low amounts of barley β-glucan
223698180|NCT02367989|DIETARY_SUPPLEMENT|4g barley β-glucan|Food containing medium amounts of barley β-glucan
223781140|NCT03607448|DEVICE|Freestyle Libre Flash Glucose Monitoring System|Subjects will wear the Abbott Sensor based FreeStyle Libre Flash Glucose Monitoring System and will receive no treatment except for safety purposes
223781141|NCT05053087|DRUG|Ropivacaine Continuous Infusion|0.2% continuous infusion 6mL/hr
223781142|NCT05053087|DRUG|Ropivacaine Intermittent Bolus|0.2% intermittent bolus infusion 8mL every 2 hours
223781143|NCT05053087|DRUG|Placebo|Saline filled catheter
223781144|NCT00235794|DRUG|temsirolimus|
223781145|NCT04388293|OTHER|Exposure of interest|Very Low Birth Weight infants admitted to tertiary NICUs in Canada.
224263637|NCT04945252|DIAGNOSTIC_TEST|Signpost caries|Identify carious lesion according to ICCMS visual criteria
224263638|NCT01502696|BIOLOGICAL|PEG IFN alfa-2b|3µg/kg weekly injections
224263639|NCT06366386|BEHAVIORAL|Screening and treatment of hypertension among PLHIV in DSD models for HIV|In all DSD models of HIV, participants will receive screening for HTN (BP measurement), treatment of hypertension using a simplified protocol of amlodipine, hydrochlorothiazide and Losartan in a stepwise manner and laboratory monitoring for HTN medication adverse events.
224263640|NCT00104910|RADIATION|Internal Radiation Therapy|
224263641|NCT00104910|RADIATION|3-Dimensional Conformal Radiation Therapy|
224263642|NCT00104910|BIOLOGICAL|Cetuximab|Given IV
224263643|NCT00104910|DRUG|Cisplatin|Given IV
224263644|NCT01229150|DRUG|AZD6244|For KRAS mutant patients randomized to the single agent arm, AZD6244 75 mg bid (twice a day).
223698181|NCT02367989|DIETARY_SUPPLEMENT|6g barley β-glucan|Food containing high amounts of barley β-glucan
223698182|NCT02367989|DIETARY_SUPPLEMENT|0g barley β-glucan with fibre|Food containing no barley β-glucan, but matches fibre content in β-glucan treatments
223698183|NCT06709937|OTHER|Prospective multicenter registry of patients with cutaneous metastases from breast carcinoma treated with electrochemotherapy.|electrochemotherapy.
223698184|NCT06545825|OTHER|Standard enteral nutrition|Enteral nutrition will be given with standard isocaloric mixtures. Mixture volume calculation will be performed after indirect calorimetry, adjusted for daily nitrogen loss.
224263645|NCT01229150|DRUG|Erlotinib|For Wild-Type KRAS patients randomized to the single agent arm, Erlotinib 150 mg qd (every day)
224263646|NCT01229150|DRUG|AZD6244 + Erlotinib|For KRAS mutant patients and Wild-Type KRAS patients randomized to the combination arm (arms are stratified based on KRAS mutational status), AZD6244 150 mg qd (every day) + erl (erlotinib) mg qd.
224263647|NCT04914351|DRUG|HY-0102|Multiple dose cohorts, 60 minute IV infusion, every two weeks, 28 days as a cycle
224263648|NCT06460272|OTHER|Medically Tailored Meals|Meals culturally tailored to provide essential nutrition
224263649|NCT06984497|OTHER|Infusion of umbilical cord-mesenchymal stem cells through peripheral veins|Umbilical cord-mesenchymal stem cells injected through peripheral veins
224263650|NCT06984497|OTHER|Infusion of umbilical cord-mesenchymal stem cells through hepatic artery|Umbilical cord-mesenchymal stem cells injected through hepatic artery
224263651|NCT06817265|DRUG|TNTL|oral, 4 tablets, 3 times a day, after meals. Take it for 24 weeks.
224263652|NCT06817265|DRUG|TNTL simulation preparation|oral, 4 tablets, 3 times a day, after meals. Take it for 24 weeks.
224263653|NCT04492553|DRUG|AndroGel|Treatment indication: hypogonadism after cancer treatment. Dosage: 1-2 sachets a day. Follows standard treatment.
223698185|NCT06679933|OTHER|Hand grip strength measurament|That intervention includes making the patient sit down and rest for 5 minutes on a comfortable chair. Then make them handle a hand dynamometer with their dominant hand and ask them to squeeze it with all of their effort. Repeat that squeeze three times with 2-minute intervals. The highest number recorded on the dynamometer is the hand grip strength of the patient.
223698186|NCT06681415|DRUG|Adding 100ml of 20% human albumin to cardiopulmonary bypass priming solution|"Adding albumin to the priming solution can help reduce hemodilution and consequent extracardiac complications by maintaining colloid oncotic pressure. Albumin helps counteract the intravascular fluid shift to the extravascular space and reduces the risk of complications associated with fluid imbalance.~Postoperative pulmonary complications following CPB can significantly impact postoperative outcomes. Patients developing PPC have prolonged mechanical ventilation, extended hospitalisation, longer ICU stays, and elevated postoperative mortality. One of the most common PPCs following CPB is pleural effusion.~Our primary objective was to evaluate the effectiveness of adding 100 ml of 20% human albumin to the CPB priming solution compared to standard priming, with a specific focus on its potential role in reducing the occurrence of pleural effusion."
223698187|NCT06681675|PROCEDURE|The group that applied the Intrapartum Care Model|"In pregnant women with cervical dilatation of 5 cm, the Personal Information Form was completed at the initial clinic admission.~•The Intrapartum Care Model was implemented for all primiparous pregnant women assigned to the intervention group during labor and after delivery by the researcher midwife, in accordance with the World Health Organization's positive birth recommendations.~Data were collected using the Personal Information Form, Labor and Postpartum Follow-up Form, Visual Analog Scale (VAS), Labor Comfort Scale (CSC), Intrapartum Fear of Labor Scale, and Women's Perception of Supportive Care Given During Labor Scale. VAS, CSC, and Fear of Labor Scale were applied to women when cervical dilation was 5 cm and 9 cm. After delivery, the Women's Perception of Supportive Care Given During Labor Scale was applied."
223698188|NCT05249790|DRUG|Recommended treatment schedule|Non-steroidal anti-inflammatory drugs (NSAiDs), Corticosteroids (Dexamethasone), Anticoagulants (LMW heparin), Gentle oxygen therapy
223698189|NCT05249790|DRUG|Usual care|Treatment regimens different from the recommended one according to family physician personal practice
223698190|NCT01298635|PROCEDURE|combined phacotrabeculectomy|trabeculectomy plus phacoemulsification with intraocular lens implantation
223698191|NCT01298635|PROCEDURE|trabeculectomy|
223698192|NCT06614829|DEVICE|Stratafix Suture|Stratafix sutures are barbed and have an antimicrobial coating. The barbs maintain tension during and allows for knotless suturing. The antimicrobial coating inhibits bacterial colonization of the wound.
223698193|NCT06614829|DEVICE|DERMABOND PRINEO|"DERMABOND™ PRINEO™ Skin Closure System is a sterile, liquid topical skin adhesive. It also incorporates a self-adhering mesh that is applied to the approximated skin edges to provide temporary skin edge alignment until the liquid adhesive is applied to achieve skin closure. It forms a strong, flexible, waterproof microbial barrier-as long as the adhesive film remains intact-that falls off naturally after 7-14 days.~Dermabond Prineo system will be applied to the skin for skin closure."
223698194|NCT06703242|OTHER|Health promotion for mothers of children with ADHD in the ultra-orthodox community|The intervention will consist of 3 modules with six sessions. Mothers will gain knowledge in topics related to understanding the ADHD health condition and its biological origins, optimal and recommended treatment options, school management techniques, and the importance of taking care of their own health.
223698195|NCT06712446|BEHAVIORAL|EFT|Participants will identify three personalized and rewarding future events not related to drug use that take place 1 week, 1 month, and 6 months in the future. Participants will be asked to rate the vividness of each personalized future positive event on a 5-pt Likert scale.A brief and personalized EFT prompt will be created for each future event . Personalized EFT prompts will be presented during delay discounting and MA demand assessments following EFT training. Participants will also receive daily text/email messages with these prompts, reminding them to engage in EFT, vividly reexperience their future events, over the week following EFT training.
223698196|NCT06712446|DEVICE|high frequency rTMS|TMS will be delivered with a MagVenture Mag Pro R30 with the Cool-B70 A/P coil with active liquid cooling . For dlPFC, we will measure position F3. The first session will begin with the acquisition of the resting motor threshold on the contralateral hand. Intermittent theta burst stimulation (iTBS) (triplet 50 Hz bursts, repeated at 5 Hz, 2 sec on and 8 sec off; 600 pulses per session) will be delivered at 110% of the resting motor threshold (RMT) and will last \~3 minutes. Participants will receive 2 sessions of iTBS to the dlPFC brain region with a 15-20-minute interval between sessions
223698197|NCT06712446|DEVICE|sham frequency rTMS|Participants will receive sham TMS to the dlPFC. They may feel the TMS from the A/P coil electrodes, but there will not be any real stimulation of the brain.
223698198|NCT06709768|BEHAVIORAL|Virtual Memory, Attention, and Problem Solving Skills for Persons with MS (MAPSS-MS)|This is a pilot test of the MAPSS-MS intervention in a virtual delivery format.
223698199|NCT06706726|PROCEDURE|sentinel lymph node biopsy|sentinel lymph node biopsy during the management of breast cancer
223698200|NCT06706726|PROCEDURE|Single-port robotic-assisted axillary lymph node dissection|Single-port robotic-assisted（Endoscopic Instrument Control System SP1000) axillary lymph node dissection during the management of breast cancer
223698201|NCT06710652|DEVICE|rTMS|Stimulation coil Cool-B65 A CO, located right lingual gyrus, stimulation frequency 1Hz, stimulation intensity 80% of motor threshold, number of stimuli 3 pulses/train, train interval 1s, 500 trains in total, 1500 total stimulation pulses, total stimulation time 20 min, treatment application once a day, continuous application for two weeks, 5 days a week.
224263654|NCT01954277|DEVICE|Electroacupuncture|Eletroacupuncture performed using acupuncture needles.
224263655|NCT01954277|DEVICE|Placebo Sham|Placebo Sham is performed using electrodes, without electrical stimulation. Lights and sounds were identical to active treatment.
224263656|NCT02995135|DRUG|BAY987517|"Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.~(Formulation Code: Z43-094)"
224263657|NCT02995135|DRUG|SFP Control|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.
224263658|NCT04917419|OTHER|Luminotherapy and /or Psychoeducation Program|TO complete
223698202|NCT06710652|DEVICE|Sham Comparator|Stimulation coil Cool-B65 P CO, located right lingual gyrus, stimulation frequency 1Hz, stimulation intensity 80% of motor threshold, number of stimuli 3 pulses/train, train interval 1s, 500 trains in total, 1500 total stimulation pulses, total stimulation time 20 min, treatment application once a day, continuous application for two weeks, 5 days a week.
223698203|NCT06706895|DRUG|Paclitaxel Polymeric Micelles for Injection combined with Fruquintinib Capsules|"Fruquintinib Capsules：4 mg / day, orally once daily on days 1-14 in 21-day cycles. If the patient has AE of grade 3 or above, the dose of fruquintinib capsules is reduced to 3 mg / day(dose discontinuation to dose reduction).~Paclitaxel Polymeric Micelles for Injection：150mg / m2 intravenously over 3 hours on Days1,8 of each 21-day cycle. Do not need special infusion device.~Paclitaxel Polymeric Micelles for Injection and Fruquintinib Capsules are used for 6 cycles. Subsequently, dual-drug or single-drug maintenance therapy was selected according to the tolerance of the patients. Subsequently, Paclitaxel Polymeric Micelles for Injection ( 120mg / m2, if the patient is intolerable, the dose can be reduced to 100mg / m2 ), until occur the disease progress, the intolerant toxicity or the patient withdrawal."
223698204|NCT06709027|DEVICE|Intervention Group (Mobile Health Management Intervention)|Participants in this group will receive a mobile health management intervention over a period of 12 weeks. This intervention includes the use of a mobile application designed for health management, psychological support, and monitoring,et al， with the aim of improving the mental health status of elderly patients with depression.
223698205|NCT06709092|DRUG|lupatadine fumarate (Luso®, Yangzijiang Pharmaceuticals)|For patients with AR, patients were given lupatadine fumarate (Luso®, Yangzijiang Pharmaceuticals) 1 tablet once daily at bedtime for 14 days.
223698206|NCT06774196|BEHAVIORAL|Behavioral Therapy Group|Includes Cognitive Behavioral Therapy (CBT), relaxation techniques, and biofeedback.
223698207|NCT06774196|PROCEDURE|Standard Care Group|Includes pharmacological treatment (e.g., NSAIDs, muscle relaxants) and physical therapy interventions
223698208|NCT04538053|DRUG|Oral cefalexin only|High-dose oral cefalexin
223698209|NCT04538053|DRUG|IV cefazolin or IV flucloxacillin followed by oral cefalexin|Standard therapy of IV cefazolin or IV flucloxacillin followed by high dose oral cefalexin
223698210|NCT02875132|DRUG|pembrolizumab|pembrolizumab at 200mg IV infusion every 3 weeks
223698211|NCT06460922|PROCEDURE|Radial osteotomy|3D printing models and personalized guides in surgical planning in distal radius osteotomies for Kienböck´s disease. Osteosynthesis with a plate in distal radius.
223698212|NCT06929442|BEHAVIORAL|Resilience Training (RT)|RT is a 4-week program of weekly 90-minute sessions in which participants are taught the following skills: mindfulness, self-compassion and mentalization.
223698213|NCT06929442|BEHAVIORAL|Life Skills Training (LST)|LST is a 4-week program of weekly 90-minute sessions, in which participants are provided information about helpful life skills, including financial literacy, health, physical and internet safety.
223698214|NCT06929390|PROCEDURE|BTVA|The eligible subjects will be stratified according to stratification factors (pure GGN/mixed GGN, lesion size ≤1cm/\>1cm, FEV1 ≤50%/\>50%) and randomized at a 1:1 ratio to two groups. Patients in the BTVA group will undergo BTVA treatment.
223698215|NCT06929390|PROCEDURE|MWA|The eligible subjects will be stratified according to stratification factors (pure GGN/mixed GGN, lesion size ≤1cm/\>1cm, FEV1 ≤50%/\>50%) and randomized at a 1:1 ratio to two groups. Patients in the MWA group will undergo MWA treatment.
223698216|NCT06905132|RADIATION|Hypofractionated Radiation Therapy|"Participants will receive preoperative 5-day HFRT (30Gy/5fx once daily over consecutive weekdays) followed by standard of care wide local excision 2-6 weeks later."
223698217|NCT05283382|DRUG|Cannabidiol Oral Product|Participants will receive a one-time dose of 600 mg Cannabidiol Isolate Gel Capsules in the form of six 100mg capsules.
223781146|NCT06387251|OTHER|30 day wellness program|30 days and will evaluate the effects of sponsor-designed 30-day wellness program consisting of 3 supplement and functional food products, recommended diet, physical activity, hydration and mindfulness activities.
223781147|NCT04885829|DRUG|Tocilizumab Prefilled Syringe|0.9ml Subcutaneous pre-filled syringes containing 162mg of Tocilizumab.
223698218|NCT05283382|OTHER|Placebo|Participants will receive a one-time dose of placebo capsules in the form of six capsules.
223698219|NCT06240741|DRUG|[68Ga]Ga-DOTA-TATE|Single intravenous injection of \[68Ga\]Ga-DOTA-TATE determined by body weight (2 Mega-Becquerel (MBq) / kilogram (kg) (0.054 Millicurie (mCi)/kilogram (kg)) of body weight up to a maximum total dose of 200 MBq (5.4 mCi)) at the imaging day (Day 1).
223698220|NCT06240741|DRUG|68Ge/68Ga Generator|Radionuclide generator
223698221|NCT06933420|DEVICE|Cern Device|The Cern Device is an Intravaginal device utilizing low level microbicidal visible light at a 450nm low level microbicidal light, in visible spectrum for treatment of vaginitis, including both bacterial vaginosis and fungal vaginitis.
223698222|NCT06935071|OTHER|Data Collection and Analysis|Patient data will be analyzed to ensure that all data fields are available and that suitable sample size is available to answer the research objectives. The rate of ambulation at discharge, ambulation at 3 month follow up (if available), time to death, and pain score between the historic cohort with a current cohort of patients will be compared.
223698223|NCT06935045|DRUG|Placebo Beverage|Participants rest in a climate controlled room maintained at 40°C and 30%RH for 120 minutes follow placebo beverage consumption (180 minutes total).
223698224|NCT06935045|DRUG|Alcohol (Ethanol)|Participants rest in a climate controlled room maintained at 40°C and 30%RH for 120 minutes follow alcoholic beverage consumption (180 minutes total).
223698225|NCT06934031|OTHER|translation software|ChatGPT, Google Translate, and UD talk
223698226|NCT06934525|BEHAVIORAL|Team-delivered, exposure-based CBT|Patient sees licensed provider 1x/month and non-licensed provider 3x/month for exposure-based cognitive behavioral therapy
223698227|NCT06934330|BEHAVIORAL|Mindfulness practice with Tao Art (Calligraphy and Song Greatest Love)|During mindfulness practice with Tao Art (Calligraphy and Song Greatest Love), participants will repeatedly trace the lines of calligraphy with fingers while listening to, singing, or chanting with Tao Song. This enables them to achieve deep concentration, while maintaining fully alert state. The practice can be done in sitting or standing, depending on the health status and age and will last 30 minutes and is done daily for six weeks.
223698228|NCT06934330|OTHER|Drinking Energized water|Participants will drink energized water from a bottle that received subtle energy transmission. They will replenish water daily and activate the transmission in the bottle to energize the water. Participants will drink about 1 litre of energized water a day for six weeks.
223781148|NCT00620477|DRUG|injection in the knee joint with 20 ml of chirocaine 0.125%|injection in the knee joint with 20 ml of chirocaine 0.125%
223781149|NCT00620477|DRUG|injection in the knee joint with 20 ml of physiological fluid|injection in the knee joint with 20 ml of physiological fluid
223698229|NCT06934746|OTHER|DSM-5 criteria.|The DSM-5 defines three levels of ADHD severity based on symptom count and frequency: 1. Mild ADHD • Symptom Count: Just meets the diagnostic criteria (6 symptoms in children for either inattention or hyperactivity/impulsivity). • Frequency: Symptoms occur but are not excessively frequent. 2. Moderate ADHD • Symptom Count: More than the minimum required for diagnosis. • Frequency: Symptoms occur frequently (e.g., several times a week). 3. Severe ADHD • Symptom Count: Many symptoms well beyond the diagnostic threshold. • Frequency: Symptoms occur daily or multiple times per day.(National Center for Biotechnology Information, n.d.)
223698230|NCT06933290|OTHER|Beverage|15 milliliter aliquot interspersed with tastants with a 3 minute break between tastants
223698231|NCT06933641|PROCEDURE|Regional Analgesia|20 cc of local anesthetic solution, comprising 10 cc of 0.5% bupivacaine and 10 cc of 0.9% NaCl bilaterally, was injected into each side once
223698232|NCT06934733|OTHER|Oral cryotherapy|Patients randomly assigned to the experimental group underwent TROP2-ADC treatment. They continuously held ice cubes and ice water from 15 minutes before the infusion, throughout the infusion process, and for 15 minutes after the infusion. Ice cubes were promptly replaced with fresh ones as they melted. Patients were instructed not to consume any food or liquids orally for 1 hour following the completion of the ice therapy.
223698233|NCT06934733|OTHER|Routine oral care|Patients in the control group did not receive oral cryotherapy during the TROP2-ADC infusion but only received routine oral care.
223698234|NCT06934655|DRUG|Semaglutide 2.4 mg|The dosing regimen will follow standard titration protocols, starting with a dose of 0.25 mg weekly for the first month, with gradual increases in dosage each month to a target dose of 2.4 mg weekly by the fifth month. To minimize the potential for side effects impacting daily activities, youth in the semaglutide group will be instructed to administer the medication weekly on Fridays.
223698235|NCT06935032|DEVICE|Twin block appliance|An appliance that facilitates forward positioning of the mandible and soft tissues
223698236|NCT06935032|OTHER|Fixed orthodontic treatment|Patients undergoing orthodontic treatment with fixed appliances
223781150|NCT01895166|PROCEDURE|EBUS-GS|EBUS is performed using an endoscope ultrasound system , which is equipped with a 20-MHz mechanical radial-type probe (UM-S20-17S;Olympus) with an external diameter of 1.4 mm and a GS (K-201; Olympus).
223781151|NCT01895166|PROCEDURE|X-ray|The radiograph fluoroscopy are performed when the probe and GS are confirmed to reach the lesion by EBUS images ,cytologic and pathologic specimens are obtained under fluoroscopic guidance.
223781152|NCT05870098|DIAGNOSTIC_TEST|All participants|"1. Clinician or self-taken, pharyngeal and rectal swabs with FCU analysed individually~2. Self-taken pharyngeal, meatal, and rectal swabs analysed as a pooled specimen~3. Self-taken pharyngeal and rectal swabs with 1.5ml FCU analysed as a pooled specimen The FCU will be done after any meatal swabs. Patients will be instructed to only pass the first 5ml into the tube, and the tube will be pre-marked with a black line. Full pictoral instructions and verbal support will be given to enable them to complete the pooling process of the swabs and urine."
223781153|NCT03356912|DRUG|Cabazitaxel|"Cabazitaxel drug products should be administered only by intravenous route.~Prednison should be administered by oral route"
223781154|NCT03356912|DRUG|Prednisone|Prednisone should be administred by oral route
223781155|NCT01279226|DEVICE|Auralevée device|Single treatment with Auralevée device.
223781156|NCT04171700|DRUG|Rucaparib|Oral rucaparib will be administered twice daily. The starting dose will be 600 mg daily (BID).
223781157|NCT04034641|DRUG|Bifidobacterium tetrad live bacteria tablet plus Helicobacter pylori quadruple eradication therapy|On day 1-14: Standard therapy: esomeprazole magnesium enteric-coated tablets, amoxicillin granules (A Mo Xian), furazolidone tablets, bismuth potassium citrate granules (Li Zhu De Le) are taken twice a day, once in the morning and once in the evening. Esomeprazole magnesium enteric-coated tablets and bismuth potassium citrate granules (Li Zhu De Le) should be taken 30min before meal; amoxicillin granules (A Mo Xian) and furazolidone tablets should be taken 30min after meal. Probiotic: Bifidobacterium tetrad live bacteria tablets should be taken at noon once a day (30 min after meal ), 9 tablets per time. On day 15-28: Probiotic: Bifidobacterium tetrad live bacteria tablets, taken at noon once a day (30min after meal), 9 tablets per time.
223781158|NCT04034641|DRUG|Bifidobacterium tetrad live bacteria tablet placebo plus Helicobacter pylori quadruple eradication therapy|On day 1-14: Standard therapy: esomeprazole magnesium enteric-coated tablets, amoxicillin granules (A Mo Xian), furazolidone tablets, bismuth potassium citrate granules (Li Zhu De Le) are taken twice a day, once in the morning and once in the evening. Esomeprazole magnesium enteric-coated tablets and bismuth potassium citrate granules (Li Zhu De Le) should be taken 30min before meal; amoxicillin granules (A Mo Xian) and furazolidone tablets should be taken 30min after meal. Placebo: Bifidobacterium tetrad live bacteria tablet placebos should be taken at noon once a day ( 30 min after meal ), 9 tablets per time. On day 15-28: Placebo: Bifidobacterium tetrad live bacteria tablet placebos, taken at noon once a day (30min after meal), 9 tablets per time.
223781159|NCT05354050|DRUG|DARE-BV1|2% Clindamycin 100 MG
223781160|NCT03238937|DEVICE|Phrenic nerve stimulator|Implantation of phrenic nerve stimulator
223781161|NCT03021226|BEHAVIORAL|Fatherhood Development|Fatherhood Development is a curriculum based program provided by a facilitator through a skill-based education intervention.
223781162|NCT03021226|BEHAVIORAL|Relationship Enhancement|Relationship Enhancement is a curriculum based program provided by a facilitator through a skill-based education intervention.
223781163|NCT03021226|BEHAVIORAL|Financial Literacy|Relationship Enhancement is a curriculum based program provided by a facilitator through skill-based education intervention.
223781164|NCT01452269|BEHAVIORAL|Deaf Weight Wise program|"Groups will consist of approximately 13 subjects who meet for 2 hours a week for 16 weeks. Group sessions will be offered at a variety of times and days of the week. A trained, deaf, ASL-fluent counselor will lead the sessions.~Subjects will be asked to complete a food and physical activity diary. Each intervention session will include a weigh-in, group sharing/problem solving, discussion of a weight management topic, and goal setting/action planning for the next week. Periodically, each subject will receive a Personal Feedback Report. Subjects will be able to earn points for complying with various aspects of the program. Points can be redeemed for small prizes (i.e. water bottles).~The maintenance phase consists of two meetings at the beginning of the 6-month maintenance period and three months later. This will consist of a weigh-in, review of self-monitored diet and physical activity, problem solving and goal setting/action planning for their long-term program."
223781165|NCT02685254|BEHAVIORAL|Structural skills training group|Weekly 2-hours sessions for 14 weeks follow the Norwegian translation of the Swedish version of the ADHD skills training manual/workbook (Hesslinger 2010; Hirvikoski 2011; Morgensterns 2015) which is based on an adaption of Marsha Linehan's dialectical behavior therapy (DBT) for borderline personality disorder into a group-based skills training program for adults with ADHD (Hesslinger 2002; Philipsen 2007). The groups embrace 7 - 10 participants, and two group leaders trained in group therapy, cognitive-behavioral treatment or DBT. Each session contains an initial short repetition and feedback on the previous session, followed by review of the homework during the first hour. After a break, a new topic with exercises and homework for the following week is introduced.
223781166|NCT02685254|OTHER|Treatment as usual|Treatment as usual includes clinical management and/or medication, and or supportive counselling by physician or nurse
223781167|NCT03791125|DRUG|Salvianolic Acid A|4 anticipated doses are 30 mg, 90 mg, 180 mg and 270 mg, respectively. All of these are single-dose study.
223781168|NCT03791125|DRUG|Placebo Oral Tablet|Placebo tablets containing no salvianolic acid A will be given to healthy subjects.
223781169|NCT00749138|DRUG|tamoxifen|giving drug tamoxifen
223698237|NCT06934850|OTHER|Hand grip strength|Collection Tools a) Hand Grip Force Measurement: Hand grip strength will be measured using a digital dynamometer. The measurement will be performed three times in the dominant and nondominant hand of the participant and the average value will be taken (1). b) Trunk Control Assessment: Trunk control will be assessed with the McGill core endurance test. This scale is a valid and reliable tool to objectively measure trunk stability and dynamic control levels (2). c) Motor skill assessment: Timed Up and Go Test: The Timed Up and Go Test was used to assess functional mobility and dynamic balance (3). The patient was told to get up from the chair, walk 3 meters, return and sit back in the chair. The time was recorded. Timed Stair Climbing Test: It consists of the individual climbing the stairs and returning to the starting point. The elapsed time was recorded
223698238|NCT06934902|BEHAVIORAL|"Old vs new objects encoding phase and fMRI"|"During the encoding phase, a set of 60 objects will be presented to the participants in their everyday life. Pictures of objects sent to their app mobile phone over a period of 3 weeks.~The following week, participants will have an fMRI. During fMRI, participants will see objects already seen or not seen during the encoding phase."
223698239|NCT06934902|BEHAVIORAL|" incongruent vs. congruent contexts  encoding phase and fMRI"|"During the encoding phase, a set of 60 objects will be presented to the participants in their everyday life. Pictures of objects sent to their app mobile phone over a period of 3 weeks. This time, the objects will be chosen according to the participant's location.~The following week, participants will have an fMRI. During fMRI, participants will see objects encoding in congruent/incongruent contexts."
223698240|NCT06933953|OTHER|Questionnaires|"Patients will complete various questionnaires at J0: FHSQ-Fr, EQ-5D-5L, Foot Function Index, Visual analog pain scale, SF-12.~Patients who needs to come back for a visit at Day 7 (+ 3 days) will complete the FHSQ-Fr questionnaire for a second time"
223698241|NCT06933537|DEVICE|Neuroelectrics StarStim 32|Using the advanced Neuroelectrics StarStim 32 device from Spain, individualized imaging modeling systems are employed to precisely target the frontal cortex. Personalized EEG-guided electrical stimulation protocols are selected. The stimulation parameters are as follows: a current intensity of 2 mA, a duration of 21 minutes per session, once daily for five consecutive days, with EEG monitoring conducted before and after electrical stimulation.
223698242|NCT06933537|DEVICE|Neuroelectrics StarStim 32|Sham stimulation is performed using the same device and procedures as the neuromodulation group. The stimulator automatically shuts off after 30 seconds, while maintaining the device's connection. This design creates an initial sensation similar to actual stimulation while preserving the double-blind nature of the study.
223698243|NCT06401707|DRUG|Perampanel|Perampanel is a non-competitive AMPA glutamate receptor antagonist.
223781170|NCT03948776|DIAGNOSTIC_TEST|BodyMetrix body composition ultrasound|Investigators will make ultrasound measurements of fat and muscle thickness at 7 positions on the arm, chest wall, and leg (subject's dominant side) using the BodyMetrix BX 2000 ultrasound machine. Clear ultrasound gel will be applied to the skin, a probe placed against the skin, and the fat/muscle thickness measurement made five times at each position. The gel is then wiped away. The images are analyzed by the BodyView Software and estimations of fat and muscle mass calculated. These will be compared to the reference technique of whole-body DXA imaging.
223781171|NCT03948776|DIAGNOSTIC_TEST|BodyMetrix body composition ultrasound only|Investigators will make ultrasound measurements of fat and muscle thickness at 7 positions on the arm, chest wall, and leg (subject's dominant side) using the BodyMetrix BX 2000 ultrasound machine. Clear ultrasound gel will be applied to the skin, a probe placed against the skin, and the fat/muscle thickness measurement made five times at each position. The gel is then wiped away. The images are analyzed by the BodyView Software and estimations of fat and muscle mass calculated. For inpatients currently admitted to the hospital, whole-body DXA imaging cannot be performed, as so the only assessment of body composition will be with the ultrasound.
224263659|NCT01381653|OTHER|Behavioral: HIV prevention intervention|Substance using HIV-negative young men who have sex with men who engage in sexual risk and use social networking (Facebook) will be recruited and enrolled in a brief intervention utilizing Motivational Interviewing over chat window to reduce their substance use and sexual risk. They will also evaluate their intervention experience at the end of their eight sessions and post-assessment.
224263660|NCT05768334|DRUG|Lubiprostone 24Mcg Oral twice daily|"The patients will be randomized (closed envelopes) into one of two groups:~1. Fifty patients will receive lubiprostone 24 mcg (microgram) twice daily.~2. Fifty patients will receive placebo twice daily (control group). All patients will be followed for 48 weeks."
224263661|NCT01186835|PROCEDURE|Combination Botulinum Toxin A and Hyaluronic Acid|One side of subject's face will randomly be assigned combination treatment.
224263662|NCT01186835|PROCEDURE|Botulinum Toxin A|Other side of subjects face with receive Botulinum Toxin A treatment alone.
224263663|NCT02011945|DRUG|Dasatinib|
224263664|NCT02011945|DRUG|Nivolumab|
223698244|NCT06401707|DRUG|Placebo|Placebo
223698245|NCT00427271|DRUG|aspirin|
223698246|NCT01080742|DRUG|Lodoz (Combination of bisoprolol and hydrochlorothiazide)|The investigator will decide in advance the best therapeutic strategy for each subject according to current practice, regardless of the potential participation of this subject in the study.
223698247|NCT06489925|DRUG|Cerebrolysin|The Cerebrolysin will be administered at least one hour after the standard treatment and no later than 24 hours after the stroke symptom onset.
223698248|NCT03748693|PROCEDURE|Hysterectomy|Surgery performed on women with a variety of gynecological indications
223698249|NCT03748693|PROCEDURE|Colporrhaphy|Surgery performed on women with POP
224263665|NCT00902538|DRUG|Olmesartan medoxomil 40 mg - Amlodipine 10 mg|Oral tablets containing Olmesartan medoxomil-Amlodipine 40-10 mg, given once daily
224263666|NCT00902538|DRUG|Olmesartan 40mg-Amlodipine 10mg-Hydrochlorothiazide 12.5mg|Coated, oral tablets containing Olmesartan 40mg-Amlodipine 10mg + 1 Hydrochlorothiazide 12.5mg oral tablet + 1 Hydrochlorothiazide 12.5mg oral, placebo tablet. All tablets are given once a day.
224263667|NCT00902538|DRUG|Olmesartan 40mg-Amlodipine 10mg-Hydrochlorothiazide 25mg|Coated, oral tablets containing Olmesartan 40mg-Amlodipine 10mg + 2 Hydrochlorothiazide 12.5mg oral tablets. All tablets are given once a day.
224263668|NCT00902538|DRUG|OLM 40mg-AML 10mg-Hydrochlorothiazide 12.5mg|Coated, oral tablets containing Olmesartan 40mg-Amlodipine 10mg + 1 Hydrochlorothiazide 12.5mg oral tablet + 1 Hydrochlorothiazide 12.5mg oral, placebo tablet. All tablets are given once a day.
224263669|NCT00902538|DRUG|OLM 40mg-AML 10mg-Hydrochlorothiazide 12.5mg|Coated, oral tablets containing Olmesartan 40mg-Amlodipine 10mg + 1 Hydrochlorothiazide 12.5mg oral tablet + 1 Hydrochlorothiazide 12.5mg oral, placebo tablet. All tablets are given once a day.
224263670|NCT00902538|DRUG|OLM 40mg-AML 10mg-Hydrochlorothiazide 25mg|Coated, oral tablets containing Olmesartan 40mg-Amlodipine 10mg + 2 Hydrochlorothiazide 12.5mg oral tablet. All tablets are given once a day.
224263671|NCT05492162|OTHER|well-being promotion intervention|"The intervention will be organized on both conferences and workshops.~Four themes will be covered :~* Well-being (Workshops)~* Smoking prevention (Conference)~* Balanced diet (Workshop)~* Optimal organization for daily healthy living (Conference)"
223698250|NCT06063278|BEHAVIORAL|l Group Therapy for BN.|9 to 10 group sessions of 90 to 120min each
223698251|NCT01139931|GENETIC|DNA methylation analysis|
223698252|NCT01139931|GENETIC|gene expression analysis|
223698253|NCT01139931|GENETIC|microarray analysis|
223698254|NCT01139931|GENETIC|polymorphism analysis|
223698255|NCT01139931|OTHER|laboratory biomarker analysis|
223698256|NCT04716088|DIAGNOSTIC_TEST|Rapid antigen test for SARS CoV2|Defining diagnostic performance of repeated testing regimen in hospital setting
223698257|NCT00000519|BEHAVIORAL|diet, reducing|
223698258|NCT00000519|BEHAVIORAL|exercise|
223698259|NCT00000519|BEHAVIORAL|diet, fat-restricted|
223698260|NCT05444621|RADIATION|Ultrasound and doppler|All patients are then assessed by transthoracic echocardiography to measure Left ventricle and Right ventricle function and to assess LVOT-VTI and SV. Doppler Ultrasound assessment of carotid arteries to assess corrected flow time (FTc), velocity time integral (VTI) and respirophasic variation in carotid artery blood flow peak velocity (ΔVpeak). The patient will be assessed pre- and post- passive leg raising (PLR) and after fluid challenge of 30 mL/Kg of IV crystalloid
223698261|NCT05932966|DEVICE|Insulin closed-loop delivery system|Insulin closed-loop delivery system
223698262|NCT00090168|DRUG|MK0653A , ezetimibe (+) simvastatin|
223698263|NCT00090168|DRUG|Comparator: atorvastatin|
223698264|NCT00090168|DRUG|Duration of Treatment: 6 weeks|
223698265|NCT04813640|DEVICE|Spectacles|Novel spectacles for myopia control
223698266|NCT06285708|BEHAVIORAL|Prolonged exposure|PE therapy is a manualized cognitive behavioral therapy consisting of imaginal exposure (repeated recounting of the most disturbing traumatic memory) followed by processing thoughts and feelings related to the imaginal experience; in-vivo exposure (approaching trauma-related situations); psychoeducation about PTSD; and controlled breathing training. Between sessions, participants listen to audio recordings of the imaginal recounting daily and complete in-vivo exercises. Typically, PE is delivered weekly for 10-12, 90-minutes sessions. For this study, participants will complete daily 60-minute sessions for 10 consecutive weekdays during a 2-week period.
223698267|NCT01854658|DRUG|GFF MDI (PT003)|GFF MDI administered as two puffs BID
223698268|NCT01854658|DRUG|GP MDI (PT001)|GP MDI administered as two puffs BID
223698269|NCT01854658|DRUG|FF MDI (PT005)|FF MDI administered as two puffs BID
223698270|NCT01854658|DRUG|Placebo|
223698271|NCT00685542|DRUG|diacerein|Diacerein 50mg bid
223698272|NCT00685542|DRUG|placebo|placebo
223698273|NCT05776368|OTHER|Syntactic comprehension battery (BCS)|"The BCS is a battery for assessing syntactic skills. In this study, only one part of the BCS will be performed, namely task C2.~It consists in assessing the ability to assign thematic roles. To do this, the participant selects the image corresponding to the sentence he/she hears on a board of 2 images.~Task C2 consists of 50 tests of 2 images. A total score is given out of 50 points. The higher the score, the more successful the test."
223698274|NCT05776368|OTHER|Montreal Cognitive Assessment (MOCA)|"The MOCA is a short 30-question test that assesses several cognitive domains and allows for early detection of cognitive disorders. The MOCA test takes about 10-15 minutes to administer and consists of several sections, the first of which is an assessment of orientation in time and space. Then there are tasks that assess memory, concentration and reasoning ability, as well as language and visuospatial ability tasks.~The MOCA score can range from 0 to 30 points, with a score of 26 points or more considered normal."
223698275|NCT05776368|OTHER|Purdue Pegboard Test|"The Purdue Pegboard Test is a test of fine motor skills and hand-eye coordination. The test consists of a perforated board with holes into which participants must insert pegs or counters.~The assessment consists of four subtests, each repeated 3 times:~* Right hand (30 seconds): The total number of pins placed in the right column with the right hand in 30 seconds.~* Left hand (30 seconds): The total number of rods placed in the left column with the left hand in 30 seconds.~* Two hands (30 seconds): The total number of pairs of rods placed in both columns using both hands simultaneously, in 30 seconds.~* Assembly (60 seconds): The total number of rods, washers and clamps assembled in the allotted time, using both hands."
223781172|NCT05191576|OTHER|Children's sleep habits questionnaire (CSHQ)|"1. Children's Sleep Habits Questionnaire is a validated tool to screen sleep behavior in young children's assessment of pediatric sleep problems.~2. DSM-V Level II Sleep Disturbance- Child Report. is retrospective, 8-item self-report used to assess the pure domain of sleep disturbances in children and adolescents age of 11-17 years in the past seven days.Higher scores indicate more severe sleep disorders. High scores on a particular domain might indicate significant and problematic areas for the child that may warrant further assessment.~3. DSM -V Sleep Disturbance -Adult Report. is used to assess the pure domain of sleep disturbances in adults for the past seven days.~   SDQ).is used to screen emotional and behavioral problems in children.~4. SDQ is used to screen emotional and behavioral problems in children."
223781173|NCT00462384|DRUG|Methoxy Polyethylene Glycol-epoetin Beta|Methoxy polyethylene glycol-epoetin beta will be administered subcutaneously every 4 weeks (at Weeks 4, 8, 12, 16, 20, 24, 28 and 32). The starting dose will be 1.2 mcg/kg body weight. Thereafter, throughout the duration of study the dose adjustments will be performed depending on the hemoglobin value.
223781174|NCT00742703|OTHER|Mineralized water|
223781175|NCT00742703|OTHER|Low mineralized water|
223781176|NCT02897843|DEVICE|transcranial magnetic stimulation|tDCS stimulation will involve ten 20 minute stimulations daily, characterized by 2 milliamps (mA) anode over the left dorsolateral prefrontal cortex (DLPFC), with the cathode placed over the right suborbital region.
223781177|NCT02897843|DEVICE|sham tDCS|sham tDCS
224263672|NCT03531827|DRUG|enzalutamide|enzalutamide is an androgen receptor (AR) antagonist that is standard care therapy for metastatic prostate cancer
224263673|NCT03531827|DRUG|CRLX101|CRLX101 is a nanoparticle-drug conjugate (NDC) comprised of a linear cyclodextrin-polyethylene glycol-base polymer conjugated to multiple 2 (S)-camptothecin (CPT) molecules (Poly-CD-PEG-Camptothecin)
224263674|NCT04745234|DRUG|Mogamulizumab|"For the first 28-day induction cycle (C1), mogamulizumab 1 mg/kg will be administered as an IV infusion through a 0.22- or 0.2-μm in-line filter over at least 60 minutes on Days 1, 8, 15, and 22.~For all subsequent 28-day cycles (C2, 3, 4, etc.), mogamulizumab 2 mg/kg will be administered as an IV infusion over at least 60 minutes on Day 1 of each subsequent therapy cycle."
224263675|NCT06820970|DEVICE|chronic remote ischemic conditioning|Using a semi-automated machine, the pressure is increased according to the patient's own blood pressure level (20-40mmHg) when the cuff is pressed, and the pressure is squeezed for 6 minutes per cycle and the rest is 4 minutes, for a total of 4 cycles per cycle.
224263676|NCT06820970|BEHAVIORAL|Mindfulness Therapy|Participants receive guided mindfulness audio sessions twice daily for \~30 minutes each throughout the perioperative period. Content includes standardized mindfulness practices (e.g., focused attention, body awareness, nonjudgmental observation) designed to reduce anxiety and improve sleep quality.
224263677|NCT06820970|OTHER|sham CRIC|The pressure was 60mmHg when the cuff was pressurized, and the other modes were the same as those of the CIRC group.
223781178|NCT06580808|OTHER|Fontan Training Group|The Fonta training group consisted of 14 children in the late postoperative period of Fontan surgery. These children underwent cardiopulmonary testing, spirometry, chest ultrasound to assess the diaphragm, 6-minute walk test, respiratory muscle strength and quality of life. These tests were performed at the initial stage and after two months of inspiratory muscle training to assess the results of these in postoperative patients and what changes the training could bring. The training was performed with the Power Breath device, the carda was quantified at 40% of the force exerted at maximum inspiratory pressure by manovacuometry. The patient was asked to perform 3 sets of 20 repetitions twice over the course of 7 days of the week. Monitoring was done in person and virtually, and the carda was increased according to the evaluator's perception of the ease of the exercise or if the patient reported it to be easy. The training lasted 2 months.
223781179|NCT00346034|DRUG|Pregabalin|150 to 600mg/day
223781180|NCT00233935|OTHER|placebo|Given PO
223781181|NCT00233935|DRUG|defined green tea catechin extract|Given PO
223781182|NCT02053233|DEVICE|Walkbot group|"The physiotherapist typed patient's information then Walkbot would adjust itself to this data and the exoskeleton legs lengthen or shorten to the patient. The computer screen would provide information about speed, duration, cadence and distance. The monitor in front of the patient can offer image and feedback during the therapy process for patients.~The whole Walkbot training process was observed by one physiotherapist and should be always ready to adjust the unloading, duration, speed and guidance force of Walkbot according to patients' different situation such as muscle spasticity, gait quality, labor-consuming and observe the changes of patients' state."
223781183|NCT02053233|DEVICE|Control group|The control group received conventional functional rehabilitation for 40 min/session, 2 sessions/day, 5 days/week for 4 weeks, 40 sessions in all. After 4-week intervention all subjects received conventional physical therapy only, 40 min/day, 5 days/week for 4 weeks. During the test period, general rehabilitation and drug treatment can be done at the same time.
223781184|NCT05995912|DRUG|etoricoxib-tramadol|Oral administration (with or without food)
223781185|NCT05995912|DRUG|Naproxen|Oral administration (with or without food)
223781186|NCT05995912|DRUG|Tramadol|Oral administration (with or without food)
223781187|NCT04950699|GENETIC|Single-nucleotide Polymorphism of genes related with Dyslipidemia|This study is an observational study to study the effect of different genotypes on the incidence of myocardial infarction
223781188|NCT01255358|DRUG|Dexamethasone|"Dexamethasone sodium phosphate (2 vials, 250 mg/10 ml each) to be administered via encapsulation into autologous erythrocytes (ERY-DEX system). Final amount administered to the patient: about 10-15 mg of dexamethasone sodium phosphate, encapsulated into autologous blood (2 vials of 250 mg each of dexamethasone sodium phosphate will be used in the ex vivo process together with 50 ml of blood previously taken from the same patient).~The treatment has to be repeated at intervals of 30 days (±10 days)"
223781189|NCT06635005|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223698276|NCT05776368|OTHER|The Box and Block Test (BBT)|"The Box and Block Test (BBT) is a standardised test of manual dexterity used to assess motor function and hand-eye coordination in people of all ages.~The subject must move, one by one, a maximum number of cubes from one compartment of the box to another of equal size for 60 seconds. He starts with the healthy upper limb or, if not, with the dominant side. A 15 second trial period is allowed at the beginning of each side."
223698277|NCT05776368|OTHER|Motor training with a tool|"The patient will do around 30 minutes of motor training with a tool (pliers). They have to put most pieces as possible in the board with the pliers. Patients hold the pliers with the right hand (dominant hand) or with the left one if not possible (motor disorder).~For E1 Arm1 and E1 Arm 4: the participant will do the motor training with a tool one time in this study.~For E3 Arm 1: the participant will do the motor training with a tool During 4 weeks (3 to 5 training sessions of 30 minutes)"
223698278|NCT05776368|OTHER|Motor training with a hand|The patient will do around 30 minutes of motor training with the hand. They have to put most pieces as possible in the board with the right hand (dominant hand) or with the left one if not possible (motor disorder).
223698279|NCT05776368|OTHER|on/off effect of tool motor training|"During 4 weeks, patients switch between tool training weeks (on) and control weeks (off) during which they don't practice motor training.~During on weeks they do 3 to 5 tool motor training sessions of 30 minutes. They use pliers with the right hand (dominant hand) or with the left one if not possible (motor disorder) and have to put most pieces as possible in the board.~During off weeks they do 3 to 5 control sessions where they only do the two linguistic tasks separated between a 30-minutes break."
223698280|NCT05776368|OTHER|linguistic tasks|"The linguistic tasks consists in the presentation of correct sentences at the center of a computer screen. The sentence can be a coordinated one ( The policeman stopped the woman and asked the question ), or a subject relative (i.e.,  The policeman who stopped the woman asked the question ), or an object relative ( The policeman who the woman stopped asked the question ). After the sentence an affirmation test is proposed of the kind  the policeman stopped the woman , and the participant has to respond ads quick as possible whether it is true or false."
223698281|NCT06250777|DRUG|Trastuzumab deruxtecan|"Chemotherapy : Every 3weeks as below until withdrawal of patient consent, progression, death or loss to follow-up:~\- Trastuzumab Deruxtecan (T-DXd) 5.4mg/kg"
223698282|NCT00697073|DRUG|Idebenone|Patients ≤ 45 kg/99 lbs: idebenone 1350 mg/day; Patients \> 45 kg/99 lbs: idebenone 2250 mg/day
223698283|NCT03220984|BIOLOGICAL|Immuncell-LC intravenous infusion using a CIK cell agent|Patients with metastatic colorectal cancer, which is refractory to the 3rd-line chemotherapy are enrolled in this study. Enrolled patients receive a total of 12 times of Immuncell-LC therapy: 8 times in every 1 week and the next 4 times in every 2 weeks. The treatment responses of immuncell-LC are evaluated by radiologic findings (Abdomin-pelvic CT and Chest CT), immune-markers and a selorogic tumor marker (Carcinoembryologic antigen (CEA)) at the 8th week and 17th week. The safety of Immuncell-LC is evaluated by the results of serologic tests, vital signs, ECOG-PS and adverse events. The follow-up period is the 1 year after the enrolled date.
223781190|NCT06635005|OTHER|Dietary Intervention|Receive the Low-EDIH dietary pattern intervention
223781191|NCT06635005|OTHER|Medical Device Usage and Evaluation|Wear an activity tracker
223781192|NCT06635005|BEHAVIORAL|Motivational Interviewing|Undergo motivational interviews
223781193|NCT06635005|OTHER|Nutritional Assessment|Participate in nutrition counseling
223698284|NCT02597868|DRUG|Capecitabine|Capecitabine is be given as a sequential treatment in Metastatic breast cancer patients who are got benefit in chemo treatment.
223698285|NCT02597868|PROCEDURE|endocrine therapy|endocrine therapy is be given as a sequential treatment in Metastatic breast cancer patients who are got benefit in chemo treatment,the medicine will be confirmed by the patient's past-treatment.
223698286|NCT02641132|DRUG|Mitomycin C 0.02%|Pterygium excision with application of mitomycin C
223698287|NCT02641132|PROCEDURE|Pterygium surgery|Two different procedures- excision of the head and the body and excision of the head only
223698288|NCT05700318|DEVICE|neurostimulator|The ShiraTronics Migraine Therapy System
223698289|NCT03025841|DRUG|Ceftaroline|
223698290|NCT05412875|OTHER|Best Practice|Given usual care
223698291|NCT05412875|DRUG|Nicotine Replacement|Given JUUL
223698292|NCT05412875|OTHER|Quality-of-Life Assessment|Ancillary studies
223698293|NCT05412875|OTHER|Questionnaire Administration|Ancillary studies
223698294|NCT03383458|BIOLOGICAL|Nivolumab|Specified dose on specified days
223698295|NCT03383458|OTHER|Placebo|specified dose on specified days
223698296|NCT01411618|OTHER|free alcohol essential oil mouthwash|All subjects were instructed to rinse twice a day, in the morning and in the evening, with 20 ml solution for 60 seconds, after which they expectorated. Subsequent rinsing with water was not allowed.
223698297|NCT03140228|DEVICE|I-Gel|I-gel is the single use supraglottic airway from intersurgical, UK (Intersurgical Ltd, Wokingham, Berkshire, UK) with an anatomically designed mask made of a gel like thermoplastic elastomer to fit over perilaryngeal and hypopharyngeal structures. It is designed to separate the gastrointestinal and respiratory tracts and also allow a gastric tube to be passed into the stomach.
223698298|NCT03140228|DEVICE|LMA|The AmbuAuraOnce (Ambu A/S, Ballerup, Denmark) is a supraglottic airway device with an inflatable cuff. It is a disposable device as well, but unlike I-gel, it does not feature a gastric channel.
223698299|NCT03798197|DRUG|30 mg estetrol (E4)|All subjects received both Treatment A and Treatment B either at the first treatment period (Period 1) or at the second treatment period (Period 2). Approximately half of the subjects was randomized to receive either Treatment A followed by Treatment B (sequence AB), or Treatment B followed by Treatment A (sequence BA).
223698300|NCT04041297|OTHER|Preoperative Pulmonary Rehabilitation|"Each prehabilitation session will last approximately 90 minutes and will include:~Endurance training at the ventilatory threshold, determined according to the initial CPET. The first session will last for 15 to 20 minutes then increase by 5 minutes each session to reach 45 minutes in total (including a 5-minute warm-up and 5 minutes of active recovery). The intensity will then increase by 5 or 10 W, as could be tolerated;~Peripheral muscle strengthening at 60% to 70% of the 1-repetition maximum of 3 main components (quadriceps press, whole-leg extension, and upper limb pull down). Three sets of 12 movements will carry out for each exercise and the load will increase weekly as tolerated;~Inspiratory muscle training using a threshold calibrated to at least 30% of the MIP. Patients will be encouraged to carry out 15 minutes of independent training daily and to increase the resistance regularly.~Education to bronchial drainage techniques as well as directed coughing."
223781194|NCT06635005|OTHER|Questionnaire Administration|Ancillary studies
223781195|NCT06635187|DIAGNOSTIC_TEST|Speech and swallowing assessment|This is an observational study in which post-stroke patients will undergo a series of assessments tapping oral-motor and speech functions. Both behavioral and instrumental examinations will be used. Their performance will be captured via an artificial intelligence(AI)-powered mobile health application. The relation between the oral/speech-motor movements captured by the app and their performance as measured via instruments/behavioral means will be investigated.
223781196|NCT06635369|DIAGNOSTIC_TEST|Periodontal Indices|Saliva, serum and periodontal indexes were obtained from patients
223781197|NCT06635083|OTHER|Telerehabilitation|A video conference software system will be installed on the subjects' laptops or tablets. Then, via video conference, strengthening/stretching exercises and breathing exercises will be performed for the areas affected by the deformity with the physiotherapist three times a week.
223698301|NCT03071471|DEVICE|MID-C|"The MID-C system is designed to correct the deformity step by step along a period of time, giving the skeletal and soft tissues accommodate any incremental correction.~The MID-C System inherent benefits are:~* Only two screws are used~* Incision size is much smaller~* Simpler operation with shorter operative time~* Less complication thanks to the three points above.~* Minimal spinal mobility loss"
223698302|NCT04234802|OTHER|Heat Education and Awareness Tools|HEAT training will be delivered to agricultural workers by research staff in this study in the spring. HEAT training uses interactive approaches to engage participants and posters with visuals. Training covers types of heat-related illness and treatments, risk factors, appropriate clothing and hydration, and keeping cool in the home and community. The HEAT awareness application was developed in collaboration with Washington State University's AgWeatherNet Program to notify supervisors signed up for the service about hot weather conditions that might increase the risk for adverse health effects for workers. The HEAT awareness application is designed to allow subscribers to select weather stations of interest and view current heat indices as well as maximum daily heat indices forecasted over the following week. This information is coupled with information about health effects and prevention of adverse heat health effects. Materials are provided in English and Spanish.
223698303|NCT04449887|DRUG|Xiangsha Liujunzi granules|A traditional Chinese medicine compound, taken three times a day, one bag at a time, for a total of 28 days
223698304|NCT04484948|OTHER|scleroderma health assessment questionnaire (SHAQ), BHT, and 6MWT|"1. Participants will perform the SHAQ.~2. BHT and 6MWT will be performed in the randomized way for each participant.~3. For BHT, the participants will be told to sit comfortably on a chair, and breath normally. After 1 minute, they were required to make a maximum expiration followed by a maximum inspiration and to hold the breath as long as possible at maximum inspiratory level. This procedure was repeated three times, with 5-minute intervals between the tests.~4. 6MWT will be performed according to the ATS guidelines.~5. Information on CXR, TTE, and PFT (FVC%, DLCO%) will be obtained from the medical record if the data was obtained within 3 months. If not, the tests will be performed.~6. BHT and PFT will be followed by six months after the first breath-holding test to confirm the responsiveness.~7. Additional 30 patients with systemic sclerosis will be collected to perform the test-retest reliability of BHT."
223698305|NCT01317381|PROCEDURE|Observational|Blood draw
223698306|NCT04537455|DIAGNOSTIC_TEST|Ultra-high frequency electrocardiography|Patients will have an ultra-high frequency electrocardiography performed.
223698307|NCT05770869|DEVICE|ALIBIRD mHealth platform|Use of a mHealth platform to follow-up and empower cancer patients in the self-management of their own health.
223698308|NCT05420675|OTHER|Single Leg Squat|After initial data collection (Demographic data, Inclusion criteria), surface electromyography EMG assessments will be obtained from 1 muscle ( Vastus Medialis). EMG evaluation will be done in different arm positions during the single leg squat. These records will be taken in 4 different situations: 1) Arms free, 2) Arms flexed to 90 degrees, 3) Hands on hips, 4) Arms across the chest.
223698309|NCT02834728|BEHAVIORAL|telephone interview|
223698310|NCT01593410|DRUG|Lenalidomide|25 mg oral lenalidomide once daily on Days 1-21 every 28 days
223698311|NCT01593410|DRUG|Dexamethasone|Cycle 1: 40 mg oral dexamethasone once daily on Days 8, 15, and 22. Cycle 2 and beyond: 40 mg oral dexamethasone once daily on Days 1, 8, 15, and 22
223698312|NCT04048187|DEVICE|Phone Application|Phone application is developed to adjust hearing aids. It incorporates functionalities like volume control and program change.
223698313|NCT00940030|OTHER|mechanical bowel preparation|fiberless diet starting 2 days before surgery. Drugs containing iron and coal plant will be stopped. Free breakfast the day before surgery. Lunch: meat broth and white meat. From 16 p. m. to 20 p. m. assumption of Polyethylene Glycol Macrogol 70 mg per 1 liter of water 4 times (1L each hour). A bowel enema (2L, glycerin 5%) will be administered at 6 a. m. the day of surgery.
223781198|NCT06636305|BEHAVIORAL|physical activity intervention|Women in the intervention group were instructed to obtain 10,000 steps per day and 150 minutes of MVPA (defined as physical activity that resulted in a heart rate in the range of 120-170 bmp) per week and were given a physical activity tracker (FitBit Charge HR 2, Fitbit, San Francisco, USA) to self-monitor progress.
223781199|NCT06634550|OTHER|Mulligan technique|The participants will receive Mulligan technique (modified SNAGs) (10 rep. / 3 sets with 5 min rest in between) for 30 minutes, 3 sessions / week in addition to lifestyle modification advice for 4 weeks.
223781200|NCT06634550|OTHER|Core stability exercise|The participants will perform core stability exercises (spinus multifiduse ex, diaphragmatic strengthening ex, frontal plank, pelvic floor ex,) 3 sessions / week for 30 min each session in addition to lifestyle modification advice for 4 weeks
223781201|NCT06634550|OTHER|Lifestyle modification advice|The participants will receive lifestyle modification advice only for 4 weeks
223781202|NCT01559402|PROCEDURE|CPAP and 100% oxygen|During pre oxygenation and induction of anesthesia 100 % oxygen is used with a continuous positive airway pressure of 10 cmH2O, during maintenance of anesthesia a positive endexpiratory pressure of 10 cm H20 is used with controlled volume ventilation aiming at an end tidal carbon dioxide (CO2) level of 5 %. During emergence from anesthesia 100 % oxygen is used.
223781203|NCT01559402|PROCEDURE|CPAP and 31% oxygen|During pre oxygenation and induction of anesthesia 100 % oxygen is used with a continuous positive airway pressure of 10 cm H2O, during maintenance of anesthesia a positive endexpiratory pressure of 10 cm H20 is used with controlled volume ventilation aiming at an end tidal CO2 level of 5 %. During emergence from anesthesia 31 % inspiratory oxygen or the inspiratory oxygen level needed to achieve a SpO2 of at least 96 % (if 31 % oxygen is not enough), is used.
223781204|NCT01559402|PROCEDURE|No CPAP and 100% oxygen|This intervention follows a standard protocol without the use CPAP during induction of anesthesia.
223781205|NCT00797667|DRUG|Telcagepant 140 mg|
223781206|NCT00797667|DRUG|Telcagepant 280 mg|
223781207|NCT00797667|DRUG|140 mg telcagepant placebo|
223781208|NCT00797667|DRUG|280 mg telcagepant placebo|
223781209|NCT01023100|DRUG|CP 690,550 oral solutions|flavored and unflavored prototype CP-690,550 formulations
223781210|NCT05085600|OTHER|Exercise|"Patients will begin performing the cervical stabilization exercise, and will taught to perform the contraction of deep neck flexor muscle activity with the help of the Stabilizer Pressure Biofeedback Unit (Chattanooga, USA) in supine.~In addition, progress will continued in the exercise of the contraction of deep neck flexor muscles in other positions.~The progression of the exercises will be adapted to each patient, depending on their evolution. Firstly, exercises will undertaken in the supine and standing positions; once these positions will mastered, the exercises progressed to asymmetric positions with cervical bending and/or rotation toward each patient's most symptomatic side."
223781211|NCT05085600|OTHER|Manual Therapy + Exercise|20-minute session. In the first 5 minutes, muscle techniques will be performed to prepare the tissue of the upper cervical spine before applying joint techniques. In the next 15 minutes, manipulation and / or mobilization techniques of the upper cervical spine, including the C2-3 segment, will be combined with cervical exercise
223781212|NCT03249038|OTHER|Measurement of external blood loss|
223781213|NCT03249038|DIAGNOSTIC_TEST|Serum Hemoglobin concentration|
224263678|NCT06820970|BEHAVIORAL|sham MFT|Sham MFT: Health Education + Relaxation (HER): A time- and attention-matched audio program (twice daily, 30 minutes) delivering perioperative recovery and sleep-hygiene education with passive relaxation (music or simple muscle loosening), excluding mindfulness-specific techniques (no present-moment/nonjudgmental awareness training, no breath-focused meditation, no open monitoring).
224263679|NCT06277492|DRUG|Single ascending doses SUL-238|PART 1: SUL-238 single ascending doses
224263680|NCT06277492|DRUG|Single dose Placebo|PART 1: Placebo single dose
224263681|NCT06277492|DRUG|Single dose SUL-238|PART 2: SUL-238 single dose for pharmacokinetics
224263682|NCT06277492|DRUG|Multiple ascending doses SUL-238|PART 3: SUL-238 multiple ascending doses
224263683|NCT06277492|DRUG|Multiple doses Placebo|PART 3: Placebo multiple doses
224263684|NCT06277492|DRUG|2000 mg SUL-238 single dose for pharmacokinetics (food effect)|PART 2B: 2000 mg single dose of SUL-238
224263685|NCT06277492|DRUG|Single dose placebo (food effect)|PART 2B: Placebo single dose
224263686|NCT06359860|DRUG|ST-1898 tablets|Supplied as 5 mg and 40 mg tablets
224263687|NCT05032742|BEHAVIORAL|mHealth parenting stress app|mHealth parenting stress app intervention to reduce parenting stress and improving youth community-based treatment engagement.
224263688|NCT06601439|OTHER|Observational Study|Observational Study
224263689|NCT06603103|PROCEDURE|SPHERIKA prosthesis|total knee arthroplasty with kinematic alignement with SPHERIKA prosthesis
224263690|NCT06603103|PROCEDURE|ORIGIN prosthesis|total knee arthroplasty with kinematic alignement with ORIGIN prosthesis
224263691|NCT06598956|DRUG|TQ05105|TQ05105 is a Janus kinase (JAK) and Rho-associated coiled-coil-containing protein kinase (ROCK) inhibitors.
224263692|NCT06979856|BEHAVIORAL|Short animated video|The short animated video (approximately 2 minutes) draws a parallel between cigarette addiction and smartphone addiction.
224263693|NCT06979856|BEHAVIORAL|Informational Control|A short fact sheet presenting written information and statistics about smartphone usage.
224263694|NCT06609278|BEHAVIORAL|harm reduction intervention|Each participant will complete a pre-test at Study Visit 1 prior to the intervention, participate in the intervention, then complete a post-test. After the intervention, participants will participate in a recorded focus group. Participants will be offered FTS, Narcan, first aid supplies at the study visit.
224263695|NCT06987708|OTHER|The Multimodal Lifestyle Intervention|The multimodal lifestyle intervention has six foci: positive cognition, exercise/movement, stress reduction, social connection, emotional well-being, and nutrition
224263696|NCT00849797|DRUG|Oxcarbazepine|600 mg Tablet
224263697|NCT00849797|DRUG|Trileptal®|600 mg Tablet
224263698|NCT05649683|BIOLOGICAL|Evaluation of cytokine production|The patient will have samples at initiation of treatment (J0), after treatments 1 and 2 (S6), after the first radiological assessment at S11 and/or the progression of the disease and/or occurrence of a grade 3-4 adverse event
224263699|NCT03115697|DRUG|Lactulose|Lactulose 20 mL
224263700|NCT03115697|DRUG|Rifaximin|Rifaximin 550 BD
223698314|NCT00940030|OTHER|enema|fiberless diet starting 2 days before surgery. Drugs containing iron and coal plant will be stopped. Free breakfast the day before surgery. Lunch: meat broth and white meat. Dinner: meat broth and fasting starting from midnight. A bowel single enema (2L, glycerin 5%) will be administered at 6 a. m. the day of surgery.
223698315|NCT00014118|DRUG|carboplatin|
223698316|NCT00014118|DRUG|paclitaxel|
223698317|NCT00014118|PROCEDURE|conventional surgery|
223698318|NCT00014118|RADIATION|radiation therapy|
223698319|NCT01413477|DRUG|Calcipotriol, Betamethasone, Calcipotriol & Betamethasone|All study patients will be randomized to receive one of four topical ointments (calcipotriol, betamethasone dipropionate, combination of both calcipotriol/betamethasone dipropionate, or Vaseline petroleum jelly). Each subject will receive one unlabelled 5g tube for application to be dispensed by pharmacist, Rudy Chin. We expect approximately 2g of TOTAL use (0.125g applied twice daily over a 5 cm x 5 cm area on one forearm for 7 days). Typically, topical steroids such as betamethasone dipropionate have been used for treating a number of inflammatory skin conditions, including eczema. In addition, vitamin D analogues such as calcipotriol are used to treat psoriasis. Both agents, in our study, will be used on a small area of normal skin for a short 7 day course.
223698320|NCT06340061|OTHER|Observational study|The ocular biomechanical differences between the normal control group and primary glaucoma patients, including those treated with conventional medication, laser therapy, and surgery, were compared. Additionally, an investigation was conducted to explore the relationship between anterior chamber parameters, corneal biomechanics, and the severity of glaucoma
223698321|NCT03657446|DRUG|Clazosentan|Continuous i.v. infusion of 20 mg/h or 60 mg/h of clazosentan for 3 h
223698322|NCT03657446|DRUG|Placebo|Matching placebo infusion
224263701|NCT03115697|BIOLOGICAL|Plasmapheresis|Plasmapheresis 8 hrly duration
223698323|NCT03657446|DRUG|Moxifloxacin|Film-coated tablet containing 400 mg moxifloxacin
223698324|NCT05449769|BEHAVIORAL|eNutriCardio personalised nutrition advice|eNutriCardio is a web-based app that administers an FFQ and delivers PN advice to the user. The advice is generated from their responses in the FFQ and considers their sex so the reports are unique to each participant. This report (referred to as a 'healthy eating report') will also include an interactive component, allowing the participant to reflect on the advice received and set personal healthy eating goals to motivate behaviour change. The messages presented in the report have been developed by the eNutriCardio Team, including a registered dietitian and registered nutritionist, are in line with UK dietary guidelines (primarily the EatWell Guide), and promote a Mediterranean-style diet (in line with NICE guidance). Therefore, the advice builds on the generalised advice given during the usual NHS CR programme.
223698325|NCT03894046|DRUG|Sulbactam|1.0 g sulbactam IV infused over 3 hours every 6 hours (q6h).
223698326|NCT03894046|DRUG|Durlobactam|"1.0 g durlobactam IV infused over 3 hours every 6 hours (q6h).~Sulbactam-Durlobactam: Treatment for 7 days up to 14 days if clinically indicated."
223698327|NCT03894046|DRUG|Colistin|Treatment for 7 days up to 14 days if clinically indicated.
223698328|NCT03894046|DRUG|Imipenem/Cilastatin 500 mg/500 mg|1.0 g imipenem/1.0 g cilastatin IV infused over 1 hour q6h. Treatment for 7 days up to 14 days if clinically indicated.
223698329|NCT00251212|BEHAVIORAL|Adapted Motivational Interviewing & Skills Training|Single session, 45 minute brief intervention during Emergency Department Visit
223698330|NCT03654859|OTHER|cardiopulmonary resuscitation|no pre-specified
224263702|NCT02955901|OTHER|3 day low residue diet prior to the colonoscopy|3 day low residue diet prior to the colonoscopy
224263703|NCT02955901|OTHER|1 day low residue diet prior to the colonoscopy|3 day low residue diet prior to the colonoscopy
224263704|NCT03986463|OTHER|Circulating tumour DNA (ctDNA)|Circulating tumour DNA (ctDNA) will be isolated from blood samples
224263705|NCT05242965|BIOLOGICAL|CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine|Given ID
224263706|NCT05242965|BIOLOGICAL|Sargramostim|Given ID
224263707|NCT05242965|PROCEDURE|Computed Tomography|Undergo CT
224263708|NCT05242965|PROCEDURE|Biopsy|Undergo biopsy
224263709|NCT05242965|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
224263715|NCT06996782|DRUG|Rilvegostomig|Rilvegostomig will be administered as an intravenous (IV) infusion.
224263716|NCT06996782|DRUG|AB248|AB248 will be administered via syringe or an IV bag.
224263717|NCT06996782|DRUG|Cisplatin|Cisplatin will be administered as SoC as an IV infusion.
224263718|NCT06996782|DRUG|Carboplatin|Carboplatin will be administered as SoC as an IV infusion.
224263719|NCT06996782|DRUG|Pemetrexed|Pemetrexed will be administered as SoC as an IV infusion.
224263720|NCT06996782|DRUG|Paclitaxel|Paclitaxel will be administered as SoC as an IV infusion.
224263721|NCT06996782|DRUG|Nab-paclitaxel|Nab-paclitaxel will be administered as SoC as an IV infusion.
224263722|NCT06996782|DRUG|Ramucirumab|Ramucirumab will be administered as an IV infusion.
224263723|NCT05660135|DRUG|Olmesartan Medoxomil/ Amlodipine Besylate/ Rosuvastatin Ca|Olomax Tab 20/5/5mg Olomax Tab 20/5/10mg Olomax Tab 40/5/5mg Olomax Tab 40/5/10mg
224263724|NCT03631056|BIOLOGICAL|Acellular Tissue Engineered Vessel (ATEV) / Human Acellular Vessel (HAV)|
224263725|NCT02901379|DRUG|Atorvastatin 80mg|Subject will be given atorvastatin 80mg for two weeks
224263726|NCT02901379|DRUG|Atorvastatin 10mg|Subjects will be give atorvastatin 10mg as part of standard therapy in hospital
224263727|NCT03022643|BEHAVIORAL|Interpersonal Social Rhythms Psychotherapy|The treatment involves 8-weeks of individual psychotherapy. Weekly sessions will be 60-minute long and will take place at the Pain Research Center. The treatment focuses on 1) the link between life events, pain severity, sleep disturbances, fatigue, and mood, 2) social and behavioral rhythms and sleep-wake disturbances, 3) identification and management of rhythm dysregulation and the triggers for it, 4) allowing and facilitating the mourning of the loss healthy self, 5) identification and appropriate management of symptoms.
223781214|NCT01986829|DEVICE|Microwave ablation|"* Microwave ablation will be predominantly used on metastatic soft tissue lesions and will include use of Covidien's Evident™ MWA System. Microwave ablation is performed under ultrasound, CT, and occasional fluoroscopic guidance with CT fluoroscopy available for intermittent use in probe placement and CT monitoring of ablation.~* Microwave antennae from Covidien (Mansfield, MA) are either introduced into the lesion co-axially through a bone biopsy needle or directly into the lesions that are amenable to such, i.e., soft tissue, lung, liver, and large lytic lesions with extensive bone destruction."
223781215|NCT01986829|DEVICE|Cryoablation|"* Cryoablation is performed under ultrasound, CT and occasional fluoroscopic guidance with CT fluoroscopy available for intermittent use in cyroprobe placement and CT monitoring of ablation.~* Cryoprobes from Endocare Inc. (Irvine CA) or Galil Medical (Arden Hills MN) are either introduced into the lesion co-axially through a bone biopsy needle or directly into the lesions that are amenable to such, i.e., soft tissue, lung, liver, and large lytic lesions with extensive bone destruction."
223781216|NCT01986829|DEVICE|Radiofrequency ablation|-Radiofrequency ablation will be predominantly used on metastatic spine lesions and will include use of the Dfine STAR ablation probe. This probe will be placed coaxially through an introducer needle into the spinal metastatic lesion.
223781217|NCT01986829|OTHER|BPI-Short form|-Prior to ablation, 1 day post-ablation, 1 month post-ablation (from first procedure if more than 1 is done), and time of disease progression
223781218|NCT01986829|OTHER|FACT-G7|-Prior to ablation, 1 day post-ablation, 1 month post-ablation (from first procedure if more than 1 is done), and time of disease progression
223781219|NCT00061490|BEHAVIORAL|Behavioral weight control and lifestyle exercise|16 weekly educational meetings vs. waitlist control
223781220|NCT02504866|OTHER|Vigorous exercise|Exercise training of vigorous intensity
223698331|NCT03587948|DIAGNOSTIC_TEST|Diabetes mellitus|Children and adolescents who is diagnosed with diabetes will be involved in case-group, and others will be involved in control-group.
223698332|NCT06009029|RADIATION|Stereotactic body radiation(SBRT)|"SBRT: 7-10 Gy/F, 5 doses~Zimberelimab: 240mg d1 iv Q21D, within 7 days after SBRT completion. Receiving a minimum of six cycles of treatment, or disease progression or intolerable toxic side effects."
223698333|NCT06009029|DRUG|Zimberelimab (GLS-010)|Zimberelimab (GLS-010),240mg d1 iv Q21D
223698334|NCT05657925|DRUG|ondansetron 8 mg|Ondansetron 8 mg prn sublingually when awakening with nausea. as per the FDA label for ondansetron.
223781221|NCT02504866|OTHER|Light to moderate exercise|Exercise training of light to moderate intensity
223781222|NCT04368923|DEVICE|Oxygen Therapy|Patients receive oxygen therapy
223698335|NCT05657925|DRUG|Matching placebo|Matching placebo will be identical in appearance to the active treatment pill
223698336|NCT01012167|DRUG|Oxytocin|Oxytocin: 24 IU in the morning and 24 IU in the evening given by nasal spray with a total of 6 puffs of the spray, 3 in each nostril at each administration
223698337|NCT01012167|DRUG|Galantamine|Galantamine: 4 mg twice a day for 1 week, then 8 mg twice a day for 1 week, then 12 mg twice a day for 4 weeks
223698338|NCT01012167|OTHER|Placebo-Oxytocin|Saline nasal spray with a total of 6 puffs of the spray, 3 in each nostril at each administration
223698339|NCT01012167|OTHER|Placebo-Galantamine|Placebo tablets twice a day for 6 weeks
223698340|NCT03835871|DRUG|Placebo|Intervention: Drug: placebo
223698341|NCT03835871|DRUG|400 µg per day Beclomethasone|Intervention: Drug: Beclomethasone 400 µg HFA per day
223698342|NCT03835871|DRUG|200 µg per day Beclomethasone|Intervention: Drug: Beclomethasone 200 µg HFA per day
223698343|NCT03835871|DRUG|100 µg per day Beclomethasone|Intervention: Drug: Beclomethasone 100 µg HFA per day
223698344|NCT00486473|DRUG|Multihance|0.5 Molar at a single dose injection
223698345|NCT00486473|DRUG|Magnevist|0.5M at a single dose injection
223698346|NCT06306053|COMBINATION_PRODUCT|tDCS+EuleriaLab|Home based: Non invasive Neuromodulation treatment + Motor Training
223698347|NCT06306053|DEVICE|tDCS|Non invasive brain stimulation
223698348|NCT06306053|OTHER|EuleriaLab|Home Motor Training
223698349|NCT00867685|DRUG|AZD2624|Single dose of 40 mg AZD2624 liquid suspension, PO
223698350|NCT00867685|DRUG|AZD2624|Single dose of 40 mg AZD 2624 (2x20mg tablets), PO
223698351|NCT00641303|PROCEDURE|acupuncture therapy|Given weekly for 8 sessions
223698352|NCT00641303|PROCEDURE|sham intervention|Given weekly for 8 sessions
223698353|NCT01823354|OTHER|Polysomnography|Polysomnography involves the collection of the electroencephalogram, electromyogram of, and electro-oculogram to differentiate the various stages of sleep. Determination of different stages and cycles of sleep will be manually by reading the EEG, EMG, EOG over periods of 30 seconds after the standardized criteria of AASM (American Academy of Sleep Medicine). Registration will take place between sleep and 23h 7am.
223698354|NCT01823354|OTHER|Clinical Scales|Index of Restless Legs Syndrome Severity, Index of insomnia Severity, Beck's Inventory of Depression, Anxiety Inventory: State-Trait, form Y.
223698355|NCT01823354|OTHER|Assessment of executive functions|"Verbal fluencies Test GREFEX (Assessment of the spontaneous flexibility), Stroop Test GREFEX (Inhibition of the automatic response Capacity ), Trail Making Test GREFEX (Assessment of flexibility reactive), Wisconsin Card Sorting Test(Overall assessment of executive functions), Working memory TAP, Flexibility TAP, Go/no go TAP, Phasic alertness (Assessment of speed information processing)."
223698356|NCT01823354|OTHER|Medical consultation|open questions
223698357|NCT04260711|DRUG|DMT|Discontinuation of patients' own disease modifying therapy (any of the interferons, glatiramer acetate, dimethylfumarate, teriflunomide)
223698358|NCT01768052|DEVICE|functional Near Infrared Spectroscopy|fNIRS monitoring during rTMS treatment sessions.
223698359|NCT02796703|DIETARY_SUPPLEMENT|Heat Inactivated probiotics|Biotikid, a probiotic mixture, will be heated to 100 degrees Centigrade for 10 minutes to inactivate and then 1 tsp will be diluted in milk and give with feeds to treatment group
223698360|NCT02796703|DIETARY_SUPPLEMENT|Placebo|2 cc of milk will be given to control group
223698361|NCT01006369|DRUG|hydroxychloroquine|hydroxychloroquine 200 mg po BID daily
223698362|NCT02439294|OTHER|Without Obstructive Sleep Apnea (syndrome)|
223698363|NCT02439294|OTHER|Mild or moderate Obstructive Sleep Apnea (syndrome)|
223698364|NCT02439294|OTHER|Severe Obstructive Sleep Apnea (syndrome)|
223698365|NCT02439294|DEVICE|CPAP|
223698366|NCT05843760|OTHER|personal information form|undergraduate student(participants) will be asked; age, weight, height, smoking and alcohol use, and headache.
223698367|NCT05843760|OTHER|headache-specific questionnaires|ıd migraine test, numeric rate scale, hit-6 headache impact test, headache information form
223698368|NCT05843760|OTHER|Questionnaires for assessing biopsychosocial status|hospital anxiety depression, Discomfort Intolerance Test, pittsburgh sleep quality index, fatigue severity scale, self compassion scale, Body Awareness Questionarre, cervical range of motion, İnternational Physical Activity Questionnaire, 12-Item Short-Form Health Survey
223698369|NCT03364569|PROCEDURE|Tranexamic acid|Participants with taking tranexamic acid (2 x 1g per day) as a preventive and without adjuvant treatment.
223698370|NCT03350165|DRUG|K-877|0.2mg tablet
223698371|NCT03350165|DRUG|Placebo|K-877 matching placebo tablet
223698372|NCT03475680|DRUG|Sennosides colonic preparation|"Mechanical bowel preparation :~Sennosides colonic preparation (X-PREP)~1 per day, on day -2 and day -1"
223698373|NCT03475680|DRUG|Oral Gentamycin|Gentamycin 80 mg, 4 per day, on day -2 and day -1; Liquid forms in individual vials
223698374|NCT03475680|DRUG|Oral Ornidazole|"Oral Ornidazole :~Ornidazole~1 g per day (2 tablet per day), on day -2 and day -1; In tablets"
223698375|NCT03475680|DRUG|Oral placebo Gentamycin|"Placebo for oral gentamycin :~Same presentation as oral gentamycin x4 per day on day -2 and day -1"
223781223|NCT04368923|PROCEDURE|Physical Therapy|Patients receive physical therapy
223781224|NCT00293540|PROCEDURE|oophorectomy|Excision of an ovary
223698376|NCT03475680|DRUG|Oral placebo Ornidazole|"Placebo for oral Ornidazole :~Same presentation as oral ornidazole~1g per day (2 tablet per day) on day -2 and day -1"
223698377|NCT02821637|OTHER|Eurofit Tests of Physical Fitness (Eurofit)|Eurofit tests are a physical skills assessment. For the study, tests performed on the 1st and the 13th session of the program, then 3 more times : 2 months, 6 months and 12 months after the 13th weekly session.
223698378|NCT02821637|BEHAVIORAL|Child Health Questionnaire (CHQ)|The CHQ is a questionnaire about quality of life. The CHQ children form (CHQ-CF87) and the CHQ parent form (CHQ-PF50) are completed each time the Eurofit tests are performed : at the 1st and 13th weekly session then 2 months, 6 months and 12 months later.
223698379|NCT02821637|OTHER|Effort rehabilitation program|Part of the routine practice of the Pediatric Obesity and Pediatric Diabetes Organization of Mulhouse, the program consists in 13 sessions of 1hour30 of adapted physical activity. The physical activity in this program use cycles of games where rules are adapted to the overweight or obese children. The activities are performed in a playful atmosphere, for example using creative games like tchoukball or peteca, with each session aiming a specific objective each time.
223698380|NCT03830242|DIAGNOSTIC_TEST|<Sup>18<Sup>F-FDG PET/CT dynamic scan|The purpose of this study is to carry out \<Sup\>18\<Sup\>F-FDG PET/CT dynamic scans and Pathological examination of metastatic central lymph nodes in newly diagnosed patients with papillary thyroid cancer, and to compare imaging findings, genomics, and pathology at the same time. The intrinsic relationship between tissue characteristics and the diagnostic value of \<Sup\>18\<Sup\>F-FDG PET/CT dynamic imaging in metastatic central lymph nodes with papillary thyroid cancer are discussed.
223698381|NCT03830242|DIAGNOSTIC_TEST|B-ultrasonography|The purpose of this study is to carry out \<Sup\>18\<Sup\>F-FDG PET/CT dynamic scans and Pathological examination of metastatic central lymph nodes in newly diagnosed patients with papillary thyroid cancer, and to compare imaging findings of B-ultrasonography , genomics, and pathology at the same time. The intrinsic relationship between tissue characteristics and the diagnostic value of \<Sup\>18\<Sup\>F-FDG PET/CT dynamic imaging in metastatic central lymph nodes with papillary thyroid cancer are discussed.
223698382|NCT06181578|PROCEDURE|ganglionated plexus ablation|This intervention involves the targeted ablation of ganglionated plexus sites, specifically focusing on the left superior ganglionated plexus (LSGP), left inferior ganglionated plexus (LIGP), right anterior ganglionated plexus (RAGP), and right inferior ganglionated plexus (RIGP).
223698383|NCT05169996|OTHER|Real Food|The game was played while sitting behind a table in the lab. The task in the game was to finish a tangram puzzle. In the Real Food condition, the tangram pieces were tempting food products (i.e., pieces of chocolate). Players had to physically move the chocolate pieces with their hands and puzzle them together.
223781225|NCT00293540|DRUG|Tamoxifen|20 mg orally every day
223781226|NCT00781326|DRUG|Nimodipine|Nimodipine will be initiated at one, 30-mg tablet three times a day for 1 week, increased to 2 tablets three times a day for 1 week, and then increased to three tablets three times a day for the remaining 30 weeks of the study. Participants who cannot tolerate the maximum dose of 270 mg/day will be maintained at the highest tolerable dose.
223781227|NCT00781326|DRUG|Placebo|Placebo will be given in doses matching those of nimodipine.
223781228|NCT04734379|DRUG|Fasudil|Oral fasudil 180 mg/day
223698384|NCT05169996|OTHER|Real Nonfood|The game was played while sitting behind a table in the lab. The task in the game was to finish a tangram puzzle. In the Real Nonfood condition, the tangram pieces were plain pieces (i.e., pieces of wood). Players had to physically move the wooden pieces with their hands and puzzle them together.
223698385|NCT05169996|OTHER|Virtual reality Food|The game was played by wearing a VR head-mounted display (HMD VR: HTC Vive) and people could interact in the virtual environment with the hand-held controllers. The task in the game was to finish a tangram puzzle. In the Virtual Reality Food condition, the tangram pieces were tempting food products (i.e., pieces of virtual chocolate). Players had to physically move the virtual chocolate pieces with the grab button on the controller and puzzle them together.
223698386|NCT05169996|OTHER|Virtual reality Nonfood|The game was played by wearing a VR head-mounted display (HMD VR: HTC Vive) and people could interact in the virtual environment with the hand-held controllers. The task in the game was to finish a tangram puzzle. In the Virtual Reality Nonfood condition, the tangram pieces were plain pieces (i.e., pieces of virtual wood). Players had to physically move the virtual wood pieces with the grab button on the controller and puzzle them together.
223698387|NCT05169996|OTHER|Virtual reality Food Branded|The game was played by wearing a VR head-mounted display (HMD VR: HTC Vive) and people could interact in the virtual environment with the hand-held controllers. The task in the game was to finish a tangram puzzle. In the Virtual Reality Food condition, the tangram pieces were tempting food products (i.e., pieces of virtual chocolate). Players had to physically move the virtual chocolate pieces with the grab button on the controller and puzzle them together. In the background of the puzzle, a chocolate brand ('Milka') is shown
223698388|NCT04673968|OTHER|prehabilitation|inhospital exercise training 5 times/week, 5\~6 weeks during nCRT; home exercise 5 times/week, 5\~6 weeks, between completion of nCRT and before surgery
223698389|NCT02219438|DRUG|Bolus|An adductor canal catheter was inserted and ropivacaine 0.2% administered as hourly bolus doses of 8 mL each: one at time point zero and then on the hour for 7 additional doses.
223698390|NCT02219438|DRUG|Basal|An adductor canal catheter was inserted and ropivacaine 0.2% administered as a continuous basal infusion (8 mL/h) from time point zero for a total of 8 hours.
223698391|NCT03378661|DRUG|Benznidazole|Benznidazole tablet
223698392|NCT03378661|DRUG|E1224|E1224 capsules
223698393|NCT03378661|DRUG|E1224 Placebo|E1224 matched placebo capsules
223698394|NCT03378661|DRUG|Benznidazole Placebo|Benznidazole matched placebo tablets
223698395|NCT06558058|DRUG|Rivaroxaban 10 mg film-coated tablet|One tablet of the test drug was given orally after an overnight fast.
223698396|NCT06558058|DRUG|Xarelto 10 mg film-coated tablet|One tablet of the reference drug was given orally after an overnight fast.
223698397|NCT00326066|DEVICE|Glaucoma Surgery|Comparing the effect in reducing IOP with two Trabecular Bypass Microstents Versus none in patients undergoing cataract surgery, with early open angle glaucoma or ocular hypertension.
223698398|NCT00326066|PROCEDURE|cataract surgery only|Subjects will undergo routine cataract surgery only (no stent implant).
223698399|NCT01722396|DIETARY_SUPPLEMENT|Vitamin D|
223698400|NCT03089320|BEHAVIORAL|Contingency Management Counseling|Contingency management (CM) is an efficacious treatment for individuals with substance use disorders. In line with operant conditioning, CM typically provides reinforcers (rewards) contingent upon attaining specified goals such as decreased substance use and/or abstinence.
223698401|NCT03089320|BEHAVIORAL|Addiction Physician Management|Patients in the CM plus stepped care arm who have PEth \> 8 ng/ml at 3 months will progress to Step 2 and receive onsite treatment from an Addiction Psychiatrist (APM) in the HIV clinic. APM will provide care that is typically provided by physicians in specialty referral programs.
223698402|NCT03089320|BEHAVIORAL|Motivational Enhancement Therapy|"Patients in the CM plus stepped care arm who have PEth \> 8 ng/ml at 3 months will progress to Step 2 and receive onsite Motivational Enhancement Therapy (MET) from the Social Worker in the HIV clinic.~MET is grounded in research on processes of natural recovery during which patients move through stages of change - precontemplation, contemplation, determination, action, and maintenance. The Social Worker's role is to assist the patient in moving through the stages of change. MET uses motivational interviewing and reflective listening to help patients identify internal sources of motivation to support reductions in alcohol."
223698403|NCT02875912|BEHAVIORAL|Family Care Rituals|"Family members being enrolled are given a pamphlet outlining the Family Care Rituals. They are informed of the opportunity to perform these rituals, but that they are in no way obligated to do so.~Family members are then surveyed at enrollment, and 90 days post ICU discharge for symptoms of PTSD, as well as depression, and anxiety.~Family members, day-time nursing, and attending physicians are surveyed for concordance of care at enrollment and ICU day 5.~Demographic information is also collected on the patient and the family members at enrollment Nursing completes surveys while the patient is in the ICU noting what care rituals, if any, are being performed. Additionally, they are asked to complete a survey indicating their opinion of the impact on the care they deliver"
223698404|NCT05115669|DEVICE|Wortie freeze plus|treatment of common and plantar warts
223698405|NCT02129114|DEVICE|ReDura Onlay|Subject will be clinically followed post-surgery until hospital discharge or within ten (10) days of the procedure and at three (3) months and six (6) months. The data up to and including the 6 month follow-up visit will be used in demonstrating the performance of ReDura Onlay.
223698406|NCT02129114|DEVICE|DuraGen|Subject will be clinically followed post-surgery until hospital discharge or within ten (10) days of the procedure and at three (3) months and six (6) months. The data up to and including the 6 month follow-up visit will be used in demonstrating the performance of DuraGen.
223698407|NCT00192361|BIOLOGICAL|CAIV-T|
223698408|NCT03302195|DRUG|Heparin|Based on patient body weight (UI/kg)
223781229|NCT00397423|DRUG|Granulocyte Colony Stimulating Factor|Granulocyte Colony Stimulating Factor,5ug/kg/day iH Qd\*5 days,3 months interval for 4 times
223781230|NCT00397423|DRUG|NS|NS 1ml iH Qd\*5 days, 3 months interval for 4 times
223781231|NCT03028376|OTHER|Blood sampling|Blood sampling from peripheral venous catheter routinely inserted in trauma patients during transportation
223781232|NCT00096941|DRUG|Pertuzumab|Pertuzumab was supplied as a single-use liquid formulation.
223698409|NCT03302195|PROCEDURE|cardiopulmonary bypass pump flow rate|Based on patient body weight (L/min/m2)
223698410|NCT05007093|DRUG|Anlotinib hydrochloride|If intolerance occurs, the dose can be downregulated
223698411|NCT02436304|DRUG|EXE844 Sterile Otic Suspension, 0.3%|
223698412|NCT02436304|PROCEDURE|Tympanostomy Tube Insertion|Surgical procedure for treating pediatric cases of recurrent or chronic otitis media
223698413|NCT02818361|DRUG|Topical tripterygium gel|
223698414|NCT02818361|DRUG|Placebo gel|
223698415|NCT00920933|BIOLOGICAL|AIN457|
223698416|NCT00920933|OTHER|Placebo|
223698417|NCT00920933|DRUG|prednisolone|
223698418|NCT00185562|DRUG|Adalimumab|
223698419|NCT04295551|DRUG|Lopinavir / ritonavir tablets combined with Xiyanping injection|Xiyanping injection, 10-20ml daily, Qd, the maximum daily does not exceed 500mg (20mL) + Lopinavir tablet or Ritonavir tablet+Alpha-interferon nebulization, for 7-14 days,
223698420|NCT04295551|DRUG|Lopinavir/ritonavir treatment|Lopinavir / ritonavir tablets, 2 times a day, 2 tablets at a time; alpha-interferon nebulization
223698421|NCT00302185|PROCEDURE|Acupuncture|Insertion of sterile, single-use acupuncture needles at 10-20 points including PC.6, HT.7, St.36, SP.6, and LR.3. Needles were connected to an electrical stimulator to mimick traditional manual stimulation with alternating patterns of stimulation for 20 minutes.
223698422|NCT00302185|BEHAVIORAL|Nurse-led supportive care|20-30 minutes of supportive attention from an experienced palliative nurse.
223698423|NCT02515643|OTHER|Endothelial dysfunction|"One month before surgery and one year after, the following procedures will be performed in donors and recipients:~1. Blood samples will be obtained for the measurement of endothelial dysfunction and low grade inflammation markers.~2. Atherosclerotic burden: carotid ultrasound to determine the number of plaques and intima-media thickness, carotid-femoral pulse wave velocity (m/s) will be performed by pulse tonometry.~3. Ambulatory blood pressure monitoring with overnight-automated ABPM monitor~4. Estimation of glomerular filtration rate by Iohexol method"
223698424|NCT03793556|DEVICE|GERDOFF® + Omeprazole|GERDOFF® Hyaluronic acid + chondroitin sulphate + hydroxide aluminium Melt-in-mouth tablet 1100 mg + Omeprazole was orally administered once a day before breakfast (2 capsules). The treatment lasted 6 weeks (+/- 2 days).
223698425|NCT03793556|DRUG|Omeprazole|Omeprazole, 2 capsules 20 mg, once a day before breakfast
223698426|NCT00398788|DRUG|OROS® hydromorphone HCL; Dilaudid CR (controlled release); Dilaudid IR (immediate release) as rescue medicine|
223698427|NCT04828239|DEVICE|laser acupuncture|400 mW, near-infrared, continuous wavelength, 810 nm. about 24J/cm2
223698428|NCT04828239|OTHER|acupuncture|Needle type: C\&G, gauge and size: 0.25x40mm
223698429|NCT04828239|DEVICE|Sham laser acupuncture|This laser pen is the same device with a red light was pasted on the acu-points in the same way, using the same protocol as for the active laser stimulation, but the laser apparatus was not switched on.
223698430|NCT01805804|DRUG|placebo/valsartan|
223698431|NCT06111521|DRUG|LY3537982|Administered orally
223698432|NCT06111521|DRUG|Digoxin|Administered orally
223698433|NCT06111521|DRUG|Rosuvastatin|Administered orally
223698434|NCT06111521|DRUG|Midazolam|Administered orally
223698435|NCT06111521|DRUG|Midazolam|Administered IV
223698436|NCT05727462|OTHER|Manual Therapy with TECAR|"The following myofascial release techniques will be applied:~Myofascial release of the upper trapezius Gross stretch, vertical gross stretch, and focused stretch of the upper trapezius Myofascial release at the cranial base Gross release of the sternocleidomastoid muscle~Additionally, the following ischemic compression technique will be applied:~Ischemic compression on the upper trapezius muscle Manual therapy manipulations will be administered in combination with a capacitive conventional electrode and two special electrode bracelets that turn the therapist's hands into anti-static electrodes. High-frequency currents will be applied at frequencies of 300 kHz, 500 kHz, and 1 MHz, with a flexible self-adhesive grounding electrode placed on the thoracic spine for reference."
223698437|NCT05727462|OTHER|Manual Therapy without TECAR|Participants in this group will follow the same manual protocol as the first group, without the application of high-frequency current. Each manual therapy session will begin with a ten-minute preparation involving light massage and stretching. The massage will include the effleurage technique, followed by petrissage and kneading, focusing on the cervical and thoracic areas, particularly the upper trapezius, suboccipital region, and cervical paraspinal muscles. Stretching will be applied to the upper trapezius, levator scapulae, and sternocleidomastoid muscles.
223698438|NCT05509751|BEHAVIORAL|GAM, exercise, health education|geriatric assessment, exercise and health education
223698439|NCT05509751|BEHAVIORAL|online chair-based exercise combined with health education|online chair-based exercise and health education for 12 weeks
223698440|NCT04416633|DRUG|Durvalumab|500-mg/120-mg IV
223698441|NCT06288009|PROCEDURE|Running locking suture|In running locking sutures, the first anchoring knot is made at one end of the wound, and a loop of suture is left from the beginning of the throw. The needle is then passed through the loop of suture, locking the suture in place. This is repeated until reaching the end of the wound, where the suture material is then tied to the loop using an instrument tie for the final throw.
223698442|NCT06288009|PROCEDURE|Standard running suture|In standard running sutures, the first anchoring knot is made at one end of the wound, and all of the suture material is pulled through after completing the throw. This is repeated until reaching the end of the wound, where the suture material is then tied.
223698443|NCT04612790|BIOLOGICAL|Benralizumab|"Benralizumab subcutaneously (SC) loading dose followed by repeat dosing of SC benralizumab plus Oral Corticosteroids per SoC tapering.~Open-Label (OLE): after completion of the double-blind treatment period, all participants will have the option of entering an OLE period, starting at week 36 benralizumab SC until study closure."
223698444|NCT04612790|BIOLOGICAL|Placebo|Placebo plus Oral Corticosteroids per SoC tapering. Open-Label (OLE): after completion of the double-blind treatment period, all participants will have the option of entering an OLE period, starting at week 36 benralizumab SC until study closure.
223698445|NCT03881410|PROCEDURE|different types of ultrasound technique|Shear-wave elastography-guided or Convention ultrasound-guided
223698446|NCT05554588|PROCEDURE|Intrathrombus Thrombolysis During Primary PCI|Intrathrombus Thrombolysis During Primary PCI
223698447|NCT05554588|PROCEDURE|Aspiration Thrombectomy During Primary PCI|Aspiration Thrombectomy During Primary PCI
223698448|NCT03764007|DRUG|18F-Fluorocholine|Given intravenously
223698449|NCT03764007|PROCEDURE|Positron Emission Tomography (PET)|Imaging technique that uses radioactive agents known as radiotracers to visualize and measure changes in metabolic processes, and in other physiological activities
223698450|NCT03460938|PROCEDURE|Remote ischemic preconditioning|RIPC: 3 periods of 5 minutes of ischemia followed by 5 minutes of reperfusion are created by inflating a blood pressure cuff on the upper extremity after induction of anesthesia and prior to surgery.
223698451|NCT04255030|BEHAVIORAL|Coping Together Booklets and Workbook|Dyads in this group will complete Coping-Together, a 6-week, booklet-based, self-directed coping and self-management skills training intervention. This intervention addresses key psychosocial challenges by offering evidence-based practical skills to: (a) manage symptoms, (b) cope with anxiety, (c) collaborate with the health care team, (d) engage in shared decision-making, (e) communicate with partner and family, and/or (f) obtain the community resources needed. A relaxation CD is also included, in addition to a workbook that accompanies the Coping-Together booklet-based intervention. The workbook aims at helping dyads choose a booklet relevant to their cancer-related challenges faced, find coping skills that best meet these challenges, and make a plan to use one of the coping skills successfully.
223698452|NCT04255030|BEHAVIORAL|Lay telephone coaching|Dyads will receive Coping-Together support via weekly telephone calls from a lay coach. Sessions will range between 10-15 minutes. The goal of coaching will be to provide information on how to use the workbook and booklets. Although no formal therapy will be provided, the coach will maintain a positive and encouraging attitude when interacting with participants regardless of their adherence to the intervention recommendations. The sessions will start with the coach setting a predetermined agenda based on the section of the workbook to review that week that week. Then, coaches will ask about the use of the booklets over the previous week, and ask participants about any required support or clarification in using the booklets. Sessions conclude with setting a goal related to the workbook, booklets and/or coping technique to focus on over the coming week.
223781233|NCT04802733|BIOLOGICAL|MSK-DA01|MSK-DA01 is an experimental product derived from human embryonic stem cells. The stem cells were converted into brain cells that produce dopamine.
223781234|NCT04802733|DEVICE|MSK-DA01 Cell Delivery Device|A device that is used for injection of fluids into the brain will be used. Some minor modifications have been made to the device to allow delivery of MSK-DA01 cells.
223781235|NCT01343056|BEHAVIORAL|Office Staff Support|The intervention includes the Office staff of primary care practices trained to provide diabetes support for behavioral goal setting were tasked to follow up with patients via phone following completion of diabetes self-management education.
223781236|NCT01343056|BEHAVIORAL|Peer Support|Community peers trained to provide diabetes support for behavioral goal setting were tasked to follow up with patients via phone following completion of diabetes self-management education.
223781237|NCT01343056|BEHAVIORAL|Usual Care Support|Diabetes educators provided patient follow up for behavioral goal setting support according to traditional clinical guidelines following completion of diabetes self-management.
223781238|NCT01343056|BEHAVIORAL|Educator Support|Diabetes educators provided patient follow up for behavioral goal setting support that was problem-focused and patient centered.
223781239|NCT02424916|BIOLOGICAL|Melanoma antigens-specific CD8+ T lymphocytes|The intervention uses an autologous somatic cell therapy medicinal product. It consists in the intravenous injection of melanoma antigens (Melan-A and MELOE-1) - specific CD8+ T lymphocytes followed by subcutaneous injections of Proleukin.
223781240|NCT03293940|PROCEDURE|Cryoablation|The cryoablation procedure, a needle will be inserted and directed toward the target pain area. More than one needle may need to be used. A CT scan will be done during the procedure to help guide the needle which will be held in position by the study doctor(s) once it reaches the target area. With the needle(s) in place, the study doctor(s) will freeze the nerve over 5 minutes. A 3 minutes thaw will follow, then a second 5 minutes freeze and a final 3minute thaw. This portion of the procedure can last from 25 to 45 minutes. Once the nerve has been properly treated, the cryoablation needle(s) will be withdrawn.
223781241|NCT03293940|PROCEDURE|Therapeutic Peripheral Nerve Block (tPNB) Injection|"During the nerve block procedure, a needle will be inserted and directed toward the target pain area. More than one needle may need to be used. A CT scan will be done during the procedure to help guide the needle which will be held in position by the study doctor(s) once it reaches the target area and anesthetic will be injected into the targeted area.~The tPNB injection consists of 4 cc of 0.25% Bupivicaine and 1 cc of 6mg/ml betamethasone."
223781242|NCT03400397|OTHER|Cool Kids programme|A manualised cognitive behavioural treatment programme that consists of 10 session within 12-16 weeks each lasting 2 hours.
223781243|NCT03231371|DRUG|Adenosine|Administration of intravenous adenosine infusion over 3 minutes (0.14 ml/kg, 3mg/ml concentration, total dose).
223781244|NCT00777517|DRUG|Lipitor|A single dose of 10 mg Lipitor tablet
223781245|NCT00777517|DRUG|Atorvastatin pediatric formulation|A single dose of 10 mg atorvastatin pediatric formulation
223698453|NCT04255030|BEHAVIORAL|Motivational Interviewing|Six, 45-60 minute weekly telephone-based sessions with a trained Motivational Interviewing Specialist to progress toward goals. Here, dyads are given one-on-one guidance from a HCP Motivational Interviewing Specialist to practice the skills they need. Calls will focus on problem-solving principles and core components of self-management (70), including: (a) identifying dyads' concerns, (b) reviewing management efforts, (c) identifying goals, (d) identifying skills needed to achieve goals, and (e) addressing barriers to applying skills to current situations, including level of self-efficacy. At each meeting, progress, subsequent goals, and corresponding plans will be discussed.
223698454|NCT05233293|PROCEDURE|Spyglass + RFA|SpyGlass direct Vision guided RFA
223698455|NCT05233293|PROCEDURE|Cytobrush + RFA|After Cytobrush ,taking RFA through ERCP
223781246|NCT06060405|DRUG|Durvalumab|Durvalumab is a monoclonal antibody that blocks the interaction of PD-L1 with PD-1 on immune cells.
223781247|NCT06060405|DRUG|Oleclumab|Oleclumab is a monoclonal antibody that binds to and inhibits the activity of CD73.
223781248|NCT02717091|DRUG|FOLFIRINOX|
223781249|NCT02717091|DRUG|gemcitabine + nab-paclitaxel|
223781250|NCT02201602|DRUG|Gliclazide|
223781251|NCT02201602|DRUG|Glibenclamide|
223781252|NCT04989998|DEVICE|Hip7 Software on Kick/ CORI platforms|Total hip arthroplasty surgery using Hip7 software on Kick or CORI platforms using R3 Polarstem implants.
223781253|NCT04989998|DEVICE|Conventional surgical procedures|THA surgery using standard, manual instrumentation and digital templating techniques using R3 polarstem implants.
223781254|NCT01040611|BEHAVIORAL|Music therapy|Patients who fit the inclusion criteria were random assigned to either experimental or control group. Patients in experimental group could choose a piece of CD and listen to music with earphone for 30 minutes. Patients in control group just rest for 30 minutes. The procedure was implemented once a day, and sustained for total 5 days.
223781255|NCT04574895|OTHER|Hematology Review|VTE study team will review VTE risk percentages provided via automated report daily on weekdays and approach the primary team directly if the patient is appropriate for clinical antithrombotic interventions.
223781256|NCT03532789|DRUG|herbal patch|One patch with medicine should be applied to the skin every other day within two weeks
223781257|NCT03532789|DRUG|placebo patch|One patch without medicine should be applied to the skin every other day within two weeks
223781258|NCT03916003|DRUG|primaquine|Primaquine regimen over 7 days (1.0 mg/kg/day for 7 days)
223781259|NCT04255095|PROCEDURE|experiment|Treatment was randomly selected according to preoperative grouping. After ERCP, naso-pancreatic drainage was chosen as treatment。
223781260|NCT04255095|PROCEDURE|control|Treatment was randomly selected according to preoperative grouping. After ERCP, nasobiliary drainage was chosen as treatment。
223781261|NCT04236349|GENETIC|immunogenetics|blood samples at day 0, week 2, month 2; at the end of treatment (month 6 or month 9 or month 12 depend on treatment duration)
223781262|NCT02970344|BEHAVIORAL|Diabetes Coping Skills Training (DCST)|Diabetes Coping Skills Training (DCST) consist of twelve 50 minutes sessions delivered over 6 months using a faded contact model ( 6 weekly session, 3 biweekly sessions and 3 monthly sessions)
223781263|NCT03795844|PROCEDURE|liver retraction Nathanson retractor|liver retractor will be used for the retraction of left lobe of liver
223781264|NCT03795844|PROCEDURE|liver retraction snake retractor|liver retractor will be used for the retraction of left lobe of liver
223781265|NCT03795844|PROCEDURE|liver retraction fan retractor|liver retractor will be used for the retraction of left lobe of liver
223781266|NCT03795844|PROCEDURE|liver retraction laparoscopic grasper|laparoscopic grasper without any special tools
223781267|NCT03697785|DEVICE|Beacon Care System|Beacon has been developed by Mermaid Care in Denmark. BEACON is a critical care ventilation assist system (http://beaconcaresystem.com/beacon-5/), which potentially enables better ventilation strategies and a more efficient patient care workflow. As an add-on to standard ventilation systems it provides ventilation recommendations 24/7 based on non-stop, personalised monitoring/diagnostics of patients. Based on unique mathematical algorithms and physiological models, it recommends changes in ventilation settings, supporting the critical decision-making processes.
223781268|NCT04008134|BEHAVIORAL|CHoBI7 health facility program|The CHoBI7 health facility program focuses on promoting handwashing with soap and water treatment to diarrhea patients and their household members during the one-week period after the patient is admitted to the health facility, when their household is at highest risk for diarrheal diseases. The CHoBI7 program includes: (1) a WASH pictorial module delivered by a health worker bedside to diarrhea patient and their household members in a health facility on handwashing with soap, water treatment, and safe water storage; and (2) a diarrhea prevention package containing chlorine tablets for water treatment, a soapy water bottle (water and detergent powder), a handwashing station, and a water vessel with a lid and tap for safe drinking water storage. Households are instructed to boil their water once their supply of chlorine tablets is completed.
224263728|NCT03022643|OTHER|Bright Light Device|All patients will be provided with a bright light device (Re-Timer) and will be instructed to use it in the first 2-hours of the day (for a minimum of 30 minutes) throughout the 8-week treatment period.
224263729|NCT00679081|DEVICE|CelTx|Single application; split-mouth design
224263730|NCT00679081|OTHER|Autologous sub-epithelial connective tissue graft|Single application; split-mouth design
224263731|NCT01366781|OTHER|Meal ingestion|Meal 511 kcal, meal 743 kcal or meal 1034 kcal
224263732|NCT06602362|OTHER|Partnered sex involving choking|When a subject submits a survey indicating that they engaged in partnered sex involving choking, they will be asked to come in for data collection within 24 hours of survey submission.
224263733|NCT06602362|OTHER|Partnered sex not involving choking|When a subject submits a survey indicating that they engaged in partnered sex that did not involve any choking, they will be asked to come in for data collection within 24 hours of survey submission.
224263734|NCT06999798|PROCEDURE|Diagnostic Mammography|Undergo mammography
224263735|NCT06999798|PROCEDURE|Resection|Undergo surgical resection of the lymph node as part of standard care.
224263736|NCT06999798|PROCEDURE|Ultrasound Imaging|Undergo ultrasound imaging. Ultrasound images will be evaluated for presence and visibility/conspicuity of the twinkling marker.
224263737|NCT06999798|DEVICE|Twinkling Marker Placement|Undergo ultrasound-guided placement of the optimized twinkling marker into the positive lymph node after confirmation of metastatic axillary lymph node involvement.
224263738|NCT07001124|DIAGNOSTIC_TEST|duochrome test and +1 blur test|"The participant is seated at a standard testing distance (typically 6 meters or 20 feet). A duochrome chart with black letters on a split red-green background is presented.~After determining the subjective refraction, a +1.00 diopter (DS) lens is added to the final prescription. The participant is asked to read the distance visual acuity (VA) chart. The expectation is that the visual acuity should drop to 4 lines on Snellen chart (6/24) when the +1.00 DS lens is added. If VA reduces to 6/24: Indicates that the refraction is not over-minused or over-plussed (proper end point of refraction). If VA remains better than 6/24: Suggests the patient was still accommodating, possibly leading to over-minus (in myopes) or under-plus (in hyperopes) and the refraction should be re-evaluated."
223698456|NCT02671409|OTHER|Neural Mobilization (exercise)|Initially patients will be informed about the procedures. After the guidelines, the hip and knee are palpated to start the joint angles. Then, the knee joint is positioned in extension and remained so throughout the treatment. In addition, the hip joint is bent until the moment that will be perceived a minimum strength of the muscles of the posterior region of thigh and leg (discarding muscle stretching). Neural mobilization is started at the time when the ankle joint will be manipulated in dorsiflexion at a frequency of approximately 20 oscillations per minute, with a pause of 25 seconds of rest. In the last two minutes of therapy, we will include cervical flexion, in order to intend the neuraxis, keeping artuculares amplitudes.
223698457|NCT05221307|OTHER|exercises|Group 1 will be given MPEs for 45 minutes, 3 days a week for 8 weeks. In the second group, traditional Neurodevelopmental Treatment (NGT-Bobath) approach will be applied for 45 minutes a day, 3 days a week for 8 weeks. Treatments will be carried out by the same physiotherapist. Evaluations will be made twice, before and after the treatment.
223698458|NCT02405754|DIAGNOSTIC_TEST|Corus CAD (ASGES)|Age/Sex/Gene Expression Score - ASGES
223698459|NCT00098098|BIOLOGICAL|rBV A/B|
223698460|NCT02938039|DEVICE|Ambu LMA|Ambu Laryngeal Mask Airways
223698461|NCT02938039|DEVICE|I-Gel LMA|I-Gel Laryngeal Mask Airways
223698462|NCT01914731|DRUG|Fecal Microbiota Transplant|"Reconstitution of normal flora by a stool transplant from a healthy individual to a C. difficile - infected recipient via frozen capsule"
223698463|NCT00807131|BEHAVIORAL|Patient follow-up|Dader method, which was developed to provide pharmaceutical care, which consists of seven steps covering the evaluation of services, benefits of interventions, and identification of unexpected occurrences. Its objectives are to improve the patient quality of life.
223698464|NCT00807131|BEHAVIORAL|Counseling|The pharmacist proceeds the counseling when the patient comes to the pharmacy to take their medicines.
223698465|NCT00807131|BEHAVIORAL|Drug dispensing|The pharmacist gives the drugs to the patient with the minimum of information necessary to guarantee a safe and effective drug intake.
223698466|NCT00807131|BEHAVIORAL|pharmacy usual care|The patient receives no information about their medicines in the pharmacy, unless he asks for it.
223698467|NCT00251173|BEHAVIORAL|Strengths Based Case Management (SBCM)|
223698468|NCT00251173|BEHAVIORAL|Motivational Enhancement Therapy (MET)|
223698469|NCT00251173|BEHAVIORAL|Brief Informational Feedback (BIF) session|
223698470|NCT03610438|DRUG|Inotuzumab Ozogamicin (IO)|"After course 1 MRD will be evaluated:~\- patients MRD negative will enter into short maintenance or long maintenance according to investigator choice. After 4 to 12 weeks in short maintenance patient will undergo SCT, otherwise, patients will enter long maintenance."
223698471|NCT03610438|DRUG|Inotuzumab Ozogamicin (IO)|After course 2 MRD will be evaluated; patients MRD negative will enter into short maintenance or long maintenance by investigator choice. After 4 to 12 weeks in short maintenance patient will undergo SCT, otherwise, patients will enter long maintenance.
223698472|NCT03412708|OTHER|Vestibular Rehabilitation supported with Virtual Reality|Patients will perform the supervised vestibular exercises in virtual reality environment using a virtual reality goggle (Samsung Gear VR SM323) and a smartphone (Samsung Galaxy S7). The virtual environments consist of 2 media provided by the videos taken with a 360 camera (Samsung Gear 360). 1) A square with people moving, noise and traffic and 2) A supermarket where the shelves are full.
223698473|NCT02373722|PROCEDURE|Mohs Surgery|Undergo Mohs surgery
223698474|NCT02373722|OTHER|Internet-Based Intervention|Watch website application based educational video
223698475|NCT02373722|BEHAVIORAL|Telephone-Based Intervention|Receive text messages
223698476|NCT02373722|OTHER|Educational Intervention|Watch website application based educational video
223698477|NCT02373722|BEHAVIORAL|Exercise Intervention|Use Fitbit
223698478|NCT02373722|OTHER|Petrolatum-Mineral Oil-Lanolin-Ceresin Ointment|Applied to the wound area
223698479|NCT02373722|OTHER|Questionnaire Administration|Ancillary studies
223698480|NCT02373722|OTHER|Survey Administration|Ancillary studies
223698481|NCT02402101|DEVICE|Procedure: active tDCS|Intensity 2 mA during 20 minutes
223698482|NCT02402101|DEVICE|Procedure: sham tDCS|sham condition as delivered by the stimulator
223698483|NCT05804097|DRUG|Hyperbaric oxygen|90-120 min sessions of hyperbaric oxygen treatment of 2.2-2.5 ATA
223698484|NCT01649050|DRUG|BGG492|
223698485|NCT01649050|DRUG|Placebo|
223698486|NCT00320931|DEVICE|Hybrid PET/CT|Rest and vasodilation stress rubidium PET and coronary angiography with CT were performed using standard doses for clinically indicated studies.
223698487|NCT06101550|PROCEDURE|partial pulpotomy|Partial removal of pulp tissue in young permanent teeth
223698488|NCT06101550|PROCEDURE|Complete pulpotomy|Complete removal of pulp tissue in young permanent teeth
223698489|NCT05441761|DRUG|liposomal mitoxantrone hydrochloride, gemcitabine, dexamethasone, and cisplatin|"Drug: Liposomal mitoxantrone hydrochloride (12 mg/m2, 16 mg/m2, 20 mg/m2) will be administered by an intravenous infusion on day 1 of each 21-day cycle.~Drug: gemcitabine (1000 mg/m2) will be administered by an intravenous infusion on day 1 of each 21-day cycle.~Drug: dexamethasone (40 mg) will be administered on day 1-4 of each 21-day cycle.~Drug: cisplatin (75 mg/m2) will be administered by an intravenous infusion on day 1 of each 21-day cycle."
223698490|NCT01252381|OTHER|12 weeks Strength exercise training|Training 3 times a week, leg extensions and leg press
223698491|NCT03572244|DEVICE|Laser-Lok|A microgrooved abutment will be placed
223698492|NCT03572244|DEVICE|Machined|A machined transmucosal healing abutment will be placed
223698493|NCT04872153|BEHAVIORAL|Dividat Senso Exergames|"The intervention period in the rehabilitation setting will be equal to the length of the stay in the rehabilitation clinic (between 2-3 weeks, according to each cantonal/regional regulations and insurance coverage) and will include short daily training sessions using the Senso (5x/week à 10- 15min), resulting in 15 to 20 training sessions in total.~Each session contains various combinations of the Dividat exergames (each of the games lasts around 2-3min)."
223698494|NCT00093548|BIOLOGICAL|alpha fetoprotein adenoviral vector vaccine|
223698495|NCT00093548|BIOLOGICAL|alpha fetoprotein plasmid DNA vaccine|
223698496|NCT00093548|BIOLOGICAL|sargramostim plasmid DNA hepatocellular carcinoma vaccine adjuvant|
223698497|NCT03731039|OTHER|Observational study|Pain assessment, Anxiety assessment, Depression assessment
223698498|NCT01669499|DRUG|Dexamethasone acetate|
223698499|NCT01669499|DRUG|Placebo|
223698500|NCT05021081|DEVICE|TRP-200|JJVC Investigational Contact Lens
223698501|NCT05021081|DEVICE|ACUVUE Oasys 1-Day|JJVC Marketed Contact Lens
223698502|NCT03055182|OTHER|Physical rehabilitation program|Patients participate during 4 weeks to a physical rehabilitation program.
223698503|NCT04935281|OTHER|percutaneous repair with an intraoperative assisted ultrasound|Under general or regional anesthesia, the patient laid in prone position In group A, an intraoperative ultrasound was done by a radiologist before the repair .
223698504|NCT04935281|OTHER|percutaneous repair without an intraoperative assisted ultrasound|For patients in group B, the course of the sural nerve was determined according to the technique described by Blackmon et al.The medial and lateral borders of both stumps were outlined by palpation with identification of the gap in-between. We used the technique described byMaffulli et al with six stab incisions, one cm each. Four incisions were on medial and lateral edge of the proximal stump and the other two were around distal stump.
223698505|NCT04137432|DRUG|Oxytocin nasal spray|Intranasal administration of 24 international units oxytocin.
223698506|NCT04137432|DRUG|Placebo|The placebo nasal sprays contains identical ingredients except for the peptide itself.
223698507|NCT05438784|PROCEDURE|orbital bone reconstruction with patient specific titanium implant|orbital defects reconstruction will be virtually planned by software and a patient specific titanium implant will be manufactured using milling technique depending on CAD-CAM technology
223698508|NCT05438784|PROCEDURE|orbital bone reconstruction with preformed titanium plate preoperatively bended on stereolithographic model|orbital defects reconstruction will be virtually planned by software and a reconstructed stereolithographic model will be 3D printed and used for preoperatively bending of preformed titanium implant.
223698509|NCT00369122|BIOLOGICAL|Bevacizumab|Given IV
223698510|NCT00369122|DRUG|Cisplatin|Given IV
223698511|NCT00369122|RADIATION|External Beam Radiation Therapy|Undergo EBRT
223698512|NCT00369122|RADIATION|Internal Radiation Therapy|Undergo brachytherapy
223698513|NCT00334685|DRUG|[S,S]-Reboxetine + Pregabalin|\[S,S\]-Reboxetine oral, tablet 2, 4 or 6 mg per day for 10 weeks Pregabalin oral, capsule, 75, 150, 300 or 600 mg per day for 14 weeks
223698514|NCT00334685|DRUG|Pregabalin|Pregabalin oral, capsule, 75, 150, 300 or 600 mg per day for 14 weeks
223698515|NCT00235469|DRUG|SPM 927|
223698516|NCT00252824|DRUG|Budesonide/formoterol Turbuhaler vs Conventional Best Asthma Therapy|
223698517|NCT00408629|BIOLOGICAL|adalimumab|Prefilled syringe, 40 mg, 160 mg at Week 0, 80 mg at Week 2, and 40 mg every other week between Weeks 4 and 50.
223698518|NCT00408629|BIOLOGICAL|placebo|Matching Placebo for prefilled syringe, 40 mg,
223698519|NCT01660204|OTHER|Preferred empirical treatment|The investigators are using a cluster-randomized cross-over design for preferred empirical treatment. One of the 3 treatment arms is used as preferred empirical therapy during a period of 4 consecutive months, after which preferred treatment will rotate to 1 of the other 2 regimens. The order of change is randomised per hospital, thereby controlling for inter-hospital variables and minimizing seasonal influences.
223698520|NCT01315964|DIETARY_SUPPLEMENT|plant stanol ester|3 gr of plant stanol esters per day in a margarine product as part of daily diet for a period of 6 months
223698521|NCT06169293|BEHAVIORAL|I-AM-WELL|"The I-AM-WELL program adopts an asynchronous online learning approach and will be delivered over one week by a trained counsellor, and a nurse researcher.~Students will attend an online self-paced program. The program will comprise of topics such as: (1) Resilience and protective factors, (2) introduction to clinical nursing education, (3) experiences of clinical attachments, and (4) stress, physical wellbeing and diet materials. Students will have access to online materials (e.g., short videos), have opportunities to discuss (e.g., forum) and infographics.~Overall, the program will be delivered over in one week lasting six hours."
223698522|NCT06557486|BEHAVIORAL|Mindfulness-Based Stress reduction|Participants assigned to the 8-week mindfulness program attended weekly 120-150 minute in-person group sessions for the entire duration. In these sessions, the instructor progressively will introduce and guide formal mindfulness practices while facilitating the sharing of experiences.
223698523|NCT01800396|DIETARY_SUPPLEMENT|Milk protein|
223698524|NCT01800396|DIETARY_SUPPLEMENT|Milk protein rich in phospholipids|
223698525|NCT06533917|DEVICE|Main Group|Thoracolumbar spine AP, Thoracolumbar spine LAT
223698526|NCT00191906|DRUG|Atomoxetine Hydrochloride|Atomoxetine, 1.2 mg/kg/day, by mouth (PO)
223698527|NCT00191906|DRUG|placebo|Placebo, every day (QD), by mouth (PO)
223698528|NCT05247593|DRUG|Dayingpian|The actual dosage of Dayingpian is adjusted according to the patient's condition. The recommended dosage of Dayingpian is 5-10 tablets each time, 2-3 times a day.
223698529|NCT05247593|DRUG|conventional mood stabilizers|Patients in the group are treated with the standard level of conventional mood stabilizers provided by psychiatrists according to treatment guidelines for bipolar disorder.
223698530|NCT06167564|DIAGNOSTIC_TEST|Routine allergy tests|Prick test, specific IgE detection
223698531|NCT06167564|DIAGNOSTIC_TEST|Newly developed microarray-based diagnostic test system|Newly developed microarray-based diagnostic test system for the detection of the specific IgE
223698532|NCT04948515|DIAGNOSTIC_TEST|laboratory test|genotyping of IL 17 and IL23
223698533|NCT04948515|DIAGNOSTIC_TEST|laboratory test|estimation of serum level of IL 17
223698534|NCT00573937|DRUG|Methadone|Oral methadone 2.5 mg every 8 hours, and oral methadone 2.5 mg every 4 hours as needed for breakthrough pain.
223698535|NCT00573937|DRUG|Morphine|Oral slow-release morphine 15 mg every 8 hours, and oral immediate-release morphine 10 mg every 4 hours as needed for breakthrough pain.
223698536|NCT02112344|RADIATION|IMRT|
223698537|NCT00333801|BEHAVIORAL|Vocational Rehabilitation Program (VRP)|Vocational Rehabilitation Program (VRP) is a treatment-as-usual method using traditional train-place approaches, such as prevocational work skills training , compensated work therapy, or transitional work experience, which consists of temporary employment in a brokered-job with time-limited support from the VRP specialist
223698538|NCT00333801|BEHAVIORAL|Individual Placement and Support (IPS)|Individual Placement and Support (IPS) is an evidence--based model of supported employment that emphasizes rapid job search within client preferences, community job development, placement in a competitive job, on-the-job training, time-unlimited follow-along supports, and integration of the IPS specialist within the treatment team.
223698539|NCT02059902|DRUG|Lidocaine|Lidocaine infusion runs for a total of 24 hours
223698540|NCT02059902|OTHER|Placebo|Normal saline runs for a total of 24 hours
223698541|NCT04275570|BEHAVIORAL|Motivational interview|The motivational interview is integrated in a structural theoretical mark. This method is a person-centered counseling style that increases the intrinsic motivation of the patient to behavioral changes through spirit, acceptance, compassion and evocation.
223698542|NCT00693849|DRUG|Escitalopram|10 mg/day as a single dose, increased to max 20 mg/day
223698543|NCT00693849|DRUG|Sertraline|50 mg/day as a single dose, increased to max of 200 mg/day
223698544|NCT00693849|DRUG|Venlafaxine-XR|75 mg/day given once daily; increased to 150-225 mg/day
223698545|NCT04543825|DEVICE|Cardiopulmonary exercise testing|Subjects will perform cardiopulmonary exercise testing which consists of biking on a cycle ergometer (recumbant stationary bicycle) while breathing through a mouthpiece or mask to measure the oxygen and carbon dioxide in the subject's breath. We will also do impedance cardiography, an FDA-approved test to check how the heart functions during exercise. For this test we will attach 6 electrodes (total) to the chest and back (similar to an EKG), so that we can measure the quantity of blood coming out of the heart on every heartbeat. Each evaluation will also include cardiac testing looking for coronary artery disease (CAD).
223698546|NCT00978978|DRUG|Propofol VS. midazolam and fentanyl, endoscopies, liver diseases|"1. Intervention group (Propofol): It will be administered as a monotherapy under direct gastroenterologists'~2. Control group (Midazolam with or without Fentanyl): Both drugs will be administered by the gastroenterologists"
223698547|NCT03532061|BEHAVIORAL|FamCare Program|6 in-person sessions of biweekly home care problem-solving skills training (FamCare) delivered by a health educator.
223698548|NCT03532061|OTHER|Caregiver Support Group|6 in-person caregiver support group sessions held biweekly and moderated by a health educator.
223698549|NCT05129423|DRUG|MTPS9579A|MTPS9579A will be administered.
223698550|NCT05129423|DRUG|Placebo|Placebo matched with MTPS9579A will be administered.
223698551|NCT04894448|BIOLOGICAL|COVID-19 Vaccine|Any COVID-19 vaccine (1 or more doses)
223698552|NCT05406141|DIETARY_SUPPLEMENT|Amino acid formula (Neocate Jr)|"Use Neocate Jr for 4 weeks, either as sole source of nutrition or oral nutritional supplement:~* Sole source of nutrition: as far as possible \>7 days, especially newly diagnosed allergy children~* Oral nutritional supplement (Neocate Jr ≥50% of daily total energy and the rest provided by food)"
223698553|NCT00259454|BEHAVIORAL|In-home intervention|occupational therapy techniques to reduce caregiver stress
223698554|NCT03464877|OTHER|Multi-station full-body supervised exercise program|The exercise program was 6-week duration, 2-3 visits per week. It was composed of 7 stations, each consisting of numerous exercises of increasing difficulty. The exercises were grouped together as follows: Hip strengthening and control (Station 1); The squat and its variants (Station 2); Elastic bands and the Bodyblade (Station 3); Abdominal planks and their variants (Station 4); Abdominal strengthening (Station 5); Back extensor strengthening (Station 6); and Lifting techniques (Station 7).
223698555|NCT06302478|BEHAVIORAL|5E program|"Participants in the 5E program group will receive 7-day nursing interventions including~* Education: health education regarding venous thromboembolism prevention~* Elevation: leg elevation of 10-20 degrees~* Exercise: ankle exercises~* Enough fluid: adequate fluid uptake~* Early application of intermittent pneumatic compression (IPC): IPC use within 48 hours after admission"
223698556|NCT02470416|DEVICE|Small bowel video capsule endoscopy (VCE) GIVEN/COVIDIEN LTD|Cases and controls will have a standard VCE procedure at our institution.
223698557|NCT00425347|DRUG|HuLuc63|Not applicable for HuLuc63.
223698558|NCT01365247|BEHAVIORAL|Concurrent Treatment of PTSD and Substance Use Disorders Using Prolonged Exposure|A manualized, twelve-week intervention applying cognitive-behavioral strategies and prolonged exposure (PE) techniques to address substance use and trauma related issues.
223698559|NCT01365247|BEHAVIORAL|Relapse Prevention Treatment|Relapse Prevention Treatment is a cognitive-behavioral skills training approach to initiating and maintaining substance use-related goals.
223698560|NCT01365247|BEHAVIORAL|Active Monitoring Control Group|Participants meet with study staff on a weekly basis for the self-monitoring of PTSD and SUD symptoms. Visits consists of self-report assessments, urine toxicology, and a brief check-in with staff to confirm general health and safety.
223698561|NCT02407418|OTHER|Spinal Manipulation|Side-posture, high-velocity low-amplitude spinal manipulation targeting the lumbar spine and sacroiliac joints
223698562|NCT02407418|OTHER|Sham Manipulation|A simulated lumbar spine manipulation in which no vertebral contact was made
223698563|NCT02566447|DEVICE|Solana Trichomonas Assay Testing|Specimen collection of urine and/or vaginal swabs for testing
223698564|NCT03218709|COMBINATION_PRODUCT|High-dose multi-vitamins with minerals|The high-dose multi-vitamins with minerals contained vitaminB1 0.72mg,vitamin B20.72mg,vitamin B12 1.35μg,folic acid 0.37mg,vitamin C 0.27mg,vitamin D 5.04μg,selenium 30.5μg per pill, respectively.
223698565|NCT03218709|COMBINATION_PRODUCT|Low-dose multi-vitamins with minerals|The low-dose multi-vitamins with minerals contained vitaminB1 0.72mg,vitamin B20.72mg,vitamin B12 1.35μg,folic acid 0.20mg,vitamin C 0.50mg,vitamin D 5.04μg,selenium 30.5μg per pill, respectively.
223698566|NCT03218709|COMBINATION_PRODUCT|Hypouricemic tablets|The hypouricemic tablets contained skipjack,salvia and rosemary extract.
223698567|NCT03218709|COMBINATION_PRODUCT|Placebo|The placebo tablets contained maltodextrin and tartrazine.
223698568|NCT02548416|PROCEDURE|Positive end-expiratory pressure|"Induction of anaesthesia is performed in a conventional manner using a target controlled infusion of propofol and remifentanil. Intubation of the trachea is facilitated by rocuronium.~As soon as correct position of the endotracheal tube is confirmed, controlled ventilation is started with a tidal volume of 7 mL/kg body weight and a respiratory frequency of 10. The fresh gas flow is set to 1 litre/min with an oxygen mixture of 40%, aiming for an inspired oxygen fraction (FiO2) of 30-35%. Positive end-expiratory pressure is set to 6 or 8 cm H20 (8 if BMI\>25) in the intervention group.~Unless the patient´s SpO2 falls below 90%, the FiO2 remains unchanged throughout the procedure."
223698569|NCT02548416|PROCEDURE|Control group, zero PEEP|"Induction of anaesthesia is performed in a conventional manner using a target controlled infusion of propofol and remifentanil. Intubation of the trachea is facilitated by rocuronium. As soon as correct position of the endotracheal tube is confirmed, controlled ventilation is started with a tidal volume of 7 mL/kg body weight and a respiratory frequency of 10. The fresh gas flow is set to 1 litre/min with an oxygen mixture of 40%, aiming for an inspired oxygen fraction (FiO2) of 30-35%. Zero PEEP is used.~Unless the patient´s SpO2 falls below 90%, the FiO2 remains unchanged throughout the procedure."
223698570|NCT05330572|OTHER|No interventions were administered to the patients as a part of this study.|No interventions were administered to the patients as a part of this study. Patients who were under topical steroid regime as a part of their management plan for lichen planus will be enrolled on the study. Details of prescribed topical steroid regime for lichen planus: type of corticosteroid, formulation, frequency of application, duration of treatment will be recorded.
223698571|NCT03207204|PROCEDURE|35% Hydrogen peroxide bleaching|Application of 35% hydrogen peroxide on buccal face of anterior teeth (15-25). The application will be performed according to the manufacturer's instructions.
223698572|NCT03207204|PROCEDURE|30% Carbamide peroxide bleaching|Protocol: Application of 35% Carbamide peroxide on buccal face of anterior teeth (15-25). The application will be performed according to the manufacturer's instructions.
223698573|NCT03207204|PROCEDURE|Violet LED bleaching 1|Protocol: Application of the Violet LED on buccal face of anterior teeth (15-25) with a distance of 8mm between the light source and teeth surface. The application will be performed for 60s, and then turned off for 30s. It will be repeated for 20x. The procedure will be performed 1 time a week.
223698574|NCT03207204|PROCEDURE|Violet LED bleaching 2|Protocol: Application of the Violet LED on buccal face of anterior teeth (15-25) with a distance of 8mm between the light source and teeth surface. The application will be performed for 60s, and then turned off for 30s. It will be repeated for 20x. The procedure will be performed 2 times a week.
223698575|NCT03207204|PROCEDURE|Photochemical protocol 1|Protocol: Application of 35% hydrogen peroxide on buccal face of anterior teeth (15-25). The application will be performed according to the manufacturer's instructions and associated with the application of Violet LED with a distance of 8mm between the light source and teeth surface. The application of Violet LED will be performed for 60s, and then turned off for 30s. It will be repeated for 20x. The procedure will be performed 1 time a week.
223698576|NCT03207204|PROCEDURE|Photochemical protocol 2|Protocol: Application of 30% Carbamide peroxide on buccal face of anterior teeth (15-25). The application will be performed according to the manufacturer's instructions and associated with the application of Violet LED with a distance of 8mm between the light source and teeth surface. The application of Violet LED will be performed for 60s, and then turned off for 30s. It will be repeated for 20x. The procedure will be performed 1 time a week.
223698577|NCT03207204|PROCEDURE|Hybrid technique 1|Protocol: Application of the Violet LED on buccal face of anterior teeth (15-25) with a distance of 8mm between the light source and teeth surface. The application will be performed for 60s, and then turned off for 30s. It will be repeated for 20x. In the last 10 illuminations of Violet LED it will be applied the 35% Hydrogen peroxide to act concomitantly with the light.
223698578|NCT03207204|PROCEDURE|Hybrid technique 2|Protocol: Application of the Violet LED on buccal face of anterior teeth (15-25) with a distance of 8mm between the light source and teeth surface. The application will be performed for 60s, and then turned off for 30s. It will be repeated for 20x. In the last 10 illuminations of Violet LED it will be applied the 30% Carbamide peroxide to act concomitantly with the light.
223698579|NCT01999114|DRUG|Buprenorphine transdermal patch|Buprenorphine patch applied transdermally
223781269|NCT04008134|BEHAVIORAL|CHoBI7 mHealth program|The CHoBI7 mHealth (mobile health) program targets five key behaviors: (1) preparing soapy water using water and detergent powder; (2) handwashing with soap at food and stool related events; (3) treating household drinking water using chlorine tablets during the one week high risk period after the diarrhea patient in the household was admitted to the health facility; (4) safe drinking water storage in a water vessel with a lid and tap; and (5) heating of household drinking water until it reaches a rolling boil after the one week high risk period. Participant households receive bi-weekly voice and text messages from the CHoBI7 mHealth program over a 12-month period. These mobile messages are sent using the VIAMO platform (www.viamo.io).
223781270|NCT04008134|BEHAVIORAL|CHoBI7 home visit program|The CHoBI7 home visit program involves two, 30-minute home visits conducted during the week after the index diarrhea patient was recruited at the health facility. A health worker reinforces the content of the CHoBI7 health facility program in the participant's home.
223781271|NCT01030224|DRUG|AZD9742|Increasing single IV infusion doses of AZD9742 given to approximately 6 cohorts of 8 subjects each (6 on active and 2 on placebo). Specific doses will be selected by the safety review committee
223781272|NCT01030224|DRUG|Placebo to match AZD9742|Single IV infusion of AZD9742 placebo given to approximately 6 cohorts of 8 subjects each (6 on active and 2 on placebo)
223781273|NCT05211219|DIETARY_SUPPLEMENT|Probiotics|According to the groups, they were involved simultaneously with the treatment, kefir group was advised to consume kefir as a liquid once a day in 14 days; the probiotics group was advised to consume as a chewable tablet once a day in 14 days; the control group was advised without additional food supplements.
223781274|NCT05211219|DIETARY_SUPPLEMENT|AOÇ Kefir|AOÇ Kefir
223781275|NCT05211219|OTHER|Food without additional food supplements|Food without additional food supplements
223781276|NCT03701659|PROCEDURE|Surgery combinate with Endocrine therapy|TUPKRP is abbreviation of transurethral plasma kinetic resection of prostate, which is an effective treatment of bladder outlet obstruction for benign prostate hyperplasia. MAB is abbreviation of Maximal androgen blockade, which is a kind of endocrinotherapy for advanced prostate cancer.
223781277|NCT03701659|DRUG|Endocrine therapy|MAB is abbreviation of Maximal androgen blockade, which is a kind of endocrine therapy for advanced prostate cancer.
223698580|NCT01999114|DRUG|Naltrexone tablet|Naltrexone tablet; 1 tablet taken orally every 12 hours
223781278|NCT01961830|DRUG|ME1100 inhalation solution|
223781279|NCT00720616|DRUG|Norditropin|Norditropin 0.1 mg/day self-administered once a day subcutaneously
223781280|NCT01070004|OTHER|Real driving situation|Continuous blue light exposure during driving compared to effects of coffee (2\*200 mg of caffeine) and coffee placebo on 4h night-time real driving situation. Inside this arm, each volunteer will be randomly allocated and will all receive : continuous blue light exposure, coffee and coffee placebo at each driving session with at least 1 week between each condition.
223781281|NCT01070004|OTHER|Driving simulator|15 minutes of physical activity at a low intensity before driving compared to effects of coffee (2\*200 mg of caffeine) and coffee placebo on 4h night-time driving simulator. Inside this arm, each volunteer will be randomly allocated and will all receive : 15 minutes of physical activity, coffee and coffee placebo at each driving session with at least 1 week between each condition.
223781282|NCT05166018|DIAGNOSTIC_TEST|SuMO Patient|"The current study is interventional insofar as the patient is collecting all of his socio-medical information. The analysis of the data provided by the patient makes it possible to establish a long-term prognosis for the patient but does not in itself constitute a parallel medical approach.~SUMO allows the surgeon to transmit post-operative advice developed by the surgeons themselves."
223698581|NCT01999114|DRUG|Placebos (for TDS and for naltrexone and for moxifloxacin)|Matching placebos
223698582|NCT01999114|DRUG|Moxifloxacin tablet|Moxifloxacin tablet; 1 tablet taken orally on Days 6, 13 and 17
223698583|NCT05052658|PROCEDURE|Neuraxial block placement|The time and ease of administering neuraxial blocks in high BMI patients,for the management of labor and delivery pain, will be assessed.
223698584|NCT04659720|DEVICE|Hydrolic lifter device|evaluation of implant stability after closed sinus lifting by hydraulic lift technique using hydraulic lifter device
223698585|NCT04659720|BEHAVIORAL|Patient satisfaction evalution using hydraulic lifter device|patients satisfaction will be evaluated numerically after using hydraulic lift technique by hydraulic lifter device for closed sinus lifting in posterior edentulous maxilla
223698586|NCT01446926|BIOLOGICAL|Pneumococcal Vaccine High Dose (Formulation 1)|0.5 mL, Intramuscular
223698587|NCT01446926|BIOLOGICAL|Tris buffered saline (Placebo)|0.5 mL, Intramuscular
223698588|NCT01446926|BIOLOGICAL|Pneumococcal Vaccine High Dose (Formulation 1)|0.5 mL, Intramuscular
223698589|NCT01446926|BIOLOGICAL|Tris buffered saline (Placebo)|0.5 mL, Intramuscular
223698590|NCT01446926|BIOLOGICAL|Pneumococcal Vaccine Low Dose (Formulation 2)|0.5 mL, Intramuscular
223698591|NCT01446926|BIOLOGICAL|Tris buffered saline (Placebo)|0.5 mL, Intramuscular
223698592|NCT01446926|BIOLOGICAL|Pneumococcal Vaccine Middle Dose (Formulation 3)|0.5 mL, Intramuscular
223698593|NCT01446926|BIOLOGICAL|Pneumococcal Vaccine Middle Dose (Formulation 4)|0.5 mL, Intramuscular
223698594|NCT01446926|BIOLOGICAL|Tris buffered saline (Placebo)|0.5 mL, Intramuscular
223698595|NCT01446926|BIOLOGICAL|Pneumococcal Vaccine High Dose (Formulation 1)|0.5 mL, Intramuscular
223698596|NCT01446926|BIOLOGICAL|Tris buffered saline (Placebo)|0.5 mL, Intramuscular
223698597|NCT04108702|DEVICE|Virtual reality heart|"Patients will either sit or stand while wearing a head mounted display (HMD, Oculus Rift). A 360° video, showing a neutral body from the back in a neutral room, will be projected onto the HMD.~We will record the patients' ECG throughout the entire experiment. Raw data (ECG) are acquired with Arduino and in-house software will detect, in real time, the peak of each R-wave from the recorded ECG data and trigger an additional visual stimulus (e.g. a flashing outline surrounding the virtual body) that flashes on and off SYNCHRONOUSLY with respect to the participant's heartbeat. The silhouette surrounding the virtual body flashes for a duration of 100ms and with a sinusoidal opacity."
223698598|NCT04108702|DEVICE|Virtual reality control|"Patients will either sit or stand while wearing a head mounted display (HMD, Oculus Rift). A 360° video, showing a neutral body from the back in a neutral room, will be projected onto the HMD.~We will record the patients' ECG throughout the entire experiment. Raw data (ECG) are acquired with Arduino and in-house software will detect, in real time, the peak of each R-wave from the recorded ECG data and trigger an additional visual stimulus (e.g. a flashing outline surrounding the virtual body) that flashes on and off ASYNCHRONOUSLY with respect to the participant's heartbeat. The silhouette surrounding the virtual body flashes for a duration of 100ms and with a sinusoidal opacity."
223698599|NCT04108702|OTHER|Standard therapy|Standard multimodal out-patient therapy program (psychological support, physiotherapy, ergotherapy).
223698600|NCT02351375|OTHER|diet|A controlled diet will be provided to participants which consists of either high protein/low carbohydrate, or of low protein/high carbohydrate.
223698601|NCT02351375|DEVICE|IntelliCap® system|
223698602|NCT05841836|DEVICE|the Suture-Mediated Closure System|To reduce the TTH(Time to hemostasis) and TTA(Time to ambulation)of common femoral artery(CFA) puncture site
223698603|NCT05841836|DEVICE|Perclose ProGlide Suture-Mediated Closure System|To reduce the TTH(Time to hemostasis) and TTA(Time to ambulation)of common femoral artery(CFA) puncture site
223698604|NCT01388595|DRUG|FLUTICASONE PROPRIONATE|1\. Fluticasone Propionate (FP) Product name: Flixotide Evohaler® Manufacturer: Allan and Hanbury's Active ingredients: Fluticasone Propionate Propellant: HFA 134a Dose: 250μg per actuation giving a total dose of 500µg per day through the spacer device with the customised nasal adaptor.
223698605|NCT01388595|DRUG|Salmeterol|Salmeterol Product Name: Serevent® Manufacturer: Allan and Hanbury's Active ingredients: Salmetrol Xinafoate Propellant: HFA 134a Dose: 25μg per actuation giving a total dose of 50µg per day through the spacer device with the customised nasal adaptor
223698606|NCT01388595|DRUG|PLACEBO|4\. Placebo inhaler to SM, FP, SM+FP Manufacturer: Cipla Ltd Active ingredients: None Propellants: HFA 134a Imported \& QP release tested in UK : DHP Clinical supplies, Powys, UK
223698607|NCT01497275|DRUG|Rituximab, Bortezomib,Y90 ibritumomab tiuxetan|Rituximab 250mg/m2 will be given on day 1 and on day 8. Bortezomib 1.5mg/m2 will be given on Days 1, 4, 8, and 11. Y90 ibritumomab tiuxetan will be given on Day 8. Dosage will be based on the platelet count obtained at the time of study enrollment. The dose will be 0.4mCi/kg unless the enrollee's platelets are between 100,000 and 150,000 in which case a dose of 0.3mCi/Kg will be used. Patients who weigh over 80 Kg will receive a maximum dose of 32mCi.
223698608|NCT04069962|BEHAVIORAL|CGA coordination by geriatric team including intensive patient coaching and follow-up|In the intervention group, the CGA including geriatric recommendations for interventions will be coordinated by the geriatric team and will be complemented with patient coaching. This intervention aims to support patient empowerment by improving self-efficacy and supporting self-management of existing age-related problems before systemic therapy or occurring during systemic therapy, and includes an individual counselling session at start of systemic therapy to discuss the recommendations with the patient and to determine their priorities.
223698609|NCT01950169|DRUG|Risedronate|The bisphosphonate group (B) receive 35 mg risedronate (Optinate® Septimum) once weekly for 12 months and calcium (1000 mg) and vitamin D3 (800 IU) (Calcichew-D3®) daily for 12 months.
223698610|NCT01950169|OTHER|Nutritional supplement|The bisphosphonate and nutritional supplemented group (BN) receive 35 mg risedronate once weekly for 12 months plus nutritional supplement (Fresubin® protein energy drink) during the first six months following hip fracture and also calcium (1000 mg) and vitamin D3 (800 IU) daily for 12 months.
223698611|NCT01950169|DIETARY_SUPPLEMENT|Calcium and vitamin D3|The patients in the control group (C) receive orally administered calcium 1000 mg and 800 IU vitamin D3 (Calcichew-D3®) daily for 12 months.
223698612|NCT02315989|RADIATION|proton therapy|proton therapy
223781283|NCT01584063|BEHAVIORAL|Healthy MOMs Healthy Lifestyle Intervention|These women received the culturally tailored Healthy MOMs Healthy Lifestyle Intervention, which included social support from Women's Health Advocates (community health workers) and peers, and the Healthy MOMs curriculum. This intervention curriculum covered topics related to healthy eating, physical activity, and stress management during pregnancy and postpartum. General information about pregnancy and the postpartum period were also provided. This intervention was delivered during 10 group meetings and 4 home visits.
223781284|NCT03029208|DRUG|Daprodustat|Daprodustat will be supplied as film coated tablets for oral administration containing 1, 2, 4, 6, 8, or 10 mg of daprodustat. Doses of 12, 16, and 24 mg of daprodustat will be provided using multiples of these tablet strengths.
223781285|NCT03029208|DRUG|Darbepoetin alfa|Darbepoetin alfa will be supplied as prefilled syringes (PFS) for SC/IV injection available in strengths: 20, 30, 40, 60, 80, 100 and 150 mcg.
223781286|NCT03029208|DRUG|Iron therapy|Iron therapy will be administered if ferritin is \<=100 ng/mL and/or TSAT is \<=20%.
223781287|NCT03591692|PROCEDURE|ACAF surgery|The main surgical procedures include discectomy of the involved levels, thinning of the anterior part of the involved vertebrae, intervertebral cages, anterior plate and screws installation, bilateral osteotomies of the vertebrae, and antedisplacement of the vertebrae-OPLL complex
223781288|NCT03591692|PROCEDURE|ACCF surgery|Removal of the vertebral body，exposed ossification of the posterior longitudinal ligament，and then removed
223781289|NCT01316744|DRUG|ketamine hydrochloride|
223781290|NCT01316744|OTHER|pharmacogenomic studies|
223781291|NCT01316744|OTHER|questionnaire administration|
223781292|NCT01316744|PROCEDURE|assessment of therapy complications|
223781293|NCT01316744|PROCEDURE|quality-of-life assessment|
223781294|NCT02804958|PROCEDURE|STEMI treated with primary PCI|Primary percutaneous coronary intervention was performed according to the current standard guidelines. Coronary angiography was performed using standard techniques. The use of thrombectomy devices, intravascular ultrasound, intra-aortic balloon pump, and percutaneous cardiopulmonary support was up to the operator.
223781295|NCT01863017|DEVICE|tDCS|
223781296|NCT06548451|DEVICE|Augmented reality guided localization|In this study, AR was utilized to assist in the localization of pulmonary nodule during sublobectomy lung resection in patient to assess the accuracy of the technique.
223781297|NCT01732835|DEVICE|HAART 300 Annuloplasty Device|Implantation of HAART 300 Annuloplasty Device for aortic valve repair
223781298|NCT02334748|DRUG|canakinumab|canakinumab
223781299|NCT02493361|DRUG|Pembrolizumab|
223781300|NCT02493361|DRUG|pIL-12|
223781301|NCT01327534|DRUG|Prasugrel|treatment with a 60 mg loading dose prasugrel, followed by a maintenance dose of 10 mg for 30 days
223781302|NCT01327534|DRUG|Clopidogrel|treatment with a 600 mg loading dose clopidogrel, followed by a maintenance dose of 75 mg for 30 days
223781303|NCT01046643|DRUG|Estradiol (E2)|One Estradiol capsule (1mg) once a day, at the same time each day, for 90 days; followed by one Progesterone (200mg) once a day, at the same time each day, for 10 days to slough endometrial lining; followed by one Placebo capsule once a day, at the same time each day, for 90 days.
223781304|NCT01046643|DRUG|Progesterone (P10) x90|One Progesterone capsule (200mg) once a day, at the same time each day, for 90 days; followed by one Placebo capsule (to mirror Progesterone capsule to slough endometrial lining in Estradiol recipients) once a day, at the same time each day, for 10 days ; followed by one Placebo capsule once a day, at the same time each day, for 90 days.
223781305|NCT01046643|DRUG|Progesterone (P10) x10|One Progesterone (200mg) capsule once a day for 10 days, to slough endometrial lining for patients taking Estradiol. Patients taking Progesterone will take an equivalent Placebo capsule during this time period.
223781306|NCT01169389|PROCEDURE|Intraarticular injection|Durolane, one vial
223781307|NCT01169389|PROCEDURE|Intra-articular injection of 0.5% Bupivacaine|
223781308|NCT01408589|DRUG|Atomoxetine, Strattera|Atomoxetine at 0, 40, 60, 80 mg/day was given for 5 days, all subjects took two capsules per day for 5 days; all active dose groups received 40 mg/day for first 3 days and where then dose escalated to dosage group assigned.
223781309|NCT02243787|DRUG|COVA322|
223781310|NCT02243787|OTHER|Placebo|
223781311|NCT04181034|BEHAVIORAL|Adolescent Family Life Program Positive Youth Development (PYD) program|Home visiting program for pregnant and parenting teens with PYD component
223781312|NCT04181034|BEHAVIORAL|Adolescent Family Life Program (AFLP)|Home visiting program for pregnant and parenting teens
223781313|NCT03827629|DRUG|Treatment A: Naloxone Nasal Spray|Participants received naloxone nasal spray following a 10 hour fast.
223781314|NCT03827629|DRUG|Treatment B: Naloxone Nasal Spray|Participants received naloxone nasal spray following a 10 hour fast.
223781315|NCT03827629|DRUG|Treatment C: Naloxone HCL Intramuscular (IM) Injection|Participants received naloxone HCl IM injection following a 10 hour fast.
223781316|NCT03237689|DRUG|Hydrocortisone|Low dose hydrocortisone (10mg)
223781317|NCT03237689|DRUG|Placebo Oral Tablet|capsules of starch 1500 powder
223781318|NCT00983229|PROCEDURE|Tracheal intubation|Insertion of a plastic tube under direct vision (built-in camera, intubating fibrescope) into trachea.
223781319|NCT03067441|DRUG|bempedoic acid|bempedoic acid 180 mg tablets taken orally, once per day.
223698613|NCT04112420|DIAGNOSTIC_TEST|Trans-esophageal echocardiography|"The department registers an unplanned admission of a patient to the intensive care unit. The indication is verified again by the intensive care physician.~In this case, the patient is then admitted to the intensive care unit, supervised by an intensive care physician, orientated and initiated therapeutic and diagnostic measures.~As part of the planned transthoracic cardiac ultrasound examination, it is then selected whether the patient is suitable according to the patient's will and the inclusion or exclusion criteria.~After clarification, time to think and consent, the examination is then carried out according to the protocol by approved doctors of the Clinic for Anesthesia, intensive care and pain therapy. Followed by digital storage for the finding.~After the subsequent operation, the investigator determines whether knowledge of detected pathologies would have an effective influence on the anesthesiological procedure or not."
223698614|NCT01784757|DRUG|ODM-201 Tablet A|Tablet A formulation of ODM-201
223698615|NCT01784757|DRUG|ODM-201 Tablet B|Tablet B formulation of ODM-201
223698616|NCT01784757|DRUG|ODM-201 capsule formulation|Capsule formulation of ODM-201
223698617|NCT04317404|DRUG|40 mg Triamcinolone acetonide|Unilateral knee steroid injection
223698618|NCT01592682|BEHAVIORAL|Smokefree counseling|Smokefree counseling intervention involves group education sessions, follow-up phone calls, tobacco exposure lab report. Comparison is usual care with referral to local in-language smoking cessation services including quitline.
223698619|NCT01923831|DRUG|Magnesium Sulfate|Magnesium sulfate 30 mg kg-1 was infused in 100mL normal saline for 10 minutes immediately before anesthesia induction. After tracheal intubation, normal saline 1.6mL ( equivalent volume as Dexamethasone 8mg) was injected, and magnesium sulfate was continuously infused at the rate of 10 mg Kg-1 h-1 until the end of surgery. (at the time of skin closure)
223698620|NCT01923831|DRUG|dexamethasone|Normal saline 100mL was infused for 10 minutes immediately before anesthesia induction. After tracheal intubation, dexamethasone 8mg was injected, and normal saline was continuously infused at the rate of 10 mg Kg-1 h-1 until the end of surgery. (at the time of skin closure)
223698621|NCT00332878|BEHAVIORAL|Stepping Stones|a comprehensive sexual and reproductive health promotion programme lasting about 50 hours comprising 13 content sessions of about 3 hours duration and 4 meetings of peer groups
223698622|NCT00332878|BEHAVIORAL|stepping Stones short|3 hour intervention on HIV and safer sex
223698623|NCT00946361|OTHER|Examinations|Growth hormone stimulation testing, Protein turnover, Dexa scan, Bone age x-ray
223698624|NCT06506682|BEHAVIORAL|Constraint Induced Movement Therapy|CIMT is an intensive upper limb therapy for children with unilateral (one sided) cerebral palsy where the child wears a constraint (splint or mit) on their dominant hand so that they use the involved (weaker) side to do activities
223698625|NCT06506682|BEHAVIORAL|CIMT + VR|Participants in the CIMT+VR group of this study protocol will do everything the CIMT group does PLUS will utilize at least 4 of the following VR technologies each day of intervention: FitMi, Tyromotion Pablo® UpperExtremity, Hocoma Armeo® Spring Pediatric, Nintendo Wii, and Parrot Drone.
223698626|NCT03584061|PROCEDURE|Fat grafting|The area of dermal pain is identified and marked prior to surgery. The surgery starts with liposuction, either on the abdomen or the thigh. The harvested fat is prepared for fat grafting by sedimenting it for 10 minutes. The fat is then injected into the painful area, marked pre-surgery.
223698627|NCT03849248|OTHER|Maternal scent cloth|The babies assigned to the intervention group will have a cloth with their mother's scent on it placed under their heads.
223698628|NCT04010032|DEVICE|Programmed intermittent epidural bolus|bolus administration of 0.15 ml of ropivacaine 0.15 ml / kg into epidural space every hour(intermittent bolus injection) using PCA device
223698629|NCT04010032|DEVICE|Continuous epidural infusion|Continuous infusion of 0.15% ropivacaine 0.15 ml / kg / h into the epidural space using PCA device using PCA device
223698630|NCT05469581|OTHER|A set of preventive interventions to improve adherence in vulnerable elderly people|"* reviewing the list of medications, delivery of an ordered list of medications, and checking medication regimen understanding;~* delivering a leaflet on the correct/safe taking of medications, discussion, explanation, and verification of understanding of the content;~* a counseling about the importance of adherence;~* handing over the medication dispenser (if the elderly person does not have one yet),~* delivering of a personal medication card, which shows the timeline of taking prescribed medication."
223698631|NCT01680887|DRUG|Varenicline|
223698632|NCT01680887|DRUG|Placebo|
223698633|NCT03326739|PROCEDURE|Arterial Line Placement|arterial line placement
223698634|NCT05578911|OTHER|"medical students group"|medical student in general practice or in specialty medicine
223698635|NCT03949842|DRUG|Inhaled corticosteroids/long-acting beta2-adrenergic/long-acting muscarinic receptor antagonists|A fixed dose of combination ICS/LABA plus LAMA once-daily was administered to COPD subjects using two separate non-ELLIPTA devices.
223698636|NCT03949842|DRUG|Fluticasone furoate/umeclidinium/vilanterol|The first strip will contain FF at a dose strength of 100 mcg will be blended with lactose. The second strip will be contain UMEC and VI at a dose strength of 25 mcg and 62.5 mcg blended with lactose and magnesium stearate with respectively.
223698637|NCT03920787|DIETARY_SUPPLEMENT|Inofolic Combi|Myo-inositol 1100 mg + D-Chiro-inositol 27,6 mg + Folic Acid 400 μg. 2 capsules every day for 1 month.
223698638|NCT03920787|OTHER|Placebo|2 capsules every day for 1 month
223698639|NCT02309593|DEVICE|PROFEMUR® Xm Femoral Stems|THA using PROFEMUR® Xm Femoral Stems
223698640|NCT04915898|OTHER|Oral Hygiene - teeth brushing|Oral hygiene using a special kit with recommended materials and instructions: Use of an ADA approved toothbrush, toothpaste with dentifrice, antiseptic mouthwash and non-drying lip moisturizer encouraged after meals and at bedtime
223698641|NCT05842733|DRUG|Naldebain|Oral Placebo A 650 mg + Naldebain 37.5 mg (0.5 mL oil solution) + Tween 20 and PEG 400 (1 capsule), multiple doses for 3 days. Dosing at 0（2 ± 2 hour after surgery）, 6 ± 2, 14 ± 2, 22 ± 2, 34 ± 2, 46 ± 2, 58 ± 2 and 70 ± 2 hours after the first dose.
223698642|NCT05842733|DRUG|SafeTynadol|Oral SafeTynadol 650 mg + Placebo B (0.5 mL oil solution) +Tween 20 and PEG 400 (1 capsule), multiple doses for 3 days. Dosing at 0（2 ± 2 hour after surgery）, 6 ± 2, 14 ± 2, 22 ± 2, 34 ± 2 46 ± 2, 58 ± 2 and 70 ± 2 hours after the first dose.
223781320|NCT01851057|BEHAVIORAL|STAR|Problem-solving and education intervention (8 total sessions)
223781321|NCT01851057|BEHAVIORAL|Education Only|Education around epilepsy (8 total sessions)
223698643|NCT05842733|DRUG|Naldebain + SafeTynadol|Oral Naldebain 37.5 mg (0.5 mL oil solution) + SafeTynadol 650 mg + Tween 20 and PEG 400 (1 capsule), multiple doses for 3 days. Dosing at 0（2 ± 2 hour after surgery）, 6 ± 2, 14 ± 2, 22 ± 2, 34 ± 2, 46 ± 2, 58 ± 2 and 70 ± 2 hours after the first dose.
223698644|NCT03239184|DEVICE|Cancer ablation|Tumors bigger than 2 cm are fit for ablation therapy, percutaneously under CT scan or ultrasound
223698645|NCT03239184|DRUG|Life information rehabilitation therapy|Each treatment: one bottle solution each day, consecutive 3 months, oral administration
223698646|NCT01747226|OTHER|Fluoride rinse|rinse with 15 ml for 1 minute
223698647|NCT01747226|OTHER|Halita|rinsing with 15 ml for 1 minute
223698648|NCT01747226|OTHER|Meridol Halitosis|rinsing with 15 ml for 1 minute
223698649|NCT01747226|OTHER|Water|rinsing with 15ml for 1 minute
223698650|NCT01717911|DRUG|Insulin|In the insulin therapy group (Humulin-N), subjects were instructed in the techniques for insulin injection and home capillary glucose monitoring. Two third daily dose was administrated before breakfast and one third at bedtime. Insulin doses were titrated every 3 days to achieve target fasting plasma glucose values between 90 and 130 mg/dl.
223698651|NCT01717911|DRUG|Metformin|The titration of metformin was used 500 mg for an adjust unit in splitting dose with the same target to the maximum daily dose of 2550 mg (1000 mg twice daily and then 850 mg tid).
223698652|NCT01717911|DRUG|Sitagliptin|The subjects treated with sitagliptin started with 100 mg before breakfast once daily. The dosage was fixed as 100mg per day. Decreased by 50mg if fasting blood glucose was \<70mg /dl, discontinued the study if blood glucose was still \<70mg/dl under sitagliptin 50mg per day.
223698653|NCT01512212|PROCEDURE|biopsy|fnab
223698654|NCT03617510|DRUG|Felbinac Trometamol Injection|Felbinac Trometamol Injection will be infused IV in 100 mL normal saline,in a 30-minute period using a programmable pump.Three days after the single dose,the drug was given 7 times,3 times/day,once every 8 hours. It means the drug was given 3 times on D3 and D4,once on D5.
223781322|NCT04842695|DEVICE|electroacupuncture group|compare the effectiveness of electroacupuncture on point B7 plus pelvic floor exercises versus pelvic floor exercises alone in women with urinary incontinence (UI) .
223781323|NCT03535818|PROCEDURE|Radiofrequency ablation|RF application to achieve complete pulmonary vein isolation +/- ganglionated plexus ablation
223781324|NCT03814447|DRUG|anti- MESO CAR-T cells|Autologous genetically modified anti- MESO CAR transduced T cells
223781325|NCT03814447|DRUG|Fludarabine|Dose: 30mg/m2/d
223781326|NCT03814447|DRUG|Cyclophosphamide|Dose: 300mg/m2/d
223698655|NCT03617510|DRUG|Placebos|Normal saline will be infused IV in 100 mL normal saline,in a 30-minute period using a programmable pump.Three days after the single dose,the Placebo was given 7 times,3 times/day,once every 8 hours.It means the Placebo was given 3 times on D3 and D4,once on D5.
223698656|NCT02501226|OTHER|Treatment as usual|Treatment as usual consisting of clinical management including assessment of the psychiatric symptoms and subsequent prescription of antidepressants.
223698657|NCT02501226|BEHAVIORAL|ENVIE psychoeducational program|"The intervention will consist of 9 weekly, 90 min sessions led by two animators. The program ENVIE will provide:1.Presentation of the program 2.Education on depressive symptoms. 3.Information about the causes leading to depression. 4.The depression's consequences. 5.Teaching about the last neurobiological and neuroanatomical knowledges about depression, through didactic presentations. 6.How to recognize his own mood state, the prodromal symptoms of relapse. 7.Didactic explanation of the neurobiological action of antidepressant, and other evidence-based medical treatments. 8 and 9. Recommendations about lifestyle and skills of behavioral activation.To enhance the active role of the patient, each session will be accompanied with homework for the patient.~The sessions may be carried out remotely, by videoconference."
223698658|NCT00702104|OTHER|survey administration|
223698659|NCT05189080|OTHER|Text message reminders|Text messages will be sent to parents/guardians of children ages 0 to 17 years who no-showed for their well child visits.
223698660|NCT05189080|OTHER|Interviews|Interviews will be conducted with a subset of participants to identify the top one or two performing text messages.
223698661|NCT05189080|OTHER|Survey|Alongside notification text messages regarding no-showed visits, participants will be invited to participate in a survey about their experience with the health system. This survey will assess reasons for missing the WCV and primary caregiver's perspective on the experience at the prior visit.
223698662|NCT03673579|DEVICE|NICU Dashboard|The NICU Dashboard is displayed on a touch screen display mounted to the wall or on a rolling cart that will be placed near the bedside. The Dashboard will integrate information from various hospital/device sources in order to provide clinicians with one location to access and collectively interpret clinical findings and environmental factors. Parents will have their own view on the Dashboard that will allow them view their baby's progress, view educational materials, and have access to other resources at their fingertips.
223698663|NCT03064230|OTHER|QoL questionnaire SF-12 and and a screening questionnaire|patient were asked to fill questionnaires
223698664|NCT03106350|OTHER|Questionnaire|The EORTC QLQ-C30 is a questionnaire developed to assess the quality of life of cancer patients. It is a copyrighted instrument, which has been translated and validated in over 100 languages and is used in more than 3,000 studies worldwide.
223698665|NCT03841812|DRUG|5mg/kg/h Propofol|5mg/kg/h Propofol continuously infused during intre-operation
223698666|NCT03841812|DRUG|Sevoflurane|1% Sevoflurane continuously using during intre-operation.
223698667|NCT03841812|DRUG|2 mg/kg/h Propofol|2mg/kg/h Propofol continuously infused during intre-operation
223698668|NCT01606644|PROCEDURE|Hyperbaric oxygen|Inhalation of 100% oxygen for 90 minutes
223698669|NCT02055417|BEHAVIORAL|Personal Approaches to Treatment Choices for HIV|
223698670|NCT02055417|BEHAVIORAL|Stress Reduction Skills Program|
223698671|NCT01770496|BEHAVIORAL|Childhood vaccination reminder / recall notification|
223698672|NCT05191342|DIAGNOSTIC_TEST|Enzyme-linked immunosorbent assay for PCSK9|Enzyme-linked immunosorbent assay for plasma PCSK9
223698673|NCT02903641|BEHAVIORAL|Personalized information|"During a prior study in June-July 2016, we collected anthropometric measures on the index children, including the children's height. Based on these data, for households assigned to the information treatment, enumerators provided personalized information to the children's primary caregiver about the index child's current height, during a baseline household visit. The enumerators carried a display card that visually showed where the child's height fell compared to healthy children of the same age and gender like those in East Africa. The enumerators emphasized to the caregivers that short stature is due to poor chronic malnutrition and is not just attributable to genetics or a recent illness. During this visit, the enumerators additionally pointed out that chronic malnutrition is not immediately life-threatening."
223698674|NCT02903641|BEHAVIORAL|Labeled cash transfer|Households received a cash transfer labeled for child food consumption and were told the money is designed to cover additional spending for food for the index child (and any other younger children in the household) over the next six weeks. Though it was given as a single, lump sum payment, the transfer was evenly split and handed to the household in six sealed envelopes, to help the households better allocate the money. To further encourage them not to spend the money all at once, each envelope was labeled with a number, the index child's name, and the dates for the week the money in the envelope should be spent. Enumerators clearly stated that this is a one-time money transfer.
223698675|NCT04525352|BIOLOGICAL|RP-L401|CD34+ enriched hematopoietic stem cells from pediatric subjects with infantile malignant osteopetrosis transduced ex vivo with lentiviral vector carrying the TCIRG1 transgene
223698676|NCT06144892|DEVICE|Proactive Therapy|Uses AI to make predictions and preventions of future apneic events.
223698677|NCT05600660|DRUG|Orelabrutinib|"Orelabrutinib will be given as 150 mg/d orally 72h after MTX infusion or MTX clearance, every 21 days for 6 cycles during induction treatment.~Daily Orelabrutinb will be administered as maintenance treatment for up to 1 year or until disease progression, intolerable toxicity, death, informed consent withdrawal or lost of follow up (whichever occurs first)."
223698678|NCT05600660|DRUG|Rituximab|375mg/m2 intravenous infusion d1, every 3 weeks for 1 cycle, 6 cycles will be prescribed for induction therapy.
223698679|NCT05600660|DRUG|Methotrexate|3.5g/m2 intravenous infusion for 4 hours in d1, every 21 days for 1 cycle, 6 cycles will be prescribed.
223698680|NCT00366132|DEVICE|Extracorporeal Shockwaves|
223698681|NCT05720208|DEVICE|SCiP|Noninvasive Spinal Cord Neuromodulator
223781327|NCT05269264|DIAGNOSTIC_TEST|Assessor A (first measurement): measurement methods and questionnaires for the assessment of LLL|pitting test at the level of the foot, leg and midline region; skinfold test at the level of the foot, leg and midline region; skin hardness test at the level of the foot, leg and midline region; measurement with MoistureMeterD at the level of the foot, leg and midline region; measurement with SkinFibroMeter at the level of the foot, leg and midline region; circumference measurements at the level of the leg and midline region; perometry at the level of the leg; water displacement measurement at the level of the foot; measurements with bio-impedance spectroscopy/analysis devices at the level of the lower limbs and a questionnaire regarding skin integrity (ICC compression questionnaire) that should be completed by the therapist and a self-reported disease-specific quality of life questionnaire (Lymph-ICF-LL) that is completed by the patient at the end of this evaluation
223781328|NCT05269264|DIAGNOSTIC_TEST|Assessor B: measurement methods and questionnaires for the assessment of LLL|pitting test at the level of the foot, leg and midline region; skinfold test at the level of the foot, leg and midline region; skin hardness test at the level of the foot, leg and midline region; measurement with MoistureMeterD at the level of the foot, leg and midline region; measurement with SkinFibroMeter at the level of the foot, leg and midline region; circumference measurements at the level of the leg and midline region; perometry at the level of the leg; water displacement measurement at the level of the foot; measurements with bio-impedance spectroscopy/analysis devices at the level of the lower limbs and a questionnaire regarding skin integrity (ICC compression questionnaire) that should be completed by the therapist
223781329|NCT05269264|DIAGNOSTIC_TEST|Assessor A (second measurement: measurement methods and questionnaires for the assessment of LLL|pitting test at the level of the foot, leg and midline region; skinfold test at the level of the foot, leg and midline region; skin hardness test at the level of the foot, leg and midline region; measurement with MoistureMeterD at the level of the foot, leg and midline region; measurement with SkinFibroMeter at the level of the foot, leg and midline region; circumference measurements at the level of the leg and midline region; perometry at the level of the leg; water displacement measurement at the level of the foot; measurements with bio-impedance spectroscopy/analysis devices at the level of the lower limbs and a questionnaire regarding skin integrity (ICC compression questionnaire) that should be completed by the therapist
223698682|NCT04926142|DEVICE|Implantation of Holter device|Implantation of a Holter device (Reveal Linq, Medtronic) for telemonitoring of cardiac rhythm
223698683|NCT04926142|PROCEDURE|Percutaneous PFO closure|Patients will undergo percutaneous closure of patent foramen ovale
223698684|NCT04214873|DEVICE|PiQo4 Laser System|PiQo4 Laser System for treatment of POH
223698685|NCT00739050|DRUG|simvastatin|simvastatin 20mg daily at nights for 12 weeks. Tablets
223698686|NCT00739050|DRUG|Comparator: Placebo|placebo daily at nights for 12 weeks. Tablets
223698687|NCT05780931|BEHAVIORAL|Study-specific rehabilitation (SSR) procedures|Study-specific rehabilitation procedures will systematically manipulated the spatial or temporal synchrony (or coordination) of visual vs. haptic inputs that the subjects receive.
223698688|NCT05704010|DEVICE|Video capsule endoscopy|Video capsule endoscopy every 2 years
223698689|NCT00619138|BEHAVIORAL|individual cognitive-behavioural therapy|1 session per week for 12 weeks
223698690|NCT00619138|BEHAVIORAL|stepped care model|three steps: short psycho-education, a 10 weeks Internet-based self-help program, 12 weeks individual cognitive-behavioural therapy
223698691|NCT02841436|DEVICE|Irreversible Electroporation (IRE) System|
223698692|NCT01461083|DRUG|[18F]MPPF|Subjects will be dosed by intravenous bolus injection of \[18F\]MPPF targeted to be 5.0 mCi, and not to exceed 5.5 mCi (not \>10% of 5.0 mCi limit) and not to exceed 5 µg of MPPF
223698693|NCT01254292|DRUG|Levonorgestrel IUD (LCS, BAY86-5028)|LCS12 insertion will occur at randomization visit (Visit 2). Duration of study treatment is 18 months with optional extension to 36 months for subjects in this group only.
223698694|NCT01254292|DRUG|Yasmin (EE30/DRSP, BAY86-5131)|Combined oral contraceptive (COC; Yasmin; 0.03 mg ethinyl estradiol and 3 mg drospirenone); Subjects will start taking COC at / on the day of visit 2 and continue taking one pill / day without any breaks for the entire study duration of 18 months.
223698695|NCT01951222|DRUG|V0162|
223698696|NCT01951222|OTHER|Placebo|
223698697|NCT02344862|DRUG|FYU-981 High dose, (Oral daily dosing for 8 weeks)|Subjects randomized to the FYU-981 High dose arm receive active drug, FYU-981 High dose.
223698698|NCT02344862|DRUG|FYU-981 Middle dose, (Oral daily dosing for 8 weeks)|Subjects randomized to the FYU-981 Middle dose arm receive active drug, FYU-981 Middle dose.
223698699|NCT02344862|DRUG|FYU-981 Low dose, (Oral daily dosing for 8 weeks)|Subjects randomized to the FYU-981 Low dose arm receive active drug, FYU-981 Low dose.
223698700|NCT02344862|DRUG|Placebo, (Oral daily dosing for 8 weeks)|Subjects randomized to the placebo arm receive placebo.
223698701|NCT05435209|DRUG|Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recombinant Vaccine|Gardasil
223698702|NCT04911413|DRUG|Tranexamic acid|The drug used in this RCT is tranexamic acid. We used three different doses of TXA in three groups.
223698703|NCT06418750|OTHER|dermo-cosmetic product|For patients in the preventive group, treatment with hand serum, gloves/slippers and fortifying solution/dissolving oil will be started on the day of the first administration of Ac bispecific. In the curative group, treatment will begin on inclusion in the study and will be adapted to the lesions present on D0. Treatment will be readjusted on a weekly basis according to the lesions present at the time of the follow-up visit.
223698704|NCT01913223|DEVICE|Nestis® jet injector system with a bi-functional catheter|
223698705|NCT02938845|BEHAVIORAL|Spielberger's State-Trait Anxiety Inventory(STAI )|State anxiety (STAI-S) refers to a temporary emotional state related to a specific situation, whereas trait anxiety (STAI-T) represents anxiety as a relatively stable personality character. Each scale has values ranging from 20 to 80, with higher scores representing more severe anxiety. The STAI has no established categories, but a cutoff score of 40 has been used to identify patients with high/very high anxiety. The validity and reliability of the Turkish versions of these instruments have been validated.
223698706|NCT02938845|PROCEDURE|total laparoscopic hysterectomy(TLH)|
223698707|NCT02938845|PROCEDURE|total abdominal hysterectomy(TAH)|
223698708|NCT02291536|DRUG|tetrahydrocannabinol|
223698709|NCT02291536|DRUG|cannabidiol|
223698710|NCT02291536|OTHER|placebo|
223698711|NCT01070862|DRUG|Thalidomide, Dexamethasone|Thalidomide 200 mg/d for 3 months, Dexamethasone 40 mg/d D1-D4 and D14-D17 for 28d-3 cycles
223698712|NCT01070862|DRUG|Vincristin , Adriamycin, Dexamethasone = VAD|Vincristin 0.4 mg/d continUous IV infusion D1-D4, Adriamycin 9 mg/m2 continuous IV infusion D1-D4, Dexamethasone 40 mg/d oral D1-D4 and D15-D18 for 2 first cycles, D1-D4 for the 3d cycle
223698713|NCT01070862|DRUG|Thalidomide, melphalan, endoxan, dexamethasone (MCDex-Thal)|Thalidomide : 200 mg/d at bedtime for 3 months , melphalan: 6 mg/m2 oral D1-D4, endoxan 600 mg/m2 IV D1, dexamethasone 40 mg/d oral D1-D4 for 28-d 4 cycles
223698714|NCT01070862|DRUG|melphalan, endoxan, dexamethasone (MCDex)|melphalan: 6 mg/m2 oral D1-D4, endoxan 600 mg/m2 IV D1, dexamethasone 40 mg/d oral D1-D4 for 28-d 4 cycles
223698715|NCT01070862|DRUG|Thalidomide, Dexamethasone|Thalidomide 200 mg/d on every other 3 months Dexamethasone 40 mg/d D1-D4, D30-D34,D60-D64, D90-D94
223698716|NCT00001443|DRUG|indinavir (MK-0639)|
223698717|NCT04856475|DRUG|Neratinib|"As per investigator's choice, eligible subjects in all cohort will receive:~* Neratinib, administered continuously at a dose of 240 mg orally once a day in combination with:~  * Capecitabine, administered continuously at a dose of 750 mg/m2, orally, twice a day (=daily dose of 1500 mg/m2) from D1 toD14 (21 days cycle) (preferred option) or~ * Vinorelbine, I.V. 25 mg/m2 on D1 and D8 (21 days cycle) or~ * Paclitaxel, I.V. 80 mg/m2 on D1, D8, and D15 (21 days cycle) Important note: The possibility to combine trastuzumab, loading dose 8 mg/kg IV followed by 6 mg/kg Q3W IV or SC 600 mg Q3W, to one of these above treatments is left at investigator's discretion OR~* Neratinib, administered continuously at a dose of 160 mg, orally, once a day in combination with:~  * T-DM1, I.V. 3.6mg/m2 on D1 (21 days cycle) (preferred option)"
223698718|NCT05664607|OTHER|for excise, nutrition consultant, nutrition supplement and psychologic intervention.|for excise, nutrition consultant, nutrition supplement and psychologic intervention.
223698719|NCT04723901|BIOLOGICAL|Dual target CAR-T cell therapy|CD19/CD22 dual target CAR-T cell therapy
223698720|NCT03799211|BEHAVIORAL|Motivational Interviewing|Phone call using motivational interviewing technique
223698721|NCT03799211|BEHAVIORAL|Treatment as Usual|will receive a regular study phone call after three months
223698722|NCT04743349|PROCEDURE|Steam inhalations|Exposure of airway mucosae to humidified steam through steam inhalation for at least 20 min (4 cycles of 5 min) daily, for 10 days.
223698723|NCT03509831|DRUG|INT-2150|"1. Period: INT-2150~2. Period: Irsogladine maleate 2 mg+Nizatidine 150 mg"
223698724|NCT03509831|DRUG|Irsogladine maleate 2 mg+Nizatidine 150 mg|"1. Period: Irsogladine maleate 2 mg+Nizatidine 150 mg~2. Period: INT-2150"
223698725|NCT02826135|PROCEDURE|abdominal compression|When there are clinical signs of hypovolemia, such as hypotension in pediatric patients with single ventricle, decreased urine output or decreased central venous pressure, right upper abdomen is gently compressed for 10 seconds. Changes of blood pressure are continuously recorded during this period. About 3 min later, intravenous colloid fluid 10 mL/kg is infused for 20 min.
223781330|NCT05269264|DIAGNOSTIC_TEST|Assessor A (2 weeks later): measurement methods and questionnaires for the assessment of LLL|pitting test at the level of the foot, leg and midline region; skinfold test at the level of the foot, leg and midline region; skin hardness test at the level of the foot, leg and midline region; measurement with MoistureMeterD at the level of the foot, leg and midline region; measurement with SkinFibroMeter at the level of the foot, leg and midline region; circumference measurements at the level of the leg and midline region; perometry at the level of the leg; water displacement measurement at the level of the foot; measurements with bio-impedance spectroscopy/analysis devices at the level of the lower limbs and a questionnaire regarding skin integrity (ICC compression questionnaire) that should be completed by the therapist and a self-reported disease-specific quality of life questionnaire (Lymph-ICF-LL) that is completed by the patient at the end of this evaluation
223698726|NCT00041821|PROCEDURE|Nasal irritation thresholds and irritant provocation|
223698727|NCT04265469|OTHER|Diabetic foot education|Give Diabetic foot education via mobile phone
223698728|NCT00764491|DEVICE|Structural Allograft Spacer|Following disc space preparation the spacer is placed in accordance with cleared labeling and supplemental instrumentation is provided as an adjunct to fixation.
223781331|NCT00723177|DRUG|AV411|Low (20 mg), and high dose (40 mg) of AV411 will be administered orally twice a day (BID) for two consecutive weeks
223781332|NCT00723177|DRUG|Placebo (PCB)|Placebo drug will be administered orally twice a day (BID) for two consecutive weeks
223781333|NCT01465893|DRUG|Vitamin D|vitamin D ,50000 unit /week
223781334|NCT01465893|DRUG|Vitamin D withheld|do not receive anything
223698729|NCT00764491|DEVICE|OptiMesh 1500S|Following disc space preparation the OptiMesh is deployed and filled in accordance with study surgical technique and supplemental instrumentation is provided as an adjunct to fixation.
223698730|NCT01922674|PROCEDURE|Standard open tension-free inguinal hernia repair with mesh|
223698731|NCT04777838|DRUG|Citalopram 10 MG|10 mg of citalopram every day
223698732|NCT04777838|DRUG|Amitriptyline|25mg of Amitriptyline every
223698733|NCT04777838|DEVICE|Bite Splint|Night use of occlusal splint
223698734|NCT00002664|BIOLOGICAL|edrecolomab|
223698735|NCT00002664|BIOLOGICAL|sargramostim|
223698736|NCT00542971|DRUG|Idarubicin|12 mg/m\^2 IV over 1 hour daily (days 1-3)
223698737|NCT00542971|DRUG|Sorafenib|Starting dose 400 mg by mouth for 7 days
223698738|NCT00542971|DRUG|Ara-C|1.5 g/m\^2 IV over 24 hours daily (days 1-4)
223698739|NCT05561374|DRUG|Low-dose OKN-007, BID|Participants will be administered low doses of oral OKN-007 two times a day daily in 28-day cycles.
223698740|NCT05561374|DRUG|Low-dose OKN-007, TID|Participants will be administered low doses of oral OKN-007 three times a day daily in 28-day cycles.
223698741|NCT05561374|DRUG|Mid-dose OKN-007, TID|Participants will be administered mid doses of oral OKN-007 three times a day daily in 28-day cycles.
223698742|NCT05561374|DRUG|High-dose OKN-007, TID|Participants will be administered high doses of oral OKN-007 three times a day daily in 28-day cycles.
223698743|NCT03654443|DIAGNOSTIC_TEST|Critical care pain observation tool|The CPOT tool is administered in a crossover manner by two study observers
223698744|NCT04524169|DRUG|Thymosin Alpha1|Thymosin Alpha 1 will be subcutaneous injected to the participants twice per week for 4 weeks.
223698745|NCT04868058|DRUG|Ropivacaine injection|Ropivacaine : 0.4 ml/kg (ideal body weight!) of 5mg/ml (20 to 30 ml bolus dose (100-150 mg), maximum dose 200 mg ropivacaine
223698746|NCT03539354|DEVICE|Temporary spinal cord stimulation|Percutaneous trial (temporary) electrodes are placed through a 14-gauge needle.The skin is entered at the medial aspect of the pedicle with the Tuohy needle usually angled 30-45° toward the midline for optimal entry into the epidural space at the interlaminar edge 1 or 2 levels of cephalad (usually, Th5-Th6 level). The 14-gauge needle is then passed with the bevel facing up at a 30-45° oblique angle to reach the depth of the midline laminar target.The Tuohy needle is then carefully removed and the operative site is cleaned with chlorhexidine and alcohol. Temporary stimulation is carried out till coronary artery bypass grafting surgery for 3 days, then stimulation turns off during surgery. At the end of coronary artery bypass grafting the temporary stimulation turns on in the intensive care unit and continues for 7 days. After that, the temporary leads will be removed.
223781335|NCT05319327|OTHER|Nutritional intervention|"A nutritional intervention program aimed to reduce UPF consumption. Nutritional intervention will not modify basal caloric intake but will record energy intake along the intervention. Nutritional counseling will be based on nutritional educational material such as encouraged and discouraged food items, recipes, menus and food shopping lists based on unprocessed or minimally processed foods.~Total intervention will last 6 months for both groups. During the intervention phase, a monthly interview with nutritionist/dietitian is scheduled. Face-to-face interviews will be carried out in months 2 and 4. Phone interviews will be carried out in months 1, 3 and 5. In the baseline and final visits (months 0 and 6) a sample and data collection will be performed."
223781336|NCT05319327|OTHER|Control|General counseling to adhere to a healthy Mediterranean diet
223781337|NCT04285606|BEHAVIORAL|Patient-led rehab with short immobilization|Short immobilization followed by patient-led shoulder rehab
223698747|NCT03539354|PROCEDURE|Coronary artery bypass grafting|Standart coronary artery bypass grafting procedure.
223698748|NCT03539354|DRUG|B-blockers|Standart b-blocker therapy will be administered in each group for AF prophylactics
223698749|NCT01367431|DIETARY_SUPPLEMENT|Xanthohumol|PK study with one capsule of one of the three doses randomly assigned
223698750|NCT00240227|DRUG|Prazosin|FDA approved medication for hypertension
223698751|NCT00240227|DRUG|placebo|
223781338|NCT04109989|DEVICE|HominisTM Surgical System|Trans-vaginal gynecological procedures
223781339|NCT06074926|BEHAVIORAL|Associative Conditioning|There will be 3 planned activities per week (9 total) within play kits provided to families. Children will first taste their assigned target vegetable and then complete an activity with their parent following provided instructions. Activity instructions will include positive parenting skills adapted from evidence-based parenting programs (i.e., Parent-Child Interaction Therapy (PCIT) and Triple-P) designed to promote positive parent-child interactions.
223781340|NCT06074926|BEHAVIORAL|Repeated Exposure|There will be 3 planned exposures per week (9 total). Exposures will include only individual tastes of the child's assigned target vegetable.
223781341|NCT00931177|OTHER|weight|weight and dehydration scores
223781342|NCT00931177|OTHER|weight and dehydration score|weight and dehydration score
223781343|NCT01465490|BEHAVIORAL|Monitoring and Feedback Intervention|Clients participate in standard treatment and complete the MMI weekly with their counselors at the beginning of each individual counseling session. Counselors have been trained to administer the MMI and will have access to the data to use during sessions.
223781344|NCT00700687|DRUG|PA32540|aspirin/omeprazole
223781345|NCT00700687|DRUG|PA32540 and celecoxib|aspirin/omeprazole and celecoxib
223781346|NCT00700687|DRUG|aspirin and [NSAID]|aspirin and \[NSAID\]
223781347|NCT03969810|BEHAVIORAL|Rounding Summary|Written summary of rounds
223781348|NCT03748498|DEVICE|laser|Application of the laser was performed through root canal and to the buccal mucosa over the apices of the target tooth
223781349|NCT06535126|DRUG|CanProFem-AK|Dosage form - vaginal suppositories (100 mg). Dosage regimen - single intravaginal administration of suppository. Vaginal suppositories are inserted as deeply as possible while the participant is lying down; the participant must remain in a horizontal position for 45 minutes after the administration. The total duration of volunteer participation in the study is one day. Medical observation (including gynaecological monitoring with vaginal bacterial swab test) of the subject condition after the drug administration will be carried out after 3, 6, 9, 12 and 24 hours. Repeated laboratory blood and urine tests will be performed after 24 hours. Participants of the study will be closely monitored for 24 hours after the initial administration of the drug to detect any immediate adverse events. If the subject experiences an immediate adverse event, appropriate treatment will be provided.
223781350|NCT04125693|DRUG|Rogaratinib (BAY1163877)|Participants will be treated with investigational drug following the treatment schedule and dosing instructions from the feeder-study protocol.
223781351|NCT04125693|DRUG|Combination drug|Any other drug specified in the protocol of the completed Bayer clinical trials that is used in combination with rogaratinib. Not all patients receive combination therapy.
223781352|NCT02066935|OTHER|kidney transplant patient|kidney transplanted patients for at least one year
223781353|NCT04504877|DRUG|Cannabidiol|Cannabidiol 300 mg daily for 4 weeks
223781354|NCT03513029|DEVICE|VytronUS Ablation System|Catheter Ablation for Paroxysmal Atrial Fibrillation
223781355|NCT05253703|OTHER|Virtual reality bicycling|This is a single arm study in which all participants will execute the same three bicycling tasks over one session (see arm/group description).
223781356|NCT06535217|PROCEDURE|Liver transplantation|Liver transplantation
223781357|NCT00043446|DRUG|intravenous T900607-sodium|
223781358|NCT00377195|RADIATION|Involved Field Radiotherapy|"The prescribed dose will be 30 Gy in 15-20 fractions, unless the orbit is to be treated, in which case the dose will be 24 Gy in 1.5 to 2 Gy fractions.~Daily fractions of 1.5-2.0 Gy will be employed. Treatment will be given 5 days per week with the planned duration of treatment not exceeding 28 days."
223781359|NCT02056301|DRUG|Hydromorphone|In keeping with standard practice at the TCH, the position of the thoracic epidural catheter tip will be confirmed by real time fluoroscopy and a single injection of 1 ml of omnipaque 180 mg/mL contrast. In keeping with current practice, a bolus of 0.2% ropivacaine 0.3 ml per kg (maximum dose 20 ml) will be administered in the epidural space to the patients in the TEA group at least 10 minutes prior to surgical incision.
223781360|NCT02056301|DRUG|Morphine|This device runs a basal infusion of pain medicine (morphine) intravenously with additional allowable patient controlled doses every 10 minutes
223781361|NCT05198232|BEHAVIORAL|Zumba High Tempo|The Zumba high tempo group will complete a 10-week (2x a week; 60 minutes per session) virtual adapted aerobic dance intervention (adapted Zumba®). Each session will consist of: a warm-up (3-5 minutes), 5-6 songs with instruction (40 minutes), and a cool down (5 minutes) for a total of about 60 minutes including rest/water breaks and time to transition. The only difference between the two adapted Zumba® programs will be the speed at which the songs will be played and the number of times through each song. The songs for the high-tempo group will be played at full speed; the songs in the high-tempo group will be repeated to ensure an equal amount of time moving for both groups. All sessions will be video recorded and examined for fidelity. This group will complete pre-test, post-test, and a 4-week follow-up.
223781362|NCT05198232|BEHAVIORAL|Zumba Low Tempo|The Zumba low tempo group will complete a 10-week (2x a week; 60 minutes per session) virtual adapted aerobic dance intervention (adapted Zumba®). Each session will consist of: a warm-up (3-5 minutes), 5-6 songs with instruction (40 minutes), and a cool down (5 minutes) for a total of about 60 minutes including rest/water breaks and time to transition. The only difference between the two adapted Zumba® programs will be the speed at which the songs will be played and the number of times through each song. The songs for the low-tempo group will be set to three-fourths speed. All sessions will be video recorded and examined for fidelity. This group will complete pre-test, post-test, and a 4-week follow-up.
223781363|NCT02073045|OTHER|educational intervention|Receive educational handouts
223781364|NCT02073045|OTHER|lymphedema survey|Ancillary studies
223781365|NCT00399477|DRUG|rasagiline mesylate|Azilect®
223781366|NCT00399477|DRUG|Rasagiline mesylate plus Mirapex|Mirapex, Azilect®
223781367|NCT00399477|DRUG|Rasagiline mesylate with Levodopa|Azilect®, Levodopa
223781368|NCT00399477|DRUG|Rasagiline mesylate with Requip|Azilect®, Requip
223781369|NCT03906058|DRUG|Anlotinib|All patients enrolled in the study will accept anlotinib treatment as a palliative treatment .
223781370|NCT01194674|DRUG|Microplasmin|Participants received an intravitreal injection of 125 µg in 100 µL of microplasmin at baseline.
223781371|NCT05235880|OTHER|Virtual reality based games|In an hour physiotherapy session first 40 minutes of session includes conventional physiotherapy program tailored to patient's needs. Last 20 minutes of session includes virtual reality based games aiming improvement on upper extremities, trunk and cognitive functions.
223781372|NCT05235880|OTHER|Conventional exercises|In an hour physiotherapy session first 40 minutes of session includes conventional physiotherapy program tailored to patient's needs. Last 20 minutes of session includes conventional physiotherapy approaches aiming improvement on upper extremities, trunk and cognitive functions.
223781373|NCT04483453|OTHER|EXPL feeding regimen|EXPL FUF (lower protein and 100% lactose) + EXPL IC (whole grains and legumes)
223781374|NCT04483453|OTHER|CTRL feeding regimen|CTRL FUF (standard protein content and carbohydrate profile) + CTRL IC (refined grains)
223781375|NCT02529020|DEVICE|Mouthguard|Condition of wearing mouthguard
223781376|NCT02529020|DEVICE|No mouthguard|Condition without mouthguard
223781377|NCT03877367|OTHER|Upper extremity manipulation|An upper extremity (glenohumeral, humeroulnar and radioulnar joints, bilaterally) or a lower extremity (coxofemoral, tibiofemoral, and tibiotalar, bilaterally) manipulation series.
223781378|NCT01987713|BEHAVIORAL|lifestyle intervention|the intervention strength (amount, frequency, duration) including a reduction in energy intake and an increase in physical activity level will be reported. The guidance/description of the treatment protocol, preparation and training of intervener, techniques to retain the research subjects will be covered to prevent the lack of intervention integrity. Besides, the schooler admitted in a university hospital will be invited to explore their health lifestyles and receive the intervention.
223781379|NCT02747342|DRUG|SHR3680; SHR3162|"SHR3680 will be administered orally in dose escalation/expansion phase,~SHR3680 will be administered orally at a fixed dose together with SHR3162 in combination phase."
223781380|NCT02532218|DRUG|ARI-3037MO|Lipid lowering treatment Statins
223781381|NCT04289753|BEHAVIORAL|EHR clinical decision support nudges|Clinical decision support nudges delivered within the EHR when conditions meet alert triggering criteria.
223781382|NCT04289753|BEHAVIORAL|Brief clinician education|Clinicians will be invited to view brief education material.
223781383|NCT01999504|OTHER|PAL-2|meal
223781384|NCT01999504|OTHER|TFH-1|Meal
223781385|NCT01999504|OTHER|Reference|Meal
223781386|NCT01646476|DEVICE|Covered stent (Bona stent pyloric/duodenal covered) insertion|self-expandable metallic stent placement was performed with a therapeutic endoscope (working channel ≥ 3.7 mm) using a through-the-scope method. All patients underwent procedures under conscious sedation with midazolam and pethidine. The length of the stricture was assessed either endoscopically or fluoroscopically; the length of the stent had to exceed that of the stricture by at least 3 cm. After the required stent length was determined, the stent was advanced through the endoscope over a guidewire until it passed across the distal end of the stricture. Then, the stent was deployed under continuous fluoroscopic control. For the Wave covered stent group, the stent was repositioned after deployment using the lasso under fluoroscopic guidance (if necessary), aligning the central portion of the stricture with the central portion of the stent which had reduced radial force and indentation. Stent positioning was confirmed endoscopically and fluoroscopically.
223781387|NCT01646476|DEVICE|Uncovered stent (Bona stent, pyloric/duodenal) insertion|Self-expandable metallic stent placement was performed with a therapeutic endoscope (working channel ≥ 3.7 mm) using a through-the-scope method. All patients underwent procedures under conscious sedation with midazolam and pethidine. The length of the stricture was assessed either endoscopically or fluoroscopically; the length of the stent had to exceed that of the stricture by at least 3 cm. After the required stent length was determined, the stent was advanced through the endoscope over a guidewire until it passed across the distal end of the stricture. Then, the stent was deployed under continuous fluoroscopic control. For the Wave covered stent group, the stent was repositioned after deployment using the lasso under fluoroscopic guidance (if necessary), aligning the central portion of the stricture with the central portion of the stent which had reduced radial force and indentation. Stent positioning was confirmed endoscopically and fluoroscopically.
223781388|NCT00034762|DRUG|risperidone|
223781389|NCT06057051|DEVICE|iStent Infinite|iStent Infinite Trabecular Micro-Bypass System
223781390|NCT02209324|DRUG|ASP2151|
223781391|NCT04679467|DIETARY_SUPPLEMENT|PKU sphere|"TYR sphere is a powdered, low phenylalanine and tyrosine protein substitute, containing a balanced mix of casein glycomacropeptide (cGMP) isolate, essential and non-essential amino acids, carbohydrate, fat, vitamins, minerals and the long chain polyunsaturated fatty acid (LCP); Docosahexaenoic acid (DHA). It contains sugars and sweetener.~The product is designed to be prescribed based on its protein content, not its energy content."
223781392|NCT03433456|BEHAVIORAL|Home visitation + HABITS program|The HABITS program will target 5 key behaviors (physical activity, increasing fruit and vegetable consumption, decreasing sugary beverages, decreasing fried foods, and encouraging regular self-monitoring and self-weighing) aimed at reducing obesity risk in mothers or primary caregivers and children.
223781393|NCT03433456|BEHAVIORAL|Standard home visitation program|Treatment in the control arm includes the content and services typically provided by the home visitation partner, which is focused on promoting caregiver and child health by providing screenings and referrals, encouraging smoking cessation, promoting safe sleep practices, and strengthening children's school readiness and achievement, social/emotional and physical development.
223781394|NCT05799495|DRUG|PF-07817883|Arm 1: low dose Arm 2: medium dose Arm 3: high dose
223781395|NCT05799495|DRUG|Placebo|Placebo
223698752|NCT02874287|DRUG|Hydroxychloroquine Sulfate Tablets|Subjects are treated with oral hydroxychloroquine sulfate tablets 200mg twice daily for 20 weeks. All the interventions are built on the guideline-based secondary prevention of coronary heart disease medications.
223698753|NCT02874287|DRUG|Placebo Tablets|Subjects are treated with oral placebo tablets 200mg twice daily for 20 weeks. All the interventions are built on the guideline-based secondary prevention of coronary heart disease medications.
223698754|NCT02121990|DRUG|Paclitaxel,|
223698755|NCT02121990|DRUG|Bevacizumab|
223698756|NCT02121990|DRUG|Cisplatin|
223698757|NCT02121990|DRUG|Olaparib|
223698758|NCT00837928|DRUG|bendamustine|40 mg/m2 will be administered IV on days 1,2,and 3 prior to surgery.on each day of SRT.
223698759|NCT00837928|OTHER|laboratory biomarker analysis|samples will be obtained on day 1 or 2 only from patients undergoing surgery on day 3 (i.e. PK samples will not be collected from patients who begin SRT on day 1).
223698760|NCT00837928|PROCEDURE|Surgical Resection of Brain Metastases|Surgical Resection of Brain Metastases Day 3 (immediately after Bendamustine)
223698761|NCT00837928|RADIATION|Stereotactic body radiation therapy|Starting at least 4 weeks after surgery (Day 1 if no surgery ); 30 Gy in 5 daily fractions(Mon-Fri)
223698762|NCT00208299|DRUG|Regadenoson|0.4 mg, bolus intravenous injection
223698763|NCT00208299|DRUG|Adenosine|0.14 mg/kg/min for 6 minutes, intravenous infusion
223698764|NCT03139279|DRUG|Dexmedetomidine|Dexmedetomidine 0.3 ug/kg intravenous bolus
223698765|NCT03139279|OTHER|Saline placebo|Intravenous saline/placebo
223698766|NCT03139279|DRUG|Propofol|Propofol titrated intravenous boluses
223698767|NCT04485910|OTHER|Single step media|Usage of single step media in embryo culture
223698768|NCT04485910|OTHER|Sequential media|Usage of sequential media in embryo culture
223698769|NCT00486174|DRUG|methylene blue|2.0 mg/kg of Methylene Blue administered every 6 hours (as required) for up to 48 hours.
223698770|NCT01336569|DRUG|Travoprost 0.004%/timolol maleate 0.5% fixed combination|
223698771|NCT03929627|OTHER|Cortisol awakening response|Cortisol awakening response
223698772|NCT02192073|PROCEDURE|Suprapectoral Biceps tenodesis|
223698773|NCT02192073|PROCEDURE|Subpectoral biceps tenodesis|
223698774|NCT04824729|PROCEDURE|Lower limb revascularization|French population of patients with lower-extremity peripheral artery disease who have undergone lower limb revascularization.
223698775|NCT04824729|PROCEDURE|Lower limb revascularization|French population of patients matching the VOYAGER PAD exclusion criteria resembling a subgroup of the PAD revascularized population.
223698776|NCT01924624|DRUG|Thalidomide|Patients in the Adjuvant group were given oral Thalidomide(at a dose of 100 mg per day) continuously during the follow-up period
223698777|NCT04348461|DRUG|Allogeneic and expanded adipose tissue-derived mesenchymal stromal cells|Two serial doses of 1.5 million adipose-tissue derived mesenchymal stem cells per kg
223781396|NCT06299501|PROCEDURE|Routine questions|The routine group of nurses receive training and supervision and will ask questions about family violence to everyone, disregarding if they suspect family violence or not.
223698778|NCT02337738|DRUG|TVP-1012 1mg|TVP-1012 1mg Tablets
223698779|NCT02337738|DRUG|TVP-1012 0.5mg|TVP-1012 0.5mg Tablets
223698780|NCT02337738|DRUG|Placebo|Placebo Tablets
223698781|NCT00253760|DRUG|dietary amino acids; cysteine and methionine|
223698782|NCT00406354|DRUG|Atomoxetine|Dosage form for the atomoxetine fast and slow titration arms consists of 2.5 mg, 10 mg, 20 mg, 25 mg, and 40 mg capsules. Double-blind treatment will consist of 3 capsules taken once per day for approximately 9 weeks.
223698783|NCT00406354|DRUG|Placebo|Double-blind treatment will consist of 3 matching placebo capsules taken once per day by mouth for approximately 9 weeks.
223698784|NCT01641510|DRUG|Prasugrel|Loading with prasugrel 30 mg followed by daily administration of prasugrel 5 mg
223698785|NCT01641510|DRUG|Clopidogrel|Loading with clopidogrel 600 mg followed by daily administration of clopidogrel 75 mg
223698786|NCT00402142|BIOLOGICAL|Dendritic cell vaccine|107 DC subcutaneous 3 doses every 2 weeks
223698787|NCT00402142|BIOLOGICAL|non pulsed dendritic cell untreated patients|107 DC subcutaneous 3 doses every 2 weeks
223698788|NCT00402142|BIOLOGICAL|pulsed dendritic cell vaccine|107 DC subcutaneous 3 doses every 2 weeks
223698789|NCT00402142|BIOLOGICAL|dendritic cell vaccine|107 DC subcutaneous 3 doses every 2 weeks
223698790|NCT00402142|BIOLOGICAL|non pulsed dendritic cell vaccine|107 DC subcutaneous 3 doses every 2 weeks
223698791|NCT05427591|PROCEDURE|"The chemomechanical caries removal agent BRIX3000® in group (1A)"|"In group(1A), the chemomechanical caries removal agent BRIX3000® was used for caries removal in primary molars."
223698792|NCT05427591|PROCEDURE|The traditional surgical treatment in group (1C)|In group(1C), the traditional surgical method (high-speed and low-speed air-rotors) was used for caries removal in primary molars.
223698793|NCT05427591|PROCEDURE|"The chemomechanical caries removal agent Carie-CareTM in group (2B)"|"In group(2B), the chemomechanical caries removal agent Carie-CareTM was used for caries removal in primary molars."
223698794|NCT05427591|PROCEDURE|The traditional surgical treatment in group (2C)|In group(2C), the traditional surgical method (high-speed and low-speed air-rotors) was used for caries removal in primary molars.
223698795|NCT01304160|RADIATION|stereotactic body radiotherapy|30Gray in 5 fractions
223698796|NCT03866187|BIOLOGICAL|ChAd155-hIi-HBV low dose formulation|Subjects in group A1 receive one dose of ChAd155-hIi-HBV low dose formulation at Day 1, by intramuscular injection in the deltoid of the non-dominant arm.
223698797|NCT03866187|BIOLOGICAL|ChAd155-hIi-HBV high dose formulation|"Subjects in groups B1 and B3 receive one dose of ChAd155-hIi-HBV high dose formulation at Day 1 and Day 113 respectively, by intramuscular injection in the deltoid of the non-dominant arm.~Subjects in groups C1 and C2 receive one dose of ChAd155-hIi-HBV high dose formulation at Day 1 and Day 113 respectively, by intramuscular injection in the deltoid of the dominant arm."
223698798|NCT03866187|BIOLOGICAL|HBc-HBs/AS01B-4 low dose formulation|Subjects in group A1 receive two doses of HBc-HBs/AS01B-4 low dose formulation, one at Day 113 and one at Day 169 and subjects in group A2 receive four doses of the low dose formulation, one dose each at Days 1, 57, 113 and 169, by intramuscular injection in the deltoid of the non-dominant arm.
223781397|NCT06299501|PROCEDURE|Questions on evidence based indication|The group of nurses will receive training and supervision and will ask questions on evidence based indication
223698799|NCT03866187|BIOLOGICAL|HBc-HBs/AS01B-4 high dose formulation|Subjects in group B1 receive two doses of HBc-HBs/AS01B-4 high dose formulation, one at Day 113 and one at 169; subjects in group B2 receive four doses, one dose each at Days 1, 57, 113 and 169; subjects in group C1 receive four co-administered doses at Days 1, 57, 113 and 169 and subjects in group C2 receive two co-administered doses at Days 113 and 169, by intramuscular injection in the deltoid of the non-dominant arm.
223698800|NCT03866187|BIOLOGICAL|MVA-HBV low dose formulation|Subjects in group A1 receive one dose of MVA-HBV low dose formulation at Day 57, by intramuscular injection in the deltoid of the non-dominant arm.
223698801|NCT03866187|BIOLOGICAL|MVA-HBV high dose formulation|"Subjects in groups B1 and B3 receive one dose of MVA-HBV high dose formulation at Day 57 and Day 169 respectively, by intramuscular injection in the deltoid of the non-dominant arm.~Subjects in group C1 receive three co-administered doses of the vaccine at Days 57, 113 and 169 and subjects in group C2 receive one co-administered dose of the vaccine at Day 169, by intramuscular injection in the deltoid of the dominant arm."
223698802|NCT03866187|DRUG|Placebo|Subjects in group A3 receive four doses of placebo, one each at Days 1, 57, 113 and 169 and subjects in group B3 receive two doses of placebo one each at Days 1 and 57, by intramuscular injection in the deltoid of the non-dominant arm. Subjects in group C2 receive 2 co-administered doses of placebo at Days 1 and 57, by intramuscular injection in the deltoid of the dominant and non-dominant arm.
223698803|NCT03182803|BIOLOGICAL|CTLA-4/PD-1 antibodies expressing mesoCAR-T|Every cycle, peripheral blood mononuclear cells (PBMC) are collected on day 0, CAR-T cells are cultured in a GMP standard workshop. Patients are given a three-day regimen of chemotherapy consisting of cyclophosphamide aimed to deplete the lymphocytes before cells infusion. Then the patients will receive an i.v.gtt infusion of CTLA-4 and PD-1 antibodies expressing mesothelin-targeted CAR-T cells at (2-5) ×10\^7 cells/kg from day 18 to day 19 (±2 days). 2 cycles are regarded as a treatment period.
223698804|NCT03392077|PROCEDURE|Caesarean section|Caesarean section will be done to deliver the baby
223698805|NCT03392077|OTHER|cervical dilatation|Cervical dilatation will be done by double gloves digital dilatation postpartum
223698806|NCT03392077|OTHER|No cervical dilatation|after delivery of the baby cervix will be remain closed
223698807|NCT01333579|OTHER|Repetitive transcranial magnetic stimulation|Repetitive transcranial magnetic stimulation, frequency of 1Hz, once a day for ten days.
223698808|NCT02720237|BEHAVIORAL|Brief Intervention|In-person individual sessions (occurring one month apart) and booster phone sessions (occurring 2-3 weeks after each in-person session), delivered by a trained counselor.
223698809|NCT02720237|BEHAVIORAL|Motivational Enhancement Therapy (MET) Intervention|In-person individual sessions (one session per week) and optional group sessions, delivered by a trained counselor.
223698810|NCT02720237|BEHAVIORAL|Cognitive Behavioral Therapy (CBT) Intervention|In-person individual sessions (one session per week) and optional group sessions, delivered by a trained counselor.
223698811|NCT02890667|OTHER|Incident cancer|The number of incident cancer cases
223698812|NCT05792787|DIAGNOSTIC_TEST|Echo-color-doppler|"To perform the initial screening patients will undergo panoramic radiography and clinical examination followed by periapical radiographs of the teeth suspected of AP using the long cone paralleling technique with a film holder. The following parameters will be recorded:~1. The number of decayed, missing and filled teeth (DMFT index)~2. The number of teeth with AP~3. Periapical Index Score All individuals will undergo a cardiovascular examination in the Unit of Vascular Surgery, University of Siena (Siena, Italy). The cardiovascular assessment included physical examination, blood pressure measurement, past medical history and echo-color-doppler for the assessment of carotid intima-media thickness (cIMT), presence of abdominal aortic aneurysm and presence of peripheral pulses."
223698813|NCT04595344|OTHER|Listening to Pure Binaural Beats|"The patients in DCG ((binaural beat group) ) and USRG (binaural beat group) listened to binaural beats.The binaural beats were produced using a software program (Audacity®, version win. 2.3.2, 2019 Audacity Team) at frequency of 10 Hz (a tone of 200 Hz in the right ear and a tone of 210 Hz in the left ear). The binaural beats that the patients in DCG-1 and USRG-1 listened to were pure frequencies, with no background music or waves."
223698814|NCT04595344|OTHER|Listening to classical music|The patients in DCG (classical music group) and USRG (classical music group) listened to classical music.The classical music that those in DCG-2 and USRG-2 listened to was Mozart's 40th Symphony.
223698815|NCT04595344|OTHER|No audio only headphone|The patients in DCG (placebo group) and USRG (placebo group) sat in a quiet room with headphones on but no audio playing
223698816|NCT05777343|OTHER|Experimental|Cognitive training combined with the recommended non-pharmacological intervention (Exercise and Pain Neuroscience Education).
223698817|NCT05777343|OTHER|Exercise and PNE|Recommended non-pharmacological intervention (Exercise and Pain Neuroscience Education).
223698818|NCT05777343|OTHER|Cognitive training|Online sessions of cognitive training.
223781398|NCT06299501|PROCEDURE|Treatment as usual|The group of nurses will ask questions when suspecting ongoing violence in the family
223698819|NCT04579029|PROCEDURE|Lymphaticovenous anastomosis surgery combined with near infrared spectroscopy imaging|Lymphoedema is well recognized as a chronic debilitating disease resulting from an abnormal collection of protein-rich fluid within the subcutaneous tissues of the body. Given the need to identify more effective treatments, more recent advances in super microsurgical techniques have seen the introduction of new procedures, perhaps the most successful of which have involved re-routing the lymphatic fluid by using microsurgery to divert small lymphatic channels into venules in the sub-dermal plane (LVA surgery). This procedure is performed under regional or general anaesthetic as a day-case operation, leaving only a few very short scars in the skin of the arm or leg.
223698820|NCT01460368|DRUG|LY2409021|Administered orally
223698821|NCT01460368|DRUG|Placebo|Administered orally
223698822|NCT01460368|DRUG|Moxifloxacin|Administered orally
223698823|NCT00629174|BEHAVIORAL|Exercise|Endurance and resistence training, 90 minutes, 3 times weekly
223698824|NCT00629174|BEHAVIORAL|Mental activity|Participation at computer lessons, 3 times weekly, 90 minutes each
223781399|NCT03105362|DIETARY_SUPPLEMENT|Enterade® oral rehydration solution|Commercially available amino acid based oral rehydration solution
223698825|NCT02866994|BEHAVIORAL|Project Connect Online|Three-hour workshop to complete personal website regarding breast cancer experience to share with friends and family
223698826|NCT02866994|BEHAVIORAL|PCO PLUS|Three-hour workshop to complete personal website regarding breast cancer experience to share with friends and family, as well as other women diagnosed with breast cancer
223698827|NCT04529915|DIAGNOSTIC_TEST|Exosome sampling|"* Centrifugation of blood plasma~* Size exclusion chromatography~* ELISA assay, Western blotting~* Deep-learning analysis"
223698828|NCT05235139|DEVICE|IOL implantation experimental (ISOPURE 1.2.3.)|Implantation of premium monofocal IOL ISOPURE 1.2.3.
223698829|NCT05235139|DEVICE|IOL implantation active comparator (Acrysof Vivity)|Implantation of EDOF IOL Acrysof Vivity
223698830|NCT01516229|DRUG|somatropin|Prescription of somatropin at the discretion of the physician
223698831|NCT01517685|DIETARY_SUPPLEMENT|Organic flax seed oil|2 tablespoons of organic flax seed oil are eaten daily for 8 weeks.
223698832|NCT01517685|DIETARY_SUPPLEMENT|fish oil|5 grams (1 tsp.) of fish oil is eaten per day for 8 weeks.
223698833|NCT00147758|DRUG|Colesevelam hydrochloride|
223698834|NCT05019794|DRUG|Infigratinib|Infigratinib (BGJ398) 125 mg orally daily, 3 weeks on, 1 week off.
223698835|NCT05126498|OTHER|no intervention|no intervention was applied
223698836|NCT00273910|DRUG|gp100:209-217 (210M)|
223698837|NCT00273910|DRUG|Montanide ISA-51|
223698838|NCT00273910|DRUG|Imiquimod|Apply imiquimod 5% cream to the skin at the site of injection daily for 5 days
223698839|NCT05177133|DRUG|Capecitabine|PO Capecitabine
223698840|NCT05177133|DRUG|Oxaliplatin|IV Oxaliplatin
223698841|NCT05177133|DRUG|Retifanlimab|IV retifanlimab
223698842|NCT00747461|DEVICE|CryoSpray Ablation|Cryospray Ablation up to 4 -5 second cycles for up to 4 treatments in the first 30 days
223698843|NCT02356315|OTHER|Functional Magnetic Resonance Imaging|Functional magnetic resonance imaging will be performed to measure brain, brainstem, and spinal cord activity.
223698844|NCT04870281|DEVICE|CRT-DX|Evaluation of overall health, including heart failure and atrial fibrillation improvement, changes in physical fitness, and general quality of life.
223698845|NCT03300323|DIAGNOSTIC_TEST|IV fluid challenge administration|Administration of an intravenous fluid challenge to assess for fluid responsiveness
223698846|NCT01212107|DRUG|FGF Receptor|LY2874455 administered orally.
223698847|NCT01212107|DRUG|Phosphate Binders|
223698848|NCT04753476|BIOLOGICAL|Injection of Secretome-MSCs|"Injection of Hypoxic Secretome-MSCs intramuscular (deltoideus) :~Day 1: 1 cc every 12 hours~Day 2: 1 cc every 12 hours~Day 3: 1 cc every 12 hours"
223698849|NCT04753476|DRUG|Standard treatment of Covid-19|Patients will be given Standard treatment of Covid-19 which accordance with National protocol
223698850|NCT05579925|BIOLOGICAL|CM310|CM310 600 mg + 300 mg, subcutaneous injection
223698851|NCT05058352|DRUG|HS269|Oral tablets, once daily. Dose escalation from 50 mg QD, through 100 mg, 200mg, 300 mg, 400 mg, to 500mg.
223698852|NCT00973271|DRUG|290 mg DCCR|290 mg diazoxide choline
223698853|NCT00973271|DRUG|435 mg DCCR|435 mg diazoxide choline
223698854|NCT00973271|DRUG|135 mg fenofibric acid|135 mg fenofibric acid
223698855|NCT00973271|DRUG|Placebo|Placebos matching each of 2 doses of DCCR and 135 mg fenofibric acid
223698856|NCT00973271|DRUG|atorvastatin|20 mg atorvastatin
223698857|NCT04025983|DIETARY_SUPPLEMENT|GastimunHp Plus|Each sachet contains 6mg of IgY and 50 mg of heat-killed Lactobacillus johnsonii No. 1088.
223698858|NCT04025983|OTHER|Placebo|The placebo contains neither IgY nor L. johnsonii.
223698859|NCT04559360|DEVICE|PRESTOapp|The intervention group will be asked to use the app for a period of 2 months.
223698860|NCT00753428|OTHER|Community-based Survey|"Questionnaires will be used to record detailed information regarding demographic and socioeconomic characteristics, maternal medical history, recent obstetrical history (including access to preventive services for mother-to-child HIV transmission), and infant medical history. Infant deaths will also be recorded as part of the survey. In cases where either the mother or infant has died, we will perform verbal autopsy interviews (Appendix 5) with surviving family members to determine cause of death and gather information regarding HIV infection and/or exposure.~Heel/finger pricks will be taken so as to perform dried blood spot cards, and test for HIV in children and adults."
223698861|NCT06207968|DEVICE|Knee surgery with FH Ortho devices|"This clinical investigation is a real-life observatory designed to collect long-term clinical data on patients who have undergone knee joint replacement or knee ligament reconstruction.~In this type of intervention, one or more medical devices distributed by FH ORTHO SAS may be used by surgeons."
223698862|NCT02620007|DRUG|Ciprofloxacin|oral Ciprofloxacin 500 mg bis in die (bid) for 12 weeks
223698863|NCT02620007|DRUG|Rifaximin|oral Rifaximin 800 mg bid for 12 weeks
223698864|NCT02620007|DRUG|Ciprofloxacin Placebo|a placebo of Ciprofloxacin bid for 12 weeks
223698865|NCT02620007|DRUG|Rifaximin Placebo|a placebo of Rifaximin bid for 12 weeks
223698866|NCT05075382|PROCEDURE|Elbow surgery for fracture|This group will undergo a surgery in order to fix a broken elbow.
223698867|NCT01244945|DIETARY_SUPPLEMENT|L. reuteri DSM 17938|L. reuteri will be administered at 1x10\^8 CFU dosage in form of tabs. In order to ensure colonization (run in), 4 tabs will be administered per os daily (4x10\^8CFU/die) for 15 days. Then administration will continue with 2 tabs daily (2x10\^8 CFU/die) for 90 days.
223698868|NCT01244945|OTHER|Placebo Group|Placebo tabs identical in form, taste and consistency to active tabs
223698869|NCT05055453|DEVICE|MyPhonak Junior App|The app is an accessory to the hearing aids which allows the user to make adjustments to their hearing aid in real-time. The hearing aid does not require the use of the app, but the objective of this study is to evaluate the effects of the user adjustments made via the app on the participant's speech intelligibility with the hearing aid.
223698870|NCT05055453|DEVICE|Phonak Sky hearing aid|A Behind-The-Ear hearing aid (BTE) fit to hearing impaired persons with mild to severe hearing loss.
223698871|NCT04733144|DRUG|Prednisolone|7,5 mg prednisolone (low dose) 30 mg prednisolone (high dose)
223698872|NCT04733144|DRUG|Dexamethasone|1,125 mg dexamethasone 4,5 mg dexamethasone
223698873|NCT04669327|OTHER|gait analysis|Vicon nexus with MTI force plate form
223698874|NCT03796832|DEVICE|Flat Flexible Shoes|Off-the-shelf commercially available shoes will be used compliant with previously published criteria: (i) heel height \<15 mm, (ii) shoe pitch \<10 mm, (iii) absent arch support/motion control, (iv) minimal sole rigidity, (v) weight \<=200g (+/-10%). Participants will be instructed to wear the shoes at least 4 hours daily for the duration of the 9-month intervention and to avoid wearing other types of shoes, if possible.
223698875|NCT03796832|DEVICE|Stable Supportive Shoes|Off-the-shelf commercially available shoes will be used compliant with previously published criteria: (i) heel height \>30 mm, (ii) shoe pitch \>10 mm, (iii) present arch support/motion control, (iv) sole rigidity, (v) weight \>300g (+/-10%). Participants will be instructed to wear the shoes at least 4 hours daily for the duration of the 9-month intervention and to avoid wearing other types of shoes, if possible.
223698876|NCT03796832|OTHER|Exercise Therapy|The 3-month supervised exercise program will consist of one group session per week of approximately 30 minutes complemented with home-based exercises 3 times per week. Group sessions will consist of a 10-min warm-up followed by a circuit training of strengthening and/or neuromuscular exercises. Subsequently, during a 6-month unsupervised home exercise program, participants will perform strengthening exercises of the lower limb muscles 3 times weekly. Throughout the 9-month intervention, participants will be encouraged to maintain a daily routine of aerobic exercises, consisting of structured activity bouts of at least 10 minutes at a moderate intensity (grade 5-6 (out of 10, maximum exertion) on a Rate of Perceived Exertion scale), achieving at least 70 minutes of weekly physical activity at 3 months and 150 minutes at 9 months.
223698877|NCT05276154|OTHER|thermoviscous bulkfill composite (Viscalor)|a relatively new product of composite resin which is transformed from high viscosity to low viscosity by the action of head produced by a heating device.
223698878|NCT03169309|DEVICE|Brain Entrainment Technology|Brain Entrainment Technology (BET), also known as Binaural Beat Technology (BBT), is a sound technology where two slightly different tones are present to each ear and the brain produces a third tone. This third tone impacts the reticular activating system which alters the action potentials of the thalamus and cerebral cortex in turn changing the brain wave frequency to alter the state of consciousness of the listener.
223698879|NCT03276988|DRUG|Period 1 GX-30, Period 2 THYROGEN®|Part B - Sequence A. GX-30 0.9mg will be administered at Day 1 and Day 2 in Period 1. After wash-out period of 2 to 3 weeks, THYROGEN® 0.9mg will be administered in Period 2.
223698880|NCT03276988|DRUG|Period 1 THYROGEN®, Period 2 GX-30|Part B - Sequence B. THYROGEN® 0.9mg will be administered at Day 1 and Day 2 in Period 1. After wash-out period of 2 to 3 weeks, GX-30 0.9mg will be administered in Period 2.
223698881|NCT01224665|PROCEDURE|therapeutic conventional surgery|Patients undergo radical cystectomy
223698882|NCT01224665|PROCEDURE|therapeutic standard lymphadenectomy|Patients undergo standard pelvic lymphadenectomy.
223698883|NCT01224665|PROCEDURE|therapeutic extended lymphadenectomy|Patients undergo extended pelvic lymphadenectomy
223698884|NCT02031211|DRUG|Etanercept|The patient will receive 0.4 ml/kg as the 25mg/ml preparation subcutaneously.
223698885|NCT02031211|DRUG|Placebo|The patient will receive 0.4 ml/kg of Normal Saline injected subcutaneously.
223698886|NCT05428098|OTHER|education|Oral and written education according to the life model
223698887|NCT05389046|DRUG|Escitalopram|Escitalopram
223698888|NCT05389046|DRUG|Escitalopram+Aripiprazole|Escitalopram+Aripiprazole
223698889|NCT05389046|DRUG|Escitalopram+omega-3 PUFAs|Escitalopram+omega-3 PUFAs
223698890|NCT05389046|DRUG|Escitalopram+Aripiprazole+omega-3 PUFAs|Escitalopram+Aripiprazole+omega-3 PUFAs
223698891|NCT05884710|OTHER|Foot core exercises|2 groups; First group is an intervention group who has contain foot core exercises and the other group is a control group.
223698892|NCT05884710|OTHER|Conventional Physiotherapy|Electrotherapeutic modalities and range of motion exercises
223698893|NCT00299182|DRUG|AMG 531|Arm A: AMG531 - 1, 3, or 10 mcg/kg subcutaneous injection administered on on days -5 and 5 (pre and post chemotherapy dose) beginning with Cycle 2; OR, Arm A: AMG531 - 1, 3, or 10 mcg/kg subcutaneous injection administered on on days 5 and 7 (post chemotherapy doses only) beginning with Cycle 2.
223698894|NCT00299182|DRUG|Rituximab|375 mg/m\^2 by vein over 4-6 hour infusion day 1, each cycle.
223698895|NCT00299182|DRUG|Cyclophosphamide|300 mg/m\^2 by vein over 3 hours every 12 hours for 6 doses (days 2-4), Cycles 1,3, \& 5.
223698896|NCT00299182|DRUG|Vincristine|1.4 mg/m\^2/dose (maximum 2 mg) by vein over 15 minutes Days 5 and 12, Cycles 1,3,\& 5.
223698897|NCT00299182|DRUG|Doxorubicin|50 mg/m\^2/dose by vein over 15 minutes on Day 5 or by continuous infusion over 24-48 hours (days 5-6), Cycles 1,3,\& 5.
223698898|NCT00299182|DRUG|Dexamethasone|40 mg/day by mouth or by vein days 2-5 and 12-15, Cycles 1,3,\& 5.
223698899|NCT00299182|DRUG|Methotrexate|200 mg/m\^2 by vein over 2 hours followed by 800 mg/m\^2 over 22 hours Day 2, Cycles 2, 4 \& 6.
223781400|NCT06477445|DEVICE|Visual feedback balance training system|Using an visual feedback balance training system to provide a dynamic balance training platform for patients to perform balance training based on visual feedback.
223781401|NCT06477445|OTHER|repetitive facilitative exercise|Repetitive facilitative exercise (RFE) is a new technology that combines multiple sensory stimuli and achieves facilitation and reinforcement of the reconstruction of paralyzed neural pathways through repeated and extensive directional exercise.
223781402|NCT06477445|OTHER|conventional therapy|Basic training, including passive joint movement and activities of daily living exercise.
223698900|NCT00299182|DRUG|Cytarabine|3 g/m\^2 by vein over 2 hours every 12 hours for 4 doses, days 3 \& 4; OR,1 g/m\^2 by vein over 2 hours every 12 hours for 4 doses, days 3 \& 4 for patients \> 60 years and for patients with serum creatinine \> 1.5 mg/dL; Cycles 2,4,\& 6.
223698901|NCT00299182|DRUG|Placebo|Arm A: Placebo - subcutaneous injection administered on days -5 and 5 (pre and post chemotherapy dose) beginning with Cycle 2; OR, Arm B: Placebo - subcutaneous injection administered on days 5 and 7 (post chemotherapy doses only) beginning with Cycle 2.
223698902|NCT00218127|DRUG|Levoacetyl Methadol|WtDosing up to 1.0 mg/kg Stable 1.0 mg/kg/day
223698903|NCT00218127|DRUG|Levoacetyl Methadol|MaxEffect+CBT evaluation to 48 mg Adjust to effect (+/-)
223698904|NCT00218127|DRUG|Levoacetyl Methadol|LAAM Fixed Dose evaluation up to 48 mg 48 mg
223698905|NCT06021665|OTHER|Fortetropin supplement|Test Formulation: 10g serving Calories: 64.8g Carbohydrates: 0.45g Fats: 5.5g Protein: 3.38g
223698906|NCT06021665|OTHER|Cheese protein|"The cheese powder will act as the control product. Cheese powder has been chosen as it matches the macronutrient content of the test product, but without the active ingredient.~Control Formulation: 20g serving Calories: 93g Carbohydrates: 8g Fats: 5g Protein: 3g"
223698907|NCT02296944|OTHER|Collection of anatomical and functional results in the appearance of the tympanic membrane after surgery|
223698908|NCT00740077|OTHER|Low calorie, sugar-free cranberry juice cocktail (54% juice)|Single-dose, 24 hour pharmacokinetic trial of 8 oz dose administered orally.
223698909|NCT03325049|BEHAVIORAL|The health-promoting conversations|The health-promoting conversations
223698910|NCT03325049|OTHER|Usual Care|Usual Care
223698911|NCT00546650|DRUG|Sumatriptan succinate|NP101 iontophoretic transdermal system
223698912|NCT00546650|DRUG|Sumatriptan succinate|oral, subcutaneous, and intranasal formulations
223698913|NCT04181320|DEVICE|Venous Leg Ulcer Standard of Care with Granulox|Granulox will be added as an adjunct therapy to defined standard of care in subjects with predominantly venous leg ulcers.
223698914|NCT06076707|DRUG|bupivacain-tramadol|Comparing effectiveness of tramadol and bupivacaine for postoperative pain treatment and prevention for cesarian section
223698915|NCT04102956|DRUG|Kallikrein|HUK has been approved by China's State Food and Drug Administration as a state category I new drug for the treatment of stroke patients. Based on the available evidence, HUK injection ameliorates neurological deficits and improves long-term outcomes.
223698916|NCT04609969|DIAGNOSTIC_TEST|RT-qPCR test|Two concurrent nasopharyngeal swab specimens are collected for each participant. Comparison between RT-qPCR and COVID-VIRO® results of RT-qPCR positive patients is used to assess COVID-VIRO® sensitivity. Conversely, comparison between RT-qPCR and COVID-VIRO® results of RT-qPCR negative patients is used to assess COVID-VIRO® specificity.
223698917|NCT04609969|DIAGNOSTIC_TEST|COVID-VIRO® test|Two concurrent nasopharyngeal swab specimens are collected for each participant. Comparison between RT-qPCR and COVID-VIRO® results of RT-qPCR positive patients is used to assess COVID-VIRO® sensitivity. Conversely, comparison between RT-qPCR and COVID-VIRO® results of RT-qPCR negative patients is used to assess COVID-VIRO® specificity.
223698918|NCT02413177|BEHAVIORAL|EEG-no RTNF|All EEG sessions are done on an individual basis. Group 2 will receive EEG (no RTNF) at weeks 3, 4, 6, and 7 of MBSR. At these time points, subjects will take part in a 1-hour EEG-RTNF session., comprised of six 3.5-minute runs. Each run will begin with a 30-second active baseline task in which subjects view adjectives and think about and decide if the word describes them. Following baseline, subjects will meditate for 3 to 7 minutes with EEG-RTNF. All subjects will be instructed to practice meditation during EEG-RTNF training, and to keep their eyes closed.
223781403|NCT02038738|DRUG|68Ga-DOTATATE will be given in tracer doses and injected intravenously to image tumors by Positron Emission Tomography.|
223781404|NCT05548790|BEHAVIORAL|Spielberger State Anxiety Inventory (STAI-S)|STAI is one of the most frequently used scales in anxiety research, although it is not a specific scale for dental anxiety
223781405|NCT05548790|BEHAVIORAL|Dental Fear Scale (DFS)|DFS is a scale developed by Kleinknecht used to determine dental fear in different dimensions. This is a Likert-type scale with a score of 1-5. It has 20 items. It examines the level of fear in terms of dentist avoidance, somatic symptoms of fear, and fear of various applications in dentistry practice
223781406|NCT05548790|BEHAVIORAL|Modified Dental Anxiety Scale (MDAS)|MDAS was developed by Humphris et al. by adding a question related to injection. The scale consists of five-point Likert-type rating with five options. The scoring in this scale varies between 5 and 25
223781407|NCT05548790|BEHAVIORAL|Visual Analog Scale (VAS)|"VAS is ideal for evaluating situations that cannot be measured using digital and oral information. In the present study, a scale comprising 100-mm closed-end line was used to measure the anxiety level. One end of the scale was labeled as no anxiety and the other end as maximum anxiety imaginable"
223781408|NCT01198600|DEVICE|Habitual contact lens|Hydrogel or silicone hydrogel contact lens per participant's habitual brand and prescription
223781409|NCT01198600|DEVICE|Lotrafilcon B contact lens|Commercially marketed silicone hydrogel contact lens
223781410|NCT01198600|DEVICE|Contact lens cleaning and disinfecting system (ClearCare)|Commercially marketed, hydrogen peroxide-based contact lens care system
223698919|NCT02413177|BEHAVIORAL|EEG-RTNF|All EEG sessions are done on an individual basis. Group 1 will receive EEG-RTNF training from the PCC at weeks 3, 4, 6, and 7 of MBSR. At these time points, subjects will take part in a 1-hour EEG-RTNF session., comprised of six 3.5-minute runs. Each run will begin with a 30-second active baseline task in which subjects view adjectives and think about and decide if the word describes them. Following baseline, subjects will meditate for 3 to 7 minutes with EEG-RTNF. All subjects will be instructed to practice meditation during EEG-RTNF training, and to keep their eyes closed.
223698920|NCT05956873|DEVICE|REVAR|Endovascular repair of ruptured TAAAs with available technique and devices: endovascular treatments were performed in urgent or emergent setting, compulsory within the first 24 hours, using an off-the-shelf stent grafts, or an available custom-made fenestrated/branched device or a physician-modified endografts with fenestrations/branches or parallel endografting for renal and visceral arteries
223698921|NCT04685031|DRUG|Nitroglycerin ointment|after venipuncture, 1.5 cm (about 2 g) of ointment was applied in the distal part of the Angio catheter and the site was dressed with sterile gauze. In three time periods of 24, 48 and 72 hours from the time of venipuncture.
223698922|NCT04685031|DRUG|Clobetasol Topical|after venipuncture, 1.5 cm (about 2 g) of ointment was applied in the distal part of the Angio catheter and the site was dressed with sterile gauze. In three time periods of 24, 48 and 72 hours from the time of venipuncture.
223698923|NCT05726916|DRUG|Soliris®|Eculizumab IV administration (900mg/w during 4w then 1200 mg at w5 and 1200mg/2w for 8w) + Blood pressure control with renin angiotensin system blockers
223698924|NCT05726916|DRUG|Renin angiotensin system blockers|Blood pressure control with renin angiotensin system blockers
223698925|NCT06170203|OTHER|Personalised Follow-up Pathway|Discharge from routine oncology Follow-Up 2 years following radical treatment for a head and neck cancer
223698926|NCT02427828|DEVICE|Visensia Respiration Rate Estimation Service (VRES)|Medical device product to provide respiration rate from PPG signal
223698927|NCT04185376|OTHER|Questionnaire|a self-administered questionnaire for the assessment of pelvic floor disorders, their risk factors and their impact of quality of life during pregnancy and postpartum period which integrates bladder, bowel and sexual function, pelvic organ prolapse, severity, bothersomeness and conditions specific quality of life in women with urinary incontinence (UI) and/or POP. The questionnaire is divided into four main domains (bladder, bowel, pelvic organ prolapse, sexual function) and each question is scored from zero to three. The additive scores are divided by the maximum reachable score and multiplied by ten, giving a value between zero (0 = no symptoms) and ten (10 = maximum symptoms) for each of the domains.
223698928|NCT00810381|DRUG|Nitroglycerin|intravenous infusion; 0, 0.125, 0.25, 0.5, 1 and 2 µg/kg/min; 20 minutes per infusion step
223698929|NCT00810381|DRUG|Isosorbide-Dinitrate|intravenous infusion; 0, 0.5, 1, 2, 4, and 6 µg/kg/min; 20 minutes per infusion step
223698930|NCT00810381|DRUG|Sodium-nitroprusside|intravenous infusion; 0, 0.25, 0.5, 1, 2, and 4 µg/kg/min; 20 minutes per infusion step
223698931|NCT00810381|DRUG|Physiologic saline solution (control substance)|intravenous infusion, infusion period 120 minutes
223698932|NCT04398316|DRUG|Lidocaine Iv|2 mg/kg over 5 minutes
223698933|NCT04398316|DRUG|HYDROmorphone Injection|1 mg over 5 minutes
223698934|NCT02463968|PROCEDURE|Venipuncture for blood draw|Samples will include blood. Blood samples will be collected via venipuncture.This is a part of standard of care of new new onset joint effusion and is not a novel intervention.
223698935|NCT02463968|PROCEDURE|Arthrocentesis for synovial fluid draw|Samples will include joint fluid analysis in participants with a knee effusion. Synovial fluid will be drawn via arthrocentesis under sterile conditions. This is a part of standard of care of new new onset joint effusion and is not a novel intervention.
223698936|NCT00154492|DRUG|activated recombinant human factor VII|
223698937|NCT05210231|OTHER|Transcranial Direct Current Stimulation|The direct electric current will be applied through a pair of sponges humidified with saline solution (150 mMols of NaCl diluted in water Milli-Q) on the electrodes (35 cm2). The electrodes (anode and cathode) will be connected to a continuous electric stimulator (Model: Microestim Foco Research, Brand: NKL, Souza Cruz, Brusque - SC, Brazil), with one energy battery (9 V) and will be mounted in accordance with the International 10-20 EEG System. For anodal polarity stimulation over the left TC, the anodal electrode will be placed over the scalp on the T3 area located at 40% of the distance on the left from the Cz point. The cathode electrode will be placed over the contralateral supraorbital area (Fp2). Thereafter, a constant electric current of 2 mA will be applied for 20 min.
223698938|NCT03624231|DRUG|Durvalumab|Durvalumab (1500 mg) starting on week 1 to complete a total of 12 months
223698939|NCT03624231|DRUG|Tremelimumab|Tremelimumab (75 mg) for up to 4 doses/cycles
223698940|NCT03624231|RADIATION|Radiotherapy|Radiotherapy with 35 fractions (administered as daily fractions of 2 Gy given 5 days every week for 7 weeks)
223698941|NCT00857428|DRUG|oxymorphone|Tablets
223698942|NCT00857428|DRUG|Oxymorphone|40 mg tablets
223698943|NCT01565642|BEHAVIORAL|Goals of care decision support|Decision aid and care plan meeting
223698944|NCT02608203|DRUG|[68Ga]-DOTANOC PET/CT|
223698945|NCT03784417|DEVICE|EUS-guided laser ablation|EUS-guided LA will be performed with an endoscopic ultrasound guided approach using a 1064-nm wavelength laser with the insertion of a 300-μm optical fiber through a 22-gauge flexible needle that is inserted in the working channel of the echoendoscope.
223698946|NCT01604187|DRUG|Fentanyl|Ten minutes before the procedure fentanyl sublingual tablet (Abstral ® 100 µg, ProStrakan) will be given to the patient.
223698947|NCT01604187|DRUG|Placebo|Ten minutes before the procedure placebo sublingual tablet will be given to the patient.
223698948|NCT03885440|OTHER|Age|Age\<40 years old is chosen as the cutoff value.
223698949|NCT03885440|OTHER|OSA|The diagnosis of OSA (obstructive sleep apnea) relies on polysomnographic data showing an apnea-hypopnea index at least 5/hr with compatible symptoms.
223698950|NCT06534034|PROCEDURE|Dental implant placement|Dental implant placement on edentulous jaw.
223698951|NCT00449410|DRUG|Atorvastatin|
223698952|NCT00449410|DRUG|ezetimibe|
223698953|NCT03847870|DIAGNOSTIC_TEST|MORU in-house ELISA test followed by IFA if positive|An in-house rickettsial IgG ELISA test will be used for this study to determine previous rickettsial infections by measuring IgG levels. All specimens will be tested for IgG antibodies using ELISA tests for scrub typhus (Orientia tsutsugamushi strains Karp, Kato, Gilliam and TA716), murine typhus (Rickettsia typhi strain type Wilmington), and spotted fever rickettsiosis (Rickettsia honei and Rickettsia conorii). If the sample tests positive, it will be retested for the same antigens using the IFA test. The sample will be considered positive if both the ELISA and the IFA are positive.
223698954|NCT01703273|BEHAVIORAL|manual based low key group intervention (innovation)|6 sessions offered over the course of 3-6 months focus on improvement of quality of life and psychosocial functioning . Topics covered are: 1) social competencies, 2) body image, 3) coping with mobbing and anger, 4) coping with stress, 5) life satisfaction, and 6) psychological well being. The planned intervention does not primarily focus on weight loss.
223698955|NCT01703273|BEHAVIORAL|standardized, manual based routine care|6 sessions offered over the course of 3-6 months with a focus on weight loss. The topics 1) causes, consequences and treatment options of obesity, 2) nutrition, 3) eating behaviors and problem solving strategies, 4) self esteem and emotional eating, 5) exercise, and 6) use of media, will be covered.
223698956|NCT03467048|DEVICE|McGrath videolaryngoscopy|"Intubations will be performed with a regular endotracheal tube of adequate diameter, usually 7.5 mm or 8.0 mm. Endotracheal tubes will be equipped with a hockey-stick-shaped stylette, which will be prepared by the anesthesiologist in advance.~The McGrath or the Macintosh blade will be introduced into oral cavity according to manufacturer recommendations and clinical practice. Minor airway manipulation procedures including BURP or Sellick maneuvers will be allowed to improve visualization of the vocal cords."
223781411|NCT03694548|BEHAVIORAL|Part A Survey|Survey designed to capture pain characteristics, attitudes and practices related to yoga, and potential acceptability of a yoga program for chronic pain in SCD.
223781412|NCT03694548|BEHAVIORAL|Part B Yoga Program|Eight in-person instructor-led group yoga sessions.
223781413|NCT02256475|DRUG|NBI-98854|
223781414|NCT03193294|DIAGNOSTIC_TEST|Stratified medicine involving a diagnostic intervention|Adjunctive tests of coronary artery function at the time of invasive coronary angiography. Diagnostic groups: stable coronary syndromes in patients with no-obstructive coronary artery disease including the following sub-groups (coronary artery vasospasm, microvascular spasm, impaired vasorelaxation due to (1) endothelial dysfunction and/or (2) non-endothelial dysfunction, or unaffected (normal test results). Medical management is linked to contemporary clinical guidelines for the management of patients with stable coronary artery disease (European Society of Cardiology (2013)).
223781415|NCT06530953|BEHAVIORAL|Patient Navigator Model|The patient navigator model is an evidence-based intervention to improve access to healthcare services.
223781416|NCT02046434|DRUG|Glycerol Phenylbutyrate|
223781417|NCT02950493|OTHER|perflutren lipid microsphere|Definity and Lumason are tools for diagnosis used in echocardiography. Compare activated Definity or Lumason with compressed Definity or Lumason.
223781418|NCT02526992|DEVICE|HR-pQCT|HR-pQCT (High Resolution peripheral micro Computerized Tomography) is a device used for 3D bone measurements at radius levels in humans.
223781419|NCT00312507|DRUG|Bovine Lipid Extract Surfactant (administered by lavage)|
223781420|NCT00312507|DRUG|Bovine Lipid Extract Surfactant (administered by bolus)|
223781421|NCT05528094|DIETARY_SUPPLEMENT|GeniusDrops|"The active ingredients listed below are safe and the study sponsor has noted there are no known side effects of the supplement. The main ingredients are:~Hibiscus flower- Has been shown to boost oxygenation to the brain and vital organs. Has also demonstrated efficacy for boosting the immune system.~Gingko leaf- Has been shown to stimulate memory by increasing mental sharpness and clarity.~Rhodiola- Helps regulate energy and stress level. Gotu kola- Has been shown to have impacts on reducing anxiety. Licorice Root- Helps boost the key brain neurotransmitter called Brain Derived Neurotrophic factor which can help with cognitive development Peppermint Leaf- Reduces fatigue while helping improve cognitive abilities. Has also been shown to promote immune system function."
223781422|NCT02438566|DRUG|Tranexamic Acid (Oral)|OTA will be given as 1950 mg 1-2 hours prior to OR and 1950 mg 2 hours after surgical close, before discharge from PACU.
223698957|NCT03467048|DEVICE|Direct laryngoscopy|"Intubations will be performed with a regular endotracheal tube of adequate diameter, usually 7.5 mm or 8.0 mm. Endotracheal tubes will be equipped with a hockey-stick-shaped stylette, which will be prepared by the anesthesiologist in advance.~The McGrath or the Macintosh blade will be introduced into oral cavity according to manufacturer recommendations and clinical practice. Minor airway manipulation procedures including BURP or Sellick maneuvers will be allowed to improve visualization of the vocal cords."
223698958|NCT01580514|DRUG|exenatide BYETTA® (Amylin-Lilly)|"After informed consent was obtained, patients who met the enrollment criteria were randomly assigned to either the control group or the exenatide group.~Patients assigned to exenatide were treated with 10 μg subcutaneous and 10 μg intravenously injection of exenatide BYETTA® (Amylin-Lilly) 5 min before the onset of reperfusion. And twice daily 10 μg subcutaneous injection was continued on the following 2 days."
223698959|NCT01580514|DRUG|Saline|"After informed consent was obtained, patients who met the enrollment criteria were randomly assigned to either the control group or the exenatide group.~Patients assigned to saline were treated with 10 μg subcutaneous and 10 μg intravenously injection of equivalent volume of normal saline 5 min before the onset of reperfusion. And twice daily 10 μg subcutaneous injection was continued on the following 2 days."
223698960|NCT01488500|OTHER|Bronchoscopy|24 hours after exposure, a bronchoscopy will be performed to allow analysis of cells and inflammatory markers in bronchial wash, bronchioalveolar lavage and lung biopsies.
223698961|NCT00156702|BEHAVIORAL|Feedback and Motivational Interviewing|
223698962|NCT00156702|BEHAVIORAL|Smoking Prevention Video|
223698963|NCT00213408|PROCEDURE|Radiofrequency catheter ablation of typical atrial flutter|
223698964|NCT03658057|DRUG|Rocuronium|whether neuromuscular blockade by administering rocuronium is performed or not.
223698965|NCT04266223|DEVICE|Mask-free surface monitoring|Mask-free headrest and couch for patient positioning for radiation therapy combined with a surface monitoring system
223698966|NCT05678582|DIAGNOSTIC_TEST|Liver biopsy|liver biopsy were taken then evaluated by histopathological examination
223698967|NCT02284360|DRUG|APOSEC™ for cutaneous use|"On day 0, a blinded and randomized test treatment with Verum and Placebo is performed on intact skin. If the subject does not reveal any adverse events, the actual treatment phase is initiated 24h later.~Following baseline evaluation on day 1, two punch biopsies (4mm) on the inner upper side of the non-dominant arm are set under local anesthesia. One wound on the upper arm (proximal or distal) will be treated with placebo and the second wound will be treated with the allocated concentration of Verum according to previous randomization scheme set for test treatment. Approximately 1ml of Verum vs. placebo will be applied on the artificial wounds.~From day 2 to 6, artificial wounds will be cleaned with 0.9 % NaCl and then allocated treatment will be administered. Wound dressing will be done daily and will cover the whole area of application.~On day 7 the treatment is terminated and the wound is evaluated with respect the extension of wound closure."
223698968|NCT01898208|DEVICE|FilmArray testing|FilmArray Blood Culture Identification (BCID) Panel is a polymerase chain reaction (PCR) panel that identifies 19 types of bacteria, 5 types of fungi, and select antimicrobial-resistance genes.
223698969|NCT01898208|BEHAVIORAL|Antimicrobial Stewardship|Real time antimicrobial stewardship: an infectious diseases pharmacist or physician will provide patient-specific recommendations to modify antimicrobial therapy.
223698970|NCT01898208|OTHER|Bacterial culture|This test identifies the pathogen responsible for an infection.
223698971|NCT01898208|OTHER|Susceptibility testing|Antibiotic susceptibility testing determines the susceptibility of a bacterial strain to a specific antibiotic or a panel of antibiotics. Antibiotic susceptibility testing determines the susceptibility of a bacterial strain to a specific antibiotic or a panel of antibiotics.
223698972|NCT05201924|BEHAVIORAL|Bedtime routine|a regular routine conducted around bedtime includes brush, book reading and regular bedtime
223698973|NCT05201924|BEHAVIORAL|Control|a healthy control checklist
223698974|NCT06424834|DRUG|Amlodipine|Amlodipine taken once orally daily at a starting dose of 2.5mg, uptitrated to a maximum of 10mg if tolerated.
223698975|NCT06424834|DRUG|Nebivolol|Nebivolol taken once orally daily at a starting dose of 5mg, uptitrated to a maximum of 20mg if tolerated.
223698976|NCT06424834|DRUG|Placebo|Placebo taken once orally daily.
223698977|NCT05652283|DRUG|Pamiparib|Pamiparib capsule 40 mg/time, twice a day, oral, 3 weeks as a cycle, 3 cycles
223698978|NCT05652283|DRUG|Surufatinib|Surufatinib 250 mg/time, once a day, oral, 3 weeks as a cycle, 2 cycles
223698979|NCT06400160|DRUG|TB511|TB511 is a peptide drug conjugate (PDC) which composed of TAMpep826 peptide. TB511 is a white amorphous powder used for subcutaneous injections. TB511 is a peptide drug conjugate that combines a transporter peptide with a specific targeting of M2 macrophages and an apoptosis-inducing peptide (dKLA). As a transporter, the M2 binding peptide acts as a drug conjugate, explicitly binding to M2 macrophages and inducing cell penetration. In the cells, the dKLA component of TB511 binds to the mitochondrial membrane, destroys the mitochondrial membrane, and induces apoptosis by causing cytochrome release, leading to the destruction of the mitochondria and subsequent death of M2 macrophages.
223781423|NCT02438566|DRUG|Tranexamic Acid (Intravenous)|IVTA will be given as 1 g intravenously at time of first incision (THA or bTKA without tourniquet) or just before 1st tourniquet application (bTKA), and then again, 1 g after final surgery closure.
223781424|NCT00900484|OTHER|biologic sample preservation procedure|
223781425|NCT00900484|OTHER|immunohistochemistry staining method|
223781426|NCT00900484|OTHER|laboratory biomarker analysis|
223781427|NCT04177108|DRUG|Atezolizumab|Atezolizumab was administered as per the dosage regimen mentioned in arm descriptions.
223781428|NCT04177108|DRUG|Ipatasertib|Ipatasertib was administered as per the dosage regimen mentioned in arm descriptions.
223781429|NCT04177108|DRUG|Paclitaxel|Paclitaxel was administered as per the dosage regimen mentioned in arm descriptions.
223781430|NCT04177108|DRUG|Placebo for Atezolizumab|Placebo was administered as per the dosage regimen mentioned in arm descriptions.
223781431|NCT04177108|DRUG|Placebo for Ipatasertib|Placebo was administered as per the dosage regimen mentioned in arm descriptions.
223781432|NCT01075659|DRUG|Nicotine|Two single doses of experimental Nicotine Replacement Therapy (NRT) 2 mg, with five hours between treatments. Seven hours duration of total follow-up period
223781433|NCT01075659|DRUG|Nicotine|Two single doses of Nicotine Lozenge 2 mg, with five hours between treatments. Seven hours duration of total follow-up period.
223698980|NCT06400160|DRUG|Keytruda|KEYTRUDA binds to the PD - 1 receptor, blocking both immune-suppressing ligands, PD L1 and PD L2, from interacting with PD - 1 to help restore T-cell response and immune response.
223698981|NCT01049399|DRUG|tideglusib|800 mg of tideglusib as a powder for oral suspension once daily in fasting conditions for 52 weeks
223698982|NCT01049399|DRUG|tideglusib|600 mg of tideglusib as a powder for oral suspension, administered once daily in fasting conditions for 52 weeks
223698983|NCT01049399|DRUG|placebo|powder for oral suspension administered once daily in fasting conditions for 52 weeks
223698984|NCT05606718|DRUG|Dapagliflozin|dapagliflozin 10mg once daily for 3 months after randomization
223698985|NCT05606718|OTHER|guideline-directed medical therapy (GDMT)|guideline-directed medical therapy (GDMT)
223698986|NCT04048200|DRUG|Fentanyl|Anesthesia will be induced by fentanyl, propofol, and rocuronium with maintenance of anesthesia using sevoflurane.
223698987|NCT04048200|DRUG|Dexmedetomidine Ketamine|No opioid will be used in induction of anesthesia. A combination of dexmedetomidine and ketamine will be infused. Sevoflurane will be used for maintenance of anesthesia.
223698988|NCT04938479|BIOLOGICAL|blood sample|D-dimer measurement in blood sample
223698989|NCT00894127|DEVICE|CyPath|CyPath diagnostic assay for the early detection of lung cancer using sputum
223698990|NCT02386306|DRUG|GC021109|
223781434|NCT01075659|DRUG|Nicotine|Two single doses of Nicotine Lozenge 4 mg, with five hours between treatments. Seven hours duration of total follow-up period.
223781435|NCT02100072|DEVICE|Nd:YAG 1440 nm laser|
223781436|NCT06468488|PROCEDURE|DIEP flap surgery without drain|Patients will undergo a breast reconstruction with a DIEP flap without the placement of drains.
223781437|NCT06468488|PROCEDURE|DIEP flap surgery with drains|Patients will undergo a breast reconstruction with a DIEP flap with the placement of drains.
223781438|NCT01723891|DRUG|Surfolase capsule|
223781439|NCT01723891|DRUG|HT-002-01|
223781440|NCT03127228|OTHER|Standard mechanical debridement|Implantoplasty will be performed for peri-implant suprabony defect and infrabony defect will be debrided with dental scalers prior to bone grafting regenerative therapy
223698991|NCT02386306|OTHER|Placebo|
223698992|NCT06402643|PROCEDURE|Pterygium Excision|Pterygium will be surgically removed utilizing conventional resection techniques, entailing a blunt resection of the head, neck, and body of the pterygium. Subsequent to the resection, the surgical site will be polished using a surgical diamond burr if deemed necessary, and hemostasis will be achieved using bipolar cautery.
223698993|NCT01945827|DEVICE|DeltaMaxx Microcoil System|
223698994|NCT03036319|DEVICE|Active tDCS|Participants will receive active tDCS at up to 4mA per electrode for up to 40 minutes for up to 260 sessions.
223698995|NCT03036319|DEVICE|Sham tDCS|Participants will receive sham tDCS for up to 260 sessions
223781441|NCT03127228|DEVICE|Er:YAG laser-assisted debridement|Implantoplasty will be performed for peri-implant suprabony defect and infrabony defect will be debrided with the aid of the laser prior to bone grafting regenerative therapy
223781442|NCT01542866|OTHER|Health Management Tool (HMT)|Mobile computing platform (ie HMT) which allows subjects to perform home monitoring tests
223781443|NCT04496258|BEHAVIORAL|Positive Emotion Induction|Participants are expected to have a positive emotional response to the more positive beach scene.
223781444|NCT04496258|BEHAVIORAL|Neutral Emotion Induction|Participants are expected to have a neutral emotional response to the neutral office scene.
223698996|NCT03036319|BEHAVIORAL|Cognitively based intervention|Participants may receive a cognitively based intervention that targets the particular cognitive and/or functional abilities of interest. This includes methods of cognitive training, cognitive remediation, and cognitive rehabilitation for up to 260 sessions
223698997|NCT03036319|DEVICE|Active tACS|Participants will receive active transcranial alternating current stimulation at up to 4mA per electrode for up to 40 minutes for up to 260 sessions
223698998|NCT03036319|DEVICE|Sham tACS|Participants will receive sham transcranial alternating current stimulation for up to 260 sessions
223698999|NCT03036319|DEVICE|Active tRNS|Participants will receive active transcranial random noise stimulation at up to 4mA per electrode for up to 40 minutes for up to 260 sessions
223699000|NCT03036319|DEVICE|Sham tRNS|Participants will receive sham transcranial random noise stimulation for up to 260 sessions
223699001|NCT03561753|DRUG|Group A (the standard 2HRZE/4HR regimen）|The standard six-month regimen is eight weeks of daily treatment with isoniazid, rifampin, ethambutol, and pyrazinamide followed by sixteen weeks of isoniazid and rifampin. The six-month regimen is the standard regimen for the treatment of drug-susceptible tuberculosis recommended by WHO.
223699002|NCT03561753|DRUG|Group B (New short course PRS regimen, 4EZ(high dose)PtoCfz)|The PRS regimen I（new short course PRS regimen） is 4 months of daily Cfz, Emb, Pto, and high dose pyrazinamide, dosed by weight.Comparison of Standard Regimen：The standard six-month regimen is eight weeks of daily treatment with isoniazid, rifampin, ethambutol, and pyrazinamide followed by sixteen weeks of isoniazid and rifampin.
223699003|NCT05633693|BEHAVIORAL|Counterpressure Maneuvers|Movements that can aid in delaying or preventing syncope by recruiting skeletal muscle pumping (via compression of major veins by contracting muscle to eject blood through cardiovascular circuit) and increased sympathetic drive (via sustaining an isometric muscle contraction). In this trial, we will be evaluating two clinically recommended isometric maneuvers (crouching, and leg crossing with muscle tensing) and two novel dynamic maneuvers that comprise discrete movement that the investigators have identified in prior work (exaggerated anterior-posterior postural sway, rhythmic gluteal clenching).
223699004|NCT05633693|BEHAVIORAL|Baseline Stand|Participants will stand quietly for 5-minutes on a force platform to allow the investigators to assess their typical response to orthostasis.
223699005|NCT05630092|DIAGNOSTIC_TEST|Maximal 6-minute Walk Test (Max_6MWT)|Instructions given to perform the walk test following the international guidelines using the phrase 'as far as you can'.
223699006|NCT05630092|DIAGNOSTIC_TEST|Normal speed 6-minute Walk Test (Nor_6MWT)|Instructions given to perform the walk test following the international guidelines except using the phrase 'at a speed you would normally walk'.
223699007|NCT06101563|PROCEDURE|Early ureteroscopy|Patients will be managed by ureteroscopic lithotripsy 7 days after drainage.
223699008|NCT06101563|PROCEDURE|Delayed Ureteroscopy|Patients will be managed by ureteroscopic lithotripsy 14-21 days after drainage.
223699009|NCT06648798|DEVICE|Limber Limb|Participants will be involved for two months using a non-inferiority design in which the participant will be assessed using their normal device (1 month) and the study device (1 month).
223699010|NCT06386146|DRUG|JAB-30355|Oral administration
223699011|NCT06386146|DRUG|JAB-30355|Oral administration
223699012|NCT05868044|DEVICE|PRIMUS|PRIMUS system
223699013|NCT03408314|OTHER|PediQUEST Response|PediQUEST Response consists of regular feedback of electronic patient reported outcomes (child symptoms and quality of life) to providers and families coupled with involvement of the palliative care team, who will meet with families and providers within three weeks of randomization and follow-up at least monthly as deemed necessary based on PediQUEST feedback reports and other clinical indications.
223699014|NCT03408314|OTHER|Usual Cancer Care|Patients assigned to the usual cancer care arm, will receive the standard care provided by participating sites + be required to complete PediQUEST surveys (but no reports will be generated).
223699015|NCT04294277|DRUG|Pemigatinib|At Day 1, prior to the start of treatment, results from screening visit evaluations are reviewed to determine eligibility requirements. Subsequent visits during treatment phase will take place at Day 8, Day 15 and Day 21 and subsequently at 3 week intervals. Timing of subsequent visits can be prolonged to max. 9 week intervals if no problems exist during the first 12 weeks of therapy. Subjects will self-administer study drug using an oral QD regimen in a continuous dosing schedule. Each dose of Pemigatinib should be taken first thing in the morning upon waking or after a 2-hour fast; subjects should then fast for an additional 1 hour after taking study drug. The starting dose is 13.5 mg Pemigatinib. Study treatment will continue until 12 months, or until the evidence of disease relapse or onset of unacceptable toxicity.
223699016|NCT00430651|DRUG|Docetaxel|Docetaxel 50 mg/m2 IV on days 1 and 15 every 28 days for 6 cycles
223699017|NCT00430651|DRUG|Carboplatin|Docetaxel 50 mg/m2 IV over 1 hour followed by Carboplatin 4 AUC IV over 1 hour on days 1 and 15
223699018|NCT01982578|DIETARY_SUPPLEMENT|Genistein|Subjects will be randomized 1:1 to receive 360 days of double blind treatment of genistein.
223699019|NCT01982578|OTHER|Placebo|360 days of double blind treatment of placebo.
223699020|NCT03001882|BIOLOGICAL|Nivolumab|Specified dose on specified days
223699021|NCT03001882|BIOLOGICAL|Ipilimumab|Specified dose on specified days
223699022|NCT04676854|DEVICE|PRIMA Bionic Vision System|Implantation of PRIMA, Vision training, follow up
223699023|NCT06225037|DEVICE|Sedline EEG monitoring|Propofol titrated according to the raw EEG and spectrogram, aiming to maintain sedation (alpha oscillations +/- slow oscillations) and preventing burst suppression, keeping the PSI greater than 25 where possible.
223699024|NCT06225037|DEVICE|Sedline EEG with output concealed|Clinician will be blinded to the sedline output but data will be collected for analysis (Sedline output will only be analysed at data analysis)
223699025|NCT00589290|DRUG|Belinostat (PDX101)|1000 mg/m\^2/day as a 30 minute intravenous (IV) infusion daily for 5 days every 3 weeks (day 1-5 of the 3 week treatment cycle). After 12 cycles of treatment, cycles will be given for 5 days every 4 weeks.
223699026|NCT01067976|DRUG|Gadobutrol (Gadavist, Gadovist, BAY86-4875)|A single bolus injection of gadobutrol 1.0 M 0.1mmol/kg body weight
223699027|NCT00566111|DRUG|ceftriaxone|2g per day which will be administered IV via midline, 7 days a week for 4 weeks.
223699028|NCT00566111|DRUG|Saline solution|Saline solution will be administered IV via midline, 7 days a week for 4 weeks.
223699029|NCT03397173|DRUG|Azacitidine|Azacitidine will be administered intravenously or subcutaneously at a fixed dose of 75mg/m2/day for 7 consecutive days, allowing interruptions for weekends and holidays within each 28-day cycle. No dose modifications will be permitted during the treatment period.
223699030|NCT03397173|DRUG|Ascorbic acid|Ascorbic acid will be administered orally daily at 1 g/day three days prior to start azacitidine and then continues daily for a total of 28 days of each 28 day cycle. No dose modifications will be permitted during the treatment period.
223699031|NCT02475031|DEVICE|TAP-C|TAP catheters with ropivacaine infusion are inserted into the TAP area after a single shot TAP block. Single shot TAP block is performed using 30ml 0.5% ropivacaine at the end of the case.
223781445|NCT02133326|DRUG|Caldolor|Subject will be given Caldolor by IV prior to surgery.
223781446|NCT02133326|DRUG|Ofirmev|Subject will be given Ofirmev prior to surgery.
223781447|NCT06574022|DRUG|Bupivacain|Intraoperative direct visualization of the pectoralis nerves and injection using a 21-gauge needle of 30 cc of 0.5% bupivacaine after mastectomy completion and prior to reconstruction, if performed, or wound closure.
223781448|NCT06574022|DRUG|Exparel|Intraoperative direct visualization of the pectoralis nerves and injection using a 21-gauge needle of 20 cc of Exparel mixed with 10 cc of 0.5% bupivacaine after mastectomy completion and prior to reconstruction, if performed, or wound closure.
223781449|NCT06574022|PROCEDURE|Intraoperative Pecs II block (IOB) & superior AT (EX or BP)|Intraoperative direct visualization of the pectoralis nerves and injection using a 21-gauge needle with superior anesthetic as determined by stage I, after mastectomy completion and prior to reconstruction, if performed, or wound closure.
223781450|NCT06574022|PROCEDURE|Preoperative Pecs II block (POB) & superior AT (EX or BP)|Preoperative Pecs II block to be administered by 1 of 6 acute pain specialized anesthesiologists in same day surgery. Patient will be lightly sedated with midazolam, at the discretion of the anesthesiologist. The pecs II block will be performed under ultrasound guidance using a 21-gauge, 80 mm length needle to administer the superior anesthetic as determined in stage I.
223781451|NCT03132116|DRUG|gentamicin|"After inclusion in the study, patient will be randomized. According to randomization, patient will receive an intra-nodal injection of gentamicin .~As well, azithromycin will be prescribed for all patients for 5 days. Patients will be followed-up each week until week 4 (Day 28)."
223781452|NCT03132116|DRUG|placebo|"After inclusion in the study, patient will be randomized. According to randomization, patient will receive an intra-nodal injection of placebo.~As well, azithromycin will be prescribed for all patients for 5 days. Patients will be followed-up each week until week 4 (Day 28)."
223781453|NCT05977595|OTHER|Quick DASH Score Visual Analog Scale Scar quality Healing Number of surgeries|Functional and aesthetic criteria : Quick DASH Score at 3 month and 6 months, Visual Analog Scale at 3 month and 6 months, scar quality (assessment by surgeon), healing (discontinuation of dressings), need for a second surgical procedure.
223781454|NCT03553745|BEHAVIORAL|Gentle Yoga Intervention|10-week exercise program structured around gentle yoga practice.
223781455|NCT03553745|BEHAVIORAL|Rigorous Yoga Intervention|10-week exercise program structured around rigorous yoga practice.
223781456|NCT03553745|BEHAVIORAL|Physical Exercise Intervention|10-week exercise program structured around cardiovascular exercise.
223781457|NCT04072965|OTHER|balance training|Thirty five females with CAI will be recruited from the Faculty of Physical Therapy, Cairo University by announcements to participate in this study. The participants will be randomly assigned into three groups; (A) Cross Education will receive single leg balance training for the non affected side (n=10), (B) Traditional training will receive single leg balance training for the affected side (n=10), (C) control group will receive no intervention (n=15).
223781458|NCT01427712|DRUG|Pancrelipase|
223781459|NCT04736784|OTHER|Food-based - beetroot juice|Beetroot juice containing approximately 340 mg nitrate daily
223781460|NCT04736784|OTHER|Food-based - leafy green vegetable juice|Leafy green vegetable juice containing approximately 340 mg nitrate daily
223781461|NCT03329352|DEVICE|F&P Full-Face Mask|The F\&P full-face mask will serve as the participant's primary PAP therapy mask for the duration of the trial period (from Visit 2 to Visit 3). For participants taking part in the study extension, they will be using the trial full-face mask as their primary PAP therapy mask for 6 months after Visit 3.
223781462|NCT02635438|DRUG|Unique Pharmaceutical Laboratories, India|Clotrimazole troche/ lozenges, 10 mg 5 times a day for 14 consecutive days
223781463|NCT02635438|DRUG|Roxane Laboratories Inc., USA|Clotrimazole Troche/ Lozenges USP, 10 mg 5 times a day for 14 consecutive days
223781464|NCT03397446|DRUG|Lisdexamfetamine dimesylate|50mg or 70mg oral capsules taken once-daily for to 2 months. The trial will begin with a 4-week titration phase, where patients will titrate up to a dose of 50mg/day or 70mg/day, followed by a 4-week maintenance phase. No dose changes will be permitted during the maintenance phase.
223781465|NCT00148057|BEHAVIORAL|Low-fat diet|
223781466|NCT02139852|DIETARY_SUPPLEMENT|Capsaicin|
223699032|NCT02475031|DRUG|TAP-S|Catheters with saline infusion are inserted into the TAP area after a single shot TAP block. Single shot TAP block is performed using 30ml 0.5% ropivacaine at the end of the case.
223699033|NCT06593106|PROCEDURE|Cryosurgery|Undergo cryodevitalization
223699034|NCT06593106|PROCEDURE|Robotic Bronchoscopy|Undergo standard of care robotic bronchoscopy with biopsy
223699035|NCT06593106|PROCEDURE|Bronchoscopy with Biopsy|Undergo standard of care robotic bronchoscopy with biopsy
223699036|NCT06593106|PROCEDURE|Resection|Undergo standard of care surgical resection
223699037|NCT06593106|PROCEDURE|Chest Radiography|Undergo chest x-ray
223699038|NCT06593106|PROCEDURE|Computed Tomography|Undergo Computed Tomography
223699039|NCT06593106|PROCEDURE|Biospecimen Collection|Undergo tissue sample collection
223699040|NCT06593106|OTHER|Electronic Health Record Review|Ancillary studies
223699041|NCT05891561|DRUG|Pertuzumab|4 cycles of taxane, pertuzumab, trastuzumab
223699042|NCT06602102|DEVICE|Mixed reality Glasses|Mixed reality glasses are devices that combine elements of augmented reality and virtual reality. They allow users to overlay digital images onto the real world, enabling interaction with virtual objects in a physical environment. These glasses typically use sensors, cameras, and tracking technology to map the surroundings and provide an immersive experience. They are used in various applications, such as gaming, education, design, and professional training.
223781467|NCT01669343|DRUG|Letrozole|Part A Monitor standard of care letrozole use for 28 days; measure blood levels of estrogens and vitamin D at start and end of period. Part B In overweight/obese participants who completed Part A, provide a double dose of letrozole and monitor use for 28 days; measure blood levels of estrogens and vitamin D at start and end of period.
223781468|NCT03330834|BIOLOGICAL|CAR-T cells to treat advanced lung cancer|"Drug: fludarabine. On days -4 through -2, fludarabine (25mg/m2) will be infused for 3 consecutive days; Drug: cyclophosphamide. On days -4 through -2, cyclophosphamide (250mg/m2) will be infused for 3 consecutive days.~Patients will receive the above chemotherapy for lymphocyte-depletion followed by PD-L1 CAR-T cells."
223781469|NCT05868798|DRUG|Ammonia Inhalant|For all AI trials, a capsule containing 0.3 mL of AI (composed of 15% of ammonia and 35% of alcohol) was used according to the manufacturer's instructions (Dynarex Corporation, Orangeburg, NY). When the ammonia fumes were released, researcher immediately held the capsule under the participant's nose to inhale until a voluntary withdrawal reflex was observed.
223781470|NCT03074006|DRUG|TEW-7197|50mg tablets (doses will be determined through dose-escalation part)
223781471|NCT04798586|DRUG|Elranatamab (PF-06863135)|BCMA-CD3 bispecific antibody
223699043|NCT06680154|DEVICE|Transcranial alternating current stimulation|Transcranial alternating current was delivered utilizing a Starstim 8-channel constant current, battery-powered electric stimulator (Neuroelectrics, Barcelona, Spain). Circular carbon rubber electrodes (2cm radius, 12,57 cm2) were used throughout the stimulation. Before placing the electrodes on the head, the subject's hair was moved to the side
223699044|NCT06680154|DEVICE|Theta burst stimulation|the intermittent theta burst stimulation (iTBS) which is regarded as safe for high-frequency neuromodulation. Compared to classical rTMS, where pulses are applied repeatedly at a fixed frequency, iTBS consists of bursts of pulse triplets. In the classical protocol, the bursts are applied for two seconds in 5Hz intervals followed by an eight-second break, before the next bursts are applied. This pattern is repeated for 190 seconds resulting in 600 pulses per protocol.
223781472|NCT04813341|OTHER|Pilates training|Bridging, roll up, one leg circle (both ways); single straight leg stretches; double leg stretches; side kick up and down; side kick circles. The participant will be instructed to perform 3-5 repetitions of these movements at the start, and to add two more repetitions for each movement every week until the end of the intervention.
223699045|NCT06680154|DEVICE|Sham (No Treatment)|In the case of sham TMS, two different sham coils (double 70mm pCool-SHAM coil, Mag\&More GmbH, Munich, Germany) will produce audible clicks at the decibel intensity corresponding to an active coil without the induction of an electromagnetic pulse. Sham tACS will be applied by only ramping the current for 15 seconds up and 15 seconds down at the beginning and end of the stimulation respectively.
223699046|NCT06685250|PROCEDURE|Laparoscopic cholecystectomy|Laparoscopic cholecystectomy
223699047|NCT06683235|DIETARY_SUPPLEMENT|flaxseed|Participants in the intervention group will be given 16 g of ground flaxseed per day for 3 months.
223699048|NCT06683222|DIAGNOSTIC_TEST|Blood sample|36 ml of blood in 3 x 7 ml dry tubes, 1 x 5 ml EDTA tube, 1 x 5 ml heparinized tube, 1 x 5 ml anti-protease tube)
223699049|NCT06683222|DIAGNOSTIC_TEST|Saliva sample|5 ml of saliva will be taken.
223699050|NCT06683222|DIAGNOSTIC_TEST|Grip test|The grip strength of the dominant arm will be measured with the participant in a standing position, with the arm close to the body and the elbow at 90◦ flexion, while the non-dominant arm will be positioned alongside the body. Three measurements will be taken for the dominant hand, and the mean value will be calculated and used for analysis. One minute is allowed between each repetition, to avoid muscle fatigue. Dynamometer quality control is ensured by regularly checking known resistance values.
223699051|NCT06683222|OTHER|MicroFET2® maximum isometric force test|The microFET2 device is used to test isometric force. The microFET2 dynamometer is battery-powered and ergonomically designed to fit in the palm of the hand. The system is microprocessor-controlled to provide accurate, repeatable muscle force readings. The microFET Clinical software automatically performs calculations and validity tests, and allows graphs to be generated from the data, enabling reports of different patient tests to be compared
223699052|NCT06683222|OTHER|Maximum isometric knee extension bench test.|The maximal isometric knee extension strength test on a specially-adapted strength bench consists in performing 3 maximal contractions with 1 minute's rest between each test.
223699053|NCT06683222|OTHER|The SPPB (Short Physical Performance Battery)|Battery of tests comprising a balance test, a walking speed test and a chair-lift test
223699054|NCT06683222|OTHER|The 6-minute walking test.|Muscular function will be determined by the 6-minute walk test to assess aerobic endurance. Participants will be asked to walk for 6 min as fast as possible on a shuttle track. The distance (m) covered in 6 min will be measured. Walking speed (m/s) will be calculated as the distance (m) covered in 6 min. A walking speed \<0.8 m/s has been defined as a low value.
223699055|NCT06683222|OTHER|Segmental impedancemetry examination.|Segmental impedancemetry involves measuring body composition using the body's resistance to the passage of a low-intensity electric current. This test is harmless to the body.
223699056|NCT06683222|OTHER|Indirect calorimetry test.|An Indirect calorimetry is the standard method for measuring energy expenditure at rest. It is based on the principle that the human body burns nutrients using O2 and producing CO2.
223699057|NCT06683222|OTHER|Fardellone's questionnaire|Completion of a questionnaires on calcium intake (Fardellone)
223699058|NCT06683222|OTHER|ONAPS questionnaire|The ONAPS questionnaire contains questions on physical activity and sedentariness
223699059|NCT06683222|OTHER|Dietary intake.questionnaire|The dietary intake questionnaire contains questions regarding the person's eating habits - how many meals a day, where they eat, whether they eat alone, what foods they eat/drink and whether they are following a particular diet and, if so, the reasons why.
223699060|NCT06686264|OTHER|core stability group A|Abdominal hollowing in supine (10 reps \& 2 sets) Single leg bridge (10 reps \& 2 sets), 3 session per week for 6 weeks Prone Single leg raise(10 reps \& 2 sets) Double leg bridge (10 reps \& 2 sets) Abdominal hallowing in 4 point kneeling(10 reps \& 2 sets), Complete Back stretch Pelvic rotations Posterior Pelvic tilt Knee to chest Piriformis stretch Maitland mobilization ( based on assessment) 10 reps 10 sec hold 2 session per day
223699061|NCT06686264|OTHER|traditional exercises group B|Complete Back stretch Pelvic rotations, 3 sessions per week for 6 week Posterior Pelvic tilt Knee to chest Piriformis stretch Maitland mobilization ( based on assessment) 10 reps 10 sec hold 2 session per day
223699062|NCT01554397|RADIATION|PET-guided Bone Marrow-Sparing Intensity Modulated Radiation Therapy (IMRT)|IMRT 45.0 Gy (intact) or 50.4 Gy (postoperative high-risk) in 1.8 Gy daily fractions over 5-5.5 weeks with PET-guided Bone Marrow-Sparing
223699063|NCT01554397|DRUG|Cisplatin|Weekly infusion of 40 mg/m2 (80 mg max) x 5 weeks
223699064|NCT01554397|RADIATION|IMRT|IMRT 45.0 Gy (intact) or 50.4 Gy (postoperative high-risk) in 1.8 Gy daily fractions over 5-5.5 weeks
223699065|NCT05807763|PROCEDURE|Laparoscopic paraesophageal hernia repair without fundoplication|"Patients undergoing laparoscopic paraesophageal hernia repair will be evaluated for risk of esophageal reflux using intra-operative impedance planimetry and endoscopic gastroesophageal valve grade. Patients deemed low risk for esophageal reflux will then be randomized to partial fundoplication or no fundoplication."
223699066|NCT06695312|OTHER|selected exercise program|therapeutic ultrasound, Static neck exercise
223699067|NCT06695312|DEVICE|High Tone Power Therapy|High Tone Power Therapy delivered in cervical region 3 times per week for four weeks
223699068|NCT06706479|DEVICE|high-definition transcranial direct current stimulation|High-definition transcranial direct current stimulation is a novel non-invasive brain stimulation technique based on the principle that when weak intensity electric currents are targeted on specific areas of the scalp, they cause underlying cortical stimulation. The anode increases cortical excitability, while cathode decreases cortical excitability.
223699069|NCT06708533|BEHAVIORAL|Physical Activity|"This intervention involves a structured 12-week walking program designed to increase routine physical activity among participants diagnosed with IBS. The intervention focuses on moderate-intensity walking, performed regularly, in line with World Health Organisation (WHO) guidelines with the aim of relieving IBS symptoms.~Key elements include:~Participants will be guided to adhere to an individualised walking protocol, ensuring consistency in activity levels.~Physical activity levels will be monitored using self-reported diaries and wearable activity trackers to ensure compliance.~Participants will also attend three scheduled visits to the university (baseline, week 6, and week 12) for biological sample collection, sub-maximal fitness assessments, and the completion of validated questionnaires on IBS symptoms, quality of life (QoL), anxiety, and depression."
223781473|NCT04813341|OTHER|Aerobic Training|"WALKING: 10 mint brisk walk excluding warm up and cool down in 5 days/ week STATIONARY CYCLE: for 10 mints, 5 days/ week~SITTING EERCISES:~Chest stretch: ask to hold for 5 seconds and perform 5 repetitions Upper body twist: ask to cross the arms against chest and hold for 5 seconds, perform 5 repetitions Hip marching: Ask the client to sit on chair with arm rest and lift each of her leg 5 times~BALANCE EXERCISES:~Sideways walking: ask to perform 10 steps on each way (side to side), 5 days/week.~Heel to Toe walk: perform at least 5 steps and increase gradually in each repetition, 5days/ week Step up and down: Ask to step up and down on given surface, 5 repetitions on each leg, 5 days/ week."
223781474|NCT01110291|DRUG|docetaxel + CEF|"Docetaxel 80 mg/m² of body surface area (BSA) will be given as an i.v. infusion during 60 minutes on day 0 in a 20-day schedule. The cycle is repeated three times.~Three weeks after the last docetaxel regimen, all patients will receive the CEF-combination treatment. In CEF-combination cyclophosphamide will be given 600 mg/m²of BSA as an i.v. infusion during 15 - 30 minutes on day 0 in a 20-day schedule. This is followed by fluorouracil given 600 mg/m² of BSA as an i.v. infusion during 15 - 30 minutes . Epirubicin will be given 60 mg/m² of BSA as an i.v. infusion during 15 - 30 minutes. This combination therapy will be repeated three times."
223781475|NCT00000153|PROCEDURE|Blue-Green Argon Laser Treatment|
223781476|NCT00000153|PROCEDURE|Red Krypton Laser Treatment|
223781477|NCT02323594|DRUG|Daclatasvir|Treatment A= single oral dose of Daclatasvir (DCV) tablet and Treatment B= single oral dose of DCV pediatric chewable tablet
223781478|NCT02323594|DRUG|Daclatasvir|Treatment C= single oral dose of Daclatasvir (DCV) pediatric chewable tablet and Treatment D= single oral dose of DCV pediatric chewable tablet
223781479|NCT02323594|DRUG|Asunaprevir|Treatment E= single oral dose of Asunaprevir (ASV) tablet and Treatment F= single oral dose of ASV pediatric chewable tablet and Treatment G= single oral dose of of ASV pediatric chewable tablet
223781480|NCT02323594|DRUG|Daclatasvir|Treatment H= single oral dose of Daclatasvir (DCV) tablet and Treatment I= single oral dose of DCV tablets
223781481|NCT03293342|BEHAVIORAL|D CBT|"Intervention:~a 3-5 session treatment of dental fear.~* Psychoeducation about anxiety~* Exploration of the individual anxiety~* Exposure to the frightening stimuli (no hiding, but actively showing in detail all components of dental treatment, preferably utilizing a mirror while doing treatment)."
223781482|NCT03293342|COMBINATION_PRODUCT|Control|"Intervention:~Traditional treatment of dental fear common sense/ benzodiazepine"
223781483|NCT04536896|OTHER|Smartphone breastfeeding application|This intervention consists of a smartphone application which contains relevant information and topics regarding proper breastfeeding knowledge for medical students.
223781484|NCT04536896|OTHER|Traditional face-to-face breastfeeding lecture|This intervention consists of the impartition of a face-to-face breastfeeding course
223781485|NCT01672151|DRUG|rapamycin|4mg oral administration on the first day, 2 mg/d oral administration for 3 months
223781486|NCT02574923|BIOLOGICAL|Autologous Bone Marrow Mononuclear Cells|Transplantation of Autologous Bone Marrow Mononuclear Cells
223781487|NCT04433767|DRUG|Transdermal Nicotine patch|"Participants will begin a 12- week open label trial of transdermal nicotine patch during the day and remove it at night (16 hours). Dose titration starting at 3.5 mg patch/daily to maximum of 21mg patch/daily.~After week 12 , dose will be slowly tapered over 3 weeks."
223781488|NCT03702829|DRUG|Inotersen|Open Label Study
223781489|NCT03699306|PROCEDURE|NG tube insertion method|a feeding tube called naso-gastric or NG tube were inserted through nostril inside the stomach randomly by one of three methods mentioned earlier
223781490|NCT01389219|OTHER|Intervention|"A comprehensive package of intervention will be developed for the mothers and newborn infants which will be comprised of;~1. Provision of postpartum maternal and immediate newborn care, including postpartum visit, maternal nutrition supplementation (iron \& vitamin A), cord care, eye care, Kangaroo Care, delayed bathing, colostrum administration and linkages to immunization services), complications/illness management through stabilization/referral of cases.~2. Provision of Information on family planning, birth spacing, LAM counseling, hygiene, danger signs recognition and complications readiness.~3. Nutrition counseling regarding immediate and exclusive breastfeeding and optimum postpartum diets.~5\. Danger signs of newborn illnesses and maternal complications associated with labor and the postpartum period, care seeking. Early referral for subsequent maternal and newborn morbidities, such as anemia, postpartum depression, fistulas, prolapsed uterus and infections."
223781491|NCT05359042|OTHER|Electronic Patient Reported Outcomes platform|The ePRO tool is developed by a third-party vendor, Conversa, and engages the patient in a chat-based interaction to assess patient symptoms and provide educational material.
223781492|NCT05359042|OTHER|Health Related Quality of Life Surveys|Surveys will be administered to participants
223781493|NCT05146791|PROCEDURE|Inlay Bristow|A modified Bristow procedure
223781494|NCT05146791|PROCEDURE|Bristow|Traditional Bristow procedure
223781495|NCT02977546|DEVICE|Noninvasive pulse contour analysis|For noninvasive pulse contour Analysis we use the CNAP-Monitor (CNSystems Medizintechnik AG, Graz, Austria)
223781496|NCT02977546|DEVICE|Pulmonary artery catheterization|As a reference method we use the Goldstandard intermittent thermodilution via a PAC which is regularly performed during the patients Hospital stay
223781497|NCT06516757|DIETARY_SUPPLEMENT|Boric Acid Suppository|Participants will complete a baseline questionnaire and a vaginal pH test before using the product, and additional questionnaires and a pH test after 3 and 7 days of product use.
223781498|NCT00298233|DRUG|Oseltamivir|Oseltamivir is a sialic acid analogue that potently and specifically inhibits the viral neuraminidases by competitively and reversibly interacting with the active enzyme site of influenza A and B viruses. Oseltamivir will be administered orally in standard formulations (capsules for adults and children at least 15 years of age; suspension for children younger than 15 years).
223781499|NCT01621750|DRUG|Clopidogrel|Clopidogrel Tablets 300 mg
223781500|NCT04806815|OTHER|A survey of 60 questions was created through the internet-based 'Google Forms surveys' site.|"The following tests will be used together with the survey;~* Menstrual Symptom Questionnaire~* Fatigue Severity Scale~* Short Form Of Coronavirus Anxiety Scale"
223781501|NCT02371369|DRUG|Pexidartinib|Each capsule contains 200 mg of pexidartinib for oral administration
223781502|NCT02371369|DRUG|Placebo|Placebo capsule matching pexidartinib capsule for oral administration
223781503|NCT04772716|PROCEDURE|operation|The intervention was not decided by the investigator but studied following emergency or elective surgeries undergoing in the system
223781504|NCT06019104|OTHER|Task-oriented training|"Task-oriented training is defined as an approach based on movement science and motor learning, where the patient makes functional movements specific to a certain task and receives feedback. Task-oriented training focuses on improving performance on functional tasks through targeted practice and repetition."
223781505|NCT06019104|OTHER|Control group|Gaze stabilization exercises included head-fixed right-left eye movements, head-fixed up-down eye movements, eye fixed right-left head movements, and eye fixed up-down head movements.
223781506|NCT04976920|DIAGNOSTIC_TEST|Overture Metabolomics Embryo Selection|Patients will have their embryos selected for transfer based on morphology alone. The embryo transfer outcome will be compared to the metabolomics result to determine the NPV and PPV of metabolomics vs implantation.
223781507|NCT03598504|DEVICE|Wearable EMG/Vibration device|The device is a combination of an EMG recorder/detector and a vibrator
223781508|NCT00977041|BEHAVIORAL|Neurofeedback|"Electrodes will be placed over the temporal lobes bilaterally and a ground electrode placed on the left earlobe. EEG activity will be amplified using a Procomp 2 or Nexus amplifier, and EEGer software will be used to provide subjects with feedback. Contingencies will be set such that alpha brain activity will be reinforced, and high beta and theta brain activity will be inhibited. Standard NF training procedures will be used, which involve simply asking subjects to relax while looking at the feedback screen and Do whatever is necessary to make and keep the bar wide. This protocol will be repeated for up to 40 60-minute sessions (that will include 30 minutes of NF training), scheduled at least weekly."
223781509|NCT05427669|DRUG|mFOLFOXIRI|mFOLFOXIRI (oxaliplatin 85 mg/m2, irinotecan 150 mg/m2, and folinic acid 400 mg/m2 followed by 5-fluorouracil 2400mg/m2 as a 46-hour continuous infusion on day 1) for 12 cycles at the most
223781510|NCT05427669|DRUG|mFOLFOX6|mFOLFOX6 (oxaliplatin 85 mg/m2, and folinic acid 400 mg/m2 followed by bolus 5-fluorouracil 400 mg/m2 and 5-fluorouracil 2400mg/m2 as a 46-hour continuous infusion on day 1) for 12 cycles at the most
223781511|NCT03191344|BEHAVIORAL|with IPSS|all patient in one group use IPSS to record the parathyroid status. the other group operation as ordinary. record the parathyroid status in verbal description
223781512|NCT01450358|OTHER|Antibiotic regimen|The medical researcher will change the antibiotic regimen (De-escalation) immediately as a result of Multiplex PCR (6-12 h).
223781513|NCT03209908|DRUG|Tenofovir Disoproxil Fumarate|Tenofovir Disoproxil Fumarate was used for the experimental group of pregnancy women in the 32 weeks during pregnancy
223781514|NCT03806829|OTHER|Water|250 ml
223781515|NCT03806829|OTHER|Red Wine|250 ml
223781516|NCT03806829|OTHER|Green Tea|250 ml
223781517|NCT03806829|OTHER|Orange Juice|250 ml
223781518|NCT05316038|DIAGNOSTIC_TEST|Oral glucose tolerance test|The test is performed on an empty stomach for at least 10 hours. The first blood sugar level is taken on an empty stomach. Then ingestion of 75g of sugar. A second blood test takes place 1 hour after the sugar intake and the third blood sugar test takes place 2 hours after the sugar intake.
223781519|NCT02859194|PROCEDURE|Veno-veno-arterial ECMO|
223781520|NCT00439777|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|During the first 3 weeks patients will receive 15 mg rivaroxaban twice-daily. Thereafter, patients will receive rivaroxaban 20 mg once-daily. Rivaroxaban will be administered orally and should be taken with food.
223781521|NCT00439777|DRUG|Enoxaparin overlapping with and followed by VKA|Enoxaparin 1.0 mg/kg twice daily with a minimal duration of 5 days. This 5 days treatment could include the period up to 36 hr before randomization if enoxaparin twice-daily was used. VKA should be started as soon as possible but not later than 48 hours after randomization.
223781522|NCT02258633|OTHER|Interactive interview and tailored family centered seatbelt safety intervention|
223699070|NCT06707129|OTHER|life-style|The patients were given health education and lifestyle intervention guidance, followed by lifestyle adjustment for at least 1 year and no more than 3 years, and a second liver biopsy was performed to evaluate liver histological changes.
223781523|NCT02405286|OTHER|Upper gastrointestinal endoscopy|Upper gastrointestinal endoscopy, if stigmata of recent hemorrhage are seen, varices are either injected with ethanolamine or banded, depending on the clinical setting and availability .
223781524|NCT00782613|DRUG|4,4-dimethyl-benziso-2H-selenazine|ALT-2074 in a 0.5% cream formulation
223781525|NCT00782613|DRUG|Placebo|Placebo in a cream formulation
223781526|NCT06350019|PROCEDURE|Penile revascularızation|The importance of resistive index in the preoperative evaluation of vascular-induced erectile dysfunction, predicting the success of penile revascularization surgery, and postoperative patient management was investigated.
223781527|NCT03734224|PROCEDURE|Adhesix mesh|Adhesix mesh
223781528|NCT03734224|PROCEDURE|Progrip mesh|Progrip mesh
223699071|NCT06709742|OTHER|Gross Motor Function Measure-88 Based Therapy|Children will be assessed initially by using GMFM-88 and selecting specific items for individuals according to his/her needs with the help of experts and family. At least 3 items will be selected for each subject in which they score less such that 0, 1 or 2. Training based on those specific items will be given to the children. This is goal-oriented training in which, according to the needs of children training will be provided.
223781529|NCT00661492|DRUG|cetuximab|Erbitux (cetuximab) IV over 2 hours (loading dose) on Day 1 (Cycle 1 only), followed by Erbitux (cetuximab) IV over 1 hour weekly thereafter
223781530|NCT00661492|DRUG|Mitoxantrone|Novantrone (mitoxantrone) IV Day 1 + Prednisone QD for ten (10) 21-day cycles Standard androgen deprivation therapy (ADT) will be continued in all patients who enter study on LHRH agonists
223699072|NCT06707597|OTHER|Patient Interaction Group|No interventions or procedures will be applied to the patients. To evaluate whether the pain, anxiety, and comfort of patients undergoing the same surgical procedure are influenced by each other, the average scale scores of patients in double and single rooms will be compared.
223699073|NCT06709105|OTHER|Kinesiotape|The application was performed using 5 cm x 5 m kinesio tape material. After preparing the standing patient in terms of clothing and skin readiness, the patient was asked to lean forward. To adhere the tape to the right paravertebral region, the lower end of the tape was first adhered 7 cm below the sacroiliac joint at the level of the paravertebral muscles. Then, while the patient was leaning forward, a slight rotation to the left was requested, and in this position, the tape was adhered upwards along the paravertebral muscles without any tension. When applying the tape to the left paravertebral region, the same procedure was mirrored as on the right, with the tape again applied without any tension. The third tape was applied while the patient was standing upright and leaning slightly forward, placed over the sacroiliac joints and parallel to the floor, stretching the tape by 25%.
223699074|NCT06709105|OTHER|Sham (no implant)|Sham Kinesio taping was applied to the patients in the control group. In this sham protocol, Kinesio bands were attached between the 12th rib on both sides and the corresponding sacroiliac joint, passing over the paravertebral muscles without employing any specific banding technique. The third tape was adhered between both sacroiliac joints, also without any adhesive technique. Patients were inquired about any discomfort and informed that the tapes would remain in place until the second session.
223699075|NCT06707948|PROCEDURE|Arthroscopic meniscus surgery|Comparison of the incidence of osteoarthritis with conservative treatment as well as arthroscopic partial resection as well as arthroscopic repair surgery for a condition known as posterior meniscus root injury.
223699076|NCT06710808|OTHER|Virtual walking and transcranial direct current stimulation|"Participants will receive VW-therapy combined with tDCS. The intervention is adapted from Soler et al. 2010 and consists of 10 sessions over 2 weeks, each session lasting around 20 minutes.~For the virtual walking the participant sits on a modified wheelchair, which is positioned at a distance of two meters from the screen. The setting provides an illusion of a third person perspective and the participant can see himself/herself walk through a forest ambience.~The tDCS session is according the same protocol from Soler et al., 2010. Hereby, the device from Starstim, Neuroelectrics will be used, which is equipped with a neoprene cap containing electrodes. The anodes will be placed over C3 or C4 (EEG 10/20 system) to target the motor cortex (M1) contralateral to the painful side and the cathodes will be placed over the contralateral supraorbital area. Symmetric pain participants receive stimulation on the dominant hemisphere. The tDCS applies a constant current of 2 mA over 20 minutes."
223699077|NCT06710236|DEVICE|Hearing instrument|Conventional, daily wear hearing instruments will be used in this study.
223699078|NCT06706843|BEHAVIORAL|Transtheoretical Model Based Motivational Interviewing|Transtheoretical Model Based Motivational Interviewing was applied to haemodialysis patients in 6 sessions.
223699079|NCT06706843|OTHER|routine clinical care|routine clinical care
223699080|NCT02137421|DIETARY_SUPPLEMENT|Resveratrol (3, 4´, 5 trihydroxystilbene)|Resveratrol (RES) (3, 4´, 5 trihydroxystilbene)
223699081|NCT03524352|OTHER|fecal microbiota|fecal microbiota in suspension
223699082|NCT03524352|OTHER|Placebo|sterile saline
223781531|NCT02745379|PROCEDURE|BFPSCs+ DFDBA+ PRF|
223781532|NCT02745379|PROCEDURE|DFDBA + PRF|
223699083|NCT06908382|DRUG|Iparomlimab and Tuvonralimab Injection|QL1706 (5 mg/kg, q3w) +Paclitaxel for injection (albumin bound) (260mg/m2 D1, q3w)+cisplatin (75mg/m2 D1, q3w)/carboplatin (AUC 5 D1) ， 3 cycles
223699084|NCT06913569|PROCEDURE|EBUS-TBNA|Participants with lymphadenopathy would receive EBUS-TBNA attempts to conduct diagnoses.
223699085|NCT06913569|PROCEDURE|EBUS-TTFB|Participants with lymphadenopathy would receive EBUS-TTFB attempts to conduct diagnoses.
223699086|NCT06921655|PROCEDURE|Variation of Pressure Support Levels|Patients will undergo six randomized PS levels (+2, +4, +6 cmH₂O above and -2, -4, -6 cmH₂O below PSPMI=0).
223781533|NCT04689984|DRUG|Standard therapy|Gabapentin, pregabalin, or amitriptyline
223781534|NCT04689984|DRUG|Astaxanthin|Astaxanthin 6 mg tablet once daily
223781535|NCT02687334|DRUG|100% Oxygen|We will investigate the changes of cerebral oxygenation during anesthesia induction of standard general anesthesia with 100% oxygen
223781536|NCT00748436|DRUG|betahistine dihydrochloride|(24mg tablet Betahistine + placebo tablet) BID per os 12 weeks
223781537|NCT00748436|DRUG|betahistine dihydrochloride|(24mg tablet Betahistine + 24mg tablet Betahistine) BID per os 12 weeks
223781538|NCT00748436|DRUG|placebo|(placebo tablet + placebo tablet) BID per os 12 weeks
223781539|NCT01024387|DRUG|AMG 479|
223781540|NCT01056744|DEVICE|Percutaneous coronary intervention with stent implantation|"Percutaneous coronary intervention with implantation of either:~\- a XIENCE® V everolimus eluting coronary stent in one of the following sizes: 3.0 x 18 mm, 3.0 x 28 mm, 2.5 x 18 mm, 2.5 x 28 mm (DES group),~or:~\- a Coroflex Blue® coronary stent postdilated with a Sequent Please® paclitaxel-eluting balloon in one of the following size combinations (stent / balloon): 3.0 x 16 mm / 3.0 x 20 mm, 3.0 x 25 mm / 3.0 x 30 mm, 2.5 x 16 mm / 2.5 x 20 mm, 2.5 x 25 mm / 2.5 x 30 mm (BMS/DEB group)"
223781541|NCT00845910|DRUG|bevacizumab [Avastin]|7.5mg/kg iv on day 1 of every 3 week cycle
223781542|NCT00845910|DRUG|capecitabine [Xeloda]|900mg/m2 po on days 1-14 of every 3 week cycle
223781543|NCT00845910|DRUG|docetaxel|60mg/m2 iv on day 1 of every 3 week cycle
223781544|NCT03855189|DRUG|Mometasone Furoate (MF)|Mometasone furoate nasal spray administered as 200 mcg total dose per day for 4 weeks.
223781545|NCT03855189|DRUG|Beclomethasone Dipropionate (BDP)|Beclomethasone dipropionate nasal spray administered as 168 mcg twice daily (BID) \[336 mcg total dose per day\] for 4 weeks.
223781546|NCT03855189|DRUG|Placebo|Placebo nasal spray administered for 4 weeks.
223781547|NCT02408614|OTHER|Slow-paced walking|Subjects will complete 47 minutes of walking on a treadmill at a slow-pace.
223781548|NCT02408614|OTHER|Moderate-paced walking|Subjects will complete 47 minutes of walking on a treadmill at a moderate pace.
223781549|NCT02408614|OTHER|Interval Training|Subjects will complete 40 minutes of walking on the treadmill alternating between a moderate and a fast pace.
223781550|NCT02408614|DEVICE|Treadmill|
223781551|NCT01687517|DRUG|Seasonal influenza vaccine available for the 2012-2013 vaccine campaign|Single injection of the vaccine at D0 (0.5mL intra-muscularly or subcutaneous for patient under anticoagulant treatment)
223781552|NCT00804947|DRUG|Intravenous busulfan and melphalan|BU is administered intravenously at a dose of 3.2 mg/kg over three hours once a day on days -5 to -3 (total dose 9.6 mg/kg), followed by MEL at a dose of 140 mg/m2 on day -2. After one day of rest, progenitor cells are infused on day 0.
223699087|NCT06924073|OTHER|ATP-Youth Enhanced Strategy (ATP-YES)|ATP-YES is a multi-component youth led implementation strategy that incorporates data audits and feedback, cyclical small tests of change and learning collaboratives
223781553|NCT02455986|BEHAVIORAL|The StepSmart Challenge|A six month pedometer based intervention designed to increase Physical Activity in school children
223781554|NCT01681693|DRUG|Metformin|Subjects will be given an oral dose of metformin once per day for two days.
223781555|NCT06432127|DRUG|Placebo|Unilateral Greater occipital nerve block at C2 level under ultrasound guide with needle in plane technique during ultrasound using normal saline 3 mL
223781556|NCT06432127|DRUG|Bupivacaine|Unilateral Greater occipital nerve block at C2 level under ultrasound guide with needle in plane technique during ultrasound using 0.5% Bupivacaine 3 mL
223781557|NCT00911365|BIOLOGICAL|autologous mesenchymal stem cells|"4\*107 stem cell (100ml) Intra arterial infusion/ one time, then 4\*107 stem cell(100ml)Intravenous infusion 3 times/monthly~-\> Total four times"
223781558|NCT00911365|BIOLOGICAL|normal saline|saline
223781559|NCT04777682|PROCEDURE|ultrasound, double balloon enteroscopy|compare intestinal ultrasound versus double-balloon enteroscopy in diagnosis of malabsorption syndrome
223781560|NCT01601301|DEVICE|PRECICE System|Lenthening of either the tibia or femur with the PRECICE System.
223781561|NCT02384148|OTHER|Circadian rhythm measurement|
223781562|NCT02384148|PROCEDURE|Skin biopsy|A 2mm diameter skin biopsy is performed by a physician using standard procedure.
223699088|NCT06934629|DEVICE|TECAR therapy|TECAR application will be 20 mins per session (10 mins capacitive and 10 mins resistive) during ankle and subtalar ROM in a pain-free range, calf muscle stretch, ankle strengthening exercises against resistance bands in all directions, weight-bearing exercise, forward lunges, bilateral and unilateral squats, bilateral and unilateral heel raises against bodyweight resistance, and balance training.
223781563|NCT04251468|DEVICE|GEPII|Saliva probes (K+Sa) will be measured using genetically encoded potassium ion indicators (GEPIIs)
223699089|NCT06934629|OTHER|therapeutic exercises|the conventional therapy which is ankle and subtalar ROM in a pain-free range, calf muscle stretch, ankle strengthening exercises against resistance bands in all directions, weight-bearing exercise, forward lunges, bilateral and unilateral squats, bilateral and unilateral heel raises against bodyweight resistance, and balance training.
223699090|NCT06934967|DRUG|LNP023|Cohort 1-administered orally a dosing scheme of 200 mg twice-daily (two 100 mg capsules). Cohort 2- administered orally a dosing scheme based on weight at the Day 1, Week 12, 26 and 38.
223781564|NCT04251468|DEVICE|Ion-selective electrodes|Plasma potassium levels (K+Pl) will be measured using standard ion-selective electrodes.
223781565|NCT01143259|DRUG|Alvimopam|The treatment group will receive 12mg of Alvimopan by mouth 30 to 90 minutes before surgery and twice daily till discharge or to a maximum of 7 days (15 doses, total) after surgery.12 mg by mouth 30 to 90 minutes before surgery and twice daily till discharge or to a maximum of 7 days.
223781566|NCT01143259|DRUG|300 mg Polyethylene|The control group will receive 300mg of polyethylene glyco by mouth 30 to 90 minutes before surgery and twice daily till discharge or to a maximum of 7 days (15 doses, total) after surgery.
223781567|NCT06331221|OTHER|Muscle fatigue Protocol|Four experimental conditions consisting of different local muscle fatigue protocols performed in the isokinetic dynamometer in random order, with at least one week of interval between them.
223781568|NCT00099983|DRUG|Risperidone|Initiate treatment with a low dose (1 mg/day HS) for week one, increasing by 1 mg/day weekly to a target dose of 3 mg/day. Escalation to a maximum of 4 mg/day will be allowed after a minimum of 4 weeks at the target dose (3 mg/day). Reduction to a lower dose will be allowed at any time, based on adverse effects. Treatment will continue for 6 months. Patients who discontinue treatment will be allowed to resume treatment at any time.
223781569|NCT00099983|DRUG|Placebo|Placebo
223781570|NCT02552836|BEHAVIORAL|Interpersonal Psychotherapy|A 12-week intervention that focuses on resolving interpersonal stressors that are linked to the onset, maintenance or exacerbation of depressive symptoms
223781571|NCT02552836|BEHAVIORAL|Supportive Psychotherapy|A 12-week intervention that focuses on non-specific factors that contribute to therapy outcome
223699091|NCT06933823|BEHAVIORAL|Dietary modification intervention involving family support|The intervention includes six one-hour, bi-weekly face-to-face sessions, along with bi-weekly phone calls over 15 weeks, to support participants in adhering to a hypocaloric and high-protein diet. The participants will be asked to invite one of their family members to attend the sessions together. Family members will be engaged in discussions to help enhance the participant's adherence to the recommended diet regimen. The aims of the sessions are to raise awareness among participants and their families about sarcopenia obesity and the recommended dietary modifications, emphasizing the critical role of family in supporting adherence to these changes. It also focuses on boosting participants' motivation, reducing barriers to dietary adjustments, and enhancing family-driven social support to help sustain long-term adherence to the prescribed regimen.
223699092|NCT06933823|BEHAVIORAL|Dietary modification intervention|The intervention includes six one-hour, bi-weekly face-to-face sessions, along with bi-weekly phone calls over 15 weeks, to support participants in adhering to a hypocaloric and high-protein diet. The sessions will only focus on educating the participants on following the dietary regimen and addressing the barriers they may encounter during dietary modification without family involving in the intervention.
223699093|NCT06934317|DIAGNOSTIC_TEST|measurement of maximum bite force using bite fork|using bite fork the bite force will be recorded for all teeth preoperative and post operative
223699094|NCT06934317|PROCEDURE|conventional root canal treatment|General principles of conventional endodontic treatment will be applied in all cases, such as the administration of an appropriate local anaesthetic and rubber dam isolation. access and cleaning and shaping using rotary files and obturation. All cases will receive a permanent restoration as a final restoration and a post-operative periapical radiograph
223699095|NCT06934317|PROCEDURE|pulp revascularization by induced bleeding|Regeneration procedures will be conducted in two appointments, adhering to the 'Clinical Considerations for a Regenerative Procedure' proposed by the American Association of Endodontists (AAE) in 2021. All cases will receive a permanent restoration as a final restoration and a post-operative periapical radiograph
223699096|NCT06934317|PROCEDURE|MTA apexification|MTA apical plug will be randomly applied to teeth with open apex
223699097|NCT06934083|BEHAVIORAL|E-health education briefs|Participants will be asked to complete self-administered questionnaire regarding the six healthy lifestyles delivered via text message to their cell phone. Then, during the six-month intervention, participants will receive text messages at intervals set by their preference but at least 2 times per week to ensure adequate space for education delivery and assessment through Likert scale text message surveys relating to Lifestyle Health Education topics including Nutrition, Physical Activity, Tobacco Avoidance, Sleep, Stress Management, and Social Connection. As to the clinical outcomes, self-reported blood pressure, blood glucose, total cholesterol, waist circumference, and body mass index (BMI) will be collected from the participants at enrollment and at the live or virtual community celebration at the close of the study.
223781572|NCT02641080|DRUG|Aspirin|If there is evidence that aspirin alone is equivocal to using both the pumps and aspirin, this could lower health care cost and burden for patients undergoing total joint arthroplasty while establishing that the rate of DVT/PE does not increase with the absence of the compression device.
223781573|NCT02641080|DEVICE|Portable Compression Device|If there is evidence that aspirin alone is equivocal to using both the pumps and aspirin, there could be lower health care cost and burden for patients undergoing total joint arthroplasty while establishing that the rate of DVT/PE does not increase with the absence of the compression device.
223781574|NCT03464682|DRUG|HS-25 10mg|HS-25 10mg 1tablet add placebo of HS-25 1 tablet, placebo of Atorvastatin 1 tablet
223781575|NCT03464682|DRUG|HS-25 10mg combination with Atorvastatin|HS-25 10mg 1 tablet , Atorvastatin 10mg 1 tablet, Placebo of HS-25 1 tablet
223781576|NCT03464682|DRUG|HS-25 20mg combination with Atorvastatin|HS-25 10mg 2 tablets, Atorvastatin 10mg 1 tablet
223781577|NCT03464682|DRUG|Atorvastatin 10mg|Atorvastatin 10mg 1 tablet, placebo of HS-25 2 tablets
223781578|NCT03464682|DRUG|HS-25 20mg|HS-25 10mg 2 tablets, placebo of Atorvastatin 1 tablet
223781579|NCT03464682|DRUG|Placebe of HS-25 and Atorvastatin|Placebe of HS-25 2 tablets, Placebo of Atorvastatin 1 tablets
223781580|NCT02288429|DRUG|colistimethate sodium|
223781581|NCT03841786|OTHER|Phosphorus-supplemented study diet|Participants will be instructed to consume a normal diet and will take a total of 1,000 mg of supplemental phosphorus per day in the form of neutral sodium phosphorus (K-Phos neutral®) for 1 week.
223781582|NCT03841786|OTHER|Control Diet|Participants will be asked to consume a normal diet supplemented with sodium and potassium chloride tablets commensurate with the extra sodium and potassium content consumed during the study diet period for 1 week
223781583|NCT03171233|OTHER|Mobilization with movement|Participants Mobilization Group with Movement are positioned knee facing the physiotherapist, are not elastic passages above the participant's malleolus and are from the physiotherapist's pelvis. The therapist applies a posterolateral slip sustained to a tibia through the belt, leaning backward, while the talus and forefoot are secured with the space between the thumb and the second finger of the hand of both hands. The participant will be instructed to perform a slow dorsiflexion movement for their maximum amplitude.
223781584|NCT03171233|OTHER|Self mobilization with movement|In the Auto Mobilization with Movement group, participants will self-mobilize the ankle on top of a box (15 centimeters with a 10 ° incline), a non-elastic band will pass below the malleoli and the back of the band will be placed in the middle of the other Lower limb, thus mobilizing the talus in the posteroinferior direction, the participant should maintain the force in that direction while making the dorsiflexion movement in closed kinetic chain until returning to the initial position again. Using the same group protocol as the therapist will help.
223781585|NCT04837638|BEHAVIORAL|Diet|No intervention. Cross-section assessment of the relationship between diet, medication, lifestyle and coronary artery calcification.
223781586|NCT00256789|PROCEDURE|Radiation|
223781587|NCT00256789|DRUG|Chemotherapy|
223781588|NCT06243653|DIAGNOSTIC_TEST|CMD test|Measured CFR and IMR
223781589|NCT00803634|DRUG|Clevidipine|Clevidipine was to be administered continuously as monotherapy during the first 30 minutes. Use of an alternative IV antihypertensive agent(s) was discouraged and was limited to where medically necessary to maintain patient safety. Patients who received an alternative antihypertensive agent along with the study drug were allowed to continue in the study. If transition to an oral antihypertensive agent was required, it was to be administered approximately 1 hour prior to the termination of clevidipine with study drug down-titrated or terminated in order to maintain the desired blood pressure level.
223781590|NCT00803634|DRUG|Standard of Care IV antihypertensive|SOC IV antihypertensive agent will be administered for a minimum of 30 min and, if medically warranted, may continue beyond 96 hours at the investigator's discretion. As with clevidipine, the SOC agent was to be administered continuously as monotherapy during the first 30 minutes. Use of an alternative agent(s) was discouraged and was limited to where medically necessary to maintain patient safety. Higher dose titration rates were required to be attempted prior to making the decision to switch to or add on an alternative antihypertensive agent(s). Patients who received an alternative antihypertensive agent with SOC were allowed to continue in the study. If transition to an oral antihypertensive agent was required, it was to be administered per institutional practice.
223781591|NCT05090501|BEHAVIORAL|High Intensity Circuit Training|The participants will execute a 12-exercise High Intensity Circuit Training protocol. Each exercise will have an active part taking 30 seconds, in which exercisers are encouraged to do as many repetitions as possible, and a resting part taking 10 seconds in which the participants rest and are informed of the next exercise. Before and after the 12-exercise routine, the participants rate their affect, arousal and perceived exertion, while using a heart rate monitor and two IMU sensors on their arms and legs.
223781592|NCT03424681|DRUG|Modafinil|Modafinil 300 mg by mouth daily
223781593|NCT03424681|OTHER|Placebo|Placebo
223781594|NCT04307186|DRUG|Gadoquatrane (BAY1747846)|Solution for IV injection, single dose
223781595|NCT04307186|DRUG|Gadobutrol (Gadovist/Gadavist)|Solution for IV injection, single dose
223781596|NCT02106468|DRUG|Prednisone tablet 5mg|This group included 15 patients who received prednisone (Delta-cortene Fort®, Lepetit, Carmano, Melano, Italy) at 40mg /day (8 tablets/day in divided dose , 4 tablet at morning and 4 at evening) for 6 weeks then 20mg/day for 2 week then to 10 mg/day for 2 week, and finally to 5 mg /day for the last 2 weeks.
223781597|NCT02106468|DRUG|Omega-3 soft capsules 1000 mg|This group included 15 patients who received Omega-3 soft gelatin capsules 1000 mg (Super Omega; Technopharma, Cairo, Egypt). The patients received instruction to take one capsule three times daily for 3 months.
223781598|NCT05760066|OTHER|Resistance Training Preconditioning|Resistance training prior to disuse-induced atrophy followed by another period of resistance training
223781599|NCT05760066|OTHER|Control|Activities of daily living prior to disuse-induced atrophy followed by a period of resistance training
223699098|NCT06933667|BEHAVIORAL|Physical Activity|Participants can chose (with input from a kinesiologist as required) from courses of varying intensity in our gym, warm water pool, or classrooms.
223699099|NCT06933667|BEHAVIORAL|Brain-healthy Eating|Participants take five foundational courses: Brain-healthy eating, Healthy protein choices, Colour your diet: Maximize the benefits of fruits and vegetables; Interpreting nutrition facts labels; and Salt and sugar: How much is too much? They are also encouraged to take additional nutrition programs.
223699100|NCT06933667|BEHAVIORAL|Cognitive Engagement|Participants can sign up for any lecture, discussion group, book club, creative arts program, etc. linked to the Cognitive Engagement risk factor.
223699101|NCT06933667|BEHAVIORAL|Social Connections|Social Connections are baked into all other programming. Our instructors are trained in how to foster connections among participants, through peer coaching, ice-breakers, etc., and are asked to leave some time at the beginning and end of programs for participants to chat. We also hold special social events such as game nights.
223699102|NCT06933667|BEHAVIORAL|Mental Wellbeing|Participants are encouraged to enroll in one a week of relevant programming (e.g., meditation, relaxation).
223699103|NCT06933446|OTHER|Myofascial Release|A myofascial release protocol, applied to the thigh muscles in post-effort recovery in water polo athletes.
223699104|NCT06933446|OTHER|Classic Massage|Massagem clássica, com pressão superficial, utilizada para atingir apenas tecidos subcutâneos, sem que haja ação sobre músculos e fáscias
223699105|NCT06350474|OTHER|Discontinuation of dornase alfa (Dnase)|Discontinuation of current dornase alfa (Dnase) therapy during 6-week study period.
223699106|NCT06350474|OTHER|Continuation of dornase alfa (Dnase)|Continuation of current dornase alfa (dnase) therapy during 6-week study period. Therapy is taken at least once daily according to each participant's pre-existing, clinically prescribed regimen (e.g., daily, twice daily)
223699107|NCT03246984|DEVICE|VasQ|VasQ device implantation in patients with a new brachiocephalic or radiocephalic fistula creation.
223699108|NCT00219167|DRUG|aliskiren|
223699109|NCT04387721|OTHER|Kind of trifocal IOL|Patients will be divided between groups based on pre-surgery corneal astigmatism. Group FineVision is made up of patients with corneal astigmatism less than 1 D. Groups FineVision Toric is made up pf patients with corneal astigmatism more than 1.25 D
223699110|NCT02545257|OTHER|Coordinated medication management model|Stage I: a prescription review conducted by community pharmacists Stage II: practical nurse-administered Drug-related Problem Risk Assessment Tool Stage III: Required health care action based on the result of the DRP -Risk Assessment Tool
223699111|NCT02570074|DRUG|Fosfomycin|Broad spectrum antibiotic
223699112|NCT04960631|DIAGNOSTIC_TEST|Double site CT guided needle biopsy|Double site CT guided needle biopsy
223699113|NCT03061383|OTHER|8% Arginine based toothpaste|toothpaste
223699114|NCT03061383|OTHER|8% strontium acetate based toothpaste|toothpaste
223699115|NCT03061383|OTHER|placebo|toothpaste
223699116|NCT06276231|DRUG|Salbutamol|Salbutamol 10mg nebulization over 5 minutes ( flow rate 5-7 liters).
223699117|NCT06276231|OTHER|0.9% Normal Saline|Normal saline nebulization over 5 minutes ( flow rate 5-7 liters).
223699118|NCT06276231|DRUG|Diclofenac Injection|75 mg of Diclofenac intramuscular Injection
223699119|NCT04533633|PROCEDURE|Retrograde Percutaneous Coronary Intervention of Chronic Total Occlusion|Retrograde CTO-PCI using epicardial collateral connections
223699120|NCT05677022|OTHER|Adapted motor activity|15-month adapted motor activity program based on a postural and functional analysis
223699121|NCT04734951|OTHER|Power/resistance exercise program|participants will complete a power/resistance program during 14 weeks. The exercise program will consist of training to improve muscle strength, neuromotor skills, flexibility, endurance, and a greater emphasis on maximum strength and power. The intensity will be set according the estimated repetition to failure.
223699122|NCT04734951|DIETARY_SUPPLEMENT|HMB supplementation|Daily oral supplementation with 237 ml of a polymeric nutritional formula added with 1.5 g of HMB (Ensure Advance®)
223699123|NCT01781533|PROCEDURE|algorithm|
223699124|NCT03502096|BEHAVIORAL|To-Go container|Subjects were provided a to-go container in which leftover foods would be packaged
223699125|NCT03502096|OTHER|Control|Subjects were not provided a to-go container with the meal
223699126|NCT00004635|DRUG|Thalidomide|Thalidomide 200 mg given orally every evening at 9pm. Treatment may continue indefinitely provided that there are no dose-limiting toxicity.
223699127|NCT00004635|DRUG|leuprolide acetate|Injections of leuprolide once a month for six months.
223699128|NCT00004635|DRUG|goserelin|Injections of Goserelin once a month for six months.
223699129|NCT00004635|OTHER|Placebo|Patients will receive the placebo if they initially received thalidomide. The starting dose of placebo 200 mg (four capsules of 100-50 mg capsules) orally once daily at bedtime.
223699130|NCT03633617|DRUG|Dupilumab|Solution for injection administered subcutaneously
223699131|NCT03633617|DRUG|Placebo|Matching placebo
223699132|NCT02169973|DRUG|JNJ-42165279|Participants will receive oral suspension of JNJ-42165279 in Part B as single dose on Day 1 (100 mg) and on Day 8 (up to 250 mg); in Part C as once daily dose (up to 100 mg) from Day 1 to Day 7.
223699133|NCT02169973|DRUG|11C-MK-3168|Participants will receive 11C-MK-3168 in the target range of 185 to 370 megabecquerel (MBq) intravenously (into a vein) before every positron emission tomography scan in Parts A, B, and C.
223699134|NCT03710005|PROCEDURE|Ascent|Dehydrated Cell and Protein Concentrate injection
223699135|NCT03710005|PROCEDURE|Standard|Standard corticosteroid injection
223699136|NCT03985111|DEVICE|Central Venous Catheter|Insertion of a central venous catheter insertion pre-operatively (electively)
223699137|NCT00149734|DRUG|Ondansetron followed by placebo|Participants will take 16mg of ondansetron daily for the first three months followed by 3 months of placebo. An atypical antipsychotic drug (olanzapine,quetiapine, or aripiprazole) will also be taken throughout the 6 months treatment period.
223699138|NCT00149734|DRUG|Placebo followed by Ondansetron|Participants will take placebo daily for the first three months followed by 3 months of 16mg of ondansetron daily. An atypical antipsychotic drug (olanzapine,quetiapine, or aripiprazole) will also be taken throughout the 6 months treatment period.
223699139|NCT00154622|BEHAVIORAL|work hardening program|
223699140|NCT02654314|DRUG|Melatonin|5 mg Melatonin nightly, beginning within 24 hours of admission
223699141|NCT02654314|OTHER|Placebo|Blue capsule matching the melatonin arm
223699142|NCT01595711|DEVICE|Pain Monitor|Measurement of cutaneous conductance
223699143|NCT01200849|OTHER|Enhanced Label|A prescription drug label that has simplified text, more white space and overall is more patient-friendly.
223699144|NCT03463174|PROCEDURE|Mandibular overdenture|Placement of an implant in the mandibular midline.
223699145|NCT03463174|OTHER|Mandibular complete denture|No intervention.
223699146|NCT00709657|DRUG|ranibizumab, bevacizumab or pegaptanib|measurements are performed one week before and after anti-VEGF intravitreal injection
223699147|NCT00215748|DRUG|Dexamethasone|
223699148|NCT02986971|DEVICE|New IMD|The contraceptive implants of the subjects in this arm are removed by the new IMD.
223781600|NCT02465229|PROCEDURE|Multimodal tissue-sampling methods before and after stricture dilation|Each participant will receive the following tissue-sampling methods in order : 1)intraductal suction, 2)intraductal forceps biopsy, 3)brushing cytology, 4)stricture dilation, 5)intraductal suction, 6)intraductal forceps biopsy and 7)brushing cytology during endoscopic retrograde cholangiopancreatography.
223781601|NCT05499923|DEVICE|Debonding|Debonding of orthodontic brackets with wing or base method with a conventional debonding plier
223781602|NCT04957602|OTHER|Blood collection|Blood collection (4\*10ml) before treatment initiation and after the first evaluation (usually 3-4 months after treatment initiation).
223781603|NCT04326491|DIAGNOSTIC_TEST|Breath Biopsy|Analysis of breath samples to identify volatile molecules specific to HCC
223781604|NCT02410395|PROCEDURE|Conventional|Two-layer technique with the first layer performed as an un-locked, continuous suture without inclusion of the endometrium and the second layer performed as an un-locked, continuous suture with the stitches placed superficially, horizontally along the first layer.
223781605|NCT02410395|PROCEDURE|Modified|The modified mattress suture is performed as a single-suture, double-layer technique with limited inclusion of the myometrium and broad inclusion of the serosal surface and myometrium, interchangeably
223781606|NCT01175226|DRUG|BTA798|BTA798 twice daily
223781607|NCT01175226|DRUG|Placebo|Placebo twice daily
223781608|NCT02953626|BEHAVIORAL|Mother Matters Online Postpartum Support Group|"Mother Matters is a 10-week online support group for women with postpartum depression. It involves: 1) A private, online forum that can be accessed by participants 24-hours per day. During regular business hours (9:00 am to 5:00 pm on weekdays) it is moderated by a psychotherapist, and there is a weekly moderated live chat hour; 2) Weekly topics with readings are provided with questions to prompt discussion on the online forum. Topics incorporate symptom management (i.e. Interpersonal Therapy, Cognitive Behavioural Therapy) and affect regulation strategies (i.e. Mindfulness, DBT) with a supportive counselling approach. External resources related to each week's topic, are also shared."
223781609|NCT05928598|BEHAVIORAL|Survey questionnaires|Participants will be enrolled before a scheduled clinic appointment. Following the clinic visit, the research staff will ask the patient to complete questionnaires electronically (or by phone if patient prefers) within three days after the baseline clinic visit and then at three months following this visit. Additionally, some data will be obtained from the participant's medical record.
223781610|NCT05928598|BEHAVIORAL|Epilepsy Visit Planner|"Participants will be identified before a scheduled clinic appointment. Prior to the clinic visit (at the site) the participants will meet with a research staff to obtain written informed consent and then present the Epilepsy Visit Planner to the patient. Participants will be encouraged to use the Planner and share the Planner's output with the provider during the clinic visit. In some cases, there could be an option for the participants to consent prior to the visit and have a virtual presentation of the Planner.~Following the clinic visit, the research staff will ask the participants to complete questionnaires electronically (or by phone if patient prefers) within three days after the baseline clinic visit and then at three months following this visit. Additionally, some data will be obtained from the participant's medical record."
223781611|NCT05928598|BEHAVIORAL|Questionnaires for Providers|Providers will be asked to complete a survey after the clinic visit for the intervention group.
223781612|NCT00150631|DRUG|Candesartan|placebo controlled double blind
223781613|NCT06157931|BEHAVIORAL|Resilient Student Training intervention (ReST)|ReST consists of one individual 60-minute session and two 90-minute group-based sessions.
223781614|NCT02944877|BEHAVIORAL|social media intervention|social media intervention
223781615|NCT00087074|DRUG|temsirolimus|Given IV
223781616|NCT00087074|OTHER|laboratory biomarker analysis|Optional correlative studies
223781617|NCT02854540|DEVICE|Hydrogel electrode-based iontophoresis|Hydrogel was administered through iontophoresis, a process of transdermal drug delivery by use of a voltage gradient on the skin.
223699149|NCT04840069|DRUG|Fluciclovine PET guided Radiotherapy|PET+MRI Based There is no GTV\_5400. The GTV\_6000 will be defined as the surgical cavity inclusive of any remaining tumor enhancement and the hypermetabolic volume. CTV\_5400 will include the GTV\_6000 plus a margin of 1.0 cm which may be reduced around natural barriers to tumor growth such as the skull, ventricles, falx, etc. CTV\_5400 must also include the entirety of the GTV\_6000. There is no CTV\_6000. PTV\_5400 is the CTV\_5400 plus a geometric 3 mm expansion in all dimensions; PTV\_6000 is GTV\_6000 plus a geometric 3 mm expansion in all dimensions. PTV may extend beyond bony margins and the skin surface. The PTV\_5400 must contain the PTV\_6000. In the setting of multi-focal disease, the primary target volumes will be defined as above, but for satellite lesions, the GTV\_6000 will be defined as any tumor enhancement and hypermetabolic volume. There will be no CTV\_6000. PTV\_6000 will be defined as GTV\_6000 plus a geometric 3 mm expansion in all dimensions.
223781618|NCT03910127|DRUG|TQB2450|TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.
223781619|NCT03910127|DRUG|Anlotinib|a multi-target receptor tyrosine kinase inhibitor
223781620|NCT03910127|DRUG|Anlotinib|matching placebo
223781621|NCT00438516|BEHAVIORAL|nurse home visitation|Nurse home visits from midway through pregnancy to child age 2
223781622|NCT02837341|DEVICE|Philips®Vital Sign Device - Camera-based system (Prototype)|"Respiratory rates monitored via camera-based system and capnography simultaneously The Philips Vital Sign Device will record chest movements by camera. The program will use an algorithm to convert the chest movements into the respiratory rate"
223781623|NCT00949351|DRUG|Aliskiren 300mg/d|Aliskiren 300mg/d v.s. placebo for 12wk
223781624|NCT00754845|DRUG|letrozole|Given orally
223781625|NCT00754845|OTHER|placebo|Given orally
223781626|NCT03352115|DRUG|Prednisolone|5 day course of oral prednisolone
223781627|NCT03352115|DRUG|Placebos|Placebo syrup
223781628|NCT04972435|DIAGNOSTIC_TEST|Contrast sensitivity|All subjects performed the contrast sensitivity measurement preoperatively and one time at 2 months postoperatively.
223781629|NCT00359450|DRUG|BMS-275183 (oral taxane)|
223781630|NCT02515162|PROCEDURE|Fischer Cone Biopsy Excisor|Electrosurgical excision method using a triangular electrode to remove the abnormal cervical Transformation zone
223699150|NCT03263585|DEVICE|Spinal orthosis Spinomed|
223699151|NCT03263585|OTHER|Equipment training|
223781631|NCT02515162|PROCEDURE|Loop Excision Procedure|Electrosurgical excision method using a circular electrode to remove the abnormal cervical Transformation zone
223781632|NCT00358267|PROCEDURE|Partial Resection of Inferior Turbinates (PRIT)|PRIT involves surgically removing a small piece off the turbinate, which also reduces its size.
223781633|NCT00358267|PROCEDURE|Radiofrequency Ablation (RFA)|RFA involves inserting a special needle into the inferior (lower) turbinate that releases high frequency energy, which produces heat. The energy and heat cause tissue denaturation (protein damage) and vaporization. The vaporization reduces tissue volume, and denaturation causes healing with scar tissue formation and contraction of surrounding tissue. This procedure can be done under local anesthesia at the doctor's office.
223781634|NCT06123767|PROCEDURE|CAS + Intravascular measuring the pressure gradient|"Measurements taken during the procedure during CAS~* placement of a FFR- micro catheter on the neuroprotection wire and taking a measurement before the stenosis and in the internal carotid artery above the stenosis~* reading the pressure gradient after obtaining a stable value (a minimum of 5 cardiac cycles)~  * the study of intravascular pressure measurements will be performed using a special micro catheter"
223781635|NCT06123767|PROCEDURE|CAS (standard)|"Animation of blood pressure measurements on the FFR console without actual measurement in carotid artery (blinding of the study to the patient) during CAS procedure."
223781636|NCT06123767|DIAGNOSTIC_TEST|Doppler ultrasonound of cephalic arteries|non-invasive assessment of carotid stenosis before surgery and assessment of results after CAS (3 and 12 months after CAS)
223781637|NCT06123767|RADIATION|Angio-CT of the neck and head|Non-invasive pre-operative assessment and post-CAS result (3 months after)
223781638|NCT06123767|OTHER|Otolaryngological examination|Hearing and balance tests (before and after CAS) - prospective follow-up
223699152|NCT05191654|DIAGNOSTIC_TEST|evaluation of cardiopulmonary parameters, gross motor development and hand grip strength|Gross motor development was evaluated with Gross Motor Function Measure (GMFM-88). Hand grip strength was measured with the Baseline Pneumatic Bulb Dynamometer. Cardiopulmonary parameters values was evaluated with echocardiography.
223699153|NCT05175027|DRUG|hypochlorous acid|Randomize
223699154|NCT00629772|DRUG|Placebo|Patients receive placebo on weeks 0, 2 and 6. They receive infliximab 5mg/kg at weeks 14, 16 and 20.
223699155|NCT00629772|DRUG|Infliximab|Patients in infliximab group receive infliximab 5mg/kg at weeks 0, 2, 6, 14 and 22. Patients in placebo then infliximab group receive placebo at weeks 0, 2, 6, then receive infliximab at weeks 14, 16 and 20.
223699156|NCT01393301|BEHAVIORAL|Integrated cognitive-behavioral therapy for smoking cessation and anxiety|Standard smoking cessation treatment and nicotine replacement therapy (NRT) plus a cognitive-behavioral therapy for anxiety, depression, or other symptoms of distress.
223699157|NCT01393301|BEHAVIORAL|Control|Enhanced standard smoking cessation treatment and NRT.
223699158|NCT02215031|DRUG|BI 44370|
223699159|NCT02215031|DRUG|Placebo|
223699160|NCT03221699|OTHER|Formula with ZnO|Forearms and axillae are treated by the volunteers once daily with a standardized amount of the roll-on with ZnO
223699161|NCT03221699|OTHER|Formula without ZnO|Forearms and axillae are treated by the volunteers once daily with a standardized amount of the roll-on without ZnO
223699162|NCT00833820|PROCEDURE|Real rTMS of the brain|Repetitive transcranial magnetic stimulation will be performed using a focal coil held over motor cortex on each hemisphere. Stimulation protocol used will be the cTBS in which three pulses of stimulation are given at 50 Hz, repeated every 200 ms for a total of 300 pulses delivered over the right motor cortex. The stimulus intensity will be set at 80% of Action Motor Threshold.
223699163|NCT00833820|PROCEDURE|Sham rTMS of the brain|Sham repetitive transcranial magnetic stimulation will be performed using the same stimulator connected to the placebo butterfly coil MCF-P-B-65 which has no stimulating effect on the cortex but produces similar auditory and tactile sensations as the active coil. The site of stimulation and the number of stimuli will be identical to those used for the active magnetic rTMS.
223699164|NCT00853073|DRUG|bevacizumab|1.0mg (0.04 cc of 25 mg/ml subconjunctival bevacizumab following bleb needling procedure
223699165|NCT00853073|OTHER|balanced salt solution|0.04 cc of balanced salt solution injected to the bleb following bleb needling procedure
223699166|NCT02758171|DRUG|Empagliflozin|
223699167|NCT02758171|DRUG|Linagliptin|
223699168|NCT05782712|BIOLOGICAL|adenosine dosage|Whole blood is collected using finger puncture followed by deposit a drop of blood (20 μL) using finnpipette, on a blotting paper (Whatman 903 protein saver cards™) and dried over night at room temperature to obtain dried blood spot (DBS).
223781639|NCT06123767|OTHER|Psychological examination|psychological examination with questionnaires (before and after CAS) - prospective follow-up
223781640|NCT06123767|OTHER|Neurological examination|neurological examination with questionnaires (before and after CAS) - prospective follow-up
223781641|NCT06123767|DIAGNOSTIC_TEST|MR cerebral perfusion|"Assessment of the cerebral perfusion alterations using DSC (dynamic susceptibility contrast) MR perfusion, before and after CAS (after 3 months):~Parametric maps of cerebral blood flow (CBF), cerebral blood volume (CBV), time to peak (TTP), and mean transit time (MTT) will be generated and used for the qualitative and quantitative analyses of the following perfusion parameters:~* cerebral blood volume (CBV) value in ml/100ml;~* cerebral blood flow (CBF) value in ml/100ml/min;~* mean transit time (MTT) value in seconds~* time to peak (TTP) value in seconds"
223781642|NCT05419206|DIAGNOSTIC_TEST|CMV DNA analysis|CMV DNA quantitative viral load levels were studied
223781643|NCT03634761|BEHAVIORAL|Competency based model|Qualified Learning course and workshop to preschool staff combined with monthly on-site coaching at preschool sites to improve overall intervention setting quality and use of evidence bases practices, provided by external expert from habilitation center.
223781644|NCT03634761|BEHAVIORAL|Comprehensive program|Comprehensive program of EIBI for Children with ASD supervised by external expert from habilitation center (treatment as usual)
223781645|NCT05166252|BEHAVIORAL|Time out from smartphone use during meal time|"One parent will be instructed to install a study app. Further, he/she press a button within the App to start a time out from the smartphone at the beginning of a meal (i.e. calls and message are blocked and the parent needs to press an extra button in order to leave the app). The app instructs all other family members to turn off their phones and to put them away. Then, the parent is instructed to take a picture with their smartphone from the smartphone-free family meal table . The time-out is over as soon as the parent presses the stop button."
223781646|NCT05166252|BEHAVIORAL|Control condition|The same as the experimental condition but without a timeout from smartphone use.
223781647|NCT02423382|PROCEDURE|Silicone oil removal|The patients in each group will receive the same procedure of silicone oil removal.
223781648|NCT00861419|DRUG|Sorafenib|Sorafenib 400 mg PO (BID)
223699169|NCT05235477|PROCEDURE|Tube technique|"An excavator (smaller than the width of the defect; evaluated pre-surgically on a study model) is used to carefully reflect the papilla away from the alveolar bone and root surfaces on the buccal aspect to access the interproximal region to prepare the bed for the graft. The excavator is used to do the same on the palatal aspect. The amount of reflection should yield a very relaxed papilla flap that permits placement of the papilla at the new coronal position without tension. The recipient site at this time should resemble a tube with two openings; one on the buccal aspect at the mucogingival junction and one on the palatal aspect."
223699170|NCT00794703|DRUG|micafungin (Mycamine)|Intravenous
223699171|NCT00794703|DRUG|itraconazole|oral
223699172|NCT04297059|OTHER|Ajyal Salima|It comprises in class-activities, meetings with parents and improvement of school foodservice
223699173|NCT00722423|BEHAVIORAL|Integrated care model|The integrated care intervention follows a manualized protocol consisting of a series of brief intervention tailored to the patients' main barriers to treatment along with a case management approach in which the integrated care mental health provider actively tracks each patients progress through the evaluation and treatment process. The integrated care mental health provider can be a clinical nurse specialist, psychologist, or licensed clinical social worker that has experience and training in the provision of psychiatric and SUD interventions. They will receive additional training on the integrated care protocol. Data will be collected at baseline, pre-treatment, and post-treatment intervals.
223699174|NCT00722423|BEHAVIORAL|Usual Care Model|
223699175|NCT01804023|OTHER|HEC placebo gel applicators|"Participants will handle, but not insert, 4 applicators containing HEC placebo gel.~Participants will vaginally insert and removed 8 applicators containing HEC placebo gel. Gel will be expelled in to the vagina from only 2 applicators."
223699176|NCT01309165|BEHAVIORAL|CO-OP|CO-OP, a client-centred, performance-based, problem solving approach has 7 key features including: client-chosen goals, dynamic performance analysis, cognitive strategy use, guided discovery, and a specific 10-session intervention format. The client and the therapist work together, using the Canadian Occupational Performance Measure (COPM), to select 3 skills and establish baseline skill performance. In the second meeting, when CO-OP actually begins, the approach is introduced to the client and the global cognitive strategy (GOAL-PLAN-DO-CHECK) is learned. In all subsequent sessions this strategy is used as the main problem-solving framework to facilitate skill acquisition.
223699177|NCT01309165|BEHAVIORAL|Standard Occupational Therapy|Participants randomized to the SOT group will receive usual out-patient rehabilitation services, with slight modifications. Specifically, a research assistant will administer the COPM to assist participants to self-select 4 personally meaningful skills. The treating SOT occupational therapists will be asked to log the activities completed in each session, and the amount of time spent in therapy.
223699178|NCT02103907|OTHER|Targeted dynamic balance training|Participants in this study group will complete dynamic balance training exercises four times per week, for ten weeks. Exercise sessions at the university will last approximately one hour, and home exercise sessions will take approximately 30 minutes to complete. Exercises will emphasize dynamic balance control, muscle strength and proprioception and will be progressed over three phases during the ten weeks (with more difficult exercises phased in, and exercises that have been mastered phased out).
223781649|NCT00861419|DRUG|AMG 706|AMG 706 125 mg PO (QD)
223781650|NCT00861419|DRUG|AMG 706|AMG 706 75 mg PO (QD)
223781651|NCT00861419|DRUG|AMG 386|AMG 386 10 mg/kg IV (QW)
223781652|NCT00861419|DRUG|Sunitinib|Sunitinib 50 mg PO (QD)
223781653|NCT00861419|DRUG|Bevacizumab|Bevacizumab 15mg/kg IV Q3W
223781654|NCT00861419|DRUG|AMG 386|AMG 386 3 mg/kg IV (QW)
223781655|NCT01266759|DRUG|NuvaRing|For the first cycle, women inserted the ring between days 1 and 5 of the menstrual cycle. Treatment continued for three cycles. Each cycle consisted of 3 weeks of ring use followed by a 1 week ring-free period.
223699179|NCT04400942|DIAGNOSTIC_TEST|Transvaginal ultrasound|Transvaginal ultrasonographic scan aims to evaluate number, size (diameter and volume), location and appearance of submucous uterine myomas, concomitant presence of adenomyosis
223699180|NCT04400942|BEHAVIORAL|Anamnesis|Anamnesis aims to collect data about age, BMI, previous hormonal therapies (such as ulipristal acetate or gonadotropin-releasing hormone agonists) with submucous uterine myomas
223699181|NCT04400942|PROCEDURE|Operative hysteroscopy|Operative hysteroscopy allows a direct evaluation of number, size (diameter and volume), location and appearance of submucous uterine myomas. This exam allows the resection of the myomas.
223699182|NCT01000402|DRUG|Psychopharmacotherapy|Lithium (according to response, serum levels, and tolerance) 150-1500mg Valproate (according to response, serum levels, and tolerance) 125-2000mg Risperidone (according to response, and tolerance)0.5-6mg Olanzapine(according to response, and tolerance)2.5-20mg Ziprasidone(according to response, and tolerance)40-160mg Topiramate (according to response, and tolerance)25-300mg Quetiapine (according to response, and tolerance)25-500mg Aripiprazole (according to response, and tolerance)5-20mg Lamotrigine (according to response, and tolerance)25-200mg Fluoxetine (according to response, and tolerance) 1-40mg Sertraline (according to response, and tolerance)25-200mg Methylphenidate (according to weight, response, and tolerance)0.3 -0.7mg/kg/day
223699183|NCT03594526|BEHAVIORAL|Maternal support to become mother|"AMACOM-PRI: Apoyo Materno para Convertirse en Madre - Primerizas. Maternal support to become first-time mothers is an intervention based on the mid-range nursing theory of Ramona Mercer, whose purpose is to empower first-time mothers in their new maternal role, favoring the mother-child bond, strengthening social support and maternal self-efficacy, consists of.~1. Four Home visits , in the first week; first month of baby life; at three months; and the fourth postpartum month.~2. Four Educational sessions and support sessions for maternal empowerment in each home visit.~3. Telephone follow-up: at 15 days; a month and a half; at two and a half months; and three and a half months postpartum."
223699184|NCT03594526|BEHAVIORAL|Control Group: usual care|"This intervention is usual care, which consists of:~1. care of the mother and her newborn during the puerperium~2. Teaching about breastfeeding."
223699185|NCT00503529|BIOLOGICAL|Tick-Borne Encephalitis (TBE) Vaccine (Inactivated)|Vaccination by intramuscular injection into the right or left upper arm (musculus deltoideus)
223699186|NCT02508857|DRUG|Ketorolac|Patients received intravenous injection of ketorolac (30 mg) in bolus; then, saline solution was continuously infused during the entire procedure (Group K),
223699187|NCT02508857|DRUG|Magnesium|Patients received intravenous magnesium sulfate (20 mg/kg) in bolus, then magnesium sulfate (2 mg/kg/h) was continuously injected during the procedure (Group M)
223699188|NCT02508857|DRUG|Saline solution|intravenous saline solution (20 ml) was injected in bolus, followed by continuous infusion of saline solution during the entire procedure (Group S).
223699189|NCT04531839|BEHAVIORAL|Evidence-based collaborative quality improvement|Evidence-based collaborative quality improvement interventions including benchmarking, potential better practice list, PDSA implementation and collaborative learning
223699190|NCT03420625|DEVICE|Foot IPC|Intermittent pneumatic compression in the foot using the A-V Impulse™, Covidien®, New Haven, CT, USA
223699191|NCT03420625|DEVICE|Rapid calf IPC|Intermittent pneumatic compression in the calf using the VenaFlow® Elite, DJO Global, USA
223699192|NCT03420625|DEVICE|Slow calf IPC|Intermittent pneumatic compression in the calf using the Kendall SCD™ 700, Covidien, Medtronic, USA
223699193|NCT03420625|DEVICE|Calf NMES|Neuromuscular electrical stimulation in the calf using the DJOTM, CefarCompex Mi-Theta 500 stimulator
223781656|NCT01266759|DRUG|Norethisterone Acetate tablets - 5mg|Norethisterone Acetate tablets 5 mg three times daily from day 5 to 26 of the cycle over three cycles. Male condom used for contraception during treatment
223781657|NCT01617291|OTHER|Induced therapeutic hypothermia|induced therapeutic hypothermia
223699194|NCT03671980|OTHER|My Medical record website|Website comprising patient records, blood and other test results, useful information on IBD, and messaging service to communicate with IBD team, plus home smartphone faecal calprotectin monitoring.
223699195|NCT00736814|DRUG|carboplatin|Given intravenously
223699196|NCT00736814|DRUG|docetaxel|Given intravenously
223699197|NCT00736814|DRUG|gemcitabine hydrochloride|Given intravenously
223699198|NCT00736814|DRUG|vinorelbine tartrate|Given intravenously
223699199|NCT04962048|DEVICE|pulse-synchronized negative pressure (PSNP) device|The machine consists of four components: an electrocardiograph (ECG), a vacuum pump, a software computing the timing of suction and drainage, and an individual suction cap for each patient. One leg will be treated with the PSNP-device. The treatment course with PSNP will be applied twice a day (with 4h +/- 2h in between) for two consecutive days.
223699200|NCT04962048|OTHER|Control - no intervention|The other leg serves as non-treated control
223699201|NCT01274650|PROCEDURE|Indirect Calorimetry|Indirect Calorimetry
223699202|NCT00854542|BEHAVIORAL|Telepsychiatry-based Culturally Sensitive Collaborative Treatment|T-CSCT: Patients in Group A will receive T-CSCT, which consists of Telepsychiatry-based Culturally Sensitive Psychiatry Assessment using the Engagement Interview Protocol (EIP) plus Care Management.
223699203|NCT01724879|DRUG|Dasatinib|Dasatinib p.o. + Chemotherapy (Dexamethasone, Cyclophosphamide, Vincristine, Methotroxate, 6-Mercapto-Purine, Cytarabine, Vindesine, VP16 (Etoposide))
223699204|NCT02337270|BIOLOGICAL|Ad5Ag85A|Aerosol administration of Ad5Ag85A
223699205|NCT04746196|OTHER|Serum galectin-3 concentration was measured.|Serum galectin-3 concentration was measured using a commercial chemiluminescent microparticle immunoassay.
223699206|NCT02053870|OTHER|Physiotherapy+conventional treatment|Patients will be treated with daily medication prescribed by the physician, during 3 weeks. Additionally, they will be involved in 9 sessions (3 times a week during 2 weeks) of respiratory physiotherapy including breathing retraining and chest clearance techniques, exercises for thoracic mobility, expansion and flexibility, cardiorespiratory exercise training and education about the disease.
223699207|NCT02053870|DRUG|Conventional treatment|Patients will be treated with daily medication prescribed by the physician, during 3 weeks.
223699208|NCT05085730|DEVICE|InMode Morpheus8 System|The InMode Morpheus8 System is a bipolar fractional radiofrequency device which uses microneedles and thermal heat to stimulate neocollagenesis and neoelastogenesis.
223699209|NCT03585842|OTHER|No intervention|No intervention
223699210|NCT04712383|COMBINATION_PRODUCT|Fitbit Care intervention arm|Entire suite of Fitbit Care.
223699211|NCT00963222|DRUG|vitamin A|1 cap vitamin A 25000 IU/day for 3 month
223699212|NCT00963222|DRUG|placebo|1 cap placebo/day for 3 month
223699213|NCT01549600|DIETARY_SUPPLEMENT|psyllium|1 level tablespoon (\~ 5.1 g psyllium husk in the psyllium product) mixed with at least 8 ounces of water, taken twice daily
223699214|NCT01549600|DIETARY_SUPPLEMENT|Microcrystalline Cellulose|1 level tablespoon (\~ 1.18 g MCC in the MCC product) mixed with at least 8 ounces of water, taken twice a day
223699215|NCT06248060|OTHER|preanaesthetic classical physical consultation|Pre-anaesthetic classical consultation before teleconsultation implementation
223699216|NCT06248060|OTHER|preanaesthetic teleconsultation|Pre-anaesthetic consultation by telephone for eligible patients according to the criteria set
223699217|NCT01976676|DIETARY_SUPPLEMENT|5-methyltetrahydrofolate|
223699218|NCT01976676|DIETARY_SUPPLEMENT|folic Acid|
223699219|NCT03507803|OTHER|Gait Biofeedback|Feedback will appear on screen in front of participants during walking. If their foot is too inverted (determined by researcher) the object on the screen will turn red and an audio tone will be heard. If the participant corrects the foot position, the object will turn green and the audio tone will not be heard.
223699220|NCT06557096|DRUG|Osimertinib 80 MG|Osimertinib is taken orally at a dose of 80mg daily for a 28-day treatment period, followed by a sequential treatment of osimertinib 80mg daily taken orally for another 28 days.
223699221|NCT06557096|DRUG|Bevacizumab|Sequential combination therapy with bevacizumab administered intravenously at a dosage of 7.5mg/kg of body weight on the first day of each cycle, with medication given once every 3 weeks, for a continuous treatment duration of 21 days.
223699222|NCT02038881|BIOLOGICAL|IMVAMUNE®|0.5 ml Modified Vaccinia Ankara Strain - Bavarian Nordic (MVA-BN®) smallpox vaccine containing at least 1 x 10E8 TCID50 per ml
223699223|NCT01419522|OTHER|Gait Training Method|Treadmill training at constant velocity
223699224|NCT00699764|BIOLOGICAL|Herpes simplex candidate vaccine- adjuvanted GSK208141|Intramuscular injection, 3 doses
223699225|NCT00699764|BIOLOGICAL|Placebo injection|Intramuscular injection, 3 doses
223699226|NCT04664192|OTHER|Patient Biospecimen Registry (observational and blood sampling)|Clinical data collected at every blood sample collection visit.
223699227|NCT05604677|PROCEDURE|Breast Surgery|Breast-conserving Surgery or modified radical mastectomy
223699228|NCT00333840|DRUG|imatinib mesilate|imatinib supplied as 100 mg and 400 mg tablets or 100 mg capsules.
223699229|NCT00333840|DRUG|interferon-alpha (INF-a)|interferon-alpha (IFN-a) subcutaneous (SC) injections escalated over 4 weeks to achieve a target dose of 5 MU/m\^2/day.
223699230|NCT00333840|DRUG|cytarabine (ARA-C)|cytarabine 20 mg/m\^2/day (max 40 mg) SC for 10 days every month.
223699231|NCT02211625|DRUG|Open-label TRV734 125 mg|125 mg
223699232|NCT02211625|DRUG|TRV734 blinded|blinded, multiple ascending dose
223699233|NCT02211625|DRUG|Oxycodone IR 10 mg|
223699234|NCT02211625|DRUG|Placebo|TRV734-matched and oxycodone placebo
223699235|NCT01975714|DRUG|Preservative-free latanoprost|
223699236|NCT01975714|DRUG|Preservative-free bimatoprost|
223699237|NCT00014482|PROCEDURE|pain therapy|
223699238|NCT00014482|PROCEDURE|psychosocial assessment and care|
223699239|NCT01453725|BIOLOGICAL|Golimumab|Golimumab 50 mg SC injection every 4 weeks
223699240|NCT01453725|BIOLOGICAL|Placebo|Placebo SC injection every 4 weeks
223699241|NCT05979506|PROCEDURE|Cutaneous wraps|"The topical treatment that will be used in this study are:~* For the body, an emollient cream with a high lipid content: Cold cream~* For the scalp and feet, an emollient preparation with keratolytic action: 10% or 30% urea, depending on the scalp and feet damage~Each of the 3 treatments (body, scalp and feet) will be carried out as follows:~* Application of different topicals all over the body and face, after taking a lukewarm therapeutic bath of 20 minutes~* Occlusion by wrapping the patient in a plastic film, then covering with a blanket~* After 1 hour, the unabsorbed excess cream is removed with a towel"
223699242|NCT01955564|DRUG|NW-3509a|single dose
223699243|NCT01685892|DRUG|Obinutuzumab|Participants will receive IV infusion of obinutuzumab 100 milligrams (mg) on Day 1 of Cycle 1, 900 mg on Day 2 of Cycle 1, and 1000 mg on Days 8 and 15 of Cycle 1 and on Day 1 of Cycles 2-6.
223699244|NCT01685892|DRUG|Venetoclax|Participants will receive multiple doses of venetoclax orally once daily.
223699245|NCT05914012|OTHER|Telerehabilitation based on Otago Exercise Program|It took a total of 21 sessions, 7 days a week for 3 weeks. The sessions lasted 30 minutes. It is recommended to do exercises with comfortable shoes at least 1 hour after a meal. Each of his exercises will be videotaped and numbered and delivered to the intervention group via social networks and the Internet or by memory. In each exercise session, the physiotherapist followed the exercise sessions through social networks and answered questions from the older adults.
223699246|NCT02518204|OTHER|BPT|Brain Performance Test (BPT) computerized cognitive assessment battery developed by Lumos Labs, Inc.
223699247|NCT02518204|OTHER|NP|"Conventional in-person Neuropsychological Assessments (NP)~Subtests from:~* HRB: Halstead-Reitan Battery~* MATRICS: Measurement and Treatment Research to Improve Cognition in Schizophrenia~* WAIS-IV: Weschler Adult Intelligence Scale - IV"
223699248|NCT01340612|DEVICE|endovascular coiling with any type of currently approved coil (first or second generation)|Standard procedure for endovascular coiling.Coils may be bare Platinum coils or any so-called second generation coils such as but not restricted to Hydrocoil or Cerecyte
223699249|NCT01340612|DEVICE|endovascular stenting with or without coiling. The stent may be any of the currently approved stents for intracranial aneurysms.|Standard procedure for stenting. Addition of coils to the stent is left to the judgment of the treating physician
223699250|NCT00875979|DRUG|Trastuzumab emtansine [Kadcyla] 3.0 mg/kg|Trastuzumab emtansine was provided as a single-use lyophilized formulation.
223699251|NCT00875979|DRUG|Trastuzumab emtansine [Kadcyla] 3.6 mg/kg|Trastuzumab emtansine was provided as a single-use lyophilized formulation.
223699252|NCT00875979|DRUG|Pertuzumab 420 mg|Pertuzumab was provided as a single-use formulation.
223699253|NCT03130608|OTHER|Inspiratory Muscle Training|Subjects will breath through a hand held valve that has adjustable resistance to strengthen the muscles used for breathing. Subjects will perform the exercise approximately 20-30 minutes, twice a day for 8 weeks.
223699254|NCT01554436|BEHAVIORAL|neuropsychological assessment|"The main criterion of evaluation of the smoking abstinence will be made by the measure of the rate of carbon monoxide (CO) in the expired air between the study start and during the study until 6 months after inclusion.~The secondary criteria of evaluation are criteria of neuropsychological order, namely the performances in the tests listed: result of NART test,Continuous Performance Test (CPT), Trail Making test, Stroop test, Iowa gambling task. (IGT), Hayling test, N back test, fluence verbal test"
223699255|NCT02736760|DRUG|Daylight photodynamic therapy using Methylaminolevulinate (MAL)|"In the Daylight photodynamic therapy arm the patients will apply a sunscreen to the whole face which is followed by lesion preparation of AKs. Following this, MAL will be applied in a thin layer to the whole face. Within 30 min after MAL application patients expose themselves to daylight for 2 hours.~5 photodynamic therapy treatment sessions (visits 1-5) will be performed within 18 months."
223699256|NCT02736760|PROCEDURE|Cryosurgery|In the control group, cryosurgery as standard reference therapy will be performed at visit 1, and in case of non-cleared or newly occurred AKs at visits 2-5. Cryosurgery of AK lesions will be investigated as standard reference therapy. Single freeze-thaw cryosurgery is performed using an open spraying procedure with liquid nitrogen with nozzle size C. After formation of an ice-ball of the required size, freeze time starts. Freeze time should lie between 5 s and 10 s.
223699257|NCT04164355|DRUG|Tadalafil 20 MG|To study retinal and choriocapillary features in patients undergoing Tadalafil 20 mg orally, on alternate days, at baseline and 1, 3, 6 months after radical prostatectomy
223699258|NCT03719586|DRUG|ZMapp|Three doses of 50 mg/kg of body weight administered intravenously every third day beginning on Day 1
223699259|NCT03719586|DRUG|Remdesivir|Administered intravenously with a loading dose on Day 1 (200 mg for adults and pediatric patients with body weight \>= 40 kg and for pediatric patients weighing \< 40 kg one loading dose of remdesivir 5 mg/kg) followed by 9 to 13 days of once-daily maintenance dosing starting on Day 2 and extending through Day 10 to 14 (100 mg for adults and pediatric patients with body weight \>= 40 kg and for pediatric patients weighing \< 40 kg remdesivir 2.5 mg/kg)
223699260|NCT03719586|DRUG|MAb114|50 mg/kg of body weight administered intravenously on Day 1 as a single infusion
223699261|NCT03719586|DRUG|REGN-EB3|150 mg/kg of body weight administered intravenously on Day 1 as a single infusion
223699262|NCT01248208|BIOLOGICAL|FluMist intranasal influenza vaccine|FluMist intranasal vaccine 0.2 mL will be given 0.1 mL in each nostril per manufacturer's instructions.
223699263|NCT01248208|BIOLOGICAL|"Intramuscular influenza injection (flu shot)"|"Subjects \< 2 years or \> 49 years or those with asthma symptoms or treatment within the past year will receive the intramuscular flu shot in a single injection.~Age 6-36 months: 0.25 mL IM x 1; Age \>36 months: 0.5 mL IM x 1 Boosters: All children aged 6 months-8 years who receive a seasonal influenza vaccine for the first time should be administered 2 doses. Children aged 6 months-8 years who received a seasonal vaccine for the first time during 2009-2010 but who received only 1 dose should receive 2 doses, rather than 1, during 2010-2011. In addition, for the 2010-11 influenza season, children aged 6 months-8 years who did not receive at least 1 dose of an influenza A (H1N1) 2009 monovalent vaccine should receive 2 doses of a 2010-11 seasonal influenza vaccine, regardless of previous influenza vaccination history. For all children, the second dose of a recommended 2-dose series should be administered 4 or more weeks after the initial dose."
223699264|NCT01922557|DEVICE|NICOM|NICOM monitoring thoracic fluid content at baseline(T1), anhepatic phase(T2), 30 mins after reperfusion(T3) and 2 hrs after reperfusion(T4).
223699265|NCT03656770|OTHER|Survey questionnaire|Each version of the questionnaire portrays a young Ugandan woman with different profiles of illness severity, treatment, and treatment response.
223699266|NCT02298608|DEVICE|Nano Knife|Percutaneous, CT guided, ablation of renal mass
223699267|NCT00178633|PROCEDURE|Bariatric surgery|Bariatric surgery was not part of this trial. This was observational trial of persons post-bariatric surger.
223699268|NCT01457469|OTHER|questionnaire administration|Ancillary studies
223699269|NCT01457469|PROCEDURE|quality-of-life assessment|Ancillary studies
223699270|NCT01457469|OTHER|counseling intervention|Undergo counseling session
223699271|NCT01457469|OTHER|internet-based intervention|Receive enhanced quitline intervention
223699272|NCT01457469|BEHAVIORAL|telephone-based intervention|Receive enhanced quitline intervention
223699273|NCT01457469|OTHER|educational intervention|Receive usual care plus
223699274|NCT01457469|DRUG|nicotine replacement therapy|Receive nicotine replacement patches
223699275|NCT01457469|OTHER|educational intervention|Receive enhanced quitline intervention
223699276|NCT05962437|DEVICE|Self-guided digital Acceptance and Commitment Therapy|Smartphone-based mobile health application (app) that delivers a self-guided, evidence-based ACT program tailored to the management of FM. This investigational digital therapeutic, referred to herein as STANZA, was inspired by a web-based ACT program for FM validated by University of Manitoba and was recently granted De Novo clearance by the U.S. FDA. The app delivers ACT in 15- to 20-minute daily doses over the course of 12 weeks without the involvement of healthcare providers. The program consists of interactive educational materials that teach ACT skills which are reinforced experientially via values exploration and identification, mindfulness, and relaxation exercises. Values-based assignments follow each lesson to assist patients in incorporating ACT skills into their daily lives. Uniquely, STANZA teaches additional skills, including self-guided physical exercise and pacing daily activities via a personally customized stepwise, gradual approach.
223781658|NCT05944900|PROCEDURE|Cyanoacrylate glue application|"The wound must be positioned in a horizontal plane, and the glueapplied uniformly overhanging the wound. Cyanoacrylate glue is contraindicated when adhesion cannot be achieved.~Cyanoacrylate glue should be applied in accordance with the instructions for use.~Wound-closing properties are only fully achieved once the first layer has fully polymerized. This depends on skin type, skin hydration and ambient humidity. If a second layer is applied, the polymerization time is extended accordingly."
223781659|NCT02682654|DEVICE|Dr. Scholl's Prototype Ankle Brace|Subjects will be instructed to wear the assigned Ankle/Knee brace for 8 ± 2 hours per day, for a minimun of 5 days out of a 7-day/1 week wear period.
223781660|NCT02682654|DEVICE|Dr. Scholl's Prototype Knee Brace|Subjects will be instructed to wear the assigned Ankle/Knee brace for 8 ± 2 hours per day, for a minimun of 5 days out of a 7-day/1 week wear period.
223781661|NCT05769673|PROCEDURE|Placement of dental implant|Placement of a dental implant on the edentulous ridge
223781662|NCT05769673|PROCEDURE|Placement of stock healing abutment|Placement of stock healing abutment after implant has been placed on the edentulous ridge
223781663|NCT05769673|PROCEDURE|Placement of customized CAD/CAM healing abutment|Placement of customized CAD/CAM healing abutment after implant has been placed on the edentulous ridge
223781664|NCT04707235|DRUG|Hydroxycarbamide|Patients, aged ≥ 2 years old, with symptomatic SCD, treated with Siklos®.
223781665|NCT03344991|OTHER|Cardboard Cot Care|When ready to be weaned from radiant warmer, infant will be placed in a reflective film-lined cot for the duration of hospitalization. Axillary temperatures will be taken at 1 hour, 6 hours, and 24 hours after placement in cot, and every 24 hours thereafter until discharge. If temperatures found \< 36.0 at any time, an additional blanket and hat will be added to infant to improve temperature. All other care will be standard of care at University Teaching Hospital, including early and exclusive breastfeeding, appropriate bundling, and Kangaroo Mother Care as continuously as possible.
223781666|NCT03344991|OTHER|Open Crib|When ready to be weaned from radiant warmer, infant will be placed in a standard of care open crib for the duration of hospitalization. Axillary temperatures will be taken at 1 hour, 6 hours, and 24 hours after placement in cot, and every 24 hours thereafter until discharge. If temperatures found \< 36.0 at any time, an additional blanket and hat will be added to infant to improve temperature. All other care will be standard of care at University Teaching Hospital, including early and exclusive breastfeeding, appropriate bundling, and Kangaroo Mother Care as continuously as possible.
223781667|NCT06460701|OTHER|m-CIMT without Kinesio taping|Baseline treatment m-CIMT will be applied includeing ROM with a sling, e.g shoulder flexion, extension, abduction, and rotation. The elbow's flexion and extension, Forearm supination is the extension of the wrist and fingers. Functional Training Using a tiny toy ball, practice tossing and catching it from various angles. Play with modeling clay, constructing towers of the toy bricks using LEGOs,Using crayons, ripping a piece of paper towel,Grasping biscuits, Using a spoon, utilizing a glass to drink, comb hair, brush teeth,Using a bubble blower,With a toy in hand, putting cap, putting lotion.stretching to shoulder's extensors, adductor, and internal rotators ,wrist and elbow flexors. strengthening exercises e.g a ball above head position in various directions,Using paper adhered to the window or wall at varying heights for drawing. The session will go for one hour.
223699277|NCT05962437|DEVICE|FM symptom tracking app (FM-ST)|Based on the same platform as STANZA, FM-ST enables self-guided daily tracking of patient-reported symptoms and functioning. Symptom tracking is commonly used in chronic pain management. FM-ST also provides access to educational materials relevant to FM and general health but does not provide any psychotherapy or healthcare professional involvement. This app mitigates potential expectation, treatment time and attention, and healthcare provider interaction biases that often occur in chronic pain studies that utilize passive comparison conditions.
223699278|NCT05962437|BEHAVIORAL|Treatment as Usual (TAU)|Usual care is mainly carried out by general practitioners and specialists in regular consultations, commonly consisting of face-to-face visits to monitor the physical and emotional status of the patient. Clinicians usually provide advice about physical exercise, diet, etc., and prescribe pharmacotherapy (pain medications, hypnotics and antidepressants)
223699279|NCT00257374|DRUG|Gatorade, Pedialyte and New Solution|
223699280|NCT00144196|DRUG|tiotropium (Spiriva)|
223699281|NCT04391491|DIAGNOSTIC_TEST|Neuregulin-1β level in plasma|Peripheral blood will be collected after randomization (plus or minus 3 days), the plasma will be assayed for neuregulin-1b, biomarkers of inflammation and fibrosis, NTproBNP
223699282|NCT04680130|DRUG|C-11 PiB|Completing PET scan looking for amyloid protein
223699283|NCT04680130|DRUG|AV1451 Tau|Completing PET scan looking for tau protein
223699284|NCT04680130|DRUG|C-11 ER176|Completing PET scan looking for neuroinflammation
223699285|NCT04299074|OTHER|addiction|questionnaire
223699286|NCT04482881|DRUG|Isosorbide Mononitrate 40 MG|giving women isosorbide mononitrate 40 MG
223699287|NCT04482881|DRUG|Isosorbide Mononitrate 60 MG|giving women isosorbide mononitrate 60MG
223699288|NCT04482881|DRUG|Misoprostol|Giving women misoprostol
223699289|NCT00004198|BIOLOGICAL|keyhole limpet hemocyanin|
223699290|NCT00004198|BIOLOGICAL|sargramostim|
223699291|NCT00004198|BIOLOGICAL|tumor cell-based vaccine therapy|
223699292|NCT03266523|OTHER|Natural images in imaging waiting rooms|Standard environment for hospital imaging waiting rooms
223699293|NCT04554173|PROCEDURE|surgical resection neurogenic tumors|Patient who was treated for a thoracic neurogenic tumor by minimally invasive surgery
223699294|NCT00924079|DRUG|nalbuphine|oral dosage form, 66 mg, single dose
223699295|NCT01076231|RADIATION|proton beam radiation therapy|
223699296|NCT01076231|DRUG|cisplatin|Given IV
223781668|NCT06460701|OTHER|m-CIMT along with kinesiotaping|"Modified constraint-induced movement therapy along with kinesiotaping will be applied. m-CIMT protocol is baseline treatment and it is is same as in the other group.~This group also participated additionally in a kinesio taping program, which utilize KT with the goal of enhancing middle and lower trapezius function to increase stability in the scapula on the afflicted side. During the application of the tape, the shoulders were kept in a low and backward posture, and the scapular alignment was manually maintained. KT was administered at the acromion and positioned medially at the spinous processes (T2-T3 for the middle trapezius and T12 for the lower trapezius). For eight weeks in a row, there will be three sessions every week"
223781669|NCT04295889|DIAGNOSTIC_TEST|Approach A (PeeSpot urine collection device).|The participant will receive the PeeSpot urine collection device (Hessels+Grob B.V., Deventer, The Netherlands), which consists of a holder containing a urine collection pad (consisting of hygroscopic material containing). The holder can be placed back into the tube and can be easily sent to the laboratory by mail. In this urine, albumin, creatinine, and the ACR will be measured in the laboratory of the Amphia hospital.
223781670|NCT04295889|DIAGNOSTIC_TEST|"Approach B (ACR | EU Test kit)."|"The participant will receive the ACR \| EU test kit (Healthy.io Ltd, Tel-Aviv- Yafo, Israel), which consists of a urine test strip, a urine cup, a color calibrator and instruction to download a smartphone application. The participants have to download the smartphone application according to the instructions included in the kit. Results will be directly shown to the participant in the app."
223781671|NCT00861497|DRUG|Bifeprunox|Flexible dosage: 20, 30, or 40 mg/day
223781672|NCT00906308|DRUG|MF101 5 g/day|PO (orally) 5 g/day (administered twice a day, BID) for up to 12 weeks
223781673|NCT00906308|DRUG|Placebo|PO (orally) matched placebo (administered twice a day, BID) for up to 12 weeks
223781674|NCT00906308|DRUG|MF101 10 g/day|PO (orally) 10 g/day (administered twice a day, BID) for up to 12 weeks
223781675|NCT00761059|DRUG|Glucose 20%|The oral application of 0,3 ml/kg Glucose 20% 3 minutes before nasopharyngeal suctioning
223781676|NCT00761059|DRUG|Aqua|The oral application of 0,3 ml/kg Aqua 3 minutes before nasopharyngeal suctioning
223781677|NCT02621905|DRUG|Sporanox|At least 2 capsules twice a day for 3 weeks
223699297|NCT01076231|DRUG|etoposide|Given IV
223699298|NCT01076231|PROCEDURE|therapeutic conventional surgery|
223699299|NCT01948037|OTHER|hydrotherapy|30-minutes/per day,for 4weeks
223699300|NCT01948037|OTHER|hydrotherapy|30-minutes/per day;4weeks
223699301|NCT02910869|GENETIC|Pathway Genomics FIT test|
223699302|NCT00142610|DIETARY_SUPPLEMENT|Vitamin|This is designed as a placebo controlled study of 500 mg alpha tocopherol combined with 2,000 mg of ascorbate, each orally administered daily for 12 weeks, on airway antioxidant levels in asthmatics.
223699303|NCT04810481|DEVICE|BIS Complete Monitoring System|The BIS™ complete monitoring system is a user-configurable patient monitoring system designed to monitor the hypnotic state of the brain based on the acquisition and processing of EEG signals. The BIS™ complete system processes raw EEG signals to produce a single number, called the BIS™ index, which correlates with the patient's level of hypnosis. A sensor placed on the patient's head transmits EEG signals to the BISx™ unit. The BIS™ unit filters and digitizes the signal, analyzes it for the artifact, and processes it using digital signal processing techniques to derive processed EEG parameters to a single Bispectral Index (BIS™), and finally sends the processed data to the monitor for display. The purpose of processing the EEG waveform data is to extract characteristic features from the complex signal that the BIS™ algorithm can utilize to derive BIS Index.
223699304|NCT01934244|DEVICE|NovaSure Endometrial Ablation|The NovaSure Endometrial Ablation device consists of a disposable single-use, conformable bipolar electrode array mounted on an expandable frame that can create a confluent lesion on the entire interior surface area of the uterine cavity. The device is inserted transcervically into the uterine cavity, and the sheath is retracted to allow the bipolar electrode array to be deployed and conform to the uterine cavity. The disposable device works in conjunction with a dedicated NovaSure RF (radio frequency) controller to perform customized, global endometrial ablation.
223699305|NCT04683562|OTHER|Pregnant women at 28-32 weeks|Pregnant women at gestational age 28-32 weeks
223699306|NCT04683562|OTHER|at delivery|women delivered at term
223699307|NCT02664610|BEHAVIORAL|Text Messaging|hypertensive participants will be randomized to receive tailored, motivational text messages
223699308|NCT03577873|OTHER|gallbladder preserved|Gallbladders will be remained after clearance of bile duct stones with ERCP and conventional therapy, such as fluid replacement and prophylactic anti infection, will be accepted.
223699309|NCT03577873|PROCEDURE|cholecystectomy|Cholecystectomy will be done right now after clearance of bile duct stones with ERCP, and then conventional therapy will be accepted.
223699310|NCT04956952|DEVICE|EECP|1 hour of treatment with EECP
223699311|NCT02575742|DEVICE|3D-Transit system|
223781678|NCT02621905|DRUG|Lozanoc|At least 2 capsules twice a day for 3 weeks
223781679|NCT01478945|DEVICE|311 nm NB-UVB light|"Narrowband UVB is now the most common form of phototherapy used to treat skin diseases. Narrow-band refers to a specific wavelength of ultraviolet (UV) radiation, 311 to 312 nm. Hospital NB-UVB usually involves whole body cabinets suitable for extensive, generalised vitiligo i.e. large or multiple lesions. Usually the whole body is exposed to the UVB for a short time (seconds to minutes). NB-UVB is also used in the treatment of many other skin conditions including psoriasis and eczema.~Hand held phototherapy units use the same lamp as the whole body units (TLO1) but only suitable for the treatment of smaller areas of skin i.e. early and focal lesions of vitiligo.~Early reports showed that these units are also safe and effective for the treatment of psoriasis of the scalp."
223781680|NCT06047197|BIOLOGICAL|RC19D2 cell injection|The functional component of RC19D2 cell injection is T cells that have been genetically modified to express anti CD19 chimeric antigen receptors.
223699312|NCT02208531|BEHAVIORAL|Psychosocial Stimulation and Nutritional Care|Psychosocial Stimulation and Nutritional Care will be provided to malnourished children and their mothers every fortnight in the Community Clinics for one year.
223699313|NCT00857883|DRUG|GSK1521498 or placebo|GSK1521498 is a mu-opioid receptor inverse agonist
223699314|NCT05962671|DRUG|Opioid-sparing based anesthesia|Intraoperative opioid-sparing maintenance comprised dexmedetomidine bolus dose of 1 mcg/kg followed by 0.3 mcg/kg/h, propofol 4-8 mg/kg/h and ketamine 25 mg/h for a max of 50 mg during the procedure, targeting bispectral index (BIS) between 45%-60%. The lean body weight will be used for calculation of the drugs.
223699315|NCT05962671|DRUG|Sevoflurane-based anesthesia|Intraoperative sevoflurane-based anesthesia, 0.8 to 1.0 Minimum alveolar concentration will be used combined with fentanyl 1 mcg/kg followed by 1 -2 mcg/kg/h and cis-atracurium, to keep bispectral index between 45% to 60%.
223781681|NCT03684798|OTHER|MCII|In this study, the research staff will work through the MCII approach with the participant as an interactive, face-to-face training. The desired future consists of imaging an abstinent life and comparing it with personally relevant obstacles. Afterwards, the most relevant obstacle will be chosen and an if-then-plan will be formed, that refers to this obstacle.
223781682|NCT03684798|OTHER|Treatment as usual|The patients in the control group will receive a 2 x 2 contingency table about the disadvantages and advantages of being abstinent and of drinking. In addition, abstinence intentions of patients in the control group will also be supported and risk situations and relapse events since the last trainings will be reappraised, but without the use of MCII.
223781683|NCT02546752|OTHER|THEO|THEO is interactive patient engagement software that runs on an iPad tablet platform (developed by Noble.MD). THEO is the intervention in this study.
223699316|NCT00369707|DRUG|Rituximab|On days 1, 8, 15 and 22 of the 1st cycle, bortezomib will be administered intravenously (through a vein) over 3-5 seconds followed by an intravenous infusion of rituximab. How long it will take to infuse the dose of rituximab is dependent upon your weight and how well you tolerate the infusion; it is estimated this first infusion may take between 3-4 hours. During subsequent cycles, bortezomib will again be given on days 1, 8, 15 and 22. However, rituximab will only be given on day 1 of each cycle.
223781684|NCT03632356|BEHAVIORAL|Stepped Care Intervention (STEP)|A stepwise progression of intervention according to the participant's response to the increasing levels of therapy. There will be 1 session of psychoeducation, followed by 5 sessions of Cognitive Behavioral Therapy (CBT) if panic symptoms do not improve at 1-month follow-up.
223781685|NCT03632356|DIAGNOSTIC_TEST|Screening only|Screening for probable panic attacks or panic disorder using the Structured Clinical Interview for DSM-5
223781686|NCT03087266|PROCEDURE|FM-SRP|Non surgical periodontal treatment performed in all dentition within 1-2 appointments in a 24 hour time frame.
223781687|NCT03087266|PROCEDURE|Q-SRP|Non surgical periodontal treatment performed in 4 sessions comprising of a quadrant (1/4) of the dentition each. Performed in 3 weeks time frame.
223781688|NCT01573702|PROCEDURE|Stereotactic Radiosurgery|21 Gy daily for 5 days
223781689|NCT01573702|DRUG|Erlotinib|150mg once daily
223781690|NCT03864900|BEHAVIORAL|The medication adherence intervention|The health belief model based medication adherence intervention comprised two main components: a 60-minute individual face to face instruction and six follow-up telephone calls.
223781691|NCT01398605|OTHER|Exercise training|Different dose of exercise training
223781692|NCT03238001|DEVICE|DCTclock|DCTclock is a quick and non-invasive test that measures cognitive function based on a computerized algorithmic analysis of the entire drawing process and output of a well-established cognitive assessment called The Clock Drawing Test (CDT).
223781693|NCT00759109|BIOLOGICAL|Peginterferon alfa-2b|Peginterferon alfa-2b, 50 μg, weekly, SC, for a period of 3 years.
223781694|NCT00759109|OTHER|Observation (no treatment)|No treatment was given to participants enrolled in the control arm (Arm B).
223781695|NCT03165045|DRUG|Spiolto® Respimat®|6 weeks
223781696|NCT00931151|DIETARY_SUPPLEMENT|Postprandial metabolic and functional measures|After ingestion of a high fat meal containing the different protein sources, the subjects undergo a series of measures of endothelial dysfunction and blood and urine sampling for the assessment of proinflammatory cytokines levels and metabolomics determinations.
223781697|NCT03925636|DIETARY_SUPPLEMENT|Specific Carbohydrate Diet|The diet removes all grains such as wheat, barley, corn, rice, and most dairy products (except yogurt fermented for 24 hours and cheese aged for grater than 30 days). The diet mainly consists of meat, fruits, vegetables, nuts, oils, and honey.
223781698|NCT00538161|OTHER|Ventilation strategy|
223781699|NCT01827904|DEVICE|Transcranial ExAblate|
223781700|NCT01827904|DEVICE|Sham Transcranial ExAblate|
223781701|NCT03115424|DRUG|Saxenda|Saxenda is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to a reduced calorie diet and increased physical activity for chronic weight management in adult patients. Subjects will be recruited and screened prior to undergoing bariatric surgery. Subjects undergoing SG will be randomized 1:1 at month 3 post surgery to Saxenda, 0.6mg SQ daily, with weekly titration of 0.6mg until maintenance dose of 3mg/daily reached. Subjects will remain on study drug for duration of study (33 months). After undergoing surgery, study visits will be timed to coincide with the standard clinical follow-up visits at months 3, 6, 9, 12, 18, 24, 30 and 36.
223781702|NCT03115424|DRUG|Placebos|Subjects will be recruited and screened prior to undergoing bariatric surgery.Subjects undergoing SG will be randomized 1:1 at months 3 post surgery to Placebo, 0.6mg SQ daily, with weekly titration of 0.6mg until maintenance dose of 3mg/daily reached. Subjects will remain on study drug for duration of study (33 months). After undergoing surgery, study visits will be timed to coincide with the standard clinical follow-up visits at months 3, 6, 9, 12, 18, 24, 30 and 36.
223699317|NCT00369707|DRUG|bortezomib|On days 1, 8, 15 and 22 of the 1st cycle, bortezomib will be administered intravenously (through a vein) over 3-5 seconds followed by an intravenous infusion of rituximab. How long it will take to infuse the dose of rituximab is dependent upon your weight and how well you tolerate the infusion; it is estimated this first infusion may take between 3-4 hours. During subsequent cycles, bortezomib will again be given on days 1, 8, 15 and 22. However, rituximab will only be given on day 1 of each cycle.
223699318|NCT04719637|DEVICE|PRDS-001 Renal Denervation Ultrasound System|Renal Denervation Ultrasound System
223699319|NCT06448078|DEVICE|External chest wall fixator|External chest wall fixator is applied in the form of external bonding to the rib fracture area
223699320|NCT06247423|DEVICE|Active group 10kHz|"For electrical stimulation in the active groups, unmodulated alternating currents with a symmetrical rectangular waveform of 10 kHz will be applied for 20 minutes. The current intensity shall be adjusted individually for each participant by increasing the current intensity until the participant reports a strong but comfortable tingling sensation just below the motor threshold. One electrode will be placed over the median and radial nerves, while the other over the radial nerve.~The intensity of the current shall be adjusted every two minutes if the tingling sensation decreases. This protocol had been used in previous studies conducted by our research group."
223781703|NCT03115424|PROCEDURE|RYGB|Subjects will be recruited and screened prior to undergoing bariatric surgery. After undergoing surgery, study visits will be timed to coincide with the standard clinical follow-up visits at months 3, 6, 9, 12, 18, 24, 30 and 36.
223781704|NCT05874258|OTHER|Real-PL training + Real-tES(tDCS)|PLtraining : around 40mins, tDCS: 20mins
223781705|NCT05874258|OTHER|Real-PL training + Sham-tES (tDCS)|PL training : around 40mins, tDCS: 20mins
223781706|NCT05874258|OTHER|Placebo-PL training + Sham-tES (tDCS)|PL training : around 40mins, tDCS: 20mins
223781707|NCT06497257|OTHER|Evaluating wrist flexor and extensor peak torque|Evaluation of wrist flexor and extensor peak torque
223781708|NCT06497257|OTHER|Evaluating functional disability|Evaluation of functional disability
223781709|NCT06497257|OTHER|Evaluating hand grip strength|Evaluation of hand grip strength
223781710|NCT05944263|BEHAVIORAL|weRISE; The gratitude, kindness and hope (GKH) program|weRISE is an arts based train the trainer intervention that promotes positive mental health through cultivating gratitude, kindness and hope among youth in schools and informal settlements in India and Kenya
223781711|NCT05944263|BEHAVIORAL|The [adapted] Stan Kutcher Teen Mental Health (TMH) program|The 'Teen Mental Health' curriculum developed by Dr. Stan Kutcher, aims to increase mental health literacy among young people ;will be used in the control group (active comparator group). The control intervention consists of eight sessions (45 minutes each) delivered by older groups of young people (ages 18-24) in schools and community settings through a didactic approach.
223781712|NCT06452615|DEVICE|Extracorporeal shockwave|The patients will receive 3000 to 6000 pulses every session by a radius of 15 mm probe (R15) at a frequency of 10 Hz, with energy gradually increasing from 1.4 to 1.5 bar
223781713|NCT02582905|DRUG|Placebo|Inactive ingredient matching the active comparators in appearance.
223781714|NCT02582905|DIETARY_SUPPLEMENT|Citicoline|Citicoline is an over-the-counter nutritional supplement that is used for neuroprotective effects. It is a naturally occurring neurochemical in the human body.
223781715|NCT02582905|DRUG|Pregnenolone|Pregnenolone is a naturally occurring neurosteroid that is synthesized from cholesterol in the adrenal glands and also in the brain. Pregnenolone produces other neuroactive steroids.
223781716|NCT05071261|DIAGNOSTIC_TEST|Hepatitis C Virus Screening|1-2 Blood Screenings for Hepatitis C Virus
223781717|NCT03792685|OTHER|Normo-carbohydrate meal intake|Subjects are going to receive the normo-carbohydrate meal.
223781718|NCT03792685|OTHER|High-carbohydrate meal intake|Subjects are going to receive the high-carbohydrate meal.
223781719|NCT03792685|OTHER|High-fat meal intake|Subjects are going to receive the high-fat meal.
223781720|NCT03792685|OTHER|High-protein meal intake|Subjects are going to receive the high-protein meal.
223781721|NCT01449916|OTHER|Simplified Severe Sepsis Protocol|Early fluid protocol, early blood cultures and antibiotics; blood cultures and titrated dopamine in selected patients; monitoring based on vital signs and physical examination
223781722|NCT06567639|PROCEDURE|Catheter ablation|"Hybrid epicardial right ventricular (RVOT-EPI) mapping and Brugada syndrome substrate ablation technique.~The procedure is performed in the hybrid operating room. The Advisor™ HD-Grid Mapping Catheter is delivered inside the chest through a working port and positioned under thoracoscopic view over the pulmonary artery that is consequently labeled on EAM. As a standard protocol the mapping catheter is positioned over the pulmonary artery and moved down progressively over the RVOT-EPI under continuous thoracoscopic view and at least three consecutive beats are required for each recording location point with a stable catheter position."
223781723|NCT01866709|DRUG|Sodium polystyrene sulfonate|Oral suspension in water of 15g sodium polystyrene sulfonate administered three times (tid) daily for 48 hours without co-administration of Sorbitol.
223781724|NCT01866709|DRUG|Silicified microcrystalline cellulose|Oral suspension in water of placebo administered three times (tid) daily for 48 hours.
223781725|NCT02138318|OTHER|High definition (HD) endoscopy|
223781726|NCT02138318|OTHER|chromoendoscopy|
223781727|NCT00240422|DRUG|Telmisartan|
223781728|NCT00240422|DRUG|Ramipril|
223781729|NCT03158558|BEHAVIORAL|Accelerated, Multi-Couple Group CBCT for PTSD|Intensive weekend retreat version of cognitive-behavioral conjoint therapy for PTSD (Monson \& Fredman, 2012)
223781730|NCT00472914|DEVICE|portable surface electromyography|
223781731|NCT05771519|BEHAVIORAL|HIV disclosure intervention|This will be a biobehavioral intervention focused on helping men with HIV to disclose their HIV status to a personal confidant inclusive with specific focus on sexual partners.
223781732|NCT03791398|DRUG|Dose level 1 ONC201 625mg|ONC201 625mg + Nivolumab 240mg IV flat dose
223781733|NCT03791398|DRUG|Dose level 2 ONC201 500mg|ONC201 500mg + Nivolumab 240mg IV flat dose
223781734|NCT03791398|DRUG|Dose level 3 ONC201 375mg|ONC201 375mg + Nivolumab 240mg IV flat dose
223781735|NCT01223664|PROCEDURE|Allogenic bone marrow stem cells transplantation|30ml allogenic bone marrow stem cells were infused to patients using interventional method via portal vein or hepatic artery as well as conserved therapy
223781736|NCT01223664|DRUG|Conserved therapy|Oral or intravenous administration
223781737|NCT00289796|BIOLOGICAL|DTPa-HBV-IPV/Hib|GSK Biologicals' combined diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliovirus and Haemophilus influenzae type b conjugate vaccine
223699321|NCT06247423|DEVICE|Sham intervention|"Sham electrical stimulation will be performed with the same equipment, time, and electrodes as in the active groups without the participants and the evaluator having a view of the device screen. The intensity of the current will be increased for 30 seconds until the sensory threshold (strong but comfortable tingling sensation) will be reached and after that, the intensity will be reduced to 0 milliamperes (mA) with 30 seconds ramp down. Participants will not receive electrical current during the rest of the placebo intervention. This protocol was used in other studies with similar interventions to blind participants."
223699322|NCT04335838|OTHER|retrospective analysis|The investigators retrospectively analyzed the outcome and possible prognostic factors in polytrauma patients.
223699323|NCT06161610|DEVICE|LITT|The patients in the intervention group will receive LITT, other treatments, including systematic therapy and radiology therapy, would be not restricted except the craniotomy of resection before tumor progression or emergency. The patient is supposed to receive LITT post-randomization within 7 days.
223699324|NCT06161610|OTHER|Control|The patients in the control group will receive the best medical management under guidelines except LITT before tumor progression. Craniotomy will not be restricted,
223699325|NCT03594435|DRUG|Ibudilast|targets neurotrophin signaling and neuroimmune function
223699326|NCT03594435|DRUG|Placebo oral capsule|matched to active drug, ibudilast
223699327|NCT05941559|OTHER|EMDR|Eye Movement Desensitization and Reprocessing
223699328|NCT05659992|DRUG|azacytidine;cytarabine;aclamycin;Chidamide;venetoclax;granulocyte|"1. azacytidine (75 mg/m2/day, days 1 to 7).~2. cytarabine (75 mg/m2 bid, days 1 to 5).~3. aclamycin (10 mg/m2/day, day1,3,5).~4. Chidamide (30 mg/day , days 0,3).~5. venetoclax (100 mg day 1, 200 mg day 2, 400mg days 3 to 14 ).~6. granulocyte colony-stimulating factor (5ug/kg/day, day 0 until agranulocytosis recovery)"
223699329|NCT06051214|BIOLOGICAL|thrombogram|blood sampling every month for 12 months
223699330|NCT03436654|DRUG|Apalutamide|240mg daily orally
223699331|NCT03436654|DRUG|Abiraterone Acetate|1000mg daily orally
223699332|NCT03436654|DRUG|Prednisone|5mg BID orally
223699333|NCT03436654|PROCEDURE|Radical Prostatectomy|A laparoscopic, robotic-assisted, or open approach to RP is permitted at the discretion of the operating surgeon.
223699334|NCT03436654|PROCEDURE|Extended Pelvic lymphadenectomy|To be performed concurrently with prostatectomy. Bilateral pelvic lymphadenectomy should include complete removal of all pelvic lymph nodes within the broad template described and includes the external iliac, hypogastric, obturator, and pre-sacral lymph nodes
223699335|NCT03436654|DRUG|GnRH agonist/antagonist|Physician's choice, for a total duration not to extend beyond the treatment phase of the protocol or 10 months from the start of investigational agent(s)
223699336|NCT03436654|RADIATION|Stereotactic Body Radiation Therapy|Subjects undergo SBRT in cycle 4, then salvage radiation therapy in cycles 7-8. Treatment repeats every 28 days for up to 10 cycles in the absence of disease progression or unacceptable toxicity
223699337|NCT02585583|RADIATION|Thalamotomy|VoA-Vop complex of the thalamous or VIM nucleus will be targeted. 100 Gy, 120 Gy, 130 Gy, 140 Gy will be the foreseen prescription dose. CyberKnife will be always used to perform the procedure.
223699338|NCT03606629|DEVICE|Endoprosthesis implantation|Endoprosthesis implantation by Percutaneous Angioplasty
223699339|NCT00597974|PROCEDURE|Angioplasty|(non-experimental) Carotid artery angioplasty and/or stent-supported angioplasty
223699340|NCT00597974|DEVICE|Stent|(non-experimental) Precise™ Nitinol Self-Expanding Stent (Cordis Endovascular, Johnson \& Johnson), S.M.A.R.T.® Control™ Stent (Cordis Endovascular, Johnson \& Johnson), Wallstent® (Boston Scientific Medi-Tech)
223699341|NCT00597974|OTHER|Neurological and neuropsychological evaluations|Clinical examinations consisting of a neurological and neuropsychological evaluation
223699342|NCT00597974|PROCEDURE|Angiography|(non-experimental) Coronary angiography
223699343|NCT01563744|PROCEDURE|EGD-assisted administration of colonoscopy prep|Interventional group receive the first 2 liters of prep solution during EGD through the scope channel if colonoscopy expected the following day.
223699344|NCT01563744|PROCEDURE|Control Group received standard prep by oral administration|Control group receive standard oral colonoscopy prep.
223699345|NCT01474369|DRUG|TAK-438|TAK-438 10 mg, tablets, orally, once daily for 4 weeks. Thereafter, TAK-438 placebo tablets, orally, once daily for 1 week.
223699346|NCT01474369|DRUG|TAK-438|TAK-438 20 mg, tablets, orally, once daily for 4 weeks. Thereafter, TAK-438 placebo tablets, orally, once daily for 1 week.
223699347|NCT01474369|DRUG|Placebo|TAK-438 placebo-matching tablets, orally, once daily for 5 weeks.
223699348|NCT00002311|DRUG|Wobenzym|
223699349|NCT05739630|DRUG|mitoxantrone liposome|Mitoxantrone liposomes with 36mg/m2 and Bu 3.2mg/kg -5 to -4, Flu 30mg/m2 -12 to -9, Ara-C 1.5g/m2 -12 to -9，CTX 15mg/kg/d -3 to -2, was used as conditioning regimen, Post Transplant Cyclophosphamide 50 mg/kg IV daily on days +3 and +4.
223699350|NCT05739630|DRUG|ATG|Control group:the conditioning regimen involved Ara-C 2g/m2 q12h -8, BU 3.2 mg/kg -7 to -5,CTX 1.8 g/m2 -4 to -3, to prevent GVHD, MTX 15mg/m2 +1d, 10mg/m2 +3,+6,+11,CsA 3mg/kg/d from -8d,MMF 1g q12h from -8d， ATG 2.5mg/kg/d -5 to -2.
223699351|NCT04319731|BIOLOGICAL|Human Amniotic Fluid|Administration of amniotic fluid in SARS-CoV-2 positive patients
223699352|NCT03361254|BIOLOGICAL|cryopreservation|cryopreservation to every patient with an indication of ECP for acute or chronic GVHD in Nancy Hospital for 18 months
223699353|NCT03971123|DRUG|Tricaprilin|Tricaprilin formulated as AC-SD-03 50g of AC-SD-03 (20g tricaprilin) mixed in 240mL dosing liquid at Hour 0 Day 1
223699354|NCT03971123|DRUG|Tricaprilin|Tricaprilin formulated as AC-LMP-01 50g of AC-LMP-01 (20g tricaprilin) mixed in 240mL dosing liquid at Hour 0 Day 1
223781738|NCT06441513|OTHER|Chinese traditional medicine nursing combined with case tracking management|First, we set up a team for the prevention of hand foot syndrome, including 1 head nurse of the tumor chemotherapy department, 2 doctors, 16 nurses (16 nurses were divided into 4 groups, each group designated a team leader) and the researchers of this experiment. Doctors are responsible for the diagnosis of HFS and the determination of traditional Chinese medicine prescriptions, head nurses and team leaders are responsible for quality control, and nurses are responsible for the assessment, intervention and evaluation of patients.
223781739|NCT06441513|OTHER|Health Education|elaborating the symptoms, mechanism and corresponding treatment measures of HFS for patients, reducing the fear of patients, helping them relax and adjust their mentality, and cooperating with observation.
223781740|NCT00853450|DRUG|AZD6482|Single intravenous infusion during a maximum of 5 hours
223781741|NCT00853450|DRUG|Clopidogrel|Oral doses given once daily during 7 days. 300 mg on day 1 and 75 mg on day 2 to 7.
223699355|NCT03971123|DRUG|Placebo|Matching placebo to AC-SD-03 50g of AC-SD-03P mixed in 240mL dosing liquid at Hour 0 Day 1
223699356|NCT03971123|DRUG|Tricaprilin|Tricaprilin formulated as AC-1202 60g of AC-1202 (20g caprlic triglyceride) mixed in 240mL dosing liquid at Hour 0 Day 1
223781742|NCT00853450|DRUG|ASA|75 mg orally once daily during 7 days in each treatment arm
223781743|NCT06223646|BIOLOGICAL|KQ-2003 CAR T-cells|KQ-2003 CAR T-cell therapy involves autologous chimeric antigen receptor T-cells, capable of targeting both human B cell maturation antigen (anti-BCMA CAR) and CD19 antigen molecules (anti-CD19 CAR) simultaneously as a cellular therapy.
223781744|NCT00876317|DRUG|Etoricoxib 60 mg|Etoricoxib 60 mg per oz per day for 14 days
223781745|NCT00876317|DRUG|Etoricoxib 90 mg|Etoricoxib 90 mg per oz for 14 days
223781746|NCT01513252|BEHAVIORAL|Gröber and Buschke test|spontaneous delayed recall score after a 5 years follow-up
223781747|NCT00365118|DEVICE|Pulsed dye laser (Candela), Intense pulsed light (Palomar)|
223699357|NCT03369470|BEHAVIORAL|App Dexterity|App based dexterity training by means of Finger Zirkus (see for more details: www.fingers-in-motion.de)
223781748|NCT01252459|RADIATION|Radiation Therapy|Experimental intervention (Arm A): High-precision re-irradiation (stereotactic fractionated radiation therapy (SFRT) and/or image guided radiation therapy, (IGRT), total dose 39 Gy, 3 Gy/d, 5x/ week. Target volume delineation based on AA-PET: GTV = AA uptake on PET, clinical target volume (CTV) = GTV+3mm, PTV = CTV+2mm
223699358|NCT03369470|BEHAVIORAL|Theraband|Active control being five traditional hand strengthening (Thera-band) exercises, which we published in our previous RCT, being feasible and effective in improving dexterity (for more details see for Kamm et al. 2015).
223699359|NCT06449898|OTHER|hemodialysis group|Data were collected from patients undergoing treatment at a hemodialysis center in Kırşehir. Participants were informed about the study objectives and provided written consent. Data collection took approximately 20-30 minutes per participant and included a face-to-face interview where socio-demographic and clinical information was recorded.
223781749|NCT01252459|RADIATION|Radiation Therapy|Control intervention (Arm B): High-precision re-irradiation (SFRT and/or IGRT), total dose 39 Gy, 3 Gy/d, 5x/ week. Target volume delineation based on T1Gd-MRI: GTV = contrast enhancement on T1Gd-MRI, CTV = GTV+3mm, PTV = CTV+2mm
223781750|NCT02422030|DRUG|Lipitor Tab. 40mg|
223781751|NCT02422030|DRUG|Trilipix 135mg|
223781752|NCT05897216|DRUG|CKD-383|QD, PO
223781753|NCT05897216|DRUG|CKD-501, D745, D150, D029|QD, PO
223781754|NCT03231384|DEVICE|Remote ischemic conditioning|"In this study, the remote ischemic conditioning treatment was composed of five cycles of bilateral upper limb ischemia intervened by reperfusion, which was induced by two cuff placed around the upper arms respectively and inflated to 200 mm Hg for 5 minutes followed by 5 minutes of reperfusion by cuff deflation.~Doctormate, IPC-906"
223781755|NCT01296958|DRUG|Niclosamide|Single oral dose of niclosamide determined by weight (dose: 11 to 34kg receive 1 gram, 35 to 50kg receive 1.5 grams, over 50kg receive 2 grams)
223781756|NCT01296958|BEHAVIORAL|Community education campaign|Education about prevention of Taenia solium infection provided in a single short (20 minute) interaction with the participant. Education was verbal with visual aids.
223781757|NCT01752140|PROCEDURE|10-core prostate biopsy protocol|Local vascular bundle anesthesia with 2% lidocaine was performed using a 22G Chiba needle. Ultrasound guided prostate biopsy using a standard biopsy device to obtain 10 biopsy cores.
223699360|NCT02943031|OTHER|Individualized Precision Therapy Programs|After bile duct tumor samples were collected, whole genome sequencing, drug screening ( including Mini-PDX and PDX) will conduct. Suitable drugs will be decided according to the different genomics classification.OS and PFS will be recorded.
223699361|NCT04888078|PROCEDURE|Bassini hernia repair|Non-mesh tissue inguinal hernia repairs
223699362|NCT03997604|DEVICE|Full Dentures created by additive manufacturing|Full dentures created by Additive manufacturing (Carbon Printers)
223699363|NCT03868761|BEHAVIORAL|Sonoma Rises|All participants will receive the intervention, Sonoma Rises, a mobile app designed by psychologists at the National Center for PTSD for wildfire survivors to facilitate recovery from disaster. Users can access evidence-informed tools to help cope with stress, heal from loss, prioritize self-care, connect with others, manage anger, and track their mood using validated assessments. There are also tools designed just for teens and users are linked to psychoeducation on disaster and health and other mental health resources and services.
223699364|NCT04225962|OTHER|Intimate quality of life questionnaire|Preparation of an intimate quality of life questionnaire
223699365|NCT01967342|BEHAVIORAL|Pain Ed|A 10-week psychosocial group treatment for chronic pain that focuses on providing information about the development, course, and treatment of chronic pain, as well as information about factors associated with reduced pain (e.g., sleep). In particular, it seeks to empower patients to take ownership of their chronic pain care through building deeper knowledge about their pain condition and their interactions with the health care system.
223699366|NCT01967342|BEHAVIORAL|CBT for Pain|A 10-week psychosocial group treatment for chronic pain that focuses on providing information and skills about the development, course, and treatment of chronic pain, as well as information about factors associated with reduced pain (e.g., sleep). In particular, it seeks to empower patients to self-manage their chronic pain through building deeper knowledge about and better skills for improving their pain condition and their interactions with the health care system.
223699367|NCT01967342|OTHER|Usual Care|A comparison condition in which patients receive standard individualized medical care from the federally qualified health center partnering on this study. Care can include basic biological interventions, such as medication or surgery, as well as supplementary care such as chiropractic or physical therapy. However, cost has a pragmatic influence on the amount of services provided, sought, and received.
223699368|NCT01986946|OTHER|Epidural Catheter - Dilaudid|Placement of an epidural catheter to administer local anesthetic and opioid (dilaudid) to the epidural space will be studied as compared to use of intravenous opioid (dilaudid) for pain control following lumbar spine fusion surgery.
223699369|NCT01986946|DRUG|Dilaudid|Patients in this arm will receive intravenous patient-controlled opioid analgesia (Dilaudid).
223699370|NCT00061347|PROCEDURE|Fiducial marker placement|Placement of fidicual markers under MRI guidance for localization of radiaiton treatment
223699371|NCT03823508|DEVICE|anodal tDCS|Patients will receive anodal tDCS during 20 minutes preceded and followed by a behavioral assessment (Coma Recovery Scale Revised) and a high density EEG. The anode will be placed over F3 in order to stimulate the left dorsolateral prefrontal cortex and the cathode over the right supraorbital area.
223699372|NCT03823508|DEVICE|sham tDCS|Identical to anodal tDCS, except that the stimulation will be stopped after 15 seconds.
223699373|NCT04674644|BEHAVIORAL|The psychosocial effects of COVID-19 pandemic on dental professionals|Analysing the psychosocial effects of COVID-19 pandemic on dental professionals using the Turkish version of the Fear of COVID-19 and Coronavirus Anxiety Scales
223699374|NCT03789214|DRUG|Placebo oral capsule|Placebo Sleep Medication
223699375|NCT03789214|DRUG|Low Dose Suvorexant|Low Dose Suvorexant
223781758|NCT01752140|PROCEDURE|Vienna nomogram prostate biopsy protocol|Local vascular bundle anesthesia with 2% lidocaine was performed using a 22G Chiba needle. Ultrasound guided prostate biopsy using a standard biopsy device to obtain a number of cores as defined by the Vienna nomogram.
223781759|NCT00624117|BEHAVIORAL|Progressive exercise|home-based exercise program, 2 to 3 exercise sessions per week
223781760|NCT03191903|COMBINATION_PRODUCT|Cingal|Hyaluronic Acid with Triamcinolone Hexacetonide
223781761|NCT03191903|DEVICE|Monovisc|Hyaluronic acid
223699376|NCT03789214|DRUG|High Dose Suvorexant|High Dose Suvorexant
223699377|NCT02178085|OTHER|Flow imaging|Participants will undergo morphological and then flow MRI. Flow MR images will be processed adequately to obtain quantitative values of arterial and venous flow as well as CSF flow.
223699378|NCT00107393|BIOLOGICAL|trastuzumab|
223699379|NCT00107393|DRUG|capecitabine|
223699380|NCT01232595|DRUG|LFF571|
223699381|NCT01232595|DRUG|Vancomycin (POC)|
223699382|NCT05962931|BIOLOGICAL|Bioengineered Artificial Mesenchimal Sheet (BAMS)|Each patient assigned to the experimental treatment group will receive 4 BAMS (1 BAMS/week) at a concentration of about 360,000 cells/cm2.
223699383|NCT05962931|PROCEDURE|Standard treatment (Control)|Each patient assigned to the control group will undergo a standard treatment procedure for uncomplicated venous ulcers.
223699384|NCT00007683|DRUG|Warfarin titrated to an INR of 2.5-3.0|anticoagulation (administered without blinding) titrated to a target INR of 2.5 to 3.0, monitored by measurements at 6 week intervals after initial titration and stabilization.
223699385|NCT00007683|DRUG|Aspirin|an antiplatelet agent whose mechanism is inhibition of thromboxane, a platelet activator) administered in a double blind manner.
223699386|NCT00007683|DRUG|Clopidogrel 75|(an antiplatelet agent whose mechanism is ADP inhibition) administered in a double blind manner)
223699387|NCT04229784|PROCEDURE|Radiofrewuency surgery|The research procedure consists of radiofrequency destruction of hemorrhoidal vascular tissue. It consists in delivering a 4 MHz radiofrequency wave current delivered at low temperature by microfibre electrodes using a large disposable needle within the hemorrhoidal vascular tissue
223699388|NCT02263131|BIOLOGICAL|IL-YANG FLU Vaccine Prefilled Syringe INJ.|IL-YANG FLU Vaccine Prefilled Syringe INJ.0.5mL or 0.25mL
223699389|NCT02263131|BIOLOGICAL|VAXIGRIP Prefilled Syringe INJ.|VAXIGRIP Prefilled Syringe INJ.0.5mL or 0.25mL
223699390|NCT01230710|DRUG|Erlotinib|Erlotinib was supplied as tablets.
223699391|NCT00750386|DRUG|Paclitaxel|175 mg/m2, I.V, every 2 weeks
223699392|NCT00750386|DRUG|Carboplatin|Carboplatin AUC, I.V, 5 every 2 weeks
223699393|NCT04200859|OTHER|Cold application|cold application using ice pack/gel pad in the control of pain experienced during chest tube removal
223699394|NCT02884531|OTHER|Patient Education and Basic Body Awareness Therapy|Patient education (1/2 day) and a Physiotherapy movement modality (12 times, once a week)
223781762|NCT03191903|DRUG|Triamcinolone Hexacetonide|Triamcinolone Hexacetonide
223699395|NCT02884531|BEHAVIORAL|Patient Education|Patient education (1/2 day)
223699396|NCT06010706|OTHER|Supervised physical therapy manual exercise program.|"1. Mobilization Techniques :~   The joint mobilization technique will be the anterior-posterior glide of the talus. The participant will be positioned in supine or long sitting.~2. Stretching Exercise:~   Passive stretching with therapist assistance was used for ankle dorsiflexion with the knee both flexed and extended. Force during passive stretching was modified to patient tolerance. Each participant flexed the knee slightly while standing on a 10° incline board. The participant was asked to slightly flex both knees until a stretch was felt in the calf muscle.~3. Strengthening Exercise:~The resistance training protocol will be based on the progressive resistance training principle and was a modification of the protocol used by Frontera et al \[10\] in older men. Plantar-flexion resistance training will be performed on a customized hydraulic apparatus, which provide a constant resistance over the entire ROM and allow for concentric as well as eccentric."
223699397|NCT06010706|OTHER|Stretching exercise, ROM, Strengthening exercises.|Patients at the control group will receive instruction for home based exercise program of physical therapy exercise. The home program primarily consisted of exercises targeting deficits in joint ROM, muscle flexibility and strength, and balance.
223699398|NCT00627549|PROCEDURE|Avaulta (surgical procedure using a mesh implant)|The use of Avaulta
223699399|NCT00627549|PROCEDURE|Conventional surgery (anterior repair)|Anterior repair surgery
223699400|NCT03277690|DRUG|Levoketoconazole|"During the double-blind Withdrawal Phase, patients will receive up to 1200 mg levoketoconazole daily.~During the double-blind Restoration Phase, patients will receive levoketoconazole plus placebo."
223781763|NCT05089539|DRUG|Angiotensin Receptor-Neprilysin Inhibition|Sacubitril/valsartan \[100 mg\] bid). Continuous treatment was maintained for at least three months.
223781764|NCT05089539|DRUG|Placebo|Placebo \[100 mg\] bid). Continuous treatment was maintained for at least three months.
223699401|NCT03277690|DRUG|Placebo|"During the double-blind Withdrawal Phase, patients will receive placebo tablets.~During the double-blind Restoration Phase, patients will receive placebo plus levoketoconazole."
223699402|NCT03815539|DEVICE|0.1% sodium hyaluronate|In dry eye group, part of the subjects will be instilled with one drop of 0.1% sodium hyaluronate in one of their eyes, then they will be tested with the devices of Oculus Keratograph 5M and Optical Quality Analysis SystemⅡ at different time points (10min, 30min, 60min, 90min and 120min).
223699403|NCT04562467|DRUG|Icosapent Ethyl 1000 MG Oral Capsule [Vascepa]|2 x 1g capsules BID as per REDUCE-IT
223699404|NCT01691898|DRUG|Obinutuzumab|Obinutuzumab 1000 mg will be administered by IV infusion on Days 1, 8, 15 of first 21-Day cycle and on Day 1 of subsequent 21-day cycles for up to 8 cycles.
223699405|NCT01691898|DRUG|Pinatuzumab Vedotin|Pinatuzumab Vedotin 1.8 or 2.4 mg/kg administered by IV infusion on Day 1 or 2 of every 21-day cycle.
223699406|NCT01691898|DRUG|Polatuzumab Vedotin|Polatuzumab Vedotin 1.8 or 2.4 mg/kg administered by IV infusion on Day 1 or 2 of every 21-day cycle.
223699407|NCT01691898|DRUG|Rituximab|RTX 375 mg/m\^2 administered by IV infusion on Day 1 of every 21-day cycle.
223699408|NCT00747812|DEVICE|Precision|Implantable Neurostimulator
223699409|NCT04852497|PROCEDURE|Ventricular tachycardia ablation|patients having undergone ventricular tachycardia radiofrequency ablation using of pace mapping strategy to identify the critical isthmus
223699410|NCT03645590|BEHAVIORAL|Stroke Ready|Stroke Ready community intervention consists of peer facilitated educational workshops, stroke music video, and mass media campaign including print materials (e.g. posters, brochure), health promotion mailers, radio/Television public health service announcements, and the Stroke Ready website and Facebook page.
223699411|NCT03812120|PROCEDURE|Dural closure with L-PRF|Evaluation of the safety and effectiveness of autologous blood-derived products (L-PRF) as an adjunct for dural repair
223699412|NCT03812120|PROCEDURE|Dural closure with classical fibrin sealants|Evaluation of the safety and effectiveness of classical fibrin sealants as an adjunct for dural repair
223699413|NCT05353309|PROCEDURE|Standard Angioplasty|Angioplasty Iliac done following standard practice
223699414|NCT05353309|PROCEDURE|Angioplasty with D images|Angioplasty Iliac under additional 3D Images merged as surgery support
223699415|NCT03540212|DRUG|Daclatasvir and sofosbuvir|"Daclatasvir is a DAAs that can inhibit the HCV non-structural (NS) 5A protein when used in combination with other HCV-therapies. It has a linear, non-time-dependent pharmacokinetic profile and nanomolar potency in vitro against HCV genotypes 1-6. It is excreted primarily via faeces, about 88% in an unchanged form while renal excretion accounts for approximately 7% of its elimination.~DOSE OF SOFOSBUVIR: 400 mg tablet orally once daily with food (in the morning) for 12 weeks for adolescents with liver fibrosis Metavir score F0-F2.~DOSE OF DACLTASVIR: 60 mg tablet orally once daily with food (in the morning) for 12 weeks for adolescents with liver fibrosis Metavir score F0-F2."
223699416|NCT05168449|OTHER|Mobile Application|mobile phone applications directed to chronic kidney disease patients to improve their medication.
223699417|NCT05843162|DRUG|Telmisartan|Subjects assigned to the test group are oral administered Telmisartan 40 mg and S-Amlodopine 2.5 mg once a day for 12 weeks. However, if the blood pressure measured at 6 weeks after random allocation (Visit 3) is MSSBP ≥140 mmHg or MSDBP ≥ 90 mmHg, increase the dose to Telmisartan 80 mg for 6 weeks from Visit 3 to Visit 4 (End of study). However, if the need of dose increasing is not required according to the tester's judgment, the current dose can be maintained.
223699418|NCT05843162|DRUG|Losartan|Subjects assigned to the control group are oral administered Losartan 50 mg and S-Amlodopine 2.5 mg once a day for 12 weeks. However, if the blood pressure measured at 6 weeks after random allocation (Visit 3) is MSSBP ≥140 mmHg or MSDBP ≥ 90 mmHg, increase the dose to Losartan 100 mg for 6 weeks from Visit 3 to Visit 4 (End of study). However, if the need of dose increasing is not required according to the tester's judgment, the current dose can be maintained.
223699419|NCT04932759|BEHAVIORAL|music listening|music listening during dental treatment
223699420|NCT00416546|DRUG|AEB071|
223699421|NCT00096083|DRUG|isolated perfusion|
223699422|NCT00096083|DRUG|melphalan|
223699423|NCT01708161|DRUG|BYL719|BYL719 is a small molecule inhibiting PI3-Kinase.
223699424|NCT01708161|DRUG|AMG 479|AMG 479 is a monoclonal antibody directed against IGF1-R.
223699425|NCT02831452|OTHER|pelvic floor muscle strength evaluation|
223699426|NCT03599388|BEHAVIORAL|Self- management for adequate sleep intervention (SASI)|Bedtimes and wake times will be prescribed each week for each participant and allow for gradual increases in sleep opportunity. Bedtimes will be set 15 minutes earlier each week provided sleep efficiency remains \>90%. Earlier betimes will extend sleep duration by increasing the opportunity for sleep. Wake times will not be changed because wake times are often determined by external demands, such as work schedules
223699427|NCT02019277|DRUG|Docetaxel|Dosing regimen to be determined by the investigator, routine clinical practices.
223699428|NCT02019277|DRUG|Nab-paclitaxel|Dosing regimen to be determined by the investigator, routine clinical practices.
223699429|NCT02019277|DRUG|Paclitaxel|Dosing regimen to be determined by the investigator, routine clinical practices.
223699430|NCT02019277|DRUG|Pertuzumab|Pertuzumab will be administered on Day 1 of the first treatment cycle as a loading dose of 840 mg, followed by 420 mg as an IV infusion every 3 weeks.
223699431|NCT02019277|DRUG|Trastuzumab|Trastuzumab will be administered at a fixed dose of 600 mg SC every 3 weeks.
223699432|NCT01780571|PROCEDURE|CPAP 5 cm H2O + PSV 5 cm H2O|Patients in the intervention group received Continuous Positive Airway Pressure (5 cm H2O) and Pressure Supported Ventilation (5 cm H2O)
223781765|NCT00993213|PROCEDURE|Standard of Care with Liposuction|Standard of Care encompasses body composition measurements, a euglycemic clamp and fat biopsies, followed by Liposuction surgery.
223781766|NCT00993213|OTHER|Standard of Care without Liposuction|Standard of Care encompasses body composition measurements, a euglycemic clamp and fat biopsies. Liposuction surgery will not be performed.
223781767|NCT00452881|DRUG|gemcitabine|Gemcitabine1250mg/m2 iv on day 1 and 15, every 4weeks, maximum 4 cycles
223699433|NCT05077527|BIOLOGICAL|Axicabtagene Ciloleucel|Given IV
223699434|NCT05077527|DRUG|Cyclophosphamide|Given IV
223699435|NCT05077527|DRUG|Fludarabine|Given IV
223699436|NCT04090073|PROCEDURE|Electroacupuncture|As above
223781768|NCT00452881|DRUG|Oxaliplatin|Oxaliplatin 85mg/m2 iv on day 1 and 15, every 4 weeks, maximum 4 cycles
223781769|NCT00452881|DRUG|Cisplatin|Cisplatin 40mg/m2 iv on day 1 and 15, every 4 weeks, maximum 4 cycles
223781770|NCT02869971|DEVICE|Embosphere® (Prostatic Arteries Embolization)|Prostatic Arteries Embolization with 300-500 µm trisacryl microspheres
223699437|NCT04090073|OTHER|Fast-track Perioperative program|As above
223699438|NCT02869607|OTHER|Data collection|
223699439|NCT04213482|RADIATION|Panoramic Radiography|Diagnostic Panoramic Dental Radiographs were taken.
223699440|NCT05982548|OTHER|VR intervention|"VR intervention of no more than 7 minutes~Participants viewed the home as a first person character and experience psychotic phenomena including auditory hallucinations."
223699441|NCT05982548|OTHER|VR control intervention|"VR intervention of no more than 7 minutes~Participants viewed the same home as a first person character without psychotic phenomena"
223699442|NCT01349231|DRUG|ketamine|Ketamine (a single 0.5mg intravenously over 40 minutes).
223699443|NCT01944033|DRUG|Bricanyl/Iprovent|5 mg Terbutaline sulfate (2ml) + 0,5 mg Ipratropium bromide (2ml) + 1ml serum saline in each nebulization which is repeated three times during 1 hour and every 4 hours during the first 24 hour protocol
223699444|NCT01944033|DRUG|Bricanyl|5 mg Terbutaline sulfate (2ml) + 3ml serum saline in each nebulization which is repeated three times during 1 hour and every 4 hours during the first 24 hour protocol
223699445|NCT01988220|OTHER|sensory retraining|
223699446|NCT01988220|OTHER|repeated sensory input|sensory stimulation without attentive learning focus
223699447|NCT04951804|PROCEDURE|EUS-CPN without bupivacaine|Under conscious sedation, an echoendoscope is advanced into the stomach, just distal to the gastro-esophageal junction. The region of the celiac plexus is identified around the takeoff of the celiac artery from the aorta. Then, under real-time ultrasound guidance, a 19g needle is used to inject a neurolytic agent such as absolute alcohol around the base of the celiac artery.
223699448|NCT04951804|PROCEDURE|EUS-CPN with bupivacaine|Under conscious sedation, an echoendoscope is advanced into the stomach, just distal to the gastro-esophageal junction. The region of the celiac plexus is identified around the takeoff of the celiac artery from the aorta. Then, under real-time ultrasound guidance, a 19g needle is used to firstly inject bupivacaine and secondly a neurolytic agent such as absolute alcohol around the base of the celiac artery.
223699449|NCT03472651|DRUG|test treatment: flupentixol/melitracen|0.5 mg flupentixol and 10 mg melitracen, film-coated tablet, single dose
223699450|NCT03472651|DRUG|reference treatment: flupentixol/melitracen|0.5 mg flupentixol and 10 mg melitracen, coated tablet, single dose
223699451|NCT00341055|DRUG|Epoetin alfa|
223699452|NCT06041490|DRUG|multi-kinase inhibitors in combination with bevacizumab|The eligible participants will start taking multi-kinase inhibitors between 4-8 weeks after liver transplantation. The choice of the specific multi-kinase inhibitor, including sorafenib, lenvatinib, or regorafenib, will be determined by the researchers based on factors such as the participant's tumor characteristics, liver function, physical condition, risk of side effects, economic status, and personal preference. The specific dosage and administration details can be found in the table provided. The maximum duration of multi-kinase inhibitor treatment will be 12 months or until any of the following conditions occur, whichever comes first: 1) The participant experiences intolerable toxic reactions that do not alleviate with dose adjustments, or 2) The participant has documented disease recurrence confirmed through imaging or withdraws from the study for other reasons.
223699453|NCT02633501|DRUG|P03277|Single intravenous (IV) bolus injection at a rate of 2 mL/second
223699454|NCT02633501|DRUG|Gadobenate dimeglumine|Single IV bolus injection at a rate of 2 mL/second
223699455|NCT02633501|DEVICE|MRI|
223699456|NCT02225769|OTHER|Management of febrile children using e-POCT|Use of the e-POCT tool by study clinicians for the clinical management of febrile episodes. The e-POCT tool is an electronic algorithm that integrates key clinical elements with the results of malaria and host biomarkers point-of-care test results (including oximetry).
223699457|NCT02225769|OTHER|Management of febrile children using ALMANACH|Management of febrile children by study clinicians using ALMANACH. ALMANACH is an improved IMCI algorithm on mobile phone or tablet
223699458|NCT04110678|DRUG|NeuroEPO|NeuroEPO \[CIMAB S.A, Havana, Cuba\]
223699459|NCT01570296|DRUG|Gefitinib and BKM120|Dose escalation study of gefitinib and BKM120 with expansion cohort
223699460|NCT05601037|PROCEDURE|Axilla dissection + Lymphovenous anastomosis|surgical bypass between lymphatic vessel and vein
223699461|NCT00967629|DRUG|Sevelamer Carbonate|This is a 4 month, prospective, comparative, crossover study. The study will be conducted in 20 patients with stage II, III or stage IV diabetic nephropathy. Patients will be randomized 1:1 to receive either 1,250 mg of calcium carbonate TID with meals (control arm) or Sevelamer Carbonate 1,600 mg (two 800 mg tablets) with meals. Each group of 10 subjects will take the assigned drug for 8 weeks. Following the 8 week treatment period, subjects will discontinue the assigned drug for a one week washout period. Following the washout period, those who were taking calcium carbonate will be crossed over to Sevelamer Carbonate therapy and those who were receiving Sevelamer Carbonate will be crossed over to calcium carbonate for a final 8 week treatment phase.
223781771|NCT02869971|DRUG|Drug therapy|Combodart (dutasteride 0.5 mg/tamsulosin 0.4 mg)
223781772|NCT00732121|DRUG|Sitagliptin|100 mg daily for 4 weeks
223781773|NCT00732121|DRUG|Placebo|Placebo
223781774|NCT00909259|DEVICE|Phrenic stimulation device|In Stage 1, a stimulation lead will be introduced via standard access methods and positioned to provide stimulation. A second lead may also be placed for sensing purposes. The proximal portions of the implanted lead(s) will remain externalized such that stimulation and observation can be made using external stimulation and recording equipment. Study subjects will be observed and stimulation will be performed for up to 2 nights of sleep in a clinically supported environment. In Stage 2, a stimulation device and lead will be permanently implanted.
223781775|NCT01823393|DRUG|Heparin|Valvuloplasty is performed in a conventional manner, ie with an injection of unfractionated heparin (50 IU / kg) at the start of procedure
223781776|NCT01823393|DRUG|NaCl|valvuloplasty is performed without heparin (placebo injection)
223781777|NCT04548882|DEVICE|Calypso Knee System|The Calypso Knee System is an extra-capsular knee implant designed to fill the therapeutic gap between conservative care and more invasive surgical interventions for knee osteoarthritis.
223781778|NCT02358889|BIOLOGICAL|hI-con1|Intravitreal injection of hI-con1 0.3 mg
223781779|NCT02358889|BIOLOGICAL|ranibizumab|Intravitreal injection of ranibizumab 0.5 mg
223781780|NCT02358889|OTHER|Sham injection|No injection is given, a needleless syringe is used to mimic an injection.
223781781|NCT00503685|BIOLOGICAL|IMC-A12|10 milligrams/kilogram (mg/kg) intravenous infusion every 2 weeks.
223781782|NCT00503685|BIOLOGICAL|cetuximab|Participants will receive cetuximab 500 milligrams/square meter (mg/m²) intravenous over 2 hours every 2 weeks.
223781783|NCT00917813|DRUG|KD-247|Cohort 1 - 4 mg/kg KD-247 IV on Days 1, 8, and 15; Cohort 2 - 8 mg/kg KD-247 IV on Days 1, 8, and 15; Cohort 3 - 16 mg/kg KD-247 IV on Days 1, 8, and 15
223781784|NCT00917813|DRUG|Physiological saline|Cohort 1 - Physiological saline IV on Days 1, 8, and 15; Cohort 2 - Physiological saline IV on Days 1, 8, and 15; Cohort 3 - Physiological saline IV on Days 1, 8, and 15
223781785|NCT02566551|PROCEDURE|PAE|Embolization of the prostate with gelatin embolization spheres via microcatheterization of the prostatic arteries.
223781786|NCT02566551|DEVICE|Gelatin microspheres|Gelatin embolization microspheres (300-500 microns) will be used as embolic material for the prostatic artery embolization (PAE) protocol
223781787|NCT02566551|PROCEDURE|TURP|Bipolar transurethral resection of the prostate
223781788|NCT02566551|DEVICE|Bipolar electrosurgery generator|A bipolar electrosurgery generator will be used to perform transurethral resection of the prostate (TURP)
223781789|NCT01027793|DRUG|Tretinoin cream 0.005%|Group 1 will receive tretinoin cream 0.05%(Vitanol A, Stiefel) that should be applied daily in areas affected by stretch marks, in both sides, for a period of 16 weeks.
223781790|NCT01027793|DEVICE|Superficial Dermabrasion|Group 2 will receive 16 sessions of dermabrasion that would be held in the research center
223781791|NCT00435123|DIETARY_SUPPLEMENT|Nutritional Supplement ProStat 64 twice a day|
223781792|NCT00435123|DIETARY_SUPPLEMENT|Placebo supplement|Patients randomly assigned to Placebo for the first 3 months will receive open label Prostat for the last 3 months
223781793|NCT06360549|DEVICE|Transcutaneous Electrical Acupoint Stimulation|Transcutaneous Electrical Acupoint Stimulation (TEAS) is a treatment that combines acupoint theory of traditional Chinese medicine with modern electrical stimulation techniques. It achieves the purpose of acupoint stimulation by applying a weak current to a specific part. TEAS operate just like ordinary electrodes with non-invasive, safe, portable, adjustable and other advantages.
223781794|NCT00377663|BEHAVIORAL|AsthmaNet|The AsthmaNet Web site will provide parents of children in the AsthmaNet group with individualized clinical information regarding their child's asthma care and with decision-making aids that they can share with their child's doctor. The web site will also prompt parents to make additional doctor appointments, as needed, to discuss their child's condition.
223781795|NCT00927927|DRUG|NNC0142-0002|Single dose, ranging from 0.0002 mg/kg up to max 7.5 mg/kg, administered subcutaneously (under the skin) on day 1
223781796|NCT00927927|DRUG|NNC0142-0002|Single dose, ranging from 0.0002 mg/kg up to max 7.5 mg/kg, administered subcutaneously (under the skin) on day 1
223781797|NCT00927927|DRUG|NNC0142-0002|Single dose, ranging from 0.0002 mg/kg up to max 7.5 mg/kg, administered subcutaneously (under the skin) on day 1
223781798|NCT00927927|DRUG|NNC0142-0002|Single dose, ranging from 0.0002 mg/kg up to max 7.5 mg/kg, administered subcutaneously (under the skin) on day 1
223781799|NCT00927927|DRUG|NNC0142-0002|Single dose, ranging from 0.0002 mg/kg up to max 7.5 mg/kg, administered subcutaneously (under the skin) on day 1
223781800|NCT00927927|DRUG|NNC0142-0002|Single dose, ranging from 0.0002 mg/kg up to max 7.5 mg/kg, administered subcutaneously (under the skin) on day 1
223781801|NCT00927927|DRUG|NNC0142-0002|Single dose, ranging from 0.0002 mg/kg up to max 7.5 mg/kg, administered subcutaneously (under the skin) on day 1
223781802|NCT00927927|DRUG|NNC0142-0002|Single dose, ranging from 0.0002 mg/kg up to max 7.5 mg/kg, administered subcutaneously (under the skin) on day 1
223781803|NCT00927927|DRUG|placebo|Single dose of 0 mg/kg administered subcutaneously (under the skin); cohort 1-7b on day 1, cohort 8-11 biweekly four times
223781804|NCT00927927|DRUG|NNC0142-0002|Multiple dose, ranging from 0.02 mg/kg up to max 4.0 mg/kg, administered subcutaneously (under the skin) four times biweekly
223781805|NCT00927927|DRUG|NNC0142-0002|Multiple dose, ranging from 0.02 mg/kg up to max 4.0 mg/kg, administered subcutaneously (under the skin) four times biweekly
223781806|NCT00927927|DRUG|NNC0142-0002|Multiple dose, ranging from 0.02 mg/kg up to max 4.0 mg/kg, administered subcutaneously (under the skin) four times biweekly
223781807|NCT00927927|DRUG|NNC0142-0002|Multiple dose, ranging from 0.02 mg/kg up to max 4.0 mg/kg, administered subcutaneously (under the skin) four times biweekly
223781808|NCT00927927|DRUG|NNC0142-0002|Multiple dose, ranging from 0.02 mg/kg up to max 4.0 mg/kg, administered subcutaneously (under the skin) four times biweekly
223699462|NCT00967629|DRUG|Calcium Carbonate|This is a 4 month, prospective, comparative, crossover study. The study will be conducted in 20 patients with stage II, III or stage IV diabetic nephropathy. Patients will be randomized 1:1 to receive either 1,250 mg of calcium carbonate TID with meals (control arm) or Sevelamer Carbonate 1,600 mg (two 800 mg tablets) with meals. Each group of 10 subjects will take the assigned drug for 8 weeks. Following the 8 week treatment period, subjects will discontinue the assigned drug for a one week washout period. Following the washout period, those who were taking calcium carbonate will be crossed over to Sevelamer Carbonate therapy and those who were receiving Sevelamer Carbonate will be crossed over to calcium carbonate for a final 8 week treatment phase.
223699463|NCT00590460|BIOLOGICAL|CAMPATH-1H|Given intravenous on days -8, -7, and -6
223699464|NCT00590460|BIOLOGICAL|Anti-CD45|"Given intravenous on days -5, -4, -3 and -2~dose is 400 micrograms/kg"
223699465|NCT00590460|DRUG|Fludarabine|"Given intravenous on days -8, -7, -6, -5 and -4~Dose is 30 mg/m2"
223699466|NCT00590460|PROCEDURE|Stem cell infusion|Stem cells are infused on day 0
223699467|NCT00140933|DRUG|MK0966; rofecoxib|
223781809|NCT00927927|DRUG|placebo|Single dose of 0 mg/kg administered subcutaneously (under the skin); cohort 1-7b on day 1, cohort 8-11 biweekly four times
223781810|NCT02541266|OTHER|Questionnaire|A short questionnaire (9 questions) will be given to the participants to complete.
223781811|NCT01976416|DRUG|Hydroxyurea|
223699468|NCT00140933|DRUG|Comparator: diclofenac, placebo|
223699469|NCT02326675|OTHER|Ice|This group will receive cryotherapy, saline rinses, an oral care diary will be completed by the subject, and a daily oral assessment will be performed by the investigators as part of their participation.
223699470|NCT02326675|OTHER|Normal Saline Solution|This group will receive saline rinses, an oral care diary will be completed by the subject, and a daily oral assessment will be performed by the investigators as part of their participation.
223699471|NCT05118243|OTHER|Control cracker|The gut symptoms caused by control crackers are studied in IBS persons
223699472|NCT05118243|OTHER|Enzyme-treated cracker|The gut symptoms caused by enzyme-treated crackers are studied in IBS persons
223781812|NCT01976416|DRUG|Placebo|
223781813|NCT01245179|DRUG|panobinostat|"Panobinostat oral capsules taken THRICE WEEKLY (Monday, Wednesday, and Friday) for 12 weeks, exploring the following dosing regimens:~1. 15 mg MWF 3 weeks on, 1 week off (if needed)~2. 15 mg MWF every week (starting dose)~3. 20 mg MWF 3 weeks on, 1 week off~4. 20 mg MWF every week"
223781814|NCT05882539|DEVICE|endotracheal tube material,Bite block Material|Exposure factors associated with tracheal intubation in patients that may influence the occurrence of oral mucosa pressure injurie, such as the material and fixation of the tracheal tube, the patient's own nutrition, the level of tissue perfusion and relevant treatment factors.
223781815|NCT04483804|COMBINATION_PRODUCT|Endocrine therapy|Endocrine therapy
223781816|NCT03387800|BEHAVIORAL|Basic health education messages|Messages containing basic health education materials, including perceived severity of smoking, perceived benefit of smoking cessation and tips on resisting situational temptations will be sent to the participants of both arms through WeChat after randomization takes place.
223781817|NCT03387800|BEHAVIORAL|WeChat interactive peer support group|Participants will be grouped together by the researcher to form closed online peer support groups (with group names they choose). Activities on the WeChat groups serve two functions: i) It enhances social support among peer members toward smoking cessation. ii) The online support group also enhances the participants' positive affect.
223781818|NCT00906646|DIETARY_SUPPLEMENT|Metabolic therapy|Coenzyme Q10 - 100 mg tds Magnesium orotate - 400 mg tds Lipoic acid - 100 mg tds Omega-3 fatty acids - 300 mg (in 1 g fish oils) tds Selenium - 200 µg
223781819|NCT00906646|DIETARY_SUPPLEMENT|Placebo|Placebo tablets
223781820|NCT00485108|DRUG|prednisolone 1%|eye drop once in each eye treated, 4 times / day for 5 days post-laser
223781821|NCT00485108|DRUG|ketorolac 0.5%|eye drop once in each eye treated, 4 times / day for 5 days post-laser
223781822|NCT00485108|DRUG|Artificial Tears (Methyl cellulose drops)|eye drop once in each eye treated, 4 times / day for 5 days post-laser
223781823|NCT04577092|OTHER|Warm-up exercise|In 10-minute warm up period; neck flexion/extension/side flexion/circumflexion (clockwise and counterclockwise), rounding shoulder back and forth, circumflexion of arm back and forth, side flexion of trunk and rising on the fingertips.
223781824|NCT04577092|OTHER|Motor-Cognitive exercise|After warm up period; participants had been asked to count back from the two-digit number while performing; in standing position, straight walk, side walk, abduction/flexion/extension of hip and hip and knee flexion; in sitting position, hip flexion, knee extension, ankle dorsi - plantar flexion.
223781825|NCT04577092|OTHER|Motor-Motor exercise|participants had been asked to hold with both hand half-filled glasses with 90 degree of flexion elbow and near the trunk while performing; in standing position, straight walk, side walk, abduction/flexion/extension of hip and hip and knee flexion; in sitting position, hip flexion, knee extension, ankle dorsi - plantar flexion.
223781826|NCT04577092|OTHER|Cool-down exercise|In 10-minute cool down period, stretching of quadriceps femoris muscle, hamstring muscle, achill tendon and cervical muscles were performed.
223781827|NCT01870700|DRUG|lactobacillus reuteri|Lactobacillus reuteri (DSM 17938) was administered in the dose of 108 colony-forming units (CFU) in tablets of a commercially available preparation (Reuflor, Italchimici, Pomezia; BioGaia AB, Stockholm, Sweden), 30 minutes after feeding, twice per day for 4 weeks
223781828|NCT01870700|DRUG|placebo|a supplementation with placebo was administered in tablets of a commercially available preparation 30 minutes after feeding, twice per day for 4 weeks
223781829|NCT06295133|BEHAVIORAL|Stress|The stress management intervention will consist of three individual sessions, each lasting one hour, with approximately 15 days between each session. The sessions will be scheduled as follow: week 5 and 6 (session 1), week 7 and 8 (session 2), week 9, 10, and 11 (session 3). During these sessions, subjective and objective indicators of stress will be recorded to assess the progress of each student.
223699473|NCT05533476|BEHAVIORAL|Multi Sensory Stimulation and Priming|In the MuSSAP intervention group, the infant wears a multisensory stimulating wristband aiming at increasing attention for the affected upper limb and readiness to initiate a goal-directed movement. Parents are instructed to present a toy to their child if the child shows attention to the affected arm and hand. Upper extremity motor activities like reaching, grasping and holding are practiced. Parents practice daily and once a week the training will be guided or conducted by a physical or occupational therapist in the home environment. An occupational therapist from the rehabilitation center will coach parents during the intervention period through the internet, by means of analyzing the videos from the home training.
223781830|NCT01623219|BEHAVIORAL|Prolonged Exposure Therapy|Exposure therapy refers to several cognitive behavioral treatment programs that involve confronting feared but safe thoughts, images, objects, situations, or activities in order to reduce unrealistic fear and anxiety. Exposure therapy for PTSD involves prolonged, imaginal exposure to the patient's traumatic memory and in vivo (in real life) exposure to trauma reminders. Prolonged exposure (PE) is a specific exposure therapy program that consists of five components: (1) psychoeducation (2) training in controlled breathing, (3) prolonged imaginal exposure to the trauma memory conducted in therapy sessions and repeated as homework, (4) prolonged in vivo exposure implemented as homework, and (5) processing of the traumatic material to correct maladaptive cognitions.
223781831|NCT00821691|DRUG|Amantadin|Amantadin caps
223781832|NCT00821691|DRUG|Placebo|Placebo caps
223781833|NCT01110239|PROCEDURE|remote limb preconditioning|3 cycles of up to 10 minutes leg ischemia
223781834|NCT00002495|DRUG|doxorubicin hydrochloride|25 mg/m\^2 on days 1 and 15
223781835|NCT00002495|DRUG|vinblastine|6 mg/m\^2 on days 1 and 15
223781836|NCT00002495|RADIATION|standard subtotal nodal irradiation|3600-4000 cGy delivered over 20 fractions
223781837|NCT02897141|DEVICE|Health Management App with symptom strategies|The mVIP group will receive a Health Management App with symptom strategies. A mobile app which includes symptom strategies from the UCSF symptom management manual.
223781838|NCT02897141|DEVICE|Control App|The attention control group will receive an app which asked them about their symptoms but did not provide symptoms strategies
223699474|NCT05533476|BEHAVIORAL|Intensive Usual Care (Upper Limb)|The Intensive Usual Care (Upper Limb) intervention is a more intensive (in duration and frequency) version of standard Usual Care with focus on the motor development of the affected upper extremity. Upper extremity motor activities like reaching, grasping and holding are practiced. Parents practice daily and once a week the training will be guided or conducted by a physical or occupational therapist in the home environment. An occupational therapist from the rehabilitation center will coach parents during the intervention period through the internet, by means of analyzing the videos from the home training.
223699475|NCT00000328|DRUG|Opioid-Related Disorders|
223699476|NCT03400566|BEHAVIORAL|Narrative|Children will be read a story book featuring vegetables for a minimum of 7 times (including twice during the familiarization phase).
223699477|NCT03400566|BEHAVIORAL|Experiential|Children will receive hands on experience with the vegetable. They will get to listen, see, feel, touch and smell the actual vegetable during the two familiarization phases.
223699478|NCT06420128|OTHER|Primary care team|Patients whose general practitioner is a member of a primary care team since at least 12 months
223699479|NCT00156520|DRUG|aprotonin; epsilon aminocaproic acid|
223699480|NCT01931930|DIETARY_SUPPLEMENT|Perilla extract|
223699481|NCT01931930|DIETARY_SUPPLEMENT|Maltodextrin|
223699482|NCT04677790|BEHAVIORAL|assigned period of specific dietary restrictions|Step by step gradual introduction of egg containing food products
223699483|NCT00352443|DRUG|everolimus|part 1: dose assigned by ETx online system PO days 1-28 daily part 2: cohort a: 5 mg PO days 1-28 part 2: cohort a: 1250 mg PO days 8-28 (cycle 1) days 1-28 (subsequent cycles)
223699484|NCT00352443|DRUG|lapatinib ditosylate|dose assigned by ETx online system PO days 1-28 daily part 2 cohort a: 1250 mg PO d 8-28 (cycle 1) days 1-28 (subsequent cycles) part 2 cohort b: 120 mg PO days 1-28 daily
223781839|NCT02369133|DRUG|paracetamol|Drugs were given intravenously by a nurse unaware of the study 15 min before surgery. Patients in group P (n = 30) received 1 g iv paracetamol, patients in group S (n = 30) received 100 ml iv %0.9 NaCl
223699485|NCT06143800|BEHAVIORAL|reactivation|During the retrieval phase, cues are presented to participants to reactivate their memories; participants in the non-retrieval group go directly to cognitive reappraisal phase.
223699486|NCT06143800|BEHAVIORAL|cognitive reappraisal intervention|"Subsequently, in the self-focused cognitive reappraisal group, participants will be instructed to use disengagement reappraisal to separate themselves from the picture situation and draw a subjective distance so as not to strongly feel the negative emotions brought by the picture. In the context-focused reappraisal group, participants will focus on the picture situation, reappraise the meaning of the picture situation, and assign positive meanings to it."
223781840|NCT02369133|DRUG|Placebo|
223781841|NCT00080223|DRUG|Pirfenidone|up to 3600 mg/day of pirfenidone given orally administered in divided doses three times daily with food, for the duration of the study
223781842|NCT00400413|PROCEDURE|fMRI|
223781843|NCT02936076|OTHER|Exercise intervention|
223781844|NCT02936076|OTHER|Delayed exercise intervention|
223781845|NCT03798808|OTHER|Consumption of fruits, vegetables and dairy products|Family Nutriathlon was an eight-week, family-based nutrition program where children and their parents were encouraged to reach individual and team goals with respect to the quantity and variety of fruit, vegetable and dairy product consumption.
223781846|NCT04369469|BIOLOGICAL|Ravulizumab|Weight-based doses of ravulizumab were administered intravenously on Days 1, 5, 10, and 15.
223781847|NCT04369469|OTHER|BSC|Participants received medications, therapies, and interventions per standard hospital treatment protocols.
223699487|NCT02544646|OTHER|Changes in Ocular rigidity|measured before the operation and 28±7 days after the operation
223699488|NCT05371730|DRUG|NCR300|Intravenous infusion of NK cells（NCR300）
223699489|NCT04537429|DRUG|Eptinezumab|up to four iv infusions of eptinezumab
223699490|NCT03352479|OTHER|Opioid Return|Calculate the percentage of prescribed to returned opioids
223699491|NCT04429360|PROCEDURE|pelvic reconstructive surgery|Pelvic reconstructive surgery
223699492|NCT03825523|OTHER|iART|After group assignment, ART will be started within the first 48 hours after admission to the hospital. ART regimen will be decided according to each subject´s the clinical characteristics
223699493|NCT03825523|OTHER|cART|After group assignment, ART is started at the discretion of the attending physician. ART regimen will be decided according to each subject´s the clinical characteristics
223699494|NCT04377243|BIOLOGICAL|V8|one pill per day either V8 or placebo
223699495|NCT01986140|DEVICE|PAXMAN Orbis Scalp Cooler|Treatment with Orbis scalp cooling cap
223699496|NCT01986140|OTHER|Control No treatment|No treatment to prevent hair loss
223699497|NCT05560204|DEVICE|Combined Pulsed-field Ablation (PFA) + Left Atrial Appendage Occlusion (LAAO)|"Pulsed-field ablation (PFA) is a non-thermal ablation technology that uses high amplitude pulsed electrical fields to ablate tissues through the mechanism of irreversible electroporation~Percutaneous LAA Occlusion (LAAO) has been emerged as an alternative to oral anticoagulants for stroke prophylaxis in patients who refused or contraindicated to OAC"
223699498|NCT04802070|DRUG|Autologous CIK|Lymphocytapheresis of the autologous ex-vivo CIK cell expanded in the Cell factory (4 dose levels)
223699499|NCT04059198|DRUG|Inarigivir soproxil|Inarigivir soproxil 400 mg tablets
223699500|NCT04059198|DRUG|Tenofovir alafenamide fumarate (TAF)|Tenofovir alafenamide fumarate 25 mg tablet
223699501|NCT04573998|PROCEDURE|LSG|bariatric surgery
223699502|NCT00331253|PROCEDURE|Indocyanine Green-Mediated Photothrombosis|
223699503|NCT04728867|OTHER|to compare the educational effectiveness of various educational tools|This prospective, randomized, blinded study is designed to compare the educational effectiveness of various educational tools including the surgical textbook, animation, and cadaveric videos in laparoscopic rectal surgery among board-certificated surgeons.
223699504|NCT04447378|DRUG|Fondaparinux 2.5Mg/0.5Ml Inj Syr|post natal thromboprophylaxis
223699505|NCT06463574|OTHER|self-adhesive resin restoration|Light cured, hybrid resin composite material which contains polymerization modulator that lessens its degree of polymerization shrinkage
223699506|NCT02378727|DEVICE|Active: Comparator Loss Of Resistance Syringe|Lumbar epidural procedure utilizing Loss of Resistance Syringe
223781848|NCT03864497|PROCEDURE|Myocardial perfusion imaging|
223781849|NCT05204134|DEVICE|Automated Insulin Delivery Settings Initialization and Adaptation Algorithm|All participants wearing the t:slim X2 insulin pump with Control-IQ technology, and wearing the Dexcom G6 sensor, will have algorithm derived insulin delivery profile settings initialization and updates at regular intervals.
223781850|NCT02536859|DRUG|insulin degludec|Dose levels will be 0.4 U/kg body weight. The trial products will be administered subcutaneously (s.c., under the skin) once daily.
223781851|NCT02536859|DRUG|insulin glargine|Dose levels will be 0.4 U/kg body weight. The trial products will be administered subcutaneously (s.c., under the skin) once daily.
223781852|NCT01871948|OTHER|"We Want to Know campaign, Patient survey at 2 time points"|Randomly assigned patients attending cancer clinics at Washington or Georgia sites during February 2013 to August 2013 will be presented with or mailed a survey about cancer communication approximately 2 weeks later and a follow-up survey approximately 3 months later. Additionally, this group will also receive a follow-up phone call approximately 4 weeks after baseline survey.
223781853|NCT05567640|BEHAVIORAL|The Unified Protocol for Transdiagnostic Treatment of Emotional Disorders (UP)|This is a cognitive behavioral treatment (CBT) for emotional disorders. This transdiagnostic intervention consists of eight modules and can be effectively applied to various disorders and problems.
223781854|NCT05567640|BEHAVIORAL|Space for depression|Digital CBT program designed to minimize the impact of depression symptoms. Emphasizes CBT strategies and mindfulness through a series of seven structured modules.
223781855|NCT05567640|BEHAVIORAL|Space for resilience|This program is built from positive psychology principles and is designed to promote resilience and well-being through seven modules.
223781856|NCT02841644|PROCEDURE|Operatively treated traumatic arthrotomy|operatively treated traumatic arthrotomy.
223781857|NCT02841644|OTHER|Non-operatively treated traumatic arthrotomy|non-operatively treated traumatic arthrotomy.
223781858|NCT05999409|OTHER|practice on birth simulator|making attempts at labor
223781859|NCT00389818|BIOLOGICAL|filgrastim|Supportive therapy: GF therapy with G-CSF, GM-CSF, or pegfilgrastim will be used in all patients, beginning on Day 3 of each cycle, until post nadir of blood counts from each chemotherapy cycle.
223781860|NCT00389818|BIOLOGICAL|pegfilgrastim|GF therapy with G-CSF, GM-CSF, or pegfilgrastim will be used in all patients, beginning on Day 3 of each cycle, until post nadir of blood counts from each chemotherapy cycle.
223781861|NCT00389818|BIOLOGICAL|rituximab|375 mg/m2 IV Day 1 of each cycle
223781862|NCT00389818|BIOLOGICAL|sargramostim|GF therapy with G-CSF, GM-CSF, or pegfilgrastim will be used in all patients, beginning on Day 3 of each cycle, until post nadir of blood counts from each chemotherapy cycle.
223781863|NCT00389818|DRUG|cyclophosphamide|750 mg/m2 IV Day 1 of each cycle
223781864|NCT00389818|DRUG|pegylated liposomal doxorubicin hydrochloride|40 mg/m2 IV Day 1 of each cycle
223781865|NCT00389818|DRUG|prednisone|100 mg PO Days 1-5 of each cycle
223781866|NCT00389818|DRUG|vincristine sulfate|1.4 mg/m2 IV Day 1 (2.0 mg maximum) of each cycle
223781867|NCT00389818|OTHER|immunohistochemistry staining method|tissue specimen collected at baseline
223781868|NCT00389818|OTHER|laboratory biomarker analysis|tissue specimen collected at baseline
223781869|NCT06572280|DEVICE|PNS group|non-invasive phrenic nerve stimulation
223781870|NCT06574308|DIAGNOSTIC_TEST|Blood cells classification|Comparison of the classification of peripheral blood and bone marrow cells with optical microscope reading with pre-classification using Scopio technology (AI based)
223781871|NCT01164046|DRUG|low molecular weight heparin|weight adjusted dose of low molecular weight heparin, any type allowed if approved, 65-75% of full therapeutic dose
223781872|NCT01164046|DRUG|vitamin K antagonists|Target INR between 2-3. Any type allowed, if approved for use in that country.
223781873|NCT03568916|DRUG|Apixaban (ATC B01AF02)|Exposure to apixaban (ATC B01AF02) will be defined as a new prescription for apixaban at cohort entry date in patients diagnosed with non-valvular atrial fibrillation. Patients are considered exposed until end of follow-up regardless of switch or interruption.
223781874|NCT03568916|DRUG|Dabigatran (ATC B01AE07)|Exposure to dabigatran (ATC B01AE07) will be defined as a new prescription for dabigatran at cohort entry date in patients diagnosed with non-valvular atrial fibrillation. Patients are considered exposed until end of follow-up regardless of switch or interruption.
223781875|NCT03568916|DRUG|Rivaroxaban (ATC B01AF01)|Exposure to rivaroxaban (ATC B01AF01) will be defined as a new prescription for rivaroxaban at cohort entry date in patients diagnosed with non-valvular atrial fibrillation. Patients are considered exposed until end of follow-up regardless of switch or interruption.
223781876|NCT03112317|OTHER|Prevention of hypothermia|Patients are routinely warmed with forced air warming blankets, regular blankets, pre warmed intravenous fluid. Routines are ensured with use of the WHO Surgical Safety Checklist. The intervention is the use of operating theatre care measures to prevent mild hypothermia in surgical patients.
223781877|NCT04261816|PROCEDURE|extubation in the operating room|Patients who underwent liver transplantation early extubation in the operating room immediately following liver transplantation
223781878|NCT04261816|PROCEDURE|extubation in the ICU|Patients who underwent liver transplantation extubation in the ICU following liver transplantation
223781879|NCT03281811|DRUG|Aminolevulinic Acid Hydrochloride|Given topically
223781880|NCT03281811|DRUG|Photodynamic Therapy|Undergo PDT
223781881|NCT03281811|OTHER|Quality-of-Life Assessment|Ancillary studies
223781882|NCT03281811|RADIATION|Radiation Therapy|Undergo RT
223781883|NCT05634616|DEVICE|Motor imagery and motor execution based BCI|We designed a motor imagery and motor execution-based BCI-controlled pedaling rehabilitation training system. Patients wore EEG caps and were instructed to imagine upper limb pedaling movements. The greater the patients' movement intention, the higher the Mscore of movement intention index on the monitor and the faster the pedaling speed
223781884|NCT05634616|DEVICE|Sham BCI|The training equipment was the same, but the program was changed to record only the EEG signal without controlling the pedaling equipment, and the Mscore score and pedaling speed displayed by the equipment in real time were pre-set training performance data of the previous pretest patients, i.e., sham neurofeedback.
223781885|NCT02605590|DRUG|AIR DNase|
223781886|NCT02605590|DRUG|Placebo|
223699507|NCT02378727|DEVICE|Experimental: CompuFlo® Epidural System|CompuFlo® Epidural is intended for use with an epidural needle for the verification of needle tip placement in the lumbar epidural space
223699508|NCT03453411|OTHER|Non interventional study|Non interventional study
223699509|NCT05899088|OTHER|Mindful Movement|Mindful Movement Program with Researcher Follow-up
223699510|NCT03219541|BEHAVIORAL|Interventional Automated mobile phone text|Participants will receive 2 messages per day in the pre-quit phase, 3 messages per day on the quit date and the first week in the post-quit phase, and 2 messages per day in the last 3 weeks of the intervention.
223699511|NCT03219541|BEHAVIORAL|Control Automated mobile phone text|Participants will receive 2 text questions each week asking the number of smoking days in the past week and the average number of cigarette smoked per day.
223699512|NCT00137683|BEHAVIORAL|one-on-one education, group education, small media|
223699513|NCT03176758|DRUG|Spinal Block|Intrathecal 10 mg Heavy Marcaine, 200 mcg Morphine + High volume local anesthesia infiltration Bupivacaine 5mg/ml + adrenaline 5 mcg/ml 3mg/kg IBW diluted with 100cc Normal Saline
223699514|NCT03176758|DRUG|General anesthetic|1-3 mg IV propofol 0.5 mg/kg IV Rocuronium + Fentanyl 2-3 mcg/kg + Morphine 0.1mg/kg IV Maintenance: Volatile anesthetic + High volume local anesthesia infiltration Bupivacaine 5mg/ml + adrenaline 5 mcg/ml 3mg/kg IBW diluted with 100cc Normal Saline
223699515|NCT03176758|DEVICE|Total knee replacement|A total knee arthroplasty surgery, which is not the intervention of interest
223699516|NCT01866722|BEHAVIORAL|Usual care|Participants will get a brief (\<5 min) telephone counseling session about quitting. After that, printed materials with resources to help quitting will be mailed to the participants.
223699517|NCT01866722|BEHAVIORAL|Reduction|Participants will have 3 telephone counseling sessions that focus on ways to reduce tobacco cigarette smoking. After the final session printed materials with resources to help quitting will be mailed to the participants.
223699518|NCT01866722|BEHAVIORAL|5Rs|Participants will have 3 telephone counseling sessions that focus on the 5Rs for quitting tobacco cigarette smoking (Relevance, Risks, Rewards, Roadblocks, Repeat). After the final session printed materials with resources to help quitting will be mailed to the participants.
223699519|NCT06203574|RADIATION|[68Ga]Ga-NOTA-T4 or [18F]AlF-RESCA-T4|The dose of \[68Ga\]Ga-NOTA-T4 or \[18F\]AlF-RESCA-T4 was calculated based on the patient's body weight to be 3.7 MBq \[0.1 mCi\]/kg, and the method of administration was intravenous push, with one single imaging administration.
223699520|NCT02490410|DIETARY_SUPPLEMENT|protein supplement|
223699521|NCT04676217|PROCEDURE|Postoperative positioning advice|The postoperative positioning advice until 3 am the same day.
223699522|NCT02702063|OTHER|passive leg raising test|Patients undergoing routine echocardiography are exposed to a passive leg raising test. Change in SV will be measured by TTE and compared to changes in SV measured by EC.
223699523|NCT02702063|PROCEDURE|right heart catheterisation|CO in patients undergoing routine right heart catheterisation will be measured and compared between 3 methodologies: right heart catheterisation, TTE and EC
223699524|NCT02702063|OTHER|TTE vs. EC + calibration group|Patients will undergo routine echocardiography. CO and SV will be measured by TTE and compared to measurements obtained from simultaneous EC-measurements.
223699525|NCT03139318|RADIATION|GRID radiotherapy|Patients will be treated with GRID radiotherapy
223699526|NCT00452478|DRUG|Lanthanum carbonate|2250mg/day starting dose of lanthanum carbonate administered orally, in divided doses, with meals (500mg 750mg and 1000mg strengths)for 2 weeks; dose titration will occur based on serum phosphorus results not to exceed 3000mg/day.
223699527|NCT02072239|DEVICE|Angioshield|The Angioshield wrap provides external structural support for the saphenous vein graft used in CABG surgery and is intended to prevent over distention of the graft under arterial pressure, potentially improving graft patency and reducing the likelihood of graft failure.
223781887|NCT03110159|DRUG|Levulan® Kerastick®|Levulan® Kerastick® for Topical Solution will be applied to a designated area for 3 hours without occlusion prior to illumination with blue light
223699528|NCT04288271|BEHAVIORAL|Adherence Intervention|"Intervention:~* Adherence Support Team (patient, parent or a significant other, Coach)~* Standardized educational videos on immunosuppressive medications, rejection, and improving adherence~* Identification of adherence barriers, self-efficacy for medication-taking, and allocation of treatment responsibility~* 'Action-Focused Problem-Solving' to address barriers selected as most important by the patient~Device:~* Electronic pillbox monitoring with text message and/or audio/visual dose reminders and access to e-pillbox website~* Feedback of electronic monitoring data at increasing intervals between initiation of the intervention at 4-week and exit at 14-week."
223699529|NCT04288271|OTHER|Healthy living education intervention|"Intervention:~* Standardized educational videos on immunosuppressive medications, rejection, and improving adherence~* Healthy living topic discussion at increasing intervals between 4-wk and 14-wk visits~* 'Action-Focused Problem-Solving' to address barriers on healthy living topic selected by the patient~Device:~• Electronic adherence monitoring without dose reminders or feedback (enrollment to 14w)"
223699530|NCT03850665|PROCEDURE|Direct Anterior Approach (DAA)|Direct Anterior Approach surgery to replace the hip.
223699531|NCT03850665|PROCEDURE|Anterolateral approach|Anterolateral approach surgery to replace the hip.
223699532|NCT00517803|DIETARY_SUPPLEMENT|Probiotic Yogurt B: with various micronutrients|175g probiotic yogurt / day 25% RDA for each nutrient
223699533|NCT00517803|DIETARY_SUPPLEMENT|Probiotic Yogurt A: Kaiser micronutrients|175g probiotic yogurt/ day 25% RDA for each nutrient
223699534|NCT00517803|DIETARY_SUPPLEMENT|Probiotic yogurt C: with basic micronutrients|175g yogurt/ day 25% RDA for each nutrient
223699535|NCT00517803|DIETARY_SUPPLEMENT|Probiotic Yogurt D: Placebo -- no added micronutrients|175g/day probiotic yogurt
223699536|NCT01527318|DRUG|Fibrate treatment|Patients will receive a dosage of 400mg Bezafibrate every day during 28 weeks
223699537|NCT05607771|DEVICE|Manual Vitrification|Oocytes will be prepared for vitrification using the manual protocol
223699538|NCT05607771|DEVICE|Automated Vitrification|Oocytes will be prepared for vitrification using the DaVitri device
223699539|NCT05581875|DRUG|Belantamab Mafodotin-Blmf|Blmf will be available as 100 mg/vial in single-use vial for reconstitution, supplied as lyophilized powder. Blmf will be delivered as IV solution over at least 30 minutes
223699540|NCT05581875|DRUG|Daratumumab|Daratumumab will be administered with subcutaneous injections. On days where Blmf is given together with daratumumab, daratumumab should be performed first.
223699541|NCT05581875|DRUG|Pomalidomide|Pomalidomide will be administered per os.
223699542|NCT05581875|DRUG|Dexamethasone|Dexamethasone will be administered intravenously or per os.
223699543|NCT00242073|PROCEDURE|MRI Prostate|
223699544|NCT01600807|DRUG|Gemcitabine, Erlotinib, OSI-906|Gemcitabine 1000 mg/m2 d1,8,15; Erlotinib 100 mg QD, OSI-906 dose to be determined BID
223699545|NCT01600807|DRUG|Gemcitabine, Erlotinib|Gemcitabine 1000 mg/m2 d1,8,15; Erlotinib 100 mg QD
223699546|NCT05420727|DRUG|Ga-68-PSMA-11 PET/CT|Ga-68-PSMA-11 PET/CT imaging
223699547|NCT05420727|DRUG|Lu-177-ITG-PSMA-1|Lu-177-ITG-PSMA-1 treatment
223699548|NCT01624337|DRUG|DHA-piperaquine|"Drug: Dihydroartemisinin piperaquine~40/320 mg tablets, 9 tablets total Arms: 2 day treatment course (4.5 tablets per day)"
223699549|NCT01624337|DRUG|placebo|
223699550|NCT01833546|DRUG|Evofosfamide|Evofosfamide infusion intravenously at an escalated dose of 240, 340 or 480 milligram per square meter (mg/m\^2) on Day 1, 8 and 15 of each 28-day treatment cycle until progressive disease, unacceptable toxicity or withdrawal.
223699551|NCT01833546|DRUG|Gemcitabine|Gemcitabine 1000 mg/m\^2 on Day 1, 8 and 15 of each 28-day treatment cycle until progressive disease, unacceptable toxicity or withdrawal.
223699552|NCT06228885|BEHAVIORAL|handwriting experiment and motor ability test|Participants will be instructed to participate in a handwriting experiment, which involves utilizing a Force Acquisition Pen (FAP) system and Near Infrared Spectroscopy (NIRS) to collect force data and cortical activation, respectively, during handwriting tasks. Children will be tasked with completing various assignments, such as tracing lines, writing numbers, and characters, among others. Additionally, assessments of motor ability and handwriting proficiency will be conducted using the Movement Assessment Battery for Children (MABC) and the Chinese Handwriting Evaluation Form (CHEF). The Pinch Holding Up Activity (PHUA) Test will also be administered to assess their sensorimotor ability.
223699553|NCT02808650|OTHER|Laboratory Biomarker Analysis|Correlative studies
223699554|NCT02808650|OTHER|Pharmacokinetic (PK) study|Correlative studies
223699555|NCT02808650|DRUG|Prexasertib|Given IV
223699556|NCT03903601|DIAGNOSTIC_TEST|Magnetic Resonance Imaging (MRI)|Magnetic Resonance Imaging (MRI) to diagnose ischemic changes in the brain.
223699557|NCT03903601|DIAGNOSTIC_TEST|Blood samples collection|Trimethylamine N-oxide (TMAO) concentration, oxidative stress markers and endothelial dysfunction markers will be determined in blood samples.
223699558|NCT03903601|DIAGNOSTIC_TEST|Neuropsychological tests|Cognitive functions assessment
223699559|NCT04048122|BEHAVIORAL|MultiContext for PD Strategy Training|This treatment is task-oriented training, a widely-used approach in neurorehabilitation, that parallels the cognitive process training used in PD to-date but with simulated functional tasks (vs. computer or paper \& pencil tasks). It has the same basic protocol as MC4PD, but it is therapist-directed, and the OT does not address strategies, metacognition, generalization, or use mediation or action plans. The OT selects treatment activities based on the client's cognitive profile and goals from a published set of activities designed for use in cognitive interventions. Graded task practice with OT feedback on performance accuracy is used to produce neurocognitive improvement (or possibly independent strategy development). The OT assigns practice of specific cognitively challenging everyday life activities for homework (but without action plans).
223699560|NCT04048122|BEHAVIORAL|Standard of Care|This treatment is task-oriented training, a widely-used approach in neurorehabilitation, that parallels the cognitive process training used in PD to-date but with simulated functional tasks (vs. computer or paper \& pencil tasks). It has the same basic protocol as MC4PD, but it is therapist-directed, and the OT does not address strategies, metacognition, generalization, or use mediation or action plans. Therefore, this is a standard-of-care approach that includes all but the proposed critical elements of MC4PD. The OT reviews pre-treatment cognitive test scores with the client but without discussion to build awareness. The OT selects treatment activities based on the client's cognitive profile and goals from a published set of activities designed for use in cognitive interventions.
223699561|NCT02044835|DRUG|Fu-zheng-qu-zhuo oral liquid|Fu-zheng-qu-zhuo oral liquid was composed of Ginseng, Astragalus, Angelica root, Tuckahoe, Rhubarb, etc. It was producted by manufacturing laboratory of Guang'anmen Hospital, China Academy of Chinese Medical Science (License code: 京药制字Z20063242)
223699562|NCT02374515|DEVICE|EndoCuff-assisted colonoscopy|Adenoma detection rate
223699563|NCT02374515|DEVICE|Standard Colonoscopy|
223699564|NCT03630367|DRUG|Dexamethasone|Intramuscular injection 8 mg
223699565|NCT03630367|DRUG|L-Carnitine 1G/5mL Injection|slow intravenous injection
223699566|NCT02350673|DRUG|Atezolizumab|Participants will receive atezolizumab IV infusion at doses of 800 mg q2w or 1200 mg q3w.
223699567|NCT02350673|DRUG|Cergutuzumab Amunaleukin|Participants will receive cergutuzumab amunaleukin IV infusion at escalated doses and at different dosing schedules in Part I and at MTD (or recommended dose) in Part II.
223699568|NCT03182062|PROCEDURE|Alveolar recruitment maneuver|To start the Alveolar Recruitment Maneuver (ARM) the ventilatory mode will be changed to pressure-controlled mode (PCV) with 20 cmH2O pressure control ventilation. A respiratory rate (RR) of 15 rpm, inspiration: expiration ratio of 1:1, FiO2 of 0.8 and PEEP of 5 cmH2O. The PEEP level will be increased in 5 cmH2O steps every 10 respiratory cycles, increasing to 15 cycles in the last level of PEEP (20 cmH2O), getting an opening pressure at 40 cmH2O airway (duration of the maneuver: 160 sec.)
223699569|NCT03182062|PROCEDURE|PEEP Titration Trial|The ventilation mode will then switch back to volume controlled ventilation with the same baseline settings but with 20 cmH2O PEEP level. Then PEEP will be reduced in 2 cmH2O steps each maintained for 5 breaths the level of PEEP with the best (higher) dynamic compliance.
223699570|NCT03182062|PROCEDURE|Lung protective ventilation|Ventilatory strategy with a PEEP level of 5 cmH2O but without recruitment maneuvers and PEEP titration trial.
223699571|NCT05432362|OTHER|Aronia Juice|The intervention is based an the additional consumption of 200 ml natural juice a day for a period of six weeks. The participants are asked to drink the natural and commercially available juice in addition to their regular diet. Further, they are asked not to change their diets and lifestyle behaviour during the intervention.
223699572|NCT05432362|OTHER|Placebo|A beverage is prepared according to a known recipe. It contains macro- and micronutrients in comparable amounts like the aronia juice. It is completely polyphenol free.
223699573|NCT00351546|DRUG|Vildagliptin|
223699574|NCT00135044|PROCEDURE|intravenous taurine in nutritional supplement|
223699575|NCT04426708|DRUG|HMS5552|single dose of HMS5552 25mg
223699576|NCT00411437|DRUG|Tolterodine ER|
223699577|NCT00411437|DRUG|Oxybutynin ER|
223699578|NCT02693392|DRUG|Oral hypoglycemic agents (pre-specified) [Metformin, Sulfonylurea]|"Patients receiving either of the following oral hypoglycemic agents~1. Sulfonylurea based oral hypoglycemic agents~2. Metformin based oral hypoglycemic agents~3. Metformin plus Sulfonylurea based oral hypoglycemic agents"
223699579|NCT02693392|DIETARY_SUPPLEMENT|Fenugreek Seed extract|Patients recruited in the study arm will receive Capsule Fenfuro 500 milligram twice daily for 12 weeks as add-on intervention to the pre-specified oral hypoglycemic agents therapy
223699580|NCT00424801|DRUG|Lercanidipine|Individual titration, max. dose 20 mg OD for 8 months
223699581|NCT00424801|DRUG|Valsartan|Individual titration, max. dose 160 mg OD for 8 months
223699582|NCT00424801|DRUG|Nicorandil|Individual titration, max. dose 20 mg BD for 8 months
223699583|NCT00424801|DRUG|Doxazosin|Individual titration, max. dose 4 mg OD for 8 months
223699584|NCT00424801|DRUG|Moxonidin|Possible add-on therapy in case target blood pressure can not be reached with a combination of the other drugs in the Vasodilatory arm. Individual titration, max. dose 0,2 mg OD for 8 months
223781888|NCT03110159|DRUG|BLU-U Blue Light Photodynamic Therapy|3 hours after Levulan® Kerastick® for Topical Solution is applied blue light illumination of designated area will be performed using the standard FDA approved treatment time of 16 minutes 40 seconds.
223781889|NCT02733497|PROCEDURE|Sympathectomy|Resection of ganglia at T3 level
223781890|NCT02733497|PROCEDURE|Sympathicotomy|Cutting of symptahetic chain at T3 level without ganglia excision
223781891|NCT01919385|DEVICE|Predictive Low Glucose Minimizer|This study is a non-randomized feasibility study enrolling type 1 diabetics who are currently using an insulin pump. Participating Investigators will closely monitor the study subject in a clinical research center environment for approximately 30 hours, while controller algorithm determined insulin doses are delivered by an insulin pump, and utilizing continuous glucose monitoring results.
223781892|NCT06572514|DRUG|immunotherapy：pembrolizumab；chemo：albumin-bound paclitaxel and cisplatin|The immunotherapy drug was pembrolizumab at a dose of 200 mg, administered on the first day of each cycle every 3 weeks. The induction chemotherapy regimen included albumin-bound paclitaxel at 260 mg/m2 and cisplatin at 75 mg/m2, given every 3 weeks, either concurrently with immunotherapy or on the second day.
223781893|NCT06574867|DEVICE|viQtor Wearable Monitoring Device|The viQtor device is a wearable medical device designed for continuous monitoring of vital signs, including heart rate (PR), respiratory rate (RR), and blood oxygen saturation (SpO2). It is worn on the upper arm and transmits data wirelessly to a cloud-based platform. This device is being evaluated as part of the standard monitoring protocol for post-operative patients in a surgical ward setting.
223781894|NCT05549674|OTHER|The COPAIN study is observational. There is no intervention.|The COPAIN study is observational. There is no intervention.
223781895|NCT03099382|BIOLOGICAL|camrelizumab|Subjects receive camrelizumab intravenous infusion at the dose 200mg on Day 1 every 2 weeks
223781896|NCT03099382|DRUG|Docetaxel|Subjects receive Docetaxel intravenous infusion at the dose 75mg/m2 on Day 1 every 3 weeks
223781897|NCT03099382|DRUG|Irinotecan|Subjects receive Irinotecan intravenous infusion at the dose 180mg/m2 on Day 1 every 2 weeks
223781898|NCT05227079|DEVICE|MultCROC multibite forcep|Alligator style 2.4 mm diameter jaws that can hold up to six samples in one pass through endoscope.
223781899|NCT05227079|DEVICE|Conventional double bite forcep|Use of conventional double bite forceps that can store up to two specimens in one pass through endoscope
223781900|NCT00499369|DRUG|irinotecan hydrochloride|Given IV
223699585|NCT00424801|DRUG|Pindolol|Possible add-on therapy in case target blood pressure can not be reached with a combination of the other drugs in the Vasodilatory arm. Individual titration, max. dose 10 mg OD for 8 months
223699586|NCT00424801|DRUG|Amiloride, hydrochlorothiazide|Possible add-on therapy in case target blood pressure can not be reached with a combination of the other drugs in the Vasodilatory arm. Individual titration, max. dose 1 tbl. OD for 8 months
223699587|NCT05812274|OTHER|Apricity C.A.R.E. Program for Cancer Adverse events Rapid Evaluation|"The Apricity CARE program for Cancer Adverse events Rapid Evaluation is a cloud-based 24/7 on-demand clinical coverage service, delivered exclusively via the ApricityRx digital care platform by certified and licensed healthcare professionals who are trained to monitor patient's symptoms and conduct standardized triage following guideline-based or protocol-specified pathways with 3 parts:~* ApricityCare™ Mobile Application - to collect health data (PGHD) on biometrics and self-reported symptoms (PRO) of symptoms and potential side effects at home, in between doctors' visits, and offers educational content in video.~* ApricityOncology™ Web-based Application - to provide authorized healthcare providers an organized, longitudinal and summarized view of a patient's pertinent cancer history and real world PGHD for purpose of symptom monitoring.~* ApricityManage™ Dashboard - a dashboard intended for administrators, sponsors or funders to track program status."
223699588|NCT06621316|DRUG|HRS-7535 Tablet|at multiple dose levels
223699589|NCT06621316|DRUG|Placebo|at multiple dose levels (matching active arm HRS-7535 Tablet)
223699590|NCT06216834|OTHER|No intervention|No intervention
223699591|NCT05577871|DRUG|Dexmedetomidine|infusion of dexmedetomidine during the off pump coronary artery bypass grafting surgery
223699592|NCT05577871|DRUG|normal saline|infusion of normal saline during the off pump coronary artery bypass grafting surgery
223699593|NCT00447317|BEHAVIORAL|BalanceWise-PD|Dietary counseling based on Social Cognitive Theory, paired with PDA-based dietary self-monitoring
223781901|NCT00499369|DRUG|leucovorin calcium|Given IV
223781902|NCT00499369|DRUG|fluorouracil|Given IV
223781903|NCT00499369|BIOLOGICAL|cetuximab|Given IV
223781904|NCT00499369|BIOLOGICAL|bevacizumab|Given IV
223781905|NCT02592733|DEVICE|CYDAR|CYDAR is an automated image mask that is cloud based adn delivered to operating theatres over a secure network. It fuses preoperative images with intraoperative images to provide more accurate image guidance for the surgeon.
223781906|NCT00296101|BEHAVIORAL|Physical Activity|
223781907|NCT02825394|OTHER|anti-Xa activity point-of-care testing (aXa-POCT)|
223781908|NCT02825394|OTHER|ecarin clotting time point-of-care testing (ECT-POCT)|
223781909|NCT00917592|DRUG|amoxicillin plus clavulanic acid|intravenous amoxicillin plus clavulanic acid 1 gr every 8 hours 48 hours followed by oral amoxicillin plus clavulanic acid 1 gr every 8 hours for 10 days
223781910|NCT00917592|DRUG|amoxicillin plus clavulanic acid|intravenous amoxicillin plus clavulanic acid for 7 days followed by oral antibiotic for 5 days
223781911|NCT05181605|DRUG|Folfirinox and Stereotactic Body Radiotherapy|Neoadjuvant treatment is composed of folfirinox plus stereotactic body radiotherapy
223699594|NCT00447317|BEHAVIORAL|Attention control|Standard peritoneal dialysis dietary education
223699595|NCT01069627|DRUG|bevacizumab [Avastin]|15 mg/kg intravenously on day 1 of every 3 week cycle
223699596|NCT01069627|DRUG|fotemustine|100 mg/m² intravenously on Days 1, 8, and 15, followed by 4 weeks of rest, then every 21 days up to 4 to 6 cycles
223699597|NCT04771884|DRUG|meropenem vancomycin ceftazidime ceftriaxone ceftizoxime linezolid|The use of antimicrobial agents depends on the clinical practice
223699598|NCT02484287|DEVICE|The Integra External Drainage Catheter.|Participants will be randomly assigned to receive 1 of 3 drains, to determine the efficacy of antibiotic-impregnated vs non antibiotic-impregnated EVD catheters, in the reduction of infection rates associated with EVD use.
223699599|NCT02484287|DEVICE|The Ventriclear EVD Antibiotic Catheter|Participants will be randomly assigned to receive 1 of 3 drains, to determine the efficacy of antibiotic-impregnated vs non antibiotic-impregnated EVD catheters, in the reduction of infection rates associated with EVD use.
223699600|NCT02484287|DEVICE|The Codman Bactiseal EVD Catheter Set|Participants will be randomly assigned to receive 1 of 3 drains, to determine the efficacy of antibiotic-impregnated vs non antibiotic-impregnated EVD catheters, in the reduction of infection rates associated with EVD use.
223699601|NCT02979717|DIETARY_SUPPLEMENT|High protein, high fiber dietary supplement|
223699602|NCT02979717|OTHER|Low protein, low fiber comparator|
223699603|NCT01248845|OTHER|Titration of various level of assistance|Exploration of the effects on diaphragmatic electrical activity (EMG) and on respiratory pattern of various level of assistance delivered by the ventilator in intubated spontaneously breathing patients in pressure support (PS) and in Neurally Adjusted Ventilatory Assist (NAVA) by step by step increasing of the level of assistance. Flow, airway pressure, transesophageal EMG signal and transcutaneous EMG signal will be recorded.
223699604|NCT02939079|DRUG|Fingolimod|Produced by Osveh ® Pharm Company in Iran
223699605|NCT02939079|DIETARY_SUPPLEMENT|Fish Oil|produced by Zahravi ® Pharm Company in Iran
223699606|NCT02939079|DRUG|Placebo (for Fish Oil)|placebo capsules to mimic Fish Oil 1 g capsules
223699607|NCT02355496|OTHER|Displaying medicare fee data|Using the computerized order entry system to make medicare fee data for a randomly selected inpatient laboratory tests transparent to providers at the time of order entry.
223699608|NCT00537875|DIETARY_SUPPLEMENT|Ginger|Capsule, 1000 mg, BID, 3 days
223699609|NCT00537875|DIETARY_SUPPLEMENT|Placebo|Capsule, 1000 mg, BID, 3 days
223699610|NCT02666716|DRUG|fluconazole|Dose according to summary of product characteristics (SPC) or local protocols
223781912|NCT04368598|DRUG|Dexamethasone|Dexamethasone, iv, 40 mg/d, for 4 days (The 4-day course of dexamethasone was repeated on days 11 to 14 in the case of lack of response by day 10)
223781913|NCT04368598|DRUG|Acetylcysteine|Acetylcysteine, po, 400mg tid, for 4 weeks
223781914|NCT04902105|DRUG|ecopipam HCL|oral tablets
223781915|NCT04902105|DRUG|Mefenamic acid|oral capsules
223781916|NCT04902105|DRUG|Divalproex Sodium ER|oral tablets
223781917|NCT01802411|DRUG|EXPAREL 266 mg|
223781918|NCT01802411|DRUG|Placebo|
223781919|NCT01383941|DRUG|Guidelines-based asthma and rhinitis/rhinosinusitis therapy|All participants receive standardized asthma and rhinitis treatment. Asthma and rhinitis medication regimens were based on 1.) the National Asthma Education and Prevention Program (NAEPP) Expert Panel Report -3 (EPR-3) and 2.) the Rhinitis and its Impact on Asthma (ARIA) 2008 guidelines-derived treatment algorithms. References: 1.) J Allergy Clin Immunol 2007; Volume 120, Issue 5, Supplement s93-140. 2.) Allergy 2008; Volume 63, Issue Supplement s86, pages 7-160.
223781920|NCT02528292|PROCEDURE|Synovial biopsy|Ultrasound guided synovial biopsy of inflamed joint
223781921|NCT02528292|DRUG|Anti-TNF therapy|Therapy will include, but not limited to Etanercept, Certolizumab Pegol, Adalimumab and Infliximab
223781922|NCT00389935|DRUG|Thalidomide|Thalidomide 50 - 200 mg once at nightime
223781923|NCT05404022|OTHER|Tailored nutrition and physical activity programme|"Physical activity prescriptions will follow recent guidance for people with cancer and the FITT principles: Frequency (weekly sessions), Intensity (how hard), Time (session duration), and Type. Programme content, duration, and intensity will be tailored for comorbidities and other limitations.~Nutrition prescription may include any or all of the following:~1. Information on side-effects that may affect eating and their mitigation~2. Feedback on physical measures (weight loss) in relation to nutrition and treatment outcomes~3. Feedback on assessment of food intake and how to improve~4. a Macmillan booklet: advice on eating and maintaining weight throughout cancer treatments.~5. a recipe book Making the most of every bite~6. tailored oral nutritional support, including use of high calorie/protein nutrition supplementation, or other macro and micronutrient supplementation as required"
223781924|NCT05522036|COMBINATION_PRODUCT|Metvix + Dermaris|Photodynamic Therapy
223781925|NCT04471181|DEVICE|Endovascular repair of ruptured abdominal aortic aneurysm (EVAR) with Medtronic Endurant|Endovascular repair (EVAR) of ruptured abdominal aortic aneurysms with Medtronic Endurant II, and IIs device
223781926|NCT03570736|PROCEDURE|Minimal invasive surgical technique|Minimal Invasive Surgical technique using either Modified Papilla Preservation or Simplified Papilla Preservation Technique.
223781927|NCT03570736|PROCEDURE|Open Flap Debridement|Buccal and lingual intrasulcular incisions will be done extending at least one tooth mesial and distal to the tooth associated with the intrabony defect. Full thickness mucoperiosteal flaps will be reflected to allow access for debridement of the defect.
223781928|NCT05042622|DEVICE|Cytokine adsorber filter|• Intervention group #1 a cytokine adsorber will be used (30 patients): patients on ECMO - subgroup A; septic patients - subgroup B.
223781929|NCT05042622|DEVICE|Extracorporeal hemoperfusion cartridge|• Intervention group #2 an extracorporeal hemoperfusion cartridge will be used (30 patients): patients on ECMO - subgroup C, septic patients - subgroup D.
223781930|NCT06440668|BEHAVIORAL|Chronic Pain Management Workshop with Non-Pharmacological Therapies|"1st Session: Welcome. Expectations. Pathophysiological mechanism of pain. Influence of emotions on pain intensity. Activities: My limiting beliefs; Affirmations in front of the mirror; Mental analgesia. / 2nd: Pain and its impact on the patient's life. Forgiveness and self-forgiveness. Ho'oponopono technique. Self-esteem. Activities: Labels that limit us; Reading When I Loved Myself for Real; Self-healing meditation; Life purpose. / 3rd: Tips to slow down aging. Promotion of healthy habits; Metta meditation; Motivation for change. / 4th: Active participation in my own healing. How to face illness. Creative visualization. Activity:Energy wheel. / 5th: Review of the tools. Resolving doubts. Workshop evaluation and scales. Guide with the tools presented. Activities: Final farewell. / At the end of each session, the homework assignments are explained, and at the beginning of the next, they are reviewed. Sessions 2, 3, 4 5: Experience of a previous workshop patient."
223781931|NCT03762226|DRUG|Anti-VEGF|Patients will undergo as part of the routine care 4 monthly anti-VEGF injections.
223781932|NCT03113539|OTHER|Modified Low-dose, EKG-gated CT without contrast for the evaluation of aortic aneurysm|"On the same day, the subject will do :~1. Modified low-dose, EKG-gated CT without contrast~2. Usual high-dose, EKG-gated CT with contrast~Comparing aortic diameters from the two protocols."
223781933|NCT04170192|PROCEDURE|Cord Blood Stem Cell Transplantation|Unrelated cord blood stem cell selection; Reduced intensity conditioning regime; GVHD prevention; Infection prevention.
223781934|NCT01590641|DRUG|Single Ascending Dose (SAD) Cohorts GS-9620|This study will enroll cohorts of 6 eligible, unique subjects per cohort, randomized to either active drug or placebo (5:1) within each cohort. Subjects in Single Ascending Dose (SAD) Cohorts will receive a single dose of GS-9620.
223781935|NCT01590641|DRUG|Multiple Ascending Dose (MAD) Cohorts|This study will enroll cohorts of 6 eligible, unique subjects per cohort, randomized to either active drug or placebo (5:1) within each cohort. Subjects in Multiple Ascending Dose (MAD) Cohorts will receive GS-9620 once weekly for two weeks (QW x 2 doses)
223781936|NCT02212223|DIETARY_SUPPLEMENT|Vitamin D3|
223781937|NCT04497701|DRUG|PEG-rhG-CSF group|Patients received a single dose of 100 ug/kg of PEG-rhG-CSF（Jinyouli®）, on the basis of actual body weight. Peg-rhG-CSF can be used prophylactically only when the interval between two chemotherapy regimens is no less than 12 days.
223781938|NCT04497701|DRUG|rhG-CSF group|Patients received 5μg/kg/d of rhG-CSF, on the basis of actual body weight.
223781939|NCT02756624|DRUG|AC-170 0.24%|
223781940|NCT02756624|DRUG|AC-170 Vehicle|
223781941|NCT06536010|DRUG|Venetoclax 100 mg d1，200 mg d2，400 mg d3-28；|VAG in the induction phase of the ND-AML treatment protocol
223781942|NCT01059617|BIOLOGICAL|GSK Biologicals' FluLaval®|Intramuscular injection
223781943|NCT01059617|BIOLOGICAL|Placebo (saline)|Intramuscular injection
223781944|NCT01059617|BIOLOGICAL|GSK Biologicals' investigational H1N1 Influenza Vaccine - GSK2340274A|Intramuscular injections
223781945|NCT01059617|BIOLOGICAL|GSK Biologicals' investigational H1N1 Influenza Vaccine - GSK2340273A|Intramuscular injections
223781946|NCT02116322|PROCEDURE|EUS-FNA with Corkscrew technique|
223781947|NCT02116322|DEVICE|Expect 19 G Flex needle|
223781948|NCT05783180|DRUG|Sesderma LACTYFERRIN™ Forte and Sesderma ZINC Defense™|Sesderma LACTYFERRIN™ Forte (64mg/20ml, TID) and Sesderma ZINC Defense™ (20mg/20ml QD)
223781949|NCT05783180|DRUG|Placebo|Sesderma LACTYFERRIN™ Forte and Sesderma ZINC Defense™ (Placebo)
223781950|NCT05520957|PROCEDURE|Tracheostomy|We collected data from all tracheotomised patients including age, sex, existing comorbidities, duration indicators (length of endotracheal intubation, day of tracheotomy, length of stay in the intensive care unit (ICU), and total length of hospital stay), respirator weaning marked with YES / NO. From the laboratory parameters, we analyzed: lactate, urea, creatinine, potassium and D-dimer. They were collected at two time intervals, before tracheotomy and after tracheotomy.
223781951|NCT01751022|DEVICE|Device: Attain Performa Pacing Lead (along with a standard CRT-D system)|Implant and follow-up of study lead, separate analysis for each lead model
223781952|NCT03556046|DIAGNOSTIC_TEST|89Zr-Girentuximab|Single diagnostic injection on Day 0, followed by diagnostic scans on Days 3 and 7±1, as well as the whole body dosimetric imaging on Days 0, 1, 3 and 7±1
223781953|NCT01464918|DEVICE|Endoscopic submucosal dissection (ESD) using device, MASTER|Performing endoscopic submucosal dissection (ESD)of the gastric/colon cancer using the device, MASTER
223699611|NCT05869565|DRUG|Sodium Chloride 0.9% infusion alone or in combination with Sodim acetate with normal saline in a ratio 1;1, 2;1 and 3;1|Patients will be enrolled in the study and randomized into one of four arms
223781954|NCT06620926|OTHER|IDH mutant-type|The first arm had IDH mutant-type, then stratified according to the treatment modality they received: adjuvant chemotherapy, adjuvant radiotherapy, adjuvant chemoradiotherapy.
223699612|NCT04093414|DEVICE|Select Secure pacing lead|A Select Secure pacing lead is placed in the bundle of His or Left bundle branch area based upon randomization
223699613|NCT04209348|BEHAVIORAL|Physical Activity Intervention|Motivational interviewing techniques helped participants set reasonable, specific, and achievable individual goals at each session: a duration (i.e., minutes) and frequency (i.e., days of the week) of walking or stepping, and potentially, a step count (i.e., a proxy for intensity). Individual goals often differed from the program goal in an effort to meet the participants 'where they are'.
223699614|NCT04209348|OTHER|Wellness Education|The following topics were addressed: postpartum contraception, maternal immunizations, infant immunizations, car seat safety and planning for your hospital stay, and safe sleep and skin to skin. No information on PA was provided to the control group (i.e., neither encouragement for PA nor instructions to limit PA).
223699615|NCT02344615|PROCEDURE|NS-guided infraclavicular block|Patients received a standard single injection infraclavicular block using the lateral sagittal approach of Klaastad. The infraclavicular brachial plexus is identified using an insulated needle connected to a nerve stimulator. Placement of the needle is considered adequate if motor response of radial nerve in the hand or wrist is still present at 0.2 - 0.5mA. Ropivacaine 0.5% 35ml is used.
223699616|NCT02344615|PROCEDURE|US-guided infraclavicular block|Infraclavicular block is performed under ultrasound guidance. Linear probe is placed in a parasagittal positon below the clavicle medial to the coracoid process and adjusted to achieve a cross-sectional image of the axillary artery. Using in-plane technique, an 22-gauge insulated needle is advanced caudally and posteriorly to the axillary artery. Subsequently, 35 ml of 0.5% ropivacaine is incrementally injected.
223699617|NCT03236831|OTHER|Clinical Recommendations|"The investigators will provide clinical recommendations to the subject's primary care provider. These will be in regards to the following:~1. Avoidance of potentially nephrotoxic medications.~2. Optimizing volume status (avoidance of volume overload or depletion)~3. Optimizing electrolytes and acid-base status~4. Minimizing IV contrast exposure when appropriate~5. Treating severe anemia~6. Optimization of hemodynamics (Mean arterial BP\>65mmHg)"
223699618|NCT02396251|DEVICE|HA experimental|
223699619|NCT02396251|DEVICE|HA comparator|
223699620|NCT05185323|OTHER|Breastfeeding usual known aids and osteopathic treatment|Breastfeeding usual known aids and osteopathic treatment
223699621|NCT05185323|OTHER|Breastfeeding usual known aids|Breastfeeding usual known aids
223699622|NCT00896636|PROCEDURE|Random fine need aspiration (rFNA)|Deep infiltration into the tissue of each breast with up to a 21 gauge needle attached to a syringe with about 4-5 passes at each location (up to 8-10 passes per breast) under local anesthesia (lidocaine).
223699623|NCT00896636|OTHER|Mammogram|Standard mammography of both breasts to obtain images for breast density measurement.
223699624|NCT04151329|BIOLOGICAL|BAT1306 and BAT8001 2.4mg/kg|Phase 1 dose titration study of BAT1306 and BAT8001 2.4mg/kg , then choose a proper dose for amplification study based on DLT result
223781955|NCT06620926|OTHER|IDH wild-type|The second arm had IDH mutant-type, then stratified according to the treatment modality they received: adjuvant chemotherapy, adjuvant radiotherapy, adjuvant chemoradiotherapy.
223699625|NCT04151329|BIOLOGICAL|BAT1306 and BAT8001 3.6mg/kg|Phase 1 dose titration study of BAT1306 and BAT8001 3.6mg/kg , then choose a proper dose for amplification study based on DLT result
223699626|NCT01598168|DRUG|Rivaroxaban|Rivaroxaban 15 mg bid until HIT excluded by local laboratory assay or platelets recovered. If HIT positive and platelets have recovered, patients will receive rivaroxaban 20 mg od until Day 30.
223699627|NCT02927262|DRUG|Gilteritinib|Oral tablet
223699628|NCT02927262|DRUG|Placebo|Oral tablet
223781956|NCT04465175|DRUG|Magnesium Sulfate|Second dose magnesium sulphate infusion over one hour
223781957|NCT04465175|DRUG|Placebo|Normal saline (2.5 ml/kg) infusion over one hour
223781958|NCT02404363|DRUG|Clopidogrel|"Clopidogrel tablets 75 mg for six months:~In case of treatment with aspirin \< or = 75 mg/d or prophylactic LMWH --\> clopidogrel 75 mg/d If aspirin = 0 + LMWH = 0 --\> clopidogrel 150 mg/d x 7days then 75mg/d"
223699629|NCT06344182|OTHER|Step Up and Down Test|Step Up and Down Test In the StUD test, the patient completes maximum number of step-up-down repetitions in 15 seconds. Starting from a standing position, the participant took a full step up, leading with the test leg, then the non-testing leg, until both knees were fully extended and both hips were at least in neutral extension. In order to stress the testing limb concentrically and eccentrically, the participant stepped off the step first with the non-testing limb, then the testing limb. The patient was asked to repeat for 15 seconds as quickly as possible. The physical therapist stood to the side of the step for safety and so that he/she could observe the technique and ensure that the participant came to a full step up and down during the test.
223699630|NCT00923936|DRUG|Liposomal Doxorubicin|Induction phase dose: Intravenous (IV) bevacizumab 15 mg/kg once, followed 7 days later by liposomal doxorubicin mg/m\^2 and bevacizumab every 3 weeks for six cycles.
223699631|NCT00923936|DRUG|Bevacizumab|Induction phase dose: Intravenous (IV) bevacizumab 15 mg/kg once, followed 7 days later by liposomal doxorubicin mg/m\^2 and bevacizumab every 3 weeks for six cycles. Maintenance phase dose: IV bevacizumab every 3 weeks for 11 cycles.
223699632|NCT02863276|PROCEDURE|Intensified insulin therapy|
223699633|NCT02061618|BEHAVIORAL|Bollywood Dance Exercise|
223699634|NCT01697358|DEVICE|Spinal Cord Stimulation (SCS)|Spinal Cord Stimulation (SCS) using the Medtronic Specify 5-6-5 multicolumn surgical lead. Subjects will undergo an SCS screening test and, if successful, an implantable neurostimulation system implant. Any SCS group subject not implanted will continue to be treated with OMM and will be followed as part of the SCS group.
223699635|NCT01697358|DRUG|Optimal Medical Management (OMM)|The investigator and subject will determine an individual OMM treatment plan, which should include non-investigational pharmacologic agents and/or therapies.
223699636|NCT00412568|PROCEDURE|Photorefractive Keratectomy (PRK)|vision correction with PRK
223699637|NCT00471146|DRUG|AG-013736|oral administration, starting dose 5 mg twice daily \[BID\] every day until unacceptable toxicity or tumor progression.
223699638|NCT00471146|DRUG|Gemcitabine|intravenous administration at 1,000 mg/m\^2 day 1, day 8 and day 15 every 4 weeks (conventional dose) until unacceptable toxicity or tumor progression.
223781959|NCT02404363|DRUG|Placebo|"Placebo tablets 75 mg for six months:~In case of treatment with aspirin \< or = 75 mg/d or prophylactic LMWH --\> placebo 75 mg/d If aspirin = 0 + LMWH = 0 --\> placebo 150 mg/d x 7days then 75mg/d"
223781960|NCT00016094|BIOLOGICAL|bevacizumab|Given IV
223781961|NCT00016094|OTHER|laboratory biomarker analysis|Correlative studies
223781962|NCT00452101|DRUG|Aquamin F|
223699639|NCT00471146|DRUG|Gemcitabine|intravenous administration at 1,000 mg/m\^2 day 1, day 8 and day 15 every 4 weeks (conventional dose) until unacceptable toxicity or tumor progression.
223699640|NCT00471146|DRUG|placebo|placebo
223699641|NCT01225627|OTHER|Coordinated discharge|In intervention group, a discharge coordinator contacts hospitalized patients the day after randomization. During hospitalization, discharge coordinator visits are scheduled according to patients' problems and home-care needs. At 48 hours after hospital discharge, a discharge coordinator calls patients by phone to check the process of adjustment to home environment and to inquire about additional needs patients might have. Thereafter, phone contacts are scheduled according to the patients' needs and 7-10 days after the hospital discharge a home visit is performed by discharge coordinator, respectively.
223699642|NCT01225627|OTHER|Control|Patients in control group will be managed by attending physician, primary care physician, and/or pneumologist in accordance with established clinical practice.
223699643|NCT02066220|RADIATION|Radiotherapy without Carboplatin|"Brain - 23.40 Gy in 13 daily fractions of 1.80 Gy Spine - 23.40 Gy in 13 daily fractions of 1.80 Gy Primary tumour boost - 30.60 Gy in 17 daily fractions of 1.80 Gy Total dose - 54 Gy Duration of radiotherapy 6 weeks~LR Arm after Amendment (Protocol version 11- 17 Nov 2014):~Brain - 18.0 Gy in 10 daily fractions of 1.80 Gy Spine - 18.0 Gy in 10 daily fractions of 1.80 Gy Primary tumour boost - 36.0 Gy in 20 daily fractions of 1.80 Gy Total dose - 54 Gy Duration of radiotherapy 6 weeks"
223781963|NCT03864614|DRUG|SAGE-217|SAGE-217
223781964|NCT03590977|OTHER|licorice extract mouthwash|mouth rinse that contains a natural herbal licorice root extract used as a preventive measure that reduce caries index.
223781965|NCT03590977|OTHER|chlorohexidine mouthwash|mouth wash that contains chlorohexidine as an active component
223781966|NCT03593083|OTHER|Low altitude: 470m above sea level|Assessment at Low Altitude (in Zurich; 470m above sea level) in order to compare this data with High altitude exposure
223781967|NCT03593083|OTHER|Säntis; 2500m above sea Level|Exposure to High Altitude (Säntis; 2500m above sea level) for approximately 5 hours
223781968|NCT04411108|OTHER|Kaia Back Pain App|The Kaia Back Pain App provides instructions on exercise execution to participants for one week
223781969|NCT04411108|OTHER|Physiotherapist Exercise Instructions and written handouts|Participants will be instructed by physiotherapists in exercise execution and receive handouts and exercise for one week
223781970|NCT04431323|BEHAVIORAL|ESPRIMO|"Participants will receive the intervention during Phase 2.~The intervention is based on the cognitive behavioral, the third-wave (mindfulness and acceptance and commitment therapy), and the positive psychology approach.~The frequency of the intervention and the specific content and aims of the psychological and physical intervention will be based on the results of the surveys and the focus group discussion (Pre-phase and Phase 1). In order to maximize the benefit of the integrated intervention, all the three components of the interventions (i.e., psychological, motor exercise and social components) will be administered in the same time period.~A preliminary theoretical framework of the intervention will be created prior to the survey phase according to the literature in the field. Specific aspects of this preliminary framework will be discussed during the co-creation phase and adapted after the analysis of the qualitative results."
223781971|NCT01760954|DRUG|Elagolix|Elagolix tablets administered orally
223781972|NCT01479660|OTHER|Control|Placebo will be orally administered daily for a period of 12 weeks in high dose and low dose
223781973|NCT01479660|DRUG|Probiotic|Probiotic Capsules (450 billion CFU) will be orally administered daily for a period of 12 weeks and Probiotic in higher dose of (3600 billion CFU) will be administered daily for a period of 12 weeks
223781974|NCT03320070|DRUG|Acthar Gel|Acthar Gel for subcutaneous (SC) injection (80 units per 1 mL)
223781975|NCT03320070|DRUG|Placebo|Placebo gel for SC injection
223781976|NCT04898335|DEVICE|Tendyne Mitral Valve System|Tendyne Mitral Valve System for mitral valve disease in a commercial setting
223781977|NCT00709969|DRUG|Artemether-lumefantrine|20mg artemether and 120 mg lumefantrine, tablet, dose based on body weight, 3 days treatment 5 - \< 10kg (BWG 1) = 6 doses of 1 tablet / 10 - \< 15kg (BWG 2) = 6 doses of 1 tablet / 15 - ≤ 25kg (BWG 3) = 6 doses of 2 tablets
223781978|NCT02559674|BIOLOGICAL|Gemcitabine|Intravenous Infusion; Patients will receive two 4-week treatment cycles consisting of gemcitabine given on Day 1, 8, 15, 29, 36, and 43. Eligible patients may receive up to 10 additional treatment cycles.
223781979|NCT02559674|BIOLOGICAL|Nab-paclitaxel|Intravenous Infusion; Patients will receive two 4-week treatment cycles consisting of nab-paclitaxel given on Day 1, 8, 15, 29, 36, and 43. Eligible patients may receive up to 10 additional treatment cycles.
223781980|NCT02559674|BIOLOGICAL|ALT-803|Subcutaneous Injection; Patients will receive two 4-week cycles consisting of ALT-803 given on Day 2, 9, 16, 30, 37, and 44. Eligible patients may receive up to 10 additional treatment cycles.
223781981|NCT04433169|DRUG|All-trans Retinoic Acid|ATRA 20 mg, three times a day, for 28 consecutive days, 28 days per cycle (q4w), 6 planned cycles
223781982|NCT04433169|DRUG|VEGFR inhibitor|VEGFR inhibitor
223781983|NCT04433169|DRUG|Chemotherapy|chemotherapy
223781984|NCT00457262|PROCEDURE|soy consumption|
223781985|NCT00122018|DRUG|N-acetylcysteine|
223781986|NCT00122018|DRUG|fenoldopam|
223781987|NCT00392561|DIETARY_SUPPLEMENT|Selenium|200 ug Selenium daily
223781988|NCT00392561|DIETARY_SUPPLEMENT|vitamin E|100 mg Vitamin E daily
223781989|NCT06065072|DEVICE|Optical measurement|Optical measurements by optical biometers and an OCT
223781990|NCT02496013|DRUG|68Ga-NEB|68Ga-NEB were injected into the patients before the PET/CT scans
223781991|NCT03676062|OTHER|exercise|All exercises programs applied three sessions per week, totally six week.
223781992|NCT03895424|DIETARY_SUPPLEMENT|IFAC|This intervention will contain the iron fatty acid complex in a capsule. The complex will be labelled with the iron isotope 58Fe
223781993|NCT03895424|DIETARY_SUPPLEMENT|MIFAC|This intervention will contain the micellarized form of the iron fatty acid complex in a capsule. The complex will be labelled with the iron isotope with 57Fe
223781994|NCT03895424|DIETARY_SUPPLEMENT|Control Ferrous Sulfate|This intervention will contain ferrous sulfate in the form of a solution labelled with the iron isotope 54Fe. A capsule with the same amount of fat as in the other arms will be administered to the participants
223781995|NCT04931511|DRUG|Compound betamethasone Injection(Gluteal muscle injection)|Gluteal muscle injection(Compound betamethasone 1ml + Sodium Chloride Injection 4ml) + Subacromial Ultrasound Guided injection(Sodium Chloride Injection 5ml)
223781996|NCT04931511|DRUG|Compound betamethasone Injection(Subacromial Ultrasound Guided injection)|Gluteal muscle injection (Sodium Chloride Injection 5ml)+ Subacromial Ultrasound Guided injection (corticosteroid 1ml+Sodium Chloride Injection 4ml)
223781997|NCT04931511|BEHAVIORAL|Physical therapy|paticipant will be teached by the Physicaltherapist to reduce the shoulder pain at home
223781998|NCT05851404|PROCEDURE|Thyroidectomy|Total thyroidectomy or lobectomy
223781999|NCT01417312|DIETARY_SUPPLEMENT|Capsules with 160 mg Teavigo (at least 94% EGCG)|Daily intake of 600 mg EGCG for 3 months
223782000|NCT01417312|DIETARY_SUPPLEMENT|Placebo|Daily intake of placebo capsules for 3 months
223782001|NCT00122512|DRUG|Tenofovir Disoproxil Fumarate|
223782002|NCT05496504|OTHER|Holter ECG|
223782003|NCT02487563|DRUG|Decitabine|Decitabine
223782004|NCT02487563|DRUG|rhTPO|rhTPO
223782005|NCT02487563|OTHER|Conventional Treatment|immunoglobulin, glucocorticoid etc
223782006|NCT03102398|DRUG|TR-399 (5% Vardenafil HCl·3H2O, topical gel)|5% Vardenafil HCl·3H2O, topical gel, 2 drops (50ul, 2.5mg), q.d.
223782007|NCT00299650|DRUG|cisatracurium|
223782008|NCT00299650|DRUG|Placebo|physiological serum infusion
223782009|NCT00299650|DRUG|Cisatracurium besilate|Cisatracurium besilate infusion (900mg/day)
223782010|NCT03821376|DRUG|Contrast enhanced ultrasound with Lumason|Following consent, they will undergo contrast enhanced ultrasound of their known renal mass(es). This will be performed at University hospital following intravenous administration of Lumason (2.5 mL per injection, maximum of 2 injections per mass).
223782011|NCT02391402|BEHAVIORAL|Cognitively Augmented Behavioral Activation|CABA uses Behavioral Activation (BA) to identify meaningful goals and activities while learning cognitive skills to aid in working toward those goals. Early sessions of CABA focus on learning about mTBI, PTSD, and lifestyle skills that can improve thinking abilities and mood. Cognitive skills taught each week include internal and external skills to help manage problems with memory, attention, and regulation of thinking processes. Investigators and patients will spend a part of each session applying the cognitive skills to managing real life situations and getting patients active in the service of personal goals.
223699644|NCT02066220|DRUG|Reduced-intensity maintenance chemotherapy|"Starts 6 weeks after radiotherapy. 6 cycles alternating Regimen A and Regimen B. Regimen A (cycles 1, 3, 5): cisplatin 70 mg/m2 day 1, CCNU 75 mg/m2 day 1, vincristine 1.5 mg/m2 days 1, 8 and 15, Regimen B: (cycles 2, 4, 6): cyclophosphamide 1 x 1000 mg/m2 days 1-2, vincristine 1.5 mg/m2 day 1.~Interval after cycle A: 6 weeks, after cycle B: 3 weeks, for a total duration of 27 weeks.~Cumulative doses of chemotherapy drugs: cisplatin 210 mg/m2, lomustine (CCNU) 225 mg/m2, vincristine 18 mg/m2, cyclophosphamide 6 g/m2."
223699645|NCT02066220|RADIATION|Radiotherapy with Carboplatin|Brain - 23.40 Gy in 13 daily fractions of 1.80 Gy Spine - 23.40 Gy in 13 daily fractions of 1.80 Gy Primary tumour boost - 30.60 Gy in 17 daily fractions of 1.80 Gy Total dose - 54 G Carboplatin 35 mg/m2 5 times/week.
223699646|NCT02066220|DRUG|Maintenance chemotherapy|"Starts 6 weeks after radiotherapy. 8 cycles alternating Regimen A and Regimen B. Regimen A (cycles 1, 3, 5, 7): cisplatin 70 mg/m2 day 1, CCNU 75 mg/m2 day 1, vincristine 1.5 mg/m2 days 1, 8 and 15 Regimen B: (cycles 2, 4, 6, 8): cyclophosphamide 1 x 1000 mg/m2 days 1-2, vincristine 1.5 mg/m2 day 1.~Interval after cycle A: 6 weeks, after cycle B: 3 weeks. Duration 36 weeks. Cumulative doses of chemotherapy drugs: cisplatin 280 mg/m2, lomustine (CCNU) 300 mg/m2, vincristine 24 mg/m2, cyclophosphamide 8 g/m2, carboplatin 1050 mg/m2 (in randomized patients)."
223699647|NCT02066220|RADIATION|WNT-HR < 16 years|Brain - 23.4 Gy in 13 daily fractions of 1.8 Gy Spine - 23.4 Gy in 13 daily fractions of 1.8 Gy Primary tumour boost - 30.6 Gy in 17 daily fractions of 1.8 Gy Boost to macroscopic metastases - 21.6 Gy in 12 daily fractions of 1.8 Gy Total dose to primary tumour - 54.0 Gy in 30 daily fractions of 1.8 Gy Total dose to cranial metastases - 45.0 Gy in 25 daily fractions of 1.8 Gy Total dose to spinal metastases - 45.0 Gy in 25 daily fractions of 1.8 Gy
223699648|NCT02066220|RADIATION|WNT-HR >= 16 years|Brain - 36.0 Gy in 20 daily fractions of 1.8 Gy Spine - 36.0 Gy in 20 daily fractions of 1.8 Gy Primary tumour boost - 18.0 Gy in 10 daily fractions of 1.8 Gy Metastases boost (cranial) - 14.4 Gy in 8 daily fractions of 1.8 Gy Metastases boost (spinal) - 9.0 Gy in 5 daily fractions of 1.8 Gy Total dose to primary tumour - 54.0 Gy in 30 daily fractions of 1.8 Gy Total dose to cranial metastases - 50.4 Gy in 30 daily fractions of 1.8 Gy Total dose to spinal metastases - 45.0 Gy in 25 daily fractions of 1.8 Gy
223699649|NCT02066220|DRUG|Induction Chemotherapy|Doxorubicin 37,5mg/m² in 24h-infusion, days 1 and 2 (If administration of doxorubicin is not deemed appropriate, doxorubicin can be substituted by carboplatin 200mg/m²) VCR 1,5mg/m² (max. dose 2mg) in short infusion, days 1, 15, 29, 43 HD-MTX 5g/m²in two doses (0.5g/m² in 0.5h and 4.5g/m² in 23.5h), days 15 and 29 (+ Leucovorin) Carboplatin 200mg/m² in 1h-infusion, days 43, 44, and 45 MTX 2mg intraventricularly, days 1-4, 15, 16, 29, 30, 43-46
223699650|NCT02066220|RADIATION|SHH-TP53 M0|"* with VCR 1,5 mg/m2 (max. 2mg), once weekly during radiotherapy, for a maximum of 6 weeks~* clinical target volume (CTV): safety margin along typical spread 10 mm: 23.4.Gy in 13 fractions to CTV.~* focal RT boost to tumour bed and residual tumour (GTV) (boost: 30.6 Gy in 17 daily fractions of 1.8 Gy)"
223699651|NCT02066220|RADIATION|SHH-TP53 M+ (germline)|craniospinal radiotherapy with boost to tumour bed, residual tumour and metastatic deposits with VCR 1,5 mg/m2 (max. 2mg), once weekly during radiotherapy, for a maximum of 6 weeks Brain - 23.4 Gy in 13 daily fractions of 1.8 Gy Spine - 23.4 Gy in 13 daily fractions of 1.8 Gy Primary tumour boost - 30.6 Gy in 17 daily fractions of 1.8 Gy Metastases boost (cranial) - 30.6 Gy in 17 daily fractions of 1.8 Gy Metastases boost (spinal) - 21.6 Gy in 12 daily fractions of 1.8 Gy Total dose to primary tumour - 54.0 Gy in 30 daily fractions of 1.8 Gy Total dose to cranial metastases - 54.0 Gy in 30 daily fractions of 1.8 Gy Total dose to spinal metastases - 45.0 Gy in 25 daily fractions of 1.8 Gy
223699652|NCT02066220|RADIATION|SHH-TP53 (somatic)|craniospinal radiotherapy with boost to tumour bed, residual tumour and metastatic deposits with VCR 1,5 mg/m2 (max. 2mg), once weekly during radiotherapy, for a maximum of 6 weeks Brain - 36.0 Gy in 20 daily fractions of 1.8 Gy Spine - 36.0 Gy in 20 daily fractions of 1.8 Gy Primary tumour boost - 18.0 Gy in 10 daily fractions of 1.8 Gy Metastases boost (cranial) - 18.0 Gy in 10 daily fractions of 1.8 Gy Metastases boost (spinal) - 9.0 Gy in 5 daily fractions of 1.8 Gy Total dose to primary tumour - 54.0 Gy in 30 daily fractions of 1.8 Gy Total dose to cranial metastases - 54.0 Gy in 30 daily fractions of 1.8 Gy Total dose to spinal metastases - 45 Gy in 25 daily fractions of 1.80 Gy
223699653|NCT02066220|DRUG|Vinblastin Maintenance|Weekly VBL (5mg/m², max. 10mg/dose) for 24 weeks
223699654|NCT00831350|DRUG|Ranibizumab|Subjects will receive study medication ranibizumab 0.5mg. Re-treatment will occur monthly through 6 injections
223699655|NCT05440188|DIAGNOSTIC_TEST|Breath Detect Platform|Use of the Breath Detect platform for respiratory health monitoring.
223699656|NCT06215612|OTHER|Blood draw, MRI|Blood draw, MRI
223699657|NCT04996641|PROCEDURE|Root canal treatment and crown|Pre-radiation one day root canal treatment and CAD/CAM chair side fabricated crowns for head and neck cancer patients
223699658|NCT01237964|DRUG|Xiaflex (FDA approved collagenase)|0.58mg of collagenase will be diluted in saline and injected in 3 points surrounding the limiting contracture
223699659|NCT03694912|PROCEDURE|Partial or radical nephrectomy|The investigators perform partial or radical nephrectomy those diagnosed as RCC.
223699660|NCT05394350|DRUG|MK-1088|Oral Tablet
223699661|NCT05394350|BIOLOGICAL|Pembrolizumab|IV Infusion
223699662|NCT00674427|BIOLOGICAL|CD3/CD28 Activated T cells|Subjects who are not in CR will receive one infusion of high dose aDLI
223782012|NCT02391402|BEHAVIORAL|Treatment as Usual|"TAU care involves psychotherapy (counseling) provided by a specialist in the treatment of PTSD. Patients will be offered individual appointments with an experienced provider on the PTSD Clinical Team (PCT). Beyond this, the specific approach will be determined by the patient and his/her provider and may include skills for managing PTSD and/or a chance for the patient to process his/her traumatic experiences. Additional treatments may be offered to patients, such as group classes and medications. TAU care may also include additional evaluation and/or treatment of mTBI, provided by the usual care offered in Portland or Seattle's respective neuropsychology clinics. Treatment for mTBI includes individual or group sessions, and is based on clinical need."
223782013|NCT01886547|OTHER|Prostate health screening|
223782014|NCT05147818|OTHER|CBC ,renal function tests , fundus Examination|Laboratory investigations
223782015|NCT04741568|BEHAVIORAL|Parental psychoeducational Intervention|"The psychoeducation intervention for parents will focus on providing skills, knowledge and support motivation for caregivers of children with diabetes.~A brief (one-day or two half days) workshop, and a website with downloadable content will be made available to review and refresh any skills and techniques."
223782016|NCT03185975|BEHAVIORAL|at-home test kit|Transgender youth in the control arm will receive test kits, but will not receive any testing intervention. Once individual results are reported, participants will be contacted via phone or email by study staff with options for referrals to services. Participants will complete follow-up surveys at 3, 6, 9, and 12 months post-testing.
223782017|NCT03185975|BEHAVIORAL|Motivational Interviewing and Certified Testing and Referral|Transgender individuals randomized to the experimental group (MI/CTR) will receive HIV counseling and testing via an online, HIPPA-compliant videoconferencing service. The session will last less than one hour and focus on HIV testing, prevention strategies, and/or linkage to HIV care, depending on the individual's test results. Participants will complete follow up surveys at 3, 6, 9 and 12 months.
223782018|NCT02048943|DRUG|dovitinib lactate|Given PO
223782019|NCT02048943|DRUG|gemcitabine hydrochloride|Given IV
223782020|NCT02048943|DRUG|paclitaxel albumin-stabilized nanoparticle formulation|Given IV
223782021|NCT02048943|OTHER|pharmacological study|Correlative studies
223782022|NCT02048943|OTHER|laboratory biomarker analysis|Correlative studies
223782023|NCT05615467|DRUG|LY3556050|Administered orally.
223782024|NCT05615467|DRUG|Metformin|Administered orally.
223782025|NCT05615467|DRUG|Iohexol|Administered IV.
223782026|NCT02230657|PROCEDURE|Same day discharge|
223782027|NCT02230657|PROCEDURE|Next day discharge|
223782028|NCT00774735|DRUG|GSK1349572|30 mg given in combination with lopinavir/ritonavir
223782029|NCT00774735|DRUG|GSK1349572|30 mg in combination with darunavir/ritonavir
223782030|NCT00151801|DRUG|estroprogestins|
223782031|NCT00151801|DRUG|interferon-beta 1a|
223782032|NCT01049555|OTHER|Actigraphy and video recording signal|Actigraphy and video recording signal during 1 hour
223782033|NCT04849234|BEHAVIORAL|newborn cries|"Their cries will be longitudinally registered from the age of birth until the first 15 minutes of birth using an automatic record device: Recorder ZOOM H4N.~The wav-sized files obtained from each recording will then be analyzed indiscriminately via an acoustic processing script created for the PRAAT software® by the post-doctoral fellows of the ENES laboratory (Sensory NeuroEthology Team) on the site of the Faculty of Sciences of Saint-Etienne."
223782034|NCT04021680|OTHER|pre-eclampsia screening program|This screening program included the use of ultrasound, biomarkers and maternal factors in calculating the risk of developing preeclampsia.
223782035|NCT05689632|DIETARY_SUPPLEMENT|Vitamin D3 + K2-MK7|Combined supplementation
223782036|NCT05689632|DIETARY_SUPPLEMENT|Placebo|MCT
223782037|NCT05689632|DIETARY_SUPPLEMENT|Vitamin D3|Vitamin D3 - 7000 IU
223782038|NCT06535191|BEHAVIORAL|Assistive Soft Skills and Employment Training (ASSET)|ASSET program is a manualized, theory-driven, 10-week soft skills intervention for autistic individuals, who seek employment or who wish to maintain employment by improving work-related social skills. Throughout a 10-week curriculum offered in a school-based group setting, ASSET addresses the following competencies for workplace success: Communication, Networking, Enthusiasm and Attitude, Teamwork, Problem-Solving and Critical Thinking, Professionalism, Mental Health and Stress Management, and Awareness of Self and Others.
223782039|NCT00803894|DRUG|MK0752|Single dose MK0752 capsules, 1000 mg: there will be a 7-day washout period between treatments.
223782040|NCT00803894|DRUG|Comparator: MK0752.|Single dose MK0752 capsules, 350 mg: there will be a 7-day washout period between treatments.
223782041|NCT00803894|DRUG|Comparator: Placebo|Single dose placebo capsules: there will be a 7-day washout period between treatments.
223782042|NCT01772992|BEHAVIORAL|CVCTPLUS|For the intervention, couples will receive HIV testing and counseling together as a dyad, and some couples will receive ARV adherence counseling (Partner-STEPS) together as a dyad.
223782043|NCT00354354|DRUG|Combivent|Nebulized Combivent (4 mL) or saline solution (0.9% NaCl) (4 mL) will be administered once only to subjects.
223782044|NCT01126593|DRUG|0.5% bupivacaine|Study group patients will receive a subacromial continuous standard spring loaded infusion catheter with 200cc of 0.5% bupivacaine in its reservoir. The bupivacaine will have an infusion rate of 4cc an hour.
223782045|NCT01126593|DRUG|Normal Saline|The placebo group will receive the same subacromial infusion catheter however, the reservoir will be filled with 200cc of 0.9% Normal Saline.
223782046|NCT01834820|DRUG|Epinephrine and Dexamethasone|
223782047|NCT01834820|DRUG|Hypertonic Saline|
223782048|NCT01834820|DRUG|Normal Saline|
223782049|NCT01407185|OTHER|Resistive Exercise Training|Resistive Exercises (between 8 and 12 exercises for both upper and lower body) at 30 to 60% of 1 RM for 2x per week for 12 months.
223782050|NCT04897295|DEVICE|Active transcranial Direct Current Stimulation|tDCS is a non-invasive brain stimulation technique. The investigators will use a BrainSTIM (EMS, Bologna, Italy)
223782051|NCT04897295|DEVICE|Sham transcranial Direct Current Stimulation|tDCS is a non-invasive brain stimulation technique. The investigators will use a BrainSTIM (EMS, Bologna, Italy)
223782052|NCT00373789|DRUG|Botulinum Toxin A, bladder detrusor muscle injection|200 U provided as a total of 6 cc of the masked substance into approximately 15 to 20 different detrusor muscle sites under direct visualization. Injections will be spread out to equally cover the entire dome of the bladder, but spare the bladder trigone and ureteral orifices.
223782053|NCT00373789|DRUG|Vehicle saline as placebo|A total of 6 cc of the masked substance into approximately 15 to 20 different detrusor muscle sites under direct visualization. Injections will be spread out to equally cover the entire dome of the bladder, but spare the bladder trigone and ureteral orifices
223782054|NCT03057119|BEHAVIORAL|Psycho-educational content (5 Minutes)|The interventionist will discuss substance use and misuse and the influence of substance use on self care.
223782055|NCT03057119|BEHAVIORAL|Readiness Assessment (10 minutes)|The interventionist will give the patient feedback on their ASSIST score and assess the patient's readiness to change based on Prochaska's stages of change.
223782056|NCT03057119|BEHAVIORAL|Goal-Setting (5 minutes)|The interventionist will use motivational interviewing techniques to identify the patients' most salient reasons for addressing substance use issues.
223782057|NCT03057119|BEHAVIORAL|Identifying and prioritizing needs (5 minutes)|The interventionist will use problem-solving techniques to help patients identify which services may best help them work towards their goals. Services will include (but are not limited to) emergency crisis services, counseling to deal with substance use, referral to local self-help groups (Alcoholics Anonymous, Narcotics Anonymous, etc.), legal assistance, faith-based counseling, mental health counseling or inpatient substance use treatment.
223782058|NCT03057119|BEHAVIORAL|Explanation of Peer Navigator and Session wrap (5 minutes)|The interventionist will use a referral resource guide to provide the contact information of agency representatives and help the patient formulate a plan for follow-up.
223782059|NCT03556761|DRUG|Oral furosemide|Furosemide (Lasix), 20 milligram, PO, PO, daily
223782060|NCT03556761|DRUG|Placebo Oral Tablet|Placebo, PO, daily
223782061|NCT05222919|DIETARY_SUPPLEMENT|Bare performance supplement|dietary supplement
223782062|NCT05222919|DIETARY_SUPPLEMENT|Placebo|Placebo
223782063|NCT01888315|DEVICE|Renal denervation with Symplicity Flex Medtronic/Ardian|Renal denervation using CE-marked devices will be performed according to best medical practice.
223782064|NCT01888315|DEVICE|Renal denervation with EnligHTN St. Jude Medical|Renal denervation using CE-marked devices will be performed according to best medical practice.
223782065|NCT01888315|DEVICE|Renal denervation with Paradise Recor|Renal denervation using CE-marked devices will be performed according to best medical practice.
223782066|NCT01888315|DEVICE|Renal denervation with V2 Vessix|Renal denervation using CE-marked devices will be performed according to best medical practice.
223782067|NCT03876041|DRUG|solumedrol|intravenous solution for injection
223782068|NCT03876041|DRUG|Dexamethasone phosphate|intravenous solution for injection
223782069|NCT00693992|OTHER|Laboratory Biomarker Analysis|Correlative studies
223782070|NCT00693992|OTHER|Placebo|Given PO
223782071|NCT00693992|OTHER|Quality-of-Life Assessment|Ancillary studies
223782072|NCT00693992|DRUG|Sunitinib Malate|Given PO
223782073|NCT02614976|DEVICE|Padding|"Padding webrill (Covidian) TM 6"
223782074|NCT04634487|OTHER|No intervention|No intervention
223782075|NCT04199247|BEHAVIORAL|Sub symptom aerobic exercise|Participants will meet with a member of the research team to undergo a bike-based exercise test at the initial test. Heart rate will be obtained at the completion of the test, and intervention participants will be asked to complete exercise at 80% of that level, 5x/week for 20-30 minutes/session over the next two months.
223782076|NCT01637012|PROCEDURE|Implantation|index angioplasty with ALEX stent implatation
223782077|NCT02653521|RADIATION|Dose adaptation|Replanning the treatment to adapt the change of PTV and movement of OARs to achieve an optimal dose distribution using online CBCT images.
223782078|NCT05519839|DRUG|qNIV Vaccine with Matrix-M Adjuvant|Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV vaccine given on Day 0 and Day 70 .
223699663|NCT00674427|BIOLOGICAL|CD3/CD28 Activated T cells|Subjects in CR 6-12 weeks after the first dose of Activated Donor Lymphocyte Infusion (aDLI) will continue to receive aDLI every 3 months for up to a year.
223699664|NCT03530800|DRUG|Dronabinol|Dronabinol for 10 weeks (5mg per day first 2 weeks, 10mg per day second two weeks, 15mg per day last six weeks)
223699665|NCT03530800|DRUG|Placebo|Placebo for 10 weeks
223699666|NCT02963935|DRUG|liraglutide|Administered subcutaneously (s.c., under the skin) once daily for 56 weeks. Dose gradually increased to 3.0 mg
223699667|NCT02963935|DRUG|placebo|Administered subcutaneously (s.c., under the skin) once daily for 56 weeks. Dose gradually increased to 3.0 mg
223699668|NCT02963935|BEHAVIORAL|CMS Intensive Behavior Therapy|Intensive Behaviour Therapy for obesity
223699669|NCT02993718|DRUG|Dexmedetomidine|As a loading dose, 0.5 μg/kg dexmedetomidine was administered over 10 min, which was then administered continuously at a dose of 0.2-0.8 μg/kg/h. Sedation was maintained at modified observer's assessment of alertness/sedation scale 3
223699670|NCT02993718|DRUG|Propofol|Propofol was infused continuously via a target-controlled infusion device, and the effect-site concentration was maintained with a range of 0.5-2.0 μg/ml. Sedation was maintained at modified observer's assessment of alertness/sedation scale 3
223699671|NCT01296438|DRUG|Faster-acting insulin aspart|Single dose of 0.2 U/kg body weight faster-acting insulin aspart injected subcutaneously (under the skin) followed by single dose of 0.2 U/kg body weight insulin aspart injected subcutaneously (under the skin)
223699672|NCT01296438|DRUG|insulin aspart|Single dose of 0.2 U/kg body weight insulin aspart injected subcutaneously (under the skin) followed by single dose of 0.2 U/kg body weight faster-acting insulin aspart injected subcutaneously (under the skin)
223699673|NCT05661214|OTHER|Teaching|The intervention in this study is teaching. Researchers, will create a pressure injury teaching content and assess this effectiveness and also, intervention groups will use Clinical Decision Support System (CDSS) as a tool to plan nursing interventions.
223699674|NCT01223638|OTHER|Audiometry|Audiometry
223699675|NCT02273531|DRUG|Asasantin ER, new formulation|
223699676|NCT02273531|DRUG|Asasantin ER, present commercial formulation|
223699677|NCT04037046|BEHAVIORAL|Screening HCV attached onto CCR screening|Patients assigned to this strategy will receive an invitation letter for HCV screening with DBS and CCR screening with FOT at the primary care center to be performed by the general practitioner
223699678|NCT04037046|BEHAVIORAL|Screening HCV attached onto CCR screening by self-testing|Patients assigned to this strategy will receive an invitation letter for self-testing for HCV screening with DBS, and CCR screening with FOT
223699679|NCT04037046|BEHAVIORAL|Screening HCV at primary care center|DBS for HCV screening at primary care center
223699680|NCT00464269|OTHER|Placebo|"* Active Substance: Placebo~* Pharmaceutical Form: Film-coated tablet~* Concentration: 2.5 mg, 10 mg and 25 mg~* Route of Administration: Oral use"
223699681|NCT00464269|DRUG|Brivaracetam 2.5 mg|"* Active Substance: Brivaracetam~* Pharmaceutical Form: Film-coated tablet~* Concentration: 2.5 mg~* Route of Administration: Oral use"
223699682|NCT00464269|DRUG|Brivaracetam 10 mg|"* Active Substance: Brivaracetam~* Pharmaceutical Form: Film-coated tablet~* Concentration: 10 mg~* Route of Administration: Oral use"
223699683|NCT00464269|DRUG|Brivaracetam 25 mg|"* Active Substance: Brivaracetam~* Pharmaceutical Form: Film-coated tablet~* Concentration: 25 mg~* Route of Administration: Oral use"
223699684|NCT05806723|DRUG|Atorvastatin 40 Mg Oral Tablet|daily drug intake during six months
223699685|NCT04945031|OTHER|cannabis|This study is observational study, we recorded history of substance used, symptoms and medication in a medical chart.
223782079|NCT05519839|DRUG|Influenza Vaccine|Intramuscular (deltoid) injections of Comparator influenza vaccine given on Day 0 and Day 70 (if applicable).
223782080|NCT05519839|DRUG|CIC Vaccine with Matrix-M Adjuvant|Intramuscular (deltoid) injections of co-formulated mix of various doses and formulations of CIC Vaccine given on Day 0 and Day 70
223782081|NCT05519839|OTHER|Placebo Comparator|Intramuscular (deltoid) injection of placebo given on Day 70.
223699686|NCT05612698|BEHAVIORAL|Aerobic training|Supervised Aerobic Training intervention (AT): Perform 50 minutes/day, 3 days/week, totalling 150 min/week at moderate intensity, as recommended by WHO, in a range of 65-75% HRMax. Due to any form of aerobic exercise involving large muscle groups and causes sustained increases in HR is likely to be beneficial, the type of aerobic exercise will be agreed with each group of patients, varying from 4 to 8 people. There will be a choice of ex-ercises and participants will be able to choose a combination of up to 2 different exercises. The participants' choice of the type of activity to be performed is expected to encourage greater adherence. The range of exercises will be brisk walking or running, swimming, and/or aerobic dancing.
223699687|NCT05612698|BEHAVIORAL|Aerobic training plus resistance training|Supervised Aerobic Training plus Resistance Training intervention (AT+RT): Perform 50 minutes/day, 3 days/week, starting with 50% of 1-repetition maximum (1-RM) and follow a progression of increasing loads up to 75% of 1-RM for optimal gains in strength and insulin action. In each session, between 5 and 10 exercises will be worked on, per-forming 10-15 repetitions, and progressing to 8-10 lifting as the weight increases, involving the major muscle groups from the core, lower body and upper body. In all sessions there will be a 3-minute warm-up at the beginning of the session and a 2-minute cool-down at the end of the session.
223699688|NCT05612698|BEHAVIORAL|High intensive interval training|Supervised High Intensive Interval Training intervention (HIIT): To be considered high intensive the heart rate needs to be above ≥85%. Perform 25 minutes/day, 3 days/week, totalling 75 min/week at a vigorous intensity, as recommended by WHO. Starting with 4 intervals lasting 1 minute keeping in a range of 85-90% HRMax, separated by 1 minute of low intensity activity (no static) (4 × 1 min intervals.) A progression will be followed by increasing the number of circuits, up to 10 (10 × 1 min intervals) \[25, 78, 79\]. In all sessions there will be a 3-minute warm-up at the beginning of the session and a 2-minute cool-down at the end of the session. Although the target popula-tion is a sedentary population, we expect the HIIT approach, despite being high intensity, to be well received, due to its growing popularity, as demonstrated by a study in which 62% of inactive participants preferred HIIT to other types of exercise.
223699689|NCT05213000|BEHAVIORAL|Exercise|90 minute exercise session
223699690|NCT04894292|OTHER|Non intervention|During the study there is no extra intervention planned for the participants.
223699691|NCT04441671|DRUG|Disodium Pyrophosphate|Absorption trial
223699692|NCT04196751|OTHER|Clinical Supervision|After baseline data collection, participants will be invited to attend training on clinical supervision (CS). Education will be delivered in 3 phases. 1-Orientation to the CS model 2-Integration of theory into practice and 3-Skill advancement for supervisors. After training, participants will be encouraged to choose a supervisor, identify objectives for skill development. They will be advised to meet their supervisor once a month for 60 minutes (Due to COVID 19 pandemic the participants can have either one-to-one session in-person or virtually (Microsoft Team), however, if the supervisor and the supervisee working in the same campus can have their one-to-one session as per their preferences. Supervisor-supervisee will be working together to achieve the stated goals. Only the recorded attendance and nature of the session will be used for research purpose. Data will be collected at baseline, 6\&12 month with pre-specified tools.
223699693|NCT00005602|DRUG|carboplatin|
223699694|NCT00005602|DRUG|cereport|
223699695|NCT00005602|RADIATION|radiation therapy|
223699696|NCT05055128|DRUG|X842|Patients will receive X842 tablets.
223699697|NCT05055128|DRUG|X842 Dummy|Patients will receive matching placebo tablets for X842.
223699698|NCT05055128|DRUG|Lansoprazole|Patients will receive Lansoprazole capsule.
223699699|NCT05055128|DRUG|Lansoprazole Dummy|Patients will receive matching placebo capsules for Lansoprazole.
223699700|NCT06235333|BEHAVIORAL|Gambling Disorder Screening Day screener|See descriptions
223699701|NCT06235333|BEHAVIORAL|Gambling Disorder Screening Day information sheet|See descriptions
223699702|NCT04161027|DRUG|Pregabalin 75mg|Pregabalin 75 mg capsule
223699703|NCT04161027|DRUG|Placebos|Placebo capsule
223699704|NCT02942875|OTHER|mirror therapy|"During MT, subjects will sit in front of a table on which a mirror will be placed vertically in the space ipsilateral to the paretic upper limb with its reflective surface facing the unaffected upper limb. The subjects are required to look at the mirror to observe the reflective image of the unaffected arm from shoulder to the hand, while it is performing certain designated movements. At the same time, the affected arm will be required to follow the unaffected arm to practice the same movements.~The upper limbs movements during the 30-min MT session are open and close of grasp; wrist flexion and extension; forearm supination and pronation; elbow flexion and extension; shoulder flexion and extension. A total of 120 repetitions for each action will be practiced."
223699705|NCT02942875|OTHER|control therapy|Control group subjects undergo the same bilateral upper limbs exercise protocol without mirror
223699706|NCT03521427|OTHER|Intensive bimanual therapy|Ninety hours of intensive bimanual therapy
223699707|NCT03521427|OTHER|Intensive neurodevelopmental therapy|Ninety hours of intensive neurodevelopmental therapy
223699708|NCT04650776|OTHER|Heat strain|The experimental procedure comprised 15 min baseline seated rest (23.2 ± 0.3°C, 24.5 ± 1.6% relative humidity), followed by 15 min seated rest and cycling in a climatic chamber (35.4 ± 0.2◦C, 56.5 ± 3.9% relative humidity; to +1.5◦C or maximally 38.5°C rectal temperature, duration 20-60 min), with a final 30 min seated rest outside the chamber.
223782082|NCT05519839|DRUG|SARS-CoV-2 rS Vaccine with Matrix-M Adjuvant|Intramuscular (deltoid) injections of in-clinic mix of various doses of SARS-CoV-2 rS vaccine given on Day 0 and Day 70 .
223699709|NCT00085904|DRUG|SB-485232|
223782083|NCT01713218|DRUG|gemcitabine|Administrated intravenously at a dose of 1000 mg/m2 over 30 minutes weekly, week 1 to 4
223782084|NCT01713218|DRUG|Vismodegib|150 mg capsule, oral, once daily
223782085|NCT01713218|PROCEDURE|Neoadjuvant chemotherapy|Combination of gemcitabine and Vismodegib during a window interval (4 weeks) before surgery
223782086|NCT01176539|DEVICE|Non-Contact Respiratory Rate Monitor|"The Non-Contact Respiratory Rate Monitor provides a measurement of respiratory rate at a single point in time for neonates, pediatrics and adults.~The Non-Contact Respiratory Rate Monitor provides a continuous monitor, measurement, and display of the respiratory rate, respiratory patterns, depth of breath, history/events and respiratory activity of a subject for neonates, pediatrics, and adults."
223782087|NCT05152979|BEHAVIORAL|Verb Network Strengthening Treatment (VNeST)|Participants are presented with a verb (representing an activity, for example, driving) orally and in writing. The participants are first asked to name someone who may perform the given activity (an agent, for example, a chauffeur), then to name an object which the given activity may be performed with (a patient, for example, a limousine). Several types of semantic clues and assistance are provided if the participant is having difficulties finding adequate nouns. This procedure is repeated for three different agents and objects related to the given verb. The participants are then asked to choose one of the three phrases participants have created and expand on it by telling where, when and why the agent is performing the activity. After this the participant are given sentences (with several foils) including the activity as well as agents and patients, and are asked to indicate whether the sentences are correct or not.
223782088|NCT00353704|DRUG|pregabalin|capsule 150 mg x 1 per orally one hour before surgery
223782089|NCT00353704|DRUG|Placebo|One capsule of saccharose (placebo) was administered about one hour before surgery
223782090|NCT00353704|DRUG|morphine|All patients were equipped with a PCA (patient controlled analgesia) for 24 hours after surgery. The sum of morphine used was registered (milligram).
223782091|NCT01277965|OTHER|50%VO2maxTBR50|The basal rate of the pump will be adjusted in accordance with the intensity of physical activity being performed for moderate physical activity (50% VO2max),a temporary basal rate will be reduced by 50%
223782092|NCT01277965|OTHER|50%VO2max TBR80|The basal rate of the pump will be adjusted in accordance with the intensity of physical activity being performed for moderate physical activity (50% VO2max),a temporary basal rate will be reduced by 80%
223782093|NCT01277965|OTHER|75%VO2max TBR80|The basal rate of the pump will be adjusted in accordance with the intensity of physical activity being performed for moderate physical activity (75% VO2max),a temporary basal rate will be reduced by 80%
223782094|NCT01277965|OTHER|75%VO2max TBR100|Turning off the pump (75%VO2max TBR100).However, in order to maintain the study blindfold, the pump will be switched off but not removed
223782095|NCT01277965|OTHER|Rest|Patient will be in rest, basal insulin flow rate will not be change
223699710|NCT06345131|OTHER|Non invasive blood pressure monitoring|Non invasive blood pressure monitoring
223699711|NCT05073978|OTHER|No intervention|This is an observational study without any intervention
223782096|NCT03155750|OTHER|Zero Time Exercise|Zero Time Exercise encourage people to increase physical exercise by simple movements that can be done any time at any places. We offer a 2-session training course to train the subjects to do zero-time exercise.
223782097|NCT03155750|OTHER|Sleep hygiene education|We offer a 2-session education course to teach the subjects about sleep hygiene practice.
223782098|NCT03116919|OTHER|Potato|Participants will be given an extra serving of potato a day
223782099|NCT03116919|OTHER|Non-starchy vegetable|Participants will be given an extra serving of a non-starchy vegetable
223782100|NCT02042482|DIETARY_SUPPLEMENT|Coenzyme Q10U, L-carnitine|
223782101|NCT02052349|DRUG|ABT-333|Dose of ABT-333
223782102|NCT05197959|DEVICE|Repetitive transcranial magnetic stimulation|Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive, non-painful procedure used to relieve chronic pain and promote short-term changes. The abductor pollicis brevis (APB) muscle of the left motor cortex will be targeted using neuronavigation software. 2000 pulses will be delivered at 10 Hz stimulation. Stimulation will be delivered at 80% of the resting motor threshold obtained from the right APB muscle. The delivery of rTMS requires \~ 11.5 minutes in total.
223782103|NCT05197959|OTHER|Sensorimotor training|Sensorimotor training is a non-invasive, non-painful procedure using nerve stimulation to cue motor action. Nerve stimulation is applied the second through the fifth digit and the median nerve at the wrist. This stimulation is used to cue a motor action. The number of stimulations will indicate the amount of movements. For example, two pulses of stimulations to the index finger would require two flexion and extension actions with the index finger. Once the stimulation occurs, the participant will flex and extend the corresponding area where the nerve stimulation was felt. This will take \~ 30 minutes to complete.
223782104|NCT06046313|DRUG|Decitabine for Injection|6mg/m2, ivgtt qd d1-10
223782105|NCT06046313|DRUG|VENCLYXTO|100mg p.o.d1, 200mg p.o.d2, 400mg p.o.d3-21,adjust by blood concentration
223782106|NCT02473614|DEVICE|Music Glove|Participants will exercise at home using the music glove for 3 times a week for 3 weeks with a minimum of 3 hours per week.
223782107|NCT02473614|OTHER|Conventional Hand Exercise Program|Participants will exercise at home using the hand exercise program designed by an occupational therapist for 3 times a week for 3 weeks with a minimum of 3 hours per week.
223782108|NCT04696068|OTHER|Porcelain plates|The patients will receive the same food in another presentation : porcelain plates instead of plastic trays
223782109|NCT06358482|BEHAVIORAL|oscillating toothbrush|oscillating toothbrush
223782110|NCT06358482|BEHAVIORAL|standard manual toothbrush|standard manual toothbrush
223782111|NCT05263531|DEVICE|remote ischemic conditioning|RIC is a physical strategy performed by an electric autocontrol device with cuffs placed on bilateral arms and inflated to design pressure for 5-min followed by deflation for 5-min, the procedures is performed repeatedly for 5 times.
223782112|NCT01473654|BEHAVIORAL|ADAPT tool|Use of ADAPT shared goal setting tool in EMR
223782113|NCT01154166|DRUG|ReQuip PR|If subjects are still eligible at the end of the placebo run-in period they will be randomized (1:1) to receive once daily doses of ropinirole PR or identical appearing placebo tablets. Dosing will start at 2 mg ropinirole PR, or placebo equivalent. During the 24 week treatment phase, the subjects dose will be adjusted according to the recommended schedule to achieve symptomatic control. All subjects must be titrated to a minimum dose of 6 mg/day.
223782114|NCT01154166|DRUG|Placebo|Placebo
223782115|NCT05440526|PROCEDURE|Herbst Group|"Herbst Group:~1. Two mini plates are chosen, the last hole in every plate is used to solder the ball housing of type IV Herbst appliance.~2. The two mini plates are placed bilateral at the mandibular symphysis and fixed by at least 3 screws, the surgical wound is sutured.~3. The surgical wound is left for 2 weeks for proper soft tissue healing, in the meantime separation in the arch, band placement on the first premolar and molar bilateral followed by impression for construction of the upper Herbst splint."
223782116|NCT05440526|DEVICE|TFBC Group|"TFBC Group:~1. The patients will be treated by fixed orthodontic appliance with using series of orthodontic NiTi arch wires for levelling and alignment.~2. Installation of series of orthodontic stainless steel arch wires until 0.0019 x 0.0025 inch for both arches.~3. Installation of the Twin Force Bite Corrector appliance for 4 to 6 months.~4. Using of class ΙΙ intra-oral elastics for both sides for 2 to 3 months."
223782117|NCT05360979|DRUG|envafolimab|Envafolimab: 300 mg, D1, Q3W, subcutaneously administered
223782118|NCT00954369|DRUG|[F-18]W372|"The individual doses of \[F-18\]W372 contain a maximum of 20 mCi for normal volunteers and 10 mCi for high probability AD subjects.~The single IP dose is administered to the study subject immediately prior to the start of PET imaging."
223782119|NCT04074642|PROCEDURE|Neurosurgery|adenoma removal
223782120|NCT00446316|DRUG|Antacids (Mg-Al-based)|the antacid (Maximum Strength Maalox®Max® Antacid/Anti-gas) at a dose level of 20 mL (equivalent to 1600 mg aluminum hydroxide and 1600 mg magnesium hydroxide).
223782121|NCT00446316|DRUG|Imatimib Mesylate (Gleevec®)|Gleevec® will be administered at a dose of 400 mg. Half of the subjects will receive Gleevec® and antacid on day 15 and Gleevec® alone on day 1. The other half will be treated in reverse order, i.e., they will receive the combination of Gleevec® and antacid on day 1, and Gleevec® alone on day 15. The antacids will be administered 15 minutes before the Gleevec® dose.
223782122|NCT04020770|OTHER|Vibrating ball|Parameters: 5 30-sec bouts of 68Hz vibration followed by a 1-minute rest.
223782123|NCT00534196|RADIATION|Permanent iodine-125 (Brachytherapy)|Observational research was conducted by grouping Brachytherapy with/without PI (permanent iodine) seed implantation.
223782124|NCT06529679|BEHAVIORAL|Split-belt Training|Walking on a split-belt treadmill in which the speed of one belt will be different (move faster or slower) than the speed of the other belt.
223782125|NCT06529679|BEHAVIORAL|Tied-Belt Training|Walking on a split-belt treadmill in which the speed of both belts is the same.
223782126|NCT01309620|DIETARY_SUPPLEMENT|Zinc gluconate|Zinc gluconate (GNC, USA), 100 mg twice daily
223782127|NCT01309620|DIETARY_SUPPLEMENT|Placebo|Placebo, Twice Daily
223782128|NCT02327026|PROCEDURE|bag-valve-mask ventilation|Airway management including initial bag-valve-mask ventilation by the medical team during OHCA. When standard bag-valve-mask ventilation is possible, the patient will be intubated in case of a return of spontaneous circulation. When standard bag-valve-mask ventilation is impossible or in case of massive regurgitation of gastric content (after randomisation), intubation of patient is the preferred alternative.
223782129|NCT02327026|PROCEDURE|tracheal intubation|Tracheal intubation during OHCA by the medical team: The standard intubation procedure is to use a non-styletted tube and no sedation. When standard laryngoscopy-assisted intubation is not possible, an alternate procedure will be used based on the French consensus conference guidelines on difficult airway management
223782130|NCT05873114|DIAGNOSTIC_TEST|Mobilization|Effects of Mobilization in Management of Post-partum Backache in Females With Normal Vaginal Delivery (NVD) and Cesarean Section Delivery
223782131|NCT05873114|DIAGNOSTIC_TEST|Muscle Energy Technique (MET)|Effects of Muscle Energy Technique (MET) in Management of Post-partum Backache in Females With Normal Vaginal Delivery (NVD) and Cesarean Section Delivery
223782132|NCT01375049|DRUG|Aztreonam for Inhalation Solution (AZLI)|AZLI 75 mg administered 3 times daily via the investigational eFlow® nebulizer
223782133|NCT04192994|DRUG|Intravitreal Antibiotic Injection|Intravitreal Antibiotic Injection
223782134|NCT04192994|PROCEDURE|Pars Plana Vitrectomy|Pars Plana Vitrectomy
223782135|NCT02066857|DEVICE|Cast made of generic plaster or fiberglass cast material|Patients will randomly receive a generic plaster or fiberglass cast for treatment of non-displaced distal radius fracture.
223782136|NCT02066857|DEVICE|"Generic off the shelf removable splint"|"Patients will be randomized to receive a generic off the shelf removable splint for treatment of a non-displaced distal radius fracture."
223782137|NCT04121962|BEHAVIORAL|Peer Mentor|Participants will be trained to be Peer Mentors and promote home-based testing to their social network
223782138|NCT04121962|BEHAVIORAL|Website only|Participants will be given instructions on how to use the project website to request kits to test for HIV at home and collect specimens for lab testing.
223782139|NCT00130767|DRUG|finasteride|
223782140|NCT04840758|RADIATION|Stereotactic Ablation Radiotherapy|Stereotactic ablation radiotherapy was performed sequentially on the primary and secondary lesions. 50Gy/4F or 70Gy/10F were used according to the specific location of the tumor。
223782141|NCT04840758|DRUG|Sintilimab|Sintilimab was started 2 weeks after the end of radiotherapy. Sintilimab : 200 mg intravenously, Q3W every cycle , given on the D1 of each cycle, and total of 4 cycles
223782142|NCT01175382|BEHAVIORAL|Behavioral training|Behavioral treatment consists of skills and strategies for postponing urination, controlling urgency and preventing urge incontinence. This includes pelvic floor muscle training, urge suppression techniques, delayed voiding, and daily bladder diaries to track increasing voiding intervals and enhance awareness of bladder habits. Training is supplemented with instructions for daily home practice between clinic visits. In addition to daytime training, nocturia is managed with fluid restriction (3 hours before bedtime and during the night) and with urge strategies.
223782143|NCT01175382|DRUG|Tolterodine + tamsulosin|Patients in drug therapy receive an anti-muscarinic (long acting tolterodine 4 mg daily) and an alpha blocker (tamsulosin 0.4 mg daily).
223782144|NCT01175382|OTHER|Combined Behavioral + Drug Therapy|Combined behavioral and drug therapy implemented in 4 clinic visits over a period of 6 weeks, followed by an additional 6 weeks of combined therapy. Behavioral treatment consists of behavioral training and includes skills and strategies for postponing urination, controlling urgency and preventing urge incontinence. This includes pelvic floor muscle training, incremental delayed voiding, and bladder diaries, supplemented with instructions for daily home practice. Nocturia is managed with fluid restriction (3 hours before bedtime and during the night) and with urge strategies. Drug therapy consists of an anti-muscarinic (sustained release tolterodine 4 mg) + an alpha blocker (tamsulosin 0.4mg daily).
223782145|NCT04016168|BIOLOGICAL|Blood sample collection|Three additional blood tubes (3 x 8mL) will be collected for this study. They will be added to the traditional diagnostic assessment carried out for their IPF, during their consultation at the competence centre for rare lung diseases. These samples will be taken by a registered nurse in the presence and under the responsibility of the investigator.
223782146|NCT03616418|DRUG|antiplatelet drugs;statins;antihypertensive drugs|
223782147|NCT02481687|OTHER|Confocal laser endomicroscopy|Probe based confocal laser endomicroscopy is a contrast based technique, consisting of a flexible catheter probe representing a bundle of optical fibers linked to a micro-objective a laser scanning unit and the control and acquisition software. The flexible confocal miniprobes can be passed through the working channels of standard endoscopes. The principle of the technique is based on a laser beam of defined wavelength being focused towards the targeted tissue and the recaptured signal is displayed as 'optical biopsies' in a single horizontal plane. The device was intended to be used for faster diagnosis and evaluation of gut diseases, by allowin in vivo histology.
223782148|NCT02869217|DRUG|Cyclophosphamide|
223782149|NCT02869217|BIOLOGICAL|TBI-1301|
223699712|NCT05027672|DRUG|Gam-COVID-Vac (rAd26) / Gam-COVID-Vac (rAd5)|A comparison of antibody levels against protein S will be performed using the Gam-COVID-Vac / Gam-COVID-Vac group as a control group and all other interventions as comparators.Comparisons will be made by contrasting the geometric means of antibody levels between each of the study arms. In addition, comparisons will be made as to whether or not the median antibody values of the alternative treatment groups are lower than: a) the 25th percentile of the median antibody value of the Gam COVID combination and b) whether the lower limit of the confidence interval of the differences in the GMC rate is lower than the conventional cut-off point of non-inferiority set at 0.67.
223782150|NCT02869217|DRUG|Fludarabine|
223782151|NCT05403047|DRUG|Fumarate, Tenofovir Disoproxil|all participants receive the intervention
223782152|NCT00774787|DRUG|imiquimod 5% cream|1 packet (250 mg cream) 3 times per week for 4 weeks
223699713|NCT05657431|OTHER|essential oils (Ylang ylang oil)|inhaler aromatherapy
223699714|NCT05657431|OTHER|placebo (saline solutions)|placebo saline solutions
223699715|NCT05657431|OTHER|essential oils (lemon oil)|inhaler aromatherapy
223699716|NCT02149875|DRUG|Dl-3-n-butylphthalide|Intravenous infusion of 100 ml dl-3-n-butylphthalide and sodium chloride injection for 10 days, twice daily.
223699717|NCT02149875|DRUG|Cerebrolysin|Intravenous infusion of 30 ml Cerebrolysin per day in 100 ml normal saline for 10 days.
223699718|NCT02149875|DRUG|Placebo|100 ml saline intravenous infusion once daily for 10 days.
223782153|NCT05980312|OTHER|Splint Immobilization|Patients will be randomized to receive a splint following their surgical procedure.
223782154|NCT05980312|OTHER|Early Motion|Patients will be randomized to receive no splint following their surgical procedure.
223782155|NCT00335244|DRUG|L-citrulline|150mg bolus X 1 after initiation of cardiopulmonary bypass followed by continuous infusion of 9mg/kg/hr IV, starting 4 hours post bolus administration and ending at 48 hours continuous infusion or discharge from the PCCU
223782156|NCT00335244|DRUG|Placebo of intravenous L-citrulline|Placebo of intravenous L-citrulline
223782157|NCT03905759|DRUG|Dronedarone|Dronedarone (200 mg twice daily starting from day before operation till 5 days after)
223782158|NCT03905759|DRUG|Amiodarone|Group A:-amiodarone (200 mg three times per day)21 administered 6 days prior to surgery through 6 days after surgery
223782159|NCT03905759|DRUG|Colchicine|Colchicine will be used at the dose of 1 mg orally, twice daily, preoperatively (1 days), and of 0.5 mg, twice daily, until hospital discharge
223782160|NCT02403310|DRUG|Selinexor|"Induction: Oral selinexor on days 1, 3, 8, 10, 15 and 17.~* Dose Level 2: 80 mg twice weekly.~* Dose Level 1 (starting dose): 60 mg twice weekly.~* Dose Level -1: 40 mg twice weekly.~Consolidation: Selinexor same dose as induction (days 1,3,8,10) unless dose limiting toxicity (DLT) dictates a dose reduction.~Maintenance: Selinexor at the same dose as induction on days 1 and 8 a 21 day cycle. They will continue for a maximum of 12 months."
223782161|NCT02403310|DRUG|Daunorubicin|"Induction: Daunorubicin 60 mg/m\^2/day (days 1-3).~Consolidation: Daunorubicin 45 mg/m\^2/day (days 1-2)."
223699719|NCT01385371|BIOLOGICAL|Grass (Phleum pratense) pollen allergen extract|One dissolving tablet sublingually once daily
223699720|NCT01385371|BIOLOGICAL|Placebo for SCH 697243|One dissolving tablet sublingually once daily
223699721|NCT02478372|DRUG|Patient Controlled Epidural (PCEA)|Following the operation, 4ml of 0.25% levobupivacaine was administered and the catheter was connected to a PCEA. Self-medication with a bolus 2ml of 0.125% bupivacaine via the PCEA system with a lockout time of 15 minutes until the following morning (post-operative day one) when it was stopped.
223699722|NCT02478372|DRUG|Local Infiltration Analgesia (LIA)|Subcutaneous infiltration during surgery using 200ml of 0.2% plain ropivacaine.
223782162|NCT02403310|DRUG|Cytarabine|"Induction: Cytarabine 100 mg/m\^2/day (days 1-7).~Consolidation: Cytarabine 100 mg/m\^2/day (continuous infusion on days 1-5)."
223782163|NCT01170780|DRUG|Dexamethasone|single use of dexamethasone IV 8 mg/2 ml
223782164|NCT01170780|DRUG|Saline|2 ml IV
223782165|NCT03663413|DEVICE|non-invasive monitor|cutaneous EEG monitor
223782166|NCT02270580|BEHAVIORAL|PN+|"we will evaluate the efficacy of a culturally tailored PN program (PN+) on improving quality of life (QoL), screening practices and treatment follow-up compliance among breast HL survivors"
223782167|NCT02270580|BEHAVIORAL|PN usual|participants will receive information brochures on breast cancer survivorship and have a minimum of 1 contact with the patient navigator
223782168|NCT02019719|DRUG|GSK1278863|GSK1278863 will be supplied as film coated tablets for oral administration containing 1 mg, 2 mg, or 5 mg of GSK1278863.
223782169|NCT02019719|DRUG|Placebo|Film coated tablets of GSK1278863 matching placebo for oral administration.
223699723|NCT03503136|DRUG|docetaxel, nedaplatin, and capecitabine|Patients receive docetaxel(60 mg/m2 on day 1), nedaplatin (60 mg/m2 on day 1) and capecitabine (625 mg/m2 bid, on Days 1 to 14) every three weeks for three cycles before the radiotherapy.
223699724|NCT03503136|DRUG|nedaplatin|Patients receive concurrent nedaplatin (100mg/m2) every three weeks for two cycles during radiotherapy.
223782170|NCT01271881|OTHER|PTA alone without use of the GORE VIABAHN|PTA alone with no stent used
223782171|NCT01271881|DEVICE|GORE VIABAHN® Endoprosthesis with Heparin Bioactive Surface|Covered stent produced by GORE VIABAHN
223782172|NCT00865527|OTHER|Fecal occult blood test|FOBT
223782173|NCT00865527|PROCEDURE|Virtual colonoscopy|computed tomographic colonography
223782174|NCT00865527|PROCEDURE|Optical colonoscopy|optical (conventional / endoscopic) colonoscopy
223699725|NCT03503136|DRUG|docetaxel, cisplatin, and fluorouracil|Patients receive docetaxel (60mg/m2 on day 1), cisplatin (60mg/m2 on day 1) and fluorouracil (600mg/m2 on Days 1 to 5) every three weeks for three cycles before the radiotherapy.
223699726|NCT03503136|DRUG|cisplatin|Patients receive concurrent cisplatin (100mg/m2) every three weeks for two cycles during radiotherapy.
223699727|NCT03503136|DRUG|docetaxel, cisplatin, and capecitabine|Patients receive docetaxel(60 mg/m2 on day 1), cisplatin (60 mg/m2 on day 1) and capecitabine (625 mg/m2 bid, on Days 1 to 14) every three weeks for three cycles before the radiotherapy.
223699728|NCT03503136|DRUG|docetaxel, nedaplatin, and fluorouracil|Patients receive docetaxel (60mg/m2 on day 1), nedaplatin (60mg/m2 on day 1) and fluorouracil (600mg/m2 on Days 1 to 5) every three weeks for three cycles before the radiotherapy.
223699729|NCT02643290|DEVICE|Peak Scoliosis Bracing System|Brace is fit to adult scoliosis patients for 2-4 hours a day and tracked for six months.
223699730|NCT04968795|OTHER|Heartfulness Meditation|A four-week Heartfulness Wellness seminar, where people are exposed to Heartfulness Meditation and its meditation tools. Participants experience: Heartfulness Guided Relaxation, Heartfulness Meditation and Heartfulness Unwinding/Rejuvenation Technique.
223699731|NCT04627337|DRUG|Saccharomyces Boulardii 250 MG|Probiotic yeast in capsules
223699732|NCT04627337|BEHAVIORAL|Dietary advice following a low fermentation diet|Medical advice was delivered to patients to follow a low fermentation diet. A list of food and beverages to avoid was delivered along with specified instructions provided by a health professional
223699733|NCT04281641|DIAGNOSTIC_TEST|TCHP|"Drug: Trastuzumab 8 mg/kg loading dose, then 6 mg/kg every 3 weeks, IV Other Name: Herceptin~Drug: Pertuzumab 840 mg as a loading dose, then 420 mg every 3 weeks, IV Other Name: Perjeta~Drug: carboplatin at target area under the plasma concentration-time curve (AUC) 6~Drug: docetaxel at a starting dose of 75 mg/m2 then to 60mg/m2 (q3w).~All study drugs were administered intravenously.~Procedure: 18-FDG-PET and 68 Ga-Affibody HER-2 Imaging PET will be performed at baseline, on day 15 and before surgery~Genomic alterations (mutations/somatic rearrangements) are detected at baseline, on day 15 and before surgery."
223699734|NCT04352946|DRUG|Hydroxychloroquine Pre-Exposure Prophylaxis|HCQ PreP 400mg daily
223699735|NCT04352946|DRUG|Placebo oral tablet|Placebo tablets 400mg daily
223782175|NCT02203019|DRUG|Propofol|Propofol will be administered for sedation in mechanically ventilated patients with sepsis.
223782176|NCT02203019|DRUG|Dexmedetomidine|Dexmedetomidine will be administered for sedation in mechanically ventilated patients with sepsis.
223782177|NCT02203019|DRUG|Fentanyl|"Fentanyl will be administered for analgesia in mechanically ventilated patients with sepsis. The use of Fentanyl is not an intervention of interest."
223782178|NCT02588040|BIOLOGICAL|Leukocyte- and Platelet-Rich Plasma (L-PRP)|The Recover L-PRP Mini Platelet Separation Kit aids in the separation of the patient's own blood components by density through the use of a Biomet Biologics centrifuge.
223782179|NCT04400552|DIETARY_SUPPLEMENT|ONS Pre-op + ONS Post-op|Participants will consume the oral nutrition supplementation (ONS) in addition to normal diet for 14 days pre-operatively and post-operatively up to participants being discharged from the hospital.
223699736|NCT01529684|DRUG|radio-labeled OSI-906|Part A: oral solution of 14C-OSI-906
223699737|NCT01529684|DRUG|OSI-906|Part B: oral tablets OSI-906
223782180|NCT04400552|DIETARY_SUPPLEMENT|ONS Pre-op + ONS Post-op + ONS Post-op 3 months|Participants will consume the oral nutrition supplementation (ONS) in addition to normal diet for 14 days pre-operatively, post-operatively up to participants being discharged from the hospital and an extended oral nutrition supplementation post-operatively up to 3 months.
223699738|NCT04234451|PROCEDURE|SPA acupuncture|"For patients in the AA group, acupuncture was performed at a selected point in the SPG by inserting the needle from the lower border of the zygomatic arch, posterior to the suture protuberance between the zygomatic process and temporal process. The needle was directed obliquely anteriorly, until nearly the whole needle was beneath the skin, and then rotated until the patient felt de-qi sensations . The patients in the AA group received four courses of active acupuncture(visit 1,2,3 and 4), twice a week during weeks 1 and 2, and then followed-up for a further 2 weeks (visit 5 during week 3 and visit 6 during week 4)."
223699739|NCT04234451|PROCEDURE|sham acupuncture|For patients in the SA group, the needle was inserted at the same acupuncture point as for patients in the AA group, but to a depth of only 2-3cm and the procedure of rotating, twirling and thrusting the needle was repeated. During the acupuncture process, the acupuncturist sat on the side of the participant, where the patient could neither see the acupuncturist's face nor the length of the needle. The patients in the SA group received four courses of active acupuncture(visit 1,2,3 and 4), twice a week during weeks 1 and 2, and then followed-up for a further 2 weeks (visit 5 during week 3 and visit 6 during week 4).
223699740|NCT01469624|DRUG|Pentoxifylline|pentoxifylline 400 mg PO three times a day for 24 hours before and 24 hours after PCI
223699741|NCT02164773|DRUG|Magnesium Sulfate|use of 50mg magnesium sulfate in caudal analgesia added to 1ml/kg of 0.25% of bupivacaine in children undergoing lower abdominal surgery for prevention of postoperative emergence agitation.
223699742|NCT02164773|DRUG|0.9%normal saline|use of 1ml of 0.9%normal saline added to 1ml/kg of 0.25% of bupivacaine in the caudal block as placebo to compare with active comparator.
223699743|NCT03029273|DRUG|Cyclophosphamide and Fludarabine|Seven days prior to infusion of TCR-T cell, subjects receive cytoreductive chemotherapy with cyclophosphamide (250-500mg/m2/day) plus fludarabine (25mg/m2/day) for 3 days.
223699744|NCT03029273|BIOLOGICAL|Anti-NY-ESO-1 TCR transduced T cells|A single dose of Anti-NY-ESO-1 TCR transduced T cells (about 5×109) will be intravenously (i.v.) administered Additionally, following infusion of Anti-NY-ESO-1 TCR transduced T cells, IL-2 subcutaneous injections (500,000 IU/day) will be administered for 14 days concomitantly to each subject.
223699745|NCT02315573|PROCEDURE|Wrist block anesthesia|The carpal tunnel release surgery will be performed under wrist block anesthesia. Group 1 will have the wrist block performed with Lidocaine and epinephrine, while Group 2 with Bupivacaine and epinephrine.
223699746|NCT05840718|DRUG|Thiamin|Patients in thiamine group received two daily dosis of 200 mg of thiamin diluted in 50 ml of 5% dextrose during 7 days
223699747|NCT00732797|BEHAVIORAL|Self-treatment booklet|A booklet outlining vestibular rehabilitation exercises
223699748|NCT00732797|BEHAVIORAL|Remote telephone support|Up to an hour's remote support from an expert vestibular therapist
223699749|NCT04737928|DRUG|Latanoprost|latanoprost 0.05%(one drop, once daily)
223699750|NCT04737928|DRUG|tafluprost|tafluprost 0.015% (one drop, once daily)
223782181|NCT04400552|DIETARY_SUPPLEMENT|Usual intake Pre-op + ONS Post-op|Participants will follow a meal plan of 2000 kcal / day using conventional foods for 14 days pre-operatively and consume oral nutrition supplementation (ONS) in addition to normal diet post-operatively up to participants being discharged from the hospital
223699751|NCT04515446|DIAGNOSTIC_TEST|Rapid test for diagnosis orientation|Rapid tests screen for influenza viruses in less than 30 minutes. They detect internal viral nucleoproteins by immunochromatography using specific antibodies attached to one or more strips.
223699752|NCT04515446|DIAGNOSTIC_TEST|quantitative PCR|Molecular biology method of gene amplification in vitro. It allows a large number of known DNA or RNA sequences to be duplicated
223699753|NCT00239395|DRUG|Meloxicam ampoule|
223699754|NCT00239395|DRUG|Meloxicam tablet|
223699755|NCT00449527|DRUG|Budesonide/formoterol pMDI|
223699756|NCT00449527|DRUG|Budesonide HFA pMDI|
223699757|NCT00619593|OTHER|Intensified diagnostic and treatment measures following 1st appropriate ICD therapy|"* Assessment of general health status (weight, BP, NYHA)~* Laboratory tests (hemoglobin, Nt-proBNP, creatinine, GDF-15)~* Echocardiography (LVEF, LVEDD, mitral regurgitation)~* Non-invasive ischemia evaluation~* Coronary angiography (if indicated by ischemia evaluation)~* Upgrade to CRT, if indicated~* Ventricular ablation (if indicated: VT storm, slow VT, bundle branch reentry)~* 24 hrs ECG Holter (Heart rate variability)~* Further treatment (if applicable)~* Changes in ICD settings, or medication"
223699758|NCT00619593|OTHER|Standard follow-up|Standard follow-up in patients without appropriate ICD therapy
223699759|NCT02955797|BIOLOGICAL|Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine|0.5 milliliter (mL), Intramuscular
223699760|NCT02955797|BIOLOGICAL|Meningococcal polysaccharide groups A, C, W-135 and Y Conjugate vaccine|0.5 mL, Intramuscular
223699761|NCT02955797|BIOLOGICAL|Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine|0.5 mL, Intramuscular
223699762|NCT02955797|BIOLOGICAL|Meningococcal polysaccharide groups A, C, W-135 and Y Conjugate vaccine|0.5 mL, Intramuscular
223699763|NCT02577562|DEVICE|Zenith® Fenestrated AAA Endovascular Graft|The Zenith® Fenestrated AAA Endovascular Graft with the H\&L-B One-Shot™ Introduction System is indicated for the endovascular treatment of patients with abdominal aortic or aortoiliac aneurysms having morphology suitable for endovascular repair
223699764|NCT02730689|DRUG|DP-R207|
223699765|NCT02730689|DRUG|Rosuvastatin|
223699766|NCT02730689|DRUG|Ezetimibe|
223699767|NCT01825070|DIETARY_SUPPLEMENT|Montmorency cherry concentrate|Tart Montmorency cherry juice concentrate
223699768|NCT00412997|DRUG|LBH589|
223699769|NCT05665023|DRUG|Bevacizumab + modified FOLFIRINOX|Bevacizumab 5mg/kg D1, oxaliplatin 85 mg/m2 D1 + leucovorin 400mg/m2 D1 + irinotecan 150 mg/m2 D1 + 5-FU 2,400 mg/m2 46h continuous infusion, every other week
223782182|NCT06419127|DIAGNOSTIC_TEST|Timelapse incubation and PGT|Patients will have their embryos cultured in a timelapse incubator and their PGT results will be compared to the data collected during timelapse incubation.
223782183|NCT05148494|DRUG|Fleet Enema|standard pre-op application, see arm description
223782184|NCT05148494|DRUG|Pico-Salax|standard pre-op application, see arm description
223782185|NCT01319318|PROCEDURE|Pars Plana Vitrectomy|Pars plana vitrectomy performed in study eye on Day 0.
223699770|NCT01443273|OTHER|Medical Records study|No interventions will be done related to the study besides summary of the Medical Files.
223699771|NCT00003976|DRUG|indisulam|
223699772|NCT04245072|PROCEDURE|Intravitreal injection|Intravitreal injection of Aflibercept 2 mg (0.05 ml) or Ranibizumab 0.5 mg (0.05 ml) to the regimen pro re nata.
223699773|NCT04245072|DIAGNOSTIC_TEST|Fluorescent angiography|Ophthalmic examination
223699774|NCT04245072|DIAGNOSTIC_TEST|Visometry|Ophthalmic examination
223699775|NCT04245072|DIAGNOSTIC_TEST|Refractometry|Ophthalmic examination
223699776|NCT04245072|DIAGNOSTIC_TEST|Slit lamp examination|Ophthalmic examination
223699777|NCT04245072|DIAGNOSTIC_TEST|Ophthalmoscopy|Ophthalmic examination
223699778|NCT04245072|DIAGNOSTIC_TEST|OKT|Ophthalmic examination
223699779|NCT00003927|BIOLOGICAL|filgrastim|
223699780|NCT00003927|DRUG|amifostine trihydrate|
223699781|NCT00003927|DRUG|cyclophosphamide|
223699782|NCT00003927|DRUG|doxorubicin hydrochloride|
223699783|NCT00003927|DRUG|paclitaxel|
223699784|NCT00003927|PROCEDURE|peripheral blood stem cell transplantation|
223699785|NCT02482207|DRUG|Rosuvastatin|
223699786|NCT02482207|BEHAVIORAL|Life style modification|
223699787|NCT00237887|DRUG|adalimumab|
223699788|NCT04248803|OTHER|GLUMA (Kulzer GmbH, Germany) desensitizing agent|GLUMA desensitizer is used to reduce tooth sensitivity
223699789|NCT05759611|OTHER|Standard integrated metabolic rehabilitation protocol + guided spontaneous breathing exercises|Physical exercise protocol before and after 12 sessions of standard integrated metabolic rehabilitation protocol + guided spontaneous breathing exercises lasting about 20 minutes per session
223699790|NCT05759611|OTHER|Standard integrated metabolic rehabilitation protocol + specific respiratory muscle training program|Physical exercise protocol before and after 12 sessions of standard integrated metabolic rehabilitation protocol + a specific respiratory muscle training program according to the protocol recently proposed by Spengler et al. (Wuthrich et al., 2015; Schaer et al., 2018), adapted according to the baseline characteristics of the respiratory function of the subjects.
223699791|NCT04834232|DEVICE|compression therapy|compression bandaging or graduated compression hosiery consists of applying a type of elastic device, mainly on the limbs, to exert a controlled pressure on the lower limbs. The controlled pressure exerted by medical compression stockings reduces the diameter of major veins, thereby increasing the velocity and volume of blood flow, along with conditions beneficial for the healing of chronic inflammatory disorders (e.g. cellulitis, erysipelas, venous leg ulcers, etc.), through reduced pro-inflammatory cytokine levels and higher levels of the anti-inflammatory cytokines.
223699792|NCT04834232|PROCEDURE|iliac vein stenting|using x-ray guidance (fluoroscopy) to place a an expandable metal mesh tube against the vein walls, acting as a scaffold to keep the veins open and improve blood flow
223699793|NCT02213354|DRUG|MF59|Microfluoridized adjuvant 59 (MF59) is an oil-in-water emulsion. Group 1-6 receive 3.75 mcg, 7.5 mcg and 15 mcg.
223699794|NCT02213354|BIOLOGICAL|Influenza Virus Vaccine, Monovalent A/H7N9 A/Shanghai/2/2013|Monovalent inactivated split influenza virus vaccine made with HA antigen derived from the influenza A/Shanghai/2/2013 virus. Monovalent influenza A/H7N9 virus vaccine. Group 1-6 receive 3.75 mcg, 7.5 mcg and 15 mcg.
223699795|NCT03577288|BEHAVIORAL|manipulation of the level of realism|"The realism of the virtual experience will be manipulated. In one condition the realism will be high and in another condition the realism will be low. In addition, emotional category of stimuli for each virtual experience condition will be manipulated. Thus, each participant will be submitted to six virtual experiences (e.g., high realism with negative stimuli, low realism with negative stimuli, high realism with positive stimuli).~The measures of the pupillary responses, gaze fixation, heart rate, head movement (only in part A) and Late Positive Potential (EEG - only in part B) will be realized. In addition, the participants will respond to the scales and questionnaire evaluating their emotion, feeling of presence and feeling of immersion."
223699796|NCT03577288|BEHAVIORAL|manipulation of the presence and size of avatar|"The presence of avatar in the virtual experience will be manipulated. In one condition the avatar will be present and in another condition the avatar will not be present. In addition, emotional category of stimuli for each virtual experience condition will be manipulated. Thus, each participant will be submitted to six virtual experiences (e.g., with avatar and negative stimuli, without avatar and negative stimuli, with avatar and positive stimuli, etc.).~Children will be exposed to only one of the two possible situations: with an avatar or without an avatar for the entire experience. Adults will be exposed to only one of the four possible situations: with standard size avatar, with giant avatar, with tiny avatar, or without avatar.~The measures of the pupillary responses, gaze fixation, heart rate, head movement will be realized. In addition, the participants will respond to the scales and questionnaire evaluating their emotion, feeling of presence and feeling of immersion."
223699797|NCT03577288|BEHAVIORAL|manipulation of interaction|"Virtual experience condition will be manipulated. In one condition the participants will be exposed to the virtual experience in which they will be able to interact with some of the stimuli, in another condition they will not be able to interact with the stimuli (passive watching). In addition, emotional category of stimuli for each virtual experience condition will be manipulated. Thus, each participant will be submitted to six virtual experiences (e.g., interaction possible - negative stimuli, interaction impossible - negative stimuli, interaction possible - positive stimuli).~The measures of the pupillary responses, gaze fixation, heart rate, head movement will be realized. In addition, the participants will respond to the scales and questionnaire evaluating their emotion, feeling of presence and feeling of immersion."
223699798|NCT03577288|BEHAVIORAL|manipulation of the nature of stimulus|The nature of the stimuli with which the participants will interact will be manipulated. During virtual experience the participants will have a choice to interact or not with the virtual environment, in one condition with animate stimuli and in another condition with inanimate stimuli. In addition, emotional category of animate and inanimate stimuli will be manipulated. Thus, each participant will be submitted to six virtual experiences (e.g., condition with animate negative stimuli, condition with inanimate negative stimuli, condition with animate positive stimuli). The measures of the pupillary responses, gaze fixation, heart rate, head movement will be realized. In addition, the participants will respond to the scales and questionnaire evaluating their emotion, feeling of presence and feeling of immersion.
223699799|NCT00561769|DRUG|Norditropin pen|12 IU per day
223699800|NCT01498978|BIOLOGICAL|ipilimumab|Given IV
223699801|NCT01498978|OTHER|laboratory biomarker analysis|Correlative studies
223699802|NCT02952729|DRUG|XMT-1522|one intravenous dose administered in-clinic every 21 days
223699803|NCT05361421|DRUG|Intensive targeting group|Intensive lipid lowering therapy with LDL-cholesterol goal of \<55mg/dL. Atorvastatin 5, 10, 20, 40, and 80mg are allowed to use and ezetimibe or PCSK-9 inhibitor may be considered in patients who could not achieve target LDL-cholesterol level even with the maximum dose of study drugs (atorvastatin 80mg) by the discretion of the investigator.
223699804|NCT05361421|DRUG|Conventional therapy group|Only moderate intensity statin therapy (atorvastatin 5, 10, and 20mg ) are allowed. Ezetimibe or PCSK-9 inhibitor is not allowed to use.
223699805|NCT05002283|OTHER|patient specific guide|harvesting palatal free gingival graft using the patient specific guide
223699806|NCT01716390|DIETARY_SUPPLEMENT|Drink that contains plant stanols|
223699807|NCT01716390|DIETARY_SUPPLEMENT|Placebo drink|
223699808|NCT04834674|COMBINATION_PRODUCT|DEB-TACE combined with apatinib and PD-1 antibody|combination of local therapy (DEB-TACE), antiangiogenic therapy (apatinib), and immunotherapy (PD-1 antibody)
223699809|NCT05912660|DEVICE|Aortic Valve Replacement|Aortic Valve Replacement (surgically or TAVI)
223782186|NCT01914848|OTHER|Advance Care Planning ACP|Patient of the intervention group get a decision aid video and library and up to 3 consultations with qualified Advance Care Planning Facilitators.
223782187|NCT01914848|OTHER|Control Group|A routine care discharge planning with the social service
223782188|NCT01594905|DRUG|Entecavir + Tenofovir (MDR group)|Entecavir 1.0mg + Tenofovir 300mg
223782189|NCT02731131|DRUG|Peginterferon alfa-2a|Peginterferon alfa-2a will be administered as 180 micrograms (mcg) once weekly via subcutaneous (SC) injection.
223782190|NCT02731131|DRUG|Ribavirin|Ribavirin will be administered as 1000 to 1200 milligrams (mg) per day in divided oral doses.
223782191|NCT02509624|DRUG|Selonsertib|6 mg tablets administered orally in fed state
223782192|NCT02995668|OTHER|Strength-Function|Preoperative functional and strength capabilities training.
223782193|NCT02995668|OTHER|Balance-Proprioception|Preoperative proprioceptive and balance capabilities training
223699810|NCT03230253|BEHAVIORAL|Sequential training|The participant will cycle on a stationary bike for 30 minutes, which includes a 3-min warm-up phase followed by the aerobic training components (25 minutes), then a 2-min cool-down phase. The target heart rate during the aerobic training phase will be 40 to 70% of maximal heart rate (HRmax). After cycling, the participant will engage in a 30-minute of computer-based cognitive training program using BrainHQ (Posit Science Inc., San Francisco, CA, USA). The following are the areas of training: visuospatial processing, attention, memory, language, and logical thinking.
223782194|NCT05515159|OTHER|electroconvulsive therapy|electrical stimulation of the brain while the patient is under anesthesia.
223699811|NCT03230253|BEHAVIORAL|Dual training|The dual-task training group will cycling concurrently with the computer-based cognitive training. The training principle of cycling and cognitive training is similar to the SEQ group; however, the training intensity will be adjusted according to each participant's ability.
223782195|NCT04704245|DRUG|epidermal growth factor (EGF)-containing ointment|The subjects applied the epidermal growth factor (EGF) ointment twice daily (morning and evening) to the lesion for 4 weeks after laser treatment.
223782196|NCT04704245|DRUG|Vehicle ointment|To compare the effect of epidermal growth factor (EGF) ointment, the control subjects applied the vehicle ointment twice daily (morning and evening) to the lesion for 4 weeks after laser treatment.
223699812|NCT03230253|BEHAVIORAL|Control training|The control participants will receive 60 minutes of health-related rehabilitation programs which involves non-aerobic physical exercise (e.g., muscle stretching, range of motion exercises, relaxation techniques) and unstructured cognitive related rehabilitation programs (e.g., watch health-related videos or read newspapers or magazines and then answer the content-related questions raised by the therapist).
223699813|NCT01165580|DRUG|valganciclovir [Valcyte]|oral dose, Days 1 and 2
223699814|NCT06558175|RADIATION|stereotactic body radiation therapy (SBRT)|Patients will be assigned to treatment doses using the TITE-CRM model.
223699815|NCT00961649|DRUG|Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension|
223699816|NCT00961649|DRUG|Brinzolamide ophthalmic suspension, 1%|
223699817|NCT00961649|DRUG|Brimonidine tartrate ophthalmic solution, 0.2%|
223699818|NCT00961649|OTHER|Vehicle|Inactive ingredients used as placebo
223699819|NCT02711345|DRUG|LTT462|ERK Inhibitor
223699820|NCT01315184|BEHAVIORAL|Recovery Line Support System|"Full time access (24 hours/7 days per week) to an automated, telephone-based, interactive, voice response (IVR)system for 4 weeks.~The program was developed based on a behavioral theory of substance abuse, and comprises four components: 1) self-assessment 2) learning about skills , 3) activities for current help and skills training, and 4) Feedback."
223699821|NCT04170842|OTHER|Music intervention|Participants will work with the music therapist to make their selections. Music therapists will provide input on how best to synchronise type, tempo and genre of music to the wound dressing procedure. As musical preference is very personal, the choice of music provided will try to strike a balance of providing what is acceptable to patients while not exposing them to music with known stimulatory effects.
223699822|NCT05923528|DEVICE|IPL|IPL treatment intensity was chosen based on the Fitzpatrick scale as follows: Fitzpatrick scale I, II, III, 10-15 J/cm2 with a 570-nm filter
223782197|NCT04704245|PROCEDURE|Q-swithced (QS) 532-nm Nd:yttrium aluminum garnet (YAG) laser|"The subjects received one session of laser treatment with a Q-swithced (QS) 532-nm Nd:yttrium aluminum garnet (YAG) laser of their solar lentigines after enrollment.~The procedure parameters were as follows: 5-10-ns pulse duration, 3.5-mm spot size, 0.9-1.1-J/cm2 fluence, and 2-Hz frequency.~The end point of laser treatment for lentigines was immediate whitening."
223782198|NCT05881941|DEVICE|using a soundproof nebulizer with a music and a funny mask added|There were 3 groups in the study. These were Experimental Group 1, using a soundproof nebulizer with a music and a funny mask added, Experimental Group 2 using a silent nebulizer with no extra attachments, and a Control Group using a routinely employed nebulizer
223782199|NCT05881941|DEVICE|using a silent nebulizer with no extra attachments|There were 3 groups in the study. These were Experimental Group 1, using a soundproof nebulizer with a music and a funny mask added, Experimental Group 2 using a silent nebulizer with no extra attachments, and a Control Group using a routinely employed nebulizer
223699823|NCT05923528|DEVICE|Heated eye mask|Heated eye mask will be used to assess its usefulness in dry eye signs and symptoms
223699824|NCT05923528|DEVICE|LipiFlow®|LipiFlow® can control the variables of temperature, pressure, and MG expression technique
223782200|NCT05881941|DEVICE|using a routinely employed nebulizer|There were 3 groups in the study. These were Experimental Group 1, using a soundproof nebulizer with a music and a funny mask added, Experimental Group 2 using a silent nebulizer with no extra attachments, and a Control Group using a routinely employed nebulizer
223782201|NCT06033989|DRUG|Hyaluronic acid|Delayed dental implant placement after application of surface treatment to enhance Osseointegration and healing .
223699825|NCT05923528|DEVICE|EyePeace®|The silicone-made flexible hand-held gadget applies regulated, vertical pressure to the closed eyelids.
223699826|NCT05600738|DEVICE|RNS/DBS activation|This will be performed to study the EEG responses to DBS/RNS stimulation electrical pulses. The stimulation frequencies will be sequentially increased and each stimulation will last for 2 minutes.There will be a 1-2 minute wash out period after each trial.
223699827|NCT04293731|DIETARY_SUPPLEMENT|Symbiter-Smectite|Symbiter-Smectite contains biomass of alive probiotic microorganism symbiosis, colony forming units - CFU/g: Lactobacillus - 1.0х109, Bifidobacterium - 1.0х109, Lactococcus - 1.0х108, Propionibacterium - 1.0х108 and Acetobacter - 1.0х105; and smectite gel (250 mg)
223699828|NCT04293731|DIETARY_SUPPLEMENT|Placebo|Placebo
223782202|NCT06033989|DRUG|sandblasted, and acid-etched|Delayed dental implant placement after application of surface treatment to enhance Osseointegration and healing .
223782203|NCT06033989|PROCEDURE|Delayed dental implant|Surgical procedure of delayed dental implant in posterior maxilla after application of surface treatment to enhance Osseointegration and healing .
223782204|NCT02124590|OTHER|Acute Exercise|Repeated isometric leg exercises at varying intensities for up to twelve minutes per bout. Leg exercises will target the quadriceps muscles.
223782205|NCT02124590|OTHER|Acute Exercise|Aerobic exercise session on a bike at 50% of peak VO2 for 30 minutes.
223699829|NCT02549729|BEHAVIORAL|pelvic floor muscle training|Women will be instructed to perform pelvic floor muscle training daily at home 4 sets of 10 maximum perceived voluntary contraction of the pelvic floor muscle sustained for 6 seconds followed by 5 flick voluntary contraction of the pelvic floor muscle. The 4 sets will be performed in 4 different positions (supine, all four, sit and standing). Twice a week they will receive a supervised session using the same protocol described above.
223699830|NCT02958501|DRUG|Colecalciferol|Drug
223699831|NCT02091908|BIOLOGICAL|Novartis Investigational H5N1 vaccine|2 doses of 0.5 ml, 3 weeks apart
223699832|NCT02091908|BIOLOGICAL|Novartis Investigational H5N1 vaccine|2 doses of 0.5 ml, 3 weeks apart
223699833|NCT02091908|BIOLOGICAL|Novartis Seasonal Influenza Vaccine|2 doses of 0.5 ml, 3 weeks apart
223699834|NCT02091908|BIOLOGICAL|Novartis Seasonal Influenza Vaccine|2 doses of 0.5 ml, 3 weeks apart
223699835|NCT01516073|DRUG|Fluticasone Propionate|FP BID for 12 weeks
223699836|NCT03664180|DRUG|Bivalirudin|IV infusion of 0.2 mg/kg/h (low-rate infusion) for at least 48h after the procedure or until discharge from CCU if it occurs later
223699837|NCT03664180|DRUG|Enoxaparin|40mg/d s.c.for at least 48h after the procedure or until discharge from CCU if it occurs later
223699838|NCT03664180|DRUG|Unfractionated heparin|IV infusion of 10 U/kg/h (maximum 1000 U) initially, adjusted to maintain ACT between 150 and 220 seconds for at least 48h after the procedure or until discharge from CCU if it occurs later
223699839|NCT03664180|DRUG|Bivalirudin placebo|Matching placebo IV infusion for at least 48h after the procedure or until discharge from CCU if it occurs later
223699840|NCT03664180|DRUG|Enoxaparin placebo syringe|Placebo syringe will be only prepared by a designated unblended medical professional on site. Placebo syringe will be presented in identical containers as a clear, colorless, sterile liquid of saline.Subcutaneous injection once a day for at least 48 hours after the procedure or until discharge from CCU if it occurs later.
223699841|NCT03664180|DRUG|Unfractionated heparin placebo|Matching placebo IV infusion for at least 48h after the procedure or until discharge from CCU if it occurs later.
223699842|NCT03715101|DRUG|Rosuvastatin|Open-label, one-sequence, multiple administration
223699843|NCT01658631|DEVICE|arterial pressure measurement (Nexfin, a noninvasive finger cuff system)|
223699844|NCT06535425|OTHER|Platelet-Rich Plasma|The PG and JG were injected with autologous PRP at baseline. The injection was performed by the same clinician with 10 years of experience in knee joint injections. Participants were seated with their knees extended, and the needle was inserted through the joint space into the intra-articular cavity of the knee, administering approximately 2.5 mL of PRP into each knee joint. Thirty millilitres of venous blood were drawn from the participant's elbow vein, and approximately 5 mL of PRP was obtained for bilateral knee joint injection by using a TD5A tabletop low-speed centrifuge manufactured in China. The first centrifugation was performed at 2500 revolutions per minute (rpm) for 3 minutes, followed by a second centrifugation at 2300 rpm for 6 minutes.
223699845|NCT06535425|OTHER|Isometric Contractions of Quadriceps|The IG and JG exercises followed the methods of our previous research, with participants undergoing an 16-week ICQ intervention five times per week. Each session consisted of isometric contractions and relaxations of the quadriceps muscle for 5 seconds each, in sets of 30 repetitions, for a total of 10 sets, with a 30-second rest between sets. During this period, researchers conducted weekly follow-up calls or face-to-face interviews with participants to understand their living conditions, ensuring that they did not change their original lifestyle habits and did not engage in any other form of regular fitness activities. Participants who did not comply were not included in the final data analysis.
223699846|NCT06535425|OTHER|Platelet-Rich Plasma Combined with Isometric Contractions of Quadriceps|Platelet-Rich Plasma Combined with Isometric Contractions of Quadriceps
223699847|NCT06535425|OTHER|Control|Initially, all participants received identical health education in the form of thematic lectures once per week for 40 minutes each. The content included the following aspects: emphasising the importance of close cooperation with physicians as key to maintaining health; the process of the occurrence and development of KOA, along with its treatment methods; the role of family and social support in improving the condition; establishing a reasonable daily activity routine, such as protecting the affected knee joint, avoiding long-distance fatigue, mountain climbing, ascending and descending high-rise stairs and various adverse body postures (prolonged standing, kneeling and squatting); and advising those who are overweight to reduce their body weight. On this foundation, the four groups of participants underwent the following interventions.
223699848|NCT01062204|DEVICE|Altrazeal|Sterile, odorless, crystalline white powder consisting of flakes of freeze dried HEMA and HPMA polymers. For application, the powder is distributed to the surface of the wound or burn where it forms a moist, flexible film and adheres to the surface of the wound.
223699849|NCT01062204|DEVICE|Aquacel Ag|Textile fiber made from sodium carboxy-methylcellulose containing 1.2% silver in ionic form.
223782206|NCT02700646|BEHAVIORAL|Developmental recommendations|
223782207|NCT02700646|BEHAVIORAL|Standard care|standard care
223782208|NCT01785589|PROCEDURE|coronary angiography|A 6 French arterial sheath was introduced into the radial artery. After administration of 5000 U heparin, the guiding catheter was advanced into the coronary ostium. Intracoronary nitroglycerin 0.2 mg was administered, and reference images were made. Significant CAD was defined as presentation of a stenosis ≥70 % in the three-epicardial vessels and ≥ 50 % in left main coronary disease. If necessary (at the discretion of the practitioner) the pressure wire was advanced across the stenosis, and Fractional flow reserve (FFR) was measured.
223699850|NCT01915966|DIETARY_SUPPLEMENT|Cardamom, ginger and orange juice gelatin|Patients will receive the recipe of the gelatin, with detailed instructions to prepare it at home, and the necessary ingredients for the gelatin. If necessary, they will be helped in the preparation of an initial batch that should last for one week of treatment. Patients will be instructed to consume the gelatin candy as necessary to alleviate the dry mouth sensation
223699851|NCT01915966|DIETARY_SUPPLEMENT|Camomile infusion with lemon juice|Patients will receive instructions to prepare the infusion at home, and the necessary ingredients. Patients will be instructed to ingest the infusion as necessary to alleviate the dry mouth sensation.
223699852|NCT04331236|BEHAVIORAL|Cognitive Behavioral Therapy|CBT trains individuals to identify and reframe dysfunctional thoughts to help improve mood and behavior. CBT intervention also includes teaching relaxation and mindfulness strategies, as well as ways to help improve functioning through the use of behavioral goal setting.
223699853|NCT04331236|OTHER|Yoga|Yoga consists of physical exercises, breathing techniques, and meditation designed to condition the physical body, calm the mind, and stabilize emotions.
223699854|NCT04020575|BIOLOGICAL|huMNC2-CAR44 CAR T cells or huMNC2-CAR22 CAR T cells|huMNC2-CAR44 T cells or huMNC2-CAR22 CAR T cells are an autologous T cell product transduced with a proprietary lentiviral vector backbone coding for humanized MNC2-scFv (the targeting head).
223699855|NCT04020575|BIOLOGICAL|huMNC2-CAR44 CAR T cells or huMNC2-CAR22 CAR T cells @ RP2D|huMNC2-CAR44 T cells or huMNC2-CAR22 CAR T cells are an autologous T cell product transduced with a proprietary lentiviral vector backbone coding for humanized MNC2-scFv (the targeting head) @ RP2D
223699856|NCT04746716|OTHER|Phone call|Phone call to the patient to complete quality of life scales
223699857|NCT01751893|DRUG|Henna|natural henna in the form of paste
223699858|NCT01751893|DRUG|Placebo|placebo
223699859|NCT05086952|DRUG|Vericiguat (BAY1021189) - Intervention A|Single dose of 10 mg vericiguat high-concentration pediatric formulation (oral liquid formulation) in fed state.
223699860|NCT05086952|DRUG|Vericiguat (BAY1021189) - Intervention B|Single dose of 10 mg vericiguat high-concentration pediatric formulation (oral liquid formulation) in fasted state.
223699861|NCT05086952|DRUG|Vericiguat (BAY1021189) - Intervention C|Single dose of 2.5 mg vericiguat low-concentration pediatric formulation (oral liquid formulation) in fed state.
223699862|NCT05086952|DRUG|Vericiguat (Verquvo, BAY1021189) - Intervention D|Single dose of 10 mg vericiguat immediate release (IR) intact tablet in fed state.
223699863|NCT05269732|BEHAVIORAL|Group Cognitive Behavioural Therapy (CBT)|The 9-week group Cognitive Behavioural Therapy (CBT) intervention for Postpartum Depression (PPD) delivered via Zoom by two trained psychologists. This intervention was developed by Dr. Van Lieshout (Principal Investigator) at the Women's Health Concerns Clinic (WHCC) at St. Joseph's Healthcare Hamilton. It was designed to be brief, simple, and applicable to women in community settings. It consists of 9 weekly 2-hour sessions where core CBT skills are learned and practiced each week. The first half of each session is devoted to core CBT content, including cognitive restructuring. The second half is devoted to group discussions co-led by participants on topics relevant to mothers with PPD (e.g., sleep, supports, role transitions). Homework is assigned at each session.
223699864|NCT03708848|DRUG|Esomeprazole|Proton pump inhibitor
223699865|NCT03708848|DRUG|Bismuth Potassium Citrate|Gastric mucosal protective drug with anti-H. pylori effect
223699866|NCT03708848|DRUG|Clarithromycin|antibiotic for H. pylori eradication
223699867|NCT03708848|DRUG|Metronidazole|antibiotic for H. pylori eradication
223699868|NCT03708848|DRUG|Levofloxacin|antibiotic for H. pylori eradication
223699869|NCT03708848|DRUG|Tetracycline|antibiotic for H. pylori eradication
223699870|NCT05769998|BEHAVIORAL|Acceptance and Commitment-based treatment|The ACT-based group intervention includes four 1-hour group sessions over two weeks. The treatment manual was developed by the authors of this study following the ACT framework and adapting materials and resources from ACT-based treatments developed for other settings. The focus of the intervention is to provide patients with pain education specific for patients who underwent TKA and to promote psychological flexibility. Each session employs experiential exercises, including mindfulness meditation, and metaphors addressing the core components of ACT.
223699871|NCT05769998|OTHER|Treatment as usual|Standard pharmacotherapy and physical exercise plan provided to all the patients in the rehabilitation unit.
223699872|NCT01161784|DIETARY_SUPPLEMENT|Probiotics fermented milk|80ml fermented milk containing min. 30 billion live L. casei Shirota strain, administered orally once a day for 4 weeks
223699873|NCT01161784|DIETARY_SUPPLEMENT|Nutrient drink|80ml fermented milk without L. casei Shirota strain, administered orally once a day for 4 weeks
223699874|NCT01237938|BEHAVIORAL|Low Glycemic Diet|Changing to low glycemic diet
223699875|NCT04676698|BEHAVIORAL|Three Good Things|"The treatment phase will last 3 weeks. However, participants will complete surveys at baseline and up to 6 months. At the end of the trial the study team will also select a limited number of entries from participants to share some of the good things which people listed. These will be edited to ensure writer anonymity and participants will be informed of this plan in the study introduction."
223782209|NCT01431066|DEVICE|Sham pulsed radio-frequency electromagnetic device|Disabled PRFE device
223782210|NCT01431066|DEVICE|ActiPatch PRFE Device|Actipatch PRFE device
223782211|NCT02940470|OTHER|Calorie restricted diet plus exercise|Daily meals plus exercise providing 1000 kcal restriction per day for 12 weeks.
223699876|NCT04676698|BEHAVIORAL|Wait list control arm and then Three Good Things|Surveys will be completed for 3 months prior to treatment and then after treatment.
223699877|NCT05772208|DRUG|Camrelizumab|camrelizumab 200mg q3w
223699878|NCT05772208|DRUG|Nimotuzumab|nimotuzumab 200mg qw
223699879|NCT05772208|DRUG|neoadjuvant chemotherapy and CCRT|the second and third neoajuvant chemotherapy with GP regimen (gemcitabine 1g/m2 d1，8 plus cisplatin 75mg/m2 ) concurrent chemotherapy: single cisplatin (80mg/m2) for two cycle definitive radiotherapy for primay lesion and lymph node region.
223699880|NCT01892865|OTHER|Scheduling using historical means|Scheduling will be performed taking into account historical means only for anesthetic, operative, and turn around time
223699881|NCT01892865|OTHER|Scheduling using regression modeling system|A regression model that uses predictor of operative length will be used to predict operative, anesthetic, and turn around time length
223699882|NCT04967378|BEHAVIORAL|HEPPI|10 weekly individual sessions, 90 minutes each, at the participants' homes. The content of sessions includes psychoeducation, cognitive training, psychotherapeutic intervention, and compensatory strategy training.
223699883|NCT05345873|BIOLOGICAL|SCTV01E|one dose of SCTV01E on D0, intramuscular
223699884|NCT05345873|BIOLOGICAL|mRNA-1273|one dose of mRNA-1273 on D0, intramuscular
223699885|NCT05212519|OTHER||For observational research
223699886|NCT03645564|OTHER|Specialized nurse consultation|The purpose of this consultation is to establish a partnership between the patient and the nursing staff. Tools were set up (notebook, movie) to answer the questions of the patient. In case of specific question, an expert will meet the patient (doctor of the service, psychologist, pharmacist or hematologist).
223699887|NCT00646789|DRUG|Comparator: MK0633|patients will receive single 50mg oral dose with follow-up observation for 5 weeks.
223699888|NCT01823978|BIOLOGICAL|BPX-201 vaccine plus AP1903|The trial design consists of 3 cohorts of 6 patients each, receiving escalating doses of BPX-201 of 10 million (M), 20M and 40M cells, respectively. Dose escalation will occur according to a 3+3 design. Patients will receive administration of BPX-201 every other week for 6 cycles (1 cycle equals 2 weeks). Approximately 1.6 mL of BPX-201 will be administered as 8 intradermal injections (200μL each) at each treatment visit. On the day following each vaccination, a single 40 mg dose of the activating agent, AP1903, will be administered via intravenous (IV) infusion over 2 hours.
223699889|NCT06966583|DIETARY_SUPPLEMENT|NAD supplement|NAD supplement NMN：NMN12000 GeneHarbor
223699890|NCT06966583|RADIATION|Radiotherapy|Low Dose Radiotherapy or Stereotactic Ablative Radiotherapy or Conventional Radiotherapy
223699891|NCT06966583|DRUG|Immunotherapy|PD-1 inhibitor
223782212|NCT02940470|OTHER|Weight management classes|Weekly 1-hour weight management classes for 12 weeks.
223782213|NCT05234099|DIAGNOSTIC_TEST|18F-FDG Positron emission tomography - MRI|All the examinations will be performed in the supine position on the same integrated 3T PET-MRI scanner
223782214|NCT05234099|DIAGNOSTIC_TEST|Multiparametric ultrasound imaging|Acquisitions of respiratory muscles (diaphragm, intercostal muscles) will be performed using two 6 MHz central frequency linear transducer (SL 10-2) driven by two identical ultrafast ultrasound devices.
223782215|NCT05234099|DIAGNOSTIC_TEST|Surface electromyography|sEMG recordings will be performed in the left side on the sternocleidomastoid muscle, the intercostal parasternal muscle, and the external oblique muscle using pairs of 20-mm-diameter silver chloride surface electrodes.
223782216|NCT05234099|DIAGNOSTIC_TEST|Transdiaphragmatic preasure measurmement|Esophageal and gastric pressures will be measured using 8-cm balloon-catheters.
223782217|NCT05234099|DIAGNOSTIC_TEST|Magnetic stimulation of the phrenic nerves|In order to quantify the contractile fatigue in diaphragm induced by the ventilatory task (described below), we will use bilateral anterior magnetic stimulation of the phrenic nerves using two Magstim 200 stimulator.
223782218|NCT05234099|DIAGNOSTIC_TEST|Ventilation against inspiratory loading|A POWERbreathe KH2 device (POWERbreathe International Ltd) will be connected on the inspiratory side of the two-way valve. Level of inspiratory loading will be randomized in order to produce different amounts of muscle work in each subject.
223782219|NCT04026100|BIOLOGICAL|CTA101|Universal CD19-directed CAR-T cells by a single infusion intravenously will be given in escalating doses. Subjects will been distributed into low dose (0.2×10\^6), medium dose (2×10\^6), and high dose (3×10\^6).
223782220|NCT03575130|DRUG|Ripasudil eye drops|Rho-kinase-Inhibitor (IMP)
223782221|NCT03575130|DRUG|Optive eye drops|Artificial tears (placebo)
223782222|NCT03575130|PROCEDURE|Descemetorhexis|Corneal endothelial cells are removed prior to IMP administration by Descemetorhexis.
223782223|NCT05404529|DRUG|Tavapadon|Oral tablets
223699892|NCT05951257|BEHAVIORAL|Personalized multimodal intervention involving hypnosis and/or music|"The three intervention modalities (music and/or hypnosis) will begin by a moment of relaxation in which we will ask the participants to focus their attention on their breathing, on relaxation and on the process of absorption into oneself. The hypnosis modality consists in visiting in imagination a pleasant place that the participant will choose and to live some metaphorical stories. The musical modality consists of listening to one or two pieces of music chosen by each participant and which brings him/her well-being, according to them. These two types of work will be preceded by a moment of relaxation in which we will ask the participants to focus their attention on their breathing, on relaxation and on the process of absorption into oneself."
223699893|NCT06543043|DRUG|Phenytoin|Administered orally.
223699894|NCT06543043|DRUG|Itraconazole|Administered orally.
223699895|NCT06543043|DRUG|sonrotoclax|Administered orally.
223699896|NCT01558739|DRUG|INC424|Ruxolitinib was provided in 5 mg tablets, packaged in bottles. 15 - 20 mg (dose based on Baseline platelet count) twice daily.
223699897|NCT02788760|DEVICE|Cervical collar (Miami J collar - Össur)|The two groups of patients will similar in every way and will be treated with the same type of cervical collar - the only difference will be the length of treatment
223699898|NCT03200158|OTHER|Endoscopy biopsy and blood|Medical operation
223699899|NCT04747639|OTHER|500 ml glucose-depleted apple juice|
223699900|NCT04747639|OTHER|500 ml conventional apple juice|
223699901|NCT04747639|OTHER|250 ml glucose-depleted apple juice|
223699902|NCT04747639|OTHER|250 ml conventional apple juice|
223699903|NCT06019585|DEVICE|Splint inmmobilization|After internal fixation with volar locking plate, groups of distal radius fractures are inmobilized with a plaster splint of París for 3 weeks
223699904|NCT06019585|DEVICE|Bandage immovilization|After internal fixation with volar locking plate, groups of distal radius fractures are inmobilized with compressive bandage for 3 weeks
223699905|NCT02562768|DRUG|LY3154207|Administered orally
223699906|NCT02562768|DRUG|Placebo|Administered orally
223699907|NCT02755298|DRUG|Acetazolamide|
223699908|NCT02755298|DRUG|Placebo|
223699909|NCT06934759|OTHER|No Intervention: Observational Cohort|There is no intervention
223699910|NCT06934928|DEVICE|GentleMax Pro (with skin cooling)|"Treatment will be performed with the GentleMax Pro laser (755 nm wavelength), which targets hemoglobin.~A negative pressure hand piece provides temporary, mild suction (\~1/2 atm) before laser exposure.~A pulse fluence of 60-100 J/cm2 (single or double pulse) will be used with 8 mm diameter exposure spot size, and 3 ms pulse duration.~The laser system includes a dynamic cryogen spray cooling device (DCD) for epidermal protection. A spurt of cryogen cools the epidermis just before arrival of the treatment laser pulse."
223699911|NCT06934928|DEVICE|GentleMax Pro (without skin cooling)|"Treatment will be performed with the GentleMax Pro laser (755 nm wavelength), which targets hemoglobin.~A negative pressure hand piece provides temporary, mild suction (\~1/2 atm) before laser exposure.~A pulse fluence of 60-100 J/cm2 (single or double pulse) will be used with 8 mm diameter exposure spot size, and 3 ms pulse duration."
223699912|NCT06933186|BEHAVIORAL|Neuropsychological rehabilitation|Neuropsychological rehabilitation includes an integrated approach, consisting of three components: cognitive training; psychoeducation; and social skills/emotional management training. Cognitive training uses a combination of different tasks (always covering attention, memory and executive functions exercises), with a 30-minute session on the online cognitive training platform and 1 hour of pencil and paper exercises in a group, in a total of 36 sessions . Psychoeducation addresses specific topics related to Alcohol Use Disorder and its cognitive impact. Social skills/emotional management training includes problem-solving exercises, assertiveness training, emotion identification and management, among others. These sessions will be held once a week, for a total of 12 sessions.
223699913|NCT06933186|BEHAVIORAL|Weekly therapeutic groups|The control group will attend weekly therapeutic groups, which consist of open groups, aimed to promote abstinence and relapse prevention, supporting the management of difficulties in the person's daily life related to consumption, promoting psychoeducation about the disease and coping strategies to deal with craving
223782224|NCT04975568|OTHER|App and face-to-face physical therapy|Patients will use an app with health tests, general information about the study, personalized HTEP based in McGill's Program after their evaluations, and several online materials related with healthcare and healthy habits linked to social media sites. During the app used they will have 6 face-to-face sessions in 6 people groups with a physical Therapist in a 3 months period
223782225|NCT04975568|OTHER|App physical therapy|Patients will use an app with health tests, general information about the study, personalized HTEP based in McGill's Program after their evaluations, and several online materials related with healthcare and healthy habits linked to social media sites.
223699914|NCT06933719|OTHER|Study on existing health data|Study on existing health data
223699915|NCT03553771|DEVICE|LVIS and LVIS JR|Braided coil assist stents used for aneurysm embolization
223699916|NCT06557031|DIAGNOSTIC_TEST|ABTest Card®REF and ABTest Card®NEW|Pre transfusional control with the ABTest Card®REF device (predicate device) and the ABTest Card®NEW device (investigational device).
223699917|NCT03252860|OTHER|Observation of compliance with the World Health Organisation Surgical Safety Checklist|Observation of use and compliance with the surgical safety checklist and associated perioperative surgical outcomes
223699918|NCT03866031|OTHER|implant-supported mandibular overdenture|The implant-supported overdentures will be placed in immediate functional loading on the same day of implants placement. A direct restorative protocol will be applied to modify the existing prosthesis to implant-supported overdentures.
223699919|NCT02165709|PROCEDURE|Salpingectomy|
223699920|NCT02165709|PROCEDURE|Traditional sterilization|
223699921|NCT05617443|DEVICE|stackable guide|different types of stackable guide
223699922|NCT03243942|DRUG|Definity|Whenever a patient undergoes cardiac catheterization, which routinely includes intracardiac pressure monitoring using a pressure catheter, as part of their standard clinical care and agrees to participate in the study, we will acquire research data. With Definity infusion, SHAPE algorithm will be initiated to determine optimum acoustic pressure. Then, at the optimum acoustic pressure SHAPE specific data will be acquired from the cardiac chambers and aorta synchronously with the pressures recorded by the catheter (as a part of the patient's standard of care). After acquiring the ultrasound imaging data, the remainder of the heart catheterization will be completed by the attending cardiologist according to the patients' standard of care.
223699923|NCT00108433|DRUG|Cefazolin IV|
223699924|NCT00108433|DRUG|Linezolid IV|
223699925|NCT00108433|DRUG|Vancomycin (IV)|
223699926|NCT05409495|PROCEDURE|periodontal surgical procedure (open flap debridement)|All surgical procedures were performed by the second periodontist. 0.12% Chlorhexidine digluconate (CHX) rinse for intraoral antisepsis and a povidone iodine solution was used for extraoral antisepsis. After local anesthesia (2% lidocaine with epinephrine 1:100,000/ Astra, Westbrough, MA) was applied, the full thickness trapezoidal flap was raised large enough to provide adequate view of the defect area. Subgingival debridement and root planning were performed with the use of area-specific curets (Gracey curets, Hu-Friedy), and granulation tissue was removed The IBD area in the control group was closed without applying any material. Then mucoperiosteal flaps were repositioned with sutured with 4/0 monoprolene sutures.
223699927|NCT05409495|PROCEDURE|periodontal surgical procedure (OFD +autogenous Titanium-prepared platelet-rich fibrin (OFD+ T-PRF))|All surgical procedures were performed by the second periodontist. 0.12% Chlorhexidine digluconate (CHX) rinse for intraoral antisepsis and a povidone iodine solution was used for extraoral antisepsis. After local anesthesia (2% lidocaine with epinephrine 1:100,000/ Astra, Westbrough, MA) was applied, the full thickness trapezoidal flap was raised large enough to provide adequate view of the defect area. Subgingival debridement and root planning were performed with the use of area-specific curets (Gracey curets, Hu-Friedy), and granulation tissue was removed (Figure 2a). The blood supply of the defect areas was taken into account. At the test site, IBDs were filled with T-PRF and T-PRF membranes were adapted over the defects both buccally and lingually, in addition to OFD (Figure 2b). Then mucoperiosteal flaps were repositioned with sutured with 4/0 monoprolene sutures.
223699928|NCT02319512|OTHER|Chewing gum|ChiczaTM organic chewing gum 6 pieces a day
223699929|NCT02319512|OTHER|Glucose|12ml glucose solution (13,6g) per day
223699930|NCT05544812|DRUG|Sintilimab ，bevcizumab/cetuximab，XELOX|"Patients in this group had previously received the following treatment regimens:~Oxaliplatin :130 mg/m2, D1, Q3W; Capecitabine :1000mg/m2, bid q2w Sintilimab for injection :200mg, D1, Q3W Bevacizumab :7.5mg/kg, D1, Q3W or cetuximab :500 mg/m, D1, Q2W"
223699931|NCT03473951|DIAGNOSTIC_TEST|Hyperuricemia|Hyperuricemia vs. normouricemia
223699932|NCT06467942|DRUG|Chinese medicine and Lactobacillus|combined drug group
223699933|NCT06467942|DRUG|Chinese medicine|Single Chinese medicine group
223699934|NCT06467942|DRUG|Lactobacillus|Single Lactobacillus group
223699935|NCT03461263|OTHER|phonophoresis treatment using pumpkin seeds oil|phonophoresis treatment using pumpkin seeds oil
223699936|NCT03186495|DRUG|Somapacitan|All subjects will receive three (0.08 mg/kg) consecutive once-weekly s.c. (under the skin) administrations of somapacitan
223699937|NCT03192956|OTHER|No active intervention|No active intervention is performed
223699938|NCT00026962|PROCEDURE|measuring estradiol and progesterone levels in saliva|
223699939|NCT01966601|DRUG|TRV027 Dose #1|TRV027 continuous intravenous infusion Dose #1
223699940|NCT01966601|DRUG|TRV027 Dose #2|TRV027 continuous intravenous infusion Dose #2
223699941|NCT01966601|DRUG|TRV027 Dose #3|TRV027 continuous intravenous infusion Dose #3
223699942|NCT01966601|DRUG|Placebo|Placebo continuous intravenous infusion
223699943|NCT06556641|DRUG|GZR33 Injection|Administered as once daily subcutaneous dose
223699944|NCT06556641|DRUG|GZR101 Injection|Administered as once daily subcutaneous dose
223699945|NCT06556641|DRUG|Placebo|Administered as once daily subcutaneous dose
223699946|NCT06556641|DRUG|Insulin Degludec|Administered as once daily subcutaneous dose
223699947|NCT05405933|DIAGNOSTIC_TEST|Propioceptive Neuromuscular Facilitation|Propioceptive Neuromuscular Facilitation With Conventional Therapy for Balance and Gait
223699948|NCT05405933|DIAGNOSTIC_TEST|Balance Exercise|Balance Exercise Along With Conventional Therapy for Balance and Gait
223699949|NCT04242550|BEHAVIORAL|Executive Function- Enhanced CBT for BED (EF-BED+CBT)|EF-BED+CBT will combine CBT (see description below) with executive function training. EF-BED will focus on teaching compensatory strategies to enhance adherence to the strategies recommended in CBT.
223699950|NCT04242550|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|"CBT will be based on the Overcoming Binge Eating book. All participants will be provided a copy of the book. CBT addresses disturbed eating patterns and problematic thoughts/beliefs related to eating, shape and weight that contribute to binge eating. CBT is the current gold standard treatment for BED."
223699951|NCT00809848|DRUG|AGN-210669 ophthalmic solution, 0.075%|AGN-210669 non-preserved ophthalmic solution, 0.075%. One drop in both eyes each morning once-daily for 2 weeks.
223699952|NCT00809848|DRUG|AGN-210669 ophthalmic solution, 0.05%|AGN-210669 non-preserved ophthalmic solution, 0.05%. One drop in both eyes each morning once-daily for 2 weeks.
223699953|NCT00809848|DRUG|AGN-210669 ophthalmic solution, 0.025%|AGN-210669 non-preserved ophthalmic solution, 0.025%. One drop in both eyes each morning once-daily for 2 weeks.
223699954|NCT00809848|DRUG|bimatoprost ophthalmic solution 0.03%|Bimatoprost ophthalmic solution 0.03%. One drop in both eyes each morning once-daily for 2 weeks.
223699955|NCT00809848|DRUG|AGN-210669 vehicle ophthalmic solution|AGN-210669 vehicle non-preserved ophthalmic solution. One drop in both eyes each morning once-daily for 2 weeks.
223699956|NCT03039452|BEHAVIORAL|High intensity interval training|Each training session will consist of a 3-5 minute warm-up, followed by 10 repetitions of 1-minute bouts at individualized training intensity with 1-minute rest periods.
223699957|NCT03633136|BEHAVIORAL|electronic video education|Solid Organ Transplantation: An Educational Mini-Series for Patients consists of 6 videos ranging in length between 3 and 23 minutes, and has been developed according to best practice for designing education for patients with end-stage renal disease pursuing transplant. Each video outlines a subsequent stage of the transplant process, featuring an animated character embarking on a transplant journey. Animated segments illustrate difficult concepts for patients with poor health literacy, and patient narratives keep the content relevant and culturally inclusive. The educational intervention was developed with experts in medication adherence, video education, motivational psychology, cultural education (First Nations perspective), healthcare providers, and most importantly patients.
223699958|NCT05314738|COMBINATION_PRODUCT|NXL Energy 1|Riboflavin drops + NXL System to Total Energy Level 1
223699959|NCT05314738|COMBINATION_PRODUCT|NXL Energy 2|Riboflavin drops + NXL System to Total Energy Level 2
223699960|NCT05314738|COMBINATION_PRODUCT|NXL Energy 3|Riboflavin drops + NXL System to Total Energy Level 3
223699961|NCT05314738|COMBINATION_PRODUCT|Sham Treatment|Sham Drops and No exposure to NXL system
223699962|NCT00935948|DRUG|Imescard compound water smartweed ointment|Patients in this arm were instructed to apply the ointment after waking up, after evacuations and before bedtime, for 5 days.
223699963|NCT00935948|DRUG|Placebo|Patients in this arm received placebo, with the exact same appearance of the Imescard ointment, and were instructed to apply it at the same intervals and period.
223699964|NCT03047876|PROCEDURE|aortic arch surgery|Children, from neonatal age to late infancy, undergoing aortic arch surgery (n=20) will have cerebral perfusion measurements during surgery, including during the cooling and rewarming phase, whilst on cardiopulmonary bypass and during the recovery period in the intensive care unit
223699965|NCT01664065|DRUG|200 mg Ceftaroline fosamil|1 h infusion
223699966|NCT01664065|DRUG|600 mg Ceftaroline fosamil|1 h infusion
223699967|NCT02160990|DRUG|Exenatide|5 mcg exenatide subcutaneously twice daily for 30 days
223699968|NCT02160990|DRUG|Placebo|placebo subcutaneously twice daily for 30 days
223699969|NCT05143385|OTHER|Virtual reality|"* Those patients who are randomly assigned as the intervention group will be given an explanatory session on the use of the video game console, controllers and game accessories.~* The intervention will begin 15 calendar days after admission.~* The intervention will be carried out once a week with a duration of 20 minutes with one of the games chosen by the patient together with the physiotherapist.~* The end of the intervention will be until the patient is discharged from hospital, with a minimum of four sessions completed in order to participate in the study.~* The intervention will be carried out with an average of six sessions in each patient, including in the study those who perform a minimum of four sessions. However, the interventions will continue until hospital discharge.~* After completion of the clinical trial, a registry table will be drawn up quantifying the number of sessions for each patient and the type of session:"
223699970|NCT00734474|DRUG|LY2189265|
223699971|NCT00734474|DRUG|Sitagliptin|
223699972|NCT00734474|DRUG|Placebo solution|
223699973|NCT00734474|DRUG|Placebo tablet|
223699974|NCT00734474|DRUG|Metformin|
223699975|NCT01601860|OTHER|Use of non-pharmacological|"Other: Non-pharmacological resources~A sequence of non-pharmacological resources were applied to the patient by the researcher according to uterine cervical dilation, as follows:~* Walking (with cervical dilation between 4 and 5 cm)~* Alternating stance associated with ENT (cervical dilatation from 6 to 7 cm)~* Shower (with dilation\> 7 cm);"
223699976|NCT01601860|OTHER|Other: Routine care|Other: Routine care Routine care of the institution performed by the staff, without the presence of the researcher that included offering a balanced meal, continuous support with the presence of a partner or family throughout labor, use of oxytocin when prescribed by the staff, use of drug analgesia when requested by the patient.
223699977|NCT01137396|DRUG|Modafinil|Modafinil 400mg PO QDaily following up-titration for \~8weeks
223699978|NCT01137396|BEHAVIORAL|Cognitive Behavioral Therapy|Once weekly cognitive behavioral therapy for cocaine dependence
223699979|NCT04497935|DRUG|PLENVU|Bowel preparation for a colonoscopy
223699980|NCT04497935|DRUG|MoviPrep|Bowel preparation for a colonoscopy
223699981|NCT00942448|DRUG|Diclofenac HPBCD|1 single injection at day of dental surgical extraction
223699982|NCT00942448|DRUG|Diclofenac HPBCD|1 single injection at day of dental surgical extraction
223699983|NCT00942448|DRUG|Diclofenac HPBCD|1 single injection at day of dental surgical extraction
223699984|NCT00942448|OTHER|Placebo s.c.|1 single injection at day of dental surgical extraction
223699985|NCT06389500|DRUG|Adebrelimab|Adebrelimab, IV
223699986|NCT06389500|DRUG|Lenvatinib|Lenvatinib, PO
223699987|NCT06389500|PROCEDURE|Hepatic Arterial Infusion Chemotherapy|GC regimen±5-FU
223699988|NCT05194865|DEVICE|cardiac MRI|assessment of the viability using CMR
223699989|NCT05194865|PROCEDURE|Percutaneous coronary intervention|direct revascularization using PCI
223699990|NCT02021578|BEHAVIORAL|Family Cognitive Behavioral Prevention|Parent training and cognitive behavioral intervention with parents. Coping skills training with children.
223699991|NCT02021578|BEHAVIORAL|Written information|Reading materials about depression
223699992|NCT06061354|DRUG|Teriparatide|mixture of 20μg of teriparatide, 0.64ml of saline solution with 1g of Bio -Oss® or 1g of Bio-Oss® will be mixed with 0.72ml of saline solution.
223699993|NCT06061354|PROCEDURE|Maxillary Sinus Augmentation|Local anesthesia will be performed, mucoperiosteal flap will be raised to access the anterior wall of the maxillary sinus. Access to the maxillary sinus will be done through osteotomy, using a piezosurgery under irrigation with saline solution. Subsequently, the Schneider's membrane will be carefully lifted and, according to the randomization process, the graft material (Bio-Oss® mixed with saline solution or Bio-Oss® mixed with Forteo®) will be delivered for placement on the sinus floor maxilla below Schneider's membrane.Next, the access window to the maxillary sinus and Schneider's membrane will be protected. The mucoperiosteal flap will be repositioned and closed.
223699994|NCT06061354|PROCEDURE|Dental Implant Installation|Local anesthesia will be performed a mucoperiosteal flap will be raised in the area for implant placement and a bone core 10 mm high and 2 mm in diameter will be removed with a 2 mm trephine bur. The bone biopsied through this nucleus is part of the region where the implant will be installed, and the height of the sample depends on the surgical planning carried out previously (3-month radiographic control). The sequence of drills to place the implant will continue, installation of the implant itself and, finally, verification of the insertion torque and measurement of the resonance frequency in the already installed implant. The mucoperiosteal flap must be repositioned and sutured.
223699995|NCT06061354|COMBINATION_PRODUCT|Bone graft|One arm:mixture of 20μg of teriparatide, 0.64ml of saline solution with 1g of Bio -Oss® In other arm: 1g of Bio-Oss® will be mixed with 0.72ml of saline solution.
223699996|NCT05591807|OTHER|Electroacupuncture|insert the acupuncture needle to SJ3(left side) and connect the electroacupuncture device for 15min, 2mA and 2Hz
223699997|NCT01585870|DRUG|Sorafenib (Nexavar, BAY43-9006)|"Sorafenib (starting dose of 200 mg bid, level 1) administration will begin on Day 11 of Cycle 1, and will be administered twice daily continuously. If the combination is well tolerated, the dose will be escalated in new cohorts to 200 mg AM and 400 mg PM (level 2), then subsequently to 400 mg bid (level 3).~If sorafenib starting dose (level 1) is not well tolerated with eribulin, the sorafenib dose will be de-escalated to 200 mg qd (Dose Level -1) in a new cohort."
223699998|NCT01585870|DRUG|Eribulin|Eribulin: 1.4 mg/m2 as an intravenous infusion on Days 1 and 8 of each 21-day cycle.
223699999|NCT02021032|DEVICE|Prolieve|Prolieve® is a transurethral microwave therapy device equipped with automated controls designed to deliver microwave energy to the prostate and balloon-administered compression for the treatment of symptomatic BPH. This device utilizes a transurethral catheter with microwave antenna to heat the prostate, with simultaneous 46 Fr. prostatic urethral catheter balloon-administered compression.
223700000|NCT04068935|PROCEDURE|fracture immobilization after reduction of displaced finger fractures|After closed reduction of a displaced finger fracture, fracture immobilization with either Buddy taping or Splint immobilization
223700001|NCT00804284|BIOLOGICAL|DTaP-IPV/Hib|0.5 mL, Intramuscular
223700002|NCT00804284|BIOLOGICAL|Other DTap Vaccines|0.5 mL, Intramuscular
223700003|NCT05027464|BEHAVIORAL|Moving to COVID-19 Vaccine Acceptance Intervention|The intervention utilizes a multi-pronged approach to increase Veteran vaccine acceptance. First, the research team will train Health Behavior Coordinators (HBCs) at VAI sites. HBCs will then train PACT teams at their site and Whole Health Coaches, Peer Specialists and other VA Staff in VAI strategies to use with unvaccinated Veterans. Whole Health Coaches, Peer Specialists and other VA Staff will conduct outreach calls, using strategies, with unvaccinated Veterans.
223700004|NCT01115361|BEHAVIORAL|Family planning for postpartum women|"A.Group education sessions regarding pregnancy risk, benefits of FP, and family planning options during the postpartum period.~B. IEC materials that deliver messages about the benefits of spacing pregnancies by at least 2 years, LAM, return to fecundity and pregnancy risk during the postpartum period and contraceptive options for postpartum women.~C. Use of a screening tool to assess pregnancy risk for postpartum women coupled with a brief counseling message and referral to FP services.~D.Convenient offer of FP services to women attending vaccination services for their infants."
223700005|NCT04539873|DRUG|Colchicine 0.5 MG|Patientes in this arm will receive study medication colchicine 1,5 orally on the first day (initially two pills of 0,5 mg and 0.5 mg at 2 hours), followed by 0.5 mg every 12 hours on days 2 to 7, and continuing with 0.5 mg per day until completing 14 ± 1 days. The duration of treatment will be 14 ± 1 days, depending on the clinical judgment of the investigator.
223700006|NCT04539873|COMBINATION_PRODUCT|CONTROL GROUP|In this case, the centers where the patients are enrolled will adhere to the Colombian guidelines (Colombian Consensus of the Colombian Association of Infectious Diseases)
223700007|NCT02497612|DRUG|Ferroquine SSR97193|Pharmaceutical form:Capsules Route of administration: oral
223700008|NCT02497612|DRUG|Artefenomel|Pharmaceutical form:Granules for suspension Route of administration: oral
223700009|NCT02497612|OTHER|Placebo|Capsules. Placebo capsules were used to keep the same number of capsules in each weight band while keeping the ferroquine dose blinded. No participant received placebo only.
223700010|NCT06306989|DRUG|Letermovir|Participants will be categorized into high-risk and intermediate-risk groups based on risk factors for CMV infection.Initiate letemovir prophylaxis on day +1 in high-risk patients and on days +7 to +14 in non-high-risk patients.(240 mg, qd in patients with concomitant cyclosporine; 480 mg, qd in patients with concomitant tacrolimus) to +100 days. For patients with comorbid GVHD who require intensive immunosuppression, consider extending the regimen to +200 days.
223700011|NCT02231697|OTHER|Non-interventional, retrospective medical chart review|Non-interventional, retrospective medical chart review
223700012|NCT04603612|PROCEDURE|Primary TURBT|"As shown in (Fig. 1), all patients will be thoroughly evaluated by medical history and physical exam, laboratory investigations, abdominal pelvic ultrasound (US). Then, all patients will be managed by cystoscopy and initial complete TURBT. Patients with benign pathology, non-urothelial carcinoma or muscle invasive disease, will be excluded from the study.~After 4-6 weeks, eligible patients will be appointed for repeat resection TURBT."
223700013|NCT00001438|DRUG|all-trans-retinoic acid with IFN-alpha2a|
223700014|NCT02286583|DEVICE|Microwave Thermography RTM-01-RES|Divide the breast into 3 circles start from the nipple with 1 cm increase in the circle diameter. Divide this circle into 8 points. This makes us detect 24 points in addition to the nipple as fixed point and the tail of the breast as separate point giving total of 26 points.
223700015|NCT00760500|OTHER|Nasopharyngeal Swab|Nasopharyngeal Swab
223700016|NCT03378765|BEHAVIORAL|Diet and physical activity monitoring|Lifestyle monitoring
223700017|NCT05731323|DRUG|D-cycloserine|Daily oral D-cycloserine dosed 25mg/17.5kg body weight during TMS treatment days (20 days).
223700018|NCT05731323|DEVICE|Transcranial Magnetic Stimulator|Repetitive Transcranial magnetic stimulation (rTMS) will be delivered using a MagPro X100 device with B70 coil and the intermittent theta burst (iTBS) protocol to the left dorsolateral prefrontal cortex. Participants will receive daily treatments (Monday-Friday) over four weeks.
223700019|NCT05828134|OTHER|protein-enriched soup|The participants in experimental group have a protein-enriched soup a day and do exercise a week
223700020|NCT02167425|OTHER|IMAT|The IMAT intervention will combine three main strategies: point-of-care (POC) CD4 screening, provider training and mentoring, and an alerts and reminder dashboard. The POC CD4 platform will provide real-time clinical staging, enabling providers within the methadone clinic to screen HIV-infected patients for ART eligibility. Coupled with this technology, appropriate training and mentoring will predispose providers to effectively link patients to ART and integration of an alert and reminder dashboard will reinforce behavior change and strengthen processes.
223700021|NCT00176787|DRUG|Capecitabine|
223700022|NCT00176787|PROCEDURE|Radiation|
223700023|NCT00176787|PROCEDURE|Surgery|
223700024|NCT02651467|OTHER|Experimental Oral Rinse 1 (1.5% w/w KOX, 0ppm F, pH 7.0)|1.5% w/w KOX, 0ppm F, pH 7.0
223700025|NCT02651467|OTHER|Experimental Oral Rinse 2 (2.0% w/w KOX, 45ppm F, pH 4.5)|2.0% w/w KOX, 45ppm F, pH 4.5
223700026|NCT02651467|OTHER|Placebo Oral Rinse (0% w/w KOX 0ppm F, pH 4.5 )|0% w/w KOX 0ppm F, pH 4.5
223700027|NCT01157923|DEVICE|MD Logic Pump Advisor|Insulin pump settings (i.e., basal plan, correction factor, carbohydrate ration and insulin activity time) will be adjusted using the MD-Logic Pump Advisor
223700028|NCT05514418|PROCEDURE|Intensive Adherence Counselling (IAC)|Intensive adherence counselling is offered to people living with HIV (PLHIV) having a non-suppressed viral load (VL) result ( a VL of 1,000 copies/ml or more) and this is given once every month for three months. In our study, we are going to give IAC to PLHIV with low-level viraemia (having a VL of 50 copies/ml but less than 1,000 copies/ml) and determine its effectiveness in causing a non-detectable VL (less than 50 copies/ml), which is desirable for PLHIV on ART.
223700029|NCT02024529|BIOLOGICAL|4 mL injection of Ampion|4 mL injection of Ampion
223700030|NCT02024529|DRUG|4 mL Injection of Placebo|4 mL Injection of Placebo
223700031|NCT00354614|DEVICE|ApneaLink Sleep Screener|Device used to evaluate for the presence of OSA
223700032|NCT05938530|DEVICE|Sirolimus drug-coated balloon|The effectiveness of sirolimus coated balloon in patients with dialysis access dysfunction has been shown in a small pilot study in the salvage of thrombosed arteriovenous graft.
223700033|NCT05938530|DEVICE|Stent graft|Stent graft has been shown to be superior than plain balloon angioplasty in the treatment of AVG dysfunction.
223700034|NCT02624960|DEVICE|Accucinch Implant|Percutaneous implantation of the Accucinch Implant in the mitral subannular space
223700035|NCT02301130|BIOLOGICAL|mogamulizumab|Mogamulizumab will be administered intravenously (IV).
223700036|NCT02301130|BIOLOGICAL|MEDI4736 (Durvalumab)|MEDI4736 will be administered intravenously (IV).
223700037|NCT02301130|BIOLOGICAL|tremelimumab|Tremelimumab will be administered intravenously (IV).
223700038|NCT03959631|BEHAVIORAL|Virtual Communities of practice|based on a web 2.0 platform in which there is interaction with other patients and with a multidisciplinary team of professionals. The intervention will be co-designed with a group of patients and a group of primary and specialized care professionals.
223700039|NCT02387138|DRUG|S-1|"S-1: Administered orally twice daily from day 1 for 7 consecutive days followed by a 7-day recovery period in a 14-day cycle.~The starting dose of S-1 will be two levels below the recommended dose defined in SIRI (20 mg/m² BID minimum) with a cohort dose escalation by 5 mg/m² increments (5 dose levels)."
223700040|NCT02387138|DRUG|Irinotecan|Irinotecan : fixed dose of 180 mg/m² IV over 90 minutes on d1 of every cycle
223700041|NCT02387138|DRUG|Oxaliplatin|Oxaliplatin : fixed dose of 85 mg/m² over 120 minutes on d1 of every cycle
223782226|NCT05401123|DEVICE|milking pump|"n the study, all mothers who come to the Lactation/Relactation outpatient clinic will be informed about the study, and mothers who accept the study will have to fill out the Conformity to Criteria Form created by the researcher. Between the ages of 20-35, postpartum 1-5. Participants who gave birth after the 37th week of pregnancy, did not have literacy problems, mental disabilities and communication problems, did not have chronic diseases, did not use any medication, and volunteered to participate in the study will be included in the study. by milking, 2 ml of first milk will be taken from the participants in the control group (via the milking pump). The collected milk will be taken to the laboratory for analysis by the researcher."
223700042|NCT02387138|OTHER|G-csf|G-csf : d8 to d13 systematically
223700043|NCT00082589|DRUG|Eplerenone|
223700044|NCT03761693|OTHER|Fasting test|"The included infants will be fasted according to local standardized procedures at the University Medical Centre Groningen. Fasting will take place under hourly blood glucose monitoring and bedside supervision by an experienced, dedicated pediatric nurse, in collaboration with a metabolic pediatrician, who will be available to attend the patient instantly. Furthermore, on request of parent(s) or guardian(s), a continuous blood glucose monitoring device can be used during the study visits.~During study visit 1, at two months of life, fasting will be continued for maximally eight hours.~During study visit 2, at six months of life, fasting will be continued for maximally twelve hours.~Fasting will be ended prematurely in the following events:~* blood glucose concentration drops \< 3.6 mmol/L;~* the child shows symptoms/signs of a low blood glucose concentration;~* patients parent(s) or guardian(s) request end of fast."
223700045|NCT06556550|RADIATION|stereotactic ablative radiation therapy|stereotactic ablative radiation therapy in effective doses to each metastatic site
223700046|NCT06556550|RADIATION|palliative radiation therapy|palliative radiation therapy (8 Gy/1 Fx, 3 Gy x 10-15 Fx, 4,5 Gy x 5 Fx)
223700047|NCT06556550|DRUG|Chemotherapy|prescribed drug line
223700048|NCT01890746|DRUG|Daunorubicin|For subjects between the ages of 18 and 60 years, 90 mg/m2/day by bolus IV injection through a freshly established free-flowing IV line for 10-15 minutes on days 1, 2, and 3. For subjects \> 60 years: daunorubicin dose was adjusted to 60mg /m2.
223700049|NCT01890746|DRUG|Cytarabine|100 mg/m2/day continuous IV infusion on Days 1 through 7.
223700050|NCT01890746|DRUG|Eltrombopag|200 mg orally, once daily, beginning on Day 4 of the first cycle of induction. After 7 days, the dose of the Investigational Product (IP) was to be increased to 300 mg if platelet counts were \<100 Gi/L. IP continued until achievement of platelet count of at least 200 Gi/L or assessment of remission of bone marrow status or a maximum of 42 days after initiation of most recent induction. In subjects of East Asian heritage 100 mg orally once daily (a 50% dose reduction) was used and after 7 days, the dose of IP was increased to 150 mg if platelet counts were \<100 Gi/L.
223700051|NCT01890746|DRUG|Placebo|Orally, once daily, beginning on Day 4 of the first cycle of induction. After 7 days, the dose given was matching 300 mg Eltrombopag if platelet counts were \<100 Gi/L. Placebo continued until achievement of platelet count of at least 200 Gi/L or assessment of remission of bone marrow status or a maximum of 42 days after initiation of most recent induction. In subjects of East Asian heritage placebo matching 100 mg Eltrombopag orally once daily was used and after 7 days, the placebo matching 150 mg Eltrombopag was given if platelet counts were \<100 Gi/L.
223700052|NCT02642029|DEVICE|Excitatory TMS|Single session of intermittent theta-burst stimulation (600 pulses in blocks of 2s, separated by 8s of pause) to cerebellar vermis.
223700053|NCT02642029|DEVICE|Inhibitory TMS|Single session of continuous theta-burst stimulation of 600 pulses to cerebellar vermis.
223782227|NCT02348216|BIOLOGICAL|Axicabtagene Ciloleucel|A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells administered intravenously at a target dose of 2 x 10\^6 anti-CD19 CAR T cells/kg.
223782228|NCT02348216|DRUG|Fludarabine|Administered according to package insert
223782229|NCT02348216|DRUG|Cyclophosphamide|Administered according to package insert
223782230|NCT02348216|DRUG|Levetiracetam|Administered according to package insert
223782231|NCT02348216|DRUG|Tocilizumab|Administered according to package insert
223782232|NCT02348216|DRUG|Dexamethasone|Administered according to package insert
223700054|NCT02642029|DEVICE|Sham TMS|Single session, using the exact same procedures as the active arms but with a sham coil, which is designed to induce the same nonspecific sensory effects of TMS (auditory and somatosensory activation) without inducing the neuromodulatory magnetic fields.
223700055|NCT05493332|PROCEDURE|HAIC(FOLFOX)|After successful percutaneous hepatic artery cannulation, superior mesenteric arteriogram and hepatic arteriogram were performed, and after confirming that the subjects were eligible for enrollment according to the results, the hepatic artery was cannulated to the predetermined position. The catheter was connected to a syringe pump in the ward for continuous pumping of chemotherapy drugs.
223700056|NCT05493332|DRUG|Oxaliplatin|85mg/m2 IVdrip from hour 0 to 2 on D1，Q3W
223700057|NCT05493332|DRUG|Leucovorin|400mg/m2 IVdrip , from hour 0 to 2 on D1 to D2，Q3W
223700058|NCT05493332|DRUG|Fluorouracil|400mg/m2 , bolus at hour 3 ; and 600mg/m2 IVdrip over 46 hours on D1 to D2，Q3W
223700059|NCT05493332|DRUG|Toripalimab|240mg IVdrip，D3, Q3W
223700060|NCT05493332|DRUG|Donafenib|0.1g. P.O, BID, continuously
223700061|NCT00951548|DIETARY_SUPPLEMENT|VSL#3|Probiotic blend of 8 different strains of lactobacilli and bifidobacteria, dosed at 900 billion bacteria/sachet). Dosage regimen is 2 sachets b.i.d. for 8 weeks
223700062|NCT00951548|DIETARY_SUPPLEMENT|Placebo|Corn Starch. Dosage regimen is 2 sachets b.i.d. for 8 weeks
223700063|NCT04613050|OTHER|Respiratory Training|"Respiratory training in form of :~Diaphragmatic breathing,Segmental breathing, Incentive spirometer:"
223700064|NCT04613050|OTHER|Aerobic training|aerobic exercises are customized according to the patient's underlying disease and residual dysfunction. These exercises will include walking on treadmill. After an initial, 5-minute warm-up phase performed on the treadmill at a low load, each endurance training session lasted 30 minutes and ended with 5-minute recovery and relaxation phase. A total of 3-5 sessions are carried out per week. Patients who are prone to fatigue should perform intermittent exercises
223700065|NCT04046055|DEVICE|Transcranial direct current stimulation at 2 mA|Uses weak electrical current (2 mA intensity) to either increase or decrease brain excitability and improve functional or cognitive outcomes.
223782233|NCT02348216|DRUG|High-dose methylprednisolone|Administered according to package insert
223700066|NCT04046055|DEVICE|Transcranial direct current stimulation at 4 mA|Uses weak electrical current (4 mA intensity) to either increase or decrease brain excitability and improve functional or cognitive outcomes.
223700067|NCT04046055|DEVICE|Sham transcranial direct current stimulation|Uses weak electrical current (2 mA intensity) at the beginning and the end of a given stimulation period to control for potential placebo-like effects or participant expectation bias.
223700068|NCT05273333|DEVICE|Ultra-gyn®|Ultra-gyn® ovule intravaginal application, every evening before bedtime for a 10 days period.
223700069|NCT05704231|BEHAVIORAL|Behavioral: Motivational Interviewing with WhatsApp video call|The intervention group will be given a motivational interview with a WhatsApp video call for 3 months. Motivational interviews will be applied every two weeks, 6 times in total.
223700070|NCT01173757|DRUG|PF-04995274|Single dose of up to 5 mg PF-04995274, delivered in solution on study day 1
223700071|NCT03041857|RADIATION|Observational use of fluoroscopy|
223700072|NCT05476406|OTHER|äKwä skincare system products|The skincare product system tested in this study was äKwä 6-step skincare system from 4Life Research USA, LLC ( https://www.4life.com/6613461/page/äKwä). Product directions state to use the following products morning and night in sequential order: First Wave Oil-to-Foam Cleanser, Glacier Glow Four-Way Toner, Precious Pool Vitamin Essence, Ripple Refine Eye Cream, and RainBurst Moisture Cream.
223700073|NCT05476406|OTHER|competitor products (control)|Participants use whatever their normal daily routine of skincare products, which are commercially available competitor products from the marketplace.
223700074|NCT01588639|DRUG|Insulin (Scilin N, BAY81-9924)|Subjects are treated with recombinant human insulin-SciLin N, SciLin R and SciLin M30 (alone or in combination) in routine clinical practice.
223700075|NCT01588639|DRUG|Insulin (Scilin R _BAY81-9924|Subjects are treated with recombinant human insulin-SciLin N, SciLin R and SciLin M30 (alone or in combination) in routine clinical practice
223700076|NCT01588639|DRUG|Insulin(Scilin M30_BAY81-9924)|Subjects are treated with recombinant human insulin-SciLin N, SciLin R and SciLin M30 (alone or in combination) in routine clinical practice
223700077|NCT06343233|OTHER|usual care|The aim is to set up a collection of clinical and instrumental data of usual care from patients hospitalized for acute heart failure aged ≥ 65; at the time of admission and after 6-12 and 18 months from the event (admission).
223700078|NCT01984788|DRUG|BCX4161|
223700079|NCT01984788|DRUG|Placebo|
223782234|NCT02348216|DRUG|Bendamustine|Administered according to package insert
223700080|NCT01971242|DRUG|Exenatide|2mg, SC (subcutaneous) once weekly. Number of weeks: 48 weeks. Exenatide is a 39-amino-acid peptide
223700081|NCT01971242|OTHER|Placebo|Placebo, 2mg, SC (subcutaneous), once weekly for 48 weeks.
223700082|NCT02422472|DEVICE|Ultrasound guided peripheral IV placement|Accucath™ 20 Gax 5.7cm catheter
223700083|NCT01134731|DRUG|paliperidone|1-5 mg daily (QD)
223700084|NCT01134731|DRUG|lithium|300-1500mg QD
223782235|NCT02348216|DRUG|Rituximab|Administered according to package insert
223700085|NCT01134731|DRUG|Placebo|1-5 placebo capsules
223700086|NCT05761041|DRUG|Sodium Fluoride Varnish (5%)|Applied at baseline
223700087|NCT05761041|BEHAVIORAL|Motivational Interviewing|Two MI sessions: face-to-face at baseline and phone call at 3 months
223700088|NCT05761041|DRUG|SDF|Applied bianually
223700089|NCT03200184|DRUG|sofosbuvir and daclatasvir|A fixed dose combination pill containing 400mg sofosbuvir and 60 mg daclatasvir given daily for 12 weeks. If a patient is cirrhotic, treatment duration would be 24 weeks.
223700090|NCT06114160|OTHER|Data collection|Data collection
223700091|NCT04521816|BEHAVIORAL|PACT Intensive Management|"Purpose: Implement a Patient Aligned Care Team (PACT) model that identifies and proactively manages Veterans at the highest risk for hospital admission and death while they are still in the ambulatory care setting.~Goal:~* Reduce emergency department and urgent care utilization, hospitalization, and mortality in complex, high risk patients~* Improve Veteran and staff satisfaction~Objectives:~* Maintain the patient in the home setting as much as possible~* Secure appropriate home environment to facilitate health and well-being~* Utilize comprehensive team-based care~* Engage appropriate VHA programs to provide interdisciplinary, coordinated, and timely management of complex medical issues"
223700092|NCT00469378|DRUG|firategrast|900 (females) or 1200 (males) mg twice daily for 24 weeks
223700093|NCT04076878|DEVICE|Mollii|The Mollii method is provided in a tight fitting, whole body suit with multiple electrodes that can be set individually. The Mollii method uses low frequencies and low intensities that evokes sensory input but does not directly elicit muscle contractions. The theoretical background of this treatment method primarily refers to the concept of reciprocal inhibition, i.e. that sensory input from a muscle may inhibit the activation of an antagonistic muscle through the activation of the disynaptic reciprocal Ia inhibitory pathway.
223700094|NCT05773443|DEVICE|Digital biomarkers|Digital application Smartwatch Sleep monitor Movement sensor EEG-sensor
223700095|NCT05975879|DIETARY_SUPPLEMENT|undenaturated collagen type II, methylsulfonylmethane, boswellia serrata, vitamin D3 (cholecalciferol), vitamin C (ARTNEO)|"Release form: capsules with an average weight of 585 mg. Active ingredients: MCM (methylsulfonylmethane) 300 mg, vitamin C (ascorbic acid) 80 mg, boswellia extract (65% boswellic acids) 50.05 mg, undenatured (native) type II collagen 40 mg, vitamin D3 (cholecalciferol) 400 IU.~Suggested Use: Adults, 1 capsule daily with meals."
223700096|NCT05975879|DIETARY_SUPPLEMENT|Placebo|Release form: capsules with an average weight of 585 mg. No active ingredients.
223700097|NCT00165659|DRUG|DONEPEZIL HYDROCHLORIDE|
223700098|NCT00676338|DRUG|exenatide once weekly|subcutaneous injection, 2mg, once weekly plus placebo oral once daily
223700099|NCT00676338|DRUG|metformin|oral, 1000-2500mg, daily plus placebo once weekly subcutaneous injection
223700100|NCT00676338|DRUG|sitagliptin|oral, 100 mg, daily plus placebo once weekly subcutaneous injection
223700101|NCT00676338|DRUG|pioglitazone|oral, 30-45mg, daily plus placebo once weekly subcutaneous injection
223700102|NCT03810339|DRUG|Toripalimab|Toripalimab, 240mg, every 3 weeks until disease progress or intolerable toxicity
223782236|NCT02348216|DRUG|Doxorubicin|Administered according to package insert
223700103|NCT01100346|DRUG|Gonal-f (Follitropin alpha)|A starting dose of 75 IU/day subcutaneously is maintained for a period of 7 to 14 days. The follitropin alpha dose would be subsequently increased by 37.5 IU/day at weekly intervals based on the ovarian response.
223700104|NCT02703233|DRUG|Nitrous Oxide|
223700105|NCT02703233|OTHER|Oxygen|
223700106|NCT02411760|PROCEDURE|3 Tesla Magnetic Resonance Imaging|Assessment of the performance of DWI/ADC measurements alone, and as an adjunct to dynamic contrast enhanced (DCE) MRI in diagnosing/characterizing breast cancer.
223700107|NCT01278836|PROCEDURE|fasciocutaneous flap|flaps which include skin, subcutaneous tissue, and the underlying fascia.
223700108|NCT00017199|DRUG|bortezomib|
223782237|NCT02348216|DRUG|Prednisone|Administered according to package insert
223700109|NCT01497717|DRUG|Adalimumab (Humira)|"Open label pilot trial.~The study includes 3 phases :~1. Open label treatment period of 24 weeks.~2. Extension follow -up (3 years): Patients who responded well to study drug and their disease relapsed within the first 12 weeks following study drug interruption will be eligible to receive the study drug for 3 years in order to comply with the Israeli Ministry of Health requirements.~3. Safety follow-up: For patients who withdraw from either the open label treatment period or extension period, for another 24 weeks."
223700110|NCT01549470|BIOLOGICAL|VRC-HIVDNA009-00-VP|Administered as a 4 mg/mL dose by IM injection in the deltoid muscle using the Biojector 2000 needle-free injection management system.
223700111|NCT01549470|BIOLOGICAL|Placebo vaccine|Administered as a 1-mL dose by IM injection in the deltoid muscle using the Biojector 2000 needle-free injection management system.
223700112|NCT02122458|DEVICE|mild-gain hearing aids with high-frequency emphasis over 6-months|open-fit hearing aids with mild amplification in the high frequencies.
223700113|NCT00412542|DRUG|Thalidomide|100 mg PO (by mouth) daily for 8 weeks
223700114|NCT00412542|DRUG|CPT-11|125 mg/m\^2 by vein weekly over 90 minutes for 4 weeks, followed by 2 weeks rest
223700115|NCT00412542|PROCEDURE|MRI Scan|Dynamic MRI scan with dye injection through vein, every 6 weeks
223700116|NCT00412542|PROCEDURE|Quantitative Sensory Tests (QST)|QST, every 12 weeks, to check for any nerve problems that may be present before starting treatment; by touching a small machine tests are done on feeling of touch, vibration, and temperature.
223700117|NCT04055961|DEVICE|Atrial Fibrillation Ablation|A procedure used to treat an irregular heart rhythm (arrhythmia)
223700118|NCT01976195|DRUG|Dexamethasone|Dexamethasone 40 mg per day, 4 consecutive days
223700119|NCT01976195|DRUG|Thalidomide|Thalidomide 150mg per day, 15 consecutive days
223700120|NCT00394823|BEHAVIORAL|Set of supportive tools/measures vs. standard care|
223700121|NCT03161093|DRUG|Fasinumab|Solution for injection in pre-filled syringe
223700122|NCT03161093|DRUG|Naproxen|Pharmaceutical form: Capsule
223700123|NCT03161093|DRUG|Fasinumab-matching placebo|Solution for injection in pre-filled syringe
223700124|NCT03161093|DRUG|Naproxen-matching placebo|Capsule
223700125|NCT03343379|OTHER|Core stability tests|A test battery comprised of field tests to evaluate core stability
223700126|NCT04532502|DRUG|Anesthetics, Inhalation|Work environmental exposure
223700127|NCT05155150|BEHAVIORAL|Providing patient-reported outcome|Patients receive personalized information on expected quality of life one year after ICU during ICU admission (during a family meeting)
223700128|NCT03922997|DRUG|Atezolizumab|Atezolizumab will be administered at a fixed dose of 1200 mg intravenously on the first day of each 21-day cycle.
223700129|NCT01031706|DRUG|Hypertonic Saline|inhaled HS (6% NaCl, 4mL) three times a day for 28 days
223700130|NCT01031706|DRUG|Placebo|4 ml 0.12% NaCl inhaled three times a day x 28 days
223700131|NCT03565978|DEVICE|BAMA solution|Use of BAMA cardiac post-discharge management solution for patients education and follow up management
223700132|NCT05499715|BIOLOGICAL|ScTIL injection|"Peripheral blood mononuclear cells (PBMCs) obtained via apheresis are used for cell preparation. PD-1 positive T cells are isolated from PBMCs, are transduced with lentivirus loaded with enhanced receptor and superamplification factor, and cell number are amplified. The obtained ScTIL is used for one-time intravenous infusion."
223700133|NCT03809676|OTHER|periodontal examination|clinical measurements were recorded
223700134|NCT03949530|DRUG|IDL-2965 Oral Capsule|Investigational drug
223700135|NCT03949530|DRUG|Placebos|Placebo
223782238|NCT02348216|DRUG|Vincristine|Administered according to package insert
223782239|NCT02348216|DRUG|Ifosfamide|Administered according to package insert
223782240|NCT02348216|DRUG|Carboplatin|Administered according to package insert
223782241|NCT02348216|DRUG|Etoposide|Administered according to package insert
223700136|NCT02124161|BIOLOGICAL|13-valent pneumococcal conjugate vaccine|One (1) dose (0.5 mL) will be administered intramuscularly into the left deltoid either at Visit 1 or at Visit 2, depending on the randomization group assigned to the subject.
223700137|NCT02124161|BIOLOGICAL|Seasonal Inactivated Influenza Vaccine|One (1) dose of SIIV will be administered intramuscularly into the right deltoid of all subjects at Visit 1.
223700138|NCT02124161|OTHER|Placebo|One (1) dose (0.5 mL) will be administered intramuscularly into the left deltoid either at Visit 1 or at Visit 2, depending on the randomization group assigned to the subject.
223700139|NCT02124161|OTHER|Placebo|One (1) dose (0.5 mL) will be administered intramuscularly into the left deltoid either at Visit 1 or at Visit 2, depending on the randomization group assigned to the subject.
223782242|NCT02348216|DRUG|Gemcitabine|Administered according to package insert
223782243|NCT02348216|DRUG|Oxaliplatin|Administered according to package insert
223782244|NCT02348216|DRUG|Cisplatin|Administered according to package insert
223700140|NCT02124161|BIOLOGICAL|Seasonal Inactivated Influenza Vaccine|One (1) dose of SIIV will be administered intramuscularly into the right deltoid of all subjects at Visit 1.
223700141|NCT02124161|BIOLOGICAL|13-valent pneumococcal conjugate vaccine|One (1) dose (0.5 mL) will be administered intramuscularly into the left deltoid either at Visit 1 or at Visit 2, depending on the randomization group assigned to the subject.
223700142|NCT04014946|DEVICE|ICD implantation|implantation of the Lumax 540 single/dual chamber ICD or successor
223700143|NCT03173027|DRUG|Fangji Huangqi pill or Fangji Huangqi pill placebo|For the treatment group (Fangji Huangqi pill group), patients will administrate Fangji Huangqi pill (4 g) in 200 milliliter hot water as the instruction and take the solution orally twice a day for 1 month. While patients in the placebo group will take Fangji Huangqi pill placebo as the same way as the Fangji Huangqi pill group. Besides that, both groups will administrate Mobic (7.5 mg once a day) in addition.
223700144|NCT06534684|DEVICE|Intermittent Theta Burst Stimulation|Intermittent Theta Burst Stimulation will be delivered with 120% of resting motor threshold with triplet 50 Hz bursts repeated at 5 Hz; 2 seconds on and 8 s off, 600 pulses per session with a total duration of 3 min 9 s. Treatment will be provided for 10 days for two consecutive weeks (except Saturdays and Sundays).
223700145|NCT02517866|DRUG|Azilsartan Medoxomil|Azilsartan medoxomil tablets
223700146|NCT04477889|OTHER|Treatment for COVID-19|Patients treated for COVID-19
223700147|NCT04226560|DEVICE|41% Silicone Hydrogel Soft Contact Lenses(SHSCL)|Silicone Hydrogel
223700148|NCT04226560|DEVICE|ACUVUE® VITA™ (senofilcon C) Brand (Soft) Contact Lens|Senofilcon C (USFDA Device License #K160212)
223700149|NCT04226560|OTHER|Contact Lens Care Product|Cefatrizine (propylene Glycol), Sodium Citrate (sodium Citrate Tribasic), Sodium Chloride, Sodium Borate (sodium Biboratesodium Tetraborate, Polyquaternium -1, Hydrochloric Acid, Sodium Hydroxide, Water Purified ( Eq to Aqueous Purified Or Purified Water ), Tetronic 1304, Myristamidopropyl Dimethylamine, Nonanoyl Ethylenediaminetriacetic Acid
223700150|NCT04226560|OTHER|Contact Lens Case|"Alcon Soft (hydrophilic) Contact Lens Case (Non-Sterile)"
223700151|NCT02657538|OTHER|Non invasive caries treatment|If the active comparator does not detect cavitation, fluoride varnish is applied on the test surface.
223700152|NCT02657538|OTHER|Invasive caries treatment|If the active comparator does detect cavitation, a composite restauration is placed
223782245|NCT02348216|DRUG|Methylprednisolone|Administered according to package insert
223700153|NCT02657538|DEVICE|Near-infrared light transillumination device (DIAGNOcam, KaVo, Biberach, Germany)|
223700154|NCT02657538|OTHER|Visual examination and bitewing (BW) radiography|established diagnostic methods
223700155|NCT00778544|DRUG|amoxicillin-clavulanic acid 600 mg- 42.9 mg/ 5 mL oral suspension|
223700156|NCT01690637|DRUG|Oseltamivir phosphate suspension|
223700157|NCT01690637|DRUG|Placebo|
223700158|NCT02322346|OTHER|Group S|"Peritonsillar infiltration with saline Additional remifentanil 1 µgr kg-1 IV was administered to the patients if HR was increased by 25 % of the basal value.~During postoperative period, symptoms such as pain, fever and dysphagia, adverse affects such as nausea and vomiting and hemorrhage were evaluated. Pain was evaluated by FLACC (Faces, leg, activity, cry, consolability), FPRS (Faces pain rating scale) ve Wong-Baker facies scales at postoperative 0, 30 and 60 minutes and 2, 6, 12 and 24 hours. Total analgesic consumption during the postoperative period were recorded. If the patients had no complication, they were discharged at the postoperative 24th hour."
223700159|NCT02322346|DRUG|Group LL|"Peritonsillar infiltration with low-dose of levobupivacaine 0.25%. Additional remifentanil 1 µgr kg-1 IV was administered to the patients if HR was increased by 25 % of the basal value.~During postoperative period, symptoms such as pain, fever and dysphagia, adverse affects such as nausea and vomiting and hemorrhage were evaluated. Pain was evaluated by FLACC (Faces, leg, activity, cry, consolability), FPRS (Faces pain rating scale) ve Wong-Baker facies scales at postoperative 0, 30 and 60 minutes and 2, 6, 12 and 24 hours. Total analgesic consumption during the postoperative period were recorded. If the patients had no complication, they were discharged at the postoperative 24th hour."
223700160|NCT02322346|DRUG|Group HL|"Peritonsillar infiltration with high dose of levobupivacaine 0.5%. Additional remifentanil 1 µgr kg-1 IV was administered to the patients if HR was increased by 25 % of the basal value.~During postoperative period, symptoms such as pain, fever and dysphagia, adverse affects such as nausea and vomiting and hemorrhage were evaluated. Pain was evaluated by FLACC (Faces, leg, activity, cry, consolability), FPRS (Faces pain rating scale) ve Wong-Baker facies scales at postoperative 0, 30 and 60 minutes and 2, 6, 12 and 24 hours. Total analgesic consumption during the postoperative period were recorded. If the patients had no complication, they were discharged at the postoperative 24th hour."
223700161|NCT01907581|OTHER|Quality of life questionnaires|
223700162|NCT01903174|DEVICE|AeroForm Breast Tissue Expander|Breast Tissue Expander using a remote control to fill the expander with Carbon Dioxide
223782246|NCT04103229|PROCEDURE|The use of different types and volumes of solutions to inflate the catheter balloon|In catheterization procedure, catheter balloon was inflated according to the type and amount of fluid appropriate to the group to which the patient was assigned.
223782247|NCT01294839|DEVICE|Right ventricular lead location|RV leads in RVOTs group will be located in right ventricular outflow tract septum, RV leads in the other two group will be implanted in right ventricular apex, for the last RVOTs and RVA groups, the accumulated ventricular pacrouping percentage should be over 80% by adjusting AV delays.
223782248|NCT00519805|DRUG|dalteparin|
223782249|NCT00519805|PROCEDURE|quality-of-life assessment|
223700163|NCT05550285|DEVICE|orbital floor recontriction|Guided Calvarial Graft Harvesting vs 3D Printed Titanium mesh
223700164|NCT01147640|DRUG|CXA-101/ tazobactam and metronidazole|CXA-101/tazobactam (1000/500 mg q8h) plus metronidazole (500 mg q8h) administered via IV infusion
223700165|NCT01147640|DRUG|meropenem plus saline placebo|meropenem IV infusion (1000 mg q8h) plus a matching saline placebo (q8h) administered via IV infusion
223700166|NCT01957774|DRUG|THR-18|THR-18 is an 18-mer peptide derived from the sequence of human plasminogen activator inhibitor 1 (PAI-1), having the ability to bind to a site of tissue plasminogen activator (tPA) distal to its catalytic site and uncouple the beneficial clot-dissolving properties of tPA from its deleterious non-fibrinolytic effects.
223700167|NCT01957774|DRUG|Placebo|
223700168|NCT04337268|DRUG|Glucagon-Like Peptide 1|Intravenous infusion (1.5 pmol/kg/min) for 60 min.
223700169|NCT04337268|DRUG|saline 0.9%|Intravenous infusion for 60 min.
223700170|NCT01364077|DRUG|Ivabradine|Ivabradine 5 mg BID titrated to 7.5 mg if tolerated
223700171|NCT01364077|DRUG|Placebo|Matched placebo
223700172|NCT00844584|PROCEDURE|epicardial radiofrequency ablation|epicardial radiofrequency ablation to treat atrial fibrillation under totally thoracoscope
223700173|NCT02650635|DRUG|Cyclophosphamide|Given IV
223700174|NCT02650635|OTHER|Laboratory Biomarker Analysis|Correlative studies
223700175|NCT02650635|BIOLOGICAL|Pegfilgrastim|Given SC
223700176|NCT02650635|OTHER|Pharmacological Study|Correlative studies
223700177|NCT02650635|DRUG|TLR8 Agonist VTX-2337|Given SC
223782250|NCT01055639|BEHAVIORAL|In-Person ACT|8 individual in-person sessions of Acceptance and Commitment Therapy (ACT): includes mindfulness, values, and committed action
223700178|NCT05993819|OTHER|pilates based core stability training and congnitive therapy|Exercises were structured in different conditions such as supine, side-lying, prone, quadruped, sitting, and standing positions. The various variations of each exercise were created so that the easier or more difficult versions of the exercises were selected according to the level of the patients, basically in the same training plan for all.the patients also will receive cognitive behavioural therapy.The CBT manual was written specifically for this trial. The sessions were collaborative in style, and the therapist used Socratic questioning wherever possible. The main aim was to challenge any behavioral, cognitive, emotional and external factors that may be contributing to MS fatigue.
223782251|NCT01055639|BEHAVIORAL|Telehealth ACT|8 individual telehealth sessions of Acceptance and Commitment Therapy (ACT): includes mindfulness, values, and committed action
223782252|NCT00525317|DRUG|"Nycoplus Magnesium (120 mg x 3 daily for 2 weeks)"|120 mg x 3 or placebo
223782253|NCT00562159|DRUG|Placebo|Placebo sublingual tablet
223782254|NCT00562159|BIOLOGICAL|SCH 697243|SCH 697243 (2800 Bioequivalent Allergen Units \[BAU\] of Phleum pratense extract, containing approximately 15 mcg Phl p 5), administered sublingually once daily.
223700179|NCT05993819|OTHER|Pilates based core stability training|Exercises were structured in different conditions such as supine, side-lying, prone, quadruped, sitting, and standing positions. The various variations of each exercise were created so that the easier or more difficult versions of the exercises were selected according to the level of the patients, basically in the same training plan for all. The exercises were gradually made more difficult to increase the stabilization of the trunk by gradually reducing the support surface, increasing the extremity loading, and adding various materials.Exercises were progressed every 2 weeks in both groups and were performed with 10 repetitions for the first 4 weeks and 15 repetitions for the next 4 weeks.
223700180|NCT00569465|DRUG|Arginine|1200 mg, once a day
223700181|NCT00569465|DRUG|Acetylcysteine|600 mg twice a day
223700182|NCT00569465|DRUG|Placebo|3 vials a day
223700183|NCT01797731|DEVICE|Digital hand-held surgical navigation system|Digital hand-held surgical navigation system used for tibial component placement in total knee arthroplasty
223700184|NCT01797731|DEVICE|Conventional tibial extramedullary alignment system|This is the standard of care for total knee arthroplasty.
223782255|NCT00562159|DRUG|Loratadine 10 mg Rescue Treatment|Loratadine 10 mg RediTabs tablets were dosed orally once daily as rescue medication among participants with a total symptom score ≥ 4 during the GPS.
223782256|NCT00562159|DRUG|Olopatadine 0.1% Rescue Treatment|Olopatadine hydrochloride 0.1% ophthalmic solution was administered intraocularly at a dose of 1 drop in each affected eye twice daily as rescue medication for rhinoconjunctivitis, as needed.
223782257|NCT00562159|DRUG|Mometasone 50 mcg Rescue Treatment|Mometasone furoate monohydrate nasal spray 50 mcg was admininstered intranasally at a dose of 2 sprays in each nostril once daily as rescue medication for rhinoconjunctivitis, as needed.
223782258|NCT00562159|DRUG|Prednisone 5 mg Rescue Treatment|"Prednisone 5 mg tablets were administered orally at a dose of 1 mg/kg/day~(maximum 50 mg/day) on Day 1 and 0.5 mg/kg/day (maximum 25 mg/day) on Days 2, 3, 5 and 7 as rescue medication for rhinoconjunctivitis among participants with a total symptom score of ≥ 4 despite treatment with loratadine and mometasone furoate nasal spray."
223700185|NCT01826773|DRUG|CardioPET™|CardioPET™ will be intravenously injected to each subject as a single radio-labeled dose of up to 8 mCi (296 MBq).
223700186|NCT03231657|DIAGNOSTIC_TEST|Placental biomarkers|sFlt1 and P1GF levels and sFlt1/PlGF ratio
223700187|NCT04489797|DRUG|Acalabrutinib|Participants will receive single oral dose of acalabrutinib on day 1 as per the arms they are randomized.
223700188|NCT04489797|DRUG|Rabeprazole|Participants will receive twice daily oral dose of 20 mg rabeprazole on days -3, -2, and -1.
223782259|NCT00562159|DRUG|Albuterol sulfate 108 mcg|Albuterol sulfate inhalation aerosol 108 mcg/inhalation was administed via inhalation at a dose of 2 inhalations every 4 to 6 hours, as needed, as rescue medication for asthma.
223782260|NCT00562159|DRUG|Fluticasone propionate 44 mcg|Fluticasone propionate inhalation aerosol 44 mcg/inhalation was administered via inhalation at a dose of two inhalations twice daily, to a maximum dose of 10 inhalations twice daily, as rescue medication for asthma among participants utilizing four or more albuterol sulfate inhalations/day for 2 days for nocturnal asthma or shortness of breath.
223782261|NCT00562159|DRUG|Prednisone 5 mg|Prednisone 5 mg tablets were administered orally at a dose of 1 mg/kg/day (maximum 50 mg/day) on Day 1 and 0.5 mg/kg/day (maximum 25 mg/day) on Days 2, 3, 5 and 7 as rescue medication for asthma at the discretion of the investigator for the treatment of asthma exacerbation.
223782262|NCT00610051|DRUG|Alprostadil|central venous access continuous delivery with 500mcg/48 hours in active arm
223782263|NCT04741425|OTHER|REST intervention|"The breastfeeding talk will be conducted by Zoom at the third trimester about breastfeeding benefits and other practical advices. There is also a sharing session by a successful breastfeeding mother and a group discussion with different breastfeeding scenarios.~Once the mothers return home after delivery, individualized breastfeeding coaching will be provided by PI through a daily Zoom videoconference within 24 hours upon hospital discharge till Day 7 after delivery.~During the last breastfeeding videoconference, mothers will be reminded to have weekly telephone follow-ups by PI from week 2 to 2 months postpartum.~Women who are randomised into the intervention group will receive REST in addition to the standard antenatal and postnatal care (described at below) by the Obstetrics Department of their delivery hospitals."
223700189|NCT03878953|DRUG|rhPTH(1-84)|Participants will receive a SC injection of initial dose of 50 mcg of rhPTH(1-84) once daily (QD) in the thigh (alternate thigh every day). If albumin-corrected serum calcium (ACSC; \[mg/dL\] = serum calcium \[mg/dL\] +0.8\*\[4-serum albumin (g/dL)\]) is \>2.25 mmol/L (\>9.0 mg/dL), a starting dose of 25 mcg will be considered. At 4 week intervals the rhPTH(1-84) dose may be increased in 25 mcg increments to a maximal dose of 100 mcg SC QD. At any time during the study as needed for safety reasons, rhPTH(1-84) doses may be decreased in 25 mcg decrements to a minimum of 25 mcg QD. If the ACSC is \>2.97 mmol/L (\>11.9 mg/dL), then the investigational product should be stopped until the calcium level is corrected.
223700190|NCT04803539|DRUG|capecitabine|capecitabine is proved to improve 5-year disease-free survival among women with early-stage triple-negative breast cancer who received standard adjuvant treatment(The SYSUCC-001 Randomized Clinical Trial)
223700191|NCT04803539|DRUG|capecitabine + camrelizumab + apatinib|Camrelizumab combined with apatinib is a safe and effective combination proved in patients with advanced TNBC in our early study
223700192|NCT03711318|DRUG|Buprenorphine/naloxone|3 week treatment with buprenorphine/naloxone
223700193|NCT01199328|DRUG|Aspirin|81mg Tablet oral, once daily
223700194|NCT01199328|DRUG|Esomeprazole|20 mg Tablet oral, once daily
223700195|NCT00804622|DRUG|telbivudine|daily oral administration,600mg,over 12 weeks
223700196|NCT00804622|DRUG|tenofovir disproxil fumarate|daily oral administration,300mg,over 12 weeks
223700197|NCT00804622|DRUG|telbivudine plus tenofovir disproxil fumarate|daily oral administration of telbivudine 600 mg and tenofovir disproxil fumarate 300 mg in combination given over 12 weeks
223700198|NCT02163980|DRUG|Caudal ropivacaine + normal saline|
223700199|NCT02163980|DRUG|Caudal ropivacaine + dexmedetomidine|
223782264|NCT00918294|DEVICE|QuickOpt|The QuickOpt algorithm will suggest values for programming AV, PV and VV delay.
223782265|NCT01391377|DRUG|Niacin/Laropiprant combination|Niacin 1g / Laropiprant 20mg for 4 weeks followed by Niacin 2g / Laropiprant 20mg for 4 weeks
223782266|NCT01391377|DRUG|Sugar pill|Placebo
223782267|NCT01513850|DRUG|Hepabulin IV|I.V.
223782268|NCT03871387|DRUG|Deep Group|"* Continuous Rocuronium (Rocnium®, Hanlim Pharm. Co., Ltd., South Korea) infusion during surgery~* Titrate Rocuronium (Rocnium®) infusion rate to maintain TOF = 0 \& PTC= 1\~2 (TOF = train-of-four. PTC = post-tetanic count)~* TOF and PTC are assessed by acceleromyography (TOF-Watch® SX, Organon Ltd., Drynam Road, Swords, Co. Dublin, Ireland).~* At the end of surgery, IV Sugammadex (Bridion®, Merck Sharp and Dohme \[MSD\], Oss, the Netherlands) injection to reverse muscle relaxation.~* Sugammadex dose = 2mg/kg at TOF ≥2 or 4mg/kg at TOF \< 2"
223782269|NCT03871387|DRUG|Control Group|"* Continuous Rocuronium (Rocnium®, Hanlim Pharm. Co., Ltd., South Korea) infusion during surgery~* Titrate Rocuronium (Rocnium®) infusion rate to maintain TOF = 1\~2~* TOF and PTC are assessed by acceleromyograph (TOF-Watch® SX, Organon Ltd., Drynam Road, Swords, Co. Dublin, Ireland).~* At the end of surgery, IV Sugammadex (Bridion®, Merck Sharp and Dohme \[MSD\], Oss, the Netherlands) injection to reverse muscle relaxation.~* Sugammadex dose = 2mg/kg at TOF ≥2 or 4mg/kg at TOF \< 2"
223782270|NCT01620463|DRUG|liraglutide|Single dose administered subcutaneously at four different dose levels: 2.5, 5.0, 10.0 and 15.0 mcg/kg. Following completion of each dose group, an evaluation will be performed to allow progression to the next dose group
223700200|NCT00091442|DRUG|Docetaxel|Docetaxel monotherapy: docetaxel 75 mg/m2 solution administered by intravenous infusion over 1 hour on Day 1 of every 21-day cycle. DOXIL in combination with docetaxel: docetaxel 60 mg/m2 solution administered by intravenous infusion over 1 hour on Day 1 of every 21-day cycle
223700201|NCT00091442|DRUG|DOXIL|DOXIL 30 mg/m2 solution administered by intravenous infusion over 1 hour on Day 1 of every 21-day cycle.
223700202|NCT00351988|BEHAVIORAL|Phenomenological Interviews|Part 1 will collect phenomenologic data to understand the meaning of caregiver burden, and the positive experiences faced when caring for a underserved patient with advanced lung cancer.
223700203|NCT00351988|BEHAVIORAL|Quantitative Interviews|Part 2 will collect quantitative data to determine the prevalence and severity of symptoms experienced by caregivers and their contribution to caregiver burden.
223782271|NCT01620463|DRUG|placebo|Single dose administered subcutaneously at four different dose levels: 2.5, 5.0, 10.0 and 15.0 mcg/kg. Following completion of each dose group, an evaluation will be performed to allow progression to the next dose group
223782272|NCT00765245|DRUG|Lenalidomide|Orally once daily on days 1-21. Treatment repeats every 28 days for 12 courses in the absence of disease progression or unacceptable toxicity.
223782273|NCT00765245|DRUG|Lenalidomide|Lenalidomide 20 mg daily, Days 1-21, followed by 7 days rest (28-day cycle). Cycles will be repeated every 28 days for a total of 12 cycles
223782274|NCT00765245|DRUG|Rituximab|Rituximab 375 mg/m2 intravenously (IV) starting on Day 8, Cycle 1 of lenalidomide. Rituximab will be repeated on Day 8 of odd numbered cycles (Cycles 1, 3, 5, 7, 9, and 11) for a total of 6 doses from randomization.
223782275|NCT02010385|DRUG|Octreotide|
223782276|NCT02010385|DRUG|Saline|
223700204|NCT06643026|OTHER|Food preference|Evaluate the impact of chemotherapy on the dietary preferences of patients with digestive cancer using a dietary and quality-of-life questionnaire at the beginning, middle and end of the chemotherapy/immunotherapy treatment.
223700205|NCT00581243|DRUG|SLV-313 SR|sustained relase tablets taken once daily for 14 days
223700206|NCT03076619|OTHER|clinical ophthalmoscopy|To study the role of clinical ophthalmoscopy in PIH in diagnosis, prognosis, differential diagnosis, line of treatment and effect of treatment.
223700207|NCT06556290|OTHER|Gluten free and casein free diet|Parents will be advised for three months to ensure that children with autism spectrum disorder follow a casein-free and gluten-free diet during this period.
223782277|NCT05874934|DEVICE|Intrahepatic biliary stent with retrieval string|Plastic biliary stent with 3-0 nylon (ethilon) thread tied to the distal end of the stent through the existing sidehole.
223700208|NCT00690222|PROCEDURE|Intracameral injection of mydriatic agent|A mixture of 0.2 % tropicamide and 2% phenylephrine will be injected into the anterior chamber at the beginning of surgery
223700209|NCT02140112|BIOLOGICAL|Trichuris suis ova|
223700210|NCT02140112|OTHER|Placebo|
223700211|NCT00903318|BEHAVIORAL|Questionnaire|Questionnaire about family's characteristics taking about 30-35 minutes to complete.
223700212|NCT02008175|RADIATION|Conventional CXL|Crosslinking was done according to the standard protocol using hypo-osmolar riboflavin (\<0.1%) to saturate the cornea following epithelial debridement and ultra - violet light of 370nm with energy density of 3 milliwatts/cm2 with riboflavin and distilled water alternated every 2 minutes was used for the procedure..
223700213|NCT00002240|DRUG|Atazanavir|
223700214|NCT00002240|DRUG|Nelfinavir mesylate|
223700215|NCT00002240|DRUG|Stavudine|
223782278|NCT00883571|PROCEDURE|house advancement flap group|A house flap of healthy tissue was incised to the depth of ischiorectal fat. The flap consisted of skin and subcutaneous tissue. The flap was sufficiently mobilized without undermining its fatty base containing perforating blood vessels. The flap should be loose and easily advanced into the anal canal. When the ''base'' of this house-shaped flap was advanced into the anal canal defect, it was fixed to the top of the excised area with 3/0 Vicryl sutures.
223782279|NCT00883571|PROCEDURE|Rhomboid flap GROUP|A rhomboid flap was incised in ischeorectal fossa and was mobilized without undermining of its fatty base into the anal canal so that the tip of rhomboid flap is sutured to the top of stricured area using vicryl 3/0.
223782280|NCT00883571|PROCEDURE|Y-V anoplasty GROUP|Y-V anoplastyis performed by making a v shaped incision in the perianal skin posteriorly starting from the lower end of the wound resultant from excision of scared area. A V-shaped flap is then dissected with preservation fatty base .The V flap is then advanced into the anal canal so that its tip is sutured to the top of structured area using vicryel 3/0.
223782281|NCT03748745|DRUG|SH229|tablet, oral, 600 mg once daily for day 1 to day 14
223700216|NCT00002240|DRUG|Didanosine|
223700217|NCT02836275|OTHER|Diffusion/Perfusion-weighted Magnetic Resonance Imaging|
223700218|NCT01631110|BIOLOGICAL|Inflexal V|Intramuscular administration (M. deltoideus) of a single dose of 0.5 mL Inflexal V
223700219|NCT06556303|OTHER|Acupressure|Acupressure
223782282|NCT03748745|DRUG|SH229|tablet, oral, 600 mg once daily for day 8 to day 14
223782283|NCT03748745|DRUG|Daclatasvir dihydrochloride|tablet, oral, 60 mg once daily for day 8 to day 14
223782284|NCT03748745|DRUG|Daclatasvir dihydrochloride|tablet, oral, 60 mg once daily for day 1 to day 14
223782285|NCT02731092|DIETARY_SUPPLEMENT|Lactoferrin|Bovine Lactoferrin 100 mg/ml dissolved in sterile water
223782286|NCT04602520|BEHAVIORAL|3 Wishes Project|Behavioral: Focused conversations at end-of-life to promote the connections between patients, family members, and clinicians.
223700220|NCT05288478|COMBINATION_PRODUCT|Dentoxol mouthrinse dosages|Subjects will have a dose regimen assigned randomly, group A: first 6 weeks 5 times a day, following 6 weeks twice a day, and group B: first 6 weeks 2 times a day following 6 weeks 5 times a day, both with a 4 week washout period in between.
223700221|NCT02175628|DEVICE|Acoustic Angiography|"Acoustic angiography imaging involves a research high frequency ultrasound scanner (VisualSonics Vevo 770) and a prototype transducer as well as conventional b-mode ultrasound to guide the location of the imaging. The conventional ultrasound will be conducted just prior to the acoustic angiography for localization. The imaging also requires administration of Definity ultrasound contrast agent.~Acoustic angiography imaging will be performed by trained medical personnel using mild compression to eliminate motion. Total imaging time is estimated to be less than 15 minutes. All image data will be de-identified and transferred for off-line analysis based on a study ID. The research images will NOT be interpreted or analyzed for clinical decisions related to the patient."
223782287|NCT02377986|BEHAVIORAL|BIT+in-home decluterring|BIT Workshop + In-home decluttering practice
223700222|NCT02148159|DEVICE|Cachexia Acupuncture-A (Peace Classic Needles® )|Acupuncture-A group will receive acupuncture in a pre-determined set of the acupuncture points.
223700223|NCT02148159|DEVICE|General Acupuncture-B (Peace Classic Needles®)|Acupuncture-B group will receive acupuncture in a pre-determined set of the acupuncture points.
223700224|NCT02869503|OTHER|Data collection|
223700225|NCT03480906|DRUG|Latanoprost|Latanoprost ophthalmic solution administered as a microdose spray
223700226|NCT03480906|DRUG|Latanoprost|Latanoprost ophthalmic solution administered as an eyedrop
223700227|NCT06465095|GENETIC|Baseline|Measurements and sampling
223700228|NCT00394160|DRUG|MK0476, Montelukast Sodium /Duration of Treatment : 14 Days|
223700229|NCT00000471|BEHAVIORAL|diet, vegetarianism|
223700230|NCT00000471|BEHAVIORAL|diet, fat-restricted|
223700231|NCT00000471|BEHAVIORAL|exercise|
223700232|NCT00000471|BEHAVIORAL|smoking cessation|
223700233|NCT00236444|DRUG|risperidone|
223700234|NCT05920694|DEVICE|Continuous Positive Airway Pressure Device (CPAP)|Metabolic studies will be performed before and after initiation of CPAP therapy, which is currently the first-line standard of care for treatment of patients with OSA, both with and without hypoxia.
223700235|NCT05920694|OTHER|Delayed Continuous Positive Airway Pressure Device (CPAP)|Metabolic studies will be performed before and after the study period of 12 weeks. After 12 weeks, participants will immediate receive CPAP therapy, which is currently the first-line standard of care for treatment of patients with OSA, both with and without hypoxia.
223700236|NCT00227929|PROCEDURE|Care Management|
223700237|NCT01781364|BEHAVIORAL|Brain Fitness Training, Posit Science SF|Computer aided cognitive training based on principles of neuroplasticity
223700238|NCT03785938|DIETARY_SUPPLEMENT|Probiotic|Liquid probiotic supplied by the company Symprove
223700239|NCT03785938|OTHER|Placebo|Placebo made of maltdextrin. Will be similar in taste and consistency
223700240|NCT05095454|DEVICE|Percutaneous epidural electrical spinal stimulation|"Abbott percutaneous trial lead for epidural neurostimulation (Model 3086)~Ripple Neuromed Nomad Neurostimulation System"
223700241|NCT05095454|DEVICE|Transcutaneous electrical spinal stimulation|Digitimer DS8R Bipolar Constant Current Stimulator
223700242|NCT04943718|BIOLOGICAL|personalized vaccine|Based on genetic and transcriptional sequencing information, personalized peptide vaccines would be designed and produced; patients would be vaccinated on day 1, 4, 8 ,15, 22 and then on week 12, 20.
223700243|NCT04974983|OTHER|Observation of neurological deficits|Observation of neurological deficits
223700244|NCT05840640|DRUG|Standard Medical Therapy|Standard medical therapy involves primary treatment with normal hospital nutrition (1800 to 2000 kcal per day). Diuretics, sodium restriction and albumin for treatment of ascites or fresh frozen plasma for coagulopathy or antibiotics for any focus of infection as spontaneous bacterial peritonitis (SBP), pneumonia, cellulitis, and urinary tract infection as indicated.
223700245|NCT05840640|DRUG|G-CSF|standard medical therapy plus G-CSF- 5μg/Kg s.c every 12 hours for 5 consecutive days
223700246|NCT05840640|DRUG|G-CSF and NAC|Standard Medical Therapy plus G-CSF with intravenous NAC (day 1: NAC at 150, 50, and 100 mg/kg in 250, 500, and 1000 ml of 5% glucose solution over 30 minutes, 4 hours, and 16 hours, respectively; days 2 through 5: 100 mg/kg/day in 1000 ml of 5% glucose solution followed by oral NAC from days 6 to 28)
223700247|NCT02153333|PROCEDURE|Serum sample|Serum samples collected at pre-vaccination and at 1-2 months post Dose 2 in the previously conducted clinical trials will be assessed for anti-PCV-1 antibodies in this study. Additionally, pre-vaccination sera samples from any infants testing positive for PCV-1 antibodies at the post-vaccination time point will also be evaluated.
223700248|NCT03254290|BIOLOGICAL|NeoMTA|A new formulation of MTA was developed in which bismuth oxide was omitted.
223700249|NCT03254290|BIOLOGICAL|Formocresol|Control group
223700250|NCT03624985|DRUG|Intravenous Lidocaine Infusion|Patients will be randomly assigned to receive 1 mg/kg lidocaine bolus and intraoperative infusion of 2 mg/min.
223700251|NCT03624985|DRUG|Placebo Infusion|Patients will be randomly assigned to receive a 1mg/kg bolus of water with 5% dextrose and an intraoperative infusion of 2mg/min. of water with 5% dextrose
223700252|NCT03857399|DRUG|Caspofungin|Considering the possibility of fungal infection, we take empiric therapy for the patients with persistent fever and agranulocytosis using caspofungin for injection.
223700253|NCT02917850|PROCEDURE|Isokinetic hip flexors strengthening|Isokinetic excentric strengthening of paretic hip flexors, 3/w during 6 weeks, in addition to conventional rehabilitation 7/w.
223700254|NCT02917850|PROCEDURE|Conventional rehabilitation|Conventional rehabilitation 10/w during 6 weeks
223700255|NCT06341101|DRUG|Perindopril|In case of side effects Perindopril will be replaced by Valsartan
223700256|NCT03032133|PROCEDURE|Regional pain control|Regional pain catheter
223700257|NCT03032133|PROCEDURE|Local pain control|Local intraarticular pain catheter
223700258|NCT01842100|DRUG|Universal antibiotic prophylaxis|100 mg twice daily for 7 days starting on the day of induced abortion
223700259|NCT01842100|OTHER|Screen-and-treat|Specific antibiotic treatment was only given if the women was found to have sexually transmitted infection(s) on screening.
223700260|NCT01553383|DEVICE|"nasal peep valve Provent"|application of nasal peep valve vs dental device and cpap
223700261|NCT03342963|DRUG|ASC-01|Aripiprazole 3 mg/sertraline 100 mg combination drug
223700262|NCT03342963|DRUG|Aripiprazole and sertraline|Aripiprazole 3 mg and sertraline 100 mg
223700263|NCT00879099|DRUG|Paroxetine|Paroxetine 20 mg once a day during two treatment periods. One treatment period lasts for 3 days.
223700264|NCT00879099|DRUG|Placebo|Gelatine capsule once a day during two treatment periods. One treatment period lasts for 3 days.
223700265|NCT00879099|DRUG|timolol maleate|Oftan Timolol 0,5 % eye drop. One drop into both eyes on day 3 after taking paroxetine or placebo capsules for three days.
223700266|NCT00879099|DRUG|timolol maleate|Timosan 0,1 % eye gel. One drop into both eyes on day 3 after taking paroxetine or placebo capsules for three days.
223782288|NCT02377986|BEHAVIORAL|In-Home Decluttering|In-home decluttering practice
223782289|NCT04450823|OTHER|no intervention|no intervention study, survey amongst health workers
223782290|NCT00053131|BIOLOGICAL|filgrastim|
223782291|NCT00053131|BIOLOGICAL|sargramostim|
223700267|NCT04996771|DRUG|Surufatinib,Etoposide,Cisplatin,Toripalimab|"In dose escalation, Surufatinib and will be administered orally (PO) once daily (QD) ,d1-21，q3w+Toripalimab 240mg,d1,q3w+Etoposide 100mg/m2,d1-3,q3w+Cisplatin 75mg/m2 , d1, q3w,4 cycles in total.~At the indication-specific expansion portion of the study, patients will receive surufatinib RP2D,d1-21，q3w+Toripalimab 240mg,d1,q3w+Etoposide 100mg/m2,d1-3,q3w+Cisplatin 75mg/m2 , d1, q3w,4 cycles in total. After the end of the first-line treatment, patients with CR, PR, and SD can continue to maintenance treatment with Surufatinib RP2D,d1-21，q3w＋Toripalimab 240mg,d1,q3w was taken orally until the disease progressed."
223782292|NCT00053131|DRUG|cytarabine|
223782293|NCT00053131|DRUG|mitoxantrone hydrochloride|
223782294|NCT01614210|DRUG|Tamoxifen|All patients will take tamoxifen 20 mg po daily for 7 days prior to surgery and for 14 days after surgery.
223700268|NCT04996771|DRUG|Surufatinib,Etoposide,Cisplatin|"In dose escalation, Surufatinib and will be administered orally (PO) once daily (QD) ,d1-21，q3w+Etoposide 100mg/m2,d1-3,q3w+Cisplatin 75mg/m2 , d1, q3w,4 cycles in total.~At the indication-specific expansion portion of the study, patients will receive surufatinib RP2D,d1-21，q3w+Etoposide 100mg/m2,d1-3,q3w+Cisplatin 75mg/m2 , d1, q3w,4 cycles in total. After the end of the first-line treatment, patients with CR, PR, and SD can continue to maintenance treatment with Surufatinib RP2D,d1-21，q3w was taken orally until the disease progressed."
223700269|NCT01667484|DRUG|Adderall XR 5mg|
223700270|NCT01667484|DRUG|Adderall XR 10 mg|
223700271|NCT01667484|DRUG|Placebo|
223700272|NCT01424709|DRUG|Gemcitabine, Docetaxel, CPT-11,Cisplatin|Based on expression levels of RRM1 and BRCA1 mRNA，one of the four regimens will be given to each patient: Gemcitabine/cisplatin, Docetaxel/gemcitabine, CPT-11/Cisplatin, docetaxel monotherapy. The chemotherapy will be repeated every 3 week. Dose reduction or interruption for toxicity could take place at any time.
223700273|NCT01424709|DRUG|gemcitabine/cisplatin|gemcitabine/cisplatin up to 6 cycles or disease progression or intolerable toxicity.
223782295|NCT01614210|PROCEDURE|Breast cancer surgery|Breast cancer surgery
223782296|NCT02911402|OTHER|sea sickness questionnaires|
223700274|NCT05929053|OTHER|Vaccine Education Program Based on Integrated Change Model|Vaccine Education Program Based on Integrated Change Model The training will take place in four sessions, one week apart, and each session will last approximately 45 minutes. The training will be carried out as group training with 4-5 people.
223700275|NCT06525597|BIOLOGICAL|Stapokibart Injection|IL-4Rα monoclonal antibody
223700276|NCT06525597|DRUG|Placebo|Placebo
223700277|NCT05421923|DRUG|SR1375 capsules|Ascending single and multiple doses of SR1375 orally
223700278|NCT05421923|OTHER|Placebo|Ascending single and multiple doses of Placebo orally
223700279|NCT03605212|DRUG|Febuxostat|Intervention is orally administered to patients in this arm.
223700280|NCT01756053|DRUG|ABT-089|Selective neuronal nicotinic receptor agonist.
223700281|NCT01756053|DRUG|Placebo|Matched placebo capsules supplied by study drug supplier.
223700282|NCT00900107|PROCEDURE|Exercise|
223700283|NCT06334458|DIAGNOSTIC_TEST|Early diagnosis for Pancreatic Cancers in high-risk asymptomatic subject groups|Early diagnosis for Pancreatic Cancers in high-risk asymptomatic subject groups by developing and validating a comprehensive cancer risk prediction algorithm (CRPA) as a clinical support tool to calculate a personalized risk profile
223700284|NCT00285818|DRUG|Mifepristone|Mifepristone is a glucocorticoid receptor antagonist.
223700285|NCT00285818|DRUG|Placebo Oral Capsule|Placebo is a capsule without a pharmacological active ingredient
223700286|NCT02798146|OTHER|blood collection|Blood samples are collected on the following days after human chorionic gonadotropin (hCG) injection: Day 0, Day 1, Day 2, Day 3, Day 4, Day 5, Day 6
223700287|NCT05836181|BEHAVIORAL|Eye Movement Desensitization and Reprocessing|Effects of Eye Movement Desensitization and Reprocessing on Anxiety, Depression, Quality of Life, Blood Pressure and Heart Rate Variability in Patients with Hypertension.
223782297|NCT01181921|DRUG|Galantamine|Type= range, unit= mg, number= 8-24, form= capsule, route= oral use. The starting dose will be 8 mg/day for 4 weeks. Subsequently, the initial maintenance dose will be 16 mg/day for 4 weeks. Then, an increase to the maintenance dose of 24 mg/day should be considered on an individual basis after appropriate assessment.
223700288|NCT04041375|BEHAVIORAL|iNSPiRED|The peer intervention will include approximately 5 to 6 contacts over a 3-month period. Peer navigators are responsible for providing emotional and social support, normalizing the difficulty of living with DM, modeling help-seeking behaviors, and connecting patients with VHA and/or CBOs to address mental health and DM self-management needs. Peer coaches are not responsible for health education directly; rather, they encourage patients to use appropriate programs in which mental health and DM self-management services are provided.
223700289|NCT04041375|OTHER|Usual Care|Veterans randomized to the usual care condition will be encouraged to follow-up with their primary care provider and/or specialty providers for management of their health conditions. They will also receive a packet of printed information that includes a list of self-management support resources in the VHA and the local community. They will receive no further specific recommendations
223700290|NCT01971840|BEHAVIORAL|MOVI-KIDS|MOVI-KIDS is a multidimensional intervention that consist of: a) for children, 4.5 h/week of a standardized recreative, non-competitive physical activity extracurricular program; b) informative sessions to parents and teachers about how schoolchildren can became more active, and c) interventions in the playground (environmental changes: equipment, facilities, painting, etc.) aimed to promote physical activity during recess (MOVI-Playground).
223700291|NCT00515177|BEHAVIORAL|Mindfulness-Based Stress Reduction|The intervention is a standardized program of mindfulness training led by an instructor. 8 weekly 2.5 hours sessions provide information on stress, cognition and health and training in a variety of mindfulness techniques including gentle yoga, body scan and sitting meditations. The program includes homework and home practice of mindfulness.
223700292|NCT00515177|DRUG|eszopiclone|"One 3 mg tablet of eszopiclone nightly for 8-weeks followed by 3-months of as needed use"
223700293|NCT05854199|BEHAVIORAL|Telehealth solution|Telehealth nutrition education platform
223700294|NCT04981392|BEHAVIORAL|Primary care text message outreach to unvaccinated patients and resources to support PCPs|"Patients: Eligible patients will receive a series of text messages from their PCP or primary care clinic recommending a study website as a trusted source of information about the COVID-19 vaccines and information on how and where to schedule a vaccination.~Providers: PCPs will receive resources to support their conversations with patients about the COVID-19 vaccines (factsheets, prescription pads, electronic smartphrase)."
223700295|NCT03819673|BEHAVIORAL|Intervention Group Care|children's assessment, setting weight management goals, provision of personalised meal plans, personalised diet and lifestyle optimization advice recommendations to children and their families, periodic re-evaluation every 3 or 6 months
223700296|NCT06210581|OTHER|Supervised Exercise Program Group|The exercise programs will performed with the physiotherapist. The treatment programs of the patients will start with warm-up exercises and continue with aerobic exercises. Strengthening exercises will be performed in lying, sitting and standing positions. Body weight or free weight will be used for strengthening exercises. Balance exercises will be performed in sitting and standing positions and will be performed with or without support according to the patients conditions. The treatment sessions will be terminated by performing relaxation exercises combined with stretching and breathing exercises.
223782298|NCT02021435|DIETARY_SUPPLEMENT|salt substitute|Free salt substitute provided
223782299|NCT00131794|BIOLOGICAL|BCG|
223700297|NCT06210581|OTHER|Internet Based Exercise Program Group|"Patients who are in the internet-based exercise program group will register cite ''https://www.telenororehab.com /'' which is web- based physiotherapy program for exercises. After the first evaluation patients will be given a username and password to log in to the system.~Before starting the exercise programs, the pages on how patients can log in to the system, how they can reach the physiotherapist through the system and how they can find individual exercise programs will be shown before the study. After logging in to their own pages, patients will be able to access video-based exercise programs that have been specially prepared for them. Patients in the Internet-based exercise program group will also be given the same exercise programs as the supervised exercise program group. The entry-exit times of patients to the system and the duration of maintaining exercise programs will be controlled from the administrator section on the system."
223700298|NCT03853343|DIETARY_SUPPLEMENT|Seaweed extract|1 capsule 3 times per day
223700299|NCT03853343|DIETARY_SUPPLEMENT|Placebo|1 capsule 3 times per day
223700300|NCT02422316|OTHER|Non-contrast Cardiac CT scan|
223700301|NCT03576222|DEVICE|PICO DRESSING|USE PICO DRESSING ON SURGICAL INCISION AFTER ABDOMINAL WALL REPAIR IN THE SURGICAL ROOM
223700302|NCT03576222|DEVICE|MEPORE dressing|MEPORE dressing
223700303|NCT05421871|BEHAVIORAL|Spinal Stabilization Exercises|Spinal Stabilization Exercises technique
223700304|NCT05421871|BEHAVIORAL|Maitland Mobilization Along With Laser Therapy|Maitland Mobilization Along With Laser Therapy technique
223700305|NCT00166465|DRUG|ALIMTA plus Oxaliplatin versus Oxaliplatin plus 5-Fluorouracil and Leucovorin (FOLFOX 4 Regimen)|
223700306|NCT03821207|BEHAVIORAL|The exercise group|The students will make exercise during the first three days of the menstrual period
223700307|NCT03821207|BEHAVIORAL|The abdominal massage group|The students will make abdominal massage during the first three days of the menstrual period
223700308|NCT03821207|BEHAVIORAL|Control Group|The students will nor massage or exercise
223700309|NCT01768767|DRUG|Placebo|
223700310|NCT01768767|DRUG|Ketamine|
223700311|NCT01768767|DRUG|Ketamine/Lithium|
223700312|NCT02819869|DRUG|Statin and Metformin use|
223700313|NCT01931332|PROCEDURE|Femoral Nerve Block with levobupivicaine|A single injection femoral nerve block (FNB) performed in the supine position with a 50mm insulated needle (NanoLine, Pajunk, Geisingen, Germany) and peripheral nerve stimulator set at 1Hz with pulse width 0.1ms. Once a quadriceps muscle twitch is identified at a stimulated current between 0.2 and 0.5mA, 20mls of 0.375% levobupivacaine (75mg) is injected in fractionated amounts after negative aspiration
223782300|NCT04587089|PROCEDURE|Irrigation|Irrigation and aspiration in the root canals with 1% sodium hypochlorite (Milton's solution).
223700314|NCT01931332|PROCEDURE|Intrathecal injection of diamorphine|500mcg of intrathecal diamorphine (ID) (dissolved in 0.5mls normal saline)
223700315|NCT04686604|OTHER|Best practice alert for the notification of patient HFrEF and recommended evidence-based medical therapies (NO drugs are being administered in this trial)|Providers will receive a best practice alert for each of their eligible patients upon opening of the order entry screen in the patient's medical record. The alert will inform the provider to the presence of HFrEF and of the patient's current left ventricular ejection fraction, most recent blood pressure and heart rate, most recent potassium and estimated glomerular filtration rate, and current evidence-based medications for HFrEF. It will also provide access to an order set with recommended evidence-based HFrEF therapies as well as a link to the best available guideline-recommended information regarding the treatment of heart failure.
223700316|NCT00622973|OTHER|Imaging: diffusion-weighted MRI|Diffusion-weighted MRI of the entire pelvis to detect lymph node metastases
223700317|NCT00622973|OTHER|Sinerem (USPIO) enhanced MRI|USPIO (Sinerem) will be administered intravenously immediately after the first MR examination at a dose of 2.6 mg Fe/kg body weight diluted in 100 ml of saline (optimal dose according to: (9, 10)) during a period of about 30 minutes under medical supervision. Postcontrast MR imaging will be performed 24-36 hours after contrast medium injection.
223700318|NCT02759874|DEVICE|specialized breathalyzer w face recognition technology|
223700319|NCT00913575|OTHER|preoperative neuromuscular training|The neuromuscular training group will receive a minimum of 8 and a maximum of 24 training sessions; as well as 4 sessions of the Knee OA School.
223700320|NCT00913575|BEHAVIORAL|knee OA School|The education group will only receive 4 sessions of the Knee OA School.
223700321|NCT01033461|DIETARY_SUPPLEMENT|calcium and probiotic|the subjects consumed for 4 weeks a yoghurt drink enriched with 10e+10 cfu/d L. paracasei LPC 37 and a bread enriched with 1 g pentacalcium phosphate per day
223700322|NCT01033461|DIETARY_SUPPLEMENT|probiotic|the subjects consumed a yoghurt drink enriched with 10e+10 cfu/d L. paracasei LPC 37 for 4 weeks
223700323|NCT01033461|OTHER|placebo|the subjects consumed a yoghurt drink without L. paracasei LPC 37 and a bread without pentacalcium phosphate
223700324|NCT04043728|BEHAVIORAL|Unified Protocol adapted for smoking cessation|Treatment components are cognitive-behavioral strategies adapted from the Unified Protocol (UP) for the Transdiagnostic Treatment of Emotional Disorders. Behavioral counseling strategies for smoking cessation, drawn from current US Public Health Service guidelines, are incorporated in each treatment module. All participants will be provided with the American Lung Association Freedom from Smoking guide to aid in their quit attempt.
223700325|NCT05160090|DRUG|Bupropion HCl MR tablets 300mg|In each study period, a single 300 mg dose of Bupropion will be administered orally with about 240 mL of water at ambient temperature, in the morning, while subjects are seated, following a 10-hour overnight fast.
223700326|NCT01033851|BEHAVIORAL|Mindfulness Based Stress Reduction|8 week course
223700327|NCT01033851|BEHAVIORAL|Stress Management Education|8 week course
223700328|NCT02349542|DRUG|Liposomal bupivacaine|One (1) 20 mL vial of 266 mg liposomal bupivacaine (3% (\~8mg free bupivacaine)) will be injected into each surgical (knee) site following simultaneous bilateral total knee arthroplasty. In addition, 30 mL of 0.25% bupivacaine (75 mg free bupivacaine) will be injected into each surgical (knee) site for a total of 83 mg free bupivacaine injected into each surgical (knee) site.
223700329|NCT04197752|OTHER|Regional anesthesia/analgesia techniques|Neuroaxial or peripheral block anesthesia/analgesia technique that is appropriate for the patient's surgery
223700330|NCT01093638|BIOLOGICAL|Oral Formulation of Insulin|Oral formulation of insulin fed concomitantly with infant formula
223700331|NCT01093638|BIOLOGICAL|Placebo|Oral formulation of placebo fed concomitantly with infant formula
223782301|NCT04587089|PROCEDURE|Filling with Guedes-Pinto Paste|The root canals will be filled with Guedes-Pinto Paste, which is a composite of 3 medications: Rifocort® (dermatologic ointment), camphorated paramonochlorophenol (PMCC) and iodoform. It will be prepared at the moment of use with the same proportion in volume of 3 visually identical parts, one for each of its components.
223700332|NCT01570166|PROCEDURE|HR|HR was carried out under general anesthesia using a right subcostal incision with a midline extension. Intra-operative ultrasonography was performed routinely to evaluate the tumor burden, liver remnant, and the possibility of a negative resection margin. Anatomic resection, in the form of segmentectomy and/or subsegmentectomy as described by Makuuchi et al. (16) was the preferred surgical method of liver resection. Pringle's maneuver was routinely used with a clamp and unclamp time of 10 min and 5 min, respectively; this technique was used repeatedly throughout the entire procedure.
223700333|NCT01570166|PROCEDURE|RFA|For PRFA, we used a commercially available system with a 375-KHz computer-assisted radiofrequency generator (Elektrotom HiTT 106, Berchtold, Medizinelektronik, Germany) and an open-perfused electrode (Berchtold, Tuttlingen, Germany) of 15 cm (or 20 cm), 14 Ga, and a 15 mm (or 20 mm) active electrode tip with microbores.
223700334|NCT04979520|DRUG|Brodalumab|Subcutaneously Brodalumab/Siliq, 210mg/1.5ml once a week
223700335|NCT00800748|DRUG|Peginterferon alfa-2a|Peginterferon alfa-2a was administered at a dose of 180 mcg SC weekly for 48 weeks to participants with genotype 1, 4, 5, 6 and to participants with HIV co-infection, or for 24 weeks to participants with genotype 2 and 3.
223700336|NCT00800748|DRUG|Ribavirin|Ribavirin was administered at a dose of 1000-1200 mg PO daily for 48 weeks to participants with genotype 1, 4, 5, 6 or 800 mg PO daily for 24 weeks to participants with genotype 2 and 3.
223700337|NCT06340516|DIAGNOSTIC_TEST|Plasma NT-proBNP|Replacement of measurement of plasma NT-proBNP instead of ECHO/MUGA at 6 months and 12 months of trastuzumab treatment to assess cardiotoxicity
223700338|NCT00114387|DRUG|DL-alpha-tocopherol|
223700339|NCT00200161|DRUG|Temozolomide|Focal RT 6000 cGy/ Temozolomide 75 mg/m2 then Temozolomide 50mg/m2 will be given to patients on days 1-28 of each 28 day cycle. Maintenance cis-retinoic acid. This therapy will start at the completion of 6 cycles of adjuvant temozolomide in all patients who have had no clinical or radiographic evidence of tumor progression.Treatment will continue in 28 day cycles until tumor progression.
223700340|NCT00200161|DRUG|Temozolomide|Focal RT 6000 cGy/ Temozolomide 75 mg/m2 plus Temozolomide 150 mg/m2 will be given to patients on days 1-7 and 15-21 of each 28 day cycle. Maintenance cis-retinoic acid. This therapy will start at the completion of 6 cycles of adjuvant temozolomide in all patients who have had no clinical or radiographic evidence of tumor progression.Treatment will continue in 28 day cycles until tumor progression.
223700341|NCT01303783|DRUG|Candesartan cilexetil (Atacand), 4 mg|4 mg of candesartan as capsule
223700342|NCT01303783|DRUG|Candesartan cilexetil (Atacand), 8 mg|8 mg candesartan as capsule
223700343|NCT01303783|DRUG|Nifedipine GITS (Adalat, BAYA1040), 20 mg|20 mg nifedipine as tablet
223700344|NCT01303783|DRUG|Nifedipine GITS (Adalat, BAYA1040), 30 mg|30 mg nifedipine as tablet
223700345|NCT01303783|DRUG|Nifedipine GITS (Adalat, BAYA1040), 60 mg|60 mg nifedipine as tablet
223700346|NCT01303783|DRUG|Placebo|3 different placebo tablets corresponding nifedipine doses and 1 placebo capsule corresponding to candesartan doses
223700347|NCT01303783|DRUG|Candesartan cilexetil (Atacand), 16 mg|16 mg of candesartan as capsule
223700348|NCT01303783|DRUG|Candesartan cilexetil (Atacand), 32 mg|32 mg of candesartan as capsule
223700349|NCT04080960|BEHAVIORAL|Lifestyle modification education|Lifestyle modification education and goal setting
223700350|NCT01502007|OTHER|Accelerometer feedback and lifestyle counseling|Subjects will meet with the exercise counselor who will use accelerometer data to provide feedback and counseling to help the user increase their activity by at least 20% each day. In subjects who achieve an increase of 20%, the counseling will focus either on maintaining activity levels or increasing activity further depending on the desire of the subject. Counseling will be provided once weekly by phone and in person at least once a month. Following the 26th week the experimental subjects will continue to wear the Fitbit and receive feedback about their activity levels for an additional 24 weeks, but they will no longer receive counseling. The control group will receive no counseling for the first 26 weeks of the study and will then crossover to get accelerometry feedback and counseling for the last 24 weeks of the study.
223700351|NCT01502007|OTHER|Accelerometer without Feedback|The accelerometer, Fitbit, will be worn continuously. Fitbit can provide feedback to subjects about their physical activity. Subjects will wear the Fitbit for two weeks (without feedback) to obtain baseline activity data. The experimental group will then be instructed on use of the fitbit. This group will receive feedback from the accelerometer for the remainder of the study. The control group will wear the Fitbit but receive no feedback for the first 26 weeks of the study. For the last 24 weeks they will crossover and receive feedback from the Fitbit accelerometer.
223700352|NCT00199485|DRUG|Angelica Sinensis|Angelica Sinensis / placebo
223700353|NCT03078400|DRUG|SPL-108|Subcutaneous injection of 150 mg administered either one time or two times per day.
223700354|NCT04298515|DIAGNOSTIC_TEST|Nesfatin-1|Blood will be taken from the patients on an empty stomach for measuring nesfatin-1 level
223700355|NCT05148065|DEVICE|BIS|Bispectral index monitoring
223700356|NCT05148065|DEVICE|PSi|Patient state index monitoring
223700357|NCT05405465|DRUG|Exposure to golimumab|Retrospective chart review to assess patient related outcomes and objective measures of inflammation at baseline, 6-10 weeks, 6 months, 12 months.
223700358|NCT00543543|BIOLOGICAL|Comparator: GARDASIL|GARDASIL (quadrivalent HPV \[Types 6, 11, 16, and 18\] L1 virus-like particle vaccine), 0.5 mL injection in 3 dose regimen
223782302|NCT04587089|PROCEDURE|Filling with CTZ Paste|The powder that composes the CTZ paste will be previously manipulated in a 1:1:2 ratio (500mg of Chloramphenicol, 500mg of Tetracycline and 1,000mg of Zinc Oxide) by Formula \& Ação (F\&A) and incorporated into the eugenol liquid at the time of use, with the aid of a flexible spatula nº 24 and on a sterile glass plate. The cleaning of the coronary chamber must be carried out with saline solution and drying with sterile cotton balls and the CTZ paste must be inserted into the cavity.
223782303|NCT03274700|DRUG|Tamsulosin.|Patients who will receive tamsulosin as a treatment for lower ureteric stones from (10-15)mm up to 8 weeks duration.
223782304|NCT03274700|DRUG|Placebo.|Patients who will receive as placebo a treatment for lower ureteric stones from (10-15)mm up to 8 weeks duration.
223782305|NCT04274517|OTHER|Sterile Water|1L of sterile water used in surgical splash basins during total joint arthroplasty to clean surgical instrumentation.
223782306|NCT04274517|OTHER|3.5% Betadine|1L of 3.5% betadine used in surgical splash basins during total joint arthroplasty to clean surgical instrumentation.
223782307|NCT04274517|OTHER|0.05% Chlorhexidine Gluconate|1L of clorhexidine gluconate used in surgical splash basins during total joint arthroplasty to clean surgical instrumentation.
223782308|NCT01886976|BIOLOGICAL|CART-138 cells|
223782309|NCT03788486|DEVICE|2-3 Joule LED blue light device|application of blue light LED light device for 2 minutes in the central lower lids, temporal lower lids and upper temporal lids twice weekly under observation for one month
223782310|NCT02162810|DRUG|Prednisolone|In order to analyze the data, we will establish a chart which will show the degree of cosmetic appearance, incidences and degree of complications. This we be assessed on a mild to severe scale.
223782311|NCT02162810|DRUG|placebo-controlled|In order to analyze the data, we will establish a chart which will show the degree of cosmetic appearance, incidences and degree of complications. This we be assessed on a mild to severe scale.
223782312|NCT05906693|OTHER|Quality of life|Parkinson's Disease Quality of Life Questionnaire (PDQ-39)
223782313|NCT05906693|OTHER|Upper limb functionality|Nine-Hole Peg Test
223782314|NCT05906693|OTHER|Grip and pinch strength|Dynamometer
223782315|NCT05906693|OTHER|Tremor amplitude|Electromyography
223782316|NCT05906693|OTHER|Depression and anxiety levels|Hospital Anxiety and Depression Scale
223782317|NCT05906693|OTHER|Clinical manifestations|The Movement Disorder Society-Sponsored Revision of the Unified Parkinson's Disease Rating Scale
223782318|NCT00706121|DRUG|Vitamin E|400 IU daily by mouth for 7 - 12 years
223782319|NCT00706121|DRUG|Selenium|200 mcg daily for 7 - 12 years
223782320|NCT00706121|DRUG|Vitamin E placebo|1 pill by mouth daily for 7 - 12 years
223782321|NCT00706121|DRUG|selenium placebo|1 pill by mouth daily for 7 - 12 years
223782322|NCT02835534|DRUG|rhTNK-tPA|Dose:16mg; Mode of admin: Single bolus Enoxaparin or unfractionated heparin for anticoagulant therapy, clopidogrel and aspirin for antiplatelet therapy before fibrinolytic therapy.
223700359|NCT00543543|BIOLOGICAL|Experimental: V503|V503 (9-valent HPV \[Types 6, 11, 16, 18, 31, 33, 45, 52, and 58\] L1 virus-like particle vaccine), 0.5 mL injection in 3 dose regimen (and a fourth injection for Cohort 1 only).
223782323|NCT02835534|DRUG|alteplase|Dose:50mg; Mode of admin: administered as an 8-mg initial IV bolus followed by an infusion of 42 mg over the next 90 minutes Enoxaparin or unfractionated heparin for anticoagulant therapy, clopidogrel and aspirin for antiplatelet therapy before fibrinolytic therapy.
223782324|NCT01116817|DRUG|Lumbar puncture (Lopinavir/ritonavir monotherapy)|Lumbar puncture at week 0
223782325|NCT01116817|DRUG|Lumbar puncture (HAART: Lopinavir/ritonavir + 2 NRTI)|Lumbar puncture at week 0
223782326|NCT03950193|OTHER|Questionnaires to evaluate psychic development of the child|Child Behaviour Checklist. This test, completed by parents and with 52 questions, is designed to screen children at high risk for emotional problems, mood disorders, anxiety, pervasive developmental problems, attention deficit and hyperactivity, antonymic reactions (oppostion, provocation) and sleep problems.
223782327|NCT06535074|OTHER|Detecting changes in lung volume with hypoxemia episodes|"Electrical impedance tomography (EIT) will be used to assess changes in lung aeration prior and during hypoxemia episodes to classify them into four different subtypes.~FE subtype: Defined as HEs preceded by reduction in EELI below the baseline.~Apnea subtype: Defined as HEs not meeting the criteria for FE subtype and preceded by cessation of breathing.~Mixed subtype: Defined as HEs meeting the criteria for both FE and apnea subtypes.~Unclassified: Defined as HEs not categorized into any of the above parameters."
223700360|NCT04383158|OTHER|PRGF ENDORET® obtained from ENDORET® POST-EXTRACTION ALVEOLUS DENTAL KIT (KMU16)|ENDORET® POST-EXTRACTION ALVEOLUS DENTAL KIT (KMU16) is a system for obtaining plasma rich in growth factors (PRGF), which can be applied in the regeneration of bone and other connective tissues in oral surgery. PRGF is a completely autologous blood platelet concentrate that stimulates tissue regeneration due to enrichment with autologous growth factors, acting as a biological system.
223700361|NCT00865670|DRUG|Azithromycin Monohydrate 600 mg Tablets|
223700362|NCT00865670|DRUG|Zithromax (azithromycin dihydrate) 600 mg Tablets|
223700363|NCT00002008|DRUG|Sargramostim|
223782328|NCT02281006|DRUG|Trans-tympanic injection of a sodium thiosulfate gel|A sodium thiosulfate hyaluronate gel will be prepared by mixing 0.55 ml of a 25% solution of sodium thiosulfate pentahydrate (Seacalphyx, DIN 02386666, Seaford Pharmaceuticals Inc.) and 0.55 ml of a hyaluronate gel (Healon 10 mg, Abbott Medical Optics Inc.). On the day before each Cisplatin treatment an otologist will deposit 0.1 ml of the gel exactly on the round window of the middle ear.
223782329|NCT06108063|DRUG|Losartan|12.5 mg oral Losartan taken for 28 days total (4 week postoperative).
223782330|NCT06108063|DRUG|Placebo - Losartan|Losartan appearance-matched Prosolv EasyTab SP placebo. 12.5 mg oral tablet taken for 28 days total (4 week postoperative).
223782331|NCT02546544|DRUG|Linsitinib|
223782332|NCT04544826|DRUG|JNJ-77474462|JNJ-77474462 will be administered as SC injection.
223700364|NCT00600535|DRUG|Stage 1 Group 1: abiraterone acetate|1000 mg capsules/day orally on Day 1. On Day 8, patients will crossover and receive tablet formulation at the same dose.
223700365|NCT00600535|DRUG|Stage 1 Group 2: abiraterone acetate|1000 mg tablets/day orally on Day 1. On Day 8, patients will crossover and receive capsule formulation at the same dose.
223700366|NCT00600535|DRUG|Stage 2: abiraterone acetate|1000 mg tablets/day orally for 12 cycles (28 days/cycle) according to assigned group from Stage 1.
223700367|NCT00600535|DRUG|Stage 3: abiraterone acetate|1000 mg tablets/day orally for 12 cycles (28 days/cycle).
223700368|NCT00600535|DRUG|Stage 3: glucocorticoid|prednisone/prednisolone 5 mg twice daily orally or dexamethasone 0.5 mg once daily for 12 cycles (28 days/cycle).
223700369|NCT00600535|DRUG|Stage 4: abiraterone acetate|1000 mg tablets/day orally for up to 24 cycles (28 days/cycle).
223782333|NCT04544826|DRUG|Placebo|Matching placebo to JNJ-77474462 will be administered as SC injection.
223782334|NCT02810535|OTHER|Observation|"Visit 1:~* Physical examination (inspection of nasopharynx, auscultation of heart and lungs)~* Completion of a Health Questionnaire~* Lung function testing with spirometry~* Skin prick test~Visit 2:~* Physical examination (inspection of nasopharynx, auscultation of heart and lungs)~* Measurement of nitric oxide in expired air (FeNO)~* Taking nasal secretion samples with a cotton carrier for 15 min~* Nasal provocation test with dust mite~* Blood sample collection to define blood count, IgE and specific IgE"
223782335|NCT02223390|BEHAVIORAL|Improving AIDS Care after Trauma (ImpACT)|
223700370|NCT00600535|DRUG|Stage 4: glucocorticoid|prednisone/prednisolone 5 mg twice daily orally or dexamethasone 0.5 mg once daily for up to 24 cycles (28 days/cycle).
223700371|NCT01617525|OTHER|Controlled Feeding Dietary Intervention|All meals will be provided during each 4-week intervention period. Participants must consume all foods provided and must not consume any outside foods during each intervention period.
223700372|NCT03686761|PROCEDURE|A Involvement with the osteotomy site of the surgery|A Involvement with the osteotomy site of the surgery
223700373|NCT02919696|DRUG|Abemaciclib|Administered orally
223700374|NCT03882190|DRUG|GnRHa|patients in the experimental group are supposed to receive GnRHa preoperatively and postoperatively according to their individual situation
223700375|NCT04308304|DRUG|MK-1942|MK-1942 1 mg, 5 mg, and/or 10 mg capsules taken twice daily (BID) by mouth.
223700376|NCT04308304|DRUG|Donepezil|Donepezil 5 mg and/or 10 mg tablets taken once daily (QD) by mouth.
223782336|NCT04351152|BIOLOGICAL|Lenzilumab|Administered as an intravenous (IV) infusion
223782337|NCT04351152|DRUG|Standard of Care|Standard of care therapy can include remdesivir and/or dexamethasone per institutional treatment guidelines or written policies
223700377|NCT04308304|DRUG|Placebo|Placebo capsule matched to MK-1942 taken BID by mouth.
223700378|NCT01270061|BEHAVIORAL|HIV testing|HIV education and counseling from a trained Research Assistant and offering of a free rapid, oral HIV test.
223700379|NCT01270061|BEHAVIORAL|General Health Screen|A video will provide health education on diabetes, hypertension, and HIV. The video will then offer free blood pressure check, blood glucose measuring, and a free, rapid oral HIV test.
223700380|NCT00945555|DRUG|Antibacterial agent for the treatment of febrile neutropenia|The antibacterial agent used by the investigators for febrile neutropenia will be determined and classified in the preference order
223782338|NCT06364046|PROCEDURE|Drug-eluting beads bronchial arterial chemoembolization|"Drug-eluting beads bronchial arterial chemoembolization generally uses platinum-containing two-drug chemotherapy platinum (cisplatin, carboplatin, nedaplatin) combined treatment, and drug-loaded microspheres are loaded with irinotecan. The dose of chemotherapy drugs is set to 75mg/m2 of platinum, and the dose of chemotherapy through catheter infusion is reduced by 25%. The dose of drug-loaded drugs is irinotecan 80mg/ m2. Chemotherapy was perfused first, followed by embolization with drug-loaded microspheres, until the blood flow in the artery supplying the tumor slowed down and approached stagnation. The number of DEB-BACE treatments is determined by the investigator, and is given as needed according to the patient's condition, usually 1-2 times, with an interval of 28±10 days."
223700381|NCT01527175|OTHER|Approach for ultrasound-guided subclavian venous catheterization|Each SCV catheterization was performed under ultrasound-guidance with supraclvicular or infraclavicular approach.
223700382|NCT03877549|DRUG|Dexamethasone|Additional of two different doses of dexamethasone via the epidural catheter during surgical closure after cesarean section
223700383|NCT04276337|DIAGNOSTIC_TEST|LiquidSCAN(Trade Mark) / CancerSCAN(Trade Mark)|LiquidSCAN : detection of circulating DNA CancerSCAN : detection of somatic mutation using tumor tissue
223700384|NCT04925726|OTHER|Land based exercise|The patients who had land based exercise
223782339|NCT06364046|DRUG|Serplulimab|Programmed cell death protein 1 inhibitor fixation was treated with serplulimab (Fuhong Hanlin Co., LTD.). It is administered by intravenous infusion, and the recommended dose is 200 mg, given once every 21 days. The medication will last for two years until disease progression or intolerable toxicity occurs. During immunotherapy, immunosuppressive agents will not be replaced and the dose will not be adjusted.
223782340|NCT06364046|PROCEDURE|Intravenous chemotherapy|Intravenous chemotherapy with irinotecan 65mg/m2 on day 1 and day 8, given once every 21 days
223782341|NCT06534307|BEHAVIORAL|Questionnaire Child Behaviour Checklist|The Child Behavior Checklist comprises items assigned to 8 subscales describing various behavioral areas. These subscales can be summed up to scores for internalizing and externalizing problems as well as a total score. Checklist scores are reported on a T-scale. Range of T-scale from scores 20 to 100 (average performance between scores 40 and 60). Higher scores mean higher amount of problems.
223782342|NCT06534307|BEHAVIORAL|Questionnaire Young Self Report|The Questionnaire Young Self Report comprises items assigned to 8 subscales describing various behavioral areas. These subscales can be summed up to scores for internalizing and externalizing problems as well as a total score.
223700385|NCT04925726|OTHER|Water based exercise|The patients who had water based exercise
223700386|NCT00211484|DRUG|Anecortave Acetate|
223700387|NCT02024438|DRUG|monosialotetrahexosylganglioside Sodium|it is extracted from pig's brain,shenjie is the brand name
223700388|NCT02024438|OTHER|placebo|saline of the same appearance as monosialotetrahexosylganglioside Sodium
223782343|NCT06534307|DIAGNOSTIC_TEST|physical examination|physical development examination including height (in cm), weight (in g) and tanner states
223782344|NCT06534307|DIAGNOSTIC_TEST|metabolic examination|metabolic development using blood analysis including blood components, metabolic parameters (Glucose, HbA1c, cholestrol)
223782345|NCT06534307|BEHAVIORAL|Questionnaire Reynolds Intellectual Assessment Scales and Screening|"The RIAS is standardized intelligence test. The RIAS provides an Total Intelligence Index (GIX, estimate of the general intelligence/g-factor), Verbal Intelligence Index (VIX) and the Nonverbal Intelligence Index (NIX). Test scores are reported on a T-scale. Range of T-scale from scores 20 to 100 (average performance between scores 40 and 60). Higher scores mean better cognitive performance."
223782346|NCT06534307|DIAGNOSTIC_TEST|electroencephalogram|neurocognitive development
223782347|NCT06534307|OTHER|Questionnaire Movement Assessment Battery for Children|"The M-ABC-2 is an standardized test to assess the motoric development. Adding up subscores addressing manual dexterity, aiming and catching, and balance delivers a total score of the motoric performance.~Test scores are reported on a T-scale. Range of T-scale from scores 20 to 100 (average performance between scores 40 and 60). Higher scores mean better performance."
223782348|NCT06534307|OTHER|Questionnaire Continuous Performance Test|The CPT measures selective attention, sustained attention as well as impulsive behavior. Checklist scores are reported on a T-scale. Range of T-scale from scores 20 to 100 (average performance between scores 40 and 60). Higher scores mean worse performance.
223782349|NCT06534307|OTHER|Questionnaire Diagnostic System for Mental Disorders|The FBB-ADHS assesses a total score for ADHD-like behavior and subscores for the symptom trias of ADHD (attention deficit, motoric hyperactivity as well as impulsive behavior, Questionnaire scores are reported on a T-scale. Range of T-scale from scores 20 to 100 (average performance between scores 40 and 60). Higher scores mean higher amount of symptoms.
223782350|NCT06534307|DIAGNOSTIC_TEST|kidney function tests|urine examination (proteomics, cytokines, lipidomics)
223782351|NCT06534307|OTHER|Questionnaire Five to Fifteen|The FTF 5-15R is a questionnaire to evaluate the child's developmental outcome in different areas of everyday life (cognition, language, and motor impairment as well as social, emotional, and behavioral problems). Individual item scores are added up per area and divided by the number of items. This results in a common scale value. Range of Percentile scores from 0 to 100 (0-90: no developmental problem; 90 and higher: hint for developmental problem). Higher scores mean worse developmental outcome.
223700389|NCT00943696|DIETARY_SUPPLEMENT|Ingestion of white wine vs. tea during and an alco|4 x 50ml glasses of white wine (12% alcohol) or tea will be taken according to a randomization scheme After the meal 1 x 20ml of Kirsch (40% alcohol) or tea will be taken
223700390|NCT05077878|BIOLOGICAL|DSPP level in GCF|quantification of DSPP
223700391|NCT05610514|OTHER|E-Cigarette|Altering the availability of e-cigarettes
223700392|NCT05610514|BEHAVIORAL|Financial Incentives|Altering the availability of financial incentives for abstaining from combustible cigarettes
223700393|NCT06573931|OTHER|Lumbar Erector Spinae Plane Block|Patients will receive lumbar erector spinae plane block at the end of surgery.
223700394|NCT06573931|OTHER|Fascia Iliaca Block|Patients will receive fascia iliaca block at the end of surgery.
223700395|NCT06573931|OTHER|Lumbar Plexus Block|Patients will receive lumbar plexus block at the end of surgery.
223700396|NCT02662634|BIOLOGICAL|AGS-003-LNG|autologous dendritic cell immunotherapy
223700397|NCT02662634|DRUG|Carboplatin|"Carboplatin is an anticancer drug (antineoplastic or cytotoxic) chemotherapy drug. Carboplatin is classified as an alkylating agent."
223700398|NCT02662634|DRUG|Abraxane|Paclitaxel destroys cancer cells by preventing the normal breakdown of microtubules during cell division.
223700399|NCT02662634|DRUG|Alimta|By inhibiting the formation of precursor purine and pyrimidine nucleotides, pemetrexed prevents the formation of DNA and RNA, which are required for the growth and survival of both normal cells and cancer cell
223700400|NCT02662634|DRUG|Cisplatin|Binds to and causes crosslinking of DNA, which ultimately triggers apoptosis
223700401|NCT02662634|DRUG|Taxol|Mechanism of action involves interference with the normal breakdown of microtubules during cell division.
223782352|NCT06534307|DIAGNOSTIC_TEST|cardiovacular examination|measurement of pulse wave velocity
223782353|NCT01025713|DRUG|GS-9411|Inhaled GS-9411
223782354|NCT01025713|DRUG|Placebo|Inhaled Placebo
223700402|NCT02662634|RADIATION|Radiation Therapy|Causes DNA strand breaks.
223700403|NCT03312998|RADIATION|Xrays|Plain x-rays anteroposterior and lateral views to determine system failure
223700404|NCT01044251|DRUG|Frovatriptan|2.5 mg po bid for 10 days
223700405|NCT01044251|DRUG|Placebo|1 tab po bid for 10 days
223700406|NCT00734370|BEHAVIORAL|Virtual Reality Exposure Therapy for agoraphobic participants|"This intervention is comprised of 10 sessions of cognitive behavior therapy for panic disorder and agoraphobia with components of~* Psycho-education, breathing training and cognitive restructuring~* Virtual reality Exposure to agoraphobic situations and interoceptive exposure~* Relapse prevention"
223700407|NCT00734370|BEHAVIORAL|Standard exposure in vivo for agoraphobic participants|"This intervention is comprised of 10 sessions of cognitive behavior therapy for panic disorder and agoraphobia with components of~* Psycho-education, breathing training and cognitive restructuring~* Standard exposure in vivo to agoraphobic situations and interoceptive exposure~* Relapse prevention (according to the protocol of Craske \& Barlow)"
223700408|NCT02328417|OTHER|Consecutive radical cystectomies|Pre-, intra- and post-operative clinical measures during radical cystectomy clinical process
223700409|NCT03297814|BIOLOGICAL|Platelet lysate|Intramuscular injection of platelet lysate
223700410|NCT03297814|BIOLOGICAL|Placebo|intramuscular injection of normal saline
223782355|NCT01476046|DRUG|GSK1995057 single dose|Single intravenous dose
223782356|NCT01476046|DRUG|Placebo|Single intravenous dose
223782357|NCT00600600|DRUG|Tigecycline|Tigecycline dosage based on age and clinical status of patient.
223782358|NCT01994486|DRUG|Telaprevir and Sofosbuvir|All subjects will have time to read and discuss IRB approved consent form prior to any study procedures. Following proper consenting, subjects will undergo physical exam including ECG and bloodwork prior to baseline visit. Subjects will return for research visits (vitals, collection of AEs, bloodwork, drug accountability) on Day 3, Weeks 1, 2, 3, 4, 6, 8, 10 and 12 of treatment and 4, 12, and 24 weeks after end of treatment. PK samples will be collected at week 2 and week 10.
223782359|NCT00001101|DRUG|ceftriaxone|
223782360|NCT00001101|DRUG|doxycycline|
223782361|NCT00930111|OTHER|2-week rotation|Attending physician is assigned to a 2-week rotation.
223782362|NCT00930111|OTHER|4-week rotation|Attending physician is assigned to a 4-week rotation.
223782363|NCT02838602|RADIATION|Carbon ions therapy|External radiotherapy by accelerated carbon nucleus in a specialized hadrontherapy center
223782364|NCT02838602|RADIATION|Advanced external radiotherapy by Xrays or protons|Radiotherapy by any appropriate advance procedure of photontherapy (IMRT, Volumetric Modulated Arc Therapy (VMAT), Tomo, etc.) or when possible by protontherapy or even a combination of both types of radiotherapy
223782365|NCT02251535|DEVICE|ATTUNE® Knee System|
223782366|NCT02251535|DEVICE|PFC® SIGMA® Knee System|
223782367|NCT00215852|DRUG|Alferon LDO|500 IU, taken orally each evening, for 10 consecutive days while holding in the mouth for at least 2 minutes prior to swallowing, for 10 daysday 5 of each 28 day cycle.
223782368|NCT05343871|BIOLOGICAL|Sinovac|"Sinovac inactivated COVID-19 vaccine:~● Full dose (0.5 ml)"
223782369|NCT05343871|BIOLOGICAL|AZD1222|"AstraZeneca ChAdOx1-S recombinant AZD1222 vaccine:~* Full dose (0.5 ml)~* Half dose (0.25 ml)"
223782370|NCT05343871|BIOLOGICAL|BNT162b2|"Pfizer/BioNTech BNT162b2 mRNA vaccine:~* Full dose (30 micrograms)~* Half dose (15 micrograms)~* One-third dose (10 micrograms)"
223700411|NCT06393036|DEVICE|Continuous Positive Airway Pressure|The intervention in this study involves the use of Continuous Positive Airway Pressure (CPAP) treatment. Although the study is designed as an observational cohort study, where patients self-selected whether to receive treatment rather than being assigned, there is still an intervention project, CPAP, present in the observational cohort. CPAP is a commonly used therapy for obstructive sleep apnea (OSA) and other sleep-related breathing disorders. The principle of CPAP treatment lies in maintaining a constant airway pressure during sleep to prevent the collapse of the upper airway and ensure unobstructed breathing. The patient wears a mask connected to a CPAP machine, which generates a steady stream of air to provide the necessary pressure.
223700412|NCT05013034|DRUG|Basiliximab Injection|Subjects will be given IV dosing with basiliximab up to a maximum of 2 treatments (day 0 and day 4) for all patients on study. Treatment for patients may stop for unacceptable side-effects, the Investigator's, or patient's decision to discontinue treatment or other reasons. Exclusion for second dose is first dose returned patient to SpO2 ≥94% on room air.
223700413|NCT05013034|DRUG|Placebo|Subjects will be given IV dosing with placebo (1/2 normal saline) up to a maximum of 2 treatments (day 0 and day 4) for all patients on study. Treatment for patients may stop for unacceptable side-effects, the Investigator's, or patient's decision to discontinue treatment or other reasons. Exclusion for second dose is first dose returned patient to SpO2 ≥94% on room air.
223700414|NCT03883399|OTHER|Survey|Survey among colorectal surgeons
223700415|NCT05667194|DRUG|KH617|KH617 is s freeze-dried powder injection
223700416|NCT00424450|PROCEDURE|lower limb artery bypass surgery|bypass of severe atherosclerotic vascular lesion
223700417|NCT00424450|PROCEDURE|percutaneous angioplasty (PTA)|PTA of severe atherosclerotic lesion
223700418|NCT05758571|DRUG|EGCG|EGCG (high pressure liquid chromatographic purity ≥ 95%; from Ningbo Hepu Biotechnology Co., Ltd.) is dissolved in 0.9% normal saline; 10ml is inhaled by atomization three times a day.
223700419|NCT02738034|OTHER|Cogmed|The Cogmed is computer software designed to train visuospatial and audio-verbal working memory, and other functions associated with working memory: attention, focus and impulsiveness. It has three versions adapted to different age groups: Cogmed for younger children, about 4-7 years, which are not yet so familiar with numbers and letters; Cogmed for children over 7 years and adolescents; and Cogmed for youth and adults over 18 years. In this study we will use the version for youth and adults over 18 years.
223700420|NCT00004397|DRUG|heme arginate|
223700421|NCT00004397|DRUG|tin mesoporphyrin|
223700422|NCT03482765|DIETARY_SUPPLEMENT|Probiotic 1|The product under investigation is a unique probiotic.
223700423|NCT03482765|DIETARY_SUPPLEMENT|Probiotic 2|The product under investigation is a unique probiotic.
223700424|NCT03482765|OTHER|Placebo|Microcrystalline Cellulose
223700425|NCT00484094|DRUG|sirolimus|Dosage and treatment duration will be decided by physician's discretion considering patient's clinical situations
223700426|NCT04118504|DEVICE|Mobile application|Lifestyle intervention on through mobile application
223700427|NCT02831140|BEHAVIORAL|Early exercises|"In postoperative phase:~Early exercises: within the first hour ;setting a half bed position, deep breathing and coughing . In the second hour, curbing vagal malaise and performing relaxation movements. In the third hour, walking about 20 to 30 minutes."
223782371|NCT05164510|GENETIC|ct-DNA guided therapy|treatment according to ct-DNA results:For Patients with abnormal gene changes of corresponding targeted drugs are recommended to use corresponding targeted therapy or immunotherapy drugs;For Patients without abnormal gene changes of corresponding targeted drugs, Treatment of Physician's Choice (TPC) is recommended.
223700428|NCT02831140|BEHAVIORAL|Removing urinary probe and all catheters.|In postoperative phase : Removing urinary probe and all catheters.
223700429|NCT02831140|BEHAVIORAL|Early alimentation|In postoperative phase :Early alimentation: in the first hour to the second hour .
223782372|NCT02548962|DRUG|Ibrutinib|
223782373|NCT02548962|DRUG|Pomalidomide|
223782374|NCT02548962|DRUG|Dexamethasone|
223782375|NCT02548962|DRUG|Placebo|
223700430|NCT02831140|BEHAVIORAL|commun interventions|"* In preoperative phase: stopping smoking at least 2 weeks, hospitalization and balanced alimentation one day before the surgery.~* In peroperative phase : no use of benzodiazepines in the anesthesia , selective intubation , maintaining vital parameters as normal and using a mini invasive surgical approach ( video thoracoscopy , video assisted thoracoscopy , thoracotomy with preservation of the posterior muscles of the chest wall~  , preservation of Serratus anterior and the front part of Latissimus Dorsi ).~* In postoperative phase : Immediate extubation ( less than 30 minutes from the surgery end) , peridural or paravertebral or intercostal block analgesia , no use of abusive antibiotic , all analgesic drugs are permitted if there are no contraindications and physiotherapy from the 6th hour."
223700431|NCT05991167|DEVICE|EndeavorRx|EndeavorRx® is an FDA cleared digital therapeutic indicated to improve attention function as measured by computer-based testing in children ages 8-12 years old with primarily inattentive or combined-type attention-deficit/hyperactivity disorder (ADHD), who have a demonstrated attention issue. EndeavorRx is deployed on mobile devices and incorporates adaptive, simultaneous cognitive tasks in a consumer-grade action videogame-based platform with high-quality graphics and reward mechanisms.
223700432|NCT03991858|OTHER|Phone call follow-up|A physical therapist made a phone call to the patient one month after his/her initial evaluation at the external rehabilitation clinic
223700433|NCT03991858|OTHER|Telerehabilitation follow-up|A physical therapist made a direct follow-up through telerehabilitation to the patient one month after his/her initial evaluation at the external rehabilitation clinic
223700434|NCT02752204|DRUG|AZD 2014|AZD2014 125mg BD - 2 days on 5 days off in a 28 day cycle
223700435|NCT02752204|DRUG|Rituximab|Rituximab 375mg/m2 will be administered intravenously on day 1 of a 28 day cycle for a total of 6 cycles.
223700436|NCT01414608|RADIATION|Brachytherapy|Undergo brachytherapy
223700437|NCT01414608|DRUG|Carboplatin|Given IV
223700438|NCT01414608|DRUG|Cisplatin|Given IV
223700439|NCT01414608|RADIATION|External Beam Radiation Therapy|Undergo external beam radiation therapy
223700440|NCT01414608|DRUG|Paclitaxel|Given IV
223700441|NCT01414608|OTHER|Quality-of-Life Assessment|Ancillary studies
223700442|NCT05352100|DIAGNOSTIC_TEST|Therapeutic Vibration Device|The Therapeutic Vibration Device is capable of applying force through the axial skeletal spine, through bidirectional compression loading (or prestressing) between the shoulder and the plantar surfaces of the feet. It is placed around the body like a mobile frame so that the applied vibration can affect the whole body. The vibration actuators (drivers) are mobile and can vary in size, frequency response, and force. The design minimizes the possibility of mechanical interference for ventilated/intubated patients.
223700443|NCT03483025|OTHER|Skin Testing of Hair cleansing products|6 different commercially available shampoos
223700444|NCT04820517|OTHER|Roy Adaptation Model Based Strengthening Program|"Applications included in the strengthening program sessions:~* Awareness study on social media addiction and its effects~* Awareness work on the correct and effective use of leisure time~* As a result of social media addiction, within the scope of Roy Adaptation Model, scenario sharing and problem solving process related to the problems arising in the fields of physical, group identity - self, role and interdependence~* Awareness work on recognizing and managing emotions~* Relaxation and Breathing Exercise in Emotion Management"
223700445|NCT06441448|BEHAVIORAL|case focus groups|The study is in a monocentric, exploratory, participatory study conceptualization phase. Within the study, a mixed-methods assessment involves various interview and group exercise formats among scientists, medical personnel, affected individuals, and their caregivers to develop components for a future psychotherapeutic program for ALS patients and their caregivers. Therapists provide an overview of therapy forms by presenting components based on format, content, and applied techniques. Case studies and focus groups are used for practical experience for the participants. Participants qualitatively assess the significance of therapeutic approaches and make a quantitative prioritization to establish a ranking of therapy components.
223700446|NCT01686828|DRUG|Acyline|300 mcg/mL administered subcutaneously (at Day 0, Week 2)
223700447|NCT01686828|DRUG|Testosterone 1.62% gel|Transdermal Testosterone Gel (either 1.25g or 5g/d) for 4 weeks
223700448|NCT01686828|DRUG|Letrozole|Letrozole oral aromatase inhibitor 5mg daily for 4 weeks
223700449|NCT01686828|DRUG|Placebo gel (for Testosterone 1.62% gel)|placebo gel manufactured to mimic Testosterone 1.62% gel
223700450|NCT01686828|DRUG|Placebo pill (for Letrozole)|Oral placebo aromatase inhibitor to mimic Letrozole 5mg/d
223700451|NCT00305214|PROCEDURE|T Wave Alternans Test|
223700452|NCT06272201|DEVICE|POSE2.0 procedure with g-Cath EZ Delivery Catheter with Snowshoe Suture Anchors|POSE2.0 (g-Cath EZ snowshoe suture anchors placed in the mid + distal body without placement in the fundus), with a moderate intensity diet and exercise program
223700453|NCT00136071|DEVICE|Transobturator tape-ARIS|
223700454|NCT00136071|DEVICE|TVT-O|
223700455|NCT02908243|OTHER|collection of baseline data|collection of baseline data including ages, types, severity, inhibitors and comorbidities
223700456|NCT04264689|PROCEDURE|serratus anterior block|ultrasound guided block
223700457|NCT04264689|PROCEDURE|thoracic epidural|thoracic epidural
223700458|NCT04264689|PROCEDURE|erector spinae block|ultrasound guided block
223700459|NCT03750461|DEVICE|Mesh Implantation|Implantation of permanent mesh (BARD Soft Mesh) into the abdominal wall for reinforcement to prevent hernia formation
223700460|NCT02202525|DRUG|Micardis®|
223700461|NCT02202525|DRUG|Other hypertensives|
223700462|NCT05171543|PROCEDURE|Periapical surgery with placement of an allograft and a membrane|Periapical surgery will be done followed by placement of an allograft into the defect and a membrane over the defect before closure of the flap.
223700463|NCT04346082|BEHAVIORAL|online mindfulness group|Each weekly mindfulness session will last 45 to 60 minutes and will be held on an online platform (e.g. Zoom) via a livestream video. It will consist of short mindfulness exercise(s) of 10-30 minutes, including mindful tasting, mindful stretching, mindful walking, and body scan followed by group discussion to share, explore and make sense of the meditative experience. The intervention will be held in Cantonese.
223700464|NCT05083468|DRUG|SR750 tablet|The volunteers will be orally administrated by single or multiple dose of SR750 tablet with 240 mL water.
223700465|NCT05083468|DRUG|matching placebo|The volunteers will be orally administrated by single or multiple dose of matching placebo with 240 mL water.
223700466|NCT06966570|OTHER|Study Product A: Mixed-macronutrient beverage|Participants will consume a beverage that contains mixed macronutrients.
223700467|NCT06966570|OTHER|Study Product B: Single-macronutrient beverage|Participants will consume a beverage that contains a single macronutrient.
223700468|NCT04176705|DRUG|Lidocaine Cream|Both sites will have lidocaine 4% topical anesthetic cream (Ferndale Laboratories, Ferndale MI) applied as thin layer and left for 30-45 minutes to minimize discomfort applied before laser treatment.
223700469|NCT04176705|DRUG|Triamcinolone Acetonide Cream|Triamcinolone acetonide cream (Bristol-Myers Squibb, Princeton, NJ) at a concentration of 20mg/ml will be applied immediately after treatment to both laser and no-laser sites - as this is often reported and there is some speculation that this may be part of the reason improvement is noted.
223700470|NCT04176705|DEVICE|Fractional Ablative Laser|Applied to only site that is randomized to laser intervention
223700471|NCT04560543|PROCEDURE|McCall suture|Laparoscopic suture including the uterosacral ligaments and the peritoneum
223700472|NCT04560543|PROCEDURE|Standard cuff closure|Standard laparoscopic barbed suture of the vaginal cuff
223700473|NCT03342521|DIAGNOSTIC_TEST|optical coherence tomography and VerifyNow|optical coherence tomography Imaging P2Y12 and Aspirin reaction units quantification by the VerifyNow
223700474|NCT04570267|BIOLOGICAL|CSL324|Sterile solution of recombinant anti G-CSF receptor monoclonal antibody for injection
223700475|NCT04570267|DRUG|Placebo|Sterile solution of CSL324 formulation buffer for injection
223700476|NCT03242824|DRUG|Fluorine F 18 Fluorodopa|Contrast used in PET
223700477|NCT03242824|RADIATION|Intensity-Modulated Radiation Therapy|Radiation of different intensities are aimed at the tumor from many angles. This type of radiation therapy reduces the damage to healthy tissue near the tumor
223700478|NCT03242824|PROCEDURE|Positron Emission Tomography|imaging test
223700479|NCT02149615|OTHER|Retinal nerve fibre layer measurement|Measurement of retinal nerve fibre layer thickness using optic coherence tomography.
223700480|NCT01607671|DRUG|Timolol maleate|Timolol 0.5% 1 drop twice daily to the effected eye for 4 weeks.
223700481|NCT02972853|BEHAVIORAL|Mindfulness Training for Primary Care (MTPC)|"For intervention description see Mindfulness Training for Primary Care (MTPC) in the study MINDFUL-PC: Integrating Mindfulness Into the Patient-Centered Medical Home - A Pilot Study"
223700482|NCT01193842|DRUG|Cyclophosphamide|Given IV
223700483|NCT01193842|DRUG|Doxorubicin Hydrochloride|Given IV
223700484|NCT01193842|DRUG|Etoposide|Given IV
223700485|NCT01193842|OTHER|Laboratory Biomarker Analysis|Correlative studies
223782376|NCT01197950|DEVICE|Manual Acupuncture|The women will receive treatment on bilateral points, both distal points and local points and the needles will be manually stimulated to reach De Qi every ten minutes during one hour.
223782377|NCT01197950|DEVICE|Electro Acupuncture|The women will receive treatment on bilateral points, both distal points and local points and the needles will be manually stimulated to reach De Qi every ten minutes during one hour. Eight needles in the painful area (local points) will be connected to an electro-stimulator and stimulated with high frequency (80 Hz) square wave pulses (0.18-ms duration) with alternating polarity. The woman will adjust the intensity of the electrical stimulation to be just under pain threshold.
223782378|NCT06535412|DRUG|IMC-002 + SOC|intravenous injection of 0.8mg/kg、1.2mg/kg and1.6mg/kg
223782379|NCT06535412|DRUG|Placebo + SOC|intravenous injection of Placebo
223700486|NCT01193842|OTHER|Pharmacological Study|Correlative studies
223700487|NCT01193842|DRUG|Prednisone|Given PO
223700488|NCT01193842|BIOLOGICAL|Rituximab|Given IV
223700489|NCT01193842|DRUG|Vincristine Sulfate|Given IV
223700490|NCT01193842|DRUG|Vorinostat|Given PO
223700491|NCT03698331|DRUG|Valbenazine|vesicular monoamine transporter 2 (VMAT2) inhibitor
223700492|NCT03698331|DRUG|Placebo oral capsule|non-active dosage form
223700493|NCT03903653|DRUG|Botulinum toxin type A|"Use of chemodenervation (botulinum toxin A) for treatment of lower extremity spasticity in ABI inpatients with regards to ankle range of motion.~(a total of 350-400 units of botulinum toxin A per treated limb)"
223700494|NCT03903653|DEVICE|Serial Casting|"Using Serial Casting in conjunction with Botox injection for treatment of lower extremity spasticity in ABI inpatients with regards to ankle range of motion.~(a total of 350-400 units of botulinum toxin A per treated limb)"
223700495|NCT03779958|OTHER|Mobile App|a mobile app that demonstrates hand therapy exercises
223700496|NCT02362178|PROCEDURE|Thromboelastography to guide blood products infusion|A TEG has been performed before invasive procedure and blood products infusion has been decided according to TEG parameters as follow: fresh frozen plasma (FFP 10 ml/kg) in case of r time\>40 mm and/or platelets (PLTs 10 units/Kg) for MA\<30 mm
223700497|NCT02362178|PROCEDURE|Standard of care coagulation tests to guide blood products infusion|Patients received FFP (10 ml/kg) if INR\>1.8 and/or PLTS (10 units/Kg) If PLTs count \< 50000/μl
223700498|NCT03848338|PROCEDURE|Electrocochleography|Electrocochleography measurement Intra-operatively and Post-operatively at follow-up appointments along with correlative measurements (Impedance, eCAP, PTA, Speech)
223700499|NCT01467583|DRUG|Fondaparinux|2.5 mg every 48 hours
223700500|NCT02130024|DRUG|Ranibizumab 0.5 mg|Administered as an intravitreal injection
223700501|NCT02130024|DRUG|Aflibercept 2.0 mg|Administered as an intravitreal injection
223700502|NCT03423134|OTHER|New adhesive strip|This is a strip made of a newly developed adhesive
223700503|NCT05274165|DEVICE|Lyric Hearing Aid- Experimental Design|Extended wear hearing aid with a fitting modification that is currently not available
223700504|NCT05274165|DEVICE|Lyric Hearing Aid- Commercially Available|Extended wear hearing aid that is currently available
223700505|NCT04637490|DEVICE|patellar component|patellar resurfacing
223700506|NCT06260098|BEHAVIORAL|Yoga with High Breath work & meditation; Low movement/postures|Participants will engage in an 8 week asynchronous yoga class focused on the internal and cognitive experience within the practice using breathing and meditation focused techniques.
223700507|NCT06260098|BEHAVIORAL|Yoga with Low Breath work & meditation; High movement/postures|Participants will engage in an 8 week asynchronous yoga class with a emphasis on the physicality and movements of the practice.
223700508|NCT02827916|DEVICE|Assessment of neuropathic pain with theThermotest device|Measure of painful neuropathy with thermotest
223700509|NCT02827916|DEVICE|Assessment of neuropathic pain with SUDOSCAN device|Measure of painful neuropathy with sudoscan Devices
223700510|NCT02827916|DEVICE|Assessment of neuropathic pain with the Neuropathic Pain Symptom Inventory.|Measure of painful neuropathy with Neuropathic Pain Symptom Inventory.
223700511|NCT02643030|BEHAVIORAL|hypercapnia|Tidal volume (6 ml/kg) and respiratory rate is adjusted to achieve the objective values of ETCO2 45mmHg
223700512|NCT02643030|BEHAVIORAL|normocapnia|Tidal volume (10 ml/kg) and respiratory rate is adjusted to achieve the objective values of ETCO2 35mmHg
223700513|NCT01690429|DEVICE|Somnocheck micro|Study nights in sleep lab with standard polysomnography plus Somnocheck micro. The Somnocheck micro is a device with pulse oxymetry and nasal cannula, which can be worn like a wristwatch. It records information about sleep disordered breathing, oxygen saturation, and pulse wave.
223700514|NCT02484690|DRUG|Faricimab|Faricimab will be administered as per the regimen specified in the individual arm.
223700515|NCT02484690|DRUG|Ranibizumab|Ranibizumab will be administered as per the regimen specified in the individual arm.
223700516|NCT02484690|DRUG|Sham Procedure|The sham is a procedure that mimics an intravitreal injection, but involves the blunt end of an empty syringe (without a needle) being pressed against the anesthetized eye. It will be administered to participants in treatment arm D at applicable visits to maintain masking.
223700517|NCT04432272|BIOLOGICAL|COVID-19 convalescent plasma|Participants will receive 1 unit of convalescent plasma procured from donors who have: 1) been symptom free for 14 days and screen negative via nasopharyngeal swab or 2) symptom free for at least 28 days or 3) individuals who have never had symptoms of COVID-19 but were found to have elevated anti-SARS-CoV-2 IgG by a serology test deemed to be of acceptable quality and fitting the current guidance by the FDA. Participants, clinicians, investigators and outcomes assessors will be blinded to the amount of anti-SARS-CoV-2 IgA and IgG present in each unit
223700518|NCT03377114|PROCEDURE|Neutral|When inserting a tracheal tube to oral cavity via nostril before use of laryngoscope in nasotracheal intubation, clinicians advance the tube with patient' head and neck in neutral position.
223700519|NCT03377114|PROCEDURE|Head tilting|When inserting a tracheal tube to oral cavity via nostril before use of laryngoscope in nasotracheal intubation, clinicians advance the tube with patient' head in head-tilting position.
223700520|NCT02127723|DEVICE|Hyaluronic acid injection (Macrolane VRF30)|Injection of Macrolane subcutaneously in the buttocks area to reduce cellulite
223700521|NCT02517216|OTHER|parabolic flight|
223700522|NCT02517216|DEVICE|MRI|
223700523|NCT04603716|OTHER|Eccentric Muscle Energy Technique|"Conventional Treatment given to both groups (Hot pack for 15 minutes, Mobilization, AROM Exercises 10 sets x 3days in a week)~Reciprocal inhibition of target muscle (i.e. levator scapulae ,pectoralis major, upper trapezius) causing relaxation, patient force is minimal towards maximal therapist force, 5-7 repetition for 2-4seconds 3 days in a week up to 6 weeks.~Muscle is taken from shortened to lengthened position."
223700524|NCT04603716|OTHER|Concentric muscle energy technique|"Group B: Concentric Muscle Energy Technique: (Autogenic inhibition of target muscle (i.e. levator scapulae ,pectoralis major, upper trapezius) patient force is greater than therapist force, 5-7repitition for 3-4seconds)Muscle is taken from lengthened to shortened position.~On eligible participants baseline assessment was done,3 session were given 3days per week, post intervention assessment was taken at 1st 3rd and 6th week"
223700525|NCT01860781|DRUG|paliperidone palmitate|paliperidone palmitate 150mgeq(1 day), 100mgeq(8days), 75mg(monthly)
223700526|NCT02389985|DRUG|CRLX101|
223700527|NCT02389985|DRUG|Paclitaxel|
223700528|NCT04976062|DIAGNOSTIC_TEST|Combined near-infrared spectroscopy and intravascular ultrasound imaging (NIRS-IVUS)|The NIRS-IVUS technique is an intravascular imaging technique, combining morphological information derived from intravascular ultrasound (IVUS) and molecular information on plaque composition, namely its respective lipid-core burden, using spectral differences between cholesterol and collagen, detected by near-infrared spectroscopy (NIRS). A combined NIRS-IVUS pullback results in a color-coded map indicating the probability of lipid-rich plaque presence in yellow, co-registered to the corresponding IVUS cross-sections.
223700529|NCT00343590|DEVICE|Whole Body Vibration machine|
223700530|NCT05927584|PROCEDURE|Transanal local excision|Transanal full thickness local excision
223700531|NCT02933112|DEVICE|Auto-titrating mandibular positioner test|Participants will undergo a theragnostic test using the auto-titrating mandibular positioner to determine if they are eligible candidates to use oral appliance therapy for their obstructive sleep apnea. The device works by moving the lower jaw forward in response to respiratory events while the participant sleeps. All participants will undergo the same test.
223700532|NCT05750160|OTHER|music therapy|Music therapy that have been made by Music Therapist after Focus Group discussion, given three times a week for 4 weeks
223700533|NCT00802087|DRUG|hydrocodone|Extended Release tablet
223700534|NCT00802087|DRUG|hydrocodone & acetaminophen combination|Immediate Release tablet, hydrocodone and acetaminophen combination product
223700535|NCT00398294|DRUG|MK0733, simvastatin / Duration of Treatment: 12 Weeks|
223700536|NCT04916769|DRUG|Bosutinib capsule|500 mg dose of bosutinib capsule contents mixed with applesauce
223700537|NCT04916769|DRUG|Bosutinib capsule|500 mg dose of bosutinib capsule contents mixed with yogurt
223700538|NCT04916769|DRUG|Bosutinib capsule|500 mg dose of intact bosutinib capsules
223700539|NCT03772678|DRUG|LSALT peptide|novel 16 amino acid peptide
223700540|NCT03772678|OTHER|0.9% Saline|saline
223700541|NCT06312722|DEVICE|Optilume® BPH Catheter System|The Optilume BPH Catheter System is a combination drug/device minimally invasive surgical therapy (MIST) comprised of an uncoated pre-dilation balloon catheter and a separate drug coated balloon (DCB) catheter. The distal end of each catheter has a semi-compliant, inflatable, double lobe balloon that is used to dilate the prostate. The double-lobe DCB catheter is coated with a proprietary coating containing the active pharmaceutical agent paclitaxel. The drug coating covers the working length of the balloon body.
223782380|NCT06536114|OTHER|CRISP: Criteria-Based Approach for the Rehabilitation for Non-Operative Shoulder Injuries|The CRISP group will undergo physical therapy treatment, directed by a research physical therapist, including both supervised physical therapy and a guided home exercise program. This approach has three phases: stabilization, to facilitate joint protection; strength and endurance, to optimize functional capacity; and power, to prepare the Service member for returning to previous level of duty.
223782381|NCT06536114|OTHER|Standard of Care|The Standard of Care group will serve as the control arm and complete a period of physical rehabilitation under the supervision of a Military Health System physical therapist without study-specific guidance or interventions.
223782382|NCT00006172|DEVICE|Bright light box|60-min light therapy shortly after awakening
223782383|NCT00006172|DEVICE|High-output negative ion generator|60-min high-density ion exposure shortly after awakening
223782384|NCT00006172|DEVICE|Low-output negative ion generator|60-min low-density ion exposure shortly after awakening
223782385|NCT01636310|OTHER|Nicotine|Two doses of nicotine will be utilized: a commercially available, high-yield nicotine cigarette (Marlboro Red; Phillip Morris brand) and a denicotinized cigarette (Murty Pharmaceuticals Inc., Lexington, KY). The high dose cigarettes contain 15.48 mg of nicotine and 16 mg of tar based on analysis by the Massachusetts Department of Public Health (MDPH, 1998). The low nicotine cigarettes contain 1.1 mg of nicotine and deliver 0.1 mg of nicotine and 2.8 mg of tar based on analyses provided by the manufacturer.
223782386|NCT01745861|DIETARY_SUPPLEMENT|Lipidem (Omega-3 fish oil lipid emulsion)|Lipidem 200 mg/ml daily infusion for 7 days maximum
223782387|NCT01745861|DIETARY_SUPPLEMENT|Lipofundin® MCT/LCT 20%|Lipofundin® MCT/LCT 20% daily infusion for 7 days
223782388|NCT06386484|DEVICE|PolarCap System|The PolarCap Coolant flows through a silicone-based head cap. An insulating neoprene cover is put on top of the cap to isolate the cold. Using PolarCap system to selective head and neck cooling for 45 minutes post fight in boxing.
223782389|NCT04393545|DEVICE|hallux valgus night splint|The HV night splint holds the hallux in abduction in order to provide a correct position. The SP group was given splints consisting of a rigid polyethylene bar along the medial of the hallux, and soft polyform and Velcro fastener parts.
223782390|NCT04393545|OTHER|exercise|The exercises involved strengthening the AbdH (abductor hallucis) and plantar fascia muscles, and stretching the hallux
223782391|NCT04393545|OTHER|Electrotherapy|Two self-adhesive electrodes were used. One was placed over the medial distal end of the first metatarsal and the other was attached to the motor point of the AbdH (inferior and posterior to the navicular tuberosity).21 The stimulation intensity was increased until a contraction was observed without causing discomfort and pain. Twenty-minute HVPGS was applied in total over three weekly sessions for four weeks.
223700542|NCT04183062|DRUG|Chemotherapy (gemcitabine & docetaxel) plus BIO-11006|"BIO-11006 will be administered at a dose of 75 mg twice daily for patients over 5 years of age and under 18 years of age or 125 mg twice daily for patients 18 years of age or older. The study drug will be administered twice daily by nebulizer over 20 minutes.~GemTax will be administered in 21-day cycles. Gemcitabine will be administered at a dose of 900 mg/m2 IV over 90 minutes on days 1 and 8. Docetaxel will be administered at a dose of 75 mg/m2 IV over 60 minutes on day 8."
223700543|NCT05483270|BIOLOGICAL|the timing of embryo transfer in freeze-all cycles|"Immediate FET group Freeze-all embryo transfer will be carried out in the menstrual cycle immediately following oocyte retrieval.~Postponed FET group Freeze-all embryo transfer will be carried out during the second menstrual cycle to 6 months after oocyte retrieval."
223700544|NCT05417217|PROCEDURE|Discontinued ventilation|Ventilation is discontinued after going on CPB and lungs are exposed to atmospheric pressure
223700545|NCT05417217|PROCEDURE|Continued ventilation|Ventilation is continued from going on CPB until clamping of the ascending aorta with tidal volume 3ml/kg ideal body weight, Fraction of inspired oxygen (FiO2) 50%, respiratory rate 5/min and Inspiratory:Expiratory (I/E) ratio 1/2.
223700546|NCT04093349|GENETIC|SPK-3006|adeno-associated viral (AAV) vector
223700547|NCT03783091|DRUG|Hydroxocobalamin|Single IV administration of Vitamin B12
223700548|NCT03783091|DRUG|Placebo|Single IV administration of saline
223700549|NCT05636826|DRUG|atherolive-drug|The patient will be assigned to one of two treatments (atherolive ) using a computer-generated randomization list (1: 1 allocation). The investigator who has the randomization code is not involved in other study procedures and does not interact with participants. The study drug (atherol) will be prescribed at a dose of 400 mg, once a day for 3 months.
223700550|NCT05636826|DRUG|Placebo Atherolive|The patient will be assigned to one of two treatments using a computer-generated randomization list (1: 1 allocation). The investigator who has the randomization code is not involved in other study procedures and does not interact with participants. Placebo will be prescribed at a dose of 400 mg, once a day for 3 months.
223700551|NCT05736198|DRUG|Dexmedetomidine|dexmedetomidine, midazolam, and fentanyl (titrated to effect) to facilitate intubation
223700552|NCT04490161|OTHER|intravenous reinstallation of cerebrospinal fluid|10ml of CSF will be taken under sterile conditions from the external ventricular drain and immediately administered intravenously.
223700553|NCT03672643|DRUG|Crizotinib|receive crizotinib orally
223700554|NCT03755388|DEVICE|Episealer|Placing Episealer device
223700555|NCT06008613|DEVICE|3D Holographic Guidance, Navigation, and Control (3D GN&C)|"Using electromagnetic (EM) guidance and tracking to precisely place a Cook Zenith Flex AAA bifurcated stent graft during EVAR. EM guidance and tracking is enabled using a system consisting of:~1. experimental 3D guidance, navigation, and control (3D-GNC) software developed by Centerline Biomedical, Inc., integrated with the company's FDA-cleared Intra-Operative Positioning System (IOPS),~2. FDA-cleared compatible sensorized guidewires added to the Cook Zenith Flex delivery system, and~3. 3D visualization on the IOPS mobile cart monitor and 3D holographic visualization overlaid on the patient during the procedure using a head mounted display (HMD), the Microsoft HoloLens 2."
223700556|NCT06572241|DRUG|Intrathecal morphine|morphine 100 mcg, included in the intrathecal component of combined spinal epidural (CSE).
223700557|NCT06572241|OTHER|Saline solution (placebo)|normal saline 0.2 ml added to the intrathecal component of combined spinal epidural (CSE).
223700558|NCT04526509|DRUG|GSK3901961|GSK3901961 as an IV infusion.
223700559|NCT04526509|DRUG|GSK3845097|GSK3845097 as an IV infusion.
223700560|NCT04526509|DRUG|GSK4427296|GSK4427296 as an IV infusion.
223700561|NCT04526509|DRUG|Cyclophosphamide|Cyclophosphamide will be used as lymphodepleting chemotherapy and will be administered via IV route.
223700562|NCT04526509|DRUG|Fludarabine|Fludarabine will be used as lymphodepleting chemotherapy and will be administered via IV route.
223782392|NCT02553330|DRUG|Placebo Cream|
223782393|NCT02553330|DRUG|Ruxolitinib Phosphate Cream|
223700563|NCT05029700|OTHER|Combined exercise training|Combined exercise group (CEG) performed 30 minutes of aerobic training and also received trunk stabilization training in about 30 minutes after a 10-minute resting period. CEG received treatment 2 times a week for 8 weeks. During trunk stabilization training, the participants were taught how to contract the transversus abdominis and multifidus muscles. Due to the progression protocol, endurance levels of trunk muscles were increased by holding each posture for longer periods. The training was started with theraband resistance, which could be repeated between 10-12 repetitions, and the repetition time was increased up to 20. Aerobic training (AT) was given using a treadmill. A heart rate monitor (Polar V800™, Finland) was used by each patient to follow heart rates during the AT. During AT, the target heart rate was calculated as 60-80% of maximum heart rates (MHR). Each exercise session consisted of a 5-minutes warm-up, 20 minutes of walking, and 5 minutes cool down on the treadmill.
223700564|NCT05029700|OTHER|Aerobic training|Control group (CG) performed 30 minutes of aerobic training.CG received treatment 2 times a week for 8 weeks. Aerobic training (AT) was given using a treadmill. A heart rate monitor (Polar V800™, Finland) was used by each patient to follow their heart rates during the AT. During AT, the target heart rate was calculated as 60-80% of maximum heart rates (MHR). Each exercise session consisted of a 5-minutes warm-up, 20 minutes of walking, and 5 minutes cool down on the treadmill.
223700565|NCT05935514|BEHAVIORAL|WW Intervention|The core of the WW food program is the Points® system which assigns each food and beverage a Points® value. Participants will be assigned a personalized daily and weekly Points® Budget, based on reported goals, and designed to create an energy deficit, using the Mifflin St-Jeor formula, which uses age, sex, height, and weight to estimate resting energy expenditure. Participants will also be provided with the FreeStyle Libre 2 Flash Glucose Monitoring System, which is intended to monitor interstitial fluid glucose levels to aid users in the management of diabetes. The System consists of the following primary components: 1) A disposable sensor that incorporates a subcutaneously implanted electrochemical glucose sensor and associated on-body electronics, and 2) A disposable, sensor application device, which is used to adhere the sensor to the skin of the user and to insert the sensor tail just below the surface of the skin.
223700566|NCT05935514|BEHAVIORAL|Usual Care|The Usual Care arm will continue to receive routine medical care by their provider, in addition to a 50-minute virtual, on-line session with a Registered Dietician, with additional materials at the time of their 6- and 12-month follow-up assessments.
223700567|NCT04309812|DEVICE|transcranial direct current stimulation (tDCS)|Electrical stimulation of scalp over a seizure focus
223700568|NCT05925075|DIAGNOSTIC_TEST|Lung Ultrasound|Lung ultrasound to be performed at scheduled intervals as described in individual cohorts.
223700569|NCT03143322|RADIATION|SBRT|SBRT will be added to systemic (standard) treatment of bone metastases.
223700570|NCT06235983|DRUG|LY3537982|Administered orally.
223700571|NCT05885542|DRUG|Cannabidiol oral solution|Double-blind cannabidiol oral solution 800 mg administered once
223700572|NCT05885542|DRUG|Placebo|Double-blind placebo oral solution administered once
223700573|NCT06277037|OTHER|Non-interventional|This is a rollover study
223700574|NCT03448653|OTHER|Colonoscopy with NBI|Colonoscopy with NBI
223700575|NCT02385214|PROCEDURE|Wide Local Excision = 1cm Margin|"A wide local excision involves removing an extra safety margin of healthy skin surrounding the original melanoma site to ensure that any remaining scattered melanoma tumour cells are removed that may have been left behind after the first initial biopsy/surgery."
223700576|NCT02385214|PROCEDURE|Wide Local Excision = 2cm Margin|"A wide local excision involves removing an extra safety margin of healthy skin surrounding the original melanoma site to ensure that any remaining scattered melanoma tumour cells are removed that may have been left behind after the first initial biopsy/surgery."
223700577|NCT05309590|DRUG|Dose|The outcomes of reducing to half of the topical steroid (i.e. fluticasone \[Flovent\] and Swallowed viscous budesonide \[Pulmicort\]) will be observed with regards to whether the patients continue to be in histologic remission. These patients will have already achieved remission on a full dose of the steroid.
223700578|NCT06501690|BEHAVIORAL|Late bedtime|Participants will go to bed 1 hour later than their habitual bedtime
223700579|NCT06501690|BEHAVIORAL|Variable bedtime|Participants will go to bed at a prescribed time that varies each day within +/-1 hour of habitual bedtime
223700580|NCT04340193|DRUG|nivolumab|Specified dose on specified days
223700581|NCT04340193|DRUG|ipilimumab|Specified dose on specified days
223700582|NCT04340193|PROCEDURE|TACE|TACE (Trans-arterial ChemoEmbolization)
223700583|NCT05274659|DRUG|KJ103|Recombinant Immunoglobulin G Cleaving Enzyme
223700584|NCT05274659|DRUG|Placebo|Placebo
223700585|NCT00818675|DRUG|Lead-In Ridaforolimus|Four 10mg tablets of ridaforolimus once daily for five consecutive days each week followed by 2 days days of treatment holiday, during the 8 week lead in treatment period.
223700586|NCT00818675|DRUG|Comparator: Blinded Ridaforolimus|Four tablets of blinded ridaforolimus administered daily for 5 consecutive days each week followed by 2 days days of treatment holiday
223700587|NCT00818675|DRUG|Comparator: Blinded Placebo|Four tablets of blinded placebo (to match ridaforolimus) administered daily for 5 consecutive days each week followed by 2 days of treatment holiday
223700588|NCT02912988|DRUG|Letrozole|Daily 150-300 IU human menopausal gonadotrophin (HMG) / Follicle stimulating hormone (FSH) from cycle day 2-4 (at least 5 days after stopping the oral contraceptive pill) and co-treatment with letrozole 2.5 mg daily from stimulation day 5 until the day before hCG administration. GnRH antagonist (cetrotide or orgalutran) 0.25 mg daily from stimulation day 5 until the day of hCG administration.
223700589|NCT05455385|OTHER|standard 12-week rehabilitation program|The standard program consisted of 1 session in the fitness room and 1 session in the sports hall/week during 12 weeks.
223700590|NCT05455385|OTHER|extra session hydrotherapy|The hydrotherapy group receives 1.5h additional hydrotherapy/week in addition to the standard program.
223700591|NCT05455385|OTHER|extra session ground exercises|The ground exercise group, receives 1.5h ground exercises/week in addition to the standard program.
223700592|NCT04282278|DRUG|Camrelizumab/sintilimab+ Standard chemotherapy|Camrelizumab/sintilimab：200mg，iv，30min，d4，q3w，24 months Standard chemotherapy：Researcher chooses standard treatment by recommended guidelines，d 1-3
223700593|NCT04282278|DRUG|Camrelizumab/sintilimab+ apatinib（Intolerance to chemotherapy / refuse chemotherapy）|Camrelizumab/sintilimab：200mg，iv，30min，d4，q3w，24 months Apatinib：250mg，d1，qd，po
223700594|NCT04282278|DRUG|Camrelizumab/sintilimab+ apatinib+ Standard chemotherapy|Camrelizumab/sintilimab：200mg，iv，30min，d7，q3w，24 months Apatinib：250mg，d1，qd，po Standard chemotherapy：Researcher chooses standard treatment by recommended guidelines，d 1-3
223700595|NCT01999101|DRUG|Px-104|28 days treatment
223700596|NCT04428437|DRUG|Lenvatinib|Prescribed by physician.
223700597|NCT01515007|DRUG|Ciprofloxacin dispersion for inhalation|
223700598|NCT01515007|DRUG|Placebo|
223700599|NCT03753269|DRUG|Fasudil Hydrochloride|2.5mg fasudil hydrochloride (diulted to 15ml by 0.9% saline )will be delivered by targeted perfusion micro-catheter into culprit vessel right after the first wire passage
223700600|NCT03753269|DRUG|Placebo saline|15ml 0.9% saline will be delivered by targeted perfusion micro-catheter into culprit vessel right after the first wire passage
223782394|NCT03043183|PROCEDURE|perioperational nutrition surpport|Oral enteral nutrition support（25 kcal/kg or 1.5 g protein/kg） for 3 days before operation
223782395|NCT04729803|BEHAVIORAL|Experimental: Attention Guidance + Exposure|"1. Participants will receive a brief standardized psychoeducation module, presented via a video recording.~2. Participants will then complete up to 10 analogue teleconferencing calls, each lasting a maximum of two minutes.~3. Between speeches participants will have a 1-minute break.~4. Participants will complete the subjective units of distress scale (SUDS) before and after each speech trial.~The experimental attention guidance condition: (1) the intervention rationale will include information about the importance of visually attending to the faces of the audience; (2) participants will be given target audience members to focus their gaze on during the their impromptu response. They will be told that they should look at and focus on the target audience member for the whole response."
223782396|NCT04729803|BEHAVIORAL|Active Comparator: Exposure Alone|"1. Participants will receive a brief standardized psychoeducation module, presented via a video recording.~2. Participants will then complete up to 10 analogue teleconferencing calls, each lasting a maximum of two minutes.~3. Between speeches participants will have a 1-minute break.~4. Participants will complete the subjective units of distress scale (SUDS) before and after each speech trial."
223782397|NCT04729803|BEHAVIORAL|Experimental: Attention Control + Exposure|"1. Participants will receive a brief standardized psychoeducation module, presented via a video recording.~   F~2. Participants will then complete up to 10 analogue teleconferencing calls, each lasting a maximum of two minutes. During each call participants will be prompted by one of the audience members.~3. Between speeches participants will have a 1-minute break.~4. Participants will complete the subjective units of distress scale (SUDS) before and after each speech trial.~The experimental attention control condition: (1) the intervention rationale will include information about the importance of attention control; (2) participants will be given target at the center of the screen to focus their gaze on during the their impromptu response. They will be told that they should look at and focus on the target for the whole response."
223782398|NCT05879744|DRUG|CLN-978|CD19xCD3 T cell engager
223782399|NCT03551938|BEHAVIORAL|Relationship skills session for YMSM partnered-individuals and couples|Relationship skills session as an addition to the current CTR and CHTC intervention for 15-24 year old YMSM and their partners.
223782400|NCT04050592|DRUG|Estradiol|Active intervention is estradiol. Hormone therapy (HT) of all 150 participants will be standardized to 2.0 mg of oral estradiol (E2) without progestogen for six weeks prior to randomization. After that participants will be randomized into three groups (A, B, C) of equal size.
223782401|NCT04050592|OTHER|Placebo|Those in groups A and B will switch from estradiol to placebo at the beginning of the 10th week after abrupt or tapered discontinuation of HT.
223782402|NCT06534281|PROCEDURE|BAO-G|Using G-iliac system to reconstruct the visceral branches of in endovascular repair of thoracoabdominal aortic aneurysm.
223782403|NCT05525624|DEVICE|TRAMPRE|discharge interventions Transition Model is discharge interventions in parents of preterm infants.
223782404|NCT05525624|OTHER|Control Group|routine neonatal clinic discharge training of the hospital
223782405|NCT00005633|BIOLOGICAL|OVA BiP peptide|
223782406|NCT00005633|BIOLOGICAL|gp209-2M antigen|
223782407|NCT00005633|BIOLOGICAL|recombinant 70-kD heat-shock protein|
223782408|NCT00005633|BIOLOGICAL|tyrosinase peptide|
223782409|NCT01718769|OTHER|questionnaire STAMP|Children will undergo an assessment using the STAMP Tool; a questionnaire including 3 questions with a summary score, according to which the nutritional risk level shall be determined. These children shall also undergo a complete dietician assessment in order to examine the validity of the STAMP Tool.
223782410|NCT05881668|BIOLOGICAL|MSC-EV|10 E10 MSC-EV particles per 100ml for a single dose. No prior HLA matching between MSC donors and recipients or liver donors
223782411|NCT06270823|PROCEDURE|Knee-to-chest-flexion manoeuvre|The obstetrician will place one hand at the neck and shoulder of the baby and gently bend the infant into dorsiflexion while with the other hand bending the hips and knees against the abdomen and chest (squatting into fetal position). This holding position will be continued for 30 seconds, while compression of the umbilical cord is avoided to maintain an undisturbed umbilical circulation to and from the infant during KCF.
223782412|NCT02167633|PROCEDURE|Decompression surgery|Patients will undergo posterior decompression/laminectomy on relevant spinal levels depending on neurological symptoms. If there is a need of spinal stabilization after decompression, patients will undergo posterior instrumentation with pedicle screws and titanium rods. Instrumentation will be done two or three levels above and below each level with metastatic affection.
223782413|NCT02167633|RADIATION|Radiosurgery|Patients treated with radiosurgery/SBRT will receive a prescribed dose of 16 Gy in 1 fraction to cover as large a fraction as possible the defined target volume
223782414|NCT02167633|RADIATION|Fractionated Radiotherapy|"Patients allocated to surgery will receive postoperative radiotherapy commencing between 10 to 21 days after decompressive surgery. Target should include the entire vertebral body and the vertebral arch at the operated level of the vertebral column.~Patients receiving postoperative radiotherapy will receive 30 Gy in 10 fractions with 3 Gy pr. fraction. The prescribed dose should cover at least 90 % of the defined target volume."
223782415|NCT02167633|DRUG|Glucocorticoids|All patients referred with clinical suspicion of metastatic spinal cord compression will receive high dose glucocorticoids. Dose adjusted to risc of side effects.
223782416|NCT02167633|DRUG|Pantoprazole|All patients receiving high dose glucocorticoids will also be prescribed with pantoprazole 40/daily to prevent gastric ulcers
223782417|NCT00668460|DRUG|Lactic acid (Dermacid)|
223782418|NCT05184413|OTHER|Multimodal treatment|A multimodal telerehabilitation intervention will be conducted through Whatsapp video calls. The combined treatment includes: 1) One 30-minute session of education in neurosciences of pain, using audiovisual material with examples and metaphors to improve the patient's understanding. In addition, two sessions of reinforcement of key contents will be held every 15 days; 2) Therapeutic exercise program: active wrist and finger exercises, stretching, mobilization exercises of the median nerve, and aerobic exercise (brisk walking). Each exercise will be dosed on a personalized basis, with a perceived exertion of 4-5 on the Borg scale. Therapeutic exercise will be self-administered, 3 sessions per week for 6 weeks. Telerehabilitation sessions will be performed every 15 days to monitor adherence and adjust the exercise dose.
223782419|NCT05184413|OTHER|Unimodal treatment|An unimodal telerehabilitation intervention will be performed through Whatsapp video calls. The treatment will include only a therapeutic exercise program: active wrist and finger exercises, stretching, mobilization exercises of the median nerve, and aerobic exercise (brisk walking). Each exercise will be dosed on a personalized basis, with a perceived exertion of 4-5 on the Borg scale. Therapeutic exercise will be self-administered, 3 sessions per week for 6 weeks. Telerehabilitation sessions will be performed every 15 days to monitor adherence and adjust the exercise dose.
223782420|NCT04517721|OTHER|Nurse-Led Transitional Burns Rehabilitation Programme (4Cs-TBuRP)|The nurse-led transitional burns rehabilitation programme (4Cs-TBuRP) is presented as an 8-week interventional programme that supports holistic care for adult burn survivors led by a specialist burn care nurse and supported by the burn care team. The intervention posits that as the adult burn survivor transitions, several physiological, psychosocial, health-related behaviour and environmental needs emerge which lead to poor quality of life. Despite this, they may be unable to return to utilise available healthcare services or have inadequate contact with rehabilitation services. To facilitate their recovery and enhance the attainment of rehabilitation outcomes, the 4Cs-TBuRP views the burn care nurse as the link between rehabilitation services and the adult burn survivor. Thus, the burn care nurse serves as the coordinator of care and actively collaborates with the burn care team and the patient/ family to ensure that continuous care is delivered in a timely manner.
223782421|NCT04376541|DRUG|Fentanyl|amount of fentanyl used in both groups
223782422|NCT02206503|DRUG|Cyclophosphamide|This protocol is a phase II multicenter, open label study designed to determine whether the addition of Cyclophosphamide to Rd (CRd) treatment significantly increases response rates and prolonged the outcome (PFS, OS) in patients who experienced a biochemical relapse, without CRAB under Rd treatment. The treatment period includes: administration of the combination CRd for 9 cycles. In order to assess the efficacy and safety of treatment, patients will attend the study center visits at least every 2 weeks. The response will be assessed after each cycle. During the LTFU period, after development of confirmed PD, all patients are to be followed for survival every 1-3 months via telephone or office visit.
223782423|NCT02206503|DRUG|Lenalidomide|
223782424|NCT02206503|DRUG|Dexamethasone|
223782425|NCT00957502|DEVICE|ENTact™ Septal Stapler|1 year aged septal staples
223782426|NCT00957502|DEVICE|ENTact™ Septal Stapler|18 Month Aged Staples
223782427|NCT05639738|OTHER|Clinical and instrumental measurements|"* Clinical evaluations~* Non-invasive instrumental measurements~* Subject's evaluations"
223782428|NCT01733004|DRUG|MM-141|
223782429|NCT01243333|RADIATION|[F-18]fluorodeoxyglucose|Undergo PET scans with \[F-18\]fluorodeoxyglucose
223782430|NCT01243333|RADIATION|[F-18]fluorothymidine|Undergo PET scans with fluorine \[F-18\]fluorothymidine
223782431|NCT01243333|PROCEDURE|Positron Emission Tomography|Undergo PET scans with 3 radiotracers (fludeoxyglucose F 18, fluorine F 18 fluorothymidine, and water O-15)
223782432|NCT01243333|RADIATION|Water O-15|Undergo PET scans with water O-15 tracers
223782433|NCT03524404|BEHAVIORAL|6 Week Intervention|Weekly interactive webinars based on the DPP curriculum at senior center.
223782434|NCT00243373|DEVICE|Barcode technology/eMAR|
223782435|NCT03181360|DRUG|Tenecteplase|Single dose intravenous injection of recombinant fibrin-specific tissue plasminogen activator (tenecteplase) 0.25 mg (200 IU) per kg body weight up to a maximum of 25 mg (5000 IU), given as a bolus over approx. 10 seconds.
223782436|NCT03181360|OTHER|Control|Best standard treatment
223782437|NCT01990235|BEHAVIORAL|PREPARE Intervention|At week 1, 3, 6, and 12 months, interviews (telephone or in person based on preference) by blinded staff will assess engagement in advance care planning(ACP), self-efficacy with ACP, and activation in and satisfaction with decision making. Blinded telephone interviews will also assess surrogate reports of patient engagement in ACP.
223782438|NCT06308939|DRUG|Eribulin|1.4mg/m\^2 day1、8，repeated every 3 week.
223782439|NCT06308939|DRUG|Sintilimab|500mg once every three weeks.
223782440|NCT01741753|DRUG|BKM120|Orally, every morning
223782441|NCT01741753|DRUG|Abiraterone|Orally, 1000 mg, every morning
223782442|NCT01741753|DRUG|Prednisone|Orally, 5 mg, every morning
223782443|NCT01865591|DEVICE|Ultrasound-based Renal Denervation|
223782444|NCT04749420|OTHER|Survey study|Cervical Radiculopathy Impact Scale (CRIS) will be applied
223782445|NCT00695331|DRUG|Misoprostol|Titrated Misoprostol Solution
223782446|NCT00695331|DRUG|Oxytocin|Titrated Intravenous Oxytocin
223782447|NCT02187757|DIETARY_SUPPLEMENT|Study Dietary Supplement (Prelipid 500 mg capsules)|Study Dietary Supplement (PreLipid 600 mg capsules) will be given to subjects twice daily 30 mins before food for 90 days along with lifestyle modification.
223782448|NCT02187757|DIETARY_SUPPLEMENT|Placebo|
223782449|NCT00003011|DRUG|marimastat|10 mg PO BID
223782450|NCT00003011|DRUG|Placebo|10 mg PO BID
223782451|NCT03243526|OTHER|fluid therapy|fluid resuscitation guided by CVP or PPV
223782452|NCT01098006|OTHER|Blood withdrawal|A single blood sample was to be taken from all subjects at the study visit. No study-related treatment was given to the study participants.
223782453|NCT01876173|BEHAVIORAL|Patient Decision Aid for an ICD (primary prevention, non-CRT)|The intervention group will receive the PtDA, which provides a lay summary that outlines the facts, risks, benefits (including probabilities), specific to the option of an implantable defibrillator or the option of medical management to prepare them for consultation with the physician. Values are assessed to reveal which features of each option are important to patients.
223782454|NCT04825457|PROCEDURE|Anchoring-tip vs. Conventional|"Anchoring-tip: the snare tip was projected from the sheath by 1-2 mm length. Consequently, a small mucosal incision was made at proximal side of lesion. Then the snare was deployed progressively and adjusted around the lesion trying to obtain free margins. At the final step of both conventional and Tip-in EMR, the lesion was resected.~Conventional: After injection of normal saline solution mix, snaring was tried for polyp resection."
223782455|NCT02618473|OTHER|non-seloken|regarding the guidelines patients receive seloken before the cardiac CT scan to lower the heart rate during the scan. The intervention in this study is to avoid the medication with seloken before the scan, and to investigate if the use of a new motion correction scan algorithm can compensate for the absence of the seloken.
223782456|NCT04137380|DRUG|Mirikizumab - IV|Administered IV
223782457|NCT04137380|DRUG|Mirikizumab - SC|Administered SC
223782458|NCT04137380|DRUG|Placebo - IV|Administered IV
223782459|NCT04137380|DRUG|Placebo - SC|Administered SC
223782460|NCT02995967|PROCEDURE|Hydrodistention|The hydrodistention will then be performed with the bladder filled at a pressure of 80 cm H2O and noted to be full as evidenced by no further influx of water into the bladder. This volume will be held in the bladder for 5 minutes.
223782461|NCT02995967|DRUG|Botulinum toxin-A|Intradetrusor injection of 100 units of botulinum toxin a
223782462|NCT02161744|BIOLOGICAL|ADSCs administration|100- 240 cc of lipoaspirate will be extracted from the patient. The stromal vascular fraction (SVF) will be isolated with minimal manipulation. The cell pellet will be reconstituted in saline solution and administered intravenously to the patient.
223782463|NCT03898817|OTHER|taking of cutaneous cells|Taking of cutaneous cells by biopsy Sample of blood
223782464|NCT02127164|DEVICE|"Veraflo device, Dakin's solution"|Veraflo device will be installed on the wound to create negative pressure after surgery. Dakin's solution will be instilled through this device into the wound at the regular intervals.
223700601|NCT01814618|DRUG|Budesonide Respules|Subjects irrigate their noses with budesonide respules. They will use one respule per nostril twice daily for three months.
223700602|NCT03659955|OTHER|Autologous blood applied to dry eye|See previous description for the study arm.
223700603|NCT01386008|DEVICE|senfilcon A contact lens|senofilcon A spherical contact lens worn in a daily wear modality
223700604|NCT01386008|DEVICE|investigational enfilcon A|investigational enfilcon A, worn daily wear modality
223700605|NCT06345092|DRUG|Vitamin C|addition of vitamin C to IPRF
223700606|NCT06345092|OTHER|Injectable platelet rich fibrin|injection of IPRF alone
223700607|NCT05907122|DRUG|ABP 206|ABP 206 will be given intravenously over a period of 30 minutes, every 4 weeks (Q4W) for a total of 12 months.
223700608|NCT05907122|DRUG|FDA-licensed Nivolumab|FDA-licensed Nivolumab will be given intravenously over a period of 30 minutes, Q4W for a total of 12 months.
223700609|NCT05907122|DRUG|EU-authorized Nivolumab|FDA-licensed Nivolumab will be given intravenously over a period of 30 minutes, Q4W for a total of 12 months.
223700610|NCT06529042|OTHER|Non-Interventional|Non-Interventional
223700611|NCT04449861|DRUG|Durvalumab plus chemotherapy|"Drug: Durvalumab IV infusions every 3 weeks for 4-6 cycles and every 4 weeks thereafter until PD or other discontinuation criteria.~Drug: Carboplatin 4-6 cycles every 3 weeks~Drug: Cisplatin 4-6 cycles every 3 weeks~Drug: Etoposide 4-6 cycles every 3 weeks"
223700612|NCT06541314|DRUG|Fluzoparib|Fluzoparib (50mg per capsule) 150mg po bid, with a treatment cycle of 28 days. Administer 2 cycles in total.
223700613|NCT04593849|OTHER|Ru-Yih-Jin- Huang-Saan(RYJHS), Wan-Yin-Gao-Jia-Jean-Wey(WYGJJW), placebo ( topical agent without therapeutic effects)|We conduct a clinical trial using topical herbal medicine, including Ru-Yih-Jin- Huang-Saan(RYJHS) and Wan-Yin-Gao-Jia-Jean-Wey (WYGJJW) in treating post fracture pain and tissue swell. 24 eligible participants diagnosed of upper limb fracture with soft tissue injury grading of C1, C0 from Tscherne classification transferred from Orthopedic outpatient clinic and inpatient will be enrolled and randomly allocated to 4 groups, including experimental group A (RYJHS group), group B (WYGJJW group), placebo group( topical agent without therapeutic effects), and control group (only oral analgesics group), with 6 participants in each group.
223700614|NCT05084651|DRUG|Ganaplacide|Treatment A/Period 1: 400 mg (4 x 100 mg tablets) at Hour 0 on Day 1 Treatment B/Period 2: 400 mg (4 x 100 mg tablets) at Hour 0, approximately 2 hours after itraconazole dosing, on Day 5.
223700615|NCT05084651|COMBINATION_PRODUCT|Lumefantrine|Treatment A/Period 1: 480 mg (2 x 240 mg sachets) at Hour 0 on Day 1 Treatment B/Period 2: 480 mg (2 x 240 mg sachets) at Hour 0, approximately 2 hours after itraconazole dosing, on Day 5.
223700616|NCT05084651|DRUG|Itraconazole|200 mg (20 mL of 10 mg/mL oral solution) q.d. on Days 1 to 18
223700617|NCT05303272|DRUG|Abatacept Prefilled Syringe|Abatacept (Orencia) was provided in prefilled glass syringes initial syringes contained 0.6ml (60mg) of concentration 100 mg/m: drug product subsequently modified to 0.4 mL (20mg) concentration (50mg/ML) drug product. Combined with standard of care prednisone 10-40mg qd
223700618|NCT05303272|DRUG|Mycophenolate Mofetil 500Mg Tab|MMF will be administered at a starting dose of 1000 milligrams (mg) Q12H and the dose will be tapered to achieve a goal of 0.5-1.0 gram (gm) Q12H. Combined with standard of care prednisone 10-40mg qd through 52 weeks.
223700619|NCT00976677|DRUG|erlotinib hydrochloride|Given PO
223700620|NCT00976677|DRUG|paclitaxel|Given IV
223700621|NCT00976677|DRUG|carboplatin|Given IV
223700622|NCT00976677|BIOLOGICAL|bevacizumab|Given IV
223700623|NCT01689961|BEHAVIORAL|Structured + monitored nutrition and exercise intervention|The exercise intervention includes a custom-designed pregnancy-specific group walking class of 30-60 min. 1x/week and a prescribed at-home walking program for 10,000 steps/day. The nutrition intervention is a high protein (25% energy) low-fat dairy food plan designed to meet energy needs and with individualized counselling. The intervention will include 2 x/month weight monitoring and records of nutrition and activity to ensure adherence.
223782465|NCT01173848|DRUG|Ergocalciferol|1.25mg weekly for 12 weeks then once a month for 3 months. or 1.25 weekly for 4 weeks then once a month for 5 months. or 1.25 monthly for 6 months
223782466|NCT01173848|DRUG|Cholecalciferol|1.25 weekly for 12 weeks then monthly for 3 months or 1.25 weekly for 4 weeks then monthly for 5 months or 1.25 monthly for 6 months
223782467|NCT03239041|BEHAVIORAL|Social navigation team|Social navigation team
223782468|NCT02772068|DRUG|Istaroxime|Subjects will be given Istaroxime, a novel SERCA2a activator one hour prior and during exercise.
223782469|NCT02772068|OTHER|Exercise|
223782470|NCT04528563|DRUG|Ketorolac Tromethamine 10 MG/ML|Non-Steroidal-Anti-Inflammatory given intravenously.
223782471|NCT04528563|DRUG|Morphine Sulfate 10Mg/1mL Injection|Opioid commonly used for acute abdominal pain given intravenously.
223782472|NCT01049880|DRUG|Gemcitabine with escalating ascorbic acid|"Gemcitabine (1000 mg/m2) weekly for three weeks and then one week off. Ascorbic acid, given twice weekly, escalating doses weekly. Week 1: 15 grams ascorbic acid per infusion Week 2: 25 grams ascorbic acid per infusion Week 3: 50 grams ascorbic acid per infusion Week 4: 75 grams ascorbic acid per infusion Week 5: 100 grams ascorbic acid per infusion~Ascorbic acid infusion dose is maintained at the level that provides a serum level of 350-400 mg/dL."
223782473|NCT04044677|DEVICE|tDSC-active|10 sessions of active Transcranial Direct Current Stimulation combined to Virtual Reality therapy followed by a one-month washout and 10 sessions of sham Transcranial Direct Current Stimulation
223782474|NCT04044677|DEVICE|tDCS-sham|10 sessions of sham Transcranial Direct Current Stimulation combined to Virtual Reality therapy followed by a one-month washout and 10 sessions of active Transcranial Direct Current Stimulation
223782475|NCT04894474|DRUG|BI 767551 intravenous|BI 767551 intravenous
223782476|NCT04894474|DRUG|BI 767551 inhalation|BI 767551 inhalation
223782477|NCT04894474|DRUG|Placebo intravenous|Placebo intravenous
223782478|NCT04894474|DRUG|Placebo inhalation|Placebo inhalation
223782479|NCT00238927|DRUG|inhaled fluticasone 750 mcg/day twice daily until 2 days without symptoms (maximum 15 consecutive days)|
223700626|NCT04175054|OTHER|Body-weight supported treadmill training in a room cooled to 16°C|Exercise will be performed on a treadmill using an overhead harness for safety in a temperature controlled-room at 16°C with 1:1 supervision. The high intensity group will maintain vigorous intensity with a target workload \>60% of heart rate reserve for 30 min (plus 5min warm up and 5min cool down) while the low-intensity group will walk at mild intensity (\<40% heart rate reserve) for the same duration. Heart rate, blood pressure, and rating of perceived exertion will be recorded throughout to monitor for potential adverse events and to ensure that target training zone heart rates are maintained. The intervention is 3 times per week for 12 weeks, with a 3-month run-in observational period to confirm disease stability, and 3-month follow-up to determine the sustainability of effects.
223700627|NCT03507400|BEHAVIORAL|Introvision: mental and emotional self-regulation|Participants learn Introvision
223782480|NCT02265705|DRUG|Baricitinib|Administered orally
223782481|NCT02265705|DRUG|Placebo|Administered orally
223782482|NCT05580900|OTHER|Livestream Modality (treatment)|For this evaluation, the livestream modality is considered the treatment.
223782483|NCT05580900|OTHER|Live Modality (control)|For this evaluation, the live or in-person modality is considered the control group.
223782484|NCT01820130|DEVICE|St Jude Medical EON mini rechargeable system|implantation of Eon Mini Neurostimulation System (IPG Model 3788)
223782485|NCT01375296|DEVICE|China-made SES (Firebird 2 and Excel)|patients with coronary 50-70% narrowing treated with China-made SES stent,i.e. Firebird 2 (cobalt-alloy platform with durable polymer coating sirolimus-eluting stent) and Excel (stainless steel platform with biodegradable polymer coating sirolimus-eluting stent).
223782486|NCT01375296|OTHER|routine medicine|patients with coronary 50-70% narrowing treated with routine medicine
223782487|NCT02853968|PROCEDURE|Blood draw/buccal swab|The research project will need a blood sample of no more than 50mL per two month period. The research project may also request a buccal swab from patients if needed.
223782488|NCT05465226|DRUG|Oliceridine|see arm description
223782489|NCT05465226|DRUG|Historical opioid use|Historical matched, control group in 2:1 ratio
223782490|NCT01821781|DRUG|Transplant preparative regimen of alemtuzumab, fludarabine, thiotepa, and melphalan|Between days -23 and -15: alemtuzumab test dose, 3mg IV or SQ Day -14: alemtuzumab, 10mg IV or SQ Day -13: alemtuzumab, 15mg IV or SQ Day -12: alemtuzumab, 20mg IV or SQ Days -8 to -4: fludarabine, 30mg/m2 IV Day -4: thiotepa 4mg/kg IV q 12 hours Day -3: melphalan, 140mg/m2 IV Day 0: stem cell infusion Day +7: G-CSF
223782491|NCT02428036|BIOLOGICAL|TBI-1401(HF10)|Patients will receive intratumoral administrations of TBI-1401(HF10). The dose is 1 mL of 1x10\^6 TCID50/mL.
223782492|NCT02428036|BIOLOGICAL|TBI-1401(HF10)|Patients will receive intratumoral administrations of TBI-1401(HF10). The dose is 1 mL of 1x10\^7 TCID50/mL.
223700628|NCT06589661|OTHER|Interview|Patients will be interviewed by the research team to learn about their experience of Cesarean delivery under general anesthetic.
223700629|NCT05881460|DEVICE|Active vibrotactile coordinated reset|Vibrotactile Coordinated Reset delivers vibratory stimulation to the fingertips of each hand. A specific pattern of vibration to each fingertip is delivered which theoretically disrupts abnormal synchrony in the brain.
223700630|NCT05881460|DEVICE|Sham vibrotactile coordinated reset|Vibrotactile Coordinated Reset delivers vibratory stimulation to the fingertips of each hand. An inactive pattern of vibration to each fingertip is delivered which theoretically will not have the effects of active vCR.
223700631|NCT01336192|DRUG|Gemcitabine|Gemcitabine 1250mg/m\^2 Day 1 and 8, 28 days per cycle until PD
223700632|NCT01336192|DRUG|Best supportive care|Best supportive care
223700633|NCT03260920|DRUG|Syntocinon|Intranasal Oxytocin
223700634|NCT00485433|DRUG|Bupivacaine HCl|Bupivacaine HCl given during hernia repair
223700635|NCT00485433|DRUG|SKY0402|SKY0402 given during hernia repair
223700636|NCT01555983|DRUG|Vaporization of Cannabis|Randomized, Controlled Crossover Trial of Vaporized Cannabis using different strengths of THC in patients with Central Neuropathic Pain Active Comparator: Vaporized High Dose 6.7% THC Active Comparator: Vaporized High Dose 2.9% THC Placebo Comparator: Vaporized Placebo THC
223700637|NCT03239964|DRUG|Dexamethasone|the wound edges are injected once with dexamethasone. A 1 mL syringe with a 30-gauge needle is used and injection is both intradermal and subdermal. Repeated alternate punctures are used to bathe the wound edges with the drug. Approximately 0.5-1 mL of dexamethasone (4 mg/mL) in wound tissue.
223700638|NCT03239964|OTHER|surgical excision|total extralesional surgical excision of the keloid is performed and minimal undermining
223700639|NCT06660550|PROCEDURE|laparoscopic inguinal hernia repair|traditional laparoscopic repair
223700640|NCT06660550|PROCEDURE|Needlescopic inguinal hernia repair|Needlescopic inguinal hernia repair
223700641|NCT06598033|DRUG|VC plus herbal medicine|Vitamin C 300 mg/day, TID, PO. Reishi, 2 g/day, BID, PO. Cordyceps, 2 g/day, BID, PO.
223700642|NCT06597760|DRUG|Enlicitide|Participants will receive 20 mg enlicitide/180 mg sodium caprate coadministered with 0.25mg Digoxin orally on Day 1, Period 2 in Arm A and on Day 1 Period 1 in Arm B.
223700643|NCT06597760|DRUG|Digoxin|Participants will receive 0.25 mg digoxin orally on Day 1 Period 1 in Arm A and Day 1 Period 2 in Arm B. They also receive Digoxin orally on Day 1, Period 2 in Arm A and on Day 1 Period 1 in Arm B coadministered with oral 20 mg enlicitide/180 mg sodium caprate.
223700644|NCT02353754|DRUG|Intrathecal morphine injection|0.2 mg
223700645|NCT02353754|DRUG|EXPAREL|266 mg
223700646|NCT06002490|DRUG|P1101|"The subjects will be treated with P1101(ropeginterferon alfa-2b), starting at a dose of 250 micrograms. The dose of P1101 will be increased to 350 micrograms 2 weeks later and to 500 micrograms another 2 weeks later, and then P1101 will be administered at a fixed dose of 500 micrograms throughout the treatment period. Although the dose may be reduced to the prior dose for reasons related to the safety or tolerability, the increased dose should be preferably maintained throughout the treatment period.~The dose of P1101 will be increased or decreased appropriately depending on the pathological condition in the range up to 500 micrograms."
223700647|NCT06002490|DRUG|Low-dose aspirin|Low-dose aspirin (acetylsalicylic acid) (75-150 mg/day) will be given as background therapy during the 12 months of study treatment, unless contraindicated.
223782493|NCT02505646|OTHER|Observational study. No special intervention will be made|Data will be recorded in a context of fluid load in a context of circulatory failure. Stroke volume will be monitored, before, after an abdominal compression and after a fluid load.
223782494|NCT00779246|OTHER|Nasal swabs for MRSA culture|Patients will have nasal swabs performed upon ICU admission, upon discharge, and every 2 weeks while they remain in the ICU.
223782495|NCT00779246|DRUG|Chlorhexidine gluconate|CHG-impregnated cloths (2%) will be used to bathe patients at least daily during the duration of their medical ICU stay. Surveillance cultures will be obtained on admission, discharge and every 2 weeks while in the ICU, but results will be blinded until conclusion of the study.
223700648|NCT06002490|PROCEDURE|Phlebotomy|Phlebotomy is performed aiming at a hematocrit \< 45%. When the hematocrit value is 45% or higher, phlebotomy is performed. The volume of phlebotomy per procedure should be 200 to 400 mL while monitoring the circulatory dynamics such as blood pressure and pulse. In the elderly and patients with cardiovascular disorders, a small volume (100-200 mL) should be considered to avoid rapid changes in hemodynamics.
223700649|NCT05961059|BIOLOGICAL|2.5 μg InvaplexAR-Detox|2.5 μg intramuscular dose of Sfl2a InvaplexAR-Detox.
223700650|NCT05961059|BIOLOGICAL|10 μg InvaplexAR-Detox|10 μg intramuscular dose of Sfl2a InvaplexAR-Detox.
223700651|NCT05961059|BIOLOGICAL|0.1 μg of dmLT|0.1 μg intramuscular dose of double mutant (LT R192G/L211A) enterotoxigenic Escherichia coli heat labile toxin (dmLT).
223700652|NCT05961059|BIOLOGICAL|Placebo|Placebo vaccination with commercially available saline solution.
223700653|NCT01672762|DRUG|ipragliflozin|oral
223700654|NCT06597916|BIOLOGICAL|Arexvy powder and suspension for injection|Arexvy powder and suspension for injection (RSV vaccine)
223700655|NCT06592300|DRUG|Tenofovir Alafenamide Film coated Tablet|The administration was performed in the morning, 30 minutes after a high-fat, high-calorie vegetarian breakfast was served following an overnight fast of at least 10 hours.
223782496|NCT00779246|OTHER|Contact isolation|All patients will be placed in contact isolation until the results of their active surveillance cultures are negative; if positive, they will remain in isolation.
223782497|NCT02523534|PROCEDURE|MRI|MRI images will be taken in conjunction with the clinically indicated cardiac MRI.
223782498|NCT02523534|PROCEDURE|ECG|ECG readings will be taken prior to the participants clinically indicated procedure.
223782499|NCT05237765|OTHER|controlled (automatic) massage|Massage methods that are performed with mechanical methods are called automated massage. Automated massage is also individual-controlled massage. This is because in automated massage, to relax, solve or reduce their pain, the individual applies the massage under their own control or under the control of someone else through a controller in a way where the duration and intensity of the massage in the body part of application vary. Individual-controlled massage devices may be in the form of chairs, cushions, beds and mattresses. These massage devices have functions such as vibrating, applying vacuum, imitating manual massage motions and applying heat.
223782500|NCT01111500|DEVICE|Donjoy ER brace|Patients will wear an external rotation brace, the Donjoy ER brace, during treatment.
223700656|NCT06592300|DRUG|Vemlidy® film-coated tablets|The administration was performed in the morning, 30 minutes after a high-fat, high-calorie vegetarian breakfast was served following an overnight fast of at least 10 hours.
223700657|NCT06668155|PROCEDURE|Autograft Group|If assigned the autograft group, the surgeon will choose either bone patella tendon bone (BPTB) or all soft tissue quadriceps tendon for the graft. The graft choice will be based upon surgeon preference.
223700658|NCT06668155|PROCEDURE|Allograft with LET Group|The allograft used will be a non-irradiated quadriceps tendon with bone plug allograft with a donor age less than 45 years.
223700659|NCT00630695|DRUG|Lanreotide LP 90|Lanreotide LP 90
223700660|NCT00630695|DRUG|Placebo lanreotide|Placebo
223700661|NCT03335111|OTHER|Remote Ischemic Conditioning Equipment|BAIPC is admistrated by 5 cycles extremities ischemia (5-minute blood-pressure cuff inflation up to 50 mmHg higher than baseline, followed by 5-minute cuff deflation) for one week.
223700662|NCT03335111|PROCEDURE|Intravenous blood collection|Nurses will collect 5 ml intravenous blood with anticoagulant and 5ml total blood at 0d, 1d and 7-10d respectively. The blood samples will be stored for laboratory assay. The blood samples only use in this trial.
223700663|NCT06468215|DRUG|Treatment Option 1 is a single-drug regimen, with oral medroxyprogesterone acetate (MPA) 500mg/d or MA 320mg/d.|Compare the efficacy of mono-therapy with progesterone versus combined therapy to determine the best treatment option.
223700664|NCT00289718|BIOLOGICAL|Twinrix™ adult|Intramuscular administration
223700665|NCT05184075|PROCEDURE|Standard hybrid coronary revascularization|Patients will undergo endoscopic coronary artery bypass grafting (endo-CABG) within four weeks after the diagnostic coronarography. Furthermore, they will receive a percutaneous coronary intervention (PCI) within four weeks after the endo-CABG.
223700666|NCT05184075|PROCEDURE|Reverse hybrid coronary revascularization|Patients will receive a percutaneous coronary intervention (PCI) within four weeks after the diagnostic coronarography. Furthermore, they will undergo the endoscopic coronary artery bypass grafting (endo-CABG) within four weeks after the PCI.
223700667|NCT02577497|DRUG|beclomethasone|
223700668|NCT02577497|DRUG|fluticasone|
223700669|NCT06517823|DRUG|Etoricoxib + Cyanocobalamin fixed dose|One tablet of 90 mg / 0.50 mg a day
223700670|NCT06517823|DRUG|Etoricoxib fixed dose|One pill of 90 mg a day
223700671|NCT04128579|DRUG|Itolizumab [Bmab 600]|EQ001
223700672|NCT06708845|BIOLOGICAL|zamtocabtagene autoleucel|chimeric antigen receptor T-cell (CAR-T) therapy
223700673|NCT06708845|DRUG|Cyclophosphamide|Lymphodepleting chemotherapy
223700674|NCT06708845|DRUG|Fludarabine|Lymphodepleting chemotherapy
223700675|NCT06709586|PROCEDURE|Thermal ablation|Thermal ablation is a treatment for secondary hyperparathyroidism. There are radiofrequency ablation (RFA) and microwave ablation (MWA). For RFA, an electrode needle is inserted into the parathyroid under imaging guidance. High - frequency current heats the tissue to cause necrosis. MWA uses electromagnetic waves to generate heat by friction. Before ablation, imaging and lab tests are done for evaluation. During the process, precise positioning and real - time monitoring are key. After that, patients are observed for bleeding, swelling and other symptoms, and tests are repeated to assess the effect.
223700676|NCT06709586|PROCEDURE|parathyroidectomy|Parathyroidectomy for secondary hyperparathyroidism is a common approach. The surgeon first makes an incision in the neck area under general or local anesthesia. Then, the enlarged parathyroid glands are carefully identified and dissected. Precise surgical skills are required to avoid damaging nearby structures such as the recurrent laryngeal nerve and blood vessels. After the removal of the abnormal parathyroid tissue, the wound is closed.
223700677|NCT06934408|DRUG|HRS-5817 Injection|HRS-5817 injection administered subcutaneously (SC).
223700678|NCT06934408|DRUG|HRS-5817 Injection Placebo|HRS-5817 injection placebo administered subcutaneously (SC).
223700679|NCT04029506|OTHER||this is an obsevational study which needs no interventions
223700680|NCT05367427|DIETARY_SUPPLEMENT|Heat treated postbiotic Bifidobacterium Longum consumption|Regular consumption in breakfast of heat treated postbiotic B. longum
223700681|NCT05367427|DIETARY_SUPPLEMENT|Placebo|Maltodextrin
223700682|NCT05662007|OTHER||no intervention
223700683|NCT05993377|OTHER|Logistic regression Cross validation Area under the RIC curves Machine learning analysis. .|we will use robust machine learning approaches, such as Random Forest and XGBoost.
223700684|NCT01854242|OTHER|Glycogen Storage Disease type Ia patients|The participants will have one blood draw for this study. The test will be performed on the blood.
223700685|NCT05399654|DRUG|TAC-001|TAC-001 is a Toll-like Receptor Agonist Antibody Conjugate (TRAAC)
223700686|NCT00978770|DRUG|systemic chemotherapy|
223700687|NCT00978770|PROCEDURE|diffusion-weighted magnetic resonance imaging|
223700688|NCT00978770|PROCEDURE|dynamic contrast-enhanced magnetic resonance imaging|
223700689|NCT00978770|PROCEDURE|magnetic resonance spectroscopic imaging|
223700690|NCT00978770|PROCEDURE|neoadjuvant therapy|
223700691|NCT02322073|PROCEDURE|Laparoscopic surgery|Roux-en-Y gastric bypass or other benign laparoscopic surgery
223782501|NCT01111500|DEVICE|Thoraco brachial brace|Patients will wear an internal rotation brace, a thoraco brachial brace, during treatment.
223782502|NCT04715594|DEVICE|1st-generation drug-eluting stent|Implantation of 1st-generation drug-eluting stent
223782503|NCT04715594|DEVICE|2nd-generation drug-eluting stents|Implantation of 2nd-generation drug-eluting stent
223782504|NCT05204524|DRUG|Temozolomide for injection combined with epirubicin|Temozolomide for injection, according to the requirements of GCP, the test drug should be sealed, kept away from light and kept at 2-8℃, with a valid period of 24 months.
223782505|NCT06216626|DIETARY_SUPPLEMENT|myota's prebiotic fibre blend|"Each 10g daily serve of supplement contains the following fibres:~* Fructooligosaccharides~* Inulin~* Resistant dextrin~* Resistant maltodextrin~* Partially hydrolysed guar gum~* Guar gum"
223782506|NCT05042219|DIAGNOSTIC_TEST|Cardiac MRI|Cardiac MRI and Echocardiography before treatment initiation of pulmonary disease and 3 months thereafter
223782507|NCT02379598|DIETARY_SUPPLEMENT|Aminoacid based formula|Formula based on aminoacid
223782508|NCT02379598|DIETARY_SUPPLEMENT|Hydrolyzed whey formula|Formula based on hydrolyzed whey protein
223782509|NCT03465540|DRUG|AMG 397|AMG 397 will be administered orally once or twice weekly as part of a 28-day treatment cycle.
223782510|NCT03465540|DRUG|Dexamethasone|Dexamethasone will be administered intravenously (IV) or orally on Days 1, 8, 15, and 22 of each 28-day cycle.
223782511|NCT03465540|DRUG|Azacitidine|Azacitidine will be administered intravenously (IV) or subcutaneously (SC) daily for the first 7 days of a 28-day cycle.
223782512|NCT06031246|PROCEDURE|Selective Lymph Node Dissection|For patients with NSCLC with CTR\>0.5 located in the apical segment, the inferior mediastinal lymph node was not need to dissected
223782513|NCT01060761|BEHAVIORAL|Rehabilitation program|"Patient and their relative receive three supportive, structured conversation with a trained nurse.~Patient and their relative receive 4 days Retreat Weekend with supportive talk and activities"
223782514|NCT00736996|DRUG|Pioglitazone|30 - 45mg tablet daily for 6 months
223782515|NCT00736996|DRUG|Placebo|Matching tablet daily for 6 months
223782516|NCT00736996|BEHAVIORAL|Endurance Exercise Training|Individualized exercise prescription, 45-75 minutes (progressive increments) three times a week
223700692|NCT03002363|BEHAVIORAL|Video Modeling Intervention|Prior to arrival of the audiological evaluation, the child and caregiver will be required to watch one of two videos created by the research personnel. One video, the intervention video, is a behavior modeling video walking through the entire audiological evaluation. It also includes tips for caregivers to practice with their child before the appointment. The other video is a placebo video that discusses hearing, listening and ears, that does not discuss tips for caregivers to practice with their child before the appointment. The placebo video is not related to the audiological evaluation.
223700693|NCT03002363|BEHAVIORAL|Placebo Video|The other video is a placebo video that discusses hearing, listening and ears, that does not discuss tips for caregivers to practice with their child before the appointment. The placebo video is not related to the audiological evaluation.
223782517|NCT02844946|BEHAVIORAL|Acceptance and Commitment Therapy|Contextually focused form of cognitive behavioral psychotherapy that uses MINDFULNESS and behavioral activation to increase patients' psychological flexibility in areas such as ability to engage in values-based, positive behaviors while experiencing difficult thoughts, emotions, or sensations.
223782518|NCT02806986|BIOLOGICAL|IGSC 20%|Weekly administration of IGSC 20% via intravenous infusion
223782519|NCT02873611|DEVICE|MRI|patients will undergo an additional MRI testing of apprx. 0.5-1 hour.
223782520|NCT02873611|PROCEDURE|genicular ablation procedure|
223700694|NCT05890144|OTHER|Big Canoe|The Big Canoe will involve an intensive, multi-modular Indigenous cultural safety education training program that is offered online and led by trained facilitators. It is 10 modules long and takes 10 weeks to complete (1 hour of learning per week).
223700695|NCT05890144|OTHER|Little Canoe|The Little Canoe involves a brief, 2-hour, interactive, computer-based Indigenous race-bias education session that is offered in a computer lab with a researcher present and followed up with 2 reinforcement/reminder emails that ask questions about strategy usage at 6 and 8 weeks after the session
223700696|NCT05890144|OTHER|Control|The control is a primary care-related training program that is time-attention matched to Arm 1 but does not contain any content on anti-bias, anti-oppression, Indigenous peoples, or any content related to the unannounced Indigenous standardized patient encounter.
223782521|NCT06580886|DEVICE|Ultrasound|All patients having ultrasound with Clarius L15/L20 and GE logic E9/E10 in same visit.
223782522|NCT06112210|OTHER|HBOT group|The HBOT will be performed in a Barox HBOT chamber (Yaklasim Makina San. Ve Tic. Ltd. Sti). Participants will be taken to the chamber immediately after the football match, where they will sit in individual chairs, and oxygen will be delivered through individual masks. The HBOT group will be exposed to 100% oxygen at 2.2 ATA (atmospheres absolute). Session will last 70 minutes.
223700697|NCT03487523|BEHAVIORAL|Text Message|As already stated
223700698|NCT02372370|PROCEDURE|Microneedle pretreatment + MAL-PDT|Interventions: microneedling of the skin using dermarollers prior to topical application of 125 microliter methyl aminolevulinate (MAL) cream followed by red light illumination after 3 hours incubation (i.e. photodynamic therapy (PDT)). Three settings are applied: mild, moderate and strong.
223700699|NCT02372370|PROCEDURE|Sandpaper pretreatment + MAL-PDT|Interventions: abrasion of the skin using Abrasive Pads for Skin Preparation prior to topical application of 125 microliter methyl aminolevulinate (MAL) cream followed by red light illumination after 3 hours incubation (i.e. photodynamic therapy (PDT)). Three settings are applied: mild, moderate and strong.
223782523|NCT06112210|OTHER|CON group|The placebo protocols will be performed in a Barox HBOT chamber (Yaklasim Makina San. Ve Tic. Ltd. Sti). Participants will be taken to the chamber immediately after the football match, where they will sit in individual chairs, and oxygen will be delivered through individual masks. The CON group will be exposed to normobaric ambient pressure (1 ATA). The session will last 70 minutes.
223782524|NCT04000165|DRUG|AG-348|This is a nonrandomized, intra-patient dose escalating clinical study. AG-348 will be administered starting at 5 mg twice a day, increasing to 20 mg twice a day, to maximum 50 mg or 100 mg twice a day. Dosing period is every 2 weeks at each dose level. Dose taper will start on Day 42 (50 mg) or Day 56 (100 mg) with dose reduced over 12 to 15 days.
223782525|NCT06535360|BIOLOGICAL|Platelet transfusion|platelet administration through intravenous access
223782526|NCT04071002|OTHER|12 weeks physical therapy programme|The programme include contrast bath, bandage, massage, active exercises, resistive exercises.
223782527|NCT03549689|DRUG|Dolutegravir (DTG) 50MG/lamivudine (3TC) 300MG FIXED DOSE COMBINATION (FDC)|Participants randomized to the Switch Arm will take DTG 50mg/3TC 300mg FDC once daily with or without food at approximately the same time each day.
223782528|NCT03549689|DRUG|Current tenofovir alafenamide (TAF)-containing ART regimen|Continuation of current TAF-containing ART for 96 weeks.
223782529|NCT02024334|DRUG|Leflunomide|
223782530|NCT00750789|DIETARY_SUPPLEMENT|dates|5 maedjool dates or 7 emery dates per day for 2 weeks each with a washout period of 2 weeks between
223782531|NCT04592757|DEVICE|Virtual mirror therapy via VR headset|Participants will perform Activities of Daily Living (ADL) in a virtual environment through a VR headset. The application is based on mirror therapy. Participants will execute certain arm movements with their non-affected arm, while seeing their affected arm perform said movement in the virtual environment.
223782532|NCT04289649|DRUG|K-924 LD|Pitavastatin 2 mg / Ezetimibe 10 mg tables
223782533|NCT04289649|DRUG|K-924 HD|Pitavastatin 4 mg / Ezetimibe 10 mg tables
223782534|NCT04289649|DRUG|K-924 LD Placebo|Pitavastain 2 mg
223782535|NCT04289649|DRUG|K-924 HD Placebo|Pitavastain 4 mg
223782536|NCT01201525|PROCEDURE|Pulsed dye laser treatment|Part 1 of the surgical scar will be treated with 4 595nm Pulsed dye laser treatments.
223782537|NCT01201525|PROCEDURE|Control|Part 2 of the surgical scar will serve as a within patient control.
223782538|NCT00841867|PROCEDURE|All subjects will undergo a 120 minute Oral Glucose Tolerance Test at study visit 2.|All subjects will ingest a 75 g glucose solution (Glucola brand) and have blood drawn at 7 timepoints over 120 minutes.
223782539|NCT06276855|OTHER|Sleep hygiene education|The sleep hygiene education booklet was prepared by the researchers by in line with the literature. The booklet contains information on the definition and benefits of sleep, sleep problems during insomnia, arrangements for regular sleep, and the principles of sleep hygiene. The principles of sleep hygiene include individual habits that facilitate sleep, proper arrangement of the physical environment, exercises before going to bed, and dietary habits. This educational content was applied to those in the experimental group. The education took an average of 30 minutes.
223782540|NCT06148129|DIAGNOSTIC_TEST|Tissue Biopsy|The Post-hysterectomy tissue biopsy was analyzed immunohistochemically for detection of estrogen and progesterone receptors, P53 and L1CAM
223782541|NCT00513669|BIOLOGICAL|PEV 301& 302 in virosomes|PEV 301 50 µg plus PEV 302 10 µg formulated in virosomes and injected at day 0 and 90
223782542|NCT00513669|BIOLOGICAL|Inflexal V (active comparator)|Inflexal V is a marketed influenza vaccine that will be given at day 0 and 90
223782543|NCT01300130|DIETARY_SUPPLEMENT|low docosahexaenoic acid formula|
223700700|NCT02372370|PROCEDURE|Curettage pretreatment + MAL-PDT|Interventions: curettage of the skin using a curette prior to topical application of 125 microliter methyl aminolevulinate (MAL) cream followed by red light illumination after 3 hours incubation (i.e. photodynamic therapy (PDT)). Three settings are applied: mild, moderate and strong.
223700701|NCT02372370|PROCEDURE|Ablative Fractional Laser (AFXL) pretreatment + MAL-PDT|Interventions: Ablative Fractional Laser (AFXL) resurfacing of the skin prior to topical application of 125 microliter methyl aminolevulinate (MAL) cream followed by red light illumination after 3 hours incubation (i.e. photodynamic therapy (PDT)). Three settings are applied: mild, moderate and strong.
223700702|NCT02372370|PROCEDURE|Non-Ablative Fractional Laser (NAFXL) pretreatment + MAL-PDT|Interventions: Non-Ablative Fractional Laser (NAFXL) resurfacing of the skin prior to topical application of 125 microliter methyl aminolevulinate (MAL) cream followed by red light illumination after 3 hours incubation (i.e. photodynamic therapy (PDT)). Three settings are applied: mild, moderate and strong.
223700703|NCT02372370|DRUG|MAL Control.|Intervention: Topical application of 125 microliter methyl aminolevulinate (MAL) cream followed by red light illumination after 3 hours incubation (i.e. photodynamic therapy (PDT)).
223700704|NCT02372370|OTHER|Untreated Control|Untreated control. No interventions.
223700705|NCT04948788|DRUG|SHR1459 ；YY-20394|SHR1459 plus YY-20394
223700706|NCT04948788|DRUG|SHR1459 ；YY-20394|SHR1459 plus YY-20394
223700707|NCT04948788|DRUG|Gemcitabine-Oxaliplatin|Gemcitabine-Oxaliplatin
223700708|NCT06556628|DEVICE|Increased Body Temperatures|Collecting data on patients whose body temperatures increase due to fighting an illness.
223700709|NCT02753933|OTHER|MRI scan|MRI head scan to be performed as the first Secondary Care contact.
223700710|NCT02753933|OTHER|Neurology Appointment|Outpatient appointment with Neurologist as the first Secondary Care contact
223700711|NCT00971880|OTHER|Clinical medical record summary|Summary of immediate and late adverse effects of blood transfusions
223700712|NCT00068328|PROCEDURE|psychosocial assessment and care|
223700713|NCT00068328|PROCEDURE|quality-of-life assessment|
223700714|NCT01081288|OTHER|Invitation for breast screening|Invitation for breast screening to women in different age groups
223700715|NCT00082342|DEVICE|Phoressor II (IOMED)|sham stimulation
223782544|NCT01300130|DIETARY_SUPPLEMENT|medium docosahexaenoic acid formula|
223782545|NCT01300130|DIETARY_SUPPLEMENT|high docosahexaenoic acid formula|
223782546|NCT01300130|DIETARY_SUPPLEMENT|breast milk|a non randomized group of breast milk fed infants was included
223782547|NCT04821596|OTHER|biological collection|"Six 5 mL heparinized tubes, approximately 24 mL of blood will be collected as per standard practice. The 5 tubes collected from a given individual will be transported directly to the laboratory. In the laboratory, peripheral blood mononuclear cells (PBMC) will be prepared for the various analyses.~However, in order to minimize the effect of agents other than CoA in MS patients, it is necessary that peripheral blood mononuclear cells are collected before treatment is given: for RR MS patients treated with first-line drugs (IFNβ, glatiramer acetate, teriflunomide and dimethyl fumarate, ...), RR MS patients treated with second-line drugs (natalizumab and fingolimod, ...) and RR MS patients treated with third-line drugs (alemtuzumab, ...)."
223700716|NCT00082342|DEVICE|Phoressor II (IOMED)|real tDCS stimulation
223700717|NCT02266498|DRUG|BIBB 515 BS|
223700718|NCT02266498|OTHER|Standard breakfast (40 g fat)|
223700719|NCT03302650|DRUG|Angiotensin II|Patients will receive angiotensin-II at a starting dose of 20 ng/Kg/min.
223700720|NCT03302650|DRUG|Normal saline|Patients will receive normal saline.
223700721|NCT03302650|DRUG|Norepinephrine|patients will receive norepinephrine infusion adjusted according to blood pressure
223700722|NCT04806503|DRUG|UNR844|Ophthalmic solution for topical ocular administration
223700723|NCT04806503|DRUG|Placebo|Placebo
223700724|NCT03589469|DRUG|Loncastuximab tesirine|intravenous infusion
223700725|NCT01182610|DRUG|Panitumumab|Panitumumab 9mg/kg on Days 1, 22, and 43
223700726|NCT01182610|DRUG|Paclitaxel|Paclitaxel 200mg/m2 on Days 1 and 22
223700727|NCT01182610|DRUG|Carboplatin|Carboplatin AUC=6 on Days 1 and 22
223700728|NCT01182610|DRUG|5FU|5FU 225mg/m2/day on Days 1-15 and 22-36
223700729|NCT03267836|DRUG|Avelumab|-10mg/kg IV
223700730|NCT03267836|RADIATION|Proton Therapy|-Proton therapy will start concurrently with the first dose of avelumab (up to 3 days before or after is permissible) and will be administered once daily during weekdays (Monday through Friday).
223700731|NCT03267836|PROCEDURE|Surgery|-Standard of care
223700732|NCT01694264|DRUG|Entecavir|Entecavir (Baraclude (Bristol-Myers Squibb) 0.5mg.) will be taken orally on an empty stomach (2 hours after a meal or at least 2 hours before the next meal), once daily from 1 week before starting anti-TNFα and continue 72 weeks after anti-TNFα is administered.
223700733|NCT01694264|DRUG|Placebo|Placebo of Entecavir (prepared by Bristol-Myers Squibb) will be taken orally on an empty stomach (2 hours after a meal or at least 2 hours before the next meal), once daily from 1 week before starting anti-TNFα and continue 72 weeks after anti-TNFα is administered.
223700734|NCT02031796|OTHER|CAVAREC Image Processing algorithm|After deployment of the TAVI prosthesis, other trans catheter valve, or stent, but before the patient care episode is completed, a set of rotational x-ray angiography images will be acquired and reconstructed using the clinical DyanCT and research CAVAREC algorithms.
223700735|NCT04650022|DEVICE|Mechanical thrombectomy|Stent retriever for treatment of cerebral arterial occlusions
223700736|NCT05377879|DEVICE|OPT-IVF dosage|Dosage predicted for each patient by the decision support tool OPTIVF
223700737|NCT03950479|DIAGNOSTIC_TEST|3D and 4D Transperineal Ultrasound|The evaluation of Pelvic Floor Muscles with 3D and 4D transperineal ultrasound using A Voluson E6 system (GE Healthcare, Zipf, Austria) with RAB 8-4-MHz volume transducer for all acquisitions. Measurements will be performed in axial planes. The levator hiatus area (LHA), the antero-posterior (AP) diameter and the left-right (LR) transverse diameter will be analyzed at rest, during pelvic floor contraction and on maximal Valsalva maneuver.
223700738|NCT04479930|OTHER|Pulmonary Care Web-Based App (HappyAir App)|The HappyAir app reminded the HappyAir group daily to use the app, indicating that they record medication intake, daily exercise time (minutes), level of tiredness after the exercises (good, little tired, very tired, or exhausted), and daily mood (happy, little sad, sad, or very sad). The HappyAir integrated plan was designed as a model of a therapeutic program based on communication that introduced the figure of the therapeutic educator (physiotherapist or respiratory coach) in order to design interventions focused on the patients and their needs, with minimal intervention and presence, making the patients responsible for their self-care and management of their illness. Patient and educator shared responsibility.
223700739|NCT02008318|DRUG|Galunisertib|Administered orally
223700740|NCT02008318|DRUG|Placebo|Administered orally
223700741|NCT00546104|DRUG|Dasatinib|An initial dose of 50 mg PO BID; following 4 weeks of treatment, dose adjustment will be based on inhibition of phosphorylation of FAK and paxillin per biopsy assessment, as well as toxicity assessment.
223700742|NCT03485391|BEHAVIORAL|Prolonged Exposure|Practice guidelines have identified that trauma-focused psychotherapies have most evidence for treatment PTSD. Prolonged Exposure (PE) is one type of trauma-focused psychotherapy. PE teaches you to gradually approach trauma-related memories, feelings, and situations that you have been avoiding since your trauma. By confronting these challenges, you can decrease your PTSD symptoms. Treatment will last anywhere from 8-12 weeks for 75-90 minutes, once per week.
223700743|NCT06110078|DRUG|Acetazolamide|Oral rinse with acetazolamide (not taken orally)
223700744|NCT05204251|BEHAVIORAL|Questionnaire|Quality of Life assessed with the SF-36 questionnaire
223700745|NCT02006888|DRUG|IBI-10090|
223700746|NCT02006888|DRUG|Placebo|Placebo
223700747|NCT00371826|DRUG|Everolimus (RAD001)|
223700748|NCT00371826|DRUG|Cyclosporine (Calcineurin Inhibitor (CNI))|
223700749|NCT00371826|DRUG|Methylprednisone/prednisone|
223700750|NCT00371826|DRUG|Mycophenolate sodium (MPA)|
223700751|NCT02649270|BIOLOGICAL|T1h|Given T1h for different groups by vein to evaluate safety and tolerability;Collecting blood samples for pharmacokinetics and pharmacodynamics after administration.
223700752|NCT00481143|DRUG|ICL670/Deferasirox|
223700753|NCT05682365|BEHAVIORAL|prevANS intervention|prevANS intervention will be self-guided and can be implemented from the prevANS web or from the participants' Smartphone (through an APP). The prevANS intervention will have different intensities depending on the risk level of the population, evaluated from the already validated risk algorithm for anxiety: predictA. Participants will be classified as moderate-high or low risk of anxiety. Both groups of risk will receive information on their level and profile (risk factors) of anxiety and psychoeducational information periodically; also, they will work towards manage stressors and enhance protective factors. However, participants with moderate-high risk of anxiety will also receive a cognitive-behavioral training (problem solving, decision-making, handling thoughts / concerns and emotions and communicational skills).
223782548|NCT04169841|DRUG|olaparib, durvalumab, tremelimumab|"STEP 1:~Olaparib 300 mg BID during 8 weeks. Olaparib tablets should be taken at the same time each day, approximately 12 hours apart with one glass of water. The tablets should be swallowed whole and not chewed, crushed, dissolved or divided. Olaparib tablets can be taken with or without food~STEP 2:~Olaparib 300 mg during 4 months as per same requirement as below. Durvalumab 1500 mg plus tremelimumab 75 mg via IV infusion Q4W, starting on Week 0, for up to a maximum of 4 doses followed by durvalumab monotherapy 1500 mg via IV infusion Q4W, starting 4 weeks after the last infusion of the combination and in response or stable after prior molecular target therapy by olaparib based on molecular sequencing."
223782549|NCT01753193|BIOLOGICAL|Anifrolumab|Intravenous infusion of anifrolumab will be administered as 1000 mg Q4W from Day 1 (Week 0) until 12-Feb-2015 (approval of protocol amendment 4); and thereafter 300 mg Q4W up to 3 years or until the sponsor discontinued development of anifrolumab, whichever came first.
223700754|NCT02488161|OTHER|No intervention|
223700755|NCT05652881|PROCEDURE|Joint Lavage|An arthrotomy will be made at the time of temporary external fixation and 1L normal saline will be used to irrigate the ankle joint.
223700756|NCT02050243|DRUG|5ALA|20mg/kg of oral suspension of 5ALA
223700757|NCT06157359|PROCEDURE|scalp nerve block|In the SNB group, bilateral scalp nerve blocks will performed using 20 mL of 0.75% ropivacaine after anesthesia induction. To cover the area of surgical incision and skull clamp, seven scalp nerves including the supratrochlear, supraorbital, zygomaticotemporal, auriculotemporal, lesser occipital and greater occipital nerves, are blocked bilaterally by injecting 1-2 ml of the solution using a 25-gauge needle.
223700758|NCT03100097|DEVICE|Aspen Horizon 627 LSO|
223700759|NCT04775069|BIOLOGICAL|BNT162b2|Intramuscular injection
223700760|NCT04775069|BIOLOGICAL|CoronaVac|Intramuscular injection
223700761|NCT04775069|BIOLOGICAL|AZD1222|Intramuscular injection
223700762|NCT00385762|DRUG|paroxetine|paroxetine 10-40mg daily x 5 weeks
223782550|NCT00383435|DRUG|Mometasone furoate/formoterol (MF/F) combination|MF/F 400/10 mcg via a metered dose inhaler (MDI) twice daily for 52 weeks
223782551|NCT00383435|DRUG|Mometasone furoate/formoterol (MF/F) combination|MF/F 200/10 mcg via a metered dose inhaler (MDI) twice daily for 52 weeks
223700763|NCT06222190|RADIATION|online-adaptive radiotherapy|A conebeam CT is taken to determine the current tumour extent and the deformations occurring in comparison to the dose distribution to be applied. Normal tissues heart, lung and tracheal tree are automatically contoured by the Ethos therapy system in that cone-beam CT. A specialist physician and a physicist are present during this process. These organ contours are used to determine the extent of the current target volume and the adaptive radiotherapy plan is adjusted to the new target volume. If the current tumour extent is not sufficiently covered by the initial radiotherapy plan planned for the series with its planned tolerances, or if the surrounding normal tissue is exposed to too much radiation, then the online adaptive radiotherapy plan for the current treatment is selected by the specialist. Otherwise, the initial radiotherapy plan is used for IGRT.
223700764|NCT05508711|DEVICE|FloTrac/Vigileo system (© Edwards Lifesciences) (Edwards Lifesciences, Irvine, CA) device|Concomitant cardiac output measurement with transesophageal echocardiography and with the FloTrac/Vigileo system (© Edwards Lifesciences) (Edwards Lifesciences, Irvine, CA) device in 3 different positions (horizontal supine, Trendelenburg and reverse Trendelenburg position).
223700765|NCT05218135|OTHER|Intervention|Learning session 1: explain key interventions, explain BIC methodology, retrospective patient record analysis Learning session 2: feedback report, share best practices, discussion, set priorities, teaching and improvement, retrospective patient record analysis Learning session 3: feedback report, share best practices, discussion, set priorities, teaching and improvement, retrospective patient record analysis Learning session 4: feedback report
223700766|NCT06463834|DRUG|Sintilimab|"Sintilimab: 200mg, iv, D1, Q3W;~DCF chemotherapy:~docetaxel 70mg/m2，iv，d1，Q3W； cisplatin 75mg/m2，iv，d1，Q3W； 5-fluorouracil 750-800mg/m2，iv，d1-d5，Q3W"
223700767|NCT04047329|OTHER|general anesthesia or neuraxial anesthesia|
223700768|NCT00573183|BEHAVIORAL|STAGE-12|The STAGE-12 intervention will consist of a combination of five group and three individual sessions. The five group sessions will be taken from the Project MATCH Twelve Step Facilitation manual as modified for use with drug abusers and adapted for delivery in a group format. The group sessions will be augmented by three individual sessions derived from the introductory and termination sessions from the TSF manual and incorporating elements of the brief intensive 12-step referral procedure.
223700769|NCT00573183|BEHAVIORAL|Treatment as Usual|
223700770|NCT03402646|BEHAVIORAL|Reminder module (SMS and Phone call)|Same as described under arm/group descriptions
223700771|NCT03402646|BEHAVIORAL|Photovoice|Same as described under arm/group descriptions
223700772|NCT01164800|DRUG|Trandolapril|Trandolapril 4 mg Tablets of Dr. Reddy's Laboratories Limited
223700773|NCT01164800|DRUG|Mavik|Mavik® 4 mg Tablets of Abbott Laboratories, USA.
223700774|NCT00231842|DRUG|Ifosfamide|Ifosfamide 1.2gm/m2/day for 5 days. Mesna 400mg/IV bolus at each ifosfamide dosing followed by 1200mg IV divided in 3L / day x 5 days. Repeat q21 days x 3 cycles. After 3 cycles, RT. After RT, Ifosfamide 1.0gm/m2/day for 5 days. Mesna 333 mg/IV bolus at each ifosfamide dosing followed by 1000mg IV divided in 3L /day x 5 days. Repeat q21 days x 3 cycles.
223700775|NCT00231842|DEVICE|Radiation Therapy|Ifosfamide 1.2gm/m2/day for 5 days. Mesna 400mg/IV bolus at each ifosfamide dosing followed by 1200mg IV divided in 3L / day x 5 days. Repeat q21 days x 3 cycles. After 3 cycles, RT. After RT, Ifosfamide 1.0gm/m2/day for 5 days. Mesna 333 mg /IV bolus at each ifosfamide dosing followed by 1000mg IV divided in 3L /day x 5 days. Repeat q21 days x 3 cycles.
223700776|NCT00231842|DRUG|Cisplatin|dosage is 20 mg/m2/day for 5 days, ever 3 weeks.
223700777|NCT02422303|DRUG|ketamine|Ketamine 0.5mg/kg will be given intravenously to group A at induction of general anesthesia.
223700778|NCT01126801|DRUG|Estradiol|Oral estradiol 1.0 mg/day for four weeks.
223700779|NCT01126801|OTHER|Placebo control|Placebo control matched to estradiol tablets. Daily dosing for one month.
223700780|NCT03994107|DRUG|Pegylated Liposomal Doxorubicin|"First phase PLD: 30mg/m2；35mg/m2；40mg/m2；IV, d1, q21d×6.~Second phase~PLD：MTD. IV, d1, q21d×6."
223700781|NCT03994107|DRUG|Albumin-bound paclitaxel|220mg/m2 IV for the first infusion，Subsequent infusions 260mg/m2,if no serious adverse reactions occur. d1, q21d×6.
223700782|NCT03994107|DRUG|Trastuzumab|8mg/kg IV for the first infusion. Subsequent infusions 6mg/kg. d1, q21d×6.
223700783|NCT01805375|DRUG|DI-B4|DI-B4 will be administered once weekly for up to a total of four weeks. The starting dose will be 0.02 mg given as an intravenous infusion. A cycle is 1 week in duration and patients should expect to receive a maximum of 4 cycles.
223700784|NCT00228683|PROCEDURE|Biology Study and Tissue Banking|Collection of specimens from Hepatoblastoma patients.
223700785|NCT04816266|DEVICE|Iol master|Iol master measures the distance between anterior pole of the cornea and the anterior surface of the lens to calculate the anterior chamber depth
223700786|NCT04816266|DEVICE|Pentacam|The Pentacam HR calculates Anterior chamber depth from the corneal endothelial layer along a line from the apex of the cornea to the anterior surface of the lens
223700787|NCT01251939|DEVICE|Near-infrared spectroscopy (NIRS)|Non-invasive monitoring device measures the quantity of reflected light photons as a function of two wavelengths, and determines the spectral absorption of the underlying tissue.
223700788|NCT04883229|DEVICE|Halo Neuroscience Neurostimulator|"Experimental: Neurostimulation of 2 milliamps anodal (active) tDCS stimulation for 20 mins during 1 hour speech therapy sessions, 3 times a week for 8 weeks, plus daily homework. Then a washout period of no treatment, followed by a 8 weeks of sham tDCS treatment during 1 hour speech therapy sessions, 3 times a week for 8 weeks, plus daily homework.~Active comparator: Experimental: Sham tDCS stimulation for 20 mins during 1 hour speech therapy sessions, 3 times a week for 8 weeks, plus daily homework. Then a washout period of no treatment, followed by a 8 weeks of neurostimulation of 2 milliamps anodal (active) sham tDCS treatment during 1 hour speech therapy sessions, 3 times a week for 8 weeks."
223700789|NCT00008203|BIOLOGICAL|aldesleukin|
223700790|NCT00008203|BIOLOGICAL|recombinant interferon gamma|
223700791|NCT00008203|DRUG|carboplatin|
223700792|NCT00008203|DRUG|cyclophosphamide|
223700793|NCT00008203|DRUG|cyclosporine|
223700794|NCT00008203|DRUG|thiotepa|
223700795|NCT00008203|PROCEDURE|autologous bone marrow transplantation|
223700796|NCT00008203|PROCEDURE|peripheral blood stem cell transplantation|
223700797|NCT02531204|DRUG|ASP1585|oral
223700798|NCT00257465|BIOLOGICAL|Autologous, DNP-modified vaccine (M-Vax)|5.0, 2.5, 0.5, or 0 cells
223700799|NCT00257465|BIOLOGICAL|Autologous, DNP-Modified Melanoma Vaccine|5 million cells
223700800|NCT00257465|BIOLOGICAL|Autologous, DNP-Modified Vaccine|2.5 million cells
223700801|NCT00257465|BIOLOGICAL|Autologous, DNP-Modified Vaccine|0.5 million cells
223700802|NCT00257465|BIOLOGICAL|Autologous, DNP-Modified Vaccine|0 cells
223782552|NCT00383435|DRUG|Mometasone furoate MDI (MF MDI)|MF 400 mcg via metered dose inhaler twice daily for 52 weeks
223700803|NCT04166500|PROCEDURE|Hysteroscopy|outpatient hysteroscopy after the first menstrual cycle in the follicular phase (9-12 days).
223700804|NCT02538081|DRUG|Risperidone plus Placebo|Standard of care including Risperidone plus Placebo
223700805|NCT02538081|DRUG|Risperidone plus DMXB-A|Standard of care including Risperidone plus DMXB-A
223700806|NCT03760055|DEVICE|nGoggle|The nGoggle is a portable visual evoked potential system that uses an EEG to acquire visual evoked potentials in response to visual stimuli presented on a virtual reality goggle. The investigators will assess the ability of the nGoggle to detect visual field loss in patients with glaucoma, as well as to discriminate among the different stages of the disease, its repeatability and reliability for patient self-testing and patient satisfaction compared to standard automated perimetry (SAP), optical coherence tomography (OCT) metrics and Diopsys NOVA (Diopsys, Inc.). In addition, patients with other diseases affecting the visual system will also be tested in order to assess whether the nGoggle can differentiate glaucoma from them.
223700807|NCT05225649|BEHAVIORAL|Behavior Change Intervention|Health coaching sessions; self-monitoring: Fitbit, home scale, and app; personalized health information by mobile health: growth charts and age-specific health behavior information via text message and email; behavior change support by mobile health: family-based health behavior goal setting via chatbot; and usual clinical care.
223700808|NCT04715425|PROCEDURE|Thoracoscopic pulmonary vein isolation without additional lesion + left atrial appendage exclusion/amputation|Bilateral pulmonary vein isolation using radiofrequency energy
223700809|NCT04715425|PROCEDURE|Catheter pulmonary vein isolation without additional lesions|Bilateral pulmonary vein isolation using radiofrequency energy
223700810|NCT04443699|BEHAVIORAL|Prospective study with two measurement points investigating the impact of viral mitigation protocols on mental health|Prospective study with two measurement points investigating the impact of viral mitigation protocols on mental health
223700811|NCT04676178|DRUG|PRA023|PRA023
223700812|NCT04676178|OTHER|Placebo|Placebo
223700813|NCT04424810|OTHER|High-quality, physician created video|The intervention group will watch a short (2-5 minute) video prior to surgery that will provide them with information about their condition and the procedure they are about to undergo (either carpal tunnel release or trigger finger release).
223700814|NCT04424810|OTHER|Standard of care|Patients in the control group will not be asked to do anything differently prior to their surgery
223782553|NCT00383435|DRUG|Formoterol MDI|Formoterol 10 mcg via metered dose inhaler twice a day for 52 weeks
223700815|NCT00545766|DRUG|Vinflunine|Vinflunine 320 mg/m2 will be administered as a 20 minute IV infusion q3w. Patients will be evaluated for toxicity after each cycle of therapy. Response to vinflunine will be assessed every 6 weeks (every 2 cycles) of treatment. A maximum of 6 cycles of therapy are planned.
223700816|NCT05259514|DEVICE|CytoSorb|The Study Product is CytoSorb. Patients included will receive a CytoSorb filter. The device has a CE-mark and is used in accordance with its CE-Certification. Patients are installed as early as possible after exclusion of the bleeding source and are treated with the CytoSorb Adsorber for 48 hours. Blood flow will be set at least 200 ml/min.
223700817|NCT03116360|DIAGNOSTIC_TEST|Diagnostic Ultrasound|The physician performing the ultrasound will be blinded to the results of the x-ray and MRI. The physician performing the ultrasound will be informed of the bone in question (ex. Tibia) and will be able to perform a focused history and exam. The bone in which acute stress fracture is suspected will then be scanned throughout its length in two orthogonal views. The criteria for diagnosing acute stress fracture on ultrasound include displaying 2 out of 3 of the following: hypoechoic periosteal elevation of cortical bone, visible cortical disruption, hyperemia surrounding the periosteal lesion on power Doppler. The ultrasound physician will then be asked to make a determination whether the ultrasound study is positive for acute stress fracture or negative/indeterminate.
223700818|NCT03423641|DRUG|Direct Acting Antivirals|The time period during which a patient is dispensed the medication and for up to 180 days after initiation of the medication.
223700819|NCT05170464|BEHAVIORAL|Acute Exercise|Brisk walking on a treadmill at ⅔ maximum heart rate as defined by 220-age (in years).
223700820|NCT05170464|DRUG|Caffeine Powder|Participants will receive powdered caffeine dissolved in one cup of water (1.2mg/kg)
223700821|NCT04732143|OTHER|Inspiratory muscle training|At least 2 weeks prior to surgery, participants will be given a Vyaire incentive spirometer device and provided with formal training on proper inspiratory muscle breathing exercise using the device. They will be instructed to perform 4 sets of these exercises per day for 14 days prior to surgery.
223700822|NCT02010710|DEVICE|INFANT software|The decision-support software to be evaluated in INFANT has been designed to run on the K2 data collection system (Guardian®). The data collection system (Guardian®) is a system for managing information from labour monitoring. It displays the CTG on a computer screen alongside other clinical data which are collected as part of routine clinical care. As such, it replaces conventional paper labour notes, the CTG machine and other recording systems for documenting care during labour.
223700823|NCT05361161|DRUG|Transarterial Chemoembolization|Arterial infusion chemotherapy (THP + oxaliplatin + raltitrexed) and THP combined with lipiodol embolization for 2 times, with an interval of 1 month.
223700824|NCT00244283|DRUG|Sevoflurane|
223700825|NCT00244283|PROCEDURE|High thoracic epidural analgesia|
223700826|NCT06406790|DEVICE|CraniSeal|CraniSeal is a PEG Dural Sealant
223700827|NCT06406790|DEVICE|DuraSeal|DuraSeal is a PEG Dural Sealant
223700828|NCT05901311|DRUG|LY3537982|Administered orally.
223700829|NCT05901311|DRUG|[¹⁴C]-LY3537982|Administered orally.
223700830|NCT05901311|DRUG|[¹⁴C]-LY3537982|Administered IV.
223700831|NCT05476536|BEHAVIORAL|self-management skills and healthy technology APP|self-management skills and healthy technology APP
223700832|NCT02298985|DRUG|Curcumin|3 g/day (3 capsules/day) for 6 months
223700833|NCT02298985|DRUG|placebo|3 g/day (3 capsules/day) for 6 months
223700834|NCT01459237|DRUG|Acthrel|Ovine Corticorelin
223700835|NCT01953861|DRUG|EC905|Oral
223700836|NCT00168701|DRUG|BG00012|
223782554|NCT00383435|DRUG|Placebo|Placebo MDI twice a day for 26 weeks
223700837|NCT04749667|OTHER|MSCs|Autologous bone-marrow derived mesenchymal stem cells
223700838|NCT04749667|DRUG|Saline|Isotonic saline
223700839|NCT01275456|PROCEDURE|Exposure to house dust mite|0 SQE/qm for 4 hours 250 SQE/qm for 4 hours 500 SQE/qm for 4 hours 1000 SQE/qm for 4 hours
223700840|NCT00268866|BEHAVIORAL|Education|
223700841|NCT05746962|DEVICE|ScopeGuide Navigated Colonoscope|colonoscopes equipped with ScopeGuide
223700842|NCT05746962|DEVICE|Navigation screen|ScopeGuide's 3D visualisation screen
223700843|NCT03299270|OTHER|Questionnaires|Quality of Life and Functional recovery questionnaires
223700844|NCT04512170|DRUG|HEC585|single or Mulltiple doses up to 10 days
223700845|NCT04512170|DRUG|placebo|single or Mulltiple doses up to 10 days
223700846|NCT04446572|BIOLOGICAL|Lactobacillus salivarius CECT5713|Starting at day 0, women of the RA and INF groups consumed (oral route) a daily sachet with \~50 mg of freeze-dried probiotic (\~9 log10 CFU of L. salivarius CECT5713) for 6 months or until a diagnosis of pregnancy (whatever happened first).
223700847|NCT03824418|PROCEDURE|Surveillance colonoscopy with chromoendoscopy|Surveillance colonoscopy with chromoendoscopy
223700848|NCT05254223|OTHER|Antiinflammatory Diet|The intervention group is recommended to follow a diet, inspired in mediterranean diet, rich in anti-inflammatory foods. They are provided with a table with the recommended foods as well as the frequency of daily/weekly/biweekly consumption.
223700849|NCT05254223|OTHER|Control Diet|The control group is recommended to follow their usual diet. Only in the case of detecting a serious nutritional problem the participant is recommended to correct it with the appropriate advice of the nutritionist.
223700850|NCT05594810|BEHAVIORAL|TAU + Addiction focussed - eye movement desensitization and reprocessing (AF-EMDR)|A total of six 45-90 min. sessions of AF-EMDR therapy with an average frequency of twice per week added to a SCP embedded in CRA. AF-EMD therapy consists of a rationale, installating a treatment goal, desensitasing mental video's, installation of positive cognition, future template and positive ending.
223700851|NCT05594810|BEHAVIORAL|TAU only: Community Reinforcement Approach (CRA) + SCP|"CRA is a comprehensive cognitive behavioural treatment that focuses on helping people discover and adopt a pleasurable, social and healthy lifestyle that is more rewarding than a lifestyle including substance use.~Within CRA a regular smoking cessation program is embedded."
223700852|NCT01331733|DRUG|hMG-HP|
223700853|NCT01331733|DRUG|hMG + GnRH antagonist|
223700854|NCT00269594|DRUG|Lamictal (lamotrigine)|
223700855|NCT04553354|PROCEDURE|cortical resections|is the removal of the epileptic focus either temporal or extra temporal area
223700856|NCT00882466|DRUG|human recombinant erythropoietin|intravenous bolus injection of EPO (50unit/kg)
223700857|NCT02288598|DEVICE|Anodal TDCS|20 minutes 1mA anodal stimulation to left inferior frontal cortex. Cathode positioned on right supra-orbital ridge.
223700858|NCT02288598|BEHAVIORAL|Fluency Training|Speech tasks will be completed using fluency-enhancing techniques: metronome-timed speech and auditory choral speech.
223700859|NCT00608972|DRUG|Doxil|Doxil 30 mg/m2 will be administered on Day 1 of each 28-day cycle.
223700860|NCT00608972|DRUG|Carboplatin|Carboplatin 30 mg/m2 will be administered on Day 1 of each 28-day cycle.
223700861|NCT00608972|DRUG|Bevacizumab|Bevacizumab 10 mg/kg will be administered on Day 1 immediately following chemotherapy and alone on Day 15 of each 28-day cycle.
223700862|NCT00221260|PROCEDURE|anesthesia|Intraoperative general anesthesia AND postoperative IV narcotic analgesia.
223700863|NCT00063323|DRUG|Bupropion|
223782555|NCT03273439|DEVICE|repetitive TMS|Prior to each TMS administration, motor threshold was determined by stimulating the left motor strip with the lowest possible energy to produce, within 10 stimuli, at least 5 evoked potentials Z0.05 . In active rTMS, 10 Hz stimulations over left DLPFC occurred at a power of 110% of motor threshold (MT) for 5-s intervals with 30-s intertrain interval. 30 trains were administered each day (MondayFriday) for 4 consecutive weeks (total stimuli=30,000).
223782556|NCT03273439|DEVICE|Sham rTMS|Sham rTMS, without stimulation
223700864|NCT03270644|DRUG|Lasmiditan|Administered orally
223700865|NCT03270644|DRUG|Propranolol|Administered orally
223700866|NCT02875054|BEHAVIORAL|Constraint induced movement therapy (CIMT)|Involves forcing use of ones affected upper extremity (UE) by physically restraining the less affected upper extremity
223700867|NCT02875054|BEHAVIORAL|Hand-arm bimanual intensive training (HABIT)|Facilitates the translation of gains to improve goal-directed bimanual performance.
223700868|NCT00902668|DRUG|lovastatin|
223700869|NCT00902668|OTHER|questionnaire administration|
223700870|NCT00902668|PROCEDURE|adjuvant therapy|
223700871|NCT00902668|RADIATION|accelerated partial breast irradiation|
223700872|NCT00902668|RADIATION|external beam radiation therapy|
223700873|NCT05130918|DEVICE|Phenolmicin P3 and Bosexil suppository|The suppository we herein investigated includes different active principles, namely: Bosexil®, that is a vegetal extract derived from the resin of the Boswellia serrata, a plant native to India. It has already been published that the Boswellic acids contained show anti-inflammatory and antioxidant properties in a variety of inflammatory diseases whose physio-pathological pathways are shared with those of prostatitis; phenolmicin P3 is a polyphenolic extract derived from beehive propolis, that also demonstrated anti-inflammatory and antioxidant properties in preclinical reports. It has also been reported to have the ability to create a microenvironment hostile to the reproduction of pathogenic bacteria.
223700874|NCT05139082|DRUG|TQB3616 capsules＋ TQB2450 injection|"TQB3616 is a highly active CDK4/6 inhibitor. Preclinical studies have shown that it has a strong inhibitory effect on the kinase activity of CDK4/6.~TQB2450 is a humanized monoclonal antibody targeting PD-L1, which prevents PD-L1 from binding to the PD-1 and B7.1 receptors on the surface of T cells, so as to restore the activity of T cells and thereby enhance the immune response, and has the potential to treat various types of tumors."
223700875|NCT04798638|DRUG|TY-9591 Tablets under Fasted Condition - Arm1|Phase 1 (period 1) fasted from 10 hours prior to dosing with 80 mg TY-9591 tablet (p o, once) and 4 hours after dosing on day 1.
223700876|NCT04798638|DRUG|Osimertinib Mesylate Tablets under Fasted Condition - Arm1|Phase 1 (period 2) fasted from 10 hours prior to dosing with 80 mg Osimertinib Mesylate Tablets (p o, once) and 4 hours after dosing on day 1.
223700877|NCT04798638|DRUG|TY-9591 Tablets after a High-fat Meal - Arm1|Phase 2 (period 3) allocated high-fat meal prior to dosing with 80 mg TY-9591 tablet (p o, once) and 4 hours after dosing on day 1.
223700878|NCT04798638|DRUG|Osimertinib Mesylate Tablets under Fasted Condition - Arm2|Phase 1 (period 1) fasted from 10 hours prior to dosing with 80 mg Osimertinib Mesylate Tablets (p o, once) and 4 hours after dosing on day 1.
223700879|NCT04798638|DRUG|TY-9591 Tablets under Fasted Condition - Arm2|Phase 1 (period 2) fasted from 10 hours prior to dosing with 80 mg TY-9591 tablet (p o, once) and 4 hours after dosing on day 1.
223700880|NCT04798638|DRUG|TY-9591 Tablets after a High-fat Meal - Arm2|Phase 2 (period 3) allocated high-fat meal prior to dosing with 80 mg TY-9591 tablet (p o, once) and 4 hours after dosing on day 1.
223700881|NCT01072669|DRUG|ambrisentan|Subjects will receive ambrisentan 5 mg orally once daily or identical placebo pills for the first 4 weeks and then increased to ambrisentan 10mg once daily\[if the lower dose is tolerated\] or identical placebo pills for the rest of the study. They will be instructed to take the 5mg/pink pills for 4 weeks and then switch to 10mg /red pills unless they are having any drug related side effects or concerns. There will be no routine visit planned at 4 weeks to assess drug tolerance unless a complication arises. Adherence to treatment will be assessed by pill counting at each follow up visit. Follow up digital blood flow measurements will be obtained with LDPI at 1 week and at 3 months, where the same protocol (as that in the initial visit) will be followed.
223700882|NCT01999153|DRUG|20 mL topically used during alginate dressing NAROPEINE|20 mL topically used during alginate dressing
223700883|NCT01999153|DRUG|20 mL topically used during alginate dressing NaCl|20 mL topically used during alginate dressing
223700884|NCT04464057|DIETARY_SUPPLEMENT|early oral feeding or early enteral nurtrion|The patients in the experimental group were fed orally within 24-48 hours after intestinal anastomosis. Start taking it at 24-48 hours after surgery until discharged. The initial dose is 1ml/kg.h, which is gradually increased to 100ml/kg daily.
223700885|NCT03227185|DEVICE|real anodal transcranial direct current stimulation (tDCS)|The MR-compatible neuroConn DC-Stimulator MR (neuroCare Group, Ilmenau, Germany) will be used in the study.
223700886|NCT03227185|DEVICE|sham transcranial direct current stimulation (tDCS)|The MR-compatible neuroConn DC-Stimulator MR (neuroCare Group, Ilmenau, Germany) will be used in the study.
223782557|NCT04792346|RADIATION|breast/chest wall radiotherapy|34 Gy/10 fxs/2 wks to the whole breast/chest wall and locoregional lymph nodes; an optional single fraction 8 Gy boost was administered with electrons to the tumor bed in patients undergoing conservative surgery
223782558|NCT01040104|OTHER|Skin sample|Taken from regularly discarded tissue during routine operation
223782559|NCT01040104|OTHER|Skin biopsy|Skin biopsy from regions exhibiting normal and/or hypertrophic scarring at day 0 and day 90
223700887|NCT02284269|DRUG|SGLT2 Inhibitors|Ipragliflozin (Suglat®), Dapaglilozin (Forxiga®), Tofogliflozin (Deberza® / Apleway®), Luseogliflozin (Lusefi®), Canagliflozin (Canaglu®), Empagliflozin (Jardiance®)
223700888|NCT03643575|DRUG|Vicks Cough Syrup for Chesty Coughs|Vicks Cough Syrup for Chesty Coughs 15 mL (containing 200 mg guaifenesin) IR syrup with 240 mL of water
223700889|NCT03643575|DRUG|Robitussin Extra Strength Chest Congestion|Robitussin Extra Strength Chest Congestion 5 mL (containing 200 mg guaifenesin) IR syrup with 240 mL of water
223700890|NCT03643575|DRUG|Organ-I- NR tablet|Organ-I- NR tablet (containing 200 mg guaifenesin) with 240 mL of water
223700891|NCT04709471|DRUG|Nicotine|Participants will reduce their nicotine intake
223700892|NCT04709471|DEVICE|Juul e-cigarette|Participants will switch to Juul pods containing less nicotine
223700893|NCT04709471|BEHAVIORAL|Reduction|Participants will reduce the number of Juul pods that they use
223700894|NCT02183896|BIOLOGICAL|Platelet-rich plasma (PRP)|
223700895|NCT02183896|DRUG|Saline|
223700896|NCT01189604|DRUG|Placebo|Infusion of placebo, same infusion rates as for arm 2
223700897|NCT01189604|DRUG|ICI35,868 (propofol)|Infusion of propofol: initiation with 0.17 mg/kg for 3 minutes followed by maintenance with 25 µg/kg/minute
223700898|NCT01189604|DRUG|ICI35,868 (propofol)|Infusion of propofol: initiation with 0.33 mg/kg for 3 minutes followed by maintenance with 50 µg/kg/minute
223700899|NCT01189604|DRUG|ICI35,868 (propofol)|Infusion of propofol: initiation with 0.5 mg/kg for 3 minutes followed by maintenance with 75 µg/kg/minute
223700900|NCT01189604|DRUG|ICI35,868 (propofol)|Infusion of propofol: initiation with 0.8 mg/kg for 3 minutes followed by maintenance with 120 µg/kg/minute
223700901|NCT01189604|DRUG|ICI35,868 (propofol)|Infusion of propofol: initiation with 0.5 mg/kg for 1 minutes followed by maintenance with 75 µg/kg/minute
223700902|NCT01189604|DRUG|ICI35,868 (propofol)|Infusion of propofol: initiation with 0.5 mg/kg for 5 minutes followed by maintenance with 75 µg/kg/minute
223700903|NCT03380715|DEVICE|Nasal nebulisation into the right nostril|400mcl of co-phenylcaine (20mg of lidocaine + 2mg of phenylephrine) is added into the nasal nebuliser device (Rinowash Nebula, Air liquid medical systems) and the solution is diluted with 4.5cc of isotonic normal saline. This Mixture is then nebulised into the right nasal cavity for approximately 3 minutes.The seated patient's head is kept flexed and nebulizer device is kept sealed within the nasal cavity while the nebulisation is done and subsequently checking nasal resistance after nasal nebulisation.
223782560|NCT01040104|OTHER|Skin biopsy|Biopsy from skin graft harvest site during routine operation on day 0 and follow-up on day 90
223782561|NCT01040104|OTHER|Blood taking|Blood taking on day 0
223782562|NCT01040104|OTHER|Blood taking|Blood taking on day 90
223782563|NCT06291272|DIETARY_SUPPLEMENT|Psyllium|15 g psyllium + 15 g inulin
223782564|NCT06291272|DIETARY_SUPPLEMENT|Methylcellulose|15 g methylcellulose + 15 g inulin
223782565|NCT06291272|DIETARY_SUPPLEMENT|Inulin|15 inulin
223700904|NCT03380715|DEVICE|Nasal Spray into the right nostril|Intervention : Administration of 4 sprays of nasal decongestions(Co-Phenylcaine(400mcl) (20mg lidocaine + 2mg phenylephrine) once into the right nasal cavity using a nasal spray and subsequently checking nasal resistance post nasal spray
223700905|NCT04336540|OTHER|Menu configuration (presence of energy labelling)|Restaurant menus are altered to accommodate energy labelling intervention
223700906|NCT04336540|OTHER|Menu configuration (more lower energy options added)|Restaurant menus are altered to include more lower energy options
223700907|NCT03081468|DEVICE|Binocular OCT prototype|Participants in the study will undergo pupil measurement using a prototype binocular OCT imaging system (Envision Diagnostics, Inc., CA). For the binocular OCT imaging system, testing will be performed twice in the same session, by the same examiner, to allow assessment of repeatability (test-retest variability).
223700908|NCT03081468|DEVICE|Konan RAPDx|Participants in the study will undergo pupil measurement using a validated, commercially available pupilometer (RAPDx; Konan Medical USA, Inc., Irvine, CA).
223700909|NCT04099095|BEHAVIORAL|Immediate Appointment|The participant will meet the British Red Cross link worker and decide upon a course of action requiring the use of local services appropriate for the participant
223700910|NCT04099095|BEHAVIORAL|Delayed Appointment|After a period of delay (control) the participant will meet the British Red Cross link worker and decide upon a course of action requiring the use of local services appropriate for the participant
223700911|NCT01056029|DRUG|G-202|Thapsigargin is Pro-drug chemotherapy which will be administered by intravenous infusion over 1 hour on Days, 1, 2 and 3 of each 28 day cycle
223700912|NCT04555343|DRUG|Tranexamic acid|1gm instilled instravesically
223700913|NCT02758314|OTHER|Evaluation of PD-1/PDL-1 expression.|Evaluate the expression of PD-1 / PD-L1 on T-cell subpopulations of peripheral blood by flow cytometry and in tumor tissue by immunohistochemistry in NSCLC, free treatment and healthy subjects
223700914|NCT00497315|DRUG|combination chemotherapy (pemetrexed + cisplatin)|pemetrexed 500 mg/m2 + cisplatin 75 mg/m2 (q 3 weeks for 3 cycles)
223700915|NCT00497315|RADIATION|thoracic irradiation + pemetrexed|pemetrexed 500 mg/m2 (q 3weeks for 2 cycles), 60 GY (30 fractions of 2 GY)
223700916|NCT05877573|DRUG|Toripalimab|Toripalimab 240mg,d1,q3w
223700917|NCT05877573|RADIATION|short-term radiotherapy|25Gy/5Fx
223700918|NCT05877573|DRUG|Oxaliplatin|135mg/m2 d1 q3w
223700919|NCT05877573|DRUG|Capecitabine|1200mg/m2 d1-14 q3w
223700920|NCT03505554|DRUG|Lorlatinib|100 mg QD
223700921|NCT03216642|DIAGNOSTIC_TEST|bacterial culture and analysis|Specimens were collected with soft-tipped applicators of sterile cotton swabs after syphilis of lacrimal passages.
223700922|NCT06058026|OTHER|World Dental Federation criteria (FDI)|Restorations were evaluated with FDI criteria.
223700923|NCT05553314|DRUG|Carvedilol|patients randomized to carvedilol group will receive carvedilol-SR.
223700924|NCT05553314|DRUG|Placebo|patients randomized to placebo group will receive placebo.
223700925|NCT01620554|DRUG|BF2.649|1 capsule per week during 2 weeks
223700926|NCT01620554|DRUG|BF2.649|1 capsule per week during 2 weeks
223700927|NCT01620554|DRUG|BF2.649|1 capsule per week during 2 weeks
223700928|NCT01620554|DRUG|BF2.649|1 capsule per week during 2 weeks
223700929|NCT01620554|DRUG|Placebo|1 capsule per week during 2 weeks
223700930|NCT04610385|PROCEDURE|radical cystectomy with urinary diversion|surgical removal of the urinary bladder and other organs and perform a urinary shunt
223700931|NCT04786392|DIETARY_SUPPLEMENT|Lutein supplement|5 mg lutein supplement.
223700932|NCT04786392|OTHER|Food, blended|5 mg lutein from baby spinach, blended.
223700933|NCT04786392|OTHER|Food, unprocessed|5 mg lutein from baby spinach, in whole food form.
223700934|NCT04137627|DRUG|Melatonin 20 MG Oral Capsule|The administration of Melatonin 20 mg in addition to neoadjuvant chemotherapy to observe the antioxidant and onco-static effect.
223700935|NCT04137627|DRUG|Placebo oral capsule|The administration of placebo capsule in addition to neoadjuvant chemotherapy
223700936|NCT03248336|PROCEDURE|office-based vergence/accommodative therapy|one -to-one treatment by a trained therapists. The subject is asked to perform 5-6 therapy procedures during a 60 minute therapy session. The subject is also asked to perform 15 minutes per day of home-based therapy.
223700937|NCT04945512|PROCEDURE|Epidural Analgesia|In the anesthesia preparation room, an epidutal catheter will be placed with a toue needle through the L4-5 spinal space. After induction of general anesthesia, 10 ml of 0.25% bupivacaine will be injected through the epidural catheter.Afterwards, peroperative and postoperative analgesia will be provided with epidural PCA.
223700938|NCT03436004|DEVICE|Colonoscopy|Patients undergoing screening colonoscopy
223700939|NCT03436004|DEVICE|Colonoscopy with specific device (Endocuff Vision)|Patients undergoing screening colonoscopy using the Endocuff Vision device
223700940|NCT05489757|DEVICE|SPY Portable Handheld Imaging (SPY-PHI) System with SPY-QP Software|Perfusion assessment with SPY Q-ICG system
223700941|NCT01457820|DRUG|Allopurinol|Stat dose Allopurinol 800mg, then 400mg BD for 5 days
223700942|NCT01457820|DRUG|Allopurinol|Stat dose Allopurinol 400mg, then 300mg BD for 5 days
223700943|NCT01457820|DRUG|Placebo|Matched placebo, stat dose, then 5 days of matched placebo BD.
223700944|NCT00986830|DEVICE|FinESS Sinus Treatment|
223700945|NCT02702804|OTHER|High Intensity Interval Training|High Intensity Interval Training
223700946|NCT04354142|DEVICE|iSpy|iSpy is a novel healthcare application that hopes to address an important clinical need by facilitating carbohydrate counting using pictures or voice recognition. Proprietary algorithms adjust for portion size and identify hidden carbohydrates (such as in ketchup or other condiments) and quantify the amount of carbohydrates in a meal.
223700947|NCT00185835|DRUG|ZD-1839|
223700948|NCT00185835|DRUG|Cisplatin|
223700949|NCT02025166|DRUG|Paracetamol|"Pain treatment with aniline analgesics (paracetamol) at the time of the procedure"
223700950|NCT02025166|DRUG|lornoxicam|"Pain treatment with NSAID (lornoxicam) at the time of the procedure"
223700951|NCT02760797|DRUG|Emactuzumab|Emactuzumab will be administered IV every 3 weeks (every cycle) during Part I and every 3 or 6 weeks (every cycle or every other cycle) during Part II.
223700952|NCT02760797|DRUG|RO7009789|RO7009789 will be administered IV every 3 weeks (every cycle).
223700953|NCT05303363|DEVICE|VV-ECMO|VV-ECMO is indicated in case of severe respiratory failure refractory to other therapies. Indications for VV-ECMO include severe pneumonia, acute respiratory distress syndrome (ARDS) (a.o. due to COVID-19) or near-drowning. ECMO is considered a 'last resort' therapy, in which other maneuvers - such as prone positioning and neuromuscular blockage - have shown to be insufficient. Patients are generally receiving invasive mechanical ventilation and are almost always unconscious, since due to the severe respiratory failure, high doses of sedatives and neuromuscular blockage are often applied to prevent further ventilator-induced damage. After the decision for VV-ECMO is made, the patient is directly cannulated in the ICU or OR following standard protocols.
223700954|NCT05487352|OTHER|hyperglycemia exposure in the first trimester|The exposure means the hyperglycemia identified by the 75g oral glucose tolerance test before the 14 weeks of gestation
223700955|NCT02583282|OTHER|Doxycycline|500 mg of doxycycline will be dissolved in 50 ml of normal saline. The combination will then be instilled through the chest tube in the pleural cavity and the chest tube drain will be clamped for 4 hours.
223700956|NCT02583282|OTHER|Iodopovidine|20 ml of 10% betadine (Microshield, Johnson and Johnson, Solan, India) will be dissolved in 80 mL of normal saline. The combination will then be instilled through the chest tube in the pleural cavity and the chest tube drain will be clamped for 4 hours.
223700957|NCT01039870|PROCEDURE|paravertebral block|postoperative pain is controlled with local analgesics delivered via PVB
223700958|NCT01039870|PROCEDURE|thoracic epidural analgesia|postoperative pain is controlled with local analgesics and fentanyl delivered via thoracic epidural catheter
223700959|NCT04928443|OTHER|Scar dressing group|Patients treated with scar dressing for surgical scar care are invited to participate this study and allocated in scar dressing group despite the length of caring period.
223700960|NCT04928443|OTHER|Regular care group|Patients receiving regular scar care are retrospectively identified with matching factors, such as gender, age, length of surgical wound and surgical procedure.
223700961|NCT03969732|DRUG|1. amyloid PET；2. T807 PET|"1. Dynamic PET acquisition for 60 minutes will be acquired after injection of 10 mCi 11C-PiB (39 frames: 8 x 15 seconds, 4 x 60 seconds, 27 x120 seconds).~2. Dynamic PET imaging 3D acquisition will be acquired 80 minutes after injection of 10 mCi 18F-T807 (4 x 300 seconds)"
223700962|NCT03870100|DRUG|SHR-1222|Pharmaceutical form: water injection Route of administration: subcutaneous
223700963|NCT03870100|DRUG|Placebo|Pharmaceutical form: water injection Route of administration: subcutaneous
223700964|NCT05285072|RADIATION|PET-CT scan|PET-CT scan using 68Ga-DFO
223700965|NCT05332730|DRUG|BAT2506 injection|50 mg, subcutaneous administration
223700966|NCT05332730|DRUG|Simponi® (EU commercially available product)|50 mg, subcutaneous administration
223700967|NCT05332730|DRUG|Simponi® (US commercially available product)|50 mg, subcutaneous administration
223700968|NCT00763711|DEVICE|Needle Guided Periurethral Injection|Bulking Agent injection using a needle guide
223700969|NCT06277557|OTHER|Virtual Reality|Virtual reality learning platform as intervention in this study
223700970|NCT02283619|OTHER|None - no intervention, observational study|No intervention, observational study
223700971|NCT05815641|DIETARY_SUPPLEMENT|food (breakfast)|The breakfast composition is 56 kcal% carbohydrates, 12 kcal% protein and 34 kcal% lipids and comprises yogurt, cereals and almonds
223700972|NCT00303901|PROCEDURE|cryosurgery|
223700973|NCT00303901|PROCEDURE|positron emission tomography|
223700974|NCT06246175|DRUG|HRS9531|Receive a single dose of HRS9531 injection
223700975|NCT05194657|DEVICE|enhanced depth of focus IOL|Acrysof IQ Vivity, enhanced depth of focus IOL
223700976|NCT05194657|DEVICE|monofocal IOL|Acrysof IQ, monofocal IOL
223700977|NCT00189995|DRUG|clozapine|
223700978|NCT00189995|DRUG|haloperidol|
223700979|NCT03359772|OTHER|Kinesthetic Ability Trainer|Kinesthetic Ability Trainer
223700980|NCT01332331|DRUG|Ambrisentan - low dose|body weight 20 to 35 kg - 2.5 mg; body weight 35 kg and over - 5.0 mg
223700981|NCT01332331|DRUG|Ambrisentan - high dose|body weight 20 to 35 kg - 5.0 mg; body weight 35 to 50 kg - 7.5 mg; body weight 50 kg and over - 10.0 mg
223700982|NCT06192277|OTHER|Screening|Patients are screened to confirm they are low risk for a penicillin allergy
223700983|NCT06192277|DRUG|Low dose Penicillin|Low risk participants are given a low-dose of oral penicillin followed by 60 minutes of observation
223782566|NCT06291272|DIETARY_SUPPLEMENT|Maltodextrin|15 maltodextrin
223700984|NCT06192277|DRUG|Standard dose Penicillin|Participants who have taken the low dose of oral penicillin and have had no reaction are provided a second higher dose of penicillin (250mg) and observed for 60 minutes.
223700985|NCT06192277|OTHER|Remove allergy label|Participants who have no reaction after 28 days have their penicillin allergy label removed from their electronic medical record and hospital record.
223700986|NCT06358404|BEHAVIORAL|PeersCOG|. The intervention will consist of 8 weekly video chats focused on emotional, appraisal, and informational support delivered by community-based older adult peer coaches to adults 60 years of age and older with subthreshold depression and SCD.
223700987|NCT00538291|BIOLOGICAL|cetuximab|
223700988|NCT00538291|DRUG|capecitabine|
223700989|NCT00538291|GENETIC|gene expression analysis|
223700990|NCT00538291|GENETIC|microarray analysis|
223700991|NCT00538291|GENETIC|polymorphism analysis|
223700992|NCT00538291|GENETIC|reverse transcriptase-polymerase chain reaction|
223700993|NCT00538291|OTHER|immunohistochemistry staining method|
223700994|NCT00591344|BEHAVIORAL|Progressive resistance training|Exercise twice a week for 2 years doing either progressive resistance training. The The PRE program consisted of 11 strengthening exercises: chest press, latissimus pull downs, reverse flys, double leg press, hip extension, shoulder press, biceps curl, rotary calf (ankle plantar flexion), triceps extension, seated quadriceps extension and back extension.
223700995|NCT00591344|BEHAVIORAL|Modified Fitness Counts|The modified Fitness Counts program was taken from Chapters 2 and 3 of the Parkinson's disease: Fitness Counts booklet and focused on non-progressive stretching, strengthening and balance exercises.
223700996|NCT02464371|OTHER|kinetic of microRNAs|blood samples will be drawn to measure microRNAs
223700997|NCT01342276|BEHAVIORAL|vHFC|Common practice for managing HF patients attending urban-based, specialized HF clinics is to have them weigh themselves daily and report any dramatic fluctuations and/or increasing symptoms to their clinic. We have transformed this model to the vHFC website such that each day, participants will logon to the vHFC and enter their weight and answer six questions regarding their current symptoms. An alert will be generated if the participant enters data outside of the desired parameters, does not enter their data for three consecutive days, or enters a comment in the text box for the vHFC nurse to view. If an alert is generated, following participant data entry, the participant is presented with a pop up window to inform them that the vHFC nurse will contact them within 24 hours. The nurse will contact the participant by telephone to discuss the alert generated and provide counselling.
223700998|NCT04671524|OTHER|Exercise protocol|a combination of stretching, range of motion, and strengthening exercise.
223700999|NCT02460107|BIOLOGICAL|Botulinum toxin type A|
223701000|NCT02460107|OTHER|Normal saline|Placebo
223701001|NCT03308032|BEHAVIORAL|Intervention|SDL intervention employs a comprehensive engagement design that includes seven innovative strategies: 1) customization of content of the training curriculum to fit individual learner's needs; 2) tailoring the length of trainings by using short video clips to allow caregivers flexibility in completing the curriculum; 3) using an instructional format (SCHOLAR) designed to maximize active learning during each training lesson; 4) progress tracking to help the learner stay focused and motivated; 5) a recommendation algorithm that facilitates the learner's transition from one training topic to the next; 6) behavioral economics-based messages, to re-engage the learner if he/she stops participating
223701002|NCT03308032|BEHAVIORAL|Control|Participants in the control group will be invited to a comparable online training course consisting of all of our training video clips, without the interactive engagement design features. These represent standard video training based on evidence-based content.
223701003|NCT02640716|BEHAVIORAL|multi-domain internet-based adaptive training program|The cognitive training will be a multi-domain adaptive training program, including processing speed, attention, long-term memory, working memory, flexibility, calculation, and problem solving. Specific training paradigms include a time perception task, visual search task, attention blink, delayed mapping task, attention span task, Go-No go task, Stroop task, task switching, and name-face match task, among others. To maintain task difficulty, the tasks will be grouped based on the task difficulty in each domain. Furthermore, each task will have various difficulty levels.
223701004|NCT02640716|BEHAVIORAL|placebo program|For the control group, tasks for processing speed and attention are included. Importantly, a fixed, primary difficulty level for all participants in the control group is set.
223701005|NCT03420417|DEVICE|Esophageal pressure measurement|Use of a nasogastric tube equipped with esophageal balloon to assess respiratory mechanics
223701006|NCT01641874|PROCEDURE|Exercise|Directional specific exercise
223701007|NCT01641874|PROCEDURE|Evidence based exercise|Quadriceps exercises and advice on aerobic exercises. Exercises are based on current evidence for the best exercises for osteoarthritic knee
223701008|NCT03181815|DRUG|Cladribine|5mg/㎡ d1-5
223701009|NCT03181815|DRUG|G-CSF|300ug d0-9
223701010|NCT03181815|DRUG|Aclarubicin|10mg d3-6
223701011|NCT03181815|DRUG|Cytarabine|10mg/㎡ q12h SC d3-9
223701012|NCT03959072|DEVICE|Robotic CTO PCI|Randomized to robotic CTO PCI.
223701013|NCT03959072|PROCEDURE|Conventional (Manual) CTO PCI|Randomized to manual CTO PCI.
223701014|NCT01464996|PROCEDURE|Adhesive: OptiBond XTR; Composite: Herculite Ultra|The intervention in Arm 1 (Adhesive: OptiBond XTR; Composite: Herculite Ultra) is a 2-step, self-etching adhesive.
223701015|NCT01464996|PROCEDURE|Adhesive: OptiBond FL; Composite: Herculite Ultra|Arm 2 (Adhesive: OptiBond FL; Composite: Herculite Ultra) is a 3-step, etch-and-rinse adhesive.
223701016|NCT04436211|PROCEDURE|Total Knee Arthroplasty|The common procedure of Total Knee Arthroplasty is investigated in order to compare the techniques of implantation (kinematic vs mechanical alignment)
223701017|NCT00751218|DRUG|desloratadine|desloratadine, 5mg oral tablets, once daily for 28 days
223701018|NCT00751218|DRUG|placebo|placebo, once daily for 28 days
223701019|NCT00751218|DRUG|cetirizine|cetirizine, 10 mg capsules once daily for 28 days
223701020|NCT01318642|DRUG|Gemcitabine|Gemcitabine on days 1, 8, and 15, followed by placebo on days 1 and 15 of every 28 day cycle.
223701021|NCT01318642|DRUG|AMG 479|Gemcitabine on days 1, 8, and 15, followed by AMG 479 20 mg/kg on days 1 and 15 of every 28 day cycle.
223701022|NCT01318642|DRUG|Placebo|Gemcitabine on Days 1, 8, and 15 followed by Placebo 20 mg/kg on days 1 and 15 of every 28 day cycle
223701023|NCT06059573|PROCEDURE|dental implant robot|Implant placement will be navigated by a dental implant robot based on a digital plan.
223701024|NCT06059573|PROCEDURE|Freehand surgery|Implant will be placed under freehand surgery.
223701025|NCT05007210|OTHER|Prenatal massage therapy|Pregnant women in the intervention group had a whole body prenatal massage therapy every week between 30th and 34th gestational weeks (once a week, 5-weeks in total and 60-minutes each).Session content for the prenatal massage therapy group was created by the researcher who was 640-hours trained massaging midwife.It included 12 different massage techniques (Osborne 2015, Osborne 2021).Also, the session, which included deep tissue and Sweden massage methods, had been applied.Each session began with the pregnant woman in a side-lying position with standart special pillows (30-minutes for left, 30-minutes for right).EFM, BPP, vital signs, FHR evaluation were carried out for all participants per visiting the hospital for the study.BPP before and after prenatal massage therapy was evaluated by an obstetrician.A phone number was set for the study, and this phone number was used by the massaging midwife.The service has been provided for pregnant women to reach her whenever they want.
223701026|NCT03749473|BEHAVIORAL|Choice + Immediate|Participants in the choice + immediate goal arm will choose a step goal and must attempt to achieve this new step goal immediately at the start of the study.
223701027|NCT03749473|BEHAVIORAL|Choice + Gradual|Participants in the choice + gradual goal arm will choose a step goal and will gradually work towards the chosen step goal over the first 8-weeks of the study.
223701028|NCT03749473|BEHAVIORAL|Assigned + Immediate|Participants in the assigned + immediate goal arm will be assigned a step goal and must attempt to achieve this new step goal immediately at the start of the study.
223701029|NCT03749473|BEHAVIORAL|Assigned + Gradual|Participants in the assigned + gradual goal arm will be assigned a step goal and will gradually work towards the chosen step goal over the first 8-weeks of the study.
223701030|NCT03749473|BEHAVIORAL|Daily performance feedback|Participants will receive daily performance feedback on their daily step count.
223701031|NCT03749473|BEHAVIORAL|Gamification|All participants in the intervention arms will be entered into a gamification platform that has points and levels designed to incorporate insights from behavioral economics.
223701032|NCT05887414|OTHER|Baseline|Measure Ottawa Decisional Regret at baseline when patients receive a diagnosis of appendicitis.
223701033|NCT05887414|OTHER|30 Day Follow Up|Measure Ottawa Decisional Regret after 30 days.
223701034|NCT02320617|PROCEDURE|Diffusion Magnetic Resonance Imaging|Diffusion weighted imaging (DWI) is a form of magnetic resonance imaging based upon measuring the random Brownian motion of water molecules within a voxel of tissue. The relationship between histology and diffusion is complex, however generally densely cellular tissues or those with cellular swelling exhibit lower diffusion coefficients, and thus diffusion is particularly useful in tumour characterisation
223701035|NCT05000697|DRUG|Oxaliplatin|Patients will receive 5FU + Oxaliplatin during the consolidation chemotherapy after long course chemoradiation
223701036|NCT05000697|DRUG|5FU|Patients will receive 5FU during the consolidation chemotherapy after long course chemoradiation
223701037|NCT05735197|DRUG|Dapagliflozin 10mg Tab|Dapagliflozin which is (SGLT2 inhibitor) will be used as add on medication.
223701038|NCT05735197|DRUG|Placebo|Placebo which has the same shape as Dapagliflozin but without active ingredient will be used as add on medication for control group.
223701039|NCT06416033|PROCEDURE|Serum Irisin|Measurement of plasma irisin level in leprosy patients.
223701040|NCT02556736|DRUG|RST-001|RST-001 is a gene therapeutic delivered by intravitreal injection
223701041|NCT04434066|PROCEDURE|Total Laparoscopic Hysterectomy|Participants will be randomized into either abdominal or vaginal morcellation at time of total laparoscopic hysterectomy
223701042|NCT00886912|OTHER|hypoxia|training in simulated altitude in a hypoxic chamber (normobaric hypoxia)
223701043|NCT00886912|OTHER|normoxia|training under normoxic conditions
223701044|NCT04687995|PROCEDURE|Endoscopic myringoplasty|Endoscopic myringoplasty by using two different grafts one each time
223701045|NCT04728022|BEHAVIORAL|Education program|Mentored high school summer research program
223701046|NCT05898685|BEHAVIORAL|Intermittent hypoxia|The intermittent hypoxia protocol will consist of eight 4-minute hypoxic cycles (arterial oxygen saturation of 80%) interspersed with normoxic cycles to resaturation.
223701047|NCT05898685|BEHAVIORAL|Intermittent normoxia|The intermittent normoxia protocol will consist of eight 4-minute normoxic cycles (compressed air) interspersed with 1-minute normoxic cycles (room air)
223701048|NCT05088720|DRUG|misoprostol 800 µg|received misoprostol 800 µg (Misotac 200 µg tablets, SIGMA pharmaceutical) once dose sublingually
223701049|NCT05088720|DRUG|misoprostol 400 µg|received misoprostol 400 µg (Misotac 200 µg tablets, SIGMA pharmaceutical) once dose sublingually
223701050|NCT05082831|BIOLOGICAL|microfracture surgery + HST003|This is an Intervention Model where all patients who are identified/confirmed candidates for microfracture surgery will be enrolled to receive the microfracture surgery (standard of care). Ten (10) patients will be randomized to receive the study intervention (HST003). HST003 will be injected into the microfracture defects (interstices) and fill the remainder of the defect to the cartilage margin following surgery. The primary purpose of the study is to compare the two groups: microfracture surgery + HST003 as compared to the microfracture surgery only group.
223701051|NCT04497207|OTHER|Scheimpflug Camera Corneal Tomography|Pentacam Sheimpflug system(Pentacam HR, Oculus Optikgeräte GmbH, software V.1.15r4 n7) is used for imaging of the anterir and posterior surfaces of the cornea to obtain corneal tomographic maps.
223701052|NCT04886739|DRUG|CGB-400|Topical gel
223701053|NCT04886739|DRUG|Vehicle Gel|Topical gel
223701054|NCT03225274|OTHER|Breathing Exercises as Therapeutic Play|"On day 1, pre- intervention assessment of respiratory status was done before administration of breathing exercises as therapeutic play and after 5 minutes of administration of Nebulization therapy, breathing exercises was administered among children for 15 minutes once in a day and then after 5 minutes 1st post-intervention assessment was done on same day.~On 2nd day again after 5 minutes of administration of Nebulization therapy, breathing exercises was administered among children for 15 minutes once in a day and after 5 minutes again post-intervention assessment was done on same day.~On 3rd day again after 5 minutes of administration of Nebulization therapy, breathing exercises was administered among children for 15 minutes once in a day and after 5 minutes again post-intervention assessment was done on same day."
223701055|NCT06402084|DIAGNOSTIC_TEST|abdominal ultrasound|abdominal ultrasound and lipid profile will be done
223701056|NCT05252065|OTHER|Cardiac biomarkers, Echocardiography,Cardiac magnetic resonance imaging|Troponin I, troponin T, hypersensitive troponin, brain natriuretic peptide and NT-proBNP are detected for cardiac biomarkers;echocardiography and cardiac magnetic resonance imaging are used to measure the functions of heart and vessels.
223701057|NCT01672736|DRUG|ASP7487, Velcade, Dexamethasone|ASP7487- Oral (75, 100, 150 mg)BID Bortezomib- 1.3 mg/m2 IV on days 1, 4, 8, 15 of each 21 day cycle up to cycle 8 and days 1, 5, 15, 22 of each 35 day cycle beyond cycle 9 Dexamethasone- 20 mg on the day of Bortezomib administration
223701058|NCT02634281|DRUG|Varenicline|Subjects in Group A will receive varenicline for six weeks while those in group B will receive placebo for 5 weeks and varenicline for 1 week. During this phase, subjects in both groups will be asked to reduce cigarette smoking by 50 percent. At week 6 all participants will be instructed to stop smoking before receiving 12 weeks of varenicline treatment
223701059|NCT02634281|DRUG|placebo|Subjects in Group A will receive varenicline for six weeks while those in group B will receive placebo for 5 weeks and varenicline for 1 week. During this phase, subjects in both groups will be asked to reduce cigarette smoking by 50 percent. At week 6 all participants will be instructed to stop smoking before receiving 12 weeks of varenicline treatment
223701060|NCT04112524|DEVICE|App|"* Alleye® Test Alleye® Test is a mobile medical software application indicated for the detection and characterization of metamorphopsia. For the mean Alleye score (±standard deviation (SD) deviations of dots from an ideal line are calculated for each eye.~* AMD-A Metamorphopsia Detector® Is based on the Amsler grid. The software uses the concept of a negative image: a distorted image can be straightened by moving the mouse. Degree and dimension of distorted lines or scotoma are transformed into indices."
223701061|NCT06341764|DRUG|Durvalumab 1120 mg|Durvalumab 1120 mg day 1 i.v
223701062|NCT06341764|DRUG|Durvalumab 1500 mg|Durvalumab i.v. at 1500 mg once every 4 weeks
223701063|NCT06341764|DRUG|Tremelimumab i.v. at 300 mg|Single dose
223701064|NCT06341764|COMBINATION_PRODUCT|Cisplatin (CDDP) 25 mg/mq i.v|Four cycles
223701065|NCT06341764|COMBINATION_PRODUCT|Gemcitabine (GEM) 1000 mg/mq i.v.|Days 1 and 8 every 21 days
223782567|NCT02682264|DRUG|CB-03-01 cream, 1%|Cortexolone 17α-propionate (USAN/INN: clascoterone) is a steroidal antiandrogen that is being developed as a 1% cream for the topical treatment of acne vulgaris.
223782568|NCT01131312|DEVICE|Thinprep|Pap test
223701066|NCT00361582|DRUG|CG5503 IR; tapentadol|
223701067|NCT05399303|PROCEDURE|obturation|obturation using different types of sealers
223701068|NCT00698984|DIETARY_SUPPLEMENT|BONISTEIN(R) bone blend|2 Capsules per day over a period of 6 months
223701069|NCT00698984|DIETARY_SUPPLEMENT|Placebo|2 capsules per day over a period of 6 months
223701070|NCT01262573|PROCEDURE|Closure of vaginal cuff|Closure of the vaginal cuff
223701071|NCT04483973|DRUG|Ebselen|Glutathione peroxidase mimetic
223701072|NCT04483973|DRUG|Placebo|Matching placebo containing excipients
223701073|NCT06476327|BEHAVIORAL|experimental 1 group|"A camera is installed on the walker used in the training, and the recorded video is mirrored in real-time to a tablet computer. Participants can view this video through smart glasses connected to the tablet computer. A glasses strap will be used to secure the glasses, ensuring there is no interference with walking.~Participants will undergo a total of 20 training sessions, five times a week for four weeks, with each session lasting 30 minutes. Participants will have a 4-minute break during the 30-minute gait training session.~Participants will be given a period to adapt to wearing the robot, and after that, the intervention will be conducted based on each participant's individual abilities and adaptation."
223782569|NCT01131312|DEVICE|Hybrid capture 2|Human Papillomavirus (HPV) Deoxyribonucleic Acid (DNA) Test
223701074|NCT06476327|BEHAVIORAL|experimental 2 group|"Participants will undergo a total of 20 training sessions, five times a week for four weeks, with each session lasting 30 minutes. Participants will have a 4-minute break during the 30-minute gait training session.~Participants will be given a period to adapt to wearing the robot, and after that, the intervention will be conducted based on each participant's individual abilities and adaptation."
223701075|NCT02810977|DEVICE|Ultrasound|Ultrasound assessment of gastric content and volume
223701076|NCT04970641|BEHAVIORAL|Three Good Things (3GT) Positive Psychology journaling activity|Evening journaling activity each day to reflect on three good things that the subject has noticed about their day's events.
223701077|NCT03339687|BEHAVIORAL|Experimental Mindset Induction|"This induction of a psychological state was extensively studied in cognitive science. Gollwitzer \& Keller (2016, p.3): The deliberative mindset is evoked by asking participants to (a) name an unresolved, important personal problem that is causing rumination but for which they have not made a decision yet and (b) reflect on whether to take action or not. Further, to enhance the depth of reflection, participants are requested to list positive and negative, short- and long-term consequences of both deciding to act and not to act; indicating the probability of the occurrence of each of these consequences is required.~The implemental mindset is evoked by asking participants to think of a personal project for which they have already made the decision to act but did not initiate any action yet. Subsequently, participants are asked to list the steps necessary for successful goal attainment and to plan out in detail when, where, and how they intend to act on each of these steps."
223701078|NCT06243484|DIETARY_SUPPLEMENT|TOTUM-070|12 weeks of TOTUM-070 supplementation with Placebo (blinded arms)
223701079|NCT06243484|DIETARY_SUPPLEMENT|PLACEBO|8 capsules per day to consume orally in two intakes
223701080|NCT04644991|OTHER|Kinesiology taping|Y-type kinesiology tape will be applied to the thoracolumbar fascia in experimental gruoup.
223701081|NCT04644991|OTHER|Six minutes walking test|Participants will be asked to walk as fast as they can for 6 minutes.
223701082|NCT04644991|OTHER|Shame Kinesiology Tape|Sham kinesiology tape will be applied to the thoracolumbar fascia in sham gruoup.
223701083|NCT00005878|DRUG|celecoxib|
223701084|NCT02002273|PROCEDURE|Switching level of suction|
223701085|NCT05192473|DEVICE|Pulse Intravascular Lithotripsy System|Treatment with Pulse Intravascular Lithotripsy System
223782570|NCT01131312|PROCEDURE|Colposcopy|Procedure performed by a healthcare practitioner to examine the cervix, vagina, and vulva.
223701086|NCT04836312|BEHAVIORAL|Soft Commitment Device|Patients randomized to the commitment device arm will be asked to visit the Way to Health platform. There, they will identify a support person, a family or friend who they speak to frequently and who is invested in their health. They will then complete a series of questions intended to create implementation intentions. Specifically, they will pick a time for their fast to begin each 24-hour period and a time for their fast to end. They will also develop strategies to deal with hunger arising during a fast period. After this process, they will sign a contract pledging to adhere to the 16:8 time-restricted feeding dietary pattern, and acknowledging that their support person will receive a copy of the contract and weekly updates about their adherence to the regimen.
223701087|NCT05634915|DRUG|Individual ATG|Individual dose of ATG: Individual dose of ATG was Intravenous infused every day from day -5 to day -2 (total ATG dose was calculated based on population pharmacokinetic modeling). Prophylaxis against graft-versus-host disease (GVHD) was performed with cyclosporine A, mycophenolate mofetil, and low-dose methotrexate.
223701088|NCT05634915|DRUG|ATG|ATG 10mg/kg: The total ATG dose was 10mg/kg. ATG was intravenously infused every day from day -5 to day -2. Prophylaxis against graft-versus-host disease (GVHD) was performed with cyclosporine A, mycophenolate mofetil, and low-dose methotrexate.
223701089|NCT00004364|DRUG|desmopressin|
223701090|NCT00812851|DRUG|Dronabinol|
223701091|NCT03860597|DRUG|Memantine|To assess the acute effects of MEM (0 vs. 20 mg) on measures of auditory processing fidelity, auditory learning and EAIP, in AP-medicated adult SZ patients and HS.
223701092|NCT03860597|DRUG|Placebos|To assess the acute effects of MEM (0 vs. 20 mg) on measures of auditory processing fidelity, auditory learning and EAIP, in AP-medicated adult SZ patients and HS.
223701093|NCT02940080|OTHER|Dietary|
223701094|NCT03800173|DRUG|galidesivir|galidesivir IV infusion
223701095|NCT03800173|DRUG|placebo|placebo IV infusion
223701096|NCT05862597|DIAGNOSTIC_TEST|HRV and Pulse diagnosis|Palpation of the 6 pulse positions (right cun, right guan, right chi, left cun, left guan, left chi) measured by the pulse diagnostic instrument.
223701097|NCT05537896|DRUG|Eravacycline|"Eravacycline will be continued until one of the following criteria is met:~* neutrophil recovery (ANC \>500, post-nadir)~* febrile neutropenia~* breakthrough infection~* any grade 3-4 toxicity related to eravacycline use~* 21 days of therapy (maximum duration allowed per study protocol)"
223701098|NCT00936611|DRUG|LBH589|
223701099|NCT02507973|OTHER|Airway Pressure Release Ventilation|Airway pressure release ventilation (APRV) is a mode of mechanical ventilation that switches between high (PHigh) and low (PLow) continuous positive airway pressure while allowing spontaneous breathing at both phases. Alveolar recruitment and oxygenation occur during PHigh whereas ventilation occurs during brief releases to PLow.
223701100|NCT02507973|OTHER|Low Tidal Volume Ventilation|After enrollment and collection of baseline Intracranial pressure and hemodynamic status for 30 minutes the participants will undergo low tidal volume mechanical ventilation (LOTV), serving as a control mode of ventilation. LOTV is most commonly used for trauma patients with lung injury. LOTV provides oxygen in smaller amounts, without overstretching the lungs
223701101|NCT00376376|DRUG|levofloxacin at 250, 500, 750, and 1000 mg doses|
223701102|NCT00140946|DRUG|MK0476; montelukast sodium/Duration of Treatment: 16 weeks|
223701103|NCT00140946|DRUG|Comparator: placebo / Duration of Treatment: 16 weeks|
223701104|NCT04120948|DEVICE|Waterlase Express Laser System|10-minute treatment with the Waterlase Express (Biolase, Irvine CA). The dorso-posterior surface of the tongue is treated with the laser in 10 passes of 60 seconds each with 10 seconds of rest in between. Laser settings were 60μs pulse width, 4W, 40Hz, 10% air and 5% water irrigation. An MC12 sapphire laser tip (Biolase, Irvine CA) is held 3mm away from the tongue in a constant sweeping motion during treatment with passes overlapping passes in alternate direction, side to side motion and front to back motion with laser fluence on the tongue surface calculated at 3J/cm2. The settings were non ablative and non thermal.
223701105|NCT04120948|DEVICE|Tongue scraper|mechanical scraping of the dorso-posterior surface of the tongue
223701106|NCT03714308|DRUG|Ivt. Aflibercept (Eylea, BAY86-5321)|Treatment is applied according to routine clinical practice and independent of the study setting.
223701107|NCT02519465|OTHER|10l/min|For inhalation was used diethilene penta-acetic triamine technetium (99mTc-DTPA) with radioactivity of 1 millicuries (Noble et al., 2007) and 0.9% saline solution with a total volume of 1 ml using vibrating mesh inhaler (Aerogen Ltd, Galway , Ireland) with the respiratory care system for the high flow ( Fisher \& Paykel healthcare, New Zealand) and nasal cannula (Fisher \& Paykel healthcare, New Zealand) with flow 10l/min
223701108|NCT02519465|OTHER|30l/min|For inhalation was used diethilene penta-acetic triamine technetium (99mTc-DTPA) with radioactivity of 1 millicuries (Noble et al., 2007) and 0.9% saline solution with a total volume of 1 ml using vibrating mesh inhaler (Aerogen Ltd, Galway , Ireland) with the respiratory care system for the high flow ( Fisher \& Paykel healthcare, New Zealand) and nasal cannula (Fisher \& Paykel healthcare, New Zealand) with flow 30l/min.
223701109|NCT02519465|OTHER|50l/min|For inhalation was used diethilene penta-acetic triamine technetium (99mTc-DTPA) with radioactivity of 1 millicuries (Noble et al., 2007) and 0.9% saline solution with a total volume of 1 ml using vibrating mesh inhaler (Aerogen Ltd, Galway , Ireland) with the respiratory care system for the high flow ( Fisher \& Paykel healthcare, New Zealand) and nasal cannula (Fisher \& Paykel healthcare, New Zealand) with flow 50l/min.
223701110|NCT01074372|DRUG|REGN727|4 cohorts (dose 1, 2, 3, 4)
223701111|NCT01074372|DRUG|Placebo|4 cohorts (dose 1, 2, 3, 4)
223701112|NCT05820061|DIAGNOSTIC_TEST|upper endoscopy|data will be collected from the enoscopy archive files in Department of Tropical Medicine and Gastroenterology,Sohag University Hospital
223701113|NCT02372240|DRUG|VLX1570 and dexamethasone|
223701114|NCT00036296|DRUG|talampanel|75mg per day divided into 3 doses for 22 days
223701115|NCT03773380|COMBINATION_PRODUCT|Breathe Anew Survivorship Program|The feasibility will be tested of the Breathe Anew Survivorship Program
223701116|NCT05567315|DRUG|local anaesthetic injection|Infiltration of 40 to 80 ml of a non-adrenalized 0.5% lidocaine solution into the vaginal wall at the level of the vaginal pouches, under ultrasound guidance. (within the limit of the toxic doses, i.e. 5mg/kg)
223701117|NCT05567315|DEVICE|hypnosis with Virtual reality mask|A 20-minute virtual reality hypnosis session is performed from the time the patient is placed on the surgical table until the end of the oocyte poncture
223701118|NCT01783054|PROCEDURE|Surgery|Subjects will then receive surgery at MUSC within 4-8 weeks following completion of chemotherapy
223701119|NCT01783054|GENETIC|Genetic Expression|Subjects will have genetic expression testing done on their tissue samples.
223701120|NCT01783054|DRUG|Chemotherapy|Patients will receive gemcitabine at 1000 mg/m2 and abraxane at 125 mg/m2 intravenously on days 1, 8 and 15 of a 28 day cycle for 2 cycles
223701121|NCT00002746|BIOLOGICAL|aldesleukin|
223701122|NCT06134960|BIOLOGICAL|KD-496|Autologous genetically modified anti-NKG2DL/CLDN18.2 CAR transduced T cells
223701123|NCT06279520|DEVICE|VR Driving Simulator|Evaluation of usual road driving abilities and assessment of response capabilities in accident-prone situations through a VR driving simulator
223701124|NCT06279520|OTHER|Computerized Neurocognitive Function Test|Evaluation of cognitive levels including attention and memory (the Trail Making Test, Digit Span Test, Auditory (or Visual) Continuous Performance Test , and Card Sorting)
223701125|NCT06279520|OTHER|Driver Test Station|Conducting qualified tests of a person's basic physical driving ability including steering, acceleration and braking, using Driver Test Station(Autoadapt AB, Stenkullen, Sweden)
223701126|NCT06279520|OTHER|On-road field driving Test|Researchers and driver's license supervisors ride in the driver's license test vehicle to evaluate the subject's actual driving ability. the validity of the VR simulator by comparing the results of the VR simulator with the actual vehicle driving ability.
223701127|NCT05660226|OTHER|Home blood pressure monitoring (telemonitoring)|Using a digital mobile phone based telemonitoring platform to A: monitor patients and adjust their treatment accordingly based on the remote monitoring outcomes and B: provide E-Coaching/self learning modules (lifestyle)
223701128|NCT05660226|OTHER|Standard care|Standard outpatient blood pressure management
223701129|NCT01162928|DRUG|Nutriflex Omega special + Oxepa|3-chamber-bag combined with enteral nutrition
223701130|NCT01162928|DRUG|Nutriflex Lipid special + Pulmocare|3-chamber-bag combined with enteral nutrition
223701131|NCT04064177|DEVICE|NICAS cardiac output monitor|Non-invasive continuous cardiac output monitoring device using total body bioimpedance.
223701132|NCT04597164|OTHER|Artificial liver support system|Patients will receive treatment of double plasma molecular adsorption system (DPMAS) and low volume plasma exchange (PE) for three times, and comprehensive internal medical treatment. The volume of plasma adsorption in DPMAS is 5000\~6000 millilitre. The volume of fresh frozen plasma used in PE is 1000 millilitre.
223701133|NCT03102112|OTHER|MRI examination|A noninvasive medical diagnostic technique in which the absorption and transmission of high-frequency radio waves are analysed as they irradiate the hydrogen atoms in water molecules and other tissue components placed in a strong magnetic field. This computerized analysis provides a powerful aid to the diagnosis and treatment planning of many diseases, including cancer.
223701134|NCT04357340|OTHER|Pulmonary Physiotherapy Techniques|Participants will receive pulmonary physiotherapy techniques in six session during three days (twice daily). Four distinguished interventions will be provided for the patients: 1) Chest expansion exercises (for prevention and treatment of potential atelectasis); 2) Techniques to Mobilize or loosen the pulmonary secretions (Active cycle breathing, Coughing techniques, Vibration and Postural drainage); 3) Hold breathing exercise (3 sets, 10 repetition) and; 4) Walking training (based on patient's tolerance until 6 minute).
223701135|NCT01674283|DRUG|Glucagon|
223701136|NCT01674283|DRUG|placebo|
223782571|NCT05094323|DRUG|Ultrasound-guided deep serratus anterior plane block with isobaric bupivacaine|Patients will receive ultrasound-guided deep serratus anterior plane block with isobaric bupivacaine.
223701137|NCT05285657|DIAGNOSTIC_TEST|Two-step malaria RDT detecting PfHRP2/pLDH (SD Ag Bioline Malaria Ag P.f/Pan: Standard Diagnostics, Hagal-Dong, Korea)|"The interpretation of the two-step malaria RDT will be done as follow:~* PfHRP2(+)/pLDH(+): falciparum malaria or co-infection with non-falciparum malaria;~* PfHRP2(-)/pLDH(+): non-falciparum malaria or falciparum malaria with deletion of hrp2;~* PfHRP2(-)/pLDH(-): negative results~* PfHRP2(+)/pLDH(-): inconclusive results and information on previous antimalarial treatment is needed to differentiate:~Within the past 28 days:~* If previous antimalarial treatment is reported, the malaria diagnosis is reported as negative result. Nonetheless, the antimalarial treatment decision will be based on malaria microscopy;~* If previous antimalarial treatment is not reported, the malaria diagnosis is reported as positive result.~Other PoC tests for bacterial infections The two-step malaria RDT will be supported by PoC test listed above to diagnose bacterial or viral infection in all patients."
223701138|NCT04997278|DEVICE|Coordinated Reset spinal cord stimulation|"Abnormal neuronal synchrony in terms of enhanced 4-9 Hz theta oscillations in EEG/MEG recordings appears to be an important pathophysiological finding in patients with neurogenic pain. To specifically counteract abnormal neuronal synchrony, we here set out to perform Coordinated Reset (CR)-Spinal Cord Stimulation (SCS). CR stimulation (Tass, 2003) aims at an anti-kindling, i.e. an unlearning or resetting of abnormal neuronal synchrony and abnormal synaptic connectivity, and, hence, long-lasting, sustained therapeutic effects that persist following cessation of stimulation (Tass \& Majtanik, 2006)."
223701139|NCT02228434|BEHAVIORAL|Monitoring and Tailored prescription|
223701140|NCT02228434|BEHAVIORAL|Happy 10 program|
223701141|NCT02228434|BEHAVIORAL|Specified nutrition education|
223701142|NCT02228434|BEHAVIORAL|General Health Education|
223701143|NCT02081183|DRUG|Mycophenolate mofetil (MMF)|1 g/day, PO BID for 2 weeks; 1.5 g/day PO TID for the next 2 weeks; and 2 g/day PO BID for the remainder of the Maintenance Phase.
223701144|NCT02081183|DRUG|Cyclophosphamide, Maintenance Phase|0.5-1 g/m\^2 IV pulse once every 3 months
223701145|NCT02081183|DRUG|Cyclophosphamide, Induction Phase|0.5 - 1 g/m\^2 IV pulse once per month
223701146|NCT02081183|DRUG|Prednisone|1 mg/kg PO once per day; reduced by 5 mg every 2 weeks up to 20 mg/day; followed by a reduction of 2.5 mg every 2 weeks until reaching the maintenance phase of 10 mg/day.
223701147|NCT01021306|DEVICE|Chiropractic w/Activator & Self Care|This technique uses a hand held instrument to deliver a quick, shallow thrust in a well defined manner. The instrument has two handles that are squeezed together until it clicks, resulting in a shallow, very quick thrust to the segment that is to be adjusted. The AMCT protocol is a structured method of chiropractic treatment that utilized a number of simple biomechanical tests in order to determine where to adjust. These tests are mostly well defined movements of body parts such as extending the head or laterally moving the mandible relative to the rest of the skull. This protocol includes treatment of the full spine and appendages as well as the area immediately around the jaw.
223701148|NCT01021306|DEVICE|Dental Care & Self Care|Following the dental exam, patients will have maxillary and mandibular polyvinyl siloxane impressions made. Interocclusal records will be made with a fast setting silicone using a metal tray. A commercial laboratory will then wax and heat process a clear acrylic resin splint attempting to capture the mandibular cusp tips in the occlusal plan of the splint. The splint will be adjusted to provide uniform posterior centric occlusal stops followed by evaluation for canine guidance. The splint will then be polished and home care instruction provided. Patients will be instructed to wear the splint at night and two hours per day.
223701149|NCT01021306|OTHER|Sham AMCT|This protocol will attempt to follow all of the procedures of the actual AMCT protocol except that when a thrust is given with the Activator instrument, the clinician will place the thumb of his left hand over the spot that would normally be adjusted. The tip of the instrument them will be placed very close to, but not touching the thumb. Consequently, the patient will feel the contact of the clinician's thumb on the spot that would be normally adjusted, and will hear the click of the instrument, but no thrust will be delivered to the patient.
223701150|NCT01021306|OTHER|Self-Care Only Group|Self care consists of an initial set of standard patient self performed treatments which will include jaw relaxation exercises, reduction of parafunction, thermal packs, low dose NSAIDs, passive opening stretches and suggestions for stress reduction.
223701151|NCT03012724|DEVICE|H7-Coil|Deep transcranial magnetic stimulation for the treatment of major dispersion disorder with the H7-Coil
223701152|NCT03012724|DEVICE|H1-Coil|Deep transcranial magnetic stimulation for the treatment of major depression disorder with the FDA cleared H1-Coil
223701153|NCT02263209|DEVICE|Bioguard Group|Patients randomised to receive the study investigative device will receive a Bioguard implant
223701154|NCT02263209|DEVICE|Control Group|Patients randomised to receive the control device will receive a Exceed Taperlock implant
223701155|NCT03203070|DRUG|Metamizol iv|Postoperative analgesia iv with Metamizol 2g/8h will be administered.
223701156|NCT03203070|PROCEDURE|TAP block|Intraoperative laparoscopic-guided TAP block will be performed with 30ml Bupivacaine 0.5%
223701157|NCT05189379|OTHER|Non-Alcoholic Odour|A chemical used in fragrances and flavouring with a smell close to a nutty, buttery structure. Used as a 1:100 deionised water dilution.
223701158|NCT05189379|OTHER|Alcoholic Odour|Alcoholic beverage beer / Alcoholic beverage red wine / Alcoholic beverage brandy / The type of the Alcoholic Odour intervention will be presented in a participant-preference basis.
223701159|NCT05189379|OTHER|Non-Alcoholic Images|Images of non-alcoholic items, namely; broom, duster, clothing iron, lightbulb, mat, mulch, penlight, rack, rock, kitchen scissors, trough, vent are presented in parallel with the non-alcoholic odour
223701160|NCT05189379|OTHER|Alcoholic Images|Images of alcoholic items, namely, beer, wine, schnapps are presented in parallel with the alcoholic odour
223701161|NCT04958668|OTHER|Post-operative intensive care using volatile sedation|Patients admitted after valve surgery are receiving intensive care using volatile sedative per anaesthetic conserving device. The subject of the study is medical and nursing time management..
223701162|NCT04160962|PROCEDURE|lappg|Laparoscopic gastrectomy for pylorus preservation
223701163|NCT01090284|DEVICE|Inguinal hernioplasty|A conventional Prosthetic Inguinal Hernioplasty (Trabucco's Technique) will be performed by using polypropylene mesh.
223701164|NCT00910273|DRUG|etanercept|etanercept 50 mg/week
223701165|NCT00754988|DRUG|Metformin|As prescribed
223701166|NCT00754988|DRUG|Placebo (matching sitagliptin)|Once daily oral administration of placebo (matching sitagliptin).
223701167|NCT00754988|DRUG|Placebo (matching taspoglutide)|Once weekly subcutaneous (sc) injection of placebo (matching taspoglutide).
223701168|NCT00754988|DRUG|Sitagliptin|Once daily oral administration of 100 mg of sitagliptin.
223701169|NCT00754988|DRUG|Taspoglutide|Once weekly subcutaneous (sc) injection of 10 mg or 20 mg of taspoglutide.
223701170|NCT01596387|DRUG|Propofol|General anesthesia will be induced administering propofol by effect site TCI system using our previously derived model, the target plasma concentration initially will be set at 4 mcg/ml. After loss of consciousness, rocuronium 0.6mg/kg, and remifentanil 0.2mcg/kg/min will be given to facilitate tracheal intubation. After intubation propofol target will be decreased to 3 for 10 minutes and then adapted to the needs of each patient to maintain stable BIS values between 40 and 50. At the end of surgery propofol infusion will be stopped, and patients will be transferred to the recovery unit extubated. Samples of 2.5 ml of arterial blood will be taken at 2, 5 and 10 min after every new target is set. Thereafter samples will be taken at 2, 5, 10, 15, 30, 60, 120 min after stopping drug infusion. Blood samples will be immediately centrifuged and then stored until analysis.
223701171|NCT04473846|DRUG|PK general anesthesia|Patients will be anesthetized using Fentanyl (2 mcg/kg) and Propofol (1-2 mg/kg).
223701172|NCT04473846|DRUG|PFK combination|Each patient received an initial dose of 0.05 ml/kg from the solution, then after waiting for 60 seconds, another 0.05 ml/kg were given. Maintenance was given as boluses of 0.025 ml/kg every three to five minutes.
223782572|NCT05094323|DRUG|Local wound infiltration with isobaric bupivacaine|Patients will receive local wound infiltration with isobaric bupivacaine.
223782573|NCT05094323|DRUG|Ultrasound-guided thoracic paravertebral block with isobaric bupivacaine|Patients will receive ultrasound-guided thoracic paravertebral block with isobaric bupivacaine.
223782574|NCT01691300|OTHER|ACT PET/CT|Old tracer but new indication
223782575|NCT02934373|DEVICE|A New Sound Processor|
223782576|NCT00059813|BIOLOGICAL|recombinant interferon alfa|Given SC
223782577|NCT00059813|BIOLOGICAL|oblimersen sodium|Given IV
223782578|NCT00059813|OTHER|pharmacological study|Correlative studies
223701173|NCT01858571|DRUG|Low dose chemotherapy|"Metronomic chemotherapy schedule : Alternating cycles of Cycle A and B (Each cycle includes 3 weeks of drug administration) with each drug rounded off to the nearest tablet/capsule size.~Cycle A~* Daily oral Thalidomide (at 3mg/kg)~* Daily oral Celecoxib (100 mg BID for patients \< 20 kg, 200 mg BID for patients 20-50 kg, and 400 mg BID for patients \> 50 kg)~* Daily oral Etoposide (50 mg/m2/d)~Cycle B~* Daily oral Thalidomide (at 3mg/kg)~* Daily oral Celecoxib (100 mg BID for patients \< 20 kg, 200 mg BID for patients 20-50 kg, and 400 mg BID for patients \> 50 kg)~* Daily oral Cyclophosphamide (2.5 mg/kg/d to a maximum of 100 mg/d) every 21 days"
223701174|NCT05965778|DEVICE|T2769|T2769: sodium hyaluronate, Trehalose, Naaga in a 12.5 mL ABAK® multi-dose bottle.
223701175|NCT05965778|DEVICE|Vismed® Multi|Hyaluronic acid
223701176|NCT06098274|BEHAVIORAL|Motivational interviewing program based on transtheoretical model|It will be determined at which stage of change of the transtheoretic model the participants in the intervention group are. A varying number of motivational interviews will be held depending on the stage of change and a maximum of 6 motivational interviews. Those in the preparatory phase will be trained on smartphone addiction. Following completion of the motivational interviewing and training content, the study scales will be re-administered and the effectiveness of the motivational interviewing and training content will be evaluated by comparison with the baseline data.
223701177|NCT05592951|DIETARY_SUPPLEMENT|Crystal Light (once serving)|Citric Acid, Potassium Citrate, Sodium Citrate, Aspartame (Phenylketonurics: Contains Phenylalanine), Magnesium Oxide, Maltodextrin, Contains Less than 2% of Natural Flavor, Acesulfame Potassium, Soy Lecithin, Yellow 5, Artificial Color.
223701178|NCT05592951|DIETARY_SUPPLEMENT|Liquid IV with amino acids (one serving)|Allulose, L-Alanine, L-Glutamine, Citric Acid, Sodium chloride, Lemon Lime Flavorings, Potassium Citrate, Trisodium Citrate Dihydrate, Dipotassium Phosphate, Syloid Silicon Dioxide, Stevia, Vitamin C, Vitamin B3, Calcium Pantothenate B5 (Vitamin B5), Vitamin B6, Vitamin B12. Liquid IV packets contain: sodium and potassium.
223701179|NCT05592951|DIETARY_SUPPLEMENT|Liquid IV with amino acids (two servings)|Allulose, L-Alanine, L-Glutamine, Citric Acid, Sodium chloride, Lemon Lime Flavorings, Potassium Citrate, Trisodium Citrate Dihydrate, Dipotassium Phosphate, Syloid Silicon Dioxide, Stevia, Vitamin C, Vitamin B3, Calcium Pantothenate B5 (Vitamin B5), Vitamin B6, Vitamin B12. Liquid IV packets contain: sodium and potassium.
223701180|NCT05592951|DIETARY_SUPPLEMENT|Liquid IV with amino acids (three servings)|Allulose, L-Alanine, L-Glutamine, Citric Acid, Sodium chloride, Lemon Lime Flavorings, Potassium Citrate, Trisodium Citrate Dihydrate, Dipotassium Phosphate, Syloid Silicon Dioxide, Stevia, Vitamin C, Vitamin B3, Calcium Pantothenate B5 (Vitamin B5), Vitamin B6, Vitamin B12. Liquid IV packets contain: sodium and potassium.
223701181|NCT01923987|RADIATION|Short Course Radiotherapy|Radiotherapy to tumor and draining lymph node with 25 Gy in 5 fractions within 5 working days
223701182|NCT01923987|DRUG|Chemotherapy|"* Oxaliplatin 85 mg/m2 IV over 2 hrs on Day 1~* Irinotecan 180 mg/m2 IV over 30-90 mins on Day 1~* Leucovorin 400 mg/m2 IV over 2 hrs on Day 1 and 2~* 5-fluorouracil bolus 400 mg/m2 IV push on Day 1 and 2 (or 5-fluorouracil infusion 600 mg/m2 IV continuous infusion over 22 hrs).~* Bevacizumab 5 mg/kg IV over 90 mins on Day 1~* Cetuximab (only for patients with K-ras wild type and positive EGFR mutation) 400 mg/m2 IV over 2 hrs on Day 1, and 250 mg/m2 IV over 1 hr on Day 8, 15, 22, 29, and 36.~* FOLFOX or FOLFIRI (+-Bevacizumab ) repeats every 14 days for up to 3 courses. Cetuximab repeats every week for up to 6 courses~* Postoperative FOLFOX or FOLFIRI (+-Bevacizumab or Cetuximab) for up to 9 cycles (total 12 cycles)"
223701183|NCT01923987|PROCEDURE|Delayed Surgery|If primary tumor and metastases is resectable after FOLFOX or FOLFIRI (+-Bevacizumab or Cetuximab) of 3 cycles, patients have surgical resection (and/or radiofrequency ablation to metastases).
223701184|NCT04953351|PROCEDURE|Cognitive registration targeted biopsy and TRUS-system biopsy|Cognitive registration is a visual guidance technique in which the surgeon samples a visually estimated location on ultrasound that corresponds to the MRI suspicious regions location. TRUS-system biopsy includes 12 biopsy cores.
223701185|NCT04953351|PROCEDURE|MRI-ultrasound fusion targeted biopsy and TRUS-system biopsy|MRI-ultrasound fusion targeted biopsy is conducted with an mpMRI-TRUS biopsy system that provides realtime fusion of TRUS images and MRI images to guide the biopsy needles. TRUS-system biopsy includes 12 biopsy cores.
223701186|NCT01987635|DEVICE|MEMO 3D ring|The experimental MEMO 3D ring is placed.
223701187|NCT01987635|DEVICE|Standard use of rigid ring.|The rigid ring is placed, which is standard procedure.
223701188|NCT01987635|PROCEDURE|3D Echocardiography|
223701189|NCT03989765|OTHER|Programme to reduce involuntary treatment episodes|See description of trial arms
223701190|NCT00195546|DRUG|DVS-233|
223701191|NCT01435902|DRUG|Fluticasone Furoate/Vilanterol Inhalation Powder|Fluticasone furoate/Vilanterol inhalation powder inhaled orally once daily for 4 weeks
223701192|NCT01435902|DRUG|Fluticasone Propionate Inhalation Powder|Fluticasone propionate inhalation powder inhaled orally twice daily for 4 weeks
223701193|NCT04325178|OTHER|Protein, calorie and macronutrient controlled diet, derived from either omnivorous or non-animal sources, alongside unilateral resistance exercise, over a three-day period.|Participants received a control diet either derived from omnivorous or non-animal food sources, providing 1.8g.kg.day of protein, for a three-day period. Calories were calculated and set to place participants in a state of energy balance. Participants completed three bouts of unilateral resistance exercise, 5 sets of 30 maximal concentric knee extension contractions, on each morning that they received the control diet. During this three-day period participants also consumed a deuterium oxide tracer allowing for the measurement of muscle protein synthesis, in rested and exercised tissue, with incremental biopsies.
223701194|NCT00785018|DRUG|C1-esterase inhibitor|C1-esterase inhibitor 100 U/kg infusion over 30 minutes.
223701195|NCT00785018|DRUG|Endotoxin administration|2 ng/kg E. coli reference endotoxin 11:H 10:K negative intravenously
223701196|NCT02406183|RADIATION|Stereotactic body radiotherapy (SBRT)|The SBRT dose will be escalated in 3 steps as described above and will be given on d39, d41 and d43
223701197|NCT02406183|DRUG|Ipilimumab|Ipilimumab 3mg/kg will be given IV on d1, d22, d43 and d64
223701198|NCT06285331|DEVICE|Automatic Bed|The automatic bed is controlled by a screen and allows clinicians to perform passive leg raising on patients without touching them physically.
223701199|NCT06285331|DEVICE|Manual|The clinicians will perform passive leg raising on patients by touching their legs physically.
223701200|NCT03841448|DRUG|Placebo|Normal saline (0.9% NaCl) matching volume of cemdisiran doses were administered SC.
223701201|NCT03841448|DRUG|Cemdisiran|Cemdisiran was administered by SC injection.
223701202|NCT04708106|OTHER|RELX ENDS Tobacco Flavor|Ad libitum use of the RELX ENDS Tobacco Flavor product
223701203|NCT04708106|OTHER|RELX ENDS Menthol Flavor|Ad libitum use of the RELX ENDS Menthol product
223701204|NCT04708106|OTHER|RELX ENDS Tobacco and Menthol Flavors|Ad libitum use of the RELX ENDS Tobacco and Menthol Flavor products
223701205|NCT02152800|DRUG|valacyclovir hydrocholoride|
223701206|NCT01193270|DRUG|Vitamin E|A single intragastric dose of dl-α-tocopheryl acetate 50 IU/kg.
223701207|NCT01193270|DRUG|Placebo|Sterile water in volume equal to that of the comparator drug
223701208|NCT06556355|OTHER|neoadjuvant chemoradiation and McKeown esophagectomy|"Treatment protocol:~1. All patients were irradiated a total prescribed dose of 40-50.4 Gy in 20-28 fractions by a 6-8 MV photons linear accelerator with the intensity-modulated radiotherapy or volumetric modulated arc therapy technique.~2. Concurrent chemotherapy was cisplatin-based.~3. McKeown esophagectomy (three incision) consisted of thoracic esophageal mobilization with lymphadenectomy, abdominal exploration and stomach mobilization with lymphadenectomy, and subsequently left cervical incision for anastomosis. The lymphadenectomy was total two-field (thoracic + abdomen)."
223701209|NCT04135742|DEVICE|Transcranial Alternating Current Stimulation|Transcranial alternate current stimulation (tACS) is a method of alternative current stimulation that can modulate neural activity by imposing local oscillatory activity.
223701210|NCT04135742|BEHAVIORAL|Cognitive Training|Cognitive training includes memory, reasoning, processing speed and role playing, etc.
223701211|NCT05024604|DRUG|Progesterone Only Product in Oral Dose Form|mini pills as a contraceptive method
223701212|NCT05024604|OTHER|office hysterscopy|office hysteroscoy
223701213|NCT01163266|DRUG|Vortioxetine|Encapsulated vortioxetine immediate release tablets
223701214|NCT01163266|DRUG|Placebo|Vortioxetine placebo-matching capsules
223701215|NCT02586064|BEHAVIORAL|Interpersonal Therapy for PTSD|Relationally focused treatment that focuses on relationship problems that may be caused or maintained by PTSD symptoms. Consists of 12 individual weekly sessions of 45 to 50 minutes. Includes psycho-education, assessing which relationships (or lack of) are causing problems for the Veteran, and addressing the problem areas identified through specific strategies (e.g. communication analysis, decision analysis, role play). Final 2 sessions focus on consolidating what has been learned, what issues remain, identifying types of relationship triggers that could reactivate symptoms, and addressing feelings about termination.
223701216|NCT02586064|BEHAVIORAL|Prolonged Exposure|Aim is to allow Veterans to re-experience traumatic events experienced during military service in a safe and supportive environment, and to re-engage in activities they have been avoiding. 12 individual weekly sessions of 90 minutes. Consists of psychoeducation, breathing retraining, imaginal exposure (repeated imaginal recall of the trauma including sensory details, and associated thoughts and feelings experienced during the trauma), and with trauma, and in vivo exposure (systematically confronting feared and avoided places and activities).
223701217|NCT05936268|DRUG|Genakumab for injection|150 mg/1ml/bottle
223701218|NCT05936268|DRUG|Colchicine|0.5mg/table
223701219|NCT01046162|DRUG|Alprazolam|Single tablet
223701220|NCT01046162|DRUG|Alprazolam|Single tablet
223701221|NCT03784703|DRUG|Atorvastatin 40 Mg Oral Tablet|40 mg per day atorvastatin (ATROVA group, n= 80) for 6 months
223701222|NCT03784703|DRUG|Rosuvastatin 10 Mg Oral Tablet|10 mg per day rosuvastatin (ROSUVA group, n= 80) for 6 months
223701223|NCT01588249|DIETARY_SUPPLEMENT|Pasteurized maple syrup|
223701224|NCT01588249|DIETARY_SUPPLEMENT|Placebo|
223701225|NCT03181893|DRUG|PF-06823859 low|A humanized immunoglobulin neutralizing antibody
223701226|NCT03181893|DRUG|Placebo Arm|Placebo contains histidine, sucrose, PS80, ethylene diamine, and triacetic acid
223701227|NCT03181893|DRUG|PF-06823859 high|A humanized immunoglobulin neutralizing antibody
223701228|NCT04924205|DEVICE|FM2 Knee Brace|Participants in this group will use the FM2 Knee Brace for their post-TKA physical therapy.
223701229|NCT01033188|PROCEDURE|Single bundle|"Procedure:~Transarthroscopic technique with medial portal placement of the femoral tunnel. Harvest of the semitendinosus/gracilis (ST/G) tendons through a 3-5 cm incision at the pes anserinus. The femoral tunnel is positioned at the anatomic foot print determined by the anatomic landmarks. The graft will be fixed with an Endobutton CL on the femur and with an Biosure PK screw in the tibia with the knee close to extension. Prior to the final fixation, the knee will be taken through flexion and extension movements.The surgery will be carried out by an experienced knee surgeon."
223701230|NCT01033188|PROCEDURE|Double bundle|"Procedure:~Transarthroscopic technique. Harvest of the semitendinosus/gracilis (ST/G) tendons through a 3-5 cm incision at the pes anserinus.Through a medial portal 2 tunnels will be anatomically placed in the foot print on the femur and the two tibial tunnels will be placed using the Smith \& Nephew drill guide. The graft will be fixed with 2 Endobuttons on the femur and with 2 Biosure PK screws in the tibia. Prior to the final fixation, the knee will be taken through 20 flexion and extension movements. The PL bundle will be fixed with the knee close to ful extension. The surgery will be carried out by an experienced knee surgeon."
223701231|NCT02121782|BIOLOGICAL|Quadrivalent influenza vaccine|GC3110A, 0.5ml, intramuscular, a single dosing at Day 1
223701232|NCT02121782|BIOLOGICAL|Trivalent influenza vaccine|GC Flu Pre-filled Syringe Inj., 0.5ml, intramuscular, a single dosing at Day 1
223701233|NCT01747148|DRUG|AVI-7100 versus placebo|dose-escalating AVI-7100 versus placebo
223701234|NCT05540444|DEVICE|RadConnect|"The study will be performed in a clinical setting at the department of radiology of LUMC, meaning that we aim to test the hypothesis that (RadConnect) can reduce the number of phone calls from a select set of extension used by technologists (the Sending Extensions) to another select set of extensions manned by radiologists (Receiving Extensions)."
223701235|NCT01706822|DEVICE|Covidien Radial Reload Stapler with Tri-Staple Technology|Case series of patients arlaedy selected to undergo a laparoscopic LAR using the Radial Reload stapler
223701236|NCT05405413|OTHER|Treatment recommendations made by Molecular Tumor Board.|"Molecular Tumor Board recommendations may include any of the following:~(A) a tumor-targeted drug (alone or in combination)~(B) an antibody-based immunotherapy (alone or in combination)~(C) neither (A) nor (B).~(D) referral to the Familial Cancer Program~(E) referral for germline genetic testing"
223701237|NCT04488939|DEVICE|Restylane® Skinboosters™ Vital (SBV)|Hyaluronic acid
223701238|NCT00968864|DEVICE|CliniMACS® (T cell depletion)|Stem cells will be collected from donors after they receive Granulocyte colony-stimulating factor (G-CSF). The cells will be processed using the CliniMACS device to select for CD34+ stem cells and to deplete T cells. Recipients will receive conditioning therapy that is based on their disease type and then receive the CD34+ stem cells.
223701239|NCT00115648|DRUG|Nevirapine|Oral NVP daily dosage
223701240|NCT00115648|DRUG|AZT|Oral AZT daily
223701241|NCT00115648|DRUG|NVP and AZT|Oral single dose NVP plus oral daily AZT during the first weeks
223701242|NCT00115648|DRUG|NVP|Oral NVP daily to age 14 weeks
223701243|NCT00115648|DRUG|NVP+AZT|Oral NVP daily plus oral AZT daly to age 14 weeks
223701244|NCT05535231|DIETARY_SUPPLEMENT|Turmeric test product|2 capsules of 490 mg Turmeric are taken with water once
223701245|NCT05535231|DIETARY_SUPPLEMENT|Turmeric comparator|2 capsules of 200 mg Turmeric are taken with water once
223701246|NCT06149026|OTHER|Physical and nutritional therapy|The patients will be evaluated and followed by a nutritionist and a physical therapist for 12 weeks. In that time, the patients will receive workouts according to their evaluations and a specific nutritional guide according to the nutritionist's evaluations.
223701247|NCT02407795|RADIATION|conventional radiotherapy|1x8Gy
223701248|NCT02407795|RADIATION|stereotactic radiotherapy|1x20Gy or equivalent dose fractionation schedule
223701249|NCT00118690|DRUG|Fluticasone propionate/salmeterol|
223701250|NCT04113720|DRUG|Levobupivacaine hydrochloride|levobupivacaine 0.25%
223701251|NCT04113720|DRUG|Levobupivacaine Hydrochloride + Dexmedetomidine|Levobupivacaine plus Dexmedetomidine
223701252|NCT05426798|DRUG|TQB2618 injection azacitidine, AZA decitabine, DAC|"Drug1: TQB2618 injection is a novel tim-3 inhibitor.~Drug2: Azacitidine (5-azacytidine) is a cytidine nucleoside analogue that selectively inhibits DeoxyriboNucleic Acid methyltransferases at low doses, resulting in gene promoter hypomethylation.~Drug3: Decitabine is a cytidine deoxy nucleoside analogue that selectively inhibits DNA methyltransferases at low doses, resulting in gene promoter hypomethylation."
223701253|NCT04815031|BIOLOGICAL|BNT162b2|Comirnaty is administered intramuscularly after dilution as a course of 2 doses (0.3 mL each). It is recommended to administer the second dose 3 weeks after the first dose. Individuals 16 years of age and older.
223701254|NCT00232648|DRUG|Pulmicort (budesonide) Respules|
223701255|NCT02728622|DRUG|Tamoxifen|endocrine treatment
223701256|NCT02728622|DRUG|Chemotherapy|Paclitaxel or pegylated liposomal doxorubicin
223701257|NCT04498312|OTHER|Extracorporeal shock wave|The participant was placed into supine lying position then the head of the shock wave was applied on the anterior or posterior aspect of the thigh which was scanned with 2000 shots for both horizontal direction and vertical direction. The period of each session was 15 minutes, 2 times/week for 4 weeks
223701258|NCT01736462|DRUG|Mapracorat|One drop of mapracorat ophthalmic suspension, 3% four times daily, at approximately four hour intervals, for 14 days in both eyes.
223701259|NCT04040946|DIAGNOSTIC_TEST|MIBI scintigraphy|Performing a MIBI scintigraphy, then, in the case of negativity, a single F18-choline PET
223701260|NCT04040946|DIAGNOSTIC_TEST|F18-choline PET|Realization of a F18-choline PET, then, in case of negativity, a MIBI scintigraphy
223701261|NCT04098848|OTHER|Cycling exercise|Intradialytic cycling exercise for 30 minutes a time
223701262|NCT02605070|DRUG|Bravelle|"Bravelle will be provided to all patients in the treatment group by the principal investigator (PI) or another member of the research team.~From week nine on, the patients will undergo a physical examination on three different occasions to assess the appearance of any adverse reactions during treatment. It will be up to the patient to communicate the appearance of signs or symptoms which could be associated with the use of the drug.~At week 12 the patient will be scheduled for another visit to perform a semen study and to measure new hormone levels. To this end, a blood test will be carried out (FSH, LH, estradiol, total testosterone, SHBG, and albumin to calculate the amount of bioavailable testosterone). A semen sample will also be obtained to carry out a spermiogram according to WHO guidelines; part of this sample will be used for epigenetic analysis."
223701263|NCT00002449|DRUG|Aldesleukin|
223701264|NCT04432025|PROCEDURE|Bariatric surgery + goal directed medical therapy|Patients will undergo bariatric surgery (RYGB or SG) with goal directed medical therapy titrated to specific end points for BP, HbA1c and lipids
223701265|NCT04432025|PROCEDURE|Bariatric surgery|Patients will undergo bariatric surgery (RYGB or SG) with usual care for diabetes mellitus undertaken by their primary care provider/general practitioner
223701266|NCT00586625|DRUG|Bepreve|One drop, both eyes, twice a day
223701267|NCT00586625|DRUG|Placebo|One drop, both eyes, twice a day
223701268|NCT03314142|OTHER|Glucose as reference food|Ten subjects (male: 7, female: 3) consumed 50g glucose diluted in 250ml water, tested three times, in different weeks, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min.
223701269|NCT03314142|OTHER|White bread as reference food|Ten subjects (male: 7, female: 3) consumed 50g available carbohydrates from white bread along with 250ml water, tested twice, in different weeks, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min.
223701270|NCT03314142|OTHER|Bread enriched with coarse wheat bran|Ten subjects (male: 7, female: 3) consumed 50g available carbohydrates from bread enriched with coarse wheat bran along with 250ml water, tested once, in different weeks, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
223701271|NCT03314142|OTHER|Bread enriched with fine wheat bran|Ten subjects (male: 7, female: 3) consumed 50g available carbohydrates from bread enriched with fine wheat bran (obtained by milling of the coarse bran) along with 250ml water, tested once, in different weeks, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
223701272|NCT03314142|OTHER|Bread enriched with fine wheat bran and carob seed flour|Ten subjects (male: 7, female: 3) consumed 50g available carbohydrates from bread enriched with fine wheat bran (obtained by milling of the coarse bran) in which 10% of the flour was substituted with carob seed flour (CSFB) along with 250ml water, tested once, in different weeks, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
223701273|NCT01225692|BEHAVIORAL|Head Injury Guideline|
223701274|NCT01052571|PROCEDURE|lumbar transforaminal epidural injections|with an injection of local anesthetic or with 1% lidocaine or 0.25% bupivacaine with 3 mg of steroid per level
223701275|NCT04444388|DIETARY_SUPPLEMENT|cocoa|Sachets of 5 grams of cocoa daily supplementation
223701276|NCT04444388|DIETARY_SUPPLEMENT|Placebo|Sachets of 5 grams of maltodextrin daily supplementation
223701277|NCT01020383|DRUG|ALX-0081|4 i.v. bolus injections, once every 6 hours; first dose of 6 mg, three subsequent doses of 4 mg
223701278|NCT01020383|DRUG|ReoPro®|0.25 mg/kg i.v. bolus injection followed by continuous i.v. infusion of 0.125 µg/kg/min (to a max. of 10 µg/min) for 12 hours
223701279|NCT02728596|OTHER|Preventive Intervention|Automated ordering system recommends prescribing or not prescribing CSF based on drug's risk level for FN
223701280|NCT02728596|OTHER|Quality-of-Life Assessment|Ancillary studies
223701281|NCT02728596|OTHER|Questionnaire Administration|Ancillary studies
223701282|NCT03892070|DIETARY_SUPPLEMENT|BETA-HYDROXY-BETA-METHYLBUTYRATE (HMB)|1.5 g of HMB will be provided for 12 weeks twice daily
223701283|NCT03892070|DIETARY_SUPPLEMENT|Mannitol|1.5 g twice daily for 12 weeks
223701284|NCT04232774|DEVICE|The Neurotronic arterial ablation catheter|a sterile, single use catheter (device) for delivering chemical agent to achieve perivascular denervation.
223701285|NCT03221270|DEVICE|tACS treatment week|10 Hz sine wave stimulation with a peak-to-peak amplitude of 2 mA for 20 minutes twice for 5 consecutive days.
223701286|NCT03221270|DEVICE|tACS sham week|10Hz sine wave stimulation with a peak-to-peak amplitude of 2 mA for 10 seconds twice a day for 5 consecutive days.
223701287|NCT03221270|DEVICE|Maintenance tACS|10 Hz sine wave stimulation with a peak-to-peak amplitude of 2 mA for 40 minutes once a weekly for 8 weeks.
223701288|NCT03221270|DEVICE|Maintenance Sham tACS|10Hz sine wave stimulation with a peak-to-peak amplitude of 2 mA for 10 seconds once a week for 8 weeks.
223701289|NCT01578421|DEVICE|4 h online hemodiafiltration (FX 100, Polyflux 210, FXCorDiax)|4 h online hemodiafiltration with measurement of clearance and removal rate by split dialysate collection and bloodside measurements
223701290|NCT03114774|DEVICE|The bispectral index (BIS) monitoring|
223701291|NCT03114774|BEHAVIORAL|Ramsay Sedation Scale (RSS) Score monitoring|
223701292|NCT01408264|DEVICE|Conventional 0.035 guidewire|0.035 guidewire
223701293|NCT01408264|DEVICE|Olympus Visiglide 0.025 guidewire|0.025 guidewire
223701294|NCT04941963|DIAGNOSTIC_TEST|Chest ultrasound|Patients will undergo chest ultrasound scanning after obtaining parent's consent. each enrolled patient will have one chest ultrasound to assess diaphragmatic function and lung ultrasound severity score.
223701295|NCT00955318|DRUG|KW-6500|Subcutaneous injection of 1to 6 mg of KW-6500 for the OFF state
223701296|NCT05788653|PROCEDURE|Thiele Massage|Transvaginal Massage
223701297|NCT05788653|PROCEDURE|Transverse Friction Massage|Transvaginal Massage
223701298|NCT06184386|OTHER|NIDCAPARENTALIM|PARENTALIM practice that strengthens the NIDCAP. It is proposed in a routine way in the NICU since 2019. PARENTALIM supports and monitors parental implication in nursing care. It is led by a speach language therapist specialized in early feeding development who proposes 5 individualized interviews and uses an educational booklet on eating development care with a lot of illustrations and few words.
223701299|NCT06184386|BEHAVIORAL|SOFS|SOFS is a behavioral practice of orofacial stimulations. Il has been mainly carried out by nurses or a speach language therapist specialized in early feeding development. SOFS has been applied through routine protocol in the NICU until 2018.
223701300|NCT04286399|DRUG|Renin-angiotensin-aldosterone system inhibitors|Research participants in the intensive therapy arm should be strongly encouraged to follow the intensive treatment strategy. Every attempt should be made to up-titrate RAS-antagonists and beta-blockers (max dosage, unless contraindicated) as well as preferentially use SGLT2i (standard dosage, as required) throughout the trial.
223701301|NCT04286399|DRUG|Beta blocker|Research participants in the intensive therapy arm should be strongly encouraged to follow the intensive treatment strategy. Every attempt should be made to up-titrate RAS-antagonists and beta-blockers (max dosage, unless contraindicated) as well as preferentially use SGLT2i (standard dosage, as required) throughout the trial.
223701302|NCT04286399|DRUG|SGLT2 Inhibitor - Sodium Glucose Cotransporter Subtype 2 Inhibitor Product|Research participants in the intensive therapy arm should be strongly encouraged to follow the intensive treatment strategy. Every attempt should be made to up-titrate RAS-antagonists and beta-blockers (max dosage, unless contraindicated) as well as preferentially use SGLT2i (standard dosage, as required) throughout the trial.
223701303|NCT04306029|OTHER|Postpartum Family Planning Package|"Postpartum Family Planning Package, which consists of provider education on contraceptive delivery in the immediate postpartum period and promotion of the WHO MEC/PFP Compendium mobile application."
223701304|NCT03985306|PROCEDURE|Inforatio technique|"We define the inforatio technique as punch biopsies taken in the periphery of the wound bed. The punch biopsies will have a diameter of two mms. The depth of the biopsies is primarily based on clinical assessment on distance to bone by assessment with a sterile wound probe and with attention to location and anatomy. The maximum depth will be 3.5 millimeters. The biopsies will be taken from one to two mms from the wound edges and with a distance of five mms between the biopsies.~Inforatio technique is applied after standard care and wound assessment."
223701305|NCT00365222|DRUG|Temozolomide|temozolomide 75 mg/m2 /d
223701306|NCT03012009|DEVICE|full ablative CO2 laser|ablation to the level of de dermal papilla
223701307|NCT03012009|DEVICE|fractional ablative CO2 laser|180 micron HP, pulse 8ms, 15% overlay, 30 W (943J/cm)
223701308|NCT03012009|DRUG|MAL|
223701309|NCT03012009|DEVICE|LED lamp|peak wavelength 630 nm, 37J/cm2
223701310|NCT03012009|DRUG|lidocaine hydrochloride 2% with epinephrine|
223701311|NCT02140242|DRUG|study part 1 - dose daunorubicin|standard induction dose of daunorubicin 60 mg/m2 on days 3-5
223701312|NCT02140242|PROCEDURE|induction cycles|single induction cycle versus double induction cycles (only patients with good response after first induction) Allocation is randomized for cytogenetic risk.
223701313|NCT03101787|PROCEDURE|Extracorporeal cardiopulmonary resuscitation (ECPR)|"In addition to the routine response team, the ECLS team are called to the ED while the patient is transported to the hospital.~The team consists of a physician skilled and qualified in femoral cannulation, a perfusionist and a scrub nurse.~Upon the patient's arrival at the emergency department, CPR will be continued, with continuation of mechanical chest compressions with minimization of interruptions.~Time from arrest to start of cannulation is \< 60 minutes."
223701314|NCT03646825|DIETARY_SUPPLEMENT|Natural Antioxidant supplement|1 capsule orally three times a day for 12 weeks
223701315|NCT02401022|DRUG|AZD8529|comparison of different dosages of drug
223701316|NCT03147677|DRUG|Alfacalcidol|
223701317|NCT03147677|DRUG|Irbesartan|
223701318|NCT00880984|DEVICE|Compression Anastomosis Ring: CAR™ 27|Creation of anastomosis in colorectal surgeries using CAR™ 27
223701319|NCT04032652|PROCEDURE|Rectal dialysis|Rectal dialysis done after 1 week on either 1200/2400 mg Asacol dose to test rectal mucosal 5-ASA levels
223701320|NCT04032652|DRUG|Rectal dialysis|Rectal dialysis done after 1 week on either 1200/2400 mg Asacol dose to test rectal mucosal 5-ASA levels
223701321|NCT04250922|DRUG|LAM561|"Subjects in Arm B will receive orally LAM561 during the Chemoradiation Phase.~Subjects in Arm B will receive LAM561 orally during the Maintenance (Adjuvant) Phase. Patients will continue to be administered with LAM561/Placebo after cycle 6 of the monotherapy phase until end of study. Adjuvant treatment will be discontinued upon determination of tumour progression as defined by RANO criteria, unacceptable toxicity, or refusal to continue study treatment."
223701322|NCT04250922|DRUG|TMZ|"TMZ will be administered at 75 mg/m2, orally, once daily, continuously from Day 1 of radiotherapy to the last day of radiation for a maximum of 49 days.~During the Maintenance (Adjuvant) Phase, all subjects will receive oral TMZ 150 - 200 mg/m2 once daily on Days 1 - 5 of each 28-day cycle for 6 cycles."
223701323|NCT04250922|RADIATION|RT|During the Chemoradiation Phase, all subjects will undergo focal RT, with one treatment given daily 5 days per week over approximately 6 weeks (and no more than 7 weeks).
223701324|NCT03565601|OTHER|Follow-up|Clinical data, radiological data and laboratory tests follow-up
223701325|NCT01172236|DRUG|Lactoferrin|"Experimental group: newborns (group A) will receive a daily dose of 100 mg of lactoferrin (Dicorfam® Elleffe 1''% 2C supplement containing lactoferrin) + standard therapy.~Control group: newborns (group B) will receive only standard therapy and they will be used as controls."
223701326|NCT01172236|DRUG|Lactoferrin|Experimental group: 650 newborns (group A) will receive a daily dose of 100 mg of lactoferrin (Dicorfam® Elleffe 1''% 2C supplement containing lactoferrin) + standard therapy.Control group: 650 newborns (group B) will receive only standard therapy and they will be used as controls.
223701327|NCT01152983|DEVICE|Rapid Ring|Rapid Ring is a ring-shaped device that encircles the distal phalanx of the middle finger and blocks the arterial blood to quickly and passively withdraw blood following a finger stick, and to reduce the pain of the lancet.
223701328|NCT02967432|DRUG|Mupirocin Topical Ointment|Mupirocin ointment 1/2 inch ribbon applied topically to each nare and umbilicus twice daily for 5 days; repeat treatment courses possible.
223701329|NCT02967432|DRUG|Petroleum Jelly|Petroleum jelly ointment 1/2 inch ribbon applied topically to each nare and umbilicus twice daily for 5 days; repeat treatment courses possible.
223701330|NCT05570383|DRUG|Dust mite drops (trade name: Changdi, Zhejiang Tawu Biotechnology Co. Ltd.).|The experimental group will be with Sublingual immunotherapy (trade name: Changdi, Zhejiang Tawu Biotechnology Co., Ltd.). The control group will be with Mometasone Furoate Aqueous Nasal Spray (NASUNA); The treatment course of the two groups will be 3 months.
223701331|NCT01047670|DRUG|Hydrocortisone|Hydrocortisone 6 mg/kg/day, 8 hourly, during 7 days or during the vasoactive drug infusion
223701332|NCT04128085|DRUG|TQB3804|A kind of tyrosine kinase inhibitor.
223701333|NCT05444101|BEHAVIORAL|Mindful attention|The Mindful attention treatment component consists of a breathing exercise and is operationalized as two sessions (1 hour each) delivered over two weeks, i.e., one session per week, with homework between sessions. Sessions will be delivered online.
223701334|NCT05444101|BEHAVIORAL|Decentering|The Decentering treatment component consists of a guided imagery exercise and is operationalized as two sessions (1 hour each) delivered over two weeks, i.e., one session per week, with homework between sessions. Sessions will be delivered online.
223701335|NCT05444101|BEHAVIORAL|Values and committed action|The Values and committed action treatment component consists of identification of personal values and committed action, and is operationalized as two sessions (1 hour each) delivered over two weeks, i.e., one session per week, with homework between sessions. Sessions will be delivered online.
223701336|NCT02635763|PROCEDURE|Femoral nerve and the lateral cutaneous nerve block|Femoral nerve block was performed using 0.5% ropivacaine (15ml) under ultrasound guide;the lateral cutaneous nerve block was performed using 0.5% ropivacaine (5ml) under ultrasound guide
223701337|NCT02635763|PROCEDURE|Lumbar plexus and sacral plexus nerve block|Lumbar plexus block was performed using 0.5% ropivacaine (25ml) under ultrasound guide; sacral plexus nerve block was performed using 0.5% ropivacaine (15ml) under ultrasound guide
223701338|NCT05065814|OTHER|Systemic lupus erythematosus group|Demographic information of systemic lupus erythematosus who accepted to participate in the study will be obtained, and respiratory and peripheral muscle strength and exercise capacity of the patients will be evaluated with a 6-minute walking test. Patients will be asked to complete the International Physical Activity Questionnaire, the numerical pain questionnaire, the Short Form-36, and the Hospital Anxiety and Depression Questionnaire. In addition, Modified Medical Research Council Dyspnea Scale will be applied by the interviewer.
223701339|NCT05065814|OTHER|Systemic sclerosis group|Demographic information of Systemic sclerosis who accepted to participate in the study will be obtained, and respiratory and peripheral muscle strength and exercise capacity of the patients will be evaluated with a 6-minute walking test. Patients will be asked to complete the International Physical Activity Questionnaire, the numerical pain questionnaire, the Short Form-36, and the Hospital Anxiety and Depression Questionnaire. In addition, Modified Medical Research Council Dyspnea Scale will be applied by the interviewer.
223701340|NCT05065814|OTHER|Healthy control group|Healthy individuals with no chronic diseases who agreed to participate in the study and gave their consent will be included in the study.
223701341|NCT05051995|DRUG|Open-label placebo|Prior to the open-label placebo administration, an explanation why placebos without concealment might be effective is offered. Participants receive placebo pills with the instruction to take 2 pills daily for 2 weeks.
223701342|NCT05051995|OTHER|No-treatment|During the no-treatment phase, participants receive no treatment for 2 weeks.
223701343|NCT03945266|BEHAVIORAL|Intervention group|During the intervention, all participants will start out at the Baseline level. The baseline level will last 2 weeks and there will be an assessment to determine weight gain over those 2 weeks. If weight gain has succeeded the recommended amount, participants will be adapted up to a new level of intervention that includes education on GWG, healthy eating and physical activity. After every 4 weeks, an assessment will be performed and adaptations up will be made if necessary. Adaptations include addition of exercise sessions, healthy eating recipe demonstrations, and meal replacements. Participants will weigh themselves daily, wear an activity monitor, record their diet, and complete paper and online surveys.
223701344|NCT03945266|BEHAVIORAL|Control group|Participants will follow the same self-monitoring/assessment schedule but will not receive the GWG, healthy eating, and physical activity education or adaptations.
223701345|NCT00876525|DEVICE|Surgical Replacement of the diseased native aortic heart valve with the Freedom SOLO Valve prosthesis|The Freedom SOLO prosthesis is designed for implantation in a supra-annular, sub-coronary position, with a single suture line.
223701346|NCT02655133|DRUG|Pentaglobin®|Immunoglobulins that will be used are IgM enriched and will be infused at 5 ml/Kg/day for 3 days.
223701347|NCT02655133|DRUG|Physiologic solution|Physiologic solution will be infused and will be infused at 5 ml/Kg/day for 3 days.
223701348|NCT00993681|BIOLOGICAL|TD Vaccine System|heat labile enterotoxin of E. coli (LT)
223701349|NCT00993681|BIOLOGICAL|TD Vaccine System|placebo
223701350|NCT02465645|DRUG|Carvedilol|
223701351|NCT02465645|DRUG|Carvedilol + Simvastatin|
223701352|NCT03316365|OTHER|Rhythmic Auditory Stimulation (RAS)|The experimental group (continuous treatment) trained daily with Rhythmic Auditory Stimulation (RAS) for 24 weeks. The control group (intermittent treatment) trained with RAS for 8 weeks, discontinued training for 8 weeks, and resumed training with RAS for 8 weeks. During treatment subjects walked for 30 minutes in a home-based environment with metronome-click embedded music downloaded to an MP3 player and listened to either free-field or via headphones. For the first 8 weeks subjects had 3 metronome rates available to choose from: 100, 105, and 110% of internal usual cadence. During the second 8 weeks available rates were 105, 110 and 115%; and during the last 8 weeks 110, 115, 120%. The control group started their last training segment at 105, 110, and 115%, but could request a change to the faster rates if comfortable.
223701353|NCT01635335|BEHAVIORAL|Latino STYLE|7-hour family-based workshop with 3-hour follow-up booster 3 months later
223701354|NCT00393354|DRUG|MK0663, Etoricoxib / Duration of Treatment : 12 Weeks|
223701355|NCT00393354|DRUG|Comparator : placebo (unspecified) /Duration of Treatment : 12 Weeks|
223701356|NCT00907868|RADIATION|partial breast irradiation|Patients undergo radiation tumor bed boost
223701357|NCT00907868|RADIATION|whole breast irradiation|Patients undergo whole breast irradiation
223701358|NCT04337385|BEHAVIORAL|Interrupting 3 hours of prolonged sitting with high intensity interval exercise|Breaking up a prolonged bout of sitting in adolescents using high intensity interval exercise
223701359|NCT04337385|BEHAVIORAL|3 hours of prolonged sitting|Participants will be asked to remain seated for 3 hours and refrain from moving their lower limbs
223701360|NCT01791010|OTHER|Inspiratory muscle training|
223701361|NCT01791010|OTHER|Training sham|Conducting fake training with the aim of blind the control group
223701362|NCT01375426|DRUG|Oral amoxicillin|
223701363|NCT01642654|OTHER|Exercise|The WG was submitted to a 16-week WEP, with combined aerobic and resistance exercises in three weekly sessions. Water temperature was approximately 30º C with an average ambient temperature of 34° C. The pool had water levels ranging between 1,20 and 1,40 meters deep.
223701364|NCT01642654|OTHER|Educational lectures|Educational lectures
223701365|NCT04680156|DRUG|Previously treated with EN3835 up to 1.74 mg or Placebo in EN3835-210 or the pivotal phase 3 studies|No treatment to be administered - Observational only
223701366|NCT00359697|DRUG|Hypertonic Saline, Mannitol|
223701367|NCT06365541|DRUG|Dapagliflozin|oral Dapagliflozin tablets 10mg/day for 6 months
223701368|NCT00603785|DRUG|Placebo|Subjects with chronic sinusitis and evidence of atopy and an elevated total IgE (\>30 and \<700 IU/ml) will be randomized to receive placebo treatment for 6 months.
223701369|NCT00603785|DRUG|Xolair|Subjects with chronic sinusitis and evidence of atopy and an elevated total IgE (\>30 and \<700 IU/ml) will be randomized to receive Xolair treatment for 6 months.
223701370|NCT05991349|DRUG|IBI129|Subjects will receive IBI129 on Day 1 of a 21-day cycle (or intervals determined by the Investigator and Sponsor based on safety, toxicity and PK data), until unacceptable toxicity, disease progression, withdrawal of consent, occurrence of other reasons for discontinuing study therapy, or for a maximum of 24 months of treatment, whichever occurs first.
223701371|NCT05885854|DRUG|XTR003|"Enrolled subjects were required to fast for ≥ 6 hours before drug administration at rest;~1. Initial intravenous injection of 18F-FDG to each subject with a dose range of 2.0-3.0 mCi (74-111 MBq). Each patient will be imaged with PET for 10 minutes at 50-70 minutes after the injection.~2. In few minutes, a single intravenous bolus injection of XTR003 will follow and administer to each patient with a dose range of 6.0-8.0 mCi (222-296 MBq). Each patient will be immediately imaged with PET for 15 minutes."
223701372|NCT03206437|BEHAVIORAL|Mindfulness-Based Stress Reduction|The MBSR course teaches mindfulness meditation skills. This 8-week course meets in person once a week for 2.5 hours. Participants are expected to complete practice assignments at home.
223701373|NCT03206437|BEHAVIORAL|Waitlist|This group will wait 8-16 weeks after their first testing visit and after their second study visit is completed they will be able to participate in an 8-week MBSR course.
223701374|NCT01736124|OTHER|computerized cognitive training|A variety of computer games tailored to address their personal cognitive deficits.
223701375|NCT01736124|OTHER|control games|A variety of computer games that are engaging but not designed to enhance cognitive skills
223701376|NCT03553927|DIETARY_SUPPLEMENT|Low Energy Diet|Caloric restriction to achieve weight loss
223701377|NCT03553927|OTHER|NHS advice on healthy eating|Advice on energy requirements as per the British Dietetic Association
223701378|NCT00531401|DRUG|Salirasib|600mg BID until disease progression or unacceptable toxicity occurs.
223701379|NCT04902131|DRUG|A MENOPUR solution for injection in pre-filled pen, 600 IU/0.96 mL|Single dose cross-over bioequivalence trial
223701380|NCT04902131|DRUG|A MENOPUR powder including solvent for solution for injection, 75 IU|Single dose cross-over bioequivalence trial
223701381|NCT05886504|OTHER|Community-based psychiatric intervention|intervention will take place in CBO offices instead of mental health department, medication will be given freely and psychiatric consultations will be free. Trained CBO members will provide individual and collective support including recall of appointments and tracing of those lost to follow-up, information on mental health, main psychiatric disorders, psychiatric medication, their potential side effects and expected benefits, contact with families and continuous support
223701382|NCT01688518|DRUG|Heated Lidocaine/Tetracaine Patch|
223701383|NCT01688518|DRUG|5% Lidocaine Patch|
223701384|NCT00659750|DRUG|Ciclesonide|200µg Ciclesonide versus Placebo
223701385|NCT00659750|DRUG|Placebo|placebo
223701386|NCT05984472|PROCEDURE|Edelweiss prefabricated veneers|Individual Randomized Clinical Trial
223701387|NCT05984472|PROCEDURE|Ceram-X Duo SphereTec with U-Veneer|Ceram-X Duo SphereTec with U-Veneer
223701388|NCT06242600|DEVICE|Drainage of the bladder by indwelling Foley catheter|Drainage of the bladder by transurethral catheterization with an indwelling Foley catheter of patients undergoing a TUR-B procedure and in need of a Foley catheter for up to 24 hrs.
223701389|NCT03098459|OTHER|Non-interventional observational prospective cohort study|Non-interventional observational prospective cohort study
223701390|NCT06119061|DRUG|Telavancin Injection|Telavancin 10mg/kg (maximum 1000mg) administered intravenously over 60 minutes (through a central venous catheter whenever available).
223701391|NCT02423772|BEHAVIORAL|Acceptance and Commitment Therapy + Mindfulness-Based Relapse Prevention + Treatment as Usual (TAU)|
223701392|NCT02887573|DRUG|Free-residue nutrients|This trial evaluated the efficiency of free-residue nutrients for the bowel prepartion of CCE.
223701393|NCT02887573|DRUG|Low fiber diet|Low fiber diet often used in the bowel prepartion of CCE. In this study, it is the control group.
223701394|NCT02887573|PROCEDURE|Colon capsule endoscopy|In the study,all patients should undergo two colonoscopies.The first is for examinations and the second for therapy.
223701395|NCT02887573|DRUG|2L PEG|2L PEG are laxatives for experiment group.
223701396|NCT02887573|DRUG|4L PEG|4L PEG are laxatives in the control group.
223701397|NCT02887573|DRUG|PEG|These PEG are for boosters. All patients will take 0.75L and 0.5L PEG for two boosters.
223701398|NCT02887573|DRUG|Mosapride citrate|5mg mosapride citrate are used to promote gastric motivity.
223701399|NCT04041739|DIAGNOSTIC_TEST|fungal osteomyelitis culture and sensitivity|swabs from ulcer tissue and bone biopsy for culture and sensitivity test and blood sampling
223701400|NCT01350518|DIETARY_SUPPLEMENT|Benefiber|"Benefiber® powder will be used as our dietary supplement intervention. Benefiber® powder contains wheat dextrin, a 100% natural fiber. Participants in the intervention arm will receive 3 supplement packets to be consumed per day.~Each active dietary supplement packet contains 8 grams of Benefiber® powder and 3 grams of TRUE® lemon flavoring, a 100% natural with no artificial ingredients or sweeteners, preservatives, sodium or gluten."
223701401|NCT01350518|DIETARY_SUPPLEMENT|TrueLemon|Each placebo dietary supplement packet contains 8 grams of Splenda and 3 grams of TRUE® Lemon sweetener. Each packet is designed to be added to 8 oz of fluid. The three packets should be consumed each day in a total of 24 fluid ounces.
223701402|NCT04562493|PROCEDURE|Transforaminal Epidural injection|Transforaminal injection will be performed under fluoroscopy guidance. The patient will be placed in the prone position and draped in the sterile manner. A 22-gauge, 3.5-inch spinal needle will be used. The selected patients will receive transforaminal epidural injection of the drug
223701403|NCT01806727|BEHAVIORAL|Community Lifestyle Weight Loss (LWL)|Changing dietary and physical activity behavior to promote weight loss
223701404|NCT01806727|BEHAVIORAL|Diabetes Self Management (DSM)|Changing diet, physical activity, self monitoring, and medication related behaviors to improve diabetes control
223701405|NCT03882788|DRUG|Isoflurane|Isoflurane (volatile anesthesia) will be delivered at 1.5-2.0%% as required for anesthetic management.
223701406|NCT03882788|DRUG|Fentanyl (high dose)|Fentanyl (narcotic anesthesia) maintenance will be with fentanyl 5 mcg/kg/hr not to exceed 10 mcg/kg/hr.
223701407|NCT03882788|DRUG|Fentanyl (low dose)|Fentanyl (narcotic anesthesia) maintenance will be with fentanyl 2 mcg/kg/hr.
223701408|NCT02138435|OTHER|MRI exercise test|Measuring cardiac output with MRI during exercise on an ergometer bicycle.
223701409|NCT02138435|OTHER|Gas-exchange exercise test|Measuring cardiac output by gas-exchange, while during exercise on an ergometer bicycle.
223701410|NCT04117139|DIAGNOSTIC_TEST|PET/MRI|A PET/MRI of the Head and Neck region is done for all patients included in the project.
223701411|NCT04460456|DRUG|SBT6050|Escalating doses of SBT6050 in Part 1 and recommended dose in Part 2
223701412|NCT04460456|DRUG|pembrolizumab|400 mg IV
223701413|NCT04460456|DRUG|Cemiplimab|350 mg IV
223701414|NCT03830112|BEHAVIORAL|Pilates exercise with Theraband|The experimental group will perform all the exercises with Theraband® in the same manner than active comparator group.
223701415|NCT03830112|BEHAVIORAL|Pilates exercise|The active comparator group will perform all the exercises without Theraband®
223701416|NCT02634749|OTHER|Systematic introduction of taste portions|A systematic introduction of plant foods from the Nordic diet
223701417|NCT02634749|OTHER|Protein reduced complementary foods|Specially prepared, protein-reduced, age-adjusted milk cereal drinks, baby cereals and baby milk, and commercially available baby foods in glass jars
223701418|NCT02634749|OTHER|Nordic diet|Taste portions, homemade and industry manufactured main meals with a predominance of Nordic ingredients
223701419|NCT04621565|DRUG|Normal saline|No hydrocortisone or other steroids are given before, during, and after the surgery, except that patients develop postoperative adrenal insufficiency. If a patient develops postoperative adrenal insufficiency, he/she needs to receive hydrocortisone treatment (20mg at 0800 and 20mg at 1600) for one month and then check the level of morning serum cortisol to decide if it is time to start the hydrocortisone taper program.
223701420|NCT04621565|DRUG|Hydrocortisone|"Hydrocortisone sodium succinate is given on the operation day (100mg at 0800 \& 100mg at 2000), the postoperative day 1 (100mg at 0800 \& 50mg at 2000), and the postoperative day 2 (25mg at 0800). Hydrocortisone (po.) is then given starting from the afternoon of postoperative day 2 (20mg at 1600 and 0800) to the end of the first postoperative week, and 20mg at 0800 during the second postoperative week. This is called the hydrocortisone taper program. If a patient develops postoperative adrenal insufficiency, he/she needs to receive hydrocortisone treatment (20mg at 0800 and 20mg at 1600) for one month and then check the level of morning serum cortisol to decide if it is time to start the hydrocortisone taper program."
223701421|NCT01468103|PROCEDURE|Surgical Iridectomy|Surgical Iridectomy is now widely used in our clinical.
223701422|NCT01468103|PROCEDURE|Laser Iridotomy|alternative choice to surgical iridectomy
223701423|NCT00185770|BEHAVIORAL|Reducing television and other screen time (SMART curriculum)|
223701424|NCT06033521|DRUG|Menopausal hormone therapy Intervention Type: Drug|Subjects who were newly diagnosed menopausal symptoms between 01 Jan 2012 and 31 Dec 2019, and were followed up for 12 months at least in the HIRA claims database
223701425|NCT02715401|DRUG|HCP1303|
223701426|NCT02715401|DRUG|HGP1201|
223701427|NCT02715401|DRUG|HIP1402|
223701428|NCT02717273|DRUG|standard|peri-operative antibiotic regimen only
223701429|NCT02717273|DRUG|extended|extended three-day course of antibiotics
223701430|NCT02717273|OTHER|liver transplant|orthotopic liver transplantation
223701431|NCT03727425|DEVICE|Robotic assisted bronchoscopy|Robotic assisted bronchoscopy of peripheral airways in human subjects for the purpose of biopsying peripheral lung lesions.
223701432|NCT03764085|DRUG|Rheosorbilact®|Administered intravenously (with speed 40-60 drip per minute) at a dose of 600 to 1,000 ml (10 to 15 ml/kg body weight per 24 hours) for 3 days.
223701433|NCT03764085|DRUG|Ringer lactate|Administered intravenously (with speed 40-60 drip per minute) at a dose of 1,000 to 2,500 ml (15 to 40 ml/kg body weight per 24 hours) for 3 days.
223701434|NCT03360747|DRUG|AKCEA-ANGPTL3-LRx|AKCEA-ANGPTL3-LRx at dose 20 mg, administered via SC injection QW.
223701435|NCT03025009|DRUG|LY3192767|Administered SC.
223701436|NCT03025009|DRUG|Basal Insulin Peglispro|Administered SC.
223701437|NCT03025009|DRUG|Insulin Glargine|Administered SC.
223701438|NCT03025009|DRUG|Placebo|Administered SC.
223701439|NCT01759511|DRUG|Simtuzumab|200 mg/mL administered intravenously biweekly (per original protocol) or 125 mg/mL self-administered subcutaneously every 7 ± 2 days (per protocol amendment 1)
223701440|NCT05338359|BIOLOGICAL|Blood sample|Blood sample of 34 mL
223701441|NCT05338359|OTHER|Phone-call|Phone-call to the participant 15 days after recruitment to fix the final diagnosis
223701442|NCT02772055|OTHER|Moxibustion|Moxibustion at three acupuncture point(EX-LE04,ST35,ST36).12 sessions of moxibustion treatment over a period of 4 weeks, 3 sessions per week.Each session will last 30 minutes.
223701443|NCT02772055|OTHER|Moxa smoke purification device|Investigators place a purification device(Shenzhen Conyson Electronic Technology Co, Ltd,C200 moxa smoke purification device,Shenzhen,China) at the top of the moxibustion to remove the moxa smoke.
223701444|NCT01887223|PROCEDURE|Transconjunctival needling revision|Surgical revision. A 25 Gauge needle was inserted under the subconjunctival space and perforate the encapsulated bled. The encapsulated bleb was ruptured with sweeping movement up and down, back and forth.
223701445|NCT01887223|DRUG|Medical treatment|Hypotensive eye drops are initialized one by one regarding intraocular pressure control. Nonspecific beta blocker and/or prostaglandin, followed by carbonic anhydrase inhibitors and/or selective alpha agonist.
223701446|NCT03318666|BEHAVIORAL|Supporting Our Valued Adolescents (SOVA)|"The SOVA intervention includes:~* a welcome email to the websites (adolescents also get a SOVA intro video and mobile app)~* adolescents will have access to the website specifically for adolescents: sova.pitt.edu~* parents will have access to the website specifically for parents: wisesova.pitt.edu~These anonymous websites aim to: (1) challenge negative health beliefs and increase depression/anxiety knowledge through daily blog posts enhanced with peer commentary; (2) promote social support through online peer interactions; and (3) encourage parent-adolescent mental health communication through same day blog posts with questions for discussion. Parents and adolescents cannot log on to each other's sites. The sites are moderated by our research team.~The SOVA websites include articles composed by SOVA Peer Ambassadors who are adolescents and young adults who have experienced symptoms of depression or anxiety and contribute monthly articles and regular comments."
223701447|NCT03318666|OTHER|Enhanced Usual Care|A social worker at the Center for Adolescent and Young Adult Health (CAYAH) clinic helps to facilitate referrals from the adolescent healthcare provider (AHCP) and contacts patients who do not schedule for within-CAYAH appointments.The study will send an extra email to the parent and adolescent that contains the content of the depart summary as well as a list of psychoeducational materials, how to contact the AHCP, CAYAH social worker, and crisis resources and the AHCP's treatment recommendation which are obtained from the electronic health record. Also, each individual will receive a phone call from a research assistant who will communicate the information in the email and offer to inform the social worker or AHCP of questions the patient or parent may have.
223701448|NCT03878342|RADIATION|Radiotherapy|two fractionation regimens will be allowed for whole-breast irradiation: 50 Gy in 25 fractions over 5 weeks or 40 Gy in 15 fractions over 3 weeks. The delivery of an additional dose to the tumour bed (boost) will be at the referring physician discretion, according to the guidelines
223701449|NCT03878342|OTHER|No Radiotherapy|No Irradiation- Active surveillance
223701450|NCT03306927|DIETARY_SUPPLEMENT|Whole yellow pea chili|Chili containing whole yellow peas
223701451|NCT03306927|DIETARY_SUPPLEMENT|Split yellow pea chili|Chili containing split yellow peas
223701452|NCT03306927|DIETARY_SUPPLEMENT|Rice chili|Chili containing long grain white rice
223701453|NCT05732623|BEHAVIORAL|Semi Quantitative Food Frequency Questionnaire (SQFFQ)|"The SQFFQ quantifies the frequency of consumption of each food and drink and the following list of variables:~* date of birth~* sex~* ethnicity~* weight (kg)~* height (m)~* BMI (kg/m2) at the time of eoCRC diagnosis and at 18 years old~* country where they live permanently~* tobacco smoking at the time of eoCRC diagnosis and at 18 years old~* sitting time~* TV-viewing time~* moderate-to-vigorous physical activity (MVPA)~* waist circumference (cm)~* home blood pressure levels (mmHg)~* fasting blood glucose (mg/dl)~* regular consumption of aspirin/NSAID and years of consumptions~* calcium and folate supplements and years of consumptions~* oral contraceptive agents and years of consumptions~* post-menopausal hormones and years of consumptions"
223701454|NCT06122116|OTHER|Physical Therapy|The PT treatment participants receive in this study will be standard of care; that is, the PT treatment regimen will not be standardized across study participants and/or dictated by study-specific criteria. Participants will be referred to the Physical Therapy Department at the Madigan Army Medical Center (MAMC). Number of PT treatments will be documented on a follow-up Chart Review.
223782579|NCT01601574|BEHAVIORAL|Weight Watchers modified program|Weight Watchers: For people with Type 2 diabetes including (1) weekly standard in-person Weight Watchers meetings, (2) use of the standard Weight Watchers online program and tools, and (3) two scheduled telephone consultations with a Certified Diabetes Educator (CDE) who will assist the participant in tailoring the standard Weight Watchers program to accommodate the participant's diabetes-related status, with additional unlimited phone and email access to CDEs at the participant's request
223701455|NCT06122116|BIOLOGICAL|Platelet-Rich Plasma Injection|PRP injection procedures will follow current clinical recommendation and standard operating procedures. Prior to the injection, the area will be sterilely prepared and anesthetized with either ethyl chloride spray or lidocaine (limited to the cutaneous and subcutaneous layer, so as not to alter the synovial contents). Then, the participant will receive LP-PRP injection in the affected knee area under ultrasound guidance. Qualified study providers will inject 2-5cc LP-PRP using an 18-gauge 1/5-inch needle for both aspiration and subsequent injection. Study providers will select the injection portal they are most comfortable with, in order to achieve an accurate intra-articular injection. The PRP injection procedure is expected to take approximately one hour.
223701456|NCT06122116|DEVICE|Photobiomodulation Therapy|PBMT is delivered with the LightForce® XPi 25W device through the Smart Hand Piece technology. PBMT will be delivered at 6 J/cm\^2 and applied in a circular pattern to the knee area.
223701457|NCT02799485|OTHER|Laboratory Biomarker Analysis|Correlative studies
223701458|NCT02799485|OTHER|Pharmacological Study|Correlative studies
223701459|NCT02799485|BEHAVIORAL|Quality-of-Life Assessment|Ancillary studies
223701460|NCT02799485|BIOLOGICAL|Recombinant EphB4-HSA Fusion Protein|Given IV
223701461|NCT05942261|OTHER|Survey to collect data|The study is a survey aimed to collect data about rehabilitation methods
223701462|NCT05635851|DRUG|Glyceryl Trinitrate Only Product in Oromucosal Dose Form|Glyceryl trinitrate will be administered via sublingual spray.
223701463|NCT05635851|OTHER|Placebo sublingual spray|A placebo sublingual spray will be administered.
223701464|NCT04829448|DIETARY_SUPPLEMENT|Protein supplement|Protein supplement equivalent to Metagenics Ultrameal
223701465|NCT06554730|OTHER|Belzutifan|There is no intervention for this study. This study will be collecting data from the EMR of consenting subjects who are taking Belzutifan.
223701466|NCT00094029|DRUG|Sutent|Sutent, 25, 37.5, or 50 mg daily
223701467|NCT04195282|OTHER|Plasma exchange|Patients will receive treatment of plasma exchange for three times in two weeks. The volume of fresh frozen plasma used in plasma exchange is about 2000 millilitre per time.
223701468|NCT04195282|OTHER|RL-1 Novel Human-derived Bio-artificial Liver Treatment|Patients will receive RL-1 Novel Human-derived Bio-artificial Liver treatment for three times in two weeks. The volume of plasma exchanged in the system is about 4000 millilitre per time.
223701469|NCT00914173|DEVICE|Scanlaf Circulator and water bath|Cold Pressor Test
223701470|NCT00914173|DEVICE|Medoc TSA 2000|Thermal stimuli pain
223701471|NCT04834752|OTHER|No intervention (Retrospective Cohort Observational)|History of PPI and H2RA prescription of the participants who were tested for COVID-19 will be reviewed.
223701472|NCT05633797|DEVICE|FibriCheck|During the patient's intensive care unit (ICU) stay, they will be monitored constantly to detect atrial fibrillation (standard care). After ICU dismissal, patients will be monitored using the FibriCheck application to detect atrial fibrillation until 30 days postoperative. Patients need to use the FibriCheck application for a minimum of 3x/day and can perform extra measurements when symptoms are present.
223701473|NCT05784545|DIETARY_SUPPLEMENT|Blueberry powder supplement|The intervention in this study is 12 weeks of daily blueberry supplementation which is comprised of freeze-dried powdered whole blueberries i.e., blueberries with water removed.
223701474|NCT05784545|DIETARY_SUPPLEMENT|Maltodextrin supplementation|The intervention in this study is 12 weeks of daily maltodextrin supplement used to mimic the carbohydrate composition of whole blueberries.
223701475|NCT06709118|DEVICE|fiberoptic|Tracheal intubation was performed with different outer diameters of fiberoptic.
223701476|NCT06707311|OTHER|patients received calcium hydroxide with glass ionomer restorative material|patients received calcium hydroxide with glass ionomer restorative material
223701477|NCT06707311|OTHER|patients received TheraCal LC with glass ionomer restorative material|patients received TheraCal LC with glass ionomer restorative material
223701478|NCT06707311|OTHER|patients received bioactive bonding with glass ionomer restorative material|patients received bioactive bonding with glass ionomer restorative material
223701479|NCT06707311|OTHER|patients received universal bonding with glass ionomer restorative material|patients received bioactive bonding with glass ionomer restorative material
223701480|NCT06708884|OTHER|Exercise|exercise programme will be implemented via telerehabilitation
223701481|NCT06708884|OTHER|Exercise|exercise programme will be implemented via face-to-face
223701482|NCT03693300|DRUG|Durvalumab|Participants will receive 1500 mg Durvalumab monotherapy via IV infusion q4w for up to a maximum of 24 months with the last administration at Week 104.
223701483|NCT01891110|PROCEDURE|ES of the abdominal muscles|ES was applied with surface electrodes and fixed stimulation parameters with individual mA, depending on each patients´ sensibility.
223701484|NCT01891110|PROCEDURE|ES of the limb muscles|Lower limb muscles were stimulated to produce a milking mechanism from the distal to proximal part of the limb to pump the venous blood from the peripheral to the central part of the body
223701485|NCT01891110|PROCEDURE|ES of limbs & abdomen|The combination of the ES of the lower limb muscles and the abdominal muscles.
223701486|NCT02582502|OTHER|Hyperbaric Oxygen|The only intervention given will be 100% oxygen under hyperbaric pressure.
223701487|NCT02598804|OTHER|5 educational workshop|
223701488|NCT02598804|OTHER|written information booklet|
223701489|NCT02206048|DRUG|Proflavine|0.01% proflavine solution topically applied to cervix before high-resolution microendoscopy (HRME) imaging.
223701490|NCT02206048|PROCEDURE|High-Resolution Microendoscopy (HRME) Imaging|in-vivo high-resolution microendoscopy (HRME) images of cervical adenocarcinoma in situ (AIS) performed immediately prior to conization.
223701491|NCT01685866|DEVICE|Vein-Viewer Vision|A medical device called Vein-Viewer Vision
223701492|NCT02692222|OTHER|Calculation of PPV and CO with two methods|
223701493|NCT01577368|DRUG|Piperacillin-Tazobactam continuous infusion|Piperacillin-Tazobactam 2gr (Loading dose DAY 1) plus Piperacillin-Tazobactam continuous infusion 8gr every 24 hours (DAY 1-14)
223701494|NCT01577368|DRUG|Piperacillin-Tazobactam intermittent infusion|Piperacillin-Tazobactam intermittent infusion 4gr every 8 hours (DAY 1-14)
223701495|NCT01403181|DRUG|Boceprevir|"In the experimental arm boceprevir (800 mg orally three times daily), PEG-IFN and ribavirin will be given for 24 weeks after the lead-in; the patients who will have undetectable HCV-RNA at week 8 will stop treatment at week 28; those who will be HCV-RNA positive at any visit between week 8 and 24 will receive an additional 20 weeks of PEG + RBV. Treatment will be discontinued if HCV-RNA is positive at week 24.~Immunological analysis will be performed longitudinally at the following time points: week -4, 0, 4 (end of lead-in), 8, 12, 24, 48, week 24 of follow-up. HCV-RNA will be quantified at the same time points and viremia will be correlated with immunological data."
223701496|NCT04244682|DEVICE|Repetitive transcranial magnetic stimulation (rTMS)|In the rTMS procedure a small plastic coil will be placed next to the participant's head. The position of the coil will be guided by neuro-navigational software utilizing the individual's MRI scan. The coil will be placed over the relevant brain region using the Brainsight TMS-MRI co-registration system for visualizing the coil position with respect to the participant's individual MRI scan. The coil will then generate a series of repetitive magnetic pulses, and stimulation will occur, disrupting typical function of the targeted brain region.
223701497|NCT03022136|OTHER|cold sensation method|Complete sensory loss to ice will be evaluated form anterior median line to posterior median line at the end of surgery.
223701498|NCT01564914|DRUG|TRC105|10 mg/kg weekly by intravenous administration on Days 1, 8, 15 and 22 of each 28-day cycle
223701499|NCT01564914|DRUG|Bevacizumab|IV
223701500|NCT03616626|RADIATION|Once Daily APBI|Adjuvant 3D Conformal Accelerated Partial Breast Irradiation to a dose of 38.5 Gy in 10 once daily fractions given over 2 weeks
223701501|NCT03616626|RADIATION|Twice Daily APBI|Adjuvant 3D Conformal Accelerated Partial Breast Irradiation to a dose of 38.5 Gy in 10 twice daily fractions given over 1 week
223701502|NCT03616626|RADIATION|Whole Breast Irradiation|Adjuvant 3D Conformal Radiation Therapy to a dose of 50 Gy in 25 fractions over 5 weeks. Boost is given as 10 Gy in 5 fractions over one week to patients with high grade tumors or age younger than 50 years
223701503|NCT04195906|DRUG|Experimental: SNF472|Administered 3 times weekly by intravenous infusion through the hemodialysis machine in conjunction with the subject's hemodialysis sessions for 12 weeks
223701504|NCT04195906|DRUG|Placebo Comparator: Placebo|Administered 3 times weekly by intravenous infusion through the hemodialysis machine in conjunction with the subject's hemodialysis sessions fo 12 weeks
223701505|NCT04195906|DRUG|Experimatenl SNF472 (Open-label)|Administered 3 times weekly by intravenous infusion through the hemodialysis machine in conjunction with the subject's hemodialysis sessions for 12 weeks
223701506|NCT04418674|DRUG|Ketamine|in this group, patient will receive ketamine at 0.3mg/kg intravenously.
223701507|NCT04418674|DRUG|Fentanyl|In this group, the patients will receive fentanyl at 1.5mcg/kg intavenously.
223701508|NCT03746171|DIAGNOSTIC_TEST|Colonic polyp characterization by BLI|"All rectosigmoid \<5 mm polyps, regardless of the presence of larger polyps, will be characterized by BLI-assisted optical diagnosis by using BASIC criteria (neoplastic vs. non neoplastic) and will be included in polyp-level assessment.~The polyp characterization will be always performed and recorded without zoom magnification. In patients in which colonoscopy will be performed with endoscopes equipped with zoom magnification, the zoom will be eventually systematically applied and the characterization with zoom will be also recorded. The post-polypectomy surveillance intervals based on BLI will be calculated by using histology estimation performed without zoom for all patients. Only polyps characterized with high confidence will be included in the analysis; the high-confidence characterization rate will be calculated."
223701509|NCT03127046|DRUG|Aceclofenac|Oral single dose administration of aceclofenac 200mg
223701510|NCT03127046|DRUG|Esomeprazole|Oral single dose administration of aceclofenac 200mg
223701511|NCT03127046|DRUG|Aceclofenac and Esomeprazole|Oral single dose administration of aceclofenac 200mg and esomeprazole concomitant
223701512|NCT04725422|DRUG|Methotrexate|second-line treatment for children with CNO/CRMO after failure to respond to NSAIDs
223701513|NCT04725422|DRUG|Sulfasalazine|second-line treatment for children with CNO/CRMO after failure to respond to NSAIDs
223701514|NCT04725422|DRUG|Leflunomide|second-line treatment for children with CNO/CRMO after failure to respond to NSAIDs
223701515|NCT04725422|DRUG|Pamidronate|second-line treatment for children with CNO/CRMO after failure to respond to NSAIDs
223701516|NCT04725422|DRUG|Zoledronic acid|second-line treatment for children with CNO/CRMO after failure to respond to NSAIDs
223701517|NCT04725422|DRUG|Etanercept|second-line treatment for children with CNO/CRMO after failure to respond to NSAIDs
223701518|NCT04725422|DRUG|Adalimumab|second-line treatment for children with CNO/CRMO after failure to respond to NSAIDs
223701519|NCT04725422|DRUG|Certolizumab|second-line treatment for children with CNO/CRMO after failure to respond to NSAIDs
223701520|NCT04725422|DRUG|Infliximab|second-line treatment for children with CNO/CRMO after failure to respond to NSAIDs
223701521|NCT04725422|DRUG|Golimumab|second-line treatment for children with CNO/CRMO after failure to respond to NSAIDs
223701522|NCT04725422|DRUG|NSAID|first-line treatment
223701523|NCT02554695|DRUG|placebo|subcutaneous saline injection
223701524|NCT02554695|DRUG|denosumab|single subcutaneous injection of denosumab 60 mg
223701525|NCT00004488|DRUG|alendronate sodium|
223701526|NCT00004488|DRUG|calcium carbonate|
223701527|NCT00004488|DRUG|cholecalciferol|
223701528|NCT04467606|BEHAVIORAL|a discharge planning using the strategy of motivational interviewing|The experimental group will receive a discharge planning which use the strategy of motivational interviewing. The discharge planning will be provided individually at the following time points: before discharge, on post-discharge days 3, 7, 14, 21, 28, and then each month till one year.
223701529|NCT00428792|DRUG|Methylphenidate 20 mg long-acting capsules|
223701530|NCT04840004|DRUG|PVT-1|Since there is no specific dose range is available for testing the anti-tumor effects of PVT-1 in clinical trials settings, in the present study the dose of PVT-1 will be up-titrated 250/160/160 mg to maximum 1000/640/640 mg as described in study methodology section.
223701531|NCT03584360|DRUG|Betamethasone-Calcipotriene Topical|Comparison between betamethasone-calcipotriol and placebo
223701532|NCT03584360|DRUG|Betamethasone-Calcipotriene Topical|Comparison between betamethasone-calcipotriol and betamethasone
223701533|NCT03584360|DRUG|Betamethasone-Calcipotriene Topical|Comparison between betamethasone-calcipotriol and propionate de clobetasol
223701534|NCT01926015|BIOLOGICAL|RotaTeq™ (V260)|Live, oral, pentavalent vaccine containing 5 human-bovine reassortant rotavirus strains
223701535|NCT01926015|BIOLOGICAL|DTP-IPV|Diphtheria, tetanus, pertussis, inactivated polio vaccine used as part of the Japanese vaccination schedule
223701536|NCT00639678|DRUG|placebo|40 mg/kg intravenously, double dose (day 0 and 14), Group 3
223701537|NCT00639678|DRUG|raxibacumab|40 mg/kg intravenously, double dose (day 0 and 14), Group 1
223701538|NCT00639678|DRUG|placebo|40 mg/kg placebo, single dose (day 0), Group 4
223701539|NCT00639678|DRUG|raxibacumab|40 mg/kg intravenously, single dose, day 0, Group 2
223701540|NCT05938517|DRUG|Betahistine dihydrochloride|Each subject received single dosages of Betahistine (24 mg, 48 mg, 96 mg) for pharmacokinetic serum draw with at least two days between the different dosages.
223701541|NCT05938517|DRUG|Selegiline-hydrochloride|In the second period, each subject was pre-treated with Selegiline (5 mg/day) for one week and treated continuously with Selegiline (5 mg/day) in combination with the single dosages of Betahistine (24 mg, 48 mg, 96 mg) with at least two days between the different dosages.
223701542|NCT00897208|OTHER|high performance liquid chromatography|
223701543|NCT00897208|OTHER|laboratory biomarker analysis|
223701544|NCT00897208|OTHER|mass spectrometry|
223701545|NCT00897208|OTHER|medical chart review|
223701546|NCT00897208|PROCEDURE|evaluation of cancer risk factors|
223701547|NCT00536679|DRUG|GSK163090 capsule, fasted|GSK163090 will be available as 1 mg hard gelatine white/white opaque capsules. Each subject will receive a single, oral dose of the study medication on the morning of Day 1. The study drug will be administered with approximately 240 milliliters (mL) of water.
223782580|NCT01601574|OTHER|Standard Care group|One session of in-person diabetic nutritional counseling with a registered dietitian, with follow-up written educational materials.
223701548|NCT00536679|DRUG|GSK163090 Tablet, fasted|GSK163090 will be available as 1 mg white coated round tablet. Each subject will receive a single, oral dose of the study medication on the morning of Day 1. The study drug will be administered with approximately 240 mL of water.
223701549|NCT00536679|DRUG|GSK163090 Tablet, fed|GSK163090 will be available as 1 mg white coated round tablet. Each subject will receive a single, oral dose of the study medication on the morning of Day 1. The study drug will be administered with Food and Drug Administration (FDA) high fat breakfast.
223701550|NCT06398236|DIETARY_SUPPLEMENT|SE5-OH tablets|SE5-OH (Fermented Soy germ, include S-equol), Crystalline cellulose, Oats fiber, Agar, Cyclic oligosaccharide, HPMC, Reduced syrup.
223701551|NCT01364649|DRUG|Vortioxetine|Vortioxetine tablets
223701552|NCT01364649|DRUG|Escitalopram|Escitalopram tablets
223701553|NCT01364649|DRUG|Placebo|Vortioxetine Placebo-matching capsules
223701554|NCT04245852|OTHER|Strength education video|The Strength education video must be watched by the patient at the University of Illinois at Chicago Faculty Practice (UICFP) prior to leaving from the 3rd physical therapy visit. The Experimental Group (EG) will watch the video in the waiting room or other quiet available rooms on the 3rd floor within the UICFP. The video will be watched from an iPad/tablet/laptop/desktop computer device as available in the clinic. The EG will also be provided a handout with a link and quick response code to the video on YouTube.com
223701555|NCT04245852|OTHER|standard PT care|standard PT care
223701556|NCT04863040|BEHAVIORAL|MOVI intervention|"Each HIIT break will last approximately 5 minutes and will not require any specific materials. The structure of the HIIT-Rest will be as follows: 1' to describe the work to be done; 3' of work following the HIIT protocol: 6 repetitions of a functional movement such as squats, Jumping Jack or running on site for 10 at high intensity (85-90% of HR max) followed by 20 of recovery (65-75% of HR max); and 1' to perform a return to calm in order to lower the activation and prepare the student body to return to class activities. To increase the workload, and after evaluation of cardiorespiratory capacity, after 12 weeks of program, the HIIT protocol will be changed to 20 of high intensity work alternating with 10 of recovery."
223701557|NCT01566734|OTHER|Cefazolin irrigation|after the surgery and before closing up the patients, 2 grams of cefazolin in 5 cc of distilled water was used to irrigate the patients
223782581|NCT01155544|BEHAVIORAL|Behavioral Intervention|Preventing recurrence of substance use.
223701558|NCT01566734|OTHER|Normal Saline Irrigation|after the surgery and before closing up the patients, 150 cc of normal saline was used to irrigate the patients and in the last group
223701559|NCT02114671|DRUG|Faldaprevir high dose|capsules, oral
223701560|NCT02114671|DRUG|Placebo|capsule, oral
223701561|NCT02114671|DRUG|Ciprofloxacin|tablets, oral
223701562|NCT02114671|DRUG|Faldaprevir low dose|capsules, oral
223701563|NCT03692468|BEHAVIORAL|Psychotherapy|Participants will complete 5, 60 minutes sessions. At each session, participants will learn strategies that have been shown to improve pain functioning and/or mood for patients who have chronic pain. The intervention will be delivered in the patient's primary care clinic.
223701564|NCT02296281|DRUG|Pirfenidone|
223701565|NCT00972582|DIETARY_SUPPLEMENT|Leucine Increase|Graded stepwise increases in leucine intakes (50, 250, 500, 750, 1000, 1250 and 1500mg/kg/day)
223701566|NCT03299465|BEHAVIORAL|Yoga|This is a single arm study and all participants will be assigned to a six-week restorative yoga intervention. Restorative yoga sessions will consist of gentle physical poses (asanas), breathing control (pranayama), and relaxation (savasana).
223701567|NCT02938429|OTHER|Physical activity measures via Actigraph GT3X+ accelerometers for 7 consecutive days|
223701568|NCT02114801|DEVICE|manual brushing|Tooth brushing
223701569|NCT02114801|DEVICE|electric toothbrush linked|Tooth brushing
223701570|NCT02114801|DEVICE|off electric toothbrush|Tooth brushing
223701571|NCT02710396|DRUG|Pembrolizumab|"Pembrolizumab is a potent and highly selective humanized monoclonal antibody (mAb) of the immunoglobulin G4 (IgG4)/kappa isotype designed to directly block the interaction between PD-1 and its ligands, PD-L1 and PD-L2 (programmed cell death (PD) proteins).~Pembrolizumab 200 mg will be administered IV every 3 weeks."
223701572|NCT02710396|DRUG|Carboplatin|Carboplatin AUC (area under curve (AUC)) = 5 IV on day 1 every 3 weeks administered for 2 cycles concurrently with cycles 1 and 2 of pembrolizumab.
223701573|NCT02710396|DRUG|Nab-paclitaxel|Nab-paclitaxel 100 mg/m2 IV on days 1, 8 and 15 every 3 weeks administered for 2 cycles concurrently with cycles 1 and 2 of pembrolizumab.
223701574|NCT02710396|DRUG|Pemetrexed|Pemetrexed 500 mg/m2 IV administered for 2 cycles concurrently with cycles 1 and 2 of pembrolizumab.
223701575|NCT06516822|PROCEDURE|CPVI-MLA|The details include: (1) EI-VOM procedure: An 8.5-French-long sheath is inserted into to the CS via the femoral vein. A JR4 catheter is inserted into the CS to identify the ostium of the VOM. Subsequently, a guide wire supported by an OTW balloon catheter is advanced into the VOM. The balloon is inflated at 6-8 atm pressure in the VOM. Ethanol is infused into VOM from distal to proximal with 3ml each time within 1-2min. After the distal EI-VOM, the balloon is deflated and adjusted to the middle part of VOM. The EI-VOM procedure in the proximal and middle part of VOM should be the same as that in the distal. After three times of EI-VOM, the contrast is injected into VOM to make it permeable and dispersed to observe the effect of alcohol ablation. (2) After EI-VOM, radiofrequency ablation is performed to achieve bilateral PVI, PWI, bidirectional block of MI and CTI, disappearance of LAI-CS potential and SVCI. (3) Any organized AT observed during the procedure is targeted as well.
223701576|NCT06516822|PROCEDURE|CPVI only|After reconstructing the left atrial geometry, CPVI is performed. Radiofrequency ablation should be applied at least 1-2 cm outside of the PV ostia for PVI to achieve a wide PVI ring. The mapping catheter PentaRay will be used to confirm the complete isolation of the PV antrum when all PV potentials within each antrum are abolished. If the AF persists after CPVI, direct current cardioversion is then be conducted to restore sinus rhythm. If spontaneous AFL/AT occurs during ablation, ablation is performed targeting the focal or critical isthmus under the guidance of high-density activation mapping. The endpoint of CPVI is to achieve complete entrance and exit block of all PV antra as recorded by PentaRay during sinus rhythm or CS pacing.
223701577|NCT00889408|BIOLOGICAL|DT2219ARL|anti-CD19/CD22 bispecific ligand-directed toxin DT2219ARL
223701578|NCT03154593|OTHER|Stage 2 - Bariatric Surgery|This observational study follows patients after routine bariatric surgery.
223701579|NCT00818597|DEVICE|EISS|Two six hour-treatments with the EISS-Immune-cell bioreactor device within 72 hours post inclusion.
223701580|NCT00812669|BIOLOGICAL|pegfilgrastim|
223701581|NCT00812669|BIOLOGICAL|rituximab|
223701582|NCT00812669|DRUG|cyclophosphamide|
223701583|NCT00812669|DRUG|fludarabine phosphate|
223701584|NCT00812669|GENETIC|cytogenetic analysis|
223701585|NCT00812669|GENETIC|fluorescence in situ hybridization|
223701586|NCT00812669|GENETIC|gene expression analysis|
223701587|NCT00812669|GENETIC|mutation analysis|
223701588|NCT00812669|GENETIC|protein expression analysis|
223701589|NCT00812669|OTHER|flow cytometry|
223701590|NCT00812669|OTHER|laboratory biomarker analysis|
223701591|NCT02672280|DEVICE|Medical Collagen Membrane with MSC|
223701592|NCT02672280|DEVICE|Medical Collagen Membrane|
223701593|NCT01348607|DRUG|methylphenidate hydrochloride|Given orally
223701594|NCT01348607|DRUG|modafinil|Given orally
223701595|NCT01348607|DRUG|placebo|Given orally
223701596|NCT00493623|DRUG|Placebo|Placebo i.v. single dose
223701597|NCT00493623|DRUG|ibandronate [Bonviva/Boniva]|3mg i.v. single dose
223701598|NCT03652883|OTHER|ItFits-toolkit|The ItFits-toolkit provides evidence-informed methods, materials, knowledge on determinants and implementation strategies, and concrete guidance on tailoring implementation strategies to local determinants of practices, apply them and evaluate their impact. It applies a standardised four-step approach to iteratively develop evidence-informed implementation strategies. The ItFits-toolkit is based on the Normalisation Process Theory (NPT), which suggests that lasting changes in practice only happen through people working together. The ItFits toolkit functions as an online self-help toolkit with minimal support. The toolkit will provide instructions for the IL to establish a core team and to create a sounding board consisting to enable co-creation.
223701599|NCT03652883|OTHER|Implementation as Usual|IAU refers to any existing efforts to embed and integrate iCBT within an organisation.
223701600|NCT02081131|PROCEDURE|Open surgery|pancreatic head resection by open method
223701601|NCT02081131|PROCEDURE|Laparoscopic surgery|laparoscopic pancreatoduodenectomy
223701602|NCT06181591|DRUG|Mirabegron 50 MG|Mirabegron (IP: Hibero) is a beta-3 adrenergic agonist used to treat overactive bladder (OAB) and neurogenic detrusor overactivity (NDO). It is used to relax the smooth muscle of the bladder in the treatment of urinary frequency and incontinence. Through a 8 weeks clinical trial, it aims to evaluate the efficacy and safety of Hibero (Mirabegron), especially in maximum voided volume.
223701603|NCT06181591|DRUG|Oxybutynin Chloride 5 MG|Oxybutynin has been used to treat overactive bladder (OAB). The subject will take 5 mg of Ditropan (Oxybutynin Chloride) twice a day, in total of 10 mg for 8 weeks.
223701604|NCT00529984|BIOLOGICAL|AVX701|4 doses of AVX701 at 4e7 IU given at T=0, 3, 6, 9 weeks. Option for subjects to receive additional immunizations every 3 months after the 4th immunization if no dose-limiting toxicities or is without progressive disease
223701605|NCT00529984|BIOLOGICAL|AVX701|4 doses of AVX701 at 1e8 IU given at T=0, 3, 6, 9 weeks. Option for subjects to receive additional immunizations every 3 months after the 4th immunization if no dose-limiting toxicities or is without progressive disease
223701606|NCT00529984|BIOLOGICAL|AVX701|4 doses of AVX701 at 4e8 IU given at T=0, 3, 6, 9 weeks. Option for subjects to receive additional immunizations every 3 months after the 4th immunization if no dose-limiting toxicities or is without progressive disease
223701607|NCT00529984|BIOLOGICAL|AVX701|4 doses of AVX701 given at the maximally tolerated dose at T=0, 3, 6, 9 weeks. Option for subjects to receive additional immunizations every 3 months after the 4th immunization if no dose-limiting toxicities or is without progressive disease
223701608|NCT00529984|BIOLOGICAL|AVX701|4 Doses of AVX701 given to Stage III colon cancer subjects at the maximally tolerated dose at T=0, 3, 6, 9 weeks. There will be no option for subjects to receive additional immunizations.
223701609|NCT05722093|DRUG|Manzi Guben granules|Administration cycle of Manzhi Guben granules: 1-4 weeks; Usage: 10g once, twice a day, washed with boiling water.
223701610|NCT04292769|DRUG|Decitabine|Decitabine 10mg / d, intravenous administration d-5 ～ d-1
223701611|NCT04292769|BIOLOGICAL|DC-CIK|Autologous DC-CIK cell infusion: the first course: d1-d3, the second course: d14-d16; the total number of cells is about 5-10 × 109;
223701612|NCT01877018|BEHAVIORAL|electronic reminder|Electronic reminder introduced into primary care medical health record, identifying invited people to the population-based colorectal cancer screening program, to promote their participation.
223701613|NCT05707936|DRUG|Normal Saline Flush 20 ml|Normal Saline Flush 20 ml
223701614|NCT05707936|DRUG|Normal Saline Flush 10 ml|Normal Saline Flush 10 ml
223701615|NCT05707936|DRUG|Heparin Flush (1000 USP, 10ml)|Heparin Flush (1000 USP, 10ml)
223701616|NCT00812747|OTHER|observation|
223701617|NCT04812730|OTHER|2D versus 3D analysis of EOS stereo radiographic analysis|The use of EOS stereo radiographic analysis and health related quality of life scores to measure the distance of the center of acoustic meati in the transversal plane with respect to the gravity line
223701618|NCT04812730|OTHER|Static versus dynamic analysis|The use of clinical postural tests and instrumented movement analysis to evaluate the importance of muscle fatigue and compensation mechanisms
223701619|NCT04812730|OTHER|Pre- versus postoperative analysis|The use of EOS stereo radiographic imaging and motion analysis to understand the compensation mechanisms in trunk, pelvis and lower limbs and the correlation between primary and secondary mechanisms.
223701620|NCT04812730|OTHER|Reliability of the dynamic evaluation|Repeated measurements of the different aspects of the dynamic evaluation protocol (strenght measurements of trunk muscles, balance evaluation and movement analysis) will serve to evaluate the test-retest reliability and intra-rater reliability of the different protocols
223701621|NCT05698056|OTHER|No intervention.|No intervention.
223701622|NCT01039844|DRUG|LOC-paclitaxel|"Phase I Starting Dose: 100 mg/m\^2 IV (intravenously) 1 hour infusion on Day 1, 8, 15, 22 and 29; and repeated every 42 days (6 weeks) per cycle.~Phase II Starting Dose: Maximum tolerated dose from Phase I."
223701623|NCT00336154|DRUG|tetracyclin|
223701624|NCT04027829|DRUG|Dexmedetomidine Hydrochloride|Intravenous infusion of dexmedetomidine at the rate of 0.5mcg/kg for 10 min, then 0.5mcg/kg/hr for 50 min.
223701625|NCT05813145|DRUG|Placebo|25 patients will receive four cycle of AC followed by paclitaxel 80 mg/m2 weekly for 12 week
223701626|NCT05813145|DRUG|Fenofibrate 160mg|25 patients will receive four cycle of AC followed by paclitaxel 80 mg/m2 weekly for 12 week in addition to 160mg fenofibrate once daily for 3 month.
223701627|NCT03048474|DRUG|nivolumab and ipilimumab|
223701628|NCT01455831|DRUG|Tinzaparin|The experimental arm will receive a subcutaneous injection of 4,500 IU of tinzaparin daily beginning at randomization and continued for 56 days following resection. There will be a minimum of one dose of pre-operative LMWH since it is not reasonable to delay surgery for the purpose of administering LMWH. The maximum duration of pre-operative LMWH will be 6 weeks.
223701629|NCT01455831|DRUG|Tinzaparin|The control arm will receive a daily subcutaneous injection of 4,500 IU of tinzaparin beginning with the first post-operative dose and continued for the duration of hospitalization.
223701630|NCT02817074|BEHAVIORAL|MIND Diet|3-year dietary counseling to adhere to the MIND diet and for mild weight loss
223701631|NCT02817074|BEHAVIORAL|Mild Weight Loss|3-year dietary counseling to reduce calorie intake by 250 kcal/day for mild weight loss
223701632|NCT05203289|DRUG|BI 695501 - higher concentration|BI 695501 - higher concentration
223701633|NCT05203289|DRUG|BI 695501 - lower concentration|BI 695501 - lower concentration
223701634|NCT02248831|DEVICE|Recording Doppler ultrasound signals noninvasively|Using ultrasound noninvasively and recording Doppler signals from the right chest wall
223701635|NCT02556658|DEVICE|General anesthesia managed by the Smartpilot® View|General anaesthesia managed by the Smartpilot® View device The intervention consists of administering hypnotics and opioids according to effect-site concentrations and interaction model provided by the Smartpilot® View software for the entire duration of general anaesthesia.
223701636|NCT02556658|DEVICE|General anesthesia managed without the Smartpilot® View|General anaesthesia without using the Smartpilot® View device The anesthetic induction will be performed by propofol or sufentanil and atracurium. The maintenance of anesthesia will be directed by desflurane and sufentanil. The dosages of anesthetics are left to the discretion of the doctor and nurse anesthetists in charge of the patient in the operating room.
224263739|NCT04478370|BIOLOGICAL|Mosquito bites|"Participants will be exposed to mosquito bites.~For the low-dose challenge, five 5 to 7-day-old nulliparous female imagoes (i.e. that have never blood fed before) will be introduced individual into 50 mL plastic tube covered with netting material.~For high-dose challenge, 47 mosquitoes will be split into four plastic cups of 10 cm in diameter covered with netting material (three cups with 12 mosquitoes and one cup with 11 mosquitoes), and 3 mosquitoes will be introduced individually into 50 mL plastic tubes.~Mosquito bites administered on participant's arm will be used to assess immediate and delayed skin reactions. Immediate and delayed skin reactions will be recorded respectively 20-30 min and 24-36 hours after the day 14 and day 21 challenges, requiring additional visits at day 15 and 22."
223701637|NCT00444652|DRUG|Enoxaparin|injection of enoxaparin a few time
223701638|NCT05879601|OTHER|immediate orthodontic retainer delivery|post orthodontic treatment patients will be given orthodontic retainer immediately after debonding.
223701639|NCT05879601|OTHER|delayed orthodontic retainer delivery.|post orthodontic treatment patients will be given orthodontic retainer after 24 hours of debonding.
223701640|NCT00659360|DRUG|saracatinib|Given orally
223701641|NCT03285672|DRUG|FP-101|Dose 1
223701642|NCT03285672|DRUG|Placebo Comparator|Dose 1
223701643|NCT04761510|BEHAVIORAL|Mindfulness-SOS for Refugees|Mindfulness-SOS for Refugees is a brief internet-based mobile-supported intervention program which is a mobile-health adaptation of MBTR-R - a mindfulness- and compassion-based, trauma-sensitive, and socio-culturally adapted group intervention program designed for FDPs. Mindfulness-SOS for Refugees entails 8 brief sessions and 9 mindfulness meditation practice exercises - delivered via audio recordings using participants' smartphones. The intervention program is specifically designed to mitigate acute stress and related mental health symptoms among FDPs. During participation in the Mindfulness-SOS for Refugees intervention program, participants will be encouraged to complete 2 sessions per week and practice each day for 4 weeks but can choose to extend this up to 8 weeks. Delivery of Mindfulness-SOS for Refugees entails administrative guidance as well as adherence-focused guidance.
223701644|NCT02239354|COMBINATION_PRODUCT|VC-01™ Combination Product|Biologic and Device
223701645|NCT02056639|DEVICE|Bioteque cup pessary|
223701646|NCT03352973|OTHER|active tDCS on the dlPFC|During active tDCS session, participants will perform the regulation of craving (ROC) and emotion regulation (ER) tasks. In the ROC task, participants will downregulate and upregulate craving elicited by gaming pictures using cognitive reappraisal. In the ER task, participants will downregulate and upregulate aversive feelings by negative pictures using cognitive reappraisal. After the active tDCS session, participants will complete a cognitive task assessing inhibitory control of attentional bias, in which participants will perform a number classification task with gaming pictures and non-gaming pictures being distractors. During the task, reaction times (RTs) wil be recorded.
224263740|NCT06999720|DRUG|HX15001 (SAD)|Part A (Single Ascending Dose), participants will receive a single intravenous dose of HX15001 at escalating dose levels in sequential cohorts (Cohorts 1-7).
224263741|NCT06999720|DRUG|Placebo|Participants will receive matching placebo across cohorts 1-7 of the study.
224263742|NCT06999720|DRUG|HX15001 (MAD)|In Part B (Multiple Ascending Dose), participants will receive multiple intravenous doses of HX15001 in cohorts 8 and 9 to assess safety, tolerability, and pharmacokinetics.
224263743|NCT06999720|DRUG|Placebo|Participants will receive matching placebo across cohorts 8-9 of the study.
224263744|NCT03756272|PROCEDURE|Bupivacaine block|stellate ganglion bupivacaine injection
224263745|NCT03756272|PROCEDURE|Placebo ganglion block|stellate ganglion sodium chloride injection
224263746|NCT01369368|DRUG|Combined use of azacitidine, valproic acid, hydroxurea and eventually donor leukocyte infusions.|Azacitidine 100 mg day 1-3 in each cycle Valproic acid, continuous therapy from day 1 All-trans retinoic acid 22.5 mg/m2 twice daily day 1-14 in each cycle Hydroxurea 500 mg initially eventually increased to 1 g daily. Eventually donor leukocyte infusions on day 10 from the second cycle.
224263747|NCT00725322|DRUG|Botulinum Toxin A|Subcutaneous injection of Botulinum Toxin Type A into the patient's scar tissue
224263748|NCT00725322|DRUG|Placebo - Saline|Subcutaneous Saline injection given at site of scar neuroma
224263749|NCT03835767|OTHER|Peanut powder and Oat flour|Peanut powder with 46% protein content is manufactured by PB2. Oat flour is manufactured by GF Harvest.
224263750|NCT03835767|OTHER|Peanut flour and Oat flour (placebo for peanut flour)|Peanut flour (12% light roast) with 50% protein content is manufactured by Byrd Mill. Oat flour is manufactured by GF Harvest.
224263751|NCT03835767|OTHER|Dry Milk Powder and Corn Starch (placebo for Milk powder)|Dry milk powder with 36% protein content is manufactured by Giant Food. Corn starch is Argo brand.
224263752|NCT03835767|OTHER|Baked milk and Rice milk (placebo for Baked milk)|Baked milk will be in the form of a muffin provided by the NIH CC Nutrition Department. Rice milk is manufactured by Rice Dream brand.
224263753|NCT01318369|DRUG|Namisol|Single dose delta-9-tetrahydrocannabinol
224263754|NCT01318369|DRUG|Diazepam|Diazepam single dose 5mg in subgroup non-opioid users and 10 mg in subgroup opioid users.
224263755|NCT01125072|OTHER|Echocardiography with strain analysis|Clinical routine echocardiogram with additional off line strain analysis
224263756|NCT07128082|DRUG|Tirzepatide|The treatment group will receive the study medication (tirzepatide) for a 12 month period starting with a 2.5mg dose once a week.
224263757|NCT07128082|DRUG|Placebo|Participants in the control group will receive a placebo instead of active study medication for a 12 month period.
224263758|NCT06867822|DRUG|ProAgio|ProAgio is a pegylated protein with a single pegylated site. The 12,131 Dalton protein is produced in E. coli and is composed of 105 amino acids with no disulfide bonds. The structure of the polyethylene glycol moiety is Methoxy PEG maleimide 30000.
224263759|NCT06867822|DRUG|FOLFIRI|FOLFIRI is a combination of three drugs: (leucovorian, fluorouracil, and irinotecan) used to treat advanced metastatic colorectal cancer. FOLFIRI is commercially available will be administered using standard dosing regimen as per institutional guidelines.
223701647|NCT03352973|OTHER|sham tDCS on the dlPFC|During the sham tDCS session, participants will perform the regulation of craving (ROC) and emotion regulation (ER) tasks. In the ROC task, participants will downregulate and upregulate craving elicited by gaming pictures using cognitive reappraisal. In the ER task, participants will downregulate and upregulate aversive feelings by negative pictures using cognitive reappraisal. After the sham tDCS session, participants will complete a cognitive task assessing inhibitory control of attentional bias, in which participants will perform a number classification task with gaming pictures and non-gaming pictures being distractors. During the task, reaction times (RTs) wil be recorded.
223701648|NCT04157543|OTHER|electroacupuncture|acupuncture with electricity
223701649|NCT02664259|PROCEDURE|VBN|VBN is carried out by a VBN software（DirectPath;Olympus,Japan) which can automatically create virtual bronchoscopic images.
223701650|NCT02664259|PROCEDURE|EBUS|EBUS is performed using an endoscope ultrasound system , which is equipped with a 20-MHz mechanical radial-type probe (UM-S20-17S;Olympus) with an external diameter of 1.4 mm.
223701651|NCT02664259|PROCEDURE|X-ray|The radiograph fluoroscopy is performed when the probe is confirmed to reach the lesion by EBUS image ,cytologic and pathologic specimens are obtained under fluoroscopic guidance.
223701652|NCT00224705|DEVICE|Molecular Adsorbent Recirculating System (MARS®)|
223701653|NCT02280070|OTHER|Laboratory test|Leukocyte, neutrophil (ANC ：stab + seg), hemoglobin, platlet, albumin, total birrilubin, AST, ALT, LDH, Creatinine, Na, K, CRP, fast blood sugar
223701654|NCT02280070|OTHER|Medical history and physical examination|medical history and physical examination
223701655|NCT02280070|OTHER|BW and height|Body weight (kg) and height (cm)
223701656|NCT02280070|OTHER|Performance status|ECOG performance status, 0: Fully active, able to carry on all pre-disease performance without restriction, 1: Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work, 2: Ambulatory and capable of all selfcare but unable to carry out any work activities. Up and about more than 50% of waking hours, 3: Capable of only limited selfcare, confined to bed or chair more than 50% of waking hours, 4: Completely disabled. Cannot carry on any selfcare. Totally confined to bed or chair, 5: Dead
223701657|NCT02280070|OTHER|Creatinine clearance|Creatinine clearance (CCr, mL/min) was estimated by Cockcroft \& Gault method using serum creatinine (mg/dL), age and body weight (kg).
223701658|NCT02280070|OTHER|Biomarker|Carcinoembryonic antigen and carbohydrate antigen 19-9
223701659|NCT02280070|RADIATION|Contrasting CT|Computed tomography
223701660|NCT02280070|OTHER|Adverse event|AE was evaluated using Common Terminology Criteria for Adverse Events (CTCAE v4.0).
223701661|NCT02280070|OTHER|HBs antigen and HCV antibody|check for exclusion criteria
223701662|NCT02280070|OTHER|Endoscopy|Endoscopy for lower digestive tract
223701663|NCT02280070|OTHER|HBs antibody and HBc antibody|Check according to hepatitis B guideline
223701664|NCT02280070|DRUG|S-1|S-1 (80 mg/m2, p.o.) is administered at day 1 -14 of the course and repeated every 3 weeks until 4 courses or meet discontinuation criteria.
223701665|NCT02280070|DRUG|L-OHP (130mg/m2)|L-OHP (130mg/m2 intravenously) is administered at day 1 of the course and repeated every 3 weeks until 4 courses or meet discontinuation criteria.
223701666|NCT02280070|DRUG|L-OHP (85 mg/m2)|L-OHP (85mg/m2) is administered by IV infusion drip for 2hr at day 1 of the course and repeated every 2 weeks until 6 courses or meet discontinuation criteria.
223701667|NCT02280070|DRUG|l-LV|l-LV (200 mg/m2) is administered by IV infusion drip for 2hr at day 1 of the course and repeated every 2 weeks until 6 courses or meet discontinuation criteria.
223701668|NCT02280070|DRUG|5-FU|5-FU (400 mg/m2) by bolus IV administration just after the L-OHP and l-LV administration. 5-FU (2,400 mg/m2) by IV continuous infusion for 46 hours using infuser pump afterwards and repeated every 2 weeks until 6 courses or meet discontinuation criteria.
223701669|NCT04768075|DRUG|Camrelizumab|Camrelizumab is a humanized anti-PD1 IgG4 monoclonal antibody
223701670|NCT04768075|DRUG|Placebo|IV infusion Simulator of Camrelizumab
223701671|NCT04768075|DRUG|Cisplatin|IV infusion
223701672|NCT04768075|DRUG|Carboplatin|IV infusion
223701673|NCT04768075|DRUG|Pemetrexed|IV infusion
223701674|NCT04768075|DRUG|Paclitaxel|IV infusion
223701675|NCT04768075|DRUG|Albumin paclitaxel|IV infusion
223701676|NCT05737849|OTHER|No Intervention|As this is an observational study, no intervention will be administered in this study.
223701677|NCT04066647|DRUG|Dexamethasone 4mg|1 mg IV dexamethasone will be pushed and miRNA levels will be checked at baseline just before injection and then at 15, 30, 45, and 60 minutes after injection.
223701678|NCT04172623|BEHAVIORAL|Real-Time Smoking Intervention|Adult smokers will use wearable technology in order to receive real-time feedback as a smoking intervention in addition to standard treatment.
223701679|NCT04172623|BEHAVIORAL|Standard Treatment|Adult smokers will receive standard outpatient tobacco treatment.
223701680|NCT03368534|DEVICE|Autologous Regenerative Technology (ART)|ART device with single-needle, fluid-assisted skin tissue harvesting technology.
223701681|NCT01250431|BEHAVIORAL|EFT (Emotional Freedom Techniques)|10 EFT sessions
223701682|NCT01209507|OTHER|Chemotherapy|This study is designed only to look at the prevalence of adrenal suppression during chemotherapy. If adrenal suppression is detected, treatment will be off-study at the treating physician's discretion.
223701683|NCT04962620|DRUG|Bovhyaluronidase azoximer|Rectally or vaginally 1 suppository of Longidaze every 2 days. The main course of treatment - 10 suppositories (for 30 days). Then (according to the doctor's decision) supportive therapy is prescribed for 1 suppository 1 time in 7 days. Course of supportive treatment - 17 suppositories for another 120 days. The patients took dienogest according to the instructions for use.
223701684|NCT01914757|BIOLOGICAL|Benralizumab|Benralizumab subcutaneously on study week 0 until study week 52 inclusive.
223701685|NCT01914757|BIOLOGICAL|Placebo|Placebo subcutaneously on study week 0 until study week 52 inclusive.
223701686|NCT00050271|DRUG|Acetyl-L-carnitine|
223701687|NCT04224038|OTHER|The Inspire Bio-resource Research Platform for Healthy Aging|Several follow-up visits will be undertaken during the 10-year time frame of this project. Some of these visits are not regularly scheduled and will be conditioned by the remote monitoring of intrinsic capacity (IC) and the onset of other major clinical conditions. Other visits correspond to the regularly scheduled (yearly or every two years (biannual visits), depending on the outcome measures) waves of data collection.
223701688|NCT02973490|DEVICE|Transanal Tube Drainage|Using transanal tube drainage after colorectal ESD
223701689|NCT01069016|PROCEDURE|Sacral nerve modulation|For one week the sacral nerve is continuously stimulated by an external pulse generator. Strength of stimulation can be adjusted by the patient.
223701690|NCT01069016|PROCEDURE|Pudendal nerve stimulation|For one week the pudendal nerve is continuously stimulated by an external pulse generator. Strength of stimulation can be adjusted by the patient.
223701691|NCT01499758|DRUG|Atorvastatin|80 Mg tablets
223701692|NCT03509883|DRUG|Drug: Apixaban sprinkle capsules|Single dose (25 x 0.1 mg capsules), oral administration
223701693|NCT03509883|DRUG|Experimental: Apixaban tablets followed by apixaban sprinkle capsules|Apixaban sprinkle capsules Single dose (25 x 0.1 mg capsules), oral administration
223701694|NCT00333177|BEHAVIORAL|Cognitive remediation training (CT)|Cognitive remediation training includes computerized cognitive training plus learning skills group.
223701695|NCT00333177|BEHAVIORAL|Healthy behavior training (HBT)|Healthy behavior training includes group skills training in nutrition, exercise, and relaxation.
223701696|NCT00333177|DRUG|Risperidone, administered orally (Oral Ris)|Oral risperidone at dosage judged optimal by treating psychiatrist
223701697|NCT00333177|DRUG|Risperidone, administered via injection (RLAI)|Risperidone in injectable form every 2 weeks, starting with 25 mg and adjusted as needed
223701698|NCT03564431|DEVICE|Magnetic resonance|magnetic resonance spectrum of brain
223701699|NCT04799574|OTHER|music therapy activities|"Music therapy activity course design (Protocol):~The researchers in this study are the leaders of the activities and the nurses who had completed training in music therapy courses and obtained a senior music activity leadership certificate and qualification, such as books and internship certificates. The course design uses the percussion music theory and Dalcroze and Orpff music pedagogy to plan activities, as follows:~Each class in the music therapy activity course design has a fixed process. The 90-minute course includes 10-15 minutes of warm-up activities, 50-60 minutes of main activities, 10-15 minutes of recovery activities, and 10 minutes of rest for the elders in the middle. The content of the weekly main activities uses different music, musical instruments, props, or rhythms to lead the rhythm music activities."
223701700|NCT02884882|OTHER|Emotional induction|Score (from 1 to 10) rated the felt for each target emotions for the following 6 dimensions: joy, sadness, fear, disgust, anger, no emotion, after the presentation of short sequences of standardized films.
223701701|NCT03278756|BEHAVIORAL|Cognitive control training|10 sessions of an adaptive paced auditory serial addition task, each lasting 15 minutes, over the course of two weeks.
223701702|NCT03278756|BEHAVIORAL|Active control training|10 sessions of an low cognitive load task, each lasting 15 minutes, over the course of two weeks.
223701703|NCT04212871|OTHER|watch food video 1|A 2 minutes video, with food content. The first study used a ramen mukbang here, the second study used a hotpot mukbang.
223701704|NCT04212871|OTHER|watch food video 2|A 2 minutes video, with food content (different content from video 1). The first study used a donut mukbang here, the second study used a hotpot cooking show here.
223701705|NCT04212871|OTHER|watch a non-food content video|a 2 minutes video without food content. The first study used a documentary introducing the forbidden city, the second study used a documentary introducing Cornell University.
223701706|NCT04524806|OTHER|stabilization splint|Stabilization splint is an appliance which applied to upper or lower jaw and regulating the occlusal forces in the temporomandibular joint that can cause disorders, also preventing excessive contraction of the masticatory muscles
223701707|NCT00004195|DRUG|eniluracil|Will be given to either subject pre-operative and metastatic disease
223701708|NCT00004195|PROCEDURE|conventional colon surgery|Only if the subject is amenable to surgical resections
223701709|NCT00628485|DEVICE|BION|"The second group will have a High Stimulation paradigm at a frequency that produces strong, fused contractions (20-30pps) for a total of 1h/d, also in two spaced sessions. Stimulation intensity will be adjusted to produce the strongest contractions that are tolerated."
223701710|NCT00628485|DEVICE|BION|"The first group will have a stimulation paradigm employing low-frequency (1-5 pps), supramaximal twitch stimulation. The period of the stimulation will probably be short for the first sessions as the muscles gain strength and fatigue resistance, but will eventually be 60 minutes per day in two spaced sessions of about 30 minutes each."
223701711|NCT00628485|DEVICE|BION|A third group of experimental subjects will have a standardized program of voluntary swallowing exercises. Their BIONs will not be activated until they have worsening of dysphagia, and thus are considered to have failed conventional therapy.
223701712|NCT05116215|DRUG|Hydrogen|Hydrogen supplement
224263760|NCT06867822|DRUG|Bevacizumab|Bevacizumab is a recombinant humanized monoclonal antibody that blocks angiogenesis by inhibiting vascular endothelial growth factor A (VEGF-A). Bevacizumab is commercially available and will be administered using standard dosing regimen as per institutional guidelines.
224263761|NCT02818842|OTHER|Primary Health Insurance Fund data|"Data collected are:~* First and last name of mother~* Age~* Mother's date of birth~* Theorical date of beginning of pregnancy~* Childbirth date"
224263762|NCT02818842|OTHER|Prenatal Diagnostic Center of Toulouse University Hospital data|"Data collected are :~* First and last name of the mother~* Mother's birth date~* Mother Obstetric history~* Course of pregnancy~* Drug exposure (name, decision period)~* Medical termination of pregnancy (date, cause ...)~* Malformations (description, test results, gender of the child,~* Weight, height and head circumference, American Pediatric Gross Assessment Record, neonatal pathology)."
224263763|NCT02818842|OTHER|Mother and child protection data collection|"Date collected are :~* Name and surname of Mother~* Date of birth of the mother~* Obstetric history of the mother (the first certificate to 8 days)~* Course of pregnancy (1st certificate to 8 days)~* Birth data (1 certificate to 8 days)~* Child gender,~* Age of the child at the time of the review,~* Weight, height and head circumference of the child~* American Pediatric Gross Assessment Record (1 certificate to 8 days)~* Neonatal diseases (1 certificate to 8 days)~* Birth defects (1 certificate to 8 days)~* Death (age at death)~* History (certificates at 9 and 24 months)~* Current diseases (certificates at 9 and 24 months)~* Psychomotor development (certificates at 9 and 24 months).~* Date of drugs issue~* Amount of drug issued~* Type of feeding (1 certificate to 8 days)"
224263764|NCT02818842|OTHER|Medicalisation Program of Information Systems data|"Data collected are :~* First and last name of the mother~* Mother's birth date~* History of abortions (date and cause)"
224263765|NCT06036134|BEHAVIORAL|Baseline surveys|Baseline surveys contained a series of scaled questions, including sociodemographic variables (age, gender, income, education level, relationship to the child), parental COVID-19 vaccine hesitancy, intentions to vaccinate child against COVID-19, and parents' attitudes, perceived norms, and perceived behavioral control about vaccinating their child against COVID-19,
223701713|NCT05619250|BEHAVIORAL|Unsupervised home-based exercise group without motivational intervention (UNSUP)|UNSUP will receive a non-supervised physical exercise intervention using a mobile app at home. The UNSUP training program comprises the same exercise structure and is based on the same muscle groups and movements as the supervised groups, but is adapted to be performed at home with the use of elastic bands and the participant's own body weight. The exercise program will be divided into 3 different levels. Each level will contain 3 different sessions including 10 warm-up and joint mobility exercises, 1 balance exercise, 7 strength exercises, 2 aerobic exercises, and 6 flexibility exercises. This multicomponent training will be performed 3 times per week (60 min/session) for 24 weeks.
223701714|NCT05619250|BEHAVIORAL|Unsupervised home-based exercise group with motivational intervention (UNSUP+)|UNSUP+ will receive a non-supervised physical exercise intervention using a mobile app at home. The UNSUP+ training program comprises the same exercise structure and is based on the same muscle groups and movements as the supervised groups, but is adapted to be performed at home with the use of elastic bands and the participant's own body weight. The exercise program will be divided into 3 different levels. Each level will contain 3 different sessions including 10 warm-up and joint mobility exercises, 1 balance exercise, 7 strength exercises, 2 aerobic exercises, and 6 flexibility exercises. This multicomponent training will be performed 3 times per week (60 min/session) for 24 weeks. Further, motivational strategies will be applied based on self-determination theory.
223701715|NCT05619250|BEHAVIORAL|Supervised center-based exercise group without motivational intervention (SUP)|SUP will attend the university facilities and will perform training in small groups, being supervised by an exercise professional. The SUP training program comprises the same exercise structure and is based on the same muscle groups and movements as the unsupervised groups, but is performed in a center using the equipment available at the facility (weight machines, free weight, stationary bikes, etc.). The exercise program will be divided into 3 different levels, progressing the difficulty every 8 weeks. Each level will contain 3 different sessions including 10 warm-up and joint mobility exercises, 1 balance exercise, 7 strength exercises (for upper and lower limbs), 2 aerobic exercises, and 6 flexibility exercises. This multicomponent training will be performed 3 times per week (60 min/session) for 24 weeks.
223701716|NCT05619250|BEHAVIORAL|Supervised center-based exercise group with motivational intervention (SUP+)|SUP+ will attend the university facilities and will perform training in small groups, being supervised by an exercise professional. The SUP+ training program comprises the same exercise structure and is based on the same muscle groups and movements as the unsupervised groups, but is performed in a center using the equipment available at the facility (weight machines, free weight, stationary bikes, etc.). The exercise program will be divided into 3 different levels, progressing the difficulty every 8 weeks. Each level will contain 3 different sessions including 10 warm-up and joint mobility exercises, 1 balance exercise, 7 strength exercises (for upper and lower limbs), 2 aerobic exercises, and 6 flexibility exercises. This multicomponent training will be performed 3 times per week (60 min/session) for 24 weeks. Further, motivational strategies will be applied based on self-determination theory.
223701717|NCT05862831|BIOLOGICAL|PM1003 Injection|Subjects will receive PM1003 by intravenous administration.
223701718|NCT00386386|OTHER|hypodermoclysis via recombinant hyaluronidase-facilitated subcutaneous infusion|Above
223701719|NCT00376064|DRUG|Octreotide acetate and cabergoline/Octrotide and Somavert|
223701720|NCT01426438|DRUG|Niacin|Extended-release niacin will be given with aspirin 325 mg by mouth in the evening and dose-escalated as follows: 500 mg once daily for 4 weeks, 1000 mg once daily for 4 weeks, then 1500 mg once daily for 16 weeks (through week 24)
223701721|NCT01426438|DRUG|Aspirin|Aspirin 325 mg will be given by mouth in the evening with extended-release niacin through week 24.
223701722|NCT01426438|DRUG|Fenofibrate|Fenofibrate will be administered as 200 mg by mouth once daily for 24 weeks.
223701723|NCT00384657|DRUG|iron sucrose|"Patients in Group I will receive iv iron sucrose, as described in the study protocol.~Patient in Group II will receive conventional treatment for chronic heart failure."
223701724|NCT03265301|PROCEDURE|Hysteroscopy|Includes Video set up, mini-hysteroscope system, continuous inflow and outflow, rod lens or fiber optic lens Zero to 30 degree angle and mechanical instruments (Scissors,Graspers , Cup biopsy forceps and bipolar instruments)
223701725|NCT03265301|PROCEDURE|Office hysteroscopy|will be done in out patient clinic without anesthesia
223701726|NCT03265301|PROCEDURE|Conventional hysteroscopy|will be done in operative room under general anesthesia
223701727|NCT02833350|DRUG|GDC-0853|Participants will receive GDC-0853 at low, mid, or high doses, orally once or twice daily for 12 weeks in Cohort 1 or 2.
223701728|NCT02833350|DRUG|Adalimumab|Participants will receive adalimumab, subcutaneously Q2W starting on Day 1 for 12 weeks.
223701729|NCT02833350|DRUG|Folic Acid|Participants will receive stable background therapy of folic acid of at least 5 mg total dose weekly (or equivalent) as per investigator's discretion.
223701730|NCT02833350|DRUG|MTX|Participants will receive stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week are allowed only if there is clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines).
223701731|NCT02833350|DRUG|Placebo|Participants will receive placebo matched to adalimumab, subcutaneously Q2W and/or placebo matched to GDC-0853, orally once or twice daily for 12 weeks in Cohort 1 or 2.
223701732|NCT02550262|DRUG|Bupivacaine|0.0625% Bupivacaine plus fentanyl 2mcg/ml
223701733|NCT02550262|DRUG|Fentanyl|0.0625% Bupivacaine plus fentanyl 2mcg/ml
223701734|NCT02550262|DEVICE|Infusion pump|Infusion pump set to deliver programmed intermittent epidural boluses (PIEB) plus patient-controlled epidural analgesia (PCEA).
223701735|NCT06166485|OTHER|take a bath|The effects of two different bathtub bath methods on physiological parameters will be compared in babies divided into 2 different groups.
223701736|NCT01691274|DRUG|PF-04895162|Tablets, 300 mg, single, 1 day
223701737|NCT01691274|DRUG|PF-04895162|Tablets, 300 mg, twice a day, 14 days
223701738|NCT01691274|DRUG|PF-04895162|Tablets, to be decided, twice a day, 14 days
223701739|NCT01691274|DRUG|Placebo|Tablets, twice a day, 14 days
223701740|NCT05809882|DEVICE|"Magstim RAPID2 neuromagnetic stimulator (Magstim) with an 8-type coil"|frequency range, 20 Hz; 90% motion threshold; 3 s of stimulation; a 57 s interval; 15 min of stimulation for each side, five times per week for a total of 20 times
223701741|NCT05809882|DEVICE|"Magstim RAPID2 neuromagnetic stimulator (Magstim) with an 8-type coil"|frequency range, 20 Hz，60% motion threshold; 3 s of stimulation; a 57 s interval; 15 min of stimulation for each side, five times per week for a total of 20 times. But with no stimulating energy output.
223701742|NCT06468852|PROCEDURE|Goal-Directed Fluid Therapy|Stroke volume variation (SVV)≤12% and cardiac index (CI)≥2.5L/min/m2 are the goals of Goal-Directed fluid therapy, while the mean arterial pressure (MAP) are kept between 65 and 90 mmHg. 5mL/kg of crystalloids will be infused during induction period, followed by an infusion rate of 2 mL/kg/h to supplement the physiological requirements. If SVV\>12% for more than 5 min, a 250 mL bolus of colloid is given. Another 250 ml bolus of colloid is administrated if SVV was still more than 12% or SV decreased over 10%. If the CI\<2.5 L/min/m2, inotropes are used to achieve this minimum CI, serving as a safety parameter to prevent the patient from being exposure to a low cardiac output state. If SVV and CI reached the s target range but MAP could not maintain the expected level, vasopressors were started. Assess the patients every 5min intraoperatively to ensure that all parameters adhere to the target range according to the study algorithm.
223701743|NCT00567307|DRUG|Red Heart Pill 2b (Polypill)|Arm A will receive the polypill (Red Heart pill 2b) which is a combination of aspirin (75 mg), simvastatin (20g), lisinopril (10mg) and hydrochlorothiazide (12.5 mg)
223701744|NCT00567307|OTHER|Standard Practice|Arm B will receive management of their CVD risk according to the usual care given to participants in similar conditions
223701745|NCT00133029|DRUG|Timing of prophylactic antibiotic administration|
224263766|NCT06036134|BEHAVIORAL|Digital Storytelling Intervention|In Aim 1, the investigators are creating intervention materials for Study Aim 2. These intervention materials include ten digital stories (each 2-3 minutes long) with a diverse sample of Hispanic parents and legal guardians who transformed from being COVID-19 vaccine-hesitant to vaccine-accepting. Each story uses individuals' own brief first-person visual narratives/stories that use digital images, audio recordings, music, and text to document personal experiences.
223782582|NCT00604981|BEHAVIORAL|Multisystemic Therapy (MST)|MST is an intensive, family centered, community based treatment originally designed for use with adolescents presenting with serious mental health problems. In this study, MST interventions are aimed at increasing adolescent and family adherence to dietary and exercise recommendations and targeting barriers within the family system, and the broader community systems within which the family is embedded (peers, schools, health care). Decreasing caloric consumption consistent with recommended intake targets, increasing daily exercise and decreasing sedentary activity, are treatment focuses depending on whether the adolescent has difficulty with this aspect of weight management or not.
224263767|NCT06036134|BEHAVIORAL|Information Control Intervention|The control group participants will receive a CDC COVID-19 vaccine information sheet appropriate for their child's age.
224263768|NCT05096286|DEVICE|Ethos Therapy|FDA-approved treatment planning system
223701746|NCT02915796|BIOLOGICAL|G-CSF + CD133(+) cells|Patients in the G-CSF + CD133(+) cells + PTA group, received 150 unit of recombinant human G-CSF intramuscular injection to mobilize CD 133 cells from bone marrow to peripheral blood. After 72-120 hrs, 100 ml suspension of peripheral arterial blood were collected and send to Good Products Manufacturing (GPM) certified laboratory (Shanghai Chen Chuan Biological Material Co. Ltd.) within 24 hrs of obtaining sample to isolate CD 133(+) endothelial progenitor cells (EPC) using magnetic cell separator. Subjects in this group, after vascular PTA treatment, received transarterial infusion of 50 ml suspension of isolated autologous CD 133(+) cells over 30 min via catheter opened into popliteal artery. The infusion of CD 133 cells was repeated after 24 hours.
223701747|NCT02915796|BIOLOGICAL|G-CSF|Subjects in this group, after vascular PTA treatment, received 150 unit of recombinant human G-CSF intramuscular injection to mobilize EPCs from bone marrow to peripheral blood. But the C133 (+) cells were not isolated from the peripheral blood to infuse transarterially as in G-CSF + CD133(+) + PTA.
223701748|NCT02915796|PROCEDURE|percutaneous transluminal angioplasty (PTA)|Subjects in this group only underwent below the knee percutaneous transluminal angioplasty .
223701749|NCT02915796|BIOLOGICAL|Placebo infusion|Neither G-CSF was injected nor CD133(+) cells. Instead, subjects received placebo infusion (50 ml of 0.9% sodium chloride injection ) over 30 min.
223701750|NCT05138107|OTHER|Synochi Scar Spray Cosmetic|Application of the cosmetic on each skin graft in a blinded fashion in different sections for a 9 month duration.
223701751|NCT05138107|OTHER|Synochi Scar Spray Placebo|Application of the placebo on each skin graft in a blinded fashion in different sections for a 9 month duration.
223701752|NCT03879395|PROCEDURE|Abdominal surgery with metastasectomy|Emergency or elective surgery on indications related to abdominally metastasized malignant melanoma
223701753|NCT01500031|DEVICE|OffRoad Re-entry Catheter System|Facilitate the placement and positioning of guidewires within the peripheral vasculature.
223701754|NCT04396340|BIOLOGICAL|XMT-1592|XMT-1592 will be administered once every 21 or 28 days until disease progression, unacceptable toxicity, or either the patient or study physician determines it is in the best interest of the patient to discontinue participation in the study.
223701755|NCT05560776|PROCEDURE|Endobronchial ultrasound|Two or three passes per lymph node
223701756|NCT04940767|DRUG|Isotretinoin|Isotretinoin is a retinoic acid analogue (13-cis-retinoic acid) supplied as oral capsules. and was approved in the US for the treatment of severe acne vulgaris in 1982 under the brand name Accutane®.
223701757|NCT04940767|DRUG|Amzeeq 4% Topical Foam|AMZEEQ® is a topical lipophilic foam containing 4% minocycline that was approved in the US for the treatment of acne vulgaris in 2019
223701758|NCT02210546|OTHER|Magnetic Resonance Imaging (MRI)|
223701759|NCT02210546|OTHER|Mammography (Mx) + ultrasonography (US)|
223701760|NCT00303173|BEHAVIORAL|Guided Imagery|
223701761|NCT05280171|OTHER|Teach back|"Discharge information was explained by the principal investigator. On the day of discharge, pictographs teach back regarding medication, exercise, diet and follow-up was given and they were asked teach back.~Teach back is a approach which is used in cognitive psychology experiments describing repeating short sequences of information helps to improve repeat back of information. This teach back technique is recommended as a universal precaution by the agency for healthcare research and quality and the national quality forum."
223701762|NCT05280171|OTHER|Standard of care|Standard of care
223701763|NCT01414660|PROCEDURE|transplantation|transplantation of islet, kidney or liver
223701764|NCT02420522|DEVICE|Repetitive Transcranial Magnetic Stimulation|A non-invasive method of brain stimulation.
223701765|NCT02420522|DEVICE|Sham Transcranial Magnetic Stimulation|A device designed to look, sound, and feel like a real magnetic stimulation coil without actually stimulating the brain.
223701766|NCT04284852|DRUG|Niraparib|PARP inhibitor
223701767|NCT02802943|BIOLOGICAL|Peptide Vaccine|Individualized multi-peptide cocktail consisting of 300 μg each of 5 HLA class I and 4 HLA class II restricted peptides. The peptides for each individual patient will be selected from a warehouse consisting of 30 different peptides restricted by the 6 most common HLA class I allotypes (A\*01, A\*02, A\*03, A\*24, B\*07, B\*08) and 4 HLA class II peptides. Peptides will be administered subcutaneously. Vaccination will take place on d1, d4, d8, d15, d22 followed by vaccinations every 4 weeks for 1 year. The peptide warehouse is selected based on our data on the non-mutant HLA-presented antigenome of CLL identified as frequently presented CLL-associated T cell epitopes with a high potential for broad clinical application.
223701768|NCT02802943|DRUG|Imiquimod|All patients will receive imiquimod (Aldara®) as local adjuvant, applied topically at the side of vaccination 18h to 24h prior to the vaccination.
223701769|NCT03356756|DIAGNOSTIC_TEST|simultaneous combined 18F-FDG PET and cardiac MRI imaging|Patients will undergo a research study performed with an integrated whole-body PET/MRI imaging system designed for simultaneous PET and MRI acquisition, immediately after standard of care PET/CT exam.
223701770|NCT05981430|BIOLOGICAL|Fecal microbiota transplant|Active comparator will receive infusion of 125mL fecal suspension via enema
223701771|NCT05981430|BIOLOGICAL|Sham fecal microbiota transplant|Placebo comparator will receive 125mL placebo enema comprised of normal saline with 15% glycerol and brown food coloring 204 (Americolorcorp).
223701772|NCT03764696|DEVICE|tight-fitting simple facemask|Oxygen will be administered by facemask at 10 L/min oxygen. The therapy will continue until after delivery
223701773|NCT00225069|PROCEDURE|Level of sympathectomy|T2 sympathectomy or T2-T3 sympathectomy
223701774|NCT02100800|OTHER|MR and CT measurements of emphysema quantification|
223701775|NCT00815607|DRUG|INXN-1001|Capsules given once daily for 14 days for 3 treatment cycles.
223701776|NCT00815607|BIOLOGICAL|INXN-3001|Intratumoral injection
223701777|NCT01604408|BIOLOGICAL|LY2495655|Administered SC
223701778|NCT01604408|DRUG|Placebo|Administered SC
223701779|NCT03660345|PROCEDURE|PPV/MP|23 gauge Pars Plana Vitrectomy with Internal Limiting Membrane Peeling
223701780|NCT03660345|DRUG|Intravitreal injection|Intravitreal ziv-Aflibercept
223701781|NCT00917501|DRUG|OMega 3|Individual omega-3 capsules contain 400 mg EPA and 200 mg DHA taken twice a day
223701782|NCT00917501|DRUG|Placebo|Placebo given twice a day which will be compared to Omega 3
223701783|NCT05668884|COMBINATION_PRODUCT|Combination of Gemcitabine, Oxaliplatin, Donafenib and Tislelizumab|Combination of Gemcitabine, Oxaliplatin, Donafenib and Tislelizumab every 3 weeks
223701784|NCT06050005|DIAGNOSTIC_TEST|Diagnostic test through functional tests and comparison of scales applied to participants in the pre-surgical and post-surgical period.|The protocol is based on the ligamentization stages, since the bibliography relates the ligamentization process with rehabilitation. These stages are necrosis, revascularization, cellular priorities and collagen formation, and different care is required for each stage. Taking these aspects into account, the authors developed recommendations to establish a protocol divided by the evaluation phases of the present work. Users should only move on to the next phase if they achieve the expected results, or that makes the total duration of each protocol vary from user to user. tests and scales will be evaluated before surgery, after 6 weeks of surgery and at the end of treatment.
223701785|NCT05276518|PROCEDURE|Closure of cesarean section incision|"After the delivery the first group will undergo Two Layer Uterine Closure:~Double-layer closure of the uterine incision will be performed using unlocked continuous Polyglactin thread sutures(1/0) for both layers, with a large portion of the myometrium and the endometrium included in the first layer. The second layer was a continuous running suture that imbricate the first layer, including serosal and myometrial tissue.~The second group will undergo continuous unlocked sutures in a single layer, Uterine closure will begin from one corner of the incision and then the uterine incision wound is closed using Polyglactin thread include endometrium, myometrium and serosa."
223701786|NCT04242329|PROCEDURE|Surgical metastasectomy|Surgical removal of metastases aimed at R0 resection.
223701787|NCT04242329|DRUG|Immunotherapy|Continued PD1-inhibitor treatment according to current treatment standards.
223701788|NCT00816296|OTHER|Blood Draw|2 tablespoons of blood will be drawn from participants at study entry, 3 months after study entry, and 6 months after study entry.
223701789|NCT00816296|OTHER|Stool collection|Stool will be collected from participants 3 times during the study -- at study entry, 3 months from study entry, and 6 months after study entry.
223701790|NCT00816296|OTHER|BodPod Measurement|Body composition will be measured using a BodPod at study entry, 3 months after study entry, and 6 months after study entry.
223701791|NCT00816296|OTHER|Liver Ultrasound|A liver ultrasound will be performed at study entry and 6 months after study entry.
223701792|NCT03009500|DRUG|Bupivacaine|
223701793|NCT03009500|DRUG|Depo-Medrol Injectable Product|
223701794|NCT03009500|OTHER|Saline (Sodium Chloride) solution|
223701795|NCT03009500|DRUG|Lidocaine|Each injection of study medications will be preceded by subcutaneous injections of 1 mLs of 2% lidocaine at each injection site to reduce discomfort of the study participants from the injections
223701796|NCT02973061|OTHER|Questionnaires|All participants families will fulfill a periodic questionnaire regarding attention, behaviour.
223701797|NCT06464796|OTHER|Motor Imagery Techniques|"* Play a video of person doing a toe-raise exercise where carrying a big barbell on his shoulders.~* The individual in the video proceeded from a neutral upright position to a tiptoe standing while loud a heavy barbell; the plantar-flexors are used in this workout.~* The members were said to imagine engaging their ankle flexor muscles in an effort to generate ankle flexion. Both limbs were used during the 10-second imaginary contraction, which was tailed by a 10-second rest. Subsequently five repetitions of the contraction, there was a 30 second pause. Two-minutes of rest were interspersed between five-sets of five-contractions. Fifty imaginary contractions in total."
223701798|NCT06464796|OTHER|Conventional Exercise Therapy|"1. ROM drills for pronation, flexion and extension.~2. Ankle strengthening trainings include stand-up on tiptoe, walking on toe-tip, hopping on single foot, and resistance exercise with a latex elastic band.~3. Proprioceptive exercise include the following exercises: (a) sit on a proprioception board and move the injured limb in a round motion; (b) stand-up with both legs on the board while performing both eyes open and closed; (c) standing with single leg on the board while performing both eyes open; and (d) exercises on a mini-tramp (stand-up on double legs, single leg stances, hops on both left and right legs and on single leg).~4. Strengthening of the muscles of ankle completed with flexible bands at moderate Intensities.~5. Training on a stationary bicycle.~6. lunges forward into a wall.~7. Steps up and down on the transverse or sagittal plane."
223701799|NCT03270371|DEVICE|Medium cut off dialysis|Hemodialysis
223701800|NCT03270371|DEVICE|Standard High Flux Dialyzer|Hemodialysis
223701801|NCT03138304|BEHAVIORAL|Video game|Night Shift is an adventure video game with the transformational goal of teaching physicians key characteristics of patients with non-representative severe injuries - injuries classified by the American College of Surgeons as life-threatening or critical but that do not fit the archetype of injuries typically requiring treatment at a trauma center.
223701802|NCT03138304|BEHAVIORAL|Educational program|Two commercially available applications designed to teach physicians the trauma triage guidelines disseminated by the American College of Surgeons.
223701803|NCT05622695|DEVICE|catheterization|Swan-Ganz catheterization (also called right heart catheterization or pulmonary artery catheterization) is the passing of a thin tube (catheter) into the right side of the heart and the arteries leading to the lungs. It is done to monitor the heart's function and blood flow and pressures in and around the heart.
223701804|NCT00878670|DRUG|EPOGAM 1000|One capsule of EPOGAM 1000 contains 932-1073 mg Oenothera seminis oleum, equivalent to 80 mg gamma-linolic acid. Children (2-12 years) take 2 capsules in the morning and evening, whereas persons over 12 years take 3 capsules in the morning and evening. The duration of the treatment is 12 weeks.
223701805|NCT04304742|PROCEDURE|hip standard radiography/ CT scan/ MRI|hip standard radiography/ CT scan/ MRI
223701806|NCT05515315|DRUG|Tislelizumab|Participants will receive Tislelizumab, 200mg, intravenously over 30 - 60 minutes, day 1 of every 3 weeks
223701807|NCT05515315|DRUG|Albumin paclitaxel|Participants will receive Albumin paclitaxel 260 mg/m2 , day 1 of every 3 weeks
223701808|NCT05515315|DRUG|Nedaplatin|Participants will receive Nedaplatin 80 mg/m2 , day 1 of every 3 weeks
223701809|NCT05515315|RADIATION|radiotherapy|50-60Gy/25-30f
223701810|NCT05291325|DRUG|3L PEG + Linaclotide|Before colonoscopy, particpant take linaclotide capsules for 3 days (1 tablet should be taken at least 30 minutes before the first meal every day). Particpant take 1500ml polyethylene glycol electrolyte solution within 1.5 hours from 20 p.m the night before the examination; and repeat the same dose of polyethylene glycol electrolyte solution 4-6 hours before colonoscopy.
223701811|NCT05291325|DRUG|3L PEG|Particpant take 1500ml polyethylene glycol electrolyte solution within 1.5 hours from 20 p.m the night before the examination; and repeat the same dose of polyethylene glycol electrolyte solution 4-6 hours before colonoscopy.
223701812|NCT05291325|DRUG|2L PEG + Linaclotide|Before colonoscopy, particpant take linaclotide capsules for 3 days (1 tablet should be taken at least 30 minutes before the first meal every day). Particpant take 1000ml polyethylene glycol electrolyte solution within 1 hours from 20 p.m the night before the examination; and repeat the same dose of polyethylene glycol electrolyte solution 4-6 hours before colonoscopy.
223701813|NCT00003568|BIOLOGICAL|aldesleukin|
223701814|NCT00003568|BIOLOGICAL|gp100 antigen|
223701815|NCT00003568|BIOLOGICAL|incomplete Freund's adjuvant|
223701816|NCT00808483|OTHER|Walking skill training program|12 individualized training sessions containing functional exercises like walking, stair climbing, balance training and with supervision and guidance from a physiotherapist.
223701817|NCT01691131|OTHER|Exercise training|Comparison of high intensity exercise training on land versus water.
223701818|NCT05211362|BIOLOGICAL|Sticky Bone and Repeated Injectable PRF (iPRF)|The surgical treatment phase was initiated only if the subjects had a full-mouth dental plaque score of less than one and a test site plaque score of 0. Following mucoperiosteal flap reflection for one tooth on either side of the defect, all granulation tissue was removed from the defects by means of Gracey 7/8 metal curettes, and root surfaces were scaled and planed using hand and ultrasonic instruments, then the defect was filled with xenograft mixed with IPRF, Finally, the flap was replaced and closed with crossed horizontal and vertical internal mattress sutures.
223701819|NCT05211362|BIOLOGICAL|bone substitute|The surgical treatment phase was initiated only if the subjects had a full-mouth dental plaque score of less than one and a test site plaque score of 0. Following mucoperiosteal flap reflection for one tooth on either side of the defect, all granulation tissue was removed from the defects by means of Gracey 7/8 metal curettes, and root surfaces were scaled and planed using hand and ultrasonic instruments, bone graft substitute was heavily condensed into the intra bony defects. The flap was replaced and closed with crossed horizontal and vertical internal mattress sutures.
223701820|NCT04553679|BEHAVIORAL|Mindfulness online intervention|A 3-week mindfulness intervention will be offered entirely online. The purpose of the intervention is: 1) to increase participants' mindfulness, and 2) to encourage participants to change their beliefs about the disability associated with stroke to improve their psychological state. Mindfulness refers to the act of being aware: aware of thoughts, aware of emotions, aware of physical sensations, aware of others. The intervention consists of educational texts, daily exercises, audio recordings and videos. Five different topics related to mindfulness will be introduced throughout the intervention.
223701821|NCT01171040|OTHER|Echocardiography, including the measurements of left atrial (LA) distensibility|The LA volumes were measured at three points: 1) immediately before the mitral valve opening (maximal LV volume or Volmax); 2) at onset of the P-wave on electrocardiography (pre-atrial contraction volume or Volp); and 3) at mitral valve closure (minimal LV volume or Volmin). The LA distensibility was calculated as (Volmax - Volmin)x 100% / Volmin. The LA ejection fraction was calculated as (Volp - Volmin)x 100% / Volp. In all patients, LA volumes were indexed to body surface area (BSA).
223701822|NCT03901651|DIAGNOSTIC_TEST|Colonoscopy with Retroview scope combing forward and retroflexed withdrawal technique|"Colonoscopy using a combined forward and retroflexed evaluation of the colonic mucosa. using the Retroview™ scope. The operator will be blind to the standard colonoscopy findings.~The operator will record the polyps and adenoma encountered, describing the size and location."
223701823|NCT03901651|DIAGNOSTIC_TEST|Colonoscopy with standard colonoscope and forward withdrawal technique|"A standard colonoscopy with forwarding viewing withdrawal technique. An HD colonoscope with I-scan technology will be used by one expert endoscopist.~Each polyp and adenoma will be recorded, including the size and location."
223782583|NCT00604981|BEHAVIORAL|Shapedown|Shapedown, is a clinic-based, adolescent weight loss intervention. Shapedown utilizes psycho educational, behavior, and family therapy techniques in a 10-week group intervention. In order to match MST's length of intervention (6 months), three follow-up sessions are added at monthly intervals.
223701824|NCT05403788|DEVICE|Intervention with virtual reality|"VR intervention with OCULUS QUEST2 (OCULUS VR, USA) consiste on a VR helmet positioned over subject head. The software consisted of a 3D environment with exercises of upper limbs and visual feedback for the treatment of cognitive and motor dysfunction. The therapist have real-time access to the activities in the 3D environment vby real-time video transmission of the helmet activity.~The program include a single session. Each session is monitored on safety aspects of the subjects with emphasis on possible side effects of virtual reality."
223701825|NCT02357979|DEVICE|Laser|CO2 - 9.3μm short-pulsed laser irradiation will occur on the occlusal enamel surface. This results in changes in crystal composition and structure, which increase the resistance of dental mineral to dissolution by acid and will work to better prevent dental caries in the occlusal surface of vital teeth when compared to fluoride therapy alone over 12 months.
223701826|NCT02357979|OTHER|Fluoride|The Fluoride varnish is painted on the occlusal surface of the tooth. Fluoride varnish makes enamel more acid resistant.
223701827|NCT02277730|DEVICE|vasopressor delivery automated system|vasopressor delivery using phenylephrine and ephedrine
223701828|NCT02277730|DRUG|phenylephrine|
223701829|NCT02277730|DRUG|ephedrine|
223701830|NCT02277730|DEVICE|manual vasopressor delivery|
223701831|NCT04746222|BIOLOGICAL|Oral capsule faecal microbiota transplantation|Single dose of 30 oral capsules containing healthy donor stool from a stool bank
223701832|NCT04746222|OTHER|Placebo|Single dose of 30 oral placebo capsules
223782584|NCT00698568|BIOLOGICAL|Herpes simplex candidate vaccine- adjuvanted GSK 208141|Intramuscular injection, 3 doses
223701833|NCT02759484|BEHAVIORAL|Home Based Enhanced Education|The Home Based Enhanced Education arm consists of a diabetes self-management curriculum delivered by Community Health Workers in the participant's home. Participants receive 24 visits: 12 biweekly visits in the first 6 months, followed by 12 monthly visits in months 6 through 18 of the study. The self-management program is derived from two pragmatic evidence-based frameworks for behavioral change.
223701834|NCT02759484|BEHAVIORAL|Clinic Based Enhanced Education|The Clinic Based Enhanced Education arm consists of two two-hour-long sessions of group diabetes self-management education, delivered by a Certified Diabetes Educator. Participants in this arm will also receive 24 newsletters with diabetes self-management education.
223701835|NCT00722332|BIOLOGICAL|HepaGam B|Hepatitis B Immunoglobulin
223701836|NCT04435587|DRUG|Ivermectin Pill|3 days of once daily oral ivermectin 600mcg/kg/d
223701837|NCT04435587|DRUG|Combined ART/hydroxychloroquine|"1. Day 1 hydroxychloroquine 400mg bid, Day2-5 hydroxychloroquine 200mg bid~2. Darunavir/ritonavir (400/100mg) q 12 hours for 5 days"
223701838|NCT00111501|BEHAVIORAL|Tobacco Use Disorder|Web-based psychoeducational intervention culturally-tailored to the LGBT community including a social support component
223701839|NCT00111501|BEHAVIORAL|Standard Web-based intervention|General psychoeducational Web-based smoking cessation intervention
223701840|NCT00871325|DRUG|Daikenchuto (TU-100)|Subjects will receive 2.5g TID (7.5g/day) of TU-100. Dosage form is a granule. Subject will take a daily dose divided three times a day for 5 days.
223701841|NCT00871325|DRUG|Daikenchuto (TU-100)|Subjects will receive 5g TID (15g/day) of TU-100. Dosage form is a granule. Subject will take a daily dose divided three times a day for 5 days.
223701842|NCT00871325|DRUG|Placebo|Subjects will receive daily dose of TU-100 placebo. Dosage form is a granule. Subject will take a daily dose divided three times a day for 5 days.
223701843|NCT01232777|DRUG|Bevacizumab|A single dosage of: 0.625mg(0.025cc)or 0.75mg(0.03cc) will be given intravitreally.
223701844|NCT03151343|DRUG|Empagliflozin|Empagliflozin tablet
223782585|NCT00698568|BIOLOGICAL|Placebo|Intramuscular injection, 3 doses
223782586|NCT05403541|DRUG|Batoclimab 680 mg SC weekly|Batoclimab is a fully human anti-neonatal fragment crystallizable receptor (FcRn) monoclonal antibody
223782587|NCT05403541|DRUG|Batoclimab 340 mg SC weekly|Batoclimab is a fully human anti-neonatal fragment crystallizable receptor (FcRn) monoclonal antibody
223782588|NCT05403541|DRUG|Matching Placebo SC|Placebo
223782589|NCT05403541|DRUG|Batoclimab 340 mg SC bi-weekly|Batoclimab is a fully human anti-neonatal fragment crystallizable receptor (FcRn) monoclonal antibody
223701845|NCT03151343|DRUG|Placebo Oral Tablet|Sugar pill, visually identical to active comparator
223701846|NCT03945214|BEHAVIORAL|Meditation|10 minute per day, 8 week digital meditation
223701847|NCT03945214|BEHAVIORAL|Healthy Eating|A single 50 minute counseling session focused on eating behaviors, and three 10-minute follow-up phone calls to check-in on eating goals
223701848|NCT03945214|BEHAVIORAL|Meditation + healthy eating|10 minute per day, 8 week digital meditation and a single 50 minute counseling session focused on eating behaviors, and three 10-minute follow-up phone calls to check-in on eating goals
223701849|NCT00388830|PROCEDURE|Ultrasound|
223701850|NCT02847975|DIETARY_SUPPLEMENT|Sodium nitrate|Sodium nitrate will be ingested orally
223701851|NCT00392860|DEVICE|Natural-Fit|Ergonomic handrim for wheelchairs
223701852|NCT00392860|DEVICE|PalmRim|Ergonomic handrim for wheelchair
223701853|NCT00392860|DEVICE|Handrim Control Group|Participants were given a new standard handrim to test. This intervention group is the control group.
223701854|NCT02573168|GENETIC|GeneSight Psychotropic (GEN)|Patient DNA will be collected for all subjects and measured for variations in drug target genes and in drug metabolizing genes.Recommendations for optimal choices and dose adjustments for the 33 most commonly prescribed antidepressant and antipsychotic medications will be provided to subjects randomized to the GEN arm. This pharmacogenomic-based interpretive report will be provided to treating clinicians of patients in the GEN arm of the study, allowing clinicians to use the report to support their treatment decisions.
223701855|NCT02573168|GENETIC|Enhanced-GeneSight Psychotropic (E-GEN)|The E-GEN test incorporates into the existing GEN product new markers that are predictive of side effect of antipsychotic-induced weight gain (AIWG). The pharmacogenomic-based interpretive report from E-GEN will be provided to treating clinicians of patients in the E-GEN arm of the study, allowing clinicians to use the report to support their treatment decisions.
223701856|NCT02573168|OTHER|Treatment as Usual (TAU)|Subjects randomized to the TAU arm will also require collection of patient DNA. A pharmacogenomic-based interpretive report will be generated from GEN, however, this report is not provided to the treating clinician until completion of the study.
223701857|NCT03108274|DRUG|Danicopan|Oral tablet.
223701858|NCT03108274|DRUG|Midazolam|Oral syrup.
223701859|NCT03108274|DRUG|Fexofenadine|Oral tablet.
223701860|NCT03108274|DRUG|Mycophenolate Mofetil|Oral tablet.
223701861|NCT01733784|OTHER|Induced central apneas|
223782590|NCT01278329|OTHER|"Garbh Sanskar audio cassette (Times Music Inc., Mumbai, India)"|Approximate playing time = 50 minutes. Mothers advised to listen to it once every day.
223701862|NCT04871971|DIETARY_SUPPLEMENT|10 g NUTRALYS®S85 Plus pea protein|To determine the glycaemic response and insulinaemic response to 50g Glucose + 10 g NUTRALYS®S85 Plus pea protein.
223701863|NCT04871971|DIETARY_SUPPLEMENT|20 g NUTRALYS®S85 Plus pea protein|To determine the glycaemic response and insulinaemic response to 50g Glucose + 20 g NUTRALYS®S85 Plus pea protein.
223701864|NCT04871971|DIETARY_SUPPLEMENT|10 g Whey protein concentrate|To determine the glycaemic response and insulinaemic response to 50g Glucose + 10 g Whey protein concentrate.
224263769|NCT06620939|DRUG|Levonorgestrel Intrauterine System (LNG-IUS)|Participants in the intervention group will receive Mirena placement after hysteroscopic polypectomy
224263770|NCT06623591|DEVICE|active Transcutaneous auricular vagus nerve stimulation|Transcutaneous auricular vagus nerve stimulation was conducted by transcutaneous electrical stimulation therapy instrument to the cymba conchae of left ear in the vicinity of the auricular branch vagus nerve. Stimulation parameters: frequency = 20 Hz; pulse width = 500 μs, twice a day, 30 minutes each time.
223701865|NCT04871971|DIETARY_SUPPLEMENT|20 g Whey protein concentrate|To determine the glycaemic response and insulinaemic response to 50g Glucose + 20 g Whey protein concentrate.
223701866|NCT04871971|DIETARY_SUPPLEMENT|50 g Glucose|To determine the glycaemic response and insulinaemic response to 50g Glucose
223701867|NCT03719820|DRUG|aggressive medical management|Aspirin (100 mg daily) and Clopidogrel (75 mg daily) for 3 months and Rosuvastatin (20mg daily) for at least 6 months as well as traditional risk factors management
223701868|NCT05490303|OTHER|recording of the probe position|For each patient, a cardiac ultrasound acquisition will be performed with an optical tracking system (infrared) recording the probe's position in real time.
223701869|NCT00074984|BIOLOGICAL|Fabrazyme (agalsidase beta)|1mg/kg Fabrazyme (agalsidase beta) every 2 weeks
223701870|NCT00074984|BIOLOGICAL|Placebo|1 mg/kg placebo intravenously every 2 weeks
223701871|NCT02470832|DRUG|RG1662|
223701872|NCT02470832|DRUG|itraconazole|
223701873|NCT05819281|DIETARY_SUPPLEMENT|Probiotic blend|(Lactobacillus acidophilus, Lactobacillus paracasei, Bifidobacterium lactis, Bifidobacterium bifidum e Lactobacillus rhamnosus - Final concentration: 1 x 1010 CFU/day).
223701874|NCT05819281|DIETARY_SUPPLEMENT|PLACEBO|Maltodextrin
223701875|NCT02023593|DRUG|FOLFIRI|Patients will receive FOLFIRI every 2 weeks: Irinotecan 180mg/m2 IV over 90 minutes on Day 1; Leucovorin IV over 2 hours on Day 1(l-LV 200 mg/m2 or dl-LV 400 mg/m2 ); 5-Fluorouracil 400 mg/m2 IV bolus on Day 1; followed by 5-Fluorouracil 2.4 g/m2 for 46 hours continuous infusion.
223701876|NCT01148888|DRUG|Magnesium|Magnesium will be administered intravenously at a dose of 50 mg/kg bolus followed by an infusion of 10 mg/kg/hr.
224263771|NCT06623591|DEVICE|sham Transcutaneous auricular vagus nerve stimulation|In the sham stimulation group, the electrodes were fixed at the left earlobe with the same stimulus parameters. Stimulation parameters: frequency = 20 Hz; pulse width = 500 μs, twice a day, 30 minutes each time.
224263772|NCT06869057|BEHAVIORAL|REDDCAT2 Post-Discharge Navigation|Those in the REDDCAT2 intervention group will be partnered with a patient navigator whose role will be to review the results of the screening survey completed at the beginning of the study. The patient navigator will help coordinate the participant's care before leaving the hospital and for 90 days after. Together, the participant and navigator will form an action plan intended to help address personal, social, or community factors affecting the participant's health. The navigator is expected to contact the participant every 2 weeks, though this can be adjusted based on their preference.
223701877|NCT00994071|DRUG|Temozolomide|
223701878|NCT00994071|DRUG|ABT-888|
223701879|NCT03468803|DIAGNOSTIC_TEST|Beta D Glucan test|Measurement of BDG before, during and after surgery
223701880|NCT02960152|OTHER|diagnostic|full-mouth periodontal examination
223701881|NCT05614232|RADIATION|Chest X-ray|Chest radiographs
223701882|NCT05384964|OTHER|Questionnaire|Questionnaire completed by ICU nurses
223701883|NCT02700113|OTHER|No intervention|Intervention is not a part of this study. This is a behavioral phenotyping study of minimally verbal individuals with Autism Spectrum Disorder.
223701884|NCT04185948|BEHAVIORAL|Mediterranean diet guidelines plus intermittent fasting|For 4 weeks participants will be encouraged to adopt the Mediterranean dietary guidelines as recommended by the Mediterranean Diet Foundation in Barcelona, Spain. In combination with these guidelines, an intermittent fasting regime involving two days of the week will be implemented. The regime will encourage individuals to consume of 500kcal per day for women and 625kcal per day for men, resulting in 75% daily caloric restriction during each of these two days.
223701885|NCT04185948|BEHAVIORAL|UK Eatwell guidelines plus intermittent fasting|For 4 weeks participants will be encouraged to adopt the UK dietary guidelines (Eatwell Guide). In combination with these guidelines, an intermittent fasting regime involving two days of the week will be implemented. The regime will encourage individuals to consume of 500kcal per day for women and 625kcal per day for men, resulting in 75% daily caloric restriction during each of these two days.
223701886|NCT01956383|DEVICE|PrePex™ device|PrePex™ device for adult male circumcision. The PrePex™ device facilitates adult male circumcision that is bloodless with no anesthesia and no sutures
223701887|NCT01170143|DRUG|Trastuzumab QW, Trastuzumab Q3W|two arms using Trastuzumab QW vs Q3W
223701888|NCT05234996|DEVICE|3 Virtual Reality headset (VR Headset),|The VRE will administer through the use of 3 Virtual Reality headset (VR Headset), containing a selection of audiovisual productions made with 360 degrees technology and selected on the basis of content, plot and production dynamics.
223701889|NCT01484223|BEHAVIORAL|Cognitive Behavioral Therapy|Four Cognitive behavioral group sessions. Each session will last two hours a week
223701890|NCT05541042|OTHER|Observational only|This is an observational study
223701891|NCT00899769|GENETIC|protein expression analysis|
223701892|NCT00899769|GENETIC|proteomic profiling|
223701893|NCT00899769|OTHER|immunoenzyme technique|
223701894|NCT00899769|OTHER|laboratory biomarker analysis|
223701895|NCT00899769|OTHER|liquid chromatography|
223701896|NCT00899769|OTHER|mass spectrometry|
223701897|NCT01064596|OTHER|blood samples|patients with a fondaparinux treatment who have 4 blood samples during the 10 days following surgery
223701898|NCT01102270|DRUG|Eszopiclone|3mg tablet once prior to sleep
223701899|NCT01102270|DRUG|Placebo|1 placebo capsule prior to sleep
223701900|NCT01720056|DRUG|Verapamil|
223701901|NCT01720056|DRUG|Kenalog 10|
223701902|NCT05021263|DRUG|IV Medications|IV magnesium sulfate, used to replete magnesium stores
223701903|NCT05021263|OTHER|placebo|placebo
223701904|NCT00004006|BIOLOGICAL|filgrastim|
223701905|NCT00004006|DRUG|carboplatin|
223701906|NCT00004006|DRUG|cyclophosphamide|
223701907|NCT00004006|DRUG|doxorubicin hydrochloride|
223701908|NCT00004006|DRUG|etoposide|
223701909|NCT00004006|DRUG|topotecan hydrochloride|
223701910|NCT00004006|PROCEDURE|autologous bone marrow transplantation|
223701911|NCT00004006|RADIATION|radiation therapy|
223701912|NCT05806086|DRUG|Panfoshu+Conventional Treatment（program-A）|On the basis of conventional treatment, panfoshu combined therapy was added.Panfoshu was taken orally once a day on an empty stomach, one capsule at a time. 1 course of treatment was 6mon, which was taken 10 days a month, stopped for 20 days for 3 months, and observed for another 3 months(unmedicated). Usage and dosage: adults and adolescents above 12yrs take one capsule (7.0mg) every day, children (1yrs-12yrs) take one capsule (3.5mg) every day.
223701913|NCT05806086|DRUG|Panfoshu+Conventional Treatment（program-B）|On the basis of conventional treatment, panfoshu combined therapy was added.Panfoshu was taken for 30 days in the first month, stopped in the second month, taken for 10 days and stopped for 20 days in a row for 3 months, and finally observed for 1 month. Usage and dosage: adults and adolescents above 12yrs take one capsule (7.0mg) every day, children (1yrs-12yrs) take one capsule (3.5mg) every day.
223701914|NCT05806086|OTHER|Conventional Treatment|Patients in this group were treated with only the conventional treatment.
223701915|NCT03437096|OTHER|venipuncture pain|postoperative sleeve gastrectomy patients pain
223701916|NCT03459170|BIOLOGICAL|BPX-501 T cells|Biological: T cells transduced with CaspaCIDe® safety switch
223701917|NCT03459170|DRUG|rimiducid|administered to eliminate BPX-501 cells in the event of GVHD
223701918|NCT02031068|BEHAVIORAL|Active Rehabilitation Program|"The active rehabilitation program will be implemented for a maximum of 6-8 weeks. Each participant will be followed by regular weekly telephone calls or personal follow-up relating to outcome from concussion and managing symptoms. The participant will receive TAU (above) in addition to the 4 components listed below:~1. Sub-maximal aerobic training for up to 15 minutes~2. Light coordination and sport-specific exercises for up to 10 minutes~3. Visualization and imagery techniques~4. Home program~A physiotherapist will supervise the rehabilitation."
223701919|NCT02031068|BEHAVIORAL|Treatment-as-usual (TAU)|"The TAU program will be implemented after the initial assessment. It will consist of 2 components:~An initial education session by an occupational therapist, relating to outcome from concussion and managing symptoms A school consultation to provide teacher education, recommend accommodations, and facilitate return to school"
223701920|NCT00827528|PROCEDURE|Traditional correction of anterior vaginal wall prolapse|"Traditional repair.~Patients diagnosed with anterior vaginal wall prolapse will be submitted to surgical correction. They will be randomized to receive a traditional repair or a graft in surgery."
223701921|NCT00827528|PROCEDURE|Biologic Graft (SIS)|"Biologic graft (SIS - Small Intestine Submucosa) in correction of anterior vaginal wall prolapse.~Patients diagnosed with anterior vaginal wall prolapse will be submitted to surgical correction. They will be randomized to receive a traditional repair or a graft in surgery."
223701922|NCT05239975|BIOLOGICAL|SCTV01C|intramuscular injection
223701923|NCT05239975|BIOLOGICAL|Comirnaty|intramuscular injection
223701924|NCT03133130|DRUG|BMT101|BMT101 is administered to 6 subjects in each of 4 groups.
223701925|NCT03133130|DRUG|Placebo|Placebo is administered to 2 subjects in each of 4 groups.
223701926|NCT00013962|DRUG|Vitamin D|
223701927|NCT06311786|DRUG|[14C]-BIIB091|Administered as specified in the treatment arm.
223701928|NCT00843531|DRUG|RAD001|5 mg/day PO (oral)
223701929|NCT00843531|DRUG|erlotinib|100 mg/day (oral)
223701930|NCT01845142|DRUG|single administration of 100.000 I.U. vitamin D|
223701931|NCT01845142|DRUG|Placebo|
223701932|NCT02632331|DRUG|ASP8825|Oral
223701933|NCT00143182|DRUG|Asenapine|Asenapine , 9 weeks
223701934|NCT00143182|DRUG|Olanzapine|Olanzapine, 9 weeks
223701935|NCT02182739|DRUG|Meloxicam|tablets or injectable solution
223701936|NCT01633073|DEVICE|LMA Supreme: control device|LMA Supreme will be placed in children weighing 5-50kg based on a computer generated randomization. One of four different sizes of airways will be used: 1.5, 2.0, 2.5, or 3.0. The size of the airway device will be determined according to the manufacturer's guidelines that are standardized by the patient's weight in kilograms.
223701937|NCT01633073|DEVICE|i-gel: comparison device|i-gel will be placed in children weighing 5-50kg based on a computer generated randomization. One of four different sizes of airways will be used: 1.5, 2.0, 2.5, or 3.0. The size of the airway device will be determined according to the manufacturer's guidelines that are standardized by the patient's weight in kilograms.
223701938|NCT02182102|DRUG|BIBF 1120|
223701939|NCT02182102|DRUG|Pemetrexed|
223701940|NCT03855865|DRUG|Rapastinel|Rapastinel (prefilled syringe, weekly intravenous IV administration).
223782591|NCT03385018|PROCEDURE|Radical total gastrectomy with D2 (D2 - #10) lymph node dissection by laparoscopic approach|"* Total gastrectomy with D2(D2-10) lymph node dissection by laparoscopic approach~* The number of trocars is 6 or less~* Roux-en-Y esophagojejunostomy with any stapling method~* Enough(negative) margin from tumor~* LN station #1, 2, 3, 4d, 4sb, 5, 6, 7, 8a, 9, (10), 11p, 11d, 12a should be examined~* Washing cytology~* Frozen biopsy for surgical margin at surgeons discretion~* Complete omentectomy for grossly serosa-involved tumor~* Combined organ resection only in cholecystectomy and splenectomy~* Indwelling nasogastric tube and drainage catheter at surgeons discretion~* D2 lymphadenectomy should be performed : dissection of LN stations No.4d, 4sb, 4sa, 2, 10 (splenic hilar LN can be left according to the clinical stage), 6, 5, 12a, 8a, 9, 7, 1, 3, 11p, 11d with prevention of pancreatic injury during suprapancreatic dissection"
223701941|NCT03855865|DRUG|Vortioxetine|Vortixetine (10 mg with available dose increase to vortioxetine 20 mg oral daily after 3 weeks of administration).
223701942|NCT03855865|DRUG|Placebo|Placebo (prefilled syringe, weekly IV administration or oral daily).
223701943|NCT01772160|OTHER|Data collection|HZ/PHN booklet, HZ/PHN file and logbook. HZ/PHN booklet will be completed by the patient and the HZ/PHN file and logbook will be completed by the participating general practitioner.
223701944|NCT02016001|OTHER|toothpaste 1 with maximum fluoride concentration|tooth paste 1 will be the tested intervention with maximum fluoride concentration (1500 ppm), which will be provided to the case group. They will brush the teeth twice daily for 2 minutes
223782592|NCT03385018|PROCEDURE|Radical total gastrectomy with D2 (D2 - #10) lymph node dissection by open conventional approach|"* Total gastrectomy with D2(D2-10) lymph node dissection by open conventional approach~* Roux-en-Y esophagojejunostomy with any stapling method~* Enough(negative) margin from tumor~* LN station #1, 2, 3, 4d, 4sb, 5, 6, 7, 8a, 9, (10), 11p, 11d, 12a should be examined~* Washing cytology~* Frozen biopsy for surgical margin at surgeons discretion~* Complete omentectomy for grossly serosa-involved tumor~* Indwelling nasogastric tube and drainage catheter at surgeons discretion~* D2 lymphadenectomy should be performed : dissection of LN stations No.4d, 4sb, 4sa, 2, 10 (splenic hilar LN can be left according to the clinical stage), 6, 5, 12a, 8a, 9, 7, 1, 3, 11p, 11d with prevention of pancreatic injury during suprapancreatic dissection"
223782593|NCT04939480|DRUG|Atezolizumab|Atezolizumab 1200 mg intravenous solution
223782594|NCT06572722|DRUG|Atezolizumab|atezolizumab adjuvant therapy
223782595|NCT06572722|DRUG|Nivolumab|nivolumab neoadjuvant therapy
223782596|NCT06572722|DRUG|Pembrolizumab|pembrolizumab neoadjuvant+adjuvant therapy
223782597|NCT02942160|BIOLOGICAL|Collagenase Clostridium Histolyticum|
223782598|NCT03566719|OTHER|Exercise program|Intervention group has been submitted to an exercise program directed to prevent and reduce fall risk
223782599|NCT02882802|BEHAVIORAL|Mindfulness Based Stress Reduction|Mindfulness Based Stress Reduction (MBSR) is a group-based intervention in which participants are taught different mindfulness meditation practices, including body scan (focusing attention to different areas of the body in sequence), sitting meditation (focusing attention to one's breathing), and Hatha yoga postures (focusing attention to different body sensations during gentle stretching). Participants also are taught how to practice mindfulness while engaging in ordinary activities including walking, standing, and eating. MBSR consists of 8, two-hour weekly sessions and will be delivered in group format. MBSR groups will be delivered virtually.
223782600|NCT02882802|BEHAVIORAL|Trauma Recovery Education Class|Trauma Recovery Education Class (TREC): TREC is a group based treatment that focuses on providing information on PTSD and traumatic reactions. TREC provides psycho-education to Veterans on PTSD, including common reactions to trauma and the role of avoidance, common problems associated with PTSD, as well as common barriers to care (e.g., stigma, maladaptive beliefs, fear). Additional content focuses on problem identification and goal setting, discussion of current problems and life issues, and treatment planning. TREC consists of 8, one-hour weekly sessions. TREC groups will be delivered virtually.
223782601|NCT01985594|DRUG|utrogestan|Oral Tablet Utrogestan 400 mg daily for 2 days
223782602|NCT01985594|DRUG|Nifedipine|Tablet Nifedipine 20 mg stat then 20 mg after 30 minutes if contraction persist and another 20mg after 30 minutes if contraction still persist followed by 10 mg three times daily for 2 days
223782603|NCT06636032|DRUG|AdMSC (CellReady®)|At day 0, patients will have AdMSC injections. Patients will be followed-up for 6 months
223782604|NCT06635343|OTHER|CPRP|In the CPRP group, a chest physiotherapy program was given by the physiotherapist 5 days a week, for 8 weeks, including respiratory control, diaphragmatic breathing, thoracic expansion exercises, and physical activity recommendations, to be applied once a day.
223782605|NCT06635343|OTHER|Experimental Inspiratuar Muscle Training|In the experimental group inspiratory muscle training was applied. Children in the experimental group started inspiratory muscle training at 30% of the measured intra-oral maximum inspiratory pressure (MIP) value with 30x2 breaths (1 minute rest between repetitions) for 5 days a week for 8 weeks. The training was carried out with MIP every week. The training was continued for a total of 8 weeks with 30% of the new value by re-measuring the MIP value every week The value was measured again and continued at 30% of the new value for a total of 8 weeks. During each inspiratory muscle training session, oxygen saturation data from the index finger were monitored with a pulse oximeter to prevent individuals from experiencing hypoxia
223782606|NCT06635278|BEHAVIORAL|Mindfulness meditation|"The experimental group received eight 60-minute weekly sessions of mindfulness meditation over eight weeks in a private and quiet room at the hospital, according to Smith's (2005) recommendation. The study intervention was an audio based MBI sent to them by the WhatsApp application. It is a free, self-paced program developed by a study researcher based on the Smith's (2005) protocol.~The theory-based program (Smith, 2005) includes the ABC standardized versions of MBI (Smith, 2005), described as follows:~* Meditation of the body (Body sense meditation)~* Meditation of the body (Rocking meditation)~* Meditation of the body (Breathing meditation)~* Meditation of mind (Mentra meditation)~* Meditation of mind (visual Image)~* Meditation of sense (External image)~* Meditation of the senses (A sound)~* Open monitoring (Mindfulness)"
223782607|NCT06636552|DRUG|Daratumumab (Subcutaneously)|"D-PAD (21-Day Cycles 1, 3 and 5):~1,800 mg (QW) SC on days 1, 8, and 15 (for Cycles 1 and 3) 1,800 mg (Q3W) SC on day 1 (for Cycle 5)~D-CVD (21-Day Cycles 2, 4, 6, 7 and 8):~1,800 mg (QW) SC on days 1, 8, and 15 (for Cycle 2) 1,800 mg (Q3W) SC on day 1 (for Cycles 4, 6, 7 and 8)~Daratumumab monotherapy (28-Day Cycles 9 to 32):~1,800 mg (Q4W) SC on day 1"
223782608|NCT03539562|DRUG|Morphine Sulfate and Promethazine|Morphine sulfate and promethazine
223782609|NCT03343262|DEVICE|ta-VNS|The transcutaneous vagus nerve stimulation (taVNS) at auricular concha is a typical representative of TCM modernization. The taVNS regulates the autonomic nervous system, which shows a good therapeutic effect for the treatment of IGT.
223782610|NCT03343262|OTHER|Electro-acupuncture|one of the most common acupuncture methods, selecting acupoints based on traditional Chinese medicine theory. It exerts the function to regulate qi and blood circulation and balance Yang and Yin energy inside body.
223782611|NCT02078323|DRUG|Linaclotide|
223782612|NCT02078323|DRUG|Placebo|
223782613|NCT01063010|DRUG|Bevacizumab|Administered intravenously 10 mg/kg over 90 minutes (+ 15 minutes)
223782614|NCT01063010|DRUG|Placebo|Placebo administered intravenously for 90 minutes (+ 15 minutes)
223782615|NCT06184698|DRUG|liposomal irinotecan|liposomal irinotecan 70 mg/m²
223782616|NCT06184698|DRUG|5-FU|5-FU 2400 mg/m²
223782617|NCT06184698|DRUG|LV|5-FU 2400 mg/m²
223782618|NCT06184698|DRUG|Bevacizumab|bevacizumab 5 mg/kg
223782619|NCT02610062|DRUG|AGS67E|Intravenous (IV) infusion
223782620|NCT05787418|DRUG|HH-120 Nasal Spray|HH-120 nasal spray 8 times per day for 7 consecutive days
223782621|NCT05787418|DRUG|Placebo|Placebo 8 times per day for 7 consecutive days
223782622|NCT05659602|BIOLOGICAL|HH-120 Nasal Spray|HH-120 Nasal Spray 8-10 times per day for 6 consecutive days
223701945|NCT02016001|OTHER|toothpaste 2 with 1000 ppm of fluoride|tooth paste 2 will be the intervention with 1000ppm of fluoride, will be used by the control group. They will brush the teeth twice daily for 2 minutes
223701946|NCT05681663|OTHER|Electroshock Wave therapy|Randomized- Controlled trial
223701947|NCT03722823|DRUG|Tucatinib|300mg oral single dose
223701948|NCT00901407|DRUG|lamotrigine|lamotrigine augmentation 25 to 100 mg tablets, 25 to 200 mg bid,10 weeks
223701949|NCT00901407|DRUG|placebo|placebo: 1-2 tablets bid; 10 weeks
223701950|NCT00901407|DRUG|paroxetine|open label paroxetine 10 to 50 mg, at bedtime for 18 weeks (8 weeks prior to randomization and 10 weeks after)
223701951|NCT03562533|DRUG|pegylated liposomal doxorubicin (PLD) + carboplatin (CD)|carboplatin AUC 5 plus paclitaxel 175 mg/m2 every 3 weeks for at least 6 cycles
223701952|NCT03562533|DRUG|carboplatin + paclitaxel (CP)|carboplatin AUC 5 plus paclitaxel 175 mg/m2 every 3 weeks for at least 6 cycles
223701953|NCT06227260|OTHER|Thai massage, Thai massage with pure coconut oil, Thai massage with oil mixed with Snake fruit extract, Control, Facial mask with Snake fruit extract, Control jelly, Jelly with Snake fruit juice|Interventions among the 3 studies were categorized as other.
223701954|NCT03004742|DIETARY_SUPPLEMENT|Flavonoid|Flavonoid rich supplement
223701955|NCT03004742|DIETARY_SUPPLEMENT|Placebo|Placebo
223701956|NCT00965809|DRUG|Tetrahydrocannabinol|Five mg. of THC in 6 drops of olive oil orally twice a day for 6 weeks.
223701957|NCT00965809|OTHER|Placebo|Subjects will take 6 drops of olive oil orally twice a day from an identical vial than those in the active arm
223701958|NCT01813188|PROCEDURE|ABM seeded onto a porous TCP and DBM|"cells collection under sedation . 114 mL are obtained and processed through a ficoll gradient.~Autologous bone marrow (ABM) cells seeded onto a porous tricalcium phosphate ceramic (TCP) and demineralized bone matrix (DBM)"
223701959|NCT01813188|PROCEDURE|autologous bone graft|autologous bone graft
223701960|NCT04306848|DEVICE|Temporary Continuous Glucose Monitoring System|This is a feasibility study evaluating the potential to utilize a continuous glucose monitoring system (CGMs) on a temporary basis, during participation in an intensive therapeutic lifestyle medicine program, to help improve the compliance with healthy lifestyle changes for people with Type 2 diabetes (T2DM) and prediabetes (PD).
223701961|NCT01865097|BEHAVIORAL|Relaxation guided imagery|An individualized relaxation guided imagery session will be conducted. After the session patients will be given a CD with the relaxation guided imagery and asked to listen to it at home.
223701962|NCT01865097|BEHAVIORAL|Relaxing music|An individualized session of listening to relaxing music will be conducted. After the session patients will be given a CD with the relaxing music and asked to listen to it at home.
223701963|NCT02488850|PROCEDURE|Surgery|
223701964|NCT02488850|RADIATION|SABR|
223701965|NCT00667160|DRUG|tacrolimus ointment|topical
223701966|NCT00667160|DRUG|pimecrolimus cream|topical
223701967|NCT02005731|DEVICE|Low intensity linear focused shockwave device ('Renova')|
223701968|NCT00576784|DRUG|pioglitazone and glimepiride|switch from any insulin treatment to 30 mg pioglitazone and 3 mg glimepiride.
223701969|NCT06034847|DEVICE|Mechanical thrombectomy in proximal large vessels|mechanical thrombectomy with retrievable stents to remove clots in proximal large vessels, combined or not with distal aspiration, combined or not with IV thrombolytics
223701970|NCT06034847|DEVICE|Rescue mechanical thrombectomy in distal vessels|In addition to mechanical thrombectomy in proximal large vessels, mechanical thrombectomy in distal vessels with small stent retrievers combined or not with contact aspiration, or intra-arterial perfusion of thrombolytics such as tPA or uPA or tenecpeplase
223701971|NCT02272426|BEHAVIORAL|CARET|Combined Aerobic and Resistance Exercise Training
223701972|NCT02272426|BEHAVIORAL|CTI|Cognitive Training Intervention
223701973|NCT02272426|BEHAVIORAL|Sham CARET|Sham Combined Aerobic and Resistance Exercise Training
223701974|NCT02272426|BEHAVIORAL|Sham CTI|Sham Cognitive Training Intervention
223701975|NCT04312750|DRUG|Lidocaine topical system 1.8%|
223701976|NCT01522248|BIOLOGICAL|Trivalent Inactivated Influenza vaccine|0.5 ml IM once only
223701977|NCT04471142|DEVICE|neuromuscular bandage|After the dressing is performed by the nursing team with a sterile gauze covering over the region of the healing points, the 7 cm wide Vitaltape® neuromuscular bandage will be applied. For the application of the bandage, maximum stretching will be performed over the region of the plastron and finished with the two ends, from two to three centimeters, without stretching. As many bundles of bandages as necessary will be applied according to the patient's body characteristics.
223701978|NCT01360593|DRUG|Gemcitabine|"Gemcitabine will be administered for 2 weekly doses every 3 weeks commencing 12 weeks prior to stereotactic radiosurgery as follows:~Gemcitabine 1,000 mg/m2 IV over 30 minutes on Day 1, and 8 of 21- day cycle. This will be done for up to 4 cycles."
223701979|NCT01360593|DRUG|Capecitabine|"Capecitabine will be taken orally twice daily on days 1-14 every 3 weeks for 4 cycles (12 weeks) prior to stereotactic radiosurgery as follows:~Capecitabine 650 mg/m2 twice daily for days 1-14 every 3 weeks for up to 4 cycles."
223701980|NCT01360593|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|"Fractionated SBRT will be delivered to patients that have stable disease, partial response, or complete response after chemo in the following manner:~12 Gy x 3 fractions (36 Gy total) This will be given every other day."
223701981|NCT03713892|DRUG|CKD-504|orally administered once with investigational drug assigned on 1d morning with 240 mL of water
223701982|NCT03713892|DRUG|Placebo|orally administered
223701983|NCT05395689|BIOLOGICAL|House dust mites allergoid from Dermatophagoides pteronyssinus and Dermatophagoides farinae|The vaccine will be administered according to a rush schedule meaning one administration each month for 1 year
223701984|NCT05395689|BIOLOGICAL|Placebo|The vaccine will be administered according to a rush schedule meaning one administration each month for 1 year
223701985|NCT05820945|OTHER|Pharmacist-led medication review|Clinical review by a primary care pharmacist of the primary care clinical history and the pharmacological treatment plan. After the review process, a meeting will be held between the pharmacist and the responsible physician in order to present proposals for pharmacotherapeutic optimization.
223701986|NCT03391089|DEVICE|BBL Experimental Navigation System|Comparison of accuracy of screw placement using experimental system.
223701987|NCT03566784|PROCEDURE|Inguinal hernia repair|Standard procedure for inguinal hernia repair
223701988|NCT03159117|DRUG|PF-06688992|(PF-06688992) will be administered on Day 1 of each 21-day cycle per the Dose Preparation and Administration Instructions (DAI) located in the Investigational Product Manual (Appendix 4Appendix 3) as an IV infusion over approximately 60 minutes. A cycle is defined as the time from Day 1 dose to the next Day 1 dose. If there are no treatment delays, a cycle will be 21 days. Each patient may receive PF-06688992 until disease progression, unacceptable toxicity, withdrawal of consent, or study termination
223701989|NCT03441269|DRUG|Oral Ibuprofen|Oral Ibuprofen will be given to all the arms; only the dosage will be different: 400mg vs. 600mg vs. 800mg
223701990|NCT03855969|PROCEDURE|Removal of a central venous access device|We are interested in those patients for which a central venous access device was removed.
223701991|NCT02940535|DRUG|Diphereline (Triptorelin embonate)|
223701992|NCT02940535|DRUG|Decapeptyl (Triptorelin)|
223701993|NCT02940535|DRUG|human menopausal gonadotropin|
223701994|NCT02940535|DRUG|human chorionic gonadotropin|
223701995|NCT00571610|DEVICE|PTMA (Percutaneous Transvenous Mitral Annuloplasty) Implant|Percutaneous access from right or left subclavian vein, diagnostic assessment, then placement of the PTMA implant in the coronary sinus, great cardiac vein.
223701996|NCT00694707|DRUG|Placebo|Placebo was supplied in capsules.
223701997|NCT00694707|DRUG|Cariprazine|Cariprazine was supplied in capsules
223701998|NCT00694707|DRUG|Risperidone|Risperidone was supplied in capsules
223782623|NCT05724186|DEVICE|Test myopia control lenses (CSL)|A pair of myopia control spectacle lenses (test lenses) will be given to subjects to wear for 12 months
223782624|NCT03447769|DRUG|Canakinumab|200 mg of canakinumab administered subcutaneously on day 1 of every 21-day cycle for 18 cycles. Canakinumab solution for injection was provided by Novartis as ready-to-use pre-filled syringes to be administered by study personnel.
223782625|NCT03447769|DRUG|Placebo|Placebo administered subcutaneously on day 1 of every 21-day cycle for 18 cycles. Placebo solution for injection was provided by Novartis as ready-to-use pre-filled syringes to be administered by study personnel.
223782626|NCT06582615|PROCEDURE|Biospecimen Collection|Undergo dried blood spot collection
223782627|NCT06582615|PROCEDURE|Cognitive Assessment|Ancillary studies
223782628|NCT06582615|OTHER|Dietary Intervention|Receive MIND counseling sessions
223782629|NCT06582615|OTHER|Dietary Intervention|Follow a personalized diet
223782630|NCT06582615|OTHER|Dietary Intervention|Receive general health recommendations counseling sessions
223782631|NCT06582615|OTHER|Medical Device Usage and Evaluation|Wear a Fitbit
223782632|NCT06582615|OTHER|Questionnaire Administration|Ancillary studies
223782633|NCT04040985|PROCEDURE|Total Knee Arthroplasty using LEGION™ Total Knee System|Primary Total Knee Arthroscopy using LEGION™ Total Knee System
223782634|NCT01123759|OTHER|Feeding low mercury fish|Subjects fed 6 oz of either tilapia (low omega-3 fish) or salmon (high omega-3 fish) for 3 months. Both fish are low in mercury
223782635|NCT05462626|BEHAVIORAL|Holistic Occupational Performance Empowerment (HOPE) Lifestyle Program|The intervention is comprised of the following sessions and themes; Session 1: Informed Consent and Pre-Testing; Session 2: Occupation and Healthy Aging; Session 3: Longevity and Thriving; Session 4: Movement Matters; Session 5: Thoughtful Eating; Session 6: Stress and Sleep; Session 7: Navigating Health Care; Session 8: Post-Testing and Discharge.
223782636|NCT04429490|OTHER|Adipose tissue sampling during surgery and urine sampling|Adipose tissue sampling during surgery and urine sampling
223782637|NCT03913273|PROCEDURE|AMI transtibial amputation|Two Agonist-antagonist myoneural interfaces (AMIs) were surgically constructed during a modified transtibial amputation procedure. Each AMI was made of natively innervated and vascularized muscle segments - an agonist and antagonist - that were surgically connected in series within the amputated residuum. Tarsal tunnels, including segments of each tunnel's native tendon component, were procured from the amputated joint. The tunnels were affixed to the residual limb tibia and the AMIs were constructed by coaptation of an agonist and an antagonist muscle to either end of the tendon passing through the tunnel. Consequently, the force produced by one muscle stretches its partner such that the AMI can communicate signals from the mechanoreceptors in both muscles to the central nervous system.
223782638|NCT03913273|PROCEDURE|Standard transtibial amputation|A standard transtibial amputation was performed according to traditional techniques. No surgical construction of agonist-antagonist myoneural interfaces (AMIs) was performed.
223782639|NCT01343407|DRUG|MK-1029 10 mg|Six capsules once daily for 5 days in Period 2, 3, or 4 in a crossover design
223782640|NCT01343407|DRUG|MK-1029 100 mg|Five capsules once daily for 5 days in Period 2, 3, or 4 in a crossover design
223782641|NCT01343407|DRUG|Placebo for MK-1029 10 mg|"Six capsules once daily for 5 days in Period 1, and the same in Period 2, 3, or 4 in a crossover design."
223782642|NCT01343407|DRUG|Placebo for MK-1029 100 mg|Five capsules once daily for 5 days in Period 2, 3, or 4 in a crossover design
223782643|NCT03950739|DRUG|Treprostinil Inhalation Powder|Treprostinil inhalation powder single-use cartridges containing either 32 or 48 micrograms of treprostinil per cartridge (QID)
223782644|NCT04639414|DRUG|Empagliflozin 10mg oral tablet / Semaglutide 1mg pen injector|Measurement of the effect of the combined treatment with semaglutide 1mg/week and empagliflozin 10 mg/d compared to matching placebo after 48-week treatment.
223782645|NCT04639414|DRUG|Empagliflozin 10mg oral tablet and placebo pen injector matching semaglutide|Measurement of the effect of empagliflozin monotherapy 10mg/d compared to matching placebo after 48-week treatment.
223782646|NCT04639414|DRUG|Placebo matching empagliflozin and placebo pen injector matching semaglutide|Measurement of the effect of the combined treatment with semaglutide 1mg/week and empagliflozin 10 mg/d OR empagliflozin monotherapy 10mg/d compared to matching placebo after 48-week treatment.
223782647|NCT02758431|DRUG|Acyline|Acyline 300ug/kg injection will be administered on Day 0 and on day 14
223782648|NCT02758431|DRUG|Placebo Gel|Placebo gel packet applied daily for 28 days.
223782649|NCT02758431|DRUG|Placebo Tablet|Placebo oral tablet taken daily for 28 days.
224263773|NCT06869057|OTHER|Treatment as Usual (TAU)|"TAU participants will receive standard care from the UMass Memorial Healthcare (UMMH) hospitalist team as appropriate. Participants will receive a printed list of community resources. No study-related patient navigation support will be provided.~In 2024, Centers for Medicare and Medicaid Services mandated social determinants of health (SDOH) screening for inpatients. UMMH will use a checklist social needs screener. It will be up to the hospitalist teams to act on SDOH screening results. The UMMH hospitalist teams may consult endocrinology and/or inpatient social services to provide support and consultation for all patients regardless of study participation or group assignment. If medically appropriate, the endocrinology service may manage medications and provide referrals for continued treatment post discharge. All services that are normally provided by hospital care teams will remain available."
224263774|NCT06679582|DRUG|Luveltamab tazevibulin|"Luveltamab tazevibulin is an antibody-drug conjugate (ADC) targeting folate receptor α (FRα or FOLR1). It consists of an IgG1 antibody (SP8166) conjugated to cathepsin cleavable 3-aminophenyl hemiasterlin payload, yielding a homogenous ADC with a drug antibody ratio of four. The active warhead (SC209) inhibits tubulin polymerization leading to mitotic arrest and cell death.~Other Names:~* STRO-002~* Luvelta"
224263775|NCT01350557|OTHER|Comprehensive care|Comprehensive care consisted of subacute care plus health-maintenance interventions to manage depressive symptoms, manage malnutrition, and prevent falls.
224263776|NCT01350557|OTHER|Subacute care|Subacute care included geriatric consultation, continuous rehabilitation, and discharge planning.
224263777|NCT05331508|BEHAVIORAL|gender-based violence screening, first-line support (LIVES) and reproductive coercion empowerment counseling (ARCHES)|Providers will (1) introduce routine client screening for GBV, including intimate partner violence, sexual violence, and reproductive coercion using a standardized screening form, in FP and ANC services,(2) for individuals disclosing GBV, provide first-line response-empathetic counseling, including listening, inquiring about experiences sensitively, and validating experiences, helping clients develop safety plans, and providing support; (3) regardless of disclosure of GBV, provide counseling and information, education and communication (IEC) materials on IPV, including reproductive coercion, and FP options, to both FP and ANC clients.
224263778|NCT00905528|DRUG|Telmisartan 80 mg/d|
224263779|NCT00905528|DRUG|Ramipril 10 mg/d|
224263780|NCT06223932|DRUG|Molnupiravir|COVID-19 diagnosed patients receiving molnupiravir will be evaluated to show if Molnupiravir is effective in reducing the combined outcome of hospitalization/death due to COVID-19 in the first 28 days when used in real life.
224263781|NCT04774705|OTHER|SNV activ group (Non-invasive transcutaneous stimulation of the vagus nerve )|A transcutaneous stimulator of the atrial branch of the vagus nerve of the TENS eco Plus type (Schwa-medico) will be used. SNV stimulation will be applied in the concha of the left ear to the subcutaneous area of the atrial branch of the vagus nerve in the left ear (cymba conchae) for each patient, at an intensity of 2 mA, 30 minutes per day for 5 consecutive days, from the day of inclusion / randomization.
224263782|NCT04774705|OTHER|Placebo group|For the control group, the stimulation electrode will be inverted so as to deliver the stimulation to the ear lobule.
224263783|NCT03010098|DEVICE|Dual-Loop TCI|the investigator modified the effect-site target concentrations by NI.If NI fall down to 46 and keep 46 more than 30 seconds,propofol and remifentanil were infused as feedback automatically to achieve the target NI of 26-46
224263784|NCT03010098|DEVICE|Open-Loop TCI|the investigator modified the effect-site target concentrations of both drugs without minimum or maximum concentration limits without using the Narcotrend monitor only depend on the experience of anesthesiologist.
224263785|NCT03651219|DRUG|Apatinib|Apatinib Mmesylate tablets 250mg/d, po, there's totally 4-6 cycles(21days per cycle)
224263786|NCT03651219|DRUG|Irinotecan|Irinotecan 80mg/m2 d1, d8, vi, there's totally 4-6 cycles(21days per cycle)
223782650|NCT02758431|DRUG|Testosterone Gel|Testosterone Gel applied daily for 28 days
223782651|NCT02758431|DRUG|Arimidex|Arimidex Oral Tablet 1mg taken orally daily for 28 days
223782652|NCT03526900|DRUG|Atezolizumab|"* Induction (four or six 21-day cycles) : Atezolizumab 1200 mg / iv + carboplatin 5 AUCs + pemetrexed 500 mg/m2~* Maintenance (21-day cycles): atezolizumab 1200 mg/iv + pemetrexed 500 mg/m2."
223782653|NCT05685485|PROCEDURE|Standard Implantation|Traditional Ahmed plantation without vicryl ligature
223782654|NCT05685485|PROCEDURE|Tied off Tube|Ahmed implantation with vicryl ligature
223782655|NCT04071951|BEHAVIORAL|Pharmacist-led Hospital Discharge Care Intervention|"Pharmacists will address medication reconciliation, medication adherence, and polypharmacy issues as appropriate. Pharmacists will rely most on their prior training, but study investigators will also encourage the use of documentation templates with reminders, Beers list, deprescribing, motivational interviewing, the Medication Adherence and Literacy tool, and post-discharge phone calls.~Pharmacists will assess patient needs and customize accordingly. All patients will receive one discharge counseling visit and one post-discharge phone call, but pharmacists will find that some patients need further phone calls, interventions, referrals, or other interactions. Some or all of the pharmacist activities may take place over the phone."
223782656|NCT06962774|DRUG|ESK-001|Single oral dose of ESK-001 in participants from all cohorts
223782657|NCT06962059|OTHER|Self-Administered Sample Collection|Participants will collect vaginal swabs and a stool sample.
223782658|NCT06961487|PROCEDURE|EndovascularThrombectomy|Endovascular thrombectomy is a minimally invasive procedure that uses catheters and devices to remove blood clots, restoring blood flow to the brain. The procedure involves inserting a catheter (a long, thin tube) into an artery, usually in the groin, and guiding it through the blood vessels to the site of the blocked artery/blood clot in the brain. After the catheter reaches the affected area, a specialized device is guided through the catheter to capture and remove the clot.
223782659|NCT06961487|DEVICE|Endovascular thrombectomy with any FDA-approved device|"The following FDA approved thrombectomy devices will be included:~Stryker Neurovascular Products:~* AXS Vecta 74 Aspiration System~* AXS Vecta Aspiration System (AXS Vecta 71 Aspiration Catheter and AXS Vecta 74 Aspiration Catheter)~* AXS Vecta Intermediate Catheters (AXS Vecta 71 Intermediate Catheter \& AXS Vecta 74 Intermediate Catheter)~* Trevo XP ProVue Retriever, 3x20 and 4x20~* Trevo XP ProVue Retriever, 4x30~* Trevo XP ProVue Retriever, 6x25~Medtronic Products:~Solitaire X Revascularization Devices:~* Solitaire X 4x20, 4x40, 6x40~* Solitaire X 3x20, 3x40~Aspiration catheters:~* React 68~* React 71~* REACT-71-115 \& REACT-71-125~MicroVention Inc. Products:~* SOFIA, Aspiration pump and tubing kit~  * SOFIA Plus Aspiration catheter~* BOBBY balloon guide catheter~* ERIC retrieval device"
223782660|NCT03264989|DRUG|crizanlizumab|Crizanlizumab was administered IV infusion over 30 minutes at the assigned dose on Week 1 Day 1, Week 3 Day 1, and then Day 1 of every 4-week cycle. Cycle = 28 days
223782661|NCT06636617|DRUG|3.70 GBq (100 mCi) of 177Lu-JH04|All 3 patients were intravenous injected with single dose 3.70 GBq (100 mCi) of 177Lu-JH04.
223782662|NCT06636617|DRUG|5.55 GBq (150 mCi) of 177Lu-JH04|All 3 patients were intravenous injected with single 5.55 GBq (150 mCi) of 177Lu-JH04
223782663|NCT06636617|DRUG|7.40 GBq (200 mCi) of 177Lu-JH04|All 3 patients were intravenous injected with single 7.40 GBq (200 mCi) of 177Lu-JH04
223782664|NCT06635018|OTHER|Resting conditions|The volunteer's hands are at rest and PI readings are taken for six minutes. After two minutes, there is always a randomized rotation of the sensors between the fingers.
223782665|NCT06635018|OTHER|Movement artifacts|The volunteer periodically spreads his/her fingers and clenches them into a fist, and PI readings are taken for six minutes. After two minutes there is always a randomized rotation of sensors between the fingers.
223782666|NCT06635018|OTHER|Circulation constriction|The volunteer's arm is constricted using a cuff to measure non-invasive blood pressure. The perfusion index value is monitored during the time of cuff pressure and cuff release. The measurement is followed by a 4-minute pause to allow the vascular supply to stabilize, the sensors are randomly rotated, and the measurement is repeated.
223782667|NCT04842955|DEVICE|Gamma tACS (40 Hz) over the superior parietal cortex|Single session of gamma tACS (40 Hz) over the superior parietal cortex
223782668|NCT04842955|DEVICE|Sham tACS over the superior parietal cortex|Single session of sham tACS over the superior parietal cortex
223782669|NCT04363905|DIETARY_SUPPLEMENT|Placebo|100 mg lactose per day for 6 weeks
223782670|NCT04363905|DIETARY_SUPPLEMENT|Ferrous sulfate|20 mg per day of elemental iron for 6 weeks
223782671|NCT00289341|BIOLOGICAL|vaccine vehicle only|Subcutaneous injection of vaccine vehicle only (5% DMSO in normal saline), followed by cross-over to Arm 1 design.
223782672|NCT00289341|BIOLOGICAL|DC/LNCaP|Subcutaneous injection of DC/LNCaP, DC/LNCaP-M1, DC/KLH
223782673|NCT03779529|DIETARY_SUPPLEMENT|Olive oil|Intervention includes dosage and amount of biophenols administered daily
223782674|NCT04327414|BEHAVIORAL|Intervention group|Standing desks
223782675|NCT05520905|OTHER|TelePrEP|HIV pre-exposure prophylaxis delivered via telemedicine.
223782676|NCT00534729|DRUG|Weekly Carboplatin & Taxol w/concurrent RT|Chemotherapy
223782677|NCT04880759|OTHER|bike desks in the classroom|Children will use bike desks for 13 weeks during school time
223782678|NCT02291718|DRUG|Isovue|iodine contrast
223782679|NCT02997358|DRUG|Doxorubicin|75 mg/m² Day 1 of each 3-weeks cycle
223782680|NCT02997358|DRUG|Trabectedin|150 μg/m²/day s.c From day 3 to day 9
223782681|NCT04724655|OTHER|gastric lavage with paraffin oil and bicarbonate|Gastric lavage will be initiated with 50 mL of Paraffin oil and 50 mL of sodium bicarbonate solution 8.4%, then aspiration will be done after 3-5 min through nasogastric tube
223782682|NCT04724655|OTHER|gastric lavage with coconut oil and bicarbonate|Gastric lavage will be initiated with 50 ml coconut oil and 50 ml sodium bicarbonate 8.4 % then aspiration will be done after 3-5 min through nasogastric tube
223782683|NCT04724655|DRUG|standard treatment|inotropes as levophid, fluids and electrolytes , endotracheal intubation, mechanical ventilation and antiarrhythmic agents as Magnesium sulfate
223782684|NCT04724655|OTHER|gastric lavage with saline and bicarbonate|Gastric lavage with saline and sodium bicarbonate 8.4% then aspiration will be done after 3-5 min through nasogastric tube
223782685|NCT00276445|DRUG|beta-1,3-glucan|
223782686|NCT05441930|DRUG|Levofloxacin Ocular Implant|Levofloxacin Ocular Implant an implant that delivers a bolus dose of levofloxacin and a constant daily dose for a further 5-7 days.
223782687|NCT05441930|DRUG|Control|Commercially available topical medications as per LEVO-CS102 Surgical Therapy Procedure.
223782688|NCT05988216|BIOLOGICAL|BRL-301|Single dose of Allogeneic Anti-CD19 CAR T cells will be infused
223782689|NCT04327466|DEVICE|Osciflow|Osciflow is a non-invasive high frequency oscillatory ventilation support delivered via a highflow nasal cannula for four hours (one hour wash-out, three hours measurement period).
223782690|NCT04327466|DEVICE|Highflow|Standard highflow therapy without oscillations delivered via a highflow nasal cannula for four hours (one hour wash-out, three hours measurement period).
223782691|NCT00002872|BIOLOGICAL|bleomycin sulfate|
223782692|NCT00002872|DRUG|doxycycline|
223782693|NCT00002872|OTHER|talc|
223782694|NCT00305058|DRUG|Morphine|0.05 mg/kg Intravenous
223782695|NCT00305058|DRUG|Hydromorphone|0.0075 mg/kg intravenous
223782696|NCT02987413|BIOLOGICAL|Autologous Mesenchymal stem cells (MSCs)|2 intrathecal autologous MSCs infusions (1x10\^8 cells) will be performed, escalated from 30 days apart
223782697|NCT00180739|PROCEDURE|Magnetic Resonance Guided Focused Ultrasound|
223782698|NCT02350959|DRUG|Atorvastatin|in moderate dosea statin group, atorvastatin 10mg will be used and maintained until follow up angiography
223782699|NCT02350959|DRUG|Atorvastatin|in high dose statin group, atorvastatin 40mg will be used and maintained until follow up angiography
223782700|NCT01711086|DEVICE|Aerolizer Followed by Inspiromatic|Participants will receive Formoterol (Foradil) 12mcg via the Foradil Aerolizer inhaler while performing lung function as part of the and not differ from other routine follow-up
223782701|NCT01711086|DEVICE|Inspiromatic followed by Aerolizer|Participants will receive Formoterol (Foradil) 12mcg via the Inspiromatic dry powder inhaler while performing lung function instead of getting it via the Foradil Aerolizer
223782702|NCT05343611|BEHAVIORAL|Combination of High Protein Diet and Physical Exercise protocol|"A high Protein Diet (HPro) will be provided to maintain individual caloric endpoint and to adjust protein intake to 0.9-1.0 g/Kg ideal body weight. Each participant will receive a tailored diet (taking into account personal preference) which will follow common general guidelines. Servings of food high in polyphenols will be limited to one per day.~Physical exercise will be undertaken three times each week for about 50 minutes per session. The intervention will consist of both aerobic and strength training exercises. Aerobic exercise will consist of walking on a treadmill with 4 x 4 minutes at (85-95% of HRmax), interrupted by 3-minute active recovery periods (60-70% of HRmax). Strength exercise consists of maximal strength training, using a seated leg press with 4 sets of 4 repetitions at \~90% of maximal strength (1RM). Rest periods between the sets will be 3-4 min."
223782703|NCT05343611|DIETARY_SUPPLEMENT|HPP Choko|Participants add to their diet with 30 g/day of 85% dark chocolate high in polyphenols
223782704|NCT05343611|DIETARY_SUPPLEMENT|HPP/VE Choko|Participants add to their diet 30 grams of 85% dark chocolate high in polyphenols, functionalized with 100 mg of Vitamin E per day.
223701999|NCT05119673|OTHER|bi-plane sonographic view to difficult peripheral vascular access using Butterfly iQ+®|Bi-plane Butterfly iQ+® sonographic visualization will be used to help Emergency Department operators to get a venous peripheral access in a population of patients considered difficult for this task based on their history or the present clinical situation.
223702000|NCT05908110|BEHAVIORAL|Health Communication Message|The health communication message is a single infographic developed iteratively with input from stakeholders (parents and providers). This image informs the parent that their child may have OSA, lists common nighttime symptoms parents may observe (e.g., snoring, apnea) and common daytime symptoms (e.g., hyperactivity, sleepiness) that can result from OSA. Parents are then encouraged to speak to their child's primary care provider if they observe these symptoms in their child.
223702001|NCT04568889|BEHAVIORAL|A $10 Survey Incentive|Individuals see a 10 dollar incentive on the flyers advertising the baseline survey.
223702002|NCT04568889|BEHAVIORAL|A $20 Survey Incentive|Individuals see a 10 dollar incentive on the flyers advertising the baseline survey.
223702003|NCT04568889|BEHAVIORAL|Emphasis of Government Involvement|Individuals see a message emphasizing the involvement of the government in the study,
223702004|NCT04568889|BEHAVIORAL|Emphasis of Academic Researchers Involvement|Individuals see a message emphasizing the involvement of academic researchers in the study,
223702005|NCT04568889|BEHAVIORAL|Cost-Benefit Frame|Individuals will see messaging that emphasizes the public health benefits of answering the survey questions in the baseline survey (cost-benefit frame).
223702006|NCT04568889|BEHAVIORAL|Duty Frame|Individuals will see messaging that emphasizes an individual's responsibility to their community in the baseline survey (duty frame),
223702007|NCT04568889|BEHAVIORAL|Racial/Ethnic Frame|Individuals will see messaging that emphasizes the disproportionate impact of COVID-19 on certain ethnic and racial groups in the baseline survey.
223702008|NCT04568889|BEHAVIORAL|No Messaging|Individuals will see no messaging in the baseline survey.
223702009|NCT00514423|OTHER|Psychoeducation by professonals|
223702010|NCT00514423|OTHER|Psychoeducation by peer-moderators|
223702011|NCT00514423|OTHER|Video-education|
223702012|NCT00514423|OTHER|Noneducational video group (control group)|
223702013|NCT04081324|DRUG|Lasmiditan|Administered orally
223702014|NCT04081324|DRUG|Placebo|Administered orally
223702015|NCT01904058|DRUG|LUM001|
223702016|NCT01904058|DRUG|Placebo|
223702017|NCT01904058|DRUG|Ursodeoxycholic Acid|
223702018|NCT01118871|DRUG|Darunavir, Ritonavir, Truvada|Darunavir 800 mg daily Ritonavir 100 mg daily Tenofovir 245 mg daily Emtricitabine 200 mg daily
223702019|NCT01118871|DRUG|Darunavir, Ritonavir and Etravirine|Darunavir 800 mg daily Ritonavir 100 mg daily Etravirine 400 mg once daily
223702020|NCT05038046|OTHER|Traditional Chinese Medicine (TCM) daycare model|Traditional Chinese Medical (TCM) daycare model provides multiple approaches of traditional Chinese medical treatment, including 5 tones of Chinese music, massage for meridians and collaterals, acupuncture, and patient education. The treatment course is one time a week, for 12 weeks (12 treatments in total).
223702021|NCT05485454|DEVICE|Aria Health Aria Free|An in-clinic therapy session with the Aria Free for a duration of 30 minutes under the direct supervision of the Principal Investigator.
223702022|NCT05485454|DEVICE|A Traditional PCD|An in-clinic therapy session with the traditional PCD for a duration of 30 minutes under the direct supervision of the Principal Investigator.
223702023|NCT01435070|PROCEDURE|Kirschner wire fixation|"The wires are passed through the skin over the dorsal aspect of the distal radius and into the bone in order to hold the fracture in the correct (anatomical) position. The size and number of wires, the insertion technique and the configuration of wires will be left entirely to the discretion of the surgeon.~A plaster cast will be applied at the end of the procedure to supplement the wire fixation as per standard surgical practice. This cast holds the wrist still and is left on until the wires are removed at the follow-up appointment."
223782705|NCT04339335|PROCEDURE|Pulsed radiofrequency of the occipital nerves|pulsed radiofrequency of the greater and lesser occipital nerves bilaterally
223782706|NCT00206063|DRUG|EXANTA|
223782707|NCT03660956|BEHAVIORAL|Exercise|Twelves-week exercise training sessions include a variety of strength, flexibility, and coordination exercises. Each exercise session lasts for one hour. Participants are expected to attend exercise session once a week and are encouraged to continue exercising at home.
223782708|NCT03660956|BEHAVIORAL|Back counselling|Procedure of back counselling includes one session back counselling, lasting one hour. The topics of back counselling session are as follows: (1) Anatomy of lumbar; (2) Factors causing low back pain; (3) Problems of physical inactivity for the lumbar; (4) Risk of poor postures for developing persistent/chronic low back pain; (5) Maintaining right posture of the lumbar; (6) Avoiding harmful loading of the back during work and leisure time.
223782709|NCT06133491|BIOLOGICAL|Daxibotulinumtonix A|SQ injections of 10u per site will be given over standard landmarks (18 sites) to patients who consent and are found eligible.
223782710|NCT02559986|OTHER|telephone interview|telephone interview about their care received during the first year of life and associated events
223782711|NCT04906018|DEVICE|Ultrasound scans|Each subject will be randomly allocated to an ultrasound machine and an expert scanner who will perform the ultrasound scans of all supported anatomical regions.
223782712|NCT05852444|DEVICE|Passive Ultrasonic Activation|Agitation of root canal irrigation solution with an ultrasonic activation device (Ultra X).
223782713|NCT05852444|DEVICE|Manual Dynamic Agitation|Agitation of root canal irrigation solution with master gutta percha cone
223782714|NCT02439086|DEVICE|PET-CT Scan|patients will have 2 PET CT scans: one before radiotherapy, and one 9 weeks after.
223782715|NCT04102501|DRUG|RT001|RT001 is encapsulated 9-cis, 12-cis-11,11-D2-linoleic acid ethyl ester, which is a site specific (C11) di-deutero synthetic homologue of LA ethyl ester. Each capsule contains 960 mg of RT001.
223782716|NCT04102501|DRUG|Placebo|The placebo product is composed of encapsulated USP safflower oil. The placebo capsules are identical in appearance and size to RT001.
223782717|NCT01361087|OTHER|Blood draw|This study includes one blood draw to measure circulating blood levels of TGF-B.
223702024|NCT01435070|PROCEDURE|Volar Locking Plate fixation|The locking-plate is applied through an incision over the volar (palm) aspect of the wrist. The surgical approach, the type of plate and the number and configuration of screws will be left to the discretion of the surgeon. The screws in the distal portion of the bone will be fixed-angle, i.e. screwed into the plate, but this is standard technique for use of these plates. The type of proximal screw will be left to the discretion of the surgeon; these may be locking or non-locking screws. The use of a cast will left to the discretion of the surgeon.
223702025|NCT03428607|DRUG|AZD6738|AZD6738 160mg QD
223702026|NCT03428607|DRUG|Olaparib|Olaparib 300mg BID
223702027|NCT03096483|DEVICE|OEC Elite system|Adults undergoing vascular, gastrointestinal (GI), urology or pain management procedures
223702028|NCT00097318|DRUG|Interferon beta-1a|
223702029|NCT03678883|DRUG|9-ING-41|Starting dose of-9-ING-41 will be administered on Day 1 and 4 each week of a 21-day cycle. 9-ING-41 will be administered intravenously over 60 minutes.
223702030|NCT03678883|DRUG|Gemcitabine - 21 day cycle|Gemcitabine 1250 mg/m2 as a 30-minute intravenous infusion on Days 1 and 8 of a 21-day cycle
223702031|NCT03678883|DRUG|Doxorubicin.|Doxorubicin 75 mg/m2, intravenous bolus on Day 1 of a 21-day cycle up to a maximum lifetime dose of 550 mg/m2.
223702032|NCT03678883|DRUG|Lomustine|Lomustine 30 mg/m² orally as a single dose, weekly for twelve weeks.
223702033|NCT03678883|DRUG|Carboplatin.|Carboplatin AUC 6 IV over 1 hour on Day 1 of a 21-day cycle.
223702034|NCT03678883|DRUG|Nab paclitaxel.|Nab-paclitaxel 125 mg/m2 intravenously on Days 1, 8 and 15 of a 28-day cycle
223702035|NCT03678883|DRUG|Paclitaxel.|Paclitaxel 175 mg/m2 intravenously over 3 hours on Day 1 of a 21-day cycle.
223702036|NCT03678883|DRUG|Gemcitabine - 28 day cycle|Gemcitabine 1000 mg/m2 intravenously over 30-minutes on Days 1, 8 and 15 of a 28-day cycle
223702037|NCT03678883|DRUG|Irinotecan|Irinotecan 350 mg/m2 intravenously over 90-minutes on Day 1 of a 21-day cycle
223702038|NCT04805177|PROCEDURE|hematoma evacuation|early minimally invasive image guided hematoma evacuation in patients suffering from ICH
223702039|NCT05739565|BEHAVIORAL|Acti-Pair program|"Motivational support by the peer (a patient with the same pathology who meets the WHO recommendations for physical activity), who will provide motivational follow-up~* The implementation of a personalized and realistic physical activity project for the patient via the physical activity support systems (sport health centers)~* Support from health professionals (GP) via the prescription of physical activity and from adapted physical activity (APA) professionals"
223782718|NCT01541657|OTHER|Ankle Joint Mobilization|The posterior ankle mobilization treatment is a manual therapy technique that consists of gently gliding your ankle in the backward direction through a pain free range of motion. This is a common therapy technique used by athletic trainers for the treatment of ankle sprains. The objective of this therapy technique is to glide the ankle into the area which restricts range of motion and gently stretch the restricted area. To begin this treatment, a certified athletic trainer with experience in applying this therapy technique will provide mild traction to the ankle joint to lightly distract the bones of the ankle joint. The athletic trainer will then apply two sets of joint mobilizations which will each last 2 minutes. Each repetition will consist of gently gliding the ankle joint in the backward direction until an area of restriction is reached. The athletic trainer will push into the restriction and then glide the ankle back to the starting position.
223782719|NCT01541657|OTHER|Foot Massage|The foot massage treatment is a manual therapy technique that consists of gently rubbing the bottom of your feet with both hands like kneading dough. To begin the treatment, you will be asked to lie comfortably on a treatment table you're your feet hanging slightly off the edge. The athletic trainer with experience in applying this therapy will place his hands on the bottom of your foot and begin to massage your feet from your toes down to your heel. The athletic trainer will perform 2 sets of 2 minutes of massage with 1 minute rest in between sets.
223782720|NCT01541657|OTHER|Calf Stretching|The calf stretching treatment is a technique that is commonly used in sports and rehabilitation. You will be asked to place your foot on a slant board located next to a wall with your heel positioned below your toes on the slant board. You will be asked to lean towards the wall until you feel tension in your calf muscles that feels like a good stretch. You will perform 2 sets of 3 stretches that are held for 30 seconds each. Between each stretch, you will rest for 10 seconds. Between each set, you will rest for 1 minute.
223782721|NCT04726865|OTHER|Naser Al-Husban|voluntary completion of an online questionnaire
223782722|NCT01224496|DRUG|Chinese herbal concoction twice a day for 6 months|Definition of each TCM syndrome is based on TCM theory. Formulation composition is based on each defined TCM syndrome with addition or removal of herbs as indicated by the patient's manifestation
223782723|NCT05207696|OTHER|retrospective data analysis|The data of the patients who underwent papilla reconstruction surgery by one of the authors (S.O.B.) using semilunar incision with either PRF or CTG in the maxillary anterior teeth were included in the study. All selected patients had consent for using their data.The data of the patients included in the study were analyzed.(Baseline (BL) and follow-up (T1( first month) , T3 (third month), T6 (sixth month)) clinical data including periodontal evaluations (gingival index (GI), plaque index (PI), papillary bleeding index, pocket depth (PD), keratinized tissue width (KTW), gingival recession), papilla-associated recordings (alveolar crest-interdental contact point (AC-IC), alveolar crest-papilla tip (AC-PT), papilla tip-interdental contact point (PT-IC), papilla height loss (PHL), interdental tissue stroke (ITS) and papilla presence index (PPI)) and patient satisfaction were analyzed.)
223782724|NCT00968617|DRUG|MK2578|MK2578 1.0 mcg/kg/month
223782725|NCT00968617|DRUG|MK2578|MK2578 2.0 mcg/kg/month
223782726|NCT00968617|DRUG|MK2578|MK2578 3.6 mcg/kg/month
223782727|NCT00968617|DRUG|Comparator: darbepoetin alfa|darbepoetin alfa
223782728|NCT01099319|DIETARY_SUPPLEMENT|Renalof|One 325 mg Renalof tablet (Orally administered) every 8 hours, for 6 months.
223782729|NCT01099319|DIETARY_SUPPLEMENT|Placebo|One Placebo tablet (Orally administered) every 8 hours, for 6 months
223782730|NCT01682291|BEHAVIORAL|Life-style modifications|Weight loss of as little as 10 lbs (4.5 kg) Adoption of the Dietary Approaches to Stop Hypertension (DASH) eating plan Dietary sodium should be reduced to no more than 2.4 g of sodium per day Regular aerobic physical activity (at least 30 minutes per day)
223782731|NCT01682291|DIETARY_SUPPLEMENT|Dietary supplements|combined pill (1 capsule/day containing Allium sativum (Dosage: 1,000 mg/day), Crataegus monogyna (Dosage: 500 mg/day), Orthosiphon (Dosage: 300 mg/day), Hibiscus sabdariffa (Dosage: 250 mg/day)
223782732|NCT05209113|OTHER|Education|A self-management module was applied to the study group. This module includes informing the patient verbally and in writing about MS disease, the importance of drug compliance, and monitoring of disease symptoms.
223702040|NCT02046733|DRUG|Ipilimumab|Induction phase: i.v. 3 mg/kg, once every 3 weeks × 4 cycles, to start within 6-8 weeks (42-56 days) from start of chemotherapy cycle 4, and not more than 2 weeks (14 days) after the date of randomisation)
223782733|NCT04258696|DEVICE|diode laser|using Ultrapak Knitted retraction cord as a gingival retraction method . using Wiser Cordless Dental Diode Laser from Doctor Smile Dental Laser By LAMBDA SpA Italy as a gingival retraction method.• The tip of diode laser, will be angled toward the soft tissue and away from the prepared tooth, will be passed along the gingival sulcus to remove the sulcular epithelium. Constant and steady short brushing strokes gently removed the lining of the sulcus in order to achieve a full 360-degree trough. The tip will be constantly cleaned with a gauze sponge wetted with hydrogen peroxide to remove debris and to eliminate potential bacterial contamination. sufﬁcient epithelium will be removed to place the impression material and visualize the ﬁnishing line. The tissue will be kept moist with water during the procedure then impression will be taken
223782734|NCT04258696|DEVICE|ultrapak Knitted retraction cord|using Ultrapak Knitted retraction cord as a gingival retraction method retraction cord will be applied for 8-10 mins then an impression will be taken , poured to obtain a cast and the die sectioned
223782735|NCT06223945|DIAGNOSTIC_TEST|Prevention algorithm|Development of an algorithm for the prevention of thrombohemorrhagic complications
223782736|NCT03498534|DRUG|Isoniazid 300Mg Tab|-TST tests will receive isoniazid 300Mg Tab for 6 months
223782737|NCT03498534|DRUG|Isoniazid 300 MG|\+ TST test will receive isoniazid 300MG Tab for 6 months
223782738|NCT03498534|DRUG|Isoniazid 300 MG|HIV positive patient will receive isoniazid 300MGTab for 6 months
223782739|NCT06458361|PROCEDURE|Type of bowel resection, surgical complexity score, intraoperative blood loss, perioperative erythrocyte transfusion, type of anastomosis|Basic information about ovarian cancer patients and factors associated with preoperative, intraoperative and postoperative periods
223782740|NCT03080519|PROCEDURE|Endovascular Therapy|Balloon angioplasty and stenting for renal artery stenosis
223782741|NCT00819182|BEHAVIORAL|Paced respiration|Breathing exercise
223782742|NCT00819182|BEHAVIORAL|Sham comparator: fast shallow breathing|sham breathing exercise
223782743|NCT01390246|DRUG|Bupropion SR|Bupropion SR 150 mg tablet
223782744|NCT01390246|BEHAVIORAL|Smoking Cessation Counseling|35-min counseling by trained research nurse
223782745|NCT01390246|DRUG|Placebo|Matching Bupropion SR placebo tablet
223782746|NCT01746823|DRUG|Cyclosporins|
223782747|NCT03567226|BEHAVIORAL|WeChat Group|"Consenting participants will be randomized to either the intervention or the control arm after successfully wearing an accelerometer for one week. The WeChat Group will be a community forum to share information, encourage each other, and receive communications from the study team. In addition, the study team will disseminate the following information through the group:~1. Daily/Weekly Reminders to exercise~2. Health education materials regarding glaucoma and general health and exercise~3. Motivational content~4. Surveys to gauge what information participants found most interesting and useful to help them exercise"
223782748|NCT03567226|BEHAVIORAL|Counselling|Study participants in the control group will receive a handout telling them to increase walking and will be counseled that walking may be helpful for the eye at the return visit
223782749|NCT03607383|DRUG|Red Rice Yeast Extract|adults requiring moderate intensity treatment will be provided red rice yeast extracts or statins, depending on the randomization; followed for compliance and adverse effects check, and reevaluated in a final visit with blood test after 8 weeks
223782750|NCT03607383|DRUG|Statin|Statin choice is done at the discretion of the treating physician for a moderate intensity treatment equivalent according the American College of Cardiology/American Heart Association (ACC/AHA) guidelines definitions, for 8 weeks
223782751|NCT02106026|OTHER|Preventive education|The intervention group received education to facilitate successful breastfeeding and symptom management as nipple pain. This was supported by strategies designed to (1) prevent problems associated with breastfeeding (nipple lesions, cracks and mastitis), (2) perform breast-care procedures, (3) strengthen information about the advantages of maternal breastfeeding (nutritional support, importance as food for the baby, availability, post-partum recovery) and (4) provide asepsis and hygiene measures.
223782752|NCT03702465|OTHER|DNA-based dietary intervention|The DNA for all arms of the study will be analysed for pre-determined single nucleotide polymorphisms (SNPs) relevant to metabolism. Participants in the intervention arm, will be provided with a hard-copy of a genetic report, which will explain how their SNPs influence their dietary habits.
223782753|NCT03702465|OTHER|DNA-based dietary intervention using an app|The DNA for all arms of the study will be analysed for pre-determined single nucleotide polymorphisms (SNPs) relevant to metabolism. Participants in the exploratory arm, will be given personalised DNA-based dietary advice via the DnaNudge App.
223782754|NCT03702465|OTHER|Control arm|Standard care for pre-diabetic individuals: dietary advice as per the NICE guidelines for individuals who have pre-diabetes.
223782755|NCT06119659|DRUG|Low dose KL001|Subjects will be dosed with single dose of KL001 at 2.5x10\^12 vg/kg.
223782756|NCT06119659|DRUG|Middle dose KL001|Subjects will be dosed with single dose of KL001 at 5.0x10\^12 vg/kg.
223782757|NCT06119659|DRUG|High dose KL001|Subjects will be dosed with single dose of KL001 at 1.0x10\^13 vg/kg.
223782758|NCT02278601|DEVICE|epidural delivery system|epidural delivery system for maintenance of labour epidural analgesia using 0.1% ropivacaine (amide local anaesthetic) with 2mcg/ml fentanyl (opioid) as maintenance solution
223782759|NCT02278601|DRUG|Ropivacaine|epidural delivery system for maintenance of labour epidural analgesia using 0.1% ropivacaine (amide local anaesthetic) with 2mcg/ml fentanyl (opioid) as maintenance solution
223782760|NCT02278601|DRUG|Fentanyl|epidural delivery system for maintenance of labour epidural analgesia using 0.1% ropivacaine (amide local anaesthetic) with 2mcg/ml fentanyl (opioid) as maintenance solution
223782761|NCT04638608|OTHER|EMBRACE (relatives)|Online support program for both relatives
223782762|NCT04638608|OTHER|EMBRACE (Health care providers)|Online support program for health care providers
223782763|NCT01438190|DRUG|Metformin, gonadotropins in step-down regimen|Metformin 850 mg cps, two cps daily for 12 weeks. gonadotropins 75IU f, step-down regimen, starting dose of 225 IU daily.
223702041|NCT02046733|DRUG|Nivolumab|Induction phase: Nivolumab i.v. 1 mg/kg, once every 3 weeks × 4 cycles, to start within 6-8 weeks (42-56 days) from start of chemotherapy cycle 4, and not more than 2 weeks (14 days) after the date of randomisation) Maintenance Phase: Nivolumab 240 mg i.v once every 2 weeks for a maximum of 12 months from start of maintenance (the first dose of maintenance nivolumab will be administered 3 weeks after the last IMP doses of induction Phase).
223702042|NCT06469515|OTHER|Elective or urgent cardiac surgery|This is a longitudinal observational study to explore postoperative cognitive recovery among older persons (aged 65 or older) undergoing elective or urgent cardiac surgery via sternotomy.
223702043|NCT06533735|BEHAVIORAL|Parent Web|Parent-Web (PW) is internet delivered and rooted in social learning and coercion theory, PW supports parenting practices and parent-child interactions encouraging prosocial behavior and emotion regulation, reduce coercive parenting, improve communication, problem solving, and warmth. PW has a universal and selective edition. Universal PW has 5 basic modules (1 module per week, 6-8 weeks) and bonus modules. Basic modules contain information, exercises, and videos of actors showing parenting practices. A family guide supports parents through modules.
223702044|NCT01296360|BIOLOGICAL|IXIARO|0.25 ml i.m. (milliliter, intramuscular)
223702045|NCT01296360|BIOLOGICAL|IXIARO|0.5 ml i.m. (milliliter, intramuscular)
223702046|NCT02835560|DRUG|Ilaprazole antisecretory drug of each quadruple therapy the Ilaprazole -based quadruple therapy|Ilaprazole -based quadruple therapy for 14 days: Ilaprazole 5mg bid, Bismuth Potassium Citrate 220mg bid, amoxicillin 1000mg bid, clarithromycin 500mg bid
223702047|NCT02835560|DRUG|Esoprazole antisecretory drug of each quadruple therapy Esoprazole-based quadruple therapy|Esoprazole -based quadruple therapy for 14 days: Esoprazole 20mg bid, Bismuth Potassium Citrate 220mg bid, Amoxicillin 1000mg bid, Clarithromycin 500mg bid
223702048|NCT02394548|RADIATION|Contralateral Esophageal Sparing Technique (CEST)|Determine whether CEST decreases rate of severe acute esophagitis
223702049|NCT02857985|DEVICE|3D RA|3D RA is realised just after angioplasty.
223702050|NCT02857985|DEVICE|MRI|MRI is realised between 24h and 96h post angioplasty.
223702051|NCT04562792|DRUG|Daunorubicin|Eligible patients with relapsed and/or refractory acute leukemia will receive daunorubicin 6.75mg/m2 daily for 5 consecutive days.
223702052|NCT03499548|OTHER|INSPiRe Programme|Intensive CBT for suicide
223702053|NCT02848170|DRUG|CS-3150|CS-3150 2.5mg, oral
223702054|NCT02848170|DRUG|olmesartan medoxomil|olmesartan medoxomil 10 mg, oral
223702055|NCT02329821|OTHER|hartmann solution|hartmann solution infusion in patients for hepatic resection
223702056|NCT02787265|DEVICE|spinal cord stimulation|
223702057|NCT03334591|DRUG|Apatinib|Apatinib 500mg with Docetaxel 60mg/m2
223702058|NCT02651831|OTHER|Focus groups and individual interviews|Focus groups conducted to explore general experiences, insights and concerns of those receiving ICM therapies. Individual semi-structured interviews to provide in-depth data on the themes identified in the focus groups.
223702059|NCT02651831|OTHER|Questionnaire|Health related quality of life questionnaire (FACT-ICM) to be completed by patients
223702060|NCT05340075|PROCEDURE|Patients who underwent percutaneous nephrolithotomy|Patients who underwent percutaneous nephrolithotomy to the contralateral kidney 2-4 weeks and 4-6 weeks after the percutaneous nephrolithotomy operation
223782764|NCT01438190|DRUG|Placebo, gonadotropins in step-up regimen|Placebo cps, two cps daily. Gonadotropins 75IU f, step-up regimen, starting dose of 75 IU daily.
223782765|NCT01094275|DRUG|Clopidogrel 75mg, Omeprazole 20mg|Clopidogrel and or Omeprazole as applicable
223782766|NCT06222255|PROCEDURE|Transanal Irrigation (TAI)|The combination of transanal irrigation (TAI) and Loperamide (Lopmin®) involves administering Loperamide orally, with a daily dosage of 2 mg for males (2 tablets once daily) and 1 tablet for females (1 tablet once daily). This is complemented by the use of TAI, a method in which patients self-administer water into the rectum through an enema, aiming to enhance bowel management and potentially alleviate symptoms associated with LARS (Low Anterior Resection Syndrome).
223782767|NCT05435599|DIAGNOSTIC_TEST|Serum regucalcin level|During routine outpatient controls, serum regucalcin level will be measured from the rest of the blood taken for examinations.
223782768|NCT03339518|BEHAVIORAL|BRIM3 educational intervention|Breast Cancer risk education and counseling
223782769|NCT03339518|BEHAVIORAL|Wait List|Booklet at the end of study
223782770|NCT03643523|DIAGNOSTIC_TEST|Albumine detection|Control of serum albumine levels in postoperatori of colorectal surgery
223782771|NCT02379585|DRUG|Doxorubicin|doxorubicin (A) 60 mg/m2 plus cyclophosphamide (C) 600 mg/m2 every 2 weeks for four cycles followed by paclitaxel (T) 75 mg/m2 every 2 weeks for four cycles (dose-dense AC + T).20
223782772|NCT02379585|DRUG|cyclophosphamide|doxorubicin (A) 60 mg/m2 plus cyclophosphamide (C) 600 mg/m2 every 2 weeks for four cycles followed by paclitaxel (T) 75 mg/m2 every 2 weeks for four cycles (dose-dense AC + T).20
223782773|NCT02379585|DRUG|paclitaxel|For patients with HER2 negative breast cancer: doxorubicin (A) 60 mg/m2 plus cyclophosphamide (C) 600 mg/m2 every 2 weeks for four cycles followed by paclitaxel (T) 75 mg/m2 every 2 weeks for four cycles (dose-dense AC + T).20
223782774|NCT02379585|DRUG|docetaxel|For patients with HER2 positive breast cancer: docetaxel (T) 75 mg/m2 every 3 weeks for four cycles. Trastuzumab (H, 8mg/kg for 1st cycle, then 6 mg/kg in subsequent 3 cycles), Pertuzumab (P, 840 mg for 1st cycle, then 420 mg in subsequent 3 cycles) will be given concurrently with docetaxel for a total of 4 cycles before surgery. For patients who do not achieve pCR, adjuvant chemotherapy with doxorubicin (A) 60 mg/m2 plus cyclophosphamide (C) 600 mg/m2 every 3 weeks for four cycles will be given, followed by trastuzumab 6 mg/kg every 3 weeks to complete 1 year of treatment. For patients with pCR, only trastuzumab 6 mg/kg every 3 weeks will be given adjuvantly to complete 1 year of treatment (TPH + AC).21
223782775|NCT02379585|DRUG|Trastuzumab|docetaxel (T) 75 mg/m2 every 3 weeks for four cycles. Trastuzumab (H, 8mg/kg for 1st cycle, then 6 mg/kg in subsequent 3 cycles), Pertuzumab (P, 840 mg for 1st cycle, then 420 mg in subsequent 3 cycles) will be given concurrently with docetaxel for a total of 4 cycles before surgery. For patients who do not achieve pCR, adjuvant chemotherapy with doxorubicin (A) 60 mg/m2 plus cyclophosphamide (C) 600 mg/m2 every 3 weeks for four cycles will be given, followed by trastuzumab 6 mg/kg every 3 weeks to complete 1 year of treatment. For patients with pCR, only trastuzumab 6 mg/kg every 3 weeks will be given adjuvantly to complete 1 year of treatment (TPH + AC).21
223782776|NCT02379585|DRUG|Pertuzumab|docetaxel (T) 75 mg/m2 every 3 weeks for four cycles. Trastuzumab (H, 8mg/kg for 1st cycle, then 6 mg/kg in subsequent 3 cycles), Pertuzumab (P, 840 mg for 1st cycle, then 420 mg in subsequent 3 cycles) will be given concurrently with docetaxel for a total of 4 cycles before surgery. For patients who do not achieve pCR, adjuvant chemotherapy with doxorubicin (A) 60 mg/m2 plus cyclophosphamide (C) 600 mg/m2 every 3 weeks for four cycles will be given, followed by trastuzumab 6 mg/kg every 3 weeks to complete 1 year of treatment. For patients with pCR, only trastuzumab 6 mg/kg every 3 weeks will be given adjuvantly to complete 1 year of treatment (TPH + AC).21
223782777|NCT03135522|DRUG|Zinc Acetate 50 Mg Oral Capsule|"* Day 0 (randomization) to day 3 Zinc acetate 50 mg per day (one capsule)~* Day 4 to day 7 If well tolerated: Zinc acetate 100 mg per day (two capsules)~* Day 8 to V5 (6 weeks) If well tolerated: Zinc acetate 150 mg per day (three capsules)"
223782778|NCT03135522|DRUG|Placebo oral capsule|"* Day 0 (randomization) to day 3 Placebo (one capsule per day)~* Day 4 to day 7 If well tolerated: placebo (two capsules per day)~* Day 8 to V5 (6 weeks) If well tolerated: placebo (three capsules per day)"
223782779|NCT04530175|OTHER|blood sampling|2 blood samples will be taken from the blood circuit 1 hour after the start of the hemodialysis session by the nurse in charge of the patient.
223782780|NCT02838017|DEVICE|Tissue Adhesive|
223782781|NCT02838017|DEVICE|Sterile strips|
223782782|NCT02120924|DRUG|Azelaic acid|Dosage form: Topical gel Dosage: Apply gel to the affected areas of the face twice daily for 12 weeks. The amount needed depends upon the size of the lesion site. Assure that enough is applied to adequately cover each lesion. Normally 0.5 g of gel is used on each 5 cm x 5 cm lesion site.
223782783|NCT02120924|DRUG|Vehicle|Dosage form: Topical gel Dosage: Apply gel to the affected areas of the face twice daily for 12 weeks. The amount needed depends upon the size of the lesion site. Assure that enough is applied to adequately cover each lesion. Normally 0.5 g of gel is used on each 5 cm x 5 cm lesion site.
223782784|NCT02120924|DRUG|Finacea|Dosage form: Topical gel Dosage: Apply gel to the affected areas of the face twice daily for 12 weeks. The amount needed depends upon the size of the lesion site. Assure that enough is applied to adequately cover each lesion. Normally 0.5 g of gel is used on each 5 cm x 5 cm lesion site.
223782785|NCT01884350|DRUG|Apixaban|
223782786|NCT06535087|DRUG|Subcutaneous immunotherapy / Standard Treatment for Asthma and Rhinitis|"1. Subcutaneous Allergen-Specific Immunotherapy:~   * Pre-treatment: Omalizumab subcutaneous injection, with the total IgE level serving as the basis for calculating the dosage for children. The appropriate dosage of omalizumab (each dose ranging from 75 to 600 mg) and administration frequency (once every 4 weeks) are determined based on the baseline IgE (IU/mL, measured before the start of treatment) and body weight (kg).~  * Mite Allergen Preparation: (Antergen/Alutard)~2. Standard Treatment:~   * Asthma: Inhaled corticosteroids (ICS) combined with long-acting beta-2 agonists, leukotriene receptor antagonists.~  * Allergic Rhinitis: Oral antihistamines, nasal antihistamines, nasal corticosteroids, anti-leukotriene drugs, cromolyn sodium, decongestants (oxymetazoline hydrochloride), and nasal saline irrigation."
223782787|NCT00319423|PROCEDURE|Patient education and supervised exercise|Patient education: 3 sessions Supervised exercise: 2-3 times/week for 12 weeks
223782788|NCT00299234|DRUG|Atomoxetine|titration schedule: 0.5 to 1.5 mg/kg/day
223782789|NCT06222996|BEHAVIORAL|vaccine hesitation training|Training will be given to primiparous expectant mothers on vaccine hesitation with the support of the web page created by the researcher
223782790|NCT04020120|OTHER|questionnaires|answer questionnaires
223782791|NCT02345512|DEVICE|Lycra Splinting Garment|Wearing of lycra splinting garment for 6 weeks
223782792|NCT06205524|BIOLOGICAL|TI-0010|Sterile liquid for injection
223782793|NCT06205524|BIOLOGICAL|Placebo|0.9% sodium chloride (normal saline) injection
223782794|NCT02018055|DRUG|Aspirin+Ticagrelor|Aspirin+ Ticagrelor after 1month of standard DAPT (Aspirin+Ticagrelor)
223782795|NCT02018055|DRUG|Aspirin+Clopidogrel|Aspirin+ Clopidogrel after 1month of standard DAPT (Aspirin+Ticagrelor)
223782796|NCT05898542|PROCEDURE|Nature-based therapy|Therapy sessions conducted outdoors
223782797|NCT02171468|DRUG|Dabigatran high dose|
223782798|NCT02171468|DRUG|Dabigatran low dose|
223782799|NCT03861000|DRUG|[C-11]T-1650|radio-labeled drug
223782800|NCT03861000|DRUG|BPN14770|selective compound
223782801|NCT01968434|DEVICE|protective cough syrup|The mucoadhesive and radical scavenging properties of the components create a protective film on the pharynx which protects irritated mucosa from cough generating stimuli such as post nasal drip, irritating elements, dehydration.
223782802|NCT01968434|DRUG|carbocisteine cough syrup|Mucolytic
223782803|NCT01855009|DIETARY_SUPPLEMENT|MannaBears|Subjects will be administered 4 MannaBears daily
223782804|NCT01855009|DIETARY_SUPPLEMENT|AlgaeCal Calcium|Subjects will be administered 750 mg AlgaeCal Calcium
223782805|NCT01855009|DIETARY_SUPPLEMENT|Calcium carbonate|Subjects will be administered 1000 mg calcium carbonate
223782806|NCT01855009|DIETARY_SUPPLEMENT|Vitamin D3|Subjects will be administered 800 IU vitamin D3
223782807|NCT06393361|DRUG|Chidamide; Decitabine; Anti-PD-1 Antibody|Chidamide 10mg/day, day1-4; 20mg/day, day 8,11, 15, 18. Decitabine 10mg/day, day1-5. Physicians will decide which immune checkpoint inhibitors will be used during treatment.
223782808|NCT06393361|DRUG|Brentuximab Vedotin, anti-PD-1 antibody.|Brentuximab Vedotin 1.8mg/kg d1, anti-PD-1 antibody d1. Physicians will decide which immune checkpoint inhibitors will be used during treatment.
223782809|NCT05707234|DEVICE|VRH|The VR headset and headphones will be placed on patients after the spinal anesthesia, once the patient is positioned and the surgical drapes installed. Patients will then undergo a 120-minute Digital Sedation™ program (Aqua+© 120 Version 1.1 or subsequent version, Oncomfort SA, Waver, Belgium). They will experience an underwater experience while listening to hypnotic script designed to induce a change in state of consciousness, increasing parasympathetic system tone and relaxation response, and reducing the perception of painful stimuli. While the session is running, HCPs can see what is projected into the VRH headset on their Sedakit's X2 controller (i.e. the tablet connected to the glasses).
223782810|NCT05707234|DRUG|Midazolam sedation|During the procedure, the patient in the control group receives pharmacological sedation, which is the standard of care currently practiced. Such sedation allows intraoperative anxiolysis, which is constantly required by patients in order to dissociate from their surroundings. Recall that total knee replacement surgery is extremely noisy, and the surrounding environment is itself an anxiety-provoking factor for the patient. Light to moderate, intraoperative sedation is carried out by intermittent boluses of midazolam 1 mg IV. Boluses are given every 5 minutes until a sedation level of -2 or -3 on the RASS (Richmond Agitation-Sedation Scale) scale is reached.
223782811|NCT06653946|DRUG|Alteplase|Following the guidelines set by the American Heart Association/American Stroke Association (AHA/ASA), inclusion and exclusion criteria for alteplase were established; 0.9 mg/kg of alteplase up to a maximum dose of 90 mg was administered intravenously to eligible individuals within 4.5 hours of the beginning of their clinical manifestations (10% bolus, 90% infusion in 1 hour). After receiving IV-alteplase, all patients continued their management and rehabilitation in the stroke unit
223782812|NCT06653946|DRUG|Alteplase|Following the guidelines set by the American Heart Association/American Stroke Association (AHA/ASA), inclusion and exclusion criteria for alteplase were established; 0.9 mg/kg of alteplase up to a maximum dose of 90 mg was administered intravenously to eligible individuals within 4.5 hours of the beginning of their clinical manifestations (10% bolus, 90% infusion in 1 hour). After receiving IV-alteplase, all patients continued their management and rehabilitation in the stroke unit
223782813|NCT02394743|RADIATION|18FDG-PET|
223782814|NCT02791633|OTHER|Questionnaire|Quality of recovery and quality of recovery follow up questionnaires
223782815|NCT02070159|DRUG|Clopidogrel 600 mg|Patients administer 600 mg of clopidogrel as conventional loading dose of clopidogrel
223782816|NCT02070159|DRUG|Prasugrel 30 mg|Patients administer 30 mg of prasugrel as lower loading dose of prasugrel.
223782817|NCT02070159|DRUG|Prasugrel 60 mg|Patients take 60 mg of prasugrel as conventional loading dose of prasugrel.
223782818|NCT04280211|OTHER|Respiratory Assessment|Spirometric measurement
223782819|NCT04280211|OTHER|Vestibular Assessment|Assessment of peripheral vestibular dysfunction, angular vestibule ocular reflex, vestibular dysfunction
223782820|NCT04280211|OTHER|Balance Assessment|Postural stability
223782821|NCT06664281|BEHAVIORAL|SIT|sprint interval training
223782822|NCT06664281|BEHAVIORAL|SIT combined RIPC|sprint interval training combined with remote ischemic preconditioning
223782823|NCT06664632|BEHAVIORAL|Exp|"Participants in this group will receive treatment using the Knee Sync Partner, a novel portable device designed to provide electrical traction and stimulation specifically for the knee joint.~controlled mechanical traction to the knee joint to reduce joint contact pressure, enhance synovial fluid flow, and increase joint space. This is expected to alleviate pain and improve mobility."
223782824|NCT06664632|DIAGNOSTIC_TEST|control|This will include a combination of isometric and isotonic exercises aimed at strengthening the knee musculature, enhancing joint stability, and reducing pain. The exercise regimen will focus on major muscle groups supporting the knee, such as the quadriceps, hamstrings, and calf muscles.
223782825|NCT03065465|DEVICE|Over-the-scope hemoclipping device|A endoscopic entrapment of tissue for control of bleeding or other applications.
223782826|NCT03065465|OTHER|Standard endoscopic treatment|Standard therapy includes injection of dilute epinephrine, thermal coagulation with multipolar electrocautery (MPEC) probe, and/or hemoclips.
223782827|NCT05667298|DRUG|Adjuvant Immunoradiotherapy (ARM1) and Adjuvant Immunotherapy (ARM1B)|"Durvalumab treatment is to begin six weeks following patient ESD/EMR surgery.~Patients may delay dosing under the following certain circumstances:~1. Dosing may be delayed per Toxicity Management Guidelines (Appendix IV), due to either an immune or a non-immune-related AE.~2. Dosing intervals of subsequent cycles may be shortened as clinically feasible in order to gradually align treatment cycles with the schedule of tumor efficacy (RECIST) and PRO assessments. Subsequent time between 2 consecutive doses cannot be less than 22 days, based on the half-lives of durvalumab (see current Investigator Brochure for durvalumab).~3. Standard of Care Arm (CROSS):~4. Patients may delay and subsequently resume dosing per local standard clinical practice.~If dosing must be delayed for reasons other than treatment-related toxicity, dosing will occur as soon as feasible."
223782828|NCT05667298|DRUG|Adjuvant chemoradiotherapy|"Durvalumab treatment is to begin six weeks following patient ESD/EMR surgery.~Patients may delay dosing under the following certain circumstances:~1. Dosing may be delayed per Toxicity Management Guidelines (Appendix IV), due to either an immune or a non-immune-related AE.~2. Dosing intervals of subsequent cycles may be shortened as clinically feasible in order to gradually align treatment cycles with the schedule of tumor efficacy (RECIST) and PRO assessments. Subsequent time between 2 consecutive doses cannot be less than 22 days, based on the half-lives of durvalumab (see current Investigator Brochure for durvalumab).~3. Standard of Care Arm (CROSS):~4. Patients may delay and subsequently resume dosing per local standard clinical practice.~If dosing must be delayed for reasons other than treatment-related toxicity, dosing will occur as soon as feasible."
223782829|NCT04725331|BIOLOGICAL|BT-001|Oncolytic Vaccinia virus containing genes encoding the 4-E03 human recombinant anti-hCTLA4 antibody and human GM-CSF administered at different dose \[Phase I, Part A\]; one dose lower and at Recommended Dose for Part B \[Phase I, Part B\] by intra-tumoral (IT) route.
223782830|NCT04725331|DRUG|Pembrolizumab [KEYTRUDA®]|Programmed death receptor (PD-1) blocking antibody administered at 200mg by intravenous (IV) infusions every 3 weeks.
223782831|NCT02352038|DEVICE|low-level laser therapy|The test teeth will receive LLLT using a 940 nanometer diode laser (EZLASE; BIOLASE Technology Inc., Irvine, CA, USA) with output power of 330 milliwatt. The experimental side was irradiated for 30 s in two sessions, delivering an energy density of 7 Joules per square centimeter.
223782832|NCT02352038|OTHER|orthodontic treatment|Orthodontic treatment will be carried out using preadjusted appliances with bonded 0.022×0.028-square inch brackets/buccal tubes and 0.014-inch NiTi archwires as the first archwires. The treatment or the major part of the treatment will be completed in 12 months.
223782833|NCT03358563|DRUG|Docetaxel|Docetaxel is a commercially marketed product that has been approved by the FDA for the treatment of metastatic prostate cancer. It is also approved for the treatment of other malignant disease, such as locally advanced or metastatic breast cancer that returns after any prior chemotherapy; locally advanced or metastatic non-small cell lung cancer that recurs after prior platinum-based chemotherapy. However, the FDA does not currently approve its use in patients with localized prostate cancer but no evidence of radiographic metastases.
223782834|NCT03358563|DRUG|Degarelix|Degarelix is a leuteinizing hormone-releasing hormone (LHRH) antagonist. Degarelix is administered at an initial dose of 240 mg subcutaneously (2 separate injections of 120mg each totaling 240 mg) two weeks prior to cycle 1 day 's 1 treatment with chemotherapy. The initial dose is followed by a maintenance dose of 80mg administered subcutaneously as a single injection every 28 days at cycle 2 day 1 (+/- 7 days) and cycle 3 day 10 (+/- 7 days)
223782835|NCT03358563|DRUG|Bicalutamide|The dose for bicalutamide tablets therapy in combination with an LHRH analog is one 50 mg tablet once daily (morning or evening), with or without food. It is recommended that bicalutamide tablets be taken at the same time each day. Treatment with bicalutamide tablets should be started at the same time as treatment with an LHRH analog.
223782836|NCT03358563|RADIATION|Ferumoxytol-enhanced MRI imaging|Ferumoxytol-enhanced MRI imaging will evaluate immune micro-environment in the prostate. Three subjects enrolled to the study will undergo the first ferumoxytol-enhanced MRI imaging within 21 days prior to start of hormonal therapy followed by second and final ferumoxytol-enhanced MRI at the conclusion of hormone therapy but prior to their prostatectomy.
223782837|NCT06348784|DIAGNOSTIC_TEST|Assesment of Different NEoplasias in the adenexa model|The ADNEX model includes nine parameters; Age, CA-125 level, Oncology center (yes/no), and 6 ultrasound features which are maximal diameter of the lesion, maximal diameter of the largest solid part, more than 10 locules (yes/no), number of papillary projections (0/1/2/3/more than 3), acoustic shadow, and ascites
223782838|NCT06348784|DIAGNOSTIC_TEST|Risk of malignancy index|The RMI was measured as follows; Menopausal status (score is 3 as all patients were postmenopausal X Ultrasound score is based on assessment of 5 features and with the presence of one feature, the score is 1 while if more than one feature is present, the score is 3; the five ultrasound features are the presence of solid components, multilocularity, bilaterality, ascites, and metastases X CA - 125 level
223782839|NCT06348784|DIAGNOSTIC_TEST|Histopathologic examination|Histopathologic examination of all excised specimens was done as this is the gold standard test for detecting ovarian malignancy
223782840|NCT06495671|DEVICE|Magnetically enhanced diffusion|Iron nanoparticle (intra-arterial) + External magnet workstation
223782841|NCT02426671|DEVICE|MuteButton sensory stimulation device|Participants are asked to use the MuteButton daily for 30-40 minutes. They receive 'pink noise' through headphones and transcutaneous stimulation on the tongue using a 'lollipop' sensor that sits on the anterior section (tip) of the tongue.
223782842|NCT02671669|BEHAVIORAL|Usual Care|Discharge packet of Heart Healthy instructions, with self-report health status, quality of life and psychosocial questionnaires, as well as other educational handouts, exit interview to review exercise progress, receive referrals to additional medical services they might need after discharge from the program, with physician.
223782843|NCT02671669|BEHAVIORAL|Movn application (MVN)|"Intervention participants will receive the same discharge packet as the UC group along with their exit interview and will receive the following:~* Participant individualized Heart Healthy instructions for post-cardiac rehabilitation will be integrated into the MVN application including daily medication reminders, physical activity prompts, educational materials, and patient-reported outcome assessment of behavior and psychosocial status.~* Text messages will be used on an ad hoc basis to provide positive feedback to the participant; two-way messaging between the participant and the research coordinator will be available to provide opportunities to answer specific questions."
223782844|NCT00390052|DRUG|triapine|Given IV and orally
223782845|NCT00390052|OTHER|pharmacological study|correlative study
223782846|NCT00390052|PROCEDURE|laboratory biomarker analysis|Correlative study
223782847|NCT06533202|BEHAVIORAL|Psychoeducational Programme|The objective of this type of programme is to equip individuals with the knowledge and skills required to navigate the challenges and capitalise on the opportunities presented by retirement. In particular, the programme strives to enhance the quality of life and attitudes towards retirement, elevate levels of life satisfaction, psychological flexibility, perceived social support and general health, self-efficacy and self-regulation, and mitigate stereotypes associated with ageing.
223782848|NCT06533202|BEHAVIORAL|Education Programme|At the end of the baseline assessment, participants will receive instructions and recommendations to facilitate a positive and healthy transition to retirement, as part of an education programme. These will focus on the benefits of an active lifestyle and general guidelines to follow.
223782849|NCT01383070|BEHAVIORAL|Lactational Counseling by Cell phone|The approach to promoting TIBF, EBF and TICF will be through cell phone counseling in addition to counseling in the hospitals during scheduled ante natal visits. Mother in the intervention group (beneficiaries) would be provided handsets and included in a subsidized calling plan.
223782850|NCT01834417|DEVICE|TexiMat|
223782851|NCT06548555|OTHER|systematic educational intervention|This is a non-interventional study and does not impose a therapy protocol, or a diagnostic/therapeutic procedure. Patients are treated according to the local prescribing information, and routine medical practice in terms of visit frequency and types of assessments performed and only these data is collected as part of the study.
223782852|NCT06189976|DIAGNOSTIC_TEST|Rapid atrial pacing|Rapid atrial pacing after TAVI
223782853|NCT05556681|DEVICE|BD™ Sirolimus Drug Coated Balloon Catheter percutaneous transluminal angioplasty|The study will enroll patients presenting with clinical evidence of an angiographically significant lesion (Lesion ≥ 70% stenosis by visual estimate) in the femoropopliteal arteries. Eligible patients will undergo percutaneous transluminal angioplasty with the investigational BD™ Sirolimus Drug Coated Balloon Catheter.
223782854|NCT02265042|DEVICE|Stimulette|electrical stimulation device by Dr. Schuhfried Medizintechnik GmbH, Vienna, Austria
223782855|NCT05427799|DIETARY_SUPPLEMENT|Honey|A mixed flora honey that will be obtained from local producers. and will be consumed by a daily dose of 0.5 g/kg body weight of honey by each participant and will be divided into two doses.
223782856|NCT05427799|DIETARY_SUPPLEMENT|Other carbohydrate alternatives such as jell-o|A daily dose of 0.5 g/kg body weight of Jell-O will be consumed by each participant and will be divided into two doses. Jell-O was selected as a source of sucrose with negligible phenolic capacity.
223782857|NCT00244504|DRUG|moxonidine|moxonidine 0.2 mg/d starting the morning of surgery until day 4 after surgery
223782858|NCT02669329|DEVICE|CoolSculpting device with vacuum applicator.|The CoolSculpting device with a vacuum applicator will be used to perform the treatments.
223782859|NCT01873794|DEVICE|Bright white light|
223782860|NCT01873794|DEVICE|Dim red light|
223782861|NCT03070522|DRUG|Prednisone|oral prednisone for 7 days during pulmonary exacerbation
223782862|NCT03070522|DRUG|Placebos|Placebo
223782863|NCT03357601|BEHAVIORAL|HIIT|The participant will perform HIIT where they will warm up for 3 minutes at 30% maximum heart rate (MHR), followed by 20 seconds of high intensity interval exercise at an all out intensity separated by 2 minutes of active recovery at 30% MHR. The interval will be repeated six times. Once completing all six intervals, participants will cool down for 3 minutes. This training program will be performed three times per week for five weeks.
223782864|NCT03357601|BEHAVIORAL|MCEET|The participant will perform MCEET, where they will warm up for 3 minutes at 30% maximum heart rate (MHR), followed by 14 minutes of moderate, continuous endurance exercise at 70% MHR. Participants will cool down for 3 minutes. This training program will be performed three times per week for five weeks.
223782865|NCT01543256|DEVICE|WallFlex™ Biliary RX Fully Covered Stent System RMV|"Temporary placement of the WallFlex Biliary RX Fully Covered Stent for treatment of benign biliary strictures secondary to chronic pancreatitis. The stent will be removed after 12 months indwell. (RMV in intervention name indicates removable)"
223782866|NCT01543256|DEVICE|Commercially available Plastic Stent Per Investigator preference|Temporary placement/exchange of multiple biliary plastic stents for treatment of benign biliary strictures secondary to chronic pancreatitis. Stents will be removed after cumulative indwell of 12 months.
223782867|NCT01318226|DRUG|ATx08-001|ATx08-001 will be administered as a 6mm white film coated tablet of 2.5 mg strength, to be taken orally at a dose of 2.5 mg or 7.5 mg, twice a day approximately every 12 hours over an 8 day period.
223782868|NCT01318226|DRUG|Placebo|Placebo will be administered as a 6mm white film coated tablet, twice a day approximately every 12 hours over an 8 day period. Placebo is identical in appearance to the ATx 08-001 tablet.
223782869|NCT03823118|DRUG|S1/Anlotinib|Anlotinib 12mg qd, day 1 to day 14 followed by 7 days off treatment in a 21-day cycle until maximum 6 cycles； S1 60mg bid, day 1 to day 14 followed by 7 days off treatment in a 21-day cycle until it can not tolerate, or disease progression.
223782870|NCT03704376|DRUG|30 ml of 0.2% ropivacaine|
223782871|NCT03704376|DRUG|15 ml of 0.2% ropivacaine|
223782872|NCT03704376|DRUG|100 mcg clonidine|
223782873|NCT03704376|DEVICE|High-frequency linear ultrasound transducer|
223782874|NCT04020991|DIAGNOSTIC_TEST|Sleep Study|Participants who noted to have Oxygen Desaturation Index more than 10 (moderate to severe OSA) will be referred to do formal sleep study and referral to Sleep Medicine Clinic
223782875|NCT01865370|DIETARY_SUPPLEMENT|Kochujang Pills|Kochujang Pills (34.5g/day)
223782876|NCT01865370|DIETARY_SUPPLEMENT|Placebo|Placebo (34.5g/day)
223782877|NCT01108848|BIOLOGICAL|Berinert® (C1 Esterase Inhibitor)|Berinert® is marketed as a lyophilized concentrate available in a single-use vial to be reconstituted with sterile water before administration as described in the prescribing information.
223782878|NCT02053948|PROCEDURE|Pursestring Wound Closure|
223782879|NCT02053948|PROCEDURE|Gunsight Skin Incision and Closure Technique|
223782880|NCT02201927|DEVICE|galvanic vestibular stimulation|
223782881|NCT04525391|DRUG|Durvalumab+AZD2811 to SCLC patients|AZD2811 must NOT be infused through a 0.2-µm or 0.22-µm filter and therefore durvalumab and AZD2811 MUST be infused through different infusion lines. In order not to exceed the endotoxin limit, durvalumab and AZD2811 mustbe administered consecutively. Durvalumab is administered first over 1 hour, followed by AZD2811 administered over 2 hours. AZD2811 should be administered at 30 minutes after the end of the durvalumab infusion, as long as there are no acute infusion reactions to durvalumab.
223782882|NCT06269770|DRUG|Tapentadol|Add tapentadol, for effective pain management in a multimodal setting during TKR.
223782883|NCT06269770|DRUG|Tramadol|Add tramadol, for effective pain management in a multimodal setting during TKR.
223782884|NCT04712942|DRUG|Pevonedistat|Patients receive pevonedistat at 20 mg/m2 i.v. (d1,3,5, q4w) up to 12 cycles
223782885|NCT04712942|DRUG|Azacitidine|azacitidine is given at a standard dose of 75 mg/m² (d1-7 or 1-5,8,9, q4w) up to 12 cycles
223782886|NCT02733900|PROCEDURE|femoral head removal|
223782887|NCT04058769|DEVICE|Premedication Guide|Software with guidelines recommendations for preoperative assessment
223782888|NCT05500469|DEVICE|Paul glaucoma drainage device (GDD)|Implantation of the GDD
223782889|NCT03330379|DEVICE|Tracoe Smart CuffmanagerTM|In patients randomly assigned to the continuous adjustment strategy, in addition to standard care, the Tracoe Smart CuffmanagerTM will be connected to the tracheal cuff. Within the 2 days following the inclusion, all the intermittent Pcuff measurements will be collected as well as the incidence of Pcuff manual adjustments
223782890|NCT06462326|DRUG|Moxifloxacin Oral Tablet|400mg per tablet
223782891|NCT06462326|DRUG|Omadacycline Oral Tablet|150 mg per tablet
223782892|NCT00074282|BIOLOGICAL|rituximab|
223782893|NCT00074282|DRUG|cyclophosphamide|
223782894|NCT00074282|DRUG|pentostatin|
223782895|NCT00074282|DRUG|Alemtuzumab|
223782896|NCT05973071|BEHAVIORAL|Tuune Supplemented Contraceptive Visit|Participants complete the Tuune contraceptive decision aid health questionnaire (Tuune for clinics) as part of their standard OBGYN clinic appointment.
223782897|NCT05973071|BEHAVIORAL|Traditional Contraceptive Visit|Participants will complete a standard OBGYN clinic appointment without using the Tuune contraceptive decision aid health questionnaire (Tuune for Clinics).
223782898|NCT00464542|DRUG|Metronidazole|500 mg, taken by mouth, two times a day, 7 days
223782899|NCT00740545|DRUG|enoxaparine 40 mg daily|Women inject ourselves every days with 40 mg of enoxaparine
223782900|NCT00740545|DRUG|placebo|Women inject ourselves every days with placebo
223782901|NCT00605241|DRUG|GSK598809|Drug
223702061|NCT05274737|DEVICE|Novel sling|The novel sling was designed and created by the principal investigator to address these concerns of the traditional slings that are currently available for postsurgical protection and immobilization after shoulder surgery. It is anticipated that the novel sling will allow the patient to be more active and more comfortable while still providing a safe healing environment after a shoulder injury or shoulder surgery.
223782902|NCT02290665|OTHER|Thermosensitive gel rectal formulation|
223782903|NCT02290665|OTHER|Saline enema|
223782904|NCT01882634|DEVICE|Ultrasound (Trademark:VScan; Manufacturer:General Electric)|Standardized measurements were made and aorta will be visualized in a minimum of three hard copy images: upper transverse projection abdominal aorta at the level of epigastrium (celiac trunk) lower transverse section for distal view of aorta (pre-bifurcation), and longitudinal section (with origin of celiac trunk or superior mesenteric artery), determining the maximum diameter in centimeters (cm)
223782905|NCT00275093|DRUG|temsirolimus|Given IV
223782906|NCT00275093|OTHER|laboratory biomarker analysis|Correlative studies
223782907|NCT00275093|OTHER|pharmacological study|Correlative studies
223782908|NCT02861690|DRUG|Liposomal Paclitaxel|Patients received Liposomal Paclitaxel 175mg/m2 every 21 days until the presence of progressive disease or unacceptable toxicity.
223782909|NCT02861690|DRUG|Nedaplatin|Patients received Nedaplatin80mg/m2 every 21 days until the presence of progressive disease or unacceptable toxicity.
223702062|NCT05274737|DEVICE|Traditional abduction sling|An abduction sling is the most common type of sling utilized to protect patients after rotator cuff surgery and total shoulder of arthroplasty and can be considered the current standard of care.
223782910|NCT01474603|DIETARY_SUPPLEMENT|n-3 PUFA in protein-enriched low-GI diet|3 g per day n-3 polyunsaturated fatty acids in a protein-enriched low-GI diet
223782911|NCT01773226|DEVICE|"Autologous Protein Solution APS(TM)"|A therapy prepared at the point-of-care from a small sample of the patient's own blood containing high concentrations of anti-inflammatory and anabolic proteins
223782912|NCT01429259|DRUG|meropenem|meropenem 40mg/kg total body weight will be administered every 8 hours. Each infusion will be infused as a 3 hour infusion.
223782913|NCT03440632|DEVICE|FES|Functional electrical stimulation of the ankle dorsiflexors during walking, using a (superficial) neurostimulator with tilt sensor.
223782914|NCT04040803|DEVICE|Transcranial alternating current stimulation (tACS) and transcranial random noise stimulation (tRNS)|Transcranial alternating current stimulation (tACS) and transcranial random noise stimulation (tRNS) are two (CE marked medical devices) new, non-invasive (over the scalp) brain stimulation (NIBS) techniques. Both tACS and tRNS deliver a weak current continuously across the brain using pads placed over the scalp, which has been shown safe and well-tolerated by healthy adults and patients. These two techniques are able to softly alter physiological function within the brain. tACS can influence the brainwaves which have been demonstrated to play important roles in movement, sensation, and thinking functions. tACS and tRNS have been investigated for several years and have been shown to be safe, well tolerated and produce beneficial results in hand movement, hearing, and working memory.
223782915|NCT04000451|DEVICE|oxyhydrogen|Hydrogen/oxygen mixed gas inhaled(proportion 2:1),3 L/min . 1 hour each time,twice a day(BID).Test Duration is seven days
223782916|NCT04000451|DEVICE|Oxygen|oxygen inhaled,3 L/min . 1 hour each time,twice a day(BID).Test Duration is seven days
223782917|NCT04000451|DRUG|Conventional treatment|Bronchodilator (LABA,LAMA) with or without ICS.Conventional treatment is invariable with which was given to COPD patients in seven days before the study
223782918|NCT02699177|DEVICE|CBF measurements|CBF measurements
223782919|NCT04269772|BEHAVIORAL|CARE|Hybrid in-person and telephone-based adjunctive intervention for bipolar disorder across the transition from prison to the community.
223782920|NCT04269772|OTHER|Treatment As Usual|Treatment as usual, unrestricted, as provided by prison and community providers.
223782921|NCT01097135|DRUG|Duraprep Surgical Solution|
223782922|NCT02295111|DEVICE|EA treatment|Electro acupuncture and traditional Chinese Medicine Health consult
223782923|NCT02295111|BEHAVIORAL|TCM health consult|Traditional Chinese Medicine Health Consult without needling
223782924|NCT02295111|OTHER|Usual Care|Standard NHS care
223702063|NCT00199875|DRUG|Yttrium-90 conjugated chimeric G250 (^90Y-DOTA-cG250)|Patients received a single infusion of \^90Y-DOTA-cG250, with escalating doses administered to sequentially enrolled cohorts until MTD determination.
223702064|NCT03506932|DIETARY_SUPPLEMENT|Untreated|Bread made with 20% yellow pea flour that was untreated.
223702065|NCT03506932|DIETARY_SUPPLEMENT|Heat treated with 0% moisture|Bread made with 20% yellow pea flour that was heat treated with 0% moisture.
223702066|NCT03506932|DIETARY_SUPPLEMENT|Heat treated with 10% moisture|Bread made with 20% yellow pea flour that was heat treated with 10% moisture.
223702067|NCT03506932|DIETARY_SUPPLEMENT|Wheat|Bread made with 100% wheat
223702068|NCT01024231|DRUG|BMS-936558 (MDX1106-04)|
223702069|NCT01024231|DRUG|Ipilimumab|
223702070|NCT02514603|DRUG|Prexasertib|Administered IV
223782925|NCT01806480|BEHAVIORAL|Person-centred proactive breastfeeding telephone support|Person-centred care is a model of care, which comprise components such as: building mutual trust and understanding; treating the person as an individual; respect the rights for the person, sharing decision-making, providing holistic care and developing therapeutic relationships. Furthermore, the care provider should have a sympathetic presence and show an engagement
223782926|NCT06391112|OTHER|Painting Based Art intervention|Painting Based Art Effect of Intervention on Maternal Anxiety and Fetal Parameters
223782927|NCT02081300|DRUG|Oral testosterone undecanoate, LPCN 1021|
223782928|NCT02081300|DRUG|Topical testosterone gel 1.62 %|
223782929|NCT03129334|BEHAVIORAL|LST Middle School Online|The adapted intervention will (1) utilize both online e-learning module (self-guided) and classroom-based sessions (facilitator led) to address PDA and concurrent ATOD abuse; (2) positively change social norms and challenge positive expectancies regarding PDA and ATOD abuse; (3) discourage diversion of prescription medications; (4) enhance protective factors by building social and self-regulation skills through interactive learning and behavioral rehearsal scenarios; and (5) incorporate booster sessions.
223782930|NCT02094703|DRUG|Levofloxacin|
223782931|NCT02094703|DRUG|Solifenacin succinate|
223782932|NCT02094703|DRUG|Placebo (for Solifenacin succinate)|
223782933|NCT02337647|OTHER|DCDC App|The DCDC app is an experimental software that allows users to map their visual distortions on a tablet computer.
223782934|NCT01203189|DRUG|ketoconazole 2% foam|Subjects in the Foam (F) group will apply ketoconazole 2% foam to the scalp twice daily for four weeks.
223782935|NCT01203189|DRUG|ketoconazole 2% shampoo|Subjects in the Shampoo (S) group will wash their hair twice weekly for four weeks with ketoconazole 2% shampoo.
223782936|NCT05403489|PROCEDURE|Bronchoalveolar lavage|In cases approved for bronchoscopy, bronchoalveolar lavage was performed and culture analysis was performed.
223782937|NCT05403489|PROCEDURE|endotracheal aspirate culture|In cases where consent for bronchoscopy could not be obtained, tracheal secretions were aspirated and culture analysis was performed.
223782938|NCT00765115|DRUG|LY450139|
223782939|NCT00765115|DRUG|placebo|
223702071|NCT02883842|BEHAVIORAL|Text messaging|Patients will receive regular semi-personalized text messages for 6 months. Each participants will receive 6 text messages per week, which will be sent at random times of the day (9.00am, 12noon, 4.00pm). They will receive one general messages, one hypertension message, one glucose control message, one lifestyle message, one medication adherence message and one physical activity message per week. Prior to study commencement, a bank of 270 messages have been developed based on guidelines and behavior change theory (BCT), and have underwent multidisciplinary expert review and qualitative review process.
223782940|NCT05812573|OTHER|no intervention|No intervention, only observation
223782941|NCT02055352|DRUG|Budesonide|Budesonide 400 mcg twice a day via Breezhaler® device
223782942|NCT02055352|DRUG|Fluticasone|Fluticasone 250 mcg twice daily via Accuhaler® device
223702072|NCT00585962|RADIATION|Proton Beam Radiation|Once a day, 5 days a week (Monday-Friday), for 8 weeks.
223782943|NCT02055352|DRUG|Indacaterol|Indacaterol 150 mcg once daily via Breezhaler® device
223782944|NCT02055352|DRUG|Salmeterol|Salmeterol 50 mcg twice daily via Diskus® device
223782945|NCT04589819|DRUG|Teriparatide|Teriparatide, an injectable synthetic parathyroid hormone, will be tested to evaluate its efficacy for decreasing the convalescence after a diaphyseal tibial stress fracture, a specific bone stress injury.
223782946|NCT04589819|DRUG|Placebos|Placebo will be a sugar solution of the manufacturer's design.
223782947|NCT03956017|DRUG|Ubiquinone|Take oral tablets as directed (2x200 mg for 3 days prior to surgery)
223782948|NCT03956017|DRUG|Placebo|Take oral tablets as directed (2x200 mg for 3 days prior to surgery)
223782949|NCT02180646|OTHER|High protein breakfast|a high protein breakfast - 500 kcal (35% protein, 45% CHO, 20% fat)
223782950|NCT02180646|OTHER|High carb breakfast|a high carbohydrate breakfast - 500 kcal (15% protein, 65% CHO, 20% fat)
223782951|NCT02062502|BIOLOGICAL|VARIVAX™ New Seed Process|Varicella virus vaccine live manufactured with a new seed process
223782952|NCT02062502|BIOLOGICAL|VARIVAX™ 2007 process|Varicella virus vaccine live manufactured with the 2007 process
223782953|NCT02062502|BIOLOGICAL|M-M-R II™|Measles, Mumps, and Rubella virus vaccine live
223782954|NCT03809182|DRUG|Dexmedetomidine|A bolus of 1ug/kg in 10 minutes, followed by an infusion of 0.5ug/kg/h until the end of surgery.
223782955|NCT03809182|DRUG|0.9% Sodium-chloride|The same infusion rate used in the dexmedetomidine group.
223782956|NCT03809182|DRUG|Fentanyl|Intraoperative fentanyl was given in case of 25% increment in the blood pressure and/or heart rate in comparison to baseline (previous anesthesia induction).
223782957|NCT03809182|DRUG|Morphine Sulfate|Boluses of 3mg of intravenous morphine were given in the postoperative acute care unit. Once the pain score was equal or less than 3/10 the patient-controlled analgesia pumps were installed and the patients were discharged to their room.
223782958|NCT04554862|DRUG|Magnesium sulfate|magnesium sulfate will be added to the block
223782959|NCT04554862|DRUG|Ketorolac Tromethamine|ketorolac will be added to the block
223782960|NCT04554862|PROCEDURE|supraclavicular block|it is done by ultrasound- guided
223782961|NCT00326508|DRUG|Daclizumab|
223782962|NCT01797146|PROCEDURE|Catheter Reminder and Evaluation Program|"This intervention will be implemented by ward nurses and responsible physicians. The details of intervention are shown below.~1. Nurse: Every morning, a ward nurse will check if any patient has a urinary catheter or a central venous catheter in place. An order sheet will be marked with a CARE-rubber stamp and the following information will be added by hand-writing.~   * Type and duration of urinary catheter use.~  * Indication of urinary catheter \_\_\_\_\_\_\_\_\_~  * Type and duration of central venous catheter use~  * Indication of urinary catheter \_\_\_\_\_\_\_\_\_~2. Responsible physician: During a morning round, a physician needs to fill the indication of catheter use. If a given physician does not fill the indication of urinary catheter use, the catheter will be automatically removed. If a given physician does not fill the indication of central venous catheter, the CARE team will be notified."
223782963|NCT04218929|OTHER|Study Formula (SF)|New infant formula for term infants fed ad lib
223782964|NCT04218929|OTHER|Comparator Formula (CF)|Commercially available infant formula for term infants fed ad lib
223782965|NCT03641482|DRUG|NBF|Once the molar is extracted, the socket is cleaned with water, NBF gel is introduced, and the flap is closed. Then, the patients are instructed to apply NBF Gel in the surgical wound 3 times per day for 7 days after brushing their teeth. Previously they have to dry the area of the wound with gauze.
223782966|NCT03641482|DEVICE|Placebo|Once the molar is extracted, the socket is cleaned with water, placebo gel is introduced, and the flap is closed. Then, the patients are instructed to apply placebo gel in the surgical wound 3 times per day for 7 days after brushing their teeth. Previously they have to dry the area of the wound with gauze.
223782967|NCT03285282|PROCEDURE|Thoracolumber interfascial plane block|Thoracolumber interfascial plane block versus placebo
223782968|NCT03844763|DRUG|Avelumab|Avelumab: 10 mg/kg every 2 weeks, untill PD or major toxicity
223782969|NCT03844763|DRUG|CTX|CTX: 50 mg Daily untill PD or major toxicity
223782970|NCT03844763|RADIATION|RT|RT: 8 Gy single shot day 8
223702073|NCT03210623|DEVICE|stent retriever(TonbridgeMT)|mechanical thrombectomy with stent retriever(TonbridgeMT), digital subtraction angiography(DSA), computed tomography(CT), magnetic resonance imaging (MRI), diffusion weighted imaging (DWI)
223782971|NCT02848508|DRUG|Metformin|
223782972|NCT00846664|PROCEDURE|Logan Short Arc Banding|Group 1 wil perform short arc banding twice a week for four weeks and have diagnostic ultrasound of multifidus measured before and after intervention
223782973|NCT05402267|PROCEDURE|Adenoidectomy|Adenoidectomy will be conducted in OA and CA groups
223782974|NCT00489970|PROCEDURE|Taking of blood samples|No treatment is planned to be given in this study. Blood samples will be collected at the following time points: 1 year, 3 years, 5 years and 9 years after the dose of vaccination.
223782975|NCT00489970|BIOLOGICAL|Boostrix|A single dose of Boostrix was administered in the primary study (NCT00346073). No treatment was given in this study.
223782976|NCT00489970|BIOLOGICAL|Adacel|A single dose of Adacel was administered in the primary study (NCT00346073). No treatment was given in this study.
223782977|NCT01093794|DRUG|Co-administration of 50 mg sitagliptin and 500 mg metformin|Co-administration of 50 mg sitagliptin and 500 mg China-sourced metformin as individual tablets with 240 ml water on Day 1 of the relevant treatment period (Sit + Met500) after fasting for at least 10 hours.
223702074|NCT03210623|DEVICE|Solitaire™|mechanical thrombectomy with Solitaire™ , digital subtraction angiography(DSA), computed tomography(CT), magnetic resonance imaging(MRI), diffusion weighted imaging(DWI)
223702075|NCT04135365|BEHAVIORAL|neurocognitive assessment|Observational study therefore there are no interventions
223702076|NCT04135365|BEHAVIORAL|neuroimaging assessment|Observational study therefore there are no interventions
223702077|NCT02894632|DEVICE|MRI compatible motion sensor (MARMOT)|MRI with motion control (several motion sensors placed on the volunteer's body)
223782978|NCT01093794|DRUG|sitagliptin/metformin 50 mg/500 mg tablet|Single dose administration of the final marketing image (FMI) sitagliptin/metformin 50 mg/500 mg fixed-dose combination (FDC) tablet with 240 ml water on Day 1 of the relevant treatment period (SitMet850 FDC) after fasting for at least 10 hours.
223782979|NCT01093794|DRUG|Co-administration of 50 mg sitagliptin and 850 mg metformin|Co-administration of 50 mg sitagliptin and 850 mg China sourced metformin as individual tablets with 240 ml water on Day 1 of the relevant treatment period (Sit + Met850) after fasting for at least 10 hours.
223782980|NCT01093794|DRUG|sitagliptin/metformin 50 mg/850 mg tablet|Single dose administration of the FMI sitagliptin/metformin 50 mg/850 mg FDC tablet with 240 ml water on Day 1 of the relevant treatment period (SitMet850 FDC) after fasting for at least 10 hours.
223782981|NCT02740127|PROCEDURE|Caudal Nerve Block (CNB)|General anesthesia given in the OR using Propofol titrated for induction. CNB given as bolus injection into the caudal canal in the operating room (OR) by attending anesthesiologist using 1% Ropivacaine (max 5mg/kg) + 1:400,000 Epinephrine + Decadron 10 mg + Clonidine 100 mcg.
223782982|NCT02740127|DRUG|Ropivacaine|Ropivacaine 1 % (max 5mg/kg) by bolus injection given by anesthesiologist in OR.
223782983|NCT02740127|DRUG|Epinephrine|Epinephrine 1:400,000 by bolus injection given by anesthesiologist in OR.
223782984|NCT02740127|DRUG|Decadron|Decadron 10 mg by bolus injection given by anesthesiologist in OR.
223782985|NCT02740127|DRUG|Clonidine|Clonidine 100 mcg by bolus injection given by anesthesiologist in OR.
223782986|NCT02740127|DRUG|Propofol|General anesthesia given in the OR using Propofol titrated for induction.
223782987|NCT02740127|BEHAVIORAL|Phone Call|Study staff calls participant about 3 days after surgery to ask about their pain, amount of pain drugs they have taken, and how satisfied they are with the type of anesthesia and pain control they received. This call should last about 5-10 minutes.
223782988|NCT04759820|DRUG|injecting Carbon Nanoparticles Suspension|injecting Carbon Nanoparticles Suspension for lymph node detection
223782989|NCT04759820|DRUG|Injecting indocyanine green|Injecting indocyanine green for lymph node detection
223782990|NCT04000906|DRUG|Nab paclitaxel|Dose escalation (7.5 mg/m2, 15 mg/m2, 25 mg/m2, 37.5 mg/m2, 52.5 mg/m2 and 70 mg/m2)
223782991|NCT04000906|DRUG|Cisplatin|10.5 mg/m2
223782992|NCT02707055|DRUG|PF-05190457|Ghrelin Receptor Inverse Agonist
223782993|NCT02707055|OTHER|Placebo|Placebo
223782994|NCT06158750|DEVICE|p64/p48 MW HPC Flow Modulation Device|Endovascular intervention with p64/p48 MW HPC Flow Modulation Device was performed in patients diagnosed with intracranial aneurysms
223782995|NCT03564496|DEVICE|tDCS Administration during MRI|All participants including healthy controls and MS patients will be given approximately 15 minutes of active tDCS during MRI. The simultaneous tDCS will be performed up to 2 mA dose intensity to determine CMRO2 changes from when the tDCS is on to when the tDCS is off. The stimulation consists of 15-min up to 2 mA tDCS using 5x5 cm electrode sponges with \~30s ramp-up and ramp-down periods.
223782996|NCT03564496|DEVICE|Remotely-supervised Daily tDCS Administration|"While the first tDCS session will be performed at clinic under the full supervision, remaining sessions 2-20 (\~ 1 month) will be completed at home with remote monitoring by the study technician. Participants in the HC subgroup who opt-in to the additional 15 minutes of imaging +tDCS may complete the first session remotely.~For at-home tDCS administration, participants will be given the specially-designed tDCS device and headset, study laptop computer for secure video monitoring with study technician (must have internet access) and access to the cognitive training program, a detailed reference manual, and a training video. The device will produce up to 2.0 mA stimulation for around 20 minutes, and will not operate without the correct headset placement. The device will also automatically abort the session if optimal conditions are not maintained. It reports and records a completion code for each session."
223782997|NCT03564496|DEVICE|Optional 15 minutes of imaging + simultaneous tDCS up to 4.0mA|Participants in the healthy control subgroup who are willing may have an additional 15 minutes of imaging combined with 10 minutes of simultaneous tDCS of up to 4.0mA added at the end of their baseline scan. In this case, after the initial imaging and tDCS portion is complete, the participant will remain on the scanner for an additional 15 minutes during which brain imaging will continue and will be combined with 10 minutes of simultaneous tDCS up to 4.0mA. This will be a one-time add-on and will not be required at follow-up.
223782998|NCT04989348|PROCEDURE|Gonadotrophin releasing hormone antagonist protocol|Women will receive antagonist (Cetrorelix 0.25mg) once subcutaneously daily from day 6 of ovarian stimulation till the day of the ovulation trigger or
223782999|NCT04989348|PROCEDURE|Progestin-primed ovarian stimulation protocol|Women will receive oral medroxyprogesterone 10 mg daily or Duphaston 10mg bd from Day 3 till the day of ovulation trigger.
223783000|NCT02977624|BEHAVIORAL|The Cognitive Orientation to daily Occupational Performance|
223783001|NCT01159938|DRUG|Lispro|Dosage based on participants with type 2 diabetes mellitus (T2DM) normal morning insulin dose and energy content of participant's normal breakfast. Subcutaneous injection given on one occasion. Administered once on low post prandial day.
223783002|NCT03914157|DEVICE|Low-energy extracorporeal ultrasound shockwave therapy (SWT)|SWT delivers 10% energy of the traditional SWT used for clinically indicated lithotripsy, evokes neovascularization, and improves regional blood flow and function in various ischemic tissues.
223783003|NCT02126293|DRUG|Zinc Supplement|
223783004|NCT02126293|PROCEDURE|Repeat blood and urine tests|
223783005|NCT02638662|OTHER|Observational|Questionnaires are completed such as self-evaluation questionnaire (STAI), Beck Depression Inventory, FertiQol International and Daily stress questionnaire
223783006|NCT05864794|DIAGNOSTIC_TEST|MRI|MRI scan of the brain
223783007|NCT00169169|DRUG|ACVBP|
223783008|NCT00169169|DRUG|ACE|
223783009|NCT00169169|DRUG|rituximab|
223783010|NCT00169169|PROCEDURE|Autologous stem cell transplant|
223783011|NCT01625429|DRUG|nab-paclitaxel|nab-paclitaxel 125mg/m2, day 1, 8, 15, q4w; carboplatin AUC 2, day 1, 8, 15, q4w; for HER-2 positive patients: trastuzumab loading dose 4mg/kg, then 2mg/kg, day 1, 8, 15, 22, q4w. All patients will receive up to four cycles except for unacceptable toxicity
223783012|NCT03214497|DEVICE|Protector|All patients which are assigned to the Protector are studied with this laryngeal mask
223783013|NCT03214497|DEVICE|Supreme|All patients which are assigned to the Supreme are studied with this laryngeal mask
223783014|NCT05073016|OTHER|neuromodulation|neuromodulation: Neuromodulation is technology that acts directly upon nerves. It is the alteration-or modulation-of nerve activity by delivering electrical or magnetic stimulus/current.
223783015|NCT05073016|OTHER|motor learning training|motor learning training requires performing a sequential training called finger taping task
223783016|NCT02942199|OTHER|MySafeRx|The MySafeRx platform is a combination of several key components, including daily videoconferencing check-ins with motivational interviewing-based recovery coaching, text-messaging reminders, secure storage of buprenorphine medication within a secure electronic pill dispenser (i.e., MedicaSafe 3000), and a standardized protocol for supervising self-administration of medication via videoconferencing.
223702078|NCT02700022|DRUG|Alisertib|Dose escalation of alisertib: level 1 - 20 mg, level 2 - 30 mg, level 3 - 40 mg PO BID on Days 1-5 of six 21-day cycles, combined with R-EPOCH Rituximab, IV infusion on day 1 of each cycle; Etoposide, IV infusion for 96 hours on days 1, 2, 3, and 4 Doxorubicin, IV infusion for 96 hours on days 1, 2, 3, and 4 Vincristine, IV infusion for 96 hours on days 1, 2, 3, and 4 Cyclophosphamide, IV infusion for 15 minutes on day 5 Prednisone, PO daily on days 1, 2, 3, 4, and 5
223702079|NCT04738734|DEVICE|CellFX System Device|The CellFX System utilizes non-thermal, localized delivery of a timed series of low energy, nanosecond electrical pulses that can trigger regulated cell death.
223702080|NCT04738734|DEVICE|Cryosurgery Liquid Nitrogen Sprayer|Cryosurgery will be standardized across all investigational sites using the Brymill Cry-Ac spray canister with standard cryoprobe.
223702081|NCT05337293|BEHAVIORAL|COPE-HF Partnership Intervention|Participants were trained to use a 4-step problem-solving process based on the Theory of Social Problem-Solving (TSPS) to manage HF-related problems experienced in the home over 12-weeks. The core belief of TSPS is effective problem-solving requires a positive problem orientation (i.e., viewing problems as a challenge versus a threat) and elicits rational problem-solving versus avoidance or impulsivity/carelessness. Problem-solving follows from a positive problem orientation and involves accurate problem identification, generation of appropriate potential solutions, active decision-making, and solution implementation and evaluation. The goal of this intervention was to move HF patients toward a positive problem orientation and use of rational problem-solving strategies that support greater HF self-care and reduce depression. The COPE-HF Partnership Intervention consisted of 1 home visit and 7 follow-up telehealth sessions led by a registered nurse interventionist.
223702082|NCT05337293|OTHER|Attention|Participants in the attention group received a sham intervention that consisted of scheduled telephone calls consistent with the timing of that received by the intervention group. During these calls, basic information was gathered on key areas of heart failure self-care management and the frequency of healthcare usage. No intervention or education was provided.
223702083|NCT03637179|OTHER|Assessment at Low Altitude (470m above sea level)|Assessment at Low Altitude (in Zurich; 470m above sea level) in order to compare this data with High altitude exposure
223702084|NCT03637179|OTHER|Exposure to High Altitude (2500m above sea level)|Exposure to High Altitude (Säntis; 2500m above sea level) for approximately 5 hours
223783017|NCT05709834|OTHER|Autogenic training|"Relaxation procedures will be performed in the following steps: First step - preparation: Each pre-eclamptic woman will be instructed about this method of treatment and its importance for reducing blood pressure to gain her confidence and cooperation during treatment. Second step - AT: The session began with a few minutes of mental relaxation as the patient will be asked to imagine herself in a lovely place that makes her relaxed. Each session include 18 exercises combining both relaxation and auto-suggestion (limb heaviness exercise, limb warmth exercise, cardiac exercise, respiration exercise, solar plexus warmth exercise, and forehead cooling exercise).~About 30 sec will be allowed for each exercise and a further 30-40 sec will allowed for continuing attention focusing by the patient. Third step - termination"
223783018|NCT05709834|OTHER|Conventional treatment|Patients will receive conventional treatment
223783019|NCT00989651|BIOLOGICAL|Bevacizumab|Given IV
223783020|NCT00989651|DRUG|Carboplatin|Given IV
223783021|NCT00989651|DRUG|Cisplatin|Given IP
223783022|NCT00989651|OTHER|Laboratory Biomarker Analysis|Correlative studies
223783023|NCT00989651|DRUG|Paclitaxel|Given IV or IP
223783024|NCT00989651|DRUG|Veliparib|Given PO
223783025|NCT03249922|DEVICE|Spinal Cord Stimulation|Implantation of a spinal cord stimulator for the control of axial back or neuropathic pain.
223783026|NCT03153332|OTHER|surgical residents' comprehension of the hepatic anatomy|Surgical residents were assigned to three different groups to evaluate different modes of patients' data. Residents were ask to state the liver segment in which the tumor resided and make a minimal resection proposal, including the tumor, the safety margin (1cm) and the dependent liver tissue. Residents were recommended to proceed in a classic way by resecting the whole liver segment. The time spent by each resident was also recorded in order to assess the quickness of comprehension and information transfer of the three different modes of presentation.
223783027|NCT02318329|DRUG|FPA144|FPA144 will be administered by IV infusion over approximately 30 minutes every 2 weeks.
223783028|NCT02328664|PROCEDURE|Flexible sigmoidoscopy or colonoscopy|Depending on the localization of the scar of the malignant polyp, either a flexible sigmoidoscopy or colonoscopy will be done to take biopsies from the polypectomy scar.
223783029|NCT04283929|OTHER|Experimental: Intervention 1 (Int1)|This intervention will consist of the following additions to the EMR package. A link on the clinician's homepage to enrol a new HIV+ patient in the EMR which will open a form for (1) entering patient demographics (2) adding the contact home address or description of area, phone number (if available), (3) the peer educator contacts (4) recording the HIV+ result and date. A report will be added that is run every week to identify HIV+ patients not linked to care. The patients identified will be checked with paper records to ensure they have definitely not visited, then contacted after one, 2 weeks and 4 weeks if he/she did not show up. After two attempted contacts, if the patient is not yet linked to care he/she will be visited at home by the health facility social worker using routine home visits by health care providers.
223783030|NCT04283929|OTHER|Experimental: Intervention 2 (Int2)|The data on availability of VL results in the EMR will come from a SQL statement to query the OpenMRS database. An alert will be fired if the patient has been enrolled for 8 months or more and does not have a viral load result in the EMR. The alert will be displayed on the patient summary and on the consult sheets, with text requesting the clinician orders a VL.
223783031|NCT04283929|OTHER|Experimental: Intervention 3 (Int3)|The data on VL results in the EMR showing detectable virus will come from a SQL statement to query the OpenMRS database. An alert will be fired if the patient has been enrolled for at least 12 months and the VL result in the EMR shows \> 1000 copies/mm3. The alert will be displayed on the patient summary and on the consult sheets requesting actions to address treatment failure (change first line medication, start second line medication, repeat VL, counselling on treatment adherence). A report will also be added to regularly check for patients with high viral load.
223783032|NCT05006625|OTHER|Collaborative Care Model|Use of the collaborative care model to screen and deliver care for depression in adolescents and young adults aged 15-24 years seeking HIV prevention and treatment services
223783033|NCT00244608|DRUG|Budesonide/Formoterol Turbuhaler|
223783034|NCT00244608|DRUG|Budesonide Turbuhaler (Pulmicort)|
223783035|NCT00244608|DRUG|Terbutaline Turbuhaler|
223783036|NCT02580149|DRUG|Ticagrelor|"Subjects will receive an oral loading dose of 180 mg ticagrelor on study day~1 followed by a maintenance dose of 90 mg twice daily for 14 days (until study day 15)."
223702085|NCT01419639|DRUG|Everolimus (RAD001) , Afinitor®|Everolimus will be provided by Novartis. Everolimus is formulated as tablets for oral administration of 2.5 mg, 5 mg, 10 mg strength. Everolimus will be self-administered (by the patients themselves) or administered by the patient's parent or guardian (for minors). The investigator will instruct the patient to take the study drug exactly as specified in the protocol. Depending the age-based dosing schedule, everolimus should be administered orally once (or twice) daily, preferably in the morning (and evening), at the same time every day with our without food. Everolimus tablets should be swallowed whole with a glass of water. The tablets must not be chewed or crushed. In cases where tablets can not be swallowed, the tablets should be disintegrated in water just prior to being taken. Everolimus will be administered orally as per the age-based dosing schedule continuously from study day 1 until progression of disease or unacceptable toxicity.
223702086|NCT03048461|DEVICE|Platelet Rich Plasma Prep System|intradermal injections of platelet rich plasma to an area of alopecia
223702087|NCT03048461|DRUG|Placebo|intradermal injections to an area of alopecia
223702088|NCT01773772|DRUG|Progesterone|Subjects will take 25-50 mg oral micronized progesterone at 1600 h and again at 2000 h. Progesterone dosing will be based on weight, with 25 mg administered to girls \< 42kg and 50 mg given to those or = to 42 kg.
223702089|NCT01773772|DRUG|Placebo|Subjects will take oral placebo suspension at 1600 h and again at 2000 h.
223702090|NCT01736020|DRUG|Dexmedetomidine|A low dose of dexmedetomidine is used during scanning after dose piloting outside the scanner for memory effects and tolerability.
223702091|NCT01736020|DRUG|Propofol|A low dose of propofol is used during scanning after dose piloting outside the scanner for memory effects and tolerability.
223702092|NCT01736020|DRUG|Ketamine|A low dose of ketamine is used during scanning after dose piloting outside the scanner for memory effects and tolerability.
223702093|NCT01736020|DRUG|Nitrous Oxide|A low dose of nitrous oxide is used during scanning after dose piloting outside the scanner for memory effects and tolerability.
223702094|NCT01736020|DRUG|Placebo|Placebo
223702095|NCT02435147|DRUG|denosumab|Patients will receive denosumab 60 mg subcutaneously every six months as part of their standard osteoporosis treatment.
223702096|NCT05785351|PROCEDURE|Laparoscopic Bariatric Surgery|Laparoscopic Bariatric Surgery: Gastric Sleeve and Roux-en-Y Gastric Bypass
223702097|NCT04211168|DRUG|Toripalimab plus Lenvatinib|"Toripalimab 240mg, every 3 weeks, intravenous infused, day 1, 6 weeks a cycle.~Lenvatinib 8mg (weight\<60kg) or 12mg (weight≥60kg), once a day, orally, day 2, 6 weeks a cycle. Dose reduction to 4mg/d or dose termination is allowed according to adverse events.~Number of cycle: until progression or unacceptable toxicity events develop."
223702098|NCT02366988|DEVICE|Endoscopic Biliary Stenting|Endoscopic probe self-expandable metallic covered stent Biliary stent will be left in place for 6 months
223702099|NCT02366988|PROCEDURE|Surgical treatment Bilio-enteric anastomosis|Bilio-enteric anastomosis including Whipple, Frey or Beger procedure, double or triple derivation
223702100|NCT00891007|BIOLOGICAL|MVA-mBN85B|Low Dose arm, 1x 10E7 TCID50
223702101|NCT00891007|BIOLOGICAL|MVA-mBN85B|Normal Dose arm, 1x 10E8 TCID50
223702102|NCT00891007|BIOLOGICAL|Rouvax|Standard measles vaccine, approved in South Africa
223783037|NCT02580149|DRUG|Clopidogrel|Subjects will receive a loading dose of 600 mg clopidogrel on the first study day followed by a maintenance dose of 75 mg once daily for 14 days
223783038|NCT01732393|DRUG|oral quercetin capsules|10 cases in case group and 10 cases in control group. Patients in the intervention group were administered two, 250 mg Quercetin capsules daily for 3 weeks. Patients in the placebo group received two placebo capsules containing lactose .Patients were examined every other day for evaluation of initiation and severity of oral mucositis.
223783039|NCT01732393|DRUG|Placebo|
223783040|NCT01492881|DRUG|Vorinostat|Oral, 400mg, taken days 4 through 11 of each cycle.
223783041|NCT01492881|DRUG|Bortezomib|subcutaneous injection, 1.3mg/m2, Days 1, 4, 8, and 11 every cycle
223783042|NCT01492881|DRUG|pegylated liposomal doxorubicin|Intravenous, 30mg/m2, Day 4
223783043|NCT01801059|OTHER|educational intervention|Receive patient activation intervention by educational video and brochure
223783044|NCT01801059|OTHER|educational intervention|Receive patient activation intervention by educational video
223783045|NCT01801059|OTHER|questionnaire administration|Ancillary studies
223783046|NCT06469320|OTHER|Online questionnaire|Pelvic floor dysfunction assessment questionnaire adapted from PFD-Sentinel
223783047|NCT02240082|BEHAVIORAL|Web-Based COPing with Shiftwork Program|COPing with Shift Work is an interactive, web-based program designed specifically for law enforcement officers to assist with the management of health and lifestyle challenges associated with shift work. The program will contain modules on sleep, physical activity, and nutrition in order to improve the health and safety of law enforcement officers and reduce their risk of chronic diseases associated with shift work. These modules will contain interactive assessments and cutting-edge scientific information on sleep, nutrition, and physical activity. Based on user input, officers will receive personalized feedback, tools, and strategies
223783048|NCT03145116|DEVICE|CT ASPHINA 509|Intraocular lens
223783049|NCT03399110|DRUG|Oxaliplatin|oxaliplatin 130 mg/m2
223783050|NCT03399110|DRUG|Capecitabine|Capecitabine 1000mg/m2
223783051|NCT01477034|DIETARY_SUPPLEMENT|Vitamin D3|2,000 or 4,000 IU/day vitamin D3 for 3 or 6 months.
223783052|NCT04333277|OTHER|Probiotic|Patients with major depression (both sexes) will receive capsules with 1 × 10\^9 CFUs of Lactobacillus helveticus in addition to a conventional antidepressant treatment for 8 weeks.
223783053|NCT04333277|OTHER|Maltodextrin|Patients with major depression (both sexes) will receive capsules of placebo (maltodextrin) in addition to a conventional antidepressant treatment for 8 weeks
223783054|NCT06114823|PROCEDURE|carpal tunnel release mini-incision|Patients were subjected to a longitudinal mini-incision started just above the proximal flexor wrist crease and then extended for 1.5 - 2 cm in a proximal direction
223783055|NCT06114823|PROCEDURE|carpal tunnel release conventional incision|Patients were subjected a longitudinal incision which was created between the thenar and hypothenar eminences along the longitudinal axis of the ring finger. Then, it was extended to the proximal flexor wrist crease.
223783056|NCT02067247|DEVICE|BeamMed Speed-of-Sound bone strength test at forearm|BeamMed Speed-of-Sound bone strength test at forearm in addition to the DEXA test
223783057|NCT03425149|BIOLOGICAL|VLA1601|purified inactivated ZIKV vaccine candidate adsorbed on alum
223783058|NCT03425149|BIOLOGICAL|Placebo|Phosphate buffered saline (PBS)
223783059|NCT00179088|BEHAVIORAL|Patient may be able to put weight on the operated leg|
223783060|NCT03786601|OTHER|Observation|The participants were assigned to different groups according to the results of HPV detection.
223783061|NCT00746837|DRUG|AZD5672|single IV doses starting at 7 mg, subsequent doses to be confirmed following review of PK and safety data after each treatment period
223783062|NCT00746837|DRUG|AZD5672|50 mg od, 12 days
223783063|NCT00746837|DRUG|AZD5672|150mg od, 12 days
223783064|NCT01017172|OTHER|serologic testing|Serologic testing will be performed baseline, day 21 and day 42
223783065|NCT05544994|OTHER|Aerobic Exercise Training|Aerobic training will be performed 3 days a week for 12 weeks at 60%-%75 of their maximum hearth rate with 30 minutes total duration consisting of 5 min warm up and 5 min cool down period in treatment group.
223783066|NCT05544994|OTHER|Home exercise program|Home exercise program will be given. This home program will include stretching, breathing, normal joint movement, for 3 to 5 days a week.
223783067|NCT00086346|DRUG|Sirolimus (Rapamune)|
223783068|NCT00086346|DRUG|Cyclosporine or Tacrolimus|
223783069|NCT04495374|DRUG|Pregabalin 300mg|Group P1 will receive a 300 mg tablet of pregabalin, 02h before the surgical procedure
223783070|NCT04495374|OTHER|Placebo|Group P0 will receive a placebo tablet, 02h before the surgical procedure
223783071|NCT02907333|BEHAVIORAL|Advice to use condoms|
223783072|NCT00035438|DRUG|St. John's Wort|
223783073|NCT01303627|DRUG|remifentanil|1-4 ng/mL i.v. infusion during the surgery, maintenance dosage till LMA removal is 1.5 ng/mL.
223783074|NCT05934045|BIOLOGICAL|RNAseq|there is no intervention done.
223783075|NCT04180826|OTHER|Observational|"Initially, the patient will be placed in a strict supine position (at 0°) in his hospital bed, according to the usual care.~In a second step, the patient will be verticalized (from 0° to 90°). Intracranial hemodynamics parameters in supine position and during verticalization will be continuously recorded by attaching the ATYS TCD-X® transcranial Doppler helmet attached with glasses.~After 15 minutes of recording, the patient will be placed back in supine position. The end of the patient's participation in the study will correspond to the removal of the ATYS TCD-X® helmet."
223783076|NCT00022568|BIOLOGICAL|recombinant vaccinia-TRICOM vaccine|
223702103|NCT00521612|DRUG|sevoflurane|Volatile anaesthetic sevoflurane 1 MAC (2,0 vol%) will be administer to the patients in the form of gas (via respiration). First 20 minutes of anaesthesia will be period of saturation of the body with anaesthetic sevoflurane. After 20 minutes the depth of anaesthesia will be titrated with level of anaesthetic sevoflurane. Change will be +10 % of sevoflurane MAC (0,2 vol%) for every change of signs that indicate shallow anaesthesia. Change will be -10 % of sevoflurane MAC (0,2 vol%) for every change of signs that indicate too deep anaesthesia. Measuring points will be every 5 minutes during surgery.
223783077|NCT00111657|BIOLOGICAL|Pegloticase|8 mg of Pegloticase administered IV every 3 weeks; total number of infusions is 5
223783078|NCT02416791|DEVICE|Robotic Therapy|Robotic therapy (MIT - Manus, Interactive Motion Technologies) will be administered for 40 minutes to the paretic upper limb.
223702104|NCT00521612|DRUG|isoflurane|Volatile anaesthetic isoflurane 1 MAC (1,2 vol%) will be administer to the patients in the form of gas (via respiration). First 20 minutes of anaesthesia will be period of saturation of the body with anaesthetic isoflurane. After 20 minutes the depth of anaesthesia will be titrated with level of anaesthetic isoflurane. Change will be +10 % of isoflurane MAC (0,12 vol%) for every change of signs that indicate shallow anaesthesia. Change will be -10 % of isoflurane MAC (0,12 vol%) for every change of signs that indicate too deep anaesthesia. Measuring points will be every 5 minutes during surgery.
223702105|NCT02542982|DEVICE|tDCS (Endomed 482; Enraf-Nonius B.V.)|non-invasive brain stimulation with pair of electrodes with saline-soaked pads through which the direct current of intensity of 2 mA is delivered
223702106|NCT00493532|DRUG|ibandronate [Bonviva/Boniva]|3mg iv every 3 months
223702107|NCT03384888|DEVICE|Active tDCS|Transcranial direct current stimulation Duration: 20 minutes; Intensity: 2 mA (miliamps); Placement of the electrodes: anode over the left M1 and cathode region over the right supraorbital region.
223702108|NCT03384888|DEVICE|Sham tDCS|Sham Transcranial direct current stimulation The procedure is the same as for active tDCS, but the stimulation is non-active / sham.
223702109|NCT00767949|BIOLOGICAL|iSONEP|single intravitreal injection of 0.2, 0.6, 1.0, 1.4 or 1.8 mg/eye
223702110|NCT02495012|DRUG|placebo|Freeze-dried powder without snake venom will be dissovled in saline
223702111|NCT02495012|DRUG|Anfibatide|Freeze-dried powder with snake venom will be dissovled in saline
223702112|NCT02590926|PROCEDURE|Fractional Flow Reserve, Myocardial|The ratio of maximum blood flow to the myocardium with coronary stenosis present, to the maximum equivalent blood flow without stenosis.
223702113|NCT04977921|OTHER|lab session|assign students to clinical modules for study the clinical lab scope of practice
223702114|NCT01035580|DRUG|Curcumin|Curcumin 500 mg capsules will be inserted intravaginally once daily for 14 days for a maximum daily dosage of 2000 mg
223702115|NCT01035580|DRUG|curcumin|all patients received the drug
223702116|NCT04510376|DEVICE|Test Article|Omeza Collagen Matrix
223702117|NCT04510376|OTHER|Positive Control|1.0 mg/mL Histamine Base
223702118|NCT04510376|OTHER|Negative Control|Aqueous Negative Control
223702119|NCT04757246|OTHER|MouthLab Device|Use of MouthLab system
223702120|NCT02450188|DRUG|Vardenafil|"In this study we used Vardenafil 10 mg orodispersible tablets. These are the only orodispersible tablets on commerce indicated for the treatment of ED. We choose this kind of tablets because of their easy way of assumption that can also have a minor psychological impact on patients.~Male patients will begin taking Vardenafil 10 mg orodispersible tablets 2 times a week for 10 weeks."
223702121|NCT02450188|BEHAVIORAL|CBST|"The CBST cognitive intervention, in according with Beck (1976), includes to help patients and their partners to gain a commonsense understanding and reframe their problems.~On the other side, the CBST behaviour intervention, how described by Meichenbaum (1993), is a method to teach patients to practice different behaviours that allows the replacement of the compromised behaviour with a functional one.~CBST interventions used in this study includes: psycho-educational interventions on ED maintaining, on anxiety's role and sexual homework. This course is structured in 10 weekly meetings. Male patients will begin taking Vardenafil 10 mg orodispersible tablets 2 times a week for 10 weeks."
223702122|NCT05820373|BEHAVIORAL|Yoga therapy|Women being allocated to the intervention group will attend a 12-week, bi-weekly, specially designed yoga therapy course. In each yoga class, participants will be taught to perform a standardized yoga sequence including postures and breathing exercise. Each class lasts 60 minutes. A DVD demonstrating the yoga sequence will be given to each participant to prompt daily home practice.
223702123|NCT05820373|BEHAVIORAL|Active control group|Women being allocated to the active control group will attend a 12-week, weekly, relaxation course. In each relaxation class, participants will be taught to learn mediation and guided relaxation, called Shavasana. Participants will be asked to lie on their back, with legs apart and their eyes closed. During the practice, participants learn how to relax the body and breath normally. Each session lasts 60 minutes.
223702124|NCT05820373|BEHAVIORAL|Passive control group|The passtive control intervention will be the standard post-operative exercises which are currently introduced to women following surgery, for all women allocated to the control group. A DVD demonstrating the post-operative exercise will be given to participants to practice at home daily.
223702125|NCT02767505|OTHER|gastric bypass|Type of surgery: gastric bypass
223702126|NCT02767505|OTHER|Sleeve gastrectomy|Typ of surgery: sleeve gastrectomy
223702127|NCT02787460|BEHAVIORAL|Behavioral Text Messages|
223783079|NCT02416791|DEVICE|Active tDCS|Active tDCS will be applied with the cathode positioned over the ipsilesional primary motor cortex and the anode over the contralateral supraorbital region for 20 minutes (1mA).
223783080|NCT02416791|DEVICE|Sham tDCS|In sham tDCS, no current will be delivered through the tDCS device.
223783081|NCT02416791|OTHER|Physical Therapy|Physical therapy will be administered for 40 minutes.
223783082|NCT02416791|OTHER|Occupational Therapy|Occupational therapy will be administered for 40 minutes.
223783083|NCT01054820|DRUG|FLECTORÂ® Patch (diclofenac epolamine topical patch) 1.3%|One FLECTOR Patch applied to the most painful area on the subject's back every 12 hours for up to 14 days.
223783084|NCT05412862|BEHAVIORAL|Positive Psychology + Motivational Interviewing|The 12-week PP-MI intervention focuses on enhancing well-being (through PP) and increasing physical activity (through MI). Each week, participants will complete a PP activity and work towards a physical activity goal, then complete a phone session with a study trainer. The PP portion of the program will focus on the cultivation of well-being through the performance of easy-to complete activities (e.g., using a strength in a new way) and review of the positive feelings they generate. The MI portion of the program will focus on assisting participants to improve physical activity levels, resolve ambivalence to behavior change, set realistic physical activity goals, problem-solve barriers, and identify resources to complete behavior change. Finally, participants will receive twice weekly text messages (for 24 weeks) to encourage completion of PP activities and engagement in physical activity.
223783085|NCT04040127|BIOLOGICAL|Cord blood stem cells|Umbilical cords are collected from eligible donors at the time of delivery and transported to the processing facility on ice (2-8℃) in Dulbecco's Modified Eagle Media (DMEM). Cords are processed immediately under aseptic conditions and MSCs are collected for culture. Culture is maintained this way until the target number of cells has been reached, at which point passaged cells are suspended in Stem Cellbanker (Amsbio, Cambridge, MA) and frozen at -80℃.
223783086|NCT04040127|OTHER|Saline solution|saline solution used to rinse the canal.
223783087|NCT00311272|BIOLOGICAL|MelCancerVac|
223783088|NCT05477355|BEHAVIORAL|Group Problem Management Plus (PM+)|Group PM+ is a low-intensity, trans-diagnostic, brief psychological intervention developed by the WHO. Group PM+ consists of five sessions delivered in five consecutive weeks and includes strategies that are aimed towards decreasing symptoms of depression, anxiety, general distress, and other related conditions. Group PM+ is designed to be delivered by non-specialists, persons without a formal education and licensure in psychology or mental health.
223783089|NCT01725646|DRUG|Omacor®|Subjects in 4 g and 2 g Omacor® will take this drug
223783090|NCT01725646|DRUG|Placebo|Subjects in placebo group will take this drug
223783091|NCT05382780|OTHER|The breather respiratory muscle trainer|The breather respiratory muscle training device is a high quality and effective trainer designed to specifically train the inspiratory and expiratory muscles in one same breathing action. The device allows for adjustable levels of resistance using easy-to-read dials, which allows you to adjust the device to the settings you require. The inhale settings allow for adjustment 1-6 with 1 being the easiest and 6 being the hardest, while the exhale settings allow for adjustment 1-5, where 1 in the easiest and 5 the hardest.
223783092|NCT05382780|OTHER|Diaphragmatic and localized breathing exercises|"A. Diaphragmatic breathing exercises:~Exercise will be performed as prescribed in the clinical guidelines for 5-10 minutes about 3-4 times per day.~B. Localized Breathing:~Exercise will be performed as prescribed in the clinical guidelines for 5-10 minutes about 3-4 times per day.~C. Mild Interval training exercise"
223783093|NCT05382780|OTHER|interval aerobic training and respiratory training|mild intensity interval aerobic training and respiratory training on treadmill
223783094|NCT00996996|BIOLOGICAL|Tositumomab and Iodine I 131 Tositumomab (Anti-B1 Antibody and Iodine-131 Anti-B1 Antibody)|"Dosimetric Dose: 450 mg of Anti-B1 Antibody infused over 70 minutes (inclusive of a 10-minute flush) immediately followed by 5 mCi (35 mg) of Iodine-131 Anti-B1 Antibody infused over 30 minutes (inclusive of a 10-minute flush).~Therapeutic Dose: Seven to 14 days after the dosimetric dose, 450 mg of Anti-B1 Antibody infused over 70 minutes (inclusive of a 10-minute flush), immediately followed by the patient-specific milliCurie activity (35 mg) of Iodine-131 Anti-B1 Antibody to deliver a total body dose (TBD) of 75 cGy infused over 30 minutes (inclusive of a 10-minute flush). Obese patients were dosed based upon 137% of their calculated lean body mass."
223783095|NCT03774186|DEVICE|Hybrid closed-loop therapy|Hybrid closed-loop therapy with a proportional integral derivative (PID) algorithm
223783096|NCT03774186|DEVICE|Sensor-augmented pump therapy|Insulin pump + non-communicating CGM
223783097|NCT02738567|PROCEDURE|patients undergoing surgery or medical procedure|
223783098|NCT03866616|BEHAVIORAL|Brain Builders Parenting Class|Brain Builders Parenting Class group sessions goal is to increase parental knowledge of brain development and increase responsive parenting
223783099|NCT03866616|BEHAVIORAL|Control (Usual care)|"This arm receives usual care (control group) consisting in: WIC participants will attend their usual appointments completed at the WIC clinics."
223783100|NCT00824590|DRUG|Dimebon|a single oral dose of 20 mg Dimebon
223702128|NCT01485393|DRUG|Dexmedetomidine|A dose of dexmedetomidine will be administered at 1mcg/kg over 10 minutes. Subjects will never receive active drugs (Zolpidem or dexmedetomidine concurrently).
223702129|NCT01485393|DRUG|Zolpidem|12.5 mg of oral Ambien CR. Subjects will never receive active drugs (Zolpidem/Ambien or dexmedetomidine concurrently).
223702130|NCT00799110|DRUG|GM-CSF|Injections given subcutaneously at the sight of vaccination on the day of the vaccination and for three days afterwards
223702131|NCT00799110|BIOLOGICAL|Dendritic Cell/Tumor Fusion Vaccine|Given subcutaneously once every three weeks for a total of three vaccines
223702132|NCT00799110|DRUG|imiquimod|Cream applied to the skin at the injection sight 2 hours before injection and for 3 days following the injection
223702133|NCT00389727|DRUG|Radiotherapy|Radiotherapy
223702134|NCT02120612|OTHER|Naloxone Education Intervention|"The Naloxone Education Intervention is a curriculum that has been adapted from New York State Department of Health's, Opioid Overdose Prevention program for non-medical responders."
223702135|NCT06333093|PROCEDURE|Cold snare|Two (2) cold snare resections of the duodenal mucosa during an already scheduled upper gastrointestinal interventional endoscopy under deep sedation (propofol).
223702136|NCT00014261|BIOLOGICAL|PEG-interferon alfa-2b|
223702137|NCT00014261|DRUG|temozolomide|
223702138|NCT02447562|DEVICE|Platform NOMHADchronic|Intervention group with a health Platform NOMHADchronic
223702139|NCT02447562|OTHER|Phone-based care group|
223702140|NCT02447562|OTHER|Usual care group|
223702141|NCT03134833|BEHAVIORAL|Automated Messaging & Monitoring|"Youth will receive messages 1-5 messages per day for 24 months. Message banks of about 750 text messages (70-120/domain) will focus on the HIV Prevention Continuum, with messages dedicated to healthcare, wellness, sexual health, drug use and medication reminders (e.g., for PrEP) for MSM and non-MSM. Youth will be able to choose the time that they receive daily texts. Text timing and the frequency of texts (e.g., if the youth comes out) will be updated at 4-month intervals.~Youth will complete weekly monitoring surveys by text message. The survey will cover seven domains related to the HIV Prevention Continuum. In case of non-response, reminder messages will be sent to the youth. After three days of non-response, a follow-telephone call will occur."
223702142|NCT03134833|BEHAVIORAL|Peer Support|"Youth will be enrolled in online, private discussion groups.~Peer Support will be offered by fellow participants and/or Youth Advisory Board members that have been trained in basic information on HIV, STI, drug use, mental health, homelessness, and stigma; using social media to create wall posts and use chat functions; and, how to initiate conversations on sensitive topics. By posting and responding to messages, Peer Supporters will encourage and broadly guide conversation related to the HIV Prevention Continuum, and other relevant topics.~Coaches and Project Coordinators will be available to provide factual information (as needed), and remove inappropriate content."
223702143|NCT03134833|BEHAVIORAL|Coaching|Youth will have access to a dedicated Coach to assist with crisis support and problem-solving, linkage to HIV and related services (e.g., for substance use, mental health), and care coordination. Coaches will be accessible electronically (using social media, e-mail, text messaging) and by phone. In cases where virtual support has failed, Coaches will be available in-person (e.g., to accompany a participant to a doctor's appointment). We anticipate that Coaches will provide each youth with 10 hours of support, on average, per year.
223702144|NCT00487682|DRUG|ASP2151|oral
223702145|NCT00487682|DRUG|Valacyclovir hydrochloride|oral
223702146|NCT04549246|RADIATION|Spatially Fractionated Radiation (GRID) Therapy|Grid therapy allows for high doses of radiation to be delivered over several spatially distinct, small regions. This permits regions of very high dose to a large tumor away from critical structures, which could be beneficial in both palliative and definitive treatments. Additionally, allowing for high doses to be delivered could pose a benefit for radioresistant histologies.
223702147|NCT00004756|PROCEDURE|Tailored educational program|
223702148|NCT00004756|PROCEDURE|Educational materials|
223702149|NCT03352310|BIOLOGICAL|autologous umbilical cord blood (UCB)|autologous UCB transfusion to the newborn infants presence of HIE and/or anemia within 48 hours after the birth
223702150|NCT03352310|PROCEDURE|standard care|standard care procedure to the newborn infants presence of HIE and/or anemia
223702151|NCT05031273|BEHAVIORAL|Residents moving into a congregate-living development with more features that support healthy living|Our team is making evidence-based recommendations to the developer and design team of an upcoming congregate-living development to support the physical activity, healthy eating, and social connections of residents moving into the new building(s). We hope for the developer to integrate into the new building(s) as many as possible of our team's built environment design and amenity recommendations into their site and/or building plans. Additionally, discussions with the municipality are also occuring on built environment design and amenity recommendations to improve the neighbourhood surrounding the site. Although our team has provided these recommendations, it is ulimatily up to the discretion of the developer and the municipality as to whether and what design and amenity changes are made.
223702152|NCT05400824|DIAGNOSTIC_TEST|Blood, DNA, feces, urine, hair and skin microbiota collection|See above
223702153|NCT00331422|DRUG|carboplatin|Carboplatin dose (milligrams (mg)) - Target Area Under the Curve (AUC) 6 x (Glomerular Filtration Rate+25) - Calvert Formula, given intravenously (IV) for 30 minutes.
223702154|NCT00331422|DRUG|paclitaxel|Paclitaxel dose = 175 milligrams per meter squared (mg/m2) over 3 hours.
223702155|NCT00331422|PROCEDURE|cytoreductive surgery|Surgery - tumor specimen collected for extreme drug resistant assay (EDR) and A1 assays for analysis
223702156|NCT01571310|OTHER|Omitted Breakfast|Experimental:The patients in Omitted Breakfast day will omit the breakfast and will continue the overnight fast until lunch. They will eat only lunch (700 kcal) at 13:30 and dinner (700 kcal) at 19:00
223702157|NCT01571310|OTHER|Breakfast|"In the Active Comparator: The patients in the Breakfast day will consume breakfast (700 kcal) at 8:00 , lunch (700 kcal) at 13:30 and dinner (700 kcal) at 19:00~(YesB): The patients in YesB will eat all three mealswill consume three meals:"
223702158|NCT01372228|BIOLOGICAL|hematopoietic stem cell infusion|Enriched hematopoetic stem cell infusion
223702159|NCT04605042|PROCEDURE|wet suction|Before pucturing the lesion, the stylet was removed and the needle was pre-flushed with 1-2 mL of saline using a 10-mL syringe, the endoscopist then punctured the lesion and replaced the 10-mL syringe with a 10-mL pre-vacuum syringe
223702160|NCT04605042|PROCEDURE|standard negative pressure suction|after puncturing the lesion, the endoscopist removed the stylet and attached a 10-mL pre-vacuum syringe for aspiration.
223702161|NCT05040399|OTHER|Locking Compression Plates|Plates and screws for sternal fixation
223702162|NCT05040399|OTHER|Sternal Wires|sternal wires used for fixation of sternum
223702163|NCT01710046|DRUG|(CP-6890,550) Tofacitinib|2 x 5 mg oral capsules taken twice daily (every 12 hours) for 12 consecutive weeks
223702164|NCT01710046|DRUG|Placebo|2 matching oral capsules taken twice daily (every 12 hours) for 12 consecutive weeks
223702165|NCT01710046|DRUG|(CP-690,550) Tofacitinib|2 x 5 mg oral capsules taken twice daily (every 12 hours) for 12 weeks
223702166|NCT01710046|DRUG|Placebo|2 matching oral capsules taken twice daily (every 12 hours) for 12 consecutive weeks
223702167|NCT03090438|PROCEDURE|Varicocele embolization|Ultrasound guided right internal jugular vein access with placement of a vascular sheath. Fluoroscopically guided selective catheterization of the left and right (if bilateral) spermatic veins to the level of the inguinal ligament. Occlusion of the spermatic vein(s) by embolization coils and a sclerosing agent (sodium tetradecyl sulphate 3%).
223702168|NCT04993560|BIOLOGICAL|BBIBP-CorV|Inactivated virus COVID-19 vaccine
223702169|NCT04993560|BIOLOGICAL|BNT162b2|mRNA-based COVID-19 vaccine
223702170|NCT05248620|DRUG|Amoxicillin Clavulanic 500/125mg or placebo|Prophylactic antibiotic treatment
223783101|NCT00824590|DRUG|Dimebon|a single oral dose of 20 mg Dimebon
223783102|NCT04535037|BIOLOGICAL|DTPa-HBV-IPV/Hib|3 doses (1 each at 2, 4 and 12 months of age) of DTPa-HBV-IPV/Hib vaccine administered by intramuscular injection into the right thigh
223783103|NCT04535037|BIOLOGICAL|DTaP5-HBV-IPV-Hib|3 doses (1 each at 2, 4 and 12 months of age) of DTaP5-HBV-IPV-Hib vaccine administered by intramuscular injection into the right thigh
223783104|NCT04535037|BIOLOGICAL|Pneumococcal 13-valent conjugate vaccine|3 doses (1 each at 2, 4 and 12 months of age) of pneumococcal 13-valent conjugate vaccine administered by intramuscular injection into the left thigh
223783105|NCT04943926|OTHER|Energy restricted diet|Nutritional complete formula diet followed by an energy restricted diet
223783106|NCT04943926|OTHER|Low carbohydrate high fat diet|Very low-carbohydrate high-fat ketogenic diet (VLCHF) diet followed by a low-carbohydrate high-fat diet (LCHF)
223783107|NCT06434532|OTHER|v-Care Online Game|A regular 2 hours traditional learning mode session - case study session and 2-hour online game session with peer-led discussion and interprofessional project submission. This spreads in 3 weeks interval
223783108|NCT06434532|OTHER|Case-based online discussion|A 2-hour traditional learning mode session with online peer-led discussion and submission of an interprofessional worksheet as an assignment
223783109|NCT02031276|DRUG|risankizumab IV|risankizumab administered by IV infusion
223783110|NCT02031276|DRUG|risankizumab SC|risankizumab administered by SC injection
223783111|NCT02031276|DRUG|Placebo|Placebo for risankizumab administered by IV infusion
223783112|NCT04842240|PROCEDURE|Pre- or sub-pectoral implant based immediate breast reconstruction|All study participants will undergo skin sparing mastectomy (with or without nipple preservation) for breast cancer or for risk reduction. Patients will undergo immediate breast reconstruction using an implant or a tissue expander. The device will be placed in pre- or sub-pectoral plane which will be supported by mesh (Tiloop/Surgimend Acellular Dermal Matrix) and/or a dermal flap.
223783113|NCT06402500|DRUG|Icon Infiltrant|White spot lesions are treated with the resin ICON (DMG, NJ, US) for masking their color. The mineral content will be measured in the lesion at baseline and after one month Quantitative light-induced fluorescence QLF.
223783114|NCT06402500|DRUG|Bioactive infiltrant|White spot lesions are treated with HI-Bond universal bioactive resin (MEDICLUS, south Korea) for masking their color. Mineral content will be measured in the lesion at baseline and after one month Quantitative light-induced fluorescence QLF.
223702171|NCT01882348|BEHAVIORAL|CEASE Intervention|The CEASE intervention works within existing systems of care to address parental smoking. Elements include (1) Identification of smokers and self-assessment of quitting preferences; (2) Counseling (brief motivational messaging elements include collaborative goal setting, set quit date, personal barriers to quitting, problem-solving strategies, implementing smoke-free homes and cars, and social support, strategies shown to increase satisfaction with the pediatric visit. (3) Medication (NRT prescription and free 1 week supply (while supplies last)-including for those cutting down to quit as recommended in latest guidelines); (4) Quitline enrollment; and (5) Review of CEASE action sheets at each visit until the family is smoke-free.
223702172|NCT03091933|BIOLOGICAL|GLIDE|Gudide Lymphocyte by Immunopeptide Derived Expansion (GLIDE) is an anti- Minor histocompatibility (MiHA) cell line
223702173|NCT05824988|OTHER|Drug exposure|Drug concentrations will be measured after one-month antimycobacterial treatment. Area under drug concentration-time curve (AUC) and maximum concentration (Cmax) will be calculated.
223702174|NCT00446420|DRUG|Propofol, midazolam, fentanyl|All drugs administered in doses according to anaesthetists' discretion during sedation for colonoscopy
223702175|NCT03189420|PROCEDURE|Tumor resection|The tumors will be resected in routine therapeutic surgeries
223702176|NCT02298231|OTHER|Standard of Care Balance Intervention|Standard balance therapy as performed by a physical therapist
223702177|NCT02298231|OTHER|Mystic Isle Balance Intervention|Balance therapy using virtual reality
223702178|NCT02298231|OTHER|Mystic Isle Balance Intervention with Dual Task|Balance therapy using virtual reality and performing cognitive tasks
223702179|NCT00992277|PROCEDURE|Ablation and skin resurfacing|
223702180|NCT03844932|DRUG|ST-0529|ST-0529 utilizes SmPill® technology to encapsulate the otherwise insoluble cyclosporine in a presolubilized, lipid-based formulation.
223702181|NCT02440971|DEVICE|S9-Autoset CS-A|The S9-Autoset CS-A is an adaptive servo-ventilation (ASV) machine. It adjusts the level of inspiratory support automatically in response to the patient's respiratory effort. Inspiratory support is increased in the presence of hypoventilation and decreased in the presence of hyperventilation.
223702182|NCT05666622|OTHER|Only routine non-surgical periodontal treatment was applied to the patients.|The study included 70 systemically healthy individuals, as a test group of 35 patients with Stage 3, Grade A periodontitis and a control group of 35 individuals with no periodontal disease. Blood samples were taken for the examination of DNI, white blood cells (WBC), immature granulocytes (IG), procalcitonin, C-reactive protein (CRP), lymphocyte count and neutrophil count. For the patients with periodontitis, blood sample assays were repeated 3 months after non-surgical periodontal treatment
223702183|NCT04128371|BIOLOGICAL|mepolizumab|Mepolizumab is a fully humanized monoclonal antibody (IgG1, kappa mAb) supplied as 100 mg of lyophilized powder in sterile, single-dose vials. Mepolizumab 100 mg vials were reconstituted according to the manufacturer, for a total dose of 700mg administered as intravenous infusion.
223702184|NCT02705872|DRUG|Chirocaine 0.07% + Sufentanil 0.3 mcg/ml 10ml/h|Continuous epidural perfusion: Chirocaine 0.07% + Sufentanil 0.3 mcg/ml with a 10ml/hour rate
223702185|NCT02705872|DRUG|Chirocaine 0.07% + Sufentanil 0.3 mcg/ml 10ml each 60 minutes|Injection of programmed intermittent boluses in the epidural space, without continuous perfusion, of the same solution (Chirocaine 0.07% + Sufentanil 0.3 mcg/ml): 10ml each 60 minutes
223783115|NCT05900024|OTHER|Funk It Cycle Bites|The intervention product contains: Organic Pumpkin Seed Butter, Prebiotic Agave Inulin, Organic Flax Seed, Organic Oat Flour, Organic Ginger, Quinoa Sprouts, Crispy Red Rice, Organic Cacao Nibs, Sunflower Seed Butter, Organic Reishi Mushroom, Organic Amaranth Seeds, Dates, Organic Button Mushroom, Acai Berry, Amla Fruit, Goji Berry, Pomegranate, Cranberry, Acerola (Cherry Juice), Rosemary Extract, Vitamin E (Mixed Tocopherols), Organic Vanilla Extract, Sea Salt, Cinnamon, Naturally Sourced Potassium Sorbate.
223783116|NCT01148810|DRUG|BAF312|
223783117|NCT01148810|DRUG|Placebo|
223783118|NCT06202261|DRUG|TQB2930 for injection|TQB2930 for injection is a HER2 bispecific antibody.
223783119|NCT06202261|DRUG|Paclitaxel for injection (albumin-bound)|It is an anti-microtubule chemotherapy drug
223783120|NCT06202261|DRUG|TQB3616 capsule|TQB3616 capsule is a Cyclin-dependent kinase 4/6 (CDK4/6) inhibitor.
223783121|NCT06202261|DRUG|Fulvestrant injection|Fulvestrant is a competitive estrogen receptor antagonist with similar affinity to estradiol
223783122|NCT06202261|DRUG|Capecitabine tablets|Capecitabine is converted to 5-fluorouracil (5-FU) by in vivo enzyme action.
223783123|NCT06202261|DRUG|Vinorelbine tartrate injection|Vinorelbine is an anti-tumor drug of vinca alkaloids.
223783124|NCT06202261|DRUG|Eribulin mesylate injection|Eribulin induces G2/M phase cell cycle arrest, mitotic spindle division, and ultimately apoptosis after prolonged mitotic arrest through its tubulin-based anti-mitotic mechanism.
223783125|NCT06202261|DRUG|gemcitabine hydrochloride for injection|Gemcitabine is a cell cycle specific anti-metabolic anticancer agent
223783126|NCT01672125|OTHER|circumferential measurements in different upper limb positions.|circumferential measurements in different upper limb positions, in 90 degrees forward flexion and depending position
223702186|NCT02297191|PROCEDURE|Thoracolumbar Interfascial Plane Block|"All participants will have two injections at the same vertebral level on each side of the back. Each injection will consist of four 5cc incremental injections with aspiration prior to each 5cc of injectate of 0.5% Ropivicaine. . Each side of the back will be injected with 20cc of .05% Ropivicaine. Ultrasound will be used in real time to guide the needle.~1. Ultrasound images will be saved using the nomenclature TLIP Anatomy~2. Photos will only include surface anatomy of the low-to-mid back.~3. Participants will be assessed for evidence of adverse reaction to local anesthesia (tinnitus, disorientation, or perioral numbness) with each 5cc dose of local anesthetic. If any adverse reactions are noted the dosing will be stopped."
223702187|NCT02297191|DRUG|Ropivicaine|
223702188|NCT03904732|DRUG|Acetylsalicylic Acid (Aspirin, BAYE4465)|Low-dose acetylsalicylic acid, Aspirin (75-150 mg)
223702189|NCT01346969|DRUG|EXC 001|Single-dose administered by injection four different times
223702190|NCT01346969|DRUG|EXC 001|Single reduced dose compared to Group 1 administered by injection at the same four time periods as Group 1
223702191|NCT01346969|DRUG|EXC 001|Single reduced dose compared to Groups 1 and 2 administered by injection at the same four time periods as Groups 1 and 2
223702192|NCT01346969|DRUG|EXC 001|Same sinlge dose as Group 1 administered by injection at the same four time periods as Groups 1, 2, and 3
223702193|NCT00563420|PROCEDURE|Bronchoscopy|
223702194|NCT02353520|OTHER|motricity index strength assessment|
223702195|NCT00479323|BIOLOGICAL|Pneumovax 23|Licensed pneumococcal vaccine (Pneumovax 23).
223702196|NCT05995808|PROCEDURE|Bone marow biopsy and aspiration|Bone marrow biopsy and biopsy aspiration
223702197|NCT05995808|DIAGNOSTIC_TEST|biochemical and heamatological tests|complete blood count ,serum urea and creatinine
223702198|NCT02308189|BEHAVIORAL|Exercise with blood flow restriction|Low load resistance exercise performed with an external pressure cuff applied over both legs or both arms during respective leg and arm exercises.
223702199|NCT02308189|BEHAVIORAL|Exercise|Low load resistance exercise performed with no external pressure cuff applied to the appendicular limbs.
223702200|NCT04004962|DEVICE|Infrared spectroscopy|Infrared spectroscopy
223702201|NCT00291889|BIOLOGICAL|Mtb72F/AS02.|
223702202|NCT05995119|DRUG|Apixaban 5 mg Oral Dissolving Film (TAH3311) and Tablet (Eliquis®)|The subjects were administered either the test (TAH3311 5 mg ODF as Treatment T1) or reference (ELIQUIS® 5 mg oral tablet as Treatment R1) product at 30 minutes following the start of a standardized high-fat, high-calorie breakfast that was preceded by an overnight fast of at least 10 hours. In the other two study periods, the subjects were administered either the test (Treatment T2) or reference (Treatment R2) product following an overnight fast of at least 10 hours. The subjects received the test and reference products in accordance with a four-sequence randomization schedule. There was a washout period of 5 days between the dosing days of any two consecutive periods.
223702203|NCT02674776|DRUG|HuZhen Capsule|Patients should take 4 tablet once and 3 times per day for 3 days.
223702204|NCT02674776|DRUG|Placebo Capsule|Patients should take 4 tablet once and 3 times per day for 3 days.
223702205|NCT04079010|PROCEDURE|BFR|Blood flow restriction (BFR) training is a non-invasive technique that uses wraps, bands, or inflated blood pressure cuffs to change blood flow within targeted muscles. Occlusion pressure of the femoral artery will be determine before each training session using the Delfi Personalize Tourniquet System for Blood Flow Restriction (2.0) which has embedded ultrasound technology to continually measure the blood flow and with auto-adjust the pressure. The target percent of occlusion is 50% of total blood flow while completed a prescribed resistance training regimen 4 times per week.
223702206|NCT04079010|DIETARY_SUPPLEMENT|Arginine|"The BFR+Arg group will consume Arginine supplement daily throughout the course of the study. Supplements were manufactured by Kyowa, a US-based cGMP-compliant contract manufacturing facility independently audited and pre-qualified by the quality compliance firm, Obvium\*Q, LLC (Dallas, TX). Manufacturing batch records for production of each of the supplements were maintained by the manufacturer and finished supplements were independently assayed for identity, purity, potency, and composition using appropriate USP, AOAC, or BAM methods at the independent, analytical laboratory, Dyad Labs (Salt Lake City, UT), prior to approval for release and consumption of the supplements by participants.~Each serving of the supplements were formulated to contain 3,000 mg L-Arginine (ARG; Kyowa). Each supplement also contained the inert and non-insulinotropic excipient ingredients, microcystalline cellulose and silicon dioxide."
223702207|NCT04079010|DIETARY_SUPPLEMENT|Placebo Pill|"The CON and BFR groups will consume placebo pill daily throughout the course of the study. Supplements were manufactured by Kyowa, a US-based cGMP-compliant contract manufacturing facility independently audited and pre-qualified by the quality compliance firm, Obvium\*Q, LLC (Dallas, TX). Manufacturing batch records for production of each of the supplements were maintained by the manufacturer and finished supplements were independently assayed for identity, purity, potency, and composition using appropriate USP, AOAC, or BAM methods at the independent, analytical laboratory, Dyad Labs (Salt Lake City, UT), prior to approval for release and consumption of the supplements by participants.~Each serving of the supplements were formulated to contain 3,000 mg Maltodextrin placebo (PLA; MALTRIN-M100; Grain Processing Corporation; Muscantine, IA). Each supplement also contained the inert and non-insulinotropic excipient ingredients, microcystalline cellulose and silicon dioxide."
223702208|NCT01020149|OTHER|MR Imaging|MRI is used to evaluate nerve regeneration after traumatic transsection and nerve repair.
223702209|NCT00912860|DRUG|Interferon beta-1a|serum free Avonex given IM once a week
223702210|NCT06436261|PROCEDURE|Hybrid Fractional Laser|A hybrid fractional HALO™ laser treatment was performed after a 7-day washout period. Subjects were numbed for 30 minutes to 1 hour prior to the procedure with a topical numbing cream containing benzocaine, lidocaine, and/or tetracaine. After numbing was completed, patients received one full-face HALO™ laser treatment with settings 350/20/20.
223702211|NCT06436261|OTHER|Facial Cleanser|Subjects were to use the provided cleanser twice daily (morning and evening) during the 7-day washout period and 7-day post-procedure timeline.
223702212|NCT06436261|OTHER|Facial Moisturizer|"Subjects were to use the provided bland facial moisturizer as follows:~WASHOUT PERIOD (7 days): After cleansing, 1-2 pumps were to be applied twice daily (morning and evening) to the full face avoiding the eye area~POST-PROCEDURE (7 days): After applying the Post-Procedure Cream and Active Comparator based on split-face randomization, the facial moisturizer was to be applied twice daily (morning and afternoon)."
223702213|NCT06436261|OTHER|Sunscreen|During the 7-day washout period and 7-day post-procedure timeline, subjects were to apply the provided basic sunscreen in the morning and afternoon after applying facial moisturizer. Sunscreen was to be reapplied as needed throughout the day per FDA recommendations.
223702214|NCT03353246|DEVICE|InfraScanner 2000™|The Infrascanner is a portable screening device that uses Near-Infrared (NIR) technology to screen patients for intracranial bleeding, identifying those who would most benefit from immediate referral to a CT scan and neurosurgical intervention.
223702215|NCT05244304|DRUG|Tinlarebant|Tinlarebant drug substance is a white to off-white substance and is dispensed as a tablet for oral administration.
223702216|NCT05244304|DRUG|Placebo|Not active drug
223702217|NCT03745807|BIOLOGICAL|NKTR-214|Specified dose on specified days
223702218|NCT03745807|BIOLOGICAL|Nivolumab|Specified dose on specified days
223702219|NCT02008578|BIOLOGICAL|Intravenous hyperimmune immunoglobulin (Flu-IVIG)|
223702220|NCT02008578|BIOLOGICAL|Placebo|
223702221|NCT00000574|DRUG|ibuprofen|
223702222|NCT03862859|DRUG|Warfarin|Dose adjusted Warfarin targeting an international normalized ratio of 2-3.
223702223|NCT04966052|OTHER|No intervention|No intervention
223783127|NCT02165722|BEHAVIORAL|4 Pillars Toolkit|"Behavioral: Pillar 1: Convenient Vaccination Services (e.g. use every visit \[chronic and acute\] as an opportunity to vaccinate; use express vaccination clinics and dedicated vaccination stations; use influenza vaccination as an opportunity to vaccinate for other vaccines).~Behavioral: Pillar 2: Patient Notification (e.g. use electronic reminders and social media for vaccination reminders; use physician recommendations).~Behavioral: Pillar 3: Enhanced Office Systems (e.g. implement Standing Order Programs; use EMR prompts; add vaccination status as a vital sign when rooming).~Behavioral: Pillar 4: Motivation (e.g. establish an office Immunization Champion to track goal progress, aided by research team feedback)."
223783128|NCT01235910|DRUG|Aliskiren|Aliskiren 75 mg once daily x 2 weeks, then aliskiren 150 mg once daily x 2 weeks, if blood pressure allows
223783129|NCT02880852|DRUG|Belimumab|Belimumab will be provided as white uniform lyophilized cake in vials with unit dose strength of 400 mg/vial plus excipients (citric acid/sodium citrate/sucrose/polysorbate) for reconstitution in 4.8 milliliter sterile water for injection (SWFI). Belimumab will be administered as 10 mg/kg intravenous infusion for over 1 hour on Day 0.
223783130|NCT02762591|DRUG|Pimavanserin tartrate|Pimavanserin tartrate 40 mg, tablet, taken as two 20 mg tablets, once daily by mouth
223783131|NCT00900991|BIOLOGICAL|split-virion pandemic influenza vaccine (H5N1 strain NIBRG-14)|
223783132|NCT04895241|DRUG|Litifilimab|Administered as specified in the treatment arm.
223783133|NCT04895241|DRUG|Placebo|Administered as specified in the treatment arm.
223783134|NCT02974361|DRUG|Ibuprofen|
223783135|NCT02974361|DRUG|Ibuprofen Lysine|
223783136|NCT02974361|DRUG|Ibuprofen-LDH|
223783137|NCT03981003|DIAGNOSTIC_TEST|Blood sample|2 x 4 ml tubes blood to screen for serum Neurofilament Light Chain and GFAP levels
223783138|NCT02172209|DRUG|BI 10773|
223783139|NCT06573125|BEHAVIORAL|MoodMover|MoodMover is a 9-week app-based program aimed at increasing physical activity (PA) among individuals with depression, delivered via Pathverse. The current version of MoodMover includes one introductory module for baseline self-monitoring, eight primary modules, and eight optional supplementary modules. The program uses a variety of formats to deliver educational content, including videos, podcasts, and illustrated articles. In addition to its structured psychoeducational content, the app provides a range of behavioral features.
223783140|NCT01210768|DRUG|Epirubicin+Cyclophosphamide|Cyclophosphamide 600 mg/m2 infusion followed by epirubicin 90 mg/m2 infusion on Day 1 in each 21-day treatment cycle. Treatment will be repeated for 4 cycles in the EC arm.
223783141|NCT01210768|DRUG|liposomal-doxorubicin+Cyclophosphamide|Cyclophosphamide 600 mg/m2 infusion followed by pegylated liposomal-doxorubicin 37.5mg/m2 infusion on Day 1 in each 21-day treatment cycle. Treatment will be repeated for 5 cycles in the LC arm.
223783142|NCT04243824|DRUG|Gallium 68 Macro-aggregated albumin|The radiotracer, Ga-68 MAA, will be administered prior to PET/MRI scan.
223783143|NCT05423509|OTHER|Dynamic myofascial manipulation|Dynamic myofascial manipulation of the muscles in the back to improve the scoliosis appearance/flexibility/rotation
223783144|NCT05423509|OTHER|Standard AIS treatment with observation or bracing|Observation with radiographs and bracing of curves greater than 20 degrees
223783145|NCT01542775|BEHAVIORAL|Aerobic Exercise Group|12 weeks Aerobic exercise
223783146|NCT01542775|BEHAVIORAL|Control Group|maintaining usual activities
223783147|NCT01459276|BIOLOGICAL|Vaccination with FAB-6011|One 0.5 mL injection of FAB-6011 trivalent influenza vaccine containing 6μgHA of seasonal A/H1N1, A/H3N2 and B influenza antigens.
223783148|NCT01459276|BIOLOGICAL|Vaccination with FluvalAB|One 0.5 mL injection of FLUVAL AB trivalent influenza vaccine containing 15μgHA of seasonal A/H1N1, A/H3N2 and B influenza antigens.
223783149|NCT05507411|RADIATION|Neoadjuvant Radiotherapy|41.4Gy/23F
223783150|NCT05507411|DRUG|Neoadjuvant Chemotherapy|Paclitaxel for Injection （Albumin Bound): 50mg/m\^2 QW Carboplatin: AUC=2 QW
223783151|NCT05507411|DRUG|Immunotherapy|Camrelizumab 200mg Q3W
223783152|NCT04828759|BEHAVIORAL|VR-treatment|The participants will be randomized either to group which receives the VR-intervention immediately (A) or to the waitlist control group (B). After the baseline assessment, the participants in the group A participate VR-intervention lasting for 8 weeks, and the participants in the group B will receive 8 weeks waitlist period. After the 8 weeks, the groups switch their places
223702224|NCT02788929|DEVICE|Fitbit Charge HR|Patients randomized to the FitBit group will receive Fitbit Charge HR, a simple, user-friendly, wrist-worn, commercially available device which provides feedback on exercise goal adherence, in combination with the Fitbit mobile platform application.
223702225|NCT02760576|DRUG|BAY 987521|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.
223702226|NCT01161108|DRUG|Fast Release Melatonin (FR MLT)|3mg capsules of melatonin will be used. The dose of FR MLT will be 3 mg for children less than or equal to 20 kg, and 6 mg for children greater than 20 kg. The study medication will be given one hour before bedtime, once daily.
223702227|NCT01161108|DRUG|Fast Release Placebo|"A matching FR MLT placebo will be compounded by the SickKids research pharmacy.~The dose of Fast Release Placebo will be 3 mg for children less than or equal to 20 kg, and 6 mg for children greater than 20 kg. The study medication will be given one hour before bedtime, once daily."
223702228|NCT01161108|DRUG|Timed Release Melatonin (TR MLT)|"3 mg capsules will be used.~The dose of TR MLT will be will be 3 mg for children less than or equal to 20 kg, and 6 mg for children greater than 20 kg. The study medication will be given one hour before bedtime, once daily."
223702229|NCT01161108|DRUG|Timed Release Placebo|"A matching TR MLT placebo will be compounded by the SickKids research pharmacy.~The dose of Timed Release Placebo will be will be 3 mg for children less than or equal to 20 kg, and 6 mg for children greater than 20 kg. The study medication will be given one hour before bedtime, once daily."
223783153|NCT04828759|BEHAVIORAL|Treatment as usual|The participants will be randomized either to group which receives the VR-intervention immediately (A) or to the waitlist control group (B). After the baseline assessment, the participants in the group A participate VR-intervention lasting for 8 weeks, and the participants in the group B will receive 8 weeks waitlist period. After the 8 weeks, the groups switch their places
223783154|NCT04120896|BEHAVIORAL|Karate group|Children in the karate group will receive the basic Goju Ryu Karate training that includes basic stances (dachi), punching (zuki), blocking (barai) and kicking techniques (keri), form training (kata), supervised sparring (kumite), and conditioning exercises (for warm up and cool down).
223783155|NCT04120896|BEHAVIORAL|Kung fu group|Children in the Ving Tsun kung fu group will receive the basic Wong Shun Leung style Ving Tsun training that includes basic stances (ma), footwork (bu), punching (quan), kicking (jie) techniques and conditioning exercises (for warm up and cool down).
223783156|NCT04465994|PROCEDURE|gastrocnemius turn-down flaps|We classified the patients with acute achilles tendon rupture by type of surgery. The group who received the gastrocnemius turn-down flaps is the intervention group.
223783157|NCT03966404|DIAGNOSTIC_TEST|EyeBOX device|The EyeBOX medical device tracks a patient's eye movement and calculates a BOX Score ranging from 0-20. The BOX score is interpreted as a binary classification for eye movement abnormalities, where anything equal to or greater than 10 is a positive result for the initial evaluation of concussion and everything below 10 is negative.
223783158|NCT01658683|BEHAVIORAL|Exercise Facilitator Intervention|The 50 week intervention includes 5 small group counseling teleconferences, 3 personal telephone calls and Heart Wise Exercise program demonstrations. During the teleconferences and personal telephone calls, the facilitator discusses the importance of exercise. Participants review their activity diaries, identify barriers to exercise maintenance experienced to date and brainstorm solutions as a group. In addition, the facilitator conducts community program demonstrations at Heart Wise Exercise program locations in Ottawa and Toronto for interested participants.
223783159|NCT06531525|DRUG|Enoxaparin|Enoxaparin 4000 IU/day by subcutaneous injection at the time of randomization and continued until delivery. Dose adjustments were made throughout the study based on symptoms such as bleeding and thrombosis.
223783160|NCT06531525|DRUG|Aspirin|Aspirin 75mg, orally, once daily at the time of randomization and continued until delivery. Dose adjustments were made throughout the study based on symptoms such as bleeding and thrombosis.
223783161|NCT06531525|DRUG|Enoxaparin|Participants in all groups will receive daily injections of enoxaparin at a dose of 4000 IU within 6 weeks at postpartum.
223783162|NCT03286491|DIAGNOSTIC_TEST|Further cardiac imaging|Study patients will be reviewed whether they will have coronary interventions in 30 days
223783163|NCT04824846|BEHAVIORAL|Integrated back pain module (IBPM)|All Ambulance drivers will be screening with the Proforma to determine their low back pain symptoms. Those workers who are diagnosed with mechanical back pain during the 12 months fulfill a self-report quality of life questionnaire (SF-36). Then Integrated back pain module (IBPM) will be delivered to them after the introduction course conducted for 1 day and then the intervention will last for 6 months. Research staff will explain how to operate and use the module. Subjects must comply with all the care and prevention guidelines of the research module so that it achieves the expected results. They also need to complete the checklist provided in the Edmodo software via their respective smartphones.
223702230|NCT02325648|DRUG|HIPEC cytoreductive surgery|At least 30 minutes prior to the prospective conclusion of the surgery, 1 μg/kg of fentanyl is administered for postoperative analgesia and 0.075mg of palonosetron is IV-infused for the prevention of nausea and vomiting. Desflurane and remifentanil administration is ceased after the surgery is concluded, muscle relaxation is evaluated by train of four (TOP) monitoring using a nerve stimulator, and the neuromuscular blockade is reversed with 0.2 mg of glycopyrrolate and 1 mg of neostigmine. When the patient recovers consciousness and begins spontaneous respiration, extubation is performed and the patient is transferred to the ICU with monitoring of their vital signs.
223783164|NCT04824846|OTHER|Health Educational Pamphlet.|In Health Educational Pamphlet (HEP) sessions, Participants will be taught the importance of movement and activity, pain management techniques, and methods for developing spinal posture awareness during activities of daily living (e.g., lifting, pushing, pulling, sitting, getting out of bed, and using a backpack).
223783165|NCT01259544|DRUG|benzoyl-L-tyrosyl-[1-13C]alanine (Bz-Tyr-Ala)|300 mg of powder form dissolved in one cup of tap water prior to breath test
223783166|NCT01259544|DRUG|benzoyl-L-tyrosyl-[1-13C]alanine (Bz-Tyr-Ala)|300 mg of 13 C di peptide in single dose powder form dissolved in one cup of tap water.
223783167|NCT04703881|DIETARY_SUPPLEMENT|AYMES ActaGain|AYMES ActaGain is a Food for Special Medical Purposes (FSMP) and must, therefore, be used under medical supervision. It is designed as a supplement to the diet but can also be used as a sole source of nutrition.
223783168|NCT03161834|OTHER|Observational|
223783169|NCT02740348|BEHAVIORAL|ZocDoc Assistance|Research assistant sets up a follow-up appointment for a subject with a primary care doctor using ZocDoc
223783170|NCT02740348|BEHAVIORAL|ZocDoc Information|Providing ZocDoc information to subjects so that they can make a follow-up appointment with a primary care doctor themselves
223783171|NCT05114681|OTHER|Assessment of Oral care as per patient personal choice|We just inquire from patients or attendants about products used, the timing for oral care.
223783172|NCT00504244|DRUG|switch to Myfortic|Myfortic 2 dd 720 mg
223783173|NCT00504244|DRUG|continuation of azathioprine|Azathioprine 2 mg/kg
223702231|NCT02197793|BEHAVIORAL|Community Mobilization Program|
223702232|NCT05985343|DRUG|Neostigmine / Glycopyrrolate|Patients will receive standard of care for reversal of neuromuscular blockade
223702233|NCT05985343|DRUG|Sugammadex|Patients will receive sugammadex for reversal of neuromuscular blockade
223702234|NCT01818661|DRUG|AV-1451|This is used to assess Tau burden in the brain.
223702235|NCT06966531|PROCEDURE|Coronary angiography|distinguish between true MI with significant lesion and MINOCA with insignificant lesions (less than 50%)
223702236|NCT04426812|OTHER|No intervention; just data collection|No intervention; just data collection
223702237|NCT06388382|OTHER|Alert tone demonstration|Patients are demonstrated the alert tone of their ICD
223702238|NCT06051591|BEHAVIORAL|Food FARMacia Program|Twice monthly delivery of groceries with about 12 meals per household member for up to 4 household members for 6 months.
223702239|NCT06051591|BEHAVIORAL|Self-directed meal preparation support|Nutrition education and anticipatory guidance to support healthy meal preparation
223702240|NCT04430192|DRUG|177Lu-PSMA-617|Patients 1-10 will be given 5GBq of 177Lu-PSMA. Patients 11-20 will be given 2 cycles of 5GBq of 177Lu-PSMA, separated by 6 weeks.
223702241|NCT05909735|PROCEDURE|transplantation of a Descemet's Membrane corneal onlay, partial LSCD|The worst seeing eye of these patients (or a randomized eye if vision is equal bilaterally) will be treated with superficial keratectomy to remove any pannus and debride the central corneal epithelium, followed by transplantation of a Descemet's membrane corneal onlay. Patient will be followed for 6 months and evaluated for improvement in visual acuity and improvement in limbal stem cell deficiency, and monitored for adverse events.
223702242|NCT05909735|PROCEDURE|transplantation of a Descemet's Membrane corneal onlay, total/near-total LSCD|The worst seeing eye of these patients (or a randomized eye if vision is equal bilaterally) will be treated with superficial keratectomy to remove any pannus and debride the central corneal epithelium, followed by transplantation of a Descemet's membrane (DM) corneal onlay. Patient will be followed for 6 months and evaluated for improvement in visual acuity, limbal stem cell deficiency, and persistent epithelial defects/recurrent erosions, and monitored for adverse events.
223702243|NCT06405139|DRUG|Nanoliposomal Irinotecan, Oxaliplatin plus Capecitabine|Nanoliposomal irinotecan 60mg/m2; Oxaliplatin 85 mg/m2; Capecitabine 800 mg/m2 twice daily, day 1 to 7; repeated every two weeks.
223702244|NCT06578559|DRUG|Cetuximab|500 mg/sqm intravenous infusion over 120-minute at cycle 1 (if well tolerated, it is administered over 90 minutes at second administration, and over 60 minutes by the third administration) every 14 days.
223702245|NCT06578559|DRUG|Encorafenib|300 mg once daily (four 75 mg oral capsules).
223702246|NCT06271538|COMBINATION_PRODUCT|Skal Pro|One sachet Skal Pro per day containing Lactobacillus plantarum 299v 1x10\^10 CFU and GOS
223783174|NCT02417246|DRUG|brand name metoprolol ER|This medication will be taken for 7 to 28 days
223783175|NCT02417246|DRUG|Generic A|This medication will be taken for 7 days
223783176|NCT02417246|DRUG|Generic B|This medication will be taken for 7 days
223783177|NCT00291382|DRUG|Salmeterol/fluticasone propionate combination|
223783178|NCT05745077|BEHAVIORAL|Telemedicine Consultation|Patients will be contacted by their surgeon over the phone to discuss surgical treatment.
223783179|NCT05745077|BEHAVIORAL|Traditional Care|Patients will proceed with their surgical consultation as per standard practice.
223783180|NCT00723775|DRUG|GSK706769 & KALETRA|GSK706769 alone and GSK706769 + Kaletra
223702247|NCT06271538|OTHER|Placebo|One sachet per day identical in shape, size, colour, packaging and taste to the Skal Pro sachet
223702248|NCT04481113|DRUG|Abemaciclib|Given PO
223702249|NCT04481113|DRUG|Niraparib Tosylate Monohydrate|Given PO
223702250|NCT05736224|DRUG|Sunscreen|The sunscreen contains bioadhesive nanoparticles (BNP) encapsulating avobenzone and octocrylene plus the non-toxic natural products diosmin, ferulic acid, cytisine and trans-resveratrol.
223702251|NCT05736224|OTHER|UV Light|UV light to the correct sites, and the Multiport 610 solar simulator used to deliver 1 MED UVR to the appropriate subsites.
223702252|NCT03472872|DRUG|Ketorolac|15mg ketorolac in 100mL 0.9% normal saline IVPB 1,000mg acetaminophen in a 100ml IVPB
223702253|NCT03472872|DRUG|Acetaminophen|1,000mg acetaminophen IVPB
223702255|NCT04932512|DRUG|ION224|ION224 will be administered by SC injection.
223702256|NCT04932512|OTHER|Placebo|ION224-matching placebo solution will be administered by SC injection.
223702257|NCT05137990|BEHAVIORAL|HIIT Exercise Intervention|Exercise trainers will provide encouragement and supervision for exercise prescription adherence and youth will select an age-appropriate music playlist from Spotify to enhance enjoyment throughout each session. Each exercise session consists of a 5-minute warm-up (10% HRmax), followed by a 20-minute HIIT protocol. The 20-minute HIIT protocol consists of seven bouts of 1-min high intensity exercise (90% HRmax) followed by 2-min of active recovery (10% HRmax). Participants will be encouraged to complete each exercise session with at least 24 hours of rest between each session.
223702258|NCT05137990|BEHAVIORAL|Stretching Intervention|This group will perform a home-based program of the same stretches utilized in the exercise group. The stretching protocol consists of one set of 4 static stretching exercises held for 30 seconds and performed 3 days/week. As flexibility exercises are low-intensity, low-impact and low-volume, minimal caloric expenditure is expected to be incurred. To increase compliance and aid in the standardization of the home-based stretching, participants will be provided a booklet of the flexibility exercises. Participants will be shown how to use the booklet and instructed in the stretching exercises by an exercise trainer prior to the intervention.
223702259|NCT06091579|DRUG|Treprostinil Palmitil Inhalation Powder|Oral inhalation using a Plastiape capsule-based dry powder inhaler.
223783181|NCT02665000|PROCEDURE|Structured training programme|Participants will undergo 5-days training sessions
223783182|NCT05827224|DEVICE|Lotrafilcon B spherical soft contact lenses|Commercially available silicone hydrogel contact lenses
223783183|NCT05827224|DEVICE|Lotrafilcon B spherical soft contact lenses with comfort additive|Commercially available silicone hydrogel contact lenses
223783184|NCT05827224|DEVICE|Lotrafilcon B toric soft contact lenses with comfort additive|Commercially available silicone hydrogel contact lenses
223783185|NCT05827224|DEVICE|Comfilcon A spherical soft contact lenses|Commercially available silicone hydrogel contact lenses
223783186|NCT05827224|DEVICE|Comfilcon A toric soft contact lenses|Commercially available silicone hydrogel contact lenses
223783187|NCT03565718|BEHAVIORAL|Dietary Intervention: Restaurant|Participants will receive instruction on how to follow a vegan diet for three weeks and will receive gift cards to local vegan soul food restaurants.
223783188|NCT03565718|BEHAVIORAL|Dietary Intervention: Standard/Grocery|Participants will receive instruction on how to follow a vegan diet for three weeks and will receive gift cards to grocery stores.
223783189|NCT02973958|DRUG|Bupivacaine|See active comparator description
223783190|NCT02973958|DRUG|Sevoflurane|See active comparator description
223783191|NCT02973958|DRUG|Acetaminophen|See active comparator description
223783192|NCT02973958|DRUG|Ibuprofen|See active comparator description
223783193|NCT02973958|DRUG|Ketorolac|See experimental arm description
223783194|NCT01523691|BEHAVIORAL|Repeated sleep restriction and recovery|Repeated cycles of sleep restriction and sleep recovery
223783195|NCT01523691|BEHAVIORAL|Control sleep|Regular amounts of sleep across study protocol
223783196|NCT01317953|DIETARY_SUPPLEMENT|epigallocatechin gallate|"Starting dose green tea catechin extract EGCG 400 mg twice a day (BID) of EGCG (400 mg caps BID), second escalated dose 800 mg BID of EGCG (2x400 mg caps BID), third escalated dose 1200 mg BID of EGCG (3x400 mg),fourth escalated dose 1600 mg BID of EGCG (4x400 mg),and fifth escalated dose 2000 mg BID of EGCG (5x400 mg),"
223783197|NCT04091399|DRUG|Stamatological tamponade Contipro|The drug is composed from the Hyaluronic acid and Octenidine dihydrochloride. It is designed to perform comparatively in pain alleviation and to promote healing of the alveolar osteitis while avoiding the side effects.
223783198|NCT03574454|OTHER|Machine Learning (ML)|Application of ML support algorithm to accelerate and enhance human interpretation of WB-MRI scans in patients with myeloma
223783199|NCT04408469|BEHAVIORAL|Online EQuIP|This online CBT treatment consists of 10 weekly modules that participants will complete over the course of 10 weeks.
223783200|NCT04408469|BEHAVIORAL|Self-monitoring control|Participants will be asked to indicate their past 7-day mood; stress experiences; and mental and behavioral health on an online survey experience once per week for 10 weeks
223783201|NCT03361813|OTHER|trans-cutaneous ultrasound guided peritonsillar infiltration|Preoperative peritonsillar infiltration of bupivacine in tonsillectomy surgery by using the ultrasound through a transcutaneous route
223702260|NCT06091579|DRUG|Placebo|Oral placebo inhalation using a Plastiape capsule-based dry powder inhaler.
223702261|NCT06654258|BEHAVIORAL|Spiritual Self-Care Smartphone App|"Participants will be asked to engage with a commercially available spiritual self-care smartphone app on a daily basis for 6 weeks. The content spans several domains, including meditation, prayer, affirmations, movement (i.e., stretching and yoga), and music. The user experience is highly personalized, allowing the user to select content that matches their current: mood or needs (e.g., anxiety, loneliness, stress, self-esteem, and sleep), time of day (e.g., recommendations for morning and evening practices), and/or availability (e.g., very brief micro-interventions lasting no more than 90 seconds or longer activities up to 30 minutes in duration). The content is delivered via a combination of audio and visual modalities on a personal smartphone that can be toggled on and off to adjust to surroundings."
223702262|NCT04060849|DRUG|Nozin|Given via nasal single-use popswabs or single-use cotton tipped applicators
223702263|NCT04060849|OTHER|Best Practice|Receive standard of care
223702264|NCT05348473|DEVICE|Alpha type|Tips of the seton will be tied as alpha-shaped.
223702265|NCT05348473|DEVICE|Beta type|Tips of the seton in this group will be overlapped and tied
223702266|NCT05348473|DEVICE|Comfort type|Knotless seton will be applied
223702267|NCT06058078|DRUG|RY_SW01 cell injection|Injected RY\_SW01 allogonic umbilical cord-derived mesenchymal stem cells(UCMSCs)
223702268|NCT06058078|DRUG|Basic treatment|Drugs for LN treatment
223702269|NCT04375228|DRUG|Rituximab|375mg/m\^2 IV weekly for 4 doses
223702270|NCT04375228|DRUG|Tocilizumab|4mg/kg IV once a month for up to 2 doses
223702271|NCT03227328|DRUG|concomitant cyclin-dependent Kinase 4/6 (CDK4/6) inhibitor plus endocrine therapy|"CDK4/6 inhibitor:~* palbociclib~* ribociclib~* abemaciclib~Endocrine therapy:~* non-steroidal or steroidal AI~* fulvestrant"
223702272|NCT03227328|DRUG|chemotherapy plus endocrine therapy (administered either concomitantly or sequentially)|"Standard Chemotherapy regimens will be classified as:~* anthracycline + taxane,~* taxane,~* anthracycline,~* capecitabine / fluoropyrimidines,~* others.~Endocrine therapy:~* non-steroidal or steroidal AI~* fulvestrant"
223702273|NCT04622462|PROCEDURE|Standard of Care Histopathology|Assessment for mild, moderate, or severe dysplasia, and risk of progression to oral cancer
223702274|NCT04622462|PROCEDURE|STRATICYTE Assessment|Assessment for risk of progression to oral cancer
223702275|NCT06679998|DRUG|Single dose, AAPB by injection, intravenous drip.|Subjects received a single intravenous infusion of AAPB for injection. Each dose of AAPB for injection was dissolved with 0.9% sodium chloride injection, the infusion volume was 100mL, once a day, and each time was continuously injected for 60 min±5min.
223702276|NCT06679998|OTHER|Single dose, placebo, intravenous drip.|Subjects received a single intravenous infusion of placebo. Each dose of placebo was dissolved by 0.9% sodium chloride injection with an infusion volume of 100mL once a day for 60 min±5min each time.
223702277|NCT06679998|DRUG|Multiple dosing, AAPB for injection, intravenous drip|Subjects received AAPB for injection with multiple intravenous drips. Each dose of AAPB for injection was dissolved with 0.9% sodium chloride injection, the infusion volume was 100mL, once a day, 60 min±5min each time, for 7 consecutive days.
223702278|NCT06679998|OTHER|Multiple dosing, placebo, IV drip|Subjects received multiple intravenous doses of placebo. Each dose of placebo was dissolved by 0.9% sodium chloride injection with an infusion volume of 100mL once a day for 60 min±5min each time for 7 consecutive days.
223702279|NCT06678620|BIOLOGICAL|Reinovax PCV24 formulation 1|One dose of Reinovax PCV24 formulation 1（0.5mL）
223702280|NCT06678620|BIOLOGICAL|Reinovax PCV24 formulation 2|One dose of Reinovax PCV24 formulation 1（0.5mL）
223702281|NCT06678620|BIOLOGICAL|Reinovax PCV24 formulation 3|One dose of Reinovax PCV24 formulation 1（0.5mL）
223702282|NCT06678620|BIOLOGICAL|PPSV23|One dose of PPSV23 (0.5 mL) contains 1、2、3、4、5、6B、7F、8、9N、9V、10A、11A、12F、14、15B、17F、18C、19A、19F、20、22F、23F and33F saccharides.
223702283|NCT03615573|OTHER|Quality of Life Surveys|Patients with breast cancer diagnosis complete questionnaires over 20-30 minutes at baseline and at 3, 6, and 12 months after enrollment.
223702284|NCT06680895|OTHER|FeNO Observation|FeNO was observed and measured among patients with advanced respiratory support
223702285|NCT06681532|PROCEDURE|Native collagen membrane and bovine bone graft in treatment of class II furcation defects in lower molars|The bovine bone graft particles will be mixed with concentrated growth factor (CGF) to form sticky bone, the furcation defect area will be condensed with the mixture and covered completely with native collagen membrane.
223702286|NCT06681532|PROCEDURE|Bovine pericardium membrane and bovine bone graft in treatment of class II furcation defects in lower molars|the bovine bone graft particles will be mixed with concentrated growth factor (CGF) to form sticky bone, the furcation defect area will be condensed with the mixture and covered completely with bovine pericardium membrane.
223702287|NCT05574998|DRUG|Recombinant human endostatin (Endostar)|"The specific treatment regimen is as follows: Non-squamous NSCLC: Endostar (210 mg, CIV for 120 h) is started on the first day of each treatment cycle and administered every three weeks. Carboplatin AUC 5-6 mg/ml/min or cisplatin 75 mg/m2 (d4) +pemetrexed 500 mg/m2 (d4) Q3W is administered in this regimen for 4 cycles followed by Endostar plus pemetrexed until disease progression or intolerable toxicity.~Squamous NSCLC: Endostar (210 mg, CIV for 120 hours) is started on the first day of each treatment cycle and administered every three weeks. Carboplatin AUC 5-6 mg/ml/min or cisplatin 75 mg/m2 (d4) + paclitaxel 175 mg/m2 (d4) Q3W.Endostar is administered after 4 cycles of this treatment regimen until disease progression or intolerable toxicity developed."
223783202|NCT03361813|OTHER|trans-oral ultrasound guided peritonsillar infiltration|Preoperative peritonsillar infiltration of bupivacine in tonsillectomy surgery by using the ultrasound through a trans-oral route
223783203|NCT02061631|DRUG|Cisplatin|Pharmaceutical form:solution Route of administration: intravenous
223783204|NCT02061631|DRUG|DOCETAXEL XRP6976|Pharmaceutical form:solution Route of administration: intravenous
223783205|NCT02061631|DRUG|Dexamethasone|Pharmaceutical form:tablet Route of administration: oral
223783206|NCT02061631|DRUG|Dexamethasone|Pharmaceutical form:solution Route of administration: intravenous
223783207|NCT04321460|DRUG|LRG-002|Capsules containing live lyophilized probiotic bacteria of Lactobacillus genus
223783208|NCT04321460|DRUG|Placebo|Capsules containing placebo
223783209|NCT01871298|OTHER|Pilot Website Evaluation Component|The pilot health website will contain educational health information such as: health-related videos, searchable map of HIV prevention and other needed health and social services, and the option to register for automatic text message updates on relevant health information.
223783210|NCT05620758|OTHER|Nd YAG laser|patients from those diagnosed with TMD will receive Nd YAG laser 1064 nm
223783211|NCT05620758|OTHER|diode laser (980 nm)|patients from those diagnosed with TMD will receive a diode laser (980 nm)
223783212|NCT05620758|OTHER|diode laser (940 nm)|patients from those diagnosed with TMD will receive a diode laser (940 nm)
223783213|NCT05620758|OTHER|diode laser (660 nm)|patients from those diagnosed with TMD will receive a diode laser (660 nm)
223783214|NCT05620758|OTHER|diode laser (635 nm)|patients from those diagnosed with TMD will receive a diode laser (635 nm)
223783215|NCT06533774|DEVICE|Phonak Audéo Lumity 90-R|This study will be using the Audeo L90-R devices, which are programmed by the hearing care professional (HCP) using Target fitting software version 8.1.
223783216|NCT04495712|DRUG|spironolactone|aldosterone blocker
223783217|NCT04495712|DRUG|placebo|identical in appearance to spironolactone study drug
223783218|NCT02349958|DEVICE|HIPEC: MMC 30mg @ T0, 10mg @ T45min|MMC 30mg @ T0, 10mg @ T45min for Appendix, Psuedomyxoma, colorectal, small bowel
223783219|NCT02349958|DEVICE|HIPEC: MMC + CDDP 30mg @ T0, 10mg @ T45min 50 mg/m2 @T0|Gastric and Pancreato-biliary HIPEC: MMC + CDDP 30mg @ T0, 10mg @ T45min
223783220|NCT02349958|DEVICE|HIPEC: CDDP 75 mg/m2 @T0|Ovarian/peritoneal/fallopian tube, Uterine CDDP 75 mg/m2 @T0
223783221|NCT02349958|DEVICE|HIPEC: CDDP+ Doxorubicin 50 mg/m2 @T0 15 mg/m2 @T0|CDDP+ Doxorubicin 50 mg/m2 @T0 15 mg/m2 @T0 Mesothelioma and Sarcoma
223783222|NCT02889549|DRUG|ticagrelor|Different doses of ticagrelor (22.5/45/90 mg, twice daily, oral) treatment for 1 month
223783223|NCT02889549|DRUG|clopidogrel|Standard dose of clopidogrel (75 mg, once daily, oral) treatment for 1 month
223783224|NCT02824068|DRUG|glucosidase alfa|Long-term use in an observational study of licenced drug
223783225|NCT05447546|DRUG|HT-6184|Oral capsule
223783226|NCT05447546|DRUG|HT-6184 Placebo|Oral capsule
223783227|NCT01308749|DRUG|Oxytocin|"Subjects will use the Syntocinon® Nasal Spray (oxytocin) twice daily for 8 weeks if they are randomized to that arm in the Randomized Phase. All subjects will use the Syntocinon® Nasal Spray twice daily for 8 weeks in the Open Label Phase.~Subjects ages 3-10 years old will be titrated up to a maximum dose of 24 International units (IU). Subjects ages 11-17 years old will be titrated up to a maximum dose of 32IU."
223783228|NCT01308749|DRUG|Placebo|Placebo Nasal Spray
223783229|NCT04726709|BEHAVIORAL|Poised for Parkinson's|Lecture, demonstration, activities, and supplemental materials designed to improve self-awareness, situational awareness, and ability to make good choices for physical and emotional self-care, moment-to-moment.
223783230|NCT03793881|BEHAVIORAL|Nutritional Strategy|Counseling based on dietary goals and mindfulness techniques.
223783231|NCT03793881|BEHAVIORAL|Dietary Prescription|Dietary prescription according to guidelines.
223783232|NCT00674310|DRUG|Ropinirole Hydrochloride|Restless Leg Syndrome
223783233|NCT02233660|OTHER|Physical Therapy Group|The physical therapy group will receive 3 treatment sessions of manual therapies including maneuvers targeted to the areas anatomically related to the median nerve (i.e., cervical spine, shoulder, elbow and wrist) of 30min of duration, once per week.
223783234|NCT02233660|PROCEDURE|Surgical Group|The surgical group will receive a surgical procedure consisting of the decompression and release of the median nerve at the carpal tunnel performed by an experienced surgeon according to standardized protocols.
223783235|NCT00844623|GENETIC|TK99UN|escalated dosis from 2x10e10 to 2x10e12 viral particles injected intratumorally
223783236|NCT01911364|DRUG|BDP/FF/GB|Superiority over Tiotropium
223783237|NCT01911364|DRUG|Tiotropium|Superiority of CHF5993 over Tiotropium
223783238|NCT01911364|DRUG|BDP/FF + Tiotropium|non inferiority vs CHF5993
223783239|NCT04712526|DEVICE|AEON Endostapler|Surgery with AEON Endostapler
223783240|NCT05209893|OTHER|Telerehabilitation|Application based video home exercise for the knee osteoarthritis
223783241|NCT05209893|OTHER|Paper Based Rehabilitation|Paper instruction based home exercise for the knee osteoarthritis
223783242|NCT01610323|OTHER|Exercise intervention|Exercise group: 12 weeks of moderate intensity physical training under individual supervision in a specialised conditioning center, with a goal of 3 1h-sessions/week (from 16 wks to 28 wks of gestation). Including aerobic and muscular training.
223783243|NCT01610323|OTHER|Standard Care|
223783244|NCT02079805|DRUG|Azilsartan|Azilsartan tablets
223783245|NCT02079805|DRUG|Telmisartan|Telmisartan tablets
223783246|NCT04631822|PROCEDURE|Spinal anaesthesia|spinal anesthesia shall be conducted with 2.5 ml 0.5% hyperbaric bupivacaine at the L3/4 interspaces in the setting position.
223783247|NCT04631822|PROCEDURE|ultrasound-guided Adductor Canal Block + dexamethasone|"Ultrasound blocks will be done immediately after spinal anesthesia, before surgical intervention. A high-frequency linear ultrasound transducer was placed transverse to the longitudinal axis of the extremity at the midthigh level at a distance approximately halfway between the iliac spine and the patella. The femoral artery was identified underneath the sartorius muscle with the vein just underneath the artery. At this position, the saphenous nerve was placed lateral to the artery in the adductor canal (Fig. 1). A 10 cm Tuohy canula 18G Gauge (Braun Medical, Melsungen, Germany) was inserted, in plane, from the lateral side of the transducer, through the sartorius muscle with the tip placed lateral to the artery. then, a 20-ml mixture of 0.25% bupivacaine, and 4 mg dexamethasone will be injected."
223783248|NCT04631822|PROCEDURE|ultrasound-guided Adductor Canal Block + dexmedetomedine|"Ultrasound blocks will be done immediately after spinal anesthesia, before surgical intervention. A high-frequency linear ultrasound transducer was placed transverse to the longitudinal axis of the extremity at the midthigh level at a distance approximately halfway between the iliac spine and the patella. The femoral artery was identified underneath the sartorius muscle with the vein just underneath the artery. At this position, the saphenous nerve was placed lateral to the artery in the adductor canal (Fig. 1). A 10 cm Tuohy canula 18G Gauge (Braun Medical, Melsungen, Germany) was inserted, in plane, from the lateral side of the transducer, through the sartorius muscle with the tip placed lateral to the artery.then, a 20-ml mixture of 0.25% bupivacaine, and 0.5 Mg/kg dexmedetomidine will be injected."
223702288|NCT06707454|DEVICE|Digital Electroencephalography (DEEG)|The enrolled patients will undergo Digital Electroencephalography (DEEG) monitoring for at least two hours. A senior epileptologist will make a DEEG interpretation to detect DEEG abnormality. DEEG patterns will be categorized according to the American Clinical Neurophysiology Society's standardized critical care DEEG terminology(normal, slowing and asymmetry, sharp and wave, periodic discharges, ictal patterns burst suppression, and electrocerebral silence)
223702289|NCT06707168|DIAGNOSTIC_TEST|Digital palpation|Digital palpation for IOP measurement
223702290|NCT06707168|DIAGNOSTIC_TEST|Cotton-tipped applicator (CTA)|Cotton-tipped applicator (CTA) for IOP measurement
223702291|NCT06710912|BEHAVIORAL|Group acceptance and commitment therapy (ACT)|The ACT intervention module utilized in this study was adapted from Hayes foundational work on ACT and Harris. A summary of the general contents and exercises in each week was in accordance with the 6 core processes of Acceptance and Commitment Therapy based on Hayes. It was conducted in the Malay language. The same workbook with guided exercise and homework were used by all the therapists to assure standardization of the intervention to ensure that each group received similar contents in each session.
223702292|NCT06710912|OTHER|Treatment as usual|Standard care and follow-up for major depressive disorder
223783249|NCT04631822|PROCEDURE|ultrasound-guided Adductor Canal Block|"Ultrasound blocks will be done immediately after spinal anesthesia, before surgical intervention. A high-frequency linear ultrasound transducer was placed transverse to the longitudinal axis of the extremity at the midthigh level at a distance approximately halfway between the iliac spine and the patella. The femoral artery was identified underneath the sartorius muscle with the vein just underneath the artery. At this position, the saphenous nerve was placed lateral to the artery in the adductor canal (Fig. 1). A 10 cm Tuohy canula 18G Gauge (Braun Medical, Melsungen, Germany) was inserted, in plane, from the lateral side of the transducer, through the sartorius muscle with the tip placed lateral to the artery.then, a 20-ml mixture of 0.25% bupivacaine"
223783250|NCT01314651|BEHAVIORAL|Stimulus Control and Sleep Restriction|5 instructions in stimulus control and individually-tailored sleep restriction
223783251|NCT01314651|BEHAVIORAL|Lifestyle Modification|5 instructions in changing general lifestyle habits (maintaining consistent liquid intake, range of motion exercises, eating a serving of protein in the morning, etc.)
223783252|NCT00849342|DRUG|insulin detemir|Safety and effectiveness (weight and HbA1c) data collection in connection with the use of the drug Levemir® in daily clinical practice.
223783253|NCT06161363|OTHER|The Morisky Medication Adherence Scale|The Morisky Medication Adherence Scale will be completed bu the patients
223783254|NCT05778305|DRUG|Dexmedetomidine|a central sympatholytic drug
223702293|NCT06710691|OTHER|Physical activity intervention using traditional strength training protocols|Strength training participants performed the 6 reps of the first exercise at the prescribed RPE and then rested for 1 minute. Participants then completed another set of their first exercise with the required rest until the prescribed sets were completed. Participants performed the second and third exercises in the same fashion. Once the first block was completed, participants rested 5 min, then completed the second block. Six exercises were completed.
223702294|NCT06710691|OTHER|Physical activity intervention using high-resistance circuit training.|An adapted version of Alcaraz's high-resistance circuit training (HRC) was utilized in the intervention. Exercises and intensities used by strength training was the same for HRC except HRC participants performed the first three exercises as a circuit with 35 seconds rest between exercises, then completed the second block of exercises in the same fashion.
223783255|NCT05778305|OTHER|normal saline|saline is given to control group
223702295|NCT06707857|OTHER|tendon neuroplastic training|Throughout the training, participants pain, range of motion and disability were monitored and they were asked to report any discomfort or unusual sign.
223783256|NCT03518177|OTHER|Hospital-based pulmonary rehabilitation|The patient will receive an 8-week Pulmonary Rehabilitation Exercise Program including breathing exercises, treadmill walking, cycle ergometer, arm ergometer training and strengthening trainning with free weights at hospital.
223783257|NCT03518177|OTHER|Home-based pulmonary rehabilitation|The patient will receive an 8-week Pulmonary Rehabilitation Exercise Program including breathing exercises, free-walking, and strengthening training with free weights at home
223783258|NCT06357728|DEVICE|Continuous glucose monitoring|Continuous glucose monitoring sensor: All study participants wear the sensor on the back of either right or left upper arm for up to 10 days. Glucose levels will be recorded from the interstitial fluid every 5 minutes using intermittent/ flash glucose scanning. Data will be captured using a receiver.
223783259|NCT02807597|DRUG|LS301|-LS301 is a small molecule consisting of a NIR fluorescent dye and an octapeptide that is cyclized through a disulfide bond.
223783260|NCT02807597|DEVICE|Cancer Vision Goggles and standard fluorescence imaging systems|-Member of the operating team will wear the CVG during surgery
223783261|NCT02807597|PROCEDURE|Surgery|-Standard of care
223783262|NCT05084196|DRUG|Melatonin|Melatonin 5 mg capsule by mouth at bedtime
223783263|NCT05084196|OTHER|Placebo Capsule|Placebo capsule by mouth at bedtime
223783264|NCT06634914|DIETARY_SUPPLEMENT|Moonbrew|A blend of adaptogens with Chamomile, Rose, and Magnesium in a powdered form, designed to be mixed in liquid and consumed 2-3 hours before bed.
223783265|NCT06635798|BIOLOGICAL|GR2001|The packaging for GR2001 injection uses a borosilicate glass vial, a brominated halobutyl rubber stopper for injectable solutions and an aluminum-plastic combination cap for antibiotic vials as its primary packaging materials. The specification is 5mg/1ml per vial.
223783266|NCT06635798|BIOLOGICAL|HTIG|The HTIG is a Chinese licensed Human Tetanus Immunoglobulin produced by Tonglu-Bio, which are derived from human plasma, and then purified and filled in the injectable vial form.
223783267|NCT04848025|DEVICE|Custom-designed tracheobronchial prostheses|Computer-assisted segmentation of airways and stent from CT data (AnatomikModeling) Fabrication of a mold and then a silicon stent by mold injection and sterilization (NOVATECH) Insertion of the stent under rigid bronchoscopy and general anesthesia
223783268|NCT01136837|OTHER|primary pcı|
223783269|NCT01981434|OTHER|Video game based obesity education|The intervention will be in the form of a videogame in which both parent and their children will participate. The game incorporates lessons from research on avatars (e.g., the Proteus Effect), and game dynamics to explore ways to increase healthy eating and exercise.
223783270|NCT04034433|PROCEDURE|Handgrip exercise program|Handgrip exercise with a rubber ball 4 weeks before the surgery until 4 weeks after the surgery 20 contractions per minute for a total of 20 minutes each day.
223783271|NCT04950335|PROCEDURE|AOPT|The Osteochondral Autograft Transplant System (Arthrex) was used to create donor plugs. Osteoperiosteal grafts were harvested from the ipsilateral anterior superior iliac spine.
223783272|NCT04950335|PROCEDURE|AOCT|Osteochondral grafts were harvested from the non-weight-bearing zone of the ipsilateral anterolateral distal femur.
223783273|NCT01775137|DRUG|TBM100|Tobramycin inhalation powder (TIP) 112mg/b.i.d
223783274|NCT03526913|PROCEDURE|PRP|PRP: autologous platelet-rich plasma
223783275|NCT03526913|PROCEDURE|STSG|skin graft: Split Thickness Skin Grafting (STSG)
223783276|NCT04606953|BEHAVIORAL|Attention Process Training (APT-II)|The exercises target different attentional components and working memory in the auditory-visual modalities. They are of increasing difficulty while being adapted to the profile of each patient in order to maximize the effects on cognitive reserve. During the sessions, the emphasis is on generalizing the gains to the most problematic daily activities in order to reduce the impact of cognitive disorders in patients' daily life.
223783277|NCT01747980|DRUG|PRX-112|Single dose level, four doses per cohort
223783278|NCT01285375|DEVICE|CDC solution|2 ml of CDC 12/mg/ml is added to 1 l of UW solution. 500 ml of of this solution is used for flushing the kidney allograft prior to transplantation
223783279|NCT01285375|DEVICE|UW-solution|500 ml of UW solution is used for flushing the kidney allograft prior to transplantation
223783280|NCT02923037|PROCEDURE|Yoga|Complete guided and home yoga sessions
223783281|NCT02923037|OTHER|tape measurement of arm|Ancillary studies
223783282|NCT02923037|OTHER|Quality-of-Life Assessment|Ancillary studies
223783283|NCT02923037|OTHER|ldex measurement of arms|
223783284|NCT03892941|DEVICE|Imaged based fitting|Mapping of the electrical input of the cochlear implant will be based on an individualized natural frequency alignment as estimated with imaging methods.
223783285|NCT04118218|OTHER|Rhizolysis pain analysis|"Definition of the subgroup of good clinical outcome after rhizolysis (called effective rhizolysis) by lumbar VAS or lower extremity pain VAS or Oswestry index decreased at 6 weeks after rhizolysis.~The efficiency criterion based on the decrease in the dolorimeter or the Oswestry index corresponds to a decrease of at least 50% \[1, 2, 3, 4\]."
223783286|NCT02192268|OTHER|PEP|
223783287|NCT02192268|OTHER|HFOO|
223783288|NCT02192268|OTHER|Assisted Coughing|
223783289|NCT05102994|DIAGNOSTIC_TEST|mutation test|detect the tumor-related mutation in introcular fluid
223783290|NCT05902195|BEHAVIORAL|Personal Resource Building and Inclusive Volunteering Intervention (PVI)|PVI is a 6-week virtual programme aimed at building up young stroke survivors' personal resources for work through engaging in inclusive volunteering activities.
223783291|NCT05902195|OTHER|Usual care|Usual stroke care services include medical and health services offered by the hospitals or community-based organisations.
223783292|NCT01298297|DRUG|Buprenorphine|0.4 mg, SL (sublingual) Buprenorphine PLUS 5 ml Placebo IV (in the vein)
223783293|NCT01298297|DRUG|Morphine|Placebo SL PLUS 5 ml Morphine sulfate (1mg/ml) IV
223783294|NCT02083523|BEHAVIORAL|Motivational Interview with Normative Feedback|NOrmative Feedback (NF) contrasts and individual's substance use to available norms for one's reference group (i.e., descriptive norms.) Essentially, NF highlights how an individual's behavior is non-normative, which in turn, is thought to lead to reduced substance use.
223783295|NCT02083523|BEHAVIORAL|Motivational Interview|The Motivational Interview (MI) addresses ambivalence about change. It's effects are mediated by how well counselors evoke change talk, or in-session client utterances about the: need for; commitment to; ability to; or steps needed, to change.
223783296|NCT03050476|DRUG|RESCAP®|intravenous application before, during, and for 24 or 96 hours after heart surgery
223783297|NCT03050476|DRUG|placebo|intravenous application before, during, and for 24 or 96 hours after heart surgery
223783298|NCT01977118|DRUG|streptokinase|50000U of injection streptokinase dissolved in 100ml of diluent instilled in to the pancreatic and/or peripancreatic collections via percutaneous catheters and clamped for 2 hours in Streptokinase group. After release of clamp, cavity will be irrigated with 100-500ml of saline. This procedure will be performed thrice daily for five days.
223702296|NCT06707857|OTHER|conventional training|Throughout the training, participants pain, range of motion and disability were monitored and they were asked to report any discomfort or unusual sign.
223702297|NCT06710470|DRUG|Deucravacitinib|As per product label
223702298|NCT06710470|DRUG|Systemic psoriasis medications|As per product label
223702299|NCT06710470|OTHER|No systemic medications|Participants not exposed to any systemic medications
223702300|NCT06708741|DRUG|Vitamin D|High dose oral vitamin D supplementation (50,000 IU/once per month)
223702301|NCT06708624|DRUG|FYB201 0.5 mg (0.05 mL of 10 mg/mL)|IVT administration of FYB201 in a PFS
223702302|NCT06707246|DRUG|Secukinumab 300 MG; Tofacitinib 11mg|Tofacitinib tablet 11mg per tablet; Secukinumab 150mg/ml
223702303|NCT06709950|BEHAVIORAL|Art therapy|Through music, painting, dance and other forms, art therapy can not only help patients regulate their emotions, relieve anxiety and depression, but also activate different areas of the brain to promote neuroplasticity, thereby promoting the recovery of motor function
223702304|NCT06709950|BEHAVIORAL|Regular therapy|Standard treatment
223702305|NCT06708546|DIETARY_SUPPLEMENT|Dielac Grow Plus|"Dialac Grow Plus is an Oral Nutritional Supplementation made by Vietnam Dairy Products Joint Stock Company - Vinamilk.~Condition: Liquid~Color: White~Date of use: 8 months from the manufactured date.~Preserve: Store in a clean, dry place, and avoid direct sunlight."
223702306|NCT06710769|PROCEDURE|Ovarian tissue removal will be performed laparoscopically|under general anesthesia concomitantly with another scheduled procedure if possible. Following removal, ovarian tissue will be shipped to University of Pittsburg Medical Center, Magee-Womens Research Institute for processing. Freezing and storing techniques will be in accordance with FDA regulations for reproductive tissues, guidelines of the American Association of Tissues Banks and any other applicable federal, state and local regulations. The tissue will be carefully separated dividing the cortex from the medulla. The cortex will then be cryopreserved for long term storage. The medulla will be shipped overnight back to the PCH Department of Pathology for histological evaluation. If pathology finds evidence of cancer in the ovarian tissue provided, they may request that all of the patient's tissue be returned to pathology for a more detailed examination, which may eliminate the tissue available for the patient's future use.
223702307|NCT03366012|DEVICE|Cytosponge|The Cytosponge consists of a 3cm diameter, polyester, medical grade spherical sponge on a string, compressed within a gelatin capsule. The capsule is swallowed while the patient or the research specialist holds onto the string. After 3-5 minutes the gelatin capsule dissolves allowing the spherical sponge to expand. The sponge is then retrieved by gently pulling on the string, thus collecting cells along the passageway through the entire length of the esophagus. The sample is then put into a preservative to be processed for immunohistochemical testing for trefoil factor 3 (TFF3) to determine diagnosis of Barrett's esophagus.
223783299|NCT01977118|OTHER|Saline irrigation|100 ml of normal saline will be instilled through percutaneous catheters in the pancreatic and/or peripancreatic collections and clamped for 2 hours. After release of clamp, cavity will be irrigated with 100-500ml of saline. This procedure will be performed thrice daily for five days
223783300|NCT02680600|DRUG|Cefepime dosing|Patients will received cefepime administered per standard-of-care as a 30 min intravenous infusion. Dosing will be based on local guidelines (the Sanford guide to antimicrobial therapy 2012-2013) using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) creatinine formula to estimate glomerular filtration rate (GFR).
223783301|NCT02680600|OTHER|Blood sampling|Blood will be sampled immediately prior to dose administration (time = 0 at the start of the 30 min infusion), at 0.5, 1, 3, 5 hours post-start of infusion and just before the subsequent dose. From day two onwards, samples will be taken at the end of the infusion and just before the next dose. For the quantification of cefepime, a validated solid phase extraction-liquid chromatography electrospray-tandem mass spectrometry method will be used.
223783302|NCT02680600|OTHER|Urine sampling|Timed urine collections were taken during one dosing interval (8 hours in a three times daily regimen) every day.
223702308|NCT06710821|DRUG|Liposomal irinotecan in combination with vincristine and temozolomide|Vincristine: 1.5 mg/m², iv, d1. l Temozolomide 150 mg/m²/d, iv drip, d1-5. l Irinotecan liposomal RP dose, iv infusion over 90 min, d1. Q3W, 4 cycles expected until disease progression or intolerable toxicity occurs
223702309|NCT06709703|PROCEDURE|Kinematic aligned total knee replacement|Replacement of worn knee cartilage using a prosthesis. The alignment is determined according to the patient's anatomy and ligament balance.
223702310|NCT06710301|OTHER|Preliminary assessment|Evaluation of the cognitive level through the Raven test and of spatial navigation skills through the Corsi test and the maze sub-test of the WISC-III.
223702311|NCT06710301|OTHER|Navigation task with EEG recording|Administration of the navigation task in an immersive virtual reality environment and EEG signal recording. The participant will wear virtual reality viewers and EEG cap. The task consists in moving and orienting themselves inside a five-way maze in order to reach a treasure. The participant will be asked to carry out 30 trials lasting a maximum of 120s each.
223702312|NCT06707181|DRUG|• The study will include 180 randomly selected patients who met inclusion criteria were randomized into four groups: silodosin 8 mg (Group A), tamsulosin 0.4 mg (Group B), silodosin 8 mg plus tadalaf|• The study will include 180 randomly selected patients who met inclusion criteria were randomized into four groups: silodosin 8 mg (Group A), tamsulosin 0.4 mg (Group B), silodosin 8 mg plus tadalafil 5 mg (Group C) and tamsulosin 0.4 mg plus tadalafil 5 mg (Group D). Drugs are given for a maximal duration of 28 days.
223702313|NCT06710496|OTHER|analysis of medical records|analysis of medical records of the patients
223702314|NCT00427947|DRUG|ropivacaine/placebo|Continuous sciatic nerve bloc
223702315|NCT04147533|DRUG|Imatinib withdrawal|withdrawal of imatinib after previous two-step dose reduction: during the first 6 months after study entry, the dose of imatinib is 50% of the standard dose (200 mg daily), during the second 6 months after study entry, the dose of imatinib is 200 mg every other day; 12 months after study entry, imatinib is discontinued, the patient is followed in line with the aims of the trial
223702316|NCT04147533|DRUG|Dasatinib|withdrawal of dasatinib after previous two-step dose reduction: during the first 6 months after study entry, the dose of dasatinib is 50% of the standard dose (40 mg daily; tablets containing 50 mg are not available on the market), during the second 6 months after study entry, the dose of dasatinib is 40 mg every other day; 12 months after study entry, dasatinib is discontinued, the patient is followed in line with the aims of the trial
223783303|NCT02680600|OTHER|Determination of renal markers|Creatinine (modified Jaffe method) and urea in serum will be determined using an Architect c16000 analyzer (Abbott, Chicago, IL, USA). Cystatin C will be determined using a particle-enhanced immunonephelometric assay (N Latex Cystatin C, Siemens Healthcare Diagnostics, Marburg, Germany) by use of a BN II nephelometer (Siemens Healthcare Diagnostics). This assay has a calibration traceable to the first certified reference material for cystatin C in human serum (ERM-DA471/IFCC). Kidney injury molecule-1 (KIM-1) in urine and uromodulin in serum will be determined using commercially available ELISA assays: Quantikine ELISA Human TIM-1/KIM-1/HAVCR (R\&D Systems, Minneapolis, MN, USA) and Uromodulin ELISA (Euroimmun, Luebeck, Germany), respectively.
223702317|NCT04147533|DRUG|Nilotinib|withdrawal of nilotinib after previous two-step dose reduction: during the first 6 months after study entry, the dose of nilotinib is 50% of the standard dose (200 mg every 12 hours), during the second 6 months after study entry, the dose of nilotinib is 400 mg every other day; 12 months after study entry, nilotinib is discontinued, the patient is followed in line with the aims of the trial
223702318|NCT06933082|BEHAVIORAL|An intervention program has been developed acceding to The field visit conducted by researcher before the start of the study and observed the work environment and the lack of commitment of workers t|An intervention program has been developed acceding to The field visit conducted by researcher before the start of the study and observed the work environment and the lack of commitment of workers to implementing the occupational health and safety program despite the existence of this program in the company.this intervention program based on health belief model in improventing workers' adherence related to occupatioan hazards prevention by wearing PPE. Validity and pre-test are applied prior to the implementation of the intervention program. The program is comprised of five main lecture each lecture is designed and scheduled for at least (45) minutes which deals with changing of workers' health beliefs about occupatioan hazards prevention.All lectures are presented at conference hall in the company.The implementation of health intervention program is initiated during the period of June 20th, 2024 to June 25th, 2024. Each lecture is designed and scheduled for approximately (45)
223702319|NCT06933238|DRUG|Fuzheng Tongfu Jiedu prescription (FZTFJD)|"Fuzheng Tongfu Jiedu prescription (FZTFJD), a kind of Traditional Chinese medicine (TCM).Conventional Western medical treatment in accordance with the 2021 International Guidelines for the Management of Sepsis and Septic Shock. . This included treatment and resuscitation begin immediately, administering antimicrobials immediately, hemodynamic management, mechanical ventilation, organ support, nutritional support, and prophylaxis for acute ulcers."
223702320|NCT06933238|DRUG|Placebo|"Fuzheng Tongfu Jiedu prescription plaebo. Conventional Western medical treatment in accordance with the 2021 International Guidelines for the Management of Sepsis and Septic Shock. . This included treatment and resuscitation begin immediately, administering antimicrobials immediately, hemodynamic management, mechanical ventilation, organ support, nutritional support, and prophylaxis for acute ulcers."
223702321|NCT06935006|PROCEDURE|Sonographic guided Erector spinae plane block|Ultrasound guided plane block using 20 ml of 0.25% bupivacaine at the level of transverse process of T8
223702322|NCT06935006|DRUG|Intravenous opioid|0.1 mg/kg morphine intravenous pre operative
223702323|NCT01748266|OTHER|microcirculatory reactivity|Microcirculation of the thenar eminence was analyzed by NIRS technology, through the StO2 and the resaturation slope after an ischemic challenge.
223702324|NCT03319173|BEHAVIORAL|Dietary intervention|"Subjects in the experimental group will receive clinically regulated meal plans designed to facilitate prolonged benign dietary ketosis (BDK) in order to regulate glucose with restored insulin sensitivity focused at reversing the impaired capacity to switch between fat and carbohydrate oxidation.~Subjects in the control group will follow the their current dietary protocol (Standard American Diet-SAD)."
223702325|NCT05928793|BEHAVIORAL|mindfulness practices|"Mindfulness, according to Kabat-Zinn, is to pay attention to the present moment in a purposeful way, without judgment. Being conscious involves both attention and awareness. Conscious awareness is an observer in the background of the state of consciousness, constantly observing the inner and outer environment. It is to direct our awareness and attention to our experiences in the present moment in an accepting way with our whole body and thoughts."
223702326|NCT02848404|DEVICE|Categorical Language Fluency Smartphone Application|4 weeks' training
223702327|NCT04652440|DRUG|PD-1 monoclonal antibody|The enrolled patients received intravenous injections of PD-1 monoclonal antibody (Tislelizumab 200mg) on the 1 day before radiofrequency or microwave ablation treatment, and 21(±7) days, 42(+7) and 63(+7) after ablation.
223702328|NCT04652440|PROCEDURE|Radiofequencey or microwave ablation|The enrolled patients received primary radiofrequency or microwave ablation on the day after the first dose of PD-1 antibody treatment.
223702329|NCT02555774|BEHAVIORAL|cognitive training|cognitive training is held 2 times a week for 3 months, 90 minutes per 1 session. It includes cognitive exercise of multiple cognitive domains such as memory, attention, calculation, executive function and visuospatial function.
223702330|NCT02555774|BEHAVIORAL|lifestyle modification|education about lifestyle modification is done by investigators at the first day of the trial and the investigators conduct weekly phone call to participants to educate the lifestyle modifications
223702331|NCT03673046|DEVICE|Smartphone-delivered cognitive behavioral therapy (CBT) for body dysmorphic disorder (BDD)|12-week Smartphone-delivered CBT for BDD. In-person cognitive behavioral therapy (CBT) is an empirically supported treatment for BDD. The app-delivered CBT in this project includes modules such as cognitive skills (e.g., cognitive restructuring, core belief work), behavioral skills (e.g., exposure with ritual prevention), and perceptual retraining/mindfulness skills.
223702332|NCT03817879|PROCEDURE|VivaSight double-lumen tube for single-lung ventilation|Procedure using a tube with a camera
223702333|NCT03817879|PROCEDURE|Conventional double-lument tube for single-lung ventilation|Procedure using a tube without a camera
223702334|NCT00522015|DRUG|rivastigmine|rivastigmine 6 mg up to 12 mg daily; Taken in two doses from 3 mg to 6 mg Rivastigmine twice a day
223702335|NCT06129565|DEVICE|Q-collar|Q-collar is placed for all patients that are admitted with low-pressure hydrocephalus
223702336|NCT05900609|DIETARY_SUPPLEMENT|WholeFiber|"WholeFiberTM is a product with high levels of prebiotic dietary fibers (\~85%) mainly consisting of inulin, and some pectin, hemi-cellulose and cellulose that is derived from the root vegetable, chicory roots.~Fiber guidelines:~Subjects receive a booklet with recipes high in fiber. Subjects are recommended to use 2 recipes + 2 snacks per day. Estimated average intake via the recipes in the recipe booklet is 24 grams/day.~General guidelines on nutrition and microbiome:~Subjects receive a link to a website with general recommendations to positively alter the gut microbiome (website Voedingscentrum and Dutch Digestive Foundation)."
223783304|NCT02680600|OTHER|Population pharmacokinetic modeling|The cefepime concentration versus time data will be fitted using the FOCE-I estimation algorithm in NONMEM® (Version 7.3; GloboMax LLC, Hanover, MD, USA). R® (R foundation for statistical computing, Vienna, Austria) will be used to graphically assess the model's goodness-of-fit and to evaluate the model's predictive capabilities. As a measure of prediction error, the absolute prediction error (APE) will be used. In short, the measured cefepime concentrations for each individual i at time point j were compared against the population predicted cefepime concentrations, i.e. the predictions for each individual without taking into account the between-subject variability (PRED in NONMEM). The distribution of APEs will be summarized by the median and 90% percentile.
223783305|NCT02680600|OTHER|Covariate screening|Renal function will be assessed by four serum based kidney markers (serum creatinine, cystatin C, urea and uromodulin) and two urinary markers (measured creatinine clearance (CrCl) and KIM-1, both on timed urine collections). Serum creatinine and cystatin C will also be used to calculate the eGFR based on CKD-EPI formulas.
223783306|NCT02680600|OTHER|Monte Carlo simulations|Based on the final covariate model, a Monte Carlo-based simulation study will be performed to evaluate the Sanford dose recommendations for ICU patients.
223783307|NCT03112616|OTHER|Vibration sessions|The patients will undergo a program of 10 sessions of vibrations of the neck muscle, each of 10 minutes, during a period of 15 days at the rate of one session per day.
223783308|NCT01595919|OTHER|Nutritional Intervention|Ad libitum amounts of beverage at a meal
223783309|NCT06097039|DEVICE|abdominal U/S|A convex transducer with a frequency range of 2-5 MHz was used for ultrasound. Based on a visual study of the intensity of the echogenicity and under the assumption that the gain setting is optimal, various (0-3) degrees of steatosis have been proposed. Grade I occurs when the echogenicity is simply increased; grade II occurs when the echogenic liver obscures the echogenic walls of the portal vein branches; and grade III occurs when the echogenic liver obscures the diaphragmatic contour.
223783310|NCT06097039|DEVICE|Fibroscan with Controlled Attenuated Parameter (CAP scan):|"Using FibroScan502 (Echosens, Paris, France), liver stiffness measurement (LSM) and CAP were acquired. Before the treatment, all subjects will be instructed to fast for at least 8 hours.~The median of 10 measurements served as the LSM score, which was only deemed credible if at least 10 successful acquisitions were made and the IQR-to-median ratio of the 10 acquisitions was below 30%. If 10 successful acquisitions are made, CAP measures were deemed trustworthy and taken into account in the final analysis.~CAP graded the degree of hepatic steatosis using the M probe in accordance with standard cut-off values (S1=222-232; S2= 233-289; and S3 290 dB/m)."
223783311|NCT04257318|OTHER|Vibrating Relaxation Tool|Use of a Vibrating Relaxation Tool in case of pain during pregnancy
223783312|NCT02785406|DRUG|suvorexant|Subjects will receive suvorexant capsules (10 mg week 1, 20 mg week 2), once daily at 10 PM.
223783313|NCT02785406|DRUG|Placebo (for suvorexant)|Subjects will receive placebo capsules once daily at 10 PM.
223783314|NCT06534606|PROCEDURE|Electrotherapy and physical agents|"Moist heat therapy: Frequency: 15 minutes, 3 times per week (alternatively) for 2 weeks.~• TENS application: Frequency: 15 minutes, 3 times per week (alternatively) for 2 weeks."
223783315|NCT06534606|PROCEDURE|Headache SNAGs|"Headache SNAGs (Sustained Natural Apophyseal Glides) 5 sets of 10 repetitions. Each repetition will be given with a 10 second hold.~• Frequency: 3 times a week for 2 weeks. 6 sessions in total."
223783316|NCT06534606|PROCEDURE|Sternocleidomastoid Release|Sternocleidomastoid Release: Group B will also receive Sternocleidomastoid release in addition with headache SNAGs. Release to the sternocleidomastoid muscle will be given once per session for 5-8 minutes.Frequency: 3 times a week for 2 weeks. 6 sessions in total.
223783317|NCT05768308|BEHAVIORAL|Internet CBT-UP intervention iCBT-UP|The self-helped internet intervention for students experiencing emotional difficulties, especially adjustment disorder. This intervention is based on transdiagnostic cbt principles - unified protocol (Barlow et al., 2018). It is a modular intervention consisting of six modules teaching different skills of dealing with emotions. Intervention is interactive and contains of video materials, quizes, texts and audio materials.
223783318|NCT05768308|BEHAVIORAL|Internet Progressive Muscle Realxation Training (iPMR)|Participants from the active control group will receive progressive muscle relaxation training (iPMR) (Bernstein, Borkovec, Hazlett-Stevens, 2000). It is also a modular intervention and, similar to the i-cbt condition, consists of 5 modules. During the intervention, participants learn how to progressively tighten and relax different muscle groups.The first module is planned for two weeks and the rest of them for one week each. Intervention consists of video materials and audio guided relaxations. Participants are encouraged to train these relaxations once a day.
223702337|NCT05900609|DIETARY_SUPPLEMENT|Kombucha|"The kombucha is produced by a minimum three-month long fermentation process. It is a live fermented herbal drink essence, without refined sugar, and an unpasteurized, organic product.~Fermented food guidelines:~Study participants in the fermented foods arm are asked to use 3 additional servings of fermented food per day, using the fermented food list / recipe booklet.~General guidelines on nutrition and microbiome:~Subjects receive a link to a website with general recommendations to positively alter the gut microbiome (website Voedingscentrum and Dutch Digestive Foundation)."
223702338|NCT05900609|DIETARY_SUPPLEMENT|Maltodextrin DE19/21|"Maltodextrin DE19/21 is a digestible carbohydrate, that is completely digested and does not reach the colon, which makes it a suitable placebo dietary compound and the reason why it is frequently used in comparable studies.~General guidelines on nutrition and microbiome:~Subjects receive a link to a website with general recommendations to positively alter the gut microbiome (website Voedingscentrum and Dutch Digestive Foundation)."
223702339|NCT00825578|DEVICE|Intra-bronchial valve (Spiration IBV)|Device: Intra-bronchial valve (Spiration IBV) The IBV is comprised of a Nitnol frame and a polymer membrane, which is held against the airway mucosa by six elastic struts and will expand and contract with airway movement during breathing. The valve is designed to conform to the size and shape of the airways. The frame has 5 flexible anchors that gently secure to the mucosal wall at a controlled depth. Valves are available in 5, 6 and 7mm diameters appropriate for different airways. During a minimally invasive procedure, a catheter is passed through a bronchoscope (a flexible tube passed into the airways through the mouth) to deploy the umbrella-shaped valves into the airways. Only flexible bronchoscopy equipment is required. The valves are designed to be removed if indicated.
223702340|NCT05449119|BIOLOGICAL|Fecal and blood sampling and collection of nutritional, cognitive and sensorimotor data|at T0, T3 months, T6 months, T9 months and T12 months
223702341|NCT05449119|OTHER|Body Mass Index (BMI)|Calculation of BMI with height measurement by heel-knee distance measurement at T0, T3 months, T6 months, T9 months and T12 months
223702342|NCT05449119|OTHER|24-hour food and beverage record|at T0, T3 months, T6 months, T9 months and T12 months
223702343|NCT05449119|OTHER|Mini Nutritional assessment (MNA)|at T0, T3 months, T6 months, T9 months and T12 months
223702344|NCT05449119|OTHER|Measurement of muscle mass by bioelectrical impedance analysis (except for participants with a pacemaker)|at T0, T3 months, T6 months, T9 months and T12 months
223702345|NCT05449119|OTHER|Measurement of sensorimotor functions|at T0, T3 months, T6 months, T9 months and T12 months
223702346|NCT05449119|OTHER|Measurement of cognitive functions|at T0, T3 months, T6 months, T9 months and T12 months
223702347|NCT01896050|DRUG|anastrozole, letrozole, exemestane|Patients were treated with one of the listed anti-hormonal medications for up to one year
223702348|NCT01896050|DRUG|Tamoxifen|Patients were treated with tamoxifen for up to one year
223702349|NCT00392015|BIOLOGICAL|NMRC-M3V-Ad-PfCA|Malaria Vaccine
223702350|NCT00392015|BIOLOGICAL|NMRC-MV-Ad-PfC, NMRC-M3V-Ad-PfCA|Malaria Vaccines
223702351|NCT06956781|BEHAVIORAL|Emotion Regulation|Participants learn to reduce acute subjective distress, stabilize negative mood, promote positive mood, and alter physiological responses to trauma
223702352|NCT06956781|BEHAVIORAL|Exposure|Participants engage in written exercises to reduce avoidance of trauma reminders and reinforce approach behaviors consistent with personal goals
223702353|NCT06956781|BEHAVIORAL|Cognitive Processing|Participants learn ways to identify, challenge, and overcome the influence of cognitive distortions resulting from trauma exposure
223702354|NCT06956781|BEHAVIORAL|Bi-lateral Stimulation|Participants engage in horizontal eye movements while recalling a traumatic memory and describing their affective and physiological state
223702355|NCT06956781|BEHAVIORAL|Psychological Placebo|Participants receive non-directive support therapy, where they will guide the treatment session but not be required to discuss prior trauma exposure
223702356|NCT03591835|OTHER|Weight+6|For the Tochen formula in Group 1, ETT depth will be calculated by taking the infant's actual weight within the last 24 h and adding 6 cm.
223702357|NCT03591835|OTHER|NTL+1|The infants in Group 2 will be intubated by measuring the NTL, the distance from the basement of the nasal septum to the the tragus of the ear. Measurements will be recorded as centimeters.
223702358|NCT01628315|DEVICE|MRI|Annual MRIs as part of participation in the ASA study.
223702359|NCT03940040|OTHER|Usual care|Usual Care
223702360|NCT03940040|OTHER|High flow nasal oxygen|High flow nasal oxygen
223702361|NCT06233981|RADIATION|Moderate-dose Hypofractionated Intensity-modulated Radiotherapy|All lesions receive moderate-dose hypofractionated intensity-modulated radiotherapy, with a gross tumor dose of 25Gy/5f, and a maximum dose of 35Gy/5f at the tumor center.
223702362|NCT06233981|DRUG|Tislelizumab|One week before or during the radiotherapy, patients receive concurrent Tislelizumab at a dose of 200mg. Subsequently, Tislelizumab is administered intravenously every 3 weeks. Follow-up examinations are conducted 1-3 months post-radiotherapy. Lenvatinib 4mg may be used for maintenance therapy with Tislelizumab if there are no contraindications. Maintenance therapy is continued until disease progression or intolerance.
223702363|NCT04325646|OTHER|Human Biological samples|Blood samples for serological tests
223702364|NCT04325646|OTHER|Human Biological samples|Blood samples, saliva, nasopharyngeal swab for serological tests
223702365|NCT01057095|GENETIC|RNA analysis|
223702366|NCT01057095|GENETIC|gene expression analysis|
223702367|NCT01057095|GENETIC|reverse transcriptase-polymerase chain reaction|
223702368|NCT01057095|OTHER|laboratory biomarker analysis|
223702369|NCT03652168|BEHAVIORAL|Meditation|10 minute a day, 8 week digital meditation
223702370|NCT00686283|BEHAVIORAL|PEP intervention|This study will explore the feasibility of adherence to a personalized exercise prescription (PEP) in adolescents with type 1 or type 2 diabetes. The PEP intervention consists of a 2-hour group education session and a 16-week personalized exercise plan implemented in the home or community setting with the use of parental support and care ambassadors. Care ambassadors will maintain consistency of interactions with specific families for the duration of the PEP intervention. This consistency will aid in establishing rapport with the adolescents and parents to answer any questions and provide guidance for adhering to the PEP plan. The PEP intervention will be mutually planned with each teen and parent based upon the assessment of the teen's personal and cultural choices, including family and community resources. Exercise frequency, duration, and intensity for the teen with diabetes will be documented with a MTI ActiGraph accelerometer (Fort Walton Beach, FL).
223702371|NCT00089414|DRUG|Ethinyl Estradiol/Drospirenone|Drug administered dependent upon arm.
223702372|NCT00089414|DRUG|Placebo|
223702373|NCT00089414|DRUG|CDB 2914|
223702374|NCT01754870|DRUG|Bendamustine and Rituximab Induction followed by Rituximab and Lenalidomide Maintenance|
223702375|NCT02925923|DRUG|Ticagrelor|After randomization, a blood sample will be obtained at baseline for platelet function study, the study drugs, crushed ticagrelor will be administered. Patients will undergo PCI using drug-eluting stents or bare-metal stents. Blood samples will be obtained at 30 mins, 2, 4, and 24 h after PCI for platelet function tests.
223783319|NCT00991250|BIOLOGICAL|SentoClone®|SentoClone® are autologous tumour-reactive lymphocytes which are expanded and infused to the patient, where they have the opportunity to seek out and attack the primary tumour and metastases. The first step is to identify the tumour draining lymph node(s), which is done in parallel to surgical resection of the primary tumour or metastasis. The sentinel and/or metinel node(s), the initial meeting place between tumour antigen and the immune system, are further dissected and collected during the surgery. The lymphocytes are extracted from the collected lymph nodes and expanded in vitro, the lymphocytes are thereafter stimulated with tumour extract and returned to the patient intravenously as an autologous cell transfusion. The administered volume will be 100 ml for cell densities less than 3x106 cells/ml and 200 ml for cell densities of 3x106 cells/ml or more.
223783320|NCT00991250|DRUG|Temodal® or Dacarbazine Medac®|"Dacarbazine (5-\[3,3-Dimethyl-1-triazenyl\]imidazole-4-carboxamide) is a widely used systemic treatment against advanced malignant melanoma. Dacarbazine is a cytostatic agent, which inhibits tumour growth by interfering with DNA-synthesises. The DNA-synthesis is inhibited by alkylation of the DNA molecule; however, it is unclear whether dacarbazine has other cytostatic impacts on cell mechanisms. Dacarbazine is inactive until liver passage, the liver converts dacarbazine to its reactive metabolites MTIC and HMMTIC, which alkylate DNA. Dacarbazine is light sensitive and needs to be administered intravenously.~A newer analogue to dacarbazine, temozolomide (Temodal®), has been developed for oral administration. Temodal® is administered in capsules and is rapidly absorbed reaching peak concentrations after 20 minutes. Temodal® is converted to MTIC at physiological pH, the same reactive molecule as dacarbazine is metabolized to in the liver."
223783321|NCT04579263|OTHER|Fecal microbiota|Transplantation of fecal microbiota of healthy donor with normal body mass index
223783322|NCT04947111|DIAGNOSTIC_TEST|Estimate the distribution of antibodies by serotype by Dengue virus in areas of low and high incidence of dengue|"Indirect IgG ELISA to estimate seroprevalence: The seropositivity will be evaluated with the Indirect IgG ELISA following the instructions of the Panbio E-DEN 01 G manufacturer, which has a specificity of 98% and a sensitivity of 100%. In brief, 10 microliters of participant serum will be used for each assay. Each kit provides a positive and negative control, as well as three calibrators, with the respective values for quality control. Samples will be classified as positive, negative or indeterminate according to the cut-off point for each ELISA kit.~Neutralizing antibody titers serotype-specific: To establish the type of humoral immunity that the selected city presents, the measurement of the neutralizing antibody titers will be carried out by means of the neutralization test by reducing the number of lytic plaques to 50% (PRNT50%) , using Vero cells and the following reference strains for each serotype: DENV-1 (HAWAI), DENV-2 (NEW GUINEA), DENV-3 (H-887) and DENV-4 (H-24)"
223783323|NCT02011880|DIETARY_SUPPLEMENT|Chinese Herbs|"Dietary Supplement:Experiment group:~Fructus Cnidii,Psoralea Corylifolin L.，monkshood~-Granules,Oral(add into the breast cancer postoperative prescription solution),A Pack(Fructus Cnidii 9g，Psoralea Corylifolin L. 15g，monkshood 9g),Bid Days,3 Periods(a month is a period),Until progression/unacceptable toxicity~Breast Cancer Postoperative Prescription~-Water Decoction,Oral,200ml,Bid Days,3 Periods(a month is a period),Until progression/unacceptable toxicity~Dietary Supplement:Contrast Group:~Breast Cancer Postoperative Prescription~-Water Decoction,Oral,200ml,Bid Days,3 Periods( a month is a period),Until progression/unacceptable toxicity"
223783324|NCT01351740|DRUG|atazanavir|switch to unboosted atazanavir 400 mg daily
223783325|NCT01351740|DRUG|atazanavir/ritonavir|Continue current regimen of atazanavir 300 mg/ ritonavir 100 mg daily
223783326|NCT04096092|OTHER|No intervention|No intervention
223783327|NCT04001465|PROCEDURE|Volumetric methacholine challenge unmodified|Bronchoprovocation challenge performed per volumetric method
223783328|NCT04001465|PROCEDURE|Modified volumetric methacholine challenge|Bronchoprovocation challenge performed per volumetric method modified to include use of ultrasonic spirometer fitted with vibrating mesh nebulizer
223783329|NCT04160819|OTHER|Assigned Interventions|Participants in the NI group received an iNIP according to energy and protein intake requirements in addition to dietary advice based on face-to-face interviews with their family members during hospitalization. After discharge, phone calls are adopted for prescribing iNIPs.
223783330|NCT01491243|DRUG|Intensive treatment with sodium bicarbonate|i.v., sodium bicarbonate (3 ml/kg/h for 1 hour, then 1 ml/kg/h for 7 h) followed by i.v. saline for 48 h in case of abnormal NGAL findings
223783331|NCT01491243|DRUG|Standard treatment with saline infusion|i.v. 1 ml/kg/h saline infusion for 48 h in case of abnormal NGAL findings
223783332|NCT00153049|DRUG|Telmisartan|
223783333|NCT00153049|DRUG|Hydrochlorothiazide|
223783334|NCT00153049|DRUG|Telmisartan + Hydrochlorothiazide|
223783335|NCT03296995|DEVICE|Flash glucose monitoring system|Flash glucose monitoring systems in critically ill patients may improve glycemic control and reduce glucose variability.
223783336|NCT03579745|PROCEDURE|Lingual orthodontics|A coil spring will be attached from the lever arm to the first molar tube
223783337|NCT04473404|DIETARY_SUPPLEMENT|Streptococcus salivarius DB-B5 - 2 billion CFU/day|The participants (n=15) will consume sachets containing Streptococcus salivarius DB-B5 (at 1 billion CFU/sachet) dissolved in water twice daily for 4 weeks.
223783338|NCT04473404|DIETARY_SUPPLEMENT|Streptococcus salivarius DB-B5 - 10 billion CFU/day|The participants (n=15) will consume sachets containing Streptococcus salivarius DB-B5 (at 5 billion CFU/sachet) dissolved in water twice daily for 4 weeks.
223783339|NCT04473404|OTHER|Placebo|The participants (n=15) will consume sachets containing a placebo (probiotic carrier) twice daily for 4 weeks.
223783340|NCT00319215|DRUG|Ramelteon 8 mg|
223783341|NCT00319215|DRUG|Zopiclone 7.5 mg|
223783342|NCT05916742|PROCEDURE|CAF|Periodontal surgical technique to treat gingival recessions
223783343|NCT05916742|PROCEDURE|i-PRF|Blood-derived biomaterial. Two sterile plastic tubes (Process for PRF, Nice, France) with a volume of 10 ml will be used to generate fluid blood concentrate. After blood collection, the tubes will be centrifuged using a Duo centrifuge (Process for PRF, Nice, France) (fixed angle rotor with a radius of 110 mm) following the protocol proposed by Choukroun et al. (2018) (600 rpm; 8 min).
223783344|NCT05916742|DEVICE|VCMX|Porcine derived collagen matrix.
223783345|NCT05916742|DRUG|Sodium dipyrone|All participants will be instructed to take 500 mg sodium dipyrone just in case of pain.
223783346|NCT05916742|DRUG|Chlorhexidine rinse|All participants will be instructed to perform 0.12% chlorhexidine rinse after the surgical procedures.
223783347|NCT05916742|DRUG|Amoxicillin 500mg|Participants enrolled in the CAF+VCMX and CAF+VCMX will be instructed to take amoxicillin 500mg (8 hours/8 hours, during 7 days) after the surgical procedures.
223783348|NCT00412087|DRUG|cholecalciferol (vitamin D3)|randomized to one of two treatments: 2000 or 4000 IU vitamin D3/day
223783349|NCT00412087|DRUG|cholecalciferol|randomized to one of 2 treatment doses: 2000 vs. 4000 IU/day vitamin D3
223783350|NCT00412087|DRUG|cholecalciferol|cholecalciferol at 2000 or 4000 IU/day to be taken througout pregnancy. This follows the initial run-in dosing of 2000 IU/day starting at 12-weeks' gestation.
223783351|NCT04183322|BIOLOGICAL|13-valent pneumococcal conjugate vaccine|
223783352|NCT00634413|DRUG|Theophylline - ADC4022|Inhaled theophylline (ADC4022) administered twice daily for 28 days
223783353|NCT00634413|DRUG|Placebo|Inhaled matching placebo administered twice daily for 28 days
223783354|NCT00634413|DRUG|Budesonide|Inhaled budesonide twice daily for 28 days
223783355|NCT01467323|DRUG|biphasic insulin aspart|Injected subcutaneously (under the skin) twice daily
223783356|NCT01467323|DRUG|biphasic human insulin|Injected subcutaneously (under the skin) twice daily
223783357|NCT04046874|DRUG|Usual Care|Pain Medication, imaging, referrals to other health services, other health care appointments
223783358|NCT04046874|OTHER|SPLIT Stratified Model of Care|Physiotherapy targeted treatment system of increasing complexity for each subgroup (low, medium or high) of risk of chronicity. Includes patient education, manual therapy and exercise
223783359|NCT05383248|BEHAVIORAL|High Reward - High Variance|Computerized reward learning task designed to increase reward responsiveness
223783360|NCT05383248|BEHAVIORAL|High Reward - Low Variance|Computerized reward learning task designed to have minimal effect on reward responsiveness
223783361|NCT06416215|OTHER|Psychological intervention based on WBT and cognitive restructuring|Participants will engage in 6 weekly group session of two hours. One part will be held by a trained dietician and will focus on nutritional education, particularly emphasizing the adoption of healthy and sustainable eating behaviors. The remaining part will be dedicated to a group psychological intervention inspired by the principles of Well-Being Therapy and will be held by a trained psychologist. During these sessions, participants will be introduced to the six dimensions of psychological well-being and will be gradually provided with cognitive-behavioral strategies to enhance psychological well-being and seek a balance between the presented dimensions. Participants will be given cognitive-behavioral tools to recognize justification cognitive mechanisms and replace them with more functional cognitions. These objectives will also be achieved through the use of a food diary to highlight emotions and thoughts experienced during food intake.
223783362|NCT06416215|OTHER|Basic Nutritional Intervention|Participants will receive treatment as usual (TAU) by participating in 6 weekly group sessions of two hours of a Basic Nutritional Intervention (BNI) held by a trained dietician. This course focuses on promoting healthier lifestyles through nutritional education, diet monitoring using a dedicated food diary, and recommendations for proper physical activity.
223783363|NCT00775749|DRUG|transdermal nicotine patch|The 7 mg transdermal nicotine patch will be applied to the right upper back prior to surgery. It will be covered with an opaque bandage to minimize inadvertent removal and conceal which patch has been placed.
223783364|NCT00775749|DRUG|placebo patch|The placebo patch will be applied to the right upper back prior to surgery. It will be covered with an opaque bandage to minimize inadvertent removal and conceal which patch has been placed.
223783365|NCT03939468|DEVICE|DES+DCB|A hybrid strategy is defined as overlapping or slightly (2-3 mm) superimposing a new generation DES implantation for a de novo lesion (located in the larger, more proximal part of the vessel) and DCB inflation for a concomitant de novo small vessel disease
223783366|NCT03332862|PROCEDURE|catheter ablation|catheter ablation for atrial fibrillation treatment
223783367|NCT01562574|DRUG|activated recombinant human factor VII|Up to three doses administered after surgery. If bleeding persisted after the third dose of trial product, conventional transfusion would be administered
223783368|NCT01562574|DRUG|placebo|Up to three doses administered after surgery. If bleeding persisted after the third dose of trial product, conventional transfusion would be administered
223783369|NCT02775526|PROCEDURE|TOT|70 patients
223783370|NCT02775526|PROCEDURE|TVT|70 patients
223783371|NCT02775526|PROCEDURE|Burch Colposuspension|70 patients
223783372|NCT01049425|DRUG|Epirubicin|4 cycles, intravenous use, day 1 every three weeks
223783373|NCT01049425|DRUG|Cyclophosphamide|4 cycles, intravenous infusion, day 1 every three weeks
223783374|NCT01049425|DRUG|Docetaxel|4 cycles, intravenous infusion, day 1 every three weeks after completion of EC-chemotherapy
223783375|NCT01049425|DRUG|Cyclophosphamide|6 cycles, intravenous infusion, day 1 every 3 weeks
223783376|NCT01049425|DRUG|Docetaxel|6 cycles, intravenous infusion, day one every three weeks
223783377|NCT04464304|DEVICE|Smartphone|Patients will participate in a similar game to the VR cohort, but will use a smartphone device.
223783378|NCT04464304|DEVICE|Virtual Reality (Oculus Quest)|Patients will participate in a game using VR.
223783379|NCT05834504|OTHER|Short distributed training (1-2 days)|"The intervention group will practice four basic skills and one procedural module on the Laparoscopic Lapsim Virtual Reality Simulator. They will practice with 1-2 days of break in between training sessions until proficiency level is achieved."
223783380|NCT00153738|DRUG|phytosterol|
223783381|NCT06530017|DEVICE|Ingested, Space Occupying hydrogel capsules|During the treatment period (24 weeks after enrollment), Subjects should take four (4) capsules (Ingested, Space Occupying hydrogel capsules or placebo) with water every day 10\~20 minutes before lunch and dinner, and drink at least 500ml of water
223783382|NCT06530017|DEVICE|placebo|During the treatment period (24 weeks after enrollment), Subjects should take four (4) capsules (Ingested, Space Occupying hydrogel capsules or placebo) with water every day 10\~20 minutes before lunch and dinner, and drink at least 500ml of water
223783383|NCT01782989|DRUG|ORACEA®|ORACEA® (40mg doxycycline) capsule daily for 24 months
223783384|NCT01782989|DRUG|Placebo|Placebo capsule daily for 24 months
223783385|NCT00834457|DRUG|abacavir/3TC/zidovudine|continued use of oral co-formulated abacavir 300mg/3TC 150mg/zidovudine 300mg for 96 weeks
223783386|NCT00834457|DRUG|abacavir /3TC plus ritonavir boosted lopinavir|fixed dose abacavir 600mg/3TC 300mg one tablet po QD for 96 weeks plus fixed dose ritonavir 33.3mg/lopinavir 133.3mg four tablets po QD for 96 weeks
223783387|NCT06371885|DEVICE|shock wave therapy|shock wave therapy will be applied one session per week, each ESWT session will involve 2,000 pulses of the focus probe at 4-bar pressure and 5 Hz frequency for twelve weeks
223783388|NCT06371885|OTHER|traditional physical therapy|the traditional physical therapy will be in form of (10 minutes hot pack around wrist and forearm and 10 minutes of gentle stretching exercises for wrist joint, three sessions per week for twelve weeks
223783389|NCT05732168|DIAGNOSTIC_TEST|A test battery for evaluation of muscle strength, balance and functional performance|Subjects with chronic ankle instability (CAI) were evaluated with five tests of strength, balance and functional performance.
223783390|NCT05209282|OTHER|Video Based Action Observation|Individuals in this group will receive video-based action observation training in addition to the conventional physiotherapy program.
223783391|NCT05209282|OTHER|Live Action Observation|Individuals in this group will receive live action observation training in addition to the conventional physiotherapy program.
223783392|NCT05209282|OTHER|Conventional physiotherapy program|Individuals in this group will only receive a conventional physiotherapy program.
223783393|NCT05201157|OTHER|acupressure group|A suitable environment will be prepared for mothers in terms of warmth and light, where privacy can be protected. The application points will be determined with the acu-point device by choosing the most comfortable position of the mother, leaving the application points exposed. The most preferred points ST36, LI4 and SP6 were selected from the points reported to affect lactation by reviewing the literature on the points to be compressed. Acupressure will be applied to points (bidirectional, right and left) for 2 minutes for a total of 6 minutes. Light pressure will be applied with the thumb of the practitioner's hand. Immediately after applying pressure for 2 minutes for each point, it will be moved to the other point in the symmetrical region and the application will be made without interruption. While practicing, the researcher will control the time using a digital wrist watch with a stopwatch
223783394|NCT05201157|OTHER|Control Group|No application will be made. The mothers in this group will fill in the Visual Similarity Scale for Fatigue twice, once between 8-12 hours post-op and once on the post-op 2nd day.
223783395|NCT05409443|PROCEDURE|Nimbus Sacroiliac Joint Radiofrequency Ablation (N-SIJRFA)|"* Electrodes are positioned along the lateral sacral crest lateral to the inflection points of the S1, S2 and S3 lateral foraminal walls along first to third transverse sacral tubercles maintaining a craniocaudal line with an interelectrode distance of no more than 15mm.~* The appropriate locations are confirmed in both AP and lateral views and the tines are deployed. Following injection of lidocaine, lesions are performed at 85 degrees Celsius for 180 seconds at each site for bipolar sites and 80 degrees Celsius for 90 seconds for the monopolar site. Following ablation, the tines are retracted for all electrodes prior to removal."
223783396|NCT05409443|PROCEDURE|Conventional Sacroiliac Joint Radiofrequency Ablation (C-SIJRFA)|"* To target the L4 medial branch and L5 dorsal ramus, an electrode will be placed in parallel between the junction of the L5 transverse process and superior articular process and the sacral ala and S1 superior articular process.~* A periforaminal electrode position will be used to target the lateral branches from S1 to S3. An 22-G cannula with a 5-mm exposed tip will be directed to a location approximately 3-5mm lateral to the PSFA of S1, S2, and S3. The analog clock positions for the probes at S1 and S2 levels will be 1:00, 3:00, and 5:30 on the right, and 6:30, 9:00, and 11:00 on the left. For the S3 level the positions at 1:30 and 4:30 on the right, and 7:30 and 10:30 on the left will be used (6,18).~* The appropriate locations are confirmed in both AP and lateral views. Following injection of lidocaine, monopolar RFA is performed for 90 seconds at 80 degrees Celsius at each location."
223783397|NCT00096135|BIOLOGICAL|filgrastim|given subcutaneously (SC)
223783398|NCT00096135|DRUG|cyclophosphamide|IV over 15-30 minutes
223783399|NCT00096135|DRUG|cytarabine|IV over 3 hours twice daily
223783400|NCT00096135|DRUG|daunorubicin hydrochloride|IV over 15 minutes
223783401|NCT00096135|DRUG|dexamethasone|oral twice daily
223783402|NCT00096135|DRUG|etoposide|IV over 1 hour
223783403|NCT00096135|DRUG|leucovorin calcium|rescue IV over 24 hours
223783404|NCT00096135|DRUG|mercaptopurine|oral
223783405|NCT00096135|DRUG|methotrexate|intramuscularly (IM)
223783406|NCT00096135|DRUG|pegaspargase|intramuscularly (IM)
223783407|NCT00096135|DRUG|therapeutic hydrocortisone|
223783408|NCT00096135|DRUG|vincristine sulfate|given IV
223702376|NCT02925923|DRUG|Eptifibatide|After randomization, a blood sample will be obtained at baseline for platelet function test, the study drugs, clopidogrel and eptifibatide bolus will be administered. Patients will undergo PCI using drug-eluting stents or bare-metal stents. Blood samples will be obtained at 30 mins, 2, 4, and 24 h after PCI for platelet function tests.
223702377|NCT02925923|DRUG|Clopidogrel|
223702378|NCT02221830|DRUG|Oxytocin|Our intervention simply replaces the standardly given normal saline with treatment (normal saline + oxytocin)
223702379|NCT02221830|DRUG|Placebo|This intervention utilizes a Placebo Camparator
223702380|NCT01970657|BIOLOGICAL|No treatment specified|No intervention
223702381|NCT01970657|BIOLOGICAL|No treatment|None specified
223702382|NCT02213523|DIETARY_SUPPLEMENT|Plant concentrate A|Screening for the optimal dosage by starting with with a low dose of 300 mg for one week then switch to 600 mg for one week.
223783409|NCT00096135|RADIATION|radiation therapy|Patients with isolated testicular relapse will start Induction with a single dose of high-dose methotrexate (HDMTX) and will not receive either testicular or cranial radiation. Patients with isolated CNS relapse will NOT receive the initial dose of HDMTX prior to Induction, but will receive 1200 cGy of cranial radiation after completing the initial 12 months of intensive systemic chemotherapy.
223783410|NCT03867331|BIOLOGICAL|5 microgram VLPM01|VLPM01 is an alpha-VLP pre-erythrocytic malaria vaccine which targets circumsporozoite protein (CSP), adjuvanted with 0.75 mg alum.
223783411|NCT03867331|BIOLOGICAL|15 microgram VLPM01|VLPM01 is an alpha-VLP pre-erythrocytic malaria vaccine which targets circumsporozoite protein (CSP), adjuvanted with 0.75 mg alum.
223783412|NCT03867331|BIOLOGICAL|30 microgram VLPM01|VLPM01 is an alpha-VLP pre-erythrocytic malaria vaccine which targets circumsporozoite protein (CSP), adjuvanted with 0.75 mg alum.
223783413|NCT03867331|OTHER|Plasmodium falciparum challenge|Expose forearms to five (5) Plasmodium falciparum (strain NF54; clone 3D7) bites
223783414|NCT00004181|DRUG|busulfan|
223783415|NCT00004181|DRUG|cyclophosphamide|
223783416|NCT00004181|PROCEDURE|allogeneic bone marrow transplantation|
223783417|NCT00004181|RADIATION|radiation therapy|
223783418|NCT01829412|OTHER|DW-MRI|MRI imaging with diffusion weighted sequences of the whole body
223783419|NCT04968938|DRUG|midomafetamine|80 mg or 120 mg midomafetamine HCl followed by a 40 mg supplement dose
223783420|NCT04968938|BEHAVIORAL|Therapy|Manualized therapy
223783421|NCT04725721|BEHAVIORAL|FIRST|FIRST is built upon five empirically supported principles of change (ESPCs-i.e., feeling calm, increasing motivation, repairing thoughts, solving problems, trying the opposite). Each principle can be applied to treatment of problems spanning depression, anxiety (including OCD and PTS), and conduct problems-thus encompassing a majority of the youths seen in outpatient care. Its design addresses breadth of problem coverage, youth comorbidity, and flux in youth treatment needs during episodes of care. It is used in conjunction with performance feedback via a web-based tracking system that gives clinicians weekly data on youth treatment response. FIRST has treatment and training efficiency, and efficient clinician skill-building is supported by group consultation.
223783422|NCT04725721|BEHAVIORAL|Usual Care|Treatment in the usual care (UC) condition will use the clinical procedures therapists consider appropriate and believe to be effective.
223702383|NCT02213523|DIETARY_SUPPLEMENT|Plant concentrate B|Screening for the optimal dosage by starting with with a low dose of 300 mg for one week then switch to 600 mg for one week.
223702384|NCT02213523|DIETARY_SUPPLEMENT|Plant concentrate C|Screening for the optimal dosage by starting with with a low dose of 300 mg for one week then switch to 600 mg for one week.
223702385|NCT02213523|DIETARY_SUPPLEMENT|Plant concentrate D|Screening for the optimal dosage by starting with with a low dose of 300 mg for one week then switch to 600 mg for one week.
223702386|NCT03643354|DIAGNOSTIC_TEST|Epley maneuver/Barbeque maneuver|Subjects will be rotated using the Rotundum Device to perform the previously described maneuvers Epley/Barbeque to evaluate the presence of BPPV.
223783423|NCT06059196|BEHAVIORAL|ARCHES (Addressing Reproductive Coercion in Health Settings)|ARCHES (Addressing Reproductive Coercion in Health Settings) includes training existing contraceptive providers to (1) provide contraceptive clients with education on reproductive coercion and methods/ways to use contraceptive methods covertly if desired, (2) provide screening for reproductive coercion and intimate partner violence, (3) provide a referral to specialized services for those disclosing intimate partner violence, (4) and offer a palm-sized mini-booklet with educational information on reproductive coercion and intimate partner violence. A mobile application was developed to guide contraceptive providers through the counselling protocol.
223783424|NCT06059196|BEHAVIORAL|BCS+ (Balanced Counseling Strategy Plus)|BCS+ (Balanced Counseling Strategy Plus) is a contraceptive counseling protocol that contraceptive providers use to help clients identify suitable contraceptive methods based on their preferences and previous contraceptive experiences. The BCS+ also includes systematic screening for other health services such as HIV/STI, cervical cancer, and breast cancer. The BCS+ was adopted by the Kenya MOH as the standard contraceptive counseling protocol in the country.
223783425|NCT05706727|DRUG|Intravenous bolus dose of Mephentermine and mephentermine|intravenous bolus dose of mephenteramine 6mg
223783426|NCT05706727|DRUG|intravenous bolus dose of phenylephrine 50 mcg|intravenous bolus dose of phenylephrine 50 mcg
223783427|NCT03473886|BEHAVIORAL|Intervention arm: PP-MI|The positive psychology exercises include gratitude-based activities, strengths-based activities, and meaning-based activities. The physical activity goal setting exercises include the following topics: health benefits, social resources, and neighborhood walkability.
223783428|NCT03524222|OTHER|Home Hospitalization|See above
223783429|NCT05436782|OTHER|core strengthening exercises|•Group B (experimental group) received routine physical therapy for 20 minutes and additionally PNF technique (rhythmic initiation, and then agonistic reversals were performed in the lower extremity in D1 flexion pattern and D1 extension pattern up to the patient's tolerance and core strengthening for 20 minutes 5 times weekly for 6 weeks. The outcome measure was measured at baseline and 6th-week interval
223783430|NCT05436782|OTHER|Routine physical therapy|•Group A (control group) will receive routine physical therapy involving muscle strengthening exercises, range of motion exercises, and stretching exercises up to the patient's tolerance. Other exercises were pelvic bridging, rolling, sitting and standing exercises, walking practice and balancing in parallel bars, and wobble board exercises. Each session was of 60 minutes 5 times weekly for 6 weeks
223783431|NCT01384617|PROCEDURE|Stapling closure of the pancreatic stump|Echelon 60 with a gold cartridge provide provides precise and uniform wide compression throughout the entire 60mm length with compressible thickness to 1.8mm, which can attach two triple-staggered rows of titanium staples.
223783432|NCT01384617|PROCEDURE|Roux-en-Y anastomosis of the pancreatic stump|end-to-side pancreaticojejunostomy into a retrocolic Roux-en-Y reconstruction. The pancreaticojejunostomy anastomosis is performed in duct-to-mucosa.
223783433|NCT03874676|OTHER|PEACE Rounds|PEACE Rounds are a routine process for providing self help to clinicians who care for difficult patients from the perspective of ethics and the need for cross-disciplinary communication. PEACE Rounds participants will be interviewed about how they experience the rounds and for their perspective on the effects on their own wellness and resilience.
223783434|NCT00874029|DEVICE|Halt Procedure|The Halt 2000 Electrosurgical Radiofrequency Ablation System is indicated for use in percutaneous, laparoscopic and intraoperative, coagulation and ablation of soft tissue.
223783435|NCT05893108|DRUG|Ethosomal gel bearing losartan 5%|A pharmaceutical company with a good manufacturing practice certificate is developing ethosomal gel bearing losartan 5%
223783436|NCT05893108|DRUG|triamcinolone acetonide 10 mg/ml|intralesional injection
223783437|NCT00856583|DRUG|Sertindole|Sertindole was supplied as 4, 12, 16, and 20 mg tablets. The start and maintenance dosages as well as dose titration were set by the investigator, in accordance with the national Summary of Product Characteristics (SPC) for sertindole; in countries where sertindole was not marketed, the European Union (EU) SPC applied (all national and EU SPCs were essentially identical). Recommended dose range: 12 to 20 mg/day. The investigators were instructed to contact H. Lundbeck A/S if they deemed it necessary to increase the dose of sertindole to 24 mg/day, which was allowed in exceptional cases
223783438|NCT00856583|DRUG|Risperidone|Risperidone was supplied as 1, 2, 3, and 4 mg tablets. The start and maintenance dosages as well as dose titration were set by the investigator, in accordance with the national SPC for risperidone. Recommended dose range: 2 to 8 mg/day
223783439|NCT01084044|DRUG|ulinastatin, saline solution|the ulinastatin group receiving ulinastatin (300,000 unit after anesthesia induction and another 300,000 unit during Y- graft anastomosis, n = 40), the control group receiving the same volume of saline solution(n = 40)
223783440|NCT03958903|DEVICE|Amygdala recording and stimulation using Neuropace RNS|Subjects will undergo a series of different, fear-related, behavioral tasks while undergoing amygdala electrophysiology recording and stimulation using the Neuropace RNS devices.
223783441|NCT03958903|BEHAVIORAL|Behavioral tasks|Subjects perform a set of fear related behavioral tasks over 2 days, with 3 tasks each day.In addition to amygdala RNS recording and stimulation, recording of electroencephalography (EEG), electromyography (EMG), and electrodermal activity (EDA) will be performed using standard techniques to capture and quantify the fear response across all tasks.
223783442|NCT03832127|DRUG|18F-Fludarabine|Two PET with 18F-Fludarabine : one at Baseline, the second one at the end of treatment of myeloma
223783443|NCT05222230|OTHER|FFP3 Mask|Participans will wear FFP3 respirators during the study.
223783444|NCT00283504|DRUG|ANTI-IGE THERAPY (XOLAIR)|Xolair dosing is based on body weight and baseline serum total IgE concentration(0.016 x kg body weight x IgE levels), with a maximum dose per 4 weeks of 750mg.Depending on their weight and IgE levels, patients get their Xolair shots every 2 or every 4 weeks.
223783445|NCT01707602|BIOLOGICAL|INTANZA® 15|intradermal vaccination
223783446|NCT01707602|BIOLOGICAL|Vaxigrip®|Intramuscular vaccination
223783447|NCT01707602|BIOLOGICAL|INTANZA® 15 T|transcutaneous vaccination
223783448|NCT04223102|PROCEDURE|Tissue collection|A flexible sigmoidoscopy is a procedure in which a flexible tubularized camera approximately 1 cm in diameter is inserted into the anus and advanced proximally to the sigmoid colon (approximately 20 cm). At that time a rectal biopsy of the tumor will be obtained as well as a sample from \>5cm proximal to the tumor, with a separate biopsy forcep. Tattoo injection, as standard of care, will be performed within 1 cm distal to the tumor to identify the location in the future or for surgical intervention. If there is inability to get proximal to the tumor then a location at least 5 cm adjacent in any direction will be sufficient so long as it is grossly normal appearing.
223783449|NCT00823082|DRUG|Antithrombin III|Single dose of antithrombin III sufficient to achieve a preoperative level of 120%
223783450|NCT02328326|OTHER|CO-IMPACT|Primary care-integrated activation and social support intervention that provides tools and training in patient activation and effective support techniques for patients and their family supporter
223783451|NCT02328326|OTHER|PACT|participants will receive PACT care for high-risk diabetes, which includes (at primary care team discretion): nurse care manager visits, diabetes education classes, chronic disease self-management groups, telehealth, clinical pharmacist visits
223783452|NCT05742373|OTHER|Exercise training in the fasted state|Four weeks of moderate intensity cycling exercise, three times a week without eating breakfast meal
223783453|NCT05742373|OTHER|Exercise training in the fed state|Four weeks of moderate intensity cycling exercise, three times a week, after eating breakfast meal
223783454|NCT01060865|DRUG|Aliskiren|150 mg during the first two weeks , 300 mg for another 10 weeks
223783455|NCT02264795|DRUG|Lidocaine|Lidocaine 2% with epinephrine 5mcg/ml
223783456|NCT02264795|DRUG|Placebo|0.9% Sodium Chloride Solution
223783457|NCT01637753|DRUG|Carmustine(BCNU)|Carmustine Sustained Release Implant
223783458|NCT01637753|PROCEDURE|Surgery|Routine tumor resection surgery
223783459|NCT01213758|OTHER|Measuring liver function by PET/CT|Measuring liver function by use of FDGal and PET/CT before, 1 month and 3 months after stereotactic radiotherapy for liver tumors
223702387|NCT03848429|PROCEDURE|Surgery for mechanical complications of acute myocardial infarction|Surgical treatment of post-AMI left ventricular free-wall rupture: sutured and sutureless repair. Surgical treatment of post-AMI ventricular septal defect: infarctectomy and infarct exclusion repair. Surgical treatment of post-AMI papillary muscle rupture: mitral valve repair and replacement
223702388|NCT02883686|BEHAVIORAL|Alma|Alma peer-mentoring
223702389|NCT00382304|DRUG|tolevamer potassium-sodium (GT267-004)|
223702390|NCT05464693|DIAGNOSTIC_TEST|ERCP biliary culture|"The sample of biliary aspirate will be assessed as follows.~1. Its macroscopic appearance will be analyzed: yellow, black, or purulent.~2. Biliary culture will be performed; if bacterial growth is observed, its identification will be carried out by means of MALDI-TOF MS mass spectrometry and antibiotic susceptibility tests will be carried out, using the automated VITEK system."
223702391|NCT00866788|DRUG|omalizumab|Administered by subcutaneous injection
223702392|NCT00866788|DRUG|placebo|Participants received a single subcutaneous placebo injection on Day 0 of the study.
223702393|NCT00866788|DRUG|H1 antihistamines|Patients received one of the following: Cetirizine 10 mg once per day (QD), Levocetirizine dihydrochloride 5 mg QD, Fexofenadine 60 mg twice per day or 180 mg QD, Loratadine 10 mg QD or Desloratadine 5 mg QD
223702394|NCT00866788|DRUG|Diphenhydramine|Diphenhydramine was provided and used on an as-needed basis (25 mg per dose)
223702395|NCT04853550|DEVICE|Strattice Mesh|Subjects will be restrospectively identified has having undergone ventral hernia repair with Strattice mesh reinforcement. Once identified long term follow-up data will be collected.
223702396|NCT06275347|OTHER|Low-fat normoprotein Controlled Ketogenic Diet.|Frank ketosis will consist of between 650 and 730 kcal/day in 5 meal times, based on commercial and vegetable preparations with low glycemic index, an average of 1.2 g of protein/kg of ideal weight/day, 20 g/day of lipids based on essential fatty acids and less than 60 g/day of absorbable carbohydrates. Patients will receive vitamin and sodium chloride, magnesium oxide, calcium carbonate. Mixed Ketosis one or two intakes of commercial preparations will be progressively replaced by proteins, which will increase by 100 to 150 Kcal/day, supplementation of vitamins and minerals will continue. Transition Stage simple carbohydrates and some complex carbohydrates are added to the previous program, in an approximate proportion of 30 to 35% protein, 25% fat and 40 to 45 % carbohydrates. Integral and maintenance phase: may vary between 1300 and 2250 kcal/day, with a macronutrient distribution of 50% carbohydrates, 25% proteins and 25% fats.
223702397|NCT06275347|OTHER|Hypocaloric Balanced Diet|Balanced hypocaloric diet (caloric intake 20% below basal metabolic expenditure measured by Multifrequency Bioelectrical Impedance or calculated according to the FAO/WHO/UN formula (FAO/WHO/UNU (1985). Energy and Protein requirements. Technical Report Series No 724, World Health Organization, Geneva). The usual caloric intake of a balanced hypocaloric diet is between 1,200 and 1,400 kcal per day with a macronutrient distribution of 50% carbohydrates, 25% proteins and 25% fats, according to the Diogenes study
223702398|NCT01509092|PROCEDURE|vitrectomy surgery|"pars plana vitrectomy +internal limiting membrane peeling done immediately after the identification of the macular hole"
223702399|NCT06556316|BEHAVIORAL|Cognitive Intervention with the Categorization Program|Cognitive intervention delivered individually. This is a hierarchical cognitive rehabilitation program
223702400|NCT06556316|BEHAVIORAL|Social Cognitive Communication Program|An 11 week group intervention targeting social and cognitive-communication abilities
223702401|NCT06556316|DEVICE|Non-Invasive Brain Stimulation with tDCS|20 minute tDCS intervention as a non-invasive neuromodulation treatment
223702402|NCT04307303|DEVICE|abdominal functional electrical stimulation|functional electrical stimulation of the abdominal muscles
223702403|NCT02742441|DRUG|122-0551 Foam|Topical Foam containing active drug
223702404|NCT02742441|DRUG|Vehicle Foam|Topical Foam containing no active drug
223702405|NCT00252915|BIOLOGICAL|GM-CSF (verum)|sagramostim
223702406|NCT03052491|DIETARY_SUPPLEMENT|Stem Cell 100+|Open-Label 10-Component Dietary Supplement
223702407|NCT06324812|DRUG|Recombinant Anti-interleukin-4 Receptor Alpha Monoclonal Antibody Injection (611)|subcutaneous injection，611 450/600mg (loading dose) + 300mg once every 2 weeks/4 weeks
223702408|NCT04793217|BEHAVIORAL|Improving AIDS Care After Trauma +|ImpACT+ integrates skills for HIV treatment adherence and coping with trauma, tailored to the South African context. This includes exploration of values informing care engagement, recognizing the synergistic stress of sexual trauma and HIV, understanding the contribution of stressors to maladaptive coping, and developing adaptive methods for coping as alternatives to avoidance. ImpACT+ will be delivered in private spaces at the primary care clinic and will consist of 6 individual sessions followed by 6 maintenance check-ins. Individual sessions focus on coping, adherence, and care engagement during an early critical period, while maintenance check-ins reinforce positive change and support ongoing implementation of skills. Evidence supports a 6-session format in low-resource settings. Individual sessions will begin within 2 weeks after the baseline survey and be completed by the 4-month assessment. Maintenance check-ins will begin following the 4-month assessment.
223702409|NCT04793217|BEHAVIORAL|Adapted Problem-Solving Therapy|Participants will receive three weekly individual sessions of adapted PST. The goal of PST is to identify problems that interfere with daily activities and address them through problem-orientation work. We anticipate stressors will include (a) relationship difficulties, including family stress, (b) financial stress and unemployment, (c) general impact of HIV infection, and (d) overall chronic stress. Thus, PST may indirectly address stressors that may impact care engagement, but will not address the intersection of HIV and trauma specifically.
223702410|NCT01645137|OTHER|osteopathic manipulative treatment|Patients from this group received osteopathic treatments twice a week for the entire length of stay in the unit.
223702411|NCT01645137|OTHER|Usual care|Patients from control group received standard care plus osteopathic evaluation only, according to the same schedule as the study group.
223702412|NCT03268837|DEVICE|Programmed Intermittent Bolus|The Smith CADD(R)-Solis Ambulatory Infusion Pump will be used to provide programmed intermittent bolus for the interscalene block.
223702413|NCT03268837|DEVICE|Continuous Infusion|The Smith CADD(R)-Solis Ambulatory Infusion Pump will be used to provide continuous infusion for the interscalene block.
223702414|NCT03848442|OTHER|'Uptime' participation|The intervention are designed for each individual and are consistent with the model for participation-based interventions. The interventions are goal-oriented (meaningful and family/client-selected goals), family/client-centered (promoted self-determination and decision making), collaborative (partnership between caregivers), strength-based (built on participant and caregiver strengths) and ecological (natural environment and real-life experiences). Design of the intervention comprised three steps: 1) Preparation period (6 weeks); 2) Intervention period (12 weeks); 3) Follow-up period (12 weeks)
223702415|NCT04877483|PROCEDURE|Acupuncture|Acupuncture is a form of treatment that inserting very thin needles through a person's skin at specific points on the body. Group GB20 and Group GB20 plus BL2 will received the acupuncture treatment.
223702416|NCT04877483|DIAGNOSTIC_TEST|Oral microbiota|Group GB20, Group GB20 plus BL2 and Healthy control will take the oral microbiota analysis.
223783460|NCT05400096|OTHER|Psychological therapy|The protocol for the group will be developed collaboratively between the chief researcher and the supervisor based in the weight management service. The protocol will contain Compassion Focused Therapy (CFT) based therapeutic approaches, but the group will integrate some Acceptance and Commitment Therapy (ACT) concepts.
223783461|NCT03452917|DRUG|Placebo|500 patients will 2 ml of normal saline
223783462|NCT03452917|DRUG|sodium nitrite 45 mg|500 patients will receive 45 mg IV sodium nitrite
223783463|NCT03452917|DRUG|sodium nitrite 60 mg|500 patients will receive a dose of 60 mg IV sodium nitrite
223783464|NCT03198000|DRUG|F# 13418-148 Eye Drops|ocular clear liquid. Tetrahydrozoline 0.05%; Glycerin 0.40% 1-2 drops will be instilled as instructed over one day
223702417|NCT04877483|DIAGNOSTIC_TEST|Schirmer's test|Group GB20 and Group GB20 plus BL2 will take the Schirmer's test.
223702418|NCT04877483|DIAGNOSTIC_TEST|Tear breakup time|Group GB20 and Group GB20 plus BL2 will take the tear breakup time test.
223702419|NCT04877483|DIAGNOSTIC_TEST|OSDI(Ocular Surface Disease Index)|Group GB20 and Group GB20 plus BL2 will take the OSDI test.
223702420|NCT04877483|DIAGNOSTIC_TEST|TCM pattern|Group GB20, Group GB20 plus BL2 and Healthy control will take the Traditional Chinese Medicine pattern diagnosis.
223702421|NCT04877483|DIAGNOSTIC_TEST|Traditional Chinese Medicine (TCM) tongue diagnosis|Group GB20, Group GB20 plus BL2 and Healthy control will take the Traditional Chinese Medicine(TCM) tongue diagnosis.
223702422|NCT04877483|DIAGNOSTIC_TEST|TCM pulse diagnosis|Group GB20, Group GB20 plus BL2 and Healthy control will take the Traditional Chinese Medicine(TCM) pulse diagnosis.
223702423|NCT04877483|DIAGNOSTIC_TEST|TCM heart rate variability|Group GB20, Group GB20 plus BL2 and Healthy control will take the TCM Heart rate variability.
223702424|NCT04877483|DIAGNOSTIC_TEST|ESSPRI(EULAR Sjögren's Syndrome Patient Reported Index)|Group GB20 and Group GB20 plus BL2 will take the ESSPRI.
223702425|NCT04877483|DIAGNOSTIC_TEST|Whole-genome genotyping(TWBv2.0)|Group GB20, Group GB20 plus BL2 and Healthy control will take the Whole-genome genotyping(TWBv2.0).
223702426|NCT04877483|DIAGNOSTIC_TEST|Cytokine markers|Group GB20, Group GB20 plus BL2 and Healthy control will take the cytokine markers(IL-17、MMP-9、BAFF、BCMA) analysis.
223702427|NCT04877483|DIAGNOSTIC_TEST|Blood biochemical analysis|Group GB20 and Group GB20 plus BL2 will take the Blood biochemical analysis(BUN,Cre,AST,ALT,ESR and CRP).
223702428|NCT04877483|DIAGNOSTIC_TEST|complete blood count (CBC)|Group GB20 and Group GB20 plus BL2 will take the CBC(WBC、RBC、Hb、Platelet) analysis.
223702429|NCT04877483|DIAGNOSTIC_TEST|SF-36(36-Item Short Form Survey )|Group GB20 and Group GB20 plus BL2 will take the SF-36 test.
223702430|NCT03386318|DRUG|Oxycodone|Serum concentration per hour from 1 to 5 h
223702431|NCT02585154|PROCEDURE|Deep Brain Stimulation applied through custom built external stimulator (Little et al., 2013, 2015)|'Classical' high-frequency Deep Brain Stimulation, which is applied irrespective of ongoing brain activity.
223702432|NCT02585154|PROCEDURE|closed-loop Deep Brain Stimulation applied through custom built external stimulator (Little et al., 2013, 2015)|Deep Brain Stimulation, which is applied depending on ongoing brain activity.
223702433|NCT02585154|PROCEDURE|Deep Brain Stimulation off|Deep Brain Stimulation is turned off.
223702434|NCT02585154|DEVICE|local field potentials and electroencephalography recordings|Simultaneous recordings of local field potentials from subthalamic nucleus and electroencephalography
223702435|NCT02202837|DRUG|etanercept|etanercept 1 x 50 mg/week or 2 x 25mg/week
223702436|NCT02202837|DRUG|etanercept|etanercept 1 x 50 mg/week or 2 x 25mg/week
223702437|NCT01404273|BEHAVIORAL|Meditation/Relaxation Response Training|1 hour weekly sessions with 20 min daily home practice for 6 weeks
223702438|NCT06166589|DRUG|Zimberelimab|Zimberelimab, 240mg, day1. Every 3 weeks as a cycle.
223702439|NCT06166589|DRUG|Oxaliplatin|Oxaliplatin 60mg/m2, day1、day8. Every 3 weeks as a cycle.
223702440|NCT06166589|DRUG|S-1|S-1(BSA \< 1.2m2, 40 mg/day; BSA = 1.2\~1.4 m2, 60 mg/day; BSA = 1.4\~1.6 m2, 80 mg/day; BSA \> 1.6 m2, 100 mg/day; bid, day1-14). Every 3 weeks as a cycle.
223702441|NCT06166589|DRUG|Irinotecan|Irinotecan, 130 mg/m2, day 1, day 8. Every 3 weeks as a cycle.
223702442|NCT03460275|DRUG|Osimertinib Mesylate Tablets|Osimertinib 80mg oral administration daily until progression or occurring intolerable treatment-related toxic effects or patients withdrawing informed consent(Based on whichever occurs first)
223702443|NCT00992290|BIOLOGICAL|Lactobacillus GG|1 capsule of lactobacillus GG BID compared to placebo BID
223702444|NCT00992290|BIOLOGICAL|Placebo|1 capsule of lactobacillus GG BID compared to placebo BID
223702445|NCT04750512|PROCEDURE|ESP block|US guided ESP infiltration (saline solution vs Ropivacaine 0.2% according to randomization): bilateral injection of 30ml (60ml total) under US guidance between the deep fascia of erector spinae muscle and the the two transverse process at the level of the 10th thoracic vertebrae
223702446|NCT04750512|PROCEDURE|TAP block|"US guided TAP block (saline solution vs Ropivacaine 0.2% according to randomization):~bilateral injection of 30ml (total 60ml) under US guidance in the plane between the internal oblique and transversus abdominis muscles at the level of the midaxillary line in the Petit triangle."
223702447|NCT02281773|DRUG|BI 409306 100 mg QD|
223702448|NCT02281773|DRUG|BI 498306 50 mg QD|
223702449|NCT02281773|DRUG|Placebo|
223702450|NCT02281773|DRUG|BI 498306 25 mg QD|
223702451|NCT02281773|DRUG|BI 409306 10 mg QD|
223702452|NCT01551901|DEVICE|Spinal fusion|Spinal fusion procedures in skeletally mature patients with symptomatic degenerative disc disease (DDD) at one or two contiguous levels from L2-S1 with up to grade 1 spondylolisthesis
223783465|NCT03198000|DRUG|F#13418-158 Eye Drops|ocular clear liquid Tetrahydrozoline 0.05%; Glycerin 0.20%, Hypromellose 0.2%, Polyethylene glycol 400 1.0% 1-2 drops will be instilled as instructed over one day
223783466|NCT03198000|DRUG|F# PF-004390 Eye Drops|Ocular clear liquid Tetrahydrozoline 0.05%; 1-2 drops will be instilled as instructed over one day
223783467|NCT04016597|DEVICE|Jaeger Masterscreen TM|Single-breath nitric oxide lung diffusing capacity
223783468|NCT04016597|DEVICE|HypAir Medisoft|Single-breath nitric oxide lung diffusing capacity
223783469|NCT03592212|DRUG|Salbutamol|Measurement of bronchodilator response (BDR)
223783470|NCT05309161|DIETARY_SUPPLEMENT|Crassocephalum rabens extract|dosage: a capsule (180 mg)/day; duration: 1 month
223783471|NCT05062928|OTHER|Virtual coach|This group will be trained and assessed by the virtual coach.
223702453|NCT04576325|DRUG|Voriconazole Inhalation Powder|For each dose, multiple inhalations will be required (4 capsules in Cohort 1 and 8 capsules in Cohort 2). All capsules for a given dose must be inhaled over a maximum 10-minute period. Cohort 1 will receive 40 mg BID and Cohort 2 will receive 80 mg BID. Both Cohorts will administer study drug for 3.5 days (7 days total).
223702454|NCT04576325|DRUG|Placebo|For each dose, multiple inhalations will be required (4 capsules in Cohort 1 and 8 capsules in Cohort 2). All capsules must be inhaled over a maximum 10-minute period. Cohort 1 will receive 4 capsules of inactive BID and Cohort 2 will receive 8 capsules of inactive BID. Both Cohorts will administer placebo capsules for 3.5 days (7 days total).
223702455|NCT01041326|RADIATION|Radiation|Pre-operative Radiation to Prostate, SV, and Pelvic Lymph Nodes
223783472|NCT00174993|DRUG|Pioglitazone|Pioglitazone 15 mg to 45 mg, tablets, orally, once daily for up to 48 months.
223783473|NCT00174993|DRUG|Placebo|Pioglitazone placebo-matching tablets, orally, once daily for up to 48 months
223783474|NCT03191084|DRUG|Low Dose THC Marijuana|Dosing via vaporized marijuana using a lower concentration of THC, participants receive this dose on two of the five study visits.
223783475|NCT03191084|DRUG|High Dose THC Marijuana|Dosing via vaporized marijuana using a higher concentration of THC, participants receive this dose on two of the five study visits.
223702456|NCT01041326|PROCEDURE|Radical Prostatectomy|Patients will undergo evaluation by a surgeon for consideration of resection after completion of radiation therapy. If a surgical resection is possible, it is recommended that patients undergo surgery four to eight weeks after completion of radiation therapy. This surgical procedure will be performed by one of the standard accepted approaches.
223702457|NCT02104752|DRUG|Curcumin|360 mg/day (divided into twice daily oral doses)
223702458|NCT02104752|DRUG|Placebo|"Inactive, matched placebo (Sugar Pill)"
223702459|NCT05439941|DRUG|EDP1815|EDP1815 is an orally administered, pharmaceutical preparation of a single strain of bacteria
223702460|NCT05692128|OTHER|Hematological and chemistry tests|Laboratory tests
223702461|NCT04958135|DRUG|Acoramidis|Film-coated immediate release oral tablet.
223702462|NCT00541684|DRUG|MK0954, /Duration of Treatment : 16 Weeks|
223702463|NCT00541684|DRUG|Comparator : atenolol /Duration of Treatment : 16 Weeks|
223702464|NCT02966431|BEHAVIORAL|Counseling|
223702465|NCT02966431|BEHAVIORAL|No Counseling|
223702466|NCT03470870|OTHER|Comparative analysis of the characteristics|"* Predictive nomogram of short-term hospitalization (less than two days after surgery)~* Factors influencing the variations of average stay lenght~* Morbidity of the ERAS program"
223702467|NCT02433561|PROCEDURE|Intraplexic catheter location (Contiplex® C, B. Braun Melsungen, AG)|The catheter tip will be placed with the aid of the ultrasound within the brachial plexus between C5 and C6
223702468|NCT02433561|PROCEDURE|Extraplexic catheter location (Contiplex® C, B. Braun Melsungen, AG)|The catheter tip will be placed with the aid of the ultrasound 2 mm away from the lateral part of the brachial plexus
223702469|NCT00440583|DRUG|chemotherapy followed by Zevalin|6 cycles of chemotherapy with CHOP (Cyclophosphamide iv 750 mg/m2 over 15-45 minutes; Doxorubicin iv 50 mg/m2 over 5-20 minutes; and Vincristine iv 1.4 mg/m2 over 5-15 minutes on day 1 and oral prednisone 40 mg/m2 on days 1-5 repeated every 21 days), followed by Zevalin
223783476|NCT03191084|DRUG|Placebo Marijuana|Dosing via vaporized marijuana with no THC, participants receive this dose on one of the five study visits.
223783477|NCT01082666|DEVICE|Continuous control of cuff pressure|Continuous control of cuff pressure using a pneumatic device (Nosten, Leved, France)
223783478|NCT01082666|DEVICE|Manual control of cuff pressure|Manual control of cuff pressure is a routine practice in ICU patients
223702470|NCT02321410|OTHER|Contrast enhanced ultrasound of the carotid plaque|visual grading of neovessel
223702471|NCT02321410|OTHER|Dynamic contrast-enhanced carotid plaque MRI|quantitative analysis of gadolinium enchantment in a region of interest
223702472|NCT02327065|DEVICE|EUS-FNA (EchoTip Ultra)|FNA,Fine needle aspiration
223702473|NCT02327065|DEVICE|EUS-FNB (EchoTip ProCore)|FNB,Fine needle biopsy
223702474|NCT00313300|DRUG|Apixaban|Tablets, Oral, 2.5 mg, twice daily, 26 weeks
223702475|NCT00313300|DRUG|Apixaban|Tablets, Oral, 10 mg, once daily, 26 weeks
223702476|NCT00313300|DRUG|Placebo|Tablets, Oral, 0, twice daily, 26 weeks
223702477|NCT00313300|DRUG|Apixaban|Tablets, Oral 10 mg, twice daily, 26 weeks
223702478|NCT03954197|OTHER|No hormone|No hormonal injection before oocytes retrieval
223702479|NCT03954197|OTHER|hCG|a subcutaneous injection of hCG (Choriogonadotropin alpha, Ovitrelle®, Merck Serono, 250 µg) is performed 36 hours before oocytes retrieval
223702480|NCT03954197|OTHER|GnRH a|a subcutaneous injection of GnRH agonist (triptorelin, Decapeptyl, Ipsen, 0,2 mg) is performed 36 hours before oocytes retrieval
223702481|NCT03145233|OTHER|Isometric exercise programme|Exercise programme where the muscle length and joint angle do not change due to the limb being held in a static position
223702482|NCT03145233|OTHER|Isotonic exercise programme|Exercise programme where both the muscle length and joint angle do change, consisting of concentric muscle actions (where the muscle shortens) and eccentric muscle actions (where the muscle lengthens)
223702483|NCT02336373|DRUG|hydroxyurea|Treat symptomatic HbSC patients to MTD on hydroxyurea, and assess for clinical improvement using the PedsQL™ Sickle Cell Disease Module version 3.0 after 6 months at MTD, compared to entrance scores
223783479|NCT00737841|DRUG|Bifidobacterium breve|1.0 g of Bifidobacterium breve, taking orally, 3 times a day for 8 weeks.
223783480|NCT00737841|DRUG|Placebo|1.0 g of placebo, taking orally, 3 times a day for 8 weeks.
223783481|NCT00633321|BIOLOGICAL|TA-NIC|TA-NIC vaccine will be administered to each subject as 7 single doses administered at Weeks 0, 2, 4, 6, 8, 12, and 16.
223783482|NCT00633321|BIOLOGICAL|Placebo|Placebo will be administered to each subject as 7 single doses administered at Weeks 0, 2, 4, 6, 8, 12, and 16.
223783483|NCT01914796|DRUG|PF-06412562|Single doses, given by oral solution, starting at 0.5 mg up to a possible maximum of 150 mg. The subject will have been fasted for 10 hours prior to the single dose. Two doses, 120 mg and 150 mg, will be split into 3 doses such that the total dose is given over 8 hours (i.e. t = 0, 4, and 8 hours). For each dosing period, 2 subjects will be given a placebo as a comparator. One dose will be given in the fed state.
223783484|NCT01914796|DRUG|PF-06412562|It is believed that for increasing doses of this compound the eye blink rate (EBR) will also increase. This arm will use EBR measurement technology to verify this hypothesis. In each dosing period, 4 subjects will be given a placebo as a comparator.
223783485|NCT03176680|PROCEDURE|Fluid therapy optimization|colloid 250 mL bolus to increase stroke volume index (SVI). If the increase of SVI is more than 10% of baseline, repeat the bolus. If the increase of SVI is less than 10% of baseline, stop the bolus.
223783486|NCT02605980|BEHAVIORAL|Sedentary time|
223783487|NCT02280603|DRUG|DA-4001C|1ml by topical application twice a day
223783488|NCT02280603|DRUG|5% minoxidil|1ml by topical application twice a day
223783489|NCT03797534|OTHER|dose regime|The initial dose of the experimental group will be calculated by the Bayesian model.
223783490|NCT03466580|BEHAVIORAL|The Carer Support Needs Assessment Tool (CSNAT) intervention|The CSNAT intervention is a caregiver-led approach where the caregiver first identifies his/her needs of support in the CSNAT, which consists of 14 support domains. Then the practitioner facilitates the intervention where the caregiver prioritizes which domains to discuss. In the conversation, the caregiver's domain priorities and subsequently identified support needs are discussed with the practitioner to agree on actions/solutions and a shared action plan. The intervention will be offered each caregiver twice: the first time between 0 and 13 days after enrollment, and the second time between 15 and 27 days after enrollment.
223783491|NCT03437499|PROCEDURE|Sustained Inflation|Application of positive pressure by face mask with T-piece resuscitator for a prolonged period of 15 seconds at a peak pressure of 25 cmH20 followed by PEEP set at 5 cmH2O
223783492|NCT03437499|PROCEDURE|Positive Pressure Ventilation|Application of positive pressure by face mask with T-piece resuscitator at a peak pressure of 25 cmH20, PEEP set at 5 cmH2, for 40 inflations/minute
223783493|NCT05255640|PROCEDURE|operation of ischemia of the lower limbs|The intervention technique is left to the judgment of the investigator to treat the ischemia
223783494|NCT04614389|OTHER|Contrast-enhanced ultrasound|Non Invasive Imaging Technique. CEUS involves the use of microbubble contrast agents and specialized imaging techniques to enhance the signal from blood, thus showing flow in macroscopic vessels as well as tissue perfusion informatio
223783495|NCT04614389|OTHER|Shear Wave Elastography|Non Ivasive Imaging Technique. Shear Wave Elastography (SWE) is a recently developed technique that uses ultrasound to noninvasively assess the mechanical stiffness of tissue by measuring tissue distortion in ponse to an acoustic radiation force impulse from a focused ultrasound beam.
223783496|NCT04614389|DEVICE|Sequoia System|UltraSound System Cleared by FDA 510 (k) K180067
223783497|NCT00366626|DRUG|Naltrexone|Naltrexone (25 mg/day for days 1-2 and 50 mg/day for days 3-7)
223783498|NCT00366626|DRUG|Placebo|Placebo for 7 days matched to Naltrexone
223783499|NCT02255175|DRUG|Estradiol|Participants will receive transdermal estradiol (100μg/day) for 3 weeks
223783500|NCT02255175|DRUG|Progesterone|Participants will receive an additional week of combined estradiol and micronized progesterone (200 mg/day) at the end of the study to precipitate menstruation.
223783501|NCT01276587|DRUG|Vitamin D3|Oral vitamin D3 100,000 IU administered monthly for six months in children and adolescents with sickle cell disease
223702484|NCT02543710|PROCEDURE|Biomarker (ER/PR) guided lymphadenectomy|"Lymphadenectomy in the pelvis and para-aortic, will, for patients who are considered otherwise low risk (endometrioid tumours grade 1 or 2, or grade 3 with \<50% myometrial infiltration (MI), with no sign of extrauterine disease), be dependent on the preoperative hormone receptor status (ER and PR).~Patients will be defined low risk when endometrioid, grade 1 or 2, or grade 3 with \<50% MI, AND positive hormone receptor status for both ER AND PR. These patients will not undergo lymphadenectomy.~Patients with endometrioid tumours grade 1 or 2, or grade 3 \<50% MI,, with either negative ER or PR status, are defined high risk and will undergo pelvic and para-aortic lymphadenectomy as part of their surgical procedure.~Patients will receive routine clinical follow-up for 5 years. Follow-up data will be collected for the study, focusing on survival and recurrence of disease. All patients will, as part of the study fill out validated quality of life questionnaires (QoL) at follow-up."
223783502|NCT01602848|OTHER|Intensive care management and coordination|Care Management Teams comprised of social workers, community based care managers, and dedicated clinicians work to meet patients' needs in both the health care setting and the community. The CIDP model incorporates motivational interviewing, harm reduction, access to housing through our community partners utilizing a Housing First approach, and provides cellular phones for patients when needed, to better enable regular communication with program staff.
223783503|NCT00987207|DRUG|cyclosporine A|a single bolus of 2.5 mg/kg, administered before aortic cross-declamping
223783504|NCT00987207|OTHER|No injection|No cyclosporine A is administered before aortic cross-declamping.
223783505|NCT03719066|BIOLOGICAL|killed whole cell oral cholera vaccine|two week interval
223702485|NCT02543710|DRUG|Biomarker guided weekly taxane treatment in endometrial/ ovarian cancer|"A 5mm tissue biopsy will be analysed for stathmin level in the recurrence as well as urine and a second 5mm biopsy on termination of study participation. The second biopsy could help explain why patients have stopped responding to the treatment. Determination of stathmin level both from the tissue and the urine will take place at the pathology department. Stathmin serves as an integrated biomarker, which enables a central biomarker analysis at Haukeland university hospital. Stathmin level is defined as high with an immunohistochemical score 9 (max score). All other scores are considered low. Pre-treatment all patients undergo CT or MRI, maximum 1 month prior to treatment start.~During treatment, urine and bloods will be collected every treatment cycle (weekly basis). Imaging will take place every 8 treatment cycles. Treatment will continue until disease progression."
223702486|NCT01334346|OTHER|Nike Pegasus|Conventional neutral supportive running footwear. Non minimalist.
223702487|NCT01334346|OTHER|Nike Free 3.0|Partial minimalist shoe with partially elevated heel, but with increased mid-sole flexibility.
223702488|NCT01334346|OTHER|Vibram Five Fingers Shoe|Full minimalist shoe. Virtually no mid-sole, therefore no heel elevation or forefoot rockering. A proxy for a barefoot running condition.
223783506|NCT04644328|BEHAVIORAL|Facebook Ads on the importance of staying safe during the Thanksgiving / Christmas holiday|Facebook ads to show a 15 second video clip recorded by MGH, Harvard and Lynn Community health center and other health care professionals. The ads will be shown before the Thanksgiving/Christmas holiday and will focus on staying safe - limiting travel and mask-wearing. The investigators will randomize exposure to the ad campaign at the ZIP code or county level.
223702489|NCT05344911|DRUG|Propofol combined with alfentanil|Anesthesia induction: midazolam 0.02 mg/kg, propofol（TCI） 3 μ g/mL, alfentanil 20 μ g/kg and rocuronium 0.6 mg/kg . Anesthesia maintenance: target-controlled infusion of propofol combined with alfentanil(0.5-2ug/kg/min)
223702490|NCT05344911|DRUG|Propofol combined with remifentanil|Anesthesia induction: midazolam 0.02 mg/kg, propofol（TCI） 3 μ g/mL, remifentanil 1μ g/kg and rocuronium 0.6 mg/kg . Anesthesia maintenance: target-controlled infusion of propofol combined with remifentanil(0.1-0.3ug/kg/min)
223702491|NCT04803461|DIAGNOSTIC_TEST|serum and urinary catecholamines|estimation of level of serum and urinary catecholamines before and after excimer light treatment for patient with non segmental vitiligo.
223702492|NCT00850343|DRUG|Certolizumab pegol|Subcutaneous (SC) injection
223702493|NCT00726375|DRUG|Etanercept (Enbrel)|Etanercept will begin within 72 hours of the diagnosis of Grade I acute GVHD and after consent for this study. Subjects receive eight doses of etanercept over four weeks. All doses will be administered by SQ injection. All subsequent doses will be given as subcutaneous injections into the skin. Injections will be given twice weekly with at least one day in between injections. The injections can be given in clinic, in the hospital, or self administered injections.
223783507|NCT05668195|PROCEDURE|systematic aerobic exercise and intelligent monitoring system in executive skill training|This is a closed-loop training initially developed by the research team in conjunction with other teams, adding a systematic aerobic exercise and intelligent monitoring system to the typical executive skill training, and is being further explored in training.
223783508|NCT05668195|PROCEDURE|executive skill training|The training program, based on Dawson and Guare's (2010) training of executive skills for children, aimed to improve the everyday performance of executive skills among children with ADHD. Qian Y and her team added some culturally adapted information, following the theory of cognitive behavioral therapy, to ensure that the concepts were acceptable to Chinese children.
223783509|NCT04277598|BIOLOGICAL|APO-2|APO-2: dose adjusted gel for topical administration.
223783510|NCT04277598|OTHER|Placebo|Placebo gel for topical administration.
223783511|NCT06015776|OTHER|Gender|Differences between men and women will be observed
223702494|NCT03703115|BEHAVIORAL|Fasting|No food for 14 -16 hours with water intake and non caloric beverages then eating balanced meals over 8 to 10 hours
223702495|NCT04716465|OTHER|Dysautonomia|Indicators of dysautonomia
223783512|NCT02596724|OTHER|Genomic and/or molecular testing of blood or tissue|Genomic and/or molecular testing of blood or tissue
223783513|NCT02080026|BIOLOGICAL|CPS-immunization|Subjects will receive four 'immunizations' with bites from 15 Plasmodium infected mosquitoes during each immunization, while taking chloroquine prophylaxis.
223783514|NCT02080026|BIOLOGICAL|Controlled Human Malaria Infection|Subjects will receive bites from 5 Anopheles mosquitoes infected with Plasmodium falciparum, NF54 strain.
223783515|NCT02080026|DRUG|chloroquine|Registered for prophylaxis against infection with Plasmodium falciparum and the treatment of acute infections.
223783516|NCT02080026|DRUG|atovaquone/proguanil|"Registered for use as an antimalarial agent for the treatment of acute infections with Plasmodium falciparum.~One tablet contains: atovaquone 250 mg, proguanil(hydrochloride) 100 mg"
223783517|NCT03356002|DEVICE|C-Scan System|"Each subject will ingest the capsule within 30 days prior to colonoscopy. The results of the C-Scan review will be compared to the findings of colonoscopy.~1. To establish the efficacy of C-Scan Capsule System and FIT in detecting patients with polypoid lesions ≥ 10mm, compared with Optical Colonoscopy~2. To evaluate the safety of the C-Scan Capsule System procedure"
223783518|NCT01455441|OTHER|Training and liraglutide|
223783519|NCT01455441|OTHER|Training and placebo|
223783520|NCT04879472|PROCEDURE|Osteosynthesis|The elderly are mainly treated by arthroplasty (total hip replacement or hemiarthroplasty) while the younger age groups, by osteosynthesis either using pins, screws or nails
223783521|NCT05647447|DRUG|Osanetant|Osanetant 200 mg orally, twice per day
223783522|NCT06347419|OTHER|Physiotherapy evaluation|In the physiotherapy evaluation, patients' spinal stability, rotary stability, and body awareness will be assessed.
223702496|NCT00745329|OTHER|sperm quality test|All participants will undergo sequential sperm quality tests and blood tests
223702497|NCT03552731|BEHAVIORAL|Surveys|GAD 7 Survey and PHQ 9 Interventional survey will be administered in both groups.
223702498|NCT00699569|DIETARY_SUPPLEMENT|hyperimmune colostrum|hyperimmune colostrum
223702499|NCT00699569|DIETARY_SUPPLEMENT|Placebo|
223702500|NCT04923438|OTHER|Telerehabilitation|The exercise program will begin with a warm-up, followed by a stretching exercise and an alphabetical exercise game called what's your name, and will end with a cool-down. The exercises will be performed 2 times a week for a total of 12 weeks, and each program will last for roughly 30 minutes. it will last. In what is your name game, 10 5-letter words containing the whole alphabet were produced and children will work out the exercises corresponding to each letter with a word they choose for each day.
223702501|NCT04923438|OTHER|Control|The same exercise program will be prepared and given to the patients who are offered and not accepted telerehabilitation, and they will be asked to do their own exercises at home. This group will also be included in the study as a control group.
223702502|NCT03120000|DRUG|PQR309|Oral PQR309, 80mg or 60mg daily or intermittent dosing
223702503|NCT04023435|OTHER|PNE edcuation|The PNE session will last 30 minutes and will be delivered in a one-on-one educational format with a clinician using prepared images, drawings and metaphors. The 30-minute PNE session was chosen to reflect a clinically meaningful intervention in a typical allocated time frame in clinical practice. The content of the PNE is described in detail elsewhere, using a metaphors to explain various aspects of pain including sensitization of the peripheral and central nervous system (sensitive alarm system metaphor); spreading pain (nosy neighbors metaphor); increases problems with focus and concentration (brain meeting metaphor) and difficulty with fatigue and sleep (lion metaphor).
223702504|NCT03380403|RADIATION|PDT|clinical treatment of infected diabetic foot
223702505|NCT03380403|OTHER|Ciprofloxacin|antibiotics and or surgical debridment
223702506|NCT03243604|DRUG|L02 (sex hormones used in treatment of neoplastic diseases) and G03 (sex hormones)|Androgen-deprivation therapies including L02 (sex hormones used in treatment of neoplastic diseases), and G03 (sex hormones)
223702507|NCT05325788|OTHER|e-Covery|Through the e-Covery app, participants will receive place-specific messages, sent when participants pass locations identified as triggers.
223702508|NCT05325788|OTHER|Comparator Condition|Through the e-Covery app, participants will receive a single general message sent daily in the morning.
223702509|NCT03824288|DIAGNOSTIC_TEST|Intraoral ultrasound|The ultrasound transducer (either Hockey Stick or Burr-Hole N11C5s transducer from BK Ultrasound) is placed on the palatoglossal arch on the affected side and sweeped from the cranial to caudal end of the tonsil to look for an abscess cavity identified as a hypoechoic area with ill-defined margins.
223702510|NCT03824288|PROCEDURE|The landmark technique|A 14G needle aspiration is inserted blindly in the superior tonsil pol where pus aspiration is attempted.
223702511|NCT00976040|OTHER|Early antiretroviral therapy|"The intervention is early initiation of antiretroviral therapy after diagnosis of Cryptococcal meningitis.~In the intervention/experimental arm, triple-drug highly active antiretroviral therapy regimens will be initiated within 7 days of diagnosis of Cryptococcal meningitis."
223702512|NCT03894332|DIAGNOSTIC_TEST|Electrical Impedance Tomography (EIT)|"After enrollment, a silicon EIT belt of proper size with 16 electrodes was placed around the patient's chest between the 4th and 6th intercostal spaces, and connected to the EIT device. All patients were ventilated in Pressure Support Ventilation (PSV) mode, with a dedicated ventilator connected to the EIT device.~We acquired 5-min EIT data records at baseline (during PSV), during the first (SBT\_0) and the last (SBT\_30) 5 minutes of SBT, and, when the patient was extubated, during spontaneous breathing soon after (SB\_0) and 30 minutes after extubation (SB\_30).~EIT and ventilator data were recorded at a sample of 20 Hz. The last 3 minutes of each record were analyzed.~We measured respiratory rate (RR); Vt changes from baseline, expressed as percent (dVt%); dEELI variations from baseline, expressed in mL; the Global Inhomogeneity index (GI); Impedance ratio (IR) and the Center of Ventilation (CoV)."
223702513|NCT00273832|PROCEDURE|coronary artery computed tomography angiogram|
223702514|NCT00273832|PROCEDURE|single photon emission computed tomography|
223783523|NCT02124967|OTHER|Exercise|A one hour exercise class including both aerobic activity and resistance training
223783524|NCT01744236|DRUG|Liraglutide|Liraglutide will be started with a titration period of 2 weeks (week 1: 0.6mg once daily and week 2: 1.2mg once daily). If liraglutide is well tolerated it will be continued for 10 more weeks in a dosage of 1.8mg once daily.
223783525|NCT01744236|DRUG|Sitagliptin|Sitagliptin 100mg will be given once daily for 12 weeks.
223783526|NCT01744236|DRUG|Exenatide|Exenatide will be administered intravenously with a loading dose of 50ng/min for 30 minutes, followed by a maintenance dose of 25ng/min during the rest of the tests
223783527|NCT01744236|DRUG|Liraglutide placebo|Liraglutide-placebo will be started with a titration period of 2 weeks (week 1: 0.6mg once daily and week 2: 1.2mg once daily). It will be continued for 10 more weeks in a dosage of 1.8mg once daily.
223783528|NCT01744236|DRUG|Sitagliptin placebo|Sitagliptin-placebo be given once daily for 12 weeks.
223783529|NCT01744236|DRUG|Exenatide placebo|Exenatide-placebo (saline) will be administered intravenously
223702515|NCT00550524|BIOLOGICAL|Autologous Stem Cell Transplantation|Autologous bone marrow aspiration (20 ml) from iliac crest. Separation of mononuclear cells using ficoll hypaque and culture in 10% fetal bovine serum and Dulbecco modified eagles medium. After confluent stage, detachment of cells with trypsin/EDTA, and subculture. Repeated passages until obtainment of required cell number. Confluent cells of last passage are washed with tyrode solution and incubate with M199 for 60 minutes. Cells are separated using trypsin/EDTA and washed 3 times with M199 and 1% HSA. Precipitate will be diluted with heparinized M199 to make solution with 6×106 cells /ml. Sample will be tested for viability and detection of CD45, CD34, CD90, CD44, CD13, CD105, and CD166 before injection. The number of cells for injection will be between 20-25 million cells; in a maximum volume of 4-6 ml. Cells will be injected in the knee joint with a 21 gauge needle.
223702516|NCT04198298|DRUG|EndoSequence|The EndoSequence® retrograde sealing material was used to provide a biologic seal at the apex.
223702517|NCT04198298|DRUG|ProRoot MTA|The ProRoot® MTA retrograde sealing material was used to provide a biologic seal at the apex.
223702518|NCT04198298|DRUG|Biodentine|The Biodentine® retrograde sealing material was used to provide a biologic seal at the apex.
223702519|NCT02254941|DRUG|Chemotherapy|Metastatic colon cancer, first line treatment with conventional chemotherapy
223702520|NCT02254941|BIOLOGICAL|Chemotherapy plus monoclonal antibody|Metastatic colon cancer, first line treatment with conventional chemotherapy plus monoclonal antibody
223783530|NCT01744236|DRUG|L-NMMA|
223783531|NCT00375089|OTHER|Group 1|Individuals with Prader-Willi syndrome. Monitoring every 6 months.
223783532|NCT00375089|OTHER|Group 2|Individuals with Early-onset Morbid Obesity.
223783533|NCT00784043|DEVICE|Cochlear Implant|Bilateral Implantation in children
223783534|NCT02541253|BIOLOGICAL|GC3110A|A single 0.5mL dose intramuscular injection
223783535|NCT02541253|BIOLOGICAL|GCFLU Pre-filled Syringe inj.|A single 0.5mL dose intramuscular injection
223783536|NCT01069783|DRUG|A3309|A3309 in two different dosage levels
223783537|NCT01069783|DRUG|A3309|A3309 in two different dosage levels for the duration of the study
223783538|NCT01069783|DRUG|Placebo|Placebo comparator once daily for the duration of the trial
223783539|NCT00097812|DRUG|zoledronic acid|
223783540|NCT00810134|PROCEDURE|Thrupass|Endovascular treatment (Thrupass) is performed as a femoropopliteal above knee endovascular recanalisation and Viabahn introduction with 6-7 mm Viabahn endo-prosthesis.
223783541|NCT00810134|PROCEDURE|Bypass|Surgical procedure is performed as a femoropopliteal above knee by-pass with 6 mm non-coated PTFE-graft
223783542|NCT05907369|OTHER|Active EC training|The active EC includes pairing contamination-related pictures (CSs) with pleasant pictures (USs). The EC training takes about 15 minutes and is administered for ten sessions (5 days a week) in 4 difficulty levels.
223783543|NCT05907369|OTHER|Sham EC training|The active EC includes pairing contamination-related pictures (CSs) with neutral pictures (USs). The EC training takes about 15 minutes and is administered for ten sessions (5 days a week) in 4 difficulty levels, the same as active EC training.
223783544|NCT05907369|OTHER|Active tDCS|For the active tDCS, the cathode is placed over the left OFC and the anode over the right cerebellum. The brain stimulation is delivered with a 2mA current intensity for 20 minutes in 10 sessions (5 days a week).
223783545|NCT05907369|OTHER|Sham tDCS|For the sham tDCS, the cathode is placed over the left OFC and the anode over the right cerebellum, the same as active tDCS. The device is on for 20 minutes, but the current intensity is under the threshold of affecting cortical activity modulation. The participants receive the sham tDCS in 10 sessions (5 days a week).
223783546|NCT01713595|DRUG|Hypertonic Saline Aerosol|A single 5ml dose of 7% Saline aerosol
223702521|NCT03836599|DRUG|Verinurad|Participants will receive verinurad 24 mg in cohort 1 and 12 mg in cohort 2 once daily.
223702522|NCT03836599|DRUG|Allopurinol|Participants will receive allopurinol 300 mg once daily.
223702523|NCT03836599|DRUG|Placebo|During Run-in Period, participants in cohort 1 will receive placebo matching allopurinol capsule once daily from Day -7 to Day -1. During treatment period, participants in cohort 1 will receive placebo matching allopurinol capsule and placebo matching verinurad capsule once daily from Day 1 to Day 7.
223702524|NCT05915078|COMBINATION_PRODUCT|Iontophoresis and tube placement|Iontophoretic delivery of TYMBION™ otic anesthetic using the Tula Iontophoresis System and tube insertion using the Tula Tube Delivery System
223702525|NCT05969808|OTHER|baseline therapy and conventional therapy|These activities included were warm-up activities, general playtime, basic gross motor activities, and free play with toys three times a week for 45 minutes for a period of 12 weeks.
223702526|NCT05969808|OTHER|baseline treatment and adaptive physical activity|The experimental group's intervention plan had the following 12 elements . Each of which was completed for 10 minutes with two-minute breaks. Warm-up activities, puzzles and manipulatives, e.g., interlocking blocks or shape sorting toys, Balloon Badminton, Obstacle course (crawl in Tunnel ), Peg board play, Tactile sensory bin exploration filled with sand, Ball roll and catch, Tracing shapes, Play dough and clay activities, Cutting and pasting.
223702527|NCT02764333|BIOLOGICAL|TPIV200|
223702528|NCT02764333|BIOLOGICAL|Durvalumab|
223783547|NCT01736813|DRUG|Maraviroc|Twelve patients with 300 mg/bid
223783548|NCT05883852|DRUG|Docetaxel|Docetaxel is a taxoid antineoplastic agent used in the treatment of breast cancer
223783549|NCT05883852|DRUG|carboplatin|Carboplatin is a DNA synthesis inhibitor which binds to DNA, inhibits replication and transcription and induces cell death.
223783550|NCT05883852|DRUG|Trastuzumab|Trastuzumab is a humanized monoclonal antibody derived from recombinant DNA,
223783551|NCT05883852|DRUG|Pertuzumab|Pertuzumab is a recombinant humanized monoclonal antibody that specifically binds to the extracellular dimerization domain (subdomain Ⅱ) of epidermal growth factor receptor 2(HER2).
223783552|NCT05883852|DRUG|Epirubicin|Epirubicin is an antineoplastic agent derived from doxorubicin.Epirubicin, like doxorubicin, exerts its antitumor effects by interference with the synthesis and function of DNA and is most active during the S phase of the cell cycle.
223783553|NCT05883852|DRUG|cyclophosphamide|An anticancer (antitumor or cytotoxic) chemotherapy drug that is classified as an alkylating agent. Alkylating agents are compounds that prevent the normal connection of the double helix chain by adding an alkyl group to the guanine base of the DNA molecule. It causes breaks in DNA strands, affecting the ability of cancer cells to proliferate.
223783554|NCT03671603|DRUG|Iodixanol|Iodixanol 270 mgI/ml or 320 mg I/ml injection will be administered as part of clinical practice according to the judgment of the site with regard to medical need.
223783555|NCT02197923|PROCEDURE|Myometrial biopsy|transvaginal ultrasound guided biopsy of the myometria
223783556|NCT02197923|PROCEDURE|endometrial biopsy|transcervical endometrial biopsy
223783557|NCT05162820|DIETARY_SUPPLEMENT|100 mg Solarplast|100 mg Solarplast delivered in capsules with the carrier of rice dextrin and medium chain triglycerides consumed daily at breakfast for 60 days
223783558|NCT05162820|DIETARY_SUPPLEMENT|Placebo|rice dextrin and medium chain triglycerides in capsules consumed daily at breakfast for 60 days
223783559|NCT05553691|DRUG|SPL026|Intravenous
223783560|NCT04191772|OTHER|Periodized, home-based running program|All participants will perform a home-based supervised exercise training program. Participants will receive weekly training instructions using a smartphone-based heart rate monitor application (Polar® app). Training sessions will involve running and the design of the training program will be based on linear periodization, where aerobic capacity is built firstly through a period of high-volume/low-intensity training before the proportion of high-intensity training is increased. The total duration of the exercise program will be 12 months with three weekly training sessions. Training progression will be dependent on initial VO2max values and running experience. VO2max classification is based on reference values described in V.H. Heyward, Advanced Fitness Assessment and Exercise Prescription, Fifth Edition, 2006, Champaign, IL: Human Kinetics.
223783561|NCT05216172|DRUG|AZD1656|active drug
223783562|NCT05216172|DRUG|Placebo|placebo
223783563|NCT03564912|DRUG|Capecitabine Oral Tablet [Xeloda]|2 week group: capecitabine 1000mg/m2 d1-10; oxaliplatin 85mg/m2; q2w 3 week group: capecitabine 1000mg/m2 d1-14; oxaliplatin 130mg/m2; q3w
223783564|NCT00921492|DEVICE|Low-frequency electro-acupuncture (EA)|2 Hz EA during 30 minutes, twice a week, 14 weeks.
223783565|NCT00921492|OTHER|Meeting a therapist - attention control|Meeting a therapist, twice a week during 30 minutes in order to control for the increased amount of attention.
223783566|NCT05637021|OTHER|Carbon dioxide insufflated during colonoscopy|Carbon dioxide is insufflated to dilate the bowel lumen during colonoscopy.Record the amount of gas insufflated during colonoscopy.
223783567|NCT00647712|DRUG|Divalproex Sodium Extended-Release Tablets 500 mg|500mg, single dose fasting
223783568|NCT00647712|DRUG|Depakote ER® Tablets 500 mg|500mg, single dose fasting
223783569|NCT04575428|DRUG|Splanchnic nerve block|Percutaneous splanchnic nerve block
223702529|NCT06159790|DRUG|GME751|Drug: GME751 Concentrate for solution for infusion, Biologic, Liquid in vial, 100 mg, 200 mg every 3 weeks, i.v. infusion Drug: Pemetrexed (i.v. infusion) Drug: Carboplatin or Cisplatin (i.v. infusion)
223702530|NCT06159790|DRUG|Keytruda-EU|Drug: Keytruda-EU Concentrate for solution for infusion, biologic, liquid in vial, 100 mg, 200mg every 3 weeks, i.v. infusion Drug: Pemetrexed (i.v. infusion) Drug: Carboplatin or Cisplatin (i.v. infusion)
223702531|NCT04936568|OTHER|Palliative Care Referral System - PCRS|Implementation of a system to help oncologists to identify criteria for referring patients to specialized outpatient palliative care (Palliative Care Referral System - PCRS)
223783570|NCT03689322|OTHER|WBV + IMT|The whole body vibration training will be performed through a vibrating platform with three axes and vibration frequency set at 35 Hz. The amplitude used will be 02 to 04 mm.The inspiratory muscle training will be performed through a device that provides inspiratory resistance.
223783571|NCT03689322|OTHER|WBV + IMTsham|The whole body vibration training will be performed through a vibrating platform with three axes and vibration frequency set at 35 Hz. The amplitude used will be 02 to 04 mm.The inspiratory muscle training sham will be performed through a device without inspiratory resistance.
223783572|NCT03689322|OTHER|WBVsham + IMTsham|Whole body vibration training will be performed through a vibrating platform coupled to a device that generates non-therapeutic low frequency vibration. The simulation of inspiratory muscle training will be performed through a device with no inspiratory resistance.
223783573|NCT05903560|PROCEDURE|endovascular recanalization via radial approach|Patients with basilar artery occlusion within 24 hours of onset will be chosen to receive endovascular recanalization via radial approach
223783574|NCT05903560|PROCEDURE|endovascular recanalization via femoral approach|Patients with basilar artery occlusion within 24 hours of onset will be chosen to receive endovascular recanalization via femoral approach
223783575|NCT00288158|DRUG|Allopurinol|
223783576|NCT00288158|DRUG|Probenecid|
223783577|NCT00288158|DRUG|Placebo|
223783578|NCT00793208|BIOLOGICAL|semi-allogeneic human fibroblasts (MRC-5) transfected with DNA|"Each vaccine consists of 1 x 10e7 DNA-transfected irradiated fibroblasts. A total of 4 weekly immunizations will be delivered to each patient. Each vaccine will be administered i.d. using a 1 mL syringe and a 25 gauge needle.~Subjects will have immunizations administered at 4 different sites for each vaccination as follows:~Site #1: Right arm Site #2: Left arm Site #3: Right thigh Site #4: Left thigh Approximately equal numbers of transfected fibroblasts will be administered at each site."
223783579|NCT03397511|BEHAVIORAL|Financial Incentives|Baseline Interview, 2 Counseling Sessions at baseline and 2 weeks post baseline, and one follow up survey at one month
223783580|NCT05106231|BEHAVIORAL|PICC Program|Participants will attend the PICC program which consists of 4 sessions that involve Visualization in Participatory Programmes (VIPP) and quizzes to evaluate retention in diabetes knowledge.
223783581|NCT05106231|BEHAVIORAL|Control|The control arm received four sessions one-on-one education program by a pharmacist. It is a Malaysian national education pharmacy-led program to instil knowledge and inculcate medication adherence.
223783582|NCT00197977|BEHAVIORAL|Educational program to address patients' expectations|
223783583|NCT01253434|DRUG|E2022|E2022 Type A patch
223783584|NCT01253434|DRUG|E2022|E2022 Type B patch
223783585|NCT01253434|DRUG|E2022|E2022 Type C patch
223702532|NCT06285773|DRUG|RIFPB block|For RIFPB, a local anesthetic will be injected into the plane between the costal cartilage and the rectus abdominis muscle at the 6th-7th costal cartilage under US guidance. The in-plane technique will be used. After confirming the block location, 10 ml of 0.25% concentration marcaine (bupivacaine) will be used (bilateral).
223702533|NCT06285773|OTHER|Postoperative analgesia management|"Patients will be administered 10mg/kg paracetamol in the postoperative period every eight hours.~If the NRS score is ≥ 4, 1 mg kg-1 iv tramadol will be administered as a rescue analgesic."
223783586|NCT01253434|DRUG|E2022|E2022 Type D patch
223783587|NCT01253434|DRUG|E2022|E2022 Type E patch
223783588|NCT02940990|RADIATION|SBRT concurrent with GM-CSF|SBRT and GM-CSF 125ug/m2 for 14 days
223783589|NCT02940990|DRUG|two-drug chemotherapy containing platinum, including carboplatin/Cisplatin + pemetrexed/docetaxel/paclitaxel/etoposide/gemcitabine/vinorelbine/albumin-bound paclitaxel|two-drug regimen
223783590|NCT04711304|BIOLOGICAL|Umbilical Cord-derived Wharton's Jelly|Intraarticular injection
223783591|NCT04711304|DEVICE|Hyaluronic acid|Intraarticular injection
223783592|NCT04711304|OTHER|Saline|Intraarticular injection
223783593|NCT05354700|DRUG|HLX07|HLX07 is a recombinant humanized anti-EGFR monoclonal antibody injection, developed by Shanghai Henlius Biotech, Inc.
223783594|NCT05354700|DRUG|HLX10|HLX10 is a recombinant humanized anti-PD-1 monoclonal antibody injection, developed by Shanghai Henlius Biotech, Inc.
223783595|NCT05354700|DRUG|carboplatin and etoposide|chemotherapeutics
223783596|NCT00210834|DRUG|epoetin alfa|
223783597|NCT03030300|DRUG|Novolin 30R;Pioglitazone;Metformin|"* Insulin (Novolin 30R) was titrated according to the level of blood glucose until reached euglycemia (FPG≤6.1mmol/L and/or P2hBG≤8.0mmol/L and/or HbA1c ≤6.5%). After glucose was well controlled within these targets for 4 weeks, insulin dosage was gradually decreased until discontinued;~* Pioglitazone hydrochloride was discontinued if the glucose was well controlled at the 6th week after the cessation of insulin;~* Metformin was the last drug that to be discontinued if the glucose was still well controlled at the 4th week after the cessation of pioglitazone."
223783598|NCT03779386|OTHER|music|music during labor and delivery
223783599|NCT03965052|DRUG|PRO 179|"* Generic name: Travoprost~* Distinctive denomination: Bristrio® (PRO-179)~* Active principles: Travoprost 0.004%.~* Pharmaceutical form: Ophthalmic solution~* Presentation: multi-dose dropper bottle, 2.5 milliliters.~* Prepared by: Sophia Laboratories, S.A. of C.V.~* Description of the solution: transparent solution, free of visible particles.~* Description of container: White bottle with 5 milliliters capacity, made of low density polyethylene."
223783600|NCT03965052|DRUG|Travatan 0.004 % Ophthalmic Solution|"* Generic name: Travoprost~* Distinctive denomination: Travatan®~* Active ingredients: Travoprost 0.004%~* Pharmaceutical form: Ophthalmic solution.~* Presentation: multi-dose dropper bottle, 2.5 milliliters.~* Prepared by: Alcon Laboratories Inc.~* Description of the solution: transparent solution, free of visible particles.~* Consult information to prescribe."
223783601|NCT03443466|DEVICE|Epidural electrical stimulation (EES)|Using loss of resistance technique and electrical stimulation
223783602|NCT03443466|DEVICE|Loss of resistance (LOR)|Using loss of resistance technique only
223783603|NCT02268591|DEVICE|Transcranial Stimulator|A non invasive brain stimulation which delivers low amplitude current through scalp electrodes by a Transcranial Stimulator
223783604|NCT00661063|DRUG|ketamine|ketamine 150 mcg/g bid
223783605|NCT00661063|DRUG|vehicle gel|bid - 12 weeks
223783606|NCT00661063|DRUG|ketamine + clonidine|ketamine 150mcg/g + clonidine 1% gel bid 12 weeks
223783607|NCT00661063|DRUG|clonidine gel 1%|bid 12 weeks
223783608|NCT03348254|DRUG|Single shot antibiotic prophylaxis|single shot preoperative antibiotic prophylaxis
223783609|NCT03348254|DRUG|Multiple shot antibiotic prophylaxis|Multiple shot perioperative antibiotic prophylaxis
223783610|NCT04740515|OTHER|pharmacists involved PPMTM|This was an open labelled randomised study. Preterm Infants With iron supplementation were recruited and arbitrarily divided into the intervention group (usual care plus PPMTM) and the non-intervention group (usual care only). Those enrolled in the research were scheduled for follow-up for eight consecutive visits. Improvements in lab results and direct costs were compared longitudinally (pre and post analysis) between the groups.
223783611|NCT02545907|DRUG|Carfilzomib|Lyophilized carfilzomib for injection reconstituted with water to a final concentration of 2 mg/mL.
223783612|NCT02545907|DRUG|Thalidomide|50mg capsule.
223783613|NCT02545907|DRUG|Dexamethasone|2mg tablet.
223783614|NCT00358735|DEVICE|ActiveCare CECT device|Patients will be treated with the ActiveCare+ CECT device starting after the induction of anesthesia, throughout the surgery and for 10-12 days after surgery. Baby aspirin (81 mg) QD can be added (depending on surgeon preference) 12-24 hours after surgery. Post discharge prophylaxis is the same for the remainder of the 10-12 days. Patients will wear the device to the duplex ultrasound when it will be discontinued by nurse.
223783615|NCT00358735|DRUG|Enoxaparin|Patients will be treated with Enoxaparin (Lovenox) for a total of 10 days beginning with 30mg BID starting 12-24 hours after surgery and continued until hospital discharge. Post discharge prophylaxis will be Enoxaparin 40mg QD for the remainder of the 10 days.
223783616|NCT02416323|OTHER|AIM HI Training|
223783617|NCT01334697|DRUG|recombinant human cardiotrophin-1|Single dose intravenous administration
223783618|NCT01334697|OTHER|Placebo|Single dose intravenous administration
223783619|NCT05561959|OTHER|topical glyceryl trinitrate gel|topical nitroglycerin medication were treated with 1 gr nitroglycerin 2% gel
223783620|NCT05561959|OTHER|Eccentric exercises|stretching exercises of the gastrocnemius (straight leg) and soleus (bended knee).
223783621|NCT00325299|DRUG|Magnesium|
223783622|NCT06446804|OTHER|None, pure observationnal study|Pure observatonnal study
223783623|NCT06567509|OTHER|Core stability exercises and Short foot exercises|Core stabilty exercises are the exercises where subjects will be trained to perform exercises like: Curl ups, bridging, side bridges, Planks, and Quadripedal stance exercises in a phased manner, each phase lasting 2 weeks. Complexities and duration of exercises will be increased in each phase. Short foot exercises for control group will include traditional treatment of stretching and strengthening of foot musculature.
223783624|NCT06567509|OTHER|Conventional foot exercises and short foot exercises|Ankle dorsiflexion, Plantar flexion, Inversion and Eversion range of motion exercises
223783625|NCT02909322|PROCEDURE|Bupivacaine and Hydromorphone|Patients receive bupivacaine and hydromorphone infusion and bolus doses during surgery and 3 days after surgery.
223783626|NCT02909322|PROCEDURE|Ropivacaine and Hydromorphone|Patients receive ropivacaine and hydromorphone infusion and bolus doses during surgery and 3 days after surgery.
223783627|NCT01233297|DRUG|Azithromycin|10 mg/kg peroral for 3 consecutive days
223783628|NCT01233297|OTHER|Placebo mixture|Placebo mixture containing no active substance.
223783629|NCT00499889|DRUG|Imatinib Mesylate|400 mg by mouth twice daily for 9 Days
223783630|NCT00499889|DRUG|Fludarabine (Fludara)|40 mg/m\^2 by vein daily for 4 Days
223783631|NCT00499889|DRUG|Busulfan|130 mg/m\^2 by vein daily for 2 Days
223783632|NCT00499889|DRUG|Antithymocyte Globulin (ATG)|2.5 mg/kg by vein daily for 3 Days
223783633|NCT00499889|DRUG|Tacrolimus|Tacrolimus levels maintained between 5-15 ng/dl, first as continuous IV infusion, and converted to oral every 12 hour dosing as tolerated. Starting day -2 until day 180.
223702534|NCT06285773|DRUG|PIFPB block|For PIFPB; the ultrasound probe for PIFB is placed 2-3 cm lateral to the upper third of the sternum, parallel to the sternum. A local anesthetic of 15 ml of 0.25% concentration of marcaine (bupivacaine) will be used between the pectoralis major and external intercostal muscles (bilateral).
223702535|NCT02646514|DEVICE|Radiofrequency ablation with stenting|"Side viewing endoscope or PTCS scope can be used for all procedures. Cholangiogram is performed to confirm the stricture location, length and diameter. And then, RF catheter (ELRA®) is advanced over a guide wire at the level of the biliary stricture and ablation at 7-10 watts for a time period of 60-120s according to the length is conducted.~After performance of RFA, metal stents are inserted to ensure adequate decompression and bile drainage."
223783634|NCT00499889|DRUG|Methotrexate|5 mg/m2 on days 1, 3, 6 and 11.
223783635|NCT00499889|PROCEDURE|Donor lymphocyte infusion (DLI)|Infusion of lymphocytes from the original bone marrow donor by vein if relapse after \>4 weeks of imatinib.
223783636|NCT00499889|PROCEDURE|Stem Cell Transplant|Infusion of donor bone marrow or blood stem cells by vein over approximately one hour on day 0.
223783637|NCT00688805|DRUG|Propranolol|40 mg given as a single oral administration in an opaque capsule
223783638|NCT00688805|DRUG|Placebo|matching capsule containing no active medication
223783639|NCT02908269|BIOLOGICAL|Fluzone Quadrivalent vaccine, 2016-2017 formulation, No Preservative|0.5 mL, Intramuscular
223783640|NCT02908269|BIOLOGICAL|Fluzone Quadrivalent vaccine, 2016-2017 formulation, No Preservative|0.5 mL, Intramuscular
223783641|NCT02908269|BIOLOGICAL|Fluzone High-Dose, vaccine, 2016-2017 formulation|0.5 mL, Intramuscular
223783642|NCT05509972|DEVICE|total knee prosthesis implantation|Total Knee Arthroplasty (TKA) represents a well-established, reliable and successful treatment option for end-stage bicompartmental osteoarthritis or comparable conditions even in young patients compromised by knee pain and limitations of daily living
223783643|NCT02578524|OTHER|Survey|
223783644|NCT04202159|DRUG|Perampanel|Perampanel tablets.
223783645|NCT04202159|DRUG|Perampanel|Perampanel oral suspension.
223783646|NCT00111943|DRUG|1% tenofovir gel|
223783647|NCT00142909|DRUG|Lofexidine|Participants will receive lofexidine. The dosing will be initiation at 0.4 mg bid and increased to 0.8mg in week 1 and 1.0 and 1.2 mg bid in week 2, and maintained at 1.2mg bid for weeks 3 to 12. They are then tapered down to 0 over the course of four days in week 12. While the target dose will be 2.4 mg daily, if any subject shows reduced tolerability at this or a lower dose, the dose will be adjusted to the maximum tolerated dose for that subject.
223783648|NCT00142909|DRUG|Placebo|Lofexidine Placebo
223783649|NCT03839238|BIOLOGICAL|hESC derived MSC like cell|Different dosage of hESC derived MSC like cell for the meniscus injured patients
223783650|NCT05274945|RADIATION|Radiotherapy|radiotherapy 45 Gy/ 25 fractions then boost 5.4 Gy/3 fractions with concurrent bolus 5-fluorouracil
223783651|NCT05274945|DRUG|consolidation chemotherapy|6 cycles of FOLFOX or CAPOX
223783652|NCT05274945|PROCEDURE|TME or APR|total mesorectal excision or abdominoperineal resection
223783653|NCT04724811|PROCEDURE|Open reduction and internal fixation (ORIF)|"Approaches used:~* Intrapelvic approach +/- iliac window~* Kocher-Langenbeck approach"
223783654|NCT02221115|DEVICE|Google Glass|The device is a wearable, voice-controlled Android device that resembles a pair of eyeglasses and displays information directly in the user's field of vision
223783655|NCT00399152|DRUG|Perifosine|Perifosine Oral Dose
223783656|NCT00399152|DRUG|Sunitinib Malate|Sunitinib oral dose
223783657|NCT01694537|DRUG|DLBS1033|The study drug is enteric coated DLBS1033, which contain 490 mg bioactive protein fraction.
223783658|NCT01694537|DRUG|placebo|Placebo is made with same size and shape with study drug.
223783659|NCT03809845|DEVICE|High-density surface electromyography|High-density surface electromyography
223783660|NCT04012398|DIAGNOSTIC_TEST|Amsterdam IADL Questionnaire short, German version|Questionnaire to assess impairments in instrumental activities of daily living
223783661|NCT05928338|BEHAVIORAL|Peer-supported, WhatsApp-assisted lifestyle modification intervention|The lifestyle modification intervention, supported by peers and WhatsApp voice calls aimed to assist participants in making dietary modifications, increasing physical activity, and achieve a weight loss of 5% of their initial body weight as well as avoid weight gain. A trained nutritionist delivered the intervention after the baseline assessment individually or in groups that covered six sessions related to dietary modifications, physical activity, set-up goals and action plans, and peer assignments and then once monthly for a year using WhatsApp voice calls to the participants and peers.
223783662|NCT01879397|DEVICE|Research Ultrasound Exam|"Collection of backscattered ultrasound data during non-invasive ultrasound exam~* ARFI based images of the carotid artery and plaque~* Ultrasound signals received by the ultrasound imaging system are recorded. These signals are discarded during the image formation process for a standard duplex ultrasound exam."
223783663|NCT01898195|DRUG|Varenicline|Varenicline will be provided for three months.
223783664|NCT01898195|BEHAVIORAL|Text Message|Text messages will be developed twice daily for three months
223783665|NCT01898195|BEHAVIORAL|Adherence Behavioral Therapy|Seven Adherence Behavioral Therapy sessions will given over a three month period
223783666|NCT01451294|DRUG|Administration of phenylephrine|Phenylephrine: 50-100µg
223783667|NCT01451294|DRUG|Administration of ephedrine|Ephedrine: 5- 10 mg
223783668|NCT01503905|DRUG|Docetaxel|75mg/m2, iv injection, day1, every 21 days
223783669|NCT01503905|DRUG|epirubicin|80mg/ m2, iv injection, day1, every 21 days
223783670|NCT01503905|DRUG|cyclophosphamide|500 mg/m2, iv injection, day1, every 21 days
223783671|NCT01503905|PROCEDURE|Modified radical mastectomy or breast-conserving Surgery|Two weeks after four cycles of neoadjuvant chemotherapy
223783672|NCT01503905|DRUG|Docetaxel (post-operative)|Two weeks after surgery,75mg/m2, iv injection, day1, every 21 days, 4 cycles totally.
223783673|NCT01503905|DRUG|Epirubicin (post-operative)|Two weeks after surgery, 80mg/m2,iv injection, day1, every 21 days, 4 cycles totally
223783674|NCT01503905|DRUG|Cyclophosphamide (post-operative)|Two weeks after surgery, 500mg/m2, iv injection, day1, every 21 days, 4 cycles totally.
223783675|NCT01503905|RADIATION|Radiation therapy|Two weeks after post-operative chemotherapy, perform radiation therapy based on 2011 NCCN guideline.
223783676|NCT01503905|DRUG|Herceptin （post-operative)|Perform herceptin therapy (one year) based on 2011 NCCN guideline if the pathological test of the operative tumor sample showed HER2 positive.
223783677|NCT01503905|DRUG|Tamoxifen (post-operative)|After radiation therapy, totally five years. Perform hormone therapy based on 2011 NCCN guideline if the tumor is ER/PR positive.
223783678|NCT02445820|DRUG|HES|2500 mL of balanced HES 130/0.4
223783679|NCT02445820|DRUG|Crystalloid|2500 mL of balanced crystalloid.
223783680|NCT01853150|DEVICE|rTMS Motor cortex|
223783681|NCT01853150|DEVICE|rTMS Supplementary motor area|
223783682|NCT05239026|BEHAVIORAL|Advanced treadmill walking|Participants will walking on a treadmill for 6 5-minute Blocks. The cadence will be progressively reduced for the first 3 Blocks. Speed will progressively increase during Blocks 4-6 while cadence from Block 3 is maintained.
223783683|NCT05239026|BEHAVIORAL|Traditional treadmill walking|Participants will walking on a treadmill for 6 5-minute Blocks. Participants will walk at self-selected cadence during Blocks 1-3. Speed will progressively increase during Blocks 4-6.
223783684|NCT00901290|DRUG|monophasic oral contraceptive|mg, oral dose
223783685|NCT00901290|DRUG|AZD7325|mg, oral dose
223783686|NCT00724347|BEHAVIORAL|Consonant Identification Training|Subjects received psychophysically adaptive, consonant identification training in consonant discrimination on PCs in their homes.
223783687|NCT04420299|DRUG|Bemiparin|Bemiparin at therapeutic dose for 10 days
223783688|NCT04420299|DRUG|Bemiparin|Bemiparin at prophylactic dose for 10 days
223783689|NCT01771406|DRUG|Nebivolol|8 weeks of Nebivolol treatment (5mg/day)
223783690|NCT01771406|DEVICE|Continuous positive airway pressure (CPAP)|8 weeks of CPAP treatment
223783691|NCT01688336|DRUG|FOLFIRINOX|"FOLFIRINOX will be given intravenously on Days 1, 15, and 28 of each 28 day cycle. Drugs are given in combination in this order:~* Oxaliplatin (85 mg/m2)~* Leucovorin (400mg/ m2)~* Irinotecan (180 mg/m2)~* 5FU (400mg/m2)bolus then 2400 mg/m2 over 46 hours"
223783692|NCT00558675|BIOLOGICAL|AlloStim|single intravenous infusion of 1 x 10\^9 AlloStim cells
223783693|NCT00558675|BIOLOGICAL|AlloStim|Intravenous infusion of 1 x 10\^9 AlloStim on day 1 and a second intravenous infusion of 1 x 10\^8 AlloStim on day 7
223783694|NCT00558675|BIOLOGICAL|AlloStim|Intravenous infusion of 1 x 10\^9 AlloStim on day 1 and a second intravenous infusion of 1 x 10\^8 AlloStim on day 7 and day 14
223783695|NCT00558675|BIOLOGICAL|AlloStim|Intravenous infusion of 1 x 10\^9 AlloStim on day 1 and a second intravenous infusion of 1 x 10\^8 AlloStim on day 7, day 14 and day 21
223783696|NCT06662669|DRUG|YL-13027|YL-13027 is a small molecule inhibitor of the TGF-βRI target.
223783697|NCT06662669|DRUG|HY-0102|HY-0102 is a recombinant anti-NKG2A humanized monoclonal antibody.
223783698|NCT06662669|DRUG|Gemcitabine|Gemcitabine is a pyrimidine antineoplastic chemotherapeutic agent.
223783699|NCT06662669|DRUG|Nab-paclitaxel|Paclitaxel for Injection (albumin bound) is a chemotherapeutic agent that acts as an antitumor agent by inhibiting tumor cell mitosis
223783700|NCT05471973|OTHER|Multidisciplinary Team|Multidisciplinary team will be established that will define gaps in care, monitor ongoing data, identify barriers to guideline-directed care, and develop and implement multifaceted intervention to address the barriers
223783701|NCT05471973|OTHER|Outreach Visits|An outreach visit consulting group from the coordinating center and trial leadership will provide external guidance on reviewing data, defining barriers, and implementing interventions
223783702|NCT05471973|OTHER|Multifaceted Intervention|These interventions are not limited to targeted engagement with non-extractors, electronic health record (EHR) decision support, creation of OR block time, use of opinion leaders, and development of clinical pathways. In addition, once patients are identified and referred to extraction centers, clinical pathways are needed to provide prompt care without clinical delay
223783703|NCT05471973|OTHER|Measurement and Feedback|The coordinating center will provide ongoing feedback related to the site's data. This will include time to diagnosis, treatment, and outcomes related to the device infection.
223783704|NCT03763422|DRUG|Temozolomide|Oral Administration of Temozolomide
223783705|NCT03763422|RADIATION|Radiotherapy|50.4 Gy in 28 fractions over 6 weeks
223783706|NCT03763422|PROCEDURE|Surgery|Surgery
223783707|NCT01385345|DRUG|Vitamin D3 cholecalciferol|High dose Vitamin D3 (200,000 units followed by 100,000 units x 3 over 6 months) plus daily 1,000 units Vitamin D3 per day vs only daily 1,000 units Vitamin D3 per day
223783708|NCT03813446|DEVICE|Device: RhythmPadBP|"Detection of heart rhythm and measurement of blood pressure~Intervention:~Patients will start by wearing a consumer SmartWatch (Huwaei SmartWatch 2, which has a CE mark) and a 60 second reading of their wrist Photoplethysmyograph (PPG) will be recorded. This will enable us to compare the PPG from the wrist with the fingertip data collected from the RhythmPadBP.~The watch will be cleaned with alcohol wipe in the same manner that the RhythmPadBP is cleaned between subjects use.~Patients will be asked to place their palms of both hands on RhythmPadBP and then the underlying heart rhythm and BP will be recorded. 12-lead ECG and BP reading will be obtained by standard devices for comparison."
223783709|NCT02945384|BEHAVIORAL|Creating Connections: Strong Families, Strong Brains|Dual-generation intervention
223783710|NCT03579329|PROCEDURE|Total Knee Arthroplasty|Effect of Total Knee Arthroplasty on Sarcopenia in Patients with Osteoarthritis in the Knee
223783711|NCT02803775|DEVICE|CRT Algorithm|Programming based on Electrogram measurement
223783712|NCT06454032|BEHAVIORAL|Fitness walking|Fitness walking for 12 weeks.
223783713|NCT06454032|BEHAVIORAL|Maintained lifestyle|Maintained their normal lifestyle, without exercise intervention.
223783714|NCT01314040|OTHER|Run in diet|Fully controlled dietary period during 9 days. Participants will receive approximately 15 en% of protein. The amount of protein intake from dairy, meat, and grain will be equal to each other
223783715|NCT01314040|OTHER|High meat protein diet|Fully controlled diet during 7 days. Participants will consume 18 en% protein, mainly from meat.
223783716|NCT01314040|OTHER|High dairy protein diet|Fully controlled dietary intervention during 7 days. Participants will consume 20 en% protein. Mainly from dairy
223783717|NCT01314040|OTHER|High grain protein diet|Fully controlled dietary intervention for 7 days. Participants will consume 20 en% of protein. Mainly from grain
223783718|NCT01903538|DEVICE|Cathodal transcranial direct current stimulation (tDCS)|Cathodal transcranial direct current stimulation (tDCS) 20min, 1mA, F3 (EEG 10/20), reference right M. deltoideus
223783719|NCT01903538|DEVICE|Sham transcranial direct current stimulation|Sham transcranial direct current stimulation (tDCS) 40s, 1mA, F3 (EEG 10/20), reference right M. deltoideus
223783720|NCT04202380|DRUG|Azithromycin|Patients will receive Azithromycin orally 1000 mg
223783721|NCT04202380|DRUG|Ampicillin|All patients will receive Ampicillin 2gm IV every 6 hours for 2 days
223783722|NCT04202380|DRUG|Azithromycin|Azithromycin 500 mg orally once
223783723|NCT04202380|DRUG|Azithromycin|Azithromycin 250 mg orally daily for 4 days
223783724|NCT04437251|DEVICE|Transcranial direct current stimulation (tDCS)|Transcranial direct current stimulation (tDCS) is an non-invasive, low-intensity direct current stimulation. The stimulation intensity is very low (0- 2 mA) to only produce tingling sensation on the scalp. From literature, there were no serious adverse effects reported after 20-minute stimulation. The main temporary side effect is skill irritation, itching sensation at the stimulation site during or after stimulation.
223783725|NCT01881139|BEHAVIORAL|exercise training|
223783726|NCT00136955|DRUG|Irinotecan|An Open Labeled, Single-Arm, Multicentre Phase II Study To Evaluate The Efficacy And Safety Of Weekly Irinotecan (60mg/sqm, D1, 8, 15) Plus Cisplatin (60mg/sqm, D1) As First-Line Chemotherapy For Advanced Or Recurrent Squamous Cell Carcinoma Of The Uterine Cervix
223783727|NCT06223412|BEHAVIORAL|video-based climate change program|The participants in this group received a series of short videos, ranging between 30- 45 minutes/ each video revolved around five core themes including The road start to green planet, The ripple effect climate change on Health, Climate Change Literacy, Strengthen resilience to overcome climate related- psychological impacts, and Sustaining phase: closing session.
223783728|NCT06094088|BEHAVIORAL|Heated Yoga|Heated yoga described in arm/group description
223783729|NCT06094088|BEHAVIORAL|Non-Heated Yoga|Non-heated yoga described in arm/group description
223783730|NCT04450264|BEHAVIORAL|African Immigrant Breast Cancer Education Program|African immigrant women are at significant risk for not participating in preventive screening, such as for breast cancer. Thus, this project will culturally adapt an existing evidenced-based, the Witness Project, by identifying potential barriers and guided by the Health Belief Model incorporate those findings into a group-based narrative education program for English and French-speaking African immigrant women. The program content will include: (1) information about the benefits of early detection of breast cancer screening, (2) education about disparities in breast cancer, (3) disparities in breast cancer screening among African immigrant women, and (4) will address the unique barriers and facilitators of African immigrant women identified in Aim 1 of this study. The program will use a culturally matched peer approach to educate and model successful experiences with mammography screening.
223783731|NCT02048332|BIOLOGICAL|Viral specific VST Infusion|"VSTs will be infused into stem cell transplant recipients who have evidence of viral infection or reactivation defined as any of the below:~* Blood adenovirus PCR ≥ 1,000~* Blood CMV PCR ≥ 500~* Blood EBV PCR ≥ 9,000~* Plasma BKV PCR \>1,000~* Plasma JC Virus PCR \>1,000~* Evidence of invasive adenovirus infection or disease, defined as the presence of adenoviral positivity in one or more sites.~* Evidence of invasive CMV infection, eg pneumonitis, retinitis, colitis~* Evidence of invasive EBV disease/infection, EBV-associated lymphoproliferation (EBV-LPD) defined as proven EBV-LPD by biopsy or probable EBV-LPD defined as an elevated EBV DNA level in the blood associated with clinical symptoms (adenopathy or fever or masses on imaging) but without biopsy confirmation, or EBV-associated malignancies.~* Evidence of symptomatic BK virus infection, which may include symptomatic hemorrhagic cystitis, or BK nephropathy.~* Evidence of PML or other CNS infection due to JC virus."
223783732|NCT05678634|BEHAVIORAL|Declarative learning with immediate feedback|Children will complete a paired associate learning task on a computer. Each response on half of the blocks will be followed by performance feedback. Feedback will be provided 500 ms following a response (button press)
223783733|NCT05678634|BEHAVIORAL|Declarative learning with delayed feedback|Children will complete a paired associate learning task on a computer. Each response on half of the blocks will be followed by performance feedback. Feedback will be provided 5000 ms following a response (button press)
223783734|NCT05678634|BEHAVIORAL|Probabilistic learning with immediate feedback|Children will complete a probabilistic learning task on a computer. Each response on half of the blocks will be followed by feedback. Feedback will be provided 500 ms following a response (button press)
223783735|NCT05678634|BEHAVIORAL|Probabilistic learning with delayed feedback|Children will complete a probabilistic learning task on a computer. Each response on half of the blocks will be followed by feedback. Feedback will be provided 5000 ms following a response (button press)
223702536|NCT02646514|DEVICE|stenting|Metal stents are inserted to ensure adequate decompression and bile drainage. The diameter and stent lengths can be changed according to the lesion.
223702537|NCT06832059|OTHER|The precise diet intervention|The intervention includes training and education in CGM use and reduction in overall carbohydrate intake guided by individualized flexible nutrition recommendations, with adjustments made according to postprandial blood glucose responses. Staff will guide participants in the daily carbohydrate intake with personalized adjustments to accommodate individual needs by the individuals. The primary goal is to minimize the participant's time spent above 10 mmol/l
223783736|NCT05678634|BEHAVIORAL|Word learning task with active feedback|Children will complete a two-choice nonword learning task in which they will be tasked with learning to associate novel objects with novel nonword names through trial and error guided by feedback. Each response will be followed by feedback either indicating that the response is correct or prompting the child to try again (i.e., to correct an error)
223783737|NCT05678634|BEHAVIORAL|Word learning task with passive feedback|Children will complete a two-choice nonword learning task in which they will be tasked with learning to associate novel objects with novel nonword names. Regardless of response accuracy on each trial, each response will be followed by a visual presentation of the correct response.
223783738|NCT00811148|PROCEDURE|Tissue Bank|Collection of clinical data and tumor tissue.
223783739|NCT06787040|OTHER|Resource-Stratified Protocol|The interventions are a set of protocols that accounts for varying levels of resources available at any given time for patients with severe traumatic brain injury across prehospital, ED, neurosurgery, and ICU. Protocols are available in the NIH-PMC website at: https://pmc.ncbi.nlm.nih.gov/articles/PMC7055642/
223783740|NCT01724138|DRUG|Deferasirox|Patients will start their deferasirox treatment with a dose of 20 mg/kg/day.
223783741|NCT01016665|DRUG|Anastrozole|Tamoxifen 20mg and anastrozole 1 mg
223783742|NCT03882125|BEHAVIORAL|Mindfulness-based relapse prevention|Psychosocial intervention integrating mindfulness practice and cognitive behavioral relapse prevention approaches
223783743|NCT05476224|BIOLOGICAL|Blood sample of 30 ml|The parameters analyzed on this blood sample: Fasting blood glucose, HbA1C, creatinine, creatinine clearance (MDRD), fasting lipid profile (total cholesterol, HDL cholesterol, LDL cholesterol, triglycerides.
223783744|NCT02136173|DEVICE|Heliosphere bag (air filled balloon)|sequential balloons . Heliosphere bag (air filled balloon)
223783745|NCT03082963|DEVICE|Electrogram Morphology Mapping (EMR)|Fifteen second AF recordings will be made using a multipolar electrode catheter to map the entire right atrium \& then the left atrium.
223783746|NCT00547391|PROCEDURE|Tonsillectomy|Tonsillectomy under general anesthesia as a day surgery using diathermy or blunt dissection. Follow up started from the day of surgery.
223783747|NCT00547391|OTHER|no intervention|No intervention (controls). Follow up started from the day of randomization.
223783748|NCT04401579|OTHER|Placebo|The matching Baricitinib placebo contains lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, and magnesium stearate. The coating for the placebo tablet is identical to that of the corresponding active tablet.
223783749|NCT04401579|DRUG|Remdesivir|Drug Remdesivir is a single diastereomer monophosphoramidate prodrug designed for the intracellular delivery of a modified adenine nucleoside analog GS-441524. In addition to the active ingredient, the lyophilized formulation of Remdesivir contains the following inactive ingredients: water for injection, sulfobutylether beta-cyclodextrin sodium (SBECD), and hydrochloric acid and/or sodium hydroxide.
223783750|NCT04401579|DRUG|Baricitinib|Baricitinib is a Janus kinase (JAK) inhibitor with the chemical name \[1-(ethylsulfonyl)-3-(4-(7Hpyrrolo(2,3-d)pyrimidin-4-yl)-1H-pyrazol-1-yl)azetidin-3-yl\]acetonitrile Each tablet contains 2 mg of baricitinib and the following inactive ingredients: croscarmellose sodium, magnesium stearate, mannitol, microcrystalline cellulose, ferric oxide, lecithin (soya), polyethylene glycol, polyvinyl alcohol, talc and titanium dioxide.
223783751|NCT03521635|DRUG|Pramipexole SR|Tablets
223783752|NCT03521635|DRUG|Pramipexole IR|Tablets
223783753|NCT00272168|BEHAVIORAL|Maryland Program for Vocational Effectiveness|psychosocial intervention that combines elements of cognitive-behavioral therapy (CBT) with work-related social skills training and basic problem solving training (SST)
223783754|NCT00272168|OTHER|Supportive Treatment for SMI|Sessions are interactive, supportive, flexible, and unstructured, and are intended to help patients adjust to their new jobs and understand how working affects their lives. The therapist stance is non-directive, and there is an emphasis on having patients share with one another, rather than having the therapists dictate the content of group sessions. The primary goals of the therapists are to engage patients in treatment and to generate discussion among members.
223783755|NCT02744534|DRUG|FACBC PET-CT Scan|"One hour prior to scanning, participants will drink one glass (450 ml) of oral contrast to allow for better pictures of abdomen and pelvic organs. The participants will have their temperature taken before and after the injection of the FACBC. Blood pressure and pulse will be taken every 15 minutes during the PET scan.~Participants will lie on a scanning bed and the bed will move slowly through the PET/CT scanner. This portion usually takes about one minute. Following this the FACBC will by administered by an intravenous (IV) catheter and the PET scan portion of the exam will begin. The table moves slowly through the scanner and many sets of PET-CT images are produced. When the imaging is complete, the scanner will send the results to a computer. The computer then generates a number of images that will be reviewed by a specially trained radiologist."
223783756|NCT02744534|PROCEDURE|Three-dimensional ultrasound-guided biopsy|"A lubricated rectal probe will be inserted and a local anesthetic to numb the prostate will be administered. The ultrasound probe allows visualization of the prostate in two-dimensional (2D) images. The probe connects to a computer that will link to the FACBC PET-CT scan results that the participant has already had performed. These combined images will provide a three-dimensional (3D) image from the FACBC PET-CT scan previously obtained as well as real-time, 2D ultrasound images, resulting in an improved visualization tool to target the biopsy needle to a suspicious lesion.~The needle tip position for each biopsy sample will be recorded on the real-time ultrasound images; this information allows the physician to either re-biopsy the same area for a follow-up examination or not to re-biopsy the same region if the original biopsy was negative.~This biopsy process is estimated to take about 10 minutes."
223783757|NCT02744534|PROCEDURE|Standard transrectal ultrasound (TRUS) guided biopsy|A lubricated ultrasound probe of about 2.5 cm in diameter is gently inserted into the rectum and a local anesthetic to numb the prostate is administered. The ultrasound probe allows visualization of the prostate in two-dimensional (2D) images and allows for the placement of a biopsy needle that collects samples of the prostate. Usually, a total of 12 biopsy specimens are collected. The procedure takes about 20 minutes. This TRUS-guided biopsy is considered as the standard method for prostate cancer diagnosis.
223783758|NCT03321331|COMBINATION_PRODUCT|Lark (JITAI)|Lark works as a just-in-time adaptive intervention (JITAI), providing interactive counseling through a chat-style interface. The app prompts users to self-monitor, set goals, review them, provides feedback, and social support.
223783759|NCT03321331|COMBINATION_PRODUCT|MyFitnessPal (no JITAI)|MyFitnessPal (MFP) is a calorie counting app, which relies on user input for food tracking, but automatically tracks activity through the phone or through integrations with wearable devices. This app provides allows to set weight and caloric goals, review them and to receive feedback, but it has limited social support, a feature that is generally lacking in calorie-counting apps.
223783760|NCT00071487|DRUG|Placebo|Placebo IV plus standard therapy (SOC) for SLE; placebo administered on Days 0, 14, 28, and every 28 days thereafter through 52 weeks in the double-blind period. In the open-label extension period, placebo patients who opted to participate received belimumab 10 mg/kg IV plus SOC every 28 days for an additional 24 weeks.
223783761|NCT00071487|DRUG|Belimumab 1 mg/kg|Belimumab 1 mg/kg IV plus standard therapy (SOC) for SLE; belimumab 1 mg/kg administered on Days 0, 14, 28, and every 28 days thereafter through 52 weeks in the double-blind period. In the open-label extension period, patients who opted to participate either continued on the same dose of belimumab or may have been switched to belimumab 10 mg/kg at the investigator's discretion for an additional 24 weeks.
223783762|NCT00071487|DRUG|Belimumab 4 mg/kg|Belimumab 4 mg/kg IV plus standard therapy (SOC) for SLE; belimumab 4 mg/kg administered on Days 0, 14, 28, and every 28 days thereafter through 52 weeks in the double-blind period. In the open-label extension period, patients who opted to participate either continued on the same dose of belimumab or may have been switched to belimumab 10 mg/kg at the investigator's discretion for an additional 24 weeks.
223783763|NCT00071487|DRUG|Belimumab 10 mg/kg|Belimumab 10 mg/kg IV plus standard therapy (SOC) for SLE; belimumab 10 mg/kg administered on Days 0, 14, 28, and every 28 days thereafter through 52 weeks in the double-blind period. In the open-label extension period, patients who opted to participate continued on belimumab 10 mg/kg for an additional 24 weeks.
223783764|NCT03790176|DRUG|Intravenous Infusion|see arm/group description. NO INTERVENTION IN STUDY GROUP B! PATIENTS OF GROUP B WILL RECEIVE CAZ/AVI INDEPENDENTLY FROM STUDY PARTICIPATION BASED ON DECISION OF THEIR TREATING PHYSICIAN
223783765|NCT04410432|BIOLOGICAL|Blood sample collection|"Additional blood volumes taken during a routine care blood test:~* 1 dry tube 5 mL for isolation and freezing of serum~* 1 x 5 mL EDTA tube to isolate and freeze plasma~* 8 heparinized 6 mL tubes for flow cytometry study"
223783766|NCT05192525|DEVICE|mChemotherapy|"The intervention is composed of one core intervention mChemotherapy, one pre-chemotherapy consultation, and two app follow-up visits. mChemotherapy will be specifically utilized to facilitate symptom self-management for intervention group covering chemotherapy for six weeks. The mChemotherapy includes six components: (i) self-monitoring, (ii) alerts, (iii) reminder, (iv) consultation, (v) my prescription, (vi) knowledge base. Intervention group participants will be given an individual username and password to log in to the mChemotherapy platform. The intervention nurses will deliver the intervention and contact patients through this platform."
223783767|NCT02566395|RADIATION|Radiation|1,200 cGy, delivered in 8 fractions of 150 cGy bid x 4 days
223783768|NCT02566395|DRUG|Cyclophosphamide|Cyclophosphamide 60 mg/kg IV daily x 2 consecutive days
223783769|NCT02566395|BIOLOGICAL|Donor Lymphocyte Infusion (DLI)|DLI containing 1 x 10E8/kg donor T-cells
223783770|NCT02566395|BIOLOGICAL|Haploidentical Stem Cell Transplantation|2-10 x 10E6/kg donor CD34+ selected cells
223783771|NCT02286544|BIOLOGICAL|Salmonella typhi vaccine (Typhim Vi®)|A peripheral venous catheter will be inserted. This catheter will be used to collect blood sample during the study day. In addition, peripheral oxygen saturation will be measured by pulse oximetry. After baseline venous blood samples have been collected, all study participants will receive 0.5 mL of the Salmonella typhi vaccine as an intramuscular injection (Typhim Vi®, Sanofi Pasteur MSD, injection solution 25 microgram/0.5 mL) Venous blood samples will be collected at 3, 6 and 8 hours after baseline. After the 8-hour blood sampling, the peripheral venous catheter will be removed and the study day ended.
223783772|NCT02286544|DRUG|Oxygen (Oxymask®)|"As in arm 1. Half an hour after vaccination is administered, oxygen treatment will be initiated at 6 L/min via Oxymask® and continued for 6 hours. During oxygen treatment peripheral oxygen saturation will be measured by pulsoximetry.~Venous blood samples will be collected at 3, 6 and 8 hours after baseline. After the 8-hour blood sampling, the peripheral venous catheter will be removed and the study day ended."
223783773|NCT02286544|DRUG|Atorvastatin|As in arm 1. Half an hour after vaccination is administered, oxygen treatment will be initiated at 6 L/min via Oxymask® and continued for 6 hours. During oxygen treatment peripheral oxygen saturation will be measured by pulsoximetry. A single dose of Atorvastatin 80 mg will be given immediately prior to start of oxygen. Venous blood samples will be collected at 3, 6 and 8 hours after baseline. After the 8-hour blood sampling, the peripheral venous catheter will be removed and the study day ended.
223783774|NCT00974168|RADIATION|Cumulative BED ≤ 100|Radiation
223783775|NCT00974168|RADIATION|Cumulative BED ≤ 130 Gy2|Radiation
223783776|NCT01227889|DRUG|GSK2118436|150 mg twice daily
223783777|NCT01227889|DRUG|Dacarbazine (DTIC)|Intravenous (IV), 1000 mg/m2 every 3 weeks until initial progression
223783778|NCT03268811|DRUG|Teduglutide|Teduglutide 0.05 mg/kg SC injection will be administered once daily into 1 of the 4 quadrants of the abdomen or either thigh or arm.
223783779|NCT01421875|GENETIC|DNA methylation analysis|
223783780|NCT01421875|GENETIC|RNA analysis|
223783781|NCT01421875|GENETIC|gene expression analysis|
223783782|NCT01421875|GENETIC|microarray analysis|
223783783|NCT01421875|GENETIC|nucleic acid sequencing|
223783784|NCT01421875|OTHER|laboratory biomarker analysis|
223783785|NCT00364481|DRUG|omeprazole|
223783786|NCT00364481|BEHAVIORAL|Tongue exercises|
223783787|NCT02824913|DRUG|P-321 Ophthalmic Solution|
223783788|NCT02824913|DRUG|P-321 Ophthalmic Solution placebo|
223783789|NCT00220194|DRUG|leuprolide acetate|
223783790|NCT06526572|DIAGNOSTIC_TEST|Brain wave analysis using electroencephalography (EEG).|Asessment of pain with objective neurophysiological assessment through brain wave analysis using electroencephalography (EEG).
223783791|NCT06526572|DIAGNOSTIC_TEST|Numerical rate Scale (NRS)|Asessment of pain with the subjective numercal rate scale method (NRS
223783792|NCT02390804|DEVICE|single-port laparoscopic hysterectomy(single port trochar)|perform laparoscopic hysterectomy via single-port access
223783793|NCT02390804|DEVICE|multi-port laparoscopic hysterectomy(multi port trochar)|perform laparoscopic hysterectomy via multi-port access
224263787|NCT05811689|DIAGNOSTIC_TEST|sm tbs group|"After collecting anthropometric data, information on environmental factors and lifestyle (smoking, alcohol intake, physical activity, sun exposure, vitamin D supplementation, fish consumption) will be acquired through a questionnaire.~The genetic and environmental aspects related to multiple sclerosis will also be studied. Disability status will be assessed through the Kurtzke Extended Disability Status Scale (EDSS). \[10\] All recruited patients will be administered the questionnaire (Multiple Sclerosis Quality of Life-54 (MSQOL-54) composed of 14 scales and 54 items. The scales investigate physical functions, limitations with respect to physical and emotional role, pain, emotional well-being, degree of energy, perceptions of one's health, social, cognitive and sexual functioning, distress, changes in health, satisfaction with sexual functioning and quality of life in general."
224263788|NCT02252120|DEVICE|Supreme|
224263789|NCT02252120|DEVICE|Laryngeal Tube|
223783794|NCT03197792|OTHER|All patients|"TEE is performed before cardiopulmonary bypass (before the opening of the pericardium, if possible) and immediately after weaning from cardiopulmonary bypass and optimization of the hemodynamic status by the attending anesthesiologist. A detailed ultrasound examination including portal vein pulsatility, splenic vein pulsatility, right and left ventricular global longitudinal strain and right and left systolic and diastolic function is recorded. A measure of portal vein pulsatility using TTE is also recorded before the onset of general anesthesia and on the morning of the 7th postoperative day.~On the 7th postoperative day, the investigators will evaluate for the presence of the primary outcome, POD + death."
223783795|NCT00354523|DRUG|Capecitabine (Xeloda)|Starting Dose 500 mg/m\^2 twice a day Days 1-14 of 21 Day Cycle.
224263790|NCT01126463|DRUG|188Re-SSS Lipiodol|Hepatic Intra-Arterial Administration of radio-active lipiodol.
224263791|NCT06683846|DRUG|Ivocizumab|Administered via intravenous (IV) infusion
224263792|NCT07015086|BEHAVIORAL|Guided Imagery and Positive Birth Experience Sharing|The positive experience will be shared by one of the researchers and the pregnant women's questions will be answered after the sharing. The mental imagery techniques prepared by Rossman (2015) to facilitate birth will be used for the mental imagery application. After the training, the mental imagery instructions will be given to the pregnant women as an audio recording in mp3 format. The pregnant women will be asked to do the mental imagery once or twice a day for at least 8 weeks. The mental imagery application takes approximately 20 minutes. The pregnant women will be reminded to do the application every day via the Whatsapp® application. The pregnant women will be asked to mark whether they do the application every day or not on the weekly follow-up chart.
224263793|NCT05288686|PROCEDURE|sentinel lymph node biopsy procedure|Patient received respective tracer injection and sentinel lymph node biopsy was performed in the operation theatre with the corresponding device.
224263794|NCT06415903|DRUG|TQB3117 tablets|TQB3117 is a protein inhibitor.
224263795|NCT00880139|PROCEDURE|Blood sampling|Determination of cytokine plasma levels (ELISA)
224263796|NCT00880139|PROCEDURE|Noninvasive measurement of systemic hemodynamics|performed once
224263797|NCT00880139|PROCEDURE|Visual acuity assessment|ETDRS charts
224263798|NCT00880139|DEVICE|Blue field entoptic technique (Blue field stimulator, BFS-2050)|performed once
224263799|NCT00880139|PROCEDURE|Ophthalmic examination and fundus photography|7 + 1 standard fields
224263800|NCT00880139|DEVICE|Retinal Vessel Analyzer (DVA)|Assessment of retinal vessel reactivity to stimulation with flickering light
224263801|NCT00880139|DEVICE|High resolution optical coherence tomography (OCT)|performed once
224263802|NCT00440934|DEVICE|Amplitude-modulated electromagnetic fields|
224263803|NCT00926887|DEVICE|Erchonia(R) EML Laser|Low level laser red light of 635 nm and delivering 1.5 joules/cm2.
224263804|NCT00926887|DEVICE|Placebo Laser|Inactive light
224263805|NCT04454307|DRUG|Tramadol|tramadol 100 mg twice daily for 10 days
224263806|NCT04454307|OTHER|Standard care delivered in the isolation hospitals.|Oxygen ventilation.
224263807|NCT02584608|DRUG|ACTIMMUNE|
224263808|NCT04198363|DRUG|Vonoprazan|Vonoprazan Tablets
224263809|NCT04198363|DRUG|Amoxicillin|Amoxicillin Capsules
224263810|NCT04198363|DRUG|Clarithromycin|Clarithromycin Tablets
224263811|NCT04198363|DRUG|Bismuth Potassium citrate|Bismuth Potassium citrate
224263812|NCT04198363|DRUG|Esomeprazole|Esomeprazole Tablets
224263813|NCT04534790|RADIATION|Low Dose Radiotherapy|anti-inflammatory effect with low-dose radiation to the lungs
224263814|NCT04893408|OTHER|observational study|
224263815|NCT05204368|DRUG|Combination of Imipenem/Cilastatin and XNW4107|Imipenem/Cilastatin 500mg/500mg and XNW4107 250mg for injection
224263816|NCT05204368|DRUG|Meropenem|Meropenem 1g for injection
224263817|NCT05344118|OTHER|Survey|REDCap survey
224263818|NCT04739358|DRUG|Tepotinib|Subjects will receive tepotinib daily in cycles of 21-day duration. Subjects in the Combination Therapy arm will continue to receive their last tolerable dose of tyrosine kinase inhibitor (TKI) together with tepotinib.
224263819|NCT03067987|DEVICE|Low Intensity Linear Shockwave Device for the Treatment of Erectile Dysfunction.|"This is a prospective, randomized, clinical study aimed to evaluate the safety and efficacy of the two treatment schedules on symptomatic erectile dysfunction patients. The patients are randomized in a 1:1 ratio into two active treatment groups.~Group A: 5 daily sessions within a week (Monday, Tuesday, Wednesday, Thursday, Friday), in which 720 shocks of treatment energy will be applied in every session to each treated region (left and right corpora cavernosa and crura).~Group B: Three sessions per week (Monday, Wednesday, Friday) for 2 consecutive weeks, in which 600 shocks of treatment energy will be applied in every session to each treated region (left and right corpora cavernosa and crura)~."
224263820|NCT00004398|DRUG|heme arginate|
224263821|NCT00004398|DRUG|tin mesoporphyrin|
224263822|NCT03442322|OTHER|transdisciplinary approach|This approach is integrated across disciplines and provides core training for all providers, staff members, and stakeholders, using a common language to address care concerns and support continuity and sustainability;
224263823|NCT03442322|OTHER|multidisciplinary approach|This is a problem-based approach that draws on the expertise of individual healthcare providers (e.g., occupational therapy) to address care concerns.
224263824|NCT05713058|BEHAVIORAL|eTRC diet|12-week dietary prescription with moderate energy restriction (approximately 200 kcal/day) focusing on the distribution of macronutrients within the day so as to avoid carbohydrate consumption after lunch
224263825|NCT05713058|BEHAVIORAL|Control diet|12-week dietary prescription with moderate energy restriction (approximately 200 kcal/day) without any recommendations on the distribution of macronutrients within the day
224263826|NCT02082808|DRUG|DTG|DTG is provided as 9 millimetre white, film-coated, round tablets debossed with SV 572 on one side and 50 on the other side
224263827|NCT02082808|DRUG|DCV|DCV is provided as a plain, green, biconvex, pentagonal film-coated tablet
224263828|NCT06022146|DRUG|Rifampin and Isoniazid|3HR regimen of isoniazid and rifampicin once daily for three months
224263829|NCT06022146|DRUG|isoniazid and rifapentine|12-dose ultra-short TPT 1H3P3 regimen of isoniazid and rifapentine 3 times a week for one month
224263830|NCT05238857|OTHER|Assessment|There will be no intervention. Only assessments will be taken from the patients and data will be analyzed.
223783796|NCT00354523|DRUG|DTIC-Dome (Dacarbazine)|Starting Dose 250 mg/m\^2 a day on Days 1-3 of 21 Day Cycle.
223783797|NCT00354523|DRUG|Gleevec (Imatinib Mesylate)|Starting Dose 400 mg a day on Days 1-21 of 21 Day Cycle.
223783798|NCT04200066|DRUG|Temozolomide, Tamoxifen, Maprotiline|Subjects will receive a combination of temozolomide and tamoxifen for two weeks. After that, they will receive a combination of temozolomide, tamoxifen and maprotiline for the remainder of the study. All drugs are administered orally. Subjects will undergo visits at the beginning of week 3, week 5 and week 7 that will involve multiple blood draws and ECGs to evaluate for pharmacokinetics and drug interactions. Response will be assessed every two months with an MRI and patients will continue on study as long as their tumors are under control and they are tolerating the regimen.
223783799|NCT05150730|OTHER|Multi professional care|Participants were instructed to respect their pain threshold during body practice and the evolution of the participants happened gradually and individually. Associated with the practice of exercise, workers received information about their disease, chronic pain, guidelines for daily activities, and the importance of physical exercise. In the second hour, the responsible psychologist addressed issues such as the repercussions of illnesses on the individual's social and affective life, self-esteem, self-image, conformism, and self-indulgence after the illness and prospects for the future. Throughout the program, participants also received informative lectures from other professionals, such as social workers, nurses, and dentists.
223783800|NCT06342362|DRUG|Magnesium sulfate|Participants would be randomly assigned to either the treatment group (receiving magnesium sulfate) or the control group (receiving a placebo or standard treatment).
223783801|NCT06342362|OTHER|placebo or standard treatment)|placebo or standard treatment)
223783802|NCT01169467|DRUG|Standard-of-Care plus Dexmedetomidine|Subjects who are treated with dexmedetomidine (Precedex) in addition to the standard of care sedation regiment
223783803|NCT01169467|OTHER|Standard-of-Care|Subjects who are treated with the standard of care sedation regiment only.
223783804|NCT04827212|BEHAVIORAL|Companion|"Companion integrates wearable sensing with the smartphone to develop a behavior-aware, virtual system that uses a human-in-the-loop approach to enable meaningful two-way communication. Companion builds rich models of typical behavior using sensors and context sensitive ecological momentary assessment to deliver intervention components and behavior change strategies using socially engaging, contextually salient, and tailored text-message conversations in near-real-time."
223783805|NCT01008033|DRUG|IDP-108|Topical application once a day for 48 weeks
223783806|NCT01008033|DRUG|Vehicle|Topical application once a day for 48 weeks
224263831|NCT01439451|PROCEDURE|perturbation training|The experimental and control groups will participate in 3 month training program twice a week 20 minutes each training session
224263832|NCT06874764|OTHER|Wireless Lighting Reaction System Training(Agility plus Cognitive)|Agility training and Cognitive trainings(cognitive trainings ready within the device: Eye for detail, Hawk eye, Juggle Factor)
224263833|NCT06544811|OTHER|Smoking Cessation Program|A free text message smoking cessation program that provides 24/7 encouragement, advice, and tips to those trying to quit smoking.
224263834|NCT06544811|OTHER|Cultural Smoking Cessation Program|A free text message smoking cessation program that provides 24/7 encouragement, advice, and tips to those trying to quit smoking and has been developed for American Indian and Alaska Native persons.
224263835|NCT07046949|PROCEDURE|ANTERİOR QUADRATUS LUMBORUM BLOCK|Ultrasound-guided anterior QL block performed preoperatively
224263836|NCT07046949|DRUG|Parenteral administration of analgesics|Intravenous opioids or NSAIDs used perioperatively.
224263837|NCT07046949|PROCEDURE|General Anesthesia (GA)|Standard general anesthesia per continious 1% propofol infusion and propofol bolus administration, atracurium and fentanyl administration.
224263838|NCT00457067|DRUG|Ranibizumab|
224263839|NCT07061847|DRUG|Lidocaine (drug)|"The study intervention involves the use of 1% cardiac preservative-free lidocaine. Lidocaine is a local anesthetic commonly used in medical procedures to numb a specific area of the body. In this case, the lidocaine is formulated at a concentration of 1% and will be diluted to 50 mL with normal saline.~This treatment is an intra-arterial bilateral lidocaine infusion into the middle meningeal artery (i.e. this is a lidocaine infusion into the brain blood vessels to turn off the pain receptors responsible for causing chronic headaches). Lidocaine is an FDA approved anesthetic (i.e. pain killer) used in common medical practice. Lidocaine, however, has not yet been approved by the FDA for this particular use. For this reason, the use of lidocaine in this study is considered investigational."
224263840|NCT07061847|PROCEDURE|Lidocaine Procedure|All patient who meet eligibility criteria at their baseline visit will be scheduled for the Liocaine procedure.
224263841|NCT06765291|BEHAVIORAL|QuitVaping|QuitVaping is a manualized intervention based on the American Lung Association smoking cessation program modified with adolescent appropriate content and language for vaping cessation from the vaping section of teen.smokefree.gov and the Truth Initiative. These behavioral support sessions will be delivered weekly during the 12-week treatment phase via videoconference or in- person.
224263842|NCT06765291|BEHAVIORAL|This is Quitting (TIQ)|A free, publicly available text message vaping cessation program from Truth Initiative, designed specifically to help adolescents who vape nicotine quit. Participants who set a quit date receive messages for a week preceding it and 30 days afterward that include encouragement and support, skill- and self-efficacy building exercises, coping strategies, and information about the risks of vaping, benefits of quitting and cutting down to quit.
224263843|NCT07064603|PROCEDURE|TCAF|tunnel coronal advanced flap
224263844|NCT06752707|DEVICE|MiGo Tracker|Perform home exercise sessions while wearing MiGo Tracker device that logs exercise data.
224263845|NCT06752707|OTHER|Conventional home exercise program|Exercise following printed sheets or booklet
224263846|NCT07060924|BEHAVIORAL|Game-Based Learning (GBL)|Participants in this group received practical training in peripheral intravenous cannulation (PIVC) using a game-based learning (GBL) simulation platform called 3D Medsim. The platform offered a scenario-based training environment that included a structured sequence of pre-test, simulated procedural performance, and post-test. Students were required to perform virtual tasks such as preparing the patient, selecting the correct equipment, identifying the puncture site, and performing cannulation. The simulation provided interactive feedback and scoring. The application was accessible via PC, tablet, or smartphone, allowing students to practice flexibly. Training was conducted under the supervision of an anesthesiologist.
223783807|NCT04250272|PROCEDURE|Thoracoscopic lobectomy|Thoracoscopic lobectomy was performed for lung cancer
223783808|NCT04898608|OTHER|Intradialytic Exercise|"Participants will do concurrent exercise (a combination of aerobic exercise and resistance training) for 30-60 minutes during the second hour of their routine hemodialysis sessions.~To determine the intensity of the prescribed exercise, maximum heart rate is used for aerobic workout and 1RM for resistance protocols.~Exercises will be performed at a moderate exercise intensity (12-14 on the Borg RPE Scale).~All protocols are tailor-made based on each individual's needs and physical abilities."
223783809|NCT04691765|DRUG|Kineret|escalating doses of drug will be administered to 3 groups of 4 patients for 7 months
223783810|NCT02264067|DRUG|Talsaclidine|
223783811|NCT02264067|DRUG|Placebo|
223783812|NCT03108924|DRUG|Gefapixant|After an overnight fast participants receive a single oral dose of 50 mg gefapixant, in one 50 mg tablet.
223783813|NCT03302962|BEHAVIORAL|Intensive Asthma Education|"One half (54) of the identified cases were randomized to receive the previously established BREATHE study educational program, emphasizing patient-centered, self management of asthma. Periodic follow-up through personal contact and surveillance of IHS RPMS or other medical provider records was conducted."
223783814|NCT03939286|OTHER|Clinical-neurological and neuropsychological tests|The tests include established standardized questionnaires and detailed clinical neuropsychological examinations (e.g., tests on cognition and perception). In order to avoid exercise effects in multiple examinations, so-called parallel procedures should be used.
223783815|NCT03939286|DIAGNOSTIC_TEST|Blood sampling|Venous blood sampling (40 ml) is performed according to the usual criteria of sterile working at baseline and after intervention.
223783816|NCT03939286|OTHER|Assessment of physical activity via fitness tracker/diary|All study participants, regardless of group classification, are randomly selected for a period of one week using Fitbit Charge 2® fitness trackers. The study participants are asked in this context to pursue their regular activity and to wear the bracelets for a week throughout. All study participants are asked to document their activities in a hand-written diary.
223783817|NCT03939286|OTHER|MRI-examinations|Standard MRI-methods, Sodium MRI, Phosphor MRS, Wholebody-Fat-MRI
223783818|NCT04634604|DRUG|Bevacizumab|For infants randomized to bevacizumab, the Intravitreous bevacizumab 0.063 mg injection will be given no later than 2 days after the diagnosis of type 1 ROP. The ophthalmologist may choose to give the intravitreous injection in the operating room or at the bedside, with or without anesthesia, after consultation with the attending neonatologist. A binocular indirect ophthalmoscope with an appropriate condensing lens should be available, and the pupils should be dilated.
223783819|NCT04634604|PROCEDURE|Laser|For infants randomized to laser treatment, it will be given in conjunction with a binocular indirect ophthalmoscope and an appropriate condensing lens, by a study-certified ophthalmologist experienced in the use of this equipment. The treating investigator will be certified as having sufficient experience with laser for ROP, and adequacy of laser treatment will be confirmed by expert review of photographs. Special laser precautions, as mandated by OSHA and facility standards, will be followed.
223783820|NCT03874364|DEVICE|Lidocaine gel|10 ml 2% lidocaine gel is instilled with a syringe through the length of the urethra and kept in site at least 5 minutes prior the introduction of the cystoscope.
223783821|NCT03874364|OTHER|Counselling|Patients receive a brochure in the waiting room explaining the procedure in details.
223783822|NCT03874364|OTHER|Monitor|Patients are allowed to view and follow the procedure on a monitor connected to the cystoscope's camera.
223783823|NCT03874364|DEVICE|Lubricating gel|10 ml plain lubrificant gel is instilled with a syringe through the length of the urethra and kept in site at least 5 minutes prior the introduction of the cystoscope.
223783824|NCT03874364|OTHER|No counselling|Patients won't receive a brochure in the waiting room explaining the procedure in details.
223783825|NCT03874364|OTHER|No monitor|Patients are not allowed to view and follow the procedure on a monitor connected to the cystoscope's camera.
223783826|NCT00189371|DRUG|paclitaxel, carboplatin, epoetin alpha|
223783827|NCT03507166|DRUG|RC48-ADC|2 mg/kg IV every 2 weeks
223783828|NCT03434119|DRUG|Insulin glargine/Lixisenatide|Insulin glargine (100 units per milliliter \[U/mL\]) and lixisenatide (33 micrograms per milliliter \[mcg/mL\]) self administered by a subcutaneous injection using a prefilled pen. Dose was individually titrated to achieve target fasting self-monitoring of plasma glucose (SMPG) of 80 to 100 milligrams per deciliter (mg/dL) (4.4 to 5.6 millimoles per liter \[mmol/L\]) while avoiding hypoglycemia.
223783829|NCT03434119|DRUG|Insulin glargine (HOE901)|Insulin glargine 100 U/mL self-administered by a subcutaneous injection using a prefilled pen. Dose was individually titrated to achieve target fasting SMPG of 80 to 100 mg/dL (4.4 to 5.6 mmol/L) while avoiding hypoglycemia.
224263847|NCT07060924|BEHAVIORAL|Model Arm Practice|Participants in this group practiced PIVC using a high-fidelity model arm simulator designed to replicate human anatomy and venous access. The training model included artificial veins (basilic, cephalic, median cubital, and metacarpal) with realistic skin layers and a circulation system that mimicked blood flow. Students practiced cannulation techniques including vein localization, needle insertion, and catheter placement. The hands-on training provided tactile and visual feedback, and all procedures were supervised by an anesthesiologist. This method aimed to develop psychomotor skills and confidence through realistic simulation.
224263848|NCT07068646|PROCEDURE|CT myocardial thickness map guided PV isolation group|Pulmonary vein isolation will be performed using the PulseSelect™ pulsed field ablation system. A pre-procedural cardiac CT scan will be used to generate an atrial myocardial thickness map. In this group, atrial segments with wall thickness \>2.5 mm identified on the CT map will receive additional PFA applications (up to 8 per PV) to ensure transmural lesion formation. All other segments will receive the standard minimum of 8 applications per vein. The ablation catheter will remain stationary to allow lesion stacking when needed.
223783830|NCT03434119|DRUG|Background therapy|Oral Anti diabetics Drugs (OADs) administered orally according to the locally approved label.
223783831|NCT04888000|OTHER|Educational Intervention|Professional development program provided to small groups of health care professionals in three different sessions over a period of one month with additional independent individual work to be completed between sessions.
223783832|NCT02700282|BEHAVIORAL|Backpack Carrying|A 12,5% of body weight backpack will be used for each measurement. Lung function will be assessed while carrying a double strap backpack, a mono shoulder backpack and without a backpack.
223783833|NCT03353428|BIOLOGICAL|LC-CTLs|2 to 4 infusions, once a week, for 1x10\^5\~4x10\^6 CTLs/kg via IV, chest or tumor injection each time
223783834|NCT05846009|DRUG|SAR442501|Subcutaneous injection
223783835|NCT05846009|DRUG|Placebo|Subcutaneous injection
223783836|NCT01060293|DRUG|High-dose furosemide|High-dose furosemide (HDF): 20 mg/h continuous IV administration for 8 hours
223783837|NCT01060293|DRUG|Low-dose furosemide|Low-dose furosemide (LDF): continuous IV administration of 5 mg/h furosemide
223783838|NCT01060293|DRUG|Low-dose furosemide combined with low-dose dopamine|Low-dose furosemide combined with low-dose dopamine (LDFD): continuous IV administration of 5 mg/h furosemide combined with 5 μg/kg/min dopamine for a total of 8 hours
223783839|NCT06430567|DEVICE|Blood flow restriction (50% AOP compression) in the rehabilitation phase after Latarjet surgery for chronic shoulder instability|"Participants undergoing shoulder instability surgery (Latarjet procedure) by a single surgeon will receive standard physiotherapy (2 sessions per week) before being randomized into 3 groups at their 6th postoperative week check-up:~Group 1) BFR Group with 50% AOP compression~Group 1 will perform a 30-minute strengthening session twice weekly during postoperative weeks 7 to 14. They will do 4 exercises, completing 4 sets with 30-second rest intervals and 1 minute between exercises, following 30-15-15-15 at 40% 1RM (repetition maximum)~Exercise :~External rotation with pulley/band Internal rotation with pulley/band Frontal elevation with hyperpronation Diagonal abduction-external rotation with pulley/band~BFR training will use the MadUp© system, placing the band proximally on the operated arm, with a central unit continuously monitoring and calibrating arm pressure."
223783840|NCT06430567|DEVICE|Blood flow restriction (10% AOP compression) in the rehabilitation phase after Latarjet surgery for chronic shoulder instability|"Participants undergoing shoulder instability surgery (Latarjet procedure) by a single surgeon will receive standard physiotherapy (2 sessions per week) before being randomized into 3 groups at their 6th postoperative week check-up:~Group 2) BFR Group with 10% AOP compression~Group 2 will perform a 30-minute strengthening session twice weekly during postoperative weeks 7 to 14. They will do 4 exercises, completing 4 sets with 30-second rest intervals and 1 minute between exercises, following 15-15-15-15 at 70% 1RM~Exercise :~External rotation with pulley/band Internal rotation with pulley/band Frontal elevation with hyperpronation Diagonal abduction-external rotation with pulley/band~BFR training will use the MadUp© system, placing the band proximally on the operated arm, with a central unit continuously monitoring and calibrating arm pressure."
223783841|NCT04998240|BIOLOGICAL|BBIBP-CorV - Inactivated SARS-CoV-2 vaccine (Vero cell)|"The Inactivated SARS-CoV-2 vaccine (Vero cell)- BBIBP-CorV manufactured by Beijing Institute of Biological Products (BIBP), China National Biotec Group (CNBG), Sinopharm, Beijing, People's Republic of China~Dose formulation: A liquid formulation containing 4μg total protein with aluminum hydroxide adjuvant (0·45 mg/mL) per 0·5 mL (2-dose schedule followed by a booster dose).~Mode of Administration:~Intramuscular~Storage Conditions: 2°C to 8°C"
224263849|NCT07068646|PROCEDURE|Empirical PV isolation group|Pulmonary vein isolation will be performed using the PulseSelect™ pulsed field ablation system according to a standardized empirical protocol. Each pulmonary vein will receive a minimum of 8 PFA applications without adjustment based on anatomical or CT-based parameters. Additional applications may be delivered at the operator's discretion based on procedural findings, but no wall thickness mapping will be used.
224263850|NCT07068165|DRUG|5mg lenalidomide|Lenalidomide 5mg/d combined with prednisone, prednisone at an initial dose of 0.6-0.8mg/kg/d for 2-4 weeks, then reduced by 5mg every 1-2 weeks until discontinued (within 24 weeks)
224263851|NCT07068165|DRUG|10mg lenalidomide|Lenalidomide 10mg/ day combined with prednisone, prednisone at an initial dose of 0.6-0.8mg/kg/ day for 2-4 weeks, then reduced by 5mg every 1-2 weeks until discontinued (within 24 weeks)
224263852|NCT07068165|DRUG|Prednisone monotherapy|The initial dose of prednisone was 0.6-0.8mg/kg/ day for 2-4 weeks, followed by 5mg every 1-2 weeks until withdrawal (within 24 weeks).
224263853|NCT07067203|DEVICE|Lafayette hand held dynamometer|"Muscle Strength Measurement:~The strength of the quadriceps (knee extensors) and hamstrings (knee flexors) of the amputated limb will be measured using a handheld digital dynamometer (Nicholas MMT, Lafayette Instruments). Measurements will be taken with the prosthesis in place. Quadriceps strength will be assessed in a supine position with the knee at 30° flexion, while hamstring strength will be assessed in a prone position with the knee at 20° flexion. Each participant will perform three maximal effort trials after a practice attempt. The highest value will be scaled to body mass for analysis."
224263854|NCT07067203|DIAGNOSTIC_TEST|Timed up and Go test|"Timed Up and Go (TUG) Test:~Participants will complete a standardized 3-meter TUG assessment to evaluate functional mobility. The test will be broken down into five components: standing, walking, turning, returning, and sitting. After one practice run, two timed trials will be conducted, and the average of both will be used for analysis. All procedures will be conducted by trained physical therapists following a standardized protocol."
224263855|NCT07068802|BEHAVIORAL|Message framing|Participants provided electronic informed consent with voluntary withdraw options. Randomization was implemented through a 1:1:1:1 allocation ratio to four conditions: Control group (Group 1, n=154) receiving a standard statement of HPV risks (In mainland China, HPV vaccines are currently approved only for female use. However, in other countries, they are also available for males. HPV can cause cancers throughout the body, from the head to the reproductive system. Thus, HPV vaccination can protect against many cancer types. Annually, over 120,000 Chinese are diagnosed with HPV-related cancers, with about 50,000 dying from them.); Intervention 1 (Group 2, n=152) adding male-specific health risks; Intervention 2 (Group 3, n=153) adding risk to female partners; Intervention 3 (Group 4, n=153) adding both personal risk and risk to female partners. The protocol involved sequential completion of pre-exposure questionnaires, timed 120-second message exposure, and immediate post-exposure asses
223783842|NCT04998240|BIOLOGICAL|Ad26.COV2.S (Recombinant, replication-incompetent adenovirus serotype 26 (Ad26) vector encoding a full-length and stabilized SARS-CoV-2 spike protein),|"Ad26.COV2.S (Recombinant, replication-incompetent adenovirus serotype 26 (Ad26) vector encoding a full-length and stabilized SARS-CoV-2 spike protein), manufactured by Johnson and Johnson in the United States of America.~Dose formulation: One dose (0.5 ml) contains contains 5 x 10 10 virus particles~Mode of administration: Intramuscular~Storage Conditions: 2°C to 8°C"
223783843|NCT04998240|BIOLOGICAL|Placebo - Normal saline (0.9% sodium chloride solution)|"Placebo - Normal saline (0.9% sodium chloride solution)~Dose formulation: Not Applicable~Mode of administration: Intramuscular~Storage conditions: 15°C to 30°C"
223783844|NCT00148343|DEVICE|Odstock Dropped-Foot Stimulator (ODFS)|Device implementation \& use for \~13 weeks (until 2nd Outcomes Assessment (1st post-treatment Outcomes Assessment)). The ODFS then will be returned to the investigators.
223783845|NCT00148343|OTHER|Conventional Standard of Care|Conventional standard of care (which may include implementation \& use of a study-specific Custom Molded Hinged Ankle Foot Orthosis (AFO)) for \~13 weeks (until 2nd Outcomes Assessment (1st post-treatment Outcomes Assessment)). The AFO, if implemented, may continue to be used afterwards since it is an element of the standard of care for this patient population.
223783846|NCT00148343|PROCEDURE|Traditional Physical Therapy Treatment|Traditional physical therapy treatment for 12 weeks.
223783847|NCT03579459|BIOLOGICAL|Clostridium difficile vaccine|Toxoid based Clostridium difficile vaccine
223783848|NCT03579459|BIOLOGICAL|placebo|Normal saline solution
223783849|NCT04153409|DRUG|LAT8881|Two 30 mg capsules of LAT8881
223783850|NCT04153409|DRUG|Placebo|Two capsules of placebo
223783851|NCT05319691|BEHAVIORAL|Yoga|The trial will be 24 weeks long and divided into two distinct parts: an initial 12-week Treatment Phase during which, yoga participants will receive a reproducible standardized weekly yoga intervention delivered virtually with additional resources for home practice, followed by a 12-week Follow-up Phase.
223783852|NCT04844281|DEVICE|Precision1® Daily Disposable Toric Contact Lens|Soft, toric contact lens used to correct distance vision and astigmatism.
223783853|NCT00353275|DRUG|Strict Glycemic control|Blood glucose target range is 80-110 mg/dL.
223783854|NCT00353275|DRUG|Conventional Glycemic Control|Blood glucose target range is 110-140 mg/dL.
223783855|NCT03448549|DRUG|Oxaliplatin|adjuvant chemotherapy
223783856|NCT03448549|DRUG|Tegafur，gimeracil and oteracil potassium|adjuvant chemotherapy
223783857|NCT03448549|DRUG|Xeloda|adjuvant chemotherapy
223783858|NCT02317458|BIOLOGICAL|Experimental|One active arm with standard of car and treatment with C3BR-CQR-1 using intramyocardial injection
223783859|NCT02317458|BIOLOGICAL|Sham comparator|One arm with standard of care undergoing a sham procedure
223783860|NCT03988179|DIAGNOSTIC_TEST|The Cholinesterase Inhibitor Prognosticator (ChIP) application for iPad|The first part of this application will be used, consisting of a visual vigilance test based on the Continuous Performance Test (CPT). Stimuli consist of a one digit number presented in the middle of the screen. For each trial the application randomly selects a specific number as the target stimulus. Patients are instructed to keep their dominant trigger finger close to the screen and press a button which is located at the bottom of the screen, whenever the target appears. In case another stimulus appears the patient is instructed to do nothing. Each stimulus is presented until the patient presses the button (maximum 3 sec.). Stimuli are presented in a random fashion with a 1, 2, 3, 4, or 5 second inter-stimuli-interval blank, which randomly varies. After an 8 stimuli practice trial, the test starts and a total of 50 stimuli are presented with a 50% target rate. Full-trial duration is approximately 5 minutes. During the trial, reaction time and accuracy of response are registered.
223783861|NCT05130112|DEVICE|high flow nasal cannula and nasal cannula|"HFNC was administered using the MyAIRVO 2 device (Fisher \& Paykel Healthcare, Auckland, New Zealand), which provides humidification and high-flow medical gas through an Optiflow NC interface (Fisher \& Paykel Healthcare, Auckland, New Zealand) is administered for 10 min..~NC is administered for 10 min."
223783862|NCT04442217|BEHAVIORAL|Prospective study with two measurement points investigating the impact of viral mitigation protocols on mental health|Prospective study with two measurement points investigating the impact of viral mitigation protocols on mental health
223783863|NCT01842139|BIOLOGICAL|basiliximab|Given IV
223783864|NCT01842139|BIOLOGICAL|WT1 126-134 peptide vaccine|Given SC
223783865|NCT01842139|DRUG|Montanide ISA 51 VG|Given SC
223783866|NCT01842139|DRUG|poly ICLC|Given SC
223783867|NCT01842139|OTHER|laboratory biomarker analysis|Correlative studies
223783868|NCT01090804|DEVICE|BreatheMAX breathing device|secretion clearance, breathing exercise
223783869|NCT01754714|DRUG|SAMe 1000 mg|1000 mg dose group: one 500 mg capsule fasting in the morning and one 500 mg capsule before dinner
223783870|NCT01754714|DRUG|SAMe 1500 mg|1500 mg dose group: two 500 mg capsules fasting in the morning and one 500 mg capsule before dinner
223783871|NCT01754714|DRUG|SAMe 2000 mg|2000 mg dose group: two 500 mg capsules fasting in the morning and two 500 mg capsules before dinner
223783872|NCT02528214|DRUG|Dupilumab|Solution for injection, Subcutaneous injection in the abdomen, upper thigh or upper arm.
223783873|NCT02528214|DRUG|Placebo|Solution for injection, Subcutaneous injection in the abdomen, upper thigh or upper arm.
223783874|NCT02528214|DRUG|Oral corticosteroid therapy (prednisone/prednisolone)|Oral administration.
223783875|NCT02528214|DRUG|Inhaled corticosteroid (ICS) therapy|Oral inhalation, stable dose (high dose) of ICS in combination with up to 2 other controller medicines (second or third controller therapy).
223783876|NCT02528214|DRUG|Albuterol/Salbutamol|Oral inhalation as needed.
223783877|NCT02528214|DRUG|Levalbuterol/Levosalbutamol|Oral inhalation as needed.
223783878|NCT03660683|DRUG|Dapagliflozin 10mg|Dapagliflozin 10mg PO QD
223783879|NCT03660683|DRUG|Saxagliptin 5mg|Saxagliptin 5 mg PO QD
223783880|NCT03660683|DRUG|Placebo Oral Tablet|Matching Placebo Tablets
223783881|NCT06114797|OTHER|Chamomile|"* Chamomile was topically applied to the oral mucosa as oral rinse.~* Based on this protocol, patients had oral rinses 3 times per day.~* Patients were instructed to perform chamomile rinses in the oral mucosa.~* Patients were instructed not to swallow the chamomile oral rinse."
223783882|NCT06114797|OTHER|Saline mouthwash|Saline mouthwash was used by elderly patients in the control arm.
223783883|NCT03862404|DRUG|Bupivacaine-epinephrine|See previous description
223783884|NCT03862404|DRUG|Normal saline|See previous descreption
223783885|NCT00941603|DRUG|SCH 900271 15mg|oral tablets; SCH 900271 - 15 mg taken once daily for 8 weeks
223783886|NCT00941603|DRUG|SCH 900271|oral tablets; SCH 900271 10 mg taken once daily for 8 weeks
223783887|NCT00941603|DRUG|SCH 900271|oral tablets; SCH 900271- 5 mg taken once daily for 8 weeks
223783888|NCT00941603|DRUG|SCH 900271|oral tablets; SCH 900271- 2.5 mg taken once daily for 8 weeks
223783889|NCT00941603|DRUG|SCH 900271|oral tablets; SCH 900271- 1 mg taken once daily for 8 weeks
223783890|NCT00941603|DRUG|Placebo|oral tablets; placebo administered once daily during the 5-week single-blind placebo run-in and diet stabilization period and during the 8 week double-blind treatment period.
223783891|NCT00407537|DRUG|Amlodipine besylate/atorvastatin calcium single pill combination|Open label amlodipine besylate/atorvastatin calcium single pill combination at multiple doses: 5/10, 10/10, 5/20, 10/20 mg prescribed at the investigator's discretion
223783892|NCT02513654|DRUG|Lamotrigine|Lamotrigine dispersible tablets supplied in 3 different strengths 25 mg, 50 mg and 100 mg. These dispersible tablets appear as white or off-white tablets.
223783893|NCT01891123|DEVICE|PK guided arm|the dose of PTX or DOC will adjust based on the plasma drug concentration of previous cycle
223783894|NCT01891123|DRUG|PTX 175mg/m2, DOC 75mg/m2|patients receive PTX or DOC dose based on body surface area every cycle, PTX 175mg/m2, DOC 75mg/m2
223783895|NCT00347308|BEHAVIORAL|Eyebrow Position|Photography of brow positions
223783896|NCT04272281|PROCEDURE|medical shared decision|The experimental group will use the share decision making tool during consultation to adapt antibiotherapy
223783897|NCT04272281|PROCEDURE|Standard medical care|control group will act as usual in their practice.
223783898|NCT02014116|DRUG|LY3009120 capsule|Administered orally.
223783899|NCT05818735|OTHER|electroacupuncture (EA) treatment|The regular acupuncture treatment will be applied at the acupoints including Baihui (GV20), Yintang (GV29), Guanyuan (RN4), Qihai (RN6), bilateral ZuSanli (ST36) and bilateral SanYinjiao (SP6). After needle insertion, rotating or lifting-thrusting manipulation will be applied for 'De qi' sensation. Three pairs of electrodes of the electroacupuncture apparatus will be connected to the needles of GV20 and GV29, and bilateral ST36 and SP6 for 25 minutes, delivering a continuous wave with a frequency of 2-8Hz which is based on the tolerance of each patient. The selection of matching acupuncture points will be determined by the acupuncturist according to the patients' different syndrome patterns.
223783900|NCT05818735|OTHER|sham acupuncture (SA) treatment|The sham acpunture treatment will be applied at the same acupoints as the EA treatment with the Streitberger placebo needles. When the blunt needle tip of the placebo needles touches the skin, the patient will get a pricking sensation, but there is no real needle inserted into the skin. The electroacupuncture apparatus will be set on the table beside the patients and two pairs of electrodes will be connected to the needles at bilateral ST36 and SP6. Acupuncturists will turn on the apparatus but all indicators will be set to '0'. Participants will be informed when needles are removed after 25 minutes. Acupuncturists will use dry cotton balls to press the skin around the acupoints when withdrawing the needles so that patients can feel the withdrawal of the 'needles'.
224263856|NCT07068984|OTHER|Differences between lower limb balances were assessed by the Y-Balance test|The Y-Balance test was used to evaluate bilateral anterior difference, composite score, lateral and posterior balance, symmetry ratio and bilateral difference
224263857|NCT07067814|DRUG|Methylene blue group|After ligation of the superior pole, 0.5-1 ml of sterile methylene blue dye was injected into the inferior thyroid artery. The thyroid tissue absorbed the dye, while the RLN remained unstained, appearing as a white structure in the tracheoesophageal groove. This aided in its early and safe identification, reducing the risk of injury during dissection.
224263858|NCT07067814|PROCEDURE|Methylene blue group|After ligation of the superior pole, 0.5-1 ml of sterile methylene blue dye was injected into the inferior thyroid artery. The thyroid tissue absorbed the dye, while the RLN remained unstained, appearing as a white structure in the tracheoesophageal groove. This aided in its early and safe identification, reducing the risk of injury during dissection.
224263859|NCT07067099|BIOLOGICAL|Plasma with neutralizing autoantibodies to Type I Interferons|Transfusion of one unit of plasma containing high titre anti-IFN-1 autoantibodies
224263860|NCT07068542|DRUG|Sacituzumab tirumotecan|Sacituzumab tirumotecan: 4mg/kg, IV, Q6W, D1, D15, D22
224263861|NCT07068542|DRUG|Tislelizumab|Tislelizumab: 400mg, IV, Q6W, D1
224263862|NCT07069413|BEHAVIORAL|tele-ImPACT|Participants will receive 12 weeks of Project ImPACT intervention as delivered via Telehealth
224263863|NCT07068958|DRUG|0.25% RCI001 Ophthalmic Solution|0.25% RCI001 Ophthalmic Solution
224263864|NCT07068958|DRUG|Placebo Ophthalmic Solution (vehicle)|Placebo Ophthalmic Solution (vehicle)
224263865|NCT07067086|OTHER|Test Cream|A facial cream (Formula# 899675 44A, 30 mL) was applied once by participants under supervision. 1g of cream was spread over the entire face and neck, followed by targeted massage on wrinkle-prone areas including forehead, crow's feet, underneath eyes, nasolabial folds, and neck folds. Clinical and photo-based evaluations were conducted at baseline (T0), 10 hours (T10h), and 24 hours (T24h) after application.
224263866|NCT07067216|OTHER|Designed scapular stabilization using pressure biofeedback|Patients will attend 1-hour physical therapy sessions twice weekly for 6 weeks. The program will include posterior capsule mobilization, scapular stabilization using pressure biofeedback (targeting lower trapezius, latissimus dorsi, pectoralis major, deep cervical flexors, and scapular retractors), and strengthening exercises using therabands: external rotation, shoulder diagonals, rows, and extensions. Additional training will involve physioball scapular exercises (up/down \& side/side), prone scapular strengthening (e.g., TYI, superman), and scapular-clock drills to improve mobility, proprioception, and stability.
224263867|NCT07067216|OTHER|Designed physical therapy program|Patients will receive cryotherapy and perform stretching exercises for the pectoralis minor and posterior capsule. Strengthening exercises using theraband will target the rotator cuff (especially external rotators) and scapular depressors/retractors. Scapular stabilization will be trained through prone exercises on a ball (T, Y, W) and on a plinth, including rowing, horizontal abduction, extension, superman, and TYI exercises. Additionally, patients will perform the scapular-clock exercise to enhance mobility, control, and proprioception.
224263868|NCT07067164|OTHER|Bulk fill resin composite restorative material|Both restorative materials were applied in a clinical setting following standard infection control protocols and material-specific preparation techniques. The interventions were performed by the same calibrated operator to ensure consistency, and evaluated using modified USPHS criteria by two blinded, independent assessors at 1 week (baseline), 6 months, and 12 months. The study employed a split-mouth design to allow direct intra-individual comparison between the two materials under similar oral conditions.
224263869|NCT07068022|OTHER|Organ dysfunction score adjusted to obstetric patients (SOFA-OBS)|The obstetric SOFA (SOFA-OBS) adjusts renal and cardiovascular variables to physiological changes of pregnancy. Moreover, it simplifies respiratory evaluation, in terms of replacing arterial blood gases (ABG) for peripheral oxygen saturation/fraction of inspired oxygen (spO2/FiO2), when ABGs were not available. Variables unchanged during pregnancy (neurologic, hepatic and platelets), won't be modified.
224263870|NCT07067710|OTHER|Motor imagery combined with action observation|To observe and imaging one action with a video resource. Not virtual reality.
224263871|NCT07067294|DEVICE|Low-Level Light Therapy|"The intervention consists of non-invasive periocular photobiomodulation using the Eye-light® device (Espansione Group, Italy), which delivers low-level polychromatic red and near-infrared light (600-1200 nm) through a specially designed mask. Participants receive two 15-minute sessions, one 7 days before and one 7 days after cataract surgery.~The treatment is designed to stimulate meibomian gland activity, improve tear film stability, reduce ocular surface inflammation.~This protocol is unique compared to standard treatments for dry eye because it targets cellular mitochondrial activity to enhance tissue repair and anti-inflammatory effects. It is non-pharmacological, non-contact, and well-tolerated, making it suitable for perioperative application. The light is delivered through closed eyelids, ensuring safety and comfort, and the device used is CE-marked for ophthalmic applications."
223783901|NCT05818735|DRUG|Escitalopram 10mg|Escitalopram will be used as the antidepressants for relieving patients' depressive mood. The dose of the drug will be the minimum clinical starting dose of 10 mg once daily, taken orally in the morning, for a period of 3 months. During the intervention period, patients will be allowed to increase the drug dose (up to 20 mg) according to their mental status. Patients will record the details of the drug dose, duration of dosing,responses and possible side effects on a drug dairy. Pateints will receive 7 tablets of escitalopram from an independent dispencer at a set time each week. They may receive additional dose of escitalopram once again during the week if necessary and it will be recorded by the dispenser.
223783902|NCT05818735|DRUG|Placebo|Placebo drugs are tablets of the same color and size as escitalopram tablets, consisting mainly of starch, and will be tested for safety before being used in the trial. The way the medication is dispensed, the details of how the medication is administered, the dosage, and the record of the drug diary are consistent with the application of the real drugs.
223783903|NCT01970033|DRUG|Placebo|"* Run in period ：oral tablets of Placebo twice daily for 2 weeks~* Phase A : oral tablets of Placebo twice daily for 24 weeks~* Phase B : SP2086 50 mg b.i.d or SP2086 100 mg q.d. for 28 weeks"
223783904|NCT01970033|DRUG|SP2086 50 mg b.i.d.|"* Run-in period: placebo twice daily for 2 weeks~* Phase A:SP2086 50 mg b.i.d for 24 weeks~* Phase B:SP2086 50 mg b.i.d for 28 weeks"
223783905|NCT01970033|DRUG|SP2086 100 mg q.d.|"* Run-in period:placebo twice daily for 2 weeks~* Phase A: SP2086 100 mg q.d. for 24 weeks~* Phase B: SP2086 100 mg q.d. for 28 weeks"
223783906|NCT04866264|DEVICE|eNutrition Optimizer|The eNutrition optimizer is based on the electronic food frequency questionnaire (FFQ) used in the multicentre randomized controlled trail DO-HEALTH \[56\] developed by the CAM. The FFQ is split up in sections of 33 food groups and contains 216 items. It asks the user on the relative frequency of consumption of the different foods showing a picture of the food in the portion size of interest. Within the eNutrition Optimizer, the FFQ will be extended to create an output of the user's adherence to the Mediterranean diet, the MIND diet and the adherence with the current dietary recommendations for micro- and macronutrients provided by the Swiss Society for Nutrition and the DACH-references, compare it to the DO-HEALTH population and give recommendations on how to improve the score.
223783907|NCT01764984|DEVICE|Total knee arthroplasty|Total knee arthroplasty using parapatellar approach and postero-stabilized implants.
223783908|NCT04099069|PROCEDURE|anesthesia|patient was insert trachial intubation or rigid bronchoscopy with ventilation under general anesthesia
223783909|NCT04546087|DEVICE|Ultrasound|Ultrasound scan of the cricothyroid membrane
223783910|NCT05225818|BEHAVIORAL|PLAN - Home|home-based intervention program for dementia evaluation, education, and care planning
223783911|NCT06152536|OTHER|Vegetarian Meal|"meal with vegetarian protein and meal with animal protein"
223783912|NCT02522533|OTHER|Physical Therapy|6 weeks of an exercise program.
223783913|NCT01230476|DRUG|Cetuximab|Cetuximab loading dose of 400mg/m2, then weekly dose of 250mg/m2 for 12 doses; Neoadjuvant Cisplatin 75mg/m2 D1, 5FU 1000mg/m2 D2-5, for 2 cycles; Concurrent Cisplatin 30mg/m2 given with radiation 70Gy/35fraction/7weeks.
223783914|NCT00511576|DRUG|MGCD0103 & Docetaxel|"In both Parts 1 and 2, subsequent doses of MGCD0103 will be escalated in 25 mg increments until the MTD of MGCD0103 in combination with each fixed dose (60 mg/m2 or 75 mg/m2) ofIV docetaxel is determined.~In both parts 1 and 2, MGCD0103 will be administered orally TIW for 3 weeks beginning on Day 1 at 1 hour prior to the start of the IV docetaxel infusion.~There will be no scheduled break between cycles and no limit to the number of cycles a subject can receive provided they do not have disease progression as defined by RECIST, or a clinically significant drug-related adverse event (AE) that does not resolve or respond to treatment intervention with 3 weeks."
223783915|NCT06121713|DIETARY_SUPPLEMENT|GCE + Low ALA|Participants will consume a pill containing 200mg green coffee extract and 200mg alpha-lipoic acid 30 minutes before a 75g oral glucose tolerance test
223783916|NCT06121713|DIETARY_SUPPLEMENT|GCE + High ALA|Participants will consume a pill containing 200mg green coffee extract and 400mg alpha-lipoic acid 30 minutes before a 75g oral glucose tolerance test
223783917|NCT06121713|DIETARY_SUPPLEMENT|Placebo|Participants will consume a placebo pill (500mg insoluble microcrystalline cellulose, 5mg magnesium stearate, 5mg silicon dioxide) prior to a 75g oral glucose tolerance test
223783918|NCT00428454|DEVICE|sirolimus-eluting stent, zotarolimus-eluting stent|PCI in chronically occluded coronary artery
223783919|NCT05369650|DRUG|Lidocaine Hydrochloride, Injectable|The lidocaine group 1, 1.5 and 2 groups were injected with 1% lidocaine 1.5mg/kg (ideal body weight, 10min infusion) after anesthesia induction, respectively, and then continued to infuse 1% lidocaine. 1mg/kg.h, 1.5mg/kg.h, 2mg/kg.h (ideal body weight) until the end of the operation, and a patient-controlled intravenous analgesia (PCIA) pump containing lidocaine (PCIA) 0.3-1.5mg/kg after surgery. h to 72h after surgery.
223783920|NCT03111927|OTHER|Infant Formula: enriched level of myelin-relevant nutrients|"Feeding with the assigned infant formula begun as soon as the child was enrolled in the study (from 2 weeks up to 5 weeks of life) and lasted up to 12 months of age (+/- 2 weeks).~The volume of feed required by the child per day depended upon age, weight, and appetite. The product was given daily ad libitum to the child from enrollment up to 12 months."
223783921|NCT03111927|OTHER|Infant formula: standard level of myelin-relevant nutrients|"Feeding with the assigned infant formula begun as soon as the child was enrolled in the study (from 2 weeks up to 5 weeks of life) and lasted up to 12 months of age (+/- 2 weeks).~The volume of feed required by the child per day depended upon age, weight, and appetite. The product was given daily ad libitum to the child from enrollment up to 12 months."
223783922|NCT00583557|DRUG|belimumab|IV 10mg/kg Q28 days
223783923|NCT02431039|DEVICE|NEOSORB PLUS|Fascia and subcutaneous tissue repaired by antibacterial suture materials (Chlorhexidine diacetate coated PGLA910)
223783924|NCT02431039|DEVICE|NEOSORB|Fascia and subcutaneous tissue repaired by non-antibacterial suture materials (PGLA910)
223783925|NCT04082065|OTHER|conventional physical therapy|hot pack for 15 minutes Myofacial release (10 minutes) and Stretching of hamstrings and Piriformis (5 reps each with 2 second hold)
223783926|NCT04082065|OTHER|cyriax lumber manipulation group|Hot Pack, Myofacial Release, stretching of hamstrings and Piriformis (five reps each with 2 seconds hold) and Cyriax Lumbar Manipulation Techniques
223783927|NCT02347761|DRUG|SUN-101 50 mcg BID eFlow (CS) nebulizer|SUN-101 50 mcg twice daily (BID) eFlow Closed System (CS) nebulizer
223783928|NCT02347761|DRUG|SUN-101 25 mcg BID eFlow (CS) nebulizer|SUN-101 25 mcg twice daily (BID) eFlow Closed System (CS) nebulizer
223783929|NCT02347761|DRUG|Placebo BID eFlow Closed System (CS) nebulizer|Placebo twice daily (BID) eFlow Closed System (CS) nebulizer
223783930|NCT02657278|PROCEDURE|Arterial Revascularization surgery or Endovascular procedure|Symptoms limited Cardiopulmonary Exercise Test (CPET) performed before and four weeks after surgical or endovascular correction of peripheral arterial disease
223783931|NCT06162520|OTHER|Contrast-enhanced computed tomography (CECT) and 3D morphological analysis|Diagnosis models are established using quantitative morphological characteristics extracted from the 3D reconstructed bile duct from contrast-enhanced computed tomography (CECT) images.
223783932|NCT00769366|BEHAVIORAL|Psychotherapy|humanistic-existential psychotherapy conducted in individual and group meetings
223783933|NCT00769366|DRUG|Medical therapy|Optimal medical therapy after Acute myocardial infarction
223783934|NCT03879798|DRUG|DS-3201b|100 mg daily
223783935|NCT03879798|DRUG|irinotecan|Irinotecan 125 mg/m\^2 intravenously on days 1 and 8 every 3 weeks in a 21-day cycle.
223702538|NCT05177705|BEHAVIORAL|Restricted access task|In the restriction period participants will have their preferred (chosen after doing a preference task, including liking) food and similar alternatives restricted by their parent for 2 weeks. In the no restricted period, participants and their parents will be given several portions of the preferred food and will consume it throughout the two-week period.
223702539|NCT00175695|DRUG|Recombinant human activated protein C or drotrecogin alpha|We are going to investigate a compound (recombinant human activated protein C (rhAPC)) that has the potential to modify disease activity in pre-eclampsia by reducing coagulation and inflammation disorders.
223702540|NCT02685046|DRUG|Imatinib|Subjects will be treated with the medicinal product imatinib, which will be administered orally in tablets of 400mg, once per day, during two weeks prior to tumor resection.
223702541|NCT05058716|DIAGNOSTIC_TEST|blood sample|weekly blood sample - coenzym q10 levels
223702542|NCT06198127|OTHER|combination of core stability exercises and kinesio-taping|the patient in the experimental group will receive the core stability exercises with kinesiology taping on trunk stabilizer muscles. the time of intervention was 30 minutes per day. The exercises such as Abdominal draw-in with a double knee to chest, Trunk twist while sitting on a medicine ball, Lying in a supine position on bed and rotating the trunk from side-to-side, Bridging exercises, the I-shaped elastic KT will apply to the four trunk muscles from their insertion to their origin: Kinesio-taping is used on global muscles such as Rectus abdominis, External obliques, Erector spinae, Quadratus lumborum. Kinesio-taping will 1 inch wide and apply on muscles for 1 to 2 days then remove for 24 hours then again apply a new one. The tension will be 10 to 15% and tape will apply on muscles which will be stretched by maintaining a posture.
223702543|NCT06198127|OTHER|Core stability exercises|After the baseline assessment, the patient in the control group will receive the core stability exercises with kinesio-taping on trunk stabilizer muscles. Time of rehabilitation will be 30 minutes per subject and four days per week. In first few minutes, the subject will be explained her/his task Subject will execute the exercises such as Abdominal draw-in with a double knee to chest 10- 15 times. Trunk twist while sitting on a medicine ball 10- 15 times. Lying in a supine position on bed and rotating the trunk from side-to-side 10- 15 times. Lying in a supine position on a mat and pulling upper and lower limbs upward 10- 15 times. Bridging exercises 10- 15 times, Deep Breathing and Wheelbarrow.
223702544|NCT03274232|DEVICE|SUNEKOS ® 200|micro-injections of the study product were performed by a specialized dermatologist, bilaterally on the face (zygomatic protuberance, nostril's angle, inferior margin of tragus, lip marionette lines, mandibular angle) of female volunteers aged 45-65 years, with photoaging of mild/moderate grade
223702545|NCT04568421|DRUG|Immunosuppressive Agents|Immunomodulatory and/or immunosuppressive drugs according to the indication of the treating physician
223702546|NCT03334110|PROCEDURE|A method of operation: LIMA-GSV-SCVBG|On the experimental group,We treat patients with the operation of LIMA-GSV composited Y graft and anastomose the GSV with selective coronary vein
223702547|NCT03334110|PROCEDURE|BIMA-SCVBG|On the other group, We treat patients with the operation of bilateral internal mammary artery composited LIMA-Right Mammary Artery（RIMA） y graft and anastomose the Right Mammary Artery(RIMA) with selective coronary vein.
223702548|NCT00560274|DRUG|Pegasys|As prescribed
223702549|NCT00560274|DRUG|Ribavirin|As prescribed
223702550|NCT00560274|DRUG|epoetin beta [NeoRecormon]|30,000 IU sc/week (starting dose)
223702551|NCT01175460|DRUG|S-1, Nedaplatin|nedaplatin was given at a fixed dose of 75 mg/m2 on Days 1, and s-1 on Days 1-14, repeated every 4 weeks for four cycles. The dose of s-1 was initially 60 mg/m2/day and gradually increased to determine the MTD and RD of this regimen.
223702552|NCT00528827|DRUG|Cardene® I.V.|"* 5 mcg/kg/min Cardene I.V.~* 2.5 mcg/kg/min Cardene I.V.~* 0.5 mcg/kg/min Cardene I.V."
223702553|NCT05718804|OTHER|Whether renal injury occurred and differences in intestinal flora|Whether renal injury occurred and differences in intestinal flora
223702554|NCT05133908|BEHAVIORAL|Sleep Hygiene and Self-Monitoring Control|An app with self-monitoring function and videos and written materials about sleep hygiene will be provided.
223783936|NCT05841784|BEHAVIORAL|MBCT-T|MBCT-T is an 8-week group-based program that combines training in mindfulness and cognitive-behavioral therapy to reduce psychological distress and negative emotions. Each weekly 1-hour session will consist of a check-in, discussion, teaching, mindfulness or cognitive behavioral practice or exercise, inquiry by the facilitator, and summary of the at-home practice.
223783937|NCT05841784|BEHAVIORAL|Booster Mindfulness Sessions|Following the standard 8-week MBCT-T program, participants in certain arms will receive monthly MBCT-T booster sessions for 4 months of follow up. Each booster session will be 1 hour long. The sessions will include a concise review and summary of the main MBCT-T sessions.
223783938|NCT05841784|BEHAVIORAL|Website Support|Participants in certain arms will receive continuous intervention support via the use of an online study website. The website will provide quick access to intervention materials and support to encourage participants to complete the at-home practice and apply the content of the MBCT-T program to real life situations.
223783939|NCT04723875|DRUG|Paclitaxel or docetaxel + Cisplatin or carboplatin|Paclitaxel 135-175mg/m2 over 3 hours or docetaxel 70-75 mg/m2， 30min ＋ Cisplatin 75-80mg/m2 or carboplatin AUC = 5, repeat per 21 days.
223783940|NCT03625570|BEHAVIORAL|Power training combined with interval treadmill training|Training will consist of unilateral and bilateral leg presses, targeting the quadriceps, hip extensors, and plantarflexors according to resistance training guidelines for muscle power training. The interval treadmill training portion will include short-bursts (30 seconds) of high speed walking intervals alternating with 30 seconds of low to moderate speed walking for a total of 30 minutes. Participants will train 3 x per week for 8 weeks. Total duration of each session will be approximately 1 hour.
223783941|NCT03625570|BEHAVIORAL|Strength training combined with traditional treadmill training|Training will consist of unilateral and bilateral leg presses, targeting the quadriceps, hip extensors, and plantarflexors following the dosing and resistance training guidelines for muscle strength. Traditional treadmill training will consist of walking at steady-state speeds for 30 minutes. Participants will train 3 x per week for 8 weeks. Total duration of each session will be approximately 1 hour.
223783942|NCT05681559|BEHAVIORAL|Medi for All|Please see description of Medi for All arm
223783943|NCT05681559|DIETARY_SUPPLEMENT|Standard Fiber Supplementation|Please see description of Fiber Supplementation arm
223783944|NCT05748405|DRUG|Placebo|Matching Tablets
223783945|NCT05748405|DRUG|AEF0217|Tablets of 100 mcg AEF0217
223783946|NCT03750318|DEVICE|Vital sign monitoring|Each patient will be set up for monitoring on admission. Duration of opioid therapy for post-operative in-patients may range from 1-3 days. Once opioid therapy is no longer required, Aingeal monitoring will be ended and each patient would be encouraged to have at least 1 day Aingeal monitoring to be recorded during the study. De-identified log files will be extracted from the Surveillance Station and reprocessed to produce counts of the number of alarms raised during monitoring. A sample of the data will be reviewed to determine whether cardiac and respiratory alarms are defined as True or False, with an overall Alarm Rate per patient per day and False Positive Alarm Rate per patient per day derived. Vital sign trend graphs for each patient will be produced.
223783947|NCT06962657|DIETARY_SUPPLEMENT|Ubiquinone 100 mg Oral Soft Gel|Active comparator arm receives three ubiquinone 100mg soft gels per day. Supplement is taken orally in divided doses, with the last soft gel not close to bedtime.
223783948|NCT06962657|DIETARY_SUPPLEMENT|Placebo|Placebo comparator arm receives three placebo soft gels per day. Supplement is taken orally in divided doses, with the last soft gel not close to bedtime.
223783949|NCT06961474|PROCEDURE|Endoscopic treatment|The endoscopic treatment methods for patients with esophageal variceal rupture bleeding usually include variceal ligation and injection of tissue adhesive.
223783950|NCT06962540|DEVICE|Hearing aid with settings customized to match their individual listening strategy|Behind-the-ear hearing aids that have been programmed based on the participant's individual listening strategy and hearing loss.
223783951|NCT06962540|DEVICE|Hearing Aid with settings based on audiogram alone|Behind-the-ear hearing aids that have been programmed based on their hearing loss and typical clinical settings.
223783952|NCT06963255|PROCEDURE|arterial revascularization|arterial revascularization
223783953|NCT06962501|DIETARY_SUPPLEMENT|Oral ketone monoester (KME)|The oral ketone monoester supplement should increase the global CBF and improve resting-state connectivity in the DMN in adults with SCD or MCI. The participants will take one dose of the supplement followed by measurement, to figure out if there are any noticeable changes.
223702555|NCT05133908|BEHAVIORAL|dCBTi-ADHD|The dCBTi adopts a multi-module approach, consisting of 7 weekly modules including psychoeducation on sleep and ADHD, insomnia, organization strategies and distractibility reduction skills, sleep hygiene, sleep restriction and prescription, circadian-related activity scheduling, stimulus control, relaxation and worry time, cognitive restructuring, and relapse prevention. In each module, participants will watch short videos to learn strategies to improve their sleep. A virtual coach is also included in the app functionality. It will be in the form of a text-based forced-choice conversation bot. It will initiate conversations with the users to check their understanding of treatment materials and guide them to come up with specific action plans to implement the treatment strategies.
223702556|NCT00752102|DRUG|Calcitriol (Rocaltrol®)|Subjects taking calcitriol will be started at 0.25 mcg 3x/week and titrated up during the next visit according to PTH levels. If at the 12 week visit, PTH is still not at goal, then calcitriol will be increased to 0.5 mcg 3x/week.
223783954|NCT06962241|OTHER|Warming group|When the pregnant women in the experimental group were laid on the operating table, they were heated from the back with a heating pad. The heating pad remained on the pregnant woman's back throughout the cesarean section. The cesarean section took an average of 35 minutes from the first surgical incision to the completion of the incision after spinal/epidural anesthesia.
223783955|NCT05678348|DRUG|Pyrimethamine|Patients will be instructed to take their dose at approximately the same time each day.
223783956|NCT03370887|DRUG|AZD8601|AZD8601 solution for injection, 0,5 mg/mL and 5 mg/mL will be given as 30 injections of 0.1 mg (3 mg per patient), or 1 mg (30 mg per patient) respectively on a single occasion
223783957|NCT03370887|DRUG|Placebo|Placebo for AZ8601 injection for solution will be given as 30 injections per patient on a single occasion
223783958|NCT06635746|DRUG|Vinpocetine|Increasing doses of vinpocetine to assess tolerability.
223783959|NCT04145752|PROCEDURE|Nurse-led femoral nerve block|The nurse perform a femoral nerve block in the emergency department in patients diagnosed with a hip fracture (x-ray)
223783960|NCT02745626|DEVICE|Appliance|Orthodontic appliance to carry out orthodontic tooth movement.
223783961|NCT03149640|DRUG|Inhaled amikacin|Once a day, inhaled amikacin at day 4, day 5 and day 6 of invasive mechanical ventilation: 20 mg/kg of ideal body weight, maximum 2 g per day.
223783962|NCT03149640|DRUG|Inhaled placebo|Once a day, inhaled placebo at day 4, day 5 and day 6 of invasive mechanical ventilation.
223783963|NCT01040130|DRUG|Olodaterol (BI 1744)|Comparison of low and high doses on exercise endurance time in COPD patients
223783964|NCT01040130|DRUG|Olodaterol (BI 1744)|Comparison of low and high doses on exercise endurance time in COPD patients
223783965|NCT01040130|DRUG|Placebo|Comparison of low and high dose and placebo on exercise endurance time in COPD patients
223783966|NCT01040130|DRUG|Olodaterol (BI 1744)|Comparison of low and high dose
223783967|NCT01040130|DRUG|Olodaterol (BI 1744) Placebo|Placebo that represents olodaterol
223783968|NCT02270320|BEHAVIORAL|Physical activity|The training is 24 forms Yang-style Tai Chi Chuan exercise, which will perform a 60-minute exercise program, three times per week for 12 weeks.
223783969|NCT01776645|BEHAVIORAL|Compassion Cultivation Training Course|
223783970|NCT01098448|OTHER|scaling and root planing|scaling and root planing as a single therapy
223783971|NCT01098448|DRUG|local tetracycline|local delivery of tetracycline fibers releasing approximately 1.7 mg/tooth in all pockets \>5mm
223783972|NCT01098448|DRUG|systemic metronidazole and amoxicillin|systemic metronidazole (250 mg tid x 14) and amoxicillin (500 mg bid x 14
223783973|NCT01098448|OTHER|surgery|periodontal surgery in residual pockets of \>4mm
223783974|NCT01098448|DRUG|local antibiotics and systemic metronidazole and amoxicillin|1.7 mg/tooth tetracycline fiber plus metronidazole (250 mg tid x14d)and amoxicillin (500 mg bid x 14d)
223783975|NCT01098448|OTHER|local tetracycline and periodontal surgery|local delivery of tetracycline fibers releasing approximately 1.7 mg/tooth in all pockets \>5mm and periodontal surgery in residual pockets of \>4mm
223783976|NCT01098448|OTHER|periodontal surgery and systemic metronidazole and amoxicillin|surgery in residual pockets \>4mm and metronidazole (250mg tidx14d) and amoxicillin (500mg bidx14d)
223783977|NCT01098448|OTHER|surgery, local tetracycline, systemic metronidazole and amoxicillin|periodontal surgery in residual pockets \>4mm, tetracycline ibers releasing approximately 1.7 mg/tooth in pockets \>5mm, systemic metronidazlo (250mg tidx14d) and amoxicillin (500 mg bidx14d)
223783978|NCT05956431|DRUG|Levosimendan Injection|The administration scheme of Levosimendan is continuous intravenous infusion at the rate of 0.05-0.2 μg/kg/min for 24 hours, and no load is given to reduce the risk of Hypotension.
223702557|NCT00752102|DRUG|Paricalcitol|Subjects taking paricalcitol will be started at 2 mcg 3x/week and titrated up during the next visit according to PTH levels. If at the 12 week visit, PTH is still not at goal, then paricalcitol will be increased to 4 mcg 3x/week.
223783979|NCT05956431|DRUG|physiological saline|The placebo group received continuous intravenous infusion of physiological saline at the rate of 0.05-0.2 μg/kg/min for 24 hours, while also receiving comprehensive cluster therapy with PCAS.
223783980|NCT02669823|OTHER|None, treatment as actual best practice|
223783981|NCT03772080|OTHER|Early counseling of prematurity in high-risk pregnancies.|Standardized information regarding prematurity, including associated complications and ways to decrease chances of preterm birth using web-based educational platform.
223783982|NCT05221164|DRUG|Aspirin 162 mg|Daily aspirin 162 mg during pregnancy to prevent preeclampsia
223783983|NCT04236557|BEHAVIORAL|Music listening|Other than usual care, subjects will listen to a 30-min individualized playlists with preferred music genres sequenced by a registered music therapist according to the ISO-Principle when agitated.
223783984|NCT04236557|BEHAVIORAL|Audio Book Listening|Other than usual care, subjects will listen to to a 30-min audio-script of book reading in Cantonese (a common dialect in Hong Kong being spoken by most people) when agitated.
223783985|NCT00298428|PROCEDURE|blood samples|blood samples before percutaneous coronary intervention (PCI) and at 4 months
223783986|NCT05809570|DIAGNOSTIC_TEST|Clinical examination|"A total of 1057 individuals who applied to Bolu Abant İzzet Baysal University, Faculty of Dentistry, Department of Periodontology and agreed to participate in the study were clinically and radiologically examined.~An intraoral scanner was utilized to capture direct optical intraoral data of a patient."
223783987|NCT02438449|PROCEDURE|Breast Reconstruction Surgery|AAT-based orTE/I reconstruction in all patients undergoing breast reconstruction following mastectomy
223783988|NCT02262845|DEVICE|The Advanix™ Pancreatic Stent and NaviFlex RX Pancreatic Delivery System and Pushers|Used to drain pancreatic ducts
223783989|NCT03453606|OTHER|Home respiratory rehabilitation|Home care is individual (often with the spouse or the carer), during 1h30, one visit per week for 8 weeks, after completion of the educational diagnosis, under direct supervision of a member of the team, with continued physical activities in autonomy the others days of the week, according to a personalized action plan. No visit is scheduled in the pulmonologist, the general practitioner or in the rehabilitation center. The team includes pulmonologist, nurses, dietician, socio-medical beautician and a administrative assistant.
223783990|NCT03453606|OTHER|Center respiratory rehabilitation|"In an outpatient setting, the course is performed in groups of 6 to 8 patients, during sessions from 3 to 7 am, under the direction of health professionals, 3 to 5 times a week, for 4 to 6 weeks, for a total of 20 to 24 sessions. Internally, patients come to complete hospitalization for 4 weeks. This duration can be modulated according to the evolution of the patients.~Supervision is carried out by the entire team including pulmonologists, nurses, physiotherapists, psychologists, activity professors adapted physicists, dietician"
223783991|NCT06186648|DRUG|Glofitamab + Obinutuzumab|Duration of each cycle is 21 days. Cycle 1: R-CHOP Cycle 2: G-CHOP + glofitamab (at this cycle onnly, Obinutuzumab will be injected instead of Rituximab in order to decreased the risk of cytokine released syndrome) Cycle 3-6: R-CHOP + glofitamab Cycle 7-8: glofitamab alone
223783992|NCT02192437|OTHER|Sulfur amino acid restricted diet|Methionine restricted diet: 70% or 90% restriction Methionine and cysteine restricted diet: 50% or 65% restriction
223783993|NCT01310036|DRUG|Erlotinib|Erlotinib 150 mg was administered orally daily until disease progression or unacceptable toxicity.
223783994|NCT00553267|DRUG|fixed dose combination of telmisartan+amlodipine|
223783995|NCT00553267|DRUG|amlodipine|
223783996|NCT03194802|BEHAVIORAL|Sleeping Without Pills Program|Participants receive this program online and are asked to log in daily for 6 weeks.
223783997|NCT03194802|BEHAVIORAL|Self-monitoring|Participants enter sleep diary data online daily for 6 weeks
223783998|NCT00346060|DEVICE|Retinal transplantation instrument|
223783999|NCT00346060|DEVICE|Fetal tissue.|
223784000|NCT03456908|COMBINATION_PRODUCT|18F-TFB-PET|Infusion of F-18 TFB and PET / CT imaging
223784001|NCT01952535|DRUG|HMS5552|
223784002|NCT01952535|DRUG|Placebo|
223784003|NCT03867877|OTHER|Periodized training with motor practice|Exercises at 75-80% of the subject's maximum for strength exercise using contractions with 2 second concentric and 3 second eccentric for the strength day. 30-80% of subjects' maximal strength for the power day with high-speed concentric and 2 second eccentric contractions, and exercises that simulate activities of daily living for the motor practice day. All resistance-training will be performed on Keiser air-driven machines. Subjects will perform 10 exercises targeting all major muscle groups. The training will last for 12 consecutive weeks, for a total of 36 visits. Each visit will be approximately 60 minutes long and will consist of 5 minutes warm-up, 50 minutes of training and five minutes of cool-down.
223784004|NCT03867877|OTHER|Simple Periodized Training|Exercises at 75-80% of the subject's maximum for strength using contractions with 2 second concentric and 3 second eccentric for the strength day. 30-80% of subjects' maximal strength for the power day, with high speed concentric and 2 second eccentric contractions, and for hypertrophy day at 60-75% of subjects' maximum strength. All resistance-training will be performed on Keiser air-driven machines. Subjects will perform 10 exercises targeting all major muscle groups. The training will last for 12 consecutive weeks, for a total of 36 visits. Each visit will be approximately 60 minutes long and will consist of 5 minutes exercise using contractions warm-up, 50 minutes of training and five minutes of cool-down.
223784005|NCT01175668|DRUG|Clonidine|This group of infants undergoing NAS will be treated with neonatal morphine sulfate and Clonidine as an adjunct medication to control the symptoms. Once stable Finnegan scores \<8 for 24h, NMS will be weaned by 10% daily till off, then Clonidine will be weaned off in a stepwise manner. Infant will not go home on any medication for NAS. NMS will be dosed as mg/kd/day divided q3h and Clonidine will be dosed as microgm/kg/day divided q6h based upon the initial Finnegan scores.
223784006|NCT01175668|DRUG|Phenobarbital|"Infants in this arm will be treated as current standard practice with NMS and Phenobarbital. NMS will be weaned by 10% daily to completely off during the hospital stay. Infants will be discharged home on Phenobarbital.~NMS will be dosed as mg/kg/day divided q3h and Phenobarbital will be dosed as mg/kg/day divided q8h based on the Finnegan scores."
223784007|NCT01269892|DIETARY_SUPPLEMENT|lactose-free milk|a milk without lactose
223784008|NCT01269892|DIETARY_SUPPLEMENT|conventional milk|a milk with lactose
223784009|NCT03236103|OTHER|Clinical Recommendations|"The clinical recommendations will regard the following:~1. Avoidance of potentially nephrotoxic medications (e.g. NSAIDs, intravascular contrast, nephrotoxic antimicrobials)~2. Optimizing volume status (avoidance of volume overload or depletion)~3. Optimizing electrolytes and acid-base status~4. Optimizing hemodynamics (Mean arterial BP\>65mmHg)~5. Assessment of kidney function with serum creatinine and/or cystatin C~None of the suggestions will be experimental. All suggestions will be based on standard nephrology practice."
223784010|NCT02443181|DEVICE|Activa PC+S|Implementation of closed loop DBS for essential tremor
223784011|NCT02565641|DRUG|Capecitabine|Capecitabine will be administered orally at 830 mg/m\^2 BID (equivalent to a total daily dose of 1660 mg/m\^2) as intermittent treatment (given days 1 to 21 q4w).
223784012|NCT02565641|DRUG|Gemcitabine|Gemcitabine will be administered at a dose of 1000 mg/m\^2 once weekly via IV infusion as intermittent treatment (repeated 4-week cycles of 3 weeks treatment and 1 week rest).
223784013|NCT01260246|DRUG|sitagliptin|pill, 100mg/daily for 6 months
223784014|NCT01260246|DRUG|placebo|placebo match for 6 months
223784015|NCT02124642|DIETARY_SUPPLEMENT|Folic acid, 400 mcg/day|The supplement regime for this arm will consist of (1) a women's multivitamin/ multimineral (MVM) supplement containing 400 mcg folic acid, (2) a capsule containing 200 mg DHA and (3) a capsule formulated to contain 10 mg iron (which represents the difference in the amount of iron in the women's MVM formulation and that in prenatal MVM supplements).
223784016|NCT02124642|DIETARY_SUPPLEMENT|Folic acid 800 mcg/day|The supplement regime for this arm will consist of (1) a women's multivitamin/ multimineral (MVM) supplement containing 400 mcg folic acid, (2) a capsule containing 200 mg DHA and (3) a capsule formulated to contain 10 mg iron (which represents the difference in the amount of iron in the women's MVM formulation and that in prenatal MVM supplements) and 400 mcg folic acid.
223784017|NCT00184860|PROCEDURE|PET-scan, MRI-scan|
223784018|NCT00882674|DRUG|RG1507|16mg/kg, 9mg/kg, 3mg/kg or 1mg/kg iv on Day 1 in one of 4 cohorts of patients
223784019|NCT04790981|OTHER|motor imaginary training|Each child shown a video of 5 minutes of illustrating normal movements while the child resting in semi-reclined sitting in quiet room in front the screen. Children then asked to close their eyes and imagine practicing the task like the illustrative video. Repetition of the exercises depend on the children ranging from 5 to 10 repetitions per exercise.
223702558|NCT02234570|DRUG|Oxfendazole|A benzimidazole carbamate antiparasitic drug. Oral Dose levels of 0.5,1, 3, 7.5, 15, 30, and 60 mg/kg will be evaluated sequentially, the dose increasing with each new cohort Group 1 to Group 7.
223702559|NCT02234570|OTHER|Placebo|Normal Saline administered with an oral dosing syringe. Group 1- Group 6
223702560|NCT05064319|DRUG|Gabapentin|After group assignment but before taking any study medication, and again 17 days later, participants will have a Magnetic Resonance Imaging (MRI) exam after completing various assessments (clinical interview, questionnaires, etc.). Group A will receive gabapentin 2-3 times a day for a total of 17 days.
223702561|NCT05064319|DRUG|Placebo|After group assignment but before taking any study medication, and again 17 days later, participants will have a Magnetic Resonance Imaging (MRI) exam after completing various assessments (clinical interview, questionnaires, etc.). Group A will receive placebo 2-3 times a day for a total of 17 days.
223702562|NCT01061216|DEVICE|Intradermal insulin delivery: BD Research Catheter Set|1 unit/hr rapid acting insulin delivered intradermally for 6 hours 4 hour washout period (no insulin delivered) 2 units/hr rapid acting insulin delivered intradermally for 6 hours 4 hour washout period (no insulin delivered)
223702563|NCT01061216|DEVICE|Subcutaneous insulin delivery:ACCU-CHEK Rapid-D Infusion Set|1 unit per hour of rapid acting insulin infusion for 6 hours 4 hour washout (no insulin delivered) 2 unit per hour of rapid acting insulin infusion for 6 hours 4 hour washout (no insulin delivered)
223702564|NCT03395665|OTHER|Estradiol level|Estradiol level measured at previous day of embryo transfer procedure
223702565|NCT03395665|OTHER|Progesterone level|Progesterone level measured at previous day of embryo transfer procedure
223702566|NCT03395665|OTHER|Endometrial thickness|Endometrial thickness measured at previous day of embryo transfer procedure
223784020|NCT04790981|OTHER|physical thertapy training|The Control group received the selected physical therapy program for one hour, three times weekly for three successive months including facilitation of balance and protective reactions from standing position, standing on one leg, weight shifting from standing, squat to standing, strengthening exercises for trunk muscles and for upper and lower extremities musculatures, gait training activities for correction of gait pattern including.
223784021|NCT03981458|DEVICE|Hyalofemme|Gel made with hyaluronic acid to be applied vaginally to treat atrophic vaginitis.
223784022|NCT03981458|DEVICE|Ialuril|Bladder instillation of hyaluronic acid to treat recurrent UTI.
223702567|NCT04753528|DEVICE|AuriMod CT01_A|AuriMod CT01 is a wearable medical device for personalised pain treatment through auricular vagus nerve stimulation. AuriMod CT01 is a battery-operated electrical stimulation device, to be placed behind the ear on the neck. AuriMod CT01 connects to three needle electrodes, which are placed in vagally innervated regions of the auricle. It emits electrical signals with a personalized set of stimulation parameters and adjustable amplitude.
223702568|NCT04753528|DEVICE|AuriMod CT01_B|AuriMod CT01 with a fixed set of stimulation parameters and adjustable stimulation amplitude.
223702569|NCT04753528|DEVICE|AuriMod CT01_C|AuriMod CT01 with a fixed set of stimulation parameters and amplitude.
223702570|NCT01238354|BEHAVIORAL|With friend|
223702571|NCT01238354|BEHAVIORAL|Without friend|
223702572|NCT01482273|PROCEDURE|CDT+US group|CDT using the EkoSonic Endovascular System with intravascular high-frequency, low-power ultrasound for 15 hours.
223702573|NCT01482273|PROCEDURE|CDT-US group|CDT using the EkoSonic Endovascular System without intravascular high-frequency, low-power ultrasound for 15 hours.
223702574|NCT03965767|DRUG|Tranexamic Acid|comparison of effect of tranexamic acid on control of bleeding when used locally in the nose or systemic use
223702575|NCT03959254|PROCEDURE|Physiotherapy post-surgical protocol for femoroacetabular impingement|"The intervention is structured in 14 weeks. Gradually the level of demand for the exercises increases over the weeks. Isometric and concentric exercises of the affected muscle groups are combined in the first weeks, as well as mobilization exercises of the joints involved in the injury. In addition, the time of permanence in a sitting, prone or supine position is prescribed. The return to the march and activities of daily life are staggered.~The number of series and repetitions to be performed is described in each exercise."
223702576|NCT02285647|DRUG|Rolapitant - Oral|Oral Treatment A Investigational Product: Rolapitant Dose: 200 mg (4 x 50 mg) Route of Administration: Oral Dosage Form: Capsule Dosing Condition: Fasted (10 hours overnight)
223702577|NCT02285647|DRUG|Rolapitant - IV|IV Treatment B Investigational Product: Rolapitant Dose: 185 mg Route of Administration: IV (30 minutes) Dosage Form: 2 mg/mL solution Dosing Condition: Fasted (10 hours overnight)
223702578|NCT01136031|DRUG|Paclitaxel and irinotecan|"In phase I part, Level Paclitaxel (mg/m²) Irinotecan (mg/m²)~1. 100 100~2. 100 120~3. 135 120~4. 135 160~every 3 week"
223702579|NCT03328767|BEHAVIORAL|Early activity and Mobilisation intervention|The early activity and mobilisation intervention is comprised of exercises based on a reproducible, physiological approach using both strength and functional activities
223702580|NCT06219304|OTHER|Multimodal functional training|40 minutes of multimodal functional training: 20 minutes of aerobic training on treadmill, 10 minutes of dynamic balance training; 10 minutes of functional strength training.
223702581|NCT06219304|OTHER|Usual care|Exercises aimed at improving balance and mobility
223702582|NCT02585843|DRUG|Spironolactone 100mg|2 capsules of study medication consist of 100mg, PO (oral) for 7 days
223702583|NCT02585843|DRUG|Spironolactone 25mg|25mg/day of spironolactone
223702584|NCT06276673|DEVICE|Delfi|Cuffs will be worn throughout the entire training session. Training session consist of lower intensity wall squats. Four sets of wall squats will be performed to failure. Arterial stiffness and muscle morphological assessments will be conducted before and after the exercise.
223702585|NCT00398918|DRUG|zonisamide|zonisamide (100 mg)one time
223702586|NCT00398918|DRUG|Placebo|Placebo Comparator
223702587|NCT00371072|PROCEDURE|trabeculectomy with mitomycin-C|
223702588|NCT03781843|DRUG|Genicular nerve block with lidocaine|The color doppler ultrasound-guided genicular nerve block at the site of the superior lateral, the superior medial, and the inferior medial genicular nerves.
223702589|NCT03781843|DRUG|Genicular nerve block with saline|The color doppler ultrasound-guided genicular nerve block at the site of the superior lateral, the superior medial, and the inferior medial genicular nerves.
223702590|NCT03781843|DRUG|Genicular nerve block with dextrose|The color doppler ultrasound-guided genicular nerve block at the site of the superior lateral, the superior medial, and the inferior medial genicular nerves.
223702591|NCT01852305|OTHER|Lab Sleep Study Group|Patients in this group will under go lab sleep study overnight at the sleep clinic.If the patient has severe sleep apnea (AHI\>30) or moderate sleep apnea (AHI\>15 to \<30) with significant co-morbidities (e.g. cardiovascular disease, diabetes), CPAP treatment will be recommended. For mild sleep apnea (AHI\>5 to \<15) or moderate sleep apnea without significant co-morbidities, CPAP will not be required. If patient is not able to tolerate or refuses CPAP, dental device and positional therapy will be recommended.
223702592|NCT01852305|DEVICE|Oximetry|The patients in the Oximetry group will undergo overnight pulse oximetry. The patients with ODI\>10 events/hour will be referred to the sleep medicine specialist.A split- night PSG will be employed to confirm OSA diagnosis. The 1st part of the night will be a sleep study and depending on AHI, CPAP titration will be done for the 2nd part of the night
223784023|NCT03023891|DRUG|Prednisone|Prednisone 60 mg tablet once
223784024|NCT06100497|DRUG|Pembrolizumab|Mainly used for neoadjuvant treatment and subsequent adjuvant or maintenance treatment
223784025|NCT06100497|DRUG|Cisplatin|Mainly used for neoadjuvant treatment and concurrent chemoradiotherapy
223784026|NCT06100497|DRUG|Paclitaxel-albumin|Mainly used for neoadjuvant treatment
223784027|NCT00827034|DRUG|Warfarin|A: a single oral dose of warfarin 25 mg administered on Day 1 of the relevant dosing period, as tablets.
223784028|NCT00827034|DRUG|Dimebon|B is oral doses of Dimebon 10 mg TID on Days 1 7 and Dimebon 20 mg TID on Days 8 17, with co administration of a single oral dose of warfarin 25 mg on Day 12 of the relevant dosing period, both as tablets
223784029|NCT00827034|DRUG|Warfarin|B is oral doses of Dimebon 10 mg TID on Days 1 7 and Dimebon 20 mg TID on Days 8 17, with co administration of a single oral dose of warfarin 25 mg on Day 12 of the relevant dosing period, both as tablets
223784030|NCT03631979|OTHER|Intestinal lavage with normal saline|Specially trained pediatric surgeon will administer 10ml/kg pre-warmed (37oC) normal saline via a single-use rectal tube of size 6FR twice per day, aiming at a depth of maximum 10 cm/kg, starting after randomization and not later than 24 hours of age, and continued until full enteral nutrition of 170ml/kg/day is achieved or NEC diagnosis (Bell stage II or more) is established, which one comes first. However, the intervention will be applied at a maximum of 2 weeks from birth.
223784031|NCT03668145|PROCEDURE|mesenchymal stem cell transplantation or placebo infusion via peripheral vein|0.1-1x10E6 MSCs/kg body weight will be administered via peripheral vein for 3 times at week 0, 4 and 8 mesenchymal stem cell mesenchymal stem cell infusion produced by Cell products of National Engineering Research Center(short for CPNERC), Tianjin, China For control group, placebo infusions will be given to the participants at the same time points
223784032|NCT00152295|DRUG|Asoprisnil/Premarin|10 mg (2-5mg tablets) asoprisnil and 0.625 mg Premarin tablets, oral daily for 6 months
223784033|NCT00093769|DRUG|bortezomib + rituximab|"Arm I: Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11. Patients also receive rituximab IV on days 1, 8, and 15 of course 1 only and on day 1 of course 2 only. Treatment with repeats every 21 days for up to 5 courses in the absence of disease progression or unacceptable toxicity.~* Arm II: Patients receive bortezomib IV over 3-5 seconds on days 1, 8, 15 and 22. Patients also receive rituximab IV on days 1, 8, 15, and 22 of course 1 only. Treatment repeats every 35 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.~Patients in either arm may crossover to the other arm if treatment is found to be ineffective."
223784034|NCT02937545|OTHER|Medication Therapy Management|Community pharmacists will provide medication therapy management in combination with pharmacogenetic testing
223784035|NCT02937545|OTHER|Pharmacogenetic testing|Community pharmacist will provide pharmacogenetic testing.
223784036|NCT02095262|OTHER|reactive auditory training|
223784037|NCT02095262|OTHER|Interactive auditory training|
223784038|NCT00273117|PROCEDURE|transnasal gastroscopy|
223784039|NCT02429128|OTHER|14 weeks exercise training|
223784040|NCT02845908|DRUG|POF|Paclitaxel plus Oxaliplatin plus Leucovorin plus 5-FU
223784041|NCT02845908|DRUG|FOLFOX|Oxaliplatin plus Leucovorin plus 5-FU
223784042|NCT02845908|DRUG|FOLFOX plus PAC(ip)|FOLFOX plus intraperitoneally PAC
223784043|NCT05457335|PROCEDURE|undergoing PGT|Preimplantation genetic testing for aneuploidy
223784044|NCT01412723|OTHER|Ferrous sulfate as dietary supplementation|Ferrous sulfate as dietary supplementation
223784045|NCT01412723|OTHER|Iron amino acid chelated as dietary supplementation|Iron amino acid chelated as dietary supplementation
223784046|NCT02096055|DRUG|Cladribine|Given IV
223784047|NCT02096055|DRUG|Guadecitabine|Given SC
223784048|NCT02096055|DRUG|Idarubicin|Given IV
223784049|NCT01985126|DRUG|Daratumumab 16 mg/kg (Part 1)|Daratumumab 16 mg/kg administered at weekly intervals (QW) for 8 weeks, then every 2 weeks (Q2W) for an additional 16 weeks, then every 4 weeks (Q4W) thereafter by intravenous infusion
223784050|NCT01985126|DRUG|Daratumumab 8 mg/kg (Part 1)|Daratumumab 8 mg/kg every 4 weeks (Q4W) continuously by intravenous infusion
223784051|NCT01985126|DRUG|Methylprednisolone|Administered in prophylactic doses intravenously (or equivalent in accordance with local standards) prior to and after study drug administration. Intravenous administration is preferred, but oral steroids may be substituted
223784052|NCT01985126|DRUG|Acetaminophen|650 to 1000 mg administered in prophylactic doses by mouth prior to study drug administration.
223784053|NCT01985126|DRUG|Diphenhydramine|25 to 50 mg administered in prophylactic doses by mouth (or equivalent in accordance with local standards) prior to and after study drug administration.
223784054|NCT01985126|DRUG|Daratumumab (Part 2)|Based on the Part 1 response rate, Group A or B treatment will be selected as the treatment regimen for participants enrolled in Part 2.
223702593|NCT03414281|PROCEDURE|TMQLB group 1|"The patient is placed in the lateral position. The curved (C1-5) probe of Philip CX50 Ultrasound Scanner is used for scan and located vertical to the iliac crest at the posterior axillary line to find the Shamrock sign. The 22-G needle is then inserted in plane and directed to the QL muscle. After the proper position of the needle tip between the psoas major muscle and the quadratus lumborum muscle is confirmed, 0. 4 ml/kg 0.5% ropivacaine with 1: 200,000 adrenaline is injected into the interfascial plane.~Followed by IPCA in the first 48h after surgery: morphine boluses: 1.5-2 mg, lockout time :10 min, 1h limitation: 6-8 mg morphine."
223784055|NCT00941187|OTHER|diffusion NO/CO method|pulmonary capillary blood volume (Vc), measured by the double diffusion NO/CO method: this method is to inhale during a deep inspiration with a mixture of helium (8-10%), CO (2000 ppm) and NO (20-40 ppm), the O2 (21%)
223784056|NCT04302792|BEHAVIORAL|Texture-modified foods for cancer patients (Stage 2)|Participants (cancer patients that require texture-modified foods) will be expected to evaluate a maximum of three meals over a 2-weeks period.
223784057|NCT04302792|BEHAVIORAL|Taste-optimised foods for cancer patients (Stage 3)|Participants (cancer patients with taste \& smell alterations) will be expected to evaluate three foods at home over a period of one month.
223784058|NCT00358046|DRUG|ILY101|
223784059|NCT02057055|OTHER|Soap 300000027003|
223784060|NCT02057055|OTHER|Soap 300000029240|
223784061|NCT06532955|DEVICE|Lymphaticovenous anastomosis using Microsure Motion Stabilizer|"The robot-assisted LVA is performed using the Microsure Motion Stabilizer, a telemanipulation tool that stabilizes a surgeon's movement during open microsurgical operations on extremities, specifically on veins and nerves that are close to the skin.~The surgeon controls a joystick, which directly copies the surgeon's movements in real-time to an instrument held by the device. The device's software scales down the motions and filters out tremor. Surgical technique and method of treatment are identical to conventional microsurgery. The device is equipped with genuine microsurgical instruments and is compatible with existing surgical microscopes. Instead of holding the instrument directly in hand, which is limited in precision and dexterity, the surgeon operates while the instrument's movements are stabilized. The modular design allows the surgeon to decide what level of manipulation assistance is required during a certain procedure."
223784062|NCT06532955|PROCEDURE|Lymphaticovenous anastomosis (manual)|Lymphaticovenous anastomosis (LVA) involves connecting a lymphatic vessel to an adjacent vein of similar size, thereby facilitating the outflow of lymphatic fluid in patients suffering from secondary lymphedema
223784063|NCT05415228|DRUG|68Ga-PSMA-11|68Ga-PSMA-11 is a radiopharmaceutical for the detection of prostate cancer using PET/CT imaging
223784064|NCT00066092|DRUG|pegfilgrastim 12 mg|Pegfilgrastim 12 mg given once for PBPC mobilization
223784065|NCT00066092|DRUG|filgrastim|Filgrastim given daily for PBPC mobilization
223784066|NCT00066092|DRUG|pegfilgrastim 6 mg|Pegfilgrastim 6 mg given once for PBPC mobilization
223784067|NCT00320658|BIOLOGICAL|MSP1 42-C1/Alhydrogel|Recombinant MSP1 42-C1/Alhydrogel vaccine (one of two doses)
223784068|NCT00320658|BIOLOGICAL|CPG 7909|Adjuvant
223784069|NCT06042647|DRUG|0.01% Halobetasol|Drug to be applied at bedtime to designated target psoriasis plaque at bedtime.
223784070|NCT06042647|DRUG|0.045% Tazarotene|Drug to be applied in combination with 0.01% Halobetasol to the designated psoriasis plaque at bedtime.
223784071|NCT06042647|DRUG|0.05% Clobetasol Propionate|Drug to be applied to designated psoriatic plaque at bedtime.
223784072|NCT03818217|DEVICE|Coach Pepper group|"Robot Pepper's height is 1.20 meters and it weighs 28 kilograms. Pepper's operation time is about 12 hours.~Pepper will be called as Coach Pepper because s/he is virtually connected via web interfaces with a theratainment app including cognitive and physical training ."
223784073|NCT03818217|DEVICE|Tablet group|The Tablet provides a theratainment app including cognitive and physical training.
223784074|NCT04279808|PROCEDURE|dilator depth|For soft tissue dilation just after guidewire insertion in central venous catheterization through the right internal jugular vein, investigators will measure the distance between the skin puncture site and outside of anterior wall of the vein with real-time ultrasonography in the measured depth group. Next, practitioner will insert the dilator by the measured length and continue to insert the central venous catheter. For the conventional group as a control group, practitioner will perform the central venous catheterization with a manner used routinely by the practitioner.
223784075|NCT05071001|PROCEDURE|MRI|"This assessment will be planned in the year after the consent signAll patients will have one brain MRI performed in Henri Mondor Hospital on a 3T MR unit (Skyra, Siemens, Erlangen). The procedure will include:~1. a 3D-FLAIR imaging~2. a morphometric study based on a 3DT1 MPRAGE gradient echo sequence (TR / TI / TE = 2300/900 /2.9 ms)~3. an analysis of the anatomic connectivity of the patient's brain assessed using a 1.5mm isotopic DTI with a high number of directions (HARDI / 65 directions / b=1500s/mm2).~4. An evaluation of neuronal dysfunction using MR Spectroscopy. Spectroscopic data will be collected using a 2D CSI laser with a short TE technique.~5. Magnetization transfer imaging providing information about integrity of membranes."
223784076|NCT00969033|DRUG|CS-1008|CS-1008
223784077|NCT00969033|DRUG|irinotecan|irinotecan
223784078|NCT03146169|BEHAVIORAL|Training group|"The training workshop includes four two-hour sessions:~Session one - a knowledge, self-efficacy, and motivation enhancement session at baseline; Session two - an interpersonal communication and leadership skills session at one week; Session three - a motivation enhancement session at one month Session four - an experience sharing session at three months"
223784079|NCT04483869|OTHER|Thermography|thermographic image a 1, 3, 5 et 10 minutes of life
223784080|NCT01618838|RADIATION|CyberKnife radiosurgery|"Treatment Planning:~Inverse planning using the CyberKnife planning system will be employed. The treatment plan used for each treatment will be based on an analysis of the volumetric dose including dose-volume histogram (DVH) analyses of the Planning Treatment Volume (PTV) and critical normal structures. The homogeneous CT model shall be used. Number of paths and beams used for each patient will vary and will be determined by the selected individual treatment plan. To reduce overall treatment time and total monitor units, 150-200 non-zero beams are recommended. No more than 250 beams shall be employed. Tuning structures shall be employed to minimize conformality index (CI) and new conformality index (nCI), preferably yielding values less than 1.20 and 1.25, respectively."
223784081|NCT00690521|DRUG|Treatment of Furosemide + Hydrochlorothiazide|A randomized, double-blind, crossover study designed to compare the efficacy of hydrochlorothiazide in combination with stable doses of furosemide in congestive heart failure patients.
223784082|NCT00690521|DRUG|Treatment of Furosemide + Metolazone|A randomized, double-blind, crossover study designed to compare the efficacy of metolazone in combination with stable doses of furosemide in congestive heart failure patients.
223784083|NCT01507168|DRUG|Placebo|iv Days 1 and 8, and every 2 weeks thereafter
223784084|NCT01507168|DRUG|GC33|1600 mg iv Day 1 and 8, and every 2 weeks thereafter
223784085|NCT03835533|DRUG|NKTR-214 (Cohort A)|NKTR-214 will be administered intravenously every 3 weeks for up to 2 years
223784086|NCT03835533|DRUG|Nivolumab (Cohort A, B and C)|Nivolumab will be administered intravenously every 3 weeks for up to 2 years to cohort A, every 4 weeks for up to 2 years for cohort B and C.
223784087|NCT03835533|RADIATION|Stereotactic body radiation therapy (SBRT) (Cohort B)|Radiation therapy will be administered at 30 - 50 Gy in 1 - 5 doses, starting on Day 1 or 2 of Cycle 1
223702594|NCT03414281|PROCEDURE|TMQLB group 2|"The patient is placed in the lateral position. The curved (C1-5) probe of Philip CX50 Ultrasound Scanner is used for scan and located vertical to the iliac crest at the posterior axillary line to find the Shamrock sign. The 22-G needle is then inserted in plane and directed to the QL muscle. After the proper position of the needle tip between the psoas major muscle and the quadratus lumborum muscle is confirmed, 0. 6 ml/kg 0.5% ropivacaine with 1: 200,000 adrenaline is injected into the interfascial plane.~Followed by IPCA in the first 48h after surgery: morphine boluses: 1.5-2 mg, lockout time :10 min, 1h limitation: 6-8 mg morphine."
223784088|NCT03835533|DRUG|CDX-301 (Cohort B and C)|CDX-301 will be subcutaneously once a day for 5 days for cohort B. CDX-301 will be subcutaneously once a day for 10 days of immune-priming lead-in for cohort C.
223784089|NCT03835533|DRUG|Poly-ICLC (Cohort B)|Poly-ICLC will be administered intramuscularly twice weekly for 3 weeks starting on Day 1 of Cycle 1
223702595|NCT03414281|PROCEDURE|TPVB|"The patient is placed in the lateral position, the spinous processes of T10 are identified and marks are made 2cm lateral to the spinous processes. The linear(L12-3) probe of Philips CX50 is placed transversally at the mark to identify the paravertebral space. Then a 22-G needle is inserted in-plane from lateral to medial and advanced until the tip reached the paravertebral space surrounded by the parietal pleura and the superior costotransverse ligament. 0.4 ml/kg 0.5% ropivacaine with 1: 200,000 adrenaline is injected into the paravertebral space of T10.~Followed by IPCA in the first 48h after surgery: morphine boluses: 1.5-2 mg, lockout time :10 min, 1h limitation: 6-8 mg morphine."
223784090|NCT03835533|DRUG|INO-5151 (Cohort C)|INO-5151 will be administered intramuscularly on Day 8 of the Immune-priming Lead-in, and on day 1 of Cycle 1, 2 and 3, then every 12 weeks thereafter
223784091|NCT03835533|DEVICE|Cellectra 2000|Electroporation device
223784092|NCT02556021|DRUG|CJ-12420 50mg|CJ-12420 50mg, tablet, once daily, oral administration for up to 4 weeks
223784093|NCT02556021|DRUG|CJ-12420 100mg|CJ-12420 100mg, tablet, once daily, oral administration for up to 4 weeks
223784094|NCT02556021|DRUG|Placebo|Placebo, tablet, once daily, oral administration for up to 4 weeks
223784095|NCT05213845|PROCEDURE|Spine flexion/extension active range of motion exercises|Five full active range of motion rehabilitation sessions will be scheduled. Four or the five following full active range of motion exercises will be performed during one rehabilitation session : spine flexion and extension (quadrupedic position), lumbar flexion and extension (sitting position), posterior and anterior pelvic tilt (sitting and standing position), lumbar flexion and extension (standing position) and Jefferson Curl exercise. All five rehabilitation sessions must be performed within 60 days
223784096|NCT03137147|BEHAVIORAL|Intervention for Sleep and Pain in Youth|See arm description.
223784097|NCT02824276|DRUG|Oxycodone or morphine sulfate immediate release (MSIR)|Oxycodone or morphine sulfate immediate release (MSIR)
223784098|NCT02824276|DRUG|Placebo Treatment|Lactose (Appearance and Weight-matched placebo capsules)
223784099|NCT04622358|DRUG|AD-214-02|1 tablet administered before the breakfast during 7 days
223784100|NCT04622358|DRUG|Rabeprazole|1 tablet administered before the breakfast during 7 days
223784101|NCT04144400|BEHAVIORAL|Direction Check App|Direction Check is a simple, inexpensive app that builds resilience through balanced values to target the everyday personal and occupational stressors faced by military populations.
223784102|NCT04144400|BEHAVIORAL|Direction Check App (Time Management Version)|Direction Check (Time Management Version) is a simple, inexpensive app that builds resilience through time management exercises to target the everyday personal and occupational stressors faced by military populations.
223784103|NCT03989817|DRUG|Vasoactive Intestinal Peptide (VIP) and Saline|12 healthy volunteers of both genders will be included in the main study. Participants will meet twice, with at least one week in between. The main study is a double-blind, randomized, cross-over trial among placebo (sterile saline, non-active substance) and VIP. Intravenous infusion of VIP / placebo (saline) will be conducted over 120 minutes. Patients will be asked after each trial day to record headache strength, accompanying symptoms, and drug use for up to 24 post-infusion.
223784104|NCT03812458|BEHAVIORAL|website and brochure|website and brochure
223784105|NCT01678326|PROCEDURE|EUS-Rendezvous or direct intervention|
223784106|NCT01678326|PROCEDURE|Advanced ERCP Biliary Access Techniques|
223784107|NCT01136291|OTHER|physical exercise|"The exercise protocol was done under supervision once a week. Pregnant women have been told to do some exercise three more times during the week unsupervised and may be the protocol of exercises or walk in mild to moderate intensity.~The exercise protocol lasted 50 minutes with 10 minutes of stretching overall, 30 minutes of exercise for muscle strengthening and 10 minutes of relaxation.~These women also received nutrition counseling and prenatal care."
223784108|NCT05531396|OTHER|Agility Training|Participants will receive 60 minutes of exercise, twice a week, for a total of 8 weeks, and training will be conducted by a well-trained physical therapist. The intervention will comprise a 5-minute warm-up, 45 minutes of main exercise, and a 10-minute cool-down period, for a total of 60 minutes each session. During the warm-up and cool-down, participants will do static and dynamic whole-body stretching exercises.
223702596|NCT04709107|OTHER|Quality of life assessment - elective|"Patients will be asked to fill up both VascuQoL-6 and SF-36 questionnaires before the procedure, as well at 30-days and 1-year follow-up visit while they are sitting in the waiting room. To assess reliability and systematic shift and variation between the two assessments, elective patients will be asked to fill the VascuQoL-6 again at the admission to hospital, as well as 1 week after the 30-days follow-up vie an e-mail link for a test-retest assessment. All questionnaires will be administered on a tablet.~During the 30-days follow-up 4 extra questions concerning patient related outcomes and occurrence of major complication will be added to the VascuQoL-6 questionnaire in the App. During every visit (preoperatively, at 30-days and 1-year follow-up) the stage of the lower limb peripheral artery disease will be noted according to the WIfI-Classification."
223702597|NCT04709107|OTHER|Quality of life assessment - emergent|"Patients will be asked to fill up both VascuQoL-6 and SF-36 questionnaires before the procedure, as well at 30-days and 1-year follow-up visit while they are sitting in the waiting room. All questionnaires will be administered on a tablet.~During the 30-days follow-up 4 extra questions concerning patient related outcomes and occurrence of major complication will be added to the VascuQoL-6 questionnaire in the App. During every visit (preoperatively, at 30-days and 1-year follow-up) the stage of the lower limb peripheral artery disease will be noted according to the WIfI-Classification."
223702598|NCT03614364|DRUG|nanoxel|D1 Nanoxel 75 mg/m2 + D5W 100mL MIV over 1hr D1 Herzuma 8mg/kg (loading dose) + N/S 250mL miv over 90mins 6mg/kg (maintenance) + N/S 250mL MIV over 30mins (since 2 cycle) repeated every 3 weeks
223702599|NCT03614364|DRUG|herzuma|D1 Nanoxel 75 mg/m2 + D5W 100mL MIV over 1hr D1 Herzuma 8mg/kg (loading dose) + N/S 250mL miv over 90mins 6mg/kg (maintenance) + N/S 250mL MIV over 30mins (since 2 cycle) repeated every 3 weeks
223702600|NCT03094429|DRUG|NaBen®|2000 mg/day or 1000 mg/day, twice daily
223702601|NCT03094429|OTHER|Placebo|0 mg total, twice daily
223702602|NCT03144921|BEHAVIORAL|psychoeducational skills training intervention|This protocol is a minimal risk care values clarification /care planning and psychoeducational skills training intervention, delivered as a workshop series plus one in-home session for people in the early stages of memory loss and their care partner together.
223702603|NCT01788046|DRUG|Etelcalcetide|Administered intravenously three times per week. The starting dose was 5 mg. The dose may have been increased at weeks 5, 9, 13, and 17 (4-week intervals) by 2.5 mg or 5 mg on the basis of the predialysis parathyroid hormone and corrected calcium concentrations obtained in the prior week. The minimum dose was 2.5 mg and the maximum dose was 15 mg.
223702604|NCT01788046|DRUG|Placebo|Administered intravenously (IV) three times per week.
223702605|NCT00751166|DRUG|Desloratadine|Desloratadine 5 mg, oral tablet, once daily in the morning, 28 days
223702606|NCT00751166|DRUG|Cetirizine|Cetirizine 10 mg, oral tablet (over encapsulated), once daily in the morning, 28 days
223702607|NCT00751166|DRUG|placebo|placebo once daily for 28 days
223702608|NCT03515083|DEVICE|Alive Cor Kardia mobile electrocardiogram monitor|Mobile ECG monitor paired with smart phone application
223702609|NCT03169543|BEHAVIORAL|Sleep deprivation|36-hours total sleep deprivation
223702610|NCT01856907|DRUG|Sitagliptin-Metformin|Experimental -dipeptidyl peptidase-4 (DPP-4) inhibitor- oral medication
223702611|NCT01856907|DRUG|Metformin|Biguanide- insulin sensitizer
223702612|NCT01856907|DRUG|Placebo pill|Will evaluate effect of lifestyle and diet only
223702613|NCT02927327|DEVICE|Zero Echo Time (ZTE) scan for head attenuation|"The GE SIGNA PET/MR MP26 software platform includes the zero echo time (ZTE) scan for head attenuation and Q.Static. The ZTE MR software feature has the potential to enable better visualization of bones, including those in the head, by employing optimal head attenuation correction in PET/MR.~PET/MR ZTE MRAC"
223702614|NCT02927327|DEVICE|Q.Static (Q. MRAC) for respiratory motion correction|"An improved Q.Static feature with Q. MRAC, where phase matching the MRAC with the quiescent phase is employed to get more accurate attenuation correction for our Q.Static PET images.~PET/MR Q Static (Q. MRAC)"
223702615|NCT01814631|OTHER|image quality and resolution|Image quality and resolution will be viewed using Aloka processor
223702616|NCT01814631|OTHER|image quality and resolution|image quality and resolution will be viewed on the EU-me2
223702617|NCT01806558|PROCEDURE|Molecular Breast Imaging|Molecular breast Imaging is a new nuclear medicine technique for imaging the breast. It uses small filed of view semiconductor-based gamma cameras that use Cadmium Zinc Telluride detectors. These have superior spatial and energy resolution to conventional sodium iodide detectors.
223702618|NCT00890266|PROCEDURE|Collagen cross-linking with hypotonic riboflavin|Topical anaesthesia, corneal epithelial debridement, application of hypotonic riboflavin 0.1% solution (20 minutes), application of UV light (30 minutes).
223702619|NCT03202888|BEHAVIORAL|Intervention|QuesGen-created mobile responsive website tool, Family Input for Quality and Safety.
223702620|NCT01870050|DRUG|Dapsone gel - verum|
223702621|NCT01919671|DRUG|Tongxinluo capsule|for 90 days
223702622|NCT01919671|DRUG|placebo capsule|for 90 days
223702623|NCT01963273|PROCEDURE|Video Assisted Ablation of Pilonidal Sinus|
223702624|NCT04312204|DRUG|Sintilimab combined with Gemcitabine and Carboplatin|"The patients will received Gemcitabine1000mg/m2(d1,d8)(iv)+carboplatin AUC 5 (d1)(iv),4 cycles, Sintilimab 200 mg (3mg/kg when the weight \<40kg ) (d1) (iv) in one cycle every 3 weeks, until PD or death.~Radiological examinations (according to the RECIST 1.1 criteria) at baseline will be repeated for tumor response evaluation following every two cycles of chemotherapy. Patients will be followed up to 30 days after the last dose of study chemotherapy, and then every 3 months."
223702625|NCT01374828|DRUG|Ketolorac|Ketorolac 30 mg in 10 ml saline will be injected at the incision sites at the conclusion of the procedure.
223702626|NCT00839722|PROCEDURE|embolization|fertility after embolization
223702627|NCT04517500|BEHAVIORAL|Home-based pulmonary rehabilitation program|Subjects will wear an activity monitor while doing at home exercises using a computer tablet
223702628|NCT04517500|BEHAVIORAL|Mindful breathing module|Additional module on the computer tablet that involves inhaling and exhaling while following an animated ball on the computer screen.
223702629|NCT04517500|BEHAVIORAL|Health coaching|Weekly coaching calls to discuss rehabilitation and health process using motivational interviewing
223702630|NCT02201849|DRUG|Study Drug|
223702631|NCT02201849|DRUG|Active Control|
223702632|NCT02201849|DRUG|Placebo|
223702633|NCT05994365|DRUG|Anlotinib Hydrochloride Capsule|Anlotinib hydrochloride is a muti-target tyrosine kinase inhibitor that inhibits both tumor angiogenesis and tumor cell proliferation.
223702634|NCT04948528|OTHER|Active Comparator: Surgery Pathology or Cystoscopy|Case group will be followed up with surgery pathology or cystoscopy.
223702635|NCT04948528|OTHER|Active Comparator: Clinical Diagnosis|Control group will be diagnosed in clinical.
223702636|NCT02824575|DRUG|Rebastinib|50 mg or 100 mg po BID continuously. Cycle duration: 21 days. Number of Cycles: 4 cycles or until progression or unacceptable toxicity develops.
223702637|NCT02824575|DRUG|Paclitaxel|Paclitaxel 80 mg/m2 weekly. Cycle duration = 21 days. Number of Cycles: 4 cycles or until progression or unacceptable toxicity develops.
223702638|NCT02824575|DRUG|Eribulin Mesylate|Eribulin 1.4 mg/m2 day 1 \& 8. Cycle duration : 21 days. Number of Cycles: 4 cycles or until progression or unacceptable toxicity develops.
223702639|NCT02987842|DEVICE|TruScan Neurofeedback|Neurofeedback and quantitative EEG system
223702640|NCT06255964|DRUG|IAP0971|Induction period (6 weeks): IAP0971 single drug bladder infusion, once a week;Maintenance period: IAP0971 single drug bladder infusion, performed at 3, 6, 12, 18, and 24 months, once a week, for 3 consecutive times
223702641|NCT06255964|COMBINATION_PRODUCT|IAP0971＋BCG|Induction period (6 weeks): IAP0971 combined with BCG,Bladder perfusion, once a week;Maintenance period: IAP0971 combined with BCG bladder perfusion,Maintain at months 3, 6, 12, 18, and 24Perfusion, once a week, three times in a row.
223702642|NCT06255964|COMBINATION_PRODUCT|IAP0971＋BCG|Induction period (6 weeks): IAP0971 combined with BCG,Bladder perfusion, once a week;Maintenance period: IAP0971 combined with BCG bladder irrigationNote, progress at months 3, 6, 12, 18, and 24Perform maintenance perfusion once a week, three times in a row.
223702643|NCT04391361|DRUG|Scopolamine, atropine, edaravone and dexmedetomidine|The patients were treated with scopolamine, atropine, edaravone and dexmedetomidine dissolved in saline.
223784109|NCT05531396|OTHER|Health Education|Participants in the control group will receive health educational guidelines. Guideline contents include home-based exercise program, nutrition recommendations, and fall prevention education. The home-based exercise program will emphasize how to safely and properly perform stretching and whole-body exercises.
223784110|NCT00141440|PROCEDURE|mechanical ventilation|evaluated the effect of two different cycling off criteria on breathing pattern, respiratory effort, and gas exchange in patients with chronic obstructive pulmonary disease
223784111|NCT02015897|PROCEDURE|Physical TherapyA|"Group A:~* Skin care~* Manual lymphatic drainage~* Bandaging using Coban™2Lite~* Guidance on physical activity"
223702644|NCT04391361|DRUG|Edaravone|The patients was treated with edaravone dissolved in the same volume of saline as the intervention applied in the experimental group.
223702645|NCT03626168|DIETARY_SUPPLEMENT|100% watermelon juice|Participants drank two 12-ounce servings of 100% watermelon juice per day for a four-week period.
223702646|NCT03626168|OTHER|Placebo beverage|Participants drank two 12-ounce servings of a placebo beverage per day for a four-week period.
223784112|NCT02015897|PROCEDURE|Physical TherapyB|"Group B:~* Skin care~* Bandaging using Coban™2Lite~* Guidance on physical activity"
223702647|NCT03369093|DRUG|Amoxicillin|Twice daily doses of injectable amoxicillin
223702648|NCT03954691|OTHER|brain tumor-immune cells communication|tumoral and immune cell isolation from biopsis
223702649|NCT06383065|OTHER|IMT Group|Inspiratory muscle training involves breathing exercises using a pressure threshold device to strengthen the muscles involved in breathing in.
223784113|NCT03421691|DEVICE|excel V Laser|excel V Laser Genesis procedure utilizing 1064 nm laser
223784114|NCT00084058|DRUG|Lopinavir/ritonavir|
223702650|NCT06365112|PROCEDURE|Endoscopy assisted|Endoscopy
223702651|NCT03109730|DRUG|ABI-H0731|A novel HBV core protein allosteric modifier (CpAM) which is being developed as a potential therapeutic advance for CHB patients
223702652|NCT03109730|DRUG|Placebo for ABI-H0731|Sugar pill manufactured to mimic the ABI-H0731 tablet
223702653|NCT03109730|DRUG|Entecavir|An antiviral medication used in the treatment of hepatitis B virus infection
223702654|NCT03109730|DRUG|Tenofovir Disoproxil Fumarate|An antiviral medication used in the treatment of hepatitis B virus infection
223702655|NCT03109730|DRUG|Pegasys|Used to treat adults with chronic hepatitis B virus who show signs of liver damage
223702656|NCT02435446|DEVICE|Cone-beam computed tomography|Cone-beam computed tomography
223702657|NCT01402765|DEVICE|Summit first|Pressure measurements are first taken on the Summit mattress. The patient is then transferred to a Nimbus 3 mattress, and the measures are repeated.
223702658|NCT01402765|DEVICE|Nimbus 3 first|Pressure measurements are first taken on the Nimbus 3 mattress. The patient is then transferred to a Summit mattress, and the measures are repeated.
223702659|NCT02418429|OTHER|waxy maize starch|pancake test meal with waxy maize starch only
223702660|NCT02418429|OTHER|waxy maize starch and Whey Protein|pancake test meal with waxy maize starch and whey protein
223702661|NCT02418429|OTHER|Resistant Starch|pancake test meal with resistant starch only
223702662|NCT02418429|OTHER|resistant starch and whey protein|pancake test meal with resistant starch and whey protein
223702663|NCT03300284|BEHAVIORAL|Questionnaires|Quality of Life Questionnaires
223702664|NCT02328183|DRUG|Polymyxin B|administrate drug by 0.75-1.25 mg/kg/dose intravenously q 12 hrs both saline and dextrose solution can be dissolved duration 7-14 days
223702665|NCT03474861|BIOLOGICAL|anticancer medication A01; immune cells IC01|"The administration of the anticancer medication A01 and immune cells IC01 will be performed in The Second Hospital of Jiaxing, Zhejiang, China.~The subjects will be observed for any side effects during this time and all the adverse events will be recorded."
223702666|NCT00850070|DRUG|sapropterin|Patients will receive sapropterin 20 mg per kilogram per day for 16 weeks
223702667|NCT00850070|DRUG|Placebo|Patients will receive a placebo identical in form and dosage to the active drug daily for 16 weeks.
223702668|NCT01529242|DRUG|Desloratadine + Prednisolone|Children (2 to 5 years): 2.5 ml 3 times a day Children (6 to 12 years): 5.0 ml 3 times a day
223702669|NCT01529242|DRUG|Dexchlorpheniramine + Betamethasone|Children (2 to 5 years): 2.5 ml 3 times a day Children (6 to 12 years): 5.0 ml 3 times a day
223702670|NCT05047770|BIOLOGICAL|HZ/su|2 doses of HZ/su vaccine administered intramuscularly, either sequentially (HZ/suSeq Group) or simultaneously (HZ/suCoAd Group) with the mRNA-1273 booster dose. The second dose of HZ/su was administered 8 weeks after the first dose of HZ/su vaccine.
223702671|NCT05047770|COMBINATION_PRODUCT|Flu D-QIV|1 dose of Flu D-QIV vaccine administered intramuscularly, either sequentially (FluD-QIVSeq Group) or simultaneously (FluD-QIVCoAd Group) with the mRNA-1273 booster dose.
223702672|NCT05047770|BIOLOGICAL|mRNA-1273|1 booster dose of mRNA-1273 vaccine administered intramuscularly at Day 1 (all groups).
223702673|NCT04382300|DRUG|pyrotinib combined with thalidomide|Single Group Assignment
223702674|NCT06051370|PROCEDURE|Ultrasound-guided glenohumeral space triamcinolone, lidocaine and saline injection|Using a 21-gauge spinal needle, the predefined steroid solution was injected under ultrasound guidance using 5- to 13-MHz linear probe into the glenohumeral space through the posterior approach
223702675|NCT06051370|PROCEDURE|Ultrasound-guided subacromial space triamcinolone, lidocaine and saline injection|Using a 21-gauge spinal needle, the predefined steroid solution was injected under ultrasound guidance using 5- to 13-MHz linear probe into the subacromial space through the anterolateral approach
223702676|NCT01878279|OTHER|Underlying medical illness|
223702677|NCT06442280|DRUG|Dapagliflozin tablet|Dapagliflozin 10 mg 1 tablet once daily
223702678|NCT06442280|DRUG|Hypertonic Saline Solution, 1 Ml|Intravenous infusion of furosemide combined with hypertonic saline solutions (100 mL) twice daily
223702679|NCT06442280|DRUG|Furosemide Injection|Furosemide 20 mg
223702680|NCT03307642|OTHER|Text message notification|Three text messages will be sent to 50% of the parents, scheduled around the standard methods of communication
223702681|NCT02391701|BEHAVIORAL|Diet|diet program 1 day a month for 3 months in 120-minute diet sessions + freely receive Atlantic Diet food (vegetables, cheese, olive oil, mussels and wine)
223702682|NCT04769661|DIAGNOSTIC_TEST|Cytokines|Doing cord blood cytokines level in preterm infants
223702683|NCT03845777|DIAGNOSTIC_TEST|Using Antiseptic solution|Using of iodine including antiseptic solutions. The investigators investigate the urine iodine status of staff before and after the using of antiseptic solution
223702684|NCT02835742|DRUG|Sargramostim|
223702685|NCT02835742|DRUG|Placebo|
223702686|NCT01181908|DRUG|single dose|Subjects will receive a single dose of GSK1144814 or placebo.
223702687|NCT04002739|DIAGNOSTIC_TEST|Polygraphy|Patients will perform polygraphy during the CCU stay (baseline) and, if found to have a diagnosis of Obstructive Sleep Apnea (OSA) syndrome, will complete the study with a follow-up visit at 90-day (follow-up). Diagnosis of OSA syndrome will require an Apnea / Hypopnea Index (AHI) more than 5 events per hour.
223702688|NCT00589992|DRUG|Ibutilide fumarate|During scheduled radio frequency ablation for atrial fibrillation patients will be infused with 1mg of ibutilide over 10 minutes.
223702689|NCT06189690|DEVICE|rTMS|Repetitive TMS will be administered by a MagPro R30 stimulator and an active/placebo MCF-B70 A/P coil. All participants will use two surface electrodes to simulate rTMS skin sensations near to stimulation site. rTMS/sham conditions will be double-blinded by a USB stick. The USB contains the information about rTMS/sham condition and this is not available to the stimulator operator. Parameters of rTMS were previously described.
223702690|NCT03047655|BEHAVIORAL|Lifestyle intervention (physical activity)|Dietary treatment with or without additional motivation on more physical activity
223702691|NCT03047655|DIETARY_SUPPLEMENT|Lifestyle intervention (PUFA/isomaltulose-enriched muffin)|
223784115|NCT00084058|DRUG|Saquinavir|
223784116|NCT01286259|DRUG|Disulfiram|Open label 500mg disulfiram per day by mouth for 14 days
223702692|NCT06310915|DRUG|Navelbine oral,Pembrolizumab|Oral vinorelbine was administered three times weekly, and pembrolizumab was administered every 3 weeks
223702693|NCT00731016|DRUG|Zoledronic acid, pravastatin|"Pravastatin : 10 mg daily~Zoledronic acid : slow (30 mn) intravenous injections, diluted into 50 ml of saline solution following this schedule :~* injection 1, S1: 0.0125 mg/kg of zoledronic acid~* injection 2, S6: 0.025 mg/kg of zoledronic acid~* injection 3, S12 and following, trimestrial basis, 0.05 mg/kg of zoledronic acid"
223702694|NCT01354327|DIETARY_SUPPLEMENT|Limicol|3 tablets / day during 4 months
223702695|NCT01354327|DIETARY_SUPPLEMENT|Placebo|3 tablets / day during 4 months
223702696|NCT05122871|OTHER|Scape Room|Practical training through scape-room with simulator
223702697|NCT05122871|OTHER|Simulation|Practical training through simulator
223702698|NCT03849807|OTHER|Experimental group|the intervention group will receive 4 weeks of chiropractic care along with usual care(Cognitive-Behavioral, psychosocial Therapy).
223702699|NCT03849807|OTHER|Control group|Participants in the group will receive usual health (Cognitive-Behavioral, psychosocial Therapy) care or wish to engage in during the course of the study as well as receiving a passive movement control intervention delivered by a chiropractor 3 times per week in the same hospital setting as the group receiving chiropractic care.
223702700|NCT00570167|PROCEDURE|Hip resurfacacing|Hip resurfacing with cementless acetabular cup and cemented femoral head
223702701|NCT00570167|PROCEDURE|Cementless total hip arthroplasty with m-o-m bearings|Cementless monoblock acetabular cup and cementless femoral stem with modular large head and metal-on-metal bearings..
223702702|NCT03616132|DEVICE|Device: Sirolimus-eluting Iron Bioresorbable Coronary Scaffold System|Implantation of Sirolimus-eluting Iron Bioresorbable Coronary Scaffold System (IBS)
223702703|NCT05416151|OTHER|Freeze-dried biotic|2 sticks of 3g consumed daily for 28 days
223702704|NCT05416151|OTHER|Maltodextrin|2 sticks of 3g consumed daily for 28 days
223702705|NCT02956070|DRUG|Dexamethasone acetate|The volunteers in the Dexamethasone acetate group (experimental group) will receive six capsules of dexamethasone 8 mg each to be administered orally, initially two days before the first bleaching query as follows: 8 mg (1 capsule) 9 am two days before the first clinical session whitening; 8 mg (1 capsule) the 9 am to 1 day before session whitening, 8 mg (1 capsule) to 9 am on the day of the first session of whitening.Clinical intervention: 1- Dry teeth and apply Gingival Barrier to both arches. 2- Light cure. 3- Firmly attach a mixing nozzle to the Pola Office+. 4- Apply a thin layer of gel to all teeth undergoing treatment. 5- Leave gel on for 8 minutes. 6- Suction it off. 7- Repeat steps 5-6 twice times. 8- After the last application, suction all the gel off, then wash and apply suction. 9- Remove Gingival Barrier. 10- A placebo gel will be applied with a brush on the labial surface of the teeth whitened for 2 to 3 minutes .
223702706|NCT02956070|DRUG|Potassium Nitrate|The volunteers in the Potassium Nitrate Group (Placebo group) will receive 6 placebo capsules, who contained the same components of de dexamethasone drug except the active ingredient (starch \[50%\], lactose monohydrate \[35%\], dibasic calcium phosphate \[14%\], and magnesium stearate \[1%\]).Clinical session:1- Dry teeth and apply Gingival Barrier to both arches. 2- Light cure. 3- Firmly attach a mixing nozzle to the Pola Office+. 4- Apply a thin layer of gel to all teeth undergoing treatment. 5- Leave gel on for 8 minutes. 6- Suction it off. 7- Repeat steps 5-6 twice times. 8- After the last application, suction all the gel off, then wash and apply suction. 9- Remove Gingival Barrier. 10- A desensitizing gel containing 6% potassium nitrate will be applied with a brush on the labial surface of the teeth whitened for 2 to 3 minutes .
223702707|NCT03172819|BIOLOGICAL|OBP-301|"Intratumoral injection directly into the dose target region of a tumor at Day 1, Day 15, and Day 29.~Additional administration of OBP-301 After the recommended dose of OBP-301 has been established, additional administration of OBP-301 is allowed. After completion of administration of OBP-301 on Day 1 - Day 29(+/- 4 days), if the target region has not disappeared, additional administration of OBP-301 is allowed after Day 43 or later.~The patients in Phase 1a, Pembrolizumab administration has continued, are included.~The recommended dose determined in the Phase 1a part will be administered 3 times biweekly (+/- 4 days); max 4 cycles."
223702708|NCT03172819|DRUG|Pembrolizumab|200 mg Pembrolizumab is infused intravenously at Day 8. Thereafter infusion will continue every 3 weeks until discontinuation.
223784117|NCT04638010|BEHAVIORAL|Cancer control navigation (CNN)|Cancer Control Navigators (CNNs) housed at 2-1-1 call centers aid callers. CNNs receive electronic summary profiles of participants assigned to navigation. Navigators call the participant, build a collaborative relationship with them, identify their needs, work with them to identify barriers to services and coordinate solutions, and provide logistic (e.g., making appointments) and emotional support. Navigation services are provided by telephone only.
223784118|NCT04638010|BEHAVIORAL|General referral (usual care)|Information Specialists at the 2-1-1 call center provide cancer control referrals specific to participant's screening or prevention needs.
223784119|NCT06262035|OTHER|Periodontitis and Peri-implantitis|Defined periodontitis at ≤ 2 non-adjacent teeth AND Defined peri-implantitis at ≤ 1 implant, in function of at least 1 year.
223784120|NCT05734859|DEVICE|Electrolyzed Alkaline Ionizer|Patients will drink EHARW calculated by 20 mL/kg body weight/day which can be divided into several times a day for drinking. The patient is recommended to drink water in an empty stomach and to drink water generated from the device as soon as possible.
223784121|NCT00127673|DRUG|Sertraline|The dose of sertraline will be up to 200 mg daily for 10 weeks. There will also be weekly meetings with study psychiatrist.
223784122|NCT00127673|BEHAVIORAL|Cognitive behavioral therapy (CBT)|CBT will include 10 weekly sessions of individual cognitive behavioral therapy.
223784123|NCT03607305|PROCEDURE|BP limb 70cm|Performance of RYGB with a BP limb of 70cm
223784124|NCT03607305|PROCEDURE|BP limb 120cm|Performance of RYGB with a BP limb of 120cm
223784125|NCT04989270|PROCEDURE|General Anesthesia|General anesthesia with intubation, ventilation, intravenous and inhalational anesthetics, opioids and muscle paralysis
223784126|NCT04989270|PROCEDURE|Regional Anesthesia|Spinal Anesthesia, Epidural Anesthesia
223784127|NCT02796339|DIETARY_SUPPLEMENT|Mastiha|
223784128|NCT02796339|DIETARY_SUPPLEMENT|Placebo|
223784129|NCT00125489|DRUG|chloroquine sulfate|
223784130|NCT00125489|DRUG|sulfadoxine/pyrimethamine|
223784131|NCT00735046|BEHAVIORAL|Cognitive behavioral therapy for early Alzheimer's disease|12 weekly individual sessions, total duration 3 months, regular involvement of patient's proxy ever second session. Intervention is manualized but is flexible with regard to individual resources and needs.
223784132|NCT00735046|OTHER|Control|Patients and proxies who are assigned to treatment as usual
223784133|NCT00884585|DRUG|Cyclosporine Vehicle|Placebo (cyclosporine vehicle) administered 4 times a day to the qualified eye(s) for 3 months.
223784134|NCT00884585|DRUG|Cyclosporine 0.010%|Cyclosporine ophthalmic solution 0.010% administered 4 times a day to the qualified eye(s) for up to 12 months; at Month 9 the dose may be adjusted to 2 times a day.
223784135|NCT03985319|DRUG|YYD601 20mg|Esomeprazole IR 10mg + Esomeprazole SR 10mg (Expected efficacy and effects: GERD)
223784136|NCT03985319|DRUG|Nexium tab 20mg|Esomeprazole magnesium trihydrate 22.3mg Effecacy and Effects: GERD and Antibiotics combined therapy to eradicate the Helicobacter pylori
223784137|NCT05290259|OTHER|Ballroom Dance|The Ballroom Basics for Balance Program is a dance focused exercise program developed by a Physical Therapist in the Madison area.
223784138|NCT04056806|DRUG|Terlipressin 1Mg Powder for Conventional Release Solution for Injection Vial|efficacy comparison between 2 days and 5 days
223702709|NCT05099081|PROCEDURE|diode laser application|Local anesthesia will be applied Lesion will be excised with diode laser (Medency, Italy) continuous wave mode 980 nm wave length with an output power 3 W in contact mode
223702710|NCT05099081|PROCEDURE|intra-lesional injection of ethanolamine oleate|"Local anesthesia will be applied Injection of ethanolamine oleate (sclerosing gent) with concentration 5% diluted in distilled water to form 2.5% ethanolamine oleate According to lesion size range from 1.5 to 3 ml of solution will be injected slowly into lesion using gauge needle until leaked from lesion.~Lesion will be compressed for 5 minutes. Lesion will be observed once a week after injection until it becomes necrotic and falls off spontaneously.~Repeated injection may be needed."
223784139|NCT00780962|DRUG|N-Acetylcysteine (NAC)|"Experimental:~* Before CT: 3 g NAC IV in 500 cc of 0.9% Sodium-chloride~* After CT: 200 mg NAC/hour in 0.9% Sodium-chloride at 67 cc/hour for up to 24 hours."
223784140|NCT00780962|DRUG|0.9% Sodium-chloride|"Placebo:~* Before CT: 500 cc 0.9% Sodium-chloride~* After CT: NS at 67 cc/hour for up to 24 hours."
223702711|NCT05797259|DRUG|Danosumab|60 mg subcutaneous Danosumab
223702712|NCT05797259|OTHER|Normal Saline|Placebo comparator arm
223702713|NCT05337696|PROCEDURE|Vertebral Implant PEEK Procedure|Vertebral Implant PEEK (VIP) procedure is a minimally invasive/percutaneous vertebral augmentation (PVA), image guided procedure. Two VIP devices are implanted in each to be treated vertebra. A cavity is drilled allowing the introduction of the implant posteriorly through the pedicle and the vertebral body upto the anterior wall. A part of the implant is embedded into the pedicle, thus providing posterior support. The other part of the device, located in the vertebral body, presents a central canula and lateral perforations, which allow acrylic bone cement diffusion, filling of the vertebral body, filling and fixing the implant, and supporting of the upper endplate. The combination of the implant and the cement allows the treatment of vertebral fractures.
223702714|NCT05337696|DEVICE|Vertebral Implant PEEK (VIP) implant|The study device is V-STRUT© Vertebral Implant manufactured by Hyprevention (VIP -Vertebral Implant PEEK), FDA cleared under K191709, indicated for use in the treatment of vertebral fractures in the thoracic and lumbar spine from T9 to L5. It is intended to be used in combination with PMMA bone cement.
223784141|NCT00617149|BEHAVIORAL|Supervised exercise for the prevention high weight gain|Each session starts with ca 5 minutes warm up, followed by 30 minutes of aerobic activity, including cool down. This is followed by 15 minutes of strength training of the upper and lower limbs, and special focus on the deep abdominal stabilization muscles. The last 5 minutes contains stretching, relaxation and body awareness exercises. The exercise-program follows the ACOG exercise prescription, and all aerobic activities will be performed at moderate intensity (60-70% of maximal heart rate), measured by ratings of perceived exertion at 11-14 (somewhat hard) on the 6-20 Borg's rating scale. Control-participants are neither encouraged nor discouraged from exercising.
223784142|NCT05861115|DEVICE|"Chang Gung Ventricular Systolic Dysfunction Screening Software"|This software is suitable for 12-lead ECG signals of adults over 20 years old, and assists doctors in screening patients for left ventricular systolic dysfunction.
223784143|NCT02319239|RADIATION|Fractionation|During a radiotherapy period the prostate movement will be monitored by temporary implanted electromagnetic detector. Rectum fixation at 15/39 fractions. DW-MRI at baseline, 3 months and 12 months.
223784144|NCT02319239|RADIATION|hypofractionated|During a radiotherapy period the prostate movement will be monitored by temporary implanted electromagnetic detector. Rectum fixation at 10/20 fractions. DW-MRI at baseline, 3 months and 12 months
223784145|NCT02319239|RADIATION|stereotactic fractionation|During a radiotherapy period the prostate movement will be monitored by temporary implanted electromagnetic detector. Rectum fixation at 5/5 fractions. DW-MRI at baseline, 3 months and 12 months
223784146|NCT03339986|BEHAVIORAL|Reduction or Replacement|
223784147|NCT03219112|OTHER|Balance rehabilitation using X-box One & Kinect|the virtual reality games (Kinect sports rivals) can be controlled with movements of the body that are registered through the kinect camera.
223784148|NCT01089140|DRUG|Tranexamic acid 10mg/kg/hr|Tranexamic acid is a synthetic antifibrinolytic drug that competitively inhibits the lysine binding sites of plasminogen, plasmin, and tissue plasminogen activator
223784149|NCT01089140|DRUG|Tranexamic acid 100 mg/kg/h infusion|Tranexamic acid is a synthetic antifibrinolytic drug that competitively inhibits the lysine binding sites of plasminogen, plasmin, and tissue plasminogen activator.
223784150|NCT01089140|DRUG|Saline solution|Saline placebo
223784151|NCT02855905|OTHER|Exercise/Rest and cold/neutral temperature|Subjects were either exercising or resting in either cold or neutral environmental temperature
223784152|NCT04895267|DEVICE|Low-field thoracic magnetic stimulation (LF-ThMS)|A 30 minutes session of low-field thoracic magnetic stimulation (LF-ThMS) is planned for each participant.
223784153|NCT03059173|DIETARY_SUPPLEMENT|Myo-Inositol + Levomefolic acid|Dietary supplement Gynositol® MTHF containing myo-inositol (4 g) and Levomefolic acid on glucosamine salts(0.736 mg) in a same bags Supplementation started on average one month before treatment with Clomiphene citrate and continued throughout cycles of Clomiphene citrate (maximum 9 cycles). Treatment will be delivered during ultrasound visit at D12 of each cycle.
223784154|NCT03059173|DRUG|Clomiphene Citrate|Clomiphene citrate 50 mg. taking D2 to D6 of each cycle (maximum 9 cycles). Treatment will be delivered during ultrasound visit at D12 of each cycle and the dose will be increased if necessary.
223784155|NCT03059173|DIETARY_SUPPLEMENT|placebo|a placebo containing only 0.736 mg of 5-MTHF, glucosamine salts
223784156|NCT01823744|DIETARY_SUPPLEMENT|micronutrient supplementation|
223784157|NCT03072901|DEVICE|EndoBarrier Gastrointestinal Liner|The EndoBarrier Gastrointestinal Liner (EndoBarrier) is a nonsurgical metabolic intervention for the treatment of Type 2 diabetes and obesity. By bypassing the duodenum and proximal jejunum, the device may alter signaling pathways that control metabolic processes.1, 2 The effect on patient's glucose levels is immediate as evidenced by meal tolerance testing.3 Since the device also promotes reduced appetite resulting in weight loss, the effect is maintained as the patient loses weight over the implant period. Most patients achieve normal HbA1c and fasting plasma glucose (FPG) levels rapidly within 3-6 months.
223784158|NCT03500874|DRUG|FUDR|Floxuridine(FUDR) 0.12 mg/kg/day，on Day 1-14 through the HAI pump.
223784159|NCT03500874|DRUG|Oxaliplatin|Oxaliplatin 180 mg/m2 IV over 90 minutes on Day 1, 15.
223784160|NCT03500874|DRUG|Leucovorin|Leucovorin 200mg/m2 ivd over 2 hours on Day 1
223784161|NCT03500874|DRUG|5FU|5-Fluorouracil 2.4 g/m2 for 46 hours continuous infusion on Day 1.
223784162|NCT03500874|DRUG|Irinotecan|Irinotecan 180mg/m2
223784163|NCT02088996|DEVICE|longwave diathermy on high power and interferential therapy|
223784164|NCT02088996|DEVICE|longwave diathermy on low power|
223784165|NCT01407861|OTHER|Relaxation Training|Patients participate in a relaxation training program under expert guidance at least three times a week over 12 weeks.
223784166|NCT01407861|OTHER|Aerobic endurance Training|Patients participate in a moderate aerobic endurance training program under expert guidance three times a week over 12 weeks.
223784167|NCT03947645|DEVICE|Ipsilesional stimulation|Device: ipsilesional transcranial stimulation, neuromuscular Stimulation over target muscle
223784168|NCT03947645|DEVICE|Contralesional stimulation|Device: contralesional transcranial stimulation, neuromuscular stimulation over target muscle
223784169|NCT02985658|DRUG|Veliparib|"Patients will start veliparib at 300 mg po BID days 1 through 21 of the first 21 day cycle, then increase to 400 mg po BID days 1 through 21 of each subsequent cycle, as tolerated by the patient.~At the treating investigator's discretion, and with principal investigator approval, veliparib may be used in combination with cisplatin and/or vinorelbine. Veliparib (300mg) will be dosed po BID on Days 1 through 14 of each 21-day cycle.~The patient will receive therapy as long as there is therapeutic benefit"
223784170|NCT02985658|DRUG|Cisplatin|Cisplatin will be administered intravenously (75 mg/m2) on Day 1 of each cycle
223784171|NCT02985658|DRUG|Vinorelbine|Vinorelbine will be administered intravenously on Day 1 and Day 8 of each 21-day cycle
223784172|NCT01870843|DRUG|Escitalopram|Escitalopram will be administered as oral tablets 10 mg per day and then the dose of escitalopram will be flexibly adjusted up to maximum of 20 mg per day for the next 7 weeks, based on the investigator's clinical judgment.
223784173|NCT02449538|DRUG|everolimus|everolimus 10 mg qd daily one cycle is 28days.
223784174|NCT00345397|DEVICE|Percutaneous endoscopic colostomy (PEC) tube|PEC placement for antegrade enemas uses commercially available PEG tubes
223784175|NCT00968604|GENETIC|BikDD Nanoparticle|Starting dose 0.04 mg/kg once weekly by vein over 10 minutes.
223784176|NCT03710434|DRUG|AZD4635 50 mg nano-suspension (reference)|Subjects will receive a single dose of AZD4635 50 mg nano-suspension (reference) in the fasted state.
223784177|NCT03710434|DRUG|AZD4635 solid oral formulation - fasted|Subjects will receive a single dose of AZD4635 solid oral formulation, in the fasted state.
223784178|NCT03710434|DRUG|AZD4635 solid oral formulation - fed|Subjects will receive a single dose of AZD4635 solid oral formulation, in the fed state.
223784179|NCT03710434|DRUG|Lansoprazole and AZD4635 50 mg solid oral formulation|Subjects will receive lansoprazole 30 mg BID for 5 days followed by a single dose of AZD4635 50 mg solid oral formulation in the fasted state.
223784180|NCT03710434|DRUG|AZD4635 solid oral formulation variant 1 - fasted|Subjects will receive a single dose of AZD4635 solid oral formulation, variant 1 in the fasted state.
223784181|NCT03710434|DRUG|AZD4635 solid oral formulation variant 2 - fasted|Subjects will receive a single dose of AZD4635 solid oral formulation, variant 2 in the fasted state.
223784182|NCT03710434|DRUG|[14C] AZD4635 IV microtracer - fasted|Subjects will receive a single dose of \[14C\] AZD4635 IV microtracer. This intervention will be co-administered with AZD4635 solid oral formulation variant 1.
223784183|NCT01910519|BIOLOGICAL|H5N1 vaccine plus AS03 adjuvant|"Administered vaccine: \[GlaxoSmithKline\] Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted.~Participants receive 2 intramuscular doses of Influenza A (H5N1) Virus with AS03 adjuvant, administered 21 (+/- 3) days apart."
223784184|NCT01910519|BIOLOGICAL|H5N1 vaccine without adjuvant|"Administered vaccine: \[GlaxoSmithKline\] Influenza A (H5N1) Virus Monovalent Vaccine without AS03 adjuvant.~Participants receive 2 intramuscular doses of Influenza A (H5N1) Virus without adjuvant, administered 21 (+/- 3) days apart."
223784185|NCT04093934|BEHAVIORAL|Psychosocial stimulation|Children will receive fortnightly sessions of psychosocial stimulation and nutritional support for one year during the study period.
223784186|NCT03176693|DRUG|Phenoxybenzamine|Non-selective alpha blocker
223784187|NCT03176693|DRUG|Doxazosin|Selective alpha blocker
223784188|NCT03920917|PROCEDURE|Cryoballoon Pulmonary Vein isolation|"1. Pulmonary vein isolation will be performed using a cryoballoon catheter.~2. Esophageal temperature will be monitored to prevent esophageal injury.~3. A 28mm second or third cryoballoon catheter will be used.~4. Esophageal temperature will be monitored to prevent esophageal injury.~5. Cryoablation will be performed for 180 secs at -45°C or below on condition that the pulmonary vein is occluded with a cryoballoon.~6. CMAP (compound motor action potential) monitoring will be done to avoid phrenic nerve damage during the freezing of the right superior pulmonary vein.~7. The procedure and cryoablation times will be evaluated.~8. Rhythm follow-up will be performed after the procedure in accordance with the aforementioned study design."
223784189|NCT03920917|PROCEDURE|Radiofrequency Pulmonary Vein isolation and Additional Right Atrial linear ablation|"1. Pulmonary vein isolation will be performed using a radiofrequency catheter.~2. Additional cavo-tricuspid isthmus ablation will be performed with a radiofrequency catheter.~3. Additional superior vena cava-right atrial septal linear ablation will be performed with a radiofrequency catheter.~4. If any other trigger came from beyond pulmonary vein is detected after the administration of isoproterenol, additional local radiofrequency ablation will be followed.~5. Evaluated the procedure and radiofrequency ablation time.~6. Rhythm follow-up will be performed after the procedure in accordance with the aforementioned study design."
223784190|NCT04266028|BIOLOGICAL|DM-101|DM-101 administered by subcutaneous (SC) injection
223784191|NCT04266028|BIOLOGICAL|Placebo to match DM-101|Placebo to match DM-101 administered by SC injection
223784192|NCT01563861|GENETIC|RNA analysis|
223784193|NCT01563861|GENETIC|gene expression analysis|
223784194|NCT01563861|OTHER|immunohistochemistry staining method|
223784195|NCT01563861|OTHER|laboratory biomarker analysis|
223784196|NCT00005981|DRUG|O6-benzylguanine|Patients receive O6-benzylguanine (BG) IV over 1 hour. Treatment continues every 6 weeks in the absence of disease progression or unacceptable toxicity.
223784197|NCT00005981|DRUG|carmustine|Carmustine IV over 1 hour (beginning 1 hour after completion of BG infusion) on day 1. Treatment continues every 6 weeks in the absence of disease progression or unacceptable toxicity.
223784198|NCT06316362|DRUG|SMOF lipid 20%|SMOF 20%; a blend of (soybean oil, medium chain triglycerides, olive and fish oil) is a new lipid emulsion product that was provided as a bolus dose of 1.5ml/kg for one hour, followed by a maintenance dose of 6 ml/kg for a period of four hours to the active comparator group
223784199|NCT06316362|OTHER|Standard treatment for carbamazepine toxicity|"Hypotension was initially treated with isotonic crystalloid; vasopressors were utilised if intravenous fluids failed to restore the hypotension. This was in the form of norepinephrine with a dose of 0.05 μg/kg/min and titrated till reaching the goal mean arterial pressure (\>65 mmHg).~Those experiencing seizures due to CBZ overdose were treated with benzodiazepines (diazepam) at a dose of 10-20 mg. Benzodiazepines are considered allosteric modulators of the gamma-aminobutyric acid channel.~MDAC (50 grammes every six hours) was given to all patients in the current study. Those with severe poisoning were given the MDAC after securing the airway with a cuffed endotracheal tube"
223784200|NCT04936412|DEVICE|Rehabilitation brace|Rehabilitation brace
223784201|NCT00841581|DRUG|Ranibizumab|Ranibizumab 0.5 mgs. (0.05 mls.) intravitreally for 6 months then as needed prn for 6 months.
223784202|NCT03960190|DEVICE|Using Eureka Breast Pump with Expression Kit|Each subject will undergo two expression sessions for single and double electric pumping in randomized order to reduce the variation.
223784203|NCT04450589|DIETARY_SUPPLEMENT|ALRV5XR|"ALRV5XR oral supplement. Dose/Route/Schedule: 1 capsule/oral twice daily. Take one capsule in the morning and one capsule in the evening. Take 30-60 minutes before food. If stomach upset occurs, subjects will be instructed to take the capsule at the beginning of a meal.~There should be no deviation from the daily nutriment regimen (although in the event a capsule or day is missed, subject should continue with regimen the following day.)"
223784204|NCT04450589|OTHER|ALRV5XR Shampoo|"ALRV5XR Shampoo. Dose/Route/Schedule: 3-7 ml, topical, daily. The amount of shampoo used will vary by subject, based on length of hair. Short hair will use approximately 3ml of shampoo per wash and long hair as much as 7 ml. For short hair, an amount equivalent to a quarter in the palm of a hand, and for long hair a half-dollar size.~There should be no deviation from the daily nutriment regimen (although in the event a day is missed, subject should continue with regimen the following day"
223784205|NCT04450589|OTHER|ALRV5XR Conditioner|"ALRV5XR Conditioner. Dose/Route/Schedule: 3-7 ml, topical, daily. The amount of conditioner used will vary by subject based on length of hair. Short hair will use approximately 3ml of conditioner per wash and long hair as much as 7 ml. For short hair, an amount equivalent to a quarter in the palm of a hand, and for long hair a half-dollar size.~There should be no deviation from the daily nutriment regimen (although in the event a day is missed, subject should continue with regimen the following day"
223784206|NCT04450589|OTHER|ALRV5XR Hair Follicle Serum (Nutriment)|"ALRV5XR topical Hair Follicle serum (Nutriment), sealed in an airless pump dispensing bottle, metered at 0.2ml per depression. Dose/Route/Schedule: 1ml, topical, daily, applied at night.~Topical serum (referred to as the Nutriment) dosage is metered as 5 x depressions of plunger per day to cover areas of thinning scalp and adjacent scalp areas. Care should be taken to limit the Nutriment in hair. Each depression is metered at 0.2ml for a daily dose of 1.0 ml. Each container has 30ml of Nutriment. Nutriment will dry within a few minutes and any on the hair will also dry. The dried effect in the hair should not cause oiliness or dryness on scalp or hair. There should be no deviation from the daily nutriment regimen (although in the event a day is missed, subject should continue with regimen the following day.)"
223702715|NCT01191411|OTHER|Mailed invitations for FIT test kits|Mailed invitations for the non-invasive immunochemical stool blood test will be the intervention compared to the standard care at John Peter Smith Hospital. Patients will be invited to complete a free home-based, non-invasive immunochemical stool blood test.
223702716|NCT01191411|OTHER|Mailed invitations for a colonoscopy|These patients will be mailed invitations to directly book a free colonoscopy, or to see a physician for free pre-operative screening at John Peter Smith Hospital.
223702717|NCT01191411|OTHER|Visit Based Care|Visit based standard care at John Peter Smith Hospital. Patients will continue to see their regular physician and follow the physician's recommendations as they normally would.
223702718|NCT01224964|DRUG|Montelukast|Montelukast, 10 mg
223702719|NCT01224964|DRUG|long acting beta2 mimetic|ICS+long acting beta2 agonist: twice daily
223702720|NCT00769210|DRUG|Simvastatin|Simvastatin 40 mg tablet
223702721|NCT02527993|DRUG|Glucobay (acarbose)|Se arm description
223702722|NCT02527993|DRUG|Januvia (sitagliptin)|Se arm description
223702723|NCT02527993|DRUG|Verapamil HEXAL (verapamil)|Se arm description
223702724|NCT02527993|DRUG|Victoza (liraglutide)|Se arm description
223702725|NCT02527993|DRUG|Signifor (pasireotide)|Se arm description
223702726|NCT02527993|DEVICE|Continuous glucose monitoring (CGM)|Continuous glucose monitoring will be performed during 6 days of the treatment period.
223702727|NCT02527993|DIETARY_SUPPLEMENT|Meal tolerance test (MTT)|A meal tolerance test will be performed at the end of the treatment period. The subjects will consume the liquid meal at baseline and blood will be drawn for continuous blood sampling.
223702728|NCT06535165|DIETARY_SUPPLEMENT|Red Beetroot Juice|200ml/d for 14 days
223702729|NCT06535165|OTHER|Placebo|200ml/d for 14 days
223702730|NCT00967603|DRUG|sunitinib|oral sunitinib 37.5 mg daily
223702731|NCT05864755|DRUG|HAIC+Durvalumab+Tremelimumab+Bevacizumab|Tremelimumab：300mg, only once in cycle 1.Durvalumab: 1500mg, iv,q3w Bevacizumab: 15mg/kg, iv, q3w HAIC: Oxaliplatin plus Fluorouracil/Leucovorin
223702732|NCT03569033|DRUG|Gefapixant|Gefapixant 45 mg will be administered orally.
223702733|NCT03569033|DRUG|Placebo|Placebo tablet matching gefapixant will be administered orally.
223702734|NCT03561363|BEHAVIORAL|High-fat diet|The aim of the intervention is to evaluate whether insulin sensitivity and selected Health parameters is affected, when the intake of saturated fatty acids or polyunsaturated fatty acids are highly increased, even when subjects are in energy balance.
223702735|NCT05582031|COMBINATION_PRODUCT|Regorafenib in combination with Tislelizumab|Regorafenib 30 mg/tablet + Tislelizumab 100 mg/10 ml vial
223702736|NCT00169754|OTHER|mapping kidney anatomy|videotape of surgical procedure to document location of attached stones and condition of calyces and papilla.
223702737|NCT04666480|DEVICE|Transcatheter mitral valve repair|Transvenous approach with a transeptal puncture to place the study device
223702738|NCT01268150|DRUG|Eribulin mesylate|Eribulin mesylate 1.4 mg/m2 will be administered as an intravenous (IV) infusion (over 2 to 5 minutes) on Days 1 and 8 of each 3-week cycle.
223702739|NCT02703831|PROCEDURE|Dual attending|Two attending spine surgeons perform surgery
223702740|NCT02703831|PROCEDURE|Single Attending|One spine attending and an assistant perform surgery. The assistant can be a spine fellow, a resident or a physician's assistant.
223702741|NCT01488305|DIETARY_SUPPLEMENT|MNP (micro-nutrient powders)|MNP is added to explore the additional value of MNP in existing AAMA program
223702742|NCT01488305|OTHER|AAMA project activities (HFP and IYCF BCC)|This is the existing AAMA program
223702743|NCT00887874|OTHER|No treatment given|Subject will only fill out a questionaire when entering the observational study.
223702744|NCT00395733|DRUG|Gadobutrol (Gadavist, Gadovist, BAY86-4875)|Participant received a single intravenous injection with Gadobutrol (1.0 M) at a volume of 0.2 mL/kg BW (dose = 0.2 mmol/kg BW) or up to 0.3 mL/kg BW when 3 Fields of View were imaged (up to dose = 0.3 mmol/kg BW)
223702745|NCT00395733|DRUG|Gadopentate dimeglumine (Magnevist, BAY86-4882)|Participant received a single intravenous injection with Gadopentate (0.5 M) at a volume of 0.4 mL/kg BW (dose = 0.2 mmol/kg BW) or up to 0.6 mL/kg BW when 3 Fields of View were imaged (up to dose = 0.3 mmol/kg BW)
223702746|NCT03725852|DRUG|GLPG1205|GLPG1205 will be provided as an oral hard gelatin capsule.
223702747|NCT03725852|DRUG|Placebo|GLPG1205 matching placebo will be provided as an oral hard gelatin capsule.
223702748|NCT03295500|RADIATION|Dose fraction forms|The investigators divide the participants randomly into 3 groups by SPSS 19.0.Three groups participants receive the different dose fraction(49Gy/7f,54Gy/6f and 55Gy/5f),which also means different Biologic Equivalent Dose.Through the research,the investigators want to find out the optimum dose fraction method,which makes the treatment safe, effective and personalized.
223784207|NCT04450589|DIETARY_SUPPLEMENT|Placebo|"Placebo oral supplement. Dose/Route/Schedule: 1 capsule/oral twice daily. Take one capsule in the morning and one capsule in the evening. Take 30-60 minutes before food. If stomach upset occurs, subjects will be instructed to take the capsule at the beginning of a meal.~There should be no deviation from the daily nutriment regimen (although in the event a capsule or day is missed, subject should continue with regimen the following day.)"
223702749|NCT01790880|BEHAVIORAL|ORLA|Practice on ORLA (Oral Reading for Language in Aphasia), a computer-based virtual therapy system.
223702750|NCT01790880|BEHAVIORAL|ORLA + Writing|Treatment includes writing of sentences in combination with ORLA
223702751|NCT00553943|DRUG|Rituximab|375 mg/m2 D1
223702752|NCT00553943|DRUG|Cytarabine|50 mg D3
223702753|NCT03930758|COMBINATION_PRODUCT|Behavior intervention of uphill exercise|40 minutes of uphill exercise
223702754|NCT03930758|COMBINATION_PRODUCT|Dietary intervention of exercise before the meal|40 minutes of uphill exercise completed 1 h before the meal
223702755|NCT03930758|COMBINATION_PRODUCT|Dietary intervention of uphill exercise|40 minutes of uphill exercise
223702756|NCT03930758|COMBINATION_PRODUCT|Dietary intervention of exercise after the meal|40 minutes of uphill exercise started 1 hour after gthe meal
223702757|NCT03930758|COMBINATION_PRODUCT|Behavior intervention of downhill exercise|40 minutes of downhill exercise
223702758|NCT03930758|COMBINATION_PRODUCT|Dietary intervention of exercise before the meal|40 minutes of downhill exercise completed 1 hour before the meal
223702759|NCT03930758|COMBINATION_PRODUCT|Behavioral intervention of downhill exercise|40 minutes of downhill exercise
223702760|NCT03930758|COMBINATION_PRODUCT|Dietary intervention of exercise after the meal|40 minutes of downhill exercise started 1 hour after the meal
223702761|NCT03930758|COMBINATION_PRODUCT|Behavioral intervention of sedentary no-exercise trial|Sedentary no-exercise trial
223702762|NCT03930758|COMBINATION_PRODUCT|Dietary intervention of eating two meals|Meals eaten at 10 and 17 h during a sedentary trial
223702763|NCT01191918|DRUG|Donepezil and Lithium|Donepezil dose will be started at 5mg/d and increased to 10 mg/d in 1 week.
223702764|NCT01191918|DRUG|Placebo plus Lithium|
223702765|NCT05835323|DEVICE|Robotic-assisted mini-PCNL|Eligible participants will be enrolled to undergo robotic-assisted PCNL using the MONARCH Platform, Urology for the removal of kidney stones. The MONARCH Platform, Urology is a novel flexible robotic device that enables the clinician to obtain both transurethral and percutaneous access to a participant's kidney under continuous visualization for therapeutic application (for example, stone removal).
223702766|NCT01931618|BEHAVIORAL|Online screening and feedback|An online single session screening procedure including individualized normative feedback.
223702767|NCT01931618|BEHAVIORAL|Online booklet.|An online booklet that covers general information about alcohol, its effect on the brain and the body, potential risks and harms of drinking, and an account of the threshold values of sensible drinking
223702768|NCT01931618|BEHAVIORAL|Online multi session follow-up|"An online multi session follow-up program (i.e., Balance). The central concept of Balance is to support continued self-regulation throughout the behavior change process. There are four key aspects of the program, the first is focus on goal setting and tracking of alcohol consumption on a day-to-day basis. The second on relapse prevention - for example, when clients report drinking more than their target, they receive individualized content aimed at preventing a full blown relapse. The third is emotion regulation, where content and assignments from positive psychology and from cognitive behavioral therapy are used. Finally, intervention covers alcohol education (i.e. the same topics as in the booklet provided to the control group)."
223702769|NCT06417125|DRUG|Dexmedetomidine Hydrochloride|Patients were premedicated with intranasal dexmedetomidine 2 μg/kg in the holding area.
223702770|NCT06417125|DRUG|Midazolam|Patients were premedicated with oral midazolam 0.5 mg/kg in the holding area.
223702771|NCT06417125|DRUG|normal Saline|Patients were premedicated with normal saline 0.02 mL/kg in the holding area.
223702772|NCT06417125|DRUG|Glucose solution|Patients were premedicated with oral sweet solution 0.25 mL/kg in the holding area.
223702773|NCT03557853|DRUG|Golimumab Injection|Simponi (golimumab) in fixed dose of 50 mg sc per month according to local label and local clinical practice.
223702774|NCT04633577|DRUG|Lidocaine IV|A bolos of 1.5mg/kg lidocaine will be administered before induction. Then, infusion of 4mg/kg/h lidocaine will maintain during procedure.
223702775|NCT04633577|DRUG|0.9% normal saline|0.9% normal saline
223702776|NCT02826278|OTHER|External genitalia measurements in female newborns|
223702777|NCT03738033|OTHER|educational platform|The platform would be opened before they entered the study.
223702778|NCT01827956|OTHER|Blood sample for identifying the polymorphism|Blood sample for identifying the polymorphism
223702779|NCT03072732|DEVICE|u-Cor System|Monitoring System
223702780|NCT03072732|DEVICE|ZOE Fluid Status Monitor|Monitoring System
223702781|NCT06391385|PROCEDURE|protective ileostomy|Preparation of the bowel was performed before surgery with the administration of intravenous perioperative antibiotic prophylaxis. The surgical procedure was performed by laparotomy, with resection of the rectum and mesorectum (TME) up to the level of the pelvic diaphragm, sparing the autonomic nerves. End-to-end anastomosis was performed either with a stapler or by hand-sewn.
223702782|NCT05751642|BIOLOGICAL|ALXN1920|Participants will receive a single dose of ALXN1920 by Subcutaneous (SC) injection.
223702783|NCT05751642|BIOLOGICAL|Placebo|Participants will receive a single dose of Placebo by SC injection, SC infusion or IV infusion.
223702784|NCT05751642|BIOLOGICAL|ALXN1920|Participants will receive a single dose of ALXN1920 by SC infusion.
223702785|NCT05751642|BIOLOGICAL|ALXN1920|Participants will receive a single dose of ALXN1920 by Intravenous (IV) infusion.
223702786|NCT06551636|OTHER|respiratory physiotherapy (AAD)|The AAD technique involves placing the physiotherapist's hands on the chest where the secretions are identified and applying pressure to the chest. The maneuver will last according to the patient's tolerance, in an average of approximately 10 min.
223702787|NCT01024218|DEVICE|NovoFine® needle 8 mm|
223702788|NCT01024218|DEVICE|autocover needle|
223702789|NCT01724411|OTHER|Resistant Starch type 3|Resistant Starch 3: 26g/day males for 11 days, 22 g/day females for 11 days
223702790|NCT05115578|DRUG|Remifentanil 1 MG Injection [Ultiva]|Group I TCI effect-site target infusion of 1.5 ng/ml of remifentanil.
223702791|NCT05115578|DRUG|Midazolam 1 MG/ML Prefilled Syringe|Group II TCI effect-site target infusion of 1.5 ng/ml of remifentanil + 1 mg Midazolam iv
223702792|NCT05115578|DRUG|Saline solution|Group III Control
223702793|NCT05115578|DEVICE|Algometry|The algometry technique is used to assess the pain pressure threshold as an analgesic effect of remifentanil concerning Minto's model prediction.
223702794|NCT01753102|DRUG|Estradiol|one tablet will be inserted daily for 14 days
223702795|NCT05192733|OTHER|Survey|This is a cross-sectional practice survey. There is no intervention.
223702796|NCT00969813|DRUG|CP-690,550|Single 10 mg dose of CP-690,550
223702797|NCT00969813|DRUG|CP-690,550|Single 10 mg dose of CP-690,550
223702798|NCT00969813|DRUG|CP-690,550|Single 10 mg dose of CP-690,550
223702799|NCT00660751|DRUG|Duloxetine|SNRIs
223702800|NCT03868306|OTHER|CBC , Iron study and Haemoglobin electrophoresis .|The study will conducting on 100 patients of microcytic hypochromic anaemia who recruited from the hematology outpatient clinic , Assiut University Children Hospital . Beside history and clinical examination , the studied cases will be subjected to the following investigations Complete blood count ( CBC ) with comparison of MCV , RBCs count , RDW and RDWI . Determination of serum ferritin , serum iron and total iron bending capacity ( TIBC ) . HB electrophoresis . Patient with HBA2 more than 3.2 % are identified as beta thalassemia trait and patients with serum ferritin less than 12 ng / ml are identified as IDA cases. Validity of both discrimination indices are evaluated by calculating there sensitivity , specificity , positive predictive value , negative predictive value and Youden index ( YI ) Based on statistical criteria in ideal test should have high sensitivity and specificity and Youden index.
223702801|NCT06174259|OTHER|intermittent fasting|16/8 intermittent fasting (limiting foods and calorie-containing beverages to a set window of 8 hours per day)
223702802|NCT00140478|DRUG|Mifepristone|200mg orally once daily
223702803|NCT01021579|DRUG|Metformin plus Placebo|PCOS patients(n=42) will be assigned to the placebo (once/day) plus metformin (500mg three times a day, n=42; group 2)
223702804|NCT01021579|DRUG|Metfomin plus Simvastatin|
223702805|NCT02563951|DRUG|GNS Spray 0.5mg|
223702806|NCT02563951|DRUG|GNS Spray 1.0mg|
223784208|NCT04450589|OTHER|Placebo Shampoo|"Placebo Shampoo. Dose/Route/Schedule: 3-7 ml, topical, daily. The amount of shampoo used will vary by subject, based on length of hair. Short hair will use approximately 3ml of shampoo per wash and long hair as much as 7 ml. For short hair, an amount equivalent to a quarter in the palm of a hand, and for long hair a half-dollar size.~There should be no deviation from the daily nutriment regimen (although in the event a day is missed, subject should continue with regimen the following day"
223784209|NCT04450589|OTHER|Placebo Conditioner|"Placebo Conditioner. Dose/Route/Schedule: 3-7 ml, topical, daily. The amount of conditioner used will vary by subject based on length of hair. Short hair will use approximately 3ml of conditioner per wash and long hair as much as 7 ml. For short hair, an amount equivalent to a quarter in the palm of a hand, and for long hair a half-dollar size.~There should be no deviation from the daily nutriment regimen (although in the event a day is missed, subject should continue with regimen the following day"
223784210|NCT04450589|OTHER|Placebo Hair Follicle Serum (Nutriment)|"Placebo topical Hair Follicle serum (Nutriment), sealed in an airless pump dispensing bottle, metered at 0.2ml per depression. Dose/Route/Schedule: 1ml, topical, daily, applied at night.~Topical serum (referred to as the Nutriment) dosage is metered as 5 x depressions of plunger per day to cover areas of thinning scalp and adjacent scalp areas. Care should be taken to limit the Nutriment in hair. Each depression is metered at 0.2ml for a daily dose of 1.0 ml. Each container has 30ml of Nutriment. Nutriment will dry within a few minutes and any on the hair will also dry. The dried effect in the hair should not cause oiliness or dryness on scalp or hair. There should be no deviation from the daily nutriment regimen (although in the event a day is missed, subject should continue with regimen the following day.)"
223784211|NCT04243876|DIAGNOSTIC_TEST|paraoxanase enzyme level|presence of paraoxonase enzyme deficiency and associated troponin elevation
223784212|NCT03846700|DEVICE|aquablation|"minimally invasive, robot-assisted and ultrasound-guided ablation of the prostate in targeted way and in heat-free way working by high pression water jet"
223784213|NCT03846700|DEVICE|holep|holmium laser enucleation of prostate
223784214|NCT03846700|DEVICE|pvp|photoselectivevaporization of prostate
223784215|NCT06558318|OTHER|Assessment of temporomandibular dysfunction|TMJ dysfunction will be measured using the Fonseca Amnestic Index. The Fonseca Amnestic Index is used to assess the severity of temporomandibular joint (TMJ) dysfunction. The index consists of 10 questions, with each question scored as 0, 5, or 10 points, depending on the severity of symptoms. The maximum total score is 100, where a higher score indicates a more severe level of TMJ dysfunction. Therefore, patients with higher scores on the Fonseca Amnestic Index are considered to have more significant TMJ issues. Based on Fonseca scores, two groups will be formed: those with scores over 20 will be labeled 'with TMJ dysfunction,' and the others 'without TMJ dysfunction.
223784216|NCT05923281|DRUG|K-877 0.2 mg/day (once daily)|K-877 0.2mg tablet
223784217|NCT05923281|DRUG|K-877 0.4 mg/day (once daily)|K-877 0.2mg tablet
223784218|NCT05923281|DRUG|Placebo (once daily)|Placebo tablet
223784219|NCT00053430|DRUG|Thalidomide|Tablet taken orally daily
223784220|NCT00053430|DRUG|Thalidomide placebo|Placebo tablet taken orally daily
223784221|NCT02279641|DRUG|RDEA3170 10 mg|
223784222|NCT02279641|DRUG|allopurinol 300 mg|
223784223|NCT02396641|OTHER|Best Supportive Care Checklist|
223784224|NCT00648479|DEVICE|The Guiding Star|
223784225|NCT00648479|DEVICE|fluoroscopy (OEC 9800 - General Electric)|
223784226|NCT00920192|DRUG|Foretinib|Phase I starting dose 30 mg/day escalated to 45 mg/day; de-escalated to 30 mg/day. MTD for Phase II dose was 30 mg/day,
223784227|NCT01556113|OTHER|Omega diet|Eligible subjects will receive omega rich diet for 12 weeks with weekly appointments to obtain food records, draw serum samples and provide meals.
223784228|NCT03021187|DRUG|semaglutide|Oral semaglutide administered once-daily for 52 weeks as an add-on to the subjects' pre-trial insulin treatment
223784229|NCT03021187|DRUG|semaglutide|Oral semaglutide (3 mg followed by 7 mg) administered once-daily for 52 weeks as an add-on to the subjects' pre-trial insulin treatment
223784230|NCT03021187|DRUG|semaglutide|Oral semaglutide (3 mg followed by 7 mg and finally 14 mg) administered once-daily for 52 weeks as an add-on to the subjects' pre-trial insulin treatment
223784231|NCT03021187|DRUG|placebo|Oral semaglutide placebo administered once-daily for 52 weeks as an add-on to the subjects' pre-trial insulin treatment
223784232|NCT06352853|OTHER|Skin incision in Cesarean Section by Diathermy|Skin incision by diathermy
223784233|NCT06352853|OTHER|Skin incision in Cesarean Section by Scalpel|Skin incision by scalpel
223784234|NCT01664078|DEVICE|Endovascular AAA repair with InCraft®|
223784235|NCT01631032|DRUG|Qi-tonifying Chinese herbal products|Chinese herbal products in capsule, 3 times a day, 3gm (6PC of 500mg capsule) each time, total 9gm per day
223784236|NCT05415098|DRUG|APG-5918|"The investigational drug product is formulated as oral tablets of 50 mg or 200 mg that contain APG-5918 as the active ingredient. APG-5918 will be orally administered once every day on 28-day cycles.~The dosage of APG-5918 depends on the dose level to which the patient is assigned. Each dose of APG-5918 will be taken orally in fasted condition in the study."
223784237|NCT03873051|BEHAVIORAL|Challenge-Focused Program|Participants receiving the Challenge-Focused intervention will complete an 8-week group program. Group sessions meet once per week for 90 minutes and include three components - discussion-based health promotion initiative, team-based physical activity games/activities, and team-based goal-setting and behavioral skills training. Among participants with high autonomous motivation, those receiving the Challenge-focused intervention are expected to show greater improvement from baseline to post- in total PA than those receiving the Rewards-Focused intervention.
223784238|NCT03873051|BEHAVIORAL|Rewards-Focused Program|Participants receiving the Rewards-Focused intervention will complete an 8-week group program. Group sessions meet once per week for 90 minutes and include three components - discussion-based health promotion initiative, group-based walking program, and individual-based goal-setting and behavioral skills training with partner-based contracts and financial incentives. Among participants with high controlled motivation, those receiving the Rewards-focused intervention are expected to show greater improvement from baseline to post- in total PA than those receiving the Challenge-Focused intervention.
223784239|NCT06563089|OTHER|blood sampling|Albumin level in blood
223702807|NCT02563951|DRUG|GNS Spray 2.0mg|
223702808|NCT02563951|DRUG|Kytril 1mg (IV injection)|
223702809|NCT02563951|DRUG|Kytril 1mg (Tablet)|
223702810|NCT03452228|DRUG|evinacumab|Administered by Intravenous (IV)
223702811|NCT03452228|DRUG|Placebo|Administered by Intravenous (IV)
223702812|NCT05742958|DRUG|Intrathecal morphine|The study will be conducted in patients undergoing arthroscopic anterior cruciate ligament reconstruction surgery under spinal anesthesia. In this arm, 0.1 mg intrathecal morphine in addition to spinal anesthesia will be used for perioperative pain management. A placebo addctor canal block will also be performed for masking in these patients. The quality of recovery will be evaluated with a postoperative quality of recovery scale (QoR-40 questionnaire) at postoperative 24-hour and 14-day.
223702813|NCT05742958|DRUG|Adductor canal block|After providing complete sensory block in the lower extremities with spinal anesthesia, the thigh where the surgery will be performed will be brought into slight abduction and external rotation while the patient is in the supine position. The blockage of the saphenous nerve in the adductor canal will be performed with 30 mL of local anesthetic (0.25% bupivacaine) solution with a 22 gauge 5-8 cm long block needle from the mid-medial part of the thigh under ultrasound guidance. The quality of recovery will be evaluated with QoR-40 questionnaire at postoperative 24-hour and 14-day.
223702814|NCT04215250|OTHER|andropulous method|Counts the CVC depth using specific equation
223702815|NCT04215250|DEVICE|ECG|Using ECG to monitor the insertion of the CVC
223702816|NCT01725607|DRUG|general anesthesia combined with dexmedetomidine infusion|general anesthesia combined with 1 μg/kg dexmedetomidine infusion after induction (Group D)
223702817|NCT01725607|PROCEDURE|general anesthesia combined with TEA|general anesthesia combined with TEA (Group E)
223702818|NCT01222624|DRUG|PankoMab-GEX™|
223702819|NCT04642612|DEVICE|TCD Measurement|"CBFV measurements will be acquired continuously with the patient supine and the head neutral. Analysis of CBFV measurements will be undertaken at 3 timepoints:~1. Patient awake and supine in the holding area~2. After sedation~3. After interscalene nerve block"
223702820|NCT02395783|DRUG|Melatonin 10 µg|Determine the dose of prenatal administration of melatonin in preterm labor to reduce brain damage in the white matter detected by diffusion tensor imaging (DTI) analysis with spatial statistics (TBSS) to the theoretical term 40 weeks
223702821|NCT02395783|DRUG|Melatonin 20 µg|Determine the dose of prenatal administration of melatonin in preterm labor to reduce brain damage in the white matter detected by diffusion tensor imaging (DTI) analysis with spatial statistics (TBSS) to the theoretical term 40 weeks
223702822|NCT02395783|OTHER|Placebo|Determine the dose of prenatal administration of melatonin in preterm labor to reduce brain damage in the white matter detected by diffusion tensor imaging (DTI) analysis with spatial statistics (TBSS) to the theoretical term 40 weeks
223702823|NCT00300105|DRUG|Tesaglitazar|
223702824|NCT03397615|BEHAVIORAL|Betadine douches|subjects received a vaginal preparation with povidone-iodine solution immediately prior to caesarean delivery
223702825|NCT02714907|DEVICE|Cortrium C3 device|Data is read from Cortrium C3 monitor
223702826|NCT02714907|DEVICE|Holter device|Date is read from Holter device
223702827|NCT04251273|OTHER|This is Quitting|Text message-based intervention for quit vaping support.
223702828|NCT04251273|OTHER|Assessment only Control|Assessment only
223702829|NCT00810693|DRUG|Riociguat (Adempas, BAY63-2521)|BAY63-2521: 1mg tid - 2.5mg tid orally for 12 weeks
223702830|NCT00810693|DRUG|Riociguat (Adempas, BAY63-2521)|BAY63-2521: 1.5mg tid orally for 12 weeks
223702831|NCT00810693|DRUG|Placebo|Matching Placebo tid orally for 12 weeks
223784240|NCT04662307|DEVICE|Intelligent cardiopulmonary rehabilitation system (ICRS)|Participants are required to wear a wristband heart rate monitor and exercise on a cycling ergometer-based ICRS for 30 minutes (5 minute of warm-up, 20 minutes of training followed by 5 minutes of cooldown). The target intensity for the 20-min training period is set at 60%\~80% HRR determined in the pretest of cardiopulmonary exercise test.
223784241|NCT03351049|DEVICE|LAL|Reactive support surface with a low air loss feature
223784242|NCT03351049|DEVICE|Non-LAL|Reactive support surface without a low air loss feature
223784243|NCT03646344|DRUG|Heme Arginate 25 MG/ML|IMP - to be administered at a dose of 3mg/kg to a maximum dose of 250mg over 30 mins. Participants will receive intervention twice during the trial, one on Day 0 (day of transplantation) and then again on D1 (20-28 hours after dose 1).
223784244|NCT03646344|DRUG|0.9% Sodium-chloride|Placebo - 100ml of 0.9% Sodium Chloride will be given over 30 mins. Participants will receive intervention twice during the trial, one on Day 0 (day of transplantation) and then again on D1 (20-28 hours after dose 1).
223784245|NCT04327284|DEVICE|Immediate placement non-occlusal loading molar implant (Straumann BLX 6.5mm)|"At the screening visit, potential subjects will be informed about the protocol and all questions related to the study will be answered. Medical and dental histories will be reviewed and physical evaluations will be performed in order to rule out local or systemic factors that would compromise the outcome of the study. A detailed extra and intra oral examination will be performed. Appropriate radiographic imaging studies will be obtained prior to the surgical visit (per the protocol of the University of Kentucky, College of Dentistry) including CBCT and intraoral scans for treatment planning implant through Straumann Guided Surgery workflow.~The duration of the present study is 1 year including the baseline or surgical visit, 2-weeks postoperative visit, 12-weeks baseline for control group and postoperative evaluations at 3, and 12 months."
223784246|NCT04327284|DEVICE|Delayed placement non-occlusal loading molar implant (Straumann BLX 5.0mm)|"At the screening visit, potential subjects will be informed about the protocol and all questions related to the study will be answered. Medical and dental histories will be reviewed and physical evaluations will be performed in order to rule out local or systemic factors that would compromise the outcome of the study. A detailed extra and intra oral examination will be performed. Appropriate radiographic imaging studies will be obtained prior to the surgical visit (per the protocol of the University of Kentucky, College of Dentistry) including CBCT and intraoral scans for treatment planning implant through Straumann Guided Surgery workflow.~The duration of the present study is 1 year including the baseline or surgical visit, 2-weeks postoperative visit, 12-weeks baseline for control group and postoperative evaluations at 3, and 12 months."
223784247|NCT00461526|DRUG|crofelemer|125 mg crofelemer vs. placebo
223784248|NCT04018872|DRUG|Itraconazole|Oral administration of itraconazole twice daily from completion of neoadjuvant chemoradiation until esophagectomy.
223784249|NCT05437679|OTHER|Blood collection|Peripheral blood will be collected from each subject at a single time point and data will be collected from a review of each subject's medical records.
223784250|NCT06333444|BEHAVIORAL|four weekly psychological counselling intervention|four weekly psychological counselling intervention delivered by university students asking help to university counselling service in Southern Italy
223784251|NCT02444650|DEVICE|Pulse wave velocity measurement Photoplethysmogram|Correlation of pulse wave velocity measurement.
223784252|NCT02444650|DEVICE|tonometer|
223784253|NCT03917693|DIETARY_SUPPLEMENT|Phytin, rice extract|Consumption of a rice extract, called phytin for a period of 2 weeks
223784254|NCT03917693|OTHER|MCC, placebo|Consumption of MCC, a placebo, for a period of 2 week
223784255|NCT00054899|BIOLOGICAL|EP2101|
223784256|NCT05223543|DIAGNOSTIC_TEST|Blood sample|extraction of blood samples from women undergoing ovarian cystectomy or oophorectomy due to suspected Dermoid cyst and analysing plasma for antibodies
223784257|NCT00917059|DRUG|Escitalopram|Fixed dose of 10 mg per day
223784258|NCT00917059|DRUG|Bupropion XL|Fixed dose of 150 mg per day
223784259|NCT06573580|OTHER|The essential public health service（EPHS）for COPD|"Each group plans to recruit 3,000 participants. For the intervention group, the community-based management includes adding COPD management-related content to the primary public health service. This includes: Providing at least four follow-ups during the project at the 3rd, 6th, 9th, and 12th months. During each follow-up, patients must complete the COPD Patient Follow-up Questionnaire and receive oral health education and targeted clinical advice from the general practitioner (GP). In addition, the GPs must also distribute educational booklets and materials, record symptom assessment results and acute exacerbation situations, and provide targeted clinical advice and clinical decisions to the COPD patients according to the checklist of Chinese guideline for management of COPD in primary care. At the baseline and the last follow-up, patients need to undergo a routine physical examination, pulmonary function test, and bronchodilator test at their community health centers"
223784260|NCT02787616|GENETIC|buccal swab|cheek swab for DNA sampling
223784261|NCT02291627|DEVICE|MAC|direct laryngoscopy
223784262|NCT02291627|DEVICE|Coopdech|Video laryngoscopy
223784263|NCT02291627|DEVICE|AirTraq|optical laryngoscopy
223784264|NCT03765281|OTHER|Navigation|Service delivered by clinical Navigator who learns about youth and family's needs and matches to appropriate services.
223784265|NCT03765281|OTHER|Resource List|Extensive list of mental health and addictions resources, information, and services. Contact information and web links provided for individuals to explore and contact resources of interest.
223784266|NCT02946294|DRUG|Bupivacaine 0.25% with epinephrine|
223784267|NCT02946294|DRUG|Bupivacaine 0.25% with epinephrine|
223784268|NCT00005787|BIOLOGICAL|epoetin alfa|
223784269|NCT00005787|BIOLOGICAL|filgrastim|
223784270|NCT00005787|BIOLOGICAL|recombinant flt3 ligand|
223784271|NCT00005787|BIOLOGICAL|recombinant interleukin-3|
223784272|NCT00005787|BIOLOGICAL|sargramostim|
223784273|NCT00005787|PROCEDURE|in vitro-treated peripheral blood stem cell transplantation|
223702832|NCT03145363|BEHAVIORAL|Intervention|The intervention group will receive 2-5 interactive text message sequences per week. These messages will invite students to reply using keywords and short free text replies. Messages come from a library of strength-based peer quotations (reviewed for safety), psychoeducational interactions, and games designed to promote emotional skills and use of resources.
223702833|NCT03145363|BEHAVIORAL|Control|"The control group will receive 1-2 (non-interactive) text messages per week containing general SoS concepts (e.g., Remember: more strengths are better when times get tough)."
223702834|NCT04139473|PROCEDURE|Hepaticojejunostomy / Duct-to-duct anastomosis|
223702835|NCT02648269|DRUG|SEL-110|
223702836|NCT02648269|BIOLOGICAL|SEL-212|
223702837|NCT02648269|BIOLOGICAL|SEL-037|
223702838|NCT01297920|DRUG|Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension|
223702839|NCT01297920|DRUG|Brinzolamide ophthalmic suspension, 1%|
223702840|NCT01297920|DRUG|Brimonidine tartrate ophthalmic solution, 0.2%|
223702841|NCT03212690|DRUG|Local standard of care|Local standard of care will include fluid resuscitation, use of vasopressor drugs and renal support.
223702842|NCT03212690|PROCEDURE|Mechanical ventilation|Mechanical ventilation will be based on volume-assist control mode, with a target tidal volume of 6-8 milliliter per kg (mL/kg) and a target plateau pressure of 30 centimeter of water (cmH2O).
223702843|NCT05548673|BEHAVIORAL|Psychoeducation|The implementation phase is planned for Ankara Yıldırım Beyazıt University (AYBU) Nursing Faculty students. The stress management training program, which consists of eight sessions, is completed in 8 weeks, once a week.
223702844|NCT05685836|DRUG|Bevacizumab Zirconium Zr-89|See Arm description.
223702845|NCT02534220|DEVICE|Manual Toothbrush|Gum Delicate Post-Surgical Toothbrush, Oral-B, Procter \& Gamble, Cincinnati, OH
223702846|NCT02534220|DEVICE|Oscillating-rotating toothbrush|Triumph 5000, Oral-B, Procter \& Gamble, Cincinnati, OH
223702847|NCT00263731|OTHER|13-C-glucose|"10 grams of 13-C-glucose intravenously, as a 30-minute piggyback infusion, 2 to 6 hours prior to scheduled surgical resection of primary lung cancer."
223702848|NCT00474760|DRUG|CP-751,871|Currently dosing at 20 mg/kg, IV on day 1 of each 28 day cycle until progression or unacceptable toxicity
223702849|NCT04920344|PROCEDURE|Transoral Surgery|Patients will undergo transoral surgery
223702850|NCT04920344|RADIATION|External Beam Radiation Therapy|Patients in Group II and Group III will undergo External Beam Radiation Therapy (EBRT) RT following transoral surgery.
223702851|NCT04920344|DRUG|Cisplatin|Patients in Group III will receive cisplatin, 30 mg/m2, administered intravenously weekly per for 6 weeks.
223702852|NCT04920344|PROCEDURE|Incisional Tumor Biopsy|Incisional biopsy of the primary tumor site will be required to confirm p16/HPV status of the tumor
223702853|NCT04920344|OTHER|Circulating tumor deoxyribonucleic acid (ctDNA) levels assessment|Assess ctDNA levels at baseline, 2 weeks, 4 weeks, 10 weeks, 24 weeks and 1 year after the surgery.
223702854|NCT04920344|OTHER|MD Anderson Dysphagia Index|MDADI is a 20 item quality of life questionnaire specifically focusing on swallowing aspects. It was originally designed for head and neck cancer patients. The total score ranges from 20 to 100 with the higher score indicating higher level of function.
223702855|NCT04920344|OTHER|University of Washington Quality of Life Questionnaire|University of Washington Questionnaire is a 15 item quality of life instrument specifically designed for head and neck cancer patients.
223702856|NCT04920344|OTHER|Euro-QOL 5 dimension scale questionnaire|A generic quality of life and cost utility instrument widely used and validated for multiple disease settings, including head and neck cancer.
223784274|NCT06572904|DRUG|Tenoxicam Injectable Product|(EPICOTIL® Tenoxicam 20 mg , Manufactured by: EGYPTIAN INTERNATIONAL PHARMACEUTICAL INDUSTRIES COMPANY, ReStore at a temperature not exceeding 30°C.)
223784275|NCT06572904|DRUG|Hyaluronic Acid 20 MG/1 ML Injection Gel/Jelly|\* (Hyalubrix® hyaluronic acid sodium salt 30 MG/2 ML, manufactured by Fidia SPA,Italy, stored at temperature \> 25 °C)
223784276|NCT05511714|DRUG|L-(11C) methionine|Injected intravenously with 20 mCi/1.7 sq m body surface area of L-\[methyl-11C\]methionine (maximum prescribed dose: 20 mCi).
223784277|NCT05336240|BEHAVIORAL|Physician Communication 2 Virtual (PCOM2-virtual)|The PCOM-standard intervention is based off of a provider communication training that utilizes presumptive technique when initiating the vaccine discussion followed by motivational interviewing if a parent continues to show hesitation. While this provider communication technique previously showed success in increasing HPV vaccination uptake, it is neither easy to disseminate nor sustainable due to it's nature of direct, intensive in-person training. Therefore, the intervention is to compare the standard-PCOM intervention to a new, PCOM2 intervention, that will be adapted virtually.
223784278|NCT05336240|BEHAVIORAL|Physician Communication Standard (PCOM-standard)|The PCOM-standard intervention is based off of a provider communication training that utilizes presumptive technique when initiating the vaccine discussion followed by motivational interviewing if a parent continues to show hesitation. PCOM-standard will be conducted in-person with providers.
223784279|NCT06161376|OTHER|S1P level|Patients will undergo urinary S1P level assessments before treatment, 6 weeks post-injection, and following any symptomatic changes that may lead to another urodynamic assessments.
223784280|NCT06487039|DRUG|EB-203|Subjects will receive EB-203 according to the following dosage and administration method for each treatment group.
223784281|NCT06575218|DEVICE|Virtual reality training|Virtual reality training
223784282|NCT06575218|OTHER|Conventional exercise and cognitive exercise|Conventional exercise and cognitive exercise
223784283|NCT06575218|OTHER|control|no intervention
223784284|NCT04712318|PROCEDURE|Relex Smile|Procedure/Surgery: Relex Smile The residual myopic refraction on Pseudophakic patients after 6 months using Relex-Smile surgery by VisuMax femtosecond laser. The residual refractive power was min -0.75D.The optical zone (lenticule diameter) and cap diameter were 6.5 and 7.5 mm respectively. After dissection of both anterior and posterior planes, the lenticule was extracted through 120 degree superior 3.5 mm incision and marked with a sterile marker(ViscotMedster).
223784285|NCT04712318|PROCEDURE|Relex smile with fresh corneal lenticule implantation|"VisuMax femtosecond laser performed flap-cut procedure with an energy cut index of 30 nJ (150nJ), spot and track spacing surface cut of 4.5 μm, side cut 2.0 μm were used to create an intrastromal pocket into the patient's cornea to receive the donor lenticule.~The stromal pocket diameter was set 7.6 to 8.0 mm (1 mm larger than the optical zone of the donor lenticule) and cap thickness was set to 130 μm from corneal surface and a 4 mm superior incision. Hinge position flap was set at 90°, angle 50° and width 4 mm, side cut angle 90°. The pocket was dissected using a blunt spatula washed with normal saline. The lenticule was held with lenticule forceps and gently inserted into the pocket through the 4 mm superior incision.~In pseudophakic patients with hyperopic astigmatism residual refraction, corneal topography-guided intrastromal fresh lenticular implantation should be performed according to the low K values."
223784286|NCT03762135|OTHER|Full version of the LIITah App.|Participants will download the LIITAH app. For the first 2 weeks the app. will only record presence in a restaurant and ask users to submit photos of their food. in week 3 all of the program features will be activated.
223784287|NCT03762135|OTHER|Partial App. (ELI and SNAP only)|Participants will download the LIITAH app. It will detect their presence in a restaurant and users will submit annotated photos of their purchases
223784288|NCT06572670|OTHER|Progressive relaxation exercise before coronary angiography|Patients in the intervention group will undergo progressive relaxation before undergoing angiography.
223784289|NCT02198547|DRUG|Magnesium Sulfate|Mg used with ropivacaine for sciatic nerve blick
223784290|NCT02198547|DRUG|Ropivacaine|Ropivacaine 7,5 mg/ml used for sciatic nerve block
223784291|NCT01915563|PROCEDURE|REST|After a SBT patients will be extubated as usual or reconnected to mechanical ventilation for 60 min before extubation.
223784292|NCT06259344|BEHAVIORAL|Fractioned Pain Science Education (FPSE)|Pain Science Education (PSE) will be administered in workshop sessions with interactive presentations, using different resources as metaphors and videos. It will be held in 2 sessions of 45 minutes each, covering 6 topics of Explain Pain and Explain Pain Supercharged books.
223784293|NCT06259344|BEHAVIORAL|Full Dosage Mode Pain Science Education (FDPSE)|Pain Science Education (PSE) will be administered in workshop sessions with interactive presentations, using different resources as metaphors and videos. It will be held in 6 sessions of 15 minutes each, covering 6 topics of Explain Pain and Explain Pain Supercharged books.
223784294|NCT06259344|OTHER|Manual Therapy|Intraoral temporalis release, Intraoral medial and lateral pterygoid (origin) technique and Intraoral sphenopalatine ganglion technique.
223784295|NCT06259344|OTHER|Orofacial and Neck Exercises (ONE)|"Orofacial Exercises: Mandibular body-condylar cross-pressure chewing technique; Post-isometric relaxation stretches-laterotrusion and opening (10 times/session; 10 seconds).~Neck Motor Control Exercises: Bracing exercises (6 hierarchical levels - HL). Extreme range of motion exercises (stable spine). Cervical isometric exercises (5 HL) directly forward, obliquely, toward right and left, and directly backward (stable spine - elastic resistive bands). Functional training with elastic resistance and exercise balls on unstable surfaces (8 HJ). The progress in each exercise domain will happen when sustaining the contraction for 10 seconds, 10 times."
223784296|NCT02040597|DRUG|Beclometasone/Formoterol/Glycopyrrolate|
223784297|NCT02874547|BEHAVIORAL|Intervention|During an in-person visit, patients receive a pamphlet in english and spanish and a storytelling Digital Versatile Disc (DVD) (developed for this project from interviews with hypertensive patients), supplemented by motivational interviewing delivered by the CHW. The CHW explores the patient's motivation to change associated with hypertension and counsels on risk factor control (tobacco, diet, physical activity). Patients receive a followup telephone call from the CHW in 2 weeks, 4 weeks, 2 months to support any changes or goals discussed at first visit. Six months after first intervention visit, patients are invited to schedule an in-person visit with the CHW at the health center to discuss goals and provide support for change.
223784298|NCT04407663|OTHER|Telemedicine to remote outpatient visit in bariatric patient|Patients that referred for the first time to our bariatric center were investigated for anthropometric, psychological and instrumental data in order to evaluate the eligibility for a future bariatric procedure. In established patients, eligibility for tele-consultation was evaluated by three experienced physicians, consulting the stored patients' data. All included patients provided oral informed consent. Patients approached the virtual visit with their personal smart devices, desktop or laptop computer. Medical counselling was performed using a desktop or laptop computer from the Hospital or home in a smart working modality. The video call was carried out using Skype platform by Microsoft®; any document drawn up by the physician was saved as pdf using the Cute Professional™ PDF software, that allows to add passwords and set security options to protect the patients' data.
223784299|NCT05640934|DRUG|Melatonin|The patients will be given 5 mg melatonin the night before surgery, 12 hours before the scheduled time of surgery, followed by another 5 mg melatonin two hours before surgery.
223784300|NCT05640934|DRUG|Placebo|The patients will be premedicated with placebo tablets, which will be administered at the same times as the melatonin group.
223784301|NCT05626192|OTHER|Anatomical dissection and Immunohistochemical techniques|Anatomical dissection and description
223784302|NCT06208618|OTHER|Education and Motivational Interviews|"The diabetes education aimed at supporting diabetes self-management in adolescents will include the following topics:~* What is Diabetes?~* Treatment in Diabetes~* Insulin Therapy~* Nutritional Therapy~* Physical Activity/Exercise~* Acute Complications of Diabetes~  * Hypoglycemia~ * Hyperglycemia~ * Diabetic Ketoacidosis~* Diabetes Management in Illness~Motivational interviews will consist of the following stages:~* First Meeting - Pre-awareness (Pre-contemplation)~* Second Meeting - Awareness (Contemplation)~* Third Meeting - Preparation~* Fourth Meeting - Taking Action (Action)~* Fifth Meeting - Maintenance~* Sixth Meeting - Termination or Review"
223784303|NCT02259608|BIOLOGICAL|BCG vaccine SSI|BCG vaccination
223784304|NCT02755389|DRUG|0 L/min oxygen via conventional nasal cannulae|Patients will have conventional nasal cannulae placed under chin prior to induction of anesthesia. Immediately post-induction these will be placed into the nares. They will be removed from the nares at the end of the study when the airway has been secured. There will be no oxygen flowing through the cannulae in this group during the study.
223784305|NCT02755389|DRUG|15 L/min oxygen via conventional nasal cannulae|Patients will have conventional nasal cannulae placed under chin prior to induction of anesthesia. Immediately post-induction these will be placed into the nares. They will be removed from the nares at the end of the study when the airway has been secured. There will be 15 L/min of oxygen flowing through the cannulae in this group during the study.
223784306|NCT02755389|DRUG|60 L/min oxygen via high-flow nasal cannulae|Patients will have high-flow nasal cannulae placed under chin prior to induction of anesthesia. Immediately post-induction these will be placed into the nares. They will be removed from the nares at the end of the study when the airway has been secured. There will be 60 L/min of oxygen flowing through the cannulae in this group during the study.
223784307|NCT02278276|DRUG|sodium polysulthionate|Bioavailable composition of α-sulfur
223784308|NCT02278276|DRUG|Placebo|400 mg capsules containing placebo
223784309|NCT03286023|RADIATION|stereotactic radiotherapy|stereotactic radiotherapy for brain metastases
223784310|NCT01812044|DRUG|subtenons anesthetic - preservative-free bupivacaine 0.75%|
223784311|NCT01812044|DRUG|topical anesthetic - 0.5 cc of lidocaine 3.5% ophthalmic gel|
223784312|NCT01812044|DRUG|topical control - 0.5 cc of Hypromellose 0.3% gel|
223784313|NCT01812044|DRUG|subtenons control - 0.5 cc of Normal Saline|
223784314|NCT01642797|DEVICE|Confocal laser endomicroscopy (Pentax, EG3870K)|Confocal laser endomicroscopy with Targeted Biopsy
223784315|NCT01642797|DEVICE|Standard White-light endoscopy (Pentax, 90i)|Standard White-light endoscopy with Standard Biopsy
223784316|NCT02720484|OTHER|Laboratory Biomarker Analysis|Correlative studies
223784317|NCT02720484|DRUG|Nivolumab|Given IV
223784318|NCT05039268|DRUG|3K3A-APC Protein|3K3A-APC with intravenous dosing of five doses of either 15mg or 30mg at 12 hourly interval. The first 8 patients will receive 15mg dose, and the next 8 patients will receive 30mg dose.
223784319|NCT05070897|OTHER|Questionnaires|"* Approved French version of the FCCHL scale~* Questionnaire on the use of digital tools adapted from the questionnaire on digital tools"
223784320|NCT05599594|OTHER|Aromatherapy|6 drops of aromatic oils used by the researcher will be dripped by the aromatic oils to take the fragrance by inhalation for 30 minutes.
223784321|NCT02500225|DRUG|Etomidate|0.2 mg/kg etomidate
223784322|NCT02500225|DRUG|Sevoflurane|8% Sevoflurane
223784323|NCT01617629|BIOLOGICAL|MUC1 Dendritic Cell Vaccine (Cvac)|"The recommended dosing regimen for CAN-003X was every 4 weeks for the first 3 doses and then every 12 weeks for 3 doses, for a total of 6 doses over 44 weeks (Regimen A, applicable to CAN-003 observational Standard of Care patients and CAN-003 Cvac patients that have progressed prior to the fourth dose of Cvac).~Participants who received more than 3 doses of Cvac in CAN-003 continued with the CAN-003 dosing schedule (Regimen B; Cvac every 4 weeks for a total of 7 doses and then every 8 weeks for 3 doses, for a total of 10 doses over approximately 48 weeks)."
223784324|NCT01337245|DRUG|Snake (Micrurus) North American immune F(ab')2 Equine|5 vials of study drug reconstituted and diluted to 250 mL Normal Saline and administered intravenously.
223784325|NCT03223558|BEHAVIORAL|timing of initiation of cardiac rehabilitation|earlier timing of cardiac rehabilitation
223784326|NCT05861544|DIETARY_SUPPLEMENT|Pomegranate juice|The pomegranate juice that will be used in the experiment is a 100% natural product without conservatives. It will kindly be donated from the company Rodi Hellas SA, Pella, Greece. The product is in line with the quality assurance certificates by the International Organization for Standardization (ISO 22000:2005), Global Gap, Grasp and Kosher.
223784327|NCT01663636|BEHAVIORAL|SMS message reminding mothers to come for their scheduled vaccines|Reminder
223784328|NCT03325413|BEHAVIORAL|Systematic inclusion of family members|Systematic inclusion of family members/ reference person in the perioperative process
223784329|NCT03325413|BEHAVIORAL|Preoperative information|Detailed preoperative information about delirium prevention and procedures
223784330|NCT03325413|BEHAVIORAL|Physical and breathing exercises|Preoperative execution of physical and breathing exercises if necessary
223784331|NCT03325413|DIETARY_SUPPLEMENT|Dietary supplements|Dietary supplements if necessary
223784332|NCT03325413|OTHER|Evaluation of long-term medication|Avoidance of unsuitable drugs for elderly if possible
223784333|NCT03325413|PROCEDURE|Regional anesthesia|Regional anesthesia whenever possible
223784334|NCT03325413|OTHER|Personal aids|Personal orientation aids until anesthesia induction
223784335|NCT03325413|DEVICE|Temperature management|Perioperative warming
223784336|NCT03325413|DEVICE|Neurmonitoring|Using Bispectral index (BIS) to measure the depth of anesthesia
223784337|NCT03325413|PROCEDURE|Pain catheter|A pain catheter will be used as postoperative pain therapy if possible
223784338|NCT05267301|DIETARY_SUPPLEMENT|AlmegaPL (FDA NDIN # 826)|The investigational product iwi/Cholesterol is a commercially available capsule-form herbal (algae) supplement containing Almega®PL, a Nannochloropsis algae-derived extract rich in eicosapentaenoic acid (EPA). EPA is a type of omega-3 essential fatty acid known to play a beneficial role in protection against cardiovascular disease. Iwi/Cholesterol is the only source of long chain omega-3 that does not contain the DHA that is present in other omega-3 sources (fish oil, krill oil, other algal oils). Almega®PL was registered at the Food and Drug Administration (FDA) as a New Dietary Ingredient (NDIN) in 2014.
223784339|NCT06531746|OTHER|Extracorporeal shock wave|"participants will receive 2000 ESWT impulses, with 1500 targeting the taut band and 500 surrounding the taut band, with an energy flux density of 0.10 mJ/mm and frequency of 8 Hz, by using an~EME S.r.l. via Degli Abeti 88/161122 Pesaro \[serial number:~EM12681015\], Italy, shock wave generator."
223784340|NCT06531746|OTHER|Selected physical therapy program|Stretching and strengthening of Iliopoas muscle and Stretching and strengthening of Lower back muscles
223784341|NCT01273272|BEHAVIORAL|Comprehensive, CBT-based, multi-component treatment|It includes eight modules: diagnosis and goal setting; psychoeducation; engagement in pleasant activities; cognitive restructuring; live review; training caregiver in behavior man-agement techniques; interventions for the caregiver; and couples counselling. It consists of 20 weekly sessions (plus appr. 5 single session with caregiver).
223784342|NCT01273272|BEHAVIORAL|Treatment as usual|Each patient/caregiver must receive at least three out of six interventions: (1) psychoeducation on dementia and treatment of dementia (oral and written); (2) appropriate medical treatment; (3) social counseling by specialized staff; (4) memory training in group setting; (5) self-help group for the patient; (6) self-help group for the caregiver.
223784343|NCT06146322|OTHER|WR|Unsweetened preload condition: 240 mL white glutinous rice, 250 kcal, 0 g β-glucan
223784344|NCT06146322|OTHER|LB|Unsweetened preload condition: 240 mL low β-glucan barley, 250 kcal, \~4 g β-glucan
223784345|NCT06146322|OTHER|MB|Unsweetened preload condition: 240 mL medium β-glucan barley, 250 kcal, \~5 g β-glucan
223784346|NCT06146322|OTHER|HB|Unsweetened preload condition: 240 mL high β-glucan barley, 250 kcal, \~6 g β-glucan
223784347|NCT06146322|OTHER|WR+50g HFCS|Sweetened condition with high fructose corn syrup (HFCS): 240 mL white glutinous rice + 50g HFCS, 391 kcal, 0 g β-glucan
223784348|NCT06146322|OTHER|LB + 50 g HFCS|Sweetened condition with high fructose corn syrup (HFCS): 240 mL low β-glucan barley + 50 g HFCS, 391 kcal, \~4 g β-glucan
223784349|NCT06146322|OTHER|MB + 50 g HFCS|Sweetened condition with high fructose corn syrup (HFCS): 240 mL medium β-glucan barley + 50 g HFCS, 391 kcal, \~5 g β-glucan
223784350|NCT06146322|OTHER|HB + 50 g HFCS|Sweetened condition with high fructose corn syrup (HFCS): 240 mL high β-glucan barley + 50 g HFCS, 391 kcal, \~6 g β-glucan
223784351|NCT05427331|DRUG|FMT capsule|Patients with insomnia need to take FMT capsules orally in an empty stomach in the morning, 16 capsules once a week, for 4 consecutive weeks
223784352|NCT02091804|BEHAVIORAL|Immediate Group|"The intervention consists of delivering the Promoting First Relationship (PFR) program. PFR comprises 10 sessions and lasts approximately 12 weeks. Each session lasts approximately 30 minutes, and begins with brief (\~10 min) discussions and education on the target topic for that week . The remaining 20 minutes will alternate between video recording a structured interaction between the caregiver and child or viewing the previous session's recording and engaging in reflective discussion about successful caregiving strategies and child's response to caregiver behavior. Trained PFR specialists who are community members use the 5 consultation strategies, labeled Joining, Positive Feedback, Instructive Feedback, Reflective Questions and Comments, and Instruction with Handouts."
223784353|NCT02091804|BEHAVIORAL|Wait-List group|"The intervention consists of delivering the Promoting First Relationship (PFR) program. PFR comprises 10 sessions and lasts approximately 12 weeks. Each session lasts approximately 30 minutes, and begins with brief (\~10 min) discussions and education on the target topic for that week . The remaining 20 minutes will alternate between video recording a structured interaction between the caregiver and child or viewing the previous session's recording and engaging in reflective discussion about successful caregiving strategies and child's response to caregiver behavior. Trained PFR specialists who are community members use the 5 consultation strategies, labeled Joining, Positive Feedback, Instructive Feedback, Reflective Questions and Comments, and Instruction with Handouts."
223784354|NCT06057246|OTHER|Test meal with postprandial samples|The mixed-nutrient test meal consists of a sandwich made with bread, spread cheese, air-cured beef, and one apple. Nutritional composition of the meal will be: total energy (TE) content 532 kcal, carbohydrates 68,4 g (49.3% TE), total fat 17.1 g (29.5% TE), protein 27.8 g (21.4% TE), and fibre 6 g. Before and over 4 hours after the meal, venous blood samples will be taken for biochemical evaluations at the time points -15'; 0'; 15'; 30'; 60'; 120'; 180'; 240'.
223784355|NCT03832946|DRUG|GB0139|GB0139 is a galectin-3 inhibitor designed to modulate the fibrogenic response to tissue injury. It is administered as inhalation once a day.
223784356|NCT03832946|DRUG|Placebo|Placebo is administered as inhalation once a day
223784357|NCT02973451|DRUG|Laparoscopic Guided Bupivacaine|Bupivacaine Laparoscopic GuidedTransversus Abdominis Plane Block
223784358|NCT02973451|DRUG|local Bupivacaine|Bupivacaine Trocar Site Infiltration
223784359|NCT02228213|BIOLOGICAL|MIS416|Intravenous administration weekly for 52 weeks
223784360|NCT02228213|DRUG|Saline|Intravenous administration weekly for 52 weeks
223784361|NCT05341089|DRUG|LY3502970|Administered orally.
223784362|NCT06535204|DIETARY_SUPPLEMENT|Aqueous extract of A. sylvestris leaves|Provided functional food made from Aqueous extract of A. sylvestris leaves
223784363|NCT06535204|DIETARY_SUPPLEMENT|microcrystalline cellulose|Provided placebo composed of microcrystalline cellulose instead of A. sylvestris leaf extract.
223784364|NCT05536947|OTHER|Bread product (standard milled)|Bread rolls made from standard milled flour.
223784365|NCT05536947|OTHER|Bread Product (micro-milled)|Bread rolls made from micro-milled whole grain flour.
223784366|NCT05536947|OTHER|Bread Product (standard aleurone)|Bread rolls made from white flour/standard milled aleurone mix
223784367|NCT05536947|OTHER|Bread product (micro-milled aleurone)|Bread rolls made from white flour/micro-milled aleurone mix.
223784368|NCT06024447|PROCEDURE|Subgingival Instrumentation|Subgingival Instrumentation will be performed in patients with Stage III and IV periodontitis.
223784369|NCT04315311|DRUG|CREON|Capsule: Oral
223784370|NCT03510481|BIOLOGICAL|PfSPZ Vaccine|PfSPZ Vaccine is Radiation attenuated, aseptic, purified, vialed, cryopreserved, NF54 P. falciparum sporozoites produced by Sanaria, Inc.
223784371|NCT03510481|DRUG|Normal Saline|Clear liquid indistinguishable from the study product will be used as a placebo rather than a comparator vaccine.
223784372|NCT03510481|DRUG|artemether 20mg/lumefantrine 120mg (AL)|Licensed antimalarial in the US and Mali for use for uncomplicated malaria.
223784373|NCT04762745|DRUG|Pomalidomide|Pomalidomide( Anyue®, Chia Tai TIANQING, China), 4mg, orally(PO), d1-21, 28d/cycle, 1cycle.
223784374|NCT04762745|DRUG|Bendamustine|Bendamustine( Leweixin®, Chia Tai TIANQING, China), 60mg/m2/d, intravenously(IV), d1-2, 28d/cycle, 1 cycle.
223784375|NCT04762745|DRUG|Dexamethasone|Dexamethasone, 40mg, PO or IV, d1, 8, 15, 22, 28d/cycle, 1 cycle.
223784376|NCT04762745|DRUG|Pomalidomide|Pomalidomide( Anyue®, Chia Tai TIANQING, China), 4mg, orally(PO), d1-21, 28d/cycle, 1cycle.
223784377|NCT04762745|DRUG|Bendamustine|Bendamustine( Leweixin®, Chia Tai TIANQING, China), 70mg/m2/d, intravenously(IV), d1-2, 28d/cycle, 1 cycle.
223784378|NCT04762745|DRUG|Dexamethasone|Dexamethasone, 40mg, PO or IV, d1, 8, 15, 22, 28d/cycle, 1 cycle.
223784379|NCT04762745|DRUG|Pomalidomide|Pomalidomide( Anyue®, Chia Tai TIANQING, China), 4mg, orally(PO), d1-21, 28d/cycle, 1cycle.
223784380|NCT04762745|DRUG|Bendamustine|Bendamustine( Leweixin®, Chia Tai TIANQING, China), 70mg/m2/d, intravenously(IV), d1-2, 28d/cycle, 1 cycle.
223784381|NCT04762745|DRUG|Dexamethasone|Dexamethasone, 40mg, PO or IV, d1, 8, 15, 22, 28d/cycle, 1 cycle.
223784382|NCT04762745|DRUG|Pomalidomide|Pomalidomide( Anyue®, Chia Tai TIANQING, China), 4mg, orally(PO), d1-21, 28d/cycle, 8 cycles. Then pomalidomide( Anyue®, Chia Tai TIANQING, China), 4mg, orally(PO), d1-21, 28d/cycle until progression or intolerable toxicities.
223784383|NCT04762745|DRUG|Bendamustine|Bendamustine( Leweixin®, Chia Tai TIANQING, China), 70mg/m2/d, intravenously(IV), d1-2, 28d/cycle, 8 cycles.
223784384|NCT04762745|DRUG|Dexamethasone|Dexamethasone, 40mg, PO or IV, d1, 8, 15, 22, 28d/cycle, 8 cycles. Then dexamethasone, 40mg, PO or IV, d1, 8, 15, 22, 28d/cycle until progression or intolerable toxicities.
223784385|NCT02762526|PROCEDURE|Lipoabdominoplasty|
223784386|NCT05257889|DIAGNOSTIC_TEST|blood and CSF studies + neuroimaging studies|blood and CSF studies + neuroimaging studies
223784387|NCT00333593|DEVICE|Large pore dialyser|
223784388|NCT00333593|DEVICE|Standard dialyser|
223784389|NCT06535815|OTHER|Cyclic enteral feeding with nighttime fasting and exogenous ketone salt supplementation (ß-hydroxybutyrate)|12 hours of enteral feeding (as per patients´individual calorimetric requirements measured by indirect calorimetry) followed by a fasting period of 12 hours supported by the supplementation of exogenous ketone salts.
223784390|NCT00000838|DRUG|Lamivudine|
223784391|NCT00000838|DRUG|Stavudine|
223784392|NCT00000838|DRUG|Zidovudine|
223784393|NCT00000838|DRUG|Didanosine|
223784394|NCT01079520|PROCEDURE|Endobronchial ultrasound (EBUS)|Minimally invasive technique to stage lung cancers
223784395|NCT01079520|PROCEDURE|Mediastinoscopy|Traditional surgical method to stage lung cancers
223784396|NCT01501318|BEHAVIORAL|Personalized feedback report|Participants receive the personalized feedback report but no additional education.
223784397|NCT01501318|BEHAVIORAL|Personalized feedback report plus education|Participants receive the personalized feedback report plus education. This is the currently implemented service approach.
223784398|NCT03917290|BEHAVIORAL|Neuromuscular training|Training will be conducted with a research assistant under the supervision of Dr. Howell (PI), a certified athletic trainer, who will meet with participants either at the individual or small group level (3-4 participants maximum). Training will be done within the Children's Hospital Colorado network-of-care locations, dependent on the location of participants. Due to in-person restrictions that have resulted from COVID-19, participants may also complete the intervention via remote (virtual) training sessions.
223784399|NCT00172510|PROCEDURE|blood drawing|
223784400|NCT04511689|DEVICE|gene-activated bone substitute mixed with autobone|gene-activated bone substitute based on octacalcium phosphate and plasmid DNA encoding VEGFA gene mixed with autobone
223784401|NCT06112236|OTHER|no intervention|no intervention
223784402|NCT04045457|PROCEDURE|dry needling|insertion of needle into active myofascial trigger point
223784403|NCT02972099|DEVICE|TcPRF|Transcutaneous Pulsed Radiofrequency is a method that is widely used for control of pain. There are no known complications. In this study a Radiofrequency generator will be used that has a separate outlet for transcutaneous use. It is used in the daily clinical practice in the Pain Center of the Swiss Paraplegic Center.
223784404|NCT02972099|DEVICE|Placebo|In the Placebo Treatment, no current will be delivered. Since no sensations are produced by TcPRF treatment the patients won't recognize the difference.
223784405|NCT04619641|DEVICE|High Flow Nasal Cannula (HFNC)|HFNC will be set at 30 L/min, with a temperature at 31° C and 100% of relative humidity
223784406|NCT04619641|DEVICE|Continuous Positive Airway Pressure (CPAP)|"CPAP will be delivered through a helmet (Castar Next, Intersurgical S.p.A., Mirandola, Italy), with an adjustable Positive End-Expiratory Pressure (PEEP) valve (2.5-20 cmH2O) set at 10 cmH2O (Intersurgical S.p.A., Mirandola, Italy). The helmet will be connected to a turbine-driven ventilator (Monnal T60, Air Liquide Medical Systems, Antony, France) set to deliver oxygen-air admixture at a continuous flow rate of 60 L/min, in order to improve CO2 wash out. No heated humidification will be applied to avoid the fog effect in the helmet"
223784407|NCT02008383|BIOLOGICAL|Panitumumab|The FDA approved dose for panitumumab is 6mg/kg IV, every two weeks. This is the dose and schedule that will be used in this study.
223784408|NCT02008383|DRUG|Cabozantinib|"There will be three parts to this phase I study: 1) the Combination Dose Finding cohort; 2) the Combination Expansion cohort; and 3) the Monotherapy MET Amplified cohort.~Cabozantinib will start at a dose of 60 mg daily with reductions to 40 and 20 mg daily possible in the dose finding cohort. The combination expansion cohort dose will determined by the dose finding cohort. The Monotherapy MET Amplified cohort will recieve 60 mg Cabozantinib daily."
223784409|NCT03062826|DRUG|dual antiplatelet therapy (aspirin + ticagrelor or aspirin + clopidogrel)|Patients who met the inclusion criteria will be treated with dual antiplatelet therapy (aspirin + ticagrelor or aspirin + clopidogrel).
223784410|NCT02863991|DRUG|ONC201|375 mg or 625 mg ONC201
223784411|NCT02863991|DRUG|Dexamethasone|20 mg dexamethasone
223784412|NCT05430529|BEHAVIORAL|Standard Smoke Cessation Service|Both of the intervention group and control group will receive standard smoke cessation service, which is same as usual practice.
223784413|NCT05430529|BEHAVIORAL|Short Advice for Control Group|If the control group participant encountering difficulties in smoke cessation caused by alcohol usage, HCP will provide short advice to them. Participant will be urged not to drink during smoke quitting. If drinking is unavoidable, participant should not drink exceed the low-risk drinking portion recommended by Department of Health, which is 2 standard alcohol units for men and 1 stand alcohol unit for women per day. HCPs will remind participants to aware their drinking portion, in order to quit smoke successfully.
223784414|NCT05430529|BEHAVIORAL|Brief Alcohol Intervention for Intervention Group|"During the face-to-face smoking cessation counseling session, HCPs will first play a 2 - 3 minutes short video with electronic devices to participants who are allocated to the intervention group.~After the short video, HCPs will ask participants to share their thoughts and willingness of alcohol control. Participants are expected to show 4 responses: (1) refuse to attempt alcohol control; agree to attempt alcohol control that (2) quit drinking totally, (3) quit drinking for 2 weeks, or (4) reduce the alcohol consumption. HCPs will deliver personalized advice according to participants' choices and encourage them to receive the WhatsApp message reminders.~In all participants, HCPs will invite them to receive WhatsApp messages reminders for incoming 4 weeks (3 messages per week).~In addition, HCPs can choose to discuss with participants the reasons for consuming alcohol.~Nevertheless, HCPs can also choose to provide AUDIT-based brief intervention to the participants."
223784415|NCT01700608|DRUG|plerixafor|plerixafor 240 mcg/kg/day at the hematopoietic recovery after chemotherapy
223784416|NCT03591744|DRUG|Bortezomib|Given SC
223784417|NCT03591744|BIOLOGICAL|Daratumumab|Given IV
223784418|NCT03591744|DRUG|Dexamethasone|Given IV and PO
223784419|NCT03591744|DRUG|Lenalidomide|Given PO
223784420|NCT03591744|DRUG|Pegylated Liposomal Doxorubicin Hydrochloride|Given IV
223784421|NCT00006060|DRUG|standard gadolinium contrast|
223784422|NCT02069600|DEVICE|Continuous Positive Airway Pressure|"CPAP applies a positive pressure into the airway to avoid its collapse during sleep.~The pressure used in each patient is calculate by an auto CPAP device during 3 months. This device calculate the pressure that avoid 95% of sleep-disordered breathing"
223784423|NCT02746692|OTHER|Fit15|"Group-based high-intensity circuit training based on functional movement patterns (e.g. squats, push-ups, burpees, jumps, ropeskipping).~Total duration 15 minutes circle training: 20s workout, 10 rest"
223784424|NCT02746692|OTHER|Endurance|Moderate intensity ergometer training. Total duration 50 minutes
223784425|NCT03177993|DRUG|3 drug dose - IDA|"Lymphatic Filariasis Mass Drug Administration (MDA) with triple drug therapy of ivermectin, diethylcarbamazine, and albendazole (IDA). Participants excluded from ivermectin will receive a topical dose of permethrin cream.~Exclusion criteria for ivermectin, diethylcarbamazine and albendazole:~* severe illness (chronic renal insufficiency, severe chronic liver disease, or any illness that is severe enough to interfere with activities of daily living);~* allergy to ivermectin, diethylcarbamazine or albendazole;~* pregnant;~* breastfeeding within 7 days of delivery;~* less than 2 years old; OR~* less than 15 kg~In addition if less than 5 years old excluded from ivermectin.~Exclusion criteria for permethrin:~* allergy to permethrin~* crusted scabies"
223784426|NCT03177993|DRUG|3 drug dose - IDA with second dose of ivermectin|"Lymphatic Filariasis Mass Drug Administration (MDA) with triple drug therapy of ivermectin, diethylcarbamazine, and albendazole (IDA). Eight days after treatment participants will be given a second dose of ivermectin alone.~Participants excluded from ivermectin will receive a topical dose of permethrin cream both on day 0 and day 8.~Exclusion criteria for ivermectin, diethylcarbamazine and albendazole:~* severe illness (chronic renal insufficiency, severe chronic liver disease, or any illness that is severe enough to interfere with activities of daily living);~* allergy to ivermectin, diethylcarbamazine or albendazole;~* pregnant;~* breastfeeding within 7 days of delivery;~* less than 2 years old; OR~* less than 15 kg~In addition if less than 5 years old excluded from ivermectin.~Exclusion criteria for permethrin:~* allergy to permethrin~* crusted scabies"
223784427|NCT03177993|DRUG|2 drug dose - DA|"Lymphatic Filariasis Mass Drug Administration (MDA) with the currently used standard of care combination drug therapy of diethylcarbamazine, and albendazole (DA).~If scabies is present in the participant or a household member permethrin cream will be provided 8 days after dose of DA.~Exclusion criteria for diethylcarbamazine and albendazole:~* severe illness (chronic renal insufficiency, severe chronic liver disease, or any illness that is severe enough to interfere with activities of daily living);~* allergy to diethylcarbamazine or albendazole;~* pregnant;~* breastfeeding within 7 days of delivery;~* less than 2 years old; OR~* less than 15 kg~Exclusion criteria for permethrin:~* allergy to permethrin~* crusted scabies"
223784428|NCT02789787|PROCEDURE|Maxillary Protraction|"Maxillary protraction is an alternative non-surgical approach to correct the Cl III malocclusion. At ages 11- 14, the maxillary sutures have not fused and can be mobilized by alternating weekly expansion and constriction with a rapid palatal expander (RPE), thereby allowing the maxilla to be protracted in order to correct the underbite. This treatment is offered to the patients, age 11-14, who have the Cl III malocclusion with or without cleft lip and palate."
223784429|NCT02789787|PROCEDURE|Orthognathic Surgery|The orthognathic surgery is the current standard of care for treating the Cl III malocclusion after pubertal growth. This treatment is offered to the patients, after pubertal growth, who have the Cl III malocclusion with or without cleft lip and palate.
223784430|NCT05368805|DRUG|Fruquintinib|Fruquintinib will be administered as a single oral 5mg dose on the morning of day 5
223784431|NCT05368805|DRUG|Dabigatran Etexilate|Dabigatran Etexilate will be administered as a single oral dose 150mg on the morning of day 1 and morning of day 5
223784432|NCT05368805|DRUG|Rosuvastatin|Rosuvastatin will be administered as a single oral dose 10mg on the morning of day 1 and the morning of day 5
223784433|NCT06290362|BEHAVIORAL|Cognitive Behavioural Theory-based group consultation|"Cognitive Behavioural Theory-based group consultation was given to the intervention group through an Instagram as online social media platform. This approach has been developed with the philosophy of Cognitive Behavioral Theory (Eskin, 2009).~For three days a week over eight weeks, informative posts were shared, asynchronous testing and self-discovery activities were carried out, and a synchronous tele-psychoeducation session was held once a week. The participants were connected to the live broadcast of the research team, and they interacted via text messages. In this interaction, further suggestions related to the goals of the week were given, previous assignments were checked, homework for the next session was given, personal experiences and the needs of the participants were determined, and necessary feedback was provided. Instagram had the feature of maintaining the records of all participants\&#39; attendance at these events."
223784434|NCT00364858|DRUG|Cerezyme|Cerezyme doses of 20-60U/kg every 2 weeks (Q2 Arm) or 40-120 U/kg every 4 weeks (Q4 Arm).
223784435|NCT03860194|DIETARY_SUPPLEMENT|Protison with High Protein 51(Original Flavor)|Contents of each supplement sachet has a calorie of 88 kcal, 12.8 g protein( including 8.5 g whey protein concentrate), 1.2 g leucine, 7.3 g carbohydrates, 0.8 g fat and 120 IU vitamin D per serving. This supplement was added 200 ml water and stirred well, then drank before meal.
223784436|NCT04442555|DIETARY_SUPPLEMENT|HVMN Ketone Ester|Commercially available ketone supplement
223784437|NCT04442555|DIETARY_SUPPLEMENT|Maltodextrin|Commercially available maltodextrin supplement
223784438|NCT00564083|PROCEDURE|sacral colpopexy|This surgery involves supporting the prolapsed vaginal wall with a piece of material (known as a graft) attached to a ligament along your backbone (or sacrum)
223784439|NCT01307501|DEVICE|Cryoablation|Application of extremely cold temperatures to the identified tumor(s).
223784440|NCT00171977|DRUG|Imatinib Mesylate|
223784441|NCT01704092|DRUG|Dexmedetomidine|
223784442|NCT01847508|DEVICE|PHILOS+|Proximal Humerus Internal Locking System with screw tip augmentation (PHILOS+) with high viscous polymethylmethacrylate (PMMA) cement (Traumacem V+).
223784443|NCT01847508|DEVICE|PHILOS|Proximal Humerus Internal Locking System (PHILOS).
223784444|NCT02206802|DRUG|5% minoxidil topical foam|5% minoxidil topical foam
223784445|NCT05108337|PROCEDURE|Superficial cervical plexus block|Ultrasound guidance will be used to determine the location of superficial cervical plexus nerve. The puncture will also be performed by ultrasound guidance, covered with opaque infusion dressing but performed with infusion of 10 ml 0.5% ropinacaine.
223784446|NCT05108337|OTHER|Control group|Ultrasound guidance will be used to determine the location of superficial cervical plexus nerve. The puncture will also be performed by ultrasound guidance, covered with opaque infusion dressing but performed with infusion of 10 ml normal saline.
223784447|NCT03130582|DRUG|high-dose etoposide|an epipodophyllotoxin, is one of the most common chemotherapy agents for lymphoma without reciprocal resistance with other kinds of agents.
223784448|NCT04295226|OTHER|Structured follow-up after stroke.|Stroke-nurse managed follow-up 3 and 12 months after stroke and multidisciplinary rounds resulting in individual treatment plans for stroke-related health problems.
223784449|NCT01274546|DEVICE|cruciate-retaining Foundation Knee system|subjects who received the cruciate-retaining Foundation Knee system greater than or equal to 10 years ago and still maintain the original device in their knee.
223784450|NCT00558285|DRUG|indacaterol/glycopyrrolate|Inhalation capsule delivered via a single dose dry powder inhaler in the morning for 14 days.
223784451|NCT00558285|DRUG|indacaterol|Inhalation capsule delivered via a single dose dry powder inhaler in the morning for 14 days.
223784452|NCT00558285|DRUG|glycopyrrolate|Inhalation capsule delivered via a single dose dry powder inhaler in the morning for 14 days.
223784453|NCT00558285|DRUG|placebo|Inhalation capsule delivered via a single dose dry powder inhaler in the morning for 14 days.
223784454|NCT04708873|OTHER|High intensity interval training|4x4 min intervals of high intensity treadmill running (80-95% of HRR, RPE 7-10 on Borg's category ratio scale of perceived exertion) interspersed with active recovery (slow jogging or fast walking at 50-70% HRR). HIIT-Resistance exercises 2 sessions per week, RPE 5 (hard) 6-8 RM, 1-3 sets of as many repetitions as possible in 60 seconds, active recovery 20-60 seconds b/w exercises,
223784455|NCT04708873|OTHER|Moderate Intensity Continuous Training|Moderate intensity continuous Aerobic exercises (Stationary cycling for 15-20 min followed by treadmill walking for 15-20 min) at 55-70% 55-70% of HRR, RPE 3-4 on Borg's category ratio scale of perceived exertion. The session will be preceded by 5-7 minute warm-up \&amp; 7-10 min cool-down.
223784456|NCT03384758|DEVICE|Compression Therapy|Therapy of the leg edema with compression stockings class I for three hours, after a short break with compression stocking class II for again three hours.
223784457|NCT02276300|DRUG|Cyclophosphamide|Treatment of mild Endoxan application three days before Her2 vaccination
223784458|NCT02276300|DRUG|Sargramostim|Sargramostim is part of Her2 vaccination
223784459|NCT02276300|DRUG|HER2-Peptid-Vakzine|Her2 vaccination is supplemented by Sargramostim and Aldara Creme application
223784460|NCT02276300|DRUG|Imiquimod|Imiquimod is part of Her2 vaccination
223784461|NCT05800522|BEHAVIORAL|Behavioral parent or child directed intervention|Control group will include different behavioral interventions that may include caretakers or the target child, and thus may vary in scope and intensity.
223784462|NCT05800522|BEHAVIORAL|Supportive Parents - Coping Kids|Intervention group will receive the transdiagnostic parent intervention (SPARCK). SPARCK is designed to include up to 12 sessions with caretakers. If necessary and applicable, children can attend sessions. The starting point for the development of SPARCK has been the Social Interaction Learning model, which represents the behavioral management perspective. In addition, SPARCK consists of empirically supported components based on attachment theory, emotion socialization, CBT, and family accommodation. Thus, content and strategies have been collected from different theories to provide a diverse toolkit tailored to address transdiagnostic problems in families with externalizing, internalizing, and caregiver challenges. SPARCK content and target strategies are tailored to the needs of the families and children, and the manual explains the content and how the target strategies may be tailored and combined.
223784463|NCT04827199|DEVICE|Artificial Urinary Sphincter implantation|"Device preparation (recharge, settings, pairing) Patient preparation Calibration procedure (to verify the device is in full working prior to implantation)~Implantation procedure which includes:~* Perineal approach and bulbar urethral dissection~* Inguinal approach~* Cuff implantation around the urethra~* Transmission cable passing~* Surgery test procedure~* Implantation of the Control Unit~* Closure of the inguinal incision~* Closure of the perineal incision~* Implant disabled mode activation"
223784464|NCT04182022|BEHAVIORAL|Contingency management: Contingent incentives|Monetary incentives are delivered to participants contingent upon on- time breathalyzer submissions and verified abstinence from alcohol.
223784465|NCT04182022|BEHAVIORAL|Contingency management: Noncontingent incentives|Monetary incentives are delivered to participants contingent upon on- time breathalyzer submissions only with no contingency on alcohol use.
223784466|NCT04874922|BEHAVIORAL|Gestational Diabetes Training Intervention based on Planned Behavior Theory|On the basis of Planned Behavior Theory, an training intervention is planned in three stages for medical nutrition, physical activity and gestational diabetes follow-up.
223784467|NCT04874922|BEHAVIORAL|Gestational Diabetes Training Intervention based on standart|Standard training for gestational diabetes will be given once at 28 weeks of gestation.
223784468|NCT05294757|OTHER|Physical exercise|1\. Hospital exercise cohort: Participants will be consecutively recruited from the scheduled patient list of the falls unit and the outpatient clinics of Hospital 1. After informed consent acquisition, patients will receive a baseline clinical evaluation. Ultrasound measurements and DXA scan will be conducted, and blood samples will be collected, processed, and stored. Patients will be included in the 16-week multicomponent physical exercise program described below. After the completion of the exercise program, at 16-week follow-up, clinical evaluation, ultrasound, DXA, and blood-sample testing will be repeated.
223784469|NCT05306652|OTHER|Supervised physical activity|patients will have a home-based physical activity prescription, defined on the functional endurance and strength tests and they will be supervised for 3 months. Once monthly they will be examined by the oncologist (visit and questionnaires) and at weeks 4, 6, 8, 10 and 12 at the sport medicine center where the three tests will be repeated. Home-based activity will be monitored daily through a specific application. Endurance improvement is defined as an increase in walking speed; strength improvement is defined as an increase of the number of repetitions
223784470|NCT05306652|OTHER|Unsupervised physical activity|patients will receive a physical activity counselling, without a real prescription and supervision, and the three test will be repeated once a month for three months at the local sport medicine center and at the oncology center (visit and questionnaires). Counselling will include general informations on physical exercise
223784471|NCT03857438|DRUG|Ongoing treatment for bipolar mania|Prescribed by the following doctor during hospitalization and after discharge
223784472|NCT03857438|DIAGNOSTIC_TEST|Audiovisual recording during guided presentation|Seven tasks such as explaining the reason to come to hospital/participate in the activity, describing happy and sad memories, counting up to thirty, explaining two emotion eliciting pictures
223784473|NCT04398524|DRUG|ISA101b|ISA101b 4 times plus cemiplimab every 3 weeks for up to 24 months
223784474|NCT00114686|DRUG|Quetiapine fumarate|
223784475|NCT00114686|DRUG|lithium|
223784476|NCT00114686|DRUG|divalproex|
223784477|NCT00098124|DRUG|milnacipran hydrochloride|
223784478|NCT02730819|DRUG|Illuminate Cream|Topical compound applied daily
223784479|NCT06099171|DRUG|Cannabidiol and β-Caryophyllene Patch|Cannabidiol with its decongestant activity has a soothing action in the area of application, thanks to the association with B-caryophyllene which assists its activity
223784480|NCT06099171|DEVICE|Oxygen-Ozone Therapy|Ozone (O3) is a molecule consisting of 3 atoms of oxygen in a dynamically unstable structure. O3 has the capacity to modulate inflammation. O3 when in contact with human fluids and tissues rapidly reacts, generating many reactive oxygen species, as hydrogen peroxide (H2O2), superoxide ion, and hydroxyl radical (OH-). It is suggested that through moderate oxidative stress generated by these reactive byproducts, O2O3 might produce positive effects in several pathologies, including musculoskeletal affections. Moreover, O2/O3 may directly regulate prostaglandins (PGS) and bradykinin, and suppress several proinflammatory mediators, such as IL-6, IL-8 and TNF-α
223784481|NCT02446561|DRUG|MRXXX|
223784482|NCT02446561|DRUG|MR1XXX|
223784483|NCT02446561|DRUG|MR2XXX|
223784484|NCT02446561|DRUG|MR3XXX|
223784485|NCT01674036|DRUG|Genz-682452|Capsules for oral administration.
223784486|NCT01674036|DRUG|Placebo|Placebo to Genz-682452
223784487|NCT04019847|DEVICE|STAK Tool|Medical stretching device
223784488|NCT04019847|OTHER|Standard treatment|Physiotherapists tailor treatment of arthrofibrosis to meet their patients' individual needs. Treatment may comprise the following: education, advice and a range of stretching exercises/techniques to change the length and density of the adhesions and shortened tissue. These include active range of movement (AROM), passive range of movement (PROM), strengthening exercises, hands-on high intensity passive physiological stretches, joint mobilisations and a home exercise programme involving full weight bearing exercises with the aim of enabling the patient to regain AROM and function
223784489|NCT02121847|DRUG|cyclosporine 0.05% ophthalmic emulsion|Cyclosporine 0.05% ophthalmic emulsion (Restasis®) eye drops administered twice daily for 6 months.
223784490|NCT02121847|DRUG|carboxymethylcellulose-based lubricant eye drops|Carboxymethylcellulose-based lubricant eye drops (Refresh OPTIVE® Advanced) administered as needed for 6 months.
223784491|NCT02524704|DEVICE|CT scan|Applied only when part of the patient's standard care
223784492|NCT01660906|DRUG|Dasatinib|tablets, oral, 100 mg, Once daily, Up to12 months on study,
223784493|NCT02331992|BEHAVIORAL|Adherence program|Participants will receive supportive messages while enrolled in the program.
223784494|NCT03372226|BEHAVIORAL|Online self-help program|The program consists of 10 modules with many interactional exercises and homework-sheets. Themes that are addressed in the online-program are for example self-esteem, sleep hygiene, problem solving strategies, mindfulness-based relaxation and attention exercises as well as gambling-specific topics such as money/debt management and impulse control. In addition, the user learns to modify negative and gambling-specific thought distortions, to integrate positive activities into his/her daily routine, strategies to deal with the urge to play as well as ways to regulate debts and to prevent relapse.
223784495|NCT01651429|BEHAVIORAL|Sleep deprivation|Participants will undergo 29 hours of sleep deprivation. They will wake up at 7:00 am on the day of the study and remain awake in the laboratory until 12:00 pm the next day.
223784496|NCT00725894|DEVICE|Pediatric Locking Nail|The nail is pre contoured with a nine-degree anterior bow and is universal for right and left femoral.
223784497|NCT02663817|DEVICE|CT Scan|
223784498|NCT02693873|BEHAVIORAL|GLA:D Canada (education and neuromuscular exercise program)|"EDUCATION: 2 sessions cover OA topics (e.g. diagnosis, causes, risk factors, symptoms, treatment). Education also aims to strengthen beliefs in the value of exercise to control and improve pain and encourage exercise adherence after the program.~EXERCISE: 12 sessions (twice weekly, each about 1-hour) are supervised by therapist(s) with individual progression of exercises when good neuromuscular functioning is demonstrated. Exercises are performed using both legs and focus on sensorimotor control, functional stability, and muscular strength. Exercises involve a 10-minute cycle warm-up followed by a 4-station circuit (i.e. 2 exercises per station with 3 progressive levels of difficulty performed in 2 to 3 sets with 10 to 15 repetitions)."
223784499|NCT01471002|DEVICE|Galil Medical patented 17G Cryoablation Needles|
223784500|NCT04180982|DRUG|SHR4640 dose1 plus Febuxostat dose1|Tablet,dose1,QD
223784501|NCT04180982|DRUG|SHR4640 dose1 plus Febuxostat dose2|Tablet,dose1, dose2 QD
223784502|NCT04180982|DRUG|SHR4640 dose2 plus Febuxostat dose3|Tablet,dose2, dose3 QD
223784503|NCT01028573|DRUG|PEG-ELS (Golytely)|4L consumed evening before colonoscopy
223784504|NCT01028573|DRUG|PEG-ELS (Golytely)|2L consumed on the evening before and 2L consumed on the morning of Colonoscopy
223784505|NCT01028573|DRUG|Miralax mixed with Gatorade|238g of PEG-3350 (Miralax) mixed with 2L of Gatorade consumed on the evening before colonoscopy
223784506|NCT01028573|DRUG|Miralax|1L of PEG-3350 + Gatorade consumed on the evening before and 1L of PEG-3350 + Gatorade consumed on the morning of Colonoscopy
223784507|NCT03478891|BIOLOGICAL|VRC-EBOMAB092-00-AB (MAb114)|VRC-EBOMAB092-00-AB (MAb114) is a human immunoglobulin (IgG1) monoclonal antibody (MAb) targeted to the Zaire ebolavirus (EBOV) glycoprotein (GP).
223784508|NCT02332031|DRUG|Sorafenib (Nexavar, BAY43-9006)|Single dose of 400 mg orally on Period 1 Day 1 and Period 2 Day 11
223784509|NCT02332031|DRUG|Levothyroxine|Single dose of 300 mcq orally from Period 2 Day 1 to Period 2 Day 14
223784510|NCT00147186|DEVICE|Hylan G-F 20|
223784511|NCT05729074|DRUG|IN-A002 Ointment 0.3% or IN-A002 Placebo Ointment|Drug: IN-A002 Ointment 0.3%, 10 g/1000 cm2 Drug: IN-A002 Placebo Ointment, 10 g/1000 cm2
223784512|NCT05729074|DRUG|IN-A002 Ointment 0.5% or IN-A002 Placebo Ointment|Drug: IN-A002 Ointment 0.5%, 10 g/1000 cm2, for 1 day Drug: IN-A002 Placebo Ointment, 10 g/1000 cm2, for 1 day
223784513|NCT05729074|DRUG|IN-A002 Ointment 1% or IN-A002 Placebo Ointment|Drug: IN-A002 Ointment 1%, 10 g/1000 cm2 Drug: IN-A002 Placebo Ointment, 10 g/1000 cm2
223784514|NCT05729074|DRUG|IN-A002 Ointment 3% or IN-A002 Placebo Ointment|Drug: IN-A002 Ointment 3%, 10 g/1000 cm2 Drug: IN-A002 Placebo Ointment, 10 g/1000 cm2
223784515|NCT05729074|DRUG|IN-A002 Ointment 5% or IN-A002 Placebo Ointment|Drug: IN-A002 Ointment 5%, 10 g/1000 cm2 Drug: IN-A002 Placebo Ointment, 10 g/1000 cm2
223784516|NCT05729074|DRUG|IN-A002 Ointment 1%|Drug: IN-A002 Ointment 1%, 3 g/1000 cm2
223784517|NCT05729074|DRUG|IN-A002 Ointment 3%|Drug: IN-A002 Ointment 3%, 3 g/1000 cm2
223784518|NCT05729074|DRUG|Elidel Cream 1% (pimecrolimus)|Drug: Elidel Cream 1% (pimecrolimus), 3 g/1000 cm2
223784519|NCT03574220|DRUG|Pembrolizumab|200mg IV every 21 days over 6 months
223784520|NCT03574220|RADIATION|Stereotactic body radiotherapy|50 Grays (Gy) in 5 fractions over 5-14 days, or 60 Gy in 3 fractions over 8-14 days
223784521|NCT02099006|DRUG|Amitriptyline|Topical application of the drug at a 2% concentration in combination with 2% Baclofen
223784522|NCT02099006|DRUG|Baclofen|Used topically at 2% concentration in combination with 2% amitriptyline
223784523|NCT02099006|DRUG|Ketoprofen|To be applied topically at a 10% concentration
223784524|NCT02099006|DRUG|Ketamine|To be applied topically at a 10% concentration
223784525|NCT02099006|DRUG|Loperamide|To be applied topically at a 5% concentration
223784526|NCT02099006|DRUG|Gabapentin|To be applied topically at a 6% concentration
223784527|NCT02099006|DRUG|placebo|Compounding base to be used alone as a placebo
223784528|NCT00003801|PROCEDURE|management of therapy complications|
223784529|NCT00003801|PROCEDURE|quality-of-life assessment|
223784530|NCT01924325|DRUG|Apixaban|orally active direct factor Xa inhibitor
223784531|NCT01924325|DRUG|Clopidogrel|an irreversible inhibitor of the P2Y12 adenosine diphosphate receptor
223784532|NCT01924325|DRUG|Aspirin|a non-steroidal anti-inflammatory drug
223784533|NCT01924325|DRUG|placebo|
223784534|NCT04620473|DRUG|Anlotinib+Capeox|to use Anlotinib hydrochloride combined with Capeox in the neoadjuvant treatment of locally advanced rectal cancer
223784535|NCT04620473|DRUG|Capeox|to use Capeox in the neoadjuvant treatment of locally advanced rectal cancer
223784536|NCT01629329|DRUG|Aspirin, Acetaminophen, Caffeine pills|One time dose of 2 pills each containing acetaminophen 250mg, aspirin 250mg and caffeine 65mg in each tablet. Simultaneous administration of placebo(5ml of saline administered IV)
223784537|NCT01629329|DRUG|Prochlorperazine 10mg|One time dose of Prochlorperazine 10mg/2ml given IV slow push. Simultaneous administration of 2 unmarked placebo pills.
223784538|NCT04829838|DRUG|intravenous levetireacetam|phenytoin is considered as control drug in the study
223784539|NCT01438541|DEVICE|Window|Dressing
223784540|NCT05790434|DIAGNOSTIC_TEST|Laboratory test|including white blood cell count, C-reactive protein, erythrocyte sedimentation rate, percent of polymorphonuclear leukocytes, albumin, and globulin
223784541|NCT05790434|DIAGNOSTIC_TEST|History taking and physical examination|including fever, joint pain, local swelling and redness, sinus
223784542|NCT05790434|DIAGNOSTIC_TEST|biopsy|including arthrocentesis culture，and frozen section
223784543|NCT04391582|OTHER|Tilapia skin|After cleaning the lesion with tap water and 2% chlorhexidine gluconate, the tilapia skin was applied and covered with gauze and bandage. These dressings were changed only if the tilapia skin did not adhere properly to the wound bed
223784544|NCT04391582|DRUG|silver sulfadiazine cream 1%|After cleaning the lesion with tap water and 2% chlorhexidine gluconate, a thin layer of silver sulfadiazine cream 1% was applied and covered with gauze and bandage. In these patients, the dressings were changed daily
223784545|NCT00607841|DRUG|Ispinesib|10 mg/m2 dose as a 1-hour intravenous infusion.
223784546|NCT00607841|DRUG|Ispinesib|12 mg/m2 dose as a 1-hour intravenous infusion.
223784547|NCT00607841|DRUG|Ispinesib|14 mg/m2 dose as a 1-hour intravenous infusion.
223784548|NCT06311994|DEVICE|Virtual reality|"Factors that may affect patient compliance with the VR-based intervention method to be applied to patients undergoing knee surgery and the factors that may affect the measurements to be performed were evaluated through a literature review and inclusion and exclusion criteria were created."
223784549|NCT01177098|DRUG|bimatoprost /timolol formulation A fixed combination ophthalmic solution|One drop of bimatoprost/timolol formulation A fixed combination ophthalmic solution administered in each eye every morning for 12 weeks.
223784550|NCT01177098|DRUG|bimatoprost/timolol fixed combination ophthalmic solution|One drop of bimatoprost 0.03%/timolol 0.5% fixed combination ophthalmic solution (Ganfort®) administered in each eye every morning for 12 weeks.
223835340|NCT05424861|BEHAVIORAL|Acupressure group|A suitable environment will be prepared for mothers in terms of warmth and light, where privacy can be protected. The application points will be determined with the acu-point device by choosing the most comfortable position of the mother, leaving the application points open. The most preferred points LI4 and SP6 were selected among the points that were reported to be effective in relieving luterus pain by scanning the literature on the points to be compressed. Acupressure will be applied to the points (bidirectional, right and left) for 2 minutes, for a total of 8 minutes. Light pressure will be applied with the thumb of the practitioner's hand. Immediately after applying pressure for 2 minutes for each point, it is passed to the other point in the symmetrical region and the application is made without interruption. While practicing, the researcher will check the time using a digital wristwatch with a stopwatch.
223835341|NCT05424861|OTHER|Control group|No application will be made. The mothers in this group will fill in the visual analog scale, which evaluates postpartum uterine pain 3 times between 6-24 hours after birth.
223835342|NCT01833117|OTHER|FID 119515A|topical ocular drops
223835343|NCT01833117|OTHER|Blink® Tears|topical ocular drops
223835344|NCT00569361|PROCEDURE|Collection of nasal epithelial cells|Collection of nasal epithelial cells by brushing
223835345|NCT04239287|DIAGNOSTIC_TEST|Lung function + exercise tests|Lung function + exercise tests
223835346|NCT04558086|DEVICE|Virtual reality|To develop the intervention strategies of hospitalized school-age children with IV placement, using interactive virtual reality(VR)as a guiding play and emotional catharsis play, to further examine the effectiveness of reducing IV pain and fear.
223835347|NCT04558086|DEVICE|Photo book|To develop the intervention strategies of hospitalized school-age children with IV placement, using Photo book to further examine the effectiveness of reducing IV pain and fear.
223835348|NCT00107874|DRUG|misoprostol|
223835349|NCT03415087|PROCEDURE|sequential intrathecal injection|intrathecal injection of fentanyl and hyperbaric bupivacaine
223835350|NCT03415087|DRUG|hyperbaric bupivacaine|intrathecal injection of intrathecal bupivacaine
223835351|NCT03415087|DRUG|fentanyl|intrathecal injection of fentanyl
223835352|NCT00004074|BIOLOGICAL|recombinant interleukin-12|Given IV
223835353|NCT00004074|BIOLOGICAL|ABI-007/carboplatin/trastuzumab|Given IV
223835354|NCT02448719|DRUG|TAK-792 30 mg|TAK-792 30 mg was administered in the morning after a fast.
223835355|NCT02448719|DRUG|TAK-792 30 mg placebo|TAK-792 30 mg placebo was administered in the morning after a fast.
223835356|NCT02448719|DRUG|TAK-792 100 mg|TAK-792 100 mg was administered in the morning after a fast.
223784551|NCT05696899|OTHER|STILL QuickTAB Medipack blended scent aromatherapy, manufactured by Soothing Scents|A resealable quick-tab dispenser with the 'therapeutic inhaled essential oils' lavender, bergamot, sweet orange, and ylang ylang.
223784552|NCT01343550|OTHER|creativity group|This is a creativity group intervention. There will be 4 groups. Each group has one session per week. Each session is a duration of two hours.
223784553|NCT05903144|OTHER|manual therapy|manual diaphragmatic release technique combined with breathing exercise
223784554|NCT05903144|OTHER|breathing exercise and prone position alone|deep breathing exercise and prone position
223784555|NCT02374827|PROCEDURE|Standard postpartum tubal ligation|Patients will undergo a standard postpartum tubal ligation by accepted documented surgical procedural methods (Modified Pomeroy or Parkland method)
223784556|NCT02374827|PROCEDURE|Complete Salpingectomy|Patients will undergo a complete salpingectomy by a documented surgical protocol established by accepted surgical procedural methods.
223784557|NCT05462366|OTHER|Sample collection|Collect breast-milk and feces from mother-infant-pairs.
223784558|NCT02194049|DRUG|BKM120|Given PO
223784559|NCT02194049|DRUG|cisplatin|Given IV
223784560|NCT02194049|DRUG|etoposide|Given IV
223784561|NCT05924152|DRUG|Adagrasib|Adagrasib
223784562|NCT05924152|DRUG|Eltrombopag + adagrasib|Eltrombopag + adagrasib
223784563|NCT04425083|OTHER|no intervention|no intervention
223784564|NCT03380442|DRUG|Psilocybin|Psilocybin ingested orally
223784565|NCT03380442|DRUG|Ketamine (Ketalar)|Ketamine administered intranasally
223784566|NCT06127069|DEVICE|chitosan brush|debridement of periodontal pockets with ultrasonic scaler first and after with chitosan brush for 2 minutes
223784567|NCT06127069|DEVICE|ultrasonic scaler|debridement of periodontal pockets only with ultrasonic scaler
223784568|NCT05349617|BIOLOGICAL|CHIKV VLP/adjuvant|PXVX0317 vaccine is comprised of chikungunya virus virus-like particles (CHIKV VLP), adsorbed on aluminum hydroxide adjuvant
223784569|NCT05349617|BIOLOGICAL|Placebo|Placebo is comprised of formulation buffer
223784570|NCT04824313|DIAGNOSTIC_TEST|Chest CT|Chest CT without intravenous contrast material
223784571|NCT04824313|DIAGNOSTIC_TEST|Chest CTA|Chest CT with intravenous contrast material
223784572|NCT04365946|PROCEDURE|Gastroscopy|Upper GI endoscopy and biopsy
223784573|NCT05032703|DEVICE|Arm ergometer|"The conventional physical therapy program included three sets of exercises as follows:~Flexibility exercises to restore joint mobility of soft tissues. Static and dynamic balance exercise. Functional walking exercises."
223784574|NCT05190393|PROCEDURE|hemivertebra resection on convex side|Patients were used hemivertebra resection procedure to treat congenital cervical scoliosis.
223784575|NCT05190393|PROCEDURE|concave distraction group|Patients were used distraction and lateral opening procedure to treat congenital cervical scoliosis.
223784576|NCT04006977|DIETARY_SUPPLEMENT|a multistrain probiotic product (DSF)|In Arm 2, participants will receive standard medical therapy plus the multistrain probiotics (DSF), 4 sachets per day.
223784577|NCT04006977|DIETARY_SUPPLEMENT|Placebo|In Arm 1, participants will receive standard medical therapy plus the placebo.
223784578|NCT03203213|PROCEDURE|Sampling of a few drops of blood, lock of hair and urine|Sampling of a few additional drops of blood to deposit them on blotting paper (DBS: Dried Blood Spot) ad hoc and to send this sample for analysis and identification of a possible toxic cause by psychoactive substance in relation to the clinical picture presented by the patient. An oriented capillary sampling is also performed if possible. Similarly a urine sample is taken if possible.
223784579|NCT05938634|BEHAVIORAL|Stage-matched interventions|Precontemplation-based intervention Contemplation-based intervention Preparation-based intervention Action-based intervention Maintenance-based intervention
223784580|NCT00492349|DRUG|Varenicline|Varenicline 0.5mg po qd x 7 days then titrated to Varenicline 0.5mg po bid x 7 weeks
223784581|NCT00492349|DRUG|Placebo|Placebo 0.5mg po qd x 7 days then titrated to Placebo 0.5mg po bid x 7 weeks
223784582|NCT04764058|DRUG|Tienam 500|Imipenem and cilastatin sodium
223784583|NCT04764058|DEVICE|Infusion|Health caregivers give the drug to the patients and monitoring the infusion rate
223784584|NCT02367911|DRUG|122-0551 Foam|122-0551 Foam applied twice daily to treat psoriasis
223784585|NCT02367911|DRUG|Vehicle Foam|Vehicle Foam applied twice daily to treat psoriasis
223784586|NCT00373776|DRUG|miltefosine 2.5 mg/kg/day for 28 days|
223784587|NCT01214772|DRUG|heparin|5000 IU subcutaneously in the day of embryo transfer until 6 week after delivery
223784588|NCT04011553|OTHER|Virtual Reality based Rehabilitation Program|"Virtual reality-based rehabilitation was implemented via MarVAJED system. At first the sensors of MarVAJED® were placed under and above the knee joint and then it was calibrated. The content of the game programs included in the MarVAJED system and how to perform these games with the exercises were explained to the participants. We used games called Crazy Wings and Blasting Ball included in the MarVAJED®.There was a bird figure in Crazy Wings game and represented knee joint of participants. Although the bird figure moved upwards during knee flexion, it moved downward in knee extension, there were some obstacles on the way of the bird went. The subjects were asked to follow the bird figure visually and to pass through the obstacles by flexing or extending their knees when they encountered obstacles."
223784589|NCT01941862|BEHAVIORAL|Psychoeducation and Cognitive Bias Modification|
223784590|NCT04584112|DRUG|Tiragolumab|Tiragolumab 840 milligrams (mg) administered by intravenous (IV) infusion on Day 1 of every 28-day cycle.
223784591|NCT04584112|DRUG|Atezolizumab|Atezolizumab 1680 mg administered by IV infusion on Day 1 of every 28-day cycle.
223784592|NCT04584112|DRUG|Nab-paclitaxel|Nab-paclitaxel 100 milligrams per square meter (mg/m\^2) administered by IV infusion on Days 1, 8, and 15 of every 28-day cycle.
223784593|NCT04584112|DRUG|Tiragolumab|Tiragolumab 420 mg administered by IV infusion Q2W.
223784594|NCT04584112|DRUG|Atezolizumab|Atezolizumab 840 mg administered by IV infusion Q2W.
223784595|NCT04584112|DRUG|Nab-paclitaxel|Nab-paclitaxel 125 mg/m\^2 administered by IV infusion QW.
223784596|NCT04584112|DRUG|Carboplatin|Carboplatin (area under the concentration-time curve \[AUC\]: 5 milligrams per milliliter per minute \[mg/mL/min\]) administered by IV infusion Q3W.
223784597|NCT04584112|DRUG|Doxorubicin|Doxorubicin 60 mg/m\^2 Q2W administered by IV infusion.
223784598|NCT04584112|DRUG|Cyclophosphamide|Cyclophosphamide 600 mg/m\^2 Q2W administered by IV infusion.
223784599|NCT04584112|DRUG|Granulocyte colony-stimulating factor (G-CSF)|G-CSF support for four doses.
223784600|NCT04584112|DRUG|Granulocyte-macrophage colony-stimulating factor (GM-CSF)|GM-CSF support for four doses.
223784601|NCT04797338|DRUG|Synarel, 0.2 Mg/Inh Nasal Spray|Intranasal treatment with Nafarelin inhaler: 200 micrograms twice daily (a total of 400 micrograms/d; Synarel, Pfizer) on the evening after oocyte retrieval, which will be continued up to the bHCG blood test, 12 days post embryo transfer. In cases with positive serum bHCG results, the treatment will be stopped.
223784602|NCT04797338|DRUG|Estrofem|A combination of oral estrogen (Estrofem or Progynova 4 mg twice daily), vaginal progesterone (vaginal Utrogestan 200mg or Endometrin 100 mg three times daily) and intramuscular injection of Hydroxyprogesterone Caproate 250 mg once every five days. The treatment will start at the day of the oocyte retrieval up to the bHCG blood test, 12 days post embryo transfer. In cases with positive serum bHCG results, the treatment will be continued up to 9+0 weeks of pregnancy.
223835357|NCT02448719|DRUG|TAK-792 100 mg placebo|TAK-792 100 mg placebo was administered in the morning after a fast.
223784603|NCT04797338|DRUG|Utrogestan|A combination of oral estrogen (Estrofem or Progynova 4 mg twice daily), vaginal progesterone (vaginal Utrogestan 200mg or Endometrin 100 mg three times daily) and intramuscular injection of Hydroxyprogesterone Caproate 250 mg once every five days. The treatment will start at the day of the oocyte retrieval up to the bHCG blood test, 12 days post embryo transfer. In cases with positive serum bHCG results, the treatment will be continued up to 9+0 weeks of pregnancy.
223784604|NCT04797338|DRUG|Hydroxyprogesterone Caproate|A combination of oral estrogen (Estrofem or Progynova 4 mg twice daily), vaginal progesterone (vaginal Utrogestan 200mg or Endometrin 100 mg three times daily) and intramuscular injection of Hydroxyprogesterone Caproate 250 mg once every five days. The treatment will start at the day of the oocyte retrieval up to the bHCG blood test, 12 days post embryo transfer. In cases with positive serum bHCG results, the treatment will be continued up to 9+0 weeks of pregnancy.
223784605|NCT00071669|PROCEDURE|Acupuncture|
223784606|NCT02043496|BEHAVIORAL|Integrative Cognitive-Affective Therapy|Integrative Cognitive-Affective Therapy is a psychotherapy treatment for binge eating that focuses on changing behaviors, feelings, thoughts, and relationships
223784607|NCT02043496|BEHAVIORAL|CBT-Guided Self Help|CBT-Guided Self Help focuses on changing behavior patterns through the use of reading and homework assignments along with sessions with a therapist.
223784608|NCT01852539|DRUG|dexmedetomidine|The dose of dexmedetomidine was determined by modified Dixon's up-and-down method, starting from 0.5 μg/kg (0.1 μg/kg as a step size).
223784609|NCT01852539|DRUG|propofol|Propofol 2.0 mg/kg was administrated
223784610|NCT01852539|DEVICE|laryngeal mask airway (LMA)|The insertion of laryngeal mask airway (LMA) was attempted, after confirming the loss of eyelash reflex,the bispectral index (BIS) score decreased below 60.
223835358|NCT02448719|DRUG|TAK-792 250 mg|TAK-792 250 mg was administered in the morning after a fast.
223835359|NCT02448719|DRUG|TAK-792 250 mg placebo|TAK-792 250 mg placebo was administered in the morning after a fast.
223835360|NCT02448719|DRUG|TAK-792 500 mg|TAK-792 500 mg was administered in the morning after a fast or after breakfast.
223835361|NCT02448719|DRUG|TAK-792 500 mg placebo|TAK-792 500 mg placebo was administered in the morning after a fast or after breakfast.
223835362|NCT02448719|DRUG|TAK-792 750 mg|TAK-792 750 mg was administered in the morning after a fast.
223702857|NCT04920344|DIAGNOSTIC_TEST|Modified barium swallow (MBS) evaluation with aspiration-penetration scale|"The videofluoroscopic modified barium swallow (MBS) study is the gold standard for for the evaluation of dysphagia, and specifically, airway protective mechanisms.~The penetration/aspiration (PEN/ASP) scale is a routinely used eight-point scale designed to describe the depth of bolus penetration into the airway and the patient response to the penetration or aspiration."
223702858|NCT03211871|DRUG|Dexmedetomidine|Intraoperative intravenous dexmedetomidine infusion 0,5 mcg/kg/h
223702859|NCT03211871|DRUG|Normal Saline Flush, 0.9% Injectable Solution_#1|Intraoperative intravenous normal saline infusion
223702860|NCT04515173|DIAGNOSTIC_TEST|Artificial intelligence diagnosis and treatment assistance system|An artificial intelligence robot that can assist psychiatrists in disease screening, diagnosis, treatment, and follow-up.
223702861|NCT05824091|DRUG|MK-7762 (TBD09)|Cohort 1: 50 mg Cohort 2: 150 mg Cohort 3: 300 mg Cohort 4: 600 mg Cohort 5: TBD Cohort 6: TBD
223702862|NCT05824091|OTHER|Placebo|A subset of participants from each of the 6 dosing cohorts will receive placebo.
223702863|NCT03376269|BIOLOGICAL|HBOT|•HBOT of 2 ATA for 90 minutes O2 100%, for 60 treatments
223702864|NCT03376269|BEHAVIORAL|Psychotherapy|creative art psychotherapy which includes self drawing and daily diary alongside professional psychotherapy sessions
223702865|NCT02345226|DRUG|FTC/RPV/TAF|200/25/25 mg FDC tablets administered orally once daily
223702866|NCT02345226|DRUG|EFV/FTC/TDF Placebo|Tablets administered orally once daily
223702867|NCT02345226|DRUG|EFV/FTC/TDF|600/200/300 mg FDC tablets administered orally once daily
223702868|NCT02345226|DRUG|FTC/RPV/TAF Placebo|Tablets administered orally once daily
223702869|NCT01848704|BEHAVIORAL|interpretation of the abstract|
223702870|NCT03086278|DRUG|AST-008|AST-008 is a toll-like receptor 9 agonist.
223702871|NCT02891109|BIOLOGICAL|Biological tests|From the blood: B and T cells extraction then co-culture B and T cells and characterization of lymphocytes by flow cytometry
223702872|NCT00001122|DRUG|Nelfinavir mesylate|
223702873|NCT00001122|DRUG|Efavirenz|
223702874|NCT00001122|DRUG|Stavudine|
223702875|NCT00001122|DRUG|Didanosine|
223702876|NCT05888077|OTHER|ESWL_LL|Extracorporeal shock wave lithotripsy using latest lithotripter and laser lithotripsy for difficult Bile duct stones
223702877|NCT00851344|DRUG|GSK835726 (10mg)|GSK835726 (10mg) tablet
223702878|NCT00851344|DRUG|GSK835726 (50mg)|GSK835726 (50mg) tablet
223702879|NCT00851344|DRUG|GSK835726 (100mg)|GSK835726 (100mg) tablet
223702880|NCT00851344|DRUG|Cetirizine (10mg)|Cetirizine (10mg) tablet as positive control
223702881|NCT00851344|OTHER|Placebo|Placebo to match active
223702882|NCT05840731|DIETARY_SUPPLEMENT|Ashwagandha|KSM-66 Ashwagandha is the active ingredient in Waithania somifera, a medicinal plant in Indian medicine. Ashwagandha is known as an adaptogen, an herb in capsule form that protects the body from stress.
223702883|NCT05840731|OTHER|Placebo|Placebo means that the capsules will not contain Ashwagandha but some other inactive substance.
223835363|NCT02448719|DRUG|TAK-792 750 mg placebo|TAK-792 750 mg placebo was administered in the morning after a fast.
223702884|NCT04924959|OTHER|Logistic Regression Analysis|Using logistic regression analysis to analyze the independent risk factors of PICC catheter displacement
223702885|NCT04206800|DIAGNOSTIC_TEST|Ejaculatory abstinence less than 24 hours|Males will have ejaculatory abstinence less than 24 hours before providing a semen sample the day of egg retrieval
223702886|NCT02773290|BIOLOGICAL|Romiplostim|Weekly SC administration
223702887|NCT05458934|OTHER|No intervention|no intervention
223702888|NCT02623920|DRUG|Brentuximab|Brentuximab vedotin IV over 30 minutes on day 1.Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
223702889|NCT02623920|DRUG|Bendamustine|Bendamustine IV over 30-60 minutes on days 1-2. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
223702890|NCT02623920|DRUG|Rituximab|Rituximab IV on day 2. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
223702891|NCT04651985|OTHER|Eccentric strengthening exercises of the Achilles tendon|This exercise will require the completion of slow active eccentric plantar flexion exercises with the forefoot positioned over the edge of a step. These exercises will be repeated twice daily (three sets of 15 repetitions with the knee in extension and three sets of 15 repetitions with the knee in flexion) during a three-month period. The amount of loading will be calibrated and progressed on a weekly basis by the physiotherapist according the participant's perceived effort and pain intensity.
223702892|NCT04473092|DEVICE|TMVR|Patients who undergo TMVR for MR at the PI´s site
223702893|NCT00052273|DRUG|capecitabine|
223702894|NCT00052273|DRUG|enzastaurin hydrochloride|
223702895|NCT06544122|DEVICE|Transcranial direct current stimulation|Anodal tDCS will be applied at an intensity of 2mA and duration of 20 minutes. The assembly of the electrodes during the tDCS sessions will be carried out as follows: primary motor cortex, the stimulation electrode (anode) will be positioned on C5 (international EEG 10-20 system), in S1 (2cm posterior to C5), at the PFCDL (Fp3), all with the cathode positioned on the region contralateral supraorbital. For cerebellar tDCS the anode will be positioned on the inion area and the cathode on the deltoide muscle.
223702896|NCT05283278|DRUG|Lactoferrin Bovine|Lactoferrin granules (Pravotin®) in a dose of 100 mg /kg/day starting from birth to the 30th day of life for neonates in group A
223702897|NCT05283278|COMBINATION_PRODUCT|Lactoferrin Bovine and probiotics|Lactoferrin granules (Pravotin®) in a dose of 100 mg /kg/day in combination with the probiotic Lactobacillus Delbrueckii and Lactobacillus Fermentum (Lacteol fort®) given in a dose of 5 billions starting from birth to the 30th day of life for neonates in group B
223702898|NCT05283278|OTHER|Placebo|Placebo will be given starting from birth to the 30th day of life for neonates in group C.
223702899|NCT04238585|BEHAVIORAL|Mobile messaging|Mobile health messages
223702900|NCT02282358|DRUG|Mocetinostat|
223702901|NCT03687112|OTHER|non ontervention / observational study|non intervention
223784611|NCT04966468|DEVICE|Virtual Reality|The Lenovo Mirage Solo Headset will be kept at home by the patient for the duration of the study (4 days). The VR headset will be equipped with 10 non-interactive videos and a short interactive game. The videos and the game are characterized by relaxing scenarios. The game will require the active interaction of the patient. At the end of the observational period, the investigator will download the usage data to detect information about the patient's use. Before and after each use of the VR headset, the patient will be asked to fulfil the Edmonton Symptom Assessment Scale (ESAS). On T0, the patient will be asked to wear a wearable device, the Empatica E4 wristband measuring physiological parameters. On day T1, the patient will return the VR headset and the wristband to the investigator and will fulfil again the HADS and BPI questionnaires.
223784612|NCT04966468|OTHER|Control|"The investigator will illustrate to the patient how to use the tablet for watching videos, suggesting using it especially in moments of psycho-physical discomfort. The tablet will be given to the patient for the duration of the study (four days). The tablet will be equipped with 10 non-interactive 2D videos characterized by relaxing settings with natural or artistic scenarios, giving a passive use to the patient. Before and after each use of the tablet, patient has to fullfil the ESAS digitally inserted into the tablet. Patient can answer by selecting the answer on the touchscreen. Without filling the scale, the patient will not be able to access the videos inserted in the tablet. On day T1, patient will return the tablet to the investigator and fill out the HADS and BPI questionnaires."
223835364|NCT02448719|DRUG|TAK-792 1250 mg|TAK-792 1250 mg was administered in the morning after a fast.
223784613|NCT01837381|PROCEDURE|TEA|Arterial feeders to tumors were identified and catheterized with a microcatheter to a branch supplying a Couinaud segment or subsegmental level for delivery of the therapeutic agent, which was Lipiodol-ethanol mixture at 2:1 ratio by volume for TEA (Lipiodol Ultrafluide, Guerbet, France; Dehydrated alcohol \[absolute alcohol\], Martindale Pharmaceuticals, United Kingdom). The agents were delivered under fluoroscopic control to completely fill up the vasculature of all tumors. The maximum total volume of Lipiodol-ethanol mixture or cisplatin emulsion to be delivered in one treatment session was 60 mL.
223784614|NCT04933955|PROCEDURE|vital pulp therapy|pulpotomy
223784615|NCT00342316|PROCEDURE|Reduced Intensity Conditioning Stem Cell Transplantation|"One of the following conditioning regimens:~1. Busulphan (orally or IV), fludarabine~2. Fludarabine, carmustine, melfalan~3. Cyclophosphamide, fludarabine"
223784616|NCT00070473|DRUG|pemetrexed disodium|
223784617|NCT00611091|OTHER|Electronic delivery of enhanced discharge information to the ambulatory physician|Follow-up appointment needs/plans
223784618|NCT00611091|OTHER|Electronic delivery of enhanced discharge information to the ambulatory physician|Laboratory follow-up needs
223784619|NCT00611091|OTHER|Electronic delivery of enhanced discharge information to the ambulatory physician|New medications
223784620|NCT02701218|PROCEDURE|Canalith repositioning procedure|Canalith repositioning procedure; single or multiple cycles
223784621|NCT01739829|DEVICE|DIABECELL (R)|10,000 IEQ per kg body weight (Total Dose) Administered in two doses: 5,000 IEQ/kg three months apart.
223784622|NCT01739829|DEVICE|DIABECELL (R)|20,000 IEQ per kg body weight (Total Dose) Administered in two doses: 10,000 IEQ/kg three months apart
223784623|NCT01114568|DRUG|Ertugliflozin 10 mg tablet|A single dose of 10 mg ertugliflozin administered as 2x5 mg material sparing formulation tablets.
223784624|NCT01114568|DRUG|Ertugliflozin OC Fast|Formulation B) Ertugliflozin 10 mg OC Fast
223784625|NCT01114568|DRUG|Ertugliflozin OC Slow|Formulation C) Ertugliflozin 10 mg OC Slow
223784626|NCT06530940|DIAGNOSTIC_TEST|Buccal Schirmer Test|"For each group, we will perform:~* SF measurement~* Buccal Schirmer test (BST) ."
223784627|NCT05544799|OTHER|No intervention|No intervension
223784628|NCT03119454|DRUG|Diprospan|Intramuscular
223784629|NCT04502329|OTHER|Diet|Energy Restriction Intermittent Fasting Diet
223784630|NCT05283694|DRUG|risankizumab|Subcutaneous Injection via prepared syringe
223784631|NCT05283694|DRUG|risankizumab|Subcutaneous Injection via syringe pump
223784632|NCT02763527|BEHAVIORAL|Smoking reduction|A brief intervention on smoking reduction plus a smoking reduction leaflet
223784633|NCT02763527|BEHAVIORAL|Smoking Cessation|A brief advice on quitting plus a leaflet on smoking cessation
223784634|NCT02460718|BEHAVIORAL|ENCOURAGE Study|This intervention tested the effects of a peer coaching program plus brief diabetes education versus brief diabetes education alone on diabetes outcomes.
223784635|NCT01956526|DEVICE|CORolla™ TAA device|
223784636|NCT00629187|DRUG|Temozolomide|Before taking part in this study, subjects will have stem cells collected in a procedure called apheresis. Once on this study, subjects will be admitted to the hospital and receive daily doses of temozolomide by mouth for 5 days. Stem cells will be given back to subjects who will remain in the hospital until blood counts have recovered. Doses of temozolomide will range from 350 mg to 1500 mg/m(squared) daily for 5 days (total dose 1750 to 7500 mg/m(squared).
223784637|NCT00902304|DRUG|Valsartan and hydrochlorothiazide (HCTZ) - monotherapy|Monotherapy arm - if monotherapy valsartan 320mg per day orally was not sufficient, then could add HCTZ up to 25 mg per day orally
223784638|NCT00902304|DRUG|Valsartan and amlodipine|From valsartan 80mg/amlodipine 5mg per day to valsartan 160mg/amlodipine 10mg per day orally
223784639|NCT00902304|DRUG|Usual care|As directed by investigator
223784640|NCT00902304|DRUG|Valsartan|Valsartan 160mg per day to 320mg per day orally
223784641|NCT00902304|DRUG|Valsartan and hydrochlorothiazide (HCTZ) - combination arm|Combination arm - from valsartan 80mg/hydrochlorothiazide 12.5mg per day to valsartan 160mg/hydrochlorothiazide 25mg per day orally
223784642|NCT00057096|PROCEDURE|On-site vs. referral methods of care|
223784643|NCT05976282|OTHER|Fecal Immunochemical Test|The Fecal Immunochemical Test (FIT) is self-administered one-time for participants, per standard of care. This allows participants to obtain their own stool specimens from bowel movements without having a regular colorectal screening procedure in the doctor's office. Participants will use the FIT at the time of their next bowel movement and return their specimens to the laboratory by mail on the same or next day.
223784644|NCT05976282|OTHER|Septin9 Test|Septin9 (SEPT9) is a blood-based test that will be offered to eligible participants one-time who refused the FIT. Participants will undergo a blood draw collected by a nurse or certified phlebotomist, 90 days after their refusal of the initial offer of FIT.
223784645|NCT03640351|DRUG|1. Use of preservative free diquafosol ophthalmic solution after cataract surgery|Participants are randomly assigned into the preservative free diquafosol group (Group 1), the preservative containing diquafosol group (Group 2) or the hyaluronate group (Group 3) using a simple unrestricted randomization method by the controller. The group 1 uses preservative free 3% diquafosol tetrasodium ophthalmic solution (Diquas-S; Santen Pharmaceutical Co, Ltd, Osaka, Japan) 6 times a day, the group 2 uses 3% diquafosol tetrasodium ophthalmic solution (Diquas; Santen Pharmaceutical Co, Ltd) 6 times a day and the group 3 uses 0.15% sodium hyaluronate ophthalmic solution (New Hyaluni 0.15%; Taejoon, Seoul, Korea) 6 times a day. All three groups instill each eye drop from postoperative day 1 to postoperative 12 weeks.
223784646|NCT03640351|DRUG|2. Use of preservative containing diquafosol ophthalmic solution after cataract surgery|Participants are randomly assigned into the preservative free diquafosol group (Group 1), the preservative containing diquafosol group (Group 2) or the hyaluronate group (Group 3) using a simple unrestricted randomization method by the controller. The group 1 uses preservative free 3% diquafosol tetrasodium ophthalmic solution (Diquas-S; Santen Pharmaceutical Co, Ltd, Osaka, Japan) 6 times a day, the group 2 uses 3% diquafosol tetrasodium ophthalmic solution (Diquas; Santen Pharmaceutical Co, Ltd) 6 times a day and the group 3 uses 0.15% sodium hyaluronate ophthalmic solution (New Hyaluni 0.15%; Taejoon, Seoul, Korea) 6 times a day. All three groups instill each eye drop from postoperative day 1 to postoperative 12 weeks.
223784647|NCT03640351|DRUG|3. Use of preservative free sodium hyaluronate ophthalmic solution after cataract surgery|Participants are randomly assigned into the preservative free diquafosol group (Group 1), the preservative containing diquafosol group (Group 2) or the hyaluronate group (Group 3) using a simple unrestricted randomization method by the controller. The group 1 uses preservative free 3% diquafosol tetrasodium ophthalmic solution (Diquas-S; Santen Pharmaceutical Co, Ltd, Osaka, Japan) 6 times a day, the group 2 uses 3% diquafosol tetrasodium ophthalmic solution (Diquas; Santen Pharmaceutical Co, Ltd) 6 times a day and the group 3 uses 0.15% sodium hyaluronate ophthalmic solution (New Hyaluni 0.15%; Taejoon, Seoul, Korea) 6 times a day. All three groups instill each eye drop from postoperative day 1 to postoperative 12 weeks.
223784648|NCT05706506|DRUG|Tirzepatide|Administered SC
223784649|NCT03278015|DRUG|Nab-paclitaxel plus Gemcitabine|Nanoparticle albumin-bound paclitaxel is given at 100mg/m2 intravenously over 30 minutes in combination with Gemcitabine 1000mg/m2 intravenously on day 1 and 8 of each 21-days cycle. Number of cycle: 6 cycles.
223784650|NCT03278015|DRUG|Gemcitabine monotherapy|Gemcitabine is given at 1000mg/m2 intravenously on day 1 and 8 of each 21-days cycle. Number of cycle: 6 cycles.
223784651|NCT03278015|DRUG|S-1 monotherapy|S-1 is orally administered (40-60 mg according to the body surface, Bid) on day 1-14 of each 21-days cycle. Number of cycle: 6 cycles.
223784652|NCT06961825|DIETARY_SUPPLEMENT|Dietary Supplement|complete, semi-elemental formula for tube feeding and orla intake based on peptides, in powder form, low in fat (32% of energy), high in MCTs (\>90% of total fat) free of fiber and gluten
223784653|NCT06962618|BEHAVIORAL|Music Motion Group|"Participants will engage in personalized, home-based motor training programs tailored to their individual goals. Each will wear a wireless Inertial Measurement Unit (IMU) on the targeted body part, which transmits movement data via Bluetooth to a tablet app. The training emphasizes task specificity and intensity, with five virtual check-ins to review progress and adjust training parameters.~The intervention studied is extrinsic feedback; the app analyzes movement data and provides feedback through music. Before each training session, the app guides participants to set personalized intensity thresholds based on current capacity. When participants meet the intensity threshold, musical elements (e.g., drumbeats, vocals) play. If they fall short, elements drop out, providing knowledge of erroneous performance."
223784654|NCT06962618|BEHAVIORAL|Control|Participants will follow personalized, home-based motor training programs designed like the Music motion group. They will wear a wireless Inertial Measurement Unit (IMU) on the targeted body part, transmitting movement data via Bluetooth to a tablet app. However, unlike the Music Motion Feedback group, participants in the Control group will not receive any extrinsic feedback during their training.
223784655|NCT03932643|DRUG|ONC-201|"ONC-201 Capsules, 125 mg~Oral ONC-201 at various dose levels will be given at weekly intervals for up to 13 cycles (52 weeks); 4-week therapy will be considered 1 cycle."
223835365|NCT02448719|DRUG|TAK-792 1250 mg placebo|TAK-792 1250 mg placebo was administered in the morning after a fast.
223784656|NCT05732454|DRUG|etrasimod|PART 1 Double Blind one 2 mg tablet once daily for up to 16 weeks PART 1 Open Label Extension one 2 mg tablet once daily for an additional 52 weeks PART 2 Open Label one 2 mg tablet once daily for up 52 weeks
223784657|NCT05732454|DRUG|Placebo|PART 1 DOUBLE BLIND Placebo - one table daily for up to 16 weeks
223784658|NCT01281358|OTHER|HOP-ON|A programme of activities which promote motor development
223784659|NCT01281358|OTHER|SMILES|Details are provided on ways for parents to interact with their premature infants
223784660|NCT01153633|DEVICE|Prontosan Wound Irrigation Solution and Prontosan Wound Gel|"The treatment procedures (after a 1 week run-in) include:~* Cleansing the wound bed, at dressing change, with Prontosan® Wound Irrigation Solution or saline solution; a sterile gauze dressing impregnated with the Prontosan® or saline solution, depending on randomisation, will be placed on the wound in the form of a moist compress and removed after 15 minutes; the wound will be sparingly covered with Prontosan® Wound Gel or inactive gel, depending on randomisation~* Secondary dressing to be a semi occlusive dressing~* Secure the dressing to the wound with tubifast and short stretch compression system Dressings will be changed and the treatment procedure will be repeated every 3 days (+/- 1 day) when clinical, microbiological, planimetry and photographic assessments will be made. The randomised solution will also be used for removal of the dressing from the wound at the start of dressing change."
223835366|NCT01024751|DEVICE|Bausch & Lomb Multi-Purpose Solution|Lens care product for disinfecting lenses on a daily basis.
223784661|NCT01153633|DEVICE|Normal Saline and Placebo Gel|"The treatment procedures (after a 1 week run-in) include:~* Cleansing the wound bed, at dressing change, with Prontosan® Wound Irrigation Solution or saline solution; a sterile gauze dressing impregnated with the Prontosan® or saline solution, depending on randomisation, will be placed on the wound in the form of a moist compress and removed after 15 minutes; the wound will be sparingly covered with Prontosan® Wound Gel or inactive gel, depending on randomisation~* Secondary dressing to be a semi occlusive dressing~* Secure the dressing to the wound with tubifast and short stretch compression system~Dressings will be changed and the treatment procedure will be repeated every 3 days (+/- 1 day) when clinical, microbiological, planimetry and photographic assessments will be made. The randomised solution will also be used for removal of the dressing from the wound at the start of dressing change."
223784662|NCT03108534|DRUG|CHF1535 NEXThaler|Rescue treatment
223784663|NCT03108534|DRUG|CHF1535 pMDI|Rescue treatment
223784664|NCT03108534|DRUG|Placebo|Rescue treatment
223784665|NCT00384085|DRUG|Insulin Glulisine|Subcutaneous injection up to 1 injection per day
223784666|NCT00384085|DRUG|Insulin Glargine|Subcutaneous injection once-a-day
223784667|NCT00384085|DRUG|Premixed Insulin|Subcutaneous injection twice-a-day.
223784668|NCT00384085|DRUG|Insulin Glulisine|Subcutaneous injection up to 3 injections per day.
223784669|NCT03783169|OTHER|Cardiovascular Sonographic Assessment|Maternal sonographic vascular measurements assessing volume status, cardiac output, and systemic vascular resistance by means of inferior vena cava collapsibility/caval index (ICV CI), end-point septal separation (EPSS) for determining left ventricular ejection fraction (LVEF), cardiac output determination (stroke volume x heart rate), stroke volume variation, \& radial artery resistance index) augments standard vital sign assessment (pulse pressure and systolic / diastolic predominance)
223784670|NCT02626559|DRUG|liposomal bupivacaine/plain bupivacaine peri-articular injection|Injection of a mixture of liposomal and plain bupivacaine around the knee during total knee arthroplasty.
223784671|NCT03365765|DRUG|Apatinib|Apatinib tablet
223784672|NCT03365765|DRUG|Oxaliplatin|Oxaliplatin Intravenous
223784673|NCT03365765|DRUG|5-fluorouracil|5-fluorouracil Intravenous
223784674|NCT05622981|BEHAVIORAL|Age-specific educational materials and monitoring|Subjects will receive age-specific behavioral modification and educational materials plus every 2-week monitoring for goals and progress at reducing BMI for 24 weeks in the pediatric primary care clinic.
223784675|NCT06038877|OTHER|Interviews|Individual semi-structured interviews
223784676|NCT06038877|OTHER|Qualitative analysis|Thematic analysis of the content of responses
223784677|NCT01427244|DRUG|trastuzumab|monoclonal antibody
223784678|NCT03152305|OTHER|Intracranial pressure variations|Self-measure of ICP will be performed outside and during menstrual migraine attacks.
223784679|NCT01359553|OTHER|Intra-articular ultrasound imaging of knee joint during arthroscopy|
223784680|NCT01359553|OTHER|Non-invasive ultrasound imaging of knee|
223784681|NCT01359553|OTHER|Quantitative MRI imaging of knee|
223784682|NCT01359553|OTHER|Contrast-enhanced CT imaging of knee|
223784683|NCT03021382|OTHER|data collection, non-intervention|
223784684|NCT04450615|OTHER|Core stability|"The exercise protocol consists of the following sets and repetitions, with a total duration of 5 weeks and a frequency of 3 sessions per week.~Dynamic exercises: 2 sets of 10 to 15 repetitions (each side) Isometric exercises: 2 sets of 5 to 15 seconds (each side) Week 1- As mentioned above Week 2- Add 1 set Week 3 - Add 5 seconds and 5 repetitions Week 4 - Add 1 set Week 5- Add 5 seconds and 5 repetitions"
223784685|NCT03904472|BEHAVIORAL|Web-based CBTI|Sessions comprise a range of cognitive and behavioral techniques and psychoeducation including sleep hygiene. During the intervention period the participant will complete daily online sleep diaries. Additionally, participants will be asked to complete multiple questionnaires.
223835367|NCT01024751|DEVICE|Ciba's Multi-Purpose Solution|Lens care product for disinfecting lenses on a daily basis.
223835368|NCT00349102|RADIATION|Free breathing|Free breathing during conformal radiation
223835369|NCT00349102|RADIATION|Breath holding|Breath holding during conformal radiation
223784686|NCT02808962|PROCEDURE|Cooled RFA of sacral lateral branches|A single target will be identified at the junction of the sacral ala and S1 superior articular process, corresponding to the location of the L5 dorsal ramus. Then, utilizing a stainless steel Epsilon Ruler (Kimberly Clark, Irving, TX, USA), three targets will be localized 8-10 mm lateral to the S1 and S2 posterior sacral foramen at the 2:30, 4:00, and 5:30 positions. Two targets will be localized at the S3 level. Local infiltration with 1% lidocaine and minimal sedation with IV midazolam will be utilized. Once suitable sensory and motor stimulation are verified and impedance is acceptable, each target will be anesthetized with 1 mL of 1% lidocaine prior to each lesion being created at 60 degrees centigrade for 2 minutes and 30 seconds.
223784687|NCT03432624|DIAGNOSTIC_TEST|Serum MicroRNA-25 detection|The level of microRNA-25 in serum of patients will be detected using the MicroRNA (microRNA-25) Qualitative Detection Kit (Fluorescent PCR Method) and following the manufacture's instruction.\*all arms are given the same intervention.
223784688|NCT00000457|DRUG|bupropion (Wellbutrin)|"1 pill in the am of 150 mg of Bupropion~1 pill (150 mg) in the AM and one in the PM for a total of 300 mg per day for subsequent 44 weeks."
223784689|NCT00000457|DRUG|Placebo|placebo pill to match (look alike) the 150 mg pill of the bupropion given in the am for 3 days and then two pills (one in the morning and one at night) for the subsequent 44 mg.
223784690|NCT05483348|PROCEDURE|Endometrial Ablation|Thermal endometrial ablation
223784691|NCT05483348|PROCEDURE|Repeated gynecological procedure|subsequent gynecological procedures such as hysterectomy for any benign indication, D\&C or repeat ablation.
223784692|NCT05240105|OTHER|no intervention, purely observational|There will be no interventions. The study is purely observational and investigates differences in naturally occuring treatments at these four types of departments for Psychosomatic Medicine.
223784693|NCT00991926|DRUG|Orlistat|orlistat (Xenical, Roche, UK)120 mg tid
223784694|NCT00991926|OTHER|normo-caloric diet|Food intake and dietary history were assessed by a skilled dietitian who used a computer-assisted interview (Winfood 1.5, Medimatica srl, Martinsicuro, Italy)
223784695|NCT01742767|DRUG|Cisplatinum|
223784696|NCT01742767|DRUG|Pemetrexed|
223784697|NCT06532175|DEVICE|Su-Jok|Su-jok seed therapy
223784698|NCT00352365|DRUG|lenalidomide|Given orally
223784699|NCT04837482|DRUG|AGN-190584|Topical eyedrop
223784700|NCT04837482|DRUG|Vehicle|Topical eyedrop
223784701|NCT04941755|DRUG|BMS-986256|Specified dose on specified days
223784702|NCT04941755|DRUG|Famotidine|Specified dose on specified days
223784703|NCT01088932|DRUG|SRX246|capsules
223784704|NCT02507895|DEVICE|MI-BCI|Subjects will be seated comfortably in front of a computer screen. An EEG cap will be comfortably worn over the head of the subject to record EEG traces of any activated cortical areas. If subjects are able to activate the device and are agreeable to participate in the second phase of the study, they will be enrolled in a 4-week BCI-MI training program of 12 sessions. Subjects will be required to perform 160 trials of MI altogether with assigned rest periods (5 mins) every 40 trials. Each session will last approximate 45 minutes excluding set up time.
223784705|NCT06186388|DIAGNOSTIC_TEST|TEMPO iMOvifa|Screening test with 28 testing points
223784706|NCT02537912|DIETARY_SUPPLEMENT|Sugarlock®|Subjects ingested 2 capsules (Experimental group) in the morning and 2 capsules in the evening (4 capsules/d) for a total of 6 weeks. Anthropometric measurements such as body weight, body fat, waistline, hipline, blood pressure (systolic blood pressure \[SBP\] and diastolic blood pressure \[DBP\]) and blood biochemical parameters including FBG, albumin, TC, TG, HDL-C, LDL-C, Cr, BUN, AST and ALT were measured every three weeks. Five subjects were randomly selected to take MRI abdominal scans before and after the trial. After 6-week consumption, anthropometric measurements were examined on week 8 for a follow-up observation.
223784707|NCT02537912|DIETARY_SUPPLEMENT|Placebo|Subjects ingested 2 capsules placebo in the morning and 2 capsules in the evening (4 capsules/d) for a total of 6 weeks. Anthropometric measurements such as body weight, body fat, waistline, hipline, blood pressure (systolic blood pressure \[SBP\] and diastolic blood pressure \[DBP\]) and blood biochemical parameters including FBG, albumin, TC, TG, HDL-C, LDL-C, Cr, BUN, AST and ALT were measured every three weeks. Five subjects were randomly selected to take MRI abdominal scans before and after the trial. After 6-week consumption, anthropometric measurements were examined on week 8 for a follow-up observation.
223784708|NCT03227770|DEVICE|hemoperfusion combined with hemodialysis|Hemoperfusion combined with hemodialysis treatment will perform at least once every two week. The hemoperfusion apparatus will use type HA130 resin hemoperfusion apparatus (Zhuhai Jafron Biomedical Co., Ltd, China)
223784709|NCT03227770|DEVICE|hemodialysis|Blood purification (including low-flux hemodialysis, high-flux hemodialysis, or hemodiafiltration) treatment ≥10 hours per week
223784710|NCT04015648|BIOLOGICAL|ChAdOx1 Zika|Single dose of ChAdOx1 Zika at different concentrations: 5 x 10\^9 vp, 2.5 x 10\^10 vp, 5 x 10\^10 vp
223784711|NCT03335553|DRUG|BMS-986235|Specified dose on specified days
223784712|NCT03335553|OTHER|Placebo|Specified dose on specified days
223784713|NCT01230593|DRUG|Hot Compress plus Tobramycin Drops and Ointment|In addition to hot compress, Tobramycin drops will be given to the affected eye 3x/day, and Tobramycin ointment will be given at night before bed.
223784714|NCT01230593|DRUG|Hot compress plus Tobramycin/Dexamethasone Drops and Ointment|In addition to hot compress, Tobramycin/Dexamethasone drops will be given to the affected eye 3x/day, and Tobramycin/Dexamethasone ointment will be given at night before bed.
223784715|NCT01230593|OTHER|Hot Compresses|Hot compresses 3x/day to eyelids
223784716|NCT05905952|DIAGNOSTIC_TEST|balance and ROM assessment|assessment of postural stability and ankle range of motion
223784717|NCT06241326|OTHER|Immunotherapy-based Combination Therapies|immunotherapy-based combination therapies in Chinese HCC patients within the practical context of real-world conditions
223784718|NCT03510572|DRUG|[18F]PI-2620|Imaging for evaluating the accumulation of abnormal tau protein in the brain
223784719|NCT06070714|DEVICE|Holmium laser with pulse modulation|The holmium laser with pulse modulation emits two separate laser pulses with a short time interval between them. The first pulse divides the water between the laser fiber tip and the stone and the second pulse hits the stone unobstructed.
223784720|NCT06070714|DEVICE|Thulium fiber laser|The thulium fiber laser has a different wavelength then the holmium laser with pulse modulation and thus has slightly different energy properties. It has also been shown to increase ablative volume and decrease retropulsion without any safety concerns.
223784721|NCT04108091|DRUG|Treatment for TTR amyloidosis|The usual adult dose is 80 mg of Tafamidis Meglumine orally once daily. The dose may be reduced if not tolerated.
223784722|NCT04108091|DRUG|Treatment for TTR amyloidosis|The usual adult dose is 61 mg of tafamidis orally once daily.
223784723|NCT00987467|DRUG|Cyclosporin 0.05% ophthalmic|Cyclosporine 0.05% ophthalmic solution, 1 drop 6 times in both eyes daily for first month, then 1 drop 4 times in both eyes daily for next month, then dosage was adjusted based on clinical disease by investigator.
223784724|NCT05853848|BEHAVIORAL|Postcard|Postcard with phone number to call for help scheduling a mammogram.
223784725|NCT05853848|BEHAVIORAL|Letter|Letter with phone number to call for help scheduling a mammogram.
223784726|NCT05853848|BEHAVIORAL|Auto-dialer|Auto-dialer with option to press button for help scheduling a mammogram.
223784727|NCT05853848|BEHAVIORAL|Live call|Live call offering help scheduling a mammogram.
223784728|NCT00765167|DRUG|Fluoride|Brush half mouth twice daily for four days
223784729|NCT00765167|DRUG|Triclosan|Brush half mouth daily for four days
223784730|NCT00765167|DRUG|Chlorhexidine gluconate|Mouth rinsing with 15 ml for 30 seconds twice a day for four days
223784731|NCT00765167|DRUG|Fluoride|Brush half mouth daily for four days
223784732|NCT06635473|BEHAVIORAL|Information support|The experimental group was given intervention measures. According to the general data survey, discharge readiness and self-efficacy assessment, parents were divided into low, middle and high discharge readiness groups and low, middle and high self-efficacy groups, respectively, using WeChat mini programs to push different content.
223835370|NCT01232556|DRUG|Inotuzumab ozogamicin|1.8 mg/m2 on day 2 every 28 days by IV infusion, 3 to 6 cycles
223835371|NCT01232556|DRUG|Rituximab|375 mg/m2 on day 1 every 28 days by IV infusion, 3 to 6 cycles
223784733|NCT06635473|BEHAVIORAL|Stress and coping|According to the results of self-efficacy and anxiety assessment, different interventions were based on different scores. Give encouragement and affirmation to parents with low anxiety and high self-efficacy. Parents with high anxiety and low self-efficacy should push stress relief methods such as mindfulness relaxation therapy in time. And through the wechat mini program to provide parents to respond to the pressure of the problem, the medical staff to give timely feedback.
223784734|NCT06635473|BEHAVIORAL|Specialist guidance|Carry out offline science popularization education and specialized training, and highly qualified specialist doctors and nurses will train parents, and parents will be assessed after training, and personalized guidance will be given according to the weak points of each parent\&#39;s assessment.
223784735|NCT06635473|OTHER|Social support and interaction|Support and encouragement for parents continue from admission to discharge, so that parents feel that even after discharge, there are people to accompany and support them.
223784736|NCT06635473|BEHAVIORAL|Parentage development|Since parents and children are separated during the hospitalization of preterm infants, we will create an environment where parents still play the role of parents, and stimulate parental competence through kangaroo care, parental touch, and breastfeeding.
223784737|NCT06635031|PROCEDURE|Oral surgery|The patients were undergone routine oral surgeries. Surgical procedures included an incision on the oral mucosa and full-thickness flap reflection, and the primary wound closure was achieved by polyglactin absorbable sutures.
223835372|NCT01232556|DRUG|rituximab + gemcitabine|rituximab 375 mg/m2 on days 1, 8, 15, and 22 of cycle 1, and day 1 of cycles 2 to 6, every 28 days by IV infusion, 3 to 6 cycles; gemcitabine 1000 mg/m2 on days 1, 8, and 15 every 28 days, 3 to 6 cycles
223784738|NCT05190081|OTHER|TASK TRAINING|A special program including motor and cognitive tasks was prepared. Both lower and upper extremity motor tasks and verbal, arithmetic, auditory, and visual cognitive tasks were planned based on evidence. The dual-task and single-task training were held 2 days a week, 40 minutes, for a total of 10 sessions for 5 weeks. A patient-appropriate task was selected for each cognitive task each week.
223784739|NCT05330663|DIETARY_SUPPLEMENT|Low protein diet with Fresubin® renal|Low protein diet with Fresubin® renal Dosage: 1 bottle per day as a replacement for one regular meal. All patients will get individualized dietary counseling aimed at achieving a protein intake of 0.6-0.8 g/kg actual body weight/day and an energy intake of 30-35 kcal/kg actual body weight.
223784740|NCT05330663|OTHER|Low protein diet with normal food|All patients will get individualized dietary counseling aimed at achieving a protein intake of 0.6-0.8 g/kg actual body weight/day and an energy intake of 30-35 kcal/kg actual body weight/day.
223784741|NCT03999606|BEHAVIORAL|Music Training - Choir participation|"Sixty participants, ages 50-65, will be recruited to partake in this study and will be randomly assigned to two groups:~participants in the experimental group will join a weekly on-line choir via Zoom, for ten weeks, directed by a professionally trained conductor from USC Department of Choral Music. The group practice will be accompanied by individual singing lessons (online or CDs) for home practice. Participants in the control group will be provided with weekly remote mindfulness lessons also on an online platform."
223784742|NCT03793101|PROCEDURE|BiMICS|Biaxial microincision cataract surgery implies performing of 2 corneal incisions under 1.8mm, removal of the crystalline lens with the use of ultrasounds and implantation of the artificial intraocular lens.
223784743|NCT06417281|DRUG|5 Aminolevulinic Acid|3±1 hours before anesthesia, participants will take 5-ALA orally at a dosage of 20 mg/kg, followed by fluorescence-guided resection of malignant glioma.
223784744|NCT01100177|DRUG|Sunitinib|Sunitinib 37.5mg/m2/d
223784745|NCT01100177|RADIATION|Radiation|Radiation therapy (60Gy) 2 Gy per day during 30 days
223784746|NCT00512135|DRUG|IncobotulinumtoxinA (Xeomin) (20 units)|Injection of a total of 20 Units incobotulinumtoxinA (Xeomin) on day one of each of up to eight cycles, reconstituted in a total injection volume of 0.5 mL administered in five equal parts of 0.1 mL to five predefined points of the glabellar area.
223784747|NCT00761501|DRUG|PN400|Oral
223784748|NCT00761501|DRUG|Naproxen (Proxen S)|Oral
223784749|NCT00761501|DRUG|Naproxen (Naprosyn E)|Oral
223784750|NCT02646423|BEHAVIORAL|Prior CD Decision App|The Prior CD Decision App begins with an explanation that its goal is to help the user better understand the two approaches to delivery she is eligible for (trial of labor after cesarean (TOLAC) and elective repeat cesarean delivery (ERCD)), and that its goal is to help her engage with her provide in making an informed, shared decision regarding which approach to undergo. It includes four sections: a calculator to estimate the likelihood of having a vaginal delivery if she undergoes TOLAC, a series of information pages that include graphical presentations of the chances of various potential outcomes of the two options, a series of values clarification exercises to help the user think through what's important to her, and a summary print out for her to keep.
223784751|NCT01853449|DRUG|Fentanyl Citrate|
223784752|NCT01853449|OTHER|CWS|Chest wall strapping to reduce vital capacity by 20% of its baseline value
223784753|NCT01853449|DRUG|Placebo|0.9% saline
223784754|NCT05063344|DEVICE|Diagnostic Test: NOWDx Syphilis Test|For this observational trial, the Intervention of interest is the NOWDx Syphilis Test.
223784755|NCT01049906|PROCEDURE|Placement of nerve block catheter|Placement of nerve block catheter with nerve stimulator and ultrasound
223784756|NCT01049906|PROCEDURE|Placement of nerve block catheter|Placement of nerve block catheter with ultrasound only
223784757|NCT02703883|DEVICE|BWST|BWST (six weeks, 3 times/week)
223784758|NCT00377819|DRUG|alendronate|70 mg oral QW
223784759|NCT00377819|DRUG|Denosumab (AMG 162)|60 mg SC q 6 mos
223784760|NCT03517774|DEVICE|3D Printed Socket|Twenty participants will be fitted with a 3D Printed socket created using 3DPrintAbility hardware and software. To do this, a 3D model of the participants residual limb will be generated which will be used to create the 3D printed sockets. These 20 participants will also receive standard care for prosthetic fitting at SJR. The fittings will be done by one prosthetist. Our team will compare the feasibility, function, quality and stability of the prosthetics through quantitative, economic and qualitative analyses. All fittings will be done under the supervision of a qualified Sunnybrook prosthetist who has previous experience with using 3D printed technologies for creation of prosthetics.
223784761|NCT04295733|BIOLOGICAL|4CMenB (Bexsero®) vaccine|Participants will receive 2 doses of 4CMenB (Bexsero®) vaccine administered intramuscularly 1-2 months apart
223784762|NCT00898716|DRUG|BMS-754807|Tablets, Oral, 20 mg, 30 mg, 50 mg, 70 mg, 100 mg, 130 mg, 160 mg, 200 mg once daily, 3-5 months, depending on response
223784763|NCT02807948|DEVICE|Pacemaker, ICD, or CRT device|MRI Scans on SJM device implanted subjects for clinical purpose
223784764|NCT03727750|DRUG|Gemtuzumab Ozogamicin|Three doses of GO 3 mg/m2 (up to one vial) as a 2 hour intravenous infusion on Cycle 1 Days 1, 4, and 7. A second cycle of GO 3mg/m² (up to one vial) on Cycle 2 Days 1, 4, and 7 will be allowed at the investigator's discretion for patients who meet the criteria
223784765|NCT06496932|OTHER|Listen to music|Women in the intervention groups will listen to nature and bird sounds through over-the-ear headphones after spinal anesthesia for cesarean section until the suturing is completed.
223784766|NCT02138591|PROCEDURE|Blood draw pre-operatively|Pre-Operative blood draw of approximately 32ml will check the following: Vitamin D (25-OHD), Calcium, Cathelicidin and Resistin levels in the blood.
223784767|NCT02138591|PROCEDURE|Blood draw post-operative Day 1|Blood draw of approximately 32ml to check the following: Vitamin D (25-OHD), Calcium, Cathelicidin and Resistin levels in the blood.
223784768|NCT02138591|PROCEDURE|Blood draw post-operative Day 2|Blood draw of approximately 32ml to check the following: Vitamin D (25-OHD), Calcium, Cathelicidin and Resistin levels in the blood.
223784769|NCT04507191|DIAGNOSTIC_TEST|immunohistochemical staining|immunohistochemical staining of programmed death-ligand 1 (PDL1) marker
223784770|NCT05222191|DRUG|Spironolactone|Study drugs will be increased if goal blood pressure is not achieved and/or serum potassium is not in safe clinical range (dosage of chlorthalidone/placebo not to exceed 25 mg daily; dosage of spironolactone not to exceed 50 mg daily).
223784771|NCT05222191|DRUG|Chlorthalidone|Study drugs will be increased if goal blood pressure is not achieved and/or serum potassium is not in safe clinical range (dosage of chlorthalidone/placebo not to exceed 25 mg daily; dosage of spironolactone not to exceed 50 mg daily).
223784772|NCT05222191|DRUG|Placebo|Study drugs will be increased if goal blood pressure is not achieved and/or serum potassium is not in safe clinical range (dosage of chlorthalidone/placebo not to exceed 25 mg daily; dosage of spironolactone not to exceed 50 mg daily).
223784773|NCT00311077|DRUG|Insulin Glulisine|
223784774|NCT00000974|DRUG|Pentamidine isethionate|
223784775|NCT02937246|DEVICE|SEMS(self-expandable metallic stent)|Find the obstruction site by ERCP(endoscopic retrograde cholangiopancreatography) and insertion the SEMS(self-expandable metallic stent) through duodenal endoscopy. Metal stents are inserted to ensure adequate decompression and bile drainage. The diameter and stent lengths can be changed according to the lesion.
223784776|NCT02937246|DEVICE|Stenting by ERCP (endoscopic retrograde cholangiopancreatography)|
223784777|NCT03830034|DRUG|Amino Acid chelated iron tab 15 mg|"Contain 75 pregnant women will recommended to take ferrotrone(iron chelated amino acid containing 15mg elemental iron) a dose recommended by the company of the product.~Iron tablets should be taken at night or at least 1 hour prior to food to maximise absorption.~Substances that inhibit absorption such as tannins \& milk should be avoided but fruit juice contain ascorbic acid taken in conjunction with iron supplements increases their absorption.~Follow up will be done for all the pregnant women included in our studies at baseline \& then 4, 8 \& 12 weeks after treatment at each visit breif history for outcomes and adverse effects will reviewed."
223784778|NCT03830034|DRUG|Ferrous Fumarate tab 350 mg( 115 mg elemental iron)|"75 pregnant women will recommended to take ferrous fumarate e.g. Hema-caps (ferrous fumarate 350 mg with elemental iron 115mg) prepared by another egyptian pharmaceutical company (Amoun pharmaceutical company) once daily but in sever cases of iron deficiency anemia (Hb\<9g/dl) this dose can be doubled as recommended by the company of the product.~Some instructions will be given to all the pregnant women included in our study as follow: Iron tablets should be taken at night or at least 1 hour prior to food to maximise absorption.~Substances that inhibit absorption such as tannins \& milk should be avoided but fruit juice contain ascorbic acid taken in conjunction with iron supplements increases their absorption.~Follow up will be done for all the pregnant women included in our studies at baseline \& then 4, 8 \& 12 weeks after treatment at each visit breif history for outcomes and adverse effects will reviewed."
223784779|NCT04810598|DRUG|Venetoclax|Oral Tablet
223784780|NCT05741736|BEHAVIORAL|five-days small group-based lifestyle modification program|healthy lifestyle, based on the promotion of a particular dietary pattern, regular physical activity, psychological support, education, and small group intervention results in weight loss
223784781|NCT04471818|DRUG|Ketamine|Ketamine (0.5 mg/kg) will be administered intravenously once every week to patients in the experimental arm of the study
223784782|NCT04471818|OTHER|Placebo|Placebo (0.5 mg/kg) will be administered intravenously once every week to patients in the experimental arm of the study
223784783|NCT01504594|PROCEDURE|Intracoronary autologous stem cell infusion|Under sedation and under sterile conditions in a fluoroscopy operation room, cardiac catheterization will be performed through the femoral artery to infuse the stem cells directly into the heart´s coronary arteries.
223784784|NCT04962464|DIETARY_SUPPLEMENT|Peak Human Labs calorie mimetic supplement|Supplement
223784785|NCT04962464|BEHAVIORAL|Fasting Mimicking Diet|Diet
223784786|NCT02721238|BIOLOGICAL|20% Albumin|
223784787|NCT02721238|OTHER|Plasmalyte|
223784788|NCT05099848|DRUG|Camrelizumab|"Procedure:~1. Taking Apatinib-Mesylate Tablets (250 mg/tablet) orally on the 1st day 30minutes after meals, once a day, for continuous medication.~2. On the 2nd day of treatment, intravenous infusion of Camrelizumab 200mg every 3 weeks.~3. On the 3rd to 4th day of treatment, HAIC was conducted through a catheter intubated into the tumor feeding artery under DSA guidance with the following chemotherapeutic drugs (mFOLFOX, oxaliplatin 85 mg/m2 in 0-2 hours, folinic acid 400 mg/m2 in 2-3 hours, 5-FU 2500 mg/m2 46 hours) pumped into the tumor artery. The HAIC is repeated every 3 weeks. The cumulative maximum sessions of HAIC is up to 8 times.~The cumulative maximum drug use period is up to 8 cycles. Patient will be administratied radical resection if possible during treatment. The patient is concurrent on medication until the treatment discontinuation criteria specified in the protocol appear."
223784789|NCT04672304|OTHER|Al-Husban University Naser|filling a questionnaire
223784790|NCT04242927|DRUG|Nicotinic acid +Routine care|Nicotinic acid is administered orally at 50 mg (grade 2) or 100 mg (grade 3) three times daily with routine care.
223784791|NCT04242927|DRUG|Routine care|Routinely apply urea ointment and provide best supportive care.
223784792|NCT05080569|DRUG|Progesterone Vaginal Product|3dd200mg
223784793|NCT05080569|DRUG|Placebo|3dd1 vaginal capsule
223784794|NCT06167668|OTHER|the routine chronic disease management mode|indoor temperature and humidity adjustment, regular ventilation and hygiene of ward and clinic environment, promotion of patients' health awareness by distributing disease brochures, regular inspection of wards, and home nursing and health guidance based on disease knowledge when discharged
223784795|NCT06167668|OTHER|the family-centered family enabling health management mode|The specific measures were as follows :(1) intervention group construction. (2) Online knowledge promotion. (3) Disease assessment.(4) Medication guidance reminder.(5) Enabling psychological counseling.
223784796|NCT01466998|OTHER|Paced Respiration|Practice paced respiration 15 minutes per day for a total of 12 weeks.
223784797|NCT01466998|OTHER|Music Therapy|Practice music therapy for 15 minutes per day for a total of 12 weeks.
223835373|NCT01232556|DRUG|rituximab +bendamustine|rituximab 375 mg/m2 on day 1 every 28 days by IV infusion, 3 to 6 cycles; bendamustine 120 mg/m2 on days 1 and 2 by IV infusion every 28 days, 3 to 6 cycles
223835374|NCT04779164|DIAGNOSTIC_TEST|knee ultrasonography|The knees of all patients were screened with ultrasonography device for the measurement of femoral cartilage thicknesses.
223835375|NCT04237480|DIAGNOSTIC_TEST|serum value 1,25(OH)2 vitamin D|statistical evaluation of the serum values
223784798|NCT02475096|BEHAVIORAL|Internet-delivered CBT|"The treatment is based on an internet-delivered CBT-treatment for adults with IBS and on the adapted version for adolescents with functional gastrointestinal disorders. The protocol has been tested in an open face-to-face CBT study of children aged 8-12 years (n=20) with promising results.~Main component in the treatment is exposure for symptoms. The purpose of the treatment is to reduce fearful and anxious responses to symptoms and lessen avoidance of symptoms in the child, and to teach the parents how parental behavior can influence symptoms in children as well as how to support exposure. Detailed behaviour analysis is made for each individual and instruction is given on how to gradually expose to symptoms to lessen fear for symptoms and widen the behavioral repertoire."
223784799|NCT05517317|COMBINATION_PRODUCT|Autologous BMMC transplantation|One administration of autologous bone marrow mononuclear cells via the hepatic artery
223784800|NCT03845608|COMBINATION_PRODUCT|Pulmonary Recruitment Maneuver|Pulmonary recruitment maneuver will be performed manually using positive-pressure ventilation to inflate the lungs and lower the diaphragm, which can increase intraperitoneal pressure mechanically and remove residual carbon dioxide from the peritoneal cavity.recieve100 mg hydrocortisone in 250 ml normal saline at end of surgery and carbon dioxide will be removed by applying gentle abdominal pressure and removing carbon dioxide by passive exsufflation
223784801|NCT05880992|BEHAVIORAL|Exercise|Aerobic and Strength exercises (equipment free, simple, modifiable)
223784802|NCT05880992|DIETARY_SUPPLEMENT|Nutrition|Counselling on daily protein target of 1.2 g/kg as well as supplementation with protein shake (provided)
223784803|NCT05880992|BEHAVIORAL|Mindfulness|Deep (box) breathing completing in the morning, evening and as needed.
223784804|NCT02982252|BEHAVIORAL|CoPILOT|Participants in all groups will receive either six or twelve hours of training in a standard powered wheelchair; however, the CoPILOT groups will use remote control technology we have developed. The technology provides the trainer with remote control of wheelchair speed and direction allowing the trainer to override the participant's actions as needed to ensure safe error-free shared controlled wheelchair training. The CoPILOT approach will accommodate varied learning needs, as per adult learning principles, while decreasing trainer input until the participant can complete tasks independently.
223784805|NCT03877042|DEVICE|Cruciate-retaining (CR) prostheses|One leg is conducted TKA with Cruciate-retaining (CR) prostheses.
223784806|NCT03877042|DEVICE|Posterior-stabilized (PS) prostheses|One leg is conducted TKA with Posterior-stabilized (PS) prostheses.
223784807|NCT02624804|BIOLOGICAL|Stem Cell Educator Therapy|"Patients will receive apheresis and then have their own blood returned to them with the educated lymphocytes"
223784808|NCT00382057|DRUG|Testosterone|
223784809|NCT00382057|DRUG|Anastrozole|
223784810|NCT00382057|DRUG|Goserelin|
223784811|NCT02359526|DRUG|IlUVIEN|All patients will receive ILUVIEN 190 micrograms intravitreal implant in applicator with an initial release rate of 0.2 microgram per day. The implant will be administered by injection according to the method of administration defined in the SmPC (ILUVIEN SmPC). Only one eye of each patient will be treated with ILUVIEN.
223784812|NCT03139487|DRUG|Rivaroxaban|15 mg q12 hours for 3 weeks followed by 20mg q24 hours for 21 weeks
223784813|NCT03139487|DRUG|Dalteparin|200 IU/kg q24 hours for 4 weeks followed by 150 IU/kg q24 hours for 20 weeks
223784814|NCT03139487|DRUG|apixaban|10 mg q12 hours for 7days followed by 5mg q12 hours for 21 weeks
223784815|NCT02771951|BEHAVIORAL|"Lights of Change"|
223784816|NCT02771951|BEHAVIORAL|Usual Care|
223784817|NCT01206738|BEHAVIORAL|Persuasive communication|The persuasive intervention aimed to reinforce the GP's beliefs about the positive consequences of managing sore throat without prescribing antibiotics.
223784818|NCT01206738|BEHAVIORAL|Action plan|This intervention was an action plan, supporting the GP to deal with two difficult prescribing situations: 1) a distressed patient (or often distressed parent of a child patient) 2) a patient demanding an antibiotic
223784819|NCT01206738|BEHAVIORAL|General intervention|No additional information was provided; the general information was the information already available to GPs about antibiotic prescribing.
223784820|NCT00760929|DRUG|Placebo|iv 9mg/kg weekly
223784821|NCT00760929|DRUG|Placebo|iv 16mg/kg every 3 weeks
223784822|NCT00760929|DRUG|RG1507|iv 9mg/kg weekly
223784823|NCT00760929|DRUG|RG1507|iv 16mg/kg every 3 weeks
223784824|NCT00760929|DRUG|erlotinib [Tarceva]|150mg oral daily
223784825|NCT01331473|PROCEDURE|Carotid Artery Stenting with Proximal Protection|Carotid artery angioplasty and stenting with proximal embolic protection provided by the GORE Neuro Protection System
223784826|NCT01331473|PROCEDURE|Carotid Artery Stenting without Protection|Carotid artery angioplasty and stenting without cerebral embolic protection
223784827|NCT02282449|DEVICE|Power Injectable Port (AngioDynamics Smart Port CT Mini)|The subjects will all receive power injectable port.
223784828|NCT02282449|DEVICE|Non-Power Injectable Port (Cook Vital Mini Port)|The subjects will all receive non-power injectable port.
223784829|NCT04154280|DIAGNOSTIC_TEST|PET/MR scan|"* The PET will be performed with 68Ga-PSMA tracer.~* The 3 tesla magnet of the MRI will be used with sequence allowing MRS acquisition, additional sequences will include T2-weighted contrast and diffusion weighted contrast.~* Images will be analyzed visually and quantitatively. Quantitative analysis will include MR parameters such as DWI apparent diffusion coefficient (ADC) and PET quantitative metabolic data such as standard uptake values (SUV) or Ki (in case dynamic PET protocol will be applied). In addition, content relationship between metabolic entities detected will be extracted.~Quantitative data will be correlated to clinical and pathological data to check accuracy, specificity and sensitivity."
223784830|NCT05325086|OTHER|Adapted information arm|A adapted booklet will be delivered to patients at the start of the stay. This booklet contains adapted information about the pulmonary rehabilitation targetting the characteristics of the openness to experiences personality traits
223784831|NCT05325086|OTHER|Neutral information arm|A neutral booklet will be delivered to patients at the start of the stay. This booklet contains neutral information about the pulmonary rehabilitation
223784832|NCT02783404|DRUG|Amoxicillin|Receiving 2 gr oral Amoxicillin before dental any manipulation and following endotracheal intubation
223784833|NCT02783404|DRUG|Amoxicillin-Potassium Clavulanate|"Receiving 2 gr/125 mg oral Amoxicillin-Potassium Clavulanate before any dental manipulation and following endotracheal intubation~Intervention: Drug: Amoxicillin-Potassium Clavulanate"
223784834|NCT05075252|PROCEDURE|laparoscopic lavage|This study aims to investigate the impact of laparoscopic lavage on the incidence of postoperative abscesses stratifying patients on the grade of appendicitis and peritoneal contamination.
223784835|NCT05245058|DRUG|SPH5030 tablets|SPH5030 tablets orally once or twice daily.
223784836|NCT04483479|DRUG|Active Investigational Treatment ENT-01|ENT-01 will be administered in tablet form, once daily in escalating doses followed by a fixed-dose for 12 weeks.
223784837|NCT05266690|DIETARY_SUPPLEMENT|Roquette Glucidex 2|Roquette Glucidex 2: Maltodextrins with high degree of polymerization
223784838|NCT05266690|DIETARY_SUPPLEMENT|Pharmacosmos Dextran 10|Pharmacosmos Dextran 10: Dextran with high degree of polymerization
223784839|NCT05266690|DIETARY_SUPPLEMENT|Roquette Glucidex 40|Roquette Glucidex 40: Glucose syrup
223784840|NCT05266690|DIETARY_SUPPLEMENT|Promitor 70|Promitor 70: Resistant Dextrin with a complex structure containing 70% non-digestible dietary fiber
223784841|NCT00317239|DRUG|Ferrous Sulfate tablets|325 mg/TID x 8 weeks
223784842|NCT00317239|DRUG|Ferric Carboxymaltose (FCM)|A maximum dose of 1,000 mg of FCM over 15 minutes on day 0, and a maximum dose of 500 mg of FCM over 15 minutes on days 17 and 31 based on Ferritin and TSAT values.
223784843|NCT06300021|DIETARY_SUPPLEMENT|TPG capsule|A dietary supplement product in capsule form containing 300 mg Turmipure Gold®
223784844|NCT06300021|DIETARY_SUPPLEMENT|TPG ready to drink|Ingredient stick containing 300 mg Turmipure Gold® mixed in 60 mL mango fruit nectar
223784845|NCT06300021|DIETARY_SUPPLEMENT|TPG dairy analog|Ingredient stick containing 300 mg Turmipure Gold® mixed in 240 mL oat milk
223784846|NCT06300021|DIETARY_SUPPLEMENT|TPG probiotic drink|Ingredient stick containing 300 mg Turmipure Gold® mixed in a 100 mL probiotic yogurt drink base
223784847|NCT06300021|DIETARY_SUPPLEMENT|TPG gummies|Pectin gummies containing 300 mg Turmipure Gold®
223784848|NCT06300021|DIETARY_SUPPLEMENT|TPG sport bar|Sport nutrition bar containing 300 mg Turmipure Gold®
223784849|NCT02358577|DEVICE|In-bed cycling|In-bed cycling will be applied using a cycle ergometer (RT300 Supine Cycle Ergometer) for 30 minutes per day in addition to Usual Care, until the physiotherapist deems that the patient is mobilizing well, or a maximum of 7 days (whichever comes first). This cycle ergometer is specifically designed for pediatric use, and can be applied to facilitate lower or upper limb cycling. The intervention will be applied by a trained physiotherapist and/or clinician. Pre-defined Safety Criteria for interrupting or aborting the intervention will be observed. Qualitative interviews will be conducted with a health care provider, the patient where possible, and a family caregiver following the intervention period.
223784850|NCT02358577|OTHER|Usual Care|Usual care physiotherapy will be applied to patients in the control arm, according to the unit specific guidelines for early mobilization. Qualitative interviews will be conducted with a health care provider, the patient where possible, and a family caregiver following the intervention period.
223784851|NCT00798798|DEVICE|Externally Implantable Tissue Expansion Device|Will Apply Externally Implantable Tissue Expansion Device for 2 Days
223784852|NCT01301963|DRUG|plerixafor|Given SC
223784853|NCT01301963|BIOLOGICAL|filgrastim|Given SC
223784854|NCT06326372|PROCEDURE|control|Fraction of inspired oxygen (FiO2) is titrated guided by oxygen saturation in that range; %95\<oxygen saturation
223784855|NCT06326372|PROCEDURE|ORi+SpO2|"Titration of fraction of inspired oxygen (FiO2) guided by ORI and oxygen saturation FiO2 will be titrated by reducing 10% if Ori\>0.01 and oxygen saturation ≥ 98% until Ori is 0.00.~FiO2 will not be changed if Ori is 0.00 and %95\<oxygen saturation≤%98 FiO2 will be increased by 10% if oxygen saturation \<95 or PaO2\<60 mmHg"
223784856|NCT02649686|DRUG|Durvalumab|
223784857|NCT02649686|DRUG|Trastuzumab|
223784858|NCT03073603|DRUG|Discontinuation of disease modifying therapy|Participants who will discontinue their current MS drug. No other changes to their treatment occur.
223784859|NCT03073603|DRUG|Standard of Care|Participants who remain on their current Disease Modifying Therapies (DMTs) without any changes. DMTs include \~14 formulations/doses of drugs approved in the US by the FDA that alter the natural history of the disease.
223784860|NCT02340039|DIETARY_SUPPLEMENT|Polyphenols|Drinks will be delivered in random order at 3 separate study visits immediately before a high-carbohydrate meal. Seven days wash-out period will be required between study days.
223784861|NCT06531720|DRUG|Chlorhexidine Gluconate|topical preparation applied on oral mucosa lesion containing 0,2% CHX
223784862|NCT06531720|DRUG|Choline Salicylate 8.7 % Oral Gel|topical preparation applied on oral mucosa lesion containing, ethanol-based
223784863|NCT06531720|OTHER|control group|no medication has been prescribed
223784864|NCT04360824|DRUG|Intermediate dose thromboprophylaxis|2\) Patients randomized to the intervention arm will receive intermediate-dose enoxaparin (1 mg/kg Subcutaneously daily if BMI\<30kg/m2 or 0.5 mg/kg Subcutaneously twice daily if BMI ≥ 30kg/m2).
223784865|NCT04360824|DRUG|Standard of Care thromboprophylaxis|Patients randomized to the standard of care arm will receive standard prophylactic dose enoxaparin (40 mg subcutaneously daily if BMI \<30kg/m2 and 30 mg subcutaneously twice daily or 40 mg subcutaneously twice daily if BMI ≥ 30 kg/m2).
223835376|NCT06047873|DEVICE|Endoscopy|clinical and endoscopic pattern in patients with upper and lower gastrointestinal bleeding
223784866|NCT04942080|BIOLOGICAL|CALR allele burden quantification|"* DNA extraction from blood sample for CALR mutation quantification (fragment analysis)~* at diagnosis and follow-up (inclusion period: 3 years)~* max 1 sample/year~* secondary outcome: mutational landscape by Next Generation Sequencing (NGS) analysis at diagnosis"
223784867|NCT05107362|DIAGNOSTIC_TEST|untrained lay user performs investigational diagnostic test|Untrained lay users (parents/guardians of pediatric subjects or friends/family members of adult subjects) collect throat swab specimens and perform the investigational diagnostic test.
223784868|NCT00304070|DRUG|Cisplatin|Given IV
223784869|NCT00304070|PROCEDURE|Conventional Surgery|Patients undergo surgery
223784870|NCT00304070|DRUG|Doxorubicin Hydrochloride|Given IV
223784871|NCT00304070|DRUG|Etoposide|Given IV
223784872|NCT00304070|BIOLOGICAL|Filgrastim|Given subcutaneously
223784873|NCT00304070|DRUG|Mitotane|Given orally
223784874|NCT00304070|BIOLOGICAL|Pegfilgrastim|Given subcutaneously
223784875|NCT00320216|DRUG|Ustekinumab|Patients will receive subcutaneous injections of ustekinumab (45 or 90 mg).
223784876|NCT00320216|DRUG|Placebo|Patients in the placebo group will receive placebo medication.
223784877|NCT00377676|DRUG|Cycloset|Usual diabetes therapy plus Cycloset
223784878|NCT00377676|DRUG|Usual Diabetes Therapy plus placebo|Placebo tablet taken orally once in the morning, beginning with one tablet daily, titrated up by 1 tablet each week to a maximum of 6 tablets daily
223784879|NCT03421197|DRUG|PPC-06 400 mg QD|Tepilamide Fumarate 400 mg tablet once per day
223784880|NCT03421197|DRUG|PPC-06 400 mg BID|Tepilamide Fumarate tablets 400 mg twice per day
223784881|NCT03421197|DRUG|PPC-06 600 mg|Tepilamide Fumarate tablets 600 mg twice per day
223784882|NCT03421197|DRUG|Placebo|white tablet with no active ingredient manufactured to mimic Tepilamide Fumarate tablets
223784883|NCT02446808|DEVICE|Intraoperative nerve monitoring|Intraoperative nerve monitoring (electromyography) is used to identify the location of somatic pelvic nerves critical to urinary continence control and erectile function in real time during robotic-assisted laparoscopic prostatectomy surgery
223784884|NCT03455283|DRUG|Clariscan|Clariscan 0.5 mmol/ml solution for injection will be administered as part of clinical practice according to the judgment of the site with regard to medical need.
223784885|NCT03455283|OTHER|Gadolinium-Based Contrast Agents|All GBCAs will be selected by the sites and recorded as by the brand names.
223784886|NCT02866890|DEVICE|Laryngeal Tube Suction|Laryngeal Tube Suction Measurement of leak pressure
223784887|NCT02612012|RADIATION|axillary radiotherapy|Whole breast irradiation and axillary level I-II areas radiotherapy. The prescription dose is 50Gy in 25 fractions in 5 weeks. Tumor bed boost is necessary with 10Gy in 5 fractions in one week.
223784888|NCT04018027|DRUG|difelikefalin 0.25 mg|Oral difelikefalin 0.25 mg administered twice daily
223784889|NCT04018027|DRUG|difelikefalin 0.5 mg|Oral difelikefalin 0.5 mg administered twice daily
223784890|NCT04018027|DRUG|difelikefalin 1.0 mg|Oral difelikefalin 1.0 mg administered twice daily
223784891|NCT04018027|DRUG|Placebo|Oral Placebo administered twice daily
223784892|NCT03787394|OTHER|adding taste enhancer|Comparing sensory profiles of food products either enriched with FAAA-conjugates or plain
223784893|NCT03094689|OTHER|Cold water immersion|
223784894|NCT03094689|OTHER|Water immersion|
223784895|NCT06486740|DEVICE|mesofiller aox|The investigated product M-AOX-2021 was applied by intradermal or subcutaneous injection by the investigator during Session 1 for all subjects and Session 2 for the subjects, for whom a touch-up was considered beneficial. The both sessions was conducted within 14 days interval.
223784896|NCT06636409|OTHER|Collection of medical data|A randomised selection of files to be analyzed will be conducted in each center to constitute a representative sample of liver transplanted patients. This represents 20% of the number of transplanted patients over the period 2008-2013 in the center, allowing a more in-depth analysis of the patients' medical records.
223835377|NCT01788020|DRUG|Dexamethasone, Rituximab, Cyclophosphamide|
223835378|NCT01788020|DRUG|Dexamethasone, Rituximab, Cyclophosphamide, Bortezomib|
223835379|NCT02225275|DRUG|Lenalidomide|Given PO
223835380|NCT02225275|BIOLOGICAL|Obinutuzumab|Given IV
223784897|NCT06634511|OTHER|core stability exercises|"Group A: core stability exercise group:15 Patients assigned to this group will undergo a core stability exercises ts.2times per week /8weeksin addition to conventional therapy (Infrared radiation (using BL 220 Infrared lamp, MT03009201 model) for 15 minutes, Transcutaneous Electrical Nerve stimulation (using model DX66053, pain modulation mode) for 10 minutes~Group B:(aerobic exercise group) 15 patients will receive aerobic exercise in the form of treadmill for 30 minutes2 session per week/8 weeks~Group C(conventional group): 15 patients will receive Infrared radiation (using BL 220 Infrared lamp, MT03009201 model) for 15 minutes, Transcutaneous Electrical Nerve stimulation (using model DX66053, pain modulation mode) for 10 minutes, Participants were treated twice weekly"
223784898|NCT05395494|DRUG|D-Cycloserine|"Daily oral D-cycloserine 100mg during TMS treatments (20 days).~Other Names:~Seromycin"
223784899|NCT05395494|DRUG|Placebo oral tablet|Daily oral placebo during the TMS treatments (20 days).
223784900|NCT05395494|DEVICE|iTBS repetitive Transcranial Magnetic Stimulation (rTMS)|Repetitive Transcranial magnetic stimulation (rTMS) will be delivered using a MagPro X100 device with B70 coil and the intermittent theta burst (iTBS) protocol to the left dorsolateral prefrontal cortex. Participants will receive daily treatments (Monday-Friday) over four weeks.
223784901|NCT06635733|BEHAVIORAL|Rhapsode Capable™ Platform (Intervention Group)|Participants in the intervention group will use the Rhapsode Capable™ platform to facilitate In-Person Skills Practice (ISP) sessions. The platform allows for scheduling ISP sessions, providing real-time performance feedback, and tracking progress. The platform integrates with the PACE adaptive learning modules, which cover pediatric acute care topics. The goal is to improve skills retention and performance in pediatric care through a blended learning approach.
223784902|NCT06635733|BEHAVIORAL|Paper-based ISP (Control Group)|Participants in the control group will also receive In-Person Skills Practice (ISP) sessions facilitated by clinical champions, but without the use of the digital platform. The ISP sessions will be tracked and scheduled using paper-based assessments. Feedback will be provided verbally or manually, and progress will be documented using paper forms. Both groups will receive the same PACE adaptive learning modules, but the method of ISP implementation differs between the groups.
223784903|NCT01316133|DRUG|tacrolimus|oral
223784904|NCT02938416|DEVICE|Isokinetic strengthening exercise|Isokinetic strengthening exercise provides muscle training throughout the range of motion of a joint at a pre-set constant speed of angular velocity. It can be performed in an eccentric or concentric way in a controlled manner, and is evidenced to be an effective and safe training method in patients with anterior cruciate ligament reconstruction, burn injury, ankle instability, osteoarthritic knee, and chronic stroke in the past literatures.
223784905|NCT02938416|DEVICE|Isotonic strengthening exercise|Isotonic strengthening exercise keeps the tension remained unchanged during the muscle's length changing. As the muscle's force changes via the length-tension relationship during a contraction, an isotonic contraction will keep force constant while velocity changes. There are two types of isotonic contractions: (1) concentric and (2) eccentric. In a concentric contraction, the muscle tension rises to meet the resistance, then remains the same as the muscle shortens. In eccentric, the muscle lengthens due to the resistance being greater than the force the muscle is producing.
223784906|NCT02938416|BEHAVIORAL|isometric strengthening exercise|home exercise education on isometric quadriceps strengthening on the day of out-patient appointment
223784907|NCT02842398|BEHAVIORAL|Balance Master|
223784908|NCT02842398|BEHAVIORAL|Customary Care|
223784909|NCT02736539|DRUG|CBS 2004 (galacto-oligosaccharides)|CBS 2004 active treatment
223784910|NCT02736539|DRUG|Placebo|Placebo treatment
223784911|NCT05348681|DRUG|RIST4721|RIST4721 tablets, 100 mg are blue, oval, biconvex film-coated tablets
223784912|NCT05348681|DRUG|Placebo|Matching placebo
223784913|NCT05668494|OTHER|immediate loading of implants|This is a randomized control clinical trial including 24 implants, immediately loaded with definitive abutment protocol and 24 implants immediately loaded with with temporary abutment protocol
223784914|NCT06059703|PROCEDURE|Blood punction|Peripheral blood sampling (5 ml) at inclusion and 3 months after treatment
223784915|NCT06059703|PROCEDURE|Central blood sampling|Central blood sampling (2 ml) at inclusion and 3 months after treatment
223784916|NCT06059703|PROCEDURE|Intracranial pressure measurement|Intracranial pressure measurement at sinus level with micro-catheter at inclusion and 3 months after treatment
223784917|NCT00782340|DRUG|Placebo|100 mg, oral, three times per day 200 mg, oral, three times per day 300 mg, oral, three times per day 400 mg, oral, three times per day 500 mg, oral, three times per day 600 mg, oral, three times per day
223784918|NCT00782340|DRUG|Droxidopa|100 mg, oral, three times per day 200 mg, oral, three times per day 300 mg, oral, three times per day 400 mg, oral, three times per day 500 mg, oral, three times per day 600 mg, oral, three times per day
223784919|NCT00216151|DRUG|Zoledronic Acid|Zoledronic Acid 4mg, every three months
223784920|NCT01271335|BIOLOGICAL|collagenase|Lyophilized powder / sterile dosage form for single local intravascular administration via the occluded coronary.
223784921|NCT05808725|DRUG|Amlodipine Freeze-Dried Powder for Oral Solution 5 mg|Amlodipine Oral Solution 5 mg is given to T1 Fasting and T2 Fed
223784922|NCT05808725|DRUG|Norvasc 5 mg tablets of Pfizer Labs|Norvasc 5 mg is given to R Fasting
223784923|NCT02316236|DRUG|dexmedetomidine|an alpha-2 receptor agonist
223784924|NCT02316236|OTHER|loading dose|0.8ug/kg of dexmedetomidine is given in 10 minutes
223784925|NCT02316236|OTHER|sustaining dose|0.4ug/kg/min of dexmedetomidine is given
223784926|NCT03124641|DEVICE|Hypothermic oxygenated perfusion (HOPE)|HOPE for 1 hour via the portal vein in a recirculating and pressure controlled system (2-3 mm Hg), 0.1 ml/g liver/min, perfusion volume 3-4 L, Belzer (UW) machine perfusion solution, perfusate temperature 10 °C, perfusate oxygenation pO2 of 60-80 kPa
223784927|NCT03124641|PROCEDURE|Conventional cold storage (CCS)|Conventional static cold storage (CCS) on temperature 4-6 °C from organ procurement
223784928|NCT04045392|BEHAVIORAL|Mediterranean diet|Two meals (breakfast and dinner) a day, five times a week, are delivered to participants' homes without charge. The meals are prepared, under the supervision of an expert nutritionist, by a chef trained on the principles of the Mediterranean diet.
223784929|NCT02078284|BIOLOGICAL|CPP|One unit of frozen CPP contains approximately 3.4 x 10\^11 irradiated platelets and approximately 6% DMSO in sterile 0.9% sodium chloride solution (total volume of 20 mL to 35 mL) stored frozen at ≤ -65°C.
223784930|NCT02078284|BIOLOGICAL|LSP|
223784931|NCT00107419|DRUG|pemetrexed disodium|pemetrexed, 500 mg/m2, IV, every 21 days until two cycles after complete response or until progression
223784932|NCT00595244|DRUG|PB127 for injectable suspension|0.175 mg/kg diluted in 150 mL Dextrose in Water 5% in glass bottles to be infused at 250 mL/hour until stead state achieve, 150 mL/hour during rest image acquisition, and 100-150 mL/hr during stress image acquistion. Single IV infusion, not to exceed 60 minutes.
223784933|NCT02621762|DEVICE|Magnesium|Magnesium in dialysate increased
223784934|NCT02621762|DEVICE|Bicarbonate|Bicarbonate in dialysate increased
223784935|NCT02961972|DIETARY_SUPPLEMENT|monohydrate and micronized creatine|oral supplementation with creatine
223784936|NCT02961972|OTHER|placebo|oral supplementation with maltodextrin (control group)
223784937|NCT01568047|DRUG|Placebo|once-daily
223784938|NCT01568047|DRUG|BIA 9-1067|BIA 9-1067 - 5 mg single-dose
223784939|NCT01568047|DRUG|BIA 9-1067|BIA 9-1067 - 15 mg single-dose
223784940|NCT01568047|DRUG|BIA 9-1067|BIA 9-1067 - 30 mg single-dose
223784941|NCT01568047|DRUG|Levodopa/Carbidopa|Levodopa 100 mg Carbidopa 25 mg
223784942|NCT01568047|DRUG|Levodopa/Benzerazide|Levodopa 100 mg Benzerazide 25 mg
223784943|NCT01663493|PROCEDURE|FNB|
223784944|NCT00561223|DRUG|iloprost Inhalation|inhale 2.5 mg, repeat times one
223784945|NCT00561223|DRUG|iloprost|inhaled 2.5 mg, repeat times one
223784946|NCT04733560|PROCEDURE|Pudendal nerve block|Vaginally administered pudendal nerve block of 10ml 0.25% Bupivacaine prior to making any surgical incisions.
223784947|NCT04733560|PROCEDURE|Sham Pudendal nerve block|Vaginally administered pudendal nerve block of 10ml Normal Saline prior to making any surgical incisions.
223784948|NCT04733560|DRUG|Bupivacaine Injectable Product|Used for pudendal nerve block in the intervention arm
223784949|NCT02633384|OTHER|SMOFlipid|Exclusive total parenteral nutrition using a new generation intravenous lipid emulsion composed of 30% LCT n-6 (soybean oil), 30% MCT (coconut oil), 25% monounsaturated fatty acids (olive oil), 15% LCT n-3 (fish oil) and α-tocopherol
223784950|NCT02633384|OTHER|Lipofundin|Exclusive total parenteral nutrition using a current intravenous lipid emulsion composed of 50% LCT (soybean oil) and 50% MCT (coconut oil)
223784951|NCT05970393|PROCEDURE|pressure support level tatrition|Baseline ventilators were set by the principle of keeping VT/PBW at 6-8ml/kg and RR at 20-30 breaths/min and the decision of the responsible ICU physician. After then the fraction of inspired oxygen (FiO2), positive expiratory end pressure (PEEP), trigger sensitivity, and cycle-off criteria remain unchanged. Upward and downward PS level adjustments were performed from the baseline PS level at a 1cm H2O interval. Every PS level was maintained for 20 minutes and then three end-inspiratory holdings (2-3seconds) and three end-expiratory holdings were performed. PMI mean value was measured and calculated at every PS level. To avoid additional injury to the lung and diaphragm, the airway peak pressure (Ppeak) was limited to 30cmH2O, and titrating PS was stopped until PMI was less than -1cmH2O and more than 3cmH2O.The inspiratory effort is measured as the pressure generated by inspiratory muscles using esophageal pressure monitoring.
223784952|NCT03640910|DEVICE|OT Equators® (Rhein83)|Attachment systems to retain an implant overdenture
223784953|NCT03640910|DEVICE|Locator® (Zest)|Attachment systems to retain an implant overdenture
223784954|NCT01283269|BEHAVIORAL|Memory Support System|Training in use of a memory notebook system
223784955|NCT01283269|BEHAVIORAL|Computer Training|Computer brain fitness training
223784956|NCT06066112|DRUG|Drug: Test (T) Amisulpride orally disintegrating tablets (200mg). Produced and supplied by Zezheng (Shanghai) Biotechnology Co., Ltd.|Randomly assign to TR or RT sequence groups based on a predetermined random table and receive the corresponding study drug according to the corresponding administration sequence.
223784957|NCT00518947|DRUG|Lithium|Treatment with lithium carbonate was initiated at a dose of 900-1200 mg/day. Serum lithium levels were monitored twice weekly, and the dose was adjusted to attain target levels between 0.8 and 1.0 mmol/L by the end of week one, with subsequent levels as high as 1.4 mmol/L permitted if needed.
223784958|NCT00518947|DRUG|verapamil|The initial dose of verapamil was 80 mg b.i.d., and this was raised by 80 mg/day every three days to a maximum of 480 mg/day, unless intolerable side effects were produced at a lower level, in which case the dose was maintained at the highest tolerated amount.
223784959|NCT00518947|DRUG|verapamil plus lithium|
223784960|NCT02962830|DRUG|Sufentanil|intra-amniotic injection of 10 micrograms of Sufentanil
223784961|NCT02992639|BEHAVIORAL|Control group|The participants who included in control group did not receive any treatment.
223784962|NCT02992639|BEHAVIORAL|Weight loss group|The participants who included in weight loss group followed a 12-week weight loss program consisting of a 300 kcal/day reduction of thier usual caloric intakes
223784963|NCT03359096|DEVICE|Therapeutic HGNS|Prior to enrollment in this study, the HGNS will have been implanted as part of clinical care, and a therapeutic voltage setting will have been determined via overnight sleep study The pulse generator, using technology from cardiac pacemakers, utilizes the signal from the pressure sensor for timing of stimulation to the tongue nerve. Patient will undergo activation of the implanted device one month post-operatively. A functional threshold (in volts) is obtained based on tongue motion during device stimulation. For the next month, the patient will have steadily increased stimulation strength by 0.1V every 2-3 nights within the preset range until the upper limit is reached.
223784964|NCT03359096|DEVICE|Subtherapeutic 'Sham' HGNS|"Sham threshold determination will be performed as follows. The patient will be in a reclined position with the mouth open while nasal breathing. Stimulation will be increased from 0.1V up by 0.1V until bulk tongue motion is detected without obvious protrusion. This process is repeated twice and the average value is used to determine sham-HGNS. The electrode configuration will remain consistent between the patient's therapeutic and sham thresholds"
223784965|NCT04937374|OTHER|Rehmannia glutinosa leaf extract|One capsule to be taken after breakfast.
223784966|NCT04937374|OTHER|Microcrystalline Cellulose (MCC)|One capsule to be taken after breakfast.
223784967|NCT06312839|OTHER|Collecting data from the medical record|"Collecting data from the medical record:~* Gastroepiploic artery diameter before and after ischaemic preconditioning~* Postoperative mortality~* Complications related to embolisation and surgery~* Length of stay in intensive care unit and total length of hospital stay"
223784968|NCT02287103|OTHER|Skipping Breakfast|NoB: The patients will omit the breakfast, will continue the overnight fast until lunch, then will eat only lunch and dinner.
223784969|NCT02287103|OTHER|Eating Breakfast|YesB: will eat all three meals
223784970|NCT06529497|DRUG|Racecadotril|The intervention group will receive racecadotril+ORS+Zinc
223784971|NCT01176253|PROCEDURE|Blood draw|Blood draw for Type I DM patients will be taken every 4 weeks for 1 year post diagnosis/healthy volunteers will have 1 blood draw
223784972|NCT03020420|OTHER|Cicatricell Cream|Cream to be applied 2 times a day for 8weeks to 6 months
223784973|NCT00133289|DEVICE|Pacemaker with Automatic Capture|
223784974|NCT03520634|OTHER|PD-L1 PET imaging|PD-L1 PET imaging
223784975|NCT04357028|DRUG|Measles-Mumps-Rubella Vaccine|Measles mumps Rubella vaccine is a weak attenuated life vaccine
223784976|NCT04357028|DRUG|Placebos|0.5 ml subcutaneous of saline will be injected in posterior triceps aspect of upper arm
223784977|NCT04671862|DEVICE|Photobiomodulation|"Parameters: combined 633nm and 870 nm @1000mW~* 1 Treatment 4J continuous prior to RT. (Within 14 days of RT start)~* 3 treatments weekly during RT (6 J at 12 Hz, 80% duty cycle)"
223784978|NCT00177229|BEHAVIORAL|Family-based treatment|20 weekly group contacts with individual coaching over first 6 months, brief monthly contacts over next 6 months, no contacts over last 6 months. Medical monitoring throughout study period.
223784979|NCT06389812|OTHER|Dual-task exercise traning|To assess the dynamic effects of each intervention, only one session (30 mins) will be provided. The chair-based exercise session consists of three parts 5 min of active stretching exercises to warm-up, 20 mins of resistance band exercises in a sitting position (Elliott-King et al., 2019) (please see the link for detailed descriptions for seated resistance band workout) and 5 min of passive stretching exercises to cold down. The motor-cognitive dual-task group will be additionally asked to do horizontal eye movements by watching a TV screen and following a duck moving from side to side (bilateral condition) while performing strengthening exercises. The duck moves successively between left and right banks of a river at a rate of 500 ms (Brunyé et al., 2009) which was previously found to improve cognitive function
223784980|NCT01944046|DRUG|Double blind phase Placebo Nasal Spray|This nasal spray will contain all of the ingredients that are in the active oxytocin spray in the same quantities, except oxytocin will NOT be added to the solution. It will be packaged using the same container system as the active oxytocin nasal spray. Each bottle's label will have its own unique nonsequential randomly assigned number and not a lot number to facilitate masking. Dose titration will occur using exactly the same criteria and procedures as for active study drug.
223784981|NCT01944046|DRUG|double Blind Oxytocin Nasal Spray|Each insufflation will deliver 8 IU or 24 IU of oxytocin. A maximum of 3 insufflations at a time will be required. Dosing will be flexible between 8 IU/day and 80 IU/day, typically in two divided doses delivered in the morning and in the afternoon. Doses will typically increase by 8 IU twice daily (BID) at week 2 and weeks 4 and 8 until achieving the target dose of 24 IU BID at week 8. Subsequently doses may be increased in 8 IU BID increments ONLY at each visit until a maximum dose of 40 IU BID is achieved.Each bottle's label will have its own unique nonsequential randomly assigned number and not a lot number to facilitate masking. During the open label phase after approximately March 2019 the study used only the 24 IU /0.10 ml formulation and the maximum dose was 72 IU per day.
223784982|NCT01944046|DRUG|Open Label intranasal oxytocin|All participants who completed the 24 week double blind phase were eligible to join a 24 week open label phase in which all participants received intranasal oxytocin
223784983|NCT05392634|DRUG|Meropenem 1000 mg|Group B: prolonged antibiotic prophylaxis \>72 hours (5 days) from the moment of the skin incision in accordance with the selected clinic drug + correction of the appointment based on clinical events after 5 days.
223784984|NCT05392634|DRUG|Amoxicillin+clavulanic acid 1200 mg or Cefuroksim 1500mg|Group A: antibiotic prophylaxis within 24 hours from the moment of skin incision according to local clinical practice;
223784985|NCT00246636|DRUG|Antara (fenofibrate) + Lovaza|Antara (fenofibrate) + Lovaza (omega-3-acid ethyl esters) \[formerly known as Omacor\]
223784986|NCT00246636|DRUG|Antara (fenofibrate)|Antara (fenofibrate) + placebo
223784987|NCT02107521|OTHER|Intracytoplasmic morphologically selected sperm injection|Sperm selection for injection will be performed at 6600x magnification
223784988|NCT02107521|OTHER|Intracytoplasmic sperm injection|sperm selection for injection will be performed under 400x magnification
223784989|NCT04276545|DRUG|IV administration of DEX to investigate the effects for functional nasal endoscopic surgery|IV administration of a single loading dose DEX (0.5μg/kg) after induction within 10 minutes.
223784990|NCT04276545|DRUG|IV administration of Midazolam to investigate the effects for functional nasal endoscopic surgery|IV administration of midazolam (0.05mg/kg) after induction.
223784991|NCT02093299|DRUG|Clopidogrel|a blood sample is drawn on all patients to determine responder status
223784992|NCT04618354|OTHER|No interventions|This clinical study is a retrospective study, and no interventions have been implemented for patients.
223784993|NCT02976766|DRUG|Gypenosides|Participants will receive gypenosides 360 mg/day (120 mg three times a day) for 10 days.
223784994|NCT02976766|DRUG|Placebo|Participants will receive placebo three times a day for 10 days.
223784995|NCT02958436|DRUG|REGN3500|
223784996|NCT02958436|DRUG|Placebo|
223784997|NCT01788683|PROCEDURE|Regenexx SD|stem cell treatment
223784998|NCT01788683|OTHER|Exercise Therapy|exercise therapy control
223784999|NCT05212974|OTHER|Questionnaires|The questionnaires include demographic data and vaccine hesitancy questions in a total of 35 items.
223785000|NCT06528119|OTHER|COVID 19 pandemic|Physiological indicators such as blood pressure, heart rate, respiratory rate, and consciousness status of COVID-19 patients are used to apply the START, MEWS, and qSOFA in COVID-19 patients.(COVID 19 病患).
223785001|NCT01485510|BEHAVIORAL|GIFT|An attachment-based assessment, then a tailored intervention aimed at maximising the chances of a maltreated child returning to the birth family.
223785002|NCT01485510|BEHAVIORAL|FACS|A social work assessment of family functioning that makes recommendations regarding future placement of a maltreated child.
223785003|NCT01761747|DRUG|ponatinib|
223785004|NCT01228162|PROCEDURE|effect of muscle relaxation on muscle trauma, control group without relaxation|effect of muscle relaxation on muscle trauma, control group without relaxation
223785005|NCT02635477|BEHAVIORAL|Intervention|Behavioral: actigraphy device, adaptive step count algorithm
223785006|NCT02635477|BEHAVIORAL|Control|Behavioral: actigraphy device, step count measurement only
223785007|NCT02007577|DRUG|salsalate|Participants will take 3, 500 mg tablets with breakfast and 4, 500 mg tablets with dinner
223785008|NCT02007577|DRUG|Placebo|Participants will take 3 tablets with breakfast and 4 tablets with dinner
223785009|NCT04595708|BEHAVIORAL|Phone Call|Calls were made by volunteers trained to engage with participants. Call structure was unscripted and call length was recommended to be between 5-10 min.
223785010|NCT02504294|BIOLOGICAL|Epoetin Hospira Arm|Epoetin Hospira Arm: Epoetin Hospira will be administered intravenously (IV) per the analogous version of the Fresenius Medical Care North America (FMCNA) cMAB 1 (inclusive of version 1.0, 1.1,...)erythropoietin stimulating agents (ESA) dosing algorithm for Epoetin Hospira for 24 weeks. Subjects will have Epoetin Hospira initiated using the same ESA dose level and frequency of administration for Epogen prior to randomization into the trial. Subjects will also receive IV iron per the FMCNA protocol that is standard of care at FMCNA clinics.
223785011|NCT02504294|OTHER|Standard of Care Arm|Standard of care arm: No interventions will be performed in this arm for the clinical study; and subjects will receive ongoing standard of care, which includes Epogen administered IV per the FMCNA cMAB 5 (inclusive of versions 5.0, 5.1,....) ESA dosing algorithm and IV iron per the FMCNA protocol that is standard of care, at FMCNA clinics during the contemporaneous 24 week period.
223785012|NCT02504294|DRUG|IV Iron|Subjects will also receive IV iron per the FMCNA protocol that is standard of care at FMCNA clinics.
223785013|NCT02504632|OTHER|test|"Peripheral venous citrated blood will be collected just before and 10-15 min after the implantation of the valve. Samples will be obtained after starting the infusion of contrast media. In peripheral venous blood before 24 h and after the procedure and at hospital discharge, 4-6 days when the usual transient thrombocytopenia after TAVI has recovered.~The results will be used to analyse the kinetics of haematological changes in peripheral blood following aortic valve replacement.~Platelet activation will be monitored by flow cytometry to assess the expression of specific membrane markers and the phosphorylation of signalling proteins, as well as the formation of platelet/monocyte aggregates."
223785014|NCT02504632|OTHER|control group|In this group, only one sample (2 tubes filled with 4.5 ml, i.e. 9ml) will be obtained in venous peripheral blood to establish reference values in age-matched, aspirin-treated, atherosclerotic population.
223785015|NCT05255016|COMBINATION_PRODUCT|PXL Platinum 330 system + Riboflavin 0.25% TE Solution|"Standard-of-care therapy (antifungal drops or fortified antibiotics and empiric antibiotic drops). In addition CXL + Riboflavin 0.25% TE solution.~After topical anesthesia, the surgeon or trained designee will apply topical riboflavin (1 drop every 2 min for 40 min with PESCHKE TE solution \[0.25%\], or longer as needed to assure adequate corneal penetration). At the end of this pre-treatment period, the eye will be examined at the slit lamp with the blue filter for the presence of riboflavin throughout the stroma. When sufficient corneal riboflavin penetration is confirmed, the eye will be aligned under the PXL Platinum 330 light. The correct aperture setting (3 to 12 mm) will be selected for the size of the eye and area needing to be treated (2 mm larger than the maximal ulcer diameter), and the eye will be irradiated at 18 mW/cm2, with pulsed mode (5 seconds on, 5 seconds off) for 10 min, during which time instillation of riboflavin will continue (1 drop every 2 min)."
223785016|NCT05255016|OTHER|Sham CXL + Artificial Tears|Standard-of-care therapy (antifungal drops or fortified antibiotics and empiric antibiotic drops). In addition, for subjects in the sham group, artificial tears (1 drop every 2 min for 40 min) will be administered. after instillation of artificial tears, the eye will be aligned under the PXL Platinum 330 light. The instrument will be kept off and the subject will be kept under the device for 10 min during which time instillation of artificial tears will be performed (1 drop every 2 min) to maintain corneal hydration. The operator will keep track of sham exposure time independently to confirm the actual duration.
223785017|NCT00003289|DRUG|7-hydroxystaurosporine|
223785018|NCT02352064|PROCEDURE|PET (18-FDG)|Every patient will have a PET
223785019|NCT04423068|BEHAVIORAL|SexHealth II|SexHealth II is an intervention that will focus exclusively on provision of hormonal contraception counseling and provision for hospitalized female adolescents
223785020|NCT04423068|DRUG|Contraceptive|"The investigators will offer initiation of the following contraceptives:~Ethinyl Estradiol and Etonogestrel 0.015mg-0.12mg vaginal ring (Nuva Ring) Etonogestrel 68mg subcutaneous implant (Nexplanon) Medroxyprogesterone 150mg/ml 150 mg IM injection Ethinyl Estradiol and Norgestimate (Sprintec) 35mcg-0.25mg tablet Norelgestromin/Ethinyl estradiol transdermal patch (Ortho Evra) Norethindrone 0.35mg tablet~Emergency Contraception:~Ulipristal 30 mg tablet Levonorgestrel 1.5mg tablet"
223785021|NCT01953926|DRUG|Neratinib|240 mg administered orally, once daily with food, continuously in 28 day cycles
223785022|NCT01953926|DRUG|Fulvestrant|500 mg administered as two 5 mL injections on Days 1, 15, and 29; then once every 4 weeks thereafter month, then Day 1 of every 4 week cycle
223785023|NCT01953926|DRUG|Trastuzumab|Initial dose of 8 mg/kg of trastuzumab administered IV on Day 1, followed by 6 mg/kg IV once every 3 weeks thereafter
223785024|NCT01953926|DRUG|Paclitaxel|80mg/m\^2 administered IV on Days 1, 8, and 15 of every 4 week cycle
223785025|NCT01153646|GENETIC|pHIV7-shI-TAR-CCR5RZ treated CD4 cells|Single dose administration x 3 of genetically modified T-cells given at 3 infusions at 6 week intervals.
223785026|NCT01142557|DRUG|Interferon beta-1a (Rebif)|A dosage of 44 µg or 22 µg interferon beta-1a (Rebif) as subcutaneous self-injection three times a week was recommended for therapy of the included, suitable MS subjects after a creep-in phase of 4 weeks.
223785027|NCT06533982|OTHER|High intensity interval exercise session|Physical activity session supervised and adapted on ergometer
223785028|NCT06533982|OTHER|Isometric neuromuscular exercise session|Physical activity session supervised and adapted with a handgrip
223785029|NCT04686448|DRUG|propofol-ketamine|patients will receive IV ketofol (0.5 mg/kg ketamine and 1 mg/kg propofol) as bolus injection over 5 minutes in the same syringe then infusion of 0.05 mg/kg/min propofol increased or decreased rate of infusion according to achieve sedation response by modified Ramasy sedation score of ≤ 4
223785030|NCT04686448|DRUG|propofol-fentanyl|patients will receive IV fenofol (1 µg/kg fentanyl and 1 mg/kg propofol) as bolus injection over 5 minutes in the same syringe then infusion of 0.05 mg/kg/min propofol increased or decreased rate of infusion according to achieve sedation response by modified Ramasy sedation score of ≤ 4
223785031|NCT06532838|PROCEDURE|Optimized treatment strategies|The optimized strategies based on 6-hour threshold from symptom onset. For malperfused patients with symptom onset within 6 hours, central repair will be performed immediately. Additional stenting will be used in patients with persistent malperfusion. For malperfused patients with symptom onset beyond 6 hours, individualized delayed central repair according to the different types of MPS will be performed after organ function improved and the patient could tolerate central repair.
223785032|NCT06532838|PROCEDURE|Traditional treatment strategies|Immediate central repair will be performed for patients with coronary and cerebral malperfusion syndrome. However, for patients with mesenteric and lower extremity malperfusion syndrome, interventional therapy will be administered through fenestration and/or stenting to ﬁrst alleviate organ ischemia. Once the patients had a resolution of organ failure, corrective open aortic repair will be performed.
223785033|NCT05850533|BEHAVIORAL|Virtual Tai Chi Easy|Unique to other mind-body therapies, Tai Chi Easy (TCE) is multi-component mind-body therapy including: 1) Gentle movement, 2) Breath practice, 3) Self-massage, and 4) Meditation.
223785034|NCT02081651|DIETARY_SUPPLEMENT|Parmigiano Reggiano cheese|
223785035|NCT02338362|DRUG|Fluticasone propionate inhaler|fluticasone propionate 250 µg metered-dose inhaler
223785036|NCT02338362|DRUG|Saline placebo inhaler|saline metered dose inhaler
223785037|NCT05588089|OTHER|Training group|"For the experimental group, Personal Information Form for Fathers and Infant Care Questionnaire were applied to the fathers in the clinic after birth as a pre-test. In the clinic, baby care training was given to fathers practically in 30-35 minutes. After the applied training, the Baby Care Training Program Content prepared by the researchers was given to the fathers."
223785038|NCT02426632|DRUG|Formulation A|Reference formulation, 10 milligram/milliliter (mg/mL)oral solution without sweetener/flavor.
223785039|NCT02426632|DRUG|Formulation B|10 mg/mL oral solution containing 2 mg/mL sucralose, masking flavor and orange flavor.
223785040|NCT02426632|DRUG|Formulation C|10 mg/mL oral solution containing 10 mg/mL sucralose.
223785041|NCT02426632|DRUG|Formulation D|10 mg/mL oral solution containing 2 mg/mL sucralose and raspberry flavor.
223785042|NCT02426632|DRUG|Formulation E|10 mg/mL oral solution containing 2 mg/mL sucralose and strawberry flavor.
223785043|NCT02426632|DRUG|Formulation F|10 mg/mL oral solution containing 2 mg/mL sucralose and orange flavor.
223785044|NCT02426632|DRUG|Formulation M1|Best scoring formulation from Session 1 with a varying concentration of sucralose (maximum 10 mg/mL).
223785045|NCT02426632|DRUG|Formulation M2|Best scoring formulation from Session 1 with a varying concentration of sucralose (maximum 10 mg/mL).
223785046|NCT02426632|DRUG|Formulation M3|Best scoring formulation from Session 1 with a varying concentration of sucralose (maximum 10 mg/mL).
223785047|NCT02426632|DRUG|Formulation N1|Second best scoring formulation from Session 1 with a varying concentration of sucralose (maximum 10 mg/mL).
223785048|NCT02426632|DRUG|Formulation N2|Second best scoring formulation from Session 1 with a varying concentration of sucralose (maximum 10 mg/mL).
223785049|NCT02426632|DRUG|Formulation N3|Second best scoring formulation from Session 1 with a varying concentration of sucralose (maximum 10 mg/mL).
223835381|NCT01153256|DRUG|magnesium sulphate|The patients of group M receive 50 mg/kg of magnesium sulphate in 100 ml of isotonic saline over 10 min immediately before anaesthesia induction. After induction of anesthesia with alfentanil (10 μg/kg) and propofol (2 mg/kg), rocuronium 0.6 mg/kg is given over 5 s in a running infusion.
223785050|NCT04448184|DRUG|Tranexamic Acid|"Patients allocated to the prophylactic Tranexamic Acid group will receive a standardized routine oral or intravenous dose of Tranexamic Acid 1 gram three times daily.~Tranexamic Acid will start when Platelet count is less than 50 x 109/L and continue until platelet engraftment. Patients in this group will not receive routine prophylactic platelet transfusions. Subjects unable to swallow oral Tranexamic Acid pills may have the tablets crushed, administered via nasogastric (NG) tube or the medication will be administered intravenously."
223785051|NCT03111498|OTHER|practice-based training programme (one-to-one teaching)|practice-based training programme (one-to-one teaching) for conducting VAD
223785052|NCT03111498|OTHER|theory-based training programme|theory-based training programme for conducting VAD
223785053|NCT04757012|DEVICE|calinange|calinange
223785054|NCT01469689|OTHER|Google Adwords|The investigators will display Google Adwords advertising the investigators' website offering online help for depression
223785055|NCT01469689|OTHER|Local organisation websites|The investigators will place adverts on local organization websites with links to the investigators' project website offering online help for depression
223785056|NCT01012882|BIOLOGICAL|sublingual immunotherapy with allergen extract|sublingual application
223785057|NCT01012882|BIOLOGICAL|sublingual immunotherapy with placebo|sublingual application
223785058|NCT02341300|DEVICE|Cast Iron Pot|Cast iron pot
223785059|NCT02341300|DEVICE|Alumnium Pot|Aluminum Skillet
223785060|NCT01028209|DRUG|[18F] PBR06|Subjects will be injected with 5mCi, not to exceed \>10% of 5mCI, of \[18F\]PBR06, followed by PET imaging.
223785061|NCT03144557|OTHER|Education|Education protocol included 4 individual sessions of verbal and graphic instructions to correct inhalation technique in patients with COPD
223785062|NCT01693432|DRUG|DS (docetaxel+S-1)|"Treatment will be delivered as a 3-week cycle.~1. Docetaxel 60 mg/m²IV on day 1~2. S-1 80 mg/m2/day PO on day 1-14"
223785063|NCT02981394|PROCEDURE|Bone Marrow Aspirate Concentrate Injection|BMAC will be collected in the outpatient setting with local anesthesia. The collection site will be the Posterior Superior Iliac Spine (PSIS). This will be visualized under ultrasound prior to collection. Local anesthesia with 1% lidocaine will be performed prior to the harvest. BMAC harvest will be performed using the Arthrex Angel BMAC System using the Arthrex collection protocol. The Arthrex Angel machine will be used to separate BMAC contents for injection based on Arthrex collection protocol. Machine settings, volume of collection and volume of output have not been standardized and will be based upon harvest and the condition treated. These will be variables recorded for consideration of optimal settings based on the patient-reported outcomes.
223785064|NCT04318340|OTHER|Tapered applicator|An applicator inserted in 2 steps that tapers at the distal vagina
223785065|NCT04318340|OTHER|Standard applicator|A 2.6 cm standard applicator is inserted and sized up to a standard 3 cm applicator if tolerable.
223785066|NCT06465849|PROCEDURE|Dentin Etching time for 5 seconds|Composite resin restorations of non-carious cervical lesions will be performed with an adhesive on dentin etched for 5 seconds in the etch-and-rinse application strategy.
223785067|NCT06465849|DEVICE|Scotchbond Universal Plus; 3M|Composite resin restorations of non-carious cervical lesions will be performed with an universal adhesive (Scotchbond Universal Plus; 3M).
223785068|NCT06465849|DEVICE|Gluma Universal Bond; Kulzer|Composite resin restorations of non-carious cervical lesions will be performed with an universal adhesive (Gluma Universal Bond; Kulzer).
223785069|NCT06465849|PROCEDURE|Dentin Etching time for 15 seconds|Composite resin restorations of non-carious cervical lesions will be performed with an adhesive on dentin etched for 15 seconds in the etch-and-rinse application strategy.
223785070|NCT00906672|DEVICE|INTEGRA®|A plaque of dermal substitute Integra® is adjusted to the size of the wound and sutured. A negative pressure bandage is placed on the wound. 7 to 11 days post surgery, the Integra® silicone layer is removed and the neoderm is covered with a skin graft.
223785071|NCT00906672|PROCEDURE|Flap technique|A flap is a part of skin, cutaneous tissue or muscle that is taken from an healthy area of the body and put on the damaged area for coverage.
223835382|NCT01153256|DRUG|normal saline|Patients in the group R-0.6 receive the same volume of isotonic saline over the same period, and rocuronium 0.6 mg/kg is given after the induction of anesthesia with alfentanil (10 μg/kg) and propofol (2 mg/kg).
223785072|NCT04396951|DEVICE|Active external overheating with heating plate, Aragonia ® MTC 400|It is a heating device that is adjustable in height up to 50 cm from the patient and generates radiant heat at low temperature (up to 39 ◦C) distributed evenly. It is equipped with an adjustable 0-9 potentiometer and has a skin temperature probe as a control and safety mechanism Measure during 6 hours with indirect calorimetry in first week
223785073|NCT04396951|DEVICE|Active external overheating with air blanket, Equator Level 1® de Smiths Medical|Composed of a unit that produces hot air and forced air adjustable from 38ºC to 43ºC. Sends hot forced air distributed by tubular blanket that convectively heats the patient by diffusing hot air directed at the patient through the textile pore of the air blanket Measure during 6 hours with indirect calorimetry in first week
223785074|NCT00680316|DRUG|Dornase alfa|2.5 mL (2.5 mg) dornase alfa nebulized once daily for 16 (+/-2) days
223785075|NCT00680316|DRUG|Placebo|2.5 mL (2.5 mg) placebo nebulized once daily for 16 (+/-2) days
223785076|NCT00167544|DRUG|Hydrocortisone|Hydrocortisone 3 mg/kg/d divided q 12h IV/PO tapered over 7 days
223785077|NCT00167544|DRUG|Placebo|Saline
223785078|NCT03305679|PROCEDURE|Direct provisional technique|The method of implantation will be accomplished directly.
223785079|NCT03305679|PROCEDURE|Indirect Provisional technique|The method of implantation will be accomplished indirectly.
223785080|NCT04069975|OTHER|Sedation|The group of patients who did endoscopies with or without sedation. (This is a choice of themselves)
223785081|NCT03585244|OTHER|weekly weight|weekly weight data collection for six months
223785082|NCT01138332|GENETIC|western blotting|
223785083|NCT01138332|OTHER|laboratory biomarker analysis|
223785084|NCT01904812|OTHER|Questionnaire about quality of life and satisfaction|
223785085|NCT03408912|DIAGNOSTIC_TEST|FFR|FFR from CMR compared to invasive FFR
223785086|NCT04153266|OTHER|No intervention is planned for this study|No intervention was/is planned for this study. The study is questionnaire-based (observational).
223785087|NCT02580097|OTHER|MRI|MRI perfusion imaging, including contrast bolus perfusion imaging and arterial spin labeling.
223785088|NCT00388687|DRUG|18F Fluoroazomycin Arabinoside (FAZA)|
223785089|NCT02388633|PROCEDURE|Plasmapharesis|Clinically-indicated LDL apheresis
223785090|NCT01704339|DRUG|QUTENZA|Single treatment with topical capsaicin 8%
223785091|NCT04144673|OTHER|Silver Hydrosol|Silver quantity will be 7 doses per day, with 50 mcg per dose.
223785092|NCT04144673|OTHER|Placebo|Placebo water with no active ingredients
223785093|NCT05847777|RADIATION|CBCT|cone beam computer tomography
223785094|NCT03790891|BIOLOGICAL|CD19-TriCAR-T/SILK|A conditioning chemotherapy regimen of fludarabine and cyclophosphamide may be administered, followed by a single infusion of CD19-TriCAR-T cells or 4 repeat infusions of CD19-TriCAR-SILK cells.
223785095|NCT06534203|OTHER|Investigation - Observational Study|In this study, there will be no intervention, instead, it will be an observational study aimed at identifying the specific physical demands of caregivers working in long-term care facilities. This information will inform future interventions that can help reduce the occurrence of work-related musculoskeletal injuries.
223785096|NCT04827004|DRUG|Anlotinib Hydrochloride Capsules|Anlotinib capsules given orally, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21).
223785097|NCT04993326|BEHAVIORAL|emPOWERed To Change Program|Online Diabetes Self-Management Education and Support along with COVID-19 prevention and protection (vaccination) education and resource information
223785098|NCT00259051|DRUG|Omeprazole|
223785099|NCT06281548|BEHAVIORAL|RESTART|Project RESTART (Resisting STigma And Revaluating your Thoughts) is a theory-informed, 4-week automated text message intervention to address self-stigma in people who use drugs. The intervention delivers two daily messages to participants for four weeks (56 messages total). Messages address the four components of the personal level of Stigma Resistance Theory: Not believing stigma/catching and challenging stigmatizing thoughts; empowering oneself through learning about substance use and one's own recovery; maintaining one's recovery and proving stigma wrong; and developing a meaningful identity and purpose apart from one's substance use. Content is informed by evidence-based psychotherapeutic approaches (e.g., Acceptance and Commitment Therapy) and health communication theory (e.g., Elaboration Likelihood Model). Messages include psychoeducation about substance use and stigma, coping advice, and suggestions for how to set personal goals, identify values, and build self-esteem.
223785100|NCT02369029|DRUG|BAY 1238097|Oral administration twice weekly. Starting dose will be 10 mg per week and dose will be escalated dependent on any dose limiting toxicities.
223785101|NCT02461121|GENETIC|HLA mismatched stem cell|HLA mismatched donor G-CSF mobilized peripheral stem cell infused 24 hours (day 0) after the completion of chemotherapy
223785102|NCT02461121|GENETIC|HLA matched stem cell|HLA matched donor G-CSF mobilized peripheral stem cell infused after the conditioning reginmen
223785103|NCT02461121|DRUG|cyclosporine A|The GVHD prophylaxis included cyclosporine A and mycophenolate mofetil
223785104|NCT02461121|DRUG|Mycophenolate mofetil|The GVHD prophylaxis included cyclosporine A and mycophenolate mofetil
223785105|NCT02461121|DRUG|Ara-C|2.0 to 3.0g/m2 per 12 hours intravenously for 6 dose
223785106|NCT02461121|DRUG|fludarabine|30 mg/m2/d for 5days
223785107|NCT02461121|DRUG|anti-lymphocyte globulin|1.5-2 mg/kg/d for 4 days
223785108|NCT02461121|DRUG|cyclophosphamide|40 mg/kg/d for 2 days
223785109|NCT01038908|OTHER|Isosulfan Blue (Patent Blue Dye V)|"1. Inject radioactive isotope and scan for sentinel node (SLN) using gamma probe~2. Pre-incision: SLN is identified~3. Inject blue dye into patient's arm~4. Complete procedure (SLNB and/or ALND)"
223785110|NCT01038908|OTHER|Isosulfan Blue (Patent Blue Dye V)|"1. Inject radioactive isotope and scan for sentinel node (SLN) using gamma probe~2. Pre-incision: SLN is not identified (No localization)~3. Inject blue dye into breast (nothing in arm)~i. No localization: Inject blue dye into arm and perform ALND ii. Localization: Complete procedure (SLNB and/or ALND)"
223785111|NCT03140436|DRUG|sodium bicarbonate powders with grain size 65 µm|sodium bicarbonate powders with grain size 65 µm
223785112|NCT03140436|DRUG|sodium bicarbonate powders with grain size 40 µm|sodium bicarbonate powders with grain size 40 µm
223785113|NCT02525107|DIETARY_SUPPLEMENT|Omega-3 capsules|SCD patients on Hydroxyurea
223785114|NCT02525107|DIETARY_SUPPLEMENT|Placebo|SCD patients on Hydroxyurea
223785115|NCT02525107|DIETARY_SUPPLEMENT|Omega-3 capsules|SCD patients not on Hydroxyurea
223785116|NCT02525107|DIETARY_SUPPLEMENT|Placebo|SCD patients not on Hydroxyurea
223785117|NCT04300738|DEVICE|CCS wit CT Scann measurement|Measurement with 2 devices
223785118|NCT05493553|DIETARY_SUPPLEMENT|Dietary supplement regimen|"The powdered, soluble fiber-based supplement contains soluble fibers, phytosterols, plant-derived polysaccharides, flavor, maltodextrin, orange juice powder, citric acid, vitamin and mineral blend, and sweetener. This is prepared in water and consumed twice per day, prior to a meal.~The yerba mate-based supplement (containing green yerba mate leaf extract, sweeteners, and flavor) is a powdered supplement prepared in water and consumed in the morning."
223785119|NCT05493553|OTHER|Dietary supplement and intermittent fasting regimen|The dietary supplement regimen is the same as in Phase 1. The intermittent fasting protocol consists of a 16-hour fasting period and an 8-hour eating window.
223785120|NCT01958151|OTHER|State-Trait Anxiety Inventory Scores|Patients are evaluated before the procedure with State-Trait Anxiety Inventory scores to determine the anxiety level.
223785121|NCT02830594|RADIATION|External Beam Radiation Therapy|Undergo palliative external beam radiation therapy
223785122|NCT02830594|OTHER|Laboratory Biomarker Analysis|Correlative studies
223785123|NCT02830594|BIOLOGICAL|Pembrolizumab|Given IV
223785124|NCT00733265|DRUG|AZD6140|single oral dose
223785125|NCT05655793|DIAGNOSTIC_TEST|Tear Fluid collection (Schirmer's strip)|Tear fluid will be collected non-invasively form all participants with the use of Schirmer's strips, which is a small paper strip placed in the lower eye lid for a maximum of 5 minutes.
223785126|NCT05655793|DIAGNOSTIC_TEST|Retinal imaging|The retina from all participants will be visualised with the use of a standard (Clarus 700 Zeiss), ultra-wide field (Optos), and cross-sectional (Optical Coherence Tomography) retinal images.
223785127|NCT01476215|DRUG|Paracetamol fast dissolution suspension|
223785128|NCT01476215|DRUG|Paracetamol medium dissolution suspension|
223785129|NCT01476215|DRUG|Paracetamol slow dissolution suspension|
223785130|NCT01476215|DRUG|Paracetamol|
223785131|NCT05408494|BEHAVIORAL|Gamified behavioral weight loss treatment|12-month mHealth fully-gamified version of the same program, comprised of a behavior change program with digital reinforcers for attainment of streaks and milestones, and an integrated neurotraining video game
223785132|NCT05408494|BEHAVIORAL|mHealth behavioral weight loss treatment|a 12-month mHealth weight loss program that includes digital self-monitoring, simplified and self-selected dietary targets, physical activity and a control (sham) non-game neurotraining
223785133|NCT02167828|BEHAVIORAL|Social Support|
223785134|NCT03538626|BIOLOGICAL|VRC-HIVMAB091-00-AB|N6LS (VRC-HIVMAB091-00-AB) is a human monoclonal antibody targeted to the HIV-1 CD4 binding site.
223785135|NCT03538626|BIOLOGICAL|rHuPH20|Recombinant human hyaluronidase PH20 (rHuPH20) is the active ingredient of the investigational ENHANZE™ Drug Product (EDP). EDP is a purified preparation of rHuPH20.
223785136|NCT00652665|DRUG|Leflunomide|Tablets, 20mg, single-dose
223785137|NCT00652665|DRUG|ARAVA|Tablets, 20mg,single-dose
223785138|NCT00288587|DRUG|IV loop diuretic|Use of conventional diuretic therapy upon hospital admission for treatment of decompensated heart failure.
223785139|NCT00288587|DEVICE|NxStage System One|Patients treated with Extracorporeal Ultrafiltration upon hospital admission for treatment of decompensated heart failure.
223785140|NCT01156701|DRUG|Receiving a prescription of Relenza for prophylaxis|Receiving a prescription of Relenza for prophylaxis
223785141|NCT01156701|OTHER|No prophylaxis with Relenza|No prophylaxis with Relenza
223785142|NCT01434602|DRUG|everolimus|Patients will be treated with daily everolimus (days 1-28) in combination with sorafenib; There is not a defined set maximum number of cycles that a patient may have; Phase I Dose Escalation: 5mg to 10mg daily.
223785143|NCT01434602|DRUG|sorafenib|Patients will be treated with sorafenib in combination with everolimus (days 1-28); There is not a defined set maximum number of cycles that a patient may have; Phase I Dose Escalation 400mg-600mg twice a day (bid) or 400mg-800mg twice a day, 7 days on and 7 days off.
223785144|NCT05960500|PROCEDURE|implant|All on six versus parallel implant distribution
223785145|NCT00022464|DRUG|temsirolimus|
223785146|NCT00778466|DRUG|metformin hydrochloride 1000 mg tablets|
223785147|NCT01835626|DRUG|Vismodegib|Vismodegib will be taken daily for 12 weeks. It should be taken at approximately the same time each day. Patients will be given a supply of vismodegib on Week 1, Day 1 to last until their next study visit. They will be asked to keep a record of each dose of vismodegib you take. After 12 weeks, they will be evaluated again to make sure they are still eligible to participate in the study. If they are eligible to continue, they will continue taking vismodeib daily as before for another 7 weeks while they receive radiation therapy.
223785148|NCT01835626|RADIATION|Radiation therapy|Radiation therapy will be started after the patient has finished taking vismodegib for 12 weeks. They will receive radiation once a day, Monday through Friday, for 7 weeks. Each radiation treatment may take up to 30 minutes.
223785149|NCT05035719|DEVICE|non-invasive cardiac output monitor|Equivalence of Caretaker cardiac output reading to reference standard
223785150|NCT05413876|OTHER|Intermittent cardiopulmonary exercise test|Exercise test with step-change from rest to a relatively low constant workload.
223785151|NCT05413876|OTHER|Incremental cardiopulmonary exercise test|Exercise test with incremental workload until maximal workload.
223785152|NCT05839769|DIAGNOSTIC_TEST|Evaluation of median nerve with ultrasound|ultrasound examination wrist
223785153|NCT05472428|COMBINATION_PRODUCT|Autologous bone marrow mononuclear cell transplantation|Transplantation of Autologous Bone Marrow Mononuclear cells
223785154|NCT01108081|BEHAVIORAL|Physical activity|Moderate-intensity physical activity
223785155|NCT01108081|BEHAVIORAL|Diet|Dietary weight loss
223785156|NCT01108081|BEHAVIORAL|Health education|Attention control intervention
223785157|NCT01764945|DRUG|BI 201335 (Reference)|soft gelatine capsule, oral administration
223785158|NCT01764945|DRUG|BI 201335 (Test)|oral solution 3
223785159|NCT01764945|DRUG|BI 201335 (Test)|oral solution 3
223785160|NCT01764945|DRUG|BI 201335 (Test)|oral solution 2
223785161|NCT01764945|DRUG|BI 201335 (Reference)|soft gelatine capsule, oral administration
223785162|NCT01764945|DRUG|BI 201335 (Test)|oral solution 1
223785163|NCT01764945|DRUG|BI 201335 (Test)|oral solution 1
223785164|NCT01764945|DRUG|BI 201335 (Test)|oral solution 2
223785165|NCT05629026|PROCEDURE|Micro-biopsies|Two micro-biopsies of limb tissue will be carried out, one on the lymphedema and one in the upper limb not affected.
223785166|NCT05188846|OTHER|SDF|"1\. Group 1: cleaning the occlusal surface to be treated with toothbrush. Decayed tissue from the affected teeth will not be removed for the SDF group.~Clinical procedure for SDF application: it will apply according to the SDF manufacturer Instructions as follows:(1) the surrounding gingival tissues and lips will be protected with petroleum jelly to avoid staining and irritation,(2) the affected tooth will be isolated and keep dry with cotton rolls and saliva ejectors, (3) one drop of SDF (SDI RIVA STAR ), will be placed into a disposable dish, (4) SDF will be applied with a micro-sponge directly to the affected tooth surface(s), (5) allowed to soak in for 2 min, then air-dried. Then will be followed by the Potassium iodide (KI) liquid to decrease discoloration caused by SDF. The KI liquid will be reapplied until no more white perception observed to form."
223785167|NCT05188846|OTHER|SDF + ART (SMART technique )|2\. Group 2: SDF+ART clinical procedure: (1)cleaning the occlusal surface to be treated with toothbrush.,(2) carious dentin will be removed using a small excavator (Spoon excavator ),(3) the cavity will be cleaned and dried, (4)cavity walls and floor will be conditioned for 10s, then washed and dried, (5) SDF will be applied as mentioned above followed by cavity restoration using resin-reinforced glass ionomer restorative material (SDI RIVA ).
223785168|NCT00648908|DRUG|Fampridine-SR|Tablets, 10 mg, BID
223785169|NCT05465889|DRUG|Oral sulfate solution (OSS)|OSS contained 17.5 g sodium sulfate, 3.13 g potassium sulfate, 1.6 g magnesium sulfate, and flavoring agents in an aqueous liquid form supplied in a 177 mL bottle. Take 177ml sodium, potassium and magnesium sulfates oral solution (diluted to 480ml) within 30 minutes 14-16 hours before colonoscopy, followed by two doses of 480ml warm water within 1 hour; Repeat the procedure 3-4 hours before colonoscopy.
223785170|NCT05465889|DRUG|Polyethylene Glycol Electrolyte|Take 1000 ml polyethylene glycol electrolyte solution within 1 hour at 8 p.m. the day before colonoscopy; take 2000 ml polyethylene glycol electrolyte solution within 2 hour 4-6 hours before colonoscopy.
223785171|NCT05077267|BIOLOGICAL|ABNCoV2 100ug|IM injection 100ug dose
223785172|NCT05077267|BIOLOGICAL|ABNCoV2 50ug|IM injection 50ug dose
223785173|NCT02911948|DRUG|Insulin degludec/liraglutide|Injected s.c. / subcutaneously (under the skin) once daily
223785174|NCT02911948|DRUG|Insulin degludec|Injected s.c. / subcutaneously (under the skin) once daily
223785175|NCT04545268|DEVICE|Neuromuscular electrical stimulation (NMES)|"NMES will carried out with four-channel myostimulator Beurer EM80 (Germany). Self-adhesive electrodes locates above the quadriceps, the duration of the NMES session was 60 minutes, including 5-minute periods of heating and hitch. Throughout the series, rectangular pulses with a frequency of 45 Hz will modulate. As a result, tonic contraction of these muscles will induce for 12 seconds, followed by a pause of 5 seconds. The amplitude of electrical exposure will select separately for each of the four channels until good muscle contraction (visually or by palpation) without pain. Electrical stimulation will start from the second day after the admission to preoperative department and will carried out during the entire preoperative period (about 10 days)."
223785176|NCT04545268|DEVICE|Transcutaneous electrical stimulation|For the Sham group, electrodes will follow the same site, but the stimulation will only increase to an intermittent tingling sensation with the machine setting on TENS instead of NMES which is not enough to make noticeable changes in muscle mass or circulation. Intensity settings will not change over time.
223785177|NCT05268146|BEHAVIORAL|Lifestyles|Co-creation process and participatory research; lifestyles
223785178|NCT03449602|DEVICE|Mini-thoracoscopy|Thoracoscopic pleural biopsy with the mini-thoracoscope
223785179|NCT03449602|DEVICE|Conventional rigid thoraoscopy|Thoracoscopic pleural biopsy with the conventional rigid thoraoscope
223785180|NCT01926106|DEVICE|nIPPV|one of the twins was randomly allocated to nIPPV
223785181|NCT01926106|DEVICE|nCPAP|another of the twins was allocated to nCPAP
223785182|NCT00586105|DRUG|Sorafenib (Nexavar, BAY43-9006)|400 mg (2 tablets of 200 mg) of sorafenib per oral (PO) twice daily (BID)
223785183|NCT01733654|BIOLOGICAL|RO4995819|The investigation of RO4995819 as adjunctive therapy in MDD patients is supported by preclinical and clinical evidence implicating dysfunction of glutamatergic pathways in the pathophysiology of depression and cognitive disorders, and accumulated evidence of the antidepressant and procognitive effects of mGlu2/3 antagonism.
223785184|NCT02679690|BEHAVIORAL|Standard Dietary Sodium Education|Standard dietary education for sodium restricted diets for patients with heart failure.
223785185|NCT02679690|BEHAVIORAL|Color-Coded Cue Cards|The use of a color-coded cue card to designate ranges of acceptable sodium content of food for comparison to labels while grocery shopping.
223785186|NCT00389558|PROCEDURE|disinfection efficacy using Biseptine|Detersion and antiseptic application when changing catheter dressing
223785187|NCT00389558|PROCEDURE|disinfection efficacy using Amukin|Detersion and antiseptic application when changing catheter dressing
223785188|NCT03819660|DRUG|Amifampridine Phosphate 10 MG Oral Tablet|Oral tablets
223785189|NCT05218967|OTHER|Virtual Reality Headset|A head-worn apparatus that completely covers the eyes for an immersive 3D experience. The VR headset will be worn during the procedure.
223785190|NCT05203419|DRUG|MHS552|MHS552 will be administered once weekly as subcutaneous injection for 4 weeks (Part A) or 12 weeks (Part B)
223785191|NCT05203419|DRUG|Placebo|Placebo will be administered once weekly as subcutaneous injection for 4 weeks (Part A) or 12 weeks (Part B)
223785192|NCT05626829|DRUG|Tranilast|Tranilast capsules 100mg 3 times per day when reradiation
223785193|NCT02703103|OTHER|Manual chest compressions|2 min of Chest compressions without mechanical chest compression system
223785194|NCT02703103|DEVICE|ARM chest compressions|2 min of Chest compressions with mechanical chest compression system LifeLine ARM
223785195|NCT04895397|DEVICE|ultrasound guided Nerve Block procedure|"In group A patients, an ultrasound guided modified pectoral nerve block will be performed Under sterile conditions, US-guided PECSII block will be on the same side of surgery . The 6-13 MHz linear probe will be put transversely in the ipsilateral clavipectoral triangle - between the clavicle medially and above and the shoulder joint laterally.~the needle will be advanced in an in-plane technique targeting the space in which the artery is located. Afterward, 10 mL of bupivacaine, 0.25%, will be injected.~the needle will be advanced in-plane targeting the plane between the pectoralis minor muscle and serratus. Two mL of saline 0.9% will be injected; then, 10 mL of bupivacaine 0.25% will be injected.~Group B: In SAPB Group, a US-guided serratus block will be done The ribs will be then counted, and when the 4th rib will be identified, the high-frequency probe will be put over it, in the mid-axillary line in a sagittal plane."
223785196|NCT02308033|DRUG|Metronidazole|
223785197|NCT02308033|DRUG|Gel vehicle|
223785198|NCT04280198|BEHAVIORAL|Triple P Parenting Videos|Four video clips from the online Triple P Parenting program will be used to promote specific positive parenting practices.
223785199|NCT04280198|BEHAVIORAL|Activity Boxes|There will be about 4 planned activities per week within activity boxes provided to families. The activities will be a context in which the positive parenting behaviors can be practiced. Each activity will take about 15 minutes. Families can pick each week whether they'd like their parenting practice to be embedded in reading activities, nature walks/active games, or arts and crafts. Instructions will be included with each activity, including prompts to allow the parent to apply learnings from that week's parenting video and to allow interactions to be child-led.
223785200|NCT04121598|OTHER|Observational|Observational data will be obtained through self-report measures, parental report measures, cognitive assessments, and a semi-structured interview.
223785201|NCT03355079|DRUG|SmofKabiven® E|In the intervention arm, SmofKabiven® E, with or without addition of Suppliven®, Vitalipid® Adult and/or Soluvit®, will be administered in addition to standard of care oral nutrition as per dietary counseling, whereas in the control arm, oral nutrition as per dietary counseling is the primary nutritional support.
223785202|NCT05762666|DEVICE|nociception level index monitor|The nociception level index (NOL) is one of the new electrophysiological devices to asses pain-related nociception and differs with its multi-parameter evaluation. It is generated from five different parameters (heart rate, heart rate variability, skin conductance level, photo-plethysmography waveform amplitude, number of skin conductance fluctuations, and their time derivatives)
223785203|NCT06308159|DRUG|Vebeglogene autotemcel|Autologous HSPCs transduced with self-inactivating lentiviral vector encoding functional HBB gene and resuspended in cryopreservative solution in the final immediate container for the intended medical use.
223785204|NCT05093452|BEHAVIORAL|Motivational Interviewing|Mothers randomized in the intervention group will receive an educational session based on the motivational interviewing (MI) approach with a midwife. The midwife will have first received a standardized 3 days training session on the content and techniques of MI. The MI intervention will be carried out in simple and understandable language in order to allow discussion and questions from parents rather than provide prescriptive and direct information. The intervention will last approximatively 15 to 20 minutes.
223785205|NCT05093452|OTHER|Information flyer|Mothers randomized in the control group will receive a locally information flyer on childhood vaccines without any oral explanation by the midwife.
223785206|NCT02559908|DEVICE|Hyaluronic Acid Injectable Gel|Hyaluronic Acid Injectable Gel (VYC-25L) injection into the chin and/or jaw areas (up to 4.0 mLs).
223785207|NCT02727101|DRUG|perampanel|Each group of 6 patients will be followed for 12 weeks of baseline observation on baseline medication. Seizure frequency will be counted, using subjects' self-reported seizure diaries. Perampanel will be titrated to 8-12 mg/day, with the final dose determined by side effects and tolerability of Perampanel at 8-12 mg/day doses. Titration will occur at the rate of 2 mg/week or two weeks, as tolerated.
223785208|NCT02405455|PROCEDURE|Cerclage|Surgical procedure which consists of a strong suture being inserted into and around the cervix to close it.
223785209|NCT02405455|DEVICE|Cervical pessary|The Arabin cervical pessary, which is CE-certified for preventing spontaneous preterm birth (CE 0482 / EN ISO 13485: 2003 annex III of the council directive 93/42 EEC). It is a vaginal device which is used to treat pregnant women for preventing spontaneous preterm birth. This device can be easily placed around the uterine cervix without pain.
223785210|NCT00809757|DRUG|Levalbuterol|90 ug Levalbuterol (2 actuations)
223785211|NCT00809757|DRUG|Levalbuterol UDV TID|0.31 ug Levalbuterol UDV TID
223785212|NCT00809757|DRUG|Placebo|Placebo (2 actuations)
223785213|NCT04982042|OTHER|Pulmonary Rehabilitation|The Pulmonary Rehabilitation Program consists of a combination of aerobic and strengthening exercises, lasting 12 weeks, with a frequency of 3 times a week, always in the morning. Each session consists of active warm-up exercises, upper and lower limb strengthening, aerobic conditioning and stretching exercises. The warm-up phase consists of intercalated calisthenic exercises for different muscle groups, according to each patient's tolerance.
223785214|NCT03955653|PROCEDURE|Femoral artey access|We will study the access to the femoral artery for cardiac catheterization or percutaneous coronary intervention
223785215|NCT04771169|OTHER|vestibular Training Group|this Group will receive vestibular Adaptation \& Balance exercises
223785216|NCT04771169|OTHER|Virtual Reality Group|This Group will receive Virtual Reality Training by using exergaming.
223785217|NCT00253864|PROCEDURE|Single row|Fixation type in arthroscopic rotator cuff repair.
223785218|NCT00253864|PROCEDURE|Double row|Fixation type in arthroscopic rotator cuff repair.
223785219|NCT04121728|DRUG|Ginkgo biloba extract|Symfona® commercial standardized Ginkgo biloba extracts are used in this study, at a rate of 2 capsules of 120 mg per day for 170 days.
223785220|NCT04121728|DRUG|Placebo|The placebo is presented in the form of capsules of identical mass, color and shape to those of the study product. It is composed of lactose, the excipients present in Symfona® 120 mg and colorants. The dosage is identical to that of the investigational product.
223785221|NCT00506961|DRUG|Rosuvastatin|10 mg rosuvastatin for 4 weeks followed by rosuvastatin or another 12 weeks
223785222|NCT00506961|DRUG|Simvastatin|20 mg simvastatin for 4 weeks followed by 40 mg simvastatin for another 8 weeks
223785223|NCT02967302|DRUG|Morphine Sulfate|active intervention
223785224|NCT02967302|DRUG|Triamcinolone|active control
223785225|NCT02967302|DRUG|placebo|placebo control
223785226|NCT04697758|DRUG|AXT107 0.1 mg|Single intravitreal injection of AXT107 0.1 mg/eye
223785227|NCT04697758|DRUG|AXT107 0.25 mg|Single intravitreal injection of AXT107 0.25 mg/eye
223785228|NCT04697758|DRUG|AXT107 0.5 mg|Single intravitreal injection of AXT107 0.5 mg/eye
223785229|NCT05178628|DRUG|Innohep|Patients will receive Tinzaparin sodium 20.000 Anti-Xa IU/ml in prefilled syringes. Administered at 175 Anti-Xa IU/Kgr of body weight, subcutaneously, once daily
223785230|NCT05178628|DRUG|Chemotherapy: Gemcitabine + Nab-Paclitaxel|All patients will receive chemotherapy per clinical practice
223785231|NCT05794867|DIAGNOSTIC_TEST|clinical weaning criteria|Xray chest and calculation of thr rapid shallow breathing rate
223785232|NCT01640691|BIOLOGICAL|Pandemic Influenza Vaccine (H5N1)|"Inactivated whole-virion vaccine~1. Administration route: Intramuscular Injection~2. Dosing schedule: 2 injections - at Day 1 and Day 22 separately~3. Dose(s): Each dose (0.5 mL) contains the 15 mcg hemagglutinin (HA) of influenza A (A/Vietnam/1194/2004)"
223785233|NCT01410448|DRUG|Everolimus|Everolimus was provided in blisters containing 0.25 and 0.75 mg tablets and was taken orally.
223785234|NCT01410448|DRUG|Mycophenolate sodium|Two 360 mg tablets were administered twice daily at 12-hour intervals. The tablets were swallowed whole in order to maintain the integrity of the enteric coating.
223785235|NCT01410448|DRUG|Cyclosporine|Cyclosporine was supplied as blisters containing 100 mg, 50 mg, 25 mg and 10 mg soft-gelatin capsules and was administered orally.
223785236|NCT01410448|DRUG|Steroids|Steroids were administered according to local clinical practice.
223785237|NCT01185574|DIETARY_SUPPLEMENT|Vitamin D supplementation|Vitamin D2 50,000 IU will be administered once a week for six months.
223785238|NCT06486753|PROCEDURE|Chevron osteotomy bunion surgery with lateral soft tissue release|Lateral soft tissue release is often performed in hallux valgus correction, and there is preliminary evidence to suggest it may be useful in improving post-surgical outcomes for the Chevron osteotomy bunion surgery.
223785239|NCT03362255|OTHER|thoracic epidural catheterization|thoracic epidural catheterization with different speed of injection
223785240|NCT05262153|PROCEDURE|Non-surgically performed scaling and root planing|Treatment of patients with periodontitis was performed using manual and ultrasonic instruments.
223785241|NCT02759900|DEVICE|Non-thermal, atmospheric plasma to treat skin lesions and acne|Non-thermal, atmospheric plasma treatment of affected area or lesions using a nanosecond dielectric barrier discharge plasma device
223785242|NCT02759900|DEVICE|Indirect non-thermal, atmospheric plasma to treat hair loss and acne|A compound of non-thermal, atmospheric plasma and medium is delivered to or generated at the target area. Plasma is generated using either microsecond dielectric barrier discharge plasma device or PiezoBrush (a helium jet plasma). The medium is an aqueous alcohol solution
223785243|NCT04979819|OTHER|Upper extremity endurance test (UULEX)|Patients will lift 5 bars consecutively rhythmically until they feel fatigued. The bars will weigh 200 grs 500 gr 1kgs and 2 kgs respectively. The duration of the test will be measured to determine the endurance levels of the patients.
223785244|NCT03385876|GENETIC|Genomic sequencing and molecular diagnostic results, if any|Samples will be stored in the pediatric genomic biorepository. A subset of samples will undergo genetic/genomic analysis.
223785245|NCT00505739|DRUG|Mifepristone|200 mg by mouth (PO) Daily x 4 Weeks
223785246|NCT05422911|DRUG|Abiraterone acetate|YONSA® (abiraterone acetate), YONSA® 500 mg (four 125 mg tablets) or 625 mg (five 125 mg tablets) administered orally once daily in combination with methylprednisolone 4 mg administered orally twice daily + physician's choice GnRH agonist/antagonist \[unless the Veteran has had prior bilateral orchiectomy\].
223785247|NCT05422911|DRUG|Apalutamide|Apalutamide, 240 mg (four 60 mg tablets) administered orally once daily + physician's choice GnRH agonist/antagonist \[unless the Veteran has had prior bilateral orchiectomy\].
223785248|NCT05422911|DRUG|Enzalutamide|Enzalutamide, 160 mg (four 40 mg capsules) administered orally once daily + physician's choice GnRH agonist/antagonist \[unless the Veteran has had prior bilateral orchiectomy\].
223785249|NCT00360529|DRUG|flibanserin|flibanserin placebo versus 50 mg qhs versus 100 mg qhs
223785250|NCT04695327|BIOLOGICAL|TILT-123|TNFalpha and IL-2 coding oncolytic adenovirus TILT-123
223785251|NCT06052501|PROCEDURE|Removable of the full arch implant-supported prostheses|The intervention planned will be the removal of full arch implant-supported prostheses and the acquisition of a digital image through a facial scanner before and after this moment.
223785252|NCT00060450|DRUG|nitric oxide for inhalation|Either 10 or 20 ppm of inhaled nitric oxide for 24 hour post transplant
223785253|NCT00060450|DRUG|Placebo|Placebo gas will be given at 10 or 20 ppm for 24 hours post transplant
223785254|NCT05155436|DRUG|Fixed Dose Combination pill of Telmisartan 40mg and Amlodipine 5 mg|Participants without prevalent hyperkalemia will receive the fixed-dose combination pill of Telmisartan and Amlodipine, once daily for 3 months.
223785255|NCT05044572|OTHER|Open chain kinetic exercises|Group A will perform open chain kinetic exercises Before the intervention all the participants will perform 20 minutes of warm up and 10 minutes of cool down. The Open kinematic chain exercises(Three sets of each exercise while one set of each exercise will be performed at the setup and remaining two sets will be guided to the patient as a home plan)-:Blackburn exercises ( 20 repetitions ) , Dynamic hug( 10 repetitions), W exercise(10 repetitions), lunges with dumbbells-forward(10 repetitions with half kg dumbbell), upward and diagonal, and Pectoralis minor stretching(3 to 5 stretches)will be performed
223785256|NCT05044572|OTHER|Forward head posture correction exercises|PatienGroup B participants will perform forward head correction exercise(22) Chin tuck Patient will Stand with upper back against a wall, feet shoulder-width apart. • Face forward, tuck your chin down, and pull head back until it meets the wall. • t
223785257|NCT02588391|BEHAVIORAL|Brain Training (Active)|Online computer games targeting attention, EF, and problem-solving match the child's skill level.
223785258|NCT02588391|BEHAVIORAL|Brain Training (Passive)|Online computer games targeting attention, EF, and problem solving are set to a consistent level.
223785259|NCT02588391|BEHAVIORAL|Brain Training (Active or Passive)|Online computer games targeting attention, EF, and problem-solving either match the child's level or are set to a consistent level depending on which version the child has already completed.
223785260|NCT00845572|BEHAVIORAL|Consta Club|Biweekly group for patients receiving Risperdal Consta injections. Each 45 minute group includes socialization time, goal-setting, illness and medication education, and refreshments.
223785261|NCT05457946|BIOLOGICAL|LBVD (Hexavalent vaccine)|Injection within the muscle into the front area of the thigh
223785262|NCT05457946|BIOLOGICAL|Pentavalent vaccine and Inactivated Polio vaccine (Sabin strains)|Injection within the muscle into the front area of the thigh
223785263|NCT04617028|DRUG|Jaktinib|Jaktinib Hydrochloride Tablets administered orally twice daily
223785264|NCT04617028|DRUG|Placebo to match Hydroxycarbamide|Placebo to match Hydroxycarbamide Tablets administered orally twice daily
223785265|NCT04617028|DRUG|Hydroxycarbamide Tablets|Hydroxycarbamide Tablets administered orally twice daily
223785266|NCT04617028|DRUG|Placebo to match Jaktinib|Placebo to match Jaktinib Tablets administered orally twice daily
223785267|NCT01601587|OTHER|A psychoeducational group intervention.|"The intervention is an introduction seminar. It will be held over FOUR hours. Up to 15 patients can participate in each seminar. The content of the was developed based on study 1. The presentation about available treatment options and patient's rights are made by multi professional health personnel and user representatives. More specifically, this will be done under the following topics:~1. What is mental health?~2. Treatment options: orientation about individual and group based treatment modalities.~3. Former patients experience with their own treatment, self-help and participation.~4. How to influence and participate actively in the treatment and patient rights.~5. What can I do while I wait for treatment and where can I otherwise do to avoid aggravation?"
223785268|NCT03103555|DRUG|Bortezomib|Bortezomib will be subcutaneously administered in 2 treatment cycles with 4 injections of 1.3 mg Bortezomib /m2 body surface per cycle.
223785269|NCT03103555|DRUG|Cyclophosphamide|Low dose cyclophosphamide will be given orally for 4 month after completion 2 cycles of bortezomib
223785270|NCT03712917|PROCEDURE|Greater Occipital Nerve Block|An enjection to paralyze the occipital nerve.
223785271|NCT03712917|DRUG|Topiramate|An antiepileptic agent used for migraine prophylaxis.
223785272|NCT03712917|DRUG|Flunarizine|A calcium overload blocker agent used for migraine prophylaxis.
223785273|NCT00119509|PROCEDURE|HPV DNA testing|
223785274|NCT00119509|PROCEDURE|Conventional management (repeat Pap smear at 6 months)|
223785275|NCT00119509|PROCEDURE|Decision aid with choice of management|
223785276|NCT02045758|DEVICE|Fingerstick|
223785277|NCT02045758|DEVICE|TAP20-C|
223785278|NCT03297840|BEHAVIORAL|Dialectical Behavioural Therapy (DBT)|Inpatient Dialectical Behavioural Therapy (DBT) according to Linehan.
223785279|NCT02098200|DEVICE|TriCinch System|Percutaneous treatment of Tricuspid Regurgitation
223785280|NCT04937569|DRUG|Ivermectin Tablets|4-days course of Ivermectin 400 microgram/kg body weight maximum 4 tablets (6mg / tablet) once daily dose before breakfast
223785281|NCT04160780|PROCEDURE|L-PRF|sinus augmentation using L-PRf as sole graft material
223785282|NCT04160780|PROCEDURE|L-PRF mixed with xenograft|sinus augmentation using L-PRF mixed with xenograft as sole graft material
223785283|NCT04160780|PROCEDURE|xenograft|sinus augmentation using xenograft as sole graft material
223785284|NCT01218438|BIOLOGICAL|Immune Globulin Intravenous (Human), 10% Solution|Intravenous infusion with IGIV, 10%
223785285|NCT01218438|DRUG|Immune Globulin Subcutaneous (Human), 20% Solution|Subcutaneous infusion with IGSC, 20%
223785286|NCT02084966|PROCEDURE|Procedure/Surgery: Transplantation: OCT of Kidney Transplant|Device: Optical Coherence Tomography of Kidney Transplant
223785287|NCT02040402|BIOLOGICAL|7-valent pneumococcal conjugated vaccine|Pneumococcal vaccine 3+1 and 2+1 schedule comparison
223785288|NCT02040402|BIOLOGICAL|7-valent pneumococcal conjugated vaccine|3+1 doses vs 2+1 doses
223785289|NCT00690703|DEVICE|RF ablation (Rita Medical Systems Model 1500x)|computed tomography-guided RF ablation with an expandable electrode needle
223785290|NCT01932164|PROCEDURE|maxillary alveolar graft by tissue engineering|Extraction of deciduous teeth of cleft lip and palate patients to obtain mesenchymal stem cells;
223785291|NCT01932164|PROCEDURE|Bone tissue engineering using mesenchymal stem cells|Secondary alveolar graft in patients with cleft lip and palate using using mesenchymal stem cell obtained from dental pulp of deciduous teeth (autogenous) associated with a biomaterial composed of collagen and hydroxyapatite.
223785292|NCT02367261|DEVICE|SPI implant|SPI implant - the original spiral implant
223785293|NCT00052468|DRUG|TCG|
223785294|NCT00052468|DRUG|TC|
223785295|NCT02591654|DRUG|Pembrolizumab|Each patient will receive pembrolizumab 200mg administered as a 30 minute intravenous (IV) infusion every 3 weeks for an indefinite period.
223785296|NCT02591654|DRUG|FLT PET|FLT PET/CT is increasingly being utilized as an early PD biomarker in cancer given the close association between FLT uptake and proliferative index.
223785297|NCT05149274|DRUG|DWP14012 Tablet A|DWP14012 10mg
223785298|NCT05149274|DRUG|DWP14012 Tablet B|DWP14012 40mg
223785299|NCT02409173|DEVICE|Noninvasive positive airway pressure flow generator device|Noninvasive positive airway pressure flow generator device.
223785300|NCT02409173|PROCEDURE|Bariatric Surgery|Standard Roux-en-Y gastric bypass
223785301|NCT06412276|BEHAVIORAL|Control|Food menu will be provided as is typical for the out of home outlet
223785302|NCT06412276|BEHAVIORAL|Product price promotions removed|Food menus with no price reductions to products
223785303|NCT06412276|BEHAVIORAL|Bulk buy reductions removed|Food menus with bundles provided but not at reduced prices
223785304|NCT06412276|BEHAVIORAL|Volume value pricing removed|Food menus with proportionate pricing for multi-size products
223785305|NCT06412276|BEHAVIORAL|No price-based incentives|Food menus with no price-based incentives offered
223785306|NCT04679129|DRUG|ASC42|Oral tablets
223785307|NCT04679129|DRUG|Placebo|Oral tablets
223785308|NCT02438241|PROCEDURE|Conventional physiotherapy Group|Patients randomized to this group will receive only conventional physiotherapy. The treatment protocol Control Group, will consist of weathered active exercises to manually lower limbs in bed (triple flexion, abduction and adduction, plantar / dorsiflexion), free active exercises of the upper limbs in the bed (shoulder flexion, shoulder flexion and horizontal functional diagonal shoulder), bronchial hygiene techniques, flow redirection, positive expiratory pressure and ventilatory blowing patterns.
223785309|NCT02438241|PROCEDURE|TENS Group|Patients randomized to this group will receive conventional physical therapy (the treatment protocol Control Group), and the end of that service, will be applied TENS. TENS is accomplished through the use of an electrical stimulation device with symmetrical biphasic current pulse. The following parameters are used: frequency: 100 Hz, pulse width: 100 µs, intensity to the greatest sensory threshold of the patient and total session time: 30 minutes. Self-adhesive electrodes will be used (Valutrode, size 5x9 cm) to be positioned in the posterolateral portion of the chest to 2 cm skin incision both upper and lower.
223785310|NCT02438241|PROCEDURE|Placebo TENS group|Patients randomized to this group will receive conventional physical therapy (the treatment protocol Control Group), will be held the same procedure as TENS group, except that TENS will be offered to the patient only for 45 seconds, and in the first 30 seconds is reached the sensory threshold of the patient and in the last 15 seconds will turn off the electrical current by 29 remaining period minutes and 15 seconds off.
223785311|NCT02091167|DEVICE|transcranial Direct Current Stimulation|Direct currents are transferred via a pair of carbonated-silicone electrodes (35 cm2) with a thick layer of high conductive gel for EEG underneath them. The electric current is delivered by an electric stimulator. To stimulate the left DLPFC, the cathode electrode is placed over F3 according to the 10-20 international system while the anode is placed over the contralateral F4 region. The currents flows continuously for 20 minutes with an intensity of 2 milliamperes.
223785312|NCT01164059|DRUG|Olanzapine|Olanzapine 10, 15, or 20 mg / day
223785313|NCT01164059|DRUG|Flupentixol|Flupentixol 6, 9, or 12 mg / day
223785314|NCT01164059|DRUG|Quetiapine|Quetiapine 400, 600, or 800 mg / day
223785315|NCT01164059|DRUG|Aripiprazole|Aripiprazole 10, 15, or 20 mg / day
223785316|NCT01164059|DRUG|Haloperidol|Haloperidol 3, 4.5, or 6 mg / day
223785317|NCT03208972|DRUG|low dose hCG|
223785318|NCT03208972|DRUG|hp-FSH|
223785319|NCT03208972|DRUG|Corifollitropin Alfa|"Corifollitropin Alfa (Elonva) dosage depending on weight, once administered first day of ovarian stimulation for all subjects, and on day 7 they proceed with the treatment of the allocated group.~\<60 kg: Elonva 100 MCG \> 60 kg: Elonva 150 MCG"
223785320|NCT05087940|DRUG|Add-on therapy|Add-on drugs prescribed by internal medicine specialists within the routine health care and independently from the study investigators - one of the following: an aldosterone receptor blocker, a loop diuretic, a thiazide in large daily dose, an alpha 1 selective blocker or a beta 1 selective blocker
223785321|NCT05019586|DRUG|levofloxacin, amoxicillin, clarithromycin|Triple therapy of Helicobacter pylori including two antibiotics and a proton inhibitor for 10 days
223785322|NCT03013647|DRUG|Methyl Aminolevulinate|"Patients will be treated with Daylight Photodynamic therapy, following these steps:~1. mild curettage of the AK lesions~2. application of a chemical sunscreen SPF 30~3. application of methyl aminolevulinate cream (Metvix R, Galderma Laboratories)~4. exposition to daylight, for 120 minutes~5. cleaning of the face"
223785323|NCT05709743|BEHAVIORAL|Experimental: Within-Subjects Attentional Information|Behavioral: Visual Search Information Type (target or distractor information) Participants will have information about targets, distractors, or neither in different trials of the intervention.
223785324|NCT06296719|OTHER|Chit-Chat|Participants will receive the 2 sessions of the Chit-Chat intervention on a weekly basis.
223785325|NCT02090907|DRUG|Levothyroxine|
223785326|NCT02090907|DRUG|Placebo|
223785327|NCT01679899|DRUG|Vildagliptin|Vildagliptin 50mg bid orally for 12 months
223785328|NCT01679899|DRUG|Gliclazide MR|Gliclazide MR 60 or 120mg orally for 12 months
223835383|NCT01153256|DRUG|normal saline|Patients in the group R-0.6 receive the same volume of isotonic saline over the same period, and rocuronium 0.9 mg/kg is given after the induction of anesthesia with alfentanil (10 μg/kg) and propofol (2 mg/kg).
223835384|NCT04622020|PROCEDURE|Cervical Plexus Block with Local Anaesthesia|Ultrasound guided intermediate cervical plexus block
223835385|NCT04622020|PROCEDURE|Cervical Plexus Block with Depot Steroids|Ultrasound guided intermediate cervical plexus block
223785329|NCT03662750|DIAGNOSTIC_TEST|Brain Imaging|"The study involves an initial screening visit and 2 study imaging visits at days 15 and 90 after the stroke episode.Patients will undergo:~1. Two 90-minute brain imaging sessions using Positron Emission Tomography (PET) (involves injection of safe radiotracers which attach to brain immune cell markers TSPOs and light up the inflamed areas in the brain),~2. Two 45-90 minute Magnetic Resonance Imaging (MRI) scanning sessions (include administration of safe chemical contrast agent Gadolinium),~3. Physical and neurological examinations (vital signs, assessments of mobility and cognitive functioning),~4. Blood testing (routine measurements, blood inflammation markers, and genetic testing for TSPO marker).~Venous cannula will be inserted into the forearm for the duration of the scans."
223785330|NCT04848766|DRUG|De-escalation Treatment Strategy of dual antiplatelet therapy|Patients receive de-escalation treatment of dual antiplatelet therapy after percutaneous coronary intervention
223785331|NCT03096782|BIOLOGICAL|Anti-Thymocyte Globulin|Given IV
223785332|NCT03096782|DRUG|Busulfan|Given IV
223785333|NCT03096782|DRUG|Clofarabine|Given IV
223785334|NCT03096782|DRUG|Cyclophosphamide|Given IV
223785335|NCT03096782|BIOLOGICAL|Filgrastim-sndz|Given SC
223785336|NCT03096782|DRUG|Fludarabine|Given IV
223785337|NCT03096782|DRUG|Melphalan|Given IV
223785338|NCT03096782|DRUG|Mycophenolate Mofetil|Given IV or PO
223785339|NCT03096782|BIOLOGICAL|Rituximab|Given IV
223785340|NCT03096782|DRUG|Tacrolimus|Given IV
223785341|NCT03096782|RADIATION|Total-Body Irradiation|Undergo total body irradiation
223785342|NCT03096782|PROCEDURE|Umbilical Cord Blood Transplantation|Undergo cord blood transplant
223785343|NCT02555410|DEVICE|Brain Sentinel Seizure Detection and Warning System|A sEMG based automated seizure detection and warning system worn on the biceps
223785344|NCT04897893|OTHER|Eicosapentaenoic acid monoglycerid (MAG-EPA)|MAG-EPA is an omega-3 fatty acid classified in canada as a Natural Health Product (NHP). The NHP is approuved under the Natural Health Product number (NPN # 80050187).
223785345|NCT02632578|BIOLOGICAL|2015 Fluvax® vaccine, BioCSL (a licensed influenza vaccine)|Subjects received licensed influenza vaccine (Fluvax®), 1ml intramuscular injection.
223785346|NCT02555046|PROCEDURE|Local Anesthesia|Use of unspecified local anaesthesia (fx lidocain or bupivacaine)
223785347|NCT01911052|OTHER|Telephone based re-education|The investigational, or experimental arm, will receive standard written instructions on preparing for a colonoscopy plus intervention such as telephone based re-education by one investigator on the day before colonoscopy.
223785348|NCT01911052|OTHER|Short message system based re-education|The investigational, or experimental arm, will receive standard written instructions on preparing for a colonoscopy plus intervention such as short message system based re-education by one investigator on the day before colonoscopy.
223785349|NCT01153594|BEHAVIORAL|Recovery Management Checkups (RMC)|After interviewers completed the quarterly research interview and determined participants' eligibility and need for early re-intervention, they transferred RMC participants who were eligible and in need to a Linkage Manager. Using motivational interviewing, the Linkage Manager: a) provided feedback to participants regarding their current substance use and related problems, b) discussed implications of managing addiction as a chronic condition, c) discussed treatment barriers and solutions, d) assessed and discussed level of motivation for treatment, e) scheduled treatment appointments, f) accompanied participants to treatment intake and stayed through the process, and g) implemented Engagement and Retention Protocol during the 14 days of treatment
223785350|NCT05872035|DEVICE|Apple Software|Amplification settings established by algorithm and further adjusted by participants per their preference
223785351|NCT05872035|DEVICE|by Audiologist|Amplification settings established by clinical reference and further adjusted by an audiologist per current best practice
223785352|NCT02575599|BEHAVIORAL|Guided self-determination programme (GSD)|The GSD intervention consist of four e-consultations with structured reflection sheets. Reflection sheets are intended to increase patients' ability to express their views and prepare them for active participation in the care process. Through the web-based platform, the subsequent four e-consultations will allow for communication between patients and nurses. The platform allows the participants to fill in the reflection sheets using their own words and drawings to express their own experiences with self-management as well as to formulate behavioral goals and plans to achieve their goals. It also permits feedback from the nurses on these reflections sheets via secure emails. Each person will be able to access the web-based program from his or her own computers or other electronic devices.
223785353|NCT06592313|PROCEDURE|Intubation|Aiway management procedure involving the Insertion of an orotracheal cannula through the oropharynx.
223785354|NCT06664346|BEHAVIORAL|Immersive virtual reality mindfulness|Immersive virtual reality mindfulness
223785355|NCT06664398|BEHAVIORAL|one HIIT|one HIIT high intensity interval training
223785356|NCT06664398|BEHAVIORAL|four HIIT|four HIIT high intensity interval training
223785357|NCT06663878|GENETIC|MWAV201|Nonreplicating, recombinant gene transfer vector
223785358|NCT06664359|OTHER|Ultrasound guided injection with local anaestethic|"Volunteers will first be asked to sit on a chair with their back facing the examiner, placing their arms in a relaxed position with their head supported on a surface in front of them. The ultrasound operator will be positioned behind the volunteer. Initially, in the sitting position, volunteers will be asked to maintain normal breathing. Once an optimal ultrasound image is obtained, the image will be frozen, and measurements will be taken from the same image in sequence. The measurements to be performed are as follows: skin-fat tissue distance, skin-trapezius muscle distance, skin-rhomboid muscle distance, skin-rib distance, skin-pleura distance, and rhomboid muscle-pleura distance. These measurements, in millimeters, will be recorded in the data collection form. The same measurements will also be taken during deep inhalation and deep exhalation in the sitting position."
223785359|NCT06664359|OTHER|Ultrasound guided injection with local anaestethic|"Volunteers will first be asked to lay prone position.The ultrasound operator will be positioned behind the volunteer. Initially, in the sitting position, volunteers will be asked to maintain normal breathing. Once an optimal ultrasound image is obtained, the image will be frozen, and measurements will be taken from the same image in sequence. The measurements to be performed are as follows: skin-fat tissue distance, skin-trapezius muscle distance, skin-rhomboid muscle distance, skin-rib distance, skin-pleura distance, and rhomboid muscle-pleura distance. These measurements, in millimeters, will be recorded in the data collection form. The same measurements will also be taken during deep inhalation and deep exhalation in the sitting position."
223785360|NCT02760238|OTHER|Observational|
223785361|NCT06612086|DRUG|Dapagliflozin (Forxiga)|we study effect of dapagliflozin on patient with pulmonary hypertension by follow up RV function and prognosis of life of patient
223785362|NCT04823598|PROCEDURE|Coached pushing and Finnish manual perineal protection|"Pushing technique: Rest will be encouraged between uterine contractions. With the onset of uterine contraction, women will be instructed to breathe normally. They will then be instructed to take a deep breath and hold (closed-glottis), and push down strongly for as long as possible (up to 10 seconds). After pushing effort, normal breathing will be encouraged, then the same pushing instruction will be repeated again.~Fetal expulsion: The expulsion rate of the fetal head will be controlled by light pressure applied on the fetal occiput. Simultaneously, the thumb and index finger of the dominant hand will be used to support the perineum, while the bent middle finger will grasp the baby's chin. Once a good grip is achieved, the investigator slowly assists in the expulsion of the fetal head from the vaginal introitus. When most of the fetal head is out, the perineal ring will be pushed under the baby's chin."
223785363|NCT04823598|PROCEDURE|Uncoached pushing and Hands-poised perineal protection|Women will not be given any instructions regarding straining and breathing, and will be allowed to follow their own pushing impulses. During the expulsion of the fetal head, the hands of the researcher will be kept in the air and ready for the intervention, but pressure will not be applied to the fetal head or perineum unless necessary (fetal hypoxic appearance, strain detection with a risk of spontaneous laceration towards the anus in the midline).
223785364|NCT03843788|DEVICE|Transcutaneous Electrical Nerve Stimulation (TENS)|Starting 8 hours after cesarean section, the TENS unit will be applied with charges above and below the incision. The device will be set to high frequency (\>75 Hz) for pain relief. Intensity of stimulation will be set to patient threshold using the forearm as a guide. Stimulation will be turned on titrated to the level which is felt but not painful for the patient. It will remain on until the patient is discharged, to be removed for toilet and showering at the patient's discretion. Once the TENS unit is applied and turned on, the patient will not have to do anything else to maintain the therapy.
223785365|NCT02899897|DEVICE|echocardiography in IV fluid therapy|
223785366|NCT06626087|DIAGNOSTIC_TEST|Prototype artificial intelligence algorithm|Developed by the University of Hong Kong
223785367|NCT06626087|DIAGNOSTIC_TEST|LI-RADS|The Liver Imaging Reporting and Data System (LIRADS) was established to standardize the lexicon, interpretation and communication of radiological findings related to HCC
223785368|NCT00932893|DRUG|PF-02341066|PF-02341066, 250 mg BID will be administered orally on a continuous schedule
223785369|NCT00932893|DRUG|Pemetrexed|Pemetrexed, 500 mg/m\^2, will be administered by i.v. infusion over 10 minutes on Day 1 of each 21-day cycle
223785370|NCT00932893|DRUG|Docetaxel|Docetaxel, 75 mg/m\^2, will be administered by i.v. infusion over 1 hour on Day 1 of each 21-day cycle
223785371|NCT03975283|DRUG|Exparel 266 MG Per 20 ML Injection|266mg of liposomal bupivacaine 266 mg, 20 mL volume, will be diluted with 20 ml of 0.25% bupivacaine (50 mg of bupivacaine) and 20 ml saline, thereby totalling 60mL volume. Total volume will be divided into two 30 ml syringes, and each will be used (per side) for the TAP blocks.
223785372|NCT03975283|DRUG|Bupivacaine Hcl 0.25% Inj|0.25% bupivacaine, 60mL total, divided into two 30mL syringes and delivered via TAP block on either side.
223785373|NCT00443547|DEVICE|Vectra-T|Patient will receive the Vectra-T plate (Sized 1 to 4 levels)
223785374|NCT00346008|GENETIC|mutation analysis|
223785375|NCT00346008|OTHER|high performance liquid chromatography|
223785376|NCT00346008|OTHER|laboratory biomarker analysis|
223785377|NCT00346008|OTHER|questionnaire administration|
223785378|NCT06074250|DIETARY_SUPPLEMENT|Fish oil|1500mg EPA +1000mg DHA daily
223785379|NCT06074250|DIETARY_SUPPLEMENT|Probiotics|Combination strain of lactobacillus and bifidobacteria
223785380|NCT06074250|BEHAVIORAL|Prebiotics|Dietary consult with follow-up to ensure target fiber intake is met.
223785381|NCT06074250|BEHAVIORAL|Diet Quality|one time dietary consult at enrollment to discuss strategies to improve overall diet.
223785382|NCT00198640|PROCEDURE|Antibiotic use|
223785383|NCT00203359|DRUG|etanercept given by perispinal administration|
223785384|NCT02301702|BIOLOGICAL|Tdap|Commercially available, U.S. and Guatemala licensed, 0.5mL intramuscular injection combination tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine
223785385|NCT02301702|BIOLOGICAL|Td|The tetanus toxoid and reduced diphtheria toxoid vaccine (Td) used for this study will be the same preparation used by the National Immunization Program of Guatemala
223785386|NCT02604784|DRUG|Pressurized IntraPeritoneal Air-flow Chemotherapy (PIPAC) fixed repeated dose|An open access with a midline 5-6 cm incision is performed and a single-port platform is positioned. A 12 mm Hg CO2 pneumoperitoneum is inflated. PC extent is evaluated according to Peritoneal Cancer Index (PCI) and peritoneal biopsies are taken. A nebulizer is connected to an intravenous high-pressure injector and inserted into the peritoneal cavity; the tightness of the abdomen has to be documented with a CO2 zero-flow. The laparoscopic camera and the nebulizer are maintained in position by a self-retaining retractor (Thompson). A pressurized aerosol containing drugs is delivered. Standard dosage of drugs for each PIPAC: Cisplatin (7.5 mg/m²) + Doxorubicin (1.5 mg/m²) or Oxaliplatin (92 mg/m²) The capnoperitoneum is then maintained for 30 minutes at 37°C. At the end, the aerosol is exsufflated through two sequential micro-particle filters into the air-waste system of the hospital.
223785387|NCT02604784|DRUG|Pressurized IntraPeritoneal Air-flow Chemotherapy (PIPAC) increasing single dose|An open access with a midline 5-6 cm incision is performed and a single-port platform is positioned. A 12 mm Hg CO2 pneumoperitoneum is inflated. PC extent is evaluated according to Peritoneal Cancer Index (PCI) and peritoneal biopsies are taken. A nebulizer is connected to an intravenous high-pressure injector and inserted into the peritoneal cavity; the tightness of the abdomen has to be documented with a CO2 zero-flow. The laparoscopic camera and the nebulizer are maintained in position by a self-retaining retractor (Thompson). A pressurized aerosol containing drugs is delivered. Escalating dosage of drugs for PIPAC: Cisplatin + Doxorubicin (from 15 mg/m² + 3 mg/m² to 100 mg/m² + 30 mg/m²) or Oxaliplatin (from 92 mg/m² to 300mg/m²).The capnoperitoneum is then maintained for 30 minutes at 37°C. At the end, the aerosol is exsufflated through two sequential micro-particle filters.
223785388|NCT03400540|DIAGNOSTIC_TEST|verbal instruction|Verbal instruction for pelvic floor contraction will be given to participants. Ultrasound examination will be conducted to asses urinary bladder displacement being a marker for pelvic floor muscle function.
223785389|NCT02370212|DIETARY_SUPPLEMENT|Creatine|
223785390|NCT02370212|DIETARY_SUPPLEMENT|Placebo|
223785391|NCT02370212|OTHER|High intensity interval training|
223785392|NCT04381026|DIETARY_SUPPLEMENT|Botanical dry extracts combination|Aframomum melgueta dry extract (50mg), Glycine max bean dry extract (100mg) and Punica granatum skin extract (100mg)
223785393|NCT04381026|DIETARY_SUPPLEMENT|Placebo|Filler agent
223785394|NCT00746954|DRUG|Acetazolamide|Cabonic Anhydrase inhibitor
223785395|NCT00746954|DRUG|Buspirone|Agonist of a 5-HT1a receptor with some D2 agonist properties.
223785396|NCT00536133|DRUG|Zinc|5 ml of syrup containing zinc gluconate equivalent to 10 mg of elemental zinc per day for 60 days
223785397|NCT00536133|OTHER|placebo|5 ml of syrup, identical in taste, color and consistency to the syrup given to zinc group, but containing no zinc
223785398|NCT00724282|DRUG|Eszopiclone|Eszopiclone 3 mg by mouth daily at bedtime for 9 days
223785399|NCT00724282|DRUG|Placebo|Placebo by mouth daily at bedtime for 9 days
223785400|NCT01759589|DRUG|Propofol|1 mg/kg propofol IV (over 15 sec) during anesthesia induction
223785401|NCT01759589|DRUG|Remifentanil and propofol|1 µg/kg IV (over 60 sec)remifentanil and 0.5 mg/kg propofol IV (over 15 sec)during anesthesia induction
223785402|NCT01759589|DRUG|Sevoflurane|Sevoflurane was started at 6% for induction and continued at 1% until the electrical stimulus was delivered
223785403|NCT05869305|DIETARY_SUPPLEMENT|whey protein isolate|Take 1 sachet/day for 12 weeks.
223785404|NCT05869305|DIETARY_SUPPLEMENT|isolated soy protein|Take 1 sachet/day for 12 weeks.
223785405|NCT05869305|DIETARY_SUPPLEMENT|placebo|Take 1 sachet/day for 12 weeks.
223785406|NCT00993447|BIOLOGICAL|CYD Dengue Vaccine|0.5 mL, Subcutaneous at Day 0, 6 and 12 months
223785407|NCT00993447|BIOLOGICAL|Tetanus Toxoid Reduced Diphtheria Toxoid Acellular Pertussis|NaCl: 0.5 mL, Intramuscular at Day 0 and 6 months; Adacel®: 0.5 mL, Intramuscular at 12 months
223785408|NCT06535594|OTHER|Laser acupuncture|Laser acupuncture therapy will be performed five times a week for 4 weeks using laser beam. The acupoints on the ear that will be treated with laser acupuncture therapy are Zhouliao (LI12), Chize (LU5), Quchi (LI11), Shousanli (LI10) and Ashi.
223785409|NCT06535594|OTHER|Physical therapy|Physical therapy method involved six elbow joint exercises. Patients performed the six exercises sequentially under guidance, each exercise performed five times, three times a day, gradually increasing weight until the movement was effective but below the pain threshold.
223785410|NCT01820728|DRUG|DA-3801 Injection|
223785411|NCT01820728|DRUG|Gonal-F®|
223785412|NCT05409014|OTHER|PFMT|The phase 1 of the protocol was awareness-raising, the athlete receives guidance from a physical therapist and learns the location of the PFM and the ability to contract them in isolation. The phase 2 is stabilization, consisting of 15 stabilization exercises, which are performed through pelvic floor contractions for 10 seconds and with the same relaxation time, repeating each group 10 times. The phase 3 is strength, the same exercises as the second phase are performed using 2 kg weights at the end of each leg and/or arm. There are eight groups of exercises and with changes in the time of slow contraction and relaxation. The phase 4 is power, in power exercises the training loads are increased and the sequence of movements is also increased. The phase 5 is to complement the power, this phase was the continuation of the previous one in the sense of potentiation of the results where ballistic movements, speed and impact fundamentally predominate.
223785413|NCT05131295|DRUG|Dapsone|Dapsone is a drug that has been used clinically for several decades due to its anti-infective effect. It has an anti-inflammatory effect due to its inhibitory action on neutrophils. Neuroprotective effects have been found experimentally with the use of dapsone, predominantly through its glutamate receptors antagonistic effect; these are the main receptors involved in neuronal excitotoxicity.
223785414|NCT05131295|DRUG|Aluminum Hydroxide Gel|Aluminum Hydroxide Gel is an antacid that works quickly to lower the acid in the stomach
223785415|NCT00142974|DRUG|Tegaserod|
223785416|NCT03551015|OTHER|Change in the timing of components of usual care|Bringing forward outpatient review, and cardiac rehabilitation after CABG by 3 and 4 weeks respectively.
223785417|NCT00000831|DRUG|Lamivudine|
223785418|NCT00000831|DRUG|Stavudine|
223785419|NCT00000831|DRUG|Zidovudine|
223785420|NCT00000831|DRUG|Didanosine|
223785421|NCT00970502|DRUG|erlotinib + celecoxib|In this phase I/II study, patients will be treated with daily erlotinib 150 mg and twice-daily celecoxib 200 to 600 mg for 14 days. Re-irradiation with IMRT will start on day 15 and will continue for 5.5 to 6.5 weeks along with erlotinib and celecoxib. After completion of radiation, patients will be given the option of continuing on erlotinib for 2 years or until unacceptable toxicity or disease progression
223785422|NCT00655187|OTHER|Collection of information|Information regarding demographic characteristics, medical history, previous participation in rotavirus clinical trials and vaccination history will be collected.
223785423|NCT00655187|PROCEDURE|Collection of stool samples|Stools samples will be collected during hospitalisation for RV testing and genotyping of RV positive samples.
223785424|NCT06116773|OTHER|Training|"Training group is supervised exercise group and will be included in a supervised cardiac rehabilitation program for 3 days a week. The program will start 2 weeks after CABG surgery and continue for 8 weeks, totaling 24 sessions. Aerobic, resistance, balance and stretching exercises will be applied within the program. Total exercise time is aimed to be ≥150 min/week for 8 weeks. A home-based exercise program will be recommended.~Moderate-intensity continuous aerobic training will be implemented using an upright exercise bike (5 minutes warm-up, 20 minutes load, 5 minutes cool down, 5 minutes recovery). Rhythmic unloaded aerobic exercises or low-load (0.5-1 kg) resistance exercises (starting from the 6th week post-op) will be performed for an average of 15-20 minutes. Balance exercises will progress from easy to difficult depending on the person's performance. Stretching exercise for the gastrocnemius muscle will be performed for 4 repetitions in a short stretching period of 15 seconds."
223785425|NCT06116773|OTHER|Control|"Patients will be informed about secondary prevention approaches which is routinely performed after discharge after CABG operation and will be recommended a home-based exercise program. Patients will be called by phone once a week and exercise monitoring will be provided. Recommended home exercise program includes:~* Breathing exercises~* Moderate intensity (RPE 4-6) walking (150 min/week).~* Posture exercises (shoulder elevation-depression, 90 degree shoulder flex-extend, 90 degree shoulder abd-add, neck joint range of motion exercises)~* They will be advised to continue range of motion exercises in the early post-operative period. (Twice a day, 10 repetitions).These exercises include ankle dorsi-plantar flexion, hip abduction-adduction, hip internal-external rotation, hip flexion-extension, arm elevation-depression in the supine position; flexion-extension in the sitting position; hip abduction-adduction, hip hyperextension and counting movements in the standing position."
223785426|NCT00870805|PROCEDURE|bilateral ultrabrief ECT|Bilateral ECT at 3-4 times seizure threshold with an ultrabrief pulse (0.3ms)
223785427|NCT00870805|PROCEDURE|bilateral standard ECT|Bilateral ECT with at 1.5 times seizure threshold with a standard pulse (1.0ms)
223785428|NCT00870805|PROCEDURE|right-unilateral ultrabrief ECT|Right-unilateral ECT at 6 times seizure threshold with an ultrabrief pulse (0.3ms)
223785429|NCT00870805|PROCEDURE|right-unilateral standard ECT|Right-unilateral ECT with at 5 times seizure threshold with a standard pulse (1.0ms)
223785430|NCT06104215|BIOLOGICAL|BGT007H Injection|BGT007H injection (d0) were infused intravenously once, and the dose group was 2.0× 10\^8 cells,5.0 ×10\^8 cells, 1.0× 10\^9 cells,3.0 × 10\^9 cells,6.0 ×10\^9 cells.
223785431|NCT03811912|DRUG|CTP-543|CTP-543 administered as 8 mg tablet.
223785432|NCT03811912|DRUG|CTP-543 Matching Placebo|Administered as tablets to aid treatment masking.
223785433|NCT05234892|DEVICE|ALTO endograft implantation|Implantantion of aorto-bisiliac ALTO endograft to exclude Abdominal Aortic Aneurysms
223785434|NCT06334770|DEVICE|Roxolid implants|four Straumann BLX® roxolid implant 15% zirconium and 85% titanium), 3.7 mm in diameter, and 10 mm in length.implants were selected with the following criteria: tapered, self-tapping, aggressively threaded,were inserted with novalock attachments.
223785435|NCT06334770|DEVICE|Titanium implants|four conventional acid etched pure implants tapered, self-tapping, threaded, two-piece, with the 10 mm length and 3.7 mm diameter were inserted with Sphero flex attachments.
223785436|NCT06478927|DRUG|Palbociclib capsules|Palbociclib capsules, oral, 125 mg/dose, qd, take 3 weeks and then stop for 1 week, 28d for one treatment cycle until disease progression or intolerable toxicity.
223785437|NCT00002334|DRUG|Saquinavir|
223785438|NCT00002334|DRUG|Zidovudine|
223785439|NCT00002334|DRUG|Zalcitabine|
223785440|NCT04993924|DRUG|Cetrorelix Acetate, Ganerelix Acetate|3-6 days of 0.25 mg starting on day 2-3 of the menstrual cycle
223785441|NCT04390438|PROCEDURE|Percutaneous Electrolysis|Needle emplacement with a galvanic electrical current
223785442|NCT04390438|PROCEDURE|Dry needling|Needle emplacement without electrical current nor substance
223785443|NCT01349634|OTHER|Iodized salt|salt for human consumption is fortified at the national level with iodine. The experimental group will receive iodized salt early. the comparison group will receive it by market forces. presently there is only enough iodized salt to meet 10% of the countries needs, and is targeted mainly to urban areas.
223785444|NCT04337099|DRUG|MBM-02 (Tempol)|Study drug will be administered orally using the capsule formulation (200 mg). The study drug will be administered 7 days a week for the entire treatment period.
223785445|NCT00967850|DRUG|Intravitreal Injection|Intravitreal injection of 1,25 mg in 0,05 ml
223785446|NCT00967850|DRUG|Photodynamic Therapy (Visudyne)|Photodynamic therapy on day 1 as described in standard clinical guidelines.
223785447|NCT01828502|BEHAVIORAL|Education|Participants in both groups will receive education by the EPA on the danger of exposure to secondhand smoke and how exposure can be prevented.
223785448|NCT01828502|BEHAVIORAL|Cotinine Education|Those randomized to the active intervention will also be provided with education utilizing the cotinine test strip in conjunction with the education from the EPA.
223785449|NCT05528081|OTHER|Phone interview|Participants will be interviewed by phone at 3, 12, 24 months after the baseline MRI scans.
223785450|NCT01438411|DRUG|Cholic Acid|10-15 mg/kg body weight/day supplied in 50 or 250 mg Cholic Acid Capsules
223785451|NCT01863680|DRUG|COL-1620|The subjects will be administered with COL-1620 vaginal progesterone gel (1.125 grams of progesterone gel containing 90 milligram that is 8 percent \[%\] gel) vaginally once daily, from the day of ovum pick-up (OPU) until Week 12.
223785452|NCT01863680|DRUG|Gonadotropin-releasing hormone (GnRH) analogue|Subjects will undergo conventional controlled ovarian stimulation (COS) therapy for in-vitro Fertilization and Embryo Transfer (IVF/ET) according to the Investigator's discretion using GnRH analogue (agonist or antagonist) preparation.
223785453|NCT01863680|DRUG|Follicle-stimulating hormone (FSH)|Subjects will undergo conventional COS therapy for IVF/ET according to the Investigator's discretion using FSH containing preparation.
223785454|NCT01863680|DRUG|Human Chorionic Gonadotropin (hCG)|Subjects will undergo conventional COS therapy for IVF/ET according to the Investigator's discretion using hCG preparation.
223785455|NCT00618514|DEVICE|Bright Tip Laser Fiber|Endovenous laser ablation treatment for varicose veins in a section of the Greater Saphenous Vein (GSV) using a laser fiber with a fitted ceramic tip on the end. Treatment performed on one leg.
223785456|NCT00618514|DEVICE|Bare Tip Laser Fiber|Endovenous laser ablation treatment for varicose veins in a section of the Greater Saphenous Vein (GSV) using a laser fiber readily available on the market with a bare tip on the end. Treatment performed on one leg.
223785457|NCT06536127|DIAGNOSTIC_TEST|Blood samples|Nk cells and ImmunoScore
223785458|NCT06322472|OTHER|The Turkish Early Language Development Test (TEDIL)|The Turkish Early Language Development Test (TEDIL) is a test that measures the receptive and expressive language skills of children between the ages of 2 and 7 years and 11 months.
223785459|NCT06322472|OTHER|The Family Literacy Scale|The Family Literacy Scale, which is a reliable and valid measurement scale, was developed by Kılıç, Doğan, and Özden (Kılıç, Doğan, and Özden 2017). The items of the scale consist of questions about parental literacy, child literacy, and early literacy. Parental Literacy Scale to identify and analyse situations such as the use of literacy skills, role modelling for children, performing simple literacy activities at home, on the street, etc. and generally helping children to learn to read and write.
223785460|NCT06322472|OTHER|The Early Childhood Phonological Sensitivity Scale (PASECP)|The Early Childhood Phonological Sensitivity Scale (PASECP), developed by Sarı and Aktan Acar (2013), measures the phonological awareness of children aged 60-72 months (Sari and Aktan Acar 2013).
223785461|NCT06322472|OTHER|The Early Literacy Home Environment Scale (ELHES)|The Early Literacy Home Environment Scale (ELHES) developed by Karaahmetoğlu and Turan is a reliable and valid questionnaire for assessing the early literacy home environment of families with children aged 0-6 years (Karaahmetoğlu and Turan 2020)
223785462|NCT06322472|OTHER|Demographic Questionaries|The demographic survey was prepared by the researchers. The demographic survey includes questions about educational status and family's socio-economic status.
223785463|NCT05294068|OTHER|standard of care for patients with cognitive impairments|clinical examination, radiological, biological and physiological examinations.
223785464|NCT05294068|OTHER|standard of care for patients with neuromotor impairments|clinical examination, radiological, biological and physiological examinations.
223785465|NCT05294068|OTHER|standard of care for patients with sensory impairments|clinical examination, radiological, biological and physiological examinations.
223785466|NCT02114593|BEHAVIORAL|Parent support program|Parent support program
223785467|NCT00566228|PROCEDURE|autologous hematopoietic stem cell transplantation|Patients undergo autologous stem cell transplantation
223785468|NCT00566228|PROCEDURE|leukapheresis|Stem cells collected
223785469|NCT00694317|DRUG|Zaleplon|Short term treatment of insomnia
223785470|NCT00956865|OTHER|Voucher|Vouchers given to reimburse transportation
223785471|NCT00956865|OTHER|Telephone Call|Telephone reminder calls
223785472|NCT00956865|OTHER|Contact|Contact at senior center to encourage follow up
223785473|NCT03806153|OTHER|Morphokinetic|The embryos will be observed at a fixed time and according to morphological criteria (Alpha Specialist Group in Reproductive Medicine and ESHRE, 2011). and all the films obtained will be analyzed. Embryos will be classified according to morphokinetic criteria (Ciray et al., 2014).
223785474|NCT05518955|BEHAVIORAL|Virtual reality and eye mask|Participates will receive a virtual reality program 30 min before their sleep and combine with the sleep routine program for consecutive 2 nights in the ICU.
223785475|NCT01787617|BEHAVIORAL|Aerobic Plus Resistance Training Group|Participants randomized to this intervention will engage in both aerobic and resistance training in accordance with Physical Activity Guidelines for Americans, that is 150 minutes of aerobic training and 2 days of additional 20 minutes of resistance training. The aerobic training component will be completed on a treadmill and target training intensity will be self-selected at 65% to 85% of maximal aerobic capacity. Each resistance training session will consist of both upper and lower body exercises: 2 sets of 9 exercises with each set consisting of 10 repetitions.
223785476|NCT01787617|BEHAVIORAL|Control Group|Participants randomized into the control group will not be provided with memberships to any exercise facility, nor will they receive behavioral instruction on how to increase physical activity. They will receive information on living a healthy lifestyle. Such minimal interventions have not been shown to increase physical activity in participants. The participants in this group will undergo the baseline, 10 week, and 20 week testing.
223785477|NCT03418454|DIAGNOSTIC_TEST|Buccal mucosa samples for Extraction of BACTERIAL DNA|"Sampling of the buccal mucosa after informed consent and prior to routine treatment. Similar sampling on follow up after 3,6,9,12 months.~Extracted BACTERIAL DNA (and not human DNA) from clinical samples will be sequenced and analyzed for the 16s rRNA (BACTERIAL ribosome)."
223785478|NCT02267395|OTHER|(1) cranio-cervical flexion test;|Test to determine level of strength for Deep Neck Flexor muscles
223785479|NCT02267395|OTHER|(2) scapular dyskinesis test|Test to determine scapular control
223785480|NCT02267395|OTHER|(3) deep neck flexor endurance test.|Test do determine endurance for the deep neck flexor muscle group.
223785481|NCT02053350|DRUG|Alanyl-glutamine|Alanyl-glutamine, 44g, taken by mouth daily for 10 days
223785482|NCT00672048|OTHER|Computer Tablet|A tablet computer based software application designed to collect structured clinical information from providers and patients at the point of care.
223785483|NCT00672048|OTHER|Continuing Education Course|Annual standard continuing education
223785484|NCT00672048|OTHER|Continuing education|Annual standard continuing education materials
223785485|NCT06241404|PROCEDURE|trigger point therapy|patients who have been treated for shoulder tendinopathy by trigger point therapy
223785486|NCT06241404|PROCEDURE|Exercise therapy|patients who have been treated for shoulder tendinopathy by exercise therapy
223785487|NCT02244944|DRUG|EZ-Urso combination therapy|Ursodiol 13-15 mg per kg per day combined with Ezetimibe (Zetia) 10 mg per day
223785488|NCT03582176|DRUG|Lactose Placebo|One capsule by mouth twice per day
223785489|NCT03582176|DRUG|Ketotifen Fumarate 2mg|2 mg tablets (over-encapsulated into one capsule) by mouth twice per day
223785490|NCT03582176|DRUG|Ketotifen Fumarate 5mg|5 mg tablets (over-encapsulated into one capsule) by mouth twice per day
223785491|NCT02100176|OTHER|Multidisciplinary intensive rehabilitation treatment|The first session comprises cardiovascular warm-up activities, relaxation exercises, muscle-stretching exercises, exercises to improve the range of motion of spinal, pelvic and scapular joints, exercises to improve the functionality of the abdominal muscles, and postural changes in supine position. The second session comprises exercises to improve balance and gait using a stabilometric platform with a visual cue and treadmill plus. The last session is a session of occupational therapy aimed to improve autonomy in daily living activities.
223785492|NCT02100176|DRUG|Rotigotine|Rotigotine 2-8 mg/24 h
223785493|NCT01928719|DRUG|Reduced Nicotine Content Cigarettes|Cigarettes contain 11.6, 7.4, 3.3, 1.4, 0.7, and 0.2 mg nicotine per cigarette
223785494|NCT01928719|DRUG|Same Nicotine Content Cigarettes|about 11.6 mg nicotine per cigarette
223785495|NCT00414700|DRUG|ChondroCelect implantation|"10.000 cells/µl cell suspension for implantation (Autologous Chondrocyte Implantation). ChondroCelect consists of characterised autologous cartilage-forming cells expressing a specific marker profile.~The dose depends on the size of the lesion. Recommended dose is 0.8 to 1.0 million cells/cm²."
223785496|NCT00414700|PROCEDURE|Microfracture|A procedure in which the subchondral bone is perforated to allow a bloodcloth to form scar tissue.
223785497|NCT06223620|OTHER|review performance of water soluble contrast|review performance of water soluble contrast study in patients admitted with SBO, will improve quality and safety, and decrease length of stay and morbidity.
223785498|NCT00260468|OTHER|Clinical examination program|Psychiatric/clinical interview MRI scan Blood samples Saliva samples Eye examination
223785499|NCT03412669|OTHER|Supporting Addiction Affected Families Effectively|Counselling
223785500|NCT03412669|OTHER|Enhanced Usual Care|Information sheet
223785501|NCT05561738|DIETARY_SUPPLEMENT|Nicotinamide Riboside Chloride|The intervention consists of 6 months to 1 year of daily oral therapy with Nicotinamide Riboside Chloride (Niagen) in addition to standard therapy.
223785502|NCT05561738|DIETARY_SUPPLEMENT|Placebo|The intervention consists of 6 months to 1 year of daily oral therapy with placebo (Maltodextran capsules of similar size, shape and color as Niagen) in addition to standard therapy.
223785503|NCT05561738|OTHER|Standard of Care|Standard of Care
223785504|NCT03170960|DRUG|cabozantinib|Supplied as 60-mg and 20-mg tablets; administered orally daily at dose levels of 20 mg, 40 mg, or 60 mg.
223785505|NCT03170960|DRUG|atezolizumab|Supplied as 1200-mg vials; administered as an IV infusion once every 3 weeks (q3w).
223785506|NCT03170960|DRUG|cabozantinib|Supplied as 60-mg and 20-mg tablets; administered orally daily at the Cohort Review Committee-determined recommended dose from the Dose Escalation Stage
223785507|NCT03170960|DRUG|cabozantinib|Supplied as 60-mg and 20-mg tablets; administered orally daily at 60 mg qd
223785508|NCT06027515|BEHAVIORAL|Prehabilitation Program|Multimodal prehabilitation program consisting of pre-surgical optimization of nutrition, physical function, and sleep health via individualized plans. Participants will also be supplied with Nestle Impact Advances Recovery Immunonutrition Drink.
223785509|NCT02635633|DEVICE|continuous thetaburst stimulation|On 4 consecutive days patients receive 5 cTBS trains with a 10min intertrain-interval. One cTBS train consists of 600 pulses delivered in bursts at theta frequency (200ms) during 40s. Each burst comprises 3 pulses at 50Hz. Focal stimulation occurs over the epileptogenic focus (EF), perpendicular to the local gyral geometry, using online neuronavigation. Stimulation intensity is set relative to the resting motor threshold (rMT) determined at baseline (80% rMT). Stimulation intensity is further adjusted to the coil-cortex distance at the EF with the following formula: adjusted MT% (AdjMT) = rMT + 2,7\*(DEF-DM1) \[DEF = distance over EF; DM1 = distance over M1\]. If rMT exceeds the capacity of the stimulator output, stimulation intensity is 100% of maximal stimulator output (MSO).
223785510|NCT05684328|PROCEDURE|WLI Then NBI Withdrawal|Patients in WLI then NBI withdrawal group will first be carefully inspected by white light imaging(WLI), each polyp found should be removed. According to the ESGE guideline of colorectal polypectomy, the lesions which size between 4-9mm should by removed by cold snare. Cold biopsy forceps could be utilized considering the difficulty in resection of flat and diminutive polyps(size ≤ 3mm). Then change to narrow band imaging(NBI) for the second withdraw to detect the lesions which found in second time but not the first.
223785511|NCT05684328|PROCEDURE|NBI Then WLI Withdrawal|Patients in NBI then WLI withdrawal group will first be carefully inspected by narrow band imaging(NBI), each polyp found should be removed. According to the ESGE guideline of colorectal polypectomy, the lesions which size between 4-9mm should by removed by cold snare. Cold biopsy forceps could be utilized considering the difficulty in resection of flat and diminutive polyps(size ≤ 3mm). Then change to white light imaging(WLI) for the second withdraw to detect the lesions which found in second time but not the first.
223785512|NCT03902704|DEVICE|Cleverscope|the device is used in patients without difficult airways predictors
223785513|NCT03902704|DEVICE|Laryngoscope / Videolaryngoscope C-MAC® Storz|the device is used in patients with difficult airways predictors
223785514|NCT04579757|DRUG|Surufatinib and Tislelizumab _ Part 1|Part 1 (all cohorts): oral surufatinib at a dose based on cohort level and intravenous tislelizumab at a 200-mg dose
223785515|NCT04579757|DRUG|Surufatinib and Tislelizumab _ Part 2|Part 2 (all cohorts): oral surufatinib at the RP2D dose selected in Part 1 and intravenous tislelizumab at a 200-mg dose
223785516|NCT03466333|DRUG|Enalapril Maleate|Enalapril maleate will be encapsulated; participants will take the drug once a day for 6 months following delivery.
223785517|NCT03466333|DRUG|Placebo oral capsule|The placebo will be encapsulated; participants will take the drug once a day for 6 months following delivery. It will be identical in appearance to the IMP.
223785518|NCT04253522|BEHAVIORAL|Cognitive training|Rehabilitation program in standard ergotherapy and cognitive training with Covirtua Software and Transcranial random noise stimulation
223785519|NCT06182254|BEHAVIORAL|Experimental group: OPTIMISTIC follow-up|follow-up by nurses specialized in collecting the patient's point of view concerning his or her state of health, in addition to the usual conventional follow-up according to routine care directive interviews carried out preoperatively and at Days 1, 3, 14 and 28 postoperatively (modified QoR-15f score, PROMS...)
223785520|NCT06182254|OTHER|Control group: Usual conventional follow-up|usual conventional follow-up according to routine care (modified QoR-15f score will be administered to all patients at visit 0 and Day 35).
223785521|NCT04293146|PROCEDURE|pre-pectoral IBBR|The breast is reconstructed by positioning a breast implant above (pre-pectoral) the pectoralis major muscle.
223785522|NCT04293146|PROCEDURE|sub-pectoral IBBR|The breast is reconstructed by positioning a breast implant below (sub-pectoral) the pectoralis major muscle.
223785523|NCT02332720|DRUG|Grazoprevir|Part A: one grazoprevir 100 mg tablet taken q.d. by mouth.
223785524|NCT02332720|DRUG|Uprifosbuvir|Part A: two or three uprifosbuvir 150 mg (300 or 450 mg total daily dose) tablets taken q.d. by mouth.
223785525|NCT02332720|DRUG|Elbasvir|Part A: one elbasvir 50 mg tablet taken q.d. by mouth.
223785526|NCT02332720|DRUG|Ruzasvir|Part A: six ruzasvir 10 mg (60 mg total daily dose) capsules taken q.d. by mouth.
223785527|NCT02332720|DRUG|MK-3682B|Part B and Part C: two FDC tablets, each containing grazoprevir 50 mg + elbasvir 225 mg + ruzasvir 30 mg, taken q.d. by mouth.
223785528|NCT02332720|DRUG|Ribavirin (RBV)|Part B and Part C: RBV 200 mg capsules taken b.i.d. by mouth at a total daily dose of 800 mg - 1400 mg based on participant body weight.
223785529|NCT06128616|DEVICE|ESWT|Extracorporeal Shock Wave Therapy
223785530|NCT06128616|DRUG|Botulinum Toxin Type A|Botulinum Toxin Type A
223785531|NCT06128616|OTHER|Serial Casting|Serial Casting
223785532|NCT06128616|BEHAVIORAL|Physical Therapy|Physical Therapy
223785533|NCT06128616|BEHAVIORAL|Occupational Therapy|Occupational Therapy
223785534|NCT05386160|DRUG|Ranibizumab Injection [Lucentis]|intravitreal injection of Ranibizumab；
223785535|NCT05386160|DEVICE|Phacoemulsification|Phacoemulsification
223785536|NCT05154864|PROCEDURE|SBUF-SMUF|Intra-operative continuous ultrafiltration
223785537|NCT02875587|DRUG|Cabergoline|Cabergoline (Dostinex; Pfizer, Italy) at a daily dose of 0.5 mg is administered orally at bed time for 8 days starting on the day of HCG administration
223785538|NCT02875587|DRUG|Calcium gluconate|Intravenous 10% calcium gluconate, 10 mL in 200 mL of physiologic saline on the day of ovum pickup, day 1, day 2, and day 3 after ovum pickup. Intravenous infusion will be performed within 30 minutes.
223785539|NCT06092996|OTHER|Time of Sling Use|Standard sling worn for only three days post operatively
223785540|NCT03846024|DEVICE|RibFx Orthosis Belt|Each patient in the interventional arm will be fitted with a RibFx orthosis belt, which is to be worn during the majority of their day (excluding showering/bathing). It will be encouraged (though not mandatory) to wear at night. Patients in both the control and interventional arm will be expected to participate in pulmonary hygiene / toilet exercises with guided and independent incentive spirometry as per our normal routine and standard of care. There are no other interventions or procedures that the patients will be subjected to for the research trial- other procedures/interventions will be performed only if the clinical care team feels they are indicated.
223785541|NCT04296617|OTHER|Medical Chart Review|Review of medical chart
223785542|NCT02673658|BEHAVIORAL|Motor + problem solving|Developmental motor tasks incorporating cognitive concepts such as object permanence
223785543|NCT02673658|BEHAVIORAL|body weight support training|Mobility tasks to change positions or move the body with assistance to initiate movement
223785544|NCT06057389|DIETARY_SUPPLEMENT|aronia melanocarpa extract|aronia melanocarpa extract (each capsule contains 150 mg of anthocyanins and 30 mg of flavonoidst；twice a day，one at a time) combined with an energy-restricted diet
223785545|NCT00686400|OTHER|TAU = treatment as usual|medication and psychosocial interventions to be chosen by treating psychiatrist
223785546|NCT03806738|OTHER|Intervention-specific Carevive questionnaire|includes standard of care questions with additional decision-making questions
223785547|NCT03806738|OTHER|Standard of Care questionnaire|includes the standard of care questions that are already in place for Carevive questionnaires
223785548|NCT03725982|DEVICE|Laevo ®|A passive exoskeleton supporting the lower back during bending and lifting tasks (for more information, visit the manufacturer's website: http://en.laevo.nl/).
223785549|NCT03725982|DEVICE|No Laevo ®|The subjects will not wear any supporting device to perform the experiment, which serves as the control condition.
223785550|NCT01703455|DRUG|Sorafenib|400 mg twice daily, on a continuous basis (each morning and evening), in 4 week cycles
223785551|NCT02995603|DEVICE|Nano-X patient rotation|Patients are required to completed validated questionnaires to quantify their experience of horizontal rotation.
223785552|NCT05227508|DIETARY_SUPPLEMENT|BRIZO|A capsule containing 400 mg. SC012 (unique soy extract)
223785553|NCT05227508|OTHER|placebo|Comprecel microcrystalline cellulose
223785554|NCT04035941|BEHAVIORAL|Cycle Nation Multicomponent Intervention|"This intervention group will receive 4 elements:~1. Practical skills programme: a workplace-based programme covering basic cycling skills, delivered by trained 'cycle champions' - HSBC staff members.~2. Cycle provision scheme: participants will have the opportunity to have their own bicycles serviced or obtain a loaned bike or e-bike from local bike shops before the start of the programme.~3. Cycle-friendly workplace culture: all offices taking part will have a minimum of secure bike parking facilities as part of an ongoing roll-out of cycle infrastructure across HSBC UK offices.~4. Our Cycle Hub app: an adapted version of an existing HSBC app including route planning, goal setting and practical skills videos, as well as supportive social interaction among participants."
223785555|NCT03755505|DIAGNOSTIC_TEST|obtain samples from sputum, feces and urine|Samples are obtained from participants. No further intervention is required. Obtained samples will be further analyzed.
223785556|NCT03319277|OTHER|Decreased opiate prescription|The experimental group will receive 5 tablets of oxycodone 5mg at time of discharge with a paper backup prescription for an additional 10 tablets.
223785557|NCT03319277|OTHER|Routine opiate prescription|The comparator group will receive 28 tablets of oxycodone 5mg at time of discharge.
223785558|NCT05826392|OTHER|Adolescent/Young Adult Self-Administered Web-Based Single-Session Intervention|Web-Based, 30-minute self-administered intervention for adolescents
223785559|NCT03089086|BIOLOGICAL|Licensed 4CMenB vaccine|Two doses (0.5 mL each) of Bexsero ® vaccine at least 1 month to \<3 months apart in adolescents.
223785560|NCT04649398|DRUG|Nimodipine|If application of nimodipine is clinically indicated patients will be enrolled in the study protocol according to the inclusion and exclusion criteria. The clinically appropriate route of administration will be administered according to the recommended regimen of the study drug; i.e. within the first 10-14 days intra-venous infusion and thereafter oral administration. Intra-arterial infusion will be performed due to severe cerebral vasospasm with impending stroke.
223785561|NCT05428566|DIETARY_SUPPLEMENT|Pulse-based diet|"An isocaloric, balanced diet with a fixed macronutrient composition of 28% fat, 55% carbohydrate, and 17% protein.~The pulse diet will include two pulse-based meals; each pulse meal will be consisted of about one cup of non-oil seed pulses, different varieties of pulses (dried beans, peas, lentils, lupine and chickpeas) will be used."
223785562|NCT05428566|DIETARY_SUPPLEMENT|TLC diet|"An isocaloric, balanced diet with a fixed macronutrient composition of 28% fat, 55% carbohydrate, and 17% protein.~The healthy TLC diet will be tailored for each participant according to their energy levels in order to achieve the following amount of nutrients: less than 7% of total calories of saturated fatty acids, up to 10% of total calories of polyunsaturated fat, up to 20% of total calories of monounsaturated fat, less than 200 mg a day of cholesterol, at least 5 to 10 grams a day of soluble fiber."
223785563|NCT03832010|DRUG|Crisaborole|Participants will be instructed to apply crisaborole to affected areas with eczema.
223785564|NCT03832010|DRUG|Hydrocortisone Ointment|Participants will be instructed to apply hydrocortisone to affected areas with eczema on face, armpits or groin.
223785565|NCT03832010|DRUG|Triamcinolone ointment|Participants will be instructed to apply triamcinolone to affected areas on the body excluding face, armpits or groin.
223785566|NCT03832010|DRUG|Aquaphor|Participants will be instructed to moisturize all over the body with Aquaphor.
223785567|NCT06258967|DRUG|ciprofol|Patients receive ciprofol as general anesthesia induction drug, using the titrated anesthesia method.
223785568|NCT06258967|DRUG|propofol|Patients receive propofol as general anesthesia induction drug, using the titrated anesthesia method.
223785569|NCT05388253|BEHAVIORAL|Static Stretching|Using Static Stretching exercises
223785570|NCT05388253|BEHAVIORAL|Deep Kneading Massage|Using Deep Kneading Massage technique
223785571|NCT06177964|DRUG|Lerapolturev|"Lerapolturev (intratumoral) will be dosed at 2x108 TCID50 in 3.0 mL x 2 doses (total dose 4x108 TCID50) by Convection Enhanced Delivery.~For the patients randomized to the lerapolturev Arm 1 of Stage 2, seven days (±2 days) following completion of the 2nd intratumoral infusion of lerapolturev, patients will begin cervical perilymphatic subcutaneous injection of lerapolturev at a dose of 2 x 108 TCID50 (in 0.5 ml diluent) around the cervical lymph node chain ipsilateral to the intracranial tumor."
223785572|NCT06177964|DRUG|Lomustine Pill|Lomustine will be given as a single oral dose of 110 mg/m2 every six weeks for up to 9 cycles.
223785573|NCT06175819|OTHER|Manuka honey( MgO 850, UMF+20) loaded nano-formulation|Assessment of the efficacy of manuka-loaded nano-formulation and manuka honey-loaded gel on the improvement of acne vulgaris
223785574|NCT06097949|DEVICE|AcuPebble SA100|This device is not being used as an interventional device but simply a monitoring tool on patients already on CPAP therapy. The device is being used within the scope of it's intended purpose as a medical device to diagnose OSA.
223785575|NCT04897958|DRUG|Degarelix|Degarelix dispensing claim is used as the reference group.
223785576|NCT04897958|DRUG|Leuprolide|Leuprolide dispensing claim is used as the exposure group.
223785577|NCT00170118|BEHAVIORAL|motivational interviewing|
223785578|NCT03132454|DRUG|Decitabine|Given IV
223785579|NCT03132454|DRUG|Dexamethasone|Given IV or PO
223785580|NCT03132454|DRUG|Palbociclib|Given PO
223785581|NCT03132454|DRUG|Sorafenib|Given PO
223785582|NCT04743908|OTHER|Social Network Strategy + COVID-19 messaging|Contextually adapted and theory-driven messages - misinformation correction and self-affirmation - to increase awareness, self-efficacy and community engagement in our adapted Social Network testing Strategy (SNS). SNS is an evidence-based testing intervention that has been widely used in multiple settings with marginalized individuals (ie substance-users) who facilitate the recruitment of their social contacts into testing services.
223785583|NCT00328510|DEVICE|GTC frame|
223785584|NCT00328510|DEVICE|Thermoplastic facemask|
223785585|NCT00328510|RADIATION|Stereotactic radiation therapy|
223785586|NCT06633263|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|Introduce self-recording with the sleep diary; Introduce basic notions of insomnia; Introduce basic notions of sleep hygiene; Introduce basic notions of sleep; Recreate a time and place dedicated to sleep; Limit time spent in bed to time slept; Promote attitudes and beliefs that favor sleep and manage worries; Relapse prevention. This intervention is empirically validated (Morin, 2022).
223785587|NCT06633263|BEHAVIORAL|Behavioral Activation Treatment for Depression|Introduce self-recording with daily activities; Introduce the basic concept of depression; Identify and increase activities associated with positive reinforcement; Reflect on life domains and values to identify reinforcing activities; Identify and decrease activities associated with negative reinforcement; Identify and decrease activities associated with negative reinforcement; Relapse prevention. This intervention is empirically validated (Ciharova et al., 2021)
223785588|NCT04097132|DEVICE|echocardiography|echocardiography for left atrial diameter, size ,Ejection Fraction Holter for detection of paroxusmal AF
223785589|NCT02298218|DRUG|Meloxicam|The intervention drug, meloxicam is safe medicine which is used to treat pain or inflammation caused by osteoarthritis or rheumatoid arthritis in adults and children who are at least 2 years old. It may also be used for purposes not listed in the medication guide. It will be taken once a daily with a dose of 0.125 mg/kg/day (high-dose group) or 0.06 mg/kg/day (low-dose group). After 6 months of medication, the maintenance will be decided by the comparison of liver stiffness score before and after the intervention.
223785590|NCT02239887|DEVICE|WaveCrest LAA occlusion device|Left Atrial Appendage Occlusion
223785591|NCT05489926|DRUG|Pamiparib|Pamiparib, 60mg PO BID
223785592|NCT05356221|DEVICE|Ponto Sound processor|Bone Anchored Hearing solution fitted to compensate for the subjects hearing loss
223785593|NCT06958094|OTHER|Gamified mobile health applications|"* Voice Volume Catcher: A game where players control a character's movement by modulating their voice volume. Louder or softer sounds move a basket to collect different types of fruits, encouraging continuous vocal engagement and fine control of breath intensity.~* Scream Go Hero: A voice-controlled platform game where players produce short or long vocalizations to make the hero character jump or move across obstacles. The game demands breath control and supports prolonged exhalations for larger jumps with an open glottis, which is beneficial for airway clearance.~* Chicken Scream: A voice-activated game where players guide a chicken character by varying their vocal intensity to make it walk, jump, and avoid enemies. Participants must dynamically adjust their breath pressure and vocal intensity while maintaining open-glottis breathing, promoting agility in respiratory control."
223785594|NCT06958094|OTHER|Conventional Airway Clearance Therapy|"* Autogenic Drainage: A technique where participants perform a series of controlled breathing cycles-deep inhalations followed by forceful exhalations-to mobilize mucus from the lower airways to the upper airways. The technique encourages breath control and helps clear secretions without the need for coughing, promoting efficient airway clearance.~* Active Cycle of Breathing Techniques (ACBT): In this technique, participants alternate between relaxed breathing, deep breaths, and huffing to mobilize and expel mucus from the lungs. It focuses on breathing control to loosen and expel secretions effectively while maintaining a steady airflow throughout the process.~* Positive Expiratory Pressure (PEP) Therapy: This technique involves exhaling against a resistance through a device, which helps to open the airways and prevent their collapse. The resistance promotes prolonged exhalations, facilitating the movement of mucus from the small airways to the larger airways for easier clearance."
223785595|NCT06958094|OTHER|Combination Treatment|"\- Gamified mHealth Apps (10 minutes):~Voice Volume Catcher~Scream Go Hero~Chicken Scream~\- Conventional Airway Clearance Techniques (10 minutes):~Autogenic Drainage~Active Cycle of Breathing Techniques (ACBT)~Positive Expiratory Pressure (PEP) Therapy"
223785596|NCT03582306|BEHAVIORAL|High chlorophyll diet - intervention 1st|Participants will be provided frozen dark leafy green vegetables, and counseled to consume 1 cup cooked dark green leafy vegetables (2 servings) daily over the 4 week period while maintaining their normal red meat intake. This will occur during the first 4 week period of the study.
223785597|NCT03582306|BEHAVIORAL|High chlorophyll diet - control 1st|Participants will be provided frozen dark leafy green vegetables, and counseled to consume 1 cup cooked dark green leafy vegetables (2 servings) daily over the 4 week period while maintaining their normal red meat intake. This will occur during the last 4 week period of the study.
223785598|NCT05027217|OTHER|No intervention|No intervention. Arms are subdivided based on patients' diagnostic status on admission to ICU.
223785599|NCT02061384|DRUG|13-cis retinoic acid|Accutane is used for the treatment of severe acne
223785600|NCT02061384|DRUG|Calcitriol|Calcitriol is a form of vitamin D given twice daily (BID)
223785601|NCT03240588|DEVICE|Neurostimulation System|Spinal cord stimulation
223785602|NCT06573632|DIETARY_SUPPLEMENT|TPN-N7 Baxter|providing TPN to all malnutrition patients preoperatively as well as postoperatively.
223785603|NCT04440111|OTHER|One year training|"At first, children will make a test to evaluate their pre- intervention basic support life knowledge.~Secondly, they will receive a theoretical class about BLS, based on European Resuscitation Council Guide 2015.~After that, they will make a practical workshop on BLS. Finally they will repeat the initial test. The second year, this group will only make the test, they won't receive any theory or practice."
223785604|NCT04440111|OTHER|Two years training|"At first, children will make a test to evaluate their pre- intervention basic support life knowledge.~Secondly, they will receive a theoretical class about BLS, based on European Resuscitation Council Guide 2015. After that they will make a practical workshop on BLS.~Finally they will repeat the initial test. The second year, this group will repeat the same process."
223785605|NCT06516588|DEVICE|Transcranial Dirrect Current Stimulation|tDCS will deliver direct current through rubber electrodes in saline-soaked sponges. Device sends a low-level current from the positive electrode, the anode, to the negative electrode, the cathode. Direct current will be transferred by a saline-soaked pair of surface sponge electrodes (35cm2) and delivered by a specially developed, battery-driven, constant current stimulator with a maximum output of 10mA. The anode will be placed over the LDLPFC and the cathode over the contralateral supra-orbital area.
223785606|NCT03199365|BEHAVIORAL|Behavioral Dietary Intervention|Undergo TSSC intervention sessions
223785607|NCT03199365|BEHAVIORAL|Behavioral Intervention|Undergo TSSC intervention sessions
223785608|NCT06634992|OTHER|Oral immunotherapy|Clinical Follow up
223785609|NCT06634758|BEHAVIORAL|Nursing interventions based on the Watson Human Caring Model|In the literature review, it was noticed that nursing care based on the Watson Human Caring Model was applied to various patient groups but not to patients with MS.
223785610|NCT03363373|BIOLOGICAL|GM-CSF + Naxitamab|Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) and Humanized IgG1 monoclonal GD2 antibody
223785611|NCT06532266|DEVICE|TechTrade Ready Heat Half Body Temperature Management Blankets|"The thermal blanket will be placed on top of the cotton blanket. Newborn will be first covered with conventional warm blanket then adding the thermal blanket on top. The thermal blanket will be placed inside a pillowcase like cotton blanket to avoid direct contact with mother or newborn."
223785612|NCT06532266|OTHER|Control|3 layers of 100% cotton woven blankets
223785613|NCT04409964|DRUG|Dexmedetomidine Hydrochloride|dexmedetomidine iv bolus followed by the infusion of 0.1-1 ug/kg/hr during general anesthesia
223785614|NCT04409964|DRUG|Lidocaine Hydrochloride|lidocaine iv bolus followed by the infusion of 1.5 mg/kg/hr during general anesthesia
223785615|NCT04409964|DRUG|Remifentanil Hydrochloride|remifentanil iv infusion of 0.5-5 ng/ml (effect site concentration using TCI) during general anesthesia
223785616|NCT06297538|DEVICE|gamma transcranial alternating current stimulation (tACS)|Transcranial alternating current stimulation (tACS) will be delivered using a BrainSTIM (EMS, Italy) connected to two electrodes (5x5cm) enclosed in sponges soaked with saline solution. One electrode will be centred over the first dorsal interosseus (FDI) hotspot and the other over P3. tACS will be delivered at peak-to-peak amplitude of 1 milliampere (mA), and with 3-seconds ramp-up and down periods. The stimulation frequency will be 70 Hz, as representative of the endogenous motor network-related gamma frequency.
223785617|NCT06297538|DEVICE|sham transcranial alternating current stimulation (tACS)|Sham-tACS will consist of ramp-up and down periods and only 1-second stimulation at 1 mA amplitude.
223785618|NCT01621360|PROCEDURE|Arthroscopic hip surgery|Hip arthroscopy
223785619|NCT01621360|OTHER|Physical therapy|Physical therapy aimed at strengthening and stabilization of the hip and appropriate analgesic and anti-inflammatory medication.
223785620|NCT06502314|BEHAVIORAL|Stress management training|"It is a psychoeducational program that includes seven modules (1. Stress and its components, 2. Stress Management, 3. Crisis and its components, 4. Crisis Management, 5. Anger and its components, 6. Anger Management, 7. Psychological resilience)~."
223785621|NCT01366833|RADIATION|Brachytherapy|Patients in arm B will receive a single dose of brachytherapy (10Gy) via a 10 or 13 mm catheter within 10days of stent insertion. Patients on the study will not be given preferential treatment, and will not be prioritized over patients treated with brachytherapy not on the study.
223785622|NCT01366833|PROCEDURE|Stent insertion|After placement of clips to mark the proximal and distal extent of the tumor, an endoscopically placed self-expanding metallic stent (WallFlex™ Partially Covered Esophageal Stent by Boston Scientific) will be inserted within 10 days of recruitment. This will be the only intervention in Arm A patients.
223785623|NCT00004010|BIOLOGICAL|bleomycin sulfate|
223785624|NCT00004010|BIOLOGICAL|filgrastim|
223785625|NCT00004010|DRUG|ABVD regimen|
223785626|NCT00004010|DRUG|cyclophosphamide|
223785627|NCT00004010|DRUG|dacarbazine|
223785628|NCT00004010|DRUG|doxorubicin hydrochloride|
223785629|NCT00004010|DRUG|etoposide|
223785630|NCT00004010|DRUG|prednisone|
223785631|NCT00004010|DRUG|procarbazine hydrochloride|
223785632|NCT00004010|DRUG|vinblastine sulfate|
223785633|NCT00004010|DRUG|vincristine sulfate|
223785634|NCT00004010|RADIATION|radiation therapy|
223785635|NCT06275646|OTHER|PRP layer|platelet rich plasma layer was applied in addition to dartos flap
223785636|NCT06275646|OTHER|dartos flap|dartos flap alone was used
223785637|NCT01836692|RADIATION|Intensity Modulated Radiotherapy treatment|Intensity Modulated Radiotherapy treatment
223785638|NCT03001648|PROCEDURE|PGS (Preimplantation Genetic Screening) with trophectoderm biopsy|PGS (Preimplantation Genetic Screening) with trophectoderm biopsy using arrays comparative genomic hybridizatioon (aCGH)
223785639|NCT01477827|OTHER|None - observational study|
223785640|NCT03943732|DIAGNOSTIC_TEST|FilmArray Pneumonia|FilmArray Pneumonia testing of tracheal sample
223785641|NCT03422250|DEVICE|transcranial direct current stimulation (tDCS)|10 daily 25-minutes tDCS sessions over two weeks.
223785642|NCT03666039|BEHAVIORAL|Trainings app|Sensorimotor trainings app for at home Training (tablet-based)
223785643|NCT03812146|BEHAVIORAL|PC-TIME|PC-TIME consists of five, 30-minute sessions delivered over 8 weeks. Intervention will be delivered by a behavioral health provider and will consist of brief Prolonged Exposure for PTSD integrated with aspects of the Motivational Interviewing counseling approach.
223785644|NCT03812146|BEHAVIORAL|PC-TAU|PC-TAU consists of Brief Advice intervention from their PC medical provider that is built into the electronic medical record as a mandatory response to a positive screen. In addition, patients who score positive on the AUDIT-C or PC-PTSD are offered a referral to the PCMHI provider within the PC clinic. PCMHI in VA consists of licensed, independent providers (typically psychologists or clinical social workers) providing brief assessment and interventions to veterans and consultation to other members of the PC team. PCMHI sessions are typically focused on assessment, psycho-education, and supportive counseling.
223785645|NCT05130658|DEVICE|Virtual reality treadmill training|C-Mill (Motekforce Link, Amsterdam, The Netherlands) is an instrumented treadmill that uses visual (on the screen as well on the treadmill) and acoustic cues for gait and balance training. The C-Mill allows for gait and balance adaptability strategy as it can provide obstacle avoidance environments, change in speed and various walking pathways in a safe and controlled environment.
223785646|NCT05130658|OTHER|Treadmill Training|Conventional gait and balance training using treadmill.
223785647|NCT05133557|OTHER|Chewing gum containing xylitol and blackberry extract (BBE)|On the day of gum chewing, four pieces of gum were provided per the assigned group, and each volunteer was requested to chew the gum four times daily (i.e., at 9 am, 11 am, 1 pm and 3 pm). Each gum chewing interval was for 20 minutes.
223785648|NCT02091726|PROCEDURE|Unicirc instrument plus cyanoacrylate tissue adhesive|Volunteers will be circumcised using the Unicirc surgical instrument and the incision will be sealed using cyanoacrylate tissue adhesive
223785649|NCT01895387|DIETARY_SUPPLEMENT|Dietary intervention-whole grains and legumes|Subjects in the whole-grain group consumed replacing of refined rice intake with 1/3 of legumes, 1/3 of barley, and 1/3 of wild rice three times per day as a carbohydrate source and increased vegetable intake to at least 6 units (30-70 g/unit) per day for sufficient dietary fiber intake.
223785650|NCT01895387|DIETARY_SUPPLEMENT|Dietary intervention-Refined rice|Subjects in the control group maintained their usual diet of refined rice
223785651|NCT03877523|DIETARY_SUPPLEMENT|Cocarnit|a metabolic complex
223785652|NCT05461872|OTHER|No intervention|No intervention
223785653|NCT00855517|DRUG|Latanoprost-PPDS|Control of IOP compared to baseline for the experimental dose of Latanoprost-PPDS for 6 weeks or until loss of efficacy.
223785654|NCT00467870|DRUG|Testosterone Undecanoate 750 mg|
223785655|NCT00467870|DRUG|Testosterone Undecanoate 1000 mg|
223785656|NCT06580626|PROCEDURE|decompression technique|14 implants will be placed in patients of missing single tooth or multiple teeth in posterior mandible with subsequent horizontal ridge augmentation by decompression technique.
223785657|NCT06580626|PROCEDURE|guided bone regenaration using Ethoss|14 implants will be placed in patients of missing single tooth or multiple teeth in posterior mandible with subsequent horizontal ridge augmentation by guided bone regeneration using β-TCP/CS synthetic bone substitute.
223785658|NCT06580626|PROCEDURE|ridge splitting technqiue|14 implants will be placed in patients of missing single tooth or multiple teeth in posterior mandible with subsequent horizontal ridge augmentation by ridge splitting technique using piezosurgery.
223785659|NCT00815841|DRUG|METHYLPHENIDATE|15-20mg during one of the two sessions
223785660|NCT05481762|DEVICE|Aided read with contextflow DETECT Lung CT|Radiologists read chest CT scabs with and without the aid of contextflow DETECT Lung CT as a second reader
223785661|NCT04157244|BEHAVIORAL|Tailored music listening intervention|The music intervention consists of listening to preferred soothing music at bedtime for 30 minutes every night for four weeks (28 sessions total). This theory based caregiver-assisted intervention builds on the evidence-based protocol of using individualized music to decrease agitation in nursing home residents. It also accounts for sleep-inducing properties of music.
223785662|NCT04174092|OTHER|completing self-questionnaires|completing self-questionnaires on quality of life, anxiety, insomnia, activity of rheumatic disease and catastrophism
223785663|NCT04965844|DEVICE|Oxygen close-loop|The Automatic FiO2 option provides automated adjustment of the ventilator Oxygen setting to maintain the patient's SpO2 in a defined target range. When using the software option, the user defines the SpO2 target range, as well as the SpO2 emergency limits, and the device adjusts the Oxygen setting to keep the patient's SpO2 in the target range.
223785664|NCT04965844|DEVICE|No intervention|Manual FiO2 adjustment according to SpO2 values
223785665|NCT02090738|DRUG|Acetazolamide group|
223785666|NCT02090738|DRUG|Standard regimen group|
223785667|NCT04933682|DRUG|ALXN2050|Oral tablet.
223785668|NCT04933682|DRUG|Fluconazole|Oral tablet.
223785669|NCT04933682|DRUG|Rifampin|Oral capsule.
223785670|NCT03900260|DEVICE|Softec HP1 Intraocular Lens|The Softec HP1 IOL is a single-piece, biconvex, ultraviolet absorbing intraocular lens designed for insertion into the posterior chamber of the human eye for visual correction of Aphakia in adults over the age of 21, and as a replacement of a damaged (cataract) natural lens.
223785671|NCT02600130|BIOLOGICAL|Longeveron Mesenchymal Stem Cells|via peripheral intravenous infusion
223785672|NCT02600130|BIOLOGICAL|Placebo|via peripheral intravenous infusion
223785673|NCT04892654|DRUG|Doravirine|Antiretroviral, Non-nucleoside Reverse Transcriptase Inhibitor
223785674|NCT04892654|DRUG|Dolutegravir|Antiretroviral, Integrase strand transfer inhibitors
223785675|NCT04892654|OTHER|Triple cART regimen|Participant standard triple cART regimen
223785676|NCT03430154|OTHER|No treatment given|No treatment given
223785677|NCT00731315|OTHER|Computer-assisted treatment group|This group will receive computer-assisted expedited treatment for uncomplicated UTI or complicated cystitis based on their symptoms and past medical history reported on the computer.
223785678|NCT00731315|OTHER|Usual care group|This group will receive usual care for an uncomplicated UTI or complicated cystitis in the Emergency Department or Community Health Center.
223785679|NCT00559559|DEVICE|ICD implant + Patient Notifier turned OFF|ICD implant, plus standard care, i.e. Patient Notifier turned off
223785680|NCT00559559|PROCEDURE|ICD Implant + Patient Notifier turned ON|ICD implant. The Patient Notifier™ feature will be turned ON.
223785681|NCT00941239|DRUG|metformin ER|850mg daily for 30 days
223785682|NCT00941239|DRUG|metformin|850 mg daily for 30 days
223785683|NCT02312739|PROCEDURE|In-office Transcervical Sterilization (Essure®)|The standard transcervical sterilization procedure is not being evaluated in this study, and will be performed in the same manner in the two study arms. The procedure includes a standardized paracervical block with 1% lidocaine. A 5mm operative hysteroscope is passed through the cervix and into the uterine cavity using normal saline for uterine distention. Each tubal ostium is identified, followed by deployment of the device into each fallopian tube. A confirmatory test, hysterosalpingogram, is required at 90 days post procedure to demonstrate successful sterilization.
223785684|NCT02312739|DRUG|Standard Oral pain medications|one 5/325mg hydrocodone/acetaminophen (Vicodin) tablet and one 1mg Lorazepam tablet given to patients randomized to the active comparator arm at least 30 minutes before the procedure
223785685|NCT02312739|DRUG|Intramuscular Ketorolac|30mg of intramuscular ketorolac given to all patients at least 30 minutes before the procedure
223785686|NCT02312739|DRUG|Placebo pills|Two placebo bills given to patients randomized to the experimental arm at least 30 minutes prior to the procedure
223785687|NCT02312739|OTHER|Oxygen|Oxygen at 5L/min given to patients randomized to the active comparator arm
223785688|NCT02312739|OTHER|Nitrous Oxide|Nitrous oxide with a maximum titration of up to 70% given to patients randomized to the experimental arm
223785689|NCT04511715|DRUG|Intravitreal Bevacizumab IVB|Intravitreal Bevacizumab IVB group (50 eyes) that receive 6 bimonthly IVBs within a period of 10 months following the enrollment
223785690|NCT04511715|OTHER|Follow-up with regular examination for determination of DR progression|regular examination for determination of DR progression
223785691|NCT05675345|DEVICE|HFNC only|HFNC for 45 minutes, with FiO2 titrated to SpO2 of 90-97%
223785692|NCT05675345|DEVICE|HFNC + CNEP10|HFNC with CNEP of 10 cmH2O for 45 minutes, with FiO2 titrated to SpO2 of 90-97%
223785693|NCT05675345|DEVICE|HFNC + CNEP20|HFNC with CNEP of 20 cmH2O for 45 minutes, with FiO2 titrated to SpO2 of 90-97%
223785694|NCT05675345|DEVICE|HFNC + CNEP30|HFNC with CNEP of 30 cmH2O for 45 minutes, with FiO2 titrated to SpO2 of 90-97%
223785695|NCT02179112|PROCEDURE|Emergency Abdominal Surgery|Emergency intra-peritoneal surgery (only exclusion: Caesarian section).
223785696|NCT00606424|DRUG|20 mCi dose for a 50 kg individual of [F-18]HX4|All subjects, normal volunteers and cancer subjects will receive HX4 administered through a previously placed suitably sized angiocatheter or a butterfly needle. Prior to injection, qualified site personnel will assay the dose in the dose calibrator and document the activity of the dose and time of assay. After injection, the line will be flushed with saline (approximately 10 mL).
223785697|NCT00444548|DRUG|[S,S]-Reboxetine|
223785698|NCT05045521|OTHER|plyometric warm up group|"participants will be asked to do 10 minutes self-paced jog on motorized treadmill.~During the plyometric intervention, subjects will perform the 2 \* 8 squat jumps, 2 \* 8 scissor jumps, and 2 \* 8 double leg bounds (2 sets of 8 repetitions) as a part of warm-up, and will have 60 s to recover between each set. Prior to the intervention, participants will be shown the technique to be used during jumping through use of three videos."
223785699|NCT05045521|OTHER|resistance warm up|"participants will be asked to do 10 minutes self-paced jog on motorized treadmill.~After the jog participants will perform the 6\*10s strides with the 15% of the weight. Velocity of the strides will be controlled by the participants.~Warmup will be followed by the 10minutes rest"
223785700|NCT05045521|OTHER|control warm up group|"participants will be asked to do 10 minutes self-paced jog on a motorized treadmill.~After the jog participants will perform the 6\*10s strides without the weight. Velocity of the strides will be controlled by the participants. Warmup will be followed by the 10minutes rest The total amount of time spended in each of the three warm-up protocols will be recorded. Participants will be instructed to wear the same pair of running shoes during the three tests."
223785701|NCT03360461|DRUG|EMI-137|EMI-137 - a fluorescent c-Met receptor targeted peptide
223785702|NCT02357836|DRUG|Itraconazole|"Once on study, itraconazole will be taken twice daily for a total of 10-14 days. After being on itraconazole for 7-10 days, Post-treatment assessments will include a skin biopsy, blood draw for the PK (pharmacokinetics) analyses and the cytokine panel, and also MRI evaluations (anticipated to last 45-50 minutes). Toxicity assessments and laboratory checks will also be conducted during that time. Following these assessments, itraconazole will be continued until the day of surgery. At the time of surgical resection, a tissue sample (with adjacent normal tissue as per standard resection technique) will be obtained to complete the analysis. Following resection, subjects will be followed per standard post-operative procedure."
223785703|NCT06349161|PROCEDURE|One-trocar-assisted pyeloplasty|Positioned in a full lateral decubitus posture. A 12mm incision was made below the 12th rib, followed by a muscle-sparing technique to access and open the Gerota's fascia. A 10mm balloon trocar was inserted, and CO2 was insufflated to a pressure of 12 mmHg at a flow rate of 3L. An operative scope with dual channels was introduced for retroperitoneal dissection, utilizing a peanut to expand the working space. The proximal ureter, UPJ, and renal pelvis were visualized, and the UPJ was mobilized and exteriorized under direct visualization to prevent torsion. Anderson-Hynes dismembered pyeloplasty was performed using a 6/0 PDS suture, with possible enlargement of the incision if necessary. A 4 French double J ureteral stent was inserted antegradely before completing the anastomosis, verified by methylene blue presence at the anastomotic site. A final retroperitoneoscopic assessment ensured proper alignment of the anastomosis, with closure of the incision site without drain placement.
223785704|NCT00752375|DRUG|Trimethoprim Sulfamethoxazole|"* Children \>3months of age will receive Trimethoprim Sulfamethoxazole (2mg/kg Trimethoprim component)per day for one year.~* Children under 3 months of age will receive amoxicillin 10mg/kg once per day for one year.~* Those children with a Sulfa allergy will receive nitrofurantoin (1mg/kg) once per day for one year."
223785705|NCT00752375|DRUG|placebo|"* Placebo matching Trimethoprim Sulfamethoxazole (2mg/kg Trimethoprim component)for children more than 3 months of age~* Placebo matching amoxicillin 10mg/kg once per day for children under 3 months of age~* Placebo matching nitrofurantoin (1mg/kg) once per day for children with a sulfa allergy."
223785706|NCT04757649|BEHAVIORAL|Safety Planning Intervention with Navigation Services|A patient navigation (PN) intervention for SGM youth/emerging adults designed to target mechanisms (i.e., decreasing thwarted belongingness and increasing suicide-related coping skills) that theoretically underlie suicide. The proposed intervention will integrate a single-session, empirically supported, suicide prevention intervention (Safety Planning Intervention; SPI) with PN services (PN+SPI). The patient navigator will deliver the SPI and continue frequent contact for the purpose of providing motivational enhancement, problem-solving, reinforcing coping strategies, and connecting participants to social support and mental health resources (e.g., SGM-specific support groups within the community).
223785707|NCT03397212|OTHER|NADA acupuncture|Ear acupuncture protocol described by National Acupuncture Detoxification Association
223785708|NCT03397212|OTHER|Sham acupuncture|Ear acupuncture using inactive sham points
223785709|NCT02211300|DEVICE|The OptiScanner|treatment of blood glucose per standard of care
223785710|NCT02211300|DEVICE|YSI 2300 STAT Plus™|
223785711|NCT04066218|OTHER|Interviews|"* Participation will serve as verbal consent.~* Qualitative PRA will call participant to schedule either phone or in person interview. If via phone, the study PRA performing the interview, will remind them to find a private space to speak.~* REDCap link will be sent for PROMIS SexFS Brief.~* PRA will perform semistructured interview and guide Think-Aloud to complete the PROMIS SexFS Brief.~* Participants will not submit responses to PROMIS SexFS Brief responses after completing the tool."
223785712|NCT01286779|BIOLOGICAL|BAX 326 (Recombinant factor IX)|The treatment with BAX 326 will be at the discretion of the investigator and will consist of either twice weekly prophylactic treatment with 50 IU/kg, modified prophylaxis, or on-demand treatment.
223785713|NCT03750487|BEHAVIORAL|e-screening & brief intervention (e-SBI)|Computer-delivered screening and brief motivational intervention targeting alcohol and drug use + goal-setting and content reinforcement
223785714|NCT03750487|BEHAVIORAL|Control e-SBI|Computer-delivered screening and brief motivational intervention targeting healthy eating and exercise
223785715|NCT05498259|DRUG|Orelabrutinib|Orelabrutinib 150mg qd PO
223785716|NCT05498259|BIOLOGICAL|Rituximab|Rituximab 375 mg/m2 IV on Day 1 of each 21-day cycle
223785717|NCT05498259|DRUG|CHOP-like Regimen|cyclophosphamide, anthracene nucleus chemotherapeutics（doxorubicin，liposomal doxorubicin, etc.）, vinca alkaloids（vincristine, vindesine, etc.），and glucocorticoid （dexamethasone，prednison, etc.）.
223785718|NCT06114420|PROCEDURE|salvage surgery|Some patients who cannot undergo surgery
223835386|NCT02200393|DEVICE|Abdominal FES|"Stimulation intensity was adjusted on a channel by channel basis until a strong visible contraction of the abdominal muscles is observed. During the session, manual adjustment of both the stimulation intensity (to compensate for fatigue) and the duty cycle is possible.~Four pairs of surface electrodes were placed on the participant's abdomen. One pair will be placed on both the right and left side of the rectus abdominis around the naval. One pair of electrodes will also be placed on both the right and left side of the external oblique muscles with one electrode being placed just below the participant's bottom rib and the other below this with a separation of around 3cm."
223785719|NCT03555669|OTHER|Depression Treatment|The depression treatment program combines measurement-based antidepressant treatment with PST with clinical response appropriate to the level of depressive severity. Patients scoring 0-4 on the PHQ-9, indicating no depression, receive no treatment. Patients scoring 5-9 on the PHQ-9, indicating mild depressive symptoms that likely are not a full major depressive episode, are offered PST. Patients scoring 10 or above on the PHQ-9, indicating moderate-to-severe depressive symptoms, are first offered anti-depressants. For this group, PST will be an alternative or augmentation option for those who do not tolerate or respond to antidepressant treatment. All patients' depressive severity is monitored with the option of modifying their treatment plan if their symptoms worsen or do not improve.
223785720|NCT00344682|DRUG|memantine|memantine 5mg - 20mg PO daily
223785721|NCT00344682|DRUG|Placebo|5mg - 20mg PO daily over 8 weeks
223785722|NCT04727866|DEVICE|transcutaneous spinal direct current stimulation (tsDCS) - coronal|20 minutes of tsDCS will be delivered at 66% of maximum tolerated intensity with cathode over C5-C7 transverse process on target side, anode over C5-C7 transverse process on non-target side.
223785723|NCT04727866|DEVICE|transcutaneous spinal direct current stimulation (tsDCS) - caudal|20 minutes of tsDCS will be delivered at 66% of maximum tolerated intensity with DCS cathode over \~T1-T4 posteriorly, anode over \~C5-T1 anteriorly
223785724|NCT04727866|DEVICE|transcutaneous spinal direct current stimulation (tsDCS) - rostral|20 minutes of tsDCS will be delivered at 66% of maximum tolerated intensity with DCS cathode over \~C3-C5 posteriorly, anode over \~C5-T1 anteriorly
223835387|NCT00369811|DRUG|Oxycodone, fentanyl|
223785725|NCT04727866|DEVICE|intermittent theta burst stimulation (iTBS)|3 minutes of iTBS (a form of repetitive TMS) will be delivered during a 5-minute interval of DCS
223785726|NCT02896855|DRUG|Docetaxel|Docetaxel (75-mg/m\^2) was administered by IV infusion every 3 weeks until disease progression or unacceptable toxicity.
223785727|NCT02896855|DRUG|Pertuzumab|Pertuzumab (840-mg loading dose for Cycle 1, followed by 420 mg for subsequent cycles) was administered by IV infusion every 3 weeks until disease progression or unacceptable toxicity.
223785728|NCT02896855|DRUG|Placebo|Placebo matched to pertuzumab was administered by IV infusion every 3 weeks until disease progression or unacceptable toxicity.
223785729|NCT02896855|DRUG|Trastuzumab|Trastuzumab (8-mg/kg loading dose for Cycle 1, followed by 6 mg/kg for subsequent cycles) was administered by IV infusion every 3 weeks until disease progression or unacceptable toxicity.
223785730|NCT03883672|BEHAVIORAL|Personality and transactional factors|"1. Pre-admission transplant questionnaire: given and collected by the transplant physician during the pre-graft consultation before entering hospitalization (approximatively 15 days before). To be completed by the patient on site (approximately 45 minutes to complete the questionnaire)~2. Transplant admission questionnaire: given during the first days of hospitalization. To be completed within 6 days and returned to the transplant physician (approximately 30 minutes to complete the questionnaire)~3. Post-transplant follow-up questionnaire: given in consultation at 6 months by the transplant physician (between 30 and 45 minutes to complete the questionnaire in consultation)"
223785731|NCT01659021|DRUG|Idelalisib|150 mg tablets administered orally twice daily
223785732|NCT01659021|DRUG|Ofatumumab|Administered intravenously
223785733|NCT04106999|DRUG|Dexmedetomidine|Drug infusion will be delivered intra-operatively
223785734|NCT04106999|DRUG|Placebos|Normal Saline will be infused as a control drug
223785735|NCT02332070|PROCEDURE|cardiac surgery|coronary artery bypass surgery and or cardiac valve surgery with cardiopulmonary bypass
223785736|NCT02508311|DRUG|Oral Albuterol Extended Release|Subjects will receive extended release Albuterol, 4mg twice daily for the first week. The remaining 15 weeks subjects will receive extended release Albuterol, 8mg twice daily.
223785737|NCT02508311|DRUG|Placebo|Subjects will receive placebo tablets twice daily for 16 weeks.
223785738|NCT00646802|DRUG|Progesterone|1 vaginal capsule, 200 mg, once daily since gestation age 36 weeks and 6 days
223785739|NCT00646802|DRUG|Placebo|1 vaginal capsule, once daily since gestational age of 36 weeks and 6 days
223785740|NCT01792089|OTHER|fat+protein meal|cream+ whey protein
223785741|NCT01792089|OTHER|Fat + protein + 13C fructose meal|cream+ whey protein +13C fructose
223785742|NCT01792089|OTHER|Fat+protein+13C fructose+glucose meal|Cream + whey protein + glucose:13C fructose mixture
223785743|NCT01792089|OTHER|13C Fat + whey protein|cream labelled with 13C palmitate + whey protein
223785744|NCT01792089|OTHER|13C Fat + whey protein + glucose+ glucose meal|cream labelled with 13C palmitate + whey protein + glucose:fructose mixture
223785745|NCT03601832|PROCEDURE|4-D navigated stereotactic radiosurgical ablation|4-D Navigated Non-invasive radiosurgical ablation of ventricular tachycardia in patients with sustained monomorphic ventricular tachycardia/tachycardias after myocardial infarction.
223785746|NCT01205685|DRUG|OSI-906|"In a pill form by mouth, twice a day (12 hours apart)~During the safety run portion of the study~* Dose level 2 = 150 mg twice a day~* Dose level 1 = 100 mg twice a day~* Dose level -1 = 100 mg twice a day~* Dose level -2 = 100 mg twice a day"
223785747|NCT01205685|DRUG|Erlotinib|"During the safety run phase of the study:~* Dose Level 2 = 100 mg/d~* Dose Level 1 = 100 mg/d~* Dose Level -1= 75 mg/d~* Dose Level -2 = 50 mg/d"
223785748|NCT01205685|DRUG|Letrozole|In a pill form, by mouth, once per day at 2.5 mg/d.
223785749|NCT01205685|DRUG|Goserelin|For pre-menopausal patients only. Given as an injection once a month at 3.6 mg/month.
223785750|NCT02169674|BIOLOGICAL|EngerixB, GlaxoSmithKline Vaccines|
223785751|NCT03659552|DEVICE|LIVE Catheter|Placement of a temporary LIVE Catheter central venous pacing device in the left jugular vein to pace the phrenic nerves and allow recruitment of the diaphragm muscle.
223785752|NCT02599168|DRUG|Propofol|
223785753|NCT02599168|DRUG|Dexmedetomidine|
223785754|NCT02599168|DRUG|Placebo (normal saline)|
223785755|NCT03769623|DEVICE|Biolimus|103 subjects with small coronary artery disease who met the inclusion/exclusion criteria were enrolled, subjects were assigned to the treatment group of Biolimus
223785756|NCT03769623|DEVICE|Powerline|103 subjects with small coronary artery disease who met the inclusion/exclusion criteria were enrolled, subjects were assigned to the treatment group of Powerline
223785757|NCT01193803|PROCEDURE|Microbiological cultures and Molecular biology|"Biological/Vaccine: Microbiological cultures and Molecular Biology Bacteriological procedures: All solid specimens will be crushed using a mechanic apparatus. Direct examination and cultures will be performed according to the guidelines applied for osteoarticular infections. Cultures and subcultures will be incubated for 15 days to 3 months for Mycobacteria.~Molecular procedures: DNA extraction will be based on Boom's method (QIAGEN kit and EZ1 BioRobot). Detections of bacteria will be performed by amplification and sequencing of the 16S rRNA gene. Some specific detections as the detection of Staphylococcus sp. and Mycobacterium tuberculosis will be added to this protocol."
223785758|NCT03790982|DRUG|Placebo of AD-35 60mg /AD-35 30mg|Placebo 60mg, oral, 1st 26 weeks; AD-35 30mg +Placebo of AD-35 30mg oral 2nd 26 weeks.
223785759|NCT03790982|DRUG|Placebo of AD-35 60mg /AD-35 60mg|Placebo 60mg, oral, 1st 26 weeks; AD-35 60mg oral, 2nd 26 weeks.
223785760|NCT03790982|DRUG|AD-35 30 mg + Placebo of AD-35 30 mg|AD-35 30 mg + Placebo of AD-35 30 mg AD-35 30 mg + Placebo of AD-35 30 mg, Oral, 52 weeks.
223785761|NCT03790982|DRUG|AD-35 60 mg|AD-35 60 mg AD-35 30 mg x two tablets, oral, 52 weeks.
223785762|NCT05321524|DRUG|OCA 0.1mg|Tablets administered orally once daily.
223785763|NCT05321524|DRUG|OCA 1.5mg|Tablets administered orally once daily.
223785764|NCT05321524|DRUG|OCA 5mg|Tablets administered orally once daily.
223785765|NCT05734508|BIOLOGICAL|MVA-BN vaccine|A live vaccine produced from the Modified Vaccinia Ankara-Bavarian Nordic strain (MVA-BN), an attenuated and non-replicating orthopox virus
223785766|NCT02620553|DRUG|Human Insulin|There is a study drug dose increase once during the study. The dose increase will occur 6 months after entering into the study. A total of 6 children will be included at each dose (3 children will not have received insulin prior to entering the study and 3 children will have received a lower dose of insulin for 6 months). Further dose increases or more frequent dose increases in individual children will not be performed during Pre-POINT. Escalation will occur in both treatment and placebo group so that participants and study investigators will remain blinded to treatment throughout the study. First dose (2.5 mg oral insulin/day) Second dose (7.5 mg oral insulin/day) Third dose (22.5 mg oral insulin/day) Fourth dose (67.5 mg oral insulin/day)
223785767|NCT02620553|OTHER|Oral Placebo|Oral Placebo is given orally daily
223785768|NCT01053026|DRUG|olmesartan|(1) Olmesartan treatment or (2) Life modification and exercise training
223785769|NCT00530361|DRUG|Nesiritide|
223785770|NCT02345057|DRUG|CS-3150|
223785771|NCT02345057|DRUG|placebo|
223785772|NCT02855099|OTHER|Rehabilitation|The duration on the rehabilitation will be 3 month and will be a multidisciplinary program that includes supervised physical activity
223785773|NCT04863066|BIOLOGICAL|CAR-T cells|The presence of latent infected cells remains a key barrier to HIV-1 functional cure. Current approach to reducing the latent HIV reservoir is to reactivate virus-containing cells to make them be detected and eliminated by host defense. Endogenous cytotoxic T-lymphocytes (CTL) may not be adequate because of cellular exhaustion and immune escape of virus. We have designed a kind of CAR-T cell based on CTL engineered to express a scFv of a broadly neutralizing anti-HIV antibody. According to our preclinical studies, CAR-T cells strongly eradicated HIV-1-infected target cells making them a particularly suitable candidate to reach a functional HIV cure. In this clinical trial, we mainly intend to evaluate the safety of CAR-T-Cell therapy on HIV patients whose plasma HIV has been successfully suppressed after antiviral therapy.
223785774|NCT04735133|DEVICE|pNBYT|pNPWT device (80mm Hg) was placed in the pNPWT group for seven days The incision area was evaluated during the first seven days, and on the 15th, 21st, and 30th days postoperatively for the presence of hematoma, seroma, wound dehiscence/evisceration, and SSI.
223785775|NCT06033261|BIOLOGICAL|mRNA-1608|Sterile liquid for injection
223785776|NCT06033261|BIOLOGICAL|BEXSERO|A vaccine indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B.
223785777|NCT05562440|OTHER|Focus Group Discussion|Each focus group will consist up to five participants in every session, two sessions each for both low and high risk group. Every FGD sessions will last for 1 to 2 hours and be conducted in Indonesian, and will be recorded. Both groups will be asked the following questions: 1) What is your opinion regarding the clarity of information in the dummy breast cancer risk prediction report?; 2) What is your opinion regarding the completeness of information in the dummy breast cancer risk prediction report?; and 3) What is your impression regarding the results presented in the dummy breast cancer risk prediction report?.
223785778|NCT03190382|OTHER|Decision Support Tool|Patients enrolled in the study will receive the decision tool prior to the first PAD clinic visit and the medical decision making conversation with the provider.
223785779|NCT02616094|DEVICE|Multi-method Neuroendocrine and Neuroimaging Procedure Scan 1|The MRI scan will be conducted on a 3-T Siemens Trio MRI system equipped with a standard quadrature head coil, using T1 MPRAGE sequence for structural scanning and T2\*-sensitive gradient-recalled single shot echo planar pulse sequence for functional scans. Two multimethod MRI scans will be conducted in the AD sample, while the controls will participate in a single scan.
223785780|NCT02616094|DEVICE|Multi-method Neuroendocrine and Neuroimaging Procedure Scan 2|The MRI scan will be conducted on a 3-T Siemens Trio MRI system equipped with a standard quadrature head coil, using T1 MPRAGE sequence for structural scanning and T2\*-sensitive gradient-recalled single shot echo planar pulse sequence for functional scans. Two multimethod MRI scans will be conducted in the AD sample, while the controls will participate in a single scan.
223785781|NCT04320069|DEVICE|Omnipod Horizon™ Automated Glucose Control System|Omnipod Horizon™ Automated Glucose Control System use in Manual Mode
223785782|NCT03135951|DRUG|SPI-2012|Supplied in prefilled, single-use syringes for subcutaneous injection and administered on Day 2 of each cycle.
223785783|NCT00955084|DRUG|XL999|XL999 for injection will be supplied as a brown, sterile injectable solution at a concentration of 5 mg/mL
223785784|NCT02585895|BIOLOGICAL|Evolocumab|Administered by subcutaneous injection once every 2 weeks
223785785|NCT02585895|PROCEDURE|Low-density Lipoprotein Cholesterol (LDL-C) Apheresis|Participants received apheresis for LDL-C according the their physician's prescription and local custom.
223785786|NCT01692704|DRUG|Selective intra-arterial floxuridine and systemic gemcitabine and cisplatin|"Intra-arterial floxuridine:0.2 mg/KG/day for 14 days, repeated day 29. Overall 3 applications.~Systemic cisplatin: 25 mg/m2 at days 1 and 8, repeated day 22. Overall 8 applications.~Systemic gemcitabine: Three different dose levels will be tested; 600 mg/m2, 800 mg/m2, or 1000 mg/m2, at days 1 and 8, repeated day 22. Overall 8 applications."
223785787|NCT02738177|DRUG|Misoprostol|2 tablets of misoprostol (i.e. 400 ug) 4 hrs prior to surgical evacuation high up in the posterior fornix (misoprostol group)
223785788|NCT02738177|DRUG|Isosorbide-5-mononitrate|2 tablets of Effox (i.e. 40 mg) 4 hrs prior to surgical evacuation high up in the posterior fornix (effox group)
223785789|NCT02738177|DRUG|misoprostol and Isosorbide-5-mononitrate|1tablets of misoprostol (i.e.200 ug) \& 1 tablets of Effox (i.e. 20 mg) 4 hrs prior to surgical evacuation high up in the posterior fornix (combination therapy group)
223785790|NCT01373086|DRUG|LFF269|
223785791|NCT01373086|DRUG|Eplerenone|
223785792|NCT01373086|DRUG|Placebo|
223785793|NCT06042348|DIAGNOSTIC_TEST|Trans abdominal ultrasound|Ultra sound of the uterus and uterine blood vessels
223785794|NCT00142480|DRUG|Capecitabine|Given orally for 14 consecutive days (days 1-14) followed by a week of no capecitabine then another week of 14 consecutive days (days 21-28).
223785795|NCT00142480|DRUG|Oxaliplatin|Given intravenously once weekly during weeks 1, 2, 4 and 5 on days 1, 8, 22 and 29
223785796|NCT00142480|DRUG|Bevacizumab|Given intravenously every two weeks during weeks 1, 3 and 5 on days 1, 15 and 29.
223785797|NCT00142480|PROCEDURE|Radiation therapy|Once daily for 5 days (Monday through Friday) for a total of 28 treatments.
223785798|NCT01844323|OTHER|Palbociclib Formulation Reference|Single 45 mg dose; Dosage form is capsule taken orally.
223785799|NCT01844323|OTHER|Palbociclib Formulation Test|Single 45 mg dose; Dosage form is capsule taken orally.
223785800|NCT01844323|OTHER|Palbociclib Formulation Test|Single 45 mg dose; Dosage form is capsule taken orally.
223785801|NCT01844323|OTHER|Palbociclib Formulation Test|Single 45 mg dose; Dosage form is capsule taken orally.
223785802|NCT01281930|PROCEDURE|Full packing into abscess cavity|After incision and drainage plain 1/4-1/2 inch gauze packing material is placed into the cavity to fill it
223785803|NCT01281930|PROCEDURE|Wick placement into abscess cavity|After incision and drainage of the abscess a piece of plain gauze 1/4-1 inch packing material that is as wide as can be easily passed through the opening is placed into the cavity spanning one diameter of the cavity
223785804|NCT05170373|PROCEDURE|ESP block|Before general anesthesia, ESP block was applied from the T12 vertebra level with 10 ml 0.5% bupivacaine HCL 5 ml 2% lidocaine HCL 5 ml 0.9% isotonic NaCl mixture
223785805|NCT05014594|DRUG|Dapagliflozin (10Mg Tab) along with standard medical therapy|Oral Dapaglifozin (10 mg/day) along with standard medical therapy will be given to Group A while a placebo of dapaglifozin along with standard medical therapy will be used in Group B
223785806|NCT05014594|DRUG|Placebo of dapaglifozin along with standard medical therapy|Standard medical therapy will include dietary restriction of sodium, treatment with diuretics, repeated LVP as needed and other supportive care. Patients on non-selective beta blockers will continue to do so with dose modifications/withdrawal as per Baveno VI guidelines.
223785807|NCT05343702|DRUG|priming with rocuronium|Following induction (paralysis after onset of the induction effect) in routine rapid sequence intubation protocols While paralysis is applied, it is aimed to shorten the half-life of rocuronium by administering a subparalytic dose of rocuronium approximately 3-5 minutes before induction in the priming technique
223785808|NCT00329277|PROCEDURE|perimetry|
223785809|NCT02509533|DEVICE|V.A.C.®|Patients received V.A.C.® Therapy (KCI medical) after a transplants of leg ulcers.
223785810|NCT02509533|DEVICE|dressing|Patients received usual dressing method (compresses) after a transplants of leg ulcers
223785811|NCT03058679|OTHER|Diet|food for the diet will be provided to the participants for 6 weeks and participants will follow the diet on their own for the remaining 6 weeks
223785812|NCT01796574|DIETARY_SUPPLEMENT|Ketogenic diet|4:1 ratio fat: carbohydrates and protein ketogenic liquid via enteral feed
223785813|NCT00574080|DRUG|Interim/Maintenance Dexamethasone|20 mg Days 1-4 every 3 weeks in the interim between treatment phases and during maintenance
223785814|NCT00574080|DRUG|Induction/Consolidation Dexamethasone|40 mg Days 1-4
223785815|NCT00574080|DRUG|Induction/Consolidation Cisplatin|10 mg/m2 by continuous infusion Days 1-4
223785816|NCT00574080|DRUG|Induction/Consolidation Adriamycin|10 mg/m2 by continuous infusion Days 1-4
223785817|NCT00574080|DRUG|InductionConsolidation Cyclophosphamide|400 mg/m2 by continuous infusion Days 1-4
223785818|NCT00574080|DRUG|Induction/Consolidation Etoposide|40 mg/m2 by continuous infusion Days 1-4
223785819|NCT00574080|DRUG|Induction Pegfilgrastim|6 mg Days 6 and 13
223785820|NCT00574080|DRUG|Transplant 1 Dexamethasone|20 mg Days -4, -3, -2, -1 and +4, +5, +6, and +7
223785821|NCT00574080|DRUG|Transplant 1 Cisplatin|20 mg/m2 by continuous infusion Days -3 and -2
223785822|NCT00574080|DRUG|Transplant 1 Adriamycin|20 mg/m2 by continuous infusion Days -3 and -2
223785823|NCT00574080|DRUG|Transplant 1 Cyclophosphamide|800 mg/m2 by continuous infusion Days -3 and -2
223785824|NCT00574080|DRUG|Transplant 1 Etoposide|80 mg/m2 by continuous infusion Days -3 and -2
223785825|NCT00574080|DRUG|Transplant 1 Melphalan|50 mg/m2 Days -2 and -1
223785826|NCT00574080|DRUG|Transplant 1 and 2 Pegfilgrastim|6 mg Day +6
223785827|NCT00574080|PROCEDURE|Autologous Peripheral Blood Stem Cell Transplant (ASCT)|Day 0
223785828|NCT00574080|DRUG|Transplant 2 Carmustine|300 mg/m2 Day -5
223785829|NCT00574080|DRUG|Transplant 2 Etoposide|200 mg/m2 Days -5, -4, -3, -2
223785830|NCT00574080|DRUG|Transplant 2 Cytarabine|400 mg/m2 Days -5, -4, -3, -2
223785831|NCT00574080|DRUG|Transplant 2 Melphalan|140 mg/m2 Day -1
223785832|NCT00574080|DRUG|Transplant 2 Dexamethasone|20 mg Days -5, -4, -3, -2, +4, +5, +6, +7
223785833|NCT00574080|DRUG|Transplant 1 and 2 Bortezomib|1 mg/m2 Days -4, -1, +3, +7
223785834|NCT00574080|DRUG|Transplant 1 and 2 Thalidomide|200 mg Days -4 to +5
223785835|NCT01930773|DEVICE|Genotyping|Patients harboring CYP2C19 \*2 alleles receive 60 mg prasugrel for PCI, while non-carriers receive 600 mg clopidogrel if not pretreated with clopidogrel.
223785836|NCT01930773|DEVICE|Phenotyping|Patients having high on-treatment platelet reactivity (HPR: greater than 208 PRU) receive 60 mg prasugrel loading dose (LD), others continue clopidogrel for PCI.
223785837|NCT06183801|DIETARY_SUPPLEMENT|Probiotics 1|Subjects take probiotics capsule(Lactobacillus fermentum,TSF331) three times a day before meal.
223785838|NCT06183801|DIETARY_SUPPLEMENT|Probiotics 2|Subjects take probiotics capsule(Lactobacillus reuteri,TSR332) three times a day before meal.
223785839|NCT06183801|DIETARY_SUPPLEMENT|Probiotics 3|Subjects take probiotics capsule(Lactobacillus plantarum,TSP05) three times a day before meal.
223785840|NCT06183801|DIETARY_SUPPLEMENT|Probiotics 4|Subjects take probiotics capsule(Lactobacillus fermentum,TSF331+Lactobacillus reuteri,TSR332+Lactobacillus plantarum,TSP05) three times a day before meal.
223785841|NCT06183801|DIETARY_SUPPLEMENT|Probiotics 5|Subjects take probiotics capsule(Lactobacillus fermentum,TSF331+Lactobacillus reuteri,TSR332+Lactobacillus plantarum,TSP05+Postbiotics PE0401) three times a day before meal.
223785842|NCT06183801|DIETARY_SUPPLEMENT|Placebo 1|Subjects take capsule three times a day before meal.
223785843|NCT06183801|DIETARY_SUPPLEMENT|Probiotics 6|After 1 month wash out, subjects take probiotics capsule(Bifidobacterium animalis subsp. lactis,CP-9) three times a day before meal.
223785844|NCT06183801|DIETARY_SUPPLEMENT|Probiotics 7|After 1 month wash out, subjects take probiotics capsule(Lactobacillus rhamnosus, bv-77+Bifidobacterium animalis subsp. lactis,CP-9) three times a day before meal.
223785845|NCT06183801|DIETARY_SUPPLEMENT|Placebo 2|After 1 month wash out, subjects take capsule three times a day before meal.
223785846|NCT05997043|DRUG|oral anti-Parkinson drugs and injection of botulinum toxin|The experimental group was treated with oral anti-Parkinson drugs and injection of botulinum toxin
223785847|NCT05997043|DRUG|oral anti-Parkinson's drugs|The control group only took oral anti-Parkinson's drugs.
223785848|NCT05605119|DRUG|AUR105|Once daily
223785849|NCT03517644|OTHER|DP|Participants are informed that they are about to receive an effective analgesic cream. They are instructed to apply the cream using a cotton pad.
223785850|NCT03517644|OTHER|OLP Hope|Participants are informed that they are about to receive an placebo cream. They are told that the cream has no active pharmacological ingredient. Therefore, participants are supposed to evaluate the subjective probability for a positive effect of the cream as rather low. However, using verbal instructions, the investigator aims to induce hope among the participants that the cream could have a positive effect for them because this placebo cream did have a positive among some former participants who were similar to the current participant. The emphasis of this similarity (regarding age and sex) aims to induce a feeling of connectedness to previous participants who reported positive effects of the placebo cream.
223785851|NCT03517644|OTHER|OLP Expectation|Participants are informed that they are about to receive an placebo cream. They are told that the cream has no active pharmacological ingredient. However, participants are told that placebos have been shown to contribute substantially to clinical outcomes such as pain intensity/unpleasantness. This positive effect of placebos is reasoned by explaining learning mechanisms such as classical conditioning. We anticipated that after hearing this instruction, participants would consider it to be likely that the placebo has a positive effect for them.
223785852|NCT03517644|OTHER|Placebo cream|The participants receive an inert placebo cream (standard basic cream with oil of thyme produced by a local pharmacy).
223785853|NCT03517644|OTHER|Heat pain|Participant receive heat pain stimuli using the suprathreshold method of the Thermo Sensory Analyser (TSA-II), a commonly used device to study pain sensation and analgesic effects.
223785854|NCT06086730|DEVICE|blow bottle positive expiratory pressure|Water was poured into a 1 L plastic container until it reached a 10 cm height. A 30 cm long tube was put into the water in the bottle, 8 cm deep. The participants were instructed to close their mouths around the tubing in the apparatus for three seconds to produce bubbles, do this for a total of 10 breaths, perform two huffs, then cough. Such exhalations were conducted in two sets of ten, with a five-minute pause in between. For each subject, a fresh, disposable tube and bottle were utilized,Because it is a homemade device and can be used with less equipment and with more ease at home . patient perform session three day per week for the duration of 8 weeks , each session last for 35-40 minutes.
223785855|NCT06086730|DEVICE|acapella|"Make sure the frequency adjustment dial has been rotated counterclockwise to the lowest frequency-resistance setting before using the Acapella for the first time.On a chair, adopt a straight stance. maintaining a straight back and relaxing your elbows on a table. Now gradually tilt your head upward to maintain the opening of your upper airways.Inhale more deeply than you frequently do. Make sure your lips are encircling the mouthpiece, then blow into the device with a strong expiration.You should ideally blow out roughly twice as quickly as usual.For around ten breaths, keep going like this.Make careful to expel to clear the secretions from the airways after the final try. You can even conduct 2 to 3 huffs to improve secretion elimination when necessary.It should be noted that while using the device, you must be capable of exhale for a minimum of three to four seconds. patient perform session three day per week for the duration of 8 weeks , each session last for 35-40 minutes"
223785856|NCT06486259|OTHER|Controlled mechanical ventilation|Patients were ventilated under similar tidal volume, respiratory rate, and plateau pressure. PEEP was the adjustment variable to reach a similar plateau pressure
223785857|NCT02529774|DRUG|Floxuridine (FUDR),Dexamethasone (DXM), Heparin in combination with Oxaliplatin and Capecitabine (CapeOX) or in combination with Oxaliplatin and Leucovorin and 5-FU (mFOLFOX6)|"Hepatic Artery Infusion for four cycles:~Floxuridine (FUDR) 500mg/d, Day 1-2; DXM 1mg/day added to FUDR 2-day infusion; Heparin 1000U/day added to FUDR 2-day infusion~In combination with Systemic Chemotherapy CapeOX for 8 cycles:~Oxaliplatin 130 mg/m\^2 iv over 2 hours, Day 1. Capecitabine 850mg/m\^2/d PO Bid, given in the morning and evening, Day 1-14~Or in combination with Systemic Chemotherapy mFOLFOX6 for 12 cycles:~Oxaliplatin 85mg/m\^2 IV over 2 hours, Day 1. Leucovorin 400mg/m\^2 IV over 2 hours, Day 1 5-fluorouracil (FU) 400mg/m\^2 IV and then 2400mg/m\^2 over 48 hours IV continuous infusion. Day 1"
223785858|NCT02529774|DRUG|Oxaliplatin and Capecitabine (CapeOX) or Oxaliplatin and Leucovorin and 5-FU (mFOLFOX6)|"Systemic Chemotherapy CapeOX alone for 8 cycles:~Oxaliplatin 130 mg/m\^2 iv over 2 hours, Day 1. Capecitabine 850mg/m\^2/d PO Bid, given in the morning and evening, Day 1-14~Or Systemic Chemotherapy mFOLFOX6 alone for 12 cycles:~Oxaliplatin 85mg/m\^2 IV over 2 hours, Day 1. Leucovorin 400mg/m\^2 IV over 2 hours, Day 1 5-fluorouracil (FU) 400mg/m\^2 IV and then 2400mg/m\^2 over 48 hours IV continuous infusion. Day 1"
223785859|NCT04071938|OTHER|Teaching to GPs|Educational modules on bladder, bowel and skin-care, and pain management will be provided to participating GPs by Spinal Cord Injury specialists
223785860|NCT04071938|OTHER|Site visits to GP practices|Visits by specialized nurses to the participating GPs at their practices to support the establishment of specialized care on-site
223785861|NCT06143618|BEHAVIORAL|escape room games|The escape room game will include a patient scenario of four female patients who are victims of violence and apply to different clinics. Necessary equipment and materials will be provided and stations will be established where four female patients who are victims of violence will be evaluated. In the game, each student will contact the patient at only one station and evaluate signs and symptoms of violence. The activities at the stations will be carried out together as a group. The group, which completes the tasks and activities and collects the puzzle pieces that will lead to the code of the lock, will complete the puzzle and enter the number codes on it into the key of the locked box on the table (4 numerical codes received), open the box and get the message 'you can escape'. The group with the most time left at the end of the game will come first and will be rewarded.
223785862|NCT06143618|BEHAVIORAL|role playing|In the role play application, there will be scenarios of four female patients who are victims of violence and apply to different clinics. Before the role play activities, students will be asked to form groups of 4-5 people, and each week, a group will be asked to choose one of the four scenarios given by lot and improvise the case-based role play activity within 40 minutes. Before the role play application, the materials that may be required for the students (clothes, materials, etc.) and the preparation of the environment (hospital, polyclinic, etc.) will be provided by the researchers in accordance with the activity to be enacted. At the end of the role play activities, students will be able to express, evaluate and discuss their feelings and thoughts within and between groups.
223785863|NCT02544243|DRUG|Vinorelbine|
223785864|NCT02544243|DRUG|Gemcitabine|
223785865|NCT02544243|DRUG|Cisplatin|
223785866|NCT00599326|DRUG|Deferasirox|250 mg of deferasirox once daily for 6 months
223785867|NCT00924885|DEVICE|Swemed Follicle Aspiration Set Reduced Single Lumen|Thin tip to penetrate the tissue
223785868|NCT00924885|DEVICE|Swemed Follicle Aspiration Set Single Lumen (1.4 mm)|Standard (1.4 mm) needle to penetrate the tissue
223785869|NCT04302857|OTHER|routine MRI|MRI with routine DTI sequence
223785870|NCT01257295|DIETARY_SUPPLEMENT|control: no fiber addition|liquid breakfast without addition of fiber
223785871|NCT01257295|DIETARY_SUPPLEMENT|breakfast with low viscous, low gelling pectin|10g of low viscous, low gelling pectin dissolved in a liquid breakfast
223785872|NCT01257295|DIETARY_SUPPLEMENT|high viscous, low gelling pectin|10g of high viscous, low gelling pectin dissolved in a liquid breakfast
223785873|NCT01257295|DIETARY_SUPPLEMENT|low viscous, high gelling pectin|10g of low viscous, high gelling pectin dissolved in a liquid breakfast
223785874|NCT01257295|DIETARY_SUPPLEMENT|high viscous, high gelling pectin|10g of high viscous, high gelling pectin dissolved in a liquid breakfast
223785875|NCT01257295|DIETARY_SUPPLEMENT|pectin supplement|10g of high viscous, high gelling pectin provided as a dietary supplement, a liquid breakfast is served seperately
223785876|NCT00120172|DRUG|oxaliplatin, capecitabine, bevacizumab|
223785877|NCT02630667|OTHER|SLOW Carbohydrate|Treatment consists of a carbohydrate blend designed to elicit a slow postprandial glycemic response
223785878|NCT02630667|OTHER|MEDIUM Carbohydrate|Treatment consists of only one carbohydrate source designed to elicit a medium/moderate postprandial glycemic response
223785879|NCT02630667|OTHER|FAST Carbohydrate|Treatment consists of only one carbohydrate source designed to elicit a fast postprandial glycemic response
223785880|NCT00784810|DRUG|Oxycodone/Naloxone|5/2.5, 10/5 and 20/10 mg oxycodone/naloxone combination, 12 hourly
223785881|NCT00784810|DRUG|Codeine/Paracetamol|15/500 and 30/500 mg codeine/paracetamol tablets, 2 tablets 6 hourly
223785882|NCT00208793|DIETARY_SUPPLEMENT|Calcium and vitamin D3 combined|Calcium 2,000 mg (as calcium carbonate) + vitamin D3 800 IU given in equal divided doses twice daily with food over 6 months
223785883|NCT00208793|DRUG|Placebo|Placebo
223785884|NCT00208793|DIETARY_SUPPLEMENT|Calcium|Calcium 2,000 mg/day as calcium carbonate in two divided doses with meals over 6 months
223785885|NCT00208793|DIETARY_SUPPLEMENT|Vitamin D3|Vitamin D3 800 IU given as 400 IU twice daily with food over 6 months
223785886|NCT01101737|OTHER|Nurse-led blood pressure clinic|Blood pressure will be measured according to protocol.For patients with blood pressure above optimal targets, treatment changes will be discussed with the patient, a visiting consultant physician and the patient's GP. If they agree, the GP will intensify anti-hypertensive treatment with monthly follow up by the specialist nurse until BP targets are achieved.
223785887|NCT02862106|BIOLOGICAL|εPA-44|subcutaneously injection of εPA-44 900μg at week 83,86,89,92,95,98,101,104,108,112,116,120,124,128
223785888|NCT02806180|PROCEDURE|Dual Operator Ultrasound Guided IV placement|Second operator holds ultrasound probe.
223785889|NCT02806180|PROCEDURE|Single Operator Ultrasound Guided IV placement|Single operator holds ultrasound probe and places IV.
223785890|NCT02508480|BEHAVIORAL|Photovoice|"The 10-session, peer-led Photovoice program, designed to empower individuals with SMI to confront public prejudice and discrimination and reduce personal stigma (self-stigma and perceived stigma), was developed and pilot tested at our Center, with primary contributions from staff with a lived experience of mental illness.~In the Photovoice sessions, participants will be given a workbook titled Combating Prejudice and Discrimination through Photovoice Empowerment. Peer leaders will facilitate discussions based on topics in the workbook. Participants will be given cameras and guidance on taking pictures and writing narratives descriptions about the pictures, specifically the ways in which the pictures relate to experiences of prejudice and discrimination."
223785891|NCT02508480|BEHAVIORAL|Enhanced Control|The control SAU condition will be enhanced with a 60-minute peer-led manualized educational group session (Leaders' Guidelines and Handout for Participants are attached). It will provide participants with information about the nature of stigma and the laws in the U.S. that protect people with disabilities from discrimination. Participants will be engaged in a discussion about their use of different strategies for proactive coping with psychiatric stigma. This session will be co-led by the same peers who will be delivering the Photovoice program to the experimental group at relevant wave and study sites. Participants randomized to the enhanced Services as Usual control condition will be invited to join a Photovoice group once they complete the final 6-month follow-up assessment.
223785892|NCT04981665|DRUG|Tislelizumab|Tislelizumab 200mg IV Q3W
223785893|NCT04981665|DRUG|TACE|TACE will be performed after curative resection (4±1w)
223785894|NCT01088451|DRUG|Combined prandial insulin therapy (CPIT)|Combined prandial insulin therapy (CPIT) applies individual combination of rapid insulin analogue and human insulin according subject's individual estimation of the type of carbohydrates in concrete mixed-meal, based on thorough education. In this study subjects use two applicators, giving two injections before main meals as per basal-bolus therapy. Insulin aspart (Novorapid, Novo Nordisk) and human insulin (Actrapid, Novo Nordisk) are used.
223785895|NCT00077025|DRUG|Gefitinib|ZD1839 (gefitinib, IRESSA) 250 mg/DAY PO + 1 mg Anastrozole (ZD1033, Arimidex)
223785896|NCT00077025|DRUG|Anastrozole|1 mg Anastrozole (ZD1033, Arimidex) + PLACEBO 1 TABLET/DAY PO
223785897|NCT04017026|DEVICE|Implantation|Implantation of 6 mm short implants
223785898|NCT01840423|DRUG|ODM-104|ODM-104
223785899|NCT01840423|DRUG|Placebo|Placebo
223785900|NCT01840423|DRUG|Entacapone|entacapone + levodopa/carbidopa
223785901|NCT01840423|DRUG|levodopa/carbidopa|entacapone + levodopa/carbidopa
223785902|NCT05250596|DRUG|Colchicine|Colchicine 1 mg (0.5 mg for patients ≤ 70 Kg) on-admission followed by 0.5 mg/day until discharge.
223785903|NCT05250596|DRUG|Atorvastatin|Atorvastatin 80 mg on admission followed by 80 mg/day until discharge.
223785904|NCT05061264|PROCEDURE|Abdominal wall reconstruction|The repair of abdominal wall defects with polyvinylidene (PVDF) mesh
223785905|NCT00563784|DRUG|Erlotinib|150 mg by mouth daily for 7 Weeks
223785906|NCT00563784|DRUG|Carboplatin|2 AUC by vein weekly for 7 Weeks
223785907|NCT00563784|DRUG|Paclitaxel|45 mg/m\^2 by vein weekly for 7 Weeks
223785908|NCT00563784|RADIATION|Radiation Therapy|63 GY/35 fractions for 7 weeks (+/- 5 days)
223785909|NCT00281541|DRUG|YM155|
223785910|NCT04499794|DRUG|ALK inhibitor|ALK inhibitor treatment on ALK fusion positive NSCLC patients
223785911|NCT01479920|DRUG|Fluoxetine|Subjects of both study arms received orally administered SSRIs for 4 weeks in an open manner. For those who were currently under antidepressant treatment, they would continue the existing treatment regimens. For those who were not medicated at the time of trial, fluoxetine (FLX) was given at an initiate dose of 10 mg/day and escalated to an optimal dose within one week, based on individual response, but the maximum dose was set at 40 mg/day.
223785912|NCT01479920|PROCEDURE|DCEAS (Hwato®/ Dongbang®)|"Six pairs of cranial acupoints are used: Baihui (Du-20) and Yintang (EX-HN3), left Sishencong (EX-HN1) and Toulinqi (GB15), right Sishencong (EX-HN1) and Toulinqi (GB15), bilateral Shuaigu (GB8), bilateral Taiyang (EX-HN5), and bilateral Touwei (ST8). All these acupoints are located on the forehead.~Disposable acupuncture needles (Hwato®/ Dongbang®, 0.30 mm in diameter and 25-40 mm in length) are inserted at a depth of 10-30 mm obliquely into acupoints, on which low- and high-frequency alternating electrical stimulation with continuous waves is conducted for 30 min. The intensity is adjusted to a level at which patients feel comfortable."
223785913|NCT01479920|PROCEDURE|n-CEA (Strietberger®)|Streitberger's acupuncture needles will be applied on the same acupoints, with the same electrical stimulation parameters, except that the needles only adhere to the skin instead of insertion.
223785914|NCT03652311|DEVICE|ThermoNeuroModulation TNM Device|Study participants will undergo 10 sessions 15 minutes each of Caloric Vestibular Stimulation across 5 days with the FDA approved CVS device. This will be administered in home by study coordinators. Participants will be asked to fill out ODAS, GAD-7, and PHQ-9 on each of the five days during treatment; there is the possibility that other drug specific surveys will be used. Participants will receive two approximately 1 hour MRI scans at the beginning and at the end of the study period.
223785915|NCT04461977|OTHER|True acupuncture|"The selection of acupuncture points is based on Traditional Chinese Medicine (Wen, 2011) and on previous studies (Jeong,2018; Bao,2018), selected as main points: bilateral baxie, SJ5, bafeng, KID3 and ST36. Modifications or additional secondary points may be indicated according to clinical judgment throughout treatment. The needles will be inserted at a depth of 10 - 15 mm, being gently manipulated to obtain de qi sensation. The needles will be left for 20 - 25 minutes. There will be once a week acupuncture treatment, for 8 consecutive weeks. The acupuncture needles will be sterile, disposable stainless steel needles size 0.20 x 30 mm, of Korean brand Dong Bang, Chungcheongnam-do."
223785916|NCT04461977|OTHER|Sham acupuncture|"Patients will receive needling at non-acupuncture points with superficial needling without manipulation to obtain de qi, located near the real points in the hands and feet. The needles will also be left for 20 - 25 minutes. There will be once a week acupuncture treatment, for 8 consecutive weeks. There will be once a week acupuncture treatment, for 8 consecutive weeks. The acupuncture needles will be sterile, disposable stainless steel needles size 0.20 x 30 mm, of Korean brand Dong Bang, Chungcheongnam-do."
223785917|NCT03966976|DEVICE|ECG monitoring & record|This is a mobile ECG recorder that not only records short portions of ECG on one or three leads, but also stores, processes and transmits their data to facilitate the diagnosis and to confirm the occurrence of AF arrhythmia episodes by the physician.
223785918|NCT03966976|OTHER|Conventional follow-up|Conventional follow-up
223785919|NCT05745857|DRUG|Avastin|Orally administered
223785920|NCT05745857|DRUG|Erbitux|Orally administered
223785921|NCT05745857|DEVICE|Fluorescence endoscopy and multi-diameter single fiber reflectance/single fiber fluorescence (MDSFR/SFF) spectroscopy|Fluorescent endoscope fiber and spectroscopy probe will be inserted through the working channel of the normal clinical therapeutic endoscope
223785922|NCT01817205|PROCEDURE|TACE with Hyperthermia Treatment|"Transcatheter arterial chemoembolization (TACE) is performed under local anesthesia with right femoral puncture. The feeding lobar hepatic artery is selectively catheterized for drug delivery.~Systemic hyperthermia is induced with an external energy source using microwave electromagnetic energy, with the patient lying supine on the treatment bed of the hyperthermia equipment, exposing the abdomen to the microwave transmitter."
223785923|NCT05135910|DRUG|Hallux Terbinafine Subungual Gel|Hallux Terbinafine Subungual Gel (HSG) administered every 1 to 2 months over 44 weeks.
223785924|NCT01299493|OTHER|Systems-level intervention to promote colon cancer screening|Intervention practices will receive access to, and assistance in implementing, evidence-based strategies for increasing colorectal cancer screening rates.
223785925|NCT03926182|DRUG|AST2818 Tablets|AST2818 Tablets: Period 1 Fasted from 10 hours prior to dosing with 80 mg AST2818 tablet (p o, once) and 4 hours after dosing on day 1. Period 2 Allocated high-fat meal prior to dosing with 80 mg AST2818 tablet (p o, once) and fasted 4 hours after dosing on day 1.
223785926|NCT03926182|DRUG|AST2818 Tablets|AST2818 Tablets: Period 1 allocated high-fat meal prior to dosing with 80 mg AST2818 tablet (p o, once) and fasted 4 hours after dosing on day 1. Period 2 fasted from 10 hours prior to dosing with 80 mg AST2818 tablet (p o, once)and 4 hours after dosing on day 1.
223785927|NCT06038773|DIAGNOSTIC_TEST|Diagnosis|"Baseline data were presented with descriptive statistics. Sociodemographic information, pregnancy status, surgical history, exercise habits, gynecologic, obstetric, urologic and gastrointestinal history of the patients were evaluated with the Patient Information Form.Pain intensity was evaluated with the McGill pain questionnaire short form. At the same time, the patients drew the areas where they felt the most pain with the pain maps scale. Pain intensity during sexual intercourse was evaluated with the Visual Analog Scale (VAS).Sexual Abuse Items on the Questionnaire (Modified from Badgley)."
223785928|NCT00102895|DRUG|CP-724,714|
223785929|NCT02009176|PROCEDURE|Laparoscopic Anatomical Hepatectomy|We let the 110 patients divide into A, B groups randomly who are meet the inclusion criteria .Group A is Laparoscopic Anatomical Hepatectomy: Anatomy the corresponding liver segment pedicle and hepatectomy along the Glisson fiber sheath
223785930|NCT02009176|PROCEDURE|Laparoscopic Aon-anatomical Hepatectomy|We let the 110 patients divide into A, B groups randomly who are meet the inclusion criteria .Group B is Laparoscopic Aon-anatomical Hepatectomy:1 to 2 cm along the edge of the tumor complete hepatectomy
223785931|NCT02356380|OTHER|Mobilization Type|"Group One: Mobilization Group: this group will receive grade 1,2,3,or 4 mobilization in prone based on the PT's clinical judgement. The treatment parameters will be recorded.~Group Two: Grade 3-4 mobilization group: this group will receive a grade 3-4 mobilization, for 30 seconds form the first through sixth thoracic vertebrae."
223785932|NCT03892772|DRUG|SAS0421a|treatment will be given for 3 days
223785933|NCT03892772|DRUG|SAS0421b|treatment will be given for 3 days
223785934|NCT03892772|DRUG|SAS0421c|treatment will be given for 3 days
223785935|NCT03892772|DRUG|placebo|placebo will be given for 3 days
223785936|NCT05152693|OTHER|Low variety|Meal components are mixed together on the plate
223785937|NCT05152693|OTHER|High Variety|Meal components are served separately on the plate
223785938|NCT05152693|OTHER|Small Portion Size|Small meal portion size
223785939|NCT05152693|OTHER|Large Portion Size|Large meal portion size
223785940|NCT05152693|OTHER|With Beverage|Meal served with water
223785941|NCT05152693|OTHER|Without Beverage|Meal served without water
223785942|NCT01380327|BIOLOGICAL|Cockroach Sublingual Immunotherapy (SLIT) - Low Dose|Participants are randomized to receive daily doses of glycerinated German cockroach (Blattella germanica) allergenic extract formulated in 50% glycerin at a concentration of 1:20 weight per volume \[w/v\] placed under the tongue (sublingual route) to dissolve. The treatment course and study duration was 3 months. Note: The extract was also administered during the preliminary dosing visits, up to three escalating doses, or until the maximum study dose (420 microliters, 1:20 w/v) was achieved.
223785943|NCT01380327|OTHER|Placebo|Participants are randomized to receive either daily (low dose) or twice-daily (high dose) placebo treatment placed under the tongue (sublingual route) to dissolve. The treatment course and study duration was 3 months. Note: The placebo was also administered during the preliminary dosing visits, up to three or seven escalating doses, or until the maximum study dose (420 or 840 microliters, 1:20 weight per volume \[w/v\]) was achieved.
223785944|NCT01380327|BIOLOGICAL|Cockroach Sublingual Immunotherapy (SLIT) - High Dose|Participants are randomized to receive twice-daily doses of glycerinated German cockroach (Blattella germanica) allergenic extract formulated in 50% glycerin at a concentration of 1:20 weight per volume \[w/v\] placed under the tongue (sublingual route) to dissolve. The treatment course and study duration was 3 months. Note: The extract was also administered during the preliminary dosing visits, up to seven escalating doses, or until the maximum study dose (840 microliters, 1:20 w/v) was achieved.
223785945|NCT01223313|DEVICE|Woman's Condom|The Woman's Condom (WC) is an investigational device manufactured by Shanghai Dahua Medical Apparatus Corp., Ltd (Dahua). Dahua's quality management system complies with ISO9001:2000, ISO13485:2003, MDD93/42/EEC. The WC consists of a 0.03-mm-thick pliable plastic pouch that easily conforms to the shape of the vagina. It is 22.9 cm (± 0.3 cm)(9 inches ± 0.1 inch) long and has a flexible soft outer ring that is designed to hug the external genitalia. The foam shapes on the outside of the pouch cling lightly to vaginal walls, ensuring stability of the device. The insertion capsule is made from dissolvable polyvinyl alcohol (PVA) and is similar to the PVA used in C-Film (Apothecus Pharmaceutical Corporation, New York, NY). The WC is a non-lubricated device. It is supplied with water-soluble lubricant with a chemical composition similar to a commercially available lubricant used in previous studies of the WC. Women will receive instruction sheets on the use of the WC and lubricant.
223785946|NCT00781300|DRUG|Loteprednol Etabonate 0.5%|Patients in the Loteprednol Group received Loteprednol Etabonate 0.5% associated with Tobramycin 0.3% in separate eyedrops for four weeks: 6 times a day during the first postoperative week, 4 times a day during the second week, 3 times a day during the third week and twice-daily during the fourth week
223785947|NCT00781300|DRUG|Dexamethasone 0.1%|The patients in Dexamethasone Group received Dexamethasone 0.1% associated with Tobramycin 0.3% in a single eyedrop for four weeks: 6 times a day during the first postoperative week, 4 times a day during the second week, 3 times a day during the third week and twice-daily during the fourth week.
223785948|NCT03899883|DRUG|Pegloticase 8 MG/ML [Krystexxa]|One time dosing of pegloticase will be administered. Participants will receive an infusion of pegloticase over two hours in the outpatient clinical and translational research center (CTRC) at Children's Hospital Colorado, and will be monitored after infusion.
223785949|NCT05308836|COMBINATION_PRODUCT|adipose-derived messenchymal stem cell|Collaborative research program between Vinmec Research Institute of Stem Cell and Gene Technology with the National Yang-Ming University in Taiwan The adipose mesenchymal stem cell line (GXIPC1) was collected from healthy donors who have screened for infectious diseases and then multiplied in large numbers. These products were produced following the GMP laboratory system and approved by Taiwan FDA for preclinical and clinical trials with completed certificates
223785950|NCT02964936|DRUG|roxadustat|Oral administration
223785951|NCT05794191|BIOLOGICAL|Vaccine Administration|PCV13 administration
223785952|NCT04081259|DRUG|LY3214996|LY3214996 is an extracellular signal-regulated kinase (ERK) inhibitor that is being developed as a treatment for patients with advanced cancer. ERK inhibitors stop the signal that a cancer cell receives telling it to grow.
223785953|NCT05865106|DEVICE|Smartphone-based speech therapy|Participants will be instructed to use the speech therapy app for 1 hour per day (5 days for 1 week) over a 4-week period.
223785954|NCT05865106|OTHER|Traditional speech therapy|Participants will receive treatment maintaining the same frequency as the intervention group.
223785955|NCT02175433|DRUG|AGS67E|intravenous (IV) infusion
223785956|NCT03348670|DRUG|Abiraterone - Usual|"* Oral~* Abiraterone Combined Chemotherapy"
223785957|NCT03348670|DRUG|Abiraterone - Study|"* Oral~* Abiraterone Combined Chemotherapy"
223785958|NCT06634966|PROCEDURE|Segmentectomy|The lungs are divided into multiple lobes. A segmentectomy involves the removal of part of one of the lobes of the lung to entirely remove a cancerous tumor. segmentectomy can preserve more normal functional lung tissues.
223785959|NCT06635330|BIOLOGICAL|anti-CD19 CAR T cell therapy|Anti-CD19 CAR-T cell therapy for R/R B-ALL pediatric patients. For patients 50 kg and less: 0.2 to 5 in ten to the power of six live CAR+ T cells per kilogram of body weight/ For patients over 50 kg: 0.1 to 2.5 in ten to the power of eight live CAR+ T cells (without considering weight).
223785960|NCT05059678|OTHER|Best Practice|Receive standard of care
223785961|NCT05059678|OTHER|Educational Intervention|Receive educational materials and attend videoconference sessions
223785962|NCT05059678|OTHER|Questionnaire Administration|Ancillary studies
223785963|NCT06634628|RADIATION|Radioligand [11C]CHDI-00491009|Intravenous injection of radioligand in the arm with PET imaging of the brain.
223785964|NCT04049526|BEHAVIORAL|The influence of different music genres on Heart Rate Variability (HRV) in preterm infants|Neonates undergo a daily randomized music listening program (25 minutes, every day, for 3 days) based on different music genres listening (soft pop-rap, pop-rock and classical music). Music programs is followed by 1 day of no music monitoring (25 minutes). An electrocardiogram is performed to evaluate HRV parameters in each neonate with and without music exposure
223785965|NCT00003878|DRUG|polifeprosan 20 with carmustine implant|
223785966|NCT00003878|PROCEDURE|conventional surgery|
223785967|NCT03850392|DEVICE|cryotherapy (Thermogel - Artsana or Cryo+ - Cryonic)|cold application (ice 30 min or cold CO2 2 min) twice during 1 day at an 8 hour-interval
223785968|NCT00716261|DEVICE|McROB Hybrid node 3-axes accelerometers and 3-axes gyroscopes|Training with the Audio-feedback device for about 30 minutes, 3 times per week for 6 weeks
223785969|NCT04704336|BEHAVIORAL|Task-shifting strategy for HTN control (TASSH) protocol|The TASSH protocol include the following 4 steps: 1). Identify HIV patients with uncontrolled HTN: trained HIV nurses will take patients' medical history (whether or not they have a diagnosis of diabetes, heart attack, stroke, heart failure, smoking). 2) Next, they will measure the patients' weight, height, waist circumference and BP with a valid automated device following standard procedures and then conduct lab tests with point-of-care testing on blood glucose, lipids and urine dip stick. 3) Initiate lifestyle counseling and medication treatment every 1-3 months: The nurses will next counsel eligible patients on lifestyle behaviors for 20 to 30 minutes (increased intake of fruits and vegetables, moderate physical activity and reduce salt intake). 4). Refer patients with complicated HTN to physicians for further care
223785970|NCT01470027|DRUG|N-acetylcysteine|900mg NAC effervescent tablets
223785971|NCT01470027|DRUG|Placebo|effervescent tablets
223785972|NCT03646513|DEVICE|SMF Short Modular Femoral Hip System|Primary Total Hip Arthroplasty with SMF Short Modular Femoral Stem Hip System.
223785973|NCT01993524|DIETARY_SUPPLEMENT|probiotic|antibiotic plus probiotic
223785974|NCT01993524|OTHER|placebo|antibiotic plus placebo
223785975|NCT04952766|BIOLOGICAL|Biological samples|"Immunocompromised subjects and healthy subjects groups will have collection of biological samples (blood with/without nasopharyngeal swabs) at Month-0, -1, -2, -3, -6, with associated data for the study of the kinetics of antibodies anti COVID-19.~Biological samples :~* Serum and plasma from each participant for the purpose of performing the SARS-CoV-2 serologic tests~* Nasopharyngeal samples (not mandatory)~Associated data :~* Demographic data~* Description of clinical manifestations related to vaccination~* Description of clinical manifestations related to SARS-CoV-2 infection, if any Blood Fractioning~* Serum and plasma aliquoted and stored under 250, 500 and 1000 µL (at -80°C)"
223785976|NCT05442411|DRUG|Ropivacaine 0.75% Injectable Solution|comparison of scalp block vs conventional post operative parecoxib
223785977|NCT05487508|DRUG|Dexamethasone|Administration of intraoperative 1 mg/kg body weight dexamethasone
223785978|NCT05487508|DRUG|Normal saline|Placebo (NaCl 0.9%)
223785979|NCT06196723|PROCEDURE|transjugular intrahepatic portal shunt|TIPS was performed by experienced clinicians in the Gastroenterology/Hepatology Department according to standard operating procedures, utilizing 8 mm or 10 mm expanded polytetrafluoroethylene-covered stents at the discretion of the local physician.
223785980|NCT06403592|OTHER|optic nerve sheath diamater|Measurement of optic nerve sheath diameter
223785981|NCT05469321|OTHER|None, pure observationnal study|None, pure observational study following the usual management of the patients
223785982|NCT01845610|DIETARY_SUPPLEMENT|Fortified fat-based paste with essential fatty acids, DHA, ARA, phytase, L-lysine, potassium, phosphorous, magnesium and manganese|Complementary food supplement providing micronutrients, essential fatty acids, DHA and ARA, phytase, L-lysine, potassium, phosphorous, magnesium and manganese
223785983|NCT01845610|DIETARY_SUPPLEMENT|Fortified fat-based paste with essential fatty acids|Complementary food supplement fortified with micronutrients and essential fatty acids
223785984|NCT01752192|DEVICE|Telerehabilitation programme|Telerehabilitation programme: Each patient in the intervention group will use a telehealth monitor. The patient will measure blood pressure, pulse and weight once or twice a week over a 3 months periode with the use of a blood pressure monitor and a weightscale connected to the monitor. The patients will also measure their steps daily by the use of a digital stepcounter. The patients will be able to see their data in a personal health record on a tablet where they can share informations with their GP, nurse and doctor at the hospital or healthcare center. The patient are also offered access to a portal called www.aktivehjerte.dk where they can find informations on rehabilitations topics in text, video and sound.
223785985|NCT01757964|BIOLOGICAL|Bacteriotherapy|
223785986|NCT02532660|DRUG|Escitalopram 10mg|Escitalopram 10mg (1 pill once a day)
223785987|NCT02532660|DRUG|LABCAT TCJUSS|LABCAT TCJUSS 1000mg daily (two 250mg capsules in the morning + 2 capsules of 250 mg at night)
223785988|NCT02532660|DRUG|LABCAT TCJUSS Placebo|LABCAT TCJUSS placebo daily (2 capsules in the morning + 2 capsules at night);
223785989|NCT02532660|DRUG|Escitalopram Placebo|Escitalopram Placebo (1 pill once a day)
223785990|NCT05727605|BEHAVIORAL|Neurocognitive tests: WAIS digit span, HVLT-R, COWAT, MOCA, WAIS digit symbol substitution, TMT A&B, Stroop Color Word Test|"Primary brain tumour patients will be evaluated longitudinally at the following timepoints: baseline (minimal 4 weeks after surgery, before radiotherapy), three months after end of radiotherapy, 1 year after end of radiotherapy and 2 years after end of radiotherapy. At each visit, neurocognitive testing, a self-report inventory and/or advanced MR imaging will take place.~Time points: baseline, 12 months post-radiotherapy and 24 months post-radiotherapy"
223785991|NCT05727605|DIAGNOSTIC_TEST|MRI|"Advanced MRI: all participants will be scanned on a 3T Siemens of Philips MR scanner (multicenter protocol): MPRAGE, FLAIR, T2, DWI, rsfMRI, SWI \& ASL~Time points: baseline, 3 months post-radiotherapy and 12 months post-radiotherapy"
223785992|NCT05727605|BEHAVIORAL|Questionnaires: EORTC QLQ C30 & BN20, STAI, CFQ, BDI-II, BRIEF-A, FACIT-F, PSQI|Time points: baseline, 12 months post-radiotherapy and 24 months post-radiotherapy
223785993|NCT05727605|OTHER|Toxicity scoring|During and after radiotherapy and at at the end of the study, adverse events will be monitored using CTCAEv5.0.
223785994|NCT05930327|OTHER|Unconditional Cash Transfer (High-Value)|Monthly, Unconditional Cash Transfer ($325) for 4-months
223785995|NCT05930327|OTHER|Unconditional Cash Transfer (Low-Value)|Monthly, Unconditional Cash Transfer ($25) for 4-months
223785996|NCT05680103|RADIATION|lateral cephalometry|lateral x-ray beam to capture lateral cephalometry of patients
223785997|NCT02393079|DEVICE|Transcranial LED Therapy (TCLT)|Whereas the geometry of the skull and to uniformly distribute the light radiation, the TLTC is applied using as light source a set of LEDs installed in a helmet, emitting radiation in the range between 600nm and 650nm with a peak at 630nm, so in the red region.
223785998|NCT02393079|DEVICE|Sham|A SHAM identical helmet will be used in the control group.
223785999|NCT05108194|BEHAVIORAL|SMS Personalized Sleep Intervention|"All participants will be enrolled in the intervention to evaluate the feasibility and acceptability of the SMS-PSI. After the data training and validation phase, participants will be provided with at least one and up to three daily text messages that offer users a specific strategy based on strategies from CBTi. All participants will have access to a user dashboard, which is a web-app that includes personalized sleep-tracking information and the opportunity to customize their messaging. The person-level acceptability and adherence to the sleep strategies will be evaluated via self-report endorsement from daily diary and whether users added suggestions to their calendars. Both adherence and acceptability will be collected and integrated with the selection algorithm to optimize subsequent SMS suggestions."
223786000|NCT02105948|DRUG|Mepolizumab|Humanised IgG antibody (IgG1, kappa) with human heavy and light chain frameworks, provided as a lyophilised cake in sterile vial. Vial to be reconstituted with Sterile Water for Injection, just prior to use.
223786001|NCT02105948|DRUG|Placebo|Sterile 0.9% sodium chloride solution
223786002|NCT04169139|DEVICE|MIST (minimally invasive surgical therapy)|REPaiR Periodontal Therapy
223786003|NCT04698980|DIAGNOSTIC_TEST|blood samples (venous and capillary at the fingertip)|For each participant, the intervention will be a fingertip sample to perform the STANDARD G6PD test and two blood samples on EDTA to perform the reference test
223786004|NCT01873365|OTHER|Data collection|Case report forms (CRFs), logbooks and booklets.
223786005|NCT03447782|DRUG|Naltrexone HCl (Bulk) Powder|For the NDPH Persistent group, patient will take naltrexone, 4.5 mg, po 1 time/day for three months-Naltrexone will be compounded from Naltrexone HCL powder
223786006|NCT06324435|DRUG|Apremilast|60mg/day
223786007|NCT04213196|DRUG|HSK21542|Intravenous injection 0.2 μg/kg solution (active or placebo, 0.5-1h after standard meal). Complete infusion within 15 min.
223786008|NCT04213196|DRUG|HSK21542|Intravenous injection 0.5 μg/kg solution (active or placebo, 0.5-1h after standard meal). Complete infusion within 15 min.
223786009|NCT04213196|DRUG|HSK21542|Intravenous injection 1 μg/kg solution (active or placebo, 0.5-1h after standard meal). Complete infusion within 15 min.
223786010|NCT04213196|DRUG|HSK21542|Intravenous injection 1 μg/kg solution (active or placebo, 0.5-1h after standard meal). Complete infusion within 2 min.
223786011|NCT04213196|DRUG|HSK21542|Intravenous injection 0.75 μg/kg solution (active or placebo, 0.5-1h after standard meal). Complete infusion within 15 min.
223786012|NCT04213196|DRUG|HSK21542|Intravenous injection 1.5 μg/kg solution (active or placebo, 0.5-1h after standard meal). Complete infusion within 15 min.
223786013|NCT04213196|DRUG|HSK21542|Intravenous injection 2.25 μg/kg solution (active or placebo, 0.5-1h after standard meal). Complete infusion within 15 min.
223786014|NCT04213196|DRUG|HSK21542|Intravenous injection 3.375 μg/kg solution (active or placebo, 0.5-1h after standard meal). Complete infusion within 15 min.
223786015|NCT04213196|DRUG|HSK21542|Intravenous injection 0.2 μg/kg solution (active or placebo, 0.5-1h after standard meal). Complete infusion within 2 min.
223786016|NCT01658787|DEVICE|Endovascular aortic repair|Treatment with Gore Endovascular Aortic Products.
223786017|NCT05062252|DEVICE|Mirror Medacta Shoulder System|Anatomic total shoulder arthroplasty system
223786018|NCT05062252|DEVICE|Medacta Shoulder System|Anatomic total shoulder arthroplasty system - standard configuration
223786019|NCT01892748|DRUG|Cholecalciferol|All patients and physicians were blinded to group assignment and treatment allocation. The first group received oral cholecalciferol of 50,000 IU/week and for 6 months. All subjects were evaluated at baseline and after the end of supplementation for clinical and laboratory parameters.
223786020|NCT01892748|DRUG|Placebo|The second group received identical placebo tablets for 6 months. All subjects were evaluated at baseline and after the end of supplementation for clinical and laboratory parameters.
223786021|NCT03705091|DIAGNOSTIC_TEST|Magnetic resonance imaging|ASL and DWI MRI
223786022|NCT01934218|DEVICE|Gel-One|
223786023|NCT01934218|DEVICE|PBS|
223786024|NCT03910153|DIETARY_SUPPLEMENT|MSPrebiotic|MSPrebiotic digestion resistant starch from potatoes (30 g) will be mixed in 1 glass (approximately 250 mL) of non-heated fluid or non-heated semi solid food and consumed. If the subject is on any medications, the potato resistant starch will be administered either 2 hours before medications or 2 hours after participants have taken their medications.
223786025|NCT03910153|OTHER|Placebo|Corn starch (30 g) will be mixed in 1 glass (approximately 250 mL) of non-heated fluid or non-heated semi solid food and consumed. If the subject is on any medications, the corn starch will be administered either 2 hours before medications or 2 hours after participants have taken their medications.
223786026|NCT04763850|OTHER|Decline Walking with real-time Feedback|Participants are walking decline with self-paced speed on an instrumented treadmill with virtual reality projection under three conditions: without instruction, with instruction for an internal focus of attention and with real-time feedback of their frontal knee alignment
223786027|NCT02930239|OTHER|Gait rehabilitating with reduced bodyweight|Patients will perform 8 sessions of gait rehabilitation with reduced bodyweight using the anti gravity treadmill during week 2-5 post-surgery.
223786028|NCT02930239|OTHER|Standardized rehabilitation following an anterior cruciate ligament reconstruction at Linkoping University Hospital|Exercises for increased movement and circulation performed on a daily basis.
223786029|NCT04239313|BIOLOGICAL|Low-dose freeze-dried recombinant tuberculosis vaccine (AEC / BC02)|Population I are coxal muscle injection of low dose vaccine.
223786030|NCT04239313|BIOLOGICAL|Low-dose adjuvant for freeze-dried recombinant tuberculosis vaccine (AEC / BC02)|Population I are coxal muscle injection of low dose adjuvant.
223786031|NCT04239313|BIOLOGICAL|Lyophilized recombinant tuberculosis vaccine (AEC / BC02) placebo|The placebo drug contains 20mg mannitol and 10 millimole(mM) phosphate buffer(PB).population I are coxal muscle injection of placebo.
223786032|NCT05496582|DIAGNOSTIC_TEST|No intervention|No intervention
223786033|NCT02804854|DRUG|Neutrophil Activation Probe (NAP)|Delivery of NAP by direct pulmonary administration followed by fibreoptic confocal microendoscopy. A total of 240 mcg (±25%) in three divided doses of 80 mcg (±25%).
223786034|NCT02232893|DRUG|Daikenchuto (TU-100)|Subjects will receive 5g TID (15g/day) of TU-100. Dosage form is granule. Subject will take a daily dose divided 3 times per day for 3 days before surgery and for 28 days after surgery.
223786035|NCT02232893|DRUG|Placebo|Subjects will receive daily dose of TU-100 placebo. Dosage form is granule. Subject will take a daily dose divided 3 times per day for 3 days before surgery and for 28 days after surgery.
223786036|NCT03369600|DEVICE|Supersonic Imagine Aixplorer SWE Ultrasound Imaging|Consented women will attend 2+ sessions where they will be imaged using the Supersonic Imagine Aixplorer for Shear Wave Elastography imaging.
223786037|NCT03887468|DEVICE|EvoCit|hemodialysis using the combination of the Evodial dialyzer with a citrate enriched dialysate
223786038|NCT03887468|DEVICE|EvoHep|hemodialysis using the combination of the Evodial dialyzer with a conventional bicarbonate based dialysate and systemic anticoagulation using unfractionated heparin
223786039|NCT06495736|DIAGNOSTIC_TEST|Experimental: ROSE technique stain|The ROSE technical group uses Diff-Quick stain for diagnosis
223786040|NCT04928950|DRUG|Activated charcoal|Activated Charcoal, Powder, USP is carbon that has been treated to create low-volume pores that increase the area available for chemical reactions and adsorption. The most common pharmaceutical uses of activated charcoal is as a purification agent and antitoxin. All Spectrum Chemical USP products are manufactured, packaged and stored under current Good Manufacturing Practices (cGMP) per 21CFR part 211 in FDA registered and inspected facilities.
223786041|NCT04747977|DRUG|OTX-DED|0.2mg dexamethasone ophthalmic insert
223786042|NCT04747977|DRUG|OTX-DED|0.3mg dexamethasone ophthalmic insert
223786043|NCT04747977|DRUG|OTX-DED|Hydrogel vehicle ophthalmic insert
223786044|NCT00124527|DRUG|Irofulven + capecitabine|
223786045|NCT03634774|OTHER|CHOICE+ Training Program|CHOICE+ is a program where team members and other stakeholders are engaged in making changes to dining in a long term care home to improve the experience. An external coach supports behaviour change.
223786046|NCT01204151|BEHAVIORAL|discrete-trial training|
223786047|NCT01587651|DRUG|Prasugrel Loading Dose|60mg given as six 10mg film coated tablets
223786048|NCT01587651|DRUG|Prasugrel Maintenance Dose|10mg maintenance dose, given as one 10mg film coated tablet
223786049|NCT01587651|DRUG|Ticagrelor Maintenance Dose|one 90mg film coated tablet
223786050|NCT02866253|DRUG|DHEA|Interventional patients should take DHEA 25mg tid 12weeks before enter the IVF cycle.
223786051|NCT04340206|BEHAVIORAL|face-to-face support and Chatbot online support group|Behavioral: Structured web- and mobile-based intervention with Youth Compass plus program to support adolescents' psychological flexibility, well-being, and subsequently support successful transition to upper secondary education. The Youth Compass plus is a five-week online program aiming to enhance adolescents' psychological flexibility by guiding adolescents in exploring their values and setting goals and changing behaviors according to their goals (week 1), and learning acceptance, defusion and mindfulness skills (weeks 2-3) and integrating these skills into their personal and social life (weeks 4-5). The participants in this condition receive weekly online support and feedback from the eCoach built within the program. In addition, they meet and get support from their human coach (i.e., psychology student) twice in the face-to-face meetings.
223786052|NCT04340206|BEHAVIORAL|only chat-robot online support group|Behavioral: Structured web- and mobile-based intervention with Youth Compass plus program to adolescents' psychological flexibility, well-being, and subsequently support successful transition to upper secondary education. The Youth Compass plus is a five-week online program aiming to enhance adolescents' psychological flexibility by guiding adolescents in exploring their values and setting goals and changing behaviors according to their goals (week 1), and learning acceptance, defusion and mindfulness skills (weeks 2-3) and integrating these skills into their personal and social life (weeks 4-5). The participants in this condition receive weekly online support and feedback from the eCoach built within the program.
223786053|NCT04340206|BEHAVIORAL|Control group, no intervention|Behavioral: No intervention
223786054|NCT03277222|BIOLOGICAL|IN insulin|IN insulin twice daily taken after breakfast and again after dinner using the nasal delivery device.
223786055|NCT03277222|BIOLOGICAL|Sterile Saline placebo|Sterile Saline placebo twice daily taken after breakfast and again after dinner using the nasal delivery device.
223786056|NCT04838743|DRUG|IDegLira|"Patients will be treated with commercially available Xultophy® (IDegLira) in a pre-filled pen injector (FlexTouch®) at the discretion of the treating physician in accordance with the Xultophy® label in Japan.~The decision to initiate treatment with Xultophy® is at the treating physician's discretion according to the approved Xultophy® label in Japan and independent from the decision to include the patient in the study."
223786057|NCT01696422|BIOLOGICAL|Dengue 1,2,3,4 (attenuated) vaccine|Dose 1000 PFU per virus (1,2,3,4) Route:subcutaneous
223786058|NCT01696422|BIOLOGICAL|TetraVax-DV Vaccine - Admixture TV003|Dose 1000 PFU per virus (1,2,3,4) Route: subcutaneous
223786059|NCT01696422|OTHER|Placebo|Route:subcutaneous
223786060|NCT01657422|BEHAVIORAL|PACE+|Patients assigned to the intervention group will receive intervention strategies over a the course of 2 years including: (1) completion of a 45-minute office-based computer program resulting in an assessment and action plan for improvement in physical activity and nutrition behaviors; (2) a provider counseling session immediately following the computerized assessment, followed by (3) 12 phone calls and 24 mailings over a 24-month period conducted by PACE+ staff members
223786061|NCT02040480|DRUG|GSK2110183 Gelatin Capsule|White opaque hard gelatin capsule with a unit dose strength of 25 milligrams (mg) for oral administration
223786062|NCT02040480|DRUG|GSK2110183 IR Tablet|White round biconvex film coated IR tablet with a unit dose strength of 25 mg for oral administration
223786063|NCT05967520|DRUG|JMKX000189|JMKX000189 will be administered orally once a day
223786064|NCT05967520|DRUG|Placebo|Placebo will be administered orally once a day
223786065|NCT03069222|OTHER|Standard Rehabilitative Treatment|The patients will participate in standard but comprehensive SCI specific rehabilitation therapy provided by the SCI program at KIR. The therapy consists of 3 hours per day, 5 days a week. Motor function therapy includes standardized procedures for range of motion, passive and active muscle activities, and therapies to improve mobility. The treatment program for the enrolled patients will be standardized by Dr. Kirshblum, Director of the SCI program at KIR and a Co-Investigator of the study. Patients usually receive 4 weeks of rehabilitation treatment; however, if any of them are discharged earlier from KIR, their out-patient treatment activities will be monitored and the patients will be tested based on the planned schedule.
223786066|NCT03498248|DRUG|lenograstim|injection of lenograstim in patients with neutropenia after cytotoxic chemotherapy
223786067|NCT05913622|DEVICE|Intra-aortic balloon pump|An IABP is placed percutaneously into the thoracic aorta and supports the heart through synchronized inflation and deflation of a balloon.
223786068|NCT00291785|DRUG|CT-2106|CT-2106 as 10 minute infusion on days 1, 15 \& 29 of each 42-day cycle
223786069|NCT00291785|DRUG|Folinic acid|Folinic acid 200 mg IV 1 hour after CT-2106 infusion on days 1, 2, 15, 16, 29 and 30
223786070|NCT00291785|DRUG|5-FU (fluorouracil)|5-FU following CT-2106 and folinic acid infusions @ 400 mg/m² IV bolus then 5-FU 600 mg/m² as a 22 hour IV infusion on Days 1, 2, 15, 16, 29, and 30.
223786071|NCT03786679|DEVICE|Ultrasling ER III orthosis|Application of orthosis and start of rehabilitation after four weeks.
223786072|NCT03052179|DIETARY_SUPPLEMENT|Poly-biotic|Before-after treatment
223786073|NCT05038644|DRUG|XmAb18968 - Dose level -1|0.1 mg IV C1D1, 0.3 mg IV C1D2, then 0.4 mg IV on D8, D15, and D22 in a 28-day cycle.
223786074|NCT05038644|DRUG|XmAb18968 - Dose level 0 (starting dose)|0.2 mg IV C1D1, 0.6 mg IV C1D2, then 0.8 mg IV on D8, D15, and D22 in a 28-day cycle.
223786075|NCT05038644|DRUG|XmAb18968 - Dose level 1|0.25 mg IV C1D1, 0.75 mg IV C1D2, then 1.0 mg IV on D8, D15, and D22 in a 28-day cycle.
223786076|NCT05038644|DRUG|XmAb18968 - Dose level 2|0.4 mg IV C1D1, 0.9 mg IV C1D2, then 1.3 mg IV on D8, D15, and D22 in a 28-day cycle.
223786077|NCT05038644|DRUG|XmAb18968 - Dose level 3|0.5 mg IV C1D1, 1.0 mg IV C1D2, then 1.5 mg IV on D8, D15, and D22 in a 28-day cycle.
223786078|NCT01383538|DRUG|FOLFIRINOX, IPI-926|"Oxaliplatin: intravenous, 50 to 85 mg/m2, over 2 hrs, once per cycle.~Leucovorin: intravenous, 400 mg/m2, over 2 hrs, once per cycle.~Irinotecan: intravenous, 120 to 180 mg/m2, over 90 minutes, once per cycle.~5-FU: intravenous, 1600 to 2400mg/m2, over 46hr continuous infusion, once per cycle.~IPI-926: oral, 130 to 160 mg/day, daily, 14 days per cycle."
223786079|NCT03971643|DRUG|vilobelimab|IV infusions of vilobelimab diluted in sodium chloride.
223786080|NCT01324492|DRUG|RAD001|
223786081|NCT01660763|DRUG|Sufentanil NanoTab PCA System/15 mcg|15 mcg Sufentanil NanoTab dosed sublingually every 20 minutes as needed for pain for at least 48 hours. Patients may elect to remain in study for up to 72 hours.
223786082|NCT01660763|DRUG|Placebo Sufentanil NanoTab PCA System|Placebo NanoTab dosed sublingually every 20 minutes as needed for pain for at least 48 hours. Patients may elect to remain in study for up to 72 hours.
223786083|NCT06189040|DRUG|BNT162b2 30µg|intramuscular administration of 30µg
223786084|NCT06189040|DRUG|BNT162b2 20µg|intramuscular administration of 20µg
223786085|NCT06189040|DRUG|BNT162b2 6µg|intradermal administration of 6µg
223786086|NCT06189040|DRUG|mRNA-1273 100µg|intramuscular administration of 100µg
223786087|NCT06189040|DRUG|mRNA-1273 50µg|intramuscular administration of 50µg
223786088|NCT06189040|DRUG|ChAdOx1-S [Recombinant]|intramuscular administration of not less than 2.5 x 10\^8 infectious units
223786089|NCT02282501|OTHER|enteral feeding by nasogastric tube.|method of administration enteral feeding by nasogastric tube.
223786090|NCT03325712|DRUG|BI 705564|Film-coated tablet
223786091|NCT03325712|DRUG|Placebo|Film-coated tablet
223786092|NCT03325712|DRUG|Midazolam|Solution for injection
223786093|NCT03174886|DRUG|AADvac1 40 µg|Active immunotherapy against neurofibrillary pathology.
223786094|NCT03174886|DRUG|AADvac1 160 µg|Active immunotherapy against neurofibrillary pathology.
223786095|NCT02692300|PROCEDURE|EEG-Guided Group|Device: Bispectral Index (BIS) processed electroencephalogram or MASIMO or NeuroSENSE
223786096|NCT02848417|DRUG|Curcumin|Perform a randomized phase I/II study comparing curcumin (increased bioavailable form, body cell mass-85, 400 mg twice a day) to glutathione (liposomal bioavailable form 630 mg bid), with a 3 month intervention and assessment of safety, efficacy and biomarker response to therapy.
223786097|NCT02848417|DRUG|Glutathione|Perform dynamic modeling studies before and after 3 months of therapy, repeating the method used previously in order to compare the response to exercise across groups and better quantify the degree of recovery in treated subjects using an exercise challenge and 9 point in time blood and saliva collections over 24 hours with genomic, cytokine, neuropeptide and cell population studies.
223786098|NCT02848417|OTHER|Placebo|"Placebo liquid 120 ml per/ bottle~Placebo capsules 60 capsules per bottle 400 mg /cap~With the addition of a Partner PI, redox/methylation expert Dr. Richard Deth, perform studies of antioxidant and methylation-related metabolic status prior to, during and after acute exercise in GWI subjects before and after interventions."
223786099|NCT05088213|PROCEDURE|suction mini percutaneous nephrolithotomy|18Fr suction sheath (Weili, China) was inserted, and 12Fr mini-nephroscope was used, kidney stones was fragmented by pneumatic lithotriptor (LithoClast Master, Switzerland) or Ho:YAG laser（0.8-1.0W\*20-30Hz）, and stone fragments was sucked out with the suction sheath.
223786100|NCT05088213|PROCEDURE|standard percutaneous nephrolithotomy|24-30Fr sheath was inserted, and 20Fr nephroscope (Richard Wolf, Germany) was used, kidney stones was disintegrated and sucked out by ultrasonic-lithotripter (LithoClast Master, EMS, Switzerland or ShockPluse-SE, Olympus).
223786101|NCT00202163|DRUG|DHEA|
223786102|NCT00202163|DRUG|Testosterone|
223786103|NCT04463641|DEVICE|Implantation of the Axone 4LV Lead|Implantation of the Axone 4LV Lead
223786104|NCT00952653|DRUG|Desvenlafaxine Succinate Sustained Release|50 mg DVS SR tablet days 1-6, period 2 only.
223786105|NCT00952653|DRUG|Midazolam|4 mg midazolam (2 mL midazolam syrup) day 1, period 1 and day 6, period 2.
223786106|NCT00017381|BIOLOGICAL|rituximab|Given IV
223786107|NCT00017381|DRUG|cyclophosphamide|Given IV
223786108|NCT00017381|BIOLOGICAL|filgrastim|Given SC
223786109|NCT00017381|RADIATION|yttrium Y 90 ibritumomab tiuxetan|Given IV
223786110|NCT00017381|PROCEDURE|peripheral blood stem cell transplantation|Undergo PBSCT
223786111|NCT00760864|DRUG|TAK-715 and methotrexate|TAK-715 25 mg, tablets, orally, twice daily and methotrexate stable dose for up to 6 weeks.
223786112|NCT00760864|DRUG|TAK-715 and methotrexate|TAK-715 50 mg, tablets, orally, twice daily and methotrexate stable dose for up to 6 weeks.
223786113|NCT00760864|DRUG|TAK-715 and methotrexate|TAK-715 100 mg, tablets, orally, twice daily and methotrexate stable dose for up to 6 weeks.
223786114|NCT00760864|DRUG|Methotrexate|TAK-715 placebo-matching, tablets, orally, twice daily and methotrexate stable dose for up to 6 weeks
223786115|NCT02265237|DRUG|ombitasvir/paritaprevir/ritonavir|tablets
223786116|NCT02265237|DRUG|ribavirin|tablets
223786117|NCT04607967|DEVICE|High Flow Nasal Oxygen|"Study participants are suffering from an acute hypoxemic respiratory distress. They have to be treated with oxygen-therapy that could be administered using a conventional oxygen device (study group CO) or High Flow Nasal Oxygen (study group HNFO). During the first 60 minutes following patients admission, patients will be randomized to one of the two study groups. In both groups, the failure of the treatment will be evaluated by the need for a therapeutic escalation fours hours after the treatment initiation."
223786118|NCT01898338|DRUG|Fosfomycin 2gr/6h iv|
223786119|NCT01898338|DRUG|Daptomycin 10mg/kg/24h iv|
223786120|NCT03593668|DRUG|Metformin|"2-week dose adjustment period（0-2weeks）\[before meals\] 0-2d： - ;250mg，po; -. 3-4d： - ;250mg，po; 250mg，po. 5-6d： 250mg，po; 250mg，po; 250mg，po. 7-9d: 250mg，po; 500mg，po; 250mg，po. 10-11d: 250mg，po; 500mg，po; 500mg，po. 12-14d: 500mg，po; 500mg，po; 500mg，po.~10-week dose stabilization period（3-12weeks） Metformin Hydrochloride Tablet 500mg tid po."
223786121|NCT03593668|DRUG|Benaglutide|"2-week dose adjustment period（0-2weeks） \[before meals\] 0-2d: -; 0.1mg，iH; -; 3-4d: -; 0.1mg，iH; 0.1mg，iH; 5-6d: 0.1mg，iH; 0.1mg，iH; 0.1mg，iH; 7-9d: 0.1mg，iH; 0.2mg，iH; 0.1mg，iH; 10-11d: 0.1mg，iH; 0.2mg，iH; 0.2mg，iH; 12-14d: 0.2mg，iH; 0.2mg，iH; 0.2mg，iH.~10-week dose stabilization period（3-12weeks） Benaglutide Injection 0.2mg，100ul，tid，iH"
223786122|NCT01412008|DRUG|Botox (botulinum toxin)|A series of three injections will be made simultaneously to the gastroc-soleus muscles of the affected lower limb; this will be the only drug intervention/injection session throughout the study, and occurs at baseline. The top injection site, closest to the knee, consists of 25 units of Botox and 0.25 cc saline. The bottom injection site, closest to the ankle, also consists of 25 units of Botox and 0.25 cc saline. The middle injection site will be considered the placebo injection, as it will not contain any Botox (0 units Botox) and 0.25 cc saline.
223786123|NCT01178853|DRUG|Warfarin|Warfarin 5 mg once daily
223786124|NCT01178853|DRUG|Warfarin 5mg + Rosuvastatin 40 mg once daily (QD)|Warfarin 5mg + Rosuvastatin 40 mg once daily (QD)
223786125|NCT01178853|DRUG|Warfarin 5 mg + Pitavastatin 4mg once daily (QD)|Warfarin 5 mg + Pitavastatin 4mg
223786126|NCT03550313|BIOLOGICAL|Multivalent|Pneumococcal conjugate vaccine
223786127|NCT03550313|BIOLOGICAL|Prevnar 13|Pneumococcal conjugate vaccine
223786128|NCT02870790|DRUG|TDF/FTC|one pill daily
223786129|NCT06197893|PROCEDURE|gingival unit graft+modified sling suture technique|The GUG was obtained from the maxillary premolar area. A sulcular incision including the marginal gingival tissue, and two vertical incisions, including the distal and mesial papillae, was made in the palatial parts of the premolars. Then, the incision lines were combined and a 1-1.5 mm thick graft of the desired dimensions was dissected. The dissected graft was fixed to the recipient site with 5/0 polypropylene suture using a modified sling suture technique. First, the needle was passed through the graft slightly apical to the mesial papilla on the buccal side and removed from the lingual aspect including lingual papilla. Subsequently, on the distal side, the needle was passed from the lingual side to the buccal side, and it was passed through the graft slightly apical to the distal papilla and removed from the lingual gingiva again. Then it was knotted on the buccal graft by returning to the buccal starting point on the mesial side.
223786130|NCT06197893|PROCEDURE|Gingival unit graft and conventional suture technique|The GUG was obtained from the maxillary premolar area. The dissected graft was fixed to the recipient site with 5/0 polypropylene suture using conventional suture technique. Conventional suture technique includes a horizontal matrix suture and 2 simple sutures. First the coronal part of the dissected graft was fixed to the recipient bed with a horizontal matrix suture, then with 2 simple sutures along the vertical incision line from mesial and distal sides with 5/0 polypropylene suture.
223786131|NCT06197893|PROCEDURE|Conventional graft and modified sling suture technique|Conventional graft dimensions were determined with aluminum foil and the foil was placed in the palatinal region at the level of the maxillary premolars, at least 2 mm away from the free gingival margin of the adjacent teeth. The exterier edges of the foil were drawn with a scalpel and the 1-1.5 mm thick graft was dissected from the donor site. The dissected graft was fixed to the recipient site with 5/0 polypropylene suture using a modified sling suture technique.
223786132|NCT06197893|PROCEDURE|Conventional graft and conventional suture technique|Conventional graft obtained from the palatinal region at the level of the maxillary premolars, at least 2 mm away from the free gingival margin of the adjacent teeth. The dissected graft was fixed to the recipient site with 5/0 polypropylene suture using conventional suture technique.
223786133|NCT04950101|OTHER|anal sampling|anal sampling will be performed both in men without HIV and men having HIV in order to see if they have HPV or not
223786134|NCT04050293|DRUG|SPN-538|Patients will receive SPN-538
223786135|NCT04050293|DRUG|Placebo|Patients will receive Placebo
223786136|NCT00380068|DRUG|Ambrisentan|Oral tablets taken once daily.
223786137|NCT05234164|DEVICE|EXIST 6F NiTi Stent System FLEX|Subjects requiring treatment of the P1 segment of the proximal popliteal artery will be treated with the Exist 6F NiTi Stent FLEX type. Subjects requiring treatment of the SFA will undergo an additional calcification review based on the Fanelli classification. Subjects graded with Fanelli 1 or 2 will be treated with the Exist 6F NiTi Stent FLEX type.
223786138|NCT05234164|DEVICE|EXIST 6F NiTi Stent System PULL|Subjects requiring treatment of the SFA will undergo a calcification review based on the Fanelli classification. Subjects graded with Fanelli grade 3 and 4 will be treated with the Exist 6F NiTi Stent PULL type.
223786139|NCT01297062|DRUG|Exenatide|IV Exenatide (therapeutic and supratherapeutic concentrations)
223786140|NCT01297062|DRUG|Moxifloxacin|Oral Moxifloxacin (400 mg)
223786141|NCT01297062|DRUG|Placebo comparator|IV Placebo (matching volume of placebo)
223786142|NCT01416792|PROCEDURE|Centrifugation|
223786143|NCT01416792|PROCEDURE|Multiple-pass hemofiltration|The residual volume from the CPB circuit is pumped though a hemofilter for multiple passes removing the crystalloid component thereby concentrating the plasma.
223786144|NCT04110808|DRUG|hypotensive anaesthesia using Nitroglycerine|"effect of hypotensive anaesthesia using Nitroglycerine vs Phentolamine on Event related potentials, quantitative Electroencephalograghy and cognitive function~Phentolamine group (30 patients): Patients will receive hypotensive anesthesia with phentolamine infusion via syringe pump by adding 20 mg (2ml) of Phentolamine to 48 ml of normal saline making it to final concentration of 0.4 mg/ml at the rate of 0.1-2 mg/min according to the patients desired target blood pressure.~Nitroglycerine group (30 patients): Patients will receive hypotensive anesthesia with nitroglycerine infusion via syringe pump by adding 5mg (5ml) of Nitroglycerin to 45ml of normal saline making it to final concentration of 100μg/ml at the rate of 0.5- 10 μg/kg/min according to the patients desired target blood pressure."
223786145|NCT02526134|DEVICE|radio opaque markers (Echo Tip Ultra Fiducial Needle - ETUF)|
223786146|NCT02894021|PROCEDURE|classic closure|mastectomy with classic closure in 2 steps, drainage by negative pressure aspiration
223786147|NCT02894021|PROCEDURE|padding|areas of padding and running sutures between subcutaneous tissue and pectoral muscle followed by closure in 2 steps, drainage by negative pressure aspiration for 48 h
223786148|NCT06421233|OTHER|massage|Endorphin massage will be given for 15 minutes every 2 hours.
223786149|NCT04964089|DRUG|KSI-301|Intravitreal Injection
223786150|NCT04964089|DRUG|Aflibercept|Intravitreal Injection
223786151|NCT04964089|OTHER|Sham Procedure|The sham is a procedure that mimics an intravitreal injection. It involves pressing the blunt end of an empty syringe (without a needle) against the anesthetized eye. It will be administered to participants in both treatments arms at applicable visits to maintain masking.
223786152|NCT06444282|OTHER|Emergency Care Action Plan|An Emergency Care Action Plan (ECAP) is a brief, pre-populated summary of suggested emergency management for children with medical complexity, embedded in a patient's electronic health record for access by providers in an emergency. Patients/families will have digital access to the ECAP and be given a paper copy. The patient's care team and caregiver(s) (parent/legal guardian) will collaborate to create an individualized ECAP containing the following content: caregiver contact information, patient summary, anticipated emergency presentations with suggested management, problem list (emergency relevant only), medication list, technology dependence, baseline important physical exam findings, baseline vital signs, allergies, advance directive information, contact information for established care providers, and other important information.
223786153|NCT03969238|BEHAVIORAL|Helpline|This helpline will aim to provide patients with new diagnosis of pain who are prescribed opioids, access to education, support and free behavioral technique to help manage their pain such as mindfulness exercises. For those with opioid use disorder, the helpline will offer support in the form of education about the disorder, opioid withdrawal symptoms, risks of overdoses, and a variety of services such as help reach appropriate care with MAT licensed providers, information on FDA-approved MAT and naloxone, and, in some cases, behavioral intervention to keep patients engaged in treatment. The opioid helpline will provide a central resource for direct services and a portal for community services. It will also serve as a referral resource for health-care professionals.
223786154|NCT05846724|DRUG|Pembrolizumab + Lenvatinib|single-arm study of pembrolizumab plus lenvatinib
223786155|NCT04411290|PROCEDURE|Total thyroidectomy (TT)|Final total thyroidectomy histopathology report should be available for correlations with preoperatively determined malignancy predictive factors, Bethesda (cytology) and TI-RADS (ultrasound findings)
223786156|NCT02012829|BEHAVIORAL|GPs communication skills and CRC screening|GPs of the intervention group received a four hours educational training focused on patients' centered care to improve GPs communication skills and enhance patients'participation in CRC mass screening . Triangulation of all qualitative data was performed in order to develop educational material and training based on the six components of the Patient-Centered Clinical Method . Two different scenarios were developed: one for a compliant patient, another for a non-compliant patient. Two videos were made with doctor and simulated patient. Interactive methods were used to elaborate educational training including role playing, the presentation of the video followed by an interactive discussion.
223786157|NCT06057350|PROCEDURE|Tumor removal|Removal of incompletely removed early-stage colon cancer
223786158|NCT05548595|DIETARY_SUPPLEMENT|Investigational|2 tablets are taken with water around the same time every day, ideally after a meal
223786159|NCT05548595|OTHER|Placebo|2 tablets are taken with water around the same time every day, ideally after a meal
223786160|NCT02261116|DRUG|Telmisartan|
223786161|NCT02261116|DRUG|Candesartan|
223786162|NCT02261116|DRUG|Placebo|
223786163|NCT05211024|DRUG|Penicillin G Benzathine|Participants in Aim 2 are receiving 28 days interval BPG intramuscular injection as part of standard of care
223786164|NCT02267382|DRUG|VT-1161|
223786165|NCT02267382|DRUG|Placebo|
223786166|NCT00058266|DIETARY_SUPPLEMENT|genistein|Given orally
223786167|NCT00058266|PROCEDURE|conventional surgery|Patients undergo surgery
223786168|NCT01165281|DRUG|Oxycodone CR|One 5 mg to 40 mg capsule twice daily for 4 weeks.
223786169|NCT01165281|DRUG|R331333 (referred to as JNS024 ER or CG5503)|One 25 mg to 200 mg capsule twice daily for 4 weeks.
223786170|NCT00113438|DRUG|Combretastatin A-4 Phosphate + Paclitaxel + Carboplatin|Combretastatin A-4 Phosphate is administered IV at 45 mg/m2 or 60 mg/m2 on Days 1, 8 and 15 followed by paclitaxel (3 hour infusion at 200 mg/m2) and carboplatin (1 hour infusion at AUC = 6) on Day 2 of each cycle. The treatment cycle is 21 days with a maximum of 21 days. Following cycle 6, subjects that have not progressed may continue on CA4P monotherapy, which will be administered at 45 mg/m2 or 60 mg/m2 on Days 1 and 8 with rest on Day 15, repeated every 21 days until disease progression.
223786171|NCT00005853|BIOLOGICAL|anti-thymocyte globulin|
223786172|NCT00005853|BIOLOGICAL|etanercept|
223786173|NCT06536075|RADIATION|Sialoscintigraphy|Sialoscintigraphy
223786174|NCT00985218|DEVICE|SMART System|microfluidic embryo culture system
223786175|NCT00985218|DEVICE|Culture dish|Standard IVF culture dish
223786176|NCT05868083|DRUG|SNC-109 CAR-T Cells|SNC-109 CAR-T Cells, first dose from 2×104 CAR+ T Cells, treatment follows the operation and the next dose would be deiced by SRC
223786177|NCT01510847|DRUG|Andriol Testocaps|Oral, 40mg, Twice a day, 30days
223786178|NCT01154634|DRUG|AZD2516, 5 mg|Capsule, oral
223786179|NCT01154634|DRUG|AZD2516, 16 mg|Capsule, oral
223786180|NCT01154634|DRUG|AZD2516, 40 mg|Capsule, oral
223786181|NCT01154634|DRUG|Placebo|Capsule, oral
223786182|NCT05806762|DEVICE|BioIntellisense|Enrolled patients will have a Fitbit placed on their wrist. There is no comparator group enrolled.
223786183|NCT01220908|DEVICE|Lung Volume Reduction Coil (LVRC)|Implantation of Lung Volume Reduction Coil(s) (LVRC)
223786184|NCT01220908|DEVICE|Coils|Lung Volume Reduction Coil(s)
223786185|NCT06164912|OTHER|Transcranial Magnetic Simulation with Pseudofeedback|Participants will receive TMS with bogus feedback that will be displayed on a screen as they imagine movement.
223786186|NCT06164912|OTHER|Transcranial Magnetic Simulation with Neurofeedback|Participants will receive TMS with live Neurofeedback that will be displayed on a screen for them as they are imagining movement
223786187|NCT00326378|DRUG|consolidation chemotherapy with Docetaxel plus cisplatin|definitive CCRT, and followed by consolidation chemotherapy with three cycles of docetaxel plus cisplatin
223786188|NCT00326378|DRUG|CCRT arm without consolidation chemotherapy|definitive CCRT with weekly Docetaxel/CDDP #6 without consolidation chemotherapy
223786189|NCT05159752|DRUG|Afamelanotide|Patients will receive afamelanotide every two weeks for twelve weeks and undergo a follow up visit 6 months later.
223786190|NCT04915469|OTHER|Standardized enhanced adherence counseling package|A standardized package was developed to support the adherence counsellor and other cadres to ensure provision of quality EAC sessions for children, adolescents and their caregivers. The package included; 1) Orientation and on job mentorship on EAC processes to clinicians, nurses, peer educators and mentor mothers. 2) Using a communication's training curriculum, providers were trained on psychosocial support and communication skills for children and their caregivers. 3) Appointment management was done using appointment dairies or a digital platform that sends patients short message services (SMS) reminders 3 days and 1 day before a scheduled clinic day. 4)Home visits. - All home visits were done according to the EGPAF standard operation procedures (SOPs) drawn from the Kenya National guidelines. 5) Individualized case management -Each EAC client was allocated a case manager who ensured that the barriers to adherence were identified and tackled both at individual and community level.
223786191|NCT02005471|DRUG|Bendamustine|Bendamustine will be administered at a dose of 70 mg/m\^2 via IV infusion on Days 1 and 2 of each 28-day cycle, for 6 cycles.
223786192|NCT02005471|DRUG|Venetoclax|"Venetoclax will be administered at an initial dose of 20 mg via tablet orally QD, incremented weekly up to a maximum dose of 400 mg during a 5-week ramp-up period. Venetoclax will be continued at 400 mg QD from Week 6 (Day 1 of Cycle 1 of combination therapy) onwards up to disease progression (PD) or 2 years, whichever occurs first.~R/C Substudy: venetoclax will be administered for 5-week dose ramp-up period to reach the target dose of 400 mg QD. Venetoclax will continue to be administered during the rituximab cycles until disease progression or for a maximum of 2 years from Cycle 1R/C Day 1 of the R/C Substudy."
223786193|NCT02005471|DRUG|Rituximab|"Rituximab will be administered at a dose of 375 mg/m\^2 via IV infusion on Day 1 of Cycle 1 and at a dose of 500 mg/m\^2 on Day 1 of Cycles 2-6.~R/C Substudy: Following the venetoclax ramp-up period, rituximab will be administered for 6 cycles consisting of a single infusion on the first day of each 28-day cycle."
223786194|NCT05005611|DIETARY_SUPPLEMENT|Placebo|"A pack of powder without probiotics.~1 pack / day"
223786195|NCT05005611|DIETARY_SUPPLEMENT|Probiotics Lactobacillus salivarius AP-32|"A pack of powder with probiotics Lactobacillus salivarius AP-32~1 pack / day"
223786196|NCT05005611|DIETARY_SUPPLEMENT|Probiotics Bifidobacterium animalis subsp. lactis CP-9|"A pack of powder with probiotics Bifidobacterium animalis subsp. lactis CP-9~1 pack / day"
223786197|NCT05005611|DIETARY_SUPPLEMENT|Probiotics Lactobacillus rhamnosus LGG|"A pack of powder with probiotics Lactobacillus rhamnosus LGG~1 pack / day"
223786198|NCT00363766|DRUG|LY573636-sodium|A loading dose to target 420 micrograms/milliliter (µg/mL) maximum concentration (Cmax) or 380 µg/mL Cmax followed by a lower chronic dose to maintain Cmax within these target ranges, intravenous, every 21 days until disease progression.
223786199|NCT02706457|OTHER|Barthel index for functionality|The Barthel Index for functionality is done standard in all patients after intensive care admission
223786200|NCT05016492|DEVICE|Visual-perceptual interactive game system|Subjects received 30-min interactive digital game training session per week. The game system contain 7 skills training, each of which was named according to the corresponding TVPS-3.
223786201|NCT05016492|BEHAVIORAL|standard rehabilitation|Subjects received the standard 4-week course of rehabilitation delivered in one 30-min session per week. The course of rehabilitation included: sensory integration therapy, cognitive function training and visual perception/auditory attention training.
223786202|NCT00221793|PROCEDURE|Deep brain stimulation|Brain Stimulation of the Subthalamic Nucleus
223786203|NCT03538535|BEHAVIORAL|Go/No-Go Active Learning (GOAL)|Behavioral Activation psychotherapy adapted to engage go/no-go learning
223786204|NCT03248284|PROCEDURE|Tendon biopsy procedure|Two tendon biopsy specimens will be obtained from one Achilles tendon with enthesitis.
223786205|NCT03066531|BEHAVIORAL|ACT-based intervention|
223786206|NCT03066531|BEHAVIORAL|CBT-based intervention|
223786207|NCT03068403|PROCEDURE|Dynamic contrast enhanced ultrasound (D-CEUS) with Sonovue® administration|Dynamic contrast enhanced ultrasound (D-CEUS) with Sonovue® administration
223786208|NCT03149783|DRUG|Ropivacaine HCL|Ropivacaine injected after placement of catheters, then infused during the operation
223786209|NCT03149783|DRUG|sodium chloride|Placebo
223786210|NCT00627705|DRUG|N-Acetyl Cysteine|"Phase 1: Oral, 900 mg daily for 4 weeks Phase 2: Oral, 900 mg twice daily 4 weeks Phase 3: Oral, 900 mg three times daily for 4 weeks~Entire intervention lasts for 12 weeks (drug administration is continuous)."
223786211|NCT00627705|OTHER|Placebo - sugar pill|"Phase 1: Oral, 900 mg daily for 4 weeks Phase 2: Oral, 900 mg twice daily 4 weeks Phase 3: Oral, 900 mg three times daily for 4 weeks~Entire intervention lasts for 12 weeks (drug administration is continuous)."
223786212|NCT03151434|DRUG|US Guided Single Shot Paravertebral Block (0.2% ropivicaine infusion)|Single shot paravertebral block will be placed under ultrasound guidance at the thoracic region prior to surgery.
223786213|NCT03151434|DRUG|US Guided Paravertebral Catheter (0.2% ropivicaine bolus)|Paravertebral catheter will be placed under ultrasound guidance at the thoracic region prior to surgery.
223786214|NCT03151434|DRUG|Thoracic Epidural (0.125% bupivicaine/hydromorphone)|Epidural catheter will be placed in the thoracic region prior to surgery.
223786215|NCT00768274|DRUG|RVX000222|RVX000222 twice daily (b.i.d.) for 28 days
223786216|NCT00768274|DRUG|Placebo|Placebo twice daily (b.i.d.) for 28 days
223786217|NCT00838344|OTHER|Medication Adherence Program (MAP)|Telephone follow-up call to individuals with diabetes (Type 2) who have missed a prescription refill by 6 or more days. Call includes assessment of refill need, discussion of diabetes care progress and any medication adherence barriers with intervention to resolve barriers.
223786218|NCT02897804|BEHAVIORAL|Knowledge alone|Increase knowledge related STIs, STI risk, alcohol impairment, condom use skills, alcohol use behavior tracking skills, testing \& treatment services.
223786219|NCT02897804|BEHAVIORAL|Self-efficacy alone|Increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
223786220|NCT02897804|BEHAVIORAL|Perceived benefits alone|Increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol.
223786221|NCT02897804|BEHAVIORAL|Perceived benefits and self-efficacy|Increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
223786222|NCT02897804|BEHAVIORAL|Injunctive norms|Correct misperceptions regarding approval of alcohol misuse \& sexual risk taking.
223786223|NCT02897804|BEHAVIORAL|Injunctive norms and self-efficacy|Correct misperceptions regarding approval of alcohol misuse \& sexual risk taking and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
223786224|NCT02897804|BEHAVIORAL|Injunctive norms and perceived benefits|Correct misperceptions regarding approval of alcohol misuse \& sexual risk taking and increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
223786225|NCT02897804|BEHAVIORAL|Injunctive norms, perceived benefits, and self-efficacy|Correct misperceptions regarding approval of alcohol misuse \& sexual risk taking; increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex; and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
223786226|NCT02897804|BEHAVIORAL|Descriptive norms alone|Correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors.
223786227|NCT02897804|BEHAVIORAL|Descriptive norms and self-efficacy|Correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
223786228|NCT02897804|BEHAVIORAL|Descriptive norms and perceived benefits|Correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors and increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol.
223786229|NCT02897804|BEHAVIORAL|Descriptive norms,perceived benefits,self-efficacy|Correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol; and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
223786230|NCT02897804|BEHAVIORAL|Descriptive and injunctive norms|Correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors and correct misperceptions regarding approval of alcohol misuse \& sexual risk taking.
223786231|NCT02897804|BEHAVIORAL|Descriptive norms, injunctive norms,self-efficacy|Correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; correct misperceptions regarding approval of alcohol misuse \& sexual risk taking; and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
223786232|NCT02897804|BEHAVIORAL|Descriptive and injunctive norms, benefits|Correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; correct misperceptions regarding approval of alcohol misuse \& sexual risk taking; and increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol.
223786233|NCT02897804|BEHAVIORAL|Descriptive and injunctive norms, benefits,efficacy|Correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; correct misperceptions regarding approval of alcohol misuse \& sexual risk taking; increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol; and Increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
223786234|NCT02897804|BEHAVIORAL|Expectancies alone|Decrease the expectation that alcohol is needed to have good sexual encounter.
223786235|NCT02897804|BEHAVIORAL|Expectancies and self-efficacy|Decrease the expectation that alcohol is needed to have good sexual encounter and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
223786236|NCT02897804|BEHAVIORAL|Expectancies and Perceived Benefits|Decrease the expectation that alcohol is needed to have good sexual encounter and increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol.
223786237|NCT02897804|BEHAVIORAL|Expectancies, perceived benefits, self-efficacy|Decrease the expectation that alcohol is needed to have good sexual encounter; increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol; and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
223786238|NCT02897804|BEHAVIORAL|Expectancies and injunctive norms|Decrease the expectation that alcohol is needed to have good sexual encounter and correct misperceptions regarding approval of alcohol misuse \& sexual risk taking.
223786239|NCT02897804|BEHAVIORAL|Expectancies, injunctive norms, and self-efficacy|Decrease the expectation that alcohol is needed to have good sexual encounter; correct misperceptions regarding approval of alcohol misuse \& sexual risk taking; and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
223786240|NCT02897804|BEHAVIORAL|Expectancies, injunctive norms, benefits|Decrease the expectation that alcohol is needed to have good sexual encounter; correct misperceptions regarding approval of alcohol misuse \& sexual risk taking; and increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol.
223786241|NCT02897804|BEHAVIORAL|Expectancies, injunctive norms, benefits, efficacy|Decrease the expectation that alcohol is needed to have good sexual encounter; correct misperceptions regarding approval of alcohol misuse \& sexual risk taking; increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol; and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
223786242|NCT02897804|BEHAVIORAL|Expectancies and descriptive norms|Decrease the expectation that alcohol is needed to have good sexual encounter and correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors.
223786243|NCT02897804|BEHAVIORAL|Expectancies, descriptive norms, and self-efficacy|Decrease the expectation that alcohol is needed to have good sexual encounter; correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
223786244|NCT02897804|BEHAVIORAL|Expectancies, descriptive norms, and benefits|Decrease the expectation that alcohol is needed to have good sexual encounter; correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; and increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol.
223786245|NCT02897804|BEHAVIORAL|Expectancies,descriptive norms, benefits, efficacy|Decrease the expectation that alcohol is needed to have good sexual encounter; correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol; and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
223786246|NCT02897804|BEHAVIORAL|Expectancies, descriptive and injunctive norms|Decrease the expectation that alcohol is needed to have good sexual encounter; correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; and correct misperceptions regarding approval of alcohol misuse \& sexual risk taking.
223786247|NCT02897804|BEHAVIORAL|Expectancies, descr& injun norms, efficacy|Decrease the expectation that alcohol is needed to have good sexual encounter; correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; correct misperceptions regarding approval of alcohol misuse \& sexual risk taking; and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
223786248|NCT02897804|BEHAVIORAL|Expectancies, desc & injun norms, benefits|Decrease the expectation that alcohol is needed to have good sexual encounter; correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; correct misperceptions regarding approval of alcohol misuse \& sexual risk taking; and increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol.
223786249|NCT02897804|BEHAVIORAL|Expectancies,desc & injun norms,benefits,efficacy|Decrease the expectation that alcohol is needed to have good sexual encounter; correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; correct misperceptions regarding approval of alcohol misuse \& sexual risk taking; increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol; and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
223786250|NCT06193993|DRUG|Abiraterone Acetate|Upon successful registration, patients would be initiated on 500 mg once daily (two 250 mg tablets), plus prednisolone 5 mg twice daily orally for mCRPC and 5mg once daily orally for mHSPC.
223786251|NCT02142049|DRUG|Ibrutinib|Ibrutinib
223786252|NCT02142049|DRUG|DA-EPOCH-R|Etoposide, Prednisone, Doxorubicin, Cyclophosphamide, Vincristine, Rituximab, Pegfilgrastim
223786253|NCT02142049|DRUG|Lenalidomide|Lenalidomide
223786254|NCT04985591|PROCEDURE|Liposuction|A small, inconspicuous incision was made in the liposuction group to dislodge fat out of the body.
223786255|NCT04985591|PROCEDURE|Other plastic surgery|Other plastic surgery like blepharoplasty or keloid excision.
223786256|NCT01704313|PROCEDURE|Interrupted|Interrupted suturing technique used aroudn the heel of the vascular anastomosis
223786257|NCT01704313|PROCEDURE|Continuous|Continuous suturing technique used for the anastomosis
223786258|NCT03369548|OTHER|Apple|2 Renetta Canada apples and 2 placebo capsules/ day
223786259|NCT03369548|OTHER|Oats|40g jumbo rolled oats with semi-skimmed milk and 2 placebo capsules / day
223786260|NCT03369548|DIETARY_SUPPLEMENT|Lactobacillus reuteri NCIMB 30242|2 probiotic capsules and 40g cornflakes with semi-skimmed milk / day.
223786261|NCT03369548|OTHER|Cornflakes|40g cornflakes with semi-skimmed milk and 2 placebo capsules/ day.
223786262|NCT01534598|DRUG|FdCyd + THU|Intravenous FdCyd with THU has been evaluated in a Phase I clinical trial with some preliminary evidence of activity. This trial will investigate oral administration of the drugs, which was shown to be feasible in an expansion cohort of the previous trial.
223786263|NCT00175604|DRUG|Botox|The babies that require a neck collar for CMT will be randomly placed into two groups. One group will receive standard treatment which includes physiotherapy and occupational therapy. The other group will receive standard treatment plus an injection of Botox.
223786264|NCT04218461|DIAGNOSTIC_TEST|PRE-DELIRIC model|To predict delirium according to risk factors in the PRE-DELIRIC model
223786265|NCT04295564|OTHER|Additional 2 weeks of CPAP|Subjects will be randomized to an additional 2 weeks of CPAP vs. discontinuing CPAP per usual care.
223786266|NCT00712023|DEVICE|warming device (a reusable, custom-made forced- air warming mattress)|"2=forced-air warming mattress~1=circulating-water mattress"
223786267|NCT03228511|DEVICE|endoscope|It is a Prospective descriptive hospital based clinical study to determine the value of introduction of endoscope after microscopic excision of cerebello-pontine angle lesions
223786268|NCT01682460|DRUG|Refresh Tears Lubricant Eye Drops (Allergan)|Eye drops QID for 1 month
223786269|NCT05363033|DEVICE|sarcopenia nursing guidance mobile application was developed|The application enhanced participants' sarcopenia-related knowledge and awareness regarding self-care
223786270|NCT04246034|PROCEDURE|Microvascular Breast Reconstruction with Vascularized Lymph Node Transfer|simultaneous free abdominal flaps with VLNT from groin are transferred on a single pedicle for breast reconstruction and postmastectomy lymphedema
223786271|NCT03726905|OTHER|respiratory muscles training|4 weeks respiratory muscles training aimed on respiratory muscles endurance and lengthening expiration time
223786272|NCT03726905|OTHER|sham respiratory muscles training|4 weeks sham respiratory muscles training with the help of breathing simulators, with a breathing resistance level set at 0
223786273|NCT03726905|OTHER|aerobic training|12 weeks treadmill walking
223786274|NCT02151279|OTHER|Chitosan as wine fining agent|The possibility of allergic reactions attributed to traces of chitosan used as a fining agent in wine has not been ruled out, particularly in shrimp allergic patients to whom small traces of the potential allergen may be enough to trigger anaphylactic reactions.
223786275|NCT02151279|OTHER|Control|
223786276|NCT02105116|DRUG|fludarabine phosphate|Given IV
223786277|NCT02105116|DRUG|cytarabine|Given IV
223786278|NCT02105116|BIOLOGICAL|donor lymphocytes|Undergo infusion of donor lymphocytes
223786279|NCT02105116|OTHER|laboratory biomarker analysis|Correlative studies
223786280|NCT02105116|DRUG|G-CSF|Given IV
223786281|NCT06134544|DIETARY_SUPPLEMENT|Isomaltooligosaccharides (IMO)|Patients will still receive standard treatment, including medicine and other invasive treatment.
223786282|NCT06133400|OTHER|Questionnaire|Questionnaire about socio-demographical status, health status and lifestyle habits
223786283|NCT06133400|OTHER|Physical measurements|Measurement of height, weight, waist circumference, blood pressure and skin pigmentation
223786284|NCT06133400|OTHER|Biological samples|Collect venous blood, saliva and stool samples
223786285|NCT00773968|DRUG|Methoxy Polyethylene Glycol-Epoetin Beta|120, 200 or 360 micrograms every 4 weeks by subcutaneous injection.
223786286|NCT03562000|DEVICE|Cough Assistance and Systematic Non-Invasive Ventilation|"A standardised bundle of intervention will be tested using the combination of two medical devices previously used in daily clinical practice but without guideline and objective selection criteria, namely:~1. A mechanical cough assistance technic using the Cough Assist device (Model E70® by Philips Respironics, Carlsbad, CA, USA) before extubation then after extubation then 3 times a day (with possible additional treatment on demand) during 7 days maximum (with a possible cessation if the patient has strictly no bronchial overload during three consecutive physiotherapy sessions)~2. A systematic Non-Invasive ventilation during 24h minimum to indirectly improve the clearance of bronchial overload and to reduce the overall risk of re-intubation related a relative hypoventilation associated to the weak cough."
223786287|NCT03562000|PROCEDURE|control group using the current gold standard of care after extubation, namely the manual drainage by a physiotherapist and the consensual use of Non-invasive ventilation|"1. After extubation, the physiotherapy will be managed according to standard care and cough assistance will be only manual. The use of a dedicated cough assistance device will be allowed if the bronchial overload clearance is repeatedly insufficient according to the physiotherapist in charge.~2. Non-invasive ventilation will not be systematic and only used in case of pre-defined condition, such as: age \> 65 years-old, BMI \> 30, Chronic cardiac failure, COPD, hypercapnia at the end of the weaning trial, post-operative admissions after abdominal and thoracic surgery."
223786288|NCT00263666|BIOLOGICAL|Rotarix|Oral vaccination
223786289|NCT00263666|BIOLOGICAL|Placebo|Oral administration
223786290|NCT00263666|BIOLOGICAL|Tritanrix-HB+Hib|Concomitant routine vaccination, IM administration
223786291|NCT00263666|BIOLOGICAL|Polio Sabin|Oral administration, concomitant routine vaccination
223786292|NCT06104410|RADIATION|Standard fractioned dose|Total dose of 6 Gy in 2 or 4 single fractions of 1.5 Gy applied twice weekly.
223786293|NCT06104410|RADIATION|Experimental single dose|Total dose of 0.5 Gy, 1Gy, 1.5 or 2Gy in 1 single fraction.
223786294|NCT01427868|DRUG|LB80380 maleate salt|183 mg (150 mg as a free base)
223786295|NCT01427868|DRUG|LB80380 free base|150 mg
223786296|NCT02492100|BEHAVIORAL|Multi-modality sexual dysfunction intervention|
223786297|NCT04654780|BEHAVIORAL|Taxes|"a High in food tax will be applied to study changes in purchasing and consumption behavior of participants in this group. The tax will correspond to a 20% increase over the market price, that is, a tax that reaches the levels recommended by the WHO."
223786298|NCT04654780|BEHAVIORAL|Subsidies|A subsidy will be applied to fruits and vegetables that means a reduction of 20% in their price, to study the changes in purchasing behavior and of the participants of said group.
223786299|NCT04654780|BEHAVIORAL|Control|Average or current food prices will apply. Based on the average of the values reported by three supermarkets
223786300|NCT01380340|OTHER|Seniors Early Intervention Planning and Discussion.|The seniors early intervention driving group is for seniors who have been identified by professionals as having to face changes to their driving status. It involves activities such as change strategies, positive psychology approaches and topic based discussion designed to mitigate the health and quality of life effects of driving regulation and cessation.
223786301|NCT01785329|DRUG|alirocumab SAR236553 (REGN727)|Pharmaceutical form:Solution for injection Route of administration: Subcutaneous
223786302|NCT03377491|DEVICE|NovoTTF-200T|Patients receive continuous TTFields treatment using the NovoTTF-200T device. TTFields treatment will consist of wearing four electrically insulated electrode arrays on the torso. The treatment enables the patient to maintain regular daily routine.
223786303|NCT03377491|DRUG|Gemcitabine|Gemcitabine 1000 mg/m\^2 over 30 minute infusion will be administered immediately after nab-paclitaxel on Days 1, 8 and 15 of each 28-day cycle.
223786304|NCT03377491|DRUG|nab paclitaxel|nab-paclitaxel 125 mg/m\^2 administered as an intravenous infusion over 30-40 minutes on Days 1, 8 and 15 of each 28-day cycle.
223786305|NCT05200195|PROCEDURE|Liver transplantation|Deceased or living donor liver transplantation for the cure of hepatocellular cancer on cirrhosis
223786306|NCT00660842|PROCEDURE|carboplatin|AUC 6 IV day 1 every 21 days
223786307|NCT00660842|DRUG|paclitaxel|175 mg/m2 IV day 1 every 21 days
223786308|NCT00660842|DRUG|carboplatin|AUC 2 IV every week
223786309|NCT00660842|DRUG|paclitaxel|60mg/m2 IV every week
223786310|NCT02552524|DEVICE|rTMS active then rTMS placebo|A 20 minute session of rTMS active at the frequency of 10 Hz then, 7 days later, a 20 minute session of rTMS placebo
223786311|NCT02552524|DEVICE|rTMS placebo then rTMS active|A 20 minute session of rTMS placebo then, 7 days later, a 20 minute session of rTMS at the frequency of 10 Hz
223786312|NCT00933569|DRUG|LACTIC ACID(ND)|treatment period: 21 consecutive days
223786313|NCT02880800|DRUG|Morphine as IVPCA|"Morphine as IVPCA: Patients will be given a patient controlled analgesia (PCA) pump containing a standard solution of morphine as below:~Morphine bolus 1mg with a lockout interval of 5 minutes, no background infusion and maximum 30 mg in 4 hours"
223786314|NCT02880800|DRUG|Hydromorphone as IVPCA|"Hydromorphone as IVPCA: Patients will be given a patient controlled analgesia (PCA) pump containing a standard solution of Hydromorphone as below:~Hydromorphone bolus 0.2 mg with a lockout interval of 5 minutes and a maximum dose of 6 mg in 4 hours."
223786315|NCT02880800|DRUG|Morphine|IV opioids: Morphine 2 to 5 mg every 1h PRN (max. 20 mg/4h)
223786316|NCT02880800|DRUG|Hydromorphone|Hydromorphone 0.5 - 1 mg every 1h PRN (max. 4 mg/4h)
223786317|NCT00108225|OTHER|LoBag Diet - test phase|A Low Biologically Available Glucose (LOBAG30), weight maintaining diet consisting of 30% carbohydrate, 30% protein, 40% fat will be provided to subjects for 5 weeks.
223786318|NCT00108225|OTHER|LoBAG Diet - control phase|A control, weight maintaining diet consisting of 55% carbohydrate, 15% protein, 30% fat will be provided to subjects for 5 weeks
223786319|NCT04824404|BEHAVIORAL|CBT4CBT-Buprenorphine + Recovery Coach|This condition will consist of the CBT4CBT-Buprenorphine intervention alongside weekly coaching sessions from a recovery professionalCBT4CBT-Buprenorphine is an 8-session (module) system for teaching a wide range of CBT skills (understanding and changing patterns of substance use; coping with craving; refusing offers of drugs and alcohol; problem-solving skills; identifying and changing thoughts about drugs and alcohol; and improving decision-making skills)
223786320|NCT06203509|BEHAVIORAL|Thrive Intervention|• The THRIVE Clinical Pathway is a standardized transitional care clinical pathway that supports Medicaid insured or Medicaid eligible individuals being managed for both chronic diseases and serious mental illness following hospitalization.
223786321|NCT04522401|DIAGNOSTIC_TEST|"consultation: Bien vieillir"|Patients will benefit from a multidisciplinary assessment including a geriatric assessment standardized by a geriatrician, an evaluation by a dietician, an evaluation by an occupational therapist. They will then be exposed to a personalized plan of care in the form of a recommendation.Then, patients will be followed at home to evaluate the implementation of their personalized care plan at 3 months of their assessment day, then at 6 and 9 months.
223786322|NCT02813850|DEVICE|oxygen therapy|Oxygen therapy early in the night (2L/min) during 4hours per days
223786323|NCT05006781|DRUG|DAOIB|The DAOIB dose in each group will be fixed during the 24 weeks duration
223786324|NCT03796624|DEVICE|Micropure 1.2.3.|"Implantation of intraocular lens (IOL). Name: MicroPure 1.2.3. It is a monofocal intraocular lens consisting of hydrophobic acrylic material. One IOL per patient will be implanted"
223786325|NCT03796624|DEVICE|PODEYE|"Implantation of intraocular lens (IOL). Name: PODEYE It is a monofocal intraocular lens consisting of hydrophobic acrylic material. The IOL will be implanted in the contralateral eye of the same patient already implanted with Micropure 1.2.3."
223786326|NCT01754662|DIETARY_SUPPLEMENT|Soy protein|2 bars daily for 8 weeks.
223786327|NCT01754662|DIETARY_SUPPLEMENT|Isoflavones|2 bars daily for 8 weeks.
223786328|NCT01754662|DIETARY_SUPPLEMENT|Cocoa|2 bars daily for 8 weeks.
223786329|NCT01754662|DIETARY_SUPPLEMENT|Placebo|
223786330|NCT03455426|DRUG|letrozole|Women will be randomizedfor ovarian stimulation with letrozole or to natural cycle IUI.
223786331|NCT00321919|DRUG|epoetin beta [NeoRecormon]|Participants in the early treatment group immediately started epoetin beta treatment to reach a target Hb level of 13-15 g/dL at the end of the correction phase.
223786332|NCT00321919|DRUG|epoetin beta [NeoRecormon]|Participants in the late treatment Group started epoetin beta treatment once a decline in Hb level to \<10.5 g/dL had occurred.
223786333|NCT04475913|OTHER|DIG Axial|patients received 4 axial implants and digital impression
223786334|NCT04475913|OTHER|DIG Tilted|received two anterior axial implants and two distal tilted implants, and digital impression
223786335|NCT04475913|OTHER|CIG Axial|patients received 4 axial implants and conventional impression
223786336|NCT04475913|OTHER|CIG Tilted|received two anterior axial implants and two distal tilted implants, and conventional impression
223786337|NCT05355974|DRUG|Norepinephrine|Norepinephrine continuous infusion at 0.10 mcg/kg/min
223786338|NCT05355974|DRUG|Lactated Ringers, Intravenous|500mL infusion run at 999mL/hr
223786339|NCT05355974|DRUG|normal saline|500mL infusion run at 999mL/hr
223786340|NCT05355974|DRUG|Plasma-lyte|500mL infusion run at 999mL/hr
223786341|NCT04372771|OTHER|Curves Circuit|The Curves Circuit consists performing 13 hydraulic resistance exercise machines that utilize bidirectional resistance that work all major muscle groups. These are interspersed with floor-based calisthenic exercises designed to maintain an elevated heart rate.
223786342|NCT04372771|OTHER|Weight Watchers|The Weight Watchers program encourages one to increase physical activity.
223786343|NCT03735329|DEVICE|Diagnostic test of SPO2|The SpO2 accuracy of the test devices will be evaluated over the oxygen saturation range between 70-100%.
223786344|NCT06352710|OTHER|OP-Tracker App|"There will be no study-specific therapeutic intervention. The OP-Tracker App will be downloaded and installed on the patient's smartphone. Preoperative assessment: baseline factors such as age, gender, medical conditions, type of disease and of surgery, EQ-5D-5L. Before and after surgery surgery, SWI (Quality of life) will be assessed daily using pop-ups; the patient will input the value (0-10) using a slide-bar. After completion of the surgery, the app will automatically modify the number of SWI assessments over time according to the occurrence of AEs. At any point in time, the patient will be able to register an AE in the smartphone app. The patient can select the AE via a drop-down menu in the app, and can additionally input free text in case of an AE of type other. Using a further drop-down menu, the patient will classify the AE according to the CDG and TDN grade. QoL assessments (EQ-5D-5L questionnaire) will pop up before, and at 3 and 12 months after surgery."
223786345|NCT02261363|OTHER|Ecig group 1|E-cigarettes were 3% nicotine and of tobacco or menthol flavor, depending on participants' usual flavor preference.
223786346|NCT01517802|DRUG|Abiraterone acetate|Type=exact number, unit=mg, number=1000, form=tablet, route=oral, abiraterone acetate once daily
223786347|NCT01517802|DRUG|Prednisone|Type=exact number, unit=mg, number=5, form=tablet, route=oral, prednisone or prednisolone twice daily
223786348|NCT04195464|OTHER|Dry needling|Dry needling is a skilled intervention that uses a thin filiform needle to penetrate the skin and stimulate underlying myofascial trigger points, muscular, and connective tissues for the management of neuromusculoskeletal pain and movement impairments
223786349|NCT04195464|OTHER|Sham dry needling|Sham Dry needling use a non-penetrating acupuncture needle
223786350|NCT06219759|OTHER|Observational study|Observational study.
223786351|NCT02590354|OTHER|ART interruption|
223786352|NCT00885404|DRUG|Lower chloride fluids (Hartmann's solution and Plasmalyte®)|Intravenous fluids used during the 6 month intervention period (after). Amount of fluids to be used is based on clinicians' discretion.
223786353|NCT06496529|BEHAVIORAL|DoF intervention|Training of specific uniarticular and single plane movement of the upper limb through an exoskeleton and videogames that will be supervised by a physiotherapist.
223786354|NCT06496529|BEHAVIORAL|Task intervention|Training of multiarticular upper limb movements (vertical, horizontal and diagonal) through videogames and also training of functional task (raise and lower your hand on the table, cleaning a table, put cream on the non-paretic arm, hold a bottle, put a piece of bread or something similar in your mouth, wash your face, brush your hair, store items in a basket, brush teeth, wrote and serve water in glass). This activities will be supervised by a physiotherapist.
223786355|NCT04609254|DRUG|Paracetamol|1000 mg of paracetamol ( parol 1000mg vial-atabay chemistry-İstanbul) intravenous (IV) was given 71 patients,
223786356|NCT04609254|DRUG|Dexketoprofen|dexketoprofen 50 mg arveles 50 mg ampoule -Menarini- Istanbul) intravenous (IV) was given 70 patients,
223786357|NCT04609254|DRUG|Ibuprofen|400 mg Ibuprofen (İntrafen 400 mg vial- Gen-İstanbul) intravenous (IV) was given 69 patients, which determined to be applied as a group.
223786358|NCT04957966|BEHAVIORAL|self-selected relaxing music|20 minutes music listening
223786359|NCT02099838|DRUG|Pioglitazone and Metformin|taking 1 tablet twice a day (before breakfast and before dinner) orally for 12 weeks
223786360|NCT02099838|DRUG|Placebo|taking 1 tablet twice a day (before breakfast and before dinner) orally for 12 weeks
223786361|NCT02301143|DRUG|nab-Paclitaxel|
223786362|NCT02301143|DRUG|Gemcitabine|
223786363|NCT02301143|DRUG|Chemoradiation|
223786364|NCT02301143|DRUG|Capecitabine|
223786365|NCT02301143|PROCEDURE|Surgery|Surgical intervention
223786366|NCT04064034|OTHER|Lateral Flow Assay (LFA)|Test to detect the Quiescin Sulfhydryl Oxidase 1 (QSOX1) protein
223786367|NCT06250686|BEHAVIORAL|combined exercise and nutrition intervention|Patients will be instructed on how to use the Physitrack app. At the start of chemotherapy, patients will be contacted by physiotherapists and dietitians from the University Medical Center Hamburg-Eppendorf either via video call using the app or by phone to discuss the first week's program. Patients can either complete the exercise program at home using the app or receive printed exercise plans in the mail to be completed with the physical therapist of their choice. The exercise program is adjusted weekly until week 9. After week 10, adjustments are made every two weeks. For each program, patients receive a 30-minute counseling session to discuss the exercises. The 30-minute nutritional counseling session occurs every two weeks. For patients receiving neoadjuvant chemotherapy, the exercise program is interrupted for the time of surgery and the two-week recovery period and resumed when chemotherapy is resumed.
223786368|NCT04518124|DRUG|Propranolol|Propranolol will be administered as monotherapy in a dose of 40-80 mg 2-3 times a day, if tolerated. The study consists of a single arm.
223786369|NCT03740490|COMBINATION_PRODUCT|Smart-T + NRT|Smart-Treatment App and Nicotine Replacement Therapy
223786370|NCT03740490|COMBINATION_PRODUCT|QuitGuide + NRT|NCI QuitGuide Treatment App and Nicotine Replacement Therapy
223786371|NCT05560867|DEVICE|robot-assisted training|These training platforms use gamified training tasks to improve motor control in the hemiparetic arm
223786372|NCT03752164|BEHAVIORAL|Yoga and Mindfulness Skills|Single brief session in which children are taught yoga and skills in mindfulness
223786373|NCT02972580|GENETIC|Genetic characterization|Confirmatory genetic testing for mutation in DMD gene (Carrier Status) for subjects in respective Cohorts
223786374|NCT00242034|PROCEDURE|CT and MRI with contrast|
223786375|NCT05626361|OTHER|Dysphagia training|Training using PowerPoint and simulation. Training includes anatomy physiology, screening and management sections. Simulation will be used for practice. Reading material will also be provided
223786376|NCT05626361|OTHER|Reading material|Reading material provided to nurses covering knowledge related to nursing evaluation and caring for dysphagia patients
223786377|NCT03881462|PROCEDURE|Axillary nerve block for artificial deltoid muscle palsy|"Axillary nerve block block (AXNB):~The ultrasound probe is placed transversally in the infraclavicular region with the arm in 90° abduction. The brachial plexus and its cords are identified l lateral to the brachial artery. The posterior cord is identified by ultrasound and is blocked - or, if the axillary nerve visible too - the axillary nerve is selectively blocked when it leaves the posterior cord and lies on the subscapular muscle accompanied by the posterior circumflex humeral artery. Using an in-plane technique, a short bevel connected to a nerve stimulator with the setting 0.5 mA current intensity, 0.1 ms impulse duration and 2 Hz impulse frequency for dual guidance, will be advanced until its tip is positioned near the nerve without eliciting motor contractions. After careful negative (for blood) aspiration local anesthetic will be applied until the targeted neuronal structure is surrounded by the injected fluid."
223786378|NCT02536508|DRUG|BGF MDI 320/14.4/9.6 μg|Budesonide, Glycopyrronium, and Formoterol Fumarate
223786379|NCT02536508|DRUG|GFF MDI 14.4/9.6 μg|Glycopyrronium and Formoterol Fumarate
223786380|NCT02536508|DRUG|BFF MDI 320/9.6 μg|Budesonide and Formoterol Fumarate
223786381|NCT01462734|PROCEDURE|human vitreous and blood serum sampling, PCR|1ml of human vitreous and 3ml of human blood serum
223786382|NCT01889420|DRUG|Combination therapy|"Following determination of the maximum tolerated dosages in the phase I portion of this study, all patients enrolled in the extension portion will receive the predetermined dosage combination of pomalidomide, everolimus and dexamethasone.~Cycles will span 28 days. Dosage schedules will be:~1. Everolimus daily for 28 days of a 28 day cycle;~2. Pomalidomide daily for 21 days of a 28 day cycle~3. Dexamethasone once weekly (on days 1,8,15,22) of a 28 day cycle."
223786383|NCT05969353|OTHER|accupunture|BFA
223786384|NCT06057896|DIETARY_SUPPLEMENT|inositol, phytoestrogens, cocoa polyphenols|myo-inositol, soy isoflavones and cocoa polyphenols
223786385|NCT04768010|DRUG|Misoprostol|Participants will started by receiving 100 micrograms of oral misoprostol twice daily. If adverse effects are not noted dose can be titrated up to 200 micrograms of misoprostol twice daily. Participants will receive a total of five doses.
223786386|NCT01230697|DRUG|Sorafenib|Sorafenib 800mg/die oral
223786387|NCT05582863|OTHER|Virtual reality exercise intervention|The experimental group performed a 75-90-minute VR exercise routine twice a week for 12 weeks.
223786388|NCT05716581|DEVICE|Catheter ablation|Catheter ablation for atrial fibrillation will be done according to the current medical praxis. Pulmonary vein isolation using either radiofrequency or pulsed-field ablation will be done in all patients. In patients with non-paroxysmal AF, additional ablation lesions (posterior wall ablation, roof or mitral isthmus line, ablation of complex fractionated atrial electrograms) could be done based on the operator´s discretion
223786389|NCT05233826|BIOLOGICAL|COVI-VAC|Intranasal, live attenuated vaccine against SARS-CoV-2
223786390|NCT04020731|BEHAVIORAL|Hypnosis|several blocks of hypnosis including entry into a hypnotic state (= induction), the hypnotic trance and the exit from hypnosis (= reassociation).
223786391|NCT05975190|OTHER|Respiratory training and relaxation techniques under adjuvant radiation therapy in DIBH in breast cancer|R\&R training provided on an MP3-player for daily practice
223786392|NCT05588518|COMBINATION_PRODUCT|desensitizing agents -10% Propolis|"10% propolis was prepared after mixing with 70% ethanol and distilled water based on the method described previously. Propolis and ethanol mixture was allowed to stay in dark place for two weeks. The mixture was stirred everyday intermittently for two weeks. Later the mixture was strained twice using filter paper to remove impurities.~Propolis in general are fairly stable without losing its antibacterial properties for over 12 months when stored without direct sunlight and at cool temperatures. Alcohol based extracts will have extended shelf life and hence ethanol-extracted propolis prepared was stored in dark amber colored bottle without any preservatives."
223786393|NCT00244738|DIETARY_SUPPLEMENT|Castor oil|Patients who received castor oil for labor induction
223786394|NCT00244738|DIETARY_SUPPLEMENT|Sunflower oil|Patients who received sunflower oil as a placebo
223786395|NCT01068431|OTHER|bandaging with trico as active controller|In general non-elastic bandaging is the compression treatment in lymphedema
223786396|NCT03088384|DRUG|Ketamine|Psychological survey instruments administered before and after a series of six low-dose infusions of ketamine.
223786397|NCT00803647|BIOLOGICAL|cetuximab|500 mg/m2 IV every two weeks on days 1, 15, 29, and 43 of each 56 day cycle, for a total of 3 cycles. Cetuximab dose will be escalated by 100 mg/m2 every 2 weeks to a maximum dose of 800 mg/m2 if, at the time of retreatment, skin rash is less than or equal to grade 1, diarrhea is grade 0 (defined as less than or equal to 3 stools per day over baseline), and the patient is not experiencing any other greater than or equal to grade 2 toxicity attributed to cetuximab.
223786398|NCT00803647|DRUG|5-FU|3000 mg/m2 IV continuous infusion over 46 hours every two weeks on days 1, 15, 29, and 43 of each 56 day cycle, for a total of 3 cycles.
223786399|NCT00803647|DRUG|oxaliplatin|85 mg/m2 IV every two weeks on days 1, 15, 29, and 43 of each 56 day cycle, for a total of 3 cycles.
223786400|NCT00803647|DRUG|leucovorin|400 mg/m2 IV every two weeks on days 1, 15, 29, and 43 of each 56 day cycle, for a total of 3 cycles.
223786401|NCT00273611|BEHAVIORAL|Pharmacist Education about Vitamin D|
223786402|NCT03064425|BIOLOGICAL|Vaginal and blood sample collection|The researchers will obtain approximately 20 mL of blood from participants. Participants will also undergo a pelvic exam where a sample of cells will be collected from the cervix using two small cytobrushes. In addition, a cervicovaginal lavage will be collected using saline.
223786403|NCT00591812|DEVICE|ComPreSs Distal Femoral Replacement System.|ComPreSs system of intramedullary fixation along with the Finn Knee system
223786404|NCT04920760|DIETARY_SUPPLEMENT|Vitamin A supplement|The supplementation protocol will be the additional care established by World Health Organization (WHO) and the United Nations International Children ʹs Fund (UNICEF) for measles (1998)(i.e. of 200,000 IU, or 50,000-100,000 IU for children \> 1 or for infants of \< 1 year of age, respectively).
223786405|NCT01200121|DRUG|Bevacizumab|Patients will receive paracentesis as needed for symptom con¬trol. In addition, patients will receive up to 4 intraperitoneal administrations of 400 mg Bevacizumabafter paracentesis has been performed. During the 8-week treatment period, a minimum interval of 14 days will be kept between applications of the study medication.
223786406|NCT01200121|OTHER|Placebo|Patients will receive paracentesis as needed for symptom con¬trol. In addition, patients will receive up to 4 intraperitoneal administrations of Placebo after paracentesis has been performed. During the 8-week treatment period, a minimum interval of 14 days will be kept between applications of the study medication.
223786407|NCT00235534|BEHAVIORAL|Immediate initiation of OCPs|
223786408|NCT00235534|BEHAVIORAL|Delayed initiation of OCPs|
223786409|NCT00863850|DRUG|bendamustine|Bendamustine 120 mg/m2 on Days 1 and 2 every 28 days (one cycle) for up to 6 cycles. Radiolabeled \[14C\] bendamustine will be given on day 1 of cycle 1 only.
223786410|NCT02431975|DRUG|Nevirapine|"Standard medication used to treat and prevent HIV/AIDS, specifically HIV-1. It is generally recommended for use with other antiretroviral medication.~The initial dose of NVP will be 6 mg per kg per dose orally twice daily until 42 weeks gestational age (2 weeks of age for infants born at term) which is the dosing selected by the NIH International Maternal, Pediatric, Adolescent AIDS Clinical Trials (IMPAACT) Network."
223786411|NCT02431975|DRUG|Zidovudine|"An antiretroviral medication used to prevent and treat HIV/AIDS. It is generally recommended for use with other antiretroviral.~ZDV will be dosed as per standard guideline and routine practices."
223786412|NCT02431975|DRUG|Lamivudine|"An antiretroviral medication used to prevent and treat HIV/AIDS. It is effective against both HIV-1 and HIV-2.~3TC will be dosed as per standard guideline and routine practices."
223786413|NCT02431975|DRUG|LPV/r|"Lopinavir is an antiretroviral of the protease inhibitor class. It is used against HIV infections as a fixed-dose combination with another protease inhibitor, ritonavir.~LPV/r will be dosed as per standard guideline and routine practices."
223786414|NCT00280332|PROCEDURE|colonoscopy|proform a follow up colonoscopy in the 5 year period from index colonoscopy
223786415|NCT00010517|PROCEDURE|Acupuncture|
223786416|NCT01540123|DIETARY_SUPPLEMENT|Berry drink|Cold pressed berry drink standardised to contain 500mg of berry polyphenols
223786417|NCT01540123|DIETARY_SUPPLEMENT|Control|Sugar matched control containing berry flavouring and no phytochemicals
223786418|NCT02575092|DRUG|Enalapril Maleate Tablets(as the program-based antihypertension)|
223786419|NCT02575092|DRUG|Enalapril Maleate and Folic Acid tablets(as the program-based antihypertension)|
223786420|NCT02575092|DRUG|Placebo|
223786421|NCT05305144|PROCEDURE|Vascular and ophthalmological examinations|"Part. 1 - Vascular checkup examinations:~After collecting classic clinical parameters (weight, height, waist circumference), the in-depth vascular workup of each participant will include the following measurements:~* Measurement of central arterial pressure,~* Measurement of arterial stiffness,~* Continuous blood pressure measurement (beat-to-beat),~* Heart rate measurement,~* 24-hour blood pressure measurement with QKD (holter).~Part. 2 - Ophthalmological examinations:~After dilating the pupil, a series of examinations will be conducted on the participant:~* Auto-refractometry~* Measurement of the axial length of the globe~* Color retinophotography of the retina,~* Adaptive Optics Exam~* SS-OCT-A exam"
223786422|NCT01181934|OTHER|A643 (nicotine)|2mg oromucosal nicotine spray- three times daily during each treatment period
223786423|NCT01181934|DRUG|placebo|placebo - three times daily during each treatment period
223786424|NCT01181934|OTHER|A643 (nicotine)|1mg oromucosal nicotine spray- three times daily during each treatment period
223786425|NCT04744363|DRUG|Stelara PFS|Pre filled syringes filled with AVT04 and Stelara
223786426|NCT00235703|DEVICE|Antimicrobial Prescribing Decision Support|
223786427|NCT05878639|DRUG|3 bottles of Lactulose oral solution|Patients will take lactulose for bowel preparation.
223786428|NCT05878639|DRUG|3L-polyethylene glycol|Patients will take 3L-polyethylene glycol for bowel preparation.
223786429|NCT02308436|DEVICE|Candida Mouthwash with Curolox™ Peptide|Prophylaxis - protection and care of teeth against caries \& acidic challenges
223786430|NCT00823719|DRUG|ofatumumab + ICE|"3 cycles of treatment will be administered. Each cycle will last 21 days. ofatumumab dose: cycle 1, day 1 - 1000 milligrams (mg); cycle 1, day 8 - 1000 mg; cycle 2, day 1 and cycle 3, day 1 - 1000 mg~ICE regimen:~ifosfamide + mesna - 5 grams (g)/meters squared (m\^2)/24 hours (hrs) continuous on day 2 of dosing cycle; carboplatin - AUC 5 (800 mg maximum) on day 2 of dosing cycle; etoposide - 100 mg/m\^2 on days 1, 2 and 3 of dosing cycle."
223786431|NCT00823719|DRUG|ofatumumab + DHAP|"3 cycles of treatment will be administered. Each cycle will last 21 days. ofatumumab dose: cycle 1, day 1 - 1000 mg; cycle 1, day 8 - 1000 mg; cycle 2, day 1 and cycle 3, day 1 - 1000 mg.~DHAP regimen:~dexamethasone - 40 mg on days 1, 2, 3, and 4 of dosing cycle; cisplatin - 100 mg/m\^2/24 hrs continuous on day 1 of dosing cycle; cytarabine - 2 g/m\^2 q12 hrs (2 doses) on day 2 of dosing cycle."
223786432|NCT03856346|DIAGNOSTIC_TEST|Biometry|Biometry for phaco-vitrectomy procedures pre- and postoperatively
223786433|NCT00025350|DRUG|gefitinib|
223786434|NCT05056103|DEVICE|TrachFlush|The attending nurses activate the TrachFlush when there are secretions present in the larger airways that need to be removed. If this results into a push of airway secretions past and above the cuff of the endotracheal tube, no further action is needed. If unsuccessful, the nurse will perform a standard tracheal suctioning procedure to remove the secretions. In a subset of patients with an endotracheal tube that allows subglottal suctioning, the exact amount of airway secretions present above the cuff will be measured each time the TrachFlush is used.
223786435|NCT06533241|PROCEDURE|renal biopsy|percutaneous renal biopsy procedure
223786436|NCT00861939|DRUG|Bupropion HCI 300 mg Extended-Release Tablets EON|
223786437|NCT00861939|DRUG|WELLBUTRIN XL 300 mg Extended-Release Tablets GlaxoSmithKline|
223786438|NCT04923386|OTHER|None (not interventional)|This is not an intervention
223786439|NCT05512494|BIOLOGICAL|Quadrivalent Influenza Vaccine (Split Virion), inactivated|The Quadrivalent Influenza Vaccine manufactured by Sinovac Biotech Co.,Ltd. The four influenza strains（including 4 antigens H1N1, H3N2, BV and BY, 15μg for each) in 0.5 mL of sodium chloride,disodium hydrogen phosphate,sodium dihydrogen phosphate water for per injection.The routine of administration is intramuscular injection into deltoid region.And the immunization schedule is one dose of quadrivalent influenza vaccine on day 0.
223786440|NCT05302466|DEVICE|gymnastics plus silicon dental bite pad|Gymnastics (see below) plus dental bite pads. The dental bite pads TJ Motion (BELY Balance GmbH \& Co. KG, Weisendorf, Germany) are made of medical silicone. Accordingly, they are BPA- and latex-free, odourless, tasteless and dimensionally stable. The splints are placed on the back molars of the lower jaw and remain in this position in the mouth for 3 minutes during the exercise. After use, the splints are rinsed with water and placed dry in the corresponding storage box.
223786441|NCT05302466|OTHER|gymnastics only|Gymnastics, which are completed daily (7x/week), each consist of three to six exercises and have a total duration of three minutes. The gymnastic programme contain low-intensity exercises from functional gymnastic or physiotherapy.
223786442|NCT04272450|DIAGNOSTIC_TEST|respiratory muscle strenght measurement|Maximum inspiratory pressure-maximum expiratory pressure. The mouth pressure measurement was performed with the Micro-RPM® instrument from SensorMEDIC. Patient placed a rubber mouthpiece with flanges, on the device, sealed their lips firmly around the mouthpiece, exhaled/inhaled slowly and completely and then tried to breath in as hard as possible. The patient was allowed to rest for about a minute and the maneuver was repeated.
223786443|NCT06543979|DRUG|lubiprostone , single arm|laxative
223786444|NCT06543979|PROCEDURE|biofeed back sessions|Biofeedback for participants with dyssynergic defecation and participants with reduced rectal sensations
223786445|NCT06543979|PROCEDURE|botox injection|Botulinum toxin injection for participants suffering from elevated anal canal pressure
223786446|NCT05230238|DEVICE|Pituitary gland stimulation|Pituitary gland stimulation via an surface electrode connected to an external neurostimulator
223786447|NCT05288543|DRUG|IPG7236- Single ascending dose|Subjects will receive IPG7236 tablets orally once on Day 1 in a fasted state
223786448|NCT05288543|DRUG|IPG7236- Multiple ascending dose|Subjects will receive IPG7236 tablets orally once daily for 10 days from Day1 to Day 10 in a fasted state
223786449|NCT05288543|OTHER|Placebo (Part A)|Subjects will receive IPG7236 tablets orally once on Day 1 (Part A) or once daily for 10 days from Day1 to Day 10 (Part B) in a fasted state
223786450|NCT04695171|DEVICE|LINX Reflux Management System|"The LINX Reflux Management System consists of a series of titanium beads each with a magnetic core connected with independent titanium wires to form an annular shape when implanted. The attractive force of the magnetic beads is designed to provide additional strength to keep a weak lower esophageal sphincter (LES) closed. During swallowing, the magnetic beads slide away from each other on the independent titanium wire links to allow esophageal distention as the bolus passes by."
223786451|NCT04695171|PROCEDURE|Fundoplication|A surgical procedure where the fundus of the stomach is wrapped around and sutured to the distal esophagus to restore the function of the lower esophageal sphincter in limiting stomach contents from refluxing into the esophagus.
223786452|NCT05857163|DRUG|Rifasutenizol capsules|400 mg, BID, taken orally within half an hour after breakfast and dinner.
223786453|NCT05857163|DRUG|Rabeprazole sodium enteric-coated tablets|20 mg, BID, taken orally within half an hour before breakfast and dinner.
223786454|NCT05857163|DRUG|Amoxicillin Capsules|1 g, BID, taken orally within half an hour after breakfast and dinner.
223786455|NCT05857163|DRUG|Clarithromycin placebo tablets|BID, taken orally within half an hour after breakfast and dinner.
223786456|NCT05857163|DRUG|Bismuth potassium citrate placebo capsules|BID, taken orally within half an hour before breakfast and dinner.
223786457|NCT05857163|DRUG|Clarithromycin tablets|500 mg, BID, taken orally within half an hour after breakfast and dinner.
223786458|NCT05857163|DRUG|Bismuth potassium citrate capsules|240 mg, BID, taken orally within half an hour before breakfast and dinner.
223786459|NCT05857163|DRUG|Rifasutenizol placebo capsules|BID, taken orally within half an hour before breakfast and dinner.
223786460|NCT05410977|PROCEDURE|Biospecimen Collection|Undergo collection of blood and stool samples
223786461|NCT05410977|OTHER|Electronic Health Record Review|Medical records reviewed
223786462|NCT06961539|OTHER|The group with virtual visits|"On the first day after open-heart surgery in the intensive care unit, in addition to face-to-face visits, video calls were made through the researcher's phone in the morning and evening."
223786463|NCT06961448|DEVICE|Hyaluronate Gel for Injection|Apply a maximum of 1.5 mL per side of the nasolabial fold using the test device (Lafullen) or the control device, with an optional touch-up of up to 0.5 mL per side at 4 weeks based on investigator assessment.
223786464|NCT06961448|DEVICE|Polycaprolactone microsphere filler|Apply a maximum of 1.0 mL per side of the nasolabial fold using the test device (Lafullen) or the control device, with an optional touch-up of up to 0.5 mL per side at 4 weeks based on investigator assessment.
223786465|NCT06250751|BEHAVIORAL|Behavioral Exercise Training (BET) intervention|Introduce and refine concept of exercise and cardiovascular health by initiating walking or cycling and provide behavioral counseling sessions to foster support for adoption and maintenance of exercise, and to troubleshoot barriers. During the first two weeks, the study team will meet with participants twice per week (virtually) to introduce the intervention, familiarize men with the exercise program, exercise logs, resistance bands for strength training. Contact will drop to once per week during weeks 3-8 (total=10 contacts in weeks 1-8). Behavioral counseling will be delivered by the PI or the study coordinator for 30-40 minutes prior to 20-30 mins of an individual or group-based strength training class.
223786466|NCT06635772|DRUG|HS-10390|HS-10390 will be administered daily
223786467|NCT06635772|DRUG|Irbesartan|Irbesartan will be administered daily as a 150-mg oral tablet. For patients who tolerate the initial dose of 150 mg after 2 weeks will increase their dose to 300 mg
223786468|NCT06636604|OTHER|DSA(Decision Support Algorithm)|Intramuscular injection will be given to 30 volunteer patients using the decision support algorithm.
223786469|NCT06027216|DEVICE|Multiplexing Prism|"Multiplexing prism is designed for spatial vision multiplexing. It allows partial light transmission through the prism allow the observer to simultaneously see the physical world through the prism and see the shifted view from the non-seeing side. It is developed to expand the field of view of individuals with just one eye."
223786470|NCT03727893|BEHAVIORAL|Roller-based Intervention Group (IG)|A group of manual wheelchair users (MWUs) with spinal cord injury (SCI) that will complete an initial exercise education and a 12-week (3 sessions per week) evidence-based high-intensity interval training (HIIT) program using the roller-based WheelMill (WMS) system.
223786471|NCT03727893|BEHAVIORAL|Control Group (CG)|A group of manual wheelchair users (MWUs) with spinal cord injury (SCI) that will complete an initial exercise education session and enroll in a 12-week (3 sessions per week) independent workout program at an accessible community-based fitness facility.
223786472|NCT03116139|DIAGNOSTIC_TEST|V/Q imaging|Standard of care
223786473|NCT03116139|DIAGNOSTIC_TEST|Computed tomography scan|Standard of care
223786474|NCT03471689|BEHAVIORAL|Mindfulness meditation|Participants will be trained to use mindfulness meditation to reduce pain perception.
223786475|NCT03471689|BEHAVIORAL|Positive reappraisal|Participants will be trained to use positive reappraisal to reduce pain perception.
223786476|NCT02863016|DEVICE|SelectBag One|Each patient will be subjected to two stages of each month, where it will be treated with online HDF postdilution with two kind of concentrates: acetic acid (Ac-HDF) and acetate-free citrate containing one (HDF-Cit ). For each of the sessions will be used online HDF postdilution with TMP biofeedback (UltraControl) and Filter high permeability.
223786477|NCT03869229|BIOLOGICAL|Intra-articular injection of ADMSC|Intervention: Intra-articular injection of Adipose-derived Mesenchymal Stem Cells (ADMSC)- ultrasound guided intra-articular injection of at least 10 million of ADMCS per procedure, maximum four procedures (i.e. injections per joint), minimum number of cells pre protocol 40 million
223786478|NCT03797027|DEVICE|Percutaneous Nephrolithotomy without an abdominal cushion|patients undergo prone PNCL without an abdominal cushion
223786479|NCT03797027|DEVICE|Percutaneous Nephrolithotomy with an 5 cm abdominal cushion|patients undergo prone PNCL with an 5 cm abdominal cushion
223786480|NCT03797027|DEVICE|Percutaneous Nephrolithotomy with an 5 cm abdominal cushion|patients undergo prone PNCL with an 10 cm abdominal cushion
223786481|NCT00743353|DRUG|F-18 RGD-K5|Study Drug F-18 RGD-K5 administered for diagnostic PET Imaging to be observed for a maximum of 4 hours, followed by 24 hour follow up
223786482|NCT05770544|DRUG|Entrectinib|"Adult and paediatric patients with body surface area (BSA) ≥1.51 m\^2 will receive entrectinib orally at a dose of 600 mg daily dose (three 200 mg capsules per day).~Paediatric patients with BSA \<1.51 m\^2 will receive entrectinib at a dose of 100 mg (BSA=0.43-0.50 m\^2) or 200 mg (BSA=0.51-0.80 m\^2) or 300 mg (BSA=0.81-1.10 m\^2) or 400 mg (BSA=1.11-1.50 m\^2).~Each cycle of treatment will consist of 28 days and patients may continue until disease progression without clinical benefit, unacceptable toxicity or withdrawal of consent."
223786483|NCT00001059|DRUG|Doxorubicin hydrochloride (liposomal)|
223786484|NCT00001059|DRUG|Filgrastim|
223786485|NCT00001059|DRUG|Bleomycin sulfate|
223786486|NCT00001059|DRUG|Vincristine sulfate|
223786487|NCT06397404|DIAGNOSTIC_TEST|Venous excess ultrasound score (VExUS) protocol|All patients upon admission undergo ultrasound assessment of diameter and collapsibility of the inferior vena cava, hepatic vein Doppler, portal vein Doppler, intra-renal venous Doppler.
223786488|NCT01972061|DEVICE|Foot stimulation|Foot stimulation electrically activates the somatic afferent nerves in the foot using FDA-approved, commercially available transcutaneous electrical nerve stimulator (TENS) and skin surface electrodes attached to the foot.
223786489|NCT01866410|DRUG|Cabozantinib S-malate|Given PO
223786490|NCT01866410|DRUG|Erlotinib Hydrochloride|Given PO
223786491|NCT01866410|OTHER|Laboratory Biomarker Analysis|Correlative studies
223786492|NCT02219932|DRUG|fampridine|
223786493|NCT02219932|DRUG|Placebo|Matched placebo
223786494|NCT02742727|BIOLOGICAL|anti-CD7 CAR-pNK cells|The allogeneic NK cells (NK-92 cell line for clinical use) are engineered to contain anti-CD7 attached to TCRzeta, CD28 and 4-1BB signaling domains. These modified cells are called chimeric antigen receptor NK cells with specificity for CD7.
223786495|NCT06529653|PROCEDURE|autogenous bone wedge|autogenous bone block harvested from chin and adjusted to be wedged intercortical in split ridge
223786496|NCT00489450|DRUG|SK3530|
223786497|NCT01490346|DRUG|Initiation of anti-retroviral therapy|Subjects begin taking a preferred initial anti-retroviral regimens as determined by their primary care provider. Intracellular levels of those medications are measured.
223786498|NCT03497923|DRUG|Magnesium Sulfate|After reversal the obention of a TOF ratio of 0.9 is avaited. 10 minutes later patients will receive a perfusion of magnesium 60 mg kg-1 over 5 minutes.
223786499|NCT01989650|OTHER|Break|A break of 15 minute will be provided after 3rd colonoscopy in a session of 6 colonoscopies in total
223786500|NCT01989650|OTHER|No break|No break will be provided
223786501|NCT00112073|DRUG|bapineuzumab|IV, Q13w
223786502|NCT00112073|OTHER|placebo|IV Q13w
223786503|NCT00093145|DRUG|Albumin-bound paclitaxel|Administered by intravenous infusion.
223786504|NCT00093145|DRUG|Carboplatin|Carboplatin dose was calculated using a modified Calvert formula (creatinine clearance was substituted for GFR): Total dose (mg) = (target AUC) x (creatinine clearance + 25). Note: AUC = 6 was initially targeted, but could be decreased due to toxicity.
223786505|NCT00093145|DRUG|Herceptin®|Administered by IV infusion
223786506|NCT00003269|BIOLOGICAL|sargramostim|
223786507|NCT00003269|DRUG|amifostine trihydrate|
223786508|NCT00003269|DRUG|cisplatin|
223786509|NCT00003269|DRUG|cyclophosphamide|
223786510|NCT00003269|DRUG|etoposide|
223786511|NCT03330665|BEHAVIORAL|Meditation|Meditate 3 times a week using headspace app
223786512|NCT00216684|DRUG|fentanyl|
223786513|NCT03057548|PROCEDURE|Cryo or RF Ablation only of Pulmonary Veins|"Artic Front Advance Cardiac Cryoabltion System used to ablate the Pulmonary Veins~OR~FDA Approved RF Ablation Catheter used to ablate the Pulmonary Veins.~Ablation of the Pulmonary Veins alone"
223786514|NCT03057548|PROCEDURE|Cryo or RF Ablation of Pulmonary Veins plus Ablation of the PLAW|"Cryoablation of the Pulmonary Veins plus RF Ablation of the PLAW~OR~RF Ablation of the Pulmonary Veins plus RF Ablation of the PLAW~Ablation of the Pulmonary Veins plus RF ablation of the Posterior Left Atrial Wall (PLAW)"
223786515|NCT04389840|DRUG|Dociparstat sodium|Dociparstat is a glycosaminoglycan derived from porcine heparin.
223786516|NCT04389840|DRUG|Placebo|0.9% Normal Saline
223786517|NCT03577002|OTHER|Serious Illness Care Program (SICP)|SICP includes the Serious Illness Conversation Guide, which provides patient-tested language for initial and follow-up conversations; training materials, including didactic materials and case studies for structured role playing; and implementation guidance including recommended approaches to identifying appropriate patients and templates for documentation of conversations
223786518|NCT06295120|DRUG|Phenoxymethylpenicillin 1.2 MIE 4 times daily|The intervention is the duration of treatment with phenoxymethylpenicillin from 3 to 7 days. Dose and frequency of the treatment is the same in the different arms.
223786519|NCT04158375|BEHAVIORAL|Resistance Exercise|Resistance (RE) training will be performed 4 days per week using a combination of upper and lower body exercises at 8-12 repetitions per set. Participants will complete 2 progressing to 4 sets of 8 to 12 repetitions per exercise, with 1 minute rest between sets. Participants will warmup for 5 minutes on a treadmill, cycle ergometer or elliptical at \~50% VO2 peak then begin resistance training. Resistance will be performed 4 days per week with lower body exercise on Monday and Thursday, and upper body on Tuesday and Friday. Wednesdays are a rest day. Participants will begin at 2 sets per exercise on weeks 1 and 2, then 3 sets for week 3, and 4 sets for weeks 4 to 12.
223786520|NCT04279249|OTHER|HEPA Air Filtration|2 HEPA air filters placed in home (one in bedroom, one in living room) for 30 days
223786521|NCT04279249|OTHER|Sham HEPA Air Filtration|2 HEPA air filter devices with filter removed placed in home (one in bedroom, one in living room) for 30 days
223786522|NCT06001775|BEHAVIORAL|Patient Priorities Care|According to patientprioritiescare.org a Patient Priorities Care conversation helps to align healthcare decision-making and care by all clinicians with patients' own health priorities. Patient Priorities Care involves not only the health outcome goals that patients want to achieve, but also their preferences for healthcare.
223786523|NCT06083207|DRUG|IBI3003|Subjects will receive IBI3003 on Day 1 in a 28-day cycle (or intervals determined by the Investigator and Sponsor based on safety, toxicity and pharmacokinetic(PK) data), until death, disease progression, intolerable toxicity, start of a new anticancer treatment, withdrawal of consent for study participation, end of the study, or for a maximum of 24 months, whichever occurs first.
223786524|NCT03015792|DRUG|Dexamethasone|Given PO
223786525|NCT03015792|DRUG|Ibrutinib|Given PO
223786526|NCT03015792|OTHER|Laboratory Biomarker Analysis|Correlative studies
223786527|NCT03015792|DRUG|Lenalidomide|Given PO
223786528|NCT03015792|OTHER|Pharmacological Study|Correlative studies
223786529|NCT03015792|OTHER|Quality-of-Life Assessment|Ancillary studies
223786530|NCT02365467|DEVICE|Valiant Mona LSA Thoracic Stent Graft System|
223786531|NCT03948724|BEHAVIORAL|Therapeutic education program|Patient will have 5 educational therapy workshops. The first educational therapy workshops will be realized at cycle 1 and the last one within 25 weeks after starting treatment
223786532|NCT03948724|BEHAVIORAL|Usual Information|Patient receive usual informations
223786533|NCT04043689|DEVICE|tACS (transcranial Alternate Current Stimulation)|"This is a single-centric comparative randomized controlled blind and cross-over study.~The order of stimulation conditions will be randomized: (right frontal tACS / occipital tACS / tACS PLACEBO). The 3 stimulation conditions will be performed with a wash-out period of at least 1 week. In this study each patient will be his own control"
223786534|NCT02043782|DEVICE|Coloplast Test|Newly developed 1-piece convex ostomy product
223786535|NCT02043782|DEVICE|Own product|The subjects Own product is used as baseline performance in this investigation. The products are commercial and available on the market, and are products manufactured by manufactures who produce convex ostomy products i.e. Coloplast, Convatec, Dansac, B.Braun, Hollister and more.
223786536|NCT02043782|DEVICE|Competitor soft convex|A commercially available soft convex product
223786537|NCT04571346|PROCEDURE|trans-obturator procedure|TOT procedure will be done using silicon-coated polypropylene tape that will be inserted at the mid-urethral portion. In group 1, a classical vertical vaginal incision will be done proximal to the external urethral meatus with dissection along the axis of the urethra till the mid-urethral zone that is identified by palpating the urethral catheter balloon through the vaginal at the bladder neck, while in group 2, two paramedian incisions will be done 1cm long in the anterior vaginal wall 2 cm apart parallel to the urethra till identification of the mid-urethral portion, communication will be done between the two incisions 1 cm wide in this area creating a tunnel where the tape will be placed, this technique provides healthy tissues proximal and distal to the tape that allows more stabilization and less migration. The rest of the procedure is the same as the standard procedure of Trans-obturator outside-in tension-free technique.
223786538|NCT06534151|DEVICE|CRT implantation|A CRT is a device (that looks like a pacemaker) that will be used to help the ventricles contract synchronously.
223786539|NCT05036616|DEVICE|Combination of extracorporeal membrane oxygenation and continuous renal replacement therapy|Combination of extracorporeal membrane oxygenation and continuous renal replacement therapy
223786540|NCT05157191|OTHER|Observational|Observational
223786541|NCT05136573|BEHAVIORAL|Combined Exercises|Combined Exercises
223786542|NCT02626715|DRUG|Reduced-Intensity Conditioning Regimen|Campath (alemtuzumab) - drug class: monoclonal antibody Droxia (hydroxyurea) - drug class: antimetabolite Fludara (fludarabine) - drug class: antimetabolite Alkeran (melphalan) - drug class: alkylating agent Thiotepa (triethylenethiophosphoramide) - drug class: cytotoxic agent
223786543|NCT02626715|DRUG|Myeloablative Conditioning Regimen|Campath (alemtuzumab) - drug class: monoclonal antibody Thiotepa (triethylenethiophosphoramide) - drug class: cytotoxic agent Fludara (fludarabine) - drug class: antimetabolite Busulfex (busulfan) - drug class: alkylating agent
223786544|NCT01306162|DRUG|Dabigatran etexilate plus dronedarone|dabigatran etexilate 150 mg plus dronedarone 400 mg as single dose
223786545|NCT01306162|DRUG|Dabigatran etexilate|150 mg as single dose
223786546|NCT01306162|DRUG|Dabigatran etexilate plus dronedarone|dabigatran etexilate 150 mg plus dronedarone 400 mg as single dose (staggered administration)
223786547|NCT01306162|DRUG|Dabigatran etexilate plus dronedarone|dabigatran etexilate 150 mg single dose plus dronedarone 400 mg bid
223786548|NCT01306162|DRUG|Dabigatran etexilate plus dronedarone|dabigatran etexilate 150 mg single dose plus dronedarone 400 mg bid (staggered administration)
223786549|NCT04351438|DEVICE|Active Comparator: centrifuge TPE with citrate|Patients who received citrate-based anticoagulation with centrifuge TPE
223786550|NCT04351438|DEVICE|Active Comparator: Filter TPE with heparin|Patients who received heparin-based anticoagulation with filter TPE
223786551|NCT04351438|DRUG|Active comparator: Filter TPE with citrate|Patients who received citrate-based anticoagulation with filter TPE
223786552|NCT01103206|DRUG|cinacalcet|Intake of a single tablet of cinacalcet
223786553|NCT01103206|DRUG|cinacalcet dose 1|PTH suppression test in primary hyperparathyroidism using cinacalcet (dose 1).
223786554|NCT01103206|DRUG|cinacalcet dose 2|Parathyroid hormone suppression test in primary hyperparathyroidism using cinacalcet (dose 2).
223786555|NCT05898867|OTHER|Saline|Open label intra-articular injection of isotonic saline.
223786556|NCT03776981|OTHER|Core Activation|Volitional activation of the transversus abdominis muscle during self-selected paced ambulation for both groups.
223786557|NCT03776981|OTHER|Core Stabilization|Six-week core stabilization program for the group of participants with knee osteoarthritis.
223786558|NCT02959437|DRUG|Azacitidine|Five doses of azacitidine will be administered by subcutaneous injection or intravenously (IV) over Days 1 to 7 in Cycles 1 through 6.
223786559|NCT02959437|DRUG|Pembrolizumab|Pembrolizumab will be administered in a 30-minute IV infusion every 3 weeks on Day 1 of each 21-day cycle.
223786560|NCT02959437|DRUG|Epacadostat|Epacadostat tablets will be administered orally twice daily.
223786561|NCT02959437|DRUG|INCB057643|INCB057643 will be orally self- administered once daily beginning on Cycle 1 Day 1 and continuously thereafter in 21-day cycles.
223786562|NCT02959437|DRUG|Pembrolizumab|Pembrolizumab will be administered in a 30-minute IV infusion every 3 weeks of each 21-day cycle starting on Cycle 2 Day 1.
223786563|NCT02959437|DRUG|Epacadostat|Epacadostat tablets will be administered orally twice daily starting at Cycle 2 Day 1.
223786564|NCT02959437|DRUG|INCB059872|INCB059872 will be orally self- administered once daily OR every other day beginning on Cycle 1 Day 1 and continuously thereafter in 21-day cycles.
223786565|NCT00864032|DRUG|Sorafenib|400mg twice daily
223786566|NCT03806985|DRUG|Placebo oral capsule|microcrystalline cellulose capsule
223786567|NCT03806985|DRUG|Low Dose Psilocybin|0.0143 mg/kg psilocybin capsule (weight-based option) or 1 mg psilocybin capsule (fixed-dose option)
223786568|NCT03806985|DRUG|High Dose Psilocybin|0.143 mg/kg psilocybin capsule (weight-based option) or 10 mg psilocybin capsule (fixed-dose option)
223786569|NCT01659723|DRUG|Hyperbaric Oxygen|100% oxygen at 240-250 kPa will be delivered to the patents for 80-90 minutes while sitting or lying in a hyperbaric oxygen chamber. Patients will receive treatment once every day, except week-ends, for 40 days.
223786570|NCT03877718|DRUG|Arm 1: CL-H1T|One capsule of CL-H1T (total dose: sumatriptan succinate 90mg/promethazine HCl 18.75 mg)
223786571|NCT03877718|DRUG|Arm 2: CL-H1T|One capsule of CL-H1T (total dose: sumatriptan succinate 90mg/promethazine HCl 37.5 mg)
223786572|NCT03877718|DRUG|Arm 3: Sumatriptan Succinate 100 mg capsule|One capsule of sumatriptan succinate 100 mg
223786573|NCT03877718|DRUG|Arm 4: Promethazine HCl 18.75 mg|One capsule of promethazine HCl 18.75 mg
223786574|NCT03877718|DRUG|Arm 5: Promethazine HCl 37.5 mg|One capsule of promethazine HCl 37.5 mg
223786575|NCT03877718|OTHER|Placebo|One capsule of placebo
223786576|NCT05499429|DEVICE|Transcranial low intensity focused ultrasound stimulation|Low intensity focused transcranial ultrasound stimulation can safely and effectively regulate neuron excitability through mechanical force.
223786577|NCT02252211|DRUG|DS-8895a 1 mg/kg|Patients received infusions with \^89Zr-Df-DS-8895a at a dose of 0.2 mg/kg on Day 1, DS-8895a at a dose of 1 mg/kg on Days 8 and 22, and \^89Zr-Df-DS-8895a at a dose of 1 mg/kg on Day 36. Patients who responded or had stable disease per RECIST version 1.1 at the Day 50 restaging may have continued to receive biweekly treatment with DS-8895a until disease progression.
223786578|NCT02252211|DRUG|DS-8895a 3 mg/kg|Patients received infusions with \^89Zr-Df-DS-8895a at a dose of 0.2 mg/kg on Day 1, DS-8895a at a dose of 3 mg/kg on Days 8 and 22, and \^89Zr-Df-DS-8895a at a dose of 3 mg/kg on Day 36. Patients who responded or had stable disease per RECIST version 1.1 at the Day 50 restaging may have continued to receive biweekly treatment with DS-8895a until disease progression.
223786579|NCT02252211|DRUG|DS-8895a 10 mg/kg|Patients were to receive infusions with \^89Zr-Df-DS-8895a at a dose of 0.2 mg/kg on Day 1, DS-8895a at a dose of 10 mg/kg on Days 8 and 22, and \^89Zr-Df-DS-8895a at a dose of 10 mg/kg on Day 36. Patients who responded or had stable disease per RECIST version 1.1 at the Day 50 restaging may have continued to receive biweekly treatment with DS-8895a until disease progression.
223786580|NCT02540200|DEVICE|BST-CarGel|BST-CarGel is a scaffolding material after microfracture treatment is performed in order to treat the chondral lesions. It assists in the repair process by stabilizing the clot in the cartilage lesion via adhesion and inhibition of clot retraction.
223786581|NCT02540200|PROCEDURE|Microfracture|It is a bone marrow stimulation technique, and the standard treatment for chondral lesions of the hip joint.
223786582|NCT03727191|OTHER|Control Group (education, guidelines, recommendations)|Nutritional education and guidelines for the consumption of a completed shreded diet and recommendations for physical activity for one month.
223786583|NCT03727191|OTHER|Experimental Group (education, guidelines, 2 pckts diet, recommendations)|Nutritional education and guidelines for the consumption of a completed shreded diet including 2 packets of 90 grams every day and recommendations for physical activity for one month.
223786584|NCT03116594|BIOLOGICAL|NBP608|Preparation of Oka/SK strain of live, attenuated zoster virus
223786585|NCT03116594|BIOLOGICAL|Zostavax|Preparation of Oka/Merck strain of live, attenuated zoster virus
223786586|NCT04717011|DIAGNOSTIC_TEST|PCR test|PCR test in two different semen samples from each patient: first with positive diagnosis for COVID-19 and the second after negative diagnosis for COVID-19.
223786587|NCT04481048|DRUG|N-Acetyl cysteine|Eight (8) weeks of treatment with an FDA approved medication, N-acetylcysteine (NAC).
223786588|NCT04481048|OTHER|Placebo|Eight (8) weeks of treatment with placebo.
223786589|NCT00421252|DRUG|clopidogrel 600 mg|Clopidogrel load \> 2hrs pre-angiography
223786590|NCT00421252|DEVICE|arterial access sheath|randomize to 5Fr vs 6Fr
223786591|NCT03569280|COMBINATION_PRODUCT|Enzalutamide or Abiraterone or Apalutamid|Antitumor treatment
223786592|NCT05467644|PROCEDURE|Treatment of Fracture Related Infection|Observational Retrospective Study. Only one group. Patients diagnosed with fracture-related infection and submitted to surgical treatment
223786593|NCT00968669|BIOLOGICAL|MEDI528 30 mg|MEDI-528 at a dose of 30 mg administered as a subcutaneous injection every 2 weeks for 24 weeks
223786594|NCT00968669|BIOLOGICAL|MEDI528 100 mg|MEDI-528 at a dose of 100 mg administered as a subcutaneous injection every 2 weeks for 24 weeks
223786595|NCT00968669|BIOLOGICAL|MEDI528 300 mg|MEDI-528 at a dose of 300 mg administered as a subcutaneous injection every 2 weeks for 24 weeks
223786596|NCT00968669|OTHER|Placebo|Placebo administered as a subcutaneous injection every 2 weeks for 24 weeks
223786597|NCT03358667|PROCEDURE|augmentation peri-implant soft tissue|the implant was cover with a 2 mm cover screw for a tent effect or with a dermal membrane after implant insertion
223786598|NCT00986999|DRUG|rosuvastatin|rosuvastatin 20 mg tablet, 1/2 tab qd increased to a full tablet qd as tolerated x 6 months with optional extension to 2 years
223786599|NCT03335358|BEHAVIORAL|Dyadic (couples-based) positive psychology intervention|Self-administered behavioral intervention in which participants complete at least 2 activities alone and 2 together each week for 8 weeks. Positive psychology activities include expressing gratitude, practicing acts of kindness, fostering relationships, working toward a goal, focusing on the positive, spirituality, and savoring.
223786600|NCT00833989|DRUG|GSK249320|I.V. infusion
223786601|NCT00833989|DRUG|PLACEBO|Placebo
223786602|NCT05293080|OTHER|Medical or interventional therapy for rhythm control in atrial fibrillation (antiarrhythmic drugs, ablation, electric cardio version)|Therapy for early rhythm control will be either by use of approved antiarrhythmic drugs (e.g. amiodarone, dronedarone, flecainide, propafenone), approved approaches and devices for ablation, or electric cardio version.
223786603|NCT05293080|OTHER|Usual care for atrial fibrillation|Usual care for atrial fibrillation according to current guidelines. Usual care will mainly comprise rate control by approved drugs. We expect, that usual care will also comprise therapy for rhythm control in a small group of patients.
223786604|NCT02370654|BEHAVIORAL|Tai chi|
223786605|NCT02370654|BEHAVIORAL|Conventional exercise|
223786606|NCT02494791|BEHAVIORAL|Questionnaire, Educational Material|Participants in this study will be given educational material about Lynch Syndrome and genetic testing for this condition. They will be asked to complete questionnaires about their family cancer history, personal health history and attitudes toward genetic testing.
223786607|NCT00433069|DRUG|Pioglitazone|Increase early virological response to pegylated interferon alpha plus ribavirin by increasing insulin sensitivity
223786608|NCT00433069|DRUG|Interferon Alfa-2a|Standard of care for chronic hepatitis C
223786609|NCT00433069|DRUG|Ribavirin|Standard of care for chronic hepatitis C
223786610|NCT00854451|DRUG|omeprazole plus amoxicillin|
223786611|NCT00854451|DRUG|omeprazole plus amoxicillin|
223786612|NCT00854451|DRUG|omeprazole plus amoxicillin|
223786613|NCT00854451|DRUG|omeprazole plus amoxicillin|
223786614|NCT04094454|DEVICE|special tampon with a diameter of 28mm|patients will use a special tampon with extended vaginal dilatation (diameter 28mm) during radiotherapy
223786615|NCT04094454|DEVICE|standard tampon with a diameter of 12-13mm|patients in Arm B will use a normal commercially available tampon (diameter 12-13mm) during radiotherapy
223786616|NCT03661853|BEHAVIORAL|Control|60 minute psycho-education on alcohol and drugs.
223786617|NCT03661853|BEHAVIORAL|Functional Analysis|"Component of standard CBT that helps to break the chain of events (external and internal) that lead from cue (trigger) to alcohol use to consequences of use."
223786618|NCT03661853|BEHAVIORAL|Cognitive Restructuring|CR is used to to help identify and change automatic, habituated thoughts that occur in response to alcohol triggers.
223786619|NCT03661853|BEHAVIORAL|Dealing With Cravings|DC is used reduce cravings for alcohol by conjuring negative images associated with alcohol, teaching distraction techniques, and teaching breathing techniques to reduce physiological arousal.
223786620|NCT01560520|BEHAVIORAL|Physical activity|Observation only
223786621|NCT04669704|OTHER|Experimental: Tablet application|"A protocol of exercises based on the current scientific evidence will be provided through a tablet application. A follow-up of the use of the application will be carried out. A minimum of 4-week home exercise intervention will be performed, which will have to be carried out daily by the patient autonomously at home for at least 5 days per week, starting after baseline measurement.~The exercise program will be individualized according to each pathology."
223786622|NCT04669704|OTHER|Comparator: Conventional treatment|In the control condition, participants will receive a home exercise program on paper. The exercise program will be the conventionally prescribed one by the Andalusian Public Health Service. Participants will be told to perform exercises during a minimum of 4 week at home for at least 5 days per week, starting after baseline measurement.
223786623|NCT02401191|DRUG|FEX60/PE10|Pharmaceutical form:tablet Route of administration: oral
223786624|NCT05234138|OTHER|Blood Sample|Blood Sample
223786625|NCT03675386|OTHER|Interventional Group|The Transitional Pain Service Program enables targeted, mechanism-based, treatment innovations aimed at reducing the incidence and severity of chronic post-surgical pain, disability and enabling safe opioid prescribing/ weaning after major surgery. The investigator's TPSP intervention uses a variety of methods to support patients to manage pain and wean off opioids. This includes physician-guided opioid and non-opioid pharmacotherapy and tapering, and clinical psychology services specializing in pain education, Acceptance \& Commitment Therapy (ACT) and e-mobile self-management tools.
223786626|NCT03675386|OTHER|Control Intervention|Patients in the control group will receive standard care, which involves standard postoperative follow-up with their surgeon/primary care provider. Patients will also be sent with a link for an online multimedia tool during each follow-up time point that will provide information and education regarding non-pharmacologic techniques for managing pain. At the end, all patients in the control arm will be invited to join the TPSP after one year of follow-up if they are still taking opioids.
223786627|NCT03818139|OTHER|radiography thorax|The ultrasound of the thorax will be performed while waiting for the X-ray thorax
223786628|NCT05282381|BEHAVIORAL|DRS : Decision Regret Scale|"The DRS is a self-administered questionnaire including 5 items assessing decisional regret in a score graduated between 0 and 100 (0 = no regret).This scale is associated with the ReTransQoL, a specific quality of life questionnaire.~Questionnaires are administrated at 1, 3, 6 and 12 months post-transplantation."
223786629|NCT05542368|DIAGNOSTIC_TEST|Thyroid tests|Thyroid function test TSH ,T3,T4 Thyroid antibody test anti TPO,antithyroglobulin
223786630|NCT01949480|PROCEDURE|Thoracotomy|
223786631|NCT01949480|PROCEDURE|Video-Assisted Thoracoscopic Surgery (VATS)|
223786632|NCT04230473|BIOLOGICAL|single dose of CNCT19|"Dose A: 0.25 x 10\^8 autologous CNCT19 transduced cells via intravenous infusion. Drug: Fludarabine Drug: Cyclophosphamide~Dose B: 1.00 x 10\^8 autologous CNCT19 transduced cells via intravenous infusion. Drug: Fludarabine Drug: Cyclophosphamide~Dose C: 2.00 x 10\^8 autologous CNCT19 transduced cells via intravenous infusion. Drug: Fludarabine Drug: Cyclophosphamide"
223786633|NCT00137033|DRUG|Celecoxib|
223786634|NCT00137033|DRUG|Naproxen|
223786635|NCT00137033|DRUG|ASA|
223786636|NCT05208073|BEHAVIORAL|Cosmetic therapy|The cosmetic therapy in this study is once a week, 60 minutes each section for a total of 6-week. Cosmetic therapy uses the teaching materials to teach the subjects skincare and makeup operation steps and use the 10-minute limb stretching to relax their minds before the activity, and then lead the research subjects to use cotton pads to apply lotion and lotion. , female subjects used powder, eyebrow pencil, and lipstick (or lip balm) to complete weekly different-themed activities and hairstyling, while men performed weekly different theme activities and hairstyling.
223786637|NCT03926507|PROCEDURE|Computed Tomography|Undergo PET/CT scan
223786638|NCT03926507|OTHER|Fluciclovine F18|Given IV
223786639|NCT03926507|PROCEDURE|Positron Emission Tomography|Undergo PET/CT scan
223786640|NCT00061295|PROCEDURE|Body weight support treadmill training|
223786641|NCT00144339|DRUG|tiotropium|
223786642|NCT00144339|DRUG|placebo|
223786643|NCT02529319|PROCEDURE|MRI-Guided Ablation|Catheter ablation of AF will be guided by a DE-MRI of the patient's heart prior to the procedure.
223786644|NCT02529319|PROCEDURE|Conventional Ablation|Catheter ablation of AF using pulmonary vein isolation (PVI) will be performed using the HRS guidelines.
223786645|NCT02268838|DRUG|E6007|
223786646|NCT02268838|DRUG|E6007 matching placebo|
223786647|NCT01273727|DRUG|Dexamethasone|intravitreal implant 0.7 mg 6 month duration
223786648|NCT01273727|DRUG|dexamethasone|intravitreal implant 0.7 mg duration 6 months
223786649|NCT01109992|DRUG|Exercise plus Regadenoson (Lexercise)|Standard Bruce exercise stress test with regadenoson injection at maximal stress with Rubidium-82 Positron Emission Tomography
223786650|NCT01109992|DRUG|Regadenoson (Lexiscan)|Regadenoson Rubidium-82 Positron Emission Tomography
223786651|NCT00232804|DEVICE|Bx Cypher stent|
223786652|NCT03799575|BEHAVIORAL|Transmission Electron Microscopy analysis|Morphology of two vitreal side of Internal Limiting Membrane in contact
223786653|NCT06270901|OTHER|High Protein Planetary Health Diet|Planetary Health Diet Meal with 62 g of protein primarily from plant origin
223786654|NCT06270901|OTHER|Low Protein Planetary Health Diet|Planetary Health Diet Meal with 36 g of protein primarily from plant origin
223786655|NCT06270901|OTHER|High Protein Western Diet|Western Diet Meal with 62 g of protein primarily from animal origin
223786656|NCT06270901|OTHER|Low Protein Western Diet|Western Diet Meal with 36 g of protein primarily from animal origin
223786657|NCT06381479|DIETARY_SUPPLEMENT|probiotics|each capsule contains Lactiplantibacillus plantarum and Lacticaseibacillus paracasei, 2 caps daily use
223786658|NCT06381479|DIETARY_SUPPLEMENT|placebo|The placebo capsule contains microcrystalline cellulose, 2 caps daily use.
223786659|NCT00013312|PROCEDURE|Determine colonic tone|
223786660|NCT05059691|OTHER|Electronic Health Record Review|Review of medical records
223786661|NCT05059691|PROCEDURE|Transbronchial Cryobiopsy Guided by Three-Dimensional Fluoroscopy|Undergo transbronchial cryobiopsy guided by three-dimensional fluoroscopy
223786662|NCT02564575|BIOLOGICAL|HPIV3-EbovZ GP Vaccine|Administered intranasally by a VaxINator device
223786663|NCT03153917|OTHER|melatonin and cortisol sampling|The study will take place over 15 days during which the nurses will wear an actigraphic wristband and will fulfill a sleep log. During 3 periods of 24 hours selected during these 15 days, including a 12h day shift (Day 2), a 12h night shift (Day 8) and a rest (Day 13), the participants will collect their urine by 4 to 8 hour periods, note the corresponding urine volumes and for each period, sample a 5 mL tube which will be analyzed later (6-sulfatoxymelatonin and urinary cortisol assays). The subjects will complete questionnaires at the beginning of the study (Horne and Ostberg, Insomnia Severity Index, Epworth, Pichot, Hospital Anxiety and Depression) and the days corresponding to the urine sampling (Karolinska and St Mary Hospital).
223786664|NCT06442371|OTHER|High Intensity interval training + Quranic Listening|In this group, participants will receive protocol of High Intensity interval training which includes squats, jumping jacks, front kicks and rope jumps 3 days per week for 6 weeks, including warmup and cool down session along with Quranic listening meditation.
223786665|NCT06442371|OTHER|High intensity interval training|In this group, participants will receive only High intensity interval training which includes squats, jumping jacks, front kicks and rope jumps 3 days per week for 6 weeks, including warmup and cool down periods with no Quranic listening meditation
223786666|NCT02952924|DRUG|Midazolam|Single dose of 100 mcg midazolam solution will be administered orally, before (Day -1) and after (Day 14) the treatment with RO7049389 or matching placebo
223786667|NCT02952924|OTHER|Placebo|Placebo matching to RO7049389 will be administered as per schedule described in individual arm.
223786668|NCT02952924|DRUG|RO7049389|RO7049389 will be administered as per schedule described in individual arm.
223786669|NCT04892134|OTHER|blood sample|40-50 ml of blood is taken
223786670|NCT03825380|DRUG|Bimatoprost|Eyedrops
223786671|NCT03825380|DRUG|Lumigan®|Eyedrops
223786672|NCT03738540|BEHAVIORAL|TALK study group|Telephone Delivered Intervention
223786673|NCT03738540|BEHAVIORAL|TALK control group|Telephone Delivered Intervention
223786674|NCT01063257|DRUG|Clofarabine|"The dosage of Clofarabine will be gradually augmented in a 3+3 design for each following dose level:~DL1 - 5mg/m2/d, DL2 - 7.5mg/m2/d, DL3 - 10mg/m2/d, DL4 - 12.5mg/m2/d (This dose may not be reached and is an optional dose level in case the MTD is not reached before and depending on further data from the ongoing MDS Phase IIa oral formulation trial).~The DLa will be the following:~DL1a - 2.5mg/m2/d, DL2a - 6.5mg/m2/d, DL3a - 8.5mg/m2/d, DL4a - 11.5mg/m2/d (In case of activation of the DL4 step). Dose levels 1a, 2a and 3a will be used for de-escalation."
223786675|NCT00832923|BEHAVIORAL|PEPAC|"The proposed enhancement of the IMPACT DC intervention will consist of three key components: (1) an enhanced IMPACT DC Asthma Clinic visit; (2) short-term case management to increase the rate of primary care follow-up visits in the first month after the IMPACT DC Asthma Clinic visit; and (3) training in an asthma care toolkit to improve communication around asthma care with the child's primary care provider."
223786676|NCT05794464|PROCEDURE|Catheter ablation and/or electrical cardioversion|Catheter ablation and/or electrical cardio version are procedures intended to treat atrial fibrillation.
223786677|NCT05973526|PROCEDURE|Percutaneous Electrolipolysis|Electrolipolysis consists in the passage of electric current to the adipose tissue, causing lipolysis. The proposed protocol consists of 2 weekly sessions for 6 weeks, totaling 12 sessions, using needles.
223786678|NCT05973526|PROCEDURE|Transcutaneous Electrolipolysis|Electrolipolysis consists in the passage of electric current to the adipose tissue, causing lipolysis. The proposed protocol consists of 2 weekly sessions for 6 weeks, totaling 12 sessions, using the surface electrodos.
223786679|NCT02352311|DRUG|DKF-313|Combination of dutasteride 0.5 mg and tadalafil 5 mg
223786680|NCT02352311|DRUG|AVODART|Dutasteride 0.5 mg
223786681|NCT02352311|DRUG|CIALIS|Tadalafil 5 mg
223786682|NCT02158299|DRUG|Avitene|
223786683|NCT02158299|DRUG|Sapylin|
223786684|NCT02158299|BEHAVIORAL|axillary drainage|
223786685|NCT02158299|OTHER|reexamine|
223786686|NCT04223011|BEHAVIORAL|In-Hospital Recovery Coach Intervention|The recovery coach will meet with the patient at least once during the hospital admission, during which he/she will reinforce the importance of continuing medication treatments, if initiated, as well as community and social supports for recovery and will discuss the plan for engaging in these services. This will include recommendations for suitable community resources for recovery services, or for housing, transportation, or other external barriers that may make it more difficult to engage in outpatient treatment. The recovery coach will encourage the participant to complete a relapse prevention plan, and help the patient organize post-discharge appointments and review medications. If applicable, family members and significant others will be encouraged to be present for these encounters.
223786687|NCT04509947|BIOLOGICAL|Ad26.COV2.S|Ad26.COV2.S will be administered as IM injection at 2-dose (high and low) levels.
223786688|NCT04509947|BIOLOGICAL|Placebo|Placebo will be administered as IM injection.
223786689|NCT04626791|DRUG|Acalabrutinib|Given PO
223786690|NCT04626791|DRUG|Bortezomib|Given SC
223786691|NCT04626791|DRUG|Cyclophosphamide|Given IV
223786692|NCT04626791|DRUG|Cytarabine|Given IV
223786693|NCT04626791|DRUG|Doxorubicin Hydrochloride|Given IV
223786694|NCT04626791|DRUG|Prednisone|Given PO
223786695|NCT04626791|BIOLOGICAL|Rituximab|Given IV
223786696|NCT04626791|BIOLOGICAL|Rituximab and Hyaluronidase Human|Given IV
223786697|NCT05591352|DIETARY_SUPPLEMENT|Chenopodium formosanum extracts sachet|consume 1 sachet per day
223786698|NCT05591352|DIETARY_SUPPLEMENT|Placebo sachet|consume 1 sachet per day
223786699|NCT00126516|DRUG|Angiotensin II Receptor Antagonists|any dosage, frequency, and duration
223786700|NCT00126516|DRUG|Angiotensin-converting Enzyme Inhibitors|any dosage, frequency, and duration
223786701|NCT05847218|DRUG|RHN-001 (one tablet 750mg)|Subjects in A1 and A2 will receive 750mg RHN-001 or matching placebo tablets in Fasted state and Fed states respectively with 240 mL ambient temperature water.
223786702|NCT05847218|DRUG|RHN-001 (750mg * 2 Tablets)|Subjects in B1 and B2 will receive 1500mg RHN-001 (750mg tablet) or matching placebo tablets in Fasted state and Fed states respectively with 240 mL ambient temperature water.
223786703|NCT03131076|DIAGNOSTIC_TEST|IPMN follow up|Follow up with MRI and laboratory blood tests
223786704|NCT01600157|PROCEDURE|Ambulant laparoscopic nephrectomy|The patients with a renal cancer diagnosis with be schedule to enter the project if they meet the inclusion criteria of the project and the postoperative period will be recorded to identified the limiting factors for ambulant laparoscopic nephrectomy.
223786705|NCT05284968|DRUG|Cell injection|All subjects will be treated with cell injection
223786706|NCT04051372|DIAGNOSTIC_TEST|Bronchoscopic Alveolar Lavage|"The diagnostic yield of different diagnostic methods for lung infection and non-infectious diseases under allo-HSCT patients.~1. Classic microbiological cultures designed for bacteria, fungi, and mycobacteria.~2. Detection of human cytomegalovirus (CMV) and EB virus in serum and BAL was tested using a Real-time PCR kit.~3. Detection of aspergillus galactomannan antigen 1,3-beta-D-glucan in serum and BAL was performed using an enzyme immunoassay method.~4. Cytological and pathogenic microscopic evaluation in BALF~5. Flow cytological analysis of T lymphocyte subsets in BALF and serum~6. Cytokine detection in BALF and serum~7. Microbiology detection in BALF by mNGS"
223786707|NCT04493398|PROCEDURE|Gracey curette.|Root planed was performed with curettes (Gracey SAS, Hu-Friedy, Chicago, IL, USA).
223786708|NCT04493398|PROCEDURE|Ultrasonic scaler.|Debridement was performed with an ultrasonic scaler (Piezon Master 400 Perio Slim Tip®; Electro Medical System, Nyon, Switzerland).
223786709|NCT04493398|PROCEDURE|Erythritol air-polishing.|Treatment was performed with a low abrasive erythritol powder (Air-flow powder plus®, EMS, Nyon, Switzerland ) applied through a Perio-Flow hand piece connected to an airflow unit (Air-Flow Master®, EMS, Nyon, Switzerland).
223786710|NCT00550225|DRUG|GSK961081|GSK961081 edisylate and succinate will be administered as capsules via DISKUS inhaler formulated with lactose as a vehicle to make 12.5 milligrams. GSK961081 succinate will be given in a dose-ascending manner with a starting dose of 300 micrograms. The dose of GSK961081 edisylate is 1500 micrograms.
223786711|NCT00550225|DRUG|GSK961081 matching placebo|GSK961081 matching placebo formulated with lactose only as a vehicle to 12.5 milligrams will be administered via the DISKUS inhaler.
223786712|NCT03867734|DRUG|Aztreonam|2g IM Aztreonam
223786713|NCT02696005|OTHER|Exercise- Based Cardiac Rehabilitation Programme|Exercise- Based Cardiac Rehabilitation Programme for patients suffering from Heart Failure.
223786714|NCT03906370|DIAGNOSTIC_TEST|Diagnostic criteria for MS|The diagnosis healthy/diseased was made by 2017 Mc Donald criteria.
223786715|NCT06182670|DEVICE|Gingival Former Abutment|"GFA is positioned on the sub-crestal implant during the surgery and it is no longer removed. This follows the one abutment one time concept and should prevent bone loss and transmucosal tunnel."
223786716|NCT06182670|PROCEDURE|Subcrestal Implant|Placement of the endosseous sub-crestal dental implant through dedicated drills with 35 Newton insertion torque. It is positioned 2 mm under the crestal bone.
223786717|NCT06182670|DEVICE|Healing Abutment|A healing abutment is positioned on crestal implant during surgery. It is removed at prosthetic finalization.
223786718|NCT06182670|DEVICE|Prosthetic Crown|A zirconia prosthetic crown finalizes the implant rehabilitation.
223786719|NCT06182670|PROCEDURE|Crestal Implant|Placement of the endosseous crestal implant through dedicated drills with 35 Newton insertion torque at level of the alveolar bone.
223786720|NCT05680168|DEVICE|Extracorporeal electromagnetic stimulation|Electromagnetic stimulation using Magneto STYM device, (Iskra medical d.o.o, Slovenia).
223786721|NCT05680168|BEHAVIORAL|Pelvic floor exercises|Pelvic floor muscle training in serial training sessions with our therapist
223786722|NCT02152267|DEVICE|tDCS|The transcranial direct current stimulation allows the neuronal membranes to neuromodulate and it can enhance or inhibit the potential actions on the cortex. Studies with animals has shown that anodal stimulation modulate the membrane in the way to depolarize which results in a long term potential in the stimulated area
223786723|NCT03934502|DRUG|Evobrutinib|Participants will receive single oral dose of evobrutinib either after an overnight fast of at least 10 hours (Treatment A), within 30 minutes after start of a light meal (Treatment B), 1 hour prior to a low-fat meal (Treatment C), or 2 hours after start of a low-fat meal (Treatment D).
223786724|NCT05641493|COMBINATION_PRODUCT|HLX208+HLX10|HLX208 is a BRAF V600E inhibitor ,and HLX10 is an anti-PD-1 monoclonal antibody.
223786725|NCT01990469|DRUG|Gemigliptin|DPP-4 inhibitor
223786726|NCT01990469|DRUG|Gemigliptin placebo|Placebo of Gemigliptin
223786727|NCT02096653|PROCEDURE|X-ray SI joint steroid injection|Injection of steroid and local anesthetic into the joint cavity using fluoroscopic guidance
223702902|NCT03814473|OTHER|Diet|"Participants provided with a brochure providing a thorough description of the diet, \~8 example recipes for each meal (i.e. breakfast, lunch, dinner, and snacks) included as a sample menu, and guidance to assist in shopping and self-preparation of food for the prescribed diet and to improve adherence. Diet consisted of following the popular paleolithic diet"
223702903|NCT02096237|DEVICE|IgE adsorber|Two plasma volumes of each patient in the apheresis group will be treated per session
223702904|NCT06382831|DRUG|Dexmedetomidine|Opioid free anesthesia
223702905|NCT06382831|DRUG|Fentanyl|Control given Opioid balanced anesthesia
223702906|NCT02004600|PROCEDURE|Photodynamic therapy (PDT)|1 session of Photodynamic therapy (PDT) on epidermis dysplasia
223702907|NCT04901676|DRUG|Leronlimab|Leronlimab 700 mg (first dose) followed by weekly 350 mg
223702908|NCT04901676|DRUG|Placebo|Placebo
223702909|NCT01771042|OTHER|Dietary weight loss at 25% energy deficit|Dietary weight loss at 25% energy deficit. Dietary macronutrient content will comprise 25% protein, 30% fat and 45% carbohydrate.
223702910|NCT01786148|BEHAVIORAL|mobile phone application|
223702911|NCT03388931|RADIATION|Radiation Therapy|Increased radiation therapy dose
223702912|NCT03388931|COMBINATION_PRODUCT|Chemotherapy|Standard-of-care chemotherapy with treatment regimen to be determined by the treating physician
223702913|NCT01356927|DRUG|DMPA|DMPA 150 mg IM given on the day of mifepristone 200 mg po for medical abortion
223702914|NCT01356927|DRUG|Etonogestrel implant|Etonogestrel implant placed at the time of mifepristone 200 mg po for medical abortion
223702915|NCT00675259|DRUG|bevacizumab|bevacizumab 10 mg/kg on days 1 and 15 administered every 28 days \[1 cycle\] for 5 cycles
223702916|NCT00675259|DRUG|carboplatin|AUC 2 IV on days 1, 8, and 15
223702917|NCT00675259|DRUG|nab-paclitaxel|100 mg/M2 IV
223702918|NCT00675259|PROCEDURE|Surgery|lumpectomy or mastectomy along with axillary lymph node dissection approximately 4-5 weeks after completion of NCT.
223702919|NCT00675259|DRUG|Adjuvant chemotherapy|All hormone receptor positive patients will receive endocrine therapy. All patients will receive 6 months of adjuvant bevacizumab at 15 mg/kg IV every 3 weeks. If using an adjuvant anthracycline-containing regimen then bevacizumab will be administered ≥ 3 weeks after completing the regimen.
223702920|NCT00468468|BEHAVIORAL|CHESS (Comprehensive Health Enhancement Support System) and Human Cancer Mentor|computer based education and support
223702921|NCT01384942|BEHAVIORAL|Meaning-Based Bereavement Group|A 12 week bereavement counselling group with tasks and themes that focus on re-constructing meaning following death.
223702922|NCT01384942|BEHAVIORAL|Conventional Bereavement Group|An 8 week traditional bereavement group that follows a more conventional approach to grief support.
223786728|NCT02096653|PROCEDURE|Landmark-guided SI steroid injection|Injection of steroid into the joint area based on palpation. The injection may be inside the joint (intra-articular) or outside the joint in the ligaments (extra-articular)
223786729|NCT06114446|OTHER|simulation group|Participants will be educated with simulation manikin for postoperative nursing care of a patient who underwent colorectal surgery
223786730|NCT06114446|OTHER|immersive virtual reality|Participants will be educated with immersive virtual simulation f for postoperative nursing care of a patient who underwent colorectal surgery
223786731|NCT06114446|OTHER|observation|All participants who participate in simulation or immersive virtual arms will be observed to assess postoperative nursing care skills
223786732|NCT04488536|DIAGNOSTIC_TEST|Clinical Frailty Scale|Frailty assessment
223786733|NCT00518024|PROCEDURE|Repetitive Transcranial Magnetic Stimulation (rTMS)|Bilateral Theta Burst Stimulation
223786734|NCT05520476|DEVICE|Neuroliten MVP system|The Neuroliten MVP system will be an App that gets uploaded to the patients iPhone from the App Store.
223786735|NCT00922493|OTHER|inspiratory muscle training|"Protocol of inspiratory muscle training using threshold IMT®: After the MIP was measured, inspiratory muscle training was initiated. The Threshold-IMT® device of a linear pressure load produces a resistance to inspiration through the use of a flow-independent one-way valve. During expiration there is no resistance because the unidirectional valve opens, while during inspiration the valve closes, becoming hard due to the resistance of the spring. The suggested protocol was: initial load of 30% of the M24, increasing daily by 10%, with training for five minutes, twice a day, seven times a week in the period from the beginning of the weaning from the MV until the extubation of the patient.~An essential factor was the use of supplemental oxygen (O2) as needed by the patient. The patients were in DD with fowler 45º."
223786736|NCT03756181|BEHAVIORAL|Five-week MSC program (MSC5wk)|This program adaptation will consist of conducted meditative practices, discussions, and background information within a group setting of no more than 25 students per group. The facilitator may discuss the student's experience and encourage group sharing within the course of the session. These discussions will reinforce the guiding principles of mindfulness meditation. There will also be sessions dedicated to incorporating or mindfulness in daily life, with more detailed instructions, as well as encouraging a 30- minute daily home practice.
223786737|NCT01494779|DRUG|Somatropin|single subcutaneous dose of 5mg
223786738|NCT01494779|DRUG|Somatropin|single subcutaneous dose of 5mg
223786739|NCT03970109|DRUG|ANS-6637|200 mg (given as 2 x 100 mg tablet) and 600 mg (given as 2 x 300 mg tablet) once a day
223786740|NCT03970109|DRUG|Placebo oral tablet|Placebo oral tablet
223786741|NCT04323436|DRUG|Spartalizumab|Concentrate for solution for infusion
223786742|NCT04323436|DRUG|Capmatinib|Film-coated tablet
223786743|NCT04323436|DRUG|spartalizumab placebo|dextrose 5% in water (D5W) for infusion
223786744|NCT03578900|DRUG|Xeros|
223786745|NCT03578900|DRUG|Citric Acid based Mouthwash|
223786746|NCT05853094|PROCEDURE|Ileostomy|Protective loop ileostomy after low anterior resection
223786747|NCT05853094|PROCEDURE|Transverse colostomy|Protective loop transverse colostomy after low anterior resection
223786748|NCT05713318|DRUG|HH-120 nasal spray|Nasal spray daily doses of HH-120 4 times added on SOC for 6 consecutive days.
223786749|NCT05713318|DRUG|HH-120 nasal spray|Nasal spray daily doses of HH-120 8 times added on SOC for 6 consecutive days.
223786750|NCT05713318|DRUG|Placebo Comparator|Nasal spray daily doses of placebo 4 times added on SOC for 6 consecutive days.
223786751|NCT05713318|DRUG|Placebo Comparator|Nasal spray daily doses of placebo 8 times added on SOC for 6 consecutive days.
223786752|NCT03662945|OTHER|Mobile Geriatric Team intervention|Person-centred intervention based on Comprehensive Geriatric Assessment
223786753|NCT01745263|DRUG|Vitamin D3|2000 IU/d
223786754|NCT01745263|DRUG|Omega 3 fatty acids|"Ratio EPA:DHA = 1:2~1 g/d"
223786755|NCT01745263|PROCEDURE|Strength Home Exercise|
223786756|NCT01745263|PROCEDURE|Flexibility Home Exercise|
223786757|NCT05372601|DIETARY_SUPPLEMENT|Relax+|Prebiotics, daily administered
223786758|NCT05372601|DIETARY_SUPPLEMENT|Maltodextrin|Placebo, daily administered
223786759|NCT05860322|DIETARY_SUPPLEMENT|Inulin|"Inulin is a water soluble non-digestible carbohydrate, and it is available in more than 36,000 species of plants. It is often used as dietary fiber and has obtained the Generally recognized as safe status (GRAS) by the Food and Drug Administration (FDA)."
223786760|NCT05860322|OTHER|Placebo|Placebo control
223786761|NCT04876508|OTHER|Accupressure|Patients in the experimental group will be given acupressure once a day for 7 consecutive days. Acupressure application will be applied by researchers who have been trained and certified on this subject. While the patients are in supine position, pressure will be applied to each acupressure point around the navel, respectively, Zhongwan (CV12), Guanyuan (CV4) and Tianshu (ST25) for 2 minutes for a total of 6 minutes.
223786762|NCT04781764|PROCEDURE|surgery|surgery
223786763|NCT02495753|PROCEDURE|Vaginal Cleansing|The vagina will be prepped in two passes with sponge sticks soaked in 1% povidone-iodine solution from a prepackaged sterile pouch.
223786764|NCT02495753|PROCEDURE|Abdominal Cleansing|The abdomen will be cleansed using chlorhexidine or betadine according to surgeon's preference prior to cesarean.
223786765|NCT00650546|DRUG|Exenatide|5 mcg twice a day titrated to 10 mcg twice a day
223786766|NCT00839072|DRUG|Trazodone HCl|100 mg immediate-release tablet, dosing q8h
223786767|NCT00839072|DRUG|Trazodone HCl|300 mg extended-release caplet, single dose
223786768|NCT05330962|OTHER|Framingham study cardiovascular disease 10-years risk assessment score|A personal interview questionnaire
223786769|NCT04894604|DEVICE|Avance® Solo NPWT System|Application of the Avance® Solo NPWT System on up to 34 study Subjects, in accordance with the IfU for up to 14 days.
223786770|NCT00139750|DRUG|CP-526,555 (varenicline)|
223786771|NCT04207190|DRUG|Gemtuzumab Ozogamicin|Given IV
223786772|NCT04207190|OTHER|Quality-of-Life Assessment|Ancillary studies
223786773|NCT04207190|OTHER|Questionnaire Administration|Ancillary studies
223786774|NCT04207190|DRUG|Talazoparib|Given PO
223786775|NCT04207190|DRUG|Talazoparib Tosylate|Given PO
223786776|NCT02936557|DRUG|BAY987521|"Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.~(Formulation Code:Z09-054)"
223786777|NCT04783753|DRUG|EDP-514|Subjects will receive EDP-514 on Days 1 and 14
223786778|NCT04783753|DRUG|EDP-514|Subjects will receive EDP-514 on Days 1 and 23
223786779|NCT04783753|DRUG|EDP-514|Subjects will receive EDP-514 on Days 1 and 8
223786780|NCT04783753|DRUG|Itraconazole|Subjects will receive itraconazole QD for 14 days
223786781|NCT04783753|DRUG|Carbamazepin|Subjects will receive carbamazepine BID for 23 days
223786782|NCT04783753|DRUG|Quinidine|Subjects will receive quinidine BID for 8 days
223786783|NCT04100772|BIOLOGICAL|13-Valent Pneumococcal Polysaccharide Conjugate Vaccine（CRM197,TT）|0.5mL,Intramuscular other name:PCV13i
223786784|NCT04100772|BIOLOGICAL|13-Valent Pneumococcal Polysaccharide Conjugate Vaccine|0.5mL,Intramuscular other name:Prevnar
223786785|NCT02635841|DRUG|Deferiprone|Ferriprox (deferiprone) 100 mg/mL oral solution
223786786|NCT01458574|DRUG|Placebo|Placebo 10 mg orally (PO) twice a day (BID)
223786787|NCT01458574|DRUG|CP690,550|CP-690,550 5 mg orally (PO) twice a day (BID)
223786788|NCT01458574|DRUG|CP-690,550|CP-690,550 10 mg orally (PO) twice a day (BID)
223786789|NCT02125786|RADIATION|Irradiation|Radiation therapy on this protocol will be based on extent of disease, extent of resection and location. The allowed treatment modalities include conformal or intensity-modulated radiation therapy using photons or proton therapy using double-scattering or spot-scanning methods. The general goal is to initiate radiation therapy within 12 weeks of last surgery performed at the time of recurrence.
223786790|NCT02125786|PROCEDURE|Surgery|When applicable, surgery will be used to remove metastases. The goal of surgery is to achieve gross total resection of all imaging visible residual tumor.
223786791|NCT02125786|DRUG|^1^8F-Fluorodeoxyglucose|This is a contrast media that will be given intravenously to aid in tumor visualization.
223786792|NCT02125786|DRUG|^1^1C-methionine|This is a contrast media that will be given intravenously to aid in tumor visualization.
223786793|NCT02125786|DEVICE|Photon therapy|Participants will receive one or both: Photon or proton therapy.
223786794|NCT02125786|DEVICE|Proton therapy|Participants will receive one or both: Photon or proton therapy.
223786795|NCT00582582|DRUG|Docetaxel plus doxercalciferol|Docetaxel 35mg/m2 IV weekly x3 every 4 weeks plus Doxercalciferol 10mcg orally every day
223786796|NCT00582582|DRUG|Docetaxel plus placebo|Docetaxel 35mg/m2 IV weekly x3 every 4 week cycle plus placebo taken orally every day
223786797|NCT03943368|DEVICE|Ceevra Reveal|3D Digital models generated using Ceevra Reveal are viewed by surgeons in connection with the case in addition to source MR image.
223786798|NCT01042457|DRUG|Mycophenolate mofetil|Drug : Mycophenolate Mofetil. Starting doses : 1000-1500 mg/day with titration based on Mycophenolic 1-hour post dose level.
223786799|NCT00870779|DRUG|5-aminolevulinic acid|20mg/kg 3 hours prior to surgery
223786800|NCT06288815|DIETARY_SUPPLEMENT|Oral fluid|"Postoperation~* Off IV fluid immediately postoperative~* Allow patients drink oral fluid as protocol for 24hr"
223786801|NCT06288815|DIETARY_SUPPLEMENT|IV fluid|"Postoperation~* IV fluid replacement as protocol for 24hr~* Allow patients drink oral fluid as usual"
223786802|NCT05658861|OTHER|Milk containing A1 and A2 beta-casein|Single dose of commercial milk
223786803|NCT05658861|OTHER|Milk containing only A2 beta-casein|Single dose of A2 milk
223786804|NCT04867564|DIAGNOSTIC_TEST|Echocardiography|Traditional echocardiography and speckle tracking echocardiography (STE) before and 1, 6, and 12 months after RT
223786805|NCT03445468|BIOLOGICAL|IL-YANG Quadrivalent Influenza Vaccine|A single 0.5mL dose administrated as an intramuscular injection.
223786806|NCT03445468|BIOLOGICAL|IL-YANG Flu Vaccine Pre-filled Syringe|A single 0.5mL dose administrated as an intramuscular injection.
223786807|NCT03691805|DEVICE|tDCS|The participants will receive anodal tDCS (transcranial direct current stimulation) of the right dorsolateral prefrontal cortex for 20 minutes on five consecutive days.
223786808|NCT03691805|DEVICE|Sham tDCS|The participants will receive sham tDCS (transcranial direct current stimulation) of the dorsolateral prefrontal cortex for 20 minutes on five consecutive days.
223786809|NCT01682837|DRUG|Potassium chloride powder|1 sachet mixed with 250 ml water (providing 20 meq K) given at breakfast and again dinner, for a total of 40 meq K/day, for 4 weeks
223786810|NCT01682837|DRUG|Potassium citrate powder|1 sachet mixed with 250 ml water (providing 20 meq K) given at breakfast and dinner, for a total of 40 meq K/day, for 4 weeks
223786811|NCT01682837|DRUG|Potassium magnesium citrate powder|1 sachet mixed with 250 ml water (providing 20 meq K) given at breakfast and dinner, for a total of 40 meq K/day, for 4 weeks
223786812|NCT01682837|DRUG|Placebo|1 sachet mixed with 250 ml water given at breakfast and dinner, for a total of 2 sachets/day, for 4 weeks
223786813|NCT03787667|DIAGNOSTIC_TEST|CT or MRI based Radiomics|Radiomic features were extracted from enhanced CT or MRI of colorectal cancer.
223786814|NCT05528120|DRUG|VC004 Capsules|Oral administration after fasting/high-fat meal
223786815|NCT05528120|DRUG|VC004 Capsules|Oral administration after high-fat/fasting meal
223786816|NCT05872633|BEHAVIORAL|Online self-management intervention|
223786817|NCT05872633|OTHER|Care-as-usual|
223786818|NCT01638923|DRUG|EV/DNG (Qlaira, Natazia, BAY86-5027)|2 days of 3 mg estradiol valerate (EV);5 days of 2 mg EV + 2 mg dienogest (DNG);17 days of 2 mg EV + 3 mg DNG;2 days of 1 mg EV;2 days of placebo. A blister card consists of 28 pills, taken orally once a day for 7 cycles of 28 days each.
223786819|NCT01638923|DRUG|placebo|Matching placebo to be taken orally daily for 7 cycles of 28 days each.
223786820|NCT04336202|RADIATION|External beam radiotherapy + Endorectal brachytherapy|In this study, all participants will receive a treatment of external beam radiotherapy without chemotherapy, which will be followed by three (3) treatments of endorectal brachytherapy with the new applicator.
223786821|NCT01388387|OTHER|Tacrolimus pharmacokinetics|tacrolimus pharmacokinetics over 12 hours
223786822|NCT01494051|BEHAVIORAL|Diet counseling|Subjects counseled how to follow either the high carbohydrate diet or the high protein diet for 4 months at home.
223786823|NCT03331120|DEVICE|ambulatory mirror image functional re-training through wearing 3D adjustable cervicothoracic Posture Corrective Orthotic(CTPCO)|Ambulatory a mirror image functional re-training This way of functional training will deliver via the use of adjustable cervicothoracic orthosis with the patient walking at approximately 2-3 miles per hour on a standard, motorized treadmill. The brace will reverse the abnormal posture according to the 3D posture analysis data. To facilitate tissue remodeling by reverse posture training, this called mirror image exercise.then the ambulatory exercises by using treadmill will be performed while the patient's mirror image posture will be held by the adjustable orthosis, ambulatory exercises for 20 minutes by using treadmill Based on Harrison et al and Hawes et al., approach, this program will be repeated 3 Times /week for 10 weeks.
223786824|NCT01736826|BIOLOGICAL|Bloodwork, baseline|36 ml of blood are drawn at baseline (last month of pregnancy for groups P and T2, inclusion for group T1) in order to quantify the following: plasma free DNA concentration, plasma nucleosome concentration, hemoglobin, platelets, leukocytes, polynuclear neutrophils, mean corpuscular volume, monocytes, mean corpuscular hemoglobin, lymphocytes, polynuclear eosinophils, polynuclear basophils, D-Dimers, Fibrin monomers, Trophoblast microparticles, Angiogenic marker CD146.
223786825|NCT01736826|BIOLOGICAL|Blood work, Months 1 & 2|36 ml of blood are drawn at 1 \& 2 months after inclusion in order to quantify the following: plasma free DNA concentration, plasma nucleosome concentration, hemoglobin, platelets, leukocytes, polynuclear neutrophils, mean corpuscular volume, monocytes, mean corpuscular hemoglobin, lymphocytes, polynuclear eosinophils, polynuclear basophils, D-Dimers, Fibrin monomers, Trophoblast microparticles, Angiogenic marker CD146.
223786826|NCT01736826|BIOLOGICAL|Bloodwork, Months -1 to -6|36 ml of blood are drawn at the third, fourth, fifth, sixth, seventh and eight months of normal pregnancy (corresponding to months -1 to -6 before comparative baseline; this group is included in the study early during pregnancy)in order to quantify the following: plasma free DNA concentration, plasma nucleosome concentration, hemoglobin, platelets, leukocytes, polynuclear neutrophils, mean corpuscular volume, monocytes, mean corpuscular hemoglobin, lymphocytes, polynuclear eosinophils, polynuclear basophils, D-Dimers, Fibrin monomers, Trophoblast microparticles, Angiogenic marker CD146.
223786827|NCT02422277|DEVICE|LI-ESWT group|"The patients in this arm will be subjected to Penile LI-SWT in the following parameters: 6 to 12 sessions with 1500 shocks per session. Each session will comprise the application of 300 shock waves (energy intensity of 0.09 mJ/mm2) to each of five different sites on the penis: three along the penile shaft and two at the crura with Frequency: 4 HZ. Energy level: 8 mJ/mm2. Rate: 120 shocks per minute.~-Intervals: 2 treatment sessions per week for 3 weeks, then 3-weeks no-treatment interval, then 3-weeks treatment period of 2 treatment sessions per week."
223786828|NCT02422277|DRUG|PDE-5 inhibitors group|The patient in this arm will receive 50 mg of phosphodiesterase-5 inhibitors, oral intake once daily for 6 monthes.
223786829|NCT00424437|DRUG|Inhaled human insulin|
223786830|NCT03034148|DIAGNOSTIC_TEST|Platelet Acetyl Coenzyme A Carboxylase analysis in CAD|
223786831|NCT05706805|DEVICE|Naviscore|Patients in whom treatment with (Naviscore) has been attempted
223786832|NCT03388580|PROCEDURE|bronchoalveolar lavage (BAL)|clinically indicated, elective BAL
223786833|NCT02959073|OTHER|Symptom Recording|Subjects muss record their allergic symptoms after contact with their cats
223786834|NCT04728243|OTHER|WHO QualityRights e-training|The WHO QualityRights online training aims to increase knowledge about the rights of people with psychosocial disabilities and change negative attitudes towards these persons and their role as rights holders. Furthermore, the training provides mental health professionals with the skills necessary to support people with psychosocial disabilities to advocate for their rights. The WHO QualityRights online training includes five core modules: 1) Human rights; 2) Mental health, disability, and human rights; 3) The right to health and recovery; 4) Legal capacity and the right to decide; 5) Free from coercion, violence, and abuse. Each module is composed of presentations, videos, interactive exercises, and forum discussions involving all participants. In the online training forum discussions, particular attention will be given to issues relevant to the Ghanaian context.
223786835|NCT04728243|OTHER|WHO COVID-19 online training|The WHO novel coronavirus 2019 online training series provides a general introduction to COVID-19 and similar respiratory infections and information on what facilities and professionals should be doing to prevent and respond to COVID-19 cases. The training is similar in length to the WHO QualityRights training (13 h 15 min vs. 19 hours) and is intended for health professionals and other stakeholders.
223786836|NCT05427786|DRUG|Nicorandil|Administer 8cc or more of the prescribed drug according to randomization into the coronary artery before starting balloon therapy. The stent treatment method follows the standard treatment method.
223786837|NCT04782323|DRUG|aQII-1|Biological/Vaccine: Investigational aQII-1 Investigational MF59 Adjuvanted Quadrivalent Influenza vaccine, containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO (World Health Organization) for quadrivalent vaccines for the respective season.
223786838|NCT04782323|DRUG|aQII-3 Investigational|Biological/Vaccine: Investigational aQII-3 Investigational MF59 Adjuvanted Quadrivalent Influenza vaccine, containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO (World Health Organization) for quadrivalent vaccines for the respective season.
223786839|NCT04782323|DRUG|aQII-6 Investigational|Biological/Vaccine: Investigational aQII-6 Investigational MF59 Adjuvanted Quadrivalent Influenza vaccine, containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO (World Health Organization) for quadrivalent vaccines for the respective season.
223786840|NCT04782323|OTHER|aQII-7 Investigational|Biological/Vaccine: Investigational aQII-7 Investigational MF59 Adjuvanted Quadrivalent Influenza vaccine, containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO (World Health Organization) for quadrivalent vaccines for the respective season.
223786841|NCT04782323|DRUG|aQII-9 Investigational|Biological/Vaccine: Investigational aQII-9 Investigational MF59 Adjuvanted Quadrivalent Influenza vaccine, containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO (World Health Organization) for quadrivalent vaccines for the respective season.
223786842|NCT04782323|DRUG|aQII-10 Investigational|Biological/Vaccine: Investigational aQII-10 Investigational MF59 Adjuvanted Quadrivalent Influenza vaccine, containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO (World Health Organization) for quadrivalent vaccines for the respective season.
223786843|NCT04782323|DRUG|aQII-11 Investigational|Biological/Vaccine: Investigational aQII-11 Investigational MF59 Adjuvanted Quadrivalent Influenza vaccine, containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO (World Health Organization) for quadrivalent vaccines for the respective season.
223786844|NCT04782323|DRUG|Licensed QII Active Comparator|Biological/Vaccine: Licensed QII Licensed Quadrivalent Influenza vaccine, containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO (World Health Organization) for quadrivalent vaccines for the respective season.
223786845|NCT06265116|OTHER|One-step universal adhesive|Each patient will receive a class II restoration using the corresponding group adhesive
223786846|NCT04572256|DRUG|Montelukast|The novel use of oral montelukast offers the potential of a disease modifying treatment to prevent irreversible cartilage loss after ACL injury. 10mg of oral Montelukast will be taken daily for 6 months post surgery.
223786847|NCT04572256|DRUG|Placebo|An oral placebo will be taken daily for 6 months post surgery.
223786848|NCT06667180|DEVICE|Low-intensity TMS|Low-intensity TMS will be applied for 4 days, 5 daily sessions of 200 s with 10-minute intersession intervals at a field intensity of 2-4 mT and frequency of 50 Hz in theta bursts.
223786849|NCT06667180|DEVICE|Transcranial Magnetic Stimulation Sham|The control group will receive the simulation of low-intensity TMS without magnetic field induction.
223786850|NCT05699759|DRUG|K8|Subjects will have the treatment administered intravitreally (one eye only) using an injector system on a 24-gauge needle to deliver a cylindrical, 3 mm long, drug eluting pellet containing 300 µg of K8. Participants will be followed for 168 days (24 weeks).
223786851|NCT06053489|OTHER|general anesthesia with remimazolam|general anesthesia with remimazolam in pediatric patients undergoing ophthalmic surgery
223786852|NCT05841017|BEHAVIORAL|Psychotherapy with Immersive Virtual Reality support.|Psychoeducational group intervention and cognitive behavioural therapy individual intervention.
223786853|NCT00820339|PROCEDURE|Selective Hepatic Vascular Exclusion|Inflow occlusion with extraparenchymal control of major hepatic veins results in total liver isolation from the systemic circulation but without interruption of caval flow.
223786854|NCT00820339|PROCEDURE|Pringle's Maneuver|Hepatic pedical clamping is performed by encircling the hepatoduodenal ligament with a tape and then applying a tourniquet or a vascular clamp until the pulse in the hepatic artery disappears distally.
223786855|NCT00677339|DRUG|L-arginine|L-arginine 6g orally daily
223786856|NCT00677339|DRUG|Vitamin D|Cholecalciferol 50000 IU once monthly orally
223786857|NCT00677339|DRUG|Placebo L-arginine|placebo L-arginine once daily
223786858|NCT00677339|DRUG|Placebo Vitamin D|placebo vitamin D orally once monthly
223786859|NCT02877485|DRUG|Triamcinolone Acetonide|2 sprays sprayed to both nostrils daily for 42 days.
223786860|NCT02877485|DRUG|Ayr saline nasal mist|110mcg (2 sprays) sprayed to both nostrils daily for 42 days.
223702923|NCT03845751|DRUG|HIFU hemi-ablation combined with ADT.|Hemi-ablation of the cancer-harbouring prostatic lobe will be carried out using HIFU energy. Short-term 3-month ADT will be administered concomitantly. Short-term ADT is administered as a single subcutaneous injection of 3-month depot of 22.5 mg of leuprolide acetate (luteinizing hormone-releasing hormone \[LHRH\] agonist). The ADT protocol starts within 1 month prior to the scheduled HIFU session
223786861|NCT06302764|DIAGNOSTIC_TEST|Qualitative & Quantitative Research|"1. Focused interviews - conducted by members of the appointed research team to recognize the issues faced by emergency medical staff in Poland, Ukraine, Portugal, and Spain with the aim of preparing the measurement framework.~2. Online questionnaire surveys - conducted using the Qualtrics platform (available in different, language versions - Polish, Ukrainian, Portuguese, and Spanish)."
223786862|NCT02835014|BEHAVIORAL|Mental Health Symptoms|Adolescents with T1DM will be asked to complete PHQ9 (depression screening), SCARED (anxiety screening) and UCLA PTSD (trauma screening)
223786863|NCT02835014|BEHAVIORAL|Self-efficacy regarding self-care and diabetes management|Adolescents with T1DM will be asked to complete the SEDM to asses self-efficacy for diabetes management
223786864|NCT02835014|BEHAVIORAL|Parenting Styles|Parents of adolescents with T1DM will be asked to complete the PSDQ to asses parenting style
223786865|NCT01700816|DEVICE|Bright light therapy|The light box will be placed vertically on a patient table or bed side 2.5 feet away from the user's eyes daily from 8 am to 8:30 am.
223786866|NCT01700816|DEVICE|Sham light|The light box will be placed vertically on a patient table or bed side 2.5 feet away from the user's eyes daily from 8 am to 8:30 am.
223786867|NCT03832192|BEHAVIORAL|care.coach Avatar (HELP-Protocolized)|care.coach human-in-the-loop avatar system with software-directed protocols based on the Hospital Elder Life Program (HELP).
223786868|NCT06004817|OTHER|evaluation of clinical severity|evaluation of clinical severity
223786869|NCT03738150|BIOLOGICAL|Sotatercept|Sotatercept injection
223786870|NCT03738150|OTHER|SOC|SOC therapy refers to combination therapy consisting of drugs from two or more of the following drug classes: an endothelin-receptor antagonist (ERA), a phosphodiesterase 5 (PDE5) inhibitor, a soluble guanylate cyclase stimulator, and/or a prostacyclin analogue or receptor agonist.
223786871|NCT05268796|BEHAVIORAL|Behavior therapy|Caregivers will be coached either in-person or via telehealth to implement function-based behavioral treatment in 1-hour sessions each week with their child over 12 weeks.
223786872|NCT05268796|OTHER|Psychoeducation|Caregivers will complete online education modules in 1-hour sessions each week over 12 weeks.
223786873|NCT06574256|OTHER|Chemotherapy symptom Management Online Education|"Randomization was achieved and data collection began. Patients were given the Chemotherapy Symptom Management Education Booklet and were informed that they would be contacted by phone.~In the second and third stages of data collection, they were called by phone on the 7th day after receiving chemotherapy treatment. The symptoms experienced by the patient were evaluated with the N-SDS and the quality of life was evaluated with the EORTC QLQ-C30. Online nursing education videos were sent to the women in the intervention group regarding the symptoms they experienced. The practices they performed from the suggestions in the education videos and education booklets sent were recorded on the nurse follow-up form.~In the fourth stage, the practices specified in the third stage were repeated on the 7th day after the third chemotherapy course, and at this stage, the satisfaction of the women in the intervention group with the online education was evaluated."
223786874|NCT06572254|OTHER|Early Childhood Development Newborn Parenting Education Program|Investigators will be adapting the model used here at the tertiary care of newborn parenting which investogators have developed based on the nurturing care framework and keys to the caregiving framework. Both models have shown reliable evidence of their effectiveness.
223786875|NCT04642105|DEVICE|Sensor-Dot and Plug 'n Patch system|We will use a small, unobtrusive wearable (Sensor-Dot) to measure different biosignals (EEG, ECG, EMG, motion, skin temperature, respiration and oxygen saturation) for up to one year using newly developed skin adhesives and patches (Plug 'n Patch system)
223786876|NCT01903447|DRUG|SSRI|
223786877|NCT01903447|BEHAVIORAL|CBT|
223786878|NCT01524640|BIOLOGICAL|Killed Bivalent (O1 and O139) whole cell oral cholera vaccine|1.5 ml single dose oral administration on day 0 and day 14
223786879|NCT01524640|BIOLOGICAL|Placebo|1.5 ml oral administration on day 0 and day 14
223786880|NCT05901129|OTHER|Serratus posterior superior intercostal plane block (SPSIPB)|Serratus posterior superior intercostal plane block is the intervention used in this study. It was performed when the patient is in lateral decubitis position. A high frequency (7-12 MHz) linear transducer of the ultrasound device is placed at the spinae scapula level in the transverse plane, and the upper medial border of the scapula, the trapezius muscle, rhomboid muscle, serratus posterior superior muscle (SPSM) and the second and third ribs are visualized. The sonovisible needle is then advanced immediately medial to the scapula, aiming for the area between the second and third ribs in order to reach the fascial plane between the SPSM and intercostal muscles. After contact of the needle with the rib gently, 1-2mL of saline is used to confirm the correct plane, and a total of 30 mL of 0.25% bupivacaine is administered to the superficial to the intercostal muscle.
223786881|NCT00745927|OTHER|CO2 insufflations|CO2 insufflations during whole procedure of colonoscopy
223786882|NCT06039332|PROCEDURE|Fitting of the audioprocessor with the auditory implant BCI602|to compare the performance with BB system in two fitting-configurations (active comparator: DSL v5, experimental: DSL-BCD) using audiometric and subjective measures
223786883|NCT05774808|PROCEDURE|Aortic valve replacement|An aortic valve prosthesis is surgically implanted to treat AR
223786884|NCT05774808|PROCEDURE|Mitral valve annuloplasty|Surgical repair of the mitral valve in which a prosthetic ring is implanted to treat MR
223786885|NCT03556319|DIETARY_SUPPLEMENT|2-HOBA|2-HOBA is a compound found in buckwheat and is given as 2-HOBA acetate
223786886|NCT03556319|DIETARY_SUPPLEMENT|Placebo|Placebo Comparator
223786887|NCT03494010|OTHER|Observation|There is no intervention. Patients will receive the HCL system as part of their clinical care.
223786888|NCT05122845|BIOLOGICAL|Blood sample|"Blood test (10 tubes of 5mL) :~\- 6 tubes for : complete blood count, platelets, reticulocyte count, TP-INR, AST, ALT, GGT ferritin, serum iron, CRP, transferrin, soluble transferrin receptors, transferrin saturation coefficient enzymatic creatinine, MDRD, ionogram calcemia, phosphoremia, PTH, 25 (OH) D3, 1.25 (OH) 2D3.~2 dry tubes 2 tube EDTA"
223786889|NCT02450994|DRUG|Dexamethasone|
223786890|NCT02450994|DRUG|Placebo|
223786891|NCT00724971|DRUG|Inotuzumab Ozogamicin (CMC-544)|1.8 mg/m2, IV on day 2 of each 28 day cycle; up to 8 cycles unless PD, unacceptable toxicity, or subject's refusal occurs.
223786892|NCT00724971|DRUG|Rituximab (Rituxan)|375 mg/m2, IV on day 1 of each 28 day cycle; up to 8 cycles unless PD, unacceptable toxicity, or subject's refusal occurs.
223786893|NCT00338338|DRUG|Lacidipine 4 or 6 mg (oral)|
223786894|NCT00338338|DRUG|Amlodipine 5 or 10 mg(oral)|
223786895|NCT04701021|BIOLOGICAL|TENDU|The vaccine is administrated by subcutaneous injections, one injection per drug substance (four separate injections) consecutively.
223786896|NCT01849367|DEVICE|Eldith Neuroconn tDCS device|
223786897|NCT00587145|DRUG|S-1,Docetaxel|"* S-1 80 mg/m2/day every 12-h p.o. on days 1(evening)-15 (morning)~* Docetaxel 35 mg/m2 mixed in d5w 250 ml iv over 60-min on days 1 and 8"
223786898|NCT05843968|DRUG|Rituximab|"2 doses of rituximab 375 mg/m\^2(maximum 500mg/day) at 6 months intervals.~Half an hour before rituximab infusion: oral acetaminophen 15mg/kg, oral or intramuscular antihistamine, methylprednisolone 2mg/kg IV. Trimethoprim-sulfamethoxazole should be administered orally from the initiation of rituximab therapy until peripheral-blood B cell recovery to prevent pneumocystis infection."
223786899|NCT05843968|DRUG|Mycophenolate Mofetil|"Mycophenolate Mofetil 20-30 mg/kg/day BID,then adjust the dosage of drugs(maximum 2g/day) to maintian the concentration for MPA-AUC is 30-50μg.h/ml. Total duration:1year.~Steroids dose:1.5mg/kg(maximum 40mg) qod for 2 weeks and gradually taper by 0.3 mg/kg every 2 weeks"
223786900|NCT05446415|OTHER|Analyze basal expression incretin for immunolabeling and mRNA expression glucagon-like secretion peptide-1 (GLP-1) and peptide YY (PYY 3-36) incretins by L cells.|Preoperative and postoperative
223786901|NCT05658081|PROCEDURE|Kono-S group|patients in this arm will receive stapled Kono-S anastomosis after bowel resection
223786902|NCT05658081|PROCEDURE|Side-to-side group|patients in this arm will receive stapled antimesenteric isoperistaltic side-to-side anastomosis after bowel resection
223786903|NCT06206005|OTHER|Observational study|evaluate implant survival, peri-implant outcome of 4 implant retained mandibular OVD after 10 years of function.
223786904|NCT01692197|DRUG|E7070|400 mg/m2 intravenously over 1 hour on Day 1 and Day 8 every 3 weeks.
223786905|NCT01692197|DRUG|Idarubicin|8 mg/m2 by vein over 1 hour daily for 3 days (Days 9-11).
223702924|NCT04849923|OTHER|Strength training session|Conduct of an 8-week strength training intervention of key muscle-tendon groups associated with knee joint stability in the training-specific setting of each participant. Participants are randomly allocated into three study groups with increasing levels of loading (Group#1: no training, Group#2: 1 training per week, Group#3: 3 trainings per week) with the same number of subjects and gender distribution in each group (n=12 per group, 6F and 6M). The same guidelines for the warm-up and the type of exercises will be given prior to the intervention study to each participant. Participants are asked to record exercise load and volume as well as monitor training-related variables and 1RM using the iOS Strength Control app. Participants perform the strength training self-directedly in their chosen fitness/training facilities as it fits into their weekly routine. Contact to the study investigator is ensured at all times in case of questions.
223702925|NCT02935231|DRUG|Nicotine Replacement Therapy (NRT)|1-week free NRT (gum/patch) plus a card containing instruction and potential side effects.
223702926|NCT02935231|BEHAVIORAL|Minimal Cessation Advice (MCA)|Brief smoking cessation advice using AWARD model. AWARD: (1) Ask smoking habit; (2) Warn about smoking risk; (3) Advice to quit as soon as possible; (4) Refer to smoking cessation service; and (5) Do-it-again: if relapse/fail.
223702927|NCT02935231|OTHER|Health warning leaflet|An A4 double-side color leaflet containing shocking pictures of diseases associated with smoking.
223702928|NCT01089673|OTHER|data collection|retrospective data collection
223702929|NCT05916820|OTHER|Tanzberger Exercises|It consists of patients who will receive Tanzberger exercise 3 sessions per week for 4 weeks. e.g. Rolling on the ball forward, Back to back sitting.
223702930|NCT05916820|OTHER|Pelvic floor muscle training|It consists of patients who will pelvic floor muscles exercise 3 sessions per week for 4 weeks. e.g. Assisted heel drop, Bridge, Dead Bug, Bird DOG
223702931|NCT04131725|DEVICE|Cardiac Performance System (NSR)|Device: Cardiac Performance System Participants will be asked to wear the Cardiac Performance System, a non-invasive sensor device on their upper abdomen. The Cardiac Performance System monitoring device will continuously monitor cardiac function. The device will be worn at the time when Pulmonary Artery Catheter procedures are conducted.
223702932|NCT06157255|DRUG|AZD4604 Inhalation Powder, 1 mg|3 mg dose, inhaled, fasted
223702933|NCT06157255|DRUG|[14C]AZD4604 Solution for Infusion 6 μg/mL (NMT 37.0 kBq/5 mL)|30 μg, intravenous, fasted
223702934|NCT06157255|DRUG|[14C]AZD4604 Oral Solution, 4 mg (NMT 37.0 kBq)|4 mg, oral, fasted
223702935|NCT02969330|DEVICE|Stimulator|
223702936|NCT02969330|DIETARY_SUPPLEMENT|Glucose|300ml tap water with 75g glucose
223786906|NCT01692197|DRUG|Cytarabine|1.0 g/m2 by vein daily on Days 9 - 12 (age \<60 years) or Days 9 - 11 (age \> 60 years).
223786907|NCT01692197|DRUG|Dexamethasone|10 mg by vein daily for 3 - 4 days with cytarabine.
223786908|NCT06531954|DEVICE|Vagus nerve stimulation|Vagus nerve stimulation group: Vagus stimulation was applied bilaterally through the ear. taVNS was performed with the Vagustim device. The stimulation pulse width was 300 microseconds, the frequency was 10 Hz, and it was biphasic with a 20-minute duration. Electrodes were placed on the concha and tragus parts of the ear, and the current was increased through these electrodes until the participant felt pain.
223786909|NCT06531954|BEHAVIORAL|Breathing exercise|Breathing exercise group: The content of breathing exercises was planned as thoracic expansion exercises. These exercises were applied to the lower, middle, and upper lobes in 3 sets of 3x10 (90 times breathing in one area) and lasted for an average of 20 minutes. Participants were asked to inhale as deeply as possible into the relevant area, hold their breath for 3 seconds, and then slowly exhale the entire breath.
223786910|NCT03032692|DEVICE|SWORD|Both arms will perform two separate sessions consisting of one exercise - shoulder flexion with elbow flexion at 90 degrees - for 4 minutes in two experimental conditions: with and without biofeedback. Group 1 will perform the exercise with biofeedback first and without biofeedback after; group 2 performed the exercise in the opposite order. The SWORD system will be used to record movement data in both sessions.
223786911|NCT03032692|OTHER|Exercise with biofeedback|
223786912|NCT03032692|OTHER|exercise without biofeedback|
223786913|NCT00476944|PROCEDURE|Percutaneous Coronary Intervention (PCI)|
223786914|NCT02520934|DRUG|Miglustat|combine miglustat and ERT to see if neurologic manifestations can be improved
223786915|NCT02520934|DRUG|ERT|enzyme replacement therapy
223786916|NCT00147966|DRUG|rituximab|treatment with rituximab
223786917|NCT06037759|DIAGNOSTIC_TEST|Cardiac Biomarkers|Blood samples will be collected at baseline (within 6 weeks of dialysis start), at 6 months post-commencement and 12 months post-commencement of haemodialysis. The blood sampling will be mid-week samples taken at the dialysis start for haemodialysis patients, with a similar approach for the PD controls. For the CKD controls, the blood samples will be scheduled around routine clinic attendance, adhering where possible to the time intervals for HD cases and PD controls.
223786918|NCT06037759|DIAGNOSTIC_TEST|Lipidomics|Blood samples will be collected at baseline (within 6 weeks of dialysis start), at 6 months post-commencement and 12 months post-commencement of haemodialysis. The blood sampling will be mid-week samples taken at the dialysis start for haemodialysis patients, with a similar approach for the PD controls. For the CKD controls, the blood samples will be scheduled around routine clinic attendance, adhering where possible to the time intervals for HD cases and PD controls.
223786919|NCT06037759|DIAGNOSTIC_TEST|Proteomics|Blood samples will be collected at baseline (within 6 weeks of dialysis start), at 6 months post-commencement and 12 months post-commencement of haemodialysis. The blood sampling will be mid-week samples taken at the dialysis start for haemodialysis patients, with a similar approach for the PD controls. For the CKD controls, the blood samples will be scheduled around routine clinic attendance, adhering where possible to the time intervals for HD cases and PD controls.
223786920|NCT01615445|DRUG|Resveratrol|Group A: resveratrol 1000 mg (500 mg twice) daily for 1 week then by tolerance and safety 2000 mg (1 000mg twice) daily for 3 weeks, followed by no medication for two weeks and then placebo for twice daily for 4 weeks.
223786921|NCT01615445|DRUG|placebo|Participants will receive placebo daily for 4 weeks, followed by no medication for two weeks and then resveratrol 1 000 mg(500 mg twice) daily for 1 week, then by tolerance and safety 2 000 mg (1 000 mg twice) daily for three weeks.
223786922|NCT03939273|DRUG|Vancomycin Oral|500 mg thrice per day for seven days
223786923|NCT03939273|DRUG|Metronidazole Oral|500 mg thrice per day for seven days
223786924|NCT03939273|DRUG|Ciprofloxacin Pill|500 mg twice per day for seven days
223786925|NCT03939273|DRUG|Fluconazole Oral Product|200 mg once per day for six days
223786926|NCT03939273|DRUG|Placebos|seven day course of placebo tablets and capsules identical in appearance and number to active treatment
223786927|NCT04859166|PROCEDURE|Organoids|A part of the tumor of approximately 1 cm3 will be removed from the primary tumor.
223786928|NCT04397081|OTHER|HPV test results|The human papillomavirus (HPV) test detects the presence of the human papillomavirus, a virus that can lead to the development of genital warts, abnormal cervical cells or cervical cancer. The procedure includes taking samples of your cervical cells using a soft brush and a flat scraping device called a spatula. This doesn't hurt, and you may not even feel the sample being taken.
223786929|NCT02948985|OTHER|treated with FOLFIRI±cetuximab|Peripheral blood samples of 10 mL were collected from the patients for CTCs analysis and tumor marker in every cycle D0 and D8. Tumor response evaluation will be performed after four cycles of chemotherapy by CT/MRI based on RECIST. Clinical data, including tumor stage, metastatic organ, objective response, progression free survival, overall survival, etc, will be collected according to study protocol.The correlation of the RAS status on CTCs and the mutant gene in ctDNA to the therapeutic response will be evaluated.
223786930|NCT04463901|PROCEDURE|Pterygium excision|Partial conjunctiva and anterior tenon's membrane underneath will be removed after the excision of pterygium tissue.
223786931|NCT04463901|PROCEDURE|Intraoperative mitomycin C|Intraoperative mitomycin C (0.02%) will be applied for 5 minutes after pterygium excision.
223786932|NCT04463901|PROCEDURE|Conjunctival autograft|A conjunctival autograft will be applied to cover the conjunctival defect after pterygium excision.
223786933|NCT04463901|PROCEDURE|Limbal conjunctival autograft|A limbal conjunctival autograft will be applied to cover the conjunctival defect after pterygium excision.
223786934|NCT04532892|DIETARY_SUPPLEMENT|Meta 18.06 Day and Meta 18.06 Night|5 visits after screening (V0-V4), including questionnaires (V0-V2-V4), salivary tests (V0 \& V4) and calls for antistress advices and adverse events, concomitant medication reporting \& compliance (V1 \& V3)
223786935|NCT04532892|DIETARY_SUPPLEMENT|Placebo Meta 18.06 Day and Placebo Meta 18.06 Night|5 visits after screening (V0-V4), including questionnaires (V0-V2-V4), salivary tests (V0 \& V4) and calls for antistress advices and adverse events, concomitant medication reporting \& compliance (V1 \& V3)
223786936|NCT02578394|DRUG|Anakinra 100mg and Placebo Depo-Medrone|Anakinra 100mg injection S/C Day 1 to Day 5 and Placebo Depo-Medrone (Lipofundin 3mL) I/M Day 1. Anakinra is an interleukin-1 receptor antagonist. Placebo for Depo-Medrone placebo is Lipofundin MCT/LCT 10%.
223786937|NCT02578394|DRUG|Depo-Medrone 120mg and Placebo (Anakinra)|Depo-Medrone 120mg in 3mL. Placebo for Anakinra supplied from manufacturer. 120mg Depo-Medrone I/M Day 1 and Placebo Anakinra 100mg injection S/C Day 1 to Day 5.
223786938|NCT02804607|OTHER|questionnaire|
223786939|NCT03086447|DEVICE|Investigational Contact Lens|Senofilcon C Toric
223786940|NCT03086447|DEVICE|Marketed Contact Lens|Air Optix for Astigmatism
223786941|NCT00217698|DRUG|cisplatin|
223786942|NCT00217698|DRUG|gefitinib|
223786943|NCT00217698|DRUG|gemcitabine hydrochloride|
223786944|NCT02006030|DRUG|ADI-PEG 20|
223786945|NCT02006030|DRUG|Transarterial chemoembolization|
223786946|NCT00847873|BEHAVIORAL|substance abuse/domestic violence treatment|This intervention is comprised of 16 sessions of cognitive behavioral therapy. 8 sessions are addressing partner violence and 8 sessions are addressing substance abuse
223786947|NCT00847873|BEHAVIORAL|Cognitive behavioral therapy addressing substance abuse|This intervention is comprised of 16 sessions of cognitive behavioral therapy addressing substance abuse.
223786948|NCT04136938|OTHER|Social marketing campaign|A social marketing campaign of prevention workshop sessions will be performed.
223786949|NCT06045624|DRUG|OR-101 (Single ascending dose)|SAD participants will receive either placebo or one of planned doses levels of 15mg, 45mg, 150mg, 450mg, 900mg, 1500mg OR-101 in dose escalating manner in cohorts 1-6.
223786950|NCT06045624|DRUG|OR-101 (Food effect)|Food effect participants (8 subjects in 9 cohorts) will only receive OR-101with a high fat meal prior to administration and subjects in corresponding dose under fasted condition will serve as their reference group
223702937|NCT02001103|DRUG|Memantine|"Pills of memantine, including 5 or 10 mg, all prepared in the same capsules as used in the placebo arm.~The Memantine 10 mg intervention arm will take 1 capsule of memantine and 1 capsule of placebo going into week 3."
223702938|NCT02001103|DRUG|Placebo|Capsules with starch inside manufactured using the same capsules as used in the other 2 arms.
223702939|NCT03505190|DRUG|RO7062931|RO7062931 will be administered SC in single ascending doses with starting of 0.3 mg/kg and subsequent doses of 1.0 mg/kg, 2.0 mg/kg and 3.0 mg/kg, respectively. Additional (optional) dose of 4.0 mg/kg may be administered based on safety, tolerability and PK data.
223702940|NCT03505190|DRUG|Placebo|Matching placebo will be administered subcutaneously (SC).
223702941|NCT03488355|OTHER|Modified laboratory report|"Report from microbiology laboratory: This POSITIVE urine culture collected from an indwelling catheter may represent asymptomatic bacteriuria or urinary tract infection. If urinary tract infection is suspected clinically, please call the microbiology laboratory for identification and susceptibility results."
223702942|NCT00000209|DRUG|Buprenorphine|
223702943|NCT06512597|BEHAVIORAL|Primary Intervention for Combination Therapy - IBD Coping Strategies Program|psychosocially credible treatments each comprised of seven 45-minute sessions over a 12-week period, delivered via telemedicine.
223702944|NCT06512597|BEHAVIORAL|Time and Attention Control - IBD Support Program|psychosocially credible treatments each comprised of seven 45-minute sessions over a 12-week period, delivered via telemedicine.
223702945|NCT04361825|DRUG|Durvalumab|Durvalumab 1500mg via IV administered for every 4weeks(fixed dosing for subjects \> 30 kg body weight) in Day 1 of each cycle and AZD 6738 240mg bid per os administered in each cycle days 1 and 7. One cycle is consisted of 28 days.
223702946|NCT01511965|OTHER|autologous (cellular therapy)|The skin sample, the preparation and implementation of the epidermal cells, are conducted on one day. A review of selected lesions is performed and a photograph. Second, are performed successively in a single day the collection of thin skin, preparing the cell suspension, a desepidermisation laser Erbium: YAG lesions of vitiligo to be grafted, and applicated.
223702947|NCT00498524|DEVICE|ICD|Received an ICD
223702948|NCT00498524|DEVICE|ICD|Have not received an ICD
223702949|NCT00704678|DRUG|SBR759|1g tid
223702950|NCT00704678|DRUG|Sevelamer HCl|1.6 g tid
223702951|NCT00704678|DRUG|Sevelamer HCl|1.5 g tid
223702952|NCT00704678|DRUG|Sevelamer HCl|0.8 g tid
223702953|NCT01776411|DRUG|forodesine hydrochloride|
223702954|NCT06557252|BEHAVIORAL|PDCA training|Improve diagnostic rate
223702955|NCT06473948|DRUG|JMKX001899|Participants will receive JMKX001899 500mg tablet, orally once on Day 1
223702956|NCT06473948|DRUG|JMKX001899|Participants will receive JMKX001899 750mg tablet, orally once on Day 1
223702957|NCT06473948|DRUG|JMKX001899|Participants will receive JMKX001899 1000mg tablet, orally once on Day 1
223702958|NCT06473948|DRUG|Placebo|Participants will receive JMKX001899 matching placebo, tablet, orally once on Day 1
223702959|NCT03896165|OTHER|Reiki|Reiki is a complementary health approach where trained providers place their hands lightly on or just above a person, in discrete positions, with the goal of facilitating the person's own healing response. A Reiki practitioner will perform the initial teaching and instruct the parent how to perform a simple 15-minute Reiki session. Parents will complete a return demonstration using light touch with their adolescent. Parents will be asked to complete a minimum of 15 minutes of Reiki with their adolescent at least five days per week for the four-week intervention period.
223702960|NCT00276497|DRUG|Pioglitazone|
223702961|NCT01634061|DRUG|BEZ235|BEZ235 will be supplied as 50mg, 100mg, 200mg, 300mg and 400mg SDS sachets. At each patient's visit, patient will reecive a prescription of an adequate drug supply for self administration at home.
223702962|NCT01634061|DRUG|BKM120|BKM120 will be supplied as 10mg and 50mg hard gelatin capsules. At each patient's visit, patient will reecive a prescription of an adequate drug supply for self administration at home.
223702963|NCT01634061|DRUG|BEZ235|BEZ235 will be supplied as 50mg, 100mg, 200mg, 300mg and 400mg SDS sachets. At each patient's visit, patient will reecive a prescription of an adequate drug supply for self administration at home.
223702964|NCT01634061|DRUG|BKM120|BKM120 will be supplied as 10mg and 50mg hard gelatin capsules. At each patient's visit, patient will reecive a prescription of an adequate drug supply for self administration at home.
223702965|NCT01811225|DRUG|Low-dose Progesterone|"The low progesterone dose is seven days of placebo Tri-sprintec + placebo generic Prometrium twice a day (7AM and 7PM)."
223702966|NCT01811225|DRUG|High-dose Progesterone|"The high progesterone dose is seven days of placebo Tri-Sprintec + 200mg of generic Prometrium twice a day (7AM and 7PM)."
223702967|NCT01904227|BEHAVIORAL|standard outpatient DBT|Patients receive 12 months of outpatient treatment as specified in the DBT manual (Linehan, 2002) in one of the participating regional psychiatric centers of Rivierduinen. The treatment is according to protocol and combines weekly individual cognitive-behavioral psychotherapy sessions with the primary therapist, weekly skills- training groups, if needed consultation and weekly consultation meetings for trainers and therapists.
223702968|NCT01904227|BEHAVIORAL|Inpatient Adaptation of DBT|"The intervention to be studied, inpatient DBT, consists of an inpatient program of 12 weeks. The department provides accommodation for 9 patients. Patients are admitted 5 days a week at the department Oost, part of the Jelgersma centre for Personality Disorders. Staff is only present in daytime. During the weekends the patients stay at home.~The therapy consists of DBT skills training (Linehan, 1996), individual psychotherapy (Linehan, 2002), crisis consultation if needed, and weekly meetings of the consultation team for all trainers and therapists for one hour. Staff also receives supervision twice-weekly."
223786951|NCT06045624|DRUG|OR-101 (Multiple ascending dose)|MAD participants will receive either placebo or one of planned doses levels of 15mg, 45mg, 135mg, 270mg, 540mg and 900mg OR-101 in dose escalating manner in cohorts 1-6. Total dosage of cohort 7 and 8 will be decided based on Safety review committe's input where cohort 8 will receive this daily for 7 days
223786952|NCT06045624|DRUG|Placebo|Participants will receive matching placebo across Part A and C of the study
223786953|NCT04297878|DIETARY_SUPPLEMENT|probiotic supplement Streptococcus salivarius K12 (Bactoblis®)|Probiotic food supplement
223786954|NCT06535113|OTHER|Clinical Practice|"All the procedures in Study will be conducted as per Clinical practice for the pathology and all the samples will be collected according to ELN guidelines.~There are no additional procedures but will be additionally collected up 20ml of peripheral blood and up to 15ml of Bone Marrow Aspirate at the same time of clinically indicated diagnostic procedures."
223786955|NCT04317612|OTHER|Active berry product|Subjects should consume the active product containing nordic berries daily during the 12 week intervention period.
223786956|NCT04317612|OTHER|Reference product|Subjects should consume a reference product (isocaloric to active product) daily during the 12 week intervention period.
223786957|NCT00893659|DIETARY_SUPPLEMENT|wheat bread with beta-glucan|3 g beta-glucan in approximately 200 g of wheat bread per day for 3 months
223786958|NCT00893659|DIETARY_SUPPLEMENT|wheat bread without beta-glucan|Approximately 200 g of wheat bread (without beta-glucan supplementation) per day for 3 months
223702969|NCT02789631|OTHER|assessment|
223786959|NCT02200822|DRUG|beta blockers|
223702970|NCT04216121|RADIATION|Local ablative therapy|Stereotactic body radiotherapy
223702971|NCT04216121|PROCEDURE|Local ablative therapy|Surgery
223702972|NCT04344548|BIOLOGICAL|Allogeneic NK transfer|Three doses of allogeneic NK cell transfer
223702973|NCT06557317|BEHAVIORAL|Black Girls for Wellness In-Person|Weekly for 12 weeks, adolescent/caregiver dyads will attend 1) an in-person Wellness Session (mindfulness, nutrition lesson, dance class, program reflection) (90 min/wk) and 2) a home cooking experience using ingredients provided at the Wellness Session (60 min/wk).
223702974|NCT00645723|DRUG|Colistin|intravenous colistin and nebulized colistin
223702975|NCT00645723|DRUG|Colistin and saline solution|intravenous colistin and nebulized saline solution
223702976|NCT00137215|DEVICE|Silverlon|dressing for donor site mamagement
223702977|NCT03883360|DRUG|Cannabidiol (CBD)|Participants receive a single dose of CBD (600 mg p.o.) per day for 12 weeks.
223702978|NCT03883360|DRUG|Placebo|Participants receive a single daily dose of the oil vehicle used to dissolve CBD but without any active ingredient, in the same amount as the CBD group, for 12 weeks.
223702979|NCT02397031|BEHAVIORAL|Mindfulness|weekly psychotherapy sessions for 10 weeks (120 min each)
223702980|NCT02397031|BEHAVIORAL|interpersonal effectiveness|weekly psychotherapy sessions for 10 weeks (120 min each)
223786960|NCT02200822|DRUG|RAAS blockers|RAAS blockers (combination of ACE-I/ARB and a mineralocorticoid receptor antagonist)
223786961|NCT01842789|DEVICE|Acessa Procedure|Acessa Procedure
223786962|NCT02276482|DRUG|Tedizolid Phophate|Tedizolid Phophate 200 mg, IV and/or oral for 6 days
223786963|NCT02276482|DRUG|Antibiotic comparator|Antibiotic comparator drug, IV and/or orally for 10 days. Antibiotic comparator included the following: Vancomycin, Linezolid, Clindamycin, Flucloxacillin, Cefazolin, Cephalexin.
223786964|NCT02276482|DRUG|Aztreonam|In countries and/or sites where aztreonam is available, adjunctive aztreonam (IV) may be initiated on Day 1 or during the first 3 days of treatment if the participant is determined or suspected to have an infection with gram-negative aerobic pathogens.
223786965|NCT02276482|DRUG|Metronidazole|Metronidazole (IV or oral) may be initiated on Day 1 or during the first 3 days of treatment if the participant is determined or suspected to have an infection with anaerobic pathogens.
223786966|NCT03588572|DRUG|Venlafaxine hydrochloride capsules|The patients in venlafaxine group begin to take the venlafaxine hydrochloride capsules after the first visitation(the first day after randomization), each containing venlafaxine 75mg, 1 capsule per day, until 4 weeks after randomization
223786967|NCT02783586|PROCEDURE|Quadratus Lumborum Block type II|Local anaesthetic injection on the posterior border of the quadratus lumborum muscle
223786968|NCT02783586|PROCEDURE|Transversus Abdominalis Plane Block|Local anaesthetic injection between internal oblique and transversus abdominis muscle
223786969|NCT02783586|DRUG|Bupivacaine|20 ml of bupivacaine with adrenaline
223786970|NCT02783586|DEVICE|Ultraplex|A non-stimulating echogenic single-shot needle designed for regional analgesia under ultrasound guidance.
223702981|NCT04228874|DEVICE|coronary artery stents|"Coronary angiography was done for all the patients according to the Judkins technique. All images were evaluated by an experienced operator, significant coronary artery disease was defined as \> 70 % luminar diameter stenos. The following data was obtained:~* Site of stent implantation within LAD. The first Diagonal branch serves as the boundary between the proximal and mid portion of the LAD. Thus, the portion of the artery prior to the origin of the 1st diagonal is known as the proximal LAD, while the segment just below the1st diagonal branch is the mid LAD. The distal segment of the LAD is the terminal third of the artery (Cao et al., 2017).~* Length, diameter and number of stents.~* TIMI flow after stent deployment."
223702982|NCT03813043|DRUG|Midazolam injection|Midazolam 2mg iv to be used as starting dose using Biased coins up and down method (BCM)
223702983|NCT00000702|DRUG|Zidovudine|
223702984|NCT04686695|DEVICE|taVNS|taVNS was applied using a Huatuo stimulator (SDZ-IIB) developed by Suzhou manufacture of Medical Device and Material. Stimulation parameters was 1 mA of electrical current at a frequency of 20 Hz with pulse duration ≤ 1 ms, for 30min,administered twice daily.
223702985|NCT05581966|DIAGNOSTIC_TEST|DV-SSP Imaging|DeepView utilizes imaging data from DFUs to aid in health care providers' assessment of wound healing potential. It is intended to be used as an aid to health care providers in the management of DFU wounds and not as a standalone prediction device.
223702986|NCT04955132|BEHAVIORAL|E-learning|The participants in the experimental arm will be able to use a food allergy e-learning tool, that provides comprehensive knowledge of the most common food allergies (milk, egg and wheat), their management and dietary guidelines.
223702987|NCT03499925|BEHAVIORAL|cognitive behaviors|Telephone consultation effectiveness and cognitive behaviors
223702988|NCT03499925|BEHAVIORAL|Telephone consultation|Telephone consultation effectiveness and cognitive behaviors
223702989|NCT02554942|DRUG|Epoetin beta|Participants will receive weekly SC injections of epoetin beta beginning at 450 IU/kg, with doses adjusted according to hemoglobin level. Treatment will continue for a total of 16 weeks.
223702990|NCT04992910|DEVICE|Functional electrical stimulation through medical device|"The patient will receive a therapy with functional electrical stimulation. For this, a device called Fesia Grasp will be used.~Duration: 80 min twice a week, for 6 weeks."
223702991|NCT04992910|OTHER|Standard therapy|Physical therapy applied to the subject. Duration: 80 min twice a week, for 6 weeks.
223702992|NCT01816529|DRUG|Diltiazem Hydrochloride 2% Cream|0.2 g applied topically to the infrascapular area of the back.
223702993|NCT01816529|DRUG|Vehicle Cream|Vehicle Cream, 0.2 g (contains no active pharmaceutical ingredient) applied topically to the infrascapular area of the back.
223702994|NCT01816529|DRUG|0.1% solution of sodium lauryl sulfate (SLS)|0.2 mL applied topically to the infrascapular area of the back will serve as a positive control.
223702995|NCT01816529|DRUG|Saline (0.9%)|0.2 mL applied topically to the infrascapular area of the back will serve as a negative control.
223702996|NCT04674202|OTHER|Phone interview|The participant will have 2 phone interview in which they will be asked about their knowledge of direct oral anticoagulants.
223702997|NCT02158975|DRUG|MLN9708|
223702998|NCT02532530|DEVICE|Near-Infrared Spectroscopy (NIRS)|Near infrared spectroscopy (NIRS) is a non-invasive technique that uses near infrared light between 700 and 1100nm which penetrates several centimeters through skin and bone structures. Light is absorbed by chromophores. There are multiple chromophores which can be detected in the NIR spectrum such as water, lipids, melanin, myoglobin, oxygenated hemoglobin and deoxygenated hemoglobin. Each chromophore has a specific absorption spectrum. By using different wavelengths, it is possible to differentiate chromophores. The difference between oxygenated hemoglobin and deoxygenated hemoglobin can be calculated using the modified Beer-Lambert law, resulting in a numeric value which is a representation of the regional cerebral oxygen saturation.
223702999|NCT00309478|DRUG|Cyclophosphamide|Cyclophosphamide 600mg/m2
223703000|NCT00309478|DRUG|Methotrexate|Methotrexate 40mg/m2
223703001|NCT00309478|DRUG|Fluorouracil implant|Fluorouracil 600mg/m2
223703002|NCT00309478|DRUG|Goserelin|Zoladex 3.6mg/28 days for 3 years
223703003|NCT00309478|DRUG|Tamoxifen|Nolvadex 20mg/day for 5 years
223703004|NCT03000569|DRUG|SAGE-217|
223703005|NCT03000569|DRUG|Levodopa|Levodopa (including carbidopa-levodopa) administered as antiparkinsonian agent(s).
223703006|NCT03000569|DRUG|Antiparkinsonian Agent(s)|Antiparkinsonian agent(s) were administered as a clinical practice as standard of care, which includes levodopa (i.e. levodopa/carbidopa) or dopamine agonists or catechol-O-methyltransferase (COMT) inhibitors or monoamine oxidase (BMAO-B) inhibitors.
223703007|NCT00265629|DEVICE|RF catheter ablation|RF ablation using mesh device
223703008|NCT02524405|OTHER|Pittsburgh Compound B [11C]-PIB|This is a cross-sectional study of patients with various forms of cognitive impairment and a healthy control group for comparison. Brain amyloid PET scans using the radioligand Pittsburgh Compound B \[11C\]-PIB, which is not yet approved for clinical use in Canada, will be performed in all subjects.
223703009|NCT03250871|OTHER|Hypnosis|Hypnosis will be supervised by a nurse trained by the French Institute of Hypnosis.
223703010|NCT03250871|OTHER|Placebo|Placebo consists in non-hypnotic relaxation suggestions and in hearing white noise through headphones
223703011|NCT02550041|OTHER|T specific response for diagnostic of aspergillus bronchitis|
223703012|NCT06119399|OTHER|Diaphragmatic Breathing Exercise|Diaphragmatic breathing exercise will be taught by placing the subject comfortably positioned with either therapist or the patient's hand directed over the abdominal area and instructing the subjects to focus on an outward movement of the abdominal area throughout inspiration and an inward movement of the abdominal area during expiration. (4 sets, and as each set had 4 complete breathing breaks, these exercises will be conducted for 3 days a week for 6 weeks)
223703013|NCT06119399|OTHER|Pursed Lip Breathing Exercise|Pursed lip breathing exercises will be performed by necessitating the subjects to inhale through their nose and then exhaling slowly for a period of 4-6 s by pursing the lips
223703014|NCT06119399|OTHER|Doming of the diaphragm|"* The physiotherapist places the thumbs just inferior to the patient's lower costal margin and xiphoid process with the thumbs pointing cephalad.~* The patient is instructed to take a deep breath and exhale. On exhalation, the physiotherapist's thumbs follow the diaphragm, which permits the thumbs to move posteriorly.~* The patient is instructed to inhale, and the physiotherapist gently resists this motion.~* The patient is instructed to exhale, and the physiotherapist gently follows this motion posteriorly and cephalad, as the thumbs are now beneath the costal margin and xiphoid process.~* The patient inhales as the physiotherapist maintains pressure on the upper abdomen and then, on repeated exhalation, encourages further cephalad excursion.~* This procedure is repeated for three to five respiratory cycles until the diaphragm domes easily at the end of exhalation."
223703015|NCT06119399|OTHER|Conventional exercise program for chronic neck pain|"Patients will perform three repetitions of stretching exercises for neck flexor, extensor, lateral flexor, and rotator for 30 seconds as warm-up and cool-down exercises, to relieve tension on each side of the neck.~Then cranio-cervical flexion exercise will be started using feedback from an air-filled pressure sensor placed behind the neck. Subjects will lay in the crook lying position. The pressure biofeedback unit will be placed below the occiput and inflated up to a baseline pressure of 20 mmHg. The subjects will be instructed to perform head-nodding action to progressively target 5 pressure levels (hold 10 seconds with brief rest periods between each contraction 3-5 seconds). This includes 3 sets in a session for 10 repetitions each with 2 minutes of rest between sets and 3days a week for 6 weeks."
223786971|NCT00318006|PROCEDURE|saline irrigation|subjects were instructed in the technique of nasal lavage (irrigation group) or nasal saline spray (spray group) and were asked to do the assigned treatment twice daily for 8 weeks. They were provided with an 8-week supply of materials (Sinus Rinse irrigations from NeilMed Products Inc, and Deep Sea nasal saline spray distributed by Major Pharmaceuticals, Livonia, Michigan).
223786972|NCT00318006|PROCEDURE|saline spray|subjects were instructed in the technique of nasal lavage (irrigation group) or nasal saline spray (spray group) and were asked to do the assigned treatment twice daily for 8 weeks. They were provided with an 8-week supply of materials (Sinus Rinse irrigations from NeilMed Products Inc, and Deep Sea nasal saline spray distributed by Major Pharmaceuticals, Livonia, Michigan).
223786973|NCT06268912|PROCEDURE|Cold Mepivacaine|change the temperature, 3% at 5ºC
223786974|NCT06268912|PROCEDURE|Mepivacaine at room temperature|no change the temperature of anesthesia
223786975|NCT00450424|OTHER|counseling intervention|Participants in the Counseling intervention will meet with the study health educator who will provide the participant with the standard MSI informed consent form and provide a brief, standardized explanation of the MSI test. At that time, the participant can ask any questions s/he wishes to ask. The patients will either sign (or not sign, if they do not consent to have the test, or wish to think further about the decision) after this discussion. Participants who have further questions will be referred to either the attending physician or the genetics counselor at each hospital site.
223786976|NCT00450424|OTHER|CD-ROM intervention|Participants who are randomized to the CD-ROM condition will complete the baseline interview and then meet with the health educator who will provide the participant with the standard MSI consent form and provide a brief, standardized explanation of the MSI test. At that time, the participant can ask any questions s/he wishes to ask. Next, the participant will be provided with the CD-ROM to view on a laptop computer in the clinic. Participants will also be given a copy of the CD-ROM to take home and keep for future reference. The CD-ROM patients will sign (or not sign, if they do not consent or wish to think further about the decision) the consent form after this discussion.
223786977|NCT05046457|DIETARY_SUPPLEMENT|Beta-cryptoxanthin (BCX)|Subjects will be randomised into one of the three study treatment arms.
223703016|NCT05968131|OTHER|Conventional Physical Therapy|"The control group will receive only strength training intervention included the following components:~Range Of Motion Exercises: movements to the extent possible of the knee (flexion-extension), ankle (dorsi-plantar flexion), forefoot (inversion-eversion) and toe (flexion-extension).~5 repetitions of each ROM exercise will be done for 2 minutes. Muscle Strengthening Exercises: active movements against resistance (using a Thera band) at the knee (flexion-extension), ankle (dorsi-plantar flexion), forefoot (inversion- eversion) and toe (flexion-extension).~Each Strengthening exercise will be performed for 5 minutes with 10 repetitions."
223703017|NCT05968131|OTHER|Conventional Physical Therapy with Proprioceptive Training Exercises|"Interventional group will receive strengthening intervention as well as proprioceptive training for 32 sessions. ROM and Strengthening exercise will be performed same as in control group.~Exercises For Proprioceptive Training: Intervention group will practice an additional 24 minutes of proprioceptive training (two minutes rest prior to performing this training). A circuit with different floor texture composed of 6 stations of exercises to stimulate the sole of foot where participant had to improve gait by stepping with alternate feet marker placed on ground and progression will be done by modify the speed and direction. Material used to build the circuit are in following order: 10 cm thick foam, a wood box with beans, a 2 cm thick mat with density lower than foam, a wooden box filled with sand, balance board to train the lateral balance reactions, a wooden box filled with cotton. Duration of this training is 24 minutes; patient will spend 4 minutes on each station."
223703018|NCT03468101|OTHER|Pulmonary Function Testing|Pulmonary Function Testing, Cardiopulmonary exercise testing, 6 Minute walk test, Thoracic CT
223703019|NCT02718066|DRUG|HBI-8000 in combination with nivolumab|"Phase 1b: HBI-8000, orally, twice a week, dose escalation 20mg, 30mg, 40mg; in combination with nivolumab 240mg intravenous infusion every 2 weeks.~Phase 2: HBI-8000 MTD or 40mg; in combination with nivolumab in accordance with the manufacturer package insert and institution's prescribing practice."
223703020|NCT00507091|DRUG|ZD6474 (vandetanib) 100mg|once daily oral tablet
223703021|NCT00507091|DRUG|Irinotecan|intravenous infusion
223703022|NCT00507091|DRUG|5-Fluorouracil|intravenous infusion
223703023|NCT00507091|DRUG|Leucovorin|intravenous infusion
223703024|NCT00507091|DRUG|ZD6474 (vandetanib) 300mg|once daily oral tablet
223703025|NCT06452589|DEVICE|FieldForce Ablation System|The FieldForce Ablation System is indicated for cardiac electrophysiologic mapping, delivery of diagnostic pacing stimuli, and pulse field ablation of cardiac tissue. When used with the FieldForce Ablation Catheter, the FieldForce System is intended to be used in the right/left atria and/or left/right ventricle to deliver PFA ablation lesions in the selected areas of the chamber.
223703026|NCT03022435|BIOLOGICAL|TIV|Influenza Virus Vaccine Suspension for Intramuscular Injection
223703027|NCT03022435|BIOLOGICAL|High-Dose TIV|High-Dose Influenza Virus Vaccine supplied in a prefilled, single-dose syringe
223703028|NCT03022435|BIOLOGICAL|LAIV|Live, attenuated influenza vaccine for Intranasal Spray
223703029|NCT04122534|BEHAVIORAL|Somatic Mindfulness Training|Educational and experiential training to reduce occupational-based secondary trauma.
223703030|NCT00644189|DRUG|Clofarabine|Taken orally once a day (in the AM) on days 1 through 21 of a 28-day cycle for a maximum of 6 cycles.
223703031|NCT06057077|DRUG|Semaglutide weekly injection|semaglutide is Glp1 AGONIST WHICH IS NEW CHALLENGE IN DIABETES DISEASE TREATMENT EITHER TYPE 2 AND IS APPROVED BY FDA FOE children aged above 12 years at obesity
223703032|NCT00524381|DRUG|Etanercept (Enbrel)|TNF-alpha antagonist, subcutaneous injection, 25 mg twice/week, 14 days.
223703033|NCT00524381|DRUG|Sodium chloride (placebo)|NaCl, isotonic saline, subcutaneous injection, 1 ml twice/week, 14 days.
223786978|NCT00801827|DRUG|F-18 (fallypride)|Subjects undergoing bariatric surgery will have Positron Emission Tomography (PET)scans of their brains using the radioligand fallypride before and after the operation.
223786979|NCT06534788|OTHER|Reciprocal Inhibition MET|Reciprocal Inhibition MET will be applied to the shortened piriformis muscle in supine and prone positions with participants using 30-50% of their maximum voluntary isometric contraction. It will include 30-50% isometric contraction of the muscle opposite to the muscle to be stretched for 7-10 seconds, followed by inhalation, exhalation and rest period of 5 seconds and then a stretch (through the new barrier with patients' assistance) of 10-60 seconds hold. RI-MET group will receive 3-5 repetitions.
223786980|NCT06534788|OTHER|Post-facilitation MET|Post-facilitation stretch technique for shortened piriformis muscle in supine and prone positions will be applied with participants using 20% of their maximum voluntary isometric contraction. It will include 20% maximal isometric contraction of the muscle to be stretched for 6-10 seconds, followed by a rapid stretch (through the new barrier) of 15 seconds hold. After stretch, the muscle is allowed to relax in the midrange for up to 30 seconds. PFS-MET group will receive 3-5 repetitions.
223786981|NCT06534788|OTHER|Conventional physical therapy|"TENS and hot pack application to provide heating effect over the painful area (10 minutes) Both groups will receive conventional physical therapy which they will be taught as a home plan. Following exercises are guided to the patient as home plan.~* Resisted abduction with Thera/resistance band~* Resisted bridging with Thera/resistance band~* Resisted clam exercise with Thera/resistance band"
223786982|NCT00201383|DRUG|cisplatin|
223786983|NCT05904847|BEHAVIORAL|Application of The Theory of Planned Behaviour for Diabetes|In the study, diabetes education consisting of a total of 4 sessions structured according to the Planned Behavior Theory will be applied to the intervention group, and a standard diabetes education consisting of a single session containing information about diabetes on the website of the Ministry of Health will be applied to the control group. The training will be given face-to-face in groups of 10-15 people. After the training, the participants will be monitored for 3 months. To increase patient empowerment and self-efficacy, the intervention group will be followed up by phone calls every 15 days to increase motivation and answer questions.
223786984|NCT05882851|BEHAVIORAL|determination of the current nutritional status of patients|No intervention was made on the patients. Nutritional status was recorded during the treatment process. Current nutritional status and other risk factors were compared according to recovery status after treatment.
223786985|NCT05517343|OTHER|Real-time endoscopic optical diagnosis|The participants assigned to real-time notification group will received the endoscopic diagnosis of the resected colorectal polyps and recommended surveillance colonoscopy schedule right after the sedated colonoscopy.
223786986|NCT05253898|PROCEDURE|Pelvic floor Physical Therapy|Purpose of pelvic floor muscle education program is reduce the symptoms of stress urinary incontinence and improving quality of life.
223786987|NCT05253898|PROCEDURE|Therapeutic Yoga Training|Purpose of this group show the effectiveness of yoga therapy on stress urinary incontinence and quality of life.
223786988|NCT01250860|OTHER|Derotational manual therapy techniques in selected segments in spine|Derotational manual therapy techniques in selected segments of spine in preparation for the exercises according to the DoboMed method.
223786989|NCT01250860|BEHAVIORAL|Sham therapy|
223786990|NCT05430412|DEVICE|Adacolumn|The study will consist of 10 sessions of Adacolumn® treatment (once per week) and a follow-up period (from week 12 to week 40 since study inclusion).
223786991|NCT01649284|DRUG|afatinib|40, 30, and 20 mg film-coated tablets
223786992|NCT01173393|PROCEDURE|PARAMEDIC COOLING|"For patients randomised to paramedic cooling:~* LMA/ Intubation and ventilation with 100% oxygen~* Measure temperature using tympanic probe and record~* Paramedic cooling using infusion of 20mL/kg cold fluid via IV during CPR~* If temperature \>34.5ºC, infuse further 10mL/kg stat~* After ROSC, infuse further (max 2 litres) ice-cold saline~* If shivering occurs post resuscitation and intubated, administer midazolam 2-5mg IV and pancuronium 8 mg."
223786993|NCT01538745|DRUG|Ketamine|0.3 mg/kg ketamine Intravenous push (IVP) over 5 minutes. Total of two possible doses.
223786994|NCT01538745|DRUG|Morphine|0.1 mg/kg Morphine IVP over 5 minutes. Total of two possible doses.
223786995|NCT06040489|DRUG|Miltefosine 50mg|Oral Miltefosine 50mg bid
223786996|NCT06040489|DRUG|Pentoxifylline 400mg|Oral Pentoxifylline 400mg tid
223786997|NCT06040489|DRUG|Liposomal Amphotericin B|Intravenous 25 to 40mg/kg
223786998|NCT05997004|DRUG|Normal Saline|After surgical creation of umbilical port Control group received injection normal saline 1ml.
223786999|NCT05997004|DRUG|Glycopyrrolate|After surgical creation of umbilical port Group II received injection Glycopyrrolate 1ml=0.2mg
223787000|NCT05374980|DIETARY_SUPPLEMENT|Yogurt|Drink a bottle of 200ml yogurt every morning and evening for 8 weeks
223787001|NCT05374980|DIETARY_SUPPLEMENT|Placebo|Drink a bottle of 200ml placebo every morning and evening for 8 weeks
223787002|NCT02997566|OTHER|Autonomic evaluation|
223787003|NCT00186303|PROCEDURE|high dose chemotherapy then autologous hematopoietic cell transplant|
223787004|NCT00186303|PROCEDURE|ablative allogeneic hematopoietic cell transplant|
223787005|NCT02389543|DRUG|Selinexor|Two different dosing schedules will be tested, once weekly and twice weekly. If the selinexor 80 mg dose is tolerated, the dose will be increased to 100 mg.
223787006|NCT02389543|DRUG|Lenalidomide|In both arms, lenalidomide will be started at 15 mg/day (Dose Level 1) and, if tolerated per DLT criteria, will be escalated to 25 mg/day (Dose Level 2).
223787007|NCT02389543|DRUG|Dexamethasone|"Dexamethasone will be given in combination with each dose of selinexor on the once weekly treatment arm.~For the twice weekly arm dexamethasone will be given in combination with each dose of selinexor and will also be given without selinexor on Days 22 and 24."
223787008|NCT05651477|DEVICE|Wearable Device (Smart Watch)|A smart watch refers to an embedded system portable watch equipped with improved functions than a general watch, and is almost always in the form of a wrist watch. The device we are using is the Samsung Galaxy 4 (SM-R860/870).
223787009|NCT05651477|DEVICE|Edge-Box|Edge-Box collects data such as air. The device we are using is the TDS Mfepc-4C2R.
223787010|NCT03447418|PROCEDURE|Multiple breath nitrogen washout|Lung Clearance Index (LCI) will be performed in healthy volunteers with a multiple breath nitrogen washout device.
223787011|NCT02252055|BIOLOGICAL|ATDC_Nantes|"ATDC treatment (1 x 106 cells/kg BW slow peripheral venous) occurs the day before transplantation into recipients also recipients of a living donor renal transplantation.~Recipients also receive prednisolone, Mycophenolate Mofetil and tacrolimus background immunosuppression ( as described in detail in the arm description)"
223787012|NCT03431168|DRUG|Azithromycin/TMPS|2 tabs po daily x 3 days at enrollment and at each monthly follow up visit
223787013|NCT03431168|DRUG|Placebo/TMPS|2 tabs po daily x 3 days at enrollment and at each monthly follow up visit
223787014|NCT00290823|DRUG|Albendazole|400 mg tablet taken orally twice daily
223787015|NCT00290823|DRUG|Dexamethasone|6mg or 8mg taken daily
223787016|NCT00290823|DRUG|Omeprazole|20 mg tablet taken orally daily
223787017|NCT01053858|PROCEDURE|intravitreal injection|intravitreal bevacizumab( 1.25 mg) or triamcinolone( 4mg) injection
223787018|NCT00875680|DEVICE|autoPPC|To test the efficacy of autoPPC machines on residual sleep-related events during a one night autotitration polysomnography.
223787019|NCT01538017|DRUG|Xiapex|Collagenase Clostridium Histolyticum
223787020|NCT01538017|PROCEDURE|Percutaneous needle fasciotomy|Percutaneous needle fasciotomy ad modum Lermusiaux and Debeyre
223787021|NCT06260657|OTHER|Histological analysis on fetal ethmoids|Immunohistological analysis (immunohistochemical or immunofluorescent) on fetal ethmoids
223787022|NCT03448146|DRUG|Para-Toluenesulfonamide|
223787023|NCT04719793|BIOLOGICAL|Umbilical Cord-derived Wharton's Jelly|Intraarticular injection
223787024|NCT04658251|GENETIC|Blood and/or skin biopsy|Blood and/or skin biopsy will be withdrawn, for RNA extraction in order to test the effect of the variant on splicing.
223787025|NCT01308580|DRUG|Cabazitaxel (XRP6258)|"Pharmaceutical form: Concentrate and solvent for solution for infusion~Route of administration: Intravenous"
223787026|NCT01308580|DRUG|Prednisone (or Prednisolone)|"Pharmaceutical form: Tablet~Route of administration: Oral"
223787027|NCT04805125|BIOLOGICAL|Moderna COVID-19 Vaccine, mRNA-1273 (100 μg)|intramuscular injection, proposed as a series of two doses (0.5 mL each), dosing is 100 microgram on day 0 and day 28
223787028|NCT04805125|BIOLOGICAL|Pfizer-BioNTech COVID-19 Vaccine BNT162b2 (30 µg)( Comirnaty®)|intramuscular injection, proposed dosing is 30 microgram of the diluted vaccine solution (0.3 mL each) on day 0 and day 21
223787029|NCT02535065|DEVICE|Zenith Low Profile AAA Endovascular Graft and ancillary components|Treatment of patients with abdominal aortic, aortoiliac, or iliac aneurysms having morphology suitable for endovascular repair
223787030|NCT05450432|DRUG|Ketamine|Study participants will start treatment including two ketamine infusion visits per week during the acute phase, for up to eight ketamine infusion visits. Participants will then be transitioned to maintenance with intranasal esketamine.
223787031|NCT05450432|DRUG|Esketamine|After one month from the eighth ketamine infusion visit, participants will initiate weekly esketamine for 12 weeks, for a total of 13 esketamine treatments. The esketamine visits will happen as per standard of care at the clinic and as instructed by the SPRAVATO Risk Evaluation and Mitigation Strategy.
223787032|NCT01592643|DEVICE|Eye Shield|The thin shield is made of silicone. The materials used to make the corneal shield all have a history of use in medical devices, contact lenses, and/or corneal shields and have been used safely in the eye.
223787033|NCT05034692|PROCEDURE|Total laparoscopic with intracorporeal anastomosis by overlap method|After the intestinal canal was dissociated and vascularized, the intestinal canal was nuded and cut off, and the distal and proximal intestinal canals were overlapped by 6 cm
223787034|NCT05034692|PROCEDURE|Laparoscopic-assisted colectomy with extracorporeal anastomosis|After the corresponding colon and blood vessels were dissociated and treated, the carbon dioxide pneumoperitoneum was removed. The appropriate length of the incision was cut at the corresponding position of the abdomen, and the incision protector was placed. The tumor was lifted together with the free intestinal canal to the outside of the abdomen. The intestinal canals at the quasi-dismembered sites on both sides of the tumor were nuded, and the colon-colon functional end-to-end anastomosis was performed.
223787035|NCT02662842|DEVICE|FlowSmart Infusion Set|Use of set for subcutaneous insulin infusion, with set change every three days.
223787036|NCT02662842|DEVICE|Current Infusion Set|Use of set for subcutaneous insulin infusion, with set change every three days.
223787037|NCT06371794|PROCEDURE|skin punch biopsy|skin punch biopsy (around 4 mm2) from each studied subject.
223787038|NCT05892354|DIETARY_SUPPLEMENT|Enteral immunonutrition|Enteral immunonutrition (Oral Impact®, Nestle), 250ml/ bottle, 2 bottles per day, from 5 days before radiotherapy to the end of radiotherapy.
223787039|NCT05892354|DIETARY_SUPPLEMENT|Standard enteral nutrition|Isocaloric standard enteral nutrition formula (ENSURE®)， 250 mL per administration, 3 times per day. Preparation of the 250 mL dose involves adding 200 mL of potable water to a cup and slowly stirring in 52.7 g of ENSURE powder (approximately 6 scoops).
223787040|NCT00974857|DEVICE|BCM|Overhydration (OH) in liters will be estimated with the BCM (Body Composition Monitor, Fresenius Medical Care, Deutschland GmbH) in order to determine dry weight at least once a month before a dialysis session.
223787041|NCT00974857|OTHER|control group|BCM results obtained at the beginning, at the 6th, and 12th months will not be given to the treating physicians. Dry weight estimation will be guided by clinical findings, telecardiography, and echocardiography as used to be.
223787042|NCT00110617|DRUG|Deferasirox (ICL670)|Deferasirox was provided in 125 mg, 250 mg, and 500 mg dispersible tablets and was administered orally at an initial dose of 20 mg/kg/day.
223787043|NCT00110617|DRUG|Deferoxamine (DFO)|Deferoxamine was supplied in vials of 500 mg and 2000 mg administered subcutaneously for a weekly dose of 175 mg/kg.
223787044|NCT00454558|DRUG|Riociguat (Adempas, BAY63-2521)|Biweekly uptitration of BAY63-2521 (Oral sGC Stimulator) starting from 1.0 mg TID up to 2.5 mg TID in steps of +0.5 mg according to safety and tolerability.
223787045|NCT01438866|OTHER|Fissure sealant|Preventing dental caries in primary molars by applying fissure sealants and fluoride varnish, and comparing caries preventive effect of sealants with fluoride varnish.
223787046|NCT01438866|OTHER|Fissure sealants and fluoride varnish|Comparing preventive effect of fissure sealants and fluoride varnish on occlusal surfaces of primary molars
223787047|NCT00240318|DRUG|Rosuvastatin calcium|
223787048|NCT00778674|DRUG|Benazepril HCl/ Hydrochlorothiazide 20 mg/ 25 mg Tablets|
223787049|NCT01697293|DRUG|Cyclophosphamide|Given IV
223787050|NCT01697293|DRUG|Doxorubicin Hydrochloride|Given IV
223787051|NCT01697293|OTHER|Laboratory Biomarker Analysis|Correlative studies
223787052|NCT01697293|DRUG|Paclitaxel|Given IV
223787053|NCT01697293|PROCEDURE|Therapeutic Conventional Surgery|Undergo modified radical mastectomy, radical mastectomy, segmental mastectomy or lumpectomy with an axillary lymph node dissection or biopsy
223787054|NCT01697293|DRUG|Triciribine Phosphate|Given IV
223787055|NCT05802238|DRUG|Tranexamic acid (TXA)|1 gram of TXA in 10mg single-dose ampule (100mg/mL) administered 10 minutes prior to surgery
223787056|NCT05802238|OTHER|Saline|control group will receive 10 mL of normal saline infused intravenously at 1 mL/min.
223787057|NCT03118960|DEVICE|Freedom Bed|This is an automatic rotational system in a bed designed to disburse capillary pressure
223787058|NCT03118960|DEVICE|Group II Low Air Loss/Alternating Pressure Mattress|Subjects placed on the Group II Low Air Loss/Alternating Pressure Mattresses will require manual repositioning every 2 hours
223787059|NCT03567538|PROCEDURE|Thoracic surgery|Thoracic surgery, pulmonary resection, minimally invasive thoracic surgery, video assisted thoracic surgery (VATS)
223787060|NCT05450289|DRUG|Nigella Sativa Oil|In this study, we use nigella sativa oil (NSO), which are packed in capsule. One capsule contained 550 mg of nigella sativa oil.
223787061|NCT05450289|DRUG|Allergen Specific Immunotherapy|In this study, we use the house dust mite allergen immunotherapy (Teaching Industry Allergen by Dr. Soetomo Hospital-Airlangga University, Surabaya, Indonesia) used was an extract of Dermatophagoides pteronyssinus via subcutaneous injection.
223787062|NCT05450289|DRUG|Standard pharmacotherapy|Standard pharmacotherapy as indicated based on patient's symptoms i.e none, antihistamine, corticosteroids, bronchodilators, etc.
223787063|NCT04431102|OTHER|PILATES METHOD|"It is intended that the Pilates program have a duration of four weeks and its realization does not suppose an excessive consumption of resources. Therefore, it must have a series of characteristics: low supervision and easily realizable by all patients, which implies flexibility in the schedule. In this sense the sessions of Pilates is adjusted to these assumptions and the Pilates monitor offers several schedules on diferent days of week.~The pregnant women assigned to the intervention group will be supervised by the midwifery of reference and trained by a Pilates monitor who will explain the training program and resolve the doubts raised by the women.~The therapeutic control will be carried out by telephone call and clinical history review between the eighth and tenth day."
223787064|NCT00102791|DRUG|ICA-17043|
223787065|NCT02133846|DRUG|TPI 287 2 mg/m2|2 mg/m2 of TPI-287 diluted with 500mL 0.9% sodium chloride. TPI-287 is a microtubule inhibitor belonging to the taxane diterpenoid (taxoid) family, and specifically to the abeotaxane class.Drug: Placebo Drug: Placebo 500mL 0.9% sodium chloride.
223787066|NCT02133846|DRUG|TPI-287 20 mg/m2|20 mg/m2 of TPI-287 diluted with 500mL 0.9% sodium chloride. TPI-287 is a microtubule inhibitor belonging to the taxane diterpenoid (taxoid) family, and specifically to the abeotaxane class
223787067|NCT02133846|DRUG|Placebo|500mL 0.9% sodium chloride
223787068|NCT02133846|DRUG|TPI-287 6.3 mg/m2|6.3 mg/m2 of TPI-287 diluted with 500mL 0.9% sodium chloride. TPI-287 is a microtubule inhibitor belonging to the taxane diterpenoid (taxoid) family, and specifically to the abeotaxane class
223787069|NCT05700799|BEHAVIORAL|Health Advocate|The Health Advocate intervention will include helping pediatric liver transplant recipients and their families address unmet household social needs (e.g., food insecurity), improve patient-provider communication, and enhance care coordination.
223787070|NCT04458350|BEHAVIORAL|Digital Promotions Group|Digital promotions on the Fresh EBT app and Facebook will run for 13 weeks, advertising a SNAP fruit and vegetable incentive at farmers' markets in New England. The intervention will be applied to zip codes randomized to the intervention arm.
223787071|NCT00704145|DEVICE|Taxus Libertè™ paclitaxel drug-eluting stent|device:Taxus Libertè™ (Boston Scientific,Natick,MS)assessed at different time points after implant
223787072|NCT00178490|DRUG|High blood pressure treatment|Participants who are identified as having high blood pressure will be given by a pediatric nephrologist a 12-month treatment plan for their high blood pressure. The treatment plan will include a combination of diet, weight loss, increased exercise, and if needed, blood pressure medication. Participants receiving medication treatment will be treated with a calcium channel blocker and/or ACE inhibitor.
223787073|NCT00931073|DRUG|Dimebon alone|Pharmacokinetics of a single oral dose of 10 mg Dimebon (tablet) will be assessed in subjects with a CYP2D6 extensive and poor metabolizer status based on genotyping as screening
223787074|NCT00931073|DRUG|Dimebon + Ketoconazole|Pharmacokinetics of a single oral dose of 10 mg Dimebon (tablet) will be assessed on Day 4 during the daily administration of ketoconazole (400 mg, Day 1-11) in subjects with a CYP2D6 extensive and poor metabolizer status based on genotyping as screening
223787075|NCT00931073|DRUG|Dimebon + Omeprazole|Pharmacokinetics of a single oral dose of 10 mg Dimebon (tablet) will be assessed on Day 5 during the daily administration of omeprazole(40 mg, Day 1-12) in subjects with a CYP2D6 extensive and poor metabolizer status based on genotyping as screening
223787076|NCT00189631|PROCEDURE|UFT/LV|
223787077|NCT00189631|PROCEDURE|Observation|
223787078|NCT02498665|DRUG|DSP-7888 Dosing Emulsion|"Dose escalation cohort: Patients will be administered escalating doses of DSP-7888 Dosing Emulsion intradermally or subcutaneously in accordance with the following regimen: once weekly for four weeks during the Induction Phase, once every 7 to 14 days for 6 weeks during the Consolidation Phase, and once every 14 to 28 days until a discontinuation criterion is met during the Maintenance Phase.~MDS cohort 1: Patients will be intradermally administered of DSP-7888 at 10.5 mg every week for 4 weeks, every 2 weeks until Week 24, and then every 4 weeks.~MDS cohort 2: Patients will be intradermally administered of DSP-7888 at 10.5 mg every 2 weeks until Week 24, and then every 4 weeks."
223787079|NCT01489579|BEHAVIORAL|Telephone Counseling for Tobacco Cessation|"The patients in the Brief, Structured, Telephone (BST) counseling group will receive tobacco cessation counseling by a trained CPCRS pharmacist as part of their routine CPCRS care. The counseling will not be scripted, but must contain three key components (recommendation to quit, discussion/recommendation of tobacco cessation medications, and discussion/recommendation of tobacco cessation methods/strategies (Appendix C). These are the same items measured by the National Committee for Quality Assurance (NCQA) for Healthcare Effectiveness and Data Information Set (HEDIS) reporting. A standard KPCO document will be mailed to the patients following the BST counseling containing information about available resources (Ready to quit patient handout)"
223703034|NCT00579878|DRUG|Leflunomide|A loading dose of 100 mg (or placebo) for three (3) days will be given. Following that three-day period, a dose of 20 mg/day will be maintained throughout the remainder of the study. This dose may be decreased to 10 mg/day at the discretion of the treating physician if minor toxicities occur (e.g., diarrhea, liver enzyme elevations
223703035|NCT00579878|DRUG|Methotrexate-Sulfasalazine-Hydroxychloroquine|"Methotrexate:~dosing starts at 10mg/week (4 tabs/wk). If total remission (according to ACR criteria found in Appendix II) has not been achieved and the labs are acceptable at the 8-week evaluation, the dose increased to 15 mg/week (6 tabs/wk);at the 16-week evaluation, the dose increased to 20 mg/week (8 tabs/wk). This dose will remain stable until the end of the study.~Sulfasalazine: dosing will start at 500 mg bid (1000 mg/day). This dose will remain steady until the 24-week evaluation. If total remission has not been achieved by this time and the labs remain acceptable,dose will be increased to 1000 mg bid (2000 mg/day) Hydroxychloroquine: dosing will be started and maintained throughout the study at 200 mg bid (400 mg/day)."
223703036|NCT00579878|DRUG|Leflunomide-Sulfasalazine-Hydroxychloroquine|Leflunomide: dose of 100 mg (or placebo) for three (3) days. Followed by a dose of 20 mg/day will be maintained throughout the remainder of the study. dose may be decreased to 10 mg/day at the discretion of the treating physician if minor toxicities occur Sulfasalazine: dosing will start at 500 mg bid (1000 mg/day). This dose will remain steady until the 24-week evaluation. If total remission has not been achieved by this time and the labs remain acceptable, dose will be increased to 1000 mg bid (2000 mg/day) Hydroxychloroquine: dosing will be started and maintained throughout the study at 200 mg bid (400 mg/day).
223703037|NCT01805128|OTHER|Facial recognition of emotions|The purpose is to consider the recognition of emotions expressed on face in patients with a schizophrenic disorder, autism and in healthy subjects.
223703038|NCT01805128|OTHER|understanding metaphors|Explore understanding of figurative language, including metaphor, in schizophrenic patients, autistic and healthy, and well understand how patients develop an interpretation from access to speaker's communicative intentionality (theory mind).
223703039|NCT01805128|OTHER|Attribution of intentionality to others in social situations depending on the type of situation|Compare the style of attribution of intentions in three populations of subjects: schizophrenic, autistic and healthy.
223703040|NCT03355781|DEVICE|magnetic resonance imaging (MRI)|brain imaging : structural anatomy, emotional congruence, anatomic connectivity, functional connectivity
223703041|NCT03355781|PROCEDURE|Blood sample|27,5 ml of blood sample : genetic analysis and biobank
223703042|NCT03355781|OTHER|Clinical psychiatric evaluation|Global Assessment Scale(GAS),Mini International Neuropsychiatric Interview(MINI),Positive and Negative Symptoms Scale(PANSS),Family Interview for Genetic Studies(FIGS),Calgary Depression Scale for Schizophrenia(CDSS),extrapyramidal side effects evaluation or Simpson-Angus scale evaluation(ESRS),Apathy Evaluation Scale(AES-C),State-Trait Anxiety Inventory(STAI),Beck Depression Inventory(BDI-13),Eysenck Personality Questionnaire-Revised(EPQ-R),Assessment of Schizotypal Personality(SPQ),Emotion Regulation Questionnaire(ERQ),Emotional Reactivity Scale(ERS),Toronto Alexithymia Scale(TAS-20),social anhedonia scale(SAS),Childhood Trauma Questionnaire(CTQ),Clinical-administered Post Traumatic Stress Disorder Scale(CAPS),Wechsler Adult Intelligence Scale(WAIS-III),Trail Making Test(TMT),Pen and paper visuospatial working memory(DOT-test),impulsivity test(GoStop),Stroop test,National Adult Reading Test(NART),Wechsler Adult Intelligence Scale(WAIS-III),Facial Emotion Recognition task(FER)
223703043|NCT00397215|BIOLOGICAL|Pandemic influenza vaccine (GSK1562902A) (adjuvanted or not)|intramuscular injection
223703044|NCT00397215|BIOLOGICAL|Fluarix|Intramuscular injection. All subjects not vaccinated with an influenza vaccine for the 2006-2007 season received Fluarix NH 2006/2007 (i.e. interpandemic GSK's influenza vaccine) at least 3 weeks before administration of the first dose of H5N1 vaccine.
223703045|NCT02291354|DRUG|Pectin|Patients allocated to experiment group will receive 12 g pectin each day for 12 weeks.
223703046|NCT02291354|OTHER|Placebo|Patients allocated to experiment group will receive 12 g maltodextrin each day for 12 weeks.
223703047|NCT02291354|PROCEDURE|Fecal microbiota transplantation (FMT)|Standardized Frozen Fecal Microbiota will be infused via nasointestinal tube.
223703048|NCT02128932|DRUG|semaglutide|Injected subcutaneously (under the skin) once weekly. Following 4 doses (4 weeks) of 0.25 mg semaglutide weekly subjects will receive 0.5 mg semaglutide weekly for 26 weeks.
223703049|NCT02128932|DRUG|insulin glargine|Injected subcutaneously (under the skin) once daily. Subjects will start on 10 IU once daily and the dose will be adjusted according to fasting plasma glucose.
223703050|NCT02122432|OTHER|Teledermatology|"General practitioner takes 3 photographs per dermatologic lesion using either a telephone with a 3Mega Pixel minimum camera or a standard camera following recommendations of the practice guidelines for teledermatology (2007) of the American Telemedicine Association.~Photographs are sent by email using a secured mail server with at least the following information=date of symptoms, symptomatology, topography of lesions, description of lesions, extension, recent drug intakes)~Photographs are read and analyzed by a single dermatologist who gives an expert answer (diagnosis and/or treatment). Answer is sent back to the general practitioner by email (using a secured mail server). Answer contains at least the following information= are photographs usable? What is the diagnosis? If necessary, which treatment should the general practitioner begin ? If necessary, does the patient need a consultation with a dermatologist ?"
223703051|NCT01872221|PROCEDURE|Surgery (based on preoperative multimodal MRI) followed by the standard radio-chemotherapy stupp protocol|
223703052|NCT01836965|BEHAVIORAL|Social Skills Intervention|Twelve week manual based social skills curriculum targeting social fluency and responsiveness.
223703053|NCT02824237|DEVICE|Improved cook stove|The investigators will conduct a pre-post intervention study to evaluate effectiveness of improved stoves and compare outcomes after two years
223787080|NCT01489579|BEHAVIORAL|Usual Care|Pharmacists randomized to Usual Care will continue to provide interventions/procedures they normally would according to usual care practices. These interventions include any of the following: no action, mailed information on the resources available to help aid tobacco cessation, telephone counseling, and/or assistance in getting tobacco cessation medications. Pharmacists who are randomized to Usual Care will be asked to continue their current approach for tobacco cessation recommendations
223787081|NCT01746342|DEVICE|Effective continuous positive airway pressure (CPAP)|
223787082|NCT01746342|DEVICE|Sham continuous positive airway pressure (CPAP)|
223787083|NCT05031702|DIETARY_SUPPLEMENT|Camellia Sinensis leaf extract|2 tablets per day of 150 mg (1 before lunch and 1 before dinner)
223787084|NCT05031702|COMBINATION_PRODUCT|Placebo|2 tablets per day of 150 mg (1 before lunch and 1 before dinner)
223787085|NCT00808379|DRUG|Chemoradiation|Chemotherapy will begin on the first day of radiotherapy and continue until the completion of radiotherapy. Capecitabine will be administered orally daily 2000 mg/m2 in two divided doses (approximately 12 hours apart) for 2 weeks followed by a 1-week rest period given as 3 week cycles.
223787086|NCT00808379|RADIATION|Additional Radiation boost to the primary tumor volume|15-20Gy
223787087|NCT01629004|OTHER|FOBT kit|Mailed FOBT kit with educational materials and mailed CRC screening invitation on behalf of family physician.
223787088|NCT01629004|OTHER|Mailed invitation|Mailed CRC screening invitation alone on behalf of family physician.
223787089|NCT04075500|DEVICE|24-h Holter monitoring|Patients will be randomized to either receive 24-h Holter monitoring or receive one of the two modes for prolonged ECG recording (interventional arms). There are two interventional arms. Patients will either undergo 28-day ECG recording using a commercially available Holter recorder that can function as a non-invasive ECG patch or receive an implantable cardiac device (REVEAL LINQ).
223787090|NCT00605436|BEHAVIORAL|Restorative yoga therapy|3-hour workshop at study initiation. Then twice-weekly group yoga classes for 5 weeks, then once-weekly group yoga classes for 5 weeks. Home yoga practice for 90 minutes/week throughout the 10 week trial.
223703054|NCT05188196|PROCEDURE|alveolar ridge preservation|Alveolar ridge preservation and augmentation commonly are performed immediately after tooth extraction to preserve or increase ridge volume within or beyond the skeletal envelope that exists at the time of extraction.
223703055|NCT06117358|OTHER||Descriptive cross section study
223703056|NCT01361568|DRUG|CR845|Single i.v. dose (0.04 mg/kg) administered preoperatively
223703057|NCT01361568|DRUG|Placebo|Single i.v. dose administered preoperatively
223703058|NCT01361568|DRUG|CR845|Single i.v. dose (0.04 mg/kg) administered postoperatively for pain
223703059|NCT01361568|DRUG|Placebo|Single i.v. dose administered postoperatively for pain
223703060|NCT01433731|DRUG|placebo for SHAPE (SHP-141)|topical gelled solution
223703061|NCT01433731|DRUG|SHAPE (SHP-141) 0.1% BID|topical gelled solution
223703062|NCT01433731|DRUG|SHAPE (SHP-141) 0.5% BID|topical gelled solution
223703063|NCT01433731|DRUG|SHAPE (SHP-141) 1.0% BID|topical gelled solution
223787091|NCT03575923|BEHAVIORAL|Urban street greening|The interventions are located on four publicly accessible sites; the total size of the floor area of green space in each of the intervention sites is small, ranging from 0.09 to 0.35 acres. Components of the interventions include tree and flower planting (expected to bloom by March 2018) and artificial tree decorations such as strings of small electric lights and tree socks (the interventions are hereafter collectively referred to as urban street greening). The total cost for all components across all four intervention sites is approximately £6,000, although this excludes artist fees connected to the project. All components of the interventions were implemented within a one week period in November 2017 by two arborists, two local artists, staff members at Southway Housing Trust, and local community members from Old Moat and a local school.
223787092|NCT06180564|OTHER|Intra-operative Infra-red thermography|. In the test group after devascularisation of the bowel segment surgeon marked the resection line using their conventional method, then IRT was used to determine the resection line using infra- red camera in rainbow display mode. Resection line was determined by abrupt colour change (corresponds to decrease in temperature \>3 degree Celsius) over the visualised bowel wall. Margins were revised if difference between surgeon and IRT determined resection lines were more than 1cm apart.
223787093|NCT06780995|OTHER|Power Exercise for Stroke Recovery (POWER)|"POWER incorporates 3 progressive phases: Phase 1 Familiarization (Week 1) as a low-intensity version of the training program to acclimate participants to the movements (body weight resisted or light weights, RPE 2-3 Fairly light to Moderate). Phase 2 Strength (Weeks 2-5) progresses loads to achieve volitional fatigue within 6-8 repetitions (RPE 7-9 Very hard to Very very hard). Phase 3 Power (Weeks 6-10) will use intensities RPE 4-6 (Somewhat hard to Very hard), and exercises will be executed at the highest possible velocity to focus on muscle power. The Power phase is intentionally designed with exercises to emphasize functional movements such as fast sit to stands, lunging and calf raises."
223787094|NCT06780995|OTHER|Strength Training Engaging Guidelines to Enhance Total Health (STRENGTH)|"STRENGTH is based on current clinical practice guidelines for RET after stroke. It will include the same Familiarization week as the POWER program (Week 1), followed by progressive conventional RET involving 3 sets of 10-15 repetitions at moderate to high intensities (RPE 4-5 Somewhat hard to Hard) (Weeks 2-10). The external resistance will be progressed to maintain this target RPE range. STRENGTH is matched with POWER in length (60-minute sessions over 10 weeks), frequency (3x/week) and format (in-person supervision)."
223787095|NCT00639717|PROCEDURE|stem cell transplant|reduced intensity, matched unrelated donor stem cell transplant
223787096|NCT00639717|DRUG|tacrolimus (standard GVHD prophylaxis)|"Tacrolimus(or cyclosporine when necessary)~Tacrolimus will begin on day -3, IV or oral.~Target trough level for tacrolimus is 8-12 ng/ml.~In the absence of GVHD, tacrolimus tapering will begin on day +56 post transplant"
223787097|NCT00639717|DRUG|mycophenolate (standard GVHD prophylaxis)|Mycophenolate will begin on day 0 at 10 mg/kg/dose (up to 1 gram per dose) every 8 hours orally or intravenously and will continue until day 28.
223787098|NCT00639717|DRUG|etanercept|Etanercept will be given at a dose 0.4 mg/kg (actual weight) up to a maximum dose of 25 mg, subcutaneously, twice weekly from day 0 to day 56 (16 doses)
223787099|NCT00639717|DRUG|methoxsalen|"Methoxsalen (UVADEX) treatments by Extracorporeal photopheresis (ECP) will be started day +28 post transplant and given weekly.~On day +70 post transplant ECP frequency will be given every other week.~On day +100 post transplant ECP will be given monthly until day +180 and stopped."
223787100|NCT01756092|PROCEDURE|Autologous Fat Graft|Participants will receive an autologous fat graft to correct either a benign breast deformity or a post segmental mastectomy deformity.
223787101|NCT04207099|DEVICE|MolecuLight i:X Imaging Device|The MolecuLight i:X Imaging Device uses built-in light-emitting diodes (LEDs) emitting 405 nm violet excitation light to illuminate the wound during fluorescence imaging in (FL-Mode). The light excites biological components of the wound and surrounding tissues. Non-biological components may also fluoresce although their presence in wounds is less common, provided the wound has been cleaned following standard care protocols. The resulting wound fluorescence wavelengths emitted are typically between 420 - 700 nm in the visible wavelength spectrum. In FL-mode, a customized fluorescence emission filter, which is mechanically placed in front of the built in imaging sensor and allows real-time capture of wound, limits the visualization of fluorescence to wavelengths between 500-545 nm, which typically appears green in color, and 600-665 nm, which typically appears red in color.
223787102|NCT04952324|OTHER|Blood sampling and determination of MTHFR mutation,vitamin B12, folic acid, homocystein and HS CRP|Periferal Blood sampling and determination of MTHFR mutation,vitamin B12, folic acid, homocystein and high sensitive CRP
223787103|NCT00211679|DRUG|Botulinum Toxin Type A|
223787104|NCT01505296|DRUG|Antiarrhythmic drug|propafenone, flecainide, sotalol, dofetilide
223787105|NCT01505296|PROCEDURE|Catheter ablation|Complete PVI
223787106|NCT04883892|PROCEDURE|BMAC|"patients will be injected with BMAC into the ankle joint, after treatment patients will be followed up to 24 months. In particular patients will be assessed after treatment at 1, 3, 6, 12 and 24 months.~During the injection, samples of BMAC will be collected for the characterization of the phenotype markers and clonogenic capability"
223787107|NCT04883892|PROCEDURE|HA|patients will be treated with two injection of HA, one every 15 days, into the ankle joint. After treatment these patients will be followed up to 24 months. At 12 months patients can decide to cross.over in the BMAC arm treatment. After cross-over patients will be assessed for further 12 months.
223787108|NCT04118153|DRUG|Abatacept|Abatacept will be administered by subcutaneous injections weekly for 3 months. Dosing is according to body weight at screening visit and will be administered as follows: up to 25 kg receive 50 mg (0.4 mL); 25 to \<50 kg receive 87.5 mg (0.7 mL), and \> 50 kg receive 125 mg (1.0 mL) per dose.
223787109|NCT01495429|PROCEDURE|Central venous catheter|Placement of a peripherally inserted central venous catheter
223787110|NCT01495429|PROCEDURE|Central venous catheter|Placement of a centrally inserted central venous catheter
223787111|NCT03775239|BEHAVIORAL|Mindfulness in Sex Therapy and Intimate Relationships (MSIR)|"Mindfulness is a mental discipline inviting intentional, non-judgmental attending of the stream of experience. Mindfulness can be seen as an adjunct to sexual therapy. Firstly, it is a way of teaching the patients and the couples to carry out sensate focus so that it can achieve its goals. Beyond this, Mindfulness may invite a stance to one's own and a partner's physical and emotional experience that is more widely beneficial. The MSIR intervention was originally developed from the Mindfulness Based Cognitive Therapy (MBCT) protocol and consists of:~Week 1: Moving into the Body Week 2: Sensing \& Exploring Week 3: Avoidance \& Intimacy- Midway individual session. Week 4: Recognising our automatic mind Week 5: Spacious Awareness Week 6: Expanding new learning"
223787112|NCT03775239|BEHAVIORAL|Treatment-as-usual|"The current treatment in Sexological Clinic is an eclectic, synthetic therapy form conducted by psychiatrists, other medical doctors, psychologists and bodytherapists.~In order to implement the bio-psycho-social character of sexual dysfunctions, the current treatment takes advantage of different elements from different therapy forms combined with pharmacological treatment if necessary.~The integrated treatment combines elements from therapy's such as cognitive behavioural therapy (CBT), psychodynamic therapy and systemic therapy together with Master and Johnson's sensate focus training, body exercises training as pelvis floor exercises, introduction of sexual aids and if necessary pharmacological treatment. The therapy can be individual treatment, couple therapy (marital therapy) or group therapy."
223787113|NCT01694303|BEHAVIORAL|Computerized Neurobehavioral Intervention|Targeted, computerized interventions completed from the participants' own home on a computer.
223787114|NCT04440553|BEHAVIORAL|Uniform random message delivery|The uniform random intervention group receives feedback and motivational messages chosen from the messaging banks with equal probabilities.
223787115|NCT04440553|BEHAVIORAL|Reinforcement learning message delivery|The adaptive intervention group receives messages chosen from the messaging banks by a reinforcement learning algorithm.
223787116|NCT02372201|OTHER|Hydro Colon Therapy plus probiotic|Probiotic intervention was done after 2-5 cycles of hydro colon therapy.
223787117|NCT02250612|DRUG|1 drop of 0.375% SYL040012 (bamosiran)|
223787118|NCT02250612|DRUG|1 drop of 0.750% SYL040012 (bamosiran)|
223787119|NCT02250612|DRUG|1 drop of 1.125% SYL040012 (bamosiran)|
223787120|NCT02250612|DRUG|1 drop of 1.5% SYL040012 (bamosiran)|
223787121|NCT02250612|DRUG|1 drop of 0.5 % timolol maleate|
223703064|NCT01206075|DRUG|Mozobil|Previously mobilized splenectomized patients who failed to yield sufficient numbers of cells with Mozobil alone will receive low doses G-CSF subcutaneously (starting at 2.5µg/kg/day and adjusted to the degree of leukocytosis), and Mozobil at 240µg/kg starting on the 4th or 5th day of G-CSF, followed by one to three leukaphereses. Previously non-splenectomized patients who failed to yield sufficient numbers of cells with Mozobil alone will receive G-CSF at 10µg/kg/day subcutaneously for 4-7 days, and Mozobil at 240µg/kg starting on the 4th or 5th day of G-CSF, followed by one to three leukaphereses.
223703065|NCT01206075|DRUG|Mozobil|Previously mobilized splenectomized patients who failed to yield sufficient numbers of cells with G-CSF in the previous study will receive low doses G-CSF subcutaneously (starting at 2.5µg/kg/day and adjusted to the degree of leukocytosis), and Mozobil at 240µg/kg starting on the 4th or 5th day of G-CSF, followed by one to three leukaphereses. Previously non-splenectomized patients who failed to yield sufficient numbers of cells with G-CSF in the previous study will receive G-CSF at 10µg/kg/day subcutaneously for 4-7 days, and Mozobil at 240µg/kg starting on the 4th or 5th day of G-CSF, followed by one to three leukaphereses.
223703066|NCT01206075|DRUG|Mozobil|Up to sixteen patients (splenectomized and non-splenectomized) who were not previously mobilized will receive Mozobil at 240µg/kg for one to three days, followed by one to three leukaphereses.
223703067|NCT06151132|PROCEDURE|Direct current cardioversion|Direct current cardioversion to maintain sinus rhythm during rhythm control strategy
223703068|NCT02225197|RADIATION|CyberKnife Radiosurgery|25 Gy delivered in 5 fractions of 5 Gy per fraction
223703069|NCT00885287|DRUG|Artemether-lumefantrine (AL)|Standard treatment-dose of artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria according to national treatment guidelines
223703070|NCT01846390|DRUG|Gemcitabine|Group 1 = 1000 mg/m2 D1, D8. Subsequent dose levels according to toxicity = 600-1000 mg/m2 D1, D15.
223703071|NCT01846390|DRUG|Dexamethasone|40 mg D1 - D4
223703072|NCT01846390|DRUG|Cisplatin|75 mg/m2 D1
223703073|NCT01846390|DRUG|Romidepsin|Dose Level 0 - 6 mg/m2 D1, D8. Subsequent dose levels according to toxicity 6-14 mg/m2 D1, D15.
223703074|NCT03515252|BIOLOGICAL|Immune Killer Cells (IKC)|
223703075|NCT04905888|COMBINATION_PRODUCT|Hyperbaric oxygen therapy|Subjects randomized to treatment will receive up to ten 90 minute treatments with hyperbaric oxygen over a 2-3 week period.
223703076|NCT00044720|DRUG|Rapamune|
223703077|NCT04668573|OTHER|Trunk exercise|Trunk exercise includes trunk muscles stretching, trunk muscles strengthening, and task-related trunk control training for 30 minutes per session, twice a week for 12 weeks.
223703078|NCT04759144|DEVICE|CamAPS FX using faster insulin aspart|"CamAPS FX closed loop system comprises:~* Dana insulin pump (Diabecare, Sooil, Seoul, South Korea)~* Dexcom G6 real-time CGM sensor (Dexcom, Northridge, CA, USA)~* An Android smartphone hosting CamAPS FX app with the Cambridge model predictive control algorithm and communicating wirelessly with the insulin pump and glucose sensor~* Cloud upload system to monitor CGM/insulin data"
223703079|NCT04759144|DEVICE|CamAPS FX using standard insulin aspart|"CamAPS FX closed loop system comprises:~* Dana insulin pump (Diabecare, Sooil, Seoul, South Korea)~* Dexcom G6 real-time CGM sensor (Dexcom, Northridge, CA, USA)~* An Android smartphone hosting CamAPS FX app with the Cambridge model predictive control algorithm and communicating wirelessly with the insulin pump and glucose sensor~* Cloud upload system to monitor CGM/insulin data"
223703080|NCT00318058|BIOLOGICAL|influenza vaccine Fluarix, Adjuvanted Fluarix|
223703081|NCT04932460|PROCEDURE|CEUS|CEUS is performed before neoadjuvant treatment and surgery to evaluate the status of axillary lymph node and locate the sentinel lymph node.
223703082|NCT04932460|PROCEDURE|blue dye|Before operation, blue dye is injected for sentinel lymph node mapping.
223703083|NCT00657358|DRUG|Lidocaine|Lidocaine 2% (2mg/ml) was administered via a computer assisted infusion to achieve a target plasma concentration of 2 mcg/ml; infused within 20 minutes.
223703084|NCT04304274|PROCEDURE|Paravertebral block-ropivacaine|Inject 25 ml 0.5% ropivacaine in the T8 paravertebral space followed with catheter insertion and continuous 0.2% ropivacaine infusion(infusion rate: 0.125ml/kg/pulse,1pulse/h)
223703085|NCT04304274|PROCEDURE|Paravertebral block-saline|Inject 25 ml 0.9% saline in the T8 paravertebral space followed with catheter insertion and continuous 0.9% saline infusion(infusion rate: 0.125ml/kg/pulse,1pulse/h)
223787122|NCT04469179|BIOLOGICAL|SAB-185|SAB-185 is a purified human immunoglobulin G (hIgG) designed to specifically bind to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) viruses. SAB-185 is purified from the plasma of immunized Tc bovines that were immunized initially (vaccinations 1 and 2) with a plasmid DNA (pDNA) vaccine that expresses wild-type SARS-CoV-2 spike protein, followed by additional immunizations (vaccinations 3 and beyond) with a recombinant spike protein from SARS-CoV-2 produced in insect cells. The purified hIgG is a sterile liquid formulated in 10 mM glutamic acid monosodium salt, 262 mM D-sorbitol, 0.05 mg/mL Tween 80, pH 5.5. The drug product will be administered intravenously and will be diluted in saline per the clinical protocol.
223787123|NCT04469179|OTHER|Normal Saline|Normal (0.9%) saline in approximately the same volume as each cohort in the experimental drug arm.
223787124|NCT03667950|PROCEDURE|Hyperspectral Imaging|Photos were taken with the hyperspectral camera of the gastrointestinal anastomosis.
223787125|NCT00272857|GENETIC|Retrovirus Construct|This study will use an experimental gene transfer procedure performed in a laboratory to insert a new FA gene into the participant's bone marrow cells. The gene-corrected bone marrow cells will then be re-infused into the participant and participants will be observed for successful gene transfer
223787126|NCT03577600|PROCEDURE|QMRT with the Cytotron®|Cytotron® utilizes a combination of instantaneous magnetic field and RF at the safe, lowerend of the EM spectrum. Radiofrequency waves are computed based on individualized PD measurements of the target lesion(s) for therapeutic purpose. Its working principle is based on the underlying theory of magnetic resonance.
223787127|NCT06956287|DEVICE|LensHooke CA0|The intervention involves the use of the LensHooke CA0 sperm-wash device, which incorporates filtration and swim-up techniques to isolate motile and morphologically normal sperm with intact DNA integrity. It is used for sperm preparation in intrauterine insemination (IUI) cycles. The device is designed to reduce oxidative stress and facilitate physiological sperm selection, providing a potential improvement over conventional density gradient centrifugation (DGC).
223787128|NCT06956287|PROCEDURE|Density Gradient Centrifugation (DGC)|The control procedure involves the standard density gradient centrifugation (DGC) method, a widely accepted technique for sperm preparation in IUI. Semen samples are processed using commercially available gradient media to isolate progressively motile sperm. This method serves as the comparator to assess the clinical performance of the LensHooke CA0 device.
223787129|NCT05922358|COMBINATION_PRODUCT|Anti-allergic treatment|"For grade I-III hypersensitivity to oxaliplatin, oxa 0.01 mg/ml, 0.1 mg/ml and 5 mg/ml were used in sequence for skin test. 5% GS was used as a negative control. Test results are read within 15 to 20 minutes.~Grade IV: Permanently stop using oxaliplatin; Grade I-II: Take orally (cetirizine 10 mg bid, dexamethasone 8 mg bid, ranitidine 150 mg bid\*3dose) the day before the next cycle of oxaliplatin. The infusion rate is 50% of the original rate; if a grade II hypersensitivity reaction occurs again, the treatment method is the same as that of a grade III hypersensitivity reaction.~Grade III: Oral drugs are the same as above. 0.5h before oxaliplatin: dexamethasone 10mg iv, cimetidine 40mg iv, promethazine 25mg im. The first bag of 10% total amount of oxaliplatin + 5% GS500ml: 5ml/h\*1h, 45ml/h\*1h, then 225ml/h\*2 hours; then dexamethasone 10mg iv; the second bag of 90% total Oxa +5%GS500ml: 100ml/h\*0.5h, then 150ml/h\*3 hours."
223787130|NCT02100982|OTHER|Customized Care|Customized Care consists of two components. The first component is a Discussion Prioritization Tool (DPT) which forces patients to make trade-offs between competing concerns to help them determine which are the most important to discuss. The second component is a customized question prompt list (QPL) to help patients communicate their priorities to the PCP. The QPL will be generated after patients use the DPT, and consists of question prompts tailored to the patients' priorities. Consented patient-participants will be told that the subsequent office visit with the PCP will be audio-recorded to assess patient-PCP communication.
223787131|NCT02100982|OTHER|Care As Usual|Participants in this condition will interact with the research staff who will help the participant use an iPad in the waiting room to complete baseline health assessments. Consented patient-participants will be told that the subsequent office visit with the PCP will be audio-recorded to assess patient-PCP communication.
223787132|NCT05973110|BEHAVIORAL|Cognitive Remediation|In each of the 12 visits, participants will complete exercises in virtual reality for two sessions of about 15 minutes separated by a break of 5 to 10 minutes. Participants then engage in a bridging conversation with study staff for about 15 minutes. More details about each condition will be added after study completion to protect the blinding of our participants.
223787133|NCT05973110|BEHAVIORAL|Active Control|In each of the 12 visits, participants will complete exercises in virtual reality will complete exercises in virtual reality for two sessions of about 15 minutes separated by a break of 5 to 10 minutes. Participants then engage in a bridging conversation with study staff for around 10 to 15 minutes. More details about each condition will be added after study completion to protect the blinding of our participants.
223703086|NCT04304274|DRUG|patient controlled analgesia with morphine|Morphine was given as intravenous patient-controlled analgesia bolus: 1-2mg, lock time: 5min, 1h limitation: 8mg
223703087|NCT06180746|BEHAVIORAL|Knowledge mobilization to facilitate the structuring of health mediation|"The ECEMSo intervention involves knowledge mobilization to facilitate the structuring of health mediation throughout French territory, and the development of a co-designed effective action plan to facilitate cancer screening uptake by people living in informal housing.~The action plan will, consider territorial specificities at the regional level. The ECEMSo project team will organize a seminar and three workshops. The aim of the seminar and workshops is to mobilize knowledge to facilitate i) the structuring of health mediation in the regions, and ii) the development of an action plan with health mediators and other stakeholders to foster organized cancer screenings uptake by underserved people. This action plan must match with the needs of people living in informal housing, and must be coordinated, suitable and feasible to implement, in terms of knowledge about people living in informal housing specificities and specific local collaborations"
223703088|NCT01254630|BIOLOGICAL|V212|V212 viral antigen for HZ, 0.5 mL subcutaneous (SC) injection per dose, in a four dose regimen, approximately 30 days apart.
223787134|NCT05872347|DRUG|SPH4336 Tablets|SPH4336 Tablets ：Administered by oral; Letrozole tablets：Administered by oral; Fulvestrant injection：Administered by intravenous infusion; Exemestane：Administered by oral.
223787135|NCT03876080|OTHER|Dry needling|The use of a solid filiform needle to treat trigger points
223787136|NCT03876080|OTHER|Sham needling|Simulated needling
223787137|NCT00858065|BEHAVIORAL|Strengthening Families Program (SFP)|Prevention program with 7 weekly group sessions for parent and child.
223787138|NCT00858065|BEHAVIORAL|Family Matters|Prevention program with 4 booklets for families to do at home with their child.
223787139|NCT04806880|DEVICE|Web-application|support for olfactory coaching consisting of the inhalation of fragrant essential oils.
223787140|NCT02597400|DRUG|Metformin|"* Metformin500 mg BID on Days 1-2, only the morning dose on Day 3. Metformin will be taken 30 minutes prior to meals;~* Metformin 500 mg BID and HMS5552 50 mg BID on Days 4-7, only the morning dose on Day 8. Metformin and HMS5552 will be taken 30 minutes prior to meals"
223787141|NCT02597400|DRUG|HMS5552|"* Metformin 500 mg BID and HMS5552 50 mg BID on Days 4-7, only the morning dose on Day 8. Metformin and HMS5552 will be taken 30 minutes prior to meals;~* HMS5552 50 mg BID on Days 9 -12, only the morning dose on Day 13. HMS5552 will be taken 30 minutes prior to meals."
223787142|NCT04840550|DRUG|Lansoprazole 15 mg|Lansoprazole 15 mg tablets will be orally administered once a day, with NSAIDs, for up to 6 months.
223787143|NCT04840550|DRUG|Tegoprazan 25 mg|Tegoprazan 25 mg tablets will be orally administered once a day, with NSAIDs, for up to 6 months.
223787144|NCT02323971|DRUG|Ticagrelor|
223787145|NCT00710047|DRUG|ZD4054|one single 10mg dose
223787146|NCT04332705|DIAGNOSTIC_TEST|Detection of Cryptosporidium infection|A biopsy or a surgical sample will be collected from every participant
223787147|NCT04913857|BEHAVIORAL|24-week SUDOKU Training Programme|12-week face-to-face training session and a 12-week facilitated self-practice
223787148|NCT04913857|OTHER|Control Arm (wait-list)|wait-list comparison group will receive the same program upon completion of the 6-month posttest evaluation on study outcomes
223787149|NCT01627392|BEHAVIORAL|Smoking abstinence|6 hour smoking abstinence
223787150|NCT01093729|DRUG|HM11260C|HM11260C 0.5mcg/kg or Placebo
223787151|NCT01093729|DRUG|HM11260C|HM11260C 2mcg/kg or Placebo
223787152|NCT01093729|DRUG|HM11260C|HM11260C 4mcg/kg or Placebo
223787153|NCT01093729|DRUG|HM11260C|HM11260C 8mcg/kg or Placebo
223787154|NCT01093729|DRUG|HM11260C|HM11260C 14mcg/kg or Placebo
223787155|NCT05997238|DRUG|without triamcinolone|The preparation contains only the basic formula. The base formula contains 150mg ropivacaine and 0.5mg epinephrine. Add normal saline and mix to 80ml.
223787156|NCT05997238|DRUG|20mg triamcinolone|20mg triamcinolone was added to the preparation. Mix 20mg triamcinolone and the basic formula to make a mixed preparation. The base formula contains 150mg ropivacaine and 0.5mg epinephrine. Add normal saline and mix to 80ml.
223787157|NCT05997238|DRUG|40mg triamcinolone|40mg triamcinolone was added to the preparation. Mix 40mg triamcinolone and the basic formula to make a mixed preparation. The base formula contains 150mg ropivacaine and 0.5mg epinephrine. Add normal saline and mix to 80ml.
223787158|NCT05997238|DRUG|80mg triamcinolone|80mg triamcinolone was added to the preparation. Mix 80mg triamcinolone and the basic formula to make a mixed preparation. The base formula contains 150mg ropivacaine and 0.5mg epinephrine. Add normal saline and mix to 80ml.
223787159|NCT00838110|DRUG|Dimebon|10 mg TID for week 1 followed by 20 mg TID through Week 26
223787160|NCT00838110|DRUG|Placebo|10 mg TID for week 1 followed by 20 mg TID through Week 26
223787161|NCT00838110|DRUG|Dimebon|10 mg TID for week 1 followed by 20 mg TID through Week 12
223787162|NCT00838110|DRUG|Placebo|20 mg matched Placebo (Cohort 2) 10 mg TID for week 1 followed by 20 mg TID through Week 12
223787163|NCT04636255|PROCEDURE|Physical Characteristics|Body Weight, Height
223787164|NCT04636255|DIAGNOSTIC_TEST|Assessment of Heart rate variability|Holter 24h
223703089|NCT01254630|BIOLOGICAL|Placebo|Vaccine stabilizer for V212 with no virus antigen, 0.5 mL SC injection per dose, in a four dose regimen, approximately 30 days apart.
223703090|NCT02959983|DRUG|Eluxadoline|Eluxadoline 100 mg oral tablets BID with food.
223703091|NCT02959983|DRUG|Placebo|Placebo matching eluxadoline oral tablets BID with food.
223703092|NCT05328674|PROCEDURE|Arthroscopic reconstruction of cartilage defects in the knee joint with the use of autogenous cartilage transplant with PRP GF (platelet plasma with growth factor)|Arthroscopic reconstruction of cartilage defects in the knee joint using an autogenous PRP GF cartilage transplant.
223703093|NCT05328674|PROCEDURE|Arthroscopic reconstruction of the cartilage defects of the knee joint using the microfracture method|Arthroscopic reconstruction of the cartilage defects of the knee joint using the microfracture method.
223703094|NCT05791175|DEVICE|Teeth scan with intraoral scanner (Trios, 3 Shape, Denmark)|Intraoral scanner will be use to monitor the changes of the teeth over time. Intraoral scanners are devices that capture three-dimensional images of teeth and are used as an alternative to conventional dental impressions.
223703095|NCT03951714|BEHAVIORAL|Marketed experience application on adherence|To evaluate the effect of electronic capture of medication intake through a smartphone app on treatment's adherence
223703096|NCT05072782|DRUG|Infliximab CT-P13|"Stratification 1: Infliximab-CT-P13~Stratification 2: Infliximab-CT-P13 in combination with immunosuppressors"
223703097|NCT05072782|DRUG|Immunosuppressors (Thiopurines or Methotrexate)|"Stratification 1 : No treatments~Stratification 2 : Immunosuppressors at same dose"
223703098|NCT06112548|PROCEDURE|primary unilateral TKA|Primary unilateral total knee arthroplasty with cruciate scarifying cemented DePuy Synthes PFC Sigma prosthesis.
223703099|NCT06112548|DRUG|Bupivacain|low body weight (0.50%, 20cc) intraoperative periarticular injection
223703100|NCT06112548|DRUG|ketorolac|1ml of 30mg/ml ketorolac intraoperative periarticular injection
223703101|NCT06112548|DRUG|epinephrine|0.5ml Adrenaline 1mg/ml intraoperative periarticular injection
223703102|NCT06112548|DRUG|Paracetamol|IV Paracetamol \[Ofirmev\] introduced every 6 hours after surgery
223787165|NCT04636255|DIAGNOSTIC_TEST|Blood Pressure and Cardiac Autonomic Control|Non-invasive photoplethysmography (Finometer® PRO) monitored by the electrocardiogram and respiratory frequency by a piezoelectric chest strap.
223703103|NCT06112548|DRUG|Ketorolac|IV Ketorolac {Toradol} introduced every 12 hours after surgery.
223703104|NCT06112548|DRUG|Tramadol|IV Tramadol \[Ultram\] introduced when needed after surgery
223703105|NCT03860610|DIAGNOSTIC_TEST|Muscle strength test|Muscle strength in knee flexion and extension and hip abduction will be tested using using a dynamometer (Biodex System 4 Pro: Biodex Medical Systems, Shirley, NY, USA)
223703106|NCT03860610|DIAGNOSTIC_TEST|Dynamic stability test during level and uphill walking|Instrumented gait analysis on an overground walkway with two embedded force plates (Kistler force plate 9260AA6, Kistler AG, Winterthur, Switzerland; sampling rate 2400 Hz) and on a treadmill with an embedded plantar pressure plate (h/p/cosmos, Zebris FDM-T, Isny, Germany)
223703107|NCT03860610|DIAGNOSTIC_TEST|Postural stability test|The overall stability index (OSI) will be assessed using the Biodex Balance System SD (Biodex Medical Systems, Inc., Shirley, NY, USA) and is determined by the variance in platform displacement from the horizontal plane.
223703108|NCT03860610|DIAGNOSTIC_TEST|EuroQol Group Health questionnaire (EQ-5D-5L)|Overall health will be assessed using the EQ-5D-5L health questionnaire
223703109|NCT03860610|DIAGNOSTIC_TEST|HOOS/ KOOS|Site specific pain and function will be assessed with the Hip Osteoarthritis Outcome Score (HOOS) and Knee Injury and Osteoarthritis Outcome Score (KOOS) depending on the affected joint (hip or knee).
223703110|NCT03860610|DIAGNOSTIC_TEST|Muscle activity test|Surface electrodes (Ag/AgCl, Noraxon, U.S.A. Inc., Scottsdale, AZ, USA: 10 mm diameter, 22 mm inter-electrode distance) will be placed bilaterally on glutaeus medius, vastus medialis, semitendinosus, tibialis anterior, gastrocnemius medialis, and peroneus longus muscles. Periods of muscle activity will be defined as intensity above 2 Standard Deviation (SD) of the resting Electromyography (EMG) signal. Duration of overlapping muscle activity between agonists and antagonists normalized to one gait cycle or of a balance test, respectively, will be determined.
223787166|NCT04636255|DIAGNOSTIC_TEST|Evaluation of Baroreflex Control|The magnitude and latency of the baroreflex control of the heart rate will be assessed by bivariate analysis using the autoregressive method.
223787167|NCT04636255|DIAGNOSTIC_TEST|Cardiac Function and Structure|Echocardiogram
223787168|NCT04636255|DIAGNOSTIC_TEST|Assessment of Coronary Anatomy and Calcium Score|Angiotomography
223787169|NCT04636255|DIAGNOSTIC_TEST|Blood Assessments|Serum and Plasma will be extracted by centrifugation. NT-pro BNP (Roche™) and c-TnI (imunoassay Elecys 2010).
223787170|NCT04636255|DIAGNOSTIC_TEST|Physical Capacity|Cardiopulmonary Exercise Test.
223787171|NCT04636255|PROCEDURE|Physical Training|Aerobic exercise: 48 sessions of 60 minutes: 5 minutes of warm-up, 40 minutes of exercise. Resistance exercise: 10 minutes of exercise and 5 minutes of recovery.
223787172|NCT05495854|DIAGNOSTIC_TEST|PCR test in the stool|"Patients randomized to the new strategy arm will receive a prescription for an Hp serology and a stool self-collection kit . Only the result of the PCR test in the stool will be considered for this arm. A positive test will determine Hp infection and the indication for treatment."
223787173|NCT03553589|OTHER|Blood sampling|Blood sampling (10 mL) prior to standard care (e.g. surgery, medical treatment)
223787174|NCT05244473|DRUG|brentuximab vedotin|Given into the vein (IV; intravenously)
223787175|NCT05244473|DRUG|Placebo|Given by IV
223787176|NCT05244473|DRUG|ART|Daily use of a combination of HIV medicines
223787177|NCT05926401|OTHER|ECG monitoring prior and after cardioversion|Continuous ECG monitoring at home 3-5 days prior to and 5-7 days after planned cardioversion
223787178|NCT02057822|PROCEDURE|Cytokins assay in tears|
223787179|NCT04014608|OTHER|Standard Practice to Prevent Hospital Onset CDI|Bleach cleaning of rooms, use of required soap/water hand hygiene for CDI patients, hand hygiene monitoring, portable ultraviolet (UV) light room disinfection, and monitoring of room cleaning.
223787180|NCT03906227|DEVICE|ENUMERATION OF CD5+ B Cells|A blood test is done to assess what percentage of CD5+ is present within CD19+. The result is then used to guide choice of arm.
223787181|NCT01262651|DRUG|Nabiximols|
223787182|NCT01262651|DRUG|Placebo (GA-0034)|
223787183|NCT06333483|BIOLOGICAL|Obecabtagene autoleucel (obe-cel)|Following lymphodepletion with chemotherapy (cyclophosphamide and fludarabine) patients will be treated with a single dose of obe-cel
223787184|NCT03165526|DEVICE|AMPLATZER™ Post-infarct Muscular VSD Occluder|The AMPLATZER™ PIVSD Occluder is intended for percutaneous transcatheter closure of post-myocardial infarct muscular VSDs in patients who are not satisfactory surgical candidates.
223787185|NCT04050189|BIOLOGICAL|Natural products: Probiotics|Probiotics intake every day (1.5 gram) from 34 weeks of gestation to delivery OR from delivery to 10 days postpartum
223787186|NCT04050189|OTHER|Placebo|Placebo intake every day (1.5 gram) from 34 weeks of gestation to delivery OR from delivery to 10 days postpartum
223787187|NCT06481501|BEHAVIORAL|ONE Mindfulness-Oriented Recovery Enhancement|One MORE is a 2-hour adaptation of the manualized MORE program and will be divided into four, 30-minute segments. In the first segment, participants will be introduced to mindfulness and guided though a body scan practice, which directs participants to systematically shift attention from one part of the body to the next. Mindful pain management will be the focus of the second segment and participants will be guided through a mindfulness of pain practice in which they will learn to deconstruct pain into sensory, emotional, cognitive, and behavioral components. The third segment will focus on managing the negative thoughts and emotion that can amplify pain with mindful reappraisal, and the fourth segment will focus on increasing the positive emotions that can attenuate pain with mindful savoring.
223787188|NCT06266767|DRUG|Levobupivacaine and Fentanyl|Programmed Intermittent Epidural Bolus
223787189|NCT02692248|DRUG|Ibrutinib|Ibrutinib 560 mg daily for 14 days during induction cycles. Maintenance phase: Continuous cycles until disease progression or unacceptable toxicity (maximum of 2 years).
223787190|NCT02692248|DRUG|Rituximab|Rituximab 375 mg/m2 IV day 1 during 4 cycles.
223787191|NCT02692248|DRUG|Gemcitabine|Gemcitabine 1000 mg/m2 IV (30-minute infusion) on day 1 or 2, 4 cycles every 14 days.
223787192|NCT02692248|DRUG|Oxaliplatin|Oxaliplatin 100 mg/m2 (3-hour infusion) on day 1 or 2, after Gemcitabine infusion, 4 cycles every 14 days.
223787193|NCT02692248|DRUG|Dexamethasone|Dexamethasone 20 mg orally or IV on day 1 and orally on days 2-3, 4 cycles every 14 days.
223787194|NCT02291887|DRUG|Ranibizumab|Intravitreal injection of Ranibizumab
223787195|NCT02291887|DRUG|Aflibercept|Intravitreal injection of Aflibercept
223787196|NCT01512225|DRUG|Domperidone maleate|domperidone maleate tablet 10 mg orally three times daily for 28 days
223787197|NCT01512225|DRUG|Placebo Tablet|placebo tablet 10 mg orally three times daily for 14 days
223787198|NCT01512225|DRUG|Domperidone maleate|domperidone maleate tablet 10 mg orally three times daily for 14 days
223787199|NCT00492999|DRUG|dexamethasone|Given by hepatic arterial infusion
223787200|NCT00492999|DRUG|floxuridine|Given by hepatic arterial infusion
223787201|NCT00492999|DRUG|fluorouracil|Given IV
223787202|NCT00492999|DRUG|irinotecan hydrochloride|Given IV
223787203|NCT00492999|DRUG|leucovorin calcium|Given IV
223787204|NCT00492999|DRUG|oxaliplatin|Given IV
223787205|NCT04969783|OTHER|Ventilated Cigarette Filter|Ventilated Cigarette Filter
223787206|NCT04969783|OTHER|Unventilated Cigarette Filter|Unventilated Cigarette Filter
223787207|NCT06006520|OTHER|control|No exercises will be given.
223787208|NCT06006520|OTHER|oro-granary exercises.|soft palate exercises language exercises facial exercises stomatognathic functions swallowing and chewing exercises
223787209|NCT06006520|OTHER|aerobic exercises|We can think of aerobic exercise as a low-intensity long-term activity using large muscle groups (between 60-80% of maximal heart rate). For example; It includes activities such as walking, cycling, jogging, aerobic dancing, swimming.
223787210|NCT01248832|BEHAVIORAL|Telephone Counseling|"Counseling is conducted in Mandarin, Cantonese, Korean, or Vietnamese by counselors at the Helpline. The protocol used is similar to that proved efficacious. However, to make the counseling culturally appropriate for Asian language speakers, we: capitalizing on first contact, present the Helpline as a credible quit smoking program staffed by experts, avoid the term counseling since it is associated with mental illness, and assume a more authoritative role and directive counseling style. Counseling is proactive (1st call is made by smoker, then subsequent calls are made by the counselor) to help reduce attrition. Counseling includes a 30-40 minute comprehensive pre-quit session plus up to 5 shorter follow-up calls (about 10 minutes) scheduled according to the probability of relapse."
223787211|NCT01248832|BEHAVIORAL|Self-Help Materials|All subjects (both in the telephone counseling group and the materials-only group) receive self-help materials in teh appropriate language. Materials were created in-house, are written in the appropriate language, and cover the essentials of the quitting process such as motivation, physiological and emotional responses to quitting, nicotine in the body, quitting aids, quitting strategies (including those that might be culturally specific such as acupuncture or herbs), setting a quit date, planning, relapse prevention, differentiating between slips and relapse, long-term maintenance, and developing the nonsmoker self-image.
223787212|NCT06499870|PROCEDURE|Biopsy|Undergo biopsy
223787213|NCT06499870|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
223787214|NCT06499870|PROCEDURE|Computed Tomography|Undergo CT
223787215|NCT06499870|DRUG|Enzalutamide|Given PO
223787216|NCT06499870|OTHER|Fluorine F 18 Piflufolastat|Undergo fluorine F 18 piflufolastat PET/MRI
223787217|NCT06499870|RADIATION|Image Guided Radiation Therapy|Undergo IGRT
223787218|NCT06499870|PROCEDURE|Magnetic Resonance Imaging|Undergo PET/MRI
223787219|NCT06499870|PROCEDURE|Positron Emission Tomography|Undergo PET/MRI
223787220|NCT06499870|OTHER|Questionnaire Administration|Ancillary studies
223787221|NCT06499870|DRUG|Relugolix|Given PO
223787222|NCT02488486|DEVICE|Automated postoperative sedation|
223787223|NCT02488486|DRUG|propofol|
223787224|NCT02488486|DRUG|remifentanil|
223787225|NCT05941650|DIETARY_SUPPLEMENT|Short Chain Fructooligosaccharides|The intervention will receive Short-Chain Fructooligosaccharides at a dose of 12 gr. every 24 hours diluted in 250 ml of water.
223787226|NCT05941650|OTHER|Corn Starch|This group will receive 12 g of corn starch as a control group.
223787227|NCT02475408|DEVICE|Amplatzer vascular plug|
223787228|NCT03884751|BIOLOGICAL|CAR-GPC3 T Cells|CAR-GPC3 T Cells injection
223787229|NCT02349295|DRUG|Placebo|Administered SC
223787230|NCT02349295|DRUG|Ixekizumab 80 mg Q4W|Administered SC
223787231|NCT02349295|DRUG|Ixekizumab 80 mg Q2W|Administered SC
223787232|NCT04273230|OTHER|Microalbuminuria detection|Detection of microalbumin in urine
223787233|NCT02863926|BIOLOGICAL|Injection of cBMA aspirate into the index leg|Injection of cBMA into the anterior tibialis muscle and upper index leg of subjects scheduled for semi-elective BKA 7-21 days before surgery
223787234|NCT05027477|DEVICE|Radical Prostatectomy|If you are in this group, you will get the standard of care treatment used to treat this type of cancer: radical prostatectomy. You will undergo this procedure as per standard clinical practice. A radical prostatectomy is a surgical procedure that removes the prostate gland. This is done by making a surgical incision and removing the prostate gland.
223787235|NCT05027477|DEVICE|TULSA Procedure|If you are in this group, you will get the TULSA Procedure. The TULSA Procedure is a minimally invasive procedure that uses directional ultrasound to produce very high temperature to ablate (destroy) targeted prostate tissue. The procedure is performed in a MRI suite (the physician can see the prostate at all times throughout the procedure) and uses the TULSA-PRO system to ablate prostate tissue. The procedure combines real-time MRI with robotically-driven directional thermal ultrasound to deliver predictable, physician-prescribed ablation of the prostate. Minimally invasive here means that the procedure is performed through natural openings in your body (the urethra) instead of creating larger openings like in traditional surgery.
223787236|NCT06042517|DEVICE|Ultrasound|The General Electric LOGIQ E10 ultrasound pulsed doppler imaging system and C1-6-D XDclear abdominal curvilinear probe will be used to administer ultrasound.
223787237|NCT06042517|DIAGNOSTIC_TEST|OGTT with unlabeled glucose and liver NMR|Subjects will undergo an OGTT with unlabeled glucose to measure liver glycogen concentration by NMR spectroscopy.
223787238|NCT06042517|DIAGNOSTIC_TEST|OGTT with carbon-13 labeled glucose and liver NMR|Subjects will undergo an OGTT with carbon-13 labeled glucose to measure liver glycogen synthesis rate by NMR spectroscopy.
223787239|NCT06042517|DIAGNOSTIC_TEST|CGM glucose reading|A continuous glucose monitor (CGM) will be collecting glucose level changes over a 10-14day time period after the ultrasound.
223787240|NCT06042517|DIAGNOSTIC_TEST|HEC - Hyperinsulinemic-Euglycemic-Clamp|A constant i.v. insulin and variable glucose infusion will be used to determine insulin sensitivity of study participants.
223787241|NCT00290940|DRUG|CS-917|
223787242|NCT00290940|DRUG|metformin hydrochloride|
223787243|NCT00290940|DRUG|pioglitazone|
223787244|NCT00533390|DRUG|efavirenz|600mg X 800mg QID during TB therapy with rifampicin associated with other antituberculosis drugs in patients concomitant treated for tuberculosis and AIDS
223787245|NCT01278277|DIETARY_SUPPLEMENT|Saffron supplementation|Saffron supplementation 20 mg
223787246|NCT01278277|OTHER|placebo|placebo supplementation
223787247|NCT00093301|DRUG|Levosimendan|
223787248|NCT00093301|DRUG|Dobutamine|
223787249|NCT03523533|PROCEDURE|Angiocatheter|Placement of angiocatheter in internal jugular vein
223787250|NCT06471465|DRUG|Bevacizumab|Drug: bevacizumab IV
223787251|NCT06471465|DRUG|Placebo|Drug: placebo IV
223787252|NCT06471465|DRUG|Prednisolone|Drug: corticosteroids IV
223787253|NCT02068573|DEVICE|Ventilation|The ventilation system is placed outside the house and provides filtered conditioned air to the child's bedroom, through insulated pipes mounted in a window opening. The window opening was built specifically for this purpose in form of a thermo plate replacing the window glass. The unit provides the bedroom with at least 2-3 air changes per hour
223787254|NCT02068573|DEVICE|Placebo Ventilation|The placebo unit (DUPLEX 370) is a completely similar installation to the active ventilation unit, but it only recirculates the air in the room instead of replacing it with fresh conditioned air.
223787255|NCT04233268|DIAGNOSTIC_TEST|Rapid Pathogen Detection|Rapid assays for pathogen detection on bronchoalveolar lavage fluid
223787256|NCT00440050|DRUG|DHA (Docosahexaenoic Acid)|950 mg soft-gel capsules which contain approximately 510 mg DHA, 2 capsules twice a day for 18 months
223787257|NCT00440050|DRUG|Placebo|2 placebo capsules twice a day for 18 months
223787258|NCT00579917|BEHAVIORAL|Cognitive Behavioral Therapy: Questionnaires|CBT, we will interview you again after you have completed the 10 sessions. We call these follow-up interviews, and they include several phone calls and a questionnaire you would be asked to complete and then mail in. Each follow-up interview will take between 60 and 210 minutes. If you wish, these follow-up interviews can be done over different days. We will do the follow-up interviews three times; at approximately 4 months, 7 months, and 10 months after you complete the baseline interview.
223787259|NCT00579917|BEHAVIORAL|Usual Care: Questionnaires|If you receive Usual Care, you will not receive CBT while you are in the study. You will complete the questionnaires at the same time as participants who receive CBT. If you receive Usual Care you will be offered 10 sessions of CBT at no charge at the end of the study.
223787260|NCT01780922|OTHER|Low Calorie Cranberry Juice Cocktail|Beverage containing cranberry at a dose of 15.2 ounces consumed within 15 minutes
223787261|NCT01780922|OTHER|Cranberry Extract Beverage|Beverage containing cranberry at a dose of 15.2 ounces consumed within 15 minutes
223787262|NCT01780922|OTHER|Non-Cranberry Beverage|Beverage absent cranberry at a dose of 15.2 ounces consumed within 15 minutes
223787263|NCT03421054|DIETARY_SUPPLEMENT|patients assuming nutraceutical containing HA|pain reduction of the affected knee in the patients assuming nutraceutical containing HA
223787264|NCT00407992|DEVICE|Occipital nerve stimulation ON|Implant of an occipital nerve stimulator switched ON
223787265|NCT00407992|DEVICE|Occipital nerve stimulation off|Implant of an occipital nerve stimulator switched OFF
223787266|NCT03179228|DEVICE|Prostate Embolization|Embolization of the prostate with acrylic polymer microspheres impregnated with porcine gelatin
223787267|NCT04412395|DIETARY_SUPPLEMENT|Lactoferrin (Apolactoferrin)|Apolactoferrin is an iron-free Lactoferrin (with very low iron saturation). Lactoferrin (Lf) is a natural glycoprotein that is found predominantly in milk. Lf represents a known component of the innate immune system present in neutrophil-specific granules and broadly distributed within the body fluids and exocrine secretions.
223787268|NCT04412395|DRUG|Placebo of excipient(s) will be administered|Placebo of the equivalent excipient will be administered to placebo group
223787269|NCT01298791|BEHAVIORAL|Sitting|Providers will sit during inpatient family-centered walk rounds throughout the communication during rounds. The participating members of the care team (attending physician, resident and medical student) will remain seated while communicating with the patient and caregiver.
223787270|NCT01298791|BEHAVIORAL|Standing|Providers will stand during inpatient family-centered walk rounds throughout the communication during rounds. The participating members of the care team (attending physician, resident and medical student) will remain standing while communicating with the patient and caregiver.
223787271|NCT06346288|PROCEDURE|Breast Milk Sampling|Pharmacokinetic (PK) samples will be taken from breast milk of lactating mothers on an established dosing regimen of commercial risankizumab at pre-dose and 1 hour after dosing on Day 1, on Days 4 (± 1), 8 (± 2), 15 (± 3), 29 (± 3), and pre-dose on Day 57 (± 3)
223787272|NCT06346288|DRUG|Risankizumab|Participants will have already been taking commercial risankizumab and will continue on commercial risankizumab. Participants will not be provided risankizumab from the study. Participants must have received at least 2 doses of 360 mg of risankizumab SC every 8 weeks postpartum prior to start of participation in this study.
223787273|NCT03339050|BEHAVIORAL|Health for Hearts United|The intervention was framed around three conceptual components (awareness building, clinical learning, and efficacy development), and four types of programming (church-initiated, joint programming, standard programming (culturally tailored post cards and newsletters), and data collection health promotion (generic materials, clinical sessions with an Registered Dietitian). Key messages were identified for the intervention including eating better, moving around more, reducing stress, and taking charge of your health.
223787274|NCT03546244|BEHAVIORAL|musical treadmill|Patients will undergo a 4-week, 2 daily, incremental session of training with musical treadmill
223787275|NCT03546244|BEHAVIORAL|Traditional treadmill|Patients will undergo a 4-week, 2 daily, incremental session of training with traditional treadmill
223787276|NCT03388619|RADIATION|Prostate bed with integrated boost|Radiation will be delivered at an escalated dose to areas of recurrent prostate cancer identified on imaging and a reduced dose will be delivered to the entire prostate bed.
223787277|NCT03388619|RADIATION|Prostate bed irradiation only|Radiation will be delivered to the prostate bed only.
223787278|NCT03388619|DIAGNOSTIC_TEST|Whole Body Bone Scan|At screening, if required by clinician.
223787279|NCT03388619|DIAGNOSTIC_TEST|18F-NaF PET Imaging|At screening, if required by clinician.
223787280|NCT03388619|DIAGNOSTIC_TEST|CT|Computed tomography of the abdomen and pelvis if clinically indicated at screening, with oral and intravenous contrast.
223787281|NCT03388619|DIAGNOSTIC_TEST|mpMRI|mpMRI of the prostate bed at screening and 6 month follow up.
223787282|NCT03388619|DRUG|ADT|After enrollment if clinically indicated (i.e., anti-androgen, gonadotropin releasing hormone agonist, or combination of both).
223787283|NCT01483001|DRUG|Cancer Stem Cells Sensitivity Assay|To test in vitro sensitivity of cancer stem cells to several antineoplastic drugs in order to personalize treatment
223787284|NCT01914926|DRUG|Metoprolol|
223787285|NCT01914926|DRUG|Diltiazem|
223787286|NCT06089161|OTHER|Standard of Care|Participants in this group will receive standard of care treatment for sleep apnea.
223787287|NCT06089161|BEHAVIORAL|Personalized OSA Treatment|Participants in this group will receive standard of care treatment plus the personalized treatment that consists of videos approximately three minutes long, virtual, accessed through web based application, that the participant watches weekly. The purpose of the video is tailored educational content for sleep apnea.
223787288|NCT03929146|DRUG|Exparel|Patients will receive a local injection of liposomal bupivacaine near the end of their shoulder arthroplasty operation.
223787289|NCT03929146|PROCEDURE|Interscalene Nerve Block|Patients will undergo a pre-operative interscalene nerve block performed by the anesthesiology team.
223787290|NCT03816904|OTHER|Blood samples|Blood samples before the introduction of chemotherapy
223787291|NCT00252642|DRUG|Peginterferon Alpha-2a|
223787292|NCT06429020|BIOLOGICAL|the AstraZeneca ChAdOx1 (AZ) vaccine, Moderna mRNA-1273 (Moderna) vaccine, and Pfizer-BioNTech BNT162b2 (BNT) vaccine.|record the condition of vaccination
223787293|NCT05234827|OTHER|Virtual Reality|Total time duration for session is 40 minutes which includes 5 min of warm exercises which include heel raises, arm circles, side leg raises, trunk rotation, elbow flexion and extension, knee flexion and extension, and shoulder internal and external rotation, 30 minutes of VR session and 5-7 min of cool down exercises which include full body stretches i.e., toe touching, pectoralis major stretch, side by side bending, quadricep stretch, hamstring stretch, trapezius stretch and deep breathing.
223787294|NCT05234827|OTHER|Control|Control group receive endurance exercise testing in which stationary cycle is used for 30 min per session. It includes lower extremity strengthening i.e., increases hamstring and quadricep strength. Total time duration for session is 40 minutes in which 5 min of warm up exercises which include heel raises, arm circles, side leg raises, trunk rotation, elbow flexion and extension, knee flexion and extension, and shoulder internal and external rotation, 30 min of bicycling and after that 5-7 min of cool down exercises which include full body stretches i.e., toe touching, pectoralis major stretch, side by side bending, quadricep stretch, hamstring stretch, trapezius stretch and deep breathing.
223787295|NCT05069350|DRUG|bupivacaine 0.5% and oxubuprocaine|using each drug as surface anesthesia before intravitreal injections
223787296|NCT00328419|DEVICE|photoprotected bags, tubing, syringes|use of photoprotected parenteral nutrition device
223787297|NCT00328419|DEVICE|standard tubing and bags|Use of standard (transparent) parenteral nutrition device
223787298|NCT02059694|DRUG|Hyaluronidase|
223787299|NCT02059694|OTHER|2 mL of lidocaine 2% with epinephrine 1:100,000 without rHuPH20|
223787300|NCT01826591|BEHAVIORAL|Low-Carbohydrate Diet|Counseling/instruction on how to follow a low-carbohydrate diet.
223787301|NCT01826591|BEHAVIORAL|Low-Fat Diet|Counseling/instruction on how to follow a low-fat diet.
223787302|NCT01826591|BEHAVIORAL|Mobile App|Mobile app to increase vegetable consumption. Participants with iPhones will be re-randomized to receive a mobile app beginning at either months 4-5 or months 7-8. The first phase during months 4-7 will be used to compare the effect of a mobile app (intervention) vs. no mobile app (waiting-list control). The a priori hypothesis is that vegetable consumption will increase among those who receive the app in both diet groups.
223787303|NCT02630264|DRUG|Endostatins|"Specification: 1mL/division, 1×1012 VP/1.0mL~E10A preparation:~1. Thaw frozen E10A stored at -20°C vials at room temperature until E10A is liquid.~2. Swirl gently. Do NOT shake.~Method of administration~1. E10A was diluted with 0.9% sodium chloride to appropriate dose according to the longest diameter of the target lesion.~2. After local anesthesia, we penetrated the syringe under normal skin subcutaneously 5 mm into the tumor or vertically into the lymph node under direct visualization and withdrew it to confirm the absence of blood.~3. Applied local compression for 10 minutes and pasted a sterile sticker on the injection site to avoid bleeding."
223787304|NCT02630264|DRUG|Paclitaxel injection|"Specification:~30mg/5mL,~Usage:~160mg/m2 on day 3, according to instruction."
223787305|NCT02630264|DRUG|Cisplatin injection|"Specification:~20mg~Usage:~Cisplatin 25mg/ m2 on day 3, 4, and 5,according to instruction."
223787306|NCT00618475|BEHAVIORAL|Cognitive behavioral therapy|"10 sessions~1 hour per week"
223787307|NCT00938873|BEHAVIORAL|Mindfulness Based Cognitive Therapy (MBCT)|Mindfulness based cognitive therapy (MBCT) is a group psycho-educational treatment designed to reduce the risk of recurrent depression by integrating mindfulness based meditation practices with cognitive therapy techniques. MBCT comprises eight weekly two-hour group sessions with an additional one hour daily 6 days a week for meditative homework practice.
223787308|NCT00692172|DRUG|Alefacept|intramuscular injection (IM)
223787309|NCT05676684|DRUG|Dapagliflozin|A: Dapagliflozin 10 mg once daily
223787310|NCT05676684|DRUG|Spironolactone + Dapagliflozin|C: Dapagliflozin 10 mg once daily plus Spironolactone 25mg/every other day or 25mg/day (can be adjusted according to potassium and renal function)
223787311|NCT02766543|DEVICE|MRI-guided Transurethral Ultrasound Ablation|Magnetic resonance imaging-guided transurethral ultrasound ablation is a novel minimally-invasive procedure where the therapeutic endpoint is prostate ablation through thermal coagulation.
223787312|NCT04443738|OTHER|phone survey|A questionnaire about the current symptoms and satisfaction for recieved treatment will be conducted over the phone for patients.
223787313|NCT05051566|DRUG|LY3502970|Administered orally.
223787314|NCT05051566|DRUG|Esomeprazole|Administered orally.
223787315|NCT02057146|PROCEDURE|Duodenoscopy, pancreatoscopy, cholangioscopy, confocal microscopy|The intervention consists of mother-baby endoscopy of the bile and/or pancreatic duct with visual inspection, confocal laser microscopy, collection of fluid for cytology, and eventually biopsy.
223787316|NCT01917526|DEVICE|oxygen mask|
223787317|NCT01917526|DEVICE|oxygen cannula|
223787318|NCT05547932|PROCEDURE|RIB+SAP blocks|RIB block will be performed after endotracheal intubation, then a SAP block will be performed. No other intervention will be performed to the patients.
223787319|NCT04621305|OTHER|normal saline|Anesthesia is maintained by sevoflurane and continuous infusion of normal saline(1ml/kg/h) is administered until about 5min before the end of the surgery. Then intravenous bolus of 0.2ml/kg normal saline is administered
223787320|NCT04621305|DRUG|Bolus Remimazolam|Anesthesia is maintained by sevoflurane and continuous infusion of normal saline(1ml/kg/h) is administered until about 5min before the end of the surgery. Then intravenous bolus of 0.2mg/kg remimazolam is administered.
223787321|NCT04621305|DRUG|Continuous Infusion Remimazolam|Anesthesia is maintained by sevoflurane and continuous infusion of remimazolam(1mg/kg/h) is administered until about 5min before the end of the surgery. Then intravenous bolus of 0.2ml/kg normal saline is administered.
223787322|NCT05802459|OTHER|EORTC QLQ-C30|central generic questionnaire associated with different disease specific modules
223787323|NCT05802459|OTHER|EORTC QLQ-OG25|module to assess the quality of life in patients with esophagogastric disease.
223787324|NCT05802459|OTHER|GIQLI|Gastrointestinal Quality of Life Index. It is a gastrointestinal quality of life scale.
223787325|NCT05802459|OTHER|SWAL QoL|Swallowing Quality of Life questionnaire. This is a quality of life and quality of attention questionnaire for patients with oropharyngeal dysphagia.
223787326|NCT05802459|PROCEDURE|Videofluoroscopy|It consists of 14 items that represent the oral and pharyngeal function observed in the VDF. It allows to quantify the severity of dysphagia.
223787327|NCT04781972|DRUG|Methylphenidate|single dose of 10 mg or 15 mg
223787328|NCT04781972|DRUG|Placebo|Matching placebo
223787329|NCT01891825|PROCEDURE|Surgical AF ablation|Minimally invasive thoracoscopic surgical ablation of atrial fibrillation
223787330|NCT01891825|PROCEDURE|Percutaneous AF ablation|Percutaneous catheter ablation of atrial fibrillation
223787331|NCT01318889|DRUG|Dexpanthenol|5% dexpanthenol Mouth wash , three times a day, 10 cc each time
223787332|NCT00434057|DEVICE|MelaFind(R)|Biopsy ratio comparison
223787333|NCT06535529|DRUG|Acetazolamide|Patients will receive acetazolamide 500 mg once daily for 3 days as add on therapy to IV loop diuretics
223787334|NCT06535529|DRUG|Dapagliflozin 10mg|patient will receive oral dapagliflozin 10 mg once daily for 3 days as add on therapy to IV loop diuretics
223787335|NCT02003001|DRUG|Botulinum Toxin|
223787336|NCT04122417|OTHER|The Effect Of Therapeutic Touch Training Given To Mothers With Preterm Babies On Attachment Level And The Responses The Baby|The study was carried out as randomized experiment to determine the effect of Yakson or Gentle Human Touch method practiced by mothers to preterm newborns on the maternal attachment level and the baby's responses.
223787337|NCT02385448|DRUG|Dienogest|The dienogest group will receive dienogest 2mg daily for 24 months postoperatively
223787338|NCT02385448|DRUG|Microgynon|The combined oral contraceptive pills group will be given cyclical Microgynon for 24 months.
223787339|NCT01753024|DIETARY_SUPPLEMENT|Enteral nutrition (EN)|All patients enrolled in this study must carry out nutritional support by enteral nutrition
223787340|NCT03669029|DRUG|Golimumab 50 mg in patients <80 kg and Golimumab 100 mg in patients >80 kg|Clinical response at week 6,14, 30 and 54 will be correlated to serum golimumab levels and anti-golimumab antibody levels.
223787341|NCT03669029|DRUG|Golimumab treatment optimization.|Golimumab dosing will be optimized in patients without clinical response at week 6.
223787342|NCT02117570|BIOLOGICAL|Clostridium difficile vaccine|0.5 mL intramuscular injection on day 1, day 8, and day 30.
223787343|NCT02117570|BIOLOGICAL|Clostridium difficile vaccine|0.5 mL intramuscular injection on day 1, day 8, and day 30.
223787344|NCT02117570|BIOLOGICAL|Placebo|Placebo (0.9 percent saline) given as a 0.5 mL intramuscular injection on day 1, day 8, and day 30.
223787345|NCT04434404|DRUG|L-Carnitine 500Mg Oral Tablet|"eighty-three eligible patients were recruited 33, 25, and 25 patients in the control group, L-carnitine group, and, Silymarin group respectively, completed the study~without cardioprotective agents in a dose of 50 mg/m2. L-carnitine group received anthracycline-containing chemotherapy in a dose of 50 mg/m2 plus L-carnitine 3 gm L-carnitine® capsules obtained from (MEPACO) was taken PO one day before chemotherapeutic cycle and 1gm /day during the following 21 days. Silymarin group received anthracycline-containing chemotherapy in a dose of 50 mg/m2 plus Silymarin as cardioprotective agent.140 mg (Legalon ® 140 mg capsule obtained from (MEDA). Silymarin was taken PO once daily after meals during the chemotherapeutic cycle. The treatment period was 6 months."
223787346|NCT01506739|DRUG|Donepezil Hydrochloride|Drug E2020 film-coated tablet: E2020 film-coated tablet (5mg) orally administered in a single dose with 200 mL water.
223787347|NCT01506739|DRUG|Donepezil Hydrochloride|Drug E2020 dry syrup 1% form (suspended): E2020 dry syrup 1% (0.5 g) will be orally administered in a single dose after suspended in 20 ml water.
223787348|NCT01506739|DRUG|Donepezil Hydrochloride|Drug E2020 dry syrup 1% form: E2020 dry syrup 1% (0.5 g) will be orally administered in a single dose with 200 mL water.
223787349|NCT01206335|DRUG|OHR/AVR118|OHR/AVR118 given subcutaneously at 4mL per day
223787350|NCT03701555|OTHER|PvP001 placebo|placebo
223787351|NCT03701555|DRUG|PvP001 100 mg|PvP001 100 mg
223787352|NCT03701555|DRUG|PvP001 300 mg|PvP001 300 mg
223787353|NCT03701555|DRUG|PvP001 900 mg|PvP001 900 mg
223787354|NCT03701555|DRUG|Maximum Feasible Dose (MFD) of PvP002|MFD of PvP002
223787355|NCT03701555|DRUG|Maximum Tolerated Dose (MTD) of PvP001|Maximum Tolerated Dose (MTD) of PvP001
223787356|NCT03701555|DRUG|MTD of PvP001 following 7 days of PPI treatment|Maximum Tolerated Dose (MTD) of PvP001 following 7 days of PPI (Proton Pump Inhibitor) treatment
223787357|NCT03701555|OTHER|PvP002 placebo|Placebo
223787358|NCT03701555|DRUG|PvP001 600 mg|PvP001 600 mg
223787359|NCT03701555|DRUG|PvP003 placebo|Placebo tablet orally.
223787360|NCT03701555|DRUG|PvP003|PvP003 tablet orally.
223787361|NCT03701555|DRUG|PvP003 150 mg|PvP003 150 mg
223787362|NCT02239523|PROCEDURE|Letter Group|At time of discharge from the hospital, patients will be sent home with a letter that includes standard recommendations for evaluation and treatment for osteoporosis. This will be asked to give the letter to their primary care physician.
223787363|NCT02239523|PROCEDURE|Intervention Group|The orthopedic department will be responsible for arranging bone density testing (DEXA) and recommending specific medication after discharge. A research assistant will call monthly to encourage treatment.
223787364|NCT04842357|OTHER|standardised video concerning clinical skill|watching a video concerning clinical skills.
223787365|NCT05091034|BEHAVIORAL|Controlling Asthma Program for Adolescents (CAMP Air)|Controlling Asthma Program for Adolescents (CAMP Air) is an e-health intervention grounded in social cognitive theory and motivational interviewing to guide teens through asthma self-care and how to navigate the health care system. It makes use of various interactive and personalized approaches.
223787366|NCT05091034|BEHAVIORAL|Attention Control Asthma Education Intervention|Using Asthma Plus, an asthma education program, teens learn about asthma and other conditions relevant to asthma and adolescents.
223787367|NCT05508282|BEHAVIORAL|Reading Bees app and children's book to enhance parent-infant reading quality (0-2 month visit)|The reading intervention will be provided at the baseline clinic well-visit (0-2 months), and is based on the SHARE/STEP approach.
223787368|NCT05508282|BEHAVIORAL|Reading Bees app and children's book to encourage alternatives to digital media (6-month visit)|The digital media (screen time) intervention will be provided at the 6-month clinic well-visit and is based on Baby Unplugged materials (book and app content).
223787369|NCT04336215|OTHER|Non-Interventional|This non-interventional study poses no additional risks to people with pre-existing conditions.
223787370|NCT03349710|BIOLOGICAL|Nivolumab|Specified dose on specified day
223787371|NCT03349710|DRUG|Cetuximab|Specified dose on specified day
223787372|NCT03349710|DRUG|Cisplatin|Specified dose on specified day
223787373|NCT03349710|RADIATION|Radiotherapy|Specified dose on specified day
223787374|NCT04141306|OTHER|Administrative data|Evaluation of month and year of birth, sex, referent doctor and surgeon
223787375|NCT04141306|OTHER|Clinical data|Evaluation of diagnostic circumstances, vital status at last follow up
223787376|NCT04141306|OTHER|Histological data|Evaluation of Pathology report of thyroid surgery
223787377|NCT04141306|OTHER|Imaging data|Evaluation of scintigraphy, MRI, scan
223787378|NCT04141306|OTHER|Biological data|Evaluation of thyroglobulin, antithyroglobulin antibodies
223787379|NCT04141306|OTHER|Further treatment|Evaluation of surgery, radiotherapy, targeted therapy
223787380|NCT01906294|DRUG|antidiabetic treatment (ATC A10B)|
223787381|NCT03223363|DIAGNOSTIC_TEST|2D and 3D ultrasonography|All of the examinations are performed with the same transabdominal ultrasonic transducer (RAB 2-5-D) on the same E8 (GE Medical Systems, Milwaukee, WI, USA) ultrasonic machine experienced operators. 2D ultrasonic measurements includes 5 standard fetal biometry parameters, and after routine 2D ultrasonography, the acquisition of 3D measurements are performed.
223787382|NCT01015742|DRUG|Stem cell Transplantation|"Busulfan: 3.2 mg/kg IV daily on days -7 to -4~Cyclophosphamide : 60 mg/m² daily on days -3 to -2~Rabbit Thymoglobulin 2.5mg/kg IV daily on days -3 to -2~Cyclosporin will begin on day -2 (IV or oral) for at least 180 days. Target trough level for cyclosporin is 200 ng/ml. In the absence of GVHD, Cyclosporin tapering will begin on day +90~Methyl prednisolone (1mg/kg/d IV) will begin on day -2 to +7 and then 0.5mg/kg until +14 posttransplant."
223787383|NCT01981135|OTHER|Clean Air|Each subject will be exposed to clean air for 2 hours. The exposure atmosphere will be at a temperature between 31-34oC (88-93 oF) and approximately 40 + 10% RH. Subjects will exercise on a bike. Each exercise session will consist of a 15 minute exercise interval at a level of up to 25 L/min/m2BSA followed by a 15 minute rest period.
223787384|NCT01981135|OTHER|Ozone|Each subject will be exposed up to 0.3ppm ozone for 2 hours. The exposure atmosphere will be at a temperature between 31-34oC (88-93 oF) and approximately 40 + 10% RH. Subjects will exercise on a bike. Each exercise session will consist of a 15 minute exercise interval at a level of up to 25 L/min/m2BSA followed by a 15 minute rest period.
223787385|NCT00648076|DRUG|Divalproex Sodium Extended-Release Tablets 500 mg|500mg, single dose fed
223787386|NCT00648076|DRUG|Depakote ER® Tablets 500 mg|500mg, single dose fed
223787387|NCT01296568|DRUG|LY2603618|Administered intravenously
223787388|NCT01296568|DRUG|Pemetrexed|Administered intravenously
223787389|NCT01296568|DRUG|Gemcitabine|Administered intravenously
223787390|NCT02877290|DEVICE|non-invasive ventilation (NIV)|
223787391|NCT00607451|DRUG|Neu-120|Capsules of 300, 900 and 2700mg; administered as a single dose with a one week washout between each administration.
223787392|NCT01721018|BIOLOGICAL|HSV1716 Intra-pleural delivery|
223787393|NCT06035133|DRUG|CapeOX + cetuximab|CapeOX + cetuximab for RAS wild-type patients and CapeOX + cetuximab for MSI-H patients. The CapeOX regimen: Oxaliplatin 130 mg/m2, intravenous injection, day 1; capecitabine 1000 mg/m2, oral, twice daily, days 1 through 14; once every 3 weeks.
223787394|NCT06035133|DRUG|CapeOX + bevacizumab|CapeOX + bevacizumab for RAS mutant patients. The CapeOX regimen: Oxaliplatin 130 mg/m2, intravenous injection, day 1; capecitabine 1000 mg/m2, oral, twice daily, days 1 through 14; once every 3 weeks.
223787395|NCT06035133|RADIATION|radiotherapy|radiotherapy
223787396|NCT05156138|OTHER|no interventions as it is a case control observational study|no interventions as it is a case control observational study
223787397|NCT04196400|DRUG|steroid betamethasone|The steroid is injected using insulin needle in the subcutaneous tissue after finishing the repair
223787398|NCT05624242|PROCEDURE|cardiac magnetic resonance imaging|all patients had magnetic resonance imaging at baseline and during follow-up.
223787399|NCT04258020|DEVICE|BiPAP|Bilevel Positive Airway Pressure (BiPAP) oxygen administration
223787400|NCT04258020|DEVICE|HFNC|Heated High Flow Nasal Cannula oxygen administration
223787401|NCT00372463|BEHAVIORAL|6-week Online Diabetes Self-Management Educational Program|
223787402|NCT01141192|DIETARY_SUPPLEMENT|vitamin D3, cholecalciferol|1 gelcap of 50,000 IU vitamin D3 plus 2 gelcaps of 5,000 IU vitamin D3 each; a total of 60,000 IU vitamin D3 dosed four weeks apart at weeks 0, 4, 8, and 12 of the 16 week study.
223787403|NCT01141192|DIETARY_SUPPLEMENT|Inactive comparator|The inactive comparator dose provided was identical in appearance to the active comparator but contained no vitamin D3
223787404|NCT03305016|DRUG|TransCon hGH|Once weekly subcutaneous injection at a starting dose of 0.24 mg/kg/week
223787405|NCT02999776|DEVICE|Laser microporation alone|The Er:YAG laser induced microporation of 5 cm2 of a plaque surface, followed by application of an OpSiteTM Flexigrid Transparent Dressing for 4 hours. This treatment will also be repeated twice weekly for 8 weeks.
223787406|NCT02999776|DRUG|Standard of care-daily administration of Daivobet|The other control treatment is Daivobet®, which is applied topically daily for 8 weeks on one pre-selected randomized plaque.
223787407|NCT02999776|DRUG|Laser microporation + topical application of Etanercept|Immediately following microporation of a 5 cm² area of the designated plaque with the P.L.E.A.S.E.® Professional laser, 0.0625 ml of Etanercept (50 mg/ml) solution for injection in pre-filled syringes will be applied to the microporated surface of the lesion. The treated area will then be covered with OpSiteTM Flexigrid Transparent Dressing for 4 hours. This treatment procedure will be repeated twice weekly for 8 weeks.
223787408|NCT01846338|DIETARY_SUPPLEMENT|green tea extract EGCG|EGCG, 500mg, tid, 4 weeks
223787409|NCT03953092|DRUG|YG1699|YG1699 at Multiple Doses
223787410|NCT03953092|DRUG|Placebos|Placebos
223787411|NCT04323852|DRUG|Vitamin D|Participants undergoing coronary artery bypass graft (CABG) surgery are randomly allocated to group A (intervention), who receive 3 doses of vitamin D (50000 U) a day for 3 days before surgery
223787412|NCT04323852|DRUG|Placebo|Placebo
223787413|NCT01938755|DRUG|levobupivacaine|levobupivacaine plus 60 mg dextrose
223787414|NCT01938755|DRUG|levobupivacaine|levobupivacaine plus 80 mg dextrose
223787415|NCT01938755|DRUG|levobupivacaine|levobupivacaine plus 100 mg dextrose
223787416|NCT05921877|DIAGNOSTIC_TEST|venous sampling|venous sampling
223787417|NCT00418535|DRUG|Concurrent Radiotherapy (RT)/cisplatin, VIPD|
223787418|NCT00745017|BEHAVIORAL|Cognitive Behavioral Therapy|All patients randomized to this condition will receive 16 consecutive weeks of manualized cognitive-behaviour therapy provided by either M.S.W or Ph.D. psychotherapists trained and certified in CBT. Treatment will be conducted according to the manualized CBT treatment for depression outlined by Beck and colleagues (Beck et al., 1979), and consistent with the protocol administered in the NIMH study.
223787419|NCT00745017|BEHAVIORAL|Interpersonal Therapy|All patients randomized to this condition will receive 16 consecutive weeks of manualized interpersonal psychotherapy conducted by M.S.W., Ph.D., or M.Ed. psychotherapists trained and certified in IPT.
223787420|NCT00745017|DRUG|Antidepressant medication|Patients patients randomized to this condition will be treated for 16 weeks with different classes of anti-depressant medications, using standardized protocols. Patients will receive 16 weeks of treatment with either a SSRI (sertraline or paroxetine) or a SNRI (venlafaxine). The dose range is as follows: sertraline 50-200 mg/day, paroxetine 20-40 mg/day, venlafaxine 75-375 mg/day. Patients unable to continue with the prescribed medication due to side effects and/or lack of response will be prescribed an alternate medication during the first two weeks of the protocol.
223787421|NCT01387568|DRUG|Lidocaine Infusion|children in group L received i.v. lidocaine 1.5 mg/kg followed by infusion at 1.5 mg. kg-1.h-1. and were continued up to 6 hours postoperatively
223787422|NCT01387568|DRUG|saline Infusion|children in group P received i.v. saline 0.9% 1 ml/kg followed by infusion at 0.1 ml. kg-1.h-1,and were continued up to 6 hours postoperatively
223787423|NCT04833023|DRUG|Haldol 2mg/ml oral solution|"Starting dose: 1mg~Maximum Dose within 24 hours: 6mg~Doses can be escalated every 2 hourly to the maximum doses allowed within 24 hours. If maximum dose of Haloperidol has been reached for the day (within 24 hours), rescue dose of Midazolam 2mg can be used (2mg Q2H PRN)."
223787424|NCT04833023|DRUG|Olanzapine Actavis 5mg orodispersible tablet|"Starting dose: 2.5mg~Maximum Dose within 24 hours: 15mg~Doses can be escalated every 2 hourly to the maximum doses allowed within 24 hours. If maximum dose of Olanzapine has been reached for the day (within 24 hours), rescue dose of Midazolam 2mg can be used (2mg Q2H PRN)."
223787425|NCT00919282|DRUG|gemcitabine, folinic acid, 5-FU|gemcitabine 1g/m² - 30 minutes folinic acid 500mg/m² - 2 hours 5-FU 750mg/m² - over 24hours
223787426|NCT04399629|BEHAVIORAL|PCIT-ED|12 sessions of PCIT-ED therapy
223787427|NCT04399629|BEHAVIORAL|Parenting Wisely|Teaches parents how to set more effective limits
223787428|NCT06529588|RADIATION|Radiation|HNCs patients who received radiotherapy was exposure (5700-7000 Gys) for fractions number (32-35) after 6 months
223787429|NCT01134029|BEHAVIORAL|Stepped Care|This group receives 2 years of a stepped care intervention including provider visits, health educator sessions, phone calls and mailings and availability of self management and group sessions, text messaging and a smoker's quit line.
223787430|NCT06380231|OTHER|kangaroo mother care (KMC)|"Kangaroo mother care is a simple care that aims to protect the health and well-being of premature babies, where skin-to-skin contact is achieved by placing the premature baby in an upright position, face down, between the parent's breasts, wearing only a diaper and a cap.~Before the experimental group infant was given to the mother, his/her hat was put on, and clothes were removed. The infant was placed in an upright position (approximately 60°) between the mother's two breasts. To enable the infant to breathe, his/her head was positioned to the right or left with ear touching the mother's chest, arms and legs were flexed, and hip was abducted. The mother supported the infant's neck and back with one hand and the hips with the other. The infant's back was covered with a cotton blanket. An noninvasive pulse Co-oximetry was attached to the right wrist of the infant to evaluate heart rate, oxygen saturation, and perfusion index."
223787431|NCT03579979|DRUG|Methylene Blue|Subcutaneous injection of injection point at the periphery of the areola or tumor, injecting 1% methylene blue 0.5ml at each point, a total of 2-3 points.
223787432|NCT03579979|DRUG|Indocyanine Green|Within 5 minutes after MB injection, 2.5mg/ml ICG 0.5ml was injected at each point, a total of 2-3 points. Methylene blue and ICG injection points do not coincide
223787433|NCT01519206|DEVICE|Ulthera System Treatment|Focused ultrasound energy delivered below the surface of the skin.
223787434|NCT00712842|OTHER|Ocular blood flow measurements|non-invasive haemodynamic measurements of retinal vessel diameters and laser Doppler velocimetry
223787435|NCT03861598|DRUG|Carvedilol|Carvedilol orally starting at 6.25 mg and increasing to 12.5 mg if tolerated after 1-2 weeks for a total of 4 cycles of treatment.
223787436|NCT00542802|DRUG|Levetiracetam|Levetiracetam tablets 250-500 mg. The drug dosage will be up-titrated from 250 mg bid in the first 2 weeks to 500 mg bid during the rest of the treatment period. The dosage can be incremented until 1500 mg bid, at Investigator judgement if crisis continue, or it can be reduced in case of adverse events
223787437|NCT00542802|DRUG|Carbamazepine|Carbamazepina tablets 200 mg. The drug dosage will be up-titrated from 100 mg die in the first 3 days to 100 mg bid during days 4 to 7, to 200 mg bid in the 2nd week, to 300 mg bid during the rest of the treatment period. The dosage can be incremented until 800 mg bid, at Investigator judgement if crisis continue, or it can be reduced in case of adverse events
223787438|NCT00496041|PROCEDURE|Registry|A Registry will be used.
223787439|NCT05219149|BEHAVIORAL|Qualitative Interviews|Conduct qualitative interviews with patients and families who are considering treatment options for new or recurrent CNS tumors to identify specific barriers to full participation in treatment and clinical trial enrollment (e.g., transportation, childcare, ancillary expenses). Qualitative interviews will be structured to comprehensively address potential barriers but also open-ended to give patients and families freedom to discuss a wide range of challenges.
223787440|NCT06634745|PROCEDURE|Standard Needle Irrigation (SNI)|"Standard Needle Irrigation (SNI):~Utilizes standard needle irrigation techniques for activating the antimicrobial solution within the root canal."
223787441|NCT06634745|PROCEDURE|Passive Ultrasonic Irrigation (PUI|"Passive Ultrasonic Irrigation (PUI):~Employs ultrasonic energy to enhance the activation and effectiveness of the antimicrobial solution in the root canal."
223787442|NCT06634745|PROCEDURE|EndoActivator (EA)|"EndoActivator (EA):~Uses a sonic activation device to facilitate the distribution and activation of the antimicrobial solution in the root canal."
223787443|NCT06634745|PROCEDURE|EDDY|"EDDY:~Involves the use of a sonic activation device that operates at high frequency to activate the antimicrobial solution within the root canal.~These descriptions focus on the general method and purpose of each intervention without delving into the specific procedural details already covered in the arm/group descriptions."
223787444|NCT05046795|DRUG|Revefenacin 175 mcg in 3 ML Inhalation Solution|Revefenacin
223787445|NCT05046795|DRUG|Placebo inhalation solution QD|Placebo
223787446|NCT02864082|DRUG|PAT-001, 0.1%|PAT-001 is a topical ointment. PAT-001, 0.1% contains 0.1% of active drug.
223787447|NCT02864082|DRUG|PAT-001, 0.2%|PAT-001 is a topical ointment. PAT-001, 0.2% contains 0.2% of active drug.
223787448|NCT02864082|DRUG|Vehicle for PAT-001 0.1%|Vehicle topical ointment contains 0.0% of active drug and is color matched to the active test article, PAT-001 0.1%.
223787449|NCT02864082|DRUG|Vehicle for PAT-001 0.2%|Vehicle topical ointment contains 0.0% of active drug and is color matched to the active test article, PAT-001 0.2%.
223787450|NCT02271126|DEVICE|TEG monitoring|anticoagulation monitoring during ECMO will be according to TEG
223787451|NCT02271126|DEVICE|APTT monitoring|anticoagulation monitoring during ECMO will be according to aPTT
223787452|NCT02271126|DRUG|Heparin|Anticoagulation provided to patients in ECMO
223787453|NCT05848141|BEHAVIORAL|Exercise training|This is a single site center-based supervised exercise intervention.
223787454|NCT02362490|DRUG|peginterferon alpha 2a|in this group,patients will receive 180 ug of peginterferon alpha 2a injection weekly for 72 weeks
223787455|NCT04678648|DRUG|RSC-1255 Dose Escalation|Phase 1a will enroll 30-40 participants to identify the dose limiting toxicity (DLT), recommended Phase 1b dose, and the safety and tolerability of RSC-1255. RSC-1255 is administered orally twice daily, without food. Each cycle is 21 days.
223787456|NCT04678648|DRUG|RSC-1255 Dose Expansion|Phase 1b will enroll 48-104 participants to further characterize the safety, pharmacology, and clinical efficacy of RSC-1255. RSC-1255 is administered orally twice daily, without food. Each cycle is 21 days.
223787457|NCT06401148|BEHAVIORAL|Cardiac rehab intervention group|Participants will complete an 8-week cardiac rehabilitation programme supported by the onsite CR service.
223787458|NCT01127178|DRUG|E7016 + TMZ|Single-Dose PK Period (single oral dose of E7016 on Day -7) in the Dose-Escalation Component; Multiple-Dose Treatment Cycles (7 days of oral E7016 + 5 days of oral TMZ) added in Cycle 1 of the Dose-Escalation Component and in Cycles 1 through 6 of the Expansion Component.
223787459|NCT03295188|DIETARY_SUPPLEMENT|Plasmalogen|Treatment group takes two 0.5 mg plasmalogen capsules per day for 12 weeks.
223787460|NCT03295188|DIETARY_SUPPLEMENT|Placebo|Placebo Group takes two placebo capsules per day for 12 weeks.
223787461|NCT06298903|OTHER|Hip Activation|Sidelying hip abduction, side plank with hip abduction, clamshell (hip abduction + external rotation), side plan with clamshell, and quadruped fire hydrant exercises will be performed for 1 minute isometric holds, 2 times per week for 8 weeks.
223787462|NCT06298903|OTHER|Hip activation + Single leg balance|"Hip activation HEP: Sidelying hip abduction, side plank with hip abduction, clamshell (hip abduction + external rotation), side plan with clamshell, and quadruped fire hydrant exercises will be performed for 1 minute isometric holds, 2 times per week for 8 weeks.~Single leg balance: variety of single leg balance exercises with different upper extremity and lower extremity positions to provide different balance stimuli. Weeks are alternated performing these exercises with eyes open and eyes closed."
223787463|NCT05026736|OTHER|Quality-of-Life Assessment|Ancillary studies
223787464|NCT05026736|BIOLOGICAL|Sintilimab|Given IV
223787465|NCT04139317|DRUG|Capmatinib|INC280 tablets were administered orally at 400 mg on a continuous twice daily (BID) dosing schedule, from Day 1 until Day 21 of each 21-day cycle.
223787466|NCT04139317|BIOLOGICAL|Pembrolizumab|Pembrolizumab was administered by intravenous infusion at 200 mg once every 3 weeks (Q3W).
223787467|NCT06963268|PROCEDURE|Sentinel Node Technique|A 0.2 ml (27 mBq) dose of 99mTc and 0.5 ml (1.25 mg/ml) of ICG is injected subperitoneally in the dorsal or ventral side of the pelvic infundibulum stump, and 0.2 ml (27 mBq) of 99mTc and 1 ml (1.25 mg/ml) of ICG intracervically. Sentinel nodes are located using the auditory signal from the gamma probe and visually via ICG staining with an infrared light system. After 30 minutes, all identified nodes are removed. Deferred histology applies ultra-staging for negative or micrometastatic nodes.
223787468|NCT06962982|BEHAVIORAL|Therapeutic Exercises|Therapeutic exercises including stretching and active exercises for neck and shoulder.
223787469|NCT06962982|BEHAVIORAL|Ergonomic Training|Recommendations for adjustments to the chair, desk, and equipment to optimize comfort and efficiency and reduce unnecessary stress and loading on neck muscles.
223787470|NCT06962982|DEVICE|Human XR device - Oculus Quest 3|Meta Quest 3 is a standalone virtual reality headset by Meta Platforms featuring a slimmer design, higher-resolution dual LCD displays, improved performance with the Snapdragon XR2 Gen 2 chip, and advanced mixed reality capabilities through color passthrough cameras and a depth sensor.
223787471|NCT06961981|BEHAVIORAL|Vinyasa Yoga|Each yoga session will begin with 2 minutes of integration poses (Child's Pose, Downward Facing Dog, Ragdoll, and Mountain Pose), followed by \~20 minutes of Sun Salutations A and B (up to 5 of each). The Standing Series, lasting \~25 minutes, will include various standing and balancing poses from the Journey into Power sequence. Seated and supine stretches (including seated stretches, a yoga inversion, a reclined twist) will last \~8 minutes, and the session will conclude with 5 minutes of Savasana for final relaxation.
223787472|NCT06962150|PROCEDURE|Surgeon-placed transversus abdominis plane block|Participants will receive a transversus abdominis plane (TAP) block intraoperatively, administered by the operating plastic surgeon. The drug components of the TAP block are 20 ml liposomal bupivacaine (Exparel) mixed with 20 ml 0.5% bupivacaine.
223787473|NCT06962150|PROCEDURE|Ultrasound-guided quadratus lumborum block|Participants will receive a quadratus lumborum (QL) block preoperatively, administered by the anesthesiologist under ultrasound guidance. The drug components of the QL block are 10 mg dexamethasone, 80 mg methylprednisolone acetate, plus either 0.25% or 0.5% bupivacaine at the dose of 0.25 mg/kg bupivacaine.
223787474|NCT06961890|BEHAVIORAL|Principals of cognitive behavioral therapy on guided changing hygiene and sugar comsuption habits|The twin pairs will also receive guidance on healthy sugar consumption and oral hygiene habits, as the first intervention among the dental interventions received. For the baseline assessment, each participant answered a questionnaire about their diet the day before and about oral hygiene, in addition to demonstrating how they perform it. Thus, the cognitive behavioral theory was applied, so that the participant can record the goals achieved weekly and monthly.
223787475|NCT04481919|DRUG|Protocolized diuretic therapy|The urine sodium, urine creatinine and serum creatinine results will be input into the diuretic calculator and the diuretic dose will be chosen based on daily goals for urine output and net negative fluid balance.
223787476|NCT06575140|DEVICE|Associative Peripheral Stimulation (APS) 1.0|Associative peripheral stimulation paired with rehabilitative exercises.
223787477|NCT06575140|DEVICE|Peripheral Neuromuscular Stimulation|Random peripheral stimulation paired with rehabilitative exercises.
223787478|NCT06054724|OTHER|Yoga-Based Respiration Training|The selected asanas, believed to be beneficial for urinary incontinence, will be practiced with a focus on breath. After the assessment session, participants will engage in three days of face-to-face yoga sessions. On the days when face-to-face sessions are held, participants will perform the second session on their own at home. The exercises will be progressively intensified during the 3rd and 5th weeks to ensure progression. The exercise program will be conducted at home, with approximately 20-minute sessions, twice a day, five days a week, for a total of 6 weeks.
223787479|NCT06054724|OTHER|Pilates-Based Respiration Training|Before starting the 6-week practice protocol, participants will be taught the transversus abdominis muscle activation and centering, pilates-specific lateral costal breathing and other key elements of pilates. Pilates exercises chosen as beneficial for urinary incontinence will be performed with a focus on breath. After the assessment session, participants will engage in three days of face-to-face pilates sessions. On the days when face-to-face sessions are held, participants will perform the second session on their own at home. The exercises will be progressively intensified during the 3rd and 5th weeks to ensure progression. The exercise program will be conducted at home, with approximately 20-minute sessions, twice a day, five days a week, for a total of 6 weeks.
223787480|NCT03621696|DRUG|Cisplatin|-100 mg/m\^2 intravenous push bolus (IVPB)
223787481|NCT03621696|RADIATION|Intensity modulated radiation therapy|-IMRT or IMPT can be used
223787482|NCT03621696|RADIATION|Intensity modulated proton therapy|-IMRT or IMPT can be used
223787483|NCT03621696|PROCEDURE|Surgery|-Standard of care
223787484|NCT03621696|OTHER|FACT-H&N|-Baseline, interim assessment (14-42 days post-surgery), day 1 of radiation, day 21 of radiation, day 36 of radiation, 6 weeks after completion of adjuvant therapy, 4 months after the completion of adjuvant therapy, 6 months after the completion of adjuvant therapy, 12 months after the completion of adjuvant therapy, and 24 months after completion of adjuvant therapy
223787485|NCT03621696|OTHER|MD Anderson Dysphagia Inventory|-Baseline, interim assessment (14-42 days post-surgery), day 1 of radiation, day 21 of radiation, day 36 of radiation, 6 weeks after completion of adjuvant therapy, 4 months after the completion of adjuvant therapy, 6 months after the completion of adjuvant therapy, 12 months after the completion of adjuvant therapy, and 24 months after completion of adjuvant therapy
223787486|NCT03621696|OTHER|University of Michigan Xerostomia Index|-Baseline, interim assessment (14-42 days post-surgery), day 1 of radiation, day 21 of radiation, day 36 of radiation, 6 weeks after completion of adjuvant therapy, 4 months after the completion of adjuvant therapy, 6 months after the completion of adjuvant therapy, 12 months after the completion of adjuvant therapy, and 24 months after completion of adjuvant therapy
223787487|NCT03621696|OTHER|Scale of Subjective Total Taste Acuity|-Baseline, interim assessment (14-42 days post-surgery), day 1 of radiation, day 21 of radiation, day 36 of radiation, 6 weeks after completion of adjuvant therapy, 4 months after the completion of adjuvant therapy, 6 months after the completion of adjuvant therapy, 12 months after the completion of adjuvant therapy, and 24 months after completion of adjuvant therapy
223787488|NCT03621696|OTHER|Neck Dissection Impairment Index|-Baseline, interim assessment (14-42 days post-surgery), day 1 of radiation, day 21 of radiation, day 36 of radiation, 6 weeks after completion of adjuvant therapy, 4 months after the completion of adjuvant therapy, 6 months after the completion of adjuvant therapy, 12 months after the completion of adjuvant therapy, and 24 months after completion of adjuvant therapy
223787489|NCT05750953|BEHAVIORAL|eHealth@Hospital-2-Home|At hospital discharge, the intervention group will receive a wireless, portable personal computer system (i.e., IPAD) that includes the eHealth application MyDignio supplied by a certified m-Health company. MyDignio app is linked to monitoring devices by Bluetooth for each patient to daily and weekly measure clinical measures such as blood pressure, pulse, temperature, and weight, and self-reported symptoms and well-being, and daily report clinical measurements to the Nurse Navigators employed in the two hospitals. The patients will receive training from the nurses on how to log on and use the MyDignio app and the monitoring devices. Telephone contact details including information about how to access technical support will be provided to each study participant shortly following discharge.
223787490|NCT06513429|BIOLOGICAL|IM19 CAR-T cells|IM19 CAR-T cells by intravenous infusion.
223787491|NCT05935540|OTHER|ACP-Family|"It consists of two sessions (45-60 mins) to be delivered within one month in a face-to-face format as long as the patient is still in the hospital. The treatment will be continued in the patient's home if he/she is discharged before the two sessions are completed.~The treatment will cover five elements in ACP, namely (1) patients' understanding of their illness, (2) patients' values and beliefs underpinning care preferences, (3) possible health conditions in the future, (4) introducing the idea of AD and its arrangement, and (5) construction of the role of substituted decision maker. A 3-min video on end-of-life treatment options will be shown to help patients and family members to clearly understand the related topic. However, there will be no restriction on the order of the five topics to be discussed during the intervention."
223787492|NCT06635096|DEVICE|Multimodal Tumor Thermal Therapy System (Shanghai MAaGI Medical Technology Co., Ltd.)|These patients will receive multimodal thermal therapy using Multimodal Tumor Thermal Therapy System.
223787493|NCT06634446|DEVICE|a mobile application for cognitive training|"Personalized cognitive training (PCT) HappyNeuronwill be delivered via a tablet or mobile application for 24 hours within 12 weeks, with a weekly supervision-call to reinforce their motivation.~HappyNeuron Pro is a digital therapy tool designed for clinicians to provide engaging cognitive therapy via a web-based platform. It is compatible with PC, Mac, iPad, and Android devices and is available in multiple languages. The tool features exercises from established cognitive remediation programs.~Functionality: The program offers 22 cognitive exercises targeting seven key functions outlined in the MATRICS framework: Processing Speed, Selective Attention, Reasoning and Working Memory, Verbal Memory, Visual Memory, and Auditory Memory. Exercises are customizable to meet individual patient needs, facilitating personalized cognitive training.~User Experience: Each session comprises brief, self-administered exercises, with the order and difficulty adjusted by clinicians."
223787494|NCT06634446|DEVICE|video games|Patients in the control group will use video games with no prominent cognitive involvement no prominent cognitive involvement
223787495|NCT04349553|BIOLOGICAL|ZH9PA and ZH9|150mL vaccine for oral administration
223787496|NCT04349553|BIOLOGICAL|Placebo|150mL vaccine for oral administration
223787497|NCT04349553|BIOLOGICAL|ZH9PA|150mL vaccine for oral administration
223787498|NCT03011684|DRUG|Tamoxifen|Given orally
223787499|NCT03011684|DRUG|Letrozole|Given orally
223787500|NCT03246360|DRUG|Modification for administration mode of cloxacillin antibiotic|"For intermittent administration, patients will benefit from cloxacillin treatment in conventional hospitalization, in accordance with national guidelines, at a dose of 150 mg / kg per day in 4 infusions, not exceeding the maximum daily dose of 12 g / day according to.~For continuous administration the same quantity of cloxacillin 150 mg / kg per day, without exceeding the maximum daily dose of 12 g / day, will be delivered by a self-propelled syringe in twice 12 hours. Patients randomly assigned to receive continuous administration will receive a dose of cloxacillin equivalent to the dose administered 4 times daily during iterative administration using a self-pulsating syringe. For the first day of the study, this loading dose will be subtracted from the 150 mg / kg dose to be administered continuously over the remaining 23 hours of the first day of the study and never exceed 12g / day.~Pharmacological dosages will be performed on the third and sixth day in both arms"
223787501|NCT04994366|OTHER|Thank you card|A card thanking the patient for choosing NYU and entrusting us with their care. The card notifies the patient that they may receive a patient satisfaction survey after discharge.
223787502|NCT03541096|BEHAVIORAL|Winter Swimming|Supervised Winter Swimming in Copenhagen
223787503|NCT03541096|BEHAVIORAL|Control group|No winter swimming activities.
223787504|NCT03315000|DRUG|Vilanterol and Fluticasone Furoate|Same as vilanterol arm description
223787505|NCT03315000|DRUG|Fluticasone Furoate|Same as fluticasone arm description
223787506|NCT03315000|DRUG|Placebos|Same as placebo arm description
223787507|NCT05831358|OTHER|Multiple Myeloma M-Protein Analysis|Participants will be screened with a blood test for monoclonal protein analysis
223787508|NCT05831358|OTHER|Multiple Myeloma Knowledge Questionnaires|Participants will complete two questionnaires to share their attitudes toward their screening experience and completion of knowledge questions to gauge community reception and participant multiple myeloma knowledge.
223787509|NCT06510075|BEHAVIORAL|Digital Health intervention|Health care information delivered via a link in a text message that is then opened in a secure browser.
223787510|NCT06510075|BEHAVIORAL|Community Health Worker|Health care information delivered via CHW.
223787511|NCT06510075|BEHAVIORAL|Digital Health Intervention plus Community Health Worker|Health care information delivered via DHI plus CHW
223787512|NCT02277782|DRUG|Hydromorphone|
223787513|NCT02277782|DRUG|Hyperbaric bupivacaine|
223787514|NCT02277782|DRUG|Fentanyl|
223787515|NCT02539264|OTHER|Smoking|Influence of smoking on parameters derived from overnight PSG
223787516|NCT02539264|OTHER|Obesity|Influence of obesity on parameters derived from overnight PSG
223787517|NCT02539264|OTHER|Benzodiazepine use|Influence of benzodiazepine use on parameters derived from overnight PSG
223787518|NCT04529213|PROCEDURE|Rapid Maxillary Expansion Treatment|The patients were treated with KBME, Hyrax and MIDME maxillary expansion appliances, respectively. All expansion appliances containing a Hyrax expansion screw positioned parallel to the second premolars and were used to correct the posterior crossbite. In the MIDME group, two mini-screws with a diameter of 1.6 mm and a length of 10 mm are located on the right and left sides between the roots of the 2nd premolar and 1st molar teeth with 60-70° angle. KBME and Hyrax expansion appliances were cemented with glass ionomer cement and MIDME was cemented with using the light-cured composite. Same protocol was applied to all patients during RME treatment. Expansion screws in all groups were activated by two turns a day.
223787519|NCT03663751|DRUG|Decitabine|low-dose decitabine: 5mg/m2 daily for 5 days
223787520|NCT02978274|DRUG|MMF|MMF withdrawal by engraftment post haplo-SCT
223787521|NCT02978274|DRUG|MMF|MMF withdrawal by 2 month post haplo-SCT
223787522|NCT05124457|DRUG|Insulin Detemir|Patients are to receive insulin detemir
223787523|NCT05124457|DRUG|Insulin NPH|Patients are to receive insulin NPH
223787524|NCT01262066|BEHAVIORAL|Lifeskills Workshop Intervention|Intervention participants attended 10 one-hour weekly group sessions. The content of the groups followed the LifeSkills Workshop manual and Video ( (Williams LifeSkills, Inc, Durham NC). The LifeSkills Workshop is a structured psycho-educational group intervention using workbooks and videotapes that draw on cognitive-behavioral techniques and stress reduction approaches.
223787525|NCT02149589|PROCEDURE|Mechanical ventilation|
223787526|NCT02466945|DEVICE|V063B-DP3003|The medical device V063B-DP3003 has been developed to relieve and decrease dentinal hypersensitivity in patients by creating a film around the sensitive tooth in order to prevent pain. Application modalities: apply a pea size amount of product (around 0.5g) onto each of the sensitive teeth, 3 times a day, by gentle massage with clean finger after each brushing of teeth. Do not rinse
223787527|NCT01661660|OTHER|observationnal|Observation during a physical exercise
223787528|NCT04996784|OTHER|Capillary blood sampling|The capillary blood sample will be obtained by pricking the fingertip using contact-activated lancet (BD Microtainer). A total of five blood drops (10 μL each) will be collected by a micropipette and will be dropped off on the blotting paper 903 S\&S (Whatman).
223787529|NCT06034600|OTHER|taping|Taping will be applied to the exercise and taping group after the exercises with theraband. Other exercises that are not performed will be performed with the tape on the skin.The application will be repeated three days a week for eight weeks.
223787530|NCT06034600|OTHER|exercise|"Stretching and strengthening exercises will be applied to both groups three days a week for 8 weeks.The exercises performed with theraband will be performed in the same way in both groups. While the other exercises will be done after taping in the taping and exercise group, the exercise group will be done without taping."
223787531|NCT01924936|BEHAVIORAL|DBT Online Program|DBT online program involving three DBT skills taught across three lessons. The DBT online program will be based on a brief DBT skills intervention previously developed and pilot tested by Dr. Whiteside. This DBT online program will provide far greater clinical intensity than Intervention 1 and will be delivered with a widely-used modular software platform suitable for an R-34 project.
223787532|NCT03007927|DRUG|Bupivacaine-Dexamethasone|Bupivacaine 1,5 mg/kg-Dexamethasone 2ml 8 mg
223787533|NCT03007927|DRUG|Bupivacaine- physiological solution|Bupivacaine 1,5 mg/kg- physiological solution
223787534|NCT00306228|PROCEDURE|Postfibrinolysis percutaneous coronary intervention|implantation of a bare-metal stent with no infusion of tirofiban 120 minutes after fibrinolysis
223787535|NCT00306228|PROCEDURE|Postfibrinolysis percutaneous coronary intervention|implantation of a bare-metal stent with infusion of tirofiban 120 minutes after fibrinolysis
223787536|NCT00306228|PROCEDURE|Postfibrinolysis percutaneous coronary intervention|implantation of a paclitaxel eluting-stent with no infusion of tirofiban 120 minutes after fibrinolysis
223787537|NCT00306228|PROCEDURE|Postfibrinolysis percutaneous coronary intervention|implantation of a paclitaxel eluting-stent with infusion of tirofiban 120 minutes after fibrinolysis
223787538|NCT05635214|PROCEDURE|real time remote tele mentored ultrasound exam|A patient will have a point of care ultrasound exam performed by a local provider with a remote expert guiding them through the exam using video conferencing.
223787539|NCT00214136|RADIATION|radiotherapy|prostate radiation to 70Gy; nodal radiation to 56Gy
223787540|NCT02817451|BIOLOGICAL|Hexaxim®: DTaP-IPV-HB-PRP-T Combined Vaccine|0.5 mL, Intramuscular at 6, 10, and 14 weeks of age + a booster at age 15 to 18 months
223787541|NCT02817451|BIOLOGICAL|Hexaxim®: DTaP-IPV-HB-PRP-T Combined Vaccine|0.5 mL, Intramuscular at 6, 10, and 14 weeks of age + a booster at age 15 to 18 months
223787542|NCT04331600|DRUG|Chloroquine phosphate|Oral chloroquine phosphate for 14 days
223787543|NCT04331600|OTHER|Telemedicine|Telemedical supervision for 42 days
223787544|NCT03650881|DRUG|Neutrogena ® Light Therapy Acne Mask (MASK)|Daily use of the OTC Neutrogena Light Therapy Acne Mask once daily for 10 minutes
223787545|NCT03650881|DRUG|Topical OTC benzoyl peroxide 2.5% gel and OTC adapalene|Daily treatment with Reference Therapy OTC topical generic benzoyl peroxide 2.5% gel in the morning and OTC generic adapalene 0.1% gel at night
223787546|NCT01318187|DRUG|paracetamol|1 gr
223787547|NCT01318187|DRUG|morphine|0.1mg/kg intravenous in 100 ml serum physiologic
223787548|NCT01318187|DRUG|Paracetamol|1 gr intravenous
223787549|NCT01318187|DRUG|Paracetamol|intravenous 1 gr
223787550|NCT01318187|DRUG|Morphine|0.1 mg/kg intravenous
223787551|NCT02427529|DRUG|Human Chorionic Gonadotropin|The addition of hormone to a daily low calorie diet to potentially aid in selective fat loss, or muscle-sparing.
223787552|NCT02427529|DRUG|Placebo|
223787553|NCT02427529|OTHER|Low calorie diet|
223787554|NCT04287920|DRUG|Acomprosate|Acamprosate will be administered orally and will be dosed at 333 mg three times a day, if tolerated it will be increased to 666 mg three times a day. Acamprosate will be administered for a total of 3 months
223787555|NCT00619021|DRUG|gemcitabine hydrochloride|4 dose levels designated by cohort; 600 mg/m\^2, 800 mg/m\^2, 1000 mg/m\^2, 1200 mg/m\^2
223787556|NCT00357305|DRUG|vorinostat|Given orally
223787557|NCT00357305|DRUG|cytarabine|Given IV
223787558|NCT00357305|DRUG|etoposide|Given IV
223787559|NCT00357305|OTHER|pharmacological study|Correlative studies
223787560|NCT00357305|OTHER|laboratory biomarker analysis|Correlative studies
223787561|NCT04313634|DRUG|Dasatinib|Dasatinib will be supplied as 100 mg tablet white to off-white, biconvex, oval, film- coated
223787562|NCT04313634|DRUG|Quercetin|Quercetin will be supplied as quercetin phytosome (sophora japonica concentrate (leaf) / phosphatidylcholine complex from Sunflower) 250 mg
223787563|NCT04313634|DRUG|Fisetin|Fisetin will be supplied in 100 mg capsules to be administered orally
223787564|NCT04254900|OTHER|evaluating energy availability|energy availability will be determined by measuring energy intake, exercise energy expenditure and fat-free mass and using the following formula: energy availability = (energy intake - exercise energy expenditure) / fat-free mass
223787565|NCT05219877|DRUG|Pre-urodynamic Levofloxacin|Levofloxacin 500 mg single dosage 1 hour before the urodynamic examination
223787566|NCT05219877|DRUG|Post-urodynamic Levofloxacin|Administering once daily Levofloxacin 500 mg for 3 days after urodynamic study
223787567|NCT00002934|PROCEDURE|long-term screening|
223787568|NCT04297540|DEVICE|Active-tDCS group|Active anodal-tDCS will be delivered over the cerebellum for 8 sessions in two weeks. tDCS will be delivered via a battery driven direct current stimulator. Saline-soaked sponges electrodes will be placed on the cerebellar vermis (anodal electrode) and over the right buccinator muscle (reference electrode). Stimulation intensity will be set at 1.5 mA. The intensity of the stimulation will be gradually increase in order to reach the 1.5 mA with a ramping-up phase of 15 sec. Similarly, a ramping-down phase of 15 sec will gradually decrease the intensity before the end of the stimulation. The duration of the 1.5mA stimulation will be 20 minutes. Soon after the end of the stimulation, the virtual reality training will be performed. The virtual reality training will took place in a child-friendly scenario. It will comprise a total of 80 trials, during which participants will be asked to compete with some avatars in order to activate and to win some objects.
224263872|NCT07067294|DEVICE|Sham (No Treatment)|"Sham-treated controls underwent the same procedural setup as the active treatment group, using the Eye-light® device (Espansione Group, Italy). However, instead of delivering therapeutic levels of light energy, the device operated in demo light mode, emitting less than 30% of the full treatment power. This setting simulated the visual and sensory experience of a low-level light therapy (LLLT) session without delivering biologically effective photobiomodulation.~The sham intervention included two 15-minute sessions: one administered 7 days before cataract surgery and one 7 days after. This approach allowed for masking of participants and investigators to minimize bias, while ensuring that patients in the control group received no active therapeutic exposure."
223787569|NCT04297540|DEVICE|Sham-tDCS group|Sham -tDCS will be delivered over the cerebellum for 8 sessions in two weeks. tDCS will be delivered via a battery driven direct current stimulator. Saline-soaked sponges electrodes will be placed on the cerebellar vermis (anodal electrode) and over the right buccinator muscle (reference electrode). Stimulation intensity will be set at 1.5 mA but the current will be applied for 30 sec. The intensity of the stimulation will be gradually increase in order to reach the 1.5 mA with a ramping-up phase of 15 sec. Similarly, a ramping-down phase of 15 sec will gradually decrease the intensity before the end of the stimulation. The duration of the 0mA stimulation will be 20 minutes. Soon after the end of the stimulation, the virtual reality training will be performed. The virtual reality training will took place in a child-friendly scenario. It will comprise a total of 80 trials, during which participants will be asked to compete with some avatars in order to activate and to win some objects.
223787570|NCT05061121|OTHER|combined effect|Compare the short- and mid-term effects of Mulligan's SNAGs, Myofascial release, and their combination on pain intensity, pain pressure sensitivity, cervical function, range of motion (ROM) and postural stability in CNSNP patients
223787571|NCT05801224|DEVICE|Nitric Oxide|20ppm for 15 minutes delivered by INO max(Nitric Oxide) Company : INO therapeutics, Inc.
223787572|NCT00762125|BEHAVIORAL|CR+ST|Addresses maladaptive beliefs in general and includes education and training in the use of specific coping strategies
223787573|NCT00762125|BEHAVIORAL|ET|Addresses beliefs and emotional arousal during confrontations with feared element (exercising) through use of counter-conditioning and corrective feedback
223787574|NCT00762125|BEHAVIORAL|AC treatment|Provides support and controls for nonspecific factors associated with exposure to therapists and other FMS sufferers, but does not directly address either maladaptive beliefs or emotional arousal
223787575|NCT03085563|DRUG|Nitrous Oxide|Nitrous oxide will be delivered in one of two ways, using the titration method or rapid infusion method. Which ever method is used will be recorded. When using the titration method, starting at 20%, nitrous oxide will be added in 10% increments every 60 seconds until the ideal level of sedation has been met (not to exceed 70% nitrous oxide). Using the rapid infusion method, after the proper flow rate has been achieved with oxygen, the flowmeter will be increased to obtain 50% concentration of nitrous oxide. After 2-3 minutes if the patient does not have adequate sedation, nitrous oxide concentration will be increased to 70%.
223787576|NCT03085563|DRUG|Midazolam|Intranasal midazolam with mucosal atomizer device administration will follow the Children's Hospital Colorado (CHCO) established policy 'Intranasal Administration (atomization) of Medications'. As per standard of care, each patient will receive a standardized dose of 0.4mg/kg (maximum dose of 10mg) of intranasal midazolam with the mucosal atomizer device for all procedures.
223787577|NCT05483426|OTHER|semi-structured Interviews|semi-structured interview conducted by a psychiatrist
223787578|NCT01502501|PROCEDURE|Harvesting and Implantation of Adipose-Derived Stem Cells (ASCs)|Local liposuction procedure to harvest the fat tissue. Adipose Derived Stem Cells are then implanted via intramyocardial and intravenous injection.
223787579|NCT04523545|DEVICE|cardiac ablation|cardiac ablation using pulsed electric field energy to cause pulmonary vein isolation
223787580|NCT00891566|PROCEDURE|Immobilization|compared the healing status for 8 weeks of immobilization with the conventional 4 weeks of immobilization after rotator cuff repair
223787581|NCT00329069|DRUG|atorvastatin (drug)|
223787582|NCT04393883|DRUG|A) Standard maintenance programme group, pembrolizumab 200mg, every 3 weeks, for a total of 2 years of follow-up and follow-up for 1 year;|(A) Standard maintenance programme group, pembrolizumab 200mg, every 3 weeks, for a total of 2 years of follow-up and follow-up for 1 year;
223787583|NCT04393883|DRUG|B) Improvement maintenance programme group, pembrolizumab 200mg, every 6 weeks, for a total of 2 years of follow-up and 1 year follow-up;|(B) Improvement maintenance programme group, pembrolizumab 200mg, every 6 weeks, for a total of 2 years of follow-up and 1 year follow-up;
223787584|NCT00982462|DIETARY_SUPPLEMENT|Docosahexaenoic acid (DHA) and arachidonic acid (ARA)|Micro-encapsulated powder containing the long-chain polyunsaturated fatty acids, DHA to ARA in a 1:1 ratio. Two foil-packets containing active intervention (200mg DHA+200mg ARA) or placebo (400 mg corn oil) per day added to a selection of recommended foods.
223787585|NCT00982462|DIETARY_SUPPLEMENT|Corn oil placebo|Micro-encapsulated powder containing corn oil as the placebo.
223787586|NCT04644354|DRUG|Nifedipine 10 mg|For both groups, when preterm labor is diagnosed, 10 mg capsule will be given sublinguially and if it is not effective in 1 hour, the same dose will be repeated again, and the same regimen will be repeated every day till preterm labor ends or proceed to a preterm birth.
223787587|NCT04021953|BEHAVIORAL|People Like Us Online Video Series Intervention|"People Like Us miniseries incorporates key sexual health messages to:~1. Increase viewers' knowledge and perceptions of HIV and other STI risk;~2. Address homophobia and sexual orientation disclosure;~3. Increase safer-sex negotiation self-efficacy;~4. Promote positive attitudes towards condom use and other safe sex behaviors;~5. Build skills and self-efficacy for practicing safer sex;~6. Provide information on HIV and other STI testing and its benefits;~7. Provide information on resources for HIV/STI testing and other mental health services;~8. Model appropriate behaviors around practicing safer sex.~Each video in the six-part series ends with an educational video segment featuring the managers of Action for AIDS and Gayhealth.sg, who provide a brief synopsis of the episode and cover key points relevant to mental and sexual health for GBQ men."
223787588|NCT04021953|BEHAVIORAL|Sexual Health Pamphlet (Standard of Care)|The control group will be provided with an e-pamphlet on sexual wellness catered to GBMSM. This e-pamphlet has been developed by the National Skin Centre and Department of Sexually Transmitted Infections Clinic specifically for information on sexual wellness among GBMSM. It comprises segments on HIV/STI symptoms, etiology, information on how to seek help for HIV/STI, behavioral and biomedical methods of HIV prevention.
223787589|NCT04838574|OTHER|15 years Follow-up group|Phone recruitment, screening interview and eligibility questionnaire. Patient inclusion during rheumatologic evaluation : questionnaire, examination and data collection in one of the 4 study hospital centers.
223787590|NCT01573845|BEHAVIORAL|Healthy Eating + Eco-Friendly Campaign|"Participants receive a 6-month school-based campaign that includes:~* A 22-lesson classroom curriculum~* Homework activities that involve the family~* Monthly parent newsletters~* A food shopping and packing guide for parents~* Food demonstrations~* A poster contest~* School wide announcements"
223787591|NCT01573845|BEHAVIORAL|Healthy Eating Campaign|"Participants receive a 6-month school-based campaign that includes:~* A 22-lesson classroom curriculum~* Homework activities that involve the family~* Monthly parent newsletters~* A food shopping and packing guide for parents~* Food demonstrations~* A poster contest~* School wide announcements"
223787592|NCT03955432|DEVICE|Reveal LINQ ICM System|The LINQ ICM (Medtronic, Inc.) is a small FDA approved cardiac monitor implanted in the subcutaneous tissue of the chest wall that is designed to continuously record a single-lead ECG, monitoring the cardiac rhythm for up to three years. The device records and stores patient's rhythm on two occasions: first when programmed criteria are met and second upon patient activation. These programmable arrhythmia criteria are based on heart rate (bradycardia, tachycardia), irregularity of heart rate and duration of rate disturbance. The LINQ ICM (or future iterations) will be utilized in this study to detect arrhythmias in our study population.
223787593|NCT01220557|BEHAVIORAL|PRIMAS|PRIMAS is a newly developed treatment and education programme for type 1 diabetic patients. It consists of 12 lessons (duration 90 minutes each), slides for diabetes educators and patient material
223787594|NCT01220557|BEHAVIORAL|DTTP|The German DTTP (Diabetes Teaching and Treatment Programme) - The German ZI Program - is an established treatment and education programme for intensified insulin treatment consisting of 12 lessons (90 minutes duration each). Flipchart for diabetes educators and patient material.
223787595|NCT04636190|DEVICE|Triathlon All-Polyethylene Tibia Knee|Triathlon All-Polyethylene Tibia Knee is an all polyethylene resurfacing knee device using either a condylar stabilizing (CS) and posterior stabilizing (PS) device.
223787596|NCT03079804|OTHER|Experimental MWM|Mobilization with Movement
223787597|NCT03079804|OTHER|Experimental Thrust|Mobilization grade 5 (Thrust)
223787598|NCT03079804|OTHER|Placebo|Procedures similar to Experimental MWM group, but without aplly any force
223787599|NCT05169879|PROCEDURE|coronal flaring|early coronal flaring will be performed using Gates Glidden drill #3 in a brushing motion away from dangerous zone
223787600|NCT05169879|PROCEDURE|Non coronal flaring|No coronal flaring will be performed
223787601|NCT04849884|DEVICE|CORI™ KNEE TENSIONER|Robotic TKA procedure with the REAL INTELLIGENCE™ CORI™ Surgical System including the use of the CORI™ KNEE TENSIONER accessory.
223787602|NCT04968548|PROCEDURE|Blood collection|Peripheral blood will be collected via routine venipuncture procedure
223787603|NCT02522715|DRUG|Cabazitaxel|Given IV
223787604|NCT02522715|DRUG|Enzalutamide|Given PO
223787605|NCT02522715|OTHER|Laboratory Biomarker Analysis|Correlative studies
223787606|NCT02522715|OTHER|Pharmacological Study|Correlative studies
223787607|NCT02522715|DRUG|Prednisone|Given PO
223787608|NCT04724317|PROCEDURE|Steroid Group|Ultrasound guided shoulder intra-articular steroid injection
223787609|NCT04724317|PROCEDURE|Ozone Group|Ultrasound guided shoulder intra-articular Ozone injection
223787610|NCT04724317|PROCEDURE|PRF Group|Ultrasound guided shoulder intra-articular pulsed radiofrequency application
223787611|NCT03609827|DRUG|Melphalan|
223787612|NCT06386666|DEVICE|Disposable fibrous ring sutures|A new disposable fibrous ring suture device developed and produced by 2020 (Beijing) Medical Technology Co., Ltd
223787613|NCT03360253|DIETARY_SUPPLEMENT|L. reuteri DSM 17938 in drops|L. reuteri DSM 17938 will be given at a dose of 5 drops containing 1x108 colony-forming units (CFU) once time per day in an oil formulation delivered from a drop bottle
223787614|NCT03360253|OTHER|Placebo|The placebo consists of an identical formulation except that the L. reuteri is not present
223787615|NCT04537195|BEHAVIORAL|ADSMP-C|A transdiagnostic, lay-led, group-based self-management program consisting of seven 2 ½ hour weekly sessions focusing on increasing patient self-efficacy in symptom management of anxiety and depression in cancer (ADSMP-C)
223787616|NCT03188939|PROCEDURE|single injection supraclavicular brachial pleuxus block|the investigator will prepare 20 gauge 10cm block needle and portable ultrasound machine , In single-injection technique using in plane method and lateral to medial direction, local anesthetic is injected at the point where the subclavian artery meets the first rib.
223787617|NCT03188939|PROCEDURE|intracluster injection supraclavicular brachial pieuxus block|the investigator will prepare 20 gauge 10cm block needle and portable ultrasound machine (Siemens ACUSON X300 Ultrasound System with linear probe 8-14 MHZ).using in plane method and lateral to medial direction , the local anesthetic(30 ml bupivacaine) is injected inside main and satellite neural cluster.( Circumferential administration of local anesthetic rather than creating a single point injection )
224263873|NCT07067658|DEVICE|Installation of Heartfelt Device|Device installed in the patient's home and capturing foot volume data which are processed in the cloud.
224263874|NCT07067658|OTHER|Enhanced Standard care|Patients with heart failure are advised to weigh daily and to report weight increase to their clinician. They should also report changes in breathlessness, tiredness and other symptoms associated with heart failure decompensation. At the start of the study, they will be reminded (or told) about the importance of self-checks and will be handed a patient booklet (from the British Heart Foundation) to standardise patients' knowledge.
224263875|NCT07067658|OTHER|Questionnaires|Patients are presented with one or more optional questionnaires (some validated, some bespoke)
224263876|NCT07067658|DEVICE|Heartfelt device alerting system|The Heartfelt device sends alerts on the active comparator arm to the patients directly (audio-visual alert on the device, and app alerts), carers and/or medical professionals.
223787618|NCT03188939|PROCEDURE|double injection supraclavicular brachial pleuxus block|the investigator will prepare 20 gauge 10cm block needle and portable ultrasound machine (Siemens ACUSON X300 Ultrasound System with linear probe 8-14 MHZ).using in plane method and lateral to medial direction , half the volume of local anesthetic(15 ml bupivacaine) is injected at intersection of first rib and subclavian artery and another half(15 ml bupivacaine) is injected supero- lateral to subclavian artery to assure spread of the local anesthetic solution in all planes containing brachial plexus
223787619|NCT03980470|DEVICE|TrueFidelity|"TrueFidelity (Deep Learning Image Reconstruction, DLIR) software by GE Healthcare.~The medical device in question is a novel reconstruction algorithm for raw CT data which is based on artificial intelligence approaches, namely deep-learning iterative reconstruction (DLIR). This DLIR algorithm will be installed on the console of the CT Revolution scanning device, which is in routine clinical use for cardiac CT scans at the Department of Nuclear Medicine at the University Hospital Zurich. Purpose of this installation is the assessment of the performance of the DLIR algorithm during a limited time span of six weeks.~The algorithm will be CE-marked at the time of installation and use (statement by GE Healthcare provided separately). Its intended use is the reconstruction of CT datasets.~Of note, the novel DLIR algorithm will not substitute any clinical routine procedures currently in use. That is, diagnosis will still be made using the standard reconstruction algorithms."
223787620|NCT06531447|DRUG|Cisplatin|Every 21 days 6 cycles
223787621|NCT06531447|DRUG|Gemcitabine|Every 21 days (First and 8th days) 6 cycles
223787622|NCT06531447|DRUG|Doxorubicin|Every 21 days 4 cycles
223787623|NCT06531447|DRUG|Cyclophosphamide|Every 21 days 4 cycles
223787624|NCT06531447|DRUG|Paclitaxel|Every 21 days 4 cycles or once a week for 12 weeks
223787625|NCT01813240|DRUG|Minocycline|
223787626|NCT01813240|DRUG|placebo|
223787627|NCT01316367|BEHAVIORAL|PRECEDE HPE model|"The model considers the influence of the following three factors on health-related behavior:~* Predisposing: factors influencing the patient's motivation to undertake the behavior to be analyzed or encouraged.~* Facilitators: factors influencing the level of easiness or difficulty the patient and his/her family have in undertaking a given behavior.~* Reinforcing: factors arising after the patient has undertaken the behavior, and which reward or punish it."
223787628|NCT01316367|BEHAVIORAL|CHPE|The CHPE model was defined according to the recommendations of the Spanish Ministry of Health National Conference on Diabetes Mellitus, which was complemented by criteria for good care of the Madrid Primary Healthcare Service for the promotion of healthy lifestyles among adults (2004-2007). The model is based on the following aspects: self-monitoring of glycaemic control, physical exercise, diet, weight management, and times of the day when the patient was most vulnerable to overeating, and given improved understanding of the relative effects of certain food choices on blood glucose control, medication adherence and smoking cessation.
223787629|NCT01196975|BIOLOGICAL|Quadrivalent seasonal influenza vaccine GSK2282512A|Single intramuscular dose
223787630|NCT01196975|BIOLOGICAL|FluLavalTM-VB|Single intramuscular dose
223787631|NCT01196975|BIOLOGICAL|FluLavalTM-YB|Single intramuscular dose
223787632|NCT00554866|OTHER|blood sample and buccal swab sample|"one blood sample (500 mL) will be obtained from each VLBW infant between 6 and12 hours after birth from an umbilical-artery or peripheral artery catheter.~Additional DNA collection buccal cell samples were obtained with a sterile OmniSwab."
223787633|NCT05157646|BEHAVIORAL|Fitness tracker|Participants will be asked to wear a Fitbit fitness tracker and report their fitness activity to the study team
223787634|NCT01365494|BIOLOGICAL|Purified Chick Embryo Cell Inactivated Rabies Vaccine|Two group (Zagreb and Essen) will receive Rabipur vaccine IM according to either Zagreb or Essen schedules.
223787635|NCT03563495|OTHER|tissue engineered group|cultured and bone marrow derived autologous mesenchymal stem cells, loaded on collagen matrix (Osteovit)
223787636|NCT03563495|PROCEDURE|autogenous bone graft group|
223787637|NCT03815851|DEVICE|prophylactic drainage|place prophylactic drainage after surgery
223703111|NCT03860610|DIAGNOSTIC_TEST|Passive range of motion|Passive range of motion will be assessed for ankle plantar-/dorsiflexion, knee flexion/extension and hip flexion/extension, ab/adduction, internal/external rotation using goniometers and recorded in degrees. The range between two maxima will be recorded.
223703112|NCT02239588|OTHER|Oral consumption|"Daily oral consumption for 12 weeks:~Placebo;~Pure Canterbury;~Other infant formula milk powder:~1. Yashili Ambery Infant Formula Milk Powder (Stage 1 0-6 months)~2. Yashili Newwit Infant Formula Milk Powder (Stage 1 0-6 months)~3. Yashili α-golden stage Infant Formula Milk Powder (Stage 1 0-6 months)~4. Abbott Similac Infant Formula Milk Powder (Stage 1 0-6 months)~5. Wyeth S-26 SMA Gold Infant Formula Milk Powder (Stage 1 0-6 months)~6. Beingmate Love plus Infant Formula Milk Powder (Stage 1 0-6 months)"
223787638|NCT03815851|DEVICE|no prophylactic drainage|Not place prophylactic drainage after surgery
223787639|NCT00852384|PROCEDURE|NIPPV and IRM|"* non invasive positive pressure support ventilation (NIPPV group)~* alveolar recruitment maneuver (IRM group)"
223787640|NCT04335877|OTHER|Private sector component + modified BCC|Intervention group will be exposed to the private sector component + modified BCC and will receive current standard care
223787641|NCT03144726|DEVICE|Negative pressure wound therapy|Negative pressure wound therapy is a commonly utilized tool in the hospital setting and will be applied to amputations in our study to determine the effect on surgical site infections
223787642|NCT03144726|OTHER|Standard dressing|A standard dressing will be applied to the amputations in this arm of the study
223787643|NCT01713803|DRUG|Buprenorphine and naloxone|
223787644|NCT05404438|OTHER|Oral Appliances|A pre-experimental, single-group pretest-posttest design was performed. At stage one, each participant underwent a 2-day general sleeping test and a 2-day sleeping test with mouth tape. At stage two, participants underwent conventional impressions for TPD and TED appliances and were then randomly assigned to wear the TPD or TED; together for two days of sleeping test with their mouth taped. After a 2-day break (washout), with the same procedure, participants wore the other appliance for another 2-day sleeping test and decided accordingly the optimal appliance that had reduced their ODI scores more. At stage three, participants wore their optimal appliance mouth-taped during sleep for 6 weeks. At the end of the intervention, all participants underwent few days sleeping test for final results.
223787645|NCT01359735|BIOLOGICAL|HP802-247|High dose HP 802-247, applied at each visit (Week 1-13) or until healed
223787646|NCT01359735|BIOLOGICAL|Bacitracin Ointment|One dose of Bacitracin ointment consists of 50 units/1 gram. This will be applied daily for 12 weeks (or until healed).
223787647|NCT04479891|DRUG|pyrotinib tablet|single oral dose of SHR6390 or co-administered with itraconazole
223787648|NCT04479891|DRUG|Itraconazole capsule|200 mg itraconazole QD
223787649|NCT06573333|PROCEDURE|Umblical Cord Clamping|Umbilical Cord will be clamped using a plastic clamp at the noted time after delivery of the neonate
223787650|NCT03619694|DEVICE|MRI Spectroscopy|Patient with brain SOL underwent MRI Spectroscopy to be compared with later pathology
223787651|NCT05173519|DEVICE|Omnibond Topical Skin Adhesive|Application of Omnibond topical skin adhesive to close incision following surgery
223787652|NCT05173519|DEVICE|Dermabond Advanced Topical Skin Adhesive|Application of Dermabond topical skin adhesive to close incision following surgery
223787653|NCT02685163|OTHER|Antioxidant ice-cream|Narutal Antioxidant ice-cream
223787654|NCT02685163|OTHER|Control Ice-cream|Natural Control Ice-cream
223787655|NCT05710068|DEVICE|RF Microneedle|Pulsed-type RF device in bipolar mode with 25 non-insulated microneedles every 2 weeks for 6 month
223787656|NCT05710068|DRUG|Combination cream|5% hydroquinone, 0.003% tretinoin, and 1% hydrocortisone twice daily for 2 months
223787657|NCT02952079|DEVICE|Blephex|Lid margin exfoliation
223703113|NCT02735408|OTHER|Kinesiotape (KT)|
223703114|NCT00183989|DRUG|Fludarabine, Mitoxantrone and Rituximab|
223703115|NCT00241358|DRUG|AMD3100|
223703116|NCT00241358|PROCEDURE|Stem Cell Transplant|
223703117|NCT00154557|BEHAVIORAL|elite judo athletes program|
223703118|NCT06045780|OTHER|nothing|disease
223787658|NCT02952079|DEVICE|MiboFlo|Lid warming treatment
223703119|NCT04214171|DIAGNOSTIC_TEST|Gait and muscle strength will be assessed|The extensor moment of the hip during gait and evaluation of the muscular strength of the hip will be evaluated
223703120|NCT03805425|RADIATION|PiXL|The system is set to deliver 30 mW/cm2 UVA irradiance in pulsed intervals of 1 second on and 1 second off to 5 to 9 mm diameter corneal annulus. Total energy delivered is 15J.
223703121|NCT05158608|DRUG|Post-transplantation Cyclophosphamide at dose 25 mg/kg/day|Post-transplantation Cyclophosphamide will be apply for GVHD prophylaxis on day +3,+4 at dose 25 mg/kg/day in combination with cyclosporine A at 3 mg/kg/day from day +5 and mycophenolate mofetil at dose 30-45mg/kg/day from day +5.
223703122|NCT05158608|DRUG|Post-transplantation Cyclophosphamide at dose 50 mg/kg/day|Post-transplantation Cyclophosphamide will be apply for GVHD prophylaxis on day +3,+4 at dose 50 mg/kg/day in combination with cyclosporine A at 3 mg/kg/day from day +5 and mycophenolate mofetil at dose 30-45mg/kg/day from day +5.
223703123|NCT04330053|OTHER|Experimental|"* Training will address issues such as: environmental security, identifying hazards that can lead to a fall, psychological support, getting up from a fall, standing techniques and calling for help.~* The exercise program will last for six months and will be based on the OTAGO exercise program, which includes five exercise groups: general warm-up, muscle strengthening exercises, balance exercises, range of motion and stretching exercises. The program will be performed individually or in groups of two people at most and will be conducted once a week in one of the 5 outpatient clinics under the supervision of a specialized OTAGO trainer, while seniors should repeat the exercises twice a week alone at home and also walk twice a week for at least half an hour."
223703124|NCT04330053|OTHER|Control|"* Information / Education about falls The participants in this group will receive the same information - education as the participants of the 1st group.~* They will be given a leaflet with general gentle exercises (not fall prevention specific) for the home."
223703125|NCT01864941|PROCEDURE|Catheter venography with balloon venoplasty|All eligible patients will undergo catheter venography with balloon venoplasty and/or sham at baseline and at week 48 (i.e. Cross over design) followed by clinical and radiologic observation for a minimum of 48 weeks after each procedure.
223703126|NCT01864941|DEVICE|Catheter venography with balloon venoplasty and balloon|
223703127|NCT05164250|DRUG|REGN5458|
223703128|NCT04686214|PROCEDURE|heating|patients were aggressively warmed using multiple heating methods such as pressurized air heater and intravenous fluid heater
223703129|NCT06652529|DRUG|AROG4-01|AROG4-01 will be administered as IV infusions in biweekly dosing interval. The first dosing day will be Day 1, 28 days cycle.
223703130|NCT06652529|DRUG|AROG4-01|"AROG4-01 will be administered as IV infusions in biweekly dosing interval. The first dosing day will be Day 1, 28 days cycle.~This study is an open label, Phase 1 dose escalation trial with two expansion cohorts. The study consists of two parts:~* Part A: Dose escalation in patients with advanced solid tumors. Approximately 8 to 20 patients in total will be enrolled in part A, covering up to 6 dose levels.~* Part B: At the dose expansion phase, AROG4-01 two cohorts of ten patients with advanced solid tumor each will be recruited. One cohort of patients with advanced MPM (cohort 1) and a second cohort of patients with other solid tumors (cohort 2)."
223703131|NCT06517836|DEVICE|iROP DL|First, to evaluate the i-ROP DL system for autonomous ROP screening. To demonstrate the sensitivity and specificity of the i-ROP DL system on images obtained by technicians in the neonatal intensive care unit (NICU) setting to detect more than mild ROP (MTMROP), defined as type 2 or worse from the Early Treatment for ROP study) compared to an image-based reference standard diagnosis (RSD).
223703132|NCT06710678|BEHAVIORAL|Physical Activity Study Break|A 10-minute walking/upper extremity light movement indoor break from study session
224263877|NCT07067944|DRUG|Ephedrine|The parturient will receive ephedrine infusion immediately before intrathecal injection till delivery of the baby at a dose of 4mg /min.
224263878|NCT07067944|DRUG|Noradrenaline|The parturient will receive noradrenaline infusion immediately before intrathecal injection till delivery of the baby at a dose of 4 microgram/minute.
224263879|NCT07069335|DRUG|Olaparib 150 MG|Subjects receive 600 mg per day, two tablets BID (total 4 tablets), oral administration
224263880|NCT06900933|PROCEDURE|Onlay bone block covered with collagen membrane|Onlay bone block covered with collagen membrane
224263881|NCT06900933|PROCEDURE|Onlay bone block without collagen membrane|Onlay bone block covered without collagen membrane
224263882|NCT07068659|OTHER|Circuit Aerobic Training|Participant will start with five-minute warm-up consisting of running at a heart rate under 100 beats per minute, followed by stretching for 20 sec. For the 30-minute aerobic portion of the exercise sessions, in weeks 1 - 2, participants will be required to complete two circuits of walking for 5 minutes, stepping up and down on a 30 cm step for 4 minutes, and walking backward and forward for 10 meters for 5 minutes. In weeks 3 - 4, participants will complete two circuits of walking for 4 1/2 minutes, stepping up and down on a 30 cm step for 4 minutes, and walking backward and forward for 10 meters for 5 minutes. In weeks 5 - 6, participants will complete two circuits of walking for 5 minutes, stepping up and down on a 30 cm step for 5 minutes, and walking backward and forward for 10 meters for 5 minutes. The rest interval between the circuits will be 5 minutes and between the sets between 30 seconds. The intensity of the aerobic exercises will be maintained at 9 - 15 on the rating of
224263883|NCT07068659|OTHER|Circuit Resistance Training|Participant will start with five-minute warm-up consisting of running at a heart rate under 100 beats per minute, followed by stretching for 20 sec. For the 30-minute resistance portion of the exercise sessions, in weeks 1 - 2, participants will be required to complete two circuits of hamstring curl with ankle weight on each leg for 5 minutes, leg raises with ankle weight on each leg for 4 minutes, and modified squats with weights for 5 minutes. In weeks 3 - 4, participants will complete two circuits of hamstring curl with ankle weight on each leg for 4 1/2 minutes, leg raises with ankle weight on each leg for 4 minutes, and modified squats with weights for 5 minutes. In weeks 5 - 6, participants will complete two circuits of hamstring curl with ankle weight on each leg for 5 minutes, leg raises with ankle weight on each leg for 5 minutes, and modified squats with weights for 5 minutes. The rest interval between the circuits will be 5 minutes and between the sets between 30 seconds. Ch
223787659|NCT03294447|BEHAVIORAL|Fall Prevention by the Occupational Therapist|The interventions included education on adaptive equipment for household activities, adaptive equipment for activities of daily living, proper footwear in all environments, proper body mechanics, position changes, home environment set up, high fall risk activities, safety awareness, low vision and home exercises programs. In addition, discussion and education occurred to improve participation in valued occupations.
223787660|NCT01548690|DRUG|Ornithine Phenylacetate|"Up to 36 patients will be enrolled into 2 groups \[\~18 with minimal renal dysfunction (Cohort 1) \& \~18 w/ comprised renal function (Cohort 2)\] and receive OCR-002 infusion for at least 72 hrs. OCR-002 will be administered in the vein and pharmacokinetics (pk) assessed for all subjects who receive the infusion.~The first 24 enrolled subjects received OCR-002 at 3 ascending dose levels (DLs 1-3) with a maximum target infusion rate equivalent to 10g/24h.~The remaining 12 patients (\~6 Cohort 1 \& \~6 Cohort 2) will be enrolled and receive identical quantities of OCR-002 at 20g/24hr continuously for 5 days (Dose Level 4)."
223787661|NCT06215638|DRUG|Bortezomib|Bortezomib 2 mg per week subcutaneously, for twelve weeks in total
223787662|NCT03006328|BEHAVIORAL|GEM|Online program designed to support health coach and primary care team counseling. It assesses current behaviors, barriers, and facilitators to weight loss via a 16-item questionnaire, provides tailored advice, and guides patients to set weight loss (5-10%), diet, and physical activity (PA) goals. After completing the tool, participants will meet with a Health Coach. Participants will receive 12 telephone coaching calls by a health coach over 12 months.
223787663|NCT03006328|BEHAVIORAL|Enhanced Usual Care|Patients in the EUC arm will receive non-tailored weight management handouts. Patients will follow-up with their primary care teams as needed.
223787664|NCT04592692|DRUG|PEGylated Liposome (PEGLip)|Intravenous co-administration of PEGLip with Simoctocog alfa
223787665|NCT05494112|DIETARY_SUPPLEMENT|Celastrol|same dose of Celastrol will be given every day for a period of 90-days to all participants.
223703133|NCT06710678|BEHAVIORAL|Social Media Study Break|Participants will engage in social media use/engagement during a 10-minute study session break
223703134|NCT05426096|OTHER|Best Practice Advisory|The BPA intervention will test the delivery of the insulin calculator (BPA) which automates the standard insulin dosing protocol guidelines through the electronic health record system.
223703135|NCT06680726|OTHER|Matching with RWD|A set of clinical and genetic data are matched to generate a RWD cohort for comparison.
223703136|NCT06680726|OTHER|Imaging Mass Cytometry|Protein expression patterns in tumor tissue and tumor microenvironment are analyzed by Imaging Mass Cytometry.
223703137|NCT06710171|BEHAVIORAL|Counseling|"The intervention consists of using a theory-informed approach to user-centered brief counselling about PrEP uptake, designed specifically to help busy front-line providers in public health, sexual health and primary care settings advance clients along the PrEP cascade (specifically, supporting clients who meet evidence-based criteria for PrEP in accepting provider recommendations to use it) and provide linkage to care for related conditions.~The intervention will be delivered to GBM through participating healthcare providers who would have completed an online training designed by the research team."
223703138|NCT06710171|OTHER|List of resources|This list includes webpages which contain generic information about GBMs sexual health, PrEP, mental health, information about province-wide info lines for the general public about sexual health and/or educational resources for providers.
223703139|NCT06708143|OTHER|Temporal Interference|Researchers apply temporal interference (TI) stimulation to the deep brain nuclei of drug resistant epilepsy patients.
223703140|NCT06710704|DEVICE|Transcutaneous pulsed radiofrequency|Patients underwent transcutaneous PRF at the affected elbow.
223703141|NCT06710704|DRUG|Methylprednisolone and mepacaine|Patients received intraarticular injections of methylprednisolone (40 mg/ml) with 1 ml mepacaine at the point with utmost tenderness in the lateral epicondyle area under aseptic conditions.
223703142|NCT01484041|DRUG|Dovitinib|Dovitinib at the recommended Phase 2 dose for 5 consecutive days followed by a 2-day rest
223703143|NCT01484041|DRUG|Aromatase Inhibitors|Patients will receive one of the aromatase inhibitors either anastrozole 1 mg po daily, letrozole 2.5 mg po daily, or exemestane 25 mg po daily
223703144|NCT06921915|OTHER|eLearning|Participants in the intervention arms view a website developed by urinary bladder experts that presents information about how to prevent inconvenient urinary urges.
223703145|NCT06924840|OTHER|Utixira Lotion tablet as regimen|"Mode of Usage: To be applied over the affected areas twice a day as a thin film and rubbed in gently and completely. Take 1 capsule twice a day for better results.~Marketed By: SAVA Healthcare Ltd Frequency: Twice a Day"
223703146|NCT06702878|COMBINATION_PRODUCT|nasal antimicrobial photodisinfection therapy|Application of NF-031 solution (methylene blue 0.01% USP (methylthioninium chloride) and 0.25% chlorhexidine gluconate) in the nares followed by 2-minutes of light with nasal illuminators. The application is repeated a second time for total treatment time of 5-minutes.
223703147|NCT00292396|DRUG|Anti IL-12 monoclonal antibody/ABT-874|Please see Arm Description for intervention description and details.
223703148|NCT00292396|DRUG|placebo|12 doses
223703149|NCT00227838|BEHAVIORAL|Behavior Therapy|
223703150|NCT02681783|DRUG|aflibercept|Therapeutic/Pharmacological Classification: VEGF - Anti-neovascularization agent Route(s) of Administration: Intravitreal Injection Dosage Form: Solution 40 mg/ml Proposed Indication: Treatment of Pigment Epithelial Detachments (PEDs) associated with neovascular Age-related Macular Degeneration (nAMD), Central serous chorioretinopathy (CSR), and idiopathic Poplypoidal Choroidal Vasculopathy (iPCV).
223703151|NCT04360941|DRUG|Palbociclib|Highly selective oral inhibitor of CDK4 and CDK6.
223703152|NCT04360941|DRUG|Avelumab|Fully human IgG1 monoclonal antibody (mAb) binds to the PD-L1 cell surface ligand and blocks its interaction with the PD-1 cell surface receptor.
223703153|NCT05037292|OTHER|PAUSE Intervention|Standardized frailty screening and utilization of a frailty review board (PAUSE Board)
223703154|NCT05117515|DEVICE|Vascular reconstruction|Vascular reconstructions in the carotid, profunda, femoral and iliac arteries
223703155|NCT06215807|PROCEDURE|Femtosecond laser arcuate keratotomy|The patient will receive femtosecond laser arcuate keratotomy and femtosecond laser-assisted cataract surgery with implantation of a monofocal intraocular lens in one eye.
223703156|NCT06215807|PROCEDURE|Toric intraocular lens implantation|The patient will receive femtosecond laser-assisted cataract surgery with implantation of a Toric monofocal intraocular lens in the contralateral eye.
223703157|NCT03428932|DEVICE|Closed Loop (Medtronic 670G)|A loaner Medtronic 670G insulin pump, Enlite 3 sensor and GST3C Guardian transmitter will be utilized
223703158|NCT03428932|OTHER|Standard Care|Subjects will continue on their current treatment (insulin pump or injections), with follow up every 3 months.
223703159|NCT05856370|DEVICE|Follow-up schedule: pre-operative baseline up to 24-months post-procedure|Follow-up assessments will be required (therefore interventional) from pre-operative baseline to 24 months post index surgery
223703160|NCT06257628|DEVICE|Index Event|Patients with at least one Beckman High Sensitivity Troponin test at the Emergency Department visit
223703161|NCT01059084|DRUG|Valacyclovir|1000 mg tid
223703162|NCT02180724|DRUG|Acalabrutinib (ACP-196)|
223703163|NCT02180724|DRUG|Acalabrutinib (ACP-196)|
223703164|NCT00645112|DRUG|cefdinir (Omnicef)|oral suspension, 7 mg/kg every 12 hours for 5 days
223703165|NCT00645112|DRUG|azithromycin|oral suspension 10 mg/kg QD on Day 1 then 5 mg/kg QD on Days 2-5 for a total of 5 days.
223703166|NCT05159388|DRUG|PRS-344/S095012|PRS-344/S095012 Monotherapy
223703167|NCT06558305|OTHER|blood sample|Total RNA will be extracted from the whole blood using a commercial extraction kit (RNA Extraction Kit, applied biotechnology Co.Ltd, Egypt) according to the manufacturer's instructions. RNA will be stored at -80°C.The extracted RNA will be used for cDNA synthesis using commercial kits (cDNA Synthesis Kit, applied biotechnology Co.Ltd, Egypt), according to the manufacturer's instruction.
223703168|NCT02837289|OTHER|Therapy taping|Therapy taping follows an anatomical pattern from the femur until tibia for correction of dynamic valgus with therapy taping.
223703169|NCT02837289|OTHER|Placebo taping|Placebo taping follows a different anatomical path without tension, eliminating all therapeutic process elements
223703170|NCT04751565|OTHER|Bleeding on Probing change reduction following peri-implant mucositis non surgical therapy|Statistically significant different in terms of Bleeding on Probing will be recorded between groups.
223703171|NCT01805440|DRUG|Uridine|Uridine is the active treatment in this clinical trial.
223787666|NCT02917109|BEHAVIORAL|LearningRx cognitive training|A clinician will deliver three 90-minute cognitive training sessions per week for 14 weeks. There are 16 different categories of leveled training procedures sequenced in intensity and difficulty for a total of 530 training tasks.
223787667|NCT01108744|DRUG|hypertonic saline|3% hypertonic saline, dosed by ideal patient weight
223787668|NCT01108744|DRUG|Mannitol|Mannitol 20% intravenous solution, dosed by patient's ideal body weight
223787669|NCT02719405|DIETARY_SUPPLEMENT|Lactobacillus GG|Lactobacillus GG
223703172|NCT01805440|DRUG|Placebo|Pill placebo is the inactive treatment comparator in this clinical trial.
223703173|NCT04450446|DRUG|Low molecular weight heparin|Anticoagulation therapy
223703174|NCT00082979|GENETIC|cytogenetic analysis|
223703175|NCT00082979|GENETIC|proteomic profiling|
223703176|NCT00082979|OTHER|cytology specimen collection procedure|
223703177|NCT00082979|OTHER|immunohistochemistry staining method|
223703178|NCT00082979|OTHER|laboratory biomarker analysis|
223703179|NCT00082979|PROCEDURE|breast duct lavage|
223703180|NCT03642119|DEVICE|iButton®|Women with frequently reported hot flashes will be undergo both real world (ambulatory; field tests) and controlled (laboratory) assessments to validate the iButton® as an objective method to assess hot flash dynamics and incidence.
223703181|NCT06556446|DRUG|Tenecteplase and Alteplase|The timepoints, dose, and type of IVT will be collected as well as any complications occuring.
223703182|NCT04279405|DRUG|YY-20394|YY-20394 80mg tablet administered orally once daily
223703183|NCT01517074|DRUG|Sirolimus|Subconjunctival injection
223703184|NCT06101758|DIAGNOSTIC_TEST|Handgrip strength test|A handgrip strength test using a hydraulic hand dynamometer will be performed
223703185|NCT06101758|DIAGNOSTIC_TEST|total body Dual Energy X-Ray Absorptiometry (DXA)|A total body Dual Energy X-Ray Absorptiometry (DXA) to estimate muscle mass will be performed
223703186|NCT06101758|DIAGNOSTIC_TEST|Muscle ultrasound|A muscular ultrasound of abdominal muscles, forearm muscles, quadriceps and gastrocnemius will be performed
223703187|NCT00690105|DRUG|tacrolimus 0.1%|ointment
223703188|NCT00690105|DRUG|fluticasone 0.005 %|ointment
223703189|NCT00795496|PROCEDURE|Histamine provocation|A dosimetric histamine challenge test in which the provocative dose of inhaled histamine producing a decrease of 15% in FEV1 is measured.
223703190|NCT00795496|PROCEDURE|Skin prick tests|Skin prick testing will be performed for: birch, timothy, mugwort, alder, pine, cat, dog, horse, house dust mite, Cladosporium herbarum.
223703191|NCT00795496|PROCEDURE|Serum IgE blood testing|One blood test to measure total serum IgE
223703192|NCT00795496|PROCEDURE|Mantoux-testing|Tuberculin (2 TU) s.c. on the forearm. The test is read after 72 hours.
223703193|NCT03777774|PROCEDURE|Passive Redon subgaleal drains|Passive non-vacuum subgaleal drains will be placed during closing stage of craniectomy. Drain used is closed suction drain system (3.2 mm in outer diameter, 10 French, round and transparent polyvinyl chloride tube with a 400 mL Redon bottle spring evacuator chamber; Privac, Primed, Germany)
223703194|NCT03777774|PROCEDURE|Vacuum Redon subgaleal drains|Active vacuum subgaleal drains will be placed during the closing stage of craniectomy. Drain used is closed suction drain system (3.2 mm in outer diameter, 10 French, round and transparent polyvinyl chloride tube with a 400 mL Redon bottle spring evacuator chamber; Privac, Primed, Germany)
223703195|NCT03777774|PROCEDURE|No Redon subgaleal drains|A subgaleal drain will be placed during the closing stage of craniectomy but it will be clamped. The drain will be unclamped if necessary. Drain used is closed suction drain system (3.2 mm in outer diameter, 10 French, round and transparent polyvinyl chloride tube with a 400 mL Redon bottle spring evacuator chamber; Privac, Primed, Germany)
223703196|NCT06120270|DEVICE|CeraFlex PFO Closure System|The Lifetech CeraFlex™ PFO occluder device is a percutaneous, transcatheter closure device for the non-surgical closure of Patent Foramen Ovale (PFO).
223703197|NCT05480930|OTHER|paper-based clinical decision support (dCDS) tool|The paper based clinical decision support tools currently employed at the TMDS that are used to triage, assess and generate treatment plans for pediatric patients.
223703198|NCT05480930|OTHER|digital clinical decision support (dCDS) tool|The intervention is a digitized version of the paper based clinical decision support tools currently employed at the TMDS that are used to triage, assess and generate treatment plans for pediatric patients.
223703199|NCT01863953|DRUG|Fixed-Combination Bimatoprost/Brimonidine|One drop fixed-combination bimatoprost/brimonidine in each eye twice daily for 6 weeks.
223703200|NCT01863953|DRUG|Bimatoprost Ophthalmic Solution 0.01%|One drop bimatoprost ophthalmic solution 0.01% in each eye in the evening for 6 weeks.
223703201|NCT01863953|DRUG|Vehicle Ophthalmic Solution|One drop vehicle ophthalmic solution in each eye in the morning daily for 6 weeks.
223703202|NCT01863953|DRUG|Brimonidine Tartrate Ophthalmic Solution 0.2%|One drop brimonidine tartrate ophthalmic solution 0.2% in each eye twice daily for 6 weeks.
223703203|NCT03716193|OTHER|Oxygen|Patients will be given oxygen via a facemask during the measurement session
223703204|NCT06271213|OTHER|observational only - no interventions as part of study|Children with asthma will be receiving biologics therapy as part of their standard of care - unrelated to this study design. All cohorts will be observed without study intervention.
223703205|NCT04222231|OTHER|Blood-flow restriction resistance training|Training program: After 10 minutes of warm-up the participant performs three exercises with BFRT for the lower extremities. The intensity is about 15-30% of 1-RM.
223703206|NCT04222231|OTHER|Classical resistance training|Training program: After warm-up the participant performs three exercises for lower body. The intensity is about 60-80% of 1-RM.
223703207|NCT01999751|DEVICE|MRI Scan|Clinically indicated MRI scan of patients with pacemaker or implantable cardioverter-defibrillator in situ.
223703208|NCT00509041|DRUG|dasatinib|50 mg PO bid
223703209|NCT02221024|PROCEDURE|Flushing with positive pressure|Placement of a sterile plug (MicroClave ICU Medica, a neutral displacement connector) on the needle cannula and flushing with positive pressure with saline solution (BD PosiFlush XS Syringes, filled with 3 ml of saline)
223703210|NCT02221024|DRUG|Normal saline|
223703211|NCT02221024|DEVICE|MicroClave ICU Medica|
223703212|NCT03252119|DEVICE|High flow humidified oxygen therapy|application of high flow humidified oxygen therapy at 2l/kg/min
223703213|NCT03424200|BEHAVIORAL|Routine care|Participants will receive routine care
223703214|NCT03424200|OTHER|Coaching plus routine care|Participants will receive coaching plus routine care
223703215|NCT00814866|DRUG|Adalimumab|Adalimumab 40 mg sub-cutaneously every two weeks
223703216|NCT06039488|BEHAVIORAL|Exercise|"A combination of resistance exercise and cardiovascular exercise (performed 2 days per week for 8-weeks) is tailored to each individual in accordance with their medical/cancer-related history, baseline assessments of physical function, and overall goals.~Resistance exercise includes 6-8 exercises targeting major muscle groups. The first week of the program is used to familiarize participants to the exercises of the program, provide coaching on safe and appropriate technique, and identifying initial load for 2 sets of 12 repetitions (equivalent to \~65% 1 repetition maximum), with a goal of working towards 4 sets of 8 reps. Additionally, participants are asked to perform 20-30 minutes of moderate-to-vigorous aerobic activity (approximately 60-85% age-predicted heart rate maximum) via walking, jogging, or cycling each session."
223703217|NCT02098252|PROCEDURE|Neurosurgery|Surgical resection to be used when the lesion is considered by a multidisciplinary team to be safely 'operable'.
223703218|NCT02098252|RADIATION|Radiation therapy|when the AVM is smaller than 3 cm, and considered to not be safely 'operable'.
223703219|NCT02098252|PROCEDURE|Embolization|Curative embolization, when the lesion is considered curable by embolization.
223703220|NCT04771312|BEHAVIORAL|Mobile app information-only intervention|Mobile app intervention. Participants view information regarding PrEP that address beliefs and barriers surrounding adoption and uptake. Participants can respond to daily questions in a diary. Participants can also use a locator tool to find where PrEP can be found near them.
223703221|NCT04771312|BEHAVIORAL|Mobile app social support network intervention|Mobile app intervention. Participants view information regarding PrEP that address beliefs and barriers surrounding adoption and uptake. Participants are shown an online chatting tool where they can discuss with each other and answer daily questions. Participants can also use a locator tool to find where PrEP can be found near them.
223703222|NCT02486666|DRUG|Enoxaparin|WEIGHT ADJUSTED FiXED DOSE OF LOW MOLECULAR WEIGHT HEPARIN (ENOXAPARIN) TO NEONATES AND CHILDREN WITH THROMBOSIS (FiXET)
223703223|NCT05920278|DEVICE|Pulse oximeter|Devices (2) were placed on the finger and the fingertip. Blood samples were taken at each stable level of oxygenation.
223703224|NCT06384898|OTHER|Remote Tai Chi|Tai Chi mind-body exercise is a complex, multi-component nonpharmacological intervention integrating physical, psychological, emotional, and behavioral elements.
223703225|NCT04406974|PROCEDURE|Surgery or treatment for local recurrence|Surgery or treatment for local recurrence
223703226|NCT04406974|PROCEDURE|Surgery for advanced colorectal cancer|Surgery for advanced colorectal cancer
223703227|NCT03031132|BEHAVIORAL|HP-Beverage Breakfast|Participants will consume high protein beverage (shake) breakfast meals each morning.
223703228|NCT03031132|BEHAVIORAL|HP-Solid Breakfast|Participants will consume high protein solid (traditional food items) breakfast meals each morning.
223703229|NCT03031132|BEHAVIORAL|Breakfast Skipping|Participants will skip breakfast each morning.
223703230|NCT00384410|DRUG|Nabilone|
223703231|NCT02806531|BIOLOGICAL|two doses enterovirus 71 vaccine|Two doses of enterovirus 71 vaccine will be given in children aged 6-35 months old, 28 days interval.
223703232|NCT03240354|DEVICE|Saline cuff|Cuff of endotracheal tube inflated with saline rather than air (control)
223703233|NCT03240354|DEVICE|Control|Cuff of endotracheal tube inflated with air
223703234|NCT04058873|DRUG|Levonorgestrel 1.5mg|Levonorgestrel 1.5mg for pericoital use
223703235|NCT02105883|OTHER|Use of identification badge during scenarios|
223703236|NCT01824342|BIOLOGICAL|Denosumab|Administered by subcutaneous injection
223703237|NCT06209931|PROCEDURE|RIRS|RIRS with tip flexible pressure-controlling ureteral access sheath versus mini PCNL for the treatment of 2-3-cm kidney stones
223787670|NCT02719405|DIETARY_SUPPLEMENT|Extensively Hydrolyzed Casein Formula|Extensively Hydrolyzed Casein Formula
223787671|NCT02719405|DIETARY_SUPPLEMENT|Amino Acid Formula|Amino Acid Formula
223787672|NCT02791048|BEHAVIORAL|Music therapy|"Music therapy is a clinical intervention conducted by qualified therapists who use shared music-making and improvisation to engage and interact with the client (s) in order to work towards specific therapeutic objectives.~This is the aim of sessions, rather than the teaching or utilising of any musical skills, and clients do not have to have any prior musical training or experience whatsoever in order to participate in and benefit from music therapy. The intervention is client-led and the therapist will guide the patient in a range of strategies and activities appropriate to the therapeutic aims in place. Sessions can be individual, or family members can also be involved if appropriate and desired."
223787673|NCT01117311|DEVICE|VNB on|The implanted Vagal Nerve Blocker will be on at the time of study.
223787674|NCT01117311|DEVICE|VNB off|The implanted Vagal Nerve Blocker will be off at the time of study.
223787675|NCT04475003|OTHER|Teaching|Teaching session about anaphylaxis
223787676|NCT03022357|OTHER|Patient assessment|Clinical examination, Examination, Questionnaires
223787677|NCT03022357|RADIATION|DATScan|In small subgroup
223787678|NCT03022357|RADIATION|Orbital X-Ray|If foreign body in eye needs exclusion
223787679|NCT03022357|OTHER|Magnetic Resonance Imaging (MRI)|MRI scanning of all subjects
223787680|NCT03457259|DEVICE|PVC and/or PICCline|Pt. will receive PVC and/or PICCline
223787681|NCT03457259|DEVICE|Midline|Pt. will receive midline
223787682|NCT01605045|OTHER|Fluoroscopy-save group|Coronary anatomy visualized under fluoroscopy, documented using the fluoroscopy-save function, and further visualized using cinematography only when higher quality is necessary (fluoroscopy-save technique) versus Coronary anatomy visualized and documented using cinematography alone (standard technique)
223703238|NCT05823532|DRUG|Infliximab|"Infliximab has FDA approval for the treatment of rheumatoid arthritis and inflammatory bowel syndrome. The current proposal represents the use of infliximab as an experimental tool to dissect the role of inflammatory processes leading to changes in brain reward circuitry and changes in specific symptom domains.~Double-blinded infusions of infliximab will be administered in the GCTSA Clinical Research Center, located at Emory University Hospital. Independent pharmacists will dispense either infliximab or placebo in a 250ml saline bag according to a computer-generated randomization list provided by the study pharmacist."
223703239|NCT05823532|DRUG|Placebo|Double-blinded infusions of saline will be administered in the GCTSA Clinical Research Center, located at Emory University Hospital. Independent pharmacists will dispense either infliximab or placebo in a 250ml saline bag according to a computer-generated randomization list provided by the study pharmacist.
223703240|NCT01629992|OTHER|Preoperative counseling|The intervention group received preoperative counseling by both orally and written. A written leaflet containing information was provided to each patient of this group.
223703241|NCT03862560|OTHER|Strength training program|Strength training program in female soccer players
223703242|NCT02661685|BIOLOGICAL|autologous IKDC-like cells|Subject received autologous IKDC-like cells every 14 days
223703243|NCT02495831|DRUG|Diclofenac sodium|Diclofenac sodium 50 mg single dose
223703244|NCT02495831|DRUG|Diclofenac sodium and safinamide|Diclofenac 50 mg single dose and safinamide 200 mg single dose
223703245|NCT00112008|DRUG|De Novo Administration of Darbepoetin Alfa|Administration Q2W for 18 weeks. starting dose is 0.75 mcg/kg rounded to the nearest dose: 20, 30, 40, 50, 60, 80, 100, 150, 200 0r 300 mcg. Titrate to maintain Hb within 11.0 - 13.0 g/dL
223703246|NCT00619736|DRUG|NSA-789|
223703247|NCT00619736|OTHER|Placebo|
223703248|NCT06012474|OTHER|Power breath plus|Power breath plus use a variable load calibrated spring. It can be adjusted from the lowest load setting (17cmH2O) when training began and increased as the patient breathing muscles adapt and become stronger (maximum load setting 274cmH2O). Use a comfortable chair, preferably straight-back so that the spine is straight at all times during the exercise. patients will be instructed to exhale calmly, followed by a maximal forced inspiration to total lung capacity using a mouthpiece and a nasal clip as an aid to prevent air leaks and will ask to make 10 breaths for 3 sets once daily for 7 days with 2min rest between sets
223703249|NCT06012474|OTHER|Incrementing the training load|The resistance will be increased incrementally, based on the rate of perceived exertion (RPE) scored by the patient on the modified Borg Scale. If the RPE is less than 5, the resistance of the inspiratory trainer will be increased incrementally by 2cmH2O. The resistance will not change if the level of perceived exertion is rated from 6 to 8, and the resistance will be decreased by 1 to 2 cmH2O if the level of perceived exertion is rated 9 or 10.
223703250|NCT06012474|OTHER|Diaphragmatic breathing exercises|"Training by using incentive spirometer:~* Loosen any tight clothing, especially around neck.~* Each patient will be instructed to sit upright with placing incentive spirometer at the same level of his mouth to promote optimal lung expansion while using the spirometer.~* The patient will be instructed to exhale letting all the breath out.~* patient will asked to close the lips around the mouthpiece of the spirometer.~* patient will be instructed to inhale slowly, breathing in until unable to do any more, this would raise the balls to the top of the column.~* patient will be asked to hold the breath as long as possible (at least five seconds) then exhale slowly.~* Session will be in the form of 30 times in sets, each set consist of 5-6 repetitions with rest 1 minute between sets.~* Intensity of exercise will be increased by increasing time of session, time of holding the breath and numbers of repetitions according to patient's status."
223703251|NCT05780190|DEVICE|New artificial liver CABA system (BS330+CA280) +PE|The new artificial liver CABA system (BS330+CA280) combioned plasma exchange in the treatment of end-stage liver disease with inflammatory status
223703252|NCT03320317|OTHER|Learning session 1|Learn form international report, Explain key interventions, Explain BIC methodology, Retrospective patient record analysis, Team measures
223703253|NCT03320317|OTHER|Learning session 2|Feedback report, Share (inter)national best practices, Discussion, set priorities, teaching and improvement, Retrospective patient record analysis
223703254|NCT03320317|OTHER|Learning session 3|Feedback report, Share best practices, Discussion, set priorities, teaching and improvement, Retrospective patient record analysis, Team measures
223703255|NCT03320317|OTHER|Learning session 4|Feedback report, Best practice symposium
223703256|NCT03789396|OTHER|Targeted Normoxia (oxygen saturation 90-96%)|The intervention (post-implementation) group will be trauma patients admitted to the ICU during the 6 months after the targeted normoxia implementation
223703257|NCT03789396|OTHER|Usual Care Oxygenation|The control (pre-implementation) group will be trauma patients admitted to the ICU during the 12 months prior to the targeted normoxia implementation
223703258|NCT04540276|DRUG|Inspiratory oxygen fraction|Median inspiratory oxygen fraction during general anesthesia
223703259|NCT00928395|DEVICE|Urgent PC|The Urgent PC Neuromodulation System is a minimally invasive neuromodulation system designed to deliver retrograde access to the sacral nerve through percutaneous electrical stimulation of the tibial nerve. The method of treatment is referred to as Percutaneous Tibial Nerve Stimulation (PTNS).
223703260|NCT03768232|OTHER|ultrasound asessment|US diaphragm measurements within 36 hours of initiation of MV. Measurements will be repeated daily for the duration of MV for the first week, then every 48 hours and 24 hours after the extubation.
223703261|NCT02095418|DRUG|Mycophenolate mofetil, Corticosteroids|tacrolimus (low dose, trough level of 5-12ng/ml)+Mycophenolate mofetil(500-1500mg/day\*, bid)+ Basiliximab + corticosteroids 500mg to 5mg or above (2 weeks)
223703262|NCT02095418|DRUG|Corticosteroids, Mycophenolate mofetil|tacrolimus (low dose, trough level of 5-12ng/ml)+Mycophenolate mofetil(500-1000mg/day\*, bid)+ Basiliximab + corticosteroids 500mg to 5mg or above (3 month±2weeks)
223787683|NCT01605045|OTHER|Standard technique|Coronary anatomy visualized under fluoroscopy, documented using the fluoroscopy-save function, and further visualized using cinematography only when higher quality is necessary (fluoroscopy-save technique) versus Coronary anatomy visualized and documented using cinematography alone (standard technique)
223787684|NCT00472667|PROCEDURE|Procalcitonin guided strategy|Procalcitonin guided strategy
223703263|NCT02778087|BEHAVIORAL|Mirror Box Therapy|The BT intervention will be delivered in 15 minute increments via a self-directed program. The subject will sit comfortably at a table or desk in front of a box, which will be positioned in the mid-sagittal plane. The subject will place his or her affected arm inside the box so that it is out of view. The subject will then place his or her unaffected arm on the table and will be instructed to focus their attention on the mirror reflection of the unaffected arm throughout the intervention. The 15 minute intervention will consist of the following movements/tasks: active range of motion (AROM), functional tasks with objects, and object manipulation.
223703264|NCT02778087|BEHAVIORAL|Sham Mirror Box Therapy|The BT intervention will be delivered in 15 minute increments via a self-directed program. The subject will sit comfortably at a table or desk in front of a box, which will be positioned in the mid-sagittal plane. The subject will place his or her affected arm inside the box so that it is out of view. The subject will then place his or her unaffected arm on the table and will be instructed to focus their attention on an opaque mirror throughout the intervention. The 15 minute intervention will consist of the following movements/tasks: AROM, functional tasks with objects, and object manipulation.
223703265|NCT01130675|OTHER|caffeinated coffee|8 oz. of caffeinated cofee/breakfast\&noon meal. No intervention for 2nd arm.
223703266|NCT05944211|DRUG|Hetrombopag Olamine|"The subjects will initiate treatment with 7.5 mg hetrombopag once a day, starting orally 24 hours after the end of chemotherapy. Platelet counts is obtained weekly and dose adjustment should be done according to platelet counts once every two weeks, and maximum dose should not exceed 15 mg daily. Subjects whose platelet count \<25×109/L for 2 weeks, the hetrombopag dose will be increased by 2.5mg. If subjects whose platelet count ≥100×109/L or who had received hetrombopag for 28 days, hetrombopag can be stopped. Hetrombopag Olamine is sponsored by Jiangsu Hengrui Pharmaceuticals Co., Ltd.~Emergency treatment: When the platelet count was less than 20×109/L, platelet transfusion was given according to the evaluation of the investigator."
223787685|NCT05804058|PROCEDURE|Revision surgery|Patients due to undergo prosthetic revision surgery for any reason (infection or aseptic)
223787686|NCT02886845|GENETIC|rs183489969,rs185670819|compare the frequency of two germline mutations in breast cancers and controls
223787687|NCT01235455|DRUG|Interferon beta-1b (Betaseron, BAY86-5046)|250 µg, sub-cutaneously, on alternate days
223787688|NCT00447863|DRUG|Levonorgestrel/Ethinyl Estradiol|
223787689|NCT02584049|OTHER|Osteopathy|3 sessions of osteopathy during 60 minutes each
223787690|NCT02584049|OTHER|Sham osteopathy|3 sessions of sham osteopathy during 60 minutes each
223787691|NCT01478789|DIETARY_SUPPLEMENT|WD-PS intervention phase|2g/d of free plant sterol in 100g yogurt
223787692|NCT01478789|DIETARY_SUPPLEMENT|PS-Ester intervention phase|2g/d of free plant sterol in 100g yogurt
223703267|NCT04549857|BEHAVIORAL|aromatherapy|"The intervention measures were taught by the researchers to perform self-massage on both wrists and finger joints in the experimental group and the comfort group, using 5ml each time (2.5ml each for one hand), 10 minutes each time (5 minutes for each hand), three times a week, It lasts for three weeks. The massage steps refer to dōTERRA's Aroma Touch Hand Technique. Before self-massage is performed, a professional must first ensure that the execution process is correct and the professional will use the phone to follow up weekly.~1. The experimental group used the base oil (sweet almond oil) to add Atlantic cedar, sweet marjoram and sweet orange essential oils. The essential oils were blended into 5% massage oil at a ratio of 3:1:1.~2. The placebo group only used base oil (sweet almond oil).~3. The control group did not provide any interventional measures and only received conventional treatment."
223703268|NCT01259765|DRUG|VHH batch 203027|The active product is 165 mg of VHH batch 203027 and 835 mg maltodextrin with 0.5% (w/w) caramel colour in 10 mL ORS. The osmolality (concentration of the osmotically active substances in the solution such as sugar molecules, salts etc. ) of this solution will be around 60 mOsmol/kg. The mixture of the 165 mg of VHH batch 203027 and 835 mg maltodextrin (0.5% (w/w) caramel colour will be provided per sachet.
223703269|NCT01259765|DRUG|Placebo product|The Placebo treatment consisted of 1000 mg of maltodextrine with 5% (w/w) caramel colour in 10 mL ORS.
223703270|NCT03056404|OTHER|additional blood sample|
223703271|NCT03056404|OTHER|respiratory functional exploration|
223703272|NCT05981339|OTHER|breathing exercises|For the diaphragmatic breathing exercise, patients are asked to perform a nasal inspiration and expiration that moves predominantly the abdomen by reducing the movement of the thorax in the semi-supine position. To give tactile stimulation, one hand of the patient is placed on the chest with the other hand on the abdominal region. Continue this exercise for three minutes.
223787693|NCT01478789|DIETARY_SUPPLEMENT|placebo|100g/d yogurt with no added plant sterol
223787694|NCT01859455|DRUG|LGT209 50 mg|Active experimental drug
223787695|NCT01859455|DRUG|LGT209 300 mg|Active experimental drug
223787696|NCT01859455|DRUG|Placebo|Placebo comparator
223787697|NCT01859455|DRUG|Statins (atorvastatin or simvastatin)|Stable doses of atorvastatin or simvastatin
223787698|NCT02458105|BEHAVIORAL|Acceptance & Commitment Therapy|A variant of cognitive behavior therapy focused on acceptance and valued living in the presence of distressing symptoms.
223787699|NCT02458105|BEHAVIORAL|Attention|Supportive conversation at a frequency and length corresponding to the experimental condition.
223787700|NCT00887172|DRUG|Jing Fang Bai Du san|The Jing Fang Bai Du san can relieve external symptoms and effectively clear up the pathogenic cold. It contains 13 herbs including, Radix Angelicae Pubescentis, Radix Peucedani, Radix Ginseng, Smilacis Glabrae Rhizoma, Rhizoma Chuanxiong, Fructus Aurantii, Radix Platycodi, GlycyrrhizaeRadix, Herba Schizonepetae, Fructus Arctii, MenthaeFolium, Radix Saposhnikoviae, Rhizoma et Radix Notopterygii.The CHM preparations were manufactured and supplied by Pura Pharm International (H.K.) Ltd., in the form of concentrated granules which follows the GMP standard. None of the herbs in these two formulas are included in the Toxic Chinese Herbal Medicine List of the Chinese Medicine Ordinance Schedule 1 or being a controlled substance, animal product, or endangered species.
223703273|NCT05981339|OTHER|osteopathic manual therapy techniques|"* Sacral release: While the patient is in the side lying position, the physiotherapist goes behind the patient, one hand is placed on the lower abdominal area, and the thenar and hypothenar areas of the other hand are placed on the basis of the sacrum. It is waited until a general relaxation is felt in the tissue under the hands (Stone, C., 2006).~* Bladder mobilization: Two hands are placed just above the pubic region and gently pressed down first to test the surface protrusion of the uterus. During the application, the pressure of the hand is adjusted according to the tension of the tissue. Hand contact is not interrupted until the fascial tissue under the hand is relaxed (Stone, C., 2006)."
223787701|NCT00887172|DRUG|Placebo|The sachets of the CHM formulae and placebo were identical in appearance except for the randomization numbers. The placebo contains Maltose-dextrine granules that are identical in weight, appearance, flavour and texture as the CHM granules. Both the Chinese medicine practitioner who assessed the subjects and the subjects were blinded to the nature of the treatment. The pharmaceutical supplier kept the medication and placebo codes, which were broken at the end of the study after completion of all the assessment and data analyses.
223787702|NCT00887172|DRUG|Ying Qiao san|The Ying Qiao san can relieve external symptoms and effectively clear up the pathogenic heat. It contains 10 herbs: Fructus Forsythiae, LoniceraeFlos, Radix Platycodi, MenthaeFolium, GlycyrrhizaeRadix, Herba Schizonepetae, Sojae Semen praeparatum, Fructus Arctii, PhragmitisRhizoma and LophatheriHerba. The CHM preparations were manufactured and supplied by Pura Pharm International (H.K.) Ltd., in the form of concentrated granules which follows the GMP standard. None of the herbs in these two formulas are included in the Toxic Chinese Herbal Medicine List of the Chinese Medicine Ordinance Schedule 1 or being a controlled substance, animal product, or endangered species.
223787703|NCT02067403|OTHER|Pressure-support Eadi optimization|
223787704|NCT02699281|DRUG|ultra-micronized palmitoylethanolamide|ultra-micronized palmitoylethanolamide 600 mg twice a day
223787705|NCT02699281|DRUG|Placebo|um-PEA like placebo twice a day
223787706|NCT04558346|DRUG|Ghrelin (OXE-103)|40ug/kg twice daily by self-injection
223787707|NCT04558346|DRUG|Placebo|40ug/kg twice daily by self-injection
223787708|NCT00194922|DIETARY_SUPPLEMENT|E. Coli Strain M17 Probiotic|30 ml PO BID for 12 weeks
223787709|NCT02439346|DRUG|BAY1143269 tablet|BAY 1143269 5 mg or 25 mg tablet. Each treatment cycle will last 21 days.
223787710|NCT02826226|DEVICE|multiple-breath-washout test|
223787711|NCT02826226|DRUG|Bronchodilator Agents|
223787712|NCT00875953|PROCEDURE|standard neck dissection|standard surgical technique
223787713|NCT00875953|PROCEDURE|Harmonic Scalpel Dissection|harmonic scalpel used for neck dissection after flaps are raised.
223787714|NCT03765437|BIOLOGICAL|Quadrivalent Influenza Vaccine|Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
223787715|NCT03872050|DIAGNOSTIC_TEST|No intervention apart from tests, including interview|No interventions
223787716|NCT04461522|PROCEDURE|Ultrasound-guided drug injection|The injection drugs were glucocorticoids and anesthetic drugs (1ml+2% lidocaine hydrochloride 0.5ml+0.9% sodium chloride 0.5ml), and the injection sites were subacromion deltoid bursa/coracoid bursa/biceps longhead tenosynosheath/glenohumeral joint bursa, etc.
223787717|NCT02356016|BEHAVIORAL|WB-EMS Intervention|Supervised WB-EMS Intervention 18 min/session (one session/week) and monthly dietary counseling for 6 months
223787718|NCT02356016|BEHAVIORAL|WB-EMS-Intervention and dietary supplementation|Supervised WB-EMS Intervention and dietary supplementation and monthly dietary counseling for 6 months
223787719|NCT02356016|OTHER|control (dietary counseling)|Monthly dietary counseling only
223787720|NCT00758953|DRUG|Danazol Once Weekly|semi-solid
223787721|NCT00758953|DRUG|Danazol Twice Weekly|semi-solid
223787722|NCT00758953|DRUG|Placebo Once Weekly|semi-solid
223787723|NCT00758953|DRUG|Placebo Twice Weekly|semi-solid
223787724|NCT02715765|DEVICE|Transcranial Direct Current Stimulation|Energetic parameters are 2mA for 20 min with SPONSTIM-25 25cm2 electrodes. Current delivery is initiated in a ramp-like fashion over 10s from 0mA to 2mA. Once at 2mA, the current is held constant for the entire session. At the end of stimulation, current is decreased in a ramp-like fashion over 10s from 2mA to 0mA. Should the participant not be able to tolerate a current of 2mA due to pain or irritation, the current will be decreased down to a minimum of 1.5mA. If 1.5 mA is still not tolerable, the participant will be removed from the study. Electrode placement is based on the international 10-20 electrode placement system. The anode is placed at the midpoint between F3 and FP1, a location corresponding approximately to the left dorsolateral prefrontal cortex, and the cathode placed at the midpoint between T3 and P3, a location corresponding to left temporo-parietal junction
224263884|NCT07068737|BEHAVIORAL|bathing care package|Participants receive a bathing care package that includes a swaddled immersion bath. Room temperature is maintained at 26-27°C with 40-60% humidity. Bath water temperature is controlled at 37-38°C. The infant is swaddled and immersed in water up to the shoulders while the head remains above water. The bath lasts no longer than 5 minutes. After bathing, the infant is gently dried without rubbing, wrapped in a towel, and placed in a pre-warmed incubator (31-34°C) for 10 minutes.
224263885|NCT07068737|BEHAVIORAL|routine bath|Participants receive routine bathing care according to NICU standards. This includes hand hygiene before the procedure, preparing necessary materials, placing the infant in a mesh sling in the bath, washing the body from clean to dirty areas with soft sponges and hospital-provided cleansing agents. The bath lasts up to 10 minutes. After bathing, the infant is quickly dried without rubbing and then diapered.
224263886|NCT07069491|DEVICE|Sphygmomanometer|Blood pressure measurement by Sphygmomanometer
224263887|NCT07068256|DRUG|Terbinafine|Terbinafine will be given at a dose of 62.5 mg in patients with a body weight \< 20 kg, 125 mg from 20 to 40 kg, and 250 mg in \> 40 kg for a period of 4 weeks.
224263888|NCT07068256|DRUG|Itraconazole|Itraconazole will be given at a dose of 5 mg/kg/day for 7 days and then 14 days off. Three such pulses will be given to the patients.
224263889|NCT07069387|BEHAVIORAL|CARE-TB digital adherence package|CARE-TB package includes pharmacist-led asynchronous video observed therapy, digital medication reminders, telecounselling and e-learning for patients.
224263890|NCT07069387|BEHAVIORAL|Standard Care|Directly observed therapy at any government healthcare facility (by nurses) or at home (by caretaker)
224263891|NCT07068009|BEHAVIORAL|Training and Support Programme on Data-driven Quality Development|"The training and support program uses a train-the-trainer strategy.~The research team:~* develop training and support materials~* organize an e-mail helpdesk support~* organize and conduct the scientific examination~The external training providers:~\- train the management representatives and the quality leaders.~The quality leader and the manager:~* elaborate and test a quality development project based on one MQI with PDCA cycle~* animate interprofessional meetings~* organize a collective workshop with residents and relatives~* engage residents and relatives in individual conversations by testing a brochure"
224263892|NCT07068789|PROCEDURE|balloon angioplasty|endovascular angioplasty of infrapopliteal arteries performed using standard balloon catheters under fluroscopic guidance to restore blood flow to the ischemic area
224263893|NCT06716424|DRUG|iGlarLixi (insulin glargine/lixisenatide)|iGlarLixi is available as a sterile solution for injection that will be administered to study participants subcutaneously
224263894|NCT07068048|DRUG|Dexametasone|"Intra-operatively, all participants recruited must have the recurrent laryngeal nerve identify and confirm with Intraoperative Nerve Monitoring (IONM) device.~After removal of thyroid gland, 8mg of dexamethasone will be diluted in 100cc of irrigation water and irrigate the operative field for 1 minute for the intervention group."
224263895|NCT07068048|DRUG|Water for injection|For the placebo group, they will received water irrigation over the operative field only which is the current standard of practice at the moment.
224263896|NCT07067125|BEHAVIORAL|AR-Supported Scoliosis-Specific Physiotherapy|This intervention consists of scoliosis-specific physiotherapy supported by AR technology. Participants will engage in postural correction exercises delivered by licensed physiotherapists using an AR system that provides real-time avatar feedback, movement guidance, and gamified motivation. The intervention aims to improve body awareness, adherence, and motivation among adolescents diagnosed with AIS. Each participant will complete at least four weeks of structured AR-supported sessions.
224263897|NCT07068516|DRUG|Tislelizumab|Received tislelizumab combined with investigator's choice of chemotherapy
224263898|NCT07068516|DRUG|SOX or CAPOX regimen|chemotherapy (SOX or CAPOX regimen)
224263899|NCT07068217|OTHER|Exercise|"Sample size was determined via G\*Power analysis: two groups (n=13 each), total n=26. Participants will be randomized using Random.org into the Rhythmic Exercise Group (REG) or the Exercise Group (EG).~Both groups will receive a supervised home-based exercise program, overseen via telerehabilitation. Exercises will be performed 3 times per week for 45-60 minutes each session, over 4 weeks (12 sessions total). Progression to the next week's program will require an 80% success rate; otherwise, the same week's program will be repeated. Online supervision will monitor weekly performance."
224263900|NCT07069543|PROCEDURE|Adenotonsillectomy|the adenotonsillectomy group children, indicated for immediate adenotonsillectomy
224263901|NCT07069543|PROCEDURE|Rapid maxillary expansion|expansion group children with a narrow palate and posterior crossbite, with indication for rapid maxillary expansion
224263902|NCT07068841|DRUG|sequentially single use of repaglinide, warfarin and omeprazole or combined with Y-3|"Take repaglinide tablets, warfarin sodium tablets and omeprazole enteric-coated capsules without Y-3.~Take repaglinide tablets, warfarin sodium tablets and omeprazole enteric-coated capsules sequentially during the use of Y-3."
224263903|NCT07069530|BEHAVIORAL|Receptive Music Therapy|Participants received six 30-minute sessions of receptive music therapy delivered by live solo piano performance over two weeks. The same playlist was performed in a fixed order at each session, held one hour before dinner. The intervention was designed to reduce depressive symptoms in dementia patients and alleviate caregiver burden using a structured, low-cost, non-pharmacological approach.
224263904|NCT07068685|OTHER|Suicide risk prediction algorithm|Use of a suicide risk prediction algorithm, developed by the Mental Health Research Network (MHRN), will be used to prompt additional mental health monitoring. Mental health monitoring will include asking patients about suicidal thoughts (via the ninth question of the Patient Health Questionnaire-9, PHQ-9), followed by suicide risk assessment (via use of a brief self-administered version of the Columbia Suicide Risk Severity Rating Scale, C-SSRS), followed by Safety Planning with a designated member of the primary care team.
224263905|NCT07069478|OTHER|Stress Intervention|Experimental Stress: Behavioral induction of acute psychosocial and physiological stress. First, participants will be provided with a speech topic and given 4 minutes to prepare a speech that they subsequently deliver in front of evaluators and a video recorder. Then, participants will complete a mental arithmetic task in front of the evaluators for 8 minutes. Then, participants will complete a cold pressor task in which they submerge their hand in ice water for 90 seconds.
223835388|NCT04243161|OTHER|Experimental|"The study variables PIM, PEM, FVC, PEF and EQ-5D quality of life questionnaire will be measured on the first day when patient incorporated into the seating position in the patient's bed. Reassessments will be performed every two week till patient discharge from hospital. After that patient will be assessed after 4 month and 1 year after the SCI.~SCIM III will be administered at discharge, 4 month later and 1 year after the injury.~Common clinical practice (pulmonary expansion exercises,drainage of secretions and training of inspiratory muscles) + expiratory muscle training at 50% load after MIP measurement.~The intensity of the treatment will be 50% of the PIM and PEM value (increasing the load in 2 cmH2O weekly). Three sets of 10 reps will be performed, with one total of 30 repetitions, resting 1 minute between each series.~The sessions will be held once per day, from monday to friday, during the entire hospital admission."
223787725|NCT02715765|DEVICE|Transcranial Random Noise Stimulation|Energetic parameters are 2mA for 20 min with SPONSTIM-25 25cm2 electrodes. Current delivery is initiated in a ramp-like fashion over 10s from 0mA to 2mA. Once at 2mA, the current alternates at 2mA with a 0mA offset applied at random frequencies over a range of 0.1 to 100 Hz. At the end of stimulation, current is decreased in a ramp-like fashion over 10s from 2mA to 0mA. Should the participant not be able to tolerate a current of 2mA due to pain or irritation, the current will be decreased down to a minimum of 1.5mA. If 1.5 mA is still not tolerable, the participant will be removed from the study. Electrode placement is based on the international 10-20 electrode placement system. The anode is placed at the midpoint between F3 and FP1, a location corresponding approximately to the left dorsolateral prefrontal cortex, and the cathode placed at the midpoint between T3 and P3, a location corresponding to left temporo-parietal junction
223787726|NCT02715765|DEVICE|Transcranial Sham Stimulation|Energetic parameters are 2mA for 20 min with SPONSTIM-25 25cm2 electrodes. The sham procedure involves only 40 sec stimulation at 2mA and then drops to 0mA with 15msec pulses every 550msec. Should the participant not be able to tolerate a current of 2mA due to pain or irritation, the current will be decreased down to a minimum of 1.5mA. If 1.5 mA is still not tolerable, the participant will be removed from the study. Electrode placement is based on the international 10-20 electrode placement system. The anode is placed at the midpoint between F3 and FP1, a location corresponding approximately to the left dorsolateral prefrontal cortex, and the cathode placed at the midpoint between T3 and P3, a location corresponding to left temporo-parietal junction
223787727|NCT00608712|DRUG|Esomeprazole|Esomeprazole 20mg oral tablet
223787728|NCT04352933|DRUG|Hydroxychloroquine - Daily dosing|"Active HCQ:~Days 1-2: Loading phase - 400mg (2 x 200mg capsules) taken TWICE A DAY for 2 days Days 3 onwards: Maintenance Phase - 200mg (1 x 200mg capsule) taken ONCE A DAY, every day for 90 days (\~3 months),~Matched Placebo HCQ:~Days 3 onwards: Maintenance Phase - 2 capsules taken ONCE A WEEK on the same day each week (every 7th day) for 90 days (\~3 months)"
223787729|NCT04352933|DRUG|Hydroxychloroquine - Weekly Dosing|"Active HCQ:~Days 1-2: Loading Phase - 400mg (2 x 200mg capsules) taken TWICE A DAY for 2 days Days 3 onwards: Maintenance Phase - 400mg (2 x 200mg capsules) taken ONCE A WEEK on the same day each week (every 7th day) for 90 days (\~3 months)~Matched Placebo HCQ:~Days 3 onwards: Maintenance Phase - 1 capsule taken ONCE A DAY for 90 days (\~3 months)"
223787730|NCT04352933|OTHER|Matched Placebo Hydroxychloroquine|"Matched placebo HCQ - daily dosing:~Days 1-2: Loading Phase - 2 capsules taken TWICE A DAY for 2 days Days 3 onwards: Maintenance Phase - 1 capsule taken ONCE A DAY for 90 days (\~3 months) Matched placebo HCQ - weekly dosing Days 3 onwards: Maintenance Phase - 2 capsules taken ONCE A WEEK on the same day each week (every 7th day) for 90 days (\~3 months)"
223787731|NCT02568787|DIETARY_SUPPLEMENT|rice bran arabinoxylan compound (RBAC)|Take 2 tablets 1 time (1 gram) per day for the 3-month intervention period.
223787732|NCT02568787|DIETARY_SUPPLEMENT|Placebo|Take 2 tablets 1 time (1 gram) per day for the 3-month intervention period.
223787733|NCT01462344|DRUG|ADVAIR 100/50mcg|fluticasone propionate/salmeterol combination (100/50mcg) twice daily (AM and PM) for 6 months
223787734|NCT01462344|DRUG|ADVAIR 250/50mcg|fluticasone propionate/salmeterol combination (250/50mcg) twice daily (AM and PM) for 6 months
223787735|NCT01462344|DRUG|FLOVENT 100mcg|fluticasone propionate (100) twice daily (AM and PM) for 6 months
223787736|NCT01462344|DRUG|FLOVENT 250mcg|fluticasone propionate (250mcg) twice daily (AM and PM) for 6 months
223787737|NCT01003249|DRUG|Baclofen|"Subjects will be randomly assigned to placebo or baclofen groups. Daily dose will be doubled every three days, up to 80 mg or when side effects appear. At the end of 4 week drug will be tapered (halved every 2 days and quitted after 2 days of using 20 mg baclofen). After the 3 week washout period, questionnaires, diary, EMG and uroflowmetry will be repeated. Then patients initially assigned to the baclofen group will be assigned to the placebo group, and those assigned to the placebo group will be assigned to the baclofen group.~Patients would then receive a dose of baclofen 10 mg PO twice daily (or placebo twice daily), and then the dose will be escalated to 80 mg."
223787738|NCT01003249|DRUG|Placebo|"Subjects will then randomly be assigned in placebo or baclofen groups. Daily dose will be doubled every three days, up to 80 mg or when side effects appear. At the end of 4 week drug will be tapered (halved every 2 days and quitted after 2 days of using 20 mg baclofen). After the 3 week washout period, questionnaires, diary, EMG and uroflowmetry will be repeated. Then patients initially assigned to the baclofen group will be assigned to the placebo group, and those assigned to the placebo group will be assigned to the baclofen group.~Patients would then receive a dose of baclofen 10 mg PO twice daily (or placebo twice daily), and then the dose will be escalated to 80 mg."
223787739|NCT00917046|BEHAVIORAL|high-intensity interval training|3 weekly sessions of high-intensity interval training in 12 weeks
223787740|NCT00917046|BEHAVIORAL|Moderate continuous training|3 weekly sessions of moderate continuous training for 12 weeks
223787741|NCT00917046|BEHAVIORAL|Recommendation of regular moderate exercise|Recommendation of regular exercise at moderate intensity at individual choice. In addition patients will meet for treadmill walking in order to motivate for post intervention testing
223703274|NCT03538548|BEHAVIORAL|CBT-RP|CBT-RP is a time-limited, manual guided intervention that aims to develop behavioral and cognitive skills needed to initiate abstinence and prevent relapse. The treatment will help individuals analyze the decision making process to minimize the influence of more immediate reinforcement, develop cognitive strategies to promote the attainment of longer-term goals, practice behavioral strategies to reduce the influence of socially mediated threats to abstinence, and outline explicit plans for managing situations that threaten their goal of abstinence.
223703275|NCT01313858|DRUG|Simponi®|
223703276|NCT01313858|DRUG|Methotrexate|Given concomitantly with Simponi®
223703277|NCT03069443|OTHER|IHG home training|Participants of the intervention group will follow the IHG home training protocol for 20 weeks. The IHG training consists of isometric contractions applied with the hands on a Wii.
223703278|NCT03481907|DEVICE|Nuvagen Collagen Powder|Daily application of Nuvagen collagen powder for 2 to 4 weeks following wounding
223703279|NCT02899299|BIOLOGICAL|Nivolumab|
223703280|NCT02899299|BIOLOGICAL|Ipilimumab|
223703281|NCT02899299|DRUG|Pemetrexed|
223703282|NCT02899299|DRUG|Cisplatin|
223703283|NCT02899299|DRUG|Carboplatin|
223787742|NCT05244525|DRUG|Bupivacaine with Epinephrine|Randomization will be performed prior to surgery and group designation will be placed within an opaque envelope in the patient's chart.The circulating nurse will prepare the pre-operative injection. Study patients will receive an injection containing a total volume of 20 mL of bupivacaine with epinephrine (0.3 mL epinephrine in 30 mL of 0.5% bupivacaine).The syringe will not be labeled, and the contents of the injection will not be disclosed to the surgeon to preserve blinding. The injection will be performed with an 18-gauge needle into the subacromial space via a posterior or lateral approach after positioning the patient in the beach chair position, but prior to prepping and draping.Throughout the case, the mean arterial pressure of the patient will be monitored. At the conclusion of the surgical procedure, the surgeon will rate visual clarity on a visual analog scale. Changes in pump pressure from the initial pressure of 35mmHg during the surgical procedure will also be recorded.
223787743|NCT05244525|DRUG|Bupivacaine alone|Randomization will be performed prior to surgery and group designation will be placed within an opaque envelope in the patient's chart.The circulating nurse will prepare the pre-operative injection. Control patients will receive an injection containing 20mL of 0.5% bupivacaine alone.Throughout the case, the mean arterial pressure of the patient will be monitored. At the conclusion of the surgical procedure, the surgeon will rate visual clarity on a visual analog scale.Changes in pump pressure from the initial pressure of 35mmHg during the surgical procedure will also be recorded.
223787744|NCT01962974|BIOLOGICAL|Golimumab 2 mg/kg IV|Study drug (golimumab 2 mg/kg IV) will be administered as an intravenous (IV) infusion at Weeks 0, 4, 12, 20 and 28.
223787745|NCT06171113|DRUG|GSK4024484C|Doses administrated orally with 240 mL of water.
223787746|NCT06171113|DRUG|Placebo|Doses administrated orally with 240 mL of water.
223787747|NCT05740930|OTHER|Partition defocus myopia management spectacle lens|Participants in the intervention group will receive the partition defocus myopia management spectacles lens and receive follow-up checks.
223787748|NCT05740930|OTHER|Spectacle lenses with aspherical lenslets|Participants in the control group will receive the spectacle lenses with aspherical lenslets and receive follow-up checks.
223787749|NCT06137300|DRUG|Urinary kallidinogenase for injection|Urinary kallidinogenase 0.15PNA once daily for 7 days.
223787750|NCT06137300|OTHER|Guideline-prescribed medical therapy|Guideline-prescribed medical therapy
223787751|NCT04107090|OTHER|lung recruitment maneuver|Lung recruitment maneuver done for ventilated preterm neonates diagnosed with respiratory distress syndrome
223787752|NCT04107090|OTHER|tracheal IL-6 level|tracheal IL-6 level was measured before and after recruitment maneuver
223787753|NCT04107090|OTHER|US guided lung recruitment maneuver|Lung recruitment maneuver done for ventilated preterm neonates diagnosed with respiratory distress syndrome guided by lung ultrasound
223787754|NCT02266628|BIOLOGICAL|RSV-F Vaccine|
223787755|NCT02266628|BIOLOGICAL|Saline Placebo|
223787756|NCT02060890|OTHER|specialized tumor board recommendation|feasibility of a specialized tumor board to come up with treatment recommendations no later than 35 days from surgery.
223787757|NCT01517698|DRUG|Placebo|placebo to RO4917523 orally once a day for 12 weeks
223787758|NCT01517698|DRUG|RO4917523 0.5 mg|0.5 mg orally once a day for 12 weeks
223787759|NCT01517698|DRUG|RO4917523 1.5 mg|1.5 mg orally once a day for 12 weeks
223787760|NCT01527201|PROCEDURE|Arthroscopic debridement|Surgeon will debride, or remove, worn out cartilage.
223787761|NCT00765908|DEVICE|Angioplasty balloon|90 second balloon inflation x 2
223787762|NCT00765908|DEVICE|Angioplasty balloon|30 seconds or less balloon inflations x 2
223787763|NCT04211103|DRUG|Pembrolizumab|Humanized antibody used in cancer immunotherapy. It targets the programmed cell death protein 1 (PD-1) receptor of lymphocytes.
223787764|NCT02752620|OTHER|Osteopathic Manipulative Treatment|
223787765|NCT02752620|OTHER|Exercise Therapy|
223787766|NCT03754023|DIAGNOSTIC_TEST|Urine-TIMP-IGFBP7 biomarker for AKI|Urine-TIMP-IGFBP7 biomarker for AKI
223787767|NCT05758025|PROCEDURE|"Resection based on thymus-vascular-inferior parathyroid complex"|"Before clearing the central lymph nodes, looking for the thyro-thymic ligament first, looking for the inferior parathyroid along the thyro-thymic ligament. Dissect and leave the thymus-vascular-inferior parathyroid complex laterally; the inner side of this layer is the tissue of the central area. Then remove the central lymph nodes. Check for parathyroids in the removed specimen, transplant the parathyroids which are removed by accident."
223787768|NCT02790385|DEVICE|Negative Pressure Wound Therapy|
223787769|NCT02790385|OTHER|Standard Gauze Treatment|
223787770|NCT04382794|DRUG|Retrospective case-control analysis|Evaluation of clinical, laboratory and instrumental parameters of diabetic patients during hospitalization for COVID-19. The data will be extracted anonymously from the computerized medical records commonly used in clinical practice by the centers involved in the study
223787771|NCT04533841|DRUG|Misoprostol|Pt will receive misoprostol for labor induction then after 30 minutes will receive ether propranolol or misoprostol
223787772|NCT04533841|DRUG|Placebo|placebo
223787773|NCT04533841|DRUG|Propranolol|Propranolol
223787774|NCT03644979|OTHER|Skydiving|Tandem skydiving (with an experienced instructor)
223787775|NCT02359721|DRUG|tablet clarithromycin 500 mg (Clarino-500) orally|orally
223787776|NCT02717793|OTHER|Strength testing|"isometric muscle strength~1RM measurement of muscle strength"
223787777|NCT02467777|DEVICE|Bair Hugger|
223787778|NCT02467777|DEVICE|VitaHeat|
223787779|NCT03900936|DIAGNOSTIC_TEST|Neuropsychological tests|This study is not an intervention as such. We are simply comparing the scores of MCI patients who subsequently went on to develop dementia vs those who did not.
223787780|NCT01474135|DRUG|0.25% AR-12286 / 0.004% travoprost|
223787781|NCT01474135|DRUG|0.5% AR-12286, 0.004% travoprost|
223787782|NCT01474135|DRUG|0.004% Travoprost|
223787783|NCT04793321|DEVICE|Baby carrier|"* It is made in china.~* It is made of Cotton-Polyester.~* It has 3 belts - 2 shoulder belts and one waist belt for superior lumbar support. Shoulder straps are padded and adjustable for the parent's comfort. It has webbing straps for shoulder and waist strap adjustment.~* It is suitable for newborn to 12-months baby~* It is available online at babyshopstores https://www.babyshopstores.com/"
223787784|NCT04793321|DEVICE|Biodex Balance System|"* The Biodex Balance System SD (The Biodex Balance System SD Model 945-300, 115 VAC, Shirley, NY, USA) is used to assess the balance in this study.~* It is an objective device that measures dynamic postural stability. It uses a circular platform that allows up to 20˚of of platform tilt in a 360˚ range of motion.~* The measures of postural stability score for BBS are the Overall Stability Index (OSI), Medial-Lateral Stability Index (MLSI), and Anterior-Posterior Stability Index (APSI). These indices are standard deviations that assess the path of sway around the zero point from the center of the platform and are measured in degrees. A high score in these stability indices indicates poor balance."
223703284|NCT00761904|BEHAVIORAL|Free Generic Samples (hydrochlorothiazide, simvastatin)|Free samples of generic hydrochlorothiazide (12.5 mg tabs) and simvastatin (20 mg tabs)
223703285|NCT03534414|DIETARY_SUPPLEMENT|Portfolio Dietary Pattern|"Portfolio Dietary Pattern consisting of 4 food components, including:~1. plant sterols (sterol-enriched margarine or supplement)~2. viscous soluble fibres (oats, barley, psyllium, eggplant, okra, etc)~3. plant protein (soy products and pulses), and~4. nuts (tree nuts and peanuts)"
223703286|NCT03534414|DIETARY_SUPPLEMENT|NCEP Based Diet|A low saturated fat, low cholesterol diet.
223703287|NCT04992598|OTHER|Hypnosis session|Hypnosis session will precede therapeutic strategies and reduction
223703288|NCT04992598|PROCEDURE|Reduction|All dislocation would be reduced Under adequate analgesia and sufficient sedation. All methods for reduction can be used.
223703289|NCT03033485|RADIATION|18F-P3BZA|18F-P3BZA is a type of 18F labeled Picolinamide targeting melanin which is highly secreted in Melanoma. The toxicity of P3BZA was evaluated by SoBran Bioscience. The final report showed that there no signs of toxicity during the conduct of the toxicity study. No treatment-related differences were noted in mean body weight and body weight changes, clinical chemistry, haematology, or coagulation parameter after a single intravenous dose of P3BZA at 0.0589mg/kg.
223703290|NCT04253223|BIOLOGICAL|REMD-477|REMD-477 will be administered as a subcutaneous injection for three weekly doses
223703291|NCT00760123|OTHER|Early Physical Therapy and Educational strategy|"Experimental group:~physical therapy including a manual lymph-drainage technique, progressive massage of the scar, and progressive active and action-assisted shoulder exercises started in conjunction with functional activities and proprioceptive neuromuscular facilitation without resistance and Educational strategy including instruction with printed materials about the lymphatic system, concepts of normal load versus overload, lymphedema source, the identification of possible precipitating factors,etc.~Other: control group: only the educational strategy"
223703292|NCT04731181|BEHAVIORAL|mobile application (little lovely dentist).|mobile application
223703293|NCT06037070|BIOLOGICAL|Platelet Rich Fibrin|PRF will be injected inside the hole that prepared to place dental implant
223703294|NCT03673449|DEVICE|SilkBridge|SilkBridge is a biocompatible silk fibroin-based scaffold, which recruits the patients' own cells to remodel or regenerate the nerve, without pre-seeding of the scaffold nor biological/chemical treatments.
223703295|NCT03041077|DIETARY_SUPPLEMENT|Instaflex Advanced|Joint function
223703296|NCT03041077|DIETARY_SUPPLEMENT|Placebo|Placebo
223703297|NCT05476198|PROCEDURE|Brachial plexus block|The effect of brachial plexus block method on preoperative anxiety levels in patients who will undergo orthopedic upper extremity surgery.
223703298|NCT05476198|PROCEDURE|General anesthesia|The effect of general anesthesia method on preoperative anxiety levels in patients who will undergo orthopedic upper extremity surgery.
223703299|NCT01935791|OTHER|Period 1 Visit 1 - Cold PET-CT Vehicle, Visit 2 -Warm PET-CT Vehicle|Temperature
223703300|NCT01935791|DRUG|Period 1 Visit 1 - Cold PET-CT Vehicle, Visit 2 -Warm PET-CT Glucagon|Hormone
223703301|NCT01935791|OTHER|Period 1 Visit 1 - Cold PET-CT Vehicle, no visit 2 as BAT negative|Temperature
223703302|NCT01935791|DRUG|Period 2 - Visit 1 Warm Control vehicle, Visit 2 Warm Glucagon, Visit 3 Cold control|Hormone
223703303|NCT01935791|DRUG|Period 2 - Visit 1 Warm Glucagon, Visit 2 Cold control , Visit 3 Warm control|Hormone
223703304|NCT01935791|DRUG|Period 2 -Visit 1 cold control, Visit 2 warm control, Visit 3 Warm glucagon|hormone
223703305|NCT01935791|DRUG|Period 2 -Visit 1 cold control, visit 2 warm glucagon, visit 3 warm control|hormone
223703306|NCT01935791|DRUG|Period 2- Visit 1 Warm glucagon, visit 2 warm control, visit 3 cold control|hormone
223703307|NCT01935791|DRUG|Period 2 - Visit 1 Warm control, visit 2 cold control, visit 3 warm glucagon|Hormone
223703308|NCT02341365|OTHER|vitamin D,AMH, AFC, reproductive outcome egg recipients|observational study of 269 donnors
223703309|NCT03018769|DRUG|Chinese Herb|
223703310|NCT05756491|OTHER|24 months of inclusion of unaccompanied patients|inclusion for 6 months of accompanied patients in conventional outpatient care (observational period) and then inclusion for 24 months of unaccompanied with remonte surveillance patients and accompanied patients (interventional period)
223703311|NCT05756491|OTHER|18 months of inclusion of unaccompanied patients|inclusion for 12 months of accompanied patients in conventional outpatient care (observational period) and then inclusion for 18 months of unaccompanied with remonte surveillance patients and accompanied patients (interventional period)
223703312|NCT05756491|OTHER|12 months of inclusion of unaccompanied patients|inclusion for 18 months of accompanied patients in conventional outpatient care (observational period) and then inclusion for 12 months of unaccompanied with remonte surveillance patients and accompanied patients (interventional period)
223703313|NCT05756491|OTHER|6 months of inclusion of unaccompanied patients|inclusion for 24 months of accompanied patients in conventional outpatient care (observational period) and then inclusion for 6 months of unaccompanied with remonte surveillance patients and accompanied patients (interventional period)
223703314|NCT02468232|DRUG|LCZ696|The target dose during the study was LCZ696 200 mg bid given orally. LCZ696 was supplied as 50 mg, 100 mg and 200 mg film-coated tablets.
223703315|NCT02468232|DRUG|Enalapril|The target dose during the study was enalapril 10 mg bid given orally. Enalapril was provided as 2.5 mg, 5 mg, and 10 mg tablets.
223703316|NCT02468232|DRUG|Placebo to LCZ696|LCZ696 Placebo 50 mg, 100 mg and 200 mg film-coated tablets
223703317|NCT02468232|DRUG|Placebo to Enalapril|Enalapril Placebo 2.5 mg, 5 mg and 10 mg tablets
223703318|NCT00506662|DRUG|insulin detemir|Treat-to-target, s.c. (under the skin) injection, once daily
223703319|NCT00506662|DRUG|insulin NPH|Treat-to-target, s.c. (under the skin) injection, once daily
223703320|NCT00002914|DRUG|piritrexim|
223703321|NCT02677532|DRUG|Paracetamol|1 g every 8 hours
223703322|NCT02677532|DRUG|Levobupivacaine wound infiltration|Wound infiltration with 10 ml levobupivacaine 0.5%
223787785|NCT04793321|OTHER|Infant mannequin|The mannequin infant has 3 Kg which corresponds to the infant's age from birth until 1month. This weight is selected as it corresponds to the age at which the infants are frequently carried by the mother .
223703323|NCT02677532|DRUG|Levobupivacaine epidural bolus|Epidural bolus of 10 ml 0.25% levobupivacaine
223703324|NCT02677532|DRUG|Sufentanil epidural bolus|Epidural bolus of 0.15 mcg/kg sufentanil
223703325|NCT02677532|DRUG|Morphine|Intravenous slow bolus of 10 mg morphine
223703326|NCT02677532|DEVICE|Epidural catheter placement|Thoracic epidural catheter placement in the T7-T8 or T8-T9 intervertebral space
223703327|NCT02677532|DEVICE|Wound infusion catheters placement|Pre-peritoneal placement of two catheters for wound infusion
223703328|NCT02677532|DRUG|Levobupivacaine plus sufentanil epidural infusion|Epidural infusion of levobupivacaine 0.12% plus sufentanil 0.4 mcg/ml at 4 ml/h for 48 h
223703329|NCT02677532|DRUG|Levobupivacaine wound infusion|Wound infusion with levobupivacaine 0.25% at 4 ml/h for 48 h
223703330|NCT02080234|DRUG|GELOX|gemcitabine ：1250mg/m2 (ivdrip) on days 1, oxaliplatin :85 mg/m2 (ivdrip) on day 1, and pegaspargase : 2500 IU/m2 (intramuscular injection) on day 1.Cycle is repeated every 14 days
223703331|NCT02080234|RADIATION|IFRT|IFRT is delivered using 6-MeV linear accelerator using 3-dimensional conformable treatment planning. The IFRT dose was 56 grays (Gy) in 28 fractions
223703332|NCT01924000|DRUG|Minoxidil lotion 1%|Minoxidil lotion 1% is applied twice daily to one eyebrow.
223703333|NCT01924000|DRUG|Placebo|
223703334|NCT00246753|DRUG|lapatinib ditosylate|1500 mg, daily until disease progression
223703335|NCT04654676|DRUG|Vildagliptin|Vildagliptin added on to stable doses of pre-mixed insulin with or without metformin
223703336|NCT01994447|OTHER|Student Enrollment|The standard informed consent process is for research nurses to provide verbal explanations of studies. In the intervention arm trained research students will use DVD's made by the studies principal investigator to explain study information in the informed consent process.
223703337|NCT06266572|BEHAVIORAL|Overcoming and Addressing Stigma in Substance Use Disorders (OASIS)|Web-based educational platform for clinicians and individuals with OUD that will decrease barriers to care and enhance treatment outcomes
223703338|NCT05968456|OTHER|Data collection|Observational study in patients undergoing thoracic, cardiac and vascular surgery.
223703339|NCT03643796|DRUG|Remifentanil|Remifentanil infusion of 0.05 to 0.2 mcg/kg/minute started just prior to induction and stopped at emergence from anesthesia.
223703340|NCT03643796|DRUG|Ketamine|Ketamine infusion of 2 mcg/kg/minute will be started at induction. It will be stopped at the beginning of the emergence from anesthesia, roughly 45 minutes from extubation.
223703341|NCT03643796|DRUG|Dexmedetomidine|dexmedetomidine bolus of 0.5 mcg/kg over 10 minutes starting 5 minutes prior to induction followed by an infusion of 0.2-0.7 mcg/kg/hour that will be stopped with the start of closing the surgical wound.
223703342|NCT01529047|BEHAVIORAL|Personalized Feedback Intervention|Printed or electronic form containing personalized information about health-relevant behaviors
223703343|NCT00270790|DRUG|Amifostine|Amifostine will be given at dose of 500 mg IV within one hour before radiation
223703344|NCT00270790|DRUG|Carboplatin|Carboplatin for 100 mg/m2 and will be administered after the taxol infusion
223703345|NCT00270790|DRUG|Taxol|Taxol will be given at a dose of 40 mg/m2 as a 3 hour infusion dose
223703346|NCT00270790|DEVICE|Radiotherapy|Radiation will be given at a dose of 1.8 Gy. for a total of 70.2 Gy
223703347|NCT01919593|DRUG|2% chlorhexidine gluconate in 70% alcohol|skin preparation before venipuncture for blood culture in even month
223703348|NCT01919593|DRUG|10%povidone iodine|skin preparation before venipuncture for blood culture in odd month
223703349|NCT01986283|DRUG|Capsule|Taken once
223703350|NCT01986283|DRUG|PF-00345439|40 mg capsule swallowed whole, taken once
223703351|NCT01986283|DRUG|PF-00345439|40 mg capsule chewed, taken once
223703352|NCT01986283|DRUG|oxycodone|40 mg solution, taken once
223703353|NCT03460860|DIETARY_SUPPLEMENT|Astaxanthin (2mg)+Lycopene (1.8mg)+D-Alpha-Tocopherol (10IU)|The intervention is to be taken once daily, for 12 weeks.
223703354|NCT03460860|DIETARY_SUPPLEMENT|Placebo|The intervention is to be taken once daily, for 12 weeks.
223703355|NCT00617851|BIOLOGICAL|Lot A of Influenza virus vaccine|1 injection of the trivalent subunit influenza virus vaccine (lot A) administered intramuscularly
223703356|NCT00617851|BIOLOGICAL|Lot B of Influenza virus vaccine|1 injection of the trivalent subunit influenza virus vaccine (lot B) administered intramuscularly
223703357|NCT00617851|BIOLOGICAL|Lot C of Influenza virus vaccine|1 injection of the trivalent subunit influenza virus vaccine (lot C) administered intramuscularly
223703358|NCT00617851|BIOLOGICAL|Comparator influenza virus vaccine|1 injection of the trivalent subunit influenza virus vaccine administered intramuscularly
223703359|NCT00617851|BIOLOGICAL|All 3 consecutive lots of influenza virus vaccine pooled|1 injection of the pooled trivalent subunit influenza virus vaccine administered intramuscularly
223703360|NCT01557049|OTHER|Control Group|No physical intervention was given, patients were treated only with medication if necessary.
223703361|NCT01557049|OTHER|Global Reeducation Group|They were treated with medication if necessary and performed GPR session once a week, during 12 weeks. All the 6 postures from GPR were used during the study.
223703362|NCT01572350|OTHER|Grid laser|Grid laser therapy acts as the standard to refer to as it is the treatment which is currently accepted by EMDDNT.
223703363|NCT01572350|DRUG|Triamcinolone Acetonide|Triamcinolone 4 mg followed by modified grid laser therapy after 3-4 weeks
223703364|NCT01572350|DRUG|Bevacizumab|Bevacizumab (1.25 mg initially, weeks 6 and 12) followed by modified grid laser therapy after3-4 weeks
223703365|NCT01200524|DRUG|AZD2423|20 mg tablet
223703366|NCT01200524|DRUG|AZD2423|50 mg tablet
223703367|NCT01200524|DRUG|Placebo|Placebo
223703368|NCT02520830|DIETARY_SUPPLEMENT|Blueberry Group|22 grams freeze-dried blueberry powder per day. Sustained intake (2x 11 grams daily over 1 month) of a drink consisting on freeze-dried wild blueberry powder dissolved in water
223703369|NCT02520830|DIETARY_SUPPLEMENT|Placebo Group|Sustained intake (2x 11 grams daily over 1 month) of a drink consisting in placebo powder dissolved in water
223703370|NCT01303861|DRUG|Varenicline|For the first 3 days after being switched from nicotine patches (occurring at one week before the target quit date), smokers in this group will receive varenicline at a dose of 0.5 mg once per day followed by 0.5 mg twice a day for the remaining 4 days of that week. Subsequently, the dose will be 1 mg twice per day, and will remain at that dose for the remainder of the 12 weeks.
223703371|NCT01303861|DRUG|Bupropion|For the first 3 days after being switched from nicotine patches (occurring at one week before the target quit date), smokers in this group will receive bupropion at a dose of 150mg once per day. Subsequently, the dose will be 150mg twice per day, and will remain at that dose for the remainder of the 12 weeks.
223703372|NCT01303861|DRUG|Nicotine patches|"Nicotine Replacement Therapy Groups:~1. For smokers with high baseline carbon monoxide (CO): 42 mg/24 h for 2 weeks before the quit date and 3 weeks after the quit date, 21 mg/24 h for 4 weeks, 14 mg/24 h for 2 weeks, and 7 mg/24 h for 2 weeks; or~2. For smokers with low baseline CO: 21 mg/24 h for 2 weeks before the quit date and 7 weeks after the quit date, 14 mg/24 h for 2 weeks, and 7 mg/ 24 h for 2 weeks.~Varenicline and varenicline in combination with bupropion groups:~1. For smokers with high baseline CO: 42 mg/24 h for 1 week~2. For smokers with low baseline CO: 21 mg/24 h for 1 week"
223703373|NCT01303861|DRUG|Nicotine Inhaler|Nicotine inhaler to use as needed after quit date
223703374|NCT02758132|BIOLOGICAL|Denosumab|One 120 mg subcutaneous injection every four weeks. Protocol therapy will consist of 28-day cycles until no clinical benefit, confirmed disease progression or unacceptable toxicity.
223703375|NCT02758132|DRUG|Enzalutamide|160 mg enzalutamide by mouth daily
223703376|NCT02758132|DRUG|Abiraterone|1000 mg abiraterone by mouth daily
223703377|NCT02758132|DRUG|Prednisone|5 mg prednisone by mouth twice daily
223703378|NCT04970355|BIOLOGICAL|Erenumab|Pre-filled syringe; s.c. injection
223703379|NCT04970355|DRUG|Placebo|Pre-filled syring; s.c. injection
223703380|NCT02476201|DEVICE|MPP ON|Patients implanted with a Cardiac Resynchronization Therapy CRT-D device and a Quartet Left Ventricular (LV) quadripolar lead and with the MultiPoint Pacing (MPP) feature activated
223703381|NCT04206059|RADIATION|MRI|A non-contrast brain MRI will be acquired for localizing EEG slow waves
223703382|NCT04206059|DIAGNOSTIC_TEST|Quantitative Sensory Testing (QST)|Quantitative sensory testing (QST) using increasing ramp thermal stimulation (32-52 ºC) will be delivered to compare arousal thresholds between conditions.
223703383|NCT04206059|DIAGNOSTIC_TEST|Home sleep study|Unattended home sleep studies will be conducted on the night preceding sedation and on the night following sedation to assess changes in slow wave homeostasis.
223703384|NCT04206059|OTHER|Acoustic stimulation (65db) up-slope of EEG with QST|Acoustic stimulation (65 db) synchronized in-phase with the up-slope of EEG slow waves
223703385|NCT04206059|OTHER|Acoustic stimulation (65db) down-slope of EEG with QST|65 dB acoustic stimulation synchronized with the down-slope of the EEG slow waves (anti-phase)
223703386|NCT04206059|OTHER|0 db with QST|sham stimulation (0 dB volume)
223703387|NCT04206059|DRUG|Dexmedetomidine|All participants will receive dexmedetomidine with sedation titrated step-wise to 2, 3 or 4 ng/ml
223703388|NCT04206059|OTHER|Breathe-Squeeze Task|All participants will be asked to perform the breathe-squeeze task throughout the experiment. This will allow us to determine loss and return of responsiveness.
223787786|NCT04793321|DEVICE|Biodex gait trainer 2 TM|"Gait Trainer 2™ ( model number:950-385, 115 VAC 50/60 Hz, made in the USA) is used for participants to walk on as walking is one of the most common daily life activities. because caregivers commonly walk while carrying their infants as it has a calming effect on crying infants~It consists of :~* Display: Use Audio and Visual Biofeedback - real-time biofeedback prompts patients into a proper gait pattern.~* Heart Rate Monitoring~* Handrail~* Open Platform"
223787787|NCT04547972|OTHER|Higher-load resistance training|This intervention will have one arm and one leg of each participant training with \~80% of their one repetition maximum
223787788|NCT04547972|OTHER|Lower-load resistance training|This intervention will have one arm and one leg of each participant training with \~30% of their one repetition maximum
223787789|NCT01806337|DRUG|Alemtuzumab|Consolidation after CHOP induction
223787790|NCT03394924|DRUG|EDP-305 1 mg|Two tablets daily for 12 weeks
223787791|NCT03394924|DRUG|EDP-305 2.5 mg|Two tablets daily for 12 weeks
223787792|NCT03394924|DRUG|Placebo|Two tablets daily for 12 weeks
223787793|NCT01303289|DIETARY_SUPPLEMENT|T-Diet plus Standard|T-Diet plus Standard is a complete balanced protein and energy oral nutrition supplement, indicated for the dietary management of patients with related malnutrition.
223787794|NCT01303289|DIETARY_SUPPLEMENT|Jevity|JEVITY is a diet for tube-fed patients in the medium to long term, to varying degrees of malnutrition with gastrointestinal disorders.
223787795|NCT02386566|DRUG|natalizumab|As described in the treatment arm
223787796|NCT03387852|DRUG|SAR440340|Pharmaceutical form: Solution for Injection, Route of administration: SC
223787797|NCT03387852|DRUG|Dupilumab|Pharmaceutical form: Solution for Injection, Route of administration: SC
223787798|NCT03387852|DRUG|Fluticasone or Fluticasone/salmeterol combination|Pharmaceutical form: Aerosol, dry powder, Route of administration: Inhaled
223787799|NCT03387852|DRUG|Placebo for SAR440340|Pharmaceutical form: Solution for Injection, Route of administration: SC
223787800|NCT03387852|DRUG|Placebo for dupilumab|Pharmaceutical form: Solution for Injection, Route of administration: SC
223703389|NCT04123652|DRUG|Lidocaine Hydrochloride 2% Intravenous Solution, DIN 02421992|"An intravenous will be started. • Lidocaine - initial dose of 5.0 mg/kg +/- 1.0 mg/kg (based on actual weight, up to maximum dose 600 mg) over 45 minutes, followed by increases of 0.5 mg/kg each infusion based on tolerability of side effects, not to exceed 7 mg/kg or 600 mg.~• Ketamine - initial dose of 0.1 mg/kg (based on actual weight) over 45 minutes (rounded to nearest 5 mg, up to maximum 15 mg), increased by 0.1 mg/kg (rounded to nearest 5 mg) each infusion based on tolerability of side effects During the infusion patient will be monitored by another MD for BP, PR, PO2. Patients will not be allowed to drive for 24 hours."
223703390|NCT02552784|BEHAVIORAL|data assessment of the state of health and quality of life of patients and their families|Study medical determinants, socioeconomic, behavioral, environmental of health, school and professional integration, and short- and medium-term quality of life of all patients residing in France for which the diagnosis of hereditary diseases metabolism with specific diet (MHMRS) was performed during their childhood.
223703391|NCT00723580|DRUG|risperidone|Five treatment conditions: 1. Baseline no medication 2. Risperidone .25 mg at bedtime (q.h.s.) x 7 days 3. Risperidone .25 mg twice daily (b.i.d.) 4. Risperidone .25 mg three times a day (t.i.d.) and 5. Risperidone .5 mg three times a day (t.i.d.).
223703392|NCT03429660|OTHER|Medical information|"The information collected are about :~* Introduction or non-introduction of treatment~* Cumulative dose of treatment~* Drug dispensation and withdrawal~* Hospitalization reason~* Safety information~* Demographic data (date of death)"
223703393|NCT02037022|BEHAVIORAL|Pivotal Response Treatment Package (PRT-P)|
223703394|NCT02364492|DRUG|MAG-TN3 + AS15|
223703395|NCT05629078|DEVICE|Toric intraocular lens Zeiss AT TORBI|Intraocular lenses are medical devices that are implanted in patients during cataract surgery. At Plymouth University NHS trust the standard lens is a monofocal non-Toric lens unless the patient has astigmatism greater than 4.00D. This study involves implantation of a toric lens in the intervention group where astigmatism is greater than 1.00D. The lens is called the toric IOLS- Zeiss AT TORBI, will be implanted bilaterally instead of standard monofocal IOLs- Zeiss CT ASPHINA, used in routine cataract surgery within NHS.
223703396|NCT03745131|OTHER|Blood draw|Blood draw to obtain serum to determine anti-orthopox antibody titres.
223703397|NCT02505295|DIETARY_SUPPLEMENT|Selenium|4 vials selenase stat and 2 vials daily for 5 days
223703398|NCT02505295|DRUG|normal saline|Normal saline infusion like intervention group
223703399|NCT02916589|DIETARY_SUPPLEMENT|Diet|
223703400|NCT01848496|PROCEDURE|Gingival displacement|Gingival displacement is a dental procedure that allows exposure of the finishing line of a dental cavity in order to produce a well-adapted restoration.
223703401|NCT04061265|DRUG|Articaine 4%/Epi 1:100000 Inj Cart 1.7Ml|Local anesthetic agent
223703402|NCT04061265|DRUG|lidocaine hydrochloride 2% and epinephrine 1:100000|Local anesthetic agent
223703403|NCT02505763|PROCEDURE|Strategy with thoracic ultrasound|This strategy involves the systematic use of thoracic ultrasound for the treatment of pleural effusion, treatment and follow up care.
223703404|NCT02125968|OTHER|interactive video game|short- and medium-term therapeutic effects
223703405|NCT02125968|OTHER|therapeutic exercise|short- and medium-term therapeutic effects
223703406|NCT00821106|PROCEDURE|Right radial|diagnostic or interventional procedures performed through right transradial approach
223703407|NCT00821106|PROCEDURE|left radial|diagnostic or interventional procedures performed through left transradial approach
223703408|NCT05532917|OTHER|Gupta score|The Gupta score is presented as an interactive risk calculation program in the 2014 guideline of the ACC/AHA. The Gupta score developed with this MICA model identified five predictors of perioperative myocardial infarction and cardiac arrest: type of surgery, functional status, creatinine increase (\>130 mmol/L or \>1.5 mg/dL), age, and American Association of Anesthesiologists (ASA) class. The frequency of cardiology consultation requests will be investigated according to the use of the Gupta score.
223787801|NCT02596451|DRUG|Diclofenac Sodium gel, 1%|
223787802|NCT02596451|DRUG|Voltaren® Gel|
223787803|NCT02596451|DRUG|Placebo|
223787804|NCT05812261|OTHER|Creating an electro-anatomical map|After the routine pulsed-field ablation procedure, the operator will create an electro-anatomical map using the ablation catheter and a 3D mapping system.
223787805|NCT06387043|OTHER|Balance exercises with Virtual Reality Glasses|Balance exercises with Virtual Reality Glasses
223787806|NCT06387043|OTHER|Balance Exercises with Stroboscopic Glasses|Balance Exercises with Stroboscopic Glasses
223787807|NCT06387043|OTHER|Balance Exercises with Visual-Based Metaphor Training|Balance Exercises with Visual-Based Metaphor Training
223787808|NCT06387043|OTHER|Traditional Balance Exercises|Traditional Balance Exercises
223787809|NCT00004093|DRUG|carboplatin|Carboplatin will be dosed at a target AUC of 5, and will be given on day 1 of each cycle
223787810|NCT00004093|DRUG|Gemcitabine|Gemcitabine will be given at 1000 mg/m2 IV over 30 minutes on days 1 and 8 of each 21-day cycle of induction chemo (following carboplatin on day 1).
223787811|NCT00004093|DRUG|paclitaxel|Paclitaxel will be given on day 1 of each week for 6 weeks at a dose of 50 mg/m2.
223787812|NCT00004093|DRUG|vinorelbine|Vinorelbine will be given on day 1 of each week for 6 weeks at a starting dose of 10 mg/m2, escalating up to 15 mg/m2 if no dose limiting toxicities are observed.
223787813|NCT00004093|RADIATION|radiation therapy|Radiation will be given at a dose ranging between 45 to 66 Gy, depending on patient-specific characteristics.
223787814|NCT00004093|DRUG|Navelbine|Navelbine will be administered at a dose of 10-15 mg/m2 in 100 cc NS to be administered over 10 minutes I.V. (one dose weekly during radiation therapy)
223787815|NCT00004093|DRUG|Taxol|Taxol will be administered at a dose of 50 mg/m2 in 250 cc of NS or D5W over 60 minutes, following Navelbine (one dose weekly during radiation therapy)
223787816|NCT03590301|BEHAVIORAL|FUNPALs Playgroup|Based on Self-Determination Theory, the FUNPALs Playgroup aims to enable and inspire parents to improve their toddlers dietary intake and physical activity habits through authoritative parenting, structured feeding practices, and a healthy home environment. Playgroups will include open but structured experiential learning activities, free play, and instruction/discussion.
223787817|NCT03590301|BEHAVIORAL|Healthy Toddler Parent Group|The parent class will serve as our instruction only control group. Parents in this class will receive information about nutrition and activity recommendations regarding their toddler age children and will discuss it in a group with other parents. No experiential learning activities, information about parenting, or children will be involved in this class.
223787818|NCT04178551|OTHER|Implementation Facilitation|The foundation of CONDUIT's implementation activities are the structured interactions between external facilitation teams and internal facilitation teams. A core set of internal facilitation activities will be used across all facilitation teams, and external facilitation teams will use additional activities based on the needs of their sites or clinical settings.
223787819|NCT00265057|DRUG|ADH -1 (Exherin™)|
223787820|NCT04695834|PROCEDURE|Neurolysis peroneal nerve|The surgical approach for entrapment at the fibular head is usually through a curvilinear incision just distal to the fibular head. The subcutaneous tissue is bluntly dissected, and the common peroneal nerve is identified proximal to the peroneus longus muscle. The peroneal nerve is then released from the surrounding fibrous tissue and fascia. The nerve is decompressed distally as it dives under the peroneus longus muscle. The decompression at this site is essential. Certain authors state that an adequate decompression should extend beyond the bifurcation in the deep and superficial peroneal nerve and should involve cutting the intermuscular septa
223787821|NCT04695834|OTHER|Maximal physiotherapy|Mobilization of ankle and foot, stretching of the calf muscles (prevention of contractures) Tonification of the dorsiflexion- and eversion muscles of the ankle Proprioceptive training Gait rehabilitation Home exercise schedule
223787822|NCT04696796|PROCEDURE|Mediolateral Episiotomy with BasIQ-4 Surgical Knife|Mediolateral episiotomy will be performed with BasIQ-4 Surgical Knife which cuts from distal to the center with inner knife.
223787823|NCT04696796|PROCEDURE|Mediolateral Episiotomy with Episiotomy Scissors|Mediolateral episiotomy will be made from the central to the distal with episiotomy scissors
223787824|NCT00438386|DRUG|Aripiprazole|
223787825|NCT04108312|DIAGNOSTIC_TEST|Anatomical MRI Scan|T1-weighted (T1w) magnetization prepared rapid gradient echo (MPRAGE) sequence (TR=8.776 milliseconds, TE=3.656 milliseconds, flip angle=8°, matrix=320x320, 0.8mm3 resolution) and T2-weighted (T2w) CUBE sequence (TR=61.803 milliseconds, TE=3200 milliseconds, flip angle=8°, matrix=320x320, 0.8mm3 resolution)
223787826|NCT02269293|DRUG|Paclitaxel|
223787827|NCT02269293|DRUG|Carboplatin|
223787828|NCT02269293|DRUG|Selinexor|
223787829|NCT04590703|BIOLOGICAL|ALLO-ASC-DFU|Application of ALLO-ASC-DFU sheet to Diabetic Foot Ulcer. This study is a follow-up study without intervention.
223787830|NCT04590703|PROCEDURE|Vehicle sheet|Application of Vehicle sheet to Diabetic Foot Ulcer. This study is a follow-up study without intervention.
223787831|NCT04695223|DRUG|Arsenic Trioxide|Refractory cancer patients without standard-of-care harboring TP53 mutation received Arsenic Trioxide Injection (0.16mg/kg,d1-5,ivgtt,28days as a duration)
223787832|NCT04105023|DIETARY_SUPPLEMENT|genistein|Administered orally once every 12 hours
223787833|NCT04105023|DIETARY_SUPPLEMENT|Placebo|Administered orally once every 12 hours
223703409|NCT06557382|BEHAVIORAL|Cognitive tests and reading-related evaluations|Tests assessing cognitive status and reading were administered. (Frankfurter; MVPT-3, TILLs; etc.)
223703410|NCT05295056|DEVICE|AFGen1 Device Wear Test|Participant wears the device for 7 days
223703411|NCT05295056|DEVICE|AFGen 1 Device Single Use|Participant wears the device in conjunction with a standard ECG
223703412|NCT00989105|OTHER|immunohistochemistry staining method|
223703413|NCT00989105|OTHER|laboratory biomarker analysis|
223703414|NCT00989105|OTHER|pharmacological study|
223703415|NCT00989105|PROCEDURE|computed tomography|
223703416|NCT00989105|PROCEDURE|magnetic resonance imaging|
223703417|NCT00989105|PROCEDURE|single photon emission computed tomography|
223703418|NCT00989105|RADIATION|technetium Tc 99m demobesin-4|
223703419|NCT01506258|PROCEDURE|Application of Stem Cells|IV infusion of autologous stem cells within the first 48 hours after birth.
223703420|NCT01506258|PROCEDURE|Observation|Control group of patients that meet the inclusion criteria but that do not wish to have the intervention.
223703421|NCT00443495|DRUG|Chitin microparticles by nasal route|
223703422|NCT03534362|DEVICE|Nasopore|Nasopore group will receive frontal drill out procedure as indicated with Kenalog-soaked Nasopore stent applied to the post-operative outflow tract
223703423|NCT03534362|DEVICE|Propel|Propel stent group will receive frontal drill out procedure as indicated followed by Propel stent placement applied to the post-operative outflow tract.
223703424|NCT02438020|DRUG|Metformin|One tablet of 500 mg will be ingested before the main meal
223703425|NCT02438020|OTHER|Placebo|A placebo tablet will be ingested daily before main meal.
223703426|NCT03656107|BEHAVIORAL|Cognitive Training|Lumosity© is a commercially available software, developed by a group of neuropsychologists, which has been used across several studies of brain training and disciplines. The brain training software targets multiple brain areas, is based online, and is relatively easy to use and administer. It has been designed to adapt to the individual's memory performance to personalise the training program to their needs. Brain exercises will be selected with the support of Lumosity© to target the following brain areas; attention, memory, visuospatial, verbal fluency, and language.
223703427|NCT01757327|DRUG|Erismodegib|
223703428|NCT01757327|DRUG|Placebo|
223703429|NCT04747080|DRUG|Dexamethasone|Dexamethasone 40 mg per day, 4 consecutive days (the 4-day course of dexamethasone is repeated in the case of lack of response by day 14).
223703430|NCT04747080|DRUG|Tacrolimus|Tacrolimus is given at a dose of 0.03mg/kg·d, and the dose is adjusted to maintain the trough concentration of tacrolimus at approximately 3-5 ng/mL for 12 weeks.
223703431|NCT03477123|DEVICE|Walking therapy with Exo-H2 exoskeleton|
223703432|NCT00275457|DRUG|pramipexole|
223703433|NCT02248701|DRUG|Testosterone Enanthate|Subjects receive testosterone (125 mg/week) by intramuscular injection
223703434|NCT02248701|DRUG|Finasteride|Subjects receive finasteride (5 mg/day) orally
223703435|NCT02248701|DRUG|Placebo injection|Subjects receive placebo (weekly) by intramuscular injection
223703436|NCT02248701|DRUG|Placebo pill|Subjects receive placebo pill (daily) orally
223703437|NCT02074930|DEVICE|Microporation by P.L.E.A.S.E. Professional / Prick needle|
223703438|NCT01049568|BEHAVIORAL|Cell Phone Intervention|"Cell phone support, including reminders, assessment of barriers to adherence, problem solving and referrals conducted by an Adherence Facilitator.~Data will be collected using the ACASI and CRFs at entry, weeks 6, 12, 24, 36, 48 and the premature discontinuation visits. Measures will assess social support, coping, self-efficacy, substance use, adherence, life stressors, perceived stress, psychological symptoms and health service utilization."
223703439|NCT00002133|DRUG|Itraconazole|
223703440|NCT04488796|BEHAVIORAL|Assigned Strategies: Opt-in|Participants will be assigned two behavioural strategies with the opt-in choice structure
223787834|NCT03266250|PROCEDURE|spinal anesthesia|Transthoracic echocardiography of inferior vena cava before spinal anesthesia
223787835|NCT02501460|OTHER|Educational handouts|Both groups of participants will receive educational handouts that explain the Physical Activity Guidelines for Americans at enrollment.
223787836|NCT02501460|OTHER|Resistance training|"Individuals in both groups will participate in an individually tailored progressive resistance training program 3 times/week for 24 weeks. During weeks 1-4 participants will be supervised twice a week tapering to once a week in weeks 5-12, every other week in weeks 13-20 and then once a month in weeks 21-24 by an American College of Sports Medicine (ACSM) Certified Exercise Specialist (trainer).~Adherence: To assure fidelity and safety of the resistance training component of the intervention, participants will initially be supervised more frequently They will complete an exercise log for each of their sessions. As the supervision level for exercise is tapered, participants may receive reminders to exercise and take their supplement/placebo via text, phone, or e-mail as needed."
223787837|NCT02501460|DIETARY_SUPPLEMENT|Supplementation|A medical quality protein supplement powder will be mixed with water or a sugar free drink mix to be taken daily within 60 minutes of training on exercise days or mid-morning on non-exercise days.
223787838|NCT02501460|OTHER|Placebo|A placebo that appears to be identical to the medical quality protein supplement powder will be mixed with water or a sugar free drink mix to be taken daily within 60 minutes of training on exercise days or mid-morning on non-exercise days.
223787839|NCT00427050|DRUG|PEP005|
223787840|NCT00659334|DRUG|Ferumoxtran-10 (Combidex)|2.6 mg/kg
223787841|NCT00659334|PROCEDURE|Neurosurgery|neuro-surgical tumor biopsy or resection to assess particle localization. Biopsy (stereotactic, when possible) will take place following the 24 hour post- Combidex MR and within 48 hrs of i.v. Combidex administration. Biopsies will be taken from the tumor, brain around tumor (BAT) and brain distant to tumor and the MR localization and histology will be compared. The tissue will be obtained by either resection or needle frameless stereotactic biopsy.
223787842|NCT00063947|DRUG|erlotinib hydrochloride|Given orally
223787843|NCT00063947|DRUG|gemcitabine hydrochloride|Given IV
223787844|NCT00063947|RADIATION|radiation therapy|Undergo radiotherapy
223787845|NCT00063947|OTHER|laboratory biomarker analysis|Correlative studies
223787846|NCT04177758|DRUG|Vitamin D|Patients randomized to the experimental arm of the study will receive 50,000IU of vitamin D3 following surgery and asked to take the medication orally following surgery.
223787847|NCT04177758|DRUG|Control|Patients randomized to the control will receive a placebo
223787848|NCT05268666|DRUG|JBI-802|LSD1/HDAC6 inhibitor
223787849|NCT00010491|PROCEDURE|Acupuncture|
223787850|NCT00010491|PROCEDURE|Moxibustion|
223703441|NCT04488796|BEHAVIORAL|Assigned Strategies: Active Choice|Participants will be assigned two behavioural strategies with the Active choice structure
223703442|NCT04488796|BEHAVIORAL|Assigned Strategies: Enhanced Active Choice|Participants will be assigned two behavioural strategies with the Enhanced Active choice structure
223703443|NCT04488796|BEHAVIORAL|Choice of Assignment: Opt-in|Participants will have the choice to be assigned strategies or to manage their own strategies. The strategies will be assigned using the Opt-in choice structure
223703444|NCT04488796|BEHAVIORAL|Choice of Assignment: Active Choice|Participants will have the choice to be assigned strategies or to manage their own strategies. The strategies will be assigned using the Active choice structure
223703445|NCT04488796|BEHAVIORAL|Choice of Assignment: Enhanced Active Choice|Participants will have the choice to be assigned strategies or to manage their own strategies. The strategies will be assigned using the Enhanced Active choice structure
223703446|NCT03236025|COMBINATION_PRODUCT|Video+brief smoking cessation+pamphlet|The videos presented the health effects of smoking, especially emphasizing the importance of smoking cessation on pregnant women, fetuses, and newborns.
223703447|NCT03236025|COMBINATION_PRODUCT|Text-message+brief smoking cessation+pamphlet|The text -message contains the same content with the videos
223703448|NCT03236025|OTHER|brief smoking cessation+pamphlet|"The pamphlet showed the general information related to the smoking cessation, the brief smoking cessation only contains a sentence like You'd better quit smoking."
223703449|NCT03531697|DRUG|Generic Loteprednol Etabonate|Drug
223703450|NCT03531697|DRUG|Reference Listed Drug (RLD)|Drug
223703451|NCT05747287|DEVICE|microcatheter|supports the insertion of the guide wire，exchange of the guide wire and the delivery of contrast media
223703452|NCT01941693|BEHAVIORAL|Integrated care|Intervention for co-morbid alcohol dependence and anxiety or mood disorder. Trained therapists will deliver specific Cognitive Behavioural Therapy based upon interventions that have been supported by randomised controlled trials for alcohol use, anxiety, and depressive disorders.
223703453|NCT01941693|BEHAVIORAL|Usual care|Counselling for all subjects will continue in accord with standard practice. Currently, programs of brief individualized motivation enhancement therapy (feedback of assessment findings, reinforcement, empathy, client's own motivation) are available.
223703454|NCT05382663|DEVICE|Alio Device|Non-invasive device worn over vasculature.
223703455|NCT00875264|DRUG|CEP-11981 (kinase inhibitor)|Patients will be treated with oral CEP-11981 once daily for 28 days, followed by a treatment-free period of 14 days. This 42-day (6-week) period will constitute 1 cycle. The starting dose for the study will be 3 mg/m2. Dose escalation from this starting dose follows a modified Fibonacci sequence.
223703456|NCT04544423|OTHER|Block group|Patients received lumbar erector spinae plane Block before operation
223703457|NCT03605407|OTHER|Patient visit prior to hospital admission|Patient and family receiving one visit prior to hospital admission for surgery
223703458|NCT00845858|DRUG|metoclopramide|30 minutes before meals and at bedtime for 4 weeks
223703459|NCT00845858|DRUG|Placebo|30 minutes before meals and at bedtime
223703460|NCT02293057|BEHAVIORAL|VOICES Group|VOICES: A program of self-discovery and empowerment includes four modules: Self (A), Connecting with others (B), Healthy living (C), and the Journey Ahead (D). All sessions are 60 minutes long and include required and optional activities.
223703461|NCT02293057|BEHAVIORAL|Girl Health Group|The Girl Health group comparison condition includes adolescent groups matched for time and attention to VOICES groups. Intervention take a psychoeducational/didactic approach and content focuses on a range of health behaviors, including substance use, exercise, nutrition and sleep.
223703462|NCT04383483|OTHER|COVICU|COVICU
223703463|NCT01077570|DRUG|repaglinide|Repaglinide prescribed at the discretion of the investigator, according to local labelling, and evaluated at week 0, 8 and 16 of the study
223703464|NCT05636644|DRUG|Taxol|All patients received TAC regimen: both groups received AC (epirubicin 75 mg/m ² and cyclophosphamide 500mg/m ²)， Group A was treated with docetaxel for 6 cycles every 3 weeks (75 mg/m on the first day ²)； Group B received six cycles of nab paclitaxel (125 mg/m ²)， every 3 weeks is a course of treatment.
223703465|NCT00880542|DRUG|sorafenib|Patients with sarcoma who have resectable disease will be treated with neoadjuvant sorafenib and ifosfamide. PET/CT will be used to assess the metabolic and radiographic response to therapy.
223703466|NCT00880542|DRUG|Ifosfamide|Patients with sarcoma who have resectable disease will be treated with neoadjuvant ifosfamide and sorafenib. PET/CT will be used to assess the metabolic and radiographic response to therapy.
223703467|NCT01724931|DRUG|LD-aminopterin|
223703468|NCT01724931|DRUG|placebo|
223703469|NCT06270771|DEVICE|OURA Ring|The OURA ring (https://ouraring.com) is a light-weight wearable device in the form of a ring that has several microsensors enabling detection of heart rate, blood oxygen level, skin temperature, and movement. The OURA ring and application can synthesize the sensory data to generate physiologic information such as sleep, activity level, resting heart rate, heart rate variability, respiratory rate, and more. The OURA ring is water resistant and has up to 5-7 days of battery life and can be fully charged in 20-80 minutes. It communicates with the OURA app and commonly used Smartphone health apps via Bluetooth connectivity with automatic syncing every week.
223703470|NCT04289623|BEHAVIORAL|Email|Email
223703471|NCT04289623|BEHAVIORAL|Loss frame|Email
223703472|NCT04289623|BEHAVIORAL|Testimonial (medical expert)|Email
223703473|NCT04289623|BEHAVIORAL|Testimonial (rank-and-file)|Email
223703474|NCT04289623|BEHAVIORAL|Social norms (percentage)|Email
223703475|NCT04289623|BEHAVIORAL|Social norms (number)|Email
223703476|NCT03566862|DIAGNOSTIC_TEST|Leicester Cough Monitor (LCM)|The Leicester Monitoring Cough (LCM) kit includes a digital flash voice recorder (Sony ICD-PX333), aA clip-on lapel microphone (Philips LFH9173) and a small carry/travel waist bag.
223703477|NCT02646657|DRUG|Vedolizumab 300 mg|Open-label VEDOLIZUMAB 300 mg at week 0,2,6, 14, 22, 30, 38, 46
223703478|NCT03758443|DRUG|TD-1473 Dose A|See Arm description
223703479|NCT03758443|DRUG|TD-1473 Dose B|See Arm description
223703480|NCT03758443|DRUG|TD-1473 Dose C|See Arm description
223703481|NCT03758443|DRUG|Placebo|See Arm description
223703482|NCT03080454|DEVICE|sham Doublestim|PathMaker MyoRegulator device
223703483|NCT03080454|DEVICE|anodal Doublestim|PathMaker MyoRegulator device
223703484|NCT01436396|BIOLOGICAL|Live, attenuated dengue serotype 1, 2, 3, and 4 virus|0.5 mL, subcutaneous at age 12, 18, and 24 months
223703485|NCT01436396|BIOLOGICAL|Yellow fever vaccine|0.5 mL subcutaneous in the deltoid at age 12 to 13 months.
223703486|NCT01436396|BIOLOGICAL|Measles, mumps, and rubella (MMR) vaccine|0.5 mL, subcutaneous at age 12 to 13 months.
223703487|NCT01436396|BIOLOGICAL|Pneumococcal Conjugated Vaccine|0.5 mL, intramuscular at age 13 to 14 months
223703488|NCT01436396|BIOLOGICAL|Hepatitis A Pediatric Vaccine|0.5 mL, intramuscular at age 13 to 14 months and 25 to 26 months
223703489|NCT01436396|BIOLOGICAL|Diphtheria, tetanus, pertussis, polio, and Haemophilus influenzae vaccine|0.5 mL, intramuscular at age 19 to 20 months
223703490|NCT01436396|BIOLOGICAL|Live, attenuated dengue serotype 1, 2, 3, and 4 virus|0.5 mL, subcutaneous at age 18 to 19 and 24 to 25 months
223787851|NCT04975373|DRUG|Intrauterine injection of hyaluronic acid|operative hysteroscopy - as a part of treatment in cases with retained placenta after delivery diagnostic hysteroscopy - as a routine evaluation after removal of placenta
223787852|NCT03441425|OTHER|Unexpected death|
223787853|NCT01060215|PROCEDURE|Normal saline|20 cc normal saline injection into the knee joint
223787854|NCT04465006|OTHER|Hippotherapy Simulator|Patients in the hippotherapy simulator group received 30 sessions of treatment for 6 weeks, 5 days a week and 1 hour a day. 45 minutes of Neurodevelopmental treatment exercises and 15 minutes of hippotherapy simulation exercise program were applied to the participants in this group.
223703491|NCT01436396|BIOLOGICAL|Yellow Fever Vaccine|0.5 mL, subcutaneous at age 12 to 13 months
223703492|NCT01436396|BIOLOGICAL|Placebo (NaCl)|0.5 mL, subcutaneous at age 12 to 13 months
223703493|NCT01436396|BIOLOGICAL|Measles, mumps, and rubella vaccine|0.5 mL, subcutaneous at age 13 to 14 months
223703494|NCT01436396|BIOLOGICAL|Pneumococcal Conjugated Vaccine|0.5 mL, intramuscular at age 13 to 14 months
223703495|NCT01436396|BIOLOGICAL|Diphtheria, tetanus, pertussis, polio, and Haemophilus influenzae vaccine|0.5 mL, intramuscular at age 19 to 20 months
223703496|NCT01436396|BIOLOGICAL|Hepatitis A Pediatric Vaccine|0.5 mL, intramuscular at age 13 to 14 months and 25 to 26 months
223703497|NCT01363674|DEVICE|Easypod™|Saizen (Somatotropin) as per Summary of Product Characteristics administered by Easypod™
223703498|NCT00250302|PROCEDURE|autologous mesenchymal stem cells implantation|
223703499|NCT00812682|DRUG|Symbicort|
223703500|NCT05708274|DRUG|CPH + hand training|Following a 10-minute rest after baseline measurements a single dose pharmacological agent or placebo will be administered, in blinded fashion, with up to 180 mL of noncarbonated water, on an empty stomach (minimum 2 hours without food). After capsule ingestion, participants will spend 50 minutes performing hand task-oriented training, resting for 10 minutes before undertaking post-intervention outcome measurements.
223703501|NCT05708274|DRUG|CD-LD + hand training|Following a 10-minute rest after baseline measurements a single dose pharmacological agent or placebo will be administered, in blinded fashion, with up to 180 mL of noncarbonated water, on an empty stomach (minimum 2 hours without food). After capsule ingestion, participants will spend 50 minutes performing hand task-oriented training, resting for 10 minutes before undertaking post-intervention outcome measurements.
223703502|NCT05708274|DRUG|ATX + hand training|Following a 10-minute rest after baseline measurements a single dose pharmacological agent or placebo will be administered, in blinded fashion, with up to 180 mL of noncarbonated water, on an empty stomach (minimum 2 hours without food). After capsule ingestion, participants will spend 50 minutes performing hand task-oriented training, resting for 10 minutes before undertaking post-intervention outcome measurements.
223703503|NCT05708274|DRUG|Placebo + hand training|Following a 10-minute rest after baseline measurements a single dose pharmacological agent or placebo will be administered, in blinded fashion, with up to 180 mL of noncarbonated water, on an empty stomach (minimum 2 hours without food). After capsule ingestion, participants will spend 50 minutes performing hand task-oriented training, resting for 10 minutes before undertaking post-intervention outcome measurements.
223703504|NCT03086993|COMBINATION_PRODUCT|Melphalan/HDS|Melphalan/HDS treatment for up to six cycles, followed by a re-induction of CisGem.
223703505|NCT03086993|DRUG|Cisplatin and Gemcitabine|continuous treatment with Cis/Gem until disease progression
223703506|NCT00053443|DEVICE|Medication Reminder System/Adherence Tracker|
223703507|NCT00216476|DRUG|Aripiprazole|10-30 mg oral once daily for 104 weeks
223703508|NCT00216476|DRUG|Risperidone Long Acting Injectable (LAI)|25 mg injection every 2 weeks until week 104. Dosage may be increased or decreased in steps of 12.5 mg. Additional oral risperidone can be administered as required until a dose increase becomes effective.
223703509|NCT00216476|DRUG|Quetiapine|Oral tablets are titrated from 50 mg daily to 300-400 mg daily in first 4 days. Subsequently treatment is maintained for 104 weeks and dosage can be adjusted with increments or decrements of 25 to 50 mg.
223703510|NCT03385200|DRUG|SonoVue|As part of the study therapy supportive ultrasound will be performed with iv Infusion of the chemotherapeutic agent.
223703511|NCT02707107|DRUG|Intravenous infusions of WCK 5222|
223703512|NCT02707107|DRUG|Placebo|
223703513|NCT00705926|DRUG|Highly Active Antiretroviral Therapy (HAART)|Participants in Groups A1 and A2 will receive HAART for either 12 or 32 weeks. Their medications will not be provided by the study.
223703514|NCT00705926|OTHER|No treatment|Participants in this group will not receive treatment at this stage of their infection.
223703515|NCT05771012|DRUG|0.05% cyclosporin (Restasis®, Allergan Inc)|study the efficacy of topical 0.05% cyclosporin eye drops (Restasis®, Allergan Inc) in management of grade 1 and 2 acquired punctal stenosis (group A)
223703516|NCT05771012|DEVICE|mini-monoka stent|insertion of mini-monoka stent in the lower punctum in management of grade 1 and 2 acqquired punctal stenosis (group B)
223703517|NCT04850820|DIETARY_SUPPLEMENT|Novel essential amino acid supplementation|This intervention will determine the impact of EAA+ on markers of whole-body net protein balance, protein synthesis, and protein breakdown following home-based resistance exercise in a free-living setting.
223703518|NCT04850820|DIETARY_SUPPLEMENT|Branched-chain amino acid supplementation (BCAA)|This intervention will determine the impact of the BCAA supplement (to be compared to EAA+) on markers of whole-body net protein balance, protein synthesis, and protein breakdown following home-based resistance exercise in a free-living setting.
223703519|NCT04850820|DIETARY_SUPPLEMENT|Isocaloric carbohydrate supplementation|This intervention will determine the impact of an isocaloric carbohydrate placebo supplement (to be compared to EAA+) on markers of whole-body net protein balance, protein synthesis, and protein breakdown following home-based resistance exercise in a free-living setting.
223703520|NCT04508348|OTHER|Human Milk|Exclusive Human Milk diet
223703521|NCT04508348|OTHER|Standard of Care|This diet will include mother's milk and/or formula
223703522|NCT02191137|DRUG|Riociguat (Adempas, BAY63-2521)|Participants received therapy with riociguat during a 10-week titration phase. The starting dose for riociguat for all patients was 0.5 milligram (mg) three times a day (TID). The dose of riociguat was increased every 2 weeks in 0.5 mg increments to 1.0, 1.5, 2.0, and 2.5 mg until patients reached their individual optimal dose based on their systolic blood pressure and well-being. After reaching their optimal dose, patients then entered a maintenance phase and remained on this dose for an additional 14 weeks. End of treatment was reached at Visit 10 after 24 weeks of treatment with riociguat.
223703523|NCT01437969|GENETIC|genotyping and/or sequencing|genotyping and/or sequencing DNA for IL28
223787855|NCT04465006|OTHER|Conventional Exercise|Patients in the conventionnal exercise group received 30 sessions of treatment for 6 weeks, 5 days a week and 1 hour a day. 60 minutes of Neurodevelopmental treatment exercises were applied to the participants in this group.
223787856|NCT06019650|BEHAVIORAL|ECMAP|The therapist will deliver 12-week training program comprised of 6 sessions at the participant's home/outpatient clinic depending upon the participants' choice within 3 months. The first two sessions will be offered weekly and then fortnightly.
223787857|NCT01815177|DEVICE|Arthroscopic transosseous fixation|
223787858|NCT01815177|DEVICE|Suture anchors|
223787859|NCT04763122|OTHER|not applicable as it is a retrospective study|It is a retrospective study
223787860|NCT00748046|DRUG|Radium-223 chloride (BAY88-8223)|The required volume of study drug to be administered to a patient was calculated using the patient's body weight.
223787861|NCT02571569|DRUG|BAY1093884|Single escalating dose with a starting dose of 0.3 mg/kg for the first cohort. Drug will be administered via IV infusion over 1 hour and SC injection. Based on safety, PK and PD results the doses for the other cohorts will be determined.
223787862|NCT02571569|DRUG|BAY1093884|Multiple dose cohort with a single 150-mg SC injection once a week for 6 weeks.
223787863|NCT02157038|DEVICE|Pedometer|
223787864|NCT02157038|DEVICE|MRI|
223787865|NCT04208022|OTHER|Respiratory evaluation|Hypermobility and Respiratory evaluation
223787866|NCT01986257|BEHAVIORAL|Emotion Regulation Group Therapy (ERGT).|
223787867|NCT03557437|DRUG|Esomeprazole|Proton pump inhibitor
223787868|NCT03557437|DRUG|Amoxicillin, Metronidazole|Antibiotics for H. pylori eradication
223787869|NCT03557437|DRUG|Bismuth Potassium Citrate|Gastric mucosal protective drug with anti-H. pylori effect
223787870|NCT06257069|DEVICE|Tremor Retrainer Smartphone Application|The Tremor Retrainer smartphone application uses the smartphone's built-in accelerometer to calculate a patient's tremor frequency when the smartphone is strapped to the patient's wrist. The application will provide auditory cues to the patient with a treatment frequency at 2/3 the patient's baseline tremor frequency for half a session, then 1/3 the patient's baseline tremor frequency for the second half of the session. Meanwhile, oscillatory movements will be continuously analyzed with frequency calculated and displayed relative to goal frequency, so that the patient receives continuous feedback via a visual dial as to whether they are meeting treatment goals. Intervention will consist of a one-week Tremor Retrainment Protocol.
223787871|NCT01365000|DRUG|NKTR118 Formulation 1|Oral dose, 25 mg
223787872|NCT01365000|DRUG|NKTR118 Formulation 2|Oral dose, 25 mg
223787873|NCT01365000|DRUG|NKTR118 Formulation 3|Oral dose, 25 mg
223787874|NCT01365000|DRUG|NKTR118 Formulation 1a|Oral dose, 25 mg
223787875|NCT01365000|DRUG|NKTR118 Formulation 3a|Oral dose, 25 mg
223787876|NCT00755482|DRUG|Aquamin F|
223787877|NCT00755482|DRUG|Placebo (maltodextran)|
223787878|NCT01781572|DRUG|LEE011|LEE011 will be administered orally once daily
223787879|NCT01781572|DRUG|MEK162|MEK162 will be administered orally twice daily
223787880|NCT00093054|DRUG|Cranberry juice|TID dosage for UTI treatment
223787881|NCT00093054|DIETARY_SUPPLEMENT|Placebo cranberry juice|TID placebo dosage to match active comparator
223787882|NCT00045110|DRUG|erlotinib hydrochloride|given orally
223787883|NCT00045110|OTHER|laboratory biomarker analysis|correlative studies
223787884|NCT00045110|OTHER|pharmacological study|correlative studies
223787885|NCT05369234|DIETARY_SUPPLEMENT|100% Aloe Vera Juice|George's 100% Aloe Vera Liquid Supplement
223787886|NCT05369234|COMBINATION_PRODUCT|Magic Mouthwash|Magic Mouthwash
223787887|NCT05369234|COMBINATION_PRODUCT|Salt and Baking soda rinse|Mouth rinse made with salt and baking soda
223787888|NCT05369234|DRUG|Carafate|Carafate taken as a slurry
223787889|NCT01218646|BIOLOGICAL|Investigational Quadrivalent Inactivated Influenza Vaccine, No Preservative|0.5 mL, Intramuscular
223787890|NCT01218646|BIOLOGICAL|Investigational Trivalent Inactivated Influenza Vaccine, No Preservative|0.5 mL, Intramuscular
223787891|NCT01218646|BIOLOGICAL|Fluzone®: 2010-2011 Trivalent Inactivated Influenza Vaccine, No Preservative|0.5 mL, Intramuscular
223787892|NCT01218646|BIOLOGICAL|Fluzone®: 2010-2011 Trivalent Inactivated Influenza Vaccine, No Preservative|0.5 mL, Intramuscular
223787893|NCT00663312|BEHAVIORAL|e.g., Protein and calorie controlled diet; Self-hypnotic relaxation|Pilot description
223787894|NCT03680755|BEHAVIORAL|Internet-based intervention for dental anxiety|Participants will complete the experimental dental anxiety management program, which will be facilitated by a person trained in psychological treatments or by dental staff. This program consists of a series of videos which provide information about dental anxiety, educate about the details of three dental procedures which are anxiety-provoking for the participant, and teach them how to cope better with the dental experience. This program will take about 60 minutes to complete.
223787895|NCT04198662|DEVICE|Cryoneurolysis with a Painblocker (Epimed International, Farmers Branch, Texas)|The cryoneurolysis device will be triggered using 2 cycles of 2-minute gas activation separated by 1-minute defrost periods. For active probes, the nitrous oxide will be deployed to the tip where a drop in temperature to -70°C will result in cryoneurolysis.
223787896|NCT04198662|DRUG|Intercostal nerve block ropivacaine with epinephrine|3 mL of ropivacaine 0.5% (with epinephrine) will be injected perineurally to provide the intercostal nerve block(s)
223787897|NCT04198662|DEVICE|Sham cryoneurolysis with a Painblocker|The cryoneurolysis device will be triggered using 2 cycles of 2-minute gas activation separated by 1-minute defrost periods. For the sham probes, the nitrous oxide will be vented prior to reaching the probe shaft, resulting in a lack of perineural temperature change.
223787898|NCT04198662|DRUG|Placebo intercostal nerve block with normal saline|3 mL of normal saline will be injected perineurally to provide placebo intercostal nerve blocks
223787899|NCT05692388|OTHER|Patient and Community Stakeholder Interviews|Thirty in-depth face-to-face patient interviews, and ten in-depth structured stakeholder interviews will be conducted to explore and identify facilitators and barriers to self-care in African American adults with DKD experiencing MDA and living in the inner-city.
223787900|NCT05692388|OTHER|Cross-sectional Study Participants|Three hundred African American adults with DKD experiencing MDA and living in the inner-city will be recruited to participate in a cross-sectional study. All participants will complete a one-time survey, and blood samples and blood pressure readings will be obtained to assess clinical outcomes.
223787901|NCT05692388|OTHER|Focus Groups and Intervention Mapping|A subsample of patient interview/cross-sectional study participants will be invited back to participate in four focus groups (five participants/group) to review components of the intervention, give feedback on appropriateness, feasibility, acceptability, and likelihood of having an impact based on their lived experiences.
223787902|NCT04102358|PROCEDURE|Medial approach infraclavicular block with single injection|infraclavicular blocks performed with single injection
223787903|NCT04102358|PROCEDURE|Medial approach infraclavicular block with triple injection|infraclavicular blocks performed with triple injection
223787904|NCT02076464|BEHAVIORAL|StudentBodies - Eating Disorders|The intervention is a structured, cognitive-behavioral guided self-help program, derived from manual-based cognitive-behavioral therapy. The intervention targets the core eating disorder pathology (e.g., extreme dietary restraint, overvaluation of shape and weight, binge eating, compensatory behaviors), focusing on helping users develop regular eating patterns, self-control strategies, problem-solving skills, and relapse prevention tools for maintenance of behavior change. The program includes daily symptom checklists, journal exercises and activities, and an asynchronous moderated online discussion group.
223787905|NCT03156023|DRUG|Rozibafusp Alfa|Administered by subcutaneous injection once every 2 weeks.
223787906|NCT03156023|DRUG|Placebo|Administered by subcutaneous injection once every 2 weeks.
223787907|NCT01895465|DEVICE|Slitted diaper|A diaper where a slit is made through which a urine collection bag is pulled through
223787908|NCT03013010|DRUG|Tegafur-Gimeracil-Oteracil Potassium|The dose of S-1 is according to body-surface area (BSA): patients with a BSA of less than 1.25 m2 received 80 mg daily; those with a BSA of 1.25 m2 or more but less than 1.5 m2 received 100 mg daily; and those with a BSA of 1.5 m2 or more received 120 mg daily. oxaliplatin 130mg/m2, intravenously, on day 1.
223787909|NCT03013010|RADIATION|Chemoradiotherapy|"Chemotherapy: S-1 40-60mg/m2 orally, oral tablet twice daily, days 1-5 of each week of radiotherapy.~Radiotherapy: 45 Gy of radiation in 25 fractions, five days per week for five weeks."
223787910|NCT03013010|PROCEDURE|Gastric resection|A standard D2 gastrectomy was recommended. The type of gastrectomy performed depended on the location and extent of the primary lesion. For middle third tumors, the gastric margin was recommended to be more than 5 cm, and a total gastrectomy was performed. For lower third tumors, a 2 cm duodenal margin was recommended and a subtotal or total gastrectomy was considered. For upper third tumors, a 3 cm esophageal margin was recommended and a total gastrectomy or esophagogastrectomy was performed. Billroth I or Roux-en-y gastrojejunostomy was performed for distal gastrectomy patients, Roux-en-y esophagojejunostomy was performed for total gastrectomy patients.
223703524|NCT00696800|DRUG|Corifollitropin alfa|On the morning of day 2 or 3 of the menstrual cycle (Stimulation Day 1), a single SC injection of 150 μg (0.5 mL) Corifollitropin Alfa was administered in the abdominal wall.
223703525|NCT00696800|BIOLOGICAL|RecFSH / Follitropin beta (Days 1 to 7)|Daily SC injections with 200 IU fixed dose recFSH were started on Stimulation Day 1 and continued up to and including Stimulation Day 7.
223787911|NCT03013010|DRUG|Oxaliplatin|The dose of oxaliplatin is according to body-surface area (BSA): 130mg/m2, intravenously, on day 1.
223703526|NCT00696800|DRUG|Placebo Corifollitropin alfa|Pre-filled syringe containing an identical solution when compared to Corifollitropin Alfa. On the morning of day 2 or 3 of the menstrual cycle (Stimulation Day 1), a single SC injection was administered in the abdominal wall.
223703527|NCT00696800|DRUG|Placebo RecFSH / follitropin beta|Identical ready-for-use solution, but without the active ingedient, supplied in cartridges for SC injection with the Follistim Pen. Daily SC injections were started on Stimulation Day 1 and continued up to and including Stimulation Day 7.
223703528|NCT00696800|BIOLOGICAL|RecFSH / Follitropin beta (Days 8 to hCG)|From Stimulation Day 8 onwards a daily SC dose of 200 IU recFSH was administered up to and including the Day of hCG.
223703529|NCT00696800|DRUG|Ganirelix|On Stimulation Day 5 a daily SC injection of 0.25 mg was started, which continued up to and including the day of hCG
223703530|NCT00696800|BIOLOGICAL|hCG|When 3 follicles \>= 17 mm were observed by USS, a single dose of 10,000 IU/USP hCG was administered; or, for those at risk for Ovarian Hyperstimulation Syndrome (OHSS), a lower dose of 5,000 IU/USP
223703531|NCT00696800|BIOLOGICAL|Progesterone|On the day of OPU, luteal phase support was started by administering micronized progesterone of at least 600 mg/day vaginally, or at least 50 mg/day intramuscular (IM), which continued for at least 6 weeks, or up to menses.
223703532|NCT02672800|BEHAVIORAL|the Reclaiming Yourself tool|This tool is a behavioural writing intervention, intended to facilitate bereavement for spousal caregivers of persons with dementia
223703533|NCT02981264|DRUG|Transcricoid Injection|
223703534|NCT02981264|DRUG|Spray as you go|
223703535|NCT05101785|DRUG|Lidocain hydrochloride 2 % with epinephrine|Local anesthesia infilteration in children
223703536|NCT05101785|DRUG|Articaine chloride 4% with epinephrine|Articaine chloride 4% with epinephrine
223703537|NCT04079946|PROCEDURE|Total Mesocolic Excision with Central Vessel Ligation|sharp dissection of the anatomical layers and the dissection of the visceral plane from the parietal one . In addition a central division of the feeding arteries at their origins is performed at the level of superior mesenteric artery for tumors of the right colon and at the level of inferior mesenteric artery or the aorta for tumors of the left colon .this allows for removal of the maximum number of lymph nodes possible.
223703538|NCT04079946|PROCEDURE|conventional surgery of cancer colon|removal of the tumor with no ligation of the vessel centrally or removal of the whole mesocolon
223703539|NCT01460017|PROCEDURE|Deep Sclerectomy|Non penetrating glaucoma surgery is a new procedure in adults that has less post operative complications with good results, it is to be applied in children.
223703540|NCT01460017|PROCEDURE|Combined Trab|Combined trabeculectomy and trabeculotomy is a standard surgery for congenital glaucoma, however, it has its known complications.
223703541|NCT03389620|DRUG|dexamethasone|0.8 mL of dexamethasone (10 mg/mL) will slowly be injected over a period of approximately 30 seconds
223703542|NCT06316115|OTHER|In Patıents Wıth Dıabetıc Foot Ulcer, Effect On Paın And Anxıety Of Stress Ball Use Durıng Sharp Debrıdement|Patients in this group participating in the study will be given a stress ball and asked to use it before the debridement procedure, and each patient will be debrided by the same person throughout the procedure. The patient's pain and anxiety will be evaluated by a nurse independent of the research before and after the debridement procedure.
223703543|NCT00835822|DRUG|Venocur Triplex®|Administered by oral route, two coated tablets per day, after the meals (breakfast and dinner), with some liquid, but not with alcoholic beverages.
223703544|NCT00835822|DRUG|placebo|Administered by oral route, two coated tablets per day, after the meals (breakfast and dinner), with some liquid, but not with alcoholic beverages.
223703545|NCT03361267|DIAGNOSTIC_TEST|Helicobacter pylori PCR test|Clarithromycin resistance (-) Triple therapy (rabeprazole 20 mg bid, amoxicillin 1000mg bid, clarithromycin 500mg bid) for 7 days Clarithromycin resistance (+) Bismuth containing quadruple therapy (rabeprazole 20 mg bid, metronidazole 500 mg tid, bismuth 300 mg qid, tetracycline 500mg qid) for 7 days
223703546|NCT03361267|DIAGNOSTIC_TEST|CLO test|CLO test : negative --\> drop out CLO test : postive --\> bismuth containing quadruple therapy
223703547|NCT05358015|PROCEDURE|vascularized bone graft for scaphois nonunion|vascularized bone graft for scaphois nonunion
223703548|NCT05985005|OTHER|online simulation of high alert medication safety training|online simulation of high alert medication safety training
223703549|NCT03810391|DRUG|Butorphanol|intravenous loading dose of 15ug/kg butorphanol,and followed by infusion of 7.5ug/kg/h butorphanol and stopped infusion until the Ramsay sedation score reached 4 points
223703550|NCT03810391|OTHER|physiological saline|intravenous infusion of the same volume of physiological saline
223703551|NCT02715245|PROCEDURE|Home-based rehabilitation|Procedure/Surgery: Home-based rehabilitation In the patient's home, the primarily applied treatment has been physical therapy, seeking to achieve the highest possible functionality and gait training. In more than 25% of cases, health education is conducted for families and caregivers. Thus, consistent with the patient's condition and their tolerance to activity and to exercise their self-care independently, rehabilitation interventions are activated that prevent sequelae derived from functional limitations.
223703552|NCT02387710|DRUG|Tiagabine|GABA reuptake inhibitor
223703553|NCT02387710|DRUG|Placebo|Placebo comparator
223703554|NCT05554575|BIOLOGICAL|BT-007 CD7 CAR-T cells|T cells purified from the peripheral blood mononuclear cell (PBMC) of subjects or subjects' relatives which depend on their conditions, transduced with 4-1BB/CD3ζ lentiviral vector, expanded in vitro for future administration.
223703555|NCT05290207|DIAGNOSTIC_TEST|The hyperinsulinaemic hypoglycaemic clamp|Glucose will be clamped at 5.0 mmol/L for approximately 30 minutes, and then be lowered to 3.0 mmol/L for 30 minutes
223787912|NCT01290367|BIOLOGICAL|Single Dose MPCs Injection|Injection of Low Dose MPCs with Hyaluronic Acid into the degenerated lumbar disc's nucleus pulposus.
223787913|NCT01290367|PROCEDURE|Single injection of saline solution|Intradiscal control injection with saline solution
223787914|NCT01290367|PROCEDURE|Single injection of hyaluronic acid|Intradiscal control injection with hyaluronic acid
223787915|NCT01290367|BIOLOGICAL|Single Dose MPCs Injection|Injection of HighDose MPCs with Hyaluronic Acid into the degenerated lumbar disc's nucleus pulposus.
223787916|NCT05764850|GENETIC|Genome sequencing|"100 extensively phenotyped pediatric and young adult patients for genotyping, metabolomic and lipidomic analyses. Polygenic risk scores for type 1 diabetes and cardiovascular disease will be performed.~For patients older than 6 years who agree to do a second visit (optional), a Mixed Meal Tolerance Test (MMTT: the gold standard for assessing beta cell function) will be done as well as transcriptomic analysis."
223787917|NCT05145231|OTHER|observational|The scales will be filled by asking the family.
223787918|NCT04638790|DRUG|Doxorubicin|25 mg/m2 i.v. day 1,15 for ABVD/AVD
223787919|NCT04638790|DRUG|Bleomycin|10,000 units/m2 i.v. days 1,15 for ABVD
223787920|NCT04638790|DRUG|Vinblastine|6 mg/m2 i.v. days 1,15 for ABVD/AVD
223787921|NCT04638790|DRUG|Dacarbazine|375 mg/m2 i.v. days 1,15 for ABVD/AVD
223787922|NCT04638790|DRUG|Etoposide|100 mg/m2 i.v. days 1-3
223787923|NCT04638790|DRUG|Doxorubicin|50 mg/m2 i.v. day 1 for EACODD-14
223787924|NCT04638790|DRUG|Cyclophosphamide|650 mg/m2 i.v. day 1
223787925|NCT04638790|DRUG|Vincristine|1,4 mg/m2 i.v. day 8
223787926|NCT04638790|DRUG|Dexamethasone|20 mg i.v. days 1-3
223787927|NCT04638790|DRUG|Dacarbazine|375 mg/m2 i.v. day 1 for EACODD-14
223787928|NCT02009475|OTHER|Interval exercise training|
223787929|NCT02009475|OTHER|Continues aerobic training|
223787930|NCT02441452|OTHER|Early rehabilitation|The physical exercises and breathing exercises are started as soon as after the Nuss procedure
223787931|NCT05739058|DEVICE|Violet-Blue Light Treatment / FlashHeal Device|"FlashHeal illuminates an area of 10 cm in diameter, located at 6-7 cm distance of the wound.~Wounds larger than 10 cm in diameter, will receive enough treatments to cover the wound bed.~To obtain full coverage the circular treatment area is relocated to cover the remaining wound field.~The wavelength is 405 nm, Full Width Half Maximum at (FWHM) 400-415 nm. Device irradiances are adjusted to the total fluences required for the Low, Medium and High group, the treatment will last 15 minutes at all dosages. Light is emitted with 1000 Hz."
223787932|NCT05911854|DEVICE|Multi-waved Locked System Laser|The M6 therapy laser is a robotized multi-target device designed to treat patients suffering pathologies affecting a wide area, and to perform automatic applications.
223787933|NCT05911854|DEVICE|Cold Compression therapy|The BioCryo Cold Compression System is a cold therapy pneumatic compression device that safely administers sequential, gradient pneumatic compression and CryoTherapy combined.
223787934|NCT05911854|OTHER|complete decongestive therapy|"Complete decongestive therapy consists of:~* Meticulous skin care with the use of emollients~* Using short stretch bandages or continuous wearing of a pressure garment~* Manual lymphatic drainage therapy~* Remedial exercises (e.g., aerobic exercise, strength training, and stretching exercises)"
223787935|NCT04191902|BEHAVIORAL|orientation|patients will be oriented
223787936|NCT06663995|DRUG|Study Group|"It will include 16 patients with periodontitis stage II, grade B, at least 2 sites with pocket PD = 4-5 mm and CAL = 3-4 mm each will receive non-surgical periodontal therapy followed by application of propolis gel.~After baseline assessment, at the same day the included participants will receive full mouth one stage debridement using hand instruments and ultrasonic scalers under local anesthesia -if needed- for patient's comfort.~2- Oral Hygiene Instructions Participants will be provided with a toothpaste, a medium toothbrush, a written oral hygiene instruction brochure (Brushing twice daily for 4-weeks using Modified Bass technique and interdental flossing).~3-Base line visit (Local delivery application): Propolis gel will be applied by syringe with blunt tip gently and removed slowly in order not to harm the tissue for group 1 patients (Test group) after phase 1 therapy at the second day (48 hours) following non-surgical periodontal therapy"
223787937|NCT06663995|DRUG|Control (placebo) group|"After baseline assessment, at the same day the included participants will receive full mouth one stage debridement using hand instruments and ultrasonic scalers under local anesthesia -if needed- for patient's comfort.~2- Oral Hygiene Instructions Participants will be provided with a toothpaste, a medium toothbrush, a written oral hygiene instruction brochure (Brushing twice daily for 4-weeks using Modified Bass technique and interdental flossing)."
223787938|NCT06662604|BIOLOGICAL|Bone marrow stem cells concentrate , platelet rich fibrin , bone graft|All participants will be treated with Bone marrow stem cells concentrate , platelet rich fibrin , bone graft.
223787939|NCT06662604|BIOLOGICAL|platelet rich fibrin and bone graft|All participants will treated with platelet rich fibrin PRF , bone graft.
223787940|NCT06663774|DIAGNOSTIC_TEST|Physical Fitness Tests|Ippon Reactive Agility Test (IRAT), Y-Balance Test, Upper-Quarter Y Balance Test, Flamingo Balance Test, Flamingo Balance Test, Standing Long Jump Test, 20m Sprint Test, Hand Grip Test, T-Agility Test, Nelson Hand Reaction Test, Judo Specific Fitness Test
223787941|NCT06664593|OTHER|integrated perinatal mental health pathway|This observational study examines whether assessing psychosocial risk factors and screening for depression and anxiety at different time points during the perinatal period, using a stepped protocol, helps to more quickly detect women with depressive and anxiety symptoms.
223787942|NCT03294434|OTHER|Diffusion tensor Imaging (DTI)|Diffusion tensor Imaging (DTI) is a technique sensitive to the ordered diffusion of water along white matter tracts and can detect subtle disruption. A diffusion tensor signature method was developed that splits the tensor information into isotropic and anisotropic diffusion components. This can differentiate regions of pure tumour from invaded white matter.
223787943|NCT01259661|OTHER|A longitudinal intervention|In our longitudinal intervention study, all eligible subjects will undergo a physical examination by a physician to rule out obvious secondary causes of hypertension and contraindications to exercise. Randomization will be performed by random member generation. The exercise participants will attend three sessions per week at the facility during the study period. Training intensity is initially set at heart rate equivalent to 60% and progress to 80% of each subject's maximal heart rate reserve for 30 min/day with a frequency of 3 days/wk. Facility-based exercise sessions will consist of treadmill walking.
223787944|NCT05513638|DIAGNOSTIC_TEST|the clinical use of artificial intelligence in the diagnosis of prostate cancer|Each study site will enroll consecutive eligible patients and randomize them to either (a) a group with human-based interpretation or (b) a group with human-artificial intelligence interactive interpretation, both of which are utilized as standards of care.
223787945|NCT05195996|DRUG|Propranolol|intravenous propranolol for case patients
223787946|NCT05195996|DRUG|Saline|intravenous saline for placebo
223787947|NCT00726752|DRUG|Axitinib (AG-013736)|Three single dose level of AG-013736 (5 mg, 7 mg and 10 mg) will be given for all patient. After single dosing at each dose level, multiple doses of 5 mg twice a day (BID) will be started.
223787948|NCT06063941|DRUG|1% Lugol's iodine solution|1% Lugol iodine solution was sprayed from the esophagogastric junction towards a location approximately 20 cm away from the upper incisors in the cervical esophagus.
223787949|NCT06063941|DRUG|5% Lugol's iodine solution|Before chromoendoscopy, a 20 ml syringe was employed to draw 3 ml of 5% iodine stock solution and 17 ml air. When staining, the iodine was quickly expelled through the endoscope's working channel at 20 cm of the esophagus from the incisor. An iodine mist was created because of the rapid spurt of the iodine solution and air, which prompts even distribution of the iodine solution on the esophageal wall. The lower segments of the esophageal wall were stained with the remaining iodine solution in the working channel by repeatedly spraying the air/iodine mixture using the syringe, resulting in consistent and uniform staining for the whole esophagus.
223787950|NCT02590718|PROCEDURE|optimized postoperative management|lying without the pillow for half an hour after lumbar puncture
223787951|NCT01665235|DRUG|Amlodipine|The amlodipine - based antihypertensive treatment group (you can add a diuretic or other )
223787952|NCT01665235|DRUG|ACEI / ARB|ACEI / ARB -based antihypertensive treatment group ( you can add the B - blockers or other)
223787953|NCT01665235|DRUG|Aspirin or Clopidogrel|aspirin 100mg / d or Clopidogrel 75mg / d (anti-platelet agents)
223787954|NCT01665235|DRUG|Atorvastatin|Atorvastatin 10 - 40mg / d ( statin therapy)
223787955|NCT01194141|BEHAVIORAL|Exercise training|aerobic exercise training, 45-60 minutes, 3x/week, 12 weeks (3-months)
223787956|NCT05422417|DEVICE|Prolonged intermittent theta burst stimulation (piTBS)|Participants in the prolonged dosage (1800 pulse) of intermittent TBS (iTBS) active stimulation group will receive 2-week three-pulse 50-Hz bursts administered every 200 milliseconds (at 5 Hz) at an intensity of 80% active motor threshold (MT) to the bilateral DMPFC, twice a day. Stimulation will be delivered to the DMPFC using a stimulator.
223787957|NCT05422417|DEVICE|20Hz rTMS|Participants in the 20 Hz rTMS (2000 pulse) active stimulation group will receive 2-week 2s- and-10s off, total 50 cycles at each hemisphere/session, at an intensity of 100% resting motor threshold (MT) to the bilateral DMPFC, twice a day. Stimulation will be delivered to the DMPFC using a stimulator.
223787958|NCT05422417|DEVICE|sham control|Half of the patients in the sham group received 2-week the same prolonged iTBS parameter stimulation (sham- prolonged iTBS), and the other half received the same 20 Hz rTMS parameter stimulation using a sham coil (sham-20 Hz rTMS), which also improved the blinding process
223787959|NCT00022412|DIETARY_SUPPLEMENT|doxercalciferol|Arm 1: Patients receive doxercalciferol once daily for 28 days. Patients then undergo prostatectomy.
223787960|NCT00022412|PROCEDURE|conventional surgery|Procedure: Prostatectomy for prostate cancer
223787961|NCT05829655|DRUG|Drug A (Blinded Drug)|Participants will receive a double-blinded oral study medication as part of their daily sessions and will provide feedback regarding the effects of the medication on various measures. Though the study medications are FDA approved, they are being used here for a non-FDA approved purpose (though the FDA has provided permission to use these drugs in this study).
223787962|NCT05829655|DRUG|Drug B (Blinded Drug)|Participants will receive a double-blinded oral study medication as part of their daily sessions and will provide feedback regarding the effects of the medication on various measures. Though the study medications are FDA approved, they are being used here for a non-FDA approved purpose (though the FDA has provided permission to use these drugs in this study).
223787963|NCT05829655|DRUG|Drug C (Blinded Drug)|Participants will receive a double-blinded oral study medication as part of their daily sessions and will provide feedback regarding the effects of the medication on various measures. Though the study medications are FDA approved, they are being used here for a non-FDA approved purpose (though the FDA has provided permission to use these drugs in this study).
223787964|NCT05829655|DRUG|Drug D (Blinded Drug)|Participants will receive a double-blinded oral study medication as part of their daily sessions and will provide feedback regarding the effects of the medication on various measures. Though the study medications are FDA approved, they are being used here for a non-FDA approved purpose (though the FDA has provided permission to use these drugs in this study).
223787965|NCT05829655|DRUG|Suvorexant (20mg/day)|Double blind administration of suvorexant once per day during residential stay until discharge.
223787966|NCT05829655|DRUG|Placebo|Double blind administration of placebo once per day during residential stay until discharge.
223787967|NCT04827576|DRUG|Magrolimab|Administered intravenously
223787968|NCT04827576|DRUG|Docetaxel|Administered intravenously
223787969|NCT06506669|PROCEDURE|Oral sedation|Oral medication for anxiolysis administered in the preoperative setting
223787970|NCT06506669|PROCEDURE|Placebo|A placebo pill with no active ingredients administered in the preoperative setting
223787971|NCT06495853|PROCEDURE|Continuous Circumferential Reinforcement of the Anastomotic|The reinforcement began on the right side of the anterior wall of the anastomosis, 0.5 cm from the anastomotic line, with continuous full-thickness sutures spaced 1 cm apart. The suture ended with fixation of the suture tail using non-absorbable vascular clips. The decision to perform splenic flexure mobilization depended on the anastomotic tension and the length of the resected bowel segment. The superior mesenteric artery and vein were divided at their roots.
223787972|NCT04425564|DRUG|metronomic XELOX|
223787973|NCT04425564|DRUG|Classic XELOX|
223787974|NCT04425564|OTHER|Blood samples for pharmacological studies|
223787975|NCT01570101|DEVICE|CE Marked Sapheon Closure System|"CE Marked Sapheon Closure System in closure of incompetent great saphenous veins GSV in a routine clinical setting."
223787976|NCT01445938|DRUG|SAR97276A|"Pharmaceutical form:solution for injection~Route of administration: intramuscular"
223787977|NCT01445938|DRUG|arthemeter + lumefantrine (ACTs)|"Pharmaceutical form:tablet~Route of administration: oral"
223787978|NCT04537923|DRUG|Tirzepatide|Administered SC
223787979|NCT04537923|DRUG|Insulin Lispro (U100)|Administered SC
223787980|NCT01261611|BIOLOGICAL|Botulinum toxin type A|I.M. (in the muscle) injection on day 1 of up to 5 treatment cycles.
223787981|NCT01261611|BIOLOGICAL|Botulinum toxin type A|I.M. injection on day 1 of treatment cycle 1.
223787982|NCT01261611|DRUG|Placebo|I.M. injection on day 1 of treatment cycle 1.
223787983|NCT03495050|DEVICE|Transcatheter Aortic Valve Implantation|Transcatheter treatment of bicuspid aortic stenosis with the Evolut Pro/XL platform
223787984|NCT02527798|DRUG|Furosemide Cohort 1|furosemide 1 mg/kg q 24 hours IV or 2 mg/kg q 24 hours enterally Cohorts will be enrolled sequentially after a safety review.
223787985|NCT02527798|DRUG|Furosemide Cohort 2|furosemide 1 mg/kg q 6 hours IV or 2 mg/kg q 6 hours enterally Cohorts will be enrolled sequentially after a safety review.
223703556|NCT06203236|DRUG|Furosemide 20 MG|"1. The median daily total dose of intravenous loop diuretic at the start of treatment will be 20 mg of furosemide.~2. Monitoring of urinary sodium excretion (natriuresis) and diuresis will begin 2 hours after treatment initiation."
223787986|NCT02527798|DRUG|Furosemide Cohort 3|furosemide 2 mg/kg q 6 hours IV or 4 mg/kg q 6 hours enterally Cohorts will be enrolled sequentially after a safety review.
223787987|NCT02527798|OTHER|Placebo|Sugar water will be administered in a equivalent volume as drug intervention.
223703557|NCT06203236|OTHER|diuretic therapy|diuretic therapy
223703558|NCT01164683|BEHAVIORAL|Peer-driven intervention|Trained peers with sleep apnea will be paired with the newly diagnosed patients over a 3-month period. During this time the trained peers will share experiences on coping strategies with CPAP device and equipment (promote self efficacy), share their positive experiences (motivational effects and outcome expectancies), share their knowledge of perceived vulnerabilities due to untreated sleep apnea (promote risk perception), share methods for improving efficacy of CPAP equipment and interface (patient education) and prepare their subjects for upcoming physician or respiratory therapist appointments (patient activation).
223787988|NCT03297788|RADIATION|SRS|"For SRS the dose prescription to the PTV will be as follows:~* 20 Gy to the 70%-isodose (lesions \< 2 cm max. diameter)~* 18 Gy to the 70%-isodose (lesions 2 - 3 cm max. diameter)~* 6 x 5 Gy to the conformally surrounding isodose (lesions \> 3 cm max. diameter)"
223787989|NCT03297788|RADIATION|WBRT|WBRT will be applied in 10 fractions with single doses of 3 Gy to the whole brain.
223787990|NCT05589051|DIETARY_SUPPLEMENT|Drink|Consume one tablet fully dissolved in 8 ounces. Take 2 tablets per day for adults (morning and evening) for 4 weeks
223787991|NCT03037710|DEVICE|HealthPatch|A multi-sensor device to collect continuous vital signs
223703559|NCT01164683|OTHER|Usual Care|All participants will receive usual care following initiation of CPAP therapy. Visits with respiratory therapist and sleep physician wherein patients are educated about the basics of the care and operation of the device, mask and related equipment. Subsequently, their CPAP adherence is monitored and appropriate interventions such as mask change and re-education undertaken as needed.
223703560|NCT04124653|DRUG|PF-06842874|Single dose administration of PF-06842874
223703561|NCT04124653|DRUG|Placebo|Single dose administration of placebo
223703562|NCT04124653|DRUG|Relative Bioavailability|Relative bioavailability assessment of modified-release formulation
223703563|NCT02612038|DEVICE|Expiratory resistance|Generic expiratory resistance will be added to the patient's respiratory circuit
223703564|NCT02612038|DEVICE|Sham expiratory resistance|Sham expiratory resistance will be added to the patient's respiratory circuit
223703565|NCT06330454|DEVICE|I-ONE|Pulsed Electromagnetic fields joint therapy
223703566|NCT05088395|OTHER|Blood sample|Depending on the clinical context studied and the biomarkers studied and/or sought, the timing of blood samples will vary between cohorts. There may be up to 4 samples taken per patient for up to 24 months.
223703567|NCT05088395|OTHER|Biopsy|If a specific tumor sample is required, it will be collected only once during the study
223703568|NCT01044706|DRUG|Bicalutamide|50 mg Oral Tablet
223703569|NCT02853344|BIOLOGICAL|Pembrolizumab|IV infusion
223703570|NCT00001095|DRUG|Indinavir sulfate|
223703571|NCT00001095|DRUG|Amprenavir|
223703572|NCT00001095|DRUG|Nevirapine|
223703573|NCT00001095|DRUG|Lamivudine|
223703574|NCT00001095|DRUG|Stavudine|
223703575|NCT00001095|DRUG|Zidovudine|
223787992|NCT03215446|DRUG|maintenance of anaesthesia with propofol|
223787993|NCT03215446|DRUG|maintenance of anaesthesia with sevoflurane|
223787994|NCT04112004|OTHER|Collecting sodium reports and outcome measures|
223787995|NCT04538729|BEHAVIORAL|Acne Vulgaris|Alternative medicine and complementary therapies that acne vulgaris patients apply without informing the doctor, how they learn these techniques, what make them use these techniques for their illness
223787996|NCT06086327|DRUG|68Ga-Pentixafor|Intravenous injection of one dosage of 74-185 MBq(2-5 mCi) 68Ga-Pentixafor. Tracer doses of 68Ga- Pentixafor will be used to image lesions of thymoma by PET/CT.
223787997|NCT03031652|DEVICE|Phacoemulsification|The device device used to provide and perform small profile entry for cataract extraction with or without option of insertion of a specified intraocular lens implant
223787998|NCT00527566|BIOLOGICAL|Mepolizumab|IV mepolizumab, 750 mg
223787999|NCT02248870|DRUG|Dexamethasone|Dexamethasone is added to Bupivacaine with Adrenaline for perineural injection
223788000|NCT02248870|DRUG|Saline|Saline is added as a placebo to Bupivacaine with adrenaline for perineural injection
223788001|NCT04745169|BEHAVIORAL|8 week home-based exercise program|Participants will be asked to complete an 8-week home-based exercise program according to guidelines from the American Heart Association and the American Association of Cardiovascular and Pulmonary Rehabilitation. At study baseline, participants will receive exercise equipment and an individualized exercise prescription from an exercise physiologist followed by 8 weekly phone calls from an exercise physiologist. Participant safety will be monitored.
223788002|NCT05450848|DEVICE|StrataXRT|StrataXRT is a flexible wound dressing for the prevention and treatment of radiation dermatitis. It is in the form of a gel which, when applied, creates a protective film that maintains skin integrity. The product is used to relieve low grade inflammatory radiation changes such as dry, itching, flaking, peeling and irritated skin. For more severe inflammatory changes with open wound components, StrataXRT reduces pain, redness and heat and helps soothe the exposed skin areas. StrataXRT can be applied where skin integrity has been compromised and may also be used in conjunction with other adjunctive treatments to improve overall results. StrataXRT contains Polydimethylsiloxanes, Siloxanes and Alkylmethyl Silicones and is transparent and odourless. It does not contain alcohols, parabens or fragrances. StrataXRT can be used with or without a secondary protective dressing. It is suitable for children and people with sensitive skin.
223788003|NCT05450848|OTHER|Sorbolene|Aqueous cream (moisturizer) that soothes itchiness and dryness of the skin, and aids skin hydration. It is non-greasy, fragrance free, colour free, GMO free, paraben free and pH balanced.
223788004|NCT03312556|DEVICE|continuous positive airway pressure (CPAP)|Continuous positive airway pressure(CPAP) will be applied during the night starting from 20:00. CPAP level will be determined during an acute CPAP trial.
223788005|NCT03312556|DRUG|Placebo|Placebo pill or patch. Single dose
223788006|NCT02420002|DRUG|Use of MEOPA during suturing|Patients randomized to this arm will receive usual care, including MEOPA inhalation during local anesthetic injection and suturing of a wound.
223788007|NCT02420002|OTHER|Use of Hypnosis during suturing|Patients randomized to this arm will receive usual care as in the other arm, but before MEOPA inhalation is started, hypnosis will be tried. The local anesthetic injection and suturing of the wound will therefore take place under hypnosis (and MEOPA if necessary).
223788008|NCT02420002|PROCEDURE|Stitch removal|6 to 15 days after the initial suturing, stitches will be removed according to usual procedures.
223788009|NCT03278665|DRUG|4SC-202 in combination with Pembrolizumab|4SC-202 in combination with Pembrolizumab
223788010|NCT00489606|DRUG|SK3530|
223788011|NCT02041195|DRUG|Setmelanotide|
223788012|NCT02041195|DRUG|Placebo|
223788013|NCT04250649|PROCEDURE|subcutaneous tissue disinfection|"Skin and subcutaneous incision (up to the muscular fascia) with superficial blade scalpel, disinfection of the subcutaneous tissue with 3cc of Betadine solution, placement of the retractors, dissection and development of the delto-pectoral interval with deep blade scalpel.~When the joint is opened, bacteriological smears are taken from 5 sites in the two groups. 1) exposed subcutaneous tissue, 2) surgeon's gloves (distal end of fingers), 3) superficial blade, 4) deep blade, 5) retractors.~The rest of the shoulder surgery procedure does not differ from what is commonly performed.~The samples are sent to bacteriology for bacterial culture. Anaerobic research is done specifically for P. acnes. The results are considered negative after 10 days."
223788014|NCT01748929|DRUG|Albendazole|
223788015|NCT01748929|DRUG|Placebo|
223788016|NCT00674986|DEVICE|Accu-Chek 360° View Blood Glucose Analysis Tool|
223788017|NCT00674986|DEVICE|Accu-Chek Aviva Glucose Meter|
223788018|NCT03477448|DRUG|Bleomycin|"an antibiotic derived from Streptomyces verticillus, has an antitumor, antibacterial, and antiviral activity that may be related to its ability to bind with DNA, causing bleomycin strand scission and elimination of pyrimidine and purine bases. The bleomycin hydrolase enzyme, which is known to inactivate bleomycin, is normally found in all body tissues but is present in very small amounts in skin .~* Intra-lesional bleomycin injection (IBI) has been used for the treatment of warts."
223788019|NCT03477448|DRUG|Purified Protein Derivative|"is an extract of Mycobacterium tuberculosis and is used for testing exposure to tuberculin protein, either from a previous vaccination or from the environment. It contains live, attenuated Mycobacterium bovis.~* Using this protein derivative for immunotherapy of warts is important for two major aspects. First, because the obligatory immunization program in many developing countries - with high prevalence of wart in many of them - includes BCG vaccination. PPD has a high prevalence of immunity in the general population. Second, although immunotherapy is generally an inexpensive method of treatment in wart patients, PPD, among conventionally used antigens, is the cheapest"
223788020|NCT00931372|DRUG|Lixisenatide (AVE0010)|Solution for subcutaneous injection 100 µg/mL
223788021|NCT00931372|DRUG|Placebo|Subcutaneous injection
223788022|NCT01611701|PROCEDURE|cryoballoon ablation|In Cryo group, 28mm balloon was introduced into the PV ostium with the best possible occlusion of the PV. Every step was controlled by fluoroscopy. Cryoenergy was applied for maximal 6 minutes per application for 2 times, resulting in a circumferential ablation lesion. Before the right superior vein was treated, a quadripolar catheter was placed in the superior vena cava to continuously stimulate the right phrenic nerve during cryoapplication. The application was stopped immediately in the case of diminished diaphragm movements.
223788023|NCT01611701|PROCEDURE|Radiofrequency ablation|n RF group, reisolation of the PV was performed by identifying the breakthrough site. Radiofrequency energy was delivered at 43°C, 35 W, 0.5 cm away from the PV ostia at the anterior wall, and was reduced to 43°C, 30 W, 1 cm away from the PV ostia at the posterior wall, with a saline irrigation rate of 17 mL/min. Each lesion was ablated continuously until the local potential amplitude decreased by \>80% or RF energy deliveries exceeded 40 s.
223788024|NCT00379613|DRUG|sugammadex|"After induction of anesthesia an intubation dose of NMBA was administered IV: 1.2 mg/kg rocuronium (arms 2-6)~At 5 minutes after administration of rocuronium, the randomized single dose of sugammadex 2.0 to 16.0 mg/kg IV was administered"
223788025|NCT00379613|DRUG|Placebo|"After induction of anesthesia an intubation dose of NMBA was administered IV: 1.2 mg/kg rocuronium (arms 2-6)~At 5 minutes after administration of rocuronium, the randomized single dose of sugammadex 2.0 to 16.0 mg/kg IV was administered"
223788026|NCT03321916|DEVICE|577-nm PASCAL laser|The Topcon/Endpoint Management System™ is a cleared medical device commonly used in the treatment of ocular disorders.
223788027|NCT01847703|PROCEDURE|Robotic surgery|Minimal invasive surgery performed with daVinci robotic system
223788028|NCT01847703|PROCEDURE|Abdominal surgery|Current gold standard
223788029|NCT00157807|PROCEDURE|bipolar radiofrequency ablation of persistent and permanent AF|
223788030|NCT02732418|DRUG|Depo-Provera CI|The active ingredient in Depo-Provera is Medroxyprogesterone acetate (MPA)
223788031|NCT02732418|DRUG|Depo-subQ 104|The active ingredient in Depo-Provera is Medroxyprogesterone acetate (MPA). Depo-subQ provera 104® (medroxyprogesterone acetate injectable suspension, 104 mg/0.65mL) for subcutaneous injection
223788032|NCT04429516|DRUG|Morphine Sulfate|over-encapsulated Morphine Sulfate prolonged release 5mg tablet, twice daily for 14 days. Patients will then crossover after a 7 day wash out period.
223788033|NCT04429516|DRUG|Placebo oral tablet|capsule containing Microcrystalline Cellulose Ph. Eur, 5 mg twice daily
223703576|NCT02913612|DRUG|0.25% Timolol Maleate Gel Forming Solution|50:50 Randomized 0.25% Timolol Maleate Gel Forming Solution
223703577|NCT02913612|DRUG|0.5% Timolol Maleate Gel Forming Solution|50:50 Randomized 0.5% Timolol Maleate Gel Forming Solution
223703578|NCT02589379|PROCEDURE|Pancreatic Resection|Endoscopic ultrasound elastography, intraoperative ultrasound elastography and magnet resonance imaging to asses pancreatic stiffness prior to pancreatic resection
223703579|NCT06410404|PROCEDURE|transversus thoracis plane block|with the patient lying in the supine position. After skin disinfection, a high frequency linear ultrasound probe will be applied parallel to and between the 4th and 5th ribs connecting at the sternum. Then, different drugs according to the different groups will be injected between the transversus thoracic muscle and the internal intercosatal muscle.
223703580|NCT06410404|DRUG|Dexmedetomidine|the dexmeditomedine group shall undergo bilateral transversus thoracis plane block with 15 ml of 25% levobupivacaine, and 0.05 ug/kg dexmeditomedine on each side of the sternum
223703581|NCT06410404|DRUG|Levobupivacaine|A local anesthetic that will be instilled in the transversus thoracic plane in a dose of 15 ml of a 25% concentration on both sides of the sternum in both groups
223703582|NCT01434407|OTHER|Dietary meal intervention|Test meals with different AGE content made by different cooking methods
223703583|NCT00885053|DIETARY_SUPPLEMENT|fish oil|Capsules. Approximately 1000 mg n-3 PUFA daily. One day + 6 weeks
223703584|NCT00885053|DIETARY_SUPPLEMENT|olive oil|Capsules. Approximately 1 g olive oil daily. One day + 6 weeks
223788034|NCT04897074|DEVICE|AKL-T01|"AKL-T01 multitasking digital treatment. AKL-T01 multitasking treatment employs perceptual discrimination attention/memory task as well as a continuous motor driving task."
223788035|NCT03801239|DIAGNOSTIC_TEST|Urodynamic Study|during visit Week 0 patients had urodynamic study
223788036|NCT03801239|DIAGNOSTIC_TEST|OABSS questionnaire fulfilment|during visit Week 0 and Week 2 patients fulfilled OABSS
223788037|NCT03801239|DIAGNOSTIC_TEST|UDI-6 questionnaire fulfilment|during visit Week 2 patients fulfilled UDI-6 questionnaire
223788038|NCT03801239|DIAGNOSTIC_TEST|IIQ-7 questionnaire fulfilment|during visit Week 2 patients fulfilled IIQ-7 questionnaire
223788039|NCT00256581|PROCEDURE|Additional rest and stress image sets on new camera|
223788040|NCT06369259|DRUG|Defactinib|Given by PO
223788041|NCT06369259|DRUG|Cetuximab|Given by IV
223788042|NCT06369259|DRUG|Avutometinib|Given by PO
223788043|NCT03328754|DEVICE|Powerscope placed bilaterally for class II correction|Powerscope placed bilaterally for class II correction
223788044|NCT03328754|DEVICE|Group 2 Forsus|Forsus placed bilaterally for class II correction
223788045|NCT05109299|OTHER|Miswak toothpaste|Dabur Meswak is scientifically formulated herbal toothpaste with pure extract of the Miswak plant 'Salvadore Persica'
223788046|NCT05109299|OTHER|Fluoride toothpaste|1450 ppm fluoride toothpaste
223788047|NCT03861013|BEHAVIORAL|Multidimensional stress prevention program (GeDStress)|The multidimensional stress prevention program (GeDStress) is composed of 8 session of 2-hour weekly sessions and integrated cognitive and behavioral strategies, mindfulness-based activities, emotional regulation and social skills exercises. Brief homework activities were given between sessions. The groups were composed by a maximum of 8 students and were led by two trained clinical psychologists.
223788048|NCT01024569|BEHAVIORAL|Wellness Recovery Action Planning (WRAP)|WRAP consists of 8 sessions lasting for 2-½ hours, convened once a week over a period of 8 weeks.
223788049|NCT02210364|DRUG|lurbinectedin (PM01183)|lurbinectedin (PM01183) 1 mg and 4 mg vials
223788050|NCT02210364|DRUG|capecitabine|capecitabine 150 mg tablets
223788051|NCT00302796|DRUG|Bioclavid|500 + 125 mg times 3 or 6
223788052|NCT00302796|DRUG|Placebo|
223788053|NCT01659931|DRUG|Montelukast|10 mg Tablet
223788054|NCT01659931|DRUG|Singulair|10 mg Tablet
223788055|NCT05028218|DRUG|TQB3824 tablets|TQB3824 is a CDC7 inhibitor, which plays important roles in the maintenance of DNA replication forks and DNA damage response pathways.
223788056|NCT00450762|DRUG|gemcitabine|
223788057|NCT00450762|DRUG|carboplatin|
223788058|NCT04137042|DRUG|Saline|Intraoperative fluid therapy is administrated by using 0.9% saline
223788059|NCT04137042|DRUG|Balanced crystalloid|Intraoperative fluid therapy is administrated by using balanced crystalloid
223788060|NCT05184725|DEVICE|SaMD CARINAE|SaMD CARINAE delivers the following digital therapeutic intervention to the patients: 1) Personalised patient-centred health education program to improve patient's disease and recovery self-management skills. 2) AI-based behaviour change program to promote healthier lifestyle habits. 3) Personalised mental well-being coaching program to improve patient's ability to cope with emotional disturbances such as stress and anxiety. 4) A collaborative digital support platform to enable information exchange between patients, caregivers, and healthcare professionals.
223788061|NCT02527668|DIETARY_SUPPLEMENT|Calcifediol|One capsule orally of Calcifediol (20 µg) per day with a meal for a duration of 6 months
223788062|NCT02527668|DIETARY_SUPPLEMENT|Vitamin D3|One capsule orally of Cholecalciferol (3200 IU) per day with a meal for a duration of 6 months
223788063|NCT02527668|OTHER|Placebo|One capsule orally of a Placebo capsule per day with a meal for a duration of 6 months
223788064|NCT05463328|PROCEDURE|laparoscopic assisted pancreaticoduodenectomy|laparoscopic assisted pancreaticoduodenectomy.
223788065|NCT05463328|PROCEDURE|Open pancreaticduodenctomy|Open pancreaticduodenctomy
223788066|NCT05777642|DIETARY_SUPPLEMENT|Oxygen Nanobubble|This contains oxygenated nanobubbles made from lecithin and natural flavourings (Liquorice, glycerol, and citric acid)
223788067|NCT05777642|DIETARY_SUPPLEMENT|Placebo|This does not contain nanobubbles and is made from natural flavourings (Liquorice, glycerol, and citric acid)
223788068|NCT01219348|BIOLOGICAL|IDO peptide vaccination|Vaccination every second week
223703585|NCT04796571|BEHAVIORAL|Proactive Symptom Monitoring and Care Coordination|Patients randomized to the intervention arm were assigned an IBD-focused care coordinator who facilitated a symptom-based monitoring algorithm and supported patient navigation to complement usual care. Symptom monitoring was facilitated through regular push notifications to participants to complete a validated PRO instrument through the Epic EMR patient portal or telephone. These notifications were scheduled on a monthly basis. The IBD-focused care coordinator made two attempts to reach each participant using portal messaging, followed by a phone call to reduce non-response. PRO questionnaires were reviewed by the care coordinator and out of range scores triggered algorithm-based recommendations to the IBD specialist including stricter monitoring of disease activity, behavioral and medication adherence counseling, facilitation of expedited follow-up with treating providers, and referrals to social work, mental health, and gastroenterology-specific behavioral health services.
223703586|NCT05074043|COMBINATION_PRODUCT|antiviral, surgical|surgical debridment
223703587|NCT02471976|OTHER|strategy promoting early consideration and collegiate vulnerability of patients|One day training with the provision of vulnerability criteria inciting an early reflection of the level of therapeutic engagement; sheets available on the internet computer support collegial reflection and traceability of decisions to limit and stop treatments, incorporating the provisions of law known Leonetti
223703588|NCT04378127|OTHER|Educational program|The educational program consisted of six thematic meetings of 3 hours each, which a 15-minute interval every hour. Each meeting had a key topic and was divided in a teaching session and in a practical session with individual training of both, subject and caregiver. Every lecture was held by a movement disorders specialist with particular expertise in each field of discussion and the content of each lessons (slides, flyers, questionnaires) was adapted to fit the audience.
223703589|NCT01561378|DRUG|Aspart insulin|40 IU of aspart insulin (200 microliters per nostril) will be administered intranasally using an intranasal mucosal atomizer device within 2 hours prior to surgery, and then four times a day for 7 days or until hospital discharge (whichever occurs first)
223703590|NCT01561378|DRUG|Normal saline|200 microliters of normal saline will be administered per nostril using an intranasal mucosal atomizer device within 2 hours prior to surgery, and then four times a day for 7 days or until hospital discharge (whichever occurs first)
223703591|NCT01561378|DEVICE|Intranasal mucosal atomizer device|Insulin and placebo will be drawn into identical syringes. Nurses will administer the insulin or placebo by connecting the mucosal atomizer device (MAD) to the syringe, placing the MAD tip in the nostril and compressing the syringe plunger to spray atomized solution into the nasal cavity.
223703592|NCT02385370|DRUG|MMC|using 0.02 MMC soaked sponged under the conjunctiva for 1 to 3 minutes
223703593|NCT02385370|DRUG|MMC|0.1 cc of 0.01% MMC is injected into the tenon.
223703594|NCT02034032|PROCEDURE|Regenexx SD|stem cell treatment
223703595|NCT02034032|BEHAVIORAL|Exercise Therapy|exercise therapy control
223703596|NCT04756869|OTHER|COVID-19 Monitoring Using Wearable Sensors and Smartphone Technology|Health care workers are on-study for 30 days, in which they wear a smart watch and temperature patches up to daily. Subjects also may provide nasal and saliva samples up to daily during the study period, and they may opt-in to blood samples lasting up to 1 year after study completion. Through a smartphone app, participants complete surveys at baseline and at study completion, as well as daily mood surveys and symptom-reporting surveys. Finally, exit interviews occur at the end of the study period, and follow-up interviews may occur at specified timepoints up to 1 year after study completion.
223703597|NCT01050491|DRUG|sitaxentan|100 mg once a day during one year. Bronchial fibroscopy
223703598|NCT01050491|DRUG|placebo|placebo, one per day, during one year. Bronchial fibroscopy
223703599|NCT00973674|DRUG|Premarin IV|One time dose of Premarin IV
223703600|NCT00973674|DRUG|Placebo|One time dose of Placebo
223703601|NCT02645721|BEHAVIORAL|Extended self-help program with guidance|See arm description for Experimental
223703602|NCT02645721|BEHAVIORAL|Briefer Self-help program, no guidance|See arm description for Active Comparator
223703603|NCT02645721|BEHAVIORAL|WL: Extended self-help program, choice of guidance intensity|See arm description for Waiting list.
223703604|NCT00058487|DRUG|epirubicin hydrochloride|
223703605|NCT00058487|DRUG|thalidomide|
223703606|NCT02666885|RADIATION|Integration of PET/MRI in radiotherapy|Integration of pretherapeutical PET/MRI in adjuvant radiotherapy
223703607|NCT03274271|BEHAVIORAL|Action planning|Action planning is the behaviour change technique used to make users specify their goal (what they are going to do, when, where, ...).
223703608|NCT03274271|BEHAVIORAL|Coping planning|Coping planning is the behaviour change technique used to make users think about possible hindrances and according solutions when trying to reach their goal.
223703609|NCT03274271|BEHAVIORAL|Self-monitoring|Self-monitoring is the behaviour change technique used to make users keep track of their goal.
223788069|NCT02274779|DRUG|ELIGARD|"Hormone therapy is recommended Eligard 45 mg acting for 6 months. It will be ideally administered the day of start of radiation therapy or within 3 months before the first day of radiotherapy.~Nevertheless, free prescription is left to investigators. When using other hormonal strategies (anti-androgen agonists, LHRH antagonists or LHRH), an administration for six months will be critical."
223703610|NCT03274271|BEHAVIORAL|Feedback and tips|In this intervention, users receive tailored feedback on their current health behaviour and tips and tricks to reach their goals. This tips and tricks include the behaviour change technique 'eliciting social support'.
223703611|NCT05806983|OTHER|Technology Based Psychosocial Program|A technology-based model-based psychosocial empowerment program will be implemented for parents and children in the control group.
223788070|NCT03754296|DEVICE|CATCHVIEW|Revascularization device
223788071|NCT03894865|OTHER|procedure1|The students will be asked to bend forward with his knees straight, feet together and hands freely and loosely hanged. if there was scoliosis the rib cage rotated and a hump appeared. Positive test indicated the presence of a rib hump and negative if there was any hump appeared
223788072|NCT03894865|OTHER|procedure2|Measurement of the angle of trunk rotation (ATR) by using a scoliometer HD smartphone application.
223703612|NCT03445520|BEHAVIORAL|Intervention Coaching Group|Parents in this group receive six, 1 hour, coaching sessions with a research staff coach, to discuss key information about transitions (knowing parent's rights about special education services, communicating effectively with school staff, knowing the roles of the school team members, how to develop and share your Snapshot, and what to do with your child over the summer to help with the transition). The coach will encourage the parent to identify a school staff member to help with preparing for the transition. If the post transition school team is not able to participate in a pre-transition meeting, then the coach will encourage the parent to share the Student Snapshot with the post-transition teacher(s) and school team when the new school year begins in the Fall.
223703613|NCT02151695|PROCEDURE|panretinal photocoagulation|
223703614|NCT02151695|DRUG|Aflibercept intravitreal injections|
223703615|NCT00629720|DRUG|alfuzosin (SL770499)|
223703616|NCT04087174|DRUG|Capivasertib|Patients will receive multiple oral dose of capivasertib.
223703617|NCT04087174|DRUG|Enzalutamide|Patients will receive 160 mg oral dose of enzalutamide.
223703618|NCT04087174|DRUG|Abiraterone|Patients will receive 1000 mg oral dose of abiraterone.
223703619|NCT00071396|DRUG|Campath-1H|15 mg/day Continuous infusion by vein (IV) for 6 days then given twice a week for remaining three weeks as 30 mg injection under skin to complete one treatment course of 4 weeks.
223703620|NCT00071396|DRUG|Rituximab|375 mg/m\^2 IV infusion on day 1, then 500 mg/m\^2 on days 8, 15, and 22.
223703621|NCT06022601|DEVICE|DNA Nudge|DNA Nudge wearable, DNA-based dietary advice
223703622|NCT00549380|DEVICE|Endologix, Inc. Endoluminal Technology|Stent-graft endoprosthesis is inserted by Delivery System via a surgical cutdown (e.g., external iliac artery, femoral artery, common iliac artery conduit, etc.) approach. The insertion method depends on each patient's anatomy and is determined by the Clinical Investigator.
223703623|NCT02838446|PROCEDURE|Cognitive Therapy|"Graded Motor Imagery has three stages:~Lateralisation (2 or 3 weeks) Motor Imagery (2 or 3 weeks) Mirror Therapy (2 or 3 weeks)"
223703624|NCT05352373|DIETARY_SUPPLEMENT|calcium|calcium carbonate
223703625|NCT05352373|DIETARY_SUPPLEMENT|placebo|sodium bicarbonate
223703626|NCT00978471|DRUG|Thiotepa|Thiotepa 8-12mg/m²/day/injection Total dose for one cure:15-50mg.
223703627|NCT00116428|DEVICE|NAVISTAR® THERMOCOOL® Catheter|The Biosense Webster NAVISTAR® THERMOCOOL® Diagnostic/Ablation Deflectable Tip Catheter is a luminal catheter with a deflectable tip designed to facilitate electrophysiological mapping of the heart and to transmit radiofrequency current to the catheter tip electrode for ablation purposes.
223703628|NCT00116428|DRUG|Antiarrhythmic drug|Subjects randomized to the antiarrhythmic drug (control) arm will be prescribed to a not previously administered class I or class III antiarrhythmic drug that is currently approved in the U.S. for treating atrial fibrillation.
223703629|NCT02321631|DIETARY_SUPPLEMENT|EPA-enriched supplement|EPA-enriched supplement is given to the patients for 3 weeks (1 week prior to surgery and 2 weeks post surgery). The supplement composes of 2.2 gm of EPA and 630 kcal daily.
223703630|NCT02321631|DIETARY_SUPPLEMENT|standard formula supplement|The standard formula supplement is given to the patients for 3 weeks (1 week prior to surgery and 2 weeks post surgery). The supplement is 630 kcal daily without EPA.
223703631|NCT00365651|PROCEDURE|Youth Soccer|
223703632|NCT04300439|DEVICE|knee total arthroplasty with two types of ancillaries|"-For the Arm A, the surgical procedure of knee total arthroplasty will be done with metallic reusable ancillary.~For the Arm B, the surgical procedure of knee total arthroplasty will be done with Efficiency single use ancillary."
223703633|NCT04504279|BIOLOGICAL|FB-401|Topical application
223703634|NCT04504279|BIOLOGICAL|Placebo|Vehicle
223703635|NCT00743899|PROCEDURE|The aggressive group|Stents were implanted in lesions with diameter stenosis \>50% and RD ≥2.25 mm and balloon angioplasty was performed in lesions with diameter stenosis \>50% and RD ≥2.0 mm and \<2.25 mm.
223703636|NCT00743899|PROCEDURE|The conservative group|Stenting was performed only in lesions with diameter stenosis \>70% and reference diameter (RD) ≥2.25 mm
223703637|NCT02387931|DIETARY_SUPPLEMENT|Vitamin D3|Nature Made Vitamin D 2000IU, 1 softgel taken daily
223703638|NCT02387931|DIETARY_SUPPLEMENT|Fish Oil|Nature Made ultra omega-3 mini fish oil 500mg, 2 soft gels taken daily
223703639|NCT02387931|OTHER|Placebo|Placebo capsule, 2 taken daily
223703640|NCT06191523|OTHER|Control Group|The control group will receive standard therapy and placebo.
223703641|NCT06191523|DRUG|Treatment Group|The participants in the treatment group will receive standard therapy and a single dose of oral melatonin 20 mg
223703642|NCT00020774|DRUG|gemcitabine hydrochloride|
223703643|NCT00020774|DRUG|lonafarnib|
223703644|NCT00020774|PROCEDURE|conventional surgery|
223703645|NCT02699359|DEVICE|HS-1000 recording|
223703646|NCT05377008|BEHAVIORAL|OPTIMAL-SSI|The purpose of the intervention feedback session will be twofold: 1) to provide the results of the previous assessment, and 2) to provide general psychoeducation on psychological and neurocognitive functioning and tailored cognitive and behavioral interventions based on the results in order to reduce the impact of psychological and neurocognitive deficits.
223703647|NCT02713204|DRUG|REGN910-3|
223703648|NCT02713204|DRUG|Intravitreal Aflibercept Injection (IAI)|
223703649|NCT00669396|DRUG|Copper T380 IUD|Copper T380 IUD
223703650|NCT00669396|DRUG|levonorgestrel|1.5 mg
223703651|NCT00358423|DRUG|Pegaptanib Sodium|0.3 mg/0.1 ml intravitreal injection, every 6 weeks, up to a total of 3 injections
223703652|NCT00358423|DRUG|Control|Sham injections, every 6 weeks, up to a total of 3 sham injections
223703653|NCT04248751|DEVICE|Regeneten|A new scaffold material made of highly purified, type I collagen from bovine tendons has shown great promise as a bioinductive implant that helps induce the formation of new tendon-like tissue over the surface of partial- or full-thickness rotator cuff tears. This new graft material has the benefit of decreasing surgery time, as it takes a few minutes to put in place, while increasing healing and tendon thickness.
223703654|NCT04248751|PROCEDURE|Debridement|The bursa will be debrided thoroughly, and rotator cuff edges will be shaved down to stable tissue. The rotator cuff will be repaired using multiple single row triple loaded suture anchor placed adjacent to the articular margin
223703655|NCT02785484|OTHER|Label with constituent disclosure message|Labels with constituent disclosure messages that include text about chemicals in cigarette smoke and health effects of the chemicals will be applied to participants' cigarette packs on the right side (the Surgeon General's warning is on the left side). At the week 2 visit, participants' packs will be labeled with 1 of 3 disclosures selected at random; at the week 3 visit, they will get one of the 2 remaining disclosures selected at random, and at the week 4 visit they will get the remaining disclosure. Study investigators developed the text and design of these labels.
223703656|NCT02785484|OTHER|Label with litter message|Labels with litter messages that include text about littering cigarette butts will be applied to participants' cigarette packs on the right side (the Surgeon General's warning is on the left side). At the week 2 visit, participants' packs will be labeled with 1 of 3 litter messages selected at random; at the week 3 visit, they will get one of the 2 remaining litter message selected at random, and at the week 4 visit they will get the remaining litter message. Study investigators developed the text and design of these labels.
223703657|NCT04701788|BIOLOGICAL|23-valent pneumococcal polysaccharide vaccine|The study group and the control group were injected with a dose of 23-valent pneumococcal polysaccharide vaccine. One month later, blood was collected and serum was separated.
223703658|NCT05202028|OTHER|Reflexology|After the physical therapy applied to the patient by the physiotherapist in the special education center for 8 weeks, 3 days a week for about 15-20 minutes. reflexology will be practiced. To families; Training will be given on sleep hygiene, nutritional recommendations and lifestyle changes.
223703659|NCT05202028|OTHER|Connective Tissue Massage|After the physical therapy applied to the patient by the physiotherapist in the special education center, 3 days a week for 8 weeks, once a day for approximately 15-20 minutes. Connective tissue massage will be applied. To families; Training will be given on sleep hygiene, nutritional recommendations and lifestyle changes.
223703660|NCT05202028|OTHER|Classic abdominal massage|After the physical therapy applied to the patient by the physiotherapist in the special education center for 8 weeks, 3 days a week for about 15-20 minutes. reflexology will be practiced. To families; Training will be given on sleep hygiene, nutritional recommendations and lifestyle changes.
223703661|NCT00276146|DRUG|oral dipyridamole, oral magnesium, or a combination of both|
223703662|NCT05263596|DIAGNOSTIC_TEST|dual x-ray absorptiometry, body impedance analysis, muscle strength measurements, ultrasound|"Results from the routine geriatric assessment:~* Mini Mental State Exam (MMSE)~* Clock-drawing test (CDT)~* Geriatric depression scale (GDS)~* Functional independence measure (FIM) at admission~* Timed up and go Test (TUG)~* Gait speed~* Hand grip strength (HGS)~* Nutritional risk screening (NRS)~Additional measurements:~* Chair-stand-test~* Clinical frailty scale (CFS)~* Calf circumference and mid-arm circumference~* Body impedance analysis (BIA)~* US~* DXA"
223703663|NCT05271071|DIAGNOSTIC_TEST|Ultrasound guided piriformis muscle and gluteus maximus muscle lidocaine injection|Ultrasound guided piriformis muscle (piriformis syndrome) and gluteus maximus muscle 5 ml %1 lidocaine injection
223703664|NCT04587544|BEHAVIORAL|Cold Water Immersion|The participants maintained their daily activities during the intervention. When daily activity ended, the intervention was begun. CWI therapy by immersed the whole part of inflamed target joints in the water at 20-30C for 20 minutes/day. The intervention was continued for four weeks. The researchers work together with the nurses of community health services to give the intervention.
223703665|NCT05382533|DIETARY_SUPPLEMENT|Menu plans|The study participants in group A and C receive defined personal nutritional counselling every two weeks and they are provided with daily menu plans (isocaloric) with optimized nutrient profiles and chosen study products (plant oils, nuts mixture etc.) over the study period of 10 weeks.
223703666|NCT04402060|DRUG|APL-9|Complement (C3) Inhibitor
223703667|NCT04402060|OTHER|Vehicle Control|Normal saline of equal volume to active arm
223703668|NCT02256072|OTHER|Plan Your Lifespan Website|Participants in the intervention arm will navigate the advance planning tool, Plan Your Lifespan, a Web-based planning tool that provides information for seniors related to advanced health planning for home services in specific content areas of: hospitalizations, falls, Alzheimer's, dementia, as well as communicating with others. A minimum of 15 minutes and a maximum of 45 minutes will be allotted for navigating this website.The Plan Your Lifespan website is also interactive in that it allows participants to enter their information and share it with others to facilitate conversations and decision-making.
223703669|NCT02256072|OTHER|Go4Life Website|Participants in the attention control arm will navigate an electronic educational session via a National Institute on Aging at NIH Website, Go4Life, a website about physical activity and exercise as it is a topic of interest to seniors. A minimum of 15 minutes and a maximum of 45 minutes will be allotted for navigating the website. The website is interactive and comparable to the intervention tool: http://go4life.nia.nih.gov/get-started).
223703670|NCT00539669|DRUG|Docetaxel|
223703671|NCT00132210|DRUG|pegylated interferon|Pegylated interferon alfa-2a or -2b in standard dosage Ribavirin in case of genotype 1 or 4 at 1000 or 1200 mg/d according to body weight ist recommended.
223703672|NCT02350569|DRUG|LDV/SOF|90/400 mg FDC tablet administered orally
223703673|NCT02754154|DRUG|Warfarin|
223703674|NCT02754154|DRUG|Apixaban|
223703675|NCT02754154|DRUG|Dabigatran|
223703676|NCT02754154|DRUG|Rivaroxaban|
223703677|NCT03998566|DEVICE|TraceIT Tissue Spacer implantation|The TraceIT Tissue Spacer will be implanted between duodenum and pancreas using endoscopic procedure. After implantation patient will have radiotherapy treatment per standard of care.
223703678|NCT05406648|OTHER|Morus nigra concentrate|The experimental group was given 20 grams of black mulberry (morus nigra) concentrate per day for 12 weeks.
223703679|NCT02572609|DRUG|Ambroxol hydrochloride soft pastille|
223703680|NCT02572609|DRUG|Mucosolvan ® adult syrup|
223703681|NCT02976792|PROCEDURE|Renal Resistive Index/NephroCheck™test|Renal Resistive Index and NephroCheck™ test before TAVI and after TAVI
223703682|NCT02942927|OTHER|Medication reduction|Systematic approach to reduction in polypharmacy.
223703683|NCT02145585|DEVICE|Test of pharmacologic anesthesia robot (labVIEW® software)|
223703684|NCT03757338|DRUG|Fingolimod Reference Formulation|To compare the rate and extent of absorption for Fingolimod when administered as a single oral dose of 3 x 0.5 mg capsules of the reference product produced by Novartis Pharmaceutical with the proposed test product manufactured by Asofarma S.A.I. y C. in healthy volunteers, under fasted conditions.
223788073|NCT02141126|OTHER|Resistance training|Usual physiotherapy care and twice weekly tailored and progressive resistance lower limb exercises Circuit-type format, sessions will last 35 minutes and will include a warm-up and cool-down period. Exercises tailored to each patient and will use ankle weights as the resistance, using 65-75% of their 1-Repetition Maximum. Intervention will last for 6 weeks.
223788074|NCT02141126|OTHER|Usual care|Standard inpatient 'usual care' physiotherapy
223788075|NCT01691066|BEHAVIORAL|Infant Toddler Years PRT|
223788076|NCT01464203|OTHER|CT coronary angiography|"CT coronary angiography:~This allows two distinct assessments of the coronary arteries to be made:~* coronary calcium scan, which is a 30 second, low-radiation scan that allows reproducible quantification of the amount of calcium in the coronary arteries to be made.~* contrast enhanced CT coronary angiogram. This is a quick, non-invasive scan to assess the patency of coronary arteries."
223788077|NCT01464203|OTHER|Standard of Care|The management of patients in this group is according to the NHS protocol and is not altered by their participation in the trial. The choice of diagnostic investigation for CAD is determined by the patient's clinical scenario and the availability of different diagnostic modalities in the recruiting hospital.
223788078|NCT05629052|PROCEDURE|Pulmonary endarterectomy|Surgical removal of a chronic clot from the pulmonary artery
223788079|NCT05629052|PROCEDURE|Balloon pulmonary angioplasty|Catheter-based intervention to dilate occluded pulmonary vessels through the insertion and inflation of a small balloon
223788080|NCT05629052|DRUG|Pulmonary hypertension (PH)-specific medication|Treatment with any PH-specific medication, i.e. endothelin receptor antagonists, phosphodiesterase type 5 inhibitors, soluble guanylate cyclase stimulators, drugs acting on the prostanoid pathway and prostaglandin I2 receptor agonists
223788081|NCT04546581|BIOLOGICAL|Hyperimmune immunoglobulin to SARS-CoV-2 (hIVIG)|Hyperimmune immunoglobulin to SARS-CoV-2 (hIVIG) is derived from the plasma of individuals who recover and develop neutralizing antibodies. Participants will receive a single infusion.
223788082|NCT04546581|OTHER|Placebo|Participants will receive a single infusion of the placebo (saline).
223788083|NCT04546581|DRUG|Remdesivir|Remdesivir will be given to participants in both groups as standard of care (SOC).
223788084|NCT04756765|DRUG|Talazoparib Tosylate|Talazoparib1 mg/day is to be administered orally on a continuous dosing schedule.
223788085|NCT05123274|BEHAVIORAL|Social Support Mobilization|Five main sessions and two booster sessions focused on providing accurate information about HIV medical care, increasing participants' feelings of resilience and self-worth, and mobilizing or creating social supports.
223788086|NCT05123274|BEHAVIORAL|Individual Care Counseling|Twenty-minute individual counseling session focused on HIV medical care
223788087|NCT01983293|DEVICE|QLV based implant strategy|
223788088|NCT01983293|DEVICE|Standard of care implant strategy|
223788089|NCT01275625|DRUG|HIV therapy|Combivir one tablet BD with maraviroc 300mg BD for 48 weeks
223788090|NCT03009045|DRUG|Tedizolid|200mg oral tedizolid one pill per day
223788091|NCT03716713|DEVICE|CeraShield Endotracheal Tube|Subjects requiring mechanical ventilation with be intubated with the CeraShield ETT
223788092|NCT01585103|DEVICE|Cytosponge|An ingestible gelatin capsule containing a compressed mesh attached to a string. The capsule is swallowed and once in the stomach, the gelatin dissolves and a spherical mesh of 3 cm diameter is released. The mesh is withdrawn through the mouth by the attached string and a cytologic specimen is collected.
223788093|NCT02434692|DEVICE|ARGOS-IO system|Implantation of ARGOS-IO pressure sensor after IOL placement within the cataract surgical procedure on day 0 (V01)
223788094|NCT06535451|OTHER|Screening|Annual LDCT, lung function test (spirometry), anxiety/depression assessments, and serum biomarkers tests over 3 years. Follow-up will continue for 5 and 10 years or until event completion (cancer diagnosis, end of follow-up, or death).
223788095|NCT01183663|DRUG|Lenalidomide|Starting dose 10 mg by mouth daily for 21 days of a 28 day cycle.
223788096|NCT01183663|DRUG|Bevacizumab|Starting dose: 5 mg/kg by vein every 2 weeks of a 28 day cycle.
223788097|NCT01183663|DRUG|Sorafenib|Starting dose: 200 mg by mouth daily for 28 a day cycle.
223788098|NCT01183663|DRUG|Temsirolimus|Starting dose: 15 mg by vein every week for a 28 day cycle.
223788099|NCT01183663|DRUG|Lenalidomide|Starting dose: 5 mg by mouth daily for 14 days of a 21 day cycle.
223788100|NCT01183663|DRUG|Oxaliplatin|Starting dose: 65 mg/m2 by vein on day 1 of a 21 day cycle.
223788101|NCT01183663|DRUG|Leucovorin|400 mg/m2 by vein on day 1 of a 21 day cycle.
223788102|NCT01183663|DRUG|5-fluorouracil|400 mg/m2 by vein through ambulatory pump on days 1-2 of a 21 day cycle.
223788103|NCT00249236|DRUG|Risperidone, oral tablets|
223788104|NCT01349569|DRUG|Lenalidomide|Dosage forms: 5, 10, 15 and 25 mg capsules. Patients will be continued on the same dose of lenalidomide as they were prior to being enrolled in the study. Doses of lenalidomide for investigation can vary from 5- 25 mg/day, orally on days 1 - 21 followed by 7 days rest (28 day cycle).
223788105|NCT01349569|BIOLOGICAL|Allogeneic Myeloma Vaccine|A total of 4 vaccines will be administered. The first three at monthly intervals and a booster at 6 months from the initial vaccine. Each vaccination will consist of five total intra-dermal injections, two each in the right and left anterior upper thighs, and one in the non-dominant upper arm (unless contraindicated). Each dose will be administered on an outpatient basis. The subject must be observed in the clinic for at least 30 minutes after vaccination is completed.
223788106|NCT01349569|BIOLOGICAL|Prevnar-13|Prevnar-13 will be administered at 0.5ml dose by intramuscular injection at the same time as GVAX vaccine.
223788107|NCT04798976|DRUG|neoadjuvant/adjuvant therapy|chemotherapy/endocrine therapy/surgery/radiotherapy
223788108|NCT05564234|PROCEDURE|laparoscopy then primary cytoreductive surgery|Laparoscopy was used to calcautation of fagotti PIV score , if less than 8 primary cytoreductive surgery were done.
223788109|NCT05564234|PROCEDURE|laparoscopy then neoadjuvant chemotherapy followed by interval cytoreductive surgery|Laparoscopy was used to calcautation of fagotti PIV score and provides the histological diagnosis , if score more than 8 the patient were received neoadjuvant chemotherapy followed by interval cytoreductive surgery
223788110|NCT02883114|DRUG|PF-06648671|Subjects will receive a single dose of PF-06648671 25 mg oral suspension on day 1 in period 1 and a single dose on Day 4 in period 2.
223788111|NCT02883114|DRUG|Itraconazole|Subjects will receive itraconazole 200 mg oral solution once a day for 14 days in period 2
223788112|NCT00716872|BEHAVIORAL|Sleep Healthy Using the Internet (SHUTi)|"SHUTi is an Internet program based on cognitive-behavioral therapy for insomnia (CBT-I). Users complete daily online sleep diaries in addition to receiving weekly access to six interactive Cores of information. As they progress through the program, users receive tailored instructions for how to improve their sleep."
223788113|NCT00716872|BEHAVIORAL|Hypnosis recordings|Subjects listen to self-hypnosis recordings designed to improve their disturbed sleep.
223788114|NCT04247620|BEHAVIORAL|DiaBetter Together|Following an intervention manual, the Peer Mentor will teach behavioral strategies and offer support to the young adult, including (a) teaching and modeling strengths-based skills for goal-setting, problem-solving, and stress management; (b) guiding participants in obtaining support from their social support network (e.g., family, friends); (c) developing a plan for accountability around diabetes management and follow-up in adult care; (d) sharing his/her transition experiences and strategies for successfully navigating the adult healthcare system; (e) discussing how to prioritize diabetes self-care; and (f) assisting them in accessing diabetes-related resources (e.g., local diabetes groups, apps, social media). Contact will be in-person, by phone, email, text message, and/or video, approximately weekly for first 3 mos, approximately biweekly for next 3 mos, and approximately monthly for last 6 mos (while COVID-19 safety recommendations are in place, in-person meetings will not occur).
223788115|NCT04247620|BEHAVIORAL|Peer Mentor Delivery|Peer Mentors deliver the intervention to multiple young adult participants, each for 12 months. Peer Mentors may take on one or more participants at a time, and Peer Mentors may stay in their role in the study (delivering the intervention) for 1-3 years.
223788116|NCT04898101|DRUG|Acalabrutinib|Participants in Cohort 1 will receive a single 100 mg oral capsule dose of acalabrutinib on Day 1.
223788117|NCT04898101|DRUG|Microtracer [14C]ACP-196|Participants in Cohort 1 will receive a single microtracer (\<10 μg; ≤1 μCi) IV solution dose of \[14C\]ACP-196 as a 5-mL IV push over 2 minutes on Day 1. Participants in Cohort 2 will receive a single 100 mL dose of acalabrutinib 1 mg/mL oral solution containing a microtracer dose (\<10 μg; ≤1 μCi) of \[14C\]ACP-196 on Day 1.
223788118|NCT01741623|DRUG|Bisoprolol Fumarate Tablet 10 mg|10 mg tablet once a day
223788119|NCT01741623|DRUG|Bisoprolol|10 mg tablet once a day
223788120|NCT01747772|DEVICE|Shear Wave Sonoelastography|Shear Wave sonoelastography (SWE) as an ultrasound technique to measure liver fibrosis was performed on patients scheduled for non-focal liver biopsy. Results were compared with pathological score from liver biopsy.
223788121|NCT03701568|DRUG|dC/dT|Collection of retrospective data from TK2 patients previously treated with dC/dT
223788122|NCT03302338|DRUG|SAFE group|simulated amniotic fluid 20cc/kg/day enterally for a maximum of 7 days.
223788123|NCT03302338|DRUG|placebo group|distilled water 20 ml/kg/day for maximum of 7 days.
223788124|NCT02172508|DRUG|Tiotropium Inhalation Capsule|
223788125|NCT02172508|DRUG|Placebo Lactose Capsule|
223788126|NCT01064037|DRUG|Cinaciguat (BAY58-2667)|Infusion of 150 µg/h during 48h.
223788127|NCT01064037|DRUG|Cinaciguat (BAY58-2667)|Infusion of 100 µg/h during 48h
223788128|NCT01064037|DRUG|Cinaciguat (BAY58-2667)|Infusion of 50 µg/h during 48h
223788129|NCT01064037|DRUG|Placebo|Infusion during 48h
223788130|NCT06252129|OTHER|Subjects undergoing a lung specimen lymph node dissection|"A lobectomy specimen's resection will undergo systematic lymph node dissection either by the patient's treating thoracic surgeon and/or by a member of the pathology team.~The protocol for a standardized lymph node dissection consists of a series of blunt peribronchial dissections starting from the hilum to the periphery, with particular attention to points of airway bifurcation where intrapulmonary lymph nodes aggregate. By emphasizing the intrapulmonary lymph node map and a standardized dissection, the team will remove more lymph nodes from the lobectomy specimen, resulting in an accurate N staging."
223788131|NCT06252129|OTHER|Control group|Control group
223788132|NCT02776358|OTHER|High Fidelity Simulation|"A HFS session for an asthma attack require:~* a 5 minutes briefing session: case and equipments presentation and choice of participants~* 15 minutes of actual simulation~* 40 minutes of debriefing~A pre and a post test will be taken by the students before and after the session and a satisfaction questionnaire at the end of the course.~Also, another test will be done after 7 days of the course."
223788133|NCT02776358|OTHER|Video case|"a video case (or video box) session in which students will attend a video-projection of a real case of an asthma attack and discuss with the trainer the different steps of the assessement and management of an asthma attack.~A pre and a post test will be taken by the students before and after the session and a satisfaction questionnaire at the end of the course.~Also, another test will be done after 7 days of the course."
223788134|NCT01421563|DRUG|Anplag|Sarpogrelate HCl 300mg once a day or 100mg three times a day
223788135|NCT05674422|DRUG|total neoadjuvant therapy|All patients will be aged 18 years or older, with histologically confirmed rectal adenocarcinoma, located in the mid or distal third (with the inferior margin within 12cm from the anal verge), clinically staged II and III (cT3-T4 and/or any TN+), scheduled to undergo TNT will be eligible. All cases and treatment decisions will be discussed by local Multidisciplinary Boards
223788136|NCT01495065|DRUG|GSK2251052 750 mg|Treatment A: 750 mg IV GSK2251052 single dose
223788137|NCT01495065|DRUG|GSK2251052 1500 mg|Treatment B: 1500 mg IV GSK2251052 single dose
223788138|NCT01495065|DRUG|GSK2251052 1500 mg BID|Treatment C: 1500 mg IV GSK2251052 BID or placebo for 12 days
223788139|NCT01495065|DRUG|GSK2251052 2250 mg|Treatment D: On Day 1 a single dose of GSK2251052 2250 mg IV administered over 60 minutes; Days 4 - 12 BID doses of GSK2251052 2250 mg IV (for 9 days), fasted
223788140|NCT01495065|DRUG|GSK2251052 3000 mg|Treatment E: On Day 1 a single dose of GSK2251052 3000 mg IV administered over 60 minutes; Days 4 - 12 BID doses of GSK2251052 3000mg IV (for 9 days), fasted
223788141|NCT01495065|DRUG|GSK2251052 0.9% saline|Treatment P: On Day 1 a single dose of 0.9% saline IV administered over 60 minutes; On Days 4 - 12 BID doses of 0.9% saline (for 9 days), fasted
223788142|NCT00978601|PROCEDURE|Multimodal analgesic protocol during minimally invasive myomectomy|Multimodal and preemptive analgesia using 8 mg of Dexamethasone iv,trocar ports infiltration with 5 mL of a local anesthetic, consisting of 0.26% ropivacaine HCL (7.5 mg/mL) and 0.74% of 0,9 % sodium chloride, before the skin incision. About 10 minutes before the surgery is completed, 4 mg Ondansetron iv and a mixture of 75 mg diclofenac and 600 mg of paracetamol intramuscularly (im) are administered.
223788143|NCT00626522|DRUG|Aclidinium bromide and formoterol|once daily
223788144|NCT00626522|DRUG|Aclidinium bromide and formoterol placebo|once daily
223788145|NCT02280044|BIOLOGICAL|Rifaximin intervention|Rifaximin administered then Challenge with C jejuni
223788146|NCT02280044|BIOLOGICAL|Placebo intervention|Placebo administered then Challenge with C jejuni
223788147|NCT05119920|DRUG|Pilocarpine Ophthalmic Topical Cream, Dose 1|Pilocarpine Ophthalmic Topical Cream, Dose 1
223788148|NCT05119920|DRUG|Pilocarpine Ophthalmic Topical Cream, Dose 2|Pilocarpine Ophthalmic Topical Cream, Dose 2
223788149|NCT05119920|DRUG|Pilocarpine Ophthalmic Topical Cream, Dose 3|Pilocarpine Ophthalmic Topical Cream, Dose 3
223788150|NCT05119920|DRUG|Placebo Ophthalmic Topical Cream|Placebo Ophthalmic Topical Cream
223788151|NCT04499092|OTHER|Personalized Neuropsychological treatment (CORE-ABI)|Personalized neuropsychological treatment. In the CORE-ABI intervention, the stimulation of cognitive functions will be provided based on a weekly evaluation of child's cognitive profile by a qualified neuropsychologist. Each session will have a duration of 45 min. While the first 30 minutes will be devoted to the stimulation of the most impaired cognitive function(s), the remaining 15 minutes will ensure the stimulation of the other cognitive subdomains. Domains addressed by the intervention will be the following: selective attention, sustained and divided attention, inhibition and shifting, visual-perceptual abilities, visual-spatial abilities, visual-constructional abilities, short-term memory, long-term memory, working-memory, categorization/reasoning/abstraction, problem-solving/planning and socio-emotional skills.
223703685|NCT03757338|DRUG|Fingolimod Test Formulation|To compare the rate and extent of absorption for Fingolimod when administered as a single oral dose of 3 x 0.5 mg capsules of the proposed test product manufactured by Asofarma S.A.I. y C. with the reference product produced by Novartis Pharmaceutical in healthy volunteers, under fasted conditions.
223703686|NCT04141046|DEVICE|XCSITE100 Stimulator - Individualized theta-tACS|20 second ramp-in and ramp-out with 40 minutes of stimulation for a total of 2440 seconds of stimulation
223703687|NCT04141046|DEVICE|XCSITE100 Stimulator - Individualized alpha-tACS|20 second ramp-in and ramp-out with 40 minutes of stimulation for a total of 2440 seconds of stimulation
223703688|NCT04141046|DEVICE|XCSITE100 Stimulator - Active Sham|20 seconds of ramp-in to 40 seconds of 10 Hz tACS with a ramp out of 20 seconds for a total of 80 seconds of stimulation
223703689|NCT03405896|OTHER|Turning|start to walk with normal speed, and then turn to approach the terminal under different angle.
223703690|NCT02229331|OTHER|Gait analysis|
223703691|NCT05321108|OTHER|Group A (GA)(Aerobic exercise group)|Aerobic Exercise has been demonstrated to be a safe strategy to improve several health outcomes in Systemic lupus erythematosus (SLE)SLE, including depressive symptoms or, even more importantly, fatigue and quality of life.
223703692|NCT05321108|OTHER|Group B (GB) (Whole-body vibration (WBV) group)|(WBV) has been growing over the years. WBVE occurs when the subject is in contact with the vibrating platform in operation and is exposed to the generated mechanical vibrations. WBV has a positive action on muscle strength, bone formation, balance, flexibility, functional capacity and fatigue.
223703693|NCT05613881|OTHER|Education and Telephone Follow-up|The individuals in this group will be given an education and training booklet by the researcher after the pre-tests are applied in the first face-to-face interview. After the first meeting, the individual will be called every 15 days, 5 times in total for 3 months, and the training will be repeated in line with the individual's needs. After 3 months, the final tests will be applied.
223703694|NCT02503410|BEHAVIORAL|Usual care|Subjects receive standard physical therapy, including outpatient visits as prescribed by the treating clinician and home-based exercises based on recommendations by the physical therapist.
223703695|NCT02503410|BEHAVIORAL|Interactive gaming|Subjects receive a combination of standard physical therapy in the clinic and home-based exercises that they perform using the Valedo system.
223703696|NCT06556472|DRUG|Terlipressin|1\. Patients in this group will receive continuous terlipressin infusion (1 mg/24 hr on day 1, increasing to 1 mg in 24 hours if target MAP not achieved ,reaching maximum terlipressin dose of 4 mg/24 hr on day 4).If target MAP not achieved by terlipressin dose ,increase noradrenaline dose keeping terlipressin maximum 1 mg ,2 mg ,3mg ,4mg at Day 1,2,3,4 respectively.
223703697|NCT06556472|DRUG|Norephrine|1\. Patients in this group will receive norepinephrine only, with a dose range of 0.05 mcg/kg/min to 0.5 mcg/kg/min to maintain a MAP \> 65 to 75 mm Hg.
223703698|NCT03386474|DRUG|Brolucizumab 6 mg|Administered as opthalmic solution for an intravitreal injection to the study eye
223703699|NCT03386474|DRUG|Aflibercept 2 mg|Administered as an opthalmic solution for intravitreal injection to the study eye
223703700|NCT06127615|DEVICE|ClearFit|Implantation of ClearFit Longeviti Craniectomy Cover
223703701|NCT00599950|DRUG|Mitomycin C and Photorefractive keratectomy (PRK)|Topical mitomycin C on the corneal epithelium of patients undergoing photorefractive keratectomy (PRK)
223703702|NCT05369767|DRUG|SAD, SHR-2004|Ascending dose
223703703|NCT05369767|DRUG|SAD, SHR-2004 placebo|Ascending dose
223703704|NCT05576675|DRUG|sufentanil + nalbuphine|sufentanil 100 μ g + nalbuphine 40 mg
223703705|NCT05576675|DRUG|Sufentanil|sufentanil 200 μ g
223703706|NCT05576675|DRUG|hydromorphone + nalbuphine|hydromorphone 10 mg+ nalbuphine 40 mg
223703707|NCT02051231|DRUG|Oxytocin|Oxytocin, 10-10mol/L to 10-5mol/L
223703708|NCT02477969|DRUG|PEX168(100µg)|PEX168,100µg,Subcutaneous injection,once a week. continued for 52 weeks
223703709|NCT02477969|DRUG|PEX168(200µg)|PEX168,Subcutaneous injection,once a week. continued for 52 weeks
223703710|NCT02477969|DRUG|Placebo|0.5ml,Subcutaneous injection,once a week.continued for 24 weeks,then followed by PEX168 100µg,qw sc. or 200µg qw sc.for 28 weeks.
223703711|NCT02477969|DRUG|Metformin|0.5mg,oral,tid.
223703712|NCT03281707|PROCEDURE|NIRS|NIRS devices patch will be applied on patients' head in order to measure the cerebral saturation of each cerebral emisphere
223703713|NCT03281707|OTHER|DO2i|Oxygen delivery standardized to the body surface area will be calculate in order to optimize tissue perfusion
223703714|NCT04442139|OTHER|Mini-Gastric Bypass|Mini-Gastric Bypass bariatric surgery
223703715|NCT00202059|DRUG|Zoledronic acid|
223703716|NCT00202059|BEHAVIORAL|Physical activity intervention|
223703717|NCT02954250|BEHAVIORAL|Mindfulness Based Cognitive Therapy|The 8-week MMBCT protocol combines the practice of specific meditation techniques with cognitive therapy principles applicable to anxiety and depression. Each session will cover a meditation practice, as well as a relevant topic for discussion. The initial sessions will introduce general concepts of mindfulness (non-judgemental awareness, being in the moment, fostering curiosity, etc.), which will be expanded to more elaborate notions that are particularly relevant to anxiety, depression and suicidal ideations (recognizing thoughts are not facts, cultivating loving kindness for oneself, improving communication with others, etc.) Participants will be encouraged to practice the mindfulness techniques between sessions, a process that will be reviewed during groups in an ongoing fashion.
223703718|NCT03980977|OTHER|skin biopsy|"skin biopsy will be taken under local anesthesia using a patch of lidocaine and prilocaine. In practice, during the skin biopsy, the skin must be cleaned with chlorhexidine or alcohol, to the exclusion of any other antiseptic. The biopsy will preferably be done with a dermatome (or punch, 12 G)."
223703719|NCT03980977|OTHER|tumor biopsy|an additional tumor sample will be taken during programmed diagnostic procedure.
223703720|NCT03980977|OTHER|blood sample|blood sample will be taken for biological collection
223703721|NCT02155881|DRUG|Ciclesonide|Ciclesonide nasal spray 50 mcg/actuation
223703722|NCT02155881|DRUG|Ciclesonide Placebo|Ciclesonide placebo-matching nasal spray
223703723|NCT05322733|DRUG|Orelabrutinib|150 mg capsules administered orally once daily (28-day cycles). Until 12 or 24 cycles and following BM undetectable MRD, or disease progression, or intolerant toxicity.
223703724|NCT05322733|DRUG|Obinutuzumab|1000 mg administered intravenously once on Day 1, 8, 15 of first cycle and on Day 1 of following cycles for maximal 12 cycles (28-day cycles).
223703725|NCT05322733|DRUG|Fludarabine|25mg/m2/day administered intravenously on Day 1-3 for every cycle (at most 6 cycles, 28-day cycles).
223703726|NCT05322733|DRUG|Cyclophosphamide|250mg/m2/day administered intravenously on Day 1-3 for every cycle (at most 6 cycles, 28-day cycles).
223703727|NCT04357782|DRUG|L-ascorbic acid|50 mg/kg L-ascorbic acid infusion given every 6 hours for 4 days (16 total doses)
223703728|NCT02188771|DEVICE|intra-articular administration of RegenoGel-SP or hyaluronic acid (HA)|Intra-articular Injection: single injection of RegenoGel SP or 3 injections of HA
223703729|NCT05043675|DRUG|[18F]APN-1607|Subjects will receive one injection of \[18F\]APN-1607 (0.1\~0.15mCi/Kg), a PET radiopharmaceutical selective for fibrillar tau. \[18F\]APN-1607 injection will be followed by a 10 ml saline flush.
223703730|NCT02028312|DRUG|Loteprednol etabonate|
223703731|NCT02028312|DRUG|Artificial Tears|
223703732|NCT02028312|DRUG|Restasis|
223788152|NCT04499092|OTHER|Sequential Neuropsychological treatment (SET-ABI)|"Sequential Neuropsychological Treatment. In the SET-ABI intervention, the stimulation of cognitive functions will be provided following a sequential order, identical for each child and for each session in each setting (neuropsychological treatment, speech therapy treatment and psychoeducational treatment). Each session will have a duration of 45 min.~Specifically, the first three weeks (weeks 1-3) of treatment will target attention; in weeks 4-6, the domain of visual-spatial and visual-constructional abilities will be addressed; in weeks 7-9, memory will be the target domain; in weeks 10-12, executive functions and socio-emotional skills will be addressed."
223703733|NCT00443105|DRUG|Tacrolimus 0.03% ointment (Protopic)|
223703734|NCT01874600|DEVICE|Brain Sentinel Seizure Detection Device and Warning System|The Brain Sentinel Seizure Detection Device and Warning System is designed to monitor Epilepsy patients and alerts caregivers that a GTC seizure is occurring
223703735|NCT05586646|DIETARY_SUPPLEMENT|alanyl-glutamine|Amino acid solution for parenteral nutrition containing dipeptide alanyl-glutamine
223703736|NCT03780543|DRUG|standard of care (SOC) Nucleoside reverse transcriptase inhibitor (NrtI)|Participants will continue on their SOC NrtI, Entecavir (ETV), Tenofovir Disoproxil Fumarate (TDF) or Tenofovir Alafenamide (TAF) tablet QD (once daily) orally as per approved package insert.
223703737|NCT03144973|DIAGNOSTIC_TEST|periosafe|mouth rinsing quick-test
223703738|NCT04548037|OTHER|PET-CT examination|The subject is placed in supine position, the head immobilized in a headrest. The imaging sequence begins with a scout view (viewing angle 90 °, 120 kV, 20 mA), then an X-ray scan is performed for the attenuation correction (120 kV, 5 mAs per slice, pitch 0.531, collimation 40 mm , FOV 70) and diagnostic CT scan (120 kV, 100-250 mA: auto mA, pitch 0.531, 40 MM, DFOV 25, ASIR 60%, thickness 1.25 mm). Finally, the positron emission tomography is acquired: static in 3D mode for 15 minutes, 30 minutes after the injection of 18 FDG, the axial field of view is 25, the matrix in 256 x 256, OSEM reconstruction 6 iterations 24 subsets, attenuation correction, diffused, and PSF. Gaussian filter, cutoff frequency of 4. Obtaining forty-seven contiguous sections of 3.26 mm thick.
223703739|NCT05342792|DRUG|PD-1 antibody|Tislelizumab：200 mg per dose, intravenous infusion over 30 minutes, every 3 weeks as a cycle for 17 cycles after concurrent chemoradiotherapy
223703740|NCT05342792|DRUG|Capecitabine|Capecitabine : 650 mg/m2 bid, orally, d1-21, every 3 weeks as a cycle for 17 cycles after concurrent chemoradiotherapy
223703741|NCT06557824|OTHER|speleotherapeutic intervention|In the study, medical records of 415 Czech children diagnosed with bronchial asthma who took part in speleotherapeutic intervention between January 2022 and October 2023 were analysed.
223703742|NCT05123196|DRUG|MT-8554|Oral Capsule
223703743|NCT05123196|DRUG|Placebo|Oral Capsule
223788153|NCT03955601|DRUG|Haploidentical HSCT using TBI free regimen, ''ATG'' with ''Post transplant cyclophosphamide''|''Busulphan'' will be used in place of ''TBI'' in equivalent myelotoxic dose to facilitate engraftment , ''ATG'' will be used to reduce GVHD and facilitate engraftment while ''combine PBSC'' and/OR ''Bone marrow harvest'' will be used
223788154|NCT03618238|DRUG|Anlotinib|12 mg daily for continus 14 days every 21 days
223788155|NCT04857268|DEVICE|wearable continuous ECG monitoring patch, ATP-C120|"ATP-C120 is a novel, single-lead ECG monitoring device which can continuously monitor the ECG signal as long as 14 days (11 days if the device is connected to the smartphone via Bluetooth) when attached to skin adjacent to the heart of patients. It weighs about 8.3 g, with a size of 84 × 39 × 8.3 mm.~When the device is attached to the patient, several predefined methods were utilized to prevent the occurrence of noise or signal loss. First, the skin was cleansed and disinfected using a 70% ethanol solution. Skin hair was removed if needed. Then the protection film was removed from the patient-side surface of the device. The device is placed at the left 3rd intercostal space 45 degrees tilted toward the inside."
223788156|NCT01766557|OTHER|Semi-controlled nutritional intervention with fish protein diet|After a controlled NCEP-based diet for 3 months, women are assigned to a cod fillet diet. At the end of this first 3 months experimental period, participants return to their NCEP-based diet for a wash-out period of 3 months. Then, each group receive the other diet for an additional 3 months period. The fish protein intake come from cod fillets and correspond to 50% of total protein, the remaining dietary proteins being from BPVEM (20%) and vegetable (30%). Lunches incorporating cod fillets are prepared by professional dietitians, provided two time per week, and are self-consumed. Participants make their breakfasts and dinners using foods from a pre-approved list. Alcohol is strictly prohibited during all periods.
223788157|NCT01766557|OTHER|Semi-controlled intervention with other animal proteins|Prior to experimental period, participants follow a controlled NCEP-based diet for 3 months. Then women are assigned to a diet containing beef, pork, veal, eggs, milk and milk products. At the end of this first 3 months experimental period, participants return to their NCEP-based diet for a wash-out period of 3 months. The two diets are isoenergetic. The protein intake from BPVEM correspond to 70% of total protein, other dietary proteins are from vegetable (30%) origin. Lunches incorporating animal proteins are prepared by professional dietitians, provided two time per week, and are self-consumed. Participants make their breakfasts and dinners using foods from a pre-approved list. The content in n-3 fatty acids is adjusted to provide equivalent amounts of n-3 fatty acids then in the cod protein diet. Alcohol is strictly prohibited during all periods.
223788158|NCT06831071|DRUG|Pimonidazole|Drug: Pimonidazole Pimonidazole is not used with therapeutic intent, and has a non-hazardous designation. It has been widely used for in vivo evaluation of intratumor hypoxia, and patients will take PO pimonidazole before the scheduled biopsy. Patients receive an oral dose of pimonidazole, a safe chemical tracer up to 24 hours prior to biopsy. Pimonidazole allows for true hypoxia staining; pimonidazole binds hypoxic proteins covalently, creating an antigen that facilitates the imaging, flow cytometry, and scRNA-seq experiments proposed. Pimonidazole has been previously used in patients and is safe and well tolerated, without anticipated adverse events.
223788159|NCT01085851|DRUG|Dexchlorpheniramine 1% lotion|Small amount applied over the lesion twice a day for 7 days
223788160|NCT01085851|DRUG|Dexchlorpheniramine 1% cream|Small amount applied over the lesion twice a day for 7 days
223788161|NCT02156674|DRUG|Naglazyme®|1 mg per kg of body weight administered once weekly as an intravenous infusion
223788162|NCT04483050|DEVICE|Hip protection orthosis|Experimental group would wear hip protection orthosis over 12 hours a day for 1 year.
223788163|NCT04232423|DRUG|Olanzapine 10 Mg ORAL TABLET|"* Olanzapine 10 mg orally, ondansetron 8 mg intravenously, and dexamethazone 8 mg intravenously 30 minutes before chemotherapeutic administration (day 1)~* Olanzapine 10 mg orally daily and dexamethazone 8 mg orally daily on day 2, 3, 4"
223788164|NCT04232423|DRUG|Olanzapine 5 Mg ORAL TABLET|"* Olanzapine 5 mg orally, ondansetron 8 mg intravenously, and dexamethazone 8 mg intravenously 30 minutes before chemotherapeutic administration (day 1)~* Olanzapine 5 mg orally daily and dexamethazone 8 mg orally daily on day 2, 3, 4"
223788165|NCT04232423|DRUG|Placebo ORAL TABLET|"* Placebo 1 tab orally, ondansetron 8 mg intravenously, and dexamethazone 8 mg intravenously 30 minutes before chemotherapeutic administration (day 1)~* Placebo 1 tab orally daily and dexamethazone 8 mg orally daily on day 2, 3, 4"
223788166|NCT02265562|DRUG|Misoprostol|60 minutes before the surgery 400 μg of misoprostol (2 tablets of 200 μg) inserted rectally
223788167|NCT02265562|DRUG|Placebo|60 minutes before the surgery 2 tablet of placebo inserted rectally
223788168|NCT02263651|PROCEDURE|Quilting suture without drainage|"In an attempt to obliterate the dead space, the skin flaps are sutured to the underlying pectoralis major with multiple parallel rows of 0/0 vicryl (or equivalent). Running sutures at periodic intervals (\<2cm) are placed from the skin flaps to the underlying muscle. Minor dimpling is considered acceptable and is expected to resolve. If severe dimpling is observed, stitches are removed and replaced.~Efficiency of quilting suture relies on a rigorous repartition of the sutures with a special attention taken to the obliteration of the largest potential dead spaces and the empty axillary apex.~The skin edges are sutured as stated before for the control group. Closed suction will not be used for draining the pectoral area."
223788169|NCT02263651|PROCEDURE|Conventional closure with drainage|"The skin flaps are not fixed subcutaneously but sutured at the edges, a closed suction drain is inserted under the flaps in the dead space created by the dissection at the pectoral area. The drain is stitched to the skin.~The skin is closed in two layers with absorbable sutures, a deep layer of 2.0 or 3.0 vicryl sutures or equivalent, and a subcuticular closure with absorbable 3.0 or 4.0 Monocryl sutures or equivalent."
223788170|NCT02598492|OTHER|arterial blood gas|Just record clinical lab data
223703744|NCT02526446|BEHAVIORAL|Self-administered acupressure|"The intervention consists of a total of 28 hours over a period of 8 weeks:~i) Individual learning and practice: The training session will be one-on-one provided twice a week for two consecutive weeks (5 hours) in the participant's home.~ii) Self-practice at home: From 3rd to 8th week, participant will engage in self-administered acupressure at home for 15 minutes twice a day for 6 weeks (21 hours).~iii) Home follow-up: During the 3rd and 4th week (i.e. after the 2-week training session), a 1-hour home visit will be conducted for reinforcement of learning and self-practice by the same team of trainers once a week for 2 weeks (2 hours)."
223703745|NCT02526446|OTHER|wait-list control|The control group will receive a wait-list control condition (the same self-administered acupressure intervention but after the intervention group has completed the treatment condition).
223703746|NCT01180101|BEHAVIORAL|Diet and exercise|This group will follow a hypocaloric diet and supervised exercise training for 12 weeks.
223703747|NCT01180101|PROCEDURE|Bariatric Surgery|Patients will undergo bariatric surgery
223703748|NCT05379777|DRUG|Remimazolam|Remimazolam The starting dose of remimazolam is 1 mg/kg/hr. If sedation does not proceed successfully, increase the infusion rate by 0.2 mg/kg/hr in the next patient. (However, if the infusion rate is less than 0.6mg/kg/hr, the dose is increased by 0.1mg/kg/hr.) If sedation has progressed successfully until the end of surgery, the next patient will use the same dose with a probability of 0.89 or 0.11 It is reduced by 0.2 mg/kg/hr with a probability of (However, if the infusion rate is 0.6mg/kg/hr or less, reduce it by 0.1mg/kg/hr.)
223703749|NCT00066729|BIOLOGICAL|NY-ESO-1 peptide vaccine|NY-ESO-1b peptide 100 μg mixed with 0.5 mL of Montanide® ISA-51
223703750|NCT04348279|DEVICE|propylene mesh|propylene mesh as a palatal stent for palatal wound
223703751|NCT00968890|BIOLOGICAL|Pandemrix (Influenza vaccine GSK2340272A)|Intramuscular injection, 2 doses
223703752|NCT00968890|BIOLOGICAL|Fluarix™|Intramuscular injection, 1 dose
223703753|NCT00968890|BIOLOGICAL|Placebo|Intramuscular injection, 1 dose
223703754|NCT02925832|PROCEDURE|Deep Topical Fornix Nerve block anesthesia|DTFNB would be performed using two sponges (2x3mm) soaked with either 0.5% bupivacaine or 0.75% ropivacaine, applied deep in the conjunctival fornices after anaesthetising the conjunctiva with proparacaine local anaesthetic drops. The sponges are to be removed after 15 minutes.
223703755|NCT02925832|DRUG|Ropivacaine|0.75% ropivacaine soaked sponges
223703756|NCT02925832|DRUG|Bupivacaine|0.5% bupivacaine soaked sponges
223703757|NCT02925832|DRUG|Proparacaine|For anaesthetising conjunctiva
223703758|NCT05668429|DRUG|Ibrexafungerp|carbon-14 (\[14\^C\])-Ibrexafungerp
223703759|NCT04046484|DRUG|Normal Saline along with standard treatment|The arm is for active comparison for PMZ-1620 (sovateltide), an endothelin-B receptor agonist. PMZ-1620 has the potential to be a first-in-class neuronal progenitor cell therapeutics that is likely to promote quicker recovery and improve neurological outcome in cerebral ischemic stroke patients. Normal saline (vehicle) with standard treatment will be provided.
223703760|NCT04046484|DRUG|PMZ-1620 along with standard treatment|PMZ-1620 (sovateltide) is an endothelin-B receptor agonist. PMZ-1620 has the potential to be a first-in-class neuronal progenitor cell therapeutics that is likely to promote quicker recovery and improve neurological outcome in cerebral ischemic stroke patients.
223703761|NCT00392080|DRUG|CJ-023,423|75 mg BID
223703762|NCT00392080|DRUG|placebo|placebo
223703763|NCT00392080|DRUG|naproxen|naproxen
223703764|NCT03088371|DRUG|Bupivacaine 0.25%|For psoas sciatic block.
223703765|NCT03088371|OTHER|Pajunk Needle|For local anaesthesia application in psoas sciatic block
223703766|NCT03088371|OTHER|Portex combined spinal epidural kit|For combined spinal epidural anaesthesia
223703767|NCT03088371|DRUG|Lidocaine 1%|For psoas sciatic block.
223703768|NCT03088371|DRUG|Bupivacaine 0.5%|For spinal anaesthesia in combined spinal epidural anaesthesia.
223703769|NCT03088371|DRUG|Lidocaine 2 %|For psoas sciatic block in the post-operative period
223703770|NCT03088371|DRUG|Bupivacaine 0.125 %|For combined spinal epidural in the post-operative period.
223703771|NCT05038943|DEVICE|Paragonix SherpaPak Cardiac Transport System|Transportation of cardiac allografts in a device maintaining constant optimal temperature to minimize freezing tissue injury
223703772|NCT00287365|DRUG|ozone|2 hour exposure to 0.4 ppm ozone
223703773|NCT06177522|DRUG|Adebrelimab|1200mg，i.v. , q3w
223703774|NCT06177522|DRUG|albumin-bound paclitaxel|125 mg/m2, i.v.,d1,d8, q3w
223703775|NCT06177522|DRUG|Gemcitabine|1.0 g/m2, i.v.,d1, d8, q3w
223703776|NCT02000180|BEHAVIORAL|Progressive Group|
223703777|NCT02298023|BIOLOGICAL|allogenic adipose stem cell injection|Intervention will be done with stem cell injection, 0.5cc (Total: 10 million cells), fibrin glue injection 0.5cc and range of motion exercise.
223703778|NCT02298023|BIOLOGICAL|fibrin glue/normal saline injection|Total 1cc of fibin glue and normal saline mixture injection and range of motion exercise
223703779|NCT02298023|BIOLOGICAL|normal saline injection|Total 1cc of normal saline injection and range of motion exercise
223703780|NCT03047707|DIAGNOSTIC_TEST|S-Shearwave and TE|S-Shearwave elastography and Transient elastography (TE) are performed to evaluate hepatic stiffness.
223703781|NCT02642302|BEHAVIORAL|HIIT With 60 sec Rest|30 sessions of High intensity interval training (all out) with 30 seconds of stimulous with 60 seconds rest on VO2Max and aerobic/ anaerobic performance
223703782|NCT02642302|BEHAVIORAL|HIIT With120 sec Rest|30 sessions of High intensity interval training (all out) with 30 seconds of stimulous with 120 seconds rest on VO2Max and aerobic/ anaerobic performance
223703783|NCT02642302|BEHAVIORAL|Control|Continuous exercise at 50-55% VO2Max with similar total work of interval training
223703784|NCT04118842|DRUG|Savolitinib|Patients will receive a single dose on Study Day 1 and Study Day 20. Savolitinib will be administrated after a high fat, high calorie breakfast to reduce the risk of adverse events.
223788171|NCT01192906|DRUG|Placebo|Oral doses, once a day for 52 weeks
223788172|NCT01192906|DRUG|bitopertin [RO4917838]|Oral dose level 1, once a day for 52 weeks
223788173|NCT01192906|DRUG|bitopertin [RO4917838]|Oral dose level 2, once a day for 52 weeks
223788174|NCT05164159|DRUG|propofol group|During induction, the propofol group starts the effect site concentration at 4.0 ng/ml with TCI and adjusts it to around 3.0 \~ 4.0 ng/ml after intubation to maintain an appropriate EEG-based depth of anesthesia.
223788175|NCT05164159|DRUG|remimazolam group|In the remimazolam group, start remimazolam at 6 mg/kg/hr and adjust it to 1 mg/kg/hr after loss of consciousness to maintain an appropriate EEG-based depth of anesthesia.
223788176|NCT03261518|PROCEDURE|inferior vena cava ultrasound|Place the patient in the supine position. The degree of elevation of the head of the bed has not been shown to make a significant difference in measurements. The diameter of the IVC for calculation of the caval index should be measured 2 cm from where it enters the right atrium .An alternative way to visualize respiratory variation is to use M-mode, with the beam overlying the IVC 2 cm from the right atrium.The inspiratory and expiratory diameter can then be measured on the M-mode image, at the smallest and largest locations, respectively.
223788177|NCT00896168|DRUG|Infliximab|Infliximab 3 mg per kg intravenous infusion at Week 0, 2, 6, 14 and 22.
223788178|NCT00896168|DRUG|Methotrexate|MTX stable dose (7.5 to 20 mg/week equal to the dose used before participation in the study) for 22 weeks.
223788179|NCT00563108|DRUG|Basiliximab|
223788180|NCT00563108|DRUG|Placebo|
223788181|NCT01560390|DRUG|Rémifentamil + KETAMINE|All consecutive mechanically ventilated patients admitted in the ICU will be randomized to receive an infusion of 0.15 mg/kg/h of kétamine or placebo. Nurses and physicians will be blinded of the allocation arm. The infusion of ketamine will be stopped as soon as remifentanil will be discontinued by the physician.
223788182|NCT01560390|DRUG|ketamine|to evaluate the impact of ketamine associated to an opioid for sedation of mechanically ventilated critically ill patients versus placebo. Sedation will be drive by nurses according to an algorithm. The investigators will evaluate the quantity of opioates used in each arm and the safety of ketamine.
223788183|NCT02241967|DEVICE|4 Real sessions of Transcranial Direct Current Stimulation|Stimulation of brain areas associated with pain perception using low amplitude direct current of 2mA delivered by electrodes attached to the scalp.
223788184|NCT02241967|DEVICE|2 Real Sessions of Transcranial Direct Current Stimulation|Stimulation of brain areas associated with pain perception using low amplitude direct current of 2mA delivered by electrodes attached to the scalp. 2 real sessions of tDCS and 2 sham.
223788185|NCT02241967|DEVICE|1 Real Session of Transcranial Direct Current Stimulation|Stimulation of brain areas associated with pain perception using low amplitude direct current of 2mA delivered by electrodes attached to the scalp. 1 real sessions of tDCS and 3 sham.
223788186|NCT02241967|DEVICE|Sham Transcranial Direct Current Stimulation|Four sessions of sham tDCS; control intervention.
223788187|NCT05211765|DIAGNOSTIC_TEST|Superior vena cava transthoracic evaluation|The superior vena cava will be observed with a cardiac ultrasound machine, its diameter in different respiratory phases evaluated and compared with fluid response.
223788188|NCT05253625|OTHER|Listening to a recorded lullaby.|A lullaby will be played from the MP4 player on the outer foot of an empty incubator, and a decibel meter (dB) will be placed in the empty incubator, so that the maximum level of the decibel meter does not exceed 50-60 dB (45-65 dB according to APA). ) (American Academy of Pediatrics. ACOG.2007) (Guidelines for Pediatrics Care. 7th edition) sound adjustment will be made. The lullaby with the mother's voice (first arm newborn mothers) adn with an unfamiliar female voice (second arm newborns) will be recorded in MP4 beforehand. The lullabies of groups A and B are lullabies performed in approximately 4 minutes and will be played repeatedly for the specified periods.
223788189|NCT04326543|DIAGNOSTIC_TEST|Swanson, Noolan and Phelham - IV edition (SNAP-IV); Conners' Parent Rating Scales (CPRS)|"* Ratings on the Swanson, Nolan and Pelham Evaluation Scale - IV (Bussing et al., 2008), were assessed during baseline visit for participants at the time of research assessment, to exclude the presence of ADHD symptoms in the healthy subjects. This scale is composed of 26 items for ADHD symptoms and ODD and was administered at baseline and at follow-up visit.~* Temperament assessment: we used the Mary Rothbart's Temperament Questionnaire, a caregivers' report measure designed to provide a detailed assessment of temperament.~* ADHD Rating scales: the Long Version of Conners' Parent Rating Scale (Conners et al., 1998) was used to quantify ADHD comorbidity symptoms, as ODD and Anxiety traits, in the children and adolescents with ADHD.~* Salivary cortisol: Sampling was performed during one ordinary weekday between 7 and 8 o'clock, within 60' after nocturnal awakening."
223788190|NCT05556863|DRUG|ELA026|Single dose of ELA026
223788191|NCT05556863|DRUG|ELA026|Multiple doses of ELA026
223788192|NCT01021969|OTHER|Fructose|Subjects consume different amounts of fructose, glucose and sucrose in a crossover design
223788193|NCT03008148|RADIATION|CCRT|CCRT Phase: Radiation(60 Gy in 2 Gy/fx) + daily Temozolomide (75 mg/m²/day for 6 weeks).
223788194|NCT03008148|DRUG|Temozolomide|Temozolomide 150-200 mg/m² Day 1-5 of 28-Day for a maximum of 6 cycles.
223788195|NCT03008148|DRUG|Siroquine|"1. Chemotherapy Phase: Temozolomide 150-200 mg/m² Day 1-5 of 28-Day for a maximum of 6 cycles + Daily JP001(2 tablets once a day) for 24 weeks (4 weeks for each cycle).~2. Maintenance Phase: JP001(2 tablets once a day) until disease progression confirmed."
223788196|NCT02031887|DIETARY_SUPPLEMENT|formula with synbiotics|
223788197|NCT02031887|DIETARY_SUPPLEMENT|formula without synbiotics|
223788198|NCT00381966|DEVICE|robotic placement device|this device is a robotic arm that utilizes a template as a guidance system to precisely inplant radioactive brachytherapy seeds directly to the prostate.
223788199|NCT05134012|DRUG|[O-15]-Water PET Myocardial Perfusion Imaging (MPI)|\[15-O\]-H2O injection is a novel PET imaging agent labeled with the radioisotope \[15-O\] administered as an intravenous (IV) injection. Participants will receive \[15-O\]-H2O treatment twice as a part of a single day imaging session. All participants will receive two IV boluses of \[15-O\]-H2O injection in a peripheral vein; one at rest and one during pharmacological stress.
223788200|NCT04988854|BEHAVIORAL|Facial expression video|Children are randomly allocated to one of three conditions: positive, neutral or no-food control, where they will watch either a positive, neutral, or no-food control video.
223788201|NCT04517396|OTHER|Fenofibrate/fenofibric acid|The randomized intervention will be fenofibrate (Tricor) at a dose of 145 mg/d or dose-equivalent preparation of fenofibrate or fenofibric acid, for 10 days. In all cases, appropriate dose reductions will be implemented for patients with chronic kidney disease as per the approved preparation label. The intended duration of randomized treatment will be for 10 days.
223788202|NCT04517396|OTHER|Placebo|The control intervention will be a placebo, for 10 days.
223788203|NCT04517396|OTHER|Usual care|All participants will otherwise receive usual medical care
223788204|NCT03724643|OTHER|Protocolized wean|Respiratory therapist determined extubation readiness based on: patent and protected airway; adequate secretion clearance; suction requirement ≤ every 2 hours; FiO2 \< 50% and PEEP = 5; and hemodynamic stability without circulatory support. The SBT included CPAP = 5 mmHg at FiO2 ≤ 0.4. Patients were assessed after 3-minutes for appropriateness to continue (SaO2 ≥ 92%; no arrhythmia; RSBI \< 105 breaths/min/L). Respiratory distress signs included RR \> 30 breaths/min, SaO2\< 90%, HR \> 140 beats/min, or a sustained change in HR of \>20%, systolic BP \>200 mmHg or \<80 mmHg, or agitation, anxiety, or diaphoresis without other cause. The SBT lasted 120 min in accordance with prior studies. Upon SBT completion, the RSBI was re-measured and an ABG was obtained.
223788205|NCT02002403|DRUG|Danazol|
223788206|NCT03283540|PROCEDURE|TaTME|Low anterior resection of the rectum entails a sharp dissection circumferentially around the mesorectum in an avascular plane between the visceral and parietal layers of the endopelvic fascia in what is known as Total Mesorectal Excision. This dissection can be achieved transanally starting down in the pelvis and going up in what is known as Transanal Total Mesorectal Excision
223788207|NCT03283540|PROCEDURE|TME|Low anterior resection of the rectum entails a sharp dissection circumferentially around the mesorectum in an avascular plane between the visceral and parietal layers of the endopelvic fascia in what is known as Total Mesorectal Excision. This surgery can also be done via an up-to-down approach beginning high in the abdomen and going low in the pelvis to achieve dissection around the mesorectum.
223788208|NCT06963164|OTHER|Helping Hand - Joint Protection Program|"Joint protection refers to a set of techniques and strategies that help reduce stress on the joints, manage pain, and prevent further joint damage. These techniques are particularly important for people with hand arthritis, as the small joints in the hands are often affected, leading to pain, stiffness, and difficulty performing daily tasks. Key principles of joint protection include:~1. Using larger, stronger joints whenever possible (e.g., using the forearm instead of the fingers to push open a door).~2. Reducing strain by spreading the load across multiple joints (e.g., carrying items with two hands instead of one).~3. Avoid tight gripping or pinching motions that can overstrain the joints.~4. Incorporating assistive devices to reduce effort during tasks (e.g., jar openers or ergonomic tools).~5. Pacing and prioritizing activities to avoid overuse of the joints and allow for adequate rest"
223788209|NCT02274714|OTHER|Questionnaire Only|Subjects will have an interview with a study coordinator to fill out questionnaires for the study
223788210|NCT00787657|DRUG|Interferon beta-1b (Betaseron, BAY86-5046)|Patients after first clinical events suggestive of MS (according to SMPC) and patients with RRMS within the first two years of diagnosis
223788211|NCT04088552|OTHER|"Go4Life-Physical Activity/Exercise Program Workout to Go 5"|"The Go4Life-Physical Activity/Exercise Program Workout to Go 5 Program is an exercise regimen provided to participants. Participants will be provided a booklet with exercise routines that requires minimal equipment and can be performed anywhere for approximately 30 minutes per session. Recommendation on staying active by increasing daily steps through walking will also be recommended as part of the regimen."
223703785|NCT04118842|DRUG|Rifampicin|Patients will receive Rifampicin once daily on Study Day 15, 16, 17, 18, 19, 20 and 21. Rifampicin will be administered 1 hour before breakfast.
223703786|NCT01928173|BEHAVIORAL|Abbreviated cognitive behavioral therapy|see arm description
223703787|NCT01928173|BEHAVIORAL|Sleep education/sleep hygiene|see arm description
223703788|NCT02552992|BEHAVIORAL|Yoga|
223703789|NCT02552992|BEHAVIORAL|Self-Directed Mind-Body Program|
223703790|NCT01728350|BEHAVIORAL|HOPE - Helping Others through Purpose and Engagement|
223703791|NCT00325273|DIETARY_SUPPLEMENT|Lactobacillus rhamnosus GG|use Lactobacillus rhamnosus GG in pregnant women from gestational 26 weeks till newborn 6 months
223703792|NCT04280835|BEHAVIORAL|Group Psychoeducation that Focused on Social Skill Development|Psychoeducation Program consists of; Preparatory Session, Recognition of Schizophrenia, Evaluating the Treatment of Schizophrenia, Stress and Coping with Stress, Improving Communication Skills, Improving Problem-solving Skills, Improving Interpersonal relationships and social activities and Evaluating Session.The sessions were held in the form of PowerPoint presentations. In the psychoeducation program, lecture, question-answer, homework, sharing experiences, group discussion, repetition, video presentation, summarization, reinforcer, and role-playing techniques were used. The day before each session, patients were phoned and reminded of the time of the session. At the end of each session, the content of the subject is given as hard copy and cookies, tea and coffee were served.
223703793|NCT04354103|DRUG|Atomoxetine|Atomoxetine
223703794|NCT05244993|DRUG|AK105|AK105: 100mg per bottle, 200mg IV Day 1, cycled every 21 days
223703795|NCT05244993|DRUG|Anlotinib hydrochloride|Anlotinib Hydrochloride: 12mg per capsule, 12 mg PO once daily on Days 1-14, cycled every 21 days
223703796|NCT05244993|DRUG|Albumin Paclitaxel|Albumin paclitaxel: 100mg per bottle, 125mg/m2 IV Days 1, 8, cycled every 21 days
223703797|NCT06306820|OTHER|Fixed PEEP|Patients will receive a fixed positive end-expiratory pressure (PEEP) of 5 cmH2O throughout the surgical procedure.
223703798|NCT06306820|OTHER|Ultrasound-guided lung recruitment|Patients will receive ultrasound-guided lung before pneumoperitoneum, after pneumoperitoneum then once an hour, until the end of surgery. Alveolar recruitment will be conducted the same as that for the conventional manoeuvre with a simultaneous continuous ultrasound assessment if atalectasis is detected until no collapsed areas are visualized. When the collapsed lung areas are absent on the sonogram, positive end-expiratory pressure (PEEP) can no longer increase at this point. Subsequently, the pressure will be maintained for approximately 10 breaths.
223703799|NCT06306820|OTHER|Individualized PEEP|Patients will receive individualized positive end-expiratory pressure (PEEP). After the first recruitment Maneuvere (RM), titration of PEEP will be performed by setting the initial PEEP to 5 cm H2O, then increasing PEEP according to the gradient of 2 cmH2O every 3 min, calculating static compliance (Cstat) according to the formula: \[Cstat = VT/Pplat - PEEP\] (Pplat = plateau pressure), then gradually increasing PEEP, until the calculated Cstat shows a downward trend, the we set its previous PEEP (corresponding to PEEP for high Cstat) as the optimal PEEP for this patient. The highest PEEP is limited to 15 cmH2O.
223703800|NCT01967173|DRUG|Flovent Diskus® 100 mcg|Flovent is an ICS
223703801|NCT01967173|DRUG|Flovent Diskus® 250 mcg|Flovent is an ICS
223703802|NCT01967173|DRUG|Flovent Diskus® 500 mcg|Flovent is an ICS
223703803|NCT01967173|DRUG|Advair Diskus® 100/50 mcg|Advair is an ICS/LABA combination
223703804|NCT01967173|DRUG|Advair Diskus® 250/50 mcg|Advair is an ICS/LABA combination
223703805|NCT02020577|DRUG|Cetuximab( erbitux®)|once per week
223703806|NCT02020577|DRUG|Afatinib|once per day
223703807|NCT01910961|PROCEDURE|limb RIPC|LRIP consisted of three cycles of left upper limb ischemia induced by inflating a blood pressure cuff on the left upper arm to 200mmHg, with an intervening 5 minutes of reperfusion, during which time the cuff was deflated
223703808|NCT04539353|OTHER|Heart Rate Variability|Heart Rate Variability will be measured with a Polar device.
223703809|NCT04539353|OTHER|Pain intensity|Pain Intensity will be measured with a Numeric Rating Scale and Visual Analogue Scale
223703810|NCT04036019|BIOLOGICAL|CD20-directed CAR-T cells with CliniMACS Prodigy® system|Autologous 2nd generation CD20-directed CAR-T cells, single infusion intravenously
223703811|NCT00061477|DRUG|Pemetrexed|
223703812|NCT00061477|DRUG|Gemcitabine|
223788212|NCT04088552|BEHAVIORAL|ActuaYa Educational Sessions|The ActuaYa Educational Sessions will be delivered by a facilitator in 3 separate sessions with each session lasting 2.5 hours for a total of 7.5 hours administered for the study duration. Each session will be conducted in separate groups of 6-10 participants. Session 1 will discuss the impact of chronic disease in the older Hispanic community. Session 2 will discuss the communication and negotiation with the family and partner. Session 3 will discuss saying goodbye and having a plan for a healthy lifestyle.
223788213|NCT03042065|DEVICE|vibrating Mesh nebulizer|Receive in the same aerosol solution 5 mg of Salbutamol (Ventolin, Glaxo, 5 mg / ml solution for nebulization) mixed with 0.5 mg Ipratropium Bromide (0.25 mg / ml) by nebulization every 20 min For 3 doses during the first hour of treatment, using vibrating Mesh nebulizer
223788214|NCT03042065|DEVICE|jet nebulizer|Receive in the same aerosol solution 5 mg of Salbutamol (Ventolin, Glaxo, 5 mg / ml solution for nebulization) mixed with 0.5 mg Ipratropium Bromide (0.25 mg / ml) by nebulization every 20 min For 3 doses during the first hour of treatment, using jet nebulizer
223788215|NCT06518421|BEHAVIORAL|Neuropsychological assessments|"* Pain questionnaires such as Numerical Pain Rating Scale is one of the most widely used multidimensional pain scales to assesses a person's pain based on the words they use to describe their pain.~* Battery of Cognitive questionnaires = The cognitive test battery was designed to assess key cognitive abilities including attention, concentration, verbal learning and memory, verbal fluency, working memory and executive function as well as global cognitive functioning and fear and anxiety~* Mnemonic Simulation Test and Rey Auditory Verbal Learning Test are the neuropsychological assessments designed to evaluate recognition and verbal memory, respectively. Both tasks have been shown to be very sensitive to hippocampal engagement and damage.~* Memory-recall interview is an interview for the interviewees to recall the event from different perspectives, such as from the preadmission date, 2-week post- and 6-month post-surgical date. This supports the memory retrieval process."
223788216|NCT06518421|DIAGNOSTIC_TEST|MR Imaging|Magnetic Resonance Imaging is a noninvasive medical imaging test that produces detailed images of almost every internal structure in the human body, including the organs, bones, muscles and blood vessels. MRI scanners create images of the body using a large magnet and radio waves.
223788217|NCT05566041|DRUG|RRx-001 + eLOOP Device|"RRx-001 is a small molecule anticancer drug which is mixed with patient's own blood using the eLOOP device~Drug: Cisplatin/carboplatin plus etoposide Standard of care platinum doublet chemotherapy"
223788218|NCT05566041|DRUG|Cisplatin/carboplatin plus etoposide|Standard of care platinum doublet chemotherapy
223788219|NCT05736341|DRUG|Remimazolam besylate|After delivery, patients in this group receives 5mg of remimazolam to induce sedation during the remaining procedures of Cesarean section.
223788220|NCT05736341|DRUG|Midazolam|After delivery, patients in this group receives 2mg of midazolam to induce sedation during the remaining procedures of Cesarean section.
223788221|NCT06233513|BEHAVIORAL|Exp 3 Speaking Task|Participant will sit in front of a computer screen in a quiet room and to produce speech based on what is on the screen. Participant may see real words or nonsense words to read. Investigators may play sounds through headphones and ask the participant to repeat them. Participant speech will be recorded by a microphone. This task takes about one hour to complete.
223788222|NCT05356052|COMBINATION_PRODUCT|INOpulse|Patients will be treated by means of an INOpulse device using an INOpulse nasal cannula
223788223|NCT05917405|DRUG|Fludarabine|30 mg/m2/day IV fludarabine for 5 days (day-6 to day-2)
223788224|NCT05917405|DRUG|Busulfan|130 mg/m2/day IV busulfan once daily for 2 days (day -4 and -3)
223788225|NCT05917405|DRUG|ATG|Thymoglobuline®: 2.5 mg/Kg/day IV for 2 consecutive days (day -2 and -1)
223788226|NCT05917405|DRUG|Clofarabine|30 mg/m2/day IV clofarabine for 5 days (day-6 to day-2)
223703813|NCT03477136|DIAGNOSTIC_TEST|ELISA to evaluate serum and seminal vitamin D level|Serum and semen samples will be collected from all participant males and ELISA method used to evaluate the level of vitamin D in serum and semen
223703814|NCT02885207|BIOLOGICAL|Focal epilepsy of unknown cause|"Male or female 18-65 years presenting focal epilepsy on the following arguments:~* Crisis with clinical symptoms indicating focal seizure~* \& / Or crisis or critical focal inter-recorded EEG interpreted by a neurologist with expertise in the field of epilepsy.~From unknown cause:~* No evidence of injury (excluding temporal or hyperintensity of hippocampal sclerosis) on brain MRI with focus on regions of interest cuts.~* No discharge or generalized photosensitivity recorded over an extended interpreted by a neurologist with expertise in the field of epilepsy video-EEG.~* No argument for metabolic or neurodegenerative genetic epilepsy.~* Normal neurological examination. Epilepsy that started within a maximum period of 2 years prior to inclusion in the study (including vegetative symptoms of temporal focal seizures).~Without treatment by benzodiazepines or anti-epileptics first-line monotherapy (excluding benzodiazepines)."
223703815|NCT00646074|BEHAVIORAL|Self-Care Talk|6 conversational sessions
223703816|NCT00749060|OTHER|conventional treatment|with our without brace
223703817|NCT00749060|PROCEDURE|kyphoplasty with balloons|Balloon Kyphoplasty which consists of placing through a percutaneous posterior approach under radiological guidance, into the fractured vertebra a balloon which is inflated with fluid and creates a cavity. This may restore part of the vertebral height loss due to the fracture. In addition, after balloon deflation, polymethylmetacrylate cement is injected with low pressure into the created cavity.
223703818|NCT00749060|PROCEDURE|vertebroplasty|Vertebroplasty consisting in the percutaneous injection into the fractured vertebra of polymethylmetacrylate cement (the cement used to fix prosthesis in joint replacement) through a posterior route through the vertebral pedicles under radiological guidance
223788227|NCT02346383|DEVICE|preset program|Change to different present program using epidural and peripheral lead to cover pain
223788228|NCT03833999|DRUG|Ondansetron 8mg|ondansetron, a 5HT3 receptor antagonist used clinically in nausea and vomiting
223788229|NCT03833999|DIAGNOSTIC_TEST|abdominal MRI|serial MRIs on day 1 and day 3 of the study, at baseline and 2 hours apart 0-6 hours after meal ingestion on day 1 and 0-4 hours after the meal on day 3
223788230|NCT03833999|DRUG|Lactulose|Participants will receive 20mls lactulose twice daily for 48 hours prior to the third study day
223788231|NCT03833999|DRUG|Placebo oral capsule|overcoated placebo tablet, identical to the ondansetron
223788232|NCT04337710|PROCEDURE|Exclusive Enteral Nutrition|Mom's milk or donor milk at 60-80 ml/kg/day after randomization within the first 24 hours.
223788233|NCT04337710|PROCEDURE|Progressive Enteral Nutrition|Mom's milk or donor milk at 20-30 ml/kg/day after randomization within the first 24 hours.
223788234|NCT01944631|DEVICE|Placebo|Nasal spray saline
223788235|NCT01944631|DEVICE|Iota-Carrageenan|Nasal spray containing 1.20 g/l Iota-Carrageenan in saline
223788236|NCT05803226|BEHAVIORAL|Slow Art Plus|Slow Art Plus involved a full 90-minute engagement, one that is built upon the existing Slow Art programme with added layers of mindfulness and self-compassion practices, as well as a response art activity that fosters symbolic dialogue and an emotional aesthetic experience between participants and the selected artwork.
223788237|NCT02805569|DEVICE|articulating stylet|patient who intubated with articulating stylet
223788238|NCT02805569|DEVICE|conventional stylet|patient who intubated with conventional stylet
223788239|NCT04389762|DIETARY_SUPPLEMENT|daily ingestion of Lactobacillus plantarum PS128|daily ingestion of 60 billion colony forming unit (CFU) of Lactobacillus plantarum PS128 (30 billion CFU/capsule)
223788240|NCT01045629|OTHER|Consent form education|Randomly stratified schizophrenic patients group, some receive consent form education, the others not.
223788241|NCT03822533|OTHER|Physiotherapist as primary assessor|Physiotherapist diagnose and treat the patient.
223788242|NCT03822533|OTHER|Physician as primary assessor|Physician diagnose and treat the patient.
223788243|NCT02489500|DRUG|Bortezomib|"Conditioning Regimen:~Drug: Bortezomib: 1.0 mg/m2/dose D -6, D -3, D +1, D + 4 Drug: Melphalan: 70-100 mg/m2/dose D -2, D -1"
223788244|NCT02489500|DRUG|Melphalan|"Conditioning Regimen:~Drug: Melphalan: 70-100 mg/m2/dose D -2, D -1 Stem Cell Transplant: D 0"
223788245|NCT02489500|DRUG|Neupogen|granulocyte colony-stimulating factor (G-CSF) mobilization 16mcg/kg x 4 days
223788246|NCT02489500|PROCEDURE|Stem Cell Collection|collect at least 2.5 million cluster of differentiation 34 (CD34)+ stem cells
223788247|NCT02489500|PROCEDURE|Stem cell infusion|infusion of previously collected autologous stem cells
223788248|NCT05633784|OTHER|Teleassistance|Support the nursing case manager through a structured teleconsultation program (telephone and videoconference support at least once a week)
223788249|NCT05633784|OTHER|Teleconsultation|Cardiological and Diabetological teleconsultation at the beginning of the program and in case of need during the program.
223788250|NCT05633784|OTHER|Telerehabilitation|Support from a physiotherapist (if needed)
223788251|NCT05633784|OTHER|Telemonitoring|Telemonitoring of patient vital signs (eg single electrocardiographic trace) and delay steps
223788252|NCT05633784|OTHER|mHealth|The support of an App for recording and monitoring parameters: delay treatment, clinical parameters such as glycemia, blood pressure, HR, symptoms, etc.
223788253|NCT05633784|OTHER|telepsycology|Psychological support (if necessary)
223788254|NCT05633784|OTHER|Quality of life|Minnesota LIVING WITH HEART FAILURE® Questionnaire (MLHFQ), Short Form Survey (SF-12) Questionnaire and Diabetes Quality of Life (DQoL) questionnaire
223788255|NCT05633784|OTHER|Biochemistry evaluation|Glycemia, glycated haemoglobin, total cholesterol, HDL and LDL, triglycerides, creatinine, BUN, creatinine clearance, BNP
223788256|NCT05633784|OTHER|Clinical evaluation|6-minute-walking test, IMC, NYHA class, Ejection fraction
223788257|NCT05633784|OTHER|State of health of the patient|Severity Index and Comordbidity index
223788258|NCT04717596|OTHER|BC4Teens Care|Healthcare providers will be trained in contraceptive counseling and provision.
223788259|NCT06361147|OTHER|Psychoeducational program for ASD|6 psychoeducation trainings for Autism Spectrum Disorder
223788260|NCT06390098|DRUG|ASN51|Oral
223788261|NCT02796326|DEVICE|improved tracheal balloon dilatation|Treatment for laryngotracheal stenosis using a modified tracheal dilatation balloon
223788262|NCT03056846|DIETARY_SUPPLEMENT|Placebo|Placebo will be taken as a capsule twice daily for 6 weeks by subjects in the group receiving this supplement (group is unknown, double-blinded).
223788263|NCT03056846|DIETARY_SUPPLEMENT|Probiotic Combination|A capsule containing a mixture of Lactobacillus gasseri, Bifidobacterium bifidum, and Bifidobacterium longum (1.5 billion cells per capsule prior to expiration) will be taken twice daily for 6 weeks by subjects in the group receiving this supplement (group is unknown, double-blinded).
223788264|NCT03056846|DIETARY_SUPPLEMENT|Bifidobacterium bifidum|A capsule containing Bifidobacterium bifidum (1.5 billion cells per capsule prior to expiration) will be taken twice daily for 6 weeks by subjects in the group receiving this supplement (group is unknown, double-blinded).
223788265|NCT03056846|DIETARY_SUPPLEMENT|Bifidobacterium longum|A capsule containing Bifidobacterium bifidum (1.5 billion cells per capsule prior to expiration) will be taken twice daily for 6 weeks by subjects in the group receiving this supplement (group is unknown, double-blinded). Inactive ingredients include gelatin, potato starch, and silica.
223788266|NCT03210506|DRUG|Peginterferon Alfa-2a|patients untreated in immune-active phase were given subcutaneous injection of Peginterferon Alfa-2a with starting dose of 180 mg/weekly in experiment group.
223788267|NCT04879238|BEHAVIORAL|BEING|60 minute yoga session that blends mindfulness techniques
223788268|NCT05915728|DRUG|Gadoquatrane (BAY1747846)|0.04 mmol Gd/kg body weight, solution for intravenous injection, single dose
223788269|NCT05915728|DRUG|Gadobutrol|Approved standard of care macrocyclic GBCA, 0.1 mmol Gd/kg body weight, solution for intravenous injection, single dose
223788270|NCT05915728|DRUG|Gadoterate meglumine|Approved standard of care macrocyclic GBCA, 0.1 mmol Gd/kg body weight, solution for intravenous injection, single dose
223788271|NCT05915728|DRUG|Gadoteridol|Approved standard of care macrocyclic GBCA, 0.1 mmol Gd/kg body weight, solution for intravenous injection, single dose
223788272|NCT02460991|DEVICE|DEB-TACE|
223788273|NCT02460991|DRUG|Sorafenib|
223788274|NCT02360709|DEVICE|CRE8 sirolimus-eluting stent|The CRE8 stent system consists of a sirolimus eluting coronary stent firmly held on the distal end of a semicompliant balloon catheter. This stent is made of cobalt chromium alloy and is coated with a thin carbon film.The outer surface of the stent has dedicated grooves for containing the pharmaceutical formulation, which is composed of the drug sirolimus and a mixture of long chain fatty acids.
223788275|NCT04183933|OTHER|Pilates Exercise|Pilates exercises will be given for 6 weeks, 3 days in a week.
223788276|NCT04183933|OTHER|Combined Exercise|Combined exercise will be given for 6 weeks, 3 days in a week.
223788277|NCT01055743|PROCEDURE|Radical resection|Radical resection of hepatocellular carcinoma
223788278|NCT01055743|DRUG|Fluorouracil Implants|Implanted during the surgical treatment
223788279|NCT00934193|DRUG|Gabapentin|Treatment will consist of a 600 mg dose of gabapentin or placebo given preoperatively the night before surgery, based on a computer generated randomized assignment. The treatment group will continue to be medicated with gabapentin 300 mg twice daily for one month following surgery. Those not included in the treatment arm of the study will continue to take a placebo for the same duration. Follow-up will consist of a postoperative visit at approximately 48 hours and a one month clinical visit.
223788280|NCT00934193|DRUG|Placebo|Treatment will consist of a 600 mg dose of gabapentin or placebo given preoperatively the night before surgery, based on a computer generated randomized assignment. The treatment group will continue to be medicated with gabapentin 300 mg twice daily for one month following surgery. Those not included in the treatment arm of the study will continue to take a placebo for the same duration. Follow-up will consist of a postoperative visit at approximately 48 hours and a one month clinical visit.
223788281|NCT02073513|DEVICE|Kinesiotape plus thenar pressure (PPTG)|"In the kinesiotape plus thenar pressure (PPTG). Kinesiotape was applied to control the cortical thumb sign. In addition a piece of plastazote aiming to give thenar pressure was also applied.~The amount of pressure was regulated so that the child felt the pressure without being irritated and without restriction in grasping functions."
223788282|NCT02073513|DEVICE|Taping Group (TG)|In the taping group (TG) kinesiotape was applied to control the cortical thumb sign.
223788283|NCT03537924|DRUG|ACETAZOLAMIDE oral capsule|Administration of 1x125mg acetazolamide in the morning, 2x125mg in the evening, starting 24 hours before departure to 3'100m
223788284|NCT03537924|DRUG|Placebo oral capsule|Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3'100m
223788285|NCT03551652|DRUG|Pharmacokinetics of rocuronium induced neuromuscular block|Measurement of rocuronium induced neuromuscular block comparing patients aged \> 80 years with patients aged 18 to 50 years
223788286|NCT06281691|DIAGNOSTIC_TEST|Xpert® Bladder Cancer Detection Test|A urine sample is analyzed with the Xpert® Bladder Cancer Detection Test
223788287|NCT02194426|DRUG|MP0250|Intravenous application by infusion of MP0250 at up to six dose levels, every other week for up to 24 infusions.
223788288|NCT00085410|DRUG|bortezomib|Given IV
223788289|NCT05970029|BEHAVIORAL|Communication style|The verbal communication between the nurse and the patient at the time of analgesic administration
223788290|NCT04255160|DRUG|Estradiol (mylan or vivelle dot patch)|Transdermal estradiol (0.1mg/day patch) will be used by women for 7 days. Administration of the patch will follow the package guidelines to change the patch after 3-4 days of use.
223788291|NCT04255160|OTHER|Placebo|A placebo patch that is visually similar to the estradiol patch will be used for the group not receiving estradiol.
223788292|NCT00396604|DRUG|indacaterol maleate|
223788293|NCT00044382|DRUG|CC-5013|
223788294|NCT01391104|DRUG|Sildenafil|Sildenafil citrate is a phosphodiesterase type-5 inhibitor. Patients will be assigned to sildenafil (20 mg tid) or placebo per os for 28 days in a randomized, double-blind manner. After a four-week wash-out period, patients will then be crossed over to the alternate therapy for the next 28 days.
223788295|NCT01391104|DRUG|Sugar Pill|Patients will be assigned to sildenafil (20 mg tid) or placebo per os for 28 days in a randomized, double-blind manner. After a four-week wash-out period, patients will then be crossed over to the alternate therapy for the next 28 days.
223788296|NCT06535984|OTHER|White Noise|White Noise Group (n=30) The third researcher turned on white noise (rain sound; link: https://www.youtube.com/watch?v=rZeM-HZeneo) before the start of the eye examination and played it to the infants until the end of the examination.
223788297|NCT06535984|OTHER|Swaddling|Swaddling group (n=30) The third researcher swaddled each infant with its thin blanket. The swaddling involved bringing the infant's left hand close to the left buttock and wrapping it with the upper right end of the blanket. Similarly, she wrapped the baby's right hand with the upper left end of the blanket by bringing it closer to the right hip. She wrapped the baby's legs with the lower part of the blanket, ensuring that the baby's head could move freely.
223788298|NCT06535984|OTHER|White Noise+Swaddling|White Noise + Swaddling Group (n=30) The third researcher swaddled the infants in this group as described in the swaddling group and turned on the white noise (rain sound; link: https://www.youtube.com/watch?v=rZeM-HZeneo) before the examination started and played it to the infants until the examination was over.
223788299|NCT05418621|DRUG|Enamel Matrix Derivative application|in the test group, EMD (Emdogain FL®, Institute Straumann AG, Basel, Switzerland) will be applied with a dedicated syringe until overflowing from the pocket border, taking particular care in avoiding trauma to the tissues.
223788300|NCT05418621|OTHER|Saline application|in the control group, a lavage of sterile saline will be applied with a syringe with a thin blunt tip until overflowing from the pocket border, taking particular care in avoiding trauma to the tissues.
223788301|NCT01525290|DRUG|Alteplase|Intravenous tissue plasminogen activator (Alteplase) 0.9 mg/kg body-weight up to a maximum of 90 mg, 10% as bolus, 90% over 1 hour as infusion
223788302|NCT01525290|DRUG|Placebo|lyophilised powder to be reconstituted as solution indistinguishable from the active drug
223788303|NCT03058770|OTHER|Sensorimotor retraining|Subjects will receive education regarding sensation and sensory retraining; practice in detection and localization of touch and in discrimination of hardness, texture and temperature in sitting and standing with vision obscured; proprioception training; and practice of these sensations in functional activities.
223788304|NCT03058770|OTHER|Relaxation technique|Subjects will perform guided relaxation by using the Jacobson technique.
223788305|NCT02473952|DRUG|IGIV-C|IGIV-C: Immune Globulin Injection (Human), 10%, Caprylate/Chromatography Purified
223788306|NCT02473952|DRUG|Placebo|
223788307|NCT01889537|BEHAVIORAL|Virtual Reality|The patient will receive virtual reality during a burn care procedure
223788308|NCT00440765|DRUG|bortezomib|dose as determined (observational study) by treating physician
223788309|NCT00455195|BIOLOGICAL|alglucosidase alfa|IV infusion of 20 mg/kg; every other week (qow)
223788310|NCT04711265|DRUG|Quadrivalent HPV [Type 6, 11, 16 and 18] L1 Virus-Like Particle Vaccine|Intramuscular injection with 3 doses of QHPV
223788311|NCT02414893|PROCEDURE|Sleeve gastrectomy|Laparoscopic vertical gastrectomy as a bariatric procedure.
223788312|NCT06245785|PROCEDURE|transarterial chemoembolisation|Before TACE, hepatic arteriography was performed to evaluate the vascular anatomy and tumour vascularity. During TACE, a vascular catheter was selectively inserted into the tumour-feeding artery with an injection containing a mixture of doxorubicin (10-50 mg) and lipiodol (2-20 mL), followed by embolisation using gelatin sponge particles. TACE was repeated when residual viable tumours were confirmed or new lesions developed in patients with adequate liver function. Laboratory assessments were performed every four to six weeks. Radiological evaluation using contrast-enhanced computed tomography (CT) or magnetic resonance imaging (MRI) was recommended during weeks 4 and 8 after treatment and every 8 weeks thereafter. However, in clinical practice, the intensity of follow-up depends on an individual's baseline characteristics and response to the last treatment.
223788313|NCT05454293|OTHER|One Talk at a Time: Race|This intervention consists of short videos that include didactic modules and social modeling for having conversations with children about race, ethnicity, culture, and discrimination. The total intervention takes approximately 1.5-2 hours to complete online, and parents can move through the videos at their own pace.
223788314|NCT05454293|OTHER|One Talk at a Time: General|This intervention consists of short videos that include modules and handouts with tips for parent-child communication strategies for navigating difficult topics, such as dating and current events.
223788315|NCT02148250|DRUG|U-500 insulin, 100 syringe units|Subjects are randomized to receive 100 syringe units of U-500 insulin. Subjects will receive opposite treatment after 4-8 weeks.
223788316|NCT02148250|DRUG|U-500 insulin, 200 syringe units|Subjects are randomized to receive 200 syringe units of U-500 insulin. Subjects will receive opposite treatment after 4-8 weeks.
223788317|NCT00786357|BEHAVIORAL|NIOSH shiftwork booklet|weekly readings about coping with shiftwork
223788318|NCT00786357|BEHAVIORAL|Sleep Enhancement Training System|4 week program of readings and relaxation programs
223788319|NCT05540236|OTHER|auricular acupressure|The experimental group were given therapeutic intervention of single ear auricular pellet acupressure at the stomach(CO4), cardia(CO3), liver(CO12), occiput(AT3), shenmen(TF4) and subcortex(AT4) acupuncture points
223788320|NCT05540236|OTHER|sham auricular acupressure|The control group were given sham intervention of single ear auricular pellet acupressure at the knee(AH4) and thoracic vertebrae(AH11) acupuncture points
223788321|NCT01529957|DRUG|Nemonoxacin Malate Sodium Chloride|Nemonoxacin Malate Sodium Chloride,intravenous injection,once daily
223788322|NCT02563912|OTHER|Handbook|Resuscitation handbook who provides drug dosages for each weight for children. For example, at the page of 15 kg, it is written that the dosage of epinephrin is 1.5 cc of 1: 10 000.
223788323|NCT02563912|OTHER|Medication chart|Medication chart who provides drug dosages for each weight for children. For example,it is written that the dosage of epinephrin is 0.01 mg/kg.
223788324|NCT00591292|DRUG|indibulin|Dose escalation of indibulin given twice daily for up to 6 months
223788325|NCT05734482|BIOLOGICAL|Secukinumab|for subcutaneous injection only
223788326|NCT01019330|OTHER|Allen's test|The Allen's test checks to make sure that radial and ulnar arteries that supply blood to the hand are not blocked. A pulse oximeter is placed on the index finger of the hand. The subject is asked to make a fist for 10 seconds.At this time, pressure is applied over the ulnar and radial arteries as to occlude (block) both of them. The pulse oximeter reading will begin to fall. Radial arterial pressure is then released. If the artery is patent (working), the pulse oximeter reading will begin to rise.
223788327|NCT01019330|OTHER|Distal pulses|Practitioner will check that the dorsalis pedis and posterior tibialis are palpable.
223788328|NCT01186523|OTHER|Long Term Energy Balance|To see if there is a variance in weight loss and energy balance between men and women with similar energy expenditure over an extended period of time.
223788329|NCT02063789|DRUG|Human immunoglobulin intravenous|After GC5107A Intravenous injection, evaluate platelet increase
223788330|NCT00546728|DRUG|Exenatide|exenatide 10 mcg twice daily
223788331|NCT00546728|DRUG|Metformin|metformin 500 twice daily
223788332|NCT02637297|PROCEDURE|Hypnotherapy|Undergo hypnotherapy
223788333|NCT02637297|OTHER|Questionnaire Administration|Ancillary studies
223788334|NCT05164822|OTHER|Necrotizing Vasculitis|"Pain scale Diagnosis of necrotizing vasculitis and peripheral neuropathy, Clinical characteristics of the disease, Biological analysis, Treatment and evolution of the disease,~Questionnaires :~Neuropathy Impairment Score (NIS) sensitive sub-questionnaire that measures extremity sensitivity.~MRC (Medical Research Council), which evaluates three motor functions on each member.~RODS questionnaire on the relationship between your daily activities and your health.~BVAS (Birmingham Vasculitis Activity Score) disease activity questionnaire. VDI (Vasculitis Damage Index) questionnaire evaluates the sequelae of the disease.~Rankin Score modified to measure the degree of disability~Two tests will be performed:~EMG (electromyogram) to evaluate the electrical activity of the muscles, Walking Test of 10 meters which aims to measure the time taken to travel 10 meters."
223788335|NCT02370602|DRUG|TAK-063|TAK-063 tablets
223788336|NCT02370602|DRUG|[^11C]T-773|\[\^11C\]T-773 IV solution
223788337|NCT03269474|PROCEDURE|Experimental Group|Subjects with EB diagnosis
223788338|NCT00001601|PROCEDURE|Electrocardiogram|
223788339|NCT00001601|PROCEDURE|Biopsies|
223788340|NCT00001601|PROCEDURE|Diagnostic imaging|
223788341|NCT01326364|PROCEDURE|Stereotactic body radiotherapy|Standard of Care
223788342|NCT01326364|DRUG|Iodixanol|IV, calculated per patient
223788343|NCT01326364|DRUG|Iohexol|IV, Calculated per patient
223788344|NCT00237744|DEVICE|Robotics training for shoulder elbow.|training utilizing a robot to assist with movement practice
223788345|NCT00237744|DEVICE|Surface Functional Neuromuscular Stimulation|training utilizing FNS to assist with movement practice
223788346|NCT00237744|OTHER|whole arm motor learning|intervention utilizing motor learning training principles to perform part and whole task practice of meaningful everyday functional tasks.
223788347|NCT01863277|DRUG|Melatonin|
223788348|NCT01863277|DRUG|placebo|
223703819|NCT00853346|BEHAVIORAL|Cognitive Behavioral Therapy|12 weeks of Cognitive Behavioral Therapy designed for adults with Parkinson's Disease and comorbid Depression
223703820|NCT00853346|BEHAVIORAL|Cognitive Behavioral Therapy|12 weeks of Cognitive Behavioral Therapy designed for adults with Parkinson's Disease and comorbid Depression
223703821|NCT02663908|DRUG|Degarelix|
223703822|NCT02663908|DRUG|Leuprolide|
223703823|NCT00963131|DRUG|antioxidants tablets|vitamin A 6600 IU, vitamin C 400 mg, vitamin E 150 IU, riboflavin 10 mg, zinc 60 mg, copper 4 mg, selenium 40 mg, manganese 4 mg and lutein/zeaxanthin 4000 micrograms.
223703824|NCT03308786|DRUG|Recombinant Interleukin-2|Subcutaneous recombinant interleukin-2 (rIL2), 5 MIU twice daily for four consecutive days(cycle) every 8 weeks for 8 cycles
223703825|NCT02987556|DEVICE|Continuous Glucose Monitoring|Collection of glucose data
223703826|NCT02987556|DEVICE|External Insulin Pump|insulin delivery
223703827|NCT02987556|OTHER|telemdecine|Remote follow up by care health providers team
223703828|NCT02987556|DEVICE|The Diabeloop Software (Model predictive control)|Diabeloop is a Closed-loop (CL) system with a Model Predictive Control (MPC) algorithm reinforced by a decisional matrix, uploaded on a dedicated android smartphone linked to Dexcom CGM and a Cellnovo or Kaleido insulin patch-pump. The Diabeloop software calculates the insulin dose according to the patient's needs.
223788349|NCT02544906|DRUG|Propofol|Infusion of propofol to prevent emergence agitation in liver transplanta recipients
223788350|NCT02544906|DRUG|dexmedetomedine|Infusion of dexmedetomedine to prevent emergence agitation in liver transplanta recipients
223788351|NCT02190331|OTHER|Interventional program postural correction training|The postural correction training program was applied in the last 15-20 minutes of each PE class, twice a week, with the supervision and help of the PE teacher.
223788352|NCT02190331|OTHER|Control Group physical education classes|Only performed the physical education classes
223788353|NCT06019468|OTHER|Envolizumab combined with radiotherapy|Application of Envolizumab combined with radiotherapy for neoadjuvant treatment of locally advanced thymic cancer. Firstly, 20-40Gy radiation therapy was administered 10-20 times. Within one week after the start of radiation therapy, Envolizumab (300 mg, D1, Q3W, subcutaneous injection) was administered. Immunotherapy was maintained for 2-4 cycles, and surgery was performed after evaluation by the attending physician.
223788354|NCT03822299|DIETARY_SUPPLEMENT|healthy feces microbiota|Suspension of healthy feces microbiota in sterile saline solution
223788355|NCT02129738|DEVICE|LoFric catheters|LoFric single use catheters to be used 4-6 times daily for 4 weeks.
223788356|NCT02097472|BIOLOGICAL|PATH-wSP|Streptococcus pneumoniae Whole Cell Vaccine adsorbed to Alum
223788357|NCT02097472|BIOLOGICAL|Synflorix|"1 dose (0.5 mL) contains:~1 μg of each of the following pneumococcal polysaccharide serotypes:~1, 5, 6B, 7F, 9V, 14, and 23 F~And 3 μg of the following pneumococcal polysaccharide serotypes:~4, 18C and 19F.~The serotypes are conjugated to either:~protein D (derived from Non-Typeable Haemophilus influenzae) carrier protein, tetanus toxoid carrier protein or diphtheria toxoid carrier protein"
223788358|NCT02097472|BIOLOGICAL|Pentavac|"Each PFS contains 0.5 ml (single dose):~Diphtheria Toxoid 20 Lf to 30 Lf Tetanus Toxoid 2.5 Lf to 10 Lf B. Pertussis 4 IU HBsAg (rDNA) 10 mcg Purified capsular HIB Polysaccharide (PRP) Conjugated to Tetanus Toxoid (carrier protein) 10 mcg Adsorbed on Aluminium Phosphate, AL+++ 1.25 mg Preservative: Thiomersal 0.005 % Dose: O.5ml by intramuscular injection."
223788359|NCT02097472|OTHER|Saline|0.9% Sodium Chloride Injection, USP
223788360|NCT03392311|DRUG|Calcipotriol ointment|The topical treatment in the study was calcipotriol ointment(Dovonex;LEO Laboratories Ltd, Ireland) twice daily for 12 weeks.
223788361|NCT03392311|BIOLOGICAL|adipose-derived multipotent mesenchymal stem cells|AD-MSCs(adipose-derived multipotent mesenchymal stem cells) were infused intravenously at a dose of 2 million cells/kg.
223788362|NCT02119416|DRUG|Placebo Administration first|"All participants received each dose on two days and the order of administration was counterbalanced.~Order of Administration for Visits 1-6: 0mg, 1mg, 2mg, 0mg, 1mg, 2mg"
223788363|NCT02119416|DRUG|Low Caffeine Administration first (1mg/kg body weight)|"On two of the 6 visits, participants received a placebo (flattened sprite) added to their beverage.~Order of Caffeine Administration for Visits 1-6: 1mg, 2mg, 0mg, 1mg, 2mg, 0mg"
223788364|NCT02119416|DRUG|High Caffeine Administration first (2mg/kg body weight)|"On two of the 6 visits, participants received a placebo (flattened sprite) added to their beverage.~Order of Caffeine Administration for Visits 1-6: 2mg, 0mg, 1mg, 2mg, 0mg, 1mg"
223788365|NCT02205710|OTHER|Computerized cognitive training|
223788366|NCT02205710|OTHER|Computerized games|
223788367|NCT04540536|OTHER|Continuous Glucose Monitoring|Participants will be provided with a Dexcom G6 continuous glucose monitor for the duration of the study.
223788368|NCT04540536|OTHER|Secure texting|A secure platform (TigerConnect) will be used for three-way communication between parents, participants, and clinical personnel
223788369|NCT03131388|DIAGNOSTIC_TEST|Access AMH Assay|
223788370|NCT04589923|DEVICE|Lifelight® Data Collect Blood Pressure Group|The staff member will prepare for and take the participant's routine observations using standard clinical equipment during the same 60-second period that video is captured of the participant's face using Lifelight® Data Collect (from which only the RGB data will be uploaded to the cloud). These measurements and RGB data capture will be repeated two times following the initial observations. Once measurements are concluded, the study staff member will complete the post-measurement observation questions.
223788371|NCT04589923|DEVICE|Lifelight® Data Collect Oxygen Saturation Group|The staff member will prepare for and take the participant's routine observations using standard clinical equipment during the same 60-second period that video is captured of the participant's face using Lifelight® Data Collect (from which only the RGB data will be uploaded to the cloud). These measurements and RGB data capture will be repeated two times following the initial observations. Once measurements are concluded, the study staff member will complete the post-measurement observation questions.
223788372|NCT04134442|DRUG|Bupivacaine Liposome Injection|"1. Standard pre-operative and post-operative medical regimen including standing acetaminophen 650mg q6hours, gabapentin 300mg q8hours and as needed oxycodone every 4 hours (unless there are contraindications due to liver function, kidney function, age, or current therapy as currently determined by APS anesthesiologist)~2. Pre-operative ultrasound guided ISNB with a 20ml mixture consisting of 10ml of 0.5% bupivacaine with epinephrine 1:200,000, and 10ml of BL 1.33%"
223788373|NCT04134442|OTHER|Standard Therapy|"1. Standard pre-operative and post-operative medical regimen including standing acetaminophen 650mg q6hours, gabapentin 300mg q8hours and as needed oxycodone every 4 hours (unless there are contraindications due to liver function, kidney function, or age as currently determined by acute pain service (APS) anesthesiologist)~2. Preoperative, ultrasound guided ISNB with a bupivacaine mixture: 20ml 0.5% bupivacaine and epinephrine 1:200,000."
223788374|NCT02284737|PROCEDURE|PADN|Contrast pulmonary artery angiography is performed to localize the pulmonary artery bifurcation level and to calculate the PA diameter. Once the anatomy is deemed acceptable, the radiofrequency ablation catheter is introduced into the distal bifurcation area of the main PA. The catheter is then maneuvered within the PA to allow energy delivery to ensure that the electrodes are tightly in contact with the endovascular surface. Two to three ablations at 1-15 W for 120 seconds at each point were performed in the distal bifurcation area of the main PA.
223788375|NCT02284737|PROCEDURE|sham PADN|The radiofrequency ablation catheter placed, no ablations for patients in the sham PADN group.
223788376|NCT02284737|DRUG|Sildenafil|Participants initially received 5 mg tadalafil for the first 2 weeks in the two groups. The tadalafil dose may have been up titrated to 40 mg after 2 weeks, with maximum effects being obtained. The up titrated of tadalafil to 40 mg was not mandatory if the investigator decided for tolerability reasons the participants should remain on 5 mg.
223788377|NCT02345148|DRUG|Esketamine|Esketamine 84 mg will be self-administered by participants as intranasal spray at 0, 5 and 10 minutes on Day 1.
223788378|NCT05496881|OTHER|Exercise Group 1|Prescribed exercises will focus on mobility and balance.
223788379|NCT05496881|OTHER|Exercise Group 2|Prescribed exercises will focus on physical fitness.
223788380|NCT05496881|OTHER|Exercise Group 3|Prescribed exercises will focus on flexibility, range of motion, and muscle tone.
223788381|NCT04163705|DIAGNOSTIC_TEST|blood sample collection|Routine Laboratory Analysis
223788382|NCT04158531|DEVICE|ECoG sensing and stimulation|Implant electrodes and a sensing+stimulation device, and use this for suppression of seizure activity
223788383|NCT04461002|OTHER|Retrospective analysis|Evaluate the correlation between tumour molecular profile and preoperative imaging data (FDG and FDOPA PET-scan and multimodal MRI).
223788384|NCT00436059|DRUG|bortezomib|
223788385|NCT02464735|DEVICE|Polysomnography|
223788386|NCT00775918|DRUG|Doxycycline monohydrate 100mg tablets|Bioequiavelnce Doxycycline monohydrate 100mg tablets fed conditions
223788387|NCT05570695|BEHAVIORAL|attention right training, ARTNF|In a first verum neurofeedback condition, participants will be instructed to focus attention on their right hand and the up-regulation of alpha oscillations in the right hemisphere relative to alpha oscillations in the left hemisphere will be incentivized through neurofeedback.
223788388|NCT05570695|BEHAVIORAL|attention left training, ALTNF|In a second verum neurofeedback condition, participants will be instructed to focus attention on their left hand and the down-regulation of right relative to left alpha oscillations will be incentivized.
223788389|NCT05570695|BEHAVIORAL|sham attention right training, ARTsham|During the first sham neurofeedback condition, participants will be instructed to focus attention on their right hand. However, the feedback signal will not mirror their brain activity. Instead, the feedback signal and the corresponding reward of the last matching verum condition completed by a previous participant, i.e., ARTNF for ARTsham, will be replayed (yoked feedback).
223788390|NCT05570695|BEHAVIORAL|sham attention left training, ALTsham|During the second sham neurofeedback condition, participants will be instructed to focus attention on their left hand. However, the feedback signal will not mirror their brain activity. Instead, the feedback signal and the corresponding reward of the last matching verum condition completed by a previous participant, i.e., ALTNF for ALTsham, will be replayed (yoked feedback).
223788391|NCT04396886|DRUG|Bintrafusp Alfa|Bintrafusp alfa will be administered intravenously every 2 weeks
223788392|NCT05360875|PROCEDURE|Endometrial scratching|An intrauterine procedure that causes mild endometrial injury
223788393|NCT03043664|DRUG|Lanreotide|Somatuline depot (lanreotide) 90 mg SQ every 3 weeks
223788394|NCT03043664|DRUG|Pembrolizumab|Keytruda (pembrolizumab) 200 mg IV every 3 weeks
223788395|NCT01440153|OTHER|Exercise Intervention|Participants from group A receive an active program aiming at improving their cardiovascular endurance, muscular strength and motor control. The level for cardiovascular training is based on the results of the maximal exercise test performed during baseline assessment. The level of training is determined at a level of 70% of the predicted maximal heart rate and was increased every 6 weeks with 5%, ending at 85%. Heart rate will be monitored during the training.
223788396|NCT01440153|OTHER|Passive Intervention|Participants from group B will receive an alternative program, in which all active parts are replaced by passive interventions. Several education sessions will be given regarding different topics, such as stress management, nutrition, injuries, etc. In addition, also practical sessions well be held to practice massage, passive stretching, taping.
223788397|NCT05476146|PROCEDURE|Rerouting of the track in high anal fitula|Treatment of high anal fistula by rerouting
223703829|NCT03374969|BEHAVIORAL|Attachment and Biobehavioral Catch-Up|Attachment and Biobehavioral Catch-up (ABC) is a 10-session, weekly intervention delivered in the family's home. ABC addresses three primary issues. First, young children who have experienced early adversity are especially in need of nurturance and parents who behave in synchronous ways and delight in them. Next, when parents behave in frightening ways, it is difficult for children to look to them for reassurance when distressed. This can be particularly difficult for children who have experienced early adversity. Therefore, this intervention helps parents learn how to: 1) behave in nurturing ways when children are distressed; 2) behave in synchronous, delighted ways when children are not distressed; and 3) avoid behaving in frightening or intrusive ways. Interventionists are provided with a manualized protocol, but tailor specific session content to each family's needs. Sessions are videotaped, both for playback to families, and for supervision.
223703830|NCT03374969|BEHAVIORAL|Developmental Education for Families|Developmental Education for Families (DEF) is a 10-session, weekly intervention delivered in the family's home. DEF focuses on enhancing gross and fine motor skills, cognition and language development. The age-based protocols (i.e., 6-24 months,) provide information about the developmental themes of focus for each week and suggest activities to enhance the target skills for that week. However, the protocols do not provide a direct script with which to conduct the sessions. Interventionists tailor the developmental program session to the needs of the child and family by considering the child's current gross, fine, cognitive and language skills and creatively preparing several activities that will address the session topics.
223703831|NCT01932359|OTHER|rapidly absorbable suture (Vicryl Rapide)|
223703832|NCT01932359|OTHER|non-absorbable suture (Ethilon)|
223703833|NCT03960814|DRUG|Insulin detemir|No treatment will be given to the patients in relation to this study. Patients have been included in this study because they have been treated with insulin glargine or detemir prior to study initiation (2004 - 2018) and according to routine clinical practice at that time. The decision to initiate treatment with commercially available insulin detemir and glargine has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician before and independently from the decision to include the patient in this study.
223703834|NCT06318234|DIAGNOSTIC_TEST|18F-FAPI，18F-FDG|FAPI and FDG combined with PET/MR imaging in patients with rectal cancer after neoadjuvant therapy
223703835|NCT04016064|PROCEDURE|Er:YAG LASER, Nd:YAG laser, elctrosurgery, conventional surgery|"1. Er: YAG laser (Fotana AT Fidelis III, Ljubljana, Slovenia) 200 mj, 10 Hz, 2 Watt and VLP (long pulse, 1000 μs); 1.3 mm diameter, 8 mm long cylindrical, a sapphire tip was used with air cooling and water irrigation.~2. Nd: YAG laser (Fotana AT Fidelis III, Ljubljana, Slovenia) was applied at 4 watts, 50 Hz, 300 μm microfiber tip and SP (short pulse: 180 μs) settings.~3. Electrosurgical (Servotome Classic System, High Frequency Surgical Equipment, Satelec, France).~4. Conventional surgical method was applied with hand instruments and gingivectomy knives."
223703836|NCT02272075|DEVICE|Mobile OCT M3 scope|
223703837|NCT02864602|DRUG|IV dexamethasone|An infusion of IV dexamethasone
223703838|NCT00062946|DRUG|(18F)fallypride|
223788398|NCT04528511|DEVICE|Continuous Electronic Monitor|All patients with NOAF complicating AMI will receive at least 5 days electronic monitoring for the evaluation of NOAF burden
223788399|NCT02120508|DEVICE|rTMS|To test the efficacy of this specific setting.
223788400|NCT04082949|BIOLOGICAL|autologous fibrin glue application as an adjunct to nonsurgical periodontal treatment of chronic periodontitis|The purpose of this study was to investigate effects of autologous fibrin glue (AFG) which was an injectable platelet concentration, on clinical parameters in the nonsurgical treatment of chronic periodontitis.Seventy-two quadrants from 18 patients included in the study and divided into 2 random split-mouth groups. Control group included 631 sites (SRP+Placebo) and AFG group included 682 sites (SRP+AFG). Both groups divided into two subgroups according to initial pocket depth (PD:5-6mm and PD≥7mm).The test group was administered AFG using a blunt dental injector in the subgingival region, as an adjunct to SRP Clinical periodontal parameters including PD, clinical attachment level (CAL), bleeding on probing (BOP), gingival index (GI) and plaque index (PI) were collected at the 1st, 3rd, and 6th months.
223788401|NCT04082949|OTHER|placebo application as an adjunct to nonsurgical periodontal treatment of chronic periodontitis|Seventy-two quadrants from 18 patients included in the study and divided into 2 random split-mouth groups. Control group included 631 sites (SRP+Placebo) and AFG group included 682 sites (SRP+AFG). Both groups divided into two subgroups according to initial pocket depth (PD:5-6mm and PD≥7mm).The control group was administered placebo as an adjunct to SRP.Clinical periodontal parameters including PD, clinical attachment level (CAL), bleeding on probing (BOP), gingival index (GI) and plaque index (PI) were collected at the 1st, 3rd, and 6th months.
223788402|NCT02010840|BEHAVIORAL|Psychoeducation program|
223788403|NCT03593655|DEVICE|Dapivirine vaginal ring|Vaginal ring containing 25 mg of dapivirine
223788404|NCT03593655|DRUG|FTC/TDF|Tablet containing 200 mg FTC/300 mg TDF
223788405|NCT06580678|DRUG|KH001|topical application of KH001
223788406|NCT06580678|DRUG|Placebo|topical application of Water for Injection
223788407|NCT06579547|RADIATION|Low Dose Computer Tomography|Participants will undergo MRI scans of their skeletal system, followed by the Intervention of a Low Dose CT scan of the same body region for comparison purposes.
223788408|NCT01981564|BEHAVIORAL|Asthma Express Intervention|Asthma Express clinic visit for asthma education + nurse home visit
223788409|NCT01981564|BEHAVIORAL|Standard Asthma Education Control Group|Asthma Express home nurse visits for asthma education
223788410|NCT04678466|BIOLOGICAL|flotetuzumab|CD123 x CD3 bispecific DART® antibody
223788411|NCT03961620|DEVICE|The SpotOn system that encompasses the registration unit (3M SpotOn Control Unit), disposable sensor (3M SpotOn Control Sensor) along with the cords and electric power unit.|Patients submitted to major surgical procedure will be assessed for core body temperature by employing SpotOn sensor device, before, during and after surgical procedure.
223788412|NCT03732209|BEHAVIORAL|Episodic future thinking|Participants will engage in episodic future thinking, prompted via text-based cues, when making decisions about dietary, exercise, and medication adherence choices.
223788413|NCT03732209|BEHAVIORAL|Control Thinking|Participants will engage in non-future-oriented control thinking, prompted via text-based cues, when making decisions about dietary, exercise, and medication adherence choices.
223788414|NCT06635044|OTHER|intradialytic exercise|HD men came to the HD unit three times weekly to receive their dialysis session which consumed 3-4 hours. During the first two hours of the men's dialysis session, a pedal exerciser (RTL10273 Deluxe Folding Pedal Exerciser, Drive Medical Co. MPN) was utilized in performing leg cycling exercises while men were sitting. Before starting the session of intradialytic cycling, a 5-minute stretching of the lower limbs was performed as a warming up. Also, as cooling down, the same period of lower limbs' stretching was performed after ending intradialytic cycling
223788415|NCT06634888|DIAGNOSTIC_TEST|Injectable platelet rich fbirin|After the leveling and alignment phase, the canines were retracted with 150gm forces. The i-PRF was prepared from the blood of each patient then injected immediately before canine retraction on the buccal and palatal aspects of the extraction sites. All patients in this study were submitted for Cone beam computed tomography (CBCT) scanning before and after canine retraction. Cone beam computed tomography (CBCT) was used before and four months after retraction, with imaging conducted using the Orthophos SL 3D X-ray machine (Dentsply Sirona, Charlotte, CA, USA) while adhering to As Low As Reasonably Achievable (ALARA) guidelines to minimize radiation exposure
223788416|NCT06634888|DIAGNOSTIC_TEST|Injectable platelet rich fbirin|All patients in this study were submitted for Cone beam computed tomography (CBCT) scanning before and after canine retraction. Cone beam computed tomography (CBCT) was used before and four months after retraction, with imaging conducted using the Orthophos SL 3D X-ray machine (Dentsply Sirona, Charlotte, CA, USA) while adhering to As Low As Reasonably Achievable (ALARA) guidelines to minimize radiation exposure
223788417|NCT03505632|DEVICE|Recruitment with low PEEP|Volume controlled ventilation with TV 6-8 ml/PBW . RR adjusted to keep the EtCO2 35-40 mmHg. I/E ratio1:2 and FiO2 0.40.Patients will receive PEEP of 5cmH2O. RM will be done by increasing the PEEP in stepwise manner. First PEEP increase to 10 cmH2O (3 breaths),then to 15 cm H2O (3 breaths) and finally PEEP raise to 20 cmH2O (10 breaths).Then PEEP decrease by 5 cmH2O increments every (3 breaths) until back to PEEP 5 cmH2O. RM will take 2 minutes. RM will be carried out at the following times: post intubation(T1) , after peritoneal insuflation(T2) ,after desuflation (T3) and before extubation(T4) . The peak airway pressure should not exceed 40 cmH2O. Monitoring of the following parameters :Dynamic lung compliance ,Horowitz index ,dead space and driving pressure .
223788418|NCT03505632|DEVICE|High PEEP without RM|Volume controlled ventilation will carried out with tidal volume 6-8 ml/kg for predicted body weight. The PBW calculated according to the formula : 50 + 0.91 × {height (cm)-152.4} for men and 45.5 + 0.91 × {height (cm) - 152.4} for women. The respiratory rate adjusted to keep the EtCO2= 35-40 mmHg. The inspiratory to expiratory ratio (I:E ratio) 1:2 and FiO2 0.40.Patients will receive high PEEP of 15cmH2O from the start and continue all through the procedure . Monitoring of dynamic lung compliance,Horowitz index,dead space and driving pressure will be carried out at the following times: post intubation(T1) , after peritoneal insuflation(T2) ,after desuflation (T3) and before extubation(T4) . The peak airway pressure should not exceed 40cmH2O.
223788419|NCT05577026|BEHAVIORAL|Educational intervention and prescription feedback|Brief educational intervention and patient and provider materials regarding prescription of opioids. Subsequent feedback on clinic prescription of opioids over 12 months.
223788420|NCT05577026|BEHAVIORAL|General information on treatment guidelines|Written information on guidelines and recommendations regarding prescription of opioids.
223788421|NCT05542355|DRUG|EXL01|Oral EXL01 once daily for up to 24 weeks (after SoC corticosteroid induction therapy).
223703839|NCT03919331|DIAGNOSTIC_TEST|Assessment of tidal volume using Electrical Impedance Tomography (EIT) during high flow nasal canula(HFNC)|After information and consent, patients under HFNC for de novo acute hypoxemic respiratory failure will undergo a ten minutes 4cmH2O continuous positive airway pressure(CPAP) test while monitored with 1)chest Electrical Impedance Tomography (EIT) 2) a pneumotachograph inserted on the ventilator circuit between the mask and the Y-piece and connected to a differential pressure sensor, and 3) respiratory inductance plethysmography (RIP). Airway flow signal will be acquired using an analog/digital converter and stored for further analysis with acknowledge software. This will allow converting EIT data into tidal volume (TV), and estimating TV under HFNC. RIP signals will allow evaluating asynchronism between chest and abdomen by calculating the phase angle, thus quantifying respiratory distress. Patients monitored with an arterial catheter, arterial blood gas measurements will be done during CPAP and HFNC. These measures will be collected the first day of HFNC, and everyday up to three days
223703840|NCT00354822|DRUG|Zevalin|Yttrium-90 (90Y) ibritumomab tiuxetan 0.4 mCi/kg is delivered to patient achieving at least a partial remission (PR) after chemotherapy as a single dose for patients with baseline platelet counts\>150x10\^9/L or 0.3 mCi/kg for patients with baseline platelet counts of 100 to 149x10\^9/L. Rituximab 250mg/sqm is given prior to therapeutic radiolabeled antibodies.
223703841|NCT02317588|DIETARY_SUPPLEMENT|Flax Oil|Participants will consume capsules containing flax oil at a dose of 4 grams of ALA per day (8 capsules a day) with a meal for 28 days (4 weeks).
223703842|NCT02317588|DIETARY_SUPPLEMENT|Fish Oil|Participants will consume capsules containing fish oil at a dose of 4 grams DHA + 0.8 grams EPA per day (8 capsules) for 28 days (4 weeks).
223703843|NCT00078793|DRUG|Enbrel®|Etanercept alone, etanercept plus methotrexate or other DMARDs
223703844|NCT05984095|OTHER|Telerehabilitation|The intervention was administered in a telerehabilitation fashion through a videocall on the phone or tablet, by a physiotherapist, in a one-to-one session.
223703845|NCT02702219|BEHAVIORAL|Mobility of the hamstrings muscles|
223703846|NCT03942666|DRUG|Treatment A|tablet of CHF 6532
223703847|NCT03942666|DRUG|Treatment B|tablet of CHF 6532
223703848|NCT03942666|DRUG|Treatment C|tablet of CHF 6532
223788422|NCT05542355|DRUG|Placebo|Oral EXL01 matching placebo once daily for up to 24 weeks (after SoC corticosteroid induction therapy).
223788423|NCT05542355|OTHER|SoC corticosteroid - Induction Period|Oral prednisone 40 mg or budesonide 9 mg once daily for 3 to 7 weeks, as assigned by the investigator
223788424|NCT05542355|OTHER|SoC corticosteroid - Tapering|"Same product as the Induction Period.~Oral prednisone: 30 mg for 1 week, 25 mg for 1 week, 20 mg for 1 week, 15 mg for 1 week, 10 mg for 1 week, 5 mg for 1 week and stop.~OR~Oral budesonide: 6 mg for 3 weeks, 3 mg for 3 weeks, stop."
223788425|NCT04336254|BIOLOGICAL|allogeneic human dental pulp stem cells (BSH BTC & Utooth BTC)|Intravenous injection of 3.0x10e7 human dental pulp stem cells solution (30ml) on day 1, day 4 and day 7, based on routine treatment of COVID-19
223788426|NCT04336254|OTHER|Intravenous saline injection (Placebo)|Intravenous injection of 3ml of 0.9% saline on day 1, day 4 and day 7, based on routine treatment of COVID-19
223788427|NCT04986553|DEVICE|Arthrex Clavicle Plates|Arthrex Clavicle Plate for treatment of clavicle fractures
223788428|NCT05605964|DRUG|Relugolix|Relugolix tablet
223788429|NCT05605964|DRUG|Leuprolide Acetate|Leuprolide acetate injection
223788430|NCT04635605|DRUG|Methylene Blue|Treatment Group. Methylene Blue 100 mg capsules, twice a day for 5 consecutive days, will be added to the current therapy of the patient, if any.
223788431|NCT04635605|DRUG|Control Test|Arm B: Control Group. Placebo capsules 100 mg twice a day for 5 consecutive days, will be added to the current therapy of the patient, if any.
223788432|NCT05327803|DRUG|Epetraborole|500 mg taken orally QD
223788433|NCT05327803|DRUG|Placebo|Placebo taken orally QD
223788434|NCT05526001|BIOLOGICAL|ELIXCYTE|ELIXCYTE, a new investigational product developed by UnicoCell Biomed, contains allogenic Adipose-derived stem cells (ADSCs). The ADSCs of ELIXCYTE for subjects were obtained from donors, and the Sponsor followed the manufacturing and testing procedures described in chemistry, manufacturing and control (CMC) information in order to assure the quality of final products.
223788435|NCT05526001|DRUG|Saline|Placebo control used in the study.
223788436|NCT01919008|DRUG|FK949E|Oral
223788437|NCT05762588|DEVICE|Juggerknot with Broadband tape|The JuggerKnot system is comprised of a coreless sleeve structure and suture. The anchors are intended for use in soft tissue to bone fixation by bunching against the bone when deployed. The anchor sleeve material is polyester. Suture materials are ultra-high molecular weight polyethylene. The device has 510K FDA clearance.
223788438|NCT05779657|DRUG|Ketamine|Intravenous ketamine 2 mg/kg (max 60 mg) over 2 minutes (diluted with isotonic saline to 5 mg/ml concentration)
223788439|NCT05779657|DRUG|Midazolam|Intravenous midazolam 0.2 mg/kg (maximum 10 mg) over 2 minutes
223788440|NCT05779657|DRUG|Placebo|Intravenous isotonic saline 0.4 ml/kg (max 12 ml) over 5 minutes
223788441|NCT06005818|DRUG|Pembrolizumab injection|PD-1 antibody
223788442|NCT06326606|DRUG|Psilocybin|Capsule containing active ingredient, psilocybin
223703849|NCT03942666|DRUG|Treatment D|tablet of CHF 6532
223703850|NCT03942666|DRUG|Treatment E|Placebo tablet of CHF 6532
223703851|NCT03942666|DRUG|Treatment F|tablet of CHF 6532
223703852|NCT05678569|DIAGNOSTIC_TEST|Dual Energy Xray Absorptiometry|DXA for diagnosis of osteoporosis
223703853|NCT01771952|DEVICE|Synvisc-One™|A single 6cc injection of Synvisc-One™ will be utilized in this study.
223703854|NCT01771952|OTHER|Sham Treatment|A single needle stick without arthrocentesis or injection.
223703855|NCT03204019|DRUG|Tegafur and Temozolomide|Tegafur 40-60mg po bid(d1-d14); Temozolomide 200mg po qd(d10-d14)
223703856|NCT03204019|DRUG|Tegafur and Temozolomide combined with Thalidomide|Tegafur 40-60mg po bid(d1-d14); Temozolomide 200mg po qe(d10-d14) Thalidomide 100mg po qd(d1-d7) /Thalidomide 200mg po qd(d8-d14)/Thalidomide 300mg po qd(d15-d21)
223703857|NCT01610661|OTHER|Diet|Unrefined-carbohydrate refers to foods made with 100% whole grains (wheat, rice, corn). Refined-carbohydrate refers to foods made with white flour (e.g., bread, pasta) or white rice. Simple-carbohydrate refers to foods made with sucrose (50% glucose/50% fructose) and high-fructose corn syrup.
223703858|NCT02789995|PROCEDURE|Human biological samples|Blood sample - Muscle biopsy - Bone marrow sample (mesenchymal stem cells)
223703859|NCT05514483|DRUG|Placebo|Single intravenous dose of 10 mL of sodium chloride (NaCl) 0.9% over 15 minutes.
223703860|NCT05514483|DRUG|Ondansetron|Single intravenous dose of ondansetron hydrochloride dihydrate 0.15 mg/kg (maximum 16 mg) in 10 mL of NaCl 0.9% over 15 minutes.
223788443|NCT06326606|DRUG|Placebo|Capsule with no active ingredients
223788444|NCT04459650|PROCEDURE|Platelet Rich Plasma system|Participants will receive PRP obtained with PRP harvesting kits on one side of the scalp and no injections on the other side of the scalp (split-scalp technique). The entire half of the intended scalp will receive inter-follicular injections of PRP under aseptic conditions at the amount of 0.05-0.1 ml/cm2 in a retrograde fashion from deep to superficial, at every centimeter throughout the treated site. For study purposes, Study Day 0 is defined as the first day of injection. Subsequently the patient will continue therapy every 4 weeks for a total of 3 injections (12 weeks).
223788445|NCT05360615|DRUG|Empagliflozin 10 MG|SGLT2 inhibitors
223788446|NCT05360615|DRUG|Placebo|Placebo
223788447|NCT06525181|OTHER|Generative Artificial Intelligence|Gen AI assisted symptom intake summarization
223788448|NCT06525181|OTHER|Standard weekly symptom intake|Standard weekly symptom intake performed by a physician
223788449|NCT02063724|BIOLOGICAL|HER-2 pulsed Dendritic Cell Vaccine|6 weekly HER-2 pulsed dendritic cell vaccines followed by 3 booster vaccines once every 3 months. Each dose will consist of between 1.0-2.0 x 10\^7 cells and will be injected into 1-2 different normal groin lymph nodes or axillary nodes.
223788450|NCT04458051|DRUG|Tolebrutinib|Pharmaceutical form: Film-coated Tablet Route of administration: Oral
223788451|NCT04458051|DRUG|Placebo|Pharmaceutical form: Film-coated Tablet Route of administration: Oral
223788452|NCT01574300|OTHER|therapeutic interventions|All therapeutic interventions are allowed, and their details recorded and correlated with data from the collected biospecimens. Examples would include single or multiple agent chemotherapy or targeted therapeutics
223788453|NCT03582124|PROCEDURE|Near-Infrared Fluorescence Imaging|Undergo imaging
223788454|NCT03582124|DRUG|Panitumumab-IRDye800|Given IV
223788455|NCT03582124|OTHER|Pharmacokinetic Study|Correlative studies
223788456|NCT03582124|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
223788457|NCT05087628|BIOLOGICAL|PRV-3279|Bi-specific antibody-based molecule
223788458|NCT05087628|OTHER|Placebo|Placebo
223788459|NCT04740294|DRUG|Magnesium Sulfate|Randomized to receive either magnesium sulfate or normal saline placebo.
223788460|NCT03516916|OTHER|Questionnaires on HRQoL and sociodemography|All patients are asked to answer a panel of questionnaires to test validity and reliability of the Colostomy Impact Score.
223788461|NCT05688813|PROCEDURE|Regional anesthesia intervention|Ultrasound-guided caudal and sacral erector spinae blocks were administered
223788462|NCT01715805|DRUG|Cariprazine|Cariprazine capsules 1.5 to 4.5 mg/day
223788463|NCT01715805|DRUG|Placebo|Dose-matched placebo capsule once per day
223788464|NCT01715805|DRUG|Antidepressant Therapy (ADT)|ADT such as bupropion, citalopram, desvenlafaxine, duloxetine, escitalopram, fluoxetine, sertraline, venlafaxine, paroxetine or vilazodone as prescribed by the physician.
223788465|NCT04936230|PROCEDURE|Biospecimen Collection|Undergo urine and blood sample collection
223788466|NCT04936230|PROCEDURE|Bone Scan|Undergo bone scan
223788467|NCT04936230|PROCEDURE|Computed Tomography|Undergo CT scan
223788468|NCT04936230|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223788469|NCT04936230|BIOLOGICAL|Pembrolizumab|Given IV
223788470|NCT04936230|PROCEDURE|Positron Emission Tomography|Undergo PET scan
223788471|NCT04936230|OTHER|Questionnaire Administration|Ancillary studies
223788472|NCT04936230|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
223788473|NCT04940325|DRUG|DS-1062a|First infusion for 90 minutes and then infusion duration can be decreased to 30 minutes if participant didn't experience infusion related reactions (IRR)
223788474|NCT06258213|DRUG|ABP-745|0.5, 5 or 25 mg tablet
223788475|NCT06258213|DRUG|Placebo|Placebo tablet
223788476|NCT05008354|DRUG|Pyridoxine|Pyridoxine tablet 40mg once daily
223788477|NCT05008354|DRUG|Placebo|Placebo tablet once daily
223788478|NCT02904304|DRUG|Desloratadine+Phenylephrine+Ibuprofen|01 tablet, orally, every 12 hours.
223788479|NCT02904304|DRUG|Placebo|01 tablet, orally, every 12 hours.
223788480|NCT04479813|DRUG|Moxonidine 0.2 MG|Subjects will be allocated to undergo conditioning or non conditioning assigned in a randomized order. Participants will be given placebo or 0.2mg of Moxonidine to take orally 20 minutes prior to the first endothelial function measurement.
223788481|NCT04479813|OTHER|placebo|Subjects will be allocated to undergo conditioning or non conditioning assigned in a randomized order. Participants will be given placebo or 0.2mg of Moxonidine to take orally 20 minutes prior to the first endothelial function measurement.
223788482|NCT02938000|DEVICE|Theraband with exercise video|Theraband exercise band for resistance training
223788483|NCT02938000|OTHER|usual care with advice to exercise|advice to exercise
223788484|NCT01821664|DEVICE|Prosthetic vascular graft|Implantation of a prosthetic vascular graft
223788485|NCT01242475|BIOLOGICAL|C-Tb|The C-Tb agent is administered by the Mantoux injection technique to each volunteer in the RIGHT or LEFT forearms according to a double blind randomisation scheme
223788486|NCT01242475|BIOLOGICAL|2 TU Tuberculin PPD RT 23 SSI|The 2TU Tuberculin PPD RT 23 SSI agent is administered by the Mantoux injection technique to each volunteer in the RIGHT or LEFT forearms according to a double blind randomisation scheme
223788487|NCT02810054|PROCEDURE|Minimally Invasive Surgical Techniques (MIST)|Using minimally invasive surgical techniques.
223788488|NCT02810054|PROCEDURE|Enamel Matrix Derivative (EMD)|Use of enamel matrix derivative for the treatment of intrabony periodontal defects.
223788489|NCT04559789|BEHAVIORAL|MindMate + Health Coaching|The MindMate app is a digital multi-domain lifestyle intervention designed to address modifiable risk factors for dementia. The app will be augmented with digital health coaching provided by Neurotrack.
223788490|NCT04559789|OTHER|Health Education|Health education materials delivered electronically
223788491|NCT02868359|OTHER|No Intervention|The study is observational.
223788492|NCT04445805|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia (CBTI)|Consists of 6 prenatal 60-min sessions and 6 monthly postnatal sessions on sleep education, sleep restriction, stimulus control, cognitive therapy, and relaxation. Treatment will be delivered via telemedicine.
223788493|NCT04445805|BEHAVIORAL|Perinatal-enhanced Behavioral Therapy for Insomnia|Consists of 6 prenatal 60-min sessions and 6 monthly postnatal sessions on sleep education, sleep restriction, stimulus control, and metacognitive exercises. Treatment will be delivered via telemedicine.
223788494|NCT04445805|BEHAVIORAL|Attention Control|Will include education on sleep, circadian rhythms, and good sleep hygiene in addition to self-monitoring with sleep diaries.
223788495|NCT03101735|DRUG|Dimethyl Fumarate (DMF)|The non-interventional design allows the observation of patients in a broad range of settings reflecting routine clinical practice. All decisions on therapeutic or diagnostic procedures, treatments, management of the disease, or resource utilisation will be at the full discretion of the treating physician without interference by a sponsor or study protocol. All treatment decisions will follow the real-life treatment behaviour.
223788496|NCT01618864|DEVICE|Luxe|Self treatment at home in the peri-orbital and cheeks areas. Frequency: Daily treatment for 4 weeks followed by bi-weekly treatments for additional 4 weeks.
223788497|NCT02742844|BIOLOGICAL|APZ2 application|Application of IMP on patients wound.
223788498|NCT06580574|DRUG|PD1/PDL1 antibody monotherapy, up to 24 weeks|non-specific, according to Drug Instructions
223788499|NCT06580574|COMBINATION_PRODUCT|Intensive immunotherapy plus anti-VEGF treatment, up to 24 weeks|Sintilimab 200mg, ivgtt, q21d; IBI310 1mg/kg, ivgtt, q42d; Lenvatinib 8mg (starting from 4mg), po, qd
223788500|NCT06580574|PROCEDURE|Radical surgery|Radical surgery will be recommended per local treatment standards.
223788501|NCT00872144|DRUG|Sativex|Sativex (or placebo) will be dispensed identical 5.5 ml containers. Participants will be instructed to start with a dose of 1 spray trans-mucosally at 1800 hrs. If there are no limiting adverse effects such as sedation or dizziness, participants will be instructed to increase the dose to 2 sprays- one in the morning and the other in the early evening on day two. Participants may increase the dose by 1-2 sprays per day to a maximum dose of 12 sprays per day given 3 sprays 4 times per day. In the initial titration phase participants will be instructed to space each dose actuation 15 minutes apart until accustomed to the preparation. Participants will titrate the dose to a level where they obtain an analgesic effect without limiting side effects.
223788502|NCT05228574|DIETARY_SUPPLEMENT|Sodium chloride (NaCl)|Sodium chloride capsules 6 grams per day for 4 weeks.
223788503|NCT05228574|DIETARY_SUPPLEMENT|Placebo|Placebo capsules, 6 grams per day for 4 weeks.
223788504|NCT05228574|DRUG|Amiloride Hcl 5mg Tab|Amiloride 5mg tablets, 20 mg per day for two weeks in open-label setting.
223788505|NCT03457532|DRUG|Gumarontinib Tablets|25mg; 50mg; 100mg; 200mg; 400mg; 600mg BID or QD(Decided by SMC accroding to the safty and PK data)
223788506|NCT04224389|PROCEDURE|transoral resection|The technique of transoral surgery will be left to the choice of the surgeon according to the equipment and the experience of the team and will be gathered. The options are: transoral surgery robot-assisted, endoscopic laser transoral surgery, transoral laser surgery classical instruments. The exact description of the resected area will be collected. of the cross-sections will be made for extemporaneous analysis if necessary in lateral margins and deep until complete excision.
223788507|NCT04224389|RADIATION|IMRT|Intensity modulation radiotherapy (RCMI or IMRT) will be performed using techniques static or rotational (arctherapy, tomotherapy). Restraint is recommended with thermoformed mask
223788508|NCT05856656|BEHAVIORAL|Music therapy|Music therapy is a technique of care, accompaniment and support, which aims to improve health and well-being.
223788509|NCT04242355|BEHAVIORAL|Transcranial Magnetic Stimulation (TMS)|Subjects will receive both active and sham TMS in a randomized crossover assignment involving two study sessions
223788510|NCT06319443|DIETARY_SUPPLEMENT|Liquid vinegar|3.5 g acetic acid
223788511|NCT06319443|DIETARY_SUPPLEMENT|vinegar pill|0.022 g acetic acid
223788512|NCT06287359|OTHER|individual interviews|Qualitative research with individual interviews
223788513|NCT05177770|DRUG|SRF617|SRF617 is a fully human antibody designed to inhibit the enzymatic activity of CD39.
223788514|NCT05177770|DRUG|etrumadenant|Etrumadenant is an A2aR and A2bR antagonist.
223788515|NCT05177770|DRUG|zimberelimab|Zimberelimab is a fully human anti-PD-1 monoclonal antibody.
223788516|NCT05259436|BEHAVIORAL|Caregiver-child Intervention|"Intervention Groups:~1. Resilience Clinic (Benioff Oakland): 6 weekly interactive group-based visits in primary care that draws from the evidence-based Circle of Security Parenting along with the principles of mindfulness;~2. ABC Intervention (Lifelong): 10 weekly home visiting sessions. ABC is an empirically supported parenting program that focuses on improving maternal sensitivity;~   and,~3. Resiliency Family Program (Santa Barbara Neighborhood Clinic): 4 primary-care-based visits, every 2-3 weeks, that include psycho-education materials drawing from the culturally-responsive, evidence-based program, Madres a Madres."
223788517|NCT05259436|BEHAVIORAL|Enhanced Primary Care|Enhanced Primary Care (control group): This includes care coordination services for community resources in addition to usual care. Participants will be asked about any unmet social needs, e.g. food insecurity, financial strain, safe places to play. Those who endorse need will be offered navigational services to link to community resources.
223788518|NCT03125720|OTHER|Image fusion of SPECT MPI and fluoroscopy venography|In this study, MPI-Fluoro Fusion tool is used to help the implanting physicians to precisely implant LV lead to the optimal/suboptimal venous segments in the guided group.
223788519|NCT06121661|DEVICE|APPRAISE Trauma Clinical Decision Support System|Real-time bedside decision-support system for trauma patient management
223788520|NCT01391962|DRUG|Cediranib|Cediranib, a small molecule inhibitor of vascular endothelial growth factor (VEGF) receptor tyrosine kinases, is showing preliminary evidence of activity in patients with alveolar soft part sarcoma (ASPS).
223788521|NCT01391962|DRUG|Sunitinib|Sunitinib, a small molecule inhibitor of vascular endothelial growth factor (VEGF) receptor tyrosine kinases, is showing preliminary evidence of activity in patients with alveolar soft part sarcoma (ASPS).
223788522|NCT01391962|OTHER|Prochlorperazine|10mg every 6 hours orally as needed for nausea,
223788523|NCT01391962|OTHER|Promethazine|12.5-25mg intravenous every 6 hours as needed for nausea.
223788524|NCT01391962|OTHER|Benzodiazepine|If promethazine is inadequate, add benzodiazepine until acute nausea is controlled.
223788525|NCT01391962|OTHER|Filgrastim|Therapeutic use per investigator's discretion according to American Society of Clinical Oncology (ASCO) guidelines.
223788526|NCT01391962|OTHER|Sargramostim|Therapeutic use per investigator's discretion according to American Society of Clinical Oncology (ASCO) guidelines.
223788527|NCT01391962|OTHER|Lomotil|2.5mg plus atropine sulfate 0.025mg/tablet dosed according to package insert.
223788528|NCT01391962|OTHER|Loperamide|4mg by mouth (PO) after first unformed stool with 2mg PO every 2 hours as long as unformed stools continue.
223788529|NCT01391962|OTHER|Vitamin B6|50-150mg orally each day for hand-foot syndrome.
223788530|NCT01391962|OTHER|Aquaphor|Topical emollient for hand-foot syndrome.
223788531|NCT01391962|DRUG|Acetaminophen|Analgesic for hand foot syndrome as needed.
223788532|NCT01391962|DRUG|Levothyroxine|Replacement therapy for participants with increases in thyroid-stimulating hormone.
223788533|NCT01391962|DRUG|Warfarin|2mg daily for prophylaxis of thrombosis.
223788534|NCT06129747|RADIATION|Radiation Therapy|"Weeks 1, 2 and 3~* Weeks 1, 2 and 3 will include 5 days of treatment.~* One radiation treatment to breast on each of the 5 days. Each radiation treatment session will last a 30 minutes."
223788535|NCT05093075|OTHER|Therapeutic Plasma Exchange|TPE procedures will be performed using a Spectra Optia ® apheresis machine (Terumo BCT, Lakewood, USA) according to usual-care procedures for apheresis. Venous access for the TPE procedures will be obtained through a double lumen dialysis catheter to provide adequate flow rates required for TPE. Regional citrate anticoagulation will be used for anticoagulation within the apheresis circuit. One to two grams of calcium chloride will be infused as per standard during TPE to prevent symptomatic hypocalcemia. Plasma volume will be calculated as per a standard formula whereby estimated plasma volume (in liters) = 0.07 x weight (kg) x (1 - hematocrit). In patients on dialysis, dialysis will be interrupted for the duration of the procedure. Antibiotics will be given after TPE to avoid clearance of the antibiotics. On the first day of TPE, a repeat dose of antibiotics will be administered after completion of TPE. Nurse clinicians trained in TPE will perform the TPE procedures.
223788536|NCT06300814|OTHER|Progressive relaxation exercise group|A video containing the progressive relaxation exercise was sent to the phones of the mothers of children diagnosed with epilepsy in the intervention group to whom progressive relaxation exercise would be applied, and the children applied progressive relaxation exercise (15 minutes of progressive relaxation exercise before bedtime for a total of 4 weeks, 5 days a week).
223788537|NCT06300814|OTHER|Music recital group|The link of the music recital (link) was sent to the phones of the mothers of children diagnosed with epilepsy in the intervention group, where the music concert will be applied, and the children listened to it (music concert was applied for 15 minutes before going to bed, 5 days a week for a total of 4 weeks).
223788538|NCT01022814|DEVICE|A disposable pad containing sensitive chemical indicators|After a urine/amniotic fluid leaking, liquid meets the diagnostic device and chemical reactions will occur in the test zones and cause a color change.
223788539|NCT03073889|PROCEDURE|Scalp Nerve Block|A scalp nerve block involves regional anesthesia to the nerves that innervate the scalp, including the supraorbital and supratrochlear nerves, branches of the ophthalmic branch of the trigeminal nerve; the zygomaticotemporal nerves, terminal branch of division two of the trigeminal nerve; the auriculotemporal nerves, terminal branch of the mandibular division of the trigeminal nerve; the greater and lesser occipital nerves. The scalp block is performed bilaterally with 10 solution of 0.75% ropivacaine.
223788540|NCT03073889|PROCEDURE|Scalp infiltration|Scalp infiltration before incision. Neurosurgeons infiltrate the planned incision by a 22-gauge needle penetrated deeply to the skin at a 45°angle with 10ml solution of 0.75% ropivacaine throughout the entire thickness of the scalp.
223788541|NCT03073889|DRUG|Ropivacaine|
223788542|NCT00709722|DRUG|NKT-01|SC, 0.5 mg/kg/day, consecutive 14 days administrations, 1 week rest, 9 cycles.
223788543|NCT06108622|DIAGNOSTIC_TEST|cbc ,u\s renalor hepatic function test if needed|just blood sample if the case needed
223788544|NCT04667117|BIOLOGICAL|Quadrivalent influenza vaccine|2020-2021, 2021-2022, or 2022-2023 inactivated quadrivalent influenza vaccine. Participants received the vaccine within 9 calendar days after the Screening Visit, before the Week 0 Visit occurred.
223703861|NCT03110094|OTHER|Adalimumab|It will be an interventional study with minimal risks and constraints, prospective, mono-centric, in current care. Patient management will not be changed during the study. It will be taken at two different tracking points (M0 and M3) 4 additional tubes and use of surplus articular fluid (M0 and M3).
223703862|NCT03110094|OTHER|Healthy volunteers|Collection of 2 tubes of blood. The values of the quantitative study of lymphocyte subpopulations will be compared to those obtained from healthy blood donors to define the standards used in this study.
223703863|NCT03630042|DRUG|Pembrolizumab|200 mg IV dose given on day 1 of a three week cycle
223703864|NCT03630042|DRUG|Rituximab|375 mg/m2 IV dose given up to 8 times in the trial
223703865|NCT05598385|PROCEDURE|Open cannulation|A small incision is made to access the FA and FA. Afterwards, the incision site is traditionally closed with sutures.
223703866|NCT05598385|PROCEDURE|Percutaneous cannulation|Cannulation is performed through a suture-mediated closure system.
223703867|NCT04210323|DEVICE|ShotBlocker®|The injection area gripped with ShotBlocker®, released after the drug administration and then the ShotBlocker® was removed. After injection, light pressure was applied to the injection area with dry cotton.
223703868|NCT04210323|DEVICE|Placebo group|The smooth surface (opposite side) of the ShotBlocker® was placed in the injection area just before administration by an experience registered nurse and the drug was injected by holding it on the skin surface during the injection. The process was managed by the researcher.
223703869|NCT01135290|DRUG|Aquaphor|
223703870|NCT01135290|DRUG|HP828-101|
223703871|NCT01491971|DRUG|Degarelix|
223703872|NCT03277157|DIETARY_SUPPLEMENT|B. lactis B94|A probiotic dose of 15 billion per capsule.
223703873|NCT03277157|DIETARY_SUPPLEMENT|Placebo|Placebo capsule
223703874|NCT04549961|OTHER|Nutrition|type and amount of food eaten or type and amount of oral nutritional supplements as well as enteral or parenteral nutrition
223703875|NCT02748473|OTHER|Pilates Exercises program|"The volunteers were divided in two groups:~Group I: Pilates exercise program involving only the Pilates exercises protocol Group II: Pilates exercises program with voluntary pelvic floor muscle contraction.~The protocol of both groups consisted of 24 bi-weekly 1-h individual sessions of Pilates exercises program.~Both groups performed the same protocol . For the group PEP + PFMC the instructor asked for the maximum contraction muscle of the pelvic floor muscle, during expirations with 5 repetitions performed alternately, thus avoiding pelvic floor muscle exhaustion.~After the 24 sessions, both groups were retested with the same measured methods of the baseline."
223703876|NCT02748473|OTHER|Pelvic floor muscle strength|evaluated the pelvic floor strength by oxford scale and vaginal pressure before and after the 12 sessions with Pilates Exercises Program on sedentary nulliparous women
223703877|NCT02748473|OTHER|3D perineal ultrasound|evaluated the pubovisceral muscle thickness and levator hiatus area by 3D perineal ultrasound before and after the 12 sessions with Pilates Exercises Program on sedentary nulliparous women
223703878|NCT05220917|DRUG|SGLT2 inhibitor|Any SGLT2i dispensing claim
223703879|NCT05220917|DRUG|DPP-4 inhibitor|Any DPP-4 inhibitor claim
223703880|NCT05220917|DRUG|GLP-1RA|Any SGLT2i dispensing claim
223703881|NCT05220917|DRUG|2nd generation SU|Any 2nd generation SU claim
223703882|NCT02210650|PROCEDURE|Symptomatic stone removal|Symptomatic stone removal by the surgical procedures called Ureteroscopy or Percutaneous Nephrolithotomy
223703883|NCT02210650|PROCEDURE|Asymptomatic kidney stones and ureteral stone removed|Asymptomatic kidney stones and symptomatic stone removal by the surgical procedure called Ureteroscopy
223703884|NCT02540109|DEVICE|HD-tDCS (Soterix Medical, Active)|Subject will be given individualized dose (number of electrodes and electrode placement) through High-Definition electrodes to target fMRI determined targets.
223703885|NCT02540109|DEVICE|HD-tDCS (Soterix Medical, Sham)|Subject will be given individualized dose (number of electrodes and electrode placement) through High-Definition electrodes to target fMRI determined targets.
223703886|NCT01580085|OTHER|polysomnography|full night supervised laboratory polysomnography
223703887|NCT04849754|DIAGNOSTIC_TEST|bone scintigraphy|Bone scintigraphy
223703888|NCT02291874|DRUG|Ipragliflozin|oral
223703889|NCT06457269|DIAGNOSTIC_TEST|Diagnosis by three human doctors|This intervention involves answering patient inquiries by different human doctors. Each patient is randomly assigned by the system to three doctors from different provinces in China selected from the database of doctors. The doctors all come from multiple online consultation platforms in China, and their diagnostic qualifications and medical licenses have undergone strict verification.
223703890|NCT06457269|DIAGNOSTIC_TEST|Diagnosis by ChatGPT-3.5 (with search capabilities)|This intervention involves answering patient inquiries by ChatGPT-3.5 with search capabilities, before answering any questions, clear the chat history from the previous patient and input the predetermined initialization statement.
223703891|NCT06457269|DIAGNOSTIC_TEST|Diagnosis by ChatGPT-3.5 (without search capabilities)|This intervention involves answering patient inquiries by ChatGPT-3.5 without search capabilities, before answering any questions, clear the chat history from the previous patient and input the predetermined initialization statement.
223703892|NCT06457269|DIAGNOSTIC_TEST|Diagnosis by ChatGPT-4.0 (with search capabilities)|This intervention involves answering patient inquiries by ChatGPT-4.0 with search capabilities, before answering any questions, clear the chat history from the previous patient and input the predetermined initialization statement.
223788545|NCT04667117|DRUG|Ofatumumab|"Auto-injector containing 20 mg ofatumumab (20 mg/0.4mL) for subcutaneous (s.c.) administration.~* Participants in Cohort 1 received loading doses of 20 mg ofatumumab s.c. at Weeks 2, 3, and 4 in the Investigational Period. In the open-label Extension Period, they administered the first dose of ofatumumab at Week 6 and continued monthly dosing until the final dose at Week 26. Novartis supplied participants in Cohort 1 with ofatumumab treatment.~* Participants in Cohort 2 continued on their commercially prescribed ofatumumab treatment during the Investigational Period. In the open-label Extension Period, they continued to administer ofatumumab monthly until the final dose at Week 28. Cohort 2 participants in the extension could have either remained on their prescribed ofatumumab or switched to study supplied ofatumumab."
223788546|NCT04667117|DRUG|iDMT|Participants in Cohort 3 continued on their commercially prescribed injectable disease modifying therapy (iDMT) during the Investigational Period.
223703893|NCT06457269|DIAGNOSTIC_TEST|Diagnosis by ChatGPT-4.0 (without search capabilities)|This intervention involves answering patient inquiries by ChatGPT-4.0 without search capabilities, before answering any questions, clear the chat history from the previous patient and input the predetermined initialization statement.
223703894|NCT06457269|DIAGNOSTIC_TEST|Diagnosis by Claude instant (with search capabilities)|This intervention involves answering patient inquiries by Claude instant with search capabilities, before answering any questions, clear the chat history from the previous patient and input the predetermined initialization statement.
223788547|NCT05531539|DEVICE|WELMO sensors vest|Wearing of a vest equipped with lung auscultation and EIT sensors for signal acquisition and transmission
223788548|NCT05593835|DEVICE|METHIS Platform|The METHIS platform is a digital healthcare platform, supported by three databases using PostreSQL (based in relational SQL). One of the databases allows adequate internal testing before production. Another database of production (secured with unique access codes) will be created to retrieve data from the practices' and the last database for the research data, where pseudonymised production data can be analysed for research purposes. The platform is integrated (via FCCN Scientific Computation Unit of the Portuguese Fundação para a Ciência e a Tecnologia) with the Software Zoom® to allow encrypted teleconsultations, with a guarantee that each patient connection is unique. The digital platform is web-based, and it can be used in multiple devices.
223788549|NCT05593835|OTHER|Goal-Oriented Care Training Program|The training program will have three stages: initial face-to-face training, which will happen before the data collection, followed by remote, asynchronous training during a 12-month period, and a final seminar to discuss the results and inquire about the usability of the GOC model and the METHIS platform. The course will be offered to the intervention group one month before the start of patient recruitment, and for the control group at least one month after the end of data collection.
223788550|NCT02418325|BIOLOGICAL|Allogeneic Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells|Super selective intravenous administration of 50 million Allogeneic Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells (UC-MSC) and intrathecal administration of UC-MSCs in dose of 100 million along with liberation therapy (when associated with CCSVI)
223788551|NCT02418325|OTHER|Liberation therapy|
223788552|NCT01634698|DIETARY_SUPPLEMENT|retinyl palmitate (UNICEF, Melbourne, Australia)|the patients received an oral dose of 1500 IU or 2500 IU, once.
223788553|NCT01195012|BEHAVIORAL|Helping HAND (Healthy Nutrition and Activity Directions)|6-month behavioral intervention targeting 5-8 year old children and their parents to improve the child's lifestyle behaviors to improve their weight status. The families met monthly with trained Health Advisors for individual sessions in the pediatric clinic with phone calls in between visits to check on progress.
223788554|NCT00644722|DEVICE|MacIntosh Green Lite (metal single use laryngoscope blades)|metal single use laryngoscope blades
223788555|NCT00644722|DEVICE|MacIntosh Green Spec II (metal reusable laryngoscope blades)|metal reusable laryngoscope blades
223788556|NCT05373394|OTHER|Test battery|motor and neuropsychological test battery
223788557|NCT02883725|OTHER|data collection|
223788558|NCT03646786|DEVICE|Virtual reality tests|"The patient will complete 3 self-questionnaires and pass 3 exploratory tests of virtual reality:~1. 10 minutes sitting test: detection of 5 targets in a 360 ° field of vision~2. 10-minute stand-up motionless test: detection of 5 targets in a 360 ° field of view and placing ingredients of a recipe~3. Standing 10-minute test: the patient moves to the site of his mission, detection of 5 targets in a 360 ° field of vision and preparing a recipe"
223788559|NCT01947946|BIOLOGICAL|Benralizumab|"Benra 30 mg q.4 Weeks is a fixed 30 mg dose of benralizumab subcutaneously on study week 0 until study week 44 inclusive.~Benra 30 mg - Placebo q.8 Weeks is a fixed 30 mg dose of benralizumab, every 4 weeks for the first 3 doses and then every 8 weeks thereafter, (placebo injections administrated at the 4 week interim visits to maintain blind). It is subcutaneously administered on study week 0 until study week 44 inclusive."
223788560|NCT01947946|BIOLOGICAL|Placebo|Placebo subcutaneously on study week 0 until study week 44 inclusive.
223788561|NCT05013333|DEVICE|AED 3 with Uni-padz|Use of AED 3 with Uni-padz by lay rescuer
223788562|NCT03446443|DRUG|Honghe Fujie lotion|Before application，wash the vaginal area with water and dry it. Take10ml Hong He Fujie into dilution bottles，added to 100ml with warm boiled water, using diluted lotion for the rinse of vulva and vagina, twice daily for 7days.
223788563|NCT03446443|DRUG|Metronidazole Suppositories|Before bedtime，wash the vaginal area and put 0.5g Metronidazole Suppositories into posterior vaginal fornix，once daily for 7days.
223788564|NCT01059760|BEHAVIORAL|Fasting First|28±4 hours of water-only fasting followed by 28±4 hours fed
223788565|NCT01059760|BEHAVIORAL|Fed First|28± 4 hours fed followed by 28± 4 hours of fasting
223788566|NCT02176135|DRUG|Auranofin|3 mg tablets
223788567|NCT00659633|DRUG|lidocaine|intravenous, effect site concentration: 2mcg/ml, 15-20 min infusion, once
223788568|NCT00385931|DRUG|Valsartan and simvastatin|
223788569|NCT03836287|DRUG|Sofpironium Bromide Gel, 15%|Active
223788570|NCT03836287|DRUG|Vehicle|Vehicle gel
223788571|NCT02000245|BEHAVIORAL|verbal expression for compassion|The doctor going to perform bronchoscopy tells a short sentence to a patient. (Hello, I'm Dr.OO. During this test, I will keep an eye on you. Don't worry)
223788572|NCT02000245|BEHAVIORAL|touch|The doctor going to perform bronchoscopy puts a hand on the patient's shoulder
223788573|NCT06163755|DRUG|Methylprednisolone 40 MG Injection|Intra-articular knee injection will be performed in patient with knee osteoarthritis who meets inclusion criteria. After Random assignment Patient will either get Intra-articular Morphine with Bupivacaine or Depomedrol with Bupivacaine.
223788574|NCT00563199|BEHAVIORAL|nurse-delivered stage-matched smoking cessation counseling|
223788575|NCT02199262|OTHER|music intervention|reminder+ 20 minutes in the morning and 20 minutes in the afternoon of music listening(classical or soft background music), delivered by compact disc players with headphones with disposable ear pads.
223788576|NCT02199262|OTHER|reflexology|reminder + 20 minutes per day feet reflexology massage provided by certified specialist in reflexology massages
223788577|NCT02199262|OTHER|reminder|Implementation of a reminder of guidelines of agitation diagnosis and management
223788578|NCT04159688|DRUG|Alcohol|Alcohol Challenge
223788579|NCT04287374|BEHAVIORAL|Multi-component Well-being Intervention|The intervention asks participants to complete exercises based on three different skills. These skills include cognitive restructuring, gratitude and behavioral activation. After completing the program, participants will pick their favorite exercise to complete on a weekly basis for homework. In order to increase compliance with the homework, participants will complete a short plan in which they will identify when, where and with who they will complete the homework. The whole intervention takes approximately 20-30 minutes to complete.
223788580|NCT04287374|BEHAVIORAL|Study Skills|Participants are taught three different study skills/strategies. They are asked to make a plan to continue using these strategies after completing the intervention. The whole intervention takes approximately 20-30 minutes to complete.
223788581|NCT03264872|BEHAVIORAL|Peer-Enhanced Motivational Interviewing|Target clients in this Peer-Enhanced Motivational Interviewing arm will receive separate one-hour Motivational Interviewing (MI) sessions, in which the therapist reviews the target clients substance use behaviors in a non-confrontational manner, listens empathetically, and reinforces any client statements indicating a desire the change. In this arm, the therapist also presents the target client's peer with data about the extent of the target client's substance use, builds the peer's motivation to help their friend, and teaches the peer communication sills they can use to influence the target client's substance use behaviors.
223788582|NCT03264872|OTHER|Waitlist Control|After the 12 week follow up period, if subjects in the Waitlist Control group desire to receive the Peer-Enhanced Motivational Interviewing intervention, that will be made available to them.
223788583|NCT00935025|DRUG|AZD1305|single and multiple oral doses, extended-release capsule
223788584|NCT00935025|DRUG|Placebo|single and multiple oral doses, capsule
223788585|NCT04974216|DRUG|Tafasitamab|Administration : IV at 12mg/Kg C1 to C3: D1, D8, D15, D22 C4 to C6: D1, D15 C7 to C12: D1
223788586|NCT04974216|DRUG|Lenalidomide|Oral administration: hard capsule C1 to C6: 20mg/day C7 to C12: 15mg/day
223788587|NCT04974216|DRUG|Rituximab|Administration: IV at 375mg/m2 C1 to C6: D1
223788588|NCT02428868|DRUG|tranexamic acid (Exacyl®)|1 gram diluted in 20 mL saline solution, in 30 minutes, five minutes before skin incision and a second 1 gram, 3 hours later
223788589|NCT02428868|DRUG|intravenous iron (Ferroven®)|2 vials of 10 mL containing each one 100 mg iron, diluted in 100 mL normal saline over 30 minutes before induction of anesthesia and repeated on day two and three.
223788590|NCT02428868|OTHER|Saline|20 mL saline in 30 minutes, five minutes before skin incision and 20 ml 3 hours later.
223788591|NCT04635722|BEHAVIORAL|Weight Management Intervention|Participants attend group and individual dietary education sessions. Participants create a diet plan that satisfies their needs. Participants aim to lose 1 pound weekly until a BMI of 25 is reached. Participants are evaluated through daily self-weighing, dietary records, and food frequency questionnaires.
223788592|NCT06336096|DRUG|Suzetrigine|Tablet(s) for oral administration.
223788593|NCT06336096|DRUG|Suzetrigine|Tablet(s) and Suspension for oral administration.
223788594|NCT02320604|DRUG|Administration of study drug|i.v. administration of Ambisome in two different dossages
223788595|NCT02324933|DRUG|Fentanyl|Fentanyl Patient Controlled Analgesia for post-operative pain management
223788596|NCT01265069|DRUG|high dose dual therapy|rabeprazole 20mg qid,amoxicillin 750mg qid for 14days
223788597|NCT01265069|DRUG|concomitant therapy|rabeprazole 20 mg,amoxicillin 1000 mg,metronidazole 500 mg,clarithromycin 500 mg, bid for 10 days
223788598|NCT00250887|DRUG|Gefitnib|
223788599|NCT05110859|OTHER|in-depth individual interviews|in-depth individual interviews to explore their perspectives on their first work experience during covid-19 pandemic
223703895|NCT06457269|DIAGNOSTIC_TEST|Diagnosis by Claude instant (without search capabilities)|This intervention involves answering patient inquiries by Claude instant without search capabilities, before answering any questions, clear the chat history from the previous patient and input the predetermined initialization statement.
223703896|NCT06457269|DIAGNOSTIC_TEST|Diagnosis by Claude 2 (with search capabilities)|This intervention involves answering patient inquiries by Claude 2 with search capabilities, before answering any questions, clear the chat history from the previous patient and input the predetermined initialization statement.
223703897|NCT06457269|DIAGNOSTIC_TEST|Diagnosis by Claude 2 (without search capabilities)|This intervention involves answering patient inquiries by Claude 2 without search capabilities, before answering any questions, clear the chat history from the previous patient and input the predetermined initialization statement.
223703898|NCT06457269|DIAGNOSTIC_TEST|Diagnosis by Gemini Pro (with search capabilities)|This intervention involves answering patient inquiries by Gemini Pro with search capabilities, before answering any questions, clear the chat history from the previous patient and input the predetermined initialization statement.
223703899|NCT06457269|DIAGNOSTIC_TEST|Diagnosis by Gemini Pro (without search capabilities)|This intervention involves answering patient inquiries by Gemini Pro without search capabilities, before answering any questions, clear the chat history from the previous patient and input the predetermined initialization statement.
223703900|NCT06562803|DEVICE|double plasma cytokine adsorption system with sequential low-dose plasma exchange|"Both groups received comprehensive medical treatment, including antiviral therapy for hepatitis B, anti-infection treatment, supportive care, symptomatic treatment, and prevention of complications. Artificial liver therapy was initiated for both groups on the day of enrollment, with treatments administered every other day for a total of two sessions.~The experimental group underwent treatment with the double plasma cytokine adsorption system with sequential low-dose plasma exchange (DPCAS+LPE). This involved using a cytokine adsorption column (CA280,Jafron Biomedical Co., Ltd., Zhuhai, China) and a bilirubin adsorption device (BS330,Jafron Biomedical Co., Ltd., Zhuhai, China) on the same treatment circuit. DPCAS treatment was performed first, with an adsorption volume of 4500ml to 5000ml over 2 to 3 hours, followed by plasma exchange (PE), with 1000ml of plasma and 500ml of 4% albumin being infused."
223703901|NCT06562803|OTHER|plasma exchange|Based on comprehensive medical treatment, the control group received plasma exchange(PE) treatment, where whole blood was processed through a plasma separator (MICROPLAS MPS 07, BELLCO S.R.L., Italy), with a portion of the plasma discarded and replaced with 1000ml of plasma and 500ml of 4% albumin.
223703902|NCT02504684|DEVICE|Endovenous 1920-nm diode laser|Patients with saphenous veins treated with a new 1920-nm diode endolaser.
223703903|NCT02504684|DEVICE|Endovenous 1470-nm diode laser|Patients with saphenous veins treated with the standard 1470-nm diode endolaser.
223703904|NCT06277219|DRUG|LAT010|LAT010 monotherapy
223703905|NCT06277219|DRUG|LAT010 + ICI|LAT010 combination with PD-1 inhibitor
223703906|NCT01422252|DEVICE|Vigi'Fall®|Precocious fall detection device
223703907|NCT04893226|BEHAVIORAL|Time-Restricted Feeding (TRF)|Subjects will be educated about the health benefits of time-restricted feeding (TRF). Each subject in the TRF group will self-select a 10 hour (10h +/- 1hr) window aligned with their active phase during which they will consume all daily calories. Subjects will text the time of their first and last daily meals for the duration of the study.
223703908|NCT06215131|BEHAVIORAL|In-person dietary weight loss counseling|The counseling content will be 30 minutes of RDN delivered educational session on energy density and portion sizes then the second 30 minutes being the RDN answering participant questions and providing feedback.
223703909|NCT06215131|BEHAVIORAL|Virtual reality dietary weight loss counseling|The counseling content will be 30 minutes of virtual reality delivered educational session on energy density and portion sizes with an RDN remotely monitoring then the second 30 minutes being the RDN answering participant questions and providing feedback through synchronous audio/video.
223703910|NCT04574323|RADIATION|Curative radiotherapy|Standard curative radiotherapy
223788600|NCT01265329|OTHER|Negative selection|Sperm selection to continue the treatment with healthy sperm
223788601|NCT05819333|OTHER|Exercise Program + Respiratory Strength Training|Strength, Flexibility, Cardiovascular exercise + respiratory strength training
223788602|NCT05819333|OTHER|Exercise Program + Respiratory Relaxation Training|Strength, Flexibility, Cardiovascular exercise + respiratory relaxation training
223788603|NCT04833647|DIAGNOSTIC_TEST|Cardio-Pulmonary-Exercise-Testing (CPET)|Cardio-Pulmonary-Exercise-Testing (CPET) . During the exercise testing, serial saturation, heart rate and blood pressure measurements were obtained. The peak oxygen consumption (VO2max) was measured and served as the primary endpoint of the study
223788604|NCT04977167|DRUG|HG146|HG146 is available as Capsule at a unit dose strength of 5 mg and 10 mg.
223788605|NCT04977167|DRUG|PD-(L)1 antibody|PD-(L)1 Antibody is available as solution for infusion or lyophilized powder for reconstitution to be administered Q3W. It will be administered as an IV infusion for 30 minutes.
223788606|NCT02542748|DRUG|Norepinephrine|norepinephrine injection
223788607|NCT02542748|DRUG|Ephedrine|Ephedrine injection
223788608|NCT05207059|BEHAVIORAL|HELMS Lifestyle Intervention|The HELMS life-course Interventions, namely 4S ('Screening', 'Size', 'Supplementation' and 'Specific case management'), are developed to deliver care throughout the journey from preconception to postpartum periods. Screening involves health and risk assessments through physical and biomarker measurements, as well as emotion and sleep evaluations for mother, and developmental assessment for children. Body Size management encompasses education on weight status awareness and mother-child health implications, both mother-child weight tracking, healthy eating and physical activity guidance. Supplementation includes multi-micronutrient, vitamin D, calcium and/or Docosahexaenoic acid (DHA) supplements, which is phase-specific for mother, and vitamin D drops supplement for child. Specific case management comprises preconception sexual health and function management, pregnancy symptoms management, postpartum recovery management, infant growth monitoring and feeding management.
223788609|NCT06400186|BEHAVIORAL|High intensity gait training in varying external environments|Participants will engage in two 45-minutes treadmill-based gait training sessions. These training sessions will occur on separate days. One session will be performed in a natural unmodified environment. One session will be performed in a movement amplification environment. The goal of each session will be to achieve 40-minutes of walking within a target heart rate range of 70-85% of estimated heart rate max. Each session will begin and end with a 2.5 minute warm-up and cool down respectively. Participants will be given rest breaks as needed.
223788610|NCT06400186|BEHAVIORAL|Treadmill walking in varying external environments|Participants will perform a series of treadmill walking trials. Each trial will consist of 400 total steps. The first 100 steps will be performed in a natural unmodified environment. The next 200 steps will be performed in 1 of 3 external environments (natural unmodified, movement amplification, or unpredictable lateral perturbations). The final 100 steps will be performed in a natural unmodified environment. Participants will be given rest breaks between trials.
223788611|NCT03391479|DRUG|Avelumab|Avelumab is a fully human monoclonal antibody (mAb) of the immunoglobulin (Ig) G1 isotype. Avelumab selectively binds to programmed death-ligand 1 (PD-L1) and competitively blocks its interaction with programmed death protein 1 (PD-1).
223788612|NCT03391479|OTHER|Best Supportive Care|As required.
223788613|NCT04065438|DEVICE|LIPOSORBER® LA-15|"LIPOSORBER® LA-15 is a blood purification therapy; selectively removes apoprotein B-containing lipoproteins such as LDL from circulating blood and rapidly reduces the plasma cholesterol level. It was originally developed for prevention of coronary atherosclerosis progression in patients with serious hyperlipidemia such as familial hypercholesterolemia.~In the late 1980's, LDL-A was used to improve dyslipidemia in Nephrotic Syndrome, initially to prevent organ damage. LDL-A was found to improve both the dyslipidemic condition and clinical symptoms (proteinuria and hypoproteinemia)."
223788614|NCT01673139|BEHAVIORAL|Interval exercise|4 times of 4 minutes intervals at an intensity of 90-95% of maximum heart rate and active pauses of 3 minutes between intervals. 3 times a week for 3 years.
223788615|NCT01673139|BEHAVIORAL|Moderate exercise|Moderate exercise with pulse about 70% of max pulse; 3 times a week for 3 years.
223788616|NCT01673139|BEHAVIORAL|Control|Given information on recommendations for physical activity.
223788617|NCT06530823|DRUG|Pemigatinib and Durvalumab|Pemigatinib combined with Durvalumab Pemigatinib: 13.5mg, oral administration, once daily, swallow the entire tablet with or without food. Take for 2 weeks and then discontinue for 1 week. Durvalumab: 1500mg, intravenous infusion, once every three weeks. Each infusion should take over 60 minutes.
223788618|NCT04396613|PROCEDURE|Closure technique|Randomized assignment to one of three known, effective closure techniques
223788619|NCT04152733|DEVICE|High flow nasal cannula|Oxygen is supplied via high flow nasal cannula. Heated air (2L/kg/min) is administered using Optiflow device (Fisher and Paykel Healthcare, Auckland, New Zealand).
223788620|NCT03297268|OTHER|Intervention with Home-Based Caregivers|We will assess whether real-time notifications of potential agitation via a wearable wrist device improves caregiver self-efficacy.
223788621|NCT04637204|DRUG|Cabozantinib|oral therapy
223788622|NCT04637204|DRUG|Axitinib|oral therapy
223788623|NCT02785367|PROCEDURE|Cord blood samples|"After delivery, 8 cord blood samples will be taken from the umbilical cord in 8 syringes of about 3 ml, washed with Heparin (Designated syringes exist in the delivery room). 4 syringes will be stored in room temperature. Thermometer will be attached to any sample, and temperature values will be indicated before any measurement.~The samples will be measured in a gas measurement device, in 4 time points: at the birth, after 15 minutes, after 30 minutes and after 60 minutes from the birth."
223788624|NCT05383677|DRUG|Anifrolumab|Anifrolumab 300 mg will be administered in intravenous infusions once per 4 weeks, for a total treatment period of 24 weeks.
223788625|NCT05383677|DRUG|Placebo|Placebo will be administered in intravenous infusions once per 4 weeks, for a total treatment period of 24 weeks.
223788626|NCT06099106|DEVICE|SEPIOLA System|Implantation of the SEPIOLA device into the left atrial appendage.
223788627|NCT02506998|BIOLOGICAL|DLE|Adjuvant treatment
223788628|NCT02506998|OTHER|Second generation anti histamines + Nasal corticosteroids|Standard treatment
223788629|NCT06372093|DEVICE|Picterus Jaundice Pro|Picterus Jaundice Pro is a smartphone based screening tool for neonatal jaundice that takes images of the skin of the newborn chest where the Picterus Calibration Card is placed.
223788630|NCT00443248|DEVICE|Vaginal Heat Wash-Out Device|No drug administered. Device tested twice with each subject.
223788631|NCT04780204|DRUG|Treatment|Tenofovir Alafenamide 25 mg oral once daily
223788632|NCT00022776|PROCEDURE|Surgical decompression|Simple decompression not requiring fusion.
223788633|NCT00022776|PROCEDURE|Physical therapy|2 physical therapy sessions per week for 6 weeks Followed by home program.
223788634|NCT05805397|BEHAVIORAL|Motivation Skills Training|Participants will complete a baseline assessment, receive weekly MST sessions in a group format for a duration of 12 weeks, and will then repeat the assessment battery from baseline immediately following treatment completion and 2-months after.
223788635|NCT05805397|BEHAVIORAL|Healthy Behaviors Control Group|Participants will complete a baseline assessment, receive weekly HBC sessions in a group format for a duration of 12 weeks, and will repeat the assessment battery from baseline immediately following treatment completion and 2-months after.
223788636|NCT04491500|BEHAVIORAL|High attitude environment|The participants will go to 4000m altitude to work for two weeks.
223788637|NCT01881308|DRUG|TNF inhibitors|
223788638|NCT01881308|DRUG|Synthetic DMARD(s)|
223788639|NCT01881308|DRUG|Co-medication: Synthetic DMARDs|Synthetic DMARDs given as co-medication for TNF inhibitors as appropriate.
223788640|NCT03291444|BIOLOGICAL|Chimeric antigen receptor T cells|After pretreatment, chimeric antigen receptor T cells will be transfused.
223788641|NCT03291444|BIOLOGICAL|peptide specific dendritic cell|After transfusion of chimeric antigen receptor T cells, Eps8 or WT1 peptide specific dendritic cell were intradermal injected.
223788642|NCT03186846|DEVICE|multimodal monitoring|LiDCO Rapid, unilateral INVOS and unilateral BIS monitors will be applied. Should there be pre-existing carotid stenosis, INVOS sensor will be applied on the same side. In case of pre-existing cerebral pathology, the INVOS sensor will be applied to the contralateral side. Baseline values of nominal stroke index (SI), cardiac index (CI), BIS, mean arterial pressure (MAP) and regional oxygen saturation (rSO2) will be recorded. Basal rSO2 will be recorded prior to preoxygenation which raises the value. • Before the induction, up to 250ml of balanced crystalloid solution will be administered. These will include antibiotics solvents and other pre-induction i.v. therapy.
223788643|NCT03186846|DEVICE|placebo|Before the induction, up to 250ml of balanced crystalloid solution will be administered. These will include antibiotics solvents and other pre-induction i.v. therapy.
223788644|NCT01805297|DRUG|Intravitreal Aflibercept Injection|One time 2.0mg aflibercept injection, following pars plana vitrectomy.
223788645|NCT01805297|OTHER|Standard Vitrectomy|Surgical intervention
223788646|NCT05501093|OTHER|sample collection|Blood, plaque, and other oral samples
223788647|NCT04455100|DRUG|SHR1459/Itraconazole|SHR1459 will be administered on Day 1 and Day 7. Itraconazole will be administered on Day 4 to Day 8
223788648|NCT00836641|BIOLOGICAL|prevenar|7-valent pneumococcal conjugate vaccine
223788649|NCT00836641|BIOLOGICAL|pneumovax|23 valent pneumococcal polysaccharide vaccine
223703911|NCT04574323|OTHER|Paleolithic lifestyle intervention|This intervention consists of daily outdoor walks or bike rides of at least 30 min duration, preferably done at noon to maximize vitamin D production, and the adoption of a Paleolithic diet. For the outdoor activity, patients were told to not use sun screen. The Paleolithic diet prescription emphasized the consumption of fatty meats and organ meats from humanely raised animals, wild-caught fish, eggs, nuts and seeds, algae, spices, vegetables and fruits. Excluded were processed foods, grains of all types, legumes, vegetable oils except for native coconut and olive oil and dairy products except for ghee. No dietary supplements were allowed.
223703912|NCT06664606|BEHAVIORAL|Pain Neuroscience Education Program (PNE)|The Pain Neuroscience Education (PNE) Program is a structured educational intervention aimed at primary school students with and without intellectual disabilities. This program introduces students to basic concepts of pain neuroscience, designed to increase understanding of pain mechanisms and promote healthy pain coping strategies. The intervention was adapted to 'easy reading' format to ensure accessibility for students with intellectual disabilities, and was delivered in both rural and urban school settings in Extremadura, Spain.
223703913|NCT03049722|DEVICE|Pacemaker|
223703914|NCT05670847|DRUG|Exogenous ketone ester|500 mg/kg orally three times daily (with at least 4 hours between each dose) for 28 days
223703915|NCT06617026|DRUG|Sucralfate|a topical rectal ointment. The patients are instructed to apply it twice a day, using a gloved finger, inside the anal canal and the perianal region for 40 days
223703916|NCT06617026|DRUG|Azadirachtin|a topical oil. The patients are instructed to apply it twice a day, using a gloved finger, inside the anal canal and the perianal region for 40 days
223703917|NCT06617026|PROCEDURE|fissurectomy and lateral sphincterectomy|fissurectomy and lateral sphincterectomy
223703918|NCT06680336|DIAGNOSTIC_TEST|Mulit-componant neuropsychological assessment|Multi-component cognitive assessment including following domains: attention \& information speed, executive functioning, verbal memory, language, visuospatial-construction and orientation.
223703919|NCT06680336|DIAGNOSTIC_TEST|Multimodal MRI|Structural MRI (e.g., MPRAGE, DTI) and functional MRI (introducing a modified working memory task for stroke patients)
223703920|NCT06681844|OTHER|Tooth Shape assessed using an intraoral scanner one after avulsion|"* Tooth Shape assessed using an intraoral scanner one after avulsion and stored as StereoLithography (STL) file~* Age, gender, reason of avulsion, type of tooth taken from the database and stored in a google sheet"
223703921|NCT06680167|DRUG|Spinal anesthesia (heavy bupivacaine 0.5%)|12.5mg of Heavy bupivacaine 0.5% will be injected intrathecally for women undergoing elective caesarean section
223703922|NCT06680167|DRUG|spinal anesthesia (hyperbaric Prilocaine 2%)|60mg of Hyperbaric Prilocaine 2% will be injected intrathecally for women undergoing elective caesarean section
223703923|NCT06680466|DRUG|YZJ-4729|Dose Group 1
223703924|NCT06680466|DRUG|morphine|morphine,
223703925|NCT06680466|DRUG|placebo|placebo
223703926|NCT06680466|DRUG|YZJ-4729|Dose Group 2
223703927|NCT06680466|DRUG|YZJ-4729|Dose Group 3
223703928|NCT06680466|DRUG|YZJ-4729|Dose Group 4
223703929|NCT06681636|BIOLOGICAL|Human papillomavirus 9-valent vaccine, Recombinant|HPV vaccine manufactured by MSD consisted of 9HPV types: 6,11,16,18,31,33, 45, 52,58
223703930|NCT06681519|PROCEDURE|Experimental Group 1 - Acupoint Pressure Experimental Group 2 - Pressure Ball Control Group - Conventional Treatment|"Interventions Group 1 - Acupoint Pressure Group 2 - Hand-Held Pressure Ball Control Group 3 - Conventional Treatment Other Names: Stress ball holding, acupoint pressure, conventional treatment~Description: Before the intervention, subjects completed a pre-test. Afterward, they assumed a relaxed, comfortable lying position. The examiner applied acupoint pressure at four specific points: Hegu (LI4), Shenmen (HT7), Neiguan (PC6), and Zhongchong (PC9).~The technique involves using the thumb pad to apply circular and vertical pressure on each acupoint, with the other four fingers stabilizing against the skin to ensure even pressure. The pressure is gradually increased from light to moderate until the patient experiences sensations of soreness, numbness, or swelling, commonly described as deqi (Ye Meiling et al., 2020).~Each acupoint is pressed vertically for 3 seconds, then rotated clockwise at a rate of 2-3 rotations per second for another 3 second"
223788650|NCT02372396|BEHAVIORAL|Compassion Meditation (CM)|Compassion meditation is a meditative practice focused on the wish that others and the self may be free of suffering. Because this particular form of meditation has been shown to elicit positive emotion and feelings of connection with other people, it is uniquely well suited to addressing PTSD, which is characterized by strong negative affect, deficits in positive emotion and social connectedness.
223788651|NCT02372396|BEHAVIORAL|Relaxation|Relaxation Training is selected as the control condition because it is a good match for nonspecific aspects of the meditative practice (e.g., attention, support, contact with a mental health provider) and it is structurally similar to meditation (e.g., restful, in session and at home exercises).
223788652|NCT02890381|BIOLOGICAL|RSV LID cp ΔM2-2 Vaccine|10\^5 plaque-forming units (PFUs); administered as nose drops
223788653|NCT02890381|BIOLOGICAL|Placebo|Isotonic diluent, administered as nose drops
223788654|NCT05010759|DEVICE|NanoTherm Ablation|Iron nanoparticles are instilled into the prostate cancer lesion and then the particles are heated using a magnetic field and this heating ablates the prostate cancer lesion.
223788655|NCT06536881|BEHAVIORAL|Fasting|The dietician will review the patient's chemotherapy schedule, and confirm the fasting window (as windows may be 24, 26 or 48 hours; and chemotherapy start times can vary from patient to patient).
223788656|NCT05217732|DRUG|ZX-7101A|tablet
223788657|NCT05217732|DRUG|Placebo|Tablet
223788658|NCT01272934|DRUG|Diclofenac Sodium|Topical gel 1%-4 times daily
223788659|NCT01272934|OTHER|Placebo|Topical gel-4 times daily
223788660|NCT04956393|BEHAVIORAL|Immediate 8-Week SOAR Program|"This is an 8-week, virtually delivered, exercise-based, knee health program delivered to knee injury participants by trained physiotherapists. The program has 3 components:~1. Knee Camp: This includes an interactive education session about knee health, 1:1 knee exam, and 1:1 counseling session to identify Specific, Measurable, Attainable, Relevant, and Time-bound (SMART) weekly home-based exercise-therapy and physical activity goals, Participants are asked to wear Fitbit's® 24-hours/day.~2. Weekly Home-based Exercise-Therapy and Physical Activity, with Tracking: At home, participants work to meet their exercise-therapy and physical activity goals. Exercises are tracked with an online bespoke form and activity, with a Fitbit.~3. Weekly PT-guided Exercise-Therapy and Physical Activity Counseling Sessions: Each week participants will attend a 1:1 virtual physiotherapist counseling session to modify SMART goals and have the option to attend a group exercise class."
223788661|NCT04956393|BEHAVIORAL|Delayed 8-Week SOAR Program|"This is an 8-week, virtually delivered, exercise-based, knee health program delivered to knee injury participants by trained physiotherapists. The program has 3 components:~1. Knee Camp: This includes an interactive education session about knee health, 1:1 knee exam, and 1:1 counseling session to identify Specific, Measurable, Attainable, Relevant, and Time-bound (SMART) weekly home-based exercise-therapy and physical activity goals, Participants are asked to wear Fitbit's® 24-hours/day.~2. Weekly Home-based Exercise-Therapy and Physical Activity, with Tracking: At home, participants work to meet their exercise-therapy and physical activity goals. Exercises are tracked with an online bespoke form and activity, with a Fitbit.~3. Weekly PT-guided Exercise-Therapy and Physical Activity Counseling Sessions: Each week participants will attend a 1:1 virtual physiotherapist counseling session to modify SMART goals and have the option to attend a group exercise class."
223788662|NCT00958035|DRUG|bimatoprost ophthalmic 0.03% solution|Apply one drop of study medication along the upper eyelid margin once daily in the evening
223788663|NCT00958035|DRUG|vehicle sterile solution (placebo)|Apply one drop of study medication along the upper eyelid margin once daily in the evening
223788664|NCT06193421|DRUG|Ambroxol Hydrochloride|75mg slow release (SR), X16/day or 300mg X4/day oral capsules.
223788665|NCT05860465|DRUG|SPH4336 Tablets|SPH4336 Tablets ：Administered by oral; Letrozole tablets：Administered by oral; Fulvestrant injection：Administered by intravenous infusion
223788666|NCT05860465|DRUG|SPH4336 Tablets Placebo|SPH4336 Tablets Placebo ：Administered by oral; Letrozole tablets：Administered by oral; Fulvestrant injection：Administered by intravenous infusion
223788667|NCT00413504|DRUG|Fondaparinux|
223788668|NCT02116634|BIOLOGICAL|mesenchymal stem cell|intra spinal injection of 1 ×10(8) mesenchymal stem cells +10cc normal saline
223788669|NCT05568992|DEVICE|AI system of optical detection of advanced adenomas|AI system of optical detection of advanced adenomas
223788670|NCT00417001|PROCEDURE|Aroma therapy|
223788671|NCT05629351|OTHER|Observational Group|"Demographic Data (Blood pressure, subcutaneous fat tissue, height, waist and hip circumference, and body weight, BMI (body mass index) and double product)~International Physical Activity Questionnaire (IPAQ)~Godin-Shephard Leisure-Time Physical Activity Questionnaire~The Dutch Eating Behavior Questionnaire~Pittsburg Sleep Quality Questionnaire~Perceived Stress Scale and Beck Depression Scale"
223788672|NCT06958081|DEVICE|Active transcranial direct current stimulation (tDCS)|2.0 mA anodal stimulation applied over FCz with cathode over Fp2 for 30 minutes using a transcranial direct current stimulation device.
223788673|NCT06958081|DEVICE|Sham transcranial direct current stimulation (tDCS)|Sham stimulation mimicking the sensations of tDCS; the current will be turned off after 30 seconds while maintaining electrode placement over FCz and Fp2.
223788674|NCT03955393|OTHER|18F-FAZA PET IMAGING TECHNIQUE IN DETECTING LYMPH NODE METASTASES IN RENAL CELL CARCINOMA PATIENTS|18F-FAZA is a highly selective PET radiotracer of hypoxia, which has been recently developed and tested in several studies (10-14). 18F-FAZA has been demonstrated to be a marker of hypoxia and pathological metabolic patterns which are common to all renal cancers.
223788675|NCT00951600|DRUG|oxcarbazepine 300 mg/5mL oral suspension|
223788676|NCT05761431|DRUG|SYHX2008 injection|Subcutaneous administration on Day 1.
223788677|NCT05761431|DRUG|Octreotide Acetate Microspheres for Injection injection|Intramuscular administration on Day 1.
223788678|NCT05761431|DRUG|Sandostatin ® injection|Subcutaneous administration on Day 1.
223788679|NCT05761431|DRUG|Placebo to SYHX2008 injection|Subcutaneous administration on Day 1.
223788680|NCT02310750|DRUG|PF-06700841 oral solution/suspension|Oral solution or suspension of study drug PF-06700841 (once daily or twice daily during multiple dosing periods)
223788681|NCT02310750|OTHER|Placebo|Matching placebo given during the single ascending and multiple dose periods
223788682|NCT02310750|DRUG|PF-06700841 tablet|PF-06700841 tablet formulation administered during the bioavailability / food effect investigation
223788683|NCT04095377|OTHER|No intervention, this is a retrospective study.|No intervention, this is a retrospective study.
223788684|NCT04349787|OTHER|Computer-aided diagnosis (CADx)|Optical diagnosis of colorectal polyps made with computer-aided diagnosis (CADx) using state-of-the-art machine learning methods and deep learning architectures.
223788685|NCT04349787|OTHER|BLI Adenoma Serrated International Classification (BASIC)|Optical diagnosis of colorectal polyps made with BLI Adenoma Serrated International Classification (BASIC), both by exert endoscopists and novices.
223788686|NCT01018901|OTHER|Survey Administration|Patients complete survey
223788687|NCT01226745|DRUG|ONO-4641|Subjects will be administered with ONO-4641 at a dose of 0.15 milligram (mg) in the core study will be administered with ONO-4641 0.15 mg in this extension study for a duration of 225 weeks.
223788688|NCT01226745|DRUG|ONO-4641|Subjects will be administered with ONO-4641 at a dose of 0.10 mg in the core study will be administered with ONO-4641 0.10 mg in this extension study for a duration of 225 weeks.
223788689|NCT01226745|DRUG|ONO-4641|Subjects will be administered with ONO-4641 at a dose of 0.05 mg in the core study will be administered with ONO-4641 0.05 mg in this extension study for a duration of 225 weeks.
223788690|NCT01226745|DRUG|ONO-4641|Subjects will receive placebo in the core study will be administered with ONO-4641 0.15 mg in this extension study for a duration of 225 weeks.
223788691|NCT01226745|DRUG|ONO-4641|Subjects will receive placebo in the core study will be administered with ONO-4641 0.10 mg in this extension study for a duration of 225 weeks.
223788692|NCT01226745|DRUG|ONO-4641|Subjects will receive placebo in the core study will be administered with ONO-4641 0.05 mg in this extension study for a duration of 225 weeks.
223788693|NCT03298126|PROCEDURE|TR BAND removal protocol|To assess radial artery patency after specific protocol used as already described in previous section.
223788694|NCT01435577|DRUG|Tapentadol|30 mg per administration, maximum 12 administrations over 48 hours
223788695|NCT01435577|DRUG|Matching Placebo|Maximum 12 administrations over 48 hours
223788696|NCT00395876|DRUG|placebo|2 mL of placebo instilled into lumen of dysfunctional CVC. Patients weighing ≥ 30 kg received 2-mL instillations of study drug (i.e., 2 mg of placebo). Patients weighing \< 30 kg received instillations of study drug equal to 110% of the internal lumen volume of the dysfunctional CVC. This dose was rounded to the nearest 0.1 mL and should not have exceeded 2 mL (2 mg).
223788697|NCT00395876|DRUG|tenecteplase|2 mL of reconstituted lyophilized tenecteplase instilled into lumen of dysfunctional CVC. Patients weighing ≥ 30 kg received 2-mL instillations of study drug (i.e., 2 mg of tenecteplase). Patients weighing \< 30 kg received instillations of study drug equal to 110% of the internal lumen volume of the dysfunctional CVC. This dose was rounded to the nearest 0.1 mL and should not have exceeded 2 mL (2 mg).
223788698|NCT00628771|BEHAVIORAL|CenteringPregnancy Plus (CP+)|The CenteringPregnancy model of group prenatal care involves skill-building in the areas of efficacy, risk assessment, negotiation, and prevention. CP+ integrates HIV prevention into prenatal care, builds on motivations for healthy pregnancy, and creates a sustainable model via reimbursement mechanisms for prenatal care. There will be ten 2-hour prenatal group sessions.
223788699|NCT00628771|BEHAVIORAL|Usual care|Usual care includes standard individual prenatal care and no prenatal group sessions.
223788700|NCT05797285|DEVICE|human keratin graft|The intervention to be applied is an advanced wound care matrix composed of human keratin to be applied at two different treatment frequencies.
223788701|NCT02792075|OTHER|5-year Follow-up|
223788702|NCT05609578|DRUG|Adagrasib oral dose of 400 mg twice daily tablets|oral dose of 400 mg twice daily tablets
223788703|NCT05609578|COMBINATION_PRODUCT|Pembrolizumab|IV infusion once every 3 weeks
223788704|NCT05609578|COMBINATION_PRODUCT|Chemotherapy: Pemetrexed|IV infusion once every 3 weeks
223788705|NCT05609578|COMBINATION_PRODUCT|Cisplatin/Carboplatin|IV infusion once every 3 weeks
223788706|NCT04388982|BIOLOGICAL|low dosage MSCs-Exos administrated for nasal drip|Dosage：5μg MSCs-Exos,Total volume： 1ml Frequency：Twice a week Duration：12 weeks
223788707|NCT04388982|BIOLOGICAL|mild dosage MSCs-Exos administrated for nasal drip|Dosage：10μg MSCs-Exos,Total volume： 1ml Frequency：Twice a week Duration：12 weeks
223788708|NCT04388982|BIOLOGICAL|high dosage MSCs-Exos administrated for nasal drip|Dosage：20μg MSCs-Exos,Total volume： 1ml Frequency：Twice a week Duration：12 weeks
223788709|NCT00747799|DRUG|Sorafenib plus Cisplatin and 5-fluorouracil|"Sorafenib with Cisplatin and 5-fluorouracil as first-line treatment of recurrence after radiotherapy patients who failed with radiotherapy in recurrent or metastatic nasopharyngeal carcinoma (NPC)~* Sorafenib 400 mg bid per daily . Every 21-day cycles.~* Cisplatin 80 mg/m2 day d1, every 21 days cycle.~* 5-fluorouracil 1000 mg/m2 day CIV 4days, repeat 21-day cycles"
223788710|NCT00966316|DRUG|aspirin，chinese herbs；|aspirin 300mg/100mg,qd,chinese herbs, one dose ，qd
223788711|NCT03183427|DIAGNOSTIC_TEST|MR of the brain|MR of the brain without gadolinium, incl. T2-weighted image
223788712|NCT01024322|DRUG|Ciprofloxicine or Vigamox or other.|Ciprofloxicine or Vigamox or other to be used qid till epithelialized.
223788713|NCT01024322|DRUG|Nonsteroidal (Acular, Voltaren Xibrom, etc)|Nonsteroidal (Acular, Voltaren Xibrom, etc) used up to qid for up to 5-10 days post-op
223788714|NCT01024322|DRUG|Steroid (FML, Pred Forte, Flarex, etc.)|Steroid (FML, Pred Forte, Flarex, etc.) to be used qid for 8 weeks.
223788715|NCT03399695|PROCEDURE|preoxygenation|spontaneous breathing
223788716|NCT00411567|DRUG|inhaled corticosteroid therapy|
223788717|NCT01415830|BIOLOGICAL|Anti-scorpion venom serum Birmex|the dose may be required for the patient according to clinical manifestations and evolution
223788718|NCT01415830|BIOLOGICAL|Anti-scorpion venom serum Alacramyn|The dose may be required fot the patient according to clinical manifestations and evolution
223788719|NCT04360148|DIETARY_SUPPLEMENT|very-low-calorie-ketogenic-diet|VLCKD-group will undergone to VLCKD for 8 weeks. VLCKD is based on protein preparations of high biological value. Total daily energy intake is \< 800 kcal.Daily carbohydrate intake is lower than 30 g/day, while daily protein intake is approximately 1.2-1.5 g/kg of ideal body weight. The following four weeks, carbohydrates are gradually reintroduced, starting from foods with the lowest glycemic index (fruit, dairy products), followed by foods with moderate and high glycemic index (bread, pasta and cereals). The goal is to achieve a hypocaloric balanced diet (HBD), as well as the controlled group. From the 12th week to the 24 th week, all subjects enrolled will continue follow-up with HBD.
223788720|NCT04360148|OTHER|hypocaloric-balanced-diet|HBD-group will undergone to hypo caloric balanced diet for 24 weeks. Total daily average energy intake is 1500-1600 kcal/day. 30% of total daily energy is composed by lipids (10% MUFA, 10% PUFA, 10% SFA), 55% carbohydrates, while daily protein intake is approximately 0.8-1.5 g /kg of ideal body weight.
223788721|NCT06235216|DRUG|Sacituzumab govitecan|Dose of 10 mg/kg intravenously
223788722|NCT03516318|BEHAVIORAL|SMART Connections|SMART Connections: Trained facilitators will deliver key informational messages and moderate online group discussions. The informational messages have been developed from key messages identified in each of the Positive Connections curriculum sessions. Each SMART Connections group will consist of approximately 15 to 20 YLHIV. Each online support group will begin with one in-person group meeting with the facilitator. During this meeting, participants meet one another and the facilitators. Facilitators will describe the intervention and set ground rules for participation. Ground rules will be discussed and accepted by the group members, but at a minimum, group members will be advised not to talk about what is discussed in the online group with people outside of the group.
223788723|NCT00781625|DIETARY_SUPPLEMENT|UREX-cap-5|Size 3, white/white capsule, each containing 180 mg of a standardized, light beige fine powder consisting of freeze-dried cultures of: Lactobacillus rhamnosus, GR-1® (50%) Lactobacillus reuteri, RC-14® (50%) Ingredients Powder: Cultures, glucose anhydrate, potato starch, microcrystalline cellulose and magnesium stearate. Capsule: Gelatine, titanium dioxide Concentration Minimum of 5.4 billion (5.4 x 109) Colony Forming Units per capsule by end of bulk shelf life. Application For use as a dietary supplement. Packaging 20,000 capsules packaged in heat-sealed foil pouch.
223788724|NCT00781625|DIETARY_SUPPLEMENT|UREX-cap-5|Size 3, white/white capsule, each containing 180 mg of a standardized, light beige fine powder consisting of freeze-dried cultures of: Lactobacillus rhamnosus, GR-1® (50%) Lactobacillus reuteri, RC-14® (50%) Ingredients Powder: Cultures, glucose anhydrate, potato starch, microcrystalline cellulose and magnesium stearate. Capsule: Gelatine, titanium dioxide Concentration Minimum of 5.4 billion (5.4 x 109) Colony Forming Units per capsule by end of bulk shelf life. Application For use as a dietary supplement. Packaging 20,000 capsules packaged in heat-sealed foil pouch.
223788725|NCT00781625|DIETARY_SUPPLEMENT|Placebo Y cap G-3|Size 3, white/white capsule, each contaiing180 mg placebo blended powder. Daily oral and vaginal intake for a total duration of 6 months
223788726|NCT06961435|BIOLOGICAL|Vedolizumab|Intravenous injection of VDZ (300mg/time) at weeks 0, 2, and 6, followed by intravenous injection of the same dose of VDZ every 8 weeks to maintain treatment.
223788727|NCT05104658|OTHER|Patient-targeted rehabilitation offers|In addition to usual rehabilitation services, patients in the intervention arm will receive patient-targeted rehabilitation offers to support the patients' participation and completion of their heart rehabilitation course.
223788728|NCT04197947|DEVICE|Neuro Omega|"A neurophysiological navigation system NeuroOmegaTM (Alpha Omega. Israel) was implemented in our group and the operation of this system for aDBS experiment is proved to be successful (Fig 9, 10). This system was proved by both FDA and tFDA. The aDBS stimulation algorithm will be integrated with NeuroOmegaTM. The aDBS stimulation control will achieve through self-developed algorithms or built-in scripting of the system. We introduce NeuroOmega system to conduct the designed aDBS experiment for its multifunction and safety. Our group has established collaboration with Department of Eelectronic Engineering in Chang Gung University (Co-PI HL Chan) and BERTEC in National Ciao Tung University (Co-PI MD Ker). Three postdoctor fellows and one senior engineer have been working on the operation of this aDBS system.~All hardware and software problems could be sorted out in time."
223788729|NCT02302079|DRUG|ASP8232|oral capsule
223788730|NCT02302079|DRUG|ranibizumab|intravitreal (IVT) injection
223788731|NCT02302079|DRUG|Placebo|oral capsule
223788732|NCT02302079|OTHER|Sham intravitreal (IVT) injection|intravitreal (IVT) injection
223788733|NCT04709536|DRUG|IBI306|Recombinant humanized Anti- PCSK9 monoclonal antibody, administered SC from BL to week 24
223788734|NCT04709536|DRUG|Placebo|Recombinant humanized Anti- PCSK9 monoclonal antibody, administered SC from BL to week 24
223788735|NCT05511987|DEVICE|Madela THOPAZ Digital Device|Digital drainage systems use electronic sensors to measure changes in pressure and thus may allow for quantification of the degree of air leak continuously and provide a graphical representation of the trend over time. Data on intrapleural pressure are also provided by some units. Together, these data may lead to expedited chest tube removal and hospital discharge with obvious financial implications.
223788736|NCT05511987|DEVICE|Atrium Analog Device|Analog drainage systems contain a sequentially numbered series of columns in the water seal chamber. The degree of air leak is assessed by observing the highest numbered column in which bubbling occurs. This provides a qualitative assessment at a specific point in time. This assessment, however, is subject to interobserver variability and does not account for variation over time.
223788737|NCT03320447|DRUG|lidocaine-prilocaine 5% cream application|The lesions were then cleansed with saline gauze, and a lidocaine-prilocaine 5% cream (EMLA®; Astra Pharmaceuticals, LP, Westborough, MA, USA) was applied to the treatment area for 30 min under occlusion
223788738|NCT03320447|DEVICE|2940-nm Er:YAG AFL pretreatment|After the anesthetic cream was removed, AFL was performed using a 2940-nm Er:YAG AFL (Joule; Sciton, Inc., Palo Alto, CA, USA) with a 500 µm ablation depth, level 1 coagulation, 22% treatment density, and a single pulse
223788739|NCT03320447|DRUG|methyl-aminolevulinate application|Immediately after the AFL, a 1-mm thick layer of methyl-aminolevulinate (16% Metvix® cream; PhotoCure ASA, Oslo, Norway) was applied to the lesion and to 5 mm of the surrounding healthy tissue. The area was covered with an occlusive dressing (Tegaderm; 3M, Co., Saint Paul, MN, USA) for 3 h, after which the remaining cream was removed with saline gauze, and the red fluorescence of porphyrins was visualized with Wood's light.
223788740|NCT03320447|DEVICE|Illuminating using red light-emitting diode lamps|Each treatment area was then separately illuminated using red light-emitting diode lamps (Aktilite CL128; Galderma S.A., Bruchsal, Germany) with peak emission at 632 nm and a total light dose of 37 J/cm2. Areas scheduled to receive MAL-PDT received the second treatment 7 days later. During the illumination, patients were asked to evaluate pain intensity using an 11-point visual analog scale.
223788741|NCT06305351|DRUG|K-757 and K-833 QD|Both administered orally once daily
223788742|NCT06305351|DRUG|K-757 and K-833 BID|Both administered orally twice daily
223788743|NCT06305351|DRUG|Matching placebo to K-757 and K-833 QD|Both administered orally once daily
223788744|NCT06305351|DRUG|Matching placebo to K-757 and K-833 BID|Both administered orally twice daily
223788745|NCT06098521|BEHAVIORAL|CONSENT|The CONSENT program is a risk-, need- and responsivity (RNR) based CBT program primarily focused on reducing risk of sexual reoffending, that consists of 18-26 one-to-one sessions in correctional settings.
223788746|NCT05564663|BEHAVIORAL|PTSD Coach App + Brief Support|PTSD Coach App + Brief Support will include downloading the PTSD Coach App for personal use and four, brief (\<20 minutes), weekly, individual support sessions. The sessions will focus on the instruction and encouragement of App use and activities (i.e., assessments, self-management strategies, and psychoeducational readings).
223788747|NCT05564663|BEHAVIORAL|Enhanced Usual Care (EUC)|EUC will consist of one brief session (with brochure) of PTSD and AUD psychoeducation and referral information for mental health clinics that provide PTSD services, with encouragement to schedule an appointment at one of the listed clinics to discuss PTSD-related symptoms.
223788748|NCT06118814|OTHER|Body Awareness Therapy Exercise|Body awareness therapy exercises were applied to the subjects in this group.
223788749|NCT06118814|OTHER|Virtual Reality Exercise|Virtual reality exercises were applied to the subjects in this group.
223788750|NCT06118814|OTHER|Core Stability Exercise|Core stabilization exercises were applied to the subjects in this group.
223788751|NCT06118814|OTHER|Home Exercise|Subjects in this group implemented a home exercise program.
223788752|NCT03772990|DRUG|Calcium Chloride|Calcium Chloride
223788753|NCT03772990|DRUG|0.9% Sodium Chloride|0.9% Sodium Chloride
223788754|NCT01461590|OTHER|Whole blood|30mls/kg transfused over fours hours
223788755|NCT01461590|OTHER|Whole blood|20mls/kg transfused over four hours
223788756|NCT01548456|PROCEDURE|Intramedullary Nailing|Surgical treatment that includes closed or open reduction and stabilization of the femur fracture with an intramedullary rod inserted using antegrade or retrograde technique
223788757|NCT01548456|PROCEDURE|Open Reduction Internal Fixation|Surgical treatment that includes open reduction internal fixation of the femur fracture with a dynamic compression plate
223788758|NCT00718718|DRUG|CNTO 136 100 mg|CNTO 136 100 mg will be administered subcutaneously (under the skin) every 2 or 4 weeks as per the appropriate randomized arm.
223788759|NCT00718718|DRUG|CNTO 136 50 mg|CNTO 136 50 mg will be administered subcutaneously every 4 weeks from Week 0 to Week 24.
223788760|NCT00718718|DRUG|CNTO 136 25 mg|CNTO 136 25 mg will be administered subcutaneously every 4 weeks from Week 0 to Week 24.
223788761|NCT00718718|DRUG|Placebo|Placebo will be adminstered subcutaneously as per the appropriate randomized arm.
223788762|NCT00718718|DRUG|Methotrexate|Stable dose of methotrexate will be maintained through Week 24.
223788763|NCT03449303|OTHER|EOI|Topically-applied oil
223788764|NCT03449303|OTHER|Placebo|Topically-applied oil
223788765|NCT04508322|DEVICE|HGA|Headgear Activator
223788766|NCT04508322|DEVICE|FA|Fixed Orthodontic Appliance
223788767|NCT03460340|DEVICE|prefrontal deep rTMS of H1 Coil|prefrontal deep rTMS of H1 Coil
223788768|NCT04541758|PROCEDURE|surgical treatment|surgical treatment and Conservative treatment
223788769|NCT04541758|PROCEDURE|Conservative treatment|Conservative treatment
223788770|NCT01117116|DRUG|fluticasone propionate and salmeterol|45/4.5 two puffs twice daily
223788771|NCT01117116|DRUG|budesonide and formoterol|80/4.5 two puffs twice daily
223788772|NCT02516059|DRUG|oxycodone/naloxone|Oxycodone and naloxone (Targin®; Mundipharma Medical Company and Mundipharma Research GmbH \& Co Basel, Switzerland): Will be orally administered at 12 hours intervals, starting with 10mg/5mg on POD 3 and move to 20mg/10mg the other day.
223788773|NCT02516059|DRUG|Oxycodone|Oxycodone (Oxycontin®, Mundipharma Medical Company and Mundipharma Research GmbH \& Co Basel, Switzerland): Will be orally administered at 12 hours intervals, starting with 10 mg on POD 3 and move to 20 mg the other day.
223788774|NCT02516059|DRUG|Placebo|Placebo (Mundipharma Medical Company and Mundipharma Research GmbH \& Co Basel, Switzerland): Will be orally administered at 12 hours intervals starting on POD 3.
223788775|NCT02516059|DEVICE|epidural catheter|
223788776|NCT05317468|OTHER|Contraceptive Counseling|Patients will receive contraceptive counseling to review all available contraceptive methods prior to their visit with a clinician.
223788777|NCT04961333|BEHAVIORAL|Multidisciplinary Rehabilitation|Body therapies to improve breathing, normalise dysfunction in the autonomic nervous system, relaxation, mindfulness, in some part Acceptance and Commitment Therapy given preferably through body therapies.
223788778|NCT01803997|BEHAVIORAL|Pink and Dude Chef Afterschool Cooking Program|12 educational cooking classes: two classes per week for six weeks (2 hours each)
223788779|NCT03937167|OTHER|Psychotherapy group|Added to standard treatment patients will participate in a standardized group of psychological intervention. 21 sessions with 10 to 12 members closed-ended groups.
223788780|NCT02311179|DEVICE|Prosthesis, BoneMaster-Exceed cup (Biomet)|Patients will be randomized preoperatively to 1) Exceed cup coated with hydroxyapatite deposited electrochemically (BoneMaster) or 2) Exceed cup coated without hydroxyapatite coating.
223788781|NCT02311179|DEVICE|Prosthesis Exceed cup without HA (Biomet)|Patients will be randomized preoperatively to 1) Exceed cup coated with hydroxyapatite deposited electrochemically (BoneMaster) or 2) Exceed cup coated without hydroxyapatite coating.
223788782|NCT04572347|OTHER|Observational|It is an observational study, and no intervention will be provided.
223788783|NCT05321498|DRUG|XPro1595|XPro1595 will be delivered by subcutaneous injection once a week.
223788784|NCT05321498|DRUG|Placebo|Placebo will be delivered by subcutaneous injection once a week
223788785|NCT03570684|DEVICE|Cable Tie|During the operation, after mobilization the rectum, the disinfected Cable Tie was introduced into the pelvic cavity.then the rectum was bundled by the tie which was easy as the tie is auto-locked. pulling the tie and the rectum would be explored clearly, and then the endoscopic linear cutter was introduced to transect the rectum. the tie made the rectum folded not applanate, that the cutter was able to transect the rectum easily and with less reloader. when the rectum was resected completely, the tie was get out with the specimen, and do not live in the abdomen.
223788786|NCT04184193|OTHER|Pulmonary Rehabilitation|Patients will perform a comprehensive, inpatient pulmonary rehabilitation program for 4 weeks duration
223788787|NCT06479447|OTHER|PORTAL-PTSD|Patients will be eligible if they are 18+ years, have had a primary care visit in the last 2 years, and have not been screened for PTSD in the last year. The validated PC-PTSD-5 (Primary Care Post Traumatic Stress Disorder-5) screener will be used. Clinics will implement visit-based and population health screening for patients enrolled in the patient portal who have not been screened for PTSD in the last year and have had a clinic appointment in the last 2 years. The PCBH care manager or patient navigator will follow-up with patients every 2 weeks to ensure they have been connected to care and re-measure their PTSD symptoms. The follow-up calls will continue until symptom remission, after which follow-ups will occur quarterly for 6 months. Primary care clinicians will receive training on trauma-informed care and PTSD management, and will be surveyed at baseline, immediately after training, and 6 months-post intervention to evaluate changes in their knowledge of trauma-informed care.
223788788|NCT05711654|BEHAVIORAL|Health coaching|Coaching interview will be held with patients at regular intervals.
223788789|NCT05490615|BEHAVIORAL|Virtual Mindfulness|Investigators have previously developed and tested a virtual mindfulness program. Six 1-hour weekly group sessions will be led on WebEx. Focus will be on skill building through the teaching of formal and informal mindfulness practices. The intervention, based on the MBSR curriculum, has been modified to make it more accessible for autistic adults. The curriculum developed for this program was designed with autistic advisors guiding the team on the length of meditations, the language used when giving instructions, and the range of techniques that would be most helpful for autistic adults. Each activity is presented as optional, recognizing that some people may find certain silent sensory experiences too distressing. Autistic advisors will participate in sessions as co-facilitators and multiple communication options will be available to group participants (text and audio, camera on or off).
223788790|NCT03577717|OTHER|computerized cognitive training|participants will be trained 30 minutes/day, 3 days/week for 4 consecutive weeks.
223788791|NCT03577717|OTHER|occupational therapy|participants will receive craft activities of occupational therapy for 30 minutes/day, 3 days/week for 4 consecutive weeks.
223788792|NCT04690855|DRUG|Talazoparib|Talazoparib 1 mg Orally Day 1 to Day 28
223788793|NCT04690855|DRUG|Atezolizumab|Atezolizumab 840 mg IV over 60 minutes Day 15 of Cycle 1 then Day 1 and Day 15 of subsequent Cycles
223788794|NCT04690855|RADIATION|Radiation|Radiation 8 Gy will be given in 3 fractions QOD beginning Day 12, 13 or 14 of Cycle 1 but 24-72 hours prior to 1st dose of Atezolizumab
223788795|NCT04341701|PROCEDURE|MRI|The procedure to study lung and heart MRI, performed on a 1.5T magnet (Siemens), without any injection or inhalation of contrast agent
223788796|NCT03911492|PROCEDURE|SCPP Management => 65 mmHg|A lumbar intrathecal catheter will be inserted pre-operatively for the measurement of Intrathecal pressure (ITP) and the collection of cerebrospinal fluid (CSF) samples. SCPP will be calculated as the difference between Mean Arterial Pressure (MAP) and the ITP.
223788797|NCT04296565|BEHAVIORAL|Usual Care|Usual Care condition involves receipt of educational materials about brain health and healthy lifestyles as well as regular contact with study staff
223788798|NCT04296565|BEHAVIORAL|WATER+CT|This is an 8 month long two phase intervention. The first phase consists of 6 months of thrice weekly pool based physical activity occurring at the Palo Alto VA Health Care System. After completion of the 6 month long water based physical activity, participants transition to a ten session cognitive training program at the Palo Alto VA. The cognitive training classes are approximately two hours in length and will be spread over ten sessions across 4 weeks.
223788799|NCT01704417|DRUG|insulin degludec|Subjects will be randomised to a treatment sequence consisting of two treatment periods in which the subjects will receive IDeg and IGlar, respectively. Administered subcutaneously (s.c., under the skin) once daily. Dose individually adjusted.
223788800|NCT01704417|DRUG|insulin glargine|Subjects will be randomised to a treatment sequence consisting of two treatment periods in which the subjects will receive IDeg and IGlar, respectively. Administered subcutaneously (s.c., under the skin) once daily. Dose individually adjusted.
223788801|NCT02891187|BEHAVIORAL|Telephone follow-up|Patients will be called for postoperative care at 1-2 weeks, 6 weeks, and 3 months
223788802|NCT02891187|BEHAVIORAL|Outpatient Clinic Visits|Patients will return to the clinic at 1-2 weeks, 6 weeks, and 3 months
223788803|NCT02820779|DEVICE|WILLIS|WILLIS® intracranial stent graft system is composed of the stent, delivery system, cobalt-based alloy stent and PTFE graft. It can effectively shunt the blood flow and keep it off of the aneurysm wall.
223788804|NCT02615223|PROCEDURE|cryoablation|Cryoablation therapy
223788805|NCT02615223|DRUG|Bicalutamide|bicalutamide
223788806|NCT02615223|DRUG|luteinizing-hormone releasing-hormone (LHRH) agonist|luteinizing-hormone releasing-hormone (LHRH) agonist
223788807|NCT01545011|OTHER|Inspiratory muscle training|Inspiratory muscle training
223788808|NCT05804773|DIAGNOSTIC_TEST|Non-invasive Measurement of cerebral blood velocity in the middle cerebral artery by transcranial pulsed Doppler (TCD) (Mean velocity, Vm, cm/s)|"Measurement of cerebral blood velocity in the middle cerebral artery by transcranial pulsed Doppler (TCD) (Mean velocity, Vm, cm/s) (recorded on Data Warehouse Connect).~For all patients Vm in (cm/s) will be collected during the adjustment of the mean arterial pressure level between 90% and 70% of the baseline value, without ever going below 60 mmHg for the patients at low risk and 80 mmHg for the patients at high cardiovascular risk. For neuro-injured patients with intracranial pressure monitoring (ICP), the lower limit of cerebral perfusion pressure (CPP = MAP - ICP) will be set at 50 mmHg"
223788809|NCT04156607|OTHER|Kinesio taping|For the fascia technique, one part of the band which were divided by 4 fans is adhered on Achilles tendon to the heel with a 0% stretch. Then the plantar fascia was stretched by the examiner and the toes were extended (ankle dorsiflexion, toe extension) and the divided part of the band was applied toward the metatarsal heads with paper-off technique (5-15%).
223788810|NCT04156607|OTHER|Sham taping|''I'' bant were cut from the middle point of the Achilles tendon to the metatarsal heads. The band was applied from the Achilles tendon to the metatarsal heads without any stretching of plantar fascia and band.
223788811|NCT04852081|DRUG|Palbociclib|Palbociclib is in the form of oral capsules. Palbociclib, capsule, 125 mg taken orally once daily for 21 consecutive days followed by 7 days off treatment to comprise a complete cycle of 28 days. Palbociclib should be taken with food
223788812|NCT04852081|DRUG|Ribociclib|Ribociclib, tablets, 600mg orally (three 200 mg tablets)taken once daily with or without food for 21 consecutive days followed by 7 days off treatment
223788813|NCT04852081|DRUG|Abemaciclib|Abemaciclib in combination with fulvestrant or an aromatase inhibitor: 150 mg twice daily Abemaciclib as monotherapy: 200 mg twice daily. (2.1)
223788814|NCT04852081|DRUG|Letrozole|Letrozole will be dosed daily at a fixed dose of 2.5 mg/day throughout the study.
223788815|NCT04852081|DRUG|Anastrozole|Anastrozole will be dosed daily at a fixed dose of 1 mg/day throughout the study.
223788816|NCT04852081|DRUG|Tamoxifen|Tamoxifen will be dosed daily at a fixed dose of 20 mg/day throughout the study.
223788817|NCT04852081|DRUG|Fulvestrant|Fulvestrant is in the form of a prefilled syringe containing 5 ml of an injection solution of 250 mg of fulvestrant for intramuscular injection. The recommended dose is once every 28 days, once at a dose of 500 mg, and on the 15th day after the initial injection, a loading dose of fulvestrant 500 mg is added.
223788818|NCT04852081|DRUG|Exemestane|Exemestane will be dosed daily at a fixed dose of 25mg/day throughout the study.
223788819|NCT04852081|DRUG|Alpelisib|Alpelisib will be dosed daily at a fixed dose of 300 mg/day throughout the study.
223788820|NCT01615731|DRUG|Mifepristone|200mg Mifepristone orally
223788821|NCT01615731|OTHER|Hygroscopic cervical dilators|Dilapan-S osmostic cervical dilators inserted through the internal os
223788822|NCT01615731|DRUG|Misoprostol|400mcg buccal misoprostol 90 minutes pre-op
223788823|NCT01615731|DRUG|Intra-amniotic digoxin|1mg digoxin administered intra-amniotically \~24 hours pre-op
223788824|NCT05921968|DRUG|Intravenous iron sucrose|"200 mg elemental iron in 100 ml 0.9 NaCl intravenous over 20 -30 minutes daily up to the total dose)~o The dose of the total iron sucrose to be administrated was calculated from the following formula: Total dose required = weight (kg) x (target Hb in g\\dL - actual Hb in g\\dL) x 2.4 + 500 mg rounded up to the nearest multiple of 100 mg"
223788825|NCT05921968|DRUG|Lactoferrin|100 mg twice daily orally before breakfast and dinner
223788826|NCT04480112|BEHAVIORAL|Technology based social interactions|Participants will be socially interacting using any available technology with members of the research team.
223788827|NCT04480112|OTHER|No research related technology based social interactions|No technology based social interactions with the research team.
223788828|NCT00908479|BEHAVIORAL|Leg Exercise Program|Participants will engage in an extra 45-60 minutes per day of self-managed lower extremity homework exercises focused on improving strength, balance and walking ability.
223788829|NCT00908479|BEHAVIORAL|Leg Management group|Therapist provides educational information about leg pain, recovery, bone density, and fall risk.
223788830|NCT02395120|BEHAVIORAL|Standard letter|Standard referral letter according to Ohio Department of Health Bureau guidelines. This letter is consistent with others used across the country.
223788831|NCT02395120|BEHAVIORAL|Intervention letter|Referral letter based on the Common Sense Model of Self-Regulation (CSM). The letter includes the cognitive dimensions of the CSM (identity, cause, timeline, consequences and control).
223788832|NCT02395120|BEHAVIORAL|Reduced intervention letter|"Reduced (removing text corresponding to timeline) CSM theory-based referral letter. The letter includes the remaining cognitive dimensions of the CSM (identity, cause, consequences and control)."
223788833|NCT02395120|BEHAVIORAL|DIG|Dental information guide (DIG) to reinforce/change illness perception, knowledge about dental caries, and resources to seek care. DIG is a brochure with illustrations which provides myths and facts about dental caries, hints for getting dental care, making appointments and Medicaid access, transportation and dentist availability resources.
223788834|NCT02395120|BEHAVIORAL|Reduced DIG|"Text and illustrations related to the timeline construct of the CSM have been removed in the reduced dental information guide."
223788835|NCT02658643|PROCEDURE|Continuous suture technique|The BDA is performed as continuous suture with two separate all-layer suture for the behind - and front-wall of the anastomosis
223788836|NCT02658643|PROCEDURE|Interrupted suture technique|The BDA is performed as interrupted suture with two separate all-layer suture for the behind - and front-wall of the anastomosis
223788837|NCT05365087|PROCEDURE|Transoral Fundoplication and Sleeve Gastrectomy|Transoral Fundoplication procedure completed prior to Sleeve Gastrectomy
223788838|NCT05365087|PROCEDURE|Gastric Bypass|Laparoscopic Roux-en-Y gastric bypass
223788839|NCT03789266|PROCEDURE|drain ablation|drain ablation will be done in Aspiration mode or in non Aspiration mode
223788840|NCT04396834|DRUG|Lorcaserin Oral Tablet|Lorcasering 10mg Oral Tablet (BID)
223788841|NCT04396834|DRUG|Placebo oral tablet|Placebo Oral Tablet (BID)
223788842|NCT03839251|DRUG|abilify maintena|aripiprazole 400mg or 300mg, IM, Once a month
223788843|NCT02676167|BEHAVIORAL|PrEP Intervention|
223788844|NCT04593446|DRUG|Oral Sulfate Tablet(ORA·FANGⓇ)|"Subjects who are randomized into experimental arm will receive 14 pills at 8 pm in the evening 2days before the surgery and another 14 pills on 6am in the morning 1day before the surgery~Subjects who are randomized into comparator will receive 170ml of solution with at 8 pm in the evening 2days before the surgery and another 170ml of solution on 6am in the morning 1day before the surgery"
223788845|NCT04593446|DRUG|Sodium Picosulfate Solution(PicosolutionⓇ)|Sodium Picosulfate Solution(PicosolutionⓇ)
223788846|NCT05933031|DRUG|Tegoprazan 50 mg Triple Therapy|Tegoprazan 50 mg/Clarithromycin/ Amoxicillin BID peroral, 14 days
223788847|NCT05933031|DRUG|Tegoprazan 100 mg Triple Therapy|Tegoprazan 100 mg/Clarithromycin/ Amoxicillin BID peroral, 14 days
223788848|NCT05933031|DRUG|Lansoprazole Triple Therapy|Lansoprazole/Clarithromycin/ Amoxicillin BID peroral, 14 days
223788849|NCT01187758|BEHAVIORAL|Workshops and focus group meetings|Multifacet intervention that includes: Guideline preparation and implementation, preparing clinic campaign, improving knowledge about Ab resistance and diagnosis of respiratory infections
223788850|NCT02526693|DIAGNOSTIC_TEST|Pupillometer|The Konan RAPDx (relative afferent pupillary defect) (Konan Medical USA, Irvine, CA) pupillometer utilizes digital, high-definition, infrared machine-vision with eye-tracking and automated blink detection technology to analyze and quantify pupillary response to light.
223788851|NCT05275894|BEHAVIORAL|Implant hygiene instructions and removal of the prosthesis|Verbal instructions on implant hygiene practices and removal of the implant supported prosthesis
223788852|NCT05275894|PROCEDURE|Non-surgical peri-implantitis treatment /microsurgery|Removal of the granulation tissue and mucosa and bone defect curettage with a steel curette 4R/4L (Hu-Friedy, Chicago, IL, USA) after applying local anestesia
223788853|NCT05275894|PROCEDURE|Implant surface decontamination 1(ultrasonic device)|Removal of supra and submucosal calculus with slim ultrasonic devices (Piezon PS instrument EMS; Nyon, Swiss).
223788854|NCT05275894|PROCEDURE|Implant surface decontamination 2 (air polishing)|Erythritol air powder-spray system (Air-flow ® master piezon, EMS, Nyon swiss) implant surface treatment. This will be performed by separating the soft tissue with the aim of a periodontal probe (CP 15, Hu-Friedy, Chicago, IL, USA).
223788855|NCT05275894|PROCEDURE|Implant surface decontamination 3 (electrolytic cleaning)|Electrolytic cleaning of the implant surface following manufacturer's instructions (GalvoSurge Dental AG, Widnau, Switzerland), with the help of a non-metal periodontal probe to separate the soft tissues and aim the implant surface in all its length.
223788856|NCT05275894|DRUG|Antibiotic treatment (Metronidazole)|Antibiotic treatment (Metronidazole 500 mg, every day/ 7 day).
223788857|NCT05275894|PROCEDURE|Modification and polishing of the prosthesis|If necessary, modification and polishing of the prosthesis to make it cleanable.
223788858|NCT00594269|DRUG|Risperidone|Discontinuation
223788859|NCT00594269|DRUG|Escitalopram|Discontinuation
223788860|NCT00594269|DRUG|Citalopram|Discontinuation
223788861|NCT00594269|DRUG|Sertraline|Discontinuation
223788862|NCT00594269|DRUG|Paroxetine|Discontinuation
223788863|NCT03581305|DRUG|18F-FDOPA|High resolution positron emission tomography (PET) of the brain and radioligands targeted against the dopaminergic (18F-FDOPA) system.
223788864|NCT03581305|DRUG|11C-DASB|High resolution positron emission tomography (PET) of the brain and radioligands targeted against the serotonergic (11C-DASB) system.
223788865|NCT00958269|DRUG|dutogliptin|100 mg QD
223788866|NCT00958269|DRUG|dutogliptin|200 mg QD
223788867|NCT00958269|DRUG|placebo|
223788868|NCT00958269|DRUG|sitagliptin|25 mg QD
223788869|NCT00958269|DRUG|sitagliptin|50 mg QD
223788870|NCT00829257|DRUG|HFA-BDP|HFA-BDP (Qvar) 100ug 2puff b.i.d
223788871|NCT00829257|DRUG|Fluticasone|Fluticasone propionate Accuhaler 250ug b.i.d.
223788872|NCT00829257|DRUG|Seretide|Fluticasone/Salmeterol (Seretide) 500/50ug, 1 puff b.i.d
223788873|NCT00778648|DIETARY_SUPPLEMENT|Juice Plus|"Juice Plus+® is a dietary supplement from concentrated fruits (apple, orange, pineapple,cranberry, cherry (acerola), papaya and peach) and vegetables (carrot, parsley, beet, broccoli, kale, cabbage, spinach, and tomato).~Subjects will take four capsules of Juice Plus+® daily."
223788874|NCT00778648|DIETARY_SUPPLEMENT|Placebo|Four capsules of placebo daily.
223788875|NCT02201069|BEHAVIORAL|health coaching|
223788876|NCT01798927|DEVICE|Ankle foot orthosis|Participants will receive a Tamarack ankle foot orthosis with a check strap for gait training as well as a home walking program.
223788877|NCT01201590|DIETARY_SUPPLEMENT|High Flavanol Cocoa|cocoa consumed as a 24g dairy based cocoa drink mix, twice a day (mid-morning \& early evening on an empty stomach), for 4 weeks.
223788878|NCT01201590|DIETARY_SUPPLEMENT|Low Flavanol Cocoa|cocoa consumed as a 24g dairy based cocoa drink mix, twice a day (mid-morning \& early evening on an empty stomach), for 4 weeks.
223788879|NCT05920551|OTHER|Gastrocnemius Stretching Exercises|The gastrocnemius stretching exercises will be performed by patients in the study group. These exercises will involve stretching the gastrocnemius muscle in a controlled manner to improve flexibility and reduce tension in the plantar fascia.
223788880|NCT05920551|OTHER|Standard care|Ultrasound therapy: A therapeutic ultrasound device will be used to apply ultrasound waves to the plantar fascia area for pain relief and to promote healing. The frequency, intensity, and duration of the ultrasound therapy will be determined by the treating physical therapist based on individual patient needs.Fascia strengthening exercises: Patients will be instructed to perform exercises targeting the intrinsic foot muscles and the plantar fascia to improve strength and function. Examples of these exercises include toe curls, towel scrunches, and arch lifts. Patients will be asked to perform these exercises daily, with the specific number of repetitions and sets determined by the physical therapist.
223788881|NCT05415813|OTHER|Ischemic Compression|It includes conventional Physical therapy, hot packs (75°C) for 20 minutes, and active stretching exercises for the upper trapezius muscle (slow, 5 repetitions per session, 10-second hold, and 10-second relaxation between two repetitions) as a baseline treatment. For the Ischemic compression, the patient will be in the supine position with the cervical spine in opposite lateral flexion to the treating part so that the upper trapezius muscle fibers were kept in a lengthened position physiotherapist will apply gradually increasing pressure to the Trigger points until the subject perceived the first noticeable pain. At that moment, the pressure will be maintained until the discomfort and/or pain eased by around 50% as perceived by the patient, at which time the pressure will be increased until the discomfort appears again. This process will be maintained for 90 seconds.
223788882|NCT05415813|OTHER|Ischemic compression with Muscle Energy Technique|The Participants will receive all the treatments given to the active comparator group and they will also receive the Muscle Energy Technique treatment in supine position and the practitioner will stabilize the shoulder of the affected side with one hand, while the ear/mastoid area of the affected side will be held by the opposite hand. The head and neck were then bent towards the contralateral side, flexed, and ipsilaterally rotated. The subjects will then shrug the stabilized shoulder towards the ear at a sub-maximal pain-free effort (20% of the available strength). The isometric contraction will be held for 7-10s. This position will be maintained for 30 seconds and repeated three to five times per treatment session. Treatment sessions will be given on alternate days.
223788883|NCT03750552|DRUG|ampreloxetine|Oral tablet, QD
223788884|NCT03750552|DRUG|Placebo|Oral tablet, QD
223788885|NCT00656591|DRUG|Methotrexate|Methotrexate
223788886|NCT01049113|DRUG|ON 013105|2-hour intravenous infusion once a week. Starting dose is 17 mg. Maximum dose will be 1525 mg.
223788887|NCT01043666|DRUG|YM178|oral
223788888|NCT01043666|DRUG|Placebo|oral
223788889|NCT01043666|DRUG|tolterodine ER|oral
223788890|NCT02449200|OTHER|Multimodal physiotherapy|Manual therapy, exercise and neural unloading tape provided twice weekly over 4 weeks by an experienced musculoskeletal physiotherapist
223788891|NCT04274608|DRUG|Botulinum toxin type A|Intragastric injection of Botulinum toxin type A
223788892|NCT04274608|BEHAVIORAL|Weight Management Program|12 week weight management program
223788893|NCT00001768|DRUG|Intravenous immunoglobulin|
223788894|NCT01453816|PROCEDURE|Harvesting and Isolation of Stem cells|Adipose-Derived Stem Cells (ASCs) will be derived from the patient's adipose-derived tissue. Liposuction using local anesthesia and syringe collection will be performed to collect the adipose tissue specimen for subsequent processing to isolate the stem cells. The cells will be delivered via catheter into the renal artery and intravenously.
223788895|NCT01037920|BEHAVIORAL|Self-affirmation exercise|The intervention exercise asks subjects to reflect on a list of 11 personal values and to circle 2 or 3 items that are most important to them. Subjects are asked then to write a few sentences to describe why they are important.
223788896|NCT01037920|BEHAVIORAL|Control|The control exercise is the same as the intervention exercise except that subjects reflect and write about values important to someone else.
223788897|NCT01003899|DRUG|afatinib (BIBW 2992)|afatinib (BIBW 2992) po QD
223788898|NCT05048147|BEHAVIORAL|Community Mobilization|The Community Mobilization (CM) strategy will include: (1) Community advisory board \[comprising local community-based organizations, government officials, and residents\], that will provide leadership support and buy-in for adoption of Clean Fuel- Clean- Stove (CF-CS) use; (2) Trained MoH community health extension workers, community health officers, community mobilizers and health education officers, who will form community action teams (CAT) to facilitate the implementation of CF-CS use via provision of support, knowledge exchange and performance feedback to the primary cooks in participating households; (3) Community dialogues with residents and households focused on shared concerns on the significance and importance of CF-CS use.
223788899|NCT05861934|BEHAVIORAL|Distant reiki group|ccording to Classical Usui Reiki, Reiki II. Remote Reiki will be practiced twice a week for 6 weeks by researchers who have completed the Phase 2 training. The time of remote reiki application will be planned by talking with the patient.
223788900|NCT06491147|OTHER|Emergency front of neck access|"The algorithm in the DAS manual will be explained. Following this, the researcher will demonstrate the scalpel spark plug technique with a 4-step approach that is frequently used in skill teaching.~In step 1 of this approach, the technique will be demonstrated without any verbal explanation.~In the 2nd step, the technique will be demonstrated with verbal expression. In the 3rd step, the participant will be asked to have the trainer do it. In the 4th and last step, the participant will apply eFONA from start to finish."
223788901|NCT00963365|DRUG|AZD6765|Single oral dose and single IV infusion of AZD6765
223788902|NCT00963365|DRUG|AZD6765|Once-daily oral dose of AZD6765 or placebo on Day 1 and on Days 4 through 9.
223788903|NCT03326687|BEHAVIORAL|Treatment ABAB|Participants will perform the phases in the ABAB order.
223788904|NCT03326687|BEHAVIORAL|Treatment BABA|Participants will perform the phases in the BABA order.
223788905|NCT00780208|DRUG|Daytrana (methylphenidate patch)|Subjects will be provided with a 7-day supply of medication at each study visit. The dose will be flexible and will be titrated based on effect and tolerability. Unless a subject is experiencing side effects, the dose will be increased if a 25% reduction in ADHD symptoms as determined by the WRAADDS is not obtained. A proposed dosing schedule is as follows: Week 1: 12.5 cm2, Week 2: 18.75 cm2, Week 3: 25 cm2, Week 4: 37.5 cm2. The dose may be decreased as needed for tolerability.
223788906|NCT04266782|OTHER|Exercise program followed by long walk in group|The subjects will be included in a training exercise program for three months followed by a long-walk in group
223788907|NCT04266782|OTHER|Exercise program followed by long walk in group (controls)|The controls matched for age will perform the same exercise program and long walk as the PD subjects
223788908|NCT04166994|BEHAVIORAL|Exercise and diet|IMPACT Intervention
223788909|NCT04166994|OTHER|No Intervention: Usual Care|No exercise or diet specialization.
223788910|NCT06788496|BEHAVIORAL|Art-based Beauty Appreciation Intervention Program (Learning to See Beauty)|The goals of the intervention program are to help individuals develop an aesthetic mindset, practice observation and appreciation skills, learn how to apply these skills to their day-to-day lives, practice emotion regulation with beauty, and incorporate more beauty into their lives. The program is designed to create a slow skill transfer from appreciation in art contexts to natural beauty and to everyday life. In the 14-day program, participants visit an art museum with guided audio, watch instructional videos about observing and appreciating beauty, and complete daily written or photo beauty journals that document the beauty they see. In addition, participants will watch video art showing how to find beauty in mundane objects, practice this in a beauty walk, and complete a planning session to include more beauty in their lives.
223788911|NCT06788496|BEHAVIORAL|Observation Program (Learning to Observe Life)|The active, matched control group will focus on developing pragmatic observation skills. Participants will be instructed to pay attention to and identify objects and elements in their surroundings without emphasizing their aesthetic value. For example, they should pay attention and count objects of the same colour they encounter, social behaviour, the people they pass on the street, or the types of buildings. The 14-day program includes a tourist trip with guided audio instruction, watching instructional videos about increasing observation skills and completing daily written or photo journals to document their observations. Further, participants will take an observation walk and plan to include more observation in their lives.
223788912|NCT04074785|DRUG|Abemaciclib|Abemaciclib 150 mg po bid
223788913|NCT04074785|DRUG|Bevacizumab|Bevacizumab 10 mg/kg IV every 2 weeks, then continue treatments for 2 cycles
223788914|NCT05197192|DRUG|Obinutuzumab|"Obinutuzumab i.v. infusion:~Cycle 1 Day 1: Obinutuzumab 100 mg i.v.~Cycle 1 Day 1 (or 2): Obinutuzumab 900 mg i.v.~Cycle 1 Day 8: Obinutuzumab 1000 mg i.v.~Cycle 1 Day 15: Obinutuzumab 1000 mg i.v.~Cycles 2-6: Day 1: Obinutuzumab 1000 mg i.v."
223788915|NCT05197192|DRUG|Venetoclax|"Venetoclax p.o.:~Cycle 1: Days 22-28: Venetoclax 20 mg (2 x 10 mg)~Cycle 2: Days 1-7: Venetoclax 50 mg (1 x 50 mg)~Cycle 2:Days 8-14: Venetoclax 100 mg (1 x 100 mg)~Cycle 2:Days: 15-21: Venetoclax 200 mg (2 x 100 mg)~Cycle 2:Days: 22-28: Venetoclax 400 mg (4 x 100 mg)~Cycles 3-12: Days 1-28: Venetoclax 400 mg (4 x 100 mg)"
223788916|NCT05197192|DRUG|Acalabrutinib|"Cycles 15-24: Days 1-28:~100 mg acalabrutinib twice daily p.o. approx. every 12 hrs (corresponding to a total daily dose of 200 mg)."
223788917|NCT06014996|DEVICE|Pulsed Field Ablation (PFA) Therapy|In the test group, subjects will undertake PVI using the PFA system including a nanosecond-scale pulsed field generator (InRythm, Insight Lifetech, Shenzhen, China), a lotos catheter that is expandable over the wire (LotosPFA, Insight Lifetech), and a customized 12-French steerable sheath (InBridge, Insight Lifetech).
223788918|NCT06014996|DEVICE|Radiofrequency Ablation（RAF）Therapy|In the control group, subjects will undergo PVI using an RFA system including CARTO VISITAG Module and the THERMOCOOL SMARTTOUCH Catheter (Biosense Webster Inc., Diamond Bar, CA, USA). PVI was performed with AI values of 400-450 in the anterior, 300-350 at the posterior wall of the LA.
223788919|NCT06429748|DEVICE|rTMS|repetitive Transcranial Magnetic Stimultion
223788920|NCT06151353|DIAGNOSTIC_TEST|REMS|Bone health assessment using REMS, an ultrasound technology developed to measure bone mineral density and bone toughness without ionising radiation
223788921|NCT00656838|BEHAVIORAL|Patients receives letter, phone call, office visit, educational materials|Behavioral
223788922|NCT01412944|DRUG|secukinumab 150mg|secukinumab 150mg (2 injections per dose)
223788923|NCT01412944|DRUG|secukinumab 10mg/kg i.v. regimen|secukinumab 10mg/kg i.v. regimen
223788924|NCT04586101|DEVICE|Trainings application|Participants have to train with the developed trainings application over six weeks. For this, individual training plans are implemented in the application based on orthopedic joint status and training recommendations of a sports scientist.
223788925|NCT01990950|DEVICE|Zenith® Fenestrated AAA Endovascular Graft|The Zenith® Fenestrated AAA Endovascular Graft with the H\&L-B One-Shot™ Introduction System is indicated for the endovascular treatment of patients with abdominal aortic or aortoiliac aneursyms having morphology suitable for endovascular repair
223788926|NCT01280487|DRUG|ZSTK474|Daily oral dosing for 21 days each cycle
223788927|NCT05225493|BEHAVIORAL|Peer to peer feedback|HIV experts contact non-HIV specialised treating physicians on individual patient care to recommend HIV testing
223788928|NCT05225493|DIAGNOSTIC_TEST|HIV rapid test|Free HIV rapid tests are provided to non-HIV specialised treating physicians to use in individual patient care in patients at risk of HIV
223788929|NCT04227015|DRUG|CTA101|CTA101 UCAR-T cell injection by intravenous infusion
223788930|NCT05965011|OTHER|Exercise training|The intervention will be a combination of both supervised and unsupervised sessions. Participants in the Nordic Walking (NW) treatment group will attend 5 one-hour group sessions, which will incorporate coaching principles.
223788931|NCT01640522|OTHER|Collaborative Care|Collaborative care intervention to manage cancer-related symptoms
223788932|NCT01640522|OTHER|Enhanced usual Care|
223788933|NCT05779995|DRUG|XW001|Inhalation solution
223788934|NCT05779995|DRUG|Placebo|Inhalation solution with matched volume
223788935|NCT01449305|DEVICE|Nanoone Woman Underwear|Chen Yi Enterprise, Co., Ltd. design a kind of negative ion materials can supply delocalized electron, and add fiber inside, make clothes to wear in the body, no external power or battery, only depend on infrared body photon hit of thermoelectric effect or heart compression pulse, blood flow of piezoelectric, therefore can sustained sufficient amount of effective negative ion, to eliminate positive ions in vivo, or make oxygen free radical to obtain the lack electrons. Decrease active free radical and get non toxic effect in short time.
223788936|NCT06957938|DRUG|Neoadjuvant Chemotherapy (NACT)|Neoadjuvant Chemotherapy with paclitaxel (or albumin - bound paclitaxel) and cisplatin
223788937|NCT06957938|DRUG|Neoadjuvant and maintenance Tislelizumab|Neoadjuvant and maintenance Tislelizumab
223788938|NCT06957938|RADIATION|Concurrent chemo-radiotherapy (CCRT)|Concurrent chemo-radiotherapy (CCRT), with cisplatin-based chemotherapy
223788939|NCT06957938|PROCEDURE|Surgery and adjuvant (chemo-)radiotherapy|Definitive surgery, with adjuvant (chemo-)radiotherapy, depending on pathologic findings.
223788940|NCT05840198|BEHAVIORAL|Recovery & Care Canine-Assisted Therapy|Active intervention. An 6-week session of structured, goal-oriented activities where youth focus on mastering dog obedience and dog training skills. Each session is 1 hour and 15 minutes in length and includes education, review of prior sessions, and specific skill-building activities. Skill-building activities progress in complexity during the course of the 6-week curriculum.
223788941|NCT05840198|OTHER|Treatment as usual|Youth in this condition receive treatment as usual from their health care providers
223788942|NCT06282341|OTHER|Race: Simulated marathon|Participants will take part in a race: simulated marathon. Before, during, immediately after and the month after the race, neuromuscular, physiological and biomechanical assessments will take place.
223788943|NCT06282341|OTHER|Race: Simulated trail|Participants will take part in a race: simulated trail. Before, during, immediately after and the month after the race, neuromuscular, physiological and biomechanical assessments will take place.
223788944|NCT06282341|OTHER|Race: Trail in nature|Participants will take part in a race: trail in nature. Before, during, immediately after and the month after the race, neuromuscular, physiological and biomechanical assessments will take place.
223788945|NCT06636630|PROCEDURE|Quadruple scleral flap|Quadruple Flap Technique (Group B) A 360-degree peritomy will be performed to expose the underlying sclera. Following evisceration of the ocular contents, careful hemostasis will be achieved. Four muscular-tendinous flaps will be developed from the recti muscles. These flaps will be dissected under minimal tension to preserve their vascular supply. The prepared flaps will be draped over the implant in a manner that the edges slightly overlap, ensuring complete coverage. The flaps will be sutured together using silk sutures, securing the implant in place.The conjunctiva will be meticulously closed over the muscle flaps with continuous absorbable sutures to enhance the healing process and minimize postoperative discomfort.
223788946|NCT06636630|PROCEDURE|Double scleral flap|The double flap technique, which involves the creation of two scleral flaps to encase and secure the implant, has been a standard approach in many surgical settings. This method aims to cover the implant adequately, thereby minimizing exposure risks and enhancing the potential for implant motility.
223788947|NCT05531994|DRUG|Montelukast sodium oral thin films with water (T)|Single-dose montelukast sodium oral thin film 5mg under fed condition with water 240 mL
223788948|NCT05531994|DRUG|Montelukast sodium chewable tablets with water (R)|Single-dose montelukast sodium chewable tablet 5mg under fed condition with water 240 mL
223788949|NCT03892486|OTHER|The high PUFA diet group|Assumptions of nutritional intervention: in a randomized manner volunteers will be assigned to one of two groups: a control group which will receive general nutritional recommendations, based on the Polish nutrition pyramid, and the intervention group which will receive nutritional recommendations, based on the Polish nutrition pyramid and will consume at least 4 tablespoons of olive oil or 30 grams of nuts every day for 12 weeks.
223788950|NCT01259713|DRUG|Liposomal amphotericin B|Ambisome 5 mg/kg twice weekly administered by IV route over 2 hours twice weekly (each dose separated alternately by 2 and 3 days each week during induction chemotherapy
223788951|NCT01259713|DRUG|Placebo|Placebo to match liposomal amphotericin B administered by IV route over 2 hours twice weekly (each dose separated alternately by 2 and 3 days each week) during induction chemotherapy
223788952|NCT06111742|DEVICE|Bedside Entertainment and Relaxation Theater (BERT)|BERT is a Nebula Capsule Max portable projector that creates a familiar theater experience designed for children to divert attention away from procedures. It is fitted with a remote control that can be utilized to manage on-screen activities. BERT can be used with any wall, ceiling, or projector screen to create the theater experience with a large screen. It can also be used with assist devices, such as steering wheel and noise-canceling headphones.
223788953|NCT02216175|OTHER|SLIT to cow's milk|Sublingual immunotherapy
223788954|NCT02216175|OTHER|Low dose OIT|Oral Immunotherapy (low dose)
223788955|NCT02216175|OTHER|Conventional OIT to cow's milk|Oral Immunotherapy
223788956|NCT06386107|BIOLOGICAL|Thrombin Generation Assay (TGA)|Hemostasis is a complex process in which genetic or environmental conditions can cause shifts either towards pro-thrombotic states resulting in thrombosis, or towards pro-hemorrhagic states resulting in uncontrolled bleeding. Tests to assess a more global hemostatic profile, such as the TGA, have appeared as a more reliable alternative to assess the real hemostatic capacity of an individual. TGA is a global dynamic assay simultaneously and continuously measuring thrombin generation. It monitors the cleavage of a fluorigenic substrate that is simultaneously compared to the known thrombin activity in a non-clotting plasma sample.
223788957|NCT02939417|OTHER|Grape seed extract|Grape seed extract - collagen cross-linking agent
223788958|NCT01242488|BIOLOGICAL|CDP6038|60 mg subcutaneously (sc) at Weeks 0, 2, 4 6, 8, and 10
223788959|NCT01242488|BIOLOGICAL|CDP6038|120 mg sc at Weeks 0, 2, 4 6, 8, and 10
223788960|NCT01242488|BIOLOGICAL|CDP6038|240 mg sc at Weeks 0, 2, 4 6, 8, and 10
223788961|NCT01242488|BIOLOGICAL|Tocilizumab (Actemra or RoActemra)|8 mg/kg intravenously (iv) at Weeks 0, 4 and 8
223788962|NCT01242488|BIOLOGICAL|CDP6038|60 mg sc at Weeks 0, 4 and 8
223788963|NCT01242488|BIOLOGICAL|CDP6038|240 mg sc at Weeks 0, 4 and 8
223788964|NCT01242488|BIOLOGICAL|CDP6038|120 mg sc at Weeks 0, 4 and 8
223788965|NCT01242488|OTHER|Placebo sc|0.9% Sodium chloride for injection at Weeks 0, 2, 4 6, 8, and 10
223788966|NCT01242488|OTHER|Placebo sc|0.9% Sodium chloride for injection at Weeks 2, 6 and 10
223788967|NCT01242488|OTHER|Placebo iv|0.9% Sodium chloride for injection at Weeks 0, 4 and 8
223788968|NCT06571656|OTHER|FID123359 test formulation|Investigational product
223788969|NCT06571656|OTHER|FID123360 test formulation|Investigational product
223788970|NCT06571656|OTHER|FID123361 test formulation|Investigational product
223788971|NCT06571656|OTHER|FID121843 ocular lubricant|Commercially available, preservative-free eye drops
223788972|NCT04603989|DRUG|HNC042 for Injection|HNC042,freeze-dried powder,multiple ascending doses, Intravenous route Multiple doses, daily for 7 days, doses: 300mg to 1200mg
223788973|NCT04603989|DRUG|Placebo Comparator|Placebo , Intravenous route , multiple ascending doses
223788974|NCT06006182|OTHER|Grape Powder|Freeze-dried grape powder
223788975|NCT03965260|BIOLOGICAL|Bacterial samples from blood or peritoneal liquids|"For each cirrhotic patient hospitalized for a bacterial infection, a blood sample or a peritoneal liquid sample was collected and analyzed for susceptibility, as it is performed in the standard of care. Our department receives only the bacterial results.~We will then describe the bacterial ecology of the center cirrhotic population in terms of infection acquisition mode, infection site, infection etiology but also drug-resistance."
223788976|NCT04846504|BEHAVIORAL|MMBFM program with clinician coach support|Clinician-delivered telephonic coaching to support participants in the Mindful Mood Balance for Moms online course for prevention of depression relapse/recurrence among perinatal women who have had prior episodes of depression but are not currently depressed.
223788977|NCT04846504|BEHAVIORAL|MMBFM program with peer coach support|Peer-delivered telephonic coaching to support participants in the Mindful Mood Balance for Moms online course for prevention of depression relapse/recurrence among perinatal women who have had prior episodes of depression but are not currently depressed. Peers will be women with lived experience of perinatal depression who are trained on the coaching protocol.
223788978|NCT04846504|BEHAVIORAL|Patient facing strategy intervention arm|Direct outreach and recruitment of participants into Mindful Mood Balance for Moms study by study teams. Participants will be women receiving prenatal care at the 4 study sites: Kaiser Permanente Colorado, Southern California, and Georgia, and HealthPartners.
223788979|NCT04846504|BEHAVIORAL|Patient facing plus clinic facing strategy intervention arm|Direct outreach and recruitment of participants into Mindful Mood Balance for Moms study by study teams, plus recommendation of / referral to the Mindful Mood Balance for Moms study by OB clinicians at the 4 study sites. OB clinicians will choose from printed materials (e.g., flyers, posters in exam rooms and waiting rooms, prescription pads) and electronic medical record prompts (e.g., smart lists, dot phrases) to facilitate engagement in the Mindful Mood Balance for Moms course. Participants will be women receiving prenatal care at the 4 study sites: Kaiser Permanente Colorado, Southern California, and Georgia, and HealthPartners.
223703931|NCT06238362|OTHER|TPAP|Algorithm for modification of CPAP therapy where pressure is reduced during the inspiratory phase though much of the expiratory phase, then is returned to full pressure near the end of the expiratory phase. Note that the same device that delivers CPAP can also deliver TPAP
223788980|NCT05935501|DEVICE|Formaderm Young|Dermal filler injection to facial areas.
223788981|NCT05935501|DEVICE|Restylane|Dermal filler injection to facial areas.
223788982|NCT03814889|DEVICE|Vibration pattern|Vibration patterns applied to the affected limb based on pilot study results.
223788983|NCT03814889|DEVICE|No vibration|These patients will wear a glove with a blinking light instead of feeling vibrations.
223788984|NCT00958919|DRUG|naloxone|10 mg naloxone in 25 ml total volume
223788985|NCT00958919|DRUG|normal saline|25 ml
223788986|NCT06060691|DRUG|Kaempferol|Kaempferol
223788987|NCT06503276|DRUG|Orelabrutinib|Orelabrutinib PO will be administered as per the schedule specified in the respective arm
223788988|NCT06503276|RADIATION|Ultra-low dose radiotherapy|2 Gy radiotherapy will be administerd twice in the first cycle
223788989|NCT00448539|DRUG|Rufinamide|Dose will be maintained within the range of 2400 to 4800 mg/day (i.e., 1200 to 2400 mg twice daily).
223788990|NCT02103439|DRUG|Algeron|1.5 µg/kg of body weight subcutaneously, once a week
223788991|NCT02103439|DRUG|PegIntron|1.5 µg/kg of body weight subcutaneously, once a week
223788992|NCT00695903|DRUG|daptomycin|daptomycin 10 mg/kg IV every 24 hours
223788993|NCT00695903|DRUG|vancomycin|Vancomycin 15 mg/kg IV, dosed to maintain trough serum concentrations of 15 to 20 μg/mL
223788994|NCT00417937|DRUG|azelaic acid 15% gel|15% gel, topically applied once daily for six weeks
223788995|NCT00417937|DRUG|azelaic acid 15% gel|15% gel, topically applied twice daily for six weeks
223788996|NCT00484705|PROCEDURE|Electroacupuncture|
223788997|NCT00484705|PROCEDURE|Physical exercise|
223788998|NCT00484705|PROCEDURE|Untreated control|
223788999|NCT02545673|BEHAVIORAL|Enhanced linkage to care|
223789000|NCT02545673|BEHAVIORAL|Standard-of-care plus|
223789001|NCT02485470|OTHER|MPACT|Maintaining Physical Activity during Cancer Treatment
223789002|NCT01100164|DRUG|Eszopiclone|Eszopiclone - once a day (30 minutes before lying down to sleep for a period of 4 weeks of treatment)
223789003|NCT01100164|DRUG|Zopiclone|Zopiclone - once a day (30 minutes before lying down to sleep for a period of 4 weeks of treatment)
223789004|NCT03821311|RADIATION|Computed tomography|End-inspiratory/end-expiratory CT is repeated 3 times corresponding to the 3 studied conditions: At baseline, through expiratory resistive loading using an adjustable PEP mask, and after 5 min of nasal high flow therapy at 25 L/min.
223789005|NCT00043420|DRUG|PF-3512676|Weekly subcutaneous injections of 0.08mg/kg PF-3512676. Treatment continues for a minimum of 8 weeks unless disease progression or unacceptable toxicity occurs, or a maximum of 24 weeks.
223789006|NCT00043420|DRUG|PF-3512676|Weekly subcutaneous injections of 0.16mg/kg PF-3512676. Treatment continues for a minimum of 8 weeks unless disease progression or unacceptable toxicity occurs, or a maximum of 24 weeks.
223789007|NCT00043420|DRUG|PF-3512676|Weekly subcutaneous injections of 0.24mg/kg PF-3512676. Treatment continues for a minimum of 8 weeks unless disease progression or unacceptable toxicity occurs, or a maximum of 24 weeks.
223789008|NCT00043420|DRUG|PF-3512676|Weekly subcutaneous injections of 0.28mg/kg PF-3512676. Treatment continues for a minimum of 8 weeks unless disease progression or unacceptable toxicity occurs, or a maximum of 24 weeks.
223789009|NCT00043420|DRUG|PF-3512676|Weekly subcutaneous injections of 0.32mg/kg PF-3512676. Treatment continues for a minimum of 8 weeks unless disease progression or unacceptable toxicity occurs, or a maximum of 24 weeks.
223789010|NCT00043420|DRUG|PF-3512676|Weekly subcutaneous injections of 0.36mg/kg PF-3512676. Treatment continues for a minimum of 8 weeks unless disease progression or unacceptable toxicity occurs, or a maximum of 24 weeks.
223789011|NCT00043420|DRUG|PF-3512676|Weekly subcutaneous injections of 10 mg PF-3512676. Treatment continues for a minimum of 8 weeks unless disease progression or unacceptable toxicity occurs, or a maximum of 24 weeks.
223789012|NCT00043420|DRUG|PF-3512676|Weekly subcutaneous injections of 25 mg PF-3512676. Treatment continues for a minimum of 8 weeks unless disease progression or unacceptable toxicity occurs, or a maximum of 24 weeks.
223789013|NCT00000893|DRUG|Nelfinavir mesylate|
223789014|NCT00000893|DRUG|Efavirenz|
223789015|NCT06151262|DRUG|Trilaciclib+mFOLFIRINOX|This was a single-arm, exploratory study of the combination of Trilaciclib and mFOLFIRINOX in patients with advanced pancreatic cancer receiving first-line therapy. Observed the incidence of chemotherapy-induced myelosuppression, and imaging was performed every four cycles to assess tumor response.
223703932|NCT06238362|DEVICE|CPAP|Gold standard for treating sleep apnea.
223703933|NCT05136690|DRUG|Nicotine patch|Nicotine 21 mg transdermal nicotine patch.
223703934|NCT05136690|DRUG|MK-4334|MK-4334 250 mg capsule taken by mouth.
223703935|NCT05136690|DRUG|Placebo patch|Placebo patch.
223703936|NCT05136690|DRUG|Placebo capsule|Placebo capsule taken by mouth.
223703937|NCT03419611|BEHAVIORAL|Multi-Modal|Intervention combining speech sound practice, AAC and receptive practice on a set of individually determined words. Words are selected based on phonological properties. Delivered 3 times per week.
223703938|NCT03419611|OTHER|Treatment as Usual|Teacher provided with word list and teacher intervening as usual.
223703939|NCT03419611|BEHAVIORAL|High Intensity Multi-Modal|Intervention combining speech sound practice, AAC and receptive practice on a set of individually determined words. Words are selected based on phonological properties. Delivered 5 times per week.
223703940|NCT06595121|DRUG|budesonide|Budesonide 1 mg/2mL nebuliser suspension
223703941|NCT06595121|DRUG|budesonide|Pulmicort(r) 1 mg/2mL nebuliser suspension
223703942|NCT06595121|OTHER|Activated Charcoal|suspension of 10g activated charcoal slurried in 70mL of water
223703943|NCT06680973|OTHER|Hospital-Based Resistance Training|"Participants will undergo resistance training using a weight training station and elastic equipment (elastic bands and tubes).~The intensity of the resistance training with the weight training station will be determined based on 1 Repetition Maximum (1RM). Resistance training with the weight training station will be conducted at 30-70% of the 1RM intensity and will include the following exercises: leg extension, pull down, chest press, and pec deck.~The intensity of resistance training using elastic equipment will be determined according to the individual's perceived exertion. Resistance training with elastic equipment will be performed at an intensity of 12-14 on the Borg Scale (moderate to somewhat hard) for movements involving hip flexion, extension, abduction, and adduction.~The resistance training regimen will consist of 8-12 repetitions, 2-3 sets, with at least 1 minute of rest between sets, twice a week for 12 weeks."
223703944|NCT06680973|OTHER|Home-Based Resistance Training|"Participants will undergo resistance training at home using elastic equipment (elastic bands and tubes). The intensity of the resistance training will be determined based on the individual's perceived exertion. The training will be conducted at an intensity of 12-14 on the Borg Scale (moderate to somewhat hard), with 8-12 repetitions, 2-3 sets, and a rest period of at least 1 minute between sets, twice a week for 12 weeks. Progression in training intensity will be achieved by increasing the weight once the perceived exertion, as measured on the Modified Borg Scale, falls below 3 (moderate) after completing 20 repetitions.~Resistance training will include exercises such as leg extension, pull down, chest press, pec deck, and movements involving hip flexion, extension, abduction, and adduction. To ensure individuals perform exercises correctly, follow-up will be conducted through online meetings every two weeks. These meetings will not be recorded."
223703945|NCT06681038|DRUG|Standard Medical Therapy|"Intravenous doublet chemotherapy FOLFIRI or FOLFIRINOX + targeted systemic therapy (anti-EGFR or anti-VEGF).~Administered every 2 weeks for 12 cycles. Dosage and administration at recommended doses."
223703946|NCT06681038|PROCEDURE|PIPAC|"In addition to standard systemic treatment, patients receive also four PIPAC procedures with pressurized aerosol containing oxaliplatin.~The PIPAC procedure is repeated up to a maximum of 4 times every 6 weeks."
223703947|NCT06681506|DEVICE|Metronomic breathing, exercise rehabilitation, external counterpulsation, extracorporeal shock wave.|Phase I rehabilitation(Metronomic breathing，exercise rehabilitation）,Phase II rehabilitation (exercise rehabilitation, external counterpulsation, extracorporeal shock) wave.)
223703948|NCT06681506|DEVICE|bedside rehabilitation and breathing, balance, flexibility, movement rehabilitation|Phase I rehabilitation (bedside rehabilitation, breathing rehabilitation), Phase II rehabilitation (breathing, balance, flexibility, movement)
223703949|NCT06680388|DRUG|Drug：CD19 CAR-T|A total of 3 dose groups were set, with dose group 1 as the starting dose, which was performed according to the traditional 3 + 3 design rule as a single intravenous infusion.
223789016|NCT01603576|DEVICE|Prototype wide view suprachoroidal retinal prosthesis|Manufacturer = Bionics Institute, Australia
223789017|NCT01757769|DRUG|Silodosin|8 mg daily for 24 weeks
223789018|NCT01923727|BIOLOGICAL|[89Zr]Df-IAB2M|A single intravenous infusion of 5 mCi of \[89Zr\]Df-IAB2M in a mass dose of 10 mg, 20mg or 50mg.
223789019|NCT00244075|DIETARY_SUPPLEMENT|nutritional supplement|either oral nutritional formula (Nepro) or intravenous IDPN solution will be administered during hemodialysis; Nepro has a total calorie amount as well as protein, carbohydrate and fat content that are comparable to that of IDPN, and will be provided at four equal amounts with 1-hour intervals throughout the study (150 ml for a total of 600 ml over 4 hours of hemodialysis); IDPN consists of 225 ml of amino acids at a concentration of 15%, 112.5 ml of dextrose at 50% and 112.5 ml of lipids at 20%, will be given at a rate of 150 ml/hr, and will provide 209 kcal/hr
223789020|NCT00244075|DRUG|recombinant human growth hormone (rcGH)|subcutaneous administration of 75 micrograms/kg/day of rcGH for 3 consecutive days
223789021|NCT00244075|BEHAVIORAL|exercise|either dual leg press (3 sets of 8-12 repetitions) beginning 30 minutes prior to hemodialysis, or modified stepper (minimum of 15 minutes up to a maximum of 90 minutes, depending upon the patient's tolerance) beginning 15 minutes post initiation of hemodialysis
223789022|NCT03682094|DRUG|VSL#3|Probiotics are dietary supplements composed of live microorganisms that are normally found within the human microbiome. Probiotics, specifically Lactobacilli and Streptococcus salivarius, have been shown to alter oral microbial composition and to inhibit oral pathogens that contribute to dental caries and periodontal disease. The probiotic chosen for this study is VSL#3, a blend of 8 strains of bacteria, including Lactobacillus and Streptococcus salivarius. VSL#3 has been well tolerated, with minimal adverse effects. VLS#3 was chosen as the treatment substance for this project due to its successful use in trials examining an array of outcomes and its combination of several strains of bacteria.
223789023|NCT01311492|BEHAVIORAL|Healthy Lifestyle Program|"The healthy lifestyle program includes upper body stretching and educational workshops. The purpose of this group is to control for general levels of staff and participant time and attention, in addition to general secular and seasonal effects that could influence the outcomes of interest. The rational for this placebo exercise activity is that it helps foster adherence to this arm of the study and increases the perceived benefit of the healthy lifestyle program to the participants without directly affecting the study outcomes."
223789024|NCT01311492|BEHAVIORAL|Physical Activity Intervention|The physical activity intervention consists of a general weekly physical activity goal of 150 minutes. This is consistent with the public health message from the Surgeon General's report that moderate physical activity should be performed for 30 minutes on most if not all days of the week (150-210 total minutes). This goal is approached in a progressive manner over the course of the trial.
223789025|NCT06055296|OTHER|COMPRENDO Peer Navigation Intervention|"Parents randomized to the intervention, COMPRENDO, will receive culture, language, and health literacy-concordant pre-accrual, accrual, and post-accrual activities in person led by a peer navigator for up to 4 weeks. Visit 1 (V1) will provide anticipatory guidance and education on a) general concepts of pediatric cancer research (standard of care, clinical trials, randomization); b) informed consent/assent, research affiliations (e.g., Children's Oncology Group); c) clinical trial types (therapeutic, non-therapeutic); d) voluntariness; and e) frequently asked questions, resources. Navigators will follow a script supported by culture, language and health-literacy concordant handouts and graphic materials, decision aids, and short video-clips. Navigators also provide support with decision-making and answer parents' questions. Three follow-up peer navigator visits (V2, V3, V4) over 4 weeks are tailored to the parents' needs."
223789026|NCT03155607|BEHAVIORAL|Virtual Reality Distraction|Patient will utilize a virtual reality device during wound care.
223789027|NCT03966157|DEVICE|Nasal Bridle|Feeding tube secured with nasal bridle
223789028|NCT05464459|PROCEDURE|Novel elbow procedure|A general anaesthetic plus upper limb nerve block is used with no tourniquet. Antibiotics and tranexamic acid are administered intravenously prior to procedure. Skin prepared by standard technique with alcoholic chlorhexidine. A posterior midline incision is made and lateral paraolecranon approach made to the elbow joint. Lateral ligament complex released for access and repaired at the end of the procedure. A 5mm high speed burr and HAPY burr instrument prepares the distal humerus. The trochlea spool and/or capitellum are resected to receive Pyrocarbon spherical prosthesis, size determined from pre-operative planning. The greater sigmoid notch is prepared in a similar manner with burr. A trial prosthesis is used to assess joint movement/stability before the Pyrocarbon spherical spacer inserted. Wound closed in layers with heavy vicryl. Skin closure with subcutaneous monocryl. Physiotherapist advice within 24 hours and immediate active mobilisation is commenced as comfort allows.
223789029|NCT00345904|BIOLOGICAL|Fluarix|
223789030|NCT06426537|DRUG|Colchicine 0.5 MG Oral Tablet|Oral administration of Colchicine in STEMI patients
223789031|NCT06385158|DRUG|GS1-144 tablet|GS1-144 tablet is an NK3R antagonist.
223789032|NCT03455972|BIOLOGICAL|anti-CD19 and anti-BCMA CAR|Participants will get auto-HSCT. Hematopoietic reconstitution after auto-HSCT, participants will get the anti-CD19 CAR T cells (1×10e+7/kg on d0) and anti-BCMA CAR T cells as split-dose (total 5×10e+7/kg, 40% on d1 and 60% on d2)
223789033|NCT03455972|DRUG|Immunomodulatory drugs|Maintenance therapy
223789034|NCT05387005|DIAGNOSTIC_TEST|UBT|H. pylori diagnostic test: C13 urea breath test
223789035|NCT05387005|DIAGNOSTIC_TEST|HPSA|H. pylori diagnostic test: H. pylori stool antigen test
223789036|NCT05387005|DIAGNOSTIC_TEST|UBT and HPSA|H. pylori diagnostic tests: H. pylori serology test, C13 urea breath test
223789037|NCT05387005|DIAGNOSTIC_TEST|Serology (two stage)|H. pylori diagnostic test: If H. pylori serology is positive, confirmation UBT will be done.
223789038|NCT04193800|OTHER|10-week rotation in primary care setting|Ten paramedics underwent a 10 week rotation into a GP practice in the Leeds area of South Yorkshire, England.
223789039|NCT00463710|DRUG|Avonex® monotherapy (6.0 MIU administered i.m. each week)|
223789040|NCT04199949|BEHAVIORAL|Inactivity|On days 1 and 6 of each main trial, the participants will be asked to attend the laboratory after an overnight fast of at least 8 to 12h to undergo brachial and popliteal arteries FMD measurements (30 min apart) using duplex-Doppler ultrasound, followed by assessment of the hand grip strength of their non-dominant hand using a hand dynamometer.
223789041|NCT02293629|DRUG|BMS-986147|
223789042|NCT02293629|DRUG|Placebo matching BMS-986147|
223789043|NCT02773589|PROCEDURE|Peroral endoscopic myotomy|Peroral endoscopic myotomy
223789044|NCT02813226|OTHER|Molecular Imaging|Baseline and follow-up FDG PET-CT and DCFPyL PET-CT
223789045|NCT04829370|OTHER|PLT|The study will be conducted by using a fractional carbon dioxide laser for acne scar treatment. After the treatment, each patient enrolled will be applied 2 mL PLT solution on the right face. Treatment mentioned above will be repeated every 3 to 4 weeks, overall 4 times treatment and one month follow up after fourth treatment. Every record will be documented in questionnaires by the principal investigator and the patient itself. Moreover, VISIA is applied for objective observation, such as spots, wrinkles, texture, pores, UV spots, brown spots, red area, and porphyrins could be objectively analyzed.
223789046|NCT04829370|OTHER|Saline|"The study will be conducted by using a fractional carbon dioxide laser for acne scar treatment. After the treatment, each patient enrolled left face be applied 2 mL normal saline.~Treatment mentioned above will be repeated every 3 to 4 weeks, overall 4 times treatment and one month follow up after fourth treatment. Every record will be documented in questionnaires by the principal investigator and the patient itself. Moreover, VISIA is applied for objective observation, such as spots, wrinkles, texture, pores, UV spots, brown spots, red area, and porphyrins could be objectively analyzed."
223789047|NCT05443035|PROCEDURE|Antimicrobial PDT and Papacarie Deproteinization|Selective removal of carious tissue with curette + antimicrobial PDT (methylene blue 5 Evilux, Color index 52015, Fórmula \& Ação + red laser at 660 nm) + deproteinization of enamel with Papacárie DuoTM + restoration.
223789048|NCT05443035|PROCEDURE|Conventional caries treatment|Selective removal of carious tissue with curette + restoration.
223789049|NCT05443035|PROCEDURE|Antimicrobial PDT and 5% NaOCl Deproteinization|Selective removal of carious tissue with curette + application of methylene blue and low-level laser (aPDT) + deproteinization of adjacent enamel with 5% NaOCl + restoration.
223789050|NCT01415791|DRUG|ICI176,334-1|Subject will receive single dose of ICI176,334-1
223789051|NCT01617421|BEHAVIORAL|Yoga|This study used Hatha yoga (influenced by Integral, Iyengar, and Kripalu yoga) which includes postures (asanas), breathing techniques (pranayama) and meditation \[9\]. Biweekly, 60-minute, bilingual yoga classes were offered for 8 weeks at a yoga studio in Washington, DC. Classes were kept small (3-10 participants) to allow for pose modifications as needed for each participant. Participants were given instructions, bilingual manuals, and yoga equipment to encourage home practice. Participants were asked to keep journals to document the frequency and duration of home practice and their experience while on the study. After the last class, a yoga DVD and a list of local yoga studios were given to encourage continued practice.
223789052|NCT06265103|OTHER|Clinical care and quality improvement|All eligible patients at each center will be included in the registry for clinical care, quality improvement and other activities that do not meet the regulatory requirements of human subjects research. Use of data for these purposes is not considered to be a human subjects research activity and will be covered under a Business Associates Agreement and a Participation and Data Use Agreement.
223789053|NCT02384759|DRUG|aflibercept|
223789054|NCT02384759|DRUG|LV5FU2|
223789055|NCT02368353|OTHER|Cognitive behavioral therapy|
223789056|NCT02368353|OTHER|Supportive therapy|
223789057|NCT00235976|DRUG|Gantacurium Chloride for Injection (AV430A)|
223789058|NCT01595295|OTHER|non interventional|
223789059|NCT06293729|DRUG|NGGT006|Single intravenous infusion of NGGT006 at low dose (7.5e12vg/kg), medium dose (1.5e13vg/kg) and high dose (3e13vg/kg).
223789060|NCT00000985|DRUG|Vidarabine|
223789061|NCT00000985|DRUG|Acyclovir|
223789062|NCT00000985|DRUG|Foscarnet sodium|
223789063|NCT04699266|DEVICE|Assigned Intervention (POD F GF)|The investigational lens (POD F GF )will be implanted to both eyes in subjects with bilateral cataract. Registration of patients and the implantation of the investigational lens (POD F GF) will be conducted in consideration of securing 44 eyes in 22 subjects as the analysis subjects
223789064|NCT04745182|BEHAVIORAL|MASTERY|A 12-week, phone-delivered intervention utilizing positive psychology (PP), motivational interviewing (MI), and specific midlife modules (e.g., on time management, financial stress, caregiving stress, or occupational stress) to promote physical activity and well-being in mid-life adults.
223789065|NCT01063400|OTHER|Observation|monitoring of physical activity for 14 days using physical activity monitoring devices along with activity diary
223789066|NCT01886898|OTHER|Infant formula|infant formula
223789067|NCT01886898|OTHER|Breastfeeding|
223789068|NCT03798860|DIAGNOSTIC_TEST|blood samples|For performing the Luminex solid phase assay (SPA) test, 7.5 ml of patient whole blood are collected from a peripheral vein.
223789069|NCT04182620|DEVICE|renal denervation|Renal denervation using the Paradise renal denervation system - a dedicated RDN catheter that delivers a circumferential ring of ablative ultrasound energy
223789070|NCT04182620|DEVICE|Catheter ablation|Catheter ablation - one of the most common procedures performed by Cardiac Electrophysiologists for atrial fibrillation
223789071|NCT05513872|DRUG|Nicotine Replacement Therapy (NRT) Sampling|Participants randomized to this condition will receive a 4-week nicotine replacement therapy (NRT) starter kit containing both nicotine lozenges and patches in their original packaging.
223789072|NCT05513872|BEHAVIORAL|Practice Quitting (PQ) Counseling|Practice Quitting (PQ) counseling will consist of four weekly treatment sessions, with an initial 45-minute session followed by three 20-minute sessions. The goals of the counseling sessions are 1) to gradually expose patients to nicotine withdrawal symptoms through practice quitting, and 2) to reduce fear and avoidance of the physical sensations associated with nicotine withdrawal.
223789073|NCT05513872|BEHAVIORAL|Motivational Interviewing (MI) Counseling|Motivational Interviewing (MI) counseling will consist of four weekly treatment sessions, with an initial 45-minute session followed by three 20-minute sessions. Counseling content will incorporate MI-consistent principles, such as open questions, simple and complex reflections, and affirmations to facilitate participant statements in favor of behavior change. Discussion will focus on the motivational topics outlined in the USPHS guidelines for smokers not ready to quit: 1) relevance of smoking cessation or reduction to the individual, 2) risks of continued heavy smoking, 3) rewards of quitting and reduction, and 4) roadblocks to success, on a 5) repeated basis.
223789074|NCT04732403|OTHER|Patient Position|The patient will be placed in an angle on the surgical table during cystoscopy.
223789075|NCT06962046|PROCEDURE|Virtual Reality|"* VR~* Spinal anaesthesia~* Limited propofol aiming for OAA/S of 4-5 (light sedation)"
223789076|NCT03199729|OTHER|Slip-only training|Subjects in this arm will receive overground, slip specific perturbation training only. The total perturbation training trials received by this group will be 24 but the protocol will consist of a total of 70-75 trials (to match the training length and time of Combined slip and trip training group).
223789077|NCT03199729|OTHER|Trip-only training|Subjects in this arm consisting of a total of 24 trials of trip specific training delivered in an identical sequence (mixed with non-trip trials) as the Group with slip only training.
223789078|NCT03199729|OTHER|Combined slip+trip training|Subjects in this arm will receive training consisting of repeated exposure to both slips and trips with a total of 24 slips plus 24 trips to keep the number of trials of each perturbation same as the perturbation specific training groups (slip only and trip only), however, the total dose will be doubled. The total trials walked (perturbed + unperturbed) will be 75.
223789079|NCT06076642|BIOLOGICAL|TAK-881|Participants will receive SC infusion of TAK-881.
223789080|NCT06076642|DEVICE|SC Investigational Needle Sets|The single-use only SC needle set will be used to administer TAK-881 to the target depth below the skin surface. One needle set (single or bifurcated) will be used per infusion.
223789081|NCT05653921|OTHER|In vivo confocal microscopy (IVCM)|In vivo confocal microscopy (IVCM) allows for visualization of the corneal structures at the cellular level, allowing for assessment of corneal nerves. With a magnification of 800 times, it makes it possible to detect and quantify changes in the epithelial layers and sub-basal nerve plexus.
223789082|NCT03833544|OTHER|Exercise training|Progressive resistance training of hip, knee, and ankle flexors.
223789083|NCT03217045|OTHER|nutrition protocol introduction|Growth comparison of 2 cohorts of infants evaluated in a before-after design
223789084|NCT02214134|GENETIC|Tumour markers testing|
223789085|NCT05761223|DRUG|Phase Ia dose-escalation part of FB849 Monotherapy|At a given level dose once daily
223789086|NCT05761223|DRUG|Phase Ib dose-expansion of FB849 monotherapy|At recommended dose for expansion cohort once daily
223789087|NCT05761223|DRUG|Phase IIb dose-escalation part of FB849 in Combination with Pembrolizumab|At recommended dose for expansion cohort once daily in combination with pembrolizumab
223789088|NCT05761223|DRUG|Phase IIb dose-expansion part of FB849 in Combination with Pembrolizumab (Type A cancer)|At recommended dose for expansion cohort once daily in combination with pembrolizumab
223789089|NCT05761223|DRUG|Phase IIb dose-expansion part of FB849 in Combination with Pembrolizumab (Type B cancer)|At recommended dose for expansion cohort once daily in combination with pembrolizumab
223789090|NCT05761223|DRUG|Phase IIb dose-expansion part of FB849 in Combination with Pembrolizumab (Type C cancer)|At recommended dose for expansion cohort once daily in combination with pembrolizumab
223789091|NCT04111549|OTHER|Home-based telehealth GOALS|Goal Oriented Attentional Self-Regulation (GOALS) is a manualized cognitive training intervention for problems with attention and executive control that has been shown to improve cognitive, emotional, and functional outcomes in civilians and Veterans with history of TBI, including Veterans 65 and older, and healthy older adults. It will be delivered to aging Veterans with history of TBI via in-home video telehealth.
223789092|NCT04111549|OTHER|In-person GOALS|Goal Oriented Attentional Self-Regulation (GOALS) is a manualized cognitive training intervention for problems with attention and executive control that has been shown to improve cognitive, emotional, and functional outcomes in civilians and Veterans with history of TBI, including Veterans 65 and older, and healthy older adults. It will be delivered to aging Veterans with history of TBI in person.
223789093|NCT05539989|BIOLOGICAL|VPM1002 Vaccine|0.1 mL (2-8x10\^5 CFU)
223789094|NCT05539989|BIOLOGICAL|BCG Vaccine|0.1mL (0.075 Mycobacterium bovis)
223789095|NCT05539989|DRUG|Placebo|0.1 mL (sodium chloride for injection 0.9%)
223789096|NCT05608993|OTHER|High Intensity Intervention|The High Intensity intervention will include clinician education, individualized clinician audit and feedback with peer comparison, and electronic health record (EHR) changes of prescription fields.
223789097|NCT05608993|OTHER|Low Intensity Intervention|The Low Intensity intervention will include clinician education and EHR changes only.
223789098|NCT01316822|DRUG|ARRY-382, cFMS inhibitor; oral|multiple dose, escalating
223789099|NCT06010589|DRUG|DWJ1558|DWJ1558
223789100|NCT06010589|DRUG|DWC202310 and DWC202311|Co-administration of DWC202310 and DWC202311
223789101|NCT05019339|BEHAVIORAL|Healthy HomeStyles|Comparison of 2 educational interventions
223789102|NCT05019339|BEHAVIORAL|Eat Healthy Be Active|Comparison of 2 educational interventions
223789103|NCT01546194|OTHER|Phone call explaining the research project|A phone call on the day before surgery will be provided to subjects explaining the nature of the clinical trial
223789104|NCT01201629|DEVICE|t DC stimulation|tDCS is a non-invasive, non-painful technique that modulates cortical excitability. tDCS can induce intracerebral current flow that is sufficiently large to achieve changes in cortical excitability. Thus, tDCS can be applied to humans non-invasively and painlessly to induce focal, lasting but reversible shifts of cortical excitability.
223789105|NCT01201629|DEVICE|tDCStimulation|1 mA of tDCS will be delivered through surface electrodes (25-35 cm2) to the unaffected motor cortex for 30 min prior to a patient's scheduled OT. In the sham group patient will receive stimulation for 30 seconds only.
223789106|NCT04226924|DRUG|Trehalose|90 mg/ml trehalose solution for IV infusion
223789107|NCT01275573|DEVICE|Repetitive Transcranial Magnetic Stimulation|Repetitive Transcranial Magnetic Stimulation will be applied on the contralateral primary cortical motor on the painful side for the Parkinson's disease patients and on the left primary cortical motor for the healthy volunteer. The stimulation frequency will be 20 Hz during 26 min with an intensity stimulation equal of 95% of the motor threshold.
223789108|NCT04214132|OTHER|Virtual Counselling Application using Artificial Intelligence|Intervention comprises of four Virtual Patients scenarios that aimed to improve nursing undergraduates communication skills in a clinical setting. These scenarios are based on authentic clinical cases (adapted from the real-life clinical case studies) focusing mainly on the communication aspects. Scenarios included 1) a middle-aged pregnant woman in her third trimester experiencing pain, 2) a middle-aged lorry driver who self-admitted to the hospital due to relapse of depressive symptoms, 3) changing a bloody dressing of a middle-aged male patient who had an operation 3 days ago, and 4) communicating with a fellow stressed student during their final preregistration clinical posting period.
223789109|NCT04333667|BEHAVIORAL|Intervention group|The intervention consists of 8 modules. Each week participants get access to a new module. Each module consists of psychoeducation and exercise parts. Most of the exercises are based on audio records. The content of the modules includes such themes as awareness and nonjudgement of senses, emotions, and thoughts. Participants can reach a psychologist on demand.
223789110|NCT02001727|OTHER|13C-Urea breath test for Helicobacter Pylori|
223789111|NCT02001727|OTHER|Questionaire|
223789112|NCT00144703|DRUG|Sirolimus|
223789113|NCT00144703|DRUG|Tacrolimus|
223789114|NCT01913067|DRUG|Cabazitaxel|Intravenous, 25 mg/m2 every 3 weeks
223789115|NCT01913067|PROCEDURE|Contrast-enhanced whole brain MRI|Evaluation of the volumetric reduction in the size of the brain lesion(s).
223789116|NCT04561479|OTHER|Pulmonary Rehabilitation|All exercise program will be applied during supervised session by a physiotherapist. Range of maximal heart rate will be screened by heart rate monitor during supervised session. Training group will receive upper extremity aerobic exercise training using arm ergometer at 60-80% of maximal heart rate (dyspnea perception at 3-4 level as well as fatigue perception at 5-6 level according to Modified Borg Scale). Inspiratory muscle training (Powerbreathe® Wellness-Inspiratory Muscle Trainer) at 50-60% of maximal inspiratory pressure (MIP) and progressive resistance training at 30-60% of 1 RM (using proprioceptive neuromuscular facilitation techniques (flexion, abduction, external rotation/extension, adduction, internal rotation) for upper extremity resistance training; using sandback for knee extensors) will be performed during 24 sessions (3 day/week; 8 weeks)
223789117|NCT04561479|OTHER|Alternative Exercises|Control group will receive alternative upper extremity exercises combined with breathing exercises. Control group will perform alternative upper extremity exercises combined with breathing exercises during 3 days/week, for 8 weeks
223789118|NCT05246423|DIAGNOSTIC_TEST|Observation group|Patients with paroxysmal atrial fibrillation undergo cardiopulmonary exercise testing, echocardiography, 24-hour ambulatory electrocardiographic monitoring and plasma biomarkers' measurement
223789119|NCT01650259|DRUG|OAD|OAD except Trazenta tablets
223789120|NCT01650259|DRUG|Trazenta|Linagliptin
223789121|NCT04139395|DRUG|68Ga-Citrate PET/MRI|Participants will be injected intravenously (IV) with 370 MBq of 68Ga Citrate. 45 -60 minutes after the radiopharmaceutical IV administration, whole body data acquisition at the PET/MRI suite will begin.
223789122|NCT04139395|DRUG|67Ga-Citrate SPECT|67Ga-Citrate will be used as the radiotracer for a regular medical care SPECT scan
223789123|NCT04139395|DEVICE|Positron Emission Tomography|Imaging with 68Ga-Citrate PET/MRI
223789124|NCT04139395|DEVICE|Magnetic Resonance Imaging|Imaging with 68Ga-Citrate PET/MRI
223789125|NCT04139395|DEVICE|SPECT|Imaging with 67Ga-Citrate radiotracer. SPECT scan will be conducted as part of regular medical care.
223789126|NCT02998567|DRUG|Guadecitabine|In arm 1 (escalation) and 2 (expansion).
223789127|NCT02998567|DRUG|Pembrolizumab|In arm 1 (escalation) and 2 (expansion).
223789128|NCT02998567|DRUG|ASTX727|In arm B2 (lung expansion) replacing guadecitabine
223789129|NCT05531214|BEHAVIORAL|Multidisciplinary Care Coordination Team|The intervention group will be patients whose primary care clinicians will be receiving guidance and recommendations from the multidisciplinary team consisting of cardiologists, nephrologists, and specialty pharmacists.
223789130|NCT04020913|DRUG|Somatropin injection|"Boys with short stature will be studied for measures of:~1. skeletal muscle strength, power, and endurance~2. muscle agility~3. lean body mass accrual~4. bone mineral density and resting energy expenditure before and after 6 months and 12 months of GH administration"
223789131|NCT06410066|OTHER|no intervention|
223789132|NCT03467659|OTHER|Cracked whole wheat porridge|Large particle whole wheat porridge was tested for gastric emptying rate, glycemic response and appetitive response.
223789133|NCT03467659|OTHER|Semolina wheat porridge|Large particle refined wheat porridge was tested for gastric emptying rate, glycemic response and appetitive response.
223789134|NCT03467659|OTHER|Whole wheat flour porridge|Small particle whole wheat porridge was tested for gastric emptying rate, glycemic response and appetitive response.
223789135|NCT03467659|OTHER|Refined wheat flour porridge|Small particle refined wheat porridge was tested for gastric emptying rate, glycemic response and appetitive response.
223789136|NCT03467659|OTHER|Refined wheat flour porridge,fine bran|Small particle refined wheat porridge with small particle bran was tested for gastric emptying rate, glycemic response and appetitive response.
223789137|NCT03467659|OTHER|Refined wheat flour porridge,coarse bran|Small particle refined wheat porridge with large particle bran was tested for gastric emptying rate, glycemic response and appetitive response.
223789138|NCT00323102|DRUG|Multihance|
223789139|NCT00444782|BIOLOGICAL|GV1001|
223789140|NCT06971497|DEVICE|ActivBraid™Collagen Co-Braid suture (Zimmer Biomet)|ActivBraid™ is a suture made from approximately half ultra-high molecular weight polyethylene and and half collagen derived from cow skin. Collagen is the most abundant protein in our bodies and serves as the building block for tendons and bones. The collagen in ActivBraid™ is intended to enhance cell attachment and tissue integration which may improve the healing of a rotator cuff repair. ActivBraid™ suture has been shown to have equivalent strength as other high strength sutures used in orthopaedic procedures and has been approved by the Food and Drug Administration (FDA) for repairing tendons. ActivBraid™ is a commercially available product that has been and is used in humans. This is the first post-market clinical study with ActivBraid™.
223789141|NCT03999619|BEHAVIORAL|Move 2 Learn|10-week (1 hour/week) program designed to target fundamental movement and pre-literacy skills with active parent involvement.
223789142|NCT00497653|DRUG|DCI|D-chiro-inositol 1200mg twicely daily for 6 weeks
223789143|NCT00497653|DRUG|Placebo|Placebo, twice daily for 6 weeks
223789144|NCT05226208|DIAGNOSTIC_TEST|Visual analogue scale (VAS)|In the postpartum period all patients filled VAS and underwent interviews from the 1st to the 3rd day after delivery.
223789145|NCT05226208|DIAGNOSTIC_TEST|General anxiety scale (GAD-2) and survey|In the postpartum period all patients filled survey with GAD-2 and underwent interviews from the 1st to the 3rd day after delivery.
223789146|NCT01204190|DRUG|Gestodene/EE Patch (BAY86-5016)|0.55 mg ethinyl estradiol (EE) + 2.1 mg gestodene (GSD) per patch; 3 treatment cycles; 21 days per treatment cycle, i.e. 3 x 7 days patch-wearing phase and a patch-free interval of 7 days
223789147|NCT01204190|DRUG|Gestodene/EE Patch (BAY86-5016)|0.35 mg ethinyl estradiol (EE) + 0.67 mg gestodene (GSD) per patch; 3 treatment cycles; 21 days per treatment cycle, i.e. 3 x 7 days patch-wearing phase and a patch-free interval of 7 days
223789148|NCT01204190|DRUG|Gestodene/EE Patch (BAY86-5016)|0.275 mg ethiny estradiol (EE) + 1.05 mg gestodene (GSD) per patch; 3 treatment cycles; 21 days per treatment cycle, i.e. 3 x 7 days patch-wearing phase and a patch-free interval of 7 days
223789149|NCT02676869|DRUG|IMP321 (eftilagimod alpha)|"Part A: Single subcutaneous injections of 1 mg (cohort 1), 6 mg (cohort 2) or 30 mg (cohort 3) of IMP321 administered every 2 weeks~Part B: Single subcutaneous injections of 30 mg of IMP321 administered every 2 weeks"
223789150|NCT02676869|DRUG|Pembrolizumab|Administered according to the approved label.
223789151|NCT05514431|PROCEDURE|Epidural|Traditional epidural catheter placement
223789152|NCT05514431|PROCEDURE|Dural Puncture Epidural (DPE) technique|Epidural catheters placed via DPE technique
223789153|NCT05514431|PROCEDURE|Combined Spinal-Epidural (CSE) technique|Epidural catheters placed via CSE technique
223789154|NCT06036121|DRUG|ADRX-0706|Antibody drug conjugate targeting Nectin-4
223789155|NCT03858803|BEHAVIORAL|Families Matter 2|Parents training in communication, youth sexual development, parental monitoring, parental use of positive reinforcement, risks facing adolescents and their management.
223789156|NCT03858803|BEHAVIORAL|Living as a Safer Teen|Prevention intervention for adolescents 13-18 that provides information, motivation, and behavioral skills to prevent STIs, HIV, and unplanned pregnancy.
223789157|NCT04710797|PROCEDURE|Completion staging surgery including systematic pelvic and para-aortic lymphadenectomy|"* open or minimally invasive surgical approach~* cytologic examinations~* All peritoneal surfaces should be visualized, and any peritoneal suspicious for metastasis should be selectively excised or biopsied~* BSO and hysterectomy~* For selected patients desiring to preserve fertility, USO or BSO with uterine preservation may be considered~* Omentectomy~* Para-aortic lymph node dissection should be performed by stripping the nodal tissue from the vena cava and the aorta bilaterally to at least the level of the inferior mesenteric artery and preferably to the level of the renal vessels~* The preferred method of dissecting pelvic lymph nodes is bilateral removal of lymph nodes overlying and anterolateral to the common iliac vessel, overlying and medial to the external iliac vessel, overlying and medial to the hypogastric vessels, and from the obturator fossa at a minimum anterior to the obturator nerve"
223789158|NCT04710797|PROCEDURE|Comprehensive staging surgery with no Lymphadenectomy|"* open or minimally invasive surgical approach~* cytologic examinations~* All peritoneal surfaces should be visualized, and any peritoneal suspicious for metastasis should be selectively excised or biopsied~* BSO and hysterectomy~* For selected patients desiring to preserve fertility, USO or BSO with uterine preservation may be considered~* Omentectomy~* In open approach surgery, exploring the pelvic and Para-aortic lymph node with hand. In minimally invasive surgery, the peritoneal above the pelvic and Para-aortic lymph node area should be open and visualized.Biopsy and frozen section of the suspicious lymph nodes"
223789159|NCT02693444|DRUG|Lidocaine|
223789160|NCT02693444|DRUG|Saline|
223789161|NCT02779257|DRUG|Pasireotide|Pasireotide will be used, in addition to diazoxide, as a medical treatment to blunt hypoglycemia in the setting of autonomous insulin secretion.
223789162|NCT02779257|DRUG|Diazoxide|Pasireotide will be used, in addition to diazoxide, as a medical treatment to blunt hypoglycemia in the setting of autonomous insulin secretion.
223789163|NCT02663128|DRUG|Lanabecestat|Administered orally
223789164|NCT01903655|OTHER|telomere length|
223789165|NCT01358526|DRUG|Oxycodone/Naloxone Controlled-release|Oxycodone/Naloxone Controlled-release tablets (10/5 mg, 20/10 mg, 30/15 mg, 40/20 mg) taken orally every 12 hours
223789166|NCT01358526|DRUG|Placebo|Placebo tablets to match OXN taken orally every 12 hours
223789167|NCT05344105|DEVICE|Low frequency convex probe (ESAOTE Fixed Color Doppler Ultrasonography Device, Italy)|A low frequency convex probe (ESAOTE Fixed Color Doppler Ultrasonography Device, Italy) device will be used while blocking in both groups.
223789168|NCT00105027|OTHER|Standard Care|CRVO: observation; BRVO: standard care
223789169|NCT00105027|DRUG|intravitreal triamcinolone injection|1 mg dose
223789170|NCT00105027|DRUG|intravitreal triamcinolone injection|4 mg
223789171|NCT02313012|DRUG|CC-90003|CC-90003 PO once daily
223789172|NCT06645119|DIETARY_SUPPLEMENT|Whey Protein Supplement|Examining the independent effect of post-exercise dietary protein ingestion on bone metabolic markers.
223789173|NCT01778465|BEHAVIORAL|Low salicylate diet|Participants followed a 7 days period under a Low salicylate diet
223789174|NCT01778465|BEHAVIORAL|Normal Diet|Participants followed a 7 days period under a Normal Diet
223789175|NCT06292273|PROCEDURE|Transversus Abdominis Plane Block with bupivacain Plus dexamethasone|Bupivacain 0.1%, 35 ml with dexmedetomidine 0.5 µG/kg on each side
223789176|NCT06292273|PROCEDURE|Transversus Abdominis Plane Block with bupivacain|plain bupivacaine 0.25%, 25 ml bilaterally
223789177|NCT05544968|DRUG|anti-CD30 Bispecific Antibody-armed anti-CD3-Activated Autologous T-cells (CD30 biAb-AATC)|anti-CD30 Bispecific Antibody-armed anti-CD3-Activated Autologous T-cells
223789178|NCT05544968|DRUG|GM-CSF|Hematopoietic agent that helps form white blood cells.
223789179|NCT00709384|PROCEDURE|Prophylactic surgical lesion|A prophylactic peroperative linear lesions connecting the tricuspid annulus with a right atriotomy (surgical dissection plus cryoablation) and the atriotomy with the inferior caval vein (cryoablation alone).
223789180|NCT04695301|OTHER|Rehabilitation protocol through a digital platform|During 3 months the patients will participate in a rehabilitation program through a digital platform
223789181|NCT03250962|DRUG|SHR-1210|SHR-1210 is a humanized anti-PD-1 monoclonal antibody.
223789182|NCT03250962|DRUG|Decitabine|Decitabine is an investigational (experimental) drug that works by depleting DNA methyltransferase 1 (DNMT1), which can increase tumor antigens and HLA expression, enhances antigen processing, promotes T cell infiltration, and boosts effector T cell function.
223789183|NCT01213017|DRUG|certolizumab pegol|400mg at week 0, 2 and 4, followed by 200 mg every two weeks for 52 weeks
223789184|NCT04173533|DRUG|Oral azacitidine|Oral azacitidine (CC-486) 200 mg tablet
223789185|NCT04173533|DRUG|Matched placebo|Oral azacitidine (CC-486) matched placebo tablet
223789186|NCT00955877|DRUG|Extended-release Epidural morphine (EREM) 80|After completion of the rhizotomy, the dura will be closed in the standard water-tight fashion with running suture. Epidural DepoDur (80μg/kg) will be placed under direct vision in the L1 laminectomy defect. It will also be dispensed 1-2 levels above and 1-2 levels below using a flexible angiocatheter.
223789187|NCT00955877|DRUG|Extended-release Epidural Morphine (EREM) 120|After completion of the rhizotomy, the dura will be closed in the standard water-tight fashion with running suture. Epidural DepoDur (120μg/kg) will be placed under direct vision in the L1 laminectomy defect. It will also be dispensed 1-2 levels above and 1-2 levels below using a flexible angiocatheter.
223789188|NCT00955877|DRUG|Control: Saline|After completion of the rhizotomy, the dura will be closed in the standard water-tight fashion with running suture. Preservative-free normal saline (2.5 ml) will be placed under direct vision in the L1 laminectomy defect. It will also be dispensed 1-2 levels above and 1-2 levels below using a flexible angiocatheter.
223789189|NCT04864015|DEVICE|Mouthpiece B1(Mouthpiece MPC-ST GMDN:62534 Generic name: Endoscopic bite block, basic, reusable|Use of a Mouthpiece B1 during standard EGD instead of a conventional mouthpiece
223789190|NCT04039516|DRUG|Lutathera|A total of 4 infusions of Lutathera to be administered every 8 weeks.
223789191|NCT00949026|DRUG|Temsirolimus (Torisel)|Dose de-escalation dependent on microdialysis results
223789192|NCT01748916|OTHER|Papaya|Post-prandial study feeding 400-506 g papaya (1.6 mg beta-carotene, 2.1 mg beta-cryptoxanthin, 13 mg lycopene), 150 g yogurt (10% fat), and 45 g of fat free bread.
223789193|NCT01748916|OTHER|Carrot|Post-prandial study feeding 25-35 g carrot (= 1.6 mg beta-carotene), 150 g yogurt (10% fat), and 45 g of fat free bread.
223789194|NCT01748916|OTHER|Tomato|Post-prandial study feeding 256-396 g tomato (= 13 mg lycopene), 150 g yogurt (10% fat), and 45 g of fat free bread.
223789195|NCT03351023|OTHER|no intervention-this was an observational study|
223789196|NCT05218252|PROCEDURE|Posterior interosseous artery flap|The use of distally based posterior interosseous artery flap from the forearm in reconstructing mild to moderate hand soft tissue defects
223789197|NCT04133844|BIOLOGICAL|Blood sample|Blood sample collection from a peripheral catheter at ECMO initiation (H0), then 2h, 6h, 12h, 24h and daily from day 2 to day 7 or at ECMO discontinuation
223789198|NCT00274534|DRUG|Tiotropium|
223789199|NCT00274534|DRUG|Salmeterol|
223789200|NCT01311102|DRUG|Lidocaine|1.33 cc 2% liquid lidocaine
223789201|NCT01311102|DRUG|Normal Saline|1.33cc normal saline
223789202|NCT03277313|BIOLOGICAL|HYQVIA|Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase (IGI, 10% with rHuPH20)
223789203|NCT03269812|PROCEDURE|laparoscopic assisted pull-through oeration|Under general anesthesia and insertion of ports for laparoscopic instruments, laparoscopic assisted mobilization of sigmoid colon and dissection till pelvis and removal of a ganglionic segment of colon and laparoscopic assisted pull through of colon then colo-anal anastomosis will be done,
223789204|NCT00507793|DRUG|Sirolimus|
223789205|NCT00507793|DRUG|Cyclosporine|
223789206|NCT05090072|BEHAVIORAL|Advance Directives|The palliative care physician engaged patients and their caregivers in an open discussion about patients' answers to the Advance Directives document, to explore and clarify all doubts and questions prompted by the document
223789207|NCT05090072|BEHAVIORAL|Control|The palliative care physician undergone a conference with both patients and caregivers and evaluated patients' symptoms using the the Edmonton Frail Scale (Bruera, 1991), adapted to the Portuguese population. The Advance Directives theme wasn't approached during this conference.
223789208|NCT02324491|DRUG|ZGN-440 for Injectable Suspension|Subjects will receive ZGN-440 twice weekly subcutaneous injections for up to 52 weeks.
223789209|NCT02324491|DRUG|ZGN-440 Placebo for Injectable Suspension|Subjects will receive placebo twice weekly subcutaneous injections for up to 52 weeks.
223789210|NCT02353793|DEVICE|ReadyHeat® blanket|Using ReadyHeat® blanket for patient warming
223789211|NCT02353793|DEVICE|Cotton wool blanket|Using cotton wool blanket for patient warming
223789212|NCT02132611|DEVICE|Diamondback 360® Coronary OAS Micro Crown|The Diamondback 360® Coronary OAS Micro Crown consists of a diamond-coated crown mounted to a shaft. The OAD ablates occlusive material in order to facilitate stent delivery. During orbit, forces press the crown against the coronary plaque, reducing calcified plaque on the vessel wall.
223789213|NCT00581529|RADIATION|IMRT|Patients on protocol will be treated with accelerated radiotherapy, 3.85 Gy per fraction, bid, for 5 consecutive days for a total dose of 38.5 Gy.
223789214|NCT03136614|DEVICE|Arteriograph|
223789215|NCT06261151|OTHER|Clinical data collection|Clinical data of elderly patients with gastric cancer who underwent open gastrectomy were collected and analyzed.
223789216|NCT04377646|DRUG|Hydroxychloroquine|400 mg at day 1 and day 2, then 400 mg weekly up to 2 months
223789217|NCT04377646|DRUG|Hydroxychloroquine (placebo)|1 pill at day 1 and day 2, then 1 pill weekly up to 2 months
223789218|NCT04377646|DRUG|Zinc|15 mg per day up to 2 months
223789219|NCT04377646|DRUG|Zinc (Placebo)|1 pill per day up to 2 months
223789220|NCT05818449|OTHER|DigiNet intervention|"Patients with initial diagnosis of NSCLC stage IV in the model region receiving the following interventions:~* broad NGS-based molecular diagnostics and, based thereupon, personalized treatment information within the national Network Genomic Medicine (nNGM) lung cancer~* regular clinical follow-up visits and data documentation in the shared central digital database by participating physicians~* monthly assessment of patient-reported outcomes (PRO) on quality of life, anxiety, and depression~* incorporation of PROs into treatment by physicians~* treatment monitoring and counseling in the case of critical conditions by expert committee"
223789221|NCT02182193|DRUG|BIBF 1120 capsules charge 1|
223789222|NCT02182193|DRUG|BIBF 1120 capsules charge 2|
223789223|NCT02182193|DRUG|BIBF 1120 drinking solution|
223789224|NCT04631666|BIOLOGICAL|DZIF-10c|SARS-CoV-2-neutralizing monoclonal antibody DZIF-10c by intravenous infusion
223789225|NCT04631666|OTHER|Placebo|Intravenous infusion of sterile normal saline (NaCl 0.9%) as placebo
223789226|NCT02194621|DRUG|Total Flavor option 1|Total toothpaste containing triclosan/copolymer/sodium fluoride with new OM complex 1 ingredient -Total Flavor Option 1
223789227|NCT02194621|DRUG|Total Flavor option 2|Total toothpaste containing triclosan/copolymer/sodium fluoride and new OM complex 2 ingredient. Total Flavor option 2
223789228|NCT02194621|DRUG|Placebo toothpaste: Crest Cavity Protection toothpaste|Placebo toothpaste: Crest Cavity Protection toothpaste w/sodium fluoride (currently marketed)
223789229|NCT04952545|DRUG|ALXN2050|Oral tablet.
223789230|NCT04952545|DRUG|Placebo|Oral tablet.
223789231|NCT02594891|DEVICE|endoscopic retrograde biliary drainage|A 8.5 F plastic stent with proximal flap （XinChang medical instrument co., LTD,Shanghai, China) will be inserted into common bile duct with standard procedure.
223789232|NCT02594891|DEVICE|endoscopic nasobiliary drainage|A nose bile duct（XinChang medical instrument co., LTD,Shanghai, China) will be inserted into common bile duct with standard procedure.
223789233|NCT06299397|BEHAVIORAL|breastfeeding - humor training|Breastfeeding and humor-based practice will continue for 35-45 minutes, once a week for 2 weeks.
223789234|NCT06299397|OTHER|Control Group|After randomization, consent was obtained from the pregnant women determined that they agreed to participate in the study. The pregnant women in the control group were given a pre-test before starting the study, an interim test 1 month after the start, and a final test 3 months later.
223789235|NCT02493127|OTHER|Standard PCS|Subject completes the standard version of the PCS Questionnaire
223789236|NCT02493127|OTHER|Grip Strength|Research Assistant takes Grip Strength Measurements
223789237|NCT02493127|OTHER|Positively Adjusted PCS|Subject completes the positively-adjusted version of the PCS Questionnaire
223789238|NCT05437627|DIAGNOSTIC_TEST|The Arabic version of Stuttering Severity Instrument-3 (ASSI3) for children and adults|"Assessment of stuttering severity: The Arabic version of Stuttering Severity Instrument-3 (ASSI3) for children and adults will be applied for assessment of severity of stuttering. (3).~Automatic detection and severity assessment of stuttering using MATLAB version 8.1.0.604 R2013a (7). Stuttering detection system has three main steps which are acoustic processing, feature extraction and classification/recognition"
223789239|NCT02763384|DRUG|BL-8040|
223789240|NCT02763384|DRUG|Nelarabine|
223789241|NCT04915963|DIETARY_SUPPLEMENT|Vitamin D supplementation|Patients are randomized to receive vitamin D or placebo and followed up for 15 days at maximum to investigate the safety and clinical efficacy of the supplements
223789242|NCT02978365|OTHER|Questionnaires|Patients will fill self-reported functional shoulder scales (1. Western Ontario Shoulder Instability index - WOSI, and 2. Disabilities of Arm, Shoulder and Hand questionnaire - DASH), as well as a Fear Avoidance Belief Questionnaire (FABQ).
223789243|NCT02978365|DEVICE|Isokinetic Strength Measurement|Isokinetic strength will be measured using a Biodex Isokinetic System 4.0 (Shirley, NY)
223789244|NCT00959023|OTHER|laboratory biomarker analysis|
223789245|NCT00959023|OTHER|medical chart review|
223789246|NCT00959023|OTHER|questionnaire administration|
223789247|NCT02169908|DEVICE|Thermotest|
223789248|NCT02169908|DEVICE|von Frey hairs|
223789249|NCT05794854|OTHER|Abdominal aerobic endurance exercise|Subjects combined treadmill running at 70% HRmax (27 minutes) with 4x4minutes (30-40% maximal strength, 1RM) of torso rotation and abdominal crunches (57 minutes), 4 days per wk for 10 weeks
223789250|NCT05794854|OTHER|Control training intervention|Subjects performed treadmill running (45 minutes) at 70% HRmax 4 days per week for 10 weeks
223789251|NCT00003135|DRUG|fluorouracil|
223789252|NCT00003135|DRUG|pegylated liposomal doxorubicin hydrochloride|
223789253|NCT00003135|PROCEDURE|hyperthermia treatment|
223789254|NCT00168025|DRUG|Immunoglobulins Intravenous (Human)|
223789255|NCT00325793|DRUG|Nicardipine|
223789256|NCT01640756|DEVICE|AqueSys Microfistula Implant|Placement of the AqueSys Microfistula Implant in the study eye
223789257|NCT05918094|DRUG|Experimental dose: modified XELOX + sintilimab|The treatment option for the modified XELOX group (study group) is 200 mg of sintilimab IV Drip Q3W, 600 mg/m2 of capecitabine PO BID for day 1-14, and oxaliplatin 78 mg/m2 IV Drip Q3W.
223789258|NCT05918094|DRUG|Standard dose: standard XELOX + sintilimab|The treatment option for the standard XELOX group (control group) is 200 mg of sintilimab IV Drip Q3W, 1000 mg/m2 of capecitabine PO BID for day 1-14, and oxaliplatin 130 mg/m2 IV Drip Q3W.
223789259|NCT04025073|OTHER|Dietary Approaches to Stop Hypertension|The DASH diet will have a reduced caloric intake by 400 kcal/day, when compared to the standard hospital diet. The DASH diet will be planned according to the following: total daily energy intake 1,900 kcal; total daily fat intake 27%; daily intake of saturated fatty acids 6%; total daily protein intake 18%; total daily carbohydrates intake 55%; cholesterol 150 mg/day; sodium 2,300 mg/day; potassium 4,700 mg/day; calcium 1,250 mg/day; magnesium 500 mg/day; and fiber 30 g/day.
223789260|NCT04025073|OTHER|Nutrition education program|The nutrition education program will consist of four lectures intended to improve the overall participants' dietary habits. The lectures will be interactive and will be organized in smaller groups (up to 10 participants) covering the following themes: My Plate dietary guidelines; Principles of a balanced diet; Reading and understanding food nutrition labels; Dietary recommendations for elevated blood pressure, dyslipidemia, and diabetes mellitus.
223789261|NCT02037347|DRUG|Palifermin|
223789262|NCT01870271|BEHAVIORAL|Developmentally adapted cognitive processing therapy|
223789263|NCT02096900|DRUG|zolpidem|Zolpidem will be given one time at 0.25 mg/kg pre-operatively
223789264|NCT02096900|DRUG|Midazolam|
223789265|NCT01176903|DRUG|Glycopyrrolate|pressurized metered dose inhaler
223789266|NCT01176903|DRUG|Tiotropium|inhalation powder, hard capsule
223789267|NCT01176903|DRUG|placebo|pressurized metered dose inhaler
223789268|NCT00006325|DRUG|Peginterferon alfa-2b|
223789269|NCT03787940|DRUG|Isoniazid|standard dose isoniazid or high dose isoniazid for participants with rapid acetylators
223789270|NCT03829904|DRUG|VGH-BPH1|A scientific Chinese granule powder
223789271|NCT03829904|DRUG|Placebo (Corn starch pill manufactured to mimic VGH-BPH1)|Corn starch pill manufactured to mimic VGH-BPH1
223789272|NCT05503108|OTHER|Fasting Mimicking diet program|Fasting mimicking diet by L-Nutra, a 4-day low caloric, low protein, vegetarian diet 3 days prior to and the day of neoadjuvant chemotherapy administration. The FMD will take place every 4 weeks, thus in total 5 times (2x during ddAC, 3x during Paclitaxel) during the neoadjuvant chemotherapy.
223789273|NCT02303964|BIOLOGICAL|Plasma|Type A thawed plasma (up to 2 units) will be administered to polytrauma subjects randomized to plasma arm of study
223703950|NCT06680999|OTHER|Data collection|Preoperative, intraoperative and follow-up data collection: consultation and anesthesia reports, hospitalization reports and imaging data to evaluate the feasibility and efficacy of endovascular treatment of superior vena cava syndromes involving the trifurcation. Data collection will last 1 month and will be performed by a Vascular Surgery resident of the hospital.
223789274|NCT02303964|DRUG|Normal saline|Normal saline will be administered to polytrauma subjects randomized to normal saline arm of study
223789275|NCT01118208|OTHER|Blister packaging medications|Dispensing prescription medications on pre-filled blister package cards.
223703951|NCT06680856|COMBINATION_PRODUCT|PRP+HA|treatment of diabetic foot ulcers with allogeneic PRP+HA
223789276|NCT01118208|OTHER|Dispense as usual|Dispensing prescription medications in standard pill bottles.
223703952|NCT06680856|COMBINATION_PRODUCT|HA|treatment of diabetic foot ulcers with HA
223703953|NCT06680947|DRUG|610|Subcutaneously injection.
223703954|NCT06680947|DRUG|610|Subcutaneously injection.
223703955|NCT06680947|DRUG|Placebo|Subcutaneously injection.
223789277|NCT00634608|OTHER|Health Information Prescription|The patient education materials will consist of approximately 21 topics representing some of the most common conditions seen at the Fairview Internal Medicine Clinic. Twenty-one e-mails, one per topic, will be created by Fairview physicians to be distributed to selected clinic patients. There will be a standard e-mail for each condition with a specific link to MedlinePlus. To create the targeted health information topic email, the physician will review the information available at MedlinePlus. The physician will then select several links of appropriate information and, using the template, will write a short annotation on each link.
223789278|NCT03034577|DRUG|Sugammadex|Reversal of neuromuscular block Sugammadex dosage will be adjusted to body weight and PTC/TOF count at the time of reversal, and not administered until PTC at least 1. Dosage will be 4mg/kg if TOF = 0 and PTC ≥ 1; and 2 mg/kg if TOF ≥1.
223789279|NCT03034577|DRUG|Neostigmine|Neostigmine 50 micrograms/kg coupled with atropine 20 micrograms/kg or glycopyrrolate 5 micrograms/kg, to a maximum dose of neostigmine of 5.0 mg. The neostigmine should not be administered until the TOF has at least 3 twitches present.
223789280|NCT05610553|OTHER|3D printing guide plate|3D-printed customized guide plate will be used to guide the puncture in percutaneous disc decompression surgeries to help to reduce intra-operative radiation, puncture time, etc..
223789281|NCT05610553|OTHER|Conventional guidance|The surgeons would place the needle according to his/her previous experience under the guidance of C-arm fluoroscopy or CT.
223789282|NCT03919422|PROCEDURE|T2 paravertebral block|Ultrasound guided T2 thoracic paravertebral block is added in ICTP group. After interscalene brachial plexus block and superficial cervical plexus block have been administrated, selective 2nd thoracic nerve root(T2) will be blocked with 10 ml of 0.25% ropivacaine(naropin).
223789283|NCT03919422|PROCEDURE|interscalene brachial plexus block and superficial cervical plexus block|An ultrasound-guided IC block using an ultrasound machine (Sonosite, USA), and an linear array probe with a sterile cover and a 22G(Gauge) block needle is performed. An in-plane approach, advancing the needle along the longitudinal axis of the ultrasound transducer and visualizing the entire shaft is employed. Twenty ml of 0.375% ropivacaine(naropin) is injected around brachial plexus and 10 ml of 0.25% ropivacaine around superficial cervical plexus.
223789284|NCT01892072|PROCEDURE|surgical treatment|all the patients in the study must have been treated by the surgery at the first time and have been confirmed as 'complete section' by the post-surgery radiological image.
223789285|NCT05788549|BEHAVIORAL|Progressive Muscle Relaxation|The Individual Identification Form, Partial Mayo Score, State-Trait Anxiety Inventory, Pittsburgh Sleep Quality Index, and IBD-QOL were filled out in person during the first meeting. The first application was done face to face with the researcher. Individuals were asked to perform subsequent applications at home.Educational booklet describing the progressive relaxation exercises with pictures was given to individuals, and a video prepared by the researcher was uploaded to their mobile phones. Individuals were asked to practice progressive relaxation exercises every day, at least once a day, in a quiet and peaceful environment for 30-minute sessions. The researcher sent reminder SMS messages to individuals twice a week for eight weeks to encourage regular practice of the progressive relaxation exercises. Four and eight weeks after the first meeting, forms were transferred to an online environment and sent to individuals via WhatsApp Messenger as a link to be completed
223789286|NCT05788549|BEHAVIORAL|Relaxative Music|The Individual Identification Form, Partial Mayo Score, State-Trait Anxiety Inventory, Pittsburgh Sleep Quality Index, and IBD-QOL were filled out in person during the first meeting. Individuals were asked to perform subsequent applications at home.Individuals were provided with a relaxing music file prepared by the researcher and were asked to listen to it at least once a day for 30 minutes in a quiet and calm environment. The researcher also sent reminder SMS messages twice a week for eight weeks to remind individuals. Four and eight weeks after the first meeting, forms were transferred to an online environment and sent to individuals via WhatsApp Messenger as a link to be completed to listen to the relaxing music regularly. At 4 and 8 weeks after the first meeting, the researcher transferred the forms to an online environment via Google Forms and asked individuals to fill them out by accessing the link sent to them via WhatsApp Messenger
223789287|NCT02574546|PROCEDURE|Mastectomy|Unilateral breast cancers planning bilateral mastectomy procedures.
223789288|NCT03119857|DRUG|Antiandrogen|
223789289|NCT03119857|DRUG|Antiandrogen+docetaxel|"Antiandrogen (bicalutamide 150 mg x 1) + docetaxel (Taxotere®) 75mg/m2 (max 2.0m2) i.v. in 60 minutes on day 1. One cycle is 21 days. Docetaxel will be given for up to 8-10 cycles or until unacceptable toxicity or consent withdrawal whichever comes first.~Antiemetic therapy may be used if necessary."
223789290|NCT03436394|DRUG|Evobrutinib|Subjects will be administered a single oral dose of evobrutinib under fasting conditions.
223789291|NCT04383912|DRUG|Botox Injectable Product|The side randomized to receive treatment will be injected with onabotulinum toxin A. Wound healing, scar characteristics, and patient satisfaction will be assessed post operatively. Scarring will be assessed by the patient, medical observers and a lay observer, all masked to the treatment vs placebo side. Standardized scales will be used, and pre-operative, intra-operative, and post-operative photographs will be taken for all participants. ImageJ software will be used to analyze the photos and measure the degree of brow lift achieved on each side, to ensure this has not been affected by onabotulinum toxin injection.
223789292|NCT04383912|OTHER|No intervention (placebo)|This group (of brows) will be receiving placebo injections containing normal saline. They will be assessed in the same manner as the treatment side.
223789293|NCT06246877|BEHAVIORAL|virtual reality applied group|"Before the K-wire is removed and dressed, the three-dimensional video that the child likes and wants to watch will be placed on virtual reality glasses and attached to the child.~During the procedure, the child will be allowed to watch videos through virtual reality glasses."
223789294|NCT05715580|OTHER|Nursing information with a Protocol|"The nursing intervention will consist of providing information to the patient with a kidney transplant.~To do this, a Committee of experts, made up of the 6 nurses from the kidney transplant Consultations of the Community of Madrid (Spain), will carry out an Information Protocol for adults with a kidney transplant, which will cover the healthy lifestyle habits described by the bibliography"
223789295|NCT05715580|OTHER|Usual clinical practice|Nursing information following the usual clinical practice
223789296|NCT05934734|OTHER|No intervention|This is an observational cross-sectional study. No intervention will be provided. Participants will be assessed and stratified into four cohorts based on self-reported symptom severity of thoracic outlet syndrome using a visual analog scale (VAS) to investigate the relationship between symptom severity and upper extremity function/neural integrity.
223789297|NCT00863096|BIOLOGICAL|Gardasil|HPV vaccine
223789298|NCT00374842|BIOLOGICAL|Fluarix™|GlaxoSmithKline Biologicals' licensed influenza vaccine
223789299|NCT00374842|BIOLOGICAL|GSK1247446A|Low-dose GlaxoSmithKline Biologicals' GSK1247446A influenza vaccine
223789300|NCT01408160|DRUG|Cytarabine|Given IV
223789301|NCT01408160|BIOLOGICAL|Deglycosylated Ricin A Chain-Conjugated Anti-CD19/Anti-CD22 Immunotoxins|Given IV
223789302|NCT01408160|OTHER|Laboratory Biomarker Analysis|Correlative studies
223789303|NCT01408160|OTHER|Pharmacological Study|Correlative studies
223789304|NCT04482751|DRUG|Corifollitropin alfa|AMH will be measured during ovarian stimulation with corifollitropin alfa
223789305|NCT03371420|DRUG|PU-AD|
223789306|NCT03371420|DEVICE|PET Scan|
223789307|NCT03371420|OTHER|Blood Draws|
223789308|NCT02534857|PROCEDURE|a shorter exposure of oocyte to spermatozoa|Shorter exposure of oocyte to spermatozoa group: oocytes will be exposed to spermatozoa for 2 hours
223789309|NCT01995123|BEHAVIORAL|Behavioral Activation Therapy|Behavioral Activation (BA) Treatment will be delivered in eight, 30 minute individual sessions over an 8-week period. BA treatment will focus on encouraging subjects to participate in activities that they find enjoyable and rewarding.
223789310|NCT01995123|BEHAVIORAL|Health and Smoking Education|Health and Smoking Education (HSE) Treatment will be delivered in eight, 30 minute individual sessions over an 8-week period. HSE treatment will focus on smoking, health, and the impact of smoking on the subject's health.
223789311|NCT01995123|BEHAVIORAL|Standard Smoking Cessation Therapy|Standard smoking cessation therapy will be delivered in eight, 20-minute individual sessions over an 8-week period.
223789312|NCT02931734|DRUG|Resin modified glass ionomer|Prophylaxis, washing and removing water excess , apply the Clinpro forming a uniform layer of 0.5mm, lightcure for 20 seconds
223789313|NCT02931734|DRUG|Potassium Nitrate 2%|Prophylaxis, apply uniformly on the teeth, wait 10 minutes, remove the gel from the teeth with cotton and abundant water.
223789314|NCT02931734|PROCEDURE|Low level laser therapy|Prophylaxis, applying infrared laser at low power in points: mesial, buccal, distal and in the apical point in the foyer of fornix with power of 110MW for 11 seconds at each point.
223789315|NCT02266069|OTHER|Care Pathway for Primary Palliative Care|Early identification of palliative care patients, anticipatory care planning, systematic symptom assessment, interdisciplinary collaboration, rigorous follow-up of the functional status of the patient and giving attention to the informal care givers.
223789316|NCT01558154|DRUG|Chinese herbs|Chinese herbs special for depression
223789317|NCT01558154|PROCEDURE|acupuncture|six acupuncture point including DU20, EX HN3, EX HN1, PC6,HT7,SP6,special for depression
223789318|NCT01558154|OTHER|Psychotherapy|Thought Imprint Psychotherapy under lower Resistance State
223789319|NCT01558154|DEVICE|Transcranial magnetic stimulation|Give magnetic stimulation at head
223789320|NCT00354874|DRUG|GW642444|drug
223789321|NCT00354874|DRUG|Placebo|placebo
223789322|NCT00354874|DRUG|salmeterol 50mcg|salmeterol
223789323|NCT05967572|OTHER|Research processes;|"1. Before Inspection: information will be obtained and premature babies will be monitored by wearing a pulse oximeter device and their heart rate and oxygen saturation value will be recorded for control purposes. By making video recordings of each premature baby; PIPP pain score, PBIC comfort score, control oxygen saturation and peak heart rate values will be recorded 3 minutes before the ROP examination. Babies will be fed and changed at least half an hour before the examination.~2. Inspection Sequence: PIPP pain score, PBIC comfort score, control oxygen saturation and peak heart rate values will be recorded and evaluated from the video recording that continues with the start of the examination.~3. End of Inspection: Infants whose both eye examinations are completed and whose monitoring and video recording continue will be recorded and evaluated 3 minutes after the end of the examination, with PIPP pain score, PBIC comfort score, control oxygen saturation and heart rate values."
223789324|NCT03362554|BEHAVIORAL|Controlled diet and exercise.|"The intervention will involve 3 weeks of a diet and exercise program designed to cause a net energy decrease of 7000 kcal/week compared to habitual behaviour. This will be achieved through:~* Five exercise sessions per week at 70% VO2 max, using 400 kcal per session.~* Reduction of their standard diet by 5000 kcal per week~Before and after this intervention period participants will take part in a trial day which includes measurement of body composition (using DEXA) and blood sugar control (oral glucose tolerance test). Samples of blood, adipose, skeletal muscle and faeces will also be taken."
223789325|NCT03925376|PROCEDURE|Redo cardiac surgery|Redo cardiac surgery is technically challenging due to scarring of tissues resulting in loss of tissue planes, adhesions, multiple comorbid factors and risk of injury during re-entry.Suggested techniques in coronary artery surgery with a left internal mammary artery include routing the graft through a slit in the pericardium to minimize the possibility of adherence to the sternal table.
223789326|NCT03708198|DRUG|Liposomal Bupivacaine|intercostal block
223789327|NCT01554072|OTHER|Home based pulmonary rehabilitation with exercise|After each group will receive the randomization their booklets containing the exercise routine that should be performed at home., to be held three times a week for two consecutive months. Is also scheduled a visit to the laboratory biweekly Respiratory Functional Assessment in which patients demonstrate their exercise routine program RP semi-home settings for any load, postural corrections and execution of physical exercise, should be refocused.
223789328|NCT04899518|DRUG|ALY688 Ophthalmic Solution|Ophthalmic Solution
223789329|NCT03882684|DIAGNOSTIC_TEST|In-situ imprinting detection|The loss of imprinting (LOI) and copy number variation (CNV) from biopsies will be tested by LiSen in-situ imprinting detection.
223789330|NCT00919269|OTHER|Cytology Specimen Collection Procedure|Correlative studies
223789331|NCT00919269|OTHER|Laboratory Biomarker Analysis|Correlative studies
223789332|NCT00848679|DRUG|Epidural lidocaine|Epidural 2% lidocaine, administered in 5mL incremental boluses. Looking at dose-response effect.
223789333|NCT00848679|DRUG|Epidural lidocaine 2%|5 x 5ml boluses of either epidural lidocaine 2% or epidural saline
223789334|NCT00821418|DEVICE|PulseHaler treatment|treatment is for two weeks, 3 times per day
223789335|NCT00821418|DEVICE|CPAP treatment (through a deactivated version of PulsHaler)|treatment is for two weeks, 3 times per day
223789336|NCT02647398|BEHAVIORAL|Vigorous aerobic training|Supervised vigorous aerobic training
223789337|NCT00157326|DRUG|tadalafil|
223789338|NCT06038565|DEVICE|RAM cannula ventilator CPAP|RAM cannula ventilator CPAP
223789339|NCT06038565|DEVICE|Occlusive interface bubble CPAP|Occlusive interface bubble CPAP
223789340|NCT03413436|DRUG|Lobaplatin|at least one cycle adjuvant chemotherapy after esophagectomy
223789341|NCT03413436|DRUG|Cisplatin|at least one cycle adjuvant chemotherapy after esophagectomy
223789342|NCT05008679|DRUG|Oseltamivir|at a dose of 75 mg twice daily
223789343|NCT06482372|DEVICE|transcranial magnetic stimulation|repetitive transcranial magnetic stimulation at both cerebral hemisphere
223789344|NCT00344123|DRUG|Tipranavir/Ritonavir|"On Day 1, subjects will receive a single 10 mg dose of rosuvastatin. Beginning on Day 3, subjects will receive a combination of TPV 500mg/RTV 200 mg twice daily for 11 days (Days 3-13).~On Day 12, subjects will receive a single 10 mg dose of rosuvastatin co-administered with TPV/r."
223789345|NCT00344123|DRUG|Rosuvastatin|"On Day 1, subjects will receive a single 10 mg dose of rosuvastatin. Beginning on Day 3, subjects will receive a combination of TPV 500mg/RTV 200 mg twice daily for 11 days (Days 3-13).~On Day 12, subjects will receive a single 10 mg dose of rosuvastatin co-administered with TPV/r.."
223789346|NCT00818948|DRUG|AMG 811|Part A of the study will enroll SLE without GN (non-renal) subjects into 3 cohorts (6 AMG 811: 2 placebo). All subjects will receive a dose of AMG 811 or placebo every 4 weeks beginning with day 1 (D1) for a total of 3 injections. Subjects will be followed through to study day 197, 5 months from the last dose of study medication. Part B of the study will enroll SLE subjects with GN into Cohorts 4, 5 and 6 (6 AMG 811: 2 placebo). Similar to Part A, subjects in Cohorts 4, 5 and 6 will be dosed every 4 weeks with AMG 811 or placebo for a total of 3 injections followed by a 5 month follow-up period. For Cohort 6, subjects will be followed by a 6 month follow-up period.
223789347|NCT01093352|PROCEDURE|Alveolar-decortication.|Following surgical exposure of the impacted tooth, the surgeon will prepare small holes (perforations) and/or grooves in the cortical bone surrounding the exposed tooth as well as in the buccal bone.
223789348|NCT01427075|PROCEDURE|LATERAL PHARYNGOPLASTY|tonsilectomy and lateral pharyngoplasty
223789349|NCT02786082|DRUG|20mg Azilsartan Tablets|Strength: 20mg, oral administration 1 tablet/ day
223789350|NCT02786082|DRUG|40mg Azilsartan Tablets|Strength: 40mg, oral administration 1 tablet/ day
223789351|NCT03969654|DEVICE|PERSONA Total Knee|Primary Total Knee Arthroplasty
223789352|NCT03969654|DEVICE|Vanguard Total Knee|Primary Total Knee Arthroplasty
223789353|NCT03969654|DEVICE|NexGen Total Knee|Primary Total Knee Arthroplasty
223789354|NCT02191982|BEHAVIORAL|Walk With Ease|Walk With Ease is the Arthritis Foundation's evidence-based walking intervention to help with fatigue and pain. The intervention is a self-directed program that helps guide participants in a safe and comfortable paced walking program with an ultimate goal of walking for 30 minutes a day, five days a week.
223789355|NCT03230916|DRUG|IMI/REL FDC|IMI/REL is supplied as a single fixed dose combination (FDC) vial; which is administered at a maximum dose of 15 mg/kg IMI and 15 mg/kg CIL (up to 500 mg IMI and 500 mg CIL) and 7.5 mg/kg REL (up to 250 mg REL).
223789356|NCT04717804|OTHER|AIP CT|An image taken over a longer time of the lungs (average intensity projection of 4DCT) will be compared with breathing during treatment.
223789357|NCT04717804|OTHER|FB (Free-Breathing) CT|A snapshot of breathing (free-breathing traditional CT) will be used to compare with breathing during treatment.
223789358|NCT06113250|DEVICE|shortwave diathermy|Shortwave diathermy (SWD) is a modality that produces heat by converting electromagnetic energy into thermal energy. pulsed shortwave diathermy (PSWD), uses high-frequency electromagnetic waves to heat tissues up to 5 cm deep. Heat is produced by the resistance of tissue to the passage of energy. Although it heats to the same depth as 1-MHz ultrasound, PSWD heats a much larger area than ultrasound does, making it ideal to heat larger joints, such as the elbow, shoulder, hip, knee, and ankle
223789359|NCT06113250|DEVICE|ultrasound waves|Ultrasound is sound with a frequency above 20,000 Hertz (Hz) and is undetectable by the human ear. However, clinical ultrasound uses much high frequencies of between 1 and 20 megahertz (MHz) and sometimes up to 75 MHz in specialized areas such as dermatology and ophthalmology. Clinically, ultrasound is used for a number of applications ranging from visualizing structures to allow safe insertion of lines and catheters to diagnostic imaging including the assessment of the movement of cardiac Production of ultrasound waves is the first part of the clinical ultrasound process. Ultrasound is generated by piezoelectric crystals. These crystalline materials contain randomly oriented electric dipoles, and when a force is applied that deforms the crystal, the dipoles are rearranged and a net charge induced across the crystal
223789360|NCT06113250|OTHER|traditional physical therapy program|splinting, stretching exercises, strengthening exercises and range of motion (ROM) exercises
223789361|NCT02283060|DRUG|Stribild|To be administered orally, once daily with food.
223789362|NCT02283060|DRUG|Atripla|To be administered orally, once daily at bedtime on an empty stomach
223789363|NCT01128413|DEVICE|Cheetah NICOM® PLRT|Cheetah NICOM® (non-invasive cardiac output monitoring)PLRT (passive leg raise testing) protocol: The patient while in a semi-recumbent position (legs level, torso up 45 degrees) will have 3 minutes of stroke volume and cardiac index monitoring. Following the 3 minutes, the patient will be placed in a leg raised position (torso level, legs up 45 degrees) for 3 minutes of stroke volume and cardiac index monitoring. NICOM® PLRT will be performed within 10 minutes after any fluid bolus in both arms with results blinded to the Routine Care arm. If saline locked or maintenance IV fluid rate, NICOM® PLRT will be performed every 30 minutes in both arms with results blinded to the Routine Care arm.
223789364|NCT01128413|DEVICE|USCOM ® (Ultrasound Cardiac Output Monitor)|Patients while in the Cheetah NICOM® PLRT semi-recumbent position (legs level, torso up 45 degrees) will have simultaneous USCOM® stroke volume and cardiac index monitoring. Following the 3 minutes of Cheetah NICOM® PLRT semi-recumbent positioning, the patient will be placed in a leg raised position (torso level, legs up 45 degrees) and have simultaneous USCOM® stroke volume and cardiac index monitoring. USCOM® monitoring will be blinded to the Routine Care arm unless used as part of a provider's routine practice. USCOM® changes in SVI or CI with PLRT will be calculated after the patient leaves the ED.
223789365|NCT01128413|DEVICE|Inferior Vena Cava (IVC) Ultrasound Collapsibility|Patients while in the Cheetah NICOM® PLRT semi-recumbent position (legs level, torso up 45 degrees) will have a simultaneous 6-12 second ultrasound recording of their IVC. These recordings will be reviewed later by an ultrasonographer and graded for volume responsiveness. The reviewing ultrasonographer will be blinded to the Cheetah NICOM® PLRT results.
223789366|NCT01128413|BEHAVIORAL|CURVES Questionnaire|The CURVES (CardiovascUlar Response \& Volume Estimation in Shock) Questionnaire consists of multiple provider questions aimed at defining the presumed shock etiology and anticipated responses to interventions. This will be administered to both arms.
223789367|NCT01128413|BIOLOGICAL|Lactate Clearance|Lactate samples will be drawn at time 0, 1, 3, \& 6 hours (or at ED departure if before 6 hours). Time 0 lactate will be revealed to the Routine Care arm and subsequent lactates revealed to the Routine Care arm only if serial lactates are part of the provider's routine practice.
223789368|NCT01128413|BIOLOGICAL|500ml Normal Saline Bolus|Patients randomized to the experimental arm and having a \>/= 15% change in stroke volume index (SVI) or cardiac index (CI) via Cheetah NICOM®PLRT will be given a 500ml normal saline fluid bolus.
223789369|NCT01128413|BIOLOGICAL|Clinician Discretion Intravenous Fluid Management|Clinicians caring for patients randomized to the Routine Care arm will within 10 minutes after any fluid bolus be asked to decide via their clinical discretion if they want to re-bolus, saline lock, or place the patient on a maintenance IV fluid rate. If the patient is on a saline lock or maintenance fluid rate, clinicians will be asked every 30 minutes to decide via their clinical discretion to re-bolus, saline lock, or place the patient on a maintenance IV fluid rate.
223789370|NCT06196268|OTHER|core strengthening exercise|CSE will constitute of abdominal hollowing, Side Bridge, supine extension bridge, straight leg rise from prone, alternate arm and leg raise from quadruped, and prone bridge
223789371|NCT06196268|OTHER|Pilates exercise|Pilates includes hundreds, one leg stretch, shoulder bridge, hip twist, scissors, side kicks
223789372|NCT05710601|PROCEDURE|Laparoscopy|Operative laparoscopies carried out according to the most recent national guidelines and following the good clinical practice of our operative unit.
223789373|NCT02587351|DRUG|Metoprolol succinate|Extended release Metoprolol succinate
223789374|NCT02587351|OTHER|Placebo|Matching placebo
223789375|NCT02570490|DRUG|sodium fusidate|
223789376|NCT02570490|DRUG|linezolid|
223789377|NCT06505200|OTHER|No intervention|No intervention
223789378|NCT05054816|DEVICE|Investigational adaptive directional microphone strategy|A receiver-in-canal hearing aid developed by the Study Sponsor used with the investigational adaptive directional microphone strategy that is expected to improve sound quality of speech in a car.
223789379|NCT05054816|DEVICE|Comparator omnidirectional microphone strategy|A receiver-in-canal hearing aid developed by the Study Sponsor used with the comparator omnidirectional microphone strategy that is used with the default settings as specified in the manufacturer's fitting software.
223789380|NCT05054816|DEVICE|Comparator fixed directional microphone strategy|A receiver-in-canal hearing aid developed by the Study Sponsor used with the comparator fixed directional microphone strategy that is used with the default settings as specified in the manufacturer's fitting software.
223789381|NCT05169970|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|Patients with a low or intermediate risk Decipher score will receive radiation targeting the seminal prostate and seminal vesicles to a dose of 40 Gy in 5 fractions delivered every other day.
223789382|NCT05169970|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|Patients with high risk Decipher scores will receive radiation targeting the prostate and seminal vesicles to a dose of 40 Gy in 5 fractions with a simultaneous integrated boost to 45 Gy of any dominant intraprostatic lesion as well as radiation to the pelvic lymph nodes to a dose of 25 Gy in 5 fractions delivered every other day.
223789383|NCT04915261|BEHAVIORAL|Lenient Arm Restriction|The study will crossover between either strict arm restriction guidelines for patients or lenient arm restrictions.
223789384|NCT04915261|BEHAVIORAL|Strict Arm Restriction|The study will crossover between either strict arm restriction guidelines for patients or lenient arm restrictions.
223789385|NCT06161987|BEHAVIORAL|Early comprehensive rehabilitation|Patients randomized to the rehabilitation intervention group will be offered comprehensive rehabilitation plan containing 18 sessions of a structured outpatient-based exercise program over 6 weeks (3 times per week).
223789386|NCT00507039|PROCEDURE|inhalative grass-pollen provocation|Subjects undergo allergen challenges with incremental doses of grass pollen allergen. In subjects, who develop a fall in FEV1 of more than 20%, this will be followed by two single-step challenges.
223789387|NCT02075593|DRUG|DTG 50 mg /ABC 600 mg /3TC 300 mg FDC tablets|The DTG 50 mg /ABC 600 mg /3TC 300 mg FDC tablet is a purple, oval, biconvex tablets. The tablet contains 52.6 mg DTG sodium which is equivalent to 50 mg DTG free acid, 702 mg ABC sulphate which is equivalent to 600 mg ABC and 300 mg 3TC.
223789388|NCT03595345|PROCEDURE|Liver transplantation|Liver transplantation
223789389|NCT06532708|OTHER|5x Oxycodone Oral Tablets|Participants will be prescribed 5 doses of 5mg tablets of oxycodone for postoperative pain relief.
223789390|NCT06532708|OTHER|16x Oxycodone Oral Tablets|Participants will be prescribed 16 doses of 5mg tablets of oxycodone for postoperative pain relief.
223789391|NCT07127770|DRUG|PF-07104091|Cyclin-dependent kinase-2 inhibitor
223789392|NCT07126652|DRUG|MF-59|MF-59 influenza vaccination
223789393|NCT07126652|DRUG|cell-based|cell-based influenza vaccination
223789394|NCT07126652|DRUG|egg-based|egg-based influenza vaccination
223789395|NCT07127341|DEVICE|Patient with removable functional appliance|Survey (quiz) for patient who had malocclusion and/or a dysfunction treated removable functional appliance about the treatment, before, during and after treatment
223789396|NCT06165445|DEVICE|transcranial direct current stimulation (tDCS)|In tDCS, direct electrical currents at the intensity of interest (2 mA for example) are generated by an electrical stimulator and are noninvasively delivered to the scalp through a pair of saline-soaked sponge electrodes (7×5 cm) or via more than two but smaller round electrodes over the target regions.
223789397|NCT06165445|DEVICE|multichannel transcranial direct current stimulation (tDCS)|In multichannel tDCS, direct electrical currents at the intensity of interest (2 mA for example) are generated by an electrical stimulator and are noninvasively delivered to the scalp through more than two and smaller round electrodes over the target regions.
223789398|NCT00034034|PROCEDURE|Acupuncture|
223789399|NCT04481256|RADIATION|External beam radiotherapy|External beam radiotherapy will be delivered to a total dose of 50.4 Gy in 28 fractions of 1.8 Gy, 5 fractions per week, starting the first day of the first cycle of chemotherapy
223789400|NCT04481256|DRUG|Bintrafusp alfa|Bintrafusp alfa will be given i.v. every three weeks on day 1, 22, and 43 at a dose of 2400 mg.
223789401|NCT04481256|DRUG|Paclitaxel|Paclitaxel 50 mg/m2 will be given intravenously (i.v.) on days 1, 8, 15, 22, 29 and 36.
223789402|NCT04481256|DRUG|Carboplatin|Carboplatin AUC = 2 will be given intravenously (i.v.) on days 1, 8, 15, 22, 29 and 36.
223789403|NCT05044663|OTHER|No intervention|This is an observational study
223789404|NCT02010060|BEHAVIORAL|Aerobic Exercise Training|Individuals randomized to the aerobic exercise training group will participate in 6 months of supervised exercise training. Exercise dose (expressed in kilocalories per kg per week \[KKW\]) during aerobic training will be 8KKW in week 1, 10KKW in week 2 and 12 KKW in week 3. the exercise dose of 12KKW will be maintained throughout the intervention. Pedometers will be worn by participant in blind-mode throughout the intervention, and removed during exercise training sessions. Participants will enter information about whether they wore their pedometer on the study website. Aerobic exercise group participants will be told to make no conscious alterations to their physical activity or dietary habits
223789405|NCT02010060|BEHAVIORAL|Aerobic Exercise+ Physical Activity|The Aerobic Exercise+ Physical Activity Group will participate in the same supervised exercise training intervention as the Aerobic Exercise Group, but will also increase the amount of non-exercise physical activity in their daily lives. After week 6 of intervention, participants will incrementally increase Non-Ex PA until they reach an average of 3,000 steps/day above baseline. Non-Ex PA will be increased with moderate physical activity consistent with daily living (i.e. leisurely walking in the evening, walking the dog etc.). Participants will also periodically have life-style counseling sessions with instructors with expertise in behavioral change support to their dietary habits
223789406|NCT06447038|DIAGNOSTIC_TEST|albumin creatinine ratio|Albumin creatinine ratio, this test is routinely performed in urine.
223789407|NCT06986525|PROCEDURE|CAF with PRF|Coronally advanced flap technique will be performed to reposition the gingival margin coronally. Platelet-rich fibrin (PRF) membranes will be placed over the exposed root surfaces and stabilized with sutures.
223789408|NCT06986525|PROCEDURE|Tunnel with PRF|A tunnel or subgingival pouch will be created using microsurgical instruments without vertical incisions. Platelet-rich fibrin (PRF) membranes will be inserted into the tunnel and the gingival tissue will be advanced coronally and sutured to cover the recession.
223789409|NCT00062933|PROCEDURE|Laparotomy|
223789410|NCT06660823|DRUG|L-thyroxine|"Patients who show signs of delayed recovery defined as either prolonged ventilation for 48 hours or delayed conscious level recovery for 48 hours despite exclusion of muscle relaxants and/or sedative drugs. Those patients will undergo CT brain, CT chest and neurological examination to exclude structural damage as per institutional protocols. Also, metabolic profile screening including full kidney function, full liver function, electrolyte to exclude correctable metabolic abnormalities. and thyroid profile (TSH, free T3, free T4) sick euthyroid patients who are having normal FreeT3, normal Free T4, low TSH and low level of free T3 or freeT4 will be included in the study according lab reference.Daily assessment of conscious level according to Glasgow Coma Scale (GCS) and spontaneous breathing trial by ICU consultant (the investigator) till ICU discharge.~Patients will receive levothyroxine via Ryle, dose of 25 to 50 ug/ day according to BMI."
223789411|NCT06660823|DRUG|Placebo Oral Tablet|patients will receive placebo oral tablet
223789412|NCT06049810|DRUG|IBI112|Participants receive Dose 1 IBI112 through week 8 \& Dose 2 IBI112 on week 20 \& Dose 1 IBI112 through week 44
223789413|NCT06049810|DRUG|IBI112/placebo|Participants receive Dose 1 IBI112 through week 8 \& Dose 2 IBI112 on week 20 \& placebo through week 44 by subcutaneous injection
223789414|NCT06049810|DRUG|IBI112/placebo|Participants receive Dose 1 IBI112 through week 8 \& Dose 3 IBI112 on week 20 \& placebo through week 44
223789415|NCT06049810|DRUG|IBI112|Participants receive Dose 1 IBI112 through week 8 \& Dose 3 IBI112 on week 20 \& Dose 1 IBI112 through week 44
223789416|NCT06049810|DRUG|IBI112|Participants receive Dose 1 IBI112 through week 8 \& Dose 3 IBI112 through week 44
223789417|NCT06049810|DRUG|IBI112|Participants receive Dose 1 IBI112 through week 8 \& Dose 2 IBI112 through week 44 by subcutaneous injection
223789418|NCT06662916|BEHAVIORAL|Microbiota-Diversity Enhancing Diet on children with Autism Spectrum Disorder|Microbiota-Diversity Enhancing Diet on Children with ASD (MIND-DASE) suggested that increasing microbiota diversity through dietary interventions can have significant benefits on the neurodevelopmental outcomes of children with ASD
223789419|NCT06664437|OTHER|EXERCISE TRAINING WITH OR WITHOUT MEDICATION|Patients were in supine lying position during the whole treatment. The techniques were performed in a rhythmic way, with 2 seconds of glide distraction and then a 2-second break. Each technique was done for 2 minutes \[36\]. Posterior gliding was performed by maintaining lateral humeral distraction with the glenohumeral in abduction range and the scapula stabilized. Then the therapist applied posterior glide in an oscillating manner. For inferior gliding, with the scapula stabilized, the therapist maintained lateral humeral distraction while applying inferior glide in the resting position of the glenohumeral joint. Patients had 3 sessions of joint mobilization per week for 6 weeks.
223789420|NCT06664437|OTHER|EXERCISE TRAINING WITH OR WITHOUT MEDICATION|Patients also in this group remained in supine lying position. Median nerve mobilization was performed by placing the scapula in a depressed position with one hand while placing the elbow in 90° flexion, forearm in supination, and wrist and fingers in extension with the other hand. Then, the therapist passively abducted the shoulder into 90- 100° and available external rotation ROM of the arm. Then from this position, the therapist extended the elbow with or without contra lateral side bending of the neck (tensioner or slider technique, respectively). Patients performed 30 repetitions of slider median nerve mobilization by performing elbow extension and wrist extension, with the neck placed in ipsilateral side bending or performing elbow flexion and wrist flexion with the neck placed in contralateral side bending. \[35\]. Tensioner technique was performed by applying simultaneous elbow extension with contralateral side bending of the neck and hold for 15 sec and relax for 10 sec .
223789421|NCT06663982|PROCEDURE|Connective tissue graft + L-PRF|"After administering local anesthesia, an atraumatic extraction will be conducted, preserving the buccal bone and carefully debriding the alveolar socket. Following papilla incisions, an intra-sulcular incision on the vestibular side of the extraction socket will be extended with a #15c scalpel, creating a socket to insert the connective tissue graft (CTG). The CTG will be harvested from the palatal area following a specific incision technique to obtain a graft around 1.5 mm thick, which will be fixed with a mattress suture.~Then the socket will be filled with L-PRF plugs. A collagen sponge will cover the extraction socket and L-PRF, secured with a 4-0 cross suture. Sutures will be removed after 15 days."
223789422|NCT06663982|PROCEDURE|L-PRF|"After administering local anesthesia, an atraumatic extraction will be conducted, preserving the buccal bone and carefully debriding the alveolar socket.~Then the socket will be filled with L-PRF plugs. A collagen sponge will cover the extraction socket and L-PRF, secured with a 4-0 cross suture. Sutures will be removed after 15 days."
223789423|NCT06664658|PROCEDURE|peep 5|he patients included in the study were divided into 2 groups. Among the patients who were going to be operated, 5 PEEP were applied to Group I (n=30) cases, and 10 PEEP to Group II (n=30) cases during ventilation with anesthesia device. All patients were evaluated by transthoracic lung ultrasonography before anesthetic induction, after tracheal intubation, after pneumoperitoneum, and 15 minutes after recovery from anesthesia. According to the lung USG protocol, a total of 6 regions, including 2 quadrants of each hemi-thorax anterior wall, 2 right and left lateral walls, and 2 quadrants of the posterior wall, a total of 12 regions in each patient were scanned, and the images were evaluated. According to the modified lung USG scoring system, each region was scored between 0-3 consistent with the degree of atelectasis
223789424|NCT06664658|PROCEDURE|peep 10|he patients included in the study were divided into 2 groups. Among the patients who were going to be operated, 5 PEEP were applied to Group I (n=30) cases, and 10 PEEP to Group II (n=30) cases during ventilation with anesthesia device. All patients were evaluated by transthoracic lung ultrasonography before anesthetic induction, after tracheal intubation, after pneumoperitoneum, and 15 minutes after recovery from anesthesia. According to the lung USG protocol, a total of 6 regions, including 2 quadrants of each hemi-thorax anterior wall, 2 right and left lateral walls, and 2 quadrants of the posterior wall, a total of 12 regions in each patient were scanned, and the images were evaluated. According to the modified lung USG scoring system, each region was scored between 0-3 consistent with the degree of atelectasis
223789425|NCT06427668|DRUG|SPG302|synthetic small molecule
223789426|NCT06427668|DRUG|Placebo|Placebo
223789427|NCT06659523|DIETARY_SUPPLEMENT|EPS supplement intervention|31 healthy individuals, male and female, were recruted at one family health unit, and randomly assigned to the intervention group, and were given for 12 weeks of one daily dose of 1.5 g powdered capsules of EPS.
223789428|NCT06659523|DIETARY_SUPPLEMENT|Placebo|29 healthy individuals, male and female, were recruted at one family health unit, and randomly assigned to the placebo group, and were given for 12 weeks of one daily dose of placebo.
223703956|NCT06681688|DRUG|Omidria, {0.3%-1% Intraocular Solution}, VIGAMOX {0.5% moxifloxacin hydrochloride}, Kenalog {0.4 ml, 10mg/ml, triamcinolone acetonide}|Eyes in the Study Arm will be treated with the following intraoperative interventions: Intracameral (OMIDRIA) phenylephrine 1.0%/ketorolac 0.3%, intracameral moxifloxacin (0.5%), and subconjunctival triamcinolone acetonide (0.4 mL, 10mgs/mL).
223789429|NCT06663306|DRUG|Pemetrexed|Intrathecal pemetrexed 50mg,twice per week (d1, d8) for 1 week, then once per 4 weeks
223789430|NCT06663306|DRUG|Bevacizumab|Intrathecal bevacizumab, once (d8)for 1 week, then once per 4 weeks.The initial dose of intrathecal bevacizumab is 5 mg, escalated to 10 mg, and then 25 mg, and then 37.5mg, and then 50mg.
223789431|NCT06663748|DRUG|ARX788|2.2 mg/kg IV infusion on Day 1 of each 42-day treatment cycle.
223789432|NCT06663007|DRUG|RC48|During the patient treatment phase, the subjects received intravenous infusion of Disitamab Vedotin(RC48) (2.0 mg/kg) every 2 weeks until disease progression or death occurred.
223789433|NCT06663007|DRUG|Envafolimab|During the treatment phase of the patient, the subjects received subcutaneous injections of Envafolimab (400 mg) every 3 weeks until the patient experienced disease progression or death.
223789434|NCT00214877|DRUG|Methylene Blue|
223789435|NCT00274053|DRUG|tiotropium|
223789436|NCT05591417|PROCEDURE|Bilevel Erector spinae plane block|Patients will receive bilevel erector spinae plane block with bupivacaine
223789437|NCT05591417|PROCEDURE|Bilateral Erector spinae plane block with dexamethasone|Patients will receive bilevel erector spinae plane block with bupivacaine and dexamethasone
223789438|NCT05591417|PROCEDURE|Bilateral Erector spinae plane block with dexmedetomidine|Patients will receive bilevel erector spinae plane block with bupivacaine and dexmedetomidine
223789439|NCT05591417|DRUG|Intravenous morphine|Intravenous morphine 0.1 mg/kg
223789440|NCT06035601|DEVICE|EHR-integrated texting platform (Urotrust)|"* An evidence-based algorithm that provides symptom triage and clinical guidance during an episode of acute UTI~* Evidence-based prevention education material on recurrent UTIs~* 5 standing orders for urinalysis and urine culture in the EHR upon enrollment~* Standard-of-care management for recurrent UTI"
223789441|NCT06035601|OTHER|Usual care|• Standard-of-care management of recurrent UTI (phone calls and/or secure EHR messages for acute symptoms) and follow up visits as determined by patients and their providers.
223789442|NCT05568394|OTHER|Manual therapy combinded with therapeutic exercise|"The treatment includes cervical mobilization and specific therapeutic exercises: craniocervical and cervical flexors and extensors, axioscapular muscles, and postural correction (30-40 minutes).~The participants will attend 20 individual treatment sessions (2 visits per week for 10 weeks)."
223789443|NCT05568394|OTHER|Routine physical therapy|"The treatment includes routine physical therapy (e.g., modalities, range of motion and/or gentle stretching exercise) (30-40 minutes).~The participants will attend 20 individual treatment sessions (2 visits per week for 10 weeks)."
223789444|NCT03891810|BEHAVIORAL|Calm|"The intervention ran for 8-wks with a 4-wk follow-up period. Intervention participants completed 7 days of Calm during Week 1. For the remaining weeks (Week 2- Week 8) intervention participants were asked to meditate during the weekday from a 10-minute meditation of their choice. Throughout the intervention, the Calm College group were sent reminder texts/emails via Google Voice to participate in the meditation sessions if participants are not meditating for more than 30 minutes a week (see Participant Scripts)."
223789445|NCT05194410|BEHAVIORAL|First 3 months of virtual, team-based exercise|Participants will be randomized onto mixed teams of medical students, residents, fellows, and attendings and registered for the virtual, team-based exercise intervention on FitRankings.com. All exercise (including walking, biking, lifting, yoga, and 40+ exercises) will be tracked via user's smartwatches (ie Apple, Garmin), smartphone fitness apps (ie MapMyRun), or manual upload, converted into Metabolic Equivalent of a Task (MET) minutes, and displayed on online leaderboards. Group activities will be encouraged by awarding raffle tickets for prizes to those who submit pictures with their teammates.
223789446|NCT05194410|BEHAVIORAL|Second 3 months of virtual, team-based exercise|Same as above
223789447|NCT05972447|PROCEDURE|Immediate implant placement of Ultrawide diameter dental implants|immediate placement of ultrawide diameter dental implants in a fresh extraction socket of mandibular molar teeth
223789448|NCT03817814|BEHAVIORAL|web-based questionnaire|Participants will complete a web-based questionnaire examining the decisions patients made about fertility preservation before and after treatment, the factors that influenced their decisions, and the ways in which patients pursue family building after treatment.
223789449|NCT04890028|RADIATION|F-DOPA PET/CT|"All subjects will be imaged~1 time injection of 2 MBq/kg of 18F-DOPA"
223789450|NCT03207529|DRUG|Alpelisib|Given PO
223789451|NCT03207529|DRUG|Enzalutamide|Given PO
223789452|NCT05306327|DIAGNOSTIC_TEST|electroencephalography (EEG)|"1. brain cortical activity using full scalp~2. cerebral blood flow velocity~3. during the dying process following planned withdrawal of life sustaining measures (WLSM)"
223789453|NCT05052359|DIAGNOSTIC_TEST|Lectin-histochemistry retrospectively performed|Lectin-histochemistry was performed on 37 archival paraffin wax-embedded specimens of various follicular thyroid tumours (10 follicular adenomas (FA), 10 minimally invasive follicular carcinomas (miFTC), 13 widely invasive follicular cancers (wiFTC) and 4 metastatic follicular thyroid cancers (metFTC)).
223789454|NCT06668493|DRUG|Nadofaragene Firadenovec|Repeat dose trial to investigate the safety and efficacy of nadofaragene firadenovec instilled into the renal pelvis
223789455|NCT06662955|BEHAVIORAL|audible cues|Terminal knee extension exercise with audible cues
223789456|NCT06662955|BEHAVIORAL|Exercise|Terminal knee extension exercise
223789457|NCT06663683|OTHER|Hip thrust|The subjects in Hip Thrust (HT) group will be instructed to perform low-load gluteus activation exercises, which included single-leg bridges, clamshells and quadruped hip extensions. One set of ten repetitions or steps will perform for each exercise. In this training program three stages which focused on enhancing hypertrophy and strength of the hip extensors in sequence. During the training period, the subjects will be instructed to maintain their usual daily activities and diet. All subjects will complete 18 sessions at a frequency of 3 sessions per week and with at least 48 hours between the sessions. Hip thrust training 3 sets with 10 repetitions in each set and 2 minutes rest between each set.
224263906|NCT07068178|DRUG|ICI-HIPET|Patients received the following interventions: On Day 0, intravenous administration of tislelizumab (an anti-PD-1 immune checkpoint inhibitor) was initiated within 3 hours post-HIPEC. Tumor tissue samples were collected before HIPEC, at 30 minutes, 60 minutes, and 90 minutes (end of HIPEC). Serum samples were collected pre- and post-HIPEC. On Day 1, additional serum samples were collected 24 hours after HIPEC-ICI completion. From Days 2-3, patients underwent paclitaxel + carboplatin chemotherapy, with serum sampling repeated at 48 hours post-HIPEC-ICI. On Days 21 and 42, the second and third cycles of neoadjuvant chemotherapy (tislelizumab + paclitaxel + carboplatin) were administered intravenously.
224263907|NCT07067385|BIOLOGICAL|Neoantigen Personalized Cancer Vaccine|Cohort 1: subjects will receive neoantigen tumor vaccine combination with Sintilimab. Cohort 2: subjects will receive neoantigen tumor vaccine combination with Sintilimab and chemotherapy .
224263908|NCT07067333|DEVICE|intramedullary nails for group A|fixation of the shaft femure fracture in this group by intramedullary nails
224263909|NCT07067333|DEVICE|plate for group B|fixation of the shaft femure fracture in the group b by plates
224263910|NCT07067580|OTHER|respiratory exercise|The experimental group will be trained on respiratory exercises by the researcher the day before the surgery. The patients will be asked to perform the post-operative respiratory exercises as 1 set (4 breaths) per hour. The patient's vital signs will be monitored before and after the respiratory exercise. Patients will not have difficulty during the respiratory exercise, they will be asked to do it gradually.
223789458|NCT06663683|OTHER|Back squat|In Back Squat (BS) resistance training the subjects starts with the standing position with the feet flat on the floor, the knees and hips in a neutral, extended anatomical position, and the spine in an upright position with preservation of its natural curves. The squat movement will begin with the descent phase as the hips, knee and ankles flex. A common instruction will be given to the subjects to descend until the top of the thigh is at least parallel with ground and the hip joint is at least level with or slightly below the knee joint. All subjects will complete 18 sessions at a frequency of 3 sessions per week and with at least 48 hours between sessions. Back squat training 3 sets with 10 repetitions in each set \& 2 minutes rest between each set.
223789459|NCT06669130|DEVICE|Xiangtong TM full degradation sinus drug stent system|use Xiangtong TM full degradation sinus drug stent system to deliver drugs into sinus
223789460|NCT06669130|DEVICE|nasopore|use nasopore to protect the post-operative sinus
223789461|NCT01920295|DEVICE|Cryoballoon ablation|
223789462|NCT05037396|DRUG|Brolucizumab|Participants received brolucizumab injection during the index period
223789463|NCT00660010|DRUG|Lupron (leuprolide acetate)|Leuprolide acetate was administered monthly by intramuscular injection starting at 300 mcg/kg with adjustments of 3.75 mg upward, at subsequent clinic visits based on physical and laboratory parameters. Dosing continued until NDA was approved, or until subject no longer required leuprolide acetate to treat CPP.
223789464|NCT01287585|DRUG|ADI-PEG 20 (arginine deiminase formulated with polyethylene glycol)|18 mg/m2, weekly, intramuscular, until disease progression or toxicity.
223789465|NCT01287585|DRUG|Placebo|weekly, intramuscular, until disease progression or toxicity.
223789466|NCT01287585|OTHER|Best Supportive Care|treatment of disease-related symptoms throughout the study.
223789467|NCT04286347|PROCEDURE|HCV, HBV, HIV tests|HCV, HBV, HIV testing during consultation with Anesthesiologist before a planned surgery
223789468|NCT05660525|DRUG|4 weeks of Nicotine lozenge|All participants will receive at least 4 weeks of the NRT Patch. Some will be randomized to receive 4 weeks of lozenge in addition to the NRT Patch. NRT temporarily replaces nicotine from tobacco to reduce motivation to consume tobacco and nicotine withdrawal symptoms.
223789469|NCT05660525|DRUG|8 weeks of Nicotine Replacement Therapy Patch|All participants will receive at least 4 weeks of the NRT Patch. Some will also be randomized to receive an additional 4 weeks of the NRT Patch
223789470|NCT05660525|BEHAVIORAL|QuitAid|All participants will receive at least 4 weeks of the NRT Patch. Some participants will also be randomized to receive the QuitAid intervention, based on a medication adherence intervention, addresses perceptions (e.g., motivation, self-efficacy, beliefs) and practicalities of using NRT (e.g., monitoring NRT use, establishing a reminder system). QuitAid includes 1 in-person session and 5 follow-up telephonic sessions with the participant's local pharmacist/technician.
223789471|NCT05660525|BEHAVIORAL|Smokefree TXT|All participants will receive at least 4 weeks of the NRT Patch. Some participants will also be randomized to receive the SmokefreeTXT is a text-messaging program offered through the National Cancer Institute's Smokefree.gov initiative, which sends pre-programmed messages timed around a quit date. Participants will receive 3-5 messages a day for 7 weeks. The first week of messages focus on preparation and the remaining 6 weeks of messages focus on post-cessation strategies (e.g., relapse prevention), all timed relative to the quit date set at enrollment.
223789472|NCT05660525|BEHAVIORAL|Tobacco Quitline|All participants will receive at least 4 weeks of the NRT Patch. Some participants will also be randomized to receive a 4-session proactive tobacco quitline, with each session lasting 20-30 minutes and occurring on days 7, 14, 21 and 28.The quitline intervention incorporates 3 phases: (1) preparing to quit, (2) quitting process, and (3) relapse prevention.
223789473|NCT05660525|DRUG|4 weeks of Nicotine Replacement Therapy Patch|All participants will receive at least 4 weeks of the NRT Patch.
223789474|NCT05660525|DRUG|8 Weeks Nicotine Lozenge|All participants will receive at least 4 weeks of the NRT Patch. Some will be randomized to receive 8 weeks of lozenge in addition to the NRT Patch. NRT temporarily replaces nicotine from tobacco to reduce motivation to consume tobacco and nicotine withdrawal symptoms.
224263911|NCT07069608|DIETARY_SUPPLEMENT|Cheers Restore|Cheers Restore contains a formulation of antioxidants, electrolytes, and plant-based compounds designed to support physiological resilience and sleep recovery after alcohol consumption. This study is structured to evaluate Cheers Restore in a real-world setting without introducing investigational or therapeutic claims.
223703957|NCT06681688|DRUG|Ketorolac (0.5%) {Toradol}, moxifloxacin (0.5%) {VIGAMOX}, prednisolone acetate (1%) {Pred Forte}|"On the Day of Surgery, eyes in the Control Arm will receive in-office drops administered by study staff according to the following schedule:~* In pre-operative holding: 1 drop ketorolac (0.5%), 1 drop moxifloxacin (0.5%)~* Immediately prior to surgery: 1 drop ketorolac (0.5%), 1 drop moxifloxacin (0.5%)~* At the conclusion of surgery while still in the operating room: 1 drop ketorolac (0.5%), 1 drop moxifloxacin (0.5%), 1 drop prednisolone acetate (1%)~* Any time in postoperative recovery: 1 drop ketorolac (0.5%), 1 drop moxifloxacin (0.5%), 1 drop prednisolone acetate (1%)"
223703958|NCT02637622|OTHER|Best-Worst Scaling (Case 2)|Respondents receive questions asking them to choose the best and worst features of a hypothetical medication.
223703959|NCT02637622|OTHER|Discrete Choice Experiment|Respondents receive questions asking them to choose the medication they prefer between a pair of hypothetical medications.
223703960|NCT04638400|DRUG|Simvastatin 40mg|Simvastatin administered daily for 6 weeks
223703961|NCT04638400|DRUG|Ezetimibe 10mg|Ezetimibe administered daily for 6 weeks
224263912|NCT04284319|PROCEDURE|DCD Heart Transplantation Using NRP|Heart Transplantation Using Normothermic Regional Perfusion (NRP) Donation After Circulatory Death (DCD)
224263913|NCT06891261|DEVICE|Piezo Surgery.|Piezotome woodpecker®: Surgic touch.
224263914|NCT06891261|PROCEDURE|Bone Discs.|bone discs mounted on staight hand piece and contra angled 1:1 gear ratio.
224263915|NCT06930794|DRUG|Vebreltinib combined with platinum-based doublet chemotherapy.|"Vebreltinib: Each cycle is 3 weeks (21 days). It is administered orally twice a day (BID), and the dosage level depends on the cohort assignment.~Platinum-based doublet chemotherapy: Each cycle is 3 weeks (21 days), and it is administered once on the first day (D1) of each cycle. Pemetrexed at a dose of 500 mg/m² plus a platinum agent (carboplatin with an area under the curve (AUC) of 5 or cisplatin at a dose of 75 mg/m²) is given by intravenous infusion for 4 to 6 cycles as the initial treatment. After that, it is switched to pemetrexed (500 mg/m²) given by intravenous infusion as the maintenance treatment."
224263916|NCT06930794|DRUG|platinum-based doublet chemotherapy.|Platinum-based doublet chemotherapy: Each cycle is 3 weeks (21 days), and it is administered once on the first day (D1) of each cycle. Pemetrexed at a dose of 500 mg/m² plus a platinum agent (carboplatin with an area under the curve (AUC) of 5 or cisplatin at a dose of 75 mg/m²) is given by intravenous infusion for 4 to 6 cycles as the initial treatment. After that, it is switched to pemetrexed (500 mg/m²) given by intravenous infusion as the maintenance treatment.
224263917|NCT02111694|BEHAVIORAL|Bottle Type|Infants will be fed from a conventional, clear bottle during one feeding and from an opaque, weighted bottle from another feeding
224263918|NCT06284993|PROCEDURE|electroacupuncture(more frequent)|With the patient in a prone position, the local skin will be routinely sterilized, Ashi points will be perpendicularly inserted into the plantar fascia layer with a depth of approximately 15-20 mm depending on the location. BL57, KI3, and BL60 will be punched perpendicularly 10-15 mm deep into the skin. All needles except the Ashi points will be manually stimulated with small, equal manipulations of lifting, thrusting, twirling, and rotating to achieve De qi (a sensation including soreness, numbness, distention, and heaviness), and the practitioner has a feeling of needle sinking and tightness. The electroacupuncture instrument is connected to the needle handle of BL57 and BL60 respectively. During the needle retention period, except for BL57 and BL60, which are connected to the electroacupuncture instrument, Ashi points and KI3 perform a small and uniform twisting technique three times every 10 min, and a total of 3 times within 30min.
224263919|NCT06284993|PROCEDURE|electroacupuncture(less frequent)|"The intervention is the same as Group M except that the frequency of acupuncture will be once per week acupuncture. During the treatment period, in addition to acupuncture, patients will be visited twice a week for a total of 8 visits by telephone or in person. If the content of the visit aligns with the established efficacy evaluation visit in the program, it will be carried out as planned. If not, the patient will be inquired about the progress of their condition since the previous treatment, any rescue medication taken, and other relevant information. Visits that do not involve improvement in relevant indicators of study concern do not need to be recorded.~The electroacupuncture will last for 30 min and will be performed three sessions per week or one session per week for a total of 12 or 4 sessions in four consecutive weeks. Participants in both groups will be treated and (or) evaluated separately."
224263920|NCT06882018|OTHER|Repeated practice guided by peers|"This approach involves repeated, peer-guided practice. Each session will involve two participants, who will support each other using the feedback grid from the first section of the Neonatal Mask Ventilation Competency Assessment Tool developed by DiLabio et al. (2018) to provide feedback on practicing technical skills."
224263921|NCT06882018|OTHER|Instructor-guided deliberate practice|In this group, practice is deliberate (PD) and is led by an instructor. Each session will be supervised by an instructor for two to four participants, and the latter will use the same feedback grid as that used in the intervention group to provide feedback.
224263922|NCT01404988|BEHAVIORAL|Telephone-Delivered BI|Behavioral Intervention will be delivered over the phone.
224263923|NCT01404988|BEHAVIORAL|Telephone-Delivered BEI|Behavioral and Environmental Intervention will be delivered over the phone
224263924|NCT01404988|OTHER|Telephone-Delivered API|Attention Placebo Intervention will be delivered over the phone
224263925|NCT06911567|DRUG|TEV-56286 Test|Administered orally
224263926|NCT06911567|DRUG|TEV-56286 Reference|Administered orally
224263927|NCT02673320|PROCEDURE|Early surgery within 48 hours|After completion of the clinical and radiological diagnosis of post-traumatic spinal cord contusion on narrow spinal canal, the patient was hospitalized. After obtaining the signed consent form, the patient was included in the protocol. After anesthetic consultation determining the feasibility or not of surgery and in the absence of other vital injury or involving life-threatening, early surgery is then realised within 48 hours. The surgical technique is a conventional cervical spinal decompression surgery. Surgery by way posterior surgery, by laminectomy in case of significant spinal stenosis greater than or equal to 3 floors will be preferred. In other cases, the type of surgery will be at the discretion of the surgeon. Then, the follow-up visits are D7, M3, Y1 and Y2.
223789475|NCT01231711|BEHAVIORAL|Vets Prevail|"The intervention has two primary components that are both delivered over the Internet:~The first component is a structured series of brief peer-to-peer instant messaging Chats structured around ensuring effective motivation, engagement, and completion. This component was modeled after Motivational Interviewing (MI) techniques. The peer-to-peer contact was provided by a master's level social worker, as well as by trained and certified combat veterans who completed the Vet-to-Vet counseling certificate program offered by the Depression and Bipolar Support Alliance (DBSA).~The second component consists of six 30-minute e-Learning Lessons using standard Cognitive Behavioral Therapy (CBT) approaches to reducing depressive and anxiety symptoms and strengthening coping skills."
223789476|NCT07127562|BEHAVIORAL|Mindfulness intervention|"Intermittent period: from the first day to at least the 21st day, and up to the 28th day, continuous implementation~Content of intervention (daily completion):~1. Mindfulness breathing exercise (10 minutes) Content: Close your eyes to perceive the breath coming in and out, pay attention to the present moment, without judgment; Tools: Chinese voice-guided audio (nurses check room or patients scan code to play); Time: to be completed between 9am and 10am;~2. Body Scan Exercise (15 minutes) Content: gradually perceive the tension, pain or relaxation of each part of the body from head to toe; Tools: Chinese audio guidance, which can be played during the infusion or before going to bed; Time: between 7-8pm;"
223789477|NCT07126301|PROCEDURE|Aromatherapy and Essential Oils|Inhale peppermint oil
223789478|NCT07126301|PROCEDURE|Aromatherapy and Essential Oils|Inhale lavender oil
223789479|NCT07126301|PROCEDURE|Aromatherapy and Essential Oils|Inhale ginger oil
223789480|NCT07126301|PROCEDURE|Aromatherapy and Essential Oils|Inhale placebo jojoba oil
223789481|NCT07126301|OTHER|Questionnaire Administration|Ancillary studies
223789482|NCT07020312|OTHER|Visualization training with neurofeedback|This technology uses electroencephalography (EEG) to measure brain activity through passive sensors placed on a cap aligned with the motor and frontal cortices. These sensors detect changes in electrical signals when patients imagine performing rehabilitation movements. The EEG data is sent to a computer, where iBrainTech™ software translates it into a virtual avatar that mimics the imagined actions. This real-time feedback-called neurofeedback-helps patients see how well they are engaging their brain during visualization. By turning the process into a video game controlled by brain signals, the platform motivates patients to focus deeply on visualizing the exercises. Repeated activation of these brain regions may help rebuild neuromuscular pathways, improve muscle control, and reduce the effects of Arthrogenic Muscle Inhibition (AMI), a common issue after orthopedic surgery.
223789483|NCT07020312|OTHER|Standard post-surgical rehabilitation therapy|Patients will follow a standard physical therapy protocol. The protocol will be assigned by their respective surgeon who conducted the procedure and will be specific to the procedure that the patient underwent.
223789484|NCT06698666|DRUG|Rosuvastatin 10 mg tablet.|"The dose of rosuvastatin was derived from literature describing the doses at which the agents' targeted actions are effective and safe. The 10- mg rosuvastatin dose reflects the lowest prescribed therapeutic dose A serum cholesterol level will be drawn from the whole participants and sent to the central laboratories of El-Demerdash hospital at baseline and at week 12.~At each visit, participants will be requested to return all unused investigational products. Adherence to medication will be assessed by a pill count."
223789485|NCT06698666|DRUG|Sertraline Pill|Both control and intervention group will receive the sertraline as a standard therapy
223789486|NCT03277235|BEHAVIORAL|Resilience model-based total care plan|12-week care plan with 5 times face-to-face intervention and weekly phone call follow-up to increase the protective factors (positive thinking. problem-solving, finding meaning, and social connection) and decrease the risk factors (disease-related distress and defense coping) of resilience
223789487|NCT03277235|BEHAVIORAL|Standard Care (in control arm)|standard care
223789488|NCT07032493|OTHER|Humidity-Ramp Protocol|Participants are exposed to 42°C and 28% relative humidity for 70 minutes. Thereafter, humidity is increased 3% until an ambient humidity of 70% is achieved. The humidity at which rectal temperature inflect is subsequently determined.
223789489|NCT07032493|OTHER|Above-inflection fixed-condition exposure (5%)|After a 1 hour equilibrium at 42°C and 28% relative humidity, humidity will be increased 3% every 10 min until it is \~5% higher than the participants' rectal esophageal temperature inflection point identified in the humidity ramp protocol. These conditions will be held constant for the remainder of the 9-hour exposure period (starting from the beginning of equilibrium). Tap water will be provided at regular intervals to limit dehydration.
223789490|NCT07032493|OTHER|Below-inflection fixed-condition exposure (5%)|After a 1 hour equilibrium at 42°C and 28% relative humidity, humidity will be increased 3% every 10 min until it is \~5% lower than the participants' individual rectal temperature inflection point identified in the humidity ramp protocol. These conditions will be held constant for the remainder of the 9-hour exposure period (starting from the beginning of equilibrium). Tap water will be provided at regular intervals to limit dehydration.
223789491|NCT07032493|OTHER|Below-inflection fixed-condition exposure (10%)|After a 1 hour equilibrium at 42°C and 28% relative humidity, humidity will be increased 3% every 10 min until it is \~10% lower than the participants' individual rectal temperature inflection point identified in the humidity ramp protocol. These conditions will be held constant for the remainder of the 9-hour exposure period (starting from the beginning of equilibrium). Tap water will be provided at regular intervals to limit dehydration.
223789492|NCT07032493|OTHER|Control fixed-condition exposure|Participants are exposed for 9-hours to 28°C with 35% relative humidity. Participant will be allowed to drink tap water ad libitum.
223789493|NCT06708182|BEHAVIORAL|SAGE LEAF Positive Emotion Skills Course|The skills will be delivered over approximately 6 weeks, and individuals can participate from any device and location with internet access. A week will consist of 1-2 days of didactic material and 5-6 days of real-life skills practice and reporting. Participants cannot skip ahead, and can only progress to the next lesson if they have completed the current one, but they can return to old lessons or exercises if they wish to. Skills include: positive events, capitalizing, gratitude, mindfulness, positive reappraisal, personal strengths, achievable goals, self-compassion.
223789494|NCT06712251|DEVICE|Velocity pAVF System|The Velocity Percutaneous Arterio-Venous Fistula System consists of a percutaneous method designed to create an arteriovenous fistula for hemodialysis vascular access.
223789495|NCT07039929|DRUG|INCB000631|Oral; Tablet
223789496|NCT07039929|DRUG|Placebo|Oral; Tablet
223789497|NCT06460311|OTHER|PEDAL and EMS|"Group A will receive EMS with Stationary cycle. EMS will be given at quadricep muscles. The pads will placed vertically in the midline along the knee and the pelvis. EMS will be given at frequency = 35 to 70 Hz, pulse duration = 100 μs, pulse period = 50 ms, Intervention will be will be performed for 60 minutes for 3 times or week for 4 weeks.~Conversely, the endurance training phase will involve securing the cycle seat while children cycle at their maximum capacity, aiming for a heart rate between 70% to 80% of their maximum. Prior to and following each session, stretching exercises targeting the calf, quadricep, and hamstring muscles will be administered, with a 10-second hold during both the warm-up and cool-down sessions. Pre and post measurements will be conducted to evaluate mobility and gait"
223789498|NCT06460311|OTHER|PEDAL|"In Group B, participants will exclusively receive the Pediatric Endurance and Limb Strengthening program without EMS. Similar to Group A, this program will incorporate the use of a stationary cycle. The warm-up and cool-down periods will also include a 10-second hold for each targeted muscle group. The intervention will consist of 60-minute sessions conducted three times per week over a span of four weeks.~Pre and post-assessments of gait and mobility will be conducted using the Gait Outcomes Assessment List (GOALTM) Questionnaire and the time up and go test."
223789499|NCT06237283|BEHAVIORAL|Early shower|Start shower after drain removal
223789500|NCT04579367|DRUG|Bempedoic acid and/or its fixed-dose combination with ezetimibe|This is a non-interventional study. No study medication will be provided to the patients. Medication will be prescribed by the treating physician in line with the clinical practice.
223789501|NCT07076134|OTHER|FCHVs and FLHWs in a community managing HTN using primary care based approach and mobile health technology|Our intervention utilizes FCHVs as a bridge between the community and health facilities to improve HTN care. FCHVs and FLHWs will receive 2 days of training to use an Android app. The app provides prompts for BP measurement and educational content on healthy lifestyles. For 3 months, FCHVs will conduct bimonthly meetings, measure BP, height, and weight, provide awareness and enter sociodemographic details of participants into the app. Participants with BP ≥130/85 mmHg (unmedicated) or ≥120/80 mmHg (on medication) will be referred to a nearby health facility by FCHVs. The data entered by FCHVs will be linked to FLHWs' terminals. FLHWs will enter required information about medication use, referrals, and follow-ups into the app and take necessary actions for the treatment of referred patients. The intervention includes 795 participants from 10 clusters with BP ≥130/85 mmHg. Data on BP, medication adherence, quality of life, and physical activity will be collected at baseline and endline.
223789502|NCT05116163|BEHAVIORAL|Individuation Intervention plus implicit bias educational modules|"Providers in the intervention are will be instructed to watch a brief set of freely available educational lessons and then they will meet with study team members to discuss their individuation countermeasure intervention. Providers will be given a choice of several individuation-related questions to better understand the unique characteristics of each patient. Once the provider decides on his/her choice phrases, the research team will assist with the development of a smart phrase (also called dot phrase) to allow them to incorporate this into a note. Once a week, providers in the intervention arm will receive an email reminding them to incorporate this question and the documentation into their encounters."
223789503|NCT05116163|OTHER|Implicit bias educational modules|Providers in the comparator arm will be given the same implicit bias educational modules to complete.
223789504|NCT07097558|OTHER|Mandala coloring group|The mandala painting intervention will be administered twice a week for 8 weeks for the mandala coloring group.
223789505|NCT07097558|OTHER|Music listening group|The music listening group will listen to classical music twice a week for 8 weeks for 30 minutes, twice a day.
223789506|NCT07097558|OTHER|control group|The control group will not receive any intervention.
223789507|NCT07098091|DRUG|YD0293|YD0293 tablet for oral administration
223789508|NCT07098091|DRUG|YD0293 placebo|YD0293 placebo tablet for oral administration
223789511|NCT07100405|DRUG|PD-1 inhibitor|An approved agent (e.g., Pembrolizumab, Nivolumab, Sintilimab, Tislelizumab, etc.) will be selected based on clinical practice and administered at standard doses and schedules.
223789512|NCT07100405|PROCEDURE|TACE|TACE is performed by using embolic agent combined with Lipiodol-pirarubicin emulsion per Investigator decision
223789513|NCT04980482|DRUG|AB-729|subcutaneous injection
223789514|NCT04980482|DRUG|Peg-IFNα-2a|subcutaneous injection
223789515|NCT05854290|BEHAVIORAL|CRT|Participants will complete an 8-week intervention, 2 sessions per week. Co-INTEGRATE sessions take 30-50 minutes to complete. Weekly on the day of the last therapy session, before or after the session, all patients, regardless of the group assigned to, will be asked to complete an electronic brief questionnaire to provide information, on sleep, recreational habits, alcohol intake, exercise, and smoking.
223789516|NCT05854290|BEHAVIORAL|CBT|Participants will complete an 8-week intervention, 2 sessions per week. Co-INTEGRATE sessions take 30-50 minutes to complete. Weekly on the day of the last therapy session, before or after the session, all patients, regardless of the group assigned to, will be asked to complete an electronic brief questionnaire to provide information, on sleep, recreational habits, alcohol intake, exercise, and smoking.
223789517|NCT05854290|BEHAVIORAL|Modifiable lifestyle factors|The therapy sessions are coupled with homework and requires some lifestyle modifications for the persons with MCI, such lifestyle adjustments are using a calendar, a diary, maintaining a sleep schedule and exercise.
223789518|NCT05854290|BEHAVIORAL|Usual care Psychoeducation|"Participants will receive 15-minute psychoeducation session twice per week for 8 weeks.~All research-related sessions will be web-based (on Zoom) and recorded (with approval).~Weekly on the day of the last therapy session, before or after the session, all patients, regardless of the group assigned to, will be asked to complete an electronic brief questionnaire to provide information, on sleep, recreational habits, alcohol intake, exercise, and smoking."
223789519|NCT06573983|OTHER|Strengthening (Physical Therapy, Gerofit)|Individuals with physical fall risk will be referred to strengthening interventions available within the VHA. These may include Physical Therapy or Gerofit (a supervised exercise program).
223789520|NCT06573983|OTHER|Cognitive Behavioral Therapy (Clinical Psychology, Occupational Therapy)|Individuals with psychological fall risk will be referred psychological interventions such as cognitive behavioral therapy, which focuses on guided talking. This can be performed by VHA occupational therapists and clinical psychologists.
223789521|NCT06573983|OTHER|Medication Reconciliation (Clinical Pharmacology)|Individuals with pharmacological fall risk will be referred to clinical pharmacology for medication reconciliation. This includes examining the current medication list and deprescribing medications, if appropriate.
223789522|NCT06573983|OTHER|Home Safety Modification (Occupational Therapy)|Individuals with environmental fall risk will be referred to occupational therapy for home safety assessments and modifications. This will involve modifying components within the home to reduce potential fall risk factors.
223789523|NCT07107217|DRUG|Camrelizumab|200 mg by intravenous (iv.) infusion every 2 weeks (Q2W) for 10 times
223789524|NCT07107217|DRUG|Doxorubicin +cyclophosphamide+ filgrastimum|Doxorubicin 60mg/m² + cyclophosphamide 600 mg/m² on Day 1 of Cycles 1-4 (Q2W) of the first neoadjuvant phase of the study, IV infusion. filgrastim (G-CSF) subcutaneously on days 2-6 of Cycles 1-4
223789525|NCT07107217|DRUG|carboplatin + paclitaxel (CP)|carboplatin AUC 2 and paclitacel 80 mg/m² will be given on day 1 every 12 weeks of the second neoadjuvant phase of the study, IV infusion.
223789526|NCT07105215|DRUG|RC278|Intravenous (IV) administration of RC278 Q3W. Patients will continue treatment until unacceptable toxicities, disease progression, or any criterion for withdrawl from the study.
223789527|NCT07105748|DRUG|Camrelizumab|Camrelizumab will be administered by IV, 200 mg every 2 weeks.
223789528|NCT07105748|DRUG|Rivoceranib (Apatinib)|Rivoceranib will be administered by oral 250 mg once daily.
223789529|NCT07105748|PROCEDURE|HAIC|FOLFOX regimen (oxaliplatin, 85 mg/m2 from hour 0-2 on day 1; leucovorin, 400 mg/m2 from hour 2-3 on day 1; and ﬂuorouracil, 400 mg/m2 bolus at hour 3 on day 1 and 2,400 mg/m2 over 24 hours) via infusion via the hepatic artery. HAIC was repeated once every 4 weeks for up to 6 cycles. Camrelizumab plus rivoceranib will be administered 1-3 days after HAIC.
223789530|NCT07114003|BEHAVIORAL|virtual reality application|The Oculus Meta Quest Pro is a virtual reality headset with 256 GB of storage. Its LCD screen offers a resolution of 1800 x 1920 pixels per eye and supports refresh rates from 90 Hz to 120 Hz. It is powered by a Qualcomm Snapdragon XR2+ processor. It features eye tracking and facial tracking, controllers with TruTouch haptics and precision tracking, and built-in 3D spatial audio support. The program, which will be played through the VR headset, is designed to use licensed programs featuring nature scenes (forest, sea, beach, etc.) and relaxing music for 20-30 minutes. The program content will be created by selecting nature sounds and music known to be effective in reducing stress and anxiety. To ensure the program's internal validity, the opinions of healthcare professionals with clinical experience will be obtained to assess whether the program achieves the intended relaxing effect.
223789531|NCT07109427|OTHER|Annual PSA Health Maintenance Reminder|The annual health maintenance reminder does not mandate PSA screening for eligible patients. Instead, it recommends that primary care providers (PCPs) initiate a shared decision-making discussion with their patients. As part of this conversation, patients will be informed of their individual risk factors-including race, family history, and germline mutations-and can then make an informed choice about whether to proceed with PSA screening.
223789532|NCT07116083|DIAGNOSTIC_TEST|µQFR|Patients with bifurcation lesions undergoing single-stent intervention are recruited. Wire-based FFR and intravascular imaging is performed, according to current guidelines, to guide PCI strategy. Angiography will be saved anonymously and sent to an independent core lab for µQFR calculation. Operaters are blinded to µQFR results.
223789533|NCT00680407|OTHER|Placebo|Placebo (5 pills, three times daily) for 48-50 week treatment period
223789534|NCT00680407|DRUG|Silymarin 700 mg|700 mg dose (5 pills, three times daily) for 48-50 week treatment period
223789535|NCT00680407|DRUG|Silymarin 420 mg|420 mg dose (5 pills, three times daily) for 48-50 week treatment period
223789536|NCT07117942|DRUG|Fermented Deglycyrrhizinated Licorice (FDGL)|Fermented Deglycyrrhizinated Licorice (FDGL) in oral powder capsules; prepared through three consecutive steps: fermentation of licorice roots, removal of glycyrrhizinic acid content (deglycyrrhizination), and lyophilization according to EUROPEAN PATENT SPECIFICATION Ep 1 925 312 B
223789537|NCT07118189|DEVICE|N95 masks and indoor air cleaner|Participants who are randomized into the intervention will receive N95 masks to be worn outdoors and an indoor air cleaner in the room that the participant spends the most time in their home. Both intervention and control arms will receive education.
223789538|NCT05568459|OTHER|Non-Interventional|No study treatment will be administered in this study.
223789539|NCT07125495|OTHER|Suction tootbrush and distiled water|All tooth surfaces, oral mucosa, and the tongue and surrounding area were cleaned every 8 hours (3x1) with distilled water and a suction toothbrush. The aspiration feature of the suction toothbrush enabled oral care and simultaneous aspiration of oropharyngeal secretions.
223789540|NCT07125495|OTHER|suction tootbrush and .12% chlorhexidine gluconate|Every 8 hours (3x1) 15 ml of 0.12% chlorhexidine gluconate oral solution (Adıgüzel, 2015) will be used with a suction toothbrush to clean all tooth surfaces, the oral mucosa, and the tongue. The aspiration feature of the suction toothbrush allows for the aspiration of oropharyngeal secretions during oral care.
223789541|NCT07125495|OTHER|Oral care sponge and with 15 ml of 0.12% chlorhexidine gluconate oral solution|All tooth surfaces, oral mucosa, and the tongue and surrounding tongue were cleaned with 15 ml of 0.12% chlorhexidine gluconate oral solution (Adıgüzel, 2015) every 8 hours (3x1) and an oral care sponge used in oral care in the intensive care unit. After oral care, oropharyngeal secretions were aspirated.
223789542|NCT07126639|DRUG|bedaquiline|Administer 400 mg orally once daily for the first two weeks, followed by 200 mg orally three times a week for the subsequent 22 weeks.
223789543|NCT07126639|DRUG|Pretomanid (Pa)|Administer 200 mg orally once daily for six months.
223789544|NCT07126639|DRUG|linezolid|Administer 600 mg orally once daily for six months.
223789545|NCT07126639|DRUG|Moxifloxacin (M)|Administer 400 mg orally once daily for six months.
223789546|NCT07126639|DRUG|Delamanid (D)|Administer 100 mg orally twice daily for six months.
223789547|NCT07126639|DRUG|Levofloxacin|Administer 800 mg orally once daily for six months.
223789548|NCT07126639|DRUG|clofazimine|Administer 100 mg orally once daily for six months.
223789549|NCT07127289|BIOLOGICAL|Autologous hematopoietic stem cell infusion|Autologous hematopoietic stem cell infusion (0.5-3.0×10\^6/kg)
223789550|NCT07128173|OTHER|Incubator Cover Group|"Incubator Cover Group: Neonatal information form was filled and consent was obtained.~Actigraphy and 24-hour sleep duration were recorded before incubator cover application.The incubators were covered with incubator covers for 24 hours.24-hour sleep durations were recorded again by actigraphy."
223789551|NCT07128173|OTHER|Control Group|Control Group:Neonatal information form was filled and consent was obtained. Actigraphy and 24-hour sleep duration were recorded. No practice other than routine medical treatment follow-up and nursing care was performed.24-hour sleep durations were recorded again by actigraphy.
223789552|NCT07127224|DIAGNOSTIC_TEST|Olfactory stimulation|"Olfactory stimulation (sniff test) combined with auditory and somatosensory stimulations during bedside neurophysiological assessments to evaluate neurological prognosis in ICU patients."
223789553|NCT07127315|DRUG|Gonadotropin-releasing hormone agonist|Patients received chemotherapy plus a gonadotropin-releasing hormone agonist.
223789554|NCT07127315|DRUG|Chemotherapy|Patients received chemotherapy alone.
223789555|NCT07126587|BEHAVIORAL|Nutrition Education and Food Delivery|Healthy frozen meals, produce boxes, and nutrition counseling
223789556|NCT07126587|BEHAVIORAL|Physical Activity Comparator|Physical activity counseling, mHealth text messaging
223789557|NCT07127146|OTHER|PET-MRI exam with administration of [11C]Carfentanil|Recording of functional neuroimaging data will begin immediately after intravenous injection of \[11C\]Carfentanil and will last for 51 minutes in a resting state. The dose will be 250 MBq/kg +-10 %.
223789558|NCT07127146|OTHER|PET-MRI exam with administration of [11C]Yohimbine|Recording of functional neuroimaging data will begin immediately after intravenous injection of \[11C\]Yohimbine and will last for 70 minutes in a resting state. The dose will be 370 MBq/kg +- 10 %.
223789559|NCT07126054|BEHAVIORAL|bibliotherapy|Bibliotherapy is a therapeutic approach that uses carefully prepared reading materials (My Surgery Story) to support individuals' understanding, coping, and anxiety, facilitated through guided reading and discussion.
223789560|NCT07127133|DEVICE|Insole and ankle device|Device that is worn as a shoe insole and around the ankle which will measure gait parameters to detect cognitive decline
223789561|NCT07127705|DIETARY_SUPPLEMENT|Placebo|2 capsules
223789562|NCT07127705|DIETARY_SUPPLEMENT|Chaga Mushroom|2 capsules
223789563|NCT07127705|DIETARY_SUPPLEMENT|Ginseng extract|2 capsules
223789564|NCT07127705|DIETARY_SUPPLEMENT|Olive extract|2 capsules
223789565|NCT07127705|DIETARY_SUPPLEMENT|Potassium Hydrogen Glucarate|2 capsules
223789566|NCT07127588|OTHER|Simulation based clinical ultrasound education|At the two hands-on teaching seminars, GPs in the intervention arm will receive training in five different clinical ultrasound examinations using an ultrasound phantom and an ultrasound simulator (Simbionix U/S Mentor). At the start of the first course day (8 hours), three basic modules will be conducted on the simulator, aimed at training hand-eye coordination and developing fundamental skills in probe movement, enhancing three-dimensional perception, and learning to use the various settings on the ultrasound simulator to achieve optimal imaging. At the first course day, the five clinical ultrasound examinations will be trained through a total of 13 simulation cases. On the second course day (4 hours), the participants will repeat the 13 simulation cases.
223789567|NCT07127588|OTHER|Traditional ultrasound education|At the two hands-on teaching seminars, GPs in the control arm will receive training in five different clinical ultrasound examinations as according to an established and validated training program. At the start of the first course day (8 hours), the five clinical ultrasound examinations will be trained using healthy volunteers and still pictures for visualizing pathology. On the second course day (4 hours), the participants will train by repeating the five clinical ultrasound examinations on healthy volunteers.
223789568|NCT07126405|OTHER|PROvider ReMote ObsTetric-Related Employment Education (PROMOTE)|An on-demand 30-minute web-based training for clinical team members that provides a high-level summary of federal employment laws, work note templates embedded into the electronic health record (EHR) that prompt the clinician team member to include relevant information, and a patient-facing infographic designed to facilitate clinician counseling.
223789569|NCT07127107|DRUG|Non-steroidal anti-inflammatory drugs (NSAIDs)|"For mild and moderate migraines e.g Ibuprofen and aspirin.~* Aspirin: Peroral (PO) tablet with standard dosages of 325 mg, 500 mg, and 400 mg effervescent; treatment dosage of up to 1000 mg~* Ibuprofen: PO tablet with standard dosages of 200 mg, 400 mg, 600 mg, and 800 mg; treatment dosage of 200 to 800 mg"
223789570|NCT07127107|OTHER|Manual therapy techniques|"Cranial manipulative osteopathy: Tension release of cranial sutures is applied while the patient in supine lying position, a pressure of 200g to3kg is applied with both thumbs for 30-40 sec or till release occurs. it includes:~1. Coronal suture The head is directed to one side and the pressure is applied with both thumbs directed parallel to each otheralong the coronal suture.~2. Sagital suture distraction The head is in the central position and the pressure is applied with both thumbs directed parallel to each other along the sagittal suture.~3. Squamous suture distraction The head is directed to one side and the pressure is applied with both thumbs parallel along the squamous suture.~4. Lamboidal suture distraction:~   The head is directed to one side and the thumbs directed parallel to each other along the lamboidal suture.~5. Occipitomastoid suture distraction The head is directed to one side and both thumbs directed parallel to each other along occipitomastoid suture."
223789571|NCT07126171|DRUG|Reduning injection|reduning Injection, intravenous drip, 20 ml per time, once a day;
223789572|NCT07126171|DRUG|The simulant of Reduning Injection|The simulant of Reduning Injection, for intravenous drip, 20 ml per time, once a day
223789573|NCT07127393|OTHER|Food|Meal with seaweed
223789574|NCT07127354|DRUG|Continue GLP/GIP|Continue GLP-1 or GIP-based therapy as prescribed prior to the procedure.
223789575|NCT07126678|DRUG|zanubrutinib, bendamustine, and obinutuzumab|"Patients will receive combination therapy with zanubrutinib, bendamustine, and obinutuzumab over 6 cycles, with each cycle lasting 28 days. The specific dosing schedule is as follows: Bendamustine 70 mg/m²: administered intravenously on Days 2-3 of Cycle 1, and on Days 1-2 of Cycles 2-6. Obinutuzumab 1000 mg: administered intravenously on Days 1, 8, and 15 of Cycle 1, and on Day 1 of Cycles 2-6 (every 28-day cycle). Zanubrutinib 160 mg orally twice daily (bid), continuously throughout Cycles 1-6.~Treatment is discontinued after 6 cycles, with no subsequent maintenance therapy."
223789576|NCT07126366|OTHER|S-PRG Barrier coat|A light-cured Giomer varnish for prolonged hypersensitivity relief. Seals and protects exposed dentinal tubules to prevent pain. Ideal for patients experiencing loss of enamel, gingival recession or temporary sensitivity due to whitening.
223789577|NCT07126366|OTHER|S-PRG Prophylaxis paste|S-PRG Prophylaxis paste is a bioactive Giomer-based paste containing S-PRG particles that release six therapeutic ions-fluoride, strontium, borate, aluminum, sodium, and silicate each contributing to remineralization, antibacterial effects, and dentin sensitivity reduction.
223789578|NCT07126457|OTHER|RIS system|The RIS system based on the Internet of Things consists of three aspects: one-way output management of the large database of head and neck tumors, two-way interaction management of artificial intelligence applications, and popular science dissemination for the general public.
223789579|NCT07128030|OTHER|Exercise|The experimental group completed a five-week supervised program combining moderate-intensity aerobic and resistance training (150 min/week). Intensity was monitored using the Borg and OMNI-Res scales after familiarization sessions. Adherence was encouraged through reminders, motivational messages, and follow-ups. Unlike prior studies, this intervention focused specifically on neurophysiological pain modulation. Sessions included step-based aerobic exercises and resistance training with elastic bands under safety protocols.
223789580|NCT07127848|PROCEDURE|Septoplasty with Mucotomy|Subtotal reconstruction of the nasal septum accompanied by radiofrequent nasal mucosal reduction of the inferior turbinates.
223789581|NCT07127848|PROCEDURE|Septoplasty with Turbinectomy|Subtotal reconstruction of the nasal septum accompanied by surgical resection of the inferior turbinates.
223789582|NCT07127848|PROCEDURE|Septoplasty with Valvuloplasty|Subtotal reconstruction of the nasal septum accompanied by surgical intervention by placing a flare sutture in the internal nasal valve area.
223789583|NCT07126756|DEVICE|STAR S4 IR Excimer Laser System|LASIK with iDesign
223789584|NCT07126756|DEVICE|VisuMax 400 Surgical Laser|small incision lenticule extraction technique
223789585|NCT07126730|DEVICE|EXOPULSE Mollii Suit + Exercise|First, spasticity will be evaluated using the Modified Ashworth Scale (MAS). Based on this evaluation, the stimulation intensity for each muscle group will be determined and recorded in the system. Once patients put on the EXOPULSE Mollii Suit and the stimulation begins, they will undergo a personalized exercise program including strengthening, balance, and gait training with scheduled rest intervals. All MS patients will undergo treatment three days per week (with at least one day between sessions) for one hour per day over four weeks.
223789586|NCT07126730|DEVICE|EXOPULSE Mollii Suit|First, spasticity will be evaluated using the Modified Ashworth Scale (MAS). Based on this evaluation, the stimulation intensity for each muscle group will be determined and recorded in the system. Patients will wear the suit and receive stimulation while resting for 60 minutes. All MS patients will undergo treatment three days per week (with at least one day between sessions) for one hour per day over four weeks.
223789587|NCT07126236|DRUG|Epcoritamab|Patients will receive 12 cycles of Epcoritamab monotherapy.
223789588|NCT07126236|DRUG|Epcoritamab, tafasitamab and lenalidomide|Patients will receive 3 cycles of Epcoritamab monotherapy and then 12 cycles of Epcoritamab, Tafasitamab and Lenalidomide.
223789589|NCT07128069|DIETARY_SUPPLEMENT|Vitamin D 400IU|Low dose vitamin D (400 IU/day)
223789590|NCT07128069|DIETARY_SUPPLEMENT|Vitamin D 4000IU|Moderate dose vitamin D (4000 IU/day)
223789591|NCT07126210|BEHAVIORAL|Family engaged, enhanced Diet intervention|"The family component includes health education via books, lectures, and short videos, parenting skills training, regular monitoring of child growth, and behavior goal setting through the mobile health platform. Motivational interviewing via telephone provides tailored behavioral support.~Kindergartens assist in health education, supervise dietary intake and physical activity, monitor children's growth monthly, and maintain communication with families.~Hospitals provide targeted health counseling and facilitate clinic access as needed.~The mobile health platform integrates modules for health education, smart growth curve tracking, behavior goal management, and home-school-hospital collaboration."
223789592|NCT07126314|OTHER|Competition based Education Format|Residents will be organized into 3 teams, each competing to amass points for critiquing articles presented during journal club, for a prize.
223789593|NCT06934876|DIAGNOSTIC_TEST|Colorimetric carbon dioxide (CO2) detection|"All patients will undergo colorimetric carbon dioxide (CO2) detection. The reading will be assessed by a clinician at the bedside who will answer yes or no to the following question, asked after 7 breaths have been delivered following intubation: Is the color change consistent with a tube located in the trachea?"
223789594|NCT06934876|DIAGNOSTIC_TEST|Waveform capnography|"All patients will undergo waveform capnography. The reading will be assessed by a clinician at the bedside who will answer yes or no to the following question, asked after 7 breaths have been delivered following intubation:  Is the waveform consistent with a tube located in the trachea?"
223789595|NCT06936709|DRUG|Colchicine 1.8 mg (loading dose) + Dextrose Oral Placebo|This intervention will be used for individuals in arm A of the study who will receive a loading dose of colchicine (1.8 mg) on postoperative day 0, and will then be given placebo oral dextrose pills to take twice daily on postoperative days 1-3
223789596|NCT06936709|DRUG|Colchicine 1.8 mg + 0.6 mg|This intervention is will be given to patients in arm B of the study who will receive a loading dose of colchicine (1.8 mg) on postoperative day 0, followed by a maintenance does of colchicine (0.6 mg) to be taken twice daily on postoperative days 1-3.
223789597|NCT06936709|DRUG|Dextrose Oral Placebo|This intervention will be for patients in arm C, the placebo arm. These patients will receive oral dextrose pills to be taken once on postoperative day 0, and twice daily on postoperative days 1-3.
223789598|NCT06940518|DRUG|Ivonescimab|Given by IV
223789599|NCT06167031|OTHER|chatbot facilitated teaching|"The experimental group will use chatbot to facilitate teaching."
223789600|NCT06167031|OTHER|lecture-based teaching|The control group only receives lecture-based teaching.
223789601|NCT06947980|DRUG|Placebo Comparator|Placebo subcutaneous injection
223789602|NCT06947980|BIOLOGICAL|CM512|CM512 subcutaneous injection
223789603|NCT06952049|BEHAVIORAL|Pain Psychoeducation|In the pain psychoeducation intervention, participants will be randomized to listen to a three-minute recording about different pain management strategies (e.g., ice, rest) to promote overall well-being.
223789604|NCT06952049|BEHAVIORAL|Mindfulness without Psychoeducation|In the mindfulness without psychoeducation intervention, participants will be randomized to listen to a three-minute mindfulness practice consisting of 1 minute of mindful breathing, 1 minute of mindful mapping, and 1 minute of mindfulness of personal meaning.
223789605|NCT06952049|BEHAVIORAL|1 Minute Psychoeducation with 2 Minutes of Mindfulness (Pain Focus)|In the 1 Minute Psychoeducation with 2 minutes of Mindfulness (Pain Focus) intervention, participants will be randomized to listen to a 1 minute of psychoeducation about mindfulness, 1 minute of mindful breathing and 1 minute of mindful mapping.
223789606|NCT06952049|BEHAVIORAL|1 Minute Psychoeducation with 2 Minutes of Mindfulness (Meaning Focus)|In the 1 Minute Psychoeducation with 2 minutes of Mindfulness (Meaning Focus) intervention, participants will be randomized to listen to a 1 minute of psychoeducation about mindfulness, 1 minute of mindful breathing and 1 minute of mindfulness of personal meaning.
223789607|NCT06952049|BEHAVIORAL|2 Minutes of Psychoeducation with 1 Minute of Mindfulness|In the 2 Minutes of Psychoeducation with 1 Minute of Mindfulness intervention, participants will be randomized to listen to a 2 minute of psychoeducation about mindfulness and 1 minute of mindful breathing.
223789608|NCT06954818|BIOLOGICAL|A zoster mRNA vaccine SYS6017|SYS6017 is an investigational lipid nanoparticle (LNP)-coated mRNA vaccine encoding the glycoprotein E (gE) of VZV, and indicated for active immunization for the prevention of zoster caused by the reactivation of latent VZV.
223789609|NCT06954818|OTHER|Placebo|saline solution
223789610|NCT02639702|DRUG|Clozapine|Switching from twice-daily to once-daily clozapine dosing regimen
223789611|NCT05780645|DRUG|ALXN2050 MR Prototype Tablet|Participants will receive various doses of the MR Prototype Tablet orally.
223789612|NCT05780645|DRUG|ALXN2050 Immediate Release (IR) Tablet|Participants will receive a single dose IR (ALXN2050 Film Coated Tablet) tablet orally.
223789613|NCT05780645|DRUG|ALXN2050 MR Prototype Mini-Tablet|Participants will receive various doses of the MR Prototype Mini-Tablet orally.
223789614|NCT07126353|OTHER|prospective observational study (clinical, hormonal and auxological data)|We collect clinical, hormonal and auxological data and compare them between the two groups.
223789615|NCT06544642|DRUG|ASP5502|Oral
223789616|NCT06544642|DRUG|Placebo|Oral
223789617|NCT06280196|DRUG|BAT3306|One vial of 4 mL of concentrate contains 100 mg of BAT3306
223789618|NCT06280196|DRUG|EU-Keytruda®|One vial of 4 mL of concentrate contains 100 mg of pembrolizumab
223789619|NCT06280196|DRUG|US-Keytruda®|One vial of 4 mL of concentrate contains 100 mg of pembrolizumab
223789620|NCT06280196|DRUG|Pemetrexed|500 mg/m2 on Day 1 of each 21-day cycle of the study
223789621|NCT06280196|DRUG|Carboplatin|Target AUC of 5 mg/mL/min on Day 1 of each 21-day cycle up to 4 cycles
223789622|NCT04158401|DEVICE|Pregnolia|The Pregnolia measurement device (CE Mark for commercialization in the EU) will be used to measure the cervical stiffness (Pcl) on all subjects.
223789623|NCT04392505|DRUG|Durvalumab Injection|Included patients will receive durvalumab (fixed dose, 1500mg Q4W) until progressive disease and no clinical benefit, intolerable toxicity or patient's wish, for a maximum duration of 12 months. Treatment with durvalumab should start \<5 weeks after last radiotherapy dosing.
223789624|NCT02026089|BIOLOGICAL|Varicella vaccine|Varivax 0.5ml subcutaneous injection
223789625|NCT05596305|BEHAVIORAL|educational psychiatry intervention|educational anti-stigma intervention related to psychiatric illness composed of a lecture, video, role models play, and open discussion
223789626|NCT05308732|DRUG|Copaiba|A 10% and 15% aqueous solution of copaiba (Copaifera Officinalis Resin) manufactured by Interativo Farmácia de Manipulação will be used, under the formula: 10% copaiba oil (Copaifera Officinalis Resin) and 15% liquid mint aroma 5% , tween 80 1%, Aqueous solution (Distilled water + 0.1% Nipagin) qsp 100%.
223789627|NCT06509906|DRUG|M9466|M9466 will be administered orally until progressive disease, unacceptable toxicity, death, or end of study.
223789628|NCT06509906|DRUG|Irinotecan|Irinotecan will be administered intravenously once every 2 weeks (q2w) until progressive disease, unacceptable toxicity, death, or end of study.
223789629|NCT06509906|DRUG|Folinic acid|Folinic acid will be administered intravenously q2w as per standard of care.
223789630|NCT06509906|DRUG|Fluorouracil (5-FU)|Fluorouracil will be administered intravenously as per standard of care.
223789631|NCT06509906|DRUG|Bevacizumab|Bevacizumab will be administered intravenously, q2w until progressive disease, unacceptable toxicity, death, or end of study.
223789632|NCT06509906|DRUG|Granulocyte colony stimulating factor (G-CSF)|G-CSF will be administered subcutaneously at every cycle of study intervention as per standard of care.
223789633|NCT00976599|DRUG|CP-690,550 + methotrexate|CP-690,550 dose is 10 mg twice daily, oral tablets, for 4 weeks Methotrexate dose is ≥ 7.5 mg / week and ≤ 25 mg / week
223789634|NCT00976599|DRUG|Placebo + Methotrexate|Methotrexate dose is ≥ 7.5 mg / week and ≤ 25 mg / week
223789635|NCT00002507|DRUG|mitomycin C|
223789636|NCT00002507|DRUG|porfiromycin|
223789637|NCT00002507|RADIATION|brachytherapy|
223789638|NCT00002507|RADIATION|radiation therapy|
223789639|NCT02276846|DEVICE|Paclitaxel-Eluting Balloon|
223789640|NCT02711774|DEVICE|ultrasonography|ONSD will be measured by a 6-13 MHz linear probe of the ultrasound machine.
223789641|NCT00222534|DRUG|Acetazolamide|
223789642|NCT00222534|DRUG|Placebo|
223789643|NCT00291148|DRUG|paroxetine|
223789644|NCT00291148|DRUG|pregabalin|
223789645|NCT06832007|DEVICE|AYO light glasses (experimental)|OUD patients are asked to wear AYO light therapy glasses (wavelength 470nm ± 2nm, irradiance 250 μW/cm2 or approx.1500 m-EDI) daily for 30 min after habitual wake-up times for two weeks.
223789646|NCT06832007|DEVICE|AYO light glasses (comparator)|The comparison group will wear the same AYO glasses but with lower intensity (1% light intensity) compared to the experimental group. This group will also self-administer 30 min of light from commercially available light glasses each morning for two weeks
223789647|NCT02675361|BEHAVIORAL|Transition program|Participants will be part of a transition program with eight key components: 1. A transition coordinator; 2. Education on congenital heart disease (CHD), treatments, health behavior, dealing with school, friends; 3. Telephone availability; 4. Information about the Grown-Up Congenital Heart Disease (GUCH) program: 5. Guidance of parents; 6. Meeting with peers: 7. A person-centered transition plan; and 8. Transfer to Grown-Up Congenital Heart Disease clinic. The intervention will be implemented by specialized nurses at the outpatient clinic of pediatric cardiology. Overall, 60 to 90 minutes per patient are spent over the 2.5 years.
223789648|NCT04757623|PROCEDURE|Purse string closure of Ileostomy|conventional proceedure
223789649|NCT05613660|DIETARY_SUPPLEMENT|Veg Collagen Peptide|Mode of Usage: 1 scoop/sachet daily Route of Administration: Oral administration with a glassful (approx. 250 mL) of water
223789650|NCT05613660|DIETARY_SUPPLEMENT|Bovine Collagen Peptide|Mode of Usage: 1 scoop/sachet daily Route of Administration: Oral administration with a glassful (approx. 250 mL) of water
223789651|NCT05613660|DIETARY_SUPPLEMENT|"Fish | Marine Collagen Peptide"|Mode of Usage: 1 scoop/sachet daily Route of Administration: Oral administration with a glassful (approx. 250 mL) of water
223789652|NCT05613660|DIETARY_SUPPLEMENT|Chicken Collagen Peptide|Mode of Usage: 1 scoop/sachet daily Route of Administration: Oral administration with a glassful (approx. 250 mL) of water
223789653|NCT00783744|DRUG|Insulin Glargine|In the morning to target FBG ≤ 100 mg/dl
223789654|NCT00783744|DRUG|Glimepiride|Glimepiride 3 or 4 mg
223789655|NCT00783744|DRUG|Metformin|At least 850 mg od
223789656|NCT00783744|DRUG|Insulin monotherapy with premixed insulin NPH 30/70|Given before breakfast and before dinner, target of pre-prandial BG ≤ 100 mg/dl
223789657|NCT00920426|DRUG|GSK1265744 30mg|GSK1265744 30 mg
223789658|NCT00920426|DRUG|Placebo|Placebo to match GSK1265744
223789659|NCT00920426|DRUG|GSK1265744 5mg|GSK1265744 5mg
223789660|NCT01432366|OTHER|SC anti-TNF|Subcutaneous (SC) anti-TNF
223789661|NCT04525404|DIAGNOSTIC_TEST|MRI (heart, brain, lungs, liver)|MRI (heart, brain, lungs, liver)
223789662|NCT04525404|DIAGNOSTIC_TEST|Bloodwork|Serum biomarkers to assess systemic inflammation, renal function, cardiac injury, liver injury and steatosis, ACE-2 related peptides, cytokines, Activin A and autoantibodies to cardiac antigens, humoral cell RNA
223789663|NCT04525404|OTHER|Cognitive testing|NIH toolbox Cognitive Measures
223789664|NCT04525404|OTHER|Olfaction testing|Brief Smell Identification Test (BSIT)
223789665|NCT04525404|DIAGNOSTIC_TEST|Spirometry|Spirometry to evaluate forced expiratory volume in 1 second and forced vital capacity
223789666|NCT04525404|OTHER|Walk Test|Walk test to record overall distance walked in 6 minutes and time taken to walk the first 25 feet
223789667|NCT01808690|DRUG|Metformin|
223789668|NCT01808690|DRUG|Placebo|
223789669|NCT03664713|BEHAVIORAL|Eye Movement Desensitization and Reprocessing (EMDR) Therapy|EMDR is an 8-phase psychological treatment composed of protocols and standardized procedures applicable to both adults and children. The eight phases (patient history, patient preparation, evaluation of the main aspects of the memory, desensitization of the traumatic memory, installation of the positive cognition, body scan, close and re-evaluation) and the protocol of the time line of past-present-future, allow a holistic evaluation of the image of the traumatic memory, and allow for the patient to be well-prepared before processing past events which underlie current pathology, current situations which cause perturbation, and challenges and possible future stimuli which might lead to the appearance of symptoms. (Shapiro, 2014)
223789670|NCT05651581|OTHER|Online module|online module including around 5 videos and several infographics covering the topics of symptoms transmission, prevention, vaccination, and treatment of the monkeypox virus.
223789671|NCT04432597|BIOLOGICAL|PRGN-2009 (Phase I)|On the phase I portion of the protocol PRGN-2009 will be administered on Day (D)1, D15, D29 followed by booster vaccines every 4 weeks for up to a year. The dose level given as booster will be the same dose participants will be receiving for D1, D15 and D29.
223789672|NCT04432597|BIOLOGICAL|PRGN-2009 (Phase II)|On the phase II portion of the protocol PRGN-2009 will be administered on just Day (D)1 and D15.
223789673|NCT04432597|BIOLOGICAL|M7824|"Subjects enrolled to Arm 1B will receive M7824 (MSB0011359C) via intravenous (IV) infusion over 1 hour (-10 minutes / +20 minutes, that is, over 50 to 80 minutes) once every 2 weeks. M7824 will be administered as a flat dose of 1,200 mg independent of body weight. M7824 is administered as an intravenous infusion with a mandatory 0.2 micron in-line filter."
223789674|NCT04432597|DIAGNOSTIC_TEST|MRI|MRI (with gadolinium) of the neck, chest, skull, and/or sinonasal, if indicated, will be used when computed tomography (CT) scan is not an option to follow the disease.
223789675|NCT04432597|DIAGNOSTIC_TEST|Bone scan|Bone scans and other imaging assessments may also be performed as clinically indicated.
223789676|NCT04432597|DIAGNOSTIC_TEST|CT scan|Imaging of the neck, chest, skull, and/or sinonasal, if indicated, will be performed every 8 weeks. In the event of a partial response (PR) or complete response (CR) tumor imaging assessments may be performed every 3 months (+/- 2 weeks) at the discretion of the investigator.
223789677|NCT04432597|DIAGNOSTIC_TEST|Brain CT|Performed at baseline and may also be performed as clinically indicated by development of new specific symptoms or on the discretion of the Principal Investigator.
223789678|NCT04432597|DIAGNOSTIC_TEST|Brain MRI|Performed at baseline and may also be performed as clinically indicated by development of new specific symptoms or on the discretion of the Principal Investigator.
223789679|NCT04432597|PROCEDURE|Biopsy (Phase I)|"Where feasible, optional biopsies may be done at baseline as well as at week 9 and will likely be computed tomography (CT) guided. If a recent (≤ 6 months preferred) outside biopsy has been performed that specimen may be used in lieu of a baseline biopsy for phase I participants.~For participants with lesions amenable to biopsy, two biopsies may be performed at baseline and at Week 9 (phase I participants)."
223789680|NCT04432597|PROCEDURE|Biopsy (Phase II)|"Where feasible, biopsies will be done at baseline as well as at week 4-5. Biopsies will be done by ear, nose and throat (ENT) under direct visualization. Where feasible at least 2 cores will be obtained. If a recent (≤ 6 months preferred) outside biopsy has been performed that specimen may be used in lieu of a baseline biopsy.~For participants with lesions amenable to biopsy, two biopsies may be performed at baseline and at Week 4-5 (phase II participants)."
223789681|NCT02247427|DEVICE|Cardiac Resynchronization Therapy Device|Cardiac Resynchronization Therapy Device pacing activity, on or off
223789682|NCT02644460|DRUG|Abemaciclib|
223789683|NCT05155826|DEVICE|Virtual Reality Headset|The patient will benefit from the placement of Cook's balloon (standard care) with the placement of the virtual reality headset on the examination table with the launch of the software before the beginning of the procedure. The virtual reality helmet will be removed at the end of the procedure.
223789684|NCT06204731|OTHER|Exercise and environmental conditions|Participants will engage in interval training and will reside and sleep at different altitudes for a period of 4 weeks. Aerobic and anaerobic capacity tests and an eccentric exercise test will be performed before and after the training intervention. Before and after the training program, somatic measurements will also be taken. Before and after the first and last workout, blood will be drawn for biochemical analysis.
223789685|NCT05616533|OTHER|biopsy of tumor before treatment|samples obtained from biopsy will be used in the zebrafish PDX model
223789686|NCT06085170|DIAGNOSTIC_TEST|Acoustic Analysis by MDVP|Acoustic measurements: Acoustic analysis using Multidimensional voice program software (MDVP) will be carried out with the sustained /a/vowel for 9 seconds, for measuring frequency, jitter, shimmer and harmonic to noise ratio of the voice
223789687|NCT01719952|DRUG|Carbetocin|"IV carbetocin 100mcg, only in selected patient given as an intravenous bolus over 30 seconds by the anaesthetist following clamping of the umbilical cord only in patient that has been randomized to this group.~pitocin 5 IU also given as an intravenous bolus over 30 seconds by the anaesthetist following clamping of the umbilical cord only in patient that has been randomized to this group."
223789688|NCT01719952|DRUG|Oxytocin|5 IU given as an intravenous bolus over 30 seconds by the anaesthetist following clamping of the umbilical cord only in patient that has been randomized to this group.
223789689|NCT05750290|DRUG|CKD-702 in combination with irinotecan|CKD-702 and irinotecan will be intravenously administered every 2 weeks.
223789690|NCT04543123|DEVICE|tDCS treatment|Participants visited the hospital four times (biweekly for two weeks). During their second visit, a research nurse instructed each participant on use of home-based tDCS equipment (YDS-301N; Ybrain Inc., Seongnam-si, Korea) and all participants thereafter conducted tDCS treatment at home once a day for 30 minutes (five times per week).
223789691|NCT04543123|DRUG|Antidepressant Drug(escitalopram)|Participants in both active and sham groups were prescribed escitalopram in combination with tDCS treatment.
223789692|NCT00282620|DRUG|Magnesium L-lactate|
223789693|NCT01821469|BEHAVIORAL|psychoeducation|Bipolar disorders are educated to learn about their pathology
223789694|NCT03576547|DRUG|Dexamethasone|Given PO or IV
223789695|NCT03576547|DRUG|Ponatinib Hydrochloride|Given PO
223789696|NCT03576547|BIOLOGICAL|Rituximab|Given IV
223789697|NCT03576547|DRUG|Venetoclax|Given PO
223789698|NCT01461668|DRUG|Retapamulin|Two times a day for 5 days
223789699|NCT01461668|DRUG|Placebo|Two times a day for 5 days
223789700|NCT01251003|BIOLOGICAL|Autologous cord blood|there is no minimum acceptable dose, and the maximum allowable dose will be 10x10(9)cells/kg given IV (in the vein), one time infusion
223789701|NCT02816580|OTHER|Blood collection|
223789702|NCT06117982|DRUG|Neupogen|Subcutaneous injection of 0.5 ml of Neupogen at a concentration of 300 micrograms/day for 4 consecutive days
223789703|NCT00377234|DRUG|Risedronate|35mg po weekly for 12 weeks
223789704|NCT00377234|DRUG|ibandronate [Bonviva/Boniva]|150mg po monthly for 3 months
223789705|NCT05166408|PROCEDURE|Buccinator myomucosal flap|Buccinator myomucosal flap for primary cleft palate palatoplasty
223789706|NCT05166408|PROCEDURE|Bardach two flap palatoplasty|Bardach two flap palatoplasty
223789707|NCT01880424|DRUG|Placebo|matching Placebo Capsules, Oral, once daily
223789708|NCT01880424|DRUG|Linaclotide|Linaclotide 290 ug Capsules, Oral, once daily
223789709|NCT06402734|BEHAVIORAL|Adherence to Gluten Free Diet|Participants with a diagnosed celiac disease were following a gluten-free diet. Study observed the adherence to the gluten-free diet for 6 weeks.
223789710|NCT03747926|DRUG|BI 705564|single-rising oral dose
223789711|NCT03747926|DRUG|Placebo|single-rising oral dose
223789712|NCT02612948|DRUG|Quetiapine|escalating dose to prevent delerium.
223789713|NCT01921569|BEHAVIORAL|Standard of Care Therapy|Rest, ice, compression, elevation (RICE), NSAID or salicylate medication for pain, Physical Therapy and stretching exercises, Reduction in impact activities, to include an arm sling.
223789714|NCT01921569|OTHER|dHACM Injection|Injection into affected area with micronized dHACM suspended with total volume of 1 cc normal saline.
223789715|NCT01921569|OTHER|Normal Saline Injection|Injection into affected area with 1.0 cc normal saline solution instead of active agent.
223789716|NCT03853629|OTHER|None. Not applicable|None. Not applicable
223789717|NCT02062632|DRUG|Doxepin Hydrochloride|Given orally
223789718|NCT02062632|OTHER|Placebo|Given orally
223789719|NCT02062632|OTHER|Quality-of-Life Assessment|Ancillary studies
223789720|NCT02062632|OTHER|Questionnaire Administration|Ancillary studies
223789721|NCT02212028|DRUG|prasugrel|the effects of whole tablets versus crushed tablets will be compared
223789722|NCT01702337|OTHER|Prevalence-based model|Static prevalence-based model to estimate vaccine effect over a one-year period at a steady state (when all women are fully vaccinated).
223789723|NCT05833750|OTHER|Reflexology|In the intervention group, reflexology was applied to the feet twice a week for 8 weeks.
223789724|NCT02730494|DEVICE|Lcr Regenerans® vaginal capsules|
223789725|NCT02730494|DEVICE|Lcr Regenerans® vaginal tablet|
223789726|NCT00581230|DEVICE|Laryngoscopy with RAMP|inflatable positioning ramp
223789727|NCT00581230|DEVICE|Laryngoscopy without RAMP|Laryngoscopy without RAMP
223789728|NCT00001533|DRUG|cyclosporine|
223789729|NCT03112382|DRUG|zinc supplement plus vitamin A and E|
223789730|NCT03112382|DRUG|vitamin A and E|
223789731|NCT01562756|OTHER|HVLA-SM|High velocity, low amplitude spinal manipulation
223789732|NCT01490632|DRUG|Placebo|Administered orally
223789733|NCT01490632|DRUG|Baricitinib|Administered orally
223789734|NCT05232045|DRUG|Automated urinary output collection system group (tight monitoring of urine output)|Automated urinary output collection system group (tight monitoring of urine output)
223789735|NCT05148377|DRUG|Liquaemin|The standardized dose for the study was 150UI / kg heparin. It was administered directly through the dialysis equipment.
223789736|NCT05148377|DRUG|Heptar|The standardized dose for the study was 150UI / kg heparin. It was administered directly through the dialysis equipment.
223789737|NCT05362864|PROCEDURE|Fracture fixation via Intramedullary Nailing|Fixation of trochanteric, sub-trochanteric, and shaft fractures and osteotomies.
223789738|NCT01801020|OTHER|temperature measuremts|temporal artery temperature measurements will be taken from the forehead
223789739|NCT01801020|OTHER|temperature measuremts|different modes of temperature measuremts will be compared to one another in the same patient. if temporal measurement is higher than oral a rectal temperature will be taken
223789740|NCT00575575|BEHAVIORAL|cognitive behavior therapy|cognitive behavior therapy once a week
223789741|NCT04035967|OTHER|Questionnaire|Impact on Family Scale (IPFAM), WeeFIM Pediatric Functional Independence Measurement, Nottingham Health Profile. State-Trait Anxiety Inven¬tory (STAI-I and STAI-II), PEDI (Pediatric Evaulation of Disability Inventory)
223789742|NCT05446987|OTHER|Position change and back massage|Changing the patient's position every two hours as follows in the same order: supine position with a head angle of 15°, semi-fowler position with a head angle of 30°, lateral right or left position with a head angle of 15°. Also, the researcher applied a simple stroke of lower back massage for 5 minutes every 2 hours
223789743|NCT05446987|OTHER|Early ambulation|The patient ambulated after 3 hours of complete bed rest in the supine position with a zero head of bed elevation angle
223789744|NCT03093831|DRUG|Ibrutinib|560mg administered orally once daily.
223789745|NCT06962176|PROCEDURE|Anterior Mitral Line Ablation|First pulmonary vein isolation (PVI) is performed - either as a first-time isolation (index procedure) or a re-isolation (in repeat procedures). Then a linear lesion is created on the anterior wall of the left atrium, from the roof line to the mitral annulus.
223789746|NCT06962176|PROCEDURE|Posterior Mitral Isthmus Ablation with Vein of Marshall Ethanol Infusion|Pulmonary vein isolation (PVI) is systematically carried out before any additional ablation lines are created - either as initial isolation or re-isolation. In this group the posterior mitral isthmus, a region between the left inferior pulmonary vein and the mitral annulus, is targeted. Endocardial ablation using a dual energy catheter (RF and PF) is combined with ethanol infusion in the vein of Marshall (VOM), which ablates the adjacent epicardial tissue to enhance lesion durability.
223789747|NCT01217710|BEHAVIORAL|Activity monitor/smartphone health coaching|Initial health coaching at enrollment will involve the collaborative creation of an action plan with personally relevant, specific actions for increasing physical activity. The short term goals will be rated for self-efficacy and modified to maximize likelihood of success. Health coaches will discuss important mediators of physical activity (e.g., self-efficacy, enjoyment, social support, problem-solving). Weekly coaching calls will involve discussion of progress toward goals and problem-solving of barriers utilizing a motivational interviewing approach. Motivational messages will also be developed and sent daily to participants via the smartphone. These messages will indicate the percentage of steps related to their daily goal.
223789748|NCT04196179|DRUG|ANG3070|ANG-3070 drug product is a an immediate release oral solid. The drug product consists of a Size 00 Swedish orange capsule containing drug substance (10 mg, 50 mg, or 250 mg) with no excipients.
223789749|NCT04196179|DRUG|Placebo oral capsule|ANG-3070 placebo capsules visually match the drug product.
223789750|NCT01351285|DRUG|up-and-down method to find out effective concentration of remifentanil for preventing cough|During the emergence from anesthesia, if the patient did not cough, the extubation was defined as smooth emergence and the predetermined effect site concentration of remifentanil for the subsequent patient was decreased by 0.5 ng/mL. Likewise, if the patient coughed anytime around extubation, it was considered a failed smooth emergence and the predetermined effect site concentration for the next patient was increased by 0.5 ng/mL. This up-and-down method was conducted independently for each of the three groups. EC50 of the remifentanil of each group was obtained using the Dixon's method.
223789751|NCT04933747|DRUG|Iberdomide|Administration of a single oral dose of 1mg iberdomide in participants
223789752|NCT04933747|DRUG|Iberdomide|Administration of a single oral dose of 1mg iberdomide in participants on 2 occasions - once on a dialysis day and once on a non-dialysis day
223789753|NCT05662033|DRUG|AZD6793|AZD6793 will be administered orally
223789754|NCT05662033|DRUG|Placebo|Placebo will be administered orally
223789755|NCT03406247|DRUG|Nivolumab|"Patients in cohorts 1 and 1bis will be administered Nivolumab 240 mg every 2 weeks during 3 first months and then 480 mg every 4 weeks during 3 months Patients in cohorts 2 and 2bis will be administered~\- nivolumab 240 mg every 2 weeks during 6 months"
223789756|NCT03406247|DRUG|Ipilimumab|"Patients in cohorts 2 and 2bis will be administered~\- ipilimumab 1mg/kg IV every 6 weeks during 6 months"
223789757|NCT02330835|BEHAVIORAL|In the Drivers Seat|Multimedia student behavior management program for school bus drivers and school administrators
223789758|NCT02330835|BEHAVIORAL|School bus driver training videos|Basic bus driving safety videos
223789759|NCT05831332|DEVICE|BTL-785-7|Treatment with the BTL-785F device with the BTL-785-7 applicator for non-invasive reduction of submental fat.
223789760|NCT06525194|BEHAVIORAL|Education|"An Interprofessional Education Program Based on the ARCS-V Motivation Model on the Theme of Chronic Disease Management and Patient Safety"
223789761|NCT00668122|DRUG|Cipro XR (Ciprofloxacin, BAYQ3939)|Ciprofloxacin XR 1000 mg orally once a day
223789762|NCT00668122|DRUG|Cipro IR (Ciprofloxacin, BAYQ3939)|Ciprofloxacin IR 500 mg orally twice a day
223789763|NCT01621698|PROCEDURE|Early paravertebral block|In this group the local anaesthetic will be injected at the start of surgery soon after incision and normal saline at the end. These will be double blinded.
223789764|NCT01621698|PROCEDURE|Late Paravertebral block.|In the late group local anaesthetic will be injected at close of surgery with normal saline at the start. This will be double blinded.
223789765|NCT06237205|DRUG|Niraparib|a highly selective PARP1 and PARP2 inhibitor
223789766|NCT05154682|DRUG|OxyCODONE 5 mg Oral Tablet|Oxycodone will be given every 4 hours as needed for 2 weeks after surgery
223789767|NCT05154682|DRUG|Acetaminophen 500Mg Tab|Acetaminophen will be taken every 4 hours for 2 weeks after surgery
223789768|NCT05154682|DRUG|Naproxen 500 Mg|Naproxen will be taken every 12 hours for 2 weeks after surgery
223789769|NCT05582876|RADIATION|Radiopharmaceutical 68Ga-PSMA-11 PET/CT|The radiopharmaceutical will be administered intravenously in doses with an activity of 1.8-2.2 MBq / kg b.w.
223789770|NCT02207010|BIOLOGICAL|AZD1775|All patients receive a single dose of the oral study drug prior to surgery for resection of GBM.
223789771|NCT05759234|DRUG|HS248 pieces|The overall safety and tolerability of PI3Kγ inhibitor monotherapy for solid tumors is good, and it has shown preliminary clinical benefits. The safety of PI3Kγ inhibitor combined with immune checkpoint inhibitor is good, and the efficacy of single drug is significantly improved. Based on the evaluation of the safety and efficacy results of HS248 preclinical and clinical studies of similar PI3Kγ inhibitors, the benefits of this product outweigh the risks for patients with advanced solid tumors who have progressed through standard treatment, have toxicity intolerance, or have no standard treatment regimen. Sufficient to support planned clinical studies.
223789772|NCT01332877|BEHAVIORAL|Enriched breakfast|high carbohydrate, high protein breakfast supplying 600 kcal as 50k% carbohydrate, 20% protein, 30% fat
223789773|NCT01332877|BEHAVIORAL|Control breakfast|Control breakfast providing 300 kcal, 13% carbohydrate, 40% protein, 48% fat
223789774|NCT05884697|OTHER|K-Talk Intervention (Storytelling and K-Bot)|The K-Talk intervention group receives a combination of a storytelling intervention and an artificial intelligence chatbot (K-Bot) education.
223789775|NCT05884697|OTHER|Storytelling Intervention|The storytelling intervention features 12 authentic stories from young Korean immigrants and Americans. Each video is about 3 minutes long and includes stories from 1st, 1.5, and 2nd generation young Korean individuals, highlighting their perceptions of HPV and HPV vaccines, and their experiences with HPV vaccination.
223789776|NCT05884697|OTHER|K-Bot Intervention|The K-Bot intervention is a conversational and button-based artificial intelligence Chatbot that is available in both English and Korean.
223789777|NCT05884697|OTHER|Written Information|The written information provided includes the Centers for Disease Control and Prevention's (CDC) details on HPV and HPV vaccines.
223789778|NCT04938245|DEVICE|Spinal Cord Stimulation|"Intraoperatively, stimulation at 12 Hz will be performed as the leads are moved into the targeted position. Amplitude will be increased to 15 mA maximum total until a response is seen on any electrode and held for 10 seconds. Stimulation and recording will be performed using the Neuralynx stim/record system.~Post-operatively, the electrodes will be tested for impedance by the clinical system and then they will be connected to the Neuralynx stim/record system. Electrode stimulation patterns will be applied with increasing amplitude until ECAPs responses are seen on recording electrodes. 42 Hz stimulation will be performed with an amplitude sweep of 0mA-10mA. At each amplitude, stimulation will be applied for 4 seconds followed by 2 seconds of rest. Pulse width will be varied from 30-450 microseconds to test effective amplitude. Bursting stimulation will be applied to detect differences in ECAPs as above."
223789779|NCT01672775|DRUG|AGS-16C3F|intravenous (IV) infusion
223789780|NCT05155865|DEVICE|Resynchronization with conduction system pacing|Implantation of permanent pacemaker with conduction system pacing (preferably left bundle branch) with or without defibrillator lead placement
223789781|NCT05155865|DEVICE|Cardiac resynchronization therapy with biventricular stimulation|Implantation of cardiac resynchronization therapy with biventricular stimulation with or without defibrillator lead placement
223789782|NCT06030726|BEHAVIORAL|Behavioral Economic Principles|The control arm will receive no letter to reflect the background vaccination uptake. Intervention arms will test the effects of different letters developed using behavioral economic principles.
223789783|NCT00006123|BIOLOGICAL|trastuzumab|
223789784|NCT00006123|DRUG|carboplatin|
223789785|NCT00006123|DRUG|carmustine|
223789786|NCT00006123|DRUG|cisplatin|
223789787|NCT00006123|DRUG|cyclophosphamide|
223789788|NCT00006123|DRUG|thiotepa|
223789789|NCT00006123|PROCEDURE|peripheral blood stem cell transplantation|
223789790|NCT05917327|DEVICE|Low-volume continuous veno-venous haemodialysis|MEX-CD1 is a hyper-chelating colloidal solution that can be added to the dialysate to be used in low-volume continuous veno-venous hemodialysis. One treatment will last 4 hours. For non-hospitalized patients, the treatment is performed on an outpatient basis.
223789791|NCT02716974|DRUG|Leuprolide Acetate|22.5mg by intramuscular (IM) injection every 3 months
223789792|NCT02716974|DRUG|Bicalutamide|bicalutamide (Casodex) 50mg by mouth daily
223789793|NCT02716974|DRUG|Docetaxel|Docetaxel (taxotere) 75 mg/m2 IV will be given on day 1 every 3 weeks, up to 6 cycles.
223789794|NCT02716974|PROCEDURE|Prostatectomy|Removal of the entire prostate gland, plus some surrounding tissue.
223789795|NCT02716974|RADIATION|Radiation|5 high dose radiation treatments to the metastatic (tumor has spread to other parts of the body) sites.
223789796|NCT03603665|BIOLOGICAL|NTM-1633|NTM-1633 is an equimolar mixture of three IgG1 monoclonal antibodies (mAb), referred to as XE02, XE06, and XE17 which bind to non-overlapping epitopes on Botulinum Neurotoxin (BoNT/E). Administered as a single intravenous infusion of NTM-1633 over one hour.
223789797|NCT03603665|OTHER|Placebo|0.9% Sodium Chloride Injection administered as a single intravenous infusion over one hour.
223789798|NCT04897165|OTHER|Resilience training with mobile HRV-BfB based on an e-learning approach (with digital lectures)|A 4-week resilience training with a mobile HRV-BfB device. Participants received access to three online lectures at the start of the first, third, and forth training week (each lasting 60 minutes) to receive a theoretical base on resilience and to learn how to exercise with the HRV-BfB device. Participants were asked to exercise three times a day for 5 minutes in their occupational and leisure time with the HRV-BfB device.
223789799|NCT04897165|OTHER|Resilience training with mobile HRV-BfB based on a blended learning approach (with live lectures)|A 4-week resilience training with a mobile HRV-BfB device. Participants attended three live lectures at the start of the first, third, and forth training week (each lasting 90 minutes) to receive a theoretical base on resilience and to learn how to exercise with the HRV-BfB device. Participants were asked to exercise three times a day for 5 minutes in their occupational and leisure time with the HRV-BfB device.
223789800|NCT02561858|OTHER|acid load test|
223789801|NCT04063189|DRUG|Clarithromycin Lenalidomide Dexamethasone (BiRd) Regimen|Clarithromycin 500mg，po，bid，d1-21; Lenalidomide 25mg，po，daily，d1-21 (dose according to creatinine clearance rate); Dexamethasone 20mg，po，daily，d1-2, 8-9,15-16, 22-23
223789802|NCT02734342|OTHER|exercise|Participants will be asked to attend eight exercise sessions within a group class environment that will last for 1 hour. The exercise programme has been developed through clinical and research evidence. During the hour, a 5 minute warm up followed by 14 exercises specific to strengthening the lower limb and improving aerobic capacity. Each exercise will be timed for two minutes with the participant reporting number of repetitions counted. A cool down will be completed at the end of the class. After each exercise class, the participant will be advised to have a recovery day to prevent overloading (De Carlo \& Armstrong, 2010). Progression of exercises will be patient led. Participants will attend twice per week for four weeks.
223789803|NCT04217863|BEHAVIORAL|GDP|Guided Disclosure Protocol
223789804|NCT03398005|DRUG|CaPre|4 x 1 g capsules administered orally once a day for 26 weeks
223789805|NCT03398005|DRUG|Placebo|4 x 1 g capsules administered orally once a day for 26 weeks
223789806|NCT05969093|DIAGNOSTIC_TEST|Tinel's Sign performed at different wrist positions|Participants will undergo the Tinel's Sign at different wrist positions while EMG activity and NCV are recorded to investigate the effect of wrist position on median nerve activity.
223789807|NCT01043770|BEHAVIORAL|Group lifestyle education|Structured group education programme based on lifestyle changes (dietary and increased physical activity)
223789808|NCT03084055|BEHAVIORAL|eMotion|eMotion is comprised of a series of weekly audio visual modules designed to increase exposure to positive activities and physical activity
223789809|NCT01206530|DRUG|Hydroxychloroquine|Dose:600 or 800 mg Route:PO daily Treatment Administration: Daily
223789810|NCT01206530|DRUG|Oxaliplatin|Dose: 85mg/m2 Route: IV infusion over 2 hours Treatment Administration: Day 1
223789811|NCT01206530|DRUG|Leucovorin|Dose: 400mg/m2 Route IV infusion over 2 hours Treatment Administration: Day 1
223789812|NCT01206530|DRUG|5-fluorouracil|Dose: 400mg/m2 Route: IV bolus immediately following leucovorin Treatment Administration Day 1
223789813|NCT01206530|DRUG|5-fluorouracil|"Dose: 2,400mg/m2 Route: IV continuous infusion over 46 hours immediately following bolus injection.~Treatment Administration: Days 1-2"
223789814|NCT01206530|DRUG|Bevacizumab|
223789815|NCT03429413|BEHAVIORAL|Protect Me 4 Application + External Quality Improvement Support|Participants will be asked to interact with the Protect Me 4 application, using an iPad tablet. During the implementation period (months 4-6), intervention clinics will receive the Protect Me 4 app and External Quality Improvement Support (practice facilitation and external and internal provider peer opinion leaders and provider incentives). Providers from intervention clinics will complete audit and feedback reports to assess HPV vaccination rates with the assistance of the practice facilitator. Providers at the intervention clinic will complete a pre-intervention survey to obtain background information (demographics, approximate HPV vaccination rates, comfort with the use of technology etc.)
223789816|NCT03429413|BEHAVIORAL|Protect Me 4 Application Alone|During the maintenance period (months 7-9), intervention clinics will receive Protect Me 4 without external support (practice facilitation and external provider peer opinion leaders). Providers from intervention clinics will complete audit and feedback reports to assess HPV vaccination rates without the assistance of the practice facilitator. Providers at the intervention clinic will complete a post-intervention survey to gain provider feedback regarding the feasibility of Protect Me 4 and changes in perceptions regarding the use of technology.
223789817|NCT05250180|OTHER|Animal Assisted Therapy|Patients enrolled in the study will be randomly scheduled to have a dog be a part of their PT and OT sessions on two days (one in the first week and one in the second week) during their stay. On these days, the therapist will lead the therapy session and integrate the dog at whatever level is appropriate based on the patient's level of functioning and therapy goals.
223789818|NCT05250180|OTHER|Control|treatment as usual as dictated by their treatment team
223789819|NCT03212469|DRUG|Durvalumab|"Preliminary steps : Safety Runs Safety run of the dual combination Durvalumab as single agent at the selected dose of 1500mg, every 4 weeks (Q4W) from C1D1 up to 13 doses~Safety run of the triple combination:~Durvalumab at 1500mg every 4 weeks (Q4W) from C1D1 up to 13 doses,~Efficacy step~* Durvalumab Q4W + Tremelimumab Q4W for up to 4 doses at the DL defined in safety runs, in conjunction with~* SBRT at C1D15, then~* Durvalumab Q4W alone for up to 9 additional doses"
223789820|NCT03212469|DRUG|Tremelimumab|"Preliminary steps : Safety Runs~Safety run of the triple combination:~Tremelimumab at 75mg/Q4W for up to 4 doses~Efficacy step~* Durvalumab Q4W + Tremelimumab Q4W for up to 4 doses at the DL defined in safety runs, in conjunction with~* SBRT at C1D15, then~* Durvalumab Q4W alone for up to 9 additional doses"
223789821|NCT03212469|RADIATION|SBRT|"Preliminary steps : Safety Runs~Safety run of the dual combination:~SBRT at C1D15.~Safety run of the triple combination:~SBRT at C1D15.~Efficacy step~* Durvalumab Q4W + Tremelimumab Q4W for up to 4 doses at the DL defined in safety runs, in conjunction with~* SBRT at C1D15, then~* Durvalumab Q4W alone for up to 9 additional doses"
223789822|NCT00501384|DRUG|satavaptan (SR121463B)|
223789823|NCT04089644|DEVICE|closed-loop system|"Hypotension will be corrected by an automated system for vasopressor administration.~Fluids will be given using a goal directed strategy (EV1000 Monitor, Edwards Lifesciences, Irvine, CA, USA)"
223789824|NCT04089644|DEVICE|Manual adjustment|"Vasopressor agents will be manually adjusted (standard practice).~Fluids will be given using a goal directed strategy (EV1000 Monitor, Edwards Lifesciences, Irvine, CA, USA)"
223789825|NCT01761435|BIOLOGICAL|Influenza vaccine|"Patients will be randomized at 1:1 rate and open label fashion, according to centers, and time elapsed since transplant and type of organ transplanted to one of this two interventions :~A arm (usual treatment): Influenza vaccine (split virion, inactivated) suspension for injection 0.5ml at the baseline.~B arm (experimental branch): Influenza vaccine (split virion, inactivated) suspension for injection 0.5ml at the baseline and 5 weeks after the first dose.~The follow-up of both arms will be at 5, 10 and 15 weeks and one year after the baseline."
223789826|NCT05653505|OTHER|Remote Ischemic Conditioning|Remote ischaemic conditioning (RIC) refers to a process whereby periods of intermittent ischemia, typically via the cyclical application of a blood pressure cuff to a limb at above systolic pressure, confers systemic protection against ischemia in spatially distinct vascular territories.
223789827|NCT00511862|DEVICE|Yttrium 90 glass microspheres|120 Gy unilobar or bilobar infusion with the second infusion occurring 3-7 weeks following treatment of the first lobe
223789828|NCT03706599|BEHAVIORAL|Therapeutic education on fever|Session for therapeutique education on fever
223789829|NCT03706599|BEHAVIORAL|Therapeutic education on household accidents|Session for therapeutic education on household accidents
223789830|NCT00856856|DEVICE|Bioabsorbable Everolimus Eluting Coronary Stent|Bioabsorbable drug eluting stent implantation in the treatment of coronary artery disease
223789831|NCT03599063|BIOLOGICAL|PF-06946860|PF-06946860 administered subcutaneously
223789832|NCT03599063|OTHER|Placebo|Placebo, administered subcutaneously
223789833|NCT05550246|DRUG|Atomoxetine|Treatment given for 3 nights
223789834|NCT05550246|DRUG|Oxybutynin|Treatment given for 3 nights
223789835|NCT05944419|DEVICE|Immediate implant surgery|Placement of immediate implant and immediate provisionalization after tooth extraction
223789836|NCT04829344|DRUG|AG-920|AG-920 Sterile Topical Ophthalmic Solution
223789837|NCT04829344|DRUG|Placebo|Placebo Topical Ophthalmic Solution
223789838|NCT02169934|DRUG|Radiolabeled TRV130|A single 2 mg IV dose administered as a 10 mL manual IV push over 2 minutes
223789839|NCT04992715|DIAGNOSTIC_TEST|[99mTc]-NM01 SPECT/CT|Technetium-99m radiolabelled anti-PD-L1 single-domain antibody (NM01) single-photon emission computed tomography (SPECT)/computed tomography (CT)
223789840|NCT02811237|OTHER|HESTIA|"Management based on the HESTIA rule:~* If the rule is negative, meaning that patient meet none of the exclusion criteria of the rule, the proposed management will be outpatient care.~* In the other cases, the patient will receive in-hospital care.~Any reason for management (hospitalization or outpatient treatment) not based on the recommendation will be explained and documented in the e-CRF."
223789841|NCT02811237|OTHER|sPESI|"Management based on the simplified PESI score:~* If the sPESI score =0, the proposed management will be outpatient care.~* In the other cases, the patient will receive in-hospital care.~Any reason for management (hospitalization or outpatient treatment) not based on the recommendation will be explained and documented in the e-CRF."
223789842|NCT03722160|DEVICE|Solo TympanostomyTube Device|The Solo Tympanostomy Tube Device is intended to deliver a tympanostomy tube through the tympanic membrane of a patient during a tympanostomy procedure.
223789843|NCT02199782|OTHER|Welsh language Cognitive Assessment|This intervention may intervene by displaying a more realisitic reflection of the patient's cognitive ability by assessing the patient in their first language
223789844|NCT03142074|OTHER|Biomechanical and microstructural analysis of ATAA|Tissue collection; microstructural testing of tissue; mechanical testing of tissue .
223789845|NCT03142074|RADIATION|ECG-gated CT|Image analysis of ECG-gated CT.
223789846|NCT02945865|OTHER|Pain assessment|Pain assessment with assessment tools
223789847|NCT02606838|DEVICE|Styx Lancing Device|Untrained Persons With Diabetes used the Styx Lancing Device with 28 and 30 Gauge lancets to obtain fingerstick and Alternate Site palm capillary blood. Study Staff tested the capillary blood using Contour NEXT Blood Glucose Meters (BGMs) and recorded the results. Meter results could be numeric, non-numeric (ie, error messages), or not obtained at all.
223789848|NCT06370767|BEHAVIORAL|Bike-Share Travel Training|Half of the participants not assigned to the waitlist will begin the bike-share intervention arm immediately after the baseline research interview. The bike-share arm will last for 8 weeks and be delivered by a community peer specialist. Half of the participants assigned to the waitlist will begin the bike-share intervention arm after an 8-week waiting period.
223789849|NCT06370767|BEHAVIORAL|Public Transportation Travel Training|Half of the participants not assigned to the waitlist or bike-share arm will begin the public transportation intervention arm immediately after the baseline research interview. The public transportation arm will last for 8 weeks and be delivered by a community peer specialist. Half of the participants assigned to the waitlist will begin the public transportation intervention arm after an 8-week waiting period.
223789850|NCT02696317|DEVICE|Senofilcon A contact lenses with HydraLuxe™|Contact lenses worn during Period 1 or 2, as randomized
223789851|NCT02696317|DEVICE|Senofilcon A contact lenses|Contact lenses worn during Period 1 or 2, as randomized
223789852|NCT00426504|PROCEDURE|Radiotherapy|Helical Tomotherapy Intensity Modulated Radiotherapy (HT-IMRT) with the intend of delivering radical radiotherapy to a dose of 66-70 Gy to involved areas and at least 50 Gy to un-involved sites to be treated prophylactically.
223789853|NCT01343368|DRUG|Leuprolide|Long-acting leuprolide 11.25 mg intramuscularly (IM) pre-transplant (HCT) and 3 months post-HCT PLUS Short-acting leuprolide 0.2 mg subcutaneously (SQ) daily for 14 days
223789854|NCT01343368|BIOLOGICAL|hematopoietic cell transplant|Conventional bone marrow transplant regimen.
223789855|NCT01343368|BIOLOGICAL|reduced intensity allogeneic HCT|A reduced-intensity conditioning transplant is a bone marrow or cord blood transplant (also called a BMT) that uses less intense treatment to prepare for transplant than a standard transplant does. While a standard transplant uses the pre-transplant treatment to destroy most of the disease cells, a reduced-intensity transplant relies on the donor's immune cells to fight disease.
223789856|NCT01925079|BEHAVIORAL|Intensive Education|"Statin Treatment：The investigator will be suggested to increase the dose of atorvastatin according to guideline if a patient's LDL-C does not achieve target level.~Patient education:~1. Routine education at discharge.~2. 4 education brochures will be delivered to patients.~3. Calendar with healthy tips will be delivered to patients before discharge.~4. A follow-up brochure with medical expert letter.~5. A total of 24 specific short messages for ACS will be developed and sent to patients (one short message per week).~6. Telephone follow ups will be performed according to a standard communication document.~At discharge, patients will be given a brochure for future follow up."
223789857|NCT01925079|OTHER|Control|"Statin Treatment：The recommended dosage of atorvastatin will be adjusted at the physician's discretion.~Patient education:~1. Routine education at discharge.~2. A follow-up brochure without medical expert letter.~At discharge, patients will be given a brochure for future follow up."
223789858|NCT02535208|OTHER|Restrictive transfusions based on SCOR assessment|RBC transfusions will be given to subjects either when participants' Hgb levels fall below defined values based on respiratory status or, despite not having reached their Hgb trigger threshold, if they manifest symptoms judged by the clinical care team to be consistent with anemia (i.e. apnea, bradycardia, or desaturation episodes) and subsequently have a NIRS evaluation that demonstrates an SCOR \< 0.73.
223789859|NCT02535208|OTHER|Liberal transfusions|In the liberal group, RBC transfusions will be given to participants when their Hgb level falls below defined values that are based on respiratory support status, as is standard practice.
223789860|NCT02794402|DRUG|Exenatide|Bydureon (Exenatide once weekly) injections s.c.
223789861|NCT02794402|BEHAVIORAL|Placebo|Placebo once weekly injections sc
223789862|NCT01178151|DRUG|Everolimus|10mg daily orally
223789863|NCT04116931|DRUG|Switch ticagrelor to clopidogrel|Switch ticagrelor to clopidogrel with 600 mg loading dose (LD)/75 mg maintenance dose（MD）12/24 hours after the last MD of ticagrelor
223789864|NCT02186119|DRUG|abicipar pegol|Abicipar pegol administered to the study eye by intravitreal injection at the visits noted per protocol.
223789865|NCT02186119|DRUG|ranibizumab|Ranibizumab (Lucentis®) administered to the study eye by intravitreal injection every 4 weeks from day 1 through week 24.
223789866|NCT02186119|OTHER|sham procedure|Sham procedure to the study eye at the visits noted per protocol.
223789867|NCT02105506|DRUG|Tachosil patch|
223789868|NCT04955639|OTHER|Control|Standard of Care - Control Smoking Cessation Program
223789869|NCT04955639|OTHER|Pivot|Pivot Program Smoking Cessation Program
223789870|NCT04447404|DRUG|DUR-928|IV infusion
223789871|NCT04447404|DRUG|Placebo|IV infusion
223789872|NCT05877001|DRUG|Tislelizumab|200mg, IV, Q3W
223789873|NCT05877001|DRUG|Regorafenib|80 mg once daily for the first 3 weeks of each 4-week cycle
223789874|NCT05877001|OTHER|HAIC|OXA 85mg/m2 IA 0-4h +5-Fu 2000mg/m2 IA 4-48h，CF 200mg/m2 IV 2-4h， Q3W
223789875|NCT05509829|DEVICE|Negative pressure wound therapy|Negative pressure wound therapy using PICO14.
223789876|NCT01369342|DRUG|Group 1: Placebo|Form=solution for injection, route=intravenous use, in a single dose.
223789877|NCT01369342|DRUG|Group 2 ustekinumab 130 mg|Type=exact, unit=mg, number=130, form=solution for injection, route= intravenous use, in a single dose.
223789878|NCT01369342|DRUG|Group 3: ustekinumab approximately 6 mg/kg|Type=range, unit=mg/kg, number=6, form=solution for injection, route= intravenous use, in a single dose.weight-range based ustekinumab doses approximating ustekinumab 6 mg/kg: 260 mg (weight \<= 55 kg), 390 mg (weight \> 55 kg and \<= 85 kg), and 520 mg (weight \> 85 kg).
223789879|NCT00321854|DRUG|pramipexole|
223789880|NCT06495775|DEVICE|quickfact|fecal sampling
223789881|NCT02501343|DRUG|Sodium Bicarbonate Oral Capsule|Sodium bicarbonate 1680 mg will be administered prior to the meal
223789882|NCT02501343|DRUG|Placebo|Sodibic-matching placebo (Stenlake Compounding Chemist, NSW, Australia) will be administered prior to the meal on a different day 1 to 2 weeks apart
223789883|NCT05003531|DRUG|IBI112 dose 2|Participants will receive placebo or dose 2 IBI112 SC
223789884|NCT05003531|DRUG|IBI112 dose 4|Participants will receive placebo or dose 4 IBI112 SC
223789885|NCT05003531|DRUG|IBI112 dose 1|Participants will receive placebo or dose 1 IBI112 SC
223789886|NCT05003531|DRUG|IBI112 dose 3|Participants will receive placebo or dose 3 IBI112 SC
223789887|NCT05003531|DRUG|placebo|Participants will receive placebo SC
223789888|NCT01951430|DRUG|Antibiotic and antifungal drugs|
223789889|NCT02123693|OTHER|Osteopathic manipulative treatment|
223789890|NCT02123693|OTHER|Sham Therapy|
223789891|NCT02123693|OTHER|No Intervention|
223789892|NCT04723576|BEHAVIORAL|Stress First Aid|"Stress First Aid (SFA) is an evidence-based intervention to mitigate the psychosocial impact of COVID-19 on Health Care Workers (HCWs). SFA was initially developed for the United States Navy and Marine Corps as a framework of actions for peer support delivered by individuals without mental health training. SFA is designed to teach simple, supportive actions that can be seamlessly integrated into work environments. SFA training focuses on five essential principles: cover (restore and support a sense of safety), calm (encourage simple strategies such as breathing), connect (engage in and promote social support), competence (improve ability to address crucial needs and concerns), and confidence (increase hope and limit self-doubt and guilt). In this study, we are adapting the SFA model to include HCW-specific examples of SFA actions and case scenarios specific to the COVID-19 pandemic and will implement SFA using a train-the trainer model."
223789893|NCT00396903|DEVICE|catheter|
223789894|NCT06276192|OTHER|Digital Physiotherapy (diSAID)|"The diSAID is developed by the research group and is a modified version of a previously tested exercise program for patients with subacromial pain. The diSAID is distributed in three stages with; Information about subacromial pain, effects of exercise, pain management and ergonomics in everyday living and at work. The training includes exercises for the rotator cuff and scapular stabilizers as well as posterior shoulder stretch. The exercises are performed 1 time/day during twelve weeks with a progression of dose, load and complexity continuously. Pain while performing the exercise program is accepted up until NRS 5 out of 10.~During ongoing treatment, there is the opportunity for counselling, individualization of exercises, adjustment of dose and load based on stated instructions from the treating physiotherapist.~Adherence, levels of pain and function is reported continuously by the patient via the digital platform."
223789895|NCT06276192|OTHER|Traditional Physiotherapy|Patients in the active control group are offered the usual treatment practice that is currently offered by physiotherapists in primary care. No predetermined directives for the active control group are defined prior to the study and can contain; home exercise programs, manual therapy and other techniques. The treating physiotherapists in this group are not involved in the digital treatment. The choice of interventions, amounts of visits and adherence is checked retrospectively via patient data and medical records.
223789896|NCT01850680|DRUG|sarilumab SAR153191 (REGN88)|Pharmaceutical form:solution Route of administration: subcutaneous
223789897|NCT01850680|DRUG|placebo|Pharmaceutical form:solution Route of administration: subcutaneous
223789898|NCT01850680|DRUG|methotrexate|Pharmaceutical form:capsule Route of administration: oral
223789899|NCT01850680|DRUG|folic acid|Pharmaceutical form:tablet Route of administration: oral
223789900|NCT01352338|DRUG|Lenalidomide, endoxan, prednisone|dose-finding
223789901|NCT01352338|DRUG|lenalidomide, endoxan, prednisone|oral therapy with lenalidomide 25mg a day during 3 of 4 week cycles. Number of Cycles: until progression or unacceptable toxicity develops.
223789902|NCT05278273|DEVICE|NeurotrackerX|At-home participants loaned the necessary equipment (e.g., 3D-glasses, computer equipment) from the research facilities and engaged in 10 training sessions over five weeks (2x per week). Participant recruitment, retention, adherence and experience were used as markers of feasibility. For program validation, twenty participants above 50 years old, who had previously completed at least eight sessions of the in-lab 3D-MOT program, were randomly selected as the control group.
223789903|NCT00175682|DRUG|Prazosin HCL|See Detailed Description
223789904|NCT06389604|OTHER|Heat acclimation|Daily repeated heat exposure to assess the effects of combined passive and active heat acclimation
223789905|NCT01920230|BEHAVIORAL|Mindfulness-ACT-intervention|Half of the participants (n=109) is assigned to intervention group. The intervention is based on Mindfulness-program presented by Williams \& Penman (2011) and on principles of acceptance-commitment therapy (ACT). It aims to increase mindfulness skills and psychological flexibility through different exercises that are developed for improving skills of being present, dealing with thoughts and feelings as well as support clarifying individual values and value-based actions. The basic principles are presented in weekly small group meetings. Participants are guided to deepen their experiences through exercises and information that is provided via specific web-site.
223789906|NCT01920230|BEHAVIORAL|No intervention|Half of the participants (n=109) don't get any special treatment. However the present study explores what kind of support they have had during the program.
223789907|NCT06062680|DRUG|Herombopag Olamine Tablets|Three Herombopag Olamine Tablets is administered to healthy subjects.
223789908|NCT01138904|DRUG|irinotecan, oxaliplatin|"OXIR: FOLFOX -\> FOLFIRI~IROX: FOLFIRI -\> FOLFOX~FOLFOX REGIMEN~D1 Oxaliplatin 85mg/m2 + 5DW 500ml MIV over 120min D1,D2 Leucovorin 50mg IV Push D1,D2 5-Fluorouracil 400mg/m2 IV Push D1,D2 5-Fluorouracil 600mg/m2 + 5DW 1000ml MIV over 22hr~Every 2 weeks~FOLFILI REGIMEN~D1 Irinotecan 150mg/m2 + 5DW 500ml MIV over 120min D1,D2 Leucovorin 50mg IV Push D1,D2 5-Fluorouracil 400mg/m2 IV Push D1,D2 5-Fluorouracil 600mg/m2 + 5DW 1000ml MIV over 22hr~Every 2 weeks"
223789909|NCT01138904|DRUG|oxaliplatin, irinotecan|"FOLFOX REGIMEN~D1 Oxaliplatin 85mg/m2 + 5DW 500ml MIV over 120min D1,D2 Leucovorin 50mg IV Push D1,D2 5-Fluorouracil 400mg/m2 IV Push D1,D2 5-Fluorouracil 600mg/m2 + 5DW 1000ml MIV over 22hr~Every 2 weeks~FOLFILI REGIMEN~D1 Irinotecan 150mg/m2 + 5DW 500ml MIV over 120min D1,D2 Leucovorin 50mg IV Push D1,D2 5-Fluorouracil 400mg/m2 IV Push D1,D2 5-Fluorouracil 600mg/m2 + 5DW 1000ml MIV over 22hr~Every 2 weeks"
223789910|NCT03669848|OTHER|Pulse CO-oximetry|Measuring blood Carbon Monoxide levels with Pulse CO-oximetry (SpCO)
223789911|NCT00907673|DEVICE|Automatic Fluid Shunt System|Fully implantable peritoneal catheter, bladder catheter, and pump
223789912|NCT00413153|DRUG|atazanavir/ritonavir|atazanavir 300mg + ritonavir 100mg once daily
223789913|NCT00413153|DRUG|lopinavir/ritonavir|patient remains on their pre-study dose of lopinavir/ritonavir
223789914|NCT01535404|DEVICE|Implantation procedure for a St-Jude Medical pacemaker system with right ventricular apex pacing|Implantation procedure for a St-Jude Medical pacemaker system with a transvenous ventricular and if applicable a right atrial lead
223789915|NCT01535404|DEVICE|Implantation procedure for a St-Jude Medical pacemaker system with left ventricular apex pacing|Implantation procedure for a St-Jude Medical pacemaker system with a transvenous left ventricular (coronary sinus) and if applicable a right atrial lead
223789916|NCT04013815|PROCEDURE|erector spinae plane block with ropivacaine|The block is performed immediately before surgery. by an ultrasound guide, with the probe positioned longitudinally, the spinous process of T5 is identified. A peripheral block needle is inserted in the cephalo-caudal direction (caliber 21G and length 10 cm) and 3 ml of physiological solution are injected to confirm the injection site: fascial plane between the erector spinae muscle and the large rhomboid, near the tip of the transverse process of T5. Once the correct position of the needle tip has been confirmed, ropivacaine 0.75% 20 ml is injected.
223789917|NCT04013815|PROCEDURE|Intercostal nerve block with ropivacaine|The intercostal nerve block will be performed by the surgeon at the time of thoracotomy from the 4th to the 8th intercostal space, by injecting 20 ml of 0.75% ropivacaine (4 ml for each space). The injection is performed at about 2-3 cm from the spine.
223789918|NCT04333394|DIETARY_SUPPLEMENT|Probiotic|The probiotic capsules will be administrated once a day. medication with Ritalin starts at the onset of the study in a dose-dependent manner and simultaneous with probiotic supplementation.
223789919|NCT04333394|OTHER|Placebo|The placebo capsules will be administered once a day. medication with Ritalin starts at the onset of the study in a dose-dependent manner and simultaneous with placebo supplementation.
223789920|NCT03204279|DRUG|Netupitant|Netupitant 1.33 mg/kg oral suspension up to a maximum of 100 mg
223789921|NCT03204279|DRUG|Palonosetron|Palonosetron 20 μg/kg solution for oral use up to a maximum of 1.5 mg
223789922|NCT03204279|DRUG|Netupitant|Netupitant 4 mg/kg oral suspension up to a maximum of 300 mg
223789923|NCT03204279|DRUG|Palonosetron|Palonosetron 20 μg/kg solution for oral use up to a maximum of 1.5 mg
223789924|NCT01334801|PROCEDURE|Blood Draw|"Two tubes of blood (about five tablespoons) will be drawn for research purposes, and these will be analyzed for the following tests:~1. BNP (Brain Natriuretic Peptide)~2. (PFA) Platelet Function Analyzer 100~3. von Willebrand Factor (vWF) antigen~4. (vWF) multimers~5. (vWF) \*activity by latex aggregation~6. Plasma stored for development of new testing approaches"
223789925|NCT03898206|OTHER|Breaking up sitting with walking breaks|See Breaking up sitting with walking breaks arm description
223789926|NCT03898206|OTHER|Prolonged sitting|See Prolonged sitting arm description
223789927|NCT06411457|DRUG|SHR-A1811+Adebrelimab|Assess the efficacy and safety of the SHR-A1811 in combination with Adebrelimab regimen in HER2 low-expressing metastatic breast cancer SHR-A1811 : 6.4mg/kg , q3w，d1, ivgtt Adebrelimab : 1200mg, q3w，d1, ivgtt
223789928|NCT01089972|DEVICE|22 gauge catheter|radial artery cannulation using 22 gauge catheter
223789929|NCT01089972|DEVICE|20 gauge catheter|radial artery cannulation using 20 gauge catheter
223789930|NCT04639453|DIAGNOSTIC_TEST|Trunk strength with hand-held dynamometer|MicroFET 2 Handheld Dynamometer is a force evaluation testing device to evaluate the strength of various trunk muscle groups in flexion, extension, and lateral (N).
223789931|NCT04639453|DIAGNOSTIC_TEST|Balance Assessment in Sitting and Standing test (BASS)|"The BASS is a test to assess static and dynamic sitting and standing balance, which has been validated for post-stroke hemiparetic patients. Each test is evaluated by a score from 0 (patient needs external support) to 4 (stable without external help) for static condition and from 0 (no possibility to pick up objects) to 3 (objects picked up without external help) for dynamic condition. The maximal score (sitting, standing, static and dynamic) is 14 points."
223789932|NCT04639453|DIAGNOSTIC_TEST|Timed Up and Go test|The participant sits on a chair, gets up, walks 3m, makes a half turn in 1m2, walks 3m and comes back to sit on the chair. The time (s) to complete the task is measured.
223789933|NCT04639453|DIAGNOSTIC_TEST|Modified Functional Reach Test (MFRT)|The MFRT is a dynamic seated balance test that measures the trunk's ability to move forward, to the paretic and non paretic side (cm).
223789934|NCT04639453|DIAGNOSTIC_TEST|Joint Position sense test (trunk)|The joint positional sense test of the trunk consists in evaluating the positional error of the trunk in the sagittal plane (mm) and in the frontal plane (mm) during a trunk flexion posture (target position).
223789935|NCT04639453|DIAGNOSTIC_TEST|Unstable sitting in a seesaw|This test evaluates the balance capacities of the subject in an unstable sitting position on a seesaw (mediolateral or anteroposterior instability) with forceplate and phone application using center of pressure variables: total displacement (mm), area (mm2), deltas (mm), mean velocity (mm/s) et maximal velocity (mm/s).
223789936|NCT04758312|BEHAVIORAL|MY-Skills Mobile|Yoga and Self-Management Education
223789937|NCT02978027|BEHAVIORAL|Brief Advice|
223789938|NCT02978027|BEHAVIORAL|NIAAA Clinician's Guide|
223789939|NCT02978027|BEHAVIORAL|Motivational Interviewing (MI)|
223789940|NCT02811562|DEVICE|manikin|
223789941|NCT02811562|DEVICE|fiberoptic bronchoscope|
223789942|NCT02811562|DEVICE|pentax-airwayscope|
223789943|NCT03620344|OTHER|ADH-Me Book and ADHD Informational Brochure|"Understanding ADHD information brochure published by American Academy of Pediatrics and a children's book about ADHD condition"
223789944|NCT03620344|OTHER|ADHD Informational Brochure Only|"Understanding ADHD information brochure published by American Academy of Pediatrics"
223789945|NCT03222518|DRUG|Paracetamol|21 pills of Paracetamol 1000mg are provided with a preconised dose of 1 pill 3 times per day over 7 days period
223789946|NCT03222518|DRUG|NSAID|14 pills of piroxicam 20 mg are provided with a preconised dose of 1 pill 2times per day over 7 days period
223789947|NCT03222518|DRUG|paracetamol-NSAID|21 identical pills of paracetamol ith a preconised dose of 1 pill 3 times per day over 7 days period+14 pills of piroxicam 20 mg are provided with a preconised dose of 1 pill 2times per day over 7 days period
223789948|NCT06019312|DIETARY_SUPPLEMENT|Sanprobi IBS®|Patients will be treated with probiotics in combination with inulin, which is able to stimulate the growing of probiotic bacteria in gastrointestinal tract.
223789949|NCT05974527|DRUG|Sublingual film containing dexmedetomidine (BXCL501)|Enrolled participants will receive an initial dose of BXCL501 180mcg. Following the FDA dosing suggestions, participants with mild or moderate hepatic impairment (Child-Pugh Class A or B) will receive a reduced initial dose of 120mcg and participants with severe hepatic impairment (Child-Pugh Class C) will receive a reduced initial dose of 90mcg. Geriatric patients (≥ 65 years old) will receive a reduced initial dose of 120mcg.
223789950|NCT03769142|PROCEDURE|All monitoring|All monitoring (TCD, BIS, NIRS) are collected from the healthy side, contralateral to the interventional side
223789951|NCT05373251|DIAGNOSTIC_TEST|Whole genomic DNA/RNA tumour sequencing|"All participants will undergo pre-radiotherapy fresh core biopsies of the tumour. DNA libraries will be created and stored for future analysis.~Participants with recurrence will have biopsy and subsequently will undergo rapid sequencing of RNA and DNA followed by bioinformatic analysis to identify somatic mutations or other abnormalities that might be drivers of an individual's cancer or predict response to therapies. These data will be compared to the literature and to a comprehensive database of drugs with the aim of identifying drugs most likely to target individual tumors based on the presence of mutated or abnormally expressed genes in the tumor. Any palliative systemic therapy treatment would be closely monitored for tolerability and response, as part of the general clinical care of someone on systemic therapy. The choice of systemic therapy will be up to the treating medical oncologist and the patient."
223789952|NCT02742948|DRUG|ceftriaxone|IV ceftriaxone (2g) will be given to all participants
223789953|NCT02322957|DRUG|FV-100|Subjects will be randomized to one of two treatment sequences: AB or BA.
223789954|NCT00124904|BEHAVIORAL|Biofeedback|
223789955|NCT00124904|BEHAVIORAL|Kegel exercises|
223789956|NCT04969250|BIOLOGICAL|Moderna mRNA-1273 COVID-19 vaccine|100 µg intramuscular injection
223789957|NCT04969250|BIOLOGICAL|Pfizer BNT162b2 COVID-19 vaccine|30 µg intramuscular injection
223789958|NCT06264050|DIAGNOSTIC_TEST|evalutaion scales|four scales will be administered to whom attend a psychological support group: BDI II (depression); Stai Y2 (trait anxiety); Cope NVI 25 (coping strategies) and Core OM (psychological state)
223789959|NCT00142493|DRUG|Propofol|1.2ug/ml
223789960|NCT00142493|DRUG|Thiopental Sodium|2.0ug/ml
223789961|NCT00142493|DRUG|Dexmedetomidine Hydrochloride|0.5ng/ml
223789962|NCT00142493|DRUG|Midazolam Hydrochloride|60ng/ml
223789963|NCT00142493|DRUG|placebo|intralipid, saline, saline with multi-Vit solution
223789964|NCT00251953|DRUG|Tesaglitazar|
223789965|NCT00251953|DRUG|Metformin|
223789966|NCT03299608|DIAGNOSTIC_TEST|Breath analysis|Spectrometric analysis of exhaled breath as screening for opportunistic respiratory infections
223789967|NCT02969889|DEVICE|Airtraq|video laryngoscope with a channel
223789968|NCT02969889|DEVICE|ILMA|
223789969|NCT04003116|DRUG|Oxygen gas|Supplementary oxygen during the first 48 hours added to conventional anticoagulant treatment. Patients will receive anticoagulant treatment according to updated guidelines.
223789970|NCT03942250|BIOLOGICAL|REGE pro dressing|REGE pro is a dressing of dried human amniotic membrane sterilized by gamma radiation
223789971|NCT03919383|DRUG|Lenvatinib|12 mg (or 8 mg) once daily (QD) oral dosing
223789972|NCT03919383|DRUG|Toripalimab|240mg intravenously every 3 weeks
223789973|NCT02499874|DRUG|Efavirenz|oral Efavirenz 400mg
223789974|NCT02499874|DRUG|tenofovir /emtricitabine|tenofovir 245 mg/emtricitabine 200mg
223789975|NCT02499874|DRUG|tenofovir/lamivudine|tenofovir 245mg/lamivudine 300mg
223789976|NCT02499874|DRUG|lamivudine/zidovudine|lamivudine 300mg/zidovudine 600mg
223789977|NCT02202226|DRUG|Lu AF35700|
223789978|NCT02202226|DRUG|Placebo|
223789979|NCT02211716|DEVICE|BeGraft Peripheral Stent Graft System|
223789980|NCT02854774|BEHAVIORAL|Muscle activation exercises|Activation of either muscles activating the knee or hip.
223789981|NCT02739581|PROCEDURE|Endoscopic Variceal Ligation|
223789982|NCT02739581|DRUG|Non selective beta blocker|
223789983|NCT02739581|OTHER|Placebo|
223789984|NCT04611503|DRUG|subretinal injection of rAAV.hPDE6A|"The first 3 patients (C1) will receive the intermediate dose 1x1010 vg. After injection of the 3rd patient of C1, the DMC will give a go/no go decision. If 'nogo', a lower dose (5x109 vg) will be given to the next group of 3 patients (C2). The DMC will give a go/no go decision. In case of a go decision, 3 further patients (C3) will be treated with the same dose. In the case of a no-go decision, the next dose will be the minimal dose 1x109 vg. In case of a 'go' decision of the DMC after the third patient, the next 3 patients will receive a subretinal injection of vector at the highest dose 5x1010 vg. The DMC will give a go/no go decision after review of all safety data available at D30 of cohort 2. If safety data is considered favourably by the DMC, then 3further patients (cohort 3) will be treated with the same dose (5x1010 vg). Should any safety concerns arise, the last three patients (cohort 3) will receive the intermediate dose (1x1010 vg)."
223789985|NCT02278328|DRUG|STX209 (15mg)|"A randomized acute dose-response design will be employed with a total study duration of 3 weeks. At each visit, baseline MEG will be obtained followed by acute single-dose drug/placebo administration, followed 60 minutes later by repeat MEG. Each participant will receive a single dose of placebo in random order and a single dose of STX209 from smallest to largest (15mg, and 30mg). MRI and MRS will be performed immediately following MEG to provide an anatomic basis for source localization as well as to assess acute effects of STX209 administration on MRS estimates of GABA and glutamate. The STX209 (15mg) intervention is the low dose"
223703962|NCT06681792|BEHAVIORAL|Climate Change Workshops Based on Protection Motivation Theory|"The experimental group will take part in seven weekly workshops. One workshop will last 40 minutes.The workshop to be applied to the experimental group will take place every week and will last 40 minutes. The workshops, which are based on the Protection Motivation Theory, consist of topics such as the balance of nature, climate change, carbon and ecological footprints, reducing the effects of climate change and adaptation workshop, acquiring environmentally friendly behaviour, recycling and the Green School Programme for sustainable environmental education.~The workshops include interactive applications such as students expressing their thoughts on the weekly themes, games, brainstorming, word cloud, planting trees, painting cloth bags, watching videos, making presentations on the themes. Motivation Theory, consist of topics such as the balance of nature, climate change, carbon and ecological footprints, reducing the effects of climate change and adaptation workshop, acquiring enviro"
223789986|NCT02278328|DRUG|placebo|A randomized acute dose-response design will be employed with a total study duration of 3 weeks. At each visit, baseline MEG will be obtained followed by acute single-dose drug/placebo administration, followed 60 minutes later by repeat MEG. Each participant will receive a single dose of placebo in random order and a single dose of STX209 from smallest to largest (15mg, and 30mg). MRI and MRS will be performed immediately following MEG to provide an anatomic basis for source localization as well as to assess acute effects of STX209 administration on MRS estimates of GABA and glutamate. The placebo intervention is the non-active placebo control dose
223789987|NCT02278328|DRUG|STX209 (30mg)|"A randomized acute dose-response design will be employed with a total study duration of 3 weeks. At each visit, baseline MEG will be obtained followed by acute single-dose drug/placebo administration, followed 60 minutes later by repeat MEG. Each participant will receive a single dose of placebo in random order and a single dose of STX209 from smallest to largest (15mg, and 30mg). MRI and MRS will be performed immediately following MEG to provide an anatomic basis for source localization as well as to assess acute effects of STX209 administration on MRS estimates of GABA and glutamate. The STX209 (30mg) intervention is the high dose"
223789988|NCT04931927|BEHAVIORAL|Making Connections Intervention-Telehealth (MCI-T)|Single session telehealth engagement intervention plus telehealth treatment as usual (TAU) \[MCI-T +TAU\]
223789989|NCT04931927|BEHAVIORAL|Treatment as usual (TAU)|Telehealth treatment as usual without the single session telehealth engagement intervention
223789990|NCT01347333|RADIATION|Stereotactic body radiosurgery|36-60 Gy / 3 fractions (12-20 Gy per fraction) OR 45-50 Gy / 5 fractions (9-10 Gy per fraction)
223789991|NCT01347333|RADIATION|Stereotactic Body Radiotherapy|26-30 Gy / 1 fraction OR 36-45 Gy / 3 fractions (12-15 Gy per fraction) OR 40-50 Gy / 5 fractions (8-10 Gy per fraction)
223789992|NCT04817553|OTHER|exposure to COVID19|Observational study of IgG4 patients with pancreatobiliary involvement who were diagnosed with COVID19
223789993|NCT06423833|DIAGNOSTIC_TEST|Trendelenburg maneuver (TM)|The investigator will measure changes in velocity time integral (VTI) and stroke volume (SV) during Trendelenburg maneuver (TM) in high-risk surgical patients by trans-thoracic Doppler echo cardiography.
223789994|NCT06423833|DIAGNOSTIC_TEST|Passive leg raising test|The investigator will measure changes in velocity time integral (VTI) and stroke volume (SV) during Passive leg raising (PLR) test in high-risk surgical patients by trans-thoracic Doppler echo cardiography.
223789995|NCT01097538|OTHER|Body-weight supported treadmill training|Patients will undergo training using the Woodway Loco-system which consists of a treadmill with an overhead pulley system connected to a support harness. BWSTT allows patients with limited mobility to safely walk upright on a treadmill with a portion of their body weight counter balanced. Three trainers will be required to assist with the BWSTT program. Two trainers will be positioned at the lower limbs to manually guide the participant through a proper gait motion and provided lower limb control. A third trainer will stand behind the participant to provide trunk support and assist with weight shifting.
223789996|NCT01097538|OTHER|Total body recumbent stepper training|Patients will train using the Nustep T4 (TRS 4000) which is a recumbent cross trainer that provides a full body workout in a seated position. The Nustep trainer allows patients to achieve a natural stepping motion against graded loads with bilateral reciprocal movement of the arms. Recumbent training is safe and easily accessible for patients of all ability levels with a swivel chair to aid in patient transfers. Foot straps, leg stabilizers and hand stabilizers may be used for added control and proper body alignment.
223789997|NCT03834779|BEHAVIORAL|DOORS-CHW Intervention|"The behavioral intervention has been developed for a collaborative CHW and re-entry program intervention that targets HIV outcomes, substance use and recidivism in HIV+ jail releasees.~Participants will be randomized to the DOORS+CHW intervention versus TAU and all participants will undergo study follow-up visits at 3, 6 and 12 months. In other words, participants randomized to the intervention arm will meet with the CHW and a staff member from DOORS. One of the primary study aims is a randomized controlled trial of an intervention which has a reasonable probability of improving the health and well-being of the subject by improving linkage to social services and the HIV clinic. The control arm will receive standard of care (referrals to case management)."
223789998|NCT02071173|DEVICE|ACUITY X4 quadripolar coronary venous lead and RELIANCE 4-FRONT defibrillation lead|"The ACUITY X4 leads are intended for chronic left ventricular pacing and sensing. The leads have 3 tip configuration designs (straight tip, short tip spiral, and long tip spiral), which is intended to provide choices for patients with different anatomies.~The RELIANCE 4-FRONT leads are designed for right-side heart applications within the ventricle, atrium, and superior vena cava. It is intended for permanent sensing, pacing, and defibrillation when used with a compatible implantable cardioverter defibrillator (ICD) or cardiac resynchronization therapy defibrillator (CRT-D).~Subjects were allowed to receive both the ACUITY X4 and RELIANCE 4-FRONT lead."
223789999|NCT02500992|PROCEDURE|Transrectal sigmoidectomy|
223790000|NCT01292928|DEVICE|Stent implantation|Stent implantation during the index procedure.
223790001|NCT04118348|BEHAVIORAL|Best Practice Alert|An Epic screen pops up for a provider during an eligible 9-11 year-old patient's visit. A prompt requires that the provider respond, either confirming the prescription of a lipid panel or opting out with an acknowledgment/reason for declining the test.
223790002|NCT04118348|BEHAVIORAL|Health Maintenance Topic|An Epic health maintenance topic appears for a provider during an eligible 9-11 year-old patient's visit. The HMT will be highlighted for enhanced visibility, until or unless action is taken.
223790003|NCT04501315|DIAGNOSTIC_TEST|Blood, cerebrospinal fluid and urine samples|In all subjects, blood (4 mL), cerebrospinal fluid (4mL) and urine (4mL) samples were collected daily as part of the clinical routine at 6:00 AM.
223790004|NCT01708850|DRUG|Rivaroxaban|All specified in arm description. One arm study.
223790005|NCT02833168|OTHER|patient-filled questionnaires|All patients answer selected questionnaires on sleep-related symptoms, sleep quality, daytime performance, and health-related quality of life.
223790006|NCT02833168|DEVICE|spiromanometry|Measurement of forced vital capacity, maximum inspiratory pressure and maximum expiratory pressure
223790007|NCT03979573|DIAGNOSTIC_TEST|Multiparametric MRI|Multiparametric prostate MRI (mp-MRI)
223790008|NCT03979573|DIAGNOSTIC_TEST|Radiomics|Radiomics analyses will consist of image intensity normalization, image coregistration and resampling, radiomic feature extraction, combination with clinical and molecular parameters, feature extraction and machine learning, model testing on validation and test cohorts and comparison to existing clinical risk models.
223790009|NCT03979573|DIAGNOSTIC_TEST|MR-guided Biopsy|MR-guided targeted prostate biopsies as well as systematic TRUS-guided biopsies (at least 12 cores) will be performed on a fusion-guided biopsy system. The biopsy cores can either be obtained transrectal or transperineal.
223703963|NCT06680843|PROCEDURE|Whole blood collection|30 mL at Day 0 with optional visits for up to 2 additional whole blood collections at least 30 days apart
223703964|NCT06702007|BEHAVIORAL|eHaRT-A|Adaptation of the Harm Reduction Treatment for Alcohol (HaRT-A) into a digital telehealth platform facilitating harm reduction treatment via patient-provider video sessions (eHaRT-A). eHaRT-A will include the three treatment components from the efficacious HaRT-A. eHaRT-A will be delivered during one-on-one sessions through video conferencing with interactive features (i.e., personalized feedback tracked over time and screen sharing).
223703965|NCT04508335|DEVICE|Reia Vaginal Pessary|Reia Vaginal Pessary
223703966|NCT06703697|OTHER|eDrugSafe|The eDrugSafe mobile web platform enables management of medication history and provides electronic access to medicinal product information (ePI). QR codes are separately provided for prescription records to facilitate direct access to ePI.
223703967|NCT06703385|OTHER|Instrument Assisted soft tissue mobilization|The blade is a surgical instrument for soft tissue mobilization, made of 100% surgical stainless steel with 8 treatment planes and 2 treatment edges. It is used to locate muscle limitations and apply gentle strokes along the affected muscle, detecting changes in soft tissue consistency. The procedure is repeated three times a week for four weeks.
223703968|NCT06703385|OTHER|Suboccipital release|The patient will lie in a relaxed supine position, with a therapist sitting on a chair. The therapist will apply pressure to the C2 area, holding it until a melting sensation is felt. The intervention time is 4 minutes. The patient will close both eyes during the Suboccipital release procedure to prevent eye movements affecting muscle tone. Interventions will be three times a week for four weeks.
223703969|NCT06703385|OTHER|conventional physical therapy program|The patient is placed in a sitting position and a hot pack is applied to the back of the neck for 15 minutes. The therapist then performs active range of motion exercises for neck flexion, extension, rotation, and lateral flexion without resistance. They also perform stretching exercises for upper Trapezius muscle and suboccipital muscle. Strengthening exercises for neck muscles are performed through isometric exercises, such as side pending to right, side pending to left, extension, and flexion. The interventions are conducted three times, peer-wise, for four weeks. The treatment aims to improve neck flexibility and overall well-being.
223703970|NCT06708481|DRUG|P11-4, a self-assembling peptide|rationally designed peptide, the monomers of which self-assemble into a biocompatible fibrillar scaffold that mimics the enamel matrix in response to particular environmental cues
223703971|NCT06708481|DRUG|P11-4, a self-assembling peptide with flouride|self assembling peptide with 500 ppm sodium fluoride
223703972|NCT06708481|DRUG|resin infilteration|Improvement of white spot lesions appearance by infiltration occurs due to a change in the refractive index since the refractive index of enamel (1.62-1.65) is different than that of air (1.00). Infiltration of the lesions with an infiltrate that has a refractive index of 1.52 is able to mask the lesion
223703973|NCT06706804|BEHAVIORAL|Wipe Bathing|In groups of 2-3 pregnant women in this group, the researcher will explain the stages of newborn wiping bath application on the newborn model, and then the pregnant women will individually apply the bath on the model. The trainings will be held in the pregnant school at the appropriate times, or in an empty room determined by the hospital administration if there is another planned training in the pregnant school. In the wiping bath training, women will be provided to perform the procedure on the model appropriate to the gender of their babies for genital area cleaning based on the gender of newborns. After the training, pregnant women will be given a home follow-up form to record the first bath time of their babies after birth, the umbilical cord fall time and the body temperature of their babies (before bathing, immediately after bathing and 10 minutes after bathing) and will be told how to fill it out.
223703974|NCT06710392|DIETARY_SUPPLEMENT|Enzyme Cocktail A|Enzyme cocktail A in the form of a capsule with a daily dose of 275mg taken 3 times a day for 4 weeks.
223703975|NCT06710392|DIETARY_SUPPLEMENT|Enzyme Cocktail B|Enzyme cocktail B in the form of a capsule with a daily dose of 50mg taken 3 times a day for 4 weeks.
223703976|NCT06710392|DIETARY_SUPPLEMENT|Placebo A|Placebo A matching investigational product A given 3 times a day for 4 weeks.
223703977|NCT06710392|DIETARY_SUPPLEMENT|Placebo B|Placebo B matching investigational product B given 3 times a day for 4 weeks.
223790010|NCT03979573|DIAGNOSTIC_TEST|Molecular Markers|Molecular markers will be analyzed on the initial and final targeted and systematic biopsy cores. The molecular panel consists of a methylation-specific PCR and a set of highly selected markers that can be detected by immunohistochemistry. The resulting data will be prospectively recorded to enable a retrospective analysis of the prognostic value.
223790011|NCT00847262|DRUG|Temisartan|Temisartan, initial dose: 40 mg per day, Max dose: 160 mg per day
223790012|NCT00847262|DRUG|Amlodipine|Amlodipine, initial dose: 5 mg per day, Max dose: 10 mg per day
223790013|NCT00925613|DEVICE|LMA Proseal|"Once surgery is completed, the patient is transferred onto a gurney. Train of four is checked. Patient is ventilated with 100% oxygen. Remifentanil 0.5 ug/ml IV is administered. 30 seconds to 1 minute later, secretions are suctioned. Depth of anesthesia is ensured by deflating, inflating, then deflating the tracheal balloon of the DLT and checking for absence of movement, swallowing, or coughing. The DLT is removed, then the LMA proseal is inserted. Respiratory and hemodynamics parameters are noted. Tolerance of the exchange (presence of cough, movement, laryngospasm, desaturation) is noted. Inhalational gas is stopped. Reversal agent is administered if appropriate. Spontaneous breathing is titrated for \<12 with boluses of fentanyl 25ug or sufentanil 2.5ug q 5mins.~If failure to insert Proseal occurs, a second attempt is made after deepening anesthesia with propofol 1mg/kg and remifentanil 0.5ug/kg IV. If failure occurs again, the patient is intubated with a tracheal tube."
223790014|NCT00925613|DEVICE|Tracheal tube|Once surgery is completed, the patient is transferred onto a gurney. Train of four is checked. Patient is ventilated with 100% oxygen. Remifentanil 0.5 ug/ml IV is administered. 30 seconds to 1 minute later, secretions are suctioned. Depth of anesthesia is ensured by deflating, inflating, then deflating the tracheal balloon of the DLT and checking for absence of movement, swallowing, or coughing. The DLT is removed, then a tracheal tube (size 7 for women, size 8 for men) is inserted. Respiratory and hemodynamics parameters are noted. Tolerance of the exchange (presence of cough, movement, laryngospasm, desaturation) is noted. Inhalational gas is stopped. Reversal agent is administered if appropriate. Spontaneous breathing is titrated for \<12 with boluses of fentanyl 25ug or sufentanil 2.5ug q 5mins.
223790015|NCT02779153|DRUG|Acthar low dose (40 U)|The 40U group will administer 0.5 mL of study medication once a day. Patients will taper study medication during Week 2 through the remainder of the study and will administer 0.5 mL of study medication twice a week. The stable Acthar regimen should be maintained for the remainder of the study. However, dose adjustments may be implemented if needed based on safety.
223790016|NCT02779153|DRUG|Acthar high dose (80 U)|The 80U group will administer 1.0 mL of study medication every day. If a patient meets dose reduction criteria, their assigned volume will be adjusted from 1.0 mL to 0.5 mL. Patients will taper study medication during Week 2 through the remainder of the study. However, dose adjustments may be implemented if needed based on safety.
223790017|NCT00130533|DRUG|Capecitabine|
223790018|NCT03691467|DEVICE|immediate dental implant|immediate dental implant placement in freshly extracted socket.
223790019|NCT03691467|DRUG|Hyaluronic Acid|topical application of hyaluronic acid
223790020|NCT00289354|DRUG|Chromium Picolinate (600 mcg Cr) + biotin (2 mg)|
223790021|NCT02952352|BEHAVIORAL|Diabetes Prevention Program|Culturally adapted diabetes prevention program
223790022|NCT01059565|DRUG|AZLI|Aztreonam for inhalation solution (AZLI; 75 mg aztreonam/52.5 mg lysine monohydrate) was administered three times a day, with at least 4 hours between doses, using the investigational nebulizer.
223790023|NCT01059565|DRUG|Placebo|Placebo to match AZLI (lactose and sodium chloride) was administered three times a day, with at least 4 hours between doses, using the investigational nebulizer.
223790024|NCT06336668|DIETARY_SUPPLEMENT|Human milk-based HMF|The study subject will be fed human milk fortified with a human-milk-based HMF.
223790025|NCT00574587|DRUG|Vorinostat|Vorinostat 200 or 300 mg PO BID on days 1-3 of each weekly paclitaxel dose
223790026|NCT00574587|DRUG|Paclitaxel|Paclitaxel 80 mg/m2 weekly for 12 weeks
223790027|NCT00574587|DRUG|Trastuzumab|Trastuzumab (if HER2-positive) 4 mg/kg, then 2 mg/kg weekly for 12 weeks including loading dose
223790028|NCT00574587|DRUG|Doxorubicin|Doxorubicin 60 mg/m2 every 2 weeks for 8 weeks
223790029|NCT00574587|DRUG|Cyclophosphamide|Cyclophosphamide 600 mg/m2 every 2 weeks for 8 weeks
223790030|NCT00574587|PROCEDURE|Surgery|Surgical excision of tumor from breast
223790031|NCT00944138|BEHAVIORAL|Relaxation methods|Relaxation methods will include mindful meditation techniques for the intervention and listening to music for the control arm
223790032|NCT01602887|DRUG|PD-0332991|isethionate hard capsule, 125 mg, single dose
223790033|NCT01602887|DRUG|PD-0332991|"freebase hard capsule with a small particle size, 125 mg, single dose"
223790034|NCT01602887|DRUG|PD-0332991|"freebase hard capsule with a large particle size, 125 mg, single dose"
223790035|NCT01602887|DRUG|PD-0332991|oral solution, 50 mg, single dose
223790036|NCT00722891|DEVICE|Purevision Lenses with ReNu Multiplus|Purevision lenses using ReNu Multiplus lens solution for 28 days
223790037|NCT00722891|DEVICE|Purevision Lenses with Optifree RepleniSH|Purevision lenses using Optifree RepleniSH lens solution for 28 days
223790038|NCT03973619|PROCEDURE|Labial Graft|As replacement of the damaged urethral tissue, we used a buccal mucosa graft (labial graft).
223790039|NCT03973619|PROCEDURE|Jugal Graft|As replacement of the damaged urethral tissue, we used a buccal mucosa graft(inner cheek - jugal graft).
223790040|NCT00403832|DEVICE|intraocular lenses: Two foldable, acrylic, sharp edged IOLs: AcrySof™ (AcrySof SA60AT, Alcon), and Akreos adapt™ (Bausch & Lomb)|
223790041|NCT02139033|DRUG|Retaine™|
223790042|NCT02941302|PROCEDURE|Detecting of Biological Borders of Gliomas|Neural navigation combined with Intraoperative ultrasound detecting the borders of gliomas, In accordance with established plan to collect multiple targets undergo pathological examination and contrast with imaging boundary to determine the biological boundaries.
223790043|NCT03952832|DRUG|Leflunomide|Given PO
223790044|NCT03952832|OTHER|Quality-of-Life Assessment|Ancillary studies
223790045|NCT03952832|OTHER|Questionnaire Administration|Ancillary studies
223790046|NCT00568529|DRUG|Capecitabine and Oxaliplatin|Capecitabine 1000mg/m2 Bid d1-14 Oxaliplatin 130mg/m2 d1 q3w
223790047|NCT02105363|OTHER|measure of skin movement on surface of the back|
223790048|NCT02105363|OTHER|Measurement of skin movement on surface of back|
223790049|NCT03263429|DRUG|Glutaminase Inhibitor CB-839|Given by mouth
223790050|NCT03263429|BIOLOGICAL|Panitumumab|Given by vein
223790051|NCT03263429|DRUG|Irinotecan Hydrochloride (phase I only)|Given by vein
223790052|NCT03263429|OTHER|Laboratory Biomarker Analysis|Correlative studies
223790053|NCT03263429|OTHER|Pharmacological Study|Correlative studies
223790054|NCT03263429|DEVICE|Imaging with 11C-Glutamine PET/CT scans and 18F-FSPG PET/CT scans|During phase II at baseline and day 28 of cycle 1
223790055|NCT00001048|DRUG|Filgrastim|
223790056|NCT00001048|DRUG|Cytarabine|
223790057|NCT00001048|DRUG|Zidovudine|
223790058|NCT00001048|DRUG|Zalcitabine|
223790059|NCT00001048|DRUG|Didanosine|
223790060|NCT00698490|BIOLOGICAL|Adjuvanted herpes simplex (gD) candidate vaccine GSK 208141|Intramuscular injection, 3 doses, 2 different formulations
223790061|NCT00698490|BIOLOGICAL|Herpes simplex virus containing gD-Alum|Intramuscular injection, 3 doses
223790062|NCT01605617|DRUG|Fesoterodine fumarate|PTNS + 4mg of fesoterodine fumarate for 12 weeks
223790063|NCT01605617|DRUG|Placebo|PTNS + placebo for 12 weeks
223790064|NCT01605617|PROCEDURE|Percutaneous Tibial Nerve Stimulation (PTNS)|PTNS is an FDA-approved procedure for the diagnosis of overactive bladder, given on a weekly basis. Participants will be given PTNS + either 4mg of fesoterodine fumarate or placebo for 12 weeks, and followed by 4 weeks of washout followed by 12 weeks of PTNS + the opposite treatment (placebo or fesoterodine fumarate).
223790065|NCT04868266|OTHER|end tidal carbon dioxide monitoring|We will monitor end tidal carbon dioxide with capnography during minimal sedation
223790066|NCT02234531|DEVICE|EVER TEACHER|"The treatment will be performed in a darkened room, to avoid distraction provided by environmental stimuli. The patients will be seat on a standard chair in front of a wall screen handling a sensorized object with plegic hand. In case of grasping deficits the hand's surface will be used as end effector (i.e. sensorized glove worn by the patient). During the treatment a specific feedback called virtual teacher will be displayed. The Reinforced Feedback in Virtual Environment (RFVE) approach consists of performing different motor tasks moving the end effector simultaneously displayed in the virtual scenario. The Virtual Reality Rehabilitation System (VRRS®. Khymeia Group, Noventa Padovana. Italy) will be used as device to provide the artificial environment."
223790067|NCT02234531|DEVICE|NEVER TEACHER|The patients allocated to NEVER TEACHER group, will be treated using the VRRS and the proceedings will be the same as described for experimental group. In this group, the patient will move the real object (e.g. ball) following the trajectory of the corresponding virtual object displayed on the wall screen in accordance with the requested virtual task and without the 'virtual teacher' support.
223790068|NCT02071004|DRUG|DS-1040b|IV of 6 mg given once over 30 minutes
223790069|NCT02071004|DRUG|Aspirin|Dispersible tablet, 300mg \& 75 mg, once daily for 5 days
223790070|NCT02767115|DIETARY_SUPPLEMENT|2% GSE mucoadhesive gel|2% GSE mucoadhesive gel administered in periodontal pockets of GSE group at T0 and 3, 6, and 9 days after T0
223790071|NCT02767115|OTHER|GSE free mucoadhesive gel|GSE free mucoadhesive gel administered in periodontal pockets of Control group at T0 and 3, 6, and 9 days after T0
223790072|NCT00443976|DRUG|Aurora kinase inhibitor AT9283|The starting dose of AT9283 will be 1.5 mg/m2 given as a 24 hour IV infusion on Days 1 and 8 every three weeks.
223790073|NCT03812796|DRUG|Domatinostat|"Domatinostat is an oral tablet which will be given at a variable dose during the Phase IIA safety run in phase of the trial.~During the Phase IIB efficacy phase of the trial patients will be treated with domatinostat at the safe and tolerated combination dose identified during the Phase IIA safety run in phase."
223790074|NCT03812796|DRUG|Avelumab|Avelumab is a monoclonal antibody which is given via an intravenous infusion at a dose of 10mg/kg every two weeks on the first day of a two week cycle. (Day 1 q 14d) from Cycle 2 onwards.
223790075|NCT03902587|DEVICE|Samsung's E-cervix technology|While patients are having their routine cervical ultrasound assessments which requires a 5 minute time period, we will use the built-in software to obtain additional E-cervix measurements to evaluate the consistency of the cervical os. This will be done within the standard 5 minute period which is typically done to observe for dynamic changes. The measurements will be obtained with the same sonogram machine, using updated software.
223790076|NCT01426165|DRUG|Magnesium Sulfate|8 grams over 4 or 8 hours depending on randomization
223790077|NCT06580665|PROCEDURE|Cryoablation|Patients undergo cryoablation.
223790078|NCT06580665|DRUG|Serplulimab|Patients undergo cryoablation. If there are no significant postoperative complications, Serplulimab should be administered immediately. Cycles with Serplulimab repeat every 3 weeks for up to 1 year in the absence of disease progression or unacceptable toxicity.
223790079|NCT01631630|DRUG|Pioglitazone|Pioglitazone is a thiazolidinedione antidiabetic. It works by lowering blood sugar by making the cells of the body more sensitive to the action of insulin.
223790080|NCT01631630|DRUG|Placebo|Placebo is an inactive tablet design to look exactly like pioglitazone
223790081|NCT05080790|DRUG|Dinutuximab Beta, Zoledronic acid, Interleukin-2|Five 5-week cycles (Q5W) of dinutuximab beta, zoledronic acid and low-dose interleukin (IL-2)
223790082|NCT04777019|OTHER|Not applicable as standard of care Colonoscopy|Not applicable since not an intervention
223790083|NCT06636981|DRUG|Cohort2: ATRA+Toripalimab+TPC|Receive 200 mg D1 of Toripalimab via intravenous infusion for a course of 21 days; TPC regimen (monoclonal antibody 10mg/kg D1, 8 intravenous infusions, 1 course of treatment every 21 days; Elibulin 1.4mg/m2 D1, 8 intravenous infusions, 1 course of treatment every 21 days; Utideron 40mg/m2 D1-5 intravenous infusions, 1 course of treatment every 21 days; Gemcitabine 1000mg/m2 D1, 8 intravenous infusions, 1 course of treatment every 21 days; Albumin paclitaxel 100 mg/m2 D1, D8, intravenous infusion, 1 course of treatment every 21 days); Capecitabine 1000mg/m2, D1-14, oral, one course of treatment every 21 days); All trans retinoic acid 20 mg bid, orally, D-3-D11, administered continuously for 14 days, stopped for 7 days, with one course of treatment lasting 21 days.
223790084|NCT06636981|DRUG|Cohort1: ATRA+Toripalimab+chemo|Receive 200 mg of Toripalimab via D1 intravenous infusion, with 21 days as one course of treatment; Albumin paclitaxel 100 mg/m2, D1, D8, intravenous infusion, one course of treatment for 21 days; All trans retinoic acid 20 mg bid, oral, D-3-D11, continuous administration for 14 days, cessation for 7 days, 21 days is one course of treatment.
223790085|NCT06640465|DIETARY_SUPPLEMENT|Ubiquinol + geranylgeraniol|Combination of ubiquinol and geranylgeraniol
223790086|NCT06640465|DIETARY_SUPPLEMENT|Geranylgeraniol|Geranylgeraniol alone
223790087|NCT06640465|DIETARY_SUPPLEMENT|Ubiquinol|Ubiquinol alone
223790088|NCT06640465|DIETARY_SUPPLEMENT|Ubiquinone|Ubiquinone alone
223790089|NCT06640465|OTHER|Placebo|Placebo capsule
223790090|NCT06595888|RADIATION|Computed Tomography|X-ray by Computed Tomography
223790091|NCT06497491|BIOLOGICAL|GNR-086|GNR-086 is administered as a subcutaneous injection at a dose of 4 mg/kg once every 4 weeks for 24 weeks.
223790092|NCT06497491|BIOLOGICAL|Ilaris®|Ilaris® is administered as a subcutaneous injection at a dose of 4 mg/kg once every 4 weeks for 24 weeks.
223790093|NCT06034990|OTHER|10-min online survey|This is a cross-sectional study. The data are collected by a 10-min online survey administered to included physicians which will be distributed via online channels such as such as official website or Facebook pages of Society of intensive care or Society of nephrology of corresponding countries.
223790094|NCT04738643|OTHER|Tobacco Use Treatment Service and Varenicline Management|The VM intervention builds upon the established TUT Service process. In addition to connecting the patient to TUT Service via electronic referral, it activates a medication management protocol that: 1) actively confirms no evidence of renal failure or pregnancy with oncology provider, 2) automates a referral to prescribing providers within the TUT Service team, prompting a call-back to patient within 24 hours, 3) provides written AVS instructions to contact TUT Service for initiation instructions and clinic appointment, and 4) pends a varenicline prescription to the medication list, ready for reconciliation by TUT Service prescribing clinicians. The protocol formalizes standard management principles for varenicline, including follow-up evaluation, pre-quit period duration, and side effect amelioration.
223790095|NCT05584215|BEHAVIORAL|Cognitive Behavioural Therapy for Psychosis Groups|Groups based on cognitive behavioural therapy for psychosis
223790096|NCT05979389|DRUG|Bicalutamide 50 mg|Bicalutamide capsules will be prepared from U.S. Pharmacopeia grade powder at a dose of 50 mg
223790097|NCT05979389|DRUG|Placebo|Matching placebo capsules of the same color, mass, and appearance to the bicalutamide capsules will be filled using microcrystalline cellulose powder.
223790098|NCT05222802|DRUG|ERAS-801|Administered orally
223790099|NCT03759873|BEHAVIORAL|Incentives|Patient earns financial incentives (gift cards) on an escalating schedule for completing cardiac rehabilitation sessions.
223790100|NCT03759873|BEHAVIORAL|Case Management|A case manager is available by phone to assist patient with attending cardiac rehabilitation sessions as well as to provide advice about cardiac symptoms and healthy behavior change.
223790101|NCT06086223|PROCEDURE|ankle arthroscopy with ORIF|we will go for fixation of the fracture with association of scope intervention pre and post fixation
223790102|NCT06086223|PROCEDURE|fracture ankle fixation without ankle arthroscopy|we will go for fixation of the fracture alone with no scope intervention
223790103|NCT06195917|DEVICE|Robotic-assisted Interventional Percutaneous transhepatic puncture|Robotic-assisted Interventional Percutaneous transhepatic puncture
223790104|NCT02676479|DEVICE|Uterine Lavage Group|"The PI places the Lavage Catheter per instructions for use~* Use of a tenaculum or cervical stitch is required~* Use of saline to wash the cervix is required~* Use of abdominal ultrasound guidance with a full bladder is required The PI records if there was clinically significant fluid loss through the cervix."
223790105|NCT05362903|OTHER|Inclisiran|Prospective observational cohort study. There is no treatment allocation. Patients administered Inclisiran by prescription will be enrolled.
223790106|NCT03579563|OTHER|AUD fitting|Prescription hearing aids will be fitted by audiologists using established procedures.
223790107|NCT03579563|OTHER|OTC+ fitting|Audiology professionals provide brief services to fit preset-based OTC hearing aids, which are simulated using prescription hearing aids.
223790108|NCT03579563|OTHER|OTC fitting|In this group, preset-based OTC hearing aids, which are simulated using prescription hearing aids, will be provided to subjects. Subjects will take the full initiative and responsibility for learning and using hearing aids.
223790109|NCT03579563|DEVICE|High-end HA|High-end hearing aids will be used.
223790110|NCT03579563|DEVICE|Low-end HA|Low-end hearing aids will be used.
223790111|NCT06962683|OTHER|Blood-Flow-Restriction Training|For the pBFR intervention, the Personalized Tourniquet System for Blood Flow Restriction from Delfi Medical Innovations Inc. (Vancouver, Canada) were used. The cuffs were applied to both lower extremities as far proximally as possible and were connected to the control device. Before starting the training program, the individual LOP was measured of both lower limb in a restring, laying position by the control device. The Intervention-Group performed the training at 80% of their individual LOP. The training was performed alternately on both lower extremities. The time intervals were set at five minutes occlusion and five minutes rest. Each leg received five intervals of BFR-induced occlusion training, resulting in a total 50 minutes of daily training. During the entire training period, the patient was in a resting position, laying in the hospital bed.
223703978|NCT06710327|DRUG|Tranexamic Acid (IV)|The intervention is administered as a clear, colorless solution infusion. The dosage administered is a 1 gram intravenous (IV) push, delivered immediately before starting the Aquablation therapy. The administration of TXA occurs only once, as a single dose preoperatively.
223703979|NCT06710327|DRUG|Placebo|Participants receive a saline solution, which is a sodium chloride (0.9%) IV infusion, identical in appearance to the TXA solution. The saline is administered as a single 1 gram-equivalent volume intravenous (IV) push, delivered immediately before the Aquablation therapy commences. This singular administration matches the frequency and timing of the TXA intervention to ensure uniformity across both study groups, maintaining the blinding of the study.
223703980|NCT06709066|DRUG|mivacurium chloride|mivacurium chloride 0.14 mg/kg induction bolus + 0.5 mg/kg/h maintenance infusion
223703981|NCT06709066|DRUG|succinylcholine|succinylcholine (1 mg/kg induction bolus + 5 mg/kg/h maintenance infusion)
223703982|NCT06709625|PROCEDURE|Transversus thoracis plane block|Transversus thoracis plane block will be applied to provide postoperative analgesia.
223703983|NCT06709625|PROCEDURE|Erector spina plane block (ESP)|Erector spina plane block will be applied to provide postoperative analgesia.
223703984|NCT06709157|DIAGNOSTIC_TEST|P24 antigens and antibody|estimation of antigens and antibodies to diagnose HIV
223703985|NCT06709157|DIAGNOSTIC_TEST|zeihl - Nelsen stain|staining sputum from patients with HIV to detect tubercle bacilli
223703986|NCT06709157|DIAGNOSTIC_TEST|culture on Lowenstein jensen media|spenciem will be inoculated on LJ media and kept for 2-8 weeks, to see small white colonies
223703987|NCT06709157|DIAGNOSTIC_TEST|Molecular detection of antibiotic resistance|to see the pattern of antibiotic resistance of tubercle bacilli
223790112|NCT06962683|OTHER|Sham-BFR|For the sham-BFR intervention, the Personalized Tourniquet System for Blood Flow Restriction from Delfi Medical Innovations Inc. (Vancouver, Canada) were used. The cuffs were applied to both lower extremities as far proximally as possible and were connected to the control device. Before starting the training program, the individual LOP was measured of both lower limb in a restring, laying position by the control device. The Control-Group was trained with a fixed pressure of 20 mmHg, independent of their individual LOP. The training was performed alternately on both lower extremities. The time intervals were set at five minutes occlusion and five minutes rest. Each leg received five intervals of BFR-induced occlusion training, resulting in a total 50 minutes of daily training. During the entire training period, the patient was in a resting position, laying in the hospital bed.
223790113|NCT06956495|DRUG|Tasipimidine|Tasipimidine solution
223790114|NCT06956495|DRUG|Tasipimidine placebo|Tasipimidine placebo solution
223790115|NCT06961682|DIETARY_SUPPLEMENT|MD|Red meats and sweets minimal consumption once or twice per month Eggs, cheese, poultry and yoghurt weekly consumption Fish and seafood two to three times per week Olive oil varing amount daily Vegetables and fruits daily consumption Legumes and whole grains (bread, pasta, rice and nuts )daily consumption Measure the effect of Mediterranean diet on patient with MetS to control hypertension, diabetes, obesity and dyslipidemia by measuring blood pressure mmHg regularly, Hba1c before, lipid profile LDL, HDL, TG weight (kg) and height (m) to calculate BMI wt kg/ht\^2 m and waist hip ratio by measuring waist and hip circumference before and after the MD
223790116|NCT06962644|OTHER|Preeclampsia developed|Preecalmpsia will be defined as per study protocol
223790117|NCT06961799|DIAGNOSTIC_TEST|Multifactorial algorithm to predict fall risk|"In this new multifactorial algorithm we will add baseline data (personal characteristics, medical history, and physical and psychological measurements) to predict an older adults risk on falls. The accuracy of this new model will be tested with a 1-year follow up on falls.~The new algorithm is inspired by the study of Lusardi et al. (2017): Lusardi MM, Fritz S, Middleton A, Allison L, Wingood M, Phillips E, Criss M, Verma S, Osborne J, Chui KK. Determining Risk of Falls in Community Dwelling Older Adults: A Systematic Review and Meta-analysis Using Posttest Probability. J Geriatr Phys Ther. 2017 Jan/Mar;40(1):1-36. doi: 10.1519/JPT.0000000000000099. PMID: 27537070; PMCID: PMC5158094."
223790118|NCT06093113|BEHAVIORAL|Alba - Youth in grief|The app will build on principles of cognitive behavioural theory and therapy (CBT) and contains five main sections: Learning, Self-assessment, Manage symptoms, Find support and a Personal space.
223790119|NCT06093113|BEHAVIORAL|Control website|The website will contain information about grief and grief reactions similar to some of the information given in the app.
223790120|NCT05445804|DRUG|300 mg Cannabidiol|300 mg CBD in Medium Chain Triglyceride oil b.i.d.
223790121|NCT05445804|DRUG|600 mg Cannabidiol|600 mg CBD in Medium Chain Triglyceride oil b.i.d.
223790122|NCT05445804|DRUG|Placebo|Medium Chain Triglyceride oil
223790123|NCT04669171|BIOLOGICAL|EO2463|Multiple dose of EO2463
223790124|NCT04669171|DRUG|lenalidomide|D1-21 of 4-weekly cycles
223790125|NCT04669171|BIOLOGICAL|rituximab|Multiple doses of rituximab
223790126|NCT06634472|OTHER|AI|AI-enabled skin perforator segmentation tool
223790127|NCT03526250|OTHER|Laboratory Biomarker Analysis|Correlative studies
223790128|NCT03526250|DRUG|Palbociclib|Given PO
223790129|NCT03526250|OTHER|Pharmacological Study|Correlative studies
223790130|NCT06008717|DEVICE|active subthalamic nucleus deep brain stimulation plus optimal drug therapy|active subthalamic nucleus deep brain stimulation (DBS) plus optimal drug therapy
223790131|NCT06008717|DEVICE|inactive subthalamic nucleus deep brain stimulation plus optimal drug therapy|optimal drug therapy alone with DBS device turned off
223790132|NCT06002165|BEHAVIORAL|Usual Care|"All clinics in North Carolina Perinatal Region IV have access to Severe HTN Bundle resources on the AIM website (https://saferbirth.org/psbs/severe-hypertension-in-pregnancy) and the locally adapted Outpatient HTN Bundle resources on the North Carolina Perinatal Region IV Provider Support Network website (https://www.mombaby.org/outpatient-bundle-for-severe-hypertension/). At baseline, the clinical leadership of all enrolled sites will receive direct communication via email that describes and provides links to the available resources. This will constitute usual care."
223790133|NCT06002165|BEHAVIORAL|ACHIEVE Multi-component Implementation Strategy|The intervention is comprised of four implementation strategies: facilitation/coaching, training, simulation, and delivering educational materials. The ACHIEVE study team, primarily the Nurse Coordinator, will engage teams within each clinic to participate in quality improvement activities utilizing these four strategies. The Nurse Coordinator will train the providers/staff on the O-HTN bundle components, facilitate corresponding office systems and workflow changes, and conduct simulations of patients with severe hypertension so care teams can practice the steps involved in recognizing and responding to episodes of severe hypertension in a timely manner.
223790134|NCT06572371|PROCEDURE|Laparoscopic pyeloplasty|The first trocar was inserted under vision through the same supraumbilical incision and the intraperitoneal cavity was inspected The second 5 mm trocar was placed in the midclavicular line 2 inches below the costal margin. The third 10 mm trocar was placed lateral to the rectus muscle at the level of the anterior superior iliac spine. In right-sided pyeloplasty, a fourth trocar was inserted below the xiphistemum for liver retraction. Incision of the line of Toldt and mobilization of the colon was the first step of the transperitoneal approach. A 4/0 polysorbe stay suture was taken in the lateral aspect of the ureter distal to uretero-pelvic junction obstruction to identify the correct orientation after dismembering the ureter. A full thickness anastomosis was started from the angle of V shape spatulation to the lower pole of the renal pelvis.
223790135|NCT06572371|PROCEDURE|Open pyeloplasty|"A flank incision with the patient in lateral position was undertaken in open pyeloplasty. After accessing the retro- peritoneum, the ureter was identified and traced cranially till the PUJ segment.~Traction sutures was placed on the renal pelvis followed by excision of the narrowing segment. The ureter was spatulated by approximately 2 cm and a reduction pyeloplasty was performed, where necessary. Anastomosis was undertaken using vicryl 4-0 sutures. The primary anastomotic site was sutured in interrupted fashion followed by a continuous running suture of the posterior wall. Next, antegrade DJ stenting was performed and the anterior wall was anastomosed. After haemostatic control a 22 Fr drain was placed in the surgical bed."
223790136|NCT06167681|BIOLOGICAL|Human Dopaminergic Progenitor Cells|Single injection of Human Dopaminergic Progenitor Cells into the putamen/striatum region of brain.
223790137|NCT06423703|DRUG|Cebranopadol|once daily for 3 days
223790138|NCT06423703|DRUG|Oxycodone IR|four times per day for 3 days
223790139|NCT06423703|DRUG|Placebo|three times per day 3 days (with cebranopadol), four times per day for 3 days (placebo arm)
223790140|NCT02647359|DRUG|Ataluren|Ataluren oral suspension will be administered as per the dose and schedule specified in the respective arms.
223790141|NCT02647359|DRUG|Placebo|Placebo will be administered as per the schedule specified in the respective arm.
223790142|NCT00460889|PROCEDURE|donor nephrectomy|The objective of this protocol is to look at the outcomes of laparoscopic donor nephrectomy performed by using hand assisted (HA)or entirely laparoscopic (LDN) surgical techniques. To define the advantages of each technique, we will use records of patients who underwent laparoscopic live kidney donation with HALDN.
223790143|NCT03775850|BIOLOGICAL|EDP1503|4 capsules taken by mouth twice daily. Each capsule will contain ≥ 7.5x10\^10 colony-forming units (CFU)
223790144|NCT03775850|BIOLOGICAL|Pembrolizumab|200 mg given by intravenous (IV) infusion once every 3 weeks
223790145|NCT00511004|DRUG|Albendazole|Comparing 400 mg to 800 mg dose
223790146|NCT00511004|DRUG|Diethylcarbamazine|Providing diethylcarbamazine more frequently in combination with albendazole
223790147|NCT02125526|DEVICE|Intra-aortic balloon pump|The intra-aortic balloon pump is placed in the descending thoracic aorta and inflates and deflates in synchrony with the cardiac cycle, providing diastolic augmentation and improving coronary blood flow, while deflating before systole, providing afterload and workload reduction for the myocardium.
223790148|NCT05809037|DEVICE|transcutaneous auricular vagus nerve stimulation|In addition to the conventional rehabilitation program, non-invasive vagus nerve stimulation will be applied to the participants through the left ear with the Vagustim™-Ear tens electrode. As a vagus stimulation protocol, 10 sessions, 30 minutes, noninvasive auricular stimulation will be applied, stimulation frequency is 10 Hz, pulse width is 300 µs, and biphasic.
223790149|NCT05809037|DEVICE|Sham stimulation|In addition to the conventional rehabilitation program, sham vagus nerve stimulation (0 mA) will be applied to the participants in the control group. Non-invasive vagus nerve stimulation will be applied to the participants through the left ear with the Vagustim™-Ear tens electrode. As a vagus stimulation protocol, 10 sessions, 30 minutes, and noninvasive auricular stimulation will be applied.
223790150|NCT01903473|DRUG|Rapamycin|"Rapamycin will be started within 2 weeks after inclusion. Rapamycin will be given at 2-6 mg loading dose for one day, followed by approximately 1 mg daily to achieve a target trough level of 5 to 10 ng/mL. The frequency of trough level measurements will be done according to the investigator choice; Rapamycin may be discontinued in case of resolution of chronic GVHD ≥ 3 months or in case of un-manageable side effects or progression of chronic GVHD.~Calcineurin inhibitor discontinuation within 2 weeks after rapamycin initiation. No other modification of immunosuppressive drugs and in particular no decrease in the dose of steroids (unless necessary for side effects)."
223790151|NCT01903473|OTHER|T regulatory cells|"One infusion of ≥ 0.5 x10E6 T reg cells/kg recipient at 60-90 days after first day of rapamycin administration and after calcineurin inhibitor discontinuation. The infusion procedure will take one hour.~Low-dose Il-2 (1x106 IU/day) will be started the day of DTI and will be continued for a period of 2months in order to expand infused donor Tregs."
223790152|NCT05646953|OTHER|Facial Beauty Oil|"Mode of Usage Step 1- Wash face, pat dry Step 2 - Gently massage 2-3 drops of Vasu Facial Beauty Oil over the face and neck till it gets absorbed and keep it overnight.~Step 3 - Use it for 60 days Frequency - Daily before going to bed. Route of Administration - Topical"
223790153|NCT02773615|PROCEDURE|Cardiac computed tomography|Non-invasive CT scan of the heart
223790154|NCT01921673|DRUG|Dovitinib and docetaxel|"In phase I portion of the study Docetaxel 45-75 mg/m2, intravenous, every 3 weeks Dovitinib 200-500 mg, oral, 5 days on/2 days off~In phase II portion of the study Recommended dose of docetaxel and dovitinib in phase I portion will be used."
223790155|NCT01792063|DRUG|Sevoflurane|
223790156|NCT01792063|DRUG|Sevoflurane|
223790157|NCT01715987|DRUG|Tenofovir Disoproxil Fumarate|300mg, oral daily for two years
223790158|NCT01715987|DRUG|Entecavir|0.5mg oral daily for two years.
223790159|NCT04126226|OTHER|Speech-language guidance|Speech-language guidance for speech enhancement and on food management in terms of consistency, volumes, utensils and temperature, beyond the care for safe and efficient swallowing.
223790160|NCT04126226|OTHER|Speech therapy exercises for swallowing|Use of lip exercises and facial muscles, laryngeal elevation maneuver and airway protection technique, 5 repetitions 3 times a day for a month.
223790161|NCT04126226|OTHER|Speech therapy exercises for speech|Use of over-articulation technique and glottal firmness exercise, 5 repetitions 3 times a day for a month.
223790162|NCT04653103|PROCEDURE|Liver biopsy|Biopsy of the liver to assess for Non-alcoholic steatohepatitis
223790163|NCT04913753|PROCEDURE|CBEU|Patients in the control group will have bacterial culture and double J removal will be performed as usual. .
223790164|NCT04913753|PROCEDURE|No CBEU|Patients in the experimental group will have bacterial culture and double J removal will be performed as usual. .
223790165|NCT03658174|DIETARY_SUPPLEMENT|Nitrate-rich beetroot juice|70mls of concentrated beetroot juice containing approximately 5-6 mmol of inorganic nitrate
223790166|NCT03658174|DIETARY_SUPPLEMENT|Nitrate-free beetroot juice|70mls of concentrated beetroot juice that has been nitrate-depleted
223790167|NCT03353935|OTHER|Validated questionnaires|Patients were administered pre- and post-operatively the three validated questionnaires ((FSFI, ICIQ-UI short form Italian, NBD score) investigating sexual, urinary, and fecal function, respectively.
223790168|NCT03345238|PROCEDURE|Deep Dry Needling|Deep Dry Needling in the upper trapezious muscle is an invasive technique of Physical Therapy.
223790169|NCT01722968|DRUG|Bevacizumab|15mg/kg administered iv every 3 weeks in combination with paclitaxel 80mg/m2 iv weekly
223790170|NCT01722968|DRUG|Paclitaxel|80mg/m2 iv weekly
223790171|NCT05976074|DEVICE|Apple Watch|The smartwatch will collect data including accelerometry, heart rate, activity, move time, exercise time, stand time, steps, walking and running distance, heart rate variability, respiratory rate, six-minute walk, and flights climbed. During sleep, the smartwatch will collect daily nighttime physiologic data such as time in bed, average sleep time, sleep efficiency, wake after sleep onset, nocturnal heart rate, and nocturnal respiratory rate.
223790172|NCT05976074|OTHER|BrainRISE app|The app will play a prerecorded video, which will walk participants through tasks which include holding your arms in different postures, repeating different vowel sounds and phrases as prompted, and tracing different patterns on the phone screen. The tasks are video and audio recorded while being completed. Completing the tremor assessment tasks will take about 10 minutes.
223790173|NCT06646666|DRUG|All-trans retinoic acid|10mg，tid，po (After apheresis and continued until post-infusion)
223790174|NCT06646666|DRUG|zanubrutinib|160mg，bid，po (prior to apheresis and continued until post-infusion)
223790175|NCT06646666|RADIATION|radiotherapy|If the patient's specific lesions are suitable for radiotherapy
223790176|NCT06646666|DRUG|CAR-T|CAR-T cell therapy
223790177|NCT06646666|DRUG|PD-1 inhibitor|IV 200 mg on D1, Q3W
223790178|NCT06056180|OTHER|Balance Training|Participants will be given static and dynamic balance training with a balance platform game console (20 minutes) containing interactive video games based virtual reality for a total of 6 weeks.
223790179|NCT06056180|OTHER|Motor İmagery Training|For motor imagery training, two visualization scenarios will be created: anterior and posterior motor imagery. One of the visualization scenarios appropriate to each individual's needs will be used. Participants will be asked to perform kinesthetic or visual motor imagery in accordance with the scenario they listened to (10 minutes).
223790180|NCT06056180|OTHER|Action Observation Training|Action observation training will be done using video modeling method. The video content will include Nintendo Wii games in which the games that the person will play in that session are played by someone else and successful scores are achieved (10 minutes).
223790181|NCT05604430|DEVICE|731 Series Ventilator|FDA cleared ventilator indicated for use in the management of acute or chronic respiratory failure or during resuscitation.
223790182|NCT06089083|OTHER|Physical function assessment|Physical assessments of frailty will be conducted in person.
223790183|NCT06089083|OTHER|Self-reported Assessments and Questionnaires|Quality of life questionnaires and self-reported measures will be provided to complete during the course of the study
223790184|NCT06089083|PROCEDURE|Surgery (Standard of Care, Non-Interventional)|Surgical data will be reviewed via medical record
223790185|NCT03695497|PROCEDURE|Direct anterior approach|total hip arthroplasty with DAA
223790186|NCT03695497|PROCEDURE|Direct Lateral Approach|total hip arthroplasty with DLA
223790187|NCT05900882|DRUG|Selinexor|Selinexor 60 mg/day, orally on d1,8,15,22
223790188|NCT05900882|DRUG|Bortezomib|Bortezomib 1.3mg/m2 intravenously on d1,8,15,22
223790189|NCT05900882|DRUG|Lenalidomide|Lenalidomide 25 mg/d (the dose will be adjusted according to creatinine clearance)
223790190|NCT05900882|DRUG|Dexamethasone|Dexamethasone 20 mg/day orally on d1-2, d8-9,d15-16,d22-23
223790191|NCT06096597|DRUG|Clarix Flo|100 mg of commercially available micronized amniotic membrane (Clarix Flo; BioTissue, Miami, FL) diluted in 10 mL of 0.9% preservative-free sodium chloride
223790192|NCT06096597|DRUG|Placebo|10 mL of 0.9% preservative-free sodium chloride
223790193|NCT06082167|DRUG|Zanzalintinib|Specified doses on specified days
223790194|NCT06082167|DRUG|Zanzalintinib-matched Placebo|Specified doses on specified days
223790195|NCT06082167|BIOLOGICAL|Pembrolizumab|Specified doses on specified days
223790196|NCT04267705|OTHER|Control|This group will receive a cup of rice 7 days/week over a 12-week period
223790197|NCT04267705|OTHER|Black bean|This group will receive a cup of black bean7 days/week over a 12-week period
223790198|NCT04267705|OTHER|Chickpea|This group will receive a cup of chick pea 7 days/week over a 12-week period
223790199|NCT04278768|DRUG|Emavusertib|Emavusertib is formulated as a tablet for oral administration for BID dosing in consecutive 28-day cycles. Emavusertib is a novel small molecule inhibitor of interleukin-1 receptor-associated kinase 4 (IRAK4). IRAK4 kinase plays an essential role in toll-like receptor (TLR) and interleukin-1 receptor (IL-1R) signaling pathways and these pathways are frequently dysregulated in non-Hodgkin's lymphoma and AML/MDS malignancies.
223790200|NCT04278768|DRUG|Venetoclax|"Ventoclax is B-cell lymphoma-2 (BCL-2) inhibitor. Venetoclax will be administered at 100 mg orally (Day 1) per the product label at the same time each day with a ramp up over 3 days to 400 mg for 21days of a 28-day Cycle. Second and subsequent cycles start with target dose level.~This arm of the study has been closed to enrollment."
223790201|NCT04278768|DRUG|Emavusertib|Emavusertib is formulated as a tablet for oral administration for BID dosing for 21 days (Days 1-21) of a 28-day Cycle.
223790203|NCT05845333|OTHER|Decision task|Participants will complete a simple and/or moral decision making functional MRI task.
223790204|NCT05980442|DEVICE|Navigated total knee arthroplasty|Total knee arthroplasty with Columbus® total knee endoprosthesis using the OrthoPilot® Elite navigation system
223790205|NCT05980442|DEVICE|Robot assisted total knee arthroplasty|Total knee arthroplasty with Triathlon® total knee endoprosthesis using the MAKO® robot system
223790206|NCT03428711|DRUG|Mesoglycan Oral Tablet|"Experimental drug: mesoglycan, already used in the treatment of chronic venous ulcers, is a complex mucopolysaccharide, composed of a mixture of glycosaminoglycans (mainly heparan-sulphate, dermatan sulfate), inhibitors of thrombin and of Factor Xa and active in restore flow-mediated vasodilation.~Used in oral formulation, hard capsules, 50 mg, twice-a-day, for 12 months. Reference therapy: placebo, organoleptically indistinguishable from the experimental drug, twice-a-day, for 12 months."
223790207|NCT03428711|DRUG|Placebo Oral Tablet|Indistinguible placebo tablet
223790208|NCT05815108|OTHER|NO INTERVENTION|NO INTERVENTION
223790209|NCT04618718|DEVICE|cerebral embolic protection during TAVR|The ProtEmbo system is an adjunctive device placed in the central arterial system at the beginning of a TAVR procedure to deflect embolic particles during the procedure and removed following the completion of the procedure.
223790210|NCT05505747|DRUG|Fisetin|Fisetin is a plant flavanol senolytic found in strawberries, persimmons, and cucumbers. This naturally derived senolytic has few side effects and previous animal models of both osteoarthritis and rheumatoid arthritis have demonstrated that the senolytic supplement fisetin reduces inflammation and slows cartilage breakdown.
223790211|NCT05505747|DRUG|Placebo oral capsule|The oral placebo will consist of corn starch and gelatin capsules
223790212|NCT05671848|OTHER|Recordings of thalamic activity|Recordings of thalamic activity will be performed at home, in ecological conditions. They will be realized during 4 distinct conditions each week between M3 and M6 post implantation: at rest and during tremor-induced movements. For these recordings, stimulation will be either turned Off or On. Three successive recordings of 30 seconds separated by 1 minute will be made for each condition.
223790213|NCT05565716|OTHER|Support Person|"Prior to randomization, participants will select their preference of the type of support person if they are assigned to this arm 1) a person they have close relationship with, or 2) a Peer Mentor, an individual who has successfully monitored their blood pressure at home using the study's equipment and also has diabetes, kidney disease, and high blood pressure. The Peer Mentor works with the research study team.~This will be provided with the same weekly blood pressure feedback that the participants will receive. The support person is encouraged to reach out to the participant at least weekly."
223790214|NCT05565716|OTHER|Social Norms|Participants will receive weekly text messages that includes their individualize blood pressure performance statistics, included frequency of blood pressure monitoring and average blood pressure, and compare it to goals provided at the beginning of the study, as well as the week prior. Participants will also has access to a leaderboard that displays blood pressure performance information all people in the study in an anonymous fashion.
223790215|NCT05813912|DRUG|Insulin Icodec|Participants will receive subcutaneously insulin icodec once weekly for 52 weeks.
223790216|NCT05813912|DRUG|Semaglutide|Participants will receive once weekly semaglutide subcutaneously starting from 0.25 mg and dose increased up to 1 mg for 26 weeks.
223790217|NCT04380636|BIOLOGICAL|Pembrolizumab|intravenous (IV) infusion
223790218|NCT04380636|DRUG|Olaparib|oral tablets
223790219|NCT04380636|DRUG|Placebo for olaparib|oral tablets
223790220|NCT04380636|DRUG|Etoposide|IV infusion
223790221|NCT04380636|DRUG|Carboplatin|IV infusion
223790222|NCT04380636|DRUG|Cisplatin|IV infusion
223790223|NCT04380636|DRUG|Paclitaxel|IV infusion
223790224|NCT04380636|DRUG|Pemetrexed|IV infusion
223790225|NCT04380636|RADIATION|Thoracic Radiotherapy|external beam radiation
223790226|NCT04380636|DRUG|Durvalumab|IV infusion
223790227|NCT05285553|DEVICE|MiSight 1 Day|Part 1 of the study - subjects will be randomized to wear MiSight 1 Day for three years.
223790228|NCT05285553|DEVICE|Proclear 1 day|"Part 1 of the study - subjects will be randomized to wear Proclear 1 day for three years.~Part 2 of the study - All the subjects will wear Proclear 1 day lenses for one year."
223790229|NCT06033235|DIAGNOSTIC_TEST|CT scan in critically ill patients in the intensive care unit|CT scan in critically ill patients in the intensive care unit
223790230|NCT03544034|BEHAVIORAL|HomeTeam Toolkit|"A multi-component intervention (8S's)~1. Safety at home through partnership.~2. Safety risk assessment at the admission~3. Safety agenda setting for coordinating efforts among professionals to prepare patient/ family for self-management~4. Safety tools. Cognitive tools to support patient/family after discharge~5. Safety education. Enhanced Patient/ family medication safety education~6. Safety briefings with patient/family A mechanism to proactively address common and patient/family specific risks.~7. Safety through learning routines across the care continuum~8. Safety assessment after discharge"
223790231|NCT03571295|DEVICE|King Vision aBlade|endotracheal intubation performed with King Vision aBlade
223790232|NCT03571295|DEVICE|direct laryngoscopy|endotracheal intubation performed with direct laryngoscopy
223790233|NCT02388386|DEVICE|PROTEUS-SENSOR|An edible sensor system, Proteus Digital™ has been developed for electronically confirming medication adherence, gathering physiologic metrics and communicating these data to patients. The system consists of two major components: an edible sensor and a wearable receiver health monitor. An electrical signal is activated upon ingestion of the Proteus Digital micro-sensor with transmission of this signal to a receiving abdominal patch to quantify medication compliance.
223790234|NCT02127801|DRUG|REGN1908-1909|
223790235|NCT02127801|DRUG|placebo|
223790236|NCT01360359|OTHER|Core Stabilization|"3 Stages: Stage 1: emphasis on neutral spine position, co-contraction of stabilizing muscles with performance feedback through observation and palpation for correct muscle activation; patient education~Stage 2: promotes maintenance of co-contraction while performing movements of the arms/legs and trunk progressing to preformance of these exercises on unstable surfaces; trunk muscle conditioning also emphasized; feedback gradually reduced.~Stage 3: emphasis on maintenance of co-contraction while performing functional activities; stable and unstable surfaces; use of perturbation and random practice to enhance motor learning."
223790237|NCT01360359|OTHER|Trunk Motion and Fitness|"3 Stages: Stage 1: reducing pain and restoring spine motion and flexibility; patient education~Stage 2: trunk muscle conditioning exercises~Stage 3: trunk muscle conditioning and cardiovascular conditioning exercises"
223790238|NCT05894343|GENETIC|AAV-GAD|Bilateral infusion of AAV-GAD
223790239|NCT04818346|DRUG|INCB054707|INCB054707 will be administered once daily
223790240|NCT04818346|DRUG|Placebo|Placebo or INCB054707 will be administered once daily
223790241|NCT05695183|DEVICE|IV SafeLock|Designed to prevent patient access to intravenous lines in the hospital setting. The device locks with an institution specific key and protects the hub as well as all tubing access points.
223790242|NCT04112147|DRUG|Antroquinonol capsule 100mg|Patients will receive 12-week of 50mg BID Antroquinonol
223790243|NCT04112147|DRUG|Antroquinonol capsule 200mg|Patients will receive 12-week of 100mg BID Antroquinonol
223790244|NCT04112147|DRUG|Placebo oral capsule|Patients will receive 12-week of 100mg BID Antroquinonol placebo
223790245|NCT01672801|DRUG|Placebo|oral administration
223790246|NCT01672801|DRUG|Nimodipine|oral administration
223790247|NCT06111950|OTHER|Blood samples|Blood samples of 5 ml to 15 ml depending on their weight
223790248|NCT06111950|OTHER|Skin biopsies|Biopsies of fragment of skin 2 to 3 mm long by 1 mm wide and 1 mm deep will preferably be taken on the inside of the arm, in the upper third, between the bend of the elbow and the hollow of the armpit under strict sterility conditions.
223790249|NCT06111950|OTHER|Fetal samples|Skin, muscle, brain and bone biopsies will be collected from fetuses in the autopsy room after the medical termination of pregnancy or miscarriage
223790250|NCT05643001|OTHER|In-patient and out-patient electronic health record alert|Electronic health record best practice alert which suggests measurement of LDL and HbA1c (in-patient) and referrals to sleep study and audiology (out-patient)
223790251|NCT00222339|BEHAVIORAL|task-specific training|
223790252|NCT06481917|OTHER|Advance care plan|Scheduling of 2 home visits by an expert nurse in the month following the return home and proposal to carry out an advance care plan.
223790253|NCT06481917|OTHER|Ergonomic analysis|Ergonomic analysis throughout the intervention
223790254|NCT06481917|OTHER|Evaluation of intervention acceptability|Evaluation of intervention acceptability after each home visit with patients and caregivers using a questionnaire
223790255|NCT00481429|DRUG|Rosiglitazone|Rosiglitazone 4mg od, increased to 4mg bg at 4 weeks if HbA1C above 7%.
223790256|NCT00837863|DRUG|Somatropin|ALTU-238 0.3 mg/kg daily
223790257|NCT00837863|DRUG|Somatropin|ALTU-238 0.6 mg/kg daily
223790258|NCT00837863|DRUG|Somatropin|ALTU-238 0.9 mg/kg daily
223790259|NCT00837863|DRUG|Somatropin|Nutropin AQ 0.043 mg/kg daily
223790260|NCT02765529|PROCEDURE|Blood sampling|
223790261|NCT06529952|PROCEDURE|hysteroscopic surgery by resection and endocoagulation|resection of lower edge, resection of upper edge and endocoagulation
223790262|NCT06529952|PROCEDURE|hysteroscopic surgery by endocoagulation only|hysteroscopic endocoagulation to the base of the niche by roller ball
223790263|NCT06529952|DRUG|hormonal treatment|using 3rd generation contraceptive pills
223790264|NCT02494284|DRUG|Clopidogrel|6-month DAPT followed by clopidogrel monotherapy
223790265|NCT02494284|DRUG|Aspirin plus clopidogrel|standard long-term dual antiplatelet strategies (24-month DAPT followed by aspirin monotherapy)
223790266|NCT06100926|DEVICE|software|virtual reality scene
223790267|NCT05800392|DRUG|DEC103|The intervention is composed by two medications: An active sublingual pill and an active oral one.
223790268|NCT05800392|DRUG|Placebo DEC103|The intervention is composed by two medications: A placebo sublingual pill and an placebo oral one.
223790269|NCT00504270|DRUG|Placebo|po daily
223790270|NCT00504270|DRUG|RG3421 120mg|120mg po daily
223790271|NCT00504270|DRUG|RG3421 20mg|20mg po daily
223790272|NCT04329624|DRUG|Levosimendan|Levosimendan 2.5 mg/ml injection contains levosimendan 2.5 mg, povidone 10.0 mg, citric acid, anhydrous 2.0 mg and ethanol, anhydrous to 1.0 mL. Levosimendan injection is a clear, yellow to orange solution. Immediately after skin incision patients allocated to the verum group will receive a dose of 12.5 mg in 500 mL of levosimendan.
223790273|NCT04329624|DRUG|Placebo|"Placebo 2.5 mg/ml injection contains riboflavine sodium phosphate 0.4 mg, dehydrated alcohol 100 mg and water for injection to 1 mL.~Immediately after skin incision patients allocated to the placebo group will receive 500 mL of 5% Glucose."
223790274|NCT00207272|BEHAVIORAL|1170-1870 kcal/day liquid diet|
223790275|NCT00207272|PROCEDURE|Gastric bypass surgery|
223790276|NCT00207272|PROCEDURE|Biopsy.visceral adipose tissue|
223790277|NCT00207272|PROCEDURE|Biopsy.omental adipose tissue|
223790278|NCT00207272|PROCEDURE|Biopsy. subcutaneous abdominal adipose tissue|
223790279|NCT00207272|PROCEDURE|Blood sample|
223790280|NCT00687037|DRUG|Cetylpyridinium chloride|
223790281|NCT01362140|DRUG|Darbepoetin alfa|Administered by subcutaneous injection every 3 weeks
223790282|NCT01362140|DRUG|Placebo|Administered by subcutaneous injection every 3 weeks
223790283|NCT02090101|DRUG|ANAKINRA|
223790284|NCT05369585|DIETARY_SUPPLEMENT|TOTUM-63|5-g per day dose of TOTUM-63 supplement, a mix of 5 plant extracts. Daily dose for 8 weeks followed by a 4 weeks follow-up period without supplementation.
223790285|NCT01673802|DRUG|CT scan|Gadoxetate (Eovist) enhanced dual energy CT
223790286|NCT00492284|DRUG|verteporfin|Reduced-fluence Visudyne (25 J/cm2, 300 mW/cm2, 83 seconds)
223790287|NCT00492284|DRUG|verteporfin|Very-low fluence Visudyne (15 J/cm2, 180 mW/cm2, 83 seconds)
223790288|NCT00492284|DRUG|ranibizumab|0.5 mg intravitreal injection
223790289|NCT00492284|DRUG|dexamethasone|0.5 mg intravitreal injection
223790290|NCT05281380|DIETARY_SUPPLEMENT|GIKAVI|Two tailormade supplements for patients; one for that underwent esophagectomy and one for (sub-)total gastrectomy.
223790291|NCT01964573|DRUG|Rotigotine|"Day 1-3: 2 mg patch once daily~Day 4-6: 4 mg patch once daily"
223790292|NCT01964573|OTHER|Placebo|"Placebo patches matching with Rotigotine 2 mg patches and 4 mg patches.~Frequency:~Day 1-3: 2 mg patch once daily~Day 4-6: 4 mg patch once daily"
223790293|NCT06042829|DEVICE|Intubation using aerosol box|Intubation time and ease of intubation using aerosol box
223790294|NCT06042829|DEVICE|Intubation without aerosol box|Intubation time and ease of intubation without aerosol box
223790295|NCT06476366|DRUG|Azathioprine|azathioprine will be started at 0.3mg/kg orally daily. Anticipated response is after atleast 1 month so testing will be done thereafter ( after checking TPMT levels)
223790296|NCT06476366|DRUG|Methotrexate|Methotrexate will be started at 5mg/week and dose escalated by 2.5mg weekly to ultimately 10mg/week. Tablet Folic acid 0.5mg will be given orally daily, skipping the day of methotrexate
223790297|NCT03179839|BEHAVIORAL|Mindfulness-based Cognitive Therapy|"The intervention will be carried out according to the handbook of the Dr. Didonna. There is a Session Agenda from Dr. Didonna for the use of the Instructor and session handouts for the participants. Some records of mindfulness practices will be given to participants for facilitating practice between sessions. Before each session, the instructor needs to review the session agenda and prepare copies of handouts for participants.~MBCT instructors were experienced psychotherapists and psychiatrists with several years' expertise in OCD treatment. They had been trained by one of the founders of MBCT, Mark Williams and the founder of MBCT for OCD, Fabrizio Didonna. Supervision will be provided by Dr.Didonna."
223790298|NCT03179839|BEHAVIORAL|Psycho-education Program|As a widely used placebo control condition, the Psycho-Education Program can play an active role through the psychological suggestion and forward thinking mostly. It is designed to be similar with MBCT in level of structure, setting and other non-specific effects of psychological intervention. All instructors will be qualified graduate students who major in clinical psychology with training in cognitive behavioral therapy and psychodynamic therapy.
223790299|NCT03179839|DRUG|sertraline, fluvoxamine|The participants can be adjustable once a week dose and the maximum dose does not exceed the maximum amount of instructions. And benzodiazepine drugs also can be used by the OCD patients with sleep disorders, but not be used continuously for more than two weeks. Besides this, other psychotropic drugs are not allowed to use. The use of drugs in this study are commonly used drugs with good safety, and its common adverse reactions include dry mouth, constipation, nausea, indigestion, dizziness, fatigue, sweating and so on.
223790300|NCT02951104|DEVICE|Ultrasonic Cardiac Output Monitor (USCOM) system|
223790301|NCT03861962|OTHER|"DNA sequencing called new generation (or NGS)"|"Redo HLA-typings with a method exploring all the genes (add DQA1, DRB3 / 4/5, DPB1 and DPA1), i.e. DNA sequencing called new generation, when this has not been done after the graft as part of the standard care"
223790302|NCT02256462|DRUG|Adalimumab|Eligible patients are those who are planned to start Adalimumab (ADA). Patients will be randomized at the first screening visits to either group 1 (interventional) or group 2 (clinical). Eligible patients, will start induction treatment (weeks 0,2) with ADA (\> 40kg 160/80/40 mg every 2 weeks or \< 40 kg 100/50/25 mg for m2 body surface area every 2 weeks). Interventions will start from the 4th injection for responding patients only (based on levels taken prior to the third injection). Responding patients will continue to the maintenance phase in which they will receive ADA every 2 weeks, either 40 mg or 25 mg/m2. At screening, and every 2 months all patients will be examined and have height, weight, PCDAI performed as well as comprehensive laboratory examinations.
223790303|NCT01692340|OTHER|Isotopically labeled lycopene, phytoene or phytofluene|We will administer 10 mg of labeled carotenoid mixed with olive oil and spread on an English muffin for consumption by participants.
223790304|NCT04153370|DEVICE|Airtraq|airtraq video laryngoscope was used for intubation of the infant
223790305|NCT04153370|DEVICE|glidescope|glidescope video laryngoscope was used for intubation of the infant
223790306|NCT04153370|DEVICE|c-mac|c-mac video laryngoscope was used for intubation of the infant
223790307|NCT04172792|DIETARY_SUPPLEMENT|high-caloric fatty diet|see arm/group description
223790308|NCT04172792|DIETARY_SUPPLEMENT|ultra-high-caloric fatty diet|see arm/group description
223790309|NCT04172792|DIETARY_SUPPLEMENT|ultra-high-caloric carbohydrate-rich diet|see arm/group description
223790310|NCT04818411|OTHER|Routine physical therapy treatment with the Stabilization exercises|The program was based on specific training of the transversely oriented abdominal muscles with coactivation of the lumbar multifidus at the lumbosacral region, training of the gluteus maximus, the latissimus dorsi, the oblique abdominal muscles, the erector spinae, the quadratus lumborum, and the hip adductors and abductors. Initially, we focused on the specific contraction of the transversely oriented abdominal muscles. After approximately 2 weeks, loading was progressively increased throughout the intervention period. The women were required to exercise for 30 to 60 minutes, 3 days a week, for 3-4 weeks.
223790311|NCT04818411|OTHER|Routine physical therapy treatment + High-velocity thrust manipulation|: For high-velocity thrust technique, a modified Chicago technique was used. For this procedure, the lumbopelvic region was targeted. The side to be treated was chosen, based on the subject's report of her most symptomatic side. The physical therapist, performed passively side bend the subject toward the painful side, rotate the upper body in the direction opposite to the side bending, and then deliver a quick posterior and inferior thrust at a grade V including a small-amplitude/high-velocity therapeutic movement. A maximum of 2 attempts per side was permitted if no pop was heard following the first attempt. If the subject showed improvement of 50% or less after the first treatment, the intervention was categorized as a failure, the examination and intervention were repeated, and the subjects were asked to return 2 to 4 days later. If the subject showed greater than 50% improvement, the intervention was categorized as a success, and study participation was concluded.
223790312|NCT06957795|OTHER|Intensive Pelvic Floor Exercise Program|Intensive pelvic floor exercise program targeting the fast (tap) and slow twitch fibers (elevator) of the pelvic floor. The tap exercise will be performed by instructing the patient to quickly contract and release the pelvic floor muscles. For the elevator exercise, the patient will be asked to contract the pelvic floor muscles for 5 seconds and hold them for 5 seconds and then slowly relax them within 5 seconds. Patients will do the exercises as a home program. The exercise program will last for 6 weeks. One set of exercise will be counted as 10 taps and 10 elevator. In the first week, patients will be asked to do 5 sets of exercises per day and the number of sets will be increased by five for 6 weeks.
223790313|NCT05034705|DEVICE|Conventional suction system|This is the conventional method of using the dental high volume suction to contain the aerosol generated during dental procedure. The saliva ejector will also be used.
223790314|NCT05034705|DEVICE|Dental aerosol box with modified high volume evacuation system|The dental aerosol box will be equipped with an exit for the high volume suction to be attached to contain the aerosol generated during dental procedure. The saliva ejector will also be used.
223790315|NCT02032472|OTHER|Measurement of Arterial Pressure|Pharmacies cooperate in measuring blood pressure of patients
223790316|NCT03066336|DEVICE|Erchonia LunulaLaser|Active Low Level Laser Light Therapy
223790317|NCT05520580|PROCEDURE|Mother's push during CS|after uterotomy, the mother was instructed and motivated to push for the delivery of the head and the shoulders of the baby. Simultaneously, the surgical assistant applied fundal pressure to support the mothers pushing if necessary
223790318|NCT00164437|BEHAVIORAL|educational CD-ROM|
223790319|NCT03649828|DIETARY_SUPPLEMENT|probiotic milk fermented with kefir grains|Participants received probiotic milk fermented with kefir grains for consumption for 11 weeks. Before and after treatment, blood samples were collected for biochemical analysis and anthropometric data were also evaluated.
223790320|NCT03649828|DIETARY_SUPPLEMENT|curd|Participants received the curd for consumption for 11 weeks. Before and after treatment, blood samples were collected for biochemical analysis and anthropometric data were also evaluated.
223790321|NCT01140191|DRUG|WR 279,396|Topical application of WR 279,396 cream (15% paromomycin + 0.5% gentamicin)once daily for 20 days
223790322|NCT01404572|DRUG|Atazanavir (current formulation)|Solution, oral, atazanavir 15 mg/5 mL with 10% aspartame, single dose
223790323|NCT01404572|DRUG|Atazanavir, powder for oral use 1 (POU1)|Solution, oral, atazanavir 15 mg/5 mL with 4.2% aspartame, single dose
223790324|NCT01404572|DRUG|Atazanavir (POU2)|Solution, oral, atazanavir 15 mg/5 mL with 4.2% aspartame and sucralose, single dose
223790325|NCT03910257|BEHAVIORAL|nutrition education module|12 activities of nutrition education module will deliver by the teacher. The activities consists of coloring my meal plate, playing pictures, story telling: Zizi and Ziko, pictures station, fruits and vegetables card, cooking class, planting bean sprouts, field visit to fruits and vegetables garden, making collages, dot to dot, watching video, making healthy snacks
223790326|NCT06705855|DEVICE|NIRS sensor placement|After written informed consent, the patient will be brought to the operating room. Skin tone will be assessed using the Monk scale. Prior to induction of general anesthesia, the right kidney will be located by surface ultrasound, the distance between the renal capsule and the skin will be measured, and a NIRS sensor will be placed on the skin overlaying the kidney. If the patient has had a right nephrectomy, the left kidney will be used. Additional NIRS sensors will then be placed over the patient's ipsilateral biceps and vastus lateralis muscles. The distance from the skin to the muscle tissue will be measured and recorded using ultrasound. NIRS sensors will also be placed on the patient's forehead to measure cerebral oximetry as is current practice at our institution for all cardiac surgeries requiring cardiopulmonary bypass.
223790327|NCT04721054|DRUG|Thoracic epidural effect on heart rate in Laparoscopic Cholecystectomy (bupivacaine and lignocaine)|patients in epidural anesthesia were given epidural anesthesia and assessed for heart rate and mean arterial pressure
223790328|NCT04721054|DRUG|general anesthesia effect on heart rate in Laparoscopic Cholecystectomy|patients in general anesthesia were given epidural anesthesia and assessed for heart rate and mean arterial pressure
223790329|NCT00355082|DRUG|lamotrigine, 300 mg/day|300 mg/day
223790330|NCT00355082|DRUG|lamotrigine, 250 mg/day|250 mg/day
223790331|NCT02948179|PROCEDURE|Preimplantation Genetic Diagnosis|Using Preimplantation genetic diagnosis, including multiple annealing and looping-based amplification cycles amplification technique, the investigators have had screened out healthy embryos by In Vitro Fertilization. Then the investigators transplanted embryos returned to the parent. Finally, participants will have healthy baby without pathogenic gene inheritance.
223790332|NCT01437592|DRUG|insulin degludec|For each subject, a single dose of NN1250 will be administered subcutaneously (under the skin)
223790333|NCT04977882|PROCEDURE|abdominal drainage|19 Fr abdominal drainage placed intraoperatively in right colic gutter
223790334|NCT04977882|DRUG|Postoperative antibiotico-prophylaxis|Ceftriaxone 2 gr and Metronidazole 1.5 gr per day for 2 days postoperatively
223790335|NCT04977882|PROCEDURE|Laparoscopic radical right colectomy with CME and D3 lymphadenectomy (RRC)|the dissection starts over the landmark given by SMV. The SMV is freed anteriorly and on its right-hand side from all the lympho-adipose tissue. Once the SMV is fully exposed, the IC vessels are dissected and divided at the junction with the efferent vessels. The dissection moves upward along the same dissection line to identify the right colic vein and the GCTH. No medial to later dissection is carried out until the SMV is completely exposed before reaching the uncinate process of the pancreas. At this point the veins to the right colon are divided but gastroepiploic vein and artery are preserved unless the tumor is located at the hepatic flexure. The divided mesentery is lifted and tilted to the right, and the medial-to-later dissection starts following the embryological plane over Fredet's fascia. The mesocolon is divided on the right side of the middle colic artery and the right branches of the middle colic vessels are divided.
223790336|NCT04977882|PROCEDURE|Laparoscopic standard D2 right hemicolectomy (STANDARD)|A medial-to-lateral surgical dissection and high tie of the ileocolic vessels (IC) is undertaken without dissecting the anterior surface of the superior mesenteric vein (SMV). The gastro-colic trunk of Henle (GCTH) is not isolated and the right colic vein (when present) and the right branches of the middle colic vessels are taken more peripherical, during the division of the transverse mesocolon. The right gastroepiploic vessels are not dissected, nor divided, unless in proximity of the tumor
223790337|NCT04418804|DIAGNOSTIC_TEST|Chest ultrasound|"Each research volunteer will undergo a chest-directed ultrasound examination using a commercial device located in the Valley Hospital and approved for clinical use. After completing the above scan, the patient will undergo another ultrasound scan using a Vantage system device (by Verasonics), which is a research ultrasound device that will be provided on loan to the Haemek Hospital by the Weizmann Institute SAMPL Laboratory prior to the start of the trial. The scan will be made with a linear transducer sampled at a rate of about 8-12Mhz and / or with a curved transducer sampled at a rate of about 4-6Mhz.~The total estimated duration of the test is approximately 30 to 40 minutes per patient."
223790338|NCT02960529|PROCEDURE|extra-peritoneal high ligation of hernia|
223790339|NCT02960529|PROCEDURE|intraabdominal high ligation of hernia|
223790340|NCT06173778|DRUG|semaglutide 2.4mg|Semaglutide 2.4mg will be self-administered once a week under the surface of the skin and will be started at 0.24mg once a week for 4 weeks; in 4-week intervals, the dose will be increased until a dose of 2.4mg is reached
223790341|NCT06173778|DRUG|Placebo|Non-active medication, self-administered
223790342|NCT06173778|DRUG|Nicotine Replacement Therapy (NRT, nicotine patch)|Participants who smoke \>10 cigarettes/day will use 21 mg patches for the first 6 weeks, 14 mg patches during weeks 7 and 8, and 7 mg patches during weeks 9 and 10. Participants who smoke 5-10 cigarettes per day will use 14 mg patches for the first 6 weeks and 7 mg patches for weeks 7-10.
223790343|NCT06173778|BEHAVIORAL|Brief Smoking Cessation Counseling|Participants will receive weekly, manual-based individual smoking cessation counseling. Counseling will be provided by master's level clinicians.
223790344|NCT05353790|OTHER|Meals + snacks: control|8 weeks meal plans matched in calories (but not macronutrients or fiber) equivalent to 1 avocado + 1 cup of mango per day
223790345|NCT05353790|OTHER|Meals + snacks: Avocado mango|8 weeks meal plans provide1 avocado + 1 cup of mango per day
223790346|NCT05893992|DEVICE|Hearing aids with noise management features for listening in noise|Device for hearing loss compensation with digital noise management features
223790347|NCT05893992|DEVICE|Hearing aid for listening in quiet environments|Device for hearing loss compensation for listening in quiet environments
223790348|NCT03658720|DRUG|200 mg Ibuprofen acid orodispersible tablet|orodispersible tablet
223790349|NCT06433687|DEVICE|HekaHeart platform medication management and remote monitoring|Onboarding to the HekaHeart platform which includes a personalized GDMT management plan along with remote monitoring kits including a scale, blood pressure cuff, and heart rate monitor. Patients engage in video and phone calls with clinicians who will use established standardized clinical protocols to guide medication and vital optimization. Once patients are determined to be maximally titrated on all GDMT, they are transitioned back to standard clinical care.
223790350|NCT06850558|PROCEDURE|Four parallel implants were installed in the interforaminal region|All participants administrated prophylactic antibiotics one day before implant placement and continued 7 days after surgery. Participants were asked to rinse their mouth with chlorhexidine mouthwash just before surgery and 7 days after surgery. Under local anesthesia, four implants were placed bilaterally in the interforaminal region. Four parallel implants (TioLogic, Dentaurum) were inserted in the inter-foraminal area using the submerged surgical approach and delayed loading protocol. By using the stereolithographic surgical guide the Implants were installed by the same surgeon with a minimum torque of 35 Ncm to give high initial stability. Relief was done in the mandibular denture over the implants and tissue conditioner (Visco-gel; DENTSPLY, Weybridge, UK) was used as a relining material. osseointegration was allowed to occur for a period of 3-6 months prior to final restoration.
223790351|NCT06560918|DEVICE|hearing aids|OTC devices for a week
223790352|NCT05792449|BEHAVIORAL|Foundational Skills Curriculum|The therapist will coach parents in the context of clinic-based play activities and help parents identify contexts and activities at home where the parents could follow up on the program at home. Intervention sessions empower and equip parents with skills and strategies to engage with their child at home. Since the program involves behavioural intervention and parent coaching, active participation of parent and child are key to each session.
223790353|NCT05792449|BEHAVIORAL|Foundational Skills Curriculum - Telerehabilitation|Parent-child interactions during activities at home will be observed through video conferencing. Parents will be encouraged to interact with their child using strategies aimed at increasing their child's attention and motivation, turn-taking routines, initiating and responding to joint attention, communication, etc. Intervention sessions empower and equip parents with skills and strategies to engage with their child at home. Since the program involves behavioural intervention and parent coaching, active participation of parent and child are key to each session.
223790354|NCT01990443|DRUG|Reslizumab IV|Reslizumab 220-mg intravenous (IV)
223790355|NCT01990443|DRUG|Reslizumab SC|Reslizumab 220 mg administered subcutaneous (SC)
223790356|NCT05577052|RADIATION|Metastatic vertebrae treated with SBRT|High-dose SBRT treatment
223790357|NCT05043649|DRUG|Camsirubicin|The dose escalation of camsirubicin will start at 265 mg/m2, with dose increments of 50% until a Grade 2 non-hematologic toxicity is observed at which point subsequent dose escalations will be in increments of 25% until an MTD is identified in patients with ASTS.
223790358|NCT03822923|OTHER|Experimental group|Neurodynamics with conventional treatment. Intervention will be applied for 6 weeks (10 reps per set, 1 set per day, 3 days per week) for 30 minutes
223790359|NCT03822923|OTHER|Control group|Conventional treatment
223790360|NCT04598152|DEVICE|TDCS - transcranial direct current stimulation|TDCS involves passing a weak current through the brain. One variant, cathodal TDCS, can be used to temporarily hyperpolarize cortical pyramidal cells, thereby decreasing neuronal connections. TDCS has been explored as a possible treatment for depression, but results to date are mixed. No work has examined whether TDCS can be used in an individually guided manner to target locations in the parietal cortex and alter the patterns of circuitry dysfunction described previously.
223790361|NCT00000216|DRUG|Buprenorphine|
223790362|NCT06650527|BEHAVIORAL|Cognitive Empathy Training|Participants will engage in a mentalization activity by captioning photos of their care recipients, reflecting on what the care recipient might be thinking or feeling. Over 10 days, caregivers will take 3-5 daily pictures of their care recipient and caption each with descriptive text representing the recipient's inner voice. This task encourages caregivers to consider the care recipient's perspective and motivations behind their behavior or emotional experiences. Photos will be shared securely via encrypted email. Utilizing accessible smartphone technology, the study allows caregivers to capture and reflect on meaningful moments with their care recipients
223790363|NCT06650527|BEHAVIORAL|Control Condition|In the control condition, participants will be asked to take 3-5 daily photographs of nature over 10 days. They will be asked to caption each photo with a description of what they see. This exercise will involve many of the same activities as the cognitive empathy training, except that participants will not be mentalizing or taking the the perspective of their PLWD or anyone else.
223790364|NCT06650527|PROCEDURE|Pre and post intervention blood spot collection|At their initial study visit, participants will provide a blood spot sample for measurement of C-reactive protein, pro-inflammatory cytokines and Epstein-Barr virus antibody titers.
223790365|NCT06650527|PROCEDURE|Pre and post intervention MRI session|In this study, caregivers will be positioned in a Siemens Trio 3T MRI scanner for functional imaging. They will view images of their care recipient care recipient, other similar care recipients care recipient, and photographs of friends or family members, pressing a button each time they see their care recipient care recipient's photo to monitor attention. The task involves viewing eight photos of four individuals with happy and neutral expressions, followed by rest periods. This sequence repeats five times, with each stimulus presented for 5 seconds and inter-trial intervals of 2, 3, or 4 seconds, totaling 11 minutes and 15 seconds. A subsequent 10-minute diffusion-weighted scan will assess brain white matter integrity, using 60 diffusion directions. All scans will be completed within 40 minutes.
223790366|NCT03346759|DEVICE|Tampon A|24 Tampax Pearl Regular Tampons for use during a single menstrual period.
223790367|NCT03346759|DEVICE|Tampon B|24 Playtex Gentle Glide 360 Regular Tampons for use during a single menstrual period.
223790368|NCT00850616|BIOLOGICAL|V526|0.5 mL intramuscular injections of MRKAd5+6 trigene vaccine (V526) in a 3-dose regimen on Day 1, Week 4 and Week 26.
223790369|NCT00850616|BIOLOGICAL|Comparator: Placebo to V526|0.5 mL intramuscular injections of placebo to MRKAd5+6 trigene vaccine (V526) in a 3-dose regimen on Day 1, Week 4, and Week 26.
223790370|NCT00335660|DRUG|AV608|
223790371|NCT05273710|OTHER|Regular toast and juice|Participants consume a single test meal composed of regular whole wheat toast and apple juice, and zinc absorption is measured.
223790372|NCT05273710|OTHER|High phytate toast and juice|Participants consume a single test meal composed of high phytate whole wheat toast and apple juice, and zinc absorption is measured.
223790373|NCT05273710|OTHER|Regular toast and juice, with folic acid|Participants consume a single test meal composed of regular whole wheat toast and apple juice, with 400 mcg folic acid; and zinc absorption is measured.
223790374|NCT01094080|OTHER|standard infant formula|infants are fed a commercial formula
223790375|NCT01094080|OTHER|modified infant formula|the modified infant formula has a different protein content than the standard formula and long chain polyunsaturated fatty acids are added
223790376|NCT01094080|OTHER|breast milk|infants are breast fed
223790377|NCT05725538|DEVICE|COVIDReApp Group|"The COVIDReApp group will be required to complete an exercise program guided by an m-health system for three times per week during 24 weeks. A 60-minute program, following the recommendations of the American College of Sports Medicine. The daily session will be divided into:~* Warm-up: 5 min. walking so that the patient can hold a conversation , monopodial balance exercise, core exercise and other respiratory and joint mobility exercises.~* Aerobic training: Walking for 10 to 20 min. so that the patient can maintain a conversation, but having to stop to breathe from time to time.~* Strengthening: It will focus on 7 exercises. a) squats, b) dead weight with stiff legs, c) lateral pull-ups, d) inverted flies, e) flies, f) unilateral rowing and g) lateral raises.~* Cool down: It will consist of stretching exercises. a) shoulders, b) triceps, c) chest, d) quadriceps, e) hamstrings, and f) back."
223790378|NCT05725538|OTHER|Control Group|Participants will receive the same intervention in the traditional way, they will receive the exercise program in paper format. They will receive a document with photos and descriptions of the exercises to be performed. Their doctors will determine if the patients will be able to exercise regularly and they will perform them for 24 weeks.
223790379|NCT03460223|BIOLOGICAL|MSC|conventional plus MSC or placebo treatment
223790380|NCT02007850|DRUG|ropivacaine|Patients receive 15 ml of 0.25% ropivacaine pre-operatively through femoral block catheter, followed by 0.2% ropivacaine continuous mode or patient controlled mode for 2 days after surgery
223790381|NCT05035901|OTHER|visual-perception motor-coordination integration program|Visual-perception motor-coordination integration program (CCVPMCI) is a Chinese characteristic-based VMI-focused program involving the most Chinese-handwriting-related skills training. CCVPMCI mainly emphasizes the training role of visual-motor integration. The idea of CCVPMCI program will involve (1) visual motor integration training affiliated with visual perception and motor coordination as warm-up exercise, (2) more focus on visual spatial perception in connect with unique visual structure of Chinese characters, (3) the trace or component elements of Chinese characters as the interesting practice material and (4) appropriate challenge for learning.
223790382|NCT06669936|DRUG|Fecal microbiota transplantation ± bezlotoxumab|Co-administration of bezlotoxumab and FMT in patients with recurrent C. difficile infections who failed FMT alone.
223790383|NCT06669000|DIAGNOSTIC_TEST|Standard X-Rays|\- Standard X-Rays: feet (Month 0)
223790384|NCT06669000|DIAGNOSTIC_TEST|Ultrasound|\- Ultrasound (score 0-24): assessment for DC (Double Contour) sign (0-3), aggregates (0-3), tophi (0-3) at MTP1s (first metatarsophalangeal joints) and DC sign (0-3) at both knees, according to the OMERACT, every 6 months until complete dissolution of urate deposits.
223790385|NCT06669000|DIAGNOSTIC_TEST|DECT of feet|DECT of feet: in tophaceous patients only (Month 0, Month 24)
223790386|NCT06669000|BIOLOGICAL|DNA sample|DNA will be collected at Month 0
223790387|NCT06669000|BIOLOGICAL|Serum collection|\- Serum will be collected at Month 0, Month 6, Month 12, Month 18, Month 24 , Month 36 and Month 48. For OMICs and epigenetic studies: Month 0, Month 6, Month 24 and Month 36.
223790388|NCT06669052|DIETARY_SUPPLEMENT|30 mg liposomal iron, capsules|a dietary supplement capsule, of mainly 30 mg liposomal iron, and Vitamin C 70mg, vitamin D3 400IU, vitamin B6 1.75 mcg, Folate 1000 mcg, b=vitamin B12 10 mcg. all in capsulated in 1 Hard gelatin capsule
223790389|NCT07127991|DEVICE|Medium Frequency Neuromuscular Electrical Stimulation (NMES)|"The medium-frequency NMES protocol, as reported in previous studies, consists of a carrier frequency of 2,500 Hz, a treatment frequency of 100 Hz, an ON time of 5 seconds (1 second ramp-up, 3 seconds contraction, and 1 second ramp-down), and an OFF time of 10 seconds. This stimulation protocol will be applied for 20 minutes per session (40 minutes of NMES per treatment day).~Two electrodes will be placed on each thigh, located at the motor point of the quadriceps muscle. Electrode positions will be marked with a semi-permanent marker to ensure consistent placement across sessions."
223790390|NCT07127991|PROCEDURE|Standard physical therapy|Participants of the fourth age (≥80 years old) will receive the standard physical therapy routinely provided during their hospitalization. This intervention involves passive mobilization of the lower limbs, specifically within the ranges of hip flexion, knee flexion and extension, and ankle flexion and extension. One set of 10 bilateral repetitions will be performed while the patient is under sedation in the ICU. Once the patient is awake, the mobilization protocol routinely used in the same unit will be followed.
223790391|NCT00404157|DRUG|Rituximab|
223790392|NCT02863562|OTHER|Kinesio taping|Kinesio taping technique was used on both ankles on the first day of training with the aim of functional and mechanical correction, following the method described by Duenas et al. It was removed on the second day of training. This procedure was repeated each week for one month.
223790393|NCT02863562|OTHER|Proprioceptive exercises|Proprioceptive exercises were performed twice a week for one month. They were incorporated into their normal training routine (twice per week), and included 20 min of standardised proprioceptive exercises: single leg balancing on stable surfaces, on bosu/togu balls, and hopping activities, all repeated with eyes open/closed.
223790394|NCT02863562|OTHER|Placebo Kinesio taping|
223790395|NCT03399422|BIOLOGICAL|i-PRF|i-PRF (injectable platelet rich fibrin) assisted upper canine retraction
223790396|NCT03399422|PROCEDURE|canine retraction|upper canine retraction will be performed in one side of patients with Class II Division 1 malocclusion patients requiring therapeutic extraction of the maxillary first premolars
223790397|NCT06720467|BIOLOGICAL|Intralesional injection of Candida albicans 1:20 w/v 10 ml vial (Allergy Laboratories, INC. Oklahoma City, USA.)|Intralesional injection of 0.2 ml of 1/1000 solution of Candida albicans antigen using an insulin syringe directly into the warts; Candida albicans 1:20 w/v 10 ml vial (Allergy Laboratories, INC. Oklahoma City, USA.). The same injection was repeated every 2 weeks until complete clearance for a maximum of six treatment sessions.
223790398|NCT03216174|PROCEDURE|NESS-EFTR|NESS-EFTR includes steps of laparoscopic seromuscular suturing, EFTR of the inverted stomach wall, and endoscopic mucosal suturing with endoloops and clips.
223790399|NCT06854601|DRUG|Mexidol|125 mg tablets
223790400|NCT06854601|DRUG|Placebo|Placebo tablets
223790401|NCT06854601|DRUG|Mexidol + Placebo|Combination of Mexidol and Placebo
223790402|NCT06384508|BEHAVIORAL|SHINE-VR|"The SHINE-VR takes place after trauma processing, e.g. after module 6 of TF-CBT or processing of the traumatic event with EMDR, and is followed by the rest of the regular treatment. SHINE-VR consists of the following 3 VR sessions à 45min:~* Introduction: getting acquainted with VR, playing a VR game developed for the feasibility study (Krupljanin et al., in preparation), receiving psychoeducation about seeking help.~* Shame: virtual group therapy setting, psychoeducation about shame, virtual peers sharing thoughts of shame and their learnings/positive affirmations.~* Self-compassion: practicing self-compassion using an immersive perspective-changing task in VR."
223790403|NCT07099339|BEHAVIORAL|Behavioral Therapy|Behavioral Therapy in form of: Learning and advices, Dietary modifications, Toilet pattern modification, Motivational rewarding system, and Diary documentation.
223790404|NCT07099339|OTHER|Kegel Exercise|Kegel Exercise done by contracting and relaxing pelvic floor muscles for seconds with hold and repetitions.
223790405|NCT07099339|DEVICE|Pudendal Nerve Electrical Stimulation|Pudendal Nerve Electrical Stimulation applied bilateral to the right and left pudendal by inserting rectal stimulator electrode anally with the other surface electrode at sacral region.
223790406|NCT07099339|DIAGNOSTIC_TEST|Anal Sphincter Muscle Activity Peak|Anal Sphincter Muscle Activity Peak was evaluated using anal pressure sensor (in mmHg) = anal squeeze pressure during maximum voluntary contraction - resting anal pressure at rest or resting tone as baseline activity
223790407|NCT07099339|DIAGNOSTIC_TEST|Bowel Diary Documentation|"Defecation Frequency and Fecal Leakage Episodes collected from the Bowel Diary that documenting bowel events daily through a period of time a week."
223790408|NCT07113249|OTHER|Foam Rolling (FR)|For the FR, participants were asked to place the roller behind their leg. Three sets, each lasting 60 seconds, with a 30-second break between sets, were performed, for a total of 90 rolls per set.
223790409|NCT07114016|DRUG|Glucosamine Hydrochloride|GlcN.H is an N-deacetyl amino sugar derived from the complete hydrolysis of chitosan known for its immunoregulatory capacity and anti-inflammatory effects.
223790410|NCT07114016|DRUG|Triamcinolone Acetonide|Topical corticosteroid (triamcinolone acetonide is a synthetic corticosteroid with potent anti-inflammatory, anti-allergic, and immunosuppressive properties which is used commonly in topical formulations)
223790411|NCT07118748|OTHER|Share making decision tool|the experimental group will apply the delegation protocol, but if the protocol recommends antibiotic therapy, the researchers will propose a shared decision using a specific tool to determine with the patient whether to deliver the antibiotic
223790412|NCT07118748|OTHER|Delegation protocol|the control group will apply the delegation protocol alone
223790413|NCT07118111|PROCEDURE|Resin infiltration|Application of a low-viscosity resin infiltrant to the anterior teeth affected by enamel defects. This procedure aims to reduce dental hypersensitivity and improve esthetic appearance.
223790414|NCT07121556|DEVICE|MFAT + HA left knee - MFAT + placebo right knee|The left knee will be treated with an injection of high-molecular-weight hyaluronic acid (4 cc) and microfragmented autologous adipose tissue (6 cc), harvested from the abdominal site.The right knee will be treated with microfragmented autologous adipose tissue (6 cc), also harvested from the abdominal site by liposuction and microfragmentation, combined with an injection of 4 cc of saline (NaCl 0.9%)
223790415|NCT07121556|BIOLOGICAL|MFAT + HA right knee - MFAT + placebo left knee|The right knee will be treated with an injection of high-molecular-weight hyaluronic acid (4 cc) and microfragmented autologous adipose tissue (6 cc), harvested from the abdominal site.The left knee will be treated with microfragmented autologous adipose tissue (6 cc), also harvested from the abdominal site by liposuction and microfragmentation, combined with an injection of 4 cc of saline (NaCl 0.9%)
223790416|NCT07121868|DRUG|Test Product (Vocarzine)|hard capsule formulation
223790417|NCT07121868|DRUG|Reference (R) Reagila ®|hard capsule formulation
223790418|NCT07122817|OTHER|Assessment|The group to be evaluated is comprised of individuals over 65 years of age, who can independently carry out their daily living activities, and whose cognitive level is sufficient to understand and answer the surveys and tests in the study.
223790419|NCT07126925|BEHAVIORAL|Personalized Fall Prevention Program|An intervention package featuring a comprehensive, multidimensional risk assessment using an improved form and a dynamic functional test (Obstacle Physical Activity Ability Test). The assessment guided the development of a personalized prevention plan, including targeted exercises, environmental adjustments, and enhanced patient/family education.
223790420|NCT07126925|BEHAVIORAL|Standard Fall Prevention Care|Standard hospital care for fall prevention, including universal precautions (e.g., clutter-free environment, non-slip footwear) and risk assessment using a standard hospital checklist.
223790421|NCT07128186|OTHER|follow-up observation|In this study, no additional interventions were administered to any enrolled participants; only 3-5 years of follow-up observation were conducted, with cognitive status data collected at both baseline and endpoint.
223790422|NCT07127822|DRUG|Iparomlimab and Tuvonralimab|Iparomlimab and tuvonralimab for experimental arm
223790423|NCT07127822|DRUG|First line chemotherapy plus PD-1/PD-L1 antibody|standard first-line chemotherapy（FOLFOX/XELOX/SOX）combined with PD-1/PD-L1 antibody for control arm
223790424|NCT07126119|DRUG|Nab-Paclitaxel|Nab-Paclitaxel 125mg/m\^2 IV will be administered on Day 1 every 3 weeks for 2-3 cycles
223790425|NCT07126119|DRUG|Tislelizumab|Tislelizumab 200mg iv will be administered on Day 1 every 3 weeks for 2-3 cycles.
223790426|NCT07126119|PROCEDURE|Radical nephroureterectomy (RNU)|Radical nephroureterectomy (RNU) will conducted after the completion of neoadjuvant therapy.
223790427|NCT07127003|PROCEDURE|Immediate Lymphatic Reconstruction|Preserved lymphatic channels are connected to nearby veins to prevent lymphedema during the axillary lymph node dissection.
223790428|NCT07126184|DIAGNOSTIC_TEST|Extended Cardiac Monitoring|This observational study involved the use of standard cardiac monitoring methods to detect atrial fibrillation in patients initially diagnosed with cryptogenic ischemic stroke. Monitoring techniques included 12-lead ECG, 24-hour Holter monitoring, and implantable loop recorders (ILRs). No experimental interventions were assigned; patients received routine clinical care.
223790429|NCT07126821|OTHER|No Interventions|No Interventions
223790430|NCT07128212|DRUG|Atorvastatin 10 mg daily|Oral atorvastatin 10 mg administered once daily at 18:00 (6 p.m.) for 24 months. Dose form: tablet. Route: oral. Indicated for participants with WMH. Adherence monitored by pill count and diary. No dose titration planned.
223790431|NCT07128212|DRUG|Placebo matching atorvastatin|Placebo tablet matching atorvastatin in appearance and packaging, containing inactive excipients only; taken orally once daily at 18:00 for 24 months.
223790432|NCT07126197|PROCEDURE|lymphovenous bypass at diseased foot dorsum|A lymphovenous bypass procedure using a lymphangiography dye (Patent Blue V or indocyanine green), 0.2 mL was injected into the skin at the toe webspaces preoperatively. 8,13,14 The paths of lymphatic vessels were traced. On the foot dorsum of the affected limb, a horizontal incision of 2-3 cm was made close to the lymphatic vessel's pathway. Under the surgical microscope, suitable lymphatic and venous vessels were identified, usually located above the deep fascia (on the superficial side, ensuring that the extensor hallucis longus tendon remains unexposed). The coaptation between the lymphatic vessels and venules followed the same principles as those for vascular anastomosis by using higher magnification under the surgical microscope (approximately 20×), finer microsurgical instruments, and 11- or 12-0 nylon sutures.
223790433|NCT07127965|BEHAVIORAL|Goal Setting and Exercise Intensity Intervention|Participants' goal-setting and exercise intensity are manipulated based on group assignment.
223790434|NCT07126613|BEHAVIORAL|Mobile Health Intervention to Reduce Alcohol Use Among Young Adults|"The mobile just-in-time adaptive intervention consists of 1) a digital participant dashboard and 2) tailored messages delivered to the participant's cellphone addressing the individual and ecological contexts of alcohol use.~The web-based intervention dashboard includes: 1) a drink counter for participants to log the number and type of drinks (e.g., beer, wine, mixed drink) they consume in a drinking occasion; 2) a calendar which summarizes the number of days on which a participant has consumed alcohol and the number of drinks consumed over the study period, broken out by drink type; 3) a log where participants can set drinking-related goals and update their progress on those goals; and 4) national and local substance use resources.~Participants will receive messages tailored to their drinking situation and ecological context during high-risk drinking times."
223790435|NCT07126561|DRUG|Trastuzumab Deruxtecan|Do not substitute trastuzumab deruxtecan with trastuzumab or ado-trastuzumab emtansine. Do not administer as an intravenous push or bolus. Trastuzumab deruxtecan is not compatible with sodium chloride 0.9% solution for infusion. During treatment, patients should be observed for infusion-related reactions (IRRs). For additional information on the management of IRRs
223790436|NCT07128251|PROCEDURE|TACE treatment|TACE treatment (cTACE): On-demand TACE therapy will be administered, with a maximum of 4 TACE sessions permitted.
223790437|NCT07128251|DRUG|Iparomlimab and Tuvonralimab Injection (QL1706)|Iparomlimab and Tuvonralimab Injection (QL1706): 7.5 mg/kg, intravenous infusion, Day 1 of each cycle, Q3W.
223790438|NCT07128251|DRUG|Bevacizumab|Bevacizumab Injection: 15 mg/kg, intravenous infusion, Day 1 of each cycle, Q3W.
223790439|NCT07126093|COMBINATION_PRODUCT|focal high-intensity focused ultrasound therapy combined with standard novel hormonal therapy|The participants in the intervention arm will receive HIFU combined with standard NHT. Depending on the location of the lesion, tumor load and the pathological conditions, hemicglandular ablation or focal ablation was selectively administered. The safe boundary was set at 3mm, with a power of 300W and a pulse width of 30ms. Novel endocrine therapy was given after HIFU treatment
223790440|NCT07126093|OTHER|Standard novel hormonal therapy only|Participants in the control arm will receive standard NHT.
223790441|NCT07127653|OTHER|Retinol-Based Day Cream|A commercially available day cream containing retinol and moisturizing ingredients. Applied twice daily (morning and evening) to the full face for 4 weeks.
223790442|NCT07127653|OTHER|Lotion and Toner Bundle|A skincare regimen including a dermalift toner and a milky lotion. Applied twice daily (morning and evening) to the full face for 4 weeks.
223790443|NCT07127731|BEHAVIORAL|Patient Portal Messaging|Participants will receive weekly messages via their patient portal including feedback on their step counts and step count goals based on data from their FitBits
223790444|NCT07127731|BEHAVIORAL|FitBit EHR Linkage|Participants will receive FitBits and link this step count data with the Electronic Health Record (EHR)
223790445|NCT07127276|OTHER|Mobile application GERDCare|Features of GERDCare that support management of GERD
223790446|NCT07127120|DIETARY_SUPPLEMENT|Prebiotic fiber blend|"Proprietary blend of 5 prebiotic fibers and normal bar excipients Product name: NeuroFiber Dosage form: Single bar/day~Storage conditions:~The Study Product delivered by Sorridi to patient/subject at the beginning of study. Any remainder will be collected by Sorridi at end of study.~Product is to be stored at room temperature in the patient's/subject's homes.~The bar will be produced and packaged at a licensed contract manufacturer experienced in producing nutritional supplements.~Labelling will be carried out by Sorridi Therapeutics."
223790447|NCT07126262|DRUG|Vosoritide|The vosoritide dose administered will be based on the participant's weight and will follow the weight-band dosing regimen approved for ACH
223790448|NCT07126262|DRUG|Placebo|Subcutaneous injection of recommended dose of placebo
223790449|NCT07128108|OTHER|Visual Transient Elastography (ViTE) Examination|Post-marketing product (Mindray Hepatus 9 Ultrasound Diagnostic System) for visual transient elastography examination in patients with liver injury.
223790450|NCT07126808|BEHAVIORAL|Simulation-Based CPR Workshop|A 4-hour, in-person simulation-based cardiopulmonary resuscitation (CPR) workshop designed for non-healthcare university students, following American Heart Association 2020 guidelines and the NLN Jeffries Simulation Framework. The training includes: (1) pre-briefing on OHCA and CPR importance; (2) instructor-led demonstration using manikins; (3) guided hands-on practice with real-time feedback; (4) scenario-based simulation with assigned team roles; and (5) structured debriefing for reflection and feedback. Skills practiced include scene safety, assessing responsiveness, high-quality chest compressions, rescue breathing, AED use, and team communication. Trainer-to-student ratio is approximately 1:6.
223790451|NCT05156268|DRUG|Pembrolizumab|Pembrolizumab will be administered intravenously (IV) at 200mg every 3 weeks.
223790452|NCT05156268|DRUG|Olaparib|Olaparib will be administered orally at 300 mg every 12 hours.
223790453|NCT04336579|BEHAVIORAL|Diaphragmatic Breathing|Simple diaphragmatic breathing exercise
223790454|NCT00738777|DRUG|Anastrozole|1 mg,QD,PO
223790455|NCT00738777|DRUG|Anastrozole+Fulvestrant|Anastrozole; 1 mg, QD, PO Fulvestrant; 500 mg, IM, day 1, 15, 29 and monthly thereafter
223790456|NCT00738777|DRUG|Tamoxifen|loading dose of 40 mg, TID, PO, during 7 days, Thereafter 20 mg, QD, PO
223790457|NCT00738777|DRUG|Tamoxifen|loading dose of 40 mg, TID, PO, during 7 days, Thereafter 20 mg, QD, PO
223790458|NCT03570398|OTHER|unenhanced abdomino-pelvic CT scan|unenhanced abdomino-pelvic CT scan
223790459|NCT03570398|OTHER|abdominal ultrasound|abdominal ultrasound
223790460|NCT01472198|DRUG|Simtuzumab|Simtuzumab administered intravenously every 2 weeks for a total of 2 infusions (Days 1 and 15)
223790461|NCT01472198|DRUG|Gemcitabine|Gemcitabine 1000 mg/m\^2 administered intravenously on Days 1, 8, and 15 of each 28-day cycle
223790462|NCT01472198|DRUG|Placebo to match simtuzumab|Placebo to match simtuzumab administered intravenously every 2 weeks for a total of 2 infusions (Days 1 and 15)
223790463|NCT05229068|BIOLOGICAL|RSV MAT|Single 120 µg dose of the RSV MAT vaccine reconstituted with NaCl solution, administered intramuscularly in the non-dominant arm, at Day 1.
223790464|NCT03327766|DIAGNOSTIC_TEST|4-Measurment of serum 25(OH)D3 using Vidas by ELFA meathod.|A specialized test of the 25(OH)D serum level was conducted and the blood samples were collected in the months of November to April. The winter months were chosen intentionally in order to limit the impact of the sun light upon 25(OH)D serum level.The test VIDAS® 25 OH Vitamin D Total was used-enzyme immunoassay with highly fluorescent measurement ELFA. According to the reference values of this method the 25(OH)D \< 20 ng/ml serum levels are considered as deficiency and the serum levels between 20 - 30ng/ml are defined as insufficiency. It's sufficient if the level of 25(OH)D is 30 to 100 ng/ml.
223790465|NCT03344679|DRUG|Bupivacaine 0.25%|Bupivacaine 0.25% for PECS block
223790466|NCT03344679|DRUG|Adenosine 12mg|Adenosine 12 mg for PECS block
223790467|NCT03344679|DRUG|Magnesium Sulphate 500 mg|Magnesium sulphate 500 mg for PECS block
223790468|NCT05105594|OTHER|survey application|Fear of movement will be evaluated with the Kinesiophopia Causes Scale. It is a 20-question survey in which the causes of fear of movement are investigated. Functional Evaluation of Treatment of Fatigue Chronic Disease will be assessed by the Fatigue Questionnaire. It consists of 13 questions assessing the level of fatigue during daily activities in the last 7 days. Quality of Life will be assessed by the Lymphedema Quality of Life Questionnaire.
223790469|NCT04473885|OTHER|Perturbation-based balance training|Participants in the experimental group will receive the balance training under perturbation on Balance SystemTM SD, including limits of stability training, maze control training, random control training. The intervention is 40 min/session, 3 sessions/week for 6 weeks.
223790470|NCT04811430|DEVICE|Randomized Traditional|Traditional ultrasound guidance was utilized to insert Midlines on simulated veins blocks not live patients
223790471|NCT04811430|DEVICE|Cue(TM) Needle Tracking Technology|Cue(TM) Needle Tracking Technology with real time needle tip tracking is used to assist ultrasound guided midline insertions on simulated veins blocks not live patients
223790472|NCT02676102|BEHAVIORAL|Control Group|Generic Video about organ donation
223790473|NCT02676102|BEHAVIORAL|Targeted Intervention|an educational video produced in partnership with the community of black men including customers, employees, and owners of BOBs. Video production was informed by entertainment education models and produced with experts including an Academy Award winning filmmaker.
223790474|NCT02676102|BEHAVIORAL|Tailored Intervention|Videos with content individualized to participant's pre-intervention Organ Donation Belief Index (ODBI).
223790475|NCT00652158|DRUG|MLN8054|"10 mg doses of MLN8054 were given orally once daily following a schedule of 5 days on/2 days off/5 days on repeated every 28 days"
223790476|NCT05125770|BIOLOGICAL|New crown vaccine|New Coronavirus vaccine
223790477|NCT06487455|DRUG|SPH7485|SPH7485： Orally, once daily, 50-400mg, 21 days per cycle
223790478|NCT03069482|DEVICE|Learn to Quit App|A smartphone app designed for individuals with serious mental illness. The main intervention components of the app are skills based on an intervention called Acceptance and Commitment Therapy that will (a) teach smoking cessation skills and (b) help cope with mental health symptoms. The app incorporates gaming features to keep users engaged, and a tracking component to record smoking habits and moods.
223790479|NCT03069482|DRUG|Nicotine patch|Participants enrolled in the study will be given an 8-week course of Nicotine patches. The 8-week course of trans-dermal nicotine patches starting at 21mg/24h for 4 weeks, then transitioning to 14mg/24h for 2 weeks, and finally to 7mg/24h for the last 2 weeks. This dosing will follow recommendations contained in the US DHHS Clinical Practice Guidelines.
223790480|NCT03069482|DRUG|Nicotine lozenge|Each participant will be given a 1-week course of 4mg Nicotine lozenges to be taken orally as nicotine cravings arise (about 10 lozenges per day). They will be directed to use them for the week following their quit date, using no more than once every 1-2 hours. This dosing will follow recommendations contained in the US DHHS Clinical Practice Guidelines.
223790481|NCT03069482|BEHAVIORAL|Technical Coaching|Coaching to assist the user on the use of each assigned smartphone app. This coaching will be delivered by research staff following a coaching procedure. These in-person coaching meetings will be brief (\~15 minutes), done on a weekly basis for 4 weeks, and will have a focus on providing technical assistance.
223790482|NCT03069482|DEVICE|NCI QuitGuide App|A smartphone app developed by the National Cancer Institute which uses recommendations contained in the US DHHS Clinical Practice Guidelines and smokefree.gov. NCI QuitGuide has the following intervention components: (a) psycho-education about the impact of smoking in health, (b) tracking of smoking habits, and (c) Tips for quitting (e.g., distraction strategies).
223790483|NCT00791765|BIOLOGICAL|Etanercept|Etanercept for subcutaneous injection.
223790484|NCT00791765|BIOLOGICAL|Placebo|Placebo for subcutaneous injection.
223790485|NCT04575896|DRUG|Glecaprevir/pibrentasvir|Glecaprevir/pibrentasvir 300mg/120mg once daily by mouth for 2 weeks post-transplant.
223790486|NCT00490191|DRUG|Somatropin|
223790487|NCT04942106|OTHER|Arm 1 - Side-lying position followed by Supine position|Infants will be observed for two bottle feedings within a 24-hour period when they reach approximately 30-50% oral feeding. In this arm, infants will be bottle-fed in the side-lying position first followed by the supine position. In the side-lying feeding position, the infant will be placed on the caregiver's lap with one ear and hip facing the ceiling at a 45 to 60 degree angle. In the supine feeding position, the infant will be placed facing the caregiver in a reclining position at a 45 to 60 degree angle. In both feeding positions, the infant's head, neck, and upper body will be supported by the caregiver to maintain a neutral straight alignment with the chin tilted down slightly without the neck being extended or in excessive flexion. The infant will also be loosely swaddled with a single blanket so their legs, shoulders, and elbows are supported in a flexed position but with the lower arms free to move.
223790488|NCT04942106|OTHER|Arm 2 - Supine position followed by Side-lying position|Infants will be observed for two bottle feedings within a 24-hour period when they reach approximately 30-50% oral feeding. In this arm, infants will be bottle-fed in the supine position first followed by the side-lying position. In the side-lying feeding position, the infant will be placed on the caregiver's lap with one ear and hip facing the ceiling at a 45 to 60 degree angle. In the supine feeding position, the infant will be placed facing the caregiver in a reclining position at a 45 to 60 degree angle. In both feeding positions, the infant's head, neck, and upper body will be supported by the caregiver to maintain a neutral straight alignment with the chin tilted down slightly without the neck being extended or in excessive flexion. The infant will also be loosely swaddled with a single blanket so their legs, shoulders, and elbows are supported in a flexed position but with the lower arms free to move.
223790489|NCT02754648|PROCEDURE|laparoscopic ovarian endometriotic cyst|
223790490|NCT00215267|DRUG|praziquantel|
223790491|NCT00103246|DRUG|silicon phthalocyanine 4|Participants receive topical silicon phthalocyanine 4 (Pc 4). One hour later, participants undergo photodynamic therapy. Treatment repeats weekly for up to 3 weeks (up to 3 total treatments for the same lesion OR up to 3 lesions treated if multiple lesions are present).Cohorts of 3 participants receive escalating doses of Pc 4 and visible light until the maximum tolerated dose (MTD) is determined.
223790492|NCT02498483|DRUG|Acetaminophen|Infants will receive 15 mg/kg of acetaminophen.
223790493|NCT04704375|DEVICE|Bio Electro-Magnetic Regulation (BEMER) Therapy|BEMER is a therapeutic modality that deploys a biorhythmically defined stimulus through Pulsed Electromagnetic Field (PEMF). This stimulus has a targeted effect on the microvasculature, and the primary effect is an improvement in tissue microcirculation. The positive effects of vasomotion on the microcirculation has been shown to result in significant increases in arteriovenous oxygen difference, number of open capillaries, arteriolar and venular flow volume, and flow rate of red blood cells in the microvasculature. Therefore, BEMER can potentially be used in the treatment of LBP by improving microcirculation in muscular tissue.
223790494|NCT04704375|PROCEDURE|OMT (osteopathic manipulative treatment)|i. OMT Myofascial release (MFR), soft tissue (ST) release, muscle energy (ME), counterstrain (CS), and balanced ligamentous tension (BLT) technique.
223790495|NCT04704375|PROCEDURE|Light touch|Treaters will place their hands lightly on the subject's lumbar paraspinal muscles in the supine and prone positions in the same area as where one would place your hands for lumbar MFR technique for the same amount of time as it would take to perform MFR in this area (approximately 5 minutes). However, no lifting or action will be done. In addition, the subject will lie down on the BEMER mat (as they would do during a BEMER session), but the device will not be activated.
223790496|NCT01114854|DRUG|Topiramate IR|
223790497|NCT01114854|DRUG|Topiramate ER|
223790498|NCT02247609|GENETIC|Anti-CD19 CAR T cells|Autologous 4th generation withdrawable lentiviral-transduced anti-CD19-CAR T cells
223790499|NCT05309304|DRUG|Cefazolin|Cefazolin Injection - 2 g/100 mL or 3 g/150 mL
223790500|NCT01429532|PROCEDURE|phacoemulsification|Cataract surgery performed with three incision-size-dependent phacoemulsification systems (1.8, 2.2 and 3.0 mm)
223790501|NCT01877408|PROCEDURE|Open surgical circumcision|Open surgical circumcision using a technique approved by the WHO (dorsal slit)
223790502|NCT01877408|DEVICE|Unicirc device with tissue adhesive|Removal of foreskin with Unicirc disposal device and wound sealing with tissue adhesive.
223790503|NCT00156065|DRUG|Haloperidol|2-8 mg BID
223790504|NCT00156065|DRUG|Asenapine|5 or 10 mg BID
223790505|NCT00156065|DRUG|Asenapine|5 or 10 mg BID
223790506|NCT04225208|DRUG|[14C]-AZD4205, single 50 mg oral dose administrated on day 1|Each subject will receive 50 mg AZD4205 oral solution (free base equivalent) containing a nominal dose of 15 µCi \[14C\]- radiolabelled AZD4205 as a single administration .
223790507|NCT04473131|OTHER|No intervention|Only blood samples will be taken from participants for this study
223790508|NCT05695365|BEHAVIORAL|Resistance Exercise Training|Participants will complete a 16-week, twice/week supervised resistance exercise training program to increase strength. Each session will last \~60 minutes and begin and end with a 5-minute aerobic warm-up/cool-down on a cycle ergometer, elliptical, treadmill, or walked laps. Training will begin with a 1-week standard familiarization process to introduce participants to the machines, teach correct lifting techniques, and ensure participant safety and comfort with each exercise machine. Participants will perform 3 sets of 8-12 repetitions on 10 Keiser resistance machines (i.e., leg press, hamstring curl, quadriceps extension, chest press, lat pulldown, shoulder press, biceps curl, triceps extension, abdominal crunch), with a 1-minute rest time between each set. Workload will begin at 50% of the estimated 1-RMs and increase by 5-10% after any session in which a participant completes 12 repetitions in all 3 sets. The workload will be tailored based on progressive increases in strength.
223790509|NCT04942171|PROCEDURE|Atrial fibrillation catheter ablation group|"1. Pulmonary vein isolation~2. Additional treatment for lesions caused by non-pulmonary veins~3. Esophageal temperature monitoring to prevent damage to the esophagus~4. Evaluation of procedure time and radiofrequency ablation time~5. Evaluation of complications after the procedure~6. Rhythm follow-up after the procedure is conducted in accordance with the above study design.~7. Conduct a survey on cognitive function and emotion before and 12 months after the procedure"
223790510|NCT04942171|DRUG|Medical therapy group|"1. Use of beta-blockers or calcium channel blockers for pulse rate control~2. Antiarrhythmic drugs are administered to patients with highly symptomatic atrial fibrillation symptoms even after pulse rate control.~3. If symptoms are not controlled even with antiarrhythmic drugs, electrical conversion to restore sinus rhythm.~4. To prevent cerebral infarction, maintain optimal anticoagulant therapy according to the risk score for cerebral infarction.~5. Conduct a questionnaire on cognitive function and emotion before and 12 months after the procedure"
223790511|NCT06156930|OTHER|Intervention group lavender oil|The group will receive aromatherapy massage with a 5% mixture prepared with sesame oil and lavender oil for 10 minutes on both lower leg areas, three times a week for four weeks.
223790512|NCT06156930|OTHER|Placebo group sesame oil|The group will receive a massage with sesame oil on both lower leg areas for 10 minutes on each leg, three times a week for four weeks.
223790513|NCT06534632|OTHER|Mother's colostrum|Oropharyngeal administration of mother's colostrum
223790514|NCT06534632|OTHER|Placebo|Oropharyngeal administration of sterile water
223790515|NCT02417038|DEVICE|Capnostream|The Capnostream capnograph (is registered with the FDA) is supplied by Covidien. The Capnostream is a portable CO2 monitor with a pulse oximetry module to measure and record SpO2 (oxygen saturation) and heart rate continuously. The Capnostream provides waveform patterns for respiratory rate and EtCO2 measurement.
223790516|NCT01292603|DRUG|Cyclophosphamide|Days 1-3 or Days 1-5 of cycles 1-6
223790517|NCT01292603|DRUG|Fludarabine|Days 1-3 or Days 1-5 of cycles 1-6
223790518|NCT01292603|DRUG|rituximab [MabThera]|One cycle of intravenous MabThera, followed by 5 cycles of subcutaneous MabThera
223790519|NCT01292603|DRUG|rituximab [MabThera]|After 4 cycles of intravenous MabThera without experiencing grade 3 or 4 infusion-related reactions. patients will receive 1 additional cycle of intravenous MabThera and 1 cycle of subcutaneous MabThera.
223790520|NCT01292603|DRUG|rituximab [MabThera]|6 cycles of intravenous MabThera
223790521|NCT03282981|DRUG|Timolol|Topical application of Timolol on non-healing diabetic foot ulcers
223790522|NCT03282981|DRUG|Non biologically active gel|Topical application of non biologically active gel (Hydrogel- standard of care) on non-healing diabetic foot ulcers
223790523|NCT00463190|DRUG|Biothree|
223790524|NCT04222348|DRUG|Metformin|850-2550 mg every 24h.
223790525|NCT04222348|DRUG|Insulin Detemir|Insulin detemir associated or not with rapid insulin analogue (aspart) according to individual glycemic controls.
223790526|NCT03434925|GENETIC|Multi-targeted next generation sequencing|Study directed at finding molecular predictors of recurrent colorectal adenomas also taking into account the intrinsic level of heterogenity imprinted in the internal differences in molecular profiles
223790527|NCT03870763|DRUG|Dimethyl Fumarate|Administered as specified in the treatment arm.
223790528|NCT03870763|DRUG|Peginterferon Beta-1a|Administered as specified in the treatment arm.
223790529|NCT03870763|DRUG|Placebo|Administered as specified in the treatment arm.
223790530|NCT05239234|OTHER|Inferior vena cava-Aorta diameter index|Before the induction of general anesthesia, inferior vena cava-Aorta diameter index and inferior vena cava collapsibility index will be measured.
223790531|NCT06034860|DRUG|MT-8421|Experimental treatment with MT-8421
223790532|NCT06034860|DRUG|Nivolumab|480 mg nivolumab administered on Day 1 of each cycle starting with Cycle 2 for all combination dose escalation and dose expansion cohorts
223790533|NCT05615792|OTHER|No intervention|No intervention
223790534|NCT02345031|DRUG|AUT00063|600 mg, orally, once a day, for 4 weeks
223790535|NCT02345031|DRUG|Placebo|orally, once a day, for 4 weeks
223790536|NCT05247996|PROCEDURE|Transcatheter arterial chemoembolization|"Treatment regimens have chosen lipiodol-based hepatic arterial chemoembolization, with lipiodol dosage varying from 5-20ml depending on tumor size. The chemotherapy drug is gemcitabine 1.0 combined with 100mg oxaliplatin, combined with 1/3 to 1 dose of solid embolic agent (the dosage is determined by the investigator based on the tumor size). After uniform emulsification, the drug is injected into the supplying blood vessels and stops when the intravascular blood flow is slow. Later, angiography is performed again, and the tumor staining disappears and the supplying artery is occlusions.~CT or MRI scans are performed 4 to 6 weeks postoperatively to assess the presence of active lesions. Repeat TACE if active lesions are still present. The frequency of TACE treatment is determined by the investigator and is given according to the patient's condition, generally 2-4 times. The interval between TACE treatments is 30-45 days, with a maximum of six cycles."
223790537|NCT05247996|DRUG|Multi-target Drug Therapy|Multi-target drugs (lenvatinib or donafenib) are selected at the patient's preference. Oral multitarget drugs are initiated 3-7 days after initial TACE treatment until tumor progression is assessed. The initial dose of lenvatinib is 8mg/ day (bodyweight \< 60 kg) or 12 mg/ day (body weight≥60 kg); Donafenil 0.2g, twice a day, taken orally on an empty stomach. If the medication is missed, there is no need to take a refill and the next dose shall be taken at the usual time.
223790538|NCT05247996|DRUG|Immunocheckpoint Inhibitor Therapy|Optional types of immune checkpoint inhibitors include Sintilimab injection and Tislelizumab injection. Treatment shall be based on the immune checkpoint inhibitors before enrollment, and it is not recommended to change the immune checkpoint inhibitors; Dosage: 200mg, iv, D1, every 21 days (Q3W), continuous until tumor progression.
223790539|NCT05247996|PROCEDURE|Systemic Intravenous Chemotherapy|GEMOX regimen (gemcitabine 1000mg/m2, oxaliplatin 100mg/m2) is given for systemic intravenous chemotherapy after the exclusion of contraindications for chemotherapy, and the presence of active lesions is assessed by laboratory and imaging examinations after every two courses of treatment. If active lesions remain, repeated systemic intravenous chemotherapy may be performed. The frequency of chemotherapy is determined by the investigator and is given according to the needs of the patient, usually 6 times with an interval of 21-28 days.
223790540|NCT02188433|BEHAVIORAL|Quit immediately (QI) / cut down to quit (CDTQ)|Use quit immediately (QI) or cut down to quit (CDTQ) interventions to achieve smoking abstinence
223790541|NCT02970500|DRUG|Methylphenidate HCl 10Mg SR|Methylphenidate HCl 10Mg SR (Phase 1) and Methylphenidate HCl 20Mg SR (Phase 2)
223790542|NCT02970500|DRUG|Placebo Group|Placebo
223790543|NCT01900990|DEVICE|Noninvasive ventilation weaning|We adopt Noninvasive Positive Pressure Ventilation in tracheotomy patients by capping the tracheotomy tube and deflating the cuff
223790544|NCT03586648|DEVICE|senofilcon A Multifocal|TEST Lens
223790545|NCT03586648|DEVICE|senofilcon A Sphere|TEST Lens Sphere
223790546|NCT03586648|DEVICE|etafilcon A Multifocal|CONTROL Lens
223790547|NCT03586648|DEVICE|etafilcon A Sphere|CONTROL Lens Sphere
223790548|NCT03190473|DEVICE|DES|PCI with implantation of a DES
223790549|NCT05308251|PROCEDURE|Lichtenstein Mesh Hernioplasty|The inguinal canal was opened and the hernia sac was dissected from the spermatic cord The deep inguinal ring was tightened with one or two polypropylene 2/0 sutures. The posterior wall of the inguinal canal was supported using the standard polypropylene mesh and fixed with 2/0 polyproline. The ilioinguinal nerve, iliohypogastric nerve, and genital branch of the genitofemoral nerve were preserved and care was taken to prevent entrapment.
223790550|NCT03248102|DIAGNOSTIC_TEST|Blowing into the mouthpiece|Blowing into the mouthpiece of diagnostic device
223790551|NCT04958018|DIETARY_SUPPLEMENT|Almonds|almond (Prunus dulcis) consumption
223790552|NCT04958018|DIETARY_SUPPLEMENT|Snack bars|324 calories/day, Nutri-Grain cereal bars, 120 kcal each
223790553|NCT04534595|OTHER|COVID-19|To study the experience of students and their families during the COVID-19 pandemic an online questionnaire will be utilized. This COVID-19 questionnaire will be administered at three time points: baseline, 6 months upon completion of the baseline questionnaire, and 12 months upon completion of the baseline questionnaire.
223790554|NCT01402453|BEHAVIORAL|Monetary Incentives|Subjects will receive a payment of $2 per mm. drop in BP from the baseline value at each follow-up visit. If a subject reaches their target BP, they will receive a minimum of $30 each time to motivate continued participation in the study and reinforce continued improvement relative to baseline BP. Lottery incentives will be added to motivate attainment of intermediate goals. For remembering to do certain actions that assist in the management of their BP, the subject will receive one entry into a lottery with an expected value of $3 per ticket. For the lottery payment, the subject will be given 3 chances to randomly select a card that may or may not show a winning monetary prize.
223790555|NCT01402453|BEHAVIORAL|Intrinsic Motivation|A)Subjects will complete an additional component to the baseline questionnaire that probes systematically for areas of experience that currently are of importance to them. Their answers will help to identify patients' intrinsic motivations for controlling their BP. B)Answers to this component will be analyzed to characterize a role self-identity that will be used by study personnel to frame their interactions with the subject for the remainder of the study. C) Role identity will be kept highly salient throughout the study by using identity primes that remind the individual that improving blood pressure levels is an important responsibility associated with that role.
223790556|NCT01089426|DRUG|Omegaven™|1 g/kg/d of Omegaven until discontinuation of PN
223790557|NCT01089426|OTHER|Historical Controls|Standard of Care
223790558|NCT02242474|DRUG|Anti-TNF suspended perioperatively|
223790559|NCT02242474|DRUG|Anti-TNFα continued perioperatively|
223790560|NCT00479245|OTHER|Set of questionnaires (respondent)|To determine the measurement characteristics of WHODAS II (World Health Organization Disability Assessment Schedule)
223790561|NCT00609687|PROCEDURE|Diagnostic Vitrectomy|"Three-port, 20-gauge pars plana vitrectomy instrumentation was utilized. An infusion line was inserted into one sclerotomy and secured to the globe. A second sclerotomy was made, and a fiberoptic light pipe was immediately inserted to minimize vitreous egress. A third sclerotomy was created, and the vitreous cutter was inserted. To obtain an undiluted vitreous sample, the vitreous was cut mechanically with the vitreous cutter, while the assistant surgeon simultaneously manually aspirated the vitreous. After sufficient undiluted sample was obtained, infusion fluid was allowed to enter the eye and a diluted vitreous sample was obtained in a similar manner. The samples were personally carried to the clinical laboratories by the operating surgeon.~Vitreous fluid analysis was guided by clinical suspicion based on the pre-operative differential diagnosis and the intraoperative posterior segment appearance."
223790562|NCT01987648|PROCEDURE|Elective Craniotomy Patients|Patients who receive an elective craniotomy (no biopsy, no awake surgery, no re-operation)
223790563|NCT05697848|OTHER|Physiotherapy combined with Pain Education|Patients with chronic low back pain receive manual therapy treatment combined with Pain Education sessions.
223790564|NCT05697848|OTHER|Physiotherapy|Patients with chronic low back pain receive manual therapy treatment
223790565|NCT00675740|DRUG|rosiglitazone|tablets 4 mg daily
223790566|NCT00675740|BEHAVIORAL|physical exercise|stationary bike 5-6 times a week
223790567|NCT00675740|OTHER|control|control without intervention
223790568|NCT00000648|DRUG|Penicillin G potassium|
223790569|NCT00000648|DRUG|Ceftriaxone sodium|
223790570|NCT03621605|BIOLOGICAL|VIB9600|"Part 1 (SAD): IV infusion (30, 100, 200, 300 or 1000 mg) or SC injection (300 mg) on Day 1.~Part 2 (MAD): IV infusion (100 and 300 mg) every 2 weeks for 4 weeks (3 doses total; Days 1, 15 and 29)."
223790571|NCT03621605|DRUG|Placebos|Placebo administered by slow IV infusion or SC injection.
223790572|NCT00907153|DIETARY_SUPPLEMENT|Vitamin D|Vitamin D 300 mcg by mouth once daily for 12 weeks
223790573|NCT00907153|DRUG|Placebo|Placebo by mouth once daily for 12 weeks
223790574|NCT05800132|DEVICE|MammoScreen|Diagnostic reading aid for breast cancer screening
223790575|NCT02212756|DRUG|DW1029M 1200mg and Metformin 1000mg|Metformin 500mg 1 Tablet and DW1029M 300mg 2 Tablets b.i.d. for 7days
223790576|NCT02212756|DRUG|Metformin 1000mg|Metformin 500mg b.i.d. for 7 days
223790577|NCT05558033|OTHER|Plyometric Exercise|Plyometric training consisting of ten different exercises \[vertical unilateral and bilateral counter movement jump, horizontal unilateral and bilateral counter movement jump, drop jump (30 cm), squat jump, step-hop (20 cm), 180 degree rotation in transverse plane, frontal plane hurdle jump (20 cm) and sagittal plane hurdle jump (20 cm)\] for 8 weeks, 3 sessions per week. Individuals will not participate in a real plyometric training. Volunteers will watch videos to be prepared (action observation) and imagine them performing those exercises (motor imagery)
223790578|NCT05558033|OTHER|Football Training|Routine football trainings
223790579|NCT01478867|OTHER|Detection of gluten in feces|Detection of Gluten in Feces
223790580|NCT05079620|DRUG|Ceftriaxone|If there is low risk for P. aeruginosa and/or methicillin-resistant staphylococcus aureus (MRSA), as deemed by the treating team: Ceftriaxone 2 g IV, every 24 hours for 5 days
223790581|NCT05079620|DRUG|Amoxicillin clavulanic acid|At any point after 24 hours, clinicians may (but are not required to) transition stable patients on ceftriaxone to the oral agent Amoxicillin + clavulanate (Augmentin) 875 mg PO or per feeding tube, twice daily for the remainder of 5 days
223790582|NCT05079620|DRUG|Cefepime|If there is significant risk of P. aeruginosa and/or MRSA as deemed by the treating team: Cefepime 2 g IV, every 8 hours for 5 days, plus vancomycin
223790583|NCT05079620|DRUG|Vancomycin|If there is significant risk of P. aeruginosa and/or MRSA as deemed by the treating team: Vancomycin IV, dosed by trough or AUC/MIC (area under the curve/minimum inhibitory concentration) monitoring for 5 days, plus cefepime. Order nasal MRSA swab and consider discontinuing vancomycin if MRSA swab is negative.
223790584|NCT05079620|DRUG|Levofloxacin|At any point after 24 hours, clinicians may (but are not required to) transition stable patients on cefepime to levofloxacin PO or per feeding tube, 750 mg every 24 hours for the remainder of 5 days
223790585|NCT03147248|BIOLOGICAL|CT-P13|CT-P13 (3 mg/kg) by IV infusion administered as a 2 hour IV infusion per dose every 8 weeks
223790586|NCT03147248|BIOLOGICAL|CT-P13|CT-P13 (90 mg) by single SC injection every other week
223790587|NCT03147248|BIOLOGICAL|CT-P13|CT-P13 (120 mg) by single SC injection every other week
223790588|NCT03147248|BIOLOGICAL|CT-P13|CT-P13 (180 mg) by double SC 90 mg injections every other week
223790589|NCT03147248|BIOLOGICAL|CT-P13|CT-P13 (120 mg) by single SC injection every other week with placebo IV at Weeks 6, 14 and 22.
223790590|NCT03147248|BIOLOGICAL|CT-P13|CT-P13 (3 mg/kg) by IV infusion administered as a 2 hour IV infusion per dose every 8 weeks with placebo SC at Week 6 and every other week thereafter up to Week 28
223790591|NCT02111590|DRUG|Immunoglobulins|SCIG dosage is individualized for each patient according to previous IVIG dosage
223790592|NCT03768479|DEVICE|18F-FES-PET|18F-FES-PET/CT imaging before and after cycle 1 treatment with the first line Fulvestrant
223790593|NCT04431596|DEVICE|Forearm cooling|forearm immersion will be performed for active cooling assessment.
223790594|NCT04431596|OTHER|Mist-fan cooling|A mist-fan will be placed in front of the participant for active cooling.
223790595|NCT05168241|OTHER|song/melodica group|"The patients who were divided into groups according to their wishes to sing or play the melodica were given warm-up training before the song group (20 min. warm-up training including breathing exercises, 20 min. singing) and melodica group (20 min. breathing). warm-up training including exercises, playing melodica for 20 minutes) was given with the researcher under the leadership of an experienced music teacher.~For two weeks, a total of 40 minutes of song/melodica training was given per week. The singing group was given an assignment to sing for at least 20 minutes a day and the melodica playing group to play the melodica for at least 20 minutes a day. The patients were asked to do their song/melodica homework for at least 20-30 minutes a day, and then they were told about the follow-up papers.~Patients in the song/melody group were followed up by telephone twice a total of 15 days at the 5th and 7th weeks."
223790596|NCT05168241|OTHER|control group|"In the first interview, the pre-tests were applied by the researcher with the face-to-face interview technique. Afterwards, nursing education was given through the training guide prepared according to Pender's health promotion model. The control group was followed up and counseled by phone, twice a day, twice a day, in the 5th and 7th weeks.~Post-tests were applied at week 10 to evaluate the effectiveness of the interventions."
223790597|NCT03929029|DRUG|Nivolumab (480 mg infusion)|Nivolumab is an antibody that prevent cancer cells from suppressing the immune response so that the body can attack and kill the cancer
223790598|NCT03929029|BIOLOGICAL|NeoVax plus Montanide|Montanide® is an activator of immunity that enhances response to vaccination through slow release of the peptides from the injection site and its ability to create an inflammation and stimulate the recruitment of specific cells of your immune system. Montanide® will be mixed with the personalized neoantigen vaccine
223790599|NCT03929029|DRUG|Ipilimumab|Ipilimumab is an antibody that prevent cancer cells from suppressing the immune response so that the body can attack and kill the cancer
223790600|NCT03771976|PROCEDURE|Cesarean section|Risk of cesarean section between the cohorts
223790601|NCT03771976|PROCEDURE|No cesarean section|Vaginal birth rate between the cohorts
223790602|NCT04907708|DRUG|Metformin|Euglycemic agent
223790603|NCT04907708|DRUG|Insulin|Hypoglycemic agent
223790604|NCT01804920|DIETARY_SUPPLEMENT|D-serine|
223790605|NCT01804920|DIETARY_SUPPLEMENT|Placebo|
223790606|NCT02672631|OTHER|physical examination|Investigators will apply for evaluate clinical median nerve function to all of groups. (Adductor pollicis power (x/5), sense exam(normal/hipoestesia/anestesia) of hand, tinnel test(+/-), DASH score, DN4 neuropathic pain score)
223790607|NCT02672631|OTHER|DTI|Investigators will apply for evaluate median nerve healing countable results to all of groups (apparent diffusion coefficient for avarage diffusion (ADC) and fractional anisotropy diffusion orientation(FA) - FA :0 means diffusion is homogenic FA:1 means tissue has heterogenic diffusion
223790608|NCT02672631|OTHER|ENMG|Investigators will apply for evaluate median nerve healing countable results to all of groups. And they will evaluate motor nerve transmission speed, sensitive nerve transmission speed and united muscle action potential
223790609|NCT00506259|DRUG|dTR Melatonin (NIH CC PDS)|
223790610|NCT00506259|DEVICE|Phototherapy (Bright Light)|
223790611|NCT00506259|DRUG|Melatonin CR|
223790612|NCT05311592|BEHAVIORAL|HERO Dads Program|The HERO Dads Program is a 4-week series of workshops for non-custodial fathers that focuses on improving parenting, offering job support, and financial counseling.
223790613|NCT04578990|OTHER|Walking intervention|"It will consist of performing the Treadmill training progression for 36-72 sessions. 3 sessions of 60 minutes, will be held weekly.~Depending on the data obtained in Visit 1, the speed will be determined for each patient and the degree of the initial slope that is comfortable when walking until it induces symptoms of moderate intermittent claudication. The progression of the intensity of the speed and incline of the slope will be increased progressively and individually for each patient."
223790614|NCT04578990|OTHER|Strength intervention|The training program consists of performing a training program with resistance exercises for 36-72 weeks. There will be 3 weekly sessions of 60 minutes, where exercises with resistance will be applied. The same guidelines will be followed as in the walking exercise, but in this case, applying force stimuli. If symptoms of moderate intermittent claudication occur (3-4) based on the Claudication Symptom Rating Scale in 5-10 minutes, a period of rest (sitting or standing) will be performed until the pain disappears at the level of the lower limb. This sequence will be repeated until the strength training session is completed. The progression of force stimuli will be increased weekly depending on the subjective perception of the patient's effort and according to the guidelines set by our group of investigation.
223790615|NCT04578990|OTHER|Concurrent intervention|The training program consists of alternating strength and resistance stimuli in the same session for 36-72 weeks. There will be 3 weekly sessions of 60 minutes, where exercises with resistance will be applied for 35 minutes and to complete the 60 minutes, the same guidelines will be followed as in the walking exercise, applying resistance stimuli. If claudication symptoms occur moderate intermittent (3-4) based on the Claudication Symptom Rating Scale in 5-10 minutes, a period of rest (sitting or standing) will be performed until the pain in the lower extremity disappears. This sequence will be repeated until the 20 minutes established to end the session are completed concurrent training. The progression of the strength and resistance stimuli will be increased weekly depending on the perception subjective effort of the patient and according to the guidelines established by our research group.
223790616|NCT00957866|DRUG|Pegylated Interferons (Peg-IFN) and Ribavirin|A anti-viral regimen with a combination of pegylated Interferons (Peg-IFN) and Ribavirin
223790617|NCT05156658|DRUG|Etonogestrel (ENG) Subdermal Implants|Etonogestrel is available as a single, white/off-white, soft, radiopaque, flexible, ethylene vinyl acetate copolymer implant, 4 cm in length and 2 mm in diameter containing 68 mg of etonogestrel. Store at 25°C (77°F); excursions permitted between 15 and 30°C (59-86°F) \[see USP Controlled Room Temperature\]. Avoid storing ENG at temperatures above 30°C (86°F).
223790618|NCT03491644|DRUG|Titrated Oxygen|Restrictive treatment with oxygen.
223790619|NCT03491644|DRUG|Liberal Oxygen|Liberal treatment with oxygen.
223790620|NCT02565290|DIETARY_SUPPLEMENT|Omega 3|Pregnant women should take 2 capsules of omega 3 (1g), 2 times a day, for 21 days.
223790621|NCT02565290|DIETARY_SUPPLEMENT|Soy Oil|Pregnant women should take 2 capsules of placebo 3 - soy oil oil (1g), 2 times a day, for 21 days.
223790622|NCT03326375|RADIATION|SBRT|Maximum dose : 60Gray (Gy) Fraction : 2 to 5
223790623|NCT01436058|BIOLOGICAL|mesenchymal stem cell|intraarticular injection of mesenchymal stem cell in patients with ankle joint osteoarthritis
223790624|NCT04386681|BEHAVIORAL|Reentry Continuum for Brain Injury (RCBI)|"Pre-Release RCBI Treatment Procedures (BICS and ICAN). BICS: consists of 12 weekly two- hour sessions. Sessions focus on brain injury education, coping skills for the various symptoms of brain injury, depression management, stress management, and self- advocacy.~ICAN: delivered once a week for 6 weeks for 2 hours per session. ICAN primarily focuses on poor perspective-taking and inability to make social inferences about others' behaviors that are related to negative attributions, and employs role playing exercises and a novel perspective-positioning technique to elicit affective and cognitive empathy to alter negative attributions and reduce anger.~Post-Release RCBI Resource Facilitation. Working with their resource facilitator, alongside their corrections case manager, to work on brain injury specific reentry planning, resource, and needs identification."
223790625|NCT04806828|OTHER|Preoperative classification|Score of inguinal hernia
223790626|NCT04788667|OTHER|A health education programme using a telerehabilitation platform|All patients enrolled in the study will receive information through the tele rehabilitation platform, although the experimental group will have specific training/education whereas the control group will only receive some general recommendations as control/sham
223790627|NCT01271322|RADIATION|neoadjuvant radiochemotherapy in metabolic non responders|Metabolic non-responders, with a SUV decrease of less than 35%, discontinue induction chemotherapy and proceed to an intensified radiochemotherapy treatment
223790628|NCT04666129|DRUG|Relugolix|"(Part 1 and Part 3) Relugolix will be administered orally as a single 360-milligram (mg) loading dose of 3 x 120-mg tablets, followed by a 120-mg dose (1 x 120-mg tablets), taken once daily at approximately the same time each day.~(Part 2) Relugolix will be administered orally as a single 360-milligram (mg) loading dose of 3 x 120-mg tablets, followed by a 240-mg dose (2 x 120-mg tablets), taken once daily at approximately the same time each day."
223790629|NCT04666129|DRUG|Abiraterone|Abiraterone acetate (1000 mg \[2 x 500-mg tablets\]) or fine-particle abiraterone acetate (500 mg \[4 x 125-mg tablets\]) will be administered orally once daily.
223790630|NCT04666129|DRUG|Prednisone|"(Part 1 only) For participants with mCSPC, a 5-mg dose of prednisone will be administered orally once daily, and for participants with mCRPC, a 5-mg dose of prednisone will be administered orally twice daily.~(Part 3 only) Prednisone 5 mg can be administered orally twice daily but is not required."
223790631|NCT04666129|DRUG|Methylprednisolone|For participants with mCRPC taking fine-particle abiraterone acetate, methylprednisolone 4 mg will be administered orally twice daily.
223790632|NCT04666129|DRUG|Apalutamide|Apalutamide 240 mg (4 x 60-mg tablets) will be administered orally once daily.
223790633|NCT04666129|DRUG|Docetaxel|Docetaxel 75 mg/m2 dose will be administered every 3 weeks as a 1-hour intravenous infusion.
223790634|NCT06489743|OTHER|6-minute walk test (6MWT)|6-minute walk test (6MWT) will be performed according to clinical standards
223790635|NCT04321837|DIETARY_SUPPLEMENT|Coral Complex 3|Coral-derived calcium supplement fortified with vitamin D3
223790636|NCT04321837|DRUG|Ibandronate|Bisphosphonate
223790637|NCT04321837|DIETARY_SUPPLEMENT|Vitamin D3|Oral vitamin D3
223790638|NCT02419157|DRUG|Selective enamel etching with 36% phosphoric acid|Etch: selective 36% phosphoric acid enamel etching
223790639|NCT02419157|DRUG|No selective enamel etching with 36% phosphoric acid|Non-etch: without phosphoric acid selective enamel etching
223790640|NCT02419157|DEVICE|Clearfil SE Bond|
223790641|NCT02419157|DEVICE|Xeno V|
223790642|NCT00628732|DRUG|Cyclophosphamide and Topotecan|Two courses of cyclophosphamide at 50 mg/m2/dose and topotecan 0.8 mg/m2/dose by mouth every morning for 14 days each.
223790643|NCT05646875|OTHER|hyperbaric oxygen therapy|Hyperbaric oxygen therapy in a pressurized chamber, duration 1-2 hours at 2-3 ATA
223790644|NCT00788840|DRUG|Insulatard|Insulatard insulin used as long-acting insulin for 16-week treatment phase of study.
223790645|NCT00788840|DRUG|Detemir|Detemir insulin used as long-acting insulin in treatment phase of study.
223790646|NCT00090389|PROCEDURE|Chinese Acupuncture|
223790647|NCT01298960|DRUG|Somatropin|0.1 IU/Kg/day from day one of stimulation until rHCG triggering
223790648|NCT00791024|DRUG|CRC-Pharma 001|50 mg
223790649|NCT00791024|DRUG|lidocaine suspension|5.0 ml lidocaine suspension(20mg/ml) adm. 10 min. before oesophagogastroduodenoscopy.
223790650|NCT02388724|DRUG|Vonoprazan|Vonoprazan tablets
223790651|NCT02388724|DRUG|Lansoprazole|Lansoprazole capsules
223790652|NCT02388724|DRUG|Vonoprazan Placebo|Vonoprazan placebo-matching tablets
223790653|NCT02388724|DRUG|Lansoprazole Placebo|Lansoprazole placebo-matching capsules
223790654|NCT03930472|BEHAVIORAL|Market vouchers|Receiving $80 in vouchers good for fruits and vegetables or for SNAP-eligible foods at 4 out of 5 markets in late July and in August, 2019.
223790655|NCT05160051|DIAGNOSTIC_TEST|68Ga-FAPI-46 PET Scan|68Ga-FAPI-46 is a radiotracer that binds with high affinity to Fibroblast Activating Protein (FAP). FAP is physiologically expressed in many tissues during embryonic development, but in adults it is expressed only in the context of wound healing, fibrotic processes, and the stroma of many malignancies. Therefore, the study seeks to validate if 68Ga-FAPI-46 PET could be established as a diagnositc tool to detect solid tumors.
223790656|NCT02232113|DRUG|CERA|changing frequency of administration from once to twice monthly under a fixed total monthly dose of CERA
223790657|NCT02268201|DRUG|Advagraf|oral
223790658|NCT02268201|DRUG|Prograf|oral
223790659|NCT00384553|DRUG|Rituximab|
223790660|NCT00384553|DRUG|DHAP|
223790661|NCT00384553|DRUG|TEC|
223790662|NCT00384553|DRUG|autologous stem cell transplantation|
223790663|NCT04647851|OTHER|Remote exercise intervention Down syndrome|See arm description
223790664|NCT02425839|DEVICE|Ultrasound exam by Supersonic Shear Imaging® technique|Each of the two observers performs twice ultrasound examination and measures of the masseter thickness and its elastic modulus, at rest and maximal voluntary contraction.
223790665|NCT02425839|DEVICE|EMG examination by electromyograph Keypoint system|Experimented neurologist performs EMG examination.
223790666|NCT02724553|DEVICE|Acrylic lens implantation|
223790667|NCT03181880|DRUG|Aclidinium bromide/formoterol fumarate combination|"Patients will be randomized to receive either Aclidinium bromide/formoterol fumarate fixed-dose combination (Duaklir™ Genuair®), or Standard Of Care (SOC) Bronchodilators.~The product in study is Aclidinium bromide/formoterol fumarate fixed-dose combination (Duaklir™ Genuair®).~Each inhaler will contain at least 60 doses (and a maximum of 68 doses) of aclidinium bromide/formoterol fixed-dose combination 400μg /12μg. Patients will be instructed to take 1 puff in the morning (09:00 ± 1 h) and 1 puff in the evening (21:00 ± 1 h) during the 12 weeks of treatment."
223790668|NCT03181880|DRUG|Standard of Care|Brochodilators
223790669|NCT04068337|PROCEDURE|Aortic root replacement with Freestyle biological prosthesis with and without hemiarch replacement|Aortic root replacement with Freestyle biological prosthesis. Some patients receive additional hemiarch replacement performing an open anastomosis to the aortic arch under antegrade cerebral perfusion through axillary artery. Comparison with patients, who were cannulated and perfused systemically
223790670|NCT01717118|BIOLOGICAL|Bivalent Vaccines|
223790671|NCT01717118|BIOLOGICAL|Tetravalent Vaccine|
223790672|NCT05403580|DRUG|Olanzapine|Given PO
223790673|NCT05403580|DRUG|Placebo Administration|Given PO
223790674|NCT05403580|OTHER|Questionnaire Administration|Ancillary studies
223790675|NCT02605954|DRUG|E/C/F/TAF|150/150/200/10 mg FDC tablets administered orally once daily
223790676|NCT02605954|DRUG|ABC/3TC|600/300 mg tablets administered orally once daily
223790677|NCT02605954|DRUG|Third Antiretroviral Agent|"Third antiretroviral agents could include one of the following:~* ATV+cobicistat (COBI; Tybost®) or ATV/COBI FDC~* DRV+COBI or DRV/COBI FDC~* darunavir (DRV; Prezista®) + RTV~* lopinavir/ritonavir (LPV/r; Kaletra®)~* atazanavir (ATV; Reyataz®) + ritonavir (RTV; Norvir®)~* efavirenz (EFV; Sustiva®)~* etravirine (ETR; Intelence®)~* nevirapine (NVP; Viramune®)~* rilpivirine (RPV; Edurant®)~* dolutegravir (DTG; Tivicay®)~* raltegravir (RAL; Isentress®)~* fosamprenavir (FPV; Lexiva®) + RTV~* saquinavir (SQV; Invirase®) + RTV~* ATV (no booster)~Drug classes:~* Protease inhibitors (PI): LPV/r, ATV, RTV, ATV, DRV, FPV and SQV~* Pharmacokinetic enhancer: COBI~* Non-nucleoside reverse transcriptase inhibitors (NNRTI): EFV, RPV, NVP, and ETR~* Integrase inhibitors: RAL and DTG"
223790678|NCT02102308|OTHER|Exercise|Multicomponent exercise
223790679|NCT02102308|OTHER|Education classes|
223790680|NCT00231634|DRUG|topiramate|
223790681|NCT05804877|BEHAVIORAL|mindfulness-based cognitive therapy|Participants in the experimental group would be arranged to attend online mindfulness-based cognitive programs for eight weeks. Each week was divided into 3 parts, which were detailed mindfulness-based skills training with pictures or short videos, techniques application in different scenarios, and concepts consolidation through a web-based assignment.
223790682|NCT05804877|OTHER|Mental health education|The mental health education was delivered on the platform of LINE to the control group 3 times a week for 8 weeks
223790683|NCT03528538|DIETARY_SUPPLEMENT|AlphaFen fenugreek 400 mg|A brand of fenugreek supplementation that was produced by SPECNOVA. Pure fenugreek without any additives.
223790684|NCT03528538|DIETARY_SUPPLEMENT|AlphaFen fenugreek 500 mg|A brand of fenugreek supplementation that was produced by SPECNOVA. Pure fenugreek without any additives.
223790685|NCT03528538|OTHER|Placebo|rice flour in a vegetable/ cellulose capsule
223790686|NCT03214367|DRUG|LY900014|Administered SC
223790687|NCT03214367|DRUG|Insulin Lispro|Administered SC
223790688|NCT03214367|DRUG|Insulin Glargine|Administered SC
223790689|NCT03214367|DRUG|Insulin Degludec|Administered SC
223790690|NCT05564013|DEVICE|Virtual reality|Up to 25 minutes of virtual reality exposure in supine position
223790691|NCT03508843|BEHAVIORAL|interactive virtual presence|installing the car seat with advice via interactive virtual presence
223790692|NCT02421484|BIOLOGICAL|Allogeneic mesenchymal stromal cells|The allogeneic mesenchymal stromal cells will be administered intravenously.
223790693|NCT05597501|BEHAVIORAL|manual-based group interventions|weekly group interventions (90min) following manuals of either CBT, integrative therapy or existential analysis\&logotherapy
223790694|NCT04592770|BEHAVIORAL|Nature based walk therapy|10 minutes stretching exercises followed by walk in nature for 50 minutes
223790695|NCT04592770|BEHAVIORAL|Sit in nature|Sit in nature for 60 minutes
223790696|NCT01654432|OTHER|Paravertebral Blocks (PVB)|
223790697|NCT04278092|DRUG|Paclitaxel|Paclitaxel 175 mg/m2, q21
223790698|NCT04278092|DRUG|Cetuximab|Cetuximab 400mg/m2 loading dose followed by weekly 250mg/m2
223790699|NCT03555396|BEHAVIORAL|SMART Couples 2|The intervention will consist of 4 sessions with activities designed to strengthen communication and support within the couple to improve adherence to antiretroviral therapy and increase linkage to drug treatment services. The activities are based on cognitive-behavioral therapy. Participants' adherence will be monitored continuously through electronic monitoring devices and surveys completed at baseline and follow-up periods.
223790700|NCT03555396|BEHAVIORAL|Standard of Care|Standard of Care consists of an appointment with an AIDS Center nurse at baseline and two months later. Under current Standard of Care in Almaty, no behavioral intervention is provided. Participants obtain prescription refills and give blood for viral load and CD4 tests once every 6 months.
223790701|NCT03878940|DIAGNOSTIC_TEST|Abdominal ´yes-no´ pathway|A set of blood samples, a FIT, and an abdominal US (and a TVUS in women)
223790702|NCT03200938|DEVICE|formocresol and zinc oxide.|Removal of the coronary pulp from primary molar teeth, use of formocresol and zinc oxide
223790703|NCT03200938|DEVICE|PBS CIMMO cement.|Removal of the coronary pulp from primary molar teeth, use of PBS cement
223790704|NCT05078190|OTHER|Social Determinants of Health|The study will perform detailed phenotyping of Social Determinants of Health using the National Institute of Minority Health and Health Disparities PhenX SDOH toolkit at baseline.
223790705|NCT06279182|BEHAVIORAL|Barre Stretching Intervention|The Barre stretching intervention will consist of a 15-minute recorded video session with static and isometric movements focused on the hands, wrists, shoulders, and neck combined with breathing exercises throughout each movement. A 15-minute Barre stretching video will be selected for this study because static and isometric stretching should be held for 10-15 seconds per movement and repeated 2-3 times for increasing blood flow and circulation which can improve heart rate variability (HRV), increase muscle suppleness in preparation for muscle activation through patient care, and reduce stress levels through regulation of the rate, depth, and pattern of breathing. The duration of 15-minutes provided the participants with adequate time to complete each stretching movement for a total of 45 seconds with 15 seconds rest between movements. There will be fifteen targeted stretching movements focused on the hands, wrists, shoulders, and neck region.
223790706|NCT03512340|DRUG|SRF231|SRF231 specifically blocks the interaction between CD47 and signal regulatory protein alpha and acts as a potent enhancer of human tumor cell phagocytosis.
223790707|NCT05703282|DRUG|AD-104-A|PO, Single-Dose, AD-104-A
223790708|NCT04770714|DIAGNOSTIC_TEST|Breast MRI|Standard of Care Breast MRI
223790709|NCT04770714|DIAGNOSTIC_TEST|Contrast Enhanced Mammography|Standard of Care Contrast Enhanced Mammography
223790710|NCT04117087|DRUG|KRAS peptide vaccine|"1. KRAS peptide vaccine will be administered on cycle 1 (days 1, 8, 15) and R-Cycle 2 Day 1 (R-C2D1). Boost vaccinations with will be administered every 28 days at Reinduction cycle 5, 7, 9, 13. Extended vaccinations will be administered on Reinduction cycles 15 to 18, 19 and beyond (180 days ± 30 days for a total of 5 years on study.~2. Drug: up to 1.8 mg KRAS peptide vaccine + 0.5mg Poly-ICLC"
223790711|NCT04117087|DRUG|Nivolumab|"1. Nivolumab will be administered as a 30 minute IV infusion (-10min/+15min) on Day 1 of each 21 day cycle. Boost Phase will be administered every 28 days on cycles 5 thru 14.~2. Drug: 3mg/kg IV, 480 mg IV"
223790712|NCT04117087|DRUG|Ipilimumab|"1. Ipilimumab (1 mg/kg) will be administered as a 30 minute IV infusion (-10min/+15min) on Day 1 of Cycles 1 and 3 of the study.~2. Drug: 1mg/kg IV"
223790713|NCT03913364|DIETARY_SUPPLEMENT|Probiotic|B. bifidum 900791-containing ice cream
223790714|NCT03913364|DIETARY_SUPPLEMENT|Placebo|Placebo ice-cream
223790715|NCT04154124|DIAGNOSTIC_TEST|PET/MR scan|whole-body PET/CT scan and pelvic PET/MR scan (MR protocol will include three plane fast spin echo T2 weighted, DWI and dynamic contrast enhanced imaging). The ad interim assessment will use a pelvic PET/MR scan only (without PET/CT), to avoid the radiation associated with whole body CT. In the staging and post-nT assessment, the addition of PET/MR to the standard use of PET/CT adds no radiation exposure.
223790716|NCT01847846|DEVICE|CPAP mask - prototype|prototype mask, wore for all sleeps for 4 and 8 weeks (as randomly selected). Mask to be used in conjunction with participant's usual prescribed CPAP settings.
223790717|NCT05127343|PROCEDURE|Sealing deep pits and fissures|Application of the pit and fissure sealant
223790718|NCT03589456|OTHER|No intervention|There are no interventions associated with this registry as it is purely observational.
223790719|NCT02635815|PROCEDURE|Upper gastrointestinal endoscopy|Upper gastrointestinal endoscopy using the Pentax video endoscope EG 3440
223790720|NCT01552213|OTHER|Minimum intervention control group|A single visit with a dietician or health educator to discuss general health risks, good eating habits, and appropriate weight gain. This will be followed by routine prenatal care per provider.
223790721|NCT01552213|OTHER|Treatment for glucose intolerance|Diet, exercise glucose monitoring, insulin if necessary
223790722|NCT00243724|DRUG|Esomeprazole|
223790723|NCT00026533|DRUG|thalidomide|
223790724|NCT01107574|DRUG|Gabapentin|Gabapentin 900 mg po HS for 6 weeks treatment per patients enrolled in the Gabapentin Arm
223790725|NCT01107574|PROCEDURE|Osteopathic Manipulative Medicine|Based on Osteopathic Structural Examination and Tender point Examination a 30 minute treatment of Osteopathic Manipulative Medicine was applied to each patient every week for 6 weeks.
223790726|NCT01107574|OTHER|Gabapentin and Osteopathic Manipulative Medicine|Combination therapy of gabapentin 900 mg po HS for 6 weeks and Osteopathic Manipulative Medicine 30 minute treatment weekly for each patient based on Osteopathic Structural Examination and Tender point Examination
223790727|NCT06133894|BEHAVIORAL|Exercise program PERMANENTO inspired by developmental kinesiology|"The intervention is based on activation of reflexive movement patterns which ensures the original reflexive control of strength, mobility and stability. After birth, we cannot control our body movements - they are reflexes hard-wired into our brains and vitally important for proper development of our body (muscular system, vestibular system, sensory system, cardiovascular system or digestive system) as well as our brain and nervous systems. During early childhood, everything becomes integrated and works perfectly according to the original design. But this design is slowly abandoned due to for example sedentary lifestyle and replaced by compensatory movement patterns that are making us weaker and defective with all the consequences that are becoming more severe as we age. The aim is restore the original design and improve posture and other crucial components of functional fitness and move better and more."
223790728|NCT02747134|BEHAVIORAL|Emotion Regulation and Mindfulness skills|
223790729|NCT02014857|PROCEDURE|Gingival Crevicular Fluid Sampling|
223790730|NCT05959850|DRUG|Ambroxol|Participants in the study will receive varying doses of ambroxol in solution, 3 times per day. Doses will be increased pending a safety review, up to a maximum of 1260mg/day. Blood tests will be conducted weekly to assess tolerance. Compliance will be monitored by returning used bottles. The study will last 32 weeks, including 24 weeks of drug administration and follow-up visits. After the final follow-up, there will be an end of study safety visit occurring 4 weeks later. The total time of participation will be 32 weeks. This includes a screening visit up to 4 weeks prior to Baseline, then a Baseline visit, followed by 24 weeks of follow-up (3x in clinic follow-up visits). These 24 weeks will be the drug administration period, meaning that the total duration of drug administration is 24 weeks. Following this drug administration and follow-up period, there will be an EoS safety-follow up visit that will occur 4 weeks after the final follow-up visit (28 weeks from baseline).
223790731|NCT05959850|DRUG|Placebo|Participants randomised to the control arm will receive a placebo for the duration of the study. The placebo will look and taste like ambroxol, but will have no active ingredient. Participants will not be told which arm they have been randomised to. The placebo will primarily be a glucose solution, however it will also have flavouring (e.g. bitters) and colouring, so as to make it look and taste like ambroxol, to maintain blinding.
223790732|NCT04256733|BIOLOGICAL|Supra-threshold and progressive doses of diluted capsaicin via a Koko Digidoser nebulizer|Participants will be exposured to increasing doses of aerosolized capsaicin (a known cough stimulant) through the Koko Digidoser nebulizer, while implementing behavioral cough suppression strategies. The concentration of capsaicin will increase incrementally as tolerated, as long as participants are still able to suppress cough. The concentration will never exceed 1000 micromolar. Participants will attend 6 treatment sessions and be given up to 12 exposures per treatment session. Participants will be encouraged to use cough suppression strategies outside of treatment sessions as much as possible to attempt to suppress cough.
223790733|NCT04256733|BIOLOGICAL|Sub-threshold doses of diluted capsiacin via a KoKo Digidoser nebulizer|Participants will be repeatedly exposed to a sub-threshold dose of aerosolized capsaicin through the KoKo Digidoser nebulizer during treatment sessions. Participants will attend 6 treatment sessions and be given up to 12 exposures per treatment session. Participants will be encouraged to use cough suppression strategies outside of treatment sessions as much as possible to attempt to suppress cough.
223790734|NCT05579860|DRUG|Olezarsen|Olezarsen will be administered by SC injection.
223790735|NCT05845229|DIETARY_SUPPLEMENT|High-N-acylethanolamine meal|Milk (150 mL), white bread (46 g), jam (10 g), cocoa powder (15 g), whole-grain cereals (30 g).
223790736|NCT05845229|DIETARY_SUPPLEMENT|Low-N-acylethanolamine meal|Milk (150 mL), whole-grain bread (80 g), jam (10 g), butter (5 g), instant coffee (2 g), dried apples (30 g).
223790737|NCT00270218|BIOLOGICAL|VRC-HIVADV014-00-VP|HIV-1 recombinant adenoviral vector vaccine given as a 1 mL intramuscular injection in the deltoid
223790738|NCT00270218|BIOLOGICAL|VRC-HIVDNA009-00-VP|HIV-1 DNA plasmid vaccine given as a 1 mL intramuscular injection in the deltoid
223790739|NCT00270218|BIOLOGICAL|FFB|Adenoviral vector FFB given as a 1 mL intramuscular injection in the deltoid
223790740|NCT00270218|BIOLOGICAL|PBS|phosphate buffered saline
223790741|NCT04289857|OTHER|Neurodynamic training|Starting from a sitting position on a stretcher, with dorsolumbar flexion, it is required to maintain that posture throughout the exercise. Sliding with the straight leg sitting consists of performing alternate movements. First, knee extension and dorsal ankle flexion will be performed, increasing neural tension, combined with cervical extension (to decrease neural tension) in the first instance. Subsequently, knee flexion and plantar ankle flexion (decreasing neural tension) combined with cervical flexion (increasing neural tension) will be performed. The dosage of the technique will be: two seconds for each movement, with 10 repetitions of each one. All sessions will be led by one of the group's researchers.
223790742|NCT05795725|DIAGNOSTIC_TEST|Artificial Intelligence-assisted Fecal Microbiome Testing|Next-generation sequencing of fecal samples and artificial intelligence analysis of test results
223790743|NCT05795725|PROCEDURE|Colonoscopy|Colonoscopy procedure
223790744|NCT01436903|DEVICE|Thermal Balloon Endometrial Ablation|Thermal Balloon Endometrial Ablation for 10 minutes after curettage
223790745|NCT04542343|BEHAVIORAL|Change in knowledge, motivation, skills, resources|Provide/enhance knowledge, modify attitudes, motivate and provide skills and resources to reduce COVID-19 related risk and challenges.
223790746|NCT02300753|DRUG|EPI-743|EPI-743 is a quinone oxidation product of alpha-tocotrienol
223790747|NCT02539342|DRUG|Caphosol|"Subjects randomized to the Caphosol Arm will use Caphosol 4 times per day as follows:~* Each dose consists of two 15 mL syringes, to be mixed at time of administration. Caphosol must be used within 15 minutes of mixing.~  o Participants may increase the use to 6 times per day if you have symptoms of mucositis.~* Using one of the syringes, rinse and gargle (if patient is able) for one minute and then spit. Repeat using the remaining syringe.~  * For younger patients (less than or equal to 6 years of age), volume may be reduced to two syringes containing 5-10 mL each.~ * For patients unable to successfully rinse and spit, caregivers may paint their mouth (using medical sponge swabs) with the solution two times. Repeat using the second syringe.~* Patients are to avoid other oral medications, other mouth cares and food or drink for 15 minutes after using Caphosol.~* Patients may use Biotene (5-10 mL) to swish and spit after the 15 minutes has passed"
223790748|NCT02539342|DRUG|Biotene|"• Use 5 to 10 mL of Biotene to swish and spit~o For patients unable to successfully rinse and spit, caregivers may paint their mouth (using medical sponge swabs) with the solution two times. Prior to swabbing the patient's mouth, pour Biotene into a cup and using the medical sponge, soak up the solution and use the swab to coat the inside of the patient's mouth. Repeat with a second swab."
223790749|NCT01816594|DRUG|BKM120|Neo-adjuvant BKM120 (oral pan-class I PI3K inhibitor, continuous daily dosing). BKM120 was administered orally 100 mg/day.
223790750|NCT01816594|DRUG|Trastuzumab|Trastuzumab is a humanized monoclonal antibody directed against the extracellular juxtamembrane domain of the HER2 receptor. Administered 4mg/kg i.v. load followed by 2mg/kg i.v. weekly.
223790751|NCT01816594|DRUG|Paclitaxel|Paclitaxel is a cytotoxic agent with proven antitumor activity in a variety of solid tumors. The antitumor activity of paclitaxel is based on tubulin-binding and stabilization of non-functional microtubule bundles, thereby blocking normal mitotic spindle development and subsequent cell division. Administered weekly 80mg/m2 i.v.
223790752|NCT01816594|DRUG|BKM120 Placebo|Neoadjuvant BKM120 placebo Administered orally 100 mg/day.
223790753|NCT03905655|DRUG|Placebo Oral Tablet|Number of placebo tablets administered orally depends on the arm
223790754|NCT03905655|DRUG|Nitazoxanide|Number of Nitazoxanide 300 mg extended release tablets administered orally depends on the arm
223790755|NCT03722251|BEHAVIORAL|Glucose beverage, control beverage, glucose beverage and active video game playing, control beverage and active video game playing|
223790756|NCT01643694|BEHAVIORAL|Electronic intervention suggesting behavioral activity|3.6 Those randomized to the intervention will be asked to choose 1 self-directed activity from an electronically provided list sent to them weekly for 10 consecutive weeks. Each activity will take less than 5 minutes to complete. They will also answer 3-5 questions weekly (items taken from the survey items list submitted).
223790757|NCT02566031|DRUG|Indacaterol and glycopyrronium (QVA149)|Capsules for inhalation delivered via SDDPI
223790758|NCT02566031|DRUG|Tiotropium|Capsules for inhalation delivered via HandiHaler® device
223790759|NCT06388525|PROCEDURE|Endoscopic Retrograde Cholangiopancreatography|
223790760|NCT05118685|DRUG|Conjugated Estrogens vaginal cream 0,625mg|the particepant will receive vaginal estrogen cream one tube every night for 14 nights; then, one tube for 2 nights in 1 week (two tubes every week) for 10 weeks.
223790761|NCT05118685|COMBINATION_PRODUCT|platelet rich plasma|First, a topical anesthetic cream will be applied to the vaginal wall. Delaying the PRP injection for 20 minutes after anesthetics application achieved complete or near-complete analgesia for the procedure. Peripheral blood will be drawn from the arm and centrifuged to yield 5 cc of PRP. then PRP will be administered to the anterior vaginal wall using 27-G needles once every 3 weeks for 4 times and PRP is mainly injected into the anterior wall of the vagina to increase the tactile sensitivity of the injection site.
223790762|NCT03879720|PROCEDURE|Endoscope assisted endotracheal intubation [EAEI]|Endoscope assisted endotracheal intubation \[EAEI\] performed by anesthesiologist with endoscopist assistance.
223790763|NCT00598429|DRUG|Inhaled Prostaglandin E1|Delivery of one dose of either high dose PGE1 (300 ng/kg/min), low dose PGE1 (150 ng/kg/min), or placebo (normal saline, the diluent for the drug) via nebulizer over a 72-hour period
223790764|NCT01788748|DEVICE|bipolar radiofrequency and infrared|
223790765|NCT01788748|DEVICE|fractional bipolar radiofrequency|
223790766|NCT02468427|OTHER|hands-on teaching|Training session of 30 minutes duration with every proband performing a vacuum extraction on a pelvic training model.
223790767|NCT02468427|OTHER|Frontal teaching|Training session of 30 minutes duration consisting of a video which demonstrates how to perform a vacuum extraction on a pelvic training model.
223790768|NCT03958370|OTHER|Fitbit|Fitbit use during physical therapy session
223790769|NCT05095753|DEVICE|Earbud|In ear headphone with embedded infrasonic hemodynography technology
223790770|NCT02040116|DRUG|Rituximab Infusion|Participants will receive their first infusion of rituximab at the standard infusion rate provided in the manufacturer labeling. If they tolerate this infusion with a grade 2 of less infusion-related reaction, the next infusion will be administered as a 90 minute rapid infusion.
223790771|NCT06061510|DIETARY_SUPPLEMENT|omega-3 polyunsaturated fatty acids|Participants in the intervention group took fish oil capsules, 6 capsules per day, divided into two doses in the morning and two doses in the evening.
223790772|NCT06061510|DIETARY_SUPPLEMENT|corn oil|Participants in the placebo group took corn oil capsules, 6 capsules per day, divided into two doses in the morning and two doses in the evening.
223790773|NCT03286374|BEHAVIORAL|Occupational rehabilitation|"The participants in the occupational rehabilitation program get both practical and theoretical intervention in groups. Four main interventions; cognitive therapy, physical activity, diets and training in work-oriented approach. The rehabilitation stay is as followed:~1. Four weeks with an institutional stay at Muritunet (BL)~2. Follow-up;~   1. Eight weeks, telephone contact between therapist at Muritunet and the participant.~  2. 16 weeks, video conference on SKYPE between all the participants and a therapist. Lecture on diets.~  3. 28 weeks, Follow-up at Muritunet. Central themes that day is education, conversation, physical test, and forms. (T1)~  4. 40 weeks, telephone contact between therapist at Muritunet and the participant.~  5. 52 weeks, Follow-up at Muritunet. Central themes that day is education, conversation, physical test, and forms. (T2)"
223790774|NCT03404128|OTHER|Questionnaires|Questionnaire for patient: satisfaction regarding rechargeable DBS battery Questionnaire for neurologist: seizure frequency, satisfaction regarding rechargeable DBS battery
223790775|NCT00121238|DRUG|cilengitide|Given IV
223790776|NCT03721991|DIETARY_SUPPLEMENT|Gama amino butyric acid (GABA)|food supplement Gama amino butyric acid (GABA) as capsules
223790777|NCT03721991|DIETARY_SUPPLEMENT|placebo|matching placebo
223790778|NCT02703350|DRUG|LY900014|Administered subcutaneously (SC)
223790779|NCT02703350|DRUG|Insulin Lispro|Administered SC
223790780|NCT01210391|OTHER|Extensively hydrolyzed whey infant formula|New hydrolyzed infant formula.
223790781|NCT01210391|OTHER|Extensively hydrolyzed casein infant formula|Commercially available infant formula.
223790782|NCT06095726|BEHAVIORAL|Peppermint Inhalation|The researcher applied two drops (0,2ml) of 2% essential oil of peppermint on a piece of cotton. Then, each child was instructed to take three breaths of the essence that had been put on a piece of cotton before starting chemotherapy session with three minutes. In addition, the piece of cotton with peppermint essence was kept at bed side table to use by child as needed throughout the chemotherapy session. Inhalation of peppermint essence was applied for three consecutive chemotherapy sessions.
223790783|NCT06095726|BEHAVIORAL|Swedish Massage|Children were received Swedish massage therapy for twenty minutes prior to chemotherapy session in a private and special room with effleurage, petrissage, friction, and tapotement and vibration movements for three consecutive chemotherapy sessions. The researcher applied facilitating olive oil in hands and pre warmed before applying massage. The massage technique was applied in prone position with mild to moderate pressure with guidance by the child's feedback and tolerance by using non-scented olive oil. Children's privacy was considered.
223790784|NCT05771753|OTHER|Stretching Exercises|6 stretching exercises 2 repetitions x1 set, 3 days/week and targeted muscles stretching (Lower Back, Lower limb)
223790785|NCT05771753|OTHER|Dynamic core stabilizing exercises|This group received core stabilizing exercises 2 repetitions x1 set, 3 days/week and the targeted muscles were abdominals, lower back, and lower limb.
223790786|NCT06111716|OTHER|Mindfulness- Based Childbirth Education|Mindfulness- Based Childbirth Education Group includes; Women were given eight-week birth preparation training. In this training, in addition to information about birth, mindfulness, mindfulness attitudes and practices, mindfulness in daily life, mindfulness in pregnancy and postpartum period, mindfulness breastfeeding and meditation practices were included.
223790787|NCT06111716|OTHER|Information-Based Birth Education|In the Information-Based Birth Education Group, women were given 4-week (4 hours per week) birth preparation training. The education given was not based on a philosophy or method.
223790788|NCT01026974|BIOLOGICAL|rMenB|
223790789|NCT01026974|BIOLOGICAL|rMenB+OMV NZ|
223790790|NCT06270966|DEVICE|Virtual Reality Cognitive Remediation|"Participants will undergo a 3-months cognitive remediation program using fully immersive VR with two sessions per week. Each session will last a maximum of sixty minutes and will be supervised by expert health professionals. The experimental group participated in an immersive VR-based CR program using the CEREBRUM software designed by clinicians and experts specializing in cognitive rehabilitation.~CEREBRUM provides 52 exercises: Attention, Working Memory, Memory and Learning and Cognitive Estimates. The intervention included 24 sessions."
223790791|NCT00303966|DRUG|sorafenib tosylate|Given orally
223790792|NCT00325468|DRUG|AMG 162|AMG 162; 60 mg/mL of Denosumab given to all subjects at Screening/Day 1, Month 6, Month 12, Month 18, Month 24, Month 30, Month 36 and Month 42
223790793|NCT03280121|DEVICE|EsophyX ZR transoral device|TIF
223790794|NCT03552874|OTHER|The Performance of Upper Limb Questionnaire (PUL)|
223790795|NCT00820833|OTHER|standard infant formula|standard infant formula given from 3 to 12 months of age, as per standard requirement
223790796|NCT00820833|OTHER|Test formula|Test formula with different protein and calorie content than standard formula, given from 3 to 12 months of age. As per standard requirement.
223790797|NCT00622128|BEHAVIORAL|Preventing Aggressive Behavior in Demented Patients|Preventing Aggressive Behavior in Demented Patients
223790798|NCT06579742|DIETARY_SUPPLEMENT|Live Conscious Beyond Collagen|Participants in the experimental arm will take 1 scoop (10.4 g) of Live Conscious Beyond Collagen supplement mixed with 12 fl oz of water in the evening after their last meal of the day for 24 weeks.
223790799|NCT06579742|DIETARY_SUPPLEMENT|Placebo|Participants in the placebo comparator arm will take 1 scoop (10.4 g) of the placebo product (Maltodextrin) mixed with 12 fl oz of water in the evening after their last meal of the day for 24 weeks.
223790800|NCT00675389|BEHAVIORAL|Peer Health Workers Intervention|Peer health workers are themselves PLWHA on ART who have demonstrated good ART adherence for at least 6 months. The peers are responsible for \~15-20 patients and are expected to visit the patients in their homes once every two weeks. At these visits, peers record a review of symptoms, client self-report of adherence, and a pill count. At the clinic, peers assist with patient organization and share their experiences, particularly with patients about to start ART. Peer health workers undergo an initial, intensive two day residential training course and are provided with a bike and basic supplies, and a modest amount of remuneration to encourage compliance with their responsibilities and promote a high program retention rate.
223790801|NCT00675389|BEHAVIORAL|Peer Health Workers and Mobile Phone Intervention|In addition to the peer health worker intervention, this arm adds a mobile phone intervention consisting of the following: during home visits, peers with mobile phones, using data collected on their home visit forms, send real-time text messages containing this clinical and adherence data back to the central clinic to be reviewed by clinical staff within a 24 hour period. Peers may also call, toll-free, back to a central clinic Warmline with any questions or concerns.
223790802|NCT01310387|BEHAVIORAL|Active pain management|Active pain management will be provided by specialized pain nurse, such as telephone counseling for toxicity control and opioid dose modification.
223790803|NCT04049630|DRUG|LEV 1 mg/kg|A combinaison of LEV 10 mg, 50 mg, and placebo will be adapted to the weight ; all the tablets will be blinded, and each participant will receive 5 tablets.
223790804|NCT04049630|DRUG|LEV 1,5 mg/kg|A combinaison of LEV 10 mg, 50 mg, and placebo will be adapted to the weight ; all the tablets will be blinded, and each participant will receive 5 tablets.
223790805|NCT04049630|DRUG|LEV 2,5 mg/kg|A combinaison of LEV 10 mg, 50 mg, and placebo will be adapted to the weight ; all the tablets will be blinded, and each participant will receive 5 tablets.
223790806|NCT04049630|DRUG|Placebo|5 tablets of placebo will be administrated to the participants.
223790807|NCT06429176|DRUG|SPL84|SPL84 solution for nebulization
223790808|NCT06429176|OTHER|Placebo|Placebo solution for nebulization
223790809|NCT06634485|DEVICE|ultrasound, spirometry|"Ultrasound assessment of~1. diaphragmatic excursion:-the probe will be angled medially ,cranially , and dorsally so that the ultrasound beam reaches the posterior third of the diaphragm, in B-mode.Then, then M-mode exploration line will be placed perpendicular to the diaphragmatic dome to obtain maximum excursion .~2. (Tdi) will be measured using a high-frequency linear probe (10 MHz) placed on (ZA).The probe will be angled perpendicular to the lateral chest wall and placed between the midaxillary and anterior axillary lines at the eighth or ninth intercostal space.~3. Quadricep\|rectus femoris muscle assessment will be done by placing the transducer perpendicular to the long axis of the thigh.~   * Spirometry:-will be performed thrice by experienced technicians at our pulmonary function laboratory. Patients will be asked to take a maximal inspiration and then to forcefully expel air for as long and as quickly as possible."
223790810|NCT02371954|BEHAVIORAL|Happy Older Latinos are Active|Health promotion intervention desgined to prevent anxiety and depression in at risk older Hispanics
223790811|NCT02371954|OTHER|Fotonovela|Comic book style informational booklet designed for people with low literacy to educate them on mental illness.
223790812|NCT00262275|DRUG|Aspirin, Clopidogrel|
223790813|NCT05913856|OTHER|Normal saline|Normal saline will be applied to irregate the oral cavity after the swabing of the surface of patients' teeth and oral cavity by a sponge swab by the primary care nurse in the MICU.
223790814|NCT05913856|OTHER|Chlorhexidine|15ml of 0.12% chlorhexidine will be applied to irregate the oral cavity after the swabing of the surface of patients' teeth and oral cavity by a sponge swab by the primary care nurse in the MICU.
223790815|NCT06273735|DIAGNOSTIC_TEST|Pre- and postoperative determination of troponin as part of the study and 24-month FU survey|An intervention is carried out as part of the normal clinical procedure regardless of the study measurement parameters.
223790816|NCT01314118|DRUG|abiraterone acetate in combination with prednisone|Abiraterone acetate will be taken as 4 x 250 mg tablets by mouth (PO) once daily. Prednisone will be taken as 2 x 2.5 mg tablets PO once daily.
223790817|NCT04321408|DRUG|Ziconotide Injection|Intrathecal analgesia with Ziconotide
223790818|NCT06434597|DRUG|SPH5030|SPH5030：Oral, QD, 600mg
223790819|NCT02162420|DRUG|Alemtuzumab|Alemtuzumab 0.2 mg/kg IV over 2 hours on days -10 to -6 from transplant.
223790820|NCT02162420|DRUG|Fludarabine|Fludarabine 40 mg/m2 IV over 1 hour on days -6 to -2 from transplant.
223790821|NCT02162420|DRUG|Cyclophosphamide|Cyclophosphamide 50 mg/kg IV over 2 hours on day -7 from transplant.
223790822|NCT02162420|RADIATION|Total Body Irradiation|TBI 200 cGy as a single fraction on day -1 from transplant.
223790823|NCT02162420|BIOLOGICAL|Stem Cell Transplant|Stem cell transplant on day 0.
223790824|NCT02162420|DRUG|Anti-thymocyte globulin|ATG (Thymoglobulin - Rabbit ) 3 mg/kg IV on days -5 to -3 from stem cell transplant.
223790825|NCT06290180|BEHAVIORAL|First Face for Mental Heatlh|First Face for Mental Health is a culturally-appropriate community-based mental health training for lay persons and others that prepares learners to provide assistance to someone having a mental health crisis. The course takes approximately 8 hours to complete.
223790826|NCT05267041|OTHER|Quality of life questionnaire|One questionnaire between diagnostic annoucement and first line treatement
223790827|NCT05267041|BIOLOGICAL|Blood sample|One optional veinous blood sampling (24 ML) between the first diagnostic annoucement and before the first treatment for lung cancer
223790828|NCT05267041|OTHER|Quality of life questionnaire|One questionnaire 6 months later after first line treatment
223790829|NCT05267041|OTHER|Quality of life questionnaire|One questionnaire before second line treatment
223790830|NCT05267041|OTHER|Quality of life questionnaire|One questionnaire 6 months later after second line treatment
223790831|NCT06582121|OTHER|Polysomnography|An overnight sleep study
223790832|NCT05898217|OTHER|Dairy Milk|Daily, each participant will consume 16 oz of the type of milk (plant based or dairy) two which they are randomized.
223790833|NCT05898217|OTHER|Soy Milk|Daily, each participant will consume 16 oz of the type of milk (plant based or dairy) two which they are randomized.
223790834|NCT05898217|OTHER|Almond Milk|Daily, each participant will consume 16 oz of the type of milk (plant based or dairy) two which they are randomized.
223790835|NCT05898217|OTHER|Oat Milk|Daily, each participant will consume 16 oz of the type of milk (plant based or dairy) two which they are randomized.
223790836|NCT03435133|DRUG|Prasugrel|60 mg oral bolus plus oral 10 mg once daily
223790837|NCT03435133|DRUG|Ticagrelor|180 mg oral bolus plus oral 90 mg every 12 hours daily
223790838|NCT05909332|DRUG|Antivascular therapy|BP102 (anti VEGFR)
223790839|NCT05909332|DRUG|Chemotherapy|ddEC-P
223790840|NCT06382298|OTHER|COTTONSEED OIL|Participants are provided a breakfast shake that meets 20% of participant's daily estimated energy needs as cottonseed oil for 28 days.
223790841|NCT06382298|OTHER|MATCHED PUFA DIET|Participants are provided a breakfast shake that meets 20% of participant's daily estimated energy needs from oils with similar fatty acid composition as CSO for 28 days.
223790842|NCT06382298|OTHER|CONTROL|Participants are provided a breakfast shake that meets 20% of participant's daily estimated energy needs as a mixture of oils that match the average American fat intake for 28 days.
223790843|NCT05444504|DEVICE|Cup|an insertable vaginal cup ('cup')
223790844|NCT05444504|DEVICE|Cup+|the cup attached via rubber tubing to a leg-secured urine collection bag ('cup+') for greater urine holding capacity
223790845|NCT03638141|DRUG|Durvalumab|Durvalumab 1500mg IV every 4 weeks for up to a maximum of 13 cycles (about 12 months) or until confirmed disease progression.
223790846|NCT03638141|DRUG|Tremelimumab|Tremelimumab 300 mg IV in combination with Durvalumab 1500mg about 2 weeks after their first DEB-TACE.
223790847|NCT04983615|DRUG|fentanyl-based sedation|fentanyl-based sedation instead of midazolam-based sedation in ventilated patients
223790848|NCT04983615|DRUG|midazolam-based sedation|midazolam-based sedation
223790849|NCT06317051|DRUG|Dapagliflozin 10mg Tab|Dapagliflozin will be administered as a comparator to the placebo to assess its effects on weight reduction
223790850|NCT06317051|DRUG|Pitavastatin 4 Mg Oral Tablet|Pitavastatin tablets will be administered as a comparator to Rosuvastatin/Ezetimibe 10mg/10mg tablets to assess and compare their effects on LDL concentrations
223790851|NCT06317051|DRUG|Rosuvastatin and Ezetimibe|Rosuvastatin/Ezetimibe 10mg/10mg tablets will be administered as a comparator to pitavastatin to assess and compare their effects on LDL concentrations
223790852|NCT06317051|DRUG|Placebo|The placebo tablets are visually identical to the active drug tablets and will be administered as a comparator to Dapagliflozin.
223790853|NCT05003349|OTHER|Occlusal Splint (OS).|OS will be made of heat-cured acrylic by the same specialized dentist. These intraoral devices will be flate, rigid, will cover the entire dental arch, and will have the lowest possible height. The perimeter of the splint will have at least 11 dental contacts, light, symmetrical and pinpoint as possible. The patients will be instructed to use the splint every night during the study Two supervisions will be carried out 30 and 60 days after the use of the OS, in order to stabilize the contact points.
223790854|NCT05003349|OTHER|Pain Neuroscience Education (PNE).|"A power point presentation with metaphors and animated videos will be used. The PNE will be held in 10 sessions of 20 minutes each. The intervention will be developed using content according to the book Explain Pain and the web page www.retrainpain.org."
223790855|NCT05003349|OTHER|Motor Imagery (MI).|"The participants will have to judge the laterality of different cervical images presented on the screen of a cell phone. The laterality task will be executed using an application called Recognize Neck, developed by the NOI group. The procedure will begin with a familiarization test with the Basic level followed by a laterality discrimination task. It will be performed using 20 images, with 5 seconds for each image, beginning with the Vanilla program and progressively increasing the difficulty using the Context and Abstract programs. The estimated time to complete the task will be about 10 minutes per session."
223790856|NCT05003349|OTHER|Action Observation (AO).|The patients will see videos showing the jaw and cervical exercises with the same series and repetitions that they will actively perform in the session. Therefore, the training of the action observation will be carried out dynamically. The patient will be asked to think and visualize the movement that he/she will have to perform later. It is estimated 10 minutes per session for the AO.
223790857|NCT05003349|OTHER|Jaw and Neck Exercises (JNE)|A jaw and neck exercise program will be carried out in 3 series of 10 repetitions per session will be planned with 1minute rest between exercise. The exercises will be executed with a total time per session of 20 minutes, initially in the clinic and later at home. In the clinic, verbal and tactile instructions will be provided for the correct execution of the exercises and later they will be sent through WhatsApp and / or mail to perform them at home.
223790858|NCT05003349|OTHER|Counselling.|Counselling include education about the anatomical, biomechanical and psychosocial factors relationed with temporomandibular disorders, guidance regarding the parafunction jaw activities for eg will be taught the resting postural position of the mandible (teeth apart, lips slightly touching and tongue not pushing against the teeth).
223790859|NCT04516122|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
223790860|NCT04516122|PROCEDURE|Dual X-ray Absorptiometry|Undergo DXA scan
223790861|NCT03733262|OTHER|De-prescribing Trial|Validated de-prescribing algorithms will be applied for any patients identified as taking one of the 9 study drugs in order to determine whether or not physician should consider a deprescribing trial. If they are are identified as candidates for deprescribing and consent to participate in the trial, they will enter the Deprescribing Trial group and begin the deprescribing trial.
223790862|NCT05585307|DRUG|Bavtavirine|Administered orally
223790863|NCT05585307|DRUG|B/F/TAF|Administered orally
223790864|NCT05585307|DRUG|Standard of Care (Substudy 01)|"Antiretroviral therapy, administered orally~Non-NNRTIs, examples: ABC/DTG/3TC; DTG plus (TAF or TDF) plus (FTC or 3TC)"
223790865|NCT05585307|DRUG|GS-1720|Administered orally
223790866|NCT05585307|DRUG|Standard of Care (Substudy 02)|"Antiretroviral therapy, administered orally~Example INSTIs: DTG/ABC/3TC or DTG/3TC"
223790867|NCT05585307|DRUG|GS-6212|Administered orally
223790868|NCT05585307|DRUG|Standard of Care (Substudy 03)|Antiretroviral therapy, administered orally
223790869|NCT05680129|DRUG|Ecnoglutide high dosage|Administered subcutaneously
223790870|NCT05680129|DRUG|Ecnoglutide low dosage|Administered subcutaneously
223790871|NCT05680129|DRUG|Dulaglutide|Administered subcutaneously
223790872|NCT05680129|DRUG|Metformin|Administered orally
223790873|NCT02945085|OTHER|Home Based Care Team|Clinical team will conduct comprehensive clinical assessments focused on cognitive impairment and depression, conduct comprehensive medication review and reconciliation, offer Problem Solving Therapy, and offer brief occupational therapy, physical therapy, nutrition, and social support services.
223790874|NCT02945085|OTHER|Telephone Based Care Team|Telephone contact will be made by nurses. Depending on level of need, follow up telephone and, in some cases, in home visits will be made by nurse or social worker from care management program.
223790875|NCT05875623|OTHER|MALPIP criteria|In the intervention group, the clinical pharmacist will apply the MALPIP criteria on all the admission and discharge medications. The intervention will consist of 4 steps: i) pharmacist review using MALPIP criteria to detect PIM, ii) discussion with doctors for deprescribing decision iii) discussion with patients and documentation of shared decision iv) follow up patients
223790876|NCT06038123|DEVICE|China market released 3.0T Magnetic resonance (MR) conditional CIED systems|To confirm safety and effectiveness of the SureScan CIED System in the clinical MRI environment when subjects receive 3.0T MRI scans without positioning restrictions (MRI scans may occur anywhere on the body)
223790877|NCT06088771|BIOLOGICAL|Dupilumab|Dupilumab will be administered at the recommended initial dosage of 600 mg (two 300 mg injections) on Day 1.
223790878|NCT06088771|BIOLOGICAL|Cemiplimab|Cemiplimab will be administered at the recommended dosage of 350 mg, as an intravenous infusion, over 30 minutes on Day 1.
223790879|NCT06230757|DRUG|Psilocybin 25mg|25mg psilocybin capsule
223790880|NCT06230757|DRUG|Placebo (active placebo)|1mg psilocybin capsule
223790881|NCT04029974|DEVICE|ErigoPro|Robotic tilt-stepper lower extremity movements at the cadence of 0, 40, and 80 steps/minute.
223790882|NCT06962189|DRUG|chemoimmunothrapy|Patients will receive 3-4 cycles of induction therapy with Sintilimab combined with platinum-based doublet chemotherapy, followed by multidisciplinary team (MDT) evaluation. For patients deemed eligible for radical lung primary lesion resection, surgery should be performed within 4-6 weeks after completing the final cycle of chemoimmunotherapy. The timing of radiotherapy for metastatic lymph nodes will be determined by MDT discussion. If deemed inoperable after induction therapy by MDT, definitive radiotherapy will be administered subsequently. All patients, in the absence of contraindications, will receive PD-1 inhibitor maintenance therapy for 1 year following local treatment.
223790883|NCT06962137|DRUG|zolbetuximab|The investigational product, Zolbetuximab, is a sterile lyophilized powder preparation with the chimeric monoclonal antibody Zolbetuximab as the active pharmaceutical ingredient.
223790884|NCT06962137|OTHER|Retrospective cohort, no intervention|No intervention
223790885|NCT06961461|OTHER|AI-assisted quality control tool|"In this study, quality control personnel will be randomly divided into an experimental group and a control group, and will use artificial intelligence-assisted quality control and manual quality control to conduct quality control on the data collected from the epidemiological survey.~Experimental group: Quality control personnel will use the AI system to perform quality control on the questionnaire recordings.~Control group: The questionnaire content was checked by manually listening back to the recordings and errors were recorded manually."
223790886|NCT06962605|BEHAVIORAL|Moderate-intensity continuous running (MICE: 60% V̇O2max)|Participants run continuously for 40 minutes at moderate intensity (60-65% V̇O2max)
223790887|NCT06962605|BEHAVIORAL|5-minute interval running (5MIN)|Participants run for 40 minutes at average moderate intensity with 5-minutes slow and fast cycles where speed is increased and decreased by 20%.
223790888|NCT06962605|BEHAVIORAL|2-minute interval running (2MIN)|Participants run for 40 minutes at average moderate intensity with 2-minutes slow and fast cycles where speed is increased and decreased by 20%.
223790889|NCT06962605|BEHAVIORAL|Resting control|Participants sit for 40 minutes in a comfortable position
223790890|NCT06961604|DRUG|NaF PET-CT|Following a non-cardiogenic thromboembolic stroke, patients will undergo NaF PET-CT imaging to identify the culprit plaque and any other vulnerable plaques at high risk for rupture
223790891|NCT06961721|BIOLOGICAL|Herpes Zoster Vaccine, Live|assigned to the vaccine group and placebo group in a 2:1 ratio.
223790892|NCT06961721|BIOLOGICAL|Placebo|assigned to the vaccine group and placebo group in a 2:1 ratio.
223790893|NCT06961578|PROCEDURE|C1-2 instrumentation|"Surgical fracture stabilization with a posterior screw-rod system from C1-2 from a posterior approach.~The routine surgery commonly lasts approximately 100 minutes and requires a hospital stay of about 6 days. An additional external bracing in the postoperative setting is not required."
223790894|NCT06961578|OTHER|External immobilization with rigid cervical collar|External immobilization with a rigid cervical collar for 12 weeks. Compliance is monitored through patient diaries, recognizing the real-world challenges of consistent brace use. Lack of adherence is considered to reflect routine clinical practice. A typical drawback of the conservative intervention in daily practice is the absolute reliance on patient compliance to wear the collar continuously for at least 12 weeks, which poses a significant challenge to this treatment strategy.
223790895|NCT03640208|BEHAVIORAL|Education presented by trained caregiver|After participants complete the Pre-test, an educational session will be presented by a trained caregiver, delivered in a lecture-style manner with Power Point projection of educational material. The slides in this presentation will be scripted to mitigate variability among different presenters. Topics addressed in the presentation include: CRC basics (including brief anatomy), data on disparity, risk factors, screening modalities, preventative measures, population disparities of CRC, colonoscopy exam and other screening tests. The emphasis will be on CRC risks factors and prevention. All required information that is needed to correctly answer post-test questions is embedded within the presentation.
223790896|NCT04597190|DRUG|Selective serotonin reuptake inhibitor|Prescribers and patients choose among three selective serotonin reuptake inhibitors (SSRI), sertraline, paroxetine, or fluoxetine based on patient's treatment history (i.e., failed SSRI trials due to side-effects or lack of efficacy) and preference. If a patient experiences problematic side effects after taking their choice of SSRI, the provider may switch them to another of the SSRI options during the first 8 weeks of follow-up. Patients on any antidepressant (including SSRIs) at enrollment will be cross-tapered over four weeks to either fluoxetine, sertraline or paroxetine (i.e., the old drug will be tapered down while the new drug is tapering up).
223790897|NCT04597190|DRUG|Serotonin-norepinephrine reuptake inhibitor|Prescribers will prescribe venlafaxine.
223790898|NCT04597190|BEHAVIORAL|Written Exposure Therapy|Written Exposure Therapy will be delivered during six 30 minute sessions. The first session includes psychoeducation about symptoms of PTSD, provides a treatment rationale for approaching the trauma memory, and discusses the use of writing as a means of doing so. In sessions 2-6, patients will write about the memory of their worst traumatic event for 20 minutes, with a focus on details of the event and thoughts and feelings that occurred during the event. Patients are directed to write about the same trauma memory during each session. The session ends with the therapist instructing the patient to allow themselves to experience any trauma-related memories, images, thoughts, and feelings in the interval between sessions. The therapist reads the narrative between sessions to make sure instructions were followed. Feedback about the narrative is provided to the patient at the beginning of sessions 3-6. This feedback is used to prompt the patient for writing in the current session.
223790899|NCT06240455|DRUG|WP1302|Each arm will be treated with methimazole. During the MMI tapering period, commences the MMI weaning by reducing the original dosage by 50%. This adjusted dose is to be administered over a two-week duration. Continue this dose reduction in the subsequent 2-week durations until achieving a dose of 2.5 mg/day or lower. Upon reaching this threshold, MMI is to be discontinued (withdrawal).
223790900|NCT06240455|DRUG|WP1302 placebo|Each arm will be treated with methimazole. During the MMI tapering period, commences the MMI weaning by reducing the original dosage by 50%. This adjusted dose is to be administered over a two-week duration. Continue this dose reduction in the subsequent 2-week durations until achieving a dose of 2.5 mg/day or lower. Upon reaching this threshold, MMI is to be discontinued (withdrawal).
223790901|NCT06240455|COMBINATION_PRODUCT|methimazole|Each arm will be treated with methimazole. During the MMI tapering period, commences the MMI weaning by reducing the original dosage by 50%. This adjusted dose is to be administered over a two-week duration. Continue this dose reduction in the subsequent 2-week durations until achieving a dose of 2.5 mg/day or lower. Upon reaching this threshold, MMI is to be discontinued (withdrawal).
223790902|NCT05826379|BEHAVIORAL|Adaptive Daily Goal Setting|Daily step goals displayed by the study application
223790903|NCT05826379|BEHAVIORAL|Interim Goal Prompt|Short-term step goals
223790904|NCT06288438|BEHAVIORAL|Motivational Interviewing Techniques|Motivational Interviewing Techniques including but not limited to open-ended questions, reflection, affirmations, and summary will be used to build participant rapport, support behavior change (physical activity), and facilitate program engagement.
223790905|NCT06288438|OTHER|Physical Therapy Interventions|Strengthening, balance, functional activities, stretching, breathing, aerobic endurance exercise.
223790906|NCT06288438|OTHER|Education|Education on general health topics which may include the following: basic nutrition, stress reduction, sleep hygiene, etc.
223790907|NCT06288438|OTHER|Health Status Updates|Health Status Updates will be completed by a trained assessor. The assessor will ask about adverse events, general health topics, medication changes, and changes in social circumstances.
223790908|NCT06288438|OTHER|Physical Therapy Consult|Participants in the control condition will be offered a physical therapy consult at the end of their 24 week study involvement.
223790909|NCT06375265|BEHAVIORAL|digital Cognitive Behavioral Therapy for Insomnia (dCBT-I)|Preoperative hybrid intervention (in-person or via phone/video) over 4 weeks, and at 2 weeks, and 1 month after surgery using content from the CBT-I Coach app from Veteran Affairs.
223790910|NCT06375265|BEHAVIORAL|Sleep Health Education|Sleep Health Education materials provided
223790911|NCT04420221|BIOLOGICAL|Sa-5Ag half dose non-adjuvanted|1 dose of Sa-5Ag (5 antigens of S. aureus) half dose, non-adjuvanted at Day 1, administered intramuscularly.
223790912|NCT04420221|BIOLOGICAL|Sa-5Ag full dose non-adjuvanted|1 dose of Sa-5Ag (5 antigens of S. aureus) full dose, non-adjuvanted at Day 1, administered intramuscularly.
223790913|NCT04420221|BIOLOGICAL|Sa-5Ag half dose adjuvanted|1 dose of Sa-5Ag (5 antigens of S. aureus) half dose, adjuvanted at Day 1, administered intramuscularly.
223790914|NCT04420221|BIOLOGICAL|Sa-5Ag full dose adjuvanted|A series of 2 doses of S. aureus candidate vaccine (Sa-5Ag full dose adjuvanted) given approximately 2 months apart (Days 1 and 61), administered intramuscularly.
223790915|NCT04420221|BIOLOGICAL|Placebo|One dose of placebo (saline solution for injection/ vial or prefilled syringe) at Day 1 for placebo Groups 1 to 3 (Dose-escalation epoch) and a series of 2 doses of placebo given approximately 2 months apart (Days 1 and 61) for placebo Group 4 (Dose-escalation epoch) and Group PoP: Placebo, administered intramuscularly.
223790916|NCT04935307|DIAGNOSTIC_TEST|MRI and paraclinical tests|The patients and controls will be evaluated using MRI and furthermore a large test battery of questionnaires and paraclinical tests. Including the following test: MCS checklist, BDS-Checklist, Symptom Checklist-92 (SCL-92), Whiteley-8, SF-36, Major Depression Inventory (MDI), GAD-10 anxiety scale, and related questionnaire, behavioral olfactory test (TDI), habituation test, pain measurement thresholds tests, Heart Rate Variability and cognitive testing.
223790917|NCT05795595|BIOLOGICAL|CTX131|CTX131 (CD70-directed T-cell immunotherapy comprised of allogeneic T cells genetically modified ex vivo using CRISPR-Cas9 gene editing components)
223790918|NCT02284438|DEVICE|Endotracheal tube|Three endotracheal tubes with different surfaces will be used
223790919|NCT00517738|OTHER|Physical training|A program of exercising under strict surveillance, with endurance and coordination maneuvers
223790920|NCT00517738|OTHER|Diet intervention|Energy intake tailored to basal metabolism and level of physical activity. Protein and sodium intake will be adjusted to 1.2-1.5 g/kg/d, and 1.5-2 g/d of salt, respectively. The latter will be adjusted only in those patients presenting ascites and/or edema
223790921|NCT05022030|DRUG|mCapOX plus cetuximab|capecitabine 1000mg/m2 po bid d1-7+oxaliplatin ivgtt 85mg/m2 d1+cetuximab ivgtt 500mg/m2, q2w
223790922|NCT05022030|DRUG|mFOLFOX6 plus cetuximab|oxaliplatin ivgtt 85mg/m2 d1+ leucovorin ivgtt 400mg/m2 d1+ fluorouracil iv bolus 400mg/m2 d1+ fluorouracil 2400mg/m2 continuous infusion for 46h+cetuximab ivgtt 500mg/m2, q2w
223790923|NCT02513563|DRUG|Carboplatin|Participants will be treated with carboplatin (area under the curve 5 (AUC5) will be used to determine the dosage) twice daily, days 1 and 2 and once a day on day 3 (5 doses) during each 21 day cycle of treatment.
223790924|NCT02513563|DRUG|Paclitaxel|Participants will be treated with paclitaxel 175 mg/m\^2 twice daily, days 1 and 2 and once a day on day 3 (5 doses) during each 21 day cycle of treatment.
223790925|NCT02513563|DRUG|AZD1775|Participants will receive AZD1775 225 mg twice daily, days 1 and 2 and once a day on day 3 (5 doses) during each 21 day cycle of treatment.
223790926|NCT06125392|DIAGNOSTIC_TEST|Coronary physiology assessment|Resting distal coronary to aortic pressure ratio, resting flow ratio, fractional flow reserve, Coronary Flow Reserve and Microvascular resistance using the thermodilution method and papaverin or adenosine, Resting distal coronary to aortic pressure ratio, resting flow ratio, fractional flow reserve, Coronary Flow Reserve and Microvascular resistance using the thermodilution method and acetylcholine.
223790927|NCT04876248|BIOLOGICAL|Belantamab Mafodotin|Given IV
223790928|NCT04876248|DRUG|Lenalidomide|Given PO
223790929|NCT00933231|DRUG|tacrolimus|Standard dose, Oral
223790930|NCT00933231|DRUG|tacrolimus|Low dose, Oral
223790931|NCT00933231|BIOLOGICAL|Simulect|IV
223790932|NCT00933231|DRUG|Cellcept|Oral
223790933|NCT00933231|DRUG|Corticosteroids|IV and Oral
223790934|NCT00933231|DRUG|Ramipril|Oral
223790935|NCT00933231|DRUG|Irbesartan|Oral
223790936|NCT04578262|PROCEDURE|Epley Manoeuvre|This manoeuvre is constituted by five steps. In the first step, while the patient is in supine posture the head will be positioned 45 degrees turned towards the unaffected ear and the head slightly overhang on the edge of the couch. In this second step maintaining the previous position of the head, physiotherapist will turn head 45 degrees turned towards the affected ear. Next, in the third step, the whole body will turn until is located 135 degrees from the baseline supine position. In the fourth step, while the head keeps turned to the affected ear the subject will be incorporated until he is sitting. In the fifth step, while the subject is seated with the head in neutral position the chin will be bended 20 degrees. Each procedure will be held among 30 seconds or two minutes, while the dizziness or the nystagmus vanish. The intervention will be conducted at the Physical Therapy Department of the University of Sevilla (Spain).
223790937|NCT04578262|PROCEDURE|Sham Manoeuvre|The sham manoeuvre consist is going to star with the participant in a neutral seated position. Sum to it, head is rotated 45 degrees towards the unaffected vestibule. After that, the participant will be guided by the physiotherapist to a lateral decubitus position towards the affected side on which his nose will be pointing above. To conclude, the seated position will be reached again without head rotation. Each position of the sham manoeuvre will be maintained along one minute. During all the process the videonystagmography glasses will be dressed by participants and they will be indicated not to close eyes in the intervention. After the execution of the manoeuvre, also this group will be evaluated 48 hours after. The intervention will be conducted at the Physical Therapy Department of the University of Sevilla (Spain).
223790938|NCT06189417|BEHAVIORAL|Health Extension Led club based Intervention|The Health Extension Workers-led club-based intervention primarily focuses on equipping individuals with the necessary knowledge and skills to enhance their self-management behavior. The intervention encompasses education on adopting healthy eating habits, promoting regular exercise, effectively managing weight, and supporting smoking cessation. It emphasizes the importance of regular blood sugar level monitoring, limiting alcohol intake, and reducing sedentary behavior. The intervention also includes counseling to provide guidance and support in adopting and maintaining healthy behaviors. Additionally, it highlights the significance of adhering to medication regimens for optimal health outcomes. If additional medical attention is required, the intervention provides referral services to nearby health facilities.
223790939|NCT06237972|PROCEDURE|4-week Perturbation-based balance training|Participants will be asked to walk over a six by two meters computer-controlled movable platform at a self-selected speed. Slip-like perturbations will be induced by the device software that moves the platform 12 inches forward at 0.46 m/s with an acceleration of 9.4 m/s2. Participants will be secured in a safety harness which will be attached to the overhead arch of the platform. Participants will be asked to go to the experimental study cite 11 times. A baseline screening, 8 training sessions, a post-training screening, and a 2 months folow up screening
223790940|NCT06237972|DEVICE|Neuromuscular electrical stimulation|NMES will be applied on tibialis anterior and quadriceps muscles during perturbation-based balance training.
223790941|NCT01518868|DEVICE|Investigational contact lens|Worn on a daily wear basis for one week.
223790942|NCT01518868|DEVICE|PureVision contact lens|Worn on a daily wear basis for one week
223790943|NCT02774057|DRUG|Captafer®|"2 pills daily. Contains~* Vitamin C, known for its property to facilitate iron absorption by reducing iron to the reduced ferrous state necessary for uptake;~* Vitamin E, an antioxidant, along with vitamin C it protects Fe++;~* Folic acid, necessary to prevent megaloblastic anemia and abnormalities in the fetal nervous system, vital during pregnancy;~* Zinc and Copper which act in different mitochondrial cytochromes-dependent systems and contribute to the use of iron by the biological systems"
223790944|NCT02774057|DRUG|Iron Sulfate|195 mg Iron supplement
223790945|NCT00373594|DRUG|Rituximab|
223790946|NCT00373594|DRUG|Fludarabine|
223790947|NCT02086357|PROCEDURE|SWUE|
223790948|NCT00934466|DRUG|MK2637|Single dose of 120 mg MK2637 capsules in one of five treatment periods.
223790949|NCT00934466|DRUG|Comparator: MK2637|Single dose of 50 mg MK2637 capsules in one of five treatment periods.
223790950|NCT00934466|DRUG|Comparator: Placebo|Single dose of placebo only in one of five treatment periods.
223790951|NCT00934466|DRUG|Comparator: Dextromethorphan|Single dose of 220 mg dextromethorphan capsules in one of five treatment periods.
223790952|NCT00934466|DRUG|Comparator: Dextromethorphan|Single dose of 110 mg dextromethorphan capsules in one of five treatment periods.
223790953|NCT01556438|BIOLOGICAL|Tabalumab|Administered IV
223790954|NCT01556438|DRUG|Bortezomib IV|Administered IV
223790955|NCT01556438|DRUG|Bortezomib SC|Administered SC
223790956|NCT01556438|DRUG|Dexamethasone|Administered orally
223790957|NCT04622696|DIAGNOSTIC_TEST|Ultrasound imaging|Subjects in the performance cohort will undergo ultrasound imaging to assess the visibility of the HydroMARK Breast Biopsy Marker at 6-12 weeks post-implant. There is no intervention in the safety cohort (retrospective chart review).
223790958|NCT05428735|PROCEDURE|Embolization|Portal Vein embolization with Glue by a transhepatic approach vs. PVE and Hepatic Vein Occlusion with Vascular plugs via a transjugular or transfemoral approach in the same session as the PVE procedure
223790959|NCT02497573|OTHER|Diffuse Weighted MRI|The DW MRI scans will be used to measure ADC and to calculate change in ADC between the 2 scans. Each scan will take approximately 30 minutes. Images will be acquired and analysed as per the separate scanning protocol.
223790960|NCT03695172|DRUG|Ropivacaine|Patients will be randomly assigned to receive one three blocks (TAP, QL, ESP)after delivery of baby with ropivicaine
223790961|NCT03695172|PROCEDURE|TAP block|Patient will receive bilateral TAP blocks after delivery and within one hour of skin closure with 25 mL of 0.2% ropivacaine with epinephrine 1:400,000 per side.
223790962|NCT03695172|BIOLOGICAL|QL block|Patients will receive bilateral QL blocks after delivery and within one hour of skin closure with 25 mL of 0.2% ropivacaine with epinephrine 1:400,000 per side.
223790963|NCT03695172|PROCEDURE|ESP block|Patients will receive bilateral ESP blocks after delivery and within one hour of skin closure with 25 mL of 0.2% of ropivacaine with epinephrine 1:400,000 per side.
223790964|NCT01494402|DRUG|D961S|Oral gelatine capsule
223790965|NCT01494402|DRUG|Esomeprazole|Oral HPMC capsule
223790966|NCT01494402|DRUG|Buffered acetylsalicylic acid|Tablet
223790967|NCT03778229|DRUG|osimertinib|osimertinib (80 mg oral OD).
223790968|NCT03778229|DRUG|savolitinib|savolitinib (300 mg oral OD or 300 mg oral BID or 600 mg oral OD)
223790969|NCT03778229|DRUG|placebo|placebo to osimertinib (oral OD)
223790970|NCT03726346|DEVICE|Toffee Full Face Mask|Participants will be placed on this arm for a total of 14+- 4 days from visit 2. Participants will be using the Toffee mask during this treatment arm.
223790971|NCT00054353|DRUG|fludarabine phosphate|Given IV
223790972|NCT00054353|DRUG|melphalan|Given IV
223790973|NCT00054353|RADIATION|total-body irradiation|Undergo TBI
223790974|NCT00054353|DRUG|mycophenolate mofetil|Given PO
223790975|NCT00054353|DRUG|cyclosporine|Given PO
223790976|NCT00054353|PROCEDURE|nonmyeloablative allogeneic hematopoietic stem cell transplantation|Undergo reduced-intensity allogeneic PBSCT
223790977|NCT00054353|PROCEDURE|peripheral blood stem cell transplantation|Undergo reduced-intensity allogeneic PBSCT
223790978|NCT00054353|OTHER|laboratory biomarker analysis|Correlative studies
223790979|NCT02734212|BEHAVIORAL|Ending Self Stigma for PTSD|Ending Self Stigma for PTSD (ESS-P) is a 9-session small-group (6-8 persons) course designed to help individuals with PTSD develop skills to effectively cope with stigma and minimize the internalization of stigmatizing beliefs and stereotypes. Sessions combine in-class lecture, discussion of relevance to group members' personal experiences, review and practice of strategies and skills, and group sharing, support, and problem-solving. Each session is designed to focus on a specific strategy for addressing self-stigma.
223790980|NCT02734212|OTHER|Enhanced Treatment as Usual|The comparison condition will consist of providing a pamphlet that discusses societal stigma and internalized stigma, and provides resources to help combat the effects of both. Participants will be given the informational pamphlet and study staff will discuss its content with the participant.
223790981|NCT05256589|DIAGNOSTIC_TEST|Sona Saliva C-19 Rapid Self-test|Rapid Antigen diagnostic device performance comparative to RT-PCR
223790982|NCT02319499|DIETARY_SUPPLEMENT|Zinc Alone|Zn-alone group received 10 mg/day of elemental zinc (as zinc sulphate)
223790983|NCT02319499|DIETARY_SUPPLEMENT|Iron and Zinc|Zn+Fe group received 10 mg/day of elemental zinc (as zinc sulphate) and 10 mg/day of elemental iron (as ferrous sulphate)
223790984|NCT02319499|DIETARY_SUPPLEMENT|Iron, Zinc and Vitamin A|Zn+Fe+vit.A group received 10 mg/day of elemental zinc (as zinc sulphate) and 10 mg/day of elemental iron (as ferrous sulphate), plus 1,000 IU/day of vitamin A
223790985|NCT02319499|OTHER|Placebo|Placebo group received no minerals/vitamin
223790986|NCT00736372|DRUG|PX-12|Intravenous infusion, dose escalation, infused over a 72 hour period on days 1, 2 and 3 of a 21-day cycle until progression or development of unacceptable toxicity
223790987|NCT00177554|DRUG|Chemotherapy and Radioimmunotherapy|CHOP-R x 3 cycles followed by zevalin and extended rituximab
223790988|NCT00021762|BIOLOGICAL|HIV-1 Immunogen|
223790989|NCT00021762|PROCEDURE|Structured Treatment Interruption|
223790990|NCT03370653|DRUG|Odiparcil|Investigational product: odiparcil 250 mg tablets
223790991|NCT03370653|OTHER|Placebo|Comparator: placebo tablets similar to odiparcil 250 mg tablets
223790992|NCT03664076|DIAGNOSTIC_TEST|COMISS score|cow's milk protein symptoms score awareness tool to select cow's milk protein allergy in infants
223790993|NCT00421499|DRUG|dark chocolate|
223790994|NCT04006327|OTHER|No intervention will be provided as this study is a cross-sectional observational study.|This item is not applicable because this study is a cross-sectional observational study and no intervention will be provided to participants.
223790995|NCT00909012|DIETARY_SUPPLEMENT|high oleic sunflower oil|placebo, which does not provide DHA
223790996|NCT00909012|DIETARY_SUPPLEMENT|microalgal oil|the supplement provides 20 mg DHA per capsule (1 or 2 are consumed per day, depending on body weight)
223790997|NCT00909012|DIETARY_SUPPLEMENT|microalgal oil|the supplement provides 40 mg DHA per capsule (1 or 2 are consumed per day, depending on body weight)
223790998|NCT00909012|DIETARY_SUPPLEMENT|microalgal oil|the supplement provides 80 mg DHA per capsule (1 or 2 are consumed per day, depending on body weight)
223790999|NCT00909012|DIETARY_SUPPLEMENT|microalgal oil|the supplement provides 130 mg DHA per capsule (1 or 2 are consumed per day, depending on body weight)
223791000|NCT01988246|DRUG|Aflibercept|Patients will be assigned to treatment with 2 mg intravitreal Aflibercept injection (0.05 mL or 50 microliters) administered at the time of surgery (post cataract excision) or sham injection.
223791001|NCT01988246|DRUG|Sham|Sham injection. No actual injection. No medication is used.
223791002|NCT03839953|BEHAVIORAL|Supervised Exercise Program|This intervention is a 12-week supervised exercise program at an established cardiac rehabilitation facility.
223791003|NCT03839953|OTHER|Best Medical Therapy|After undergoing revascularization for critical limb ischemia, patients will receive best medical therapy under the supervision of a vascular internal medicine specialist. This care will include advice on smoking cessation, physical activity guidelines, blood pressure regulation, statin administration and possible anti-platelet administration.
223791004|NCT05088928|DRUG|Apixaban|Direct Acting Oral Anti coagulant
223791005|NCT05088928|DRUG|Rivaroxaban|Direct Acting Oral Anti coagulant
223791006|NCT00688636|DRUG|infliximab|5 mg/kg IV at baseline, 2 weeks, 6 weeks and then every 8 weeks x 6
223791007|NCT00688636|DRUG|placebo|placebo IV at baseline, 2 weeks, 6 weeks and then every 8 weeks x 6
223791008|NCT00450827|BIOLOGICAL|bevacizumab|
223791009|NCT00450827|BIOLOGICAL|filgrastim|
223791010|NCT00450827|PROCEDURE|autologous hematopoietic stem cell transplantation|
223791011|NCT00450827|RADIATION|iodine I 131 monoclonal antibody 3F8|
223791012|NCT04385953|DIAGNOSTIC_TEST|Quantra System|Diagnostic device to monitor coagulation properties of a whole blood sample at the point-of-care
223791013|NCT02361853|OTHER|Exposure: abundance of Immature Myeloid Cells counts in blood samples|
223791014|NCT02361853|OTHER|Exposure: abundance of Immature Dentritic Cells counts in blood samples|
223791015|NCT02361853|OTHER|Exposure: abundance of Immature monocytes counts in blood samples|
223791016|NCT02361853|OTHER|Exposure: abundance of Immature neutrophils counts in blood samples|
223791017|NCT06478784|OTHER|Resistance training|"The experimental group (ACTIVE GROUP) will perform a circuit-based muscular strength program at high intensity three days per week for 10 weeks.~Each session will last approximately 45 minutes.~The Resistance training program will be supervised by staff from the Department of Health Sciences and Sports of the Miguel de Cervantes European University of Valladolid and will be carried out at the facilities of the Miguel de Cervantes European University of Valladolid."
223791018|NCT06478784|OTHER|Low aerobic training|"Patients assigned to this group will perform exercise in static bicycle during 45 minutes three days a week, with a duration of 10 weeks.~This second group, despite performing the aerobic exercise, is considered control, since they will perform low-intensity aerobic exercise (50% of the maximum power developed in cycloergometer)~The Resistance training program will be supervised by staff from the Department of Health Sciences and Sports of the Miguel de Cervantes European University of Valladolid and will be carried out at the facilities of the Miguel de Cervantes European University of Valladolid."
223791019|NCT06275204|DRUG|Bismuth-based quadruple therapy|"Participants who are positive with H. pylori will receive bismuth-based quadruple therapy:~Antibiotic 1 - Amoxicillin 4 x 500 mg or Clarithromycin 2 x 400 mg, Antibiotic 2 - Metronidazole 4 x 400 mg, Proton pump inhibitor - Esomeprazole 2 x 40 mg, Colloidal bismuth - Bismuth oxide 4 x 120 mg."
223791020|NCT06275204|DRUG|Levofloxacin-based quadruple therapy|"In case there will be a treatment failure after Protocol I is completed, the remaining patients with a positive infection will be referred to a secondary treatment:~Antibiotic 1 - Levofloxacin 1 x 500 mg, Antibiotic 2 - Metronidazole 4 x 400 mg, Proton pump inhibitor - Esomeprazole 2 x 40 mg, Colloidal bismuth - Bismuth oxide 4 x 120 mg."
223791021|NCT06275204|DRUG|Standard triple therapy|"Participants who are positive for H. pylori will receive a standard triple therapy:~Antibiotic 1 - Amoxicillin 2 x 1000 mg, Antibiotic 2 - Clarithromycin 2 x 500 mg, Proton pump inhibitor - Esomeprazole 2 x 40 mg."
223791022|NCT06275204|DRUG|Levofloxacin-based triple|"Participants with treatment failure will be recommended second line treatment - levofloxacin-based:~Antibiotic 1 - Levofloxacin 2 x 500 mg, Antibiotic 2 - Amoxicillin 2 x 1000 mg, Proton pump inhibitor - Esomeprazole 2 x 40 mg"
223791023|NCT02020954|PROCEDURE|ECG, echocardiography, cardiac MRI, sera biomarkers|
223791024|NCT02741960|DRUG|metformin|500 mg metformin three times daily
223791025|NCT02741960|DRUG|placebo|500 mg placebo three times daily
223791026|NCT00333463|BEHAVIORAL|Intervention|The intervention group watched an educational video, reviewed current barriers to drop-taking and possible solutions with a study coordinator, received regular phone call reminders, and had audible and visible reminders activated on their DA devices.
223791027|NCT03131518|BEHAVIORAL|Access to an e-bicycle with trailer|Participants will be provided with an e-bike with trailer for 3 months.
223791028|NCT03131518|BEHAVIORAL|Access to a longtail bicycle|Participants will be provided with a longtail bike for 3 months.
223791029|NCT03131518|BEHAVIORAL|Access to a traditional bike with trailer|Participants will be provided with a traditional bicycle with trailer for 3 months.
223791030|NCT06198569|OTHER|PNF EXERCISES|"Scapular PNF exercise training (6 Weeks) Exercise Frequency 3 days/week Exercise Intensity 60% of 1 maximum repetition Exercise Duration: 5-minute warm-up 20 minutes (2 sets of 15 repetitions) exercise training 5 min cool down Exercise Type Scapular patterns~* Anterior elevation-Posterior depression~* Anterior depression-Posterior elevation PNF techniques~* Repetitive stretching~* Rhythmic stabilization"
223791031|NCT06198569|OTHER|strength exercises|"Upper limb exercise training (6 Weeks) 3 days/week 60% of 1 repetition maximum 5 minute warm up 20 min exercise training 5 min cool down~Upper extremity movements - Scapular retraction - Shoulder flexion - Shoulder extension - Shoulder abduction - Shoulder adduction Resistant exercise training with Theraband and weights"
223791032|NCT04556708|OTHER|salin irrigation|Non-surgical periodontal treatment (SRP and oral hygiene instructions) was performed and subgingival irrigation with saline was performed. Gingival crevicular fluid (GCF) samples were taken for vascular endothelial growth factor (VEGF) and insulin-like growth factor-1 (IGF-1) examination.
223791033|NCT04556708|OTHER|ozonated water irrigation|Non-surgical periodontal treatment (SRP and oral hygiene instructions) was performed and subgingival irrigation with ozonated water was performed. Gingival crevicular fluid (GCF) samples were taken for vascular endothelial growth factor (VEGF) and insulin-like growth factor-1 (IGF-1) examination.
223791034|NCT04556708|OTHER|chlorhexidine irrigation|Non-surgical periodontal treatment (SRP and oral hygiene instructions) was performed and subgingival irrigation with 0.12% chlorhexidine digluconate was performed. Gingival crevicular fluid (GCF) samples were taken for vascular endothelial growth factor (VEGF) and insulin-like growth factor-1 (IGF-1) examination.
223791035|NCT00607555|DEVICE|Insertion of specialized feeding tube for monitoring of EAdi|The specialized feeding tube will be inserted into the esophagus and positioned at the level of the crural diaphragm. EAdi will be measured with miniaturized coated stainless steel electrodes mounted on the feeding tube. The tube is connected to a monitor where EAdi will be recorded continuously throughout the entire study period
223791036|NCT04053764|DRUG|Crizanlizuamb|Crizanlizumab is a concentrate for solution for infusion, i.v. use. Supplied in single use 10 mL vials at a concentration of 10 mg/mL. One vial contains 100 mg of crizanlizumab
223791037|NCT04053764|DRUG|Standard of Care|HU/HC (hydroxyurea/hydroxycarbamide) and/or ACE (angiotensin-converting enzyme) inhibitors and/or ARBs (angiotensin-receptor blocker)
223791038|NCT02935062|BEHAVIORAL|Traditional Phonological Therapy|Phonological therapy based on generalizing the sounds presented by figures, repetition and naming words.
223791039|NCT02935062|BEHAVIORAL|Software Phonological Therapy- SIFALA|The phonological thearapy of this group will be based on software use with phonological model already developed, using naming and repetition of sounds.
223791040|NCT02935062|BEHAVIORAL|Placebo Therapy|No intervention to improve speech.
223791041|NCT06216457|DEVICE|AI software for Stroke|AI Software for Non-Contrast Head CT (Computed Tomography) and CT Angiography, utilized for Code Stroke screening, notification and triage.
223791042|NCT03872349|OTHER|Monounsaturated fatty acids diet|During 4 weeks, subjects eat a diet high in monounsaturated fatty acids and will have a duodenal gastroscopy and a kinetic study at the end of the 4-week period.
223791043|NCT03872349|OTHER|Saturated fatty acids diet|During 4 weeks, subjects eat a diet high in saturated fatty acids and will have a duodenal gastroscopy and a kinetic study at the end of the 4-week period.
223791044|NCT02384954|BIOLOGICAL|Rituximab|Intravenous infusion 375 mg/m\^2.
223791045|NCT02384954|BIOLOGICAL|N-803|Intravenous infusion for Phase 1 cohort 1, 2 and 3; subcutaneous injection for Phase 1 cohort 4, 5, 6 and 7. Phase 2 dosing was based off of the MTD determined in Phase 1.
223791046|NCT05509296|DEVICE|SINOMED CBC|The Coronary Dilatation Balloon Catheter is indicated for the treatment of hemodynamically significant coronary artery stenosis, including in-stent restenosis and complex type C lesions, for the purpose of improving myocardial perfusion.
223791047|NCT05509296|DEVICE|NSE Coronary Dilatation Catheter|The Coronary Dilatation Balloon Catheter is indicated for the treatment of hemodynamically significant coronary artery stenosis, including in-stent restenosis and complex type C lesions, for the purpose of improving myocardial perfusion.
223791048|NCT05627180|BEHAVIORAL|Tailored Health Literacy follow-up in cancer|"1. Participants are invited to a consultation with the project nurse where the project nurse will use baseline data to identify the patient's HL needs, QOL, symptom burden and issues related to self-management of their cancer and treatment. These data will be used together with an interview questionnaire specifically developed to communicate HL needs (i.e. CHAT), which form the basis for the individualized HL support.~2. Actions: Based on results of the consultation, the project nurse and the patient will use a worksheet of possible actions to identify those most relevant to the patient's individual needs. Based on this, different self-management tasks and actions will be offered, and an individual tailored follow-up plan will be made. The patient and the project nurse will use a workbook containing information on the follow-up plan that will be added into medical record.~3. Telephone/digital conversations with the project every second month for a period of 9 months."
223791049|NCT00566267|DRUG|simvastatin 20 mg/ezetimibe|see protocol
223791050|NCT01557413|PROCEDURE|Intramedullary nail|the fracture was reduced and fix by an intramedullary humeral nail (Multilock, SYNTHES, Switzerland) using an open surgery. An anterolateral approach will be performed, the patient sit in beach chair position under general anesthesia. If required additional sutures will be authorized to fix the tuberosities.
223791051|NCT01557413|PROCEDURE|Locked plate|the fracture was reduced and fix by a locking plate using an open surgery (SURFIX, Integra, France). A deltopectoral approach will be performed, the patient sit in beach position under general anesthesia. If required, additional sutures will be authorized to fix the tuberosities.
223791052|NCT06344312|DRUG|Yangxue Qingnao Granules|When receiving intravenous thrombolysis with ateplase, two bags of Yangxue Qingnao Granule Simulator were randomly taken orally. Afterwards, one bag of Yangxue Qingnao Granule/ Simulator was taken three times a day for a total of two weeks.
223791053|NCT06028269|DEVICE|Smartphone playing a sound|A sound will be played from a portable device (smartphone) during movement
223791054|NCT03818412|PROCEDURE|Archival tumor tissue collection and blood draws|Archival tumor tissue will be collected for testing of circulating tumor DNA. Blood draws will be taken for testing of circulating tumor DNA.
223791055|NCT03521960|DRUG|Buspirone oral capsule|15 milligrams, three times daily
223791056|NCT03521960|DRUG|Placebo oral capsule|0 milligrams (placebo), three times daily
223791057|NCT04656626|BEHAVIORAL|brief mindfulness based intervention|The 20 minute daily mindfulness sessions for 2 weeks consist of the following guided meditation practices: 1. Bring your attention to a primary object of focus 2. Maintain a moment-moment awareness 3. When your mind naturally drifts into thinking (mind wandering); just notice you are thinking, and then bring your attention back to your object of focus 4. When a strong sensation arises, again, notice the sensation or emotion and return to your breath. 5. As you gain confidence, you may practice maintaining this focus while observing thoughts flowing through your mind or sensations in your body while showing no concern for the content 6. You may even label your thoughts 7. Thank yourself for your efforts and for taking this time.
223791058|NCT04656626|BEHAVIORAL|Progressive muscle relaxation|"Control group:~Control group will be given an mp3 audio recording of a 20-minutes of progressive muscle relaxation will be sent directly as SMS messages and emails to be heard by the participants through their personal device of their choice, such as a smart phone."
223791059|NCT00907829|DRUG|lidocaine|comparison of the effect of the drug to help improve finger function
223791060|NCT00907829|DEVICE|muscle stimulator|comparison of the effect of stimulated muscle(s) on finger function
223791061|NCT03359265|DEVICE|underpants|
223791062|NCT04421781|OTHER|Retrospectively review of medical data in patients treated by Salvage HIFU for isolated macroscopic recurrence in the prostatic bed after radical prostatectomy and salvage or adjuvant EBRT|Patients were treated using dedicated post-EBRT parameters (5-s pulse, 5-s waiting period, 90% of the acoustic power). Between July 2005 and November 2018, at Edouard Herriot Hospital (Lyon, France), 22 consecutive patients were treated with S-HIFU for a local recurrence after RP and salvage or adjuvant EBRT. The oncological outcomes (treatment failure-free survival, progression-free survival), the adverse events and urinary incontinence were retrospectively reviewed.
223791063|NCT01733056|BIOLOGICAL|Flu Vaccine|Administration of Fluzone (Influenza Vaccine)
223791064|NCT01408368|PROCEDURE|Bilateral subtotal thyroidectomy|The intervention consisted of bilateral subtotal thyroidectomy (leaving on both sides of the neck thyroid stumps of approximately 2 g of normal remnant tissue each).
223791065|NCT01408368|PROCEDURE|Total thyroidectomy|The intervention consisted of total extracapsular thyroidectomy.
223791066|NCT03185611|DRUG|Rifaximin|Antibiotics
223791067|NCT03185611|DRUG|Azathioprine|immunomodulator
223791068|NCT05991752|DIAGNOSTIC_TEST|ROMA score evaluation|Every 4 months, for 3 years, patients in the experimental group will done a biological examination based on assessment of the ROMA score (CA125+HE4 assay).
223791069|NCT04551170|DRUG|Theophylline|oral theophylline
223791070|NCT04551170|DRUG|Placebo|Placebo capsule or elixir
223791071|NCT01118390|DEVICE|Laser Nd:YAG 1064nm|Patients with leg telangiectasias are treated with 3 sessions of Nd:YAG 1064nm, with 14 days interval
223791072|NCT01118390|OTHER|Sclerotherapy|Patients with leg telangiectasias are treated with 3 sessions of sclerotherapy, with 14 days interval
223791073|NCT03543826|COMBINATION_PRODUCT|Protocol for rocuronium neuromuscular block|The protocol includes specified appropriate rocuronium dosing and a valid pre-reversal assessment of the adductor pollicis response guides optimal neostigmine vs. sugammadex reversal.
223791074|NCT01910129|DEVICE|gammaCore|vagal verve stimulation 3 times a day 8 hours apart
223791075|NCT04445818|BEHAVIORAL|More appreciation|
223791076|NCT04445818|BEHAVIORAL|Less criticism|
223791077|NCT04445818|BEHAVIORAL|More Fruit and Vegetable|
223791078|NCT03487835|OTHER|Kinesiotape|
223791079|NCT03487835|OTHER|No application|This group have no application during study time
223791080|NCT03934385|BEHAVIORAL|Mental Rehearsal|After each exposure session, participants complete three rehearsal/retrieval exercises that involve viewing images of spiders and completing multiple-choice and free-response questions. Exercises involve retrieving information specific to the spider exposures, reflecting on the experience, and highlighting expectancy violation (i.e., that the participant's feared outcome did not occur).
223791081|NCT03934385|BEHAVIORAL|Exposure|All participants complete two exposure sessions. The first set of exposures consists of ten 30-second trials hovering one's hand 3 inches over a live tarantula. The second set of exposures consists of ten 30-second trials placing one's hand inside the spider's terrarium with all five fingertips touching the bottom.
223791082|NCT01126983|DEVICE|Suture|Suture (2.0 Mono-filament nylon suture) will be used to secure the leads to the skin. Benzoin and Steri-strips will also be used.
223791083|NCT01126983|DEVICE|Lead Anchor|Suture (2.0 Mono-filament Nylon suture) will be applied over the lead anchor(Lead Anchor St.Jude Medical Co, model-long, No# 1106) to the skin. Benzion and Steri-strips will also be used.
223791084|NCT03150056|DRUG|GSK525762|GSK525762 will be administered.
223791085|NCT03150056|DRUG|Abiraterone|Abiraterone will be administered.
223791086|NCT03150056|DRUG|Enzalutamide|Enzalutamide will be administered.
223791087|NCT03150056|DRUG|Prednisone|Prednisone will be administered as a concomitant medication in combination with abiraterone
223791088|NCT00604253|DRUG|insulin detemir|
223791089|NCT00604253|DRUG|insulin NPH|
223791090|NCT02173977|OTHER|ARM A- Agonist/Antagonist protocol|In vitro fertilization (IVF/ICSI)
223791091|NCT02173977|OTHER|ARM B- Antagonist protocol|In vitro fertilization (IVF/ICSI)
223791092|NCT00091312|DRUG|FOLFIRI regimen|
223791093|NCT00091312|DRUG|fluorouracil|
223791094|NCT00091312|DRUG|irinotecan hydrochloride|
223791095|NCT00091312|DRUG|leucovorin calcium|
223791096|NCT00091312|PROCEDURE|adjuvant therapy|
223791097|NCT05888597|DRUG|L-menthol|(Sigma-Aldrich, St. Louis, US)
223791098|NCT05888597|OTHER|Placebo|Strawberry scent (Sigma-Aldrich, St. Louis, US)
223791099|NCT03595904|BEHAVIORAL|E-Motivate group|Participants in the e-Motivate group will receive standard clinical care which includes patient navigation (e.g., scheduling and reminders). They will also complete a 20-minute, motivational interviewing informed tablet app in the clinic immediately after they receive a referral for a screening colonoscopy. The tablet app consists of educational videos, interactive exercises (e.g., decisional balance), and personalized feedback (e.g., print summary).
223791100|NCT03595904|BEHAVIORAL|Usual Care Group|Participants in the usual care group will receive standard clinical care for patients referred for a screening colonoscopy. In particular, they will receive patient navigation which includes scheduling the colonoscopy appointment, making reminder calls, and providing print materials regarding the bowel prep instructions.
223791101|NCT01581281|DRUG|Amitriptyline|Amitriptyline will be administered twice daily at home during the 8-week titration period followed by a 16 week maintenance phase of the highest tolerated dose. The morning dose is a placebo pill. Dosing of amitriptyline will be weight-based.
223791102|NCT01581281|DRUG|Topiramate|Topiramate will be administered twice daily at home during the 8-week titration period followed by a 16 week maintenance phase of the highest tolerated dose. Dosing of topiramate will be weight-based.
223791103|NCT01581281|DRUG|Placebo|Placebo will be administered twice daily at home during the 8-week titration period followed by a 16 week maintenance period.
223791104|NCT00991354|BIOLOGICAL|PENNVAX-B|DNA vaccine encoding the Gag, Pol, and Env proteins of HIV
223791105|NCT00991354|BIOLOGICAL|IL-12 DNA plasmids|Adjuvant for HIV vaccines
223791106|NCT03193164|DEVICE|Neuromuscular Electrical Stimulation|The patient will be positioned on a headboard at 30° in the decubitus position with the limbs raised to 20°. The location of the electrical current will be cleared with trichotomy when necessary. Adhesive electrodes 90 x 50 mm will be positioned in the gastrocnemius. The stimulator device will be the Neurodyn II (Ibramed, Sao Paulo, Brazil) to provide symmetrical biphasic pulses of 50 Hz, 250 µsec pulse duration, 2 seconds on (1 second of time of rise and 1 second of time of decay), and 5 seconds of rest during 30 minutes at an intensity capable of generating visible contractions and articular motion.
223791107|NCT03193164|OTHER|Decubitus Position with the limbs raised to 20º|The patient position will be the same used for intervention protocol (headboard to 30°, decubitus position with the limbs raised to 20°) for 30 minutes, without NMES.
223791108|NCT03998787|OTHER|Neurophysiological assessment|Kinematic analysis of movement and transcranial magnetic stimulation
223791109|NCT03157713|BEHAVIORAL|Goal-Directed Financial Incentives|Patients will receive financial incentives for using a food diary, verified by entries in in the BookFactory Food Diary or another food diary, including internet/app-based diaries ($30 monthly); achieving 75 minutes of physical activity per week in first three months, as verified by a wearable fitness tracker ($20 monthly); achieving 150 minutes of physical activity per week in last three months, as verified by a wearable fitness tracker ($20 monthly); enrollment in a clinic-based or commercial weight loss program ($150 one time); and active participation in clinic-based or commercial weight loss program, as verified by the program ($60 monthly).
223791110|NCT03157713|BEHAVIORAL|Enhanced Usual Care|Patients will receive a food diary (BookFactory Food Diary), wearable fitness tracker (Fitbit), exercise and nutrition education materials (American Heart Association's Walking For Better Health and How to Eat Healthy), and referral information for intensive weight loss programs. This information will comprise these commercial and hospital-based weight loss programs that are evidence-based: Weight Watchers and Jenny Craig; the Veterans Administration's MOVE! and TeleMOVE! programs; Bellevue Hospital's Medical Weight Management Clinic and Intensive Nutritional Treatment programs; and New York University Langone Medical Center's Weight Management Program. We will also provide brief instructions on how to use the food diary and Fitbit Charge HR.
223791111|NCT03157713|BEHAVIORAL|Outcome-based Financial Incentives|Patients will receive financial incentives for clinically significant weight loss, as confirmed at monthly weigh-ins. At 30 days, they will receive $50 if they lose ≥1.5% to \<2.5% of baseline weight or $100 if they lose ≥2.5% of baseline weight. At 2 months and 3 months, they will receive $50 if they lose ≥2.5% to \<5% of baseline weight or $100 if they lose ≥5% of baseline weight. At 4, 5, and 6 months, they will receive $100 if they lose ≥2.5% to \<5% of baseline weight or $150 if they lose ≥5% of baseline weight. To employ the behavioral economic concept of regret aversion, patients will be given feedback at each assessment point about incentives they would have received had they achieved a loss of at least 2.5% of baseline weight.
223791112|NCT02187991|DRUG|Paclitaxel|either 60 mg/m2 intravenously (IV) on days 1, 8 and 15 of a 28-day cycle (on Paclitaxel plus Alisertib arm) or 90 mg/m2 IV on days 1, 8 and 15 of a 28-day cycle (on Paclitaxel Alone arm)
223791113|NCT02187991|DRUG|Alisertib|40 mg BID (twice a day) on days 1-3, 8-10, and 15-17 of a 28-day cycle
223791114|NCT04223180|DEVICE|Robotic assisted intervention|Robotic treatment of the upper limb (30 sessions, 5 times a week) using a set of 4 robotic devices: Motore (Humanware); Amadeo, Diego, Pablo (Tyromotion). The training will include motor-cognitive exercises specifically selected to train spatial attention, vision and working memory, praxis, executive function, and speed of processing.
223791115|NCT04616157|BEHAVIORAL|ICBT-I|Cognitive-behavioral therapy for insomnia
223791116|NCT01558622|DRUG|dexketoprofen trometamol|50mg intravenous infusion
223791117|NCT01558622|DRUG|tramadol hydrochloride|100mg intravenous infusion
223791118|NCT01558622|DRUG|pethidine hydrochloride|50mg intravenous infusion
223791119|NCT01558622|DRUG|dexketoprofen trometamol + tramadol hydrochloride|intravenous infusion of 50mg dexketoprofen trometamol + 100mg tramadol hydrochloride
223791120|NCT01558622|DRUG|dexketoprofen trometamol + pethidine hydrochloride|intravenous infusion of 50mg dexketoprofen trometamol + 50mg pethidine hydrochloride
223791121|NCT01558622|DRUG|vitamin c|500mg intravenous infusion
223791122|NCT01392560|DRUG|BI 10773|Oral once daily
223791123|NCT01994330|DRUG|desmopressin|0.3 mcg per kilogram administered in 30 minutes a half hour previous to surgical incision
223791124|NCT00388414|DRUG|duloxetine|30-60mg of duloxetine daily
223791125|NCT00388414|DRUG|Placebo|Placebo pill once daily
223791126|NCT04210453|DRUG|Vitamin C|"Participants in Vitamin C group are administered IV vitamin C diluted in 100 cc normal saline 1 day before surgery, at rewarming during surgery, 3 hours after surgery, and every 6 hours thereafter until postoperative 24 hours."
223791127|NCT04210453|DRUG|Control (Normal saline)|"Participants in Control group are administered IV 100cc normal saline at the same timepoint as above."
223791128|NCT05892679|OTHER|acupressure|"Acupressure will be formulated according to the standards of the World Health Organization and applied to the determined points in a certain order. Since the reactions of individuals will be different from each other, the stiffness and pressure will be adjusted according to the sensitivity of the individual in order not to cause tissue damage. Pressures will be applied manually by a single practitioner. A total of 8 points with parallel points will be studied, with four points in each lower extremity. There will be a total of 12 minutes of pressure on 8 points, with an average of 90 seconds on each point, and approximately 10-15 seconds of warming and preparatory scrubbing before pressing on the area where the points are located.~Considering the studies done, a person will be given acupressure three times a week for four weeks."
223791129|NCT02457572|PROCEDURE|Valsalva maneuver|Valsalva maneuver was performed after sternotomy with the constant airway pressure of 30cmH2O for 2 breaths duration.
223791130|NCT02457572|OTHER|Fluid loading|We record the cardiac index values before and after volume expansion with 6ml/kg of balanced crystalloid
223791131|NCT04916223|OTHER|Therapeutic massage|"The massage therapists were scheduled on a rotating schedule with two alternates scheduled for each day to ensure adherence to assigned study arm and to avoid therapist effect as much as possible. For each enrolled subject, the therapist assessed the subject and created a treatment plan depending on his/her individual needs and preferences. For example, if a subject reported bothersome lower extremity pain, the therapist might focus the massage on that lower extremity or might avoid massaging that lower extremity, depending solely on the preference of the subject. Massage duration was determined by the assigned study arm."
223791132|NCT00241254|DRUG|Cyclophosphamide (drug)|IV cyclophosphamide infusion administered every 4 weeks during 1 year and every 8 weeks during 1 year.
223791133|NCT00241254|DRUG|Methylprednisolone (drug)|Control group : IV methylprednisolone infusion administered every 4 weeks during 1 year and every 8 weeks during 1 year.
223791134|NCT04104867|DRUG|Itopride|the patients are instructed to take one pill of Itopride at 8.00 AM, 12.00 AM, 4.30 PM respectively before the dat of colonoscopy. Lastly, they are instructed to take the fourth pill at 6.00 AM on the day of colonoscopy.
223791135|NCT04104867|DRUG|Domperidone|the patients are instructed to take one pill of Domperidone at 8.00 AM, 12.00 AM, 4.30 PM respectively before the dat of colonoscopy. Lastly, they are instructed to take the fourth pill at 6.00 AM on the day of colonoscopy.
223791136|NCT04104867|OTHER|Placebo|the patients are instructed to take one pill of placebo at 8.00 AM, 12.00 AM, 4.30 PM respectively before the dat of colonoscopy. Lastly, they are instructed to take the fourth pill at 6.00 AM on the day of colonoscopy.
223791137|NCT00875836|DRUG|Buspirone|Flexible dose, up to 60 mg daily
223791138|NCT00875836|DRUG|Placebo|Flexible dose, up to 60 mg daily
223791139|NCT00059800|RADIATION|boron neutron capture therapy|
223791140|NCT04597320|DRUG|Fentanyl|"The fentanyl group was prepared by 1ug/kg fentanyl in 5ml normal saline, assembled with 5ml injection, labeled as Anesthesia inducer."
223791141|NCT04597320|DRUG|Esketamine|"The esketamine group was prepared by 0.5mg/kg esketamine in 5ml normal saline, assembled with 5ml injection, labeled as Anesthesia inducer."
223791142|NCT04597320|DRUG|Midazolam|"Midazolam 0.05mg/kg+ Anesthesia inducer was applied to all patients for procedural induction by intravenous injection. According to the MOAA/S score of the patients, midazolam could be added 0.5mg per time at more than 2 minutes until the MOAA/S score reached 3, the maximum infusion dose of midazolam was less than 10mg and less than 0.1mg/kg."
223791143|NCT01211925|PROCEDURE|distal venous arterialisation|The investigators perform reverse revascularisation of the ischemic limb with arterial blood supply from patent in flow artery to the superficial dorsal venous arch.
223791144|NCT01211925|DRUG|Aspirin|100 mg per day continuous
223791145|NCT01319448|DRUG|Proguanil|Proguanil tablets, 1.5mg/kg/day
223791146|NCT01319448|DRUG|mefloquine plus artesunate|This treatment is given once a day for 3 days. Patients weighing 5-8 kg receive one paediatric tablet per day, those weighing 9-17 kg two paediatric tablets, those weighing 18-29 kg one adult tablet and those weighing 30 kg and two adult tablets.
223791147|NCT01319448|DRUG|Sulfadoxine-pyrimethamine plus amodiaquine|amodiaquine plus sulfadoxine-pyrimethamine supervised at each bimonthly clinic visit (amodiaquine 10mg/kg per day for three days and sulfadoxine-pyrimethamine (25/1.25 mg/kg) on the first day).
223791148|NCT06119633|PROCEDURE|Immediate tissue expander and lipofilling after mastectomy|Implant-based breast reconstruction and fat grafting after salvage or prophylactic mastectomy in patients previously exposed to radiation therapy on the breast as adjuvant treatment after breast conserving surgery (BCS) or on thoracic wall for Hodgkin Lymphoma (HL).
223791149|NCT02082054|DRUG|PSE 120 mg, CM 8 mg, Atr 0.36 mg|"Pseudoephedrine 120 mg, chlorpheniramine 8 mg, atropine 0.36 mg white, scored, tablets with M27 on scored side and plain on the other side"
223791150|NCT02082054|DRUG|PSE 120 mg, CM 8 mg, Atr 0.24 mg|"Pseudoephedrine 120 mg, chlorpheniramine 8 mg, atropine 0.24 mg white, scored, tablets with M27 on scored side and plain on the other side"
223791151|NCT02082054|DRUG|PSE 120 mg, CM 8 mg, Atr 0.12 mg|"Pseudoephedrine 120 mg, chlorpheniramine 8 mg, atropine 0.12 mg white, scored, tablets with M27 on scored side and plain on the other side"
223791152|NCT02082054|DRUG|PSE 120 mg, CM 8 mg|Pseudoephedrine 120 mg, chlorpheniramine 8 mg tablets dosed BID
223791153|NCT02082054|DRUG|Atropine 0.24 mg|"Atropine sulfate 0.24 mg white, scored, tablets with M27 on scored side and plain on the other side"
223791154|NCT05974969|DRUG|BCD-264|a single intravenous infusion of BCD-264
223791155|NCT05974969|DRUG|Darzalex|a single intravenous infusion of Darzalex
223791156|NCT02242747|DRUG|ingenol mebutate|an application a day for three consecutive days in a pre-determined area
223791157|NCT02242747|DRUG|5% 5-FU|two applications a day for four weeks in a pre-determined area
223791158|NCT00337714|PROCEDURE|CVC impregnated with silver nanoparticles (AgTive®)|insertion of medicated silver nanoparticles CVC
223791159|NCT00337714|PROCEDURE|CVC cannulation|placement of conventional trilumen CVCs
223791160|NCT04519918|BEHAVIORAL|AOA|AOA represents an invasive non-physiological technique.
223791161|NCT00342862|DRUG|Amevive exposure|Observational
223791162|NCT00198562|DRUG|Amlodipine, Losartan|amlodipine: 2.5-10 mg once daily for 5 years losartan: 25-100 mg once daily for 5 years
223791163|NCT06490484|DRUG|HSK16149 20mg BID|Drug: HSK16149 20mg BID HSK16149 20mg, orally twice a day; treatment period: 4 weeks fixed dose.
223791164|NCT06490484|DRUG|Pregabalin 150mg BID|Drug: Pregabalin 150mg BID Pregabalin 150mg, orally twice a day; treatment period: 1 week titration and 3 weeks fixed dose.
223791165|NCT04019938|RADIATION|Dual-energy X-ray absorptiometry|Cystatin C is measured as a part of routine investigation at the time of admission.
223791166|NCT04089033|PROCEDURE|Pneumatic Retinopexy|The PnR technique is performed as per the PIVOT trial under local anaesthetic. First, patients will undergo a thorough scleral-depressed peripheral retinal examination to identify all pathologic features. Second, laser retinopexy will be applied to all breaks, lattice degeneration, or both in the attached retina before gas injection. Third, breaks in the detached retina will be treated with cryotherapy before gas injection or (preferably) laser retinopexy 24 to 48 hours after gas injection, with additional laser retinopexy applied at any point per surgeon discretion. Finally, anterior chamber paracentesis will be used to express as much fluid as safely possible (generally 0.3ml), followed by intravitreal injection of 100% SF6 (ideally 0.6 ml). Patients will be positioned face down for 6 hours and then raise their head 30 degrees every hour (steam roll) and then positioned to the responsible break.
223791167|NCT04089033|PROCEDURE|Pars Plana Vitrectomy|For PPV, a standard 3-port PPV (23 or 25-gauge) will be performed, including posterior hyaloid detachment, core vitrectomy and 360 peripheral vitreous shave. Subretinal fluid will be drained either through the peripheral break or through a posterior retinotomy with use of heavy liquid to assist with appropriate drainage at the discretion of the responsible surgeon. A complete air-fluid exchange will be performed. Endolaser Retinopexy or transconjunctival cryopexy will be performed to treat any retinal pathology, including lattice degeneration and breaks in the attached and detached retina. A iso-expansible concentration of SF6 or C3F8 gas will be injected at the completion of the surgery. Choice of gas will be at the discretion of the responsible surgeon. Patients will be positioned immediately face down for the first 24 hours and then according to the position of the responsible break.
223791168|NCT00549926|DRUG|Fluvastatin|
223791169|NCT00549926|DRUG|Pravastatin|
223791170|NCT00549926|DRUG|Pitavastatin|
223791171|NCT00549926|DRUG|Atorvastatin|
223791172|NCT05057533|OTHER|a questionnaire based on Rome IV Diagnostic criteria of IBS|"The Rome IV criteria for the diagnosis of IBS require that patients have had recurrent abdominal pain on average at least 1 day per week during the previous 3 months that is associated with two or more of the following~1. Related to defecation (may be increased or unchanged by defecation)~2. Associated with a change in stool frequency~3. Associated with a change in stool form or appearance The Rome IV criteria (May 2016) only require abdominal pain in defining this condition; discomfort is no longer a requirement owing to its nonspecificity, and the recurrent abdominal pain. \[2\] Supporting symptoms include the following:Altered stool frequency Altered stool form Altered stool passage (straining and/or urgency) Mucorrhea Abdominal bloating or subjective distention."
223791173|NCT00981591|DRUG|Iloprost|Inhaled via Aerogen nebulizer, 0.5 mcg/kg every 2 hours; uptitrated to effect, to maximum dose of 30 mcg every 30 minutes
223791174|NCT00981591|DRUG|Placebo|Inhaled via Aerogen nebulizer, 0.5 mcg/kg every 2 hours or more
223791175|NCT06512662|PROCEDURE|Consultations with paramedics|"Patients of experimental arm will beneficiate of supplemental consultations with paramedics intervenants at 1 month, 3 months and 6 months after surgery :~* dietetician~* speech therapist~* psychologist~* advanced practice nurse~During these consultations, several scales will be performed to assess the patient's condition (anxiety, nutritional status, psychological condition, speech therapy status)."
223791176|NCT05989503|DRUG|Sacubitril-valsartan|Sacubitril-valsartan titration at the discretion of the treating physician
223791177|NCT05989503|DRUG|SGLT2 inhibitor|Either empagliflozin or dapagliflozin 10 mg/day
223791178|NCT00607334|BEHAVIORAL|Word-learning|Exposure to five nonwords for three sessions of controlled interaction with the experimenter
223791179|NCT00607334|BEHAVIORAL|Word-learning|Exposure to five nonwords for three sessions of controlled interaction with the experimenter
223791180|NCT04179487|DIAGNOSTIC_TEST|OPTICA CTPA Protocol|Low dose CT pulmonary angiogram protocol
223791181|NCT06529107|BEHAVIORAL|intermittent catheterization protocol based on the best evidence|A best evidence-based protocol for intermittent catheterization after radical cervical cancer surgery
223791182|NCT00700401|DRUG|peginterferon alfa-2a [Pegasys]|180 micrograms/week sc for 24 weeks
223791183|NCT00700401|DRUG|ribavirin [Copegus]|800mg po daily for 24 weeks
223791184|NCT03273946|DRUG|Fluticasone propionate|Fluticasone propionate is an inhaled corticosteroid to be used via a pediatric spacer device with a face mask for prophylactic treatment of asthma.
223791185|NCT02541929|DIETARY_SUPPLEMENT|Docosahexaenoic acid|
223791186|NCT02999165|OTHER|Breast feeding|Infants on respiratory support will be allowed to attempt to breast feed (with a top up nasogastric tube feed if required).
223791187|NCT02999165|OTHER|Nasogastric feeding|The control intervention is feeding via nasogastric tube
223791188|NCT06435234|BEHAVIORAL|risky sexual behavior intervention|Intervening in risky sexual behaviors among college students
223791189|NCT02202473|DRUG|Lamivudine|
223791190|NCT02202473|DRUG|Lamivudine+Oxymatrine Capsules|
223791191|NCT03605095|DRUG|nitroglycerin|Vasodilatator solution is dropped on the gingiva.
223791192|NCT02568527|DEVICE|PLGA scaffold|Poly-Lactic-co-Glycolic Acid (50:50) biodegradable, synthetic scaffold
223791193|NCT02638038|DRUG|INT131|INT- 131
223791194|NCT01044004|DRUG|Armodafinil|Armodafinil 150 mg/day for 13 weeks
223791195|NCT01044004|DRUG|placebo|Placebo 150mg/day for 13 weeks
223791196|NCT01044004|DRUG|Armodafinil|Armodafinil 150 mg/day for 13 weeks
223791197|NCT01044004|DRUG|placebo|Placebo 150mg/day for 13 weeks
223791198|NCT06294301|BIOLOGICAL|LP-005 Dose 1 (Single)|A single dose of LP-005 (Dose 1) was administered intravenously.
223791199|NCT06294301|BIOLOGICAL|LP-005 Dose 2 (Single)|A single dose of LP-005 (Dose 2) was administered intravenously.
223791200|NCT06294301|BIOLOGICAL|LP-005 Dose 3 (Single)|A single dose of LP-005 (Dose 3) was administered intravenously.
223791201|NCT06294301|BIOLOGICAL|LP-005 Dose 4 (Single)|A single dose of LP-005 (Dose 4) was administered intravenously.
223791202|NCT06294301|BIOLOGICAL|LP-005 Dose 5 (Single)|A single dose of LP-005 (Dose 5) was administered intravenously.
223791203|NCT06294301|BIOLOGICAL|LP-005 Dose 6 (Single)|A single dose of LP-005 (Dose 6) was administered intravenously.
223791204|NCT06294301|BIOLOGICAL|Placebo (Single)|A single dose of placebo was administered intravenously.
223791205|NCT06294301|BIOLOGICAL|LP-005 Dose 7 (Multiple)|LP-005 (Dose 7) was administered multiple times intravenously.
223791206|NCT06294301|BIOLOGICAL|LP-005 Dose 8 (Multiple)|LP-005 (Dose 8) was administered multiple times intravenously.
223791207|NCT06294301|BIOLOGICAL|LP-005 Dose 9 (Multiple)|LP-005 (Dose 9) was administered multiple times intravenously.
223791208|NCT06294301|BIOLOGICAL|Placebo (Multiple)|Placebo was administered multiple times intravenously.
223791209|NCT03969069|DEVICE|MAPLe|Additional assessment with MAPLe
223791210|NCT03715933|DRUG|INBRX-109|Tetravalent DR5 Agonist Antibody
223791211|NCT03715933|DRUG|Carboplatin|Chemotherapy
223791212|NCT03715933|DRUG|Cisplatin|Chemotherapy
223791213|NCT03715933|DRUG|Pemetrexed|Chemotherapy
223791214|NCT03715933|DRUG|5-fluorouracil|Chemotherapy
223791215|NCT03715933|DRUG|Irinotecan|Chemotherapy
223791216|NCT03715933|DRUG|Temozolomide|Chemotherapy
223791217|NCT01538381|DRUG|Afatinib|Afatinib for 2 weeks at a dose of 40 mg/day
223791218|NCT01538381|OTHER|Observation|Observation
223791219|NCT05289362|DEVICE|Basket group|Under ERCP, the basket is preferentially used to remove the pancreatic duct stones, and then the balloon is used to evaluate the effect and remove the residual stones.
223791220|NCT05289362|DEVICE|Balloon group|Under ERCP, the balloon is preferentially used to remove the pancreatic duct stones, and then the basket is used to evaluate the effect and remove the residual stones.
223791221|NCT02558010|DRUG|Methadone|Perioperative IV methadone to be given
223791222|NCT02558010|OTHER|Normal Saline|control arm
223791223|NCT02558010|DRUG|Morphine|Both groups will receive morphine via Patient-Controlled Analgesia (PCA) pump.
223791224|NCT00965432|DRUG|STX107|Single dose of an oral suspension
223791225|NCT02697253|DRUG|Exendin 9-39 and Sitagliptin|"Infusion of exendin 9-39 at the rate of 600 pmol/kg/min, infusion time 80 minutes. An average of 18.2mg will be infused in a forearm vein during an oral glucose (30g) preload.~100mg tablet will be administered at 2200 hours the night before the visit. The day of the visit, the patient will take another 100mg tablet at 0700 hours."
223791226|NCT02697253|DRUG|Placebo|"Infusion of 0.9% saline solution (placebo infusion) for 80 minutes. An average of 18.2mg will be infused in a forearm vein during an oral glucose (30g) preload.~100mg Placebo tablet will be administered at 2200 hours the night before the visit. The day of the visit, the patient will take another 100mg placebo tablet at 0700 hours."
223791227|NCT00295750|DRUG|Degarelix|Initial dose of 240 mg SC (by injection under the skin) on day 0. Maintenance dose of 160 mg SC (by injection under the skin) given every 28 days for 364 days.
223791228|NCT00295750|DRUG|Degarelix|Initial dose of 240 mg SC (by injection under the skin) on day 0. Maintenance dose of 80 mg SC (by injection under the skin) given every 28 days for 364 days.
223791229|NCT00295750|DRUG|Leuprolide 7.5 mg|Leuprolide (Lupron Depot) 7.5mg IM (in the muscle every 28 days starting at day 0.
223791230|NCT00430768|BIOLOGICAL|rAAV1-CB-hAAT|
223791231|NCT05323318|OTHER|Neuropsychological Sequelae|Neuropsychological Sequelae after SARS-CoV-2 symtomatic infection
223791232|NCT05715294|OTHER|Music Application|A music CD was prepared within the scope of passive music listening practice. To determine the music, the researcher advice and literature knowledge of Turkish Music A music CD was prepared within the scope of passive music listening practice. To determine the music, the researcher advice and literature knowledge of Turkish Music Research and Promotion Society (TUMATA) was used. In the music application, the selecting instrumental music (ussak maqam which is Turkish Music Maqam) was used. The prepared Music CD will be played on the phones of patients with android processor phones. Patients will be told that they should listen to the music lying down and in a comfortable position, and that they should not use headphones while listening to music. Before going to bed, the patients will be listened to music composed in Ussak maqam for 50 minutes every day for 7 days.
223791233|NCT04424381|DRUG|Rivaroxaban 20 MG Oral Tablet [Xarelto]|The subjects randomly received single oral administration of Rivaroxaban 20 MG Oral Tablet \[Xarelto\].
223791234|NCT04424381|DRUG|Rivaroxaban 20 MG Oral Tablet|The subjects randomly received single oral administration of Rivaroxaban 20 MG Oral Tablet.
223791235|NCT04075123|OTHER|CPAP|The two NRS strategies being compared will be initiated at the time of first extubation (NRS support practices prior to initial intubation will be as per local unit guidelines and practices) and all subsequent extubations (if applicable) until 32 weeks PMA. For instance, a unit adopting post-extubation NCPAP strategy will initiate this mode following the initial and all subsequent extubations until 32 weeks PMA whereas centres adopting post-extubation NIPPV will initiate NIPPV following initial and all subsequent extubations until 32 weeks PMA.
223791236|NCT04164992|DEVICE|EUSRA electrode needle connected to a radiofrequency generator (VIVA RF generator; STARmed, Seoul, S. Korea)|The operative needle (EUSRA-STARMED) is a novel monopolar 18 gauge radiofrequency ablation (RFA) electrode that is placed in the echoendoscope operative channel. It is 140 cm long with a sharp conical 1 cm tip for energy delivery. The needle is associated with an internal cooling system connected via a pump to an external cold saline solution source (0 °C) that prevents the charring of the tip and improves the ablation accuracy.
223791237|NCT00987974|DRUG|rosuvastatin|rosuvastatin 20 mg/day for 3 days.
223791238|NCT00987974|DRUG|atorvastatin 3 days|atorvastatin 80 mg/day for 3 days.
223791239|NCT00987974|DRUG|placebo|placebo for 3 days.
223791240|NCT00987974|DRUG|rosuvastatin 7 days|rosuvastatin 20 mg/day for 7 days
223791241|NCT00987974|DRUG|atorvastatin 7 days|atorvastatin 80 mg/day for 7 days.
223791242|NCT00987974|DRUG|placebo 7 days|placebo 7 days
223791243|NCT00626431|DRUG|Leuprolide acetate - Formulation A|Leuprolide acetate was administered as 2 intramuscular (IM) injections of Formulation A, 45 mg 6 month depot, 24 weeks apart.
223791244|NCT00626431|DRUG|Leuprolide acetate - Formulation B|Leuprolide acetate was administered as 2 intramuscular (IM) injections of Formulation B, 45 mg 6 month depot, 24 weeks apart.
223791245|NCT02199028|DRUG|Hyaluronidase|150 units/ml - subjects injected 1 milliliter (ml) into the catheter hub prior to connecting the insulin infusion set on Day 1 and 3 of infusion set wear.
223791246|NCT02199028|OTHER|Control|No hyaluronidase administered into insulin infusion set.
223791247|NCT02791724|BEHAVIORAL|Desiconnect|Desiconnect is an Internet intervention for persons with epilepsy and elevated depression. Content is continuously adapted to patients' concerns and needs. Techniques to overcome depression (e.g., cognitive restructuring, behavioral activation) and to cope with anxiety symptoms (e.g., exposure, role of avoidance, mindfulness exercises) are conveyed in interactive sequences that are accompanied by audio recordings, illustrations, and worksheets. Topics covered also include coping with epilepsy symptoms, identifying and coping with seizure auras and triggers, and the role of nutrition and exercise. Patients are also prompted to regularly complete brief symptom severity self-monitoring questionnaires. Optional daily text messages with motivational content accompany the program. The program can be accessed for 180 days after registration.
223791248|NCT02791724|OTHER|CAU|Care as Usual
223791249|NCT00793468|DRUG|GSK598809|GSK598809 once daily for 12 weeks
223791250|NCT00793468|DRUG|Nicotine Replacement Transdermal Patch|All subjects will be treated during the 4 week open-label smoking cessation phase of the study. During Weeks 1-3, subjects will receive 21mg/day, and during Week 4, subjects will receive 14 mg/day. Those subjects who reached continuous abstinence on at least week 4 of the open-label phase will receive 7mg/day during Week 5 while taking GSK598809 or placebo.
223791251|NCT00793468|DRUG|Placebo|Placebo once daily for 12 weeks
223791252|NCT01771198|DRUG|SIMVASTATIN|SIMVASTATIN tablet of 40mg once a day during 30 days
223791253|NCT03204097|DRUG|placebo|Oral prophylaxis followed by placement of placebo gel
223791254|NCT03204097|DRUG|Alendronate|Oral prophylaxis followed by placement of Alendronate gel
223791255|NCT03204097|DRUG|Aloe Vera|Oral prophylaxis followed by placement of Aloe Vera gel
223791256|NCT04622579|DRUG|lenalidomide combined with rituximab|lenalidomide and rituximab are dilivered as described, parameters concerning efficacy and safety are also obtained.
223791257|NCT04974164|BIOLOGICAL|Inactivated COVID-19 Vaccine|Each vial contains 0.5 mL (a single dose) and contains 600SU of inactivated SARS-CoV-2 virus antigen
223791258|NCT04532814|OTHER|Exercise|Cycling 60% VO2 max
223791259|NCT03766022|DEVICE|Neo dental implant Alpha Bio Tec. Ltd.|Neo dental implant is used to restore missing teeth
223791260|NCT06273644|OTHER|Carbohydrates|Half of the patients will initially follow Diet Plan A with 60-65 E% carbohydrates for 4 weeks, followed by a 4-week washout period, and then Diet Plan B with 40-45 E% carbohydrates for 4 weeks. The other half will start with Diet Plan B for 4 weeks, followed by a 4-week washout period, and then Diet Plan A for 4 weeks . Diet Plans A and B contain recommended and adequate nutrients according to the Nordic Nutrition Recommendations 2023 (NNR2023) for maintaining a stable weight.
223791261|NCT05322616|DRUG|JK07|Recombinant fusion protein consisting of a fully humanized immunoglobulin G1 monoclonal antibody and an active polypeptide fragment of the human growth factor NRG-1
223791262|NCT05322616|DRUG|Matching Placebo|Vehicle control
223791263|NCT04370054|BIOLOGICAL|PF-07055480 (giroctocogene fitelparovec): Recombinant AAV2/6 Human Factor VIII Gene Therapy|Single IV infusion
223791264|NCT04674345|DRUG|Sorafenib|The initial dose of sorafenib is 400 mg orally twice daily and is adjusted in case of suspected toxicity (dose range, 200-800 mg daily).
223791265|NCT04873375|DRUG|Cemiplimab|After inclusion patients will be treated with Cemiplimab 350mg intravenously every three weeks
223791266|NCT02515136|BEHAVIORAL|Stimulus-response|See summary
223791267|NCT00722761|DRUG|drospirenone and ethinyl estradiol|Drosperinone (3mg) and ethinyl estradiol (0.02mg) tablet given once daily for 24 weeks
223791268|NCT00722761|DRUG|Placebo tablet|Placebo tablet (no active drug) given once daily for 24 weeks
223791269|NCT02407509|DRUG|VS-6766|
223791270|NCT02407509|DRUG|Everolimus|
223791271|NCT01973881|PROCEDURE|T1 Weighted MRI (magnetic resonance imaging)|"Enrolled subjects will have an MRI scan performed at baseline (within 1 month before beginning therapy), at the time of a scheduled bone marrow biopsy or end of treatment cycle (6 months), and after 12 months.~Please note: Patients in this study will be treated with chemotherapy as determined by the hematologist or the treatment protocol for an independent clinical trial for therapy of myelofibrosis. Treatment and monitoring will be performed under the usual standard of care that includes physical examinations, laboratory testing, and other indicated imaging examinations."
223791272|NCT03375619|OTHER|Long-Term Follow-Up of Participants who Received CAR-T cells|No study drug is administered in this study. Participants who received CAR-T cells in a previous trial will be evaluated in this trial for long-term safety and efficacy.
223791273|NCT05692024|DRUG|Nestlé NESCAFÉ® TASTER'S CHOICE® House Blend capsule.|Each coffee capsule will contain 400 mg Nestlé NESCAFÉ® TASTER'S CHOICE® House Blend.
223791274|NCT05692024|DRUG|Placebo|Each placebo capsule will contain 400 mg of microcrystalline cellulose with flavor and food-coloring substances.
223791275|NCT03815721|DEVICE|Stimulette r2x+|device for repetitive transcutaneous spinal cord stimulation
223791276|NCT06227585|DEVICE|REVEAL 475 System|The REVEAL 475 system will be evaluated for its ability to visualize nerve-fluorescence following bevonescein administration.
223791277|NCT06227585|DRUG|Bevonescein|All patients will receive a single dose of bevonescein 500 mg via IV infusion 1-5 hours before surgery.
223791278|NCT01371318|OTHER|Online Wound Electronic Medical Record|Online Wound Electronic Medical Record is a medical informatics tool that synthesizes data about complex wound problems from multiple sources and is innovative in its capability to performing these critical tasks: i) identification of the information needed to make treatment decisions at the point of care in real time ii) use intelligent search and report features to identify patients who require emergency interventions, and iii) provide evidence-based clinical decision support to clinicians
223791279|NCT02300714|PROCEDURE|oblique view approach|
223791280|NCT02222220|DRUG|Metoclopramide|30 mg/day during 4 weeks
223791281|NCT02222220|DRUG|placebo|
223791282|NCT05672628|DEVICE|Oculus VR|During the first visit, the Oculus headset will be placed on the stroke survivor's head and demonstrate how to use the headset. participant will be then allowed to play a game using the hand controllers for up to 30 minutes. Finally, a copy of exercises for their home rehabilitation program will be provided. During the next rehabilitation visits, a trained research assistant will guide the stroke survivor with using the gaming headset. The session will be stopped every 20 minutes to make sure that the stroke survivor is feeling well and to give them a break. The stroke survivor may stop the session at any time. This session will last for an hour.
223791283|NCT00131157|PROCEDURE|expert support for interpretation of spirometry|
223791284|NCT07119892|BEHAVIORAL|Lifestyle Modification (Exercise + Diet)|Participants received a 12-week supervised aerobic exercise program (5 sessions per week at 70% of age-predicted maximum heart rate) and dietary counseling with a calorie-restricted Mediterranean-style diet of 1,200 kcal/day. The intervention was culturally adapted, including modifications for Ramadan.
223791285|NCT07119853|OTHER|Microteaching|"Students in the experimental group watched the Advanced Life Support Team Dynamics Video. The video was uploaded to the university's education management system, and a student monitoring report was generated, ensuring that all students could watch it."
223791286|NCT07123402|DRUG|TRD205 tablets|orally ;Take TRD205 1 tablets and Placebo 2 tablets
223791287|NCT07123402|DRUG|TRD205 tablets|orally ;Take TRD205 2 tablets and Placebo 1 tablets
223791288|NCT07123402|DRUG|TRD205 tablets|orally ;Take TRD205 3 tablets and Placebo 0 tablets
223791289|NCT07123402|DRUG|Placebo|orally ;Take Placebo 3 tablets
223791290|NCT07126080|BEHAVIORAL|Incontinence Coping Training|"Intervention: Women in the experimental group will receive a four-week training program on managing urinary incontinence. The training will cover the following topics:~* Definition, types, and risk factors of urinary incontinence~* Treatment and prevention of urinary incontinence~* Symptoms of urinary incontinence and non-drug management strategies (addressing eating and toilet habits, such as limiting caffeinated beverages and cautioning spicy foods)~* The importance and implementation of Kegel exercises After the training, the experimental group will be reminded to practice Kegel exercises, and post-tests will be administered at 1 and 3 months. The control group will also receive post-tests at 1 and 3 months. Training will be conducted individually online."
223791291|NCT07126158|RADIATION|Stereotactic body radiotherapy|MRIdian and Ethos (adaptive radiation platforms)
223791292|NCT07126158|DRUG|Defactinib|Taken with 30 minutes of a meal
223791293|NCT07126158|DRUG|Avutometinib|Can be taken without regard to food.
223791294|NCT07127484|PROCEDURE|Hemoadsorption|Patients in intervention group will receive standard treatment plus hemoadsorption therapy administered once on days 1, 3, and 5 following enrollment.
223791295|NCT07127614|DIAGNOSTIC_TEST|MRI|pre-operative MRI scan
223791296|NCT07127614|DIAGNOSTIC_TEST|Histo-Pathological examination of the resected tumor tissues|histo-pathological examination of the resected tumor tissues with the lymph nodes involved to determine the pathological depth of invasion
223791297|NCT07126132|PROCEDURE|Coronary Angiography|Standard coronary angiography was performed via the radial or femoral approach on all participants to assess the presence and severity of coronary artery disease. Angiograms were used to determine coronary stenosis, which formed the basis for classifying participants into the CAD group (≥50% stenosis) or the control group (\<50% stenosis).
223791298|NCT07126132|DIAGNOSTIC_TEST|Hpx•apoB Product Measurement|Fasting blood samples were collected from all participants to measure the novel Hpx•apoB product. Plasma hemopexin (Hpx) was quantified using liquid chromatography-tandem mass spectrometry (LC-MS/MS) and apolipoprotein B (apoB) was measured using standard automated methods. This biomarker was the primary variable of interest for its association with CAD.
223791299|NCT07126067|PROCEDURE|Lung Ultrasound and PEEP Application|Application of Lung Ultrasound and PEEP After intubation, PEEP starts at 5 cmH2O. The first lung ultrasound (USG) is performed after 5 minutes. If the lung consolidation score is ≥2, PEEP increases by 2 cmH2O and is reassessed every 5 minutes until the score is \<2. If \<2, PEEP remains unchanged as the optimal level. This process is repeated after pneumoperitoneum, peritoneal deflation, and position changes. In Group U, PEEP is determined by USG, with a maximum of 20 cmH2O, a plateau pressure of 30 cmH2O, and a peak inspiratory pressure of 40 cmH2O.
223791300|NCT07126067|PROCEDURE|Application of PEEP with Dynamic Compliance|"Application of PEEP with Dynamic Compliance~* After endotracheal intubation, PEEP will be applied as 5 cmH2O.~* The first dynamic compliance (TV/Ppeak-PEEP) monitoring will be performed automatically by the ventilator (Mindray) 5 minutes after endotracheal intubation, and the PEEP value will be increased by 3 cmH2O. The obtained Cdyn value will be repeated after six respiratory cycles, and if there is an increase, the PEEP value will be increased by 2 cmH2O. When a decreasing trend is observed in the Cdyn value as a result of consecutive automatic measurements of 6 respiratory cycles, the PEEP value applied in the previous measurement will be determined as the most appropriate PEEP value for the participant."
223791301|NCT07126275|DEVICE|Mirror App Journaling and Mood Tracking Study|Mirror is a mobile journaling app developed by the Child Mind Institute (CMI) for youth who want to explore and improve their mental health, particularly addressing symptoms related to depression. The Mirror app enables users to express their thoughts and emotions through multimodal entries (i.e., written, voice, selfie video) and provides prompts to facilitate journal entries using unique, emotionally supportive features to help users identify and process emotions. Users can also complete free-form, unguided journaling, and can complete daily mood tracking and see changes/progress over time.
223791302|NCT06273774|DRUG|MK-8189|Oral Tablet
223791303|NCT06273774|DRUG|Placebo|Oral Tablet
223791304|NCT06365580|DRUG|Kylo-0603 capsule|Administrated orally.
223791305|NCT06365580|DRUG|Placebo|Administrated orally.
223791306|NCT02258477|DIETARY_SUPPLEMENT|Sequence 1|100 calorie beverage during week 1; 10 calorie beverage during week 2; control beverage beverage during week 3; 50 calorie beverage during week 4.
223791307|NCT02258477|DIETARY_SUPPLEMENT|Sequence 2|Control beverage during week 1; 100 calorie beverage during week 2; 50 calorie beverage during week 3; 10 calorie beverage during week 4.
223791308|NCT02258477|DIETARY_SUPPLEMENT|Sequence 3|50 calorie beverage during week 1; control beverage during week 2; 10 calorie beverage during week 3; 100 calorie beverage during week 4.
223791309|NCT02258477|DIETARY_SUPPLEMENT|Sequence 4|10 calorie beverage during week 1; 50 calorie beverage during week 2; 100 calorie beverage during week 3; control beverage during week 4.
223791310|NCT05163808|DRUG|zatolmilast|Subjects will receive a 15 mg or 25 mg dose of zatolmilast (BPN14770) or placebo
223791311|NCT05163808|DRUG|Placebo|Placebo
223791312|NCT04298567|DRUG|Rivaroxaban (Xarelto,Bay 59-7939)|Rivaroxaban (2.5 mg \[BID\])
223791313|NCT04298567|DRUG|Acetylsalicylic acid(ASA)|ASA (75mg \[QD\]; dose according to local label.
223791314|NCT04915794|OTHER|Simulation of preeclamptic pregnancy care|It is an important step in providing safe care to patients, as a learning environment is provided in which environmental risks are minimized with simulation applications. Simulation-based trainings are environments that allow each student to learn, equitable, based on adult learning principles, and open to different learning styles. In these environments, interests and needs are defined together by the learner and the educator. By keeping the experiences of the learner at the forefront, the opportunity is given to learn by doing and is supported with feedback.
223791315|NCT06819670|DRUG|Prednisolone|active drug
223791316|NCT06819670|DRUG|Famotidine|active drug
223791317|NCT06819670|DRUG|Placebo|non-active drug
223791318|NCT03766971|BEHAVIORAL|7 days of Tobacco Cessation|Participants will be randomly assigned to 7 days of tobacco cessation.
223791319|NCT03766971|BEHAVIORAL|21 days of Tobacco Cessation|Participants will be randomly assigned to 21 days of tobacco cessation.
223791320|NCT03766971|DRUG|Cannabis|Participants will receive cannabis.
223791321|NCT04657822|DRUG|Crizanlizumab|Concentrate for solution for infusion for Intravenous use
223791322|NCT06669260|PROCEDURE|TEThA technique|Patient in an orthostatic position, previously marked varicose veins will be punctured with a tracing adjacent to them, surrounding their edges. Applying an augmented reality device and Doppler ultrasound (Doppler USG), the marking will be complemented in the supine position. These punctures will in turn be carried out using the TEThA technique - endovenous thermoablation of tributary veins by means of transfixation - and will be done sequentially as they are treated one by one with endo- and perivenous thermoablation under generous tumescence with 0.08% lidocaine in saline solution. The laser used to treat the tributary veins will also be 1470 nm and will be fired as the fiber is removed at a speed of 1 mm/sec and power ranging from 5 to 7 watts.
223791323|NCT06669858|OTHER|manual therapy|"In first session 6 techniques were applied to favorise fluids circulation, respiratory mecanism end equilibration of pressions (all were external soft tissue techniques, without manipulation): on cervico dorsal hinge, on cranial diaphragm, on thoracic diaphragm, on pelvic diaphram, on liver and spleen organ, on lumbar fasciae.~In second session 6 techniques were applied in order to improve quality and quantity of legs and pelvis mobility (all were external sof tissue techniques, without manipulation) : on cervico dorsal hinge, on cranial diaphragm, on thoracic diaphragm, on pelvic diaphram, on pubic symphysis, on legs and pelvis and on lumbar fasciae"
223791324|NCT06669858|OTHER|Sham|Wide ligth touch pressure applied with the 2 hand at day 2-4 and day 90
223791325|NCT06670547|PROCEDURE|Endoscopic retrograde cholangiopancreatography (ERCP)|Endoscopic retrograde cholangiopancreatography (ERCP)
223791326|NCT04232254|BEHAVIORAL|Animal-based Protein Foods|Participants will consume animal-based protein foods.
223791327|NCT04232254|BEHAVIORAL|Skewed Protein Distribution|Participants will consume 3 meals per day consisting of 10-, 30-, 60% of dietary protein for breakfast, lunch, and dinner, respectively.
223791328|NCT04232254|BEHAVIORAL|Plant-based Protein Foods|Participants will consume plant-based protein foods.
223791329|NCT04232254|BEHAVIORAL|Balanced Protein Distribution|Participants will consume 5 meals per day consisting of 20% of dietary protein per meal.
223791330|NCT05546281|OTHER|No intervention|No intervention
223791331|NCT05819749|BEHAVIORAL|Diabetes Homelessness Medication Support Program in Spanish|There will be 10 sessions offered within 12 weeks to participants. Sessions will last 30-60 minutes. During sessions a diabetes wellness coach will use behavioral activation and motivational interviewing to get to know participants and set goals to improve diabetes care. The coach will encourage a focus on medication adherence behaviors to the extent that participants are willing. The coach will also help with resources and care coordination. The coach will also provide brief diabetes education as needed.
223791332|NCT06598306|DRUG|Tarlatamab|Administered by SC injection.
223791333|NCT05166005|DRUG|vitamin D|Patients will be randomised to receive either high dose vitamin D (50,000 IU weekly) on the first and second week or low dose vitamin D (2,000 IU daily).
223791334|NCT04717934|DEVICE|GAL1906|hyaluronic acid dermal filler gel
223791335|NCT06669429|DRUG|RS-C1001|Subjects will receive RS-C1001 tablets orally as a single ascending dose
223791336|NCT06669429|DRUG|RS-C1001|Subjects will receive RS-C1001 tablets orally as a multiple ascending dose
223791337|NCT06669429|DRUG|RS-C1001|Subjects will receive RS-C1001 tablets orally as a single dose after intake of a high-calorie, high-fat breakfast
223791338|NCT06669429|DRUG|placebo|Subjects will receive placebo matching tne RS-C1001 dose orally as a single ascending dose
223791339|NCT06669429|DRUG|placebo|Subjects will receive placebo matching tne RS-C1001 dose orally as a multiple ascending dose
223791340|NCT06669429|DRUG|Placebo|Subjects will receive placebo matching tne RS-C1001 dose orally as a single dose after intake of a high-calorie, high-fat breakfast
223791341|NCT03574571|DRUG|Docetaxel 75 mg/m2|Docetaxel 75 mg/m2 will be administered IV every three weeks for 10 doses.
223791342|NCT03574571|DRUG|Docetaxel 60 mg/m2|Docetaxel 60 mg/m2 will be administered IV every 3 weeks for 10 doses.
223791343|NCT03574571|DRUG|Radium-223|Radium-223 will be administered at 55 kBq/kg, 6 injections at 6 weeks intervals.
223791344|NCT05916196|DRUG|18F-Fluoroestradiol|18F-FES PET/CT
223791345|NCT06617455|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
223791346|NCT06617455|DRUG|Fezolinetant|Given PO
223791347|NCT06617455|DRUG|Placebo Administration|Given PO
223791348|NCT06617455|OTHER|Quality-of-Life Assessment|Ancillary studies
223791349|NCT06617455|OTHER|Questionnaire Administration|Ancillary studies
223791350|NCT06994195|DRUG|BL-B01D1|Administration by intravenous infusion for a cycle of 3 weeks.
223791351|NCT06994195|DRUG|Liposomal doxorubicin, Paclitaxel or Topotecan|Administration by intravenous infusion for a cycle of 4 weeks.
223791352|NCT03016871|DRUG|Carboplatin|Given IV
223791353|NCT03016871|DRUG|Etoposide|Given IV
223791354|NCT03016871|DRUG|Ifosfamide|Given IV
223791355|NCT03016871|OTHER|Laboratory Biomarker Analysis|Correlative studies
223791356|NCT03016871|BIOLOGICAL|Nivolumab|Given IV
223791357|NCT03958136|PROCEDURE|Metastasis biopsy|Metastasis biopsy will be performed for multi-omic analysis
223791358|NCT03958136|BIOLOGICAL|Biomarkers blood, urine and microbiota samples|Biomarkers blood, urine and microbiota samples for multi-omic analysis
223791359|NCT03958136|BEHAVIORAL|Patient Reported Outcome (PRO)|Patient Reported Outcome (PRO) will be collected throughout the study duration to assess quality of life, anxiety, depression distress, physical activity and food habits.
223791360|NCT06770777|BEHAVIORAL|Tiered whole health support for people living with COPD|The website design allows study participants to choose the intervention tier(s) that meets their needs. There are three tiers from Tier 1: Information only, Tier 2 Reflective Writing, and Tier 3 LCSW Psychotherapeutic Intervention. Participants will also be able to choose multiple tiers if they are interested in continuing their participation. First Tier: The website offers standardized information about COPD care, healthcare navigation, and whole-person care. Information includes symptom management, disease progression and trajectory, healthcare navigation concepts, and directs people to the VA website with information about whole-person care. Second Tier: If participants choose, they can also select writing prompts with opportunities to reflect on their whole-person care and adjustment to illness. Third Tier: People living with COPD can also select to have asynchronous interaction with a licensed clinical social worker providing the narrative-based psychotherapeutic intervention.
223791361|NCT07126782|BIOLOGICAL|Ex-vivo expanded allogeneic γδ T cells|Cells will be extracted from a healthy donor by apheresis, followed by ex-vivo expansion and activation. The ex-vivo expanded γδ T cells from donors will be adoptively transfused.
223791362|NCT07127523|OTHER|Social Skin|This group receives a cleanser, serum, and cream.
223791363|NCT07127523|OTHER|Placebo|This group receives a cleanser, serum, and cream.
223791364|NCT06531356|BIOLOGICAL|autologous amniotic fluid|10 cc of amniotic fluid aspirated after opening uterine incision in cesarean section, then Injected in edges of skin before closure
223791365|NCT06531356|OTHER|No amniotic fluid injected in skin edges|conventional closure of skin
223791366|NCT05632510|DIAGNOSTIC_TEST|The Edinburgh Postnatal Depression Scale (EPDS)|The Edinburgh Postnatal Depression Scale (EPDS) is a self-administered questionnaire of 10 items, is recommended by the NICE guideline and French National Authority for Health for screening peripartum women, validated in French and well accepted.
223791367|NCT05542043|OTHER|Data collection|"The data includes anamnestic and clinical data from women whose placental histology reveals a diagnosis of placental dysfunction.~Maternal data on the following characteristics: age, ethnicity, BMI, pregnancy, parity, number of abortions without curettage, multiple births, previous birth mode.~Risk factors for placentation disorders (increased maternal age, increased pregnancy and parity, increased BMI, placenta previa, nicotine abuse, multiple births, hypertension, diabetes, infections, bleeding, abortion curettage, hysteroscopy ± cavum curettage, caesarean section, fibroid removal, Asherman' s syndrome, status after IVF, endometritis) and birth mode.~Data on peripartal and postpartum surgical measures."
223791368|NCT01551732|BEHAVIORAL|ACT|10 session manualized cognitive behavioral anger control therapy
223791369|NCT01551732|BEHAVIORAL|ACT with RAGE-Control|10 session manualized cognitive behavioral anger control therapy augmented with interactive biofeedback videogame.
223791370|NCT02327754|DRUG|Topiroxostat BID, (Oral daily dosing for 28 weeks)|The dose of topiroxostat is increased up to 160 mg/day in a stepwise manner.
223791371|NCT02327754|DRUG|Placebo BID, (Oral daily dosing for 28 weeks)|Subjects randomized to the placebo arm will receive placebo.
223791372|NCT00550485|DRUG|escitalopram|escitalopram 4 mg
223791373|NCT00252655|DRUG|Rapamune and Prograf|
223791374|NCT06073730|PROCEDURE|Experimental: Venetoclax in combination with Decitabine (+-sorafenib)|Venetoclax (VEN) 100mg d1, 200mg d2, 400mg d3-14 Decitabine (DEC) 20mg/m2/q8h, d4-6 (infusion time \>2h) Sorafenib 600mg/d, d8-14 (FLT3/ITD mutation positive patients)
223791375|NCT06073730|PROCEDURE|Active Comparator: Standard dose of Venetoclax + Azacitidine|Venetoclax (VEN) 100mg d1, 200mg d2, 400mg d3-28 Azacitidine (AZA) 75mg/m2/d, d3-9
223791376|NCT04073602|DRUG|RC48-ADC|The eligible patients will be treated with RC48-ADC, an antibody-drug conjugate, 2.0 mg/kg, once every two weeks until investigator-assessed loss of clinical benefit, unacceptable toxicity, investigator or participant's decision to withdraw from therapy, or death (whichever occurs first).
223791377|NCT00924287|DRUG|in vitro tumor reactive, chimeric T cell receptor (CAR ) gene-transduced PBL plus IV aldesleukin|720,000 IU/kg every 8 hours for a maximum of 15 doses
223791378|NCT00924287|DRUG|Cyclophosphamide|60 mg/kg/day x 2 days intravenously (IV) in 250 ml 5% dextrose in water (D5W) with mesna 15 mg/kg/day x 2 days over 1 hour
223791379|NCT00924287|DRUG|Fludarabine|25 mg/m\^2/day intravenous piggyback (IVPB) daily over 30 minutes for 5 days.
223791380|NCT00924287|DRUG|Mesna|3 mg/kg/hour intravenously diluted in a suitable diluent over 23 hours after each cyclophosphamide dose.
223791381|NCT05884346|OTHER|Ultrahigh-frequency ultrasound|Arterial remodeling of the digital arteries will be measured by ultrahigh-frequency ultrasound and will be compared in heart failure patients with preserved ejection fraction with and without identified macroscopic coronary disease
223791382|NCT00265369|DRUG|Spores of Bacillus Clausii Probiotic Strain|
223791383|NCT04935502|OTHER|Home based exercises with postural and ergonomic training|Group A will be treated with stretching and strenghtening exercises for 40 minutes along with postural and ergonomic training for 15 minutes session 3 days/week for 4 week.
223791384|NCT04935502|OTHER|Home based exercises|Group B will be given stretching and strengthening exercises for 40 minutes, every alternate day (3 days per week) for 4 weeks.
223791385|NCT04769167|OTHER|Stool and Blood Specimen Collection|Stool and Blood specimens will be collected at 3 designated time points
223791386|NCT04769167|OTHER|Follow-up Medical Record Review|Participant medical records as well as the medical records of infants during study enrollment will be reviewed up to 3 years from the date of enrollment.
223791387|NCT01625897|DRUG|MP-214|Patients who meet eligibility criteria will be administered a once daily oral fixed dose (3mg or 6mg) of MP-214 for four weeks, then flexible dose (1.5-9mg) of MP-214
223791388|NCT01625897|DRUG|Risperidone|Patients who meet eligibility criteria will be administered a once daily oral fixed dose (4mg) of risperidone for two weeks, then flexible dose (2-12mg) of risperidone
223791389|NCT06136390|OTHER|Oxytocin|Oxytocin nasal spray in combination with mindfulness based group therapy (MBGT).
223791390|NCT06136390|OTHER|Placebo|Placebo nasal spray in combination with mindfulness based group therapy (MBGT).
223791391|NCT02358603|DIAGNOSTIC_TEST|Chronotropic Incompetence Diagnostic Algorithm|
223791392|NCT01912612|DRUG|Duloxetine|Subjects will receive 30 mg duloxetine orally for 7 days, then 60 mg duloxetine orally for 28 days, then 30 mg duloxetine orally x 14 days.
223791393|NCT06088940|DIETARY_SUPPLEMENT|Multistrain Probiotic|The probiotic capsule contains Lactobacillus and Bifidobacterium strains, ingested orally once daily.
223791394|NCT06088940|OTHER|Placebo|Placebo is composed of maltodextrin, that is an identically formulated and packaged inactive substance
223791395|NCT05197335|DEVICE|Chimaera short nail (length = 180 mm) in combination with one or two telescopic cephalic screws|The enrolled patients will proceed by undergoing the surgery necessary for the application of the medical device under observation (Chimaera), which coincides with the start of the treatment period.
223791396|NCT02640768|OTHER|educational training|implementation of a structured educational program for physicians and nurses
223791397|NCT04508894|DRUG|Supraclavicular Brachial Plexus Block with bupivacaine|"drug: 20 ml 0.5%bupivacaine plus 20 ml 0.9% normal saline is administered around the brachial plexus on the operative side Drug: IM diclofenac sodium (75 mg amp) is injected if VAS more than 4.~Device: ultrasound-guided supraclavicular Brachial Plexus nerve block"
223791398|NCT04508894|DRUG|Supraclavicular Brachial Plexus Block with Ketamine|"drug: 20 ml 0.5%bupivacaine, 20 ml 0.9% normal saline plus 1mg\\kg ketamine is administered around the brachial plexus on the operative side Drug: IM diclofenac sodium (75 mg amp) is injected if VAS more than 4.~Device: ultrasound-guided supraclavicular Brachial Plexus nerve block"
223791399|NCT04508894|DRUG|Supraclavicular Brachial Plexus Block with Dexmedetomidine|"drug: 20 ml 0.5%bupivacaine, 20 ml 0.9% normal saline plus 1µg\\kg dexmedetomidine is administered around the brachial plexus on the operative side Drug: IM diclofenac sodium (75 mg amp) is injected if VAS more than 4.~Device: ultrasound-guided supraclavicular Brachial Plexus nerve block"
223791400|NCT00881387|BIOLOGICAL|rituximab|Given IV
223791401|NCT00881387|DRUG|gemcitabine hydrochloride|Given IV
223791402|NCT00881387|DRUG|vinorelbine ditartrate|Given IV
223791403|NCT04380402|DRUG|Atorvastatin|Atorvastatin 40 mg tablet
223791404|NCT03939052|DIETARY_SUPPLEMENT|Free amino acids intake|Oral consumption of eight hourly experimental meals- -4 tracer free experimental meals containing a mixture of free amino acids and calories from protein free flavoured liquid, protein free cookies and corn oil -4 isotopically labeled experimental meals. The same protocol will be repeated with glycomacropeptide (GMP).
223791405|NCT04139070|DRUG|Bleomycin|Electroporation in combination with systemically administered bleomycin
223791406|NCT05552651|DRUG|Envafolimab|300mg,sc,d1,Q3W;
223791407|NCT05552651|DRUG|Albumin-Bound Paclitaxel|130mg/m2,iv,D1,D8,Q3W
223791408|NCT05552651|DRUG|Carboplatin|AUC=5, iv,D1,Q3W
223791409|NCT04953390|DEVICE|Phonak Audeo hearing aid|Commercially available hearing aid with three different microphone settings: DIR1, DIR2, and DIR3
223791410|NCT04953390|DEVICE|Phonak hearing aid with multiple directionality settings, adjustable via a mobile app|Commercially available hearing aid with multiple directionality settings which will be adjustable by user via a mobile app during a home trial period.
223791411|NCT02008890|BIOLOGICAL|Secukinumab 300mg|Secukinumab was used as 150 mg pre-filled syringes (PFS) in a double-blinded fashion. Secukinumab 300 mg s.c. (two PFS injections of the 150 mg dose) self-administered
223791412|NCT02008890|BIOLOGICAL|Secukinumab 150mg|secukinumab 150 mg s.c. (one PFS injection of the 150 mg dose + one PFS injection of placebo) self-administered
223791413|NCT02008890|BIOLOGICAL|Placebo|secukinumab placebo s.c. (two PFS injections of placebo) self-administered
223791414|NCT06022757|DRUG|XNW5004|XNW5004 an EZH2 inhibitor, BID, administered in continuous
223791415|NCT06022757|DRUG|KEYTRUDA® (pembrolizumab) 25 mg/mL Solution for Injection|KEYTRUDA® (pembrolizumab) a programmed death receptor (PD-1) blocking antibody administered at 200mg by intravenous (IV) infusions every 3 weeks.
223791416|NCT02921529|OTHER|TEAS|Electric stimulation was given through electrode attached to specific acupoints
223791417|NCT02921529|OTHER|false stimulation|Electrodes were attached to specific acupoints without electric current
223791418|NCT06963060|DRUG|Gemcitabine nab-PaclitaxelLenvatinibTislelizumab|"Receive Gemcitabine (1000 mg/m² IV on Days 1 and 8) and nab-Paclitaxel (125 mg/m² IV on Days 1 and 8) every 3 weeks.~Take Lenvatinib (4-8 mg orally daily on Days 1-21).~Receive Tislelizumab (200 mg IV on Day 1) every 3 weeks."
223791419|NCT03626155|BEHAVIORAL|Walking|Walking will last 50 minutes and will be at 5.0 km/h and at 0.5% incline
223791420|NCT03626155|BEHAVIORAL|Seated Control|Participants will be asked to sit quietly and read during a 50 minute control period
223791421|NCT02707354|DEVICE|Probe based confocal laser endomicroscopy (Cellvizio)|"The probe is a miniaturized microscope in the form of a fiber which is inserted through the endoscope and brought into contact with the mucosa. It thus allows for a live virtual biopsy, that is to say, obtaining real-time microscopic virtual image of the mucosa. It requires an intra-veinous injection of 5 mL of 10% fluorescein diluted in 50 cc of saline serum. The images obtained during the examination will be recorded via the endomicroscopy console so that two endoscopists blinded from the macroscopic and histological findings can review the data."
223791422|NCT04567472|BEHAVIORAL|Helping Ease Anxiety and Depression following Stroke|HEADS: UP online is a group-based mindfulness course with an accompanying text-based manual. HEADS: UP comprises 9 x 2.5 hour mindfulness sessions, which incorporate a 30-minute break. A 6-hour silent retreat is offered in week 7. A follow-up session will be offered 6 - 8 weeks after the end of the course. Course materials include accessible information packs delivered weekly, electronically, and CD/audio resources to complement the sessions. The accompanying text-based manual will be delivered 'up front' (hard copy and electronic). A summary email and reminder of personal practice will be sent to participants after each session, including links to audio resources complementing class-based sessions. Signposting to other resources and media, including sites with downloadable voice files e.g. Mindfulness Scotland will be included.
223791423|NCT05890443|BEHAVIORAL|Exercise|Before starting the research, self-management training in rehabilitation was given to both groups. While the exercise practices were carried out in the experimental group, encouraging reminders were made by following the background web page created in the experimental group.
223791424|NCT01577979|BEHAVIORAL|Text Message Reminder/Recall|Adolescents will be randomly selected from the participating private practices and safety net organization clinics. Parents of selected adolescents will receive a text message to alert them that their child is due for a vaccine or well-care visit. The text message will provide response instructions. The responses can be one of three options: 1) the parent will call the clinic to schedule a visit, 2) the parent would like the clinic to call them to schedule a visit, or 3) the parent would like to stop any future text message reminders. Parents who would like the clinic to call them to schedule an appointment will be contacted by their child's provider to set up a visit. Parents may receive up to 3 text message reminders, unless they chose to stop any future messages.
223791425|NCT01577979|BEHAVIORAL|Parent Preference|Parents of adolescents being seen within the managed care organization's intervention clinics will be asked about their reminder method preference at their child's 1st HPV immunization. The preference options include phone call, text message, or email. The preference for contact method will be recorded and utilized for the 2nd and 3rd dose reminders. The clinics' usual method of reminder will be used for all other parents.
223791426|NCT02478294|PROCEDURE|Thoracoscopic LAA Excision plus AF Ablation|In this group, patients receive thoracoscopic LAA excision plus AF ablation, which means thoracoscopic left atrial appendage excision plus atrial fibrillation ablation.
223791427|NCT02478294|DRUG|Warfarin or Novel Oral Anticoagulants|In this group, patients receive warfarin or novel oral anticoagulants
223791428|NCT02207816|PROCEDURE|Blood sampling|Annual blood sampling (Year 1, Year 2 and Year 3) during the present study.
223791429|NCT02207816|BIOLOGICAL|Malaria Vaccine 257049 (MALARIA-055 PRI)|Administered intramuscularly into the left deltoid, during the MALARIA-055 study (NCT00866619).
223791430|NCT02207816|BIOLOGICAL|Meningococcal C Conjugate Vaccine (MALARIA-055 PRI)|Administered intramuscularly into the left deltoid, during the MALARIA-055 study (NCT00866619).
223791431|NCT02207816|BIOLOGICAL|Cell-culture rabies vaccine (MALARIA-055 PRI)|Administered intramuscularly into the left deltoid, during the MALARIA-055 study (NCT00866619).
223791432|NCT02207816|BIOLOGICAL|TritanrixHepB/Hib (MALARIA-055 PRI)|Administered intramuscularly into the left deltoid, during the MALARIA-055 study (NCT00866619).
223791433|NCT02207816|BIOLOGICAL|Polio Sabin Oral Polio Vaccine (GSK) (MALARIA-055 PRI)|Administered orally, during the MALARIA-055 study (NCT00866619).
223791434|NCT04377165|BEHAVIORAL|Gamification|This will provide the user with the newsfeed function and the addition of a gamification function
223791435|NCT04377165|BEHAVIORAL|Newsfeed function|This will provide the user with reliable accurate information on the pandemic.
223791436|NCT04997005|DEVICE|AMIStem-P|Performance of Total Hip Arthroplasty (THA) with AMIStem-P femoral stem implant
223791437|NCT01092338|DRUG|Cholecalciferol (Vit D3)|To test two oral daily doses (4000 vs. 7000 IU) of cholecalciferol (D3) dietary supplement (capsules or liquid) over a 3-month period in 44 children, adolescents and adults with HIV/AIDS.
223791438|NCT03984799|PROCEDURE|Bronchoscopy|Samples obtained during bronchoscopy and blood samples will be evaluated to define inflammatory markers of COPD
223791439|NCT05100082|DRUG|Cabozantinib|Cabozantinib tablets
223791440|NCT05445284|BEHAVIORAL|Group education sessions for parents plus usual diabetes care|≥3 in person/virtual group education sessions for parents in addition to usual diabetes care, every 3 months for 12 months
223791441|NCT05445284|OTHER|Usual diabetes care|Usual diabetes care, every 3-month for 12 months
223791442|NCT04226430|DEVICE|Cytokine aphaeresis|The Cytosorb cartridge was either used alone in hemoperfusion mode or, if renal replacement therapy was clinically indicated, inserted proximally into a conventional continuous veno-venous hemofiltration (CVVH) or continuous veno-venous hemodiafiltration (CVVHDF) circuit. Before the start of the Cytosorb therapy, adequate anti-coagulation was confirmed when target partial thromboplastin time (PTT) of 60±80 seconds, or an activated clotting time (ACT) of 180±210 seconds was achieved with systemic heparin. Antibiotics were administered after each Cytosorb therapy whenever possible.
223791443|NCT02647112|OTHER|Bladder EpiCheck|Urine test for the monitoring of bladder cancer recurrence
223791444|NCT03150472|DEVICE|Graft Matrix|Both Graft matrix products are supplied sterile, for single use only and packed in vials or a syringe-like applicator. All products consist of the same bone graft particles with the only variants being due to different amounts per package or different containers.
223791445|NCT01200212|DRUG|Taxane, Avastin|Taxane (Investigator can choose between Paclitaxel (80 mg/m2 weekly or Docetaxel 75 mg/m2 day 1 q 22) + Bevacizumab (15mg/kg) i.v. day 1 q 22 Given until progression, unacceptable toxicity, patient's request or withdrawal from study
223791446|NCT01200212|DRUG|Taxane, Avastin, Xeloda|Taxane (Investigator can choose between Paclitaxel (80 mg/m2 weekly or Docetaxel 75 mg/m2 day 1 q 22) + Bevacizumab (15mg/kg) i.v. day 1 q 22 + Capecitabine 1800 mg/m2 day 1-14 q22 Given until progression, unacceptable toxicity, patient's request or withdrawal from study
223791447|NCT01443481|DRUG|Dovitinib|Starting dose to be determined based on the study outcome of the mild and moderate hepatic impairment groups
223791448|NCT02288468|DEVICE|Vercise™ Deep Brain Stimulation System|"The Vercise™ DBS System includes a Stimulator with DBS Leads for unilateral or bilateral stimulation. There are also DBS Extensions that allow the DBS Leads mounted in the skull to be extended to reach the Stimulator implanted near the clavicle.~The rechargeable Vercise DBS System utilizes current steering across eight contacts per DBS Lead to provide precise positioning of stimulation. The Stimulator is controlled by a handheld Remote Control, and can be interfaced with a Clinician's Programmer using the Bionic Navigator™ Software. Periodically, the Stimulator battery must be replenished with an RF (radiofrequency) charging device provided in the Patient DBS Charging Kit."
223791449|NCT03102814|BEHAVIORAL|Current rehabilitation|The control group will receive the rehabilitation currently offered at each of the participating centers.
223791450|NCT03102814|BEHAVIORAL|The BRIDGE program|The experimental group will additionally receive the BRIDGE program, which comprises motivational interviewing, structured goal-setting, tailored follow-up, plans for self-management, and individualised written feedback that participants can use to monitor their progress and share with important care givers.
223791451|NCT06393049|OTHER|Hyperglycaemic clamp|"Following an overnight fast, the investigators will perform simultaneous samples from the arterial line, the venous line, and microdialysis and consider these samples as baseline values.~If the patient's blood glucose level is at 8-10 mmol/L at baseline, the investigators will not proceed with the intervention and instead evaluate if the intervention can take place the following day.~After baseline values are measured, intravenous glucose 20% (200g/1,000 ml) is infused to raise the glucose levels in both plasma and extravascular glucose compartments with approximately 3 mmol/L."
223791452|NCT00293735|DRUG|labetalol (seizure prevention)|"20mg IV (can be increased to an escalating dose of maximum of 80 mg (20mg, 40 mg, 80 mg q 20min) Cumulative max of 240 mg.~20mg labetalol PO every 6 hours"
223791453|NCT00293735|DRUG|MgSO4 (seizure prevention)|4-6g bolus over 20 minutes; 1-2 grams/hr Discontinued 24 hours after delivery.
223791454|NCT05549401|DRUG|CKD-348(4) F1|QD, PQ
223791455|NCT05549401|DRUG|CKD-348(4) F2|QD, PQ
223791456|NCT05549401|DRUG|CKD-828, D097, D337|QD, PQ
223791457|NCT06041724|DRUG|Envafolimab combined with recombinant human endostatin and first-line chemotherapy|"Envafolimab: 300mg day1, s.c. Q3W; Recombinant human endostatin: 210mg day1, Intravenous pump for 72 hours, Q3W; Temozolomide: 150 mg/m2 d1-5, i.v. Q3W; Cisplatin: 25 mg/m2 d1-3, i.v. Q3W.~All of the above drugs were used for 6 cycles, and then Envafolimab and recombinant human endostatin continued only in patients with no progression in the first stage until disease progression as defined by RECIST1.1, unacceptable toxicity, withdrawal from the study or death, or no more than 2 years."
223791458|NCT05129826|BEHAVIORAL|the association between periodontitis and malnutrition status|be determine the association between periodontitis and malnutrition status in older adult.
223791459|NCT03857659|DIAGNOSTIC_TEST|Point-of-care ultrasound (POC-US)|POC-US evaluation will be conducted using the portable ultrasound machine, which is capable of straight-line measurements for assessment of the amniotic fluid, as well as ellipse measurements for determination of abdominal circumference. POC-US evaluation will be conducted every 4 weeks from 28-36 weeks.
223791460|NCT03857659|DIAGNOSTIC_TEST|Routine antenatal care|Routine care with fundal height measurement at each antenatal appointment every 2 weeks from 28-36 weeks. As well as clinically indicated obstetric ultrasound by a Registered Diagnostic Medical Sonographer (RDMS)
223791461|NCT03857659|DIAGNOSTIC_TEST|Formal ultrasound|Formal growth ultrasound performed between 36-38.6 weeks by RDMS.
223791462|NCT01991626|DIETARY_SUPPLEMENT|micronutrient powder|
223791463|NCT01991626|DIETARY_SUPPLEMENT|micronutrient powder (containing FeSO4), phytase|
223791464|NCT01991626|DIETARY_SUPPLEMENT|Iron pyrophosphate (FePP)|
223791465|NCT01991626|DIETARY_SUPPLEMENT|Iron sulphate|
223791466|NCT03527225|OTHER|Music|The patient's preferred music will be played during the first radiotherapy treatment session from speakers located inside the treatment room. The duration of the music will be 10 to 20 minutes. The music will be turned off at the patient's request if it bothers them. Length of music playing and if the patient requested that it be turned off, will be recorded.
223791467|NCT00765843|DEVICE|orthoses|orthoses are provided for use in standardized shoes that all subjects receive
223791468|NCT00709280|DRUG|7% Hypertonic Saline (HS)|Administered via inhalation twice daily for 48 ± 4 weeks. The delivery system is a PARI Sprint Junior nebulizer with a PARI Baby face mask or mouthpiece driven by a PARI Pro Neb compressor.
223791469|NCT00709280|DRUG|0.9% Isotonic Saline (IS)|Administered via inhalation twice daily for 48 ± 4 weeks. The delivery system is a PARI Sprint Junior nebulizer with a PARI Baby face mask or mouthpiece driven by a PARI Pro Neb compressor.
223791470|NCT01569516|DRUG|Octohydroaminoacridine Succinate Tablets|1mg, tid
223791471|NCT01569516|DRUG|Octohydroaminoacridine Succinate Tablets|1st-2nd week, 1mg, tid 3rd -16th week, 2mg, tid
223791472|NCT01569516|DRUG|Octohydroaminoacridine succinate Tablets|1st-2nd week, 1mg, tid, 3rd -4th week, 2mg, tid, 5th-16th week, 4mg, tid
223791473|NCT01569516|DRUG|Placebo|0mg, tid
223791474|NCT04272268|DEVICE|Nasal High flow Oxygen|If the patient is successfully extubated within 4 hours following surgery and meets the post surgery inclusion/exclusion criteria, Nasal high flow oxygen will be administered continuously using a humidifier machine for 5 days. Breathing circuits and nasal cannulae will be connected to the machine to deliver oxygen at 20L/min to the patient.
223791475|NCT02277106|DRUG|SAGE-547|
223791476|NCT02277106|DRUG|Placebo|
223791477|NCT06155968|PROCEDURE|QL block|"The curvilinear probe (2 5 MHz, SonoSite Turbo M) is placed in the transverse axial plane just cranial to the iliac crest. The shamrock sign was visualised (viz., the transverse process (TP) of vertebra L4 is the stem, whereas the erector spinae muscle (ESM) posteriorly, quadratus lumborum (QL) muscle laterally and the psoas major (PM) muscle anteriorly represent the three leaves). The needle is introduced using an in plane technique from the posterior end of the transducer through the QL muscle. The target for injection is the fascial plane between the QL and PM muscles.."
223791478|NCT06155968|DRUG|PCA|the PCA pump will be connected in a separate cannula. The pump contains 0.5 mg nalbuphine/ ml. the basal rate is 5ml/h and lock out time is 10 min
223791479|NCT01064739|DIETARY_SUPPLEMENT|Fava beans|Participants will receive 100g of fresh fava beans for breakfast and lunch on one study day and prior to this study day will be restricted to a fixed sodium low monoamine diet
223791480|NCT01064739|OTHER|Fixed Sodium Diet|Fixed sodium low monoamine diet
223791481|NCT02766751|BEHAVIORAL|HIVPASS|The 7-session HIVPASS intervention is provided to individuals randomized to the HIVPASS study arm.
223791482|NCT02766751|BEHAVIORAL|Health Education|The 7-sessions of Health Education is provided to individuals randomized to the Health Education study arm.
223791483|NCT04287023|OTHER|individual physical therapy|cardiovascular warm-up activities, stretching exercises, strengthening exercises, functional, gait and balance training, recreational games and ended with relaxation exercises - individual
223791484|NCT04287023|OTHER|group physical therapy|cardiovascular warm-up activities, stretching exercises, strengthening exercises, functional, gait and balance training, recreational games and ended with relaxation exercises - groups of 10 patients
223791485|NCT05762835|BEHAVIORAL|Virtual family-centered rounds (FCR)|"Parents will be given the option to join FCR virtually or in-person; this intervention is changing the behavior of how providers deliver healthcare and how parents engage in their child's care.~The NICU team members will use a computer with a speaker and pan-tilt-zoom camera, mounted on a stand with wheels to launch telehealth connections using the secure application called ExtendedCare. From within this telehealth connection, a NICU team member will send an electronic message (e.g. via text or email) to the subscribed parent(s) and wait for the parent to join the visit to establish a secure videoconference. The message to the parent includes a link that can be clicked to open a browser that allows the parent to join the telehealth visit. FCR will then proceed in usual fashion with the NICU team members and - if in attendance - parent(s)."
223791486|NCT03984669|DIAGNOSTIC_TEST|The Juvenile Disease Activity Score (JADAS)|The JADAS includes the following four measures: physician's global assessment of disease activity, measured on a 0-10 visual analog scale (VAS) where 0 = no activity and 10 = maximum activity; parent global assessment of well-being, measured on a 0-10 VAS where 0 = very well and 10 = very poor; the erythrocyte sedimentation rate (ESR), normalized to a 0 to 10 scale; and a count of joints with active disease.
223791487|NCT03984669|BIOLOGICAL|(1-3)-ß-D-Glucan (BDG) assay (Fungitell)|Evaluation of the (1,3)-Beta-D-Glucans level in patients with JIA and correlation of the higher serum BDG levels with JIA activity of disease, comparatively with usual markers
223791488|NCT06031701|BEHAVIORAL|Neuro-psychosocial teleassistance program|The intervention is carried out in groups of 5 participants and is organised in 12 sessions: 1 session per week of 1h duration. The intervention is aimed at strengthening aspects of social cognition, self-esteem, social skills and aims at a reduction of symptomatology and a general improvement of psychological well-being.
223791489|NCT02136277|DRUG|Hartmann's solution|Administered in 250ml boluses, until cardiac output has been optimised.
223791490|NCT03681626|PROCEDURE|no tracheal suction|No tracheal suctioning during extubation
223791491|NCT03681626|PROCEDURE|tracheal suction|tracheal suctioning during extubation
223791492|NCT04566029|BIOLOGICAL|Blood test|The patients' blood will be collected in four 5mL heparinized tubes
223791493|NCT04566029|BIOLOGICAL|Stool sample|The patients' stools will be collected at home
223791494|NCT04566029|OTHER|Questionnaires|At each visit, the following questionnaires will be collected: QLQ-C30 and EQ5D-5L Appendix 16.2 and PRO CTCAE
223791495|NCT01431625|OTHER|Combined Training (endurance and strength exercises)|"All patients underwent a training program to be held for 12 weeks in sessions of 60 minutes:~1. .- 20 minutes of bicycle ergometer with an initial load level of about 70% of baseline peak oxygen consumption, increasing the load every two weeks as tolerated.~2. \- Weightlifting in 2 sets of 6 reps of 5 simple exercises. These are held at a station multigimnastyc (CLASSIC Fitness Center, KETTLER) and are as follows: pulls Chest, Shoulder press, Butterfly, Leg extension and Leg curls. The resistance will be increased gradually from 70% of the maximum weight you can lift the patient in a single maneuver (Test 1RM). Every two weeks the maximum weight is re-evaluated to adjust the training load in each patient."
223791496|NCT03881735|DRUG|Enasidenib|Given PO
223791497|NCT03881735|PROCEDURE|Hematopoietic Cell Transplantation|Undergo HCT
223791498|NCT00794612|DRUG|Dermacyd Femina Pocket BR (Lactic Acid)|Dermacyd Femina Pocket BR (Lactic Acid) during 21 consecutive days
223791499|NCT02549898|DRUG|Feraheme|Feraheme is an USPIO agent, which will be applied as a contrast agent to visualize vascular inflammation in unilateral migraine without aura.
223791500|NCT02549898|DRUG|Cilostazol|Cilostazol will be applied to provoke migraine attacks in migraineurs
223791501|NCT02549898|OTHER|USPIO-MRI|USPIO-MRI scans will be performed in order to assess possible vascular inflammation associated with migraine attacks.
223791502|NCT02549898|OTHER|BBI-MRI|Black blood MRI scans will be performed in order to asses changes in vessel wall thickness due to possible vascular inflammation associated with migraine attacks.
223791503|NCT01571362|DRUG|ALO-02|20 to 160mg total daily dose of oxycodone, divided into symmetric doses and administered twice daily
223791504|NCT01571362|DRUG|Placebo|oral placebo, divided into symmetric doses and administered twice daily
223791505|NCT06442553|DEVICE|GRR laser|A total of 15 sessions were applied to each patient for three weeks, five times per week.
223791506|NCT06442553|DEVICE|Nd:YAG laser|A total of 10 sessions, five sessions per week, were applied
223791507|NCT00458328|DRUG|Z-338|
223791508|NCT05123508|DEVICE|2940nm and BBL treatment|2940nm and BBL treatment
223791509|NCT05123508|OTHER|Non-treatment side (Control)|No treatment
223791510|NCT00485485|DRUG|Imatinib Mesylate|400 mg by mouth daily
223791511|NCT00485485|DRUG|Docetaxel|60 mg/m\^2 by vein (IV) over 1 hour every 3 weeks
223791512|NCT03780764|OTHER|"A Pre-adjusted edgewise brackets: 3M Gemini Unitek, 0.022 Roth prescription brackets"|"A pre-adjusted edgewise fixed appliance (3M Gemini Unitek, 0.022 Roth prescription brackets) on one side of lower arch. The standardized bonding technique was applied according to the manufacturer's instructions. Teeth alignment was initiated using round 0.016 NiTi arch wire until 0.016X0.022 NiTi was reached. The NiTi arch wires were placed into brackets slots and tied with elastomers (figure of 8)."
223791513|NCT03780764|OTHER|"Self- ligating brackets: Unitek™ Gemini SL Self-Ligating Brackets, 0.022 Roth prescription brackets"|"Self-ligating brackets (Unitek™ Gemini SL Self-Ligating Brackets, 0.022 Roth prescription brackets) on the other side of lower arch. The standardized bonding technique was applied according to the manufacturer's instructions. Teeth alignment was initiated using round 0.016 NiTi arch wire until 0.016X0.022 NiTi was reached. The NiTi arch wires were placed into brackets slots and held in place by bracket's gate in the self-ligating brackets side."
223791514|NCT01669629|DEVICE|delefilcon A|Daily wear soft contact lens for bilateral distance vision correction use.
223791515|NCT01669629|DEVICE|etafilcon A|Daily wear soft contact lens for bilateral distance vision correction use.
223791516|NCT05940532|DRUG|Sugemalimab and Chemotherapy|"Chemotherapy: Paclitaxel 175mg/m2 D1, Carboplatin AUC=5 or DDP 75mg/m2 D1 for NSCLC; Pemetrexed 500mg/m2 D1, Carboplatin AUC=5 or DDP 75mg/m2 D1 for non-squamous NSCLC; intravenous infusion every 3 weeks, for up to four cycles.~Sugemalimab: 1200 mg by intravenous infusion every 3 weeks, for up to 2 years."
223791517|NCT03570294|DRUG|Atosiban|The initial dose of Atosiban (Tractocile, Ferring Pharmaceuticals A/S, Copenhagen, Denmark) will be give as a single intravenous bolus dose (6.75 mg in 0.9 ml isotonic sodium chloride solution). This will be follow immediately by intravenous infusion of 300 μg/min of Atosiban in 5% glucose for 3 hours, and then 100 μg/min for up to 48 hours. Venous blood samples from a forearm vein will take before and after 48 hours of continuous administration tocolytic therapy with Atosiban.
223791518|NCT04117035|PROCEDURE|Gamma Knife Radiosurgery (GKRS) personalised procedure|Personalised GKRS treatment
223791519|NCT04117035|PROCEDURE|GKRS standard care|Standard GKRS treatment
223791520|NCT02324439|DRUG|Omega Nutrition cold-milled flaxseeds|Patients who are currently in clinical remission will receive a daily 20g dose of cold milled flaxseed as a dietary supplement to determine if this intervention prolongs clinical remission.
223791521|NCT03774628|BIOLOGICAL|Chengdu Kanghua (one booster shot)|A rabies vaccine (human diploid cell) for human use, Freeze-dried produced by Chengdu Kanghua Biological Products Co.,Ltd. 1.0 ml experimental vaccine on day 0
223791522|NCT03774628|BIOLOGICAL|Chengdu Kanghua (two booster shots)|A rabies vaccine (human diploid cell) for human use, Freeze-dried produced by Chengdu Kanghua Biological Products Co.,Ltd. 1.0 ml experimental vaccine on day 0 and 3
223791523|NCT01221597|BIOLOGICAL|AA4500|2 injections separated by at least 24 hours but not more than 72 hours. At least 24 hours but not more than 72 hours after the 2nd injection of the treatment cycle, the investigator will model the plaque (ie, gradual, gentle stretching of the flaccid penis in the direction opposite to the curvature). Treatment may be repeated after 42 days (± 5 days) for up to 4 treatment cycles.
223791524|NCT01221597|BIOLOGICAL|Placebo|2 injections separated by at least 24 hours but not more than 72 hours. At least 24 hours but not more than 72 hours after the 2nd injection of the treatment cycle, the investigator will model the plaque (ie, gradual, gentle stretching of the flaccid penis in the direction opposite to the curvature). Treatment may be repeated after 42 days (± 5 days) for up to 4 treatment cycles.
223791525|NCT05020639|DRUG|TQB3820 tablets|TQB3820 is a novel cereblon-modulating agent.
223791526|NCT05271617|DIAGNOSTIC_TEST|VIDAS® NEPHROCLEAR™ CCL14|Measurement of CCL14 in sample aliquots after being subjected to different testing conditions
223791527|NCT05526105|DIAGNOSTIC_TEST|Gastric Ultrasound|Gastric ultrasound in the supine and right lateral decubitus position for patients going for operative intervention with a protected airway.
223791528|NCT00617760|BIOLOGICAL|Group C Meningococcal Polysaccharide-Tetansu Toxoid Conjugate (MenC-TT) vaccine and 7-valent Pneumococcal CRM197-conjugate vaccine (PCV7)|MenC-TT vaccine (0.5 ml) to be administered in the left thigh muscle, PCV7 (0.5 ml) to be administered in the right thigh muscle
223791529|NCT00617760|BIOLOGICAL|7-valent Pneumococcal CRM197-conjugate vaccine (PCV7)|PCV7 (0.5 ml) to be administered in the right thigh muscle
223791530|NCT00617760|BIOLOGICAL|Group C Meningococcal Polysaccharide-Tetansu Toxoid Conjugate (MenC-TT)|MenC-TT vaccine (0.5 ml) to be administered in the left thigh muscle
223791531|NCT00406835|PROCEDURE|Whole-Brain Radiation Therapy, Stereotactic Radiosurgery|
223791532|NCT01815164|BEHAVIORAL|Hypnotherapy|Gut-directed hypnotherapy administered by an experienced hypnotherapist.
223791533|NCT01815164|BEHAVIORAL|Educational intervention|Educational intervention vith education regarding Irritabel bowel Syndrome.
223791534|NCT05881616|OTHER|Specimen samples and baseline data collection|The remaining serum samples from routine blood tests of subjects will be collected (without additional blood collection), with a serum sample size of approximately 1 mL per subject. The samples will be pre-processed and stored at ultra-low temperatures. At the same time, clinical baseline data of subjects will be collected from outpatient or inpatient medical records, including but not limited to age, height, weight, blood pressure, and gestational age.
223791535|NCT05881616|OTHER|Specimen samples and baseline data collection|The remaining serum samples from routine blood tests of subjects will be collected (without additional blood collection), with a serum sample size of approximately 1 mL per subject. The samples will be pre-processed and stored at ultra-low temperatures. At the same time, clinical baseline data of subjects will be collected from outpatient or inpatient medical records, including but not limited to age, height, weight, blood pressure, and gestational age.
223791536|NCT05881616|OTHER|Specimen samples and baseline data collection|The remaining serum samples from routine blood tests of subjects will be collected (without additional blood collection), with a serum sample size of approximately 1 mL per subject. The samples will be pre-processed and stored at ultra-low temperatures. At the same time, clinical baseline data of subjects will be collected from outpatient or inpatient medical records, including but not limited to age, height, weight, blood pressure, and gestational age.
223791537|NCT01495767|OTHER|Filling in a psychometric questionnaire|Juvenile patients attending the uveitis are asked to fill in a psychometric questionnaire
223791538|NCT03229369|PROCEDURE|Isolated anatomic ACL reconstruction|Hamstrings free grafts using a two-incision intra-articular Anterior Cruciate ligament (ACL) reconstruction technique. Both ST and gracilis will be prepared with doubled strands, a standard quadrupled graft. The femoral tunnel will be performed in outside-in manner. The tibial tunnel will be drilled in the center of the ACL tibial footprint, sparing the ACL tibial stump, when possible. ACL graft will be first fixed in the femur and then in the tibia, both with an interference screw at 30 degrees of knee flexion.
223791539|NCT03229369|PROCEDURE|Combined Anterior Cruciate Ligament and Anterolateral Ligament reconstruction|Hamstrings free grafts using a two-incision ACL reconstruction with the addition of a gracilis prolongation for ALL reconstruction. ACL graft will exhibit a quadruple strand (tripled ST + single gracilis) and the ALL graft, a single strand with the gracilis prolongation. ALL tibial tunnel will be performed with a 5mm drill, 1cm distal to the articular level, midway from the fibular head and Gerdy Tubercle, crossing the tibia toward its anteromedial cortex, 1cm distal to the ACL tunnel. Femoral ACL and ALL tunnels are coincident and located posterior and proximal to the lateral epicondyle. Intra-articular surgery will be performed in the same manner as comparative group. Gracilis prolongation is routed through the tibial ALL tunnel and then retrieved in the anteromedial aspect of the tibia, 1cm distal to the ACL tunnel entrance. ALL is fixed in full extension and neutral rotation, tying both graft extremities with 3 knots.
223791540|NCT01621217|DRUG|Cetuximab|Will be given weekly intravenously during study treatment.
223791541|NCT01621217|DRUG|Mitomycin C|Will be given intravenously twice together with 5-Fluoruracil during study treatment.
223791542|NCT01621217|DRUG|5-Fluoruracil|Will be given intravenously twice together with Mitomycin C during study treatment
223791543|NCT01621217|RADIATION|Radiotherapy|Radiotherapy, once daily with a total dose of 54 Gy, given in 27 fractions.
223791544|NCT03432975|DRUG|Povidone-Iodine 10%|The side of the mouth receiving the subgingival irrigations of povidone iodine 10% (test group)
223791545|NCT03432975|DRUG|Saline Solution|The other side of the mouth will be irrigated with a sterile saline solution (control group)
223791546|NCT06162767|PROCEDURE|Esophagectomy by Ivor-Lewis Procedure|Esophagectomy was conducted by Ivor-Lewis Procedure.
223791547|NCT06162767|PROCEDURE|Esophagectomy by Optimized Sweet Procedure|Esophagectomy was conducted by Optimized Sweet Procedure.
223791548|NCT05278910|OTHER|Soybean oil + Roasted wheat flour|Assign soybean oil capsule and roasted wheat flour
223791549|NCT05278910|DIETARY_SUPPLEMENT|Fish oil + Roasted wheat flour|Assign fish oil and roasted wheat flour
223791550|NCT05278910|DIETARY_SUPPLEMENT|Soybean oil + Vegetable and fruit extracts|Assign soybean oil and vegetable and fruit extracts
223791551|NCT05278910|DIETARY_SUPPLEMENT|Fish oil + Vegetable and fruit extracts|Assign fish oil and vegetable and fruit extracts
223791552|NCT04955912|OTHER|music medicine|To reduce premenstrual symptoms by applying music medicine to people with premenstrual syndrome
223791553|NCT03847324|OTHER|Pain Neuroscience Education|"This program is mainly based in Explain Pain concept, used in multiple rehabilitation programs. Its aim is to change the subject's pain understanding, teaching them the biological processes underneath the pain construct, as a mechanism to reduce itself and its related maladaptive thoughts and behaviors."
223791554|NCT03847324|OTHER|Multimodal Physiotherapy|This intervention will be divided in pain neuroscience education, orthopedic manual therapy and therapeutic exercise.
223791555|NCT03847324|OTHER|Usual Care|Usual care will be divided in: preoperative biomedical group-based education, postoperative hospital rehabilitation and home-based postoperative physiotherapy.
223791556|NCT01508468|DRUG|symptomatic treatment (Converting Enzyme inhibitor, Angiotensin II, Anti-renin, Aldosterone antagonist diuretic, Beta blocker, Calcium inhibitor, statin)|Converting Enzyme inhibitor , Angiotensin II receptor antagonist, Anti-renin, Aldosterone antagonist diuretic, Beta blocker, Calcium inhibitor, statin.
223791557|NCT01508468|DRUG|experimental (Non Immunosuppressive Symptomatic Treatment (NIST) and Rituximab)|NIST and IV infusion of Rituximab 375mg/m² at day (1) and day (8)
223791558|NCT02043210|BEHAVIORAL|Standard Treatment as Usual|Treatment normally offered at this clinic which could include individual or group substance use counseling sessions one time per week lasting one hour each time.
223791559|NCT02043210|BEHAVIORAL|CBT4CBT plus Standard treatment as usual|Subjects work with a computerized program in Spanish that teaches skills for stopping substance use and increasing coping skills. Computerized sessions are one time per week and last about one hour per session. Plus Standard treatment as usual
223791560|NCT05845138|DRUG|SHR-A1811 for injection ; capecitabine|SHR-A1811 for injection; Capecitabine tablets
223791561|NCT05668117|DEVICE|Depuy Synthes Advanced Retrograde femoral nail|The Advanced Retrograde Femoral Nailing System (RFNA) is designed to improve fixation and stabilization of distal femur and femoral shaft fractures by reducing toggle and loss of reduction.
223791562|NCT00408473|DRUG|Flecainide|
223791563|NCT02077257|DRUG|Rosuvastatin|Rosuvastatin 20 mg/d compared to 10 mg/day
223791564|NCT03842657|COMBINATION_PRODUCT|anticoagulation of the dialysis circuit|Each patient included in this study will receive two heparin-free dialysis sessions with heparin-grafted membrane (control group) or RCA with calcium-free citrate-containing dialysate and calcium reinjection according to the ionic dialysance (experimental group), alternatively
223791565|NCT05725005|DRUG|ASN51|Oral capsule
223791566|NCT05978843|BEHAVIORAL|Monetary benefit to purchase fruits and vegetables|Participants will receive varying benefit amounts to purchase fruits and vegetables.
223791567|NCT06961942|OTHER|Training|A structured teaching module for fellows in training will be prepared and conducted at three university centres, namely University Hospitals Leuven, Ljubljana University Medical Centre, and CHU de Bordeaux. The training module will include short endoscopic videos (different from the pre- and post-training set), which participants will score in real-time using a polling application. This will be followed by a step-by-step demonstration of each scoring principle with explanations of the reasoning behind specific scores. Each scoring system will be reviewed in a short training video that provides a structured demonstration, highlights common pitfalls, and showcases typical IBD-associated endoscopic features. After the video training, participants will have the opportunity to ask questions to the experts.
223791568|NCT06294184|DEVICE|tdcs lDLPFC|The current is 2mA, duration is 1200s, fade in 30s, fade out 30s, anode is on the F3, cathode is on the FP2.
223791569|NCT06294184|DEVICE|tdcs rVLPFC|The current is 2mA, duration is 1200s, fade in 30s, fade out 30s, anode is on the F6, cathode is on the FP1.
223791570|NCT06294184|DEVICE|Sham|The current only persist in the fisrt 30s, duration is 1200s, fade in 30s, fade out 30s, anode is on the F3/F6, cathode is on the FP2/1.
223791571|NCT06807047|OTHER|Epilepsy Management at School Mobile Health Application|Teachers who meet the inclusion criteria will use the EpiSchool
223791572|NCT06807047|OTHER|Digital Epilepsy Education Guide|Teachers who meet the inclusion criteria will use the EpiGuide
223791573|NCT04642638|DRUG|INO-4800|INO-4800 was administered ID on Day 0 and Day 28.
223791574|NCT04642638|DEVICE|CELLECTRA® 2000|EP using the CELLECTRA® 2000 device was administered following ID delivery of INO-4800 on Day 0 and Day 28.
223791575|NCT04642638|DRUG|Placebo|Sterile saline sodium citrate (SSC) buffer (SSC-0001) was administered ID on Day 0 and Day 28.
223791576|NCT04642638|DEVICE|CELLECTRA® 2000|EP using the CELLECTRA® 2000 device was administered following ID delivery of sterile saline sodium citrate (SSC) buffer (SSC-0001) on Day 0 and Day 28.
223791577|NCT00990652|DRUG|Bortezomib|Before surgery, an injection of bortezomib is given on days 1, 4, and 8. After surgery, bortezomib is given on days 7 and 21 of each cycle (1 cycle = 28 days).
223791578|NCT00990652|DRUG|Temozolomide|After surgery, temozolomide is taken by mouth on days 1-7 and 14-21 of each cycle (1 cycle = 28 days).
223791579|NCT03074630|DRUG|Dapagliflozin|5 weeks 10mg dapagliflozin once daily
223791580|NCT03074630|DRUG|Rosuvastatin|9 weeks 10mg dapagliflozin once daily
223791581|NCT04347681|OTHER|convalescent plasma from recovered COVID 19 donor|After obtaining informed consent, Eligible Patients who have severe COVID-19 and have not recovered yet will be infused with the donated convalescent plasma (10-15 ml/kg body weight of recipient)19 at least once \& if possible, daily, for up to 5 sessions.
223791582|NCT01196338|BEHAVIORAL|Early weight-bearing and range of motion exercises|"* 0 weeks to 2 weeks: Posterior plaster slab or cast, non-weightbearing, crutches;~* At 2 week visit to clinic: Posterior plaster slab or cast removed, staples/stitches removed placed in orthosis, with instructions to be weightbearing as tolerated. Instructions for limited range of motion to be given;~* At 2 weeks to 6 weeks: Weightbearing as tolerated in orthosis, follow range of motion instructions;~* After 6 weeks: Instructions to continue weightbearing as tolerated, wean from orthosis."
223791583|NCT01196338|BEHAVIORAL|non-weight bearing, no range of motion|"* 0 weeks to 2 weeks: Posterior plaster slab or cast, non-weightbearing, crutches;~* At 2 week visit to clinic: Posterior plaster slab or cast removed, staples/stitches removed, BK fibreglass cast or other orthosis applied, with instructions to continue non-weightbearing;~* At 2 weeks to 6 weeks: Ankle remains immobile and non-weightbearing;~* After 6 weeks: Begin weightbearing as tolerated. Instructions for limited range of motion to be given, and wean from orthosis."
223791584|NCT05040009|BEHAVIORAL|integrated foot care program|"1. Regular foot care and examination by an adequately trained professional: -~2. Structured education:~Educational modality will be provided to patients in a structured way. This will take many forms: one-to-one verbal education session last around 30 min motivational interviewing, video education, booklets, pictorial education via animated drawing or descriptive images structured foot care education consists of information on:~1. Foot ulcers and their consequences~2. Preventative foot self-care behaviors~3. Wearing adequately protective footwear~4. Undergoing regular foot checks~5. Practicing proper foot hygiene~6. Seeking professional help in a timely manner after identifying a foot problem~3-Adequate footwear 4-Foot-related exercises and weight-bearing activity 5-Foot examination and screening 6- Instructions about foot self-management"
223791585|NCT05932745|OTHER|E-liquid coolant (No WS-3) for non-menthol (1)|Adult users of e-cigarette will be exposed to distinct e-liquid coolants without WS-3.
223791586|NCT05932745|OTHER|E-liquid coolant (No WS-3) for low menthol (1)|Adult users of e-cigarette will be exposed to distinct e-liquid coolants without WS-3.
223791587|NCT05932745|OTHER|E-liquid coolant (No WS-3) for high menthol (1)|Adult users of e-cigarette will be exposed to distinct e-liquid coolants without WS-3.
223791588|NCT05932745|OTHER|E-liquid coolant (Low WS-3) for non-menthol (2)|Adult users of e-cigarette will be exposed to distinct e-liquid coolants with low WS-3 concentration.
223791589|NCT05932745|OTHER|E-liquid coolant (Low WS-3) for low menthol (2)|Adult users of e-cigarette will be exposed to distinct e-liquid coolants with low WS-3 concentration.
223791590|NCT05932745|OTHER|E-liquid coolant (Low WS-3) for high menthol (2)|Adult users of e-cigarette will be exposed to distinct e-liquid coolants with low WS-3 concentration.
223791591|NCT05932745|OTHER|E-liquid coolant (High WS-3) for non-menthol (3)|Adult users of e-cigarette will be exposed to distinct e-liquid coolants with high WS-3 concentration.
223791592|NCT05932745|OTHER|E-liquid coolant (High WS-3) for low menthol (3)|Adult users of e-cigarette will be exposed to distinct e-liquid coolants with high WS-3 concentration.
223791593|NCT05932745|OTHER|E-liquid coolant (High WS-3) for high menthol (3)|Adult users of e-cigarette will be exposed to distinct e-liquid coolants with high WS-3 concentration.
223791594|NCT05932745|OTHER|E-liquid coolant (Low WS-23) for non-menthol (4)|Adult users of e-cigarette will be exposed to distinct e-liquid coolants with low WS-23 concentration.
223791595|NCT05932745|OTHER|E-liquid coolant (Low WS-23) for low menthol (4)|Adult users of e-cigarette will be exposed to distinct e-liquid coolants with low WS-23 concentration.
223791596|NCT05932745|OTHER|E-liquid coolant (Low WS-23) for high menthol (4)|Adult users of e-cigarette will be exposed to distinct e-liquid coolants with low WS-23 concentration.
223791597|NCT05932745|OTHER|E-liquid coolant (High WS-23) for non-menthol (5)|Adult users of e-cigarette will be exposed to distinct e-liquid coolants with high WS-23 concentration.
223791598|NCT05932745|OTHER|E-liquid coolant (High WS-23) for low menthol (5)|Adult users of e-cigarette will be exposed to distinct e-liquid coolants with high WS-23 concentration.
223791599|NCT05932745|OTHER|E-liquid coolant (High WS-23) for high menthol (5)|Adult users of e-cigarette will be exposed to distinct e-liquid coolants with high WS-23 concentration.
223791600|NCT02085408|DRUG|Daunorubicin|Given IV
223791601|NCT02085408|DRUG|Cytarabine|Given IV
223791602|NCT02085408|DRUG|Clofarabine|Given IV
223791603|NCT02085408|DRUG|Decitabine|Given IV
223791604|NCT02085408|OTHER|Observation|Undergo clinical observation
223791605|NCT02085408|PROCEDURE|Allogeneic hematopoietic stem cell transplantation|Patients with an HLA-identical donor proceed to allogeneic stem cell transplantation.
223791606|NCT02246517|DRUG|N2O|
223791607|NCT02246517|DRUG|Oxygen|
223791608|NCT03317977|BEHAVIORAL|Reach for Control|In Phase 1 (weeks 1-4), the CHW conducts an initial intake and then completes a comprehensive functional analysis (FA) of behavior to determine the causes of poor asthma management for each youth regarding asthma management. In Phase 2 (weeks 5-20) is a treatment phase and consists of a combination of mandatory cognitive-behavioral skills training (CBST) modules (received by all families) and flexible CBST modules chosen and individualized based on the results of the Phase 1 FA. This includes but not limited to In-vivo Asthma Skills Training, Improving Family Communication and Behavioral Contracting. Phase 3 (weeks 21-24) involves termination planning and relapse prevention
223791609|NCT03317977|BEHAVIORAL|MATCH|Managing Asthma Through Case Management in Home (MATCH) is the current intervention provided by WCHAP to youth with poorly controlled asthma and their families.
223791610|NCT03346876|PROCEDURE|Nuss surgery|surgical correction for pectus excacatum
223791611|NCT00005076|BIOLOGICAL|cetuximab|
223791612|NCT00005076|DRUG|irinotecan hydrochloride|
223791613|NCT05432648|DIETARY_SUPPLEMENT|Green bean puree|Green bean contains both soluble and insoluble fiber, which may have different extent of influence on the gut microbiome. Using a real food rather than a purified fiber such as pectin is more practical and more acceptable to families.
223791614|NCT01734681|DRUG|G-202|
223791615|NCT05638867|DRUG|Aspirin + Clopidogrel + Rivaroxaban|Triple antithrombotic therapy: aspirin 75-100 mg orally once daily, clopidogrel 75 mg orally once daily, and rivaroxaban 2.5 mg orally twice daily
223791616|NCT05638867|DRUG|Aspirin + Clopidogrel|Dual antithrombotic therapy: aspirin 75-100 mg orally once daily, clopidogrel 75 mg orally once daily
223791617|NCT04291963|PROCEDURE|DGG + TUN|In the DGG group, CTG was obtained at palatal mucosa by means of intra-oral de-epithelialization of the FGG using a 2.3 mm diameter diamond burr (801G/023, EMS, Aldrich Co., USA) with NaCL 0.9% saline irrigation
223791618|NCT04291963|PROCEDURE|SCTG + TUN|In SCTG group, graft was harvested through the single-incision approach at palatal mucosa
223791619|NCT04732286|DRUG|Atezolizumab|Atezolizumab will be administered intravenously at a dose of 1200 mg on Day 1 of each 21-day cycle.
223791620|NCT04732286|DRUG|Bevacizumab|Bevacizumab will be administered by IV infusion at a dose of 15 mg/kg on Day 1 of each 21-day cycle.
223791621|NCT03288662|OTHER|CT and histopathological classification|Cross-sectional descriptive study on 53 patients with diagnosed of thymoma by CT and had postoperative histopathology results as thymic epithelial tumors. Base on the characteristics in Chest CT scan in each postoperative histopathology results.
223791622|NCT00890955|DRUG|Amrubicin|"* Dose Level -1: 20mg/m2~* Dose Level 1: 25mg/m2~* Dose Level 2: 30mg/m2~* Dose Level 3: 35mg/m2~* Dose Level 4: 40mg/m2~Amrubicin will be given as a slow IV push or infusion over approximately 5 minutes once daily for 3 consecutive days starting on day 1 of each 21 day cycle."
223791623|NCT00890955|DRUG|Cyclophosphamide|Cyclophosphamide will be given at a fixed dose as 500mg/m2 IV infusion over 30-60 minutes on day 1 of each 21 day cycle (following amrubicin).
223791624|NCT04027556|OTHER|low dose CT contrast media - lean body weight|CT contrast media (iobitridol 350mgI/kg) is administrated at a dose of 450mgI/kg based on lean body weight.
223791625|NCT04027556|OTHER|Standard dose CT contrast media|CT contrast media (iobitridol 350mgI/kg) is administrated at a dose of 560mgI/kg based on total body weight.
223791626|NCT01612403|DIETARY_SUPPLEMENT|zinc sulfate|every participant took two capsules of zinc sulfate per day for three months (each one 220mg)
223791627|NCT06041035|DRUG|QLS31905|Administered as an intravenous infusion.
223791628|NCT06041035|DRUG|Nab paclitaxel|125 mg/m2 administered as IV infusion on D1/D8/D15 of each cycle.
223791629|NCT06041035|DRUG|Gemcitabine|1000 mg/m2 administered as IV infusion on D1/D8/D15 of each cycle.
223791630|NCT06041035|DRUG|Oxaliplatin|85 mg/m2, intravenous infusion, D1/D15, up to 6 cycles.
223791631|NCT06041035|DRUG|Capecitabine|1000 mg/m2, oral, bid, D1-D7,D15-D21, up to 6 cycles.
223791632|NCT06041035|DRUG|Cisplatin|25 mg/m2, intravenous infusion, D1/D15, up to 6 cycles.
223791633|NCT03400891|BEHAVIORAL|Program based on the theory of planned behaviour|14 sessions of one hour to work TPB constructs: attitude, subjective norms, perceived behavioural control and intention.
223791634|NCT05812651|OTHER|Inspiratory muscle fatigue|"Muscle training according to the protocol that tends to induce inspiratory muscle fatigue. (60-80% MIP). Inspiratory resistive loading by starting at 60-80% (MIP) increasing every 10 minutes by 10% then measure MIP, until MIP measurement decrease of more than 10% from baseline will be performed.~When report a lower score of MIP and participants could no longer worked out, performed the functional mobility tests and see if there any variation."
223791635|NCT01369862|BIOLOGICAL|GHB16L2|A/Brisbane/59/07(H1N1)-like delNS1, A/Brisbane/10/07(H3N2)-like delNS1, B/Florida/04/06-like delNS1 virus reassortants
223791636|NCT01369862|BIOLOGICAL|Placebo|SPGNH buffer
223791637|NCT01478568|DRUG|mirabegron|oral
223791638|NCT01478568|DRUG|desipramine|oral
223791639|NCT04288908|OTHER|Cyberball experimental task|Cyberball is an experimental task in which participants have to pass a ball to two virtual players during 60 passes in total
223791640|NCT01587664|DEVICE|NewBreez ILP|NewBreez ILP implantation
223791641|NCT05291208|COMBINATION_PRODUCT|Combined tACS and Cognitive Training Program|The program contemplates 12 WM training sessions based on tasks of storage and manipulation of verbal and visuospatial information, with a frequency of twice a week during six weeks (total of 12 sessions). Patients will receive real electrical stimulation for 10 minutes during verbal working memory task. This includes 10s periods of phase-in and 10 s of phase-out and will be done in parallel with the cognitive intervention program in sessions 3, 4, 5, 6, 7, 8, 9, and 11. The electrical stimulation will be applied with two 3x1 arrays of electrodes. The central stimulation electrodes will be positioned in F3 and CP3 (10-20 system). The AC stimulation will be one mA from the baseline to the stimulation peak. The stimulation will have a gamma sine waveform (80Hz) over the positive phase of the theta oscillation (between 4 and 8 Hz, adjusted by each subject, Reinhart et al, 2019) phase-locked between arrays with impedances always under 10 kOhm.
223791642|NCT05291208|BEHAVIORAL|Traditional Cognitive Training Program|Participants will start a cognitive intervention program identical to the intervention group. Still, unlike the intervention group, they will receive placebo electrical stimulation, i.e., an electrical current will be applied for a short period at the beginning of the session (30 seconds), and then the stimulation will be stopped. This procedure induces a sensation in the skin similar to the real stimulation without generating a detectable impact on the brain state. They will be performed in parallel to the cognitive intervention program in sessions 1, 2, 3, 4, 5, 7, 9, and 10.
223791643|NCT01507870|PROCEDURE|onlay mesh placement|prophylactic onlay mesh in patients with median laparotomy
223791644|NCT04938895|BEHAVIORAL|Black Respondents Exposure to a Photo|Black survey respondents will be randomly assigned to one of four treatments. In each treatment arm, the subject will view a photo of an NIH investigator. We experimentally vary treatment along two dimensions: whether the investigator is a man v. woman and whether the man is white vs. black. We will survey participants' willingness to participate in a clinical trial and how their initial response is impacted by other characteristics such as perceived trustworthiness and quality.
223791645|NCT01713413|DEVICE|Oxymizer|Using first the Oxymizer and 24 h later the conventional nasal cannula.
223791646|NCT01713413|DEVICE|conventional nasal cannula|Using first the conventional nasal cannula and 24h later the Oxymizer
223791647|NCT06340269|DEVICE|MEX-CD1 Dialysis|"MEX-CD1 is a hyper-chelating colloidal solution that can be added to the dialysate to be used in Slow low-volume continuous veno-venous hemodialysis. One treatment will last 3 hours and 20 minutes.~Patients enrolled are hospitalized in Intensive Care Unit."
223791648|NCT00319098|BIOLOGICAL|Adjuvanted pandemic influenza candidate vaccine|2 doses, intramuscular injection
223791649|NCT00319098|BIOLOGICAL|Fluarix|One intramuscular injection
223791650|NCT00319098|BIOLOGICAL|Placebo|One intramuscular injection
223791651|NCT01528189|OTHER|Hyperinsulinemic normoglycemic clamp|Patients will receive an IV infusion of 2 mU/kg/min (0.12 U/kg/hour) starting in the operating room. Dextrose 20% will be titrated to maintain blood glucose between 4 and 6 mmol/l. At the end of surgery, the insulin infusion will be stopped and the dextrose infusion weaned off in the postanesthesia care unit.
223791652|NCT01528189|OTHER|Standard glucose management|Blood glucose levels will be treated by a standard insulin sliding scale.
223791653|NCT05178082|BEHAVIORAL|Educational Video-based Pain Program|Educational videos with 10 modules with information about pain.
223791654|NCT05178082|BEHAVIORAL|Empowered Relief Program|Educational online session for skills acquisition to manage pain. Empowered Relief TM by Beth Darnall ©2013-2022 Stanford University
223791655|NCT00965523|DRUG|Eribulin Mesylate|Eribulin mesylate 1.4 mg/m\^2 intravenous infusion (IV) given over 2 to 5 minutes on Day 1 and 8 every 21 days.
223791656|NCT01108653|OTHER|Usual care sick-leave management|Patients randomized to usual care. Follow up after discharge by general practitioner (GP) according to local practice.
223791657|NCT01108653|OTHER|Structuralised sick-leave program|Patients randomized to the structuralized program will get full time sick-leave for 2 weeks after discharge.Cardiologist will be responsible for individual adaption of each patient's sick-leave and follow-up.
223791658|NCT01762046|DRUG|Glipizide|
223791659|NCT01762046|DRUG|Metformin|
223791660|NCT01762046|OTHER|Oral Glucose Tolerance Test|
223791661|NCT04227782|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|Magnetic Resonance Imaging
223791662|NCT04227782|OTHER|Stable Isotope Study|Stable Isotope study
223791663|NCT00868023|DRUG|CHF 1535 Next DPI|CHF 1535 DPI : BDP/Formoterol : 100/6 µg (daily dose : BDP/Formoterol : 400/24 µg)
223791664|NCT00868023|DRUG|Foster BDP/Formoterol|BDP/Formoterol 100/6 µg (daily dose : BDP/Formoterol : 400/24 µg)
223791665|NCT00868023|DRUG|CHF 1535 Next DPI|CHF 1535 DPI : BDP/Formoterol : 100/6 µg (daily dose : BDP/Formoterol : 100/6 µg)
223791666|NCT00868023|DRUG|Foster BDP/Formoterol|BDP/Formoterol 100/6 µg (daily dose : BDP/Formoterol : 100/6 µg
223791667|NCT00868023|DRUG|Placebo|Placebo
223791668|NCT00408369|DRUG|DB289|
223791669|NCT04880304|OTHER|Soccer Heading|A standardized and reliable soccer heading protocol will be used for the experiment. A triaxial accelerometer embedded in a head-band pocket and positioned directly below the external occipital protuberance (inion) to monitor linear and rotational head accelerations. A JUGS soccer machine will be used to simulate a soccer throw-in with a standardized ball speed of 25mph. The ball speed is similar to when soccer players make a long throw-in from the sideline to mid-field. Soccer players frequently perform this maneuver during practice and games. Subjects will stand approximately 40ft away from the machine to perform the heading. Participants perform 20 standing headers with 1 header per 30 seconds. The subjects will be instructed to direct the ball back toward the JUGS soccer machine in the air.
223791670|NCT04880304|OTHER|Soccer Heading|A standardized and reliable soccer heading protocol will be used for the experiment. A triaxial accelerometer embedded in a head-band pocket and positioned directly below the external occipital protuberance (inion) to monitor linear and rotational head accelerations. A JUGS soccer machine will be used to simulate a soccer throw-in with a standardized ball speed of 25mph. The ball speed is similar to when soccer players make a long throw-in from the sideline to mid-field. Soccer players frequently perform this maneuver during practice and games. Subjects will stand approximately 40ft away from the machine to perform the heading. Participants perform 20 standing headers with 1 header per 30 seconds. The subjects will be instructed to direct the ball back toward the JUGS soccer machine in the air.
223791671|NCT02039050|DRUG|Tiotropium|
223791672|NCT02039050|DRUG|Aclidinium|
223791673|NCT01939028|PROCEDURE|lymph node mapping|Undergo lymph node mapping using isosulfan blue and/or indocyanine green solution
223791674|NCT01939028|PROCEDURE|sentinel lymph node biopsy|Undergo SLN biopsy
223791675|NCT01939028|DRUG|isosulfan blue|Undergo lymph node mapping using isosulfan blue and/or indocyanine green solution
223791676|NCT01939028|DRUG|indocyanine green solution|Undergo lymph node mapping using isosulfan blue and/or indocyanine green solution
223791677|NCT01939028|PROCEDURE|therapeutic conventional surgery|Undergo hysterectomy, bilateral salpingo-oophorectomy and/or complete pelvic lymphadenectomy
223791678|NCT01939028|PROCEDURE|lymphadenectomy|Undergo para-aortic lymphadenectomy
223791679|NCT06196762|DRUG|XKH002 Injection|240 mg/4 mL/vial（60 mg/mL）
223791680|NCT03600337|BEHAVIORAL|Working to Optimize Wellness in Tees with PCOS (WOW)|5 week, 75 minutes weekly, integrated mindfulness-based mental and physical health promotion intervention
223791681|NCT03282890|OTHER|CHRP-BB|The CHRP-BB intervention is a theory-based, manual-guided, HIV risk reduction and PrEP adherence intervention. It is an integrated evidence-based intervention that uses a coping skills training approach to primary prevention and is delivered in a small group modality by two trained intervention facilitators using a motivational enhancement therapeutic style to address high risk drug- and sex-related HIV risk behaviors and PrEP adherence. Importantly, the CHRP-BB intervention includes specific behavioral and mHealth strategies designed and tested to accommodate difficulties stemming from moderate to severe neuro-cognitive impairment (NCI).
223791682|NCT02955511|DEVICE|Blade MAC size 3|Patient will be intubated using the DL- Blade MAC size 3
223791683|NCT02955511|DEVICE|Blade MAC size 3.5|Patient will be intubated using the DL- Blade MAC size 3.5
223791684|NCT02955511|DEVICE|Inscope Blade size 3.5|Patient will be intubated using the Inscope Blade size 3.5
223791685|NCT01870141|BEHAVIORAL|Cognitive-Behavioral Intervention|"1 weekly individual 45 min-session for 24 weeks. The program comprises the following cognitive-behavioral strategies:~* self-monitoring~* problem solving~* goal definition~* cognitive restructuring~* activation of personal and social resources"
223791686|NCT02815553|PROCEDURE|Direct Transthoracic Cardiac Tumor Radio Frequency Ablation Therapy|
223791687|NCT02815553|PROCEDURE|Direct Transthoracic Cardiac Tumor Laser Ablation Therapy|
223791688|NCT03913741|DRUG|tisotumab vedotin|Tisotumab vedotin will be administered intravenously once every 21 days. The dose levels will be determined by the starting dose and the escalation steps taken in the trial
223791689|NCT05338788|OTHER|neck pain and dual task|"The Neck Disability Index (NDI) was used to assess neck pain related disability. The Biodex Balance System was used to assess postural control.Clinical test of sensory integration of balance (mCTSIB), athletic single leg test (ASLT), limits of stability (LOS), and fall risk assessment were performed with and without a cognitive task.In order to avoid the order bias of postural control measurements during Single-task and Dual-task for each case, the order of the measurements was determined by randomization on the first day by using sealed envelope method. After single/double task randomization was made, the order of tests was also randomized by using sealed envelopes containing two different orders (1-mCTSIB, 2-ASLT, 3-Fall test, 4-LOS and 1- LOS, 2- Fall test, 3- ASLT, 4-mCTSIB)."
223791690|NCT04789057|DRUG|Atorvastatin 40 Mg Oral Tablet|p.o., once daily
223791691|NCT04789057|DRUG|Placebo|p.o., once daily
223791692|NCT05774964|DRUG|Oxaliplatin|Oxaliplatin via intravenous drip on d1 at a dose of 130 mg/m2 × patient 's body surface area
223791693|NCT05774964|DRUG|S1|Orally on d2-d15 at 20 mg three times daily
223791694|NCT05774964|DRUG|Cetuximab|Cetuximab combined with chemotherapy was administered simultaneously, once every three weeks,and intravenous drip was performed before oxaliplatin at a dose of 250 mg/m2 × body surface area.
223791695|NCT05774964|DRUG|Metronidazole|Metronidazole 0.4g/time, qd
223791696|NCT05774964|DRUG|Vitamin A|Vitamin A 5,000 units/time, qd
223791697|NCT05774964|DRUG|Folic acid|Folic acid 5 mg/time, qd
223791698|NCT04282135|DIAGNOSTIC_TEST|MCC IMS|Diagnosis by MCC IMS
223791699|NCT00576069|DRUG|budesonide/formoterol|2 inhalations 2X/daily in treated arm/group. No placebo group
223791700|NCT00576069|DRUG|fluticasone/salmeterol|fluticasone 100ug/salmeterol 50ug, 1 inhalation bid noplacebo fluticasone 250ug/salmeterol 50ug, 1 inhalations bid no placebo Spiriva handihaler daily or respihaler 2 inhalations daily no placebo group
223791701|NCT00576069|DRUG|mometasone/formoterol|"200/5 mcg two puffs bid 100/5 mcg two puffs bid Breo Ellipta once daily Spiriva capsule handihaler once daily or Spiriva respihaler 2 in~no placebo group"
223791702|NCT00576069|DRUG|Prednisone|0-15 mg daily as needed
223791703|NCT05475951|DIAGNOSTIC_TEST|Biomarker measurement of pannexin-1 and gasdermin-D|These biomarkers were measured in the placental and adipose tissues of the participants.
223791704|NCT05984953|DRUG|statin|40 mg of rosuvastatin daily for 8-12 weeks
223791705|NCT05984953|DRUG|evolocumab|140 mg evolocumab every 2 weeks (26 weeks)
223791706|NCT00856050|DRUG|letrozole|Taken orally once a day continuously
223791707|NCT05447117|PROCEDURE|Micropulse laser|532 nm green subthreshold micropulse laser (GSML) as a treatment for acute central serous chorioretinopathy (CSCR).
223791708|NCT00737126|DRUG|Folic acid|Administration of a daily tablet containing 5 mg of folic acid for 4 months.
223791709|NCT00737126|DRUG|Placebo|Administration of an oral placebo pill
223791710|NCT02439710|OTHER|Quality of life measure (survey)|The QoL tool is a questionnaire
223791711|NCT05916690|DRUG|Electrochemotherapy with bleomycin or cisplatin|Combination of drug delivery platform (electroporation) and drug (bleomycin)
223791712|NCT03734627|DRUG|Octreotide Acetate|50mcg octreotide acetate by subcutaneous injection 10 minutes prior to a 400kcal mixed meal challenge
223791713|NCT03734627|DRUG|Saline Solution|Equivalent volume of 0.9% saline by subcutaneous injection 10 minutes prior to a 400kcal mixed meal challenge
223791714|NCT03734627|DRUG|Paracetamol|Paracetamol 1g by mouth consumed with a 400kcal mixed meal challenge
223791715|NCT03734627|DRUG|Sulfasalazine|1g sulfasalazine by mouth consumed with a 400kcal mixed meal challenge
223791716|NCT03734627|DIAGNOSTIC_TEST|Duodenal biopsy|Biopsy from the second part of the duodenum taken at routine endoscopic surveillance, undertaken for another clinical indication.
223791717|NCT01289912|DRUG|RAD001|"RAD001 is formulated as tablets of 5.0 mg strength, blister-packed under aluminum foil in units of 10 tablets and dosed on a regular basis. RAD001 tablets should be opened only at the time of administration as drug is both hygroscopic and light-sensitive.~Patients will be instructed to take 4.5 mg/m2 of RAD001 orally with a glass of water at regular intervals at the same time in the morning after a light, nonfat breakfast."
223791718|NCT01289912|DRUG|Placebo|"Matching placebo will be provided as a matching tablet and will also be blister packed under aluminum foil in units of 10. Matching placebo tablets should be opened only at the time of administration as drug is both hygroscopic and light-sensitive.~Patients will be instructed to take 4.5 mg/m2 of the matching placebo orally with a glass of water at regular intervals at the same time in the morning after a light, nonfat breakfast."
223791719|NCT02739438|OTHER|Electronic cigarette use|Subjects who use electronic cigarettes daily and have not used conventional cigarettes in the previous 3 months.
223791720|NCT02739438|OTHER|Cigarette use|Subjects who smoke at least ¼ pack cigarettes per day for the past 1 year, with no history of electronic cigarette use in the last 30 days.
223791721|NCT02739438|OTHER|Control group|Subjects with no history of prior conventional cigarette (\< 100 cigarettes lifetime) or electronic cigarette use.
223791722|NCT03568864|OTHER|Low nucleotide meal|The participants will consume a mixed meal (sandwich) containing a nucleotide depleted mycoprotein product (low in nucleotides)
223791723|NCT03568864|OTHER|High nucleotide meal|The participants will consume a mixed meal (sandwich) containing a non nucleotide depleted mycoprotein product (high in nucleotides)
223791724|NCT00862160|DEVICE|ROCsafeTM|using minimized perfusion circuit while CABG
223791725|NCT00232492|DRUG|Placebo males|Intravenous saline bolus (Placebo-control) males
223791726|NCT00232492|DRUG|Ketamine 0,1 mg/kg males|0,1 mg/kg ketamine iv bolus males
223791727|NCT00232492|DRUG|Ketamine 0,3 mg/kg males|0,3 mg/kg ketamine iv bolus males
223791728|NCT00232492|DRUG|Ketamine 0,5 mg/kg males|0,5 mg/kg ketamine iv bolus males
223791729|NCT00232492|DRUG|Placebo females|Intravenous saline bolus (Placebo-control) females
223791730|NCT00232492|DRUG|Ketamine 0,1 mg/kg females|0,1 mg/kg iv bolus ketamine females
223791731|NCT00232492|DRUG|Ketamine 0,3 mg/kg females|0,3 mg/kg iv bolus ketamine females
223791732|NCT00232492|DRUG|Ketamine 0,5 mg/kg females|0,5 mg/kg iv bolus ketamine females
223791733|NCT05525494|BEHAVIORAL|Text Fixed R/R Messages with Direct Appointment Schedule Link|Participants in this arm will receive up to 3 R/R messages by text. R/R message will be sent with a Direct Appointment Scheduling link and instructions to make a flu vaccine appointment.
223791734|NCT05525494|BEHAVIORAL|Text Pre-Appointment Reminder|Participants will receive a Pre-Appointment Reminder via text when they schedule a visit during the study period.
223791735|NCT05525494|BEHAVIORAL|Portal Pre-Commitment Prompt with Tailored R/R Messages with Direct Appointment Schedule Link|Participants in this arm will receive a pre-commitment prompt message by portal in September. Tailored R/R messages will be sent monthly by portal based on time and place selected by patients (up to 3). R/R message will be sent with a Direct Appointment Scheduling link and instructions to make a flu vaccine appointment.
223791736|NCT05525494|BEHAVIORAL|Portal Fixed R/R Messages with Direct Appointment Schedule Link|Participants in this arm will receive up to 3 R/R messages by portal. R/R message will be sent with a Direct Appointment Scheduling link and instructions to make a flu vaccine appointment.
223791737|NCT05525494|BEHAVIORAL|Portal Pre-Appointment Reminder|Participants will receive a Pre-Appointment Reminder advising them to ask their doctor for the flu vaccine at their upcoming appointment via portal when they schedule a visit during the study period.
223791738|NCT00762320|DRUG|Low dose Kaletra tablets|Lopinavir/Ritonavir tablets 100mg/25mg
223791739|NCT02566954|OTHER|3D measurement of the lower limb by EOS|"The intervention is to performed an additional radiologic exam by the EOS® system of imaging. This imaging is not usually realized for the patient.~3 dimensional study of lower limbs and feet of children in standing position will be performed using the EOS® system (EOS® Imaging, France)"
223791740|NCT00620841|OTHER|genotyping|Restriction fragment lenght polymorphisms
223791741|NCT03753165|OTHER|High intensity interval exercise|High intensity interval exercise at 80% of the maximal heart rate derived from the maximal graded exercise. Each individual will undergo 12 sessions of HIIE over a period of six weeks
223791742|NCT00398008|DRUG|Buprenorphine/Subutex|Opioid agonist medication to treat opiate dependence
223791743|NCT00398008|DRUG|Naltrexone|Opioid antagonist medication to treat opiate dependence
223791744|NCT00398008|BEHAVIORAL|Drug counseling|DC-HIV: Drug Counseling that provides education about HIV, drug abuse and dependence; encourages medication adherence; uses motivational enhancement techniques; encourages life style changes; and teaches cognitive and behavioral coping skills to prevent relapse
223791745|NCT05252767|BEHAVIORAL|Patient Engagement Tools|Experimental participants will receive the patient engagement tools or the educational guide after randomization. The participants in the experimental cohort will utilize the tools between visits with their clinic providers. During visits, clinic providers will review the completed tools with participants.
223791746|NCT05252767|BEHAVIORAL|Educational Guide|Control participants will receive a brief educational guide about pain management.
223791747|NCT01683864|DRUG|positive cytology with HIPEC|HIPEC with mytomycin and cisplatin
223791748|NCT03512665|DIETARY_SUPPLEMENT|Full dose supplement|A 7ml vial composed of a mixture of pine, macadamia and pomegranate oils.
223791749|NCT03512665|DIETARY_SUPPLEMENT|Low dose Supplement|A 7 mL vial composed of a mixture containing 50% study supplement (Pine, macadamia and pomegranate oils) and 50% sunflower oil.
223791750|NCT03512665|OTHER|Control Oil|A 7ml vial composed of sunflower oil with appearance and organoleptic properties similar to those of the supplement provided in the intervention groups.
223791751|NCT00867217|DIETARY_SUPPLEMENT|High Dose Vitamin D|High Dose Vitamin D3 (3 capsules of 10,000 IU) weekly for 24 weeks.
223791752|NCT00867217|DIETARY_SUPPLEMENT|Placebo|Placebo comparator
223791753|NCT00867217|DIETARY_SUPPLEMENT|Standard Dose Vitamin D3|Standard Dose Vitamin D3 (600 IU of vitamin D3 daily)
223791754|NCT00867217|DRUG|Letrozole 2.5mg|All subjects received letrozole as standard of care.
223791755|NCT01881126|DRUG|bimatoprost 0.01%|Bimatoprost 0.01% administered to both eyes once daily for 12 weeks.
223791756|NCT01881126|DRUG|travatan 0.004%|Travatan 0.004% administered to both eyes once daily for 12 weeks.
223791757|NCT01881126|DRUG|timolol 0.5%|Timolol 0.5% administered to both eyes once daily for 12 weeks.
223791758|NCT01881126|DRUG|hypromellose 0.3%|Hypromellose 0.3% lubricant eye drops (for masking purposes) administered to both eyes once daily for 12 weeks.
223791759|NCT00003954|DRUG|melphalan|Given IV
223791760|NCT00003954|PROCEDURE|autologous hematopoietic stem cell transplantation|Undergo autologous bone marrow or PBSCT
223791761|NCT00003954|PROCEDURE|autologous bone marrow transplantation|Undergo autologous bone marrow or PBSCT
223791762|NCT00003954|PROCEDURE|peripheral blood stem cell transplantation|Undergo autologous bone marrow or PBSCT
223791763|NCT00003954|RADIATION|total-body irradiation|Undergo TBI
223791764|NCT00003954|PROCEDURE|peripheral blood stem cell transplantation|Undergo donor PBSCT
223791765|NCT00003954|DRUG|cyclosporine|Given IV and PO
223791766|NCT00003954|DRUG|mycophenolate mofetil|Given PO
223791767|NCT00003954|BIOLOGICAL|therapeutic allogeneic lymphocytes|Undergo DLI
223791768|NCT06135337|DEVICE|Thioderm Elate|Test Device
223791769|NCT06135337|DEVICE|Juvéderm Ultra 3|Active Comparator Device
223791770|NCT06224452|DRUG|ibrutinib exposure|We will extract all atrial fibrillation cases involving adult patients associated with ibrutinib exposure with an available ibrutinib daily dose
223791771|NCT03776513|BEHAVIORAL|an MRI examination|The MRI examination implies the realization of an emotional associative memory task
223791772|NCT03993769|OTHER|A19010-F|A snus product
223791773|NCT03993769|OTHER|B19010-F|A snus product
223791774|NCT05656950|PROCEDURE|Assessment|Oral health of the patient was evaluated by the researcher using a flashlight, tongue depressor and Oral Evaluation Guide.
223791775|NCT01726868|DEVICE|Liposorber LA-15 System|Six sessions of blood purification treatment with Liposorber LA-15 System.
223791776|NCT00037219|DRUG|Anidulafungin, VER002|
223791777|NCT01298128|DRUG|NuvaRing|NuvaRIng 21 days for IVF pre-treatment.
223791778|NCT01298128|DRUG|marvelon|marvelon 21 daily
223791779|NCT01090453|BIOLOGICAL|GSK2202083A vaccine|3 doses given at 2, 4 and 12 months of age
223791780|NCT01090453|BIOLOGICAL|Prevenar 13®|3 co-administered doses
223791781|NCT01090453|BIOLOGICAL|Infanrix hexa™|3 doses given at 2, 4 and 12 months of age
223791782|NCT01090453|BIOLOGICAL|Menjugate®|3 co-administered doses
223791783|NCT01090453|BIOLOGICAL|Rotarix™|Oral, two doses
223791784|NCT02859857|DRUG|BXQ-350|BXQ-350 is a novel anti-neoplastic therapeutic agent configured from two components: Saposin C (SapC), an expressed (human) lysosomal protein, and the phospholipid dioleoylphosphatidyl-serine (DOPS), a phospholipid located on cell membranes. When both the components are assembled together stable SapC-DOPS nanovesicles are formed(clinical formulation BXQ-350).
223791785|NCT00149513|BEHAVIORAL|Targeted Case Management|A nurse case manager will assess and follow intervention arm subjects for six months. Nurse case manager will help subjects acquire needed community health services.
223791786|NCT00149513|BEHAVIORAL|Usual care|Participants will receive usual care.
223791787|NCT04730050|DRUG|TT-01025-CL|Oral tablet
223791788|NCT04072159|BEHAVIORAL|Community Pharmacists Vaccinating Against Cancer|Upon completing informed consent, parents of children who have received Dose 1 of the HPV vaccine at the recent clinical visit will be invited to participate in the study. Upon completing the demographic form and pre-test survey for the study, they will be randomized to intervention or control group. Participants in the intervention group will be asked to complete the additional vaccine doses with their community pharmacist. A provider from the participating clinic will electronically prescribe the HPV vaccine dose. Participants in the control group will be scheduled to return to the clinic (based on the vaccine schedule) to complete the vaccine series. The research team will conduct a follow-up survey six months after baseline for each participant. A sample (n=30) of intervention and control group participants will be invited to participate in an in-depth interview to gauge both parents' and children's' acceptability of this intervention.
223791789|NCT06230289|PROCEDURE|Transabdominal plane block|Patients agreeing to participate will be allocated to the control group (Group C, n=25) or the block group (Group B, n=25). The allocation will be randomized using a web-based data entry and randomization platform (by using envelope selection method) by an anesthesiologist not involved in the study. At the end of the surgery, patients in Group B will receive a four-point TAP block, while no interventional procedures will be performed on patients in Group C.
223791790|NCT02464449|BEHAVIORAL|Behavioral: AI-CBT|AI CBT engine will make recommendations to step-down or step-up intensity of CBT follow-up based on what patient reports and what other similar patients report. Stepped care model.
223791791|NCT02464449|BEHAVIORAL|Behavioral: Standard Telephone CBT|Controls receive 10 hour-long standard telephone CBT sessions, a pedometer/log after baseline, and a Patient Handbook.
223791792|NCT04474236|OTHER|thoracic lung ultrasound|Patients will be recruited the day of their hospital admission. All patients will be assessed by thoracic Computed Tomography scan then immediately before/after CT scan, patients will be clinically assessed (Q-SOFA, SpiO2/FiO2) and a lung ultrasound evaluation (mean time of evaluation 7 min +/- 3 min; fully respect of COVID-19 barrier measures) will be performed by an investigator. Patients clinical status and outcomes will be extracted from patient's medical file at day 1 and day 28 from patient's admission by investigators blinded from previously recorded lung ultrasound data.
223791793|NCT01177904|OTHER|Cease progsterone at 5|Cease administration of progsterone at first US at 5 weeks
223791794|NCT01177904|OTHER|control group: progesterone 8|Control group: progesterone until 8 weeks of pregnancy
223791795|NCT00522275|DRUG|lacosamide|50mg or 100 mg tablets, up to 800 mg/day given twice daily (BID) throughout the trial
223791796|NCT03536806|DRUG|Saline 0.9%|Patients assigned to control group will be administered saline 0.9% in bolus of 10 cm3 within 2-3 minutes. BP will be measured before injection.
223791797|NCT03536806|DRUG|Canrenone|Patients assigned to canrenone group will be administered canrenone in bolus of 200 mg diluted to 10 cm3 within 2-3 minutes in one dose. Drug administration will be stopped in case of serious adverse event. Further treatment of the patient will depend on clinical condition and will follow appropriate clinical guidelines.
223791798|NCT01371344|DRUG|Tacrolimus granules|oral
223791799|NCT01371344|DRUG|Tacrolimus capsules|oral
223791800|NCT00832273|DEVICE|ELAD®|liver assist system
223791801|NCT02666950|DRUG|Cytarabine|Given SC
223791802|NCT02666950|OTHER|Laboratory Biomarker Analysis|Correlative studies
223791803|NCT02666950|OTHER|Pharmacological Study|Correlative studies
223791804|NCT02666950|OTHER|Quality-of-Life Assessment|Ancillary studies
223791805|NCT02666950|OTHER|Questionnaire Administration|Ancillary studies
223791806|NCT02666950|DRUG|WEE1 Inhibitor AZD1775|Given PO
223791807|NCT00208416|PROCEDURE|DePuy MI System|A minimally invasive surgical technique used in total hip replacement.
223791808|NCT00208416|PROCEDURE|Conventional surgical technique|A conventional surgical technique used in total hip replacement
223791809|NCT04984148|DIAGNOSTIC_TEST|CT|Contrast-enhanced thoracic computed tomography
223791810|NCT02567084|DEVICE|"CERAMENT™ |BONE VOID FILLER"|Implantation of bi-phasic ceramic bone substitute to provide bone generation and bone remodeling in patients with benign bone tumors.
223791811|NCT00695669|BIOLOGICAL|Influenza A (H5N1) Virus Monovalent Vaccine|Two doses administered intramuscularly (IM), the first in the deltoid region of the non-dominant arm and the second in the deltoid region of the dominant arm.
223791812|NCT02351531|DIETARY_SUPPLEMENT|Extensively Hydrolyzed formula|
223791813|NCT05045625|DEVICE|HD Study Electrode|The HD Study Electrode is an array of 8 columns of stimulation contacts arranged in 8 rows with a low-volume electrode body. This array of stimulation electrodes contact patterns of bi-poles and tri-poles may be applied to the spinal cord for assessment of dermatomal selective stimulation patterns.
223791814|NCT06180824|DRUG|Gelafundin|"Insulin will be diluted with gelafundin colloid fluid in 50mls syringe and tubing (same product manufacturer).~Blood glucose level will be taken from arterial line at presentation or prior to start insulin and checked using glucometer. Then, at 2 hour and 6 hours after initiation of treatment."
223791815|NCT00092131|DRUG|Comparator: Montelukast|Montelukast 10 mg tablet administered orally as a single witnessed dose before exercise challenge
223791816|NCT00092131|DRUG|Comparator: Placebo|Placebo tablet administered orally as a single witnessed dose before exercise challenge
223791817|NCT02341417|DRUG|Cinacalcet|Cinacalcet was provided as 5 mg capsules for sprinkling or as 30 mg film-coated tablets for swallowing. The protocol-specified doses were: 1, 2.5, 5, 7.5, 10, 15, 30, 60, 90, 120, and 180 mg.
223791818|NCT04494152|DIAGNOSTIC_TEST|Transthoracic echocardiography|Standard Point-of-Care echocardiographic examination in the intensive care unit.
223791819|NCT00109538|DRUG|Lonafarnib|200 mg twice daily (BID, ie, approximately 12 hours apart with food), oral, continuously, or until unacceptable toxicity or transformation to AML, or disease progression, or other discontinuation criteria
223791820|NCT00109538|OTHER|Placebo|BID, oral, continuously, or until unacceptable toxicity or transformation to AML, or disease progression, or other discontinuation criteria
223791821|NCT04087538|DIAGNOSTIC_TEST|Troponin T and I|Does the use of troponin T or I increase the number of patients referred to coronary angiography
223791822|NCT02512575|DRUG|AZD9567 Monohydrat|AZD9567 oral suspension 0.5 to 10 mg/ml
223791823|NCT02512575|DRUG|Placebo oral suspension/ Placebo capsule|Matching placebo
223791824|NCT02512575|DRUG|Prednisolone|Prednisolone 60mg oral capsules (12 capsules of 5 mg each).
223791825|NCT03549650|DRUG|Pentosan Polysulfate Na 100Mg Cap|"Participants will be randomly assigned to receive Pentosan Polysulfate Na 100Mg Cap TID for 6 weeks.~For blinded distribution, each bottle of medications will be labeled with a random number for identification.~The study participants will be monitored every 2 weeks with phone calls from the study team to evaluate their condition and decide if the medication is tolerated and whether it should be continued or stopped."
223791826|NCT03549650|DRUG|Placebo oral capsule|"Participants will be randomly assigned to receive Placebo oral capsule TID for 6 weeks.~For blinded distribution, each bottle of medications will be labeled with a random number for identification.~The study participants will be monitored every 2 weeks with phone calls from the study team to evaluate their condition and decide if the medication is tolerated and whether it should be continued or stopped."
223791827|NCT04602533|DRUG|Durvalumab|Induction phase: Durvalumab (1500 mg once every 3 weeks) for 4-6 cycles in combination with standard of care (Radiochemotherapy) Maintenance phase: Durvalumab (1500 mg once every 4 weeks) until PD or unacceptable toxicities.
223791828|NCT04602533|DRUG|standard of care|"Radiochemotherapy: Cisplatin (75 mg/m² (BSA) D1#) or alternatively Carboplatin (AUC 5 D1) and Etoposide (100 mg/m² (BSA) D1-3) once every 3 weeks for 4-6 cycles and concomitant Radiotherapy (60±6 Gy, 1.8-2 Gy/d or 45±1.5 Gy (1.5 Gy per fraction twice daily, with 4 hours or more between fractions) with start at latest at beginning of cycle 3, ideally during cycle 1) followed by prophylactic cranial irradiation (PCI, if clinically indicated and according to local standard at any time after completion of radio-chemotherapy))~A simultaneous administration of platinum-based chemotherapy (preferred Cisplatin) and radiotherapy for at least 2 cycles should be performed."
223791829|NCT04298138|BIOLOGICAL|Dengue virus 3 Live Virus Human Challenge (DENV-3-LVHC)|Dengue subtype 3 Challenge Virus (DENV-3) strain CH53489 administered as a single injection.
223791830|NCT05224414|BEHAVIORAL|Cognitive bias modification for interpretation bias|Sessions of scenario-based CBM-I training for OCD will be administered, based on the widely-used paradigm of ambiguous scenario training developed by Mathews and Mackintosh (2000), in which participants are presented with scenarios that are ambiguous in whether or not they are threatening. Participants will complete a computer task consisting of a series of written scenarios designed to improve interpretation and attributional biases; these scenarios conclude with word fragments, which participants must fill in to resolve the ambiguity.
223791831|NCT05224414|BEHAVIORAL|Psychoeducation|Sessions of psychoeducation will be administered, which will describe symptoms of anxiety, the nature of biased thinking in anxiety, and summarize common psychosocial as well as pharmacological treatments for anxiety. The sessions will provide relevant information but will not provide training in changing thinking styles.
223791832|NCT03335462|OTHER|Paravertebral injections|Paravertebral injections will be performed in the thoraco-lumbar plexus area under CT guidance
223791833|NCT03335462|OTHER|CT scan|CT scan will be performed as the needles are kept in their position after injecting the contrast
223791834|NCT04051346|DIETARY_SUPPLEMENT|Low Oxalate Diet|Participants will consume a diet that is controlled in its daily contents of oxalate and calcium, and in its content of carbohydrate, fat, and protein. Participants will be asked not to take any dietary supplements, to exercise strenuously, or to consume food or drink that is not provided to them
223791835|NCT04051346|DIETARY_SUPPLEMENT|High Oxalate Diet|Participants will consume a diet that is controlled in its daily contents of oxalate and calcium, and in its content of carbohydrate, fat, and protein. Participants will be asked not to take any dietary supplements, to exercise strenuously, or to consume food or drink that is not provided to them.
223791836|NCT04819269|DRUG|Tivanisiran sodium ophthalmic solution|1 drop in the affected eye(s) once daily
223791837|NCT04819269|DRUG|Vehicle ophthalmic solution|1 drop in the affected eye(s) once daily
223791838|NCT04060394|DRUG|Phase I and Phase II: LAE001/prednisone + afuresertib|In the Phase I portion of the study will identify the RPD2 of the combined therapy. In the Phase II will evaluate LAE001/prednisone + afuresertib at the RP2D (Cohort 1) and docetaxel/prednisone + afuresertib (Cohort 2).
223791839|NCT05583591|DEVICE|Combined cataract surgery with Hydrus microstent|Device designed to help lower intraocular pressure by improving aqueous outflow through the trabecular meshwork. Used in combination with cataract surgery.
223791840|NCT05583591|DEVICE|Combined cataract surgery with iStent Inject W|Device designed to help lower intraocular pressure by improving aqueous outflow through the trabecular meshwork. Used in combination with cataract surgery.
223791841|NCT02964845|BEHAVIORAL|WISH with CHW and referral to HFM|6 intervention counseling sessions with a peer CHW, as well as CHW facilitated linkage to primary care and HIV risk reduction.
223791842|NCT02964845|OTHER|Enhanced Treatment as Usual|Linkage to Primary care.
223791843|NCT01047839|BIOLOGICAL|IC51|0.25 ml, 2 i.m. vaccinations at Day 0 and 28
223791844|NCT01047839|BIOLOGICAL|IC51|0.5 ml, 2 i.m. vaccinations at Day 0 and 28
223791845|NCT01047839|BIOLOGICAL|IC51|0.5 ml, 2 i.m. vaccinations at Day 0 and 28
223791846|NCT06338696|OTHER|No intervention|No intervention
223791847|NCT06175065|DRUG|RLS-0071|RLS-0071, will be administered as an IV infusion 10 mg/kg. Planned infusion duration is 8 minutes.
223791848|NCT06175065|DRUG|Placebo|Placebo control (commercial sterile saline), will be administered as an IV infusion. Planned infusion duration is 8 minutes.
223791849|NCT06437769|OTHER|reiki|effect of reiki application to women who have been hospitalized by ceserean during the hospitlalization process on anxiety depression comfort and breastfeesing
223791850|NCT05414682|OTHER|MIND+SOUL Diet|The MIND+SOUL Diet is an adapted brain-healthy soul food diet.
223791851|NCT01857531|DRUG|Ganaxolone|"Pre-Quit Period:~Beginning at Session P1, subjects will receive ganaxolone at a dose of 400mg total daily (200mg bid) for the first three days, 800mg total daily (400mg bid) for the next three days and 1200mg total daily (600mg bid) for the remainder of the first four weeks.~Post-Quit Period:~Following the quit-day, subjects will receive ganaxolone at a dose of (1200mg total daily) for the next week. Down-titration of ganaxolone will begin at post-quit week two. Subjects will receive ganaxolone at a dose of 800mg total daily (400mg bid) to take for three days and 400mg total daily (200mg bid) to take for three."
223791852|NCT01857531|DRUG|Nicotine Patch|"Pre-Quit Period:~Beginning at Session P2, subjects will receive active 21mg/24h nicotine patches to apply daily for the next two weeks.~Post-Quit Period:~Following the quit-day, subjects will continue to apply active nicotine patches daily for the remainder of the study (21mg/24h for four weeks, 14mg/24h for one week, and 7mg/24h for one week)."
223791853|NCT06073574|DIAGNOSTIC_TEST|Cardiac MRI|MRI Scans as specified in the corresponding arm group.
223791854|NCT06565507|DRUG|Oxfendazole single dose|Subjects will receive active oxfendazole, 20 mg/kg/day, orally, as a single dose. Oxfendazole placebo will be used at days 4 and 7 to maintain blinding between the two intervention arms.
223791855|NCT06565507|DRUG|Oxfendazole three doses|Subjects will receive active oxfendazole, 20 mg/kg/day, orally, in three days (1, 4 and 7)
223791856|NCT06565507|DRUG|albendazole plus praziquantel regime|Subjects will receive a combination of albendazole plus praziquantel, as a standard treatment for brain cysticercosis (neurocysticercosis), orally, for ten days. Albendazole will be given at 15/kg/d and praziquantel at 50/kg/d.
223791857|NCT02814318|BIOLOGICAL|Vaginal and rectovaginal swab cultures|The only intervention that will occur in this study is obtaining vaginal and recto-vaginal swab cultures upon admission to the labor and delivery room and every two hours to follow until 8 hours after administration of IV vancomycin or IV penicillin.
223791858|NCT06966388|DRUG|Azelaic Acid|A thin layer of Azelaic acid should be applied to the entire area of radiation treatment twice daily, each day of the week (including weekends) starting one week prior to the start of radiation, then during the entire course of radiation treatment (usually 3-5 weeks), and for 3 weeks following the completion of radiation treatment.
223791859|NCT05388903|DRUG|DS-2325a|Subcutaneous injection (starting dose 30 mg)
223791860|NCT05388903|DRUG|DS-2325a|Intravenous infusion (starting dose 100 mg)
223791861|NCT05388903|DRUG|Placebo|Subcutaneous injection
223791862|NCT05388903|DRUG|Placebo|Intravenous infusion
223791863|NCT05054023|DRUG|Soulagel®|topic gel
223791864|NCT05054023|DRUG|Arthrosyl®|topic gel
223791865|NCT05914610|DRUG|Envolimab|Envolizumab 300mg, D1, ih, Q3W 4-6cycles
223791866|NCT05914610|DRUG|Fruquintinib|Fruquinitinib 3mg/d, QD, PO, D1-D14, Q3W 4-6cycles
223791867|NCT05914610|DRUG|Oxaliplatin|Oxaliplatin 130 mg/m2, ivgtt 0-2h, D1, Q3W 4-6cycles
223791868|NCT05914610|DRUG|Tegafur|Tegafur was calculated according to body surface area , P.O., bid, d1-d14#And the dosage according body surface area:\<1.25m2, 40mg every time;1.25-1.5m2,50mg every time; \>1.5m2, 60mg every time Q3W 4-6cycles
223791869|NCT05665777|DRUG|Qingyan Lihou Decoction|Chinese medicine granules
223791870|NCT05665777|OTHER|Placebo|Placebo granules
223791871|NCT02576067|DRUG|Low dose methotrexate|Study participants will additionally receive 1 mg daily oral folate.
223791872|NCT02576067|DRUG|Placebo|
223791873|NCT04987515|PROCEDURE|fenestration decompression combined with secondary curettage|First，fenestration decompression was performed. then, patients return every 3 months for follow up. If the cystic cavity area was gradually reduced after one year of follow-up, patients should be considered for secondary curettage surgery.
223791874|NCT02726451|OTHER|Basic Skin Care|Facial Wash, Hydrator Plus Broad Spectrum SPF 30, and Rebalance skin care products (PCA SKIN®)
223791875|NCT02726451|OTHER|Active Skin Care|Sensi Peel®, Rejuvenating Serum, and C\&E Strength Max skin care products (PCA SKIN®) in addition to the Facial Wash, Hydrator Plus Broad Spectrum SPF 30, and Rebalance skin care products (PCA SKIN®)
223791876|NCT02089672|DEVICE|Catheter ablation|This is observational trial studying the effects of a standard intervention of a catheter ablation procedure.
223791877|NCT06537453|OTHER|Virtual Care|Participants will go through Virtual hospital programs following the processes established by these programs in Alberta.
223791878|NCT06540443|DRUG|MPB-2043 of 0.5 mg/kg|Participants will undergo MRI scans without the administration of a contrast agent (unenhanced MRI) and IV-infused MPB-2043 for 1 hour.
223791879|NCT06540443|DRUG|MPB-2043 of 1.0 mg/kg|Participants will undergo MRI scans without the administration of a contrast agent (unenhanced MRI) and IV-infused MPB-2043 for 1 hour.
223791880|NCT06540443|DRUG|MPB-2043 of 2.0 mg/kg|Participants will undergo MRI scans without the administration of a contrast agent (unenhanced MRI) and IV-infused MPB-2043 for 1 hour.
223791881|NCT06540443|DRUG|MPB-2043 of 3.0 mg/kg|Participants will undergo MRI scans without the administration of a contrast agent (unenhanced MRI) and IV-infused MPB-2043 for 1 hour.
223791882|NCT06101199|OTHER|Acute Intermittent Hypercapnic Hypoxia|15 x \[1 min 9% O2, 4% CO2, and balance N2, followed by 1.5 min normoxia\];
223791883|NCT06101199|OTHER|Transcutaneous spinal cord stimulation|Open-loop, continuous, high-frequency electrical stimulation at 150 Hz with a tolerable current amplitude of \~25-35 mA and a pulse width of 400 µsec, using a biphasic symmetric waveform. Paired with Respiratory Resistance Training and Hand Grip Strength Training.
223791884|NCT06101199|OTHER|SHAM Acute Intermittent Hypercapnic Hypoxia|Normoxia for the amount of time AIHH is delivered.
223791885|NCT06101199|OTHER|SHAM Transcutaneous spinal cord stimulation|"Open-loop, continuous, high-frequency electrical stimulation at 150 Hz with a tolerable current amplitude of 0mA and a pulse width of 400 µsec,using a biphasic symmetric waveform.~Paired with Respiratory Resistance Training and Hand Grip Strength Training."
223791886|NCT04429607|DEVICE|Erbium:YAG Laser|Erbium:YAG 2940nm will be performed using single spot, multiple pulses on lesions.
223791887|NCT04429607|DEVICE|Pulsed Dye Laser|PDL will be performed using settings of 6-10 J/s2 on lesions.
223791888|NCT04429607|DEVICE|Nd:YAG Laser|Nd:YAG 1064nm will be performed using settings of 60-110 J/s2 on lesions.
223791889|NCT04429607|PROCEDURE|Electrodessication and curettage|Electrodessication and curettage will be performed using an epilating needle, followed by curettage on lesions.
223791890|NCT05758753|DEVICE|Quantitative Sensory Test|Quantitative Sensory Test (Medoc Ltd, Israel), QST is a non-invasive neurophysiological method that refers to a group of procedures that assess the perceptual responses to systematically applied and quantifiable sensory stimuli (modalities including heat, cold and vibration) for the purpose of characterizing somatosensory function or dysfunction. For this test, subjects will be seated comfortably on a chair in a quiet room, or laying supine in a horizontal examination chair, with ambient temperature of 24-25◦ C. Medial upper eyelid; just below the supraorbital notch, nasolacrimal sac area; 4-5 mm medial to nasal cantus, and non-dominant forearm will be used as test sites. Patients will be instructed in detail of the nature of the test and the need to react attentively and promptly to change in temperatures.
223791891|NCT04039672|PROCEDURE|Skin biopsy|5mm skin metastasis or primary melanoma biopsy
223791892|NCT05353283|BEHAVIORAL|Motivational Interviewing Counselling|Motivational interviewing-based counseling will be provided to the participant based on the results of the urine test
223791893|NCT05353283|DEVICE|Point-of-care Urine Tenofovir Measurement|Urine will be collected and the presence or absence of tenofovir will be measured with the point-of-care urine tenofovir test.
223791894|NCT04773587|DRUG|Roflumilast Cream 0.15%|Roflumilast Cream 0.15% - Active
223791895|NCT04773587|DRUG|Vehicle Cream|Cream - Vehicle
223791896|NCT06495684|DEVICE|Anodal tDCS + Social Learning|Anodal tDCS lowers neuronal membrane potentials, leading to increased probability of depolarization from incoming stimuli.
223791897|NCT06495684|BEHAVIORAL|Placebo Anodal tDCS + Social Learning|Social learning tasks are completed on a computer and consist of viewing video modeling of social interactions, facial emotion detection practice, and videos for emotion and empathy learning.
223791898|NCT06333678|DRUG|Durvalumab|10 mg/kg IV every 2 weeks or 1500 mg/kg IV every 4 weeks for up to 12 months.
223791899|NCT06333678|DRUG|Sotorasib|960 mg, Patients who do not tolerate sotorasib at 960 mg can be dose reduced to 120 mg.
223791900|NCT05784350|DRUG|fluid boluses guided by IVC diameter via US/administration of pre-operative IV Odansetrone|"group A will undergo fluid repletion guided by their IVC-CI - if a collapsible IVC, defined as a CI equal or greater than 43%, is observed, patients will receive repeated Lactated Ringer's 500 ml boluses followed by repeated IVC-CI measurements until their CI is less than 43%, and up to 1.5L.~Group B will undergo the same intervention, with the addition of intravenous ondansetron 4 mg in 10 ml normal saline 20 minutes before induction of general anesthesia."
223791901|NCT06850389|DEVICE|ChitoCare® medical Wound Healing Gel|ChitoCare® medical Wound Healing Gel is a medical device containing ChitoClear® chitosan. The device is indicated for the treatment of acute and chronic wounds and other skin conditions, including partial thickness burn wounds.
223791902|NCT06850389|DEVICE|ChitoCare® medical Healing Spray|ChitoCare® medical Healing Spray is a medical device containing ChitoClear® chitosan. The device is indicated for the treatment of acute wounds and other skin conditions.
223791903|NCT05808309|OTHER|Salivary sampling|Salivary sampling for genomic material (DNA and RNA (for primary outcome measures); proteins and DNA methylation (for secondary outcome measures)
223791904|NCT02372409|DEVICE|MRI-guided laser ablation|
223791905|NCT02372409|DRUG|Doxorubicin|
223791906|NCT02372409|DRUG|Etoposide|
223791907|NCT02372409|DEVICE|Dynamic contrast-enhanced (DCE) MRI|
223791908|NCT02372409|DEVICE|Dynamic susceptibility contrast (DSC) MRI|
223791909|NCT01204892|PROCEDURE|TAP Block|Patient will received bilateral ultrasound-guided TAP block with total of 30 ml of ropivacaine 0.5% after induction of general anesthesia
223791910|NCT01204892|PROCEDURE|Local infiltration|20 ml of Ropivacaine 0.5% will be injected at port sites after induction of general anesthesia. 7 ml each for 10 mm ports, 3 ml each of 5 mm ports
223791911|NCT04989790|OTHER|PICU Up!|PICU Up! incorporates the screening process for determining a patient's appropriate activity level into the daily rounding workflow for all PICU patients, with a tiered activity plan based on clinical parameters to individualize goals based on each child's unique needs. While the patient's PICU Up! level is based on objective criteria, the interprofessional team collectively determines the daily activity goal(s) through shared decision-making which is documented in the medical record on morning rounds. The intervention facilitates daily discussion of 1) analgesia; 2) extubation readiness testing; 3) sedation level and goal; 4) delirium screening and management; 5) mobility goal including physical and occupational therapy consultation by PICU Day 3; 6) sleep promotion; and 7) family engagement in mobility.
223791912|NCT05004324|BIOLOGICAL|FURESTEM-AD® inj. 5.0 X 10^7 cells/1.5 mL|the following study drug is injected respectively into both upper arms, both thighs, and abdomen (total of 5 regions)
223791913|NCT05004324|BIOLOGICAL|Placebo|the following study drug is injected respectively into both upper arms, both thighs, and abdomen (total of 5 regions)
223791914|NCT05977140|DRUG|CDI-988|SARS-CoV-2 3CL protease inhibitor
223791915|NCT05977140|DRUG|Placebo|matching placebo
223791916|NCT04457648|DEVICE|manuka honey 16% eye drops ( Optimel )|16% manuka honey eye drops, australian FDA approved
223791917|NCT04457648|DEVICE|systane eye drops|systane lubricant eye drops
223791918|NCT05932693|OTHER|E-liquid coolant (WS-3, 0.05%)|Adult users of e-cigarette will be exposed to five e-liquid coolants WS-3: 0.05%.
223791919|NCT05932693|OTHER|E-liquid coolant (WS-3, 0.1%)|Adult users of e-cigarette will be exposed to five e-liquid coolants WS-3: 0.1%.
223791920|NCT05932693|OTHER|E-liquid coolant (WS-3, 0.5%)|Adult users of e-cigarette will be exposed to five e-liquid coolants WS-3: 0.5%.
223791921|NCT05932693|OTHER|E-liquid coolant (WS-3, 1.0%)|Adult users of e-cigarette will be exposed to five e-liquid coolants WS-3: 1.0%.
223791922|NCT05932693|OTHER|E-liquid coolant (WS-3, 2.0%)|Adult users of e-cigarette will be exposed to five e-liquid coolants WS-3: 2.0%.
223791923|NCT05932693|OTHER|E-liquid coolant (menthol, 0.05%)|Adult users of e-cigarette will be exposed to five e-liquid coolants menthol: 0.05%.
223791924|NCT05932693|OTHER|E-liquid coolant (menthol, 0.1%)|Adult users of e-cigarette will be exposed to five e-liquid coolants menthol: 0.1%.
223791925|NCT05932693|OTHER|E-liquid coolant (menthol, 0.5%)|Adult users of e-cigarette will be exposed to five e-liquid coolants menthol: 0.5%.
223791926|NCT05932693|OTHER|E-liquid coolant (menthol, 1.0%)|Adult users of e-cigarette will be exposed to five e-liquid coolants menthol: 1.0%.
223791927|NCT05932693|OTHER|E-liquid coolant (menthol, 2.0%)|Adult users of e-cigarette will be exposed to five e-liquid coolants menthol: 2.0%.
223791928|NCT05932693|OTHER|E-liquid coolant (WS-23, 0.05%)|Adult users of e-cigarette will be exposed to six e-liquid coolants WS-23: 0.05%.
223791929|NCT05932693|OTHER|E-liquid coolant (WS-23, 0.1%)|Adult users of e-cigarette will be exposed to six e-liquid coolants WS-23: 0.1%.
223791930|NCT05932693|OTHER|E-liquid coolant (WS-23, 0.5%)|Adult users of e-cigarette will be exposed to six e-liquid coolants WS-23: 0.5%.
223791931|NCT05932693|OTHER|E-liquid coolant (WS-23, 1.0%)|Adult users of e-cigarette will be exposed to six e-liquid coolants WS-23: 1.0%.
223791932|NCT05932693|OTHER|E-liquid coolant (WS-23, 2.0%)|Adult users of e-cigarette will be exposed to six e-liquid coolants WS-23: 2.0%.
223791933|NCT05932693|OTHER|E-liquid coolant (WS-23, 4.0%)|Adult users of e-cigarette will be exposed to six e-liquid coolants WS-23: 4.0%.
223791934|NCT01808313|DRUG|ambrisentan|Ambrisentan 5 mg will be administered to eligible subjects for 12 weeks
223791935|NCT00054535|BIOLOGICAL|aldesleukin|
223791936|NCT00054535|BIOLOGICAL|recombinant fowlpox-tyrosinase vaccine|
223791937|NCT00054535|BIOLOGICAL|vaccinia-tyrosinase vaccine|
223791938|NCT02759159|PROCEDURE|true acupuncture|"acupuncture at the four-gateacupoints, three times per week and last for 6 months"
223791939|NCT02759159|PROCEDURE|sham acupuncture|"acupuncture at the places 1cm from the true four-gate acupoints,three times per week and last for 6 months"
223791940|NCT00733317|DRUG|0.5 mg/ml budesonide nebules|Children will receive 0.5 mg/ml budesonide nebules every 20 minutes for 3 times
223791941|NCT00733317|DRUG|Saline|Children will receive 2 ml of saline every 20 minutes for 3 times
223791942|NCT00477191|DRUG|Etanercept|TNF-alpha antagonist 50 mg twice a week x 3 mos and the 50 mg once a week for 3 months.
223791943|NCT01211626|DRUG|ANA773|ANA773 Tosylate Capsule
223791944|NCT01211626|DRUG|Placebo|Matching Placebo Capsule
223791945|NCT01116570|OTHER|Physical training|Physical training during 24 weeks
223791946|NCT01116570|OTHER|Control|No intervention
223791947|NCT00251810|DEVICE|Cerebral State Monitor|All patients monitored with BIS and CSM, results hidden for the anesthesiologist.
223791948|NCT01289067|DRUG|Satraplatin|Satraplatin 80mg/m2 day 1-5 every 35 days Prednisone 5 mg twice daily every 35 days
223791949|NCT02399579|OTHER|Provocation test|The participants will perform 8 provocation tests. Every provocation test consists of petting the cat until the participants become symptomatic. The symptoms of cat allergic participants with the cat owner's cat will be recorded before and after petting the cat.
223791950|NCT05814523|DRUG|Ganaxolone|Ganaxolone will be administered as IV solution.
223791951|NCT05814523|DRUG|Placebo|Placebo will be administered as IV solution.
223791952|NCT05814523|DRUG|Standard of care|A non-anesthetic medication not previously used for treatment of SE within the current episode and will be administered at a dose sufficient for the termination of SE according to investigator judgment.
223791953|NCT04656847|DRUG|in daily everyday routine practice|patients with HTN and CAD treated with the the single pill combination bisoprolol/perindopril for 12 weeks in the daily clinical practice Retrospective screening and evaluation of patient's eligibility to inclusion/ exclusion criteria for entering the study allows mitigating a potential risk of deliberative medicine administration within the observational program.
223791954|NCT03506971|OTHER|Psychologist's evaluation|The research coordinator psychologist will evaluate: the development of the baby, the early interactions between the baby and his mother, attachment, maternal psychiatric symptoms, the experience of parenting and maternal sensitivity.
223791955|NCT03506971|OTHER|Pediatric Nurse's interventions|"Pediatrics nurses perform preventive home visits that are based on : joint observation with the parents of the baby, play with the baby and his parents, interview with the parents on their parenthood~Rhythm of home visits:~* 1 every month from birth to 1 year~* 1 every 2 months from 1 year to 2 years~* 1 every 3 months from 2 years to 4 years"
223791956|NCT03506971|OTHER|Joint home visits|"Coordinating psychologist and the referent pediatric nurse will perform home visits. During this time, the psychologist evaluate : the development of the baby, the early interactions between the baby and his mother, attachment, maternal psychiatric symptoms, the experience of parenting and maternal sensitivity.~Rhythm of joint home visits:~* 1 at 4 months~* 1 at 24 months"
223791957|NCT01737580|DRUG|resiquimod|
223791958|NCT01737580|DRUG|placebo gel|
223791959|NCT06470529|DEVICE|drug eluting stents|different types of drug eluting stents
223791960|NCT06427226|DRUG|Dapagliflozin 10mg Tab|Dapagliflozin 10 mg tab once daily given during the duration of AC cycles.
223791961|NCT03301051|BIOLOGICAL|Quadrivalent VLP Vaccine|Single dose of a 30 µg/strain of Quadrivalent VLP Vaccine
223791962|NCT03301051|BIOLOGICAL|Placebo|Single dose of a Placebo
223791963|NCT02042235|BEHAVIORAL|Parent-implemented intervention|In order to achieve the programme of parent-implemented language intervention, a detailed protocol for speech therapists recruited and trained for the present study has been established. The techniques and attitudes favouring use of oral language will be taught to the parents during 15 sessions with the parent(s) and child.
223791964|NCT05229692|DEVICE|NEUBIE|"Participants will be asked to undergo electrical stimulation with the NEUBIE at their treatment threshold. Treatment threshold will be described as uncomfortable, but not painful (a 7 out of 10 on a perceived intensity scale).~Session length: ≤ 30 minutes Treatment frequency: 2x per week for 5 weeks~Week 1 post-op (treatments 1-2) Activity: Passive Neubie on Abdominals \& Obliques~Weeks 2-3 (treatments 3-6)~* Passive Neubie~* Isometric movements with Neubie on abdominals and obliques~* Active mobilizations with Neubie on abdominals and obliques~Weeks 4-5 (treatments 7-10)~* Active mobilizations with Neubie on abdominals and obliques~* Core Strength Exercise circuit with Neubie on abdominals and obliques"
223791965|NCT06463288|PROCEDURE|Jacobsons Breathing Technique|Quality of life, cough and sputum analysis, spirometry, and shortness of breath were assessed.
223791966|NCT06463288|PROCEDURE|Pranayama Technique|Quality of life, cough and sputum analysis, spirometry, and shortness of breath were assessed.
223791967|NCT00047879|BIOLOGICAL|PEG-interferon alfa-2b|0.3 µg/kg of IFN alfa-2b (PEG-Intron once weekly) plus daily oral thalidomide, subcutaneous injection
223791968|NCT00047879|DRUG|Thalidomide|Two 50mg tablets (100 mg total dose) every night before bedtime starting on day one.
223791969|NCT04251000|DEVICE|Joovv Mini|the smallest photomodulation device in the Joovv infrared light product line.
223791970|NCT05276466|DIAGNOSTIC_TEST|Polymerase Chain Reaction and Next-Generation DNA Sequencing|"The qPCR Rapid Screening Panel is a quantitative real-time PCR test for bacteria and fungi.~Next-Generation DNA Sequencing is the Comprehensive Sequencing test will detect virtually all microbial organisms and fungal pathogens that may be present in patient specimens."
223791971|NCT06454747|DRUG|SM-030 gel 0.64%|Topical application to face twice daily for 12 weeks.
223791972|NCT06454747|DRUG|Placebo gel|Topical application to face twice daily for 12 weeks.
223791973|NCT06454747|DRUG|SM-030 gel 0.08%|Topical application to face twice daily for 12 weeks.
223791974|NCT05725291|DRUG|AMT-116|Administered intravenously
223791975|NCT05987683|PROCEDURE|Thread-Embedding Acupuncture, Sham Thread-Embedding Acupuncture|Thread-Embedding Acupuncture: using a 29-gauge TEA needle with a 50-mm PDO (polydioxanone) thread Sham Thread-Embedding Acupuncture: using a 29-gauge TEA needle but thread-removed, just needle alone
223791976|NCT06015854|BIOLOGICAL|Vvax001 therapeutic cancer vaccine|Patients will receive three immunizations, with an interval of 3 weeks between each immunization at weeks 0, 3 and 6. Each vaccination will be given as two injections; 1 injection in each leg. The injections will be administered intramuscularly in the upper legs, preferably in the m. vastus lateralis.
223791977|NCT01785238|OTHER|renal echography|renal echography to analyse the kidney
223791978|NCT01785238|OTHER|Blood sampling|Blood sampling to analyse different parameters of renal function
223791979|NCT01785238|OTHER|collection of an urine sample|Collection of an urine sample to perform analysis of renal function parameters
223791980|NCT01785238|OTHER|Blood pressure measurement|
223791981|NCT05744687|DRUG|SPH4336 Tablets 400mg|"SPH4336 Tablets ：Orally, 400mg once a day; 28 days/cycle~Letrozole tablets ：Orally, 2.5mg once a day; 28 days/cycle"
223791982|NCT05744687|DRUG|SPH4336 Tablets Placebo|"SPH4336 Tablets Placebo：Orally,28 days/cycle~Letrozole tablets ：Orally, 2.5mg once a day; 28 days/cycle"
223791983|NCT00026273|DRUG|FOLFIRI regimen|
223791984|NCT00026273|DRUG|fluorouracil|
223791985|NCT00026273|DRUG|irinotecan hydrochloride|
223791986|NCT00026273|DRUG|leucovorin calcium|
223791987|NCT02131298|DRUG|Palbociclib Alone|A single 125 mg dose of palbociclib free base capsule given orally alone in the fed state, followed by 120 hours of PK sample collection
223791988|NCT02131298|DRUG|Palbociclib plus itraconazole|Itraconazole 200 mg once daily with food for a total of 11 days; on Day 5, a single oral 125 mg dose of palbociclib will be given with itraconazole after a meal, followed by 168 hours of PK sample collection.
223791989|NCT05387291|BEHAVIORAL|Intervention group|The intervention group will undergo an education program related to the circumcision process for the child's relatives/guardians.
223791990|NCT05387291|BEHAVIORAL|Control group|The control group will receive the usual intervention of the center.
223791991|NCT03219983|DRUG|Ropivacaine|Patients will have an interscalene block under ultrasound guidance and receive .5% ropivacaine pre-operatively. Upon arrival to the Post-Operative Care Unit a continuous infusion of .5% ropivacaine will be started at 8ml/hr and increased by 2ml/hr every 15 minutes for pain score \> 4 with a maximum rate of 14ml/hr. Infusion will be delivered by ON-Q Select-a-Flow pump (volume 750ml)
223791992|NCT03219983|DRUG|liposomal bupivacaine|A total injection volume of 100ml will be comprised of 60ml 0.9% normal saline+ 20ml .5% bupivacaine + 20ml liposomal bupivacaine will be administered into the deep tissue of the operative are with an 18 or 20 gauge needle.
223791993|NCT00622167|DEVICE|Integrated Backscatter IVUS|All subjects have Integrated Backscatter IVUS and Dual Source CT imaging.
223791994|NCT00622167|DEVICE|Dual Source Computed Tomography|All subjects have DSCT and IBIVUS imaging
223791995|NCT06210256|PROCEDURE|unidirectional valve apparatus|In the unidirectional valve group, we attached the unidirectional valve device to the lumen's distal port when one-lung ventilation initiated.
223791996|NCT06210256|PROCEDURE|occluding the non-ventilated endobronchial lumen|In the closed operative lumen group, we closed the lumen's distal port of non-ventilated lung when one-lung ventilation initiated.
223791997|NCT03722134|PROCEDURE|MOCA|Great saphenous vein occlusion with a mechanochemical chateter which cause mechanical injury to vessel intima and gives sclerosant to the intima.
223791998|NCT03722134|PROCEDURE|EVLA|Great saphenous vein occlusion with a thermal laser chateter
223791999|NCT03722134|PROCEDURE|RFA|Great saphenous vein occlusion with a thermal radiofrequency chateter
223792000|NCT01930110|OTHER|60-minute exercise|Patients will be admitted at the research clinical facility at 14:30. Closed-loop strategy will start at 15:30. At 18:00, patients will performed a 60-minute exercise at 60% of VO2 max. Patients will be discharged at 20:00.
223792001|NCT01930110|OTHER|40-minute interval exercise|Patients will be admitted at the research clinical facility at 14:30. Closed-loop strategy will start at 15:30. At 18:00, patients will performed a 40-minute interval exercise. Patients will be discharged at 20:00.
223792002|NCT00035126|DRUG|epothilone b|
223792003|NCT05915702|DRUG|Gadoquatrane (BAY1747846)|0.04 mmol Gd/kg body weight, solution for intravenous injection, single dose
223792004|NCT05915702|DRUG|Gadobutrol|Approved standard of care macrocyclic GBCA, 0.1 mmol Gd/kg body weight, solution for intravenous injection, single dose
223792005|NCT05915702|DRUG|Gadoterate meglumine|Approved standard of care macrocyclic GBCA, 0.1 mmol Gd/kg body weight, solution for intravenous injection, single dose
223792006|NCT05915702|DRUG|Gadoteridol|Approved standard of care macrocyclic GBCA, 0.1 mmol Gd/kg body weight, solution for intravenous injection, single dose
223792007|NCT02357628|DEVICE|Wound treatment with RO-NPT|
223792008|NCT02357628|DEVICE|Wound Irrigation|
223792009|NCT02683538|DEVICE|Separable cluster electrode (Octopus®)|Patients undergo RFA under ultrasound guidance, and separable cluster electrodes are used for RFA in monopolar switching mode, using multiple overlapping technique to create larger ablative zones.
223792010|NCT02818881|OTHER|High-speed yoga|
223792011|NCT02818881|OTHER|Low-speed yoga|
223792012|NCT05247151|OTHER|Oxytocin|Oxytocin nasal spray in a positive social setting.
223792013|NCT05247151|OTHER|Placebo|Placebo nasal spray in a positive social setting.
223792014|NCT02623673|DRUG|simultaneous treatment with intravitreal injection of bevacizumab 1.25mg and intravitreal implant of dexamethasone 0.7mg.|
223792015|NCT06288984|DEVICE|active rTMS|The magnetic stimulation coil was tangent to the scalp and kept parallel for 10 minutes a day, 5 days a week for 4 weeks
223792016|NCT06288984|DEVICE|sham rTMS|The magnetic stimulation coil was tangent to the scalp and kept perpendicular for 10 minutes a day, 5 days a week for 4 weeks
223792017|NCT05920369|OTHER|low-energy extracorporeal shockwave and a tailored exercise program|"the patient will be positioned lying supine with the affected shoulder in an abducted position to expose the axillary cords. Each patient received a total of 3000 shocks, which were delivered to different areas, including 1000 shocks to the axillary area, 500 shocks to the upper arm, 1000 shocks along the course of the cords, and 500 shocks to the antecubital space. Extracorporeal shock wave therapy (ESWT) was administered in two sessions during the first two weeks of the intervention, and one session each in the 3rd and 4th weeks. The energy flux density was 4 Hz with a range of 0.056-0.068 mJ/mm.~Snow Angel, Butterfly Wings, Forward Pinky Slide, Corner Stretch, Chest Stretch, Self-tissue Stretching, Overhead Moose Stretch, and Crescent Side Bend exercises"
223792018|NCT05920369|OTHER|low-energy extracorporeal shockwave|the patient will be positioned lying supine with the affected shoulder in an abducted position to expose the axillary cords. Each patient received a total of 3000 shocks, which were delivered to different areas, including 1000 shocks to the axillary area, 500 shocks to the upper arm, 1000 shocks along the course of the cords, and 500 shocks to the antecubital space. Extracorporeal shock wave therapy (ESWT) was administered in two sessions during the first two weeks of the intervention, and one session each in the 3rd and 4th weeks. The energy flux density was 4 Hz with a range of 0.056-0.068 mJ/mm.
223792019|NCT05920369|OTHER|tailored exercise program|Snow Angel, Butterfly Wings, Forward Pinky Slide, Corner Stretch, Chest Stretch, Self-tissue Stretching, Overhead Moose Stretch, and Crescent Side Bend exercises
223792020|NCT04146714|OTHER|Substance use questionnaire|Screening questionnaire about substance use based on the Detection of Alcohol and Drug Problems in Adolescents (DEP-ADO) survey.
223792021|NCT04146714|OTHER|Physical activity questionnaire|Screening questionnaire about physical activity, based on the short version of the International Physical Activity Questionnaire (IPAQ).
223792022|NCT00572234|DRUG|bupropion SR|12 week course of bupropion SR 150 mg, BID
223792023|NCT03106818|DRUG|bupivacain with magnesium sulphate|will receive bupivacain 0.125% and magnesium sulphate 5% infusion in the presternum , for 48 hours
223792024|NCT03106818|DRUG|Bupivacaine only|will receive bupivacain 0.125% infusion in the presternum , for 48 hours
223792025|NCT03106818|DRUG|conventional|only conventional post operative analgesics will be used
223792026|NCT06961734|BEHAVIORAL|follicular group|Exercised at Fatmax intensity four times per week and plus three additional exercise during the late follicular phase of each cycle.
223792027|NCT06961734|BEHAVIORAL|luteal group|Exercised at Fatmax intensity four times per week and plus three additional exercise during the mid- luteal phase of each cycle.
223792028|NCT06961734|BEHAVIORAL|Control group|Exercised at Fatmax intensity four times per week.
223792029|NCT05331261|PROCEDURE|Total diz replacement ameliyatı|Breath exercises
223792030|NCT05427279|DIETARY_SUPPLEMENT|Placebo|The participant will consume a supplemental dose of a placebo (20g maltodextrin with 50mg vitamin C)
223792031|NCT05427279|DIETARY_SUPPLEMENT|Hydrolized Collagen|The participant will consume a supplemental dose of Hydrolized collagen (20g with 50mg vitamin C)
223792032|NCT05427279|DIETARY_SUPPLEMENT|PrimaColl|The participant will consume a supplemental dose of PrimaColl, a vegan collagen supplementation (20g with 50mg vitamin C)
223792033|NCT05427279|DIETARY_SUPPLEMENT|Whey protein|The participant will consume a supplemental dose of whey protein (20g whey isolate with 50mg vitamin C)
223792034|NCT06447064|OTHER|Cases & Controls|Participants will complete a brief online questionnaire at REDCap about their health, clinical history and lifestyle choices. The participant will only need to provide a photo ID and utility bill for ID verification, if the retailer cannot match participant details. After recruitment the participants purchase history in the past 6 years will be requested from the retailers.
223792035|NCT01990196|DRUG|degarelix|"Every 4-week Treatment: A starting dose of 240 mg of Degarelix is taken subcutaneously (SQ) -placed under the skin by injection- the first month. Doses continue every 4 weeks at 80 mg SQ.~Dose for a drug may have to be modified based on development of adverse events on a case by case basis as per the judgment of treating physician."
223792036|NCT01990196|DRUG|enzalutamide|"Once Daily Treatment: A starting dose of 160 mg of Enzalutamide is taken by mouth once daily.~Dose for a drug may have to be modified based on development of adverse events on a case by case basis as per the judgment of treating physician."
223792037|NCT01990196|DRUG|trametinib|"Once Daily Treatment: If randomized into Group 2, then 2mg of Trametinib is taken by mouth daily.~Dose for a drug may have to be modified based on development of adverse events on a case by case basis as per the judgment of treating physician"
223792038|NCT01990196|DRUG|dasatinib|"Once Daily Treatment: If randomized into Group 3, then 100mg of Dasatinib is taken by mouth daily.~Dose for a drug may have to be modified based on development of adverse events on a case by case basis as per the judgment of treating physician"
223792039|NCT06559488|DRUG|Bevacizumab Injection [Avastin]|Intravitreal bevacizumab (1.25 mg/0.05 mL) was injected at the completion of vitrectomy surgery.
223792040|NCT06559488|PROCEDURE|Pars Plana Vitrectomy|routine procedure of pars plana vitrectomy in vitreous hemorrhage for proliferative diabetic retinopathy patients
223792041|NCT06372275|BEHAVIORAL|Values Clarification Mobile Application|Participants in the intervention group will be asked to answer a series of values clarification writing prompts related to physical activity once a day over four weeks.
223792042|NCT06372275|BEHAVIORAL|Self-Reflection Mobile Application|Participants in the control group will be administered writing prompts in the same format and frequency as the values intervention, but with prompts focused on self-reflection related to physical activity.
223792043|NCT02188381|OTHER|Stool Sample and Blood Sample|All subjects will provide a stool sample and a blood sample at baseline. Subjects in NCT02133872 will provide a second stool sample and blood sample at their 3 month visit.
223792044|NCT05318976|DRUG|XPro1595|XPro1595 will be delivered by subcutaneous injection once a week
223792045|NCT05318976|DRUG|Placebo|Placebo will be delivered by subcutaneous injection once a week
223792046|NCT01115439|DRUG|artesunate plus sulfadoxine-pyrimethamine (AS+SP)|artesunate plus sulfadoxine-pyrimethamine (AS+SP)
223792047|NCT02325882|DRUG|Dexmedetomidine|Dexmedetomidine mixed fentanyl based intravenous PCA
223792048|NCT02325882|DRUG|Fentanyl 1|conventional fentanyl-based epidural PCA
223792049|NCT02325882|DRUG|Fentanyl 2|conventional fentanyl based intravenous PCA
223792050|NCT03586635|OTHER|neurological exam|"Patients participating in the study are recruited from the investigator's tertiary multiple sclerosis management centre. They are systematically examined neurologically as part of their routine follow-up.~the patient will be exceptionally examined by two distinct persons, a senior doctor and a junior doctor (internal or external) independently.~At the end of the neurological examination, each examiner will evaluate the EDSS score in a classical way (using paper definitions) then using the smartphone application"
223792051|NCT02983734|DRUG|D-cycloserine|Partial agonist of N-methyl-D-aspartate (NMDA) receptor
223792052|NCT02983734|DRUG|Placebos|Sugar pill
223792053|NCT04226638|DIAGNOSTIC_TEST|Dynamic ultrasound|Diagnosis was based on clinic suspicion and positive ultrasonography dynamic maneuvers by reproducing pain and slipping rib exam
223792054|NCT03615157|OTHER|Exercise rehabilitation|Patients will be submitted to a twelve-week combined exercise program of aerobic and peripheral muscle training. They will be randomized in two groups: Home-based and Supervised.
223792055|NCT02221206|DEVICE|Mini-Screw implant|Mini-screw implants (VectorTASTM8\*1.4mm, Ormco Corporation, USA) were placed between maxillary first molar and second molar after local anesthetic on both sides
223792056|NCT01954017|BIOLOGICAL|STP206|Live Biotherapeutic
223792057|NCT01954017|OTHER|Control|Sterile Water
223792058|NCT05894200|OTHER|Glass Ionomer cement pit and fissure sealant, Silver Diamine Fluoride|GC Fuji 7, e-SDF
223792059|NCT02888405|OTHER|High-carbohydrate diet|
223792060|NCT02888405|OTHER|Low-carbohydrate diet|
223792061|NCT03216837|DEVICE|Cathodal transcranial direct current stimulation|The primary intervention will be cathodal (inhibitory) tDCS over the contralesional M1. Soft, replaceable 25cm2 electrodes (Soterix, NYC) will be placed on clean, dry areas of the scalp. The cathode will be placed over the contralesional M1, precisely mapped for each patient using neuronavigated (Brainsight2, Rogue Research, Montreal QU) MRI-TMS co-registration over the hotspot for the contralateral first dorsal interosseous muscle. The current-controlled model stimulator (Soterix, NYC) will automatically ramp up slowly over 30 seconds to the treatment current of 1.0 milliamp. tDCS will be administered each day during the first 30 minutes of the daily 1:1 therapy sessions.
223792062|NCT03216837|DEVICE|Sham transcranial direct current stimulation|Soft, replaceable 25cm2 electrodes (Soterix, NYC) will be placed on clean, dry areas of the scalp. The cathode will be placed over the contralesional M1, precisely mapped for each patient using neuronavigated (Brainsight2, Rogue Research, Montreal QU) MRI-TMS co-registration over the hotspot for the contralateral first dorsal interosseous muscle.The current-controlled model stimulator (Soterix, NYC) will automatically ramp up slowly over 30 seconds to the treatment current of 1.0 milliamp and then ramp down over 30 seconds to 0 milliamps. Sham will be administered each day during the first 30 minutes of the daily 1:1 therapy sessions.
223792063|NCT00176098|PROCEDURE|Hypnoanalgesia; Hypnotic shielding|
223792064|NCT04385732|DEVICE|2D or 3D Melanoma Surveillance Photography|Total body imaging using 2D or 3D Melanoma Surveillance Photography plus digital dermoscopy.
223792065|NCT04679220|PROCEDURE|Preheating|For preheating RC prior to placement, a device called Therma-flo TM RC warming kit (Vista, Wisconsin, USA) was used according to manufacturer's instructions to preheat resin composites
223792066|NCT02271386|BEHAVIORAL|Supporting Practice for ADHD (SPA)|"The SPA intervention will last for 8 months for each study arm (first 8 months of the study for the intervention group, last 8 months for the control group). The intervention includes 3 components: 1) a series of web-based educational presentations to provide education to providers about evidence-based practice for managing ADHD and strategies for promoting effective communication with families 2) Collaborative consultation designed to address clinical issues arising in practice will be provided by members of the study team.~3\) Providers will be given systematic performance feedback with regard to their use of evidence-based practices for ADHD every 2 months during the 8-month intervention period."
223792067|NCT00320346|BIOLOGICAL|Pandemic Influenza Vaccine|
223792068|NCT00435370|DRUG|Tropisetron|10 mg/day
223792069|NCT00435370|DRUG|Placebo|placebo
223792070|NCT00435370|DRUG|Risperidone|6mg/day
223792071|NCT01235039|DRUG|VIAject®25|Two vial presentation for reconstitution and single dose of 12 IU subcutaneous injection and 25 IU/mL
223792072|NCT01235039|DRUG|VIAject®7|One vial presentation and single dose of 12 U for subcutaneous injection and 100 IU/mL
223792073|NCT01235039|DRUG|Insulin Lispro|One vial presentation and single dose of 12 IU for subcutaneous injection and 100 IU/mL
223792074|NCT05505838|DRUG|Patisiran|Patisiran administered by intravenous (IV) infusion
223792075|NCT00746603|DRUG|Simvastatin|All patients will start at 10mg of simvastatin, and then, based on results of interim evaluation escalated to 20mg and then 40. Patients will stay on maximally tolerated dose of drug until the end of the study at 26 weeks.
223792076|NCT05094960|DIAGNOSTIC_TEST|Blood samples|5 blood samples for each patient during CABG (coronary artery bypass grafting) surgery pre/on/post cardiopulmonary bypass machine
223792077|NCT02021279|DEVICE|MatriStem Pelvic Floor Matrix|
223792078|NCT02021279|PROCEDURE|native tissue repair|
223792079|NCT02030977|DIETARY_SUPPLEMENT|Resveratrol|
223792080|NCT02030977|OTHER|placebo|
223792081|NCT05450874|PROCEDURE|hepatectomy|
223792082|NCT00158743|DRUG|Anti-digoxin antibody (FAB fragment)|intravenous administered, dose based on weight (assuming 4ng/mL EDLF concentration). Dose every 6 hours x 48 hours.
223792083|NCT00158743|OTHER|sodium chloride|
223792084|NCT00337766|DRUG|Desmopressin (DDAVP)|
223792085|NCT00337766|DRUG|Placebo|
223792086|NCT00423124|GENETIC|HSV-TK|Infusion of genetically modified lymphocytes (1x10\^6-1x10\^7 c/kg): first at +21-+49 days after HSCT; in absence of immune reconstitution and GvHD further infusions up to 4 will be administered on monthly basis.
223792087|NCT03674177|BIOLOGICAL|GSK3888550A RSV Maternal vaccine formulation 1|Single dose administered intramuscularly at Day 1 in the deltoid region of the non-dominant arm
223792088|NCT03674177|BIOLOGICAL|GSK3888550A RSV Maternal vaccine formulation 2|Single dose administered intramuscularly at Day 1 in the deltoid region of the non-dominant arm
223792089|NCT03674177|BIOLOGICAL|GSK3888550A RSV Maternal vaccine formulation 3|Single dose administered intramuscularly at Day 1 in the deltoid region of the non-dominant arm
223792090|NCT03674177|DRUG|Placebo (Normal Saline)|Single dose administered intramuscularly at Day 1 in the deltoid region of the non-dominant arm
223792091|NCT03633383|DEVICE|Transcatheter aortic valve|Self-expandable aortic valve prothesis
223792092|NCT01011010|DRUG|doxorubicin hydrochloride|"TACE (day 18-20): Doxorubicin 50mg and mitomycin C 10mg mixed with lipoidal and injected in proportion to liver volume being treated, followed by embospheres. Administered until there is a pruned tree appearance on angiography. If a second TACE is to be performed it should be performed within 8 weeks of the first procedure."
223792093|NCT01011010|DRUG|mitomycin C|"TACE (day 18-20): Doxorubicin 50mg and mitomycin C 10mg mixed with lipoidal and injected in proportion to liver volume being treated, followed by embospheres. Administered until there is a pruned tree appearance on angiography. If a second TACE is to be performed it should be performed within 8 weeks of the first procedure."
223792094|NCT01011010|DRUG|sorafenib tosylate|Sorafenib 400mg BID continuously post TACE beginning when LFTs return to entry criterion. Discontinue at time of disease progression (progression in a lobe that has already been embolized, new lesions in an untreated lobe, or evidence of extrahepatic progression).
223792095|NCT01011010|OTHER|laboratory biomarker analysis|Serum VEGF levels are required: pre TACE (day of procedure, time B), 24 hours post TACE (+/- 6 hours, time C), day 7 post first TACE (± 1 day, time D), day 28 post reinitiation of sorafenib (± 3 days, time E). These levels will not be repeated for patients receiving a second TACE procedure.
223792096|NCT01011010|OTHER|pharmacological study|Treatment with sorafenib will continue on a daily basis until disease progression (see definition protocol Section 7) or unacceptable toxicity is encountered. At the end of treatment, no further therapies are currently recommended.
223792097|NCT03701724|DEVICE|Systematic maintenance rTMS|Same parameters as the initial course (session of 8,5 minutes, at 1 Hz, on the right dorsolateral prefrontal cortex (DLPFC) targeting with either neuronavigation or the Beam). The frequency is : 2 sessions / week during 1 month, then 1 session / week during 2 months and finally 1 session every 2 weeks during 8 months.
223792098|NCT03701724|DEVICE|rTMS course in case of relapse|Same parameters as the initial course. The frequency is the same as the initial course: one daily session on 5 consecutive working days from Monday to Friday for at least 20 to 30 sessions over 4 to 6 weeks.
223792099|NCT03701724|DEVICE|sham rTMS|The sham stimulation consists of the identical rTMS procedure at the identical location using a commercial figure-eight sham coil. However, it does not produce the identical tactile sensation. A local electrical stimulation will be delivered with two disposable Electromyogram (EMG) electrodes using a transcutaneous electrical nerve stimulation (TENS) Stimulator.
223792100|NCT00522249|DRUG|Pegylated Alfa Interferon|Each patient will receive PEG-Intron administered subcutaneously one day per week of each 6 week cycle. The dose of PEG-Intron is determined based on the patient's weight and the dose level.
223792101|NCT00522249|DRUG|sunitinib|Patients will receive sunitinib orally as a single daily dose on Days 1-28 of each 42-day cycle. The dose will depend on the dose level.
223792102|NCT00522249|DRUG|erlotinib|Tarceva will be administered orally, 1-42 of each 42 day cycle. Dose will depend on dose level. Supplied as 150-mg, 100-mg and 25-mg strengths, white film-coated tablets for administration.
223792103|NCT04321720|OTHER|3-g mustard footbath|A ten-minute pre-intervention rest period followed by a 20-minute footbath with 12 l of warm water (40 °C) and 36 g mustard flour (3 g per l), followed by a ten-minute post-intervention rest period.
223792104|NCT04321720|OTHER|6-g mustard footbath|A ten-minute pre-intervention rest period followed by a 20-minute footbath with 12 l of warm water (40 °C) and 72 g mustard flour (6 g per l), followed by a ten-minute post-intervention rest period.
223792105|NCT04321720|OTHER|12-g mustard footbath|A ten-minute pre-intervention rest period followed by a 20-minute footbath with 12 l of warm water (40 °C) and 144 g mustard flour (12 g per l), followed by a ten-minute post-intervention rest period.
223792106|NCT04321720|OTHER|Warm water only|A ten-minute pre-intervention rest period followed by a 20-minute footbath with 12 l of warm water (40 °C), followed by a ten-minute post-intervention rest period.
223792107|NCT03819335|DEVICE|mySugr app|mySugr is a mobile medical app for diabetes management. It has been developed by Roche Diabetes Care and it has two versions, free and Pro. It allows to carry out the diary of diabetes, including the collection and analysis of data on glycaemia, food, physical activity or insulin dose. In addition, it is compatible with continuous glucose measurement systems. It has the possibility to add functionalities such as estimation of HbA1c levels, more detailed data analysis or integration with Google Fit type motion sensors, as well as a bolus calculator, reminders for measuring blood glucose or photo gallery in the Pro version, which is the one that will be provided to the patients for the study.
223792108|NCT03819335|OTHER|Standard care|Face-to-face visits
223792109|NCT00714168|BEHAVIORAL|Standard Behavioral Weight Loss Program|This program will include group sessions that will focus on modifying eating and physical activity behaviors to improve weight loss.
223792110|NCT00714168|BEHAVIORAL|Stepped-Care Weight Loss Program|In this program, increases in the intensity of treatment will be based on participants' abilities to achieve predetermined weight loss goals. Participants will initially receive less contact with program staff. The intensity and/or frequency of contact will then increase at 12-week intervals, based on weight loss progress until a 10% weight loss is attained and maintained. The program will stay constant, unless weight loss drops below the 10% level.
223792111|NCT04135053|BIOLOGICAL|Lyophilised Neisseria lactamica|Previously lyophilised Neisseria lactamica will be reconstituted and intranasally given to participants
223792112|NCT00451854|PROCEDURE|Random, no advanced notice drug and alcohol testing|
223792113|NCT01436994|PROCEDURE|Block and Replace|The primary objective of treatment is to maintain a euthyroid state with TSH and thyroid hormone levels in the local laboratory normal range. Carbimazole is commenced in a dose of 0.75 mg/kg/day (propylthiouracil - for dose see below) with the aim being to completely preventing endogenous thyroxine production. Thyroxine is then added in a low replacement dose as the thyroid hormone levels fall into the lower half of the laboratory normal range. The principle measure of control during the first 6 months will be thyroid hormone levels rather than TSH. Carbimazole is the preferred treatment because of the increased risk of hepatotoxicity with propylthiouracil but patients who are treated with propylthiouracil can also be recruited and randomised. 1mg of carbimazole is approximately equivalent to 10 mg of propylthiouracil.
223792114|NCT01436994|PROCEDURE|Dose Titration|"The primary objective of treatment is to maintain a euthyroid state with TSH and thyroid hormone levels in the local laboratory normal range.~Carbimazole is commenced in a dose of 0.75 mg/kg/day until thyroid hormone levels fall into the local laboratory normal range. The dose is then reduced to 0.25 mg/kg/day with the intention of maintaining a euthyroid state as reflected by a free thyroxine and TSH within the normal range.~Most paediatricians in the UK commence thyrotoxic children on carbimazole rather than propylthiouracil. Carbimazole is the preferred treatment because of the increased risk of hepatotoxicity with propylthiouracil but patients who are treated with propylthiouracil can also be recruited and randomised. The guidelines detailed above can be used in the knowledge that 1mg of carbimazole is approximately equivalent to 10 mg of propylthiouracil."
223792115|NCT01436994|DRUG|carbimazole|Carbimazole 5mg and 20 mg tablets Administered as a once or twice daily regimen with total daily dose adjusted according to prevailing biochemistry
223792116|NCT01436994|DRUG|propylthiouracil|50 mg tablets administered once daily with the dose adjusted according to the prevailing biochemistry
223792117|NCT01436994|DRUG|thyroxine|25mcg, 50mcg and 100mcg tabletes administered once daily with the dose adjusted according to the prevailing biochemistry
223792118|NCT03585647|PROCEDURE|hip arthroplasty|Hip replacement is a surgery for people with severe hip damage. The most common cause of damage is osteoarthritis.
223792119|NCT02920905|DRUG|Lidocaine|"Two intravenous cannulae will be placed; one in a vein on the dorsum of the hand to be operated (22 gauge) and the other in the opposite hand. A double tourniquet will be positioned on the upper arm of the hand to be operated. Arm will be elevated for 2 min.~Circulatory isolation of arm will be confirmed by inspection of the color of the limb, absence of radial pulse and loss of pulse oximetry tracing in the ipsilateral index finger. The upper (proximal) tourniquet will then be inflated to a pressure of 100 mmHg above the systolic blood pressure of the patient. The anesthetic solution will be prepared by an observer and will be given over a period of 90 seconds."
223792120|NCT02920905|DRUG|atracurium|"Two intravenous cannulae will be placed; one in a vein on the dorsum of the hand to be operated (22 gauge) and the other in the opposite hand. A double tourniquet will be positioned on the upper arm of the hand to be operated. Arm will be elevated for 2 min.~Circulatory isolation of arm will be confirmed by inspection of the color of the limb, absence of radial pulse and loss of pulse oximetry tracing in the ipsilateral index finger. The upper (proximal) tourniquet will then be inflated to a pressure of 100 mmHg above the systolic blood pressure of the patient. The anesthetic solution will be prepared by an observer and will be given over a period of 90 seconds."
223792121|NCT02920905|DRUG|Mg sulphate|"Two intravenous cannulae will be placed; one in a vein on the dorsum of the hand to be operated (22 gauge) and the other in the opposite hand. A double tourniquet will be positioned on the upper arm of the hand to be operated. Arm will be elevated for 2 min.~Circulatory isolation of arm will be confirmed by inspection of the color of the limb, absence of radial pulse . The upper (proximal) tourniquet will then be inflated to a pressure of 100 mmHg above the systolic blood pressure of the patient. The anesthetic solution will be prepared by an observer and will be given over a period of 90 seconds."
223792122|NCT03143218|BIOLOGICAL|RABIPUR®|Year 1 (2017) Three doses of rabies vaccine (April, May, June) Year 2 and 3 (2018/19) One dose of Hepatitis A vaccine (June)
223792123|NCT03143218|BIOLOGICAL|RTS,S/AS01|Year 1 (2017) Three doses of RTSS/AS01 (April, May, June) Year 2 and 3 (2018/19) One booster dose of RTSS/AS01 (June)
223792124|NCT03143218|DRUG|SMC with SP+AQ|Year 1, 2 and 3(2017/18/19) Four cycles of SMC (SP+AQ) during the malaria transmission season One cycle of SMC for children above one year of age consisting of sulphadoxine - pyrimethamin (SP) 500mg/25 mg, and amodiaquine (AQ) 150mg on day 1, and AQ 150mg on days 2 and 3. Infants will receive half of these doses.
223792125|NCT03143218|DRUG|SMC placebo|Year 1, 2 and 3(2017/18/19) Four cycles of SMC placebo during the malaria transmission season
223792126|NCT00502125|PROCEDURE|Reflectance Confocal Imaging|A photograph will be taken of any abnormal areas inside the mouth. A small probe will expose the oral lining to a small amount of light. Some of this light will be reflected back into the probe, and be picked up by a computer. Pictures will be made of the tissue.
223792127|NCT01579708|BEHAVIORAL|Program SI! educational intervention|School-based educational program to improve the knowledge, the attitudes, and the habits of children, their parents and teachers, with respect to a healthy lifestyle behavior.
223792128|NCT06496152|OTHER|questionnaire|online form used to collect all information used in questionnaire
223792129|NCT05084872|DRUG|Hydroxychloroquine|Patients will be treated by hydroxychloroquine at a dose of 6 to 6.5mg/kg/day during 12 month
223792130|NCT02832323|BIOLOGICAL|Reticera|A blood sample (before dialysis) under the usual conditions will be performed at D0 (= the day of Mircera® injection) 9 days (+/- 1 day) after each injection Mircera® for hemoglobin and reticulocytes dosage for a period of 6 months.
223792131|NCT01817049|BEHAVIORAL|HAPA-based coach education workshop|A 3.5 hour workshop will target HAPA constructs by providing injury risk information (risk perceptions), FIFA 11+ effectiveness evidence (outcome expectancies), and hands-on experience administering the 11+ program to a soccer team (task self-efficacy). Action planning and coping planning exercises will also be conducted.
223792132|NCT01817049|BEHAVIORAL|placebo attention control|
223792133|NCT03690505|BEHAVIORAL|Interviews|informant-based questionnaire semi-structured individual interviews focus group interviews
223792134|NCT01561248|DRUG|polyethylene glycol solution for daily bowel lavage.|At admission,patients with severe EHEC infection received two liters of orally administered electrolytes- balanced polyethylene glycol solution for bowel lavage. Treatment was continued with one liter of polyethylene glycol solution daily for repetitive intestinal lavage during the clinical course.
223792135|NCT06361082|PROCEDURE|ACL reconstruction|ACL reconstruction
223792136|NCT03177304|OTHER|Web based IPT Training|
223792137|NCT04475744|DRUG|G-CSF treatment for Bone marrow derived stem cell Mobilization|Mobilization treatment. On the fifth day, collection will be started.
223792138|NCT04475744|PROCEDURE|Platelet Rich Plasma ovarian injection|Mobilized peripheral blood will be obtained to prepare the PRP for injection. Both ovaries will be injected when proper anatomical access can be assessed.
223792139|NCT01672632|OTHER|Overfeeding|We overfed 40 young, healthy adults by 40% of their baseline energy requirements for 8 weeks. The diet consisted of 41% carbohydrate, 44% fat, and 15% protein.
223792140|NCT02283866|DRUG|Administering desflurane according to the patient's BIS value|Administering desflurane according to the patient's BIS value
223792141|NCT02283866|DRUG|Administering desflurane at 1 MAC|Administering desflurane at 1 MAC
223792142|NCT05238935|OTHER|prescribed physiotherapy course|provide full assessment and treatment program as postoperative rehabilitation management
223792143|NCT03081455|DIAGNOSTIC_TEST|Diagnostic Test|Genetic Diagnostic Testing
223792144|NCT02293187|DIETARY_SUPPLEMENT|vitamin D3|Dose for intervention arm is 800 IU/day for first 4 months. At 4 months, if vitamin D level \<70 nmol/L, a second 800 IU capsule will be added to regimen (total of 1600 IU/d) for remainder of study.
223792145|NCT02293187|OTHER|Placebo|Those in the placebo group will receive 1 capsule for first 4 months. At 4 month visit, one capsule will be added to regimen to be taken throughout the remainder of the study.
223792146|NCT03065894|OTHER|Matched Physical Therapy Intervention|"Patients who are medium-risk will receive up to 6-8 physical therapy (PT) visits over a 3 month period that is guided by published evidence based practice guidelines. The PT treatment will be tailored to the physical findings and specific patient needs, and appropriate exercises, spinal mobilization/manipulation, strengthening/stretching as well as a home program will be given to improve patient pain and function and reduce disability.~Patients who are high-risk will receive the evidence based PT treatment as deemed necessary. In addition, the PT treatment will incorporate principles of psychologically informed practice to address psychosocial barriers (e.g., fear avoidance, anxiety, etc) that may be impeding disability reduction. This may include instruction on chronic pain rehabilitation techniques such as the use of: pacing in order to maintain or increase activity; graded activity principles in order to increase function; and pain education and understanding responses to pain."
223792147|NCT03065894|OTHER|Current Care in Family Medicine|Patient education, medication management
223792148|NCT03580265|DEVICE|laser phototherapy device with low level laser|The wavelength of low level laser is 808nm and the power output of low level laser is 300mW.
223792149|NCT00000129|PROCEDURE|Radial Keratotomy|
223792150|NCT04894253|BIOLOGICAL|SRAS-CoV-2 vaccination immunological response|"Follow for 18 months a single group of 30 patients with systemic lupus after their SRAS-CoV-2 vaccination.~Intervention includes immunological analysis on additional volume of blood collected as part of routine care."
223792151|NCT01752504|BEHAVIORAL|Community Mobilization|The proposed study seeks to continue C2P, a community mobilization intervention, which entails developing coalitions to plan for and bring about structural changes for purposes of reducing HIV incidence and prevalence among youth in targeted communities at five ATN sites. The C2P community mobilization model entails: determining a geographic area and population of focus for the coalitions to prioritize their planning and action; developing coalitions that have a shared vision and mission; developing a strategic plan focused on structural changes to reduce risks associated with HIV; documenting processes; providing feedback as technical assistance to the coalitions; hosting regular working group meetings; and on-going capacity building.
223792152|NCT03456193|PROCEDURE|LA transplant|"The proposed study treatment will include three central components:~* Harvest of the left atrium and pulmonary veins from a suitable donor~* Excision of the left atrium and portions of stenotic pulmonary veins from the patient with pulmonary vein stenosis~* Implantation of the donor posterior left atrium and portions of pulmonary veins into the patient."
223792153|NCT06193876|OTHER|Petitgrain and ylang-ylang essential oil|Petitgrain and ylan-ylang essential oil will be dropped to the handchief and students will smell it 3 times in a day.
223792154|NCT03655353|DIAGNOSTIC_TEST|ABY-PET|Diagnostic PET for HER2 expression
223792155|NCT03755453|DEVICE|Hearing aid: Phonak Audéo B90-Direct|Hearing aids will be fitted to the participants individual hearing loss.
223792156|NCT02298192|DRUG|insulin degludec/liraglutide|For subcutaneous (s.c., under the skin) injection, once daily. Subjects will be instructed to continue with the same dose of OADs (metformin alone or in combination with pioglitazone), as prior to the trial.
223792157|NCT01681589|DEVICE|Transcranial Direct Current Stimulator (TDCS)|Group will receive active TDCS
223792158|NCT01681589|DEVICE|Control Group|This group will receive Sham TDCS
223792159|NCT01681589|OTHER|Healthy Control Group|Healthy Controls will be involved in the Study. Healthy Controls will receive no Intervention. There will be 1 screening visit and 1 testing visits.
223792160|NCT04517266|RADIATION|omit of IMI group|clincial high risk breast （≥2 risk factors）patients with 18-gene low risk an indication for regional nodal irradiation will received 2 Gy for 25 fractions to chest wall or whole breast and supraclavicular lymph nodes irradiation and sequential tumor bed boost of 2 Gy for 5 fractions following breast conserving surgery.
223792161|NCT04517266|RADIATION|IMI group|clincial high risk breast （≥2 risk factors）patients with 18-gene low risk an indication for regional nodal irradiation will received 2 Gy for 25 fractions to chest wall or whole breast and supraclavicular lymph nodes irradiation and sequential tumor bed boost of 2 Gy for 5 fractions following breast conserving surgery.
223792162|NCT02223234|BEHAVIORAL|Emails and 4 Home Visits|Weekly emails and 4 home visits with health educator
223792163|NCT02223234|BEHAVIORAL|Control|Monthly emails on child health
223792164|NCT02223234|BEHAVIORAL|Emails and 2 home visits|Weekly emails and 2 home visits with health educator
223792165|NCT03684629|BEHAVIORAL|the response of KPI and corresponding suggestion|Standardized templates of medical record, evidence-based clinical pathway, and written care protocols are applied in all hospitals.The KPI of the AIS patients who were admitted to a single hospital continuously at the time of hospitalization were studied. Feedback system of performance measures: the hospital included in the study upload the medical records of all AIS patients by medical records scanning system since that month into the group. Quality control platform of Cerebral apoplexy in Zhejiang province extracts and analyze the data through the computer and calculates the corresponding monthly KPI. The hospitals will receive their own monthly KPI and the monthly highest KPI of all hospitals included in the study. Expert online consultation: based on the compare of the monthly KPI of all hospitals, Quality control platform will give corresponding suggestions to all hospitals for the improve of next month.
223792166|NCT02907346|BEHAVIORAL|Reinforcement for wearing CGM|The intervention will reinforce patients for wearing CGM and for uploading it and reviewing its data.
223792167|NCT04625543|DRUG|Sintilimab Injection plus Paclitaxel and Cisplatin|Paclitaxel 150mg/m2 on day 1, every 3 weeks, for two cycles; Cisplatin 70mg/m2 on day 1, every 3 weeks, for two cycles; Sintilimab Injection 200mg on day 22; 4-6 weeks after completion of preoperative therapy, Mckeown esophagectomy will be performed if there is no contraindication.
223792168|NCT04625543|DRUG|Paclitaxel and Cisplatin|Paclitaxel 150mg/m2 on day 1, every 3 weeks, for two cycles; Cisplatin 70mg/m2 on day 1, every 3 weeks, for two cycles; 4-6 weeks after completion of preoperative therapy, Mckeown esophagectomy will be performed if there is no contraindication.
223792169|NCT04402177|DRUG|Methyl Prednisolonate|Corticosteroid treatment
223792170|NCT05989633|OTHER|Dermocosmetic product: Selenium Disluphide Shampoo (Dercos DS)|to assess the benefit of Dercos DS in subjects with dandruff
223792171|NCT05218005|DIAGNOSTIC_TEST|Research-based genetic test for Familial Hypercholesterolemia|Next-generation targeted sequencing assay to identify DNA variants in genes known to cause Familial Hypercholesterolemia
223792172|NCT04764396|COMBINATION_PRODUCT|Heparin will be used for needle priming (BD PosiFlush™ Pre-Filled Heparin Lock Flush Syringe)|The fine needle biopsy (FNB) needle will be flushed with 1 mL of heparin (100 USP/mL) and then flushed with air. Pass 1, 2, and 3 will be collected in separate jars and sent to pathology, as per standard clinical procedures. Between passes, after tissue is extracted from the needle, the needle will be flushed with 1 mL of heparin (100 USP/mL) and flushed with air before next pass is made.
223792173|NCT04764396|DRUG|Saline|FNB will be performed as current standard methods in the medical procedure unit without the use of heparin priming. Pass 1, 2, and 3 will be collected in separate jars and sent to pathology, as per standard clinical procedures. Between passes, after tissue is extracted from the needle, the needle will be flushed saline and or air as per current standards of care.
223792174|NCT02962713|PROCEDURE|ART with Equia|Occlusal-proximal ART restorations in primary molars using Equia (Easy/Quick/Unique/ Intelligent/Aesthetic) will be performed. No local anesthesia will be used. Infected carious tissue will be removed with hand instruments, and the cavities restored with GIC (Glass Ionomer Cement). The cavity will be filled with GIC. After the press-finger technique, the excess of material will be removed and occlusion will be checked.
223792175|NCT02962713|PROCEDURE|ART with Giomer Beautifil-Bulk Restorative|Occlusal-proximal ART restorations in primary molars using Giomer will be performed. No local anesthesia will be used. Infected carious tissue will be removed with hand instruments, and the cavities restored with Giomer Beautifil-Bulk Restorative and occlusion will be checked.
223792176|NCT05020223|OTHER|Vital pulp therapy|Vital pulp therapy different modalities for management of deep carious lesion in primary teeth
223792177|NCT01053208|DRUG|Ibuprofen and Diphenhydramine Citrate|Ibuprofen and Diphenhydramine Citrate 200mg/38mg Caplets
223792178|NCT02115958|BIOLOGICAL|cancer stem cell vaccine|
223792179|NCT05679492|BIOLOGICAL|Meplazumab foe injection|Meplazumab is a humanized anti-CD147 immunoglobulin 2 (IgG2) monoclonal antibody which is expected to block the binding of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein to the human host-cell-expressed CD147, thereby blocking entry of SARS-CoV-2 into human tissue. This expectation is based on in vitro functional studies using Vero E6 cells infected with SARS-CoV-2 that demonstrated effective meplazumab mediated virus gene copy number inhibition upwards of 90% as evaluated by quantitative polymerase chain reaction. Meplazumab may also inhibit COVID-19 associated cytokine storm syndrome based on inhibition of the pro inflammatory factor Cyclophilin A host-cell CD147 interaction.
223792180|NCT05679492|OTHER|Normal saline|Normal saline
223792181|NCT03986853|PROCEDURE|Blood sampling|Blood sampling under general anesthesia
223792182|NCT00074035|DRUG|pentostatin|4 mg/sq m IV infusion over 20-30 min q 2 weeks
223792183|NCT00407446|DRUG|sildenafil|
223792184|NCT04597853|DIAGNOSTIC_TEST|Assessment of lung mechanics and heart-lung interactions|Impedance tomography, right-heart catheterization, oesophageal pressure measurements, indirect calorimetry and classic mechanical ventilation parameters
223792185|NCT02289300|DRUG|DCB-BO1202|"The assignment will be as follows:~(Each DCB-BO1202 300mg capsule contains 150mg active ingredient)~DCB-BO1202: 4 DCB-BO1202 300mg capsules, t.i.d., orally.~Duration of Administration: 96 weeks ((11 treatment weeks + 1 observation week) \* 8 cycles)"
223792186|NCT02289300|DRUG|Placebo|"The assignment will be as follows:~Placebo: 4 matched placebo, t.i.d., orally.~Duration of Administration: 96 weeks ((11 treatment weeks + 1 observation week) \* 8 cycles)"
223792187|NCT02289300|DRUG|DCB-BO1202+Placebo|"The assignment will be as follows:~(Each DCB-BO1202 300mg capsule contains 150mg active ingredient)~DCB-BO1202+Placebo: 2 DCB-BO1202 300mg capsules plus 2 matched placebo, t.i.d., orally.~Duration of Administration: 96 weeks ((11 treatment weeks + 1 observation week) \* 8 cycles)"
223792188|NCT00611013|DEVICE|Magnetic Resonance Imaging|Some participants may receive MRI contrast agent, 0.1 mmol/kg
223792189|NCT06104475|OTHER|CT scan|A CT scan will be requested for every patient in addition to the chest X-ray
223792190|NCT01097967|OTHER|CPAP|
223792191|NCT02653482|DRUG|Dapagliflozin|
223792192|NCT02653482|DRUG|Dapagliflozin matching placebo|
223792193|NCT03133975|DRUG|Vitamin D3 (Treatment)|Single high dose vitamin D3 in treatment of dyslipedemia
223792194|NCT03133975|OTHER|Mixed diet of carbohydrate and protein (Control)|Mixed diet of carbohydrate and protein
223792195|NCT00223418|DRUG|aripiprazole|
223792196|NCT00383448|DRUG|Clofarabine|days -7 through -3: 40 mg/m\^2 intravenously over 2 hours
223792197|NCT00383448|PROCEDURE|Total body Irradiation|Administration of TBI: The dose of TBI will be 200 cGy given in a single fraction on day -1. The dose rate will be between 10-19 cGy/minute prescribed to the midplane of the patient at the level of the umbilicus.
223792198|NCT00383448|DRUG|Melphalan|day -2: 140 mg/m\^2 intravenously over 30 minutes
223792199|NCT00383448|BIOLOGICAL|Hematopoietic Stem Cell Transplantation|receives infusion of stem cells on day 0
223792200|NCT00383448|DRUG|Alemtuzumab|0.3 mg/kg intravenously (IV) days -12 through -8
223792201|NCT00383448|DRUG|mycophenylate mofetil|Day -3 through Day 30: 1 gram three times daily (total daily dose 3 grams/day) if the recipient is \>50 kg, or 15 mg/kg three times daily if the recipient is ≤50 kg. The same dosage is used orally or intravenously. Consider dose modification if renal impairment (GFR\<25 mL/minute corrected)
223792202|NCT00383448|DEVICE|Cyclosporine A|"Patients will receive CsA therapy beginning on day -3. Dosing of CsA will be 2.5 mg/kg/dose intravenously (IV); if the recipient body weight is \<40 kg, dosing will be 3 times daily, and if \> 40 kg twice daily. An attempt will be made to maintain a trough cyclosporine level of 250 mg/L to 350 mg/L. Once the patient can tolerate oral medications and has a normal gastrointestinal transit time, CsA will be converted to an oral form at a dose 2.5 x the current IV dose (maximum 12.5 mg/kg/day as initial oral dose).~CsA taper begins at day +100."
223792203|NCT00383448|DRUG|Hydroxyurea|hydroxyurea (HU) beginning day -28 and continuing through alemtuzumab administration
223792204|NCT00874861|BIOLOGICAL|Peptide vaccine + Poly-ICLC|"Subcutaneously in right or left upper arms with intact draining axillary nodes. Each will be injected to the same location in the same arm as the previous vaccine was administered. In case of no intact axillary lymph nodes as draining nodes, vaccines will be administered in the upper thigh on the same side with intact inguinal lymph nodes.~Vaccine will be administered on weeks 0,3,6,9,12,15,18 and 21. Poly-ICLC First course(20 mg/kg i.m., up to 1640 µg/injection) will be administered on an outpatient basis in the Clinical \& Translational Research Center (CTRC)the day of the first GAA/TT-vaccine and on day 4 after the vaccine. For each of the repeated vaccinations (on Weeks 3,6,9,12,15,18 and 21) poly-ICLC will be administered on day of the vaccine and on day 4 after the vaccine."
223792205|NCT00479011|PROCEDURE|fluid management based on arterial pulse pressure variation|
223792206|NCT01257867|DIETARY_SUPPLEMENT|Lithia water|Oral intake of approximately 2 litres (2L) daily for 4 weeks
223792207|NCT01257867|DIETARY_SUPPLEMENT|Natural spring water with negligible lithium levels|Oral intake of approximately 2 litres (2L) daily for 4 weeks
223792208|NCT04654416|DRUG|Corticosteroid with or without colchicine|We describe the clinical outcome of patients treated with corticosteroid and colchicine
223792209|NCT01943201|DEVICE|new bedsheet|sleeping 5 nights on the new bedsheet
223792210|NCT01943201|DEVICE|conventional bedsheet|sleeping 5 nights on the conventional bedsheet
223792211|NCT00765193|OTHER|Inspection of covered areas|Clinicans performed a two-step examination for skin cancer, with clinical examination of individual lesions was aided by the use of dermoscopy, as needed. In the first step, physicians performed inspection of problem areas and uncovered areas only, and lesions suggestive of melanoma or non-melanoma skin cancer were noted. In the second step, TBSE was performed. Following both examinations, lesions suggestive of melanoma or non-melanoma skin cancer were excised or biopsied. Histopathologic diagnosis was recorded for each of the biopsied or excised lesions.
223792212|NCT04241861|OTHER|Respiratory support (High-flow oxygen therapy)|Noninvasive respiratory support respiratory support
223792213|NCT04241861|OTHER|Respiratory support (Helmet PSV)|Noninvasive respiratory support respiratory support
223792214|NCT04241861|OTHER|Respiratory support (Helmet CPAP)|Noninvasive respiratory support respiratory support
223792215|NCT00149253|DRUG|a single-dose of Etoricoxib before induction of anesthesia|
223792216|NCT01535716|BEHAVIORAL|hemodynamic optimization strategy driven by the ECOM|"goal directed hemodynamic therapy is based on the ECOM evaluation of stroke volume variation (SVV) \& cardiac index (CI).~goals:~* SVV \< 11%~* IC \> 2,2 ml/min/m²~During the anesthesia"
223792217|NCT01535716|BEHAVIORAL|standard management strategy|"goal directed hemodynamic therapy will be set and performed by the attending anesthetist, based on the analysis of further clinical parameters: Standard monitoring : heart rate, saturation index~* Diuresis \> 0,5ml/kg/h~* Blood pressure , PAM \> 65 mmHg~* Pulse pressure variation~* CVP 8 to 12 cmH20~* Visual aspect of the heart~* Overload signs During the anesthesia"
223792218|NCT01864564|OTHER|Early Screen|Women will be randomized to be screened for gestational diabetes at 14-19.9 weeks gestation (early=intervention) versus routine screening at 24-28 weeks.
223792219|NCT05883813|PROCEDURE|sustained natural apophyseal glides (SNAGS)|SNAGS will be given with patient in sitting position and the therapist will be standing behind the patient. The therapist will place the thumb on the spinous process of the vertebra. Move spinous process upward towards the eyeball direction \& maintain the glide and ask the patient to turn (rotation) his head slowly in painful direction, sustain the mobilization until head turn to the midline. Three repetitions of each glide will be given and each glide will be maintained for 10 seconds at end range.
223792220|NCT05883813|PROCEDURE|suboccipital muscle release|Sub-occipital muscle release will be applied with the patient in the supine position with the eyes closed and the physiotherapist's hands placed under the patient's head, in contact with the sub-occipital muscles. The physiotherapist progressively increased the pressure exerted during the 10 minutes of treatment.
223792221|NCT05883813|PROCEDURE|Supplemental therapy|General warm-up exercises, TENS, hot pack, trapezius stretching
223792222|NCT01060982|DEVICE|Ultrasonic ablation device|One High Intensity focused ultrasound session before surgery. Use of appropriate energy for each patient
223792223|NCT02491008|DRUG|Levothyroxine|The intervention will start with Levothyroxine 50 mcg daily (reduced to 25 mcg in subjects \<50 kg of body weight or if known coronary heart disease - previous myocardial infarction or symptoms of angina pectoris) vs. matching placebo; at 3 months, if the serum TSH level is \<0.4 mU/L, dose will be reduced by 25 mcg; TSH \>=0.4 and \<4.6 mU/L, no change to dose; TSH \>=4.6 mU/L, additional 25 mcg. The process will be repeated at 12 months, then annually; mock titration will be performed in the placebo group. The maximum possible dose of Levothyroxine which will be prescribed is 150 mcg (after 4 increments of 25 mcg at 3 months, 1, 2, 3 years; from the starting dose of 50 mcg).
223792224|NCT02491008|DRUG|Placebo|"Control patients will obtain a placebo pill of the same characteristics as the intervention drug, and mock titration will be carried out identically to the intervention drug.~Pharmaceutical composition of placebo (100 mg): Lactose monohydrate 66 mg, Maize starch 25 mg, Gelatin 5 mg, Croscarmellose sodium 3.5 mg, Magnesium stearate (vegetable source) 0.5 mg."
223792225|NCT02065531|OTHER|Myofascial Soft Tissue Release|Protocol: Transverse Plane-Level Clavicular Release. Diaphragmatic Transverse Plane Release. Square the Lumbar Fascia Release. Gluteal Fascia Release. Hint Of Pubic Region Release. Fascia Psoas Release. Lumbo-sacral Decompression. Pelvic Floor Release.
223792226|NCT02065531|OTHER|Mobilization with impulse technique.|Subject in lateral decubitus with extension and lower limb traction contact the couch with contralateral lower limb was performed triple flexion and left trunk rotation. This technique reduces the slack (tension joints) of the ventral pelvis, head and into the contralateral side of the sacrum support (base) with the forearm.
223792227|NCT03077724|DRUG|Fish oil|Fish oil supplementation
223792228|NCT03077724|DRUG|Placebos|Olive Oil capsules
223792229|NCT05041673|DRUG|Metformin|Antidiabetic drugs
223792230|NCT00895401|DIETARY_SUPPLEMENT|Nepro with Carb Steady|Nepro with Carb Steady is a commercially available renal specific oral nutritional supplement designed to meet the nutrient needs of dialysis patients. The supplement is 8 oz and provides 425 kcal and 19 grams of protein.
223792231|NCT00895401|OTHER|Standard of Care|Standard of Care for malnourished maintenance hemodialysis patients
223792232|NCT01496352|DRUG|DFA-02|Modified release product containing gentamicin and vancomycin for application at the conclusion of surgery after closure of the fascia and prior to skin closure
223792233|NCT01496352|DRUG|Placebo|DFA-02 placebo
223792234|NCT05343039|DEVICE|Non-invasive Transcutaneous Nerve Stimulation (tVNS)|Participants will engage in 25-minute tVNS sessions every day for 30 days.
223792235|NCT05343039|DEVICE|No Intervention|Participants will not receive any intervention.
223792236|NCT03156049|PROCEDURE|Sphenopalatine block|patients will receive bilateral sphenopalatine ganglion block using 3ml mixture of 2ml 2% lidocaine plus 1ml dexamethasone 4mg (on each nostril).
223792237|NCT03156049|PROCEDURE|Greater occipital nerve block|patients will receive bilateral greater occipital nerve block using a mixture of 3ml of 2ml 2% lidocaine plus 1ml dexamethasone 4mg (on each side of the occipital region).
223792238|NCT04075435|DRUG|high CBD/low THC sublingual solution|Hemp derived solution to be administered sublingually twice daily.
223792239|NCT06736275|DRUG|SXRN|"SXRN is a naked plasmid DNA drug targeting miRNA. Accelerated titration and 3+3 dose escalation:In light of ethical considerations and with the aim of minimizing the number of patients possibly exposed to potentially ineffective doses, an accelerated titration strategy will be implemented in the early dose escalation phase (2 mg dose group) in this study, with only 1 subject enrolled. If no DLT occurs to the 3 subjects under the given dose in the DLT valuation window (the 1st cycle, 3 weeks), the study will proceed to the next dose (dose escalation in the same subject is not allowed); if one subject develops DLT, 3 additional subject s will be included to the current dose group; if ≥2 DLTs occur in the dose group with 3 or 6 subject s, the dose escalation will be stopped. The decision is made by discussion among the investigators whether to terminate the escalation or consider adjusting the dose for exploration."
223792240|NCT04787757|PROCEDURE|Percutaneous cardiac procedure|Collection and analysis of intraprocedural information to provide artificial intelligence algorithms
223792241|NCT04414696|BEHAVIORAL|Exercise intervention|eHealth exercise intervention for postpartum women at increased risk of depression
223792242|NCT07127367|BEHAVIORAL|Memory Training|Memory retraining exercises will be administered on a laptop computer twice a week for five weeks (10 training sessions).
223792243|NCT03602417|DEVICE|Flare type stent|Flare type has a wide diameter at proximal portion to prevent stent migration.
223792244|NCT03602417|DEVICE|Conventional D-type stent|This stent is an original full covered stent to treat malignant colorectal obstruction.
223792245|NCT00999258|DRUG|sirolimus|"The subjects assigned to the sirolimus conversion group will be initiated on sirolimus 5mg po daily at which time their tacrolimus dose will be decreased by 50%. Sirolimus levels will be checked within a week and adjusted in a linear fashion to achieve a trough goal of 12-15ng/ml in subjects within 1 year post-transplant, and 8-12 ng/ml in subjects more than 1 year post-transplant. Tacrolimus will be continued in these subjects until sirolimus target trough levels are achieved. Thereafter, tacrolimus will be discontinued indefinitely.~The subjects assigned to the tacrolimus maintenance group (control group) represent our present standard of care."
223792246|NCT04462861|DEVICE|Central venous access device (CVAD) Snuggie Securement Device|Participants will be given a prototype of a CVAD securement device for a three week trial. Descriptive data relating to user satisfaction will be collected at 1 and 3 weeks
223792247|NCT06012734|DRUG|LB-100|IV on day 1 and day 3
223792248|NCT06012734|DRUG|Atezolizumab|IV on day 1
223792249|NCT04581525|DEVICE|transcranial direct current stimulation|
223792250|NCT04616508|BEHAVIORAL|motor control assessment|Basic science study of control of reaching movements
223792251|NCT00275795|PROCEDURE|NAET Procedures|
223792252|NCT02807896|OTHER||This study is cohort.
223792253|NCT04367350|DIAGNOSTIC_TEST|laboratory biomarkers|creatine kinase, troponin, urine myoglobin, and autoimmune antibodies
223792254|NCT04367350|DIAGNOSTIC_TEST|muscle ultrasound|Muscle echogenicity in the upper and lower extremities, the accessory respiratory serratus anterior muscle, and abdominal wall according to qualitative ultrasound assessment (Heckmatt score)
223792255|NCT03034642|PROCEDURE|Bronchoscopy with bilateral bronchoalveolar lavages|Bronchoscopy with bilateral bronchoalveolar lavages
223792256|NCT02062268|BEHAVIORAL|health education & law enforcement|
223792257|NCT01785303|BEHAVIORAL|CBT-I|Cognitive Behavior Therapy for Insomnia (CBT-I) consists of 4 weekly sessions delivered individually. The focus of these sessions is on modifying behaviors and cognitions related to sleep and insomnia.
223792258|NCT01785303|PROCEDURE|CPAP|CPAP is an FDA-approved medical device used to treat obstructive sleep apnea. This device consists of a mask, hose, and machine that blows continuous air which maintains a consistent pressure of airflow preventing the upper airway from collapsing during sleep.
223792259|NCT03457753|DRUG|Riluzole Oral Soluble Film|Riluzole Oral Soluble Film (ROSF) containing Riluzole 50mg .
223792260|NCT00735995|BEHAVIORAL|Cognitive behavioral therapy (individual)|The Coping Cat program, 12 weekly sessions, two additional parent meetings
223792261|NCT00735995|BEHAVIORAL|Cognitive behavioral therapy (group)|The Coping Cat program, 12 weekly sessions, two additional parent meetings
223792262|NCT01588184|DRUG|Bevacizumab|Bevacizumab will be administered at 7.5 or 15 milligrams per kilogram (mg/kg) intravenously every 3 weeks (Q3W), or 5 or 10 mg/kg intravenously every 2 weeks (Q2W).
223792263|NCT03722186|DRUG|SHR-1603|SHR-1603 monotherapy
223792264|NCT01744522|PROCEDURE|Leech therapy|Leech therapy: Using medicinal leeches After piercing the skin and injecting anticoagulants (hirudin) and anaesthetics, they suck out blood of the incision. After 30 to 60 minutes they fall off and the wound -after a short time of after-bleeding- is bandaged up.
223792265|NCT05836766|DRUG|Y-6 sublingual tablets|Take Y-6 sublingual tablets for 28 days continuously.
223792266|NCT05836766|DRUG|Placebo tablets of Y-6 sublingual tablet|Take Placebo tablets of Y-6 sublingual tablet for 28 days continuously.
223792267|NCT05912400|DIAGNOSTIC_TEST|Blood draw|• An additional 10 mL of blood will then be drawn for mitochondrial testing purposes.
223792268|NCT05912400|OTHER|FACIT-F and Pain Scales|• Questionnaires regarding pain and fatigue will be provided for the subject to review and answer.
223792269|NCT01454206|BEHAVIORAL|iSBIRT|"Participants will be screened for substance use, view information about the health effects of substance use on the computer, and receive advice from the primary care provider regarding the health effects of substance use. Those found to be at high risk will complete an internet-based program encouraging them to change their substance use."
223792270|NCT06094634|BEHAVIORAL|The Brief Alcohol Intervention (BAI): Behavioral|The BAI draws from Motivational Interviewing (MI)/Motivational Enhancement Therapy (MET) and Cognitive Behavioral Therapy (CBT) and comprises 2 in-person face-to-face sessions and 2 booster telephone sessions by a trained counselor.
223792271|NCT03044067|OTHER|Pain neuroscience education + Exercise|A session of Pain neuroscience education + Exercise covers the activity, strength and endurance of lower and upper muscles of the extremities. Besides that it will be covered the understanding and acknowledgement about how pain is processed.
223792272|NCT03044067|OTHER|Exercise|A session of exercise covers the activity, strength and endurance of lower and upper muscles of the extremities.
223792273|NCT02980159|OTHER|Triage liaison physician|A triage liaison physician is present from 7:30 am to 10:30 pm, Monday to Friday, with the mission to evaluate quickly patients who cannot be immediately installed in an ED room
223792274|NCT02522494|BEHAVIORAL|Pamphlet|An educational intervention delivered prior to patients' visits with primary care physicians.
223792275|NCT02522494|BEHAVIORAL|Video|An educational intervention delivered prior to patients' visits with primary care providers.
223792276|NCT02514629|DRUG|Placebo|
223792277|NCT02514629|DRUG|Metformin|
223792278|NCT02514629|DRUG|Testosterone Undecanoate|
223792279|NCT02514629|DRUG|Metformin + Testosterone Undecanoate|
223792280|NCT01354158|DRUG|Droxidopa|Dose titration of placebo, 100mg, 200mg, 400mg of Droxidopa will be given to assess the effects of Droxidopa on blood pressure and cerebral blood flow.
223792281|NCT02811861|DRUG|Lenvatinib|
223792282|NCT02811861|DRUG|Everolimus|
223792283|NCT02811861|DRUG|Pembrolizumab|
223792284|NCT02811861|DRUG|Sunitinib|
223792285|NCT05854511|DRUG|Sofosbuvir 200 MG Oral Tablet plus Daclatasvir 30 mg Oral tablets|Daclatasvir 30 mg orally once daily plus Sofosbuvir at a dose of 200 mg (2x 100 mg tablets) orally once daily for 12 weeks.
223792286|NCT05688995|BIOLOGICAL|Naser Al-Husban|COVID-19 vaccines
223792287|NCT01764165|OTHER|Oxygen|oxygen at a rate of 2 L/min will be delivered through a small nasal cannula throughout sleep.
223792288|NCT01764165|OTHER|High flow of room air|Warm and humidified air at rates of 20 L/min will be delivered through a small nasal cannula throughout sleep
223792289|NCT00176579|PROCEDURE|dual x-ray absorptiometry|Dual x-ray absortiometry by densitometer will be performed to measure bone mineral density
223792290|NCT04912648|OTHER|Longitudinal follow up|Repeat follow up at 3,5 and 10 years
223792291|NCT03837652|OTHER|Use of bone-borne palatal expander & maxillary osteotomy|Application of bone-borne palatal expander in conjunction with maxillary osteotomy for expansion of constricted maxillae
223792292|NCT00898118|GENETIC|polymerase chain reaction|
223792293|NCT00898118|OTHER|flow cytometry|
223792294|NCT00898118|OTHER|laboratory biomarker analysis|
223792295|NCT00898118|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
223792296|NCT04537091|PROCEDURE|rESWT|rESWT was administered once per week for 3 weeks with 4 bar pneumatic pressure, 10 Hz frequency, with 2000 pulses. Radial shock waves were transmitted to the greater trochanteric region with the maximum pain/tenderness that was identified with patients' reaction with small circular movements with an adequate amount of contact gel
223792297|NCT04537091|PROCEDURE|PRP injection|PRP injection is performed with a high resolution 7-12-megahertz linear probe ultrasonography device. 15 ml of blood will be drawn from the patients and the blood will be centrifuged for 5 minutes. 4-5 ml PRP will be injected into the affected gluteal tendons accompanied by ultrasonography.
223792298|NCT06781723|BEHAVIORAL|Resistance Exercise|Participants will perform leg press and leg extension immediately prior to ingestion of rice and beans or isolated mixture.
223792299|NCT06781723|DIETARY_SUPPLEMENT|Isolated Mixture|Participants will ingest isolated mixture of crystalized amino acids, maltodextrin, fiber and oil immediately after resistance exercise.
223792300|NCT06781723|OTHER|Rice and Beans|Participants will ingest cooked rice and beans meal immediately after resistance exercise.
223792301|NCT05924646|DIETARY_SUPPLEMENT|Sodium Chloride Capsules|Table salt in slow release capsules.
223792302|NCT05924646|OTHER|Microcystalline Cellulose Capsules|Microcrystalline Cellulose Capsules (Placebo)
223792303|NCT00360308|DRUG|Placebo|
223792304|NCT00360308|DRUG|E2007|
223792305|NCT00360308|DRUG|E2007|
223792306|NCT00822029|DRUG|FOSAMAX|patient receiving one tablet (oral use) 70 mg Fosamax by week
223792307|NCT00822029|OTHER|PLACEBO|patient receiving one tablet (oral use) placebo by week
223792308|NCT00400010|BEHAVIORAL|Expert System Intervention|Questionnaires on motivation to change and alcohol consumption were assessed in a clinical interview. Data were entered in a Computer and a fully automatized feedback letter was generated by an expert system. The printed feedback letter was handed out to patients by study staff the following day.
223792309|NCT05596591|DEVICE|Focused extracorporeal shockwave therapy|High energy level shockwaves (between 0.28-0.60 mJ/mm\^2) will be focused over the subchondral bone with the bone marrow lesion, previously localized on MRI.
223792310|NCT04376021|BEHAVIORAL|Babywearing|Increase mother-infant physical contact through babywearing
223792311|NCT03588533|DRUG|Trastuzumab|"* Trastuzumab (Herzuma) 8mg/kg loading over 90min (1st cycle)~* Trastuzumab (Herzuma) 6mg/kg maintenance over 30min (2nd cycle\~ ) every 3 weeks"
223792312|NCT03588533|DRUG|Capecitabine|\- Capecitabine 1000mg/m2 p.o. bid D1-D14 every 3 weeks
223792313|NCT03588533|DRUG|Cisplatin|\- Cisplatin 60\~100mg/m2 i.v. D1 every 3 weeks
223792314|NCT04224077|DIAGNOSTIC_TEST|Optimisation of DTI sequences|Optimisation of DTI sequences in the study of lumbar roots by MRI
223792315|NCT01343511|BIOLOGICAL|human cord blood mononuclear cells|Participants will be given rehabilitation therapy plus hCB-MNCs transplantation.
223792316|NCT01343511|BIOLOGICAL|human cord blood mononuclear cells and human umbilical cord mesenchymal stem cells|Participants will be given rehabilitation therapy plus and hCB-MNCs and hUC-MSCs transplantation.
223792317|NCT03461003|OTHER|NICHE method|Based on underlying comorbidities at enrollment, patients will be assigned to either an unrestricted protocol (amlodipine versus lisinopril) or a restricted protocol (losartan versus lisinopril). Two drugs are tested in randomized order. Failure to achieve BP control at maximum doses of the first two drugs will result in augmentation with a diuretic (hydrochlorothiazide). BP control is assessed with 24 hour ambulatory monitoring at the end of each 2 week treatment period. Side effect tolerability is assessed with a questionnaire.
223792318|NCT03461003|OTHER|Usual care|Physician preference will dictate choice and adjustment of antihypertensive medication, BP measurement modality, interval between visits, and assessment of side effects.
223792319|NCT03461003|DRUG|Amlodipine|Calcium-channel blocker; antihypertensive
223792320|NCT03461003|DRUG|Lisinopril|Angiotensin-converting-enzyme (ACE) inhibitor; antihypertensive
223792321|NCT03461003|DRUG|Hydrochlorothiazide|Thiazide diuretic; antihypertensive
223792322|NCT03461003|DRUG|Losartan|Angiotensin II receptor blocker (ARB); antihypertensive
223792323|NCT03045666|OTHER|Exercise program|patients who are stable on Macitentan therapy (received in both groups before enrollment) and will exercise at a pulmonary rehabilitation program twice a week for 12 weeks
223792324|NCT00127075|DRUG|nomegestrol acetate|10 mg/day
223792325|NCT00127075|DRUG|estradiol|75 mcg, once a week
223792326|NCT00127075|DRUG|placebo|matching placebo treatments
223792327|NCT06395662|OTHER|Observational|Search for biomarkers
223792328|NCT03489304|DRUG|Zaleplon|non-benzodiazepine hypnotic agent
223792329|NCT01656551|DRUG|Gemcitabine|
223792330|NCT01656551|DRUG|Pemetrexed|500 mg/m2 day 1 every 3 weeks
223792331|NCT01656551|DRUG|Cisplatin|60 mg/m2 day 1 every 3 weeks
223792332|NCT03991611|OTHER|Administration of the IPREA3 questionnaire|On the day of the ICU discharge, the bedside nurse administers to the patient the 18-item IPREA questionnaire i.e the nurse asks the patient to rate from 0 to 10 the severity of each discomfort source contained in the IPREA3 questionnaire experienced during the entire stay in the ICU
223792333|NCT03991611|OTHER|Immediate feedback through electronic reminder messages|After the nurse had administered the questionnaire, warning messages are displayed on the screen corresponding to the key points to prevent the three discomforts reported with the highest scores
223792334|NCT03991611|OTHER|Targeted interventions in each ICU to reduce discomforts|"These targeted interventions are implemented through the coordination of two local champions.~The central coordination IPREA3 team sends each month to the local champions monthly and cumulative discomfort scores of their unit (overall score of discomfort and scores for each item) and their ranking relative to other units assigned to the interventional arm i.e applying the IPREA3 program.~The local champions organize monthly meetings with the unit staff to present the results in terms of perceived discomforts measured by the IPREA questionnaire, identify main discomfort sources and actions to be conducted to reduce the discomforts reported with the highest scores in the unit and those that are most easily preventable, and assess the efficacy of already applied measures."
223792335|NCT03991611|OTHER|6 months follow-up to assess the prevalence of PTSD symptoms|Psychologist will collect the PCL-5, HAD-S, WHOQOL-BREF, LEC-5 items during the telephone follow-up, 6 months after ICU discharge .
223792336|NCT03991611|OTHER|1 year follow-up to assess psychiatric morbidity|Psychologist will collect the PCL-5, HAD-S, WHOQOL-BREF, LEC-5 and CTQ items during the telephone follow-up, 1 year after ICU discharge .
223792337|NCT01227681|DRUG|G-CSF|G-CSF(granulocyte-colony stimulating factor) is planned injected subcutaneously
223792338|NCT01227681|DRUG|Placebo|Sodium Chloride (NaCl) 0.9 %
223792339|NCT02239679|DRUG|Aminolevulinic Acid|20% ALA applied to face for one hour prior to 10 J/cm2 blue light
223792340|NCT02239679|DRUG|Topical Solution Vehicle|Levulan Kerastick containing vehicle ingredients only. Vehicle solution applied to face one hour prior to 10 J/cm2 blue light
223792341|NCT02239679|DEVICE|BLU-U|10 J/cm2 blue light delivered at 10 mW/cm2
223792342|NCT02239679|PROCEDURE|Cryotherapy|Liquid nitrogen cryotherapy by standard of care method to all visible/palpable actinic keratosis (AK) lesions at screening.
223792343|NCT04572048|OTHER|Single-day NRP Training|NRP training course completed in one single day of 8 hours
223792344|NCT04572048|OTHER|longitudinal NRP training|NRP training course completed over one year by attending nine 30-minute modules.
223792345|NCT00228020|DRUG|basiliximab, MMF(mycophenolate mofetil), cyclosporine, prednisone (or equivalent)|
223792346|NCT00228020|DRUG|MMF, cyclosporine, steroids|
223792347|NCT01898819|DRUG|Dexmedetomidine|
223792348|NCT01898819|DRUG|saline|
223792349|NCT02278094|DEVICE|Tongue Muscle Trainer (TMT)|Subject will be instructed to compress the Iowa Oral Performance Instrument (IOPI) IOPI's bulb using tongue in three directions (anterior and both lateral sides). Then, hold 30-35 seconds each time. Subjects will be encouraged to do 60 minutes of exercise daily then continue three to five times a week for a total of 3 months.
223792350|NCT02278094|DEVICE|Threshold Inspiratory Muscle Trainer (TIMT)|Resistance of the TIMT devices will be set from 30% of the maximum inspiratory pressure. Nose clip follow by normal breathing. Seal the mouth to the device's mouth piece then inhale through the device. Subjects will be encouraged to do 60 minutes of exercise daily then continue three to five times a week for a total of 3 months.
223792351|NCT02278094|PROCEDURE|Walking Exercise|Subjects will be encouraged to perform walking exercise in the field 10000 steps/ 60 minutes daily then continue three to five times a week during first months. Followed by 12500 steps and 15000steps per day during the second and third months.
223792352|NCT02278094|DEVICE|Continuous Positive Airway Pressure (CPAP)|CPAP regular therapy per day (use ≥ 4 h/day) then continue three to five times a week for a total of 3 months.
223792353|NCT03583918|DEVICE|HighThroughput Micro Coring Device|Assess Safety and Efficacy for skin treatments through micro-excisional skin removal with micro-coring device
223792354|NCT00002933|DRUG|irinotecan hydrochloride|Irinotecan IV at a starting dose weekly for 4 weeks followed by 2 weeks of rest. Treatment continues in the absence of disease progression or unacceptable toxicity. Tumor status is reassessed every 12 weeks during study. Patients attaining a complete response may receive additional courses of treatment. Patients are followed until death.
223792355|NCT00066248|DRUG|cyproheptadine hydrochloride|Receive 0.25mg/kg cyproheptadine hydrochloride once daily for 4 weeks. If subject responds to treatment (stable or increased weigh), go off study. If subject does not respond (loses weigh), subject will switch to10 mg/lg/day of megestrol acetate for 4 weeks.
223792356|NCT00066248|DRUG|megestrol acetate|Receive 0.25mg/kg cyproheptadine hydrochloride once daily for 4 weeks. If subject responds to treatment (stable or increased weigh), go off study. If subject does not respond (loses weigh), subject will switch to10 mg/lg/day of megestrol acetate for 4 weeks.
223792357|NCT00152776|DRUG|ovaria comp 10 globuli 3 times per day 24 weeks|order of intervention and placebo varies between Groups I-III
223792358|NCT05461222|DEVICE|"Balt Goldballoon"|"Fetal endoscopic tracheal occlusion (FETO) is a procedure where a balloon is placed in the main airway or windpipe of the fetus, to help with the development of the lungs. This is performed using a fetoscope, a small camera that is inserted into the amniotic cavity and deploying the FETO Goldballoon into the fetal trachea."
223792359|NCT01217073|DRUG|Omarigliptin|Omarigliptin 0.25, 1, 1.5, 10 or 25 mg oral capsule administered once weekly. For omarigliptin 3 mg, participants received two omarigliptin 1.5 mg capsules.
223792360|NCT01217073|DRUG|Placebo to omarigliptin|Matching placebo to omarigliptin 0.25, 1, 1.5, 10 or 25 mg oral capsule administered once weekly. For matching placebo to omarigliptin 3 mg, participants received two matching placebo to omarigliptin 1.5 mg capsules.
223792361|NCT01217073|DRUG|Pioglitazone|Pioglitazone 15 mg oral tablet or capsule administered once daily
223792362|NCT01217073|DRUG|Metformin|Metformin 500 mg oral tablet administered once or twice daily
223792363|NCT01217073|DRUG|Placebo to metformin|Matching placebo to metformin oral tablet administered once daily
223792364|NCT01815268|BIOLOGICAL|HD Vaccine|Nursing home residents over 65 years are allocated to receive high-dose vaccine. Residents under 65 years are provided standard-dose vaccine.
223792365|NCT01815268|BIOLOGICAL|SD Vaccine|Nursing home residents are allocated to receive standard-dose vaccine.
223792366|NCT01815268|BIOLOGICAL|Free Vaccine|Nursing home facilities are provided free standard-dose vaccine for their staff.
223792367|NCT01815268|BIOLOGICAL|Usual Care|Nursing home staff will have access to influenza vaccine, per standard of care. No free vaccine provided as part of study.
223792368|NCT04879901|DIAGNOSTIC_TEST|surface EMG|surface EMG estimation with Carrying backpacks forward or backward
223792369|NCT01339754|DRUG|trabectedin|1.3 mg/mq as a 3 hour continuous infusion every three weeks
223792370|NCT01339754|DRUG|trabectedin|1.3 mg/mq as a 3 hour continuous infusion every three weeks until progression
223792371|NCT02573974|OTHER|Samples|Blood samples, muscle biopsy and sample of hair
223792372|NCT03989466|BIOLOGICAL|Alemtuzumab|Given IV
223792373|NCT03989466|DRUG|Itacitinib|Given PO
223792374|NCT01469533|OTHER|Spinal mechanical manipulation intervention|Subjects in experimental group are assessed through use of the Activator Methods (AM) assessment protocol. Spinal adjustment of the indicated pelvis, sacrum and lumbar spine is performed through the use of spinal mechanical manipulation. In this study leg length analysis only uses Position #1 and Position #2. Mechanical manipulation is delivered with the Activator Ⅳ Adjusting Instrument (AAI Ⅳ; Activator Methods International, Ltd, Phoenix, AZ) set in the maximal force setting 4, as it is used in routine clinical practice. The Activator Ⅳ delivers a very short duration (\<5 ms) force-time impulse with a peak force magnitude of approximately 176N.
223792375|NCT01469533|OTHER|Sham manipulation intervention|Subjects in the control group receive a protocol identical to that described above, with the following exception: a sham mechanical thrust is delivered during the AM protocol. The sham procedure is accomplished by setting the expansion control knob on the Activator Ⅱ to the zero (off) position. The expansion control is used to adjust the spring compression and thus the amount of excursion of the instruments' stylus. In the zero position, no excursion of the stylus occurs, although the same clicking sound that the instrument produces during normal use is heard after manual activation of the mechanical trigger.
223792376|NCT00042679|DRUG|Gemcitabine|
223792377|NCT00042679|DRUG|Carboplatin|
223792378|NCT00042679|DRUG|LY900003|
223792379|NCT00002574|BIOLOGICAL|recombinant interferon alfa|
223792380|NCT00002574|DRUG|omacetaxine mepesuccinate|
223792381|NCT05079074|DIAGNOSTIC_TEST|ctDNA testing|ctDNA testing was performed for late-stage metastatic breast cancer patients to trace their ctDNA abnormality.
223792382|NCT02047045|PROCEDURE|acupuncture|Electro-acupuncture at bilateral ST25, SP14 ,and ST37. Patients will be treated once per day for 30 minutes, 5 times/week for the first 2 weeks and 3 times/week for the next 6 weeks. Each treatment cycle will include 28 sessions for continuous 8 weeks.
223792383|NCT02047045|DRUG|Prucalopride|Prucalopride Succinate will be taken orally at the dose of 2mg/day in the morning before breakfast. Each treatment cycle will be given for continuous 32 weeks.
223792384|NCT03548298|PROCEDURE|ARAT|After confirmation of GERD, participants will undergo to ablation with Hybrid-APC (ARAT). Participant will be admitted to hospital 24 hrs before procedure. Technique consist in ablation with hybrid-APC, submucosal injection of saline solution with methylene blue at 3-4 cm from 60-70% cardias and 1 cm esophageal. After procedure they will be kept on surveillance and will be followed-up with clinical, endoscopic, esophageal manometry and pHmetry up to 1 year after procedure.
223792385|NCT03565510|DIETARY_SUPPLEMENT|High-Protein Diet|The high-protein diet is composed of 35% of carbohydrate, 40% of protein, and 25% of lipid constructed around a soy protein-based meal replacement.
223792386|NCT02634411|DRUG|8 days of effective antibiotic treatment|"Antibiotics used for usual care in PA-VAP treatment : Penicillins, Cephalosporins, Monobactams, Carbapenems, Fluoroquinolones, Aminoglycosides (list not exhaustive).~Antibiotic treatment should be started just after realization of bacteriological sampling, and then converted into a narrow-spectrum therapy, based on culture results, for a total duration of effective antibiotic therapy against pseudomona aeruginosa of 8 days."
223792387|NCT02634411|DRUG|15 days of effective antibiotic treatment|"Antibiotics used for usual care in PA-VAP treatment : Penicillins, Cephalosporins, Monobactams, Carbapenems, Fluoroquinolones, Aminoglycosides (list not exhaustive).~Antibiotic treatment should be started just after realization of bacteriological sampling, and then converted into a narrow-spectrum therapy, based on culture results, for a total duration of effective antibiotic therapy against pseudomona aeruginosa of 15 days."
223792388|NCT04022200|DEVICE|Paclitaxel DCB|The length of the DCB catheter should be chosen to exceed the target lesion for at least 2mm (at both proximal and distalends). The catheter(s) will be inflated for 30 to 60s with a minimum of 7 atm. Predilation of the diseased coronary segment with a uncoated balloon/scoring balloon/cutting balloon before the use of DCB will be encouraged. DES should be implanted if the angiographic result after DCB alone therapy is not satisfactory due to significant recoil/residual stenosis or dissection (Type C-F).
223792389|NCT04066114|BIOLOGICAL|lulizumab pegol|25 mg subcutaneously (SC) on Day 1 post transplantation then 12.5 mg SC weekly through day 77 (Week 11)
223792390|NCT04066114|BIOLOGICAL|antithymocyte globulin (rabbit)|Study participants are administered four doses of rabbit anti-thymocyte globulin, total dose 6 mg/kg given in divided doses on the day of transplantation and days 1-3.
223792391|NCT04066114|DRUG|methylprednisolone|500 mg (IV) on Day 0 (day of transplantation), 250 mg (IV) on Day 1 and 125 mg (IV) on Day 2
223792392|NCT04066114|BIOLOGICAL|tocilizumab|8 mg/kg (IV) on Day 2 post transplantation followed by 162 mg (SC) every 2 weeks through day 168 (Week 24)
223792393|NCT04066114|DRUG|Prednisone|"Beginning on Day 3 post transplantation, taken orally: 60 mg daily~* Days 4 through 10: 30 mg daily~* Days 11 through 17: 20 mg daily~* Days 18 through 24: 10 mg daily~* After Day 24: continued taper of dose to final maintenance dose of 5 mg, per protocol"
223792394|NCT04066114|DRUG|everolimus|Initial dose of 0.75 mg taken orally twice daily on Day 14 days after transplantation. Dose will be titrated to target trough levels 3-8 ng/mL.
223792395|NCT04066114|BIOLOGICAL|belatacept|5 mg/kg (IV) every 4 weeks starting on Day 84 (Week 12) and continuing through Day 364 (Week 52)
223792396|NCT04066114|DRUG|mycophenolate mofetil|mycophenolate mofetil is started no later than one day after transplant at 1000mg PO twice daily provided WBC count permits, staying on it until everoliumus level is within therapeutic range. Participants that do no tolerate everolimus can stay on or switch back to mycophenolate mofetil 1000 mg twice daily and remain in trial.
223792397|NCT04066114|DRUG|mycophenolic acid|mycophenolic acid is started no later than one day after transplant at 720mg PO twice daily provided WBC count permits, staying on it until everoliumus level is within therapeutic range. Participants that do not tolerate everolimus can stay on or switch back to 720 mg twice daily of mycophenolic acid and remain in trial.
223792398|NCT03399760|BIOLOGICAL|i-PRF|i-PRF (injectable platelet rich fibrin) assisted upper canine retraction
223792399|NCT03399760|PROCEDURE|canine retraction|upper canine retraction will be performed in one side of patients with Class II Division 1 malocclusion patients requiring therapeutic extraction of the maxillary first premolars
223792400|NCT03631186|DRUG|Semaglutide|Patients will be treated with commercially available semaglutide in a prefilled pen injector (FlexTouch® variant) according to routine local clinical practice at the discretion of the treating physician. Other anti-hyperglycaemic treatments will be prescribed at the physician's discretion.
223792401|NCT00728819|DEVICE|Tapered PICC|Standard peripheral central catheter placement in the Brachial, Basilic or Cephalic veins
223792402|NCT00728819|DEVICE|Non-tapered PICC|Standard peripheral central catheter placement in the Brachial, Basilic or Cephalic veins
223792403|NCT04111081|OTHER|Auricular pressure|Select related auricular points: Shenmen(TF4), sympathetic(AH6a), rectum(HX2), anus(HX5), stomach(CO4), subcortical(AT4). The auricle skin of the patient was disinfected 24 hours after the operation, and wanghuoxing seed will be used for stimulation. Ask patients press every two hours for one minute at each point. When the pain is severe, do pressure compressions at each point for 2 minutes once hour.
223792404|NCT04111081|OTHER|Shame auricular pressure|Select unrelated auricular points: eye(LO5), occipital(AT3), tonsil(LO7,8,9), lower auricular root(R3), dorsum auricular kidney(P5) and dorsum auricular lung(P2). The auricle skin of the patient was disinfected 24 hours after the operation, and wanghuoxing seed will be used for stimulation. Ask patients press every two hours for one minute at each point. When the pain is severe, do pressure compressions at each point for 2 minutes once hour.
223792405|NCT05599529|OTHER|Differential attainment|Differential attainment related to covid, ethnicity and international graduate status
223792406|NCT02451800|OTHER|in-class yoga|In-person yoga classes that meet for 3x/week for 3 months. Each class is 1 hour.
223792407|NCT02451800|OTHER|yoga by DVD|Individuals are asked to follow a 1-hour DVD on yoga 3x/week for 3 months.
223792408|NCT02451800|OTHER|stretching by DVD|Individuals are asked to follow a 1-hour DVD on stretching exercises 3x/week for 3 months.
223792409|NCT06213025|BEHAVIORAL|web-based Educational program promoting response and willingness to handle elderly|promote the response and willingness of gerontological nurses in handling elderly abuse cases. By employing a rigorous experimental design, this research seeks to contribute evidence-based insights that can inform educational strategies to empower nurses in safeguarding the well-being of elderly individuals.
223792410|NCT02564523|BIOLOGICAL|Ad26.ZEBOV|One 0.5 mL intramuscular (IM) injection of (5x10\*10 viral particles)
223792411|NCT02564523|BIOLOGICAL|MVA-BN-Filo|One 0.5 mL IM injection of (1x10\*8 infectious units)
223792412|NCT02564523|BIOLOGICAL|Placebo|One 0.5 mL IM injection of 0.9% saline
223792413|NCT03403725|DRUG|MEN1309|MEN1309 solution for intravenous infusion once every 3 weeks
223792414|NCT04100447|DRUG|Tranexamic Acid|A total of 700 mL of study drug should be completely consumed orally 2-12 hours prior to surgery as a split dose; 350 mL 6-12 hours prior to surgery and the remaining 350 mL 2-6 hours prior to surgery.
223792415|NCT00373334|DRUG|nizatidine (axid)|nizatidine (axid)
223792416|NCT00373334|DRUG|nizatidine (axid)|nizatidine (axid)
223792417|NCT00373334|DRUG|placebo|placebo
223792418|NCT05005832|OTHER|multi day walking|Over the course of 14 days, the pilgrims will cover a distance of about 300 km.
223792419|NCT04862143|DRUG|Alpelisib|Participants received a daily oral dose of 300 mg of alpelisib film-coated tablets for a total of 12 cycles, with each cycle lasting 28 days.
223792420|NCT04862143|DRUG|Fulvestrant|Participants were administered fulvestrant at a dose of 500 mg via intramuscular injection on Cycle 1 Day 1 and Cycle 1 Day 15, and on Day 1 of each 28-day cycle thereafter until Cycle 12.
223792421|NCT04862143|DRUG|Goserelin|Pre-menopausal women were administered a dose of 3.6 mg of goserelin injection via intramuscular route, beginning on Cycle 1 Day 1. Subsequently, the same dose was administered on Day 1 of each 28-day cycle throughout the study.
223792422|NCT02575846|DIETARY_SUPPLEMENT|Enteral Intake - Human Milk|Comparing formula and human milk
223792423|NCT02575846|DIETARY_SUPPLEMENT|Enteral Intake - Formula|Comparing formula and human milk
223792424|NCT06530914|DRUG|MRG003 combined with Pucotenlimab|Both interventions all drugs intravenous infusion, D1, once every 3 weeks, a total of 3 cycles.
223792425|NCT06530914|DRUG|MRG003 combined with Pucotenlimab+Cisplatin|All interventions all drugs intravenous infusion, once every 3 weeks, a total of 3 cycles.
223792426|NCT06215274|OTHER|Relationship of the cognitive leisure activity levels, cognitive function, and MRI characteristics.|The cognitive leisure activity levels, cognitive function, and MRI characteristics in people in the preclinical stage of Alzheimer's Disease (AD).
223792427|NCT03174223|DRUG|deep neuromuscular block|a continuous dosing of rocuronium is used to achieve neuromuscular block of 1-2 twitches post tetanic count
223792428|NCT02123654|DRUG|Daclatasvir|
223792429|NCT02123654|DRUG|Asunaprevir|
223792430|NCT02123654|DRUG|DCV 3DAA|
223792431|NCT02123654|OTHER|Placebo for DCV 3DAA|
223792432|NCT02123654|OTHER|Placebo for Daclatasvir|
223792433|NCT02123654|OTHER|Placebo for Asunaprevir|
223792434|NCT02828722|OTHER|Controlled light and noise|"Purpose: The day-night ratio of the environmental illumination (limit 8 lux) and that of the noise level (limit 20 dBA) must correspond to the necessary value required by a healthy human body as defined by the National Sleep Foundation (USA).~Implementation: Simulation of the daytime period is performed with blue predominant artificial light with colour temperature between 5500 and 8000 K with lux values of 1000-1200 measured at the head of the patient. Simulation of the nighttime period is performed with a sleeping mask and earplugs."
223792435|NCT02828722|OTHER|Controlled nutrition|"In compliance with the standard daily nutrition protocol, nutrition is carried out only during daytime both in case of enteral and parenteral feeding in accordance with European Society for Clinical Nutrition and Metabolism 2016 guidelines.~Nutritional regimen should be stopped for 8 hours/24 at night (non-nutritional period may be depending on the work schedule of the actual ICU) , even if the daily energy/protein target is not reached."
223792436|NCT02019160|DRUG|25% AgNO3 solution followed by 5% NaF varnish|Dosage of 4.4μg±1.4μg fluoride per use
223792437|NCT02019160|DRUG|38% SDF solution followed by placebo varnish|Dosage of 8.8μg±2.8μg fluoride per use
223792438|NCT03019211|OTHER|Exercise|
223792439|NCT03725917|OTHER|Physiotherapy protocol|The intervention will consist of a physiotherapy protocol twice a week for twelve weeks. The protocol will be done in three phases, constituting each month, a phase of the protocol. The first two phases will include therapeutic exercise of progressive difficulty and manual therapy, while the last phase will include only one week of manual therapy and therapeutic exercise, the last three weeks being composed only of therapeutic exercise
223792440|NCT03591341|DIAGNOSTIC_TEST|melatonin level in pumped breast milk|diagnostic test of melatonin level in pumped breast milk
223792441|NCT03885531|DEVICE|Total knee arthroplasty with Journey II CR Total Knee System|TKA with Journey II CR Total Knee System
223792442|NCT01726192|PROCEDURE|Placement of a femoral catheter with the hydrolocalization technique|Placement of femoral nerve catheter with the hydrolocalization technique, using ropivacaine 0.6%
223792443|NCT01726192|PROCEDURE|Placement of a femoral neurostimulating catheter|
223792444|NCT05194774|PROCEDURE|Greater Trochanter epiphysiodesis|epiphysiodesis by cortical screw and washer
223792445|NCT03771482|BEHAVIORAL|Quiztime modules|Text Messaging or Email system
223792446|NCT03031938|DRUG|Investigational medical product (IMP) administered in parent study|IMP as administered in parent study. IMP would have been either placebo, tanezumab, celecoxib, naproxen, diclofenac, administered in parent study
223792447|NCT02962687|BEHAVIORAL|Care management via videoconference|12-week nurse care management for medically complex Veterans with CI delivered via videoconference
223792448|NCT02962687|BEHAVIORAL|Care management via telephone calls|12-week nurse care management for medically complex Veterans with CI delivered via telephone calls
223792449|NCT06333925|DEVICE|High Frequency Repetitive Transcranial Magnetic Stimulation (HF rTMS)|10 Hz rTMS over the right dorsal lateral prefrontal cortex (dlPFC)
223792450|NCT06333925|DEVICE|Sham Repetitive Transcranial Magnetic Stimulation (sham- rTMS)|inactive rTMS over the right dorsolateral prefrontal cortex (dlPFC)
223792451|NCT06333925|BEHAVIORAL|Cognitive Restructuring|Cognitive restructuring is a cognitive behavioral intervention through which participants learn how to think differently about misophonic sound triggers in order to feel less emotional arousal.
223792452|NCT03670316|DRUG|Algorithm Treatment|Varenicline was selected as the first line of treatment for patients willing to take a medication twice per day and wanting cessation. Following varenicline, bupropion and then NRT are subsequent options. In terms of preference for NRT, nicotine patches would be the first option followed by lozenge, gum, inhaler, and nasal spray. The order of NRT within the algorithm is based upon patient familiarity and number of clinical trials supporting their use. Combination NRT (e.g., patch and lozenge) or adding NRT to varenicline or bupropion is offered to participants who have made an unsuccessful quit attempt with these medications in the past. If none of these medications are appropriate, then the participant is offered counseling only.
223792453|NCT03670316|OTHER|Quitline only|eTAU participants will complete the same algorithm questions but will not have this information sent to their provider, although their provider may elect to prescribe medication as part of standard of care. Participants will be referred to a quitline for behavioral support services for cessation.
223792454|NCT05780203|BEHAVIORAL|One session exposure treatment|One session exposure treatment during which patients will be confronted with a height-related situation.
223792455|NCT05780203|BEHAVIORAL|Sham Cognitive Bias Modification training|Sham Cognitive Bias Modification training procedure matched in format to active training but adapted to not target height-related, interpretational processing biases.
223792456|NCT05780203|BEHAVIORAL|Active Cognitive Bias Modification training|Active Cognitive Bias Modification training targeting height-related, interpretational processing biases.
223792457|NCT06388343|OTHER|Evaluation of Children's Listening and Processing Skills|The Evaluation of Children's Listening \& Processing Skills (ECLiPS; (Barry \& Moore, 2021; Barry et al., 2015; Petley et al., 2021) is a caregiver-report outcome measure to profile auditory and cognitive real-world abilities important for successful listening and (auditory) processing.
223792458|NCT06388343|BEHAVIORAL|Multidisciplinary behavioral assessment|By collecting behavioral measures, the investigators wish to understand the functional implications of the presented problems. Children will complete various well-chosen tasks using a tablet, in the presence of a trained clinician. Tablets are used as they are ubiquitous, cost-effective, and have excellent quality audio output. The investigators will apply the concept of differential testing (Dillon \& Cameron, 2021; Lagacé et al., 2010) to narrow down the range of deficits that lead to deficient scores. The investigators distinguish four (partly overlapping) categories of behavioral measures: 1) auditory processing, 2) (nonsense) speech sound processing in quiet and in noise, excluding semantics, 3) meaningful speech in quiet and in noise, language processing, and 4) neurocognitive (including attention, memory, processing speed) processing.
223792459|NCT05981274|DIAGNOSTIC_TEST|serum biomarker.|serum biomarker:CTX-II, COMP, hsCRP, TNF-a, CTX-I, sRANKL, OPG, and Osteopontin (OPN)
223792460|NCT01921439|BEHAVIORAL|Personalized Feedback|Personalized feedback reflecting the participant's current level of nicotine addiction, money spent on cigarettes, time spent smoking, and health effects of smoking.
223792461|NCT03876652|DEVICE|Pacemaker with Closed Loop Stimulation (CLS)|In active mode of closed loop sensor (CLS), evaluate its impact on quality of life and recurrence of syncope.
223792462|NCT02479412|DRUG|800 μg AZD7594 once daily|Once daily dosing of 800 µg AZD7594 for 14 days; each dose of AZD7594 inhalation powder will be administered via a dry powder monodose inhaler as 2 hard capsules with 2 inhalations per capsule
223792463|NCT02479412|DRUG|250 µg AZD7594 once daily|Once daily dosing of 800 µg AZD7594 for 14 days; each dose of AZD7594 inhalation powder will be administered via a dry powder monodose inhaler as 2 hard capsules with 2 inhalations per capsule
223792464|NCT02479412|DRUG|58 µg AZD7594 once daily|Once daily dosing of 800 µg AZD7594 for 14 days; each dose of AZD7594 inhalation powder will be administered via a dry powder monodose inhaler as 2 hard capsules with 2 inhalations per capsule
223792465|NCT02479412|DRUG|Placebo once daily|Once daily dosing of Placebo to AZD7594 for 14 days; each dose of Placebo inhalation powder will be administered via a dry powder monodose inhaler as 2 hard capsules with 2 inhalations per capsule
223792466|NCT02479412|DRUG|Salbutamol|Inhalation as needed
223792467|NCT03627481|PROCEDURE|Endoscopic sinus surgery|Endoscopic sinus surgery for nasal polyposis
223792468|NCT00454051|DRUG|Omalizumab|Omalizumab was supplied as a sterile, freeze dried preparation, to be reconstituted to deliver 150mg of omalizumab. Each vial was reconstituted with 1.4ml of sterile water for injection. The appropriate dose and dosing frequency of omalizumab were determined by baseline total IgE and body weight. A dosing table was used following the European Summary of Product Characteristics (SmPC) of omalizumab.
223792469|NCT00454051|DRUG|placebo|Placebo was a physiological salt solution, administered according to the same administration scheme to respect the same dosing frequency and injected volume.
223792470|NCT06302166|OTHER|High Intensity Circuit training (HICT)|High Intensity circuit training consisting of circuits of high intensity exercises and progressed up to 8 weeks will be provided.
223792471|NCT06302166|OTHER|Intermittent Fasting (IF)|Time restricted feeding will be used in which the intervention will begin with a 12:12 window leading to a 16:8 IF protocol.
223792472|NCT06302166|OTHER|Combination of HICT and IF|The participants will follow both HICT and IF for 8 weeks.
223792473|NCT02049073|DRUG|Zonisamide|Zonisamide 100 mg or 200 mg pill administered orally every day for 2 weeks
223792474|NCT02049073|DRUG|Methylprednisolone|Methylprednisolone 32 mg or 64 mg pill administered orally once
223792475|NCT02628054|BIOLOGICAL|Typhoid Vaccine|Typhoid Vaccine injection given 7 days apart
223792476|NCT02628054|BIOLOGICAL|Placebo|Saline injection given 7 days apart
223792477|NCT04338100|PROCEDURE|Follow-up at 14 days|Point of care chest ultrasonography and 14-day follow-up to assess the evolution of the infection and care requirement (invasive ventilation or death)
223792478|NCT01848873|DRUG|Amlodipine|amlodipine 5mg daily
223792479|NCT01848873|DRUG|amlodipine-FA tablet, low dose group|5mg amlodipine combined with 0.4 mg of folic acid, daily.
223792480|NCT01848873|DRUG|amlodipine-FA tablet ,high dose group|amlodipine 5mg and folic acid 0.8mg daily
223792481|NCT00401570|DRUG|Volociximab|Volociximab: 10 mg/kg or 15mg/kg every week or every other week (qowk) via IV infusion for up to 104 weeks.
223792482|NCT00401570|DRUG|Gemcitabine|Gemcitabine: Standard chemotherapy regime at 1 g/m2 once per week for 3 weeks via IV infusion, followed by one week with no treatment
223792483|NCT05510843|DRUG|THB001|100 mg capsules for oral administration
223792484|NCT02836808|BEHAVIORAL|CAIPaDi|Patients are attended in 1 day by 9 specialists (endocrinologist, diabetes educators, nutritionist, psychologist, dentists, psychiatrist, physical activity specialist, foot care and ophthalmologist). They are attended in 4 monthly visits. After the initial phase, patients come back to the Center at 1 and 2 years for evaluation and reinforcement.
223792485|NCT03195257|OTHER|GIP|On 3 matched days with 'hypoglycemia' (i.e. plasma glucose clamped between 3-7 mol/L for 120 minutes) either GIP (4 pmol/kg/min), glucagon-like-peptide-1 (GLP-1) (1 pmol/kg/min) or placebo (saline) was administered; and on 2 separately matched days with 'hyperglycemia' (i.e. clamped at 12 mmol/L for 90 minutes) either GIP (4 pmol/kg/min) or saline was administered.
223792486|NCT03195257|OTHER|GLP-1|On 3 matched days with 'hypoglycemia' (i.e. plasma glucose clamped between 3-7 mol/L for 120 minutes) either GIP (4 pmol/kg/min), glucagon-like-peptide-1 (GLP-1) (1 pmol/kg/min) or placebo (saline) was administered; and on 2 separately matched days with 'hyperglycemia' (i.e. clamped at 12 mmol/L for 90 minutes) either GIP (4 pmol/kg/min) or saline was administered.
223792487|NCT03195257|OTHER|Saline|On 3 matched days with 'hypoglycemia' (i.e. plasma glucose clamped between 3-7 mol/L for 120 minutes) either GIP (4 pmol/kg/min), glucagon-like-peptide-1 (GLP-1) (1 pmol/kg/min) or placebo (saline) was administered; and on 2 separately matched days with 'hyperglycemia' (i.e. clamped at 12 mmol/L for 90 minutes) either GIP (4 pmol/kg/min) or saline was administered.
223792488|NCT03529474|OTHER|Psychology and Physiotherapy group|"Psychological program: 4 sessions,2 hours each,4 months~* Psychoeducation.Influence of psychological factors on chronic pain: modulators of pain experience. Biopsychosocial model of pain.~* Training techniques of psychological management of pain:Diaphragmatic Breathing and Progressive Muscle Relaxation to control vicious circle pain-tension-pain.~* Kinesiophobia. Rational regulation of the activity level:Cognitive therapy (management of irrational believes about pain) and Organisation of time and reinforcement activities.~Physiotherapy program:3 sessions per week,1 hour per session,4 months:~* Aerobic exercise:walking, cycling~* Warm-up: active ROM exercises of inferior and superior extremities (ISE)~* Progressive resistance training with elastic bands of ISE~* Stretching of ISE"
223792489|NCT03529474|OTHER|Placebo comparator: control group|Control group Normal daily activities Usual daily activities
223792490|NCT03886103|DRUG|14C labeled PXL770|Single administration
223792491|NCT01087853|DRUG|Crystalloid|2 litres intravenous infusion in 60 minutes
223792492|NCT01087853|DRUG|Colloid|1 litre intravenous infusion over 30 minutes
223792493|NCT02264028|DRUG|[14C]-DK-AH 269 CL, solution for infusion|
223792494|NCT02264028|DRUG|[14C]-DK-AH 269 CL, drinking solution|
223792495|NCT03117738|DRUG|AstroStem|Autologous adipose tissue derived mesenchymal stem cells (AdMSC)
223792496|NCT03117738|OTHER|Placebo-Control|Saline with 30% auto-serum
223792497|NCT03845348|OTHER|TD03|Shampoo TD 3 days
223792498|NCT03845348|OTHER|TD07|Shampoo TD 7 days
223792499|NCT03845348|DRUG|Ketoconazole 2% Shampoo|Ketoconazole 2% Shampoo
223792500|NCT06354101|DRUG|Tirzepatide|Once-weekly subcutaneous injectable
223792501|NCT06354101|DRUG|Semaglutide|Once-weekly subcutaneous injectable
223792502|NCT01546896|DRUG|buspirone+alprazolam|day 1\~7: buspirone 10mg/d + alprazolam 0.5mg / day 8\~28: buspirone 20mg/d + alprazolam 0.5mg / day 29\~56: buspirone 20\~30mg/d + alprazolam 0.5mg
223792503|NCT01546896|DRUG|alprazolam|0.5mg/d
223792504|NCT05319067|OTHER|Stool sampling|Stool sample taken at home 24 hours before hospital visit
223792505|NCT04522518|DEVICE|PmP-C App|"The key features of PmP-C App include: About Me (entering child's demographic data e.g. age, gender, family members), My participation (answering frequency and involvement of activities), and My goal (selecting 3 important activities they desire to change and identify things that made them easy or hard to do, i.e. participation goals and environmental supports or barriers). The App is to be manipulated adult interviewers but also can be manipulated by the child if they are able to."
223792506|NCT04099810|DIAGNOSTIC_TEST|three-dimensional echocardiography|"A focused echocardiographic exam will be performed. In details will be acquired:~* high frame rate imaging clips acquired in a static position with attention to endocardial border optimization, minimum of 3 beats recorded with 'Acquire 2', of: a. Left ventricle 2c/3c/4c; b. left ventricle SAB, SAX-M, SAX-A; c. right ventricular focused apical view.~* Full volumes: a. 3d left ventricular apical acquisition; b. right ventricular apical acquisition; c. subcostal right ventricular acquisition."
223792507|NCT05314439|DRUG|ION904|ION904 will be administered by SC injection.
223792508|NCT05314439|DRUG|Placebo|Placebo will be administered by SC injection.
223792509|NCT05851365|DRUG|Hyperpolarized Bicarbonate (13C)|Given IV
223792510|NCT05851365|PROCEDURE|Magnetic Resonance imaging|Magnetic resonance imaging is a medical imaging technique used in radiology to form pictures of the anatomy and the physiological processes of the body
223792511|NCT01835886|OTHER|Patients will ascend and descend a flight of 10 steps|Patients referred to pulmonary rehabilitation with documented lung disease will ascend and descend a flight of 10 steps for a period of 30 seconds
223792512|NCT05625048|OTHER|Transperinal ultrasound guided instruction in pelvic floor muscle training|The physiotherapists uses transperinal ultrasound as a biofeedback or pedagogical tool to improve the muscle contractions and visualize the muscle work.
223792513|NCT02504073|OTHER|No intervention|No intervention
223792514|NCT03986112|BIOLOGICAL|carotid sonography and inferior vena cava sonography|Carotid and venous ultrasonography is performed in a comfortable state. Corrected blood flow after carotid ultrasound and carotid artery blood flow rate were measured. After inferior vena cava sonography, the collapsibility Index by measuring the largest and smallest diameter during the respiratory cycle will be obtained. Propofol 2 mg / kg is administered and remifentanil is maintained at 4.0 ng / mL using the Target Control System. Blood pressure and heart rate are measured at prior to induction, 1 minute after induction, immediately after intubation, and at 1, 3, 5, 7 and 10 minutes after intubation. Post-induction hypotension is considered as a decrease of 20% or more of baseline blood pressure or a mean arterial blood pressure of less than 60 mmHg. In the event of hypotension in accordance with the above definition, repeated administration of ephedrine 4 mg or phenylephrine 50 mcg is used.
223792515|NCT06236022|DRUG|Sirolimus|at a dose of 2 mg once daily
223792516|NCT03274843|OTHER|Activity of everyday life|Kitchen workshop
223792517|NCT00135148|PROCEDURE|Filling out a questionnaire on libido and possible partner relationship|
223792518|NCT00135148|PROCEDURE|Sex steroid analysis|
223792519|NCT04826354|DRUG|Rosuvastatin and Ezetimibe|Rosuvastatin Versus Rosuvastatin plus Ezetimibe
223792520|NCT04826354|DRUG|Rosuvastatin|Rosuvastatin
223792521|NCT02248792|DRUG|Methotrexate|
223792522|NCT02625103|PROCEDURE|Blood sampling|blood samples for s-clozapine and s-desmethyl-clozapine analysis are collected at 10, 11, 12, 13 and 14 hours post evening-clozapine-administration
223792523|NCT02625103|DRUG|Clozapine|Registration of the exact time of drug administration. Also postponement of any morning clozapine administration until ended blood sampling.
223792524|NCT03667053|DRUG|dasiglucagon|glucagon analog
223792525|NCT03667053|DRUG|placebo|placebo for dasiglucagon
223792526|NCT03667053|DRUG|GlucaGen HypoKit|native glucagon
223792527|NCT06425354|DEVICE|Mechanical ventilation|Mechanical ventilatiom
223792528|NCT04022668|RADIATION|Coronary angiogram|Routine coronary angiogram, if indicated
223792529|NCT01877538|OTHER|[11C]donepezil PET|Positron Emission Tomography (PET) imaging of acetylcholinesterase with the ligand \[11C\]donepezil
223792530|NCT00209417|DRUG|Iodixanol 320-Arm 1|
223792531|NCT00209417|DRUG|Iopamidol 300-Arm 2|
223792532|NCT00487162|PROCEDURE|intensive glycemic control|intravenous insulin titrated every 30 minutes to serum glycemic level of 80-100mg/dl
223792533|NCT00487162|DRUG|conventional glycemic control|Novo regular insulin administered when glucose level exceeded 200 mg/dl and titrated to maintain level between 180-200 mg/dl
223792534|NCT00089726|BIOLOGICAL|CG8123|
223792535|NCT00089726|DRUG|Cyclophosphamide|
223792536|NCT00441610|DRUG|Gimatecan|
223792537|NCT04049175|DRUG|Treatment A|Tablet of CHF 6532
223792538|NCT04049175|DRUG|Treatment B|Tablet of CHF 6532
223792539|NCT04049175|DRUG|Treatment C|Tablet of CHF 6532
223792540|NCT04049175|DRUG|Treatment D|Tablet of CHF 6532 placebo
223792541|NCT03939377|OTHER|Questionnaire and treatment|EVA questionnaire every day for 7 days. treatment (real or simulated) at J3 and J5
223792542|NCT05588726|BEHAVIORAL|Sleep Hygiene|Once weekly coaching calls with advice on sleep hygiene
223792543|NCT05588726|BEHAVIORAL|Mindfulness|Once weekly coaching calls with advice on mindfulness
223792544|NCT01945606|DRUG|Placebo (treatment 1)|Oral administration of placebo tablets
223792545|NCT01945606|DRUG|BAY1067197 (treatment 2)|Oral administration of a single dose of 30 mg (3×10 mg Tablet) BAY1067197
223792546|NCT02732938|DRUG|PF-04136309|PF-04136309 oral dosing
223792547|NCT02732938|DRUG|Nab-paclitaxel|Nab-paclitaxel IV dosing
223792548|NCT02732938|DRUG|Gemcitabine|Gemcitabine IV dosing
223792549|NCT05183971|OTHER|Proprioceptive Functional Analysis System|Proprioceptive testing and Physical Performance Tests
223792550|NCT00636870|DRUG|Fexofenadine|
223792551|NCT00127374|BEHAVIORAL|Dietary and physical activity modifications|
223792552|NCT03927950|DRUG|escitalopram|escitalopram 10-20mg per day 12 weeks
223792553|NCT03927950|DRUG|bupropion|bupropion 150-300mg per day 6 weeks
223792554|NCT03305120|OTHER|pain VAS evaluation|each patient has to answer to a questionnaire about pain
223792555|NCT04117932|DRUG|Ustekinumab|Ustekinumab (90 mg subcutaneously at weeks 0, 4, 16), in association with topical superpotent corticosteroid (10-30 g per day during the first 4 weeks, then every other day during 4 weeks).
223792556|NCT01792011|DEVICE|PVI-guided fluid management|In this study of 25 adult patients undergoing OLT, we prospectively record PVIwithin 5 minutes during dissection and anhepatic phase of OLT by Masimo pulse oximeter.In this study of 25 adult patients undergoing OLT, we prospectively record study data within 5 minutes during dissection and anhepatic phase of OLT. Study data included measurements of PVI,thermodilution cardiac output, Stroke volume variation (SVV) and Pulse pressure variation (PPV).
223792557|NCT04530448|DRUG|Sodium bicarbonate|Sodium bicarbonate 225 mEq (225 mL of an 8.4% solution) intravenously over 1 hour. Sodium bicarbonate 8.4% solution should not exceed 900 ml (4 boluses) in 24 hours.
223792558|NCT04530448|OTHER|Standard of Care|Standard of Care treatment
223792559|NCT02592382|DIETARY_SUPPLEMENT|Xylitol spray|xylitol nasal spray will be administered to this arm three times daily for three months
223792560|NCT02907021|DRUG|standard-of-care treatments for LV impairment|Treat patients with mild or moderate LV impairment by standard-of-care treatments for LV impairment using ACE-I and beta-blockers
223792561|NCT01738048|PROCEDURE|Reconstruction|Reconstructive surgery after mastectomy, either by expander or autologous tissue. Includes both primary and secondary reconstruction
223792562|NCT03214913|OTHER|Early Goal Directed Therapy|EGDT therapy ：30ml/kg in the first bolus to have a CVP 8-12 mmHg and MAP 65-85 mm Hg,and urine output ≥0.5 ml/kg/h, ScvO2 ≤70%；If not, use noradrenine，red blood cell transfusion if necessary.
223792563|NCT03214913|OTHER|Ruijin Strategy|"Ruijin Strategy：10\~5ml/kg/h，crystalloid vs colloid 2:1 resuscitation;using noradrenaline at the same time;red blood cell transfusion if necessary.~target： fulfillment of two or more of four criteria:1. HR \<120 beats/min, 2.MAP 65-85 mm Hg, 3. urine output ≥1 ml/kg /h 4. HCT 25%\~35%."
223792564|NCT03928080|DIAGNOSTIC_TEST|Bleeding on brushing|Index tests are bleeding on brushing and aMMP-8 Gold standard: clinical diagnosis performed by specialist
223792565|NCT01491854|OTHER|Bloodsampling|Bloodsampling
223792566|NCT05496127|OTHER|Sensorimotor Exercises and Yoga|Within the content of sensorimotor exercise; oculomotor exercise, laser target exercise and postural stability exercise were applied. 14 yoga poses were applied within the content of Yoga Exercises.
223792567|NCT03496155|BEHAVIORAL|Build and Support Your Teen's Strengths|"This is a clinic based psychoeducational intervention for adolescent patients and their parents to improve parent-teen communication about teen strengths. The intervention is designed, if possible, to coincide with the adolescent patients' well-child visits and consists of the following components: (1) In-person or over the phone orientation session with a trained health coach and parent, (2) Distribution of psychoeducational materials to the parent, (3) Endorsement and delivery of key messages from the health care provider, and (4) Booster phone call placed by the health coach."
223792568|NCT05199818|DRUG|Palonosetron HCl Buccal Film 0.5 mg|Palonosetron HCl Buccal Film and IV palonosetron placebo, both administered on Day 1
223792569|NCT05199818|DRUG|IV Palonosetron 0.25 mg|IV Palonosetron and Palonosetron HCl Buccal Film placebo, both administered on Day 1
223792570|NCT01433354|DRUG|AFQ056|The investigational drug, AFQ056, will be provided as hard gelatin capsules. Two different oral dosage strengths,25mg and 100 mg, identical in appearance, will be used.
223792571|NCT02943148|OTHER|Davey score for striae gravidarum|
223792572|NCT04760093|DIETARY_SUPPLEMENT|Low polyphenol concentration extra virgin olive oil (EVOO)|Subjects will complete a consecutive 28-day period of consuming low polyphenol concentration EVOO daily.
223792573|NCT04760093|DIETARY_SUPPLEMENT|High polyphenol concentration extra virgin olive oil (EVOO)|Subjects will complete a consecutive 28-day period of consuming high polyphenol concentration EVOO daily.
223792574|NCT04694274|DEVICE|stabilization splint|The device made of a hard acrylic on stone cast of the upper jaw in the centric relation position. It has a thickness of 1.5 mm at the level of the first molar.
223792575|NCT04694274|PROCEDURE|physical therapy|Home-exercise program included exercises for passive and active stretching, joint mobilization, passive extension, and translational movements to the right, left, and forward.
223792576|NCT04694274|DEVICE|placebo splint|The placebo splint was made of thin heat-treatable foil (0.5 mm). The foil was heated and printed over a plaster model of the upper jaw resulting in a very thin film over the occlusal surfaces of all teeth.
223792577|NCT04526366|DEVICE|Continuous Positive Airway Pressure|Continuous Positive Airway Pressure device deployed for at least one night synchronously with polysomnography.
223792578|NCT04526366|DEVICE|Polysomnography|Polysomnography deployed for at least one night synchronously with Continuous Positive Airway Pressure.
223792579|NCT03033823|DRUG|Magnesium|Usual care (i.e. without any restriction of drug therapy) plus oral tablet magnesium supplementation: 426.6mg of magnesium per day three times daily (i.e. 142.2 mg for each shot) throughout the study (i.e. fifteen days). In case of diarrhea, nearly half-dosage will be used (i.e. 189.6mg).
223792580|NCT03033823|DRUG|Placebo Oral Tablet|Usual care (i.e. without any restriction of drug therapy) plus oral placebo, totally similar to the verum, three times daily throughout the study (i.e. fifteen days). In case of diarrhea, nearly half-dosage will be used.
223792581|NCT00845663|DRUG|Certolizumab pegol|Auto-injection device (test) containing 1 mL of certolizumab pegol liquid formulation, 200 mg/mL; 2 injections
223792582|NCT00845663|DRUG|Certolizumab pegol|Pre-filled syringe (reference) containing 1 mL of certolizumab pegol liquid formulation, 200 mg/mL; 2 injections
223792583|NCT03806270|DRUG|Midazolam|Demizolam 15mg/ml ampules, given orally with cherry juice
223792584|NCT03806270|DRUG|Hydroxyzine Dihydrochloride|Atarax 2mg/ml syrup, given orally
223792585|NCT06095570|DRUG|Ciprofol|For induction of anesthesia, an experimental dose of ciprofol was given, and when the patient lost consciousness and the Modified Observer's Alertness/Sedation scale(MOAA/S score) was less than 1, then intravenous sufentanil and rocuronium bromide were administered, and tracheal intubation was performed 3 minutes later
223792586|NCT06095570|DRUG|Remimazolam|For induction of anesthesia, an experimental dose of remimazolam was given, and when the patient lost consciousness and the Modified Observer's Alertness/Sedation scale(MOAA/S score) was less than 1, then intravenous sufentanil and rocuronium bromide were administered, and tracheal intubation was performed 3 minutes later
223792587|NCT05545072|DRUG|Dupilumab|Dupilumab will be administered subcutaneously at a dose of 300 milligrams (mg) in a 2 milliliter (mL) solution every 2 weeks until the end of treatment (EOT) at Week 52. Participants will receive a total of 26 doses.
223792588|NCT05545072|DRUG|Placebo|A placebo to match dupilumab will be administered subcutaneously every 2 weeks until the end of treatment (EOT) at Week 52. Participants will receive a total of 26 doses.
223792589|NCT05545072|DRUG|Intranasal Corticosteroid Sprays (INCS)|All participants will undergo standardized background therapy with intranasal corticosteroid sprays (INCS) per standard of care (SoC). This will continue throughout the entire study. Participants either receive fluticasone propionate or mometasone furoate.
223792590|NCT03592511|DIETARY_SUPPLEMENT|WGPF-burger|Volunteers consumed a WGPF-burger daily
223792591|NCT03592511|DIETARY_SUPPLEMENT|Control-burger|Volunteers consumed a Control-burger daily
223792592|NCT04583995|BIOLOGICAL|SARS-CoV-2 rS/Matrix M1-Adjuvant|Alternating intramuscular (deltoid) injections of SARS-CoV-2 rS co-formulated with Matrix-M1 adjuvant (0.5 mL) on Days 0 and 21.
223792593|NCT04583995|OTHER|Placebo|Alternating intramuscular (deltoid) injections of placebo (0.5 mL) on Days 0 and 21.
223792594|NCT04583995|BIOLOGICAL|Licensed seasonal influenza vaccine|Single intramuscular injection of licensed seasonal flu vaccine, administered ideally in opposite deltoid to SARS-CoV-2 rS with Matrix-M1 adjuvant or placebo injection on Day 0.
223792595|NCT04535401|PROCEDURE|Biopsy|Undergo tumor biopsy
223792596|NCT04535401|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223792597|NCT04535401|PROCEDURE|Diagnostic Imaging|Undergo imaging
223792598|NCT04535401|DRUG|Elimusertib|Given PO
223792599|NCT04535401|DRUG|Fluorouracil|Given IV
223792600|NCT04535401|DRUG|Irinotecan Hydrochloride|Given IV
223792601|NCT04535401|DRUG|Leucovorin Calcium|Given IV
223792602|NCT00153764|DRUG|Cooper Complete One-A-Day Vitamin Supplement|
223792603|NCT06787417|PROCEDURE|Restricted Kinematically-aligned Arthroplasty|Robot Assisted with Restricted Kinematically-Aligned TKA.
223792604|NCT06787417|PROCEDURE|Mechanically-Aligned Arthroplasty|Robot Assisted with Mechanically Aligned TKA.
223792605|NCT01360606|RADIATION|Stereotactic Body Radiation Therapy|"SBRT:~Patients will receive one of the following radiation regimens:~* 50 Gy in 5 fractions (10 Gy/fx) delivered over a 2-week period.~* 60 Gy in 5 fractions (12 Gy/fx) delivered over a 2-week period.~* 75 Gy in 5 fractions (15 Gy/fx) delivered over a 2-week period."
223792606|NCT03817424|DRUG|VIB7734|Participants will receive VIB7734 via injection.
223792607|NCT03817424|DRUG|Placebo|Participants will receive placebo matching to VIB7734 via injection.
223792608|NCT06568705|RADIATION|Moderate hypofractionated Radiation Treatment|The online adaptive radiotherapy workflow is used to deliver radiation dose. The CTV of ipsilateral breast receives a dose of 43.5Gy in 15 fractions in patients who underwent breast conserving surgery or mastectomy.
223792609|NCT06568705|RADIATION|Ultrafractionated Radiation Treatment|The online adaptive radiotherapy workflow is used to deliver radiation dose. The CTV of ipsilateral breast receives a dose of 26Gy in 5 fractions in patients who underwent breast conserving surgery or mastectomy.
223792610|NCT04863092|BEHAVIORAL|Educational Intervention|The workshops will last approximately 60 minutes, with 20 minutes to educate participants and 10 minutes to discuss the materials and answer any questions. Prior to and after the presentation, the CHE will administer the pre- and post-intervention survey to participants. Group sizes will be capped to 25 individuals per group.
223792611|NCT01345006|BIOLOGICAL|MA09-hRPE|"Cohort 1 50,000 cells~Cohort 2 100,000 cells~Cohort 2a Better Vision 100,000 cells~Cohort 3 150,000 cells~Cohort 4 200,000 cells"
223792612|NCT05893914|PROCEDURE|Dry Needling and intramuscular electrical stimulation to trigger points|Dry needling will be applied to trigger points in at least two of the following posterior cervical muscles; splenius capitis, splenius cervicis, semispinalis capitis/cervicis, cervical multifidi (from C2-4) and obliquus capitis inferior. Following elicitation of a local twitch response, needles will be left in place and connected to a charge generating device for intramuscular electrical stimulation.
223792613|NCT04515186|DRUG|Meglumine Antimoniate|Vials of a 5mL solution. Each vial contains 405 mg of Sb5+ corresponding to 8.1% Sb5+ (81 mg/mL).
223792614|NCT04515186|DRUG|Miltefosine|50 mg capsule
223792615|NCT04515186|DEVICE|Thermotherapy machine|Localized Current Field radio-frequency generating device
223792616|NCT04059926|OTHER|insert apossing lumen metal stent|insert apossing lumen metal stent
223792617|NCT05467553|DRUG|Ursodeoxycholic acid|Ursodeoxycholic Acid 15 mg/kg PO QD for 60 weeks
223792618|NCT05467553|DRUG|Ropeginterferon alfa-2b|P1101 450 µg SC Q2W add-on at treatment week 12 for 48 weeks
223792619|NCT05467553|DRUG|Tenofovir Alafenamide|TAF 25 mg PO QD for 60 weeks
223792620|NCT06461039|DRUG|NNC0487-0111 A|NNC0487-0111 A will be administered subcutaneously.
223792621|NCT06461039|DRUG|NNC0487-0111 C|NNC0487-0111 C will be taken orally.
223792622|NCT06461039|DRUG|Levonorgestrel 150 μg + Ethinylestradiol 30 μg (Oral contraceptive OC)|Levonorgestrel 150 μg + Ethinylestradiol 30 μg (Oral contraceptive OC) will be taken orally.
223792623|NCT06461039|DRUG|Acetaminophen - 500 mg/15 ml|Acetaminophen - 500 mg/15 ml will be taken orally.
223792624|NCT03726034|BEHAVIORAL|Life Story Book|The protocol of life story book creation is validated in Hong Kong. The life story book would contain two elements: (1) the development of the older adults over the course of his/her lifetime (i.e. from childhood to old age); and (2) the psychosocial development and ways of life of the older adults (e.g. education, marriage, career, and hobbies). The product of the intervention will be a written story with pictures or other memorabilia that are meaningful to the older adults. There is no limitation on the number of words, pages, and pictures. Four to six 60-minute scheduled sessions will be needed for the older adult and the live-in migrant caregivers to discuss and produce the lifestory book at home.
223792625|NCT03726034|BEHAVIORAL|Self-selected social activities|To control the possible social interaction effects on the dyadic relationship and wellbeing, the caregivers of the control group will conduct self-selected social activities with older adult at home individually for four times weekly.
223792626|NCT02273141|DRUG|NER1006, Day Before-Only Dosing|The subject will self-administer both doses of NER1006 in the evening of Day 1 with 1-2 hours interval. Subject will take mandatory additional clear fluid after each dose.
223792627|NCT02273141|DRUG|SP+MS, Day Before-Only Dosing|The subject will self-administer SP+MS in the morning of Day 1 and afternoon of Day 1. Subject will take mandatory additional clear fluid after each dose.
223792628|NCT02287935|PROCEDURE|Limberg flap|Patients were divided into two groups, group 1 were treated with Limberg flap technique (n= 37) . Two groups were compared with a statistical in terms of fluid collection, wound infection, flap edema, hematoma, partial wound separation, return to daily activities, pain score, completes healing time, painless seating and patient satisfactions
223792629|NCT02287935|PROCEDURE|Karydakis procedure|Patients were divided into two groups, group 2 were treated with Karydakis flap (n= 34). Two groups were compared with a statistical in terms of fluid collection, wound infection, flap edema, hematoma, partial wound separation, return to daily activities, pain score, completes healing time, painless seating and patient satisfactions
223792630|NCT01703364|DRUG|Lenalidomide|"Lenalidomide: day 8-21 of cycle 1 and day 1-21 of cycles 2-6; Starting Dose: 5 mg (first 5 patients) and 10 mg (further 5 patients) increase Lenalidomide dose via dose levels (10)/15/20/25 mg/d every 28 days if no limiting toxicity occurs~Fludarabine: 25 mg/m2 iv d1-3 or 40 mg/m2 po d1-3; repeat every 28 days~Rituximab: 375 mg/m2 iv day 4 on cycle 1 and 500 mg/m2 iv day 1 on cycles 2-6; repeat every 28 days"
223792631|NCT01374542|PROCEDURE|Respiratory endoscopy|Bronchoscopy, thoracoscopy, endobronchial ultrasound
223792632|NCT06372470|OTHER|Zestril|N/A, this is an observational study.
223792633|NCT04084808|DIETARY_SUPPLEMENT|Solution ingestion|Subjects will be required to ingest 1 liter of the experimental solution, spread over the 45 minutes of exercise. A first ingestion of 167 mL of solution will be made at rest, right before starting warmup, and another dose (167 mL) after it. Four additional doses of 167 mL will be ingested immediately after the first four 3-minute bouts at 95% of Maximal Aerobic Power. A final dose (167 mL) will be ingested after the last effort.
223792634|NCT04084808|BEHAVIORAL|Cognitive flexibility|"Subjects will be required to undergo the Stroop task. They will have to answer as quickly as possible, with push buttons, to a colour stimulus, following specific rules, and get the highest possible number of right answers. The flexibility block will show a pre-signal on a screen in front of the subject (a square or a cross will be shown). The form presented will indicate if the subject must use the colour of the writing, or the word written. Each block will consist of 50 trials, 25% of which switching the condition of answer. During this test, reaction time in milliseconds (ms) as well as the number of right answers will be measured.~This test will be measured before the exercise protocol, during the 3-minutes exercise bouts, and every 15 minutes during the 45 minutes following exercise."
223792635|NCT04084808|PROCEDURE|Brain oxygenation|"Optic imagery (Near-infrared spectroscopy, or NIRS) is a non-invasive technique allowing a fine investigation of the inner workings of the brain. It allows discrimination of oxygenated hemoglobin from deoxygenated hemoglobin, which informs on the coupling between blood flow and oxygen consumption inside the brain. To measure brain oxygenation with NIRS, optodes will be installed on the subject's skin without glue or transmission gel.~\[ Time Frame: During Stroop's task (i.e.before the exercise protocol, during the 3-minutes exercise bouts, and every 15 minutes during the 45 minutes following exercise). \] Measured with near-infrared spectroscopy (NIRS)."
223792636|NCT04084808|OTHER|Palatability|Subjects will be asked to fill out a short form on the palatability of the solution ingestion, after ingesting the first solution and at the end of exercise, after ingestion the last solution.
223792637|NCT04084808|PROCEDURE|Blood glucose|Blood glucose will be measured with a puncture on the tip of a finger to get a droplet of blood.
223792638|NCT04084808|BEHAVIORAL|Perceived exertion|Perceived exertion will be assessed using 3 scales : Borg (RPE), and DP-15 scale for mental effort (Delignières, Brisswalter, \& Legros, 1994). These scales will be administrated at the end of each 3 minute high intensity bout.
223792639|NCT04084808|BEHAVIORAL|High Intensity Interval Training bouts|6 3-minute bouts at 95% of maximal aerobic power will be done on a bike. Each bout will be separated by 3 minutes of passive recovery. The last bout will be followed by 45 minutes of rest.
223792640|NCT01754831|DEVICE|Fluoride varnish|Topical application of fluoride varnish on present teeth
223792641|NCT03461068|DIETARY_SUPPLEMENT|Ketone monoester|Acute ingestion of (R)-3-hydroxybutyl (R)-3-hydroxybutyrate prior a 2-hour oral glucose tolerance test.
223792642|NCT03461068|DIETARY_SUPPLEMENT|Placebo|Acute ingestion of a taste-matched placebo prior a 2-hour oral glucose tolerance test.
223792643|NCT01048528|BEHAVIORAL|Cognitive Behavioral Stress Management (CBSM)|The intervention employs CBSM techniques interwoven with information in a supportive group format. The information portion of the intervention focuses on learning to cope with daily stressors, and learning about optimal use of social support. Avoidance coping is discouraged, and acceptance and reframing are instead encouraged as coping responses. Health behavior change, framed as a coping technique, will also be discussed using motivational interviewing techniques. Relaxation techniques include progressive muscle relaxation, guided imagery, autogenics, meditation, and deep breathing. The goal of the CBSM intervention is thus to reduce distress through a variety of techniques.
223792644|NCT03843229|DRUG|Cinobufacini injection|The treatment group receives Cinobufacini injection 20ml via hepatic artery during TACE operation , Cinobufacini injection 20ml+5% Glucose injection 500ml from the second day of TACE until 7th day, and Cinobufacini tablet 3 tablets Tid for 2 months.
223792645|NCT03843229|PROCEDURE|Transarterial Chemoembolization(TACE)|TACE consists of an injection containing a mixture of chemotherapeutic agents and lipiodol followed by embolization with polyvinyl alcohol (PVA) particles until complete stasis was achieved in the tumor-feeding vessels.Tumor-feeding vessels should be selected/superselected whenever possible.
223792646|NCT03843229|DRUG|cinobufacini tablet|The treatment group receives Cinobufacini injection 20ml via hepatic artery during TACE operation , Cinobufacini injection 20ml+5% Glucose injection 500ml from the second day of TACE until 7th day, and Cinobufacini tablet 3 tablets Tid for 2 months.
223792647|NCT02076152|DEVICE|FMISO PET|
223792648|NCT02076152|DEVICE|MRI|"MR scans will be performed with the same sequences and in the same order during each visit, including T1- and T2-weighted volumetric images, fluid attenuated inversion recovery (FLAIR), contrast agent enhanced T1-weighted permeability, diffusion tensor imaging (DTI), T2/T2\*-weighted perfusion scans, and MR Spectroscopy. The Autoalign package available from the manufacturer will be used to achieve the same slice prescription in the same patient at each visit. Each MRI will last 60-75 minutes versus 45 minutes for standard brain MRIs."
223792649|NCT02076152|DRUG|Bevacizumab|A cycle is defined as 28 days (1 month). The study duration is 12 months (12 cycles). Patients will be treated after 12 months or at the time of progression per discretion of their responsible physician.
223792650|NCT02076152|DRUG|CCNU|A cycle is defined as 28 days (1 month). The study duration is 12 months (12 cycles). Patients will be treated after 12 months or at the time of progression per discretion of their responsible physician.
223792651|NCT02635880|DEVICE|Investigational Enlighten Device|Up to 3 laser treatments, spaced 4 to 6 weeks apart
223792652|NCT03199625|BEHAVIORAL|Cognitive therapy|
223792653|NCT03199625|BEHAVIORAL|Behavior therapy|
223792654|NCT03199625|DRUG|SSRI antidepressants|
223792655|NCT04862793|DEVICE|Colonoscopy Progression Score (CoPS)|The Colonoscopy Progression Score consists of five different aspects: Travel length, Tip progression, chase efficiency, shaft movement without tip progression and looping.
223792656|NCT04862793|DEVICE|Colonoscopy Retraction Score (CoRS)|The Colonoscopy Retraction Score consists of three different aspects: Tip Retraction, Retraction Efficiency, and Retraction Distance.
223792657|NCT00278434|DRUG|Zoledronate|
223792658|NCT00278434|OTHER|Placebo (Saline)|
223792659|NCT04313881|DRUG|Magrolimab|Administered intravenously
223792660|NCT04313881|DRUG|Azacitidine|Administered either subcutaneously (SC) or intravenously (IV) according to region-specific drug labeling
223792661|NCT04313881|DRUG|Placebo|Placebo to match magrolimab administered intravenously
223792662|NCT00496665|DRUG|Vandetanib|Taken orally once a day in 28-day cycles (the dose will vary)
223792663|NCT00496665|DRUG|Cyclophosphamide|Metronic Chemotherapy: Low dose pills taken every day of each 28-day cycle
223792664|NCT00496665|DRUG|Methotrexate|Metronic Chemotherapy: low dose pills taken on days 1 and 2 of each week
223792665|NCT05080400|DIETARY_SUPPLEMENT|White rice|Jasmine rice 179g of cooked weight
223792666|NCT05080400|DIETARY_SUPPLEMENT|Gellan gum|Food grade hydrocolloid polysaccharide 5.5g dissolved in 356g cooking water containing 185g rice
223792667|NCT03680599|BEHAVIORAL|Connection to Health for Smokers|Connection to Health for Smokers includes 5 core components supported by online tools: (1) comprehensive electronic patient survey, (2) automated summary report to flag areas of difficulty (3) interactive priority setting, (4) interactive action planning, and (5) electronic text reminders and followup.
223792668|NCT03680599|BEHAVIORAL|Enhanced Standard of Care|Participants will complete a survey and receive standard one-on-one smoking cessation according to a usual care protocol delivered by health educators
223792669|NCT04027153|OTHER|Fee based delivery|Testing willingness to pay for services to simplify delivery is innovative as the strategy could increase funds for HIV care making home delivery cost neutral.
223792670|NCT03438162|BEHAVIORAL|Education|Patients randomized in the intervention group received pre-discharge pharmacotherapeutic education. The education was conducted by a qualified physician.
223792671|NCT01572727|DRUG|Paclitaxel|intravenous paclitaxel 80 mg/m2 per week given until progression
223792672|NCT01572727|DRUG|BKM120 matching placebo|"Buparlisib maching plaxcebo were supplied as 100 mg and 50 mg hard gelatin capsules.~Buparlisib placebo was dosed on a flat scale of mg/day and was not adjusted to body weight or body surface area."
223792673|NCT01572727|DRUG|BKM120|Buparlisib (BKM120) were supplied as 100 mg and 50 mg hard gelatin capsules. Buparlisib was dosed on a flat scale of mg/day and was not adjusted to body weight or body surface area.
223792674|NCT00095264|DRUG|Darbepoetin Alfa|
223792675|NCT01360151|DRUG|ranibizumab(Lucentis), verteporfin(Visudyne)|ranibizumab(Lucentis) : 0.5mg/0.05ml - intravitreal injection verteporfin (Visudyne) : 15mg (6mg/m2)- intravenous injection
223792676|NCT03734731|DEVICE|Monochromatic Infrared Photo Energy (MIRE)|Apply Monochromatic Infrared Photo Energy (MIRE) to the affected nerve
223792677|NCT03734731|DEVICE|Transcutaneous Electrical Nerve Stimulation|Apply Transcutaneous Electrical Nerve Stimulation (TENS) to the affected nerve
223792678|NCT03734731|DRUG|Opioids|Prescribe Opioids to treat for pain or circulatory disorders, dosage to be determined by Principal Investigator
223792679|NCT03734731|DRUG|Cannabis|Prescribe Cannabis to treat for pain or circulatory disorders, dosage to be determined by Principal Investigator. Comparing Opioid results to Cannabis results with objective nerve testing
223792680|NCT04313231|DIAGNOSTIC_TEST|Next Generation Sequencing|"Sequencing of patient samples will be performed in the facilities of ZIMCL. Following DNA extraction, the sequencing of granulocytes as well as of lymphocytes (control) will be carried out. IN addition to whole exome sequencing, a panel from SOPHIA GENETICS (which is also available for routine diagnostics) will be applied including the following MDS specific genes: ASXL1, BRAF, CBL, CEBPA, CSF3R, DNMT3A, EZH2, FLT3, HRAS, IDH1, IDH2, KRAS, MPL, NPM1, NRAS, RUNX1, SF3B1, SRSF2, TET2, TP53, U2AF1, WT1, ZRSR. Each patient sample will be bulk sequenced, meaning that relevant mutations are detected down to an allele frequency of 2%."
223792681|NCT04313231|DIAGNOSTIC_TEST|Tumorimmunological examinations - multiplex assays/quantitative polymerase chain reaction|"Inflammasome activation is quantified by analyses of inflammasome-associated cytokine patterns. Multiplex assays for the quantification of the inflammasome-specific cytokines will be done from serum as well as from supernatants the stimulated blood cells. Cytokine quantification is carried out with Luminex FlexMap 3D. Serum cytokine levels will be quantitated in parallel.~Quantification of RNA expression levels of inflammasome-related gene products will be performed by qPCRs from unstimulated and stimulated (=cryotube) blood cells. The necessary RNA extraction will be performed using a RNA extraction kit."
223792682|NCT04313231|DIAGNOSTIC_TEST|flow cytometry|A detailed evaluation of the individual immune status is being conducted by the analysis of two specialized panels: Panel A provides a broad overview over various immune cell populations, while Panel B identifies T-cell sup-populations.
223792683|NCT04313231|DIAGNOSTIC_TEST|Metagenomics of stool samples|DNA will be extracted from frozen fecal samples applying a bead-beating method using a GNOME DNA Isolation Kit (MP Biomedicals). DNA quality will be assessed using an Agilent 4200 TapeStation (Agilent Technologies). After final precipitation, DNA samples will be re-suspended in TE buffer and stored at -80 °C for further sequencing analysis. To this end, sequencing libraries will be generated using a Nextera XT DNA Sample Prep Kit (Illumina). Library quality will be confirmed using an Agilent 4200 TapeStation. Whole-genome shotgun sequencing of fecal samples will be carried out on a HiSeq2500 platform (Illumina).
223792684|NCT04313231|DIAGNOSTIC_TEST|Clinical/demographic data|Demographic and clinical data include: age, age at initial diagnosis, sex, diagnosis, actual comorbidities, medication at inclusion in study, cytogenetic and molecular profiles and standard laboratory parameters (blood count, differential leukocyte count, biochemistry, iron status, inflammatory markers like CRP, albumin, fibrinogen).
223792685|NCT04313231|OTHER|Elicitation of the HRQoL|Evaluation of HRQOL, of functional activities and of performance status will be done by the patient and/or the physician using validated scores.
223792686|NCT04657146|OTHER|Biorepository|"Tumor collection (\> 1cm3): Intraoperatively~Peripheral blood collection:~* Intraoperatively (60mL)~* Post-resection (30mL)~* Post- standard of care treatment (30mL)~Bone marrow aspiration:~* Intraoperatively (10mL)~* Post-resection (5mL)~* Post- standard of care treatment (5mL)"
223792687|NCT04541238|DIAGNOSTIC_TEST|MRI|Magnetic resonance imaging
223792688|NCT02596815|PROCEDURE|Median Nerve Neural Mobilization|Nonsurgical noninvasive Median Nerve neural mobilization procedure was applied by a physical therapist continuously during 2 minutes in 5 different occasions with 1 minute of rest between each 2 minute application of the Neural Mobilization technique. The intervention was applied during a period of 6 weeks. The maximum level of elbow extension movement degree without the reproduction of symptoms during the application of the Median Nerve Neural mobilization treatment was determined through the baseline use of a Universal Goniometer Device.
223792689|NCT02596815|DEVICE|Goniometer|
223792690|NCT03977519|PROCEDURE|MA|Huatuo Brand needles (0.30×25mm,0.30×40mm or 0.30×75mm) will be used.Participants will receive manual acupuncture for 30 minutes each time.After acupuncture,we will twist the needles every 10 minutes for about 30 seconds.The patients will be treated in their first day of dysmenorrhea, once a day for three consecutive days. And the treatments will last for three consecutive menstrual cycles.
223792691|NCT03977519|PROCEDURE|TENS|Huatuo Brand electrode patch (50mm×50mm) and the SDZ-V EA apparatus (Suzhou Medical Appliance) will be used.Participants will receive transcutaneous electric nerve stimulation for 30 minutes each time.They will be treated in their first day of dysmenorrhea, once a day for three consecutive days. And the treatments will last for three consecutive menstrual cycles.
223792692|NCT01606449|PROCEDURE|Surgical Therapy|"Open Anti-reflux fundoplication according to Nissen-Rossetti, floppy Nissen, Belsey MK IV,Collis Nissen, Collis-Belsey.~Minimally-Invasive fundoplication according to floppy Nissen, left thoracoscopic Collis-laparoscopic Nissen."
223792693|NCT01474681|BIOLOGICAL|HSC835|
223792694|NCT02102087|DEVICE|Initial Specimen Diversion Device (ISDD)|
223792695|NCT02102087|DEVICE|Lab standard practice (LSP)|
223792696|NCT00517712|DRUG|Single agent arsenic trioxide|duration of maintenance therapy, 6 months versus 12 months
223792697|NCT01856127|DRUG|Vilazodone|Vilazodone is a newly introduced antidepressant which, in contrast to the selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) appears to have a minimal adverse effect on sexual functioning
223792698|NCT01856127|DRUG|Sertraline|Sertraline hydrochloride (trade names Zoloft, Lustral) is an antidepressant of the selective serotonin reuptake inhibitor (SSRI) class.
223792699|NCT01972516|DRUG|Tivozanib|
223792700|NCT02457039|PROCEDURE|Dense cranial electroacupuncture stimulation|"DCEAS is a is a novel stimulation mode in which electrical stimulation is delivered on acupoints located on the forehead.~Six pairs of acupoints are used: Baihui (GV20) and Yintang (EX-HN3), left Sishencong (EX-HN1) and Toulinqi (GB15), right Sishencong (EX-HN1) and Toulinqi (GB15), bilateral Shuaigu (GB8), bilateral Taiyang (EX-HN5), and bilateral Touwei (ST8).~Disposable acupuncture needles (Hwato®, 0.30 mm in diameter and 25-40 mm in length) are inserted at a depth of 10-30 mm perpendicularly or obliquely into acupoints. Manual manipulation is then conducted to evoke needling sensation, followed by electrical stimulation (ITO ES-160, continuous waves at 2 Hz)."
223792701|NCT02457039|PROCEDURE|Body acupuncture|"Following acupoints are used: Shui-Gou (GV26), Shen-Men (HT7). He-Gu (LI4), Wai-Guan (TE5), Zhong-Wan (CV12), Guan-Yuan (CV4), Zu-San-Li (ST36), Feng-Long (ST40) and San-Yin-Jiao (SP6).~Disposable acupuncture needles (Hwato®, 0.30 mm in diameter and 25-40 mm in length) are inserted at a depth of 10-30 mm perpendicularly or obliquely into acupoints. Manual manipulation is then conducted to evoke needling sensation. No electrical stimulation is delivered."
223792702|NCT02457039|PROCEDURE|Least acupuncture stimulation|The acupoints chosen are less related to the treated syndromes based on Traditional Chinese Medicine (TCM) theory; the number of acupoints used and the intensity of electrical stimulation are also lower than the comprehensive acupuncture regimen. The following 6 acupoints will be used in LAS control: bilateral Tong-Tian (GB17), bilateral Shou San-Li (LI10) and bilateral Fu-Yang (BL59). Electrical stimulation will be only performed on bilateral Tong-Tian (GB17) and the intensities are adjusted to a level at which patients just start feeling the stimulation.
223792703|NCT02457039|DRUG|Cytoxan-containing chemotherapy regimens|"Each subject shall receive oral administration or venous injection or both with adjuvant or neoadujuvant chemotherapy regimens, as decided by clinical oncologist.~In clinical practice, the most commonly used Cytoxan-containing regimens include but are not limit to:~AC (x4) \[Adriamycin + Cytoxan\], TC (x4) \[Taxotere + Cytoxan\], AC-P (4+4) \[Adriamycin + Cytoxan + Paclitaxel\], TAC (x6) \[Taxotere + Adriamycin + Cytoxan\], or AC-PH (4+4) \[Adriamycin + Cytoxan + Paclitaxel + Herceptin\]."
223792704|NCT01850225|DEVICE|Auditory brainstem implant|
223792705|NCT02147548|DRUG|etifoxine|
223792706|NCT02147548|DRUG|lorazepam|
223792707|NCT02147548|DRUG|Placebo|
223792708|NCT02415816|PROCEDURE|Diffusion Weighted Magnetic Resonance Imaging|Diffusion weighted magnetic resonance imaging (DWI MRI) is a method that does not involve radiation and can be used to assess the primary tumor as well as to image the entire patient, from head to toe. Diffusion weighted MRI uses a strong motion probing gradient to detect the movement of water in tissue. Tissues that are composed of tightly packed cells, such as tumors, allow less water movement than tissues with loosely packed cells. As tumors respond to therapy they become necrotic and cells are less tightly packed. This change in water diffusivity can be quantitated using DWI. Therefore, DWI provides a non-invasive, non-ionizing, and quantitative method of assessing tumor response at a cellular level and does not depend on a change in tumor size
223792709|NCT03998618|BEHAVIORAL|Acceptance and Commitment Therapy|Across six weekly 50-minute sessions, patients in the Acceptance and Commitment Therapy condition will practice various mindfulness exercises, clarify their values, and set specific goals consistent with their values. Sessions will incorporate discussion of patients' cancer experiences. Through in-session and home practice of skills, participants will learn new and more adaptive ways to respond to fatigue. Participants will receive handouts on session topics and a compact disc (CD) that we developed to guide mindfulness practices.
223792710|NCT03998618|BEHAVIORAL|Education/Support|Across six weekly 50-minute sessions, patients in the education/support condition will discuss their concerns, including symptoms and other cancer-related stressors, with a therapist providing psychological support. The therapist will direct patients to resources for practical and health information and contact information for psychosocial services. Sessions will include an orientation to the patient's medical center, education regarding common cancer-related symptoms and quality-of-life concerns, and an overview of resources for addressing these concerns. The therapist will also describe resources for addressing financial concerns and methods of evaluating health information available via the Internet and other modalities. Participants will receive handouts on session topics and will be asked to review them as homework.
223792711|NCT04051229|BEHAVIORAL|6-week exercise training program|Participants will walk at 50% Heart Rate Reserve (HRR) 3 to 5 days per week for 6 weeks at the Department of Health and Exercise Science Clinical Research Center under the supervision of study staff.
223792712|NCT04051229|BEHAVIORAL|Standardized isoenergetic high fat diet|Prior to the submaximal exercise testing visits, all participants will be provided with 3 days of a standardized isoenergetic high fat diet (20% of kcals from carbohydrate, 65% fat; 15% protein) to promote lipid oxidation. The meals will be prepared and provided by the Clinical Research Unit of Wake Forest Baptist Health. Participants will pick up 3 days' worth of food and snacks 4 days prior the testing visit. For the 3 days leading up to the visit, participants will eat the provided foods and complete a compliance assessment.
223792713|NCT04429308|PROCEDURE|Photodynamic Therapy|Photodynamic Therapy consists of (Levulan Kerastick (aminolevulinic acid HCL) topical solution, 20% + BLU-U Photodynamic Light Therapy)
223792714|NCT04429308|DRUG|Chemical Peels|Chemical peels consists of a combination of Jessner's Solution: Composed of Salicylic Acid (14%), Medical Grade Lactic Acid (14%), Medical Grade Resorcinol (14%), Denatured Ethyl Alcohol AND 35% Trichloroacetic acid peels
223792715|NCT06448871|DIAGNOSTIC_TEST|Ultrasound assessment of the right lower extremity muscles|Rectus femoris cross sectional area (RFCSA), RF muscle thickness, vastus lateralis (VL) muscle thickness, Gastrocnemius medialis (GM) muscle thickness, VL pennation angle (PA), and GM PA.
223792716|NCT06448871|DIAGNOSTIC_TEST|Dual-energy X-ray absorptiometry (DXA) scan|skeletal muscle mass (SM), appendicular skeletal muscle mass index (ASMI), total lean body mass (LBM), total fat mass (BF), percentage fat mass, and fat mass index (FMI).
223792717|NCT02025777|DEVICE|Capsule Endoscopy|
223792718|NCT02195986|DRUG|Estradiol Vaginal Cream, 0.01%|Estradiol Vaginal Cream, 0.01% (1 x 2g for 7 days)
223792719|NCT02195986|DRUG|Estrace® 0.01% cream|Estrace® 0.01% vaginal cream ( 1 x 2g for 7 days)
223792720|NCT02195986|DRUG|Placebo Vaginal Cream|Placebo Vaginal Cream ( 1 x 2 g for 7 days)
223792721|NCT01357798|DRUG|Botulinum toxin type A|Botulinum Toxin group Will have the syringe with Botulinum toxin type A . During the study the patients will be following in the headache's clinic where the evaluator will graduate the pathologies' evolution.
223792722|NCT01357798|DRUG|0,9% saline|0,9% saline group Will have the syringe with 0,9% saline. During the study the patients will be following in the headache's clinic where the evaluator will graduate the pathologies' evolution .
223792723|NCT03958344|DRUG|Prednisolone|Oral Tablet
223792724|NCT03958344|DRUG|Triamcinolone + Betamethason|A compound long acting and short acting injectable steroid
223792725|NCT02513017|BEHAVIORAL|Stimulus Control Instructions and Sleep Restriction Therapy|Please refer to arm/group descriptions.
223792726|NCT03699943|PROCEDURE|CaverStem|
223792727|NCT06963008|DRUG|inhaled BMD003(CFTR mRNA)|BMD003 is the world's first freeze-dried CFTR Mrna product (stored at 2-8 ℃), which is reconstituted with injection water before use, nebulized through a vibrating sieve atomizer, and inhaled into the lungs through the mouth and nose.
223792728|NCT02047019|DRUG|Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106)|Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106), 30/16 mg, tablet, orally, once daily
223792729|NCT02047019|DRUG|Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106)|Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106), 60/16 mg, tablet, orally, once daily
223792730|NCT02047019|DRUG|Candesartan Cilexetil|Candesartan Cilexetil, 16 mg, capsule, orally, once daily
223792731|NCT02047019|DRUG|Candesartan matching placebo|Candesartan matching placebo, capsule, orally, once daily
223792732|NCT02047019|DRUG|Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106) 30/16mg matching placebo|Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106) 30/16mg matching placebo, tablet, orally, once daily
223792733|NCT02047019|DRUG|Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106)|Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106), 60/16mg matching placebo, tablet, orally, once daily
223792734|NCT02834780|DRUG|H3B-6527|H3B-6527 by mouth once or twice daily at specified doses.
223792735|NCT01716312|DRUG|Omalizumab|For each subject, treatment with omalizumab will start with a loading dose of 600 mg followed by a maintenance dose of 300 mg every 4 weeks. The study drug will be administered as a subcutaneous injection. On Week 0 and Week 16 the medication or placebo will be administered to subjects via 4 subcutaneous injections; the remaining weeks 2 injections will be administered.Subjects will be given written directions on dealing with adverse reactions. They will also receive an Epi-Pen before discharge and instructions on how to use it.
223792736|NCT06962722|OTHER|Upper limb motor control training (uMCON)|The exercise program protocol was determined using elbow flexion (Biceps brachii) and elbow extension (Triceps) on a special platform developed for the arm. In this computer-based exercise, participants are asked to follow a small ball on the screen in different lines at certain percentages of maximum muscle strength (10%, 25%, 50%, and so on). Neuromuscular training will be worked on with this exercise.
223792737|NCT00986167|DRUG|Quetiapine XR|The daily dose of oral Quetiapine XR at the start of therapy is 300 mg on Day 1, 600 mg on Day 2 and up to 800 mg after Day 2. The dose will be adjusted within the usual effective dose range of 400 to 800 mg/day, depending on the clinical response and tolerability of the individual patient.
223792738|NCT03449030|DRUG|TAK-164|TAK-164 intravenous infusion.
223792739|NCT03449030|DRUG|89Zr-TAK-164|89Zr-TAK-164 intravenous infusion
223792740|NCT02165150|OTHER|Wheelchair-bound Senior Elastic Band exercise program|three times per week, 40 minutes per practice
223792741|NCT06167187|PROCEDURE|bilateral inferior alveolar nerve block|Placing the tip of the thumb or forefinger into the coronoid notch (retromolar fossa) to help visualize the vertical height at which the needle will enter, and retracting the cheek to expose the pterygomandibular triangle. Placing the barrel of the syringe over the contralateral lower 1st and 2nd premolars and resting the side of the needle tip against the lateral edge of the pterygomandibular raphe, aiming the tip of the needle into the pterygomandibular triangle, with the bevel facing the ramus. Advancing the needle tip slightly into the mucosa until it is stopped by the ramus (typically after about 2 to 2.5 cm of insertion) and withdrawing needle 1 mm away from bone. Aspirating to rule out intravascular placement. If aspiration reveals intravascular placement, withdrawal of the needle will be done 2 to 3 mm, then reaspirating prior to injection. Slowly injecting about 2 to 4 milliliters of bupivacaine 0.5% anesthetic in each side..
223792742|NCT06167187|DRUG|Ketorolac and fentanyl|in control group, Patients will not receive the block and pain will be controlled according to institutional protocol using 30 mg ketorolac IV and fentanyl increments as needed.
223792743|NCT00637221|DRUG|NPL-2009|Single doses of either 50mg, 100 mg or 150 mg NPL-2009
223792744|NCT02755987|DRUG|ANG1005|
223792745|NCT03104634|DRUG|Aclidinium bromide/formoterol fumarate dihydrate|Cross-over design with washout interval. Randomized order of active and placebo arm
223792746|NCT03104634|DRUG|Placebo|Placebo and delivery device matched to active intervention
223792747|NCT02715128|DEVICE|Transcranial direct current stimulation (tDCS)|non-invasive electric brain stimulation method
223792748|NCT03095040|DRUG|CM082 combined with everolimus|CM082 tablets (200 mg, 2 tablets) taken orally once a day on 28-day cycles, everolimus tablets (10 mg, 2 tablets) taken orally once a day on 28-day cycles
223792749|NCT03095040|DRUG|CM082|CM082 tablets (200 mg, 2 tablets) taken orally once a day on 28-day cycles, dummy tablets for everolimus (2 tablets) taken orally once a day on 28-day cycles
223792750|NCT03095040|DRUG|Everolimus|Everolimus tablets (10 mg, 2 tablets) taken orally once a day on 28-day cycles, dummy tablets for CM082 (2 tablets) taken orally once a day on 28-day cycles
223792751|NCT06110923|DRUG|CKD-846|once administration of Investigational Product
223792752|NCT06110923|DRUG|D091|once administration of Investigational Product per day
223792753|NCT05381974|DRUG|Psilocybin|Open-Label
223792754|NCT03044301|COMBINATION_PRODUCT|Intramuscular ZENEO® injection|Sodium Chloride (0.9 %)
223792755|NCT03044301|COMBINATION_PRODUCT|Subcutaneous high ZENEO® injection|Sodium Chloride (0.9 %)
223792756|NCT03044301|COMBINATION_PRODUCT|Subcutaneous low ZENEO® injection|Sodium Chloride (0.9 %)
223792757|NCT04303897|DEVICE|XEN Glaucoma Stent|Data are collected from patients who are implanted with XEN via the specific urgent medical needs for named patient use regulatory pathway in Hainan
223792758|NCT05312775|PROCEDURE|Double-layer uterine closure|In the intervention group, double-layer closure of the uterus will be performed using unlocked multifilament continuous running sutures for both layers and the endometrial layer will be included in the first layer. The second layer is a continuous running suture that imbricates the first layer
223792759|NCT05312775|PROCEDURE|Single-layer uterine closure|The control group will receive a single-layer closure using unlocked continuous running multifilament sutures and the endometrial layer will be included
223792760|NCT02440958|DRUG|modified FOLFIRINOX regimen|Modified FOLFIRINOX regimen consisted of oxaliplatin at a dose of 60 mg per square meter, given as a 2-hour intravenous infusion, after 60 minutes, of irinotecan at a dose of 120 mg per square meter, given as a 90-minute intravenous infusion, immediately followed by leucovorin at a dose of 400 mg per square meter, given as a 2-hour intravenous infusion through a Y-connector. This treatment was immediately followed by fluorouracil at a dose of 400 mg per square meter, administered by intravenous bolus, followed by a continuous intravenous infusion of 2400 mg per square meter over a 46-hour period every 2 weeks
223792761|NCT02429882|DRUG|Brodalumab 210 mg|210 mg brodalumab will be administered subcutaneously
223792762|NCT02429882|DRUG|Placebo|Placebo will be administered subcutaneously
223792763|NCT05093036|OTHER|Variations in PrEP care delivery at public health services|Variations on routine PrEP care at the Public Health Services in the Netherlands: online PrEP care and reduced frequency of monitoring
223792764|NCT01968239|DRUG|Ranibizumab|comparison of different re-treatment criteria for intravitreal injection of ranibizumab
223792765|NCT03882476|DIAGNOSTIC_TEST|InSight|Clinical decision support (CDS) system for sepsis detection
223792766|NCT02469194|OTHER|Blood Draw|5-10 cc of whole blood will be obtained using standard, sterile venipuncture techniques
223792767|NCT02101892|DRUG|Amitriptyline|per os, daily, evening
223792768|NCT02101892|DRUG|placebo|per os, daily, evening
223792769|NCT06343766|GENETIC|DNA collation and genotyping|"DNA collation and genotyping of specific genes ENAM rs3796703, AMBN rs4694075), TUFT1 rs78802584 and KLK4 rs2242670 through PCR and sequencing for various SNPs~Dental examinations by comparing dental covariates such as the number of DMF-T index, presence of biofilm, gingivitis, fluorosis, and detection of interproximal caries with caries progression."
223792770|NCT03580876|DRUG|addition of azathioprine|impact of addition of azathioprine after a switch of a second anti-TNF agent
223792771|NCT03580876|DRUG|Switch to a second anti-TNF drug alone|Switch to a second anti-TNF drug alone without addition of azathioprine
223792772|NCT02081846|OTHER|Nurse Home Visit|We will complete a single center, parallel, randomized, standard-of-care-controlled prospective study to determine the efficacy of a nurse home visit program, an intervention adapted from those studied in other populations (i.e., adults, high-risk infants) and re-engineered through Aim 2, in improving pediatric patient transitions from hospital to home
223792773|NCT02081846|OTHER|Standard of Care|Control patients will be randomized to receive standard-of-care at discharge. This care at our institution includes pediatric hospitalist to PCP (primary care physician) verbal and written communication prior to discharge, written documentation for the family regarding prescribed medication regimen, recommended follow-up with outpatient PCP and relevant consultant(s), and delivery of prescribed medications from the hospital pharmacy to the patient's bedside.
223792774|NCT02657980|DEVICE|Yband(YDT-201N)|transcranial Direct Current Stimulation (tDCS) 2mA for 30 min; 30 sec of ramp-up and -down; left (anode) and right (cathode) Dorsolateral prefrontal cortex (DLPFC)
223792775|NCT02657980|DEVICE|Sham-Yband(YDT-201N)|transcranial Direct Current Stimulation (tDCS) 2mA for 30 sec; left (anode) and right (cathode) Dorsolateral prefrontal cortex (DLPFC)
223792776|NCT03282227|DRUG|M207 Microneedle System|M207 Microneedle System 3.8 mg
223792777|NCT00680212|DIETARY_SUPPLEMENT|dietary carotenoids|spinach containing 1 - 2 mg beta-carotene rice containing 0.5 mg beta-carotene synthetic beta-carotene 0.5 mg oil capsule
223792778|NCT00680212|DIETARY_SUPPLEMENT|spinach, rice, and synthetic beta-carotene|spinach containing 1 - 2 mg beta-carotene rice containing 0.5 mg beta-carotene synthetic beta-carotene, 0.5 mg oil dose
223792779|NCT01952327|DEVICE|The pleurapump system|Implantation of the pleurapump system
223792780|NCT04029922|DRUG|MT-5111 (experimental study drug)|Experimental treatment with MT-5111
223792781|NCT01333124|RADIATION|chemoradiotherapy with Gemcitabine|All patients will receive gemcitabine 400 mg/m2 as an intravenous 30-min infusion on day 1, 8, 15, 22, and 29 with radiotherapy.After 4-6 week from end date of chemoradiotherapy, patients undergo preoperative evaluation including CT, PET, CA19-9, CEA. If the patient is feasible for resection on this evaluation, the surgery is performed in 1 to 2 weeks. After surgery, patients will receive gemcitabine 1000 mg/m2 as an intravenous 30-min infusion on day 1, 8, and 15 for every 28 days. Subjects will be treated for at least 1 cycle and to a maximum of four cycles of adjuvant chemotherapy unless there is documented relapse, unacceptable adverse events or withdrawal of consent.
223792782|NCT01333124|RADIATION|Radiation: chemoradiotherapy with Gemcitabine|Radiation: chemoradiotherapy with Gemcitabine
223792783|NCT04637412|OTHER|Menu label|Participants will be shown a sample of items from a restaurant menu, displayed with labels
223792784|NCT04582630|DIETARY_SUPPLEMENT|omega 3 fatty acid|Participants will take 0.1-0.2 g/kg/day of omega 3 fatty acids for 7 days.
223792785|NCT02937168|DRUG|Reslizumab|Reslizumab will be administered as per the dose and schedule specified in the arm.
223792786|NCT02937168|DRUG|Fludeoxyglucose F 18 (FDG)|FDG will be administered by IV infusion prior to each PET/CT scan.
223792787|NCT02937168|DRUG|Placebo|Placebo matching to reslizumab will be administered as per the schedule specified in the arm.
223792788|NCT05119959|OTHER|ECD intervention for CHEUs|The bi-weekly community health worker-delivered ECD 1 hour intervention using the modules from the SUPERCDZ curriculum which is a Zambian adaptation of UNICEF's Nurturing Care Framework
223792789|NCT05119959|OTHER|Usual care for CHEUs|No ECD interventions will be provided by community health workers. Children will be followed at clinics for growth and monitoring, vaccinations on a MoH approved schedule.
223792790|NCT00222651|DRUG|tenecteplase|
223792791|NCT04879914|DIETARY_SUPPLEMENT|Butyrate|3 cps/die 300 mg/cps
223792792|NCT04879914|DIETARY_SUPPLEMENT|Placebo|3 cps/die 300 mg/cps
223792793|NCT00797654|BEHAVIORAL|Information-motivation-behavior skills and cognitive processing therapy|Treatment will include elements from effective interventions for reducing risky sexual behaviors and reducing post-traumatic stress disorder (PTSD) symptoms.
223792794|NCT00797654|BEHAVIORAL|Pre and Post HIV-Test Counseling|Treatments are aimed at assessing and reducing behaviors that put participants at high risk of HIV infection.
223792795|NCT03310151|PROCEDURE|Imagined movements|Imagined wrist movements, 10-15 minutes, 4 times a day.
223792796|NCT05972096|BEHAVIORAL|Combination DBT, self-compassion and contextual-based skills|Psychotherapy combination. Skills of DBT plus self-compassion and contextual skills
223792797|NCT05461625|PROCEDURE|ACL reconstruction|Anterior cruciate ligament reconstruction
223792798|NCT05461625|OTHER|ALL anatomic|anatomic anterolateral ligament reconstruction
223792799|NCT05461625|OTHER|ALL tenodesis|anterolateral ligament teondesis
223792800|NCT04872764|OTHER|duration of hospitalization, mortality rate|duration of hospitalization, mortality rates of patients hospitalised for COVID-19 evaluated and compared in patients with and without acute kidney injury.
223792801|NCT05131048|OTHER|conventional group|this group will perform conventional therapy
223792802|NCT05131048|OTHER|experimental group|this group will perform home based exercises
223792803|NCT05949762|PROCEDURE|Venetoclax in Combination With Azacitidine and HA Regimen|"Patients diagnosed with primary AML based on morphology, immunophenotyping, and history and meeting the inclusion exclusion criteria were induced with Venetoclax in combination with Azacitidine and HA regimen.~Details for:~Venetoclax 200mg d1-10 Azacitidine 100mg/d (or 50-75mg/m2/d), d2-7 Hautriacontin 2mg/m2/d, d3-7 Cytarabine 100mg/m2/d, d3-8 (infusion 24h)"
223792804|NCT00739349|DRUG|NOVA22007 ''Cyclosporine''|Cyclosporine 0.05% Ophthalmic Cationic Emulsions
223792805|NCT00739349|DRUG|NOVA22007 ''Cyclosporine''|Cyclosporine 0.1% Ophthalmic Cationic Emulsions
223792806|NCT00739349|DRUG|vehicle/placebo|vehicle/placebo
223792807|NCT03276351|DEVICE|Long-Stemmed with Hybrid Fixation|Long-stemmed revision implant with hybrid fixation for total knee arthroplasty
223792808|NCT03276351|DEVICE|Short-Stemmed with Augmented Fixation|Short-stemmed primary implant with augmented fixation for total knee arthroplasty
223792809|NCT05737810|OTHER|No treatment given|No treatment given
223792810|NCT00003857|DRUG|tamoxifen citrate|
223792811|NCT00003857|PROCEDURE|adjuvant therapy|
223792812|NCT00003857|RADIATION|radiation therapy|
223792813|NCT01655030|DIETARY_SUPPLEMENT|creatine monohydrate|
223792814|NCT01655030|DIETARY_SUPPLEMENT|placebo|
223792815|NCT02748915|OTHER|Electrophysiological and psychoacoustic tests|
223792816|NCT00006127|DRUG|amifostine|
223792817|NCT03943095|OTHER|Potassium Nitrate|The test dentifrice contains 5% w/w potassium nitrate.
223792818|NCT03943095|OTHER|Stannous Fluoride|The test and control dentifrices contain 0.454% w/w stannous fluoride (1100 ppm fluoride).
223792819|NCT04358445|OTHER|Magnesium-Rich Artificial Cerebrospinal Fluid|The Magnesium-Rich Artificial Cerebrospinal Fluid (MACSF) is composed of several qualified clinical intravenous injections according to a specific formula, which has similar physical and chemical properties to physiological CSF. MACSF will be freshly made and used. It will be prepared by trained professionals on a specific workbench and sent to the operating room in a special container. Finally, it will be used in the operation by the neurosurgeons. Aseptic principles should be enforced strictly during the whole procedures, including preparation, transportation and application.
223792820|NCT00889213|PROCEDURE|Falciform patch and fibrin glue application|Following standard surgical exploration, the pancreatic gland will be mobilized appropriately to the level of transaction in the pancreatic neck, body or tail. The gland may be divided by stapling device, electrocautery or sharp division. Suture material will be at the discretion of the surgeon but may include absorbable or non-absorbable braided on mono-filament. Those patients randomized to autologous falciform patch will have the falciform membrane harvested. The falciform patch will be laid over the suture line of the resected pancreatic stump and secured to the pancreatic capsule utilizing #4-0 PDS suture placed at 12, 3, 6, and 9 o'clock positions. Fibrin glue (Vitagel) will be utilized to fill the potential space within this membranous capsule. Fibrin glue will be prepared as per standard instructions. Drains will be placed in the splenic bed and/or adjacent to the stump of the pancreas for postoperative fluid evacuation.
223792821|NCT00889213|PROCEDURE|standard pancreatic closure|Following standard surgical exploration, the pancreatic gland will be mobilized appropriately to the level of transaction in the pancreatic neck, body or tail. The gland may be divided by stapling device, electrocautery or sharp division. Suture material will be at the discretion of the surgeon but may include absorbable or non-absorbable braided on mono-filament.
223792822|NCT02724943|BEHAVIORAL|BMI screening|Physician screening of patients to identify patients who are overweight or obese.
223792823|NCT02724943|BEHAVIORAL|Next Steps brief clinical intervention|This intervention included identification of children who were overweight or obese, and Next Steps brief counseling materials for the healthcare provider (prior to enrollment in the intervention).
223792824|NCT02724943|BEHAVIORAL|MEND/CATCH|MEND 2-5 and MEND/CATCH 6-12 programs are multi-component interventions including behavioral, nutrition, and physical activity sessions. In the intensive (first 3 months) phase, MEND 2-5 entailed nine weekly sessions and MEND 6-12 entailed 18 twice weekly sessions.
223792825|NCT02724943|BEHAVIORAL|MEND/CATCH Transition Phase|The transition phase (next 9 months of the 12-month program) included monthly 90-minute sessions for parents and children included MEND reviews, cooking classes, Being Well book, CATCH activities and MEND World activities. Children were enrolled in YMCA sports teams or programs offered twice weekly to encourage physical activity. Weekly text messages were sent to parents to reinforce behavioral objectives of the intervention.
223792826|NCT02724943|BEHAVIORAL|Next Steps Self-Paced Booklet|Next Steps booklet for parents and children to work on nutrition and physical activity targets in a self-directed manner. Families were encouraged to seek repeated clinical visits to address child obesity as a follow up to the self-paced booklet.
223792827|NCT00472095|OTHER|Fotonovela|
223792828|NCT00472095|OTHER|Placebo Fotonovela|
223792829|NCT00249951|DRUG|Alkaline citrate|Prophylactic alkaline citrate medication during the first 8 weeks of life versus placebo solution to prevent nephrocalcinosis of prematurity.
223792830|NCT02186951|DRUG|Amoxicillin - clavulanic acid|Amoxicillin-clavulanic acid 1g, three times a day during 2 days, started within one hour after randomization and before the beginning of hypothermia.
223792831|NCT02186951|DRUG|Placebo|Placebo 1g, three times a day during 2 days, started within one hour after randomization and before the beginning of hypothermia.
223792832|NCT04730297|DRUG|paracetamol 500 mg plus codeine 30 mg preoperative administration|each patient 30 minutes before surgery received paracetamol 500 mg plus codeine 30 mg
223792833|NCT04730297|DRUG|ibuprofen 400 mg preoperative administration|each patient 30 minutes before surgery received ibuprofen 400 mg
223792834|NCT04730297|DRUG|Placebo oral tablet preoperative administration|each patient 30 minutes before surgery received placebo
223792835|NCT04537962|OTHER|Colgate Periogard® mouthwash|Patients will be submitted to antisepsia of the oral mucosa with Colgate Periogard® mouthwash
223792836|NCT04537962|OTHER|Colgate Peroxyl® mouthwash|Patients will be submitted to antisepsia of the oral mucosa with Colgate Peroxyl® mouthwash
223792837|NCT04537962|OTHER|Colgate Total® Mouthwash|Patients will be submitted to antisepsia of the oral mucosa with Colgate Total® Mouthwash
223792838|NCT04537962|OTHER|Toothpaste with sodium monofluorophosphate|Patients will be submitted to brushing with toothpaste with sodium monofluorophosphate
223792839|NCT04537962|OTHER|Toothpaste with sodium fluoride and zinc|Patients will be submitted to brushing with toothpaste with sodium fluoride and zinc
223792840|NCT04537962|OTHER|Toothpaste with tin fluoride|Patients will be submitted to brushing with toothpaste with tin fluoride
223792841|NCT05323526|DIAGNOSTIC_TEST|Catquest-9SF questionnaire|Patients complete the questionnaire preoperatively and postoperatively.
223792842|NCT05323526|DIAGNOSTIC_TEST|Demographics and clinical parameters|The following clinical parameters are evaluated: age, gender, ocular and systemic comorbidities, educational level, preoperative and postoperative monocular distance uncorrected visual acuity (UVA), distance best spectacle-corrected visual acuity (BSCVA) of the eye for cataract surgery, binocular distance UVA and BSCVA, refraction, spherical equivalent (SE), and intraocular pressure.
223792843|NCT04748744|COMBINATION_PRODUCT|Butyrylcholinesterase|Value of Butyrylcholinesterase as a Marker of Surgical Site Infection Following Surgery for Colorectal Diseases
223792844|NCT00864448|DRUG|Ramipril10 mg Capsules, single dose|A: Experimental Subjects received Purepac formulated products under fasting conditions
223792845|NCT00864448|DRUG|Atlace® 10 mg capsules, single dose|B: Active comparator Subjects received Monarch Pharmaceuticals Inc. formulated products under fasting conditions
223792846|NCT03871647|DRUG|Beta blocker|perioperative beta blockers
223792847|NCT01445899|DRUG|PF-04523655 (Stratum I)|PF-04523655 (a small interfering RNA) - a single IVT injection
223792848|NCT01445899|DRUG|ranibizumab|6 monthly IVT injections of ranibizumab (Stratum II)
223792849|NCT01445899|DRUG|PF-04523655 (Stratum II)|6 monthly IVT injections of PF-04523655 (a small interfering RNA)
223792850|NCT05071157|BEHAVIORAL|echocardiography|"* speckle tracking echocardiography~* evaluation of cardiac variability by recording heart rate as several hours (POLAR watch)~* bioimpedance~* blood test for biological assays (metabolomic analysis)"
223792851|NCT01913600|DEVICE|Resolute Integrity Stent|Drug eluting stent (DES)
223792852|NCT02378168|OTHER|no intervention; retrospective study|
223792853|NCT00679939|DRUG|Rosiglitazone|up to 8mg/day
223792854|NCT00679939|DRUG|Metformin|up to 2000mg/day
223792855|NCT01357967|DRUG|SSRI monotherapy|SSRI (paxil CR, es-citalopram, fluoxetine, sertraline) start with (paxil CR 12.5mg, es-citalopram 10mg, fluoxetine 20mg, sertraline 50mg) for 1 week up to maximal dosage, flexible dosage, usually in the morning
223792856|NCT01357967|DRUG|Seroquel XR adjunctive|"Quetiapine group:~seroquel XR 50mg Day 1 --\> 50mg Day 2 --\> 150mg Day 3 --\> 150mg Day 4 --\> adjustment usually at hs but can be daytime"
223792857|NCT01875926|BIOLOGICAL|ALX-0171|single dose of 200 mg ALX-0171 via oral inhalation
223792858|NCT01875926|BIOLOGICAL|ALX-0171|repeated doses of 200 mg ALX-0171 via oral inhalation once daily for 5 consecutive days
223792859|NCT01875926|BIOLOGICAL|ALX-0171|Single dose of 0.3 mg/kg body weight ALX-0171 via intravenous administration
223792860|NCT00596440|DRUG|Transdermal nicotine patch|8 weeks; 4 weeks of 21mg, 2 weeks of 14mg, and 2 weeks of 7mg.
223792861|NCT05717933|DIAGNOSTIC_TEST|thyroid hormones|Thyroid function among pediatric patients with type1 diabetes mellitus at the first presentation, from patients' characteristics to disease severity
223792862|NCT02804542|OTHER|Observational|
223792863|NCT02804542|OTHER|Retrospective review|
223792864|NCT01325168|DRUG|syntocinon nasal spray|nasal oxytocin - 24 IU, 3 inhalations of 4IU to each nostril (45 sec waiting between the inhalations)
223792865|NCT01325168|DRUG|placebo nasal spray|nasal placebo - 24 IU, 3 inhalations of 4IU to each nostril (45 sec waiting between the inhalations)
223792866|NCT04413890|DRUG|Dinoprostone vaginal gel|Prostaglandin gel 0.5, 1 or 2 mg
223792867|NCT03166761|DRUG|Dexamethasone|Dexamethasone injection into the sacroiliac joint
223792868|NCT03166761|DRUG|Triamcinolone Acetonide|Triamcinolone injection into the sacroiliac joint
223792869|NCT00229125|DRUG|Gabapentin|
223792870|NCT00229125|DRUG|Lorazepam|
223792871|NCT01396967|DEVICE|surgery|cataract surgery
223792872|NCT04414982|BEHAVIORAL|Intervention Values Affirmation|Participants are asked to circle the two or three values that are MOST important to them. Next, participants are asked to think about times when the values chosen might be important to THEMSELVES and then write a few sentences to describe when and why they might be important.
223792873|NCT04414982|BEHAVIORAL|Control Values Affirmation|Participants are asked to circle the two or three items that are LEAST important to them. Next, participants are asked to think about times when the values chosen might be important to SOMEONE ELSE and then write a few sentences to describe when and why they might be important.
223792874|NCT03459430|OTHER|Core stability training|Effect of different core stability programs using diverse training intensities
223792875|NCT00788996|BEHAVIORAL|Brief intervention based in clinical practice guide|Minimal counseling at smoking parents with babies minor 1 year-old
223792876|NCT00827450|DIETARY_SUPPLEMENT|Ctl|Control, isocaloric diet; no coffee
223792877|NCT00827450|DIETARY_SUPPLEMENT|High fructose diet; no coffee|Hypercaloric, high fructose diet; no coffee
223792878|NCT00827450|DIETARY_SUPPLEMENT|fully torrefied, caffeine-free coffee|Hypercaloric, high fructose diet + coffee
223792879|NCT00827450|DIETARY_SUPPLEMENT|partially torrefied, caffeine-free coffee|Hypercaloric, high fructose diet + coffee
223792880|NCT00827450|DIETARY_SUPPLEMENT|Partially torrefied, caffeinated coffee|Hypercaloric, high fructose diet + coffee
223792881|NCT05214872|DIAGNOSTIC_TEST|laboratory parameters - complete blood count|"the complete blood count was analyzed using Sysmex K-4500 Automated Hematology Analyzer (by GMI Inc., USA):~* hemoglobin (HGB) \[g/dl\];~* red blood count (RBC) \[10\^12/l\];~* hematocrit (HCT) \[l/l\];~* white blood cells (WBC) \[10\^9/l\];~* platelet count (PLT) \[10\^9/l\]"
223792882|NCT05214872|OTHER|body mass index (BMI) [kg/m^2] calculation|body mass index (BMI) \[kg/m\^2\] was calculated by dividing a person's weight (post-HD weight in HD group) \[kg\] by the squared their body height \[m\]
223792883|NCT05214872|DIAGNOSTIC_TEST|selected parameters of oxidative stress (1)|"Serum concentration of:~* advanced glycation ends products (AGE) \[µg/mg protein\];~* 3-nitrotyrosine (3-NT) \[µmol/mg protein\];~* advanced oxidation protein products (AOPP) \[µmol/mg protein\];~* carboxymethyle(lysine) (CML) \[µg/mg protein\]~were determined with the enzyme immunoassay methods (ELISA) using Shanghai Sunred Biological Technology Co kits, China."
223792884|NCT05214872|DIAGNOSTIC_TEST|metalloproteinases|"metalloproteinases in the serum \[ng/ml\]:~* metalloproteinase 9 (MMP-9) in the serum was determined by the ELISA method using the Quantikine Human MMP-9 (total) kit, by R\&D Systems, Canada;~* tissue inhibitor of metalloproteinase 1 (TIMP-1) in the serum - was determined by the ELISA method using the Quantikine Human TIMP-1 kit, manufactured by R\&D Systems, Canada;~* the MMP-9/TIMP-1 ratio was calculated by the quotient of the MMP-9 and the TIMP-1 concentration."
223792885|NCT05214872|DIAGNOSTIC_TEST|parameters of lipids metabolism in the serum|"* total cholesterol (T-C) \[mg/dl\] - was assessed by routine techniques using Cobas Integra 400 plus biochemical analyzer by Roche Diagnostics, USA;~* low-density lipoprotein cholesterol (LDL-C) \[mg/dl\] - was assessed by routine techniques using Cobas Integra 400 plus biochemical analyzer by Roche Diagnostics, USA;~* high-density lipoprotein cholesterol (HDL-C) \[mg/dl\] - was assessed by routine techniques using Cobas Integra 400 plus biochemical analyzer by Roche Diagnostics, USA;~* triglycerides (TG) \[mg/dl\] - were assessed by routine techniques using Cobas Integra 400 plus biochemical analyzer by Roche Diagnostics, USA;~* the concentration of low-density lipoprotein (LDL-C) cholesterol - was determined from Friedewalds' equation (LDL-C \[mg/dl\] = total cholesterol (T-C) \[mg/dl\]- HDL-C \[mg/dl\]- TG\[mg/dl\]/5)."
223792886|NCT05214872|DIAGNOSTIC_TEST|parameters of iron metabolism|"* iron concentration \[mg/dl\] - was analyzed with the Cobas Integra 400 plus biochemical analyzer from Roche Diagnostics, USA;~* total iron-binding capacity (TIBC) \[mg/dl\] - was analyzed with the Cobas Integra 400 plus biochemical analyzer from Roche Diagnostics, USA;~* the unsaturated iron-binding capacity (UIBC) \[mg/dl\] was determined by an equation in which iron concentration in plasma is subtracted from TIBC \[mg/dl\];~* ferritin \[ng/ml\] concentration was determined with the Modular E-170 biochemical analyzer from Roche Diagnostics, USA."
223792887|NCT05214872|DIAGNOSTIC_TEST|selected inflammatory markers|"* high-sensitivity C-reactive protein (hsCRP) \[mg/l\] was measured using DADE Behring, USA and the DADE nephelometer Behring Analyzer II;~* neopterin \[nmol/l\] was determined by using the Neopterin ELISA kit, DRG International, Inc., USA;~* interleukin 18 (IL-18) \[pg/ml\] concentration was determined by Colorimetric Sandwich ELISA, Quantikine Human IL-18 R\&D Inc., USA."
223792888|NCT05214872|DEVICE|carotid intima-media thickness (IMT)|"carotid intima-media thickness (IMT) \[mm\] was measured by The Accuson CV 70 system (Siemens) with a 10 megahertz (Mhz) transducer.~Two longitudinal projections were assessed (anterolateral and posterolateral). The distal 1 cm of the common carotid artery just proximal to the bulb was measured by means of a computer analysis system (Medical Imaging Applications, LLC)."
224263928|NCT02673320|PROCEDURE|Delayed surgery at 15 days|After completion of the clinical and radiological diagnosis of post-traumatic spinal cord contusion on narrow spinal canal, the patient was hospitalized. After obtaining the signed consent form, the patient was included in the protocol. After anesthetic consultation determining the feasibility or not of surgery and in the absence of other vital injury or involving life-threatening, delayed surgery is then realised at 15 days. The surgical technique is a conventional cervical spinal decompression surgery. Surgery by way posterior surgery, by laminectomy in case of significant spinal stenosis greater than or equal to 3 floors will be preferred. In other cases, the type of surgery will be at the discretion of the surgeon. Then, the follow-up visits are D7, M3, Y1 and Y2.
223792889|NCT05214872|DEVICE|non-invasive cardiological examinations|"For non-invasive cardiological examinations, the Portapres device (Finapres Medical Systems (FMS), the Netherlands), the SphygmoCor tonometer (AtCor Medical), the Colin blood pressure monitor (BMP)-7000 (Japan) were used.~Main assessed variables: heart rate (HR) \[beats per minute \[bpm\]\]; ejection duration (ED) \[millisecons\]; peripheral systolic (pSBP) and diastolic blood pressure (pDBP) \[mm Hg\]; peripheral mean arterial pressure (pMAP) \[mm Hg\]; peripheral end-systolic pressure (pESP) \[mm Hg\]; central systolic (cSBP) and diastolic blood pressure (cDBP) \[mm Hg\]; central mean arterial pressure (cMAP) \[mm Hg\]; central augmented pressure (cAP) \[mmHg\]; central mean pressure of diastole (cMPD)\[mm Hg\]; central mean pressure of systole (cMPS) \[mm Hg\]; central end-systolic pressure (cESP) \[mm Hg\]."
223792890|NCT05214872|DEVICE|vessel stiffness assessment|"The following parameters of vessel stiffness were assessed by Pulse Trace 2000 (Micro Medical Ltd., Rochester, Kent, United Kingdom):~* reflection index (RI) \[in percentages \[%\]\];~* vascular stiffness index (SI) \[m/s\];~* peripheral pulse pressure (pPP) \[mm Hg\];~* central puls pressure (cPP) \[mm Hg\]~* peripheral pulse pressure/central pulse pressure (pPP/cPP ratio)."
223792891|NCT05214872|OTHER|cardiovascular (CV)-related death recording during 2-year follow-up|During a 2-year follow-up from the enrollment to this study, CV-related fatal incidents history has been recorded for each subject separately. The primary endpoint was fatal acute myocardial infarction (AMI) or acute ischemic stroke or any unexpected or sudden death only if autopsy proved CV-related. If there was doubt about the cause of death or there was no contact with the patient during the two years from study enrollment, that patient was excluded and not considered further.
223792892|NCT05214872|DIAGNOSTIC_TEST|glucose (Glu)|glucose (Glu) \[mg/dl\] was assessed in the serum by a routine technique using Cobas Integra 400 plus biochemical analyzer by Roche Diagnostics, USA.
223792893|NCT05214872|DIAGNOSTIC_TEST|klotho|klotho \[ng/ml\] - was analyzed in the serum by Human KL(Klotho) \[ng/ml\] ELISA Kit, Shanghai Sunred Biological Technology Co kit, China.
223792894|NCT05214872|DIAGNOSTIC_TEST|fibroblast growth factor 23 (FGF-23)|FGF-23 \[pg/ml\] - was analyzed in rhe serum using Human FGF-23 ELISA Kit, Sigma-Aldrich, USA.
223792895|NCT05214872|DIAGNOSTIC_TEST|parameters of calcium and phosphate metabolism|"* total and ionized calcium \[mg/dl\],~* phosphate \[mg/dl\],~* intact parathormone (iPTH) \[mg/dl\]~were assessed by routine techniques using Cobas Integra 400 plus biochemical analyzer by Roche Diagnostics, USA."
223792896|NCT05214872|DIAGNOSTIC_TEST|liver enzymes activity assessment|"activity of:~* alanine transaminase (ALT) \[U/l\];~* aspartate transaminase (AST) \[U/l\];~* alkaline phosphatase (ALP) \[U/l\]~were assessed by routine techniques using Cobas Integra 400 plus biochemical analyzer by Roche Diagnostics, USA."
223792897|NCT05214872|DIAGNOSTIC_TEST|total protein and albumin|"* total protein (TP) \[g/dl\];~* albumin (ALB) \[g/dl\]~were assessed in the serum by routine techniques using Cobas Integra 400 plus biochemical analyzer by Roche Diagnostics, USA."
223792898|NCT05214872|DIAGNOSTIC_TEST|creatinine and urea|"* creatinine in the serum \[mg/dl\] - the assay is based on the reaction of creatinine with sodium picrate as described by Jaffe (Jaffes' colorimetric method) - was assessed by routine techniques using Cobas Integra 400 plus biochemical analyzer by Roche Diagnostics, USA;~* urea \[mg/dl\] in the serum - was assessed by routine techniques using Cobas Integra 400 plus biochemical analyzer by Roche Diagnostics, USA."
223792899|NCT05214872|DIAGNOSTIC_TEST|selected parameters of oxidative stress (2)|myeloperoxidase (MPO) \[ng/ml\] in the serum- was determined by the ELISA method using the Quantikine Human MPO test by R\&D Systems kit, Canada.
223792900|NCT05214872|DIAGNOSTIC_TEST|selected parameters of oxidative stress (3) sRAGE|soluble receptor for advanced glycation end products (sRAGE) \[µg/mg protein\] in the serum was tested with enzymatic immunoassay (Quantikine ELISA) using R\&D Systems kit, Canada.
223792901|NCT05214872|DIAGNOSTIC_TEST|selected parameters of oxidative stress (4) MG, CEL, carbamyl protein groups|"* methylglyoxal (MG) \[µg/mg protein\];~* carboxyethyle(lysine) (CEL) \[µg/mg protein\];~* carbamyl protein groups \[µg/mg protein\] were assessed in the serum by competitive enzyme immunoassay (competitive ELISA) using kits from Cell Biolabs Inc, USA."
223792902|NCT05214872|DIAGNOSTIC_TEST|selected electrolytes assessment|"* potassium (K) \[mmol/l\];~* sodium (Na) \[mmol/l\];~* magnesium (Mg) \[mg/dL\]~were assessed in the serum by routine techniques using Cobas Integra 400 plus biochemical analyzer by Roche Diagnostics, USA."
223792903|NCT05214872|DIAGNOSTIC_TEST|NT-pro-brain natriuretic peptide (NT-proBNP)|NT-proBNP \[fmol/ml\] - was analyzed in the serum by enzyme immunoassay using the Nt-proBNP kit from Biomedica, Slovakia.
223792904|NCT05214872|OTHER|estimated glomerular filtration rate (eGFR) calculation|eGFR \[ml/min/1.73m\^2\] - according to the Kidney Disease: Improving Global Outcomes (KDIGO) 2012 recommendations was calculated based on the Modification of Diet in Renal Disease (MDRD) formula: eGFR = 186 x \[creatinine concentration in mg/dl\] - 1.154 x \[age in years\] - 0.203 x \[0.724\] for the female gender.
223792905|NCT04364646|BEHAVIORAL|Personalized Integrated Chronotherapy|Based on their baseline sleep-wake schedule and real-life constraints (work and other responsibilities), an initial sleep schedule is set that allows 7.5 hours of sleep and provides time for participants to sit in front of the morning bright light.
223792906|NCT05614297|DIAGNOSTIC_TEST|Knee joint laxity test|Patients seen in an outpatient clinic in connection with an ACL injury or in connection with short or long-term follow-up after ACL surgery, will undergo a clinical assessment of their knee injury as part of standard care. This includes an assessment of knee joint laxity using both the Rolimeter and the Lachmeter, to allow for an assessment of agreement between the two methods.
223792907|NCT00187018|BIOLOGICAL|Bone marrow transplant|
223792908|NCT04837066|DIAGNOSTIC_TEST|Dynamic Vision Testing (Bertec Vision Advantage System) and Balance Error Scoring System|Assessment tool and computerized tests designed to evaluate postural stability and vestibulo-ocular reflex (VOR) function while assisting with return to play decision after a sports-related concussion.
223792909|NCT02156713|BEHAVIORAL|CIMT Camp|
223792910|NCT00105326|DRUG|paliperidone ER|
223792911|NCT01774565|DEVICE|Fully Automated Closed-Loop Insulin Delivery|
223792912|NCT01774565|DEVICE|Conventional insulin therapy|
223792913|NCT03411967|DRUG|Apatinib|apatinib mesylate tablets 500mg, po, qd, continued until the next cycle, taking on an empty stomach (daily taken at the same time), every 3 weeks For one cycle, a total of 4 to 6 cycles of treatment, apatinib has been taken until the disease progresses, intolerable toxicity.
223792914|NCT03411967|DRUG|Docetaxel|Docetaxel, 60 mg / m2, d1, iv ,every 3 weeks For one cycle, a total of 4 to 6 cycles of treatment
223792915|NCT02269670|DRUG|everolimus|Given PO
223792916|NCT02269670|DRUG|anastrozole|Given PO
223792917|NCT02269670|DRUG|letrozole|Given PO
223792918|NCT02269670|DRUG|tamoxifen citrate|Given PO
223792919|NCT02269670|DRUG|fulvestrant|Given IM or PO
223792920|NCT02269670|DRUG|megestrol acetate|Given PO
223792921|NCT03083587|BEHAVIORAL|Normal lifestyle|Normal lifestyle
223792922|NCT03083587|BEHAVIORAL|Exercise|Mild exercise 3 min every half hour
223792923|NCT03083587|PROCEDURE|muscle and fat biopsy|Biopsy under local anesthesia
223792924|NCT03083587|DEVICE|Continuous glucose monitoring|Glucose concentrations during the study period
223792925|NCT03083587|DEVICE|Activity monitoring (ActivePal)|Objective measurements of standing and sitting time
223792926|NCT05732233|DEVICE|Ultivision AI|Ultivision AI is a computer-assisted detection (CADe) device intended to aid endoscopists in the real-time identification of colonic mucosal lesions (such as polyps and adenomas) in adult patients undergoing colorectal cancer screening and surveillance examinations.
223792927|NCT00789087|PROCEDURE|Videothoracoscopic talc poudrage (VT).|Videothoracoscopic talc poudrage
223792928|NCT00789087|PROCEDURE|Talc slurry through a chest tube (DT).|Talc slurry through a chest tube
223792929|NCT03584698|DRUG|Misoprostol 100Mcg Tab|women will receive misoprostol 100 mcg (Misotac, Sigma Pharmaceuticals, Egypt) vaginally applied every 6 hours till cervical dilatation.
223792930|NCT03584698|DRUG|Evening Primrose Oil 1000 MG|women will receive 4 capsules evening primrose oil 1000 mg (Primrose plus, Ema Pharm, Egypt) vaginally applied every 6 hours till cervical dilatation.
223792931|NCT03877445|DEVICE|exposition half-face|Patients will be included in the study and exposed on a half-face from Day1 to Day5. The other half-face will serve as unexposed control. The effect of blue light on the melasma lesions will be assessed from Day 1 to Day 6 using chromametry and a modified Melasma Area and Severity Index on standardized photographs
223792932|NCT06362681|OTHER|Fluoride|Application of remineralizing agents on teeth and molars with MIH during 24 months of follow-up.
223792933|NCT02023970|DEVICE|Patients receiving animal-derived bioprosthetic heart valves.|
223792934|NCT02023970|OTHER|Echocardiography (1)|
223792935|NCT02023970|OTHER|Echocardiography (2)|
223792936|NCT02023970|OTHER|Echocardiography (3)|
223792937|NCT02023970|BIOLOGICAL|Blood sample (1)|
223792938|NCT02023970|BIOLOGICAL|Blood sample (2)|
223792939|NCT02023970|BIOLOGICAL|Blood sample (3)|
223792940|NCT00415987|PROCEDURE|Hematopoietic Stem Cell Transplantation|
223792941|NCT05023304|DRUG|Dextenza 0.4Mg Ophthalmic Insert|The insert, containing 0.4 mg of active pharmaceutical product, is placed within the canaliculus to provide a sustained and tapered delivery of drug to the ocular surface over 30 days after a one-time insertion. The attributes of the insert reduce the risks for improper corticosteroid tapering and unwanted peaks and troughs in drug concentration.
223792942|NCT05023304|DRUG|Topical prednisolone acetate|Standard of care topical drop regimen with four week taper
223792943|NCT04195503|PROCEDURE|Liver Transplantation|Surgical removal of liver containing tumor(s) and transplantation of new healthy liver graft
223792944|NCT02429063|OTHER|Bright White Light|The light will be administered via a Litebook Elite or Litebook Advantage (Litebook®, Ltd., Medicine Hat, Canada). The Litebook® is a small (6×5×1 in.) and lightweight (8 oz.) box and will be fitted with adherence monitors to record at what time and for what duration the light box is turned on. The Litebook® is designed to be placed on a table approximately 18 inches from the participant's head and within 45° of the midline of the visual field. The BWL Litebook® looks identical to the DRL and utilizes 24 white light-emitting diode (LED) lights and does not emit ultraviolet light.
223792945|NCT02429063|OTHER|Dim Red Light|The light will be administered via a Litebook Elite or Litebook Advantage (Litebook®, Ltd., Medicine Hat, Canada). The Litebook® is a small (6×5×1 in.) and lightweight (8 oz.) box and will be fitted with adherence monitors to record at what time and for what duration the light box is turned on. The Litebook® is designed to be placed on a table approximately 18 inches from the participant's head and within 45° of the midline of the visual field. The DRL Litebook looks identical to the BWL box and contains red lights rather than white LED lights.
223792946|NCT03146520|DEVICE|EarlyTect Colon Cancer|SDC2 methylation assay by qPCR using EarlyTect Colon Cancer kit
223792947|NCT04657211|OTHER|Prospective observational cohort study|prospective observational cohort study
223792948|NCT05009992|DRUG|ONC201|Given orally (PO)
223792949|NCT05009992|RADIATION|Radiation Therapy|Undergo radiation therapy
223792950|NCT05009992|DRUG|Paxalisib|Given PO
223792951|NCT06294704|OTHER|bariatric surgery|Having undergone bariatric surgery and on a closed-loop insulin pump after bariatric surgery
223792952|NCT05134454|DIAGNOSTIC_TEST|Extended ECG investigation|At least two long-term ambulatory ECG recordings with a duration of 14 days each using Philips ePatch (https://www.myheartmonitor.com/device/epatch/). The two recordings should be 2-4 months apart.
223792953|NCT03558867|DRUG|Metformin + Healthy diet|Metformin (1500 mg/d, Extended Release) + Healthy, low fat diet
223792954|NCT03558867|DRUG|Metformin + Personalized diet|Metformin (1500 mg/d, Extended Release) + Algorithm-based personalized diet
223792955|NCT03508453|BIOLOGICAL|IC14|Monoclonal antibody against CD14
223792956|NCT03508453|OTHER|Placebo|sterile normal saline for injection prepared to be identical to study drug
223792957|NCT02993068|OTHER|Educational Intervention|Watch genetic testing online educational video
223792958|NCT02993068|OTHER|Genetic Counseling|Receive post-telephone genetic counseling
223792959|NCT02993068|OTHER|Genetic Counseling|Receive pre-telephone genetic counseling
223792960|NCT02993068|OTHER|Laboratory Biomarker Analysis|Correlative studies
223792961|NCT02993068|OTHER|Questionnaire Administration|Ancillary studies
223792962|NCT02693665|BEHAVIORAL|FAmily CEntered Advance Care Planning for Teens with Cancer|3 session weekly intervention: 1) survey completed by adolescent and family (surrogate decision maker) separately with facilitator; 2) Respecting Choices structured interview about patient's representation of illness, goals of care, hopes, treatment preferences; 3) completion of an advance directive.
223792963|NCT03373604|DRUG|18F-MK-6240|18F-MK-6240 is a PET radioligand that binds abnormal tangles made of the protein tau. These tau tangles develop in the brain in people with Alzheimer's disease.
223792964|NCT03373604|PROCEDURE|Lumbar Puncture (optional)|Subjects have the option to have lumbar puncture performed for the measurement of Alzheimer's disease biomarkers in cerebrospinal fluid.
223792965|NCT05790343|BEHAVIORAL|BAPHYC|Nine weekly peer led group meetings
223792966|NCT06572436|BEHAVIORAL|Multimedia information training|The multimedia information training consisted of a 5-minute video containing detailed amniocentesis and chorionic villus sampling application information. A 5-minute video was developed by the authors and used for research purposes only. The video was designed to provide pregnant women with a comprehensive overview of the amniocentesis and chorionic villus sampling procedure, its benefits, and potential risks, and included real-life images to depict all aspects of the procedure.
223792967|NCT02322944|BEHAVIORAL|Quality improvement strategies and tools|Training in standardized treatment pattern; building quality management team and determining improvement goals; tools (a wristband in order to remind all medical staff involved in the treatment process; workflow posters and cards; a CRF including a flowchart to inform the management steps); periodical quality feedback report and regular quality meeting; study website serving as the communication platform.
223792968|NCT02322944|BEHAVIORAL|Process optimization|Examining local hospitals' workflow to determine the key link affecting the rate of reperfusion therapy and its timeliness (such as thrombolytic drug preparation, cardiac catheterization laboratory preparation, transferring from the ER to the cath lab, interventional medical team gathering, etc.) and systems (such as pre-paid policy for thrombolysis or PPCI)
223792969|NCT01065961|DRUG|Decadron|Decadron will be given at a dose of 0.2 mg/kg intraoperatively, followed by Decadron 4 mg. every 6 hours for 24 hours.
223792970|NCT01065961|DRUG|Saline|Placebo saline will be given intraoperatively as well as 4 doses every 6 hours for 24 hours.
223792971|NCT02465593|DRUG|PEP503|The volume of PEP503 to be administered is based on the baseline tumor volume of each patient. There will be 4 dose levels in Phase Ib.
223792972|NCT02465593|DRUG|5-fluorouracil|225 mg/m2 a day, 5 days/week for 5 weeks during radiotherapy period
223792973|NCT02465593|DRUG|capecitabine|825 mg/m2 BID 5 days/week for 5 weeks during the radiotherapy period
223792974|NCT02465593|PROCEDURE|surgical resection|Approximately 8 weeks after the completion of chemoradiotherapy, surgical resection of the tumor (total mesorectal excision, TME) will be performed once the tumor become resectable.
223792975|NCT02465593|RADIATION|Radiotherapy|Intensity-modulated radiation therapy (IMRT) or intensity modulated arc therapy (IMAT) of 5,000 cGy in 25 fractions (200 cGy/fraction, 5 times/week) to gross tumor and involved nodes and 4,500 cGy in 25 fractions (180 cGy/fraction, 5 times/week) to pelvis, starting at 24 hours after PEP503 injection.
223792976|NCT05699434|BEHAVIORAL|Obstetrics and Gynecology residents and experts'|Obstetrics and Gynecology residents and experts' knowledge of, attitudes toward, practice behaviors, and self-confidence levels of caring for lesbian, bisexual, and transgender (LBT+) patients in Turkey (Istanbul)
223792977|NCT00710424|DRUG|Sativex|containing THC (27 mg/ml):CBD (25 mg/ml), in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring. Maximum permitted dose was eight actuations in any three hour period and 24 actuations (THC 65 mg: CBD 60 mg) in 24 hours
223792978|NCT00710424|DRUG|Placebo|containing peppermint oil, 0.05% (v/v), quinoline yellow, 0.005% (w/v), sunset yellow, 0.0025% (w/v), in ethanol:propylene glycol (50:50) excipient.
223792979|NCT04132609|BEHAVIORAL|Cognitive bias modification|: In CBM, the task presentation and timing is the same as attentional bias, except the probe always replaces the neutral word. It ensures that: 1) the duration of CBM and control training should not differ; 2) CBM and control participants receive equal practice on the motoric aspects of the task; and 3) CBM and control participants are exposed to the same word cues. Based on previous data, duration of CBM and control trainings will be about 10 minutes.
223792980|NCT04132609|BEHAVIORAL|Standard attentional bias|"the standard attentional bias task, a drug or pain-related word is presented next to a neutral word for 500ms. Subsequently, a probe (i.e., a q or p) replaces the drug/pain word or the neutral word at an equal rate. The participant's task is to indicate the location of the probe as quickly as possible by pressing q or p. Attentional bias is calculated from the difference in reaction times (i.e., neutral cue minus drug/pain cue) to indicate the location of the probe, with higher values indicating greater attentional bias. For all tasks, opioid and pain words will be presented in separate blocks in counterbalanced order. Neutral words paired with opioid or pain words will be matched for length and frequency of use in the English language."
223792981|NCT06050460|DRUG|SA55 Injection|Novel coronavirus broad-spectrum neutralizing antibody SA55 injection
223792982|NCT06050460|OTHER|Placebo for SA55 injection|Placebo for Novel coronavirus broad-spectrum neutralizing antibody SA55 injection
223792983|NCT03701750|DRUG|Low Molecular Weight Heparin (enoxaparin sodium)|enoxaparin sodium 40mg/day subcutaneously after oocyte collection, and routine luteal phase support after embryo transfer until clinical pregnancy confirmed by ultrasound
223792984|NCT02860728|BEHAVIORAL|Individualized Resistance Training|Lower body resistance exercises will be prescribed in various combinations over multiple days and individually modified and progressed to achieve advances in both movement pattern, intensity, and exercise volume.
223792985|NCT02220972|DRUG|Perampanel|
223792986|NCT02220972|DRUG|Placebo|
223792987|NCT02433353|DRUG|Venlafaxine XR|Serotonin norepinephrine reuptake inhibitor
223792988|NCT02433353|BEHAVIORAL|EMDR|psychotherapy
223792989|NCT02433353|DRUG|Placebo|Look-alike venlafaxine XR tablets containing no active drug
223792990|NCT03212105|BEHAVIORAL|60 Second Video|The mindfulness intervention will be a video-flash found at http://www.pixelthoughts.co. In this exercise patients are asked to write down a concern or worry, and watch it get put into perspective within a 60 seconds time frame.
223792991|NCT03212105|OTHER|Educational Brochure|The educational pamphlet will contain information about pain and stress, which patients will be able to read within 60 seconds.
223792992|NCT03745664|DRUG|Methylprednisolone Sodium Succinate|During hospitalization, 40 mg of methylprednisolone (20 mg/ml) will be given intravenously twice a day (20 mg every 12 hours).
223792993|NCT03745664|DRUG|Saline Solution for Injection|During hospitalization, 2 ml of Saline Solution for Injection will be given intravenously twice a day (2 ml every 12 hours).
223792994|NCT01962493|OTHER|Sodium bicarbonate/ Sodium Fluoride|Toothpaste containing sodium bicarbonate and sodium fluoride as cosmetic
223792995|NCT01962493|OTHER|Sodium fluoride|Toothpaste containing sodium fluoride as cosmetic
223792996|NCT01962493|DRUG|Chlorhexidine digluconate|Mouthwash containing chlorhexidine digluconate
223792997|NCT01431677|PROCEDURE|Muscle Biopsy|
223792998|NCT01732367|DRUG|Lamivudine plus adefovir|Lamivudine 100mg QD for 96 weeks + Adefovir 10mg QD for 96 weeks
223792999|NCT01732367|DRUG|Tenofovir|Tenofovir 300mg QD for 96 weeks
223793000|NCT04948203|DRUG|Sirolimus|Triangular-shaped tablet
223793001|NCT04514159|DRUG|ZN-c5|ZN-c5 is the study drug.
223793002|NCT04514159|DRUG|Abemaciclib|Abemaciclib (VERZENIO®) is an approved drug.
223793003|NCT03311438|OTHER|Oral health intervention program|Intervention: All parents were encouraged to brush their children's teeth twice a day, with adjusted amount of fluoride toothpaste according to age. Additional fluoride tablets with dose according to age were recommended from two years of age. The children's parents were given written information about the importance and benefits of optimal oral hygiene and explaining the link to infective endocarditis. A pamphlet, lift the lip program, with instruction of looking for early signs of tooth decay, how to intervene and contact local Public Dental Service (PDS) clinic. Dietary advice was also given. The child's responsible dentist or dental hygienist at the local PDS was contacted with information about the project and the findings from examination.
223793004|NCT05626400|BIOLOGICAL|Senl-T7|Patients will be treated with CD7 CAR-T cells
223793005|NCT02245152|DIETARY_SUPPLEMENT|LNS|A monthly dose of LNS (31 sachets of 20g) will be distributed to mothers attending well-baby visits and participating in small group counseling
223793006|NCT02245152|BEHAVIORAL|Child's health and nutrition topics|"After the well-baby visit. Caregivers will be invited to participate in a small group counseling or BCC (2-3 caregivers at a time).~Every month a set of topics related to child's health and nutrition will be treated. These BCC sessions will be organized in an interactive way centering around the condition of the participating children."
223793007|NCT02245152|BEHAVIORAL|National policy well-baby visits|
223793008|NCT05112926|DEVICE|Embosphere Microspheres|Embosphere Microspheres are 100-300μm small, compressible, hydrophilic, biocompatible spheres made of acrylic polymer and porcine-derived gelatin used for embolization of geniculate artery.
223793009|NCT03776136|DRUG|lenvatinib|Administered orally once a day during each 21-day cycle.
223793010|NCT03776136|BIOLOGICAL|pembrolizumab|Administered as an IV infusion on Day 1 Q3W.
223793011|NCT01817413|PROCEDURE|Mineral trioxide aggregate|An apical barrier of mineral trioxide aggregate (MTA cement) will be placed in the tooth root at the open apex in order to achieve root end closure via an apexification technique
223793012|NCT01817413|PROCEDURE|Revascularisation|Pulp revascularisation will be induced by instrumentation through the open apex so that a blood clot forms within the root canal in order to achieve root end closure via apexogenesis
223793013|NCT03620942|DRUG|Phenylephrine|"Phenylephrine will be administered with conditions as below:~1. When systolic blood pressure is between 90-110% of baseline, 25mcg phenylephrine will be given either in infusion or bolus if heart rate ≥ 60 beats/min;~2. When systolic blood pressure is less than 90% of baseline, 25 to 75mcg phenylephrine will be given either in infusion or bolus if heart rate ≥ 60 beats/min."
223793014|NCT03620942|DRUG|Ephedrine|"Ephedrine will be administered with conditions as below:~1. When systolic blood pressure is between 90-110% of baseline, 2mg ephedrine will be given either in infusion or bolus if heart rate \< 60 beats/min;~2. When systolic blood pressure is less than 90% of baseline, 2 to 6mg ephedrine will be given either in infusion or bolus if heart rate \< 60 beats/min."
224263929|NCT00681161|OTHER|continuous positive airway pressure (CPAP)|Standard of care treatment for OSA, requires a mask attached by tubing to a device providing continuous pressure of air at a given cm of water pressure, acting as a splint to open airway at night to relieve obstruction.
224263930|NCT06425302|DRUG|Golcadomide|Specified dose on specified days
224263931|NCT06425302|DRUG|Rituximab|Specified dose on specified days
224263932|NCT06425302|DRUG|Cyclophosphamide|Specified dose on specified days
224263933|NCT06425302|DRUG|Doxorubicin|Specified dose on specified days
224263934|NCT06425302|DRUG|Vincristine|Specified dose on specified days
224263935|NCT06425302|DRUG|Prednisone|Specified dose on specified days
224263936|NCT06425302|DRUG|Bendamustine|Specified dose on specified days
224263937|NCT00829764|DRUG|Doxycycline Monohydrate|25 mg 5 mL dose
224263938|NCT00829764|DRUG|Doxycycline Monohydrate|25 mg 5 mL dose
224263939|NCT04594252|DRUG|ALXN1840|Administered orally as tablets.
224263940|NCT01677754|DRUG|RO4602522|Participants will receive RO4602522 orally once daily for 12 months.
224263941|NCT01677754|DRUG|Placebo|Participants will receive placebo for RO4602522 orally once daily for 12 months.
224263942|NCT01677754|DRUG|Donepezil|Stable dose as background medication
224263943|NCT01677754|DRUG|Memantine|Stable dose as background medication in combination with AChEIs
224263944|NCT01677754|DRUG|Rivastigmine|Stable dose as background medication
224263945|NCT01677754|DRUG|Galantamine|Stable dose as background medication
224263946|NCT06503666|BEHAVIORAL|ZAIMARA|"The ZAIMARA curriculum focuses on strengthening communication between adolescent girls and young women (AGYW) and their mother figures (MF) to make healthy sexual decisions, to learn more about HIV, sexually transmitted infections (STIs), and pre-exposure prophylaxis (PrEP). The topics in the curriculum focus on effective communication, mothers talking to daughters on sex, HIV, STIs and PrEP. The intervention consists of participants attending a two day workshops with their MF.~Other names:~ZAIMARA"
224263947|NCT06503666|BEHAVIORAL|Health Promotion|"The health promotion (HP) curriculum focuses on healthy living by encouraging good nutrition, improving knowledge on violence recognition, management and support/resources, exercise, informed consumer behavior, alcohol and substance use.The intervention consists of participants attending a two day workshops with their MF.~Other names:~HP"
224263948|NCT03927495|DRUG|KN046|Cisplatin+paclitaxel will be administered once every three weeks for four cycles. During the period of radiotherapy, KN046 will be administered once every two weeks until progressive disease, unacceptable toxicity or up to 2 years.
223793015|NCT03620942|DEVICE|ADIVA System|"1. When systolic blood pressure (SBP) is 100-110% of baseline, 25mcg phenylephrine (infusion) is given if heart rate ≥ 60 beats/min, and 2mg ephedrine (infusion) is given if heart rate \< 60 beats/min;~2. When SBP is 90-100% of baseline, 25mcg phenylephrine (infusion or bolus) is given if heart rate ≥ 60 beats/min, and 2mg ephedrine (infusion or bolus) is given if heart rate \< 60 beats/min;~3. When SBP is 80-90% of baseline, 50mcg phenylephrine (infusion or bolus) is given if heart rate ≥ 60 beats/min, and 4mg ephedrine (infusion or bolus) is given if heart rate \< 60 beats/min;~4. When SBP \< 80% of baseline, 75mcg phenylephrine (infusion or bolus) is given if heart rate ≥ 60 beats/min, and 6mg ephedrine (infusion or bolus) is given if heart rate \< 60 beats/min."
223793016|NCT03620942|DEVICE|DIVA System|"DIVA system works as below:~1. When systolic blood pressure is between 90 to 100% of baseline, 25mcg phenylephrine (bolus) will be given if heart rate ≥ 60 beats/min, whereas 2mg ephedrine (bolus) will be given if heart rate \< 60 beats/min;~2. When systolic blood pressure is less than 90% of baseline, 50mcg phenylephrine (infusion or bolus) will be given if heart rate ≥ 60 beats/min, whereas 4mg ephedrine (infusion or bolus) will be given if heart rate \< 60 beats/min."
224263949|NCT03927495|RADIATION|palliative radiotherapy|3D conformal radiation therapy will be administered for esophageal lesion or nearby lymph node. Stereotactic body radiation will be administered for metastatic lesion.
224263950|NCT03927495|DRUG|KN046|Cisplatin+paclitaxel will be administered once every three weeks for four cycles. After completion of radiotherapy, KN046 will be administered once every two weeks until progressive disease, unacceptable toxicity or up to 2 years.
224263951|NCT06408636|OTHER|Cardiac MRI|All selected patients completed a cardiac magnetic resonance examination without other interventions.
224263952|NCT01513044|DRUG|Mycophenolate Mofetil|Mycophenolate Mofetil 250 mg capsules of Dr. Reddy's Laboratories Limited
224263953|NCT01513044|DRUG|Mycophenolate Mofetil|250 mg capsules of Roche Laboratories Inc.
224263954|NCT04547179|DRUG|Fremanezumab-Vfrm|Patients will receive three injections of Ajovy® if in the corresponding arm of the study.
224263955|NCT04547179|DEVICE|BLAfit®|Usage of the BLAfit device, a fixed orthotic appliance that allows users to tone facial muscles with one minute usage per day
224263956|NCT04547179|OTHER|Saline|Patients will receive three injections of saline if in the corresponding arm of the study. This is a placebo meant to simulate the Ajovy® injection.
224263957|NCT05226741|DEVICE|Head protection device|The participants are fitted with a form of head protection over the craniectomy and provide feedback on design, use, and comfort
224263958|NCT01361334|DRUG|Pazopanib|800 mg QD p.o.
224263959|NCT03578809|BIOLOGICAL|MEDI6012|MEDI6012
224263960|NCT03578809|OTHER|Placebo|Placebo
224263961|NCT02753985|OTHER|Survey|
224263962|NCT02577133|DIETARY_SUPPLEMENT|Lactobacillus reuteri DSM 17938|Lactobacillus reuteri DSM 17938 1,000,000,000 CFU per day (5 drops) for 28 days
224263963|NCT02577133|DIETARY_SUPPLEMENT|Placebo|The placebo consisted of an identical bottle with distilled water
224263964|NCT02867085|OTHER|Observational|The BoHemE study does not provide any recommendations for treatment. Guidelines for osteoporosis treatment and standardized instructions for MDS patients are available, however the choice of treatment is up to the treating physician and should be reported as such.
224263965|NCT04746976|DRUG|Diroximel Fumarate|As described in the arm.
224263966|NCT01952691|DEVICE|kinesiotaping|correction method was used to align hallux.
224263967|NCT01466374|DRUG|Placebo|Normal Saline, Intravenous (IV), 0 mg, Once a week for the first week and every other week thereafter, 11 weeks
224263968|NCT01466374|DRUG|Placebo|Normal Saline, Intravenous, 0 mg, Every other week, Up to 337days
224263969|NCT01466374|DRUG|BMS-936557 (Anti-IP-10 Antibody)|Solution for IV administration, Intravenous, 10 mg/kg, Once a week for the first week and every other week thereafter, 11 weeks
224263970|NCT01466374|DRUG|BMS-936557 (Anti-IP-10 Antibody)|Solution for IV administration, Intravenous, 20 mg/kg, Once a week for the first week and every other week thereafter, 11 weeks
224263971|NCT01466374|DRUG|BMS-936557 (Anti-IP-10 Antibody)|Solution for IV administration, Intravenous, 7.5 mg/kg, Every other week, Up to 337 days
223793017|NCT07114692|BIOLOGICAL|Stromal vascular fraction transplantation|Subcutaneous fat was harvested from either the abdomen or the posterior inner thigh region and then digested with 600 U of collagenase (Shanghai Qiaoyuan Biological Pharmaceutical Co., Ltd, Shanghai, China) at 37°C and 150rpm for three hours. After enzymatic digestion, the lower aqueous phase liquid was aspirated to acquire the stromal vascular fraction (SVF). The SVF cell-pellet was washed and adjusted to 2×10\^6 cells/mL. Lidocaine cream will be applied to the expanded skin to achieve surface anesthesia. The skin was marked with methylene blue and a total of 0.5ml (around 1×10\^6 cells) were transplanted intradermally at the center of each 2cm×2cm squares. The expander was inflated two times a week using constant pressure inflation method, where the intracapsular pressure was monitored using a pressure meter and the inflation was halted when the pressure reached 100 mmHg.
223793018|NCT07114692|BIOLOGICAL|Normal saline injection|Lidocaine cream will be applied to the expanded skin to achieve surface anesthesia. The skin was marked with methylene blue and a total of 0.5ml 0.9% normal saline were transplanted intradermally at the center of each 2cm×2cm squares. The expander was inflated two times a week using constant pressure inflation method, where the intracapsular pressure was monitored using a pressure meter and the inflation was halted when the pressure reached 100 mmHg.
223793019|NCT07120269|DIAGNOSTIC_TEST|Nasal swab to collect material for RT-PCR SAA evaluation|Nasal swab for parallel identification of SARS-Cov2 and SAA expression
223793020|NCT07121569|DRUG|Oral lumbrokinase DLBS1033|DLBS1033: 490 mg, DISOLF film-coated tablet, Dexa Medica, 2 tabs t.i.d
223793021|NCT07121569|DRUG|Placebo|Placebo by Dexa Medica, 2 tabs t.i.d.
223793022|NCT07122349|DEVICE|Cannabis Impairment Test|Automated Drug Recognition Expert Ocular Tests administered via VR Headset, includes test for Lack of Smooth Pursuit, Horizontal and Vertical Gaze Nystagmus, Lack of Convergence, and Pupillary Rebound Dilation. Tests are preceded by an automated system calibration process.
223793023|NCT07126704|DRUG|FB-101|FB-101 10mg
223793024|NCT07126704|DRUG|Placebo for FB-101|Placebo for FB-101
223793025|NCT07127601|PROCEDURE|Ultrasound guided erector spinae plain block (ESPB).|Depending on the size of patient, either a 27 g 3 cm hypodermic needle or a 21 g 5 or 10 cm short bevel needle was used. All blocks were performed with the ultrasound guidance in the parasagittal position and with continuous in-plane needle visualization. The local anesthetic was deposited in the fascial plane deep to the erector spinae muscle superficial to the transverse processes, after confirming the correct tissue plane by hydro-dissection. protocols for choosing 0.25% bupivacaine with a dose of 0.5ml/kg was determined by the age and weight of the patient.
223793026|NCT07127172|DEVICE|N1 Implant|The N1 Implant is a type of implantable brain-computer interface.
223793027|NCT07127172|DEVICE|R1 Robot|The R1 Robot is a robotic electrode thread inserter that implants the N1 Implant.
223793028|NCT07128043|DEVICE|ultrasound therapy and cassava wax hot immersion|participants sat in a comfortable position with their hand placed on a pillow or cushion. Ultrasound gel was applied to the base of the painful finger, and ultrasound therapy was performed for 5 minutes at a frequency of 3 MHz and an intensity of 0.5-1 W/cm. Afterward, the hand was cleaned and immersed in cassava wax heated to 125°F (51.7°C). The affected hand was dipped into the wax for 3 seconds, then removed. This process was repeated for 10 cycles. The hand was then wrapped in a plastic bag and a towel for 15 minutes before the wax was removed and peeled off.
223793029|NCT07128043|DEVICE|ultrasound therapy|1\. ultrasound therapy Ultrasound gel was applied to the base of the painful finger, and ultrasound therapy was performed for 5 minutes at a frequency of 3 MHz and an intensity of 0.5-1 W/cm.
223793030|NCT07126743|OTHER|exposure to organic pollutant|Small samples of subcutaneous and visceral adipose tissue will be analyzed for the presence and concentration of specific organic pollutants using validated analytical chemistry methods, such as gas chromatography-mass spectrometry (GC-MS) or liquid chromatography-mass spectrometry (LC-MS).
223793031|NCT07128264|BEHAVIORAL|Laughter Yoga|"Laughter eliminates feelings such as hopelessness, anger, and anxiety, thereby alleviating stress, depression, and anxiety, raising the pain threshold, reducing stress, accelerating blood circulation, strengthening immunity, improving quality of life, strengthening memory, reducing tension, and relaxing muscles. Based on these positive effects, laughter yoga is a complementary treatment method that combines humor and laughter. Laughter yoga sessions will be conducted online via Microsoft Teams in a quiet and peaceful environment at home.~The first 10-minute section consists of warm-up exercises (warming up and clapping). The second 10-minute section consists of deep breathing exercises that prepare the lungs for laughter. The third 10-minute section consists of childlike games that induce laughter without humor. The fourth and final 15-minute section consists of laughter exercises that enable laughter without any jokes, comedy, or humor."
223793032|NCT07128290|DRUG|CISGEM + Rilvegostomig|"Administration of 4 cycles pre-operative and 4 cycles post-operative of Cisplatine associated to Gemcitabine with rilvegostomig~RILVEGOSTOMIG : For each cycle one administration at D1 every 3 weeks~• 750 mg IV administration over 60 minutes (up to a total of 90 minutes). CISGEM: For each cycle administration at D1 and D8 every 3 weeks~* Cisplatine 25 mg/m² in 1 hour IV in 1000 ml NaCl 0,9 % then 500 ml NaCl 0,9 %~* Gemcitabine 1000 mg/m² en 30 mn IV dans 250 ml NaCl 0,9 %"
223793033|NCT07127679|OTHER|Two minutes before the ROP examination, 2 mL of freshly expressed breast milk was administered to infants in the experimental group using a syringe, placing the milk on the front of the tongue. As par|Data were collected using the premature infant information form, the premature infant vital signs record form, the Premature Infant Pain Profile (PIPP), and the Neonatal Stress Scale. Two minutes before the ROP examination, 2mL of freshly expressed breast milk was administered to infants in the experimental group using a syringe, placing the milk on the front of the tongue. As part of routine care, all infants were swaddled and given a pacifier before the procedure. Video recording began 3 minutes prior to the ROP examination and continued until the infant stopped crying post-examination. Recordings were assessed by two independent observers to determine pain and stress scores, as well as parameters such as heart rate, oxygen saturation, perfusion index, and duration of crying.
223793034|NCT07126964|OTHER|40-hour prone session (intervention)|Patients will undergo PP sessions lasting for 16 hours. Maintaining PP for up to an extra 8 hours will be permitted, allowing PP sessions in the comparator group, to last a maximum of 24 hours.
224263972|NCT01466374|DRUG|BMS-936557 (Anti-IP-10 Antibody)|Solution for IV administration, Intravenous, 15 mg/kg, Every other week, Up to 337 days
224263973|NCT01466374|DRUG|BMS-936557 (Anti-IP-10 Antibody)|Solution for IV administration, Intravenous, 15 mg/kg or optimal dose, Every other week, Open
223793035|NCT07126964|OTHER|16-hour prone session (control)|Patients will undergo PP sessions lasting for 16 hours. Maintaining PP for up to an extra 8 hours will be permitted, allowing PP sessions in the comparator group, to last a maximum of 24 hours.
223793036|NCT07126223|BEHAVIORAL|Hot water foot bath|A 20-minute hot foot bath therapy using a specially designed foot spa device (41°C) applied in the early postoperative period. Follow-up includes pain evaluation via Numeric Rating Scale (NRS) and monitoring of first flatus time.
223793037|NCT07127575|DEVICE|Resistance Breathing Device|The AIRpen is a multifunctional stress management tool that helps users engage in diaphragmatic breathing at differing resistance levels, as well as other common stress relieving behaviors such as fidgeting
223793038|NCT07127575|DEVICE|Electronic Resistance Breathing Device|The Smart AIRpen functions just as the original AIRpen device and has been augmented with sensors to measure use patterns to determine whether the AIRpen is being used for fidgeting or breathing.
223793039|NCT05237141|DRUG|Etonogestrel implant|Implant insertion in second menstrual cycle prior to ovulation
223793040|NCT01420406|OTHER|0 mg retinol activity equivalents|0 mg retinol activity equivalents (RAE) as white-fleshed sweet potatoes and a corn oil capsule
223793041|NCT01420406|OTHER|12 mg of BC|12 mg of BC as orange-fleshed sweet potatoes and a corn oil capsule
223793042|NCT01420406|OTHER|6 mg of CX|6 mg of CX as tangerines and a corn oil capsule
223793043|NCT01420406|OTHER|1.0 mg RAE|1.0 mg RAE vitamin A as retinyl palmitate in corn oil, and white-fleshed sweet potatoes
223793044|NCT01823718|BIOLOGICAL|Injection of allogenic CTL EBV specific|
223793045|NCT01297933|DRUG|Omegaven|10% Omegaven 1g/kg/day, Intravenous by continuous infusion in conjunction with parenteral nutrition, until the patient no longer requires parenteral nutrition or until participation in the study is terminated.
223793046|NCT04846608|OTHER|Observation|Observation
223793047|NCT06669988|DEVICE|VR|VR - Immersive instruction using virtual reality.
223793048|NCT06669988|DEVICE|Video|Video - Educational content presented through video.
223793049|NCT06669988|DEVICE|written materials|Written Materials - Instruction using text and images.
223793050|NCT06669598|OTHER|Whole Body Electromyostimulation|The ETG group underwent in two 20-minute training sessions per week (12 weeks), with 72 hours of rest between sessions. Each session included aerobic activities such as rowing and treadmill exercises, combined with supervised WB-EMS stimulation. This stimu-lation utilised a rectangular waveform at 35 Hz, 350 μs, with continuous pulse dura-tion
223793051|NCT06669598|BEHAVIORAL|control group|The CON group underwent three weekly training sessions for twelve weeks, con-sisting of 20 minutes of aerobic activity, performed on a treadmill and rowing machine, without the WB-EMS superimposition.
223793052|NCT05624775|BEHAVIORAL|Virtual Culinary Medicine|The virtual curriculum will include five 90-minute sessions (to be held weekly or bi-weekly). Participants will cook and engage virtually (with video and sound on) from their home kitchens via the digital platform. Participants will also be expected to shop for groceries ahead of the sessions to participate in the program. A gift card will be provided for groceries ($20 per class = $100 total).Asynchronous virtual educational content (cooking skills videos, animated nutrition education videos, and additional recipes) will be provided to engage and retain participants beyond initial sessions. Recipes will provide enough food for a family of four. clinic patients
223793053|NCT07127627|DEVICE|PET/CT|positron emission tomography/computed tomography
223793054|NCT07127068|DIETARY_SUPPLEMENT|Omega-3 Suplementation|The intervention group will receive a daily oral supplementation of 2000 mg omega-3, which will not be administered to the control group. Blood samples will be collected from all participants at baseline and at the end of the study to evaluate selected serum parameters. To minimize nutritional variability, individualized diets appropriate for coronary artery disease and chronic kidney disease were prescribed to both groups at the beginning of the study. Unlike many other intervention studies, this trial specifically targets end-stage renal disease patients and includes an evaluation of the intervention's impact in relation to dialysis initiation.
223793055|NCT07127068|OTHER|No intervention|Participants in the control group will not receive any dietary supplementation. Blood samples will be collected at baseline and at the end of the study to assess selected biochemical parameters. Standard dietary care appropriate for coronary artery disease and chronic kidney disease will be maintained throughout the study.
223793056|NCT07126340|OTHER|Foot massage and cold application|The patient will receive both cold application and foot massage after total knee arthroplasty.
223793057|NCT07126340|OTHER|Cold application|After total knee arthroplasty, the patient will receive routine cold application.
223793058|NCT07126145|OTHER|Not applicable- observational study|no interventions were involved
223793059|NCT07127198|DIETARY_SUPPLEMENT|Beverage Variant 1 (low gelation properties)|The first interventional product for this study is a drink containing protein and fiber at a concentration 1. It will come in a ready to drink format for the participants.
223793060|NCT07127198|DIETARY_SUPPLEMENT|Beverage Variant 2 (medium gelation properties)|The first interventional product for this study is a drink containing protein and fiber at a concentration 2. It will come in a ready to drink format for the participants.
223793061|NCT07127198|DIETARY_SUPPLEMENT|Beverage Variant 3 (high gelation properties)|The first interventional product for this study is a drink containing protein and fiber at a concentration 3. It will come in a ready to drink format for the participants.
223793062|NCT07127198|OTHER|Control group (no gelation property)|The control product for this study is a drink containing protein and fiber. It will come in a ready to drink format for the participants.
223793063|NCT06675500|DRUG|Magnesium sulphate|Intravenous Magnesium sulphate followed by oral tablets of Magnesium sulphate
223793064|NCT06675500|DRUG|Placebo|Intravenous infusion of Normal saline 0.9 followed by starch oral tablets
223793065|NCT03822858|DRUG|Intrathecal MSC-NP injection|"Between 5 to 10 million MSC-NPs will be administered intrathecally in each dose.~10 million cells is the maximum dose. Treatment will consist of 3-5 doses spaced 3 months apart."
223793066|NCT04919135|BIOLOGICAL|Umbilical Cord Mesenchymal Stem Cells transplantation|Patients assigned to UC-MSC administration groups will receive two administrations at a dose of 1.5 million cells/kg patient body weight via the IV route with a 3-month intervening interval
223793067|NCT04919135|DRUG|standard frailty treatment and supplementary medication|Hightamine (Hankook Korus Pharm, Korea), Total calcium (Nugale Pharmaceutical, Canada), Bioflex (Ausbiomed, Australia)
223793068|NCT06715605|BIOLOGICAL|tolerogenic dendritic cells (tolDC)|In brief, clinical-grade tolDC vaccines will be prepared from leukapheresis starting material of non-mobilized blood and subsequent immunomagnetic selection of CD14+ monocytes using a CliniMACS device. CD14+ monocytes will then be cultured in GMP-grade cell culture medium supplemented with 2% human AB serum, GM-CSF, IL-4 and 1 alpha,25 dihydroxyvitamin D3. At day 4, tolDC will be stimulated using a cytokine cocktail to induce a migratory phenotype. At day 6, tolDC will be harvested, loaded with antigen, resuspended, and cryopreserved. Separate aliquots of the cell product are prepared for final quality control and quality assurance (QC/QA) assessment. This includes cell count, viability, phenotypic analysis using flow cytometry, and induction of T cell hyporesponsiveness in allo-MLR.
223793069|NCT06715605|BIOLOGICAL|Standard-of-care|Standard-of-care on first-line treatment such as interferon-beta, glatiramer acetate, teriflunomide, dimethylfumarate, ponesimod and ozanimod.
223793070|NCT06704399|OTHER|Acceptance and Commitment Therapy-Based Psychoeducation|Psychoeducation based on acceptance and commitment therapy will be applied to the experimental group.
223793071|NCT06704399|OTHER|control group|No intervention will be applied to the control group.
223793072|NCT07044557|OTHER|Withholding perioperative Dexamethasone|Patients will not receive perioperative Dex before, during, and up to 3 weeks after surgery.
223793073|NCT07038642|BEHAVIORAL|Pharmacy Clinical Decision Support System for Asthma Management|A pharmacy clinical decision support system that generates individualized advice for asthma patients is provided to the pharmacist/RPht/assistant/student.
223793074|NCT07049783|BEHAVIORAL|Exercise|A single standardized, in-lab, 30-minute monitored treadmill exercise session
223793075|NCT04722965|PROCEDURE|Fistulotomy with marsupialization|A probe is placed in the fistula tract and it's laid open over that probe. The tract is curretted. Wound edges are sutured to the bottom of the fistula using interrupted sutures of vicryl 3-0 completing the marsupialization.
223793076|NCT04722965|PROCEDURE|Fistulotomy with open wound|A probe is placed in the fistula tract and it's laid open over that probe. The tract is curretted. The wound is left open.
223793077|NCT06758544|DRUG|Oncolytic virus VRT106|VRT106, IV
223793078|NCT06758544|DRUG|Chemotherapy|21 days/cycle, administered up to 6 cycles
223793079|NCT04146376|OTHER|Use of a postpartum diary and additional blood draws|"A diary will be used to capture postpartum hemorrhage (PPH), Wilate and tranexamic acid use, other drug use, bleeding episodes, and treatment schedules.~Several blood draws additional to what is expected for routine clinical care will also be taken."
223793080|NCT04146376|DRUG|VWF replacement therapy with Wilate|This study design uses on-label Wilate for VWF replacement therapy for delivery and the postpartum period in VWD patients whose VWF levels are \<100% in the third trimester of pregnancy
223793081|NCT04146376|DRUG|Tranexamic acid|This study design uses tranexamic acid for prophylaxis for postpartum hemorrhage for all women with VWD
223793082|NCT04146376|OTHER|Use of a postpartum diary and additional blood draws.|"A diary will be used to capture postpartum hemorrhage (PPH), tranexamic acid use, other drug use, bleeding episodes, and treatment schedules.~Several blood draws additional to what is expected for routine clinical care will also be taken."
223793083|NCT07127796|OTHER|Dietary Supplement - Fish-derived Vitamin D|"Cholecalciferol (vitamin D3). Other components: polyunsaturated fatty acids (PUFA), arabic gum, maltodextrin, pea protein hydrolisate, hard gelatine capsules.~The fish derived vitamin D extract was obtained from sardines (Sardina pilchardus) waste ( whole fish) recovered by CNR-IRBIM (Centro Nazionale delle Ricerche-Istituto per le Risorse Biologiche e le Biotecnologie Marine) and sourced from a professional fishing fleet operating in the Adriatic Sea (Central Mediterranean). Fishes have been homogenized, freeze dried and extracted by using a Supercritical Fluid Extractor (SFE-CO2) in the laboratories of ENEA (Agenzia nazionale per le nuove tecnologie, l'energia e lo sviluppo economico sostenibile), then analyzed for the content of vitamin D3 and other bioactives by HPLC-DAD technique in the laboratories of University of Camerino and finally microencapsulated in the laboratories of University of Piemonte Orientale for the preparation of final supplement."
223793084|NCT07127796|OTHER|Dietary Supplement - Synthetic Vitamin D|Cholecalciferol (vitamin D3). Other components: medium-chain triglycerides, alfpha-tocopherol acetate, hard gelatin capsules.
223793085|NCT07126886|OTHER|Standard of Care|Beginning at the screening visit, participants will receive weekly treatment with standard of care (cleaning, debridement, ulcer moisture balance, and offloading) until ulcer closure, or a maximum of 20 weeks, whichever occurs first.
223793086|NCT07126886|OTHER|XPURT + SOC|Participants will receive weekly applications of XPURT and Standard of Care until ulcer closure, or a maximum of 20 weeks, whichever occurs first.
223793087|NCT07126496|OTHER|Internet-Based Intervention|Receive information via online text
223793088|NCT07126496|OTHER|Questionnaire Administration|Ancillary studies
223793089|NCT07126496|OTHER|Virtual Technology Intervention|Receive information via ALEX Research Portal and vCHE
223793090|NCT07066124|BEHAVIORAL|Progressive Relaxation Exercises training was given to the pregnant women in the intervention group and their practice was provided for six weeks.|Progressive Relaxation Exercises training was given to the pregnant women in the intervention group and their practice was provided for six weeks. After the first encounter, Pittsburgh Sleep Quality Index and Quality of Life Scale were re-administered to the pregnant women in the third and sixth weeks to evaluate their sleep and quality of life.
223793091|NCT07062042|BEHAVIORAL|Narrative Exposure Therapy|Narrative Exposure Therapy (NET) is a short-term, trauma-focused intervention developed for individuals exposed to multiple traumatic events, including refugees and survivors of war and organized violence. It is grounded in principles of cognitive-behavioral therapy and testimonial therapy. NET helps adults reconstruct a coherent narrative of their life by integrating fragmented traumatic memories through structured exposure within a chronological autobiographical framework. Core components include lifeline construction, imaginal exposure to traumatic events, and reprocessing of emotional responses. The method emphasizes stabilization through therapeutic structure and is supported by evidence from randomized controlled trials showing reductions in PTSD symptoms. The approach is protocol-driven and applicable in low-resource settings under supervision, as outlined in the practice document.
224263974|NCT02955004|PROCEDURE|Electrical cardioversion|Transthoracic direct current electrical cardioversion
223793092|NCT07127887|OTHER|KM Resource - AI|"The KM resource (an online resource sheet) was developed for the Public Health Agency of Canada about the prevention of post-covid condition (PCC). The resource presents recommendations that were developed by an international group according to standards for guideline development.~The resource has already been AI translated using ChatGPT 4.0 into French as well as six languages common to newcomers across Canada (Arabic, Punjabi, Ukrainian, Tagalog, Chinese, Spanish)."
223793093|NCT07127887|OTHER|KM Resource - Professional|"The KM resource (an online resource sheet) was developed for the Public Health Agency of Canada about the prevention of post-covid condition (PCC). The resource presents recommendations that were developed by an international group according to standards for guideline development.~The resource has already been professionally translated into French as well as six languages common to newcomers across Canada (Arabic, Punjabi, Ukrainian, Tagalog, Chinese, Spanish)."
223793094|NCT06932341|OTHER|Non-interruptive|Non-interruptive BPA (appears as a visual cue but does not require clinicians to alter workflows) directing clinicians to reference the EHR-embedded, evidence-based clinical guideline for the care of bronchiolitis.
223793095|NCT06932341|OTHER|Interruptive|Interruptive BPA (requires clinicians to interact with the alert to continue the workflow) directing clinicians to reference the EHR-embedded, evidence-based clinical guideline for the care of bronchiolitis.
223793096|NCT00783926|BIOLOGICAL|H5N1 Influenza Vaccine, Whole virion, Vero cell-derived, Inactivated Influenza Vaccine, non-adjuvanted (reverse genetic reassortant/H5N1 hemagglutinin antigen)|2 x 0.5 mL intramuscular injections 21 days apart (one of six different doses of hemagglutinin antigen without adjuvant)
223793097|NCT02621931|DRUG|Fremanezumab|Fremanezumab was provided as a sterile, unpreserved, aqueous solution for injection, 225 mg/1.5 mL pre-filled syringe for single-use administration. The 675 mg dose was given as 3 injections; doses of 225 mg were given as a single injection. Study drug was administered at the clinical site.
223793098|NCT02621931|DRUG|Placebo|Placebo 1.5 mL pre-filled syringes identical in appearance to active intervention. Study drug was administered at the clinical site.
223793099|NCT04969523|PROCEDURE|lobectomy|Intravenous es-ketamine 0.5mg/kg or saline during lobectomy
223793100|NCT00872352|PROCEDURE|EMG|Nerve conduction study will be consisted of sequential evaluation of the motor nerves: median, ulnar, peroneal and tibial; and the sensory nerves: median, ulnar, superficial peroneal and sural nerves using a standardized protocol
223793101|NCT04390737|DRUG|HH2853 Tablets|Proposed daily dose (BID): 50mg, 100mg, 200mg, 400mg, 600mg, 800mg, 1000mg. It is possible for additional and/or intermediate dose levels to be added during the course of the study. Cohorts may be added at any dose level below the MTD in order to better understand safety, PK or PD.
223793102|NCT05071118|DRUG|Pregabalin 150mg|pregabalin patients (group P) received capsules containing 150mg of pregabalin in the ward then transferred to OR to receive spinal anesthesia before surgery
223793103|NCT05071118|DRUG|Placebo|The patients received placebo capsules in the ward Then transferred to OR to receive spinal anesthesia before surgery .
223793104|NCT03114826|GENETIC|To study the polymorphism of the gene encoding VEGF (rs699947) as a predictive marker|Study the polymorphism of the gene encoding VEGF (rs699947) as a predictive marker of the occurrence of renal cell carcinoma in renal transplant patients.
223793105|NCT02394782|DEVICE|RebiSmart®2.0|Rebif (interferon beta-1a) will be administered by RebiSmart®2.0 as specified in Summary of Product Characteristics.
223793106|NCT02394782|DEVICE|MSdialog™|Rebif (interferon beta-1a) will be administered by MSdialog™ as specified in Summary of Product Characteristics.
223793107|NCT02925455|DEVICE|Contralaterally-controlled functional electrical stimulation|Contralaterally-controlled functional electrical stimulation (CCFES) is electrical stimulation of weak muscles of an impaired limb controlled via movement of the unimpaired contralateral limb.
223793108|NCT02925455|DEVICE|Hand therapy video games|Hand therapy video games are designed to provide therapy to weak muscles of an impaired limb via goal-directed movements.
223793109|NCT03248739|DEVICE|Clear Bactiseal 'large' catheter (EVD)|Antibiotic-impregnated 'large' catheter (inner diameter 1.9 mm, outer diameter 3.4 mm)
223793110|NCT03248739|DEVICE|Orange Bactiseal 'small' catheter (EVD)|Antibiotic-impregnated 'small' catheter (inner diameter 1.5 mm, outer diameter 3 mm)
223793111|NCT06635382|OTHER|Universal single bond adhesive|Will be applied and light cured for 20 seconds.
223793112|NCT06635382|OTHER|DMSO|DMSO application on tooth followed by active application of universal single bond adhesive and light cured for 20 seconds.
223793113|NCT00159211|DRUG|UMULINE NPH|UMULINE NPH at bed time with a increasing dose up to get a fasting glycemia under 1.1 g/l
223793114|NCT00159211|DRUG|pioglitazone|30mg daily. After 2 months, if HbA1c has not decreased at least of 1%, the dosage should be increased to 45 mg daily
223793115|NCT00254254|DRUG|Exenatide - Exenatide - Placebo|Exenatide 2.5 mcg, single dose, followed by Exenatide 5 mcg, single dose, followed by placebo 0.02 mL, single dose. All are subcutaneous injections.
223793116|NCT00254254|DRUG|Exenatide - Placebo - Exenatide|Exenatide 2.5 mcg, single dose, followed by placebo 0.02 mL, single dose, followed by Exenatide 5 mcg, single dose. All are subcutaneous injections.
223793117|NCT00254254|DRUG|Placebo - Exenatide - Exenatide|Placebo 0.02 mL, single dose, followed by Exenatide 2.5 mcg, single dose, followed by Exenatide 5 mcg, single dose. All are subcutaneous injections.
223793118|NCT06470932|DIAGNOSTIC_TEST|Follow-up consult|Patients will be ask to participate to a follow-up consult
223793119|NCT00007189|DRUG|Naproxen Sodium (Aleve)|
223793120|NCT00007189|DRUG|Celecoxib (Celebrex)|
223793121|NCT05451654|DRUG|Placebo|The administration of the treatment consists in a deposit in the gingivo-jugal groove of each cheek with a graduated pipette
223793122|NCT05451654|DRUG|Experimental drug|The administration of the treatment consists in a deposit in the gingivo-jugal groove of each cheek with a graduated pipette
223793123|NCT00064727|DRUG|Avandia (Rosiglitazone)|
223793124|NCT00064727|DRUG|Avanclia (Rosiqlitazone)|
223793125|NCT02125175|RADIATION|Hypofractionated IMRT boost Radiotherapy|
223793126|NCT01889953|OTHER|EUS-guided biliary drainage|"Based on the patient's condition, the will receive:~* Rendezvous technique~* Direct transluminal access transesophageal technique~* Direct transluminal access transduodenal technique~* or direct transluminal access using transgastric approach"
223793127|NCT01923259|DRUG|Donepezil|Donepezil Hydrochloride tablets,23 mg
223793128|NCT00276471|DEVICE|Implantable pulse generator and electrodes|
223793129|NCT05795582|DEVICE|POPMETRE® (Axelife , France)|Measurement with 2 devices
223793130|NCT03443960|DRUG|TNX-102 SL 5.6 mg|Subjects randomly assigned to this treatment will place 2 tablets simultaneously under the tongue until dissolved, and not to crush or chew them.
223793131|NCT03443960|DRUG|Amrix 30 mg|Subjects randomly assigned to this treatment will swallow 1 capsules with a cup of water, and not to crush or chew it.
223793132|NCT05180760|BEHAVIORAL|Smartphone app use|Smartphone app use in the active arm
223793133|NCT05180760|BEHAVIORAL|Standard of care|Standard of care
223793134|NCT04004611|DRUG|Mirikizumab|Administered IV and SC
223793135|NCT05484674|PROCEDURE|Deroofing and laser|Deroofing and laser to axilla
223793136|NCT04420689|DRUG|Bevonescein|Bevonescein Sterile Solution is an intravenously administered, synthetic, peptide dye conjugate indicated for the real-time intraoperative fluorescence detection and localization of nerve tissue.
223793137|NCT01575366|BEHAVIORAL|Tracking training|The paretic finger movement training at different velocities included two 5-week periods of five days per week, 2-hours per day phases. The frequency for the higher-velocity training is 0.8 Hz, whereas the lower frequency training is 4 times slower, at 0.2 Hz. The two periods are each followed by a 3-week baseline period. The subject is seated in front of a laptop computer with the paretic forearm resting on the arm of the chair in a quiet room at home. The position of the forearm is pronated. An electrogoniometer, composed of a potentiometer attached to a custom hand splint, is placed on the paretic index finger with the potentiometer centered at the metacarpophalangeal joint. To keep the training session time equal between the two training phases, the duration of each slow training trial is 5 sec, compared to 20 sec for each fast training trial. Ultimately, the total number of required finger extension/flexion training movements is equal between the two phases.
223793138|NCT01055821|DRUG|pegylated interferon and ribavirin|48 weeks
223793139|NCT01055821|BIOLOGICAL|TG4040 + SOC|6 injections
223793140|NCT01055821|BIOLOGICAL|TG4040 + SOC|13 injections
223793141|NCT04315077|DIETARY_SUPPLEMENT|Oceanix®|Ingredient contains highly active antioxidant enzymes, including superoxide dismutase (SOD), as well as essential fatty acids, vitamins, amino acids and minerals.
223793142|NCT04315077|OTHER|Resistance Training|5 days of supervised and programmed whole-body resistance training.
223793143|NCT00515502|DRUG|GSK573719|250 micrograms (μg) per blister, administered via dry powder inhaler, dose-ascending study doses began at 250 ug, then 500 ug, and 1000 μg
223793144|NCT00515502|DRUG|Tiotropium|strips of five capsules, each containing 18 μg administered via dry powder inhaler
223793145|NCT00639873|DRUG|Artesunate|2 or 4 mg/kg/day for 7 days
223793146|NCT00639873|DRUG|quinine-doxycycline|quinine-doxycycline for 7 days
223793147|NCT04720079|PROCEDURE|Subcutaneous infiltration of intercostobrachial nerve|Preoperative subcutaneous infiltration of intercostobrachial nerve with 10ml of 0.5% ropivacaine
223793148|NCT04720079|PROCEDURE|T2 paravertebral nerve block|Preoperative ultrasound guided T2 paravertebral nerve block with 10ml of 0.5% ropivacaine
223793149|NCT03317002|DRUG|AZD5718|Oral dose of AZD5718 (tablet)
223793150|NCT03317002|DRUG|AZD5718|Oral dose of AZD5718 (tablet)
223793151|NCT03317002|DRUG|Placebo|Matching placebo (tablet)
223793152|NCT03058211|DIAGNOSTIC_TEST|Echocardiography|Standard protocols
223793153|NCT03058211|DIAGNOSTIC_TEST|Cardiac Magnetic resonance|MRI with late gadolinium increase and T1 mapping
223793154|NCT02645981|DRUG|Donafenib|Donafenib is an oral multikinase inhibitor with antiproliferative and antiangiogenic effects
223793155|NCT02645981|DRUG|Sorafenib|Control
223793156|NCT03647501|DEVICE|Interbody cage (titanium)|Subject will be implanted with a 3D-printed titanium cage during their lumbar interbody fusion surgery.
223793157|NCT03647501|DEVICE|Interbody cage (PEEK)|Subject will be implanted with a poly-ether-ether-ketone (PEEK) cage during their lumbar interbody fusion surgery.
223793158|NCT00436657|DRUG|CHPP of Cisplatin|Starting dose of 100 mg/m\^2 intraperitoneally delivered as Continuous Hyperthermic Peritoneal Perfusion (CHPP) over 90 minutes at a flow rate of 1.5L/min and a peritoneal temperature of 42.5°Celsius.
223793159|NCT00436657|PROCEDURE|Abdominal Surgery|Surgical removal of abdominal tumors.
223793160|NCT04701398|OTHER|Multimodal prehabilitation|Exercise + nutritional supplementation + psychological advice
223793161|NCT02462746|DIETARY_SUPPLEMENT|L-Cysteine|The trade name is New Root Herbal Inc.
223793162|NCT02935335|DRUG|Menotrophin|
223793163|NCT01636882|BIOLOGICAL|CVA21|
223793164|NCT02799966|DEVICE|Myndmove|20 sessions of 1 hour treatments with the MyndMove device (functional electrical stimulation) to the muscles of the upper limb(s), conducted 3 to 5 times per week, over 4 to 7 weeks.
223793165|NCT00353717|DRUG|cetuximab paclitaxel|weekly iv paclitaxel 80 mg/m2 and cetuximab 250 mg /m2
223793166|NCT02212574|DRUG|Lomustine|Chemotherapy Cycle A Lomustine (CCNU) is given by mouth on Day 1.
223793167|NCT02212574|DRUG|Vincristine|Chemotherapy Cycle A Vincristine is given directly into a vein (IV) over one minute or using a minibag over several minutes by some institutions on Days 1, 8, and 15.
223793168|NCT02212574|DRUG|Cisplatin|Chemotherapy Cycle A Cisplatin is given directly into a vein over 8 hours on Day 1.
223793169|NCT02212574|DRUG|Cyclophosphamide|Chemotherapy Cycle B Cyclophosphamide is given into a vein over 1 hour on Days 1 and 2.
223793170|NCT02212574|DRUG|Mesna|Chemotherapy Cycle B MESNA, a drug to protect the bladder from the effects of cyclophosphamide, will be given 15 minutes before each dose of cyclophosphamide and repeated at 3 and 6 hours.
223793171|NCT02212574|DRUG|Vincristine|Chemotherapy Cycle B Vincristine is given directly into a vein directly into the vein (IV) over one minute or using a minibag over several minutes by some institutions on Days 1 and 8.
223793172|NCT05758064|DRUG|Duphaston|10 mg tablet will be given twice
223793173|NCT05758064|DRUG|prolutex|subcutaneous injection daily
223793174|NCT03391674|OTHER|Fecal Microbiota Transplantation|Fecal Microbiota Transplantation through oral capsules after omeprazole pre-treatment
223793175|NCT05403008|OTHER|Zirconomer improved|Zirconomer improved, is a nano zirconia reinforced glass ionomer, which has improved the mechanical, esthetic and handling properties than its previous successor.
223793176|NCT05034003|DEVICE|Zirconia crown|Esthetic crowns for capping primary incisor with caries
223793177|NCT05034003|DEVICE|composite strip crown|Esthetic resin restoration for primary incisor with caries
223793178|NCT03469323|DRUG|Succinylcholine|Giving mini-dose succinylcholine to facilitate lung collapse during nonintubated VATS.
223793179|NCT03469323|DRUG|Placebo|Giving placebo (normal saline) to facilitate lung collapse during nonintubated VATS.
223793180|NCT04875481|OTHER|Psychiatric diagnosis|Kiddie Schedule for Affective Disorders \& Schizophrenia (K-SADS) for DSM-5
223793181|NCT04875481|OTHER|ASD diagnosis|Autism Diagnostic Interview-revised (ADI-R) and Autism Diagnostic Observation Scale (ADOS)
223793182|NCT01016210|DRUG|Leuveris|IV
223793183|NCT01016210|DRUG|Leuveris|All recruited women will be treated similarly employing the recombinant FSH and the fixed GnRH antagonist. Concomitantly, on the same day of the antagonist administration r-LH will be administered daily and continued until human chorionic gonadotropin (hCG) day.
223793184|NCT02639260|DRUG|N-acetyl D-mannosamine|dose escalation
223793185|NCT01512862|DRUG|Calcitriol|Dosage of 0.25 mcg administered orally once daily for 6 weeks and dose escalated to 0.5 mcg orally once daily up to 6 months
223793186|NCT01512862|DRUG|Placebo|Dosage of 0.25 mcg administered orally once daily for 6 weeks and dose escalated to 0.5 mcg orally once daily up to 6 months
223793187|NCT04700293|DIETARY_SUPPLEMENT|AYMES AMSTERDAM|AYMES AMSTERDAM is a Food for Special Medical Purposes (FSMP) and must, therefore, be used under medical supervision. It is not designed as a sole source of nutrition.
223793188|NCT02898974|BEHAVIORAL|Medical Marijuana|To investigate the effects of medical marijuana usage on physical function we will employ an observational case-control design
223793189|NCT05999955|DRUG|Neomycin/ Dexameythasone/Xylometazoline|The active-control in the phase II study was a commercial form of nasal spray containing Dexamethasone/Neomycin/Xylometazoline. This formulation is approved by Vietnam's Ministry of Health as a treatment regime for rhinosinusitis. Dexamethasone sodium phosphate is fluoromethyl prednisolone, a synthetic glucocorticoid. Dexamethasone has the main effects of glucocorticoids as anti-inflammatory, antiallergic and immunosuppressant. Neomycin sulfate is an antibiotic belonging to the group of aminoglycosides that have a bactericidal mechanism due to inhibition of bacterial protein biosynthesis. In this study, the nasal spray is used as an adjunct to Amoxicillin/Clavulanate standard treatment
223793190|NCT05999955|COMBINATION_PRODUCT|Bacillus subtilis DSM32444|Postbiotic DSM32444 is manufactured by HURO BIOTECH Company as a drug-grade active pharmaceutical ingredient. The Class A medical device containing Postbiotic DSM32444 is called Sperovid, which is manufactured by Dong Duoc Viet under ISO 13485:2016 standards for medical device. Sperovid has registration number: 220000033/ PCBALA In this study, the nasal spray is used as an adjunct to Amoxicillin/Clavulanate standard treatmen.
223793191|NCT01710176|DRUG|epirubicin 60 mg/m2/day (days 1, 2) and ifosfamide 3 g/m2/day (days 1, 2, 3)|
223793192|NCT01710176|DRUG|gemcitabine 900 mg/m2 (days 1 and 8) and docetaxel 75 mg/m2 (day 8)|
223793193|NCT01710176|DRUG|trabectedin 1.3 mg/m2|
223793194|NCT01710176|DRUG|high-dose ifosfamide 14 g/m2, given in in 14 days|
223793195|NCT01710176|DRUG|etoposide 150 mg/m2/day (days 1, 2, 3) and ifosfamide 3g/m2/day (days 1, 2, 3)|
223793196|NCT01710176|DRUG|gemcitabine 1800 mg/m2 (day 1) and dacarbazine 500 mg/m2 (day 1)|
223793197|NCT02571504|BEHAVIORAL|Plasticity-based Adaptive Cognitive Remediation (PACR)|Web-based cognitive training program focused on improving attention and executive function (designed by Posit Science)
223793198|NCT00175851|DRUG|Seletracetam (ucb 44212)|
223793199|NCT03905200|DIAGNOSTIC_TEST|3D-speckle tracking imaging|The strain peak value and strain peaking time of each segment (including 16 segments) of the left ventricular myocardium can be obtained by 3d-sti technology.
223793200|NCT02322671|DRUG|Reference Montelukast|It is available as pink, round, bi-convex-shaped chewable tablet of reference 5 mg montelukast sodium (innovator product). that has to be placed on the tongue and chewed immediately.
223793201|NCT02322671|DRUG|Test 1 Montelukast|It will be provided as pink, round, bi-convex-shaped chewable tablet of test formulation 1: 5mg montelukast sodium (GW483100) that has to be placed on the tongue and chewed immediately.
223793202|NCT02322671|DRUG|Test 2 Montelukast|It will be provided as pink, round, bi-convex-shaped chewable tablet of test formulation 2: 5mg montelukast sodium (GW483100) that has to be placed on the tongue and chewed immediately.
223793203|NCT01171326|DRUG|Topical Minocycline Foam FXFM244|FXFM244 - 1%, FXFM244 - 4% to be applied twice daily during 7 days
223793204|NCT01426191|DRUG|xinzhijun|"durg:Cefotaxime sodium and sulbactam sodium for injection(2:1)~1.5-3.0g,iv,bid or tid for 5-12 days;~Serious infections:1.0-1.5g,iv,tid or qid for 5-12 days"
223793205|NCT02039037|DEVICE|Acupuncture|Acupuncture Group, which will hold acupuncture needles brand Dong Bang 20x15 in specific spots for the treatment of low back pain.
223793206|NCT02039037|DEVICE|Electroacupuncture (device 585)|Electro will be added through the use of electrical stimulation to the Electro Accurate use of the device 585 at the same points Pulse.
223793207|NCT03788837|DRUG|ILOPROST|The patient will receive treatment with intravenous ILOPROST therapy at a dose of 0.5ng/kg/min with increments of 0.5 ng/kg/min every 30 minutes up to a maximum posology of 1,5 ng/kg/min for 48h.
223793208|NCT03788837|DRUG|NaCl|The patient will receive treatment with intravenous NaCl 0.9% (placebo-double blinded) with increments of infusion rate every 30 minutes for 48h
223793209|NCT02052505|PROCEDURE|Medication review|The medication review will be based on the nurses experience, clinical knowledge and predefined categories of inappropriate prescribing
223793210|NCT04301336|DRUG|Omega 3|Omega-3 supplementation (300-400mg EPA \& 200-300mg DHA) per day for 8 consecutive months up to 10 months
223793211|NCT04301336|DRUG|Vit D|"50 patients from each participating hospital that will receive Vit-D medication (1500 IU to 3500 IU ) per day for 8 consecutive months up to 10 months.~in addition to the experimental treatment, this group will receive the traditional treatment of hydroxyurea, Folic acid, pain killer plus regular blood transfusion with a dose de-escalation methods till efficacy of experimental treatment proved."
223793212|NCT04301336|DRUG|Zinc sulfate|"50 patients from each participating hospital that will receive Zinc supplements (15 mg to 50 mg ) per day for 8 consecutive months up to 10 months.~in addition to the experimental treatment, this group will receive the traditional treatment of hydroxyurea, Folic acid, pain killer plus regular blood transfusion with a dose de-escalation methods till efficacy of experimental treatment proved."
223793213|NCT04301336|DRUG|Statins (Cardiovascular Agents)|"50 patients from each participating hospital that will receive Simvastatin orally (20 mg to 40 mg ) per day for 8 consecutive months up to 10 months.~in addition to the experimental treatment, this group will receive the traditional treatment of hydroxyurea, Folic acid, pain killer plus regular blood transfusion with a dose de-escalation methods till efficacy of experimental treatment proved."
223793214|NCT04301336|DRUG|Hydroxy Urea|50 patients from each participating hospital that will receive the ordinary treatment of Hydroxyurea (20 mg/kg/day) with monitoring blood count every 2 weeks maximum daily dose: (40 mg/kg/day) for 8 consecutive months up to 10 months.
223793215|NCT04301336|DRUG|Folic Acid Supplementation|Folic Acid dose of 0.5 to 1 mg daily for 3 to 4 weeks until definite hematologic response
223793216|NCT04301336|DRUG|Morphine Sulfate|Morphine medication as a pain killer is administered, if Patient weight \<50 kg: Opioid naïve: Initial: 0.05 mg/kg/dose; usual maximum initial dose: 1 to 2 mg/dose.
223793217|NCT04301336|PROCEDURE|blood transfusion session|Regular blood transfusion session based on patient hematological profile starts from one session every 2 weeks.
223793218|NCT02244866|DRUG|Pergoveris (FSH and LH)|Drugs are injected subcutaneously everyday until ovarian follicles reach 17mm in diameter.
223793219|NCT02244866|DRUG|Follitropin alpha (FSH)|Drugs are injected subcutaneously everyday until ovarian follicles reach 17mm in diameter.
223793220|NCT02750254|DRUG|Fludarabine|
223793221|NCT02750254|RADIATION|Fractionated total body irradiation|
223793222|NCT02750254|DRUG|Busulfan|
223793223|NCT02750254|DRUG|Cyclophosphamide|
223793224|NCT02750254|RADIATION|Single dose total body irradiation|
223793225|NCT02750254|DRUG|Melphalan|
223793226|NCT02750254|DRUG|Granulocyte-colony stimulating factor|
223793227|NCT02750254|PROCEDURE|Stem cell transplant|
223793228|NCT02750254|DRUG|Azacitidine|
223793229|NCT04161508|DRUG|Sugammadex Injection|injection of sugammadex for the reversal of neuromuscular blockade at the end of the surgery
223793230|NCT04161508|DRUG|Neostigmine Injection|injection of neostigmine for the reversal of neuromuscular blockade at the end of the surgery
223793231|NCT02868060|DRUG|Romiplostim|
223793232|NCT02871648|DRUG|Placebo|Placebo prepared by Investigation Drug Services at Brigham and Women's Hospital
223793233|NCT02871648|DRUG|Fludrocortisone|Fludrocortisone 0.1 mg
223793234|NCT02871648|DRUG|Eplerenone|Epleronone 100 mg
223793235|NCT05346289|PROCEDURE|Elective surgery for intact AAA|Elective surgery including the following modalities: open repair, endovascular repair (EVAR), fenestrated end-vascular repair (FEVAR).
223793236|NCT04799626|DRUG|biapenem,meropenem,piperacillin and tazobactam,tigecycline,levofloxacin.etc|biapenem,meropenem,piperacillin and tazobactam,tigecycline,levofloxacin.etc extended infusion time or continuous infusion for 24 hours;Tigecycline changed standard does for treatment.
223793237|NCT04447326|DRUG|Toripalimab, Endostar Combined With Radiotherapy and Chemotherapy|Toripalimab: 240 mg, Q3W, starting on D1, for totally 12 cycles Endostar: 7.5 mg/m2/d, continuous intravenous pumping for 10 days, Q3W, starting on D1, for totally 5 cycles
223793238|NCT04447326|DRUG|IC＋CCRT|IC＋CCRT
223793239|NCT00395902|DRUG|Sensipar after Post Transplant|
223793240|NCT00273312|DRUG|Patupilone|Patupilone was in dosage strength of 10 mg/4 mL as a clear, colorless concentrate for solution for injection in individual 10 mL glass vials
223793241|NCT01540851|BEHAVIORAL|Care Navigator|Subjects assigned to the Care Navigator intervention group will receive 10 calls from a care navigator after discharge from the hospital for 5 months after their total knee replacement.
223793242|NCT01540851|OTHER|Standard Post-Operative TKA Care|Subjects assigned to the Standard Post-Operative TKA Care group will receive the current standard of care for post-operative care
223793243|NCT00439868|DRUG|WellbutrinXL|WELLBUTRIN XL tablets will be available with dose strength of 150 and 300 mg.
223793244|NCT00439868|DRUG|placebo|Matching placebo tablets to WELLBUTRIN XL.
223793245|NCT05138718|DIAGNOSTIC_TEST|18F-FDG PET/CT|Perform a 18F-FDG PET/CT to patients with history of myocardial infarction
223793246|NCT02238262|DRUG|Telmisartan|
223793247|NCT04434989|RADIATION|Stereotactic Body Radiation Therapy|SBRT for perivascular HCC
223793248|NCT04434989|PROCEDURE|radiofrequency ablation|RFA for perivascular HCC
223793249|NCT00960466|BEHAVIORAL|Distress Thermometer and Problems List|When using the distress thermometer and problem list (DT\&PL), the nurse or radiographer asks the patient to indicate distress over the past week on a visual analogue scale from 0 (no distress) to 10 (high distress). Next, from a list of 42 items, patients identify practical, family, emotional, spiritual or physical problems that have caused distress. The completion of the DT\&PL should be a collaborative exercise with patients able to review what is written on the assessment sheet. Potential solutions will be discussed which may involve the following: i) concerns that can be resolved immediately (e.g. providing information, prescribing an analgesic); ii) concerns that require patient actions (e.g. participating in support groups); iii) concerns that require a referral (e.g. mental health specialist, social or pastoral care). The meeting will end with a summary plan of action.
223793250|NCT00960466|BEHAVIORAL|Usual psychosocial support|If patients express concerns about psychosocial issues, then clinic staff will discuss these issues, offer advice or make a referral as they see fit. However, no formal time will be set aside to monitor patient distress using the DT, elicit problems using the PL or develop a plan of action based on these tools. Because of the nature of the intervention, both the patient and the therapist will be aware of treatment assignment.
223793251|NCT06241274|OTHER|Moxibustion|Subjects received moxibustion covering Shenque, Zhonggong, Guanyuan, and Qihai for 30 minutes every day for 14 days.
223793252|NCT06241274|OTHER|Symptomatic supportive treatment|Symptomatic supportive treatment.
223793253|NCT03588208|OTHER|Progressive resistance training program|Progressive resistance training program were performed twice a week for 12 weeks. The charge intensity was progressively increased from 40% to 80% of 1 repetition maximum. The following muscle groups were worked: trunk flexors and extensors, elbow flexors and extensors, knee flexors and extensors, hip abductors and adductors and shoulder abductors. In addition to strength training.
223793254|NCT03588208|OTHER|Educational Program|Structured education program were performed during one hour class once a week for five weeks
223793255|NCT02013622|DRUG|Brexpiprazole|Treatment (16 weeks) Up to 4 mg/day, once daily dose, tablets, orally
223793256|NCT04827511|OTHER|Refraction measurement with auto-ref-keratometer Canon|Refractive measurement and vitamin D level dosing
223793257|NCT00432731|BIOLOGICAL|VARIVAX®|
223793258|NCT00432731|BIOLOGICAL|M-M-RTM II|
223793259|NCT05885672|BEHAVIORAL|Online psychoeducational lifestyle intervention|A webpage-baed intervention focused on lifestyle interventions that aim to reduce metabolic syndrome severity.
223793260|NCT01763931|DRUG|Digoxin|Digoxin once daily for 2 weeks prior to definitive breast surgery.
223793261|NCT04650555|DRUG|BIO 300 Oral Powder|Amorphous solid dispersion of genistein milled into a powder
223793262|NCT05668728|OTHER|Group 1: Peppering|Before injection we will palpate the muscles of trapezius, m. rhomboideus, m. levator scapula for finding painful trigger points, and we will mark the point. the skin will be cleaned with an appropriate antiseptic. Before the needle is inserted, the area to be applied will be palpated once again to detect the painful trigger point between the thumb and index fingers. The needle will be guided to painful trigger points detected by palpation. Stainless steel 25x25 mm needles will be used for dry needling. The needle will be inserted and removed until the local twitch response disappears, at least 10 times at each point found. Afterwards, the patient will be given a standard exercise program for the neck muscles. With this method, dry needling will be applied to the patient 4 times a week, once a week.
223793263|NCT05668728|OTHER|group 2: spin and wait|Just before the injection, painful trigger points in the bilateral muscles of trapezius, m. rhomboideus, and m. levator scapula will be identified and marked by palpation, and the skin will be cleaned with an appropriate antiseptic. Before the needle is inserted, the area to be applied will be palpated once again to detect the painful trigger point between the thumb and index fingers. The needle will be guided to painful trigger points detected by palpation. Stainless steel 25x25 mm needles will be used for dry needling. After the dry needle is inserted at each point found, it will be spinned counterclockwise and left. Waiting time for each patient will be limited to 15 minutes. Afterwards, the patient will be given a standard exercise program for the neck muscles. With this method, dry needling will be applied to the patient 4 times a week, once a week.
223793264|NCT05668728|OTHER|group 3: Peppering and spin and wait|Just before the injection, painful trigger points in the bilateral muscles of trapezius, m. rhomboideus, and m. levator scapul will be identified and marked with palpation, and the skin will be cleaned with an appropriate antiseptic. Before the needle is inserted, the area to be applied will be palpated once again to detect the painful trigger point between the thumb and index fingers. The needle will be guided to painful trigger points detected by palpation. Stainless steel 25x25 mm needles will be used for dry needling. After the needle is inserted and removed, it will be spinned counterclockwise for 15 minutes in each patient until the local twitch response disappears, at least 10 times at each point found. Afterwards, the patient will be given a standard exercise program. With this method, dry needling will be applied to the patient 4 times a week, once a week.
223793265|NCT03765866|PROCEDURE|Thromboelastometry guided transfusion|Comparing resuscitation strategies with standard MTP v.s. ROTEM guided MTP
223793266|NCT00889538|DRUG|placebo|50 mL of 1/2 normal saline IV
223793267|NCT00889538|DRUG|glutathione|glutathione 600 mg IV
223793268|NCT00889538|DRUG|glutathione, vit C and NAC|Glutathione 600 mg IV Vitamin C 2000 mg IV N-acetylcysteine 20 mg/kg IV (max dose = 600 mg) Mix above three in 1/2 NS for a total volume of 50 mL
223793269|NCT06009081|BEHAVIORAL|postural exercise|The exercises consisted of 4-way neck isometric exercises and stretching exercises for the activation of deep cervical flexors (chin tuck exercise) and combined with this exercise. This protocol consisted of protocols studied in similar studies.
223793270|NCT06009081|BEHAVIORAL|aerobic exercise|The walking program was carried out daily on a flat surface with a target of 7000 steps. This goal is based on the American College of Sports Medicine reports on the minimum recommended levels of physical activity required to achieve health benefits, which includes several design elements.
223793271|NCT02115555|BEHAVIORAL|HIT-aided approach|Subjects randomized to this approach will be using the HIT-aided monitor.
223793272|NCT02115555|BEHAVIORAL|Contracted conflict management system|Subjects randomized to this arm will be using the behavioral contracted conflict management system.
223793273|NCT02115555|BEHAVIORAL|HIT plus contracted conflict management|Subjects randomized to this arm will use both the HIT-aided approach and the behavioral contract conflict management system.
223793274|NCT03206346|DRUG|Ingavirin|Ingavirin ( Imidazolyl ethanamide pentandioic acid) capsules, 60 mg once daily, regardless of meal, for 5 days.
223793275|NCT03206346|DRUG|Placebo oral capsule|Placebo, capsules daily for 5 days.
223793276|NCT05735236|DEVICE|BFR Cuff|The BFR cuff will be applied to the proximal thigh of the surgical leg while the patient completes specified physical therapy exercises.80% occlusion pressure will be determined by PT's in clinic through the use of a Delphi unit. Subjects will then be able to use the Saga Fitness app to adjust this pressure if it differs from the automatic calibrated pressure.
223793277|NCT04588961|PROCEDURE|Trapeziectomy with suspensionplasty|Surgical removal of trapezium bone and ligamentoplasty of first metacarpal bone using abductor pollicis tendon
223793278|NCT04588961|PROCEDURE|Joint alloplasty|Surgical removal of degenerated joint surfaces nad replacement using modern designed prothesis
223793279|NCT04307004|OTHER|Unattended blood pressure measurement|Participants will have their blood pressure measured three times with an automated blood pressure monitor with a technician not present in the room.
223793280|NCT04307004|OTHER|Attended blood pressure measurement|Participants will have their blood pressure measured three times with an automated blood pressure monitor with a technician present in the room.
223793281|NCT04307004|OTHER|Ambulatory blood pressure monitoring|Participants will have their blood pressure measured every 30 minutes over 24-hours using an ambulatory blood pressure monitor.
223793282|NCT04307004|OTHER|Home blood pressure monitoring|Participants will have their blood pressure measured three times overnight while they are asleep using a home blood pressure monitor.
223793283|NCT06116903|GENETIC|Blood sampling|Blood sampling for testing of the detection of molecular abnormalities in exosomes of glial tumors
223793284|NCT05043090|DRUG|savolitinib|Tablets : 3 × 200 mg tablets once daily
223793285|NCT05043090|DRUG|durvalumab|Concentrate for solution for IV infusion : 1500 mg durvalumab every 4 weeks
223793286|NCT05043090|DRUG|sunitinib|Capsules : 2 x 25mg capsules once daily 4 weeks on, 2 weeks off
223793287|NCT05523284|DIAGNOSTIC_TEST|SonoPODography|SonoPODography (SPG) is a novel ultrasound-guided technique whereby saline is injected through the cervix and flushed into the POD, creating an acoustic window for diagnosing superficial endometriosis.
223793288|NCT06523673|RADIATION|Stereotactic Body Radiotherapy|The dose of radiation therapy is determined by the radiologist based on the clinical parameters of the lesion, including tumor size and location. In most cases, radiotherapy fractionation regimens range from 27-30 Gy/3 Fractions or 30-50 Gy/5 Fractions, and appropriate radiotherapy doses covering 27-70 Gy/3-10 Fractions can also be selected by the radiologist based on radiation limitations of neighboring endangered organs.
223793289|NCT06523673|DRUG|second-line systemic therapy|a second-line docetaxel/albumin-bound paclitaxel-based systemic therapy regimen
223793290|NCT03541759|DRUG|Hydromorphone Hcl 4Mg Tab|Hydal retard 4Mg Tab 2 times after surgery as basic medication. Hydal retard 2.6Mg maximum 2 per 24h when NRS \> 5.
223793291|NCT03541759|DRUG|Piritramide 15mg s.c.|Dipidolor 15mg s.c. 2 times after surgery as basic medication. Dipidolor 7.5mg s.c. maximum 2 per 24h when NRS \> 5.
223793292|NCT06240442|OTHER|Fasted exercise|Bodyweight interval exercise performed 5 minutes before the start of a mixed-macronutrient breakfast meal
223793293|NCT06240442|OTHER|Fed exercise|Bodyweight interval exercise performed 10 minutes after the start of consuming a mixed-macronutrient breakfast meal
223793294|NCT03637205|PROCEDURE|ECLS insertion|After diagnostic angiography the culprit lesion should be identified and revascularization (preferably by PCI, alternatively CABG) should be planned. ECLS insertion should be performed preferably before revascularization
223793295|NCT03637205|OTHER|Revascularisation and optimal medical treatment|After diagnostic angiography the culprit lesion should be identified and revascularization (preferably by PCI, alternatively CABG) should be planned.
223793296|NCT04745611|DIAGNOSTIC_TEST|MRI|3T cranial MRI with T1-, and T2 weighted imaging, a FLAIR sequence, diffusion-weighted imaging and susceptibility-weighted sequence
223793297|NCT04745611|DIAGNOSTIC_TEST|Neuropsychological assessment|Montreal Cognitive Assessment (MoCA), Rey-Auditory Verbal Learning Test (RAVLT), Trail making A/B, Stroop, Digit Span Coding, Judgement of line orientation (JOLO), Boston Naming Task (BNT), Controlled Oral Word Associations Task (COWAT), Category Fuency, Test of Memory Malingering (TOMM)
223793298|NCT04745611|DIAGNOSTIC_TEST|Questionnaires Patient|EuroQol-5D-5L (EQ-5D-5L), Utrecht Scale for Evaluation of Rehabilitation-Participation - Restrictions (USER-P-R), NeNeSCo-Q (questionnaire created for this study, including common neurological symptoms), Checklist for post-IC cognitive complaints (CLC-IC self-report), Hospital Anxiety and Depression Scale (HADS), Primary Care Post-Traumatic Stress Disorder (PC-PTSD-5), Utrecht Coping List (UCL) (subscale passive coping), PROMIS physical functioning short form, Items of Insomnia Severity Index (ISI) \& Pittsburgh Sleep Quality Index (PSQI), Fatigue Severity Scale (FSS), Social Support List (SSL-12-I)
223793299|NCT04745611|DIAGNOSTIC_TEST|Questionnaires Family|EuroQol-5D-5L (EQ-5D-5L), Utrecht Scale for Evaluation of Rehabilitation-Participation - Restrictions (USER-P-R), Checklist for post-IC cognitive complaints (CLC-IC proxy-report), Hospital Anxiety and Depression Scale (HADS), Primary Care Post-Traumatic Stress Disorder (PC-PTSD-5), Utrecht Coping List (UCL) (subscale passive coping), Social Support List (SSL-12-I), Caregiver Strain Index (CSI)
223793300|NCT01753687|OTHER|Ocular scattering of the tear film|
223793301|NCT01753687|OTHER|Optical Coherence Tomography (OCT)|Tear film thickness as measured with OCT
223793302|NCT01753687|OTHER|Measurement of tear film osmolarity|
223793303|NCT03175133|OTHER|Strength exercise|Strengthening exercises performed with physical therapist.
223793304|NCT00908154|DRUG|Placebo|Tablets to match GSK1014802
223793305|NCT00908154|DRUG|GSK1014802|Sodium channel blocker
223793306|NCT02824133|DRUG|AZD4547|80 mg bd (per os)
223793307|NCT06292156|DEVICE|Theta treatment group|The target 'active' electrode was placed over the MFC and the second 'return' electrode was placed over the medial parietal cortex. 6 Hz stimulation was used and a alternating current of 2mA was applied for 30min each day(Monday-Friday) for 3consecutive weeks
223793308|NCT06292156|DEVICE|Alpha active control group|The target 'active' electrode was placed over the MFC and the second 'return' electrode was placed over the medial parietal cortex. 10 Hz stimulation was used and a alternating current of 2mA was applied for 30min each day(Monday-Friday) for 3 consecutive weeks
223793309|NCT06292156|DEVICE|Sham control group|Sham stimulation lasted 30 s (15 s of ramp- up and 15 s of ramp-down).
223793310|NCT01324271|DEVICE|Acclarent Tympanostomy Tube Delivery system (TTDS)|placement of tympanostomy tube under local anesthesia
223793311|NCT05130970|DRUG|Garadacimab|Participants received garadacimab intravenous (IV) loading dose followed by 3 subcutaneous (SC) doses.
223793312|NCT05130970|DRUG|Placebo|Participants received a matching placebo IV loading dose, followed by 3 SC doses.
223793313|NCT04369560|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|60-cm wide bore 3T scanner (Siemens AG, Erlangen, Germany) with a 32-channel pelvic phased-array coil placed over the bladder.
223793314|NCT04369560|DRUG|Gadobutrol intravesical administration (4mM)|A paramagnetic macrocyclic gadolinium-based contrast agent administered intravenously for use in magnetic resonance imaging. Contrast-enhancement is a result of the neutral complex of gadolinium and dihydroxy-hydroxymethylpropyl- tetraazacyclododecane-triacetic acid (butrol).
223793315|NCT04369560|DRUG|Ferumoxytol intravesical administration (5 mM)|An iron preparation (Fe3O4) approved for intravenous treatment of anemia in the setting of renal failure, comprised of superparamagnetic iron oxide nanoparticles which are coated by a semi-synthetic carbohydrate shell in an isotonic, neutral pH solution.
223793316|NCT04907253|DRUG|Quercetin|500 mg twice daily
223793317|NCT04907253|DRUG|Placebo|twice daily
223793318|NCT05966454|DRUG|Multiple standard of care antibiotics for appendicitis, at physicians' discretion|Standard of Care Antibiotic use will be restricted to none or up to 24 hours of post-operative antibiotics.
223793319|NCT05966454|DRUG|Multiple standard of care antibiotics for appendicitis, at physicians' discretion|Standard of Care Antibiotic use will be permitted for 24 hours or up to 4 days of post-operative antibiotics.
223793320|NCT06268574|DRUG|RVU120|RVU120 is a potent, selective inhibitor of CDK8 and its paralog CDK19
223793321|NCT05109091|DRUG|ATH434 dose level 1|ATH434 taken BID
223793322|NCT05109091|DRUG|ATH434 dose level 2|ATH434 taken BID
223793323|NCT05109091|DRUG|Placebo|Placebo taken BID
223793324|NCT03996473|DRUG|Radium-223 dichloride (Xofigo, BAY 88-8223)|55 kBq/kg, intravenous (IV) injection, every 6 weeks for up to 6 administrations
223793325|NCT03996473|DRUG|Pembrolizumab|200 mg, IV infusion, every 3 weeks for a maximum of up to 35 administrations
223793326|NCT04066127|DEVICE|Non-ischemic heart preservation (NIHP)|The device is a miniaturized and fully automated heart-lung machine, housed in a portable device (weight 32 kg), that enables transportation between hospitals. The reservoir is filled with 2.5 liters of the perfusion solution plus approximately 500 mL compatible washed and leucocyte-filtered red blood cells from the hospital blood bank. The NIHP system software is adjusted to maintain a mean blood pressure of 20-25 mmHg in the aortic root, giving a coronary flow between 150 mL/min and 250 mL/min.
223793327|NCT04066127|DEVICE|Standard ischemic cold static storage (SCS)|The device is a cool box that enables transportation between hospitals. The heart is stored on ice slush in the box at a temperature of approximately 4-8 °C.
223793328|NCT06116591|BIOLOGICAL|mPnC candidate|monovalent pneumococcal conjugate candidate
223793329|NCT06116591|BIOLOGICAL|mPnC control|monovalent pneumococcal conjugate control
223793330|NCT05036486|GENETIC|next-generation sequencing|Tumor tissue will be collected from advanced BTC patients for real-time next-generation sequencing analysis
223793331|NCT04769037|DIETARY_SUPPLEMENT|B. infantis|Activated B. infantis EVC001; Bifidobacterium longum subsp. infantis; 8 x 109 colony forming units (CFU) per day
223793332|NCT04769037|DIETARY_SUPPLEMENT|Placebo|Lactose identical in appearance and taste to the active supplement
223793333|NCT01339585|DEVICE|Transcranial direct current stimulation (tDCS)|Eldith Direct Current Stimulator (NeuroConn GmbH, Germany)
223793334|NCT03855449|BEHAVIORAL|eDECIDE Web-based Intervention Group|"Will conduct 18 week in-person group sessions of the DECIDE curriculum with recruited volunteers. This is part 1 or phase I of the eventual pilot clinical trial. Participants will attend weekly group sessions to learn problem-solving skills and management of their diabetes.~After the completion of the task analysis participants will be recruited for the eDECIDE web-based intervention"
223793335|NCT04620278|GENETIC|DNA or RNA Sequencing|Samples will be used for whole exome (DNA) or RNA sequencing
223793336|NCT04373239|PROCEDURE|Assisted Reproductive Technology|Assisted reproductive technology includes IVF and IVF+ICSI.
223793337|NCT05823259|OTHER|Hybrid Telehealth Program: Respiratory Muscle Training and Patient Education|"A testing session will be held where subjects will undergo respiratory muscle testing using the Pro2Fit device to measure PIMax and PEmax. During this session, subjects will be instructed in a respiratory muscle training home program utilizing a provided device call the Breather. They will be instructed to perform this program consisting of breathing exercises for 2 sets of 10 repetitions, twice a day at a difficulty level of 5-7 on the Visual Analogue Scale (VAS) scale for 8 weeks. Subjects will be shown how to follow a training program every day utilizing the free companion application to the device Breather Coach. If subjects have issues with using technology, they will be provided a physical log to record when they complete sessions. Ten to fifteen-minute Zoom sessions with the study coordinator will be held once a week to check in on how the program is progressing, compliance, and if the resistance can be increased."
223793338|NCT05823259|OTHER|Standard Physical Therapy Care|A group of patients who receive standard physical therapy care for chronic constipation at the University of Miami that consists of biofeedback therapy, manual therapy, therapeutic exercise, and patient education.
223793339|NCT06506435|BEHAVIORAL|Two Dimensional (2D) Informational Video|A 30-minute informational video. The two dimensional (2D) video provides information about the radiotherapy process. Participants will receive this one-time intervention in-person, prior to treatment.
223793340|NCT06506435|BEHAVIORAL|First-Person Virtual Reality Video|A 30-minute virtual reality video, experienced through a headset, provides an immersive portrayal of the radiotherapy process from a first-person perspective. Participants will receive this one-time intervention in-person, prior to treatment.
223793341|NCT06506435|BEHAVIORAL|Third-Person Virtual Reality Video|A 30-minute virtual reality video, experienced through a headset, provides an immersive portrayal of the radiotherapy process from a third-person perspective. Participants will receive this one-time intervention in-person, prior to treatment.
223793342|NCT02988973|DRUG|roxadustat|Oral administration
223793343|NCT02988973|DRUG|DA|Subcutaneous administration
223793344|NCT05157971|DRUG|Cyclophosphamide|Given IV
223793345|NCT05157971|DRUG|Cytarabine|Given SC, IV or IT
223793346|NCT05157971|DRUG|Daunorubicin Hydrochloride|Given IV
223793347|NCT05157971|DRUG|Mercaptopurine|Given PO
223793348|NCT05157971|DRUG|Methotrexate|Given IT
223793349|NCT05157971|DRUG|Pegaspargase|Given IM or IV
223793350|NCT05157971|DRUG|Prednisone|Given PO
223793351|NCT05157971|DRUG|Venetoclax|Given PO
223793352|NCT05157971|DRUG|Vincristine Sulfate|Given IV
223793353|NCT05631249|DRUG|Sotorasib 120Mg Tab|Daily sotorasib treatment until progression, unacceptable toxicity, death, or lost to follow-up
223793354|NCT04783155|DEVICE|POWERBreathe Plus®|Commercially available pressure-threshold device
223793355|NCT04783155|OTHER|Cardiopulmonary rehabilitation post lung transplant|Pulmonary function, lung diffusing capacity for carbon monoxide, inspiratory muscle strength, and diaphragm dimensions will be assessed in each patient. Each patient will also undergo a cardiopulmonary exercise test (CPET), 6 minute walk test, and an inspiratory muscle endurance test
223793356|NCT04808401|DRUG|Oxygen|Two FIO2 settings during stable general anaesthesia resulting in normoxaemic and hyperoxic arterial oxygen partial pressures.
223793357|NCT06962917|OTHER|Cross sectional study|This study is a cross-cultural study, not an intervention study. A total of 1,523 participants (484 from Germany, 548 from the United States, and 491 from Japan) were recruited.
223793358|NCT06961812|DIAGNOSTIC_TEST|Questionnaire and Physical Exam|"Next, the risk of falling will be assessed by a healthcare professional using a hetero-questionnaire and physical tests, as proposed in the algorithm for global recommendations (routine care).~These tests include a detailed characterisation of the history of falls, the Timed Up and Go, the Five Times Sit to Stand, the 4 m walking speed and the Short Physical Performance Battery."
223793359|NCT06961812|DIAGNOSTIC_TEST|Safe Self-Administered Questionnaire|"All people who agree to take part in the study will first complete the SAFE self-questionnaire (intervention).~the Self Assessment for Falls in the Elderly (SAFE), an auto-questionnaire that converts the binary items and performance tests of the 2022 World Guidelines for Falls Prevention and Management into visual analogue scales (100 mm each)."
223793360|NCT06962124|OTHER|serum sodium measurment|serum sodium measurment
223793361|NCT06961617|DRUG|LioCyx-M, HBV antigen-specific TCR-redirected T cells|Via intravenous (IV) infusion
223793362|NCT06962319|DRUG|dihydroartemisinin-piperaquine (DP)|Weight-based dosing of 3 (\<60kg), 4 (6-80kg) or 5 (\>80 kg) 40/320 mg tablets of dihydroartemisinin-piperaquine given once daily for 3 days
223793363|NCT06962319|DRUG|Pyronaridine-artesunate (PA)|Weight-based dosing of 2 (24-\<45 kg), 3 (45-\<65kg), or 4 (\>=65 kg) 180/60 mg tablets of pyronaridine-artesunate, once daily for 3 days.
223793364|NCT06962319|DRUG|Artemether-lumefantrine|1 x 80/480 or 4 x 20/120 mg tablets of artemether-lumefantrine, given twice daily, approximately 8 hours apart for 3 days
223793365|NCT06962813|PROCEDURE|Radiofrequency V Eraser|standar of care sclerotherapy
223793366|NCT06961656|OTHER|Intervention Group-Jigsaw IV technique|Wound care training with the Jigsaw IV technique method
223793367|NCT06961656|OTHER|Control Group-Traditional methods|Wound care training with traditional methods
223793368|NCT06962527|BEHAVIORAL|Uncertainty-focused single session intervention|Digitally/computer administered 30-minute self-guided intervention for adults ages 25-60
223793369|NCT06962527|BEHAVIORAL|Maintaining a healthy lifestyle single session intervention|Digitally/computer administered 30-minute self-guided intervention for adults ages 25-60
223793370|NCT06962748|DIAGNOSTIC_TEST|cerebral blood flow measurment|measuring CO using cerebral blood flow
223793371|NCT06962748|DIAGNOSTIC_TEST|TTE CO measurment|measuring CO using TTE
223793372|NCT06962748|DIAGNOSTIC_TEST|ETCO2|measure the average ETCO2 over 30 minutes period
223793373|NCT06962072|PROCEDURE|Surgical resection with or without radiotherapy and/or chemotherapy|The surgical resection of STS serves as the primary treatment, aiming to completely remove the tumor with a wide margin of surrounding healthy tissue to minimize the risk of recurrence. Radiotherapy and/or chemotherapy may be incorporated depending on the tumor's type, stage, and grade.
223793374|NCT06962423|OTHER|AI system|Participants will complete the research task with the AI system developed by out team to perform automated biomedical research.
223793375|NCT06962709|OTHER|Warmed lidocaine|Lidocaine warmed to 98 F
223793376|NCT06962228|PROCEDURE|Anal fistula surgery|Anal fistula incision, anal fistula excision, anal fistula hanging
223793377|NCT04737200|DIETARY_SUPPLEMENT|Time-of-day of enteral nutrition provision (daytime first)|Enteral nutrition (tube feeds) will be provided during the daytime followed by nighttime.
223793378|NCT04737200|DIETARY_SUPPLEMENT|Time-of-day of enteral nutrition provision (nighttime first)|Enteral nutrition (tube feeds) will be provided during the nighttime followed by daytime.
223793379|NCT03921515|OTHER|Blister induction|Blister induction involves creating 8 blisters on the forearm and removing the tops of the blisters for primary cell culture derivation. After blister induction, subjects may have an optional overnight admission to assess cell infiltration in response to autologous serum and/or sterile saline solution.
223793380|NCT03921515|OTHER|Skin Biopsies|The skin biopsies will involve up to 4 biopsies: 2 initial punch biopsies 2 mm in diameter, followed by a punch biopsy 3 (plus or minus 1) and 7 (plus or minus 2) days later using a 3 mm punch to encompass the initial biopsy sites, capturing the tissue at 3 and 7 days of healing.
223793381|NCT05081128|DEVICE|programmable CSF shunt valve|Brain shunt surgery using a programmable CSF shunt valve
223793382|NCT05762302|DIAGNOSTIC_TEST|MeMed BV test|Following the MeMed BV test result, the clinician will decide whether or not to prescribe an antibiotic for your condition
223793383|NCT00310219|PROCEDURE|computed tomography|
223793384|NCT00310219|PROCEDURE|positron emission tomography|
223793385|NCT01155947|DRUG|Anastrozole|Anastrozole Tablets 1 mg of Dr.Reddy's Laboratories Limited
223793386|NCT00922454|PROCEDURE|Endovascular Repair of the abdominal aorta|"Patients will undergo or have undergone endovascular aneurysm repair which is minimally invasive approach using endoluminal placement of a stent graft.~EVAR, CTA imaging, 1, 6 12 months post treatment."
223793387|NCT00922454|DEVICE|Cook Zenith Stent-Graft|Cook Zenith AAA Endovascular Graft
223793388|NCT00922454|DEVICE|Talent Stent-Graft|Talent AAA Abdominal Stent Graft System
223793389|NCT04166357|DIAGNOSTIC_TEST|neuromuscular ultrasound|Neuromuscular ultrasound refers to a field in medicine in which ultrasound is used to diagnosis and guide treatment for people with neuromuscular diseases. Neuromuscular ultrasound is often combined with electrodiagnosis, and particularly nerve conduction studies and EMG, to improve the accuracy of diagnosis and add anatomic information to the functional information obtained with electrodiagnosis. It has been demonstrated that neuromuscular ultrasound adds value to the diagnosis of nerve disease in over 80% of cases.
223793390|NCT03257826|DEVICE|kirschner wire|retrograde percutaneous kirschner wire was applied to stabilize the tibia.
223793391|NCT06351358|DEVICE|Sculptra treatment|Subjects will receive treatment of Sculptra at baseline. Subjects will receive a second treatment of Sculptra at Week 4 visit. At the Week 8 visit, subjects will receive an optional treatment of Sculptra.
223793392|NCT06351358|DEVICE|Restylane Treatment|Subjects will receive treatment Restylane Lyft or Restylane Contour at baseline. Subjects will receive an optional touch-up of Restylane Lyft or Restylane Contour at Week 4 visit.
223793393|NCT04778033|OTHER|Sperm collection|Those recruited will supply a single sperm sample 1-2 months following the second dose of the vaccination. The sample will be analyzed for macroscopic and microscopic features in the IVF laboratory and will be discarded immediately afterwards.
223793394|NCT01381692|DRUG|Bortezomib|Given IV or SC
223793395|NCT01381692|DRUG|Dexamethasone|Given PO
223793396|NCT01381692|OTHER|Laboratory Biomarker Analysis|Correlative studies
223793397|NCT01381692|OTHER|Quality-of-Life Assessment|Ancillary studies
223793398|NCT01381692|BIOLOGICAL|Rituximab|Given IV
223793399|NCT01381692|DRUG|Temsirolimus|Given IV
223793400|NCT01270347|DRUG|MP-376 (Levofloxacin Solution for Inhalation)|MP-376 (Aeroquin, Levofloxacin solution for Inhalation) 240 mg administered BID for 28-days treatment followed by 28 days off treatment
223793401|NCT01270347|DRUG|TIS (Tobramycin Inhalation Solution)|Tobramycin Inhalation Solution administered BID over 3 consecutive cycles of 28-days treatment followed by 28 days off treatment
223793402|NCT05799157|DRUG|VDMN-21 Patch Low Dose|Microneedle patch containing 125 mcg of active drug
223793403|NCT05799157|DRUG|VDMN-21 Patch High Dose|Microneedle patch containing 250 mcg of active drug
223793404|NCT05799157|DRUG|Vehicle Patch|Placebo microneedle patch containing no active drug (i.e., placebo)
223793405|NCT04789668|DRUG|Bintrafusp Alfa|Given IV
223793406|NCT04789668|DRUG|Pimasertib|Given PO
223793407|NCT04789668|OTHER|Quality-of-Life Assessment|Ancillary studies
223793408|NCT06695637|RADIATION|active cTBS|"Transcranial Magnetic Stimulation (TMS) is a non-invasive neuromodulation technique which employs magnetic fields to stimulate neural activity in the brain. cTBS is a specific TMS protocol, wherein bursts of high-frequency magnetic pulses are repeatedly applied in a rhythmic pattern, mimicking the theta rhythm of neural oscillations. Studies suggest that cTBS has the potential to modulate cortical excitability and synaptic plasticity, leading to alterations in targeted brain function.~Baseline measures will be collected to develop individualized targets for stimulation and also understand how brain structure and activity may change in response to cTBS."
223793409|NCT06695637|RADIATION|sham cTBS|The intervention group receives cTBS and the control group receives sham stimulation using the sham option in the coil that makes the same noise and feeling without delivering significant amount of magnetic energy into the brain. Both groups are exposed to drug and neutral pictures before and after receiving stimulation. People in the active group will receive cTBS with corrected individualized stimulation intensity to have 1 V/m in targeted brain regions while in the sham group people will only receive sham condition with a similar look, sound, and feel of active stimulation.
223793410|NCT05195645|DRUG|Abatacept 250 MG|Abatacept will be administered by intravenous injection over 1h15 to 2h30 on D1, D5+/-2 and D14+/-2 at 10mg/kg (arm A), or 20mg/kg (arm B) or 25mg/kg (arm C) depending on the randomization (max 3 000 mg per administration). Starting Day 21 (after evaluation of the primary outcome), other injection of abatacept may be given (D22 at D90) with dosage (10 or 20mg/kg max) decided by the treating physician (max 2 500 mg per administration) as a function of the relapse or not of the ICI myocarditis after immunosuppressant therapeutics tapering. After day 21, the administrations will be carried out in open but the blind administration 1 to 3 (D1 to D21) will be kept.
223793411|NCT02189798|DEVICE|HiRes 90K™ Advantage implant with HiFocus™ Mid-Scala electrode|HiRes 90K™ Advantage implant with HiFocus™ Mid-Scala electrode will be implanted in adults with partial deafness (considerable low frequency acoustic hearing profiles with severe-to-profound high frequency sensorineural hearing loss).
223793412|NCT02189798|DEVICE|EAS sound processor|Patients with partial deafness (considerable low frequency acoustic hearing profiles with severe-to-profound high frequency sensorineural hearing loss) implanted with HiRes 90K™ Advantage implant with HiFocus™ Mid-Scala electrode will be fitted with the EAS sound processor.
223793413|NCT04543110|DRUG|Durvalumab|Durvalumab prior to Radical Cystectomy in Patients With Muscle-Invasive Bladder Carcinoma
223793414|NCT04543110|RADIATION|Immune Modulating Radiation|Neoadjuvant Immune-Modulating Radiation prior to Radical Cystectomy in Patients With Muscle-Invasive Bladder Carcinoma
223793415|NCT00529399|DRUG|GAD-Alum|Participants will receive 3 injections of 20 micrograms GAD-Alum subcutaneously. The first two injections are given 4 weeks apart and the second and third are given 8 weeks apart.
223793416|NCT00529399|DRUG|GAD-Alum and Aluminum hydroxide|Participants will receive 3 injections subcutaneously. The first two will contain 20 micrograms GAD-Alum vaccine and are given 4 weeks apart. The third injection will be Aluminum hydroxide alone and will be given 8 weeks after the second injection.
223793417|NCT00529399|DRUG|Aluminum hydroxide|Participants will receive 3 injections of Aluminum hydroxide alone, subcutaneously. The first two injections are given 4 weeks apart and the second and third are given 8 weeks apart.
223793418|NCT02486328|DRUG|Midazolam|Dosage adjustment
223793419|NCT02486328|DRUG|Meperidine|Dosage adjustment
223793420|NCT02486328|DRUG|Remifentanil|Dosage adjustment
223793421|NCT02486328|DRUG|Propofol|Dosage adjustment
223793422|NCT02968784|DEVICE|ExAblate MRgFUS|ExAblate treatment of prostate cancer less than or equal to Grade 7
223793423|NCT03936686|OTHER|Survey tool to assess CVD risk factor knowledge|The survey tool was used to assess the participant's knowledge level and their previous methods of education regarding cardiovascular disease risk factors.
223793424|NCT03998826|DRUG|Piroxicam|20mg piroxicam
223793425|NCT03998826|DRUG|Placebo|placebo
223793426|NCT06242444|DRUG|Experimental Dentifrice|Dentifrice containing 1150 ppm fluoride and 5% KNO3.
223793427|NCT06242444|DRUG|Placebo Control Dentifrice|Dentifrice containing 0 ppm fluoride and 5% KNO3.
223793428|NCT06242444|DRUG|Reference Dentifrice|Dentifrice containing 1100 ppm fluoride as SnF2.
223793429|NCT01303666|PROCEDURE|Intra-articular CSI|After full aseptic preparation, 40 mg triamcinolone acetonide and 2 ml 1% lignocaine were injected into the joint cavity using the medial patello-femoral approach via a 21-gauge needle.
223793430|NCT01303666|PROCEDURE|TI of the knee|"This was done as a day case procedure under local anaesthetic. The medial patello-femoral approach was used. After full aseptic preparation, the skin and soft tissues were infiltrated with 5e10 ml of 1% lignocaine. The joint was then instilled with a further 10 ml of 1% lignocaine.~After an initial puncture using a scalpel, a 3.2 mm diameter wrist arthroscope was advanced into the joint cavity. Up to 1 l of 0.9% normal saline was then irrigated through the joint: saline was run into the joint until fully distended and then allowed to flow out of the joint in a cyclical method until the aspirated fluid runs clear for at least three successive cycles."
223793431|NCT02208180|BEHAVIORAL|Return of genomic results on cardiovascular disease risk|"Experimental group: Participants will receive genomic cardiovascular disease risk information.~Comparator: Participants will receive lifestyle cardiovascular disease risk information. Genomic risk information will be returned after the conclusion of the study."
223793432|NCT05790733|OTHER|Standard intubation|This involves the use of 5% Xylocaine nebulizer spray and a single-use cannula. The nurse checks its expiry date and that the quantity is sufficient to practice the 7 instillations in one nostril and the other 7 in the mouth. A waiting time is respected and the installation of the NGS can begin. She will also set up a fast for 2 hours after this local anesthesia.
223793433|NCT05790733|OTHER|Hypnosis|"Hypnosis is a particular psychological state marked by the functioning of the individual at a level of attention other than the ordinary state of consciousness. It can, under certain conditions, give the appearance of sleep or somnambulism without sharing all the characteristics.~As part of the treatment, hypnosis is widely used for pain control. The adverse effects reported are nil. One of its main benefits is improved patient comfort. Another benefit is the reduction of exposure to anesthetic products.~The installation of the NGS with hypnosis will be carried out according to the protocol set out in appendix 4."
223793434|NCT00179023|DRUG|Trimethaphan|Start dose: 0.05 ml/min (0.5 mg/min), IV infusion. The dose will be increased every 2-4 minutes to 1, 2, 4, and 5 mg/min. Total duration: 1 hour
223793435|NCT00179023|DRUG|Trimethaphan|Start dose: 0.05 ml/min (0.5 mg/min), IV infusion. The dose will be increased every 30 minutes to 1, 2, 4, and 5 mg/min. Total duration: 1-2 hours
223793436|NCT00179023|DRUG|Pseudoephedrine|30mg tablet,VO. Single dose.
224263975|NCT00199901|BIOLOGICAL|NY-ESO-1 ISCOMATRIX®|"100 μg of NY-ESO-1 protein formulated with 120 μg of ISCOMATRIX® adjuvant.~Each patient will receive four intramuscular injections of NY-ESO-1 ISCOMATRIX® vaccine. The first three doses will be given at four-week intervals, days 1, 29, and 57, (± 3 days of scheduled date). The fourth injection will be given at month 6 (day 183 ± 3 days)."
224263976|NCT00199901|BIOLOGICAL|ISCOMATRIX® adjuvant|"120 μg of ISCOMATRIX® adjuvant~Each patient will receive four intramuscular injections of ISCOMATRIX® adjuvant alone. The first three doses will be given at four-week intervals, days 1, 29, and 57, (± 3 days of scheduled date). The fourth injection will be given at month 6 (day 183 ± 3 days)."
224263977|NCT05028569|DRUG|BOTOX|Intramuscular Injection
224263978|NCT05028569|DRUG|Placebo|Intramuscular Injection
224263979|NCT06335186|DIAGNOSTIC_TEST|upper endoscopy|to detect esophageal or gastric varices
224263980|NCT01279109|BEHAVIORAL|Social network building intervention|Group support and 12 weekly health education/skills building sessions during pregnancy
224263981|NCT01279109|BEHAVIORAL|Home visit|Three home visits during pregnancy focused on providing education on infant injury prevention
224263982|NCT05546398|DRUG|Bempedoic Acid 180Mg/Ezetimibe 10Mg Tab|No study drug was administered during this study.
224263983|NCT05546398|OTHER|No study drug|No study drug was administered during this study.
224263984|NCT05403268|DEVICE|DeltaScan|Twice daily DeltaScan observations
223793437|NCT01820676|DEVICE|iUni G2+|The iUni G2+ Unicompartmental Resurfacing Device (iUni) is an FDA cleared and CE Marked implant designed for patients with damage isolated to either the medial or lateral tibiofemoral compartment of the knee. The patient-specific iUni is designed from a CT scan of an individual patient's knee using a design process which interactively maps the diseased area and defines the extent of misalignment present in the knee. This process allows definition of the shape and size of the femoral and tibial components of the implant, as well as the disposable instrumentation (Fitz).
223793438|NCT02145546|DRUG|Amiodarone|Amiodarone: 200mg three times a day for two weeks, then change to 200mg per day for the rest of the study.
223793439|NCT02145546|DRUG|Propafenone|150mg per 8 hours, 3 times per day
223793440|NCT02145546|DRUG|Sotalol|80mg twice per day.
223793441|NCT00727272|DRUG|Quinine Sulfate Capsules 324 mg|One 324 mg capsule administered after an overnight fast of at least 10 hours.
223793442|NCT00727272|DRUG|Quinine Sulphate Tablets 300 mg|One 300 mg tablet administered after an overnight fast of at least 10 hours.
223793443|NCT00727272|DRUG|Quinine Sulfate Capsules 324 mg|One 324 mg capsule administered thirty minutes after the initiation of a standardized, high-fat breakfast.
223793444|NCT03061253|OTHER|Electronic Cigarette and behavioural change support.|The nicotine strength of Group A (nicotine-inclusive e-cigarettes) cartridges will be 18 mg/ml of nicotine strength. All participants will receive up to 6 behavioural change support sessions over the 3-month intervention period.
223793445|NCT03061253|OTHER|Nicotine-Free Electronic Cigarette and behavioural change support.|Group B participants will receive nicotine-free cartridges for the period of the intervention. All participants will receive up to 6 behavioural change support sessions over the 3-month intervention period.
223793446|NCT03061253|OTHER|Nicotine Replacement Therapy and behavioural change support.|Group C participants will be referred to smoking cessation services where they will be expected to receive Nicotine Replacement Therapy and up to 6 behavioural change support sessions over the 3-month intervention period, as per current guidelines.
223793447|NCT05595304|PROCEDURE|prosthetic refunctioning|Active treatment followed by regular interventions
223793448|NCT05595304|PROCEDURE|conventional prosthetic treatment|new prosthesis
223793449|NCT00242112|PROCEDURE|MRI Prostate|
223793450|NCT02882568|BIOLOGICAL|blood analysis|Pilot study, single center, interventional including 15 obese subjects with acute sepsis. Inflammatory and immunological tests during acute phase and one month later after a presumed return parameters at baseline
223793451|NCT01736228|DEVICE|DIABECELL|two transplants of 10,000 IEQ/kg DIABECELL (administered at least 12 weeks apart)- total of 20,000 IEQ/kg
223793452|NCT00651664|DRUG|alisertib|Alisertib (MLN8237) capsules
223793453|NCT02573519|RADIATION|11C Donepezil PET/CT scan|Donepezil binds with high affinity to acetylcholine esterase in the cholinergic synapses. The quantity of density of acetylcholine esterase in the abdominal organs including the intestinal wall are demonstrated by 11C Donepezil PET/CT scan. The PET-signal are measured as Standard-uptake values (SUV) in the internal organs. After 6 hours of fast CT- and PET-scans are performed after injection of iv. contrast and about 500MBq (megabecquerel) \[11C\]donepezil. The CT scan is used for anatomical location of the internal organs. The scan-field includes the heart and the abdominal organs. Total scan time is about 60 minutes.
223793454|NCT02573519|DEVICE|3D-Transit|"3D-Transit: 3D-Transit for minimal invasive and ambulant describing of regional transit times and contractions pattern of the bowel. The motility and the passage time is measured by 3D-Transit The description of location and rotation of the capsule is dynamic and very precise. It permits precise detailed description of the gastrointestinal contraction pattern and regional passage time. 3D-transit consist of three different parts:~1. A wireless electromagnetic capsule to be swallowed by the subject~2. A portable detector plate comprising four sensors worn in a belt around the waist~3. Specific software for visualizing and analyzing data"
223793455|NCT02573519|DRUG|3D-Transit during treatment with Pyridostigmine|3D-Transit and Pyridostigmine: The motility and the passage time is measured by 3D-Transit (as mentioned above) in diabetic patients during administration of Pyridostigmine 60 mg administrated 4 times with 4 hours between each administration. Pyridostigmine is increasing the amount of cholinergic neurotransmitter and is suggested to have a reversible effect on the cholinergic denervation. The mechanism of action of Pyridostigmine in the human body is well-known and the drug is used as a tool to determine if the disturbance in the guts are reversible in diabetic patients.
223793456|NCT02573519|DEVICE|3D-Transit after Malone appendicostomy|3D-Transit (as earlier described) is performed after Malone appendicostomy. The patients are suppose use the antegrade edema technic during the 3D-transit examination.
223793457|NCT01027546|DRUG|Tranexamic Acid|Administer 15 mg/kg body weight of tranexamic Acid mixed in 100 mL saline intravenously over 15 min before the skin incision
223793458|NCT05688904|DRUG|Imipramine|Topical 4% Imipramine
223793459|NCT05688904|OTHER|Vehicle|Vehicle
223793460|NCT00003951|DRUG|exatecan mesylate|
223793461|NCT00402753|BEHAVIORAL|Ambulatory Physical Exercise Program|supervised exercise, 2 x / week
223793462|NCT03239119|BIOLOGICAL|rE-4 5 mcg|Placebo Lead In (5 mcg) for 4 weeks / rE-4 5 mcg for 4 weeks / rE-4 5 mcg for 26 weeks - All are subcutaneously injected twice daily
223793463|NCT03239119|BIOLOGICAL|rE-4 10 mcg|Placebo Lead In (5 mcg) for 4 weeks / rE-4 5 mcg for 4 weeks / rE-4 10 mcg for 26 weeks - All are subcutaneously injected twice daily
223793464|NCT03239119|BIOLOGICAL|Placebo 5 mcg|Placebo Lead In (5 mcg) for 4 weeks / Placebo 5 mcg for 4 weeks / Placebo 5 mcg for 26 weeks - All are subcutaneously injected twice daily
223793465|NCT03239119|BIOLOGICAL|Placebo 10 mcg|Placebo Lead In (5 mcg) for 4 weeks / Placebo 5 mcg for 4 weeks / Placebo 10 mcg for 26 weeks - All are subcutaneously injected twice daily
223793466|NCT02992262|DEVICE|Point of care ocular ultrasound|
223793467|NCT05121753|DIETARY_SUPPLEMENT|Survey investigating Infant formula feeding in newborns|A database will be created that allows individuals to register and enter information about the premature infant's feeding history and symptoms/ medical history.
223793468|NCT04980053|OTHER|massage|Intervention group Control group
223793469|NCT03725644|BEHAVIORAL|parent-training program|Parents in the treatment group received the training program from the registered pediatric occupational therapist in six hours over three weeks. The occupational therapist provided suggestions and gave feedback. The parents were encouraged to interact with their children for at least 15 hours per week. Between the fourth and 14th weeks, the parents implemented the intervention programs at home and recorded the daily intensity. The occupational therapist met with the parents and children at monthly intervals (the seventh and 11th weeks) at the laboratory to discuss any difficulties they encountered and to practice the child-initiated activities.
223793470|NCT03725644|BEHAVIORAL|traditional program|Parents in the control group also conducted a 14-week program. They received six hours of training over three weeks.Between the fourth and 14th weeks, the parents implemented parent-led activities at home and recorded the daily intensity. The parents were encouraged to do activities with their children for at least 15 hours per week. The occupational therapist met with the parents at monthly intervals (the seventh and 11th weeks) at the laboratory to discuss any difficulties they encountered while practicing the parent-led activities.
223793471|NCT00959517|DRUG|artesunate (AS)|Recommended dosage over 3 days (for all interventions)
223793472|NCT00959517|DRUG|sulphadoxine-pyrimethamine (SP)|
223793473|NCT00959517|DRUG|Chloroquine (CQ)|
223793474|NCT00959517|DRUG|primaquine (PQ)|
223793475|NCT02184793|DEVICE|EMD (Inclinomax)|EMD (electronic monitoring device) : recording the head of bed inclination degree with digital display and alarm on
223793476|NCT02159833|OTHER|Intranasal challenge with active substance (food protein)|
223793477|NCT02159833|OTHER|Intranasal challenge with placebo|
223793478|NCT05475418|PROCEDURE|Adipose tissue derived exosomes|200-300ml of the subject adipose tissue before centrifugation was collected, and the extracellular vesicles were retained after tissue homogenate and filter screening. The extracellular vesicles were mixed with sterile hydrogel and applied directly to the wound surface, and the wound was covered with an inert protective dressing.
223793479|NCT03948568|COMBINATION_PRODUCT|Endocrine Therapy and Radiotherapy|Endocrine therapy and radiotherapy administered either concurrently or sequentially
223793480|NCT05821738|DRUG|Avapritinib|administered orally
223793481|NCT05258825|DRUG|Monoferric|A single intravenous dose of 1000 mg of Monoferric will be administered to a patient 3-4 weeks before anticipated surgery.
223793482|NCT01031147|OTHER|Examination|3D-TOF-MRA was performed for suspected patients to detect intracranial aneurysm, and subsequently underwent digital subtraction angiography
223793483|NCT02571218|DEVICE|Substrate+mCPVA|The intervention in the experimental arm includes using a research software (investigational device) to map AF substrate and guide ablation.
223793484|NCT02571218|DEVICE|mCPVA|The intervention in the active comparator arm includes using the commercially available EnSite Velocity mapping and ablation system for modified circumferential pulmonary vein ablation.
223793485|NCT04404712|DRUG|[11C]MK-3168|One PET scan involving administration of PET ligand \[11C\]MK-3168
223793486|NCT06961903|OTHER|physiotherapy programme|A program consisting of therapeutic ultrasound, hot pack, massage, and McKenzie exercises was administered as the intervention.
223793487|NCT06961903|OTHER|Functional Taping|"A program consisting of therapeutic ultrasound, hot pack, massage, and McKenzie exercises was administered as the intervention. In addition, the taping method applied in this study can be defined as a Function-Oriented Taping Application to Preserve Extension: Lumbar Extension Taping, which was specifically designed to maintain lumbar extension."
223793488|NCT06961903|OTHER|Manual Therapy|"A program consisting of therapeutic ultrasound, hot pack, massage, and McKenzie exercises was administered as the intervention.Manual Therapy (MT), which literally means hands-on treatment, is an evidence-based therapeutic approach consisting of skilled hand movements and maneuvers applied to produce therapeutic effects and to treat musculoskeletal dysfunctions and pain. In addition to the standard program, manual therapy was also administered in this study."
223793489|NCT06961903|OTHER|Stereodynamic Interference Current|A program consisting of therapeutic ultrasound, hot pack, massage, and McKenzie exercises was administered as the intervention.In addition, the stereodynamic interference current method was applied in this study. A 'Y' electrode was used during the application. Due to the rapid development of accommodation, the current intensity was frequently increased during the session. The average treatment duration was 15 minutes, and a frequency of 50-100 Hz was used to achieve analgesic effects.
223793490|NCT05229289|OTHER|Standard Medical Treatment|"Standard medical therapy (SMT):~Lactulose (Titrated to 2-3 soft bowel movements per day) Oral LOLA can be used as an alternative or additional agent to treat patients non-responsive to conventional therapy Oral BCAAs can be used as an alternative or additional agent to treat patients non-responsive to conventional therapy Diet Daily energy intakes of 35-40 kcal/kg ideal body weight Daily protein intake 1.2-1.5 g/kg/day Small meals or liquid nutritional supplements evenly distributed throughout the day Oral BCAA supplementation in patient's intolerant of dietary protein (to allow recommended nitrogen intake to be achieved and maintained)"
223793491|NCT05229289|OTHER|Fecal Microbiota Transplant|Fecal Microbiota Transplant
223793492|NCT02014714|DRUG|Morphine|Drug: Morphine Depending on the randomization schedule, 0.1mg of morphine or will be added to the intrathecal mixture.
223793493|NCT02014714|DRUG|Fentanyl|Drug: Fentanyl 40mcg Depending on the randomization schedule, 40μg of fentanyl will be added to the intrathecal mixture.
223793494|NCT00081367|BEHAVIORAL|CBT|Participants will receive ten weekly sessions of treatment. Suicidal thoughts or attempts, hopelessness, depression, health care utilization, and overall psychological and social adaptation will be assessed.
223793495|NCT00081367|BEHAVIORAL|Standard care alone|Participants will receive standard care for suicide prevention.
223793496|NCT03719456|PROCEDURE|Retrograde Intrarenal Surgery|
223793497|NCT02415400|DRUG|Apixaban|
223793498|NCT02415400|DRUG|vitamin K antagonist|
223793499|NCT02415400|DRUG|Acetylsalicylic acid|
223793500|NCT02415400|OTHER|Acetylsalicylic acid placebo|
223793501|NCT05027165|OTHER|Non-interventional|No intervention
223793502|NCT00062127|DRUG|irinotecan hydrochloride|Given IV
223793503|NCT00062127|DRUG|thalidomide|Given orally
223793504|NCT00062127|OTHER|pharmacological study|Correlative studies
223793505|NCT04570826|OTHER|Meditation.|The caregivers received eight sessions lasting each one two hours with the following sequence: before each practical exercises they always received 15 minutes about scientific theoretical evidence explaining the importance of doing them: to get a comfortable posture they received 25 minutes of mobility, flexibility, balance, strength and endurance exercises. To increase lung capacity, 25 minutes of costal, diaphragmatic and clavicular breathing exercises. Finally, to have an open attitude without distractions or judging they practiced 25 minutes of body awareness exercise observing sensations, thoughts and perceptions with gratitude and compassion.
223793506|NCT04570826|OTHER|Scientific descriptions about meditation.|The control group received scientific descriptions about meditation.
223793507|NCT02270450|PROCEDURE|therapeutic conventional surgery|Undergo abdominal surgery
223793508|NCT02270450|PROCEDURE|gastrointestinal complications management/prevention|Undergo non-surgical management
223793509|NCT02270450|OTHER|quality-of-life assessment|Ancillary studies
223793510|NCT02363738|DRUG|Infliximab|Intravenous infliximab (5mg/kg) at baseline, week 2 and 6 under clinical observation. Infliximab will be prescribed adjunctively to a conventional mood stabilizer or atypical antipsychotic agent.
223793511|NCT02363738|OTHER|Saline|Intravenous placebo (saline solution) at baseline, week 2 and 6 under clinical observation. Placebo will be matched to infliximab in color and consistency and will be administered adjunctively to conventional mood stabilizer or atypical antipsychotic agent.
223793512|NCT00601926|BIOLOGICAL|bevacizumab|15 mg/kg over 90 minutes every 3 weeks
223793513|NCT04097457|BEHAVIORAL|"Parent training for disruptive behaviors manual (Bearss, Johnson, Handen, Butter, Lecavalier, Smith & Scahill, 2018)"|"The intervention is a short term parent training program based on behavioral principles, which can be delivered by trained therapist. The manual includes eleven core sessions, home visit session, follow-up telephone booster sessions and seven supplemental sessions, designed to be delivered individually to parents in an outpatient setting.~The protocol will be administered to groups of 3-4 parents, with a quantitative pretest-post test design evaluated at five time points, including a follow up at one month post intervention. The protocol will be administered in various community and educational locations, such as schools and community centers"
223793514|NCT00558311|DRUG|Clazosentan|Intravenous clazosentan administered by continuous infusion at 5 mg/h
223793515|NCT00558311|DRUG|Placebo|Placebo administered by continuous infusion matching clazosentan administration
223793516|NCT01968213|DRUG|Rucaparib|Oral tablets administered twice daily with 8 oz (240 mL) of water on an empty stomach or with food; 28-day cycles of treatment. Doses should be taken as close to 12 hours apart as possible, preferably at the same times every day. Tablets should be swallowed whole.
223793517|NCT01968213|DRUG|Placebo|Oral tablets administered twice daily with 8 oz (240 mL) of water on an empty stomach or with food; 28-day cycles of treatment. Doses should be taken as close to 12 hours apart as possible, preferably at the same times every day. Tablets should be swallowed whole.
223793518|NCT06496893|DIETARY_SUPPLEMENT|IP 1200 mg per soft gel capsule|Two soft gels to be taken with breakfast and two soft gels to be taken with dinner
223793519|NCT06496893|DIETARY_SUPPLEMENT|Placebo Comparator: Placebo 1200 mg per soft gel capsule|Two soft gels to be taken with breakfast and two soft gels to be taken with dinner
223793520|NCT03581721|DEVICE|enFlow® IV fluid warmer and from July 2019 Fluido®Compact IV fluid warmer|"The fluid warmer will be set up by an external co-investigator in every patient included in the study. It will be turned on in patients belonging to the warming group, and turned off in the control group"
223793521|NCT03351374|OTHER|Software|multi-module system of web software tools
223793522|NCT00153777|DRUG|Cellulose Sulfate gel (6%)|
223793523|NCT05903001|DIAGNOSTIC_TEST|Diaphragm Ultrasound|Ultrasound of the Diaphragm at the end of inspiration and expiration
223793524|NCT05903001|DIAGNOSTIC_TEST|Intercostal Muscle Ultrasound|Ultrasound of the Intercostal Muscles at the end of inspiration and expiration
223793525|NCT05903001|DIAGNOSTIC_TEST|Borg scale|Questionnaire for Perceived Exertion (Borg Rating of Perceived Exertion Scale)
223793526|NCT05903001|DIAGNOSTIC_TEST|MRC Breathlessness Scale|The MRC Dyspnoea Scale allows the patients to indicate the extent to which their breathlessness affects their mobility.
223793527|NCT05903001|DIAGNOSTIC_TEST|Respiratory Questionaire|Specialized respiratory questionnaire with different domains (Emotional Domain, Dyspnea Domain, Mastery Domain, Fatigue Domain)
223793528|NCT05903001|DIAGNOSTIC_TEST|GINA classification of Asthma|Patients are classified according to the GINA classification of Asthma.
223793529|NCT05903001|DIAGNOSTIC_TEST|Measurement of respiratory mouth pressure|Inspiratory and expiratory Measurement of respiratory mouth pressure
223793530|NCT05903001|DIAGNOSTIC_TEST|SNIP|Measurement of Sniff Nasal Inspiratory Pressure
223793531|NCT05903001|DIAGNOSTIC_TEST|6-minute walking distance|The maximum walking distance achieved in 6 minutes
223793532|NCT05903001|DIAGNOSTIC_TEST|60 seconds sit-to-stand test|number of repetitions achieved in sitting down and standing up in 60 seconds
223793533|NCT05903001|DIAGNOSTIC_TEST|Electromyography|electromyography of the muscles of respiration via superficial electrodes
223793534|NCT05903001|DIAGNOSTIC_TEST|Lung Function|Measurement of lung function via body plethysmography
223793535|NCT05903001|DIAGNOSTIC_TEST|CAT-Questionnaire|COPD Assessment Test (CAT)
223793536|NCT05903001|DIAGNOSTIC_TEST|European Society of Cardiology (ESC)/ European Respiratory Society (ERS) risk group|Patients with pulmonary hypertension are classified according to the ESC/ERS risk group.
223793537|NCT01542918|DRUG|Lenalidomide|"Formulation of Dosage forms: 5 mg, 10 mg, 15 mg and 25 mg capsules.~Dosage: 10 mg - 30 mg (Treatment 1 and Treatment 2)~Route of administration: Oral"
223793538|NCT01542918|DRUG|Rituximab|"Formulation of Dosage forms: 100 mg/IO mL and 500 mg/50 mL solution in a single-use vial~Dosage: 375 mg/m2, intravenous (Treatment 2, Cycle 1 only); 25 mg intraventricular injection (Treatment 2, all cycles)~Route of administration: Intravenous (Treatment 2, Cycle 1 only); Intraventricular injection (Treatment 2, all cycles)"
223793539|NCT03731689|DRUG|Intrauterine lavage therapy|Intrauterine lavage treatment was performed within 3 to 7 days after the first menstrual period after surgery.
223793540|NCT03731689|DRUG|Intrauterine gel-injection therapy|Intrauterine gel-injection treatment was performed within 3 to 7 days after the first menstrual period after surgery.
223793541|NCT01293448|DEVICE|Cryoballoon Ablation|"Device: CryoBalloon Ablation System(TM) C2 Therapeutics Inc. received FDA market clearance for the CryoBalloon Ablation System on September 29, 2010. The System is a Class II device intended to be used as a cryosurgical tool for the destruction of unwanted tissue in the field of general surgery, specifically for endoscopic applications. (K101825)"
223793542|NCT05947877|PROCEDURE|Non-pharmacological pain management strategies|Non-pharmacological pain management strategies
223793543|NCT03232970|OTHER|Full Plate Diet|12 weekly sessions on how to incorporate more fiber in the diet.
223793544|NCT04458948|DRUG|Hydroxychloroquine|Hydroxychloroquine 400 mg BID, on day 1 and then 200 mg BID day 2 through 7 IV or po for 5 days. If the condition of the patient does not allow for oral therapy, HCQ can be given via a feeding or NG tube. Azithromycin can be given intravenously.
223793545|NCT04458948|DRUG|Azithromycin|Azithromycin 500 mg, IV or po for 5 days
223793546|NCT02087163|DEVICE|Movement Enhancement Technique|Conventional Orthodontic treatment
223793547|NCT02087163|DEVICE|Clear Aligner|Orthodontic treatment with Clear Aligner
223793548|NCT00519181|DRUG|Valproic Acid|Valproic acid by oral route (20mg/Kg/day) during one year.
223793549|NCT02405520|BIOLOGICAL|low dosage HPV Vaccine|Participants would intramuscularly receive low dosage of HPV 6/11 bivalent vaccine at 0, 1, 6 month for 3 doses.
223793550|NCT02405520|BIOLOGICAL|medium dosage HPV Vaccine|Participants would intramuscularly receive medium dosage of HPV 6/11 bivalent vaccine at 0, 1, 6 month for 3 doses.
223793551|NCT02405520|BIOLOGICAL|high dosage HPV Vaccine|Participants would intramuscularly receive high dosage of HPV 6/11 bivalent vaccine at 0, 1, 6 month for 3 doses.
223793552|NCT02405520|BIOLOGICAL|Aluminium Adjuvant|Participants would intramuscularly receive aluminium adjuvant at 0, 1, 6 month for 3 doses.
223793553|NCT01567618|DRUG|Docetaxel|"Docetaxel 50mg/m2 iv drip, repeat every two weeks;~Efficacy will be evaluated every three cycles."
223793554|NCT01567618|DRUG|Fluorouracil|Fluorouracil 400mg/m2 iv D1; Fluorouracil 2400mg/m2 civ 46 hours; repeat fortnightly and evaluate every two cycles
223793555|NCT04163302|BIOLOGICAL|CD19-PD1-CART Cell|This study was a single-center, open-label, single-arm, non-randomized clinical trial, which has 3 groups by infusion dose level. Firstly, each dose group has 3 patients. The pretreatment regimen of cyclophosphamide (25mg/m2 for 3 consecutive days) and fludarabine (10mg/kg for 3 consecutive days) was given before CART cells were reinfused. CART cells were reinfused on the third day after the pretreatment. If no serious side effects emerges in the group, then the next group uses the subsequent higher dose. If serious side effects emerges in a single patients in any dose level, 3 more patients will be enrolled to the same dose level. After 9 or more patients, the investigators select the safest dose and recruit more patients for CART test to explore its effectiveness.
223793556|NCT01993069|BEHAVIORAL|Iyengar-based Yoga Training|6 weekly Iyengar-based yoga classes
223793557|NCT02797925|OTHER|Training|Long slow strength training of the tendon for 3 months to improve function
223793558|NCT03934398|DIAGNOSTIC_TEST|Cardiovascular Assessments|Participants will undergo the following cardiovascular assessments: 24-hour blood pressure monitoring, arterial stiffness measurements, endothelial function measurements.
223793559|NCT03934398|DIAGNOSTIC_TEST|Actigraphy|Participants will wear an actigraph device for 7 days to measure participant's activity and sleep.
223793560|NCT03934398|DIAGNOSTIC_TEST|Laboratory assessments|Participants will provide blood and urine samples for laboratory assessments.
223793561|NCT03934398|DIAGNOSTIC_TEST|Emotional/Behavioral Assessments|Participants and parents will fill out questionnaires for emotional/behavioral assessments
223793562|NCT04520984|OTHER|Integrated ambulatory palliative and nephrology care|"Monthly ambulatory care visits with the kidney palliative care team in the intervention group for three months.~The intervention in this study is addition of a palliative care team to the care team of the subject. This intervention will not change or impact their regular nephrology care. The subjects in the intervention arm will be seen by the palliative care team three times over the 12-week study period (once per month).The intervention will be delivered by a physician trained in both palliative care and nephrology, the PI of the study."
223793563|NCT04520984|OTHER|Standard nephrology care|Standard nephrology care
223793564|NCT01899846|DRUG|Hydroxyprogesterone caproate 250 mg/ml|
223793565|NCT03850769|DRUG|nab-paclitaxel and S-1|Nab-Paclitaxel: 120 mg/m2 d1, 8, S-1: Body surface area \< 1.25 m2, 80 mg/d; Body surface area ≥ 1.25 m2 \< 1.50 m2, 100 mg/d; Body surface area ≥1.5 m2, 120 mg/d; Bid, d1-14;
223793566|NCT03782155|DRUG|glutamine supplementation|powder 14g
223793567|NCT03782155|DRUG|HMB|powder 3g
223793568|NCT03782155|DRUG|Placebo|powder 17g
223793569|NCT01390454|PROCEDURE|Ultrasound of the elbow 1, days 7 to 15|The primary endpoint is evaluated a first time via an ultrasound exam.
223793570|NCT01390454|PROCEDURE|Ultrasound of the elbow 2, days 7 to 15|The primary endpoint is evaluated a second time by a second practitioner.
223793571|NCT01390454|PROCEDURE|Ultrasound of the elbow 3, days 45 to 90|A third ultrasound is performed only on tennis elbow patients between days 45 and 90.
223793572|NCT04325750|PROCEDURE|TECAR Therapy|The intervention will be performed with the T-Care TECAR® therapy machine at the latent trigger points of both gastrocnemius. The professional will apply the therapy with the generator that emits radio frequency signals of 0.5 MHz at a variable power with a maximum of 300W. The frequency to be used will be 500MHz with an intensity of 40% and with direct current.
223793573|NCT04325750|OTHER|Placebo|simulated TECAR Therapy (machine off)
223793574|NCT06535048|DRUG|Entecavir；Tenofovir Disoproxil Fumarate (TDF)； Tenofovir alafenamide fumarate (TAF)；Interferons|"Entecavir: Participants will receive Entecavir 0.5 mg orally once daily for the duration of the study.~Tenofovir Disoproxil Fumarate (TDF): Participants will receive TDF 300 mg orally once daily for the duration of the study.~Tenofovir alafenamide fumarate (TAF): Participants will receive TAF 25 mg orally once daily for the duration of the study.~Interferon (IFN): Participants will receive IFN 180 µg subcutaneously once weekly for at least 12 weeks."
223793575|NCT02576678|DRUG|Apremilast|
223793576|NCT03146624|OTHER|attachment retained obturator|obturator which retained by attachment
223793577|NCT03146624|OTHER|clasp retained obturator|obturator which retained by clasp
223793578|NCT03362905|DRUG|Lidocaine topical|Local anesthetic for reduction of IUD associated pain
223793579|NCT03545854|PROCEDURE|Erector Spinae Plane Block|Ultrasound guided injection of coloring solution (methylene blue diluted in water) with a 18G echogenic tuohy needle deep to the plane of the erector spinae muscles.
223793580|NCT01926756|PROCEDURE|Straight catheterization|Patient will receive the current standard practice of straight catheterization intraoperatively.
223793581|NCT01926756|PROCEDURE|No straight catheterization|Patients will not be catheterized which is an experimental change from the current practice at our hospital.
223793582|NCT03863340|BEHAVIORAL|interruptions of work tasks|"During each activity two interruptions/breaks were selected randomly from a set of ten predetermined actions:~Active break types:~* Move shoulder and upper back~* Swing arms near the body~* Three slow but forceful elevations of the shoulders, a relaxation exercise based on the principles developed by Jacobson~* Stand up and stretch~* Slowly turn head in all possible directions.~Passive break types:~* Tell a couple of jokes~* Stand up and have a drink~* Relaxing the trapezius~* Questions on actual posture and feelings of comfort / discomfort.~* A short rest on the couch"
223793583|NCT00687648|DRUG|anastrozole|Given as previously prescribed
223793584|NCT00687648|DRUG|cyclophosphamide|Given by mouth
223793585|NCT00687648|DRUG|exemestane|Given as previously prescribed
223793586|NCT00687648|DRUG|letrozole|Given as previously prescribed
223793587|NCT00687648|DRUG|methotrexate|Given by mouth
223793588|NCT00687648|DRUG|prednisolone|Given by mouth
223793589|NCT01158131|BEHAVIORAL|Balance after Baby Lifestyle Intervention Program|Participants in this intervention will receive support from a lifestyle coach and gain access to a website with online presentations that contain healthy eating and physical activity educational tips. Weekly phone conversations with the lifestyle coach, as well as logging diet and physical activity will also be required of intervention participants.
223793590|NCT02491671|DEVICE|Hemopatch|
223793591|NCT02491671|PROCEDURE|standard preventive measures|
223793592|NCT00682734|DRUG|metoclopramide|metoclopramide 20 mg
223793593|NCT00682734|DRUG|metoclopramide|metoclopramide 40 mg
223793594|NCT00682734|DRUG|metoclopramide|metoclopramide 10 mg
223793595|NCT00682734|DRUG|Diphenhydramine 25mg|Diphenhydramine 25mg, administered as an intravenous drip over 20 minutes
223793596|NCT03621644|RADIATION|Stereotactic MRI-guided On-table Adaptive Radiation Therapy|Radiation therapy will be delivered with an integrated magnetic resonance imaging (MRI)-guided radiotherapy delivery system (ViewRay MRIdian or MRIdian Linac). The prescribed dose will be 50 Gray (Gy) in 5 fractions. Stereotactic body radiotherapy (SBRT) fractions will be delivered at least twice per week, and with at least 18 hours between fractions. Each participant will be aligned in the treatment system with MRI image-guidance. On-table adaptive re-planning will be used when clinically indicated. In all patients, real-time MRI imaging will be used throughout treatment delivery to monitor the target location and control the radiation beam as necessary.
223793597|NCT02251990|DRUG|Grazoprevir/Elbasvir|FDC tablet containing 100 mg of grazoprevir and 50 mg of elbasvir taken q.d. by mouth for 12 weeks.
223793598|NCT02251990|DRUG|Placebo|Placebo tablet matching grazoprevir/elbasvir FDC tablet taken q.d. by mouth for 12 weeks.
223793599|NCT04290026|DRUG|metoclopramide versus granisetron|ِِِِAssessment of the effect of metoclopramide versus granisetron on gastric volume in patients undergoing caesarean section by us
223793600|NCT01614665|DRUG|Tacrolimus|Participants receive an initial total daily dose of tacrolimus depending on the type of organ transplant (heart = 0.075 mg/kg; liver/kidney = 0.3 mg/kg), to be given orally (or via nasogastric tube for liver transplant recipients) in 2 doses in the morning and the evening. The first dose is administered in the morning within days of skin closure (heart = 4 days; liver = 2 days; kidney = within 24 hours following reperfusion). Subsequent tacrolimus doses are taken orally twice a day in the morning and evening and are adjusted on the basis of clinical evidence of efficacy, occurrence of adverse events and observing the recommended whole blood trough level ranges (day 1 through 21 = 10 to 20 ng/mL; day 22 through 365 = 5 to 15 ng/mL).
223793601|NCT01614665|DRUG|Tacrolimus prolonged release|Participants receive an initial total daily dose of tacrolimus prolonged release depending on the type of organ transplant (heart = 0.075 mg/kg; liver/kidney = 0.3 mg/kg), to be given orally (or via nasogastric tube for liver transplant recipients) in 1 dose. The first dose is administered in the morning within days of skin closure (heart = 4 days; liver = 2 days; kidney = within 24 hours following reperfusion). Subsequent tacrolimus prolonged release doses are taken orally once a day in the morning and are adjusted on the basis of clinical evidence of efficacy, occurrence of adverse events and observing the recommended whole blood trough level ranges (day 1 through 21 = 10 to 20 ng/mL; day 22 through 365 = 5 to 15 ng/mL).
223793602|NCT02654626|DRUG|KBP-7072|Drug Intervention
223793603|NCT02654626|OTHER|Placebo|
223793604|NCT03392714|DRUG|R-B(O)AD|rituximab 375 mg/m2 on day 1; vincristine 1.4 mg/m2 on day 1, omitted in patients ≥70 years of age due to risk of neurotoxicity; bendamustine 75 mg/m2 over 1 h on days 2 and 3; cytarabine 1000 mg/m2 over 3 h on days 2-4; dexamethasone 20 mg on days 1-4, administered intravenously
223793605|NCT04166253|DRUG|Vitamin D|Alfacalcidol oral tablets once daily
223793606|NCT03265600|BEHAVIORAL|Mindfulness Training for Primary Care|MTPC is a referral-based, insurance-reimbursable 8-week program that can be delivered as group psychotherapy by Patient-Centered Medical Home-integrated behavioral clinicians or as an 8-week primary care group visit delivered by a primary care provider. MTPC groups are 2 hours long for 8 weeks with a 7-hour weekend day of silent practice. MTPC emphasizes mindfulness-oriented skills for self-regulation, self-management of chronic illness, and health behavior change. All participants complete an action planning protocol during Week 7.
223793607|NCT03265600|BEHAVIORAL|60-minute Introduction to Mindfulness|Participants in the low-dose comparator arm receive a 60-minute introduction to mindfulness. Participants are introduced to the definition(s) of mindfulness, brief mindfulness practices, discussion, and an orientation to an 8-week mindfulness group. They are also given a list of leading community, online, print, and smartphone mindfulness resources.
223793608|NCT02368249|DRUG|Terlipressin|Patients are receiving a post-operative intravenous terlipressin treatment in association with human albumin to preserve the renal function
223793609|NCT02368249|DRUG|Placebo|Patients are receiving a post-operative intravenous Ringer's lactate solution
223793610|NCT06454357|DRUG|B007|B007：high dose/low dose: Subcutaneous injection was administered on days 1 and 15
223793611|NCT01342874|DIETARY_SUPPLEMENT|Inositol|inositol exposure in early GDM
223793612|NCT00535730|BIOLOGICAL|Zoster Vaccine, Live, (Oka-Merck), ZOSTAVAX™|0.65 mL injection Zoster Vaccine, Live, (Oka-Merck) over 4 week vaccination period
223793613|NCT00535730|BIOLOGICAL|Comparator: placebo (concomitant-vaccine matched)|Pneumococcal Vaccine, Polyvalent (23-valent) 0.5 mL Placebo injection over 4 week vaccination period.
223793614|NCT00535730|BIOLOGICAL|Pneumococcal Vaccine, Polyvalent (23-valent), PNEUMOVAX™ 23|Pneumococcal Vaccine, Polyvalent (23-valent) 0.5 mL injection over 4 week vaccination period.
223793615|NCT03337529|OTHER|Vitamin C|200 mg Vitamin C will be given on daily basis for 8 weeks
223793616|NCT03337529|OTHER|Placebo|200 mg placebo will be given on daily basis for 8 weeks
223793617|NCT06443268|DIAGNOSTIC_TEST|questionnaire, hair samples, blood samples, clinical exam|The following parameters will be sequentially assessed in caregivers and patients (baseline, at 3 months and at 12 months): 1) quality of life / functioning will be determined through questionnaires (SF-36, EQ-5DL, ECOG (Eastern Cooperative Oncology Group) / Karnofsky, Barthel Index, ICIQ) 2) stress levels \& anxiety levels, caregiver burden will be assessed by the following questionnaires: Distress Thermometer, SBQ-G, GAD-7, PHQ-9, PSS-10, ZBI, PAC. Cortisol will be measured in hair to indicate stress within the past 3 months \[18\]. Fasting glucose, lipid profiles and HbA1c along with blood count, sodium, potassium, creatinine, TSH (thyroid-stimulating hormone) will be measured in routine blood samples from patients at the time of clinical checkups. Blood pressure, pulse and BMI will be determined during clinical visit in patients and additionally in caregivers.
223793618|NCT05767944|OTHER|local anaesthesia infiltration|Infiltration of 150 mg of lidocaine solution per ray at site of surgical incision for flexor tendon repair in the palm, the 2 proximal \& distal phalanges
223793619|NCT05767944|OTHER|brachial plexus block|ultrasound-guided infiltration of local aesthetics around brachial plexus trunks \& divisions
223793620|NCT03070613|DRUG|Fluorescent Lectin Application|Fluorescein conjugated wisteria floribunda (a lectin).
223793621|NCT04330638|OTHER|Usual Care|Usual Care
223793622|NCT04330638|DRUG|Anakinra|Anakinra will be given as a daily subcutaneous injection of 100 mg for 28 days or until hospital discharge, whichever is first
223793623|NCT04330638|DRUG|Siltuximab|Siltuximab will be given via single IV infusion at a dose of 11 mg/kg
223793624|NCT04330638|DRUG|Tocilizumab|Tocilizumab will be given via single IV infusion at a dose of 8 mg/kg with a maximum infusion of 800 mg/injection
223793625|NCT03575273|BEHAVIORAL|Sniffin' Sticks Odor Identification and Hedonic Scale|This task measures odor identification accuracy and perceived pleasantness of odors.
223793626|NCT03575273|BEHAVIORAL|Sucrose Taste Preference Assessment|This task measures participant ratings of sucrose preference.
223793627|NCT03575273|BEHAVIORAL|Food Preferences Task|Participants rate images of various food stimuli. Variables derived include relative preferences and reaction time (in milliseconds).
223793628|NCT03575273|BEHAVIORAL|Progressive Ratio (PR) Task|In the PR task, the subject is required to make an increasing number of operant responses for each successive reward
223793629|NCT03575273|PROCEDURE|Clinical Electrophysiology|To examine motivated attention in response to food stimuli, brain electrophysiology via event related potentials (ERPs) will be assessed while participants view and rate images of food and non-food items.
223793630|NCT03575273|DIETARY_SUPPLEMENT|Standardized Meal and Hunger and Satiety Ratings|Participants will receive a standardized meal and complete hunger and satiety ratings.
223793631|NCT04176627|DEVICE|Lung ultrasound|One-time lung ultrasound study completed on peritoneal dialysis patients at monthly clinic visit
223793632|NCT02218567|BEHAVIORAL|questionnaire qualilty of life|
223793633|NCT02218567|BEHAVIORAL|psychological interview|
223793634|NCT02218567|BEHAVIORAL|psychological tests|
223793635|NCT02218567|OTHER|Motor evaluation|
223793636|NCT02218567|BEHAVIORAL|Behavioral evaluation|
223793637|NCT02218567|BEHAVIORAL|cognitive tests|
223793638|NCT02698072|OTHER|Therapeutic exercise|20-25 minutes aerobic exercise, 20-25 minutes strength exercise and 10-15 minutes stretch exercise.
223793639|NCT02698072|DEVICE|Dry needling|Dry needling needle AGUPUNT®
223793640|NCT02698072|DEVICE|Sham dry needling|Sham dry needling DONGBANG-ACUPRIME®
223793641|NCT02293538|DRUG|FID 114657 eye drops (10 ml)|Lubricating eye drop for temporary relief of burning and irritation due to dryness of the eye
223793642|NCT02293538|DRUG|Saline control eye drops (15 ml)|Saline eye drops (15 ml)
223793643|NCT02293538|DEVICE|Habitual contact lenses|Commercially marketed biweekly or monthly replacement soft contact lenses as prescribed by eye care practitioner, brand and power
223793644|NCT03576157|OTHER|Kilkari|Kilkari is an outbound service that delivers weekly, time-appropriate audio messages about pregnancy, childbirth, and childcare directly to families on their mobile phones, starting from the second trimester of pregnancy until the child is one-year-old.
223793645|NCT04401384|DRUG|Diclectin|Diclectin (combination of 10 mg doxylamine and 10 mg pyridoxine hydrochloride in a delayed release tablet) During the first two days, patients will start with an initial oral dose of 2 tablets at bedtime. If the symptoms assessed on the second day are not relieved, 3 tablets will be administered on the third day (1 tablet in the morning and 2 tablets at bedtime). On the third day if the symptoms are still not relieved, another tablet will be added in the afternoon on the fourth day (1 tablet in the morning, 1 tablet in the afternoon and 2 tablets at bedtime). Therefore, the maximum assigned dosage of Diclectin or placebo tablets do not exceed 4 tablets per day. The treatment duration will lasts for 14 days.
223793646|NCT04401384|DRUG|Diclectin placebo|Diclectin placebo will be packed and tested by a commercial pharmacy supply company specifically for this study. It have the same appearance, size, batch, odor, and taste compared with Diclectin. During the first two days, patients will start with an initial oral dose of 2 tablets at bedtime. If the symptoms assessed on the second day are not relieved, 3 tablets will be administered on the third day (1 tablet in the morning and 2 tablets at bedtime). On the third day if the symptoms are still not relieved, another tablet will be added in the afternoon on the fourth day (1 tablet in the morning, 1 tablet in the afternoon and 2 tablets at bedtime). Therefore, the maximum assigned dosage of placebo tablets do not exceed 4 tablets per day. The treatment duration will lasts for 14 days.
223793647|NCT04401384|DEVICE|Active acupuncture|Participants will receive active acupuncture every day for 2 consecutive weeks, a total of 14 sessions. The needle will be left for 30 minutes. After de qi induced by acupuncture, the paired electrodes of the electroacupuncture device will be connected to the needle handle horizontally (except for PC6).
223793648|NCT04401384|DEVICE|Sham acupuncture|Blunt-tipped placebo needles will be used. Participants will receive sham acupuncture every day for 2 consecutive weeks, a total of 14 sessions. The needle will be left for 30 minutes. After de qi induced by acupuncture, the paired electrodes of the electroacupuncture device will be connected to the needle handle horizontally (except for PC6). Then, the paired electrodes of the electroacupuncture device will be connected to the needle handle horizontally (except for PC6).
223793649|NCT05172765|DEVICE|Transcutaneous Electrical Nerve Stimulation Device|Low-level, electrical stimulation of the outer ear (LLTS), using a transcutaneous electrical nerve stimulation (TENS) device.
223793650|NCT01566045|PROCEDURE|Core Needle TRUS Needle biopsy (Transrectal ultrasound)|Standard of care 12-core TRUS sextant needle biopsy of the medial and lateral margins of the right and left apex, mid-gland and base of the prostate
223793651|NCT01566045|PROCEDURE|Core Needle MRI/US image fusion guided needle biopsy|Directed prostate needle biopsies at MR-image identified targets in addition to the standard ultrasound 12-14 core biopsies
223793652|NCT05187676|DEVICE|Oxygen saturation measurement using the IPAM device|Skin oxygen saturation rate will be measured (%) using the non-contact optical device under evaluation called IPAM
223793653|NCT05187676|DEVICE|Transcutaneous oxygen partial pressure (TcPO2) using the PeriFlux6000 device|Skin TcPO2 will be measured (mmHg) using the reference device called PeriFlux6000
223793654|NCT01414387|PROCEDURE|Carotid filter|"Patients randomized to this group will receive filter devices to prevent cerebral embolization during carotid stenting, assessed by intraoperative transcranial Doppler and postoperative cerebral DW-MRI.~The filter used for this trial is the RX accunet embolic protection system manufactured by abbott."
223793655|NCT01414387|PROCEDURE|Carotid reversal of flow|On the flow reversal arm two type of devices will be used. The first is the Gore flow reversal system, manufactured by LW Gore and the second device is the IVANTEC MoMa Ultra Embolic protection device, manufatured by IVANTEC.
223793656|NCT03813940|BIOLOGICAL|HPV Vaccine,135μg/0.5ml|HPV vaccine (135μg/0.5ml) administered intramuscularly according to a 0, 1, 6 month vaccination schedule
223793657|NCT03813940|BIOLOGICAL|HPV Vaccine,270μg/1.0ml|HPV vaccine (270μg/1.0ml) administered intramuscularly according to a 0, 1, 6 month vaccination schedule
223793658|NCT02248298|DRUG|2h-AFL-PDT|AFL therapy was performed using a 2940-nm Er:YAG AFL (Joule; Sciton Inc., Palo Alto, CA, USA) at 300-550µm ablation depth, level 1 coagulation, 22% treatment density, and a single pulse. In the 3h-MAL-PDT group, the above mentioned procedures were not performed. Immediately after AFL treatment, an approximately 1-mm thick layer of MAL (Metvix, PhotoCure ASA, Oslo, Norway) was applied to the lesion and on 5 mm of surrounding normal tissue. The area was covered with an occlusive dressing (Tegaderm, 3M, St. Paul, MN, USA). After incubation for 2 hours, the dressing and cream were removed, and the area was cleansed with saline. The area was irradiated with a red light-emitting diode lamp (Aktilite CL 128; PhotoCure ASA, Oslo, Norway) with peak emission at 632 nm, placed 5 cm away from the skin surface and total light dose of 37 J/cm-2
223793659|NCT02248298|DRUG|3h-AFL-PDT|AFL therapy was performed using a 2940-nm Er:YAG AFL (Joule; Sciton Inc., Palo Alto, CA, USA) at 300-550µm ablation depth, level 1 coagulation, 22% treatment density, and a single pulse. In the 3h-MAL-PDT group, the above mentioned procedures were not performed. Immediately after AFL treatment, an approximately 1-mm thick layer of MAL (Metvix, PhotoCure ASA, Oslo, Norway) was applied to the lesion and on 5 mm of surrounding normal tissue. The area was covered with an occlusive dressing (Tegaderm, 3M, St. Paul, MN, USA). After incubation for 3 hours, the dressing and cream were removed, and the area was cleansed with saline. The area was irradiated with a red light-emitting diode lamp (Aktilite CL 128; PhotoCure ASA, Oslo, Norway) with peak emission at 632 nm, placed 5 cm away from the skin surface and total light dose of 37 J/cm-2
223793660|NCT02248298|DRUG|3hr-MAL-PDT|an approximately 1-mm thick layer of MAL (Metvix, PhotoCure ASA, Oslo, Norway) was applied to the lesion and on 5 mm of surrounding normal tissue. The area was covered with an occlusive dressing (Tegaderm, 3M, St. Paul, MN, USA). After incubation for 3 hours, the dressing and cream were removed, and the area was cleansed with saline. The area was irradiated with a red light-emitting diode lamp (Aktilite CL 128; PhotoCure ASA, Oslo, Norway) with peak emission at 632 nm, placed 5 cm away from the skin surface and total light dose of 37 J/cm-2.
223793661|NCT00322348|DRUG|Goserelin acetate|3.6 mg intramuscular depot injection given every 4 weeks
223793662|NCT00322348|DRUG|Goserelin acetate|10.8 mg intramuscular depot injection given every 12 weeks
223793663|NCT05315193|OTHER|Structured In-patient and Home plan|A patient education session and a protocol comprise of 3 days. It consists of three different levels having progressive activities. The in-patient protocol will start from the day of the procedure. Each level contains 2 to 6 tasks, performed in sets of 5-10 repetitions 3 times a day. Home plan: Walking 3 days a week starting from normal pace ((RPE: 8-9) for10 minutes and progressively increased intensity and duration over the period of 12 weeks (RPE: 13-14).
223793664|NCT05315193|OTHER|Conventional Therapy|"In-Patient: Wound care, Bed mobility:~AROMS (10 Reps\*3sets\*TD), Breathing Exercise (10 Reps\*3sets\*TD), Mobilization (Walk as per patient tolerance) Patient Education: To keep the heart healthy Diet Avoid strenuous exercise and lifting heavy objects Avoid valsalva manure, Quit smoking Lower cholesterol levels, Maintain a healthy weight Control other conditions, such as diabetes and high blood pressure Take medications as prescribed by your doctor Get regular exercise: Walking at a normal pace as per tolerance (RPE up to 10)"
223793665|NCT04588350|DEVICE|i-SEP autotransfusion system|Intraoperative recovery and washing of the processed blood by i-SEP autotransfusion system in surgeries where a bleeding is expected
223793666|NCT03816748|DEVICE|High flow nasal cannula, HFNC|The HFNC used in this study can supply more than 40-60 L/min of oxygen flow, which is many times higher than the traditional nasal cannula. In addition, HFNC provides heating and moisturizing functions, so the patients 'nasal and oropharyngeal cavities do not dry out. This way, the patients can wear HFNC continuously for many days. Furthermore, when the patients close their mouths, HFNC can create a PEEP of 6-8 cmH2O, which helps with lung expansion after chest surgeries and lowers the risk of pneumonia related to lung collapses.
223793667|NCT01417299|DIETARY_SUPPLEMENT|RPh201|Patients will receive 400 microliter s.c., of RPh201 twice a week for 3 months
223793668|NCT01417299|DIETARY_SUPPLEMENT|saline|Patients will receive 400 microliter s.c., of saline twice a week for 3 months
223793669|NCT00936858|DRUG|RAD001|
223793670|NCT03349450|BIOLOGICAL|DPX-Survivac|DPX-Survivac Priming dose of 0.5ml on Study days 7 and 28. DPX-Survivac Booster dose of 0.1ml on Study days 84, 140, 196, 252, 308, and 364.
223793671|NCT03349450|BIOLOGICAL|Pembrolizumab|Pembrolizumab 200mg administered intravenously every 3 weeks, commencing on study day 7 to a total of 18 infusions
223793672|NCT03349450|DRUG|Cyclophosphamide 50mg|Cyclophosphamide 50mg twice daily by mouth, administered 7 days on / 7 days off, stating at study day 0, until study day 384
223793673|NCT00303524|DRUG|Goserelin acetate|Injection 3.6 mg monthly
223793674|NCT00303524|DRUG|Goserelin acetate|injection 10.8 mg every 3 months
223793675|NCT01978613|DRUG|NNC0113-0987|Tablets for once-daily oral administration. Multiple doses with sequential dose increments over 10 weeks. The end-dose levels and the dose levels during the escalation regime may be adapted during trial conduct based on safety evaluations.
223793676|NCT01978613|DRUG|placebo|Tablets for one-daily oral administration.
223793677|NCT02106299|DEVICE|Regen sling|Subjects of this group were submitted to surgical treatment of stress urinary incontinence with a Regen sling (medprin).
223793678|NCT02106299|DEVICE|tension-free vaginal tape-obturator(TVT-O)|Subjects of this group were submitted to surgical treatment of stress urinary incontinence with a transobturator sling TVT-O™ (gynecare™, USA).
223793679|NCT06470854|DRUG|Nebulized Dexmedetomidine|Nebulized Dexmedetomidine was prepared to provide 1 µg/kg and the calculated dose of DXM was diluted by 4-ml of 0.9% saline and was provided in the nebulizer to be nebulized in twice daily; i.e. every 12 hours for 72 hours
223793680|NCT06470854|PROCEDURE|Bilateral greater occipital nerve block|The injection solution was prepared by mixing 2-ml of 2% lidocaine with 2-ml (8 mg) of dexamethasone. A line was drawn extending between the mastoid process and the external occipital protuberance, this line was divided as a medial third and lateral two-thirds to localize the occipital artery and the greater occipital nerve was located on the medial side of the artery where it exits out of the trapezius fascia into the nuchal line about 5-cm lateral to midline and injection was performed bilaterally to achieve bilateral block.
223793681|NCT04321538|DEVICE|Gocheck Kids|GoCheck Kids is a photoscreening device. It takes a special picture of the eyes that allows for detection of refractive error and eye misalignment.
223793682|NCT04321538|DEVICE|Welch Allyn Spot Vision Screener|The Welch Allyn Spot Vision Screener is a photoscreening device. It takes a special picture of the eyes that allows for the detection of refractive error and eye misalignment.
223793683|NCT04321538|DIAGNOSTIC_TEST|Physical Exam|Retinoscopy and an oculomotor testing will constitute the physical examination.
223793684|NCT03974542|BEHAVIORAL|telephone outreach|The navigator should make at least five (5) attempts to reach the participants on different days (at least one (1) attempt in weekend) and different time slots (at least one (1) attempt each in am, pm and evening). If the navigator only reached voice mail after the 1-month intervention period, a standard script will be read and a contact number will be provided.
223793685|NCT01279499|DRUG|Sevoflurane|Intraoperatively Sevoflurane will be guided by a target end tidal concentration 1 - 2 MAC .Every rise of BP or HR \> 15% of baseline will be followed by a bolus SEVO inhalation 8% MAC for 2 minutes
223793686|NCT01279499|DRUG|Sevoflurane|Intraoperatively sevoflurane will be guided by a target BIS of 40 - 50. If a positive sympathetic response occured (an elevation of the HR and/or MAP greater than 15% above baseline) a bolus SEVO 8 MAC will be administered for 2 minutes.
223793687|NCT01279499|DRUG|Propofol- Remifentanyl|"Anaesthesia will be induced with a continuous IV Propofol infusion (21mg/kg TBW for 5 min, 12 mg/kg TBW for 10 min and then 6 mg/kg TBW), followed by an IV bolus of Remifentanyl (1 μg/kg IBW) and succinylcholine (1mg/kg IBW).General anesthesia will be maintained with continuous intravenous administration of Propofol at 150-300mcg/kg/min (doses based on ideal body weight).~Every rise of BP or HR \> 15% of baseline will be followed by a Remifentanyl bolus IV (1 μg/kg IBW) and increase in the continuous infusion rate of Remifentanyl from 0.1 to 1.0 μg/kg/min"
223793688|NCT01279499|DRUG|Propofol, Remifentanyl|"Anaesthesia will be induced with a continuous IV Propofol infusion (21mg/kg TBW for 5 min, 12 mg/kg TBW for 10 min and then 6 mg/kg TBW), followed by an IV bolus of Remifentanyl (1 μg/kg IBW) and succinylcholine (1mg/kg IBW). General anesthesia will be maintained with continuous intravenous administration of Propofol at 150-300mcg/kg/min (ideal body weight).~The depth of anesthesia will be adjusted so as to accomplish a BIS score between 40 and 50 Every rise of BP or HR \> 15% of baseline will be followed by a Remi bolus IV (1 μg/kg IBW) and increase in the continuous infusion rate of Remi from 0.1 to 1.0 μg/kg/min"
223793689|NCT03556462|OTHER|Sleep Health Education|Parents and children receive sleep health education
223793690|NCT04878562|BEHAVIORAL|I-COPE|The patient survey will be sent out via MyChart 3 days before the visit. It asks about current pain, goals, treatment history, treatment preferences, and health status. Alternatively, patients will be asked to compete a survey in clinic on paper or a tablet. The surveys will be identical, except screening for screening for depression and opioid use will depend on the availability of previous scores. Survey and the EHR will help auto-generate best practice advisories (BPAs) and a tailored smart set. The smartset is based on AGS and CDC guidelines for chronic pain and opioids. It shows which treatment options are not recommended based on the patient's history, comorbidities, and preferences. The smartset also includes links to decision aid and patient education tools. Personalized action plan will be created with pain rating and goal, treatment plan, and relevant tips and educational materials. Action plan will be clearly laid out using max 6 grade reading level, and simple graphics.
223793691|NCT01953081|DRUG|TD-8954|
223793692|NCT01953081|DRUG|Metoclopramide|
223793693|NCT00205283|DRUG|Nelfinavir|
223793694|NCT04208841|BEHAVIORAL|Person-Centered Care Quality Improvement Collaborative Sustain|Sustain improvements during QI collaborative focused on PCC
223793695|NCT04208841|BEHAVIORAL|Person-Centered Care Quality Improvement Collaborative Spread|Implement change package developed during QI Collaborative
223793696|NCT01840540|DRUG|Arterial infusion of autologous mesenchymal stem cells|
223793697|NCT03119324|DEVICE|B-Cure® diode laser|B-Cure laser® (Good Energies, Haifa, Israel) 808nm diode laser application in contact mode over painful area twice a day for 7 consecutive days
223793698|NCT03119324|DEVICE|B-Cure® diode laser sham device|B-Cure laser® (Good Energies, Haifa, Israel) application by sham device twice a day for 7 consecutive days
223793699|NCT03119324|DRUG|Nimesulide Ratiopharm® and Flexiban®|Five consecutive days assumption of Non Steroidal Anti Inflammatory drug, Nimesulide Ratiopharm® 50mg twice a day, followed by five consecutive days assumption of Myorelaxant, Flexiban®, 10mg once a day, followed by five consecutive days assumption of 50mg of Non Steroidal Anti Inflammatory drug, Nimesulide Ratiopharm®, twice a day
223793700|NCT01161316|DRUG|mFOLFOX-6 + cetuximab until disease progression or early withdrawal.|"Treatment regimen:~mFOLFOX-6, day 1, every two weeks; OXALIPLATIN 85 mg/m2; FOLINIC ACID 400 mg/m2; 5-FU 400 mg/m2 IV bolus; 5-FU 2400 mg/m2 continuous infusion for 46 hours~Cetuximab weekly. Cetuximab 400 mg/m2 the first time the treatment is administered; 250 mg/m2 for subsequent administrations."
223793701|NCT01161316|DRUG|8 cycles of mFOLFOX-6 + cetuximab, followed by cetuximab alone until disease progression or early withdrawal.|"Treatment regimen.~mFOLFOX-6. day 1 every two weeks. OXALIPLATIN 85 mg/m2; FOLINIC ACID 400 mg/m2; 5-FU 400 mg/m2 IV bolus; 5-FU 2400 mg/m2 continuous infusion for 46 hours~Cetuximab weekly. Cetuximab 400 mg/m2 the first time the treatment is administered; 250 mg/m2 for subsequent administrations."
223793702|NCT01355393|BIOLOGICAL|HER-2/neu peptide vaccine|Given ID
223793703|NCT01355393|BIOLOGICAL|sargramostim|Given ID
223793704|NCT01355393|DRUG|rintatolimod|Given ID
223793705|NCT03805724|OTHER|Plaque Samples|After carefully drying of the selected site and isolation by cotton roll, plaque samples will be collected by sweeping movement of the probe at gingival crevices of the tooth aspect with pervious inclusion criteria for obtaining of the plaque sample. Samples will be immediately dipped in sterile Eppendorf tubes containing PVA.
223793706|NCT01791933|DRUG|herbal medicine|120ml of Chuna herbal medicine(Ostericum koreanum, Eucommia ulmoides, Acanthopanax Sessiliflorus, Achyranthes bidentata, Psoralea corylifolia, Peucedanum japonicum, Cibotium barometz, Lycium chinense, Boschniakia rossica, and Cuscuta chinensis) taken twice a day 30 minutes after meals for more than 2 months
223793707|NCT01791933|PROCEDURE|Chuna manual therapy|A type of Korean spinal manual therapy administered 5\~10 minutes at physician's discretion 1-2times a week for more than 2 months Applies mobilization using High-Velocity, Low-Amplitude thrusts to joints slightly beyond the passive ROM and manual force within the passive ROM without thrusts.
223793708|NCT01791933|PROCEDURE|Acupuncture|Acupuncture using sterilized disposable needles, sized 0.30X40mm. Needles left for 15\~20 minutes, selecting 6 acupoints(both BL23, BL24, BL25 ) and other acupoints at physician's discretion, using a total of 10\~20 acupoints 1-2times a week for more than 2 months
223793709|NCT01791933|PROCEDURE|Bee-venom pharmacoacupuncture/pharmacoacupuncture|pharmacoacupuncture using 30G sterilized bee venom. Selecting 6 acupoints(both BL23, BL24, BL25) and other acupoints at physician's discretion, concentration 10,000:1, 0.1 cc per acupoint, total amount injected 1.0 cc/session 1-2times a week for more than 2 months
223793710|NCT05956301|DEVICE|Conventional Oxygen Therapy|Conventional Oxygen Therapy will be administered through Nasal catheter
223793711|NCT05956301|DEVICE|High-flow nasal oxygen|High Flow Nasal Cannula will be administered
223793712|NCT05956301|DEVICE|Supraglottic jet oxygenation and ventilation|Nasal jet tube will be administered
223793713|NCT03195192|OTHER|biomarker study|This is a biomarker study
223793714|NCT04262544|BEHAVIORAL|iCardia4HF|Participants in the intervention group will receive the following main components in addition to usual care: 1) the Heart Failure Health Storylines mobile app which supports daily self-monitoring and management of vital signs and symptoms; 2) three connected health devices (Fitbit activity tracker, Withings Cardio Body weight scale and blood pressure monitor), and 3) a program of tailored text-messages targeting health beliefs, self-efficacy, and HF-knowledge.
223793715|NCT04262544|OTHER|Usual Care|Participants assigned to the control group will receive usual care and the same connected health devices (Fitbit activity tracker, Withings weight scale and blood pressure monitor) as patients in the intervention group, but without the heart failure health storylines mobile app and text-messaging program. Usual care includes patient education before hospital discharge, and follow-up visits at the outpatient HF clinic a week after discharge and monthly thereafter depending on the patient's condition. Patient education includes literacy-sensitive, education material about HF self-care developed by the Sheps Center for Health Services Research,and a 40-minute education session with an APN and a dietician to review and discuss the education material provided to the patient.
223793716|NCT06475612|OTHER|Death|Mortality group.
223793717|NCT06475612|OTHER|Survival|Survival group.
223793718|NCT02846974|DEVICE|Pulse oximeter|A pulse oximeter will be used for calibration
223793719|NCT02305927|DIETARY_SUPPLEMENT|Vitamin D3 (cholecalciferol)|Supplements containing 3,000 IU vitamin D3 taken orally once per day by the mother starting from the second trimester until 12 months postpartum
223793720|NCT02305927|OTHER|Placebo|Placebo supplements taken orally once per day by the mother starting from the second trimester until 12 months postpartum
223793721|NCT00887497|PROCEDURE|Angioembolization|Angioembolization
223793722|NCT04395105|DRUG|High-Dose Dexamethasone|IV Dexamethasone administered once daily: 16 mg from day 1 to 5 and 8 mg from day 6 to 10
223793723|NCT06164717|BEHAVIORAL|Auditory feedback perturbation during speech|The intervention consists of manipulating real-time auditory feedback during speech production. In our lab, such feedback perturbations can be implemented with either a stand-alone digital vocal processor (a device commonly used by singers and the music industry) or with software-based signal processing routines (see Equipment section for details). Note that the study does not investigate the efficacy of these hardware or software methods to induce behavioral change in subjects' speech. Rather, the study addresses basic experimental questions regarding the general role of auditory feedback in the central nervous system's control of articulatory speech movements.
223793724|NCT06164717|BEHAVIORAL|Visual feedback perturbation during reaching|The intervention consists of manipulating real-time visual feedback during upper limb reaching movements. In our lab, such feedback perturbations can be implemented with a virtual reality display system.
224263985|NCT06678399|DRUG|KELI-101|KELI-101 consists of ex vivo expanded placental mesenchymal stromal cells (PMSCs) in a 10% cryopreservation solution.
223793725|NCT06164717|OTHER|DBS stimulation ON/OFF|"Patients who have been previously implanted with a DBS stimulator for their clinical care will be tested in two speech motor learning tasks with the stimulation ON and with the stimulation OFF.~Note that (1) patients routinely turn the stimulation OFF and back ON (examples are, for some patients, to sleep, to save battery, etc), and (2) we are not in any way evaluating the stimulator itself or its clinical effectiveness but only whether or not two forms of speech motor learning (adaptation to auditory feedback perturbation and speech sequence learning) are affected differently by having the stimulation ON or OFF.~implant ON/OFF prior to participation in the speech auditory-motor learning tasks and speech sequence learning tasks. This intervention can be implemented by the subject themselves as all patients have a hand- held controlled that they use to switch stimulation ON/OFF."
223793726|NCT00989287|BIOLOGICAL|GSK2340272A|Two intramuscular injections in the deltoid region of the non-dominant arm.
223793727|NCT00989287|BIOLOGICAL|GSK2340269A|Two intramuscular injections in the deltoid region of the non-dominant arm.
223793728|NCT02495051|PROCEDURE|esophageal biopsies|
223793729|NCT01746004|DRUG|[^14C]-LY2157299|\[\^14C\]-LY2157299 monohydrate administered as oral solution
223793730|NCT04949373|DEVICE|High-intensity laser therapy (HILT)|"High intensity laser therapy-Patients will receive pulsed laser treatment, using a HIRO 3 device (ASA Laser, Arcugnano, Italy), five times a week for a period of three weeks, and one session per day for a total of 15 sessions. A 3-phase treatment program will be performed on each session.~Other: Tendon and nerve gliding exercises will be performed three times a day with 10 repetitions each time for 3 weeks. Exercises will be performed by a trained physiotherapist.~Other: Rest splint(at night) Participants will be splinted in neutral position with standard cotton-polyester splints.The patients will be encouraged to use the splints during nighttime for 12 weeks."
223793731|NCT04949373|DEVICE|Sham High-intensity laser therapy (sham HILT)|"Sham high intensity laser therapy-Participants will receive pulsed laser treatment, using a HIRO 3 device (ASA Laser, Arcugnano, Italy), five times a week for a period of three weeks, and one session per day for a total of 15 sessions.~Other: Tendon and nerve gliding exercises will be performed three times a day with 10 repetitions each time for 3 weeks. Exercises will be performed by a trained physiotherapist.~Other: Rest splint(at night) Participants will be splinted in neutral position with standard cotton-polyester splints.The patients will be encouraged to use the splints during nighttime for 12 weeks."
223793732|NCT04250454|BEHAVIORAL|CONTRACT|"The intervention will consist of four elements:~1. Personal meeting - detailed information to the parents before the age of 15 weeks CA (1-3 days)~2. Home Activity Plan (HAP)~3. Home-based Feedback training~4. Electrical muscle stimulation~Combination of these elements has been chosen in order to ensure that optimal muscle growth is achieved through multi-modal stimulation of the motor and cognitive development of the child."
223793733|NCT00729833|DRUG|CP-751,871|CP-751,871 IV, every 3 weeks
223793734|NCT00729833|DRUG|Sunitinib|Sunitinib - daily dosing
223793735|NCT03451734|DRUG|antipsychotic medications|olanzapine, risperidone, aripiprazole, amisulpride, ziprasidone, and haloperidol groups
223793736|NCT03451734|DRUG|adjunctive group|antipsychotic plus placebo, antipsychotic plus sulforaphane(3 tables per day, consisting of 30 mg of SFN-glucosinolate per day), and antipsychotic plus minocycline(200mg per day) groups.
223793737|NCT03451734|DRUG|metformin and lifestyle intervention|different dose metformin combines lifestyle intervention
224263986|NCT06678399|OTHER|Vehicle (placebo)|Plasmalyte
224263987|NCT02845791|BEHAVIORAL|Interactive Lifestyle programme workshop|Participants will attend eight 90 minute sessions of an interactive lifestyle programme along with their parent(s)/guardian(s).
224263988|NCT05776901|DEVICE|C-STRESS|Participants were asked to use the C-STRESS app daily for 6 weeks to participate in Cognitively Based Compassion Training (CBCT) lessons, watch guided meditation videos, complete short reflective exercises, and engage with other content provided in C-STRESS (i.e., attending drop-in sessions, journaling, completing mood and wellbeing check-ins, and reading educational articles on depression, anxiety, and stress)
224263989|NCT05911919|DEVICE|brainQuant module of brainTale-care platform|brainQuant is a software module of brainTale-care medical device (a medical device software as a service (web platform) ) for the automatic processing of brain diffusion Magnetic resonance images and the provision of the diffusion regional standardised parameters.
224263990|NCT00917735|DRUG|Green tea extract supplement|Two green tea extract capsules twice daily after breakfast and dinner for one year
224263991|NCT00917735|OTHER|Placebo|Two placebo capsules twice daily after breakfast and dinner for one year
224263992|NCT04080999|DEVICE|r-TMS|The interventions have a total administration time of 75 minutes per day.For TMS stimulation, the coil will be positioned tangentially on the target area. Each r-TMS session will last 15 minutes and will be administered every other day (e.g. Monday-Wednesday-Friday, Monday-Wednesday-Friday, Monday). The visual scanning treatment involves the presence of a therapist, who administers various visual scanning tasks, used to increase patient's awareness and to teach strategies to improve spatial exploration abilities (Pizzamiglio et al.,1992).Trainings include three increasing levels of difficulty (9 possible combinations). Each level of difficulty will be exercised until the patient reaches a level of accuracy of 75%. The CCT will be carried out in 50 minutes sessions for 5 days a week within 15 days (11 sessions in total). On the days when the r-TMS is also administered, the administration of the CCT will immediately follow the brain stimulation.
223793738|NCT03102723|DRUG|Cangrelor|"1. Cangrelor treatment: IV Cangrelor as a single IV bolus (30 μg/kg) followed by an infusion (4 μg/kg/min) of at least 120 minutes duration or until PPCI procedure has ended (whichever is longer) - this will be initiated prior to PPCI. This dosing regimen is identical to that used in the CHAMPION trials.~   Or~2. Placebo control: IV normal saline as a single IV bolus followed by an infusion of at least 120 minutes duration or until PPCI procedure has ended (whichever is longer) - this will be initiated prior to PPCI."
223793739|NCT04513990|PROCEDURE|Biospecimen Collection|Undergo collection of nasopharyngeal, oral, saliva, and nasal samples
223793740|NCT04513990|OTHER|Questionnaire Administration|Demographic information, sample collection type preferences; clinical outcome information
223793741|NCT04762381|DRUG|Dexamethasone phosphate|24 mg dexamethasone infused peroperatively
223793742|NCT04762381|OTHER|Placebo|Saline
223793743|NCT02339961|RADIATION|Ultrasound radiation|Recording Doppler ultrasound noninvasively from the right chest wall
223793744|NCT04930068|OTHER|low caloric diet|A low-calorie diet is a structured eating plan that restricts daily caloric intake, commonly for weight loss. Following a low-calorie diet typically means consuming around 1,200 to 1,500 calories per day, which creates a calorie deficit that can lead to weight loss. A low-calorie diet can be effective, but it requires a lot of discipline to work and be safe.
223793745|NCT00349453|DRUG|Deferiprone (L1)|50-100 mg/kg body weight daily
223793746|NCT00349453|DRUG|Deferiprone (L1)|75 mg/kg body weight daily
223793747|NCT00349453|DRUG|Desferrioxamine|35-50 mg/kg body weight on 2 or more days per week
223793748|NCT00097331|DRUG|SB683699|
223793749|NCT00417079|DRUG|cabazitaxel (XRP6258) (RPR116258)|25 mg/m\^2 administered by intravenous (IV) route over 1 hour on day 1 of each 21-day cycle
223793750|NCT00417079|DRUG|mitoxantrone|12 mg/m\^2 administered by intravenous (IV) route over 15-30 minutes on day 1 of each 21-day cycle
223793751|NCT00417079|DRUG|prednisone|10 mg daily administered by oral route
223793752|NCT04594161|DEVICE|Percutaneous Nephrostomy|A Percutaneous Nephrostomy will be placed in patients with obstructive urolithiasis
223793753|NCT04594161|DEVICE|Double J catheter|A Double J catheter will be placed in patients with obstructive urolithiasis
223793754|NCT00694603|DRUG|Cetuximab|Given intravenously once per week.
223793755|NCT00737165|BEHAVIORAL|Multimodal suicide prevention program|"A community intervention of multimodal suicide prevention program includes following components:~1. Building support networks for suicide prevention and mental health promotion in public health system~2. Primary prevention of suicide and suicide related behaviors~3. Secondary prevention of suicide and suicide related behaviors~4. Tertiary prevention; after care for suicide survivors~5. Suicide prevention targeting for people with substance/alcohol- related disorders , schizophrenia and other mental health disorders~6. Suicide prevention targeting for people with work-related problems"
223793756|NCT00737165|BEHAVIORAL|Suicide prevention program as usual|Usual suicide prevention program
223793757|NCT02002169|OTHER|Shower Technique Protocol|Video and educational pamphlets of the STP will be used to assist in training participants randomized to this intervention. The participant must successfully demonstrate the STP on a training mannequin and be deemed by the study coordinator as ready to independently and correctly perform it before proceeding.
223793758|NCT02002169|OTHER|Standard CVC Care|Nuanced differences may be present at participating units; however, the key components of the intervention are 1) HD nurse delivery of CVC care 2) chlorhexidine or povidone cleansing 3) dry gauze dressing 4) standardized frequency. For both STP and control arms, participants whose HD centre uses polysporin triple ointment as part of standard CVC care will continue to have it applied as per program policy.
223793759|NCT03602651|OTHER|Hamilton-anxiety scale (HAM-A)|Evolution of anxiety disorders is evaluated by the Hamilton-anxiety scale (HAM-A)
223793760|NCT01192438|PROCEDURE|Laser-based thermotherapy|MRI-guided transperineal placement of a laser probe into the prostate
223793761|NCT05234684|DRUG|Orelabrutinib + R-CHOP|The orelabrutinib is a white, round, uncoated tablet. The R-CHOP include rituximab, cyclophosphamide, doxorubicin, vincristine, and prednison.
223793762|NCT05234684|DRUG|Placebo + R-CHOP|The placebo is a white, round, uncoated tablet. The R-CHOP include rituximab, cyclophosphamide, doxorubicin, vincristine, and prednison.
223793763|NCT01862705|OTHER|Thoracic spine manipulation|TSM thrust or non-thrust
223793764|NCT01696487|DIETARY_SUPPLEMENT|High oral Fructose challenge (150g per day for 28 days)|
223793765|NCT04739501|PROCEDURE|TACE|Trans-arterial chemoembolization in patients with hepatocellular carcinoma
223793766|NCT03943030|OTHER|Pulmonary rehabilitation|The PR program will consist of supervised physical exercise sessions, which will be held 3 times a week for 8 weeks, and weekly educational sessions. Exercise sessions include aerobic exercise (30 min to 45 min) and lower limb and upper limb strength training, as well as warm-up and muscle stretching exercises after exercise. The exercise load will be individualized and determined from the patients' baseline tests, being increased progressively throughout the sessions. A baseline evaluation will be performed, which will be repeated after 9 weeks, including: clinical and laboratory parameters, endothelial function (FMD) and brachial ankle index (ABI) and exercise tests. Outcomes usually used in the assistance to evaluate PR will also be measured.
223793767|NCT00003038|DRUG|doxorubicin hydrochloride|
223793768|NCT00003038|DRUG|suramin|
223793769|NCT00331747|DRUG|Glatiramer acetate|
223793770|NCT01687257|DRUG|SOF|SOF 400 mg tablet administered orally once daily
223793771|NCT01687257|DRUG|RBV|RBV tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
223793772|NCT00969501|DRUG|EUFLEXXA|2.5 mL of EUFLEXXA (per injection) x 3 injections
223793773|NCT01280279|OTHER|education for behavioral modification|a systematized 30-minutes education program for behavioral modification (SBMP) by watching videos and discussion with a specialized continence nurse practitioner.
223793774|NCT00809887|DRUG|Micafungin lock therapy|
223793775|NCT05046184|DRUG|Ketamine Hydrochloride|Subjects with MDD will receive 2 weeks of twice-weekly 40-minutes long IV infusion of ketamine (0.5 mg/kg). Ketamine will be dissolved in 0.9% saline in a total volume of 100 mL and administered with an infusion pump at a constant rate.
223793776|NCT05046184|DRUG|Midazolam injection|Subjects with MDD will receive 2 weeks of twice-weekly 40-minutes long IV infusion of midazolam (0.02 mg/kg). Midazolam will be dissolved in 0.9% saline in a total volume of 100 mL and administered with an infusion pump at a constant rate.
223793777|NCT04403698|DRUG|Alendronate Effervescent Oral Tablet|At the earliest three months but no later than four months after the last denosumab injection, subjects will be randomized to effervescent alendronate administered for either 24 or 48 weeks
223793778|NCT04899349|DRUG|Alpelisib|Alpelisib (tablets) administered at 300mg orally once daily on a continuous dosing schedule starting on Cycle 1 Day 8 in a 28 days cycle.
223793779|NCT04899349|DRUG|Fulvestrant|Fulvestrant (prefilled syringe) 500mg administered intramuscularly at Cycle 1 Day 1 and 15 after randomization and then at Day 1 of each subsequent cycle during the randomized treatment phase.
223793780|NCT04899349|DRUG|Metformin XR|Metformin XR (tablets) administered at a starting dose of 500mg orally once daily on a continuous dosing schedule starting on Cycle 1 Day 1 in a 28 days cycle. Dose titration from 500 mg once a day to 2000 mg once a day.
223793781|NCT04899349|DRUG|Dapagliflozin + metformin XR|Dapagliflozin + metformin XR administered as a single tablet combination at a starting dose of 5 mg dapagliflozin + 500 mg metformin XR orally once daily on a continuous dosing schedule starting on Cycle 1 Day 1 in a 28 days cycle. Dose titration from 5 mg dapagliflozin + 500 mg metformin XR orally once daily to 10 mg dapagliflozin + 2000 mg metformin XR once daily
223793782|NCT04899349|DRUG|Dapagliflozin|Dapagliflozin (tablet) at a starting dose of 5mg orally once daily on a continuous dosing schedule starting on Cycle 1 Day 1 in a 28 days cycle. Dose titration from 5 mg to 10 mg once daily
223793783|NCT06961695|BEHAVIORAL|VR Mindfulness-Based Relaxation|"VR Mindfulness-Based Relaxation is a behavioral intervention that utilizes a VR application designed to reduce anxiety and promote relaxation. Participants in the experimental group will undergo a single VR session, scheduled on the day of hospital admission (one day prior to surgery).~The session lasts approximately 10 minutes and features an immersive beach environment combined with an audio-guided mindfulness exercise focused on breath awareness. Following the session, participants will engage in a brief, structured debriefing, during which they will reflect on what they felt, what they discovered, and how they can apply these insights during their hospital stay.~Participants will also be instructed to practice the 4-1-4 breathing technique three times per day during hospitalization. This technique involves inhaling for 4 seconds, holding the breath for 1 second, and exhaling for 4 seconds. It is intended to promote relaxation and support autonomic nervous system regulation."
223793784|NCT02808455|DRUG|(Treatment A)|Four 100-mg capsules of pacritinib administered as a single oral dose
223793785|NCT02808455|DRUG|(Treatment B)|A single 80-mg oral solution dose of pacritinib
223793786|NCT00679003|BEHAVIORAL|SLCBT|Social learning and cognitive behavioral therapy
223793787|NCT00679003|BEHAVIORAL|ES|Education and support (information about nutrition and gastrointestinal system)
223793788|NCT03273413|DRUG|Pravastatin|Anti-inflammatory, anti-oxidative stress, and anti-proliferative therapy
223793789|NCT03273413|DRUG|Placebo|Inactive tablet
223793790|NCT02672046|OTHER|Assessment at the Clinic of Sports Injuries|Assessment at the Clinic of Sports Injuries as well as a new algorithm (using patient-reported symptoms will be applied
223793791|NCT03989804|BEHAVIORAL|Targeted follow-up|2 phone calls and 1 e-mail delivered over 6-8 weeks after enrollment aiming to help and support members to get started using the fitness center and its services.
223793792|NCT05956119|DEVICE|dry needling + physiotherapy (standard/usual care)|same that arm descrption
223793793|NCT05956119|OTHER|sham dry needling + physiotherapy (standard/usual care)|same that arm description
223793794|NCT03671837|OTHER|Oxygen|15 L/min O2
223793795|NCT03671837|OTHER|Air|15 L/min air
223793796|NCT03336619|DRUG|Nitazoxanide|Nitazoxanide 600 mg administered orally twice daily for five days
223793797|NCT03336619|DRUG|Placebo|Placebo administered orally twice daily for five days
223793798|NCT01163370|DIETARY_SUPPLEMENT|creatine supplementation|20g/d for 7 days followed by 5g/d for 23 weeks
223793799|NCT01163370|OTHER|exercise training|resistance training twice a week for 24 weeks
223793800|NCT01163370|OTHER|placebo (dextrose)|20g/d for 7 days followed by 5g/d for 23 weeks
223793801|NCT06021301|OTHER|Platelet-Rich Fibrin and Microneedling|First, MN will be done in the required area with insulin syringe gauge 30,The interdental papilla will vertically and horizontally measured in mm. By establishing a ratio and proportion, the number of microchannels in the region to be treated will calculated to be 250 microchannels per square cm Then, a venous blood sample will be taken for each patient using a 10-ml injector into i-PRF tube containing no anticoagulant and centrifuged at room temperature for 3 min at 700 rpm (60 g force). The 30-gauge dental injector needles will be used for injection of i-PRF. The needle will be inserted at 45° angle, 2-3-mm apical to the involved papilla and all surrounding areas will receive iPRF. Each involved papilla will be injected with an amount till blanching is visible . This method will be repeated for 4 times at 10 days intervals consecutively.
223793802|NCT04092374|PROCEDURE|Locking compression plates|Fixation of sternal fracture using locking compression mechanism
223793803|NCT02820623|BEHAVIORAL|Self-report|
223793804|NCT02820623|BEHAVIORAL|Chart-Stimulated Recall|
223793805|NCT02820623|BEHAVIORAL|Behavioral Rehearsal|
223793806|NCT06533943|OTHER|Exercise program|Each intervention session is divided into three different parts according to the specific aim such as warm-up (about 15 minutes) at the beginning, main exercises (about 30 minutes), and stretching and relaxation (about 15 minutes) at the end.
223793807|NCT06562569|DEVICE|non-invasive cervical vagal nerve stimulation ncVNS|The ncVNS device is a rechargable, handheld device that generate a proprietary frequency-modulated electrical stimulus at low voltage (max 24V) with a max current output of 60mA. The signal consists of 1ms bursts of 5kHz sine waves repeated at 25Hz. Two stainless steel contact surfaces coated with conductive gel deliver the stimulus to the neck in the vicinity of the vagus nerve.
223793808|NCT06490146|OTHER|No intervention|this is an observational study
223793809|NCT06147102|PROCEDURE|Surgery|Surgical treatment for the unruptured intracranial aneurysm
223793810|NCT06147102|PROCEDURE|Endovascular|Endovascular treatment for the unruptured intracranial aneurysm
223793811|NCT06124625|PROCEDURE|Rehabilitation combined to a digital maintenance program|Individuals in this group undergo a 3-week inpatient rehabilitation program followed by a 12-week maintenance program (2 sessions per week à 90 minutes, digital and live). The multimodal programs consist of physiotherapy, training therapy, medical support, cognitive training, education and psychological support.
223793812|NCT06124625|PROCEDURE|Rehabilitation without maintenance program|Individuals in this group undergo a 3-week inpatient rehabilitation program followed by a 12-week usual care period.
223793813|NCT03956498|OTHER|Patients with cervix or vaginal cancer treated by radiotherapy and brachytherapy|"* Nurse-led sexological consultations, beginning before brachytherapy and until 2 months after brachytherapy.~* Questionnaires to be completed by the patient before brachytherapy, 2 months after the end of brachytherapy and 1 year after the end of brachytherapy : Female Sexual Function Index (FSFI), Quality of Life Questionnaire-Core 30 (QLQ-C30), and Quality-of-Life questionnaire cervical cancer module QLQ-CX24."
223793814|NCT04584372|DIETARY_SUPPLEMENT|High-nitrate intervention|The 2×70 mL of nitrate-rich (i.e., 'high nitrate') beetroot juice contains 12.9 mmol nitrate (NO3-).
223793815|NCT04584372|DIETARY_SUPPLEMENT|Low-nitrate intervention|The 2×70 mL of nitrate-depleted (i.e., 'low nitrate') beetroot juice contains 0.04 mmol (or less) nitrate.
223793816|NCT01468402|PROCEDURE|Magnetic Resonance Image|The leiomyomas were evaluated individually. MR was used to evaluate morphology: the radiological dimension(s) of the leiomyoma and uterus and the volume. The number of leiomyoma fibroids was determined, and their location in the myometrium. Perfusion and the characterization of the T2 signal were also evaluated.
223793817|NCT05515432|DRUG|Single oral dose of BAY3283142 IR (immediate release) tablet|Single oral dose of BAY3283142 in participants with renal impairment compared to an age, gender and weight matched control group in an open-label study design
223793818|NCT01965834|DRUG|Fenofibrate|Upon screening, registration and enrollment, all subjects will receive Fenofibrate 160 mg orally daily for at least 2 months and may continue receiving study medication for as long as in the opinion of the investigator there is clinical benefit in doing so. Patients with calculated creatinine clearance \< 50 mL/min will receive a reduced dose of 54 mg orally daily.
223793819|NCT04936022|OTHER|Isometric Exercise|Prescribed 6 months of isometric exercise training (three sessions per week, comprised of 4 x 2-minute bouts with 2-minute recovery periods in-between).
223793820|NCT04936022|BEHAVIORAL|Standard care lifestyle advice|Healthy lifestyle advice for hypertension, given by a healthcare professional.
223793821|NCT00345774|DRUG|PRX-08066|
223793822|NCT02863640|DEVICE|Color retinography|
223793823|NCT02863640|DEVICE|Optical coherence tomography|
223793824|NCT02863640|DEVICE|Fundus autofluorescence imaging|
223793825|NCT02858739|DEVICE|BIOFREEDOM STENT|
223793826|NCT00008853|BIOLOGICAL|GBS III-TT-SSI|
223793827|NCT00008853|BIOLOGICAL|GBS III-TT-MPHL|
223793828|NCT05282524|DEVICE|Transvaginal ultrasound performed by a woman herself (with remote healthcare professional supervision)|Imaging performed by woman on herself with remote healthcare professional (HCP) supervision. The ultrasound device used is cleared for HCP-supervised use in environments where healthcare is provided by trained HCPs. No changes to the design or manufacture have been made for this study.
223793829|NCT02612402|DEVICE|messages generated by learning algorithm|THIS INTERVENTION HAS BEEN INCLUDED IN THE LEARNING ALGORITHM ARM The app measures physical activity by the phone accelerometer and sends SMS messages to encourage activity. An automatic learning algorithm for encouraging physical activity learns the patterns of response for each patient and chooses the best messages for the patient to encourage activity.
223793830|NCT02612402|DEVICE|constant weekly message reminding patient to exercise|THIS INTERVENTION HAS BEEN INCLUDED IN THE CONTROL ARM The app measures physical activity by the phone accelerometer and sends a constant SMS messages to remind the patient to exercise.
223793831|NCT01735123|DIETARY_SUPPLEMENT|dietary intervention|hydrolyzed vs. nonhydrolyzed infant formula
223793832|NCT03483636|DRUG|Lemborexant|Film-coated oral tablet
223793833|NCT03483636|DRUG|Alcohol|0.6 g/kg (female) or 0.7 g/kg (male) of 40% ethanol (volume per volume) vodka diluted in a low-calorie beverage (e.g., cranberry beverage), for a total volume of 300 mL (approximately 150 mL per aliquot).
223793834|NCT03483636|DRUG|Placebo|Film-coated oral tablet
223793835|NCT03729219|BIOLOGICAL|E. coli ETVAX|Oral suspension Sterile water is added to dmLT . Vaccine is poured to the effervescent solution and needed amount of dmLT is added.
223793836|NCT03729219|OTHER|Placebo|Oral suspension
223793837|NCT02488434|DEVICE|fertile chip|a new method for sperm selection on ivf cycles by using microchannel system.
223793838|NCT04587440|OTHER|Pelvic inclination measurement|Ultra-sound based measurements of the pelvic inclination lying, standing and seating position. EOX X-ray in seating position.
223793839|NCT02239783|DEVICE|total hip arthroplasty implant|
223793840|NCT02205944|OTHER|Progressive Handgrip Exercise|"Group 1 (Normal Exercise Group): Daily, at home for 20 minutes using an adjustable handgrip trainer up to 8 weeks prior to a scheduled surgery for fistula creation. The exercise intensity is tailored using the Borg CR100 scale (Borg \& Borg, 2001).~Group 2 (Restricted Blood Flow Exercise Group): Same as the exercise performed by Group 1 with controlled tourniquet."
223793841|NCT04775446|OTHER|Data collection|Data entered in a secure computer database
223793842|NCT03985618|PROCEDURE|Caesarean section|Planned pre-labour Caesarean section at 38-40 weeks. For patients planning Caesarean Section, surgical planning, precise timing and method of Caesarean section is at the discretion of the most responsible care provider, as per local procedures.
223793843|NCT03985618|PROCEDURE|Induction of Labour|Planned induction of labour at 38-40 weeks. For patients planning induction of labour, precise timing and method of induction of labour is at the discretion of the most responsible care provider, as per local procedures.
223793844|NCT00006154|DRUG|Indinavir sulfate|400 mg tablets equaling 1600 mg daily
223793845|NCT00006154|DRUG|Ritonavir|100 mg liquid capsules equaling 400 mg daily
223793846|NCT00006154|DRUG|Abacavir sulfate|300 mg capsules equaling 600 mg daily. Administration based on individual results after 16 weeks.
223793847|NCT00006154|DRUG|Efavirenz|200 mg capsules equaling 600 mg daily
223793848|NCT00006154|DRUG|Stavudine|30-40 mg capsules equaling 60 or 80 mg daily
223793849|NCT00006154|DRUG|Didanosine|250-400 mg E.coated tablets equaling 250 or 400 mg daily
223793850|NCT00006154|DRUG|Aldesleukin|Subcutaneous injection equaling 15 x 10\^6 IU daily dose. Administration based on individual results after 16 weeks and randomization.
223793851|NCT03913585|BEHAVIORAL|Lifestyle intervention|Upon inclusion and consent all patients receive a questionnaire to estimate risk of disease and risk behavior. Information about lifestyle is systematically registered and collated with existing Electronic Patient Record (EPR) data and the patients risk of developing a lifestyle-related disease is estimated based on validated algorithms for risk of type-2 diabetes, cardiovascular disease and COPD (Stratification). All patients receive digital feedback including a personal health profile and targeted advice. Patients at high risk of lifestyle-related disease(s) are offered targeted prevention activities at the GP including a health examination and if needed a health dialog. Patients with health risk behavior are offered behavior counselling in the municipality and community health services, if necessary. Patients diagnosed with a lifestyle related disease and patients with a healthy lifestyle are not offered any further services.
223793852|NCT01432119|DEVICE|SIR-Spheres|100% full dose SIR-Spheres on Day 1 of Cycle 1. SIR-Spheres with yttrium-90 microspheres will be given through a catheter in a vein in the groin.
223793853|NCT01432119|DRUG|Cetuximab|Starting Dose: 200 mg/m2 by vein weekly. During Cycle 1, patients will receive cetuximab during Weeks 2-4. In Cycles 2 and beyond, patients will receive cetuximab weekly.
223793854|NCT01432119|DRUG|Erlotinib|Starting dose: 100 mg by mouth daily. Erlotinib will be given starting with Cycle 2 at 100 mg by mouth daily. If tolerated, the dose will be increased to 150 mg by mouth daily in Cycle 3.
223793855|NCT01432119|PROCEDURE|Break-Through Scan|"Nuclear medicine break-through scan performed within 29 days before receiving SIR-Spheres. The results of this test will be used to determine if a full or partial dose of SIR-Spheres with yttrium-90 microspheres will be delivered."
223793856|NCT05637138|DEVICE|tcpCO2 measure|Measurement of tcpCO2 by medical grade sensor: non-thermostatted, at 35°C, 38°C, 41°C and 44°C
223793857|NCT05637138|DEVICE|tcpO2 measure|Measurement of tcpO2 by medical grade sensor: non-thermostatted, at 35°C, 38°C, 41°C and 44°C
223793858|NCT05637138|DEVICE|measurement of tissue conductivity to CO2: KS|measurement of tissue conductivity to CO2: KS by CAPNOS sensor : non-thermostatted, at 35°C, 38°C, 41°C and 44°C
223793859|NCT05637138|DEVICE|measurement of microcirculation|measurement of microcirculation by CAPNOS sensor : non-thermostatted, at 35°C, 38°C, 41°C and 44°C
223793860|NCT03364205|BEHAVIORAL|solution-focused interview technique|This approach helps an individual make decisions about behavioral change, focusing particularly on his or her past achievements and looking forward to a time when the problems cease to exist.
223793861|NCT06025331|PROCEDURE|BIO-RSA|Bony increased offset-reversed shoulder arthroplasty(BIO-RSA) will be performed.
223793862|NCT06025331|PROCEDURE|RSA|Conventional reversed shoulder arthroplasty(RSA) will be performed.
223793863|NCT00001651|OTHER|[6,6-2H2]-glucose|\[6,6-2H2\]-glucose will be administered as a continuous IV infusion for one to five days.
223793864|NCT02599194|DRUG|18F-FSPG|Administered intravenously (IV)
223793865|NCT02599194|DRUG|18F-FDG|Administered intravenously (IV)
223793866|NCT01087008|DRUG|zoledronic acid|Zoledronic acid 4 mg every 4 weeks for a total of 12 treatments
223793867|NCT01087008|OTHER|No treatment control|Patients doesn't receive treatment
223793868|NCT05978765|DEVICE|Dry Cupping|treated by using dynamic cupping. Heating pad will be applied for 10 minutes as a base treatment then olive oil or petroleum jelly will be applied and a cup will be placed, a vacuum will be created by using vacuum pump then the cup will be moved to and fro or in figure of 8 for 5 minutes.
223793869|NCT05978765|OTHER|Myofascial Release|e treated by soft tissue myofascial release. Heating pad will be applied for 10 minutes as a base treatment,petroleum jelly will be applied to the area follow by soft tissue myofascial release technique for 5 minutes either criss cross, along the fiber or in figure of 8
223793870|NCT01182753|RADIATION|carbon ion therapy|"Arm A (carbon ion therapy):~Total dose to the PTV2 - 45 Gy E in 3 Gy E /d, 4 - 6 days a week, 15 fractions Total dose to the PTV1 - 60 Gy E ± 5%, further 4 - 6 fractions a 3 Gy E."
223793871|NCT01182753|RADIATION|proton therapy|"Arm B (proton therapy):~Total dose to the PTV2 - 50 to 56 Gy E in 2 Gy E /d, 4 - 6 days a week, 25 - 28 fractions Total dose to the PTV1 - 70 Gy E ± 5%, further 6 - 10 fractions a 2 Gy E."
223793872|NCT04158947|DRUG|Afatinib|"Dose-escalation Phase (Phase I) - Afatinib Dose-escalation will proceed on the basis of dose limiting toxicity (DLT) during Cycle 1 starting at 20 mg/day.~Dose level 1: 20 mg/day; Dose level 2: 30 mg/day; Dose level 3: 40 mg/day; Dose level 4: 50 mg/day.~Dose-evaluation Phase (Phase II) - Patients will receive the highest dose of Afatinib with T-DM1 found in Phase I as study therapy"
223793873|NCT04158947|DRUG|T-DM1|"Dose-escalation Phase (Phase I) - Trastuzumab emtansine (T-DM1) will be given at 3.6 mg/kg IV Day 1 every 21 days.~Dose-evaluation Phase (Phase II) - Trastuzumab emtansine (T-DM1) will be given at 3.6 mg/kg IV Day 1 every 21 days."
223793874|NCT01233791|DRUG|Vaginal Diazepam Suppository|10mg compounded vaginal suppository
223793875|NCT01233791|DRUG|Placebo Suppository|Patients will be asked to use one vaginal suppository every night for 28 days
223793876|NCT04604587|DRUG|1. amyloid PET；2. T807 PET|"1. Dynamic PET acquisition for 70 minutes will be acquired after injection of 10±5 mCi 11C-PiB~2. Dynamic PET imaging 3D acquisition will be acquired 80 minutes after injection of 10 mCi 18F-T807"
223793877|NCT03792113|PROCEDURE|Periodontal Flap Surgery|Periodontal access flap surgery will be performed in both test site followed by control site in each subject
223793878|NCT03792113|OTHER|Autologous fibrin glue|Autologous fibrin glue procured from the subject's own venous blood will be used to approximate periodontal flaps following access periodontal surgery
223793879|NCT03792113|OTHER|4-0 silk suture|Conventional 4-0 black silk suture will be used to approximate periodontal flaps following access flap surgery
223793880|NCT00744653|PROCEDURE|Electrochemotherapy|Electric pulses , duration 100 microseconds, about 400 V given at 5000 Hz. Drug used is Bleomycin.
223793881|NCT03334123|OTHER|Functional training and cycling|"First 8 weeks: patients will perform 20 minutes of functional training before their dialysis procedure. The exercise program will be run by kinesiologists, who will also teach patients how to perform exercises on their own at home. During intradialysis cycling 3 times weekly participants will cycle on adapted ergometer. Participants will start with 10 - 15 minutes of cycling and then gradually increase time and intensity up to 45 minutes of duration.~Second phase of 8 weeks: participants will no longer perform functional training before dialysis but will be motivated, monitored and advised to perform functional exercise at home on non-dialysis days for 20-30 minutes and continue with cycling sessions during the dialysis procedures three times weekly."
223793882|NCT03334123|OTHER|Cycling|"First 8 weeks: cycling on an adapted ergometer during dialysis; starting with 10 - 15 minutes of cycling and then gradually increasing time and intensity up to 45 minutes of duration.~Second 8 weeks: continue with cycling at the target duration and intensity during dialysis."
223793883|NCT06427785|DRUG|Remimazolam besylate|Thirty patients underwent elective lower extremity surgery receive spinal anesthesia, and then remimazolam besylate was given intravenously with an induction dose of 3mg/min. When the MOAA/S (Modified Observer's Assessment of Alertness/Sedation) score was ≤1, remimazolam besylate was maintained at 1mg/min for 24min, and finally stopped. Wavelet index, MOAA/S score, blood pressure, heart rate, respiratory rate, and pulse oxygen saturation were continuously monitored during the period.
223793884|NCT03826667|DEVICE|Polyetheretherketone (PEEK) Shoulder Suture Anchors|"PEEK Suture Anchors, which include:~* HEALICOIL™ PK Preloaded Suture Anchors~* BIORAPTOR™ 2.3 PK Suture Anchors/BIORAPTOR™ Curved 2.3 PK Suture Anchors~* BIORAPTOR™ Knotless Suture Anchors~* MULTIFIX™ S Ultra Knotless Fixation System~* FOOTPRINT™ Ultra PK Suture Anchors~* TWINFIX™ Ultra PK Suture Anchors/TWINFIX™ Ultra Preloaded and with Needles~* SPEEDSCREW™ Knotless Fixation System~* SpeedLock Knotless Fixation Device"
223793885|NCT01586143|DRUG|paracetamol|This is a clinical study that aims to investigate and compare the efficacy of transbuccal paracetamol 125 mg with that of paracetamol 1g administered intravenously in patients with acute pain of moderate intensity accepted to emergency room following a minor trauma of the lower limbs and/or superiors. To this end, several pain scoring will be performed using a visual analogue scale (VAS) at various times after drug administration.
223793886|NCT01586143|DRUG|Placebo|
223793887|NCT03047668|DIETARY_SUPPLEMENT|diet with/without supplementation|diet with/without supplementation with PUFAs
223793888|NCT00911872|DEVICE|collagen (EVOLENCE)|injectable collagen
223793889|NCT00617344|BIOLOGICAL|Tetravalent CYD Dengue Vaccine , 5555 formulation|A 0.5 mL dose, Subcutaneous at 0, 6, and 12 months, respectively.
223793890|NCT00617344|BIOLOGICAL|Tetravalent CYD Dengue Vaccine , 5553 formulation|A 0.5 mL dose, Subcutaneous at 0, 6, and 12 months, respectively
223793891|NCT00617344|BIOLOGICAL|Tetravalent CYD Dengue Vaccine, 4444 formulation|A 0.5 mL dose, Subcutaneous at 0, 6, and 12 months, respectively
223793892|NCT03386123|BEHAVIORAL|Cognitive Behaviour Therapy for Insomnia|Continuous maintenance of sleep diary, cognitive behaviour therapy, including cognitive restructuring, and behavioural change focusing on sleep restriction and safety behaviours.
223793893|NCT03386123|BEHAVIORAL|Standard Audiological Care|Maintenance of sleep diary at key times. Psycho-education, provision of bedside sound generator.
223793894|NCT03386123|BEHAVIORAL|Sleep Support Group|Maintenance of sleep diary at key times. Social support focused on tinnitus and sleep problems.
223793895|NCT02649868|PROCEDURE|Transarterial embolization (TAE)|Transarterial embolization
223793896|NCT02649868|DEVICE|LC Bead LUMI|LC Bead LUMI has been designed as a radiopaque version of the LC Bead
223793897|NCT04885023|OTHER|Hippotherapy|The hippotherapy program for 10 weeks
223793898|NCT05624658|COMBINATION_PRODUCT|Combined Lipid-lowering Therapy|the effect of high-dose combined lipid-lowering therapy (statins+ezetimibe vs statins+PCSK9 inhibitors) on the vulnerability characteristics of atherosclerotic plaques assessed using multimodal imaging (coronary artery computed tomography and optical coherence tomography), as well as biomarkers in patients with acute coronary syndrome for 52 weeks.
223793899|NCT01247129|PROCEDURE|Delay procedure of SIEA flap.|Ligating the deep inferior epigastric artery ipsilaterally to the planned raising of the SIEA flap 2 weeks prior to the reconstructive procedure.
223793900|NCT03977220|DRUG|Nab-paclitaxel combined with S-1|Nab-paclitaxel combined with S-1 treating diffuse type of stage Ⅲ gastric cancer as adjuvant setting
223793901|NCT01029223|DRUG|ivabradine|
223793902|NCT01029223|DRUG|metoprolol|
223793903|NCT01029223|DRUG|placebo|
223793904|NCT05652062|DEVICE|Prizvalve® system|Transcatheter valve-in-valve replacement
223793905|NCT01913418|DRUG|Suan-Zao-Ren Tang|SZRT is composed of five herb ingredients as follows: Semen Zizyphi Spinosae (Suanzaoren), Sclerotium Poriae Cocos (Fuling), Radix Ligustici Chuanxiong (Chuanxiong), Rhizoma Anemarrhena (Zhimu), and Radix Glycyrrhizae (Gancao).The SZRT granules were packed in aluminum foil packages and administered orally at a dose of 4 g, three times per day for four weeks.
223793906|NCT01913418|DRUG|Suan-Zao-Ren Tang placebo|The Suan-Zao-Ren Tang placebo granules are prepared with 4 g starch inside the same colored and sized foil packages.
223793907|NCT03784339|OTHER|Physiotherapy + education|Participants will take part in a 30 minute education session surrounding fear of movement and catastrophizing thoughts. They will then receive standard care, which will involve strength exercises and taping if needed.
223793908|NCT03784339|OTHER|Physiotherapy|Standard physiotherapy care
223793909|NCT01373528|DRUG|Budesonide irrigation|A budesonide (1 mg) in saline (240 mL) irrigation solution is applied to the sinonasal cavities twice daily. 120 mL of the solution is applied via irrigation in the AM, and 120 mL again in the PM.
223793910|NCT06015321|DRUG|Enzalutamide|enzalutamide 160 mg PO daily
223793911|NCT04706468|DRUG|TG-1000|Capsules taken orally
223793912|NCT05186623|DRUG|Vedolizumab, Ustekinumab, or Tofacitinib|Drug administration and prospective follow-up for evaluating response
223793913|NCT02048228|DRUG|genotyping guided therapy Ticagrelor, Clopidogrel|CYP2C19\*2 carriers will be given 90 mg ticagrelor twice daily, and non-carriers and patients in the standard treatment group will be given 75 mg clopidogrel daily.
223793914|NCT02048228|DRUG|standard therapy clopidogrel|All patients will be administrated with clopidogrel 75 mg daily for 5 consecutive days.
223793915|NCT01327326|DRUG|Naltrexone|Oral, 50 mg, 1 Time Dose
223793916|NCT01327326|DRUG|Placebo|Oral, 1 Time Dose
223793917|NCT00941330|DRUG|Exemestane|25 mg daily by mouth for 6 to 12 months.
223793918|NCT00941330|DRUG|Docetaxel|Docetaxel (75 mg/m²) into a vein once every 3 weeks for 6 cycles (6 times in about 24 weeks).
223793919|NCT00941330|DRUG|Cytoxan|Cytoxan (600 mg/m²) into a vein once every 3 weeks for 6 cycles (6 times in about 24 weeks).
223793920|NCT06397469|DEVICE|MediTrain|MediTrain is a tablet-based, meditation-inspired, cognitive training game aimed at improving self-regulation of internal attention and distractions. It was developed in collaboration with meditation thought-leader Jack Kornfield, and Zynga, a world-class video game company. It was created to make benefits of concentrative meditation more easily accessible to anyone, including complete novices. This is achieved by creating a game that yields quantifiable and attainable goals, provides feedback, and includes an adaptive algorithm to gradually increase difficulty as users improve.
223793921|NCT06397469|DEVICE|Worder|Worder was designed to enhance visual motor and visual spatial skills in individuals of all ages and cognitive abilities. Visual processing is required for all cognitive abilities that involve vision including attention, working memory, and task management. Worder's goal is to improve cognitive function more broadly by developing this critical skill underlying multiple abilities.
223793922|NCT04731649|BEHAVIORAL|Families Talking Together Plus (FTT +)|FTT + consists of three online intervention sessions of approximately 60-90 minutes each, that cover content from nine modules designed to teach parents effective communication skills, build parent-adolescent relationships, help parents develop successful monitoring strategies, and teach adolescents assertiveness, refusal skills, and how to use a condom correctly and every time.
223793923|NCT05400798|DEVICE|Adipose Derived Regenerative Cells|single injection of adipose-derived regenerative cells (ADRCs) into the partial-thickness rotator cuff tear
223793924|NCT05400798|DEVICE|Corticosteroid|a single corticosteroid injection into the associated subacromial space
223793925|NCT06266416|BEHAVIORAL|IMARA for Black Male Caregivers and Girls Empowerment|IMAGE is delivered by trained Black female facilitators to improve girls' SRH outcomes, prevention HIV/STIs, and reduce sexual violence. Over the two days, some components of the curriculum are delivered separately to male caregivers and girls, covering parallel content, and other sections are delivered jointly in a single group. The curriculum, extensively tailored for the target population and pilot tested, addresses Black girls' sexual development, risk for sexual violence, female anatomy, body positivity, HIV/STI knowledge and attitudes, and condom use. IMAGE is designed to strengthen bonds and communication between male caregivers and girls by encouraging perspective-taking (i.e., reverse role play) and conflict resolution.
223793926|NCT06266416|BEHAVIORAL|Time-matched control program|FUEL will engage Black male caregivers and girls to promote good nutrition, exercise, and informed consumer behavior. Topics include the impact of media on body image, evaluating nutritional labels to make healthy food choices, eating balanced meals, establishing regular exercise routines, and how families and communities can support healthy behavior. FUEL includes a brief video about HIV/AIDS and other STIs but otherwise does not otherwise address sexual health. Like IMAGE, FUEL is delivered in groups of 6-8 dyads over two workshop days (\~10 hours total) in one weekend. Parts of the curriculum are delivered separately to girls and male caregivers covering parallel content and other components are delivered jointly.
223793927|NCT06670352|DRUG|Placebo|QD or BID, 24-weeks fixed dose.
223793928|NCT06670352|DRUG|HSK39297 50mgBID|24-weeks fixed dose.
223793929|NCT06670352|DRUG|HSK39297 100mgBID|24-weeks fixed dose.
223793930|NCT06670352|DRUG|HSK39297 200mgQD|24-weeks fixed dose.
223793931|NCT06680674|OTHER|Routine care for people with diabetes, with or without obesity, in the hospital setting|Routine care for people with diabetes, with or without obesity, in the hospital setting, including routine pharmacological treatment for diabetes and obesity.
223793932|NCT04640051|PROCEDURE|LAAO|LAAO by use of 3D in silico simulation by FEops HEARTguide as part of the pre-procedural assessment and device size selection
223793933|NCT06632041|DIAGNOSTIC_TEST|Complete blood count|Study haemtological disturbances in neonates with necrotizing enterocolities
223793934|NCT06632041|OTHER|Complete blood count|Haemtological disturbances in neonates with necrotizing enterocolities
224263993|NCT04080999|DEVICE|SHAM|Device: SHAM Stimulation and Visual Scanning training. In the control group, the coil of the r-TMS will be positioned at 90° on the target area, thus no specific cortical modulation will be implemented (SHAM stimulation). For the SHAM group, the CCT protocol will be administered with the same modalities and time frame as detailed for the intervention group.
223793935|NCT07026942|BIOLOGICAL|Universal donor derived CD33 CAR-NK|Universal donor derived CD38KO CD33 CAR-NK manuctured on-site. The NK cells are derived from the peripheral blood of universal donors with desirable HLA/KIR types and CMV status, modified by CRISPR/Cas9 targeting the CD38 locus, using AAV6 vector to insert a CD33-targeted CAR gene into the CD38 locus, and expanded in number.
223793936|NCT06025526|OTHER|aktivplan|"The aktivplan digital intervention consists of a digital planning calendar for regular heart-healthy physical activity Towards the end of rehabilitation phase II, health professionals introduce aktivplan and plan a personalised physical activity plan together with their patients using shared decision-making. The physical activity plan is devised for the time after discharge from cardiac rehabilitation.~In the aktivplan smatphone app, the patient can view their personalised physical activity plan, check off completed activities, enter additional unplanned activities, and open short videos with exercise instructions.~Additional functions of aktivplan include patient-centered goal-setting, automated messages to the patient (motivational messages and reminders), and the possibility for health professionals to monitor all their patients' adherence to the physical activity plan and to contact individual patients directly via the app."
223793937|NCT06025526|OTHER|Usual care|Usual care (standard of care) according to international and national cardiac rehabilitation guidelines.
223793938|NCT04936282|DRUG|Grafalon|When Borderline lesions are present in protocol biopsy, administer Grafalon ® 6 mg/kg/day in a single day. Then continue with the normal treatment: Steroids (5 mg/day), tacrolimus (0.1 mg/kg/day) and mycophenolate (1000 mg/day).
223793939|NCT04936282|DRUG|Normal Treatment|When Borderline lesions are present in protocol biopsy, administer the normal treatment: Steroids (5 mg/day), tacrolimus (0.1 mg/kg/day) and mycophenolate (1000 mg/day)
223793940|NCT05467033|DRUG|Desmopressin|desmopressin 0,3ug/kg in 100ml 0,9% NaCl managed as intravenous infusion;
223793941|NCT05467033|DRUG|intravenous infusion NaCl|0,9% NaCl managed as intravenous infusion
223793942|NCT06695156|BEHAVIORAL|Meditation|The objective of this study is to assess the safety, feasibility, and effects of the practice of the Transcendental Meditation technique in adults with migraines. This study will involve 30 male and female participants recruited from migraine treatment facilities and migraine support groups in the US. The study will span three months, with all participants practicing Transcendental Meditation (TM) while continuing their usual lifestyle and medication regimen. Pre-data will be collected through symptom analysis, headache patterns, and evaluation questionnaires. All potential subjects will use a migraine App for 30 days prior to inclusion in the study, both as a means of assessing migraine status and of ability to adhere to study protocols during the study. In addition, all subjects will take the PHQ-9 to screen for levels of depression that might impair participation in the study. All the subjects will receive TM instruction, followed by bi-weekly
223793943|NCT07128134|DEVICE|Low Level Laser Therapy|"Although low-level laser therapy has been applied in cases of periodontitis, there are only a limited number of studies investigating its additional benefits in implants with peri-implantitis. This study aims to contribute to the literature on this subject.~In addition to surgical periodontal treatment, low-level laser therapy (LLLT) was applied three times (on the same day as the initial treatment, on the third day, and on the seventh day) to the implants in the test group diagnosed with peri-implantitis. The 940 nm indium gallium arsenide phosphor diode laser (Epic Biolase, Irvine, CA, USA) will be applied perpendicular to the periodontal pocket for 20 seconds at a fixed distance of 15 mm and a continuous wavelength (3.41 J/cm2 application with a 1.76 cm2 spot and 0.3 W average output)."
223793944|NCT07128134|PROCEDURE|Non-surgical Periodontal Treatment|Peri-implantitis diagnosis will be made in the control group, and non-surgical periodontal treatment of implants will be performed using titanium curettes (Hu-Friedy, Chicago, IL, USA).
223793945|NCT07127913|DEVICE|Device: Stimulation-ON|Active neurostimulation from the NeuroPace RNS® System triggered by a biomarker
223793946|NCT07127913|DEVICE|Device: Stimulation-OFF|No neurostimulation from the NeuroPace RNS® System
223793947|NCT07127913|DEVICE|Device: Stimulation -ON Active Control|Active neurostimulation from the NeuroPace RNS® System triggered with a fixed duty cycle
223793948|NCT07126717|DIETARY_SUPPLEMENT|Placebo|Food-grade maltodextrin
223793949|NCT07126717|DIETARY_SUPPLEMENT|Zynamite® S|Water-soluble mango leaf extract standardized to 60% of mangiferin
223793950|NCT06750588|DRUG|bacteriophage preparation|NTR-101 will be given orally to participants once daily for 7 days
223793951|NCT06750588|DRUG|Bacteriophage preparation|NTR-101 will be given orally to participants once daily for 7 days
223793952|NCT06750588|DRUG|bacteriophage preparation|NTR-101 will be given orally to participants twice daily for 7 days
223793953|NCT06750588|DRUG|bacteriophage preparation|NTR-101 will be given orally to participants three times daily for 7 days
223793954|NCT07059013|DEVICE|Chatbot|"The Chatbot will be designed using open-source conversational AI, such as GPT. The Chatbot will include three modules: individual strength, information, and Peer Networks.~1. Individual Strength Include eight positive psychology exercises: positive introduction, personal strengths, using strengths, three good things, gratitude letter/visit, hope and optimism, active/constructive responding, and savoring.~2. Information Include available healthcare services, parenting skills for children with ASD, the health information for ASD, the financial assistance provided by public and private funding, educational resources, and community resources.~3. Peer Networks Participants can share their experiences about adapting after their child's diagnosis and read others' sharing."
223793955|NCT07059117|OTHER|Hedonic mapping|During the first session, participants will be presented with risotto samples differing in MSG content and thus umami taste intensity, assigned based on Booth's method (Booth et al., 1983). Based on these individual ratings, umami taste intensities of the ad libitum test meals will be calculated per participant.
223793956|NCT07059117|OTHER|Ad libitum risotto test meal|During the ad libitum test meal, participants will be presented with 800 grams of risotto with either high-, low-, or optimum umami taste intensity.
223793957|NCT07126665|DRUG|MHB088C for Injection|Intravenous administration
223793958|NCT07126665|DRUG|MHB039A for Injection|Intravenous administration
223793959|NCT07127666|OTHER|Structured Agenda-Setting Tool|We are testing a novel clinical visit agenda-setting intervention developed through participatory research methods for the pediatric inpatient environment. This structured agenda-setting (SAS) intervention will be co-designed to include structured discussion topic areas with the option for patients (when appropriate) and their care partners to consider and indicate their priority topic areas and take notes before, during, and after a clinical visit.
223793960|NCT07126249|DRUG|pimicotinib capsules|pimicotinib capsules
223793961|NCT00506493|DEVICE|Cardioblate Surgical Ablation System|This investigation is a prospective, nonrandomized multicenter clinical trial evaluating the outcome of patients with AF requiring concomitant open heart surgery plus the Cardioblate Surgical Ablation System using the modified Maze III procedure. The trial population includes patients requiring valve replacements or repairs, atrial septal defect (ASD) repairs, patent foramen ovale (PFO) closure or coronary artery bypass grafts (CABG) procedures.
223793962|NCT00506493|PROCEDURE|Surgical RF Ablation|This investigation is a prospective, nonrandomized multicenter clinical trial evaluating the outcome of patients with AF requiring concomitant open heart surgery plus the Cardioblate Surgical Ablation System using the modified Maze III procedure. The trial population includes patients requiring valve replacements or repairs, atrial septal defect (ASD) repairs, patent foramen ovale (PFO) closure or coronary artery bypass grafts (CABG) procedures.
223793963|NCT06945718|PROCEDURE|beyond D2 regional lymph node dissection|dissect the lymph nodes outside the extent of D2 LN region.
223793964|NCT06953674|DRUG|Normal Saline (0.9% NaCl)|For the primary purpose of fluid therapy or resuscitation in the emergency room and during hospitalization. The interventions will be administered intravenously whenever isotonic intravenous fluid administration is ordered by the treating provider for fluid resuscitation and/or maintenance in the emergency room and during inpatient hospitalization. Assignment to the intervention arm will be adhered to from enrollment to discharge. The total volume, rate, initiation, cessation, and co-interventions will be left to the discretion of the treating provider. Adherence will be ensured by dual interventions at the level of pharmacy IV fluid supply and physician order. The fluids will be physically administered according to the standard intravenous procedures and those outlined in the manufacturer's instructions.
223793965|NCT06953674|DRUG|balanced crystalloid|For the primary purpose of fluid therapy or resuscitation in the emergency room and during hospitalization. The interventions will be administered intravenously whenever isotonic intravenous fluid administration is ordered by the treating provider for fluid resuscitation and/or maintenance in the emergency room and during inpatient hospitalization. Assignment to the intervention arm will be adhered to from enrollment to discharge. The total volume, rate, initiation, cessation, and co-interventions will be left to the discretion of the treating provider. Adherence will be ensured by dual interventions at the level of pharmacy IV fluid supply and physician order. The fluids will be physically administered according to the standard intravenous procedures and those outlined in the manufacturer's instructions.
223793966|NCT02097979|BEHAVIORAL|Glaucoma Educational Intervention|
223793967|NCT05009342|DEVICE|below-knee soft resin cast|Patients have soft resin boot between day 0 (inclusion visit) and day 21 (follow-up visit n°1)
223793968|NCT05009342|DEVICE|Below-knee rigid resin cast|Patients have rigid resin boot between day 0 (inclusion visit) and day 21 (follow-up visit n°1)
223793969|NCT03849274|COMBINATION_PRODUCT|Smart Scar Care Pad=Pressure Garment|Smart Scar Care Pad (SSCP) + conventional Pressure Garment in the management of HS in adult with total hip replacement (THR) and total knee replacement (TKR)
223793970|NCT03849274|DEVICE|Pressure Garment|Conventional Pressure Garment (PG) alone in the management of HS in adult with total hip replacement (THR) and total knee replacement (TKR)
223793971|NCT05981768|DRUG|Cytisinicline|film-coated oral tablets containing 3 mg cytisinicline
223793972|NCT00114868|DRUG|Vitamin A|
223793973|NCT01740674|OTHER|Electronic data collection|
223793974|NCT01704170|DEVICE|Kona Externally Focused Ultrasound Therapy|
223793975|NCT00493818|DRUG|GSK690693|
223793976|NCT04443023|DEVICE|chosen TAVI valve|chosen TAVI valve
223793977|NCT04461951|OTHER|Lifestyles (exposure)|no intervention
223793978|NCT01760239|BEHAVIORAL|Clinical Decision Support (CDS)|The Clinical Decision Support (CDS) tool will be activated when a BP is entered in the vital sign section of the EHR. The CDS tool includes six key features: (i) prompts regarding the need for height data to classify the BP by percentile (ii) prompts to repeat any BP that is ≥90% or ≥120/80 mm Hg (iii) classification of BPs by percentile, including classification of those in pre-HT, stage 1 HT and stage 2 HT range (iv) review of previous HT diagnoses and BPs in order to classify elevated BPs as incident (first or second elevated BP) or persistent (third or greater elevated BP) (v) tailored CDS based on HT category and previous diagnoses (vi) graphical representation of current and historical BP data by age and BP percentile.
223793979|NCT02414048|DRUG|Pimonidazole|Pimonidazole will be administered orally and will serve to demarcate the hypoxic areas in the tumour
223793980|NCT05800535|DRUG|Study of the adverse effects of long-term oncological treatments|Cognitive and muscular evaluation of patients who have received oncological treatments, away from the latest treatments to assess their impacts
223793981|NCT05800535|BEHAVIORAL|Study of the long-term side effects of oncological treatments on the anxiety-depressive and cognitive state of patients|Cognitive and anxiety-depressive evaluation of patients who have received oncological treatments, away from the latest treatments to assess their impacts
223793982|NCT02985866|DEVICE|Artificial Pancreas|Use of CTR at home for 3 months
223793983|NCT02985866|OTHER|Sensor Augmented Therapy|Use of personal pump with study CGM \& glucometer at home for 3 months
224263994|NCT03681587|OTHER|Control situation|"Standard breakfast usually offered monotonous control condition at the retirement home: the time of distribution, the duration of ingestion and the composition will be habitual. This meal and subsequent meals will be measured over 3 consecutive days with observation periods at breakfast time in order to identify the variables of pleasure, feasibility, commensality and conviviality in 2 situations: alone in the room or with others in the dining room."
223793984|NCT05134181|DRUG|sacroiliac joint injection|"Intervention will be done at complete aseptic conditions by ultrasound at frequency of 4-5 MHz patient in prone position. The ultrasound transducer will be oriented in a transverse orientation at the level of the sacral hiatus. Here the sacral cornuae are identified. Moving the transducer laterally from here, the lateral edge of the sacrum is now identified. This bony edge is~followed in a cephalad direction with the transducer maintained in a transverse orientation. A second bony contour, the ileum, is now identified. The cleft between both bony contours represented the sacroiliac joint. This will be found at 4.5 cm depth. Real-time imaging will be used to direct a 22G spinal needle into the SIJ, where 2% lidocaine and triamcinolone or methylprednisolone will be injected under direct vision.The needle will be removed, a sterile dressing will be applied"
223793985|NCT04886024|OTHER|Advanced Glycation End Products (AGEs)|Advanced Glycation End Products (AGEs) releated with energy metabolism, In this study, the possible relationship between the serum levels of Advanced Glycation End Products (AGEs) of endometriosis patients and the disease and its stage is evaluated.
223793986|NCT03081845|DIETARY_SUPPLEMENT|Oral consumption of milk A1 in study phase 1|Oral consumption of 250 ml of milk containing both A1 and A2 type beta casein 2 times per day after meal for 5 days in study phase 1.
223793987|NCT03081845|DIETARY_SUPPLEMENT|Oral consumption of milk A2 in study phase 1|Oral consumption of 250 ml of milk containing only A2 type beta casein 2 times per day after meal for 5 days in study phase 1.
223793988|NCT03081845|DIETARY_SUPPLEMENT|Oral consumption of milk A1 in study phase 2|Oral consumption of 250 ml of milk containing both A1 and A2 type beta casein 2 times per day after meal for 5 days in study phase 2.
223793989|NCT03081845|DIETARY_SUPPLEMENT|Oral consumption of milk A2 in study phase 2|Oral consumption of 250 ml of milk containing only A2 type beta casein 2 times per day after meal for 5 days in study phase 2.
223793990|NCT05380648|PROCEDURE|Total knee arthroplasty|Total knee arthroplasty surgery will be performed by different orthopedist.
223793991|NCT01189968|DRUG|Demcizumab|The 6 subjects in the first cohort will receive demcizumab 5 mg/kg once every 3 weeks; the 6 subjects in the subsequent cohort will be treated with 10 mg/kg once every 3 weeks; and the 6 subjects in the final cohort will be treated with 15 mg/kg once every 3 weeks. A Data Safety Monitoring Board (DSMB) will review the data for the 6 subjects in each dose cohort after the last subject in that cohort has been on study for 56 days and then decide whether it is safe to escalate to the next highest dose cohort. Once the dose-escalation portion of the study has been completed, 14 additional subjects will be treated at the highest dose level that the DSMB deems as safe.
223793992|NCT01384708|DRUG|proflavine|1-10 ml of proflavine (derived form dissolving 10mg proflavine hemisulfate USP in 100 ml sterile water)
223793993|NCT04274907|DRUG|Venetoclax|Tablet: Oral
223793994|NCT04274907|DRUG|Pembrolizumab|Intravenous (IV) Infusion
223793995|NCT00214357|BEHAVIORAL|Mindfulness-based stress reduction|
223793996|NCT01387880|DRUG|Everolimus|"Patients with KRAS mutant tumours are treated with cetuximab, everolimus and irinotecan as third line.~Patients with KRAS wildtype tumours that have progressed on therapy with cetuximab and irinotecan are treated with cetuximab, everolimus and Irinotecan."
223793997|NCT01387880|DRUG|Everolimus|1.66 mg per day up to 7½ mg per day
223793998|NCT03675022|DRUG|Dupilumab|The investigational drug is dupilumab, 300mg in 2ml solution for subcutaneous application. All Patients will receive dupilumab, 300mg, every two weeks (8 subcutaneous injections total).
223793999|NCT03709355|DRUG|Elpida®|Elpida® capsules, 20mg
223794000|NCT03709355|DRUG|Rifampin|Rifampin capsules, 150mg
223794001|NCT03709355|DRUG|Rifabutin|Rifabutin capsules, 150mg
223794002|NCT03709355|DRUG|Clarithromycin|Clarithromycin Film-coated tablets, 250mg
223794003|NCT03709355|DRUG|Omeprazole|Omeprazole Film-coated tablets 20mg
223794004|NCT03709355|DRUG|Atorvastatin|Atorvastatin Film-coated tablets, 80mg
223794005|NCT03709355|DRUG|Levonorgestrel+Ethinylestradiol|Levonorgestrel 150 μg + Ethinylestradiol 30 μg, Film-coated tablets
223794006|NCT01229761|DRUG|cotrimoxazole prophylaxis|100mg/20mg per day (or 2.5 mL of syrup from a 200mg/40mg per 5mL suspension) from 1-6 months, followed by 200mg/40mg per day (or 5 mL of syrup from a 200mg/40mg per 5 mL suspension) from 6 to 12 months
223794007|NCT01229761|DRUG|cotrimoxazole placebo|100mg/20mg per day (or 2.5 mL of syrup from a 200mg/40mg per 5mL suspension) from 1-6 months, followed by 200mg/40mg per day (or 5 mL of syrup from a 200mg/40mg per 5 mL suspension) from 6 to 12 months
223794008|NCT01229761|BEHAVIORAL|exclusive breastfeeding until 6 months of age|Breastfeeding for 6 months, followed by formula feeding for 6 month. Breastfeeding infants will be prophylaxed with maternal highly active antiretroviral therapy (HAART) (if available) or with infant nevirapine.
223794009|NCT01229761|BEHAVIORAL|breastfeeding for 12 months|Breastfeeding infants will be prophylaxed with maternal HAART (if available) or with infant nevirapine.
223794010|NCT00109291|DRUG|Placebo|
223794011|NCT00109291|DRUG|peginesatide|
223794012|NCT05382260|OTHER|Listening to music|After 5 minutes baseline, participants would listen to three kinds of music with 3 minutes washout and another 5 minutes baseline in the end, while EEG would record their cortical activity. And the order of the three kinds of music is random.
223794013|NCT00692094|BIOLOGICAL|Melatonin|0.025 mg-0.5 mg, daily given at a time when it is expected to delay the timing of the body clock.
223794014|NCT00692094|BIOLOGICAL|Melatonin|0.025 mg - 0.5 mg, daily, at a time when melatonin should advance the timing of their body clock.
223794015|NCT00692094|BIOLOGICAL|Melatonin|0.025 mg - 10 mg, daily, at a time when melatonin should advance the timing of their body clock.
223794016|NCT00692094|BIOLOGICAL|Melatonin|0.025 mg - 20 mg, daily, at a time when the melatonin should advance the timing of the body clock.
223794017|NCT04658303|DRUG|Pimonidazole|Pimonidazole is not used with therapeutic intent, and has a non-hazardous designation. It has been widely used for in-vivo evaluation of intratumor hypoxia, and patients will take PO pimonidazole before the scheduled biopsy. Patients receive an oral dose of pimonidazole, a safe chemical tracer up to 24 hours prior to biopsy. Pimonidazole allows for true hypoxia staining; pimonidazole binds hypoxic proteins covalently, creating an antigen that facilitates the imaging, flow cytometry, and scRNA-seq experiments proposed. Pimonidazole has been previously used in patients and is safe and well tolerated, without anticipated adverse events.
223794018|NCT02265302|DRUG|BIIL 284 oral solution|
223794019|NCT02265302|DRUG|BIIL 284 wetability improved formulation (WIF) tablets|
223794020|NCT02265302|DRUG|Placebo|
223794021|NCT04455789|PROCEDURE|routine lung protective, conventional mechanical ventilation|routine lung protective, conventional mechanical ventilation with stabil PEEP
223794022|NCT02668081|PROCEDURE|Endoscopic papillary balloon dilation|treatment of endoscopic papillary balloon dilation
223794023|NCT02668081|PROCEDURE|Endoscopic sphincterotomy|treatment of endoscopic sphincterotomy
223794024|NCT00686166|BIOLOGICAL|cetuximab|"Chemotherapy cycle 1: Cetuximab, 400 mg/m\^2, IV, Day 1; Cetuximab, 250 mg/m\^2, IV, Days 8,15,22,29~Chemotherapy+ Radiation Cycle 2: Cetuximab, 250 mg/m\^2, IV, Days 50,57,64,71,78"
223794025|NCT00686166|DRUG|capecitabine|"Chemotherapy Cycle 1: Capecitabine, 1650 mg/m\^2/day, PO, Monday-Friday (Day 1-35)~Chemotherapy+ Radiation Cycle 2: Capecitabine, 1650 mg/m\^1, PO, Monday-Friday (Day 50-84)"
223794026|NCT00686166|DRUG|oxaliplatin|"Chemotherapy Cycle 1: Oxaliplatin, 50 mg/m\^2, IV, Days 1,8,15,22,29~Chemotherapy+ Radiation Cycle 2: Oxaliplatin, 50 mg/m\^2, IV, Days 50,57,71,78"
223794027|NCT00686166|PROCEDURE|therapeutic surgical procedure|Surgical resection
223794028|NCT00686166|RADIATION|radiation therapy|IMRT (intensity-modulated radiation therapy)
223794029|NCT06209879|DRUG|SYSTANE™ Hydration Lubricant Eye Drops|SYSTANE™ Hydration Lubricant Eye Drops (Hyaluronic Acid \[HA\] 0.15%; Polyethylene Glycol 400 0.4%; Propylene Glycol 0.3%)1-2 drops 4 times a day) and 0.1% FML (1-2 drops 3 times a day) in both eyes for 12 week
223794030|NCT00508066|DRUG|Bupivacaine|Bupivacaine 0.25 - 0.5% @ 4ml/hr for 72 hours
223794031|NCT00508066|DRUG|Normal Saline|Normal Saline, 4ml/hour for 72 hours.
223794032|NCT02580708|DRUG|Rociletinib|
223794033|NCT02580708|DRUG|Trametinib|
223794034|NCT05645354|BEHAVIORAL|SmokefreeSGM|Participants will be enrolled in a text-based smoking cessation program specifically designed to respond to the needs of LGBTQ+ smokers.
223794035|NCT05645354|BEHAVIORAL|SmokefreeTXT|Participants will be enrolled in a text-based smoking cessation program specifically designed to respond to the needs of the general population
223794036|NCT06151145|BEHAVIORAL|Usual care|Participants in usual care will be emailed monthly educational modules with information on maintaining weight loss.
223794037|NCT06151145|BEHAVIORAL|SELF|"The SELF group will receive a wireless smart body weight scale and wearable physical activity tracker, and text messages."
223794038|NCT06151145|BEHAVIORAL|STEP|The STEP intervention consists of 4 steps that are progressive and based on response to treatment. Step 1: Digital health intervention. The first step will be the digital health intervention as described under SELF. Step 2: Monthly, in-person counseling. Participants who move to Step 2 will be provided with monthly, in-person counseling. Step 3: Twice per month counseling. Step 3 will be twice-monthly counseling, spaced at every other week. Step 4: Meal replacements. Participants will be prescribed a partial meal replacement program.
223794039|NCT02380092|DEVICE|LEGION™ Primary TKS with VERILAST™ Bearing Surface|All study subjects will be treated with LEGION™ Primary TKS with VERILAST™ Bearing Surface as per standard clinical practice.
223794040|NCT02681913|DRUG|Adenosine|This group receives intermittent warm blood cardioplegia enriched with adenosine
223794041|NCT06243146|OTHER|Titration of Inspired Oxygen|Titration of Inspired Oxygen During One-Lung Ventilation
223794042|NCT06635525|BIOLOGICAL|Influenza vaccination|Single-dose
223794043|NCT06635525|BIOLOGICAL|SARS-CoV-2 vaccine|Single-dose
223794044|NCT06533228|DIAGNOSTIC_TEST|Magnetic Resonance Imaging (MRI) or Magnetic Resonance Enterography (MRE)|Abbreviated magnetic resonance enterography (MRE) imaging to detect active inflammation in patient's with known Crohn's Disease.
223794045|NCT03244527|DIETARY_SUPPLEMENT|BCAA supplement|Before each exercise session (described later), the research assistant will give subjects 40g of BCAA or placebo supplement according to the treatment assignment and ask them to drink it down right away.
223794046|NCT03244527|OTHER|Aerobic exercise|The exercise intervention includes 24 aerobic stationary cycling sessions (30 min/session, 3 session/week, and 8 weeks). The exercise sessions proceed under the supervision and guidance of a therapist.
223794047|NCT01549613|DRUG|Daptomycin|• Daptomycin will be given in a one-time dose of 4mg/kg in a one-time dose to be infused over 2 minutes at the initiation of patient therapy in the RDTC cellulitis protocol.
223794048|NCT01549613|DRUG|Vancomycin|• Vancomycin will be given in a dose of 15mg/kg at baseline and again at 12 hours to be infused over 1 to 2 hours.
223794049|NCT02216123|DRUG|Tafenoquine|Tafenoquine will be supplied as a dark pink, capsule-shaped, film-coated tablet that is plain on both sides. Each tablet will contain 150mg TQ.
223794050|NCT02216123|DRUG|Tafenoquine Placebo|Placebo TQ tablets will be supplied as a dark pink, capsule-shaped, film-coated tablet that is plain on both sides, with common excipients of appropriate quality.
223794051|NCT02216123|DRUG|Chloroquine|"One of two formulations of commercially available generic chloroquine may be utilized in this study:~1. tablets containing 500 mg chloroquine phosphate (equivalent to 300 mg chloroquine free base); or,~2. tablets containing 250 mg chloroquine phosphate (equivalent to 155 mg chloroquine free base)."
223794052|NCT02216123|DRUG|Primaquine|Commercially available primaquine containing primaquine phosphate united states pharmacopeia (USP), 26.3 mg (equivalent to primaquine base 15 mg) will be utilized in this study. Primaquine, a pink film-coated tablet imprinted W on one side and P97 on the other side. The PQ tablets for this study have been over-encapsulated in a Swedish orange size B supro capsule.
223794053|NCT02216123|DRUG|Primaquine Placebo|Placebo to match PQ will be supplied as Swedish orange size B supro capsules with common excipients of appropriate quality.
223794054|NCT06326515|BEHAVIORAL|psychoeducation|"To identify and recognize the cognitive distortions To explore the automatic thoughts and emotions about illness Evaluate and respond to thoughts, emotions, and beliefs Automatic thought records were used by patients with some help from therapist (Chattopadhyay et al., 2017).~The cognitive errors were corrected using individual cognitive strategies (Chattopadhyay et al., 2017)."
223794055|NCT06326515|BEHAVIORAL|Stigma Reduction and Relapse Management|"To improve ability to effectively cope with lapse and relapse (Brown \& Vanable, 2008).~To improve relapse management skills (Brown \& Vanable, 2008). Emphasized skill development to cope with OUD-related stressors (Zhang, 2021). To change their conception of OUD (Tshabalala \& Visser, 2011). To change their sense of self-worth and to empower them with more adaptive ways of thinking (Tshabalala \& Visser, 2011).~To deal with their experience of stigma (Tshabalala \& Visser, 2011)."
223794056|NCT04866316|OTHER|There is no active intervention as this is a service evaluation|There is no active intervention as this is a service evaluation
223794057|NCT01795833|OTHER|Short text messages|In addition to structured education on healthy lifestyle provided at baseline, subjects in the arm will receive short text messages containing educational, motivational and supportive content on diet, physical activity, and smoking (if appropriate) during the study period. The content will be appropriate to the stage of the transtheoretical model of behavioural change that the subject is in. This will be assessed by questionnaire at each visit to clinic.
223794058|NCT04439526|DRUG|Guselkumab|Participants with moderate facial and/or genital psoriasis treated with guselkumab (as prescribed by their physician) in real world practice will be observed in this study.
223794059|NCT01605513|DRUG|interferon|PEG-IFN-SA (new interferon) was injected subcutaneously one times per week for 12 times.
223794060|NCT04110613|DIETARY_SUPPLEMENT|noFast: Start tube feeds within 1 hour of procedure|Earliest possible initiation of tube feeding after bedside PEG tube procedure.
223794061|NCT02725632|DEVICE|CPAP|The patients on CPAP treatment will be followed-up for 1 month.
223794062|NCT05334498|OTHER|Motor dual-task gait training|Patients were instructed to walk either on treadmill or on the land. During walk; patients were instructed to perform five tasks. The patients performed tossing and catching the ball, rehanging loops on hoops, buttoning and unbuttoning the shirts, holding the cup in water without the spilling and receiving with returning the water. Each activity were performed for three minute and 15 minutes were provided for performing all the tasks
223794063|NCT05334498|OTHER|Cognitive dual-task gait training|Patients were instructed to walk either on treadmill or on the land. During walk; patients were instructed to perform five tasks. The patients performed sharp coloring, subtraction, counting, verbal analogical reasoning and backward spelling. Each activity were performed for three minute and 15 minutes were provided for performing all the tasks
224263995|NCT03681587|OTHER|Experimental situation|"Salty/sweet breakfast varied experimental situation: the time of distribution and the duration of mealtime will be open and the composition will be varied with sweet/savory foods. This meal and subsequent meals will be measured over 3 consecutive days with observation periods at breakfast time in order to identify the variables of pleasure, feasibility, commensality and conviviality in 2 situations: alone or in the room or with others in the dining room."
224263996|NCT03581994|DIAGNOSTIC_TEST|DDI Test Report|Test results of simulated patients
224263997|NCT01964872|DRUG|JNJ-38877618: Part 1a|Single ascending dose administered orally in liquid formulation (Formulation A). The planned dose range for Parts 1 and 2 will be 6 to 1200 mg.
223794064|NCT05964478|OTHER|Multi-component hand hygiene intervention in primary schools not connected to functional water supply system in Nigeria and Palestine|Each participating school receives: (i) Two Gravit'eau handwashing stations (http://www.graviteau.ch): these systems recycle on-site greywater and operate through gravity and a manual foot pump, and can be produced locally. (ii) Behavior change activities: Developed by a group of expert psychologists (http://www.ranasmosler.com/ranas), utilizing the risks, attitudes, norms, abilities, and self-regulation (RANAS) approach. (iii) WASH infrastructure rehabilitation and soap dispenser installation. (iv) Controlled chlorine monitoring: Equipment provided for monitoring chlorine concentration in water storage, with staff training. (v) Preventive maintenance: Trained circuit rider inspects infrastructure regularly under WASH committee supervision
223794065|NCT01118533|DEVICE|metal reusable blades MacIntosh|laryngoscope blades
223794066|NCT01118533|DEVICE|Single use plastic blades HEINE XP®|laryngoscope blades
223794067|NCT05191758|DIETARY_SUPPLEMENT|FPP supplement|Participants will take the supplements per randomization
223794068|NCT02935491|DEVICE|Transcatheter Aortic Valve Implantation (TAVI)|"TAVI is a well-accepted method for aortic valve replacement without surgery. It is currently proposed to patients at high surgical risk or contraindicated to surgery. It consists of introducing a valve inserted inside a stent by the femoral artery in most cases.~Aortic calcifications will be determined by the analysis of the CT-scan performed systematically before the procedure. A semi-automated software (CreaTools) will be used"
223794069|NCT04477187|DEVICE|Dermal Handpiece|Radiofrequency (RF) will travel through the RF generator through the electrodes and into the dermal layer beneath the surface of the skin. The microneedles of the dermal cartridges coupled with the thermal heat will stimulate neocollagenesis and neoelastosis, aiding in the reduction of submental laxity.
223794070|NCT00002587|DRUG|paclitaxel|
223794071|NCT00002587|DRUG|topotecan hydrochloride|
223794072|NCT01104610|DEVICE|Breas Vivo 40|The Vivo 40 will be used either in CPAP mode, PSV mode without Target Volume or PSV mode with Target Volume
223794073|NCT02795273|DRUG|Grass-SPIRE|
223794074|NCT02795273|DRUG|Placebo|
223794075|NCT05055102|OTHER|Data collection|demographics co-morbidities risk factors operative, hospital and vascular follow-up data
223794076|NCT04585932|DRUG|Apalutamide|Given PO
223794077|NCT04585932|DRUG|Degarelix|Given SC
223794078|NCT04585932|DRUG|Leuprolide Acetate|Given IM
223794079|NCT04585932|OTHER|Quality-of-Life Assessment|Ancillary studies
223794080|NCT04585932|OTHER|Questionnaire Administration|Ancillary studies
223794081|NCT04585932|RADIATION|Radiation Therapy|Undergo RT
223794082|NCT06243705|DEVICE|Robot-Pet|The robot-pet makes sounds like a real cat and responds to touch and petting
223794083|NCT06243705|DEVICE|Virtual Reality Glasses|VR glasses allow you to see videos and films projected on the screen more realistic. With its filtering feature, it combines two different images in the brain and provides the perception of depth in the image and creates a 3D space environment
223794084|NCT00852631|DRUG|Quetiapine fumarate (Seroquel)|600mg Extended release tablet, oral, once daily
223794085|NCT02130310|BIOLOGICAL|CureXcell®|CureXcell® is a cell based therapy obtained from donated whole blood. The blood is collected from healthy young adults, the white blood cells are separated and then activated by hypo-osmotic shock.
223794086|NCT02130310|OTHER|Placebo injection|Normal saline injected at each centimeter of ulcer bed
223794087|NCT03546894|DRUG|Brigatinib|Brigatinib tablets.
223794088|NCT03546894|DRUG|Alectinib|Alectinib capsules.
223794089|NCT03546894|DRUG|Ceritinib|Ceritinib capsules.
223794090|NCT03546894|DRUG|Lorlatinib|Lorlatinib capsules.
223794091|NCT03546894|DRUG|Any FDA Approved ALK Inhibitors|FDA approved ALK inhibitors available for treatment.
223794092|NCT06141811|BIOLOGICAL|ALLO-ASC-DFU|Application of ALLO-ASC-DFU sheet to Diabetic Foot Ulcer. This study is a follow-up study without intervention.
223794093|NCT06141811|PROCEDURE|Vehicle sheet|Application of Vehicle sheet to Diabetic Foot Ulcer. This study is a follow-up study without intervention.
223794094|NCT02204995|PROCEDURE|Trapeziectomy with LRTI|Trapeziectomy with Ligament Reconstruction and Tendon Interposition
223794095|NCT02204995|PROCEDURE|Trapeziectomy|Trapeziectomy
223794096|NCT02486289|DRUG|Emeramide|Mercury chelator NBMI ((N1,N3-bis(2-mercaptoethyl) isophthalamide)
223794097|NCT02486289|DRUG|Placebo|NBMI Placebo
223794098|NCT00464815|BIOLOGICAL|Meningococcal vaccine GSK134612|One intramuscular dose
223794099|NCT00464815|BIOLOGICAL|Mencevax™ ACWY|One subcutaneous dose
223794100|NCT06050850|BEHAVIORAL|NOURISH-ALL|Our NOURISH-ALL intervention will build on this existing NOURISH-T family based behavioral intervention with families of cancer survivors. The intervention, NOURISH-ALL, will adapt these family-based health promotion strategies to the early ALL treatment context.
223794101|NCT00254982|BIOLOGICAL|Infliximab|Infliximab 5 mg/kg was given as an induction regimen at week 0, 2, and 6 weeks after the first infusion and then at week 14.
223794102|NCT00223860|DRUG|Human chorionic gonadotropin (hCG)|
223794103|NCT00223860|DRUG|Luteinizing hormone releasing hormone (LHRH)|
223794104|NCT02593994|DEVICE|Onyx Drug Eluting Stent group|
223794105|NCT04110769|DIAGNOSTIC_TEST|next generation sequencing|the investigator will compare genetic mutation between responder and non-responder using next generation sequencing examination.
223794106|NCT04110769|DIAGNOSTIC_TEST|following next generation sequencing|The patient will be examined next generation sequencing before changing palliative chemotherapy for non-responders.
223794107|NCT00000392|DRUG|Peptide T|
223794108|NCT00000392|DRUG|Placebo|
223794109|NCT03125304|OTHER|acupuncture|They will be treated seven days before expected menstrual onset with once a day and three times a week for therapy. During the menstrual period,they will be treated everyday when they are having pain.Every treatment lasts 30 minutes. The trial period will consist of three menstrual cycles of treatment and three menstrual cycles in the follow-up period.
223794110|NCT06188572|OTHER|Michigan Neuropathy Screening Instrument|A two-step test consisting of symptom questionnaire and physical examination was used. The symptom questionnaire includes 15 questions about the legs and feet. Physical examination includes assessment of the appearance of the feet, Achilles reflex, thumb vibration and monofilament tests.
223794111|NCT06188572|OTHER|Numeric Pain Scale|"In this simple method, which is frequently used to measure pain intensity in the clinic and whose validity and reliability have been demonstrated, the participant is asked to mark a number on a 10 cm scale with numbers ranging from 0 (no pain) to 10 (unbearable pain) for the pain."
223794112|NCT06188572|OTHER|Mandibular Function Disorder Questionnaire|This valid and reliable scale evaluating mandibular dysfunction consists of two dimensions and 17 questions.A high total score obtained from the questionnaire indicates a high level of impairment in jaw function
223794113|NCT06188572|OTHER|Fonseca Anamnestic Index|This scale, which is valid and reliable as a TMJ disorder assessment tool, includes 10 questions. The presence of TMD is accepted in those with a score of 25.
223794114|NCT06188572|OTHER|Ferrans&Powers Quality of Life Index Diabetes Version|This index consists of two parts and a total of 68 items. A high score indicates a good quality of life.
223794115|NCT00982358|DRUG|Valsartan|
223794116|NCT00982358|OTHER|Placebo|
223794117|NCT05394870|OTHER|manual lymphatic drainage (massage)|Patients will begin treatment with manual lymphatic drainage in the affected extremity. In this context, while the patients are in the supine hook position, lymph drainage will be applied first to the neck and then to the abdomen. After the stimulation of the central lymph nodes, the lymph circulation will be increased by stimulating the axillary lymph nodes of the relevant region. First, the proximal part will be drained and it will be advanced towards the distal. Drainage will be repeated depending on the edema at the distal forearm-wrist level.
223794118|NCT05394870|OTHER|Splint treatment|The splint routinely given to patients diagnosed with mild to moderate carpal tunnel syndrome will be given to both groups in these patients
223794119|NCT03203369|BIOLOGICAL|UCART123|Allogeneic engineered T-cells expressing anti-CD123 Chimeric Antigen Receptor given as a single dose following a lymphodepleting regimen.
223794120|NCT02998281|DEVICE|Threshold (IMT)|Training is going to perform by using a pressure threshold- loading device (Threshold, IMT, USA) used to inhale against a same-pressure load every inhalation for strengthening primarily the diaphragm and rib cage muscles. The device pressure is adjusted according to PImax, and reliability/reproducibility has been demonstrated.
223794121|NCT02836418|DRUG|ATYR1940|Concentrate for solution for infusion
223794122|NCT06395064|DRUG|Dimenhydrinate|Dimenhydrinate 50mg intravenously
223794123|NCT02931279|DEVICE|PASS OCT® Spinal System|Posterior osteosynthesis of the cervical and upper thoracic spine
223794124|NCT06311695|DEVICE|Contrast Enhanced Mammography|Contrast Enhanced Mammography
223794125|NCT02355808|BEHAVIORAL|Tailored Leaflet|
223794126|NCT02355808|BEHAVIORAL|GP visit|
223794127|NCT01564550|DRUG|Insulin|Insulin is given as a constant infusion( 0,6 mU/kg/min) during the hyperinsulinemia period of the study lasting four and a half hour.
223794128|NCT01564550|DRUG|insulin|Insulin is given as a constant infusion( 0,6 mU/kg/min) during the hyperinsulinemia period of the study lasting four and a half hour.
223794129|NCT01564550|OTHER|diet|The subjects ingest a three day isocaloric diet (55 % carbohydrate,30% fat, 15 % protein)prior to the study day.
223794130|NCT01564550|OTHER|no diet|The subjects will ingest a non-restricted diet prior to the study day.
223794131|NCT01695967|PROCEDURE|turbinate cauterization|
223794132|NCT02207920|BIOLOGICAL|AIDSVAX B/E Vaccine|600 mcg/mL to be administered as 1 mL intramuscular (IM) injection
223794133|NCT02207920|BIOLOGICAL|DNA-HIV-PT123 Vaccine|4 mg/mL to be administered as 1 mL IM injection
223794134|NCT02207920|BIOLOGICAL|Placebo for DNA-HIV-PT123|Sodium chloride for injection USP, 0.9%; administered as 1 mL IM injection
223794135|NCT02207920|BIOLOGICAL|Placebo for AIDSVAX B/E|Sodium chloride for injection USP, 0.9%; administered as 1 mL IM injection
223794136|NCT06356064|DEVICE|Extracorporeal shock wave therapy|Radİal ESWT and focus ESWT
223794137|NCT06382350|DEVICE|MiniMed 780 G|none, observational study
223794138|NCT04866550|OTHER|Data collection|Daily record of temperature, weight, heart rate, systolic blood pressure and oxygen saturation
223794139|NCT05817695|DEVICE|Leadless pacemaker|To observe the effect of pacemaker implantation at different sites on cardiac synchronization and tricuspid regurgitation
223794140|NCT00682487|OTHER|Hair sampling for cortisol|Hair sampling for cortisol
223794141|NCT00682487|OTHER|Hair sampling for cortisol|Hair sampling for cortisol
223794142|NCT03430674|BEHAVIORAL|Exercise|Exercise, questionnaires and blood draws.
223794143|NCT01886924|BEHAVIORAL|Brief Computer MI for Smoking Cessation|Brief computer MI intervention to motivate tobacco quitline use
223794144|NCT01886924|BEHAVIORAL|Nutrition Control|Computer delivered nutrition education control condition
223794145|NCT04729257|DEVICE|Philips IntelliSpace Cognition (ISC).|Philips ISC is a Class-II Medical Device in the US that aids in assessing cognition and helps inform the HealthCare Professional (HCP) to make a diagnosis and treatment plan. ISC can be used in a variety of healthcare environments such as neurology and neuropsychology practices.
223794146|NCT04729257|DIAGNOSTIC_TEST|Paper-Pencil Tests.|The same cognitive tests that are on the ISC platform are performed using paper and pencil (rather than digitally) as is the case in standard clinical practice.
223794147|NCT05437458|OTHER|Delirium (exposure)|No interventions.
223794148|NCT00712868|DRUG|Lactic acid|Once a day
223794149|NCT00591474|DIETARY_SUPPLEMENT|probiotics|100 gms of a yogurt drink containing probiotics will be given to pVRE positive patients for 4 weeks
223794150|NCT00591474|DIETARY_SUPPLEMENT|yogurt|100 gms of pasteurized yogurt drinks with no live cultures will be given to VRE positive patients for 4 weeks
223794151|NCT00990223|DRUG|Eplerenone or Placebo|Eplerenone 100 mg or Placebo, daily for 10 days.
223794152|NCT00485290|BEHAVIORAL|meal (food intake)|600 kcal. (16% protein, 49%carbohydrate, 35% fatt)
223794153|NCT05152433|DEVICE|E-BRAiN therapy|The therapy system E-BRAiN is a purpose-built therapy system using a socially interactive humanoid robot and provides individualised therapy for arm rehabilitation based on the evidence-based therapies arm basis training, arm ability training, or mirror therapy for arm rehabilitation (paresis) or neurovisual training (neglect).
223794154|NCT05152433|BEHAVIORAL|Conventional therapy|Conventional therapy specifies the neurorehabilitation therapy as applied as regular treatment.
223794155|NCT02294890|PROCEDURE|Total knee arthroplasty|
223794156|NCT03783182|DRUG|Betamethason Sodium Phosphate|Glucocorticoid
223794157|NCT03783182|DRUG|10% glucose solution|Glucose solution that can be used for injection, but in this case it is used perorally (one ml)
223794158|NCT01613248|DRUG|MK-1602|Single 1, 10, 25, 50 or 100 mg dose of MK-1602 taken at onset of migraine of moderate or severe intensity. Dosage form is film coated tablet for oral administration. Dose is provided to participants as a blinded bottle of tablets packaged to achieve the various MK-1602 dose levels to be studied. Participants will be instructed to take all study medication from the bottle when they treat their migraine headache.
223794159|NCT01613248|DRUG|Placebo-matching MK-1602|Single administration of placebo-matching MK-1602 taken at onset of migraine of moderate or severe intensity. Dosage form is film coated tablet for oral administration. Dose is provided to participants as a blinded bottle of tablets packaged to achieve placebo study medication. Participants will be instructed to take all study medication from the bottle when they treat their migraine headache.
223794160|NCT01613248|DRUG|Rescue medication|"If moderate or severe migraine headache pain continues 2 hours after dose of study medication or if migraine headache comes back within 48 hours,~Participants will be allowed to take their own rescue migraine medication, which may include analgesics (e.g., nonsteroidal anti-inflammatory drugs \[NSAIDs\]), anti-emetics, triptans or other medication not explicitly excluded."
223794161|NCT03640260|BEHAVIORAL|breathing regulation with physical activity|The subjects will have education leaflets with breathing and oximetry level evaluation training.
223794162|NCT05350241|OTHER|Split-belt treadmill training|Participants in the split-belt walking group (experimental group) performed repeated split-belt treadmill training with an error-augmentation strategy (exaggeration of the initial step-length asymmetry) for 60 minutes, three times per week for 12 successive weeks. The training was conducted under close supervision of a licensed pediatric physical therapist according to safety performance guidelines defined by the American Academy of Pediatrics.
223794163|NCT05350241|OTHER|Standard physical therapy|Participants in the control group received the standard physical therapy program. Each session lasted for 60 minutes, repeated three times a week, over 12 consecutive weeks. The program consisted of advanced balance training, gait training, postural and flexibility exercises, and strength training exercises.
223794164|NCT01952496|OTHER|Assisted Standing Treatment Program|"Assisted standing treatment program will include at least 2 hours a day, 5 days a week (a total of at least 10 hours a week) for a period of \~9 months.~Arm: Force-measuring platform"
223794165|NCT05098054|DRUG|Soticlestat|Soticlestat tablets.
223794166|NCT00001430|PROCEDURE|PBSC|
223794167|NCT00001430|DRUG|IL-2|
223794168|NCT00001430|DRUG|EPOCH II|
223794169|NCT01016769|DRUG|Temsirolimus + Weekly Paclitaxel + Carboplatin|"Temsirolimus Per dose escalation scheme Level 1 (15 mg) 2 (20 mg) Level 3 (25 mg) IVPB 30 minutes weekly (3 weeks on, 1 week off) days 1 and 8.~Paclitaxel 80 mg/m2 IVPB 1 hour weekly (2 weeks on, 1 week off) days 1 and 8. Carboplatin AUC 1.5 IVPB 30 minutes days 1 and 8. On Day 15 of each cycle, patients begin the rest week."
223794170|NCT02015676|DRUG|trastuzumab|Initial loading does of 4 mg/kg IV, followed by 2 mg/kg IV weekly, until disease progression
223794171|NCT02015676|DRUG|paclitaxel|60 mg/m\^2 IV weekly; dose increased to 70 mg/m\^2, and subsequently 80 mg/m\^2, after 2 treatment cycles with no evidence of DLT until disease progression
223794172|NCT02015676|DRUG|Myocet|40 mg/m\^2 IV weekly; dose increased to 50 mg/m\^2 IV after 2 treatment cycles with no evidence of DLT for 6 cycles
223794173|NCT00476476|DRUG|Erlotinib|Orally every day for about 4-6 weeks
223794174|NCT00344786|DRUG|CNF2024 (BIIB021)|"Dose starting at 12.5 mg/d, p.o. as a once-daily dose for 21 days followed by a 1-week rest period.~Dose escalation will proceed according to the predetermined scheme until the maximum tolerated dose (MTD) is reached due to dose limiting toxicities (DLT) during the first course of treatment."
223794175|NCT00004827|DRUG|docosahexaenoic acid|
223794176|NCT00195910|DRUG|Morphine|0.1 mg/kg IV morphine
223794177|NCT00195910|DRUG|Hydromorphone|0.015 mg/kg IV hydromorphone
223794178|NCT00971048|DEVICE|HP828-101|Topical test article applied once daily
223794179|NCT00971048|DEVICE|Hydrogel/Hydrocolloid|Hydrogel for DFU and Hydrocolloid for PU (3M Tegaderm Hydrogel for DFU; ConvaTec DuoDERM Hydroactive Gel for PU); Topical test articles applied once daily
223794180|NCT01189279|DRUG|bimatoprost Formulation A|bimatoprost Formulation A applied topically to the scalp once daily on Day 1 and Days 4-17.
223794181|NCT01189279|DRUG|bimatoprost Formulation B|bimatoprost Formulation B applied topically to the scalp once daily on Day 1 and Days 4-17.
223794182|NCT01189279|DRUG|bimatoprost Formulation C|bimatoprost Formulation C applied topically to the scalp once daily on Day 1 and Days 4-17.
223794183|NCT01046305|BEHAVIORAL|Interview & Questionnaires|30 Minute Interview about what it is like to have CML, followed by symptom questionnaire, quality-of-life questionnaire, and demographic questions taking another 10 minutes for all 3 questionnaires.
223794184|NCT01046305|BEHAVIORAL|Rating Questionnaire|Questionnaire developed in Part 1 to rate the relevance of symptom items, given to 3-5 physicians, 3-5 nurses, 2-4 patients and their family caregivers, taking about 10 minutes.
223794185|NCT01046305|BEHAVIORAL|MDASI-CML Questionnaire|Patient questionnaires about CML symptoms over 1 year, completed in person or using Interactive Voice Response (IVR) system every 2 weeks.
223794186|NCT00243204|DRUG|talabostat mesylate|
223794187|NCT00243204|DRUG|docetaxel|
223794188|NCT04850300|PROCEDURE|Total knee prosthesis with medial condylar stabilization|Surgery will be done of Total knee prosthesis with medial condylar stabilization
223794189|NCT04850300|PROCEDURE|Total knee prosthesis with central pivot stabilization|Surgery will be done of Total knee prosthesis with central pivot stabilization
223794190|NCT02540018|DEVICE|Transluminal Angioplasty with Paclitaxel-coated Luminor® Balloon Catheter in the Superficial Femoral and Popliteal Arteries|"Endoluminal guidewire passage of the stenotic and occlusive femoro-popliteal lesion must be performed. A pre-dilatation follows. Then the investigational procedure (DEB) is assigned by randomization.~Luminor35®-DEB PTA catheter is applied."
223794191|NCT02540018|DEVICE|Transluminal Angioplasty with and non-coated (CE-marked) plain old angioplasty balloon (POBA) catheter|Endoluminal guidewire passage of the stenotic and occlusive femoro-popliteal lesion must be performed. A pre-dilatation follows. Then the investigational procedure is assigned by randomization. POBA catheter is applied.
223794192|NCT03321396|DEVICE|sodium alginate mixed with calcium lactate|"The product is used in Endoscopic submucosal dissection which is accomplished by steps listed as follows: lesion marking, submucosal injection, mucosal incision, submucosal dissection, then en-bloc resection. It's a new submucosal injection regimen, sodium alginate mixed with calcium lactate, which turned to calcium-alginate gel, we called it as Gut Guarding Gel."
223794193|NCT01973933|DRUG|Metformin and Pyrimethamine|
223794194|NCT01944501|PROCEDURE|Transcranial Magnetic Stimulation|TMS over the left temporoparietal cortex
223794195|NCT01944501|PROCEDURE|Transcranial Direct Current Stimulation|TDCS over the left temporoparietal cortex
223794196|NCT04243317|BEHAVIORAL|Lifestyle & diet|The control group will receive lifestyle and dietary advice accompanied by meal replacements and dietary plans.
223794197|NCT04243317|BEHAVIORAL|Lifestyle, diet & sleep|The control group will receive lifestyle and dietary advice accompanied by meal replacements and dietary plans. The experimental group will additionally receive a sleep improvement program based on CBTi.
223794198|NCT04024618|PROCEDURE|Parenteral Nutrition/Enteral Nutrition|Patients randomized to the parenteral nutrition arm will receive nutrition by IV and patients randomized to the enteral nutrition arm will receive nutrition by NG tube.
223794199|NCT04020900|OTHER|Respiratory management|Data on respiratory management were collected at different time: data regarding the induction period, ventilatory parameters set and measured during a stable period, ventilatory change made during anaesthesia, use of recruitment manoeuvres, data regarding weaning and extubation
223794200|NCT04781374|DRUG|Neratinib|Oral, once daily with 28 consecutive days defined as a treatment cycle, dosage per protocol ,
223794201|NCT02374905|DEVICE|Drinksmeter|Web-based application delivering Identification and Brief Advice of Alcohol Use
223794202|NCT02374905|BEHAVIORAL|Brief Advice of Alcohol Use|Lifestyle counseling regarding alcohol intake and completion of Audit-10 questionnaire done chair-side with clinician
223794203|NCT01654549|DRUG|H.pylori eradication|Omeprazole (20 mg/BD)+ Amoxicillin (1 g/day)+ Bismuth subcitrate (240 mg/BD)+ Azithromycin (500 mg/BD)
223794204|NCT02301312|DEVICE|POSS-PCU vascular graft|New vascular access graft
223794205|NCT03768167|PROCEDURE|Posterolateral corpectomy|Investigators' goal in this study is to report clinical series of 26 patients in Sohag university hospital with dorsolumbar metastatic lesions from different primaries treated by single-stage posterolateral circumferential corpectomy with reconstruction by a pyramesh titanium cage and account the degree of improvement regarding the pain.
223794206|NCT00315250|DRUG|[123I]β-CIT|"Single Photon Emission Computed Tomography~SPECT imaging uses the single photon emissions from radioactive compounds that are (most commonly) injected into a patient and are metabolized by specific organs or body systems. SPECT imaging is performed by using a gamma camera to acquire multiple 2-D images (also called projections), from multiple angles. A computer is then used to apply a tomographic reconstruction algorithm to the multiple projections, yielding a 3-D dataset. This dataset may then be manipulated to show thin slices along any chosen axis of the body, similar to those obtained from other tomographic techniques, such as MRI, CT, and PET. The resulting SPECT images reflect body/organ function as opposed to specific anatomy of other imaging modalities such as CT or MRI."
223794207|NCT03385928|DRUG|Tranexamic Acid|Investigational product given within 2 hours of symptom onset
223794208|NCT03385928|DRUG|Normal saline|Placebo given within 2 hours of symptom onset
223794209|NCT06018480|OTHER|Creatine Monohydrate|The supplementation is the intervention.
223794210|NCT06018480|OTHER|Maltodextrin (Placebo)|Placebo to Creatine Monohydrate
223794211|NCT02519010|DRUG|Amlodipine/Valsartan|1 tablet contains Amlodipine 10 mg \&valsartan 160 mg
223794212|NCT02519010|DRUG|Exforge|1 tablet contains Amlodipine 10 mg \&valsartan 160 mg
223794213|NCT01805492|BEHAVIORAL|Dr. Dean Ornish Program for Reversing Heart Disease|Prospective, nonrandomized clinical intervention to stabilize or reverse progression of heart disease through changes in lifestyle. Lifestyle intervention consisted of four components: 1) a very low fat vegetarian diet (\<10% of calories from fat); 2) 180 minutes/week of moderate aerobic exercise; 3) one hour of stress management each day; and 4) weekly group support sessions.
223794214|NCT04991168|OTHER|Questionnaire|Two questionnaires used to assess the state of knowledge and practices in oral health. An oral assessment will be carried out for voluntary patients.
223794215|NCT03382496|OTHER|Non-Interventional|Non-Interventional
223794216|NCT02607995|BEHAVIORAL|Behavioral standardized manual-based multidisciplinary routine care|Behavioral standardized manual-based multidisciplinary routine care (lifestyle intervention). Six sessions offered over the course of three to six months with a focus on weight loss. The topics 1) causes, consequences and treatment options of obesity, 2) nutrition, 3) eating behaviors and problem solving strategies, 4) self esteem and emotional eating, 5) exercise, and 6) use of media will be covered.
223794217|NCT01638910|DRUG|EV/DNG (Qlaira, BAY86-5027)|Oral estradiol valerate and dienogest (2 days 3.0 mg estradiol valerate (EV), 5 days 2.0 mg EV + 2.0 mg dienogest (DNG), 17 days 2.0 mg EV + 3.0 mg DNG, 2 days 1.0 mg EV, 2 days placebo), one table oral daily for 13 treatment cycles (1 cycle = 28days)
223794218|NCT04913844|OTHER|Physical performance tests and observational assessments|There will be no interventions. Physical performance tests and observational assessments will be conducted.
223794219|NCT02738268|DEVICE|Low-level laser therapy|Low-Level Laser Therapy will be applied, twice a week, from the start of radiotherapy treatment in combination with the standard skin care.
223794220|NCT02738268|DEVICE|sham laser|
223794221|NCT05591508|DIETARY_SUPPLEMENT|Ketogenic Diet|Ketogenic diet will be in the form of artificial powder which can be diluted and given through NG tube. It will be started at a ratio of 1:1 followed by daily increment (2:1,3:1 and 4:1) till a urine ketone of 2+ is seen
223794222|NCT03999879|DIAGNOSTIC_TEST|Measure of OxPhos upregulation|OxPhos upregulation \[i.e., lower phosphocreatine (PCr)-to-ATP ratio levels\] in the PET AG mask. PIB+ NL subjects will show OxPhos downregulation (i.e. increased PCr/ATP ratio that indicate the presence of metabolically inert PCr that cannot be used as ATP) when compared to PIB- NL subjects in the PETAG mask
223794223|NCT03999879|DIAGNOSTIC_TEST|lactate (measured with 1H-MRSI)|PIB+ NL subjects will show increased levels of lactate (measured with 1H-MRSI) when compared to PIB- NL subjects in the PETAG mask.
223794224|NCT01257841|DRUG|Leptin administration|Leptin 0.05 mg/kg sc daily in divided doses (0800, 1400, 2000, and 0200h) for four days.
223794225|NCT01257841|BEHAVIORAL|Fasting|Complete fasting, save for water and multivitamin, for four days.
223794226|NCT05886270|OTHER|Housing Assessment/Safety Modifications|A GHHI Assessor will complete three home visits to assess home injury hazards and provide a scope of work that includes home modifications that directly address each of the identified home injury hazards. The Assessor will also provide do-it-yourself education materials and injury prevention supplies to assist them in completing the modifications.
223794227|NCT03776955|DRUG|Carvedilol|Oral tablet
223794228|NCT04332796|DRUG|Chorhexidine scrub|Chorhexidine scrub was given to patients for 4 weeks
223794229|NCT04332796|DEVICE|ZnO-NPs socks|ZnO-NPs socks was given to patients for 4 weeks
223794230|NCT04332796|COMBINATION_PRODUCT|Combination of chorhexidine scrub and ZnO-NPs socks|Combination of chorhexidine scrub and ZnO-NPs socks was given to patients for 4 weeks
223794231|NCT04335045|DRUG|Placebo|1\~8 Placebo capsule(s) corresponding to each PH100 dose
223794232|NCT04335045|DRUG|PH100 100mg|1 x 100 mg PH100 oral capsule
223794233|NCT04335045|DRUG|PH100 200mg|1 x 200 mg PH100 oral capsule
223794234|NCT04335045|DRUG|PH100 400mg|2 x 200 mg PH100 oral capsules
223794235|NCT04335045|DRUG|PH100 800mg|4 x 200 mg PH100 oral capsules
223794236|NCT04335045|DRUG|PH100 1200mg|6 x 200 mg PH100 oral capsules
223794237|NCT04335045|DRUG|PH100 1600mg|8 x 200 mg PH100 oral capsules
223794238|NCT06634576|DEVICE|Smooth pursuit neck torsion test|Used custom-made system to stimulate the procedure of smooth pursuit neck torsion test in the current study, the multiple axis motion platform can adjust the neck postures to three different neck motion planes, seven different neck postures.
223794239|NCT03314415|DEVICE|Aldebaraan Nao H25|The Aldebaraan Nao H25 is a humanoid robot with the capability to interact with people through small movements, gestures, and speech. It does not physically touch the participant at any time.
223794240|NCT01854099|BIOLOGICAL|PEP-CMV|500 µg of PEP-CMV vaccine given intradermally on day 6-8 of each monthly TMZ cycle (standard 200 mg/m\^2 x 5 days) with group 1.
223794241|NCT01854099|BIOLOGICAL|PEP-CMV|500 µg of PEP-CMV vaccine given intradermally on day 22-24 of each monthly TMZ cycle (standard 200 mg/m\^2 x 5 days) with group 2.
223794242|NCT01854099|BIOLOGICAL|PEP-CMV|500 µg of PEP-CMV vaccine given intradermally on day 22-24 of each monthly TMZ cycle (dose-intensified 100 mg/m\^2 x 21 days) with group 3.
223794243|NCT04100200|DIETARY_SUPPLEMENT|Mixed berries|Strawberry and red raspberry
223794244|NCT04100200|DIETARY_SUPPLEMENT|FOS|Fructo-oligosaccharide
223794245|NCT04100200|DIETARY_SUPPLEMENT|Control|Placebo similar in color to mixed berry supplement without any polyphenols
223794246|NCT04100200|DIETARY_SUPPLEMENT|Combination|Mixed berry composite + FOS
223794247|NCT06166225|BEHAVIORAL|Internet-based weight loss program|12-month, automated and behaviorally-based, Internet-delivered weight loss and weight loss maintenance program
223794248|NCT06166225|BEHAVIORAL|Yoga|9-month Iyengar yoga program consisting of live (Zoom) yoga classes delivered 1-2 times per week during months 4-12, and self-guided yoga practice recommendations.
223794249|NCT06166225|BEHAVIORAL|Health and Wellness|9-month health and wellness program consisting of live (Zoom) yoga classes delivered 1-2 times per week during months 4-12.
223794250|NCT04224155|DEVICE|enVista MX60EFH trifocal intraocular lenses (IOLs)|enVista MX60EFH trifocal intraocular lenses (IOLs) implanted bilaterally
223794251|NCT04224155|DEVICE|enVista MX60E monofocal intraocular lenses (IOLs)|enVista MX60E monofocal intraocular lenses (IOLs) implanted bilaterally
223794252|NCT04310592|BIOLOGICAL|CYNK-001|CYNK-001 is an allogeneic off the shelf cell therapy enriched for CD56+/CD3- NK cells expanded from human placental CD34+ cells.
223794253|NCT06511232|DRUG|Intraosseous Morphine|More recently, intraosseous infusion of analgesics and antibiotics has gained traction in the total joint arthroplasty literature. In knee arthroplasty patients, the combination of a spine and adductor canal block with an intraosseous infusion of morphine into the tibial tubercle prior to incision yielded lower pain in the immediate postoperative period and at 2 weeks, less pain medication use, and significantly better patient-reported outcomes while also reducing systemic opioid exposure in the early postoperative period compared to the spine and adductor block alone.3 No study to date in the available literature has evaluated the efficacy of intraosseous morphine infusion in managing acute postoperative pain in patients undergoing ACL reconstruction with bone-patellar tendon-bone autograft, so that is the intended evaluation point with this project.
223794254|NCT05597254|DIETARY_SUPPLEMENT|Probiotic with niacin and berry extract|1 capsule daily of probiotic with niacin supplementation for 8 weeks
223794255|NCT05597254|DIETARY_SUPPLEMENT|Probiotic without niacin and berry extract|1 capsule daily of probiotic without niacin supplementation for 8 weeks
223794256|NCT05597254|DIETARY_SUPPLEMENT|Placebo|1 capsule daily of placebo supplementation for 8 weeks
223794257|NCT00439205|DEVICE|FastEEM4 System|The FastEEM4 probe is moved toward the edge of the lesion(s) until it measures what appears to be normal mouth tissue.
223794258|NCT00439205|DEVICE|Multispectral Digital Microscope|The MDM instrument will take pictures of abnormal-appearing and normal-appearing areas in the mouth.
223794259|NCT05356260|DEVICE|URincontrol4men|The intervention is built as an app
223794260|NCT05356260|OTHER|Care as usual|CAU will be that typically provided by GPs. Also patients will be informed about a page on thuisarts.nl regarding male LUTS. The pragmatic trial design means that care can vary depending on the preferences of patients and GPs in this group.
223794261|NCT06952114|DRUG|Stem Cells Lenses|Each subject will wear Stem Cells Lenses for four consecutive days. After a 4-day treatment period, a 14-day follow-up observation period will be conducted to monitor for potential adverse events.
223794262|NCT06961526|PROCEDURE|Esophageal band ligation|upper endoscopy will be performed within 6 months before starting atezolizumab-bevacizumab therapy in HCC patients. Esophageal band ligation for small non-risky varices before starting atezolizumab-bevacizumab therapy. Endoscopy will be repeated 3, 5, 9, 12 months after atezolizumab-bevacizumab therapy
223794263|NCT06962436|DEVICE|Robotic bronchoscopy system|Utilization of a robotic bronchoscopy system for the biopsy of patients with peripheral pulmonary lesions suspected of malignancy
223794264|NCT06962436|DEVICE|Ultrathin bronchoscope combined with virtual bronchoscopic navigation|Utilization of ultrathin bronchoscope combined with virtual bronchoscopic navigation for the biopsy of patients with peripheral pulmonary lesions suspected of malignancy
223794265|NCT06962670|OTHER|Biomaterial collection|All subjects will be asked to provide biomaterial (blood or saliva) for bio marker screening and analysis. Additional biomaterial (breath, urin, stool) is optional.
223794266|NCT06962670|OTHER|BayPass mobile application|"All subjects will be asked to use the study-specific mobile application BayPass to complete questionnaires and provide results from screening examinations over a course of 12 months."
223794267|NCT05596045|DRUG|ASC10|Participants will be randomized to receive 200, 400 and 800 mg ASC10 BID for 5.5 days
223794268|NCT05596045|DRUG|Placebo|Participants will be randomized to receive placebo
223794269|NCT06962293|DEVICE|MAG-ESD assisted ESD|Flexible magnetic traction device would be used to assist the ESD procedure. Real time adjustment of traction could be achieved by controlling the EPM position and orientation anytime during the procedure.
223794270|NCT03644186|DRUG|Paclitaxel|Chemotherapy plus HER2 Blockade
223794271|NCT03644186|DRUG|Trastuzumab|Chemotherapy plus HER2 Blockade
223794272|NCT03644186|DRUG|Pertuzumab|Chemotherapy plus HER2 Blockade
223794273|NCT03644186|DRUG|Palbociclib|CDK Inhibition plus Hormonal Therapy plus HER2 Blockade
223794274|NCT03644186|DRUG|Letrozole|CDK Inhibition plus Hormonal Therapy plus HER2 Blockade
223794275|NCT03644186|DRUG|Trastuzumab|CDK Inhibition plus Hormonal Therapy plus HER2 Blockade
223794276|NCT03644186|DRUG|Pertuzumab|CDK Inhibition plus Hormonal Therapy plus HER2 Blockade
223794277|NCT04897776|DEVICE|Central Thalamic Stimulation|Stimulation of the bilateral thalamic CL is a promising approach in human patients to improve conscious arousal. To restore conscious arousal by stimulation of the thalamic intralaminar CL it is necessary to provide bilateral stimulation, placing one lead in each thalamus. Bilateral thalamic CL stimulation was shown previously to improve human conscious arousal and is based on existing research in patients with disorders of consciousness.
223794278|NCT04897776|DEVICE|Hippocampal Stimulation|The hippocampus has been a target for brain stimulation for seizure reduction in epilepsy. While the efficacy of HC stimulation varies considerably among different studies, the surgical procedure and therapeutic electrical stimulation are well tolerated by patients, with few peri-operative complications being reported, and histopathologic analysis not revealing a difference between stimulated and non-stimulated hippocampal tissue (Han et al. 2014)
223794279|NCT05754450|DRUG|AVTX-803|L-fucose crystalline powder
223794280|NCT05586230|DRUG|Pretomanid|Administered orally based on participant's weight
223794281|NCT05586230|DRUG|Optimized background regimen (OBR) for multidrug-resistant TB (MDR-TB)|Non-study prescribed OBR will vary according to local, national and/or international guidelines for treatment of children with MDR-TB. Administered in addition to single dose of Pa.
223794282|NCT06643351|OTHER|Standard Intrapartum Glucose Target Range|Intrapartum maternal glucose management involves frequent blood sugar checks and the use of insulin intravenous drip as needed. Maternal capillary blood sugar is checked every 4 hours in early labor, 2 hours in active labor and hourly during the second stage of labor. The frequency of maternal glucose monitoring will not differ by study group. The goal intrapartum glucose target range will be 70-110mg/dl. Insulin infusion will be initiated when maternal capillary glucose exceeds 110 mg/dL. Once an insulin infusion is initiated, glucose monitoring frequency will occur by protocol. A hypoglycemia protocol is initiated if the maternal blood sugar is less than 60mg/dl.
223794283|NCT06643351|OTHER|Liberalized Intrapartum Glucose Target Range|Intrapartum maternal glucose management involves frequent blood sugar checks and the use of insulin intravenous drip as needed. Maternal capillary blood sugar is checked every 4 hours in early labor, 2 hours in active labor and hourly during the second stage of labor. The frequency of maternal glucose monitoring will not differ by study group. The goal intrapartum glucose target range will be 70-160mg/dl. Insulin infusion will be initiated when maternal capillary glucose exceeds 160 mg/dL. Once an insulin infusion is initiated, glucose monitoring frequency will occur by protocol. A hypoglycemia protocol is initiated if the maternal blood sugar is less than 60mg/dl.
223794284|NCT05852015|BEHAVIORAL|Treatment-as-Usual (TAU)|TAU consists of weekly outpatient-based group therapy for substance use disorder
223794285|NCT05852015|BEHAVIORAL|Digital Mindfulness Treatment|The digital mindfulness-based treatment is a multimedia app-based program teaching mindfulness skills to facilitate recovery from substance use disorder
223794286|NCT05392062|OTHER|Pathophysiology of gas exchange|Exploration of pathophysiology of gas exchange
223794287|NCT06459921|DRUG|SOX+Sintilimab|Patients would be allocated to the SOX+Sintilimab group.
223794288|NCT06459921|DRUG|FLOT+Sintilimab|Patients would be allocated to the FLOT+Sintilimab group.
223794289|NCT05403762|OTHER|ESENTA™ Skin Barrier Spray (ConvaTec, UK)|The skin protectant will be applied on clean and dry skin exposed to urine and stool. After application, the solvent evaporates leaving a silicone film on the skin surface.
223794290|NCT05403762|OTHER|Hydrophobes Basisgel DAC|The skin protectant will be applied on clean and dry skin. It contains 95% paraffin oil and creates a hydrophobic layer on the skin surface.
223794291|NCT06634641|BIOLOGICAL|blood test|Only carrying out additional immunological assays during blood tests before initiation of treatment, six months after initiation of treatment and then one year after initiation of treatment.
223794292|NCT06636461|PROCEDURE|microfragmented adipose tissue loaded on allograft|microfragmented adipose tissue loaded on allograft on ridge preservation
224263998|NCT01964872|DRUG|JNJ-38877618: Part 1b|Single dose administered orally in capsule formulation (Formulation B). The planned dose range for Parts 1 and 2 will be 6 to 1200 mg.
224263999|NCT01964872|DRUG|JNJ-38877618: Part 1c (optional)|Single dose administered orally in an alternative capsule formulation (Formulation C). The planned dose range for Parts 1 and 2 will be 6 to 1200 mg.
224264000|NCT01964872|DRUG|JNJ-38877618: Part 2|Single ascending dose administered orally in the formulation selected based on Parts 1a, 1b, and 1c (if applicable). The planned dose range for Parts 1 and 2 will be 6 to 1200 mg.
224264001|NCT01964872|DRUG|JNJ-38877618: Part 3|Multiple ascending dose and formulation determined in Part 2 (not to exceed 600 mg) administered orally.
224264002|NCT01964872|DRUG|JNJ-38877618: Part 4 (optional)|Single dose and formulation as determined in Part 3 administered orally in older healthy male participant cohort.
224264003|NCT01964872|DRUG|Placebo: Parts 1a, 2, 3, and 4 (optional)|Administered orally matched to study drug
224264004|NCT03561558|DRUG|Ibuprofen D|Ibuprofen D, oral suspension, 200 mg / 5ml, manufactured by LLC Pharmtechnology, Belarus
224264005|NCT03561558|DRUG|Nurofen® for Children|Nurofen® for Children, Oral Suspension, 100 mg / 5 ml, marketed by Reckitt Benckiser Healthcare International Ltd, UK
224264006|NCT06018818|DEVICE|Amvia/Solvia pacemaker family|Implantation of a pacemaker or CRT-P devices
223794293|NCT04034030|DEVICE|Transcranial Magnetic Stimulation|"Each patient will receive a 10 minute treatment of one time stimulation of the Epileptogenic Cortical Area (ECA). The TRPMS cap will be worn over the previously fixed scalp EEG electrodes. The procedure during this treatment session will consist of positioning a device microstimulator component centered on an area of focal epileptiform discharges (identified with EEG electrode placement) with the patient relaxing in a chair.~The stimulus parameters used will be 120 stimulus trains of 100 ms in duration, each train delivered every 5 s for total session duration of 10 min. . The investigators will measure the subject for adequate placement of the device prior to stimulation. Once the placement of the device is confirmed, the study technician administrating the treatment will turn on the device using the app downloaded on an electronic device connected by Bluetooth to the device."
223794294|NCT05398029|DRUG|VERVE-101|Intravenous (IV) infusion.
223794295|NCT04001673|BEHAVIORAL|Pharmacist's intervention|Information about bDMARDs management.
223794296|NCT05698238|DRUG|CA9hu-1|Humanized monoclonal antibody to human carbonic anhydrase IX
223794297|NCT00193700|DRUG|Testosterone Gel (1%)|
223794298|NCT06211205|DEVICE|Customized 3D printed nostril retainer combined with lip taping|the infants will receive a customised nostril retainer appliance to enhance the nasal esthetics combined with lip tape to approximate the labial and alveolar segments
223794299|NCT06211205|PROCEDURE|Lip taping|the infants will receive lip tape to approximate the labial and alveolar segments
223794300|NCT05893758|DEVICE|The Cera™ PFO Occluder|The Cera™ PFO Occluder is a percutaneous, transcatheter closure device for the non-surgical closure of Patent Foramen Ovale (PFO).
223794301|NCT04769076|COMBINATION_PRODUCT|Paclitaxel（Albumin-bound）|Three courses of albumin-bound paclitaxel combined with cisplatin and PD-1 monoclonal antibody neoadjuvant treatment followed by cisplatin combined with IMRT (intensity modulated conformal radiotherapy) concurrent radiotherapy and chemotherapy
223794302|NCT04391023|DEVICE|Sham Transcranial Direct Current Stimulation (tDCS)|tDCS is a non-invasive brain stimulation technique in which a very weak electrical current (2 mA) is applied to the scalp at the beginning of the session and then remains at 0 mA for the duration of the session to control for placebo-like effects. The anode and cathode will both be placed over the cerebellum.
223794303|NCT04391023|BEHAVIORAL|Balance Training|The balance training protocol will include balance training exercises on both compliant (i.e., foam pad and trampoline) and firm surfaces.
223794304|NCT04391023|DEVICE|2 mA Transcranial Direct Current Stimulation|tDCS is a non-invasive brain stimulation technique in which very weak electrical current (2 mA) is applied to the scalp for 20 minutes. The anode and cathode will both be placed over the cerebellum.
223794305|NCT04391023|DEVICE|4 mA Transcranial Direct Current Stimulation|tDCS is a non-invasive brain stimulation technique in which very weak electrical current (4 mA) is applied to the scalp for 20 minutes. The anode and cathode will both be placed over the cerebellum.
223794306|NCT02645734|DRUG|bevacizumab|1.25 mg of bevacizumab is injected
223794307|NCT02645734|DRUG|ziv-aflibercept 1.25 mg|1.25 mg of ziv-aflibercept is injected
223794308|NCT02645734|DRUG|ziv-aflibercept 2.5mg|2.5 mg of ziv-aflibercept is injected
223794309|NCT02910622|OTHER|Chimio-oncogramme|Cells fragment are cultured for 7 days. The effects of chemotherapy are studied on these cells through chimio-oncogramme.
223794310|NCT02683096|OTHER|Observation|Viable Infants with a failed hearing screen or a diagnosis of SGA who are born at either St. John's Hospital or MMC at ≥ 28 weeks gestation.
223794311|NCT01869491|DRUG|Compound Sodium Alginate Double Action Chewable Tablets|2 tablets four times daily
223794312|NCT01869491|DRUG|Matching placebo tablets|2 tablets four times daily
223794313|NCT03786029|DRUG|Acetaminophen|"Patients will receive 320mg (10ml) Acetaminophen (Strawberry flavour), wait for 30 minutes after the administration, then they will be given the local anesthesia injection. Then the child will be asked to point to the face that fits the degree of pain on the self-reporting pain scale WBFS immediately after the injection.~The tooth will be extracted 10 minutes after the injection, then the child will be asked to record the degree of pain on the same scale immediately after the extraction.~Pain will be re-evaluated 15 minutes after the extraction.~The scale will be given to the parents in order to evaluate the post-extraction pain in 1 to 6 hours while the child is at home.~Parents' satisfaction will be evaluated using Likert fifth scale."
223794314|NCT03786029|DRUG|Placebo|"Patients will receive 10ml Strawberry Juice (placebo), wait for 30 minutes after the administration, then they will be given the local anesthesia injection. Then the child will be asked to point to the face that fits the degree of pain on the self-reporting pain scale WBFS immediately after the injection.~The tooth will be extracted 10 minutes after the injection, then the child will be asked to record the degree of pain on the same scale immediately after the extraction.~Pain will be re-evaluated 15 minutes after the extraction.~The scale will be given to the parents in order to evaluate the post-extraction pain in 1 to 6 hours while the child is at home.~Parents' satisfaction will be evaluated using Likert fifth scale."
223794315|NCT03786029|DRUG|Ibuprofen|"Patients will receive 200mg (10ml) of Ibuprofen (Strawberry flavour), wait for 30 minutes after the administration, then they will be given the local anesthesia injection. Then the child will be asked to point to the face that fits the degree of pain on the self-reporting pain scale WBFS immediately after the injection.~The tooth will be extracted 10 minutes after the injection, then the child will be asked to record the degree of pain on the same scale immediately after the extraction.~Pain will be re-evaluated 15 minutes after the extraction.~The scale will be given to the parents in order to evaluate the post-extraction pain in 1 to 6 hours while the child is at home.~Parents' satisfaction will be evaluated using Likert fifth scale."
223794316|NCT00493922|PROCEDURE|Rapid diagnostic test|Introduction of rapid diagnostic test for malaria
223794317|NCT00493922|PROCEDURE|Microscopy|Microscopy for diagnosis of malaria
223794318|NCT00493922|PROCEDURE|Clinical diagnosis for malaria|The use of Clinical diagnosis for the diagnosis of malaria
223794319|NCT04237506|BEHAVIORAL|Targeted ballet dance|The one-hour ballet dance class will be provided twice per week for six weeks. The syllabi are adapted from the Joffrey Ballet Academy and Royal Academy of Dancing that are targeting grades primary to level 1 and typically developing kids at the age of 6 to 10 years old. PI will be the class instructor, and the class structure will follow the guidelines in 'Dance program for physical rehabilitation and participation in children with cerebral palsy' by Lopez-Ortiz et al.
223794320|NCT04009291|COMBINATION_PRODUCT|TransCon PTH|TransCon PTH drug product is supplied as a clear solution containing TransCon PTH with a nominal PTH(1-34) content of 0.3 mg/mL in a pre-filled pen intended for subcutaneous injection.
223794321|NCT04009291|COMBINATION_PRODUCT|Placebo for TransCon PTH|Placebo is supplied as a clear solution containing the formulation buffer for TransCon PTH in a pre-filled pen intended for subcutaneous injection.
223794322|NCT05758337|DEVICE|Vibropneumostimulation|New vibrators and techniques of vibropneumostimulation of periimplant tissues have been developed, which will allow us to develop a new concept of the relationship of bone remodulation processes around implants of various designs.
223794323|NCT05191940|RADIATION|Particle-therapy using protons or carbon ions|According to the radiation plan (between 25 and a maximum of 40 Gy). Planning Target Volume 1 : 25 Gy (Relative Biological Effectiveness) in 5 fractions of 5 Gy (Relative Biological Effectiveness) Planning Target Volume 2 : A simultaneous integrated boost (SIB) will be delivered to the Planning Target Volume 2: 40 Gy (Relative Biological Effectiveness) in 5 fractions of 8 Gy (Relative Biological Effectiveness).
223794324|NCT05191940|DIAGNOSTIC_TEST|Blood sampling|Evaluation before treatment-start, after treatment and follow-up period.
223794325|NCT05191940|DIAGNOSTIC_TEST|Magnetic resonance imaging|For treatment planning as well as for follow-up radiological tumor assessment.
223794326|NCT05191940|DIAGNOSTIC_TEST|Computertomography|For treatment planning as well as for follow-up radiological tumor assessment.
223794327|NCT05191940|DIAGNOSTIC_TEST|18-F-FluorDesoxyGlukose Positron Emission Tomography-Computer Tomography (18F-FDG-PET-CT)|For treatment planning as well as for follow-up radiological tumor assessment.
223794328|NCT05918705|PROCEDURE|Ultrasound optic nerve sheath diameter / eyeball transverse diameter ratio|"Ocular ultrasonography will be performed once daily on patients diagnosed with sepsis associated encephalopathy at the bedside by two experienced examiners, who will be blinded to patients' clinical data, following the CLOSED protocol for ONSD sonography.~ONSD will be measured at 3 mm behind the merging point of the nerve from the papilla optic disc. The maximum external diameter of ONSD will be measured in the transverse plane perpendicular to the optic nerve and the maximum diameter of ETD (parallel lens) on this plane will be measured.~Two measurements will be taken for each eye; horizontal and vertical. The sequence for measurements will be left eye horizontal; left eye vertical; right eye horizontal; right eye vertical.~The ONSD measurements in the transversal and the sagittal plane for each eye measured by the two examiners will be averaged. Then, ETDs measurements will be averaged to obtain averaged ONSD/ETD ratio as a data to record the mean values of ONSD/ETD ratio."
223794329|NCT06486922|BEHAVIORAL|StEP OUT|The details of program structure and content will evolve as the study progresses based on feedback from participants, interventionists, and the community advisory board. Initially, we will plan to have 5 formal sessions structured as groups with multiple participants receiving the session simultaneously, primarily via remote videoconference, though sessions may occur individually, based on participant schedule and preference. All sessions are designed to be supportive, educational, and interactive, with opportunities to practice skills and discuss feeding and parenting concerns.
223794330|NCT05092516|DEVICE|Active tDCS|2 mA of anodal stimulation will be applied to the left prefrontal cortex over the F3 electrode based on the International 10-10 EEG system.
223794331|NCT05092516|DEVICE|Sham tDCS|Sham stimulation will be applied to the left prefrontal cortex over the F3 electrode.
223794332|NCT06647095|DIETARY_SUPPLEMENT|D-Limonene Gelcaps|Capsules containing d-Limonene will be optionally given during the breath test to all participants of all groups
223794333|NCT06647095|DIETARY_SUPPLEMENT|Fish Oil Concentrate, 1000 Mg Oral Capsule|Capsules containing fish oil will be optionally given during the breath test to all participants of all groups
223794334|NCT05279495|DEVICE|In a double-blinded fashion, 250 mg CANNAXR cream|Determining the Efficacy of topically applied CANNAXR cream in Decreasing UVA Premutagenic and Photoaging markers 8-oxo-dG and the common deletion. 250 mg TOPICAL CBD CANNAXR Cream will be randomized for application to a delineated 50 cm2 area of either the left or right, hip/buttocks skin twice daily for 2 weeks
223794335|NCT05279495|DEVICE|Topical VEHICLE cream|Determining the Efficacy of topically applied VEHICLE cream in Decreasing UVA Premutagenic and Photoaging markers 8-oxo-dG and the common deletion. 250 mg VEHICLE cream will be randomized for application to a delineated 50 cm2 area of either the left or right, hip/buttocks skin twice daily for 2 weeks
223794336|NCT05833737|DRUG|Belantamab mafodotin|Injection for refractory/relapsed multiple myeloma
223794337|NCT04098133|OTHER|data collection for demographic data|data collection for demographic data (age, gender, hospital admission and discharge date, length of stay, hospitalization prior to current hospital stay (acute care facilities, long-term healthcare centres, nursing homes), discharge destination, outcome, cause of death, travel history, previous exposure to antibiotics and proton pump Inhibitors)
223794338|NCT04098133|OTHER|data collection for clinical data|data collection for clinical data (comorbidities, Charlson Comorbidity Index, immunosuppressive treatment, date of diagnosis of CPB, days between hospital admission and diagnosis of CPB, type of consecutive infection, indwelling vascular hardware, urinary catheterization, surgical therapies)
223794339|NCT04098133|OTHER|data collection for treatment data|data collection for treatment data (antibiotic therapy, immunosuppressive therapy, concomitant medication)
223794340|NCT04098133|OTHER|data collection for microbiological data|data collection for microbiological data (species of CPB, type of sample, date of sample, history of colonization or infection with any antibiotic resistant pathogen)
223794341|NCT05110183|DEVICE|electrical stimulation|A cochlear implant electrode will be inserted through a cochleostomy into scala tympani of the cochlear basal turn. Custom software on a laptop computer will be used to control the delivery of a sequence of charge balanced current pules.
223794342|NCT05110183|OTHER|optical stimulation|Optical fibers will be inserted through a cochleostomy into scala tympani of the cochlear basal turn. Custom software will be used to control the delivery of a sequence of charge balanced current pules.
223794343|NCT05110183|OTHER|combined optical and electrical stimulation|A short hybrid array consisting of optical sources and electrical contacts will be inserted through a cochleostomy into scala tympani of the cochlear basal turn. Biphasic electrical current pulse and optical pulse delivery will be controlled in amplitude and timing by a computer.
223794344|NCT05704634|DRUG|Cemiplimab|Given by Injection under the skin every 2 weeks
223794345|NCT05704634|DRUG|Kevzara (Sarilumab)|Given by IV (vein) over about 30 minutes every 3 weeks.
223794346|NCT05140941|DRUG|Sofosbuvir/Velpatasvir 400 MG-100 MG Oral Tablet|One Sofosbuvir/Velpatasvir 400 MG-100 MG Oral Tablet taken once daily for 84 days.
223794347|NCT06479161|DRUG|Tranexamic acid|1.95 grams oral
223794348|NCT04821778|RADIATION|Radiotherapy|50-66Gy/1.8-2.2Gy/25-30f
223794349|NCT04821778|DRUG|Platinum based chemotherapy|q1-3W according to physician's preference
223794350|NCT04821778|DRUG|Paclitaxel based chemotherapy|q1-3W according to physician's preference
223794351|NCT04821778|DRUG|Immunotherapy|Anti-PD-1/PD-L1 Antibody
223794352|NCT04821778|DRUG|5-FU Analog based chemotherapy|W1-5 qW or d1-14, q3W according to physician's preference
223794353|NCT04821778|DRUG|Nimotuzumab|200-400mg, d1,qW
223794354|NCT03842995|BEHAVIORAL|Genetic Counselor|Standard of Care
223794355|NCT03842995|BEHAVIORAL|Trained Healthcare Provider|Neonatologists and Neonatology Nurse Practitioners that receive training to deliver whole genome sequencing results
223794356|NCT03529604|OTHER|Saliva sampling|Saliva was collected from the mouth floor using a specially designed saliva collecting apparatus.
223794357|NCT03529604|DIAGNOSTIC_TEST|ELISA|Saliva samples will be analyzed using enzyme-linked immunosorbent assay (ELISA) for the detection of SCCA1, SCCA2 and TROP2.
223794358|NCT03529604|DIAGNOSTIC_TEST|HPLC|High-performance liquid chromatography (HPLC) will be used to measure Ap4A concentrations in saliva.
223794359|NCT01380483|DRUG|doxycycline monohydrate|Tablets, 100 mg, single, oral dose
223794360|NCT01380483|DRUG|doxycycline monohydrate|Capsule, 100 mg, single, oral dose
223794361|NCT04541134|DRUG|Pelubiprofen 45mg|Pelubiprofen 45mg 1 tab for moderate or severe menstrual pain, bid for 3days(prn)
223794362|NCT04541134|DRUG|Placebo|Placebo1 tab for moderate or severe menstrual pain, bid for 3days(prn)
223794363|NCT02656797|DRUG|Topical Amphotericin-B 0.4% liposomal gel|Topical Amphotericin-B 0.4% liposomal gel
223794364|NCT05804565|PROCEDURE|Bone Saw|The surgeon will use an oscillating microsaw to transect the metatarsal shaft
223794365|NCT05804565|PROCEDURE|Bone Cutter|The surgeon will use a manual bone cutter to transect the metatarsal shaft
223794366|NCT05553808|DRUG|Docetaxel|Docetaxel was administered as IV infusion.
223794367|NCT05553808|DRUG|Feladilimab|Feladilimab was administered as IV infusion.
223794368|NCT01802372|BEHAVIORAL|WHO CVD risk assessment package|Arm#1 (Intervention Group): Provided Ghana's National Health insurance and the WHO CVD Risk Assessment package for 12 months.
223794369|NCT01802372|BEHAVIORAL|Health Insurance only|Arm#2 (Control group): Provided Ghana's National Health Insurance for 12 months, brief behavioral counseling at baseline, and usual care.
223794370|NCT03902379|OTHER|Internet-Based Intervention|Receive CCI intervention
223794371|NCT03902379|OTHER|Quality-of-Life Assessment|Ancillary studies
223794372|NCT03902379|OTHER|Questionnaire Administration|Ancillary studies
223794373|NCT03902379|OTHER|Survey Administration|Ancillary studies
223794374|NCT00578994|DEVICE|Oxford® Meniscal Unicompartmental Knee System|Oxford® Meniscal Unicompartmental Knee System is a medial, unicompartmental knee prosthesis containing three components: a femoral component, a tibial component, and a tibial meniscal bearing.
223794375|NCT01299246|PROCEDURE|Michigan Neuropathy Screening Instrument|Peripheral neurological assessment was carried out using MNSI. The diabetes nurse educators assessed five parameters on both feet and counted the total points, ranging from 0 to10: (1) Appearance of feet; if abnormal, then inspection of lower limbs for deformities was carried out; (2) Identification of foot ulceration; (3) Vibration perception of the big toe; (4) Ankle reflexes; (5) touch-pressure sensation test with a 10 g Semmes-Weinstein monofilament.
223794376|NCT01597544|PROCEDURE|CISC instruction pre-operatively|Patients allocated to the pre-operative CISC teaching group will be taught how to perform CISC by one of urogynecology nurses working at the Women's Health Care Centre. Patients will be allowed to practice until they feel comfortable with the technique. This should take approximately 30 minutes. The session will take place on the day of their pre-operative medical appointment (PAF), which normally occurs less than a month before the surgery. If a patient is not seen in PAF or is seen more than a month before her surgery, a separate appointment for CISC teaching during the month preceding the surgery will be organized. Post-operatively, a nurse from the hospital gynecology unit will review the technique to make sure the patient is still comfortable with performing CISC.
223794377|NCT05406687|OTHER|Health Navigator Model|The Health Navigator Model will be a longitudinal, person-centered and community-based intervention focused on addressing both primary and secondary cancer prevention, as well as reducing wider barriers to healthcare. Health Navigators (HNs) will be professionals who have a background in social care and an understanding of the local user population, and will be embedded in settings familiar and accessible to people experiencing homelessness. The primary aspects of the HN role will be to identify the health needs and barriers of users, promote cancer awareness and education, facilitate timely access to healthcare services and cancer screening, provide practical assistance, delivered through regular in-person meetings, and utilize wider stakeholders, including healthcare professionals, to deliver the intervention. A comprehensive training package will be delivered to the HNs, covering population specific knowledge, interpersonal skills, cancer education and local resources.
223794378|NCT01143948|DRUG|Glargine & Glulisine|Basal Glargine \& bolus Glulisine
223794379|NCT01143948|DRUG|Regular insulin|Sliding scale regular insulin
223794380|NCT01143948|DRUG|NPH & regular insulin|Basal NPH \& bolus regular insulin
223794381|NCT03335033|COMBINATION_PRODUCT|Contrast-enhanced ultrasound|Subjects will receive a low mechanical index (0.17-0.20) imaging during ultrasound contrast agent intravenous infusion. Real-time cine-loop including longitudinal and transverse images obtained at least 3 seconds before and 5 minutes after the appearance of the contrast effect in the lumen of the carotid artery will be acquired and digitally stored for offline analysis. Also use of a 3D ultrasound transducer to evaluate the feasibility of using US images with contrast to assess the residual diameter of the diseased vessel. Specifically, two 3D acquisitions of each lesion would be obtained after contrast has been injected.
223794382|NCT03335033|DEVICE|Shear Wave Elastography|Shear wave elastography will be performed with the General Electric Logiq E9 scanner acquiring images of each plaque in the longitudinal and transverse imaging planes. In each plane 10 measurements will be made and the in-phase/quadrature (IQ) data will be saved for further analysis. The plaque area in the imaging plane will be user-defined to extract the wave velocity values for a ROI analysis.
223794383|NCT03335033|DEVICE|Ultrasound Examination|A standard carotid US examination using Duplex imaging will performed using a linear array transducer to obtain longitudinal and transverse images. All ultrasound measurements will be made by a trained registered vascular technologist. Severity of stenosis of the plaque will be measured based on established protocol and guidelines.
223794384|NCT05086133|DEVICE|transcranial magnetic stimulation|transcranial magnetic stimulation with continuous theta burst pattern, 90% RMT, 50Hz within train and 5Hz train for 200 train and 40 second in total.
223794385|NCT05086133|DEVICE|sham stimulation|TMS coil vertical to the brain surface, with same protocol as cTBS
223794386|NCT04148443|OTHER|Preoxygenation|participants will receive 3 minutes of preoxygenation before intubation
223794387|NCT04148443|OTHER|Preoxygenation (longer)|participants will receive 5 minutes of preoxygenation before intubation
223794388|NCT00785655|DRUG|Dermacyd PH_DETINLYN (Lactic Acid)|
223794389|NCT01346748|DRUG|statin|Sinvastatin 80 mg per day - 21 days versus placebo
223794390|NCT04802538|DEVICE|OstoRing®|Participants will use the OstoRing® along with their standard pouching equipment.
223794391|NCT01438502|DRUG|HyperHAES® (hypertonic saline/HES)|After arrival to the operating theatre both study groups will receive an infusion of acetated Ringers solution 4 ml/kg/hour. Additionally both groups for 4 hours will receive 1 ml/kg/hour of a blinded solution. This solution will be either acetated Ringers solution or HyperHAES® (7.2 % NaCl/ 6 % hydroxyethyl-starch (200/0.5)).
223794392|NCT02938598|BEHAVIORAL|Maternal Depression Education and Care-Seeking Motivation|Multicomponent behavioral and educational intervention. The investigators are only testing 3 components: Engagement, Problem-Solving, and Follow-Up Motivation
223794393|NCT03598270|DRUG|Placebo|Volume equivalent to 1200 mg of atezolizumab drug product. Intravenous Day 1
223794394|NCT03598270|DRUG|Carboplatin|Intravenous. Day 1
223794395|NCT03598270|DRUG|Paclitaxel|175 mg/m². Intravenous. Day 1
223794396|NCT03598270|DRUG|Niraparib|200 mg or 300 mg. Oral. From day 1 to 21
223794397|NCT03598270|DRUG|Gemcitabine|1000 mg/m². Intravenous. Day 1 and day 8.
223794398|NCT03598270|DRUG|Pegylated liposomal doxorubicin (PLD)|30 mg/m². Intravenous. Day 1
223794399|NCT03598270|DRUG|Atezolizumab|1200 mg. Intravenous. Day 1
223794400|NCT01041638|BIOLOGICAL|Aldesleukin|Given IV
223794401|NCT01041638|OTHER|Diagnostic Laboratory Biomarker Analysis|Correlative studies
223794402|NCT01041638|BIOLOGICAL|Dinutuximab|Given IV
223794403|NCT01041638|DRUG|Isotretinoin|Given PO
223794404|NCT01041638|BIOLOGICAL|Sargramostim|Given IV or SC
223794405|NCT05110092|BEHAVIORAL|leg resistance combined with breathing exercise training|The exercise group was provided breathing and leg resistance exercise manuals. The exercise involved 5 minutes of abdominal breathing in a relaxed sitting position, followed by 10 minutes of leg resistance training.
223794406|NCT01652144|DRUG|AT7519M|
223794407|NCT03152552|DRUG|LIK066|LIK066 was supplied in different doses as tablets taken orally.
223794408|NCT03152552|DRUG|Placebo|Placebo was supplied as tablets and capsules taken orally.
223794409|NCT03152552|DRUG|Empagliflozin|Empagliflozin was supplied as capsules taken orally.
223794410|NCT00567242|BEHAVIORAL|Word-finding with intention component|Word-finding trials (picture-naming) with intention manipulation (initiating word-finding trials with a complex left-hand movement). 8 (or more) baseline sessions over 4 days followed by 30 treatment sessions (2 sessions/day, 5 days/week for 3 weeks).
223794411|NCT00567242|BEHAVIORAL|Word-finding with no intention component|Word-finding trials with no intention manipulation. 8 (or more) baseline sessions in 4 days followed by 30 treatment sessions (2 sessions/day, 5 days/week for 3 weeks).
223794412|NCT04113122|DIAGNOSTIC_TEST|Skin biopsy|A 4 mm skin biopsy will be performed at the upper leg of the patient. Before the skin biopsy local anesthesia is applied subcutaneously. In these skin biopsies senescent cells will be detected by p16, p21 and yH2Ax staining. Furthermore, we will measure platinum levels in the skin biopsies.
223794413|NCT04113122|DIAGNOSTIC_TEST|Subcutaneous fat biopsy|"An abdominal subcutaneous fat biopsy will be performed 7-10 cm on the right side of the umbilicus. Before the fat biopsy local anesthesia is applied subcutaneously. An amount of 30 mg fat tissue will be collected using needle aspiration.~In these fat biopsies senescent cells will be detected by p16, p21 and yH2Ax staining. Furthermore, we will measure platinum levels (ICP-MS), adipocytokines (leptin, adiponectin, interleukin-6, PAI-1, TNF-α), p53 activation indirectly by measuring p21 or mdm2 expression using immunohistochemistry, microRNA regulation of insulin signaling in adipose tissue: miR-103, miR-107, miR-29."
223794414|NCT05263011|OTHER|Avocado|1 avocado as evening snack
223794415|NCT05263011|OTHER|low fat yogurt|1 serving of low fat yogurt matching calories of 1 avocado
223794416|NCT05263011|OTHER|low fat yogurt + fiber +fat|low fat yogurt mixed with ultra processed olive oil + fiber supplement, equivalent to fat and fiber content in 1 avocado
223794417|NCT03154008|BEHAVIORAL|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy will follow the Adolescent Coping with Depression Course (CWD; Clarke et al., 1999), an established 16-session group treatment protocol, and consist of behavioral activation, relaxation skills, cognitive therapy, social skills, problem solving, and relapse prevention.
223794418|NCT05054608|OTHER|No intervention|Observational study. No intervention.
224264007|NCT06039605|DEVICE|Transcranial Direct Current Stimulation|Transcranial Direct Current Stimulation (tDCS) is a minimal risk, non-invasive, neuromodulatory technique that involves the emission of a weak electrical current, traditionally via the placement of two electrodes attached to the scalp of a participant. tDCS is widely used for research purposes, the US FDA considers trials of tDCS as non-significant-risk. There are several review articles supporting the safety of tDCS usage in controlled human trials. According to a published meta-analysis , the use of conventional tDCS protocols in human trials (≤40 min, ≤4 mA) has not produced any reports of a Serious Adverse Effect or irreversible injury across over 33,200 sessions.
223794419|NCT05899933|PROCEDURE|Non-surgical peri-implant therapy|"2 weeks after baseline examination, non surgical therapy will be applied in implants diagnosed with peri-implantitis prior to enrollment in surgical therapy.~Firstly, participants will be instructed in oral hygiene. Professional supragingival and subgingival debridement of implants/ teeth, including the selected for the study implants, will be performed. Local anesthesia will be performed, when needed. Targeted implants will be treated with PEEK-coating ultrasonic tips (Instrument PI; EMS), titanium curettes (IMPM11/12T, IMPM13/14T; Hu-Friedy), rubber cup and polishing paste. Possible adjustments to implant-borne prostheses will be considered, whenever possible. Re-evaluation of non-surgical therapy will be performed after 6 weeks.~At the 6-week reevaluation, participants with peri-implant probing pocket depth ≥5 mm and bleeding on probing and/or suppuration in patients with full mouth plaque score ≤20% will proceed to surgical therapy."
223794420|NCT05899933|PROCEDURE|Implantoplasty|"Screw-retained supraconstructions and, when possible, cement-retained restorations will be removed.~Following local anesthesia, intrasulcular incisions will be performed and full-thickness flaps will be elevated on the buccal and lingual aspects of affected implants. Granulation tissue will be removed, and titanium-coated curettes (IMPM11/12T, IMPM13/14T; Hu-Friedy) and NiTi brushes (NEGRIN IN DENTAL) will be applied to remove hard deposits on implants. Osseous recontouring will be performed when indicated followed by irrigations with saline. Implantoplasty will be applied using tungsten carbide burs of various shapes and sizes (Peri-implantitis Kit; Meisinger) followed by irrigations with saline. Flaps will be readjusted and closed with sutures in order to allow a non-submerged healing. Supraconstructions will be reconnected after the surgery."
223794421|NCT05899933|PROCEDURE|Erythritol Air-abrasive device|"Screw-retained supraconstructions and, when possible, cement-retained restorations will be removed.~Following local anesthesia, intrasulcular incisions will be performed and full-thickness flaps will be elevated on the buccal and lingual aspects of affected implants. Granulation tissue will be removed, and titanium-coated curettes (IMPM11/12T, IMPM13/14T; Hu-Friedy), and NiTi brushes (NEGRIN IN DENTAL) will be applied to remove hard deposits on implants. Osseous recontouring will be performed when indicated followed by irrigations with saline. Implant surface decontamination with an air-abrasive device (AIRFLOW® MAX, AIRFLOW® Prophylaxis Master; EMS) with erythritol powder (AIRFLOW® Plus Powder; EMS) will be applied followed by irrigations with saline. Flaps will be readjusted and closed with sutures in order to allow a non-submerged healing. Supraconstructions will be reconnected after the surgery."
223794422|NCT05899933|PROCEDURE|Prophylaxis|Supramucosal biofilm removal of implants/ teeth will be performed at, 3, 6, 9 and 12 months after surgical therapy for the Implantoplasty group and the Erythritol Air-abrasive device group and at 2 weeks, 3, 6, 9 and 12 months after baseline examination for the control group. Targeted implants will be treated with an air-abrasive device (AIRFLOW® MAX, AIRFLOW® Prophylaxis Master; EMS) with erythritol powder (AIRFLOW® Plus Powder; EMS). During these appointments, patients will be re-motivated and re-instructed to oral-hygiene measures.
223794423|NCT01750073|DRUG|Cyclophosphamide|Given IV
223794424|NCT01750073|DRUG|Doxorubicin Hydrochloride|Given IV
223794425|NCT01750073|OTHER|Laboratory Biomarker Analysis|Correlative studies
223794426|NCT01750073|DRUG|Paclitaxel|Given IV
223794427|NCT01750073|RADIATION|Radiation Therapy|Undergo RT
223794428|NCT01750073|PROCEDURE|Therapeutic Conventional Surgery|Undergo mastectomy or breast conserving surgery
223794429|NCT01750073|BIOLOGICAL|Trastuzumab|Given IV
223794430|NCT02457221|DRUG|Tacrolimus capsules|oral
223794431|NCT02457221|DRUG|Cyclophosphamide injections|intravenous injection
223794432|NCT02457221|DRUG|Prednisone|oral
223794433|NCT00882947|DRUG|Ventavis (Iloprost, BAYQ6256)|Iloprost solution for inhalation, BAYQ6256, Synthetic Prostacyclin analog
223794434|NCT01022762|DRUG|repaglinide|Individually adjusted dose for 16 weeks
223794435|NCT01022762|DRUG|gliclazide|Individually adjusted dose for 16 weeks
223794436|NCT00491049|DRUG|0.5% levofloxacin eye drops|
223794437|NCT03215797|DRUG|phenylephrine|phenylephrine 100ug/ml IV infusion at a rate of 5ml/h in case of hypotension.
223794438|NCT03215797|DRUG|Norepinephrine|Norepinephrine 5ug/ml IV infusion at a rate of 5 ml/h in case of hypotension
223794439|NCT05585424|OTHER|AOT intervention|"The treatment will last 4 weeks, with an intensity of 3 sessions per week. During the sessions the MCI patient will observe his MCI partner and perform a programme of upper limb motor activities. At the same time the mild patient imitates the movement performed by the physiotherapist, all based on the AOT.~The activities will be based on items of the FUGL-MEYER scale. The sessions will last between 15 and 20 minutes and will be held three days a week. The intervention will last 5 weeks, with an initial assessment, 11 intervention sessions and a final assessment."
223794440|NCT01302119|DRUG|AN2690 Topical Solution, 5%|AN2690 Topical Solution, 5%, applied once daily for 48 weeks
223794441|NCT01302119|DRUG|Solution Vehicle|AN2690 Topical Solution, Vehicle, applied once daily for 48 weeks
223794442|NCT01244152|BEHAVIORAL|Intensive diabetes self-management education|18 group classes led by a dietitian and peer supporters, and weekly telephone calls by peer supporters. Intervention focus was on diet and physical activity.
223794443|NCT01244152|BEHAVIORAL|Enhanced standard diabetes education|2 3-hour diabetes education classes taught by a health educator at a local clinic
223794444|NCT04084314|BIOLOGICAL|Erenumab|Erenumab was supplied as a pre-filled pen (auto-injector) for subcutaneous injection.
223794445|NCT01055769|DRUG|Linezolid|"1. Linezolid OS 600 MG~2. Linezolid Tablet 600 MG"
223794446|NCT01055769|DRUG|Linezolid|"1. Linezolid Tablet 600 MG~2. Linezolid OS 600 MG"
223794447|NCT02235493|BIOLOGICAL|Retrospective Case Only|
223794448|NCT06305338|OTHER|Optical Coherence Tomography|the study releated measurements will be performed: IOLMaster 700, Casia 2 and Pentacam HR.
223794449|NCT05576987|BEHAVIORAL|Education|Students selected for the experimental group will be trained by the researcher for school accidents prepared in line with the components of the Health Belief Model.The training program will be planned as 30 minutes per week for 4 weeks. Before the training and at the end of the training (at the end of the 4th week), the students will be applied personal information form and a behavior scale for safety precautions in school accidents.
223794450|NCT04838899|RADIATION|Stereotactic Body Radiation Therapy (SABR)|SABR to oligoprogressive metastases while continuing abiraterone therapy
223794451|NCT05152680|DRUG|[14C]-NV-5138|Single dose, given as oral solution, 1600 mg
223794452|NCT02436148|OTHER|Prosthetic for major lower limb amputation|Prosthetic for major lower limb amputee
223794453|NCT06099626|OTHER|Different types of disease|Groups were observed according to disease type
223794454|NCT00000179|DRUG|Trazodone|
223794455|NCT00000179|DRUG|Haloperidol|
223794456|NCT01798329|DIETARY_SUPPLEMENT|probiotic VSL#3|"VSL#3 is a probiotic that reduces:~* urease faecal activity~* faecal pH~* inflammatory cytokine"
223794457|NCT06427772|PROCEDURE|bipolar hemiarthroplasty|bipolar hemiarthroplasty for neck femur fracture
223794458|NCT00802074|DRUG|Raltegravir|400mg BID
223794459|NCT00802074|DRUG|Fosamprenavir|1400mg BID, 700 mg BID or 1400 mg QD
223794460|NCT00802074|DRUG|Ritonavir|100 mg BID or QD
223794461|NCT01632748|DEVICE|Neurotech Vital Device|5 minute treatment
223794462|NCT01632748|DEVICE|Modified Neurotech Vital Device|5 minute stimulation
223794463|NCT05875948|DRUG|R2R01|Pharmaceutical form: sterile 2R vials containing 10 mg of R2R01.
223794464|NCT05875948|DRUG|Terlipressin|"In the US, terlipressin is supplied as a sterile, preservative-free, lyophilized, white-to- off-white powder for intravenous (IV) administration. Each vial contains 0.85 mg Terlivaz, equivalent to 1 mg terlipressin acetate, and 10.0 mg mannitol. Terlivaz requires reconstituting in saline (5mL).~In the EU, terlipressin is supplied in a clear glass vial with 5 ml of injection solution, containing 1 mg terlipressin acetate corresponding to 0.85 mg terlipressin."
223794465|NCT05746845|BIOLOGICAL|Blood sample|"Blood sampling will be done on three groups:~Group 1: Healthy volunteers, so-called control donors whose blood samples will be ordered from the EFS (French Blood Establishment) Group 2: Stable MS patients without inflammatory activity of the disease treated with high efficacy treatment (Natalizumab or Ocrelizumab) Group 3: Stable MS patients without inflammatory disease activity treated with moderately effective treatment (Teriflunomide or Fumarate)"
223794466|NCT03049410|PROCEDURE|Intracorporeal Robot Assisted Radical Cystectomy|Intracorporeal robot assisted radical cystoprostatectomy or anterior exenteration
223794467|NCT03049410|PROCEDURE|Open Radical Cystectomy|Removal of bladder and adjacent organs
223794468|NCT02631798|DIETARY_SUPPLEMENT|Food grade dye mucosal staining|mucosal staining with food grade dye
223794469|NCT00160433|DRUG|Asoprisnil|0.5 mg Tablet, oral Daily for 12 weeks
223794470|NCT00160433|DRUG|Asoprisnil|1.5 mg Tablet, oral Daily for 12 weeks
223794471|NCT00160433|DRUG|Asoprisnil|5.0 mg Tablet, oral Daily for 12 weeks
223794472|NCT00160433|DRUG|Placebo|Tablet, oral Daily for 12 weeks
223794473|NCT00697749|BIOLOGICAL|HBV-MPL vaccine 208129|2-dose intramuscular injection
223794474|NCT00697749|BIOLOGICAL|Engerix™-B|3-dose intramuscular injection
223794475|NCT01191489|DEVICE|High Flow Conditioned Oxygen Therapy in High Risk Patients|OptiFlow system (R) with nasal cannula.
223794476|NCT01191489|DEVICE|Non-invasive mechanical ventilation|Bilevel pressure support through a facial mask
223794477|NCT01191489|DEVICE|Conventional Oxygen Therapy|Conventional Oxygen Therapy with nasal cannula or Venturi facial mask.
223794478|NCT06647797|BEHAVIORAL|HOPE Clinical Communication Campaign|"* Patient-facing educational materials~* Provider counseling training and job aid"
223794479|NCT04086420|BEHAVIORAL|Mindfulness|Received instructions to exercise at moderate intensity while listening to an audio-recorded mindfulness-based physical activity intervention
223794480|NCT04086420|BEHAVIORAL|Heart-Rate|Given a heart rate monitor, told to exercise within the moderate intensity range (64-76% of estimated maximum heart rate)
223794481|NCT03463902|DEVICE|left IFG anodal|"Single session of transcranial direct current stimulation (tDCS) over left IFG anodal stimulation~2 mA Stimulation of 10 min, anodal electrode over left IFG, cathodal electrode over right IFG, 30 sec ramp to start and 30 sec ramp to stop"
223794482|NCT03463902|DEVICE|left IFG cathodal|"Single session of transcranial direct current stimulation (tDCS) over left IFG cathodal stimulation~2 mA Stimulation of 10 min, cathodal electrode over left IFG, anodal electrode over right IFG, 30 sec ramp to start and 30 sec ramp to stop"
223794483|NCT03463902|DEVICE|left IPL anodal|Single session of transcranial direct current stimulation (tDCS) over left IPL anodal stimulation 2 mA Stimulation of 10 min, anodal electrode over left IPL, cathodal electrode over right IPL, 30 sec ramp to start and 30 sec ramp to stop
223794484|NCT03463902|DEVICE|left IPL cathodal|Single session of transcranial direct current stimulation (tDCS) over left IPL cathodal stimulation 2 mA Stimulation of 10 min, anodal electrode over left IFG, cathodal electrode over right IFG, 30 sec ramp to start and 30 sec ramp to stop
223794485|NCT03463902|DEVICE|Placebo|Single session of placebo tDCS over left IFG 10 min duration, 30 sec ramp during start and end
223794486|NCT03743038|DRUG|FMX101 vehicle|FMX101 vehicle - hydrophobic oil based vehicle (Test Article A)
223794487|NCT03743038|OTHER|Hydro-alcohol solution|Hydro-alcohol solution based vehicle (Test Article B)
223794488|NCT04083248|BEHAVIORAL|Feasibility group|Same as arm description
223794489|NCT01300546|DRUG|Sumatriptan/Naproxen Sodium|Each tablet of Treximet for oral administration contains Sumatriptan 85mg / Naproxen Sodium 500mg. Study medication is to be administered within 1 hour of migraine onset on 14 or fewer days per month in the Treatment Period.
224264008|NCT05276479|OTHER|Anonymous online survey on dietary habits and mental health|Assessment of regular feeding behavior and mental health
224264009|NCT05427708|DEVICE|Capnometry-Guided Respiratory Intervention|See: Arm/group descriptions
224264010|NCT05427708|BEHAVIORAL|Psycho-Education|See: Arm/group descriptions
223794490|NCT01300546|DRUG|Naproxen Sodium|Each tablet of Naproxen Sodium for oral administration is provided in 500mg tablet. Study medication is to be administered within 1 hour of migraine onset on 14 or fewer days per month in the Treatment Period.
223794491|NCT02580565|OTHER|telephone interview|Clinical assessment for screening and a phone call for questionnaire administration
223794492|NCT01446458|DRUG|Modified FOLFIRINOX|Patients receive modified FOLFIRINOX Chemotherapy for 4 cycles (1 cycle = 15 days). Modified FOLFIRINOX: Oxaliplatin 85 mg/m2 intravenous infusion on day 1; Irinotecan 180 mg/m2 intravenous infusion on day 1; 5-Fluorouracil 2400 mg/m2 continuous intravenous infusion on days 1 to 3; pegylated filgrastim (neulasta) 6 mg subcutaneous injection on day 3.
223794493|NCT01446458|RADIATION|Stereotactic Body Radiotherapy (SBRT)|Patients will receive Stereotactic Body Radiotherapy (SBRT) to pancreas tumor 2 weeks following chemotherapy. SBRT is given in 3 daily fractions at designated doses per treatment cohort. Starting dose level-Dose level 1: 10 Gy SBRT to primary tumor volume (PTV) / 2 Gy SBRT to the retroperitoneal margin daily for a total Gy to Gross tumor volume (GTV) of 36 Gy. There are weekly toxicity assessments for 4 weeks. This is a standard 3 + 3 design with 4 dose levels.
223794494|NCT04584060|COMBINATION_PRODUCT|ERAS protocols|ERAS protocols including avoidance of prolonged pre-operative fasting and early removal of Ryle, surgical drains and urinary catheter
223794495|NCT04584060|COMBINATION_PRODUCT|Early oral feeding|Chewing gum, oral magnesium and alvimopan can be started early postoperatively, Initiation of feeding-Oral sips on day 1, step up day 2 onward
223794496|NCT04584060|COMBINATION_PRODUCT|Prophylaxis against DVT|Patient will wear well-fitting compression stockings and receive pharmacological prophylaxis with LMWH. Encourage to mobilize out of bed after effect of general anesthesia has weaned off.
223794497|NCT02160587|DRUG|Chloraprep|ChloraPrep will be compared to ZuraPrep with regard to skin sensitization and irritation.
223794498|NCT02160587|DRUG|0.9% Physiological Saline|0.9% Physiological Saline will be compared to ZuraPrep with regard to skin sensitization and irritation.
223794499|NCT02160587|OTHER|ZuraPrep without IPA|ZuraPrep without IPA will be compared to ZuraPrep with regard to skin sensitization and irritation
223794500|NCT03936855|PROCEDURE|Direct composite resin|"For both groups: The teeth will have the enamel surface conditioned with 37% phosphoric acid. For the restorative procedure, the same adhesive system will be used~GROUP ACTIVE COMPARATOR~1. Insert resin-modified glass ionomer cement into the pulp chamber;~2. Complete the restoration by incremental technique using conventional composite resin in increments of 2mm;~EXPERIMENTAL GROUP~1. Insert Bulk Fill composite inside the pulp chamber to the height of 5 mm;~2. Complete the insertion of the Bulk Fill resin to the limit of the caval surface angle in the occlusal"
223794501|NCT05476939|DRUG|Everolimus|Tablets of 2.5 mg or 10 mg. The prescribed dose is 5 mg/m²/day, orally, once daily. Dose will be capped at 10 mg once daily.
223794502|NCT05476939|DRUG|ONC201|Capsules of 125mg. The prescribed dose is 375mg/m², once daily at Day 1 and Day 2 of each week. Dose will be capped at 625 mg per dose.
223794503|NCT05476939|RADIATION|Radiotherapy|"All patients will be treated with 30 conventional single daily fractions of 1.8 Gy to a total of 54 Gy over a planned period of 6 weeks. Dose may be increased up to 60 Gy for adult patients with supratentorial ND-DMG. The clinical target volume will include all the areas of abnormality on T2/FLAIR sequences with a 1-cm margin.~Radiotherapy will have to start within a maximum of 4 weeks for DIPG, up to 6 weeks for other DMG H3K28-altered (ND-DMG), after the biopsy or last surgery. The study medication will be started at Day 1 (+3 days max) of radiotherapy. Reirradiation is permitted only at disease progression according to local practice.~In case of metastatic disease or intramedullary tumors, patients can be included in the study. In this situation, radiotherapy will have to start within a maximum of 4 weeks for DIPG, up to 6 weeks for other DMG H3K28-altered (ND-DMG), after the biopsy or last surgery while targeted treatment will start at the end of the irradiation."
223794504|NCT04647526|DRUG|[Lu-177]-PNT2002|Participants randomized to Arm A will receive 6.8 GBq (±10%) of \[Lu-177\]-PNT2002 every 8 weeks for 4 cycles
223794505|NCT04647526|DRUG|Abiraterone|Abiraterone (1000 mg orally qd with: 5 mg bid prednisone or 0.5 mg qd dexamethasone)
223794506|NCT04647526|DRUG|Enzalutamide|Enzalutamide (160 mg orally qd)
223794507|NCT03846830|DEVICE|Incremental Velocity Error (IVE)|A lightweight headband has electronics attached that detect head velocity and move a laser target at a fraction of the head velocity.
223794508|NCT03846830|BEHAVIORAL|Traditional Vestibular Rehabilitation (VPT)|Standard of care, meta-analysis vetted, eye and head motion exercises to reduced morbidity associated with dizziness and imbalance.
223794509|NCT06649292|DRUG|SHR-A1904|SHR-A1904
223794510|NCT06649292|DRUG|Paclitaxel, Docetaxel, Irinotecan|Paclitaxel, Docetaxel, Irinotecan
223794511|NCT06412731|OTHER|Cera-bur|Dental caries removal using a low-speed handpiece and a ceramic bur and restoring the cavity with Glass ionomer filling material
223794512|NCT06412731|OTHER|Brix3000|Chemical-dissolving active dental caries and hand instrument used for removing the lesion then restoring with Glass ionomer filling material
223794513|NCT06412731|OTHER|E-SDF|Arresting the infected dentin and the demineralized lesion covered with Glass-ionomer filling
223794514|NCT06561529|DEVICE|Gastric Bypass Stent System|The Gastric Bypass Stent System is intended to be used in weight loss treatment for obesity holds potential as a non-invasive technique for managing hepatic fibrosis. This clinical investigation will be used to evaluate the safety and performance of the investigational device for the intended use.
223794515|NCT04568538|OTHER|Training program|"A training program and booklet content for the education to be given to mothers includes the following topics.~* What is shaken baby syndrome and what is its cause?~* What are the harms caused by shaken baby syndrome?~* How is shaken baby syndrome understood?~* What problems can shaken baby syndrome cause?~* What are the measures to be taken? For the training and the content of the booklet, expert opinion was obtained from 10 academic members who are experts in the field of Child Health. An evaluation form was created for pre-test and post-test measurements. Expert opinions were also received for these forms.~Mothers of 2-4 months old babies who applied to Akdeniz University Hospital Pediatric Outpatient Clinic for check-up were randomized with a sealed envelope and accepted the study. In this way, intervention and control groups can be determined. After the pre-test is done in the intervention group, 2-month training, booklet and tele-consultancy services will be provided."
223794516|NCT02167022|OTHER|Physical and occupational therapy|The type of physiotherapy to be administered is Perception-Action (P-A). The P-A (motor) intervention is a child-driven approach without the need for special equipment and considers the child and environment as a single unit.Treatment is a coupling of the child with the environment. The environment is changed to enable, enhance or stimulate movement. The action is initiated by the child with the therapist augmenting the child's environment using touch (tactile information) or light support (cushions, bolsters, and gentle touch or pressure) to assist and/or alter the child's active movement. Toys are used and positioned in different places to encourage movement of upper and lower extremities and the trunk; reaching, turning, sitting balance, crawling, walking.
223794517|NCT05504460|DEVICE|Hydrogen-Oxygen Generator with Nebulizer, AMS-H-03|Treatments in the test group will lasts for 12 months, and symptomatic treatment will be provided based on the actual symptoms of the subjects. Subjects in the test group will be required to receive inhalation for at least 4 days every 7 days with at least 3780L inhaled every 7 days (It is recommended to inhale at least 540L per day; If the flow rate is 3L/min, it is recommended that the cumulative inhalation time should be at least 3 hours per day. If the flow rate is 1.5L/min, it is recommended that the cumulative inhalation time should be at least 6 hours per day).
223794518|NCT05504460|OTHER|basic treatment|supportive treatment determined by the investigator based on the condition of the patients
223794519|NCT05530135|OTHER|Exercise program|Exercise program
223794520|NCT05530135|OTHER|Cognitive behavioural therapy|Cognitive behavioural therapy
223794521|NCT05530135|OTHER|Standard clinical care|Standard clinical care
223794522|NCT05903417|DRUG|Intrapleural fibrinolytic with alteplase 5mg and pulmozyme 5 mg|The number of installation of intrapleural t-PA/DNase depends on the discretion of the treating physician (at least 6 hours apart between each dose). 5mg of Alteplase (t-PA) and 5mg DNase are diluted in each 50ml of 0.9% sodium chloride solution. t-PA and DNase are not mixed together in one syringe. In brief , both medication are administered sequentially which t-PA is first instilled intrapleurally and the chest tube is then clamped for 45 minutes, then unclamped to allow free drainage for 45 minutes. The same procedure is then repeated for DNase. Selection of the timing of treatment and removal of chest tube are depending on the chest physician's judgement.
223794523|NCT05903417|OTHER|Saline irrigation with 250 mls normal saline (over 1 hour)|subjects were administered 250 ml of 0.9% sodium chloride via chest tube a three way tap from a drip stand which were allowed drainage freely over 1 hour. Pleural irrigation will be performed minimum of 3 installations and maximum of 9 installation (3 times per day).
223794524|NCT04988308|DRUG|Bermekimab|Bermekimab will be administered subcutaneously.
223794525|NCT04988308|DRUG|Adalimumab|Adalimumab will be administered subcutaneously.
223794526|NCT04988308|DRUG|Placebo|Placebo will be administered subcutaneously.
223794527|NCT04867577|DIAGNOSTIC_TEST|CT scan of lung and spine|Dual energy CT scan of thorax and spine
223794528|NCT01308216|PROCEDURE|low level laser therapy procedure|Transcranial low level laser therapy by automatic scanning noncontact over both cerebral hemispheres.
223794529|NCT00670774|DRUG|Eculizumab|"* Patients will be given 1200 mg of eculizumab intravenously over 30 minutes, 1 hour prior to surgery.~* Patients will be given 900 mg of eculizumab on Day 1 post-transplant.~* Patients will then be given 900 mg of eculizumab weekly through 4 weeks post-transplant~* At week 4, patients will be assessed for B cell flow cytometry cross match (FCXM). Patients with B cell FCXM less than 200 will stop eculizumab treatment. Patients with B cell FCXM greater than or equal to 200 will continue eculizumab treatment every 14 days from week 5 through week 9. The dose will be increased to 1200 mg and dosing will now be every 2 weeks instead of weekly. Similar discontinuation assessments will be performed at week 9, 26, 39 and 52.~* In addition, eculizumab 600 mg will be administered immediately after each plasmapheresis (PP) and immediately after any fresh frozen plasma (FFP) that is given post-transplant during the treatment period"
223794530|NCT01022437|OTHER|Geranium Oil with component PN-34|Geranium oil as a topical application to the body that is numb, time to determine how long it takes for the feeling to return, if it does so, and if the return of feeling is maintained by daily topical application of oil over 12 weeks. This including the process of absorption, distribution and localization.
223794531|NCT04744480|PROCEDURE|The combined topical anesthesia induction group|The superior glottic mucosa would be anesthetized 3 times with a vaporizer before intravenous anesthesia. After the intravenous induction, a catheter would be inserted to provide the subglottic anesthesia，3-5ml 2% lidocaine would be used for supraglottic anesthesia, and 3ml 1% tetracaine would be used for subglottic anesthesia.
223794532|NCT01808157|DRUG|CT327 ointment|
223794533|NCT01808157|DRUG|placebo|
223794534|NCT03341910|DRUG|DFD-03 Lotion, 0.1%|DFD-03 Lotion will be applied to the face (avoiding areas around the eyes and mouth) twice daily, approximately 12 hours apart, and washed off after 1 minute.
223794535|NCT03341910|DRUG|Tazorac Cream, 0.1%|Tazorac Cream will be applied to the face (avoiding areas around the eyes and mouth) once daily in the evening and left on overnight.
223794536|NCT03341910|DRUG|DFD-03 Vehicle Lotion 0%|Vehicle Lotion will be applied to the face (avoiding areas around the eyes and mouth) twice daily, approximately 12 hours apart, and washed off after 1 minute.
223794537|NCT03341910|DRUG|Tazorac Vehicle Cream 0%|Vehicle Cream will be applied to the face (avoiding areas around the eyes and mouth) once daily in the evening and left on overnight.
223794538|NCT04273633|DEVICE|Monopolar 448 kilohertz radiofrequency stimulation|448kilohertz capacitive resistive monopolar radiofrequency will be applied on the dominant shoulder
223794539|NCT04273633|DEVICE|Placebo comparator|To simulate a 448kilohertz capacitive resistive monopolar radiofrequency application on the dominant shoulder
223794540|NCT02170168|OTHER|integrated palliative care program|a standardised care pathway, an educational programme and information to general public, patients and their carers
223794541|NCT02474927|DRUG|Carfilzomib|Carfilzomib will be used in combination with the conventional therapy (plasma exchange and intravenous immunoglobulins)
223794542|NCT00866840|DRUG|riluzole|100 mg orally twice daily
223794543|NCT04596254|OTHER|Pomegranate Juice|Collection of Mother's milk before and after juice consumption
223794544|NCT02243033|DEVICE|MR-guided laser focal therapy|Placement of laser applicator under MRI guidance and real-time MR thermal imaging of tissue necrosis.
223794545|NCT02856464|OTHER|DLI will be administered to all patients at Month 4 (+/- 20 days) after stem cell transplant regardless of peripheral blood CD3 chimerism (including if they have full donor chimerism)|
223794546|NCT02856464|OTHER|DLI will be administered from Month 6 (+/- 20 days) after stem cell transplant according to institutional practice|
223794547|NCT02625623|DRUG|Avelumab|Avelumab was administered as a 1-hour intravenous (IV) infusion at 10 milligram per kilogram (mg/kg) once every 2-week treatment cycle until confirmed progressive disease or unacceptable toxicity along with best supportive care (BSC).
223794548|NCT02625623|DRUG|Irinotecan|Irinotecan was administered at a dose of 150 mg/m \^2 on Day 1 and 15 of a 4-week treatment cycle until disease progression or unacceptable toxicities along with BSC.
223794549|NCT02625623|DRUG|Paclitaxel|Paclitaxel was administered at a dose of 80 mg/m\^2 on Day 1, 8, and 15 of a 4-week treatment cycle until disease progression or unacceptable toxicities along with BSC.
223794550|NCT02625623|OTHER|Best Supportive Care (BSC)|BSC is defined as treatment administered with the intent to maximize Quality of life without a specific antineoplastic regimen and is based on investigator's discretion. BSC was administered once every 3 weeks.
223794551|NCT05518929|DRUG|Ciprofol|The sedation of gastrointestinal endoscopy with Ciprofol
223794552|NCT05518929|DRUG|Propofol|The sedation of gastrointestinal endoscopy with Propofol
223794553|NCT05867446|BEHAVIORAL|pecha kucha|pecha kucha training
223794554|NCT01208454|DRUG|Isotretinoin|Given PO
223794555|NCT01208454|OTHER|Laboratory Biomarker Analysis|Correlative studies
223794556|NCT01208454|OTHER|Pharmacological Study|Correlative studies
223794557|NCT01208454|DRUG|Vorinostat|Given PO
223794558|NCT01316926|DRUG|Test formulation|Paroxetine Hydrochloride 25 miligrams (mg) tablet with controlled release (Paxil CR) manufactured by GlaxoSmithKline Inc. - Mississauga - Canada (test formulation)
223794559|NCT01316926|DRUG|Reference formulation|Paroxetine Hydrochloride 25 mg tablets with controlled release (Paxil CR) manufactured by SmithKline Beecham (Cork) Limited - Cidra - Puerto Rico (reference formulation)
223794560|NCT04313803|DEVICE|CGM|Dexcom CGM system
223794561|NCT00205569|BEHAVIORAL|First Steps Educational Curriculum|10 sessions with the research participant to review an educational curriculum regarding brain injury rehabilitation and community reintegration
223794562|NCT01763944|BEHAVIORAL|Low carbohydrate diet|The Low carbohydrate diet intervention recommends patients to limit carbohydrate intake to less than 20 gram per day.
223794563|NCT05146674|DRUG|Tadalafil 5mg|"Our prospective, randomized, study will consist of a 1-week baseline period and 12-week double-blind treatment period During the baseline period, patients' characteristics, including medical and sexual history, physical examination results, vital signs, HPMDQ score, IPSS, International Index of Erectile Function (IIEF) score, PMD volume, and uroflowmetry results; and laboratory results, including urine analysis results, will be recorded.~After the baseline period, patients will be randomly assigned, 1:1, to the treatment or control groups using a computer-generated system. Both study groups will be advised to do bulbar urethral massage in addition to pelvic floor muscle exercise (explained later) during the study period, treatment group will be given tadalafil 5 mg (treatment group) daily or no medication (control group)."
223794564|NCT04278053|DIETARY_SUPPLEMENT|inositol-stabilized arginine silicate|Participants were asked to complete the experimental protocol in a 2-hour fasted state. Each participant's brachial artery FMD was assessed twice during each trial, once before supplement ingestion, and again 60 minutes post-ingestion. Male participants were required to wait for a minimum of seven days between trials as a supplement washout period. Female participants reported for supplement trials outside of their follicular phase of the menstrual cycle so that results were not confounded by changes in serum estradiol, which can significantly attenuate flow-mediated dilation. Sixty minutes after supplement consumption, each participant was asked which supplement they thought they had consumed. Participants were also asked whether they experienced any adverse side effects.
223794565|NCT00808808|BIOLOGICAL|Choice of TIV or FluMist with baseline advertisement|An intervention arm offering choice of TIV or FluMist with baseline advertisement, including advertisement to highlight the availability of FluMist
223794566|NCT00808808|OTHER|Choice of TIV or FluMist with enhanced advertisement and incentives|An intervention arm offering choice of TIV or FluMist with enhanced advertisement and additional incentives for receiving an influenza vaccination
223794567|NCT00808808|BIOLOGICAL|Control - Usual care offering TIV only with baseline advertisement|A control arm of usual care offering TIV with baseline advertisement
223794568|NCT00509847|DRUG|human lactoferrin peptide 1-11|(A) hLF1-11 (once-daily 0.5mg IV for 10 days): Group #1, n=10; OR (B) Placebo (to match hLF1-11): Group #2, n=10
223794569|NCT00777725|DEVICE|FibroScan|Liver scan, similar to an ultrasound.
223794570|NCT02909972|DRUG|ALRN-6924|Fixed dose of ALRN-6924 per cohort, administered IV, Days 1, 8, and 15 every 28 days.
223794571|NCT02909972|DRUG|ALRN-6924 in combination with cytarabine|Cytarabine (100 or 200 mg/m2) will be administered as an IV infusion followed by ALRN-6924 on Days 1, 8, and 15 every 28 days.
223794572|NCT06305572|DIAGNOSTIC_TEST|QFR|Patients suspected with CAD undergoing diagnostic coronary angiography with an indication for to perform invasive FFR were included. QFR was analyzed in an independent core laboratory (Uijeongbu Eulji Medical Center) using the software package QAngio XA 3D 2.1 (Medis Medical Imaging Systems, Leiden, the Netherlands).
223794573|NCT03708939|DIETARY_SUPPLEMENT|Glucose|Daily consumption of 5g of glucose, for 14 days.
223794574|NCT03708939|DIETARY_SUPPLEMENT|Aspartame|Daily consumption of six commercially available sachets containing aspartame and glucose as bulking agent (1g each sachet), for 14 days.
223794575|NCT03708939|DIETARY_SUPPLEMENT|Sucralose|Daily consumption of six commercially available sachets containing sucralose and glucose as bulking agent (1g each sachet), for 14 days.
223794576|NCT03708939|DIETARY_SUPPLEMENT|Saccharin|Daily consumption of six commercially available sachets containing saccharine and glucose as bulking agent (1g each sachet), for 14 days.
223794577|NCT03708939|DIETARY_SUPPLEMENT|Stevia|Daily consumption of six commercially available sachets containing Stevia and glucose as bulking agent (1g each sachet), for 14 days.
223794578|NCT03708939|OTHER|No Supplement|Follow up without any dietary supplementation.
223794579|NCT03094572|OTHER|visual motor tasks|"This exercise involves manipulating an object that corresponds to a racket, this racket has a virtual avatar that animated a virtual ball. The purpose is to make it bounce to a given height. This comes close to ping-pong game."
223794580|NCT01055366|DRUG|Elazop (Azarga)|Administer one drop of ELAZOP in treated eye(s) twice a day for up to 12 weeks
223794581|NCT02352948|DRUG|MEDI4736 (durvalumab)|MEDI4736 (durvalumab) treatment by intravenous infusion
223794582|NCT02352948|DRUG|Vinorelbine|Vinorelbine by intravenous infusion. Administered at a dose of 30 mg/m2 iv on Days 1, 8, 15 and 22 of a 28-day cycle.
223794583|NCT02352948|DRUG|Gemcitabine|Gemcitabine by intravenous infusion. Administered at a dose of 1000 mg/m2 iv over 30 minutes on Days 1, 8, and 15 of a 28-day cycle.
223794584|NCT02352948|DRUG|Erlotinib|Erlotinib administered at a dose of 150 mg once daily as a tablet for oral administration
223794585|NCT02352948|DRUG|MEDI4736 (durvalumab) in combination with tremelimumab (anti-CTLA4)|MEDI4736 (durvalumab) in combination with tremelimumab (anti-CTLA4) treatment by intravenous infusion
223794586|NCT02352948|DRUG|tremelimumab (anti-CTLA4)|tremelimumab (anti-CTLA4) treatment by intravenous infusion
223794587|NCT01694862|PROCEDURE|Integrated FP/PNC service delivery|The intervention uses a procedural tool building on existing MoH procedures. It has nine components: strengthening protocols, guidelines and training materials for integrated HIV-SRH care; training, mentorship; developing a mentoring and supervisory package; improving provider capacity; ensuring availability of minimum levels of equipment and supplies for integrated services; support supervision; organizational change (including reviewing use of available rooms) and role clarification; improving availability of IEC/BCC materials on FP and HIV; strengthening the referral system between FP and ART and the data collection and recording systems.
223794588|NCT06209710|PROCEDURE|Balloon Pulmonary Angioplasty combined with Pulmonary Artery Denervation|Participants in the intervention arm will undergo a combination of Balloon Pulmonary Angioplasty (BPA) and Pulmonary Artery Denervation (PADN), as part of this phase 2/3 clinical trial. The trial aims to determine the optimal number of radiofrequency (RF) ablation points required for effective PADN based on pulmonary artery size or diameter. The BPA procedure addresses segmental and subsegmental thrombi masses through pulmonary artery dilation, while the PADN procedure involves the placement of a denervation catheter near the bifurcation of the main pulmonary artery. RF energy is selectively applied, and ablation points are determined based on individual patient characteristics and expected therapeutic effects. This unique approach seeks to customize the intervention to the patient's specific pulmonary anatomy, contributing to the overall effectiveness of the treatment strategy.
223794589|NCT06209710|PROCEDURE|Balloon Pulmonary Angioplasty with Sham Pulmonary Artery Denervation|Participants receive Balloon Pulmonary Angioplasty (BPA) combined with a sham Pulmonary Artery Denervation (PADN) procedure. The sham PADN involves catheter placement mimicking the actual procedure without the application of radiofrequency energy
223794590|NCT01846130|DIETARY_SUPPLEMENT|Leucine|
223794591|NCT01846130|BEHAVIORAL|Exercise|
223794592|NCT01846130|DIETARY_SUPPLEMENT|Whey protein|
223794593|NCT04879186|PROCEDURE|Peripheral endovascular angioplasty|Peripheral endovascular angioplasty - using endovascular techniques to treat peripheral artery occlusive lesions.
223794594|NCT00689650|DEVICE|1540 nm fractional laser|
223794595|NCT02756767|OTHER|Survey|
223794596|NCT02696148|DRUG|liraglutide|For subcutaneous (s.c., under the skin) injection once daily.
223794597|NCT02696148|DRUG|placebo|For subcutaneous (s.c., under the skin) injection once daily.
223794598|NCT01872169|OTHER|Disordered eating screening questionnaire|
223794599|NCT02732925|DEVICE|Arm 2 Balloon Kyphoplasty|"Arm 2 Balloon Kyphoplasty (Medtronic LCC) and Conservative Treatment~Subjects will be blinded and randomised to Arm 2 and will undergo a general anaesthetic and undergo a balloon kyphoplasty surgical procedure. They will also be treated with conservative management.~Below is a list of the conservative management they will be managed by their Doctor:~1. Bisphosphonates~2. Pain relief~3. Systemic chemotherapy for Myeloma disease~4. Bed rest~5. Radiotherapy~6. Physiotherapy"
223794600|NCT02732925|PROCEDURE|Conservative Management|"Patients recruited to Arm 1 and Arm 2 will undergo conservative management for Multiple Myeloma recommended by their Consultant Hematologist.~* Concomitant treatment with bisphosphonates~* Pain relief as required~* Systemic chemotherapy for Myeloma disease~* Bed rest~* Radiotherapy~* Physiotherapy"
223794601|NCT01692535|PROCEDURE|Intubation|Intubation with one of the six videolaryngoscopes
223794602|NCT04378348|BEHAVIORAL|Motivational Interview (MI)|The MI dialogue will begin with an introduction where the LDL is asked about the type of work he does and his concerns regarding dangers in his workplace. This will be followed by a decisional balance exercise where the interviewer will engage the LDL in thinking about the pros and cons of taking jobs with many dangers and jobs with less dangers. Using a figure of a traffic light, the interviewer will proceed to measure how important it is for the LDL to reduce the dangers in his work place and identify his reasons for its importance. Next, the interviewer will measure the LDL's level of confidence in his ability to reduce the dangers in his workplace.Together, they will develop a plan to reduce the dangers in the workplace. Finally, the interviewer will summarize the safety plan to the LDL and will explain that the team will return to the corner in one month to see how the implementation of his plan went and to conduct a post-test survey
223794603|NCT04378348|BEHAVIORAL|Participatory Group Activity|Participants will view a figure of a pyramid representing the steps they can take to reduce the dangers in their workplace and the things that are in their control to reduce the dangers followed by pictures of dangerous work environments. They will be engaged in hazard identification and situational awareness by identifying and sharing out loud the dangers they see in the picture. Participants will also engage in problem solving by coming up with strategies they could use to reduce the dangers they identified in the picture and will measure their level of confidence in their ability to implement the strategies they have come up with, should they find themselves in a similar work situation. The group facilitator will summarize what the group has said and what they have learned during the group activity and will ask participants to voluntarily make a personal promise to take concrete steps to reduce the dangers at their work.
223794604|NCT04378348|BEHAVIORAL|Control Condition|At control corner sites, we will recruit another 35 Latino day laborer participants.Participants in the control group will receive OSHA pamphlets with standard workplace safety and health information. During our needs assessment survey, we collected information regarding workrelated injuries. Results from this survey indicate the following 4 categories are the highest cause of injury among surveyed Latino day laborers: 1) moving heavy objects, 2) falls, 3) being struck by falling or lying objects, and 4) serious cuts. The OSHA materials that will be distributed to participants will include safety and health information regarding these four topics. Furthermore, given that the LDL are continuously exposed to the sun (e.g., at the corner while waiting for work, at work, and on their way to and from work), heat exposure will also be included in the OSHA materials.
223794605|NCT06129669|DRUG|Indocyanine green|Administration of ICG during surgery and recording of the fluorescence video to perform data analyses
223794606|NCT00236548|DRUG|risperidone|
223794607|NCT03317600|DEVICE|Lidocaine|Intervention is a nerve block with Lidocaine 2% with Adrenaline.
223794608|NCT03317600|DRUG|Placebo|"Intervention is a placebo nerve block with isotonic saline"
223794609|NCT06503211|BIOLOGICAL|UTAA09 injection|The subjects, who sign the informed consent forms and been screeneinclusion/exclusion criteria, will be assigned into 3 x 108\~1 x 1010 CD19-CAR - γδT cells.
223794610|NCT04364958|OTHER|A web based-Patient Decision Aid (PtDA) (shown on the computer)|Patient decision aids (PtDAs) are tools that assist patients in making health decisions, when there is uncertainty about treatment choice, incorporating their personal preferences and values about the available treatment options. This PtDA will include information about GAD symptoms, diagnosis, causes, and benefits and risks associated to psychological and pharmacological treatments for GAD (based on the Clinical Practice Guidelines-GAD). It will also include a values clarification exercise, in which patients will have to rate the importance attributed to the different aspects of treatments (e.g., mode of administration, benefits, risks, time to improvement, probability of relapse).
223794611|NCT04364958|OTHER|A web-based fact sheet (one page shown on the computer) with general information on mental health as a part of usual care.|Patients in the control group will receive a fact sheet (one page) with general information on mental health as a part of usual care provided by the Canary Islands Health Service.
223794612|NCT01680328|OTHER|19 injections|Subjects will receive 19 injections in randomised order of which 13 will be in the abdomen and 6 in the thighs. Out of the 19 injections, 2 are needle insertions only. The remaining 17 injections represent different combinations of injection speed and volume of sodium chloride 0.9% solution for injection. The order of the injection speed and volume combinations will be blinded for the subject and the pain will be evaluated by the subject on a VAS (Visual Analogue Scale).
223794613|NCT01680328|DRUG|sodium chloride 0.9% solution|Solution for injection.
223794614|NCT01166633|DRUG|pitavastatin|pitavastatin 2mg per daily
223794615|NCT01166633|DRUG|atorvastatin|atorvastatin 10mg per daily
223794616|NCT03838042|DRUG|Nivolumab and Entinostat|Patients entering phase I will receive one week entinostat without nivolumab (priming phase) before receiving the combination treatment of nivolumab and entinostat.
223794617|NCT03834064|BEHAVIORAL|Oral health promotion strategy|The proposed intervention is comprised of four components : (a) planned action including a behavioral contract Activity 1) with caregivers and action planning for oral health (Activity 2), (b) caregiver capacity building with didactic training (Activity 3), observational learning and caregiver practice (Activity 4); (c) environmental adaptations with location of oral health activities and reminder posters - physical environment (Activity 5) and administrative oral health support- (social environment (Activity 6); and (d) reinforcement with caregiver coaching (Activity 7).
223794618|NCT00983073|DRUG|Tapentadol|"Tapentadol Prolonged Release (PR) Titration and Optimal Dose Period: Starting at 50 mg Tapentadol PR twice daily, adjusting at 50 mg PR steps (upwards or downwards) as necessary to achieve a balance between pain relief and a satisfactory level of tolerability. Participants were not permitted to exceed 500 mg of Tapentadol per day.~Maintenance Period: Participants continuing on the dose established in the previous period."
223794619|NCT01453595|DRUG|BEZ235|"BEZ235 will be taken orally twice daily starting on Day 1, Cycle 1, self-administration will continue twice daily on a continuous schedule with cycle length defined as 28 days. Increasing dosing levels of BEZ235 will be studied sequentially (beginning with Dose Level 1, BEZ235 400mg by mouth twice daily) as per the treatment noted below.~Cohort-1a BEZ235 300 mg by mouth twice daily Cohort 1 BEZ235 400 mg by mouth twice daily Cohort 2 BEZ235 600 mg by mouth twice daily Cohort 3 BEZ235 800 mg by mouth twice daily"
223794620|NCT00229333|DRUG|Escitalopram|
223794621|NCT03547089|DEVICE|Viveve®|A single treatment using Viveve® with 110 pulses administered to the vaginal introitus at 90 J/cm2
223794622|NCT04392765|DEVICE|eXciteOSA|eXciteOSA transoral neurostimulation device
223794623|NCT04817280|OTHER|Ice Swimming|The intervention is not made in the course of a research study. Ice swimming has been introduced earlier by a given group. The group was made up of people who already swim in ice.
223794624|NCT03722368|BEHAVIORAL|RCHC|The RCHC group will receive a three hour psychoeducational intervention on common stress responses among healthcare providers and coping skills. They will also receive a booster session one month later which will reinforce these skills.
223794625|NCT03722368|BEHAVIORAL|RCHC+|The RCHC group will receive a three hour psychoeducational intervention on common stress responses among healthcare providers and coping skills. They will also receive a booster session one month later which will reinforce these skills. This intervention group will also receive on-going support groups and one on one counseling as needed.
223794626|NCT03722368|OTHER|Waitlist control|This group will served as the control group and will receive treatment as usual until the end of the study. At the end of the study they will have the opportunity to take part in the RCHC or RCHC+
223794627|NCT04484467|DIETARY_SUPPLEMENT|Food Supplement With Standardized Menthol, Limonene, and Ginger|Components of Standart Zdorovya GASTRO: Peppermint oil (40% menthol, 1.5% limonene) - 240 mg, Ginger oil (14% gingerol) - 50 mg, olive oil - 440 mg, 1 capsule, 730 mg, once a day for 30 days
223794628|NCT04484467|OTHER|Placebo|Components of placebo Olive oil - 730 mg, 1 capsule, 730 mg, once a day for 30 days
223794629|NCT01133652|DEVICE|Veinviewer|Veinviewer machine
223794630|NCT01133652|DEVICE|Ultrasound|Ultrasound
223794631|NCT01133652|OTHER|Conventional technique|Conventional IV placement by nurses
223794632|NCT02906150|DRUG|Thymalfasin (Thymosin alpha 1, Ta1)|Patients will be randomized to Thymosin alpha 1 plus SoC for treatment duration of 12 months. All patients will be followed for approximately 12 months or until the total number of PFS events required will be observed.
223794633|NCT02906150|DRUG|SoC (chemotherapy and platinum agent)|Patients will be randomized to SoC for treatment duration of 12 months. All patients will be followed for approximately 12 months or until the total number of PFS events required will be observed.
223794634|NCT07127328|DEVICE|Patient with removable funcitonal appliance|Patients who have a malocclusion and/or a dysfunction treated by removable functional appliance
223794635|NCT06483373|DRUG|SPH7854|SPH7854： Orally, 50-3200mg
223794636|NCT06483373|DRUG|Placebo|Placebo：Orally；
223794637|NCT00613951|DRUG|insulin degludec/insulin aspart|Formulation B: Treat-to-target dose titration scheme, injection s.c., twice daily
223794638|NCT00613951|DRUG|insulin degludec/insulin aspart|Formulation B: Treat-to-target dose titration scheme, injection s.c., twice daily
223794639|NCT00613951|DRUG|biphasic insulin aspart|Treat-to-target dose titration scheme, injection s.c., twice daily
223794640|NCT00613951|DRUG|metformin|Tablets, 1500-2000 mg/daily
223794641|NCT03630666|DRUG|IADT|Patient will receive one injection of IADT at randomization
223794642|NCT03630666|COMBINATION_PRODUCT|IADT + radiotherapy|Patient will receive one injection of IADT at randomization then will receive irradiation 3 months after injection of IADT
223794643|NCT06670144|OTHER|Dietary pattern|(regular meat-eater, occasional meat-eater, fish-eater, vegetarian, and vegan; Mediterranean diet)
223794644|NCT06670144|OTHER|Alcohol intake|(Frequency and intake of beer, wine, sherry, and spirits were collected by asking the number of specified units (pints, glasses or measures) of each type of alcoholic beverage (beer or cider, wine, sherry or fortified wines, and spirits) per week.)
223794645|NCT06670144|OTHER|Fruit and vegetables intake|(Intake of fruits, vegetables, fruits and vegetables combined from food frequency questionnaire)
223794646|NCT06670144|OTHER|Tea consumption|(Intake of tea from food frequency questionnaire)
223794647|NCT06670144|OTHER|Coffee consumption|(Intake of caffeinated coffee and decaffeinated coffee from food frequency questionnaire)
223794648|NCT06670144|OTHER|Fish intake|(Intake of fish from food frequency questionnaire)
223794649|NCT06670144|OTHER|Meat intake|(Intake of red meat, processed meat, and poultry from food frequency questionnaire)
223794650|NCT06670144|OTHER|Vitamin D intake|(Estimated intake of vitamin D, derived from food frequency questionnaire and any recorded supplemental intake)
223794651|NCT06669390|DRUG|NG11-2|"NG11-2 dose level will vary from 0.92 mg/mL to 5.5 mg/mL during the dose escalation process. The NG11-2 is given as an oral rinse.~Throughout the radiotherapy regimen, no more than 60 minutes prior to the completion of radiotherapy, on each weekday the patient will rinse their mouth with 12.5 ml of NG11-2 for between 90 \& 120 seconds duration, gargling twice for approximately three seconds each if possible during this period then expectorate the solution."
223794652|NCT06996561|DRUG|Nalbuphine Injection|Anaesthesia induction will be done with propofol (2 mg/kg) nalbuphine (0.1mg/kg) and atracurium (0.6mg/kg) intravenously. Maintenance of anaesthesia will be achieved with oxygen (O2), nitrous oxide (N2O) in 1:2 ratio and isoflurane (0.8-1%). Intermittent top up of the study drug 1-2 ml boluses will be administered if either the patient's HR or BP increased to 20 % above baseline and when other causes of tachycardia and hypertension are excluded. Timing of analgesia will be recorded. Pain will be assessed for 24 hours postoperatively using verbal rating scale (VRS) with 0 = no pain and 10 = worst pain. Sedation will be assessed as 0=no sedation, 1= mild sedation, (eye-opening on verbal commands), 2= moderate sedation (eye-opening on painful stimulus), 3= deep sedation (not waking up on pain). All patients will be prescribed paracetamol one gram IV six hourly and nalbuphine 1-2 mg IV infusion in the first 24 hours post operatively.
223794653|NCT06996561|GENETIC|Next Generation Sequencing|5ml of blood samples by venipuncture will be obtained from the first 70 patients half an hour before extubation at the time of muscle closure. These blood samples will be processed for DNA analysis. Only the 15 samples where pain persisted despite nalbuphine administration, with a pain score remaining above 4, continuous use of rescue analgesia, or any documented opioid side effects (such as nausea, vomiting, or sedation), or the need for additional analgesia within 24 hours, will be sent for NGS analysis. These samples will undergo whole exome sequencing via NGS, based on patient parameters and pain scores, after being categorized as responders or non-responders to nalbuphine
223794654|NCT06996561|GENETIC|whole exome sequencing|Only the 15 samples will be sent for NGS based on patient parameters and pain scores after being categorized as responders or non-responders to nalbuphine
223794655|NCT06667453|DRUG|PGN-EDODM1|Administered by intravenous (IV) infusion
223794656|NCT06667453|OTHER|Placebo|Administered by intravenous (IV) infusion
223794657|NCT06613841|DRUG|Fluciclovine F18|To perform metabolic phenotyping of treatment naïve and recurrent GBM by multitracer \[18F\]Fluciclovine and 18F-FDG PET.
223794658|NCT03760237|OTHER|observation only|No intervention, observational study only
223794659|NCT06672718|DRUG|SPY002-091|Experimental
223794660|NCT06672718|OTHER|Placebo|Placebo
223794661|NCT04439110|BIOLOGICAL|Trastuzumab Emtansine|Given IV
223794662|NCT04951336|DIETARY_SUPPLEMENT|FoTv|Fomitopsis Officinalis and Trametes Versicolor
223794663|NCT04754581|OTHER|Maximal ATP Production (ATPmax)|ATPmax will be measured in order to determine in vivo mitochondrial capacity. The magnetic resonance scans to measure mitochondrial energetics will also be performed.
223794664|NCT04754581|OTHER|Exercise Testing (VO2max)|Aerobic fitness level will be assessed while participant pedals on a stationary bicycle/walk on a treadmill. The volume of oxygen intake and carbon dioxide (CO2) production will be measured.
223794665|NCT04754581|PROCEDURE|Muscle Biopsy|Sample muscle cells from the left leg Vastus Lateralis (thigh) muscle.
223794666|NCT04754581|PROCEDURE|Adipose Tissue Biopsy|Sample fat tissue from the abdomen.
223794667|NCT04754581|OTHER|Hyperinsulinemic euglycemic clamp|Measurement of insulin sensitivity.
223794668|NCT04754581|OTHER|PET imaging|After an overnight fast, an intravenous catheter will be placed in each arm (one with arterial line for PET infusion, and the other for infusion of insulin, glucose, and 6,6 D2 glucose tracer. FDG-glucose will be injected followed by 90-minute PET scanning of the thigh.
223794669|NCT05244356|BEHAVIORAL|Health message exposure|Participants exposed to a health message and requested to read it completely. Subsequently requested to answer post intervention questions that form basis for outcome measures.
223794670|NCT00651508|DRUG|KOS-1584|25 mg/m2, IV (in the vein) on day 1 and 8 of each 21 day cycle until progression or unacceptable toxicity develops.
223794671|NCT00645398|DRUG|Pregabalin|Pregabalin 225 mg BID taken orally, 2 capsules BID for 13 weeks (1 week titration phase + 12 weeks fixed-dose phase).
223794672|NCT00645398|DRUG|Pregabalin|Pregabalin 150 mg BID taken orally, 2 capsules BID for 13 weeks (1 week titration phase + 12 weeks fixed-dose phase).
223794673|NCT00645398|DRUG|Pregabalin|Pregabalin 300 mg BID taken orally, 2 capsules BID for 13 weeks (1 week titration phase + 12 weeks fixed-dose phase).
223794674|NCT00645398|DRUG|Placebo|Matching placebo capsules taken orally, 2 capsules BID for 13 weeks (1 week titration phase + 12 weeks fixed-dose phase).
223794675|NCT06670430|DEVICE|experimental group|This group will include 30 type II diabetic patients with peripheral neuropathy Patients will receive TENS and NMES for 30 minutes 3 days per week,for 10 weeks with medical treatment
223794676|NCT06670430|DEVICE|control group|This group will include 30 type II diabetic patients with peripheral neuropathy Patients will receive placebo TENS and NMES for 30-min sessions, 3 days per week, for 10 weeks with medical treatment
223794677|NCT06670066|BEHAVIORAL|Let's Talk Birth Control|Let's Talk is an innovative, multi-level intervention addressing adolescents and providers that includes both in-person and online components and is feasible to implement in clinical settings. The three core components are: (1) a printed contraceptive decision aid (CDA) with a QR code linking to the Method Explorer (ME) page on Power to Decide's online birth control website, Bedsider; (2) the Bedsider ME, with information on the full range of contraceptive methods and a personalized method comparison feature; and (3) an online training for providers on Patient-centered Contraceptive Counseling (PCCC), including use of the CDA to support shared decision-making with adolescents.
223794678|NCT06668974|OTHER|Mendelian Randomization|This study utilizes a bidirectional Mendelian randomization approach to analyze genetic data from individuals with allergic rhinitis and asthma. No active intervention is applied; genetic variants serve as instrumental variables to assess causal associations between the conditions.
223794679|NCT06669273|OTHER|CEST MRI sequence at 3T|"The MRI will be performed at the Clermont Ferrand University Hospital on the 3T research MRI on a Siemens MRI system (MAGNETOM VIDA, Siemens Healthcare, Erlangen, Germany), the emission of the radiofrequency pulses and the reception of the signal will be done using a coil dedicated to the abdo-pelvic region. The images will be analyzed by the radiologist.~MRI is non-irradiating medical imaging. It is practiced according to good practices and the recommendations of the French Society of Radiology.~* Acquisition of morphological T1, T2 sequences for the identification of areas of interest on the pelvic area.~* Acquisition of the CEST MRI sequence (acquisition time 5 min)~* Acquisition of functional sequences, DWI diffusion-weighted images and dynamic DCE sequence after injection of a single dose of non-linear gadolinum.~The imaging report will reveal the presence or absence of tumor lesions in the prostate and their location. Data will then be compared to the histopathological analysis."
223794680|NCT07002216|DRUG|Brentuximab Vedotin|Participants will receive 1.8 mg/kg of Brentuximab Vedotin intravenously (IV) for up to 30 minutes on Day 1 of each 21-day cycle period for up to 4 cycles in accordance with institutional procedures.
223794681|NCT07002216|DRUG|Etoposide|Participants will receive 150 mg/m\^2 of Etoposide intravenously (IV) for up to 60 minutes on Days 1-3 of each 21-day cycle period for up to 4 cycles in accordance with institutional procedures.
223794682|NCT07002216|DRUG|Cyclophosphamide|Participants will receive 1250 mg/m\^2 of Cyclophosphamide intravenously (IV) for up to 60 minutes on Day 1 of each 21-day cycle period for up to 4 cycles in accordance with institutional procedures.
223794683|NCT07002216|DRUG|Doxorubicin|Participants will receive 40 mg/m\^2 of Doxorubicin intravenously (IV) for up to 30 minutes on Day 1 of each 21-day cycle period for up to 4 cycles in accordance with institutional procedures.
223794684|NCT07002216|DRUG|Dacarbazine|Participants will receive 250 mg/m\^2 of Dacarbazine intravenously (IV) for up to 120 minutes on Days 2-3 of each 21-day cycle period for up to 4 cycles in accordance with institutional procedures.
223794685|NCT07002216|DRUG|Dexamethasone|Participants will self-administer 40 mg of Dexamethasone orally on Days 1-4 of each 21-day cycle period for up to 4 cycles in accordance with institutional procedures.
224264011|NCT06461988|DRUG|Talquetamab|"Talquetamab Step up dosing:~C1D1: 10 mcg/kg C1D3: 60 mcg/kg C1D5: 400 mcg/kg C1D15: 800 mcg/kg~Talquetamab 800 mg/kg SC Q4W in 28-day cycle for Cycles 2-13"
223794690|NCT06091189|BEHAVIORAL|Relevant Trier Social Stressor Test (TSST)|The Relevant TSST condition is a behavioral intervention that catalyzes an internalized stress response in the presence of a relevant social identity.
223794691|NCT06091189|DRUG|Ethanol|The initial drink in the alcohol condition will contain 0.3 g/kg (males) or 0.2 g/kg (females) of 80-proof ethanol, adjusted for body weight, and subsequent drinks will contain 0.1 g/kg of ethanol. None of the control (placebo) drinks will contain ethanol.
223794692|NCT06091189|BEHAVIORAL|Placebo Trier Social Stressor Test (TSST)|The Placebo TSST is an established behavioral intervention that does not prompt significant stress responses.
223794693|NCT06091189|BEHAVIORAL|Placebo Beverage|Placebo drinks will not contain ethanol; Drinks given to participants in the placebo beverage condition will contain a mixer that does not contain ethanol.
223794694|NCT06091189|BEHAVIORAL|Irrelevant Trier Social Stressor Test (TSST)|The Irrelevant TSST condition is a behavioral intervention that functions as an alternative comparative condition, given no internalized stress response is expected in the presence of an irrelevant social identity.
223794695|NCT06670742|DEVICE|running|Running 10 kilometers on a treadmill
223794696|NCT07126860|BEHAVIORAL|Structured combined resistance and aerobic training|"The 12-week intervention phase comprises the initial 12 weeks of a home-based combined resistance and aerobic training protocol for the intervention arm. Training will commence 8 weeks (when medically cleared, a reduction to minimally 4 weeks is possible) after RP or completion of EBRT, or any time for PC patients undergoing systemic treatment. As part of their visit for baseline testing, participants will be familiarized with the online platform incorporating the training program, including the correct execution of the exercises. In addition, the online platform includes demonstration videos of all exercises.~Detailed information about the training program will be available for patients and investigators via a website and smartphone application. Additionally, participants will receive a printed document explaining the training program, the repetitions in reserve (RIR) scale (Helms et al., 2016), and the online tool/app for tracking."
223794697|NCT07126860|BEHAVIORAL|Standard of Care|Participants randomized to the SOC arm will also be informed about the benefits of exercise and motivated to engage in exercise under their own management (self-directed exercise). They will receive a booklet with general information and guidelines about physical activity in prostate cancer patients, but without any specific exercise prescriptions.
223794698|NCT07126379|BEHAVIORAL|Family Foundations|FF is an 8-session program for families of children aged 0-12 years targeting parent mental health and family conflict. It will be delivered via telehealth by an allied health professional (i.e., social work, psychology, counselling qualification) trained in FF. The 8 sessions can be delivered flexibly (1 or 2 sessions per week). The duration between sessions can vary as per the needs of the family. We are allowing up to 11 weeks from randomisation for FF to be completed. FF is a manualised program which provides instruction on discussion activities, skills practice, video and workbook exercises for every session. Sessions are based around the content areas of: emotion regulation, stress management, healthy communication, coparenting, conflict resolution, and problem solving.
223794699|NCT07126379|BEHAVIORAL|Family Life Check-In|Families allocated to Family Life Check In will receive this condition from a Clinical Research Nurse, employed at the Primary site (deakin University) with 2 weeks of randomisation. This brief intervention will be comparable to care typically provided to parents/caregivers seeking support for mental health difficulties and/or family/parent relationships issues from a community health service at intake. Family Life Check-In involves a brief (\~30 minute) telephone consultation involving: a) an assessment of the families' needs with one or all parents, b) referral to local services including GP to discuss a mental health care plan, c) provision of reputable Australian web-based resources about supporting children during crises (Raising Children Network, Phoenix Disaster Recovery), and (d) telephone and online support services (BeyondBlue; Lifeline, PANDA, MensLine, KidsLine, Parentline).
223794700|NCT07127029|DEVICE|Petrolatum coating of fast-absorbing gut suture|6-0 fast absorbing gut suture was coated with sterile petrolatum and a single interrupted suture was placed into the skin of the deltoid
223794701|NCT07128160|OTHER|Clinical and Demographic Assessment|"1. Expanded Disability Status Scale (EDSS) (Kurtzke, 1983): This scale will be used for neurological disability assessment~2. Multiple Sclerosis Functional Composite (MSFC): This composite will be used for the assessment of functional performance in patients with MS. It includes: a) Timed 25-foot walk (T25FW), b) Nine-hole peg test (9HPT) for both hands, and c) Paced auditory serial addition test (PASAT).~3. Toronto Alexithymia Scale (TAS-20): This scale reports Alexithymia. It is a 20-item self-report questionnaire measuring three domains: Difficulty identifying feelings (DIF), Difficulty describing feelings (DDF), and externally oriented thinking (EOT). A score ≥ 61 indicates alexithymia (Bagby, Parker \& Taylor, 1994).~4. Montreal Cognitive Assessment (MoCA), (Nasreddine ZS et al, 2005): a 30-point tool that investigates visuospatial abilities, language, attention, memory, abstraction, and orientation, with scores \<26 suggestive of mild cognitive impairment"
224264012|NCT06461988|DRUG|Talquetamab and Lenalidomide|Lenalidomide 10 mg, 3 weeks on 1 week off, until PD/ intolerance, C2-13 (Lenalidomide 5 mg for creatinine clearance 30-60 ml/min)
224264013|NCT06840509|DEVICE|CorSky ICD or CRT-D|Subjects with an indication for an ICD or CRT-D device will be implanted with a CorSky device of the CorSky ICD family according to standard implantation procedures. Device programming will be done according to the medical needs of the subjects.
223794702|NCT07128160|OTHER|Corticospinal Inhibition Assessment|"Corticospinal inhibition will be evaluated using Transcranial Magnetic Stimulation (TMS) (Ayache et al., 2022; Chalah et al., 2018). All TMS assessments will be conducted according to international safety guidelines. The following parameters will be measured:~1. Motor Evoked Potentials (MEPs) will be recorded from the abductor pollicis brevis muscle.~2. Cortical silent period (CSP) will be assessed to measure corticospinal excitability and inhibition.~3. The interhemispheric inhibition (IHI) is a parameter reflecting the transcallosal GABA-mediated inhibitory activity. It will be obtained at complete muscle rest using figure-of-eight coils (MC-B70; MagVenture), connected with a MagPro\_R20 (Medtronic Inc., USA) generator connected to a butterfly coil."
223794703|NCT07128160|OTHER|Radiological Assessment|"All patients will undergo brain and spinal cord Magnetic Resonance Imaging (MRI) using a 1.5T scanner. Brain MRI sequences include: T1-weighted, T2-weighted, FLAIR, and post-contrast sequences. Spinal MRI (cervical and thoracic) includes T2-weighted and STIR sequences. Radiological assessment focused on:~* Number and location of T2/FLAIR lesions~* Presence of contrast-enhancing lesions~* Degree of brain atrophy (qualitatively)~* Spinal cord lesion load A neuroradiologist will review MRI findings, blinded to the clinical and neuropsychological data"
223794704|NCT07127042|DRUG|Low-dose BT-114143|Intravenous infusion of BT-114143 Injection is started 10-15 minutes before skin incision at a Low-dose BT-114143, and 50mL of normal saline is administered intravenously 3 hours (±10 minutes) after the end of the surgery.
223794705|NCT07127042|DRUG|High-dose BT-14143|Intravenous infusion of BT-114143 Injection is started 10-15 minutes before skin incision at a High-dose BT-114143, and 50mL of normal saline is administered intravenously 3 hours (±10 minutes) after the end of the surgery.
223794706|NCT07127042|DRUG|Tranexamic Acid (IV)|Intravenous infusion of TXA is started 10-15 minutes before skin incision at a dose of 20mg/kg, and intravenous infusion of TXA is initiated 3 hours (±10 minutes) after the end of the surgery at a dose of 1g.
223794707|NCT07126847|DIAGNOSTIC_TEST|Renal Ultrasonography|To investigate the primary and secondary signs of stones with ultrasound and to additionally use the Stone criteria in patients with suspected nephrolithiasis.
223794708|NCT07127055|OTHER|No intervention|Control group will take standard diet
223794709|NCT07127055|OTHER|gluten free diet|This group received gluten free diet
223794710|NCT04348604|BEHAVIORAL|Customized Adherence Enhancement for Adolescents and Young Adults (CAE-AYA)|"Customized Adherence Enhancement for Adolescents and Young Adults (CAE-AYA): CAE-AYA participants will have 4 core in-person sessions (45-60 minutes each) spaced about 1 week apart over a period of approximately 4 weeks and one booster in-person session approximately 4 weeks after completion of the 4 core sessions (total of up to 5 in-person sessions spaced out over 8 weeks). There will be one follow-up phone call with a study interventionist, approximately 6 weeks post-baseline (timed half-way between completion of the core sessions and the booster session). All AYAs assigned to the CAE-AYA arm will receive all 4 modules (Psychoeducation on BD Medications; Communication with Providers \& Caregivers; Medication Routines; and Targeting Risky Behavior via Modified Motivational Enhancement Therapy (MET)), with the content within each module being customized to developmental stage and behavioral experience."
223794711|NCT04348604|BEHAVIORAL|Enhanced Treatment as Usual (ETAU)|Enhanced Treatment as Usual (ETAU): ETAU will consist of usual clinical care with prescribing clinicians and therapists, augmented by written materials specific to BD for AYAs and 6 follow-up telephone calls to briefly review the materials and be available for questions by social workers with mental health experience and at least some experience in working with AYA with BD. In order to ensure that there is not treatment contamination, different trained interventionists will be used for CAE and eTAU. Therapists will briefly review the materials and be available for questions during the phone calls. Materials will cover general self-management in BD. The calls will be relatively brief (maximum of 20-30 minutes).
223794712|NCT02097108|DRUG|Raltegravir|
223794713|NCT06670690|DRUG|Atenolol 50 MG|patients will be premedicated with atenolol (50mg)
223794714|NCT06670690|DRUG|Propranolol Pill|patients will be premedicated with propranolol (10mg)
223794715|NCT06670690|DRUG|Ivabradine|patients will be premedicated with Ivabradine (5mg)
223794716|NCT04797403|BEHAVIORAL|Stepped-care protocol adapted from the SPRINT intensive-treatment algorithm|The core component of the intervention is protocol-based treatment using the SPRINT intensive BP management algorithm. Implementation strategies include dissemination of SPRINT study findings, team-based collaborative care and shared-decision making, blood pressure audit and feedback, home blood pressure monitoring, and health coaching.
223794717|NCT05394103|DRUG|Q901|The study drug Q901 will be administered by IV infusion over a 30-minute period using a QW dosing schedule for 4 weeks, followed by a Q2W interval dosing schedule thereafter
223794718|NCT05394103|DRUG|KEYTRUDA® (pembrolizumab)|KEYTRUDA® (pembrolizumab) will be administered Q6W
223794719|NCT00127608|PROCEDURE|Collection of clinical samples|"The following samples were obtained from each subject:~* Vesicle fluid (VF) and vesicle swabs (VS) from four vesicles (for a total of eight samples)~* Papule swabs (PS) from four papules~* Crusts from two lesions~* One throat swab (TS) Up to 15 samples were to be obtained for each subject, when possible. VFs, VSs, PSs, and crusts were either stored dry or in liquid medium. TS samples were stored in liquid medium.~After extraction of DNA, samples were tested for the presence of varicella virus using a Quantitative Polymerase Chain Reaction (Q-PCR) technique."
223794720|NCT00016133|BIOLOGICAL|BCG vaccine|
223794721|NCT00016133|BIOLOGICAL|autologous tumor cell vaccine|
223794722|NCT00016133|DRUG|fluorouracil|
223794723|NCT00016133|DRUG|leucovorin calcium|
223794724|NCT00016133|PROCEDURE|adjuvant therapy|
223794725|NCT05245864|OTHER|blood flow restriction|Blood flow to the legs will be mostly restricted temporarily during physical therapy exercises for the initial several weeks of physical therapy.
223794726|NCT05245864|OTHER|physical therapy standard of care|the current standard of care after surgery for ACL repair.
223794727|NCT06633640|COMBINATION_PRODUCT|Conventional flap with algae-based substitute (AlgOss) combined with collagen membrane.|The graft material will be prepared following the manufacturer instruction, transferred into a sterile cup than the mixture is condensed without overfilling in the intrabony defect to the level of the surrounding bony walls. The filled site will be than covered with collagen membrane.
223794728|NCT02546583|DRUG|Increased Intravenous Bolus Loop Diuretic Dose (Bumetanide or Furosemide)|An increase to 2.5x the Visit 1 dose of loop diuretic (bumetanide or furosemide).
223794729|NCT02546583|DRUG|IV Chlorothiazide|
223794730|NCT04111445|DRUG|ADG116|IV infusion at Day 1 of each cycle
223794731|NCT07127939|DIAGNOSTIC_TEST|AI-based Ocular Diagnosis Model for TCM Constitutions|AI-based Ocular Diagnosis Model for Identifying Traditional Chinese Medicine (TCM) Constitutions
223794732|NCT07128004|DEVICE|tDCS|would provide direct current for 40 minutes in 20 minute interval at 2 mA
223794733|NCT07128004|DEVICE|sound therapy|would provide acoustic ripples along with tDCS
223794734|NCT06741449|PROCEDURE|keystone flap|facio-cutaneous flap used to cover the defect after removal of the disease
223794735|NCT06741449|PROCEDURE|lay open|after removal of the disease, the wound is left open to heal by granulation tissue
223794736|NCT06741202|BEHAVIORAL|Men's MST Group|see above
223794737|NCT06741202|BEHAVIORAL|Present-Centered Group Therapy|see above
223794738|NCT06183931|DRUG|ALXN2220|Participants will receive ALXN2220 via IV infusion.
223794739|NCT06183931|DRUG|Placebo|Participants will receive placebo via IV infusion.
223794740|NCT06598579|BEHAVIORAL|Mindfulness-based Cognitive Therapy|Mindfulness-Based Cognitive Therapy (MBCT) is a form of psychotherapy that combines principles of cognitive therapy with mindfulness practices focused on increasing non-judgemental awareness of the present moment. It was designed to help individuals, particularly those with depression, stop rumination and a cycle of negative thought patterns that lead to emotional distress including depression. It is a well established depression EBT. The Vietnamese version of the program (MBCT-VN) is a group treatment involving from five to ten participants (depending on how many participants are able to be recruited) per group.
223794741|NCT06598579|BEHAVIORAL|Treatment-as-usual involving Buddhist meditation|MBCT and other mindfulness interventions were originally derived from Buddhist meditation, modifed to be non-secular and focused on treatment of depression and other mental health and behavioral problems rather than on spiritual development. In the present study, a treatment-as-usual condition involving Buddhist meditation will be used. The project will assess the characteristics of the Buddhist meditation delivered for the control group participants at pagoda meditation retreats but will not influence this control condition in any way.
223794742|NCT06511921|BIOLOGICAL|early biologic therapy|biologic therapy for perforated Crohn's disease in the early postoperative period
223794743|NCT06511921|BIOLOGICAL|late biologic therapy|no biologic therapy for perforated Crohn's disease up to 2 to3 months in the post operative period
223794744|NCT01329029|DRUG|Roflumilast|500 µg, once daily
223794745|NCT01329029|DRUG|Placebo|once daily
223794746|NCT06873360|OTHER|Clinical interviews with patients and Usability interviews and glove testing.|"Clinical interviews with patients: These will be conducted by nursing staff with an approximate total of 50 patients during their treatment at the Hospital. Each interview will last 15 minutes. Under no circumstances will the patient be required to answer any question.~Usability interviews and glove testing: 10 patients selected from the previous interviews will test different gloves with various textures and levels of stiffness. Additionally, other questions will be asked focusing on refining the design. This evaluation will help determine the most suitable materials for the device's manufacturing, achieving a balance between comfort, discretion and functionality."
223794747|NCT06887036|DRUG|Methylene Blue|"Subjects will be initially treated with an initial dose of 200mg/day for 8 weeks at which point the investigators will assess the effect of the treatment.~Those patients that obtain a complete response will continue their treatment up to a total of 24 weeks with the same dose. Those who do not reach a complete response will be exposed to the next higher dose of 400mg/day for the following 8 weeks and the investigators will then again assess the effect of the treatment.~Those patients that obtain a complete response will continue their treatment up to a total of 24 weeks with the same dose. Those who do not reach a complete response will be exposed to the next higher dose of 600mg/day for the following 8 weeks and the investigators will then assess the effect of the treatment."
223794748|NCT07074444|DRUG|Albendazole|Participants receive albendazole tablets orally at a total daily dose of 10 mg/kg for 7 consecutive days. The daily dose will be administered in two divided doses. If the calculated dose results in a non-integer number of tablets, the dose will be adjusted to the nearest whole tablet as per the physician's recommendation.
223794749|NCT07074444|DRUG|Tribendimidine|Patients receive tribendimidine enteric-coated tablets orally at 0.4 g once daily (QD) for 3 consecutive days.
223794750|NCT07074444|DRUG|praziquantel|Participants receive praziquantel tablets orally at 25 mg/kg per dose, three times daily (TID) for 2 consecutive days. If the calculated dose results in a non-integer number of tablets, the dose will be adjusted to the nearest whole tablet as per the physician's recommendation.
223794751|NCT07075315|DRUG|Umbilical cord Mesenchymal stem cell|ucMSC 1 million/kg will be given once a week for 4 week . 250 ml normal saline will be infused 30 minutes prior to ucMSCs infusion. The fresh ucMSCs will then be infused through IV canula peripherally over 30 minutes followed by a further 250 ml normal saline over 20-30 minutes.
223794752|NCT07075315|DRUG|Steroid|Prednisolone 40 mg once daily for 7 days as inpatients. After that Lille score will be calculated on day 7. Responders (Lille score \< 0.45) will be continued on steroids for a total of 4 weeks, followed by 2 weeks oftapering before stopping the therapy. In patients who were non responsive to steroids (Lille score \> 0.45) at day 7, steroids will be stopped at day 7 and will receive only SMT.
223794753|NCT07075315|OTHER|Standard Medical Treatment|All patients will receive the standard medical treatment.
223794754|NCT07086482|COMBINATION_PRODUCT|Cyanoacrylate tissue adhesive|Cyanoacrylate tissue adhesive is a chemical synthetic and hybrid tissue sealant possessing strong, rapid acting adhesive properties and is often used in general surgery. Recently, cyanoacrylate tissue adhesive has been effectively introduced into dentistry to close wounds and stop ischemic areas from forming in periodontal aesthetic surgeries. As well as in exposed membranes to preserve the bone graft after guided bone regeneration, in post-extraction sockets, and to seal any surgical flap. This material has strong hemostatic, bacteriostatic, and sealing qualities.
223794755|NCT07086482|DEVICE|Collagen sponge|Collagen sponge is an organic polymer that promotes the development of blood clots, and it resorbs quickly and completely over time. Collagen sponge create a matrix at the bleeding site, encourage platelet activation and aggregation, and engage the extrinsic coagulation pathway. Thus, it can be utilized as the first choice for wound healing.
223794756|NCT07086742|DEVICE|Smart Mask V1 System|PPG-based sensors integrated into a PAP-compatible face mask to measure SpO2 and PR.
223794757|NCT07085754|BEHAVIORAL|Sleep Deprivation|Sleep deprivation for up to 24 hours with no naps or other sleep periods
223794758|NCT07084779|DEVICE|AI|"Following the completion of a pre-biopsy prostate MRI, the radiologist will interpret the MRI. Once interpreted by the radiologist alone, the radiologist will interpret the scan while aided by AI. A systematic biopsy in conjunction with radiologist-identified targets will be completed per standard of care, with the optional inclusion of up to 2 AI-detected targets.~When completing a biopsy per SOC, the prostate is divided into quadrants. In addition to noted targets, samples are taken systematically from each quadrant. If targets are detected by AI that were not identified by the physician when reviewing the MRI, these targets will be sampled. Sampling of these targets will not be in addition to the systematic sampling in each quadrant, but in place of up to two of the samples biopsied systematically"
223794759|NCT06535750|OTHER|Exercise|Participants were randomly divided into two treatment groups. There are 10 patients in each group. The patients in the control group received a standard treatment programme, while the patients in the experimental group received strengthening exercises with theraband in addition to the standard treatment programme. Treatment sessions for both groups lasted 50-55 minutes and were performed three days a week. Details of the study groups are given below.
223794760|NCT06888102|DRUG|Neoadjuvant Epigenetic Therapy|Participants will be assigned to receive one of the study interventions and will be monitored for safety and response. The duration of epigenetic therapy will be dependent on the treatment administered and will continue for the duration described in the cohort appendix for each respective combination, unless the participant: is no longer clinically benefiting (NLCB, as evidenced by symptomatic or radiographic disease progression and/or clinical deterioration); experiences any toxicity meeting specified discontinuation criteria (as described in the cohort appendix for each respective combination) or unacceptable toxicity in the best clinical discretion of the treating physician (i.e., Investigator discretion); reaches the maximum duration of study intervention; or withdraws consent.
223794761|NCT07082283|PROCEDURE|Pacing Protocol for Pacing Group|"At four standardized time points (H0: arrival in the ICU, H6, H12, H24), a transient pacing sequence at 70, 80, and 90 bpm is conducted, with each rate applied for 10 minutes to allow stabilization, followed by recording of the hemodynamic profile and blood pressure, as follows:~* If the patient has a spontaneous rhythm between 50 and 69 bpm, measurements are taken at the spontaneous rate, then at 70 bpm, 80 bpm, and finally 90 bpm~* If the patient has a spontaneous rhythm between 70 and 79 bpm, measurements are taken at the spontaneous rate, then at 80 bpm, and finally at 90 bpm~* If the patient has a spontaneous rhythm between 80 and 89 bpm, measurements are taken at the spontaneous rate, then at 90 bpm~* If the patient has a spontaneous rhythm ≥ 90 bpm, measurements are taken at the spontaneous rate only"
223794762|NCT07082283|PROCEDURE|Pacing Protocol for Non-pacing Group|"At H0, H6, H12, and H24, they will undergo transient pacing at 70, 80, and 90 bpm, following the same measurement protocol (10 minutes per rate), followed by recording of the hemodynamic profile and blood pressure, as follows:~* If the patient has a rhythm between 50 and 69 bpm, measurements will be taken at the spontaneous rate, then at 70 bpm, 80 bpm, and finally 90 bpm~* If the patient has a rhythm between 70 and 79 bpm, measurements will be taken at the spontaneous rate, then at 80 bpm, and finally at 90 bpm~* If the patient has a rhythm between 80 and 89 bpm, measurements will be taken at the spontaneous rate, then at 90 bpm~* If the patient has a rhythm ≥ 90 bpm, measurements will be taken at the spontaneous rate only~Outside the pacing periods at different rates, patients in the non-pacing group will remain on their spontaneous sinus rhythm."
223794763|NCT06904482|BIOLOGICAL|Haplo-Identical / Cord Blood Transplant|"Cord Blood Unit Selection Cord Blood Unit Selection should be consistent with published guidelines5 with the understanding that the goal cell dose is 1x105 CD34 cells/kg in this protocol. ABO matching and donor specific antibodies should be taken into account in the selection of the CB unit.~Haplo-Donor Selection Haplo-identical siblings and younger male donors are preferred. ABO matching, CMV compatibility, and donor specific antibodies should be taken into account in the selection of the donor."
223794764|NCT06144151|DEVICE|NeurOptics® NPi®-300 Pupillometer|The pupilometer is a non-invasive device which will be placed in front of your eyes, one at a time. It looks like a handheld spotlight or scanner, with a small plastic guide sticking out that will be placed against your cheek to help keep the device in place during the scan. It will not touch your eye. Both your left and right eyes will be measured with the device each time. Scanning with the pupilometer will take less than 5 minutes total for both eyes.
223794765|NCT05145361|DRUG|B001 injection|B001 injection 50mg/5mL Intravenous solution
223794766|NCT05145361|BIOLOGICAL|Placebo|Placebo 5mL Intravenous solution
224264014|NCT06830993|BEHAVIORAL|"Move More Personalized Exercise Program"|"Move More - a personalized exercise program involving both in center and out-of-center exercise. Our novel intervention provides patient's the autonomy to choose the types of physical activity and exercise that they are willing and able to participate in. In brief, it involves working one-on-one with patients to develop an activity prescription that aims to get participants to move more, by any means necessary."
224264015|NCT06830993|BEHAVIORAL|Intradialytic Exercise Program|"Those in the intradialytic exercise group will undergo a variety of exercises including intradialytic cycling and resistance (strength training)."
224264016|NCT06191276|BEHAVIORAL|STEP@Home Intervention|STEP@Home is a multi-component exercise program designed for prefrail older adults that incorporates active strategies to promote long-term engagement. The optimal level of training is 45-60 minutes of exercise three times per week for at least 20 weeks. For prefrailty management, emphasis is placed on balancing and resistance training (around 15-20 min each) to improve muscle strength and gross mobility and prevent falls. Aerobic and flexibility exercises (10 min each) are also included to improve fitness and walking pace. Sixteen training tasks, including but not limited to those recommended by Vivifrail, for each exercise component (namely, resistance, balance, flexibility and aerobic training) will be adopted. A training manual with step-by-step illustrations of each task in pictures and text will be provided to the subjects, together with a set of simple, easy-to-access equipment (water bottle, elastic band and weight-bearing belt) to support task fulfilment.
224264017|NCT06191276|BEHAVIORAL|Usual care|Usual Care Activities will be provided by the elderly community center such as dementia or caregiver supporting service. They will be allowed to use the regular service provided such services are not related to physical activity or exercise training.
224264018|NCT06257355|BIOLOGICAL|CSB-001 Ophthalmic Solution 0.1%|CSB-001: human recombinant dHGF (5-amino acid deleted hepatocyte growth factor)
224264019|NCT06163001|BEHAVIORAL|Supervised aerobic and resistance exercises|4 weeks of preoperative supervised aerobic and resistance exercises
223794767|NCT07094386|PROCEDURE|External Oblique Intercostal Plain Block|The patient will be placed in the supine position. After sterilization of the skin, a high-frequency linear probe (6-13 MHz) will be placed obliquely medial to the anterior axillary line, the 6th and 7th ribs, skin, subcutaneous tissues, and external oblique muscle \[EOM\], intercostal muscles, pleura, and the lung will be identified. An 80 mm 22-gauge block needle (Stimuplex® D, BBraun, Germany) will be inserted in-plane to the US-probe in a craniocaudal direction directed under EOM. After confirmation of negative blood aspiration, 2-3 mL of normal saline will be injected for hydro-dissection to verify the correct needle tip placement then 30 mL of 0.25% bupivacaine will be injected between the EOM and intercostal muscles
223794768|NCT07094386|PROCEDURE|Quadratus Lumborum Block|Quadratus lumborum block will be performed. The patient will be placed in the lateral decubitus position After sterilization of the skin, a low frequency convex probe (5-8 MHz) will be positioned horizontally in the anterior axillary line half way between the subcostal margin and the iliac crest then will be advanced in the cranial direction to visualize the triple abdominal muscle layers and identifying the posterior border of the EO muscle (hook sign) with the underlying IO musclenforming a roof over the QL muscle. The QL muscle could be visualized with its attachment to the lateral edge of the transverse process of the L4 vertebral body. An 80 mm 22-gauge block needle will be inserted in-plane to the US-probe in an anterolateral to posteromedial direction. The needle tip will be placed between the middle layer of the thoracolumbar fascia and the QL muscle. After confirmation of negative blood aspiration, 30 mL of 0.25% bupivacaine will be injected.
223794769|NCT07094386|DRUG|Bupivacaine %0.25 (isobaric)|A single injection of 30 mg of 0.25 % bupivacaine will be administered as part of the External Oblique Intercostal Plain Block under ultrasound guidance, after confirming needle placement between the external oblique and intercostal muscles.
223794770|NCT07094386|DRUG|Bupivacaine %0.25 (isobaric)|A single injection of 30 mg of 0.25 % bupivacaine will be administered as part of the Quadratus Lumborum Block under ultrasound guidance, after confirming of correct needle placement and negative aspiration.
223794771|NCT06907615|DRUG|HLX43 DOSE 1 (2.0 mg/kg)|Dose 1; 2.0 mg/kg; HLX43 is an anti-PD-L1 monoclonal antibody conjugated with a novel high potency DNA topoisomerase I (topo I) inhibitor, with a drug-antibody-ratio (DAR) of 8.
223794772|NCT06907615|DRUG|HLX43 DOSE 2 (2.5 mg/kg)|Dose 2; 2.5 mg/kg; HLX43 is an anti-PD-L1 monoclonal antibody conjugated with a novel high potency DNA topoisomerase I (topo I) inhibitor, with a drug-antibody-ratio (DAR) of 8.
223794773|NCT03840343|BIOLOGICAL|Autologous adipose-derived mesenchymal stem/stromal cells (MSC) Lower Dose|Two MSC infusions of 2.5x10\^5 cells/kg at time zero and three months; single kidney, intra-arterial delivery
223794774|NCT03840343|BIOLOGICAL|Autologous adipose-derived mesenchymal stem/stromal cells (MSC) Higher Dose|Two MSC infusions of 5.0x10\^5 cells/kg at time zero and three months; single kidney, intra-arterial delivery
223794775|NCT05579249|DRUG|Semaglutide|Participants will receive semaglutide 2.4 milligrams (mg) subcutaneous (s.c.) injection once weekly for 52 weeks.
223794776|NCT05579249|DRUG|Orlistat|Participants will receive one of 4 commercially available anti-obesity medication chosen by the study doctor for 52 weeks. The 4 anti-obesity medications are orlistat per os \[by mouth\] (p.o.), phentermine/topiramate extended release p.o., naltrexone/bupropion extended release p.o. or liraglutide 3.0 mg s.c injection.
223794777|NCT05579249|DRUG|Phentermine/Topiramate|Participants will receive one of 4 commercially available anti-obesity medication chosen by the study doctor for 52 weeks. The 4 anti-obesity medications are orlistat per os \[by mouth\] (p.o.), phentermine/topiramate extended release p.o., naltrexone/bupropion extended release p.o. or liraglutide 3.0 mg s.c injection.
223794778|NCT05579249|DRUG|Naltrexone/Bupropion|Participants will receive one of 4 commercially available anti-obesity medication chosen by the study doctor for 52 weeks. The 4 anti-obesity medications are orlistat per os \[by mouth\] (p.o.), phentermine/topiramate extended release p.o., naltrexone/bupropion extended release p.o. or liraglutide 3.0 mg s.c injection.
223794779|NCT05579249|DRUG|Liraglutide|Participants will receive one of 4 commercially available anti-obesity medication chosen by the study doctor for 52 weeks. The 4 anti-obesity medications are orlistat per os \[by mouth\] (p.o.), phentermine/topiramate extended release p.o., naltrexone/bupropion extended release p.o. or liraglutide 3.0 mg s.c injection.
223794780|NCT04133831|OTHER|Total Survival|"The overall or total survival rate at each center is displayed in the table of outcome statistics.~Total survival is computed from survival rates of both transplant and waitlist patients: \[(number of patients surviving after transplant at end of year + number of patients alive on waitlist at end of year)\] / \[number of patients alive on waitlist at start of year\]."
223794781|NCT04133831|OTHER|Stratified Transplant Survival|"The transplant survival rate in the table of outcome statistics is stratified into two groups: (i) patients who received excellent donor organs and (ii) patients who received less than optimal donor organs.~Stratified transplant survival is computed from survival rates of transplant patients who received each quality category of organ.~excellent transplant survival = \[number of patients surviving after transplant with excellent organ\]/\[number of patients for whom excellent organ was accepted for transplant\] marginal transplant survival = \[number of patients surviving after transplant with marginal organ\]/\[number of patients for whom marginal organ was accepted for transplant\]"
223794782|NCT07103057|DEVICE|Viz HCM|Viz HCM is a Software as a Medical Device (SaMD) intended to receive 12-lead ECG recordings collected as part of a routine clinical assessment and analyze them in parallel to the standard of care. The device uses a machine learning based algorithm to analyze 12-lead ECGs and identify ECGs with suspected HCM.
223794783|NCT07100392|DRUG|tauroursodeoxycholic acid (TUDCA)|TUDCA (250 mg, twice daily) will be administered orally until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
223794784|NCT07100392|DRUG|Camrelizumab|Camrelizumab will be administered by IV, 200 mg on day 1 of each 14 day cycle until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
223794785|NCT07100392|DRUG|Regorafenib|Regorafenib 80 mg was given orally once daily on days 1-21 of a 28-day cycle until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
224264020|NCT06163001|DIETARY_SUPPLEMENT|Dietary supplementation|4 weeks of preoperative Standard medical therapy which will consist of dietary advice and supplementation
224264021|NCT02158741|BEHAVIORAL|Home Visits and Lifestyle Education Support|
224264022|NCT02376881|DRUG|Erythropoietin|20,000 IU epo IV infusion in 100 ml normal saline in 2 hr for 3 successive days
223794786|NCT07116278|DEVICE|QuantalX DELPHI-MD (TMS-EEG)|Direct Electro-Physiological Imaging medical device (DELPHI-MD), developed by QuantalX Neuroscience, is a neurophysiological assessment system which utilizes a specific TMS-EEG protocol that automatically analyzes specific features of this brain response to reproduce numerical output measures. DELPHI-MD has previously shown to differentiate different healthy age groups, mild dementia and Parkinson's Disease (PD) from age matched healthy control. In addition, DELPHI-MD measures are correlated to white matter microstructural differences in post stroke and TBI patients. This multimodal approach allows for the evaluation of several neurophysiological mechanisms such as cortical reactivity, excitation and inhibition in local and distal regions, effective connectivity, and neural plasticity, characterized as modifications that outlast the stimulation period. The investigators predict that Delphi-MD has the potential to identify features of brain function altered in pain syndromes.
223794787|NCT07121153|DRUG|NNC0487-0111 A|Participants will receive single dose (level 1, level 2, level 3) injection of NNC0487-0111 A subcutaneoulsy.
223794788|NCT07121153|DRUG|Placebo A|Participants will receive single dose (level 1, level 2, level 3) injection of placebo A subcutaneoulsy.
223794789|NCT07127237|DRUG|Bisacodyl 5 MG|On the day prior to the procedure, the group receiving bisacodyl will take 4 tablets (5 mg each) at 4:00 PM. Subsequently, at 6:00 PM, they will dissolve 3 sachets of PEG in 3 liters of water (1 sachet per liter) and ingest half of the preparation, that is, 1.5 liters over a period of 2 hours. At 10:00 PM, they will ingest the remaining 1.5 liters over another 2-hour period.
223794790|NCT07127237|DRUG|Prucalopride 2mg|On the day prior to the procedure, the group receiving prucaloprida will take 1 tablet (2 mg) at 4:00 PM. Subsequently, at 6:00 PM, they will dissolve 3 sachets of PEG in 3 liters of water (1 sachet per liter) and ingest half of the preparation, that is, 1.5 liters over a period of 2 hours. At 10:00 PM, they will ingest the remaining 1.5 liters over another 2-hour period.
223794791|NCT07127497|BIOLOGICAL|Sintilimab combined with XELOX|Sintilimab (3 mg/kg, IV, qd for patients with body weight \< 60 kg; 200 mg, IV, qd for patients with body weight ≥ 60 kg) combined with XELOX (oxaliplatin 130 mg/m2, IV, qd + capecitabine 1000 mg/m2, bid, d1 - d14, q21d) for 2-4 courses
223794792|NCT06953076|DRUG|Relugolix/estradiol/norethisterone acetate|Oral therapy administered to patients with symptomatic uterine fibroids presenting with abnormal uterine bleeding
223794793|NCT04990401|BEHAVIORAL|Behavioral Activation Teletherapy|A total of 10 teletherapy sessions to be delivered over 12-14 weeks, designed to increase physical activity among depressed individuals.
223794794|NCT06100874|DRUG|Sacituzumab Govitecan|Trop-2-directed antibody-drug conjugate, 180 mg single-dose glass vial, via intravenous infusion per protocol.
223794795|NCT06100874|DRUG|Trastuzumab|Humanized IgG1 kappa monoclonal antibody, 150mg single-dose vial, via intravenous infusion per protocol.
223794796|NCT06100874|DRUG|Trastuzumab and Hyaluronidase-oysk|Recombinant monoclonal antibody, 6 mL vial, via subcutaneous injection per protocol.
223794797|NCT07126509|PROCEDURE|Partial Pleurectomy|A partial pleurectomy is a surgical procedure where part of the pleura, the lining of the lung cavity, is removed. This may be done to remove tumors, excess tissue, or to treat lung complications.
223794798|NCT01266642|RADIATION|External Beam Radiation Therapy|Undergo HF-WBI
223794799|NCT01266642|RADIATION|External Beam Radiation Therapy|Undergo CF-WBI
223794800|NCT01266642|RADIATION|Hypofractionated Radiation Therapy|Undergo HF-WBI
223794801|NCT01266642|OTHER|Laboratory Biomarker Analysis|Optional correlative studies
223794802|NCT01266642|OTHER|Quality-of-Life Assessment|Ancillary studies
223794803|NCT01266642|OTHER|Questionnaire Administration|Ancillary studies
223794804|NCT01266642|RADIATION|Whole Breast Irradiation|Undergo HF-WBI
223794805|NCT01266642|RADIATION|Whole Breast Irradiation|Undergo CF-WBI
223794806|NCT03854461|BEHAVIORAL|Personalised dietary advice and educational material|As within arm/group description
223794807|NCT03854461|BEHAVIORAL|Educational material|As within arm/group description
223794808|NCT03280173|DRUG|tafamidis|bioavailability study
223794809|NCT04529668|DRUG|vitamin D supplementation|vitamin D supplementation
223794810|NCT04529668|DRUG|usual therapy for nasal polyposis|steroids ( systemic and local )
223794811|NCT00487266|OTHER|Acupuncture|Acupuncture of low back and legs.
223794812|NCT03339674|BEHAVIORAL|Psychoeducational Group Intervention on Alcohol Drinking Related to Stress|Manualized and standardized psychotherapeutic group intervention with three sessions of 60 min duration each which are to be delivered in a one-week period.
223794813|NCT03339674|BEHAVIORAL|Cognitive Training|Manualized and standardized psychotherapeutic group intervention with three sessions of 60 min duration each which are to be delivered in a one-week period.
223794814|NCT05735067|OTHER|Blood sample collection|5 ml of blood samples were withdrawn from RRMS patients
223794815|NCT02800850|BEHAVIORAL|Bright Light|
223794816|NCT02800850|BEHAVIORAL|Placebo Light|
223794817|NCT03877094|BEHAVIORAL|Nature virtual reality video|the patient will receive a head-set dispositive to watch a nature virtual reality video during the whole procedure of breast biopsy
223794818|NCT03031691|DRUG|brontictuzumab|starting dose of 1.5mg/kg administered intravenously (IV)
223794819|NCT03031691|DRUG|trifluridine/tipiracil|
223794820|NCT01367873|DRUG|Placebo|Oral, matching number of placebo capsule(s) with active arm
223794821|NCT01367873|DRUG|VIA-3196|Oral, capsule(s)
223794822|NCT03962387|OTHER|Not applicable(observational study)|Not applicable(observational study)
223794823|NCT05453825|BIOLOGICAL|navicixizumab+paclitaxel|navicixizumab 3 mg/kg Q2W; paclitaxel 80 mg/m2 weekly
223794824|NCT05453825|BIOLOGICAL|navicixizumab+irinotecan|navicixizumab 3 mg/kg Q2W; irinotecan 180 mg/m2 Q2W
223794825|NCT05453825|BIOLOGICAL|navicixizumab monotherapy|navicixizumab 3 mg/kg Q2W
223794826|NCT04519840|OTHER|nill|nill
223794827|NCT01898468|PROCEDURE|Pericostal Closure Technique|
223794828|NCT01898468|PROCEDURE|Intracostal Closure Technique|
223794829|NCT05895032|OTHER|Exercise|12-week exercise intervention
223794830|NCT05895032|OTHER|Usual Care|usual care
223794831|NCT05518656|BEHAVIORAL|Experimental intervention|Daily lessons received by email to be completed the same day
223794832|NCT05518656|BEHAVIORAL|Comparison intervention|Daily lessons receive by email to be completed the same day
224264023|NCT02376881|OTHER|placebo|100 ml normal saline in 2 hr for 3 successive days
223794833|NCT02427126|DRUG|Apixaban|Apixaban is an oral anticoagulant currently approved for prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation, for the treatment of deep vein thrombosis and pulmonary embolism, and for the prophylaxis of systemic embolism after orthopedic surgery
223794834|NCT02427126|DRUG|Aspirin|Acetylic Salicylic Acid 100mg o.d.; 12 Months
223794835|NCT06509126|DRUG|Panitumumab|Administered at the dosage of 6mg/kg as 60 minutes, or 90 minutes for doses over 1000 mg, intravenous infusion
223794836|NCT06509126|DRUG|Irinotecan|Administered at the dosage of 180 mg/m2 over 60 minutes intravenous infusion
223794837|NCT06509126|DRUG|5-fluorouracil|Administered at the dosage of 400 mg/m2 (bolus intravenous infusion) followed by continuous intravenous infusion over 46 hours at the dosage of 2400 mg/m2
223794838|NCT06509126|DRUG|L-folinic acid|Administered at the dosage of 200 mg/m2 over 120 minutes as intravenous infusion
223794839|NCT03259633|DRUG|Selumetinib|open-label, single-arm, multicenter intermediate access protocol
223794840|NCT02526732|OTHER|individual training program|Training period of 8 weeks: Independently running exercises for 30-45 minutes two to three times a week. Every two weeks group training sessions are offered accompanied by a sports physician.
223794841|NCT05420155|PROCEDURE|Surgical resection|Surgical treatment of hepatic hydatidic cyst
223794842|NCT00857207|BEHAVIORAL|Goal Management Training|Enhanced Goal Management Training is a 10-week group therapy that teaches strategies to improve an individual's ability to complete everyday tasks.
223794843|NCT01073423|BEHAVIORAL|Music Therapy|1-hour music therapy sessions, administered in group format 3 times per week for 8 weeks.
223794844|NCT01073423|BEHAVIORAL|Yoga|1-hour yoga sessions administered in group format 3 times per week for 8 weeks
223794845|NCT03952858|OTHER|Telerehabilitation Group|The telerehabilitation Group receives physiotherapy supervised exercises on-line. The Community Center Group receives the traditionel training offer in the municipality Center for older people.
223794846|NCT03827954|OTHER|HeartMapp+CT|HeartMapp+CT is a mobile system that includes physiological modules that support self-monitoring and exercises that promote heart health, and computerized plasticity-based adaptive cognitive training modules that train participants to enhance cognitive functions and ultimately heart failure outcomes.
223794847|NCT01835457|DRUG|Lipopolysaccharide|LPS is used to elicit an inflammatory response in all subjects.
223794848|NCT01835457|BEHAVIORAL|Concentration/meditation|A self-taught concentration/meditation technique that Mr Wim Hof developed himself, characterized by cycles consisting of a few minutes of hyperventilation followed by breath holding for up to 1-2 minutes and deep concentration (mindset).
223794849|NCT00019916|BIOLOGICAL|aldesleukin|
223794850|NCT00019916|BIOLOGICAL|p53 peptide vaccine|
223794851|NCT00019916|PROCEDURE|in vitro-treated peripheral blood stem cell transplantation|
223794852|NCT01702727|DEVICE|I-BiTTM game|30 minutes intervention weekly for 6 weeks.
223794853|NCT01702727|DEVICE|Non-I-BiTTM game|30 minutes intervention weekly for 6 weeks.
223794854|NCT01702727|DEVICE|I-BiTTM DVD|30 minutes intervention weekly for 6 weeks.
223794855|NCT01205594|DEVICE|ITPR|the ITPR will be inserted in the anesthesia circuit and activated to provide -10 mmHg ETP.
223794856|NCT01240174|BEHAVIORAL|Demonstration of near zero antibiotic prescribing for patients with acute bronchitis|A controlled, continuously-monitored, implementation of an EHR-integrated diagnosis and treatment algorithm for acute bronchitis in a large, diverse primary care practice.
223794857|NCT05119894|DRUG|Brexpiprazole LAI: Dose 1|Cohort 1: Single Dose Intramuscular Injection: Brexpiprazole LAI Dose 1
223794858|NCT05119894|DRUG|Brexpiprazole LAI: Dose 2|Cohort 2: Single Dose Intramuscular Injection:Brexpiprazole LAI Dose 2
223794859|NCT05119894|DRUG|Brexpiprazole LAI: Dose 3|Cohort 3: Single Dose Intramuscular Injection:Brexpiprazole LAI Dose 3
223794860|NCT05119894|DRUG|Brexpiprazole LAI: Dose 4|Cohort 4: Single Dose Intramuscular Injection:Brexpiprazole LAI Dose 4
223794861|NCT01499004|DRUG|tofacitinib (CP-690,550) modified-release formulation A|A single dose of 22 mg tofacitinib (CP-690,550) modified-release formulation A administered with food.
223794862|NCT01499004|DRUG|tofacitinib (CP-690,550) modified-release formulation B1|A single dose of 22 mg tofacitinib (CP-690,550) MR-B1 formulation administered with food
223794863|NCT01499004|DRUG|tofacitinib (CP-690,550) modified-release formulation A|A single dose of 22 mg tofacitinib (CP-690,550) modified-release formulation A administered without food
223794864|NCT01499004|DRUG|tofacitinib (CP-690,550) modified-release formulation B1|A single dose of 22 mg tofacitinib (CP-690,550) modified-release formulation B1 administered without food
223794865|NCT01499004|DRUG|tofacitinib (CP-690,550) modified-release formulation B2|A single dose of 22 mg tofacitinib (CP-690,550) modified-release formulation B2 administered without food
223794866|NCT01499004|DRUG|tofacitinib (CP-690,550) immediate-release formulation|A single dose of 10 mg tofacitinib (CP-690,550) immediate-release formulation administered without food
223794867|NCT02002481|OTHER|transport|The manikin will be resuscitated during a transport in a vessel by a professional team (emergency physician / paramedic).
223794868|NCT04592068|DEVICE|Retinal multi-diseases diagnosed by DL algorithm|DL algorithm automatically classify multi-diseases from fundus photography and differentiate major vision-threatening conditions and other retinal abnormalities.
223794869|NCT04592068|OTHER|Retinal multi-diseases diagnosed by expert panel|Expert panel classifies multi-diseases from fundus photography and differentiate major vision-threatening conditions and other retinal abnormalities.
223794870|NCT06388668|DIAGNOSTIC_TEST|Lipid panel|Lipid panel measuring levels of LDL, non-HDL and apoB
223794871|NCT02224768|DRUG|Ipilimumab|
223794872|NCT02947126|DRUG|Hypertonic Saline|Inhaled 7% Hypertonic saline
223794873|NCT02947126|DRUG|Isotonic Saline|Inhaled 0.9% Isotonic saline
223794874|NCT02947126|DRUG|Indium-DTPA|Inhaled Indium 111 DTPA
223794875|NCT02947126|DRUG|Technetium Sulfur Colloid|Inhaled Technetium99m sulfur colloid
223794876|NCT02789280|BEHAVIORAL|Activities.|"Increasing activity level included a brief description of how activities affect mood. Participants were then asked to choose the activities they could use to improve their mood from an available list of helpful activities; users were also able to generate their own helpful activities. Participants were also presented with examples of unhelpful activities such as staying in bed and being isolated"
223794877|NCT02789280|OTHER|Wait list|will receive the behavioral activation condition after one week of completing baseline assessment.
223794878|NCT00990834|DRUG|simvastatin|simvastatin 80 mg PO daily for one to eight months.
223794879|NCT03100617|BEHAVIORAL|Psychosocial caregiver intervention|Modified version of the REACH-VA intervention for family caregivers of persons with dementia. The intervention has several components including 1) caregiver education, 2) risk assessment, 3) caregiver needs assessment, 4) caregiver skill building and problem solving, and 4) caregiver stress reduction.
223794880|NCT00955357|DRUG|Lacosamide|"Oral Lacosamide:~Subjects Titration Phase (6 Weeks):~Week 1 - 50 mg tablet Twice daily (bid); Week 2 - 100 mg tablet bid; Week 3 - 150 mg tablet bid; Week 4 - 200 mg tablet bid; Week 5 - 200 mg tablet bid; Week 6 - 150 mg tablet bid OR Week 6 - 200 mg tablet bid~Maintenance Phase (24 Weeks):~200 mg tablet bid OR 150 mg tablet bid~Taper Phase (1 - 3 Weeks):~50 mg tablet bid for 1 week OR 100 mg tablet bid for 1 week OR 150 mg tablet bid for 1 week"
223794881|NCT06263621|BEHAVIORAL|"Intervention Standard"|"The two cafes will offer entrees in two sizes, a smaller and larger size. In the intervention cafe, the smaller size will be labeled Standard during the intervention period, and Small during all other times. In the control cafe, the smaller size will always be labeled Small. The larger size will always be labeled Large for both cafes during the duration of the study."
223794882|NCT01258608|DRUG|Mapatumumab|Mapatumumab will be supplied as a lyophilized formulation in 10 mL vials containing 100 mg mapatumumab for intravenous infusion at the dose of 30 mg/kg.
223794883|NCT01258608|DRUG|Placebo|Normal saline solution for intravenous infusion will be administered as placebo for mapatumumab
223794884|NCT01258608|DRUG|Sorafenib|Sorafenib will be supplied as tablets, each containing 274 mg sorafenib tosylate, equivalent to 200 mg of sorafenib, to be administered 400 mg (2 x 200 mg tablets) orally twice daily.
223794885|NCT06248918|BEHAVIORAL|WATSOCPAP|Participants will receive an supervised and individualized exercise plan, activity tracker, and physical activity coaching program based Social Cognitive Theory. Participants will be administered strengthening and aerobic exercise program, structured and individualized according to the person's individual capacity and needs, under the supervision of a physiotherapist. The activity tracker will provide real-time activity information about daily steps, time spent with MVPA (minutes/day) and sedentary time. The nurse-led physical activity coaching program was planned according to the Social Cognitive Theory (SCT) components such as self-regulation, outcome expectation, social support and perceived environment. The interventions will continue with online and the 12-week program will be completed.
223794886|NCT00000779|BIOLOGICAL|Aluminum hydroxide|
223794887|NCT00000779|BIOLOGICAL|MF59|
223794888|NCT00000779|BIOLOGICAL|rgp120/HIV-1IIIB|
223794889|NCT00000779|BIOLOGICAL|rgp120/HIV-1MN|
223794890|NCT00000779|BIOLOGICAL|rgp120/HIV-1 SF-2|
223794891|NCT00000779|BIOLOGICAL|Env 2-3|
223794892|NCT01009931|DRUG|12-O-tetradecanoylphorbol-13-acetate|The initial dose of TPA will be 1 mg/week x 3 weeks (Day 1, 8, 15). Up to 6 cycles.
223794893|NCT01009931|DRUG|Dexamethasone|Dexamethasone 10 mg PO qid will start 24h prior to TPA and continue for 24h after TPA x 3 weeks. Up to 6 cycles.
223794894|NCT01009931|DRUG|Choline magnesium trisalicylate|"Choline magnesium trisalicylate 1500 mg PO TID will begin 24h prior to TPA and continue for 24h post TPA x 3 weeks.~Up to 6 cycles."
223794895|NCT03044483|OTHER|Measurement of sublingual microcirculatory parameters|Measurement of the sublingual microcirculatory function using the CytoCam-IDF imaging device to establish the normal range for each age group noted.
223794896|NCT01719835|DRUG|Cyclophosphamide|750mg/m2 IV every 21 days
223794897|NCT01719835|DRUG|Gemcitabine|1000mg/m2 IV Days 1, 8, 15 every 28 days
223794898|NCT01719835|DRUG|Doxorubicin|50mg/m2 IV every 21 days
223794899|NCT01719835|DRUG|Vincristine|1.4mg/m2 (max 2mg) IV every 21 days
223794900|NCT01719835|DRUG|Prednisolone|100mg PO Days 1-5 every 21 days
223794901|NCT01719835|DRUG|methylprednisolone|1000mg oral or IV Days 1-5 every 28 days
223794902|NCT01719835|DRUG|Cisplatin|100mg/m2 IV Day 15 every 28 days
223794903|NCT05670899|PROCEDURE|CAD PEEK frame-work|Construction of PEEK framework will be done conventionally by lost wax technique using a vacuum press device. The wax pattern will be invested in a mold using special investment. Then it will be heated and melted to produce a mold into which PEEK will be vacuum pressed. The framework will be fitted on the master cast
223794904|NCT02110641|BEHAVIORAL|Weight Loss Counseling|The intervention will be based on the Diabetes Prevention Program weight loss program, which uses a combination of reduced caloric intake, increased physical activity, and behavior therapy. The content of the weight loss program will be similar for the in-person and telephone interventions, but the approach will vary (i.e., in-person vs. telephone counseling). The weight loss intervention will be conducted by a Registered Dietitian, who has training in exercise physiology and behavior modification.
223794905|NCT01297231|OTHER|MRI|"Baseline Breast-MRI within 1 year before starting tamoxifen (allows for surgery, chemotherapy and radiation before the start of tamoxifen).~During Tamoxifen Treatment:~* Blood will be drawn for CYP2D6 genotype testing. Analysis of samples will be performed internally at MSKCC.~* Follow-up breast MRI after 9-12 months of tamoxifen therapy. In patients whom further breast MRI screening and/or follow-up is clinically indicated, follow-up breast MRIs may be performed within 3 months (before or after) the 2, 3, and 4 year time points during tamoxifen treatment. All breast MRIs will be performed using the same technique.~* Follow-up for all patients during and after tamoxifen should include routine standard clinical assessment and imaging such as mammography and breast MRI when clinically indicated."
223794906|NCT03204253|DRUG|rFSH + r-LH in combination|29 women stimulated with rFSH supplemented by rLH in the late follicular phase started at the same time of starting the antagonist administration.
223794907|NCT03204253|DRUG|rFSH alone|32 women who were stimulated with recombinant FSH alone
223794908|NCT04354467|DIAGNOSTIC_TEST|urine neutrophil gelatinase -associated lipocalin|urine biomarker is measured and batched procesessed
223794909|NCT03532074|DIAGNOSTIC_TEST|assessment of bowel symptoms before surgery|validated questionnaires (Knowles-Eccersley-Scott-Symptom Questionnaire and Gastrointestinal Quality of Life Index) are filled in by patients with rectosigmoid endometriosis before surgery
223794910|NCT03532074|DIAGNOSTIC_TEST|assessment of rectosigmoid during laparoscopy|indocyanine green (0.25 mg/kg) is administered through peripheral line. A near-infrared camera-head (KARL STORZ Gesellschaft mit beschränkter Haftung \& Co., Tuttlingen, Germany) is used to visualize bowel perfusion before and after the removal of the rectosigmoid nodule. To estimate the vascularization, a scale with a score between 0 and 4 is used
223794911|NCT03532074|DIAGNOSTIC_TEST|follow up and assessment of bowel symptoms after surgery|validated questionnaires (Knowles-Eccersley-Scott-Symptom Questionnaire and Gastrointestinal Quality of Life Index) are filled in by patients with rectosigmoid endometriosis after surgery
223794912|NCT03532074|DIAGNOSTIC_TEST|assessment of rectosigmoid perfusion during robot-assisted laparoscopy|indocyanine green (0.25 mg/kg) is administered through peripheral line. The robotic Firefly imaging system (daVinciXi surgical platform; Intuitive Surgical, Sunnyvale, CA) is used to visualize bowel perfusion before and after the removal of the rectosigmoid nodule. To estimate the vascularization, a scale with a score between 0 and 4 is used
223794913|NCT01437826|DRUG|antioxidants|tablets composed of 200 mcg selenium \[as l-selenomethionine\], 30 mg zinc, 2 mg vitamin A \[retinol\], 180 mg vitamin C \[ascorbic acid\] and 30 mg vitamin E \[D-α-tocopherol acetate\]
223794914|NCT01437826|DRUG|placebo|placebo had an identical appearance as intervention
223794915|NCT03853668|BEHAVIORAL|exercise|control group (n=40) did aerobic exercises on treadmill for 10 weeks experimental group (n=40) did combined aerobic and resisted exercises for 10 weeks
223794916|NCT01140217|DRUG|Norethindrone Acetate|Norethindrone Acetate Transdermal Delivery System
223794917|NCT02319811|PROCEDURE|Cryopreserved meniscus transplants|Lateral or medial cryopreserved meniscus transplants implanted into appropriately indicated patients.
223794918|NCT03616548|DIAGNOSTIC_TEST|Endoscopic surveillance|Magnifying endoscopy under narrow band imaging system via chimney ileostomy after intestinal transplantation
223794919|NCT04710810|OTHER|umbilical cord blood mononuclear stem cells|UCB samples (70-130 ml of initial volume) were aseptically drained in blood-collection bags with 35 mL of citrate phosphate dextrose (CPDA-1) anticoagulant. Red blood cell-depleted/plasma-reduced nucleated cells were isolated by sedimentation in dextran-40, resuspended in autologous plasma with 10% dimethylsulfoxide and 1% dextran-40, and aliquoted in 3.8 ml vials with target doses of 3.0±0.2 x 10⁶ cells per vial. Vials were cooled to -90⁰C, quarantined in the vapor phase of liquid nitrogen. Tested for HIV-1/2, hepatitis B and C, HTLV-1/2, HSV-1 and -2, CMV, syphilis, and sterility. Characterized by AB0/Rh, CD34/CD45-positive cell content. Before injection sample thaws in the water bath at +37⁰C and washes from an excess amount of DMSO in 40 mL of physiological saline containing 2.5% human serum albumin and 5% dextran-40. After centrifugation and supernatant withdrawal, the UCB resuspends in 40 ml of the same solution at a target dose of 250±10 x 10⁶ viable cells per sample.
223794920|NCT01532115|DRUG|BIA 9-1067|50 mg and 800 mg of BIA 9-1067 (single-dose)
223794921|NCT01532115|DRUG|Placebo|single-dose
223794922|NCT01532115|DRUG|moxifloxacin|400 mg moxifloxacin (single-dose)
223794923|NCT05389579|DEVICE|electric blanket|"After the patients were taken to their own beds after surgery, the researcher covered them with a wool blanket from the top of clavicle to the bottom of their feet, put the sphygmomanometer on the arm without an IV line, positioned the sphygmomanometer so that the instrument panel was on the blanket and measured the patients' blood pressure. Then, the electric blanket was operated at the warm level for the experimental group, and it was turned off and unplugged when their body temperature reached 36.0 °C."
223794924|NCT04757987|OTHER|Pain|As above
223794925|NCT01726881|DEVICE|Thermal stimulation|"Stimulation using a Thermal Sensory Analyzer:~2001, Maddock ltd., Israel."
223794926|NCT01726881|DEVICE|Mechanical stimulation|Stimulation using Semmes-Weinstein-Monofilament Touch Test Sensory Evaluators
223794927|NCT01726881|DEVICE|Transcutaneous Electrical Nerve Stimulator (TENS)|A portable stimulator designed to Physical treatment of pain. TENS - Cedar rehab X2. Chattanooga group.USA.
223794928|NCT01235390|DIETARY_SUPPLEMENT|Walnuts|The consumption of assigned walnuts once a day during 4 weeks
223794929|NCT05786690|OTHER|Interventions|the temporospatial and kinematic gait characteristics
223794930|NCT05885152|OTHER|Whole-body electrical stimulation|Performed using Miha Bodytec equipment, properly calibrated, with electrodes on the quadriceps, hamstrings, glutes, biceps, triceps, pectorals, abdomen, trapezius, latissimus dorsi and quadratus lumborum muscles.
223794931|NCT00867438|PROCEDURE|Sigmoidoscopy|
223794932|NCT01835392|PROCEDURE|Remote Ischemic Preconditioning|Lower limb ischemia/reperfusion cycles
223794933|NCT01835392|OTHER|Control|Sham placement of blood pressure cuff without inflation
223794934|NCT04098939|DIAGNOSTIC_TEST|Diaphragm evaluation|Ultrasound and radiographic evaluation of diaphragm function
223794935|NCT00908167|DRUG|Sorafenib|Please see detailed description.
223794936|NCT00908167|DRUG|Cytarabine|Please see Detailed Description.
223794937|NCT00908167|DRUG|Clofarabine|Please see Detailed Description.
223794938|NCT01252823|DEVICE|Implantation of ILR|Subcutaneous implantation of ILR under local anesthesia
223794939|NCT06423846|DRUG|Total intravenous anesthesia group|Patients in the TIVA group had anesthesia induced with propofol 2 mg/kg , fentanyl 1 ug/kg and maintained with propofol. 200 ug/kg/min, fentanyl 0.1ug/kg/min, dexmedetomidine 1 ug/kg/hour
223794940|NCT06423846|DRUG|sevoflurane group|For patients in the SEVO group, general anesthesia was induced with propofol 2 mg/kg, fentanyl 1 ug/kg and then maintained with sevoflurane in air and oxygen, dexmedetomidine 1 ug/kg/hour.
223794941|NCT04928963|DIETARY_SUPPLEMENT|Prolon - FMD|Prolon by L-Nutra is a medically-designed dietary kit providing the food to eat for five days. Day 1 of Prolon provides \~4600 kJ (11% protein, 46% fat, and 43% carbohydrate), whereas days 2-to-5 provide \~3000 kJ (9% protein, 44% fat, and 47% carbohydrate) per day.
223794942|NCT00981981|DIETARY_SUPPLEMENT|Wheat bran|21g per day of ready to eat breakfast cereal containing wheat bran with 8g of total dietary fiber and 0.5g beta-glucan.
223794943|NCT00981981|DIETARY_SUPPLEMENT|3g high MW|20.2 grams per day of ready to eat cereal containing 6g total dietary fiber and 3g oat beta glucan with high molecular weight
223794944|NCT00981981|DIETARY_SUPPLEMENT|4g medium MW|28.5g ready to eat cereal containing 8g total dietary fiber and 4g oat beta glucan with medium molecular weight
223794945|NCT00981981|DIETARY_SUPPLEMENT|3g medium MW|21.1g of ready to eat cereal containing 6g total fiber and 3g oat beta glucan with a medium molecular weight
223794946|NCT00981981|DIETARY_SUPPLEMENT|4g low MW|28.7g ready to eat cereal containing 8g total dietary fiber and 4g oat beta glucan with low molecular weight
223794947|NCT02943408|BEHAVIORAL|person-centered mental health intervention|We anticipate that the PCMHI will be comprised of three, one-hour sessions offered over three to six weeks, scheduled at the participants' preference. Sessions will be one-on-one and the peer support specialist interventionist.
223794948|NCT02943408|BEHAVIORAL|health and wellness|The control condition will be an educational health and wellness intervention for stress related disorders that will match the experimental condition for time and attention. The control condition will be three, one hour, individual sessions covering the symptom cycle, managing stress, and identifying social supports.
223794949|NCT06380218|BEHAVIORAL|Nutrional and physical activity program|Nutritional prevention and physical activity workshops associated with a substitution of saturated and/or trans fatty acids by cis-unsaturated acids via the consumption of Primevère margarine to influence lifestyle habits, quality of life and improvement of the lipid profile of women with cardiovascular risk
223794950|NCT01106833|DRUG|Sirolimus + calcineurin inhibitor + prednisone|"The target serum level for sirolimus is 3-12 ng/mL. The target serum level for tacrolimus is 5-10 ng/mL. The target serum level for cyclosporine is 120-200 ng/mL.~Prednisone is administered initially as a single early morning dose of 1 mg/kg/day (or equivalent). If prednisone at a dose of 1 mg/kg/day (or equivalent) is contraindicated, patients may begin prednisone between 0.5-1 mg/kg/day."
223794951|NCT01106833|DRUG|Sirolimus + prednisone|"The target serum level for sirolimus is 3-12 ng/mL.~Prednisone is administered initially as a single early morning dose of 1 mg/kg/day (or equivalent). If prednisone at a dose of 1 mg/kg/day (or equivalent) is contraindicated, patients may begin prednisone between 0.5-1 mg/kg/day."
223794952|NCT05582720|BEHAVIORAL|Conventional burger|Participants initially randomized to this intervention arm will be provided with a total of 8 conventional burgers and will be asked to consume them twice weekly for 4 weeks. Conventional burgers will be produced by Hellenic Catering S.A. using standard procedures. Participants will also be instructed to maintain their usual dietary intake, physical activity level, prescribed medications and dietary supplements, as well as to refrain from any weight loss effort during the intervention. After a 2-week wash-out period (no burger consumption), participants will cross over to the other intervention arm.
223794953|NCT05582720|BEHAVIORAL|Vegan burger|Participants initially randomized to this intervention arm will be provided with a total of 8 vegan burgers and will be asked to consume them twice weekly for 4 weeks. Vegan burgers will be produced by Hellenic Catering S.A. using novel technologies. Participants will also be instructed to maintain their usual dietary intake, physical activity level, prescribed medications and dietary supplements, as well as to refrain from any weight loss effort during the intervention. After a 2-week wash-out period (no burger consumption), participants will cross over to the other intervention arm.
223794954|NCT05488392|PROCEDURE|Hypothermia with intrajugular cooling|Hypothermia with intrajugular cooling will be applied after successful recanalization of the culprit internal carotid artery/middle cerebral artery. The perfusion rate will be set at 30 ml/min. Low temperature saline will be infused into the internal jugular vein for 10 min, 15 min, 20 min, 25 min, and 30 min successively.
223794955|NCT04376138|OTHER|BCI intervention|30 minutes intervention that occurs 3 times per week, with a goal of 12 sessions total.
223794956|NCT04376138|OTHER|Conventional Therapy|30 minutes intervention that occurs 3 times per week, with a goal of 12 sessions total.
223794957|NCT04000568|OTHER|Respiratory support: NAVA -NIV and PC-NIV|The infants enrolled will receive respiratory assistance by NAVA-NIV and PC-NIV in a randomized order
223794958|NCT01621126|DEVICE|Intra-operative neuromonitoring (XLTEK/NATUS EP Protektor)|Device: Intra-operative neuromonitoring A XLTEK/NATUS EP Protektor machine (at MGH) or a Cadwell Cascade Elite neuromonitoring machine (at BWH), both FDA approved for intra-operative neuromonitoring, will deliver the electrical stimulus applied transcranially to stimulate the motor cortex, while motor evoked responses will be recorded from different myotomes from both upper limbs. Also the same equipment will deliver electrical stimulus to stimulate peripherally the median and ulnar nerves at the wrists, with recording of the thalamocortical potentials in the scalp channels.
223794959|NCT02062359|BIOLOGICAL|Anti-NY ESO-1 T cell receptor (TCR) cluster of differentiation 62L (CD62L)+ cells|"Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of anti-NY ESO-1 T cell receptor (TCR) CD62L+ cells and high dose aldesleukin.~On day 0, cells (1x10e9 to 2x10e11) will be infused intravenously on the Patient Care Unit over 20-30 minutes."
223794960|NCT02062359|DRUG|Aldesleukin|Aldesleukin 720,000 IU/kg intravenous (IV) (based on total body weight) over 15 minutes approximately every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses).
223794961|NCT02062359|DRUG|Cyclophosphamide|On days -7 and -6: Cyclophosphamide 60 mg/kg/day X 2 days intravenous (IV) in 250 ml dextrose 5% in water (D5W) with Mesna 15 mg/kg/day X 2 days over 1 hr.
223794962|NCT02062359|DRUG|Fludarabine|On days -5 to -1: Fludarabine 25 mg/m(2)/day intravenous piggyback (IVPB) daily over 30 minutes for 5 days.
223794963|NCT00886340|BEHAVIORAL|Enhanced standard care|One appointment with nurse practitioner (20 minutes) One appointment with nutritionist (45 minutes)
223794964|NCT00886340|BEHAVIORAL|Lifestyle counseling|Enhanced standard care Six appointments with nurse practitioner (20 minutes)
223794965|NCT03355417|OTHER|OT-SI|Occupational therapy using a sensory integration approach (OT-SI) 3x per week for 10 weeks. A typical session will be 1 hour (total of 3 hours per week).
223794966|NCT01949311|DRUG|Dupilumab|
223794967|NCT04843033|DRUG|SH3809 tablet|Starting dose 2mg,oral administered once daily. If tolerated subsequent cohorts will test increasing doses (4mg,6mg,8mg,10mg,12mg) of SH3809.
223794968|NCT00201084|BEHAVIORAL|Uncertainty reduction|At physician discretion, 24 hour ambulatory BP monitoring and/or electronic bottle cap monitoring and/or lifestyle counseling
223794969|NCT02939040|BEHAVIORAL|Positive Activities|"The PPB intervention involves noting at least one positive event each day, writing it down on a slip of paper and then depositing this piece of paper in a piggy bank. This practice is to take place at the end of the day, every day over a circumscribed period of time. At the end of the deposit period the participant closes the account and makes a full withdrawal by taking all of the slips out of the piggy bank and reading each one the night before surgery."
223794970|NCT03449810|PROCEDURE|DSE plus MET group A|"The Dynamic stabilization exercises will consist of seven exercises, which are aimed to strengthen the lumbar stabilizing muscles. All seven dynamic stabilization exercises will be performed once and always in random order.~The procedure for MET involves voluntary contraction of the participant's muscle in a precisely controlled direction, at varying levels of intensity, against a distinctly executed counterforce applied by the therapist. In this type of therapy, a participant contracts muscles by pushing against resistance provided by the therapist. The therapist then assists the participant in stretching, strengthening and relaxing those muscles."
223794971|NCT03449810|PROCEDURE|DSE alone group B|The DSE in this arm is the same a described in group A, i.e. it involves seven exercises activities administered randomly at every session of the study intervention.
223794972|NCT03449810|PROCEDURE|Standard Physiotherapy treatment group C|In the control group, the participants will receive standard physiotherapy treatment offered for the management of chronic NSLBP patients in Nigeria. Therefore, individuals randomized to this therapeutic group will be treated with classical massage, therapeutic exercises and a combination of interferential therapy and therapeutic ultrasound (INF/UTS) applied to the lumbosacral region.
223794973|NCT02508467|DRUG|Fisogatinib (BLU-554)|
223794974|NCT03272633|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Receive IHC
223794975|NCT03272633|BIOLOGICAL|Irradiated Allogeneic Cells|Correlative studies
223794976|NCT02672254|RADIATION|Samples with 2 treatments|Study the concomitant effects between chemo- and radiotherapy by means of cellular techniques.
223794977|NCT00559650|DRUG|Placebo|Will be standard therapy and placebo versus, Uptitration from 100-600µg/g, intravenous, over maximum 48 hours
223794978|NCT00559650|DRUG|Cinaciguat (BAY58-2667)|Will be standard therapy and BAY 58-2667, Uptitration from 100-600µg/g, intravenous, over maximum 48 hours
223794979|NCT03412682|DRUG|Budesonide (6 mg)|Budesonide (6 mg) administered once a day along with three mesalazine placebo three times a day, over an 8-week treatment period.
223794980|NCT03412682|DRUG|Budesonide (9 mg)|Budesonide (9 mg) administered once a day along with three mesalazine placebo three times a day, over an 8-week treatment period.
223794981|NCT03412682|DRUG|Mesalazine (3,600 mg)|Mesalazine (3,600 mg) administered once a day plus three mesalazine 400 mg three times a day, over an 8-week treatment period.
223794982|NCT03455374|DEVICE|Treatment with CSI atherectomy device|Following peripheral angiography, patients with significant SFA or below the knee artery disease (≥ 50%) or total occlusions (100%) will have a baseline OCT imaging of the target vessel and the lesion be treated with proper size CSI burr. Repeat OCT imaging will be performed after CSI. Drug eluting balloon angioplasty may be performed in discretion of the operator. If DEB is used, a final OCT imaging will be performed to assess lesion expansion and possible dissections. Balloon sizing will be based on 1:1 vessel ratio with the length covering from minimally diseased distal segment to minimally diseased proximal segment. We will try to avoid use of stents.
223794983|NCT02120027|DRUG|Ibodutant 10 mg|Oral tablet, to be given once daily.
223794984|NCT02120027|DRUG|Placebo|Oral tablet (identical in appearance and weight to ibodutant tablets) to be given once daily.
223794985|NCT00875004|BIOLOGICAL|epoetin beta|
223794986|NCT00875004|DRUG|systemic chemotherapy|
223794987|NCT00875004|PROCEDURE|quality-of-life assessment|
223794988|NCT03192605|OTHER|Blueberry|Blueberry - 150 grams wild blueberries (whole fruit)
223794989|NCT03192605|OTHER|Placebo|Placebo - matched for calories and fiber
223794990|NCT04106726|DRUG|Soolantra® Ivermectin cream 1%|Apply topically to the face once daily for 84 consecutive days.
223794991|NCT04106726|DRUG|Ivermectin cream 1%|Apply topically to the face once daily for 84 consecutive days.
223794992|NCT04106726|DRUG|Placebo for Ivermectin cream 1%|Apply topically to the face once daily for 84 consecutive days.
223794993|NCT04275466|PROCEDURE|necrotic cavity lavage|"1. At least two 30- to 36-Fr drainage tubes will be placed into each necrotic cavity. One of these drainage tubes will be used as the lavage tube; the other tube is designed for drainage.~2. Lavage will begin on the first day after debridement, and the relevant indices will be evaluated every 7 days to decide whether to continue the lavage.~3. 1200 mL of normal saline will be lavaged into each necrotic cavity every day at a speed of 200 mL/h for 3 hours each time and for a total of two times. The start times of lavage will be 08:00 and 20:00.~4. The lavage and drainage volumes of the first hour and second hour of each lavage session will be calculated. The lavage of the next hour will be stopped if the lavage volume minus the drainage volume is \>100 mL.~5. Lavage will be suspended if abdominal pain and distention occur, the maximum body temperature is \>38.5ºC, or the abdominal pressure is ≥15 mmHg during the lavage procedure."
223794994|NCT05549973|DRUG|Anlotinib Hydrochloride Capsule|Anlotinib hydrochloride is a muti-target tyrosine kinase inhibitor.
223794995|NCT04222101|DIAGNOSTIC_TEST|Oral glucose tolerance test|measure insulin, glucose and FGF21 levels in response to oral glucose challenge
223794996|NCT06495788|DEVICE|High-intensity laser therapy (HILT)|"* Pulsed high-intensity laser therapy (HILT) will be applied 3 sessions per week for 8 weeks with pulsed emission (1064 nm), very high peak power (3 kW), a short duration (120-150 ms), and low frequency (10-40 Hz).The probe is fixed vertically at 90° to the most painful points while the patients sit on a chair and wear safety eyewear.~* Conventional treatment ( 3 days per week for 8 weeks).: in the form of~* Hot pad: It will be used over the temporomandibular joint (TMJ) for 5 minutes at the beginning of each session.~* Ultrasound therapy (US): it will be applied over the TMJ with pulsed intensity of 1.0 W/cm2 at a 1MHz frequency for 5 min/session.~* TENS: one electrode is placed over the TMJ and the other just above the mandibular angle. it will be applied with a low frequency of 50 HZ, tolerable intensity for 15 minutes.~* Exercise therapy: anterior, medial and lateral glide of the mandible. Each glide will be done 10-15 repetitions, 5-6 times in a session, 10 minutes as a total."
223794997|NCT06495788|DEVICE|placebo high-intensity laser therapy|The same treatment procedure will be applied in the placebo group as in the experimental group, but the laser device is turned off during applications, in addition to the conventional treatment in the form of hot pad, US, TENS, and exercise therapy.
223794998|NCT01002872|DRUG|Lanthanum Carbonate (Fosrenol)|Randomization To either Lanthanum Carbonate 1 pill TID/Placebo 1 pill three times a day (TID) Day 15 If phosphorus is 3.5mg/dL-5.5mg/dL Continue with 1 pill TID. If phosphorus \<3.5mg/dL Reduce to 1 pill twice a day (BID). If Phosphorus \>5.5mg/dL 1 pill with breakfast 1 pill with lunch 2 pills with dinner Day 30 If phosphorus is 3.5mg/dL-5.5mg/dL Continue with 1 pill TID If phosphorus is \<3.5mg/dL Reduce to 1 pill daily. If phosphorus \>5.5mg/dL 1 pill with breakfast 2 pills with lunch 2 pills with dinner Day 45 If phosphorus is 3.5mg/dL-5.5mg/dL Continue with 1 pill TID If phosphorus \<3.5mg/dL stop the drug If phosphorus is \>5.5mg/dL 2 pills with breakfast 2 pills with lunch 2 pills with dinner
223794999|NCT01002872|DRUG|placebo|Initial dose of placebo will be 1 pill three times a day
223795000|NCT02919800|BIOLOGICAL|MOD-5014|MOD-5014, a long-acting modified recombinant Factor VIIa
223795001|NCT02919800|OTHER|MOD-5014 Placebo|Placebo solution for SC injection containing the same inactive ingredients used in the active drug product at matching volumes
223795002|NCT02479568|DIETARY_SUPPLEMENT|Control|500 mL (250 mL; 2 times/day) of placebo drink for 12 weeks
223795003|NCT02479568|DIETARY_SUPPLEMENT|100% Florida OJ|500 mL (250 mL; 2 times/day) of 100% Florida OJ for 12 weeks
223795004|NCT02479568|DIETARY_SUPPLEMENT|100% Florida OJ-enriched|500 mL (250 mL; 2 times/day) of 100% Florida OJ-enriched for 12 weeks
223795005|NCT00414817|BEHAVIORAL|Automated Phone-Based Refill Reminders|The BREATHE EASY Medication Reminder Program uses interactive voice recognition phone technology to offer timely reminders to patients to refill their ICS medication, educational messages about ICS, and may offer to transfer them to a refill line or to speak with a pharmacist if they have questions.
223795006|NCT03263754|BEHAVIORAL|Pocket Medic|10 short digital films utilising self-determination theory aiming to increase patient self-management
223795007|NCT03263754|BEHAVIORAL|Pulmonary Rehabilitation|PR follows National Institute for Clinical Excellence guidelines delivering 14 sessions over 7 weeks utilising a multidisciplinary approach
223795008|NCT05554068|DRUG|Shingrix|Shingrix vaccine will be given to all eligible patients at one to three year post allogeneic stem cell transplantation.
223795009|NCT02077764|PROCEDURE|OCT and coronary angiography|
223795010|NCT02077764|PROCEDURE|Right heart cat.|
223795011|NCT02077764|RADIATION|PET|
223795012|NCT02077764|PROCEDURE|Echocardiography|
223795013|NCT02077764|PROCEDURE|exercise test|
223795014|NCT02077764|OTHER|blood samples|
223795015|NCT03035292|DIAGNOSTIC_TEST|Red-reflex assessment|The red reflex was examined in the standard manner using direct ophthalmoscope by medical student examiner
223795016|NCT03035292|DIAGNOSTIC_TEST|Infrared-reflex assessment|The infrared reflex was examined using a modified smart phone camera by a medical student examiner
223795017|NCT01241357|DEVICE|Hepatic biomagnetic susceptibility measurement|Subjects will first have an ultrasound study to determine the location of the liver and measure the distance from skin surface to the liver. Subjects will then be examined with the high Tc susceptometer to determine the amount of iron in the liver. The entire procedure will usually take one-half hour or less.
223795018|NCT02974790|PROCEDURE|Echocardiography|Two-dimensional imaging echocardiography
223795019|NCT04352179|BEHAVIORAL|Virtual Education Simulation|"The simulations will be developed using Kognito's proprietary Conversation Platform.~In this pilot study, the simulations will be a bundle of four topic-based conversations with Linda, a virtual peer with a chronic disease. The four wellness topics are:~1. Fitness \& Nutrition~2. Smoking Cessation~3. Alcohol Use~4. Distress \& Anxiety"
223795020|NCT02396654|OTHER|2D and 5D LB ultrasound comparison for fetal weight estimation|2D and 5DUS LB will be done for term pregnant women and fetal weight will be estimated by the hadlock formula. Accuracy of estimated fetal weight by both techniques will be compared to actual birth weight.
223795021|NCT05678764|DEVICE|Conversational Information Collection Tool|Conversational Information Collection Tool that facilitates the self-referral to talk therapy.
223795022|NCT01579591|OTHER|VSL#3|1 sachet (4.5x1011 viable lyophilized bacteria)three times in a day, during RT and for 2 weeks before and for 4 weeks afterwards.
223795023|NCT01579591|OTHER|Placebo|1 sachet, three times in a day, during RT and for 2 weeks before and for 4 weeks afterwards
223795024|NCT05251051|BEHAVIORAL|pediatric physical therapy|Pediatric physical therapists will provide weekly home therapy using standard of care/best evidence procedures
223795025|NCT05251051|OTHER|Care Coordination|A navigator will be assigned who will assist families in obtaining Early Intervention services and other therapy services if needed
223795026|NCT05703568|OTHER|virtual reality|14 elderly participants receive intervention protocol of group- based virtual reality training program (XBOX Kinect games: Your Shape: Fitness Evolved) in which total 16-sessions were given for twice a week for eight weeks for 45-minutes.
223795027|NCT05703568|OTHER|Virtual reality|14 elderly participants receive intervention protocol of individual virtual reality training program (XBOX Kinect games: Your Shape: Fitness Evolved) in which total 16-sessions were given for twice a week for eight weeks for 45-minutes.
223795028|NCT00974324|DRUG|endostar and CHOP|"endostar, 7.5m g/m2, intravenous, Day 2-15, repeat every 3 weeks~CHOP: Cyclophosphamide, Hydroxydaunorubicin, Oncovin, Prednisone"
223795029|NCT00900068|OTHER|immunoenzyme technique|
223795030|NCT00900068|OTHER|laboratory biomarker analysis|
223795031|NCT00900068|OTHER|medical chart review|
223795032|NCT00818857|BEHAVIORAL|Early Intervention|At the point of randomization the early group will receive increasingly intensive reminders to complete specific cancer screening tests.
223795033|NCT00818857|BEHAVIORAL|Delayed intervention|One year from the point of randomization patients will begin to receive increasingly intensive reminders to complete specific cancer screening tests.
223795034|NCT01925950|DRUG|orBec|
223795035|NCT01925950|DRUG|Placebo|
223795036|NCT03068338|DEVICE|Robotic Sock|Soft robotic actuator used in a sock design technology to perform plantarflexion and dorsiflexion of the foot about the ankle joint.
223795037|NCT03068338|DEVICE|Intermittent pneumatic compression|Conventional device used by hospitals
223795038|NCT05185310|PROCEDURE|Ablation|Ablation strategy during repeat AF ablation
223795039|NCT00381940|DRUG|ifosfamide|Given IV
223795040|NCT00381940|DRUG|bortezomib|Given IV
223795041|NCT00381940|DRUG|vinorelbine tartrate|Given IV
223795042|NCT00381940|BIOLOGICAL|filgrastim|Given IV or SC
223795043|NCT03162224|DRUG|MEDI0457|MEDI0457 7 mg will be administered intramuscularly followed by electroporation (EP) using CELLECTRA®5P device.
223795044|NCT03162224|DEVICE|CELLECTRA®5P device|MEDI0457 7 mg will be administered intramuscularly followed by EP using CELLECTRA®5P device.
223795045|NCT03162224|DRUG|Durvalumab|Durvalumab will be administered intravenously at a dose of 1500 mg every 4 weeks.
223795046|NCT05931692|DIAGNOSTIC_TEST|Virtual reality|Virtual environment that triggers fear of falling
223795047|NCT05931692|DIAGNOSTIC_TEST|Electroencephalogram|Detect brain waves in response to fear of falling
223795048|NCT05931692|DIAGNOSTIC_TEST|Electromyography|Measures muscle activity and response to fear of falling
223795049|NCT05931692|DIAGNOSTIC_TEST|Motion Capture system|Measures postural and gait responses to fear of falling
223795050|NCT05931692|DIAGNOSTIC_TEST|Polar H10 Heart Sensor|Heart rate monitor
223795051|NCT05931692|DIAGNOSTIC_TEST|Inertial measurement Unite|Measure Postural sway
223795052|NCT00717990|DRUG|Capecitabine|Capecitabine 2000 mg/m2 p.o. daily, for days 1-14, every 3 weeks for 6 cycles
223795053|NCT00717990|DRUG|Bevacizumab|Bevacizumab 7.5 mg/kg intravenous (IV) on day 1 every 3 weeks for 6 cycles
223795054|NCT00717990|DRUG|Irinotecan|Irinotecan 250 mg/m2 IV on day 1 every 3 weeks for 6 cycles
224264024|NCT06150703|DRUG|Ovulation induction with hCG + Luteal phase support with vaginal progesterone|hCG 250µg subcutaneously between 36h and 38h before oocyte retrieval + Progesterone 600mg/d (200mg morning, noon and evening) vaginally from the evening of the puncture until the pregnancy test result
224264025|NCT06150703|DRUG|Ovulation triggering by Triptorelin + Luteal phase support by Nafarelin|Triptorelin 0.2 mg subcutaneously between 36h and 38h before oocyte retrieval as a single dose Nafarelin 400µg /day (200µg in the morning 200µg in the evening) nasally from the evening of the oocyte retrieval until the first pregnancy test
224264026|NCT03407209|OTHER|consumption of local anesthetic measurement|consumption of local anesthetic measurement in both groups
224264027|NCT01896713|OTHER|MS3TMRI|Multispectral 3 Tesla MRI imaging with contrast followed by biopsy
224264028|NCT00592969|DRUG|metformin|
224264029|NCT00592969|DRUG|biphasic insulin aspart|
224264030|NCT01002287|DEVICE|SprayShield Adhesion Barrier System|Adhesion Barrier Device
224264031|NCT01002287|PROCEDURE|Good Surgical Technique Alone|Good Surgical Technique Alone
224264032|NCT00889486|DRUG|TZP-102|
223795055|NCT02642250|DRUG|Metronidazole|The data will be recorded for physical examination including gender , age, height, weight, temperature, heart rate ,respiratory rate and blood pressure of the subject, number of stool per day, stool with or without mucus or mixed with blood along with abdominal cramps, dehydration, nausea, vomiting and related clinical information will be carefully recorded. Statistical tools and tabulated results will be used to identify the similarities and differences in safety, efficacy and tolerability of treatment.
223795056|NCT02642250|DRUG|Entoban|To evaluate the safety and efficacy of coded herbal formulation (Entoban) through randomized clinical study and compared with Metronidazole DS for treatment of gastrointestinal infections for improving the health of the community with due regard to the prevalence of disease and the feasibility of using alternative treatments.
223795057|NCT05090579|PROCEDURE|Group I (BN10)|patients will receive an ultrasound-guided TAP block with 20 mL of 0.25% bupivacaine, 1 mL of 10 mg of nalbuphine plus 4 mL of normal saline to reach 25 mL as total volume on each side of the abdominal wall
223795058|NCT05090579|PROCEDURE|Active Comparator:Group ll (BN20)|patients will receive an ultrasound-guided TAP block with 20 mL of 0.25% bupivacaine, 2 mL of 20 mg of nalbuphine plus 3 mL of normal saline to reach 25 mL as total volume on each side of the abdominal wall
223795059|NCT05090579|PROCEDURE|Active Comparator:Group lll (B)|patients will receive 20 mL of 0.25%bupivacaine plus 5 mL of normal saline to reach 25 mL as total volume on each side of the abdominal wall
223795060|NCT04162769|DRUG|Etrasimod 1 mg|Etrasimod 1 mg tablet taken by mouth, once daily
223795061|NCT04162769|DRUG|Etrasimod 2 mg|Etrasimod 2 mg tablet taken by mouth, once daily.
223795062|NCT04162769|DRUG|Etrasimod matching placebo|Etrasimod matching placebo tablet by mouth, once daily.
223795063|NCT03663231|DEVICE|Biotene|Biotène Dry Mouth Moisturizing Spray contains water, polyglycitol, propylene glycol, sunflower oil, xylitol, milk protein extract, potassium sorbate, acesulfame K, potassium thiocyanate, lysozyme, lactoferrin, lactoperoxidase. 3 sprays, approximately 15 mL.
223795064|NCT03663231|DEVICE|Placebo|IND/IDE exempt device primarily water
223795065|NCT00324870|DRUG|vorinostat|Given orally
223795066|NCT00324870|DRUG|bevacizumab|Given IV
223795067|NCT00725452|BIOLOGICAL|Infliximab|Infliximab initial induction therapy consisting of 3 Infliximab infusions at weeks 0, 2, and 6 given in specialized centers. A maximum of 6 maintenance infusions will be given in doses and intervals due to the discretion of the physicians.
223795068|NCT00620750|DRUG|Extended release injectable naltrexone (Vivitrol)|Three sequential monthly injections of extended release injectable naltrexone (Vivitrol), with option to extend participation for an additional 12 months.
223795069|NCT04710082|PROCEDURE|Photorefractive keratectomy (PRK)|Photorefractive keratectomy (PRK) is a surgical procedure used by ophthalmic surgeons to treat patients presented with refractive errors and involves corneal epithelial removal followed by application of excimer laser to correct different refractive errors including Myopia, Hyperopia and Astigmatism.
223795070|NCT02635854|OTHER|Septic choc group|Specific platelet activation markers, circulating leukocyte-platelet aggregates will be assessed in peripheral venous blood at the admission in intensive care unit and 48 hours later for leukocyte-platelet aggregates measurements.
223795071|NCT02635854|OTHER|Orthopedic surgery group|Specific platelet activation markers, circulating leukocyte-platelet aggregates will be assessed in peripheral venous blood during the orthopedic surgical anesthesia consultation.
223795072|NCT02178748|BIOLOGICAL|MVA85A|Single dose of 1x10\^8pfu MVA85A intramuscular vaccination
223795073|NCT03817996|OTHER|Fluid challenge|250ml of saline in Responders (those who increased \>10% their cardiac output after a passive leg raising maneuver).
223795074|NCT00275197|DRUG|Sertraline and Elzasonan Combination|
223795075|NCT00275197|DRUG|Sertraline|
223795076|NCT00275197|DRUG|Placebo|
223795077|NCT03633968|PROCEDURE|maxillary sinus lift|maxillary sinus floor elevation by using balloon through either small or large antrostomy without using graft material with simultaneous implant placement
223795078|NCT05047367|BEHAVIORAL|cross-sectional survey study|Beck Depression Scale, Beck Anxiety Scale for psychological evaluation, Visual Analogue Scale and PainDETECT Questionnaire for pain, Pittsburgh Sleep Quality Scale and Epworth Sleepiness Scale for sleep quality
223795079|NCT06222515|DIAGNOSTIC_TEST|Bladder diary|3-day bladder diary record including fluid intake, urine amount, urgency and incontinence.
223795080|NCT00526266|BEHAVIORAL|Emotional Freedom Techniques (EFT)|A half hour treatment with EFT following a standardized protocol. Both Range of Motion (ROM) physical issues are treated with EFT, as well as any possible emotional issues underlying limited ROM.
223795081|NCT00526266|BEHAVIORAL|Diaphragmatic Breathing (DB)|"Diaphragmatic Breathing (DB) instead of EFT tapping, but with all the Setup Statements and components of the Experimental Group, with the exception of tapping. DB is substituted for tapping."
224264033|NCT00889486|DRUG|Placebo|
224264034|NCT06556017|DIAGNOSTIC_TEST|Diagnosis of SSI|Comparison of the manual system and ChatGPT for SSI diagnosis in colorectal surgery procedures enrolled in the SSI surveillance programme.
224264035|NCT01608984|PROCEDURE|Remote ischemic preconditioning (RIPC)|"3 cycles of 5 min left upper arm ischemia by inflation of a blood pressure cuff to 200 mmHg and 5 min reperfusion.~The applied anesthesia protocol avoids the use of propofol. Drugs: isoflurane+sufentanil anesthesia Anaesthesia is maintained by inhaled isoflurane in concentrations 0.7-0.8 % end-tidal with additional sufentanil injected during surgery, as required. In the CABG-arms, during extracorporal circulation patients receive isoflurane via a vaporizer incorporated in the extracorporeal gas supply in the same concentrations."
224264036|NCT01608984|PROCEDURE|Coronary artery bypass grafting (CABG) without remote ischemic preconditioning protocol|The applied anesthesia protocol avoids the use of propofol. Drugs: isoflurane+sufentanil anesthesia Anaesthesia is maintained by inhaled isoflurane in concentrations 0.7-0.8 % end-tidal with additional sufentanil injected during surgery, as required. During extracorporal circulation patients receive isoflurane via a vaporizer incorporated in the extracorporeal gas supply in the same concentrations.
223795082|NCT06213948|DRUG|Mirtazapine 15 MG|"Mirtazapine~* Commercial name: Remeron® SolTab~* Pharmaceutical form: film-coated tablets (15 mg)"
223795083|NCT06068855|DRUG|BOTOX|Intramuscular Injections
223795084|NCT06068855|DRUG|Placebo|Intramuscular Injections
223795085|NCT04911790|BIOLOGICAL|Experimental Group|SARS-CoV-2 Inactivated Vaccine 600SU inactivated virus in 0·5 mL of aluminiumhydroxide solution per injection
223795086|NCT01578811|DRUG|Placebo|Dosage
223795087|NCT01578811|DRUG|SK-MS10|Dosage
223795088|NCT01578811|DRUG|SK-MS10|Dosage
223795089|NCT00746590|DRUG|Prolarix (tretazicar co-administered with caricotamide)|Prolarix (26.6 mg/m2 tretazicar co-administered with 200 mg/m2 caricotamide) administered intravenously every 21 days until disease progression
223795090|NCT03222193|DEVICE|TRP|3 months of TRP tongue retraining
223795091|NCT03907319|DEVICE|SIS System|Software technology for visualization of anatomical structures in the brain
223795092|NCT03979170|PROCEDURE|Lung tumor resection|lung tumor resection
223795093|NCT03006250|DRUG|Desflurane|Desflurane is the volatile agent with low blood: gas partition coefficient (0.42), its uptake and elimination from the body of a patient are rapid, which results in a fast onset of anesthesia and a fast recovery from anesthesia. This property provides desflurane as an ideal agent for the ambulatory anesthesia. However, its pungent odor is concerned to irritate the upper airway and may cause significant respiratory complications.
223795094|NCT03006250|DRUG|Sevoflurane|Sevoflurane has a blood: gas partition coefficient of 0.65, which is slightly greater than desflurane. The major advantage over desflurane is the better scented. It is considered to be less airway irritation in LMA anesthesia with smooth induction and recovery.
223795095|NCT03671096|OTHER|Intrastromal TCA Inlay|An intrastromal inlay that will be provided to correct the required hyperopic correction
223795096|NCT03298139|OTHER|3 levels of gravity (1G, 1.8G, 0G).|healthy volunteers will experience 3 levels of gravity (1G, 1.8G, 0G).
223795097|NCT00517491|DRUG|lanreotide (Autogel formulation)|120 mg administered every 28 days via deep subcutaneous injection. A total of 4 injections will be administered during the study.
223795098|NCT01270451|OTHER|Lifestyle intervention to prevent weight regain|To study if subjects receiving extra guidance in diet and physical activity experience less weight gain compared to a control group.
223795099|NCT01362738|PROCEDURE|RFCA of PV and extra-PV triggers|PVAI and isolation of extra PV triggers
223795100|NCT01362738|PROCEDURE|LAA isolation along with the conventional ablation strategy|PVAI + isolation of extra PV triggers + LAA isolation
223795101|NCT04402866|DRUG|TD-0903|Study Drug to be administered by inhalation
223795102|NCT04402866|DRUG|Placebo|Placebo to be administered by inhalation
223795103|NCT04091074|DRUG|Ticagrelor|Half of patients undergoing carotid stenting take ticagrelor+aspirin
223795104|NCT04091074|DRUG|Clopidogrel|Other half ofpatients undergoing carotid stenting take clopidogrel+aspirin
223795105|NCT04091074|PROCEDURE|Carotid stenting|Patients with carotid stenosis will undergo carotid stenting
223795106|NCT06473896|DRUG|Ketalar|a dissociative anesthetic used medically for induction and maintenance of anesthesia
223795107|NCT06473896|DRUG|Dexmedetomidine|an agonist of α2-adrenergic receptors in certain parts of the brain used for sedation
223795108|NCT06147895|BIOLOGICAL|CVI-HBV-002|Investigational Product
223795109|NCT00728390|DRUG|PF-00299804|CP-751,871 at recommended dose on Day 1 and 2 of cycle 1, then on Day 1 every 3 weeks; and PF-00299804 orally at recommended dose once daily.
223795110|NCT02777151|DRUG|REGN3470-3471-3479|
223795111|NCT02777151|DRUG|Placebo|
223795112|NCT02821273|OTHER|Modified INSURE technique|modified INSURE means intubation-surfactant-X-ray relieved-extubation. Extubation and noninvasive ventilation is used after the X-ray relieving.
223795113|NCT02821273|OTHER|INSURE technique|INSURE means intubation-surfactant-extubation. Extubation and noninvasive ventilation is used after surfactant administration.
223795114|NCT04832503|BEHAVIORAL|PROMPT- treatment|PROMPTs for Restructuring Oral Muscolar Phonetic Targets
223795115|NCT04832503|BEHAVIORAL|LNSOM-treatment|Language Non-Speech Oral Motor Treatment
223795116|NCT02024906|DIETARY_SUPPLEMENT|soy protein isolate (SPI)|
223795117|NCT02024906|DIETARY_SUPPLEMENT|milk protein isolate (MPI)|
223795118|NCT03376581|PROCEDURE|Platelet rich plasma|Blood drawn from each participant will be spun down to separate platelets. Platelets will be injected into that patient's scalp.
223795119|NCT02125201|DRUG|Fentanyl|A neonate will recieve Fentanyl intranasal or intravenous 5 minutes before the procedure The nurse will check his pain scale If the pain scale will be more than 4 the neonate will recieve the second dose of Fentanyl
223795120|NCT01463748|OTHER|Graptopetalum paraguayense E. Walther|Graptopetalum paraguayense E. Walther
223795121|NCT01463748|OTHER|Placebo|starch
223795122|NCT04871789|DIAGNOSTIC_TEST|Laboratory and instrumental examination|All patients will undergo a comprehensive examination to identify the consequences of COVID-19
223795123|NCT04292626|DIAGNOSTIC_TEST|SPECT with 99mTc-1-thio-D-glucose|One single intravenous injection of 99mTc-1-thio-D-glucose, followed by gamma camera imaging directly postinjection and after 2, 4, 6 and 24 hours.
223795124|NCT00181948|DRUG|atomoxetine (Strattera)|
223795125|NCT06340620|DEVICE|Endoscopic ultrasound examination|Endoscopic ultrasound examination will be performed.
223795126|NCT04678492|DRUG|Esomeprazole|High-dose esomeprazole and amoxicillin dual therapy: given for 14 days at a dose of esomeprazole 40mg 1 tablet TID plus amoxicillin 500 mg 2 capsules TID
223795127|NCT04678492|DRUG|Amoxicillin|High-dose esomeprazole and amoxicillin dual therapy: given for 14 days at a dose of amoxicillin 500 mg 2 capsules TID plus esomeprazole 40mg 1 tablet TID
223795128|NCT04678492|DRUG|Bismuth|Bismuth-containing quadruple therapy: given for 14 days at a dose of bismuth 110 mg 2 capsules BID plus esomeprazole 40 mg 1 tablets BID，tetracycline 250mg 2 capsules TID and furazolidone 100mg 1 tablets BID
223795129|NCT04678492|DRUG|Esomeprazole|Bismuth-containing quadruple therapy: given for 14 days at a dose of esomeprazole 40mg 1 tablet BID plus bismuth 110 mg 2 capsules BID，tetracycline 250mg 2 capsules TID and furazolidone 100mg 1 tablets BID
223795130|NCT04678492|DRUG|Tetracycline|Bismuth-containing quadruple therapy:given for 14 days at a dose of tetracycline 250mg 2 capsules TID plus furazolidone 100mg 1 tablets BID，esomeprazole 40 mg 1 tablets BID and bismuth 110 mg 2 capsules BID
223795131|NCT04678492|DRUG|Furazolidone|Bismuth-containing quadruple therapy:given for 14 days at a dose of furazolidone 100mg 1 tablets BID plus tetracycline 250mg 2 capsules TID，esomeprazole 40 mg 1 tablets BID and bismuth 110 mg 2 capsules BID
223795132|NCT00386880|OTHER|Sounds|
223795133|NCT05278455|BEHAVIORAL|Lifestyle Medicine|A smartphone-delivered application with a series of lifestyle medicine components, including lifestyle psychoeducational, physical activity, dietary recommendations, stress management, sleep management, and motivation and goal-setting techniques.
223795134|NCT02313467|DRUG|Topical application of 1.5% Butenyl ALA|
223795135|NCT02313467|DRUG|Topical application of sham control|
223795136|NCT05602714|OTHER|Collection Data|
223795137|NCT00408213|DRUG|mycophenolate mofetil [CellCept]|1g po bid
223795138|NCT00408213|DRUG|Placebo|po bid
223795139|NCT03545867|BEHAVIORAL|Seated control (CON)|Seated rest
223795140|NCT03545867|BEHAVIORAL|Moderate intensity continuous (MICT)|Arm cycling at a continuous power output
223795141|NCT03545867|BEHAVIORAL|High intensity interval training (HIIT)|Arm cycling at power outputs that vary between high and low intensity intervals
223795142|NCT03545867|BEHAVIORAL|Circuit resistance training (CRT)|Alternating between six upper extremity resistance maneuvers interspersed with low-resistance/high-speed arm cycling.
223795143|NCT03545867|OTHER|Liquid Meal|A liquid meal consisting of 600 kcal comprised of 50% carbohydrate, 35% fat, and 15% protein (by kcal).
223795144|NCT05684081|BEHAVIORAL|Digital payment|The proposed intervention is designed to support the implementation of polio campaigns through digital payments
223795145|NCT05308173|PROCEDURE|Surgical Aortic Valve Replacement|Cardiac surgery under cardio-pulmonary bypass, via sternotomy or minimally invasive approach with the replacement of native valve with a biological or mechanic prosthesis.
223795146|NCT05308173|PROCEDURE|Transcutenous Aortic Valve Implantation|Transfemoral implantation of aortic bioprosthesis with one of the devices available in Poland.
223795147|NCT05368779|BEHAVIORAL|The internet-based psychosocial intervention|Participants were provided psychoeducation on intimate partner abuse, psychological trauma, Social Learning Theory, and Cognitive Behavioral Therapy methods. Intimate partner abuse and psychological trauma were discussed in the context of sociocultural factors. Cognitive Behavioral Therapy approaches were used to attempt to normalize intimate partner abuse, psychological trauma and their effects on participants. Participants were exposed to trauma gradually with record of sessions watching and imaginary exposure methods for reducing avoidance behaviours. Schemas, intermediate beliefs, and automatic thoughts of participants were studied using Cognitive Behavioral Therapy approaches and cognitive restructuring was fulfilled. The universality of mental pain, the meaning of life, the integrate trauma into life histories of participants, expectations for the future romantic relationships, and post traumatic growth were all discussed in accordance with the goals and values of participants.
223795148|NCT00297154|BEHAVIORAL|Lifestyle Modification (diet, exercise, and behavior)|Patients recieve weekly sessions with dietician, replace 2 meals/day with meal replacement beverage, and initiate a walking program.
223795149|NCT02385305|DEVICE|Pressure support ventilation by anesthesia machine (Apollo, Dräger)|Pressure support ventilation will be applied by anesthesia machine (Apollo, Dräger) with pressure support (PS) of 3, 8, 13 and 18 cmH2O in this order, with slope of 1.0 second and no PEEP. The fraction of inspired oxygen will be titrated to achieve SpO2 over 98%. Five minutes will be allowed to achieve equilibrium at each PS level after which an additional recording of one minute of data will be obtained. Once the Pressure support ventilation is completed at 18 cmH2O, ventilation will be carried out in reverse order of PS; 13, 8 and 3 cmH2O of PS.
223795150|NCT03882333|OTHER|Acute exercise|30 min acute exercise (bicycle at stationary cycle)
223795151|NCT02346305|DEVICE|Non-invasive ventilation|Home NIV installation
223795152|NCT02557841|DEVICE|tDCS|Current will be applied by a DC stimulator (NeuroConn Plus, Germany).The active electrode (anode: 5x7 cm²) will be placed over the left cerebellar hemisphere (3 cm lateral to the inion) and the reference (5x7 cm²), over the left arm with current intensity of 2mA, fade in and fade out of 10 seconds, during 20 minutes.
223795153|NCT02557841|DEVICE|tDCS|Current will be applied by a DC stimulator (NeuroConn Plus, Germany). The active electrode (cathode: 5x7 cm²) will be placed over the left cerebellar hemisphere (3 cm lateral to the inion) and the reference (5x7 cm²), over the left arm with current intensity of 2mA, fade in and fade out of 10 seconds, during 20 minutes.
223795154|NCT02557841|DEVICE|tDCS|Sham ctDCS (NeuroConn Plus, Germany) will be applied at the same parameter settings used on cathodal ctDCS however, current duration will be only 30 seconds. Moreover, device automatically turned off without volunteer's perception, but volunteers will be with electrodes montage for 20 minutes.
223795155|NCT04769427|DEVICE|PDO max threads|To determine the effects of absorbable Polydioxanone (PDO) thread non-surgical rhinoplasty on quality of life (FACE-Q scale)
223795156|NCT00520780|DRUG|Ferinject ® (Ferric carboxymaltose)|"Ferinject® will be administered in doses of 200 mg (4 mL) weekly up to iron repletion (correction phase of variable duration depending on individual iron deficit). The calculated dose will be rounded to the next 100 mg iron, i.e. the final dose may be 100 mg iron depending on the individual iron deficit.~After the correction phase, Ferinject® will be given monthly in doses of 200 mg until the 24th week (maintenance phase)."
223795157|NCT00520780|DRUG|Normal saline (0.9%)|During the correction phase, patients will receive the number of normal saline injections (4 mL weekly) corresponding to the calculated total iron dose needed according to the individual iron deficit. During the maintenance phase, placebo patients will receive 4 mL normal saline monthly.
223795158|NCT02412930|PROCEDURE|Ultrasound-guided Paravertebral Block|"paravertebral block was performed by ultrasound guidance at T11, T12 and L1 levels, using 0.5% bupivacaine total dose of 15 mL in group P. The injection site was covered with sterile drapes, after cleaning with 10% povidone-iodine solution.~After, patients in both groups were performed patient controlled analgesia (PCA). The PCA was prepared with 400 mg tramadol into 100 mL of saline. The doses of tramadol in the PCA were bolus dose 0.1 mgkg-1 every 20 minutes without a background infusion."
223795159|NCT02412930|DRUG|Group Tramadol|Patients in group T were given intravenously a loading dose of tramadol of 1 mgkg-1, 45 minutes before the end of surgery. After,patients in both groups were performed patient controlled analgesia (PCA). The PCA (CADD Legacy PCA pump, Smiths Medical MD, Inc., St. Paul, MN) was prepared with 400 mg tramadol into 100 mL of saline. The doses of tramadol in the PCA were bolus dose 0.1 mgkg-1 every 20 minutes without a background infusion.
223795160|NCT02412930|DRUG|Bupivacaine|
223795161|NCT02412930|DEVICE|Ultrasound|
223795162|NCT04478968|OTHER|presence of AVF|Functioning AVF may have cardiotoxic potential
223795163|NCT06497452|DRUG|Glofitamab|Glofitamab will be administered at the discretion of the physician per local clinical practice and local labeling
223795164|NCT04357327|DIAGNOSTIC_TEST|rapid salivary test|a rapid salivary test to detect SARS-CoV-2 spike protein in saliva with a lateral flow immunoassay
223795165|NCT00361543|DRUG|Raloxifene hydrochloride|120 mg per capsule (1 tablet daily)
223795166|NCT00361543|OTHER|Lactose Capsules|1 tablet daily for 12 weeks
223795167|NCT02633137|DRUG|Lenalidomide|
223795168|NCT02633137|DRUG|R-CHOP|"* Rituximab 375 mg/m\^2 IVPB with premedications Day 1~* Cyclophosphamide 750 mg/m\^2 IVPB Day 1~* Doxorubicin 50 mg/m\^2 IVP Day 1~* Vincristine 1.4 mg/m\^2 IVP (capped at 2 mg) Day 1~* Prednisone 100 mg PO Daily on Days 1-5 or 2-6"
223795169|NCT02633137|DRUG|high-dose cytarabine (HIDAC)|
223795170|NCT05400434|BEHAVIORAL|Standard Parent-Child Interaction Therapy (PCIT)|PCIT is an evidence-based behavioral parenting intervention. It is administered as weekly, one-hour sessions with a bilingual PCIT therapist for 18 weeks in one of three PCIT clinics embedded within neighborhood community agencies or virtually.
223795171|NCT05400434|BEHAVIORAL|Natural Helpers (NH)|Natural helpers are lay people to whom others naturally turn for advice, emotional support, and tangible aid. Families received weekly sessions with a natural helpers in their home or virtually for 30-45 minutes for a maximum of 18 weeks. During sessions, natural helpers work with families to (1) explain parenting principles in a culturally and responsive manner; (2) support them in their skill acquisition; and (3) troubleshoot structural barriers to service and other basic life needs.
223795172|NCT04531046|DRUG|axicabtagene ciloleucel|Patient-specific (autologous) product cryopreserved in cryostorage bag
223795173|NCT03506958|PROCEDURE|Standard trauma care|In both groups, all procedures and management will be done according to the hospital's standard of care.
223795174|NCT05875181|DEVICE|tFUS|tFUS is a brief stimulation of a part of the brain called the ventral striatum with low-intensity sound waves that pass through the scalp and skull safely.
223795175|NCT05875181|DEVICE|Sham tFUS|Sham tFUS goes through the motions of applying tFUS to the brain. Participants will know that one session will be a sham, but they will be blinded to which session is the sham
223795176|NCT06160947|OTHER|Usual Medical Care|In both the intervention and control arms of the study, usual medical care will be defined as any and all medical care provided to patients with chronic non-cancer back or neck pain at an Ontario CHC, including: primary care provider consultation visits, prescription medication (e.g., muscle relaxants, anti-inflammatories, anti-depressants, opioid and non-opioid analgesics), referral for diagnostic testing (e.g., lab work, imaging) or specialist consultation, as well as other co-interventions (e.g., visits with nurses, dieticians, social workers, or physiotherapists) as determined by their PCP. PCPs will also engage study participants in a formal effort to reduce their opioid use within the framework of each CHC's current opioid-reduction practices.
223795177|NCT06160947|OTHER|Usual Medical Care + Chiropractic Care|Treatment sessions may include high-velocity, low-amplitude spinal manipulative therapy, as well as any or all of the following: spinal mobilization, soft-tissue massage/trigger point therapy, education and reassurance (e.g., pain management, ergonomic and activities of daily living recommendations), and home advice (e.g., icing, spinal stretching, core muscle strengthening, and cardiovascular exercises). As part of the intervention, chiropractic clinicians will engage PCPs in a collaborative effort to support opioid tapering. Consistent with current clinical practice guidelines, participants will be provided up to a maximum of 18 chiropractic visits during the active care period, although participants may continue with treatment after the 12-week period (e.g., one visit, every 2-4 weeks) to manage episodes of exacerbation/flare-up.
223795178|NCT01972841|DRUG|Solifenacin succinate|Oral tablet
223795179|NCT01972841|DRUG|Mirabegron|Oral tablet
223795180|NCT01972841|DRUG|Placebo to match solifenacin succinate|Oral tablet
223795181|NCT01972841|DRUG|Placebo to match mirabegron|Oral tablet
223795182|NCT03696017|OTHER|Multi-domain assessment battery|Assessments of emotion regulation, neurocognitive performance, pain, sleep, and substance use. There is no therapeutic intervention; all participants are already independently in treatment for their substance use disorder and we are simply assessing them at baseline visit and 3-month follow-up.
223795183|NCT05808101|OTHER|Neuro-QoL T-score determination|Neuro-Qol depression scale, using a T-score of 55 as a threshold
223795184|NCT03712891|DIETARY_SUPPLEMENT|Coffee|Patients will receive coffee in a Styrofoam cup at a temperature of 125 degree Fahrenheit or less. Coffee will be offered to the patient in the PACU once the patient's gag reflex has been restored following their procedure. Volume of estimated coffee consumption will be measured using a sample scale (with a maximum of 300mL of coffee offered)
223795185|NCT06635317|DRUG|Aspirin|100 mg/day orally for 25 days
223795186|NCT06635317|DRUG|enoxaparin|40 mg/day subcutaneously for 28 days, with the dose reduced to 20 mg for patients weighing less than 50 kg or with an estimated glomerular filtration rate less than 30 mL/min/1.73 m².
223795187|NCT01887938|BIOLOGICAL|HGT-1110|Participants will receive IT injection of HGT-1110.
223795188|NCT06733103|BEHAVIORAL|Stroke Cognitive Behavioural Therapy|This is the only intervention in this clinical (feasibility) study
223795189|NCT05166161|DRUG|PTC923|PTC923 powder for oral use will be suspended in water or apple juice prior to administration.
223795190|NCT04675398|DEVICE|Summit RC+S|Using the RC+S pulse generator, patients receive clinically-optimized open loop DBS stimulation to the pallidum.
223795191|NCT04675398|DEVICE|Summit RC+S|Using the RC+S pulse generator, the patients will receive closed-loop stimulation at random time points. These random stimulation times will in total equal the total amount of time of active movement.
223795192|NCT04675398|DEVICE|Summit RC+S|Using the RC+S pulse generator, the patients will receive closed-loop stimulation during time of contralateral limb movement (e.g. left brain stimulation during right leg/arm movement).
223795193|NCT04675398|DEVICE|Summit RC+S|Using the RC+S pulse generator, the patients will receive closed-loop stimulation during time of no movement for the contralateral limb (e.g. left brain stimulation while right leg/arm is not moving).
223795194|NCT04235036|DRUG|Rituximab|Rituximab is given IV weekly x 4 weeks (to be started on study day 7 ± 3 days), then IV q3months x 4 doses (months 4, 7, 10, 13).
223795195|NCT04235036|DRUG|Ibrutinib|Ibrutinib is given orally every day (28-day cycles) for a total of 12 cycles.
223795196|NCT05363813|DEVICE|M/L-10 Multi-Fire Clip Applier and M/L-10 Clip Cartridge (Multi-Fire Clip System)|Permanent ligation of vessels and ducts as part of minimally invasive laparoscopic surgery.
223795197|NCT05830942|BEHAVIORAL|Walking Exercise|aerobic walking exercise using complex (cognitively engaging) walking tasks
223795198|NCT05830942|DEVICE|Prefrontal Active tDCS|20 minutes of 2 milliamp transcranial direct current stimulation (tDCS) of prefrontal regions, delivered at each session
223795199|NCT05830942|DEVICE|Prefrontal Sham tDCS|30 seconds of 2 milliamp transcranial direct current stimulation (tDCS) of prefrontal regions, delivered at each session
223795200|NCT03761602|OTHER|Not applicable (for observational studies)|This study is an observational study. No intervention will be administered for research purposes.
223795201|NCT05721859|DEVICE|revision hip arthroplasty|revision hip arthroplasty
223795202|NCT03777098|DEVICE|Strepic® Device|The Strepic® device is a qualitative point-of-care diagnostic test for the detection of GAS pharyngitis. The test uses direct visualization of the pharynx with a light source of specified wavelengths, causing excitation of endogenous fluorophores that emit a characteristic colored light pattern. White light images may give additional diagnostic accuracy through use of an artificial intelligence analysis of a large set of images of GAS and non-GAS pharyngitis.
223795203|NCT06309953|DRUG|Miebo|Miebo treatment
223795204|NCT03348748|OTHER|Laboratory Biomarker Analysis|Correlative studies
223795205|NCT03348748|OTHER|Quality-of-Life Assessment|Ancillary studies
223795206|NCT03348748|DRUG|Stereotactic Body Radiation Therapy|Undergo lowest-dose of SBRT
223795207|NCT03348748|DRUG|Stereotactic Body Radiation Therapy|Undergo lowest- or higher-dose of SBRT
223795208|NCT03348748|DRUG|Stereotactic Body Radiation Therapy|Undergo highest-dose of SBRT
223795209|NCT03348748|PROCEDURE|Thoracic Surgical Procedure|Undergo thoracic surgery
223795210|NCT03282448|BEHAVIORAL|family therapy|The family-based intervention is informed by Dialectical Behavior Therapy Skills Training for Adolescents (Rathus \& Miller, 2014).
223795211|NCT06292455|OTHER|Elastic resistance training|six-weeks elastic resistance training of upper limb. Three days per week. volume per session would be 10 repetitions and three sets. 2 minute rest interval between each set.
223795212|NCT06292455|OTHER|Conventional Resistance Training|players follow their routine exercise protocol
223795213|NCT05597969|BEHAVIORAL|FoodCoach|The FoodCoach app displays transparent analysis and recommendations regarding participant's food purchases recorded on their loyalty cards. It tries to help participants understand why and how they should/can shop more healthily, motivating them to change their unhealthy food purchase behavior.
223795214|NCT00126412|DRUG|123I-mIBG (meta-iodobenzylguanidine)|
223795215|NCT00002109|DRUG|Thymopentin|
223795216|NCT00002109|DRUG|Stavudine|
223795217|NCT00002109|DRUG|Zidovudine|
223795218|NCT00002109|DRUG|Zalcitabine|
223795219|NCT00002109|DRUG|Didanosine|
223795220|NCT03256162|DRUG|Ketamine|A sub-anaesthetic dose of ketamine will be administered in four infusions, each one week apart.
223795221|NCT03256162|DRUG|Midazolam|A sub-anaesthetic dose of midazolam will be administered in four infusions, each one week apart.
223795222|NCT06256133|PROCEDURE|Enhanced Recovery After Surgery protocol|Preoperative oral carbohydrate loading, Ultrasound-assisted thoracic epidural catheter placement, Intraoperative individualized goal-directed fluid therapy, Active warming techniques, The inspired fractional concentration of oxygen was maintained, Multimodal postoperative nausea and vomiting (PONV) prevention strategies, Anesthesia was maintained using a target-controlled infusion (TCI) of propofol and remifentanil, Scheduled administration of an intravenous (IV) or oral nonsteroidal anti-inflammatory drug (NSAID) (50 mg of dexketoprofen)
223795223|NCT00508430|DRUG|ASP8825|oral
223795224|NCT00508430|DRUG|Placebo|oral
223795225|NCT05891002|DEVICE|Cirq® Robotic Alignment Module Cranial|Robotic navigation for cranial biopsy procedure
223795226|NCT05666453|BIOLOGICAL|LIV-GAMMA SN Inj.|LIV-GAMMA SN Inj. is administered at a dose of 0.6 g/kg/day from anhepatic phase to Day 2 post-operative to patients undergoing ABO-incompatible liver transplantation as an experimental group.
223795227|NCT05666453|OTHER|No intervention|None of investigational drugs are administered to patients.
223795228|NCT01804452|OTHER|Observational Study|
223795229|NCT01904448|DEVICE|Auditory Brainstem Implantation in Children|
223795230|NCT01015989|OTHER|CARE+ Kenya brief computer risk assessment session|The computer will ask patients questions about taking HIV medicine. The computer will also ask patients questions about sexual and substance use activities. We will repeat the session every 3 months up to 9 months total.
224264037|NCT01608984|PROCEDURE|Off-pump Coronary artery bypass surgery without remote ischemic preconditioning|The applied anesthesia protocol avoids the use of propofol. Drugs: isoflurane+sufentanil anesthesia Anaesthesia is maintained by inhaled isoflurane in concentrations 0.7-0.8 % end-tidal with additional sufentanil injected during surgery, as required.
224264038|NCT06561542|DRUG|LX22001 for Injeciton|single dose: 25mg,50mg,100mg,200mg ,intravenous infusion. repeat doses: 50mg,100mg , intravenous infusion,once daily for 3 days.
224264039|NCT06561542|DRUG|Tegoprazan tablet|50mg,oral,single dose
223795231|NCT01015989|OTHER|CARE+ Kenya computer counseling session|The computer will ask patients questions about taking HIV medicine. The computer will also ask patients questions about sexual and substance use activities. The computer will let patients look at short videos on various HIV medicine and HIV risk reduction topics and will then help patients create a health plan. Patients will get an anonymous print out at the end of the session and can choose to share with health care provider. There are questions about depression, suicide, or domestic violence. If a patient's answers indicate that they may be depressed, suicidal, or currently in an abusive relationship, we will refer them to a health worker at the clinic. We will repeat the session every 3 months up to 9 months total.
223795232|NCT05713617|BEHAVIORAL|PODER Familiar|Educational intervention designed to improve healthy behaviors of families of children with intellectual and developmental disabilities.
223795233|NCT04492254|DRUG|Enoxaparin|The treatment provided will be enoxaparin sodium 40mg/0.4 mL. All doses will be provided in pre-filled, single-dose syringes for subcutaneous injection.
223795234|NCT02510495|PROCEDURE|"30 group"|A small sphincterotomy (EST) was performed prior to the EPBD, the length of a small sphincterotomy was considered as no larger than the range which from the orifice to the top one-third of the papilla. a CRE balloon (diameter 8, 9, 10, 11, 12, 13.5, 15; Boston Scientific) was chosen according to the diameter of bile duct. It was placed across the papilla orifice and then gradually filled with diluted contrast in 15 seconds. When the waist disappeared, the balloon was inflated till 30 seconds prior deflated. The stones were then retrieved by a basket or retrieval balloon. Mechanical lithotripsy was used if necessary.
223795235|NCT02510495|PROCEDURE|"60 group"|A small sphincterotomy (EST) was performed prior to the EPBD, the length of a small sphincterotomy was considered as no larger than the range which from the orifice to the top one-third of the papilla. a CRE balloon (diameter 8, 9, 10, 11, 12, 13.5, 15; Boston Scientific) was chosen according to the diameter of bile duct. It was placed across the papilla orifice and then gradually filled with diluted contrast in 15 seconds. When the waist disappeared, the balloon was inflated till 60 seconds prior deflated. The stones were then retrieved by a basket or retrieval balloon. Mechanical lithotripsy was used if necessary.
223795236|NCT02510495|PROCEDURE|"180 group"|A small sphincterotomy (EST) was performed prior to the EPBD, the length of a small sphincterotomy was considered as no larger than the range which from the orifice to the top one-third of the papilla. a CRE balloon (diameter 8, 9, 10, 11, 12, 13.5, 15; Boston Scientific) was chosen according to the diameter of bile duct. It was placed across the papilla orifice and then gradually filled with diluted contrast in 15 seconds. When the waist disappeared, the balloon was inflated till 180 seconds prior deflated. The stones were then retrieved by a basket or retrieval balloon. Mechanical lithotripsy was used if necessary.
223795237|NCT02510495|PROCEDURE|"300 group"|A small sphincterotomy (EST) was performed prior to the EPBD, the length of a small sphincterotomy was considered as no larger than the range which from the orifice to the top one-third of the papilla. a CRE balloon (diameter 8, 9, 10, 11, 12, 13.5, 15; Boston Scientific) was chosen according to the diameter of bile duct. It was placed across the papilla orifice and then gradually filled with diluted contrast in 15 seconds. When the waist disappeared, the balloon was inflated till 300 seconds prior deflated. The stones were then retrieved by a basket or retrieval balloon. Mechanical lithotripsy was used if necessary.
223795238|NCT01915134|DRUG|Recombinant Human Endostatin plus gemcitabine and cisplatin|target therapy plus chemotherapy:4-6 cycles of Recombinant Human Endostatin plus gemcitabine and cisplatin:Endostatin：7.5mg/m2/d,d1-14,concomitant with chemotherapy for 4-6 cycles.Gemcitabine and cisplatin:4-6 cycles of GP chemotherapy with gemcitabine 1000mg/m2,d1,8,cisplatin80mg/m2,d1.Chemotherapy will be given once every three weeks.
223795239|NCT01915134|DRUG|Gemcitabine and cisplatin|only chemotherapy：Gemcitabine and cisplatin:4-6 cycles of GP chemotherapy with gemcitabine 1000mg/m2,d1,8,cisplatin80mg/m2,d1.Chemotherapy will be given once every three weeks.
223795240|NCT03819491|DIETARY_SUPPLEMENT|COQUN ORAL FORMULATION|COQUN ORAL FORMULATION is a food supplement based on Coenzyme Q10 MINIACTIVES®
223795241|NCT05111236|OTHER|Routine physical therapy|Rehabilitation strategies in management of children with spastic CP
223795242|NCT05111236|OTHER|Traditional massage|Rehabilitation strategies in management of children with spastic CP
223795243|NCT00540280|RADIATION|Surgery alone or surgery plus preoperative Gemcitabine-Cisplatin|Surgery + Chemo + RT
223795244|NCT04686903|PROCEDURE|Epiduroscopy treatment|Device Epiduroscop, procedure mecahnical lysis, laser, radiofrequency + drug administration into the epidural space (corticosteroid methylprednisolone acetate 80mg and solution of hyaluronidase 150 I.U. in 10mL of saline) Follow-up: before procedure, 6 months and 12 months after procedure
223795245|NCT04686903|PROCEDURE|Racz catheter epidural procedure|"Device Racz catheter, two procedures during clinical trial observation~* First procedure after enrolment into the study mechanical lysis and drug administration into the epidural space (corticosteroid methylprednisolone acetate 80mg and solution of hyaluronidase 150 I.U. in 10mL of saline)~* Second procedure after 6 months mechanical lysis + drug administration into the epidural space (corticosteroid methylprednisolone acetate 80mg and solution of hyaluronidase 150 I.U. in 10mL of saline)"
223795246|NCT04686903|PROCEDURE|Caudal epidural block|"Technique Caudal epidural block~Three procedures during clinical trial observation :~* First procedure after enrolment into the study drug administration into the epidural space (corticosteroid methylprednisolone acetate 80mg and solution of hyaluronidase 150 I.U. in 10mL of saline)~* Second procedure after 4 months drug administration into the epidural space (corticosteroid methylprednisolone acetate 80mg)~* Third procedure after 8 months drug administration into the epidural space (corticosteroid methylprednisolone acetate 80mg)"
223795247|NCT01909310|PROCEDURE|head extension|the lungs are ventilated with the patient´s head extended
223795248|NCT01909310|PROCEDURE|neutral position|the lungs are ventilated with the patient´s head in neutral position
223795249|NCT01909310|PROCEDURE|anaesthesiologist´s position|the lungs are ventilated with the patient´s head positioned deemed ideal by the anaesthesiologist
223795250|NCT04699279|DRUG|Rosuvastatin 10mg|Rosuvastatin 10mg is taken by oral or nasal feeding every day at ang time.
223795251|NCT00233077|BEHAVIORAL|Patient Assistance|Patients will be surveyed to assess their knowledge about cancer \& its treatment, experience with \& access to health care system, trust, depression, social support \& self-efficacy. A Brief Screening Needs Assessment will be done to ascertain practical, informational or psychosocial needs; based on their responses, an individualized action plan to connect with patient assistance programs will be created for the intervention group. We will ask intervention patients if they connected with any programs in their action plan. For those who didn't connect, we will give their name to an outreach worker. The outreach worker will call patients and identify reasons for not contacting the assistance programs.
223795252|NCT00233077|BEHAVIORAL|Information only|Control patients will be sent a pamphlet about breast cancer \& its treatment. We will call all patients 2 weeks later and ask if they received the packet. If they didn't, we will send the packet again.
223795253|NCT04307823|OTHER|Treadmill training|"3 days per week, starting at shorter duration 5-20min and progressed to 30- 40mins.~Training% or Intensity was kept 40-70%,~Training Heart Rate (HR) was calculated through formula:~HR max HR rest\*Ex intensity + HR rest Rate of Perceived Exertion (RPE) 9-14 ON 6 -20 RPE scale The session was terminated if sustained ventricular arrhythmia, symptomatic drop in blood pressure, ST elevation, or development of severe symptoms"
223795254|NCT04307823|OTHER|Treadmill protocol and Respiratory training|"Treadmill protocol~Spirometry:~Volumetric exercises, using incentive Spirometer 10-15 repetitions~Slow breathing training:~5 minutes: spontaneous breathing, 4 minutes: controlled breathing (15 breaths/min) 4 minutes of controlled breathing (6 breaths/min) Treatment provided for 3 days in a week for a period of 4 weeks"
223795255|NCT00384228|DRUG|Nilotinib|
223795256|NCT03378167|BIOLOGICAL|MICROBIOTA|Fecal microbiota enema (RBX2660) infused via colonoscope x 1 + oral microbiota capsules (RBX7455) x 6 weeks. The fecal microbiota enema (RBX2660) prepared by Rebiotix has received Health Canada Clinical Trials Application (CTA), and U.S. Food and Drug Administration Investigational New Drug Application (IND) approval for clinical trials in patients with recurrent Clostridium difficile infection, and pediatric inflammatory bowel disease. The human-derived fecal oral microbiota capsule (RBX7455) has received U.S. Food and Drug Administration Investigational New Drug Application (IND) approval for clinical trials in patients with recurrent Clostridium difficile infection.
223795257|NCT03378167|BIOLOGICAL|PLACEBO|"Placebo enema (Normal Saline) infused via colonoscope x 1 + oral placebo capsules (dextrose-containing capsules) x 6 weeks.~NOTE: Patients randomized to the control group will be given the option of receiving open-label treatment, with the intervention therapy, either: upon completion of the trial, or if they are removed from the trial due to disease exacerbation or other adverse event, at the discretion of their primary gastroenterologist."
223795258|NCT00596765|BEHAVIORAL|Neuropsychological Cognitive Behavioral Therapy|Neuropsychological Cognitive Behavioral Therapy encompasses 2 foci: First emphasis is on neuropsychological compensatory strategies for the treatment of deficits in attention, memory, and executive functions. Secondly, cognitive behavioral intervention techniques are employed to support the patient in the process of coping with chronic illness: i.e. improve regulation of negative affect, diversify the impaired self-concept after acquired brain injury, and adjust important life-goals to changed circumstances.
223795259|NCT04459026|PROCEDURE|combination|instillation and infiltration of ropivacaine
223795260|NCT04459026|PROCEDURE|infiltration|local infiltration ropivacaine
223795261|NCT04459026|PROCEDURE|instillation|intraperitoneal ropivacaine instillation
223795262|NCT06405373|BEHAVIORAL|ReCharge|ReCharge is an emotions-focused intervention that utilizes core components of Acceptance and Commitment Therapy (ACT) to address and minimize diabetes distress. This 5-week, group-based, virtual intervention will include a stepwise process to address diabetes distress and provide opportunities to practice new skills. Weekly assignments between the sessions will reinforce class material and give additional practice opportunities. Participants will be expected to interact in each session and will have opportunities to share their experiences and be engaged in discussion with the group and the facilitator.
223795263|NCT06405373|BEHAVIORAL|TakeCharge|TakeCharge is a problem-solving focused intervention that empowers participants to identify and make meaningful changes in their blood glucose management and other diabetes-related behaviors. This 5-week, group-based, virtual intervention will include a stepwise process to analyze data and resolve challenging situations surrounding diabetes management and provide opportunities to practice new skills. Weekly assignments between the sessions will reinforce class material and give additional practice opportunities. Participants will be expected to interact in each session and will have opportunities to share their experiences and be engaged in discussion with the group and the facilitator.
223795264|NCT01744028|DEVICE|Remote Patient Monitoring|Remote patient monitoring system including exacerbations of chronic pulmonary disease Tool - Patient Reported Outcome (EXACT PRO), Lung Monitor, and Pulse Oximeter
223795265|NCT01744028|OTHER|Usual care|Patients in the usual care arm will continue their normally established procedures of nurse/physician contact and evaluation, as is considered standard for each individual practitioner in the study.
223795266|NCT04790318|PROCEDURE|Trans-incisional Quadratus lumborum block|patients will receive combined general anesthesia and quadratus lumborum block (trans-incisional) with 0.5 mL/kg of bupivacaine 0.2 %. with maximum volume was limited to 20 ml
223795267|NCT04790318|PROCEDURE|Caudal block|patients will receive combined general anesthesia and caudal analgesia (just after wound closure) with 1.25 mL/kg of bupivacaine 0.2 % (three parts 0.25 % bupivacaine to one part saline.
223795268|NCT03205995|BIOLOGICAL|OMS721|Intravenous loading dose followed by daily subcutaneous injections
223795269|NCT00884429|PROCEDURE|Chest physiotherapy - Conventional|Percussion Postural Drainage and thorax compression
223795270|NCT00884429|PROCEDURE|Chest physiotherapy - actual techniques|Slow prolonged expiration and clearance rhinopharynx retrograde
223795271|NCT00884429|PROCEDURE|3-Airway suction|Airway suction
223795272|NCT03793985|DRUG|T|CKD-391 40/10mg
223795273|NCT03793985|DRUG|R|D086 and D337 co-administration
223795274|NCT03332524|DRUG|SP160412 Ibuprofen 400 mg and Chlorpheniramine maleate 4 mg|2 Ibuprofen and capsules Chlorpheniramine maleate 3 time per day for 72 hours
223795275|NCT03332524|DRUG|2 capsules Ibuprofen and 1 placebo|Ibuprofen and placebo
223795276|NCT03332524|DRUG|capsule Chlorpheniramine 4mg and 1 Placebo|Chlorpheniramine 4mg and one capsule Placebo 3/72days
223795277|NCT06961773|OTHER|Low energy availability|Participants follow 6 days of a low-energy availability diet. The kilocalories of each diet are prescribed individually based on their fat-free mass.
223795278|NCT06961773|OTHER|High energy availability|Participants follow 6 days of a high-energy availability diet. The kilocalories of each diet are prescribed individually based on their fat-free mass.
223795279|NCT02308748|DRUG|Dofetilide|"* 8 am: Placebo~* 12 pm (noon): 250 µg~* 5:30 pm: 250 µg"
223795280|NCT02308748|DRUG|Mexiletine|"* 8 am: weight x 4 mg/kg~* 12 pm (noon): Same as at 8 am~* 5:30 pm: Same as at 8 am"
223795281|NCT02308748|DRUG|Lidocaine|"* 9 am : 30 µg/min per kg (loading) for 60 minutes and 10 µg/min per kg (maintenance) for 30 minutes~* 2 pm: 55 µg/min per kg (loading) for 60 minutes and 20 µg/min per kg (maintenance) for 30 minutes~* 7:30 pm: 52 µg/min per kg (loading) for 60 minutes and 20 µg/min per kg (maintenance) for 30 minutes"
223795282|NCT02308748|DRUG|Moxifloxacin|"* 9 am: 5.63 mg/h per kg (loading) for 1 hour and 0.26 mg/h per kg (maintenance for 30 minutes)~* 2 pm: 6.14 mg/h per kg (loading) for 1 hour and 0.49 mg/h per kg (maintenance for 30 minutes)~* 7:30 pm: 2.23 mg/h per kg (loading) for 1 hour and 0.49 mg/h per kg (maintenance for 30 minutes)"
223795283|NCT02308748|DRUG|Diltiazem|• 7:30 pm: 330 µg/h per kg (loading) for 60 minutes and 61 µg/h per kg (maintenance) for 30 minutes
223795284|NCT02308748|DRUG|Placebo|Placebo (#2 Gelcap or IV saline)
223795285|NCT06963073|OTHER|Diabetic DM|The intervention group will receive 45 minutes of diabetes education. Three telemonitoring sessions will be held 2 weeks, 1 month and 3 months after the education. During the monitoring, participants will be asked to monitor their blood sugar and HbA1C values, if any. Nothing will be done to the control group. The same monitoring will be held for the control group 3 months later.
223795286|NCT01306773|DRUG|H1N1 convalescent plasma and oseltamivir|Oseltamivir 75mg bid orally during ICU hospitalization + 500mL convalescent plasma containing \>= 1:160 of neutralizing antibody to Pandemic influenza A H1N1
223795287|NCT01306773|DRUG|Oral Oseltamivir alone|Oral Oseltamivir 75mg bid during ICU hospitalization
223795288|NCT06164626|PROCEDURE|Extraction|extraction: in all groups, extraction will be performed
223795289|NCT06164626|RADIATION|low level laser therapy|extraction: in all groups, extraction will be performed Treatment with low-intensity infrared 808 nm laser therapy will be applied in 2 stages: one in the immediate postoperative period and 10 days after surgery.
223795290|NCT06164626|BIOLOGICAL|Plenum® OSShp and Plenum® Guide|extraction: in all groups, extraction will be performed Immediately after tooth extraction, the biomaterials Plenum® OSShp and Plenum® Guide (Brazil) will be added to the dental socket, serving as a bone substitute and maintaining alveolar dimensions.
223795291|NCT04490486|BIOLOGICAL|UCMSCs|100 x 106 (100 million) UCMSCs delivered via peripheral intravenous infusion.
223795292|NCT04490486|OTHER|Placebo|Placebo, a solution of 1% human serum albumin in Plasmalyte A, delivered via peripheral intravenous infusion
223795293|NCT03369444|BIOLOGICAL|FLT180a|FLT180a is a replication-incompetent adeno- associated viral vector. The vector is composed of a DNA vector genome encapsidated in an adeno-associated virus derived protein capsid. The expression cassette contains DNA encoding Factor IX.
223795294|NCT01184287|DRUG|Ranpirnase|Cycles 3 and until patient progression, on days 1,8 and 15 in a 21 day cycle
223795295|NCT02628210|OTHER|map3® Cellular Allogeneic Bone Graft|Patients will receive map3® Cellular Allogeneic Bone Graft
223795296|NCT06186752|BEHAVIORAL|MyIBD|MyIBD has two components: (1) an electronic, templated document that presents brief, actionable, tailored guidance from IBD specialists to families and other providers who care for a pediatric patient with IBD; and (2) regular, short prompts sent through the electronic patient portal to remind patients to refer to and use their MyIBD document to guide decisions about care in between appointments.
223795297|NCT00435773|PROCEDURE|Single Leeching|
223795298|NCT00435773|PROCEDURE|Repeated Leeching after 4 weeks|
223795299|NCT00435773|PROCEDURE|Placebo Leeching|
223795300|NCT00002564|OTHER|educational intervention|
223795301|NCT00002564|PROCEDURE|therapeutic dietary intervention|
223795302|NCT06202521|DRUG|CX-4945 (SARS-CoV-2 domain)|CX-4945 will be administered at 400 mg BID for up to 5 days (Day 1 to Day 5) in addition to SOC.
223795303|NCT06202521|DRUG|Placebo (SARS-CoV-2 domain)|The dosage and frequency is the same as active drug.
223795304|NCT06202521|DRUG|CX-4945 (Influenza virus domain)|CX-4945 will be administered at 400 mg BID for up to 5 days (Day 1 to Day 5) in addition to SOC.
223795305|NCT06202521|DRUG|Placebo (Influenza virus domain)|The dosage and frequency is the same as active drug.
223795306|NCT05949723|DEVICE|Golf simulator device|The golf simulator can accurately predict the flight trajectory and landing point of the ball using high-speed moving object measurement technology, giving the user the impression that they are playing on a real golf course.
223795307|NCT01398488|BEHAVIORAL|Patient education|Patient education by health care professional compared to education via tablet PC
223795308|NCT06498765|OTHER|Pacifier Use|The newborns in the experimental group were given a pacifier, unlike the control group. The newborns were placed in a phototherapy incubator and each time they were placed in a phototherapy incubator, the newborns were given a pacifier for an average of 5 minutes. The researcher encouraged the babies to take the pacifier.
223795309|NCT02541890|BEHAVIORAL|Work place intervention|Meeting at the work place including the patient, the employer and the rehabilitation therapist. Aim of meeting is to discuss challenges and possibilities in the patient's return to work process and to make a plan for return to work.
223795310|NCT02275104|DEVICE|Contrast-enhanced ECG-gated multi-detector computed tomography|Depending on potential contra-indications to iodine-enhanced computed tomography. It will be performed using the usual method on a 64-slice dual energy scanner. Data will be acquired after the injection of 120 mL iodine contrast media. Contrast will be injected at the rate of 4 mL/s without additional saline flush in order to obtain homogeneous enhancement of the 4 cardiac chambers, there by simplifying subsequent segmentation. The objective will be to obtain a 3-dimensional imaging of cardiac structures
223795311|NCT02275104|DEVICE|Magnetic resonance imaging|Depending on potential contra-indications to gadolinium-enhanced magnetic resonance. It will be performed on the 1.5 Tesla clinical device associated to MUSIC equipment (Magnetom Avanto, Siemens, Erlangen, Germany). Myocardial fibrosis will be imaged using a free-breathing delayed-enhancement method initially developed for atrial imaging. The method uses a 3-dimensional, inversion recovery-prepared, ECG-gated and respiratory-navigated Turbo Fast Low Angle Shot sequence with fat saturation. Acquisition will be initiated 15 minutes after the injection of a double-dose of gadolinium-based contrast media.
223795312|NCT02275104|DEVICE|Positron emission tomography|Only in patients with a contra-indication to magnetic resonance imaging. It will be performed on a PET/CT 600 device. Acquisition will be preceded by a standard metabolic preparation for 18 fluoro-deoxy-glucose viability imaging. The objective will be to obtain a 3-dimensional imaging of ventricular scar.
223795313|NCT02275104|DEVICE|Body surface mapping|It will be obtained using a 252-electrode vest. The position of each electrode with respect to epicardium will be assessed at multi-detector computed tomography prior to mapping. In patients referred for ventricular arrhythmia, body surface mapping will aim at recording the clinical arrhythmia whenever possible. In patients referred for atrial arrhythmia, body surface mapping will aim at recording atrial fibrillation.
223795314|NCT02275104|PROCEDURE|Cardiac ablation procedure|Ventricular procedures will be performed endocardially using trans-septal or retro-aortic approach, potentially combined with sub-xiphoid epicardial access. Atrial procedures will be performed endocardially using trans-septal approach to access the left atrium. Bi-atrial bipolar contact mapping will be performed at high density during atrial fibrillation prior to ablation.
223795315|NCT01655290|OTHER|Gadovist® (Gadobutrol), Multihance® (Gadobenate dimeglumin)|Other (Diagnostic)
223795316|NCT00970138|DRUG|apatinib tablet|"A850: apatinib 850 mg qd p.o. plus placebo qd p.o. until disease progression or intolerable toxicity or patients withdrawal of consent~B425: apatinib 425 mg bid p.o. until disease progression or intolerable toxicity or patients withdrawal of consent~Cpla: placebo bid p.o. until disease progression or intolerable toxicity or patients withdrawal of consent"
223795317|NCT00999375|BEHAVIORAL|Education|
223795318|NCT00999375|BEHAVIORAL|Problem Solving|
223795319|NCT00999375|BEHAVIORAL|Social Learning|
223795320|NCT00999375|BEHAVIORAL|Behavior Modification|
223795321|NCT03525366|OTHER|Radiofrequency ablation|Radiofrequency Ablation (RFA) as an intervention is part of standard of care at Memorial Herman Hospital, Houston.
223795322|NCT05068817|OTHER|Pilates mat exercises|"Pilates mat exercises: Each Pilates session will last for one hour and commence with a 10 minute warm up and finish with a 10 min cool down. The subjects will be taught the 5 key elements of Pilates (lateral costal breathing, centring which is a neutral position of the lumbar spine with activation of the core muscles, ribcage placement, shoulder blade placement and neutral position of the cervical spine with slight upper cervical flexion at the cranio-cervical junction).~Pilates exercise program will consist of warm up exercises, main treatment program (10 level) and cooling down exercises."
223795323|NCT05068817|OTHER|cervical stabilization exercises|training of deep cervical flexor muscles with pressure biofeedback unit, 20 min/day, 3 days/week for 12 weeks.
223795324|NCT05068817|OTHER|conventional physiotherapy|10 min hot pack on cervical area range of motion exercises and isometric neck exercises as a home program 3 days/week for 12 weeks
223795325|NCT05925127|BIOLOGICAL|NVX-CoV2373 (5μg)|Coformulated prototype SARS-CoV-2 rS vaccine with Matrix-M adjuvant: supplied as a solution for preparation for injection, at a concentration of 10 μg/mL and 100 μg adjuvant per mL, respectively
223795326|NCT05925127|BIOLOGICAL|NVX-CoV2601 (5μg)|The vaccination regimen will comprise one IM injection on Day 0 at a dose of 5 µg of antigen with 50 µg Matrix-M adjuvant.
223795327|NCT05925127|BIOLOGICAL|NVX-CoV2601(5μg)|The vaccination regimen will comprise one IM injection on Day 0 at a dose of 5 µg of antigen with 75 µg Matrix-M adjuvant.
223795328|NCT05925127|BIOLOGICAL|NVX-CoV2601 (35μg)|The vaccination regimen will comprise one IM injection on Day 0 at a dose of 35 µg of antigen with 50 µg Matrix-M adjuvant.
223795329|NCT05925127|BIOLOGICAL|NVX-CoV2601(35μg)|The vaccination regimen will comprise one IM injection on Day 0 at a dose of 35 µg of antigen with 75 µg Matrix-M adjuvant.
223795330|NCT05925127|BIOLOGICAL|NVX-CoV2601(50μg)|The vaccination regimen will comprise one IM injection on Day 0 at a dose of 50 µg of antigen with 100 µg Matrix-M adjuvant
223795331|NCT05925127|BIOLOGICAL|Bivalent BA.4/5|The bivalent BA.4/5 (or recommended mRNA vaccine at the time of the conduct of this study) Omicron subvariant/prototype licensed mRNA vaccine will be procured and stored per the manufacturer's instructions. For this vaccine group, treatment will be administered open label as a single IM injection
223795332|NCT00434382|DRUG|Sevoflurane|
223795333|NCT00434382|DRUG|Isoflurane|
223795334|NCT00434382|DRUG|Desflurane|
223795335|NCT00434382|DRUG|Propofol|
223795336|NCT00434382|DRUG|Fentanyl|
223795337|NCT00434382|DRUG|Sufentanil|
223795338|NCT00434382|DRUG|Alfentanil|
223795339|NCT00434382|DRUG|Remifentanil|
223795340|NCT00434382|DEVICE|Midlatency auditory evoked potentials|
223795341|NCT05452057|BEHAVIORAL|Prehabilitation|"A Registered Kinesiologist will provide your exercise prescription during your first visit for the study. Your exercise sessions will consist of moderate-intensity cardiovascular (or aerobic) exercise, like brisk walking, for 30 minutes. You will also perform resistance exercises (weight lifting) for 30 minutes that will help strengthen your muscles with a focus on muscles that may be affected by your surgery. To complete your exercises, you will receive resistance bands, exercise ball, and exercise manual.~You will also meet with a Registered Dietician within a week of consent to receive information on healthy eating and you will receive protein to improve your nutritional health.~A consult with an expert in psychology to discuss ways to reduce your stress within a week of consent. Some strategies to help reduce your stress may include breathing exercises, being mindful, or other relaxation methods."
223795342|NCT06072196|DRUG|Novel hormonal therapy|As provided in real-world setting
223795343|NCT06374212|DRUG|Anifrolumab|900mg maintenance dose every 4 weeks for 12 weeks then 600mg loading dose every 4 weeks until week 20
224264040|NCT06561542|DRUG|Esomeprazole sodium for injection|80 mg intravenous infusion for 30 min followed by a continuous infusion of 8 mg/h for 71.5h
224264041|NCT03163160|PROCEDURE|Pelvic floor manual therapy group|Soft-tissue (myofascial) stretching techniques on pelvic floor muscles through external and internal (intra-vaginal) mobilizations. One weekly session for four weeks.
224264042|NCT03163160|PROCEDURE|Pelvic floor electrolysis group|"An ultrasound-guided application of a galvanic electrolytic current with an acupuncture needle in the soft tissue of pelvic floor. EPI technique was applied using a specifically device (EPI-X Omega Advanced Medicine, Barcelona, Spain) which produces modulated galvanic electricity. This is applied using a modified electrosurgical scalpel that incorporates acupuncture needles (0.3 mm in diameter) of different lengths. The intensity can be adjusted by changing either the duration of stimulation or the output current (mA) of the device.~One weekly session for four weeks."
224264043|NCT02997176|DRUG|Talazoparib|Daily oral doses of talazoparib 0.5 mg
224264044|NCT04273386|OTHER|Evaluation|The study will be carried out with the method of filling the evaluation form which is printed on paper with ballpoint pen.
224264045|NCT02396888|DRUG|Insulin|Half of the wound surface was treated daily with 10 units of intermediate insulin.
224264046|NCT02396888|DRUG|Placebo|Half of the wound surface was treated daily with 0.1 cc of normal saline.
224264047|NCT01624233|DRUG|80 mg ixekizumab|Administered SC
224264048|NCT04158128|OTHER|non-intervention|non-interventional, prospective cohort study
224264049|NCT00373256|DRUG|Sunitinib|Sunitinib 25 mg daily by oral capsules with titration up to 37.5 mg,
224264050|NCT00373256|DRUG|paclitaxel|Paclitaxel 90 mg/m2 IV, 3 weekly doses every 28 days until progression or unacceptable toxicity.
224264051|NCT00373256|DRUG|bevacizumab|Bevacizumab 10 mg/kg IV every 2 weeks.
223795344|NCT05935345|BEHAVIORAL|Addressing NSSI in schools|During the four months of active experimental condition, adolescents receive five sessions of the youth aware of mental health program in the class room, and one additional session on NSSI. Parents and school staff receive an online psychoeducation on NSSI. School health care personnel receive a 2-day workshop on NSSI and suicidality.
223795345|NCT05935345|OTHER|Control condition|Participating adolescents, parents, teachers and health care personnel receive no intervention during four months
223795346|NCT03570619|DRUG|Nivolumab|"Patients in arms Metastatic CRPC and Experimental: Solid Tumors (non-prostate) will begin receiving combination therapy with nivolumab 3 mg/kg IV and ipilimumab 1 mg/kg IV every 3 weeks for up to 4 cycles if tolerated, followed by nivolumab maintenance therapy at flat dose 480 mg IV every 4 weeks through the end of the planned study duration, for up to 104 weeks of total therapy.~Patients in arm Metastatic CRPC will receive therapy with monotherapy nivolumab therapy at flat dose 480 mg IV every 4 weeks for up to 104 weeks of total therapy."
223795347|NCT03570619|DRUG|Ipilimumab|Patients in arms Metastatic CRPC and Experimental: Solid Tumors (non-prostate) will begin receiving combination therapy with nivolumab 3 mg/kg IV and ipilimumab 1 mg/kg IV every 3 weeks for up to 4 cycles if tolerated, followed by nivolumab maintenance therapy at flat dose 480 mg IV every 4 weeks through the end of the planned study duration, for up to 104 weeks of total therapy.
223795348|NCT06265428|DRUG|DB-1303/BNT323|Administered I.V.
223795349|NCT06265428|DRUG|T-DM1|Administered I.V.
223795350|NCT06128109|DEVICE|Thioderm Strong|Test Device
223795351|NCT06128109|DEVICE|Juvéderm VOLUMA Lidocaine|Comparator Device
223795352|NCT05256173|OTHER|Melatonin Tablets|Melatonin Tablets was given 3 tablets (6.21mg) daily at the beginning of bedtime at night for a total of 4 weeks.
223795353|NCT05256173|OTHER|Lactasin Tablets|The placebo group was given at the beginning of bedtime at night for a total of 4 weeks.
223795354|NCT05256173|DEVICE|transcutaneous vagus nerve stimulation|transcutaneous vagus nerve stimulation treatment, frequency 10Hz, stimulation site is the anterior wall of the left external auditory canal (tragus), used twice a day, each treatment for 30 minutes, a total of 4 weeks.
223795355|NCT05256173|DEVICE|sham transcutaneous vagus nerve stimulation|In the sham stimulation group, the stimulation site was the left earlobe with a frequency of 10Hz, which was used twice a day for 30 minutes for a total of 4 weeks.
223795356|NCT00239174|DRUG|SR147778|
223795357|NCT06398327|PROCEDURE|PULPOTOMY TREATMENT|During pulpotomy treatment, a bleeding sample was taken from the pulp and levels of presepsin, IL-6 and IL-8, which are important inflammation markers, were determined. During the treatment, MTA, Neo MTA, Biodentine and ZOE groups were randomly selected and the remaining pulp tissue was covered. After pulpotomy treatment, the teeth were followed for one year. Treatment success was evaluated according to the material used in teeth with high levels of inflammation at the beginning.
223795358|NCT02485210|PROCEDURE|Endodontic treatment|It will be done the endodontic treatment using the photosynamic therapy for decontamination of the root chanel.
223795359|NCT02979262|BEHAVIORAL|Fathers for Change|
223795360|NCT02979262|BEHAVIORAL|Parent Education|
223795361|NCT06579378|DEVICE|VSail 3D|"The CEREBRUM software with virtual sailing scenarios is made up of exercises of variable difficulty, designed to train different cognitive functions, in particular attention, memory, learning, cognitive estimates, working memory, executive functions, motor abilities and language. The different degrees of difficulty are designed to adapt to the user's functional diagnosis. The operator who conducts the intervention must adapt the difficulty level to the user's residual abilities, so that the exercises are neither too easy nor too complex. Each session, after an initial part of welcome, psychoeducation and orientation to the instrument, involves alternating virtual reality exercises, positive and corrective feedback, and suggestions of practical homework related to the cognitive function trained during the session that the individual should try during daily life."
223795362|NCT06579378|OTHER|WEB-Health|The intervention includes a series of 3 webinars focused on active ageing promotion. In particular, each webinar will regard topics related to healthy lifestyle, such as physical activity in old age, effective communication, stress management, technologies and health. Each webinar will be conducted by a mental health professional, and it will be delivered in real-time in a group (plenary).
223795363|NCT02445612|BIOLOGICAL|MA09-hRPE|Cohort 1 50,000 cells Cohort 2 100,000 cells Cohort 2a Better Vision 100,000 cells Cohort 3 150,000 cells Cohort 4 200,000 cells
223795364|NCT01565707|DRUG|Solifenacin Succinate Suspension|Children aged 5 to 11 years and adolescents aged 12 to 17 years received solifenacin succinate liquid suspension once a day orally via syringe for 12 weeks along with non interventional diary assisted urotherapy consisting of overactive bladder (OAB) information, awareness, instruction, life-style advice and documentation of voiding habits and symptoms for OAB. The initial dose started with the equivalent of 5 mg in adults, referred to as pediatric equivalent dose (PED) of 5 mg (PED5), based on body weight for three weeks and was titrated up or down in up to three titration steps of three weeks each to reach the optimal dose. Titration up or down could lead to weight-based doses equivalent to doses in adults of 2.5 mg, 5 mg, 7.5 mg or 10 mg once daily and were referred to as PED2.5, PED5, PED7.5 and PED10. The minimum dose was PED2.5, and the maximum dose was PED10. The decision to titrate up or down was made by the investigator using information from the 7 day patient diary.
224264052|NCT00373256|DRUG|paclitaxel|Paclitaxel 90 mg/m2 IV, 3 weekly doses every 28 days until progression or unacceptable toxicity.
224264053|NCT01877122|DEVICE|Proflex® Mesh Mesh implantation|Implantation of mesh in the incision of inguinal area
224264054|NCT01877122|DEVICE|Marlex® Mesh Implant|
224264055|NCT02867358|DRUG|KT07 Capsule|
224264056|NCT02867358|OTHER|Placebo|
224264057|NCT05488795|BEHAVIORAL|Team-Based Home Blood Pressure Monitoring|Implementation of best practices for hypertension control using a practice wide team-based home blood pressure monitoring intervention
224264058|NCT02987634|OTHER|PeriActive|mouthwash
223795365|NCT01565707|DRUG|Placebo|Children aged 5 to 11 years and adolescents aged 12 to 17 years received matching placebo liquid suspension once a day orally via syringe for 12 weeks along with non interventional diary assisted urotherapy consisting of overactive bladder (OAB) information, awareness, instruction, life-style advice and documentation of voiding habits and symptoms for OAB. The initial dose started with the equivalent of 5 mg in adults, referred to as pediatric equivalent dose (PED) of 5 mg (PED5), based on body weight for three weeks and was titrated up or down in up to three titration steps of three weeks each to reach the optimal dose. Titration up or down could lead to weight-based doses equivalent to doses in adults of 2.5 mg, 5 mg, 7.5 mg or 10 mg once daily and were referred to as PED2.5, PED5, PED7.5 and PED10. The minimum dose was PED2.5, and the maximum dose was PED10. The decision to titrate up or down was made by the investigator using information from the 7 day patient diary.
223795366|NCT01565707|BEHAVIORAL|Urotherapy|Non interventional diary assisted urotherapy consisting of overactive bladder (OAB) information, awareness, instruction, life-style advice and documentation of voiding habits and symptoms for OAB.
223795367|NCT05207813|DEVICE|Intracept Procedure|Intraosseous Basivertebral Nerve (BVN) Ablation
223795368|NCT03736434|BEHAVIORAL|Mindfulness and DASH Diet Education|"Mindfulness and DASH diet education will include a didactic presentation on stress, theoretical material related to mindfulness, the somatic mind/body connection, relaxation, yoga, meditation, self-awareness, and bodily cues relating to emotional reactivity. Practices will include the body scan, gentle yoga movement, walking/sitting meditation, breathing, relaxation. Additionally, daily 20 min individual practices are done at least 5x/week delivered via a compact disc player or on a preloaded device. Each participant is asked to track his/her daily meditation practice and given a diary for adherence records. A combination of didactic, experiential, and hands-on activities will be done to deliver DASH diet guidelines."
223795369|NCT03736434|BEHAVIORAL|Education group|The attention control group will attend eight, 2.5 hours sessions on non-health topics such as personal safety, fire prevention, cold weather protection, disaster preparation, internet safety, aging in place, how to know when it's time to move and managing your money.
223795370|NCT00000744|DRUG|Fluconazole|
223795371|NCT04956718|OTHER|Cold Pressor Test (CPT)|Cold Pressor Test (CPT): apparatus for the task is a tank of water of temperature of 4 °C (+-0.5 °C), with instruction to immerse the hand until too uncomfortable to continue. A maximum time limit per immersion of 3-5 min is applied. Quantitative measurement can then be made of pain threshold (point first perceived as painful) and tolerance time.
223795372|NCT04956718|OTHER|Placebo NaCl Nasal spray|placebo nasal spray containing NaCl solution
223795373|NCT04628689|OTHER|quadratus lumborum block by paraspinous sagittal shift approach|quadratus lumborum block by paraspinous sagittal shift approach
223795374|NCT05404542|DRUG|Tavapadon|Oral tablets
223795375|NCT01168492|DRUG|ketamine|0.5mg/kg ketamine iv
223795376|NCT03848533|DRUG|melatonin|"The administration of melatonin will be indicated at night before bedtime to avoid alterations of the circadian cycle. It will be contained in bottles labeled Medication 2 to maintain the masking. This intervention will be indicated in two groups (Melatonin plus metformin and Melatonin plus placebo)"
223795377|NCT03848533|DRUG|metformin|"For the intervention with metformin, prolonged-release tablets will be used to reduce adverse effects and improve adherence to treatment. It will be contained in bottles labeled Medication 1 to maintain masking. This intervention will be indicated in two groups (Melatonin plus metformin and metformin plus placebo)"
223795378|NCT03848533|DRUG|Placebo|"The placebo may be contained in bottles labeled Medication 1 or Medication 2 depending on the time of administration, and the group in which it is used. Placebo will be used in two groups (Melatonin plus placebo and Metformin plus placebo)"
223795379|NCT01714128|DRUG|Diagnostic Imaging ( 6α-[18F]fluoro-17β-estradiol (FES))|FES-PET/CT imaging
223795380|NCT06534398|DEVICE|Dental implant prosthesis with cantilever extension|A retrospective study on the radiographic and clinical findings of implant-supported dental prostheses with cantilever extensions in place and function for at least 10 years
223795381|NCT03332368|OTHER|Traditional Chinese medicine|Chinese medicine has a long history of prevention and treatment of breast cancer, the effect is obvious. Chinese medicine its mechanism of action is from the whole, adjust the body yin and yang, blood, viscera function balance, emphasizing the combination of governance and external treatment of the combination of thinking, according to different clinical syndromes, using syndrome differentiation.
223795382|NCT01012869|DEVICE|everolimus-eluting stent|everolimus-eluting stent (Xience, Abbott Vascular) or Promus (Boston Scientific)
223795383|NCT06349369|DEVICE|transcranial direct current stimulation|tDCS is a non-invasive neuromodulation technique that has gained attention for its potential to influence neural activity and address cognitive and functional deficits in individuals with schizophrenia. It involves applying a weak direct electrical current to the scalp, which can increase or decrease the excitability of underlying brain regions.
223795384|NCT05585723|BEHAVIORAL|Questionnaires completion|Prospective, qualitative, observational, single-center study. 1) Two independent translations of the original questionnaires into French, 2) Back-translation of the consensus version into English by a professional bilingual translator 3) We will submit this final version to two opinion leaders in France. 4) Evaluation of the clarity, comprehension and acceptability of the translation of the questionnaire.
223795385|NCT05887193|DEVICE|Biothesiometry|Biothesiometry using Biothesiometer (Bio Medical Instrument Co, Ohio, United States of America), placed on glans penis and second finger of nondominant hand.
223795386|NCT05887193|DEVICE|Near Infrared Spectroscopy|Penile oxygen pressure using TCM5 Flex and tc84 electrode (Radiometer Medical ApS, Brønshøj, Denmark) placed on glans penis.
223795387|NCT05887193|DEVICE|Cycling on a home trainer|Riding a static bike Wahoo Bike (Wahoo Fitness LLC, Atlanta, Georgia, United States of America) for 3x 10 minutes at 65-85% of each individual subjects maximal heart rate.
223795388|NCT05887193|DEVICE|Bike Fitting|Setting standardized posture of the rider on the bike using Retül technology (Retül, Specialized Bicycle Components Inc., Boulder, Colorado, United States of America)
223795389|NCT02263404|DEVICE|Deep Brain Stimulation|DBS Implant Stimulation
223795390|NCT00115700|DRUG|Cyclophosphamide|1000 mg/m2 I.V. on day 1
223795391|NCT00115700|RADIATION|Radiotherapy|The prescribed dose to the target volume will be 30 Gy. Daily fractions of 1.5-2.0 Gy will be employed.
223795392|NCT00115700|DRUG|Vincristine|1.4 mg/m2 (maximum single dose of 2 mg) I.V. on day 1
223795393|NCT00115700|DRUG|Prednisolone|50 mg/m2 orally daily for days 1 - 5
223795394|NCT00115700|DRUG|Rituximab|375 mg/m2 IV Infusion day 1
223795395|NCT04237662|PROCEDURE|Root Instrumentation|Instrumentation of the root surface in order to achieve debridement
223795396|NCT04237662|DEVICE|Enamel Matrix Derivative application|Enamel Matrix Derivative will be applied in the sites with at least 6 mm of pocket depths
223795397|NCT04405596|DRUG|Ambroxol Hydrochloride|The treatment regimen consists of a titration phase and a maintenance phase. Participants begin the titration phase (Weeks 1 and 2) taking 6 capsules a day (450mg or 0 mg) divided BID (3 capsules in the morning and 3 capsules in the evening). The first medication dose will be taken at the end of Baseline visit and in the presence of the study Neurologist. Possible side effects will be observed for 30 minutes. Medication dose will increase bi-weekly to 12 capsules on Weeks 3 and 4, and 18 capsules on Weeks 5 and 6 divided BID. At the end of titration (Week 5) participants will have reached a maximum of 1350mg or 0mg per day, depending on group allocation. In the maintenance phase, participants will remain in their maximum dose (1350mg or 0mg) from Week 5 to Week 52 (End of Trial).
223795398|NCT04405596|OTHER|Placebo|The treatment regimen consists of a titration phase and a maintenance phase. Participants begin the titration phase (Weeks 1 and 2) taking 6 capsules a day (450mg or 0 mg) divided BID (3 capsules in the morning and 3 capsules in the evening). The first medication dose will be taken at the end of Baseline visit and in the presence of the study Neurologist. Possible side effects will be observed for 30 minutes. Medication dose will increase bi-weekly to 12 capsules on Weeks 3 and 4, and 18 capsules on Weeks 5 and 6 divided BID. At the end of titration (Week 5) participants will have reached a maximum of 1350mg or 0mg per day, depending on group allocation. In the maintenance phase, participants will remain in their maximum dose (1350mg or 0mg) from Week 5 to Week 52 (End of Trial).
223795399|NCT03591068|DRUG|Fluticasone Propionate|OPN-375 186 μg BID, Delivered via exhalation delivery system
223795400|NCT06119100|DIAGNOSTIC_TEST|Ultrasound characterization of stenotic lesion type|Target lesion type will be classified as restrictive, hyperplastic or mixed using high frequency Duplex ultrasound, before the angioplasty procedure and at 6 months follow up.
223795401|NCT05216094|OTHER|smart phone App|stroke subjects completed tasks-oriented program demoed in the smart phone app with affected upper limb or bilateral arm movement for 12 weeks
223795402|NCT05216094|OTHER|conventional rehabilitation|stroke subjects receive conventional rehabilitation home program with smart phone app ,without task-oriented program demoed function, for 12 weeks
223795403|NCT01460329|DEVICE|Ultrasonic Cardiac Output Monitor (USCOM).|This device is FDA approved and based on the principles of ECHO using continuous-wave Doppler ultrasound to measure cardiac output.
223795404|NCT03578874|DRUG|Sorafenib|PO
223795405|NCT03578874|DRUG|Capecitabine|PO
223795406|NCT03578874|DRUG|Oxaliplatin|IV
223795407|NCT04357626|OTHER|Inpatient Rehabilitation|Observational electronic records review study during inpatient rehabilitation
223795408|NCT04554875|DIAGNOSTIC_TEST|A scoring system|The scoring system was used to rate score patients.
224264059|NCT05025033|DRUG|PD-1 antibody, paclitaxel or irinotecan, Apatinib mesylate|PD-1 antibody 200mg intravenous drip every 3 weeks; Apatinib 250mg/day; Chemotherapy: Irinotecan 150mg/m2, intravenous drip every 2 weeks, or Paclitaxel 150mg/m2, intravenous drip, once every 3 weeks.
224264060|NCT05630768|DRUG|Risedronate Sodium 35 MG [Actonel]|Risendronate Sodium Tab. 35mg, orally, once weekly
223795409|NCT04805723|PROCEDURE|VATS|"Video-assisted thoracoscopic surgery is a minimal invasive technique in which used to diagnose or treat for lung diseases. During this surgery, one or two small incisions are opened via camera and surgical instruments in patient's chest wall. Thus, less muscle and nerve tissue are damaged.~Thoracotomy is an open surgical technique in which allowing visualization of the inside of the thorax. During this surgery, an incision in patient's chest wall is made between the ribs and some muscles important for respiration are cutted to remove a part of lung."
223795410|NCT04805723|PROCEDURE|Thoracotomy|Thoracotomy is an open surgical technique in which allowing visualization of the inside of the thorax. During this surgery, an incision in patient's chest wall is made between the ribs and some muscles important for respiration are cutted to remove a part of lung.
223795411|NCT00493766|DRUG|LBH589|
223795412|NCT00615966|DRUG|Diannexin|single dose, 200 µg/kg IV
223795413|NCT00615966|DRUG|Placebo|Single dose, IV
223795414|NCT00615966|DRUG|Diannexin|Single dose, 400 µg/kg IV
223795415|NCT03923413|OTHER|Blood samples|Blood samples for MP evaluation
223795416|NCT01371851|DRUG|Doxazosin extended release|initially maintained on doxazosin extended release 4 mg once a day for 7 days, then the dose is increased to 8 mg once per day for the duration of the trial.
223795417|NCT03926091|DRUG|Docetaxel|Docetaxel chemotherapy (injection)
223795418|NCT03926091|DRUG|Cyclophosphamide|Cyclophosphamide chemotherapy (injection)
223795419|NCT00833638|DRUG|Placebo|One tablet orally daily
223795420|NCT00833638|DRUG|Tadalafil|Orally once daily
223795421|NCT06161675|BEHAVIORAL|QuitAid|Participants will receive the QuitAid intervention, based on a medication adherence intervention, which addresses perceptions (e.g., motivation, self-efficacy, beliefs) and practicalities of using NRT (e.g., monitoring NRT use, establishing a reminder system). QuitAid includes 1 in-person session and 5 follow-up telephonic sessions with the participant's local pharmacist/technician. Smokers not ready to quit will receive up to two sessions focused on using NRT to cut down cigarette use. If a smoker decides they are ready to quit at the 2- or 4-week follow-ups, they will receive the full QuitAid intervention.
223795422|NCT06161675|BEHAVIORAL|SmokefreeTXT|All participants will receive the SmokefreeTXT is a text-messaging program offered through the National Cancer Institute's Smokefree.gov initiative, which sends pre-programmed messages timed around a quit date. Participants will receive 3-5 messages a day for 7 weeks. The first week of messages focus on preparation and the remaining 6 weeks of messages focus on post-cessation strategies (e.g., relapse prevention), all timed relative to the quit date set at enrollment. For smokers not ready to quit, participants will receive two week-long pre-quit modules, Practice Quit and Daily Challenges. These modules will help the smoker become comfortable with not smoking for short periods of time and build skills before they attempt to quit. If a smoker decides they are ready to quit at the 2- or 4-week follow-ups, they will receive the ready to quit treatment.
223795423|NCT06161675|DRUG|Nicotine Replacement Therapy Patch|All participants will receive up to 8 weeks of NRT in the form of patch. At the 4-week follow-up, all participants still smoking will be offered an additional 4 weeks of NRT, regardless of readiness to quit. NRT temporarily replaces nicotine from tobacco to reduce motivation to consume tobacco and nicotine withdrawal symptoms.
223795424|NCT06161675|DRUG|Nicotine lozenge|All participants will receive up to 8 weeks of NRT in the form of lozenge. At the 4-week follow-up, all participants still smoking will be offered an additional 4 weeks of NRT, regardless of readiness to quit. NRT temporarily replaces nicotine from tobacco to reduce motivation to consume tobacco and nicotine withdrawal symptoms.
223795425|NCT02967627|DEVICE|Incisional Negative Pressure Wound Therapy (iNPWT)|Incisional Negative Pressure Wound Therapy devices are lightweight, self contained, portable battery powered (or line powered), suction pumps for medical procedures where secretions and other body fluids and infectious materials must be removed through the application of continuous or intermittent negative pressure. The pumps are operated through computer software, having help and alarm features. The device is indicted for management of chronic, acute, traumatic, subacute and dehisced wounds, partial-thickness burns, ulcers (such as diabetic or pressure), flaps and grafts. The pumps may be used at patient's bedside. These are suitable for use in either hospitals or long term care facilities and nursing homes. These devices will be applied to closed laparotomy incisions with the aim to provide three days of continuous negative pressure of - 100mmHg.
223795426|NCT02967627|DEVICE|Sterile Gauze Dressing|In most cases, self-adhesive, absorbent dressings will be used for standard wound therapy. However, surgical teams may decide on alternative forms of sterile gauze dressings, as long as the wound site is kept clean and dry. Dressings should be taken down on the second post-operative day.
223795427|NCT01356017|DRUG|Telmisartan 80mg, S-amlodipine 5mg|Telmisartan 80mg and S-amlodipine 5mg, Oral, Once a day, for 9 days + Wash out (19 days)
223795428|NCT01356017|DRUG|Telmisartan 80mg|Telmisartan 80mg, Oral, Once a day, for 9 days + Wash out (19 days)
223795429|NCT00490646|DRUG|ixabepilone|"Ixabepilone 40 mg/m\^2 was administered as a 3-hour I.V. continuous infusion on Day 1 in a 21-day cycle until disease progression or unacceptable toxicity.~For the first cycle, ixabepilone was administered the day following the first dose of trastuzumab (in the first cycle trastuzumab was given on Day 0); in all the following cycles, ixabepilone was administered immediately after the subsequent doses of trastuzumab if the preceding dose of trastuzumab was well tolerated."
223795430|NCT00490646|DRUG|docetaxel|Docetaxel 100 mg/m\^2 was administered as a 1-hour IV continuous infusion on Day 1 in a 21-day cycle until disease progression or unacceptable toxicity. For the first cycle, docetaxel was administered the day following the first dose of trastuzumab (i.e. in the first cycle trastuzumab was given on Day 0); in all following cycles, docetaxel was administered immediately after trastuzumab if the preceding dose of trastuzumab was well tolerated.
224264061|NCT05630768|DRUG|Calcium Vitamin D combination|orally, once daily for concomitant drug
224264062|NCT04778878|DEVICE|Mediracer® NCS|A point-of-care, hand-held nerve conduction device
224264063|NCT04241458|DRUG|BI 703621|BI 703621
224264064|NCT04241458|DRUG|Placebo|Placebo
224264065|NCT04241458|DRUG|Midazolam|Midazolam
224264066|NCT05985525|DEVICE|Skeletal muscle and cerebral NIRS (research device)|NIRS applied on skeletal muscle and brain on days 1, 3, and 8 of ICU admission. Monitoring applied for up to 24hrs on each day.
224264067|NCT06144424|DRUG|Oral EP262|Once daily
224264068|NCT06144424|DRUG|Placebo|Once Daily
223795431|NCT00490646|DRUG|trastuzumab|Trastuzumab was administered as an IV infusion on Days 1, 8, and 15 of each 21-day cycle at a dose of 2 mg/kg until disease progression or unacceptable toxicity. In cycle 1, a loading dose of 4 mg/kg was administered as a 90-minute IV infusion on a day before initial administration of chemotherapy (i.e. on Day 0). Trastuzumab was given immediately prior to ixabepilone (Arm A) or docetaxel (Arm B) in all subsequent cycles as a 30-minute IV infusion if the initial dose was well tolerated.
223795432|NCT00307827|DRUG|Visilizumab|Visilizumab administered intravenously once per day for two days
223795433|NCT03079752|BEHAVIORAL|Developmental Screening|Child participants were screened for sensory and developmental problems and referred for further evaluation and treatment of suspected problems at 12 and 24 months of age
223795434|NCT03079752|BEHAVIORAL|Screening plus Transportation|Child participants were screened for sensory and developmental problems and referred for further evaluation and treatment for suspected problems at 12 and 24 months of age; their mothers were provided with free transportation for prenatal and well-child care through child age 2.
223795435|NCT03079752|BEHAVIORAL|Screening, Transport, Prenatal Visits|Child participants were screened for sensory and developmental problems and referred for further evaluation and treatment for suspected problems at 12 and 24 months of age; their mothers were provided with free transportation for prenatal and well-child care through child age 2, and were provided an average of 9 home visits by nurses during pregnancy.
223795436|NCT03079752|BEHAVIORAL|Screen, Transport, Prenatal/Inf Visits|Child participants were screened for sensory and developmental problems and referred for further evaluation and treatment for suspected problems at 12 and 24 months of age; their mothers were provided with free transportation for prenatal and well-child care through child age 2, and were provided an average of 9 home visits by nurses during pregnancy and 23 during the child's first two years of life.
223795437|NCT05608629|DEVICE|Transcutaneous Non-Invasive Vagus Nerve Stimulation|The parasym is a system for delivering a fixed signal to stimulate the auricular branch of the vagus nerve. The device used is available without prescription in UK and EU. Similar devices have been used to treat migraine and one is in testing to be used for atrial fibrillation.
223795438|NCT04388020|DEVICE|Tabletop prototype of eSpecs: Active projection of defocused image in the peripheral visual field|For the right/test eye, a defocused image is projected onto the peripheral retina while the subject views a distant, in-focus image
223795439|NCT04388020|DEVICE|Tabletop prototype of eSpecs: No Active projection of defocused image in the peripheral visual field|For the left/control eye, no image is projected onto the peripheral retina. The subject views a distant, in-focus image.
223795440|NCT01702753|DIETARY_SUPPLEMENT|Bifidobacterium animalis subsp. lactis|
223795441|NCT02047838|OTHER|Anti-mullerian hormone (AMH) level dosage.|
223795442|NCT02047838|OTHER|Follicle-stimulating hormone (FSH) level dosage.|
223795443|NCT02047838|OTHER|Antral follicle count (AFC).|
223795444|NCT01237639|OTHER|Red blood cell Transfusion|Transfusion of Red blood cells to based on daily complete blood count
223795445|NCT05205265|DEVICE|Rivet Shunt|The Rivet Shunt device will be implanted via a percutaneous, transcatheter approach
223795446|NCT02959996|DRUG|Liposomal bupivacaine|liposomal bupivacaine injection in the Pfannenstiel incision
223795447|NCT02959996|DRUG|Placebo|placebo injection in the Pfannenstiel incision
223795448|NCT02962908|BIOLOGICAL|FLU-v|Subcutaneous injection in the upper arm with 500 ug of FLU-v as 0.5ml suspension in 0.01M HCl and 0.01M NaOH
223795449|NCT02962908|BIOLOGICAL|adjuvanted FLU-v|Subcutaneous injection in the upper arm with 500ug of FLU-v emulsified in 0.25ml of Montanide ISA-51 adjuvant (Seppic, France) and 0.25ml of water for injection
223795450|NCT02962908|BIOLOGICAL|Saline|Subcutaneous injection in the upper arm with 0.5ml of saline
223795451|NCT02962908|BIOLOGICAL|Adjuvanted placebo|Subcutaneous injection in the upper arm with an emulsion made with 0.25ml of Montanide ISA-51 adjuvant (Seppic, France) and 0.25ml of water for injection
223795452|NCT00002803|DRUG|cyclophosphamide|
223795453|NCT00002803|DRUG|doxorubicin hydrochloride|
223795454|NCT00002803|DRUG|vincristine sulfate|
223795455|NCT00002803|PROCEDURE|conventional surgery|
223795456|NCT03386370|DEVICE|"Indigo Mechanical Thrombectomy System"|"Removal of acute clot (\< 14 days) from the artery causing lower limb ischemia, using the Indigo System by Penumbra"
223795457|NCT00083018|GENETIC|cytogenetic analysis|
223795458|NCT00083018|GENETIC|proteomic profiling|
223795459|NCT00083018|OTHER|cytology specimen collection procedure|
223795460|NCT00083018|OTHER|immunohistochemistry staining method|
223795461|NCT00083018|OTHER|laboratory biomarker analysis|
223795462|NCT00083018|PROCEDURE|breast duct lavage|
223795463|NCT01823848|DRUG|Sodium phosphate enema|Rectally administered medication to treat constipation
223795464|NCT01823848|DRUG|Normal saline enema|Rectally administered medication to treat constipation
223795465|NCT01823848|DRUG|Mineral oil enema|Mineral oil enema administered to treat constipation. 66ml per rectum
223795466|NCT06064227|OTHER|training intervention|"In this experimental study, the subject matter and sessions of the educational intervention, the effect of which was tested, were prepared based on evidence on preventable risk factors through health behavior change. The educational intervention consists of the following topics:~Nutrition and physical exercise, chronic disease management and polypharmacy, anti-smoking and stress management, preventive health services, access to health screenings and immunization."
223795467|NCT02283931|DEVICE|TTE / NICOM|
223795468|NCT00072267|DRUG|7-hydroxystaurosporine|
223795469|NCT00072267|DRUG|topotecan hydrochloride|
223795470|NCT02768961|DRUG|sofosbuvir|"Subjects will be treated according to the current guidelines on HCV treatment taking into account the stage of fibrosis, genotype, previous treatments, etc.~Sofosbuvir will be used in association with ledipasvir. In some cases, ribavirin can be added to this combination according to current guidelines"
223795471|NCT02768961|DRUG|ledipasvir|"Subjects will be treated according to the current guidelines on HCV treatment taking into account the stage of fibrosis, genotype, previous treatments, etc.~Ledipasvir will be used in association with sofosbuvir. In some cases, ribavirin can be added to this combination according to current guidelines"
223795472|NCT03932604|DEVICE|Atrial sensing On mode|Single lead VDD-ICD programmed as atrial sensing On mode.
223795473|NCT01261338|DRUG|olestra|non-absorbable dietary fat
223795474|NCT05602636|DRUG|bupivacaine, midazolam|Patients will be provided with midazolam (up to 2 mg) if requested. No opioids will be administered before the incision. At the first patient complaint of pain, the intraoperative anesthesia team will document the quality and location of pain, and 50 microgram of fentanyl will be administered if the patient requested it or pain score more than 3
223795475|NCT05545553|DEVICE|Piezosurgery|Piezosurgery used as an osteotomy device
223795476|NCT05545553|DEVICE|Conventional burs|Conventional burs used as an osteotomy device
223795477|NCT01283412|DRUG|Placebo|Placebo (saline) iv. during the operation and stoped 30min before end of the surgery
223795478|NCT01283412|DRUG|Dexmedetomidine|Dexmedetomidine 0.1\~0.2ug/kg/h iv. during the operation, and stoped 30min before end of surgery
223795479|NCT00988312|BIOLOGICAL|autologous idiotype-protein pulsed dendritic cells|Vaccination with autologous idiotype-protein pulsed dendritic cells on 5 occasions every 4 weeks
223795480|NCT05714189|OTHER|Low FODMAP diet|The Low FODMAP diet is an avoidance diet and consist of three phases. In the first phase, all nutrients high in FODMAPs (high-FODMAPS) are eliminated from the daily diet over a period of 2 to 6 weeks to calm down the bowel. The second phase consists of the addition of FODMAP challenges. During this phase the patient continues the Low FODMAP diet, but will reintroduce one high-FODMAP nutrient once every three days to see whether exposure to this high-FODMAP causes IBS symptoms. When this is not the case, the patient can continue eating this high-FODMAP group in their daily diet. In the third and final phase, the diet is fully personalized. This personalization is based on whether the patient tolerated the high-FODMAP nutrient or not during the FODMAP challenges. Only when the high-FODMAP nutrient is not tolerated, it is advised to permanently remove it from the daily diet.
223795481|NCT05714189|OTHER|Endometriosis diet|The endometriosis diet The endometriosis diet is a patient experience based, avoidance diet developed by women diagnosed with endometriosis. Therefore no specific recommendations exist regarding the application of the endometriosis diet. With the endometriosis diet, women avoid nutrients they noticed provoked or aggravated their endometriosis-related symptoms such as red meat, coffee, sugar, lactose and soy.
223795482|NCT01295554|OTHER|NCE MRA and CE MRA|"Each patient will receive on the same day:~* NCE MRA~* CE MRA usually performed in the clinical routine~After each MRA examination, the CE images will be interpreted by a radiologist and the report transmitted to the prescriber within the usual delay. The radiologists in charge of this interpretation will not be involved in the evaluation of NCE images nor in the comparison between CE and NCE images."
223795483|NCT03195933|OTHER|Cortisol|We compared placebo vs. 20 mg oral dose of cortisol, which pharmacologically elevated cortisol levels.
223795484|NCT03195933|OTHER|Placebo|We compared placebo vs. 20 mg oral dose of cortisol, which pharmacologically elevated cortisol levels.
223795485|NCT04360733|OTHER|Blood draw|serial blood draw and subsequent deep immune phenotyping analysis, (ii.) immune activation assays, (iii.) transcriptome and (iv.) epigenome analysis in an overarching (v.) bioinformatics data analysis
223795486|NCT01544868|OTHER|Use of Stable Isotope to Measure Energy Expenditure and Protein Turnover|Two pre-dose urine specimens will be collected prior to an oral dose containing 0.22 g/kg total body water of 100% 18O water (or 1.2 g/kg per body weight of 10% 18O water) and 0.11 g/kg per body weight of 99.9% deuterium oxide. Then the patient will receive a single dose (4mg/kg, less than 2% of normal daily intake of 1.1g per person) of 15N glycine tracer. For this, patients will drink a dose of 15N glycine (4mg.kg 1dissolved in 20 ml of saline) mixed in 50 cc of apple juice or other liquid beverage, followed by a 50 cc wash of water. 24 hour urine collection will commence immediately. Twenty-four hour urines will be used for determining the 15N NH3 and 15N urea enrichment. Each urine container will contain 5 ml of 15N HCl for trapping the urinary ammonium. Urine will be collected each day for 3 days, for determination of the total urinary nitrogen, urea creatinine, and ammonia excretion.
223795487|NCT05983822|DEVICE|Technological Group|Specific rehabilitation for the recovery of hand function using the end-effector robot
223795488|NCT05983822|OTHER|Conventional Treatment|Conventional rehabilitation
223795489|NCT04216810|OTHER|muscle strengthening exercises|segmental stabilization exercises
223795490|NCT04216810|OTHER|muscle strengthening exercises and dry cupping|segmental stabilization exercises and dry cupping
223795491|NCT00000502|PROCEDURE|cardiopulmonary resuscitation|
223795492|NCT02313428|DEVICE|Topical Oxygen Chamber for Extremities|Surrounds a limb and applies oxygen topically at a pressure slightly greater than atmospheric pressure to aid healing of chronic skin ulcers
223795493|NCT01521676|GENETIC|molecular alteration|research of molecular alteration
223795494|NCT02055131|DRUG|aspirin|
223795495|NCT00564122|DEVICE|Artificially-Intelligent Stethoscope|After subjects' medical visits are complete, the heart sounds of all subjects will be recorded and assessed by an artificially-intelligent stethoscope. Attempts will be made to make satisfactory 20-second recordings from a total of eight positions on the chest with the patient in supine and upright positions.
223795496|NCT00564122|OTHER|Physical Examination|A Pediatric Cardiologist will examine each subject to the extent needed to make clinical assessments. This represents the ordinary standard-of-care.
223795497|NCT05374421|DEVICE|Erchonia® THL™|The Erchonia® THL™ is made up of (2) 405-nanometer violet laser diodes mounted in a portable handheld device. The diodes are positioned approximately 4 inches from the skin and applied in a continuous back and forth sweeping motion from the top of the ear down the side of the neck. The treatments will be self-administered by the subject at his or her's place of residence, once per day for 28 days. Each procedure administration lasts 5 minutes per ear, for a total of 10 minutes.
223795498|NCT05374421|DEVICE|Placebo Laser|The Placebo Laser has the same appearance as the Erchonia® THL™ but does not emit any therapeutic light. The diodes are positioned approximately 4 inches from the skin and applied in a continuous back and forth sweeping motion from the top of the ear down the side of the neck. The treatments will be self-administered by the subject at his or her's place of residence, once per day for 28 days. Each procedure administration lasts 5 minutes per ear, for a total of 10 minutes.
223795499|NCT05768698|DIAGNOSTIC_TEST|Software algorithm|Validation of a software package based on an artificial intelligence algorithm for automated non-invasive estimation of LVFP against invasively measured ones by left and right heart catheterization
223795500|NCT05977894|OTHER|Reduced Environmental Stimulation Therapy|"During floatation-REST (Reduced Environmental Stimulation Therapy), the participant enters a tank that is approximately 5 feet wide, 7 feet long and 5 feet high. The tank is filled with a 10 inch height of water containing enough Epsom salt (magnesium sulfate) to create body buoyancy. The water temperature is 93.5 degrees F, an approximate equivalent for normal skin temperature. Ear plugs are used to mitigate sound and the tank is without light illumination to prevent visual stimulation. The sessions are typically 60 minutes in duration. The individual is Floating-in Solitude, Darkness, Silence, and Thermal-Neutrality. This experience reduces external sensory nervous system input and creates an extraordinarily deep state of mental and physical relaxation."
223795501|NCT05253872|OTHER|The MelaCare intervention|"The primary principles applied will be:~* Meta-cognitive strategies and normalization of emotions~* Self efficacy related to SSE and knowledge on when to seek a doctor for clinical examination~The intervention will include 4 components:~* An educational booklet~* Doctor consultation to ensure correct SSE skills and compliance to the protocol~* 3-5 sessions with a experienced and specially trained melanoma nurse~* Use of patients' answers from the Patient Reported Outcome 'Functional Assessment of Cancer Treatment - Melanoma' (FACT-M) at the nurse sessions to address current emotional and/or physical sequelae."
223795502|NCT05548101|PROCEDURE|ICSI|Using the injecting pipet, one sperm will be isolated. Using the tip of the injecting pipet, the sperm tail will be broken by trapping it between the pipet and bottom of the dish. The sperm will be picked up in the pipet. The oocyte will be positioned so the polar body is at the 12 o'clock or 6 o'clock position. The sperm injecting pipet will be positioned at the 3 o'clock position of the oocyte. The injecting pipet will be advanced into the oocyte cytoplasm and the cytoplasm will be gently aspirated until the oocyte membrane breaks. The sperm will then be injected into the cytoplasm of the oocyte. The pipet will then be withdrawn from the oocyte.
223795503|NCT05440864|DRUG|Tremelimumab|Pre-operatively Tremelimumab will be administered first for 1 hour; the Durvalumab infusion (1hr) will start approximately 1 hour (maximum 2 hours) after the end of the Tremelimumab infusion. Post-operatively patients will receive Durvalumab Q4W to complete up to 12 months of treatment or a maximum of 11 cycles of adjuvant Durvalumab
223795504|NCT00557115|OTHER|Early pulmonary rehabilitation (EPR)|Multidisciplinary exercise programme in the format of standard pulmonary rehabilitation. Consists of 2 supervised exercise and educations sessions per week for up to 16 sessions within 3-months. Participants are encouraged to keep an exercise diary at perform at least one exercise session at home unsupervised.
223795505|NCT00064805|BEHAVIORAL|Cognitive Therapy to Improve Reading|
223795506|NCT02899728|DRUG|Carboplatin|Given IV
223795507|NCT02899728|DRUG|Cediranib|Given PO
223795508|NCT02899728|DRUG|Cediranib Maleate|Given PO
223795509|NCT02899728|DRUG|Cisplatin|Given IV
223795510|NCT02899728|DRUG|Etoposide|Given IV
223795511|NCT02899728|DRUG|Olaparib|Given PO
223795512|NCT00501150|DRUG|linezolid|Linezolid is an antimicrobial with activity against MRSA that can be given orally.
223795513|NCT01034124|DRUG|warfarin, vitamin K, midazolam|warfarin tablet single dose (10 mg) vitamin K tablet single dose (10 mg) midazolam syrup single dose (5 mg)
223795514|NCT02448784|DRUG|Donepezil Hydrochloride|Initial dose for oral use is 3 mg once daily. The dose is increased to 5 mg after 1-2 weeks. Following at least 4 weeks of dosing at 5 mg, the dose is increased to 10 mg. The dose may be decreased to 5 mg depending on the symptoms of the participant.
223795515|NCT00208208|DRUG|Ziprasidone|
223795516|NCT02889991|OTHER|High Intensity Dry Needling|"This technique follows the criteria established by Dr Hong C-Z. This technique is known as fast in and fast out technique and uses repeated insertion of the acupuncture needle in the myofascial trigger point, with the aim to get multiple local twitch responses. The technique ends when the local twitch responses disappear."
223795517|NCT02889991|OTHER|Low intensity Dry Needling|Technique proposed by the main investigator and based on the studies of Professor Dr. Jay P. Shah and the mechanisms of neuromodulation that transmits us the acupuncture scientific evidence.
223795518|NCT02889991|OTHER|Fascial Mechanotransduction Dry Needling|"The Fascial Mechanotransduction Dry Needling Technique, strikes with the acupuncture needle until it reaches and pierces the myofascial trigger point. Then the acupuncture needle is rolled in the connective tissue, which causes an intense coupler that we define as needle grasp. Finally, the acupuncture needling is pulled-out twice.~The screwing and the two pull-out of the acupuncture needle is performed in the infraspinatus and supraspinatus muscles and we describe it as mechanotransduction cycle. Each cycle lasts 30 seconds and the whole technique lasts 3 minutes per session."
223795519|NCT02889991|OTHER|Technique Placebo of Dry Needling|"Technique with a total duration of 3 minutes per session:~* To locate the myofascial trigger points of infraspinatus and supraspinatus muscles and put each bridle on them.~* Monitor longitudinally taut band, with index and middle fingers.~* Percuss with tube and needle placebo (Sham needle) on Infraspinatus.~* Remove the tube and needle placebo from the device. Reintroducing the placebo needle into the tube and strike on the supraspinatus. Repeat this sequence without interruption for 3 minutes.~* Remove the bridles and perform hemostasis with cotton.~* We will give end to the technique placebo of dry needling."
223795520|NCT03254680|DIETARY_SUPPLEMENT|Turmeric|Twenty patients will be enrolled and treated with a stable dose of orally administered turmeric oil daily for 3 months.
223795521|NCT05652517|PROCEDURE|Vein of Marshall ethanol infusion|Vein of Marshall ethanol infusion performed during the radiofrequency catheter ablation of persistent or long-standing persistent atrial fibrillation.
223795522|NCT02157805|OTHER|beef meat|"Meat cooking conditions~1. st condition : beef meat cooked during 5 minutes at 55°C~2. nd condition : beef meat cooked during 30 minutes à 90°C"
223795523|NCT05290558|DRUG|Bu Shen Yi Jing Pill|"Bu Shen Yi Jing Pill contained Radix Pseudostellaria, Fructus Lycii, Radix Et Rhizoma Salviae, Rhizoma Dioscorea, Semen Plantaginis, Semen Cuscuta, Patriniae Herba, Herba Epimedii, Radix Ophiopogonis, Fructus Rubi, Fructus Corni, Bupleurum roots, Fructus Schisandrae Chinensis, Radix Et Rhizoma Glycyrrhizae.~Dosage of the study drug is as follows: 3 pills each time, for 3 times a day, taken for 6 days every week for 1 year"
223795524|NCT05290558|DRUG|Placebo Drug|"Placebo contains the ingredients: grounded black rice and permitted colouring. The ingredients are encapsulated within a gelatine capsule.~Dosage of the study drug is as follows: 3 pills each time, for 3 times a day, taken for 6 days every week for 1 year"
223795525|NCT05214209|BEHAVIORAL|Digital health supported|Participants will be issued a fitness tracker, a Bluetooth enabled glucometer, and a custom developed app which they can communicate digitally to the study investigators either as a group or individually. In the beginning of the study, participants will be taught on how to use the program, how to interact with their coach, and the importance of maintaining motivation throughout the program. Participants will have access to a pharmacist-participant messaging, group messaging, daily challenges for behavior change, education articles (weekly bite-sized content over 4 weeks), food logging, steps and exercise logging, and feedback. They will be asked to log their weight, meals, and physical activity within the program on a weekly basis. Pharmacist will monitor participant progress through a web-based dashboard. Community pharmacist will be assisting users in setting specific, measurable, attainable, realistic, and time-based goals on a weekly basis.
223795526|NCT05214209|BEHAVIORAL|Usual care|Participants will be issued a fitness tracker and Bluetooth enabled glucometer but these functions will not be enabled or linked to any app. All participants will be given physical tracking sheets to log in their food intake, blood glucose levels and food diary but will not have access to a personal coaching. Participants are free to seek any assistance for their medical care during the study period.
223795527|NCT03789721|OTHER|Medical Record Abstraction|Collect clinical and epidemiological data through medical record abstraction and self-reported questionnaire survey semi-annually.
223795528|NCT03789721|OTHER|Biospecimen Sample Collection|Collect research samples, when feasible for those diagnosed with ALD.
223795529|NCT05557942|DRUG|AV-101|AV-101 (imatinib) administered via dry powder inhalation
223795530|NCT03808675|BEHAVIORAL|Aerobic walking|The investigators will use self-administered continuous walking exercise at a moderate intensity level, defined as 40-59% of heart rate reserve or 64-77% of heart rate at gas exchange threshold (HRGET) by ACSM as in the investigators' preliminary study (PMID: 24991037 PMCID: PMC4132568). The HRGET will be determined as the heart rate at VO2max during graded cycle ergometry. The total duration of the exercises will be 150 min/week per 2008 Physical Activity Guidelines for Americans and American Heart Association recommendations, conducted in three 50 min sessions. The aerobic walking intervention will take place outdoors (e.g., trails, sidewalks, parks) or indoors (e.g., track in a local gym or a mall) depending on the preferences of the subject and weather. Session duration will be 20 min the first week and will be advanced by 5 min per week over 6 weeks.
223795531|NCT03808675|BEHAVIORAL|Usual care with PD specific health education|"In this study, patients will receive their usual medical treatment for motor and non-motor symptoms from their~primary neurologist. The investigators will use a streamlined form of PD specific health education prepared by the VA: My Parkinson's Story, which consists of a series of short videos prepared by the VA PADRECCs addressing various aspects of PD. These 6-12 minutes long videos are freely available on YouTube. The investigators can also provide them on a CD if subjects desire. They start with a patient testimony about the topic of the episode, followed by comments of experts in the field. The title of the episodes are: Early Parkinson's, Medications, Exercise, Memory, Visual Disturbances, Depression, Sleep, Speech and Swallowing, Impulsive Behaviors, Driving, Pain, Dyskinesias, Deep Brain Stimulation, Advanced Parkinson's Disease, Falls, The Caregiver, Hospitalization, Genetics, Environmental Exposure, Atypical Parkinsonism"
223795532|NCT06216002|DIAGNOSTIC_TEST|Train of four nerve stimulator|Patient receive nerve stimulation by TOF-scan equipment at recovery room after surgery.
223795533|NCT06218667|DRUG|Copanlisib|Dose level 1 (starting dose): 45 mg of copanlisib IV weekly x 3 weeks on/1 week off Dose level 2 (standard dose): 60 mg of copanlisib IV weekly x 3 weeks on/1 week off
223795534|NCT06218667|DRUG|Degarelix|Degarelix (GnRH antagonist): 240 mg loading dose sub-cutaneous once on C1D1; 80 mg maintenance dose on C2D1 and C3D1.
223795535|NCT06218667|PROCEDURE|Radical Prostatectomy|Standard treatment
223795536|NCT03353818|BEHAVIORAL|Golf|A free golf course and free membership for one year in a golf club will be given to participants.
223795537|NCT03353818|BEHAVIORAL|No intervention|Patients acting as controls will not be restricted in any ways.
223795538|NCT03961165|DRUG|Butylscopolamine Bromide 20 MG/ML|1 mL Butylscopolamine Bromide 20 mg/mL i.v. Single dose.
223795539|NCT03961165|DRUG|Sodium Chloride 9mg/mL|1 mL Sodium Chloride 9 mg/mL i.v. Single dose.
223795540|NCT00371891|PROCEDURE|Multidetector Computed Tomography Coronary Angiography|1 Multidetector Computed Tomography Coronary Angiography
223795541|NCT01076569|OTHER|laboratory biomarker analysis|Correlative studies
223795542|NCT02723838|BIOLOGICAL|REOLYSIN®|3 cycles (each cycle = 21 days). Cohort 1: 3x10E10 TCID50 intratumoral via cystoscopy on Day 1 of each cycle. Cohort 2: 3x10E10 TCID50 intratumoral via cystoscopy on Day 2 of each cycle.
223795543|NCT02723838|DRUG|Gemcitabine|3 cycles (each cycle = 21 days). Cohort 1: 1000mg/m2 intravenously on Day 2 and Day 9 of Cycle 2 and Cycle 3. Cohort 2: 1000mg/m2 intravenously on Day 1 and Day 8 of each cycle.
223795544|NCT02723838|DRUG|Cisplatin|3 cycles (each cycle = 21 days). Cohort 1: 70 mg/m2 intravenously on Day 2 of Cycle 2 and Cycle 3. Cohort 2: 70 mg/m2 intravenously on Day 1 of each cycle.
223795545|NCT02680054|DRUG|Insulin, Asp(B28)-|This insulin dose is sometimes given for fat and protein content of food in children using insulin pumps, in prolonged boluses. The investigators are replicating this in children using multiple insulin injections at various times related to the meal
223795546|NCT06383975|PROCEDURE|Pulsed field ablation with posterior wall isolation|Extended pulmonary vein isolation including posterior wall isolation using pulsed field ablation
223795547|NCT06383975|PROCEDURE|Radiofrequency ablation and vein of Marshall ethanolization|Radiofrequency pulmonary vein re-isolation (when necessary), vein of Marshall ethanol infusion with roof and mitral lines
223795548|NCT04800874|DRUG|BBP-418|BBP-418 is being developed for the treatment of patients with Limb-Girdle Muscular Dystrophy Type 2I (LGMD2I) for which no approved therapy currently exists. It targets the molecular defect at the source by supplying excess substrate to the mutant enzyme thus boosting glycosylation of muscle α-dystroglycan. The BBP-418 drug product will be packaged in sachets and provided in a carton for in-clinic and at home use.
223795549|NCT05568888|DRUG|BE1116|4-Factor Prothrombin Complex administered by intravenous (IV) infusion
223795550|NCT05568888|DRUG|Placebo|Administered by IV infusion
223795551|NCT00003718|DRUG|temozolomide|
223795552|NCT04398277|BEHAVIORAL|Daily Coping Toolkit|"1. Emotion Labelling Activity: Participants rate 10 discrete negative and positive emotional words on a likert scale (0-4).~2. Expressive Writing and Self Distancing Activity: Participants respond to an open-ended prompt to write about their day in an open text box in response to the prompt: What was today like for you? After this is completed, they are prompted that if the experience was very challenging, to revisit that experience in their mind by taking a fly on the wall perspective (Kross \& Ayduk, 2016).~3. Positive Emotion Generation Activity (1 v. 2 prompts) Participants are prompted to take a deep breath and then respond to 1 (or 2) of 8 possible prompts in which they can generate positive emotions. In response to each, they are asked to describe their thoughts or memories in open-ended text box."
223795553|NCT06585969|DRUG|Trastuzumab deruxtecan (T-DXd)|Trastuzumab deruxtexan every three weeks
223795554|NCT06585969|DRUG|Ribociclib with ET|Ribociclib with endocrine therapy
223795555|NCT06585969|DRUG|Abemaciclib with ET|Abemaciclib with endocrine therapy
223795556|NCT06814002|DIETARY_SUPPLEMENT|Meal with 400 kilocalories|Meal with 400 kilocalories
223795557|NCT06814002|DIETARY_SUPPLEMENT|Meal without calories|Meal without calories
223795558|NCT05009849|OTHER|Yoga Exercises|The exercises in the Exercise I arm (Yoga and conventional exercises) will be upgraded to Phase II. Patients will be allowed to attend a minimum of four out of seven days in Phase I and II. Patients will be assessed at 6-9 months for compliance to phase II exercises. Only if patients are fulfilling the criteria for accuracy, sequence and duration of phase II exercises, will they be taught phase III exercises. Patients who are unable to do phase II exercises accurately or demonstrate non compliance to the exercise routine at first follow up visit/ 6-9 months will be re taught phase II exercises. These patients will be upgraded to phase III only if able to perform phase II adequately at assessment. Six months after completion of phase III exercises, patients will be assessed for compliance to phase III exercises. These women's will be assessed at the subsequent 6-9 month follow up and compliance will be evaluated.
223795559|NCT03656133|RADIATION|Radiotherapy fractionation|Standard fractionation at 2Gy once daily or Hyperfractionation at 1.2 Gy twice daily (≥ 6 hours apart)
223795560|NCT03829215|DEVICE|CAERVest cooling device|The CAERVest device will be filled and placed on the supine patient's chest immediately after return of spontaneous circulation. After admission to the emergency department, the device will be removed, when a temperature below 34°C is reached.
223795561|NCT01839734|DRUG|Lubiprostone|Lubiprostone 24 mcg by mouth (PO) once-daily
223795562|NCT00655980|DRUG|Vitamin B12 and folic acid|1 mg vitamin B12 IV 5 mg folic acid IV in 100 ml NS infusion
223795563|NCT00655980|DRUG|Nitrous oxide and placebo|
223795564|NCT00655980|OTHER|standard of care|
223795565|NCT01953796|DRUG|clomiphene|For both protocols follow up of the follicular growth has been made by frequent tvUSS monitoring, which have the advantage of providing direct information about the size and number of follicle and measurement of endometrial thickness during clomiphene medication.
223795566|NCT02353923|DIETARY_SUPPLEMENT|OcuStem Supplementation|2800 mg daily dosage of OcuStem, 2 capsules BID.
223795567|NCT01146236|DEVICE|Sutures|Orthopedic surgical wounds closed with sutures
223795568|NCT01146236|DEVICE|Staples|Orthopedic surgical wounds closed with metallic staples
223795569|NCT03200522|OTHER|Prudent diet|Six days of meals provided with high amounts of fruits and vegetables, whole grains, fiber, omega-3 fatty acids, low-fat dairy products, and overall high levels of antioxidants.
223795570|NCT03200522|OTHER|Western diet|Six days of meals provided with high amounts of processed foods, fast foods, sweets, omega-6 fatty acids, and a low intake of fiber.
223795571|NCT06491121|OTHER|Technology supported High Intensity Training|patients will perform a 12-week HIT program comprising of 1,5h exercise therapy sessions twice a week. The program is a combination of cardiorespiratory interval, general resistance, and core muscle strength training, all at high intensity. phase 2 is a similar 12-week HIT program at home, supported by a smartphone application
223795572|NCT06491121|OTHER|Moderate Intensity Training|patients will perform a 12-week MIT program comprising of 1,5h exercise therapy sessions twice a week. The program is a combination of cardiorespiratory continuous load, general resistance and core muscle training, all at moderate intensity. Phase 2 is a similar 12-week MIT program at home with an exercise program on paper.
223795573|NCT06491121|OTHER|High Intensity Training|patients will perform a 12-week HIT program comprising of 1,5h exercise therapy sessions twice a week. The program is a combination of cardiorespiratory interval, general resistance, and core muscle strength training, all at high intensity. phase 2 is a similar 12-week HIT program at home with an exercise program on paper.
223795574|NCT06467006|OTHER|Use of IA for proximal humeral fracture prognosis|None (prognosis study)
223795575|NCT06100627|DRUG|AP301|Orally administered
223795576|NCT05540522|BIOLOGICAL|Quadrivalent influenza modRNA vaccine|Quadrivalent influenza modRNA vaccine (single dose)
223795577|NCT05540522|BIOLOGICAL|Quadrivalent influenza vaccine|Licensed quadrivalent influenza vaccine (single dose)
223795578|NCT05555394|OTHER|Basic Body Awareness Therapy|The intervention will be twice a week during 12 weeks. It lasts 90 min of movements of daily life, massage and self-reflections.
223795579|NCT05555394|OTHER|Stretching Exercise|It consists in stretching movements of whole body
223795580|NCT02247505|DRUG|Harnal-D Cap. 0.2mg|
223795581|NCT02247505|DRUG|Cialis Tab. 5mg|
223795582|NCT03820661|DEVICE|Ultrasound|High resolution ultrasound pre-operatively and intra-operatively
223795583|NCT06606470|BEHAVIORAL|All providers Better Communication Skills program' (ABCs) interprofessional provider education|The 'All providers: Better Communication Skills program' (ABCs) is a virtual, person-centred education curriculum for interprofessional health care providers. The ABCs program adopts a blended format (i.e., participants engage in both asynchronous online modules \[five\] and synchronous interactive workshops \[three\]) that has relevance to learners and clinicians at all levels of training and practice. The ABCs program focuses on four essential elements of being a skillful communicator: principles of effective communication, conversation structure, communication skills, and reflective practice. The program consists of virtual modules that provide any clinician with practical tools, tips, and strategies to implement when communicating with seriously ill patients and their families. Terminology is clarified and consistent, the complexities of conversations are simplified and the fundamental approach and structure can be applied to different contexts.
223795584|NCT05435612|DEVICE|cochlear implant|Patients enrolled in the study undergo the cochlear implant surgery.
223795585|NCT03881345|DRUG|Anticoagulants|anticoagulation according to the main diagnosis
223795586|NCT03881345|PROCEDURE|Open surgery|removal of blood clots with open surgery
223795587|NCT03881345|PROCEDURE|Thrombolysis|removal of blood clots with thrombolysis
223795588|NCT03881345|PROCEDURE|Venous stenting|elimination of vein obstruction by stenting
223795589|NCT06670326|BEHAVIORAL|Imagery Rescripting|Experimental: Baseline-Preparation-Imagery Rescripting-Post Treatment Each participant follows this sequence: (1) 5-9 weeks waitlist during which no treatment is offered; (2) 4 weekly preparatory sessions. During these sessions the rationale of ImRs will be explained in more detail and a list of painful (childhood) memories to be addressed with ImRs is to be compiled, based on any further input from the patient; and a case conceptualization is made; (3) 12 sessions (45-60 minutes) of ImRs will be offered to participating patients. The treatment for PAD will be based upon the protocol described by Arntz \& Weertman (1999); (4) After end of active treatment (ImRs) 4 weeks follow during which only weekly assessments are done.
223795590|NCT06669923|BEHAVIORAL|iSIPsmarter Program|web-based behavioral intervention to reduce sugary drink intake
223795591|NCT06669923|BEHAVIORAL|Patient Education|website with information about cancer screening and prevention (e.g. screening tests for seven types of cancer)
223795592|NCT06669065|DEVICE|extraoral versus intraoral scanning techniques|different data acquisition techniques for full-arch dental implants
223795593|NCT06669468|OTHER|PFME|All patients were asked to mark the exercise at a daily home schedule. Patients who did not complete more than 20% of the list according to the daily home program were excluded from the study.
223795594|NCT06669468|OTHER|PFME + Anal ES|Anal ES was applied 3 days a week, 20 minutes a day, for a total of 24 sessions for 8 weeks.
223795595|NCT06669468|OTHER|PFME + Perineal ES|Perineal ES was applied 3 days a week, 20 minutes a day, for a total of 24 sessions for 8 weeks.
223795596|NCT03754803|OTHER|HIV symptom distress module (SDM) questionnaire|The SDM is a 20-item self-reported measure that addresses the presence and perceived distress linked to symptoms commonly associated with HIV or its treatment.
223795597|NCT03754803|OTHER|HIV treatment satisfaction questionnaire (TSQ)|The HIV TSQ is a 10-item-self-reported scale that measures overall satisfaction with treatment and by specific domains e.g., convenience and flexibility.
223795598|NCT05933148|DEVICE|Siemens 7T MRI|The active neurofeedback session will be done within the 7T MRI.
223795599|NCT05933148|DEVICE|Sham Neurofeedback|The sham Neurofeedback resembles the active condition but participants will not see their own brain activity and will instead view a past participant's active feedback from their same population group.
223795600|NCT05802745|OTHER|Reintubation|Patients requiring re-intubation for acute respiratory failure.
223795601|NCT00439907|PROCEDURE|End-to-end repair of the external anal sphincter muscle|Surgical procedure: End-to-end repair of the external anal sphincter muscle
223795602|NCT00439907|PROCEDURE|Overlap repair of the external anal sphincter muscle|Surgical procedure: Overlap repair of the external anal sphincter muscle
223795603|NCT01951482|DRUG|Pemetrexed/Platinum|pemetrexed 500mg/m2 combined with cisplatin 75mg/m2 or nedaplatin 80mg/m2 intravenously on day 1 of each 3-week cycle for four to six cycles, followed by pemetrexed maintenance every 3 weeks.
223795604|NCT01951482|DRUG|Bevacizumab and Pemetrexed/platinum|bevacizumab (7.5mg/kg, intravenously on day 1 of each 3-week cycle) plus pemetrexed-platinum chemotherapy (pemetrexed 500mg/m2 combined with cisplatin 75mg/m2 or nedaplatin 80mg/m2 intravenously on day 1 of each 3-week cycle) for four to six cycles, followed by bevacizumab plus pemetrexed maintenance every 3 weeks.
223795605|NCT05239039|DRUG|spesolimab|spesolimab
223795606|NCT06669637|DEVICE|Ablation|Ablation procedure for Atrial Fibrillation
223795607|NCT06670898|DRUG|[14C] NS-580|Oral suspension
223795608|NCT05910736|BEHAVIORAL|Medicare AWV Practice Redesign Toolkit|Electronic health record-based tools coupled with practice redesign strategies and approaches
223795609|NCT05424068|BEHAVIORAL|In-person rehabilitaiton group|participants who have chosen to complete the study intervention by coming in for their 8 week education and exercise sessions.
223795610|NCT05424068|BEHAVIORAL|Virtual rehabilitation group|Participants who have chosen to complete the study virtually instead of in-person sessions.
223795611|NCT06670807|DIETARY_SUPPLEMENT|Probiotic Arm|Fifty of the participants will consume 1 capsule/day of the dietary supplement AB-MIND+CECT7481 for 16 weeks. The capsule should be taken just before breakfast. The researchers will instruct the volunteers to maintain their usual lifestyle (diet, physical activity, sleep habits) throughout the intervention period.
223795612|NCT06670807|OTHER|Placebo|Fifty of the participants will consume 1 capsule/day of the PLACEBO for 16 weeks. The capsule should be taken just before breakfast. The researchers will instruct the volunteers to maintain their usual lifestyle (diet, physical activity, sleep habits) throughout the entire intervention period.
223795613|NCT06669078|DRUG|Nal-lRl+Oxaliplain+5- FU +PD 1|Nal-lRl+Oxaliplatin+5- FU +PD-1, these drugs are given on d1, d15, 28 days as one cycle, SBRT is performed during the third and fourth cycle.
223795614|NCT06669078|DRUG|Nal-lRl+Oxaliplain+5- FU|Nal-lRl+Oxaliplatin+5- FU, these drugs are given on d1, d15, 28 days as one cycle.
223795615|NCT07127640|OTHER|Exercise|An aerobic exercise session on a recumbent exercise bike with a 5-minute warm-up period, followed by a 40-minute cool-down period and ending with a 5-minute cool-down at decreasing speed.
223795616|NCT07127952|DEVICE|Video Capillaroscopy|A non-invasive imaging technique used to assess capillary structure and morphology in the nailfold area, commonly used in evaluating microvascular changes associated with connective tissue diseases.
223795617|NCT06615531|BEHAVIORAL|Advanced multi-component meditation practice|The study intervention is a multi-component advanced guided meditation practice that incorporates elements of focused attention, non-dual, and loving kindness and compassion meditation techniques as well as breathwork components. The practice includes sitting, lying down, standing, and walking components and is carried out at 7-day advanced meditation retreats lead by Joe Dispenza, D.C. These retreats include lecture-based instruction and up to 35 hours of meditation practice.
223795618|NCT06669910|OTHER|only assesment|only assesment
223795619|NCT06507605|BIOLOGICAL|R21|R21 is a portion of Pf circumsporozoite protein fused with hepatitis B surface antigen in the form of non-infectious virus-like particles (VLPs) produced in yeast cells (Hansenula) by recombinant DNA technology.
223795620|NCT06507605|BIOLOGICAL|Pfs230D1-CRM197|Recombinant Pfs230 domain 1 (Pfs230D1; a subdomain of a surface antigen of gametocytes, gametes, and zygotes, in the mosquito stage of Pf conjugated to CRM197 and adjuvanted with 50μg of Matrix-M.
223795621|NCT06507605|BIOLOGICAL|Pfs230D1-EPA|Recombinant Pfs230D1 conjugated to a recombinant Pseudomonas aeruginosa ExoProtein A (EPA)
223795622|NCT06507605|OTHER|Matrix-M|Vaccine adjuvant that contains purified saponin (from Quillaja saponaria Molina) and cholesterol and phosphatidyl choline. Matrix-M will be used at a 50μg dose for vaccinations.
223795623|NCT06293235|OTHER|Lifestyle and metabolic indicators|Socio-demographics, health history, behavioural characteristics, environmental exposures, anthropometric measurements, body fat composition, metabolic and stress biomarkers, semen physical and molecular characteristics.
223795624|NCT06464835|DEVICE|Transcranial magnetic stimulation|The treatment parameter for iTBS was 80% stimulus intensity. The stimulation frequency was 50Hz in the plexus and 5Hz in the interplexus. Each burst stimulus consisted of 3 consecutive pulses, 2s stimulus, 8s interval, and repeated 20 times, a total of 600 pulses, and the duration of stimulation was 189s. NMES treatment parameters for output waveform for two-way square wave, wave width 700 ms, positive and negative half wave (300 ms) between 100 ms intermittent, stimulating frequency 50 hz, treatment when the output intensity range of 0 \~ 25 ma, stimulating electrodes pasted in bilateral mandibular hyoid muscle movement points, output intensity in patients with tongue bone muscle group it is advisable to have a sense of fashion, extrusion. Each treatment lasted 30 minutes, once a day, 5 times a week for 2 weeks.
223795625|NCT05705687|DRUG|BEP Protocol|anticancer therapy
223795626|NCT05705687|DRUG|Dose-dense regimen|T-BEP-Oxaliplatin followed by Cisplatin - Ifosfamide - Paclitaxel
223795627|NCT05705687|PROCEDURE|Early tumor resection or HD-CT|TIP protocol + early surgery or high-dose chemotherapy if surgery not feasible or metastatic disease
223795628|NCT04201548|OTHER|Endurance Training|"These patients will perform an aerobic exercise with a moderate intensity cycle ergometer. The exercise session on an exercise bike will last 33 minutes at a constant load, starting from an intensity equal to the load of 60% of the maximum load (max watt) achieved at the incremental test.~Working volume = 60 X 33 = 1980"
223795629|NCT04201548|OTHER|Long High Intensity Interval Training|"The patients assigned to the Long-HIIT group will perform a 32-minute interval work with 4x4 protocol (active phase x passive phase) performing 4 minutes at an intensity of 80-85% of the Max Watt (active phase) spaced from 4 minutes to 40% of the Max Watt (passive phase). The goal of high intensity work will be to bring the heart rate to a level close to 85-90% of the maximum cardiac frequency achieved in the incremental exercise test. If this target is not reached within the session, the load of the next one will be increased in the following session with 10 watt steps.~Working volume = 16 X 85 + 16 x 40 = 2000"
223795630|NCT04201548|OTHER|Short High Intensity Interval Training|"The patients assigned to the Short-HIIT group will perform an interval work with initial intensity equal to 100% of the Max Watt highlighted in the incremental exercise stress test in the phase (30 seconds) followed by a passive phase of 30 seconds at 50% of the Max Watt for a period of 26 minutes a day. The intensity will be gradually increased during the sessions with symptom-based progression, according to the protocol of Maltais et al. with steps of 10 watts each increment.~Working volume = 13 X 100 + 13 x 50 = 2050"
223795631|NCT03555331|BEHAVIORAL|Child Safety Control Intervention|In the study period which spanned from early infancy through age 3 years, the child safety intervention group was given an educational program with messages focused on child and home safety, guided by the American Academy of Pediatrics and the Academy's guide for health supervision, Bright Futures. The observation-only study extension will not include any intervention, rather it will assess any long term outcomes from the education given to parents when their children were 0-2 years old.
223795632|NCT03555331|BEHAVIORAL|Responsive Parenting Intervention|During infancy, the Responsive Parenting group was given an educational program containing messages providing developmentally appropriate guidance to parents of infants on responsive parenting and healthy lifestyle aimed at preventing rapid weight gain in infancy and overweight at age 3 years. The new study period will not include any intervention, rather it will assess any long term outcomes from the education given to parents when their children were 0-2 years old.
223795633|NCT06925022|OTHER|Strength training session during Early Follicular Phase|"The strength training sessions follow guidelines and recent meta-analyses to optimize long-term outcomes. Participants will complete a standardized warm-up protocol consisting of 5 minutes on a stationary bike, lower limb mobility exercises, and 5 repetitions at 40% of their 1-RM on each machine before each strength training session. Subsequently, they will perform four exercises for the lower limbs, including bilateral leg press, unilateral leg extension, unilateral hip extension, and plantar flexion, using conventional weight machines (. Session intensity will be set at 70-75% of 1-RM, with a volume of 4 sets of 10 repetitions, leaving 1-2 reps in reserve (RIR), and with 120 seconds of rest between sets.~This phase occurs at the beginning of the menstrual cycle (days 2-5 after the onset of menstruation)."
223795634|NCT06925022|OTHER|Strength Training Protocol during Late Follicular Phase|The strength training sessions follow guidelines and recent meta-analyses to optimize long-term outcomes. Participants will complete a standardized warm-up protocol consisting of 5 minutes on a stationary bike, lower limb mobility exercises, and 5 repetitions at 40% of their 1-RM on each machine before each strength training session. Subsequently, they will perform four exercises for the lower limbs, including bilateral leg press, unilateral leg extension, unilateral hip extension, and plantar flexion, using conventional weight machines (. Session intensity will be set at 70-75% of 1-RM, with a volume of 4 sets of 10 repetitions, leaving 1-2 reps in reserve (RIR), and with 120 seconds of rest between sets. This phase occurs approximately between days 11-13 of the menstrual cycle.
223795635|NCT06925022|OTHER|Strength Training during Mid-Luteal Phase|The strength training sessions follow guidelines and recent meta-analyses to optimize long-term outcomes. Participants will complete a standardized warm-up protocol consisting of 5 minutes on a stationary bike, lower limb mobility exercises, and 5 repetitions at 40% of their 1-RM on each machine before each strength training session. Subsequently, they will perform four exercises for the lower limbs, including bilateral leg press, unilateral leg extension, unilateral hip extension, and plantar flexion, using conventional weight machines (. Session intensity will be set at 70-75% of 1-RM, with a volume of 4 sets of 10 repetitions, leaving 1-2 reps in reserve (RIR), and with 120 seconds of rest between sets. This phase occurs around days 19-28 of the menstrual cycle, following ovulation.
223795636|NCT07127458|DRUG|Adolescent PCOS group receiving oral contraceptives|Participants diagnosed with polycystic ovary syndrome (PCOS) during adolescence will receive a combined oral contraceptive (ethinylestradiol 30 µg + drospirenone 3 mg) once daily for six consecutive months. The intervention aims to regulate menstrual cycles, reduce hyperandrogenic symptoms, and evaluate changes in anxiety and depression scores over time.
223795637|NCT06713603|BEHAVIORAL|TAMI Coach|The investigators address the problems of intrinsic motivation, Evidence Based Practice (EBP) education, and referral tailoring using a digital-coaching intervention that 1) promotes readiness to change, 2) educates and builds confidence about EBP's, and 3) creates a tailored quit plan sensitive to social obstacles and needs.
223795638|NCT03829254|DRUG|NUC-7738|NUC-7738
223795639|NCT03829254|DRUG|Pembrolizumab|Pembrolizumab
223795640|NCT07079241|OTHER|Naloxone-responder: A volunteer first responder system connected to emergency dispatch service and alerting overdose and first aid educated volunteers with naloxone to suspected opioid overdoses|The model is a smartphone-based alert system with an app which is connected to dispatcher centers. Volunteer first responders will be alerted in addition to standard emergency medical service (like ambulance) to suspected opioid overdoses and also cardiac arrests. The aim is to see if volunteers equipped with naloxone and with up-do-date knowledge of overdose treatment and first aid can arrive and reverse the condition safely prior to emergency service arrival.
223795641|NCT06822998|DRUG|HF50|HF50 is a liposomal T-cell engager with an unique design based on the lipid bilayer. It was also named a T cell Redirecting Antibody Fragment-anchored Liposomes (TRAFsome). The liposomal surface carries anti-CD3ε and anti-HER2 antibody-conjugated lipid molecules, enabling T-cell redirection and activation at HER2-positive or HER2-low tumor sites. In addition, the liposome internal space contains a TLR7/8 agonist Resiquimod (R848), which has been shown to help modulate the myeloid cells in the tumor micro-environement to complement the immune activation effects.
223795642|NCT07085000|OTHER|No Intervention - Observational Assessment|No intervention is applied. Preoperative cognitive status (MoCA) and physical frailty (CFS) are assessed as part of observational data collection. Postoperative follow-up includes decision satisfaction and adherence evaluations.
223795643|NCT06904079|OTHER|Gamified Digital Rehabilitation|The gamification intervention measures are as follows: Currently, the initial version of the community mental health rehabilitation interactive game mainly focuses on six dimensions of medication management, including the importance of taking medication, identifying and dealing with adverse reactions to antipsychotic drugs, learning self-management of medication, assessing the effectiveness of medication treatment, long-term management of medication treatment, and discussing issues related to medication effects with medical staff. Next, we will continue to design a series of games themed on symptom management and psychological rehabilitation, and implement game-based digital rehabilitation interventions for patients in the intervention group based on these games.
223795644|NCT06904079|BEHAVIORAL|Routine Care|Receive regular psychiatric medication treatment and regular community rehabilitation services, including regular follow-ups, rehabilitation guidance, and community education,etc.
223795645|NCT01756950|BIOLOGICAL|2 mg/kg CR8020|administered as a single 2-hour intravenous infusion
223795646|NCT01756950|BIOLOGICAL|5 mg/kg CR8020|administered as a single 2-hour intravenous infusion
223795647|NCT01756950|BIOLOGICAL|15 mg/kg CR8020|administered as a single 2-hour intravenous infusion
223795648|NCT01756950|BIOLOGICAL|30 mg/kg CR8020|administered as a single 2-hour intravenous infusion
223795649|NCT01756950|BIOLOGICAL|50 mg/kg CR8020|administered as a single 2-hour intravenous infusion
223795650|NCT01756950|BIOLOGICAL|Placebo|administered as a single 2-hour intravenous infusion
223795651|NCT02107209|PROCEDURE|Bronchoscopic Lung volume reduction|Fiberoptic bronchoscopy is used to inject the biological agents into the targeted lung segment
223795652|NCT01990846|DRUG|Flufirvitide 3|
223795653|NCT01990846|DRUG|Placebo for Flufirvitide-3|
223795654|NCT00785408|DRUG|AC2307|subcutaneous, twice daily, low dose
223795655|NCT00785408|DRUG|placebo|subcutaneous, twice daily, low dose
223795656|NCT00785408|DRUG|AC2307|subcutaneous, twice daily, middle dose
223795657|NCT00785408|DRUG|placebo|subcutaneous, twice daily, middle dose
223795658|NCT00785408|DRUG|AC2307|subcutaneous, twice daily, high dose
223795659|NCT00785408|DRUG|placebo|subcutaneous, twice daily, high dose
223795660|NCT05662384|OTHER|No intervention is planned|Observational study, no intervention
223795661|NCT04274452|BIOLOGICAL|efgartigimod|Intravenous infusion of efgartigimod
223795662|NCT04274452|OTHER|Placebo|Intravenous infusion of placebo
223795663|NCT04560166|DRUG|Naxitamab and GM-CSF in combination with irinotecan and temozolomide|"* Irinotecan, solution for infusion (20 mg/mL)~* Temozolomide, capsules (5 mg, 20 mg and 100 mg)~* The humanized immunoglobulin isotype G (IgG1) monoclonal antibody (mAb) naxitamab, solution for infusion (4 mg/mL)~* Sargramostim (GM-CSF), lyophilized 250 µg single use vial (250 µg/vial)"
223795664|NCT04010071|DRUG|axitinib plus toripalimab|"Axitinib 5mg, twice a day, orally, 4 weeks a cycle. Dose reduction from 5mg twice a day to 3mg twice a day should be considered according to adverse events.~Toripalimab 240mg, every 3 weeks, intravenous infused, 6 weeks a cycle. Number of cycle: until disease progression or unacceptable toxicity events."
223795665|NCT05087082|OTHER|Virtual Hospital at Home - Home admission of epidemic patients|Admitting COVID-19 patients at home
223795666|NCT06018792|DIAGNOSTIC_TEST|Molecular Culture|PCR based bacterial profiling technique, that creates a differentiating microbial signature based on amplification of the interspace region in bacterial ribosomal RNA. Results on gel capillary electrophoresis are analyzed with software to recognize these signatures.
223795667|NCT04246983|DIAGNOSTIC_TEST|Opportunistic infection Ultrasound (OpUS) screening|this point-of-care ultrasound protocol will include lung ultrasound, assessment of pericardial and pleural effusions, ascites, abdominal lymphadenopathy and splenic micro abscesses, as well as a focused ultrasound of liver and kidneys.
223795668|NCT04861857|DIETARY_SUPPLEMENT|Parmigiano Reggiano|subjects will receive 50 g/die of the dietary supplement
223795669|NCT04861857|DIETARY_SUPPLEMENT|Whey Protein|subjects will receive 20 g/die of the dietary supplement
223795670|NCT00593567|DRUG|gentamicin-collagen sponge|Inserted daily into open ulcer
223795671|NCT00593567|DRUG|Levofloxacin|750mg oral levofloxacin daily
223795672|NCT02993445|OTHER|Alternate Nostril Breathing|
223795673|NCT02993445|DEVICE|Foot Reflexology|
223795674|NCT04826601|OTHER|essential oils|A total of 40 cancer patients receiving chemotherapy will be recruited as participants in this study. Blood orange and rosewood will be chosen as the essential oils for aromatherapy in this study. Essential oils will be applied to all participants by inhalation for 30 minutes.
223795675|NCT00998179|DEVICE|Acu-TENS|Application of Acu-TENS (with electrical output from the machine)
223795676|NCT00998179|DEVICE|Placebo-TENS|Application of Acu-TENS (without electrical output from the machine)
223795677|NCT04081467|OTHER|Bed rest|10-day of complete bed rest
223795678|NCT06020222|DEVICE|cryotherapy|Both hands and feet received cryotherapy gloves and boots, and the frequency was once every three weeks. Each cycle was 90 minutes, and the cycle was performed 4 times.
223795679|NCT06020222|OTHER|education|Provide preventive CIPN education leaflets
223795680|NCT00491985|BIOLOGICAL|A/H5N1 Inactivated, split-virion pandemic influenza vaccine|0.5 mL, Intramuscular
223795681|NCT00491985|BIOLOGICAL|A/H5N1 Inactivated, split virion pandemic influenza vaccine|0.5 mL, Intramuscular
223795682|NCT00491985|BIOLOGICAL|A/H5N1 Inactivated, split virion pandemic influenza vaccine|0.25 mL, Intramuscular
223795683|NCT02119260|DRUG|GSK2798745 solution|Clear, colourless GSK2798745 (0.1 to 0.4mg) solution in aqueous citrate buffer with 4% captisol
223795684|NCT02119260|DRUG|GSK2798745 suspension|Aqueous suspension of GSK2798745 (\>=0.5 mg)
223795685|NCT02119260|DRUG|GSK2798745 capsule|White Opaque granule filled capsules of GSK2798745 (\>=0.5 mg)
223795686|NCT02119260|DRUG|Placebo solution|Clear, colourless solution of aqueous citrate buffer with 4% captisol
223795687|NCT02119260|DRUG|Placebo suspension|Visually matching aqueous suspension of hypromellose acetate succinate powder
223795688|NCT02119260|DRUG|Placebo capsule|Matching white opaque placebo blend filled capsule
223795689|NCT02987075|OTHER|Compacting embryo transferring|transfer of 2 utilizable compacting embryos
223795690|NCT02987075|OTHER|Non- compacting embryo transferring|transfer of 2 utilizable non-compacting embryos have 7-9 cells with under 20% fragmentation.
223795691|NCT00375154|DEVICE|Noninvasive Positive-Pressure Ventilation (NPPV)|
223795692|NCT00844857|DRUG|Olanzapine Fluoxetine Combination (OFC)|OFC doses are capsules of 3 milligrams (mg) olanzapine and 25 mg fluoxetine (3/25), 6/25, 12/25, 6/50, or 12/50 mg to be taken orally once daily in the evening for 8 weeks.
223795693|NCT00844857|DRUG|Placebo|Orally, once daily in the evening for 8 weeks.
223795694|NCT02057874|DEVICE|3 Tesla Magnetic Resonance Imaging|3T MRI consists of a series of radiofrequency (RF) pulse sequences optimized for acquiring CEST-, MT-, DW-, and DCE-MRI data in one seamless imaging examination. For DCE, MR contrast agent will be intravenously administered.
223795695|NCT02057874|DRUG|Magnevist® (Intravenous (IV) administration of MRI contrast agent)|For the acquisition of DCE-MR data, the FDA-approved contrast agent Magnevist® (gadopentetate dimeglumine, 0.1 mmol/kg) will be delivered intravenously by the MR technologist at a rate of 2 mL/sec (followed by a saline flush) via a power injector after the acquisition of a set of baseline dynamic scans. The entire sequence lasts approximately 8 minutes.
223795696|NCT00432757|DRUG|Ketotifen with a Contact Lens (generic name not yet established)|
223795697|NCT06020092|PROCEDURE|Bone augmentation with I-BCP|The extraction socket will be filled after tooth extraction with I-BCP, in order to achieve bone regeneration and prevent volume loss after tooth extraction.
223795698|NCT06020092|PROCEDURE|Bone augmentation with BX|The extraction socket will be filled after tooth extraction with BX, in order to achieve bone regeneration and prevent volume loss after tooth extraction.
223795699|NCT01245465|OTHER|Profermin|Medical Food (food for special medical purposes)
223795700|NCT05213195|DRUG|NKG2D CAR-NK|NKG2D CAR-NK infusion through peritoneal in stage 1 and later combined with intra venous in stage 2.
223795701|NCT01757834|DEVICE|SWUS Elastography|
223795702|NCT01738984|BEHAVIORAL|MomZing Web Program|Online web platform that is accessed via a television connected to internet
223795703|NCT01738984|BEHAVIORAL|Standard Exercise DVD|Standard exercise DVD that demonstrates exercises a women does with an infant.
223795704|NCT05390840|DRUG|MG-O-1002|MG-O-1002 ophthalmic solution in one concentration (0.8%) ocular administration 3 drops in study eye
223795705|NCT05390840|OTHER|Placebo|The placebo is 0.9% saline ocular administration 3 drops in study eye
223795706|NCT03910413|DIAGNOSTIC_TEST|Duel Energy CT|Enrolled subjects will complete a dual energy ct for evaluation of esophageal varices
223795707|NCT03230227|DRUG|Bupivacaine magnesium|bupivacain 0.125% magnesium sulfate 5%) infusion in the presternum , for 48 hours
223795708|NCT03230227|DRUG|Bupivacaine only|bupivacaine 0.125% infusion in the presternum , for 48 hours
223795709|NCT03031587|OTHER|Additional MRI acquisition sequences|It deals with specific sequences of rapid imaging acquisition in gradient echo (4 to 5 slices/cardiac cycle) with synchronization on the surface ECG systematically included in a cardiac MRI examination, together with update of the slice position depending on the respiratory state (established technique of navigator echo). The acquisition is repeated over 300 cardiac cycles to monitor myocardial temperature changes
223795710|NCT03031587|DEVICE|MRI|cardiac MRI
223795711|NCT01624038|DRUG|Hydroxyurea ,Epiao|"Hydroxyurea (Myers-Squibb, USA) was administered in dosages ranging from 15 up to 35 mg/kg/day orally over 7 days/week.~Erythropiotien therapy (rHuEPO - Epiao) from 250 to 500 IU/kg rHuEPO subcutaneously three times a week."
223795712|NCT01624038|DRUG|hydroxyurea, blood transfusion|* Hydroxyurea was administered in dosages ranging from 15 up to 35 mg/kg/day orally over 7 days/week. Hydroxyurea toxicity was defined as a white cell count of less than 2500/μL or a platelet count of less than 100,000/μL, in which case the drug was discontinued.
223795713|NCT03143114|PROCEDURE|Myomectomy|Laparotomy then incision in the uterine wall to remove the myoma followed by closure of the uterine incision
223795714|NCT01592032|DRUG|Vancomycin antimicrobial-lock solution|Randomization of 5 patients into vancomycin antimicrobial-lock solution arm for 1, 3, 5, 7 and 10 days according to HPLC corrected by urea gradient. The arm can be stopped any time from day 1 to day 10 in case of antimicrobial concentration less than 1 mg/mL.
223795715|NCT01592032|DRUG|Teicoplanin antimicrobial-lock solution|Randomization of 5 patients into teicoplanin antimicrobial-lock solution arm for 1, 3, 5, 7 and 10 days according to HPLC corrected by urea gradient. The arm can be stopped any time from day 1 to day 10 in case of antimicrobial concentration less than 1 mg/mL.
223795716|NCT01592032|DRUG|Linezolid antimicrobial-lock solution|Randomization of 5 patients into linezolid antimicrobial-lock solution arm for 1, 3, 5, 7 and 10 days according to HPLC corrected by urea gradient. The arm can be stopped any time from day 1 to day 10 in case of antimicrobial concentration less than 1 mg/mL.
223795717|NCT01592032|DRUG|Daptomycin antimicrobial-lock solution|Randomization of 5 patients into daptomycin antimicrobial-lock solution arm for 1, 3, 5, 7 and 10 days according to HPLC corrected by urea gradient. The arm can be stopped any time from day 1 to day 10 in case of antimicrobial concentration less than 1 mg/mL.
223795718|NCT01592032|DRUG|Tigecycline antimicrobial-lock solution|Randomization of 5 patients into tigecycline antimicrobial-lock solution arm for 1, 3, 5, 7 and 10 days according to HPLC corrected by urea gradient. The arm can be stopped any time from day 1 to day 10 in case of antimicrobial concentration less than 1 mg/mL.
223795719|NCT02145221|OTHER|Music Therapy|
223795720|NCT02159248|DRUG|Tolfenamic acid + gemcitabine + radiation|"Cohort 1: 200mg of oral tolfenamic acid, three times per day for 6 1/2 weeks, in combination with weekly intravenous gemcitabine at 400mg/m2 for 5 doses and external beam radiation for 5 1/2 weeks (28 doses at 1.8 Gy/Fx/day).~Cohort 2: 400mg of oral tolfenamic acid, three times per day for 6 1/2 weeks, in combination with weekly intravenous gemcitabine at 400mg/m2 for 5 doses and external beam radiation for 5 1/2 weeks (28 doses at 1.8 Gy/Fx/day).~Cohort 3: 600mg of oral tolfenamic acid, three times per day for 6 1/2 weeks, in combination with weekly intravenous gemcitabine at 400mg/m2 for 5 doses and external beam radiation for 5 1/2 weeks (28 doses at 1.8 Gy/Fx/day).~Cohort 4: 800mg of oral tolfenamic acid, three times per day for 6 1/2 weeks, in combination with weekly intravenous gemcitabine at 400mg/m2 for 5 doses and external beam radiation for 5 1/2 weeks (28 doses at 1.8 Gy/Fx/day)."
223795721|NCT05225623|BEHAVIORAL|BWLT|This group will attend 16 2-hour group-based weekly sessions in Small Changes BWLT in addition to their treatment at the Balfour Medical Clinic
223795722|NCT05225623|BEHAVIORAL|Waitlist Control for BWLT|This group will receive treatment as usual at the Balfour Medical Clinic and put on a waitlist for the Small Changes BWLT program
223795723|NCT02297568|DRUG|Calciferol|Comparison 25OHD levels between calciferol and placebo
223795724|NCT02297568|DRUG|placebo|
223795725|NCT01770054|OTHER|obtention of a blood sample|a blood sample will be obtained to measure glucose, HDL cholesterol, triglycerides, and for genetic testing
223795726|NCT00997087|DRUG|Flumazenil|Sublingual daily
223795727|NCT02245932|DIETARY_SUPPLEMENT|Resveratrol|4 weeks of 150 mg resveratrol (2 times 75mg/day)
223795728|NCT02245932|DIETARY_SUPPLEMENT|Placebo|4 weeks of placebo supplementation (two doses per day)
223795729|NCT00240487|DRUG|Nitric Oxide|Subjects will receive inhaled Nitric Oxide at a dose of 10 parts per million (ppm) for a 4 hour study period. Blood gases will be collected once an hour.
223795730|NCT00240487|OTHER|No Intervention|Subjects will receive no intervention (i.e., no nitric oxide treatment) for a 4 hour study period. Blood gases will be collected once an hour. During this time, all subjects will receive standard clinical care.
223795731|NCT05599802|BIOLOGICAL|SARS-CoV-2 variant mRNA vaccine low dose|50μg/dose
223795732|NCT05599802|BIOLOGICAL|SARS-CoV-2 variant mRNA vaccine high dose|100μg/dose
223795733|NCT03786731|BEHAVIORAL|Transdiagnostic Intervention for Sleep and Circadian Dysfunction (TranS-C)|TranS-C integrates elements of evidence-based interventions, namely cognitive-behavioural therapy for insomnia, delayed sleep phase type, and interpersonal and social rhythm therapy.
223795734|NCT05203926|PROCEDURE|MRI scan|Subjects will undergo T1 and STIR sequence MRI of sacroiliac joints (SIJ ) (pelvis MRI) as well as SIJ plain X-ray for assessment of radiographic sacroiliitis. The study will utilize 3 Tesla with phased array coil to maximize signal to noise ratio for image quality. This is a single procedure, which takes about 60 minutes. 1 radiologists, blinded to all clinical information, will evaluate for presence of acute and structural lesions. Images will be scored for presence or absence of acute and/or structural lesions in a global manner.
223795735|NCT05638399|DRUG|Denosumab 60 mg/ml [Prolia]|60 mg subcutaneously per 6 month
223795736|NCT05638399|DRUG|Zoledronate|5mg, intravenous infusion once a year
223795737|NCT00440531|BIOLOGICAL|Comparator: RECOMBIVAX HB™ Hepatitis B Vaccine (Recombinant)|RECOMBIVAX HB™ (currently licensed product) given IM (Intramuscular) in 3 doses of 10 mcg (micrograms)/1.0 mL each over 6 months.
223795738|NCT00440531|BIOLOGICAL|Comparator: Modified Process Hepatitis B Vaccine (Experimental)|Modified Process Hepatitis B Vaccine (Experimental) given IM (Intramuscular) in 3 doses of 10 mcg (micrograms)/1.0 mL each over 6 months.
223795739|NCT00440531|BIOLOGICAL|Comparator: ENGERIX-B™ (currently licensed product)|ENGERIX-B™ given IM (Intramuscular) in 3 doses of 20 mcg (micrograms)/1.0 mL each over 6 months.
223795740|NCT00447057|DRUG|Pemetrexed|500 mg/m² intravenous (iv) over 10 minutes on the first day of each 21-day cycle until disease progression (PD) or unacceptable toxicity
223795741|NCT00447057|DRUG|Erlotinib|150 mg given orally (po), daily (QD), starting on the first day of the first cycle
223795742|NCT00447057|DRUG|Pemetrexed|500 mg/m² iv over 10 minutes on the first day of each 21-day cycle until PD or unacceptable toxicity
223795743|NCT00447057|DRUG|Erlotinib|150 mg given po, QD, starting on the first day of the first cycle
223795744|NCT00226330|DRUG|Tesaglitazar|(0.5 or 1 mg)
223795745|NCT00226330|DRUG|Pioglitazone|(15, 30 or 45 mg)
223795746|NCT05774366|DRUG|Remimazolam|General anesthesia was induced with 12 mg/kg/hr of intravenous remimazolam. When loss of consciousness was achieved, the infusion rate of remimazolam was reduced to 1mg/kg/hr for maintenance. At the end of surgery, 0.2 mg of flumazenil is administered.
223795747|NCT05774366|DRUG|Desflurane|Desflurane (1 minimum alveolar concentration (MAC) of end-tidal desflurane concentration) is used for the maintenance of general anesthesia. Induction of general anesthesia is achieved with 1-2 mg/kg of intravenous propofol bolus.
223795748|NCT02415426|BEHAVIORAL|Metacognitive Training Program during mild to moderate depression|Diagnostic and therapeutical interventions are not part of this study. As part of this study, the change of cognitive and psychosocial achievement/behavior in patients with mild to moderate depression after taking part in the training program is being investigated. The training program seeks to enable group members to recognize and correct the often automatic and unconscious thought patterns that accompany depression, in part by viewing this depressive thought process at a distance (i.e., depersonalizing). In addition, dysfunctional assumptions about one's thought processes, as well as dysfunctional coping-strategies (i.e., thought suppression, rumination as problem-solving) are targeted (Lena Jelinek \& Steffen Moritz, http://clinical-neuropsychology.de/metacognitive\_training\_for\_depression.html).
223795749|NCT04487093|DRUG|neoantigen vaccine + EGFR-TKI|"Patients received subcutaneous injection of individualized neoantigen peptides vaccine at a dose of 200ug per peptide once a week for 5 weeks.~The targeted drugs are used continuously according to the instructions and dosage until disease progression or intolerance."
223795750|NCT04487093|DRUG|neoantigen vaccine + anti-angioge|neoantigen vaccine + anti-angioge
223795751|NCT02073695|PROCEDURE|Operative procedure to fix proximal humeral|Operative fixation by the shoulder team at Torbay Hospital
223795752|NCT02073695|DEVICE|Neutral Rotation Brace|Performed at the end of the surgical procedure at Torbay Hospital
223795753|NCT02073695|OTHER|Physiotherapy review|Physiotherapy review on day of surgery, and post-surgery at 6 weeks, 3 months and 1 year.
223795754|NCT02073695|OTHER|Functional outcome forms filled in|
223795755|NCT02073695|OTHER|Postal functional outcome scores|Sent to patient at 9 weeks post surgery
223795756|NCT02073695|OTHER|Post-operative Radiographs|Performed at 6 weeks and 3 months at shoulder clinic appointment at Torbay Hospital
223795757|NCT05741580|PROCEDURE|Evolution of symptoms|percentage of patients with improvement in their symptoms
223795758|NCT00738946|DRUG|Intermittent preventive treatment with AQ+ SP|Amodiaquine (10 mg/kg over 3 days) and Sulfadoxine Pyrimethamine (25 mg of sulfadoxine + 1.25 mg of pyrimethamine per kg in a single dose) or placebo administered over 3 rounds of one month interval
223795759|NCT01834066|BIOLOGICAL|Stem Cell|Intralesional transfer of Autologous Stem cell (MNCs) per dose. 6 doses in 3 months
223795760|NCT00981890|DRUG|Sunitinib|Sunitinib is a tablet that is taken by mouth every day. Patients will be treated with Sunitinib alone for 7 days. On the seventh day of taking the drug they will be given SRS. Sunitinib will continue for seven days per week after SRS, and depending on how far along the study is when patients join, they may continue taking the drug for up to 13 weeks after SRS.
223795761|NCT02468401|PROCEDURE|Percutaneous coronary intervention|Patients planned for coronary angiography or percutaneous coronary intervention will be managed using a protocol that allows us to use minimal volumes of contrast dye
223795762|NCT01698684|DRUG|Placebo|One dose 15 minutes before attempting intercourse
223795763|NCT01698684|DRUG|Avanafil 100 mg|One dose 15 minutes before attempting intercourse
223795764|NCT01698684|DRUG|Avanafil 200 mg|One dose 15 minutes before attempting intercourse
223795765|NCT03236298|DEVICE|CADD-Solis Ambulatory Infusion System|The CADD-Solis pump will administer programmed intermittent boluses of 0.0625% Bupivacaine plus fentanyl 2mcg/ml.
223795766|NCT03386903|DEVICE|Ture acupuncture|"Patients receive true acupuncture treatment by Zhoushi coordinated points at the Bai-hui (DU20), Shen-ting (DU24), bilateral Ben-shen (BG13), Shen-men (HT7), San-yin-jiao (SP6) with Deqi sensation. The needles are retained for 20 minutes in every course, three times per week and last for 3 months."
223795767|NCT03386903|DEVICE|Sham acupuncture|Patients receive sham acupuncture stimulation by non-acupoint points (superficial insertion, 0.2 cun, No needle sensation (de qi) is elicited) at the bilateral mid-point between Shuaigu(GB8) and Touwei(ST8), Touwei(ST8) and Yangbai(GB14), front tibia, the junction of biceps and triceps.
223795768|NCT05074628|DRUG|Nitrofurantoin capsules|methyl cellulose powder (MC) will be added to Nit solution to get a thick paste like consistency mixture.
223795769|NCT01993225|DRUG|Androxal 12.5 mg/25 mg|
223795770|NCT01993225|DRUG|Placebo Capsules|
223795771|NCT01993225|DRUG|AndroGel 1.62%|
223795772|NCT01993225|DRUG|Placebo Gel|
223795773|NCT02940366|DRUG|Pitavastatin 4 mg orally daily|Pitavastatin 4 mg orally daily for 24months
223795774|NCT02940366|DRUG|Atorvastatin 20 mg orally daily|Atorvastatin 20 mg orally daily for 24months
223795775|NCT06043739|DRUG|Filgotinib|Commercially developed film-coated tablet administered orally
223795776|NCT06043739|DRUG|Filgotinib|Film-coated mini-tablets administered orally
223795777|NCT00484003|DRUG|Pimecrolimus cream 1%|
223795778|NCT01737957|DEVICE|Low-fluence PRP with 532nm green LASER|To administer low-fluence PRP in a single session for PDR
223795779|NCT01737957|DEVICE|Full-Fluence PRP with 532nm LASER|To administer full-fluence PRP in two sessions for PDR
223795780|NCT01562210|DRUG|Olaparib|"Olaparib will be given orally BID for 36 days, administrated with a 12 hour interval. Olaparib will start 2 days before RT and will continue for 2 days after the last RT fraction. Olaparib is also given during the non-radiotherapy days but no maintenance treatment is given after radiotherapy is finished.~The first cohort will receive Olaparib with a dose of 25mg BID combined with Cisplatin and RT. Thereafter in both with and without cisplatin arms dose escalation will follow to 50mg, 100mg, 200mg, 300mg and 400mg BID."
223795781|NCT01562210|DRUG|Cisplatin|6 mg/m2 (5 days/week), 1-1.5 hr before the irradiation (week 1 to 5), given as a 5-minutes intravenous infusion.
223795782|NCT01562210|RADIATION|Radiation|A total dose of 66 Gy will be given in 24 fractions from week 1 to 5, excluding the weekends.
223795783|NCT01843192|DEVICE|Endocutter|
223795784|NCT01471054|DRUG|Ozurdex|"Eyes in the Ozurdex group can have a maximum total of three Ozurdex insertions in the first 12 months after enrolling into the study. The criteria for retreatment with Ozurdex are:~i.The study eye must have shown initial favorable response to prior Ozurdex implant (\>10% decrease in central macular thickness with maintenance \[change in BCVA of \<=1 line\] or improvement of visual acuity \[increase of BCVA of \>1 line\]) ii. Interval since last Ozurdex implant should be \> 4 and \< 12 months. iii. The study eye must show definite evidence of recurrence of macular edema."
223795785|NCT01471054|DRUG|Bevacizumab|Eyes in the Bevacizumab group can have a maximum total of twelve bevacizumab injections in the first year after enrolling into the study. All patients will receive 6 monthly injections after entering the study. After the sixth injection (at month 5) the interval between injections will be extended to 6 weeks if the study eye has shown initial favorable response to prior intravitreal bevacizumab.
223795786|NCT03509649|PROCEDURE|Cervical spine manipulation|High-velocity low-amplitude thrust joint manipulation to the cervical spine
223795787|NCT04493216|DRUG|GSK3640254|GSK3640254 was available as a 25 mg and 100 mg tablets to be administered via oral route.
223795788|NCT04493216|DRUG|ABC/3TC|ABC/3TC was available as abacavir 600 mg/lamivudine 300 mg tablet to be administered via oral route.
223795789|NCT04493216|DRUG|FTC/TAF|FTC/TAF was available as emtricitabine 200 mg/tenofovir alafenamide 25 mg tablet to be administered via oral route.
223795790|NCT04493216|DRUG|Dolutegravir|Dolutegravir was available as a 50 mg tablet to be administered via oral route.
223795791|NCT04493216|DRUG|Placebo|Placebo matching GSK3640254 was administered in the form of tablets via oral route.
223795792|NCT02672787|BEHAVIORAL|ED-based behavioral intervention|Data collection, antihypertensive adherence assay, antihypertensive interview and EHR review, barrier identification, personalized goal setting, communication with PCP, and reminder messages/engagement messages.
223795793|NCT02672787|BEHAVIORAL|ED usual care plus education|Data collection, antihypertensive adherence assay, antihypertensive interview, EHR review, and usual care education.
223795794|NCT02269566|DRUG|HollisterStier|0.1 ml of 30 AU/ml for Df or Dp, 10 AU/ml for Cat hair, and/or 1:1/10 weight/volume for dog hair/dander 3 injections into an inguinal lymph node
223795795|NCT02269566|DRUG|Normal saline|0.1 ml of normal saline 3 injections into an inguinal lymph node
223795796|NCT00083057|DRUG|gefitinib|
223795797|NCT00083057|DRUG|paclitaxel|
223795798|NCT00083057|RADIATION|radiation therapy|
223795799|NCT01928368|DRUG|AMG 282|Single dose either subcutaneously or intravenously on day 1.
223795800|NCT01928368|DRUG|AMG 282 Matching Placebo|Single dose of matching AMG 282 placebo either subcutaneously or intravenously on day 1.
223795801|NCT01559844|DRUG|Sofosbuvir|Sofosbuvir 400 mg (2 x 200 mg tablets) administered orally once daily
223795802|NCT01559844|DRUG|Ribavirin|Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)
223795803|NCT04325438|OTHER|Pharmaceutical Care|"Pharmaceutical care interventions are categorised into 2 aspects:~1. Pharmacists' expertise aspect: medications review, identification and solution for the drug-related problem, adverse events, and other medication-related clinical problems. Therapeutic drug monitoring (TDM) is performed for any dose adjustment to the Rifampicin.~2. Motivational behavioral intervention to improve medication adherence (i.e. medications information and counseling to study participants)."
223795804|NCT04917133|BEHAVIORAL|Adapted Physical Activity program|classic 4-week rehabilitation program (standard care) + 6 APA workshops per week with collective care
223795805|NCT04917133|OTHER|Control|classic 4-week rehabilitation program (standard care)
223795806|NCT02172755|DRUG|BIA 2-093|During the whole study, subjects were to receive a single 600 mg dose of BIA 2-093 (Phase A) followed by 600 mg BIA 2-093 once daily for 8 days in Phase B. Phase B was to begun 96 hours post-Phase A dose.
223795807|NCT02181803|DRUG|MK-8189|MK-8189, oral, 2 mg and/or 10 mg tablets, taken QD for a total daily dose of 2 mg, 4 mg, 8 mg, 10 mg, 12 mg, 14 mg, 16 mg, 20 mg, or 40 mg
223795808|NCT02181803|DRUG|Placebo|Placebo matching oral 2 mg and/or 10 mg MK-8189 tablets, taken QD
223795809|NCT02181803|DRUG|Base Monotherapy|For Part 2 only: participants need to be on monotherapy with an atypical antipsychotic medication (eg, Olanzapine, Quetiapine, Paliperidone, Asenapine, Iloperidone, Aripirprazole, Lurasidone, Risperidone \[not to exceed daily dose of 6 mg\], or Ziprasidone.) The participant should be on a stable and well tolerated treatment regimen for at least 2 months prior to screening. NOTE: Clozapine is not allowed.
223795810|NCT00630110|DRUG|docetaxel|docetaxel (75 mg/m2)
223795811|NCT00630110|DRUG|NPI-2358 + docetaxel|NPI-2358 (30 mg/m2) + docetaxel (75 mg/m2)
223795812|NCT03824379|DIETARY_SUPPLEMENT|Magnesium citrate|magnesium citrate equivalent 20-30 mmol elemental magnesium
223795813|NCT03824379|DRUG|Antidiabetic|insulin or oral hypoglycemics
223795814|NCT00951041|BIOLOGICAL|GSK investigational vaccine GSK2340272A|Two intramuscular injections
223795815|NCT00951041|BIOLOGICAL|GSK investigational vaccine GSK2340269A|Two intramuscular injections
223795816|NCT05113628|DIAGNOSTIC_TEST|methylene blue identification|"After ligation of the middle thyroid vein and the upper pole of the thyroid, the thyroid lobe was retracted medially and diluted methylene blue (0.5 ml methylene blue 2% was diluted by 5ml normal saline) was sprayed over the lower thyroid pole and the perilobar area. This area contains structures including recurrent laryngeal nerve, parathyroid glands, and inferior thyroid vessels which were observed After spraying.~The vocal cord mobility was assessed intraoperatively by the anesthesiologist at time of extubation. The serum calcium was measured on the 2nd postoperative day. There was no routine use of postoperative calcium supplementation. Hypocalcemia was defined when the serum calcium level was less than 8 mg/dl."
223795817|NCT01260220|PROCEDURE|Circumferential Antral Ablation|The goal is to complete ablation in all segments around the pulmonary veins until a circle of ablation lesions is created in the antrum with at least 30 seconds of ablation, 25W on the posterior surface, 30W on the anterior surface at each site, and change in the local electrogram. Entry and Exit block will be confirmed in each vein. The left superior pulmonary vein and left inferior pulmonary vein will be isolated with one circle, and the right superior and right inferior pulmonary veins will be isolated with one circle.
223795818|NCT01260220|PROCEDURE|Segmental Antral ablation|If the patient is in atrial fibrillation, ablation will begin in the segment with the highest frequency signals in the pulmonary vein antrum. If the patient is in sinus rhythm, mapping and ablation will occur during coronary sinus pacing. Segments with the earliest signals in the Lasso catheter will be targeted, and reassessed after each ablation lesion. This will continue in a segmental fashion on the antrum until pulmonary vein isolation is achieved. Lasso should be moved between veins between lesions to assess the earliest electrogram. Entry and exit block will be confirmed at each vein.
223795819|NCT01514448|DRUG|Everolimus (RAD001)|Everolimus was used as commercially available formulated tablets of 10 mg strength
223795820|NCT02881723|PROCEDURE|Surgery|
223795821|NCT02881723|RADIATION|Radio- chemotherapy|
223795822|NCT02314624|BEHAVIORAL|Behavioral Activation for Depression, Cognitive Behavior Therapy for Insomnia, Collaborative Assessment and Management of Suicidality|Evidence-based interventions for treating depression and concurrent problems
223795823|NCT02314624|BEHAVIORAL|Care-as-Usual Psychotherapy|Usual care psychotherapy for depression and concurrent problems
223795824|NCT03278938|DRUG|bupropion|FDA approved drug for treating depression
223795825|NCT03278938|DRUG|citalopram|FDA approved treatment for depression
223795826|NCT04945317|OTHER|ROSE (presence of cytotech) & liquid prep|Standard of care EBUS will include presence of trained cytotechnologist providing on-site cytopathology feedback to bronchoscopist during the procedure. Sample is liquid.
223795827|NCT04945317|OTHER|NO-ROSE (absence of cytotech) & liquid prep|Standard of care EBUS will NOT include presence of trained cytotechnologist providing on-site cytopathology feedback to bronchoscopist during the procedure. Sample is liquid.
223795828|NCT04945317|OTHER|ROSE (presence of cytotech) & tissue clot sample|Standard of care EBUS will include presence of trained cytotechnologist providing on-site cytopathology feedback to bronchoscopist during the procedure. Sample is a tissue clot.
223795829|NCT04945317|OTHER|NO-ROSE (absence of cytotech) & tissue clot sample|Standard of care EBUS will NOT include presence of trained cytotechnologist providing on-site cytopathology feedback to bronchoscopist during the procedure. Sample is a tissue clot.
223795830|NCT01983748|BIOLOGICAL|Autologous Dendritic Cells loaded with autologous Tumor RNA|
223795831|NCT03162575|BEHAVIORAL|Mindfulness-Based Cognitive Therapy|Structured MBCT intervention based on the protocol of Williams, Teasdale, and Segal (2002)
223795832|NCT01620866|OTHER|Eye Movement Desensitization Reprocessing (EMDR)|EMDR is an effective treatment in PTSD but has never been tested in bipolar traumatized patients.
223795833|NCT05559034|BEHAVIORAL|Cognitive intervention|This is a cognitive intervention consisting in the repetition according to three blocks, of cognitive tasks (Stroop and N-back tasks) at variating workload levels (low, middle and high levels). Each cognitive task will be presented for each workload level during three minutes.
223795834|NCT01436825|DRUG|Recombinant Factor VIII (Kogenate FS, BAY14-2222)|Prophylactic treatment : 20-40 UI /Kg administered all 2 in 3 days .
223795835|NCT03676855|PROCEDURE|bladder dissection|Comparison between bladder dissection at the beginning of cesarean section For morbidly adherent placenta and between delaying dissection until planning for cesarean hysterectomy
223795836|NCT06469710|DEVICE|leukapheresis|Leukapheresis employs the density differential between leukocytes and other blood components to selectively separate leukocytes and return all other components of the blood to the patient. It can process multiple blood volumes in the body circulation, thereby enabling the concentration of nucleated cells to be significantly increased. The procedure is performed while maintaining no significant change in the patient's circulating blood volume, and it is a routine clinical procedure that is well tolerated and safe. CTC can be greatly enriched in a concentrated sample of leukocytes because it has a similar density to that of leukocytes and other nucleated cells. The density of CTCs is similar to that of nucleated cells, such as leukocytes, which enables their enrichment in single leukocyte concentrate samples.
223795837|NCT01180855|DRUG|Placebo|Placebo pill nightly for 42 nights.
223795838|NCT01180855|DRUG|Rozerem 8mg|Rozerem 8mg pill, nightly for 42 nights
223795839|NCT01180855|OTHER|Rozerem 8mg in combination with Multi Component Behavior Therapy|Rozerem 8mg pill nightly for 42 nights with 4 sessions and 2 telephone calls of Multi Component Behavior Therapy.
223795840|NCT03151005|DRUG|Metformin-GLP-1 Receptor Agonist|metformin oral with exenatide/liraglutide subcutaneous injection.
223795841|NCT03151005|DRUG|Metformin-Oral Contraceptive(OC)|metformin with Diane 35 oral intake.
223795842|NCT05090709|OTHER|Spinal Mobilisation Intervention|30 minutes spinal mobilisations, rate = 0.37Hz, 22 beats per minute, force = less than grade 1, threshold of 80N, location = L1-L5.
223795843|NCT05090709|OTHER|General Massage|30 minutes manual touch with no specifications or recordings on rate, pressure or location of touch.
223795844|NCT01263951|DRUG|Everolimus|One 5 mg. tablet daily.
223795845|NCT01263951|DRUG|Sorafenib|200 mg. twice daily.
223795846|NCT01959451|DRUG|Prasugrel|see Arm description
223795847|NCT01959451|DRUG|Clopidogrel|see arm description
223795848|NCT03531047|PROCEDURE|Customised CXL|As for standard CXL, following mechanical removal of the corneal surface layer (epithelium), 0.1% riboflavin drops will be applied every 2 minutes for 10 minutes prior to ultraviolet A (UVA) irradiation - UVA power, distribution and timing as determined by analysis of Pentacam tomography scans. A bandage contact lens will be applied to encourage regrowth of the corneal surface and reduce post-operative pain.
223795849|NCT04855422|DIAGNOSTIC_TEST|Allosure|AlloSure Analysis For the AlloSure test, 10-20 mL of blood will be obtained in Streck Cell-Free DNA BCT tubes and shipped to CareDx, Inc. (Brisbane, CA) at ambient temperature in insulated packaging to minimize temperature fluctuation. The AlloSure test will be performed at the CareDx CLIA/CAP-accredited clinical laboratory. Samples will be tested, and results provided within 3 days of blood draw
223795850|NCT04855422|DIAGNOSTIC_TEST|AlloMap|AlloMap Kidney is intended to aid in the identification of SPK transplant recipients who have a low probability of rejection at the time in testing in conjunction with standard clinical assessment. For the AlloMap-Kidney test, approximately two tubes of blood will be obtained in PAXgene Blood RNA tubes and shipped to CareDx, Inc. (Brisbane, CA), where it will be tested.
223795851|NCT01010594|BEHAVIORAL|dietary treatment|A standard dietary treatment except that they are advised to restrict their fruit intake.
223795852|NCT01010594|BEHAVIORAL|dietary treatment|A standard dietary treatment.
223795853|NCT03656601|DIAGNOSTIC_TEST|3D pelvic ultrasound|3D pelvic ultrasound by transperineal route
223795854|NCT06635928|DEVICE|Bright light therapy|30min daily of 10.000 lux bright light therapy
223795855|NCT04221997|DRUG|sertraline|Sertraline is an antidepressant in a group of drugs called selective serotonin reuptake inhibitors (SSRIs)
223795856|NCT03968913|DRUG|Anakinra injection|anakinra 150mg in 5milliliters of sterile saline will be injected into the knee joint
223795857|NCT03968913|PROCEDURE|sterile saline injection|5 milliliters of sterile saline will be injected into the knee joint
223795858|NCT03912259|DRUG|Dupilumab|"Pharmaceutical form: solution,~Route of administration: SC"
223795859|NCT03912259|DRUG|Placebo|"Pharmaceutical form: solution,~Route of administration: SC"
223795860|NCT03912259|DRUG|Emollient (moisturizer)|"Pharmaceutical form: cream,~Route of administration: topical use"
223795861|NCT05240716|OTHER|FES program|8 weeks intervention. 3 sessions per week. Previous to the intervention, volunteers will familiarize with the electrical stimulation by receiving three trials of the stimuli. Electrical current intensity will be set for each volunteers, with the capacity of generating a muscle contraction without inducing discomfort in the volunteer. During the FES program, patient in standing position will perform a step, while electrical current stimulation will be applied to the skin over the tibial nerve on the contralateral of the stimulation side. The FES will be delivered during the paretic plantarflexor activation according to the gait cycle. The FES session will consist of 5-minutes stimulation blocks with breaks between blocks (total session time: 30 minutes). For safety reasons, a physical therapist will supervise all the FES intervention sessions.
223795862|NCT04651023|DIETARY_SUPPLEMENT|Nelumbo nucifera Leaf Extract|Hot water extracted Nelumbo nucifera Leaf, mainly containing quercetin and quercetin 3-O-glucuronide.
223795863|NCT03496038|PROCEDURE|L-PRF|The use of the L-PRF as graft material for sinus augmentation procedure will be analysed
223795864|NCT03496038|PROCEDURE|DBBM|The use of bovine xenograft as graft material for sinus augmentation procedure will be analysed
223795865|NCT04786444|BIOLOGICAL|Biological Vaccine VLA1553|Single intramuscular vaccination on Day 1 with one of three Lots of VLA1553, a lyophilized live-attenuated Chikungunya vaccine candidate
223795866|NCT02403726|PROCEDURE|Operation|Analyzation of demographic, medical, gender and socio-economic aspects of osteoporosis associated vertebral fractures treated with operation.
223795867|NCT02403726|PROCEDURE|Non-operative treatment|Analyzation of demographic, medical, gender and socio-economic aspects of osteoporosis associated vertebral fractures treated with non-operative treatment.
223795868|NCT06219746|DIAGNOSTIC_TEST|PSMA-imaging|Subjects undergo additional imaging i.e. PSMA/SPECT/CT and PSMA/PET/CT
223795869|NCT04219748|BEHAVIORAL|Case Management|"Participants will receive an intensive Case Management (CM) intervention conducted by a multidisciplinary team (Psychiatry, Social Work, Nursing) during 2 months. The intervention will encompass attending weekly or biweekly appointments with the CM team, the interviews will last approximately 30 minutes.~This CM intervention will include referral to Hospital Clínic de Barcelona Addiction Outpatient Clinic and a personalised assessment of the medical, psychiatric and social situation of each individual by the CM team. An individualised care plan will be established and periodically reviewed by the multidisciplinary team in response to a better understanding of patient needs or to a change in patient health condition.~The intervention will offer motivational interviewing psychotherapy to enhance motivation to reduce or to quit alcohol use, in crisis intervention, coordination of care, patient education and self-management support, and assistance to navigate in the healthcare system."
223795870|NCT05952180|DEVICE|Virtual reality and Cycloergometer|The session performed uses a standard cycloergometer, with the participant pedaling in a seated position with the lower limbs. A 43 inches TV screen is placed in front of the cycloergometer where the participant will watch a video of a walk through a natural environment on. The speed of the walk is linked to the pedaling speed so that the faster the participant pedals, the faster the video goes too. The session last 30 minutes in the participant's room.
223795871|NCT05952180|OTHER|Standard cycloergometer|the session uses usual cycloergometer with the participant pedaling in a seated position with the lower limbs. The session lats 30 minutes in the participant's room.
223795872|NCT01541228|DEVICE|Photodynamic therapy with light dose of 70 J/cm2 using a broad-band red light source|"Patients take part in intraindividual (left-right) comparison study when having at least 2 non-hyperkeratotic actinic keratoses (AK) on the left and right sides of the face/scalp.~Punch biopsies in 3.5 millimetres diameter performed to confirm the diagnosis of AK.~Patients randomized so that half of them would receive a light dose of 70J/cm2 as their first split face/scalp treatment on the left side. Photodynamic therapy with the light dose of 70 J/cm2 using a broad-band red light source (570-670 nm,Curelight®, PhotoCure, Oslo, Norway) and 20% 5-ALA. Treatment repeated twice with two weeks interval."
223795873|NCT01541228|PROCEDURE|Photodynamic therapy with 100J/cm2 light dose using a broad-band red light source|"Patients take part in intraindividual (left-right) comparison study when having at least 2 non-hyperkeratotic actinic keratoses (AK) on the left and right sides of the face/scalp. Punch biopsies in 3.5 millimetres diameter performed to confirm the diagnosis of AK.~Patients randomized so that half of them would receive a light dose of 100J/cm2 as their first split face/scalp treatment on the left side. Photodynamic therapy with the light dose of 70 J/cm2 using a broad-band red light source (570-670 nm,Curelight®, PhotoCure, Oslo, Norway) and 20% 5-ALA.Treatment repeated twice with two weeks interval."
223795874|NCT03752229|DEVICE|Acti-Lance Lite|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
223795875|NCT03752229|DEVICE|Acti-Lance Universal|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
223795876|NCT03752229|DEVICE|Acti-Lance Special|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
223795877|NCT03752229|DEVICE|Medlance Plus Super Lite|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
223795878|NCT03752229|DEVICE|Medlance Plus Lite|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
223795879|NCT03752229|DEVICE|Medlance Plus Universal|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
223795880|NCT03752229|DEVICE|Medlance Plus Extra|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
223795881|NCT03752229|DEVICE|Medlance Plus Special|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
223795882|NCT03752229|DEVICE|Prolance Micro Flow|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
223795883|NCT03752229|DEVICE|Prolance Low Flow|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
223795884|NCT03752229|DEVICE|Prolance Normal Flow|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
223795885|NCT03752229|DEVICE|Prolance High Flow|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
223795886|NCT03752229|DEVICE|Prolance Max Flow|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
223795887|NCT03752229|DEVICE|Prolance Pediatric|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
223795888|NCT03752229|DEVICE|Haemolance Micro Flow|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
223795889|NCT03752229|DEVICE|Haemolance Low Flow|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
223795890|NCT03752229|DEVICE|Haemolnace Normal Flow|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
223795891|NCT03752229|DEVICE|Haemolance High Flow|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
223795892|NCT03752229|DEVICE|Haemolance Max Flow|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
223795893|NCT03752229|DEVICE|Haemolance Pediatric|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
223795894|NCT03752229|DEVICE|MediSafe Solo 29 Gauge|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
223795895|NCT03752229|DEVICE|MediSafe Solo 23 Gauge|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
223795896|NCT03752229|DEVICE|ergoLance Micro Flow|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
223795897|NCT03752229|DEVICE|ergoLance Normal Flow|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
223795898|NCT03752229|DEVICE|ergoLance High Flow|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
223795899|NCT03752229|DEVICE|Medlance (light blue)|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
223795900|NCT03752229|DEVICE|Medlance (blue)|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
223795901|NCT03752229|DEVICE|Medlance (dark blue)|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
223795902|NCT03752229|DEVICE|Medlance (yellow)|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
223795903|NCT03752229|DEVICE|Medlance (orange)|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
223795904|NCT03752229|DEVICE|Medlance (red)|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
223795905|NCT03752229|DEVICE|Unistik 3 Extra|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
223795906|NCT03752229|DEVICE|Unistik 3 Comfort|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
223795907|NCT03752229|DEVICE|Unistik Touch|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
223795908|NCT03752229|DEVICE|ReadyLance (blue)|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
223795909|NCT03752229|DEVICE|ReadyLance (orange)|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
223795910|NCT03752229|DEVICE|AssureLance|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
223795911|NCT03752229|DEVICE|AssureLance MicroFlow|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
223795912|NCT03752229|DEVICE|Surgilance|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
223795913|NCT03752229|DEVICE|Surgilance Lite (grey)|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
223795914|NCT03752229|DEVICE|Surgilance Lite (purple)|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
223795915|NCT03752229|DEVICE|SteriLance Lite2|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
223795916|NCT03752229|DEVICE|SensiLance (pink)|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
223795917|NCT03752229|DEVICE|SteriLance Press|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
223795918|NCT03752229|DEVICE|SensiLance (orange)|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
223795919|NCT03752229|DEVICE|mylife|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
223795920|NCT03752229|DEVICE|VeriFine|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
223795921|NCT03752229|DEVICE|Microdot|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
223795922|NCT02131272|DRUG|Insulin detemir|Administered subcutaneously (s.c., under the skin) once or twice daily. The subjects' pre-trial OAD's i.e. metformin treatment should continue unchanged during the treatment period.
223795923|NCT02131272|DRUG|Insulin NPH|Administered subcutaneously (s.c., under the skin) once or twice daily. The subjects' pre-trial OADs i.e. metformin treatment should continue unchanged during the treatment period.
223795924|NCT02131272|BEHAVIORAL|Diet/exercise|Intervention will be performed through family based changes in eating and activity behaviours.
223795925|NCT02486926|OTHER|Sevoflurane|Anesthesia of patients was maintained only with sevoflurane.
223795926|NCT02486926|DRUG|Remifentanil|Anesthesia of patients was maintained with both sevoflurane and continuous remifentanil infusion.
223795927|NCT02486926|DRUG|Alfentanil|Anesthesia was maintained with both sevoflurane and continuous infusion of remifentanil. Alfentanil was administrated (5ug/kg) to patients 10 minutes before the end of surgery.
223795928|NCT02486926|DRUG|Thiopental|General anesthesia was induced with thiopental 5 mg/kg, rocuronium 0.6 mg/kg and sevoflurane in all patients.
223795929|NCT02486926|DRUG|Rocuronium|General anesthesia was induced with thiopental 5 mg/kg, rocuronium 0.6 mg/kg and sevoflurane in all patients.
223795930|NCT05734118|DEVICE|Perfusion assessment by means of the SPY-PHI camera|Minutes after injection of ICG, the intestinal perfusion can and will be assessed using the SPY-PHI camera by Stryker Endoscopy. The operative plan will not be changed based on the results of the perfusion assessment. Images will be recorded and evaluated postoperatively.
223795931|NCT00440648|DRUG|sevelamer carbonate, sevelamer hydrochloride|Starting dose individualized for each patient and fixed daily dose throughout both treatment periods
223795932|NCT00440648|DRUG|sevelamer hydrochloride, sevelamer carbonate|Starting dose individualized for each patient and fixed daily dose throughout both treatment periods
223795933|NCT00605800|OTHER|blood drawn|Baseline levels of bone marrow derived liver stem cells from normal healthy volunteers, which will be drawn once Two 5ml blue tubes).
223795934|NCT00605800|OTHER|blood drawn|At the time of preoperative testing, patients will have two extra test tubes (5cc blue top) of blood drawn for determination of pre-operative base line levels of bone marrow derived liver stem cells in peripheral blood. Intraoperatively, blood will be drawn after liver resection (two tubes of 5cc blue top). Two extra tube of blood will be drawn at the same time of routine postoperative blood drawing to determine levels of bone marrow derived liver stem cells in peripheral blood on post-operative days #1, and #3.
223795935|NCT05188573|DEVICE|Early detection pancreatic cancer test|Blood collection and pancreatic cancer early detection testing with return of results
223795936|NCT05188573|DEVICE|Early detection pancreatic cancer test and MRI Imaging|Blood collection and pancreatic cancer early detection testing with return of results and MRI Imaging
223795937|NCT05560672|OTHER|Human Umbilical Cord blood mononuclear cells|Intravenous infusion of cord blood mononuclear cells
223795938|NCT04195009|PROCEDURE|major surgery under opioid free anesthesia without regional anesthesia|measuring nociception in every patient but blinded for attending anesthesiologist
223795939|NCT04474626|DRUG|Isoquercetin|Oral, 1 time per day, per predetermined dosed per 28 treatment cycle.
223795940|NCT06204627|DEVICE|TDCS|Technique of non-invasive brain stimulation by direct current (TDCS) which involves the modulation of excitability and brain activity, capable of promoting reorganization of the cortical representation of the body schema or motor planning, and consequently, pain relief.
223795941|NCT06204627|DEVICE|Recognize (hand) - Laterality|This technique stimulates the ability to recognize hand images as right/left quicklPatients with chronic pain present delayed recognition of hand laterality, which is related to the duration of symptoms and the pain evoked by the execution of the movement. Thus, this technique can have beneficial effects in breaking the pain.
223795942|NCT06204627|OTHER|Sham TDCS|TDCS sham: The device remains inactive for 20 minutes.
223795943|NCT06204627|OTHER|Landscape recognition|Image recognition training that does not refer to right/left discrimination.
223795944|NCT02462876|DEVICE|GORE® VIABAHN® Endoprosthesis|Treatment of Popliteal Artery Aneurysm with the GORE® VIABAHN® Endoprosthesis.
223795945|NCT04417023|OTHER|B3 for NMD: Bench to Bedside and Back|Transformative discoveries leading to improved care in Neuromuscular Disease
223795946|NCT04320628|DEVICE|AnaSept®|AnaSept® AnaSept® Antimicrobial Skin and Wound Cleanser is a clear liquid consisting of 0.057% sodium hypochlorite (NaOCl) in an isotonic saline. It has a broad-spectrum of antimicrobial action inhibiting the growth of Staphlyococcus aureus, Psuedomonas aeruginosa, Escherichia coli, Proteus mirabilis, Serratia marcescens, Clostridium difficile, including antibiotic resistant Methicillin Resistant Staphylococcus aureus (MRSA), Vancomycin Resistant Enterococcus faecalis (VRE), Carbapenem Resistant E.coli (CRE) and Acinetobacter baumannii, that are commonly found in wound bed as well as fungi such as Candida albicans and Aspergillus niger. However, NaOCL is non-toxic to mammalian cells.
223795947|NCT04320628|OTHER|NSS|NSS
223795948|NCT05986175|OTHER|Motor Imagery Training|The motor imagery training will be given with an audio recording containing 15 minutes of motor imagery training. The protocol will be administered by a physiotherapist 3 times a week for 8 weeks.
223795949|NCT05986175|OTHER|Core Stabilization Exercises|Jeffreys' Core (body) Stabilization Exercises will be implemented. The protocol consists of exercises that progress gradually from the first level to the third level. The first level consists of static contraction training on a stable surface; the second level is dynamic training on stable surfaces; and the third level is dynamic and resistant training on an unstable surface. Each session is scheduled to last 45 minutes, with 5 minutes of heating and 5 minutes of cooling exercises. The protocol will be administered by a physiotherapist 3 times a week for 8 weeks.
223795950|NCT01922115|DRUG|Trospium Chloride|Subject will be administered either placebo or 60 mg dosage of Sanctura XR for treatment of overactive bladder. Subject will take Sanctura XR once every morning. Blood will be drawn for plasma extraction at each visit.
223795951|NCT01922115|DRUG|Placebo|
223795952|NCT03191318|OTHER|ERAS pathway|ERAS pathway after laparoscopic sleeve gastrectomy
223795953|NCT03191318|OTHER|Standard pathway|Standard pathway after laparoscopic sleeve gastrectomy
223795954|NCT04977050|DIAGNOSTIC_TEST|Quidel quickvue antigen test for COVID-19|rapid antigen test on nasal swab specimen for COVID-19
223795955|NCT05082038|DEVICE|Mandibular partial rehabilitation with IF Tapared implants|2 IF Tapared Implants (Group IF) on one side of the mandible
223795956|NCT05082038|DEVICE|Mandibular partial rehabilitation with CF Tapared implants|2 CF Tapared Implants (Group CF) on the other side of the mandible
223795957|NCT05807451|PROCEDURE|High Tibial Osteotomy (Uniplanar and Biplanar )|High Tibial Osteotomy using monoplanar and biplanar osteotomy techniques
223795958|NCT02552004|DEVICE|pCLE|Histological examination by pCLE technique preceding the frozen section
223795959|NCT02552004|DRUG|IV fluorescein administration|IV Fluorescein (fluorescent contrast agent) administration
223795960|NCT03280758|BEHAVIORAL|Muscle Strengthening exercises|Participants will be required to participate in resistance training 3 hours per week.
223795961|NCT04917523|BIOLOGICAL|SARS-CoV-2 Vaccine (Vero Cell), Inactivated|0.5 mL per dose, containing 6.5U inactivated SARS-CoV-2 antigen
223795962|NCT02203474|DRUG|Tiotropium HFA BAI 5 mcg|
223795963|NCT02203474|DRUG|Tiotropium 18 mcg Capsule|
223795964|NCT02203474|DRUG|Placebo|Placebo
223795965|NCT02107118|BIOLOGICAL|ARM 1: AdMSC: adipose stem cells|Adipose tissue will be harvested from all patients as previously described and stem cells will be cultured. Cells are returned to the study doctor for installation into the subject every 2 weeks for 3 months.
223795966|NCT02107118|OTHER|ARM 2: Placebo|Adipose tissue will be harvested from all patients as previously described and stem cells will be cultured. For those subjects in the placebo arm, the stem cells will be frozen for later use after one year when the patients cross over into the treatment arm.
223795967|NCT03025906|DRUG|Phenobarbital|In the PB group, a loading dose of 20 mg/kg (may give an additional 10 mg/kg) begins at a rate of 50 mg/min followed by IV 100 mg q6 h.
223795968|NCT03025906|DRUG|Valproate|In the VPA group, a loading dose of 30 mg/kg (may give an additional 15 mg/kg) begins at a rate of 3 mg/kg per min followed by a continuous infusion at a rate of 1-2 mg/kg per hour.
223795969|NCT01786512|DRUG|Omecamtiv Mecarbil Matrix F1 Formulation|Modified release tablets for oral administration
223795970|NCT01786512|DRUG|Omecamtiv Mecarbil Matrix F2 Formulation|Modified release tablets for oral administration
223795971|NCT01786512|DRUG|Placebo|Modified release tablets matching to omecamtiv mecarbil
223795972|NCT01786512|DRUG|Omecamtiv Mecarbil Swellable Core Technology F2|Modified release tablets for oral administration
223795973|NCT03464812|BEHAVIORAL|DSMES|It is primarily an educational intervention that is focused on assisting patients improve their management and coping with type 2 diabetes.
223795974|NCT06013644|DEVICE|Acupuncture needle|a weekly session for 4-6 weeks on needle for each acupoint for at least 20 minutes the included acupoints are ST6, ST7, SI 18, ST 19, GB 2
223795975|NCT06013644|DEVICE|Dry needle|a weekly session for 4-6 weeks the trigger point is held by thumb and index fingers and the needle approaches the point perpendicular to the skin and rotated clockwise for 2-3 minutes
223795976|NCT06013644|DRUG|Botox Injectable Product|each patient will receive a one time treatment of a suitable dose (estimated by the research team) according to the severity of the symptoms
223795977|NCT03166618|DEVICE|Juvéderm® VOLUMA XC|Juvéderm® VOLUMA XC hyaluronic acid injectable gel
223795978|NCT01954979|DRUG|Abatacept|The study will follow a standard 3+3 design with two escalating doses of abatacept to determine the maximum tolerated dose (MTD): 3 mg/kg (dose level 1) and 10 mg/kg (dose level 2). Dose-limiting toxicities (DLTs) are defined as any Grade 3 or 4 toxicities judged to be probably or definitely related to abatacept.
223795979|NCT04455672|DEVICE|splints|"* Scaning of the maxillary and mandibular cast in the centric relation.~* The CAD/ CAM splints will be designed using Exocad s.~* The design will include all maxillary teeth and the occlusal surfaces will be flat and smooth.~* The difference in design between the ARS and the stabilization splint, is that the ARS will have an anterior ramp to allow for posterior disocclusion of posterior teeth, while the stabilization splint will not have such a pronounced anterior ramp.~* Both splints will be printed using Dent2 3D printer and then cured using Dentcure.~* All patient will be asked to wear their spints during sleeping only.~* In each group, patient will be recalled after 1week,2 weeks 1,2and 3monthes then change for the other splint for another 3 months ."
223795980|NCT05707533|PROCEDURE|TVM using the Vaginal Adventitia Reserved and Anatomical Implant Technique|The Transvaginal mesh procedure with Vaginal Adventitia Reserved and Anatomical Implant Technique for the treatment of POP. The Cefoxitin Injection Solution was used for Prophylactic antibiotics
223795981|NCT00522158|DRUG|simvastatin|
223795982|NCT00522158|DRUG|atorvastatin|
223795983|NCT04546308|OTHER|Resistance exercise training|Eight weeks whole-body resistance exercise training (80%1 repetition maximal, 3 sessions per week) followed by a 4-week detraining intervention
223795984|NCT00605293|DRUG|methoxy polyethylene glycol-epoetin beta|120, 200 or 360 micrograms iv/month (starting dose)
223795985|NCT00605293|DRUG|Epoetin alfa|As prescribed
223795986|NCT00950066|DRUG|IRBESARTAN (SR47436)|Oral administration of Irbesartan 150mg or 300mg once a day
223795987|NCT00950066|DRUG|Amlodipine|Oral administration of Amlodipine 5mg once a day
223795988|NCT00950066|DRUG|Irbesartan / Amlodipine|Oral administration of Irbesartan 150 mg / Amlodipine 5mg or Irbesartan 300mg / Amlodipine 5mg once a day
223795989|NCT00950066|DRUG|Placebo|Oral administration of a placebo once a day
223795990|NCT04593433|OTHER|Museum virtual guided tours|The intervention is a participatory art-based activity which consists in MMFA virtual guided tours. Each virtual guided tour is performed with a group of 5 participants. They meet online one time per week for a 20 to 25 min of a visit tour during a 3-month period. Each tour is different and supervised by a MMFA trained guide.
223795991|NCT02353650|DIETARY_SUPPLEMENT|Q10|
223795992|NCT02353650|DIETARY_SUPPLEMENT|placebo|
223795993|NCT01891916|DIETARY_SUPPLEMENT|Extensively hydrolyzed casein formula + LGG|Extensively hydrolyzed formula containing Lactobacillus GG
223795994|NCT03154801|OTHER|Paramedical care|Paramedical early detection of sexual dysfunction and sexual health counseling
223795995|NCT00798720|DRUG|vorinostat|400 mg by mouth once daily for days 1-14 of each 21 day cycle
223795996|NCT00798720|DRUG|bortezomib|1.3 mg/m2 IV on days 1, 4, 8, 11 of each 21 day cycle
223795997|NCT03137303|DEVICE|Spirometry at initial visit|Initial visit for the intervention group, an initial demographics form and health questionnaires. To evaluate the breathing, a pre and post broncho dilator will be performed as well as a spirometry test.
223795998|NCT03137303|DRUG|Albuterol|The post broncho dilator spirometry test will be preformed after a breathing medication called Albuterol. Albuterol is used in standard practice for COPD and is commonly used during spirometry.
223795999|NCT03137303|DEVICE|Spirometry at 12-month follow-up|At the end of the 1 year followup, the patient will be scheduled for a pre and post BD spirometry test and undergo the same spirometry protocol as the intervention group.
223796000|NCT00986206|DIAGNOSTIC_TEST|Biomarker LPA and HE4|Non Interventional Trial
223796001|NCT02852551|DRUG|PAT-1251|
223796002|NCT02852551|DRUG|Placebo|
223796003|NCT05682053|DIAGNOSTIC_TEST|Multiparametic MRI|patients will have a Multiparametric MRI
223796004|NCT02934490|DEVICE|Mesh|Meshes were made by Gynemech TM PS, (Johnson \& Johnson Shanghai Medical Equipment Co. SFDA registration No. 3460365, size 10 × 15cm)
223796005|NCT02170987|DRUG|Dabigatran etexilate low|
223796006|NCT02170987|DRUG|Dabigatran etexilate high|
223796007|NCT02170987|DRUG|Moxifloxacin|
223796008|NCT02170987|DRUG|Placebo|
223796009|NCT03604081|OTHER|CIMT|Intervention group will receive one hour of intense massed practice of lower extremity either in the form of shaping or task practice.
223796010|NCT03604081|OTHER|Conventional Physical Therapy|1 hour as per current standard of care that follows stroke clinical practice guideline.
223796011|NCT04530890|DIAGNOSTIC_TEST|Blood samples|Only blood samples at different times of treatment
223796012|NCT05959122|DIAGNOSTIC_TEST|CBC serum iron serum ferritin|"1. Fully automated blood cell counter (sysmex-Xs 800i) and AU 480-Chemistry auto-analyzer (Beckman Coulter Diagnostics-USA) was used for measurement of hemoglobin and serum iron levels~2. Chemiluminescence assay using an Abbott i2000SR analyser was used to measured serum ferritin"
223796013|NCT01204801|DEVICE|Focused Microwave Thermotherapy|Anthracycline Doxorubicin 60mg/m2 (or Epirubicin 100 mg/m2) + Standard of Care chemotherapy and drugs + Thermotherapy. Thermotherapy at first 3 chemotherapy treatments for Anthracycline chemotherapy nominally every 21±7 days plus Standard of Care chemotherapy. (A targeted tumor temperature of 44ºC (plus or minus 1.5ºC) and a targeted thermal dose of 80 equivalent treatment minutes (plus or minus 20 treatment minutes)). In the event that the targeted minimum cumulative thermal dose of 180 equivalent treatment minutes is not achieved in the first three treatments, an optional fourth thermotherapy treatment may be administered in combination with the fourth course of Anthracycline and standard of care chemotherapy. Standard of care (including breast imaging, drugs, and radiation) will be provided to all eligible subjects during and following the above study treatments.
223796014|NCT01204801|DRUG|Chemotherapy (control)|Anthracycline Doxorubicin 60mg/m2 (or Epirubicin 100 mg/m2) + Standard of Care chemotherapy and drugs. Anthracycline chemotherapy nominally every 21±7 days. Standard of care (including breast imaging, drugs, and radiation) will be provided to all eligible subjects during and following the above study treatments.
223796015|NCT00689767|DEVICE|CINATRA™ Coronary Stent System|Bare metal cobalt chromium stent implantation
223796016|NCT00689767|DEVICE|CINATRA™ ISA 247 Coated Coronary Stent System|Drug coated cobalt chromium stent implantation
223796017|NCT01556373|OTHER|NA : non interventional study|NA : non interventional study
223796018|NCT03322969|DRUG|Paclitaxel/DDP|receiving the modified chemotherapy
223796019|NCT03322969|DRUG|XELOX/SOX|receiving the original chemotherapy
223796020|NCT05667220|DRUG|Sitagliptin|Sitagliptin monotherapy group (Group A): 20 eligible patients were planned to be included and given Sitagliptin 100 mg Qd orally; the treatment period was 1 week.
223796021|NCT05667220|DRUG|Sitagliptin combined with Beidougen capsule|Sitagliptin combined with Beidougen capsule treatment group (Group B): 20 eligible patients were planned to be included and given sitagliptin 100mg Qd orally combined with Beidougen capsule 60mg Tid orally. The treatment period was 1 week.
223796022|NCT01440400|PROCEDURE|Ultrasound guided spinal anesthesia|Using the ultrasound to identify the spinal puncture level, mid-line and the depth of the dura.
223796023|NCT02566018|PROCEDURE|treatment/medical device|The new treatment algorithm was applied to all patients with proximal humerus fracture as from May 2013 onwards
223796024|NCT02566018|PROCEDURE|standard|The old treatment algorithm was applied to all patients with proximal humerus fracture up to May 2013.
223796025|NCT05550116|OTHER|Giomer|fluoride-releasing coating material containing surface reaction-type pre-reacted glass-ionomer (S-PRG) fillers
223796026|NCT05550116|OTHER|Two composite resin sealants|Unfilled composite resin sealants
223796027|NCT02858050|DEVICE|Portal-724 MEMs Cap|
223796028|NCT05186870|OTHER|Outcome measures|Observational study
223796029|NCT00546585|BIOLOGICAL|Influenza A/H7N7 Vaccine|Monovalent subvirion H7N7 vaccine, 4 dose levels of vaccine, each subject will receive 2 doses (7.5, 15, 45, or 90 micrograms); the same dose will be given at Day 0 and Day 28.
223796030|NCT00546585|DRUG|Placebo|Sterile normal saline for injection (0.9%); 0.5 ml volume sodium chloride injection. Subjects will receive 2 doses on Day 0 and Day 28.
223796031|NCT02943603|DRUG|mFLOFOX6 + pembrolizumab|the combination of mFOLFOX6 + pembrolizumab is the single intervention even though the is dosed differently.
223796032|NCT06034587|DIAGNOSTIC_TEST|multimodal ultrasound|An Aixplorer ultrasound machine (SuperSonic Imaging, Ltd, Aixen-Provence, France), equipped with AngioPLUS(AP) and shear wave elastography(SWE) functions, was used for all examinations using a 4-15MHz linear probe.AP function can detect microvessels of lesions,SWE can evaluate the stiffness of lesions and high frequency ultrasound can measure the thickness and volume of keloid.
223796033|NCT06034587|RADIATION|radioisotope applicator therapy|The radioisotope applicator therapy utilized 90Sr-90Y(0094SR814975) isotope, customized by the China Atomic Energy Research Institute. The element therapy instrument used had overall dimensions of 2.8cm x 2.8cm, with an effective treatment area of 2.0cm x 2.0cm. It delivered a radiation dose of 5.0Gy/h. Each patient received superficial radiation therapy through a single 90Sr source, administered in repeated doses. The isotope therapy instrument was customized to fit the exact size of the keloid, ensuring coverage the irradiation range extending 0.5cm beyond the keloid's edge. During treatment, the surface of the applicator was aligned with the irradiated area and directly contact the surface of the keloid tissue. The treatment was carried out low-dose irradiation method, over 5 sessions, with each session delivering a dose of 2Gy. Each irradiation lasted for 25min.
223796034|NCT00668954|DIETARY_SUPPLEMENT|Pomegranate Juice|Group A drinks 8 oz. pomegranate juice/day for 12 weeks
223796035|NCT00668954|DIETARY_SUPPLEMENT|Placebo Juice|Group B drinks 8 oz. placebo juice/day for 12 weeks
223796036|NCT06096051|PROCEDURE|Use of fixed-dosed 4F-PCC|Determine if fixed-dose 4F-PCC is safe and effective in patients with DOAC-associated ICH when compared to weight-based dosing.
223796037|NCT03663868|DIAGNOSTIC_TEST|CC-Test|Classification of the oocyte/embryo based on the gene expression pattern observed in the cumulus cells
223796038|NCT00478348|PROCEDURE|Prosthetic repair of abdominal incisional hernia|Rives-Stoppa repair of incisional hernia
223796039|NCT03210805|DIETARY_SUPPLEMENT|Omega-3 Polyunsaturated Fatty Acids Supplementation|28 days of a commercially available supplement. 4 capsules per day.
223796040|NCT05455099|RADIATION|Carotid ultrasound examination 1|Participants will be assigned to obese group (body mass index 24.0-27.9 kg/m²). Carotid pulse wave velocity of all participants were measured by ultrafast ultrasound imaging technology using SuperSonic Imagine's explorer ultrasound system.
223796041|NCT05455099|RADIATION|Carotid ultrasound examination 2|Based on the inclusion criteria, 1200 overweight Han people（body mass index ≥28.0 kg/m²） and both sexes will be recruited in the analysis. The values of ultrafast pulse wave velocity will be obtained.
223796042|NCT03561090|DRUG|IW-3718|oral tablet
223796043|NCT03561090|DRUG|placebo|oral tablet
223796044|NCT03561090|DRUG|Standard-dose PPIs QD|background therapy
223796045|NCT04082546|PROCEDURE|Surgical unroofing of muscle-briged coronary artery|Medical therapy with beta-blockers or calcium-channels blockers
223796046|NCT00373399|DRUG|Inactive Marijuana (0% THC)|Placebo marijuana was administered using a cued-smoking procedure, which produces reliable increases in heart-rate and plasma THC. All marijuana cigarettes were administered in a double-blind fashion.
223796047|NCT00373399|DRUG|Low THC marijuana (1.8 %THC)|Active marijuana (1.8 % THC) was administered using a cued-smoking procedure, which produces reliable increases in heart-rate and plasma THC. All marijuana cigarettes were administered in a double-blind fashion.
223796048|NCT00373399|DRUG|High THC marijuana (3.9% THC)|Active marijuana (3.9%) was administered using a cued-smoking procedure, which produces reliable increases in heart-rate and plasma THC. All marijuana cigarettes were administered in a double-blind fashion.
223796049|NCT05225246|OTHER|Data collection on reasons for unplanned readmission to the University Hospital Basel within 30 days of leaving the hospital|Descriptive analysis of the reasons for unplanned readmissions after cardiac surgery and predictive factors for unplanned readmissions and validation of risk scores
223796050|NCT00962195|DIETARY_SUPPLEMENT|purple sweet potato (PSP)-juice|Daily oral intake of 3x 125 ml of PSP-juice or control juice
223796051|NCT01549431|DRUG|Panobinostat|"Panobinostat will be supplied as 5-mg or 20-mg pink/opaque-colored, hard gelatin capsules. Panobinostat is administered orally three times per week.~* Standard 3+3 design~* 3 out of 4 weeks"
223796052|NCT01549431|DRUG|Carfilzomib|"Carfilzomib in Cycle 1 will be initiated intravenously at 20 mg/m² on Days 1 and 2 and escalated to 27 mg/m² for Days 8, 9, 15, and 16 of Cycle 1 and for the duration of treatment.~* Standard 3+3 design~* Days 1/2, 8/9 and 15/16 every 4 weeks"
223796053|NCT01549431|DRUG|Dexamethasone|Dexamethasone (4 mg) must be given prior to each carfilzomib infusion during Cycle 1. Dexamethasone pre-dose should continue through Cycle 2 if fever is observed post-dose, Cycle 2 Day 1, or thereafter associated with the infusion of carfilzomib.
223796054|NCT06579482|DRUG|Aesculus hippocastanum, and associations|combination product
223796055|NCT05193591|OTHER|Autoantibodies evaluation in lupus|"Biological analysis: anti-C1s, anti-HMGB1 and anti-C1q autoantibodies; C1s, HMGB1 and C1q proteins.~Purification of patients' autoantibodies (anti-C1s, anti-HMGB1and anti-C1q). Identification of the molecular targets recognized by anti-C1s, anti-HMGB1 and anti-C1q autoantibodies purified from the SLE patients' serum."
223796056|NCT06578962|OTHER|Phase 1: short intensive treatment phase|During the treatment phase (phase 1), all subjects of the study applied the tested product RV3438G, thrice a week, for 2 weeks.
223796057|NCT06578962|OTHER|Phase 2 : Tested product RV3438G associated with gentle balancing shampoo|"During maintenance phase (phase 2):~the tested product RV3438G was applied once a week for 8 weeks the gentle balancing shampoo RD1089O was applied twice a week alternately with the RV3438G shampoo, for 8 weeks."
223796058|NCT06578962|OTHER|Phase 2 : Tested product RV3438G associated with neutral shampoo|"During maintenance phase (phase 2):~the tested product RV3438G was applied once a week for 8 weeks the neutral shampoo RD0057H was applied twice a week alternately with the RV3438G shampoo, for 8 weeks."
223796059|NCT06578962|OTHER|Phase 2 : neutral shampoo|"During maintenance phase (phase 2):~the neutral shampoo RD0057H was applied thrice a week for 8 weeks."
223796060|NCT06580288|DRUG|Finerenone|10mg or 20mg
223796061|NCT06580288|DRUG|Placebo|10mg or 20mg
223796062|NCT05441085|DEVICE|programed intermittent epidural bolus interval 90 (EI90)|programed intermittent epidural bolus interval 90 (EI90) of 10 ml, 0.0625% bupivacaine plus 2 μg/mL fentanyl
223796063|NCT05728723|DEVICE|Android Application|Android Application for 3 months
223796064|NCT05728723|BEHAVIORAL|Pharmacy education|Pharmacy education in hypertensive patients
223796065|NCT03362567|OTHER|Sustained Natural Apophyseal Glides|Subjects in SNAGS group were treated with sustained natural apophyseal glides, twice weekly for six weeks
223796066|NCT03362567|OTHER|Mechanical Cervical Traction|subjects in MCT received mechanical cervical traction, for 15 minutes each session twice in a week for six weeks
223796067|NCT00033696|BIOLOGICAL|filgrastim|
223796068|NCT00033696|DRUG|carboplatin|
223796069|NCT00033696|DRUG|etoposide|
223796070|NCT00033696|DRUG|paclitaxel|
223796071|NCT00033696|DRUG|topotecan hydrochloride|
223796072|NCT00033696|RADIATION|radiation therapy|
223796073|NCT06431282|OTHER|CO2 laser + HA|Probands will be treated with a CO2 laser. Afterwards a HA gel will be applied. To measure microscopic cellular changes, a multiphoton tomography will be used.
223796074|NCT06431282|OTHER|Thulium laser + HA|Probands will be treated with a thulium laser. Afterwards a HA gel will be applied. To measure microscopic cellular changes, a multiphoton tomography will be used.
223796075|NCT02507518|PROCEDURE|PET scan imaging|a PET scan will be done 2 weeks before the start of maintenance therapy and another 16 days after to predict the earlier response to treatment
223796076|NCT02489396|BEHAVIORAL|Nutrition facts automatically or not automatically displayed|"For two months nutrition information on the Rosie site will be displayed in a tab that consumers can click on to display the nutrition facts panels of products. Investigators will use NuVal scores to determine the fifteen healthiest, and fifteen least healthy items in six grocery categories; chips, cookies, cereal \& breakfast, yogurt, ice cream, and frozen pizza. We will then compare the number of clicks on nutrition information for healthier versus less healthy items to determine if there's a possibility of willful ignorance coming into play when choosing to purchase less healthy items."
223796077|NCT02489396|BEHAVIORAL|Nutrition facts in color|For two months the font on products' nutrition facts labels will be displayed in red or green. For this proof-of-concept intervention, the color of a label's display will be determined randomly, in order to gather a clearer picture of whether label color could be leveraged to influence product choice. Items in each grocery category will be randomly assigned to receive green or red labels during the intervention period, so 50% of products in each category have red nutrition facts labels, and 50% have green nutrition facts labels. We will then compare proportions of green to red items purchased during the intervention period with the proportion of those same items purchased during the baseline period, when all labels were in black font.
223796078|NCT02489396|BEHAVIORAL|Nutrition Facts Label in Larger Font|For two months the serving size and calorie lines on the nutrition facts labels will be displayed in a larger font for every item on the Rosie site. Average calories in customer purchases will be quantified using purchase data, and the average calories for online-grocery orders during baseline and intervention periods will be compared.
224264069|NCT05539469|DEVICE|Ortodontika app|parents will download and use Ortodontika smartphone application for all the duration of the study. It will be an aid during orthopedic treatment. During the activations, a notification will be set to remind the daily activation of RME. After the end of the activation protocol, parents will receive a notification every 2 weeks to instruct their children to proper oral hygiene maneuvers. Parents will have to show their children the videos for oral hygiene maintenance every 2 weeks until the end of the study.
224264070|NCT05539469|OTHER|Verbal instructions|verbal instructions will be given chairside to patients and parents regarding RME activation and its cleaning, together with instructions for daily oral hygiene manoeuvres.
223796079|NCT02489396|BEHAVIORAL|Healthier Items First|For two months, instead of the product popularity default-display option in the online store, thirty healthier items will be displayed on the first page in each grocery category. All grocery categories where there is scoring variation between healthy and less-healthy options (i.e. cereal, chips, bakery, sauces, etc.) will be included in the intervention. The thirty-targeted healthy items will be identified using NuVal scores. NuVal scores will not actually be displayed as part of the shopping site, and will be used exclusively as a guide to systematically determine targeted items in each food category. The proportion of targeted healthy items purchased in each category versus non-targeted items purchased during the intervention will be compared to the proportion of targeted vs. non-targeted items purchased during the baseline period.
223796080|NCT06109792|PROCEDURE|implant supported mandibular overdenture|In this crossover study, the patients received overdentures with two successive different pick-up techniques for the locator retentive caps; each technique was evaluated for patient satisfaction with blue and pink retentive inserts.
223796081|NCT05805592|BEHAVIORAL|Screen-to-Move-Program (STEP)|"It is planned as 6 sessions, 1 session per week for children and parents. The program will be introduced to children and parents under the call with Screen-to-Move-Program (STEP)."
223796082|NCT04909242|DRUG|DZD9008|In the double blind, randomised, placebo-controlled trial (Part A - SAD), healthy adult participants will be randomized to receive DZD9008 at different dose levels. There are 5 planned dose cohorts, starting from 50 mg once daily. If tolerated, subsequent cohorts will test increasing doses of DZD9008 or matching placebo, namely 100 mg, 200 mg, 300 mg and 400 mg.
223796083|NCT04909242|DRUG|Placebo|In the double blind, randomised, placebo-controlled trial (Part A - SAD), healthy adult participants will be randomized to receive matching placebo for DZD9008 at different dose levels. There are 5 planned dose cohorts of matching placebo for DZD9008, starting from 50 mg once daily.
223796084|NCT04909242|DRUG|DZD9008|In Part C, healthy adult participants will be enrolled to receive a single dose of DZD9008 as suspension in period 1 and as tablet in period 2.
223796085|NCT04909242|DRUG|DZD9008|Healthy adult participants will be randomized to receive DZD9008 single dose at a defined dose under a cross-over condition with or without food (low-fat in Part B; high-fat in Part D).
223796086|NCT00910923|DRUG|JNJ-38431055|
223796087|NCT04274920|OTHER|Bioactive Glass|Bioactive glass was incorporated in resin composite and its adhesive
223796088|NCT04274920|OTHER|Light cured calcium hydroxide|Light cured calcium hydroxide
223796089|NCT04731454|OTHER|Control Diet (CD)|All food was provided to participants for the duration of the intervention (8 days), including prepared lunches and dinners and ingredients for breakfasts and snacks. A sugar-sweetened juice drink was provided for consumption of one portion per day. Water, milk, coffee, tea and alcohol were consumed as usual.
223796090|NCT04731454|OTHER|Healthy Nordic Diet (ND)|All food was provided to participants for the duration of the intervention (8 days), including prepared lunches and dinners and ingredients for breakfasts and snacks. Water, milk, coffee, tea and alcohol were consumed as usual.
223796091|NCT02077348|DRUG|Insulin withdrawal|Withdrawal of usual (evening) insulin, replaced by Insuman Rapid (10% of the amount of usual evening insulin) as a continuous IV- administration overnight until 8 o'clock on the study day.
223796092|NCT02077348|DRUG|Norditropin|0,4 mg of GH administered at 7.05 A.M. on the study day.
223796093|NCT05699330|DEVICE|Bilateral subgenual cingulate deep brain stimulation (SGC DBS)|Deep Brain Stimulation (DBS) is a neurosurgical procedure involving the implantation of deep brain electrodes, connected via a subcutaneous extension wire, to an implantable pulse generator (IPG, or 'battery') that is implanted below the collarbone. All patients will receive deep brain stimulation (DBS) targeting the subgenual cingulate (SGC) bilaterally. No other changes to pre-existing treatment will be made. This is the only arm in this experiment.
223796094|NCT02163733|DRUG|AZD9291 tablets|AZD9291 tablets: Part A 80mg od, days 1 and 10 only. Part B 80mg od for 12 months.
223796095|NCT02163733|PROCEDURE|Pharmacokinetic sampling - AZD9291|Blood samples taken pre and post dosing of AZD9291 following either a period of fasting or consumption of a meal.
223796096|NCT02163733|OTHER|Dietary Fasted|Fasted from 10 hours prior to dosing with 80mg AZD9291 tablet and 4 hours after dosing
223796097|NCT02163733|OTHER|Dietary High Fat|Allocated breakfast prior to dosing with 80mg AZD9291 tablet
223796098|NCT02163733|PROCEDURE|Pharmacokinetic sampling - AZ5140 and AZ7550|Blood samples taken pre and post dosing of AZD9291 following either a period of fasting or consumption of a meal.
223796099|NCT04347551|OTHER|High velocity/low amplitude cervical spine manipulation|The participants will receive a single cervical spine rotary manipulation to the previously identified palpable cervical segmental fixation. During the performance of the manipulation, the supine participant will rest their arms at the sides of their body. Next, the index finger of the chiropractor's contact hand will be placed on the lamina of the restricted cervical segment. The chiropractor will then rotate the participant's head contralaterally until the barrier of the cervical segments volitional end range is reached. The chiropractor's other hand will be placed behind the participant's head to induce gentle neck rotation contralateral to the chiropractor's thrusting hand. The chiropractor will deliver a manual thrust, with the thrust vector directed towards the participant's opposite eye.
223796100|NCT00713648|DRUG|catridecacog|35 IU/kg body weight, i.v. administration, once every 4 weeks
223796101|NCT04552964|OTHER|Single arm|Far Best Corrected Visual Acuity (BCVA) ; Intra-Ocular Pressure (IOP) assessment ; Fundus examination ; Automated visual field ; Slit lamp examination ; Pregnancy test ; Patient Satisfaction Questionnaire
223796102|NCT03607929|PROCEDURE|optimal|Physiological Saline Solution
223796103|NCT03607929|PROCEDURE|variability|Other solutions
223796104|NCT04681612|DIAGNOSTIC_TEST|MSNA|"Assessed via Muscle Microneurography during the first 14 days of the acute phase.~Indices: busts/min, busts/100bpm"
223796105|NCT04681612|DIAGNOSTIC_TEST|Heart Rate Variability|Assessed via 24hr ECG monitoring during the first 14 days of the acute phase. Indices: Time-domain, Frequency-domain, Non-linear
223796106|NCT04681612|DIAGNOSTIC_TEST|Blood Pressure Variability|Assessed via Ambulatory BPM during the first 14 days of the acute phase. Indices: SD, wSD, ARV, CV
223796107|NCT04681612|DIAGNOSTIC_TEST|CMR|Cardiac Magnetic Resonance during the first 14 days of the acute phase. Assessment of oedema, Late Gadolinium Enhancement ischaemic pattern. Assessment of cardiac function parameters
223796108|NCT04681612|DIAGNOSTIC_TEST|History, Lab, clinical and hemodynamic parameters|1\. Description of event, 2. Risk factors, 3. Medical history, 4. ECG parameters, 5. ECHO parameters, 6. Hemodynamic parameters of acute phase and hospitalization, 7. Coronary angiogram paraemeters, 7. Complete lab parameter assessment, 8. Thrombofilia assessment, 9. SF-12 QoL and Anxiety and Depression Scale (HADS) questionnaires
223796109|NCT02633800|DRUG|Patritumab|Patritumab initial loading dose is 18 mg/kg IV over 60 minutes followed by a maintenance dose of 9 mg/kg IV over 60 minutes (± 10 minutes) every three weeks
223796110|NCT02633800|DRUG|Cetuximab|Cetuximab 400 mg/mg/m\^2 IV loading dose, followed by 250 mg/m\^2 weekly
223796111|NCT02633800|DRUG|Cisplatin|Cisplatin at 100 mg/m\^2 IV infused over 1 hour, every three weeks up to a maximum of 6 cycles
223796112|NCT02633800|DRUG|Carboplatin|Carboplatin IV over 30 to 60 minutes, every 3 weeks for a maximum of 6 cycles
223796113|NCT02633800|DRUG|Placebo|Placebo to match patritumab
223796114|NCT05968001|DRUG|Obinutuzumab|obinutuzumab (G)-contained regimens, including GB, G-CHOP, and G-CVP.
223796115|NCT00480103|DEVICE|in vivo (ANECOVA D-1) or in vitro culture in 25-µl droplets of cleavage medium (Medicult®) under paraffin oil|
223796116|NCT02176551|DRUG|Product 0405|Product 0405 will be administered topically twice daily for 28 days.
223796117|NCT02176551|DRUG|Placebo for Product 0405|Placebo for Product 0405 will be administered topically twice daily for 28 days.
223796118|NCT03212157|OTHER|Glucose infusion|Infusion of 20% dextrose (drug) and using this as an imaging tracer in detecting and staging tumours.
223796119|NCT03212157|DIAGNOSTIC_TEST|Magnetic Resonance Imaging (MRI)|MRI scanners (device) use strong magnetic fields, radio waves, and field gradients to generate images of the organs in the body. Specifically using the MRI scanner with the infusion of dextrose in detecting and staging tumours.
223796120|NCT03212157|DIAGNOSTIC_TEST|FDG PET|FDG is a sugar (glucose) labelled with a small amount of radioactivity which goes to parts of the body that use glucose for energy. PET/CT images are acquired on a single scanner. An FDG PET scan can be used to assess the presence, location and severity of cancers.
223796121|NCT03603210|DEVICE|Drug coated balloon angioplasty|Drug coated balloons are semi compliant percutaneous coronary angioplasty balloons coated with a chemotherapeutic drug such as Paclitaxel used with an excipient which allows rapid absorption to vessel wall upon balloon expansion for 30-60s. This allows coronary angioplasty without any permanent or semi- permanent stent or scaffold provided there are no vessel threatening dissections or significant acute recoil.
223796122|NCT00082173|DRUG|Moxifloxacin|400mg daily for 8 weeks
223796123|NCT02771444|DEVICE|Tomo Assessment|A four-view tomosynthesis examination
223796124|NCT00644631|DRUG|sildenafil|sildenafil 50 mg (initial dose) tablet by mouth 30 to 60 minutes prior to sexual activity for 12 weeks; depending upon safety, efficacy and tolerability, the dose could be increased to 100 mg or reduced to 25 mg, if necessary.
223796125|NCT00644631|DRUG|placebo|placebo tablet by mouth 30 to 60 minutes prior to sexual activity for 12 weeks
223796126|NCT04602130|OTHER|Control|"The control group (n: 48) received no intervention except for the routine clinical practices. The newborns' physiological measurements before, immediately after and 30 minutes after the interventions were taken and recorded on the Newborn Follow-up Form."
223796127|NCT04602130|OTHER|Massage|"The researcher applied massage (n: 48) to the newborns. The newborns' physiological measurements before, immediately after and 30 minutes after the interventions were taken and recorded on the Newborn Follow-up Form."
223796128|NCT04602130|OTHER|Sponge Bathing|"The researcher applied sponge bathing (n: 48) to the newborns. The newborns' physiological measurements before, immediately after and 30 minutes after the interventions were taken and recorded on the Newborn Follow-up Form."
223796129|NCT04602130|OTHER|Tub Bathing|"The researcher applied tub bathing (n: 48) to the newborns. The newborns' physiological measurements before, immediately after and 30 minutes after the interventions were taken and recorded on the Newborn Follow-up Form."
223796130|NCT01733732|OTHER|SYSTANE® BALANCE Lubricant Eye Drops|
223796131|NCT01733732|OTHER|SYSTANE® Gel|
223796132|NCT05362890|DEVICE|DEVICE OPERATING UNDER THE CONTINOUS POSITIVE AIRWAY PRESSURE|The principle of operation is to prevent the closure and the narrowing of the structures of the upper respiratory tract by applying positive pressure. The device consists of a mask that protects the nose and/or mouth, a tube that connects the mask to the monitor and a monitor that blows air into the tube. A pressure in the range of 4 to 20 cm water is applied, depending on the individual needs of the patient to keep the airway open. The use is considered to be effective when the patient uses it continuously for at least 4 hours at bedtime. Today's modern devices have memory cards for storing data on the regularity and time of use of the device during the night and the efficiency of the device itself. For therapy to be considered effective, the number of apneas and hypopneas must be less than 5 per hour of sleep.
223796133|NCT00604526|RADIATION|High dose rate (HDR) brachytherapy using Iridium 192 radioactive seeds|"Pre-tx Sexual function questionnaire Quality of Life baseline, Treatment with HDR (Two days) Treatment: Iridium 192 radioactive seeds temporarily inserted into patient. Post treatment (after HDR) Month 1 (+/- 2 weeks), 3 (+/- 1 month), 6 (+/- 1 month), 9 (+/-1 month), 12 (+/- 1 month)\* NCI CTC GU and GI assessment,IPSS, IIEF, PSA lab test, Prostate HRQOL~\*After 1 year, will follow up with doctor about every 6 months."
223796134|NCT05586568|DRUG|XZP-3621 tablet and itraconazole oral liquid (for Arm1)|There are 2 periods, for the 1st period, the subjects will only take XZP-3621 tablets QD on Day1. For period 2,the subjects will take itraconazole from Day11 to Day13，they will take itraconazole in combinaiton with XZP-3621 on Day14，then take itraconazole only, from Day15 to Day27.
223796135|NCT05586568|DRUG|XZP-3621 tablet and Rifampicin capsules (For Arm 2)|There are 2 periods, for the 1st period, the subjects will only take XZP-3621 tablets qd on Day1 . For period 2,the subjects will take Rifampicin from Day11 to Day17，they will take Rifampicin in combinaiton with XZP-3621 on day18，then take Rifampicin only, from Day19 to Day26.
223796136|NCT05586568|DRUG|XZP-3621 tablet and esomeprazole tablet (For Arm3)|There are 2 periods, for the 1st period, the subjects will only take XZP-3621 tablets QD on Day1 . For period 2,the subjects will take esomeprazole from Day11 to Day 15，they will take esomeprazole in combinaiton with XZP-3621 on Day16.
223796137|NCT05154279|DRUG|Terlipressin|intramyometrial terlipressin vs carbitocin vs saline as placebo
223796138|NCT05283967|DIAGNOSTIC_TEST|urine colorimetric assay|Colorimetric assays will be performed for urine drug concentrations of rifampin, isoniazid and pyrazinamide from urine collected throughout one dosing interval. Assay results will experimental only and not used to change patient care.
223796139|NCT01291498|DEVICE|High Intensity Focused Ultrasound|One or two HIFU sessions
223796140|NCT04342351|DRUG|sacubitril/valsartan|sacubitril/valsartan will be applied from 25mg/b.i.d for 1-2 weeks,50mg b.i.d for 2 weeks, to target dosage 100mg b.i.d for 3 months unless severe safety outcome occurs
223796141|NCT04342351|DRUG|perindopril|Drug: perindopril will be applied from 2mg for q.d for 1-2 weeks, 4mg q.d 2 weeks, to target dosage 8mg q.d for 3 months unless severe safety outcome occur
223796142|NCT04342351|OTHER|Cardiopulmonary Exercise Test|All patients will undergo a first CPET prior to initiation of treatment, a second one after 3 months, and a third one after 6 months of treatment.
223796143|NCT04342351|OTHER|Echocardiogram|An echocardiogram (ultrasound of the heart) will be performed prior to initiation of treatment and then again 3 months, 6 months later.
223796144|NCT01162681|DRUG|A-623|High dose given subcutaneously once a week for up to 52 weeks
223796145|NCT01162681|DRUG|A-623|Low dose given subcutaneously once a week for up to 52 weeks
223796146|NCT01162681|DRUG|A-623|High dose given subcutaneously once every 4 weeks for up to 52 weeks
223796147|NCT01162681|OTHER|Placebo Comparator|Placebo comparator is a matched volume given subcutaneously once a week or once every 4 weeks for up to 52 weeks
223796148|NCT01738750|OTHER|Cost Information Included|
223796149|NCT01094925|DRUG|lactose|Single oral dose
223796150|NCT01094925|DRUG|Gabapentin 300mg|Single oral dose of 300mg gabapentin
223796151|NCT01094925|DRUG|Gabapentin 600mg|Single oral dose of 600mg gabapentin
223796152|NCT02256215|DRUG|Vitamin D|
223796153|NCT05387824|DEVICE|Magnetic stimulation -Armchair type MS • NovaMag NT-60|MS was applied two days a week, 20 minutes a day, a total of 12 sessions for 6 weeks.
223796154|NCT05387824|DEVICE|Electrical Stimulation- TTNS|TTNS were performed 2 days a week, for 30 min a day, for a total of 12 sessions for 6 weeks.
223796155|NCT05387824|BEHAVIORAL|Bladder Training|"Control group All women were informed about BT for 30 minutes. Then it was given as a written brochure to be implemented as a home program.~BT, consisting of four stages, did not contain any PFMT programs in two groups."
223796156|NCT03894852|DIAGNOSTIC_TEST|PCR and cytogenetics|detection of SRSF2 gene mutation and cytogenetic studies
223796157|NCT04741308|BEHAVIORAL|cognitive behavior therapy|The CBT intervention is a 8-times group-based intervention that meets 2-3 weeks.Each session will be performed during chemotherapy and will last for 60 min, including 45 min cognitive behavior therapy and 15 min relaxation training.Our CBT intervention is designed to be conducted in groups of 3 to 6 patients led by two group facilitators. Group leaders will: guide participants relaxation training, develop a supportive group environment, encourage emotional expression, assist participants develop a sense of self-confidence, identify maladaptive coping and encourage adaptive coping responses.
223796158|NCT04206189|DIETARY_SUPPLEMENT|carbohydrate group - carbohydrate (400ml)|Randomly selected patients of the carbohydrate group are given oral carbohydrate (400ml) 2-3 hours before surgery. In contrast, patients in the control group are fasted water 2 hours before surgery according to the standard protocol.
223796159|NCT04139564|DEVICE|EaseVRx headset|EaseVRx is a virtual reality therapy intended to treat chronic pain
223796160|NCT04139564|DEVICE|Active control VR sham program|VR, 2d visual wildlife scenes similar to some EaseVRx content
223796161|NCT02526654|DIAGNOSTIC_TEST|Heidelberg Edge Perimeter|HEP measures peripheral vision
223796162|NCT02526654|DIAGNOSTIC_TEST|Octopus Visual Field|OVF measures peripheral vision
223796163|NCT02526654|DIAGNOSTIC_TEST|Optical Coherence Tomography|OCT measures retinal nerve fiber layer thickness
223796164|NCT06102941|DEVICE|Cognitive Control Training (CT)|4 weeks of an at-home computerized cognitive training program (AKL-T01) delivered on iPad (25 minutes/day, 5 days/week). Styled as a child-friendly video game, AKL-T01 CT taps focused attention, response inhibition, and working memory using a series of games with individually titrated difficulty to engage cognitive control processes.
223796165|NCT00002568|DRUG|cisplatin|
223796166|NCT00002568|DRUG|paclitaxel|
223796167|NCT00002568|PROCEDURE|conventional surgery|
223796168|NCT05400343|PROCEDURE|Standard care (control group)|"Following 24 hours from admission to the ICU, the standard care will be continued according to conventional ICU protocols~The mean fluid intake will range from (2-3L per day) targeting zero or slightly negative balance (up to - 300ml). Various parameters will be used to attain this goal based on case-by-case clinical judgment."
223796169|NCT05400343|PROCEDURE|US-guided ﬂuid management (active group)|Within 24 hours from admission to the ICU, IVC and lung sonography will be performed every other day and according to their measurements, the volume of fluid therapy will be adjusted.
223796170|NCT05400343|OTHER|Standard ICU Care|All patients will receive the usual care for 24 hours according to ICU policies. The main target is to maintain an adequate intravascular volume and good urine output. The mean fluid intake will range from (2-3L per day) targeting zero or slightly negative balance (up to - 300ml). Various parameters will be used to attain this goal based on case-by-case clinical judgment. Lung sounds, heart rate, blood pressure, temperature, urine output, Lactate, haemoglobin, haematocrit, serum urea, creatinine, sodium, potassium, chloride, and bicarbonate values
223796171|NCT00249106|BIOLOGICAL|ADVAX|
223796172|NCT05735873|OTHER|Low-energy diet|Twenty-one pre-made, low-energy meals delivered weekly to the subject for 12 weeks.
223796173|NCT04104581|OTHER|Control Refined Grain Diet|Subjects will be fed the average American diet except it will be free of whole grains
223796174|NCT04104581|OTHER|Low Whole Grain Oat Diet|Subjects will be fed the average American diet with addition of a low level of whole grain oats
223796175|NCT04104581|OTHER|High Whole Grain Oat Diet|Subjects will be fed the average American diet with addition of a high level of whole grain oats
223796176|NCT04104581|OTHER|Low Whole Grain Wheat Diet|Subjects will be fed the average American diet with addition of a low level of whole grain wheat
223796177|NCT04104581|OTHER|High Whole Grain Wheat Diet|Subjects will be fed the average American diet with addition of a high level of whole grain wheat
223796178|NCT03709368|OTHER|Hardware|Community sessions will be provided to each of the sub-villages (n=27) teaching participants how to build a tippy tap, how to build an improved latrine, and how to make liquid soap. In addition, an existing water gravity flow scheme will be rehabilitated and extended, 350 tippy taps and 350 pans for pour flush latrines will be distributed, and sanitation blocks will be built in four schools. Within these schools, SWASH school hygiene clubs will be organized.
223796179|NCT03709368|BEHAVIORAL|CLTS|CLTS sanitation and HW sessions will be given. A first session will focus on sanitation, covering 7 exercises: 1) sanitation or social map, 2) transect walk, 3) shit calculation, 4) medical expenses, 5) shit flow diagram, and 6) water/shit demo, 7) community declaration. A second session will focus on HW, involving 10 exercises: 1) anal cleansing materials, 2) shit and shake, 3) cassava/egg demonstration, 4) charcoal smearing, 5) smelly hands, 6) feces on baby nappies, 7) scratch \& smell, 8) wall contamination, 9) food sharing, 10) dirt under fingernails. These sessions will take approximately 3-5 hours each. Follow-up community meetings and household visits will take place to monitor improvement.
223796180|NCT03709368|BEHAVIORAL|PHAST|PHAST sessions are based on the 'PHAST step-by-step guide: A participatory approach for the control of diarrhoeal disease' of the World Health Organization. Considering the overlap with some CLTS activities, only a selection of the full guideline will be enrolled, namely: 1) Health problems in our community, 2) Good and bad hygiene behaviors, 3) Investigating community practices, 4) How diseases spread, 5) Blocking the spread of disease, 6) Selecting the barriers, 7) Choosing sanitation improvements, and 8) Choosing improved hygiene behaviors. These 8 activities will be enrolled in approximately 40 community groups. Each activity will take between 30 minutes - 2 hours to complete.
223796181|NCT03709368|BEHAVIORAL|RANAS|Nine household visits of 20-40 min each will be offered at a frequency of one visit every two months. The content of these add-on visits is based on the RANAS manual: 'Systematic Behavior Change in Water, Sanitation and Hygiene - A practical guide to using the RANAS approach' (www.ranasmosler.com). First, baseline data is gathered through a questionnaire to better understand the context that is at play. Next, this data is analyzed in a do'er non-do'er analysis. Only those behavioral factors that are significantly different between do'ers and non-do'ers will be included in the intervention, as these are, at least theoretically, considered to be decisive for HW and latrine use behavior in the current setting.
223796182|NCT03709368|BEHAVIORAL|mini-RANAS|Nine household visits of 20-40 min each will be offered at a frequency of one visit every two months. The content of the mini-RANAS add-on intervention is based on the 'Norm Behavior Change Techniques' from the RANAS manual 'Systematic Behavior Change in Water, Sanitation and Hygiene - A practical guide to using the RANAS approach' (www.ranasmosler.com). During the mini-RANAS household visits, emphasis will be put on norms and volunteers will encourage participants to become a role model by improving HW and sanitation infrastructure and behavior.
223796183|NCT03709368|OTHER|Placebo poster|One household visit will be offered. During this visit, a placebo poster will be distributed focusing on first aid. The topics to be discussed are burns, cuts and grazes. The main goal of this household visit is to avoid jealousy among the control cohort.
223796184|NCT05832450|OTHER|Red cell concentrate transfusion|Perioperative data of patient undergoing elective brain tumor resection with requirements of red cell concentrate transfusion.
223796185|NCT03137134|DRUG|Crizotinib|Crizotinib in a coated microsphere formulation
223796186|NCT03137134|DRUG|Esomeprazole|Proton pump inhibitor, esomeprazole
223796187|NCT04289818|OTHER|Health Coaching|Health Coaching as face to face with a coach
223796188|NCT00990158|DRUG|Phytonadione (Vitamin K1)|A daily dose of 150 micrograms of vitamin K medication given orally for a total of 7 months
223796189|NCT00990158|DRUG|Placebo|A daily dose of matching placebo medication given orally for a total of 7 months
223796190|NCT00002153|DRUG|A-007|
223796191|NCT06451172|DRUG|ASO|Anticipated 20 Participants will receive a single group administered via eye drops in the study eye.
223796192|NCT02541708|DRUG|Ferric carboxymaltose|Intravenous Ferric carboxymaltose given at a calculated dose of 20mg/kg body weight in 1-3 infusions according to severity of anemia
223796193|NCT02541708|DRUG|Ferrous sulfate + folic acid|Three dried ferrous sulfate and folic acid tablets every morning 30 mins before the meal. If side effects occur the drug may be taken with the meal or in 2 separate doses per day. The treatment will be pursued for 3 months after correction of anemia
223796194|NCT06372769|DIAGNOSTIC_TEST|electromyograph and kinesiograph|"The sEMG of the anterior temporalis (TA), masseter (MM), sternocleidomastoid (cervical group, CG), and digastric (DA) were recorded simultaneously with an sEMG device (K7/EMG, USA) using disposable silver/silver chloride bipolar surface electrodes.~First, sEMG was conducted on four pairs of muscles (TA, MM, CG, and DA) in the MPP, and subjects were guided to maintain the face and jaw as relaxed as possible. To determine the relative efficiency of muscle function, the second test was performed to measure the sEMG of TA and MM during the maximal biting force against natural dentition. In the third test, subjects were guided to clench three times to monitor early motor unit recruitment as they closed from rest through freeway space to initial tooth contact.~Kinesiographic recordings were performed using a kinesiograph (K7/Computerized Mandibular Scanning (CMS), USA) that measured the maximum mouth opening (MMO) and opening and closing velocities."
223796195|NCT04092218|OTHER|Questionnaire|"Data will be obtained through a written questionnaire to determine the type of parenting style of parents or caregivers.~The collected data will be saved and tabulated on computer and finally statistically analysed."
223796196|NCT02438618|PROCEDURE|Surgery for Ponto bone anchored hearing aids|
223796197|NCT03583216|DIAGNOSTIC_TEST|Diabetic pregnancy|Blood samples will be drawn before delivery to evaluate Factor XII level.
223796198|NCT03583216|DIAGNOSTIC_TEST|Non-diabetic pregnancy|Blood samples will be drawn before delivery to evaluate Factor XII level.
223796199|NCT04386096|OTHER|Mehealth for ADHD software with medication continuity tools|Medication continuity tools integrated within the mehealth for ADHD software will assess factors influencing medication continuity for each adolescent and recommend tools to address relevant factors. Tools include 1) a system to track outcomes and resolve uncertainty about the need for and/or benefit from medicine, 2) a module to address stigma, 3) a module to help manage side effects, and 4) reminders to take medicine and/or request refills.
223796200|NCT04386096|OTHER|Mehealth for ADHD software with no medication continuity tools|"The mehealth for ADHD software has multiple functionalities including 1) online training regarding the American Academy of Pediatrics (AAP) ADHD guidelines; 2) an ADHD workflow wizard that guides pediatricians through the creation of an efficient office workflow to deliver quality ADHD care; 3) online collection of parent- and teacher-report ADHD rating scales for the assessment of ADHD as well as monitoring response to medication treatment; 4) integrated algorithms that automatically score rating scales in real time and provide pediatricians with assessment and treatment reports as well as immediate warnings; 5) an online pediatrician report card; and 6) a Plan-Do-Study-Act wizard that allows pediatricians to select a practice behavior to improve based on their report card and guides them through the creation of small tests of change to improve their office systems."
223796201|NCT00345241|DRUG|Systane Ocular Drops (OTC)|
223796202|NCT00345241|DRUG|Placebo - Saline Drops|
223796203|NCT03626948|DRUG|SK-1403|Patients receive SK-1403 three times a week administered by intravenous bolus injection at the end of each hemodialysis for the whole treatment periods (52 weeks), with individual dose adjustment.
223796204|NCT02025881|DRUG|Carboplatin + etoposide|"Carboplatin 160 mg/m\^2 Day 1 to day 5, as an intravenous infusion over 1 hour. Dilution in 5 % glucose saline or sodium chloride 9 mg/ml (0.9%).~Etoposide 100 mg/m\^2 D ay 1 to day 5, as an intravenous infusion over 1 hour. Dilution in physiological saline or 5 % glucose saline while not exceeding a concentration of 0.4 mg/ml etoposide in the infusion bottle."
223796205|NCT02025881|DRUG|Thiotepa|Thiotepa 200 mg/m² Day-3 to day-1, as an intravenously infusion over 1 hour dilution in 200 ml/m\^2 of 5% glucose saline or sodium chloride 9 mg/ml (0.9%).
223796206|NCT02025881|DRUG|Cyclophosphamide + Busilvex|"Cyclophosphamide:~* Level 1 20 mg/kg/day~* Level 2 30 mg/kg/day~* Level 3 40 mg/kg/day~* Level 4 50 mg/kg/day~Busilvex:~\< 9 kgs 0.8 mg/kg/dose -\> 3.2 mg/kg/day; 9 à \< 16 kgs 0.96 mg/kg/dose -\> 3.84 mg/kg/day; 16 à 23 kgs 0.88 mg/kg/dose -\> 3.52 mg/kg/day; \> 23 à 34 kgs 0.76 mg/kg/dose -\> 3.04 mg/kg/day; \> 34 kgs -\> 0.64 mg/kg/dose."
223796207|NCT02025881|DRUG|Temozolimide + Irinotecan|"During 2 cycles of 21 days:~* Temozolomide: 100 mg/m\^2/day PO from Day 1 to Day 5;~* Irinotecan: 10 mg/m\^2/day IV from Day 1 to Day 5 + from Day 8 to Day 12"
223796208|NCT02025881|COMBINATION_PRODUCT|Etoposide + radiotherapy|"* Etoposide: 35 mg/m\^2/day PO during 21days~* Radiotherapy: 1.8 Gy/fraction/day (total dose: 54 Gy)"
223796209|NCT02025881|DRUG|Temozolomide|150 mg/m\^2/day PO during 5 days, during 6 cycles of 21 days
223796210|NCT02376218|DRUG|Hypertonic 50% dextrose pleurodesis|Intrapleural administration of 180ml of hypertonic dextrose solution.
223796211|NCT00108095|DRUG|intravenous ondansetron|
223796212|NCT01260350|DRUG|SOF|Sofosbuvir (SOF) tablets administered orally once daily
223796213|NCT01260350|DRUG|RBV|Ribavirin (RBV) capsules administered orally in a divided daily dose
223796214|NCT01260350|DRUG|PEG|Peginterferon alfa-2a (PEG) administered via subcutaneous injection once weekly
223796215|NCT01260350|DRUG|LDV|Ledipasvir (LDV) tablets administered orally once daily
223796216|NCT01260350|DRUG|GS-9669|GS-9669 tablets administered orally once daily
223796217|NCT01260350|DRUG|LDV/SOF|LDV/SOF fixed-dose combination (FDC) tablet administered once daily
223796218|NCT06143826|OTHER|Progressive muscle relaxation exercises|Progressive muscle relaxation exercises involve contracting and relaxing 16 muscle groups in the body (hand, upper arm, forearm, forehead, nose, cheek, chin, neck, shoulder, chest, abdomen, waist, stomach, calf, hip, foot). During the exercise, the individual perceives the changes in the muscles during the contraction and relaxation of the muscles. Relaxation exercise is applied along with correct and deep breathing.
223796219|NCT06113627|OTHER|Resistance Therapeutic Exercise|"Strength exercises will be aimed at large muscle groups, such as the shoulder, chest, back and also muscle groups of the lower extremities. In the initial 2 weeks, intervention will start with low intensities of around 55-65% of 1RM, which allows to perform around 15-20 repetitions. The first week there will be performed 2 series, while in the second week it will be 3 series.~Moderate intensity in the 2nd week, corresponding to 65-75% of 1RM and allowing for around 8-12 repetitions. 3 series will be maintained throughout this period of time.In addition to the progressive change in intensity, throughout the intervention the load will be increased by 5-10% when the patient performs the exercise too easily or when they can perform more repetitions than estimated. Rest between sets will be 2-3 minutes."
223796220|NCT05641558|DRUG|611 150mg|subcutaneous injection, 150 mg (single dose treatment period) + 300mg (loading dose, week 0) + 150mg QW (maintenance dose, from Week 1 to Week 15, 15 cycles)
223796221|NCT05641558|DRUG|611 300mg|subcutaneous injection, 300 mg (single dose treatment period) + 600mg (loading dose, week 0) + 300mg Q2W (maintenance dose, from Week 1 to Week 15, 8 cycles)
223796222|NCT05641558|DRUG|611 600mg|subcutaneous injection, 600 mg (single dose treatment period) + 600mg (loading dose, week 0) + 300mg QW (maintenance dose, from Week 1 to Week 15, 15 cycles)
223796223|NCT05641558|OTHER|Placebo|During the study, placebos shall be filled timely according to the administration of the test drug to ensure the consistency of the times of administration in each group, so as to maintain the blind state.
223796224|NCT01936064|DIETARY_SUPPLEMENT|Jobelyn + Cyclophosphamide-Epirubicin6|Jobelyn (dietary Supplement) to be used with Cyclophosphamide-Epirubicin6
223796225|NCT01936064|DRUG|Placebo + Cyclophosphamide - Epirubicin 6|Routine drugs for the treatment of breast cancer to be used with Placebo
223796226|NCT03130400|PROCEDURE|Observational gait analysis procedure|All the participants underwent a standard observational procedure: i) diagnosed with knee injuries/arthritis; ii) For KOA, take radiographic examination (x-ray) and take gait analysis on a treadmill in barefoot; iii) For knee injuries, take gait analysis before surgery, the disease of patients was confirmed by surgery (knee arthroscopy); iv)Normal people take an physical examination to avoid other disease;
223796227|NCT02088268|OTHER|wound healing|wound healing
223796228|NCT01099904|DRUG|RO5024048|multiple oral doses for 5 days
223796229|NCT04644250|DRUG|Toripalimab|Participants will also receive Toripalimab(240mg) VD 30 min on days 3, 24 and 45，3 cycles in total.
223796230|NCT04644250|DRUG|Paclitaxel liposome/Carboplatin|Participants will receive carboplatin (AUC=2) VD 30min and paclitaxel liposome (50mg/m²) CIV 24h on day 3,10,17,24,31, 5cycles in total.
223796231|NCT04644250|RADIATION|Intensity-modulated radiotherapy|A total of 41.4 Gy, 23 fractions of 1.8 Gy on Day 1 to 31.
223796232|NCT05457608|DEVICE|Lens A|monthly replacement multifocal silicone hydrogel contact lens 15 minutes of daily wear
223796233|NCT05457608|DEVICE|Lens B|daily disposable multifocal silicone hydrogel contact lens 15 minutes of daily wear
223796234|NCT02884297|DRUG|Contrast agent: SonoVue®.|SonoVue® Injection: will be done through the peripheral venous way already set up by the anesthetist for its injection. None venous dedicated way will be established. The injection will take place when the woman will be under general anesthesia, ventilated and under constant cardio-respiratory monitoring.
223796235|NCT04319211|OTHER|Determination of physical activity, quality of life, stress levels of isolated people at home with the danger of coronavirus.|The study will include those who isolate themselves at home for fear of contracting Coronavirus disease or suspected of having it. The last three sections of the International Physical Activity Questionnaire (IPAQ) will be used to evaluate the current physical activity level of the participants. Parameters such as housework, home care and family care, rest, sports and leisure physical activities, sitting time will be evaluated. Short Form 12 (Short Form12- SF12) quality of life scale will be used to evaluate health-related quality of life. Beck Depression Scale will be applied to investigate the stress levels of the individuals participating in our study.
223796236|NCT06385808|DRUG|MTBF regimen|"The subjects will be treated with mitoxantrone hydrochloride liposome combined with thiotepa, busulfan and fludarabine as conditioning regimen prior to allo-HSCT.~Mitoxantrone hydrochloride liposome 24mg/m\^2 ivgtt d-7; Ctepide 5mg/kg ivgtt d-6\~-5; Busulfan 0.8mg/kg q6h ivgtt d-4\~-2; Fludarabine 50mg/m\^2 ivgtt d-4\~-2."
223796237|NCT04439422|BEHAVIORAL|Short ADHD Intervention|Short, intensive psychological intervention based on CBT and DBT practices
223796238|NCT04439422|OTHER|Self-help material with limited therapist support|Self-help material from an evidence-based treatment manual for adult ADHD with access to limited therapist support via Internet (control group)
223796239|NCT02530307|DRUG|HT-3951|
223796240|NCT02530307|DRUG|Placebo|
223796241|NCT06213766|DIAGNOSTIC_TEST|Cognitive assessment|"Group 1: Cognitively healthy subject:~After signing the consent form, during the only visit of the study, the investigator will administer to cognitively healthy subjects two cognitive screening tests to ensure that they meet the criteria for group 1. If performance on the cognitive scales prove to be borderline or below current standards (Montreal Cognitive Assessment ≥ 26/30 and MacNair Cognitive Difficulties Self-Rating Scale ≥15) for at least one of the 2 tests, the participant will prematurely end the study and may be offered an in-depth cognitive assessment as part of routine care.~Group 2: Patients suffering from Alzheimer's disease:~After signing the consent form, during the only visit of the study, the investigator will administer to patients the Montreal Cognitive Assessment to assess cognitive status."
223796242|NCT06213766|OTHER|Questionnaires|"For every participants (group 1 and 2):~During the only visit of the study and after the intervention 1, the participants will answer questionnaires about:~* Demographic data such as age, gender, weight, height, education level;~* Lifestyle habits such as usual mode of transport, sense of direction, use of GPS device, and video game practice;~* Quality of sleep over the previous month and the previous night;~* Cognitive reserve questionnaire from Rami et al., 2011;~* Concomitant treatment and comorbidities."
223796243|NCT06213766|DEVICE|Spatial navigation task with eye-tracking.|"For every participants (group 1 and 2):~During the only visit of the study and after interventions 1 and 2, the participants will complete the spatial navigation task with eye-tracking.~The participants will play the Sea Hero Quest video game and take on the role of the captain of a small boat that has to find its way through an aquatic environment. At the start of each level, the player is shown a map of the environment, with the boat's initial position and the buoys it must reach as quickly as possible in a set order. Once the map has been memorised, it disappears and the navigation begins.~Participants will play 6 levels of Sea Hero Quest (two training levels and four different navigation levels). This intervention will be proposed by a trained team member and participants will play on a digital tablet connected to an eye-tracker. The total duration of the task is 30 min (training phase + assessment sequences)."
223796244|NCT06213766|BIOLOGICAL|Blood sampling|"For every participants (group 1 and 2):~During the only visit of the study and after interventions 1, 2 and 3, a state-qualified nurse will take venous samples from 3 tubes of 4ml each.~These blood samples will be frozen and stored until the end of the study when they will be analysed:~* Sample 1: plasmatic Quanterix p-tau217 assay;~* Sample 2: apolipoprotein E genotyping;~* Sample 3: measurement of plasmatic creatinine levels. Neither the cognitively healthy subjects, nor the patients, nor the clinicians in charge of the patients included will be informed of the results of these biological assays (absence of clinical interest established at the present time of the APOE genotype and the p-tau217 protein level, absence of modification of the care pathway, in adequacy to the bioethics law of August 02, 2021. Creatinine level is used in this study as an adjustment variable to interpret the p-tau217 protein level and will not be used for clinical interpretation."
223796245|NCT00245895|DRUG|Aranesp|Aranesp
223796246|NCT05394246|DRUG|FluoAB|Drug Injection: FluoAB (fluorescent-labeled IgG)
223796247|NCT05607693|DRUG|SHR3680 tablets|Subjects start taking SHR3680 tablets 240 mg/dose/day orally on an empty stomach on D1, and the timing of administration daily should be consistent when possible.
223796248|NCT01603069|DRUG|AZD3241 300 mg BID|The following dose escalation schedule will be used for 300 mg BID: 100 mg BID from Day 1 through Day 7. On Day 8, the patients will start maintenance treatment of 300 mg BID for the duration of the treatment period.
223796249|NCT01603069|DRUG|AZD3241 600 mg BID|The following dose escalation schedule will be used for 600 mg BID: 100 mg BID from Day 1 through Day 7 and 300 mg BID from Day 8 through Day 14. On Day 15, the patients will start maintenance treatment of 600 mg BID for the duration of the treatment period.
223796250|NCT01603069|DRUG|Placebo|Placebo to AZD3241 BID
223796251|NCT02621099|DEVICE|Hybrid optical-gamma imaging|Acquisition of images using the camera as additional steps to the standard SLNB procedures.
223796252|NCT04608370|BEHAVIORAL|Active tPBM session|In this project, taking the method of random, double blindness and control, participants in the active tPBM group will take active tPBM session. After that, N-back tests and neuroimaging biomarkers will be compared between active tPBM group and sham tPBM group.
223796253|NCT04608370|BEHAVIORAL|Sham tPBM session|In this project, taking the method of random, double blindness and control, participants in the sham tPBM group will take sham tPBM session. After that, N-back tests and neuroimaging biomarkers will be compared between active tPBM group and sham tPBM group.
223796254|NCT03474341|DIAGNOSTIC_TEST|MRI|"* Anatomical (T2W) and functional MRI (DWI and DCE) at a 1.5T Siemens or Philips scanner~* DWI series: sagittal (sIVIM) and high-resolution transversal (HR tDWI)~* DCE serie: dynamic20~* In total, three MRI scan series (before, during, after nCRT)~* Measurements: i.a. change in apparent diffusion coefficient (ADC) or area-under-the-gadolinium-concentration time curve (AUC) within tumor delineation over time, radiological (qualitative) assessment of residual disease"
223796255|NCT03474341|DIAGNOSTIC_TEST|PET-CT|"* According to European Association of Nuclear Medicine (EANM) Research Ltd guidelines (EARL)~* In total one additional PET-CT (during nCRT) for study purposes. A PET-CT scan at diagnosis and after nCRT are included in the standard diagnostic work-up for esophageal cancer.~* Measurements: i.a. change in TLG (Total Lesion Glycolysis), SUVmax (Standardized Uptake Value) or Ktrans within tumor delineation over time"
223796256|NCT03474341|DIAGNOSTIC_TEST|Endoscopy|Additional endoscopy and/or endoscopic ultrasonography (EUS) with biopsies of the primary tumor site and other suspected lesions in the esophagus after completion of nCRT and prior to surgery
223796257|NCT03474341|DIAGNOSTIC_TEST|Blood samples|"* Blood samples at three different time points (before, during and after nCRT) will be collected~* Blood will be collected in cell-free DNA collection tubes~* Purpose: isolation of ctDNA and subsequent mutation analysis by means of Next Generation Sequencing~* Measurements: the presence of, and changes in, ctDNA during nCRT"
223796258|NCT06225765|PROCEDURE|Transoral endoscopic thyroidectomy vestibular approach (TOETVA)|Remote access thyroid surgery
223796259|NCT06225765|PROCEDURE|Traditional Open Thyroidectomy|Open thyroidectomy via trans-cervical approach
223796260|NCT04870216|OTHER|Questionnaire regarding intimate protections habit.|Questionnaire regarding intimate protections habit.
223796261|NCT00032695|DRUG|methionine|
223796262|NCT02794285|BIOLOGICAL|Anifrolumab|Anifrolumab IV administration every 4 weeks from Week 0 to Week 152 for a total of 39 doses
223796263|NCT02794285|DRUG|Placebo|Placebo IV administration every 4 weeks from Week 0 to Week 152 for a total of 39 doses
223796264|NCT06231173|OTHER|Visual Feedback Therapy and Conventional Therapy|In experimental group individuals will receive visual feedback therapy and Conventional rehabilitation therapy. In visual feedback therapy, bilateral method is used to receive the visual feedback from the mirror. This visual feedback therapy consists of the following parts as the patient is asked to follow the involved hand that did the mimicking while the non-involved side will be performing wrist flexion, wrist extension, ulnar deviation, radial deviation, supination, pronation, and closing hand and opening hand.In conventional therapy, Patients are given a rest time of 20 seconds in each activity and a 1-minute break in each segment in order to reduce fatigue of the noninvolved hand. The treatment will be applied by the therapist standing at the side of the patient. Then technique will be applied according to subject's tolerance for duration of 15 minutes in each sitting. This treatment protocol will be 5 times/week for 4 weeks in the hospital setting.
223796265|NCT06231173|OTHER|Conventional Therapy|In control group individuals will receive only conventional therapy. In conventional therapy, Patients are instructed to perform a sandbag and hand grip exercise with a resistive exercise for the non-involved side. At last, patients are instructed to perform a moving small object (ball of wool) and card flip operation to induce wrist and finger movements as functional activities. Patients are given a rest time of 20 seconds in each activity and a 1-minute break in each segment in order to reduce fatigue of the non involved hand. The treatment will be applied by the therapist standing at the side of the patient. Then technique will be applied according to subject's tolerance for duration of 15 minutes in each sitting. .This treatment protocol will be 5 times/week for 4 weeks in the hospital setting.
223796266|NCT03602131|DRUG|Chidamide|30 mg oral twice weekly for 2 weeks
223796267|NCT03602131|DRUG|Cladribine|6 mg/m2 intravenously once daily for 5 days
223796268|NCT03602131|DRUG|gemcitabine|2500 mg/m2 intravenously twice weekly for 1 week
223796269|NCT03602131|DRUG|Busulfan|3.2 mg/kg intravenously once daily for 4 days
223796270|NCT03602131|PROCEDURE|Autologous hematopoietic stem cell transplantation|autologous hematopoietic stem cells infusion after ChiCGB chemotherapy
223796271|NCT02869087|DEVICE|Akesys Prava Scaffold|Implantation of the Akesys Prava Sirolimus Eluting Bioresorbable Peripheral Scaffold System
223796272|NCT03692533|DIAGNOSTIC_TEST|Immunohistochemistry|"Histopathological study and evaluation:~For each case, the tissue samples will be evaluated by the pathologist for detecting the histopathology and in cases of malignant renal spicemens the pathologist will also assess the histologic type, Fuhrman nuclear grade, cellular invasion of perinephric fat, and the extent of any vascular invasion seen by microscopy.~Immunohistochemistry:~Immunohistochemical staining will be performed by using the following antibodies: Geminin and Minichromosome maintenance-2 (MCM-2).~Evaluation of the immunohistochemical staining will be performed by light microscopy. The interpretation of immuno-reactivity will be performed in a quantitative manner by analyzing the extent of the staining positivity of the tumor cells. Immuno-staining of greater than 10% of tumor cells is required for scoring as a positive case."
223796273|NCT00095225|DRUG|Avastin (bevacizumab)|
223796274|NCT00095225|DRUG|Tarceva (erlotinib HCl)|
223796275|NCT00151307|DEVICE|INVOS cerebral oximeter|
223796276|NCT02362698|OTHER|electro-acupuncture|"13points were selected including he-gu(LI4), nei-guan(PC6), tai-chong(LR3) and san-yin-jiao(SP6) from both sides, bai-hui(GV20) and si-shen-cong(EX-HN1) from head.~HANS-200A acupoints stimulator, which had two output channels, was connected to some selected points. Dilatational wave was adopted in this research, the frequency of rarefaction wave was 2 hertz and condensation wave was 100 hertz, with a waviness width of 0.3ms. Switched the stimulator on after connected the poles to the needles, adjusted the intensity of output gradually from 0 milliampere to the extent of subject's maximum tolerance. Then needles would be remained on the body for half an hour."
223796277|NCT02362698|OTHER|psychological intervention|Cognitive behavioral therapy was adopted by national accredited professional psychologist, in the form of team work and individual counseling, aim to help IA participants to understand their deviant behaviors, correct unhealthy cognitive states and eventually retrieve normal life style.
223796278|NCT04452708|DEVICE|HFNC|HFNV vs NIV vs conventional nasal cannula
223796279|NCT04833387|DRUG|PD-1 antibody|Capecitabine:Dose of 1650mg/m2,14days; Radiation:50Gy/25 fractions;IBI308: 200mg on day1 of each cycle, 3 cycles; Surgical therapy:The resection (LAR), intersphincteric resection (ISR), or abdominoperineal resection (APR)
223796280|NCT05077787|OTHER|Massage therapy|Massage therapy includes stroking, kneading, rolling, tapping, vibration and effleurage over the face, chest ,abdomen and back. Massage therapy will be given for 5 minutes and will be repeated twice.
223796281|NCT05077787|OTHER|Kinaesthetic stimulation|Kinaesthetic stimulation includes passive flexion and extension movements of shoulder joint, elbow joint, hip joint, knee joint and both lower limbs together. It will be given for 5 minutes in each intervention
223796282|NCT00802568|BIOLOGICAL|anti-thymocyte globulin|
223796283|NCT00802568|DRUG|busulfan|
223796284|NCT00802568|DRUG|fludarabine phosphate|
223796285|NCT00802568|PROCEDURE|allogeneic bone marrow transplantation|
223796286|NCT00802568|PROCEDURE|nonmyeloablative allogeneic hematopoietic stem cell transplantation|
223796287|NCT03876834|OTHER|respiratory training|Respiratory training was done by using threshold inspiratory muscle trainer(Respironics, New Jersey , USA, No.8373-0730)
223796288|NCT03686852|OTHER|same medications but different dosages|The main difference between the groups is due to the different dose of r-FSH which will be given to pa-tients after the 7 days of CFA; namely that patients who need additional r-FSH following corifollitropin-alfa will be randomized on day 8 of the stimulation into 3 study groups. In group A, B and C, ovarian stimula-tion with Corifollitropin alfa (Elonva®, MSD) will be used for ovarian stimulation, followed by 50IU (Group A), 150IU (Group B) or 250IU (Group C) of recFSH (Puregon®, MSD)
223796289|NCT02683850|DIETARY_SUPPLEMENT|Omega-3 SPM™ softgel|This four week, prospective, non-randomized, open-label study is assessing the impact on quality of life from taking an Omega-3 SPM™ softgel supplement in adults with pain symptoms at screening of 4 or higher on the PROMIS-43 Profile - Pain Intensity subscale.
223796290|NCT00011505|DRUG|G-CSF|
223796291|NCT00011505|PROCEDURE|Leukapheresis|
223796292|NCT05227001|BIOLOGICAL|PF-07852352 Influenza saRNA 1|Intramuscular injection
223796293|NCT05227001|BIOLOGICAL|PF-07836391 Influenza saRNA|Intramuscular injection
223796294|NCT05227001|BIOLOGICAL|PF-07836394 Influenza saRNA|Intramuscular injection
223796295|NCT05227001|BIOLOGICAL|PF-07836395 Influenza saRNA|Intramuscular injection
223796296|NCT05227001|BIOLOGICAL|PF-07836396 Influenza saRNA|Intramuscular injection
223796297|NCT05227001|BIOLOGICAL|PF-07867246 Influenza saRNA|Intramuscular injection
223796298|NCT05227001|BIOLOGICAL|Placebo|Intramuscular injection
223796299|NCT05227001|BIOLOGICAL|Quadrivalent influenza vaccine (QIV)|Intramuscular injection
223796300|NCT05227001|BIOLOGICAL|PF-07871987 Influenza saRNA|Intramuscular injection
223796301|NCT05227001|BIOLOGICAL|PF-07914705 Influenza saRNA|Intramuscular injection
223796302|NCT05227001|BIOLOGICAL|PF-07915048 Influenza saRNA|Intramuscular injection
223796303|NCT00676767|DIETARY_SUPPLEMENT|Resistant Starch Type 4|
223796304|NCT00676767|DIETARY_SUPPLEMENT|Dextrose|
223796305|NCT00676767|DIETARY_SUPPLEMENT|Puffed wheat|
223796306|NCT05782764|DRUG|To explore the efficacy and safety of immune checkpoint inhibitor combined with endostar and chemotherapy in the treatment of advanced lung squamous cell carcinoma (stage IIIB-IV).|immune checkpoint inhibitor combined with endostar and chemotherapy in the treatment of advanced lung squamous cell carcinoma (stage IIIB-IV).
223796307|NCT06129773|PROCEDURE|antibiotic coated vicryl used for fascial closure|in this group fascial closure was done with antibiotic coated vicryl to compare with non coated vicryl after lapaprotomy in contaminated wounds
223796308|NCT06224738|BIOLOGICAL|human HER2-targeted CAR-M cells|The human anti-HER2 chimeric antigen receptor macrophages (anti-HER2 CAR-M cells) independently developed use adenoviral vector system to genetically engineer autologous macrophages to express CAR molecules containing single-chain antibodies, which specifically bind to the human HER2 antigen to recognize and kill tumor cells.
223796309|NCT01194960|DRUG|Docetaxel|Subjects will receive 10 cycles of Docetaxel alone until toxicity or progression.
223796310|NCT01194960|DRUG|TroVax|Trovax on Days 1,10, 22 and then Weeks 7, 10, 13, 19, 25, 31 and 37
223796311|NCT00868439|DRUG|patiromer|Active investigational drug
223796312|NCT00868439|DRUG|placebo|placebo
223796313|NCT00650832|DRUG|TMC114; darunavir; Prezista|
223796314|NCT00345982|DRUG|Serdolect|16 mg, 12 weeks
223796315|NCT00345982|DRUG|placebo|placebo
223796316|NCT04149405|PROCEDURE|Phase 1 periodontal therapy|Scaling and root planning with ultrasonic and hand instruments under local anesthesia.
223796317|NCT04149405|DRUG|Bisphosphonate therapy|Using aclasta: intravenous infusion of 5 mg of zoledronic acid once a year
223796318|NCT01494831|BEHAVIORAL|TF-CBT|15 sessions of group-based, trauma-focused cognitive behavioral therapy
223796319|NCT04220164|OTHER|Education and inform the optimal threshold of LDL-C levels|Physicians educate patients and provide a clear information about optimal LDL-C value according to individual patient's condition according to current guidelines
223796320|NCT00894231|DRUG|levocetirizine (Xyzal)|5mg po QD
223796321|NCT00894231|DRUG|placebo|sugar tablet
223796322|NCT03215836|PROCEDURE|Bronchoscopy and Nasal Epithelium Brush Sampling|After meeting screening criteria, participants will undergo further evaluation to determine whether or not inclusion and exclusion criteria are met. Participants will undergo a baseline evaluation, lung function testing and a subsequent bronchoscopy and nasal epithelial brush sampling in those that meet study enrollment.
223796323|NCT01139307|OTHER|cell culture procedure|
223796324|NCT01139307|OTHER|laboratory biomarker analysis|
223796325|NCT06088264|DRUG|BMS-986322|Specified dose on specified days.
223796326|NCT04109703|DEVICE|High Level Pulsed Heat delivered by Generation 5 devices from Soovu Labs Inc.|The Soovu Labss Inc. battery powered device is a one inch diameter heating pod that attaches to the user via a ring system. The device may be programmed to deliver a wide variety of treatment algorithms. Control of the devices are through a phone-based bluetooth connection. For this study the treatment algorithm used for subjects in this arm (experimental) used a temperature that was ramped from skin temperature to a peak temperature of 45° C and cycled for 30 minutes.
223796327|NCT04109703|DEVICE|Low Level (37 degrees C) delivered by the control device Generation 5 devices from Soovu Labs Inc.|The Soovu Labs Inc. battery powered device is a one inch diameter heating pod that attaches to the user via a ring system. The device may be programmed to deliver a wide variety of treatment algorithms. Control of the devices are via a phone-based bluetooth connection. For this control arm of the study the treatment algorithm held a steady temperature of 37 degrees C for a 30 minute period.
223796328|NCT00606372|PROCEDURE|OPCAB - the off-pump coronary artery bypass|surgical myocardial revascularisation without use of cardio-pulmonary bypass, using stabilising devices on beating heart
223796329|NCT05514353|DRUG|PBI-100 Topical Cream|PBI-100 Topical Cream in 1 of 3 dose levels
223796330|NCT05514353|DRUG|Vehicle Cream|The Vehicle Cream formulation contains the same excipients as the active cream
223796331|NCT01015391|DRUG|T2|1.5mg/kg/day, PO (per oral),three times a day: until progression or unacceptable toxicity develops
223796332|NCT01015391|DRUG|Azathioprine|2.5mg/kg, PO (per oral) one time a day:until progression or unacceptable toxicity develops the first month:1.5mg/kg,PO,one time a day the second month:2.0mg/kg,PO,one time a day since the third month:2.5mg/kg,PO,one time a day
223796333|NCT01487811|DRUG|biphasic insulin aspart 30|Single dose administrated subcutaneously (s.c., under the skin)
223796334|NCT02167074|DEVICE|25G FNA needle|
223796335|NCT02167074|DEVICE|20G ProCore FNB needle|
223796336|NCT03491865|BEHAVIORAL|REAL media Plus curriculum|REAL media Plus is a 7-level, interactive, self-paced, e-learning media literacy curriculum to prevent youth smoking and vaping use.
223796337|NCT03671668|OTHER|titanium bases using intra oral luting cement technique|comparing between screw retained prosthesis constructed on transmucosal abutments versus titanium bases in terms of crestal bone loss and patient satisfaction
223796338|NCT00733538|DRUG|zometa|patients receiving treatment during their follow-up
223796339|NCT02710799|OTHER|Teleconsultation|The teleconsultations will be performed by medical doctors, mostly family physicians, but also internists and endocrinologists. The teleconsultations will follow a structured format to discuss some topics on the disease and access the relevant information (based on the state's protocols). The doubts from the primary care physician will be addressed.
223796340|NCT02710799|OTHER|Protocol|The informations provided in the referral list will be evaluated through the state's referrals protocols.
223796341|NCT01212367|BIOLOGICAL|SCH 721015|1.0 x 10e12 viral particles on Days 1 and 4
223796342|NCT01212367|BIOLOGICAL|SCH 721015|3.0 x 10e11 viral particles on Days 1 and 4
223796343|NCT01507220|DRUG|morphine sulfate|Patients in this group will receive IV morphine sulfate (or Sponsor-approved equivalent) via patient-controlled analgesia (PCA) pump, as needed. The PCA pump will be set up postsurgically as soon as possible and prior to the patient leaving the post-anesthesia care unit (PACU) or immediately upon transfer to the floor if the stay in the PACU is less than 1 hour. All morphine sulfate (Group 1) patients will receive the same opioid in their PCA pump.
223796344|NCT01507220|DRUG|bupivacaine liposome extended-release injectable suspension|"Patients in this group will receive 266 mg EXPAREL diluted with preservative free 0.9% normal saline to a total volume of 30 cc and administered via wound infiltration prior to wound closure. When not contraindicated, 30 mg IV ketorolac will be given at the end of surgery. If not indicated, an IV non-steroidal anti-inflammatory drug (NSAID) may be substituted per the site's standard of care.~All patients will be offered rescue analgesia, as needed."
223796345|NCT00937924|DRUG|Meperidine, Midazolam|
223796346|NCT00937924|DRUG|Diphenhydramine|
223796347|NCT00937924|DRUG|Promethazine|
223796348|NCT04230044|DRUG|Perampanel|Perampanel tablets.
223796349|NCT05909631|OTHER|Beetroot juice|250 ml of concentrated beetroot juice, were given to participants in the BJ groups .This was carried out in the morning, 30 minutes before breakfast, and on an empty stomach.
223796350|NCT05909631|OTHER|placebo|250 ml of a placebo
223796351|NCT05909631|OTHER|Mediterranean diet alone (MeD)|Mediterranean diet alone (MeD)
223796352|NCT05909631|COMBINATION_PRODUCT|Mediterranean diet with beet juice (BJ+MeD)|Mediterranean diet with beet juice (BJ+MeD).
223796353|NCT00430794|DRUG|Spironolactone|
223796354|NCT04910893|DEVICE|Cytokine Adsorption|Cytokine adsorption therapy will be provided continuously for 72 hours by means of the CytoSorb® (CytoSorbents Corporation, Monmouth Junction, USA) column, run in series to a veno-venous continuous hemodialysis system, which will be exchanged every 24 hours.
223796355|NCT04910893|OTHER|Standard of Care|Standard intensive care of patients suffering septic shock
223796356|NCT00224874|DRUG|Etanercept|Etanercept \[25 mg subcutaneously twice weekly for up to 4 weeks; discontinue if in complete response by 4 weeks\].
223796357|NCT00224874|DRUG|Mycophenolate Mofetil|Mycophenolate mofetil (MMF) \[20 mg/kg (maximum 1 gm) orally or intravenously twice daily; continue through prednisone taper, then taper MMF over 4 weeks\].
223796358|NCT00224874|DRUG|Denileukin Diftitox|Denileukin Diftitox (ONTAK®) \[9 mcg/kg intravenously Days 1, 3, 5, 15, 17, 19\].
223796359|NCT00224874|DRUG|Pentostatin|Pentostatin \[1.5 mg/m2 daily for 3 days; Days 1-3 and repeat Days 15-17
223796360|NCT05655754|DRUG|Methohexital|anesthesia during ECT
223796361|NCT05655754|DRUG|Ketofol|anesthesia during ECT
223796362|NCT04460742|BEHAVIORAL|CAPABLE Transitions|The CAPABLE Transitions intervention group will receive an occupational therapy-led multidisciplinary in-home intervention in which the study occupational therapist (\<6 visits), registered nurse (\<5 visits), and handyman (\<2 visits) work with participants over 3-4 months. This intervention group also will receive home health agency care as usual services. CAPABLE Transitions in embedded within a home health agency and includes a care transitions emphasis.
223796363|NCT04460742|BEHAVIORAL|Home Health Agency Care|Both the CAPABLE Transitions intervention and care as usual treatment arms will receive home health agency care as usual services, which can include nursing, health aide, medical social work, and occupational, physical, and speech therapy services. Home health agency clinicians will determine the types and duration of CHHA services that the study participants receive; these services will be completely independent from the research study.
223796364|NCT05985187|DRUG|TQB2440 injection + Trastuzumab + Docetaxel|"TQB2440 injection is a biosimilar of Perjeta® (Pertuzumab injection) developed by Chia Tai Tianqing Pharmaceutical Group. Trastuzumab is a recombinant DNA-derived human IgG monoclonal antibody against P185 glycoprotein regulated by HER2 gene in cell nucleus. Docetaxel is a selective L-type calcium channel blocker.~Fluorouracil + epirubicin + cyclophosphamide for 3 cycles is a routine chemotherapy method after neoadjuvant surgery for breast cancer.~The combination of Pertuzumab and Trastuzumab will enhance the antitumor activity and is used as the double targeted maintenance."
223796365|NCT05985187|DRUG|Perjeta + Trastuzumab + Docetaxel|"Perjeta® with the general name Pertuzumab injection, is a recombinant humanized monoclonal antibody targeting the extracellular second domain of human epidermal growth factor receptor 2 (HER2). Trastuzumab is a recombinant DNA-derived human IgG monoclonal antibody against P185 glycoprotein regulated by HER2 gene in cell nucleus. Docetaxel is a selective L-type calcium channel blocker.~Fluorouracil + epirubicin + cyclophosphamide for 3 cycles is a routine chemotherapy method after neoadjuvant surgery for breast cancer.~The combination of Pertuzumab and Trastuzumab will enhance the antitumor activity and is used as the double targeted maintenance."
223796366|NCT01353014|OTHER|Dietary advice with genetic information|This group will receive dietary advice for caffeine, vitamin C, sugar and sodium based on genes that affect the metabolism of or sensitivity to caffeine, vitamin C, sugar and sodium.
223796367|NCT01353014|OTHER|General dietary recommendations|This group will receive general dietary recommendations from recognized health organizations for caffeine, vitamin C, sugar and sodium, with no genetic information.
223796368|NCT03528070|DRUG|Tranilast|Subjects will be treated with tranilast
223796369|NCT03932851|OTHER|IVF-ET|HBV-infected pregnant women and non-HBV-infected pregnant women underwent IVF operation
223796370|NCT04940429|DEVICE|Neurofit|This involves sitting on a chair with a head and chin rest to maintain stability. Patients will then follow a moving object on the computer screen with their eyes which allows estimation of individual oculometrics along with a composite score. No physical contact or placement of invasive devices will be performed.
224264071|NCT06471413|OTHER|The Prevention Toolbox : BOAT®|The Prevention Toolbox targets all forms of violence, but in particular sexual and gender-based violence, through 1 out of 5 themes (Relationships and sexuality) and 10 out of 34 sub-themes. The other 4 themes (Psychosocial skills, Respect and difference, From the virtual to the real, and Understanding and respect for the law) cover all the risk and protection factors for all types of violence.
224264072|NCT05829915|DEVICE|ROXPro© system (A-Champs)|The intervention consisted in 24 sessions (3/week) of a cognitive-multisensory-physical exercise program carried out in the patient's own home. The exercise program was designed by qualified personal trainers and psychologists, and implemented with the ROXPro© system (A-Champs) (https://a-champs.com; accessed on 8 January 2022). This system consists of small devices that provide visual, auditory and vibration stimuli with which the patient interacts. Through its mobile application, it allows the development of numerous sensory-cognitive-motor exercises adapted to the characteristics of the patients.
224264073|NCT05829915|OTHER|No exercise program|The control group did not received the physical exercise program
224264074|NCT05526391|DRUG|TAK-341|TAK-341 IV infusion
224264075|NCT05526391|DRUG|Placebo|TAK-341 placebo-matching IV infusion
223796371|NCT04940429|DIAGNOSTIC_TEST|Psychometric hepatic encephalopathy score|During the number connection tests, the participant is asked to join dots between numbers or numbers and letters in a timed fashion and the number of seconds required is the outcome. In the line tracing test, participants are required to trace a line between two parallel lines and the time required is noted. Also, the number of times the subject strays outside the line (line tracing test error) is captured. In the digit symbol test, participants are required to pair numbers with special symbols. An individual's score reflects the number of correct pairs achieved in 120 seconds. In the serial dotting test, participants are asked to dot the center of a group of blank circles and the time required to complete the test is the outcome. Psychometric tests will be completed at their post-operative visits.
223796372|NCT00056251|PROCEDURE|H&P; ECG; Blood tests; voiding diary; Cystoscopy|
223796373|NCT06580132|DIETARY_SUPPLEMENT|Pectin|Pectin fibre (20g) was randomly allocated to eligible participants in order to test specific effects on gut microbiome composition and metabolic markers.
223796374|NCT06580132|DIETARY_SUPPLEMENT|Maltodextrin|Maltodextrin (10g) served as a control/ placebo to compare the effects observed with pectin.
223796375|NCT05449951|OTHER|Dry needling|In dry needling filiform needle without a bore is used to mimic acupuncture t beyond the use of medicines. On the basis of purpose process and skill level it differs from acupuncture. DN is frequently used to treat pain caused by musculoskeletal structures, including as myofascial pain disorders
223796376|NCT05449951|OTHER|sustained stretching|sustained stretching is a treatment protocol in which muscle goes into a stretch position for period of time which reduce spasticity
223796377|NCT02099474|OTHER|Study of pharmacokinetic properties of raltegravir during the 3rd trimester of pregnancy|Introduction of a catheter for performing 5 blood samples in pregnant women infected by HIV-1, before the raltegravir intake, 0.5, 3, 8 and 12 hours after the intake at each of two visits (between 30 and 37 weeks of amenorrhea, and 4 to 6 weeks after delivery)
223796378|NCT02565043|DEVICE|RENASYS TOUCH Negative Pressure Wound Therapy System|RENASYS TOUCH NPWT System was administered to all participants.
223796379|NCT03764332|DEVICE|Stabilometry|To evaluate the static balance of subjects when barefoot and when using three types of footwear with their eyes closed or open.
223796380|NCT05377580|DRUG|Period 1 IBI112 Placebo|Intravenous Injection
223796381|NCT05377580|DRUG|Period 2 IBI112 dose 3|Subcutaneous injections
223796382|NCT05377580|DRUG|Period 1 IBI112 dose 1|Intravenous Injection
223796383|NCT05377580|DRUG|Period 1 IBI112 dose 2|Intravenous Injection
223796384|NCT05377580|DRUG|Period 2 IBI112 dose 4|Intravenous Injection
223796385|NCT05377580|DRUG|Period 2 IBI112 Placebo|Subcutaneous injections
223796386|NCT02960100|OTHER|Informational Intervention|Receive standard HPV vaccine information (HPV VIS)
223796387|NCT02960100|OTHER|Media Intervention|Receive targeted HPV vaccine narrative-style video
223796388|NCT02960100|OTHER|Survey Administration|Ancillary studies
223796389|NCT05072080|BIOLOGICAL|CHIKV VLP/adjuvant|CHIKV VLP vaccine is comprised of chikungunya virus virus-like particles (CHIKV VLP), adsorbed on aluminum hydroxide adjuvant 2%
223796390|NCT05072080|BIOLOGICAL|Placebo|Placebo is comprised of formulation buffer
223796391|NCT04957537|BEHAVIORAL|semantic therapy and semantic re-education|"Patients will be followed over two periods Phase A (randomized, 6 to 8 weeks) - Phase B (5 weeks).~Phase A : Baseline Phase A, which constitutes the control period of semantic therapy, will be composed of lexico-phonological training exercises (Piroux-Davous, 2018). This phase will last 6 to 8 weeks (i.e. 18 to 24 sessions) depending on the randomisation, at the rate of 3 speech therapy sessions of 45 minutes per week.~Phase B : Semantic re-education The sessions will consist of training based on the analysis of semantic traits (Coustaut, 2019). This phase will last 5 weeks (i.e. 15 sessions), at the rate of 3 speech therapy sessions of 45 minutes per week.~In accordance with the application of the SCED methodology, repeated measurements will be carried out every second session during phases A and B. They will consist of proposing the oral naming task (lasting 10 minutes)."
224264076|NCT06390943|OTHER|Facility-based feeding support package plus (FB-FSP+)|Package of materials to support facility-based feeding and lactation, KMC and WASH, including a training curriculum, training guide, and implementation materials, such as Standard Operating Procedures (SOPs) and job aides
224264077|NCT06390943|OTHER|Transition-to-home feeding support package plus (TTH-FSP+)|Package of materials to support transition-to-home feeding and lactation, KMC and WASH, including a training curriculum, training guide, and implementation materials, such as Standard Operating Procedures (SOPs) and job aides
224264078|NCT03414450|DRUG|ETC-1907206|ETC-1907206 gelatin capsules will be dosed every other day (EOD) and contain 10 mg or 50 mg of ETC-1907206.
223796392|NCT01191164|PROCEDURE|Partial Breast Irradiation Utilizing Permanent Breast Seed Implant|"Target Volumes: The surgical cavity will be assessed with US \& CT scans. The Clinical Target Volume (CTV) will encompass the surgical cavity plus 1 cm uniform expansion. The Planning Target Volume (PTV) will be the CTV plus 0.5 cm.~Dose Selection/Prescription: A minimal peripheral dose of 90 Gy (same as in the OCC study) will be prescribed to the PTV. This dose is chosen as biologically equivalent, over a 2 month period, to 50Gy in 25 fractions, for α/β of 2Gy54.~Implant Procedure and QA: This will be performed as an outpatient procedure under conscious sedation and local anesthesia, by a team with several years experience in brachytherapy and conscious sedation administration. The technique used in this pilot study will be based on the OCC technique. It is intended that two oncologists and one physicist will spend 2-3 days at the OCC to acquire detailed and firsthand knowledge of the technique and its implementation at that centre."
223796393|NCT01961336|DRUG|Testosterone|10 mg of testosterone gel applied on the external side of the thigh for 21 days starting from the first day of menstruation prior to initiation of ovarian stimulation with rFSH for IVF/ICSI
223796394|NCT03067038|DEVICE|Single incision laparoscopic cholecystectomy|Laparoscopic cholecystectomy with single port device
223796395|NCT03067038|DEVICE|Three port laparoscopic cholecystectomy|Laparoscopic cholecystectomy with three port
223796396|NCT03960905|OTHER|Children with the usage of anti-infective drugs|According to the models of population pharmacokinetics,the investigators and want to correlate use of antibiotics with treatment effectiveness and safety in children.
223796397|NCT04777045|DRUG|Diltiazem Hydrochloride|"Diltiazem hydrochloride is a calcium ion influx inhibitor (slow channel blocker or calcium antagonist). It is a white to off-white crystalline powder with a bitter taste. It is freely soluble in water, methanol and chloroform. It has a molecular weight of 450.98.~It provides its therapeutic effects by blocking the influx of calcium ions into vascular smooth and cardiac muscle cells during membrane depolarization. The decrease in intracellular calcium causes relaxation of smooth muscle cells and cardiac myocytes by inhibiting actin-myosin interactions. Vasodilation subsequently results in decreased peripheral vascular resistance. The antihypertensive effect of diltiazem in hypertensives is greater than in normotensives.~Diltiazem is registered for the treatment of hypertension, heart rate control in supraventricular tachycardia, chronic stable angina pectoris and angina pectoris resulting from coronary artery spasm."
223796398|NCT04777045|DRUG|Placebo|Matching placebo capsules, given QD per oral use. Placebo capsules will be used in the same manner with the same dose titration.
223796399|NCT06635967|DEVICE|frequency-specific rTMS|Patterned repetitive transcranial magnetic stimulation will be performed at specific frequencies and inter-train intervals
223796400|NCT06635967|DEVICE|1 Hz rTMS|Low-frequency rTMS will be performed at a frequency of 1Hz
223796401|NCT06635707|DRUG|Urapidil|"1. Control systolic blood pressure within 130-140mmHg using urapidil and maintain this level for 7 days;~2. Reduce intracranial pressure through dehydration therapy with mannitol, positioning of the body, and other means to prevent cerebral hernia. Surgical interventions such as decompressive craniectomy may be performed if necessary;~3. Aim for a body temperature control target of ≤37.5°C;~4. The anticoagulation reversal target is INR \< 1.5, with correction methods including the use of vitamin K, prothrombin complex concentrate (PCC), or fresh frozen plasma (FFP);~5. The blood glucose control targets are 6.1-7.8mmol/L for non-diabetic study participants and 7.8-10.0mmol/L for diabetic study participants."
224264079|NCT03414450|DRUG|dasatinib|dasatinib tablets at 140 mg will be dosed every day
224264080|NCT05457413|PROCEDURE|Sleeve gastrectomy|Bariatric surgery
224264081|NCT05889143|DRUG|Ezetimibe/Rosuvastatin|Patient treated with Crezet Tablet
224264082|NCT00947076|DRUG|Fluoxetine Hydrochloride Capsules, 40 mg (Geneva Pharmaceutical, Inc)|
224264083|NCT00947076|DRUG|Fluoxetine Hydrochloride Capsules, 40 mg (Prozac) (Eli Lilly)|
224264084|NCT04304066|OTHER|18F-WL12 PET or 68Ga-WL12 PET|WL12, labeled with PET radio-nuclide ( Ga-68 or F-18)will be used as a molecular imaging tracer for PET/CT scanning
224264085|NCT05322967|OTHER|Time of ordinary antihypertensive medication intake|Time of ordinary antihypertensive medication intake
224264086|NCT02543489|DEVICE|Flex IM rod|
224264087|NCT03767374|PROCEDURE|Inguinal swab sample|Inguinal samples using swab at cross-sectional visit
224264088|NCT03767374|PROCEDURE|Anal swab sample|Anal samples using swab at cross-sectional visit and at 6-month visit (for those with ESBL and/or CRE colonization)
224264089|NCT03767374|PROCEDURE|Fecal sample|Fecal sample at cross-sectional visit and at 6-month visit (for those with ESBL and/or CRE colonization)
224264090|NCT03767374|OTHER|Risk factor assessment|Patients will be asked questions on risk factors associated with MDR/XDR colonization at cross-sectional visit and at 6-month visit (for those with ESBL and/or CRE colonization
224264091|NCT05586880|OTHER|Experimental: EnXtra 300 mg/ capsule|One capsule to be taken 3±0.5 hours prior to second gaming session on Day 1 followed by 1 capsule daily after breakfast for 5 days
223796402|NCT06635707|DRUG|Urapidil and Esmolol|"1. Utilize both urapidil and esmolol to control systolic blood pressure within 130-140mmHg and maintain this level for 7 days;~2. Reduce intracranial pressure through dehydration therapy with mannitol, strategic positioning of the body, and other measures to prevent cerebral hernia. Surgical interventions such as decompressive craniectomy may be performed if necessary;~3. Aim for a body temperature control target of ≤37.5°C;~4. The anticoagulation reversal target is INR \< 1.5, with correction methods including the administration of vitamin K, prothrombin complex concentrate (PCC), or fresh frozen plasma (FFP);~5. The blood glucose control targets are 6.1-7.8mmol/L for non-diabetic study participants and 7.8-10.0mmol/L for diabetic study participants."
223796403|NCT06636188|OTHER|Digi-Coach Chatbot|Participants will have access to the Digi-Coach chatbot in addition to usual care. The research nurse will provide training on how to navigate the chatbot and ask participants to query all their cancer related concerns in the chatbot.
223796404|NCT06635681|DRUG|combined chemotherapy|"Induction therapy(1 cycle):~Daunorubicin 60mg/m2/d d1-3 Cytarabine 100mg/m2/d d1-7 Venetoclax 100mg d-2, 200mg d-1, 400mg d1-7 If the first course of treatment did not result in CR, patients with therapeutic target could be treated with targeted drugs, and the patients without targets would be treated with HAV regimen: Cytarabine 100mg/m2/d, d1-5, Homoharringtonine 2mg/m2 d1-5, Venetoclax 100mg d-2, 200mg d-1, 400mg d1-7.~Consolidation therapy(3 cycles):~Cytarabine 2g/m2 q12h d1-3 Venetoclax 400mg d1-7 For patients with CBF and CEBPA dual mutations, the dose of cytarabine is 3g/m2.~Maintenance treatment(6 cycles):~Azacitidine 75mg/m2/d d1-5 Venetoclax 400mg d1-7~Allogeneic hematopoietic stem cell transplantation is recommended for high-risk groups and intermediate-risk with positive measurable residual disease."
223796406|NCT00814294|DRUG|placebo|placebo capsule,0 units, quater in die (QID) for 18 weeks
223796407|NCT00814294|DRUG|Oral Hepatic Directed Vesicles (HDV)-Insulin (U-15)|Oral HDV-I Caps; 15 U; quater in die (QID) for 18 weeks.
223796408|NCT00814294|DRUG|Oral Hepatic Directed Vesicles (HDV)-Insulin (U-5)|Oral HDV-I; Caps; 5 U; quater in die (QID) for 18 weeks.
223796409|NCT05891821|DRUG|Balstilimab|An anti-programmed death (ligand) 1 \[PD-(L)1\] monoclonal antibody
223796410|NCT01314274|DRUG|Bevacizumab|100mg intranasal submucosal bevacizumab in 10ml
223796411|NCT01314274|DRUG|NaCl|10ml of 0.9% NaCl intranasal submucosal
223796412|NCT03152526|DEVICE|Interventions|CliniMACS® CD3 and CD19 Reagent System
223796413|NCT00922285|OTHER|psychosocial support for caregiver|6 weekly 60 minute sessions
223796414|NCT00922285|OTHER|questionnaire administration|Evaluated at baseline, week 1 and week 6 of art therapy
223796415|NCT00922285|PROCEDURE|quality-of-life assessment|Evaluated at baseline, week 1 and week 6 of art therapy
223796416|NCT00922285|PROCEDURE|stress management therapy|6 weekly 60 minute sessions
223796417|NCT02918110|DRUG|Misoprostol|Women needed to be induced will get orally administrated solution of misoprostol (Cytotec®) or vaginal slow release misoprostol (Misodel®)
223796418|NCT02395042|DRUG|LiRIS®|LiRIS® is a drug-device combination product which is placed in the bladder during cystoscopy and remains in the bladder, gradually releasing lidocaine until removed from the bladder via cystoscopy.
223796419|NCT02395042|DRUG|LiRIS Placebo|LiRIS placebo is a drug-device combination product, matching the LiRIS® which is placed in the bladder during cystoscopy, remains in the bladder until removed from the bladder via cystoscopy
223796420|NCT02807558|DRUG|Tamibarotene|Administered as oral tablets
223796421|NCT02807558|DRUG|Azacitidine|Administered via intravenous (IV) or subcutaneous (SC) infusion
223796422|NCT02807558|DRUG|Daratumumab|Administered via IV infusion
223796423|NCT05300425|OTHER|Blood sample collection|Blood sample collection (at baseline and approximately two years after baseline). Enzyme-linked immunosorbent assays will be used to screen for IgG and IgM antibodies directed against the three pathogens (Leptospirosis, Tularemia, Hepatitis E).
223796424|NCT05300425|OTHER|Data collection|Data collection on sociodemographic questions e.g. profession, leisure activities, animal contact
223796425|NCT06962761|DRUG|Vit D|in this study we use a combination of vit d and probiotics
223796426|NCT06962462|DRUG|Methyl Cellulose Placebo|Oral administration of inert methyl cellulose placebo tablets once daily for 3 months. Used as a comparator in healthy control participants to evaluate changes in Endothelin-1 and E-selectin serum levels.
223796427|NCT06962371|DEVICE|cerebral embolic protection|Use of Transverse Medical Inc. Point-Guard CEP device.
223796428|NCT04461301|PROCEDURE|Multimodal Prehabilitation|A multimodal prehabilitation program (exercise, nutrition, anemia correction and smoking cessation).
223796429|NCT06340906|OTHER|Electroacupuncture|EA at 10 standardized acu-points that were chosen for their therapeutic effects: Zhongwan (CV12), Guanyuan (CV4), Neiguan (PC6), Shenmen (HT7), Hegu (LI4) bilateral, Zusanli (ST36), Sanyinjiao (SP6), Zhaohai (KI6), Taichong (LR3) bilateral, Tian Shu (ST25) bilateral.
223796430|NCT04969198|DRUG|Combination nicotine replacement therapy (Nicotine patch + nicotine mini-lozenge)|Nicotine patch and mini-lozenge dosing will be based off the 2008 Public Health Services (PHS) Clinical Practice Guideline and package insert with adjustments to account for the delayed start 1-week post-TQD. All participants will receive 2mg mini-lozenge due to the superior palatability of the 2mg lozenges. Participants are encouraged to use at least 5 mini-lozenges per day for the full 8 weeks. Participants who report any smoking or nicotine use (e.g., even a cigarette puff, e-cigarette use) in the 3 days before C-NRT distribution will receive 4 weeks of 14mg and 4 weeks of 7mg nicotine patches. Participants who report complete abstinence from smoking and nicotine in the 3 days before C-NRT distribution will receive 8 weeks of 7mg nicotine patches.
223796431|NCT02701985|DRUG|Placebo|Matching-placebo capsules will be administered orally, 2 times a day with food.
223796432|NCT02701985|DRUG|RO5459072|RO5459072 at a dose of 100 milligrams (as capsules) will be administered orally, 2 times a day with food.
223796433|NCT02034747|DRUG|Advagraf|oral
223796434|NCT02034747|DRUG|Corticosteroid|oral
223796435|NCT06421987|DEVICE|Near Infrared Spectroscopy (NIRS)|NIRS is a portable, non-invasive, brain imaging device.
223796436|NCT05138419|OTHER|"CKD What You Need To Know Workbook System"|139 page Workbook including CKD Action Plan, Web-Based Resources, Interactive CKD Patient education material
223796437|NCT05138419|OTHER|CKD Action Plan|Goals based on international guidelines that can protect kidney function (1 knowledge and 10 action goals) Patient education material used separately for control arm.
223796438|NCT05138419|OTHER|CKD Web-based Resource List|CKD Patient education material used separately for control arm
223796439|NCT05138419|OTHER|Food Label reading exercise|CKD Patient education material used separately in all arms.
223796440|NCT05642390|DEVICE|Breast implant|Patients operated for breast augmentation or reconstruction.
223796441|NCT03913611|OTHER|Accelerated rehabilitation protocol|Patients in this group will undergo an accelerated rehabilitation protocol, without movement restrictions. Movement restriction will instead be governed by patient comfort.
223796442|NCT03913611|OTHER|Traditional rehabilitation protocol|Patients in this group will undergo a traditional rehabilitation protocol, with movement restrictions and sling use for 6 weeks following surgery.
223796443|NCT01673932|BIOLOGICAL|UCBMC|Transplant 10-40 million viable UCBMC suspension into brain adjacent to the infracted site
223796444|NCT01673932|PROCEDURE|surgery|
223796445|NCT04609891|DRUG|Avatrombopag|10×109/L\<PLT\<75×109/L, avatrombopag tablet 60 mg once a day for 5-10 days.
223796446|NCT01640808|DRUG|NIK-333(peretinoin)|600mg (8 x 75mg capsules) orally, twice a day
223796447|NCT01640808|DRUG|Placebo|Placebo (8 x Placebo capsules) orally, twice a day
223796448|NCT02068807|DIETARY_SUPPLEMENT|Lutein drops|After randomisation, the infant received orally a total dose of 0.28 mg of lutein in two doses: within 6 hours after birth and at 36 hours of life
223796449|NCT02068807|DIETARY_SUPPLEMENT|Glucose drops|After randomization, newborns received 0.5 mL of 5% glucose solution in two doses: within 6 hours (hrs) after birth and at 36 hrs of life.
223796450|NCT06367621|DEVICE|iStatis Syphilis Antibody Test|1500 stored samples (plasma/serum) will be tested in a routine testing environment using the iStatis Syphilis Antibody Test diagnostic device. Results of tests will not be used for patient management decisions (observaltional).
223796451|NCT04954118|PROCEDURE|Internal jugular vein cannulation|The clinicians performed an internal jugular vein cannulation using personal protective equipment (PPE) or both of the aerosol box and PPE provide insertion of a central venous catheter in COVID-19 patients.
223796452|NCT06302751|DEVICE|Care 4 Today ® (Johnson and Johnson) mobile app|Care 4 Today ® (Johnson and Johnson) mobile app will cover the perioperative period spanning through the preoperative assessment day (approximately -seven to -one from surgery) to 30 days after surgery and will monitor the adherence to preoperative and postoperative recommendations.
223796453|NCT06338982|PROCEDURE|Interoperative wisdom tooth removal in conjunction with BSSO|The objective of the present randomized controlled trial is to assess the fracture pattern, condylar segment positioning, frequency of complications, and PROMs following BSSO with or without impacted mandibular third molars. this is illustrated by the fact that the test group had their wisdom teeth removed in connection with the sagittal split of the mandible (the BSSO surgery). Subsequently, all outcome measures are compared with the control group, who had their wisdom teeth removed 6 months prior their BSSO surgery.
223796454|NCT01435083|DRUG|Desmopressin|120 µg, oral lyophilisate, sublingual use
223796455|NCT05063838|OTHER|Pharmacogenomic optimisation of anaesthetic medications|Personalisation of anaesthetic plan based on pharmacogenomic results and international guidelines.
223796456|NCT06545097|DRUG|Cebranopadol|Once a day for 2 days; once daily on Day1 (with Cebranopadol 200ug).
223796457|NCT06545097|DRUG|Cebranopadol|Once daily on Day 2 (with Cebranopadol 400 ug)
223796458|NCT06545097|DRUG|Placebo|Once daily for 2 days
223796459|NCT01390467|DRUG|Cantab®|Randomized study, double-blind, crossover, controlled versus placebo.
223796460|NCT04215042|DRUG|sodium chloride infusion|
223796461|NCT00990639|DRUG|candesartan for hepatic fibrosis|"Candesartan group(42 patients): oral candesartan at a daily dose of 8 mgin addition to ursodeoxycholic acid (UDCA, 600 mg/day) for 6 months.~UDCA group(43 patients): oral ursodeoxycholic acid (UDCA, 600 mg/day) only for 6 months"
223796462|NCT02437591|DRUG|fidaxomicin|oral
223796463|NCT01641250|DRUG|RO5429083|Multiple escalating doses
223796464|NCT01641250|DRUG|cytarabine|1000 mg/m2 iv daily for 5 consecutive days, up to 4 cycles
223796465|NCT02866565|DRUG|adipose-derived regenerative cells (ADRCs)|injection of the experimental treatment
223796466|NCT01019876|DRUG|Fludarabine|
223796467|NCT01019876|DRUG|Cyclophosphamide|
223796468|NCT01019876|DRUG|Busulfan|
223796469|NCT01019876|DRUG|Alemtuzumab|
223796470|NCT01019876|DRUG|Rabbit Anti-thymocyte Globulin|
223796471|NCT01019876|DRUG|Horse Anti-thymocyte Globulin|
223796472|NCT06313762|DEVICE|Pico G2 Virtual Reality Glasses (Pico Interactive Inc), together with an Android AOYODKG tablet|They will experience in first person the two and a half minute graphic adventure, called Leia\&amp;amp;amp;amp;#39;s World, during the administration of the vaccines.
224264092|NCT05586880|OTHER|Microcrystalline cellulose (MCC) 300mg|One capsule to be taken 3±0.5 hours prior to second gaming session on Day 1 followed by 1 capsule daily after breakfast for 5 days
224264093|NCT06492876|GENETIC|FT-003|Administered via intraocular injection.
224264094|NCT05869721|OTHER|Yoga|The yoga forms are designed from the modified traditional Hatha yoga style consisting of pranayama, asana, meditation with additional relaxation elements. The selected postures will engage core and upper limb muscle and which proposed to strengthen the whole body, increase flexibility of shoulder and limbs, particularly, improve upper limb mobility and functions; also, the progression of the yoga therapy is targeted to reach the variations of postures. The combined relaxation elements reinforced to achieve restoration of the body so as to improve sleep.
224264095|NCT06258421|OTHER|No Intervention|Observatory Study
224264096|NCT05124366|PROCEDURE|dental prophylaxis + oral hygiene instructions|Follow up: 2 weeks and 4 weeks
224264097|NCT03463226|DIAGNOSTIC_TEST|Cardiopulmonary exercise test|Oxygen consumption (VO2) and carbon dioxide output (VCO2) were measured by means of gas exchange on a breath-by-breath basis. The patients were initially monitored for 2 minutes at rest when seated on the ergometer, after that they were instructed to pedal at a pace of 60-70 rpm and the completion of the test occurred when, in spite of verbal encouragement, the patient reached maximal volitional fatigue.
224264098|NCT03463226|DIAGNOSTIC_TEST|Muscle Sympathetic Nerve Activity|Multiunit post-ganglionic muscle sympathetic nerve recordings were made using a tungsten microelectrode placed in the peroneal nerve near the fibular head. Nerve signals were amplified by a factor of 50,000 to 100,000 and band-pass filtered (700 to 2000 Hz). For recording and analysis, nerve activity was rectified and integrated (time constant 0.1 seconds) to obtain a mean voltage display of sympathetic nerve activity.
224264099|NCT03463226|DIAGNOSTIC_TEST|Dual-energy X-ray absorptiometry|Dual-energy X-ray absorptiometry (DXA) scan was used to measure total lean mass, body fat and bone mineral content.
224264100|NCT03463226|DIAGNOSTIC_TEST|Venous occlusion plethysmography|Venous occlusion plethysmography was used to assess non-invasively blood flow.
224264101|NCT03463226|DIAGNOSTIC_TEST|Blood sample collection|Blood samples were drawn in the morning after 12h overnight fasting.
224264102|NCT03463226|DIAGNOSTIC_TEST|Dynamometers for Handgrip Strength|Muscle strength was assessed by handgrip dynamometer using the mean value of three attempts.
224264103|NCT01246258|OTHER|Vestibular evoked myogenic potentials (VEMPs)|Standard test of balance function
224264104|NCT01246258|OTHER|Utricular centrifugation test|Standard test of balance function
224264105|NCT04193241|PROCEDURE|Closure of chest tube wound|At the time of chest tube removal, the chest tube site or thoracostomy wound will be closed in such a way as to prevent an iatrogenic pneumothorax or contamination of the pleural space
224264106|NCT05543135|DIAGNOSTIC_TEST|basic audiological evaluation|pure tone audiometry\&immitancemetry
224264107|NCT02645253|DRUG|AZD7594 inhalation powder (200 μg)|200 μg AZD7594 inhalation powder via multi-dose dry powder inhaler (DPI)
224264108|NCT02645253|DRUG|AZD7594 inhalation powder (400 μg)|Cohort 2: 400 μg AZD7594 inhalation powder via multi-dose DPI Cohort 3: 1600 μg (4 x 400 μg inhalations) AZD7594 inhalation powder via multi-dose DPI
224264109|NCT02645253|DRUG|AZD7594 pressurized inhalation suspension (200 μg)|400 μg (2 x 200 μg inhalations) AZD7594 pressurized inhalation suspension via pressurized metered dose inhaler (pMDI)
224264110|NCT02645253|DRUG|AZD7594 placebo inhalation powder|AZD7594 placebo inhalation powder via multi-dose DPI
223796473|NCT06313762|BEHAVIORAL|Traditional Distractors|The control group participants will receive traditional distractors, such as being held by the parent or guardian who accompanies them to the appointment, receiving stickers at the end of the appointment, or receiving rewards that the parent or guardian has prepared from home, during the administration of the vaccines.
223796474|NCT06313762|BIOLOGICAL|Triple Viral + Varicella Vaccine at 3 years of age|Administration of vaccines in 3-year-old children, as appropriate according to the vaccination schedule
223796475|NCT06313762|BIOLOGICAL|Hepatitis A + Diphtheria-Tetanus-Pertussis Vaccine at 6 years of age.|Administration of vaccines in 6-year-old children, as appropriate according to the vaccination schedule.
223796476|NCT03359980|DRUG|fecal microbiota transfer|transfer of fecal microbiota from healthy donors to the patients
223796477|NCT05366777|DRUG|acetaminophen/ibuprofen fixed-dose combination|Intravenous acetaminophen (1000 mg)/ibuprofen (300 mg) fixed-dose combination (total 100 ml)
223796478|NCT05366777|DRUG|Saline|100 ml of normal saline
223796479|NCT01178086|DRUG|Rituximab|Rituximab IV
223796480|NCT02385344|DEVICE|Medistim device|This registry is intended to document surgical findings, procedural changes, and adverse events occurring prior to discharge
223796481|NCT00058838|DRUG|sumanirole|
223796482|NCT05734794|DRUG|Rituximab|Rituximab dose: 4 doses of 375 mg/m2 rituximab at 1-week intervals( within +7 days), associated with trimethoprim-sulfamethoxazole(25-50 mg/kg/day orally twice per day, 3 days per week. If the patient is not allergic) for three months from the first rituximab dosing date(Day 1). Four doses of rituximab are necessary whether the patient achieves complete remission.
223796483|NCT05734794|DRUG|Steroid|Daily oral prednisone/prednisolone 2 mg/kg/d (maximum 60 mg/d) for 6 weeks followed by alternate day prednisone/prednisolone, 1.5 mg/kg (maximum of 50 mg), for other 6 weeks. Vitamin D and calcium(adjusted according to the blood calcium level) were administered for three months.
223796484|NCT01308242|DRUG|Sevelamer Carbonate|Sevelamer 800 mg by mouth three times daily with meals for 3 months
223796485|NCT01384994|DRUG|Folic Acid|400 mg/m2, 2h infusion, d1, q2w
223796486|NCT01384994|DRUG|5-FU|400 mg/m2 bolus iv, d1, q2w
223796487|NCT01384994|DRUG|5-FU|2400 mg/m2 46-h infusion, d1-2, q2w
223796488|NCT01384994|DRUG|Oxaliplatin|85 mg/m2 d1, q2w
223796489|NCT01384994|DRUG|Panitumumab|6 mg/kg BW every 2 weeks
223796490|NCT01384994|DRUG|Panitumumab|Panitumumab maintenance phase (3 months) 9mg/kg BW every 3 weeks
223796491|NCT01384994|DRUG|Folic Acid|400 mg/m2, 2-h infusion, d1, q2w
223796492|NCT01384994|DRUG|5-FU|400 mg/m2 bolus iv, d1, q2w
223796493|NCT01384994|DRUG|5-FU|2400 mg/m2 46-h infusion, d1-2, q2w
223796494|NCT01384994|DRUG|Oxaliplatin|85 mg/m2 d1, q2w
223796495|NCT03543254|DRUG|BoNT-A|"90U BoNT-A, given in one treatment as 18 injections of 5u (0.2 ml) each, on specific preselected sites along the sutures of the skull.~First 100 U of Botox® is solved in 4 ml (cc) of isotone saline water (9 mg/ml), distributed in 4 syringes. This is half the usual concentration, allowing for better diffusion in order to reach the target structures."
223796496|NCT02389972|DRUG|Dasatinib|
223796497|NCT00990691|DRUG|Administration of a high dose of desipramine|"Administration of a daily dose of desipramine correlated with the patient's weight :~* From 15 to 25 kg : 50 mg ;~* From 26 to 35 kg : 75 mg ;~* From 36 to 45 kg : 100 mg ;~* \> 46 kg : 150 mg."
223796498|NCT00990691|DRUG|Administration of a low dose of desipramine|"Administration of a daily dose of desipramine correlated with the patient's weight :~* From 15 to 25 kg : 25 mg ;~* From 26 to 35 kg : 50 mg ;~* From 36 to 45 kg : 75 mg ;~* \> 46 kg : 100 mg."
223796499|NCT00990691|DRUG|Administration of a placebo|Administration of a daily dose of placebo
223796500|NCT01840267|DEVICE|ultrasonographic measurement of optic nerve sheath diameter|A thick layer of gel is applied on the upper closed eyelid. The linear 13- to 6-MHz ultrasound probe is then placed in the gel, without exerting pressure on the eye. Two measurements are taken for each optic nerve: one in the transverse plane, with the probe being horizontal, and one in the sagittal plane, with the probe being vertical. The final ONSD is the mean of these measurements.
223796501|NCT01587534|DRUG|Norzyme|Patients will be randomized to receive either pancreatic enzyme replacement therapy or placebo. Patients will use two capsules three times daily during main meals and one capsule three times daily during in between snacks. The pancreatic enzyme preparation under investigation is Norzyme ® 6 - 9 tablets per day.
223796502|NCT06430450|DIAGNOSTIC_TEST|Clinical measurements and saliva samples collection|Clinical measurements will be taken from all patients and saliva samples will be collected for biochemical analysis.
223796503|NCT05210192|DRUG|Lidocaine Hydrochloride 1% Solution for Injection_#2|Injection into the sphenopalatine ganglion of the patients in both groups will be made by entering the arcus zygomaticum and oriented at a 45 degree angle towards the opposite tooth. Injections will be made with a dental injector. The first group will be injected with 4ml of 1% lidocaine. Injections will be repeated weekly for the first 4 weeks, then monthly. At the end of the 1st and 3rd months of the treatment, the patients will be evaluated in the routine outpatient clinic control, and the two groups will be compared statistically by questioning the frequency of pain, the number of attacks, the severity of pain (VAS), and the duration of pain.
223796504|NCT05210192|DRUG|Placebo|Injection into the sphenopalatine ganglion of the patients in both groups will be made by entering the arcus zygomaticum and oriented at a 45 degree angle towards the opposite tooth. Injections will be made with a dental injector. The second group will be injected with 4ml of 0.9% saline. Injections will be repeated weekly for the first 4 weeks, then monthly. At the end of the 1st and 3rd months of the treatment, the patients will be evaluated in the routine outpatient clinic control, and the two groups will be compared statistically by questioning the frequency of pain, the number of attacks, the severity of pain (VAS), and the duration of pain.
223796505|NCT00234065|DRUG|Cilostazol|oral tablet, 100 mg twice a day and placebo of aspirin once a day, 1 to 5years
223796506|NCT00234065|DRUG|Aspirin|oral tablet, placebo of cilostazol twice a day and 81 mg once a day, 1 to 5 years
223796507|NCT04666168|BIOLOGICAL|Auto CAR-T|Biological: Auto CAR-T
223796508|NCT04666168|DRUG|Cyclophosphamide,Fludarabine|Drug: Cyclophosphamide,Fludarabine
223796509|NCT04666168|PROCEDURE|Leukapheresis|Leukapheresis
223796510|NCT00126438|DRUG|123I-mIBG (meta-iodobenzylguanidine)|Single Dose
223796511|NCT06445491|OTHER|Control order|Participants will perform an initial baseline of tests, order of 1- 2- 3
223796512|NCT06445491|OTHER|Randomized sequence|the testing order will be randomized for follow up testing.
223796513|NCT03711773|OTHER|Group Physical Therapy Classes|Three times weekly, these subjects will have one hour group physical therapy sessions with either a physical therapist, physical therapy assistant, or personal trainer. These sessions will be aimed to improve strength and function in a low-impact setting designed specifically for those with joint pain.
223796514|NCT05083247|DRUG|mFOLFIRINOX or Gemcitabine nab-paclitaxel|oxaliplatin IV, irinotecan IV, leucovorin IV and 5-FU IV OR Gemcitabine IV Nab paclitaxel
223796515|NCT05083247|RADIATION|Isotoxic High-Dose (iHD)-SBRT|Radiation therapy
223796516|NCT05083247|PROCEDURE|Surgery|Surgery
223796517|NCT00433784|DRUG|Clopidogrel|
223796518|NCT00433784|PROCEDURE|Blood sampling - platelet aggregation|
223796519|NCT00433784|PROCEDURE|Blood sampling - genotyping|
223796520|NCT05283174|OTHER|Blood sampling to test drug level|To collect blood sample during acute stroke and measure NOAC concentration.
223796521|NCT02198027|DRUG|Bupivacaine|23 G spinal needle will be introduced along the nephrostomy tube for peri-tubal infiltration of 10 ml of 0.25 % Bupivacaine into renal capsule to skin.
223796522|NCT02198027|OTHER|Normal saline infiltration|23 G spinal needle will be introduced along the nephrostomy tube for peri-tubal infiltration of 10 ml of normal saline into renal capsule to skin
223796523|NCT04036175|DEVICE|High-Flow Nasal Oxygen / Non-invasive ventilation / Standard oxygen|Device High Flow Nasal Oxygen: gas flow of 50L:Min and FiO2 adjusted to obtain SpO2\>= 92% Device NIV: Pressure-support level to achieve an expired tidal volume between 6 and 8 ml/kg and PEEP level of 5 cmH2O and FiO2 adjusted for SpO2\>= 92%
223796524|NCT03007823|BIOLOGICAL|High-activity natural killer|Each treatment: 8-10 billion cells in all, transfuion in 3 times, i.v.
223796525|NCT05202561|BIOLOGICAL|RNA tumor vaccine|Subjects will receive single dose of RNA tumor vaccine injection on day 1, day 4, day 7, and day 14, each dose of 600 ng.
223796526|NCT05202561|BIOLOGICAL|RNA tumor vaccine+Navuliumab|RNA tumor vaccine+Navuliumab Subjects will receive maintenance therapy with a PD-1 inhibitor in addition to monotherapy with the RNA tumor vaccine injection. Subjects received a single dose of RNA vaccine injection on day 1, day 4, day 7, and day 14, with each dose of 600 ng. Inhibitors, accept the Navuliumab on day 14, the recommended dose is 3 mg/kg, intravenous injection every 2 weeks.
223796527|NCT05565430|OTHER|Acute Hyperventilation|Laryngoscopy to assess vocal cord function during acute hyperventilation in normal subjects and asthmatics.
223796528|NCT05565430|OTHER|Chronic hyperventilation|Laryngoscopy to assess vocal cord function during acute hyperventilation in normal subjects and asthmatics.
223796529|NCT05565430|DRUG|Effects of anticholinergic medication|Laryngoscopy to assess vocal cord function after administration of anticholinergic medication.
223796530|NCT06877715|OTHER|psychological and sensorial tests|children receive questionnaires and sensorial test
223796531|NCT03664479|DEVICE|4 channel Electrical Stimulation Device|electrical stimulation at muscles which related with deglutition
223796532|NCT05864664|PROCEDURE|Wide awake local anaesthesia no tourniquet technique|"Patient awake with no form of sedation or analgesia~* A mixture of lidocaine, adrenaline, normal saline, bicarbonate is used to get 40-50ml solution~* Injection is performed around incision site - superficial to deep including periosteum~* Incision is performed in the normal fashion~* Plate and screws are removed and incision is closed"
223796533|NCT00137930|BIOLOGICAL|Live attenuated rotavirus vaccine|
223796534|NCT05538962|DIAGNOSTIC_TEST|Sensor skin|Skin sensor to detect inflammatory molecules in sweat
223796535|NCT02709668|DIETARY_SUPPLEMENT|Enlyte|gel cap of reduced B vitamins
223796536|NCT02709668|OTHER|placebo|identical to Enlyte
223796537|NCT00570674|DRUG|Abraxane|
223796538|NCT00570674|DRUG|Erbitux|
223796539|NCT00570674|DRUG|Carboplatin|
223796540|NCT00570674|RADIATION|Intensity Modulated Radiation Therapy|
223796541|NCT03519750|DRUG|Melatonin 25 mg|24-48 hour monitoring of plasma melatonin as well as adverse events.
223796542|NCT01331057|OTHER|NEEL test|An assessment for children in French with items extracted from the NEEL test
223796543|NCT01331057|OTHER|ELAL test|An assessment of mother tongue with the ELAL of AVICENNE
223796544|NCT01331057|OTHER|Interview|For parents of children include in the study: A semi -structured interview
223796545|NCT00005801|BIOLOGICAL|therapeutic allogeneic lymphocytes|
223796546|NCT00005801|PROCEDURE|peripheral blood stem cell transplantation|
223796547|NCT00005801|RADIATION|radiation therapy|
223796548|NCT00791206|PROCEDURE|Real preconditioning|Preconditioning will consist of four 5 minutes cycles of upper limb ischemia interspaced with 5 minutes of reperfusion, using a blood-pressure cuff inflated to a pressure 15 mmHg greater than systolic arterial pressure.
223796549|NCT00791206|PROCEDURE|Sham preconditioning|Preconditioning will consist of four 5 minutes cycles of upper limb ischemia interspaced with 5 minutes of reperfusion, using a blood-pressure cuff inflated to a pressure 10mmHg with the same cycling protocol as the real preconditioning.
223796550|NCT00817180|OTHER|Positive Expiratory Pressure (PEP)|Physiotherapy technique for airway clearance
223796551|NCT00817180|OTHER|High Frequency Chest Wall Oscillation (HFCWO) using InCourage Vest System|Physiotherapy technique for airway clearance.
223796552|NCT00799292|DRUG|Vasopressin|20cc of dilute vasopressin (20units in 50cc normal saline). At beginning of the procedure 5cc injected were injected at 2,4,8 and 10 o'clock on the cervix
223796553|NCT04428879|DRUG|Topotecan Episcleral Plaque|Sustained Release Episcleral Topotecan Plaques (Chemoplaques) are glued to bare, dry sclera of the eye under conjunctiva and Tenon's capsule. A rolling six dose interpatient escalation schema will be employed. Chemoplaques with 0.6 mg and 0.9 mg of topotecan HCl formulation are available. Patients will receive 1 or 2 Chemoplaques per eye, to deliver 5 escalating doses: 0.6, 0.9, 1.2 \[2x0.6\], 1.5 \[0.6+0.9\] or 1.8 \[2x0.9\] mg. The prescribed dose will escalate or de-escalate by 0.3 mg at each level, and no patient will receive more than 1.8 mg of topotecan hydrochloride due to the physical limitations if the devices available. The planned removal is 42 days ± 7, unless dose limiting toxicity is observed, in which case the plaque is removed as soon as possible. The observation period for the purposes of dose-escalation will be 63 days (i.e. 21 days following Chemoplaque removal on day 42).
223796554|NCT06450132|DRUG|Atropine Ophthalmic|0.05% atropine ophthalmic solution
223796555|NCT06450132|DEVICE|MiSight 1-day disposable contact lenses|soft multifocal contact lenses
223796556|NCT05974449|DRUG|Vaginal Lactobacillus capsules|This product is a micro-ecological preparation made from live Lactobacillus and is used for the treatment of vaginosis caused by disorders of the flora.
223796557|NCT02923804|DIETARY_SUPPLEMENT|Omega-3|3x 1g capsules taken daily for 6 months
223796558|NCT02923804|DIETARY_SUPPLEMENT|Olive oil|3x 1g capsules taken daily for 6 months
223796559|NCT00352482|DRUG|Sildenafil (50 mg)|
223796560|NCT02539810|DEVICE|Renal artery Angioplasty plus stenting.|renal artery stenting
223796561|NCT02539810|DRUG|Anti hypertensive, statin and antiplatelet medication.|Slow release indapamide 1.5 mg/d (or furosemide 40 mg/d if eGFR is \< 30 mL/min/1.73m²) + irbesartan 300 mg/d + amlodipine 10 mg/d + aspirin 75 mg/d (or clopidogrel 75 mg/d in case of allergy or gastrointestinal intolerance to aspirin) + atorvastatin 20 mg/d. After randomization, bisoprolol 10 mg/d, prazosin 5 mg/d, and rilmenidine 1 mg/d and spironolactone 12.5 to 25 mg/d, will be sequentially added from months two to five in both groups if home blood pressure remains more than or equal to 135/85 mm Hg.
223796562|NCT00746122|PROCEDURE|Open repair|Standard treatment of emergency open surgery
223796563|NCT00746122|PROCEDURE|EVAR|Emergency endovascular aneurysm repair
223796564|NCT02678130|DEVICE|InterFuse T|Transforaminal Lumbar Interbody fusion (TLIF)
223796565|NCT02678130|DEVICE|Standard of Care TLIF (Stryker AVS Unilif)|Transforaminal Lumbar Interbody Fusion (TLIF)
223796566|NCT06145243|OTHER|Home based exercise|Patients will be given a visual brochure with pictures explaining the exercises. Patients will perform the resistance exercises in the given exercise program for 8 weeks, 2 days a week for 8-12 repetitions and 3 sets using resistance bands.Progress of the home exercise group will be checked by phone every week.
223796567|NCT06145243|OTHER|Video-based resistive exercise|A video recording of the exercises will be taken and given to the patients as a video recording.Patients will perform the resistance exercises in the given exercise program for 8 weeks, 2 days a week for 8-12 repetitions and 3 sets using resistance bands.Progress of the video-based exercise group will be checked by phone every week.
223796568|NCT06145243|OTHER|Supervised resistive exercise|Patients will perform their exercises under the supervision of a physiotherapist.Patients will perform the resistance exercises in the given exercise program for 8 weeks, 2 days a week for 8-12 repetitions and 3 sets using resistance bands.
223796569|NCT03530930|DRUG|Comarum Palustre|Comarum Palustre tablets 500 mg BID, 1 month
223796570|NCT03393000|DRUG|Trans Sodium Crocetinate plus SOC|Trans Sodium Crocetinate (TSC) plus the Standard of Care (SOC): SOC composed of radiation and temozolomide for 6 weeks followed by 4 weeks of rest followed by six (6) 28-day cycles of temozolomide
223796571|NCT03393000|OTHER|Standard of Care (SOC)|Standard of Care (SOC): SOC composed of radiation and temozolomide for 6 weeks followed by 4 weeks of rest followed by six (6) 28-day cycles of temozolomide
223796572|NCT00160680|DRUG|Levocetirizine|"* Pharmaceutical form: Tablet~* Concentration: 5 mg~* Route of administration: Oral use"
223796573|NCT02877043|PROCEDURE|resection pulmonaire|
223796574|NCT01773070|DRUG|ABT-450/ritonavir|ABT-450 coformulated with ritonavir. Drug is not administered -- this study is follow-up for participants previously receiving the drug.
223796575|NCT01773070|DRUG|ABT-333|Drug is not administered -- this study is follow-up for participants previously receiving the drug.
223796576|NCT01773070|DRUG|ABT-267|Drug is not administered -- this study is follow-up for participants previously receiving the drug.
223796577|NCT02063334|DIETARY_SUPPLEMENT|Vitamin D3|In total 25 pills will be taken by the subjects, each containing 80 micrograms of vitamin D3 or placebo. Of the 25 pills, 13 will be taken in the morning with breakfast and 12 with lunch.
223796578|NCT02063334|DIETARY_SUPPLEMENT|Placebo|
223796579|NCT02001857|DRUG|1 TachoSil hemostatic sponge (9,5 cm x 4,8 cm) placed on each side on the external iliac artery.|at the end of surgery
224264111|NCT02645253|DRUG|AZD7594 placebo pressurized inhalation suspension|AZD7594 placebo pressurized inhalation suspension via pressurized metered dose inhaler (pMDI)
224264112|NCT00000458|DRUG|sertraline (Zoloft)|
224264113|NCT00000458|BEHAVIORAL|cognitive behavior therapy|
224264114|NCT01016782|DRUG|0444|A thin film of gel will be applied and rubbed into the entire face once daily for a period of 70 days
224264115|NCT02895802|BEHAVIORAL|Verbal instructions with picture diagram|verbal instructions and picture diagram
224264116|NCT02895802|BEHAVIORAL|Verbal instructions with video of ADSC|Verbal instructions and watching video depicting ADSC
223796580|NCT03697902|DIAGNOSTIC_TEST|Ultrasonographic Measurement on Fetal cisterna magna length|"The length measurement on the fetal cisterna magna (CM) with an angle of 0° between the transducer and the axial cerebellar plane of the fetal head (midline structures will be perpendicular to the ultrasound beam). After that, CM will be measured again after moving the transducer approximately 30° towards the fetal occiput.~Measurements will be performed on the axial cerebellar plane using internal landmarks including the cavum septi pellucidi, thalamus, third ventricle, cerebral peduncles and cerebellar hemispheres.The anteroposterior measurement will be made between the posterior border of the cerebellar vermis and the internal face of the occipital bone.~All the ultrasonography examinations were performed abdominally, using 3-5 megahertz (MHz) transducers."
223796581|NCT04244890|DEVICE|Uninterrupted CPAP for the first hours of life|Directly at birth the infant will be supported with PPV with PEEP as needed, followed by nasal CPAP. Support will be provided with a single device for up to four hours.
223796582|NCT04375748|DIAGNOSTIC_TEST|Performing routine care (clinical and paraclinical tests)|ECG, standard biology and cardiology tests, and routine transthoracic echocardiography (TTE), MRI
223796583|NCT04375748|DIAGNOSTIC_TEST|Examinations for the research:|"Systematic research by polymerase chain reaction (PCR) for Covid-19 in the blood and in an oro-pharyngeal swab, in addition to the usual immunologic, bacteriological, viral and parasitic tests carried out as part of the routine care of all patients with suspected myocarditis.~A 30-days phone call follow-up (vital status) and a systematic 1-year follow-up will be realized (clinic, biology, ECG, TTE, +/- MRI)"
223796584|NCT02577666|BEHAVIORAL|Ecologically Based Therapy|6 months of community reinforcement approach and case management, 3 months of rental assistance for housing
223796585|NCT02577666|BEHAVIORAL|Housing Only|receives 3 months of project supported rental assistance
223796586|NCT02577666|BEHAVIORAL|Treatment as Usual|receives services as normally offered within the community
223796587|NCT03086304|DEVICE|transcutaneous acupoint electrical stimulation|Transcutaneous acupoint electrical stimulation is same to the traditional Chinese medicine acupuncture treatment,treat diseases by stimulate different acupuncture points.
223796588|NCT03086304|DEVICE|no transcutaneous acupoint electrical stimulation|the choice of acupoints are same with TEAS group,tape over the electrode but don't give electroacupuncture stimulation.
223796589|NCT01777659|DEVICE|Transcutaneous electrical nerve stimulation|Patients will be treated with conventional TENS (ENDOMED 684 Device, ENRAF-Nonius B.V., Rotterdam, Netherlands) for 5 days (4 times/day; 30 min/session) applied on cervical region (C7-T4). TENS intervention was applied as described elsewhere.
223796590|NCT04899882|OTHER|KinHémo|Evaluation and cardiovascular training, combination of resistance and flexibility training
223796591|NCT03484975|DEVICE|Observation group|Collect coronary images with a hybrid IVUS OCT system.
223796592|NCT01313702|DRUG|polipillV1|polipill version 1: aspirin 75mg, simvastatin 40mg, lisinopril 10mg, atenolol 50mg
223796593|NCT01313702|DRUG|polipillV2|Polipill version 2: aspirin 75mg, simvastatin 40mg, lisinopril 10mg, hydrochlorothiazide 12.5mg.
223796594|NCT01313702|DRUG|usual care|the drugs used in clinical practice, defined by physician
223796595|NCT01104194|DIETARY_SUPPLEMENT|omega-3 fatty acids supplements (fish oil)|1.74g eicosapentaenoic acid (EPA) and 0.25g docosahexaenoic acid (DHA)
223796596|NCT01104194|DIETARY_SUPPLEMENT|Placebo|softgel capsules (identical in appearance to fish oil capsules) containing olive oil. 3 capsules/day, 4 weeks
223796597|NCT00259532|PROCEDURE|Ultrasound and contrast agent|contrast-enhanced ultrasound combined with the gastrointestinal hormones Secretin and Cholecystokinin, which triggers the enzyme production of pancreas
223796598|NCT00258258|DRUG|paricalcitol|
223796599|NCT00258258|DRUG|zoledronic acid|
223796600|NCT03944525|DEVICE|High flow nasal cannula|Oxygen-therapy via HFNC
223796601|NCT03944525|DEVICE|Continuous positive airway pressure|Non-invasive CPAP ventilation
223796602|NCT05668962|DRUG|Selpercatinib|Selpercatinib Oral, twice daily during initial treatment period (28 Days). A second course of selpercatinib if the participant is demonstrating clinical benefit to the initial course selpercatinib and deemed clinically appropriate by the treating investigator
223796603|NCT05668962|DRUG|Sodium Iodine I-131|I-131 NaI, oral, is a standard treatment for all types of follicular-derived thyroid cancers, except anaplastic thyroid cancer
223796604|NCT05668962|DRUG|rhTSH|"RhTSH injection, dosage per protocol, timing per protocol during the initial treatment period per standard of care.~Participants may receive a second course of rhTSH if the participant is demonstrating clinical benefit to the initial course rhTSH and deemed clinically appropriate by the treating investigator."
223796605|NCT05590780|OTHER|Clinical Attachment level|1-year
223796606|NCT00380848|PROCEDURE|Hemodiafiltration|
223796607|NCT03065868|DRUG|H. pylori eradication (Amoxaxillin, Lanston, Clarithromycin)|H. pylori eradication (Triple Therapy) as first line treatment if eradication failure, quadruple therpy will be provided as 2nd line treatment
223796608|NCT03977675|DRUG|Ketamine|Patients are assigned to one of three ketamine doses (0.3, 0.5, or 0.7 mg/kg) that will be administered intravenously.
223796609|NCT03235167|DRUG|CpG DNA|CpG DNA concentrate
223796610|NCT03235167|PROCEDURE|transcatheter arterial chemoembolization|transcatheter arterial chemoembolization (TACE) therapy for liver cancer
223796611|NCT03235167|DRUG|Placebo - Concentrate|CpG DNA vehicle
223796612|NCT04134156|PROCEDURE|sleeve gastrectomy|5-port sleeve gastrectomy
223796613|NCT04134156|PROCEDURE|one anastomosis gastric bypass|5-port one anastomosis gastric bypass
223796614|NCT02450331|DRUG|Atezolizumab|Atezolizumab will be administered at a dose of 1200 milligrams (mg).
223796615|NCT02178605|PROCEDURE|Cervical arthrodesis with rhBMP-2|Cervical arthrodesis with rhBMP-2
223796616|NCT06580262|OTHER|Routine care|"The investigator takes care of the patient according to the protocol in force in his department and decides on the final orientation of the patient (transfer to intensive care unit/ICU, hospitalization or home discharge).~No recommendations or instructions are given to the investigators. Each investigator is free to decide on his care and the terms of transfer, hospitalization and discharge."
223796617|NCT05211388|PROCEDURE|RFA controlled using echo decorrelation imaging|"The tumor will be ablated using standard clinical RFA control algorithms specified by the RFA device manufacturer and implemented on the RFA generator, with echo decorrelation imaging providing an additional stopping criterion.~The targeted ablation zone will be subdivided into one or more contiguous control subvolumes encompassing the tumor. An echo decorrelation threshold will be chosen to provide a target specificity (e.g. 90%) for local ablation prediction, based on ROC curve analysis for ablation prediction in clinical RFA and MWA as well as in controlled ablation of ex vivo human liver tumors. Controlled RFA treatments will proceed until the average cumulative decorrelation exceeds this predetermined threshold within each control subvolume.~To avoid compromising patient safety, treatments will not be extended beyond manufacturer-specified end points."
223796618|NCT05211388|PROCEDURE|RFA controlled using standard manufacturer-specified algorithms|The tumor will be ablated using standard clinical RFA control algorithms specified by the RFA device manufacturer and implemented on the RFA generator, e.g. based on temperatures measured by thermocouples integrated into the RFA probe. 3D echo decorrelation imaging will be performed in real time during ablation, but will not be used to modify treatments.
223796619|NCT02324218|OTHER|Data collection|Data extraction from CPRD database of UK.
223796620|NCT00254033|DRUG|Dextroamphetamine|
223796621|NCT00254033|DRUG|Methylphenidate|
223796622|NCT02612987|BEHAVIORAL|Internet-based Cognitive Behaviour Therapy (iCBT)|
223796623|NCT04499573|DRUG|CD19/CD22 CAR-T|"The treatment plan will be based on stratification by the initial leukemia burden.~Patients with low disease burden will receive a lymphodepletion chemotherapy of fludarabine (total dose 120mg/m2) and cyclophosphamide (total dose 750mg/m2) over 5 days.~Patients will high disease burden will receive a lymphodepletion chemotherapy of fludarabine (total dose 120 mg/m2), cyclophosphamide (total dose 750 mg/m2), cytarabine (total dose 900 mg/m2), etoposide (total dose 450 mg/m2), dexamethasone (total dose 30 mg/m2) over 5 days.~Based on interim analysis the following dosing approach will be implemented starting April 2021:~Cohort 1: CD19+ disease, low and high burden: 1st dose - 150k/kg, 2nd dose - 850k/kg Cohort 2: CD19- disease, low and high burden: 1st dose - 500k/kg, 2nd dose - 500k/kg Cohort 3: HSCT+CAR-T: 100k/kg"
223796624|NCT04406948|DRUG|MGCND00EP1|Patients will take cannabis oil during the study
223796625|NCT04406948|DRUG|Placebo|Patient will take carrier oil during the study
223796626|NCT04406948|DIAGNOSTIC_TEST|ECG|"A standard 12-lead ECG will be recorded using digital ECG recording equipment provided to the investigational site. The ECG has to be performed prior to laboratory samplings at time points indicated in the Schedule of Assessments.~The ECG recording will be reviewed by investigator and case of need consultation with cardiologist will be performed. The investigator has the final decision on the clinical significance of the ECG results."
223796627|NCT04406948|DIAGNOSTIC_TEST|EEG|An EEG is an electrophysiological monitoring method that records the electrical activity and measures voltage fluctuations resulting from ionic current within the neurons of the brain. In clinical contexts, EEG refers to the recording of the brain's spontaneous electrical activity over a period of time.
223796628|NCT04406948|DIAGNOSTIC_TEST|Blood and urine collection|safety blood tests - hematology\\blood count and biochemistry standard blood tests urinalysis - urine test analysis
223796629|NCT03823781|DRUG|Milrinone|The study intervention is an intravenous infusion of milrinone or placebo.
223796630|NCT03823781|DRUG|Normal saline|The study intervention is an intravenous infusion of milrinone or placebo.
223796631|NCT02723864|DRUG|Veliparib + VX-970 + Cisplatin|Ataxia-telangiectasia-related (ATR) protein kinase is central to the deoxyribonucleic acid (DNA) damage response and homologous recombination, activating a series of phosphorylation cascades, culminating in cell cycle arrest to allow time for DNA repair. Poly (ADP-ribose) polymerase (PARP) plays a pivotal role in base-excision repair of single strand breaks formed either due to direct genotoxic stress or during the processing of double strand breaks. Preclinical studies show ATR inhibitor M6620 (VX-970) synergizes with cisplatin to induce DNA damage and antitumor activity. The addition of PARP inhibitor veliparib with VX-970 allows for impairment of DNA repair, induction of a breast cancer gene (BRCA) null phenotype, and potentiation of the antitumor activity of cisplatin.
223796632|NCT00112268|BEHAVIORAL|QuitLink (office support system for quit line referral)|
223796633|NCT01402141|DIETARY_SUPPLEMENT|Chungkookjang|Chungkookjang(35g/say)for 12 weeks
223796634|NCT01402141|DIETARY_SUPPLEMENT|Placebo|Placebo(35g/day) for 12 weeks
223796635|NCT02191696|DEVICE|IMED-4 recording|
223796636|NCT03148470|DEVICE|Sham iTBS|Placebo stimulation for the iTBS group
223796637|NCT03148470|DEVICE|Sham cTBS|Placebo stimulation for the cTBS group
223796638|NCT03148470|DEVICE|intermittent theta burst stimulation (iTBS)|Excitatory theta burst stimulation
223796639|NCT03148470|DEVICE|continuous theta burst stimulation (cTBS)|inhibitory theta burst stimulation
223796640|NCT00405626|DRUG|Bellis Perenis ,Arnica montana|
224264117|NCT02895802|BEHAVIORAL|verbal instructions w. video of w/o DS|verbal instructions and watching video depicting person without DS washing her hands
224264118|NCT02895802|BEHAVIORAL|verbal instructions w. video w/DS|verbal instructions and watching video depicting person with DS washing his hands
224264119|NCT03371186|OTHER|Community Health Worker|The intervention is designed to address these primary drivers of underutilization of reproductive, maternal, newborn, and child health services in rural Nepal, namely: poverty, lack of social support, and poor birth planning. The investigators have worked with a cadre of Community Healthcare Workers who, in addition to the responsibilities of local community health volunteers, have added responsibilities, training, and managerial support. These women support their community members in their homes to identify and overcome social barriers and plan for emergency healthcare needs. The goals are to increase utilization of services, maternal and neonatal health knowledge, self-efficacy, social support, and emergency planning among mothers
223796641|NCT01288482|DEVICE|AeroEclipse II breath-actuated nebulizer|The AeroEclipse II (Trudell Medicinal International, London, ON, Canada) is a breath-actuated nebulizer that allows for the creation of aerosol only in response to the patient's inspiratory flow, resulting in virtually no drug loss to the environment and providing a safer healthcare and patient environment by significantly reducing second-hand drug exposure and the possibility for transmission of viral airborne pathogens.
223796642|NCT01288482|DEVICE|English-Wright continuous-mode nebulizer|The English-Wright is a continuous-mode nebulizer, designed to operate continuously with tidal breathing, producing an aerosol which is lost to the environment possibly posing a hazard to any fellow-patients, family members, or health-care workers in the vicinity. It is the only device recommended by the American Thoracic Society guidelines that is available on the market and it has recently been discontinued. For these reasons it is necessary to review the use of other nebulizers and validate their performance.
223796643|NCT06485817|DRUG|Oxycodone|"3.1mg oxycodone/70 kg body weight was administered as the main drug intervention.~Based on body weight, the study nurse/anesthetist adjusted the (unknown) content in two syringes by removing enough fluid to reach a volume that would result in a dose equivalent of 3.1mg/70kg (0,043 mg/ml pr kg) should the syringes contain oxycodone.~The first dose was administered 5 minutes after the state induction task. The second dose was adjusted according to the performance on the self-administration task (but maximum 100% of the first dose) and administered 45 later."
223796644|NCT06485817|DRUG|Placebo|"Pure saline was administered as the placebo condition.~Based on body weight, the study nurse/anesthetist adjusted the (unknown) content in two syringes by removing enough fluid to reach a volume that would result in a dose equivalent of 3.1mg/70kg (0,043 mg/ml pr kg) should the syringes contain oxycodone.~The first dose was administered 5 minutes after the state induction task. The second dose was adjusted according to the performance on the self-administration task (but maximum 100% of the first dose) and administered 45 later."
223796645|NCT06485817|BEHAVIORAL|Stress State Induction|"ReSST is an in-house hybrid online-lab implementation of two stress induction paradigms based on the Trier Social stress test (TSST) and Iowa Social Singing Stress Test (I-SSST).~The set-up was tailored to allow repeated stress induction without diminishing effects that allowed for an online experiment panel. Stress and control state inductions were administered every-other session. The singing version of the stress test was always administered last as it was deemed more stressful during piloting."
223796646|NCT06485817|BEHAVIORAL|Control State Induction|Two different control tasks matched to the stress conditions on key parameters outlined in the protocol.
223796647|NCT05717868|OTHER|Kinesiology taping|5 cm wide and 0.5 mm thick waterproof, porous and adhesive tape will be applied to the posterior neck of the participants while sitting comfortably in a neutral position. The first tape (Y-strip) is placed over the posterior cervical extensor muscles with approximately 25% tension. The top strip will be placed perpendicular to the Y strip on the mid-cervical region. The participant's cervical spine is flexed to obtain tension in the posterior structures.
223796648|NCT05717868|OTHER|Self-mobilization|The towel will be placed on the posterior arch of the fifth cervical vertebra and pulled horizontally across the face. The participant will be instructed to apply pressure to the towel and turn their head to the restricted side, then maintain the finishing interval for three seconds. The participant will be asked to apply extreme pressure in the bending position with towel support. The procedure should be painless and repeated 10 times.
223796649|NCT00454948|BEHAVIORAL|Home-based nutrition sessions and play group exercise|
223796650|NCT00454948|BEHAVIORAL|Group-based nutrition sessions and mail-out activities|
223796651|NCT03643952|DRUG|Daptomycin for Injection|Once daily administration of 5, 7, 9, 10, or 12 mg/kg intravenous (IV) daptomycin infused with 25-50 mL saline over 30-60 minutes depending upon infection type and age level.
223796652|NCT01358968|DRUG|LY2603618|Administered intravenously as a 1-hour infusion.
223796653|NCT01358968|DRUG|Desipramine|Administered orally
223796654|NCT01358968|DRUG|Pemetrexed|Administered intravenously as a 10-minute infusion.
223796655|NCT01358968|DRUG|Gemcitabine|Administered intravenously as a 30-minute infusion.
223796656|NCT01049048|DIETARY_SUPPLEMENT|Vitamin D3|2500 IU Vitamin D3
223796657|NCT01049048|DIETARY_SUPPLEMENT|Placebo|No (0 IU) vitamin D3 added to cookie.
223796658|NCT04892355|DEVICE|Root canal irrigation|Devices used during root canal irrigation
223796659|NCT03594669|OTHER|Intervention|Multi-modal sensorimotor training interventions, including vestibular, oculomotor, neuromotor, and postural control/ balance exercises.
223796660|NCT06304259|DRUG|Saline|Submucosal infiltration injection of 1 mL cryo-treated saline maintained at a temperature of 2 to 5°C before the normal local anaesthetic routine
223796661|NCT06304259|DRUG|Saline|root canal treatment with final flush of cold saline maintained at a temperature of 2 to 5°C
223796662|NCT00968682|BIOLOGICAL|trastuzumab|
223796663|NCT00968682|OTHER|laboratory biomarker analysis|
223796664|NCT00968682|PROCEDURE|assessment of therapy complications|
223796665|NCT03630874|OTHER|Evaluate the impact of a prescription support tool|"From a systematic review of international guidelines (2012-2018), we developed a prescription support-tool synthesizing national and international guidelines on chronic management (≥ 1 month) of oral AT agents without considering in-hospital management and bridging therapy.~In the experimental group, the tool will be provided with an explanatory guide. Selected physicians will receive 3 different clinical vignettes, each corresponding to a specific situation for which the physician will have to indicate (thanks to the tool) the right prescription of ATs by answering a multiple-choice question, with the number, type, duration and dosage of AT provided."
223796666|NCT05290350|OTHER|OSA|EXPOSURE TO OBSTRUCTIVE SLEEP APNEA
223796667|NCT02308384|BEHAVIORAL|Intervention|CME, Start-package and status mail
223796668|NCT01413568|DRUG|POL6326|
223796669|NCT01413568|PROCEDURE|Leukapheresis|
223796670|NCT01413568|PROCEDURE|PBSC Transplant|
223796671|NCT01992380|DRUG|Flortaucipir F18|IV injection, 370 MBq (10 mCi), two doses up to four weeks apart
223796672|NCT01992380|PROCEDURE|Brain PET scan|positron emission tomography (PET) scan of the brain at 80-100 and 110-130 minutes after injection
223796673|NCT03438123|DEVICE|CZT SPECT imaging|Acquisition of SPECT (single photon emission computed tomography) imaging utilising a camera system with solid-state cadmium zinc telluride (CZT) detectors to visualise injected, or otherwise introduced, radioactivity in the human body.
223796674|NCT02614716|DRUG|LY3090106|Administered SC
223796675|NCT02614716|DRUG|Placebo|Administered SC
223796676|NCT06373757|OTHER|Nano-HAP/Chitosan hydrogel|The periodontal pockets more than or equal 3-5mm were isolated. Chitosan and nano-HAP hydrogel were prepared in the same steps that were mentioned in the methodology and then the prepared gel was applied to the test site of patients with the deepest probing pocket measurement once per week for 3 weeks. Periodontal dressing (Coe-pack) was to secure the hydrogel in place.
223796677|NCT02242864|DRUG|Micardis®|
223796678|NCT02242864|DRUG|MicardisPlus®|
223796679|NCT00425048|PROCEDURE|wearing gloves|
223796680|NCT01130948|OTHER|altitude exposure|exposure to 490m, 1700m and 2590m
223796681|NCT05022680|BEHAVIORAL|mhealth|the peer-led intervention with mHealth technology (an application (APP) and Sports bracelet)
223796682|NCT00815295|DRUG|Sorafenib|Phase 1 - Dose level 1 : Sorafenib will be given 200 mg twice daily oral, Phase 1 - Dose level 2 : Sorafenib will be given 400 mg twice daily oral, Phase 2 : Sorafenib will be given at the maximum tolerated dose from Phase 1
223796683|NCT00815295|DRUG|Cetuximab|Cetuximab will be given at standard approved dose: 400 mg/m2 loading dose followed by 250 mg/m2 weekly.
223796684|NCT03972111|DRUG|TPOXX 200Mg Capsule|TPOXX 600 mg (three 200 mg.) capsules twice daily for 14 days
223796685|NCT00530855|DRUG|Lacosamide|50 mg and 100 mg Lacosamide tablets taken for 50 -400 mg twice daily dosing for up to 2 years
223796686|NCT02816151|DRUG|full dose at 16 UI/kg for Dysport or 6,5 UA/kg for Botox|Intradetrusor injection under general anesthesia. Injection done through 25 points of 1cc each.
223796687|NCT02816151|DRUG|half dose at 8 UI/kg for Dysport or 3,25 UA/kg for Botox|Intradetrusor injection under general anesthesia. Injection done through 25 points of 1cc each.
223796688|NCT01420055|DRUG|fingolimod|
223796689|NCT01292876|DEVICE|Extracellular Matrix|Extracellular Matrix
223796690|NCT04783467|BEHAVIORAL|Time Restricted Eating (TRE) Schedule|\[See arm/group descriptions\]
223796691|NCT04003168|DRUG|Human BCMA targeted T Cells Injection|Autologous genetically modified anti-BCMA CAR transduced T cells
223796692|NCT02692326|PROCEDURE|Cyclic parenteral nutrition|Cyclic parenteral nutrition was provided according to a method described by Longhurst et al. Patients were initially cycled of PN for 1 hour per day with increased rate of 1 hour with a maximum time out of PN of 4 hours for preterm babies \< 37 weeks GA and 6 hours for term newborns. Glucose was monitored at half the time without PN to detect the hypoglycemia.
223796693|NCT01848080|BEHAVIORAL|Tai Chi based exercise program|A Tai Chi based exercise program that uses movement repetition favoring directional adjustments in space, supervised by a physiotherapist, has been shown to be effective in improving balance in individuals with physical impairments, including those presenting with sequelae following a stroke.
223796694|NCT05450315|BEHAVIORAL|Stride to Survive:An Exercise Guide for Young Adult Cancer Survivors|
223796695|NCT05450315|BEHAVIORAL|Canadian Physical Activity Guidelines|
223796696|NCT01081093|PROCEDURE|additional temporary pacewire|Placement of an additional pacing wire on the left side of the heart after aortic valve replacement in patients with hypertrophic cardiomyopathy
223796697|NCT03435874|BIOLOGICAL|ChAd63 RH5|Vaccine
223796698|NCT03435874|BIOLOGICAL|MVA RH5|Vaccine
223796699|NCT03435874|BIOLOGICAL|Rabies Vaccine|Vaccine
223796700|NCT03731468|DRUG|local anesthetic|ultrasound guided superficial cervical block in thyroid surgery
223796701|NCT03731468|DRUG|Dexamethasone|dexamethasone will be added to ultrasound guided superficial cervical block in thyroid surgery
223796702|NCT05156190|OTHER|bright classrooms with light level over 1000 lux|Grade 2 primary school students at the intervention groups will study in bright classrooms for three years and incidence of myopia will be compared with those in conventional classrooms
223796703|NCT01012830|DRUG|Huperzine A|Huperzine A in 200 microgram (mcg) capsules taken twice daily for 8 weeks.
223796704|NCT01175850|DEVICE|Drug-Coated Balloon (DCB)|balloon dilatation and provisional stenting with IN.PACT DCB
223796705|NCT01175850|DEVICE|PTA Balloon: Balloon Angioplasty|balloon dilatation and provisional stenting with standard non-coated PTA balloon
223796706|NCT04708444|DIAGNOSTIC_TEST|CD318|Flowcytometric marker
223796707|NCT04432987|DRUG|Pulmozyme|"PULMOZYME contains an active substance called dornase alpha as an active substance. Dornase alpha is a human-made version of a protein called DNase in your body and is also known as recombinant human deoxyribonuclease 1 or rhDNase.~Drug will be administered at a dose of 2,5 mg/2 times per day for 7 days"
223796708|NCT00046358|DRUG|Lovostatin|
223796709|NCT00046358|DRUG|Ibuprofen|
223796710|NCT05475054|PROCEDURE|Minimally invasive liver resection|A liver resection performed by minimally invasive (keyhole) surgery
223796711|NCT05622669|OTHER|Observational|Sensed and lived experience data from all groups without a specific behavioural or drug intervention
223796712|NCT04101305|DIAGNOSTIC_TEST|IsoPic|Biomimetic circulating epithelial cell enrichment followed by epithelial cell detection and single cell DNA sampling and sequencing
223796713|NCT02535273|DRUG|Dexmedetomidine|load dosage：Intravenous injection dexmedetomidine 1 µg/kg，completed within 10 minutes.
223796714|NCT02535273|DRUG|Lidocaine|local anesthesia：0.67% lidocaine local anesthesia layer by layer to the periosteum at the puncture site，Establish puncture channel, injection 5ml 0.67% lidocaine into the vertebral body through the catheter, and observe 5-10min before operation
223796715|NCT02535273|DRUG|Low-dose Dexmedetomidine|maintenance dose：Intravenous infusion of dexmedetomidine 0.3 μg/kg/min until the end of surgery
223796716|NCT02535273|DRUG|Moderate-dose Dexmedetomidine|maintenance dose：Intravenous infusion of dexmedetomidine 0.5 μg/kg/min until the end of surgery
223796717|NCT02535273|DRUG|High-dose Dexmedetomidine|maintenance dose：Intravenous infusion of dexmedetomidine 0.7 μg/kg/min until the end of surgery
223796718|NCT02535273|DRUG|normal saline|Intravenous injection normal saline equal quantity，completed within 10 minutes. Intravenous infusion of normal saline 0.125 μg/kg/min until the end of surgery
223796719|NCT03098134|BEHAVIORAL|Behavior Therapy|Virtual Reality and Video based Exposure Therapy
223796720|NCT03098134|OTHER|Health Education|Video based health education covering common myths and false believes about dental surgeries
223796721|NCT00679120|DEVICE|Oxford Uni Knee|Oxford Uni Knee inserted at the time of surgery
223796722|NCT00679120|DEVICE|Oxford Uni Knee|Oxford Uni Knee inserted at the time of surgery
223796723|NCT00679120|DEVICE|Oxford Uni Knee|Oxford Uni Knee inserted at the time of surgery (porous coated and HA coated)
223796724|NCT02436265|DRUG|Dexamethasone|IV dexamethasone
223796725|NCT02436265|DRUG|Ropivacaine|Ropivacaine only
223796726|NCT03966833|BEHAVIORAL|IPT-G|14 weeks of group-based interpersonal therapy (IPT-G)
223796727|NCT03966833|BEHAVIORAL|Unconditional Cash Transfer|Lump sum cash transfer
223796728|NCT05853679|DEVICE|Lumoral Treatment|The device will be used 5 to 7 times per week according to the manufacturer's instructions.
223796729|NCT05853679|OTHER|Standard oral hygiene instructions according to the Finnish Dental Association|Participants will be instructed to clean their teeth twice per day by an electric toothbrush, an interdental brush, and flossing.
223796730|NCT03584932|BEHAVIORAL|LINK2 Youth Services Navigation Intervention|There will be 6 in-person sessions delivered by a youth services navigator, plus weekly check-in calls after session 2 for a total of six months. As part of the learning sessions, the participant will learn important information about HIV and how to get the most out of his/her HIV care.
223796731|NCT01616901|PROCEDURE|Spontaneous breathing trial|"5 spontaneous breathing trial will be tested by the patients in the same order :~* 7 cm H2O continuous positive airway pressure~* T piece~* 7 cmH2O of pressure support~* 0 cmH20 of pressure support~* 7 cm H2O pressure support ventilation with 7 cmH20 of end expiratory pressure."
223796732|NCT04899830|DEVICE|Telepresence robot|From the application installed on a tablet, the patient hospitalized in a center for a period of at least 2 months can start from the center where he is hospitalized the mobile robotic telepresence assistance device installed at home to communicate with his family, his friends, his neighbors,…)
223796733|NCT03901326|DIAGNOSTIC_TEST|CT-FFR assessment|When subjects are randomized to the CTA/CT-FFR arm, FFR based on the coronary CTA imaging will be measured. DEEPVESSEL FFR workstation is very dedicated software utilizing the original CTA imaging to meter simulated FFR values based on a machine learning algorithm. The first step is to extract a 3D coronary artery model and generate coronary centerlines which are similar to the routine reconstruction of coronary CTA. The centerlines are extracted using a minimal path extraction filter. Then a novel path-based deep learning model, referred to DEEPVESSEL FFR, is used to predict the simulated FFR values on the vascular centerlines. Deep learning algorithm is used to establish characteristic sample database of coronary hemodynamics characteristic parameters. When deep training model is proved to be valid, it is applied to a new lesion-specific measurement. Lesion-specific CT-FFR is defined as simulated FFR value at distance of 20mm away from the lesion of interest.
223796734|NCT06005805|DIETARY_SUPPLEMENT|Mastic gum|Mastic gum 3g/pack daily for 21 days
223796735|NCT06005805|BEHAVIORAL|Dietary modification|Adhere to the dietary recommendations for Korean dyspepsia patients
223796736|NCT00253968|DRUG|Eplivanserin|oral administration
223796737|NCT00253968|DRUG|placebo|oral administration
223796738|NCT00961090|DRUG|Aminolevulinic Acid|20 mg/kg mixed in 50cc water and taken orally 3 hours prior to surgery
223796739|NCT02189551|BEHAVIORAL|Gait training with Lokomat Pro|
223796740|NCT02189551|BEHAVIORAL|Gait training with Lokomat Pro FreeD|
223796741|NCT04211038|DEVICE|inspiratory threshold load device|"Before experiment ,every subject use a flanged mouthpiece attached to a manually operated occlusion valve in order to measure maximal inspiratory pressure (MIP)at functional residual capacity .~And then, the healthy subjects will be increased the neural respiratory drive by increasing the pressure in a water-sealed inspiratory threshold loading device. At last, all subjects will do Incremental cycle ergometry test with the assisstance of NPPV."
223796742|NCT05830955|OTHER|Lullaby group|The preterm newborns who are going to listen a live lullaby from their mothers' voice will be the first group (Lullaby group).
223796743|NCT05830955|OTHER|Breast milk group|The preterms in the second group (Breast milk group) are going to smell their mothers' breast milk.
223796744|NCT05830955|OTHER|Control group|The preterms in the third group (Control group) are going to recieve rutin nursing care interventions.
223796745|NCT00446381|DRUG|Macugen (pegaptanib)|Pegaptanib 0.3 mg by intravitreal injection once pre-operatively
223796746|NCT00446381|DRUG|Macugen (Pegaptanib)|Pegaptanib 0.3 mg by intravitreal injection once pre-operatively.
223796747|NCT01814371|DRUG|2% mupirocin ointment|Participants over 1 month of age, apply ointment to the anterior nares twice daily for 5 days.
223796748|NCT01814371|OTHER|Bleach Bath (dilute)|Participants over 1 month of age, pour 1/4 cup of bleach into a bath tub filled 1/4 full of water. Soak in bath for 15 minutes daily for 5 days.
223796749|NCT01814371|BEHAVIORAL|Hygiene Protocol|"Follow key hygiene tips:~* Throw out all lotions or creams that you dip your hands into and replace with pumps or pour bottles.~* Use liquid(pour or pump) soaps instead of bar soaps.~* Wash hands frequently or use hand sanitizer(with more than %60 alcohol) such as Germ-X or Purell.~* Do not share personal care items such as razors, brushes, or deodorant.~* Wash all sheets and towels in hot water. Wash sheets every week.~* Use towels and wash cloths only once before washing and do not share."
223796750|NCT05480150|DRUG|Escitalopram Oxalate Tablets|Starting at 5mg qn, the treatment dose was titrated to 10-20mg qn within 1 week and maintained for 4 weeks
223796751|NCT05480150|DRUG|Quetiapine Fumarate Tablets|Starting at 50mg qn, the treatment dose was titrated to 300-400mg qn within 10 days, and maintained the treatment for 4 weeks.
223796752|NCT05480150|DRUG|Lurasidone|Starting at 20mg qn, the treatment dose was titrated to 40mg qn within 6 days,and maintained the treatment for 4 weeks.
223796753|NCT01692782|DRUG|SEP-225289|SEP-225289 4mg once daily
223796754|NCT01692782|DRUG|SEP-225289|SEP-225289 8mg once daily
223796755|NCT01692782|DRUG|Placebo|Placebo once daily
223796756|NCT03252587|DRUG|BMS-986165|Specified dose on specified days
223796757|NCT03252587|OTHER|Placebo|Specified dose on specified days
223796758|NCT06241248|DIAGNOSTIC_TEST|Rapid sepsis diagnostic test|The different stages of the OCEAN Dx whole blood bacterial identification test. Identification is carried out using 9 ml of whole blood taken at the patient's bedside, and is provided after comparing the DNA sequence of the bacteria with a database. The rapid sepsis diagnostic test developed by OCEAN Dx can identify the bacteria responsible for the infection in just 4 hours at present, and soon in 3 hours. Subject to future innovations, it will probably even be possible to obtain a positive result for the presence of bacteria in the patient's sample in just 2 hours.
223796759|NCT02846090|DRUG|Dexmedetomidine to reduce the IOP|Dexmedetomidine 50 micrograms group (D50) in which peribulbar block was given using 10 ml of a mixture of local anesthetics. The mixture was composed of 5 ml of 0.5% bupivacaine +4.5 ml of 2% lidocaine +0.5ml of 50 micrograms of Dexmedetomidine with 150 IU hyaluronidase.
223796760|NCT05612074|DRUG|Inhaled Nitric Oxide|Inhaled nitric oxide (Medical grade, in NO/N2 tanks) will be delivered in a oxygen-air-nitrogen mixture for 30 minutes three times per day
223796761|NCT04052204|DRUG|avelumab|Investigational fully human anti-PD-L1 monoclonal antibody
223796762|NCT04052204|DRUG|Bempegaldesleukin|Investigational CD122-biased cytokine agonist
223796763|NCT04052204|DRUG|talazoparib|poly (adenosine diphosphate \[ADP\] ribose) polymerase (PARP) inhibitor
223796764|NCT04052204|DRUG|enzalutamide|androgen receptor inhibitor
223796765|NCT03540654|OTHER|Budget impact|Budget impact, using a probabilistic markov model, of discontinuing TKI treatment in patients with CML in deep molecular response since at least two years, compared with current practice (treatment during entire life), from the healthcare system point of view
223796766|NCT04415450|BEHAVIORAL|Nutrition Education counseling|In the context of health education program, an educational intervention was developed by the research team based on a training module. The nutrition education contained introductory messages and focused on meanings of healthy diet, eating a variety of food, eating well with the locally available food, hazards of maternal malnutrition, important supplements to be taken during pregnancy, harmful substances to be avoided, and measures of alleviating common discomforts associated with nutrition during pregnancy. The training program was carried out in the form of counseling using printed materials and flip charts for pictorial representation. Self-reading of leaflets containing the core messages for every topic prepared in the native language of the participants was also employed as the women in the study had one each.
223796767|NCT06580795|BEHAVIORAL|Student citizens' assembly|The intervention consists in participating in a deliberative mini-public, a student citizens' assembly whose mission is to to co-create a list of concrete proposals that would improve the access of USPN students to sustainable diets and physical activity
223796768|NCT02506842|DRUG|nab-paclitaxel|Patients firstly receive nab-paclitaxel 100 mg/m\^2 (iv, 30 minutes) on days 1, 8, and 15 for 3 weeks, followed by one week without treatment. Treatment repeats until there is disease progression or recurrence.
223796769|NCT02506842|DRUG|gemcitabine|Patients secondly receive gemcitabine 1000 mg/m\^2 (iv, 30 minutes) on days 1, 8, and 15 for 3 weeks, followed by one week without treatment. Treatment repeats until there is disease progression or recurrence.
223796770|NCT02506842|DRUG|oxaliplatin|Patients receive oxaliplatin 85 mg/m\^2 (iv, 2 hours) on days 8 and 22 with 42 days as a cycle. Treatment repeats until there is disease progression or recurrence. Oxaliplatin is given before folinic acid and fluorouracil when the three drugs are given on the same days.
223796771|NCT02506842|DRUG|folinic acid|Patients receive folinic acid 200 mg/m\^2 (iv) on days 1, 8, 15 and 22 for 4 weeks, followed by 2 weeks without treatment. Treatment repeats until there is disease progression or recurrence.
223796772|NCT02506842|DRUG|fluorouracil|Patients receive fluorouracil 2000 mg/m\^2 (iv, 24 hours) on days 1, 8, 15 and 22 for 4 weeks, followed by 2 weeks without treatment. Treatment repeats until there is disease progression or recurrence.
223796773|NCT03945188|DRUG|Etrasimod|Etrasimod 2 mg tablet by mouth, once daily up to 52 weeks of treatment
223796774|NCT03945188|DRUG|Placebo|Etrasimod matching placebo tablet by mouth, once daily up to 52 weeks of treatment
223796775|NCT04233476|DRUG|99mTc-3PRGD2 injection|A diagnostic drug targeting integrin αvβ3, technetium-99m \[99mTc\] labeled hydrazinonicotinamide-PEG4-E\[PEG4-c(RGDfk)\]2 (99mTc-3PRGD2), will be intravenously injected to the participants for imaging of lung cancer and mapping lymph node metastasis via single photon emission computed tomography/ X-ray computed tomography (SPECT/CT) .
223796776|NCT01515410|DRUG|DM-1992|72.5mg carbidopa/230mg levodopa
223796777|NCT01515410|DRUG|Sinemet IR|Immediate-release tablet containing 25mg carbidopa and 100mg levodopa
223796778|NCT01552850|DRUG|Oxycodone|1X40 mg PF-00345439 formulation A capsule with water and under fed condition
223796779|NCT01552850|DRUG|Oxycodone|1X40 mg PF-00345439 formulation B capsule with water and under fed condition
223796780|NCT01552850|DRUG|Oxycodone|1X40 mg PF-00345439 formulation C capsule with water and under fed condition
223796781|NCT01552850|DRUG|Oxycodone|1X40 mg PF-00345439 formulation D capsule with water and under fed condition
223796782|NCT01552850|DRUG|Oxycodone|40 mg oxycodone oral solution (5 mg/5 ml) with water and under fed condition
223796783|NCT05214833|BEHAVIORAL|Real Neurofeedback|During neurofeedback, the brain activity in response to a motor task is recorded in real-time and displayed back to the participants.
223796784|NCT05214833|BEHAVIORAL|Sham Neurofeedback|During sham neurofeedback, a signal which resembles the participant's brain activity is used instead of the actual brain activity.
223796785|NCT03931148|DIAGNOSTIC_TEST|Geriatric Assesment with neuropsychological test more specific on decision making|The following tests will be made : MoCA, FAB, TMT, Stroop-Victoria, JAT
223796786|NCT03931148|DIAGNOSTIC_TEST|Functional RMI|With specific test of decision making (IGT) specially adapted to the population
223796787|NCT03931148|DIAGNOSTIC_TEST|High Resolution EEG|With specific test of decision making (BART) specially adapted to the population
223796788|NCT03931148|OTHER|Qualitative interview|Qualitative semi-directed interviews with participants, their caregivers and their geriatrician to analyse everyday life decision making ability.
223796789|NCT05030402|PROCEDURE|Maitland|An assessment is carried out at the beginning of the treatment, at the end and 2-4 weeks after finishing the treatment. The EVA ASES, DASH and SF-36 scales are included and the biomechanics study is used for the range of mobility.
223796790|NCT05030402|PROCEDURE|Tens, exercise, SW|An assessment is carried out at the beginning of the treatment, at the end and 2-4 weeks after finishing the treatment. The EVA ASES, DASH and SF-36 scales are included and the biomechanics study is used for the range of mobility.
223796791|NCT05030402|PROCEDURE|Conventional physiotherapy|An assessment is carried out at the beginning of the treatment, at the end and 2-4 weeks after finishing the treatment. The EVA ASES, DASH and SF-36 scales are included and the biomechanics study is used for the range of mobility.
223796792|NCT01982240|DRUG|Plecanatide|Plecanatide tablets QD for 12 weeks
223796793|NCT01982240|DRUG|Placebo|Matching placebo tablets QD for 12 weeks
223796794|NCT01982240|DRUG|Bisacodyl|Rescue medication
223796795|NCT04896489|DRUG|Hydrocortisone 20 MG|Participants receive Hydrocortisone 20 MG
223796796|NCT04896489|OTHER|Placebo|Participants receive placebo
223796797|NCT03546881|PROCEDURE|fusion imaging guidance technology|Imaging fusion guidance overlay used during PAOD endovascular revascularisation
223796798|NCT03546881|PROCEDURE|2D X-ray screen|2D X-ray screen during PAOD endovascular revascularisation
223796799|NCT04534231|DRUG|Nicotine patch|Nicotine transdermal patches as per product monograph
223796800|NCT03388567|OTHER|Staff pharmacy whith intervention|Pharmacists who will receive continuous education through technology and communication tools, as well as accompaniment and advice from a pharmaceutical chemist
223796801|NCT04592445|DEVICE|Satera GSN Ablation|The Axon procedure consists of a small needle puncture made in the groin to pass standard sheaths, wires, and access devices into the femoral vein, using standard access methods. The right GSN will be ablated transvenously from the right intercostal veins where it crosses at the 10th and 11th thoracic vertebrae from the intercostal vein intersection with the azygos vein. Placement of the access devices and Axon catheter is confirmed using standard fluoroscopic imaging. Once positioning is confirmed, GSN ablation can commence accordingly .
223796802|NCT04592445|DEVICE|Sham Control|The sham procedure consists of a small needle puncture made in the groin to pass a standard femoral introducer sheath approximately 10 cm into the femoral vein, using standard access methods. The Axon Catheter and associated access accessories will not be inserted into the patient. The sham procedure duration will be similar to the treatment time for subject receiving the Axon therapy (\~30 minutes).
223796803|NCT06495619|BEHAVIORAL|treatment-as-usual|life style modification intervention for weight loss
223796804|NCT06495619|BEHAVIORAL|combined TAU and guided self-help|combined TAU and guided self-help for improving eating behaviors
223796805|NCT06495619|BEHAVIORAL|combined TAU, GSH, and biofeedback|combined TAU, GSH, and biofeedback for improving eating behaviors and interoceptive awareness and arousal regulation
223796806|NCT01803074|DRUG|BMS-955176|BMS-955176
223796807|NCT01803074|DRUG|Placebo matching with BMS-955176|Placebo matching with BMS-955176
223796808|NCT01803074|DRUG|Atazanavir|Atazanavir
223796809|NCT01803074|DRUG|Ritonavir|Ritonavir
223796810|NCT01803074|DRUG|Tenofovir|Tenofovir
223796811|NCT01803074|DRUG|Emtricitabine|Emtricitabine
223796812|NCT02521090|BIOLOGICAL|EGFRBi-Armed Autologous T Cells|Given IT and IV
223796813|NCT02521090|OTHER|Laboratory Biomarker Analysis|Correlative studies
223796814|NCT02081573|BEHAVIORAL|Brief CBT|During the course of the twice/month diabetes management phone sessions the nurse care manager will work collaboratively with the patient to identify a dysfunctional belief that may be affecting adherence and could be improved by a brief CBT intervention (5-7 minutes). The care manager will utilize the CBT phone app to identify a CBT intervention that will be most appropriate for the situation. Each intervention is described step by step in the app. The nurse will go through the intervention and when completed will assure the patient's understanding.CBT interventions are geared towards helping the patient identify and restructure thinking that is impairing successful self-management of a chronic disease
223796815|NCT05772780|DEVICE|MP-3 microperimeter|Biofeedback stimulation two days a week
223796816|NCT05772780|DEVICE|MP-3 microperimeter|Biofeedback stimulation three days a week
223796817|NCT04216108|DEVICE|Vitrectomy (23G gauge needle)|Vitrectomy surgery with 23G gauge needle technique
223796818|NCT04216108|DEVICE|Vitrectomy (27G gauge needle)|Vitrectomy surgery with 27G gauge needle technique
223796819|NCT00571454|BEHAVIORAL|telephone depression care management|"1 call per week for first 4 weeks~1 call every other week for next 8 weeks"
224264120|NCT03371186|OTHER|Continuous Surveillance|Each patient identified by a Community Health Worker will undergo a complete diagnostic evaluation by the hospital-based clinicians and will be enrolled in the study only if they are identified as currently pregnant, have recently given birth, or have a child under the age of 24 months. Continuous surveillance systems ensure that the entire population is surveyed every three months and has a three month touchpoint with a Community Health Worker.
223796820|NCT03121157|BEHAVIORAL|Multi-Component Technology Based Intervention|The intervention group receives two sessions of computer-delivered MI via software programmed to target adherence to medications and text messaged adherence reminders between sessions. Sessions are provided by an avatar. The intervention engages the youth with the avatar's communication of empathy, optimism, and autonomy support. The intervention focuses the youth on adherence and relevant health behaviors with feedback on adherence, asthma symptoms, and tailored education. Participants are guided in the planning process through goal setting activities. The length of the intervention sessions are about 30 minutes each, with the total duration of the visit (assessment and intervention) lasting about 1.5 hours.
223796821|NCT05995028|BIOLOGICAL|Universal CD7-specific CAR gene-engineered T cells|Infusion of 4SCAR7U T cells
223796822|NCT02352558|DRUG|BBI608|Patients will receive BBI608 orally twice daily, with doses separated by approximately 12 hours. The starting dose for all cohorts will be 240 mg twice daily. Subsequently, cohorts at alternate dose-levels (480 mg twice daily) may be enrolled as determined by the criteria for dose-escalation.
223796823|NCT02352558|DRUG|Dexamethasone|Dexamethasone will be taken orally at a dose level of 40 mg once weekly, on Days 1, 8, 15, and 22 of each Cycle. Patients over the age of 75 years are allowed to begin dexamethasone at a dose of 20 mg once weekly, on Days 1, 8, 15, and 22 of each Cycle. Dexamethasone should be taken with food or milk, and a minimum of 2 hours should separate a dose of dexamethasone from a dose of BBI608.
223796824|NCT02352558|DRUG|Bortezomib|Bortezomib will be administered at 1.3 mg/m2/dose as a 3-5 second bolus intravenous (IV) injection or subcutaneous injection twice weekly for 2 weeks (Day 1, 4, 8, and 11) followed by a 10-day rest period (Day 12-21).
223796825|NCT02352558|DRUG|Imatinib|Imatinib will be taken orally once daily with a meal and a large glass of water. For patients having difficulty swallowing, imatinib can be dissolved in water or apple juice for intake. The dose of imatinib is 400 mg for CML patients in the chronic phase and 600 mg for CML patients in the accelerated phase or in blast crisis. A minimum of 2 hours should separate a dose of imatinib from a dose of BBI608.
223796826|NCT02352558|DRUG|Ibrutinib|Ibrutinib will be taken orally once daily with water. Do not open, break, or chew the capsules. The dose of ibrutinib is 420 mg for patients with normal liver function and is 140 mg for patients with mild liver impairment (Child-Pugh class A). A minimum of 2 hours should separate a dose of ibrutinib from a dose of BBI608.
223796827|NCT01618162|DRUG|insulin degludec/liraglutide|Injected subcutaneously (under the skin) once daily. Dose individually adjusted.
223796828|NCT01618162|DRUG|placebo|Injected subcutaneously (under the skin) once daily.
223796829|NCT05829161|BEHAVIORAL|no intervention|no intervention
223796830|NCT02901457|OTHER|"The Healthy Body Image intervention"|Interactive workshops (3 x 90 minutes) include training techniques to increase media literacy, enhance self-esteem, positive body image, awareness of perfectionism, and include discussions related to truths and myths related to life style factors. Homework is an extension of each workshop that is simple and not time-consuming tasks to increase reflection and awareness of how all the mentioned factors are a part of their lives.
223796831|NCT01445925|PROCEDURE|Pulmonary vein isolation (PVI)|Using a 4mm irrigated tip radiofrequency ablation catheter a series of lesions \>2 mm outside pulmonary vein (PV) ostia will be made to encircle and electrically isolate the pulmonary veins in two ipsilateral pairs (wide area circumferential ablation, WACA). A 20-pole PV mapping catheter will be used to confirm electrical isolation. If the patient is in atrial fibrillation at this stage, sinus rhythm would be restored with electrical cardioversion and PVI would be confirmed in sinus rhythm
223796832|NCT01445925|PROCEDURE|Pulmonary vein isolation + linear lesions|Using a 4mm irrigated tip radiofrequency ablation catheter a series of lesions \>2 mm outside PV ostia will be made to encircle and electrically isolate the pulmonary veins in two ipsilateral pairs (wide area circumferential ablation, WACA)34. A 20-pole PV mapping catheter will be used to confirm electrical isolation. Once PVI has been achieved, patients will go onto to receive additional linear ablation lesions. These will include a left atrial roof line, mitral isthmus line, (including ablation inside the coronary sinus if necessary), and ablation on the cavotricuspid isthmus. If the patient is in atrial fibrillation at this stage, the acute end-point would be signal obliteration at the ablated area. Once sinus rhythm is restored with electrical cardioversion, PVI would be confirmed in sinus rhythm and conduction block across the LA roof line, Mitral line and CTI will then be verified with appropriate pacing manoeuvres.
223796833|NCT01445925|DRUG|Pharmacological Substrate modification|at least 6 weeks therapy with oral amiodarone prior to the ablation procedure and 6 weeks post.
223796834|NCT05253248|DIETARY_SUPPLEMENT|OMIS|This is an open-label micronutrient supplementation trial in healthy adult volunteers. We are planning to supplement healthy adult volunteers, once a day, with a standard over-the-counter multivitamin supplement for a period of 30 consecutive days.
223796835|NCT02693275|DEVICE|Quotient® System iPad Test|See arm/group description
223796836|NCT01250977|DRUG|Donepezil|
223796837|NCT01250977|DRUG|Placebo|
223796838|NCT02964416|DRUG|Injection Tramadol|
223796839|NCT02964416|OTHER|placebo|0.9% Normal saline in 10 ml syringe
223796840|NCT04133233|DRUG|ILT101|Treatment administration consists in a first course of five-day treatment (induction), followed by a single injection every week for 4 weeks (maintenance; from Week 3 to Week 6)
223796841|NCT04133233|DRUG|Placebos|Treatment administration consists in a first course of five-day treatment (induction), followed by a single injection every week for 4 weeks (maintenance; from Week 3 to Week 6)
223796842|NCT03386279|DRUG|PF-04965842|one single dose of 600 mg by mouth
223796843|NCT03386279|DRUG|Moxifloxacin|one single dose of 400 mg by mouth
223796844|NCT03386279|DRUG|Placebo|one single dose by mouth
223796845|NCT06580483|OTHER|amalgam restoration|An abutment tooth is restored on a side by amalgam plug
223796846|NCT06580483|OTHER|nano-composite|An abutment tooth is restored on a side by nano-composite
223796847|NCT05732909|DIETARY_SUPPLEMENT|D-β-hydroxybutyrate/D 1,3 butanediol monoester|Ketone monoester
223796848|NCT04079621|DRUG|primaquine|Primaquine regimen over 7 days (0.5mg/kg/day for 7 days)
223796849|NCT04859764|DEVICE|Reparel knee sleeve|Unlabelled thermo-active knee sleeve that improves bloodflow to knee and decreased pain
223796850|NCT04859764|DRUG|Corticosteroid injection|intraarticular knee injection of betamethasone and bupivacaine 0.5% (dose is determined by joint size)
223796851|NCT04859764|DEVICE|Placebo knee sleeve|unlabeled compression knee sleeve
223796852|NCT02212704|OTHER|Vestibular stimulation by use of the turntable (static roll-tilt while the head is roll-tilted relative to the trunk)|
223796853|NCT02212704|OTHER|3D-video-head impulse testing|Evaluation of semicircular canal function. This intervention is part of the screening to determine suitability for this study
223796854|NCT02212704|OTHER|Vestibular-evoked myogenic potentials (VEMPs)|Evaluation of otolith function. This intervention is part of the screening to determine suitability for this study
223796855|NCT06099067|DRUG|Canagliflozin|Canagliflozin dispensing claim is used as the exposure drug in CANVAS replication
223796856|NCT06099067|DRUG|DPP4 inhibitor|DPP4 inhibitor dispensing claim is used as the reference drug in CANVAS and LEADER replications
223796857|NCT06099067|DRUG|Liraglutide|Liraglutide dispensing claim is used as the Exposure drug in LEADER replication
223796858|NCT06099067|DRUG|Saxagliptin|Saxagliptin dispensing claim is used as the Exposure drug in SAVOR-TIMI replication
223796859|NCT06099067|DRUG|2nd generation Sulfonylurea|2nd generation Sulfonylurea dispensing claim is used as the Exposure drug in SAVOR-TIMI replication
223796860|NCT06069206|OTHER|T2Bacteria® Panel (direct-from-blood testing)|Providers will be prompted to order the T2Bacteria® Panel (direct-from-blood testing) and accompanying communications regarding panel results will be delivered.
223796861|NCT06069206|OTHER|Usual Care|Standard blood cultures.
223796862|NCT06551974|BEHAVIORAL|Guided self-help plus IPT|The participants allocated in the intervention GSH arm will have access to self-help materials (workbook and videoclips), forum groups (interactional materials), online interpersonal group sessions for 8 weeks. The proposed online GSH will be adapted from two online interventions developed and tested with people with eating disorders by the Eating Disorders Research Unit team at King's College London, with a cooperation of the University of Palermo research team (Cardi et al., 2020). The GSH will include self-help materials, i.e. a written workbook and a library of 74 brief video-clips with the goal of providing psychoeducation about eating disorders and interpersonal difficulties and describing and modelling the use of helpful strategies to reverse abnormal eating behaviours. Participants will also attend a weekly online forum with interactional materials, and an online interpersonal group session.
223796863|NCT06551974|BEHAVIORAL|Guided self-help|The participants allocated in the intervention GSH arm will have access to self-help materials (workbook and videoclips), forum groups (interactional materials), online interpersonal group sessions for 8 weeks. The proposed online GSH will be adapted from two online interventions developed and tested with people with eating disorders by the Eating Disorders Research Unit team at King's College London, with a cooperation of the University of Palermo research team (Cardi et al., 2020). The GSH will include self-help materials, i.e. a written workbook and a library of 74 brief video-clips with the goal of providing psychoeducation about eating disorders and interpersonal difficulties and describing and modelling the use of helpful strategies to reverse abnormal eating behaviours.
223796864|NCT06551974|BEHAVIORAL|TAU|The Treatment as Usual is the usual or routine care provided to participants in the outpatient setting.
223796865|NCT06079463|OTHER|progressive relaxation exercise|"Step 1: Take a comfortable position (sitting or lying down) and wear comfortable, non-tightening clothes.~Step 2: Try to relax with eyes closed, without focusing on thoughts, by focusing on your own body muscles.~Step 3: Right and left, respectively, hands, arms (triceps muscle), chest, abdomen, hips, legs (thigh muscles), feet and toes, neck, shoulder (scapula muscles) and muscle groups on the face (around the eyes, chin) and eyebrow muscles) by concentrating on contracting and relaxing these muscles.~Step 4: Focusing on the muscle groups of the whole body, contracting and relaxing.~Step 5: Opening the eyes slowly, trying to feel the feeling of comfort in the body (Turkish Psychologists Association Progressive Relaxation Exercises)."
223796866|NCT06961500|DRUG|Obinutuzumab|1000mg i.v., administered on Day 1/8/15 (D1/8/15) of Cycle 1 (C1), and D1 of C2-6
223796867|NCT06961500|DRUG|CHOP|a) Cyclophosphamide: 750 mg/m2 i.v. drip, administered on D1; b) Doxorubicin: 50 mg/m2 i.v. drip (or Epirubicin: 70mg/m2 i.v. drip), administered on D1; c) Vincristine: 1.4 mg/m2 i.v., administered on D1; d) Prednisone: 100mg/d po, administered on D1-5.
223796868|NCT06961500|DRUG|Bendamustine|90 mg/m2 i.v. drip, administered on D1-2.
223796869|NCT06962254|DRUG|Imatinib|"1. Imatinib is binding to the ATP-binding site of BCR-ABL, blocking its activity and preventing uncontrolled proliferation to target the BCR-ABL fusion protein in chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). It also inhibits PDGFR and c-KIT receptors, suppressing tumor growth and angiogenesis in gastrointestinal stromal tumors (GIST).~2. Preclinical studies have shown that imatinib combined with MEK inhibitors can suppress the growth of KRAS-mutated pancreatic adenocarcinoma."
223796870|NCT06962254|DRUG|Trametinib|Trametinib inhibits the MEK1 and MEK2 enzymes, preventing the downstream phosphorylation and activation of ERK1/2, which are crucial for the RAS-RAF-MEK-ERK signaling pathway. By blocking this pathway, trametinib reduces cell proliferation and induces apoptosis in tumor cells harboring pathway mutations.
223796871|NCT04054154|DEVICE|Shear Wave Elastography|Undergo shear wave elastography
223796872|NCT04054154|PROCEDURE|Tumor Interstitial Fluid Pressure Measurement|Undergo tumor pressure measurement
223796873|NCT06576362|PROCEDURE|Echoguided transuterine vaginal biopsy performed before myomectomy or hysterectomy|Echoguided transuterine vaginal biopsy performed before myomectomy or hysterectomy
223796874|NCT06574815|PROCEDURE|Early implant loading|Patients underwent definitive restoration at 6 weeks after implant surgery (early loading).
223796875|NCT06574815|PROCEDURE|Delayed implant loading|Patients underwent definitive restoration at 6 months after implant surgery (delayed loading).
223796876|NCT06574815|PROCEDURE|GBR using an SIS membrane|An small intestine submucosa (SIS) membrane was used in the guided bone regeneration (GBR) surgery.
223796877|NCT06574815|PROCEDURE|GBR using an Bio-Gide membrane|An Bio-Gide membrane was used in the guided bone regeneration (GBR) surgery.
223796878|NCT06731946|DEVICE|Flow diverting|Flow diverter has become the standardized treatment method for Intracranial aneurysms (IAs), which is different from angioplasty, coiling, etc.
223796879|NCT04934423|DEVICE|Direct Current Transcranial Stimulation - tDCS|Active intervention
223796880|NCT04934423|DEVICE|Sham Intervention|Direct Current Transcranial Stimulation - Sham intervention
223796881|NCT05163574|DIETARY_SUPPLEMENT|High dose OIT|Patients will receive daily a high dose of peanut flour (300 mg peanut protein) mixed with well-tolerated fruit mousse.
223796882|NCT05163574|DIETARY_SUPPLEMENT|Low dose OIT|Patients will receive daily a low dose of peanut flour (150 mg peanut protein) mixed with well-tolerated fruit mousse.
223796883|NCT02477111|DEVICE|Endovascular abdominal aortic aneurysm repair|Subjects with infrarenal abdominal aortic aneurysms who meet all inclusion criteria and none of the exclusion criteria will be treated with the INCRAFT Stent Graft System.
223796884|NCT00989768|DRUG|Botulinum Toxin Type A (Dysport®)|"Botulinum toxin A (Dysport®)will be administered according to an equivalence ratio of 2,5:1. Both reconstituted in the same volume per point, injected in the forehead determined site.~-Dysport®: 5 units will be injected in the left or right forehead side."
223796885|NCT00989768|DRUG|Botulinum Toxin Type A/Botox®|2 units will be injected in the left or right forehead side.(opposite side of dysport injection)
223796886|NCT00989768|DRUG|Botulinum Toxin Type A/Dysport®|"Botulinum toxin A (Dysport®)will be administered according to an equivalence ratio of 2:1. Both reconstituted in the same volume per point, injected in the forehead determined site.~-Dysport®: 4 units will be injected in the left or right forehead side, 2:1 ratio Dysport/Botox."
223796887|NCT02192502|DRUG|human albumin 5%|
223796888|NCT02192502|DRUG|HES 130/0.4 (Voluven)|
223796889|NCT02579252|BIOLOGICAL|AADvac1|
223796890|NCT02579252|DRUG|Placebo|
223796891|NCT03390205|DIAGNOSTIC_TEST|Optical coherence tomography angiography under dark and light adaptation|Optical coherence tomography angiography under dark and light adaptation with pupil dilatation
223796892|NCT03883633|BEHAVIORAL|ReCODE Protocol|Functional medicine approach to address symptoms of Alzheimer's and cognitive decline
223796893|NCT06508281|OTHER|experimental group|. Anatomy model videos prepared by the researchers for the experimental group students will be uploaded to Google Drive and sent via link. Students will be asked to log in from their computer or mobile phone and watch anatomy model videos whenever and wherever they want
223796894|NCT05850832|DRUG|Esmolol|loading dose 1 mg/kg followed by maintenance dose of 30 μg/kg/min throughout the surgery.
223796895|NCT05850832|DRUG|Magnesium sulfate|loading dose 40 mg/kg over a period of 15 mins and maintenance 15 mg/kg/h throughout the surgery.
223796896|NCT05574660|DIETARY_SUPPLEMENT|High-Fat/High-Sugar (HF/HS) Diet|
223796897|NCT05574660|DIETARY_SUPPLEMENT|Low-Fat/Low-Sugar (LF/LS) Diet|
223796898|NCT04244032|BEHAVIORAL|Working Memory Training|Participants complete up to 12 sessions of computerized training (30-45 min each) in a working memory task designed to utilize individually-adapted difficulty levels.
223796899|NCT04244032|BEHAVIORAL|Inhibitory Control Training|Participants complete up to 12 sessions of computerized training (30-45 min each) in an inhibitory control task designed to utilize individually-adapted difficulty levels.
223796900|NCT04244032|BEHAVIORAL|Bias Modification Training|Participants complete up to 12 sessions of computerized training (30-45 min each) in a bias modification task designed to utilize individually-adapted difficulty levels.
223796901|NCT04737460|GENETIC|AAV9/CLN7|Enrollees will receive gene therapy via a viral vector
223796902|NCT06283472|BEHAVIORAL|High-Intensity Cue|Participants in the high-intensity group will receive high-intensity image cues that represent self-reported events they did on the previous day and self-reported events they look forward to in the future.
223796903|NCT06283472|BEHAVIORAL|Low-Intensity Cue|Participants in the low-intensity group will receive low-intensity image cues that represent self-reported events they did on the previous day and self-reported events they look forward to in the future.
223796904|NCT02672111|DRUG|CAM2038 q1w or q4w exposure to SL BPN/NX|
223796905|NCT02672111|DRUG|CAM2038 q1w or q4w new to BPN treatment|
223796906|NCT01839110|DRUG|Ranolazine|Ranolazine at 500mg by mouth twice per day and after two weeks will increase to 1000mg by mouth twice per day and continue for a total of 26 weeks.
223796907|NCT01839110|DRUG|Placebo|Placebo by mouth twice per day for a total of 26 weeks.
223796908|NCT03347968|BIOLOGICAL|MEDI0382|All participants will receive MEDI0382
223796909|NCT03347968|DRUG|Warfarin|All participants will receive Warfarin
223796910|NCT03347968|DRUG|Esmolol|All participants will receive Esmolol
223796911|NCT04959370|DEVICE|internal fixation implantation of dynamic hip screw|Dynamic hip screws (DHS) are a femoral head-sparing orthopedic device used to treat femoral neck fractures.
223796912|NCT04959370|DEVICE|internal fixation implantation of cannulated compression screw|Cannulated Screw is designed to provide a minimally invasive method of anatomical fixation.
223796913|NCT02837627|OTHER|Tube feeding|During the study period, enteral feeds will be administered according to different tube feeding modalities: bolus feeding followed by the removal of the feeding tube; bolus tube feeding with permanence of the feeding tube for the whole post-prandial period; continuous feeding over a 3-hour period.
223796914|NCT02046980|PROCEDURE|Gufoni|
223796915|NCT02046980|PROCEDURE|Vibration|
223796916|NCT02046980|PROCEDURE|Sham|
223796917|NCT01367327|BEHAVIORAL|Loaded sit-to-stand exercise|Loaded sit-to-stand exercise at home, 3 times a week for 6 weeks
223796918|NCT01367327|BEHAVIORAL|Synchronized music|Synchronized music for loaded sit-to-stand exercise to guide movement
223796919|NCT01328574|DRUG|TRC105|15 mg/kg intravenously
223796920|NCT06187753|DIAGNOSTIC_TEST|Sensory Profile|The Sensory Profile has 125 items that represent 14 functions of sensory processing and allows parents to report on their child's behavior.
223796921|NCT02967185|BEHAVIORAL|Brief Behavioral Therapy for Insomnia|Treatment will consist of 4 weekly, 1 hour sessions and will be conducted by a trained graduate assistant on an individual basis. Treatment components will include education about aging and sleep. It will also include instruction in techniques designed to: (a) promote good sleep habits, (b) restrict the use of the bed and bedroom to sleep and sleep-conducive activities, (c) modify bed and wake times to better match the participants sleep needs, and (d) promote relaxation. Daily home practice of these techniques will be encouraged. Participants will maintain logs of their home practice sessions and will continue to record their daily sleep habits throughout treatment.
223796922|NCT01107184|PROCEDURE|Remote ischemic conditioning|Patients will have a automated inflator cuff placed on the upper arm during surgery. The cuff will be used to induce fore arm ischemia by inflation to 200 mmHg for 3 x 5 minutes, interspersed with 5 minutes of no-inflation and thus reperfusion.
223796923|NCT01107184|PROCEDURE|Sham|Patients will have a automated inflator cuff placed on the upper arm during surgery which will not be inflated.
223796924|NCT00456638|DRUG|Depodur|Depodur vs. traditional management
223796925|NCT00003298|DRUG|cisplatin|Cisplatin was administered as part of the neoadjuvant regimen. It was given at a dose of 75 mg/m² via IV over approximately one hour, on day 1 of each cycle. Three cycles were given.
223796926|NCT00003298|DRUG|fluorouracil|Postoperative regimen 5-FU, along with Leucovorin, was given by IV bolus, with 5-FU given immediately after the Leucovorin
223796927|NCT00003298|DRUG|leucovorin calcium|Both 5-FU and Leucovorin will be given via IV bolus, with Leucovorin given immediately before 5-FU.
223796928|NCT00003298|DRUG|paclitaxel|Paclitaxel was administered as part of the neoadjuvant regimen. It was given at a dose of 175 mg/m² as a 3 hour continuous intravenous infusion on day 1. Three cycles were given.
223796929|NCT00003298|PROCEDURE|surgery|"The surgical procedure performed involved a radical subtotal or total gastrectomy.~A complete surgical resection was required"
223796930|NCT00003298|RADIATION|radiation therapy|Concomitant chemotherapy and radiation therapy course: 5-FU 400 mg/m²/day + Leucovorin 20 mg/m²/day on days 1-4 of week one and days 1-3 of week 5 of XRT. Combined chemotherapy and radiation therapy were to begin 4 weeks after day 1 of the initial course of chemotherapy
223796931|NCT01930370|DRUG|Bicarbonate hemodialysis solution (low concentration)|One-week experimental session (3 dialysis treatments) with low dialysate bicarbonate (28 mmol/L)
223796932|NCT01930370|DRUG|Bicarbonate hemodialysis solution (high concentration)|One-week experimental session with high dialysate bicarbonate (38 mmol/L)
223796933|NCT05378945|DRUG|Varenicline Tartrate Nasal Spray|Intranasal delivery of OC-01 (varenicline solution) 0.6 mg/mL twice a day (BID) for 28 days
223796934|NCT05378945|DRUG|Placebo (vehicle)|Intranasal delivery of placebo (vehicle) twice a day (BID) for 28 days
223796935|NCT04093622|GENETIC|Genetically engineered NK cells|No study drug is administered in this study. Subjects who received lentivirus-mediated genetically engineered NK Cells in a previous trial will be evaluated in this trial for long-term safety and efficacy.
223796936|NCT00930293|BEHAVIORAL|Interpersonal Psychotherapy for Depression with Panic and Anxiety Symptoms (IPT-PS)|16 weekly IPT-PS sessions, each lasting approximately 45 minutes
223796937|NCT00930293|BEHAVIORAL|Brief Supportive Psychotherapy (BSP)|16 weekly BPS sessions, each lasting approximately 45 minutes
223796938|NCT00930293|DRUG|Citalopram hydrobromide|A 20-week regimen of citalopram hydrobromide monotherapy on a flexible dosing schedule ranging from 10 to 60 mg/day
223796939|NCT05061251|DRUG|BAY 2402234|Patients will receive 3 doses of 5mg each of BAY 2402234. Drug will be given Day 1 and Day 2 prior to standard-of-care craniotomy for tumor resection and 1 dose on the morning of surgery.
223796940|NCT00695643|DRUG|Mesalazine|3 g per day
223796941|NCT00695643|DRUG|Placebo|0 g per day
223796942|NCT05141669|DRUG|Fingolimod|Participants who initiated fingolimod to treat multiple sclerosis (MS)
223796943|NCT01798550|DRUG|Enoxaparin|Twice daily dosing
223796944|NCT00105638|BEHAVIORAL|educational program, by telephone|
223796945|NCT01716429|BEHAVIORAL|Vegan diet|Vegan dietary approaches for weight loss
223796946|NCT01716429|BEHAVIORAL|Low calorie diet|Reduced calorie diet for weight loss
223796947|NCT04947800|DEVICE|Pulmonary rehabilitation program + EA Lung Mu-Shu+ St36|Standard of care pulmonary rehabilitation program plus electro-acupuncture with mA electricity at varying frequencies to the Lung Mu-Shu points and St36 points
223796948|NCT04947800|DEVICE|Pulmonary rehabilitation program + Lv7/Gb26|Standard of care pulmonary rehabilitation program plus electro-acupuncture with mA electricity at varying frequencies to the Lv7/Gb26 points
223796949|NCT05335317|DEVICE|Laser Treatment|"Laser radiation is emitted by a series of pulses following each other through a pause. The duration of one pulse is 20-200 ns, the pause between pulses is 30 us. The energy of one pulse is about 1 mJ.~General laser radiation parameters for 1st and 2nd stages are: beam with diameter of 4 millimeters (mm) scans treatment area by 4 circles with step of 2 mm (50% overlap), average power of 10-25 Watt (W), treatment time in one point of 1-10 seconds (s), treatment step of 5 mm (total handpiece length of 10 centimeter (cm), 20 treatment points along vagina), from 1 to 5 repetitions of total vagina treatment. General laser radiation parameters for 3d stage are: beam diameter of 6 mm, average power of 15-30 W, duration of ns-pulses packet of 100 milliseconds (ms), pause between packets of 50 ms, treatment duration up to 65 s, treatment in permanent motion with speed of 10-50 mm/s.~The procedure is performed without anesthesia. The doctor always focuses on the participant's feeling of warmth."
223796950|NCT05335317|DRUG|Topical hormone estriol|Estriol suppository ((17 beta)-estra-1,3,5 (10)-trien-3,17-diol). Active ingredient of 0.5 milligram in 1 suppository. Daily dose will be 1 suppository.
223796951|NCT05335317|DIAGNOSTIC_TEST|Сlinical blood analysis|Taking blood from a vein for Clinical blood analysis (to include the participant in the study).
223796952|NCT05335317|DIAGNOSTIC_TEST|Сlinical urine test|Urine sampling for Clinical urine test (to include the participant in the study).
223796953|NCT05335317|DIAGNOSTIC_TEST|Vaginal smear|Vaginal smear for flora investigation (to include the participant in the study), immunocytochemical examination and cytology (to evaluate procedure efficiency).
223796954|NCT05335317|DIAGNOSTIC_TEST|Cervical oncocytology test.|Cervical smear for oncocytology test (to include the participant in the study).
223796955|NCT05335317|DIAGNOSTIC_TEST|Extended colposcopy|Extended colposcopy is performed under a microscope using a Lugol to determine external changes in the epithelium in order to determine atrophy and pathologies of the cervix and vaginal vault (dysplasia, erosion, cancer, etc.) (to include the participant in the study).
223796956|NCT05335317|DIAGNOSTIC_TEST|Pelvic ultrasound|Pelvic ultrasound investigation to determine pathologies of the pelvic through a gynecological probe (to include the participant in the study).
223796957|NCT05335317|OTHER|King's Health Questionnaire|The King's Health Questionnaire will be used to collect feedback on changes in the participants life quality (to evaluate procedure efficiency).
223796958|NCT05335317|DIAGNOSTIC_TEST|Vaginal Health Index|Vaginal Health Index will be investigated by clinical examination for vaginal elasticity, vaginal secretions, epithelial mucous membrane, vaginal hydration. pH (potential of hydrogen) will be investigated by test-lines paper (to evaluate procedure efficiency).
223796959|NCT05335317|DIAGNOSTIC_TEST|Ultrasound investigation|Ultrasound investigation with General Electric Voluson E8 Expert for assessing blood vessels (Doppler sonography) and vaginal wall thickness measurement (to evaluate procedure efficiency).
223796960|NCT05335317|DIAGNOSTIC_TEST|Perineometry|Pressure force of vaginal walls measurement with IEASE device (to evaluate procedure efficiency).
223796961|NCT05335317|DIAGNOSTIC_TEST|Optical coherence tomography|Optical non-invasive method of investigation vaginal mucus morphological and functional condition.
223796962|NCT05335317|DIAGNOSTIC_TEST|Biopsy|Biopsy of the vaginal wall to assess the condition of the vaginal wall and compare the obtained data with the data of optical coherence tomography.
223796963|NCT05335317|DIAGNOSTIC_TEST|Femoflor screen|Femoflor screen for the study of vaginal microbiocenosis, specifically for the detection of the pathogens, opportunistic flora and normal flora and their qualitative and quantitative evaluation (to include the participant in the study).
223796964|NCT00035529|DRUG|Placebo|Solution, i.v infusion, 0 mg, Days 1 \& 15 then monthly, 10 months.
223796965|NCT00035529|DRUG|BMS 188667 (Abatacept)|Vial, i.v infusion, 2mg/kg, Days 1 \& 15 then monthly, 10 months.
223796966|NCT00035529|DRUG|BMS 188667 (Abatacept)|Vial, i.v infusion, 10 mg/kg, Days 1 \& 15 then monthly, 10 months.
223796967|NCT00901693|DRUG|AL-46383A Ophthalmic Solution|
223796968|NCT00901693|DRUG|AL-46383A Ophthalmic Solution Vehicle|
223796969|NCT00022256|DRUG|motexafin gadolinium|
223796970|NCT00022256|RADIATION|radiation therapy|
223796971|NCT01397838|DRUG|Pro-Bone|500 mg Capsules of Pro-Bone twice daily
223796972|NCT01994954|OTHER|RHO|Recorded oximetry data will be downloaded from home oximeters, analyzed, and used to assist in supplemental oxygen weaning decisions.
223796973|NCT02270333|DEVICE|Inspiratory muscle training|"Treatment group received inspiratory muscle training (IMT) using threshold loading device (POWERbreathe Classic, IMT Technologies Ltd. Birmingham, England) at 40% of maximal inspiratory pressure (MIP).~The MIP was measured at supervised session each week, and 40% of measured MIP value was the new training workload.~The treatment group trained for 30 min-per/day, 7 days/week, for 6 weeks. Six sessions at home and 1 session were performed at department."
223796974|NCT02270333|DEVICE|Sham inspiratory muscle training|"Control group received sham inspiratory muscle training (IMT) at fixed workload, 5% of MIP using threshold loading device (POWERbreathe Classic device IMT Technologies Ltd. Birmingham, England).~The control group trained for 30 min-per/day, 7 days/week, for 6 weeks. Six sessions at home and 1 session were performed at department."
223796975|NCT03516448|DRUG|Gan Fu Le Tablets|6 Tablets，tid,po
223796976|NCT03516448|DRUG|Tyroserleutide for injection|6mg/d, 5days,ivgtt
223796977|NCT03516448|DRUG|Placebo|0mg/d, 5days,ivgtt
223796978|NCT04881201|PROCEDURE|blood sample|blood sample
223796979|NCT01964170|DRUG|degarelix|subcutaneous
223796980|NCT01964170|DRUG|Goserelin|subcutaneous
223796981|NCT03632382|DIAGNOSTIC_TEST|3D acquisition of maxillofacial characteristics|A 3D acquisition of maxillofacial characteristics will be performed for each patient in order to validate a predictive model comparable to data obtained by polysomnography
223796982|NCT06046274|BIOLOGICAL|Pembrolizumab|Pembrolizumab intravenous (IV) infusion
223796983|NCT06046274|BIOLOGICAL|Acasunlimab|Acasunlimab IV infusion
223796984|NCT06440148|BIOLOGICAL|SCLEROSTIN|Pathogenesis of mastocytosis bone disease
223796985|NCT02369094|OTHER|acupressure|A 15 minutes structured acupressure protocol with specific acupoints and applications technique will be performed on the elderly participants twice a week by the research team in YCHSS centers. The caregiver of the elderly will be trained and perform the same acupressure protocol on the elderly at 2 additional occasions during the week. The total trial period is 12 weeks.
223796986|NCT02330718|OTHER|No intervention|
223796987|NCT04597268|DRUG|Dexmedetomidine|intravenous dexmedetomidine 1 mic/kg
223796988|NCT04597268|DRUG|Ketamine|ketamine 1mg/kg
223796989|NCT04597268|DRUG|Midazolam|midazolam 0.05 mg/kg
223796990|NCT06265077|DRUG|Placebo|Placebo
223796991|NCT06265077|DRUG|famotidine and loratadine|famotidine 20 mg once daily and loratadine 10 mg once daily
223796992|NCT02217930|DRUG|WCK 2349|
223796993|NCT02217930|DRUG|Placebo|
223796994|NCT02217930|DRUG|Moxifloxacin|
223796995|NCT00338065|BEHAVIORAL|Postural change|Intraocular pressures, blood pressures, and retinal thicknesses are measured with postural changes
223796996|NCT00338065|BEHAVIORAL|Water drinking|Intraocular pressures, blood pressures, and retinal thicknesses are measured with water drinking.
223796997|NCT02920827|COMBINATION_PRODUCT|Dapivirine Vaginal Ring|A platinum-catalysed silicone elastomer matrix vaginal ring containing 25mg of dapivirine used over 28 days
223796998|NCT02920827|COMBINATION_PRODUCT|Placebo vaginal ring|Placebo vaginal ring containing no dapivirine
223796999|NCT02154763|DRUG|Ropivacaine|
223797000|NCT02154763|DRUG|Normal Saline|
223797001|NCT02901015|BEHAVIORAL|Assessment battery A|"Social cognition tests version A are administered to the patients"
223797002|NCT02901015|BEHAVIORAL|Assessment battery B|"Social cognition tests version B are administered to the patients"
223797003|NCT00837174|DRUG|Vorinostat in combination with Bortezomib|Patients will be treated with oral vorinostat on days 1 through 14 followed by a 7-day rest period, for a 21-day treatment cycle for up to 6 cycles in the absence of disease progression or unacceptable toxicity. The patients will receive once-daily oral vorinostat (400 mg) with bortezomib 1.3 mg/m2 as an IV push on days 1, 4, 8, 11.
223797004|NCT00526123|DEVICE|Symmetric Tip Catheter|Dialysis catheter
223797005|NCT00526123|DEVICE|Conventional Split-tip Catheter|Dialysis Catheter
223797006|NCT02059967|DRUG|Paclitaxel|Given IV
223797007|NCT02059967|RADIATION|image-guided adaptive radiation therapy|Undergo IGART
223797008|NCT02059967|DRUG|carboplatin|Given IV
223797009|NCT00649194|DRUG|Rabeprazole Sodium Delayed-Release Tablets 20 mg|20mg, single dose fed
223797010|NCT00649194|DRUG|Aciphex® Tablets 20 mg|20mg, single dose fed
223797011|NCT00490893|DRUG|Detemir|
223797012|NCT06481748|OTHER|Batman|"The investigators foresee several teams engaged throughout the day to ensure greater variability, each team will consist of three students for the experimental condition (Batman; pregnant girl, observer) and two students for the control condition (pregnant girl and observer), plus the presence in both cases of a member of the research team. The 'pregnant girl' will be properly prepared and equipped with a sponge prosthesis to simulate pregnancy. In addition, the subject dressed as Batman must be prepared to play the role in a natural and non-invasive manner. During this phase, the student observers collaborating in the study will carefully record the behavior of the passengers in the underground."
223797013|NCT06533033|DRUG|Rapid Release Capsules Melatoni|"Twenty-five will be given melatonin therapy in combination with the conventional treatment.~2 tablets,30 minutes before sleeping once daily for 8 weeks."
223797014|NCT06533033|DRUG|Triamcinolone Acetonide ointment, Kenacort-A orabase|"Twenty-five will be given topical corticosteroid applied twice to three times daily.~Topical antifungal will be applied three to four times daily. This conventional treatment will be given to the patients for 8 weeks"
223797015|NCT00088231|DRUG|Imatinib Mesylate (Gleevec)|"600 mg by mouth every day (for AML, CML-BP) for a 28 day cycle.~400 mg by mouth every day (for AMM) for a 28 day cycle."
223797016|NCT00088231|DRUG|PTK 787 (vatalanib)|"For 1 week prior to receipt of the study combination regimen, all patients will receive single agent PTK 787 at the dose specified for that dose level of the study combination regimen to allow stabilization of PTK 787 levels.~Starting dose: 250 mg by mouth every day for a 28 day cycle."
223797017|NCT02045238|DRUG|Hypertonic Saline|Sodium Chloride 3% solution, previously prepared in 5 mL syringes.
223797018|NCT02045238|RADIATION|Chest X-Ray|
223797019|NCT02045238|OTHER|Respiratory virus screening test|Immunofluorescence analysis of nasal aspirate
223797020|NCT00220298|DRUG|Testosterone undecanoate (TU) - NebidoTM|Drug treatment with 14 injections of one ampoule of Nebido (1000 mg of testosterone undecanoate) at individually adjusted injection intervals
223797021|NCT03651089|DRUG|SP16|subcutaneous injection of experimental anti-inflammatory drug
223797022|NCT03651089|DRUG|Placebos|subcutaneous injection of sterile saline
223797023|NCT05003089|DRUG|BAY1834845|Tablet, oral.
223797024|NCT05003089|DRUG|BAY1830839|Tablet, oral.
223797025|NCT05003089|DRUG|Prednisolone|Tablet, oral.
223797026|NCT05003089|DRUG|Placebo|Tablet, oral.
223797027|NCT01568333|DRUG|Decitabine|Decitabine 3.5mg/m2，ivdrip，qd x 3d, every four weeks for one cycle. It will be given three cycles.
223797028|NCT01454583|DRUG|Aliskiren|Aliskiren (Rasilez®, Novartis) is the first clinically available substance with direct renin inhibition (DRI) which effectively lowers blood pressure.
223797029|NCT01454583|DRUG|ACE-I/ARB|
223797030|NCT01454583|DRUG|No RAS-inhibition|
223797031|NCT02774070|RADIATION|Plain X-ray|antero-posterior, lateral neutral, flexion, extension and open-mouth views
223797032|NCT02774070|RADIATION|Magnetic resonance imaging|Magnetic resonance imaging sagittal T1W,T2W and STIR, axial T1W and coronal T2W and post contrast sagittal and axial sequences
223797033|NCT01689064|PROCEDURE|Stamm Approach|
223797034|NCT01689064|PROCEDURE|Posterior Septectomy|
223797035|NCT04361929|DEVICE|Ultrasound|The following ultrasound measurements will be assessed: DS-HB, HMDR, TT, TT-S, TW, EW, ET, DS-E, and DS-V.
223797036|NCT04434560|DRUG|Nivolumab|Nivolumab will be given at the FDA-approved dose of 3 mg/kg.
223797037|NCT04434560|DRUG|Ipilimumab|Ipilimumab will be given at the FDA-approved dose of 1 mg/kg.
223797038|NCT06174714|BEHAVIORAL|Indonesia Substance Use Reduction for Female Therapy (Indo-SURFT)|4 weeks of motivational interviewing/motivational enhancement therapy (MI) followed by 8 weeks cognitive behavioral therapy (CBT) using Indo-SURFT module.
223797039|NCT04306198|DEVICE|Osteosynthesis with Trochanteric Fixation Nail (TFN), using a lag screw as a proximal fixation.|Closed reduction and surgical stabilization of intertrochanteric hip fractures using Trochanteric Fixation Nail (TFN), with lag screw as proximal fixation
223797040|NCT04306198|DEVICE|Osteosynthesis with Trochanteric Fixation Nail (TFN), using a helical blade as a proximal fixation.|Closed reduction and surgical stabilization of intertrochanteric hip fractures using Trochanteric Fixation Nail (TFN), with helical blade as proximal fixation
223797041|NCT06335134|DRUG|XW003 injection|Administered subcutaneously
223797042|NCT06335134|DRUG|Metformin|Administered orally
223797043|NCT06335134|DRUG|Warfarin|Administered orally
223797044|NCT06335134|DRUG|Rosuvastatin|Administered orally
223797045|NCT06335134|DRUG|Digoxin|Administered orally
223797046|NCT05574569|BEHAVIORAL|Group 1: Play Therapy|Play therapy will be given to children having emotional and behavioral problems.
223797047|NCT05574569|BEHAVIORAL|Group 2: Mindful Parenting|Culturally adapted mindful parenting worksheets will be given to the parents of children having emotional and behavioral problems.
223797048|NCT05574569|BEHAVIORAL|Group 3: (Combined Interventions of both Group 1 & 2)|Play therapy will be given to children and in addition, culturally adapted mindful parenting worksheets will be given to the parents of children having emotional and behavioral problems.
223797049|NCT01603264|BIOLOGICAL|PF-05280014|Concentrate for solution for infusion, sterile vial 150 mg, single-dose 6 mg/kg administered as 90-minute infusion on day 1
223797050|NCT01603264|BIOLOGICAL|Herceptin|Concentrate for solution for infusion, sterile vial 150 mg, single-dose 6 mg/kg administered as 90-minute infusion on day 1
223797051|NCT01603264|BIOLOGICAL|Herceptin|Concentrate for solution for infusion, sterile vial 440 mg, single-dose 6 mg/kg administered as 90-minute infusion on day 1
223797052|NCT03046459|BIOLOGICAL|BNZ132-1-40|pegylated peptide inhibiting IL-2, IL-9 and IL-15
223797053|NCT02656433|DEVICE|Transcranial Random Noise Stimulation|A special Helmet supply weak electrical currents in the head
223797054|NCT02656433|OTHER|Physiotherapy|Standard of care physiotherapy aimed to the motor impairment the subject presents
223797055|NCT03837912|BEHAVIORAL|Patient reported safety experiences fed back to PC providers|The intervention will involve three key stages: a) Measurement: Patients will be invited to complete the Patient Reported Experiences and Outcomes of Safety in Primary Care (PREOS-PC) questionnaire using a tablet-computer. b) Feedback: Using a bespoke online tool, the information will be processed and presented to each centre in the form of a Feedback Report, which will offer comparisons with other centres along with a set of recommendations for addressing the problems identified. c) Action planning and change: centres will form an Action Planning Team, which will be responsible for analyzing the report, considering which area(s) should be improved, and developing, implementing and monitoring an action plan to address the safety problems identified.
223797056|NCT05758844|PROCEDURE|safe-line technique|Safe-line approach
223797057|NCT00253591|DRUG|cisplatin|
223797058|NCT00253591|DRUG|vinorelbine tartrate|
223797059|NCT00253591|RADIATION|radiation therapy|
223797060|NCT02639130|DRUG|Exendin [9-39]|Exendin \[9-39\] at 350 and 500 pmol/kg/min for infusion as challenge agent
223797061|NCT02639130|DRUG|Placebo|Placebo infusion as challenge agent
223797062|NCT06063226|OTHER|Experimental|Orally administred probiotics with L. plantarum and L. rhamnosus
223797063|NCT06063226|OTHER|Negative control|Only routinary oral hygiene procedures
223797064|NCT06063226|OTHER|Positive control|Orally administred placebo without probiotics
223797065|NCT03130751|BEHAVIORAL|Pocket Coach for AYA with Cancer|The Pocket Coach for AYA with Cancer is a psychosocial intervention to be delivered through a mobile platform. Intervention content is based on Mindfulness Based Stress Reduction (MBSR) and the Resilience in Illness Model \[Dr. Joan E. Haase et al\] and includes modules on relaxation, mindfulness, cognitions, and self-compassion.
223797066|NCT04369092|OTHER|DYMUS|DYsphagia in MUltiple Sclerosis (DYMUS) that was questionnare and Eating Assessment Tool (EAT-10) were used for assess swallowing problem. All individuals were classified according to DYMUS. The DYMUS Score was 1 or 2 was taken as mild swallowing problems, 3 or more was taken as severe swallowing problems. Patients were divided into three groups; first group that include patients without swallowing problems, second group that include patients with mild swallowing problems, third group that include severe swallowing problems.
223797067|NCT02677116|DRUG|Olaratumab|Olaratumab administered IV.
223797068|NCT02677116|DRUG|Doxorubicin|Doxorubicin administered IV.
223797069|NCT02677116|DRUG|Vincristine|Vincristine administered IV.
223797070|NCT02677116|DRUG|Irinotecan|Irinotecan administered IV.
223797071|NCT02677116|DRUG|Ifosfamide|Ifosfamide administered IV.
223797072|NCT00290641|BIOLOGICAL|filgrastim|
223797073|NCT00290641|BIOLOGICAL|graft-versus-tumor induction therapy|
223797074|NCT00290641|DRUG|cyclophosphamide|
223797075|NCT00290641|DRUG|cyclosporine|
223797076|NCT00290641|DRUG|fludarabine phosphate|
223797077|NCT00290641|DRUG|mycophenolate mofetil|
223797078|NCT00290641|PROCEDURE|umbilical cord blood transplantation|
223797079|NCT00290641|RADIATION|radiation therapy|
223797080|NCT03182868|DEVICE|PAS Goggle|PAS goggle is a self-contained stimulus and sensing device that is designed to deliver the visual stimuli currently delivered via light projected on a wall while simultaneously recording the movement of the eyes. Each vestibular testing session last about 15 minutes.
223797081|NCT02191553|BEHAVIORAL|Control group relaxation techniques|Jacobson's progressive muscular relaxation, emotional imagining and Schultz's autogenic training.
223797082|NCT02191553|BEHAVIORAL|Loving-kindness meditation|Following Kristin Neff protocol
223797083|NCT02191553|BEHAVIORAL|Body scan|Body scan: Attention being directed with detailed awareness to every part of the body for a sustained period of time.
223797084|NCT02191553|BEHAVIORAL|Sitting practice|In the sitting exercise, participants are guided to pay attention to a certain range of still points, starting with attention to breathing. In this exercise attention is fully concentrated on a single object: the sensation attached to breathing. If the mind wanders or is distracted by an external stimulus, attention is gently returned to sensations derived from breathing.
223797085|NCT02958969|DRUG|Apixaban|apixaban 2.5 mg orally twice daily for primary prevention of VTE for a duration of 6 months
223797086|NCT04183764|DRUG|MAX-40279-01|"Part 1: Dose escalation, MAX-40279-01 twice daily with dose modifications based on tolerability criteria.~Part 2: Dose expansion, Recommended doses from Part 1."
223797087|NCT03753061|DEVICE|Aspiration Catheter|Patients will be treated for mechanical recanalization with Aspiration Catheter within 8 hours after stroke onset plus standard medical management.
223797088|NCT03753061|DEVICE|Solitaire FR|Patients will be treated for mechanical recanalization with Solitaire FR within 8 hours after stroke onset plus standard medical management.
223797089|NCT05086367|OTHER|Diaphragmatic and pursed lip breathing|Breathing exercises were performed. Two breathing techniques were applied to the participants. Diaphragmatic and pursed lip breathing were intervened along with routine physical therapy.
223797090|NCT05086367|OTHER|Routine Physical Therapy|Routine physical therapy exercises were performed in which neck isometrics and neck range of motion exercises were performed
223797091|NCT04514848|DEVICE|INSTI Multiplex HIV-1/2 Syphilis AB test|For the detection of antibodies to syphilis and HIV
223797092|NCT04514848|DEVICE|Multiplo Rapid TP/HIV test|For the detection of antibodies to syphilis and HIV
223797093|NCT03122418|BEHAVIORAL|Personal Fitness Device|Subjects will be given a personal fitness device to use to encourage exercise routinely. The impact this has on the individual perception of their quality of life will be the primary outcome for this study
223797094|NCT04632875|BEHAVIORAL|Loving-Kindness Meditation|Approximately 15-minute sessions are administered 6 days per week
223797095|NCT04632875|BEHAVIORAL|Relaxation Meditation|Approximately 15-minute sessions are administered 6 days per week
223797096|NCT04879550|DIAGNOSTIC_TEST|Antithrombin III|Antithrombin III deficiency causes thrombosis. Is thrombosis in ECMO patients related to Antithrombin III deficiency? Groups with and without thrombosis will be separated and whether it is related to Antithrombin III deficiency will be evaluated.
223797097|NCT02363946|DRUG|ARC-AAT Injection|RNA interference-based, liver-targeted therapeutic
223797098|NCT02363946|OTHER|Placebo|0.9 % normal saline
223797099|NCT02363946|DRUG|Diphenhydramine|Diphenhydramine 50 mg p.o. was administered 2 hours (±30 minutes) pre-dose as antihistamine pre-treatment.
223797100|NCT03047200|BIOLOGICAL|Islet cell transplantation|The process is based on the enzymatic isolation of the pancreatic islets of Langerhans from an organ procured from a cadaveric donor; the islets obtained are injected into the liver of the recipient via percutaneous catheterization of the portal venous system . This procedure allows the selective transplantation of the insulin-producing cell population avoiding open surgery as well as the transplantation of the duodenum and the exocrine pancreas and their related morbidity.
223797101|NCT04453631|DEVICE|active tDCS|26 transcranial direct current stimulation sessions, each lasting 20 minutes, with a current intensity of 2 mA, the cathode placed over the right dorsolateral prefrontal cortex and the anode placed over the left deltoid muscle.
223797102|NCT04453631|DEVICE|sham tDCS|tDCS is controlled in this intervention: sham mode.
223797103|NCT04453631|BEHAVIORAL|CBT-UP|15 psychotherapy sessions (1/week) following the Unified Protocol for Transdiagnostic Treatment of Emotional Disorders developed by Barlow et al. 2018.
223797104|NCT04453631|BEHAVIORAL|Psychoeducation|To control for the cognitive-behavioral intervention we will use psychoeducation materials.
223797105|NCT03905889|DRUG|Abemaciclib|Subjects will by given oral Abemaciclib every 12 hours for 14 days followed by 7 days off (i.e. a 21 day cycle). The initial dose will be 100 mg (Dose level 1) followed by 150 mg (Dose Level 2) depending on tolerability and toxicity assessment of the combination of medications. If at Dose Level 1 subjects cannot tolerate the combination of medications, the Abemaciclib would not be increased, and the dose will remain stable at 100 mg (Dose Level -1).
223797106|NCT03905889|DRUG|Sunitinib|Subjects will take oral Sunitinib daily for the 21-day cycle. Dosing will be at 50 mg for both Dose Levels 1 and 2. If the combination of the 2 medications is not tolerated by Subjects at Dose Levels 1 a lower dose of Sunitinib (37.5 mg) will be given (Dose Level -1).
223797107|NCT04253743|OTHER|Nevada Healthy, Hunger-Free Kids Demonstration Benefits|SNAP households with children under age 5 incomes below 75% of the federal poverty level living in Clark County, Nevada received $40 in extra SNAP benefits per eligible child, and access to case management and nutrition education.
223797108|NCT01967732|OTHER|THS 2.2|Single use of the Tobacco Heating System 2.2 (THS 2.2)
223797109|NCT01967732|OTHER|CC|Single use of subject's own conventional cigarette (CC)
223797110|NCT01967732|OTHER|NNS|Single administration of 1 mg of nicotine
223797111|NCT06429254|OTHER|Experimental group|Life Scale will be administered as pre-tests to the EFT group. After the pre-tests, the first EFT session will be conducted. A second EFT session will take place 30 days later, followed by post-tests. During this period, affirmations will be provided as needed based on individual difficulties, perspectives, support systems, past traumas, and emotional blockages experienced by the woman. Each session is planned to last approximately 45 minutes to 1 hour.
223797112|NCT03342638|DRUG|Cyclophosphamide|Potent immunosuppressive agent; an alkylating agent
223797113|NCT03342638|DRUG|Mesna|Medication used to decrease the risk of hemorrhagic cystitis prophylaxis
223797114|NCT03342638|DRUG|rATG|A predominantly lymphocyte-specific immunosuppressive agent which contains antibodies specific to the antigens commonly found on the surface of T cells
223797115|NCT03342638|DRUG|Methylprednisolone|Steroid
223797116|NCT03342638|DRUG|G-CSF|Granulocyte-colony stimulating factor; a glycoprotein that stimulates the bone marrow to produce granulocytes and stem cells and release them into the bloodstream
223797117|NCT03342638|BIOLOGICAL|IVIg|Sterile, purified immunoglobulin G (IgG) products manufactured from pooled human plasma and typically contain more than 95% unmodified IgG, which has intact Fc-dependent effector functions and only trace amounts of immunoglobulin A (IgA) or immunoglobulin M (IgM).
223797118|NCT03342638|BIOLOGICAL|Autologous Stem Cells|Infusion of participant's own stem cells
223797119|NCT02211326|BEHAVIORAL|Genotype-guided dosing algorithm for warfarin|Intervention：initial dosing of warfarin for the first 3 days of treatment will be determined by IWPC( International Warfarin Pharmacogenetics Consortium) algorithm (PG-1),a second dose adjustment will be made after 3 doses of warfarin using a dose revision algorithm (PG-2) that combined INR values,the dose will be adjusted depending on the measurements of INR values after 7 days.The overall follow-up period is 12 weeks.
223797120|NCT02211326|BEHAVIORAL|Standard initiation dose for warfarin|Intervention：initial dosing of warfarin for the first 3 days of treatment will be determined by standard initiation dose. Following this initiation dose of warfarin,the dose will be adjusted depending on the measurements of INR values after 3 days.The overall follow-up period is 12 weeks.
223797121|NCT03536000|DIAGNOSTIC_TEST|Fetal echocardiography using the aCMQ-Strain method|Fetal echocardiography using the aCMQ-Strain method (Automated Cardiac Motion Quantification) at 24, 28, 32 and 36 weeks of gestation
223797122|NCT04936152|OTHER|mime therapy using tablet PC mirror application|"After the baseline assessment, The patient in the experimental group will receive mirror therapy and mime therapy.~Exercises time period is 30 min/session~Mime Therapy Using Tablet PC:~Mirror therapy using tablet PC mirror application We will use a tablet PC mirror application that can convert images from right to left. In the mirror group, the mirror application was used during the exercise. Patients watched the tablet PC screen. The mirror application converts the image from right to left.~• Mime therapy include Mime therapy will consists of auto massage- effleurage and kneading for 10 to 15minutes on both the sides of the face, stretching exercises of the muscles of the affected side followed by facilitation, specific low intensity exercises to co-ordinate both the halves of the face, active assisted exercises for affected side of the face, exercises of mouth and eye with simultaneous inhibition of synkinesis if present."
223797123|NCT04936152|OTHER|the control intervention including the mime therapy|After the baseline assessment, The patient in the experimental group will receive mime therapy Mime therapy include Mime therapy will consists of auto massage- effleurage and kneading for 10 to 15minutes on both the sides of the face, stretching exercises of the muscles of the affected side followed by facilitation, specific low intensity exercises to co-ordinate both the halves of the face, active assisted exercises for affected side of the face, exercises of mouth and eye with simultaneous inhibition of synkinesis if present.
223797124|NCT06115733|DRUG|Fruquintinib、Capecitabine Tablets|"Phase Ⅰb dose exploration trial of fuquinitinib combined with capecitabine (n=6-9) :~3\) Capecitabine: 1000 mg/m² orally, twice a day on days 1-21 of each cycle, 28 days for one treatment cycle.~4\) Fuquinitinib: 1 to 21 days per cycle, orally, once a day, 28 days for a treatment cycle. There are two dose gradients of fuquintinib: 2mg/d, and the initial dose of 3mg/d is 2mg/d. According to the 3+3 dose climbing principle, dose exploration is carried out in the order of 2mg/d→3mg/d, as follows:~Phase II: Dose extension trial (n=47) :~The recommended dose of fuquinitinib combined with capecitabine, as determined in phase I b, continued to enroll 47 patients in the dose-expansion phase trial until the patient became intolerant of toxicity or disease progression."
223797125|NCT01584622|DEVICE|CADence System|Non-invasive detection of \> or equal to 50% stenosis in any of the major coronary arteries.
223797126|NCT01924650|DRUG|PH-797804|Tablet, 6 mg, single dose
223797127|NCT01924650|DRUG|PH-797804|Tablet, 6 mg, single dose
223797128|NCT01924650|DRUG|PH-797804|Tablet, 6 mg, single dose
223797129|NCT01924650|DRUG|PH-797804|Tablet, 6 mg, single dose
223797130|NCT01924650|DRUG|PH-797804|Tablet, 6 mg, single dose
223797131|NCT01924650|DRUG|PH-797804|Tablet, 6 mg, single dose
223797132|NCT02216058|DEVICE|NOYA CoCr Biodegradable Coating Sirolimus-Eluting Stent System|
223797133|NCT03327987|BIOLOGICAL|standard of care influenza vaccine|The standard of care annual 2017-2018 influenza vaccine will be used for this study.
223797134|NCT00554970|DRUG|MAP0010 low dose|a single dose of MAP0010 low dose delivered by nebulization twice daily for 7 days as per protocol
223797135|NCT00554970|DRUG|MAP0010 high dose|a single dose of MAP0010 high dose delivered by nebulization twice daily for 7 days as per protocol
223797136|NCT00554970|DRUG|Budesonide inhalation suspension 0.25mg|a single dose of Pulmicort Respules® 0.25mg delivered by nebulization twice daily for 7 days as per protocol
223797137|NCT00554970|DRUG|Budesonide inhalation suspension 0.5mg|a single dose of Pulmicort Respules® 0.5mg dose delivered by nebulization twice daily for 7 days as per protocol
223797138|NCT03028974|BIOLOGICAL|Fluzone®|Fluzone® Quadrivalent: Quadrivalent influenza virus vaccine
223797139|NCT03028974|BIOLOGICAL|FluMist®|FluMist® Quadrivalent: Quadrivalent influenza virus vaccine live, intranasal spray
223797140|NCT02654808|DEVICE|AirSeal trocar|"The AirSeal® trocar is a valveless trocar that has been designed to replace the trap door and silicone valve of standard trocars with a curtain of forced CO2 gas. With the AirSeal® trocar, escaping gas is collected at the proximal end of the trocar, filtered, and redirected into the peritoneal cavity to maintain the pressure differential. The result is an invisible barrier that instantaneously responds to changes in intra-abdominal pressure, either by allowing more CO2 inflow with pressure drops or by serving as a pressure relief valve during pressure spikes."
223797141|NCT02654808|DEVICE|Standard trocar|"A standard insufflation trocar delivers CO2 into the abdominal cavity to create workspace and uses either a trap door or silicone valve to prevent the egress of CO2 during laparoscopy in order to maintain intra-abdominal pressures. The standard trocars are not equipped to respond to changes in the intra-abdominal pressures in order to trigger an increase or decrease in the flow rate of CO2 gas."
223797142|NCT00935376|BEHAVIORAL|Sleep Education Program|Treatment as usual.
223797143|NCT00935376|BEHAVIORAL|Mind-Body Bridging Program|Bridging aims to reduce the impact of negative thought patterns that contribute to stress in the body.
223797144|NCT00935376|BEHAVIORAL|Mindfulness Meditation Program|Mindfulness Meditation Program is based on Mindfulness-Based Stress Reduction, which teaches participants awareness and mindfulness skills using techniques that include a basic meditation practice and yoga.
223797145|NCT00113568|DRUG|Tranexamic acid tablets (XP12B)|Two 650 mg tranexamic acid tablets (XP12B) taken 3 times daily (3900 mg/Day) for a maximum of 5 days during monthly menstruation
223797146|NCT04279223|PROCEDURE|Laparoscopic cholecystectomy|Comparative study to investigate the effect of small-scale trocar use on the development of trocar site hernia in laparoscopic cholecystectomy
223797147|NCT01292239|DRUG|Placebo|Placebo capsule taken by mouth once daily for 12 weeks
223797148|NCT01292239|DRUG|TMC435|100-mg capsule taken by mouth once daily for 12 weeks
223797149|NCT01292239|DRUG|Peginterferon alfa-2a (pegIFN alfa-2a)|PegIFN alfa-2a (PEGASYS) will be administered according to the manufacturer's prescribing information as 180 mcg once weekly injected subcutaneous (under the skin) for up to 24-48 weeks for patients randomized to TMC435 and for up to 48 weeks for patients randomized to placebo.
223797150|NCT01292239|DRUG|Ribavirin (RBV)|RBV (COPEGUS) will be administered according to the manufacturer's prescribing information. If body weight is \> 80 kg the total daily dose of RBV will be 1000 mg, taken by mouth as 400 mg (2 tablets of 200 mg) after breakfast and 600 mg (3 tablets of 200 mg) after supper. If body weight is \> 60 kg to \<=80 kg the total daily dose will be 800 mg, taken by mouth as 400 mg (2 tablets of 200 mg per intake) after breakfast and supper. If body weight is \<=60 kg the total daily dose of RBV will be 600 mg, taken by mouth as 200 mg (1 tablet of 200 mg) after breakfast and 400 mg (2 tablets of 200 mg) after supper. Total duration of RBV will be 24-48 weeks.
223797151|NCT00450086|DRUG|Budesonide|9 mg per day
223797152|NCT00450086|DRUG|Mesalazine|3 g per day
223797153|NCT00450086|DRUG|Placebo|0 g per day
223797154|NCT04728529|PROCEDURE|USSM protocol|"In the initial step, all subjects will receive emergency management: oxygen support, vascular access, and fluid therapy. Doppler ultrasonography by Ultrasound Cardiac Output Monitoring (USCOM) is also performed to record initial stroke volume (SV), cardiac index (CI), and systemic vascular resistance (SVR). The initial fluid resuscitation is 20 mL/kg body weight, then the response measured by clinical and USCOM examination. If any improvement of clinical sign and normal SVI, CI, SVR, intervention will be stopped. In contrary, if shock persist, subsequent fluid resuscitation and/or vasoactive therapy will be administered, guided by USCOM.~The therapeutic goal of USCOM: SVI 30-60 mL/m2, CI 3.3-6.0 L/minute/m2, and SVRI 800-1600 d.s/cm5/m2"
223797155|NCT04728529|PROCEDURE|ACCM protocol|In the initial step, all subjects will receive emergency management: oxygen support, vascular access, and fluid therapy. Doppler ultrasonography by Ultrasound Cardiac Output Monitoring (USCOM) is also performed to record initial stroke volume (SV), cardiac index (CI), and systemic vascular resistance (SVR). The initial fluid resuscitation is 20 mL/kg body weight, then the response measured by clinical. If any improvement of clinical sign, intervention will be stopped. In contrary, if shock persist, subsequent fluid resuscitation and/or vasoactive therapy will be administered, guided by clinical parameter.
223797156|NCT02712034|BEHAVIORAL|MAT + A-CHESS|"Subjects randomized to MAT + A-CHESS will receive MAT plus the A-CHESS recovery support system which provides:~1. Self-directed, interactive modules that teach basic recovery support, harm-reduction, and psychosocial functioning skills.~2. The latest information about addiction and recovery support, monitoring prompts, and peer and family support.~3. Advice on where to go for help and on how to make the best use of health and human services; and~4. A way to talk with experts in the area of addiction and other study participants by sending anonymous messages in the A-CHESS discussion groups.~5. A way to keep your health care team up to date through reports based on information entered into A-CHESS (i.e. alcohol and drug use, depression, MAT side effects)."
223797157|NCT02712034|OTHER|MAT|"Patients will receive treatment consisting of a recovery plan, appropriate pharmacology, routine urine screens, and regularly scheduled behavioral interventions, such as monthly group counseling sessions or sessions with a recovery coach. Appropriate pharmacology may include methadone; naltrexone; buprenorphine; and in the case of overdose, naloxone; and other medications and combinations of medications as part of the patient's standard clinical care."
223797158|NCT01492075|DRUG|PCRA (Intermittent injection)|Intermittent injection of LA intraabdominally
223797159|NCT00262821|DRUG|cisplatin|Given IV
223797160|NCT00262821|DRUG|tirapazamine|Given IV
223797161|NCT05712590|OTHER|dietary habit|As it is observational study, women that follow three different dietary patterns will be inlcuded .
223797162|NCT05181163|DIAGNOSTIC_TEST|swab|Swabs from site of infection will be taken
223797163|NCT01509898|DEVICE|Water jet|use of water jet for a month
223797164|NCT03498833|OTHER|Test-retest reliability testing|Set of patient reported outcome measures
223797165|NCT00898469|GENETIC|polymorphism analysis|
223797166|NCT04687891|DIAGNOSTIC_TEST|transabdominal ultrasound and transvaginal ultrasound|Within a week before scheduled delivery,antepartum transabdominal and transvaginal ultrasound will be performed with moderately full bladder.
223797167|NCT01489033|BIOLOGICAL|Subcutaneous immunotherapy with Phleum pratense pollen extract|Increasing doses up to a maximum dose of 500 TSU
223797168|NCT06307587|PROCEDURE|dry needling|The vastus intermedius will be approached with DN from the lateral aspect and the pincer approach will be followed. The Hong fast-in and fast out technique with multiple rapid needle insertions will be performed following previous recommendations (Chou, et al., 2014). The control group will receive the rehabilitation program alone. A headless 0.25 × 25-mm needle (Stainless steel, Agupunt A1038P, 158 Caspe, Barcelona, Spain) will be used. The penetration depth will be varied according to the patient. Hemostasis will be performed for 1 minutes. DN will be performed medial to the sartorius muscle limit to avoid saphenous nerve adverse effects during DN (Henry et al., 2016).
223797169|NCT02057900|BIOLOGICAL|Human embryonic stem cell-derived CD15+ Isl-1+ progenitors|Epicardial delivery of a fibrin patch embedding human embryonic stem cell-derived CD15+ Isl-1+ progenitors
223797170|NCT00785369|DEVICE|Reflectance confocal microscopy|Reflectance confocal microscopy (VivaScope 1500)
223797171|NCT01410773|DEVICE|Ninja 2 Investigational Blood Glucose Monitoring System|The Ninja 2 meter is a Bayer investigational meter that uses an investigational sensor.
223797172|NCT03044379|DRUG|Dapivirine gel (0.05%)|MTN-026/IPM 038 will use the HTI pre-filled applicator, the same applicator that has been utilized in other rectal studies.
223797173|NCT03044379|OTHER|Universal HEC placebo gel|
223797174|NCT01734304|BIOLOGICAL|DC vaccination for postremission therapy in AML|Vaccination with TLR7/8-matured DCs electroporated with mRNA encoding WT1, PRAME, and CMVpp65
223797175|NCT01867151|DIETARY_SUPPLEMENT|Gluten Free Diet|
223797176|NCT01867151|DIETARY_SUPPLEMENT|Normal Diet|
223797177|NCT01988779|DRUG|oral levofloxacin|
223797178|NCT01988779|DRUG|nebulized levofloxacin|
223797179|NCT04504487|OTHER|Drain Removal|Abdominal drain placed during surgery removal
223797180|NCT00584727|DEVICE|senofilcon A toric contact lens|contact lens
223797181|NCT00584727|DEVICE|alphafilcon A toric|contact lens
223797182|NCT00584727|DEVICE|etafilcon A sphere|contact lens
223797183|NCT02895087|OTHER|Diurnal Variation Group|This intervention occurs over one 24-hour period. Eligible participants will be required to be admitted into a supervised environment for 24-hours arriving no later than 0730. Blood draws will then be taken every 4 hours (0800, 1200, 1600, 2000, 2400 and 0400). Care will be taken to ensure the total blood draws (including the screening visit) stay within Red Cross Guidelines (less than 500 ml every 8 weeks).
223797184|NCT02895087|OTHER|External Stress Group|"2 visits will be required, each lasting approximately 2.5 hours in the afternoon.~At both visits participants will rest quietly for 15 minutes, then have 3 blood draws and 4 saliva samples over approximately one hour. Participants will also be required to complete short questionnaires about their mood and experience.~At the second visit, participants will also complete some thinking and talking tasks. In addition the autonomic nervous system of the participant's will be monitored throughout the visit."
223797185|NCT03942133|PROCEDURE|ultrasound-guided short-axis placement of catheter at the entrance of the adductor canal|Ultrasound probe is placed at the entrance of the adductor canal in short axis ，insertion of a PAJUNK Contiplex S catheter with the tip of the catheter located at the entrance of the canal
223797186|NCT03942133|PROCEDURE|ultrasound-guided long-axis placement of catheter at the middle of the adductor canal|Ultrasound probe is placed at the middle of the adductor canal in long axis with the caphelad end of the probe aligned with the entrance of the canal. insertion of a PAJUNK Contiplex S catheter with the tip of the catheter located at the middle of the canal
223797187|NCT04214704|DEVICE|Genteel lancing device|Painless lancing device that helps to improve and assess self-monitoring frequency and HbA1c respectively
223797188|NCT04214704|DEVICE|Conventional lancing device|Conventional lancing device
223797189|NCT01484548|BIOLOGICAL|LEISH-F3 + GLA-SE|20 ug of LEISH-F3 and 2 ug of GLA-SE adjuvant. 3 injections at Days 0, 28, and 56.
223797190|NCT01484548|BIOLOGICAL|LEISH-F3 + GLA-SE|20 ug of LEISH-F3 and 5 ug of GLA-SE adjuvant. 3 injections at Days 0, 28, and 56.
223797191|NCT01484548|BIOLOGICAL|LEISH-F3 alone|20 ug of LEISH-F3 antigen alone. 3 injections at Days 0, 28, and 56.
223797192|NCT02293044|DEVICE|Crest® Sensi-Stop™ Strips|
223797193|NCT05186948|DEVICE|Eye-Tracking|Eye-tracking technology and algorithms used to successfully capture and track eye movements using an electronic tablet and the embedded camera of the device.
223797194|NCT03273634|DRUG|Lansoprazole Pill|once daily at night time
223797195|NCT03273634|DRUG|Placebo|Placebo
223797196|NCT06578923|DIAGNOSTIC_TEST|Standard of care|12 months after the IOL implantation: measurement of intraocular pressure, slitlamp and fundus examination, visual acuity, manifest refraction.
223797197|NCT06578923|BEHAVIORAL|Patient satisfaction questionnare|VFQ- 25 (Visual Function Questionnare) to be completed during 12 month visit.
223797198|NCT01789554|OTHER|MLS dispatch for bystander CPR|
223797199|NCT04085783|PROCEDURE|PRP|Platelet Rich Plasma
223797200|NCT00377403|DRUG|Acetaminophen|"Symptomatic treatment:~Dose: 500mg every 4 to 6 hours for pain or fever"
223797201|NCT00377403|DRUG|Amoxicillin|"Intervention drug:~Dose: 500mg tid for 10 days"
223797202|NCT00377403|DRUG|Dextromethorphan hydrobromide with guaifenesin|"Symptomatic treatment:~Dose: 10mls every 4 to 6 hours for cough"
223797203|NCT00377403|DRUG|Guaifenesin|"Symptomatic treatment:~Dose: 600mg every 12 hours to thin secretions"
223797204|NCT00377403|DRUG|Pseudoephedrine Sustained Action|"Symptomatic treatment:~Dose: 120mg every 12 hours for nasal congestion"
223797205|NCT00377403|DRUG|Saline spray (0.65%)|"Symptomatic treatment:~Dose: 2 squeezes per nostril as needed for nasal congestion"
223797206|NCT01511848|DRUG|DFP (ferriprox) and deferasirox (ICL 670)|"Drug: Ferriprox It will be given orally in the morning Other Name: DFP Initial dose 25/mg/kg 3 times/d (better tolerated if started and then built up over 4 weeks).~Dose may be increased up to 100mg/kg/day guided by serum ferritin. Agranulocytosis risk 1-2%. Monitor TLC and granulocytic count / 2weeks. Patients need to be continually educated about this risk, know that they must stop DFP if they have a fever or infection.~Drug: Deferasirox will be orally administered at a dose of 20 mg/kg once daily at evening for 5 days.~Other Name: ICL670"
223797207|NCT01511848|DRUG|DFP, DFO|"Drug: Deferoxamine It will be administered subcutaneously over 8 hours for 5 days at a dose of 40 mg/kg.~Other Name: Desferal, DFO Drug: DFP DFP: will be orally administered at a dose of 75mg/kg orally in 3 divided doses for 7 days"
223797208|NCT04756687|DRUG|Dimethyl fumarate|Administered as specified in the treatment arm.
223797209|NCT06579651|DEVICE|Nailfold videocapillaroscopy (NVC)|Nailfold videocapillaroscopy (NVC) is the validated technique to assess SSc microvascular damage and is useful for the early diagnosis and follow-up of SSc micro- angiopathy.
223797210|NCT00627848|DRUG|rivastigmine|Acute dose 3 mg or placebo. Thereafter 1.5 mg x 2 ad 30 days and thereafter increasing the dose upto 4.5 mg x 2 according to instructions.
223797211|NCT05884840|DIAGNOSTIC_TEST|HELENA|"The current CV risk screening program in based using the REGICOR risk function, which is integrated in the primary care electronic health record. This risk function predicts the probability within 10 years of developing a coronary event. Those who are categorized as high risk, obtaining a 10% of probability, are candidates of receiving lipid lowering drugs and recommendations on healthy life habits.~What this intervention suggests is that, besides the REGICOR estimation, the electronic health records will also incorporate a new CV risk function, REASON. The model predicts the risk of holding a pathologic ABI score, in people aged 50-74 years old who are apparently free of CV. Patients who obtain a score ≥ 7 will undergo a PAD screening program with ABI test. If the value of the test is ≤0.9, the REGICOR, physicians will recommend indications of the Health Catalan Institute's CV and lipid Guidelines to the patients."
223797212|NCT05008666|DRUG|Sintilimab|"1. To evaluate the short-term objective efficacy of sintilimab Sequential combined with chidamide and azacitidine in the treatment of ENKTL-HLH patients.~2. To evaluate the long-term efficacy and safety of sintilimab Sequential combined with chidamide and azacitidine in the treatment of ENKTL-HLH patients.~3. Exploring biomarkers that may have predictive effects."
223797213|NCT05008666|DRUG|Chidamide|"1. To evaluate the short-term objective efficacy of sintilimab Sequential combined with chidamide and azacitidine in the treatment of ENKTL-HLH patients.~2. To evaluate the long-term efficacy and safety of sintilimab Sequential combined with chidamide and azacitidine in the treatment of ENKTL-HLH patients.~3. Exploring biomarkers that may have predictive effects."
223797214|NCT05008666|DRUG|Azacitidine|"1. To evaluate the short-term objective efficacy of sintilimab Sequential combined with chidamide and azacitidine in the treatment of ENKTL-HLH patients.~2. To evaluate the long-term efficacy and safety of sintilimab Sequential combined with chidamide and azacitidine in the treatment of ENKTL-HLH patients.~3. Exploring biomarkers that may have predictive effects."
223797215|NCT05008666|DRUG|L-DEP|L-DEP
223797216|NCT02568241|OTHER|Interferon Alfa-2b|High-risk acute leukemia patients receive prophylactic DLI at day 30-60 after hematopoietic stem cell transplantation,they received interferon α-2b (subcutaneously at dosages of 3 million units 2-3 times per week) . Interferon treatment continues for 6 months in the absence of disease progression or unacceptable toxicity.
223797217|NCT04380922|OTHER|Periodontal screening|Periodontal data collection (PPD, REC, CAL)
223797218|NCT04859504|DEVICE|transcranial alternating current stimulation (NE Starstim)|dual-channel theta-tACS over right DLPFC and cerebellum simultaneously
223797219|NCT06387901|DRUG|Paclitaxel Chemotherapy|Participants will receive paclitaxel, a taxane chemotherapeutic agent used in the treatment of breast cancer. The administration involves an intravenous infusion of paclitaxel at a dosage of 80 mg/m². The treatment is scheduled once a week, continuing for a total duration of 12 weeks. This regimen is part of a (neo-)adjuvant therapy for female patients diagnosed with stage II or III breast cancer. The intervention aims to assess the pharmacokinetics of paclitaxel in relation to patient body composition and physical activity, evaluating its impact on dose-limiting toxicities and overall treatment efficacy.
223797220|NCT05964140|DRUG|Different post-operative antibiotic regimens following surgical treatment of mandible fractures|"The 3 study arms represent the most common antibiotic regimens used in current clinical practice following surgery for mandible fractures. The control group is the most common approach.~All patients will receive 1 dose of IV antibiotics (co-amoxiclav 1.2g), if no penicillin allergy, on induction of anaesthesia, prior to their surgery.~The participants will be randomised to the following (1:1:1):~Group A: No further antibiotics Group B: 2 further postoperative IV doses of co-amoxiclav 1.2g Group C: 2 further postoperative IV doses (as above), followed by a 5-day course of oral co-amoxiclav 625mg every 8 hours if no penicillin allergy (Control)."
223797221|NCT01634126|BEHAVIORAL|1 FIT kit|Patient receives 1 FIT
223797222|NCT01634126|BEHAVIORAL|2 FIT kit|Patient receives 2 FIT kits
223797223|NCT05502432|DEVICE|Active repetitive transcranial magnetic stimulation|Consecutive 15-day active treatment with 1 Hz of repetitive transcranial magnetic stimulation
223797224|NCT05502432|DEVICE|Sham repetitive transcranial magnetic stimulation|Consecutive 15-day sham treatment with 1 Hz of repetitive transcranial magnetic stimulation
223797225|NCT01938612|DRUG|MEDI4736|MEDI4736 will be administered by IV infusion every 14, 21 or 28 days.
223797226|NCT01938612|DRUG|tremelimumab|tremelimumab is administered by IV infusion every 4 weeks
223797227|NCT01922076|DRUG|Adavosertib|Given PO
223797228|NCT01922076|OTHER|Laboratory Biomarker Analysis|Correlative studies
223797229|NCT01922076|OTHER|Pharmacological Study|Correlative studies
223797230|NCT01922076|RADIATION|Radiation Therapy|Undergo radiation therapy
223797231|NCT00378989|BEHAVIORAL|Consultation at the occupational health services|Consultation at the occupational health services
223797232|NCT04311606|DRUG|Sub-tenon injection of saline followed by a sub-tenon injection of aflibercept|The study will randomly assign a total of eight subjects into this treatment arm to receive a sub-tenon injection of saline followed by injection of 4 mg aflibercept (total volume 1.1 ml) in the worse eye. Injections will be given three times: on day 1, day 14 and day 28. Subjects will be followed until day 90.
223797233|NCT04311606|DRUG|Sub-tenon injection of hyaluronidase (HA) followed by a sub-tenon injection of aflibercept|The study will randomly assign a total of eight subjects into this treatment arm to receive a sub-tenon injection of hyaluronidase (HA) followed by injection of 4 mg aflibercept (total volume 1.1 ml) in the worse eye. Injections will be given three times: on day 1, day 14 and day 28. Subjects will be followed until day 90.
223797234|NCT04311606|DRUG|Sub-tenon injection of hyaluronidase (HA) alone|The study will randomly assign a total of eight subjects into this treatment arm to receive a sub-tenon injection of hyaluronidase (HA) injection alone (total volume 1.1 ml) in the worse eye. Injections will be given three times: on day 1, day 14 and day 28. Subjects will be followed until day 90.
223797235|NCT04853680|DEVICE|Anti-adhesion barrier (Collarbarrier)|Collagen derived anti-adhesion barrier
223797236|NCT01766622|DRUG|[18F]-CP18|7mCi, IV (in the vein) at baseline
223797237|NCT01766622|PROCEDURE|PET/ CT|At baseline, Within 3 days after the initial Birinapant dose, A third \[18F\]-CP18 PET/CT will be obtained within 3 days following cycle 2, day 15 Birinapant therapy
223797238|NCT01181050|DRUG|NNC0142-0002|A single dose of 4 mg NNC 0142-0000-0002/kg bodyweight. Administered subcutaneously (s.c., under the skin).
223797239|NCT01181050|DRUG|placebo|A single dose of 4 mg NNC 0142-0000-0002 placebo/kg bodyweight. Administered subcutaneously (s.c., under the skin).
223797240|NCT05907382|DRUG|JMKX003002 will be administered orally|oral once
223797241|NCT05907382|DRUG|JMKX003002 will be administered orally|oral once
223797242|NCT05907382|DRUG|JMKX003002 will be administered orally|oral once
223797243|NCT05907382|DRUG|Placebo in Cohorts 1 to 5|oral once
223797244|NCT05907382|DRUG|Placebo in 2 Cohorts|oral once
223797245|NCT06962267|DRUG|TQB2916 Injection|A Phase II clinical study to evaluate the efficacy and safety of TQB2916 injection combined with gemcitabine and albumin-paclitaxel as first-line treatment for metastatic pancreatic cancer.
223797246|NCT06962267|DRUG|Chemotherapy|Chemotherapy is a systematic treatment.Chemotherapy drugs go into the body orally or intravenously, and they circulate throughout the body, and because of that, they can be used for advanced cancer, and they can also be effective against metastasized cancer cells.There are many chemotherapeutics, but the underlying mechanism is to kill fast growing cells.
223797247|NCT00403624|DRUG|OXALIPLATIN|
223797248|NCT01018394|DRUG|nicotine lozenges|4 mg nicotine lozenges for a maximum duration of 12 weeks used ad lib - up to 8 nicotine lozenges per day.
223797249|NCT01018394|DRUG|tobacco-free snuff|Tobacco-free snuff used ad lib for a maximum of 12 weeks
223797250|NCT00683644|DRUG|Zinc|Zinc taken once daily
223797251|NCT00683644|DRUG|Placebo oral capsule|Placebo capsules taken once daily
223797252|NCT05814913|BEHAVIORAL|CaCBT for psychosis|The CaCBT intervention is based on the intervention manual developed by David Kingdon and Douglas Turkington, and culturally adapted by our group. CaCBT aims to take a collaborative approach to gaining an understanding of the symptoms
223797253|NCT05814913|BEHAVIORAL|Culturally adapted Family Intervention (CulFI) for psychosis|CulFI intervention comprises of Family psychoeducation; cognitive-behavioural skills training for stress-management, coping and problem solving; crisis intervention and suicide risk management; relapse prevention; education and support regarding the family environment, including communication training. The components are designed to facilitate an understanding about psychosis, the emotional impact of the illness on family relationships, to promote more adaptive coping strategies and minimize relapse risk.
223797254|NCT05808387|DIETARY_SUPPLEMENT|Resveratrol|Trans-resveratrol, 1000 mg daily for 90 days
223797255|NCT05808387|DIETARY_SUPPLEMENT|Placebo|Starch, 1000 mg daily for 90 days
223797256|NCT01650753|DIETARY_SUPPLEMENT|Probiotic Powder|Bifidobacterium longum subsp longum AH1206 freeze dried and provided as a powder in a sachet (10\^10 cells/sachet)
223797257|NCT01650753|DIETARY_SUPPLEMENT|Placebo powder|powdered maltodextrin inthe same volume and the freeze dried probiotic in a similar size sachet
223797258|NCT02388802|PROCEDURE|Oocyte retrieval and freezing|10 Patients will undergo oocyte retrieval and freezing
223797259|NCT02388802|PROCEDURE|Deceased Donor Allograft Excision|Appropriately matched uterine transplant allografts will be excised from deceased donors
223797260|NCT02388802|PROCEDURE|Uterine Transplantation|Following egg freezing the patients will undergo uterine transplant from deceased donors
223797261|NCT02388802|DRUG|Immunosuppressive Agents|Patients will be appropriately immunosuppressed, whilst being closely monitored clinically, radiologically and immunologically.
223797262|NCT02388802|PROCEDURE|In-vitro fertilisation|12 months after successful transplantation,the patients will undergo IVF
223797263|NCT02388802|PROCEDURE|Caesarean Section|Following successful conception and antenatal period, the babies will be born by Caesarean Section
223797264|NCT06078904|DRUG|Colchicine 0.5 MG|Colchicine 0.5 MG, one pill a day, oral intake
223797265|NCT06078904|DRUG|Colchicine 0.375 MG|Colchicine 0.375 MG, one pill a day, oral intake
223797266|NCT06078904|DRUG|Colchicine 0.25 MG|Colchicine 0.25 MG, one pill a day, oral intake
223797267|NCT06078904|DRUG|Placebo|Placebo, one pill a day, oral intake
223797268|NCT01592318|DRUG|danoprevir|Fixed dose combination tablet with ritonavir, single oral dose
223797269|NCT01592318|DRUG|danoprevir|Reference tablet, single oral dose
223797270|NCT01592318|DRUG|ritonavir|Fixed dose combination tablet with danoprevir, single oral dose
223797271|NCT01592318|DRUG|ritonavir|Reference tablet, single oral dose
223797272|NCT05918926|BEHAVIORAL|Exercise|Individualised remote exercise intervention
223797273|NCT04999813|COMBINATION_PRODUCT|Comprehensive intensive intervention|"* Health education ② Medication guidance: antihypertensive therapy, hypoglycemic therapy, lipid-lowering therapy~  * Diet guidance: A healthy diet requires low-salt, low-oil, more fruits and vegetables, more cellulose, appropriate amount of protein, restricted fat and cholesterol foods, etc. Quit smoking, drink less alcohol, and limit alcohol intake.~    * Exercise guidance: Do aerobic exercises of medium and low intensity at least 5 times a week, and exercise for at least 30 minutes each time.~      * Weight loss guidance."
223797274|NCT02058615|BEHAVIORAL|Male Spouse Transition Toolkit|
223797275|NCT01417026|DRUG|Intranasal Oxytocin (Trade name: Syntocinon)|This is a double-blind placebo-controlled trial of intranasal oxytocin in children and adolescents with ASD. Subjects will be randomized to 24 IU intranasal oxytocin or placebo for a 5 day period with concomitant game play of computer games, which are designed to enhance face perception skills. Measures of social function and cognition will be administered before and after the intervention period.
223797276|NCT04674124|BEHAVIORAL|Brief Online Mindfulness Intervention|A nine-week mindfulness course compromising of 9x weekly 15 minute group sessions which will be on an online platform and daily micro meditations for participants to undertake.
223797277|NCT01669122|DRUG|nicotine|4 mg nicotine lozenge experimental
223797278|NCT03762473|DRUG|Study Group|Patients will convert from current tacrolimus dose to an Envarsus dose that is 80% of the total tacrolimus dose. They will take envarsus once daily in the morning and have 24 hour trough levels monitored at the standard of care interval for tacrolimus. Dosing will be titrated to achieve goal levels.
223797279|NCT03762473|DRUG|Control Group|Post transplant patients (kidney transplant alone) performed between 10-2016 and time of enrollment with standard of care immunosuppression, no prior rejection, prior BK or opportunistic infection, whom had a negative BK screening at month 1 and concentration/dose of \< 1 at month 1, and BK data available and month 2,3, 6,9,12.
223797280|NCT04144842|BIOLOGICAL|ATOR-1017|ATOR-1017 is a human monoclonal antibody targeting 4-1BB (CD137)
223797281|NCT04982900|DRUG|furmonertinib|AST2818 is an irreversible and highly selective EGFR inhibitor independently discovered and developed by Allist. It has the potential to become the best-in-class drug in the third-generation EGFR-TKIs. Data from the preclinical studies and the completed clinical studies show that AST2818 has the following advantages: 1) AST2818 has good target selectivity and tissue distribution specificity; 2) The objective response rate of AST2818 for the patients with locally advanced or metastatic NSCLC with EGFR T790M mutation is outstanding, reaching 74.1% in the key registration clinical study; 3) AST2818 has a good safety profile and is well-tolerated; 4) AST2818 and its active metabolites have a superior ability to penetrate the blood-brain barrier, and have a good therapeutic efficacy on brain metastases frequently seen in patients with NSCLC.
223797282|NCT04982900|DRUG|Placebo|The placebo has the same appearance, weight, and physical and chemical properties as the study drug, and is provided by the researcher to the subjects in control group.
223797283|NCT01542606|DEVICE|NORMA-SENSE|The NORMA-SENSE gen 3 polymer matrix is stained by blue or green color on a pale yellow background when the pH level of the fluid in contact with it is greater than the cutoff value, and the user can consider any stain of color, which is different from the original background, as a positive result of the test.
223797284|NCT01229540|GENETIC|genetic analyzer|
223797285|NCT05598190|DEVICE|Pro-Yellow laser 577|4 session for cases with digtal photo before and after sessions
223797286|NCT04014764|OTHER|This is a non-interventional study|N/A. This is a non-interventional study. Following consent, the subject will have biospecimen samples taken during routine standard of care procedures, and provided to Sponsor for analysis. Optional research blood draws may occur at treating physician's discretion to obtain additional tissue samples.
223797287|NCT04824482|OTHER|Robot-assisted treadmill gait training (RTGT)|Locomotor training guided by the robotic device (Lokomat Hocoma) according to a pre-programmed gait pattern with the help of robot-driven exoskeleton orthoses. The process of gait training is automated and controlled by a computer under supervision of a physiotherapist.
223797288|NCT04824482|OTHER|Therapist-assisted treadmill gait training (TTGT)|Locomotor training via a repetitive execution of walking movements manually guided by a physiotherapist during treadmill gait training.
223797289|NCT05855980|PROCEDURE|Wound closure|Wound is closed or left open to heal secondarily after amputation.
223797290|NCT05132699|DRUG|Cannabidiol (CBD) oral solution|An oral strawberry flavored liquid, taken as a 2.5ml (250mg) dose twice a day
223797291|NCT05132699|DRUG|Placebo|An inert strawberry flavored oral solution, taken as a 2.5ml dose twice a day
223797292|NCT05132699|BEHAVIORAL|Massed Prolonged Exposure (mPE)|mPE, delivered daily Monday through Friday over two weeks, utilizes exposure-based interventions to target psychological mechanisms (i.e., experiential and behavioral avoidance; maladaptive cognitive changes) that are thought to maintain trauma-related symptoms.
223797293|NCT03533712|DIETARY_SUPPLEMENT|Fortified balanced energy-protein (BEP) supplement|"The product contains the following target nutrients:~* Total energy: 250-500 kcal per daily serving~* Fat content: 10-60% of energy intake~* Protein content: 16 g (range 14-18 g) with a Digestible Indispensable Amino Acid Score (DIAAS) of ≥ 0.9~* Carbohydrate (CHO) Content: no specific recommendations, relative to fat and protein content.~* Trans Fats: \<1% energy intake Micronutrients include the following: A, D, E, K, B1 (thiamin), B2 (riboflavin), B3 (niacin), B6 (pyridoxine), B9 (folate), B12 and C; minerals: iron, zinc, iodine, calcium, phosphorous, copper, and selenium.~The final composition of macro en micronutrients will be available after the acceptability testing (phase 1) and will be determined by 1) the product type and 2) the preferred taste."
223797294|NCT03533712|DIETARY_SUPPLEMENT|Fe and folic acid supplement|Routine iron and folic acid supplementation.
223797295|NCT03009526|DRUG|Sulfadoxine-pyrimethamine|500 mg sulfadoxine and 25 mg pyrimethamine
223797296|NCT03009526|DRUG|dihydroartemisinin-piperaquine|40 mg dihydroartemisinin and 320 mg piperaquine
223797297|NCT00375687|DRUG|Triptorelin|
223797298|NCT02421614|OTHER|high-protein low-carbohydrate diet with high olive oil|
223797299|NCT02421614|OTHER|high-protein low-carbohydrate diet with high sunflower oil|
223797300|NCT00786929|PROCEDURE|Catheter drainage|
223797301|NCT00786929|DRUG|Conservative treatment|
223797302|NCT00148967|DEVICE|Implantable Cardioverter Defibrillator|
223797303|NCT01437449|DRUG|Docetaxel|30 mg/m² by intravenous (IV) administration
223797304|NCT01437449|DRUG|Cisplatin|30 mg/m² by intravenous (IV) administration
223797305|NCT01437449|DRUG|Cetuximab|400 mg/m² by intravenous (IV) administration, thereafter 250 IV
223797306|NCT01437449|DRUG|Carboplatin|Area under the free carboplatin plasma concentration versus time curve (AUC)=2 by intravenous (IV) administration
223797307|NCT03880305|DIAGNOSTIC_TEST|complete blood count|complete blood count
223797308|NCT06178991|BIOLOGICAL|Influenza and COVID-19 Combination A|Combined influenza and Pfizer-BioNTech COVID-19 Vaccine
223797309|NCT06178991|BIOLOGICAL|Licensed influenza vaccine|Licensed influenza vaccine
223797310|NCT06178991|BIOLOGICAL|COVID-19 Vaccine|Pfizer-BioNTech COVID-19 vaccine
223797311|NCT06178991|BIOLOGICAL|Influenza and COVID-19 Combination B|Combined influenza and Pfizer-BioNTech COVID-19 vaccine
223797312|NCT06178991|BIOLOGICAL|Placebo|Saline Solution
223797313|NCT06178991|BIOLOGICAL|Investigational influenza vaccine|Investigational influenza vaccine
223797314|NCT06370598|BIOLOGICAL|TP-122A|Bacteriophage cocktail targeting Psa
223797315|NCT03451838|DIAGNOSTIC_TEST|Ultrasound|Ultrasound will be done to every pregnant lady
223797316|NCT03451838|DIAGNOSTIC_TEST|HbA1c level in blood|a blood sample will be taken to measure HbA1c level
223797317|NCT01367262|DRUG|LY2886721|Administered orally
223797318|NCT05716698|DIETARY_SUPPLEMENT|Pleurotus citrinopileatus after bio-optics (10 ug group)|The participants took D2 10ug per day for a total of 4 weeks.
223797319|NCT05716698|DIETARY_SUPPLEMENT|Pleurotus citrinopileatus after bio-optics (100 ug group)|The participants took D2 100ug per day for a total of 4 weeks.
223797320|NCT01204827|DEVICE|13C Methacetin Breath Test (BreathID)|
223797321|NCT02049086|BEHAVIORAL|SBIRT-PM|Screening, Brief Intervention and Referral to Treatment with Pain-Management advice (SBIRT-PM)
223797322|NCT02049086|BEHAVIORAL|Pain Module|The pain module of SBIRT-PM with no substance abuse focus (Pain Module Only)
223797323|NCT02858895|DRUG|MDNA55|MDNA55 is an engineered circularly permuted interleukin-4 (cpIL-4) genetically fused to the catalytic domain of the pseudomonas exotoxin A (PE).
223797324|NCT06651073|OTHER|Observational|There is no intervention involved in the study. It is purely observational.
223797325|NCT06824480|BEHAVIORAL|debriefing group|Women who volunteered to participate in the study and met the participation criteria were informed about the study. The first session will be held face to face in the clinic for 40 minutes. Then, the second session will be held by phone within 4-6 weeks after birth, with a total of 2 meetings with each woman for approximately 40 minutes.
223797326|NCT06824480|BEHAVIORAL|control group|he women in the control group will be asked how the birth went within 12-24 hours after birth by the researcher as part of their routine care, but no detailed analysis or interpretation will be made.
223797327|NCT05602376|BEHAVIORAL|U=U testing messaging scripts|On site testing days randomized to the intervention, trained health promoters employed by the mobile testing venues will use U=U messaging scripts to invite men in the vicinity to seek HIV testing services on that day. On intervention days, the U=U messaging will also be used by counselors at the testing venue when referring those who test HIV positive to clinic-based ART initiation services provided by the local Department of Health
223797328|NCT05602376|BEHAVIORAL|U=U adherence messaging scripts|After receiving standard ART initiation and adherence counselling from a DoH clinic nurse per South African National Guidelines, RCs will deliver a U=U message and hand participants a small business card with a brief U=U message on it. Participants will then receive monthly SMS booster messages (but can opt out) and monthly in-clinic booster messages during routine medical refill visits, again with a business card for messaging reinforcement.
223797329|NCT06600646|DIAGNOSTIC_TEST|Bronchoscopy|Bronchoscopy will be performed in patients with refractory or unexplained chronic cough and healthy controls.
223797330|NCT03163758|DEVICE|real Repetitive Transcranial Magnetic Stimulation|The rTMS treatments were performed using a Medtronic MagPro type magnetic stimulation device (Medtronic, Minneapolis, MN, USA) and a figure-of-eight coil (MC-B70, Medtronic). Coils were placed tangent to the scalp. The stimulation protocol involved 50 trains of 20 pulses applied over the ipsilesional M1 at a frequency of 5 HZ, with the stimulus intensity set at 120% of the resting motor threshold of the unaffected extremity.
223797331|NCT03163758|DEVICE|sham Repetitive Transcranial Magnetic Stimulation|The sham rTMS was performed on the same site as the rTMS treatment group but without any true stimulations. Coils were placed perpendicular to the scalp.
223797332|NCT06322108|DRUG|Botensilimab + Balstilimab|Botensilimab is a fragment crystallizable (Fc)-engineered human immunoglobulin G1 (IgG1) monoclonal antibody that targets cytotoxic T lymphocyte-associated protein 4 (CTLA-4). Balstilimab is a human monoclonal antibody that targets programmed cell death protein 1 (PD-1).
223797333|NCT06331000|DRUG|elexacaftor-tezacaftor-ivacaftor treatment|Effect of one year elexacaftor-tezacaftor-ivacaftor treatment on glucose tolerance abnormalities in adult patients with cystic fibrosis
223797334|NCT06665763|OTHER|Sodium Lactate Solution|Infusion of sodium-lactate solution
223797335|NCT06665763|OTHER|Saline infusion (placebo)|NaCl solution
223797336|NCT04907942|OTHER|EMA + EMA and FACE Stress|1 wk of EMA (2 daily surveys per day delivered during waking hours to evaluate momentary affects) plus 2 weeks of EMA and FACE stress
223797337|NCT04907942|OTHER|EMA Alone|Three weeks of EMA consisting of 2 daily surveys per day delivered during waking hours to evaluate ecological momentary affects.
223797338|NCT06670729|OTHER|Quran listening|listening to quran recitation via head phone
223797339|NCT06670729|OTHER|silent headphones group|headphones were silent, patient do not listen to any thing
223797340|NCT05501860|DRUG|AG-920|AG-920 Sterile Topical Ophthalmic Solution
223797341|NCT05501860|DRUG|Placebo|Placebo Sterile Topical Ophthalmic Solution
223797342|NCT01818323|OTHER|Intra-tumoral T4 immunotherapy|Intra-tumoral administration of a single dose of T4-positive patient-derived T-cells (at five escalating dose levels) contained within 1-4 mL. Cohort 6 patients receive CAR T-cells (dose level 3) after lymphodepletion with fludarabine and cyclophosphamide. Cohort 7-8 patients receive T4 cells after lymphodepletion as above, combined with 4 doses of nivolumab.
223797343|NCT05520138|DRUG|Enzalutamide|As provided in real-world setting
223797344|NCT05520138|DRUG|Abiraterone acetate|As provided in real-world setting
223797345|NCT06628921|DRUG|Eptinezumab 100 or 300 mg ev|Eptinezumab administered for migraine prevention in patients but with ongoing migraine attacks.
223797346|NCT06630871|DRUG|Distitamab Vedotin in combination with Tislelizumab|On the day after the initial TURBt procedure, use trastuzumab (200mg)+ Distitamab Vedotin (120mg \[≤ 60Kg\] or 2.0mg/Kg \[\>60Kg\]) every 3 weeks (Q3W). Simultaneously arrange for the patient to complete a second TURBt within 6 weeks, and continue to use 3 courses of Trastuzumab+Vediximab (Q3W) after surgery until the endpoint of 3-year follow-up
223797347|NCT02038673|DRUG|ASP5878|oral
223797348|NCT06732232|DRUG|CD19/CD20/BCMA CAR-T|CD19/CD20/BCMA CAR T therapy
223797349|NCT07128017|BEHAVIORAL|Mindfulness-Based Cognitive Therapy (Internet-delivered)|A 4-week (30 days), unguided online adaptation of the Mindfulness-Based Cognitive Therapy (MBCT) program. The intervention consisted of six sequential modules delivered through a secure web platform, including guided mindfulness meditations, body scan, mindful movement, and cognitive-behavioral exercises. Participants received audio recordings, written materials, and reflective tasks, along with automated reminder emails. No therapist guidance was provided.
223797350|NCT07128017|BEHAVIORAL|Progressive Muscle Relaxation (Internet-delivered)|A 4-week, unguided online progressive muscle relaxation (PMR) program adapted from Bernstein and Borkovec's protocol. The program included six sequential modules teaching systematic tensing and relaxing of major muscle groups, gradually reducing the number of groups until relaxation could be achieved through recall alone. Materials included audio recordings, written instructions, and automated reminder emails. No therapist guidance was provided.
223797351|NCT07128017|BEHAVIORAL|No Intervention - Waitlist Control|Participants in this arm received no active intervention during the 4-week waitlist period but completed all study assessments on the same schedule as intervention arms. After the waiting period, participants were offered the choice to take part in either the online MBCT or PMR program.
223797352|NCT02725554|DEVICE|StimRelieve Halo System|The StimRelieve Halo System is intended as the sole mitigating agent, or as an adjunct to other modes of therapy used in a multidisciplinary approach for chronic migraine as defined by the Third edition of the International Classification of headache disorders (ICDH-3). The system provides treatment by delivering small controlled electrical pulses to the occipital and supraorbital nerves, as it has been shown that for chronic migraine headaches the response to combined systems appears to be substantially better than occipital nerves stimulation alone.
223797353|NCT06776614|PROCEDURE|Decompressive Craniectomy|"The DC will be performed through a standard trauma incision, a retro-auricular C-shape or a Kempe incision and execute a 15x15 cm craniotomy with a C-shape durotomy. Dural closure will be at the discretion of the surgeon and the availability of resources, including duroplasty with aponeurotic galea, a suturable dural patch, a non-suturable dural patch, or simply a superficial dural cover with hemostatic materials like Surgicel® or Gelfoam®. There are multiple techniques for DC. The elected technique will be at the discretion of the treating neurosurgeon, but only front-parietal-temporal DC will be considered. The removed bone flap may be stored in an abdominal pouch in the right or left upper abdominal quadrants or by freezing in a bone or blood bank freezer."
223797354|NCT06776614|PROCEDURE|Expansion Craniotomy|"The EC will be performed through a retro-auricular C-shape incision and executing a 15x15 cm craniotomy with a C-shape durotomy. Dural closure will be at the discretion of the surgeon and the availability of resources, including duroplasty with aponeurotic galea, a suturable dural patch, a non-suturable dural patch, or simply a superficial dural cover with hemostatic materials like Surgicel® or Gelfoam®. The expansion craniotomy will be finished with a cranioplasty using a full set of 3-5 Rialto plates for bone graft closure. The selected technique will be at the discretion of the treating neurosurgeon, but only front-parietal-temporal EC will be considered."
223797355|NCT06140121|BEHAVIORAL|Virtual Reality Physical Therapy|Participants are allowed to freely choose one game from the game list. Participant will be asked to wear a validated activity tracker - ActiGraph. Baseline heart rate will be collected for 1 minute. Participants will be wearing the ActiGraph during Physical Therapy session. Participants receiving VR intervention will be instructed to wear an Oculus Quest 2 headset (Meta, Inc., Menlo Park, CA) and participate in VR applications under the supervision of the physical therapist.
223797356|NCT06140121|BEHAVIORAL|Traditional Physical Therapy|Participants will receive traditional Physical Therapy sessions (standard care) under the supervision of the accredited physical therapist. Participants will be wearing the Actigraph during Physical Therapy session. Participants will perform regular physical exercise, such as 20 minutes walking or biking on a stationary bike, under the supervision of a physical therapist.
223797357|NCT06573970|DRUG|Atomoxetine|Atomoxetine is a selective norepinephrine reuptake inhibitor medication used to treat attention deficit hyperactivity disorder (ADHD), and executive dysfunction. Dispensing of blinded medication (40mg to 80mg ATX or placebo) will begin at randomization and will be dispensed at weeks 2, 4, 8, and 12. The initial dose of ATX is 40mg or placebo and will be given for one week, the dose will be titrated to 80mg if tolerated in the second week through week 12.
223797358|NCT06573970|DRUG|Placebo|placebo pill appears like real atomoxetine pill but has no therapeutic ingredient and benefit. The same schedule to distribution as Atomoxetine arm.
223797359|NCT05763420|DEVICE|AH Plus Bioceramic Sealer|A bioactive, calcium silicate-based sealer will be used in combination with the core root canal filling material (gutta-percha). It's premixed and is dispensed in the root canal via a fine disposable syringe.
223797360|NCT05763420|DEVICE|AH Plus Sealer (resin-based)|A resin-based sealer will be used in combination with the core root canal material (gutta-percha). It consists of two pastes that are mixed together in equal amounts prior to application.
223797361|NCT06668350|OTHER|Smoking outcomes|Participants will be assessed on several smoking outcomes including puffing behavior, subjective effects, and exhaled carbon monoxide
223797362|NCT04894643|RADIATION|Proton Ions|According to the radiation plan (between 50.4 and a maximum of 60.2 Gy) after Chemotherapy with Nab-PACLitaxel (Abraxane®) + Gemcitabine and concomitant to Capecitabine.
223797363|NCT04894643|DRUG|Nab-PACLitaxel|"Chemotherapy will be delivered upfront for three cycles (week 2-4, week 6-8 and week 10-12) with combined Nab-PACLitaxel (Abraxane®) and Gemcitabine Therapy.~It will be administered as intra venous infusion over 30 minutes."
223797364|NCT04894643|DRUG|Gemcitabine|"Chemotherapy will be delivered upfront for three cycles (week 2-4, week 6-8 and week 10-12) with combined Nab-PACLitaxel (Abraxane®) and Gemcitabine Therapy.~Gemcitabine will also be administered as intra venous infusion over 30 minutes immediately after Nab-PACLitaxel."
223797365|NCT04894643|DRUG|Capecitabine|Concomitant to proton-radiotherapy (on the same days, within week 14-19)
223797366|NCT04894643|PROCEDURE|Surgical resection of the pancreas (when feasible)|Pre surgical re-evaluation will be performed at week 21 after enrollment. Patients fulfilling surgery-entry criteria, which consist of no distant metastasis, no massive ascites, no massive pleural effusion, no serious infection, no serious, unresolved chemoradiotherapy related, adverse events and adequate organ system function, will undergo surgery on week 22 (± 1 week). This should be performed via laparotomy.
223797367|NCT05694559|BEHAVIORAL|Genetic Testing and Counseling|Participants will complete testing
223797368|NCT05694559|BEHAVIORAL|Screening Form|Participants will complete forms with demographics and history
223797369|NCT07109700|DRUG|HDM1005 1|administered SC, QW, 20 weeks
223797370|NCT07109700|DRUG|HDM1005 2|administered SC, QW, 20 weeks
223797371|NCT07109700|DRUG|HDM1005 3|administered SC, QW, 20 weeks
223797372|NCT07109700|DRUG|HDM1005 4|administered SC, QW, 20 weeks
223797373|NCT07109700|DRUG|Placebo|administered SC, QW, 20 weeks
223797374|NCT07109700|DRUG|Dulaglutide 1.5 MG|administered SC, QW, 20 weeks
223797375|NCT07111364|OTHER|observational diagnostic model development|observational diagnostic model development
223797376|NCT06932406|OTHER|Self-management intervention|"This intervention will implement a self-management protocol. It will consist in 5 strategy levels: educational concepts and dynamics, cognitive behavioural tools and processes, therapeutic exercise of the orofacial region, guidelines and strategies for lifestyle modification and mindbody tools.~Several of the above 5 strategies will be employed in each session. Education will include TMD concepts, pain neurophysiology, contextualisation of pain in terms of perceived stress, anxiety and others. Exercises will aim to train motor control, strength and mobility. Cognitive behavioural tools will be used to modulate pain relationship through behaviour modification. Processes such as cognitive distraction, gradual exposure to movement or the scheduling of self-care activities will be used. Mindbody strategies such as relaxation exercises and pain acceptance will seek to reduce the patient's frustration with pain. Structured guidelines will be included to achieve desirable lifestyle changes."
223797377|NCT06932406|OTHER|Clinical Practice Guideline Intervention|"Following the guidelines, 5 sessions of education, cognitive behavioural tools, jaw exercises and manual therapy will be conducted.~The educational sessions will teach about TMD and basic pain concepts. A single type of cognitive behavioural tool will be employed. The aim will be to decrease bruxing and parafunctional activity during wakefulness. This will be done by training the jaw relaxation position, which will then be generalised to activities of daily living with the help of some conditioning through positive and negative reinforcement. Exercise activities will aim to train motor control, strength and mobility. Manual therapy will be carried out in the orofacial region by means of soft tissue techniques and joint mobilisation."
223797378|NCT06231693|DRUG|Trastuzumab deruxtecan|Patients with RE\<10% and HER2-Low breast cancer that have received Trastuzumab-deruxtecan in the metastatic setting
223797379|NCT03049046|DRUG|CC100|synthetic caffeic acid phenethylester
223797380|NCT03049046|DRUG|Placebos|Diluent
223797381|NCT03216876|DRUG|Ursolic acid|Ursolic acid (UA) is a natural triterpenoid carboxylic acid, which has been studied for its anti-proliferative and anti-inflammatory activities.
223797382|NCT06951789|OTHER|Molecular hydrogen|Hydrogen gas, purity \>99.9%, flow rate 600 ml/min (two generators 300 ml/min each).
223797383|NCT06951789|OTHER|Placebo|Ambient air, flow rate 600 ml/min (two pumps 300 ml/min each).
223797384|NCT05467176|DRUG|Relugolix|Relugolix 120-mg tablet administered orally once daily following an oral loading dose of 360 mg (3 x 120-mg tablets) on Day 1
223797385|NCT02728388|DRUG|aminolevulinic acid|"Drug: Levulan Kerastick~Drug: Topical placebo~Device: Omnilux Revive~Procedure: Photodynamic therapy~Other: Tumor growth rate measurements"
223797386|NCT02277444|DRUG|Golimumab|Golimumab 80 mg/m\^2 IV infusion at Weeks 0, 4, and every 8 weeks through Week 244. At Week 252, participants who meet the criteria for the optional Extended Treatment Period (ETP) may continue treatment with golimumab 80 mg/m\^2 every 8 weeks after completion of the Week 252 assessments.
223797387|NCT02277444|DRUG|Methotrexate|Methotrexate BSA-based dose (10 to 30 mg/m\^2 per week for participants with BSA \<1.67 m\^2, or minimum of 15 mg/week for participants with BSA \>=1.67 m\^2) weekly at least through Week 28.
223797388|NCT03576768|DEVICE|Real cTBS|This will be delivered with the Magventure Magpro system; 600 pulses with the active sham coil (double blinded using the USB key)
223797389|NCT03576768|DEVICE|Sham cTBS|This will be delivered with the Magventure Magpro system; 600 pulses with the active sham coil (double blinded using the USB key). The MagVenture MagPro system has an integrated active sham that passes current through two surface electrodes placed on the skin beneath the B60 coil.
223797390|NCT03576768|DEVICE|Real iTBS|This will be delivered with the Magventure Magpro system; 600 pulses with the active sham coil (double blinded using the USB key).
223797391|NCT03576768|DEVICE|Sham iTBS|This will be delivered with the Magventure Magpro system; 600 pulses with the active sham coil (double blinded using the USB key). The MagVenture MagPro system has an integrated active sham that passes current through two surface electrodes placed on the skin beneath the B60 coil.
223797392|NCT06154343|DRUG|GQ1005|an antibody drug conjugate
223797393|NCT03888339|PROCEDURE|Commercially available high abutments placement|Patients will be randomly selected for the commercially available high abutments option. Two or three implants will be placed following the drilling protocol suggested by the manufacturer. Implants will be placed 0.5mm subcrestal. Once the implants have been placed, periapical radiographs and clinical pictures will be taken. Implants will be uncovered 10 weeks after being placed. After performing the incision and elevation a minimal flap, conventional high transmucosal abutments will be screwed using the torque recommended by the manufacturer. Once the abutments have been screwed, periapical radiographs and clinical pictures will be taken. The abutments will not be unscrewed thereafter throughout the study.
223797394|NCT03888339|PROCEDURE|Modified shape abutments|Patients will be randomly selected for the modified shape abutments option. Two or three implants will be placed following the drilling protocol suggested by the manufacturer. Implants will be placed 0.5mm subcrestal. Once the implants have been placed, periapical radiographs and clinical pictures will be taken. Implants will be uncovered 10 weeks after being placed. After performing the incision and elevation a minimal flap, modified high transmucosal abutments will be screwed using the torque recommended by the manufacturer. Once the abutments have been screwed, periapical radiographs and clinical pictures will be taken. The abutments will not be unscrewed thereafter throughout the study.
223797395|NCT00061802|DRUG|risperidone, quetiapine|
223797396|NCT00785291|BIOLOGICAL|Bevacizumab|Given IV
223797397|NCT00785291|DRUG|Ixabepilone|Given IV
223797398|NCT00785291|OTHER|Laboratory Biomarker Analysis|Correlative studies
223797399|NCT00785291|DRUG|Nab-paclitaxel|Given IV
223797400|NCT00785291|DRUG|Paclitaxel|Given IV
223797401|NCT00785291|OTHER|Questionnaire Administration|Ancillary studies
223797402|NCT05202925|OTHER|Musical Training Program|a weekly 45-minute lesson, one-to-one musical training
223797403|NCT03110341|DRUG|Erythropoietin|rhEPO 750U/kg was injected within 72h after birth, subsequent injection was given every other day for 2 weeks (a cumulative dose of 5,250U/kg over the course of 7 separate intravenous injections.
223797404|NCT03110341|DRUG|Normal saline|placebo (Normal saline 3 ml/kg birth weight) was injected within 72h after birth, subsequent injection was given every other day for 2 weeks.
223797405|NCT05543291|BEHAVIORAL|renal function|levels of eGFR
223797406|NCT02877511|DRUG|BAY987517|Applied liberally to the skin (Formulation: Y73-161
223797407|NCT02877511|DRUG|Sunscreen Lotion (Y65-110)|Applied liberally to the skin
223797408|NCT04967768|OTHER|Questionnaire about impact of the COVID-19 pandemic on orthopaedic resident training|Answers were collected for the effects of the COVID-19 pandemic on the real-life experiences of orthopaedic residents
223797409|NCT00235092|DEVICE|Cypher Sirolimus-Eluting Stent|
223797410|NCT00235092|DEVICE|Taxus Paclitaxel-Eluting Stent|
223797411|NCT06064084|DIAGNOSTIC_TEST|Oral glucose tolerance test|Oral glucose tolerance test 50g
223797412|NCT06064084|OTHER|Intravenous isoglycaemic glucose clamp|Intravenous isoglycaemic glucose clamp
223797413|NCT06064084|OTHER|Liquid Mixed meal test|Liquid Mixed meal test 520 kcal
223797414|NCT05144932|DEVICE|Stroke Alarm|The patients are in this clinical trial instructed to use the device continuously for 1 month.
223797415|NCT03151980|PROCEDURE|Hamam treated skin and sun exposure|Hamam is a skin treatment (soaping and scrubbing).
223797416|NCT03151980|OTHER|Untreated skin and sun exposure|Skin that will not receive Hamam.
223797417|NCT03103243|BEHAVIORAL|Mindfulness Based Group Sessions|In-person group intervention sessions conducted with a combination of meditation, group exercise (yoga), group discussions, deep breathing and other mindfulness based practices.
223797418|NCT03578003|OTHER|Morning Bright Light Therapy|60 minutes of bright light therapy (10,000 lux) received within 90 minutes of waking
223797419|NCT04159974|DRUG|Durvalumab 50 MG/ML|IV Infusion
223797420|NCT04159974|DRUG|Tremelimumab|IV Infusion, Combination with Durvalumab
223797421|NCT05877443|PROCEDURE|Open system|Oxygen delivered on open system, for example high flow nasal cannula or low flow oxygen by nasal cannula or face mask
223797422|NCT05877443|PROCEDURE|Non-invasive mechanical ventilation|Respiratory support by for example continues or bilevel positive airway pressure
223797423|NCT05877443|PROCEDURE|Invasive mechanical ventilation|Respiratory support delivered through endotracheal tube or tracheostomy
223797424|NCT01928420|DRUG|Drug: NIC5-15|A natural product, found in many foods and plants with mild insulin sensitizing effects
223797425|NCT01928420|DRUG|Placebo|Subjects with Alzheimer's Disease placebo comparator
223797426|NCT01741376|DRUG|Progesterone|Progesterone 200 mg twice daily
223797427|NCT01741376|DRUG|Placebo|
223797428|NCT02979639|BIOLOGICAL|GSK Biologicals Herpes Zoster subunit (HZ/su) vaccine (GSK 1437173A)|2 doses administered by intramuscular (IM) injection into the deltoid muscle of the non-dominant arm on a 2 month schedule.
223797429|NCT04837300|OTHER|Resisted Sprint Traininig|The Participants in this group had received plyometrics exercises; double leg jumping, drop jumping, hopping, bounding and hurdling.
223797430|NCT02344043|DEVICE|Near infrared spectroscopy|This device uses near infrared spectroscopy to measure tissue oxygen levels (0-100%). The sensors are placed on the subjects' forehead to measure brain tissue oxygenation
223797431|NCT01477125|BEHAVIORAL|Flex working memory training|30-40 minutes of working memory training, 5 days a week for 5 weeks
223797432|NCT04584034|DRUG|Salbutamol|Salbutamol will be delivered using a Babyhaler spacer device. Ventolin will be used, brandname for Salbutamol sulfate. Ventolin contains the propellant HFA 134a.
223797433|NCT04584034|DRUG|Placebo|The placebo will be delivered using a Babyhaler spacer device. The placebo will contain only the propellant HFA 134a.
223797434|NCT03464968|DRUG|Oxaliplatin,5FU, leucovorin|mFOLFOX
223797435|NCT03464968|DRUG|irinotecan,5FU, leucovorin|mFOLFIRI
223797436|NCT01394965|PROCEDURE|ECG electrodes|Cardiac mapping of patients before and after ablation to develop future treatment/diagnostic options for cardiac patients.
223797437|NCT02646228|OTHER|molecular profiling, patient derived cells|"molecular profiling,patient derived cells sample and experimental methods-Blood sample,tumor tissue or primary cultures of human effusions.~Malignant ascites, pleural effusions, or pericardial effusions will be collected from patients with metastatic cancer."
223797438|NCT03348579|OTHER|Guidelines publication and application|Passing recommendations on using the guidelines in the intensive care units
223797439|NCT03348579|OTHER|Targeted experience feedback|"Targeted experience feedback: On top of the standard training, the centers receive an analysis of the evolution of the practices of their center and the future of their patients between phases 1 and 2, as well as these same values for the data set. The centers are then called to conduct a meeting to determine their priority improvement points based on this audi"
223797440|NCT05824065|DRUG|OMA102|1 mg
223797441|NCT05824065|DRUG|OMA102|2 mg
223797442|NCT05824065|DRUG|Placebo|OMA102 - Placebo
223797443|NCT04050865|DRUG|Dexamethasone, 0.4mg|Ophthalmic Insert
223797444|NCT04050865|DEVICE|Placebo plug with no drug|Ophthalmic Insert
223797445|NCT01466985|DRUG|Doravirine|Doravirine tablets, orally, once daily for 7 days at a dose of 25 mg in Panel A and 200 mg in Panel B; dose in Panel C to be determined (≤200 mg).
223797446|NCT01466985|DRUG|Placebo|Placebo tablets once daily for 7 days.
223797447|NCT06105073|PROCEDURE|Pulmonary Rehabilitation Program|Consecutive patients who attend with a confirmed diagnosis of Systemic Sclerosis associated Interstitial Lung disease, at the Speciality Hospital from the Medical Center La Raza IMSS. The anxiety and depression questionnaire will be applied to them. Goldberg, as well as the SF-36 questionnaire to evaluate quality of life and the SySQ questionnaire to evaluate functionality, to include these data in the analysis, these questionnaires are validated in our population and have been widely used. All participants (T0) will undergo Forced Spirometry, Carbon Monoxide Diffusion Capacity and Cardiopulmonary Exercise Test. Then they will enter a supervised pulmonary rehabilitation program that consists of 36 sessions, which is equivalent to 12 weeks. At the end of this period (T1), again the respiratory function tests (spirometry, DLCO and Cardiopulmonary Exercise Test) as well as the Goldberg, SF-36 and SySq questionnaires.
223797448|NCT03500614|BEHAVIORAL|Air cleaner use method 1|All interventions in the first cohort will start at noon on Tuesday or Thursday and continue to the next morning of Tuesday or Thursday.
223797449|NCT03500614|BEHAVIORAL|Air cleaner use method 2|All interventions in the second cohort will start from the beginning to the end of smog episodes.
223797450|NCT00877643|OTHER|Upstream therapy|Aldosterone receptor antagonists and statins, dietary restrictions, counseling, and cardiac rehabilitation.
223797451|NCT00877643|OTHER|Conventional rhythm control|Usual care for atrial fibrillation and heart failure according to the present guidelines
223797452|NCT05338723|DRUG|Rosuvastatin 20mg|20 mg of oral rosuvastatin 24 hours prior to the first cycle of chemotherapy and once daily for the rest of the follow-up period (6 months).
223797453|NCT01096992|DRUG|Bendamustine|"Phase 1: Starting Dose of 20 mg/m2 IV on Days 1,2,3 (after fludarabine)~Phase 2: 30 mg/m2 by vein (fixed) on Days 1,2,3 (after fludarabine)"
223797454|NCT01096992|DRUG|Fludarabine|Course 1: 20 mg/m2 intravenous (IV) on Days 2,3,4 Courses 2-6: 20 mg/m2 IV, Days 1,2,3
223797455|NCT01096992|DRUG|Rituximab|Course 1: 375 mg/m2 IV, Day 4 (after fludarabine) Courses 2-6: 500 mg/m2 IV, Day 1
223797456|NCT04047043|DIAGNOSTIC_TEST|serum taurine|blood sample for serum taurine level
223797457|NCT01762150|DRUG|Sorafenib|Sorafenib 400mg BID by oral until progressed;
223797458|NCT01762150|DRUG|Gemcitabine|Gemcitabine: 1000mg/m2, administered by intravenous drip for 30\~60min on Day 1 and 8,for 4 cycles;
223797459|NCT01762150|DRUG|Cisplatin|Cisplatin: 25mg/m2, administered by intravenous drip on Day 1-3, with appropriate liquid hydration,for 4 cycles.
223797460|NCT02594748|BEHAVIORAL|Self-management education|The intervention group will receive diabetes self-management education based on the idea of extended theory of planned behavior .
223797461|NCT02594748|BEHAVIORAL|Routine care|They will attend the routine lecture in hospital sit and listen, usually 1-2 times during one week in hospital
223797462|NCT04205630|DRUG|SYD985|SYD985 powder for concentrate for solution for infusion
223797463|NCT00155389|DRUG|Helicobacter pylori eradication|"For subjects who received the first-line treatment, the costs included the initial 13C-UBT, one-week triple therapy (esomeprazole 40mg once daily, amoxicillin 1g twice daily, and clarithromycin 500mg twice daily), and the confirmatory 13C-UBT. For subjects in whom the initial treatment failed, the costs further included the re-treatment consisting of ten-day triple therapy (esomeprazole 40mg once daily, amoxicillin 1g twice daily, and levofloxacin 500mg once daily), and the confirmatory 13C-UBT.~The first round of study was between 2004 and 2005, the second round was between 2008 and 2009, and the third round was between 2012 and 2013."
223797464|NCT04526535|DIAGNOSTIC_TEST|Lung ultrasound|Lung ultrasound performed with a portable device with an 8 zones protocol within the first 24 hours after and ST-segment elevation acute myocardial infarction
223797465|NCT01247402|DEVICE|drug eluting balloon angioplasty|3 microgram Paclitaxel/mm2 on balloon, 60s application
223797466|NCT01247402|DEVICE|standard balloon angioplasty|standard balloon angioplasty
223797467|NCT05017922|PROCEDURE|transarterial chemoembolization combined with endoscopic therapy|TACE: The tip of the catheter was advanced into tumor-feeding artery based on the tumor location and size. 5-Fu was injected. Then the chemolipiodolization was performed, using oxaliplatin, epirubicin and lipiodol. If stagnant flow did not realized, then injected pure lipiodol. If the tumor-feeding artery still cannot be completely embolized, several absorbable gelatin sponge particles would be injected. Endoscopic therapy: After the site of esophageal varices was identified by the gastroscopy, spiral ligation using the EVL device (COOK, MBL-6-F) was performed and ensure the varices were fully inhaled, 1-3 rubber bands were used totally. After EVL, water was sprayed to the ligation sites to check for bleeding. If gastric varices were found, EIS was performed using the 'sandwich method' of hypertonic glucose-tissue adhesive-normal saline. Make sure the needle entered the varieose vein before inject drugs, and repeated the injection if necessary.
223797468|NCT05005780|DEVICE|Negative peak triggered 100 Hz triplet burst TMS|MagVenture MagPro X100: Ipsilesional negative peak triggered 100 Hz triplet burst TMS.
223797469|NCT05005780|DEVICE|1 Hz rTMS|MagVenture MagPro X100: Contralesional 1 Hz rTMS.
224264121|NCT03371186|OTHER|CB-Integrated Management of Newborn and Childhood Illness|Safe delivery care; effective neonatal resuscitation; management of childhood diarrhea, malnutrition, and pneumonia; and treatment of traumatic and congenital surgical conditions can reduce child mortality. Community Based Integrated Management of Newborn and Child Illness (CB-IMNCI) has shown substantial reductions in neonatal and early child mortality. Community Health Workers will use CB-IMNCI as the clinical protocol for ongoing care to the community.
224264122|NCT03371186|OTHER|Group Antenatal and Postnatal Care|The proposed model will change antenatal and pediatric care in three major ways: 1) conduct care in a group setting, 2) provide expert and facilitated peer counseling, and 3) incorporate emergency planning. The group setting is designed to create a supportive social network among women facing similar challenges. The opportunity for counseling beyond the current standard will promote detailed emergency planning and the sharing of context-specific advice from peers to overcome barriers to access care. This intervention draws on the strength within communities of women to change health-seeking behaviors.
223797470|NCT01393782|DRUG|Angiotensin II|All patients will have their vasopressors titrated to a mean arterial pressure (MAP) of 65 mm of Hg (standard MAP goal in the ICU for patients suffering from shock). Patients will then be randomized to control or IV AII. In the interventional arm, AII will start at a dose of 20ng/kg/min; the dose can then be titrated up to 30ng/kg/min, and then to 40ng/kg/min. The intervention will last for 6 hours. Each patient will start with the assigned starting dose indicated above. After the first hour, if the patient is still requiring standing norepinephrine (the standard vasopressor for the treatment of shock in the GW ICU), the dose of the control/interventional drug can be increased 50%. After the second hour, if the patient is still requiring a standing dose of norepinephrine, the control/interventional can be increased again to twice the initial dose. At the end of 6 hours, the study drug will be titrated off.
223797471|NCT01677273|DIETARY_SUPPLEMENT|Hydrolyzed casein|30 g protein/supplement, 4 supplements/visit
223797472|NCT01677273|DIETARY_SUPPLEMENT|Intact casein|30 g protein/supplement, 4 supplements/visit
223797473|NCT01677273|DIETARY_SUPPLEMENT|Intact whey protein|30 g protein/supplement, 4 supplements/visit
223797474|NCT06096493|PROCEDURE|curative surgery for cancer rectum|Curative surgery for cancer rectum.
223797475|NCT00433901|BEHAVIORAL|Targeted parental instruction for positive lifestyle change with follow-up calls.|
223797476|NCT01911403|PROCEDURE|Manual compression|Closure procedure by Manual compression
223797477|NCT01911403|DEVICE|Angio-Seal|Closure procedure by angio-Seal
223797478|NCT00587327|DRUG|Barusiban|Solution for IV treatment. Bolus and infusion for 4 hours
223797479|NCT00587327|DRUG|Atosiban|Solution for IV administration. Bolus and infusion for 4 hours
223797480|NCT00587327|DRUG|Placebo|Saline solution for IV administration. Bolus and infusion for 4 hours.
223797481|NCT01605929|PROCEDURE|Retroclavicular Brachial Plexus Block and Catheter Insertion|A Sonosite ultrasound machine will be used to visualize the nerve and needle simultaneously. A Braun 18 g 4 inch Touhy needle with markings will be inserted into the skin and advanced toward the nerve. Once the optimal location is determined under ultrasound visualization, the local anesthetic, mepivacaine, will be injected beside the nerves. The dose of drug will be mepivacaine 1.5%, 0.5 cc/kg (with a minimum 30 cc and maximum of 50 cc.) A Braun 20 g closed tip polyamide catheter will be inserted next to the nerve and left in place to allow for additional medication to be given postoperatively.
223797482|NCT00863252|DRUG|mycophenolate mofetil|Orally at 0.75 g bd to 1 g bd for 6 months
223797483|NCT00863252|DRUG|angiotensin blockade|Continuation of angiotensin blockade
223797484|NCT02328833|OTHER|Experimental strategies of guidelines implementation|Experimental strategies of Depression Guidelines implementation in Primary Care Centers. The active process includes the establishment of local implementation teams, seminars, regular feedback and follow-up visits for four months.
223797485|NCT02785341|OTHER|questionnaires every 6 weeks (T0, T1, T2, T3 and T4)|Questionnaire MFI 20 Questionnaire life satisfaction Scale of measurement of the positive and negative affects Questionnaire QLQ-C30 (EORTC) Questionnaire on the personal goals
223797486|NCT02785341|OTHER|6-minute walk test) every 6 weeks (T0, T1, T2, T3 and T4)|
223797487|NCT02785341|OTHER|leptin level with a blood test every 12 weeks (T0, T2 and T4)|blood sample
223797488|NCT03432923|DRUG|Benzocaine 8 mg|Benzocaine 8 mg, oval, white to slightly beige to yellow film coated tablet. One lozenge to be dissolved slowly in the mouth every 2 hours. Max 6 per day, max treatment 5 days.
223797489|NCT03432923|DRUG|Placebo|Placebo, oval, white to slightly beige to yellow film coated tablet. One lozenge to be dissolved slowly in the mouth every 2 hours. Max 6 per day, max treatment 5 days.
223797490|NCT00476216|DRUG|Combination of Arixtra with chemotherapy|"Single arm, 2 cohort feasibility study:~Carboplatin will be administered intravenously over approximately 30 minutes after paclitaxel infusion is completed and the dose will be calculated on basis of an area under the curve (AUC) of 6, according to the formula administered every 21 days. Paclitaxel will be administered 200 mg/m2 over 3 hours every 21 days.~Patients in both cohorts 1 \& 2 will receive standard chemotherapy alone during cycle 1.~Cohort 1:During subsequent cycles (2-4) patients will receive a daily prophylactic dose (day 1 through 21) of Arixtra and continue 21 days after the last course of chemotherapy.~Cohort 2: Patients in cohort 2 will receive standard chemotherapy alone during cycle 1. During subsequent cycles, the patient will receive a therapeutic weight based dose of Arixtra for the first 2 days of each chemotherapy cycle followed by a daily prophylactic dose of Arixtra (day 3 through 21) until the next course of chemotherapy."
223797491|NCT05031364|BEHAVIORAL|Behavioral Interventions for Anxiety in Children with Autism (BIACA)|In the BIACA CBT program (e.g., Wood et al., 2020), clinicians work with families for 16 weekly sessions that include both the child and parent(s). In BIACA, anxiety, rigidity and inflexible routines, and irritability are all addressed using in vivo exposure therapy strategies during sessions as well as parent (and teacher) training to promote regulation across settings. ASD-related clinical needs that can impact mental health and emotion regulation such as friendship skills and social entry skills (e.g., joining games at school) are addressed with modeling, self-management, and parent- (or teacher-) implemented social coaching in daily settings. For youth with limited communication, therapy is adapted through the use of play-based representations of challenging situations and an emphasis on more action-oriented exposure therapy.
223797492|NCT05031364|BEHAVIORAL|Treatment-as-Usual Supplemented by Internet-Based Self-Instruction (MEYA)|Participating clinicians are expected to have varied training in numerous psychological therapy procedures (e.g., insight-oriented procedures, cognitive interventions, family therapy, etc.), any or all of which they may choose to implement with a participating child. These practices will be characterized through the Therapy Procedures Checklist (Weersing et al., 2002). Additionally, participating clinicians will be provided with information about self-instruction resources on CBT for children with autism, namely, the Modular Evidence-Based Practices for Youth with Autism (MEYA) website developed by our research group. MEYA is freely accessible to clinicians worldwide at meya.ucla.edu. MEYA incorporates treatment elements of both BIACA (Wood et al., 2020) and SEBASTIEN (Wood et al., 2021), which was designed to address additional autism-related clinical needs (e.g., reciprocal conversation). Clinicians in this arm will provide up to 16 therapy sessions.
223797493|NCT06367205|DRUG|Goal-Directed Fluid Therapy (GDFT)|Norepinephrine will be administered intravenously at a rate of 0.06 µg/kg/min, followed by the implementation of fluid therapy guided by SVV until reaching our target. In instances where SVV ≤ 13%, indicative of adequate effective circulating blood volume, the fluid infusion rate will be adjusted to 1 ml/kg/h. Conversely, if SVV \> 13%, denoting inadequate effective circulating blood volume, a rapid infusion of 1 ml/kg of crystalloid fluid will be administered over 2 minutes, with subsequent observation of fluid reactivity after a further 2-minute interval. This process is reiterated until SVV ≤ 13% is attained. Should SVV \> 13% recurs during surgery, the aforementioned intervention is repeated.
223797494|NCT06367205|DRUG|Regular Fluid Therapy|Anesthesiologists will rely on their clinical expertise and intraoperative circulatory hemodynamic assessment to regulate fluid infusion rates and administer medications as necessary
223797495|NCT03638895|DEVICE|ECAL Indirect Calorimeter|The ECAL is an open-circuit portable indirect calorimeter that measures both volume of CO2 expired and O2 consumed using a small mixing chamber. Participants will breathe through a mouthpiece with a nose clip applied whilst lying in a restful and comfortable position for 15 minutes. ECAL device will provide breath-by-breath measurements of the resting energy expenditure and respiratory quotient which will allow both practitioners and participants to monitor their metabolic health and compare the effect of dietary and physical activity intervention over the course of the structured intensive lifestyle intervention (24-weeks).
223797496|NCT03638895|BEHAVIORAL|Diet, exercise & behaviour modification therapy|Standard care (SC) - participants receive standard care (diet, exercise \& behaviour modification therapy) as part of the multicomponent weight management intervention within the tier 3 weight management service. Practitioners will rely on standard predictive equations to provide dietary advice and intervention.
223797497|NCT05759416|DRUG|Melatonin2%gel|Intra-pocket application of 2% Melatonin gel
223797498|NCT05759416|DRUG|PLACEBO|placebo intra-pocket application
223797499|NCT04919265|OTHER|No intervention - mother-infant cohort study|There are no interventions because it is a mother-infant cohort study
223797500|NCT00868855|DRUG|Bradykinin|Bradykinin, 0.2 ug - 2ug/minute, one time intracoronary infusion over 6 minutes. Drug (bradykinin) will be infused into the left main coronary artery via diagnostic catheter (JL4) at an escalating rate of 0.2, 0.6, 2 g/ml (1ml/min). A 5F Multipurpose catheter will be advanced to coronary sinus for blood sampling.
223797501|NCT03078270|DRUG|botulinum toxin A|Single treatment visit for 5 injections of botulinum toxin A, 40 units (for females) and 50 units (for males)/
223797502|NCT03078270|OTHER|Placebo|single treatment visit for 5 injections of normal saline
223797503|NCT04573465|BEHAVIORAL|Phone Coaching|Participants receiving phone coaching receive one 10-15 minute phone call each week from their randomly assigned peer-support coach. During coaching calls, the peer-support coach will discuss ACT Guide usage with the participant (e.g., asking how many modules the participant completed, asking what the participant liked/disliked about the modules, etc.).
223797504|NCT04573465|BEHAVIORAL|Text Message Coaching|Participants receiving text message coaching receive text messages on a weekly basis from their randomly assigned peer-support coach. Text messages from the peer-support coach will discuss ACT Guide usage with the participant (e.g., asking how many modules the participant completed).
223797505|NCT04573465|BEHAVIORAL|ACT Guide|ACT Guide is an online self-help program based on acceptance and commitment therapy (ACT), targeting acceptance, mindfulness, and values-based processes. It is intended to be used for 20 to 40 minutes at time, a few times a week. While using ACT Guide, participants will read about concepts relevant to ACT and engage in guided experiential exercises, with additional exercises being assigned to be completed in between sessions as homework.
223797506|NCT04648189|DRUG|Cetuximab|A single dose of cetuximab, 400mg/m2, will be administered 72 to 48 hours prior to surgery
223797507|NCT04133155|DRUG|nab paclitaxel plus gemcitabine|Nab-paclitaxel 125 mg/m2 weekly for 3 weeks, every 4 weeks Gemcitabine 1000 mg/m2 weekly for 3 weeks, every 4 weeks
223797508|NCT03531424|PROCEDURE|Angiographic guided PCI|Angiographic guided PCI is coronary revascularization based on stand-alone angiography.
223797509|NCT03531424|PROCEDURE|Augmented-Reality CTA guided PCI|Augmented-Reality CTA guided PCI is coronary revascularization based on systematic use of CTA datasets displayed in augmented-reality glass plus coronary angiography.
223797510|NCT03872921|DRUG|norUrsodeoxycholic Acid|oral treatment
223797511|NCT00383487|DRUG|Calcitriol|0.5 micrograms/kilogram q weekly
223797512|NCT00383487|DRUG|Naproxen-n-butyl nitrate|400 mg BID, oral
223797513|NCT01825629|OTHER|Multidisciplinary therapy|"Physical Therapy: Cervical traction, Cranium fore flexion 15 °, Open-close mouth dental contactless (10 mm), Opening movement with a small resistor (one finger on chin), Flexion of the head, without actually lifting, resisting in the front, Occipital extension, Cranium fore flexion 15 °, Cervical traction.~Myofascial Therapy: Induction suboccipital, compression - decompression of the temporomandibular joint, horizontal induction of the temporomandibular joint, deep fascia induction in the temporal region, deep induction of the masseter fascia, deep induction of the external pterygoid, and induction of intraoral pterygoid.~Deontology therapy: the patient are going to port a deprogramming occlusal splint every night, an average of 8 hours per day, for 15 weeks."
223797514|NCT01825629|OTHER|Placebo|
223797515|NCT00002426|DRUG|Adefovir dipivoxil|
223797516|NCT01544322|DRUG|ME-344|"experimental drug, dose escalation with 5 planned dose cohorts of 1.2 mg/kg, 2.5 mg/kg, 5 mg/kg, 10 mg/kg, 20 mg/kg; Cycle 1 is 3 weekly IV infusions on Days 1, 8, and 15. After safety assessment, if there is clinical benefit, weekly dosing may continue until withdrawal.~Once the highest tolerated dose has been determined, patients will be enrolled to receive IV infusions 2 days each week. Cycle 1 at the highest dose level is 3 weekly IV infusions on days 1, 2, 8, 9, 15 and 16. After safety assessment, if there is clinical benefit, weekly dosing may continue until withdrawal."
223797517|NCT05540925|PROCEDURE|Liver resection|"All patients underwent curative-intent resection for early-stage HCC (a solitary tumor nodule≤5 cm, or multiple nodules≤3, each≤3 cm).~We did not take any other intervention. We retrospectively analyzed the prognostic performance of patients with wide (≥1cm) or narrow (\<1cm) resection margin in different groups."
223797518|NCT03099993|OTHER|Measurement of maximal forces of elbow pronosupination and flexion-extension|Maximal forces of elbow pronosupination and flexion-extension will be measured with a portable dynamometer.
223797519|NCT03064516|PROCEDURE|Endocrown|In experimental group, the researches will be performed in the Endocrown group- only the ceramic restoration will fill the pulp chambre in teeth treated endodontically. Cusps will be preserved.
223797520|NCT03064516|PROCEDURE|Onlay and fiber pin|In control group, the researches will be performed in the onlay ceramic restorations with glass fiber pin group in endodontically treated teeth- the teeth receive a fiberglass pin in the main root canal and composite resin filling. Cusps will be preserved.
223797521|NCT04905394|PROCEDURE|subchondroplasty|subchondroplasty is an innovative percutaneous procedure in which calcium phosphate, biocompatible material similar to the native bone apatite with osteoinductive properties, is injected inside BML areas. The purpose of subchondroplasty is the patient's symptoms relief, improving the mechanical strength of subchondral bone, stimulating bone remodeling to avoid bone sagging, and slow down the arthritic degenerative process to postpone arthroplasty.
223797522|NCT03228056|DIAGNOSTIC_TEST|pain intensity measured in VAS scale|Pain intensity in 0-100 mm VAS scale is measured every 4 hours on standard ruler beginning from the end of the surgery.
223797523|NCT01409148|BIOLOGICAL|124I-labeled monoclonal antibody Mu 11-1F4|Single infusion of radiolabeled antibody: 2mCi (1 mg)
223797524|NCT01974167|DRUG|Eldecalcitol|Eldecalcitol 0.75 microgram once daily orally
223797525|NCT01974167|DRUG|Alfacalcidol|Alfacalcidol 1 microgram once daily orally
223797526|NCT00385580|DRUG|dasatinib|Tablets, Oral, 100 mg or 70 mg, twice daily, treatment may continue until disease progression
223797527|NCT00385580|DRUG|dasatinib|Tablets, Oral, 100 mg, once daily (QD) treatment may continue until disease progression
223797528|NCT03251625|DRUG|Probiotic Formula Capsule|
223797529|NCT04245280|DRUG|Ropivacaine 0.5% Injectable Solution|ropivacaine 0.5% with epinephrine 2.5 mcg/ml
223797530|NCT04245280|DRUG|Saline Solution|normal saline solution (NaCl 0.9%)
223797531|NCT05239130|DEVICE|Auralya|Auralya® is a sterile, injectable, non-pyrogenic, re-absorbable medical product made of reticulated hyaluronic acid of non-animal origin, produced via bacterial fermentation. Auralya® is a colourless gel contained in a pre-filled, graduated, disposable, and sterile glass syringe with a Luer adapter.
223797532|NCT03468556|DRUG|SNP-610|Subjects will take 2 tablets once a day orally for 12 weeks
223797533|NCT03468556|DRUG|Placebo Oral Tablet|Subjects will take 2 tablets once a day orally for 12 weeks
223797534|NCT05245929|DEVICE|Distalization|Distalizing the posterior maxillary segment
223797535|NCT04185805|DRUG|DWP14012 tablet A|Period 1: DWP14012 tablet B Period 2: DWP14012 tablet A
223797536|NCT04185805|DRUG|DWP14012 tablet B|Period 1: DWP14012 tablet A Period 2: DWP14012 tablet B
223797537|NCT02668523|DEVICE|Raindrop Near Vision Inlay|To improve the near and intermediate vision in subjects who have previously undergone cataract surgery (pseudophakic subjects)
223797538|NCT06056375|BEHAVIORAL|Reclaiming Nature Intervention|The purpose of the community intervention is to prevent health disparities in Black, Latinx, Pilipinx, and Pacific Islander communities of San Francisco, California.
223797539|NCT05506787|DRUG|Esketamine|Esketamine
223797540|NCT05506787|DRUG|Placebo|Placebo
223797541|NCT03232983|DRUG|LY900014 (SC)|Administered SC
223797542|NCT03232983|DRUG|LY900014 (IV)|Administered IV
223797543|NCT01627327|DRUG|fluticasone furoate/vilanterol 100/25mcg|inhalation powder
223797544|NCT01627327|DRUG|tiotropium bromide 18mcg|inhalation powder
223797545|NCT00108602|DRUG|acetazolamide|
223797546|NCT04041960|OTHER|Transcranial magnetic stimulation (TMS)|The TMS protocol to be used, excitatory intermittent theta burst stimulation (iTBS), has been shown to have minimal risk in children as young as 6 (Hong et al., 2015), as well as adults (Huang et al., 2005). This stimulation paradigm uses a series of theta burst stimulation (TBS) units. Each unit consists of 3 pulses of stimulation given at 50 Hz (Huang et al., 2005). Excitatory iTBS consists of 20 sets of 10 TBS units (2 second duration) repeated every 10 seconds for a total of 190 seconds. One session of excitatory stimulation delivers a total of 600 pulses.
223797547|NCT04294966|DRUG|Dextrose|Administering dextrose to healthy volunteers for our placebo group
223797548|NCT04294966|DRUG|Dronabinol|THC (Marinol® \[dronabinol\]; Solvay Pharmaceuticals) will be orally administered in doses of 7.5 mg and 15 mg, in opaque capsules with dextrose filler. Placebo capsules contain only dextrose. These doses of THC are known to produce performance impairments as well as subjective intoxication with little to no adverse reactions in experienced occasional, but non-daily cannabis users.
223797549|NCT04294966|DRUG|Dronabinol|THC (Marinol® \[dronabinol\]; Solvay Pharmaceuticals) will be orally administered in doses of 7.5 mg and 15 mg, in opaque capsules with dextrose filler. Placebo capsules contain only dextrose. These doses of THC are known to produce performance impairments as well as subjective intoxication with little to no adverse reactions in experienced occasional, but non-daily cannabis users.
223797550|NCT06242626|OTHER|observation|analysis of clinical, laboratory and haemodynamics parameters
223797551|NCT02077179|BEHAVIORAL|HIP Program|"The entirety of the HIP Program is delivered through an interactive mobile website.~The physical activity portion of the program consists of daily step counting, prescribed aerobic activity, structured strength and toning workouts, and daily stretching. The program was designed by a local trainer, specializing in postnatal exercise, to increase gradually in intensity, while encouraging a more active lifestyle. The program is designed to be completed at home with minimal equipment.~The nutrition portion of the program consists of 16 video tutorials developed by a local Registered Dietitian and weekly diet logs. The video tutorials cover all aspects of healthy eating, from the basics of Canada's Food Guide, to smart snacking, to eating healthy over the holidays."
223797552|NCT00745810|OTHER|Cardiopulmonary bypass|sequential changes of oxidative injuries before and after cardiopulmonary bypass
223797553|NCT04477252|DEVICE|App-core|"Farmalarm App of the Inmovens group - Vall d´Hebrón Hospital will be used, adapted and updated by the main researcher. The App will have the rehabilitation option where the user can consult the description of the exercise and view a demonstration video so that it can be carried out correctly at home, independently or with help. The administrator therapist of the App has the permission to create users, contact them directly through chat or video-call and personalize the exercise program.~The exercises that will be carried out in this study phase, are described in previous studies by the author Rosa Cabanas et al. All possible exercises will be included in the administration platform, and according to of each user, the prescription of some exercises or others will be made."
223797554|NCT04477252|OTHER|Conventional physiotherapy|Conventional physiotherapy is considered neuromotor development therapy as the most frequently used therapy in the management of stroke patients and in the center where the study is performed.
223797555|NCT06064396|OTHER|Gong's Mobilization|The duration of intervention will be 4 weeks, 3 sessions a week, a total of 12 sessions will be given to the study participants. Each session will last for 30 minutes. Conventional physical therapy will be given to participants along with Gong's Mobilization.
223797556|NCT06064396|OTHER|Stecco Fascial Therapy|The duration of intervention will be 4 weeks, 3 sessions a week, a total of 12 sessions will be given to the study participants. Each session will last for 30 minutes. Conventional physical therapy will be given to participants along with stecco fascial therapy.
223797557|NCT03673254|DEVICE|rotational atherectomy device|angioplasty with rotational atherectomy device on a nonselected population
223797558|NCT04528069|DEVICE|ACRYSOF® IQ PanOptix® Toric Trifocal IOL|Single-piece, ultraviolet and blue-light filtering, foldable, multifocal toric IOL intended to provide vision to aphakic subjects at near, intermediate, and distance and to correct pre-existing corneal astigmatism. This device is approved in Australia.
223797559|NCT04528069|PROCEDURE|Cataract surgery|Cataract extraction by phacoemulsification, followed by implantation of the IOL per investigator's standard of care and instructions for use
223797560|NCT03365024|BEHAVIORAL|Computerized Cognitive Behavioral Therapy for Insomnia|A computerized insomnia intervention that employs the same behavioral, educational, and cognitive treatment components that underlie non-computerized CBT-I.
223797561|NCT03365024|BEHAVIORAL|Sleep Education|A web-based program will deliver components of sleep education via an Internet platform
223797562|NCT05955703|BEHAVIORAL|ppm based training|The training program based on the precede proceed model was applied to hemodialysis patients for 8 sessions. Eight sessions of training were given to the experimental group within the scope of the model, a booklet was developed in line with the trainings and posters were prepared.
223797563|NCT06025474|DRUG|Vortioxetine 20Mg Tab|Encapsulated vortioxetine immediate release tablets, once daily
223797564|NCT06025474|DRUG|Paroxetine 20 Mg Oral Tablet|Encapsulated paroxetine tablets, once daily
223797565|NCT06025474|DRUG|Sertraline 50 MG|Encapsulated sertraline tablets, once daily
223797566|NCT06025474|DRUG|Citalopram 20mg|Encapsulated citalopram tablets, once daily
223797567|NCT06025474|DRUG|Escitalopram 10mg|Encapsulated escitalopram tablets, once daily
223797568|NCT06025474|DRUG|Duloxetine 60 MG|Encapsulated duloxetine tablets, once daily
223797569|NCT06025474|DRUG|Pregabalin 75mg|Encapsulated pregabalin tablets, once daily
223797570|NCT02525874|DRUG|dimethyl fumarate|Initial oral dose for 7 days with maintenance dose thereafter
223797571|NCT00006041|BIOLOGICAL|MUC1-KLH conjugate vaccine|
223797572|NCT00006041|BIOLOGICAL|MUC1-KLH vaccine/QS21|
223797573|NCT00006041|BIOLOGICAL|QS21|
223797574|NCT00006213|DRUG|BMS-214662|Given IV
223797575|NCT00006213|OTHER|pharmacological study|Correlative studies
223797576|NCT00006213|OTHER|laboratory biomarker analysis|Correlative studies
223797577|NCT02486484|DRUG|ziv-aflibercept|zaltrap injection
223797578|NCT02161133|BEHAVIORAL|Problem-Solving Therapy|Problem-Solving Therapy is a treatment approach that teaches patients strategies to address real-life problems.
223797579|NCT02161133|BEHAVIORAL|Health Education|Health Education provides didactic information about Gulf War Illness
223797580|NCT00268294|DEVICE|Cardiac Resynchronization Therapy|
223797581|NCT04928820|PROCEDURE|Computed Tomography|Undergo PET/CT
223797582|NCT04928820|OTHER|Gallium Ga 68 Gozetotide|Given IV
223797583|NCT04928820|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
223797584|NCT03220490|BEHAVIORAL|5 minute interval between regular glaucoma drops - Long term|In the selected eye, the patient will be asked to take his two regular IOP reduction drugs while keeping a five minute time interval between instillation of the first and second drug for a duration of one month.
223797585|NCT03220490|BEHAVIORAL|no interval between regular glaucoma drops - Long term|In the selected eye, the patient will be asked to take his two regular IOP reduction drugs one after the other with no waiting period for a duration of one month.
223797586|NCT03220490|DRUG|IOP reduction of Brimonidine and Timolol with time interval|"In the selected eye the subject will be given two types of IOP reduction drops: first Brimonidine, Alphagan® (an alpha-agonist) followed by Timolol, Tiloptic® (a beta-blocker). The drops will be given with a time interval of five minutes between the first and second drop."
223797587|NCT03220490|DRUG|IOP reduction of Brimonidine and Timolol no time interval|"In the selected eye the subject will be given two types of IOP reduction drops:first Brimonidine, Alphagan® (an alpha-agonist) followed by Timolol, Tiloptic® (a beta-blocker). The drops will be given one after the other with no waiting period."
223797588|NCT00696748|DRUG|Nebido (testosterone undecanoate)|Nebido (testosterone undecanoate) intramuscular 4 ml by scheme
223797589|NCT00696748|DRUG|Placebo|Placebo 4 mL intramuscular
223797590|NCT04158050|DRUG|IL5 Antagonist or anti-IL5R-antibody or Omalizumab|mepolizumab, reslizumab, benralizumab and omalizumab in severe asthma
223797591|NCT04437784|PROCEDURE|Laparoscopic Trans-Abdominal Pre-Peritoneal|Laparoscopic trans-abdominal pre-peritoneal repair using 2 separate meshes fixed by endoscopic tackers
223797592|NCT04437784|PROCEDURE|Open pre-peritoneal repair|Open pre-peritoneal single mesh repair with suture fixation
223797593|NCT04437784|PROCEDURE|Bilateral Lichtenstein repair|Bilateral standard Lichtenstein repair using 2 separate meshes with suture fixation
223797594|NCT05019092|DIAGNOSTIC_TEST|Ultrasound examination of lower limb veins|Ultrasound examination will be performed by trained physicians using a commercially available ultrasound system and 5.0-15.0 MHz linear probe. The examinations consists of a comprehensive B-mode ultrasound protocol, from thigh to ankle, employing compression and color-Doppler at selected sites, according to the Consensus Conference of the Society of Radiologists in Ultrasound.
223797595|NCT04341116|DRUG|TJ003234|patients receive a single infusion
223797596|NCT04341116|DRUG|Placebo|patients receive a single infusion
223797597|NCT01845740|DRUG|milatuzumab|Milatuzumab has been used in clinical trials for multiple myeloma, non-Hodgkin's lymphoma and leukemia in the intravenous dosing form. In this study, milatuzumab is being given subcutaneously in patients with lupus.
223797598|NCT01845740|DRUG|Placebo|Placebo will be administered subcutaneously once weekly for 4 weeks.
223797599|NCT04154202|OTHER|Bone Scan|Bone Scan: three-phase planar Bone Scan and a SPECT/CT \[perfusion, blood pool and SPECT/CT of the relevant region of interest (ROI), and a whole-body planar late bone scan\].
223797600|NCT00498719|BEHAVIORAL|Cognitive Training Program|Cognitive training sessions over a 4 to 6 month training period, each lasting about 2 hours.
223797601|NCT00498719|OTHER|Control Group|Standard educational support.
223797602|NCT00363675|BEHAVIORAL|Functional hand tests|Chilren were tested after healed hand burns for functional ability.
223797603|NCT02006082|DEVICE|Telemedicine video-consultation (TVC)|All patients enrolled in the study, were previously monitored by TVC, and the number and length of hospital stays within 6 and 12 months following TVC were compared to similar numbers before TVC in comparable time periods. Thus, TVC is actually not to be considered as an intervention.
223797604|NCT02825082|PROCEDURE|Abdominal emergency surgery|all abdominal emergency surgery procedures
223797605|NCT02995772|DRUG|Aromatase Inhibitors (Arimidex)|Comparison of efficacy with chemotherapy
223797606|NCT02995772|DRUG|Tamoxifen|Comparison of efficacy with chemotherapy
223797607|NCT02995772|PROCEDURE|SOB|Comparison of efficacy with chemotherapy
223797608|NCT02995772|DRUG|FAC|Comparison of efficacy with hormonal therapy
223797609|NCT02995772|DRUG|Aromatase Inhibitors (Femara)|Comparison of efficacy with chemotherapy
223797610|NCT02995772|DRUG|Aromatase Inhibitors (Aromasin)|Comparison of efficacy with chemotherapy
223797611|NCT04794803|DRUG|Reparixin|Reparixin was administered via oral tablets 1200 mg TID for 7 days. In case of improvement, treatment can be prolonged at discretion of the investigator up to a maximum of 21 days of treatment in total or live discharge from the hospital, whichever comes first.
223797612|NCT04794803|DRUG|Standard of care|Standard of care
223797613|NCT01189916|PROCEDURE|Endoscopically assisted Appendectomy Surgery|Using endoscopic instruments a small incision will be made in the rectum wall and the endoscope will be advanced into the insufflated peritoneal cavity. At least one laparoscopic trocars will be placed through the abdominal wall for laparoscopic instrument insertion to manipulate and cut tissue. The flexible endoscope will provide visualization of the surgical field and flexible endoscopic instruments may be used to augment surgical manipulation with the laparoscopic instruments. The appendix will be removed through the anus. Endoscopic clips, sutures or tissue anchors (TAS)will be used to close the rectal access site.
223797614|NCT02162784|DRUG|Budesonide/Procaterol, 180/10mcg X1|one puff
223797615|NCT02162784|DRUG|Budesonide/procaterol 180/10 mcg X 2|2 puffs
223797616|NCT02162784|DRUG|Albuterol HFA MDI 100mcg X2|HFA MDI, 100mcg, 2 puffs
223797617|NCT05788757|DEVICE|Optetrak Total Knee System|Total Knee Arthroplasty using Exactech's Optetrak branded components.
223797618|NCT04124926|DRUG|Vonoprazan|Over-encapsulated tablet administered orally with approximately 240 mL water, 30 minutes prior to the morning meal.
223797619|NCT04124926|DRUG|Lansoprazole|Over-encapsulated capsule administered orally with approximately 240 mL water, 30 minutes prior to the morning meal.
223797620|NCT04603534|OTHER|Aged Simulation Suit|The aged simulation suit (Sakamoto Model M716, Tokyo, Japan) will be worn by students. The simulation suit consist of a several items such as loads, a soft material band with Velcro, glasses, ear plugs, gloves, belts and a cane. All the items are need to simulate one's posture just like in elderly person. Small, medium and large sizes of suits are provided by the company thereby each suit is suitable for each student related to their wearing size. Prior to this study, a total of three sets of suits will be gathered. Then, each student will perform each pre-defined scenarios step by step after the suit is worn. During the activities no help or leading will be given to the students. However, one of the researchers will supervise the students during the activities so that to integrate a safe platform. In addition, each student will be informed that if he/she can terminate the activity whenever it is required.
223797621|NCT04618185|DIAGNOSTIC_TEST|Magnetic Resonance Imaging (MRI)|MRI to study gut function and transit without the risk of exposure to ionising radiation.
223797622|NCT01508039|OTHER|Chitin Micro Particle|"The total spray volume for each application is 0.4 ml equivalent to a total single-dose for chitin of 2 mg (0.5 mg per 0.1 ml spray).~A total single-dose for LPS, of 2 mg of endotoxin from Enterobacter agglomerans (0.5 mg per 0.1 ml spray)"
223797623|NCT03725683|DEVICE|Increased caliber balloon|"Imaging of target lesions was performed before surgery to evaluate the characteristics of target lesions.~Postoperative to discharge Laboratory examination: blood routine, renal function, biochemical, coagulation functionTo determine and record the ABI(ankle-brachial pressure index);Records Rutherford classification; record the application of anticoagulant and antiplatelet agents; Records of adverse events."
223797624|NCT03725683|DEVICE|matched caliber balloon|"Imaging of target lesions was performed before surgery to evaluate the characteristics of target lesions.~Postoperative to discharge Laboratory examination: blood routine, renal function, biochemical, coagulation functionTo determine and record the ABI index;Records Rutherford classification; record the application of anticoagulant and antiplatelet agents; Records of adverse events."
223797625|NCT00423176|DRUG|MFNS and antibiotic|MFNS BID for 29 days plus amoxicillin/clavulanic acid BID for 10 days
223797626|NCT00423176|DRUG|Matching Placebo nasal spray plus antibiotic|Matching placebo nasal spray BID for 29 days plus amoxicillin/clavulanic acid BID for 10 days
223797627|NCT00003132|DRUG|bryostatin 1|
223797628|NCT00003132|DRUG|cisplatin|
223797629|NCT00003260|DRUG|FOLFIRI regimen|
223797630|NCT00003260|DRUG|FOLFOX regimen|
223797631|NCT00003260|DRUG|fluorouracil|
223797632|NCT00003260|DRUG|irinotecan hydrochloride|
223797633|NCT00003260|DRUG|leucovorin calcium|
223797634|NCT00003260|DRUG|oxaliplatin|
223797635|NCT01919242|PROCEDURE|gastrectomy|gastrectomy with D1 + lymph node dissection for clinically early gastric cancer, and gastrectomy with D2 lymph node dissection for clinically advanced gastric cancer
223797636|NCT01940042|BEHAVIORAL|CO2 was removed by means of trandelenburg positions|
223797637|NCT01587508|DRUG|meloxicam/cyclobenzaprine hydrochloride|two oral capsules a day during approximately 07 days
223797638|NCT01587508|DRUG|meloxicam - Movatec®|two oral tablet a day during approximately 07 days
223797639|NCT01587508|DRUG|cyclobenzaprine - Miosan®|two oral tablet a day during approximately 07 days
223797640|NCT00898885|PROCEDURE|oral biopsy|oral mucosa and salivary gland biopsy after bone marrow transplantation
223797641|NCT03871595|DRUG|BI 894416|3 tablets with 10 milligram (mg) of BI 894416 (total: 30 mg) were administered as one single oral dose with 240 milliliter (mL) of water.
223797642|NCT05449964|PROCEDURE|SCALING AND ROOT PLANING (SRP)in single sitting|SCALING AND ROOT PLANING (SRP) IS THE PRIMARY COURSE OF NON-SURGICAL PERIODONTAL TREATMENT THAT INVOLVES REMOVAL OF SUPRA-GINGIVAL AND SUB-GINGIVAL BIOFILM AND CALCULUS FOLLOWED BY THOROUGH ROOT PLANING.
223797643|NCT05449964|PROCEDURE|SCALING AND ROOT PLANING (SRP)in two sittings|SCALING AND ROOT PLANING (SRP) IS THE PRIMARY COURSE OF NON-SURGICAL PERIODONTAL TREATMENT THAT INVOLVES REMOVAL OF SUPRA-GINGIVAL AND SUB-GINGIVAL BIOFILM AND CALCULUS FOLLOWED BY THOROUGH ROOT PLANING.
223797644|NCT03048851|DEVICE|Low dosage SES group|The participants were randomly assigned to one of the five intervention groups. Low dosage SES group received the SES (Micro-Z Mini, Prizm Medical Inc., USA) training in addition to traditional rehabilitation. Each SES session involved electrical stimulation followed by UE training in addition to home program.The novel SES programs were conducted twice per week, for 12 weeks. Each SES session involved electrical stimulation followed by UE training in addition to home program. The SES was applied to the forearm and whole hand with mesh glove (Electro-Mesh Glove-Sleeve Electrode Kit) for 45 minutes and arm with wrap for 45 minutes. The pulse width was set to 300us for all stimulation levels. The frequency was set to 100 Hz and 10 Hz.
223797645|NCT03048851|DEVICE|High dosage SES group|The participants were randomly assigned to one of the five intervention groups. High dosage SES group received the SES (Micro-Z Mini, Prizm Medical Inc., USA) training in addition to traditional rehabilitation. Each SES session involved electrical stimulation followed by UE training in addition to home program.The novel SES programs were conducted twice per week, for 12 weeks. Each SES session involved electrical stimulation followed by UE training in addition to home program. The SES was applied to the forearm and whole hand with mesh glove (Electro-Mesh Glove-Sleeve Electrode Kit) for 90 minutes and arm with wrap for 90 minutes. The pulse width was set to 300us for all stimulation levels. The frequency was set to 100 Hz and 10 Hz.
223797646|NCT03048851|DEVICE|VRCIT group|The participants were randomly assigned to one of the five intervention groups. VRCIT group received the VRCIT training plus traditional rehabilitation, conducted twice per week for 12 weeks. Each VRCIT session involved practice of functional tasks with the more affected UE followed by virtual-reality based eye-hand coordination tasks with the more affected UE for, plus home program, and restraint of the less affected UE for 1.5 hours per day. The functional training of the more affected UE focused on massive practice of functional activities using the more affected arm, with the principles of shaping and repetitive task practice applied during training. The VRCIT combined CIT and commercially available VR-based systems including Sony Playstation EyeToy and Nintendo Wii.
223797647|NCT03048851|DEVICE|VRCIT+SES group|The participants were randomly assigned to one of the five intervention groups. VRCIT+SES group executed VR programs by affected UE in Mesh-gloves (Electro-Mesh Glove-Sleeve Electrode Kit) with the optimal SES (Micro-Z Mini, Prizm Medical Inc., USA) protocol formulated from the 1st phase study. The VRCIT program was conducted 1.5 hours/time, twice/week for 12 weeks. The VRCIT combined CIT and commercially available VR-based systems. Some commercially programs, such as Sony Playstation EyeToy (Sony Computer Entertainment America, Foster City, Calif., USA), and Nintendo Wii (Nintendo Domestic Distributor, College Point, N.Y., USA).
223797648|NCT03048851|PROCEDURE|traditional rehabilitation program|The participants were randomly assigned to one of the five intervention groups. The absence of muscle contractions was controlled by the investigator the sham stimulation was carried out identically, but the stimulation amplitude was set to 0 milliampere(mA). Subjects were not informed about the stimulation level and were instructed to distract attention from the stimulation.
223797649|NCT02694705|DEVICE|Continuous Positive Airway Pressure (CPAP)|CPAP provided by a portable Draeger Oxylog® 3000 plus ventilator
223797650|NCT02694705|DEVICE|Bag-Valve-Mask (BVM)|Preoxygenation provided by BVM device, oxygen flow rate 15 l/min
223797651|NCT02694705|DEVICE|Non-rebreather Mask (NRM)|Preoxygenation provided by NRM, oxygen flow rate 15 l/min
223797652|NCT05640349|BIOLOGICAL|Positive blood culture|Positive blood culture recorded at the microbiology laboratory of University Hospital of Nic
223797653|NCT06579716|OTHER|Traditional balance exercise|All patients in both group received a traditional balance exercise program, 3 sessions per week, for 6 weeks. Each session of exercise comprised 10 min of warm-up, 40min of balance exercise, and 5min of cool down. Warm-up included treadmill walking. Balance exercise comprised two sets of sit to stand, one leg stance, tandem stance and 30 squats. The first set of exercises was performed on a stable surface, whereas the second set of exercises was performed on an unstable surface by using Thera band stability trainer. Each set of each exercise was performed for 3 min, with 1-2 min of rest in between the exercises. Cool-down included deep breathing, abdominal breathing, and mild stretching.
223797654|NCT06579716|OTHER|Resistance exercise|All patients in both group received a resistance exercise program, 3 sessions per week, for 6 weeks. Each patient was seated in sitting position and the weight sandbags was applied at the dorsum of the foot. The resistance was set to be around 40%-60% of the 1RM. The patient performed the exercise for 3 bouts, every bout 10 repetitions. The one repetition maximum (1RM) was established prior to the training period using the following equation: 1 RM = Weight (kg) X (1 + {0.033 X number of repetitions)}.
223797655|NCT06579716|OTHER|Whole-body vibration (WBV)|Patients were asked to stand barefoot on the vibratory platform with an even distribution of weight on both feet and familiarized with WBV at a lesser frequency and amplitude. Then, they were asked to bend their knee 30º to the vertical; thereafter, to obtain a greater muscular response, WBV training was performed at a frequency of 30 Hz and an amplitude of 2mm. The exercise comprised five bouts of a 30-sec vibration with a 1-min elapse between the bouts.
223797656|NCT06579716|OTHER|Kineso tape|Kineso tape was applied to dorsiflexors 24 hours a day and was replaced every 5 days for patients who were taped in accordance with Kenzo Kase's Kinesio taping Manual. For taping, each patient's leg was placed in a relaxed position while he sat on a taping table. The skin was to be free of oils and lotions, to avoid anything that might limit the acrylic adhesive's ability to adhere to the skin. So, the subject's skin was cleaned with alcohol prior to tape application. For the Tibialis anterior, tape was measured from the muscle origin to the insertion while the muscle was stretched. The base of the tape was applied to the origin at the lateral condyle and superior 2/3 of anterolateral surface of tibia. Then the subject was asked to stretch the foot into plantar flexion and eversion; taping was then finished toward the insertion at the medial and plantar surface of medial cuneiform and base of the first metatarsal.
223797657|NCT04823377|OTHER|Usual care|Patients receiving systemic anticancer treatment in their last days of life
223797658|NCT04823377|OTHER|Optimization of the medical decision|Impact of the use of an optimization device of the decision of cancer treatment on aggressiveness of end of life care
223797659|NCT04867369|DRUG|Bupivacaine 20mL 0.5%|Interscalene nerve block with 20 mL 0.5% bupivacaine.
223797660|NCT04867369|DRUG|Bupivacaine 20mL 0.25%|Pecs II fascial plane block with 20 mL 0.25% bupivacaine.
223797661|NCT04867369|DRUG|Bupivacaine up to 15mL 0.25%|Local infiltration of 0.25% bupivacaine by the surgeon, up to 15 mL.
223797662|NCT03827187|OTHER|Motor imagery based EEG-BCI|Information gathered in this study may be useful when considering diagnosis of prolonged disorder of consciousness and successful adoption of device could lead to assistive communication intervention with therapeutic benefits. Participants undergo quick assessment to test ability to engage in task, if successful this implies they are minimally conscious, have some awareness of self and memory intact to remember commands. During training participant undergoes multiple sessions whereby they are conducting two different imagined movements to move a sound across the azimuthal plane in a direction dictated by an auditory cue. Participant will receive auditory feedback on the position of the sound which acts as a reflection of how well the participant is engaged in the task in terms of performance and consistency across trials. The participant will move on to use the imagined movements to answer a series of biographical, situational, basic logic and numbers/letters questions.
223797663|NCT05554237|DRUG|Placebo|Placebo
223797664|NCT05554237|DRUG|PF-07612577|PF-07612577
223797665|NCT05554237|DRUG|PF-06264006|PF-06264006
223797666|NCT06636877|DRUG|BR1019|One tablet administered alone
223797667|NCT06636877|DRUG|BR1019-2|One tablet administered alone
223797668|NCT06636877|DRUG|BR1019-3|One tablet administered alone
223797669|NCT06540339|OTHER|Snapshot-audit studies do not necessitate any intervention in the defined cohorts.|Snapshot-audit studies do not necessitate any intervention in the defined cohorts.
223797670|NCT04435366|DRUG|Avacincaptad Pegol|Avacincaptad Pegol Intravitreal Injection
223797671|NCT04435366|DRUG|Sham|Sham Administration (includes placement of the blunt opening of an empty, needleless syringe barrel on the conjunctiva in the inferotemporal quadrant of the eyeball to simulate the pressure of an injection)
223797672|NCT06962410|OTHER|Hybrid Closed-Loop Artificial Pancreas System|The pump was loaded with ultra-short-acting insulin (Manufacturer: Novo Nordisk A/S, Denmark; Approval Number: National Drug Approval No. J20050097; Specification: 3 mL: 300 U). The total daily insulin requirement was calculated at 0.2-0.4 U/(kg·d) based on the patient's weight. During operation, the system automatically adjusted the basal rate according to the blood glucose level. After the physician issued a large-dose order based on previous treatment experience and blood glucose conditions, the nurse manually entered the large-dose treatment instruction in the AAPS software.
223797673|NCT05926180|DRUG|DZD9008 and Probe drugs (midazolam, digoxin, rosuvastatin)|Patients will receive single oral doses of probe drugs alone and after at least 27 days of treatment with DZD9008, 300 mg, once daily, until a treatment discontinuation criterion is met. Each patient will receive a single oral dose of DZD9008 on Day 7, and DZD9008 once daily for 27 days from Day 9 to Day 35. Patients will also receive a single oral dose of 2 mg midazolam on Day 1 and Day 32, and oral dose of 10 mg rosuvastatin and 0.25 mg digoxin cocktail on Day 2, Day 7 and Day 33.
223797674|NCT04050683|PROCEDURE|Study - Transjugular Intrahepatic Portosystemic Shunt (TIPS)|Prior to and 1-3 days after the TIPS procedure, the following blood tests are done for research purposes: Brain Natriuretic Peptide (BNP); Endothelin-1; Tumor Necrosis Factor-alpha (TNF-a); Endothelial Nitric Oxide Synthase (eNOS). Subjects with abnormal heart pressures during TIPS will have a right heart catheterization (RHC) to monitor heart function, blood flow, and pressures in and around the heart. The subject will be admitted to the Cardiovascular Intensive Care Unit and have a TTE all of which are standard of care. Routine follow-up visits will occur in IR Clinic at 2 Weeks (± 3 days), 4-6 weeks and 4-6 months. Visits will include: blood draws for research related blood tests as listed above; standard of care ultrasound of the abdomen; TTEs; and for at least one year, routine lab testing, imaging, medications, and subject overall condition will be assessed for long term outcomes. Diagnostic RHC will be done as needed per standard of care.
223797675|NCT04050683|PROCEDURE|Control - Transjugular Intrahepatic Portosystemic Shunt (TIPS)|"Subject's with normal heart pressures who are having elective (planned in advance and not due to an emergency) TIPS due to refractory ascites (fluid build up in the belly that does not go away or comes back shortly after being removed). Prior to and 1-3 days after the TIPS procedure, the following blood tests are done for research purposes: Brain Natriuretic Peptide (BNP); Endothelin-1; Tumor Necrosis Factor-alpha (TNF-a); Endothelial Nitric Oxide Synthase (eNOS). The subject will be admitted to the hospital after TIPS for standard of care monitoring.~Routine follow-up visits will occur in IR Clinic at 2 Weeks (± 3 days), 4-6 weeks and 4-6 months. Visits will include: blood draws for research related blood tests as listed above; standard of care ultrasound of the abdomen; and for at least one year, routine lab testing, imaging, medications, and subject overall condition will be assessed for long term outcomes."
223797676|NCT02921997|DRUG|AS03|AS03 oil-in-water emulsion adjuvant.
223797677|NCT02921997|BIOLOGICAL|Influenza Virus Vaccine, Monovalent A/H3N2v A/Minnesota/11/2010 NYMC X-203|Inactivated monovalent subvirion H3N2v vaccine containing hemagglutinin (HA) of A/Minnesota/11/2010 NYMC X-203 virus.
223797678|NCT02921997|BIOLOGICAL|Monovalent influenza A/H7N9 virus vaccine|Monovalent influenza A/H7N9 virus vaccine.
223797679|NCT03896035|BEHAVIORAL|Behavioral Intervention Group|The behavioral intervention is designed for older Veterans with cLBP and depression and will include 8 individual telephone sessions delivered by health coaches over a period of 10-20 weeks (up to 5 months total, accounting for additional time between sessions if needed).
223797680|NCT03492281|DRUG|vibegron|single daily oral dose of vibegron 75 mg for 12 weeks
223797681|NCT03492281|DRUG|Vibegron placebo|placebo to match vibegron (experimental drug)
223797682|NCT03492281|DRUG|Tolterodine Tartrate ER|single daily oral dose of tolterodine tartrate ER 4 mg for 12 weeks
223797683|NCT03492281|DRUG|Tolterodine placebo|placebo to match tolterodine (active comparator)
223797684|NCT01506193|BIOLOGICAL|PriorixTetra™|One dose administered subcutaneously
223797685|NCT01506193|BIOLOGICAL|Meningitec|One dose administered intramuscularly
223797686|NCT02526264|OTHER|Education program|Verbal education prior tu surgery administered to all patients in order to inform about the surgery and outcomes
223797687|NCT04100746|PROCEDURE|supramalleolar osteotomy|surgical intervention by using low tibial osteotomy
223797688|NCT04298593|DEVICE|Cardiostat|This is a prospective observational study including patients accepted by the heart team for a TAVI procedure. There will be no restriction regarding the type of valve and approach used for the TAVI procedure. Following the TAVI procedure, the patients will be under telemetry until hospital discharge and, at hospital discharge, they will be monitorized up to 4 more weeks using the CardioSTAT® device.
223797689|NCT03343236|RADIATION|Radiotherapy|All patients will undergo radiotherapy or surgery, or combined modality treatment
223797690|NCT04749719|DEVICE|remotely supervised transcranial direct current stimulation|Low levels of electrical current are applied across the scalp to induce small changes in brain activity. This is done using remote supervision.
223797691|NCT04575467|DRUG|CBL-514|CBL-514 will be administered via injection into the subcutaneous adipose layer.
223797692|NCT01915615|OTHER|None - this is an observational study|None - this is an observational study
223797693|NCT04752423|OTHER|Pre operative assessment|"Anxiety assessment : Numeric rating scale (patient and caregiver), APAIS scale (patient), Covi Scale (Caregiver)~Verbalization : anesthesia-related concerns (expressed by patient and considered by caregiver)"
223797694|NCT01320046|OTHER|Questionnaires, gynecological exam , vaginal smear, and measurement of urine leakage|"Patients will undergo the following evaluation:~1. Questionnaires- age, medical background, BMI, UI characteristics , usage of pads, other hygiene practices,hormonal therapy, presence of allergic tendency and history etc.~2. Medical history.~3. Gynecological exam including bladder/rectum/uterine prolapse, vaginal atrophy, discharge, findings of VCD (as part of the usual evaluation in the clinic).~4. Vaginal smear: this will be used for vaginal pH measurement and for wet mount, which will assess estrogen deficiency, yeast infection and other inflammatory conditions. Vaginal smears are done as part of the usual evaluation in the clinic.~5. Evaluation of the severity of urinary incontinence will be done by collection and weighting of pads during 24 hours."
223797695|NCT00001020|BIOLOGICAL|rgp120/HIV-1IIIB|
223797696|NCT00001020|BIOLOGICAL|rgp120/HIV-1MN|
223797697|NCT04070924|OTHER|Bandaid|Bandaid dressing
223797698|NCT04070924|OTHER|Conventional bulky soft tissue dressing|Conventional bulky soft tissue dressing
223797699|NCT04789538|OTHER|monofocal lens|not applicable as patients are already implanted with the monofocal intraocular lens
223797700|NCT02257268|BEHAVIORAL|VAMOS program - Active life improving health|All participants that will be assigned to change behavior group will participate of a change behavior program, entitled VAMOS (Active Life Improving Health), for 12 weeks. VAMOS is a lifestyle promotion program, that includes physical activity and healthy eating habits. The program is composed by a weekly meeting, in group, lasting about 90 min. In each weekly meeting, will be discussed guidelines and strategies for physical activities practices in different domains and for adoption of a healthy diet. All aspects and strategies included in the program are based in behavior changes theories. The participants of this group will receive an educational material and, in the middle of the program, they will earn a pedometer to aid in motivation and in the self-monitoring physical activity.
223797701|NCT00743366|DRUG|Marijuana|0,6.2% THC
223797702|NCT00743366|DRUG|Quetiapine|200 mg/day
223797703|NCT00743366|DRUG|Placebo oral capsule|
223797704|NCT03206203|DRUG|Atezolizumab|Given by vein
223797705|NCT03206203|DRUG|Carboplatin|Given by vein
223797706|NCT03206203|OTHER|Laboratory Biomarker|Correlative study
223797707|NCT03206203|OTHER|Quality-of-Life Assessment|Ancillary studies
223797708|NCT02459873|BEHAVIORAL|Computer games to assess change in executive function skills|Children get access to computer games for 10 weeks for an hour each week.
223797709|NCT03006523|PROCEDURE|Intrauterine insemination|IUI will be performed with a Wallace® insemination 2 Catheter (Cooper Surgical, Trumbull, CT, USA) depositing 0.2 or 0.5 ml of the sperm sample at the uterine fundus. All IUIs will be performed between 12 p.m. and 4 p.m. After the procedure, 10 min of bed rest will be prescribed. Inseminations will be performed every day of the week, including weekends.
223797710|NCT04508439|DRUG|Enoxaparin|Identify the benefit of different doses of low molecular weight heparin (enoxaparin) on the established clinical response due to lack of ventilatory support, length of hospital stay or death in patients requiring hospital care for COVID-19 infection.
223797711|NCT05686057|DEVICE|percutanous coronary angiography with stenting|Revascularization will be done by percutanous intervention after assessment of coronary stenosis by diagnostic coronary angiography under local anaesthesia with fluoroscopic guidance in acute/chronic coronary syndrome cases. The severity of stenosis will be done by modified gensini score from angiogram. An sST2 ELIZA test will be done after withdrawal of the cases' samples.
223797712|NCT01483924|DRUG|Apo805K1|Sequential parallel dose escalation.
223797713|NCT05349344|OTHER|Aerobic circuit training|Aerobic Exercise Training, 3 times a week for 8 weeks, (Tuesday, Thursday \& Saturday, 24 sessions Total) 30 min each time, at 60-80 % of HR max (moderate intensity).
223797714|NCT05349344|OTHER|Outdoor walk|30minutes Walking outside below 40% of HR max for 2 months.(3 times per week for 8 weeks).
223797715|NCT03589898|DRUG|Gabapentin|Single dose of gabapentin 900 mg
223797716|NCT06060171|PROCEDURE|Aortic valve intervention|Surgical or transcatheter aortic valve intervention
223797717|NCT05142267|DRUG|Placebo|"In randomized order (crossover) across 3 laboratory sessions, participants will undergo laboratory evoked thermal pain response testing with: 1) 0.13 mg/kg of oral oxycodone (in 1mg/ml syrup) plus 20ml i.v. saline placebo, 2) 8mg of i.v. naloxone (in 20ml saline vehicle) plus oral placebo syrup (quantity matching oxycodone syrup volume), or 3) 20ml i.v. saline placebo plus oral placebo syrup (quantity matching oxycodone syrup volume).~Thermal pain testing utilizes a Medoc TSAII NeuroSensory Analyzer. This equipment is used to assess heat pain threshold and tolerance using an ascending method of limits protocol."
223797718|NCT05142267|DRUG|Oxycodone|"In randomized order (crossover) across 3 laboratory sessions, participants will undergo laboratory evoked thermal pain response testing with: 1) 0.13 mg/kg of oral oxycodone (in 1mg/ml syrup) plus 20ml i.v. saline placebo, 2) 8mg of i.v. naloxone (in 20ml saline vehicle) plus oral placebo syrup (quantity matching oxycodone syrup volume), or 3) 20ml i.v. saline placebo plus oral placebo syrup (quantity matching oxycodone syrup volume).~Thermal pain testing utilizes a Medoc TSAII NeuroSensory Analyzer. This equipment is used to assess heat pain threshold and tolerance using an ascending method of limits protocol."
223797719|NCT05142267|DRUG|Naloxone|"In randomized order (crossover) across 3 laboratory sessions, participants will undergo laboratory evoked thermal pain response testing with: 1) 0.13 mg/kg of oral oxycodone (in 1mg/ml syrup) plus 20ml i.v. saline placebo, 2) 8mg of i.v. naloxone (in 20ml saline vehicle) plus oral placebo syrup (quantity matching oxycodone syrup volume), or 3) 20ml i.v. saline placebo plus oral placebo syrup (quantity matching oxycodone syrup volume).~Thermal pain testing utilizes a Medoc TSAII NeuroSensory Analyzer. This equipment is used to assess heat pain threshold and tolerance using an ascending method of limits protocol."
223797720|NCT03160027|DEVICE|Vielight Neuro Gamma|The Vielight Neuro Gamma is headset that delivers transcranial (through the scalp and skull) and intranasal (through the nose) near infrared (NIR) light. The device is engineered for increased efficacy and easy domestic use for comprehensive brain photobiomodulation (PBM). The NIR lights are pulsed at a 40 Hz rate, which correlates with electroencephalogram (EEG) gamma brain wave entrainment.
223797721|NCT01002326|BEHAVIORAL|Cognitive-Behavioral Therapy|20 sessions of Cognitive-Behavioral Therapy
223797722|NCT02219126|OTHER|Dietary intervention|
223797723|NCT01386528|DRUG|nonacog beta pegol|The patients will receive nonacog beta pegol at screening just prior to and during surgical intervention, administered intravenously (into the vein).
223797724|NCT05888636|OTHER|ChIP-seq, NGS, ATAC-seq|Bone narrow sampling
223797725|NCT04797247|DRUG|lerodalcibep|PCSK9 inhibitor
223797726|NCT03565887|DRUG|RVL-1201|RVL-1201 ophthalmic solution 0.1%
223797727|NCT03565887|OTHER|Vehicle ophthalmic solution|Vehicle placebo ophthalmic solution
223797728|NCT01235208|OTHER|"The Dr. Fedon Lindbergs Vektcoach Treatment"|Diet and lifestyle treatment
223797729|NCT00536003|DRUG|progesterone|vaginal capsules containing 200 mg of natural progesterone, once a day, until 36 6/7 weeks of gestation or until preterm delivery (whichever occurs first).
223797730|NCT00536003|DRUG|placebo|vaginal capsules containing placebo, once a day, until 36 6/7 weeks of gestation or until preterm delivery (whichever occurs first).
223797731|NCT01152580|DIETARY_SUPPLEMENT|melatonin|3mg p.o. at bedtime daily
223797732|NCT01152580|DIETARY_SUPPLEMENT|sugar pill|lactose p.o. at bedtime daily
223797733|NCT02073396|DIAGNOSTIC_TEST|Blood test|Patients will undergo the tests of thrombosis, before and after stabilisation of their cardiac condition. Cardiac stabilisation will be provided by clinical cardiac teams, outside and independently from the study.
223797734|NCT00323596|BEHAVIORAL|physical activity program of strength and balance retraining|
223797735|NCT02636634|OTHER|imaging|
223797736|NCT00715546|PROCEDURE|autologous transplantation of liposuction material enriched with adipose-derived stem cells|Lipoinjection enriched with adipose-derived stem-cells.
223797737|NCT04216316|DRUG|Berzosertib|Given IV
223797738|NCT04216316|PROCEDURE|Biospecimen Collection|Correlative studies
223797739|NCT04216316|DRUG|Carboplatin|Given IV
223797740|NCT04216316|PROCEDURE|Computed Tomography|Undergo CT
223797741|NCT04216316|DRUG|Gemcitabine Hydrochloride|Given IV
223797742|NCT04216316|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223797743|NCT04216316|BIOLOGICAL|Pembrolizumab|Given IV
223797744|NCT02829853|GENETIC|Genetic analysis by SANGER and WHOLE EXOME NEXT GENERATION SEQUENCING|Patients with sarcoidosis patients are monitored in the regular follow-up in one of 28 GSF clinical centers. Blood sampling was performed in two 5ml classical heparinized tube, as used for red/white/platelets blood cells analysis. The patients receive complete information on the SARCFAM protocol and sign an informed consent stating that the genetic study will be conducted on the BTNL2 gene and genes related to immunity, including loci other than BTNL2.DNA was extracted from a 1-5 ml sample of blood and stored in frozen conditions until analysis. Genomic DNA is captured using Agilent in-solution enrichment methodology (Human Clinical Research Exome, Agilent) with their biotinylated oligonucleotides probes library, followed by paired-end 75 bases massively parallel sequencing on Illumina HiSEQ 400. For each genomic position, the exomic frequencies (Homo \& HTZ) are determined from all the exomes already sequenced and/or the exome results provided by 1000G, EVS, HapMap database.
223797745|NCT00362518|DIETARY_SUPPLEMENT|Study Arm A|Control: no vitamins (placebo only). This study will provide baseline metabolic and surrogate marker changes that are caused by the high fat meal. Study arms B, C, and D will be statistically compared to this study.
223797746|NCT00362518|DIETARY_SUPPLEMENT|Study Arm B|This study arm will provide information on the response of atherogenic surrogate markers to a high fat supper when a low dosage form of vitamin C is administered (250 mg) and Vitamin E (200 IU).
223797747|NCT00362518|DIETARY_SUPPLEMENT|Study Arm C|This study arm will provide information on the response of atherogenic surrogate markers to a high fat supper when a medium dosage form of vitamin C administered (500 mg)and Vitamin E (400 IU).
223797748|NCT00362518|DIETARY_SUPPLEMENT|Study Arm D|This study arm will provide information on the response of atherogenic surrogate markers to a high fat supper when a high dosage form of vitamin C is administered (1000 mg) and Vitamin E (800 IU).
223797749|NCT05034523|RADIATION|MRI Voxel based morphometry|Voxel based morphometry through analysis of 3D T1 weighted sequence to assess total intracranial volume. All participants were scanned on the 1.5Tesla MR scanner (Achieva, Philips Medical Systems, Best, NL) with a 16-channel head coil at the diagnostic radiology department.
223797750|NCT04067466|DIETARY_SUPPLEMENT|Fiber product|Fiber product with inulin, maltodextrin, gum guar and plum powder.
223797751|NCT04067466|DIETARY_SUPPLEMENT|Control product|Placebo product with maltodextrin and plum powder
223797752|NCT01290432|DIETARY_SUPPLEMENT|Inofolic Plus|Inofolic Plus contains folic acid and myoinositol and melatonin
223797753|NCT00850473|DIAGNOSTIC_TEST|PET/CT|Patient will have one imaging modality - a Positron Emitting Tomography CT which includes F-18 FDG and heparin/intralipid infusion and Contrast Dye.
223797754|NCT05305196|OTHER|Eccentric-focused exercises|"Three eccentric-focused exercises:~1. Shoulder external rotator eccentric contraction in shoulder abduction 90 degree~2. Shoulder external rotator eccentric contraction in shoulder abduction 0 degree~3. Shoulder abductor eccentric contraction in shoulder abduction 90 degree"
223797755|NCT05305196|OTHER|Stretching exercises|"1. Modified sleeper stretch~2. Modified cross-body stretch"
223797756|NCT05305196|OTHER|Hot pack|Hot pack application on shoulder region
223797757|NCT05305196|OTHER|Massage|Massage for upper trapezius
223797758|NCT00449176|DRUG|tapentadol (CG5503) ER|50, 100, 150, 200, 250 mg twice daily for 15 weeks
223797759|NCT00449176|DRUG|oxycodone CR|10, 20, 30, 40, 50 mg twice daily for 15 weeks
223797760|NCT00449176|DRUG|placebo|matching placebo twice daily for 15 weeks
223797761|NCT01329367|BEHAVIORAL|Control group|"Subjects will receive Nutritional education together with weight management counselling for overweight and obesity.~-10 weekly personal interviews with a registered nutritionist for body weight control."
223797762|NCT01329367|BEHAVIORAL|Protein group|"Participants will receive Nutritional education and personalised structured meal plan with a calorie restricted diet (20-40% of the subject's energy expenditure at baseline) according to obesity degree, encouraging high consumption of legumes and fish (protein rich diets).~-10 weekly personal interviews with a registered nutritionist for body weight control."
223797763|NCT01329367|BEHAVIORAL|Antioxidant group|"Participants will receive Nutritional education and personalized structured meal plan with a calorie restricted diet (20-40% of the subject's energy expenditure at baseline) according to obesity degree, encouraging high consumption of fruits and vegetables (antioxidant rich diets).~-10 weekly personal interviews with a registered nutritionist for body weight control."
223797764|NCT00528138|OTHER|Laboratory Test|CRP, white blood cell count, hepatic function tests
223797765|NCT05978921|OTHER|Strength physical exercise programme|12 multi-joint strength exercises will be developed. Participants will be taught the rating scale of perceived exertion (RPE) based on the number of repetitions in reserve (RIR). Participants will be asked that during the performance of each of the exercises they must perceive an effort between 7-8 within the overall score of the scale (0-10; 0 = no effort at all and 10 = cannot perform one more repetition, i.e. maximal effort). When subjects perform the 12 repetitions with lower perceived exertion than the set effort in two consecutive sessions with full range of motion the training load will be increased by about 2-10% following the American College of Sports Medicine guidelines and reassessed using the RIR-based RPE. Patients in the usual treatment group will continue to participate in their existing rehabilitation programmes, but will not be included in the strength training programme.
223797766|NCT05978921|OTHER|Normal life|Normal life and carry out all the activities they have been doing previously.
223797767|NCT05363566|DEVICE|airway divice|inserted airway device
223797768|NCT06486467|OTHER|Fluid challenge (cristalloids) OR passive leg raising|"Patients in whom fluid administration is considered necessary, based on hypoperfusion criteria will be included in the trial.~One member of group A and one of group B will proceed independently to evaluate LVOT VTI, guided by the UltraSight AI software to obtain the best 5-chamber view. The measure of LVOT VTI will be calculated as the average of three consecutive cardiac cycles.~The order of acquisition between group A and B will be randomized. Each operator will be blinded to the values obtained by the other.~After baseline LVOT VTI measurement, a 250 mL fluid challenge of crystalloids or a passive leg raising test (non-pharmacological and reversible fluid challenge of roughly 250 mL), depending on the appreciation of the clinician will be performed. Measurements will be repeated immediately after the fluid challenge by the same operators, still blinded to each other, guided by the UltraSight AI software. The order of the 2nd acquisition will be the same as the 1st acquisition"
223797769|NCT01045746|DEVICE|Stochastic resonance whole-body vibration A|over four weeks, three times a week with 5 Hz, Noise 4 and than over four weeks three times a week with 1 Hz, Noise 1.
223797770|NCT01045746|DEVICE|Stochastic resonance whole-body vibration b|over four weeks, three times a week with 1 Hz, Noise 1 and than four weeks three times a week with 5 Hz, Noise 4.
223797771|NCT05371184|DRUG|L-Glutamine, Oral Powder for Reconstitution|Glutamine is an essential amino acid. It will be provided in a powder form. It will be dissolved in at least 8 ounces of hot or cold liquid. It can also be mixed with a soft food such as pudding, applesauce, or yogurt. Then it will be Stirred and then eaten or drunken The Glutamine will be as an add on to the Standard of care
223797772|NCT05371184|OTHER|Standard of care|Hydroxyurea 15-25 mg per kg per day and/ or blood transfusion therapy
223797773|NCT04901858|DIAGNOSTIC_TEST|Aspiration of haemarthrosis and high definition MRI|Aspiration of haemarthrosis and high definition MRI
223797774|NCT03595644|RADIATION|SBRT+TKI|Received SBRT after three months after EGFR-TKI treatment
223797775|NCT03595644|DRUG|TKI|Received EGFR-TKI treatment
223797776|NCT03809481|DRUG|Danaparoid Sodium|inhibits thrombin generation by indirect anti-Xa inhibition and direct inhibition of factor IX activation
223797777|NCT03809481|DRUG|Argatroban|Synthetic direct thrombin inhibitor
223797778|NCT00314197|BEHAVIORAL|Telephone Linked Care - Behavior Change Counseling System|
223797779|NCT00314197|BEHAVIORAL|Telephone-linked behavioral counseling|
223797780|NCT02265900|OTHER|Exercise|One type of exercise
223797781|NCT02265900|OTHER|Exercise|A different type of exercise
223797782|NCT03173040|DRUG|NiuBangZi pill or NiuBangZi pill placebo|For the treatment group (NiuBangZi pill group), patients will be instructed to dissolve NiuBangZi pill (4 g) in 200 mL hot water and take the solution orally twice a day for 3 months. While patients in the placebo group will take NiuBangZi pill placebo as the same way. Besides that, both groups will also administrate MTX (5 mg per week) in addition, and glucocorticoid (less than 5mg a day) if necessary, but any other drugs especially herbs not permit.
223797783|NCT00891267|DRUG|Olmesartan medoxomil tablets low dose|Olmesartan medoxomil tablets low dose, taken once daily for 6 weeks
223797784|NCT00891267|DRUG|Olmesartan medoxomil tablets high dose|Olmesartan medoxomil tablets high dose, taken once daily for 6 weeks
223797785|NCT00891267|DRUG|Amlodipine|Amlodipine tablets taken once daily for 6 weeks
223797786|NCT06141148|DIAGNOSTIC_TEST|sputum analysis|sputum analysis to diagnose tuberculosis
223797787|NCT06141148|DIAGNOSTIC_TEST|lymph node biobsy|to diagnose tuberculous lymphadenitis
223797788|NCT03222648|OTHER|Structured Responsive Exercise Training|Twice weekly, 8 week structured responsive exercise training programme. Protocol used the same as that used in previous EMPOWER Trial (Loughney et al. 2016)
223797789|NCT03222648|OTHER|Usual Care|Continuation of usual care
223797790|NCT04299672|PROCEDURE|Postural reconstruction|Interventions are described in group descriptions
223797791|NCT05755308|PROCEDURE|Autologous FMT|Autologous faecal microbiota transplantation by colonoscopy.
223797792|NCT05755308|PROCEDURE|Placebo FMT|Placebo FMT will consist of 250 mL water. Placebo infusions will be delivered by colonoscopy.
223797793|NCT01625221|DEVICE|Magnetic Anal Sphincter|The implantable single-use Magnetic Anal Sphincter (FENIX) device consists of a series of titanium beads with magnetic cores that are linked together with independent titanium wires forming an annular shape. The device is supplied sterile and is placed through an open incision.
223797794|NCT04180618|OTHER|Personal health wallet service for emergency situation|Patients(caregivers) and medical staffs will be provided the personal health wallet service and evaluate the effectiveness and satisfaction for the service.
223797795|NCT03541070|DEVICE|Kinesiology tape|Kinesiology taping (KT) was developed by Kenzo Kase in the 1970s. KT has similar thickness and flexibility to the skin. These tapes are used in orthopedic and sports injuries as well as neurological and rheumatic diseases, pediatric patients, lymph edema and painful conditions. These tapes are used for correcting muscle function, increasing circulation, increasing proprioception, reducing pain, and repositioning the sublease joint according to the usage method
223797796|NCT05163366|DRUG|GROUP A|Rectal Ketamine will be administered at 6 mg/kg and with a rectal nozzle it's infused through the rectum. The rectal ketamine will be administered after scoring pain just before the start of the procedure and then about 15 minutes later the procedure will start when the patient has achieved a nystagmus.
223797797|NCT05163366|DRUG|GROUP B|The tradition standard protocols involve the use of 0.3mg/kg of oral morphine about an hour before the start of the procedure before the start of the procedure to allow for the onset of action of oral morphine for every single procedure in this arm.
223797798|NCT00001587|PROCEDURE|Isolated hepatic portal and arterial perfusion|
223797799|NCT00001587|DRUG|Melphalan|
223797800|NCT06580236|DRUG|B11-FC|Infusion
223797801|NCT06580236|DRUG|Botulinum neurotoxin type A|Infusion
223797802|NCT06580236|OTHER|Placebo|Infusion
223797803|NCT01206998|DRUG|Vaginal progesterone gel|Subjects will receive daily vaginal progesterone gel provided by Columbia laboratories (1.125g progesterone gel containing 90mg (8%) progesterone)
223797804|NCT01206998|DRUG|Placebo vaginal gel|Subjects will receive daily placebo vaginal gel, made of an identical bioadhesive delivery system as the active drug
223797805|NCT01473667|PROCEDURE|Superficial Cervical Plexus Block (SCP) block|SCP block using 10-15ml of 1% Ropivacaine
223797806|NCT01473667|PROCEDURE|Local site infiltration|Local site infiltration using 2% lidocaine
223797807|NCT00599612|DRUG|GW856553|A dose of 10mg GW856553 containing 50µCi of \[14C\]GW856553 will be delivered as 100mL of a 0.1mg/mL GW856553/0.5 µCi/mL oral solution.
223797808|NCT02219022|OTHER|Control group|
223797809|NCT02219022|OTHER|Experimental group|
223797810|NCT03015402|DRUG|Sodium Nitrite|40 mg PO (by mouth) TID (three times each day) for 10 weeks
223797811|NCT03015402|DRUG|Placebo Oral Capsule|Placebo capsule that is of identical size, shape, and color to experimental drug capsule PO (by mouth) TID (three times each day) for 10 weeks
223797812|NCT04606355|DIAGNOSTIC_TEST|Visual Acuity|autostereoscopic, monocular dynamic force choice test
223797813|NCT04606355|DIAGNOSTIC_TEST|stereopsis|autostereoscopic dynamic forced-choice depth perception test
223797814|NCT04606355|DIAGNOSTIC_TEST|Color vision|autostereoscopic forced choice monocular or binocular color vision tests
223797815|NCT06102265|PROCEDURE|sterilization|the use of sterilization methods and the reuse of gowns
223797816|NCT04775914|PROCEDURE|PCI + Ischemic conditioning|IPOST is repeated for 4 cycles (60 sec obstruction followed by 60 sec perfusion each) and followed by stent implantation with a 1.1/1.0 ratio of stent diameter/reference vessel diameter and a stent length sufficient to cover the entire lesion from healthy to healthy area of the vessel. During the first cycle of re-occlusion of full vessel occlusion is secured by a small injection of contrast.
223797817|NCT04775914|PROCEDURE|Stent with ultrasound|IVUS catheters are to be advanced at least 20 mm distal to the culprit lesion. After administration of intracoronary nitroglycerine, an IVUS-pullback is to be performed at 0.5mm/second using a commercially available imaging system. Stent size and landing zones are decided based on the IVUS.
223797818|NCT00312793|DEVICE|stimulation of the quadriceps muscle with Myospare|
223797819|NCT02335073|OTHER|Venous blood|
223797820|NCT04169308|DRUG|Restylane-L® Filler injection|Restylane-L® Filler injection into the soft tissue of the nose
223797821|NCT03213158|DRUG|Ixazomib Oral Capsule|Highly sensitized kidney transplant candidates on the waitlist for more than 24 months will receive ixazomib 3 mg (and dexamethasone 20 mg) on days 1, 8, and 15 of a 28 cycle. Patients will take ixazomib and dexamethasone for twelve (12) 28-day cycles.
223797822|NCT04576468|PROCEDURE|Open flap debridement|Surgical intevention
223797823|NCT04576468|PROCEDURE|perforated membrane|surgical intervention
223797824|NCT04576468|PROCEDURE|leucocyte - platelet rich fibrin|surgical intervention
223797825|NCT04873648|BEHAVIORAL|caloric reduced -intermitted fasting diet|obese women with food addiction and binge eating follow intermittent calorie restriction diet ( time-restricted eating - typically 16 -hour fasting and 8-hour eating)
223797826|NCT04873648|BEHAVIORAL|Daily calorie restriction|obese women with food addiction and binge eating disorder follow a Daily calorie restriction diet
223797827|NCT04873648|BEHAVIORAL|Control group|obese women without food addiction and binge eating disorder follow a Daily calorie restriction diet
223797828|NCT01684748|DRUG|Olmesartan medoxomil|Crossover intervention comparing antihypertensive medication to no drug intervention.
223797829|NCT03434938|BEHAVIORAL|Motivational interviewing|"MI sessions' goals will to obtain patients' collaboration, creating a shared tailored approach to complement the individual geriatric rehabilitation plan, and reinforcing engagement and adherence at 3 months.~All 20-minutes sessions will follow the logical sequence of MI by Rollnick and Millner (engaging, focusing, evoking and planning) in a semi-structured format to ensure homogeneity. Content will include: 1) Creating engagement with patients by exploring their preferences, values, goals, and their knowledge and expectations about rehabilitation and recovery, 2) enhancing motivation by evoking patients' strengths and abilities, 3) follow-up and reinforcement, and 4) adapting the plan to the improved abilities and to home setting after discharge."
223797830|NCT01995461|DRUG|bilateral transforaminal epidural steroid injections|BTESI with local anesthetic and steroid, and the use of x-ray contrast, under fluoroscopy guidance performed by the PI. 10mg of dexamethasone (1cc) mixed with 1cc of 2% preservative-free xylocaine (lidocaine) will be injected on each side of the stenotic segment under fluoroscopic guidance after confirming epidural x-ray contrast (1-2cc) spread right before the steroid mixed with local anesthetic injection. The injection may be repeated, but not before 2 weeks after the first injection.
223797831|NCT00466518|DRUG|Administration of sitagliptin|Sitagliptin 100 mg daily for 3 months
223797832|NCT00712361|DEVICE|Non Invasive peripheral blood screening (Cnoga Medical Ltd.,SofTouch,OnlyTouch, CM-CL-R-007, CMC 07015922,HT 4502, HTA 4502)|Non Invasive screening of various independent peripheral blood parameters: Glucose, hemoglobin, Hematocrit, blood pressure, pulse, SpO2, CO2, pH.
223797833|NCT00134979|DRUG|Formoterol|
223797834|NCT05717556|PROCEDURE|Internal Jugular Vein Catheterization|Inserting a cannula into the internal jugular vein
223797835|NCT03372200|DRUG|FYU-981|Oral daily dosing for 14 weeks
223797836|NCT03372200|DRUG|Febuxostat|Oral daily dosing for 14 weeks
223797837|NCT00202202|PROCEDURE|consultation format|
223797838|NCT04763057|DRUG|NeoPUTTY MTA|NeoPUTTY, a premixed bioactive bioceramic MTA that triggers hydroxyapatite and supports healing
223797839|NCT04763057|DRUG|calcium hydroxide|Calcium hydroxide the gold standard for IPT
223797840|NCT00824226|DIETARY_SUPPLEMENT|magnesium|magnesium 350 mg tablets once a day for 3 weeks
223797841|NCT05223985|DEVICE|Depth Coagulation Electrode|SEEG and thermocoagulation
223797842|NCT00736645|DIETARY_SUPPLEMENT|selenomethionine|Given orally
223797843|NCT00736645|DRUG|finasteride|Given orally
223797844|NCT00736645|OTHER|placebo|Given orally
223797845|NCT00979836|DRUG|Calcium Dobesilate|500 mg/ three times/day for 6 months (capsules)
223797846|NCT00219076|DRUG|aliskiren|
223797847|NCT00700921|DRUG|Lovastatin|40mg po once daily
223797848|NCT00700921|DRUG|Placebo|One capsule, once daily
223797849|NCT01049126|OTHER|ChemoFx|Chemoresponse Marker Assay
223797850|NCT00003214|DRUG|carboplatin|
223797851|NCT00003214|DRUG|cisplatin|
223797852|NCT00003214|DRUG|cyclophosphamide|
223797853|NCT00003214|DRUG|doxorubicin hydrochloride|
223797854|NCT00003214|DRUG|in vitro sensitivity-directed chemotherapy|
223797855|NCT00003214|DRUG|paclitaxel|
223797856|NCT02955264|DIETARY_SUPPLEMENT|D-Galactose|D-Galactose is an oral powdered dietary supplement to be taken by mouth.
223797857|NCT03565081|DEVICE|PWS elastic band training group|PWS participants received 9 sets exercises for the major muscle groups, over 24 weeks, three times a week, for a total of 72 sessions.
223797858|NCT01866228|OTHER|Consultation Recording|
223797859|NCT06132880|DRUG|Human Urinary Kallidinogenase|Intravenous injections of urinary kallidinogenase (0.15 peptide nucleic acids (PNA) in 0.9% NaCl) intravenous drip QD for 10 days.
223797860|NCT06132880|OTHER|Clinical Routine Treatment|Conventional therapy of acute ischemic stroke after based on Chinese guidelines
223797861|NCT02080468|DRUG|lomitapide|20 mg
223797862|NCT02080468|DRUG|EE/norgestimate|1x0.035-mg EE/0.25-mg norgestimate tablet
223797863|NCT00047801|DRUG|TLK286 in combination with docetaxel|
223797864|NCT03547843|BEHAVIORAL|Group-based education|The group-based educational program consists of two sessions that run over two consecutive weeks. Each session consists of a lecture from a recruited expert on the topic of the session and by expert patients with a following discussion of the topic facilitated by the course leader.
223797865|NCT03547843|BEHAVIORAL|Waiting list|No educational intervention for the duration of the 10 weeks. During this period participants can receive standard treatment.
223797866|NCT03547843|OTHER|Standard treatment|Diagnostic treatment with medication. In addition, some patients receive cognitive behavioral therapy (not systematically given to every patient). If needed, patients are also offered assistance with regard to economy, housing, education, and work as well as contact with family and network.
223797867|NCT00881179|DRUG|Clarithromycin 250 mg Tablets (Geneva Pharmaceuticals, USA)|
223797868|NCT00881179|DRUG|Biaxin (Clarithromycin) 250 mg Tablets (Abbott Laboratories, Inc, USA)|
223797869|NCT00295022|DRUG|Placebo|"* Pharmaceutical form: Over-encapsulated tablet~* Route of administration: Oral use"
223797870|NCT00295022|DRUG|Montelukast|"* Pharmaceutical form: Over-encapsulated tablet~* Concentration: 10 mg~* Route of administration: Oral use"
223797871|NCT00295022|DRUG|Levocetirizine|"* Pharmaceutical form: Over-encapsulated tablet~* Concentration: 5 mg~* Route of administration: Oral use"
223797872|NCT00734630|DRUG|nebivolol|"Encapsulated Nebivolol 5mg, 10mg, 20mg, or 40mg total daily dosage, oral administration once daily~Lisinopril 10mg, 20mg total daily dosage, oral administration Losartan 50mg, 100mg total daily dosage, oral administration"
223797873|NCT00734630|DRUG|Placebo|Lisinopril 10mg, 20mg total daily dosage, oral administration Losartan 50mg, 100mg total daily dosage, oral administration
223797874|NCT03211286|DRUG|Tranexamic Acid|1 g of intravenous tranexamic acid in 100 mL of saline solution
223797875|NCT03211286|DRUG|Saline Solution|saline solution 100 mL intravenous
223797876|NCT04489043|OTHER|Exercise and healthy lifestyle recommendations|In the present study, renal transplant patients with proven prediabetes will do a planned exercise programme to test the impact of this treatment on the reversibility of prediabetes. Thus, the persistance of recurrency of prediabetes assessed by an Oral Glucose Tolerant Test (OGTT) at intermediate time points (3, 6 and 9 months) will be checked in order to increase the frequency and duration of aerobic exercise and eventually to add anaerobic/resistance training.
223797877|NCT04204629|DRUG|HIP1601 40mg|Single dosing of HIP1601 40mg, PO
223797878|NCT03742700|BEHAVIORAL|Cigarette smoking|T-smokers were asked to smoke a cigarette of one of the popular brands (0.6mg nicotine per one cigarette) according to their everyday habits.
223797879|NCT03742700|BEHAVIORAL|E-cigarette use|E-smokers and dual users were instructed to use e-cigarettes (12 mg/ml nicotine) in accordance with everyday habits for 5 minutes.
223797880|NCT03742700|BEHAVIORAL|Simulation of the use of e-cigarette|The control subjects were asked to simulate the use of e-cigarettes (a device without e-liquid where aerosol was not created or inhaled).
223797881|NCT06497244|PROCEDURE|micro osteo-perforation|the patient will receive miniscrew micro osteo-perforation in one side every month with molar distalization and the other side the distalization without micro osteo-perforation
223797882|NCT05943457|DIETARY_SUPPLEMENT|Vitamin K2 or menaquinone-7|Vitamin K2 (MK7) 360 mcg/day orally once daily for 6 months
223797883|NCT05943457|OTHER|Placebo|Placebo pills will be administered orally once daily for 6 months
223797884|NCT02701712|RADIATION|Magnetic resonance - guided radiation therapy (MRgRT)|Use of magnetic resonance (MR) visualization for interventional radiotherapy in cancer patients
223797885|NCT04568135|OTHER|survey|survey
223797886|NCT05381155|BEHAVIORAL|A single-session behavioral intervention composed of a brief evocation of the childbirth memory followed by a Tetris gameplay|"The intervention is composed of two tasks:~1. The childbirth narration task (8-10 min.): To trigger the malleability of the traumatic childbirth memory through memory reactivation, a psychologist will ask the participants to briefly narrate their childbirth and the moment associated with their most frequent or distressing CB-ITM. This intervention part will take place on the maternity ward to use this context as a reactivation cue.~2. The visuospatial task (3 min. practice + 20 min. gameplay): Participants will be instructed to engage in a Tetris gameplay for 20 minutes on a handheld gaming device (Nintendo 3DS), which is assumed to disrupt memory reconsolidation. This part of the intervention will take place in a neutral room."
223797887|NCT05695781|DRUG|BRM421 Ophthalmic Solution|A topical drop of BRM421 ophthalmic solution.
223797888|NCT05695781|DRUG|Vehicle|A topical drop of vehicle (minus active) ophthalmic solution.
223797889|NCT03084666|DEVICE|Zimmer ATS tourniquet system|The tourniquet is the same kind that is used in orthopedic surgeries to limit blood loss in arm or leg surgery. It can be inflated to a set pressure for a set amount of time.
223797890|NCT01201057|DRUG|0.5% SPL7013 Gel|Vaginal gel
223797891|NCT01201057|DRUG|1.0% SPL7013 Gel|Vaginal gel
223797892|NCT01201057|DRUG|3.0% SPL7013 Gel|Vaginal gel
223797893|NCT01201057|OTHER|Placebo Gel|Vaginal gel
223797894|NCT00369330|DEVICE|external electrical cardioversion|
223797895|NCT06230003|DRUG|Ropivacaine|Ultrasound guided ESP block either with the local anesthetic of 0.5% of Ropivicane 20 mL bilaterally (intervention group) or normal saline (control group) before surgery which will take 5-10 minutes in a 1:1 ratio.
223797896|NCT06230003|DRUG|normal saline|Ultrasound guided bilateral ESP block either with normal saline
223797897|NCT04259086|DRUG|DaxibotulinumtoxinA for injection|Intramuscular injection
223797898|NCT02060851|OTHER|standard PN|Group 1: a control group who received standard PN
223797899|NCT02060851|DRUG|Vifor|iron sucrose, 200 μg/kg per day, was given everyday with PN,
223797900|NCT02060851|DRUG|Vifor and EPO|EPO, 400U/kg, was given twice a week (Monday and Friday). IS, 200 μg/kg per day, was given everyday with PN, and the dose was continued until 2 weeks after birth
223797901|NCT05318794|DRUG|Doxorubicin and Cisplatin|Pressurised intraperitoneal aerosol chemotherapy
223797902|NCT05094531|OTHER|Primary prevention programm|This programm aims to adress three dimensions : (i) biophysiology (flexibility of the autonomic nervous system), (ii) psychology (flexibility of coping strategies, sens of mission) and (iii) the social (stigmatization, seeking health care).
223797903|NCT01850979|DRUG|Tacrolimus|tacrolimus 0,03% eyedrops (olive oil vehicle) every 12 hours for 3 months placebo : olive oil eyedrops every 12 hours for 3 months
223797904|NCT01850979|DRUG|Olive Oil|All patients in this groups receive eye drops containing olive oil (vehicle of tacrolimus eye drops) twice a day (every 12 hours) for 90 days.
223797905|NCT03792126|OTHER|Implicit Learning Approach|"All mobility focussed rehabilitation sessions will utilise the Implicit Learning Approach (ILA), as usual care. This includes rehabilitation (delivered by a physiotherapist, occupational therapist or therapy assistant) that focusses on sitting, sit to stand, standing, stepping, transfers and walking. The content of therapy will be based on the treatment guidelines and intervention manual - and primarily involves changing the quantity and focus of attention of instructions and feedback.~As this is a clinically grounded, pragmatic trial, therapists will have freedom to tailor the specific content of each treatment session to patient need, whilst remaining true to the ILA."
223797906|NCT06226246|BEHAVIORAL|HEROS VR CPR training program|HEROS VR training program which combined video training and VR session
223797907|NCT06226246|BEHAVIORAL|Conventional HEROS CPR training program|Conventional HEROS training program using video learning
223797908|NCT03240692|DEVICE|Accelerated theta-burst stimulation treatment|"All participants will receive intermittent theta-burst stimulation (iTBS) to the left dorsal lateral prefrontal cortex (L-DLPFC). The L-DLPFC will be targeted utilizing the Localite neuronavigation system. Stimulation intensity will be standardized at 90% of resting motor threshold (adjusted for cortical depth).~Stimulation will be delivered to L-DLPFC using the Magventure Magpro X100 and/or the NextStim TMS system."
223797909|NCT06005233|DEVICE|Smartwatch|Smartwatch with PPG- and 1-lead ECG derived analysis of cardiac arrhythmia. Analysis will be performed centrally at the Cardiology Core Lab at the Klinikum Rechts der Isar.
223797910|NCT02300220|DRUG|Ciprofloxacin|500 mg, twice daily for 1 week (oral)
223797911|NCT02300220|DRUG|Placebo|One capsule, twice daily for 1 week
223797912|NCT04322682|DRUG|Colchicine|Patients in this arm will receive study medication colchicine 0.5 mg per os (PO) twice daily for the first 3 days and then once daily for the last 27 days. If a dose is missed, it should not be replaced.
223797913|NCT04322682|DRUG|Placebo oral tablet|Patients will receive the placebo 0.5 mg per os (PO) twice daily for the first 3 days and then once daily for the last 27 days. If a dose is missed, it should not be replaced.
223797914|NCT06568562|DRUG|XL092|XL092 will be supplied as a tablet that will be taken at home once a day. Participants should drink at least 8 ounces of water with each dose of XL092. Participants should not eat at least 2 hours before taking the dose and 1 hour after. Participants will be given enough XL092 to take at home for a full cycle.
223797915|NCT06112756|DRUG|Elinzanetant|Oral
223797916|NCT06112756|OTHER|Placebo|Oral
223797917|NCT00173108|BEHAVIORAL|clinic-based intervention program and home-based intervention program|The intervention includes education of child development skills, health and feeding consultation, intervention of mother-infant interaction, and parent support. Clinic-based intervention program is delivered in clinic while home-based intervention program is delivered at home.
223797918|NCT00349089|DRUG|Pemetrexed|Pemetrexed 500 mg/m2 d1 and Cisplatin 75 mg/m2 d1; q d22
223797919|NCT00349089|DRUG|Cisplatin|"Pemetrexed 500 mg/m2 d1 and Cisplatin 75 mg/m2 d1; q d22~Comparator:~Vinorelbine 25 mg/m2 d1, 8, 15, 22; q d29 Cisplatin 50 mg/m2 d1, 8; q d29"
223797920|NCT00349089|DRUG|Vinorelbine|Vinorelbine 25 mg/m2 d1, 8, 15, 22; q d29
223797921|NCT01027000|BIOLOGICAL|rituximab|
223797922|NCT01027000|DRUG|busulfan|
223797923|NCT01027000|DRUG|cyclophosphamide|
223797924|NCT01027000|DRUG|fludarabine phosphate|
223797925|NCT01027000|DRUG|methotrexate|
223797926|NCT01027000|DRUG|sirolimus|
223797927|NCT01027000|DRUG|tacrolimus|
223797928|NCT01027000|PROCEDURE|allogeneic stem cell transplant|
223797929|NCT01835951|OTHER|Grouped Debriefing|Debriefing consists in an analysis by the investigator of the management of the anaesthesia crisis simulated in the presence of all the subjects included in the Groupe Debriefing group.
223797930|NCT01835951|OTHER|Individual Debriefing|Individual debriefing consists in a individual meeting between each subject of the study and the investigator to analyze the management of the anaesthesia crisis simulated.
223797931|NCT03119467|DRUG|RP4010|Escalating doses starting at 25 mg
223797932|NCT02455648|PROCEDURE|ESD/EMR plus Cell Sheet|"Patients receive ESD/EMR plus CellSheet:~Autologous oral mucosa/buccal-derived epithelial cells, cultured on temperature-sensitive membrane (Cell Sheet) that are inserted 2 weeks later on the occasion of the ESD or EMR"
223797933|NCT02455648|PROCEDURE|ESD/EMR|"only ESD/EMR: Autologous oral mucosa/buccal-derived epithelial cells, cultured on temperature-sensitive membrane (Cell Sheet) but NOT used for insertion in the patient during/after ESD/EMR two weeks later"
223797934|NCT00554879|PROCEDURE|Acupuncture|Needles placed bilaterally on the ears at the auriculotherapy points. Additional needles placed in both index fingers. A third set of needles inserted on both index fingers between LI-1 adn LI-2.
223797935|NCT00554879|PROCEDURE|Sham acupuncture|Four needles will be placed on the left and right upper shoulder areas. Small circular adhesive tape will be placed in an ear area, but not on the acupuncture points.
223797936|NCT02804568|DRUG|ALKS 3831|Oral capsule, daily administration
223797937|NCT02238379|DRUG|Oxytocin|24 International Units of Oxytocin in a Nasal Spray
223797938|NCT02238379|OTHER|Placebo|Placebo will contain all ingredients except the active oxytocin in the Nasal Spray.
223797939|NCT00009828|DRUG|leucovorin calcium|
223797940|NCT00009828|DRUG|paclitaxel|
223797941|NCT00009828|DRUG|tegafur-uracil|
223797942|NCT01176487|OTHER|questionnaire administration|
223797943|NCT01176487|PROCEDURE|quality-of-life assessment|
223797944|NCT01176487|RADIATION|3-dimensional conformal radiation therapy|
223797945|NCT01176487|RADIATION|palliative radiation therapy|
223797946|NCT01176487|RADIATION|whole-brain radiation therapy|
223797947|NCT04123067|DRUG|Pioglitazone 45 mg|45mg Pioglitazone daily for three subsequent days, initiated within 12h of stroke symptom onset
223797948|NCT04123067|DRUG|Placebo oral tablet|placebo daily for three subsequent days, initiated within 12h of stroke symptom onset
223797949|NCT00441090|DRUG|Placebo|Placebo tablets 2.5, 5, 10 and 20 mg taken orally once daily for 28 days.
223797950|NCT00441090|DRUG|Avatrombopag tablets|Avatrombopag tablets 2.5, 5, 10 and 20 mg taken orally once daily for 28 days.
223797951|NCT00410033|DRUG|soluble human insulin|
223797952|NCT00410033|DRUG|isophane human insulin|
223797953|NCT00410033|DRUG|insulin aspart|
223797954|NCT02089256|DRUG|Liraglutide|"Graded glucose infusion test (GGIT)will be performed on baseline. 1 week later treatment with liraglutide 0.6mg/day (injected between 21.00-23.00) will be initiated.~GGIT will be repeated 12 hours after first injection and after 21 days on-treatment (12 hours after last injection)."
223797955|NCT06170541|DEVICE|Aquilion Precision|Ultra-High Resolution CT (UHR CT) capable of resolving anatomy as small as 150 microns, providing CT image quality with resolution typically seen only in cath labs. The UHR detector is newly designed to provide more than twice the resolution when compared with today's CT technology, with an all-new detector as well as tube, gantry and reconstruction technologies.
223797956|NCT06170541|DEVICE|Conventional Computed Tomography|Conventional reconstruction Computed Tomography (CT) represents a pivotal approach in medical imaging.
223797957|NCT06205667|PROCEDURE|Computer Guided Arthrocentesis|patients are going to be injected intra-articular within the superior joint space of the affected TMJ through custom guided template planned in a manner inspired by earphone design to get support from the tragus.
223797958|NCT06205667|PROCEDURE|Conventional Arthrocentesis|patients are going to be injected intra-articular within the superior joint space of the affected TMJ using conventional method anatomical landmark determination
223797959|NCT01441102|DRUG|Dextromethorphan hydrobromide|Participants instructed to take 60 mg dextromethorphan capsules orally two times a day for 24 months.
223797960|NCT05599828|DRUG|AMG 510|Oral Tablet
223797961|NCT05599828|DRUG|Omeprazole|Capsule
223797962|NCT05599828|DRUG|Famotidine|Tablet
223797963|NCT04389450|BIOLOGICAL|PLX-PAD|PLX-PAD, allogeneic ex vivo expanded placental mesenchymal-like adherent stromal cells
223797964|NCT04389450|BIOLOGICAL|Placebo|Placebo solution for injection
223797965|NCT06504615|DRUG|nivolumab + chemotherapy|As prescribed by the treating clinician, as per product label
223797966|NCT04893486|DRUG|PTX-022|QTORIN 3.9 % Sirolimus Topical Gel
223797967|NCT04893486|DRUG|Vehicle comparator|Vehicle comparator topical gel
223797968|NCT03085485|DRUG|Ivacaftor 150 MG|Ivacaftor is a CFTR potentiator
223797969|NCT03085485|DRUG|Placebo|placebo pills
223797970|NCT03746366|RADIATION|[C-11]|Radiolabel
223797971|NCT03746366|DRUG|Pittsburgh Compound B|Tracer
223797972|NCT04571398|OTHER|ApricityRx mobile application|AE detection and monitoring software
223797973|NCT00005057|BIOLOGICAL|adenovirus RSV-TK|
223797974|NCT00005057|DRUG|ganciclovir|
223797975|NCT00605280|DRUG|Standard of Care|Clinicians decision to use optional laser therapy.
223797976|NCT00605280|DRUG|Macugen|Intravitreal injection of Macugen 0.3mg/90ul every 6 weeks up to 2 years.
223797977|NCT04986176|DRUG|HC-1119|oral
223797978|NCT04986176|DRUG|Placebo|oral
223797979|NCT06221566|OTHER|Muscle Energy Technique|"Muscle energy technique (MET) for upper trapezius and levetor scapulae muscle of neck with 7 to 10 second hold, 3 to 5 repetitions.~Transcutaneous electrical nerve stimulation (TENS) with Cold pack.~Home exercise program (HEP) will receive by both the groups which will be not supervised by the principal investigator or any other investigator."
223797980|NCT06221566|OTHER|Stretching Exercises|"Stretching exercises program for upper trapezius and levetor scapulae muscle of neck with 10 second hold, 15 repetitions.~Transcutaneous electrical nerve stimulation (TENS) with Cold pack.~Home exercise program (HEP) will receive by both the groups which will be not supervised by the principal investigator or any other investigator."
223797981|NCT04663048|PROCEDURE|PiXL|Phototherapeutic intrastromal corneal collagen cross-linking (PiXL) performed in a high-oxygen environment without corneal epithelial debridement, for treatment of low grade myopia.
223797982|NCT01710072|DRUG|aspirin|
223797983|NCT03152253|BEHAVIORAL|Text My Quit (TMQ)|Text messages designed to aid smoking cessation
223797984|NCT03152253|BEHAVIORAL|Peer Support|A group chat room for peer support
223797985|NCT03152253|OTHER|Motivational Messages|Generic motivational messages not related to smoking cessation
223797986|NCT01662882|DRUG|florbetapir (18F)|IV injection, 370 MBq(10mCi), single dose
223797987|NCT02234869|DRUG|Interferon Beta|Subcutaneous injection
223797988|NCT02234869|DRUG|BIIB017 (Peginterferon beta-1a)|Single-use, disposable, prefilled pen for subcutaneous injection
223797989|NCT05243758|DEVICE|Group video fiberscope of experienced practitioner|One of the classical alternatives to laryngoscopy in difficult endotracheal intubation is video laryngoscopyvideo fiberscope( Karl Storz GmbH \&Co. KG, Tuttlingen, Germany). Reaching the image from the patient with pre- and from the cervical point of view, or from the cervical point of view, to be completed with a good view from a large screen to be completed with an image before and within intubation. It also facilitates learning in education.
223797990|NCT05243758|DEVICE|Group video laryngoscope of experienced practitioner|Intubation Pending Difficult as well as challenging . Fiberoptic (fiberscope) intubation is the gold standard in difficult airway. Lacking this supplement, it will be widely used for practice, as it is suitable for video laryngeal.
223797991|NCT05243758|DEVICE|Group video fiberscope of less experienced practitioner|One of the classical alternatives to laryngoscopy in difficult endotracheal intubation is video laryngoscopy video fiberscope( Karl Storz GmbH \&Co. KG, Tuttlingen, Germany). Reaching the image from the patient with pre- and from the cervical point of view, or from the cervical point of view, to be completed with a good view from a large screen to be completed with an image before and within intubation. It also facilitates learning in education.
223797992|NCT05243758|DEVICE|Group video laryngoscope of less experienced practitioner|Entubation pending difficult as well as challenging . Fiberoptic (fiberscope) intubation is the gold standard in difficult airway. Lacking this supplement, it will be widely used for practice, as it is suitable for video laryngeal.Storz DCI Video Laryngoscope (Karl Storz GmbH \&Co. KG, Tuttlingen, Germany)
223797993|NCT05258110|DRUG|midazolam|midazolam
223797994|NCT05258110|DRUG|BI 425809|BI 425809
223797995|NCT02959489|BEHAVIORAL|Alzheimer's Disease Risk Disclosure|Subjects will learn a numerical risk estimate for the chance of progressing to dementia of the Alzheimer's type.
223797996|NCT02959489|BEHAVIORAL|Amyloid Brain Imaging and Alzheimer's Disease Risk Disclosure|"Subjects will learn their own elevated or not elevated amyloid results and a numerical risk estimate for the chance of progressing to dementia of the Alzheimer's type."
223797997|NCT02961465|DEVICE|Sacral Neuromodulation|"SNM starts with a screening phase. In this phase a tined lead is inserted into the third sacral foramen and attached to an external stimulator, after which the patient enters a four-week stimulation test period.~If the screening phase is successful (defecation frequency (DF) ≥3 a week), the external stimulator is changed for a pacemaker that is implanted in the buttocks. If the screening phase is unsuccessful (DF \<3 a week), the lead is explanted. Patients are asked to limit the use of additional conservative treatments for constipation (such as laxatives and colonic irrigation) to what is necessary to relieve (the most severe) complaints. What is necessary to relieve complaints is determined by the patient."
223797998|NCT00115115|DRUG|Dopamine infusion to brain dead organ donors|Dopamine infusion administered at a dosage of 4µg/kg/min starting after brain death has been proven until to surgical procurement of the kidneys
223797999|NCT01935817|DRUG|Silybin 94 mg + vitamin E 90 mg + phospholipids 194 mg complex|
223798000|NCT01935817|DRUG|Placebo|
223798001|NCT05260801|OTHER|Bright Lighting|The bright lighting condition will administer the light intensity as determined from the finding of Study 1. Bright lighting condition will last for two weeks (Weeks 2-3 or 4-5), be limited to the 10 workdays, and be active for 8 hours per day.
223798002|NCT05260801|OTHER|Placebo Lighting|The placebo condition will expose participants to 150 lux, a light level that is equivalent to average room lighting. Placebo lighting condition will last for two weeks (Weeks 2-3 or 4-5), be limited to the 10 workdays, and be active for 8 hours per day. The placebo lighting condition will be applied to minimize the bias and false improvements that might occur due to experiencing new lighting conditions and devices.
223798003|NCT04101643|DRUG|evolocumab|Eligible patients receive subcutaneous injections of evolocumab 420 mg
223798004|NCT05789043|DRUG|camrelizumab+apatinib+TMZ|camrelizumab 200mg，q2w+apatinib 250mg，qd+TMZ 200mg/m2，day1-5/28
223798005|NCT05789043|DRUG|camrelizumab+apatinib|camrelizumab 200mg，q2w+apatinib 250mg qd
223798006|NCT05789043|DRUG|camrelizumab|camrelizumab 200mg，q2w
223798007|NCT00843167|DIETARY_SUPPLEMENT|broccoli sprout extract|Given orally
223798008|NCT00843167|OTHER|placebo|Given orally
223798009|NCT03030222|DRUG|Empagliflozin 10 mg Tab|Empagliflozin 10 mg Tab
223798010|NCT03030222|DRUG|Placebo Oral Tablet|Empagliflozin matching placebo
223798011|NCT02291614|DRUG|AMG 211|continuous intravenous infusion (cIV) infusion in cycles from 7 to 28 days
223798012|NCT05060328|OTHER|Medical Device Usage and Evaluation|"Use Google Translate Conversation Mode translation application."
223798013|NCT05060328|OTHER|Survey Administration|Complete survey
223798014|NCT02806375|PROCEDURE|Allogeneic hematopoietic stem cell transplantation|Day 0: Infusion of unmanipulated graft
223798015|NCT02806375|DRUG|Busulfan|Days -5 through -3: Busulfan 1 mg/kg po qid №10
223798016|NCT02806375|DRUG|Fludarabine monophosphate|Days -7 through -2: 30 mg/m2/day iv qd x 6 days
223798017|NCT02806375|DRUG|Cyclophosphamide|Day +3 and +4: 50 mg/kg/day iv qd
223798018|NCT02806375|DRUG|Ruxolitinib|Days -8 through -2 15 mg tid
223798019|NCT02806375|DRUG|Ruxolitinib|Days +5 through +100: 7.5 mg bid
223798020|NCT06291168|OTHER|Chiropractic Manipulation (HVLA - High Velocity Low Amplitude)|"Participants in the groups receiving DNS will be asked to hold the lower leg in the side lying position with the lower leg in the extended position and to clamp the upper leg to the lower leg with hip and knee flexion. During the application, the HLVA technique will be applied once by positioning the hypothenar part of the physiotherapist's hand on the transverse process of the lumbar vertebra where tenderness is felt by palpation and vertebral subluxation is thought to be present.~After determining that the movement disorder of the sacroiliac joints of the participant is caused by the impaired movement of the ilium in the posterior and inferior direction or the impaired movement of the ilium in the anterior and superior direction, the participant will be asked to take a side lying position.HVLA spinal manipulation was performed for less than one second from posterior to anterior, inferior to superior and medial to lateral directions."
223798021|NCT06291168|OTHER|Yoga-Based Exercise Program|"Yoga treatment includes exercise, respiration, balance and coordination, and stretching and will be performed by a physiotherapist with yoga certification. Patients will be evaluated before treatment, two weeks later, after treatment (at the end of the 8th week) and at the end of the 12th week after treatment (control).~Yoga exercises will be practiced with the classical yoga program, divided into groups of 3-4 people, for 8 weeks, 2 days a week, 60 minutes a day.~It will be applied as a yoga session program including breathing and warm-up exercises, suyanamaskar, various relaxation techniques and asanas."
223798022|NCT06291168|OTHER|Conventional Exercises|Spinal stabilization exercises for the lumbar region will be given in 3 phases following the protocol given to the chiropractic manipulation group. The exercises will be performed two days a week with a physiotherapist. In order to facilitate the memorization and follow-up of the exercises, short videos will be made to facilitate compliance with the exercises by showing the exercises and methods of prevention of low back pain. Individuals will be called to the hospital two days a week for 8 weeks.
223798023|NCT03479320|DRUG|Lidocaine|Postoperative analgesic effects will be compared between lidocaine and normal saline group
223798024|NCT03479320|DRUG|Placebo|Postoperative anlagesic requirements will be calculated and compared with experimental group
223798025|NCT03577210|PROCEDURE|augmentation genioplasty|augmentation genioplasty with patient-specific PEEK implant
223798026|NCT01662310|DRUG|Paliperidone|Paliperidone extended-release (ER) oral tablet will be administered at a starting dose of 3 milligram (mg) up to 12 mg once daily for 8 weeks in Run-in or Stabilization phase, and 3-12 mg fixed dose oral tablet will be administered in DB phase. Participants who will enter open-label extension phase will receive paliperidone as 3-12 mg per day.
223798027|NCT01662310|DRUG|Placebo|Participants who transitioned from run-in or stabilization phase will receive matching placebo to paliperidone ER once daily during DB phase of the study.
223798028|NCT04010994|PROCEDURE|Transorbital electrical stimulation|Transorbital ACS using 8-12 Hz with 0,5-1,5 mA Intensity, during the first two weeks 1/day, after 2/week for 10 weeks, as a home treatment
223798029|NCT03088826|DRUG|Morphine Sulfate|15mg PO morphine sulfate
223798030|NCT03088826|DRUG|Oxycodone|10mg Oxycodone
223798031|NCT03088826|DRUG|Acetaminophen|650 mg Acetaminophen
223798032|NCT03051503|DRUG|The Transdermal Therapeutic System-Fentanyl (TTS-F)|(TTS-F) group (n=30) 50ug/h patch, placed 12 hours preoperatively
223798033|NCT03051503|DEVICE|Intravenous patient-controlled analgesia (PCA) morphine|IV PCA morphine for pain in the postoperative period.
223798034|NCT03973008|RADIATION|Adjuvant Chemoradiotherapy|DT 45Gy/25F/5W, using IMRT technology, synchronous tegio single drug chemotherapy
223798035|NCT03973008|DRUG|Adjuvant Chemotherapy|Oxalis 130mg/m2 intravenous drip on day 1, tegio 80-120 mg daily, twice, half an hour after breakfast and dinner, for 14 consecutive days
223798036|NCT02462707|DRUG|PF-03084014|gamma-secretase inhibitor, formulated in tablets for oral administration containing 10 mg, 50 mg and 100 mg. Patient will receive 80 mg, 100 mg or 150 mg twice daily of PF-03084014 with continuous dosing schedule
223798037|NCT06109987|OTHER|World Dental Federation criteria (FDI)|Restorations were evaluated with FDI criteria.
223798038|NCT05085587|DRUG|Test|2 inhalations of Test and Reference product in each study period
223798039|NCT05085587|DRUG|Reference|2 inhalations of Test and Reference product in each study period
223798040|NCT00683826|DIETARY_SUPPLEMENT|L-Leucine 8gr|Supplementation in the form of a liquid meal (premixed leucine powder solutions with flavor made by the Bionutrition Unit of the Irving Insitute for Clinical and Translational Research (IICTR)). Dosing of leucine will be a combination of 2 ounces of liquid per 1 gm of leucine. L-leucine was purchased (FCC quality) from Spectrum Chemical,California. Certificate of analysis enclosed (99.89% leucine).Liquid meal preparation: Grape juice and crystal light mixes will be used for the preparation of liquid meals that will be given to each participant each week. Participants will consume two 8 ounce drinks (packaged in two 10 ounce bottles) per day. Each drink will be individually prepared with 8 grams of leucine.
223798041|NCT00683826|OTHER|Liquid meal|Liquid meal preparation (contents): Grape juice and crystal light mixes will be used for the preparation of liquid meals that will be given to each participant each week. Participants will consume two 8 ounce drinks (packaged in two 10 ounce bottles) per day. The placebo group will have the same drinks listed above with no leucine incorporated.
223798042|NCT00683826|DIETARY_SUPPLEMENT|L-Leucine 4g|Supplementation in the form of a liquid meal (premixed leucine powder solutions with flavor made by the Bionutrition Unit of the Irving Insitute for Clinical and Translational Research (IICTR)). Dosing of leucine will be a combination of 2 ounces of liquid per 1 gm of leucine. L-leucine was purchased (FCC quality) from Spectrum Chemical,California. Certificate of analysis enclosed (99.89% leucine).Liquid meal preparation: Grape juice and crystal light mixes will be used for the preparation of liquid meals that will be given to each participant each week. Participants will consume two 8 ounce drinks (packaged in two 10 ounce bottles) per day. Each drink will be individually prepared with 4 grams of leucine.
223798043|NCT01619202|BEHAVIORAL|Risk Anticipation -Perception Training|Web-based computer training program designed to teach novice teen drivers how to properly scan for hazards
223798044|NCT00994838|OTHER|reduced calorie diet|10% reduction in total daily calories (≈ 300 kcal reduction) from carbohydrates and fat from the usual daily energy consumption
223798045|NCT03282318|DRUG|ASP6294|Participants will receive 320 mg ASP6294 subcutaneous injection at 4-week intervals at baseline (Day 1/Week 0), Week 4 and Week 8.
223798046|NCT03282318|DRUG|Placebo|Participants will receive placebo to match 320 mg ASP6294 subcutaneous injection at 4-week intervals at baseline (Day 1/Week 0), Week 4 and Week 8.
223798047|NCT05934513|DRUG|GFH009|patients are planned to be administrated with GFH009 every week in a 21 days cycle, intravenous infusion
223798048|NCT01825213|DEVICE|Multispectral CT of the liver|Analysis of the background liver and liver lesions will be performed on Multi Spectral CT images and compared to histology.
223798049|NCT06543446|PROCEDURE|ICD implantation|Surgical implant of ICD device
223798050|NCT06134349|OTHER|Lithium MR imaging|After obtaining written informed consent and within four weeks of reaching a stable therapeutic serum lithium concentration, lithium MR imaging will be performed using a 7 Tesla MR system (Achieva, Philips Medical Systems, Eindhoven, The Netherlands) with a dual-tuned 7Li/1H volume head coil (RAPID Biomedical GmbH, Rimpar, Germany). Various approaches, including whole-brain, voxel-wise, parcellation, mean, and regions of interest, will be applied to measure lithium concentrations.
223798051|NCT04556578|PROCEDURE|High-flow extracorporeal CO2 removal|Applying of a CO2 removal using an extracorporeal circulation with a flow of 2-3.5L/min in order to reduce the aggression induced by the mechanical ventilation.
223798052|NCT06052410|OTHER|Early Intervention|Based on the principles of the Goal, Activity and Motor Enrichment (GAME) approach, which is an evidence-based early intervention approach for children at risk of developmental delay between 24-36 months, activity-based training is aimed at the development of sensory and cognitive skills in addition to the training of motor skills, which are intensively discussed in the content of the approach. Individualized early occupational therapy intervention including strategies was implemented.
223798053|NCT06052410|OTHER|Home Programme|For the control group, evaluation tests were first applied to the babies selected by simple random sampling method. An individualized home program was given according to the evaluation results. Home programs include activities for every skill area and were prepared together with the parents, taking into account the criteria suggested for the success of the home program. Based on these criteria, it was checked whether the family had received another home program, and while preparing the program, care was taken not to overload the parents, importance was given to the family's willingness to receive the home program, activities and goals were decided in cooperation with the parent, thus facilitating the applicability of the activities in daily life, ensuring that the number of activities was 6. Care was taken to ensure that the activity was not too much, the parent was given the necessary time to implement the program, and a phone call was made to the parent every 3 weeks.
223798054|NCT05101239|DEVICE|MRI imaging exam|3T MRI scan using with ultra high performance gradient subsystem (MAGNUS MRI)
223798055|NCT06239168|DIETARY_SUPPLEMENT|Citrus extract|As described in experimental arm
223798056|NCT06239168|DIETARY_SUPPLEMENT|Maltodextrin|As described in comparator arm
223798057|NCT04365660|DRUG|18-F FTC 146|Radiotracer, 10 mCi at pre- and post- chemotherapy, intravenous administration
223798058|NCT00497302|BEHAVIORAL|RBT|Contingency management and behavioral counseling including motivational interviewing
223798059|NCT00497302|BEHAVIORAL|usual care|receives usual comprehensive care at Center for Addiction and Pregnancy
223798060|NCT01811550|OTHER|Glycemic Control|
223798061|NCT03013114|DRUG|Bortezomib|Bortezomib was given by intravenous bolus injection at a dose of 1.3 mg/m2 on days 1, 4, 8 and 11, repeated every 21 days. It will be given four cycles.
223798062|NCT00048516|DRUG|paricalcitol capsule|
223798063|NCT04302350|PROCEDURE|nitrous oxide|During one-lung ventilation with an open chest, the nonventilated lung collapses initially due to elastic recoil, which quickly brings the lung down to its closing capacity. Remaining gas in the lung is then removed by absorption into the pulmonary capillary blood. The rapid diffusion properties of N2O（Blood gas distribution coefficient is 0.47）would be expected to speed lung collapse and so facilitate surgery. The previous study suggested that increasing the concentration of N2O in mixtures of N2O/O2 will lead to a faster rate of collapse. When using nitrous oxide in oxygen during lung ventilation, ongoing oxygen uptake by blood shunting will serve to increase the partial pressure of nitrous oxide in parts of the lung that are still expanded. This will soon result in a partial pressure gradient for nitrous oxide uptake also, with a consequent faster rate of lung collapse than would occur in a patient being ventilated with 100% oxygen.
223798064|NCT03024073|PROCEDURE|BB-Phaco|Phacoemulsification with bilateral bifocal lenses implantation
223798065|NCT02118220|OTHER|Concussion Questionnaire|
223798066|NCT04659655|PROCEDURE|automated annular suturing|RAM® Automated Suturing Technology. The RAM® DEVICE and SEW-EASY® DEVICE are automated suturing devices indicated for use in the approximation of soft tissue and prosthetic materials when used in conjunction with RAM® COR-SUTURE® QUICK LOAD® surgical suture. Devices will be used for the approximation of respective replacement valves during surgical aortic or mitral valve replacement as described in the study protocol. Cases may include use of the RAM® RING/RAM® RACK devices for suture management and the Aortic Root Retractor (ARR) with delivery device.
223798067|NCT04994457|DEVICE|Virtual Reality Visual Field|A head-mounted perimeter with a wireless remote connected to a laptop that monitors responses
223798068|NCT04994457|DIAGNOSTIC_TEST|Standard Automated Perimetry|Standard of care perimeter
223798069|NCT02768896|BEHAVIORAL|Baseline|Patients will walk naturally with EEG measuring brain waves
223798070|NCT02768896|BEHAVIORAL|visual stimuli|Patients will walk naturally with EEG measuring brain waves while seeing a grid through glasses
223798071|NCT02768896|BEHAVIORAL|Auditory stimuli|Patients will walk naturally with EEG measuring brain waves while hearing an auditory stimuli
223798072|NCT02768896|BEHAVIORAL|Visual and auditory stimuli|Patients will walk naturally with EEG measuring brain waves while seeing a grid through glasses and hearing an auditory stimuli simultaneously
223798073|NCT03584451|BEHAVIORAL|rehabilitation sport|rehabilitation Sport over 52 weeks after THA, start 6 weeks postoperatively
223798074|NCT06489613|DIAGNOSTIC_TEST|M protein detection by iMS-LC Assay|"iMS-LC Assay (intact M-protein Screening-Light Chain Assay) technology is a new method for the specific identification of M-proteins in peripheral blood, based on mass spectrometry recognition of intact clonal immunoglobulin light chains. Combined with AI algorithm models, M-proteins can be easily distinguished from the polyclonal background, enabling automated identification and quantitative analysis of M-proteins.~Previous studies have shown that the detection limit of the iMS-LC Assay is several times higher than that of IFE. Additionally, the iMS-LC Assay requires only 5 μL of peripheral blood serum for detection, offering advantages over traditional methods in terms of higher sensitivity, non-invasiveness, lower sample volume requirements, reduced detection costs, and higher throughput."
223798075|NCT03306212|DRUG|Botulinum toxin A|
223798076|NCT03306212|OTHER|Occupational Therapy|
223798077|NCT03306212|OTHER|Intermittent serial casting|
223798078|NCT00149058|DRUG|Erythropoietin|
223798079|NCT03694639|OTHER|ganglion impar block|CT sections were done in the axial plane 4 mm slice thickness to detect the site of sacrococcygeal disk. After a suitable section was confirmed, two distances were measured, one from patient's spine to the proper site of entry and the other from the site of entry to the target point.22 gauge spinal needle 12 cm was introduced until reach anterior to sacrococcygeal disk. When the needle tip location was ideal, 2 ml lidocaine mixed with1ml of radiopaque dye was injected. CT sagittal section was done to verify the retroperitoneal distribution of the dye. After good contrast spread confirmation, 5 ml bupivacaine 5% with 14 mg/2 ml betamethasone was injected
223798080|NCT05175755|OTHER|Patients|The procedure involves taking a total of 12 ml of blood.
223798081|NCT00313404|BIOLOGICAL|Safety tested norovirus inoculum|This is a safety tested live infectious norovirus inoculum that has been placed in groundwater that meets EPA drinking water standards
223798082|NCT01311674|BIOLOGICAL|hepatitis B vaccine|Primary vaccination series 20 µg/1.0 mL at baseline, month 1, month 6; followed by booster vaccinations 20 µg/1.0 mL
223798083|NCT01311674|BIOLOGICAL|hepatitis B vaccine|Primary vaccination series 40 µg/2.0 mL at baseline, month 1, month 2, month 6; followed by booster vaccinations 20 µg/1.0 mL
223798084|NCT00435604|DRUG|Hylenex|
223798085|NCT04408573|OTHER|Cycling deep brain stimulation|Deep Brain Stimulation applied in cycling - periods of stimulation ON intercalated with periods of stimulation OFF
223798086|NCT03524040|DEVICE|SEB-250|Gold microparticles (SEB-250) are massaged into 2 or 3 2x2 cm facial areas and exposed to 2 pulses from a diode laser
223798087|NCT06085248|DEVICE|Subject-specific optimized RAS|Walking with metronome-based RAS cueing
223798088|NCT06085248|BEHAVIORAL|Active walking|walking without RAS cue
223798089|NCT04074980|DIAGNOSTIC_TEST|Venous and Fingerstick blood draws|Fingerstick sampling to collect blood from subjects Venepuncture to collect blood samples from subjects
223798090|NCT04074980|DIAGNOSTIC_TEST|Venous blood draw|Venepuncture to collect blood samples from subjects
223798091|NCT03234426|OTHER|Perturbation|Manual perturbations were given at waist region,over the Shoulders. in following positions- sitting, kneeling, standing positions,10 perturbations were given in forward,backward,both right and left side, 6 days in a week all precautionary measures taken for the patient's safety
223798092|NCT03234426|OTHER|Conventional Physiotherapy Treatment|Conventional Physiotherapy treatment were given to participants included in this group for 30 mins daily for 4 weeks
223798093|NCT00364429|DRUG|[123]I-CNS 1261|Study Drug
223798094|NCT00364429|DRUG|Lorazepam|Study Drug
223798095|NCT00364429|DRUG|Risperidone|Study Drug
223798096|NCT02012491|DRUG|Misoprostol|
223798097|NCT02012491|DRUG|Mifepristone|
223798098|NCT03278418|PROCEDURE|Tricuspid Valve Repair|It will be performed according to the surgeon preference
223798099|NCT03278418|PROCEDURE|Left-sided valve surgery|It will be performed according to the surgeon preference
223798100|NCT06447857|OTHER|Cardiac MRI|This retrospective study included patients diagnosed with STEMI at the Affiliated Hospital of Xuzhou Medical University. All patients underwent CMR.
223798101|NCT03283904|OTHER|Multicomponent physical activity intervention|School-based multicomponent intervention
223798102|NCT00450411|RADIATION|125-Iodine|Brachytherapy to the prostate via 125-iodine (I-125) seeds with a planned dose of 140 Gy
223798103|NCT00450411|RADIATION|103-palladium|Brachytherapy to the prostate via 103-palladium (Pd-103) seeds with a planned dose of 120 Gy
223798104|NCT00688818|DRUG|Quetiapine|Patients will be initiated on 50 mg of Quetiapine XR and will be titrated to a maximum dose of 300 mg based on response and tolerability. Dosing will be flexible up to Week 8, and then will remain fixed for until the end of the 12 week period.
223798105|NCT00688818|DRUG|Placebo|Patients will be initiated on 50 mg of Placebo and will be titrated to a maximum dose of 300 mg based on response and tolerability. Dosing will be flexible up to Week 8, and then will remain fixed for until the end of the 12 week period.
223798106|NCT02137369|DRUG|Selective serotonin re-uptake inhibitor|Escitalopram, 20mg-40mg daily or Sertraline 50-150 mg daily for 12 weeks
223798107|NCT02137369|BEHAVIORAL|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy, standardized, 16 sessions over 12 weeks.
223798108|NCT02137369|OTHER|Combination treatment (SSRI + CBT)|study participants who do not remit in the first 12 weeks will be offered combination treatment of both treatments for 12 more weeks.
223798109|NCT00912548|DRUG|goserelin|"1. Zoladex™ administration:~   Zoladex™ depot is available as a sterile disposable syringe. The depot is administered subcutaneously under the abdominal skin under sterile conditions. If necessary the injection site may be pre-treated with a local anaesthetic.~2. Sequence of administration Zoladex depot:~   The substance is administered for 24 months (2 years) at 28-day intervals (a period of 34 days between 2 administrations must not be exceeded).~3. Dosage:~   Each depot contains 3.6mg Zoladex. The substance Zoladex is contained in a while cylindrical rodlet .~4. Storage instructions for Zoladex™ Zoladex™ is kept a room temperature."
223798110|NCT00912548|DRUG|tamoxifen|"1. Dose and period of Tamoxifen therapy:~   Tamoxifen is administered in tablet form. Each day 2 X 10 mg or 1 X 20 mg Tamoxifen are taken in the form of the respective tablet.~2. Storage instructions for Tamoxifen Tamoxifen is stored at room temperature away from light."
223798111|NCT02430194|DRUG|lonafarnib|antiviral farnesyl transferase inhibitor
223798112|NCT02430194|DRUG|ritonavir|CYP 3A4 inhibitor, lonafarnib booster
223798113|NCT02430194|DRUG|Pegylated interferon-alfa-2a|immunomodulator
223798114|NCT03249519|RADIATION|Radiation|50.4 Gy
223798115|NCT03249519|RADIATION|brachytherapy|35-40 Gy
223798116|NCT03249519|DRUG|Cisplatin|weekly 40 mg/m\^2 (6cycles)
223798117|NCT03249519|OTHER|Hyperthermia|10 times
223798118|NCT03105310|DRUG|Pegylated interferon alfa|Pegylated interferon alfa
223798119|NCT03105310|DRUG|Ezetimibe|Ezetimibe
223798120|NCT00781976|DRUG|AZD7295|700mg per day maximum
223798121|NCT00781976|DRUG|Placebo|matched placebo
223798122|NCT03298646|DRUG|Lidocaine Hydrochloride|10 ml of 2% lidocaine on hysteroscopic infusion media during office hysteroscopy.
223798123|NCT03298646|DRUG|Diclofenac|100 mg Diclofenac oral tablet one hour before the procedure.
223798124|NCT06303050|OTHER|Mental Imagery with task Oriented training group|Study will be conducted after the approval of Ethical review board. After the initial evaluation will be done on participants underlying eligibility criteria. The experimental group will receive 20 minutes of MI training followed by 25 minutes of TOT for a total of 45 minutes, 5 days per week for 6 weeks. During each 45 minutes of session, the participants will perform warm-up exercise for 5 minutes to prepare the body for functional task and to improve overall performance. Regular breaks will give to the participants to avoid overexertion and fatigue during 45 minutes of continues practice. The 2 minutes rest period will provide to the partici-pants during each practice session
223798125|NCT06303050|OTHER|Task Oriented training group|Study will be conducted after the approval of Ethical review board. After the initial evaluation will be done on participants underlying eligibility criteria. The control group will receive the Task oriented training for 25-30 minutes, 05 days a week for 06 weeks consisting of Warm up Period, Task oriented training In standing, forward stepping and sideward stepping, reaching in standing, Transition from sit to stand, Walk then back to sit, Walk with even steps, Walk with carrying objects.
223798126|NCT06059495|DRUG|Dostarlimab|"After inclusion: dostarlimab 500mg IV 30min q3w (± 2-3 days) for 4 cycles (C1-C4)~Then:~At wk12 • If cCR: dostarlimab 1000mg q6w for 2 cycles (C5-C6)~• If downstaging at UGI endoscopy, and no disease progression (PD)/or mets on TAP-CT, \<3 biopsies with tumor cells: dostarlimab 500mg q3w for 4 cycles (C5-C8)~• If loco/loco-regional PD on TAP-CT, macroscopic tumor on UGI endoscopy, no distant mets, and \>2 positive biopsies at wk12 followed by surgery and if Becker-TRG 1a, 1b, or 2 after surgery: dostarlimab 1000mg q6w for 6 cycles (C5-C10)~At 24wk~• If cCR at 12 and 24 wks: dostarlimab 1000mg q6w for 4 cycles (C7-C10)~• If downstaging at UGI endoscopy without PD on CT at wk 12 with \<3 biopsies with tumor cells at wk12 and cCR: dostarlimab 1000mg q6w for 4 cycles (C9-C12)~• If downstaging at UGI endoscopy without PD on CT at wk 12 with and no cCR, surgery will be proposed and if Becker-TRG 1a, 1b, or 2 after surgery: dostarlimab 1000mg q6w for 4 cycles (C9-C12)"
223798127|NCT04750746|OTHER|Control group|Conventional Therapy Passive ROM and/or AROM exercises Muscle strengthening; Therapeutics stretching of the shoulder, the elbow, the wrist, and the fingers. Activities of daily living training, including eating, grooming, dressing, toileting, and transfer
223798128|NCT04750746|OTHER|Experimental Group|Interventional therapy Xbox Kinect (Xbox 360, Microsoft,) For training, programs such as Boxing and Bowling in the Kinect sports pack and Rally Ball, 20,000 Leaks, and Space Pop in the Kinect adventure pack, all of which required the use of the upper extremities, will be selected
223798129|NCT03969719|DRUG|Placebo|Placebo
223798130|NCT03969719|DRUG|PF-06835919|150 mg once daily
223798131|NCT03969719|DRUG|PF-06835919|300 mg once daily
223798132|NCT05188001|OTHER|Not an Interventional Study|Not an interventional Study
223798133|NCT01188434|BEHAVIORAL|ITSAN|integrated behavioral intervention for substance abuse, parenting skills, and basic needs
223798134|NCT01188434|BEHAVIORAL|Services as Usual|Services as usual referred by child welfare
223798135|NCT04847869|DEVICE|Ellex Integre NIR laser|The Ellex Integre NIR (near Infrared Light) Laser dose of 200 mW/cm2 for 90 seconds for 12 treatments at 2 to 3 day intervals over 5 weeks.
223798136|NCT00726726|DRUG|Interacting drugs - Cooperstown Cocktail (midazolam, warfarin, (+ vitamin K), caffeine, omeprazole and dextromethorphan)|Capsules + Tablets + Oral solution, Oral, Midazolam: 5 mg, Warfarin: 10 mg (vitamin K 10 mg), caffeine: 200 mg, omeprazole: 40 mg, dextromethorphan: 30 mg once daily, Day 1, 1 Day
223798137|NCT00726726|DRUG|BMS-708163|Capsules, Oral, 150 mg, once daily, days 6-15, 10 Days
223798138|NCT00726726|DRUG|BMS-708163 + Cooperstown Cocktail|Capsules + tablets + Oral solution, Oral, BMS-708163: 150 mg + Midazolam: 5 mg, Warfarin: 10 mg (vitamin K 10 mg), caffeine: 200 mg, omeprazole: 40 mg, dextromethorphan: 30 mg, BMS-708163, once daily, days 16-20 midazolam,warfarin, (+ vitamin K), caffeine, omeprazole and dextromethorphan once daily on Day 16, 5 Days
223798139|NCT04184791|DEVICE|Deep Brain Stimulation|Each DBS electrode contact will be reprogrammed in 60hz and High Frequency Stimulation (180hz) in the Levodopa ON (medicated) and OFF (unmedicated) conditions.
223798140|NCT02644187|DEVICE|BF-RhodoLED|Infrared light, with total dose of 37J/cm2.
223798141|NCT02644187|DEVICE|Aktilite CL128|Infrared light, with total dose of 37J/cm2.
223798142|NCT02644187|DRUG|BF200-ALA/5-aminolevulinic acid|Prodrug applied to whole treatment area previous to illumination with either light source.
223798143|NCT03580733|DRUG|caspofungin antifungal therapy|caspofungin
223798144|NCT03580733|OTHER|placebo|placebo
223798145|NCT01639885|DRUG|Interferon Alfa-2b|1ug/kg (max 100ug) 7 days before and 22 days after first treatment with gemcitabine
223798146|NCT01639885|DRUG|Interferon Alfa-2b|1ug/kg (max 100ug) 7 days before and 22 days after first treatment with gemcitabine
223798147|NCT01639885|BIOLOGICAL|p53 SLP|8.2.3 The p53 SLP vaccine consists of 9 synthetic 25-30 amino acids long overlapping peptides, spanning amino acids 70-235 of the wt-p53 protein (patent number WO2008147186). Peptides are prepared at the GMP facility of the Department of Clinical Pharmacy and Toxicology of the LUMC. At the day of immunization peptides (0.3 mg/peptide) were dissolved in dimethyl sulfoxide (DMSO, final concentration 20%) admixed with 20 mM phosphate buffer (pH7.5) and emulsified with an equal volume of Montanide ISA-51.The vaccine (2.7mL) is administered subcutaneously.
223798148|NCT03686046|OTHER|Exploratory use|Participants will be accompanied by a researcher while wearing the open-source speech processing platform as a hearing aid - adjusted to their needs using a widely accepted Fitting prescription. Using a hand-held controller, they will readjust to their liking as the acoustic conditions change. After returning to the laboratory, they will complete speech perception tests using under their self-selected amplification conditions and respond to a structured interview dealing with perceived performance of the device and its acceptability as a hearing aid during possible field studies.
223798149|NCT01190592|OTHER|Resistance Training with Milk Supplementation in Adolescents|"On resistance training days, the RT+ milk group will receive milk (280kcals) immediately following exercise and milk at another time during the day. The RT+ juice group will receive fruit juice immediately following resistance exercise and juice again another time during the day. The RT+ water group will receive water following resistance exercise and water at another time during the day.~On non training days, students in the RT+ milk group will receive milk. Students in the RT+ juice group will receive juice. The RT+ water group will receive water during the school day. On non-RT days, the total volume of milk, juice, or water will be split into two administration times during the school day."
223798150|NCT01918735|DRUG|Placebo|Placebo control matched to the oral or intravenous experimental comparator drug
223798151|NCT01918735|DRUG|GWP42006|"Oral administration of 25 (Group/dose level 1a and 1b), 75 (Group/dose level 2a and 2b), 200 (Group/dose level 3a and 3b) and 400 mg GWP42006 (Group/dose level 4a and 4b), provided as 50 mg/mL GWP42006 solution in sesame oil containing flavourings and sweetener, for dilution on the day of dosing, as required.~Additional intravenous administration of 5 mg GWP42006 and 10 mL Solutol HS 15 solution to Group/dose level 3a and 3b subjects."
223798152|NCT02130193|DRUG|Danirixin|Danirixin is available as 50 or 75 mg white, film coated immediate release tablet.
223798153|NCT02130193|DRUG|Placebo|Subjects will receive danirixin matching placebo
223798154|NCT01421576|DIETARY_SUPPLEMENT|High fat meal|offer high fat-meal in the morning before drug intake.
223798155|NCT01297959|DRUG|E-101 Solution 300 GU/ml|8 mL of E-101 Solution
223798156|NCT01297959|DRUG|Saline solution|Saline solution matched to E-101
223798157|NCT02127424|PROCEDURE|Nurse-driven HIV targeted screening|
223798158|NCT02127424|PROCEDURE|Current practice|
223798159|NCT01667432|BIOLOGICAL|Peginterferon alfa-2a|Peginterferon alfa-2a commercial product (PEGASYS®) was supplied as a solution in prefilled syringes.
223798160|NCT02464189|OTHER|Q-Kap|
223798161|NCT01348867|OTHER|Structured care led by a nurse consultant|"For the intervention group, patients will be followed up according to the following protocol. The structured care team consists of:~i) Diabetes Nurse Consultant to reinforce compliance; educate patients on insulin injection techniques and reinforce self-care including self blood glucose monitoring and lifestyle interventions, titration of medication.~ii) Technical Service Assistance to remind patients to take medications and/or give insulin injection, monitor blood glucose as prescribed, attend their next clinic appointment, encourage patients to report all side effects, self initiated change in regimen or concerns to diabetes nurse consultant and/or their doctors at the next follow up visit."
223798162|NCT02077166|DRUG|Ibrutinib|
223798163|NCT02077166|DRUG|Lenalidomide|
223798164|NCT02077166|DRUG|Rituximab|
223798165|NCT05566223|DRUG|Fludarabine|Day -7 to Day -3 : Fludarabine 25 mg/m\^2/dose as a 1 hour intravenous infusion per institutional guidelines once a day for 5 doses beginning on Day -7. Fludarabine will be started approximately 1 to 2 hours after the cyclophosphamide on Day -6 and Day -5.
223798166|NCT05566223|DRUG|Cyclophosphamide|Day -6 and Day -5: Cyclophosphamide 60 mg/kg/dose as a 2 hour intravenous infusion with Mesna 15 mg/kg/dose, 1st dose prior to Cyclophosphamide infusion then at 3,6,9 and 12 hours later.
223798167|NCT05566223|BIOLOGICAL|CISH Inactivated TIL|Day 0 : Each bag of autologous CISH inactivated TIL for infusion will be administered intravenously (IV) on the Patient Care Unit over 10-20 minutes at assigned dose level.
223798168|NCT05566223|DRUG|Aldesleukin|Days 1-4 : Aldesleukin at 720,000 U/kg as an intravenous infusion, every 8 -12 hours but, no more than 24 hours apart as tolerated for up to 6 doses.
223798169|NCT05566223|DRUG|Pembrolizumab|Administered as maintenance therapy in some patients starting at first follow-up (400 mg/dose starting Day 28 /Week 4 then every 6 weeks thereafter until disease progression, unacceptable toxicity, or up to 24 months)
223798170|NCT04341506|DEVICE|Non-contact ECG|A non-contact ECG will be used to detect a patient cardiac electrical activity.
223798171|NCT06667921|DEVICE|Ultrasound|Ultrasound will be used to measure the hyomental distance in neutral position (HMDRn), hyomental distance in extended position (HMDRe), (HMDR) and (DSE).
223798172|NCT06670014|DEVICE|repeech|Participants in this group will use the repeech application for a period of 4 weeks, with recommended usage of 5 days per week for 30 to 60 minutes per session. A designated speech-language pathologist (SLP) will set individualized treatment goals and customize the content of the therapy sessions based on each participant's baseline assessment. The repeech intervention will be tailored to meet the specific needs of each participant to improve speech intelligibility and communication abilities.
223798173|NCT06670014|OTHER|Workbook|Participants in the control group will use a workbook provided by the sponsor for the treatment of dysarthria, due to the lack of a standardized care protocol for this condition. The recommended usage is the same as the treatment group: 5 days per week, for 30 to 60 minutes per session over a period of 4 weeks. After each self-treatment session, participants will record their activities on a checklist to monitor adherence and ensure compliance with the study protocol.
223798174|NCT06670040|PROCEDURE|Transcranial Magnetic Stimulation|All TBS sessions will be delivered at the same site, intensity (up to 90% RMT), pattern and duration. Treatment conditions differ only in the amount of intracranial activation induced (i.e., negligible activation in sham condition). TBS sessions consist of triplet 50 Hz bursts repeated every 200 msec (5 Hz), delivered to the left DLPFC in an intermittent (2 seconds on/8 seconds off) pattern for a total of 600 pulses per session; duration of 3 minutes 9 seconds.
223798175|NCT06670040|PROCEDURE|Transcranial Magnetic Stimulation Sham|We will use a robust sham technique that suitably replicates the sensory experience (auditory and peripheral activation) of active TBS with minimal intracranial activation. The Magstim Horizon™ sham coil will be utilized for treatment delivery. This sham coil is visually identical to the active coil and replicates the sounds and sensation of the magnetic stimulation. All sham treatment will be delivered at the same site, intensity (up to 90% RMT), pattern and duration. Treatment conditions differ only in the amount of intracranial activation induced (i.e., negligible activation in sham condition). TBS sessions consist of triplet 50 Hz bursts repeated every 200 msec (5 Hz), delivered to the left DLPFC in an intermittent (2 seconds on/8 seconds off) pattern for a total of 600 pulses per session; duration of 3 minutes 9 seconds
223798176|NCT06669689|DEVICE|operating position|In the Trendelenburg position, the operating table was tilted head down at an angle of 20-25°. In the Reverse Trendelenburg position, the operating table was tilted head up at an angle of 20-25°.
223798177|NCT06669689|DEVICE|pneumoperitoneum|Pneumoperitoneum was established with an intra-abdominal pressure of 10-15 mmHg.
223798178|NCT06669962|DIAGNOSTIC_TEST|Study of coronary microcirculation and biomarkers of microvascular dysfunction|Patients with tako-tsubo syndrome will undergo to coronary angiography, ventriculography and assessment of physiological indexes of coronary circulation as per clinical practice
223798179|NCT03408717|OTHER|Questionnaires|Questionnaires including Pain catastrophizing scale (PCS), Central Sensitisation Inventory (CSI), Coping Strategies Questionnaire-Revised (CSQ-R), Brief Symptom Inventory-18 (BSI-18), Perceived Stress Scale (PSS), EQ-5D-3L and Eysenck Personality Questionnaire (EPQ) will be administered to the patient.
223798180|NCT03408717|OTHER|Mechanical Temporal Summation assessment|A 180 gram von Frey filament is applied on the subject's forearm. Patient will then be asked to rate the pinprick pain score on a verbal rating scale, 0-100. Following this, 10 consecutive touches at random locations are applied with a 1 second interstimulus interval and within a 1 cm diameter circle. The patient will then be asked to rate the 10th pain score (0-100). The Mechanical Temporal Summation Score is obtained by the difference between the 11th pain score and the 1st pain score. If the score is greater than zero, the patient is implied to have presence of Mechanical Temporal Summation.
223798181|NCT03408717|OTHER|Pain threshold assessment|Pressure is applied 90 degree straight down force on the subject's right/left centre of the trapezius muscle using an algometer, with a speed of pressure \~ 1kgf/s. The above procedure is then repeated 3 times at each site (left/right) which is indicated on the pressure mark with each time having the reading recorded. When patient shows no response ≥ 6kgf, the threshold is recorded as 6kgf. The patient upon feeling pain will say stop or raise the hand to terminate the test. The mean value is obtained by averaging the readings and will then be recorded as the threshold estimate.
223798182|NCT07127718|BIOLOGICAL|Prophylactic Plasma Transfusion|ABO/Rh-type compatible fresh frozen plasma (FPP) units will be thawed to 37° prior to administration. Plasma transfusion will be administered intravenously, 1 unit for 4 hours every 12 hours. There will be two consecutive days for the transfusion for a total of 4 units.
223798183|NCT07127718|DEVICE|Hemoperfusion|The hemoperfusion (HP) procedure will follow the standard procedure of National Kidney and Transplant Institute (NKTI) using Jafron HA330 hemoperfusion cartridge. First, an internal jugular catheter is attached to the patient. Alternatively, an arteriovenous fistula or arteriovenous graft may be placed on the patient. The patient will then be hooked to a hemodialysis machine. Blood pump speed will be set to 150-200mL/min, and HP will last for 2 to 2.5 hours. Whole blood will flow through the sorbent HA330 cartridge and back to the patient. Anticoagulation is not necessary due to the short treatment time. Hemoperfusion will be repeated after 12-24 hours for at least three days.
223798184|NCT07127718|DEVICE|Extracorporeal Membrane Oxygenation|"A veno-venous ECMO (VV ECMO) will be applied by aseptically inserting a venous cannula into the femoral veins. The patients will be hooked to an ECMO machine. Patients without significant bleeding or vascular intervention will be managed with an activated clotting time set at 140-180 sec by 800-1000 U/h of heparin. Otherwise, heparin will be titrated to maintain a partial thromboplastin time of 60-80 sec.~ECMO settings are as follows:~* Mean blood pressure of \>60 mm~* SaO2 at \>90% with a flow of 3.5-4.5 L/min~* Hematocrit at \>35%~* Platelets \>50000-100000/mL~* Transfusions will be done when necessary~Criteria for weaning:~* ABG:~  * pH 7.35-7.45~ * PaO2 \>80 mm Hg~ * PCO2 \<45 mm Hg~* Under the following conditions:~  * Gas blender FiO2 of 0.21~ * Sweep gas of 0 L/min at an ECMO flow of 2 L/min~ * Ventilator mode (if applicable):~    * FiO2 of 0.6~   * Tidal volume of 6 mL/kg~   * PEEP of 8 cmH2O~   * RR of 12-16/min for VV ECMO or 3 L/min of O2 via nasal prong with awakening ECMO patients"
223798185|NCT07127718|OTHER|Conventional therapy|Conventional therapy for leptospirosis includes antibiotics, fluids, inotropes, renal replacement therapy, ventilator support, and other treatment that the attending physician deems necessary.
223798186|NCT05677087|BEHAVIORAL|PREPARE Nutrition Education Module|The Perinatal Remote Education for Pandemic Resilience (PREARE) program is a 6-week intensive program aimed at increasing maternal and infant dietary diversity as well as maternal health literacy. Modules that will be completed in the program include education on early initiation of breastfeeding, food groups and the benefits of a balanced diet, appropriate meal frequency for mother and infant, and appropriate sources of health information. Information on personal hygiene and COVID-19 hygiene protocols as well as danger signs during pregnancy are included in the module to improve maternal knowledge on safety protocols and pregnancy complications.
223798187|NCT06713863|OTHER|BEtter AT LEarning (BEATLE)- Digital Care Pathway|"BEATLE is a digital care pathway consisting of ten episodes resembling an online course. The episodes are designed to be multimodal and immersive, incorporating text, recorded voice, pictures, cartoons, videos and peer support through given examples and case stories. Participants are encouraged to access BEATLE through a web browser on a computer, although it is also accessible through a mobile application. Participants have control over the pace of completing the BEATLE, but there must be a minimum five-day break between episodes. In other words, it is possible to complete the BEATLE in seven weeks.~All participants are referred to the BEATLE by a neuropsychologist and are strongly authenticated in the healthvillage.fi online platform. Each participant is assigned a designated neuropsychologist who tracks their progress in the BEATLE and to whom messages and questions can be sent by the participant."
223798188|NCT06730542|DRUG|Zanubrutinib|Zanubrutinib capsules will be self-administered orally by participants at a starting dose of 160 mg twice a day (BID) or 320 mg once a day (QD)\* at the beginning of Cycle 2 of Pola-R-CHP therapy.
223798189|NCT06730542|DRUG|Methotrexate|Participants will receive Methotrexate as per standard of care (SOC).
223798190|NCT06730542|DRUG|Polatuzumab Vedotin|Participants will receive Polatuzumab Vedotin as per standard of care (SOC).
223798191|NCT06730542|DRUG|Rituximab|Participants will receive Rituximab as per standard of care (SOC), as part of combination standard of care Pola-R-CHP therapy.
223798192|NCT06730542|DRUG|Cyclophosphamide|Participants will receive Cyclophosphamide as per standard of care (SOC), as part of combination standard of care Pola-R-CHP therapy.
223798193|NCT06730542|DRUG|Doxorubicin|Participants will receive Doxorubicin as per standard of care (SOC), as part of combination standard of care Pola-R-CHP therapy.
223798194|NCT06730542|DRUG|Prednisone|Participants will receive Prednisone as per standard of care (SOC), as part of combination standard of care Pola-R-CHP therapy.
223798195|NCT06732817|DEVICE|Active rTMS was administered using a transcranial magnetic stimulator (Rapid2; MagStim).|Active rTMS was sequentially administered over the left DLPFC and left TPJ sites one hour apart, for 3 weeks (21 consecutive days), using a transcranial magnetic stimulator (Rapid2; MagStim) with a 70-mm air-cooled figure-of-eight coil. Stimulation at 20 Hz (2 seconds on, 28 seconds off) was applied over the left DLPFC with an intensity set at 100% of the individual resting motor threshold (RMT), delivering a total of 1,600 pulses daily. Continuous theta burst stimulation (cTBS) was applied over the left TPJ at either 100% of the individual RMT or at the highest intensity that the stimulator could deliver for this protocol (50% of maximum output). Three daily sessions of cTBS were administered, separated by two 15-minute breaks, delivering a total of 1,800 pulses daily. The coil was navigated in real-time using a frameless neuro-navigation system (Brainsight; Rogue Research, Montreal, Quebec, Canada).
223798196|NCT04630730|DRUG|Recombinant intravesical BCG (Bacillus Calmette-Guérin VPM1002BC)|1 dose of VPM1002BC, live, 1-19.2 x 108 colony forming units (CFU) on day 1, 8 (+/- 1 day) and 15 (+/- 1 day)
223798197|NCT04630730|DRUG|Atezolizumab|Neoadjuvant immunotherapy with atezolizumab, 4 cycles 1200 mg fixed dose iv infusion on d1 q3w starting 4-16 weeks after date of surgery
223798198|NCT04630730|DRUG|Cisplatin|Neoadjuvant chemotherapy with cisplatin: 4 cycles 70mg/m2 iv infusion on d1 q3w (starting on d22)
223798199|NCT04630730|DRUG|Gemcitabine|Neoadjuvant chemotherapy with gemcitabine: 4 cycles 1000 mg/m2 iv infusion on d1 and d8 q3w (starting on d22)
223798200|NCT03962894|DRUG|Prednisolone|During a sequenced rollout protocol change for several EMS agencies, those agencies will adopt protocol change to administer prednisolone to children with asthma attacks in the prehospital environment prior to ED arrival.
223798201|NCT06938997|OTHER|Virtual clinical auditory hallucination solution combining AR/VR technology|"This study, titled Effectiveness of AR/VR-integrated OSCE on Psychiatric Nurses' Comprehensive Auditory Hallucination Care Ability: A Randomized Controlled Trial, involves both experimental and control groups watching videos. The control group views standard educational videos, while the experimental group uses AR/VR technology, virtual patient interaction platforms, and educational videos in a simulated clinical environment. Four scripts were developed: two for training and two for pre/post-testing. All scripts and OSCE checklists are researcher-developed, reviewed by experts, and pilot tested."
223798202|NCT06938997|OTHER|Auditory Hallucination Care Video|The videos include professional knowledge and skills related to auditory hallucinations.
223798203|NCT06432166|DRUG|2-hydroxybenzylamine acetate|2-hydroxybenzylamine acetate (2-HOBA) is taken three times per day for 16 weeks
223798204|NCT06432166|OTHER|Placebo|Placebo taken three times per day for 16 weeks.
223798205|NCT01530217|DRUG|Ibuprofen.|Ibuprofen Group will be receive a dose of non-steroidal antiinflammatory drug ibuprofen 400 mg. All the participants will be watched to ensure that they took the drugs 1 hour prior to treatment. A second dose of ibuprofen (400 mg), will be administered a every 8 hours after the first dose during 48 hours.
223798206|NCT00000279|DRUG|Clonidine|
223798207|NCT00815867|DRUG|epoetin beta (NeoRecormon ®)|"comparison of administration of high dosage of epoetin vs no administration of epoetin~30000 UI: 4 injections"
223798208|NCT03123146|BEHAVIORAL|Functional Behavior-Based Cognitive Behavioral Therapy|Fb-CBT involved nine 2-hour weekly sessions with three to four children in each group and two therapists. Therapy consisted of group activities, individual work in parent-child dyads, group parent training, and social skills exercises.
223798209|NCT03553004|DRUG|Niraparib Treatment|Niraparib treatment by mouth (oral)
223798210|NCT01965405|DRUG|Bupropion|Participant will receive a prescription for Bupropion hydrochloride and will self-administer according to dosage instructions from the study psychiatrist.
223798211|NCT01965405|BEHAVIORAL|Brief Counseling|Participants are provided with brief counseling for smoking cessation.
223798212|NCT01965405|BEHAVIORAL|High-magnitude prize contingency management|Prize based contingency management condition in which participants have the chance to win incentives (prizes) when they provide biological test results (expired carbon monoxide and cotinine) that are negative for recent smoking.
223798213|NCT01965405|BEHAVIORAL|Monitored support to quit smoking|Brief supportive sessions and monitoring of smoking cessation efforts.
223798214|NCT01965405|BEHAVIORAL|No additional treatment|No additional treatment will be given.
223798215|NCT01965405|BEHAVIORAL|Prize contingency management for abstinence|Prize based contingency management condition in which participants have the chance to win incentives (prizes) when they provide biological test results (expired carbon monoxide and cotinine) that are negative for recent smoking.
223798216|NCT01965405|BEHAVIORAL|Low intensity prize contingency management|Prize based contingency management condition in which participants have the chance to win incentives (prizes) when they provide biological test results (expired carbon monoxide and cotinine) that are negative for recent smoking.
223798217|NCT01074398|GENETIC|gene expression analysis|
223798218|NCT01074398|GENETIC|polymorphism analysis|
223798219|NCT01074398|GENETIC|protein expression analysis|
223798220|NCT01074398|OTHER|immunohistochemistry staining method|
223798221|NCT01074398|OTHER|laboratory biomarker analysis|
223798222|NCT04209816|DIAGNOSTIC_TEST|Lipoprotein kinetics|Lipoprotein kinetic apply protocol that endogenously label proteins and fatty acids with stable isotope-labeled amino acid and glycerol tracers. De novo lipogenesis is measured after ingestion of deuterated water to measure newly formed fatty acids in VLDL. Liver fat is measured with magnetic resonance spectroscopy and lipolytic enzymes with heparin test.
223798223|NCT03426384|BEHAVIORAL|Mymee Program|A combination of digital therapeutics and telephonic health coaching is used to identify and test dietary, lifestyle, and environmental triggers in order to reduce symptoms of auto-immune disease.
223798224|NCT06444906|DEVICE|Dermacyte Matrix|The appropriate square centimeters of Dermacyte Matrix is applied directly to the target DFU that is free of debris and necrotic tissue. The Dermacyte Matrix will be applied at weekly intervals or for up to 10 applications.
223798225|NCT06444906|OTHER|Standard of Care (SOC)|SOC therapy will consist of debridement of nonviable tissue, saline-moistened non-occlusive dressing, weight off-loading to decrease pressure on extremity, aggressive treatment of infection and arterial revascularization if indicated at weekly intervals or for up to 10 applications.
223798226|NCT03921125|DEVICE|Massimo for Pleth variability index|To assess fluid response
223798227|NCT00003508|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with advanced mesothelioma will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1.hourly interEach infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
223798228|NCT04498130|BEHAVIORAL|12-Week Home Exercise Group|12 week home-based program consisting of: weekly Zoom group chats; exercise videos; free exercise equipment and pedometer; an exercise manual with worksheets to promote increased physical activity; access to a unique group social media page
223798229|NCT04498130|BEHAVIORAL|Education Comparison Group|12 week home-based program consisting of: weekly check-in phone calls; exercise videos; free exercise equipment and pedometer; an exercise manual with worksheets to promote increased physical activity; access to a unique group social media page.
223798230|NCT05952635|PROCEDURE|Tip bendable suction ureteral access sheath|Patient use tip bendable suction ureteral access sheath during flexible ureteroscopy to see if flexible ureteroscopy with S-UAS offers the better treatment outcomes in terms of clinical effectiveness and post-operative complications.
223798231|NCT05682092|DIETARY_SUPPLEMENT|WonderLab Collagen Tripeptide Drink|the participant in this arm will use the assigned product 25ml one time, twice a day.
223798232|NCT05682092|DIETARY_SUPPLEMENT|Ordinary Drink|the participant in this arm will use the assigned product 25ml one time, twice a day.
223798233|NCT02219893|DRUG|MOC31PE Immunotoxin|Patients who meet inclusion criteria will be treated with a single intraperitoneal MOC31PE immunotoxin instillation for 6 hours on the first day after CRS and HIPEC
223798234|NCT04296695|DRUG|B/F/TAF|randomized, multicentered, open-lable RCT, one arm with B/F/TAF and one arm with TDF/3TC/EFV
223798235|NCT04296695|DRUG|TDF/3TC/EFV|TDF/3TC/EFV
223798236|NCT01712009|DRUG|Naproxen|
223798237|NCT01712009|DRUG|Loratadine|
223798238|NCT01712009|BIOLOGICAL|Pegfilgrastim|Commercially available pegfilgrastim (Neulasta®) will be used in the study, and is considered background therapy. Pegfilgrastim is administered as a single 6 mg subcutaneous injection 24 hours to 72 hours after completion of chemotherapy.
223798239|NCT01712009|DRUG|Chemotherapy|The choice of chemotherapy regimen (agent, dose, and schedule) is at the discretion of the treating physician.
223798240|NCT03625401|DRUG|AD-35 60mg group|AD-35 60mg QD
223798241|NCT03625401|DRUG|Placebo group|Placebo: 3 placebo of AD-35 30mg tablets
223798242|NCT02685722|BIOLOGICAL|UC-MSCs Gel group|This study for a six-month trials,Randomized, open, and parallel comparison before and after its own,Stage test includes screening stage, stochastic screening of more than a month difficult to heal wounds 20 people.By generating a random number of principle,Observation of UC-MSCs Gel group patients efficacy, safety and tolerability of selective parameter.
223798243|NCT02685722|OTHER|Gel group|This study for a six-month trials,Randomized, open, and parallel comparison before and after its own,Stage test includes screening stage, stochastic screening of more than a month difficult to heal wounds 20 people.By generating a random number of principle,observed and compared Gel group patients may be no efficacy.
223798244|NCT05668169|OTHER|Family-centered support program for caregivers of stroke survivors|Once participants joined the family-centered support group, participants received 90-minute interventions, including an introduction to stroke and rehabilitation education, problem-solving skills training, and long-term care information. Investigators also invited participants to join the instant messaging application-based 24-h peer-support group for caregivers. On the second and fourth days after receiving the interventions, the researcher visited the participants to review and practice the content provided on the first day; each session was 30 to 40 minutes long. The researcher contacted the participants one week after participants joined the study to discuss their care difficulties or experiences and did so three times biweekly thereafter via the instant messaging application.
223798245|NCT01912924|DEVICE|Spinal cord stimulator (Boston Scientific)|spinal cord stimulator trial leads and hand held battery
223798246|NCT06311279|PROCEDURE|Anterior resection of Rectal cancer|Anterior resection of cancer rectum and type of anastomosis (End to end or side to end)
223798247|NCT02160314|DEVICE|pessary|disposable, single-use pessary
223798248|NCT02160314|DEVICE|Absorbent pad|
223798249|NCT01751126|DRUG|NOVA22007 ''Ciclosporin''|Sterile, ophthalmic cationic oil-in-water emulsion containing 1 mg/ml Ciclosporin.
223798250|NCT01751126|DRUG|Placebo|Sterile, drug-free, cationic ophthalmic oil-in-water emulsion containing 0 mg/ml Ciclosporin.
223798251|NCT00654719|DIETARY_SUPPLEMENT|NutriDrink|Nutritional supplementation that contains 600 kcal/day: protein content 20 g, carbohydrates 72 g, fat 26 g
223798252|NCT00654719|DIETARY_SUPPLEMENT|Placebo|Nutritional supplementation containing only 12 kcal/day
223798253|NCT06282679|DRUG|Botulinum Toxin Type A Injection [Botox]|you are asked to return to the hospital for follow-up at weeks 2, 4, 8, and 12
223798254|NCT04979559|DEVICE|Mobile health apps|Mobile health application intervention including screening and early intervention such as diet and physical activity suggestion
223798255|NCT04979559|OTHER|Standard care|Regular practice for screening and early intervention for prediabetes patient in primary health cares setting
223798256|NCT01377480|DRUG|Posaconazole|POS 40 mg/mL oral suspension
223798257|NCT01377480|DRUG|Placebo for posaconazole|Placebo oral suspension
223798258|NCT01377480|DRUG|Benznidazole|BNZ 100 mg oral tablet
223798259|NCT06463444|DRUG|HAIC + Tislelizumab +lenvatinib|"All patients were treated with HAIC combined with tislelizumab and lenvatinib.~1. HAIC was adopted of the FOFOLX 6 program, Folinic acid+5-fluorouracil+Oxaliplatin, 21 days between second HAIC treatments with a window of ±3 days.~2. Lenvatinib was started before HAIC treatment, discontinued during HAIC treatment, Oral 8 mg or 12mg once a day depending body weight.~3. First treatment with Tislelizumab was started 0-1 days after HAIC, 200 mg IV, followed by a second treatment 21 days later."
223798260|NCT05024851|OTHER|Questionnaires|Evaluation of the Psychogenic and Neurogenic Components using questionnaires
223798261|NCT02657616|DRUG|vitamin-k-antagonists|
223798262|NCT02657616|DRUG|Novel oral anticoagulants|
223798263|NCT02093767|DIETARY_SUPPLEMENT|Synergy1|The prebiotic preparation, Synergy-1, consists of 1:1 inulin and oligosaccharide. The chicory derived inulin has a degree of polymerization (DP) of 10 to 60 (average DP of 25). The oligofructose is produced by partial enzymatic hydrolysis of chicory derived inulin and has a DP ranging between 3 and 7 (average DP of 4).
223798264|NCT03297515|DIETARY_SUPPLEMENT|Madeos|Arm 1: Omega 3
223798265|NCT03297515|DIETARY_SUPPLEMENT|Placebo|Arm 2 : Placebo
223798266|NCT02837640|DRUG|levodopa-carbidopa|sinemet 200/50 1/2 tablet b.i.d. for 2 days and then t.i.d for 6 months
223798267|NCT01946542|DRUG|beet juice concentrate|single dose of beet juice concentrate, roughly 70 mL
223798268|NCT01946542|OTHER|placebo|
223798269|NCT01826240|BEHAVIORAL|MBCT+SPI|Safety Planning Intervention (SPI), a very brief intervention focused on identifying personalized coping strategies to manage acute suicidality, is combined with Mindfulness-Based Cognitive Therapy (MBCT), a group intervention comprised of mindfulness training and cognitive therapy techniques. Treatment lasts 9 weeks.
223798270|NCT04536311|PROCEDURE|internal fixation of mulitiple rib fracture|The dislocated rib fracture was anatomically reduced, and then fixed with appropriate equipment to prevent the fracture from being displaced again
223798271|NCT00871689|BIOLOGICAL|aldesleukin|IL-2 will be administered (9 million units; 5 million units if weight is less than 45 kg) every other day beginning on day +3 for a total of 6 doses and again on day +60 every other day for 6 doses.
223798272|NCT00871689|DRUG|cyclophosphamide|60 mg/kg over 1 hour intravenously (IV) on days -7 and -6.
223798273|NCT00871689|DRUG|fludarabine phosphate|25 mg/m\^2 intravenously (IV) over 1 hour on days -7 through -5.
223798274|NCT00871689|PROCEDURE|umbilical cord blood transplantation|On day 0, transplantation will occur with double T-cell depleted (TCD) umbilical cord blood (UCB) units
223798275|NCT00871689|RADIATION|total-body irradiation|administered on days -5 through -2; 330 cGy daily
223798276|NCT03940599|DEVICE|step counter|Fitbit
223798277|NCT03940599|DEVICE|weight scale|BodyTrace weight scale
223798278|NCT03940599|DEVICE|step counter with screen covered|Fitbit with screen covered
223798279|NCT01127880|DRUG|Ancef or Clindamycin|1 gm of Ancef or 300 mg Clindamycin for those who are penicillin allergic
223798280|NCT01127880|DRUG|Placebo|.9% Normal Saline as a placebo
223798281|NCT05592054|PROCEDURE|Balloon guide catheters (BGCs)|MT procedure with Balloon guide catheters (BGCs)
223798282|NCT05592054|PROCEDURE|Standard guide catheter|MT procedure with standard guide catheter
223798283|NCT02244905|BEHAVIORAL|Positive Deviance|The recipients of the Positive Deviance intervention are the staff members of the three wards in the intervention arm, while the outcomes are measured among the patients receiving care in the three wards in the intervention arm. Key components of the intervention were invitation to participate voluntarily, open-ended dialogues with staff members to discover barriers and seek solutions to prevent HAI, discussion of outcomes, and encouragement to prioritize and implement the solutions generated.
223798284|NCT02244905|OTHER|Standard-of-Care Infection Control approach|Standard-of-Care Infection Control approach
223798285|NCT00590902|DRUG|OSI-774: erlotinib, TarcevaTM|150 mg, 100 mg and 25 mg tablets
223798286|NCT02342522|DEVICE|Remote ischemic conditioning|An automated autoRIC™ cuff will be placed on the upper arm and inflated to 200mmHg for 5 minutes and then deflated for 5 minutes, a cycle which will be undertaken 4 times in total.
223798287|NCT02342522|DEVICE|Control|An automated autoRIC™ cuff will be placed on the upper arm and a simulated inflation and deflation protocol will be applied.
223798288|NCT03924479|DEVICE|PowerBreathe (Breathing muscle training)|The breathing muscle breathing training will consist of using the PowerBreathe training for 8 weeks. The PowerBreathe is an inspiratory pressure threshold trainer.The valve blocks the airflow until the threshold pressure is achieved by breathing in forcefully into the device.
223798289|NCT01037855|OTHER|Non-intervention observational study|Non-intervention observational study
223798290|NCT04821479|BIOLOGICAL|Mesenchymal stem cells (MSC)|Intrathecal injections of autologous bone marrow derived mesenchymal stem cells
223798291|NCT05307380|DIAGNOSTIC_TEST|"functional pain scale"|French translation of the Defence and Veterans Pain Rating Scale (DVPRS)
223798292|NCT02422602|DRUG|Xarelto|Taking conventional charge
223798293|NCT02422602|OTHER|Experimental: Personalized information intervention|
223798294|NCT01986881|DRUG|Ertugliflozin|Oral, once daily, for up to approximately 6 years
223798295|NCT01986881|DRUG|Placebo|Matching placebo to ertugliflozin administered orally, once daily, for up to approximately 6 years
223798296|NCT01986881|DRUG|Glycemic Rescue|Doses of background anti-hyperglycemic agents (AHA), medications will be required to be held constant in all participants enrolled for the initial 18 weeks of the trial with 2 exceptions: First, participant will be prescribed glycemic rescue therapy if they meet specific, progressively more stringent, glycemic thresholds based on repeated, confirmed fasting plasma glucose (FPG) measured at a central laboratory. Second, a participant experiencing clinically significant hypoglycemia according to the investigator at any time during the trial is permitted to have the dose of appropriate background AHA (e.g., insulin, sulfonylurea \[SU\], glinide) reduced or discontinued as per the judgment of the investigator or the treating physician. Choice and dosing of glycemic rescue will be at the discretion of the investigator or the treating physician consistent with standards of care for management of patients with Type 2 diabetes mellitus (T2DM) within the country of the investigational site.
223798297|NCT05261893|OTHER|Elongation Longitudinaux Avec Decoaption Osteo Articulaire|It creates tension in the spine and stretch the fascia and is a myofascial stretch technique and manual physical therapy tool
223798298|NCT05261893|OTHER|Post Facilitation Stretching|Post Facilitation Stretching effectively decreases hamstring muscle tightness while also increasing popliteal angle range. Post-facilitation exercise can help to relieve knee pain. It effectively raises ROM or aligns collagen fibers due to the muscle contraction performed immediately before stretching.
223798299|NCT05183022|DEVICE|Total30 Sphere Contact Lenses|Participants will be refit into Total30 Sphere contact lenses and followed for 1 month.
223798300|NCT03160989|OTHER|physical exercises|The intervention will consist of a single session and after ten weeks of combined physical exercises (aerobic and resisted). All volunteers will participate in the same procedure.
223798301|NCT00244790|BEHAVIORAL|Diet|crossover low vs high protein diet before and after weight loss
223798302|NCT00290862|DEVICE|Percutaneous Vertebral Augmentation of compression fractures|Study eligible patients with painful osteoporotic compression fractures will be randomized to percutaneous vertebroplasty with CORTOSS (treatment group) or PMMA (active control group).
223798303|NCT03672838|BEHAVIORAL|hand-held dynamometer|Strength of one weak muscle group and of the biceps of the dominant arm will be measured using a hand-held dynamometer. An average of three readings will be used as one observation. Three observations per patient will be obtained on one day with a minimum of 15 minute rest period between each observation.
223798304|NCT04080804|DRUG|Nivolumab|A fully human anti-programmed death 1 (PD-1) monoclonal antibody checkpoint inhibitor, that blocks a signal that prevents activated T cells from attacking the cancer cells.
223798305|NCT04080804|DRUG|Relatlimab|A monoclonal antibody with anti-Lymphocyte-activation gene 3 (LAG-3) (immune checkpoint receptor protein found on the cell surface) activity.
223798306|NCT04080804|DRUG|Ipilimumab|A monoclonal anitibody that targets CTLA-4, a protein receptor, that down regulates the immune system.
223798307|NCT06169514|OTHER|No intervention|No intervention
223798308|NCT02922348|DRUG|Hormone Replacement Therapy|Hormone replacement therapy as indicated in Arm 1
223798309|NCT02922348|DRUG|Combined Oral Contraceptives|Combined oral contraceptives as indicated in Arm 2
223798310|NCT03676426|OTHER|Web platform for advance care planning/advance directive|Ourcarewishes (OCW) is a web-based platform to document advance care planning based at Penn. OCW contains more detailed content on preferences and values than a standard advance directive and allows electronic sharing with loved ones and transmission to the Penn EHR.
223798311|NCT03676426|OTHER|Standard advance directive|Patients receive a paper copy of an advance directive used by social workers at Penn Medicine and are encouraged to complete on their own.
223798312|NCT01834105|DRUG|Liuwei Dihuang Pills|
223798313|NCT05437133|DEVICE|Custom fabricated elbow extension orthosis|custom low temperature thermoplastic orthosis (Splint) holding the elbow in maximum extension at night
223798314|NCT05582564|OTHER|abstract vs concrete texts|The main experiment involved two groups of participants and two different articles about vaccine-related thrombosis taken from two Italian newspapers. One article used a more abstract descriptive style and language, while the other used a more anecdotical style and concrete language: each group read only one of these articles. Both articles are the same length and describe an episode of vaccine-related thrombosis. The abstract text uses a more formal and impersonal language, reporting more scientific considerations; the concrete text uses a more familiar and emotional style and provides a more anecdotical description of the case. Texts were also weighted according to a concreteness semantic vocabulary. French received translated versions.Two other groups were assigned categorization tasks; one was asked to complete a concrete categorization task and the other an abstract categorization task.
223798315|NCT06135103|DRUG|talfirastide|TXA127, a pharmaceutically formulated angiotensin (1-7) heptapeptide, identical to the endogenously produced, non-hypertensive derivative of angiotensin II (Ang II) is a sterile solution containing angiotensin (1-7) \[A(1-7)\], supplied in a 3 mL, single-use, stoppered vial.
223798316|NCT06135103|DRUG|Placebo|Placebo is a sterile solution containing supplied in a 3 mL, single-use, stoppered vial.
223798317|NCT00698594|BIOLOGICAL|sublingual allergen extract|Group of children with allergic rhinitis 6-18 years old. receiving seasonally grass pollens sublingual allergen extract (Staloral 300 IR, Stallergenes, France) (n=20) - seasonal SLIT group
223798318|NCT00698594|BIOLOGICAL|sublingual allergen extract|Group of children with allergic rhinitis 6-18 years old receiving yearly grass pollens sublingual allergen extract (Staloral 300 IR, Stallergenes, France) (n=20) - yearly SLIT group
223798319|NCT00698594|BIOLOGICAL|placebo|Group of children with allergic rhinitis 6-18 years old receiving placebo in sublingual applicator (Staloral 300 IR, Stallergenes, France) (n=20) - placebo group
223798320|NCT02683564|DRUG|BOW015|monoclonal antibody against TNF-alpha
223798321|NCT02683564|DRUG|Remicade|monoclonal antibody against TNF-alpha
223798322|NCT05616962|DIETARY_SUPPLEMENT|Diosmiplex|diosmin glycoside in combination with alkaline granules known as alka4-complex
223798323|NCT02541552|DRUG|Ropivacaine 0.5%|Varying volume according to motor response of previous subject
223798324|NCT04450537|BEHAVIORAL|Vape Messaging Intervention|Participants will be exposed to 10 vape education messages
223798325|NCT04167501|OTHER|biological sample analysis|HPV Prevalence analysis
223798326|NCT03382964|BIOLOGICAL|VLA1553|I.M. vaccination with a live-attenuated Chikungunya virus (CHIKV) vaccine candidate
223798327|NCT01936480|DRUG|Moxifloxacin 400mg once time|
223798328|NCT01093118|DRUG|TMI-358|Micro implant monthly x 3
223798329|NCT01093118|DRUG|MMI-467|Micro implant monthly x 3
223798330|NCT04959058|DEVICE|Volunteer|An ultrasound machine will be used to calculate the elastographic value of the brachial plexus in three different positions.
223798331|NCT06443619|PROCEDURE|unilateral USG-deep SAPB with glucose|patients will receive unilateral USG-deep SAPB ; 15 ml 0.5 % isobaric bupivacaine with addition of 15ml glucose 10% to (30 ml total volume).
223798332|NCT06443619|PROCEDURE|unilateral USG-deep SAPB without glucose|will receive unilateral USG-deep SAPB; 15ml 0.5% isobaric bupivacaine to be diluted with 15ml isotonic saline0.9% (30 ml total volume).
223798333|NCT00173901|DRUG|ceftazidime|
223798334|NCT00676182|OTHER|Telerehabilitation|Rehabilitation via computer assisted internet capabilities
223798335|NCT06071962|DRUG|Adezunap (AP707)|Sublingual spray with maximum application of 16 actuations per day or a maximum daily dose of 17,6mg THC distributed over 4 daily intakes.
223798336|NCT06071962|DRUG|Placebo|Sublingual spray with maximum application of 16 actuations per day distributed over 4 daily intakes.
223798337|NCT05446324|DRUG|Gallium-68-tilmanocept|All participants receive a cervical injection with 10 MBq 68Ga-tilmanocept in an outpatient setting (at least one week) before surgery. Within 30-90 minutes post-injection a PET with contrast enhanced CT is performed (PET/CT). Data (i.e. detection rate) from the imaging modalities are collected.
223798338|NCT06162650|RADIATION|Short-course radiotherapy|Short-course radiotherapy, 5×5 Gy.
223798339|NCT06162650|DRUG|mFOLFOX6|Oxaliplatin 85 mg/m2, leucovorin 400 mg/m2, infusinal 5-fluorouracil 2400 mg/m2 every 2 weeks, for 9 cycles
223798340|NCT00059644|DRUG|Ecraprost in lipid emulsion|
223798341|NCT03774901|DRUG|Avelumab|intravenous 10 mg/kg every 2 weeks
223798342|NCT04250727|DEVICE|ZYN|30 current non-treatment seeking adult smokers will be switched from smoking cigarettes to ZYN oral nicotine pouches containing either 3mg or 6mg concentration nicotine salts.
223798343|NCT04358172|OTHER|'Oral and Denture Guide' mobile application|'Oral and Denture Guide' mobile application provides evidence-based information about cleaning aids and material for dentures, denture care and oral hygiene instructions.
223798344|NCT01829438|BEHAVIORAL|Listening to fast music|
223798345|NCT01829438|BEHAVIORAL|Listening to preferred music|
223798346|NCT01829438|BEHAVIORAL|Listening to slow music|
223798347|NCT00379522|DRUG|Vasopressin|10 minutes after standard shock treatment 10 IU arginine vasopressin will be injected; if shock persists for 5 minutes, another 10 IU arginine vasopressin will be injected; after 5 minutes persisting shock, the last 10 IU arginine vasopressin will be injected; Total duration: approx. 15 minutes; Dose per intravenous injection: 10 IU; max. dose: 30 IU arginine vasopressin
223798348|NCT00379522|DRUG|Saline placebo|Placebo for arginine vasopressin
223798349|NCT04039399|PROCEDURE|Ischemic Conditioning|Ischemic conditioning is a well-defined, non-invasive procedure which consists of inflating a blood pressure cuff around a limb (in our study, the paretic leg), inflating the cuff to 225 mmHg to occlude blood flow to the limb for 5 minutes, releasing the cuff for 5 minutes, and repeating 5 times. In our study, participants will receive one session of the intervention (45 minutes total).
223798350|NCT04039399|PROCEDURE|Sham Ischemic Conditioning|There will also be an IC Sham group which is identical to the IC intervention, except the cuff is only inflated to 10 mmHg, which is a high enough pressure to perceive cuff tightness but not high enough to have any physiological effects.
223798351|NCT02698124|DRUG|Decitabine|
223798352|NCT02200718|BIOLOGICAL|NeuroVax|NeuroVax consists of a Trivalent TCR Peptide Formulation in IFA BV5S2, BV6S5 BV13S1
223798353|NCT02200718|BIOLOGICAL|IFA Incomplete Freund's Adjuvant|IFA Incomplete Freund's Adjuvant is a vaccine adjuvant composed of a light mineral oil and a surfactant system designed to make a water-in-oil emulsion
223798354|NCT00444808|DRUG|Intranasal calcitonin|
223798355|NCT03281148|DEVICE|Computer guided implant insertion group|Implants will be immediately inserted in fresh extraction sockets using CAD/CAM guides
223798356|NCT03281148|DEVICE|Free hand implant insertion group|Implants will be immediately inserted in fresh extraction sockets using free hand technique
223798357|NCT03224182|DRUG|Qapzola|Qapzola administered by the intravesical route.
223798358|NCT03224182|DRUG|Placebo|Qapzole-matching placebo administered by the intravesical route.
223798359|NCT02822222|DRUG|Magnesium citrate, tribasic anhydrous soft gelatin capsule|110 mg elemental magnesium/capsule
223798360|NCT02822222|DRUG|Placebo soft gelatin capsule|0 mg elemental magnesium/capsule
223798361|NCT04279314|DRUG|Trofinetide|Trofinetide solution of 30-60 mL based on subject's weight at Baseline, administered twice daily by mouth or gastrostomy tube (G-tube)
223798362|NCT02481310|DRUG|Cyclophosphamide|Given IV
223798363|NCT02481310|DRUG|Cytarabine|Given IT or intraventricularly
223798364|NCT02481310|DRUG|Doxorubicin Hydrochloride|Given IV
223798365|NCT02481310|DRUG|Etoposide|Given IV
223798366|NCT02481310|DRUG|Ixazomib Citrate|Given PO
223798367|NCT02481310|OTHER|Laboratory Biomarker Analysis|Correlative studies
223798368|NCT02481310|DRUG|Methotrexate|Given IT or intraventricularly
223798369|NCT02481310|DRUG|Prednisone|Given PO
223798370|NCT02481310|BIOLOGICAL|Rituximab|Given IV
223798371|NCT02481310|DRUG|Therapeutic Hydrocortisone|Given IT or intraventricularly
223798372|NCT02481310|DRUG|Vincristine Sulfate|Given IV
223798373|NCT05407454|OTHER|Questionnaire|The original form of the Diabetes Quality of Life-Brief Clinical Inventory was first developed in 1999 to establish a valid and reliable form of diabetes-specific quality of life. Inventory items were developed to address the issues that have the greatest impact on assessing patient self-care behaviors and satisfaction with diabetes care. Items are ranked on a 5-point Likert scale and are in two general formats. One format includes satisfaction with treatment and quality of life and is scored from 1 (very satisfied) to 5 (not very satisfied). The second format includes the frequency of adverse effects of diabetes itself or diabetes treatment and offers response options from 1 (never) to 5 (always). Therefore, higher scores on the DQL-BCI items and subscales include negative values indicating problem frequency or dissatisfaction. In order to use the DQL scale more efficiently in clinics, Burroughs et al. organized the 15-item DQL-BCI in 2004.
223798374|NCT02675387|DEVICE|Buzzy|Two minute application of a hand held vibrating device (Buzzy, MMJ labs, Atlanta GA, USA) before the administration of anesthesia
223798375|NCT02675387|DRUG|2%Lidocaine|1.8ml of 2%Lidocaine HCl to be administered via a 21mm needle (30 Guage)
223798376|NCT06111651|BEHAVIORAL|Parenting Intervention|parent training program with an added emphasis on ethnic-racial socialization and healthy lifestyle behaviors
223798377|NCT00004070|BIOLOGICAL|IL-12|
223798378|NCT00708240|DRUG|Escitalopram|Escitalopram will be provided in unit doses commercially available, with a starting dose, minimum effective dose, and maximum effective dose of 5 mg, 10 mg and 20 mg, respectively, given once daily.
223798379|NCT00643916|BIOLOGICAL|Meningococcal Polysaccharide Diphtheria Protein Conjugate (Menactra®)|0.5 mL, Intramuscular (at age 9 and 12 months)
223798380|NCT00643916|BIOLOGICAL|Meningococcal Polysaccharide Diphtheria Protein Conjugate (Menactra®)|0.5 mL, Intramuscular (at age 9 and 15 months)
223798381|NCT00643916|BIOLOGICAL|Meningococcal Polysaccharide Diphtheria Protein Conjugate (Menactra®)|0.5 mL, Intramuscular (at age 12 and 15 months)
223798382|NCT00643916|BIOLOGICAL|Meningococcal Polysaccharide Diphtheria Protein Conjugate (Menactra®)|0.5 mL, Intramuscular (at age 15 months)
223798383|NCT00643916|BIOLOGICAL|Meningococcal Polysaccharide Diphtheria Protein Conjugate (Menactra®)|0.5 mL, Intramuscular (at age 18 months)
223798384|NCT00643916|BIOLOGICAL|A/C/Y/W-135, Meningococcal Polysaccharide Vaccine (Menomune®)|0.5 mL, Subcutaneous (at 3 years to \<6 years of age)
223798385|NCT00499031|BIOLOGICAL|Cetuximab|Given IV
223798386|NCT04779970|OTHER|Cessation of ongoing treatment|Cessation of ongoing treatment
223798387|NCT06121154|DIAGNOSTIC_TEST|SARC-F questionnaire|"The SARC-F scale has 5 questions which evaluate strength, assistance in ambulation, rising from a chair, stair climbing, and falls. The cut off point for predicting sarcopenia is score 4; 4 and more means risk of sarcopenia."
223798388|NCT06121154|DIAGNOSTIC_TEST|Gait speed|Low gait speed was defined as walking below than 0.8 meters per second.
223798389|NCT06121154|DIAGNOSTIC_TEST|The chair rise test|the chair rise test (measures the strength of leg muscles), it measures the time taken for 5 times of rising from the sitting position without using arms, and was defined as low when the time taken was more than 15 seconds
223798390|NCT06121154|DIAGNOSTIC_TEST|Grip strength|Grip strength was measured with a hand-held dynamometer (Baseline, White Plains, New York, USA), and the cut-off thresholds were 32 kg for males and 22 kg for females
223798391|NCT06121154|DIAGNOSTIC_TEST|Visual analog scale|The visual analogue scale (VAS) was used for measuring general body pain severity, which was assessed from 0 (no pain) to 10 (worst possible pain)
223798392|NCT04547010|DIETARY_SUPPLEMENT|Soy Isoflavone supplement|Participants received 60 mg of soy-isoflavone supplement per day.
223798393|NCT00477230|DEVICE|Endoscopic Ablation System|Single ablation procedure with Endoscopic Ablation System
223798394|NCT00477230|DRUG|Standard Anti-arrhythmic Drug (AAD) Therapy|Medication as prescribed by physician.
223798395|NCT01259050|DRUG|Zinc and Copper|Optizinc 90 mg/d Copper 1 mg
223798396|NCT04963127|DIAGNOSTIC_TEST|Computed Tomography of the skeleton using a Dual-Energy-/Multi-Energy-/Spectral acquisition mode|CT acquisition using a Dual-Energy / Multi-Energy / Spectral acquisition mode
223798397|NCT04963127|DIAGNOSTIC_TEST|Computed Tomography of the skeleton using a conventional single-energy / non-spectral acquisition mode|CT acquisition using a standard single energy / non-spectral acquisition mode
223798398|NCT03780348|DIAGNOSTIC_TEST|New Method|A 'new' WHZ tool will be used to assess children.
223798399|NCT03780348|DIAGNOSTIC_TEST|Existing Method|'Existing' WHZ tools will be used to assess children
223798400|NCT00643058|BIOLOGICAL|LPS endotoxin|"Low challenge: saline (diluent), 5000EU, 10,000EU and 20,000EU LPS endotoxin as tolerated~High challenge: Saline (diluent), 40,000EU and 80,000EU as tolerated~Diluent Challenge: 3 X Sterile saline inhalation (2 ml)"
223798401|NCT03971682|BEHAVIORAL|PSYCHOPATHY.COMP program.|"The PSYCHOPATHY.COMP program is a structured individualized program for detained youth based on Compassion Focused Therapy, aimed to develop a compassionate motivation in these youth.~Treatment As Usual Treatment As Usual (TAU) in Portuguese juvenile detention facilities is primarily aimed to increase educational and professional qualifications, as well as to promote behavioral regulation."
223798402|NCT03971682|OTHER|Treatment As Usual - TAU|Treatment As Usual (TAU) in Portuguese juvenile detention facilities is primarily aimed to increase educational and professional qualifications, as well as to promote behavioral regulation.
223798403|NCT01143688|DRUG|albuterol|
223798404|NCT01143688|DRUG|placebo inhaler|
223798405|NCT01143688|PROCEDURE|placebo acupuncture|
223798406|NCT05049759|BEHAVIORAL|Confident, Active and Happy Youth|The three target goals of the intervention (confident, active and happy) link closely to the core symptoms of internalizing disorders. Thus, a core symptom of anxiety is a lack of confidence in one's ability to cope with a given fearful situation. The ensuing behavioral reaction is avoidance of the situation and/or enduring it with excessive discomfort. Similarly, a core symptom of a depressive disorder is lowered mood. Regarding both depression and anxiety, both disorders are associated with less physical activity, and low levels of physical activity conversely help maintain the disorders. As such, the aim is to alleviate symptoms and supplement ongoing treatment in CAMHS.
223798407|NCT00640627|DRUG|Celecoxib|200 mg oral capsule once daily for 6 weeks
223798408|NCT00640627|DRUG|Placebo|Matched oral placebo for 6 weeks
223798409|NCT05047055|DRUG|Isoniazid|Intensive Phase for 2 months and Continuation phase for 2 months dose: 75 mg (2 tablets for 30 - 34 Kg, 3 tablets for 35 - 49 Kg, 4 tablets for 50 - 64 Kg, 5 tablets for 65 - 75 Kg and 6 tablets for \>75 Kg) as a fixed-dose combination.
223798410|NCT05047055|DRUG|Rifampicin|Intensive Phase for 2 months and Continuation phase for 2 months dose: 150 mg (2 tablets for 30 - 34 Kg, 3 tablets for 35 - 49 Kg, 4 tablets for 50 - 64 Kg, 5 tablets for 65 - 75 Kg and 6 tablets for \>75 Kg) as a fixed-dose combination.
223798411|NCT05047055|DRUG|Pyrazinamide|Intensive Phase for 2 months only dose: 400 mg (2 tablets for 30 - 34 Kg, 3 tablets for 35 - 49 Kg, 4 tablets for 50 - 64 Kg, 5 tablets for 65 - 75 Kg and 6 tablets for \>75 Kg) as a fixed-dose combination.
223798412|NCT05047055|DRUG|Ethambutol|Intensive Phase for 2 months and Continuation phase for 2 months dose: 275 mg (2 tablets for 30 - 34 Kg, 3 tablets for 35 - 49 Kg, 4 tablets for 50 - 64 Kg, 5 tablets for 65 - 75 Kg and 6 tablets for \>75 Kg) as a fixed-dose combination.
223798413|NCT05047055|DRUG|Moxifloxacin|Intensive Phase for 2 months and Continuation phase for 2 months dose: 400 mg for 30 to 64 yrs AND 600 mg for 65 and above years of age.
223798414|NCT03523468|PROCEDURE|uniportal sleeve lobectomy|central lung cancer sleeve resection performed by uniportal VATS
223798415|NCT03523468|PROCEDURE|open sleeve lobectomy|central lung cancer sleeve resection performed by open chest
223798416|NCT03105674|DRUG|Multi-drug local anesthetics (Combination)|"1. Ropivacaine 0.5% - 30 ml~2. Ketorolac 30mg/ml - 1 ml~3. Kenalog 10 mg/ml - 5 ml~4. Lidocaine 1% with Epinephrine 1:100,000 - 20ml"
223798417|NCT03105674|DRUG|Standard local anesthetics (Combination)|Marcaine and Lidocaine
223798418|NCT00004549|PROCEDURE|Magnetic resonance imaging|
223798419|NCT00184548|DRUG|eptacog alfa (activated)|"Sterile, freeze-dried powder in single-use vials to be reconstituted with sterile water for injection.~Three doses of 200, 100 and 100 mcg/kg to be administered bolus i.v. (intravenous) over approx. three hours."
223798420|NCT00184548|DRUG|placebo|placebo
223798421|NCT02606279|DRUG|valsartan|Valsartan will be given in increasing doses (from 40 mg to 80 mg) to those in the valsartan arm.
223798422|NCT02606279|OTHER|Placebo|
223798423|NCT02925910|DEVICE|Shock absorbing wheelchair|2 randomised groups will try the softwheel wheelchair compare to regular one, but in different order.
223798424|NCT02184611|DRUG|Umeclidinium bromide|Blended with lactose and magnesium stearate dry white powder of umeclidinium 62.5 mcg to be inhaled via a NDPI
223798425|NCT02184611|DRUG|Placebo|Blended with lactose and magnesium stearate dry white powder to be inhaled via a NDPI
223798426|NCT01900938|PROCEDURE|Continuous infusion of propofol|Propofol is continuously administered intravenously via infusion pump starting with 20 mg/kg/hr and then titrated to about 5 mg/kg/hr according to patients' sedation level.
223798427|NCT01900938|PROCEDURE|Intermittent bolus injection of propofol|A loading dose of 2 mg of midazolam and 0.4 mg/kg of propofol is initially injected and then repeated intermittent bolus injection of 20 mg of propofol is followed according to patients' sedation level.
223798428|NCT01900938|DRUG|Midazolam|
223798429|NCT01900938|DRUG|Propofol|
223798430|NCT06202833|DEVICE|Acupuncture with regulating immunity as the core of treatment|The patient was supine, the acupuncture points were disinfected with 75% ethanol, and the acupuncture points on the head and neck were first acupuncture, and then the acupuncture points on the abdomen and limbs. baihui: When the 1.5 inch millimeter needle is needled, the tip of the needle and the acupoint are at a 15-30 ° Angle, and the needle is about 1 inch flat along the subcutaneous area. The twisting speed is about 200 times per minute, and the stitches are once every 15 minutes, and each stitch is about 30 seconds. zhongwan, tianshu: 1.5 inch needle straight puncture 1 inch, small amplitude lifting and twisting. guanyuan, qihai: 1.5 inch millimeter needle downward oblique puncture 1 inch, small amplitude lifting and twisting. The above acupoints were measured by obtaining qi, and the needles were retained for 30min, once a day.5 days a week for 4 weeks.Twenty days in total.
223798431|NCT06202833|DEVICE|Needles that are not on acupoints|In this group, acupuncture treatment was performed at 1cm side of the selected points of the Tongyuan acupoint acupuncture group.The piercing Angle is the same as the test group, only piercing, not twisting.Once a day, 5 days a week for 4 weeks.Twenty days in total.
223798432|NCT06221189|BEHAVIORAL|ACT-CSP|The ACT treatment will consist of three 45 to 60-min weekly sessions to be delivered to the caregiver in an individual format via online videoconferencing application e.g. ZOOM or WhatsApp within 3 weeks. The ACT-CSP can be delivered via face-to-face on request. Each session has a specific content with pre-planned materials and mindfulness exercises and metaphors. Psychological-based homework will be assigned at the end of each session. The components of ACT process will be emphasized in the intervention programme, which include perspective taking, self-as-context and defusion (i.e. recognizing worry thoughts as thoughts only), identifying values and acceptance of present-moment experience with respect to the values, and committed action.
223798433|NCT02348450|DRUG|Irinotecan|40mg
223798434|NCT02348450|DRUG|Etoposide|5ml：0.1g
223798435|NCT02348450|DRUG|Cisplatin|6ml：30mg
223798436|NCT01808950|DRUG|0.06% Resiquimod Gel - A|single 60mg dose
223798437|NCT01808950|DRUG|0.06% Resiquimod Gel - B|single 100mg dose
223798438|NCT01808950|DRUG|0.06% Resiquimod Gel - C|shave biopsy of BCC followed by single 100mg dose
223798439|NCT00854633|DRUG|Talactoferrin|Enteral, 150 mg/kg twice per day
223798440|NCT00854633|DRUG|Placebo|Oral, twice per day
223798441|NCT01459510|BEHAVIORAL|Play Nicely Program|Multi media educational intervention
223798442|NCT01792479|DRUG|BIND-014|
223798443|NCT01907191|DRUG|liposomal bupivacaine|(Ultrasound guided injection of liposomal bupivacaine) for patients undergoing hip arthroscopy
223798444|NCT01907191|DRUG|Bupivacaine|(around the anterior, lateral and medial aspect of hip joint) for patients undergoing hip arthroscopy
223798445|NCT04203693|DRUG|Tildrakizumab|The study physicians will choose the treatment independently of the enrolment in the study according to routine care.
223798446|NCT00142779|DRUG|Fluoxetine|
223798447|NCT04323813|DIAGNOSTIC_TEST|Liquid biopsy|Detection and quantification of EMT-transcription factor mRNA levels in blood
223798448|NCT00985725|DRUG|SPD489 (Lisdexamfetamine dimesylate)|Oral, 20, 30, 40, 50, 60, and 70mg capsules, once daily
223798449|NCT00985725|DRUG|Matching placebo|oral, once daily
223798450|NCT05182879|DIAGNOSTIC_TEST|Assessement with GERONTOPOLE scale|"The practitionner assesses the frailty of the elderly outpatient with the GERONTOPOLE scale and compares it with the évaluation gériatrique standardisée (GDS)"
223798451|NCT04857931|DRUG|Colchicine|Patients meeting all inclusion criteria and no exclusion criteria will be randomly assigned to receive either colchicine (0.5mg once daily), colchicine (0.5mg twice daily) or matched placebo (1:1:1 allocation ratio), in addition to standard of care.
223798452|NCT04857931|DRUG|Placebo|Patients meeting all inclusion criteria and no exclusion criteria will be randomly assigned to receive either colchicine (0.5mg once daily), colchicine (0.5mg twice daily) or matched placebo (1:1:1 allocation ratio), in addition to standard of care.
223798453|NCT00107003|DRUG|lapatinib ditosylate|
223798454|NCT00107003|PROCEDURE|Adjuvant therapy|
223798455|NCT00107003|PROCEDURE|Conventional surgery|
223798456|NCT00107003|PROCEDURE|Neoadjuvant therapy|
223798457|NCT03563716|DRUG|Atezolizumab|Atezolizumab at a fixed dose of 1200 mg will be administered first by IV infusion Q3W on Day 1 of each 21-day cycle.
223798458|NCT03563716|DRUG|Tiragolumab|Tiragolumab at a fixed dose of 600 mg will be administered by IV infusion Q3W on Day 1 of each 21-day cycle.
223798459|NCT03563716|DRUG|Placebo|Placebo will be administered by IV infusion Q3W on Day 1 of each 21-day cycle.
223798460|NCT01353352|OTHER|Clinical decision rule - clearing the c-spine|The goal of phase IV of the Canadian C-Spine Rule project is to evaluate the safety and potential impact of an active strategy to empower ED triage nurses to evaluate and clear the c-spine of very low-risk trauma patients.
223798461|NCT06333054|DRUG|Pyrethrum Extract|Treatment with Goldgeist® Forte
223798462|NCT06333054|DEVICE|Silcap Shampoo|Treatment with Silcap Shampoo
223798463|NCT03595579|DRUG|AXS-05|AXS-05 taken twice daily for 6 weeks.
223798464|NCT03595579|DRUG|Bupropion|Bupropion taken twice daily for 6 weeks.
223798465|NCT03326505|BIOLOGICAL|Umbilical cord derived Mesenchymal Stem Cells|Allogenic umbilical cord derived stem cells which are to be injected intrathecally as a treatment option for consenting MS patients
223798466|NCT03326505|OTHER|Supervised physical therapy|A combined physical therapy program of Balance, strengthening and endurance exercises
223798467|NCT02331381|DEVICE|Magnetic resonance imaging|
223798468|NCT00003125|BIOLOGICAL|ALVAC-CEA vaccine|
223798469|NCT00003125|BIOLOGICAL|aldesleukin|
223798470|NCT00003125|BIOLOGICAL|sargramostim|
223798471|NCT00003125|BIOLOGICAL|vaccinia-CEA vaccine|
223798472|NCT06413251|OTHER|Boxing Training|The boxing training intervention will consist of three exercise sessions per week on nonconsecutive days for six weeks. Participants will be instructed to complete 10 rounds of three minutes with a one-minute resting period interspersed. Four rounds will consist of heavy bag punching (e.g. straight, jab, hook) at 60% VO2max and three rounds at 90-95% VO2max, while the remaining 3 rounds will be focused on mitt work at 60% VO2max.
223798473|NCT06413251|OTHER|Control flexibility|The control group will perform three days per week 10 minutes of dynamic articular movement, five minutes of uni pedal stance, and five minutes of stretching of the upper limbs for six weeks.
223798474|NCT02583425|DRUG|DFN-11 Injection|
223798475|NCT05719454|DEVICE|CNT testing|The effect of CNT on blood pressure will be obtained throughout the year long follow up period.
223798476|NCT06580691|PROCEDURE|Subcision plus Plasma gel injection Vs Subcision plus Cog PDO threads|"Plasma Gel: was injected into the scarred areas immediately after subcision. Thread Treatment: Cog PDO threads were inserted using a blunt-tipped cannula in a Z pattern within the scarred areas, filling the pockets created by subcision."
223798477|NCT04040660|DRUG|NexoBrid|NexoBrid is presented as lyophilized powder and gel vehicle for preparation of a gel for cutaneous use. The API is a concentrate of proteolytic enzymes enriched in Bromelain extracted from the stem of Ananas comosus (pineapple plant)
223798478|NCT02744222|BIOLOGICAL|BCD-054 180 mcg|180 mcg intramuscularly once every two weeks
223798479|NCT02744222|BIOLOGICAL|Avonex®|30 mcg intramuscularly once a week
223798480|NCT02744222|BIOLOGICAL|BCD-054 240 mcg|240 mcg intramuscularly once every two weeks
223798481|NCT02744222|OTHER|Placebo|intramuscularly once a week (0,5 ml)
223798482|NCT06185257|DEVICE|EEG|"Methodology Subjects selected are divided into 3 groups A. Patient with chronic kidney disease under dialysis B. Patients with nephrotic syndrome~* Patients in remission~* Patients relapse C. Normal control group~Detailed history including age, sex , residence ,complain, renal symptoms will be taken.~Detailed examination, lab investigations, and treatment will be recorded~Imaging ( EEG) , results of the three groups will be assessed and compared and lab investigation ( lipid profile of all patients) will be measured"
223798483|NCT01261702|DRUG|Placebo|Normal saline IV
223798484|NCT01261702|DRUG|magnesium sulphate|The magnesium group (Group M, n=16) received 50 mg/kg of magnesium sulphate infusion in 10 minutes before induction and then 15 mg/kg/hr until the end of the surgery.
223798485|NCT03346226|DRUG|Dexmedetomidine Hydrochloride|Dexmedetomidine is given to patients during spinal anesthesia at the dose of 0.5 μg/kg，adjusted the dose to keep BIS between 70-80 until 30 minutes before the end of surgery
223798486|NCT03346226|DRUG|Propofol|Propofol is given with an initial ratio of 2-10mg/kg/h, when the operation starts，adjust the propofol's dose to keep BIS between 70-80 before the end of surgery
223798487|NCT01633879|BEHAVIORAL|audio-CD parent education|audio CD stories in English and Spanish that support positive parenting practices
223798488|NCT01633879|BEHAVIORAL|health and success parent and school|Parenting education and school intervention
223798489|NCT05228899|DRUG|Zofin|1mL of Zofin will be administered intravenously, containing 2-5 x 10\^11 particles/mL. Zofin will be diluted in 100 mL of sterile saline.
223798490|NCT05228899|OTHER|Placebo|1mL of Placebo (normal saline) will be diluted in 100 mL of sterile saline and administered intravenously.
223798491|NCT01030861|DRUG|Teplizumab|intravenous infusions
223798492|NCT01030861|DRUG|Placebo infusion|Placebo for Teplizumab
223798493|NCT04480294|DRUG|HRS5091|"Single dose in group 1-5~Multiple doses in group 6-9"
223798494|NCT04976738|DRUG|Cybis™ 10:25 THC:CBD oil|Cybis™ 10:25 containing 10 mg/mL of D9-THC and 25 mg/mL of CBD, formulated in medium chain triglycerides (MCT)
223798495|NCT04339231|PROCEDURE|sphenopalatine ganglion block|"The block of the sphenopalatine ganglion will be performed bilaterally, using a cotton bud soaked with 1% ropivacaine, placed in the mucosa of the posterior wall of the nasal cavity, through both nostrils.~Once placed in the proper position, the swab will remain for about 20 minutes to absorb the local anesthetic from the mucosa."
223798496|NCT01164995|DRUG|MK-1775 and carboplatin|Carboplatin will be administered in a dose resulting in AUC5 (i.v. 30 min) at day 1 of each cycle. Concomittantly with the start of the carboplatin infusion 225 mg of MK-1775 will be administered as an oral capsule, followed by 4 additional doses at 12 hour increments ( = 5 BID doses of MK-1775 in 2.5 days in total). One cycle will last 21 days.
223798497|NCT03549910|PROCEDURE|APRVplus protocol|Physiology-driven APRVplus protocol
223798498|NCT03549910|PROCEDURE|Low tidal volume ventilation|Low tidal volume lung protective ventilation
223798499|NCT03903133|DRUG|Vitamin E|vitamin E supplementation for three months (400-600 mg/day) (400 mg/day in those weighed less than 20 kg and 600 mg/day in those weighed at least 20 kg)
223798500|NCT00158938|DEVICE|EASYTRAK 3 left ventricular pacing lead|
223798501|NCT03411655|DEVICE|Ambu Aura GainTM|Time and success rate
223798502|NCT03411655|DEVICE|Ambu® Aura-ITM|Time and success rate
223798503|NCT00249925|BEHAVIORAL|Home-Based Intervention|
223798504|NCT00249925|BEHAVIORAL|Multi-component home-based intervention|
223798505|NCT06532214|DIAGNOSTIC_TEST|International Study Group for Liver Surgery (ISGLS)|According to the ISGLS criteria, the patient was judged to have liver failure and further analysis
223798506|NCT03434951|DRUG|Bupivacaine Hydrochloride, Spinal|Intrathecally administered 12,5mg bupivacaine for spinal anaesthesia
223798507|NCT03434951|DRUG|Morphine hydrochloride, Spinal|Intrathecally administered morphine 0,2mg (2mg/ml, 0,1ml)
223798508|NCT03434951|DRUG|Placebo - Concentrate|Intrathecally administered saline solution 0,9% 0,1ml to match morphine volume
223798509|NCT01844804|BIOLOGICAL|PF-06438179|Single-dose of 10 mg/kg administered as an intravenous infusion in not less than 2 hours on Day 1
223798510|NCT01844804|BIOLOGICAL|Remicade|Single-dose of 10 mg/kg administered as an intravenous infusion in not less than 2 hours on Day 1
223798511|NCT01844804|BIOLOGICAL|Remicade|Single-dose of 10 mg/kg administered as an intravenous infusion in not less than 2 hours on Day 1
223798512|NCT06273423|OTHER|OULA, Mind-body Physical Activity|Group dance fitness program with focus on the mind-body connection
223798513|NCT00541515|DEVICE|continuous glucose sensors and insulin pump|continuous glucose sensors and insulin pump
223798514|NCT06477575|DEVICE|neurocognitive therapy based on new technologies|"The cognitive neurorehabilitation program is based on gaming through the use of the Nintendo Switch device. The following games have been chosen: Pufferfish, Hex Egg, Mystic Totem, Thor's Thunder, since they are games that work on selective attention, concentration and processing speed, which are the variables to be studied in this project.~Hardware: Nintendo Switch Software: 60 in 1 game Games: Pufferfish, Hex Egg, Mystic Totem, Thor's Thunder. Therapy time: 30 minutes effective. Number of Sessions: 2 per week / Number of weeks: 8 Total number of intervention sessions: 16 sessions Place: Thercli Center (Don Benito)."
223798515|NCT06477575|OTHER|conventional neurocognitive therapy|"The cognitive neurorehabilitation program for group active comparator is based on playing more conventional board games that work on selective attention, concentration and processing speed, which are the variables to be studied in this project.~Traditional games and token book. Games: Dobble, Lynx, Crazy cups, Jungle speed, animalea, ghost. Card: Stimulate and learn level 3 and 4. Therapy time: 30 minutes effective. No. of sessions: 2 per week / No. of weeks: 8 Total number of intervention sessions: 16 sessions Place: Thercli Center (Don Benito)."
223798516|NCT01745432|DEVICE|ADBLOCK|Laparoscopic surgery
223798517|NCT00249535|BEHAVIORAL|Contingency management|Rewards (prizes) for abstinence
223798518|NCT04460118|PROCEDURE|Bristow surgery fixed by the screw|Bristow surgery fixed by the screw
223798519|NCT04460118|PROCEDURE|Bristow surgery fixed by the suture button|Bristow surgery fixed by the suture button
223798520|NCT04199858|BEHAVIORAL|Baseline pain stimulations|During baseline pain stimulations, a comparison block will include 6 high- and 2 moderate-pain stimulations.
223798521|NCT04199858|BEHAVIORAL|Conditioning|"During nocebo induction trials, the conditioned stimulus (i.e., a sham medical gel that can increase pain sensitivity, named TDA and contained in either a brown or a blue jar) is paired to unconditioned high-pain stimuli (nocebo trials). Lower 'baseline' pain is paired with no gel application (control trials)."
223798522|NCT04199858|BEHAVIORAL|Evocation|"During nocebo evocation, lower pain stimulations are administered both after the administration of the conditioned stimulus (i.e., a sham medical gel TDA) and the control stimulus (no medical gel), in order to evoke nocebo responses to the sham hyperalgesic medication."
223798523|NCT04199858|OTHER|Electroencephalography (EEG)|In the single group of participants, EEG recordings will be conducted during baseline, during a first resting-state of 5-minutes, during induction/evocation of nocebo responses, and during a second resting-state of 5-minutes.
223798524|NCT01490996|DRUG|Oral complex C3 curcumin + chemotherapy|Daily oral capsule(s)
223798525|NCT01490996|DRUG|Chemotherapy only|Standard care chemotherapy
223798526|NCT05245669|BIOLOGICAL|ENZ215|healthy volunteers receive ENZ215 (60mg) once
223798527|NCT05245669|BIOLOGICAL|EU Sourced Prolia|healthy volunteers receive Denosumab (60mg) once
223798528|NCT05245669|BIOLOGICAL|US Sourced Prolia|healthy volunteers receive Denosumab (60mg) once
223798529|NCT03886818|DEVICE|Standard dressings|Standard dressings will be used from surgery to wound healing
223798530|NCT03886818|DEVICE|PICO strategy|The PICO system with negatif pression will be used from surgery to day 7. After that, standard dressing will be used untill the wound Healing.
223798531|NCT01597050|DRUG|R932333|R393233 6% (60 mg/g), bid
223798532|NCT01597050|DRUG|Placebo|Placebo, bid
223798533|NCT03602170|BEHAVIORAL|High-Intensity Interval Training|Supervised exercise sessions will be performed on a upright cycle ergometer. Training sessions involve 20 minutes of exercise by completing 10 repetitions of 60 seconds of exercise at 90-95% maximal heart rate with 60 seconds of active rest between each repetition at 50-60% maximal heart rate.
223798534|NCT03602170|BEHAVIORAL|Moderate-Intensity Continuous Training|Supervised exercise sessions will be performed on a upright cycle ergometer. Training sessions involve 30 minutes of continuous exercise at 65-70% maximal heart rate.
223798535|NCT01936584|PROCEDURE|TAPP repair for inguinal hernias|
223798536|NCT01936584|PROCEDURE|TEP repair for inguinal hernia|
223798537|NCT01936584|OTHER|EuraHS-QoL questionnaire|questionnaire administration
223798538|NCT01936584|OTHER|Carolina Comfort Scale|questionnaire administration
223798539|NCT00483184|BIOLOGICAL|Veldona,|Very low dose oral natural human interferon alpha lozenges
223798540|NCT01785966|BEHAVIORAL|Daily checklist and clinician prompting|"Interventions are:~Checklists: The checklists are arranged in a paper notebook (one per patient) with a daily list on each page, as most ICUs do not have electronic health record systems. During the multidisciplinary visit, the checklist items are read aloud by the nurse and answered by participants of the visit. The checklist is applied at least once on all week days preferably in the mornings, although we strongly suggest applying it also on weekend days.~Daily Goals and Clinician Prompting: During the clinical discussion of each patient and the application of the checklist, the intensivists write down the daily goals in a standardized form and read them aloud to the team. Every afternoon between 3 and 5 PM, a nurse reviews the daily goals and takes note of any pending items. Subsequently, the nurse prompts the on-call physician, requesting solutions for these pending items."
223798541|NCT00558428|DRUG|fixed dose combination of telmisartan+amlodipine|
223798542|NCT00558428|DRUG|amlodipine|
223798543|NCT00615043|PROCEDURE|Bladder biopsy|provision of bladder tissue via cystoscopic biopsy during planned TURBT
223798544|NCT03229954|DRUG|iron isomaltoside (Monofer) intravenous infusion|"The investigational drug is a newest formulation of intravenous iron. The drug, iron isomaltoside (Monofer), will be infused one single high dose with infusion time more than 30 minutes (\< 1,000 mg) or 60 minutes (≥ 1,000 mg). The dosage is determined using the Ganzoni formula and divided when the calculated dose exceeds 20 mg/kg.~If the calculated dose exceeds 1,500 mg, the patient will be excluded from trial for patient safety."
223798545|NCT03229954|DRUG|Ferrous sulfate(Feroba-YOU) per oral|160 mg/day of ferrous sulfate (Feroba-YOU) will be taken per oral for 12 weeks.
223798546|NCT04677972|DRUG|Ebselen|Glutathione peroxidase mimetic
223798547|NCT04677972|DRUG|Placebo|Matching placebo containing excipients
223798548|NCT02766530|OTHER|PETMR study|Use of PETMR study to evaluate the treatment response of breast cancer women
223798549|NCT03386968|BEHAVIORAL|Active video gaming|"Children will visit Blythedale for 8 sessions, one 45-session visit per week, in place of one of the child's typical physical therapy sessions. During each session, children will play a video game on the X-Box Kinect system, using the games Kinect Adventures and Kinect Sports. The child will first play a Kinect Adventures game, which requires ambulating, ducking, and dodging one's way through an obstacle course."
223798550|NCT03386968|BEHAVIORAL|Usual care physical therapy|Children will attend their usual care physical therapy appointments at Blythedale.
223798551|NCT03671005|BEHAVIORAL|Mindfulness-based group therapy|see above
223798552|NCT03671005|OTHER|Treatment as usual|see above
223798553|NCT05111795|DEVICE|Selective Internal Radiation Therapy with QuiremSpheresTM Holmium-166 Microspheres|SIRT work-up procedure and SIRT procedure
223798554|NCT01147224|DRUG|Alvesco|This is an observational study. Therefore, the physician decides about dosage according to individual needs.
223798555|NCT02054767|DRUG|Intervention: inferior alveolar nerve block injection|-22 patients received inferior alveolar nerve block injections of 3.6 mL (equivalent to 2 cartridges)
223798556|NCT05224050|BEHAVIORAL|Cognitive-Behavioral Smoking Cessation|Participants will be provided with six individualized smoking cessation counseling sessions designed to help them prepare to quit, set a quit date, behaviorally manage early abstinence, and to resume cessation upon lapse.
223798557|NCT05224050|BIOLOGICAL|Heart Rate Variability Biofeedback|Participants will be provided with seven individualized trainings in resonance breathing using biofeedback to help improve self-regulation.
223798558|NCT05224050|DRUG|Nicotine patch|All participants will be offered up to eight weeks of transdermal nicotine patch, beginning on their quit date.
223798559|NCT00473798|BEHAVIORAL|Questionnaire|Questionnaire
223798560|NCT05422326|BIOLOGICAL|aH5N6c on Day 1|MF59-adjuvanted cell-culture derived subunit inactivated monovalent A/H5N6 vaccine (aH5N6c) for intramuscular (IM) administration, containing 7.5 μg H5N6 hemagglutinin (HA) (A/Guangdong/18SF020/2018 (H5N6)-like) + 0.25 mL MF59 (approximately 0.5 mL total volume)
223798561|NCT05422326|BIOLOGICAL|aH5N6c on Day 22|MF59-adjuvanted cell-culture derived subunit inactivated monovalent A/H5N6 vaccine (aH5N6c) for intramuscular (IM) administration, containing 7.5 μg H5N6 HA (A/Guangdong/18SF020/2018 (H5N6)-like) + 0.25 mL MF59 (approximately 0.5 mL total volume) given 3 weeks after the first aH5N6c vaccination
223798562|NCT05422326|BIOLOGICAL|Placebo on Day 22|Saline placebo (sterile, 0.5 mL) given 3 weeks after the aH5N6c vaccination
223798563|NCT04960111|DEVICE|RSA|application of tantalium microsphere around knee prosthesis and RSA X-ray post operative to detect early mobilization in follow up.
223798564|NCT05156918|OTHER|Exercise|Participants will rotate between three exercise machines (randomly assigned rotation order at outset): A Concept C2 rowing machine, a stationary bicycle, and a treadmill. Study participants will use a different machine each day so that they are using each of the three exercise machines once per week. Two treadmills, two bikes, and two rowers are available during each exercise session. Participants will be randomly assigned to one of three machine orders: treadmill-rower-bike, rower-bike-treadmill, or bike-treadmill-rower. We will employ a percent of heart rate protocol as an exercise intensity measure (77-93% of age-adjusted maximum heart rate) rather than a less well-defined maximal effort protocol or rating of perceived exertion scale. For the purposes of this exercise protocol high intensity exercise will be defined as 77-93% of age adjusted maximum heart rate.
223798565|NCT05156918|OTHER|Non Exercise|There are no modifications to regular diet or exercise habits for 30 days.
223798566|NCT04749030|OTHER|Faecal microbiota transplantation (FMT) capsules|The faeces is minimally processed through a series of centrifugation steps and dispensed into double-coated, acid resistant enterocapsules. A single treatment includes approximately 22 capsules (\~50 grams of original donor faeces).
223798567|NCT04749030|OTHER|Placebo capsules|The placebo capsules are produced from a suspension of 50% glycerol, 40% sterile saline and 10% food coloring in enterocapusles
223798568|NCT03907124|DRUG|Genetically-guided treatment with FDA-approved psychotropic drugs|Psychiatric patients in this experimental arm will receive genetically-guided treatment with psychotropic medications
223798569|NCT03907124|DRUG|Treatment as usual (TAU)|All subjects assigned to TAU group, which is the control arm, will continue to receive FDA-approved psychotropic medications for psychiatric indications investigated in this study
223798570|NCT04238806|DRUG|Desflurane Inhalational agent|Desflurane inhalational agent administration during the whole cardiac surgical operation with cardiopulmonary bypass versus administration of desflurane inhalational agent before and after cardiopulmonary bypass during the whole period of cardiac surgical operation.
223798571|NCT06124209|DRUG|TachoSil|TachoSil used in Vena Cava Inferior anastomosis during liver transplantation.
223798572|NCT02115594|DRUG|Fulvestrant|
223798573|NCT02115594|DRUG|Entinostat|
223798574|NCT02115594|DRUG|Placebo|
223798575|NCT03797768|BEHAVIORAL|Behavioural-FCHV Visit|Female Community Health Volunteer will visit selected households on average 3 times a year for providing health promotion messages on improving lung health status and avoiding risk factors to COPD.
223798576|NCT05615298|RADIATION|Mammography|FFDM (Full-Field Digital mammography)
223798577|NCT03546517|OTHER|Dry Needling|Dry needling of biceps brachii, brachialis, flexor digitorum superficialis and flexor digitorum profundus, triceps brachialis, extensor digitorum and adductor pollicis
223798578|NCT03546517|OTHER|Sham Dry Needling|Sham Dry needling of biceps brachii, brachialis, flexor digitorum superficialis and flexor digitorum profundus, triceps brachialis, extensor digitorum and adductor pollicis
223798579|NCT01851148|OTHER|osteopathic manipulative treatment|It consists of 8 sessions in 6 months. Each osteopathic session is based on a structural evaluation and an indirect technique treatment.
223798580|NCT01851148|OTHER|sham treatment|"Sham therapy was administered with subjects lying supine on the treatment table while the operator used light manual contact to treat the subject. The practitioner's attention was distracted by subtracting serial seven calculation in silence"
223798581|NCT01851148|DRUG|triptans|administration of triptans drug treatment according to international guidelines
223798582|NCT04184063|DRUG|NBMI|NBMI active treatment
223798583|NCT04184063|OTHER|Placebo|Placebo for comparison
223798584|NCT01838798|OTHER|Baseline activities|Initial consent procedures and baseline data collection.
223798585|NCT01838798|OTHER|Clinical interview with a psychologist|"Clinical interview with a psychologist.~This interview with a psychologist will take place after patient consent procedures, and at least 2 days after discontinuation of sedation, and before leaving the ICU. This interview will include:~* An inventory of peritraumatic distress symptoms~* A questionnaire on peritraumatic dissociative experiences~* An assessment of related, potential impacts~* The HADS questionnaire"
223798586|NCT01838798|OTHER|Telephone interview 2 months after ICU discharge|"At 2 months after leaving the ICU, a psychologist will contact the patient with questions regarding his/her representation of hospitalization. This implies the following:~* Questionnaires assessing memories and stressors (Questionnaires ICUMT, and ICU-SEQ~* An assessment of psychological trauma~* An assessment of potential impacts"
223798587|NCT01838798|OTHER|Clinical interview with a psychologist|"At 4 months after ICU discharge, the patient has a clinical interview during which a psychologist will:~* assess cognitive functions~* evaluate clinical symptoms of depression~* assess quality of life~* assess symptoms of post traumatic stress"
223798588|NCT01982149|GENETIC|Group 1|Perform gene expression studies of airway epithelium to correlate findings in the gene expression of nasal bronchial epithelium
223798589|NCT01982149|GENETIC|Group 2|Correlate gene expression data from nasal and bronchial epithelium
223798590|NCT01982149|GENETIC|Group 3|Correlated nasal epithelial gene expression with the ultimate diagnosis (by biopsy or surgery)
223798591|NCT01137474|DRUG|Dapagliflozin|Oral tablets administered as 2.5, 5, or 10 mg, once daily for up to 12 weeks
223798592|NCT01137474|DRUG|Placebo-matching dapagliflozin|Oral tablets administered as 0 mg once daily for up to 12 weeks
223798593|NCT02194270|DRUG|Ambroxol hydrochloride - soft pastille|
223798594|NCT02194270|DRUG|Ambroxol hydrochloride - syrup - low dose|
223798595|NCT02194270|DRUG|Ambroxol hydrochloride - syrup - high dose|
223798596|NCT02219048|DRUG|Placebo|680 micrograms BID, Orally inhaled placebo for 12 weeks
223798597|NCT02219048|DRUG|PF-03715455|680 micrograms BID, Orally inhaled PF-03715455 for 12 weeks
223798598|NCT04983550|DRUG|SG001|Recombinant Anti-PD-1 Fully Human Monoclonal Antibody Injection, 240 mg q2w
223798599|NCT04983550|DRUG|Doxorubicin hydrochloride liposome injection|Doxorubicin hydrochloride liposome injection 40mg/m \^2 q4w
223798600|NCT02073084|DRUG|K-877 Low Dose|K-877 Low Dose
223798601|NCT02073084|DRUG|Moxifloxacin|
223798602|NCT02073084|OTHER|Placebo|
223798603|NCT02073084|DRUG|K-877 High Dose|K-877 High Dose
223798604|NCT00911534|DRUG|rabeprazole sodium|One rabeprazole extended release (ER) 50 mg capsule daily; rescue medication will be provided to subjects to take as needed.
223798605|NCT00911534|DRUG|Placebo|One rabeprazole placebo capsule daily; rescue medication will be provided to subjects to take as needed.
223798606|NCT00006136|DRUG|arginine butyrate|
223798607|NCT00006136|DRUG|epoetin alfa|
223798608|NCT00000602|DRUG|hydroxyurea|
223798609|NCT06530862|OTHER|ESWT+stretching exercises|Participants in this group will receive ESWT treatment
223798610|NCT06530862|OTHER|Dry needling+stretching exercises|Participants in this group will receive Dry needling treatment
223798611|NCT03479372|DRUG|PAN-90806 Ophthalmic Suspension|PAN-90806 provided in single-use dropper bottles for topical ocular administration
223798612|NCT04454866|DRUG|Single injection of penehyclidine|A dose of penehyclidine hydrochloride (0.5 mg/5 ml) is injected intravenously before anesthesia induction. A patient-controlled intravenous analgesia pump is provided after surgery, which is established with a mixture of placebo (normal saline 5 ml), sufentanil (1.25-1.5 ug/kg) and tropisetron (10 mg), diluted with normal saline to 100 ml, and programmed to administer a continuous infusion at a rate of 2 ml/h for 48 hours.
223798613|NCT04454866|DRUG|Continuous infusion of penehyclidine|A dose of penehyclidine hydrochloride (0.25 mg/5 ml) is injected intravenously before anesthesia induction. A patient-controlled intravenous analgesia pump is provided after surgery, which is established with a mixture of penehyclidine hydrochloride (0.25 mg/5 ml), sufentanil (1.25-1.5 ug/kg) and tropisetron (10 mg), diluted with normal saline to 100 ml, and programmed to administer a continuous infusion at a rate of 2 ml/h for 48 hours.
223798614|NCT04454866|DRUG|Placebo|A dose of placebo (normal saline 5 ml) is injected intravenously before anesthesia induction. A patient-controlled intravenous analgesia pump is provided after surgery, which is established with a mixture of placebo (normal saline 5 ml), sufentanil (1.25-1.5 ug/kg) and tropisetron (10 mg), diluted with normal saline to 100 ml, and programmed to administer a continuous infusion at a rate of 2 ml/h for 48 hours.
223798615|NCT01388816|DRUG|DRL-17822 or placebo|DRL-17822 50, 150 or 300 mg or matching placebo once daily after breakfast
223798616|NCT04013711|DIAGNOSTIC_TEST|Thermography|Thermograms will be acquired of both treated and non-treated cancer site for comparison.
223798617|NCT02554968|OTHER|Questionnaires|
223798618|NCT05946811|DRUG|Macitentan 10mg|Macitentan 10 mg oral once daily for 3 months. vs placebo
223798619|NCT04884438|BEHAVIORAL|Psychological intervention for the promotion of gratitude|"A brief intervention protocol has been developed for the promotion of gratitude. The protocol is manualized and the content will be explained to each participant in the videoconference sessions, and a copy of the manual will be given (or sent) to the patients at the end of the therapy sessions.~The structure and contents of the intervention are summarized below:~1. Psychoeducation about gratitude and its effects on health (both physical and psychological).~2. Gratitude towards life:~   1. Gratitude walk~  2. Three positive things~  3. Sharing gratitude~3. Social gratitude:~   1. Daily thanks to others~  2. Gratitude letter~  3. Proof of gratitude~4. Self-gratitude: this part includes an exercise aimed at fostering self-gratitude in three different areas:~   1. Gratitude for the things I do to take care of my physical health.~  2. Gratitude for what I do to take care of my mental health, my self-esteem and my personal development.~  3. Gratitude for what I do to take care of others."
223798620|NCT03548740|BIOLOGICAL|Human Papillomavirus|women with high-risk Human Papillomavirus or not
223798621|NCT02478619|OTHER|IMT group|"Patients will be instructed to do a daily inspiratory muscle training at home with the preset load at 50% of the maximal inspiratory pressure, during 30 minutes for 4 weeks before bariatric surgery.~They will also receive the routine physical therapy in the post operative period."
223798622|NCT02478619|OTHER|Control group|Patients will be instructed to do a daily inspiratory muscle training at home with the minimal inspiratory load of the respiratory resistance device, during 30 minutes for 4 weeks before bariatric surgery. They will also receive the routine physical therapy in the post operative period.
223798623|NCT00030719|BIOLOGICAL|filgrastim|
223798624|NCT00030719|BIOLOGICAL|monoclonal antibody Ch14.18|
223798625|NCT00030719|DRUG|busulfan|
223798626|NCT00030719|DRUG|carboplatin|
223798627|NCT00030719|DRUG|cyclophosphamide|
223798628|NCT00030719|DRUG|etoposide|
223798629|NCT00030719|DRUG|isotretinoin|
223798630|NCT00030719|DRUG|melphalan|
223798631|NCT00030719|DRUG|vincristine sulfate|
223798632|NCT00030719|PROCEDURE|bone marrow ablation with stem cell support|
223798633|NCT00030719|PROCEDURE|conventional surgery|
223798634|NCT00030719|PROCEDURE|peripheral blood stem cell transplantation|
223798635|NCT00030719|RADIATION|radiation therapy|
223798636|NCT03963726|RADIATION|stereotactic radiotherapy|The liver metastases were treated with Cyberknife stereotactic radiotherapy.Using multimodal image fusion to outline the target area.According to the volume, location, organ function and other factors, the dosage of radiotherapy was determined. The range of BED value of radiotherapy was 90-120 when the distance between the tumor and gastrointestinal tract was more than 5 mm (alpha/beta=10) and 70-90 when the distance between the tumor and gastrointestinal tract was less than 5 mm (alpha/beta=10).
223798637|NCT03963726|OTHER|microwave alabation|The colorectal cancer patients with liver metastases will receive microwave ablation.3D printing template was used to assist microwave ablation.For those whose lesions are directly smaller than 5.0cm, the ablation time is about 10 min and 15 min, and the ablation time is more than 15min in patients larger than 5.0cm.
223798638|NCT04775680|BIOLOGICAL|ADG106 injection|ADG106 injection, intravenous infusion, is administered as body weight every 3 weeks for 21 days as a cycle
223798639|NCT04775680|BIOLOGICAL|PD-1 antibody injection|PD-1 antibody injection is administered as an intravenous infusion and at a dose of 240mg every 3 weeks for 21 days as a cycle
223798640|NCT05105295|BIOLOGICAL|Inactivated COVID-19 vaccine|receive a third dose of inactivated COVID-19 vaccine
223798641|NCT01791218|PROCEDURE|CABG, AVR or CABG+AVR and PVI|
223798642|NCT01791218|PROCEDURE|CABG, AVR or CABG+AVR|
223798643|NCT00335322|DRUG|Truvada (fixed dose combination of tenofovir + emtricitabine) + Stocrin (efavirenz)|Truvada (tenofovir 300mg qd + 200mg qd) once daily Efavirenz 600mg qd once daily
223798644|NCT00335322|DRUG|Truvada (fixed dose combination of tenofovir + emtricitabine)+ ritonavir/atazanavir (r/ATV)|Tuvada (tenofovir 300mg qd + 200mg qd) once daily ritoanvir/atazanavir 100mg/300mg qd once daily (taken with food)
223798645|NCT00335322|DRUG|Truvada (fixed dose combination of tenofovir + emtricitabine) + zidovudine (ZDV) + abacavir (ABC)|Tuvada (tenofovir 300mg qd + 200mg qd) once daily zidovudine 250mg/300mg qd (taken in two equal doses approximately 12 hours apart) Abacavir 600mg qd
223798646|NCT06171191|BEHAVIORAL|Move-ARound And Get Active|The intervention consists of seven sessions for parents and preschoolers, providing strategies to encourage compliance with the 24-hour movement behavior guidelines for preschoolers of the World Health Organisation.
223798647|NCT02166008|DRUG|Repamipide|
223798648|NCT02166008|DRUG|Placebo|
223798649|NCT05289726|DRUG|Traditional chinese medicine TDX105|Experimental group Traditional chinese medicine TDX105
223798650|NCT05289726|DRUG|Placebo|he control group received placebo granules mixed with dextrin and food coloring
223798651|NCT00413387|DRUG|beclomethasone dipropionate plus formoterol fumarate combination|100mcg beclomethasone diproprionate plus 6 mcg formoterol
223798652|NCT00413387|DRUG|budesonide plus formoterol combination|200mcg budesonide plus 6 mcg formoterol
223798653|NCT02557152|DEVICE|GentleWave System Treatment|
223798654|NCT04270214|DRUG|Dysport Injectable Product|Dysport injections optimized using kinematics
223798655|NCT05717634|DIAGNOSTIC_TEST|Hysteroscopy|Patients with suspected endometrial pathology, will undergo hysteroscopy with endometrial biopsy or endometrial lesion excision.
223798656|NCT03215732|DIAGNOSTIC_TEST|HBV testing with dried blood spots (DBS) technique|Survey participants will be tested at home for chronic HBV infection using the DBS technique (collection of drops of whole blood dried onto filter paper).
223798657|NCT01632605|DRUG|Sirolimus|Coated tablets, 1mg and 2mg available. Daily oral single dose with trough levels of 4-8ng/mL. Total intake for 6 months.
223798658|NCT06496633|PROCEDURE|Percutaneous Intramyocardial Septal Radiofrequency Ablation|PIMSRA procedure represents a significant breakthrough in the treatment of HOCM patients, as it uses a unique transmyocardial approach to directly and precisely insert a radiofrequency electrode needle into the hypertrophied IVS for targeted ablation
223798659|NCT02275065|DRUG|Bictegravir|Bictegravir tablet(s) administered orally once daily
223798660|NCT02275065|DRUG|Placebo|Placebo to match bictegravir administered orally once daily
223798661|NCT01981733|DEVICE|geko|The geko is a neuromuscular stimulator device, which when applied stimulates the common peroneal nerve
223798662|NCT06273098|BEHAVIORAL|Bladder Health Education|This will be a combination of bladder health education and awareness events, additional resources such as a water station to support healthy bladder behaviors, and tailored changes to classroom bathroom policies that are TBD (e.g. mobile technology bathroom passes).
223798663|NCT02982005|DRUG|KHK4827|Administered KHK4827 by subcutaneous (SC) injection until week 62.
223798664|NCT02982005|DRUG|Placebo|Administered placebo by subcutaneous (SC) injection until week 12. Administered KHK4827 by SC injection from week 13 until week 62.
223798665|NCT06275152|DEVICE|Remote ischemic conditioning|RIC is a non-invasive therapy that performed by an electric auto-control device with cuff placed on arm. RIC procedure during which bilateral arm cuffs are inflated to a pressure of 200mmHg for five cycles of 5 min followed by 5 min of relaxation of the cuffs.
223798666|NCT06275152|DEVICE|Sham Remote Ischemic Conditioning|The sham-RIC procedure during which bilateral arm cuffs are inflated to a pressure of 60mmHg for five cycles of 5 min followed by 5 min of relaxation of the cuffs.
223798667|NCT00010179|DRUG|lurtotecan liposome|
223798668|NCT01775904|DRUG|LY2886721 in a Capsule|Administered orally.
223798669|NCT01775904|DRUG|LY2886721 in an orally disintegrating tablet (ODT)|Administered orally.
223798670|NCT00518115|DRUG|Albiglutide (GSK716155) or exenatide|Albiglutide weekly subcutaneous injection or exenatide twice daily injection
223798671|NCT05729763|OTHER|3D-PADUA nephrometric score|Evaluation of the PADUA nephrometric score with 3D images
223798672|NCT05729763|OTHER|2D-PADUA nephrometric score|Evaluation of the PADUA nephrometric score with 2D images
223798673|NCT02234674|OTHER|Current intensive CDP|"Standard Intensive CDP including~* manual lymph drainage,~* pressotherapy and~* bandaging"
223798674|NCT02234674|OTHER|intensive CDP where Stendo pulsating suit replaces pressotherapy|The intervention consist to perform daily during 5 days an intensive CDP where pressotheray is replaced by Stndo pulsating suit sessions.
223798675|NCT04891419|DEVICE|JUVÉDERM® VOLUMA® with Lidocaine|JUVÉDERM® VOLUMA® with Lidocaine injectable gel
223798676|NCT05426551|OTHER|Dual isotope method|The digestibility of amino acids will be determined within each arm by the collection of ileal digesta owing to naso-ileal intubation device and by plasma samples with the dual isotope method.
223798677|NCT02466022|DRUG|Dexmedetomidine|Bolus dose prior to spinal anesthetic
223798678|NCT02466022|DRUG|Bupivicaine|Intrathecal hyperbaric bupivicaine 12.75mg
223798679|NCT02466022|DRUG|Normal Saline|Bolus 0.1cc/kg Normal Saline over 10 min
223798680|NCT02466022|DRUG|Fentanyl|Intrathecal Fentanyl 10ug
223798681|NCT02466022|DRUG|Midazolam|0-4mg of IV Midazolam prn for rescue sedation
223798682|NCT01428648|BEHAVIORAL|Ballroom Dancing Classes|bi-weekly, 12-Week ballroom dance classes
223798683|NCT04091139|BEHAVIORAL|Unified protocol for adolescents (UP-A)|"The Unified Protocol (UP) is an emotion-focused, cognitive-behavioural intervention that is developed to target core temperamental characteristics underlying anxiety and depressive disorders. The goal of the UP is to help patients to cultivate a greater willingness to experience uncomfortable emotions and to reduce maladaptive emotion response tendencies, so as to lessen the intensity and frequency of uncomfortable emotions. Ehrenreich and colleagues modified from the original UP and developed the UP for adolescents (UP-A).~A Chinese treatment protocol would be developed based on the UP-A. Contents of the treatment includes motivational enhancement, psychoeducation of emotion, avoidance and emotion driven behaviours, interoceptive exposure, cognitive reappraisal, emotion awareness training and emotion exposure. It consists of 10 to 12 individual sessions for the adolescents, and 4 to 6 sessions for parents or guardians."
223798684|NCT04091139|BEHAVIORAL|Treatment as usual (TAU)|TAU participants will receive usual clinical psychological service provided in the clinic (i.e. treatment as usual) in the first 12 weeks, before they start receiving same individual treatment program based on UP-A.
223798685|NCT06360939|RADIATION|SBRT|Delivery of 25Gy in a single dose fraction to target area within 6 weeks of randomization
223798686|NCT06360939|PROCEDURE|CA|CA (endocardial and/or epicardial at operator discretion) within 6 weeks of randomization.
223798687|NCT03417167|OTHER|US-guided synovial biopsy|Needle Synovial biopsy performed using a Tru-cut® device.
223798688|NCT04866173|OTHER|Dog|Subjection to standardised stress situations in the presence of a dog and a person
223798689|NCT04866173|OTHER|No Dog|Subjection to standardised stress situations in the presence of a person
223798690|NCT00127244|PROCEDURE|Periodontal Treatment|
223798691|NCT03712644|DEVICE|FFR-guided coronary revascularization|Stenoses in range of 50-90% diameter stenosis in major coronary arteries will be assessed by FFR, and revascularized if FFR equal to or lower than 0.80. Lesions above 90% diameter stenosis in will be revascularized without further assessment.
223798692|NCT04443140|DIAGNOSTIC_TEST|PCR, lung ultrasound|PCR for Covid-19
223798693|NCT01845675|DRUG|temozolomide or dacarbazine-based chemotherapy, endostatin|
223798694|NCT05462665|BEHAVIORAL|theory training|theory training
223798695|NCT05462665|BEHAVIORAL|theory and simulation training|theory and simulation training
223798696|NCT05704075|PROCEDURE|Transverse Tibial Transport (TTT)|Transverse tibial transport is a novel adaptation of concepts used in distraction histogenesis. The most common use of this surgical principle is in bone lengthening surgery, which is a well-established surgical procedure by applying an external fixator to the bone, creating a corticotomy, and gradually lengthening the bone at the optimal rate of 0.5mm/12hrs. The biological mechanisms of distraction histogenesis involve activating signalling pathways such as cytokines Interleukin 1 and Interleukin 6, pro-inflammatory markers TNF alpha, pro-osteogenic TGF-beta, BMPs and pro-angiogenic factors VEGF and angiopoietin . TTT utilises the concept of distraction histiogenesis, but distraction is performed in the transverse plane instead of a longitudinal distraction. In addition, the period of distraction is coupled with a corresponding compression period and ultimately results in no net change in limb length.
223798697|NCT05704075|PROCEDURE|Conventional|Dressing + Negative Pressure Wound Therapy
223798698|NCT02848248|DRUG|SGN-CD123A|Intravenous infusion in 3-week cycles
223798699|NCT00827918|DRUG|MK-8998|MK-8998 6 mg capsules twice daily with food on Days 1 through 7. On Day 8, dosage will be increased to 8 mg capsules twice daily. Treatment period is 4 weeks. There will be a period of time when all participants will receive placebo.
223798700|NCT00827918|DRUG|Comparator: Olanzapine|Olanzapine 5 mg tablets twice daily with food on Days 1 through 7. On Day 8, dosage will be increased to 5 mg tablets in the morning and 10 mg tablets in the evening. Treatment period is 4 weeks. There will be a period of time when all participants will receive placebo.
223798701|NCT00827918|DRUG|Comparator: Placebo|Placebo tablets matching olanzapine tablets and MK-8998 capsules
223798702|NCT05283317|BIOLOGICAL|Mesenchymal stem cells|Standard therapy of sepsis as suggested in the guidelines were given to all patients and additionally MSCs treatment was applied to the patients in the study group.
223798703|NCT03623087|DRUG|Cisplatin|SIMPLE
223798704|NCT03623087|DRUG|Gemcitabine|SIMPLE
223798705|NCT03623087|DRUG|Etoposide (VP-16)|SIMPLE
223798706|NCT03623087|DEVICE|Ifosfamide|SIMPLE
223798707|NCT03623087|DRUG|Dexamethasone|SIMPLE
223798708|NCT03623087|DRUG|L-asparaginase|SIMPLE
223798709|NCT05050201|DEVICE|Sleepio|Digital CBT application for insomnia
223798710|NCT02119351|DEVICE|ViaValve™ Safety IV Catheter|Safety peripheral IV catheter with a blood control feature
223798711|NCT02119351|DEVICE|ProtectIV® Plus Safety IV Catheter|Safety peripheral IV catheter with no blood control feature
223798712|NCT04183270|OTHER|Questionnaires|The survey will focus on non-valvular atrial fibrillation patients, who will start treatment with a NOAC, and their treating physician.
223798713|NCT01761097|DEVICE|Endocuff attachment|Endocuff
223798714|NCT03609762|BEHAVIORAL|EQ-5D-5L HRQOL results be available to the attending doctor|all subjects attending the intervention clinics will complete the electronic EQ-5D-5L before seeing the doctor during each follow-up visit for the musculoskeletal problem, a print out of the longitudinal EQ-5D-5L data (Table 1) since recruitment will be given to the patients to show to the attending doctors during the consultation. The doctors will provide the management based on the usual clinical information and the additional EQ-5D-5L HRQOL results. The doctor will complete the clinician-reported follow-up clinical data form (CRF) of each eligible patient at the end of the consultation.
223798715|NCT00127101|DRUG|vorinostat|Dose escalation study starting with vorinostat 200 mg q.d. capsules (1 capsule daily) and rising up to vorinostat 400 mg q.d. capsules (1 capsule daily). Up to 6 months of treatment.
223798716|NCT00127101|DRUG|Comparator: bexarotene|Dose escalation with bexarotene 150 mg/m2 capsules rising up to 300 mg/m2 capsules (1 capsule daily). Up to 6 months of treatment.
223798717|NCT04231812|DEVICE|Laparoscopic Tissue Morcellation working space (bag)|"The LapBox is working space (bag) intended for use as a laparoscopic instrument port and tissue containment system that creates a working space allowing for visualization during power or manual morcellation procedure following a laparoscopic procedure for the excision of benign gynecologic tissue that is not suspected to contain malignancy"
223798718|NCT00325611|BEHAVIORAL|Multidisciplinary palliative care team met with patient|
223798719|NCT06267053|DIAGNOSTIC_TEST|Direct digital radiography|All the participants had anterior posterior and lateral knee xray taken within 3 months of diagnosis
223798720|NCT06267053|DIAGNOSTIC_TEST|25-OH Vitamin D|All the participants had serum 25-OH Vitamin D levels measured from venous blood within 30 days of diagnosis
223798721|NCT06267053|DIAGNOSTIC_TEST|Vitamin B12|All the participants had serum Vitamin B12 levels measured from venous blood within 30 days of diagnosis
223798722|NCT06267053|DIAGNOSTIC_TEST|Folic acid|All the participants had serum folic acid levels measured from venous blood within 30 days of diagnosis
223798723|NCT05584891|PROCEDURE|mastoidectomy and mastoid oblitration|Forty pediatric patients with cholesteatoma indicated for radical mastoidectomy or modified radical mastoidectomies will be enrolled in our study and we will be grouped into two groups: one will undergo radical mastoidectomy alone and their operation results will be compared to other group which includes twenty pediatric patients with mastoid obliteration operation.
223798724|NCT01302847|DRUG|DTG film-coated tablets|DTG film-coated tablets initial starting dose at \~1 mg/kg with a maximum dose of 50 mg; orally once daily. Participants weighing ≥ 35kg received the proposed dose of 50 mg of DTG film-coated tablets.
223798725|NCT01302847|DRUG|DTG granules for suspension|DTG granules for suspension initial starting dose at \~0.64 mg/kg with a maximum dose of 32 mg; orally once daily.
223798726|NCT01302847|DRUG|DTG dispersible tablets|"DTG dispersible tablets initial starting dose of \~0.8 mg/kg with a maximum dose of 30 mg; orally once daily. The proposed weight-band dosing was:~Weight band 3 to \<6 kg: 5 mg DTG dispersible tablets; Weight band 6 to \<10 kg: 15 mg DTG dispersible tablets; Weight band 10 to \<14 kg: 20 mg DTG dispersible tablets; Weight band 14 to \<20 kg: 25 mg DTG dispersible tablets; Weight band ≥20 kg: 30 mg DTG dispersible tablets."
223798727|NCT01302847|DRUG|DTG dispersible tablets|"DTG dispersible tablets initial starting dose of \~1.25 mg/kg with a maximum dose of 30 mg; orally once daily. The proposed weight-band dosing was:~Weight band 3 to \<6 kg: 5 mg DTG dispersible tablets; Weight band 6 to \<10 kg: 15 mg DTG dispersible tablets; Weight band 10 to \<14 kg: 20 mg DTG dispersible tablets; Weight band 14 to \<20 kg: 25 mg DTG dispersible tablets; Weight band ≥20 kg: 30 mg DTG dispersible tablets."
223798728|NCT01302847|DRUG|DTG dispersible tablets|"DTG dispersible tablets initial starting dose of \~1.25 mg/kg with a maximum dose of 30 mg; orally once daily. The proposed weight-band dosing was:~Weight band 3 to \<6 kg: 5 mg DTG dispersible tablets; Weight band 6 to \<10 kg: 15 mg DTG dispersible tablets."
223798729|NCT06534567|OTHER|Mediterranean Diet|Mediterranean diet adherence
223798730|NCT06534567|OTHER|Physical activity|Physical activity level
223798731|NCT02342067|DRUG|Cenicriviroc|CVC 150 mg QD on Days 1-10, washout on Days 11-20, PGZ 45 mg QD on Days 21-30, and CVC 150 mg QD + PGZ 45 mg QD on Days 31-40
223798732|NCT02342067|DRUG|Pioglitazone|PGZ 45 mg QD on Days 1-10, washout on Days 11-20, CVC 150 mg QD on Days 21-30, and CVC 150 mg QD + PGZ 45 mg QD on Days 31-40
223798733|NCT00297752|DRUG|ceriumnitrate silversulfadiazine (flammacerium)|treatment of patients with facial burns with CE-SSD
223798734|NCT00297752|DRUG|silversulfadiazine (flammazine)|treatment of patients with facial burns with SSD
223798735|NCT04259268|OTHER|Quality of preoperative information register|Register of principal (grade ASA classification) and secondary variables (allergies, antiplatelet or blood thinners prescriptions, cardiovascular diseases, present medication)
223798736|NCT04259268|OTHER|Suitability of information contained in the informed consent|Register of information regarding specific individual risks and personal data (patient and doctor identification and signature)
223798737|NCT00734227|PROCEDURE|Emergency portacaval shunt|
223798738|NCT00734227|OTHER|Emergency TIPS|
223798739|NCT01765634|BIOLOGICAL|Mesenchymal stem cells|Mesenchymal stem cells will be intravenously infused via a central venous catheter(at a dose of 1×10\^6 cells/kg, over 15 min) each week, four times for a cycle.
223798740|NCT01765634|BIOLOGICAL|Non-mesenchymal stem cells|Other second line drugs are taken.
223798741|NCT04464928|OTHER|Facebook Advertisements|Counties will receive advertisements to VoicesForPFD.org's webpage on urinary incontinence on Facebook Ads when triggered by user characteristics indicating elevated risk of female urinary incontinence.
223798742|NCT04464928|OTHER|Google Advertisements|Counties will receive advertisements to VoicesForPFD.org's webpage on urinary incontinence on Google Ads when triggered by keywords relevant to female urinary incontinence.
223798743|NCT03487250|DEVICE|TenJet System|Percutaneous ultrasound guided medial and lateral tenotomy using the TenJet HydroSurgery System
223798744|NCT03516331|DRUG|FDL176 & FDL169 coadministration|CFTR corrector and potentiator
223798745|NCT00374322|DRUG|lapatinib|Lapatinib 1500 mg (6 tablets) daily for 12 months
223798746|NCT00374322|OTHER|placebo|6 tablets daily for 12 months
223798747|NCT05153980|DEVICE|Warm-up + Blood Flow Restriction cuff (smart-cuff pro device, acting as pressurized tourniquet)|Blood Flow Restriction
223798748|NCT05153980|OTHER|Warm-up|Warm-up without any special intervention (no Blood Flow Restriction)
223798749|NCT02019368|DIETARY_SUPPLEMENT|Placebo|
223798750|NCT02019368|DIETARY_SUPPLEMENT|Aged garlic extract|
223798751|NCT02950246|PROCEDURE|perineural catheterization implementation|Skin preparation (disinfection) with 10 ml of 2% alcoholic Chlorhexidine Perineural catheterization implementation Ultrasonography use
223798752|NCT02950246|DRUG|2% alcoholic chlorhexidine|
223798753|NCT02950246|DRUG|povidon iodine|
223798754|NCT00277667|DRUG|Quetiapine|Oral dosing: 50mg (Day 1), 100mg (Day 2), 150mg (Day 3), 200mg (Day 4), followed by flexible dosing from 50mg to 800mg through day 56.
223798755|NCT05449834|DRUG|Fibrinogen Concentrate|3g Fibrinogen Concentrate
223798756|NCT05449834|OTHER|Cryoprecipitate|10U WB or 4U Apheresis Cryoprecipitate
223798757|NCT02069444|PROCEDURE|Macintosh laryngoscope|intubation criterias withMacintosh laryngoscopein pediatric patients
223798758|NCT02069444|PROCEDURE|Truview EVO2 laryngoscope|intubation criterias with Truview EVO2 laryngoscope in pediatric patients
223798759|NCT02495272|DRUG|Oxytocin|Oxytocin 10IU Administered intramuscularly.
223798760|NCT05378633|RADIATION|SRS|Stereotactic Radiotherapy (SRS)
223798761|NCT05378633|RADIATION|Whole Brain Radiotherapy|Whole Brain Radiotherapy (WBRT)
223798762|NCT03381495|DRUG|Ropivacaine Hydrochloride, Sufentanil|In this research one group will receive epidural analgesia(Ropivacaine Hydrochloride, Sufentanil), data will be collected and analyzed between this group and non-epidural analgesia group.
223798763|NCT03662204|OTHER|Blood Sample Collection|Subjects participating in the study will have blood drawn at enrollment.
223798764|NCT00829387|BEHAVIORAL|CBT plus standard pharmaceutical care (CBT/SC)|Ten sessions of individual treatment delivered by a doctoral level psychologist.
223798765|NCT00829387|BEHAVIORAL|Diabetic Education plus standard pharmaceutical care (ED/SC)|Ten individual sessions of diabetes educations delivered by a doctoral level psychologist under the supervision of a certified diabetes educator.
223798766|NCT01923155|PROCEDURE|Colonoscopy|
223798767|NCT00796081|DRUG|ER OROS paliperidone, paliperidone ER|
223798768|NCT00707031|DRUG|Lixisenatide (AVE0010)|Self administered by subcutaneous injections once daily within the hour preceding breakfast.
223798769|NCT00707031|DEVICE|Pen auto-injector|
223798770|NCT00707031|DRUG|Exenatide|Self administered by subcutaneous injections twice daily within the hour preceding breakfast and within the hour preceding dinner.
223798771|NCT00707031|DEVICE|Prefilled pen injector|
223798772|NCT00707031|DRUG|Metformin|Metformin to be continued at stable dose (at least 1.5 gram per day) up to the end of treatment.
223798773|NCT03519854|DRUG|Placebo|0.9% NaCl administered as a fast IV bolus dose (within 30 seconds).
223798774|NCT03519854|DRUG|Sugammadex|Sugammadex administered as a fast IV bolus dose (within 30 seconds), dosed according to participant actual body weight.
223798775|NCT03519854|DRUG|Esmeron®|Esmeron® administered at 0.6 mg/kg as a fast IV bolus (within 10 seconds), dosed according to participant actual body weight.
223798776|NCT01821261|DEVICE|Mouth Rinse 19668-012|20 ml of experimental mouth rinse 19668-012 for 30 seconds, twice daily
223798777|NCT01821261|DRUG|Mouth Rinse 500347078842|10 ml of mouth rinse 500347078842 for 60 seconds, twice daily
223798778|NCT01821261|DRUG|Toothpaste 035000513007|Approximately one inch of toothpaste 035000513007, twice daily
223798779|NCT05433870|OTHER|Whether the PE or E patient combined with PRES|According to the Diagnostic criteria of PRES, all the patients grouped into two groups.
223798780|NCT04786158|DRUG|Apomorphine|Reporting the effects of subcutaneous apomorphine on pain and on quality of life
223798781|NCT03157609|DEVICE|Thermometry|Within the same patient comparison of 2 thermometry methods: SpotOn skin sensor versus oesophageal temperature probe
223798782|NCT04447170|PROCEDURE|Simple repair or Graham technique|Simple suture with or without omental protective patch
223798783|NCT02747238|DEVICE|Ultrasound|The ultrasound imaging of the lumbar spine in different scanning planes facilitates the identification of the landmarks necessary for appropriate epidural space location in pregnant patients. There are two acoustic windows that are effective for lumbar spine sonographic assessment: one seen on the transverse approach, and the other seen on the longitudinal paramedian approach. The ultrasound single-screen method using the transverse approach of the lumbar spine provides reliable information regarding the landmarks required for labor epidurals. The correct interspace and midline position are identified for correct placement of the CSE analgesia.
223798784|NCT02747238|PROCEDURE|No ultrasound|Palpation of anatomical landmarks is used for placement of labor analgesia
223798785|NCT02747238|PROCEDURE|Epidural infusion|An epidural infusion will be started in both groups, regarding of the technique used for placement, and the same solution of Bupivacaine 0.0625% with 2mcg fentanyl/cc will be used in both groups
223798786|NCT05069090|BEHAVIORAL|Lockdown and other social distancing measures|During the study period, the Chilean Ministry of Health established a five-step process for social distancing measures. These ranged from full lockdown (step 1) to almost no restrictions (step 5). Even under full lockdown, citizens were able to obtain permits for essential activities. Citizens had a maximum of two permits per week and were obtained in a virtual station of the Chilean Police Force (Carabineros de Chile).
223798787|NCT00815282|OTHER|Human papilloma virus vaccine (cervarix)|vaccination at 0, 1 and 6 months
223798788|NCT02568748|BIOLOGICAL|CIK|Cytokine -induced killer cells in Egyptian patients with advanced hepatocellular carcinoma as treatment or adjuvant treatment in comparison with traditional treatment.
223798789|NCT02568748|PROCEDURE|TACE|Trans-arterial chemoembolization
223798790|NCT01571505|BIOLOGICAL|IPV vaccination|Randomized IPV or OPV to children aged at 39weeks.
223798791|NCT01567384|DRUG|OSI-906 and Pemetrexed|"Pemetrexed will be administered intravenously on day 1 of cycle 1 at a dose of 500 mg/m2 as a 10-minute infusion. Subsequent doses will be defined by tolerability.~OSI-906 will be administered orally twice daily (12 hours apart) at approximately the same times each day on a continuous schedule, beginning on Day 0 of cycle 1."
223798792|NCT01944904|DIETARY_SUPPLEMENT|Sugar Pill|The placebo is identical in appearance to the XOS and contains 505mg maltodextrin
223798793|NCT01944904|DIETARY_SUPPLEMENT|XOS 2.8|2.8g XOS is white or off-white crystalline substance and contains 500mg XOS 70P and 20mg maltodextrin
223798794|NCT01299948|DRUG|Prednisolone|5 mg prednisolone orally per day
223798795|NCT01015157|PROCEDURE|Roux-en-Y laparoscopic gastric bypass for morbid obesity|Primary bariatric surgery. Standard laparoscopic procedure with linear stapling divising of the stomach (Echelon 60 stapler, GOLD cartridges) with or with Seamguard reinforcement
223798796|NCT00951275|DRUG|tocilizumab [RoActemra/Actemra]|8mg/kg iv every 4 weeks for 6 months
223798797|NCT00951275|DRUG|Standard DMARDs (Disease Modifying Anti Rheumatic Drugs)|As prescribed
223798798|NCT05944965|DRUG|Atomoxetine 80 mg plus Oxybutynin 5 mg|80mg Atomoxetine and 5mg Oxybutynin administered 30mins prior to bed
223798799|NCT05944965|DRUG|Atomoxetine 80 MG|80mg Atomoxetine administered 30 mins prior to bed
223798800|NCT05944965|DRUG|Placebo|Placebo and placebo (sugar pill) administered 30 mins prior to bed
223798801|NCT02320565|PROCEDURE|3D Laparoscopy|3D Laparoscopy approach
223798802|NCT02320565|PROCEDURE|Standard Laparoscopy|Standard laparoscopy approach
223798803|NCT04575636|DIAGNOSTIC_TEST|Magnetic Resonance Lymphography|Magnetic Resonance Lymphography using Siemens 3T MRI unit and Gadobutrol as a contrast agent to visualize the lymphatic system
223798804|NCT01420848|OTHER|Auriculotherapy|Auriculotherapy stimulates points to achieve better emotional balance, mental and physiological.
223798805|NCT01420848|OTHER|Placebo Group|They were evaluated at the baseline,twelve sessions and 15-day follow-up and received 12 sessions through the Fist and Outer ear points.
223798806|NCT06286150|PROCEDURE|Surgical robot system|SHURUI Single-port surgical robot system
223798807|NCT05737082|DRUG|HCP2201|Take 2 tablets once per period
223798808|NCT05737082|DRUG|RLD2205|Take 2 tablets once per period
223798809|NCT05737082|DRUG|RLD2206|Take 1 tablet once per period
223798810|NCT02446301|DRUG|Bain®|Nalbuphine HCl 20mg, IM injection
223798811|NCT02446301|DRUG|SDE|Sebacoyl Dinalbuphine Ester 150mg/2ml, IM injection
223798812|NCT03295890|PROCEDURE|Dry Needing|Dry Needling
223798813|NCT01826864|BIOLOGICAL|sargramostim|Given SC
223798814|NCT01826864|PROCEDURE|sentinel lymph node biopsy|Undergo sentinel lymph node biopsy
223798815|NCT01826864|OTHER|laboratory biomarker analysis|Correlative studies
223798816|NCT01826864|OTHER|hypertonic saline|Given SC
223798817|NCT05483504|DRUG|F61 injection|Colorless or slightly yellow liquid, may be slightly opalescent
223798818|NCT05483504|DRUG|F61 Placebo|Colorless or slightly yellow liquid, may be slightly opalescent
223798819|NCT00100685|DRUG|Volociximab (anti-α5β1 integrin monoclonal antibody)|Volociximab intravenously (Cohort 1: 10 mg/kg every other week or Cohort 2: 15 mg/kg once a week) for up to 104 weeks or until disease progression, whichever occurs first.
223798820|NCT05445648|DRUG|Tislelizumab Injection|After patient recruitment, every patient first receives a regimen of tislelizumab injection 200 mg every time , q3w, 4 times in total. Then all patients, if operable, undergo TURBT. The first day after TURBT, patients again start to receives a regimen of tislelizumab Injection 200 mg every time , q3w, 4 times in total. Meanwhile, on the eighth day after TURBT, patients start to receive radiotherapy. The total radiation dosage is 50.4 Gy (patients receive radiotherapy 28 times, dosage being 1.8 Gy every time), with the total radiation dosage on pelvis area being 45 Gy and total radiation dosage on bladder area being 50.4 Gy.
223798821|NCT05445648|PROCEDURE|Transurethral resection of bladder tumor|After the initial tislelizumab injection regimen, patients undergo clinical assessment and receive transurethral resection of bladder tumor if operable.
223798822|NCT05445648|RADIATION|Adjuvant radiotherapy|On the eighth day after TURBT, patients start to receive radiotherapy. The total radiation dosage is 50.4 Gy (patients receive radiotherapy 28 times, dosage being 1.8 Gy every time), with the total radiation dosage on pelvis area being 45 Gy and total radiation dosage on bladder area being 50.4 Gy.
223798823|NCT04304664|OTHER|Mindfulness- Based Intervention|"Mindfulness- Based Intervention in a psychological intervention, based on mind- body connection.~The protocol includes a 10- weeks program, with weekly group sessions of 2 hours and one all-day session after seven weeks. The intervention have standardized core elements consisting of different mental and physical mindfulness exercises: 1) body-scan exercises (paying close attention to all body parts, from the feet to the head), 2) mental exercises focusing one's attention on breathing, 3) physical exercises with focus on being aware of bodily sensations and one's own limits during the exercises, and 4) practicing being fully aware during everyday activities by using the breath as an anchor for attention. Essential to all parts of the program is developing an accepting and non-reactive attitude to what one experiences in each moment."
223798824|NCT04621110|DRUG|intranasal dexmedetomidine|Dexmedetomidine (precedex®) will be administered by intranasal route in 1ug/kg each dose, repeating at most 3 times to see if it can give enough sedation to painful procedure. To assess the level of sedation the study will use Ramsay sedation scale.
223798825|NCT04621110|DRUG|intranasal fentanyl|Fentanyl will be administered by intranasal route in 1,5ug/kg each dose, repeating at most 3 times to see if it can give enough pain relief for painful procedure. To assess pain control the study will use Face, Legs, Activity, Cry, Consolability scale ( FLACC)
223798826|NCT04621110|DRUG|intravenous ketamine (ketalar®)|Ketamine (ketalar®) will be administrated by intravenous route in 1mg/kg dose and the study will use this drug to compare the efficiency of intranasal drugs.
223798827|NCT04621110|DRUG|intravenous midazolam|Midazolam will be administrated by intravenous route in 0,1mg/kg dose and the study will use this drug to compare the efficiency of intranasal drugs.
223798828|NCT04807465|DEVICE|G-Premio Bond in etch&rinse mode|The phosphoric acid gel was applied to enamel and dentin washed for 5s and was dried gently with air spray. The adhesive system was applied to enamel and dentin surfaces and leave it in place for 10s.
223798829|NCT04807465|DEVICE|G-Premio Bond in selective-etch mode|The phosphoric acid was applied only on enamel for 10-15s then washed and was gently dried with air spray. The adhesive system was applied to enamel and dentin surfaces.
223798830|NCT04807465|DEVICE|G-Premio Bond in self-etch mode|The adhesive system was applied to the enamel and dentin surfaces.
223798831|NCT03283774|OTHER|current clinical practice|quality management (data registration, drug prescription, diagnostic and clinical tests ...), in primary care of patients with diabetes mellitus
223798832|NCT04567108|BEHAVIORAL|Maintain usual SSBs|Instruction/guidelines to maintain baseline intake of SSBs (months 0-6); then switch to water only (months 6-12)
223798833|NCT04567108|BEHAVIORAL|Substitute to non-SSBs|Instruction/guidelines to eliminate SSBs and replace, where possible, with beverages consistent to group assignment (months 0-6); then switch to water only (months 6-12)
223798834|NCT04567108|BEHAVIORAL|Study app|Engage with a motivational mobile app to track beverage intake and complete study data collection
223798835|NCT04567108|BEHAVIORAL|Beverage delivery|Select from approved beverages for a monthly at-home delivery (months 0-6)
223798836|NCT05874765|DIAGNOSTIC_TEST|Diagnostic and Statistical Manual of mental disorder- fifth edition ( DSM5)|Diagnostic and Statistical Manual of mental disorder- fifth edition ( DSM5) , will be used to diagnose and classify the Tics among all included patients
223798837|NCT05748548|OTHER|Thoracic kyphosis- Lumbal Lordosis angle measurement|In order to determine the kyphosis, the degrees determined by measuring the spinous processes of the T12 T1, T2 and L1 vertebrae with an inclinometer while the individuals are standing will be collected. In order to determine the degree of lumbar lordosis, the measurement between the spinous processes of the T12L1 and S2S3 vertebrae will be made and the degree of lordosis will be determined by adding the degrees found. While the reference values for thoracic kyphosis are 20-45 degrees, this value is 20-40 degrees for lordosis. These measurements will be made with an inclinometer. Measurements will be repeated 3 times and the results will be recorded by taking the average of the measurements.
223798838|NCT05748548|OTHER|Back Muscle Endurance Test - Sorenson Test|The endurance of the back muscles will be evaluated with the Biering Sorensen Test (Static Back Endurance Test).
223798839|NCT05748548|OTHER|Surface EMG activation|We will try to find out which of the exercises such as pressing back the back, waist extension on the balance ball, lumbar extension while in the active prone position, Superman exercises have better lumbar extensor muscle activations.Muscle activations of individuals will be evaluated using superficial EMG. An 8-channel EMG Noraxon MiniDTS system (Noraxon, USA, Inc, Scottsdale, AZ) will be used to measure signals from the muscles.
223798840|NCT03502382|DIAGNOSTIC_TEST|x-ray|Radiological: standing antero-posterior full-length digital images of the lower extremities
223798841|NCT01464541|PROCEDURE|operative fracture size vs CT fracture size|comparing actual intraoperative fracture size to the CT fracture size
223798842|NCT01464541|PROCEDURE|orbital fracture intraoperative measurement|comparing intraoperative fracture size to the CT orbital fracture size
223798843|NCT02341430|DEVICE|Symbotex™ Composite Mesh|Repair of a Grade I or II ventral hernia according to VHWG classification system with Symbotex™ Composite Mesh
223798844|NCT03735264|DRUG|Anlotinib Hydrochloride plus Docetaxel|Anlotinib Hydrochloride (12mg QD PO d1-14, 21 days per cycle) and Docetaxel (75mg/m2 IV d1)
223798845|NCT02393872|BEHAVIORAL|Feel4Diabetes-intervention|Community-based intervention.
223798846|NCT02741401|OTHER|Usual post-operative care|Usual post-operative care concerning patients who underwent surgery because of gastrointestinal malignancy
223798847|NCT02741401|OTHER|Hand-foot massage|Hand-foot massage administered during 5 consecutive days postoperatively by trained volunteers, concerning patients who underwent surgery because of gastrointestinal malignancy
223798848|NCT03153579|DRUG|LSD|"Lysergic Acid Diethylamide~200ug per os, single dose"
223798849|NCT03153579|DRUG|Placebo|Capsules containing mannitol looking identical to LSD
223798850|NCT02128464|PROCEDURE|Patient specific cutting guides|Patient specific cutting guides are custom-made for each patient based on Magnetic Resonance Imaging (MRI). Before surgery, MRI of the knee is done and used to create a cutting guide that is formed to the exact shape of the knee. The patient specific cutting guides have platforms that can be attached to the bone, so the rod does not need to be placed in the leg bone.
223798851|NCT02128464|PROCEDURE|Standard knee cutting guides|Standard cutting guides use traditional instrumentation to determine knee implant positions. During surgery, a rod is placed in the leg bone and the cutting guide is attached to that rod.
223798852|NCT02479230|BIOLOGICAL|tumor blood vessel antigen peptide-pulsed alpha-type-1 polarized dendritic cell vaccine|Given ID
223798853|NCT02479230|DRUG|gemcitabine hydrochloride|Given IV
223798854|NCT01779726|RADIATION|CT scan before chest physician|Patients referred to department of lung medicine are randomised according to the month of birth. Patients born in even months are CT scan before a consultation with a chest physician
223798855|NCT01779726|RADIATION|Usual diagnostic workup|Patients born in odd months seen in the department of lung medicine by a chest physician and maybe then CT scanned (usual workup practice according to the fast track evaluation)
223798856|NCT04740489|BEHAVIORAL|Phase 3 Cardiac rehabilitation|Phase 3 CR is a comprehensive outpatient programme, considered the core rehabilitation phase, in which participants receive structured exercise, health education, risk factor modification and psychological support. Upon discharge from clinically supervised phase 3 CR participants are generally signposted to long-term community-based exercise classes (phase 4). The current study will take place within a core phase 3 CR programme in the UK.
223798857|NCT01735890|DRUG|CJ Amlodipine/Valsartan 10/160mg Novartis Exforge 10/160mg|single dose
223798858|NCT00036881|DIETARY_SUPPLEMENT|zinc sulfate|
223798859|NCT00036881|OTHER|placebo|
223798860|NCT03778879|DRUG|CCX872-B|CCX872-B concurrent with stereotactic body radiation therapy for pancreatic adenocarcinoma.
223798861|NCT00282022|DRUG|laromustine|
223798862|NCT04062357|DRUG|Lidocaine 5% spray|Group 1 (n₌75); was given on demand lidocaine 5% spray for 8 weeks (One to two applications (1-2 ml) of lidocaine 5% sprays; contain 5 -10 mg of lidocaine, in a metered dose aerosol-delivery system).
223798863|NCT04062357|OTHER|Placebo|Group 2 (n₌75); was given placebo in form on demand alcohol spray for 8 weeks.
223798864|NCT04133727|BEHAVIORAL|Use of an ageing suit|The simulation suit consists of a pair glasses which simulates narrowing of visual field; a pair of gloves ; a vest ; elbow and knee wraps and sand bags worn on the wrists and ankles
223798865|NCT04133727|OTHER|Polypharmacy workshop|Participants will conduct a full medication review for older adults within 1 hour and develop a medication list which can be used for counselling of older adults
223798866|NCT03372122|DRUG|Chlorhexidine Gluconate|A cloth to cleanse and disinfect the skin
223798867|NCT03372122|COMBINATION_PRODUCT|HUBS with Hibiclens|A dry cloth to be used in combination with water and antimicrobial soap to cleanse and disinfect the skin
223798868|NCT02813070|DRUG|[18F] Flutemetamol|PET brain imaging and Magnetic resonance brain imaging
223798869|NCT04470245|DIAGNOSTIC_TEST|magnetic resonance imaging (MRI)|Our study will include healthy volunteers (to refine the scanning sequence) and patients undergoing surgery for CTS. Patients will be scanned before and after their operation using cutting-edge diffusion MRI techniques.
223798870|NCT03195010|BIOLOGICAL|Platelet Transfusion|Undergo lower dose platelet transfusion
223798871|NCT03195010|BIOLOGICAL|Platelet Transfusion|Undergo higher dose platelet transfusion
223798872|NCT01284465|BEHAVIORAL|Education and patient liaison combination|Group education sessions with Patient liaison using ecological momentary assessment principles
223798873|NCT01284465|BEHAVIORAL|Control group|Group education sessions at baseline, 3 and 6 months
223798874|NCT03710915|DRUG|HG146|HG146 will be administered every other day for 14 days, followed by 1 week off the drug with each treatment cycle of 21-days.
223798875|NCT05450965|DRUG|Onvansertib|Onvansertib at a dose of 15 mg/m2 orally on Days 1-14 of a 21-day cycle. Treatment will continue until disease progression or intolerable toxicity.
223798876|NCT05411458|OTHER|Aerobic and Relaxation Exercises|"12-week treatment program; A - 6 weeks of aerobic exercise (AE) (outdoor walking program) 6 week program B - Jacobson Progressive Relaxation Exercises (JIGE) (done by patients at home). The 6-week B program (JIGE) was applied in addition to the aerobic exercise (AE) program.~Aerobic exercise (AE) program:The aerobic training program was applied as walking for 40 minutes in the open air. The Rating of Perceived Exertion (RPE) Borg Scale (6-20) was used to determine the walking pace, and they were asked to walk according to the light (11-12) level according to the Borg scale.~An exercise program is 30-45 minutes, and the applications are done every other day and 3 days a week.The treatment programs started with the evaluation of the cases by the physiotherapist and are followed up using the Telerehabilitation method. At the beginning of each week, the patients were called and checked, and their exercise treatments were completed at the end of 12 weeks."
223798877|NCT03565445|DRUG|ASP1948|Intravenously (IV)
223798878|NCT03565445|DRUG|nivolumab|Intravenously (IV)
223798879|NCT03565445|DRUG|pembrolizumab|Intravenously (IV)
223798880|NCT06122714|DRUG|AZD4144 Part A|Part A: Participants will be administered a single oral dose on Day 1.
223798881|NCT06122714|DRUG|AZD4144 Part B|Part B: Participants will be administered a single dose on Day 1, and repeated dosing will commence from Day 4 until Day 11 (inclusive) and a single dose on Day 12.
223798882|NCT06122714|DRUG|Placebo Part A|Part A: Participants will be administered a single oral dose of matching placebo on Day 1.
223798883|NCT06122714|DRUG|Placebo Part B|Part B: Participants will be administered a single dose of matching placebo on Day 1, and repeated dosing will commence from Day 4 until Day 11 (inclusive) and a single dose on Day 12.
223798884|NCT04770025|DEVICE|High-density transcranial alternating current stimulation|High-density electrode configuration with transcranial alternating current stimulation in the beta (15-40Hz) frequency range
223798885|NCT04770025|DEVICE|Sham stimulation|High-density electrode configuration with sham stimulation
223798886|NCT04770025|BEHAVIORAL|Motivational interviewing|Motivational interviewing session focused on alcohol use, approximately 30 minutes in length
223798887|NCT05295498|DEVICE|Active repetitive transcranial magnetic stimulation|High frequency rTMS over the primary motor area to induce the long term potentiation of primary motor areas for the muscles of upper extremity.
223798888|NCT05295498|DEVICE|Sham repetitive transcranial magnetic stimulation|Sham stimulation to mimic the high frequency rTMS over the primary motor area.
223798889|NCT06440915|OTHER|Theraputic drug monitoring|High Performance Liquid Chromatography (HPLC) is used to determine the plasma concentrations of isavuconazole
223798890|NCT06440915|DRUG|Isavuconazole|Isavuconazole
223798891|NCT02504658|BEHAVIORAL|Lifestyle text messages|"Throughout the course of the four-week study, the experimental participants will receive one text message each morning related to general nutrition and exercise goals, and an additional goal status update message on Monday, Wednesday, and Friday evenings. The goal status update message will ask the participants about the status of attaining their nutrition or physical activity goals. Participants may log their progress toward attaining their goals by using the mobile health dashboard feature on BodiMojo.com from a computer or a web-enabled smartphone to indicate their goal status (still working on it or completed it). Participants will be encouraged, via the text messages, to look at information on the BodiMojo program found on the Bodimojo.com website."
223798892|NCT02504658|BEHAVIORAL|Attention Control Group|"Once participants randomized to the control group have completed the baseline assessment, they will be asked to write down two health goals with the RA. The same goals will be suggested for this group as for the Intervention group (see Appendix). They will take home a copy of the goals they have set. The participants will be also given a 16-page pamphlet from NIDDK A Guide for Teenagers: Take Charge of Your Health! to take home to read over."
223798893|NCT06021717|DRUG|Ketamine-Morphine|PCA ketamine (Ketamine HCl, Pfizer Inc., US) 0.5 mg plus morphine 0.5 mg ml-1 (ratio 1:1)
223798894|NCT06021717|DRUG|Morphine|PCA morphine (Pfizer Inc., US) 1 mg ml-1
223798895|NCT01389973|DRUG|ustekinumab 90 mg|Subcutaneous injections of ustekinumb 90 mg at Weeks 0 and 4 and every 8 weeks until the dose for the Long-Term Extension has been selected then every 8 weeks through Week 196 with the selected dose.
223798896|NCT01389973|DRUG|ustekinumab 45 mg|Subcutaneous injections of ustekinumb 45 mg at Weeks 0 and 4 and every 8 weeks until the dose for the Long-Term Extension has been selected then every 8 weeks through Week 196 with the selected dose.
223798897|NCT01389973|DRUG|ustekinumab 180 mg|Subcutaneous injections of ustekinumb 180 mg at Weeks 0 and 4 and every 8 weeks until the dose for the Long-Term Extension has been selected then every 8 weeks through Week 196 with the selected dose.
223798898|NCT01389973|DRUG|Placebo|Subcutaneous injections of placebo at Weeks 0 and 4 and every 8 weeks until the dose for the Long-Term Extension has been selected then every 8 weeks through Week 196 with the selected dose.
223798899|NCT02289391|DRUG|Anesthesia induction|-Intravenous injection midazolam 0.05 mg/Kg,fentanyl 4μg/Kg,etomidate 0.2 mg/Kg,cisatracurium 0.15 mg/Kg in proper order.
223798900|NCT02289391|DRUG|Anesthesia maintenance|"* Continuous intravenous remifentanil O.2μg/(kg•h) and propofol 3\~8mg/(kg•h).~* Intermittent intravenous atracurium 0.05mg/kg. Maintain partial pressure of carbon dioxide(PETCO2) to 30\~40 mmHg and bispectral index (BIS) to 45\~60."
223798901|NCT02289391|DRUG|Assisted anesthesia|Intervention 'Assisted anesthesia' has been included in Arm Descriptions.
223798902|NCT06332885|DEVICE|Zephyr Endobronchial Valve|Zephyr Valve provides an alternative technique to achieve bronchoscopic lung volume reduction (BLVR) using a minimally invasive approach. Zephyr Valve is a tiny unidirectional valve. During BLVR, multiple valves are placed to occlude a hyperinflated lobe of the lungs, allowing air to escape while blocking airflow into the treated lobe. This is intended to result in a reduction in lung volume and hyperinflation in the targeted area. Consequently, the remaining lobes can expand more fully, the overall lung works more efficiently, with resultant improvement in overall lung function in patients with hyperinflation associated with severe emphysema.
223798903|NCT00428350|DRUG|Quetiapine Fumarate (Seroquel)|
223798904|NCT00696254|BEHAVIORAL|Nerve excitability measurement|
223798905|NCT03375944|OTHER|Rehabilitation|"The purpose of this work package is to evaluate short- and long-term clinical effects of optimal, continuous and regularly controlled tele-rehabilitation, which is based on exercise training, intensive dietary and educational program focused on lifestyle and risk factors modification. The main expectations of OCR is to normalize annual mortality to the level of the low risk healthy population."
223798906|NCT04365582|DRUG|Azithromycin|500 mg day 1 ; 250 mg/day for 4 days
223798907|NCT04365582|DRUG|Hydroxychloroquine|200 mg x 3/day for 10 days
223798908|NCT04365582|DRUG|Lopinavir 200Mg/Ritonavir 50Mg Tab|400/100 mg (2 tablets) x 2/day for 15 days
223798909|NCT05598216|DIAGNOSTIC_TEST|no intervention, Serum LDL cholesterol calculation|The serum LDL cholesterol concentrations will be calculated using at least three different equations (Friedewald, Sampson, Martin-Hopkins)
223798910|NCT02245958|OTHER|No Intervention|No treatment (intervention) was administered.
223798911|NCT02626780|DEVICE|GID SVF-2|Comparison of the number of hairs before and after treatment of autologous adipose-derived SVF as a percentage increase or decrease in growth.
223798912|NCT02357251|OTHER|Enhanced recovery protocol|
223798913|NCT04304833|OTHER|Provider-Based Care Model Arm|The PI will be supplementing standard care by providing and training each patient in the use of an analog (not internet connected) vital sign kit for 6 months: weight scale, blood pressure cuff, pulse oximeter. A Log for recording their vital sign measures.
223798914|NCT04304833|BEHAVIORAL|mHealth Model Arm|The PI will provide each patient with weight scale, blood pressure cuff, \& pulse oximeter kit connected to a Bluetooth-paired Android Health Tablet for 6 months. Daily vital sign readings will be sent to the secure cloud-based software. If the readings are out-of-range, the Registered Nurse Call Center will be automatically alerted and triaged.
223798915|NCT05558657|OTHER|Home-based, acupressure combined with nursing education|"The intervention group will focus on 11 acupoints on the abdomen (RN12, RN4, ST25), back (BL20, BL21, BL22, BL23, BL24, BL25), and limbs (LI4, ST36). The participants or their caregivers can perform acupressure 30 minutes after meals and twice a day. Participants can choose between two sets of acupressure: (1) Acupressure of the abdominal and back acupoints in a seated position, or (2) Acupressure of the abdominal and limb acupoints in a supine position. Each session lasts approximately 15 minutes.~Besides, the intervention group will also receive nursing education on the basis of receiving acupressure intervention including (1) dietary guidance: help patients to formulate a reasonable diet plan, (2) cultivate regular defecation habits, (3) understand appropriate defecation environments and postures, and (4) Moderate exercise to increase gastrointestinal motility."
223798916|NCT05558657|OTHER|Home-based, manual light touch of the abdomen combined with nursing education|Control group or their caregivers will apply the manual light touch to the abdomen in any direction or body position at home. In keeping consistent with the intervention group, abdomen touching will also be administered twice daily for approximately 15 minutes each for 10 days. Participants will also receive nursing education.
223798917|NCT02878473|PROCEDURE|Deceased donor Liver Transplantation|Deceased donor orthotopic liver transplantation
223798918|NCT03080129|DIETARY_SUPPLEMENT|Fresubin energy|dietary protein energy supplement
223798919|NCT03456700|DRUG|Auranofin|Given PO
223798920|NCT03456700|OTHER|Laboratory Biomarker Analysis|Correlative studies
223798921|NCT03456700|DRUG|Sirolimus|Given PO
223798922|NCT06647550|DRUG|HD-6277 100mg|PO, QD
223798923|NCT06647550|DRUG|HD-6277 50mg|PO, QD
223798924|NCT06647550|DRUG|HD-6277 25mg|PO, QD
223798925|NCT06647550|DRUG|Placebo|PO, QD
223798926|NCT00225433|DRUG|follitropin beta|Follitropin beta
223798927|NCT00225433|DRUG|ganirelix acetate|Ganirelix acetate
223798928|NCT04154787|DRUG|LNP023|Investigation of LNP023
223798929|NCT04154787|DRUG|Rituximab|Comparison of rituximab dose
223798930|NCT03253224|DRUG|Magnesium Sulfate|Magnesium group receives magnesium sulfate (50 mg/kg) in 100 mL of normal saline over 15 min during induction of anesthesia, followed by a continuous magnesium sulfate infusion (15 mg/kg/h) until the end of surgery.
223798931|NCT03253224|DRUG|Normal saline|Normal saline group receives the same volume of normal saline, administered according to the same method as in the magnesium group.
223798932|NCT01951625|DRUG|Vericiguat (BAY1021189) (1.25 mg)|1.25 mg BAY1021189 tablets
223798933|NCT01951625|DRUG|Vericiguat (BAY1021189) (5 mg)|5 mg BAY1021189 tablets
223798934|NCT01951625|DRUG|Placebo|
223798935|NCT06483750|DEVICE|Systane iLux Treatment|The Systane iLux is an approved thermal pulsation device to treat dry eye disease. The application of heat and compression to both eyelids melts meibum in the obstructed glands to restore the secretion and production of meibum to the eye. The Systane iLux will only be administered to the eye to undergo cataract surgery.
223798936|NCT00778765|DRUG|400 mg Gabapentin Capsules|
223798937|NCT05066464|OTHER|Fluid Resuscitation|Fluid Resuscitation for Suspected Sepsis in Paediatric Emergency Departments
223798938|NCT03053050|DRUG|SEL|Tablets administered orally once daily
223798939|NCT03053050|DRUG|Placebo to match SEL 6 mg|Tablets administered orally once daily
223798940|NCT03053050|DRUG|Placebo to match SEL 18 mg|Tablets administered orally once daily
223798941|NCT02703675|DEVICE|Excel Cryo Cooling Collar|Therapeutic hypothermia in the study will be initiated by The Excel Cryo Cooling system consisting of a unique cervical immobilization collar and a cooling element. Once activated, the cooling element achieves a temperature of -3.0 °C to -5.0 °C within seconds. The collar is fitted around the subject's neck and the cooling element is applied the the front of the neck over the carotid arteries and secured in place by the collar. The Excel System provides consistent cooling regardless of patient size or weight, by cooling of the blood traveling through the carotid triangles.
223798942|NCT00057668|BEHAVIORAL|Multi-Setting Early Intervention|
223798943|NCT00057668|BEHAVIORAL|Community Intervention|
223798944|NCT06667115|OTHER|PNF exercise|Foundational PNF D2 shoulder flexion exercise incorporating shoulder flexion, abduction, and external rotation. This exercise was performed at a metronome-guided pace of 14 beats per minute to establish a consistent baseline.
223798945|NCT06667115|OTHER|PNF exercise with virtual reality gaming|Combined the PNF D2 shoulder flexion exercise with a virtual reality motion capture game (the U-Ball game).
223798946|NCT06667115|OTHER|PNF with concurrent feedback|"PNF exercise with the addition of auditory concurrent feedback (Sword) which referenced the action of unsheathing a sword in a diagonal upward direction."
223798947|NCT02470546|DRUG|Metformin|Metformin 1000mg twice a day
223798948|NCT02470546|DRUG|Placebo|Placebo 1000mg twice a day
223798949|NCT06670157|OTHER|Detachable Clip|After the varicose vessels basically disappeared under the endoscope, the removable titanium clamp was removed
223798950|NCT06670612|OTHER|nature based music concert|It will be a resource for healthcare professionals to develop a behavior that will support patients in intensive care in relieving their pain and stabilizing their physiological parameters with nature-based music, and will contribute to the literature.
223798951|NCT06669481|OTHER|Semiquantitative 131I-MIBG Scintigraphy Assessment|Patients received thyroid blockade using solution of potassium iodide before the examination. After intravenous administration of 111 MBq of 131I-MIBG, whole body planar images were acquired at 24 hours (Day 1) and 48 hours (Day 2), respectively.
223798952|NCT06670820|DEVICE|Active rTMS|iTBS targeting the left dorsolateral prefrontal cortex (DLPFC) per session, total10 sessions
223798953|NCT06670820|DEVICE|Sham rTMS|sham iTBS targeting the left dorsolateral prefrontal cortex (DLPFC) per session, total 10 sessions
223798954|NCT06669299|PROCEDURE|Re-Do ventricular tachycardia ablation|1\. Programmed ventricular stimulation (PVS); 2. Mapping during Sinus Rhythm (SR) or right ventricular pacing in pacing dependent patients; 3. Late Potentials identification; 4. VT(s) induction with diastolic pathway mapping when possible; 5. Catheter Ablation in SR or, at the operator's discretion, in VT if tolerated by the patient; 6. If VT is not inducible or the diastolic pathway is not mappable, a substrate ablation approach will be performed. 7. PVS is repeatedly attempting to reinduce VT after completing; 8. Endpoint: non-inducibility of any VT.
223798955|NCT06669299|DRUG|Antiarrhythmic Drug Therapy (amiodarone, sotalol, or mexiletine)|The patients with a positive NIPS already on antiarrhythmic drugs (AAD) before the index procedure will re-start the original antiarrhythmic therapy. Patients who were not on AAD will start a new drug at the operator's discretion (amiodarone, sotalol, or mexiletine) according to clinical practice.
223798956|NCT06670989|BEHAVIORAL|Fixation training|Training (adapting) microsaccades during fixation
223798957|NCT03129828|DRUG|Ibrutinib and Bortezomib + R-CHOP|A pre-phase therapy with Prednisone 100 mg p.o. is mandatory from d-4 until d0. Patients receive 6 cycles of a combined immunochemotherapy with the anti-CD20 antibody Rituximab (375 mg/m2 d0 or d1) together with 6 cycles of a chemotherapy consisting of Cyclophosphamide (750 mg/m2 d1), Doxorubicin (50 mg/m2 d1), Vincristine 1 mg absolute d1), Prednisone (100 mg absolute p.o. d1-5) and Bortezomib s.c. (1.3 mg/m2 C1 on d3 and 8, other cycles d1 and d8), in 21-day intervals and Ibrutinib 560 mg p.o. for individuals \< 65 years and 420 mg p.o. for individuals ≥ 65 years (from d6 of C1 until d21 of C6), followed by two additional 3-week cycles of Rituximab (375 mg/m2).
223798958|NCT03171298|PROCEDURE|Laparoscopic Assisted Transanal Total Mesorectal Excision|"* Abdominal approach with laparoscopic mobilization of the left colon~* Laparoscopic isolation and transection of inferior mesenteric vessels .~* Transabdominal dissection of the upper rectum and mesorectam.~* Insertion of transanal platform and the creation of pneumorectum.~* Occlusion of rectum 2 cm distal to the rectal lesion via purse string.~* Transanal dissection of lower and mid mesorectam~* The specimen will be extracted transanally"
223798959|NCT05338333|DEVICE|Lehfilcon A multifocal contact lenses|Investigational frequent replacement soft contact lens indicated for the optical correction of presbyopia
223798960|NCT05338333|DEVICE|Lotrafilcon B multifocal contact lenses|Commercially available frequent replacement soft contact lens indicated for the optical correction of presbyopia
223798961|NCT05338333|DEVICE|CLEAR CARE®|Hydrogen peroxide-based contact lens cleaning and disinfecting solution
223798962|NCT06669793|DEVICE|biolimus-coated balloon|238 subjects with de novo large vessel coronary lesions who met the inclusion/exclusion criteria were enrolled; subjects were assigned to the treatment group of Biolimus-coated balloon.
223798963|NCT06669793|DEVICE|paclitaxel-coated balloon|237 subjects with de novo large vessel coronary lesions who met the inclusion/exclusion criteria were enrolled; subjects were assigned to the treatment group of paclitaxel-coated balloon.
223798964|NCT05815329|OTHER|cognitive training|After the multidimensional evaluation at T0, the participants will be randomly allocated into an experimental group and a wait list control group. Specifically, cognitive training will be offered to half of the outpatients included in this research by means of technological devices (Neurotablet). A neuropsychologist will supervise the cognitive training offline (about 30 minutes per 5 days, 8 weeks) and through a face-to-face 1 hour-session each week per each outpatient.
223798965|NCT01296451|BIOLOGICAL|MVA-NSmut|Genetic vaccine against Hepatitis C virus infection
223798966|NCT01296451|BIOLOGICAL|AdCh3NSmut|genetic vaccine against Hepatitis virus infection
223798967|NCT01296451|BIOLOGICAL|AdCh3NSmut1|genetic vaccine against Hepatitis virus infection
223798968|NCT06670846|DEVICE|Lollipop|Distraction using a Lollipop 15 minutes before anesthesia
223798969|NCT06670846|DRUG|distraction using intranasal Midazolam|Distraction using intranasal Midazolam 15 minutes before anesthesia
223798970|NCT06669559|OTHER|DROM-Test|DROM test: a tool for assessing the ability to decide on returning home
223798971|NCT00254202|DRUG|Iloperidone|
223798972|NCT00254202|DRUG|Ziprasidone|
223798973|NCT00254202|DRUG|Placebo|
223798974|NCT05780346|OTHER|TGNB-CARE (Connecting and Reflecting Experience)|12 session 60-minute mentalizing-focused parenting group with approximately 6 caregivers, facilitated by a mental health clinician
223798975|NCT02459574|PROCEDURE|AVATAR-AF ablation|Experimental ablation protocol
223798976|NCT02459574|DRUG|Anti-Arrhythmic therapy|"Group 2 will be prescribed medication listed below:~Amiodarone; Dronaderone; Sotalol Beta blockers; Calcium channel blockers; Flecainide; or Propafenone.~You will then be discharged from clinic. A research nurse will contact you by phone to make sure there are no problems and can make hospital appointments if needed."
223798977|NCT02459574|PROCEDURE|Conventional AF ablation|Conventional ablation procedure
223798978|NCT05924126|OTHER|empiric antibiotic therapy|septic ICU patient given broad spectrum antibiotic therapy
223798979|NCT00251745|DRUG|Dexlansoprazole MR|Dexlansoprazole MR 60 mg, capsules, orally, once daily for 4 weeks.
223798980|NCT00251745|DRUG|Dexlansoprazole MR|Dexlansoprazole MR 90 mg, capsules, orally, once daily for 4 weeks.
223798981|NCT00251745|DRUG|Placebo|Dexlansoprazole placebo-matching capsules, orally, once daily for 4 weeks.
223798982|NCT06626191|PROCEDURE|Interscalene brachial plexus block|"Interscalene brachial plexus block will be performed on the patients using 30 ml of local anesthetic solution (0.25% bupivacaine) under ultrasound guidance.~Additionally, in the postoperative period a paracetamol dose of 1 g every 8 hours and a dexketoprofen dose of 50 mg twice daily were administered iv for multimodal analgesia."
223798983|NCT06626191|PROCEDURE|Serratus posterior superior intercostal plane block|"Patients will undergo serratus posterior superior intercostal plane block using 30 ml of local anesthetic solution (0.25% bupivacaine) under ultrasound guidance.~Additionally, in the postoperative period a paracetamol dose of 1 g every 8 hours and a dexketoprofen dose of 50 mg twice daily were administered iv for multimodal analgesia."
223798984|NCT06626191|PROCEDURE|Group without peripheral nerve block|In the postoperative period a paracetamol dose of 1 g every 8 hours and a dexketoprofen dose of 50 mg twice daily were administered iv for multimodal analgesia.
223798985|NCT00636649|DRUG|Escitalopram|10-20 mg
223798986|NCT00636649|DRUG|Placebo|Placebo
223798987|NCT04839679|BEHAVIORAL|Culturally Oriented Educational Brochure|Culturally appropriate educational brochure summarizing pertinent treatment information in a visual manner
223798988|NCT04839679|BEHAVIORAL|Mayo Clinic Educational Booklet|"An Introduction to Radiation Simulation and Treatment- Barbara Woodward Lips, Patient Education Center"
223798989|NCT04866017|DRUG|Tislelizumab|200 mg intravenously every three weeks
223798990|NCT04866017|DRUG|Durvalumab|10 milligrams per kilogram (mg/kg) intravenously once every 2 weeks (or 1500 mg intravenously once every 4 weeks where the dosage has been approved by a local health authority)
223798991|NCT04866017|DRUG|Ociperlimab|900 milligrams (mg) intravenously every three weeks
223798992|NCT04866017|DRUG|Chemotherapy|"The chemotherapy regimen for the study treatment was selected at the investigator's discretion and may include one of the following options:~* Cisplatin (50 mg/m²) on days 1 to 5 of each cycle, combined with etoposide (50 mg/m²) on days 1 and 8, both administered intravenously for 2 cycles. Each cycle was 28 days.~* Carboplatin (AUC 2) weekly for 6 weeks, combined with paclitaxel (40-50 mg/m²) weekly for 6 weeks, both administered intravenously.~* Cisplatin (75 mg/m²) combined with pemetrexed (500 mg/m²) on day 1 of each cycle, administered intravenously for 2 cycles. Each cycle was 21 days.~* Carboplatin (AUC 5) combined with pemetrexed (500 mg/m²) on day 1 of each cycle, administered intravenously for 2 cycles. Each cycle was 21 days.~The pemetrexed plus platinum regimen was only for participants with non-squamous histology."
223798993|NCT04866017|RADIATION|Radiotherapy|All participants recieved radiotherapy using either a standardized 3-dimensional conformal radiotherapy technique, or intensity modulated radiotherapy (IMRT) on a linear accelerator delivering a beam energy of ≥ 6 MV. The total dose of radiotherapy was 60 Gy, administered in 30 once-daily fractions of 2 Gy and 5 fractions per week for 6 weeks.
223798994|NCT01475136|DRUG|LY2140023|
223798995|NCT04780334|DIAGNOSTIC_TEST|COVID-19 RT-PCR|Nasopharyngeal swabs for COVID-19 RT-PCR
223798996|NCT04780334|DIAGNOSTIC_TEST|Biosensor|Portable and Connected Biosensor viral
223798997|NCT06723951|OTHER|QUALAS survey|Participants will be asked to complete the surveys at one (controls) and two (patients) timepoints.
223798998|NCT03415620|PROCEDURE|Music listening|Patient is given an ipod with earphone and with saved playlist of different music genres. Music listening session will be given for 30 minutes before, during and after surgery. Questionnaires will be asked to fill in. All the earphones will be disinfected following the hospital's infection control guideline.
223798999|NCT06733779|OTHER|observation|cross-sectional study
223799000|NCT06733727|DRUG|Letrozole|Letrozole pre-treatment in addition to misoprostol as medical management for silent miscarriage
223799001|NCT06733727|DRUG|Mifepristone|Mifepristone pre-treatment in addition to misoprostol as medical management for silent miscarriage
223799002|NCT06731920|DIAGNOSTIC_TEST|cervical medial branch block|ultrasound-guided cervical medial branch block with fluoroscopic control and digital subtraction angiography
223799003|NCT06732219|BEHAVIORAL|Functional Communication Training|Functional Communication Training (FCT) focuses on teaching an appropriate functional communicative response (FCR) to access the reinforcer maintaining severe problem behavior (SPB). This procedure involves selecting an appropriate topography for the FCR (e.g., touching a card, exchanging a picture) and using a backward chaining approach. The training will progress from full physical prompts to partial prompts and eventually to independent, unprompted responses, all within a trial-based format.
223799004|NCT06732219|BEHAVIORAL|Extinction-Correlated Stimuli|A distinct extinction-correlated stimulus (e.g., a laminated picture card) will be used in all treatment sessions where severe problem behavior (SPB) is subject to extinction contingencies. This stimulus will also be present during relapse challenges (described below). The selection of the stimulus will be individualized for each participant to ensure it has no prior association with treatment-related contexts, minimizing the influence of pre-existing learning histories.
223799005|NCT06732219|BEHAVIORAL|Caregiver Fading|"Behavioral Skills Training (BST) will be used to teach caregivers to (1) implement the behavioral intervention package (i.e., differential reinforcement of alternative behavior with extinction) in a controlled setting with confederates and (2) transition into behavioral sessions with the participant while gradually phasing out the clinical therapist.~Caregivers will begin by implementing mastered intervention components alongside the therapist during sessions with the participant, where the therapist will provide in-situ feedback. Once the caregiver demonstrates at least 80% treatment integrity across two consecutive sessions, the therapist will systematically increase their distance by 3 meters each session (maintaining at least 80% integrity) until they are fully removed from the treatment area."
223799006|NCT06732219|BEHAVIORAL|Structured-Probe Schedule Thinning|"Once a clinically significant decrease in severe problem behavior (SPB) is achieved (defined as an 80% reduction from the baseline mean rate), schedule thinning will be implemented. This process involves reducing the density of reinforcement by introducing a multiple schedule with alternating periods where reinforcement for the functional communication response (FCR) is available and unavailable.~Schedule thinning will begin immediately at the terminal schedule, with an 80% reduction in reinforcer density from treatment. Specifically, the FCR will be placed on extinction for 540 seconds and reinforced for 60 seconds during each session. This schedule was selected based on prior analyses of effective reductions in reinforcer density. If the treatment effect remains strong (defined as maintaining at least an 80% reduction in SPB relative to baseline), schedule thinning will proceed at this step until three consecutive sessions show consistent results."
223799007|NCT06732219|BEHAVIORAL|Multiple-Context Generalization Training|In multiple-context training, treatment will be implemented at the terminal schedule (i.e., after completing schedule thinning) in new contexts, including unique locations and with different individuals, distinct from the setting used during the initial treatment phase.
223799008|NCT06732336|DIAGNOSTIC_TEST|89Zr-trastuzumab|Patients will receive an intravenous dose of 0.5 MBq/kg (max 60 MBq) of 89Zr-trastuzumab in order to perform a PET imaging session 3-6 days later.
223799009|NCT06733233|DRUG|T-DXd combined with immune checkpoint inhibitor|Subjects who are eligible for the study and have signed informed consent will receive T-DXd in combination with an immune checkpoint inhibitor. The specific dosing regimen is as follows: T-DXd (5.4 mg/kg i.v. q3w) every 3 weeks for a total of 8 courses. Teraplizumab (240 mg/kg i.v. q3w), 1 course every 3 weeks for a total of 8 courses.
223799010|NCT06732024|PROCEDURE|Vaccum assisted closure|close skin and SC tissue by vaccum device
223799011|NCT06732024|PROCEDURE|primary wound closure|close skin and SC tissue by primary closure
223799012|NCT01575353|DEVICE|Venturi mask|The patients will receive oxygen delivered through a conventional Venturi mask. The FiO2 (color coded) will be adjusted in order to obtain a SpO2 between 92% and 98% in hypoxemic patients and between 88% and 95% in hypercapnic patients.
223799013|NCT01575353|DEVICE|Nasal high-flow|The patients will receive oxygen delivered through the nasal high-flow system (Optiflow™). The FiO2 will be adjusted in order to obtain a SpO2 between 92% and 98% in hypoxemic patients and between 88% and 95% in hypercapnic patients. Gas flow will be set at 50l/min.
223799014|NCT04257266|DEVICE|Ice Pack Cooling|5 ice packs (Cryo cooling pack or commercial ice pack) will be placed on the subject for 30 mins after exercise-induced hyperthermia
223799015|NCT03811184|DIAGNOSTIC_TEST|MemScreen|Neuropsychological test on smartphone or digital tablet, on self assesment.
223799016|NCT00883506|DRUG|Lisinopril 40 mg Tablet (Zestril) under fed conditions.|
223799017|NCT00883506|DRUG|Lisinopril 40 mg Tablet under fasting conditions.|
223799018|NCT00883506|DRUG|Lisinopril 40 mg Tablet under fed conditions.|
223799019|NCT03878732|DIAGNOSTIC_TEST|Bindex measurement|One time bone density measurement with ultrasound device
223799020|NCT01635608|DRUG|Acetaminophen|administration of 500 mg paracetamol
223799021|NCT01635608|DRUG|Talinolol|administration of 50 mg talinolol
223799022|NCT01635608|DRUG|Amoxicillin|administration of 500 mg amoxicillin
223799023|NCT01635608|OTHER|non-caloric water|administration of 240 ml water
223799024|NCT01635608|OTHER|caloric water|administration of 240 ml caloric water (containing 25.5 g sucrose)
223799025|NCT04171102|DEVICE|ProFlor Hernia implant|Inguinal hernia repair
223799026|NCT05040555|COMBINATION_PRODUCT|R-CDOP|Rituximab 375mg/m2, D0; Cyclophosphamide 750mg/ m2, D1; Doxorubicin hydrochloride liposome 30-35mg/ m2, D1; Vindesine 3mg/ m2, D1; Prednisone 60mg/ m2, D1\~5.
223799027|NCT05228548|OTHER|Perioperative blood transfusion|Perioperative blood transfusion
223799028|NCT01925664|BEHAVIORAL|Doula|This intervention included doulas providing weekly home visits during the last trimester of pregnancy and up to three months postpartum. Home visits focused on prenatal health, preparation for childbirth, breastfeeding education, and developing a relationship with the baby. Doulas also were present in the hospital during labor, delivery, and postpartum providing emotional support, non-medical comfort measures, and breastfeeding counseling.
223799029|NCT04918784|DEVICE|Restrata®|Restrata® is a sterile, single use device intended for use in local management of wounds. Restrata® is a soft, white, conformable, non-friable, absorbable matrix that provides a moist environment for the body's natural healing process to occur. Restrata® is made from synthetic biocompatible materials and was designed to include a fibrous structure with high porosity, similar to native extracellular matrix.
223799030|NCT04918784|DEVICE|Wound Dressing|Alginate or Foam wound dressing is intended to manage wounds.
223799031|NCT02773550|DRUG|Bortezomib|Low dose of bortezomib
223799032|NCT02773550|DRUG|Melphalan|
223799033|NCT02773550|DRUG|Prednisone|
223799034|NCT03113292|OTHER|Pilates|"The protocol will be composed by the following exercises, structured in each session according to progression, difficulty and focus (respiration, stability, muscle strength and joint mobility): Arm Arcs, Bent Knee Opening, Sidelying, Dead Bug, Femur Arcs, Quadruped Series, Single Leg Stretch, Prone Press Up, Sidekick (Front to Back 1 e 2), Leg Pull Front, Mermaid, Spine Stretch, The Hundred, Pelvic Clock, Bridging, Stanging Roll Down, Swan, Saw, Dart, Swimming, Book Opening.~."
223799035|NCT03113292|OTHER|Home Exercises|The protocol will be divided into 3 phases, each one composed by the following exercises and structured according to difficulty progression and focus (postural reeducation, muscle strength, balance, joint flexibility): Muscle strength exercises composed by abdominal exercises; back extension exercises; gluteus maximus exercises. Stretching exercises for the lower back, pelvis, iliopsoas muscle, tensor fascia latae muscle).
223799036|NCT03217448|DRUG|Dabigatran etexilate|Subjects should take Dabigatran etexilate 150mg twice a day for 6 months after randomization.
223799037|NCT03217448|DRUG|Warfarin|Subjects should take Warfarin for 6 months after randomization and the dose will be changed according to investigator's judgment.
223799038|NCT01834885|DRUG|QVA149|QVA149 via inhaler twice a day
223799039|NCT01834885|DRUG|fluticasone/salmeterol|fluticasone/slameterol via inhaler twice a day
223799040|NCT00388310|PROCEDURE|Culture|Culture
223799041|NCT00739375|PROCEDURE|Primary arterio-venous vascular access creation|Primary arterio-venous vascular access creation, ECHO with pulmonary artery pressure measurements, Assessment of blood NO metabolite levels
223799042|NCT05634239|BEHAVIORAL|Health Education|"Interview, clinical examination and health education conducted by the clinic nurse.~Appointment with the physiotherapist including the assessment of physical functioning, use of assistive mobility devices, and amount of help needed in activities of daily living."
223799043|NCT02489955|DRUG|Amikacin|
223799044|NCT02489955|DRUG|Tobramycin|
223799045|NCT02489955|DRUG|Colomycin|
223799046|NCT00238030|DRUG|L-thryoxine|2 mcg/kg iv or 2 mcg/kg po at time of enrollment
223799047|NCT00238030|DRUG|iv thryoxine|thyroxine 2 mcg/kg iv
223799048|NCT00915031|DEVICE|UroCool|Hypothermia Endorectal Device
223799049|NCT04274270|DRUG|Endostar|Radiotherapy was performed with a cyberknife or accelerator stereotactic radiotherapy, which lasted 3-10 days.After the end of radiotherapy,S1 60mg, BID, day 1-28, as taken orally, and repeated every 6 weeks, with concurrent Endostar therapy: 210mg was used by intravenous infusion for 7 consecutive days during each cycle of chemotherapy, and 30mg was used every 24 hours.
223799050|NCT01253525|BIOLOGICAL|Ramucirumab (IMC-1121B )|8 milligrams/kilogram (mg/kg) intravenously on Days 1 and 15 of each 28-ay cycle
223799051|NCT01253525|DRUG|Paclitaxel|80 milligram/square meter (mg/m2) intravenously Days 1, 8, and 15 of each 28 day cycle
223799052|NCT03664466|DIETARY_SUPPLEMENT|astaxanthin|astaxanthin capsules 12 mg twice daily
223799053|NCT03664466|OTHER|Placebo|placebo capsules twice daily
223799054|NCT06052696|DRUG|Gardasil 9 Suspension for Injection|"After randomisation in the Gardasil arm, women will receive 3 Gardasil vaccinations~1. First injection: preferable at time of start treatment (imiquimod, lase or surgery). Window 4 weeks prior to treatment start (because surgical treatment can be postponed for logistical reasons) and 4 weeks after start treatment.~2. Second injection: should be administered at least 1 month after the first injection and 3 months before the third injection.~3. Third injection should be administered at 3 months after second injection. All injections should be administered within 1 year."
223799055|NCT06052696|DRUG|Placebo|"After randomisation in the PLacebo arm, women will receive 3 Placebo vaccination with NaCl 0.9%~1. First injection: preferable at time of start treatment (imiquimod, lase or surgery). Window 4 weeks prior to treatment start (because surgical treatment can be postponed for logistical reasons) and 4 weeks after start treatment.~2. Second injection: should be administered at least 1 month after the first injection and 3 months before the third injection.~3. Third injection should be administered at 3 months after second injection. All injections should be administered within 1 year."
223799056|NCT02306070|DRUG|Metformin|metformin treatment + standard of care dietary and exercise advice
223799057|NCT02306070|DRUG|No metformin treatment|no metformin treatment + standard of care dietary and exercise advice
223799058|NCT04179175|DRUG|secukinumab|secukinumab 300mg every 2 weeks
223799059|NCT04179175|DRUG|secukinumab|secukinumab 300mg every 4 weeks
223799060|NCT00610116|DEVICE|Electronic Repositioning|Change of pacing vectors for CRT pacing
223799061|NCT01760889|DRUG|SPD489 low dose range (40mg, 80mg, and 100mg)|"Capsule, dose titration,~* 40 mg capsule once-daily for 1 week; then~* 80 mg capsule once-daily for 4 weeks; then,~* 100 mg capsule once-daily (if unable to tolerate 100 mg dose between weeks 5 to 6, then dose to be decreased to 80 mg once-daily for the remaining 21 weeks;~* if able to tolerate 100 mg dose then will continue on 100 mg capsule once-daily for 21 weeks"
223799062|NCT01760889|DRUG|SPD489 high dose range (120mg, 140mg and 160mg)|"Capsule, dose titration,~* 40 mg capsule once-daily for 1 week; then~* 80 mg capsule once daily for 1 week; then~* 120 mg capsule once-daily for 1 week, then,~* 140 mg capsule once-daily for 2 weeks, then~* 160 mg once capsule once-daily (if unable to tolerate 160 mg dose between weeks 5 to 6, then dose to be decreased to 140 mg once-daily for the remaining 21 weeks;~* if able to tolerate 160 mg dose then will continue on 160 mg capsule once-daily for 21 weeks"
223799063|NCT01760889|DRUG|Placebo|One capsule a day for 26 weeks
223799064|NCT05819814|GENETIC|Disclosure of high polygenic risk result for coronary artery disease|The disclosure of a high polygenic risk result for coronary artery disease involves a clinical report coupled with a virtual meeting with a genetic counselor.
223799065|NCT00392405|DRUG|3 amps of sodium bicarbonate mixed in one liter of D5W|
223799066|NCT00265980|DRUG|Subcutaneous Placebo|Twice daily injections of saline in the same volume as will be used for leptin injections.
223799067|NCT00265980|DRUG|Leptin|Leptin will be given as twice daily subcutaneous injections in doses titrated to replicate 8 a.m. circulating leptin concentrations measured in the same subjects prior to weight loss.
223799068|NCT04007458|BEHAVIORAL|Letter|MaineGeneral Radiology will generate a reminder letter about their need for an annual low dose CT scan to the subjects in this arm.
223799069|NCT04007458|BEHAVIORAL|Community Health Worker Phone Call|Patients will receive a phone call from community health worker, offering to help them overcome barriers to repeat annual screening and offering to help them schedule their screening.
223799070|NCT01816750|DEVICE|Cardiac GSI|A novel method of computed tomography scanning (Cardiac Gemstone Spectral Imaging - Cardiac GSI) and image reconstruction (Adaptive Statistical Iterative Reconstruction- ASIR.
223799071|NCT01273233|BIOLOGICAL|Inactivated Enterovirus Type 71 Vaccine|A Sinovac EV71 vaccine contains inactivated EV71 virus, aluminum hydroxide, sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate and injection water. The EV71 vaccine is supplied in one mono-dose vial containing 0.5 mL of viral suspension with EV71 virus antigen of 200U and 400U (Elisa unit)
223799072|NCT01273233|OTHER|Placebo|Placebo is suspension with a little ivory precipitation, composition of which is aluminum hydroxide diluents.
223799073|NCT02647606|PROCEDURE|MILS|MILS(Manual in-line stabilization) will be applied during intubation. With MILS, different kinds of laryngoscope will be evaluated in a simulated difficult airway.
223799074|NCT02647606|DEVICE|McGrath videolaryngoscope|McGrath videolaryngoscope will be used for intubation
223799075|NCT02647606|DEVICE|Pentax AWS videolaryngoscope|Pentax AWS videolaryngoscope will be used for intubation
223799076|NCT02647606|DEVICE|Macintosh laryngoscope|Macintosh laryngoscope will be used for intubation
223799077|NCT01533701|OTHER|Fetal scalp blood scalp, amniotic fluid, maternal blood and umbilical cord sampling|Fetal blood sampling is conducted when a non reassuring cardiotocographic pattern occurs to detect fetal hypoxia during labor. Amniotic fluid, maternal blood is sampled in cases of fetal blood sampling. Umbilical cord blood sampling is conducted at delivery.
223799078|NCT04382105|OTHER|Observation of salivary IL-6 levels|Observation of salivary IL-6 levels and correlation of salivary IL-6 levels with periodontal disease
223799079|NCT04163887|PROCEDURE|hepatectomy|Resection colorectal liver metastases using a laparoscopic approach or an open approach.
223799080|NCT04573621|PROCEDURE|Pelvic drain|A pelvic drain is placed
223799081|NCT04573621|OTHER|No pelvic drain is placed|A pelvic drain is not placed
223799082|NCT02281799|DRUG|Azathioprine|"Patients will be commenced on an alternative thiopurine to that used initially, according to the standard dosing schedule used by their IBD clinician.~For example, if the initial thiopurine-related pancreatitis occurred while taking Azathioprine, the patient will be restarted on 6-MP, and vice versa."
223799083|NCT06221202|OTHER|Stories in the Moment Dance Program - Online|Stories in the Moment is a co-creative dance, movement and storytelling program for persons living with dementia and care partners.
223799084|NCT04381520|OTHER|Heat-sensitive moxibustion plus antihypertensive drugs|In this arm, patients will administer heat-sensitive moxibustion by themselves or by the help of their family after professional training. Patients will maintain their original antihypertensive drugs. The periods of treatment and follow-up will be one year.
223799085|NCT04381520|DRUG|Antihypertensive drugs|In this arm, patients will maintain their original antihypertensive drugs. The periods of treatment and follow-up will be one year.
223799086|NCT05042778|OTHER|Auriculotherapy|A licensed acupuncturist (holder of civil liability insurance) with more than nine years of experience with this technique will apply auriculotherapy. Indwelling fixed semipermanent needles embedded in a skin-coloured adhesive tape will be used at the actives auricular points around the vagus nerve area.
223799087|NCT03640702|OTHER|Protocol change|To examine the effect of prolonging the second stage of labor on the rate of cesarean delivery, maternal and neonatal outcomes
223799088|NCT03176420|PROCEDURE|angioplasty and stenting of occluded cervical ICA|The procedure is performed under monitored anesthetic care. We will perform a thorough and complete six-vessel diagnostic angiogram to completely characterize the occlusion and presence of collaterals. A distal protection device is used unless technically can't be delivered beyond the occlusion or when the occlusion extends beyond the petrous segment of the internal carotid artery. Balloon angioplasty is performed followed by deployment of covered stents to jail the clot/organized thrombus. The carotid reconstruction is performed from the distal to the proximal segment with coronary stents that are telescoped until normal flow is encounter. The Blood pressure is managed rigorously during and after the procedure to minimize the chances of reperfusion hemorrhage.
223799089|NCT00744770|DRUG|TMC278|
223799090|NCT00006155|DRUG|SU5416 and carboplatin|
223799091|NCT05699733|DEVICE|mechanical traction for knee joint|All participants will receive a single session per condition. This session will consist of continuous mechanical knee traction for 30 minutes while the participant assumes a supine position with the treated limb in semiflexion (30° of flexion). the treated limb will be supported using the traction bed's table that is used for this purpose. The knee position angle will be measured by a standard goniometer. Pelvis and thigh straps will be used to fix the body and prevent slippage during the application of the traction force. A customized leg cuff will be placed around the lower leg (above the ankle joint), and a traction rope will be extending horizontally from the cuff to the traction device. 48 hours of washing out will separate the sessions of different conditions
223799092|NCT03111056|BEHAVIORAL|Alc-ERDT|Web-based cognitive behavioral skills-based alcohol intervention that incorporates emotion regulation and distress tolerance skills
223799093|NCT04378322|BEHAVIORAL|Nutrition and food purchasing tool + telenutrition|Participants will be asked to use a meal planning and food purchasing feature regularly (at least once every two weeks) and schedule appointments with a registered dietitian.
223799094|NCT04378322|BEHAVIORAL|Nutrition and food purchasing tool|Participants will be asked to use a meal planning and food purchasing feature regularly (at least once every two weeks).
223799095|NCT04378322|BEHAVIORAL|Nutrition education tool|Participants will be asked to review nutrition education materials online.
223799096|NCT02729181|DEVICE|DRX9000|
223799097|NCT03428425|DRUG|paclitaxel apatinib S-1|"HIPEC: 43℃, 60min. the drug is paclitaxel : 70mg/m2 d1 d3 d5, The interval is not less than 24h , A total of three times.~apatinib：500mg qd po, 28 days is a cycle.preoperative 2 cycles, 2 cycles after surgery.~S-1： According to the body surface area, BSA \<1.25m2，40mg bid; 1.25m2≤BSA≤1.5m2，50mg bid; BSA \>1.5m2, 60mg bid. Take the medicine twice daily for 2 weeks, then suspend for 1 week. preoperative 3 cycles, 3 cycles after surgery"
223799098|NCT03364322|OTHER|Observation|Observation
223799099|NCT05032209|OTHER|follow-up of children with severe asthma in adulthood|follow-up of children with severe asthma in adulthood
223799100|NCT04499807|OTHER|AFib detection with wearable smart watch|Patients will transmit two rhythm strips every day through both the devices and additional transmission whenever they have symptoms (palpitations, skipped beats, shortness of breath and chest pain). The transmitted rhythm strips are de-identified and analyzed after assigning a unique ID for research purposes.
223799101|NCT00178425|PROCEDURE|Serial blood sampling as described in protocol|
223799102|NCT00178425|PROCEDURE|Estimation of Creatinine Clearance at regular intervals|
223799103|NCT03642925|DIETARY_SUPPLEMENT|Meal replacement diet|Obese subjects were requested to replace two meals/day (breakfast and lunch or dinner) by balanced nutritional meal replacement diet (equal to 240 kcal) for 8 weeks with one regular meal and make sure the daily target calorie limit should be less than 1500 kcal/day for men and 1200 kcal/day for women.
223799104|NCT02330432|BIOLOGICAL|Mycobacterium w|Single daily dose of 0.3 mL of Mw (heat-inactivated Mw \[0.5 × 10\^9\]; Immuvac, Cadila Pharma, Ahmedabad, India) in the deltoid region for 3 consecutive days
223799105|NCT02330432|OTHER|Best standard care|Antibiotics as early as possible; Norepinephrine \> vasopressin \> epinephrine for hypotension; Blood glucose 140-180 mg/dL; DVT and stress ulcer prophylaxis; Low tidal volume mechanical ventilation; Standard VAP, CLABSI prevention bundles
223799106|NCT04768400|DRUG|Arm I (MEP)|Arm I (MEP): Motor evoked potential will be measured in various degree of the neuromuscular blockade.
223799107|NCT04924283|BEHAVIORAL|Tetris and Assessments|Participants will complete assessments on their phone to rate cravings for alcohol. Participants will complete a visual cognitive interference task (i.e., play Tetris on their phone) after endorsing a alcohol craving, and then re-rate craving after the task.
223799108|NCT04924283|OTHER|Assessment Only|Participants will complete assessments on their phone to rate cravings for alcohol.
223799109|NCT05769985|OTHER|Caregiver's responses and patient satisfaction|Interaction between caregivers' responses and patient satisfaction about those responses
223799110|NCT00225654|DEVICE|coronary stent|
223799111|NCT03801785|OTHER|Pacifier|The pacifiers used in this clinical trial have the same shape and material. They are produced by Artsana S.P.A. for soothing children. As such, the FDA has no jurisdictions over pacifiers (US FDA regulations May 15, 2012 https://www.fdaimports.com/blog/pacifiers-fda-change-abi-system/) because they are not medical devices intended for teething.
223799112|NCT01047592|DRUG|sarcosine|sarcosine, 2 g/d , oral, for 12 weeks
223799113|NCT01047592|DRUG|sarcosine+ BE|sarcosine(2 g/d) + BE (1 g/d ), oral, for 12 weeks
223799114|NCT01047592|DRUG|placebo|placebo,oral, for 12 weeks
223799115|NCT05104528|DEVICE|OSYPKA Medical ICONTM Noninvasive CardiometerTM Model C3|Based on its precedent electrical impedance. 4 electrodes are placed on the patient: 2 on the left of the neck and the other 2 on the left lower chest . A low magnitude (2 mA), high frequency (30-100 KHz) alternating electrical current (AC) of constant amplitude is applied through the outer electrodes, and the resulting voltage is received by the inner electrodes. The ratio of the detected voltage to the applied current is the bio-impedance. The principle on which this is based is that during systole, red blood cells flow in a parallel manner, which allows the electrical current to flow easily thereby improving the electrical velocity and decreasing impedance. While during diastole, RBCs are randomly arranged, consequently hindering the electrical current (increased impedance) and decreasing electrical velocimetry. The changes of impedance over time are integrated in a complex algorithm that allows to measure CO and the other parameters.
223799116|NCT05104528|DEVICE|Fujifilm Sonosite M-Turbo C Ultrasound system|A low-frequency phased array transducer (3.5-5 MHz) will be used to assess the IVC, which lies in the retroperitoneum, to the right of aorta. At or near the junction with the hepatic veins, we will measure the IVC diameter. To properly visualise the IVC, the probe will be inserted in the subxiphoid 4-chamber position with the probe marker oriented vertically to find the right ventricle and atrium. We will see the convergence of the IVC with the right atrium as the probe is progressively aimed towards the spine. We will then follow the IVC inferiorly, to detect the meeting of the hepatic veins with the IVC. M-mode Doppler sonography of the IVC will be used to graphically document the absolute size and dynamic changes in the calibre of the vessel during inspiration and expiration. After the visualisation of the IVC, we will freeze the US screen, and using the caliper function on the US machine, maximum and minimum diameters of the IVC will be documented.
223799117|NCT05256108|DRUG|Oxycodone 40 mg|Participants will be administered a single dose of 6 capsules containing oxycodone and placebo in a randomized crossover manner
223799118|NCT05256108|DRUG|Tramadol 600 mg|Participants will be administered a single dose of 6 capsules containing tramadol in a randomized crossover manner
223799119|NCT05256108|DRUG|Placebo|Participants will be administered a single dose of 6 capsules containing placebo in a randomized crossover manner
223799120|NCT05256108|DRUG|Cebranopadol 600 µg|Participants will be administered a single dose of 6 capsules containing cebranopadol and placebo in a randomized crossover manner
223799121|NCT05256108|DRUG|Cebranopadol 1000 µg|Participants will be administered a single dose of 6 capsules containing cebranopadol and placebo in a randomized crossover manner
223799122|NCT05796856|DEVICE|repeated low level light device (Eyerising [Suzhou Xuanjia Optoelectronics Technology)|crossover device (repeated low level light device with wavelength of 810/650 nm- alternate to first group) Cross over arms after one month of use and one month of washout period.
223799123|NCT01459432|OTHER|Venepuncture and blood sample collection.|Venepuncture and blood sample collection.
223799124|NCT04149925|DEVICE|AEON Endostapler|Surgery with AEON Endostapler
223799125|NCT04149925|DEVICE|Echelon Flex Powered Stapler|Surgery with Echelon Flex Powered Stapler
223799126|NCT01452633|DRUG|0.25% bupivicaine will be injected at the study port site prior to incision|Injection will precede the incision
223799127|NCT01452633|DRUG|Saline will be injected at the study port site prior to incision|Injection will precede incision
223799128|NCT01452633|DRUG|Saline will be in injected into the port site prior to closure|Saline will be injected into the port site prior to the closure without any preincisional intervention
223799129|NCT01452633|DRUG|0.25% bupivicaine will be injected into the port site prior to closure|0.25% bupivicaine will be injected into the port site at closure without any preincisional intervention
223799130|NCT02586025|DRUG|FEC Chemotherapy|Fluorouracil 500-600 milligrams per square meter (mg/m2), epirubicin 90-120 mg/m2, and cyclophosphamide 500-600 mg/m2 by intravenous (IV) infusion every 3 weeks for three cycles (Cycles 5-7). FEC chemotherapeutic agents will be administered following surgery on Day 1 of each specified cycle.
223799131|NCT02586025|PROCEDURE|Surgery|All participants who are eligible for surgery will undergo surgery and have their pathologic response evaluated.
223799132|NCT02586025|DRUG|Docetaxel|Docetaxel IV infusion in 3-week cycles. Neoadjuvant treatment: 75 mg/m2 for Cycles 1-4.
223799133|NCT02586025|DRUG|Pertuzumab|Pertuzumab IV infusion in 3-week cycles. Prior to surgery (neoadjuvant treatment): 840 milligrams (mg) loading dose for Cycle 1, followed by 420 mg for Cycles 2-4. After surgery and 3 cycles of FEC chemotherapy (adjuvant treatment): 840 mg loading dose for Cycle 8, followed by 420 mg for Cycles 9-20)
223799134|NCT02586025|DRUG|Placebo|Placebo by IV infusion in 3-week cycles as neoadjuvant treatment (Cycles 1-4)and as adjuvant treatment (Cycles 8-20)
223799135|NCT02586025|DRUG|Trastuzumab|Trastuzumab IV infusion in 3-week cycles. Neoadjuvant treatment: 8 milligrams per kilogram (mg/kg) loading dose for Cycle 1, followed by 6 mg/kg for Cycles 2-4. Adjuvant treatment: 8 mg/kg loading dose for Cycle 8, followed by 6 mg/kg for Cycles 9-20.
223799136|NCT01175525|DRUG|CROMOLYN|Cromolyn 200mg (dissolved in water) given 4 times a day
223799137|NCT01175525|DRUG|sugar pill|sugar pill Dissolved in water taken 4 times daily 30 minutes prior to meals
223799138|NCT06384586|DIETARY_SUPPLEMENT|Placebo shot|60ml shot served in an amber bottle and consumed after 40 minutes of baseline assessments
223799139|NCT06384586|DIETARY_SUPPLEMENT|Functional energy shot|60ml shot served in an amber bottle and consumed after 40 minutes of baseline assessments
223799140|NCT03493243|OTHER|Questionnaires|2-hour clinical observation
223799141|NCT03104764|DEVICE|Scalpel|Labial frenulum removed by scalpel
223799142|NCT03104764|DEVICE|Er:YAG laser|Labial frenulum removed by Er:YAG laser
223799143|NCT00175825|OTHER|Placebo|Daily oral dose of two equal intakes, morning and evening, of Placebo in a double-blinded way for the 7-week Treatment Period
223799144|NCT00175825|DRUG|Brivaracetam|Daily oral dose of two equal intakes, morning and evening, of Brivaracetam over the 7-week Treatment Period
223799145|NCT02478411|PROCEDURE|Cycle ergometer physiotherapy|15 minutes of cyclo ergometer physiotherapy with MOTOmed ® Letto 2 device with passive, motor-assisted and active-resisted exercise of the lower and upper extremity, and 15 minutes of conventional physiotherapy
223799146|NCT02478411|PROCEDURE|Conventional physiotherapy|30 minutes of conventional physiotherapy
223799147|NCT01981694|DRUG|PF-06649751|Single doses, given by oral solution, starting at 0.25 mg up to a possible maximum of 7.5 mg. The subject will have been fasted for 10 hours prior to the single dose. For each dosing period, 3 subjects will be given a placebo as a comparator. One dose will be given in the fed state.
223799148|NCT01981694|DRUG|PF-06649751|It is believed that the maximum tolerated dose of this compound the eye blink rate (EBR) will also increase. This arm will use EBR measurement technology to verify this hypothesis. In each dosing period, 5 subjects will be given a placebo as a comparator.
223799149|NCT05129319|DRUG|prabotulinumtoxinA|Injection of glabellar rhytids
223799150|NCT06005766|BEHAVIORAL|Metacognitive Skills Training (MCT)|The goal of the metacognitive skills training group developed by Moritz and co. is to strengthen the social and metacognitive skills of the patients participating in the group. The group consists of 10 sessions during which exercises and discussion are emphasized. The themes of the group sessions are, for example, jumping to conclusions -bias, empathy, and memory. Detailed information is available from the MCT website (https://clinical-neuropsychology.de/metacognitive\_training-psychosis/). Overall there is meta-analysis-level evidence for the moderate effectiveness of MCT on positive symptoms of psychotic illnesses, such as delusions. Prior studies have argued that the unique factor underpinning MCT's efficacy is its impact on various cognitive biases, and that participating in the group especially reduces patients' tendency to jump to conclusions, which is a cognitive style associated with delusions and deficits in social perception and reasoning.
223799151|NCT06005766|OTHER|Treatment as usual|Medicinal treatment deemed appropriate by the attending physician, psychiatric ward treatment, and others forms of treatment recommended to the patients based on their treatment plans (e.g., work therapy, dialectical behavior therapy, talk therapy)
223799152|NCT00004122|BIOLOGICAL|BCG vaccine|
223799153|NCT00004122|BIOLOGICAL|recombinant interferon alfa|
223799154|NCT02030015|DRUG|miglustat|The Syner-G therapy regimen includes treating with orally-administered miglustat for the duration of the 60-month study.
223799155|NCT02030015|OTHER|Ketogenic Diet|The Syner-G therapy regimen includes switching the research subject to a full-time ketogenic diet for the 60-month duration of this study.
223799156|NCT00365391|BIOLOGICAL|bevacizumab|Given IV, 10 mg/kg, days 1 and 15 in every cycle
223799157|NCT00365391|DRUG|erlotinib hydrochloride|Given orally, 150 mg, every day during each cycle.
223799158|NCT00608010|PROCEDURE|Vitrification|Embryos were vitrified according to a previously described technique
223799159|NCT00608010|PROCEDURE|Slow freezing|Embryos were frozen with slow freezing technique
223799160|NCT00977353|DRUG|citalopram|20-60 mg/day, oral, for 6 weeks
223799161|NCT00977353|DRUG|sarcosine|500-1500 mg/day, oral, for 6 weeks
223799162|NCT04888390|BEHAVIORAL|Muti-model exercise intervention|The Muti-model exercise intervention include aerobic exercise training by ergometer or treadmill, resistance exercise by using elastic band and flexibility exercise by active stretch. The total training program takes for 60 minutes, 2-3 times per week for 3 months.
223799163|NCT04888390|BEHAVIORAL|Disease and exercise suggestion|The participants will be provided by educational program about heart failure self-care and home-based exercise approach.
223799164|NCT01429129|DRUG|Nicotine replacement therapy|Nicotine transdermal patches as per product monograph
223799165|NCT01039051|BEHAVIORAL|Diet and Lifestyle Intervention in Chinese Postpartum Women|For individual postpartum woman, we will set antepartum participatory training courses, provide specially prepared brochures and supporting VCD, set up a specialized counseling hotline and give individual bedside guidance after birth. For their family members, we will invite every postpartum woman's husband and mother to take part in workshops or seminars, making them know some basic knowledge of postpartum care, and persuading them to promote adoption of the diet and lifestyle we advocated by the postpartum woman. For community environment, we will put up posters about basic knowledge of postpartum care in the community bulletin boards for general population educating and mobilize community leaders and heads from and maternal and child health centers for maximum support.
223799166|NCT04130516|DRUG|LNS8801 -Small molecule, orally bioavailable, selective agonist of GPER|LNS8801 -Small molecule, orally bioavailable, selective agonist of GPER
223799167|NCT04130516|BIOLOGICAL|Pembrolizumab - anti-PD-1 antibody|pembrolizumab- anti-PD-1 antibody
223799168|NCT02070055|OTHER|No intervention|
223799169|NCT01406626|BEHAVIORAL|Peer Navigator|Peer navigation intervention to improve linkage to and retention in HIV care and suppress viral load for underserved HIV+ persons in Los Angeles
223799170|NCT03199222|DEVICE|Prosthetic smart socket technology with patient prompting|The smart socket technology will send feedback to the user's smartphone with suggestions including the removal or application of prosthetic socks over the residual limb or other volume management strategies to improve fit and comfort.
223799171|NCT02538731|PROCEDURE|dilation-assisted stone extraction|
223799172|NCT02538731|DEVICE|Spyglass Guided Laser Lithotrips|
223799173|NCT01263808|DRUG|Indacaterol 150 µg|Once daily (QD) via single-dose dry powder inhaler (SDDPI)
223799174|NCT01263808|DRUG|Indacaterol 300 µg|QD via SDDPI
223799175|NCT01263808|DRUG|Indacaterol 600 µg|QD via SDDPI
223799176|NCT01263808|DRUG|Placebo|QD via SDDPI
223799177|NCT01263808|DRUG|Placebo/moxifloxacin|Placebo QD via SDDPI for 14 days, followed by a single dose of moxifloxacin 400 mg
223799178|NCT00745745|DEVICE|Device Implantation|ICD lead implantation
223799179|NCT03014674|BIOLOGICAL|Lyophilized mepolizumab|Mepolizumab will be provided as white, uniform, lyophilized cake in vials with unit dose strength of 100 mg/vial for reconstitution in 1.2 mL sterile water for injection (SWFI). Following reconstitution it forms a clear to opalescent, colorless to pale yellow solution for SC injection.
223799180|NCT03014674|BIOLOGICAL|Liquid mepolizumab|Mepolizumab will be provided as a clear to opalescent, colorless to pale yellow sterile solution for SC injection, supplied in a single-use, prefilled autoinjector or safety syringe containing 100 mg/mL mepolizumab with sodium phosphate, citric acid, sucrose ethylenediaminetetraacetic acid and polysorbate 80.
223799181|NCT03014674|DEVICE|Prefilled autoinjector|Single use, disposable autoinjector will be assembled with the prefilled syringe containing the drug product. It will enable automatic delivery of the drug product under the power of a spring mechanism following activation of the device. Start and end of injection clicks will inform the user of correct use. A plastic needle will cover shield the needle before and after injection to minimize the potential for needle stick injuries.
223799182|NCT03014674|DEVICE|Prefilled Safety Syringe|Single use, disposable safety syringe with a retracting needle guard and locking system.
223799183|NCT05603468|DRUG|platelet rich plasma|Platelet rich plasma group: after the surgery of rotator arthroscopic rotator cuff repair, 3ml PRP (LongTai Biological Company) was injected into the rotator cuff tear under the rotator arthroscope for a time. PRP production process: before anesthesia, 20ml arterial blood was drawn and injected into the PRP tube. The blood was fully oscillated in the tube, and then placed in a centrifuge with 1500g for 9min to remove excess plasma and make 5ml PRP. 3ml is used for injection and 2ml is used for quality control.
223799184|NCT05603468|DRUG|Corticosteroid|Corticosteroid group: after the surgery of rotator cuff repair under arthroscopy, 1mL prednisone (MSD) + 2mL sodium hyaluronate (biochemical Industry Co., Ltd.) was injected under arthroscopy.
223799185|NCT05603468|DRUG|Normal saline|Normal saline
223799186|NCT02784483|DRUG|Atezolizumab (1200mg via IV infusion)|Patients will get atezolizumab every 21 days for up to 1 year
223799187|NCT00002411|DRUG|Nelfinavir mesylate|
223799188|NCT00002411|DRUG|Lamivudine|
223799189|NCT00002411|DRUG|Stavudine|
223799190|NCT00002411|DRUG|Zidovudine|
223799191|NCT00002411|DRUG|Didanosine|
223799192|NCT04125368|BEHAVIORAL|Health Facility Interventions|"1. Intensified counselling on dietary diversity and increased meal frequency during pregnancy.~2. Strengthened government distribution of IFA supplies with counseling about its importance, managing side effects, and reminder about subsequent supplies.~3. Weight-gain monitoring with messaging to mothers about healthy diet and adequate rest; excess weight gain as a danger sign.~4. Intensified counseling on importance, benefits, and how-tos of early initiation of breastfeeding and exclusive breastfeeding."
223799193|NCT04125368|BEHAVIORAL|Community Interventions|"1. Home visits to pregnant women by HEWs to discuss maternal nutrition (dietary diversity, adequate food intake, IFA supplementation, and weight gain), early breastfeeding practices, provide ANC and Pregnant Women Conference referrals, and engage husbands.~2. HEWs use A\&T intervention tools (e.g. posters and maternal nutrition follow-up card) at Pregnant Women Conferences/ Mother Support Groups to reinforce maternal nutrition messages, encourage ANC attendance, distribute IFA tablets, measure and track weight gain, promote early breastfeeding practices, and encourage husband participation.~3. HEWs and community volunteers (Women's Development Army (WDA), imams, etc.) deliver maternal nutrition messages and encourage ANC visits at kebele and community meetings."
223799194|NCT04125368|BEHAVIORAL|Health System Interventions|"1. Trainings on the maternal nutrition interventions for health center heads, nurse-midwives, HEWs, community volunteers (WDA, imams, etc.), woreda health officers, and other key actors.~2. Supportive supervision of maternal nutrition activities conducted by woreda nutrition officers, woreda health officers, TDA or A\&T."
223799195|NCT05843916|DRUG|Recombinant human alpha galactosidase A (agalsidase beta)|All participants will receive 2 doses of Fabrazyme® with approximately 14 days between them. The dose will be 1 mg/kg of body mass every 2 weeks
223799196|NCT05843916|DRUG|Recombinant human alpha-galactosidase A (agalsidase beta)|All participants will receive AGA BETA BS for 54 weeks. The dose will be 1 mg/kg of body mass every 2 weeks
223799197|NCT03665610|DRUG|ozanimod|ozanimod
223799198|NCT01248273|BIOLOGICAL|Globo-H-GM2-sTn-TF-Tn-KLH conjugate, plus the immunological adjuvant QS-21|The injection will be administered subcutaneously during weeks 1, 2, 3, 7 and 19, totaling five injections over the course of the study. Three dose levels are planned: 25 mcg, 50 mcg and 100 mcg. We plan to vaccinate six patients at each dose level unless 2 dose limiting toxicities are observed, and an expansion cohort of 6 patients will be enrolled at the highest dose level achieved.
223799199|NCT06449040|DRUG|Liposomal amphotericin B (AmBisome®)|Liposomal amphotericin B (AmBisome®) - intravenous use, twice a week until total dose is achieved
223799200|NCT01958632|PROCEDURE|Nerve reconstruction|
223799201|NCT00833560|DRUG|Cyclophosphamide|In Part 1, cyclophosphamide with dose ranging from 900 to 1500 mg will be administered intravenously on Day 1 of each 21 day cycle for 3 cycles to determine optimal dose. In Part 2, optimal dose determined in Part 1 will be administered on Day 1 of each 21 day cycle for 3 cycles.
223799202|NCT00833560|DRUG|Bortezomib|Bortezomib 1.3 mg/m2 will be administered intravenously on Days 1,4,8, and 11 of each 21 day cycle for 3 cycles in both parts (Part 1 and Part 2).
223799203|NCT00833560|DRUG|Dexamethasone|Participants will receive dexamethasone 40 mg orally or intravenously on Days 1, 2, 4, 5, 8, 9, 11, and 12 of each 21 day cycle for 3 cycles in both parts (Part 1 and Part 2).
223799204|NCT01785680|OTHER|Integrated Protocol|Implement an integrated protocol in Sierra Leone for the management of MAM and non-complicated SAM that uses a single anthropometric indicator as well as the same food but in different doses to treat the continuum of malnutrition. MAM children will be given 75 g/kg/day of RUTF whereas SAM will be given 175 gr/kg/day of RUTF until MUAC\>12.5 cm is reached. Then child will be given LNS, a bed net, albendazole, zinc, referral for immunizations compliant with current WHO recommendations, oral rehydration salts to give if the child has more than three loose watery stools in 24 hours, and asked to return for follow-up in 1, 3 and 6 months. Caretakers will be instructed to seek medical care sooner if the child has fever, poor appetite or signs of an acute illness.
223799205|NCT01785680|OTHER|Current protocol|Current protocol for treating MAM in emergencies is supplemental food distribution, often providing a fortified blended food (FBF) that requires cooking. This treatment is the standard today for treating children with MAM.
223799206|NCT00970879|DRUG|cotrimoxazole|800 mg sulfamethoxazole and 160 mg trimethoprim daily, from 28 weeks of gestation until delivery
223799207|NCT00970879|DRUG|mefloquine|mefloquine 15 mg/Kg three times, between 16 and 28 weeks, 24 and 32 weeks, then 28 and 36 weeks of pregnancy
223799208|NCT05236686|PROCEDURE|Hepato-celiac lymphadenectomy|Hepato-celiac lymphadenectomy in the treatment of epithelial ovarian cancer, with a maximum cytoreduction, in the circumstance of primarily diagnosed advanced epithelial ovarian cancer (primary debulking surgery or interval debulking surgery) and of platinum-sensitive recurrent ovarian cancer (no more than 4 lines of therapy).
223799209|NCT03839264|DIAGNOSTIC_TEST|Graft stenosis and thrombosis|
223799210|NCT05527379|DEVICE|Virtual reality|"When the patient is ready to have the CIP procedure the tablet will be presented to him so that he can view and choose the immersive film that suits him best.~Before fitting the virtual reality helmet and the start of the film, the patient's anxiety will be evaluated by ENS on a scale of 0 to 10 . The patient's anxiety will also be evaluated at the end of the procedure.~The patient will be contacted by telephone by an investigator between D+1 and D+5 in order to reassess and remotely from the pose, his memorization of the gesture and to look for adverse events."
223799211|NCT03687567|PROCEDURE|Preimplantation genetic diagnosis|
223799212|NCT05805995|PROCEDURE|vertebral derotation|"* Incentive spirometer (Mediciser): Used for breathing exercises.~* Cycle ergometer ( Mijnhardt , St. Paul, MN): Used for lower limb exercise."
223799213|NCT06083025|DEVICE|CleaRing|The Hanita CleaRing device is an intraocular implant designed for inhibition of PCO leading to reduction in the Nd:YAG treatment rate. The device is implanted into the capsular bag after the extraction of the crystalline lens and prior to implantation of the IOL. The device is manufactured by Hanita Lenses from a hydrophilic acrylic co-polymer which is being used for the production of Intra-ocular lenses.
223799214|NCT05527366|OTHER|Vagus stimulation|The Vagus Stimulation Group received auricular vagus stimulation for a total of 15 sessions of 25 minutes 5 days a week. The patients were applied with vagustim device consisting of TENS device with electrodes placed bilaterally in the outer ear with headphones that can be selected according to ear size. During the application, the gel was used to avoid causing any damage and to ensure conductivity. It is placed so that tragus and konkaya are facing. The pulse duration of the TENS device is less than 500 microseconds, the frequency is 10 Herzt, the module was applied in TENS mode and in the form of a biphasic asymmetric wave.
223799215|NCT05527366|OTHER|Consevative treatment|A total of 15 sessions 5 days a week, 20 minutes of hotpack, 20 minutes of TENS, 5 minutes of 1,3 watt/cm2 ultrasound consisting of a total of 25 minutes of treatment was applied to the neck area.
223799216|NCT03202706|PROCEDURE|Samples of adipose tissue|Samples of visceral and subcutaneous adipose tissue collected during hernia surgery
223799217|NCT06525324|PROCEDURE|Immediate implant surgery with T-PRF and xenograft|"A mucoperiosteal flap will be raised and atraumatic extraction will be done. An immediate implant with T-PRF and xenograft will be placed according to the standard protocol.~The surgical wound closure will be coapted with mattress and single interrupted sutures"
223799218|NCT06525324|PROCEDURE|Immediate implant surgery with PRF and xenograft|"A mucoperiosteal flap will be raised and atraumatic extraction will be done. An immediate implant with PRF and xenograft will be placed according to the standard protocol .~The surgical wound closure will be coapted with mattress and single interrupted sutures"
223799219|NCT02292017|DEVICE|Embolization of intracranial aneurysm|Cerebral angiogram will be performed, target aneurysm measurements are performed including dome height, width, and depth as well as the neck length. Aneurysm volume will be calculated. During the embolization, framing, filling, and finishing should be done with Target Coils. In the event of aneurysms with a wide neck a Neuroform Stent may be used to ensure the best clinical and angiographic outcome. Immediate post procedure angiography is performed using the same pre-treatment views to assess results and complications.
223799220|NCT03048344|DRUG|ORH-2014|ORH-2014 capsule 5 mg orally with dose escalations of 5 mg intervals.
223799221|NCT03048344|DRUG|ORH-2014|ORH-2014 capsule at recommended dose orally.
223799222|NCT01718028|OTHER|Propylene glycol 0.6% ocular emulsion|
223799223|NCT01718028|OTHER|Sodium chloride 0.9% saline solution|
223799224|NCT01642680|OTHER|A tailored physical activity program during chemotherapy|The early group will start the PA program during chemotherapy for 3 months, and after completion of chemotherapy for 3 months (total 6 months). The PA program will consist of two components: improvement of physical fitness and empowerment to adopt a healthy lifestyle. Longitudinal effects of this PA program will be evaluated at 5 time points: before chemotherapy; at start of the PA program and at 3, 6 and 18 months after start of the PA program. Safety parameters will be monitored throughout the study period.
223799225|NCT01642680|OTHER|A tailored physical activity program after chemotherapy|The late group will start the PA program after completion of the chemotherapy for 6 months. The PA program will consist of two components: improvement of physical fitness and empowerment to adopt a healthy lifestyle. Longitudinal effects of this PA program will be evaluated at 5 time points: before chemotherapy; at start of the PA program and at 3, 6 and 18 months after start of the PA program. Safety parameters will be monitored throughout the study period.
223799226|NCT04719780|BEHAVIORAL|Emotionally Focused Therapy for Individuals|Emotionally Focused Therapy for Individuals (EFIT) is formulated as a transdiagnostic treatment to treat depression and anxiety, adapted from the well-studied Emotionally Focused Therapy. EFIT has been formulated as an attachment-based alternative to current cognitive approaches (e.g., Cognitive Behavioural Therapy). The strong evidence for insecure attachment as an underlying factor in psychopathology, especially depression and anxiety, positions this theory well as a foundational principle to support psychotherapy for these conditions.
223799227|NCT04719780|BEHAVIORAL|Self-Help CBT Training|Individuals in the Waitlist Control Group will receive access to MoodGym, a self-help online program that helps teach CBT interventions. This access will last 15 weeks and is self-driven, meaning participants proceed through the program at their own pace.
223799228|NCT01460550|PROCEDURE|Retrocolic gastro- or duodeno- jejunostomy in hte pancreaticoduodenectomy|The duodenojejunostomy or gastrojejunostomy was constructed in two layers or single layer. For the retrocolic reconstruction, the jejunal loop was anastomosed to the duodenum or stomach through a separate mesocolic window on the left of the middle colic vessels.
223799229|NCT01460550|PROCEDURE|Antecolic gastro- or duodeno- jejunostomy in the pancreaticoduodenectomy|The duodenojejunostomy or gastrojejunostomy was constructed in two layers or single layer. For the antecolic reconstruction, the jejunal loop about 30 cm distal to the hepaticojejunostomy, was brought up anterior to the transverse colon and anastomosed to the duodenum or stomach.
223799230|NCT02139722|BEHAVIORAL|Video Doctor, PA + PPN|The intervention consists of a Video Doctor and Provider Alert. For the Video Doctor, we will develop a series of 30-60 seconds video clips, a branching algorithm, and a mobile application linking the baseline survey to the clips. The Provider Alert is a point-of-care reminder printout generated by the mobile application to facilitate patient-provider communication. The intervention integrates guidelines, literature, guidance from the Systems Model, our prior work, and input from patients and providers.
223799231|NCT02080871|DEVICE|Stenting of the Common and/or External Iliac Arteries|Balloon expandable stenting of iliac occlusive disease.
223799232|NCT02696655|BEHAVIORAL|Behavioural intervention|Behavioural intervention administered by healthcare professionals targetting multiple lifestyle behaviours
223799233|NCT05201573|OTHER|Observational|This is an observational study of long term follow up data for patients who previously received the DIAM implant
223799234|NCT04150679|PROCEDURE|duodenojejunostomy access loop|ROUX en Y hepaticojejunostomy with duodenojejunal anastomosis as permanent access
223799235|NCT04150679|PROCEDURE|hepaticojejunostomy without access loop|ROUX en Y hepaticojejunostomy without access loop
223799236|NCT00591890|DRUG|indibulin|dose escalation of indibulin given twice daily for 21 days, to be repeated every 28 days.
223799237|NCT00234052|BIOLOGICAL|bevacizumab|5 mg/kg administered intravenously over 90 minutes on day 1 of each cycle (cycle = 3 weeks)
223799238|NCT00234052|DRUG|carboplatin|Administered intravenously at a dose of AUC=6 over 30 minutes on day 1 of each cycle (1 cycle = 3 weeks)
223799239|NCT00234052|DRUG|pemetrexed|Administered intravenously at a dose of 500 mg/m2 over 10 minutes on day 1 of each cycle (1 cycle = 3 weeks)
223799240|NCT06457074|DRUG|Finerenone Oral Tablet|Eligible patients will be started finerenone at 20mg per day, Dose will be adjusted every four weeks to achieve the targeted blood pressure (the mean office blood pressure \<140/90 mmHg).
223799241|NCT06457074|DRUG|Spironolactone Oral Tablet|Eligible patients will be started spironolactone at 20mg per day, Dose will be adjusted every four weeks to achieve the targeted blood pressure (the mean office blood pressure \<140/90 mmHg).
223799242|NCT03603080|DRUG|Administration of weight loss drug (Metformin or Topiramate)|Patients in this arm will receive either Metformin (500 mg, twice per day) or Topiramate (50 mg, once per day) starting at 4 weeks after laparoscopic sleeve gastrectomy
223799243|NCT02428296|DRUG|Sirolimus|Low dose sirolimus will be given in daily dosing to achieve trough levels of 2-6 ng/ ml.
223799244|NCT00505245|OTHER|Interview|Complete interview
223799245|NCT00505245|OTHER|Quality-of-Life Assessment|Complete quality of life assessment
223799246|NCT00505245|OTHER|Questionnaire Administration|Complete questionnaires
223799247|NCT05617690|DRUG|Cyclopol|Cyclopol 0.4mg/kg, sufentanil 0.2-0.4ug/kg and rocuronium 0.6mg/kg will be used for anesthesia induction. Anesthesia maintenance strategy is cyclopol 0.8-2.4 mg/kg/h and remifentanil 0.15 - 0.2 μg/kg/h
223799248|NCT05617690|DRUG|Propofol|Propofol 1-3mg/kg, sufentanil 0.2-0.4ug/kg and rocuronium 0.6mg/kg will be used for anesthesia induction. The anesthesia maintenance strategy is propofol 4-8mg/kg/h and remifentanil 0.15 - 0.2 μ g/kg/h
223799249|NCT03355638|DRUG|Aflibercept Injection [Eylea]|patients received monthly 0.5 mg aflibercept intravitreal injections for 3 months, after which monthly injections were administered pro re nata
223799250|NCT03355638|DRUG|Pranoprofen Eyedrops|Patients were given a bottle of eyedrops for self-administration of 0.1% pranoprofen (Pranoflog, Sifi SpA, Aci Sant'Antonio, CT, Italy). Pranoprofen dosage was 1 drop in the study eye, 3 times a day, over the 12-month study period
223799251|NCT03355638|DRUG|Omega-3 Supplementation|Ppatients were given daily tablets of Omega-3 supplementation provided free of charge by the company (Azyr Mega; Sifi SpA, Aci Sant'Antonio, CT, Italy).
223799252|NCT03840590|DEVICE|CSK AI system|CSK system is equipped with the endoscopic mainframe and alarms the examiners when suspect lesions appear.
223799253|NCT03840590|DEVICE|Standard Colonoscopy|This is the routine examination in nowadays clinical practice. Both the equipment and the procedure are as usual as clinical routine.
223799254|NCT00402181|BIOLOGICAL|Siltuximab|Siltuximab 6 mg/kg as intravenous infusion once every 2 weeks for 12 cycles and duration of each cycle is 28 days.
223799255|NCT00402181|DRUG|Dexamethasone|Dexamethasone 40 mg tablet orally on Day 1 to 4, 9 to 12 and 17 to 20 for maximum 4 cycles after that on Day 1 to 4 up to 12 cycles and duration of each cycle is 28 days.
223799256|NCT03346720|OTHER|Semi-structured interviews|These interviews will be conducted following an interview guide. Interviews will be conducted in English or Thai at a place convenient and familiar to the interviewee. It is estimated that each interview will last between 45 minutes to an hour.
223799257|NCT03346720|OTHER|Focus group discussions (FGDs)|These will be conducted following an interview guide. FGDs will be conducted in English or Thai. In addition, a note taker will be present to take notes. FGDs will take place at a place convenient and familiar to the participants. It is estimated that each FGD will last between 1 to 1.5 hours. FGDs will typically consist of homogenous groups e.g. study nurses.
223799258|NCT04232514|DRUG|HEC74647|Administered HEC74647 200 mg orally once daily in fed state
223799259|NCT04232514|DRUG|HEC110114|Administered HEC110114 800 mg orally once daily in fed state
223799260|NCT03919136|DEVICE|Wrist-worn measurement device (LiveMetric)|Evaluation of the wrist-worn measurement devices accuracy referenced to interventional (A-line) measurements.
223799261|NCT02710279|BEHAVIORAL|Trier Social Stress Test (TSST)|"For the TSST the participants are instructed to imagine having applied for their dream job and that they are now invited to a job interview. Three successive phases: (1) A preparation period (3 min), (2) a free speech: explain why you are the best candidate for the job (5 min), (3) a mental arithmetic complex task (5 min). The two tasks (task 2 and 3) are performed in front of a selection committee, three persons dressed in white lab coats, acting in a reserved manner and providing no facial or verbal feedback. Additionally, participants are told that they are video-taped and told that their performance will be evaluated. (in fact, there is no video-tape, just a false camera). After the TSST, patients have to answer to a questionnaire on their smartphone, 5 times a day during 7 days."
223799262|NCT02710279|DEVICE|smartphone|
223799263|NCT05423925|PROCEDURE|Bipolar hysteroscopic myomectomy|Bipolar hysteroscopic myomectomy.
223799264|NCT05423925|PROCEDURE|Monopolar hysteroscopic myomectomy|Monopolar hysteroscopic myomectomy
223799265|NCT01615328|DEVICE|Cervios ChronOs|The ACDF surgery will be carried out with Cervios ChronOs after randomization procedure.
223799266|NCT01615328|DEVICE|Bonion|The ACDF surgery will be carried out with Bonion after randomization procedure.
223799267|NCT00487409|PROCEDURE|Bipolar electrosurgical generator and instruments|laparoscopic colectomy using the Ligasure device
223799268|NCT00487409|PROCEDURE|Disposable stapling instruments|laparoscopic colectomy using clips, cautery and stapler
223799269|NCT02022579|PROCEDURE|DCE-MRI and DWI|DCE-MRI defined lesion(s) compared with biopsy results or 1-year follow up
223799270|NCT01090570|DRUG|PLX3397|Once-daily oral capsules
223799271|NCT02340741|PROCEDURE|conventional prophylaxis of aeroembolism|167 patients will be enrolled. Will perform standard way of aeroembolism prevention
223799272|NCT02340741|PROCEDURE|conventional prophylaxis plus CO2 insufflation|167 patients will be enrolled. Will perform standard way of aeroembolism prevention and insufflation of carbon dioxide
223799273|NCT02340741|PROCEDURE|cardiac surgery with opening of heart chambers|Patients with different clinical diagnoses, which is planned to cardiac surgery with the opening heart cavities
223799274|NCT04900129|COMBINATION_PRODUCT|Menthol 0.02%, Methyl salicylate 0.05%, N- Acetyl cysteine 1.2 gm%, and Diclofenac sodium 1gm%|inhaled vapor containing Menthol 0.02%, Methyl salicylate 0.05%, N- Acetyl cysteine 1.2 gm%, and Diclofenac sodium 1gm% twice daily in addition to conventional treatment. That is, 100 gram of emulsion contain diclofenac sodium 1 gram, N-acetyl cysteine 1.2 gm, menthol 20 mg, and methyl salicylic acid 50 mg.
223799275|NCT02606903|DRUG|BI 695501 prefilled syringe|
223799276|NCT02606903|DRUG|BI 695501 autoinjector|
223799277|NCT03656705|BIOLOGICAL|CCCR-NK92 cells|CCCR-NK92 cells will be administered intravenously over 1h. The starting dose of CCCR-NK92 cells will be 1×10e7-1×10e8,twice a week. The first evaluation of the efficacy after 3 weeks of treatment.
223799278|NCT00906841|DRUG|90Y-DOTA-hLL2|Consolidation : Fractionated RIT (8 weeks after the end of R-CHOP: 2 injections of 15 mCi/m2 of 90Y-DOTA-hLL2 and hLL2 at day 1 and day 8)
223799279|NCT01930357|BIOLOGICAL|Purified Vero Rabies Vaccine Serum Free (VRVg)|0.5 mL, Intramuscular (Day 0, Day 7 and Day 28).
223799280|NCT01930357|BIOLOGICAL|Imovax® Rabies: Human Diploid Cell Vaccine (HDCV),|0.5 mL, Intramuscular (Day 0, Day 7 and Day 28).
223799281|NCT02548455|DEVICE|Quartet 1457Q LV Lead|
223799282|NCT01787448|DRUG|Topical gel vehicle|0.2 ml applied every 2 days (or 3 days if over the weekend) over 22 days (9 applications) followed by 10-14 day rest period and one subsequent re-application
223799283|NCT01787448|DRUG|Topical gel vehicle|0.2 ml applied every 2 days (or 3 days if over the weekend) over 22 days (9 applications) followed by 10-14 day rest period and one subsequent re-application
223799284|NCT01787448|DRUG|Sodium lauryl sulfate 0.1%|0.2 ml applied every 2 days (or 3 days if over the weekend) over 22 days (9 applications) followed by 10-14 day rest period and one subsequent re-application
223799285|NCT01787448|DRUG|Sodium chloride solution 0.9% (saline)|0.2 ml applied every 2 days (or 3 days if over the weekend) over 22 days (9 applications) followed by 10-14 day rest period and one subsequent re-application
223799286|NCT04051164|OTHER|Progressive Muscle Relaxation Technique|"PMRT begins by assuming a comfortable position of lying down, sitting or leaning back.~Patient is asked to take a breathe in and intentionally contract muscle and hold muscle and after that release all tension and focus on sensation of relaxation. Each muscle group is tensed for 5-7 seconds and relaxed for 20-30 seconds. PMRT is given twice a day for one week."
223799287|NCT04051164|OTHER|Conventional treatment|Strengthening exercises of residual limb: After amputation strengthening exercises of residual limb is necessary to prevent shortening of muscles and tightening of joints, moreover it is necessary to make residual limb strong and flexible in order to use a prosthesis. This include Hip abduction, prone hip extension and Prone position. Gait training: This include standing exercises in the parallel bars with or without the prosthesis. Initial walking exercises in which the patient is taught to raise each knee alternately and to try to take weight on his limb as much as possible. Deep Breathing exercise: Deep breathing 10-15 repetitions twice a day.
223799288|NCT03764839|BEHAVIORAL|"Perioperative Digital Behavioral Pian Medicine My Surgical Success"|"The My Surgical Success website include 45 minutes of psychoeducation material developed and delivered by Beth Darnall, PhD. Viewers learn basic skills to improve regulation of pain-related distress. Treatment includes an app and a personalized plan for surgical success."
223799289|NCT03294330|DRUG|IC-Green KIT|fluorescence lymphangiography with the use of IC-Green
223799290|NCT06468774|PROCEDURE|Laparoscopic surgery|"The patients in the MALS group will be treated through transperitoneal ventral approach for the laparoscopic release of the celiac artery. Median arcuate ligament and any muscle or nerve tissue crossing the cranial surface of the celiac artery will be divided to release the celiac artery from compression.~In the patients with CMI open antegrade or retrograde bypass to celiac artery or superior mesenteric artery or both will be performed.~For operative treatment will be performed in general anaethesia whereas the endovacular treatment with PTA with stent for CMI will be performed in local anaethesia."
223799291|NCT02295514|BIOLOGICAL|PTP1B dosage|PTP1B sampled and dosed during sepsis
223799292|NCT04085848|OTHER|music therapy|4 music therapy sessions during a period of time of 48 hours. Each session lasts 30 minutes.
223799293|NCT01925716|OTHER|Corn oil|corn oil 56 g/day for 21 days
223799294|NCT01925716|OTHER|Olive oil|olive oil 56 g /day for 21 days
223799295|NCT03046212|DEVICE|Transcutaneous electrical nerve stimulation|TENS: it was applied in the conventional mode, through four self-adhesive electrodes of size 5x9cm positioned about five centimeters from the edges of the surgical scar, with frequency of 100 Hz and pulse duration of 100μs, for 30 minutes. The intensity was adjusted according to the maximum tolerance of the patient and was it increased during the application time with their permission.
223799296|NCT03046212|OTHER|Exercises|Active exercises of plantar flexion and dorsal flexion of the ankles, flexion and extension of the knees and adduction and abduction of the hips, in both lower limbs. All exercises were performed with the patient in the supine position in the bed, in 10 repetitions.
223799297|NCT04818580|PROCEDURE|Progressive Tension Sutures|In each patient, one side of the chest will receive progressive tension sutures inside the mastectomy pocket, from pectoral fascia to underside of mastectomy flap. 2-0 Vicryl about 15-20 sutures per chest. Both sides will receive bilateral drains (standard of care)
223799298|NCT01509729|PROCEDURE|Sham operation|A randomized group of patients received a placebo patch. As a supplement, each patient was given a dose of morphine, as required.
223799299|NCT01509729|PROCEDURE|Knee arthroscopic surgery|A randomized group of patients was given small patches with active 5% lidocaine.
223799300|NCT02261493|BIOLOGICAL|OnabotulinumtoxinA|OnabotulinumtoxinA injected into the protocol-specified areas. Subjects will receive at least 1 and up to 3 treatments.
223799301|NCT02261493|DRUG|Normal Saline|Placebo (normal saline) injected into the protocol-specified areas on Day 1.
223799302|NCT05624177|DIETARY_SUPPLEMENT|Streptococcus salivarius M18 probiotic 1 billion colony forming units chewing gum (chew 5 minutes)|Probiotic Streptococcus salivarius M18 products are commercially available in traditional formats such as a chewable tablet (lozenge) for local delivery to the oral cavity to provide health benefits. In this study, a chewing gum formulation will be evaluated for its potential of delivering probiotic Streptococcus salivarius M18 to the oral cavity.
223799303|NCT05624177|DIETARY_SUPPLEMENT|Streptococcus salivarius M18 probiotic 1 billion colony forming units chewing gum (chew 10 minutes)|Probiotic Streptococcus salivarius M18 products are commercially available in traditional formats such as a chewable tablet (lozenge) for local delivery to the oral cavity to provide health benefits. In this study, a chewing gum formulation will be evaluated for its potential of delivering probiotic Streptococcus salivarius M18 to the oral cavity.
223799304|NCT05836493|PROCEDURE|Ring annuloplasty|A prosthetic ring is implanted to treat tricuspid regurgitation
223799305|NCT05836493|PROCEDURE|Suture procedure|Suture techniques such as Kay or De Vega are used to reduce tricuspid annulus in order to treat tricuspid regurgitation
223799306|NCT05538624|DRUG|AVB-001 (Dose Escalation Phase)|One of four ascending doses of AVB-001 planned for IP, single dose administration in each dose level cohort of the Dose Escalation Phase (Part 1).
223799307|NCT05538624|DRUG|AVB-001 (Dose Expansion Phase)|The MTD/RP2D as determined in the Dose Escalation Phase will be further evaluated in the Dose Expansion Phase.
223799308|NCT00447148|PROCEDURE|3-dimensional coronary angiography|3-dimensional coronary angiography
223799309|NCT01375348|DRUG|Ultiva (remifentanil) or placebo|0.1microg/kg/min remifentanil administered as infusion Max infusion time is 20min
223799310|NCT01918410|DEVICE|Contact Lens with alginic acid|Worn for 7 days, at least 8 hours a day
223799311|NCT01918410|DEVICE|Contact Lens without alginic acid|Worn for 7 days, at least 8 hours a day
223799312|NCT00083408|DRUG|Pamidronate|
223799313|NCT00083408|DRUG|Thalidomide|
223799314|NCT03270449|OTHER|Multidisciplinary intervention|10 week multidisciplinary education and exercise
223799315|NCT03833882|DEVICE|MAF1217|The study population will have to self-administer the study treatment in a TID posology.
223799316|NCT03833882|OTHER|Cationorm|The study population will have to self-administer the study treatment in a TID posology.
223799317|NCT02425332|DEVICE|Lokomat gait trainer|
223799318|NCT00003006|GENETIC|reverse transcriptase-polymerase chain reaction|
223799319|NCT00003006|OTHER|immunohistochemistry staining method|
223799320|NCT01523054|DRUG|Metoprolol- Toprol XL|Extended release tablet, 200mg once daily for 4 days
223799321|NCT01523054|DRUG|Metoprolol- Lopressor|Immediate release tablet, Day 1 50 mg four times daily, Day 2, 3 and 4 100 mg twice daily
223799322|NCT02230956|BIOLOGICAL|onabotulinumtoxinA|onabotulinumtoxinA (botulinum toxin Type A) injection into the intra-articular space of the study knee.
223799323|NCT02230956|DRUG|Normal Saline|Normal Saline (placebo) injection into the intra-articular space of the study knee.
223799324|NCT00338884|DRUG|Sunitinib malate|Sunitinib malate starting dose 37.5 mg daily continuous daily schedule
223799325|NCT05196464|BEHAVIORAL|Acceptance and Commitment Therapy (ACT) Workshop|ACT workshops are single-day workshops that last 5-6 hours. The workshops will 1) Acceptance and Mindfulness Training emphasizing new ways of managing troubling thoughts, feelings, and physical sensations (e.g., learning how to recognize, and develop cognitive distance from unhelpful thoughts) and strategies to willingly face experiences that cannot be changed; and 2) Committed Action Training to help Veterans clarify what matters most to them (e.g., valued domains including family, friends, spirituality, career) and what they want to stand for in life, how they want to behave, and what strengths and qualities they want to develop. Within this context, the workshop will encourage engagement in, rather than avoidance of, actions consistent with valued directions, including engagement in healthcare. Workshop participants will be given homework related to implementing a key coping skill.
223799326|NCT05196464|BEHAVIORAL|Treatment as usual (TAU)|TAU will consist of a consult to a mental health provider at their rural clinic. The patient will then be scheduled for an intake and offered traditional mental health treatment options. Treatment options are likely to include outpatient individual psychotherapy, psychotherapy groups, or medication management.
223799327|NCT06117280|OTHER|Paraxanthine 200 mg|For the three-day test cycle, participants will take one capsule per day amounting to 200mg of paraxanthine.
223799328|NCT06117280|OTHER|Paraxanthine 300 mg|For the three-day test cycle, participants will take one capsule per day amounting to 300mg of paraxanthine.
223799329|NCT06117280|OTHER|Placebo|The placebo will contain resistant dextrin. For the three-day test cycle, participants will take one capsule per day amounting to 300mg of resistant dextrin.
223799330|NCT03112018|BEHAVIORAL|data strengthening|Data strengthening: initial training, monthly data collection and feedback on data quality, access to dashboards, periodic Data Quality Assessments
223799331|NCT03112018|BEHAVIORAL|modified Safe childbirth checklist - control|modified Safe Childbirth Checklist (mSCC) implementation: provision of the mSCC to facilities, limited feedback and mentoring on its use
223799332|NCT03112018|BEHAVIORAL|modified Safe childbirth checklist - enhanced|modified Safe Childbirth Checklist (mSCC) implementation: provision of the mSCC to facilities, ongoing intensive feedback and mentoring on its use
223799333|NCT03112018|BEHAVIORAL|PRONTO training|Health provider training (PRONTO): initial 2-days modular training followed by a 6-week mentoring sessions (Kenya) or periodic modular refreshers and supplemental mentoring (Uganda), each over a 9-12 month period
223799334|NCT03112018|BEHAVIORAL|QI cycles|Quality Improvement Cycles (QI): facility teams performing PDSA cycles with mentoring support and twice annual Learning Collaborative sessions, plus opportunities to apply for small amounts of funds to support change efforts
223799335|NCT02396745|DEVICE|Subjects undergoing TECR with ECM placement (ACell MatriStem, Boston Scientific WallFlex))|"TECR will be performed to resect the entire length and area of BE lesion.~ECM PLACEMENT:~Following resection, the exposed area will be covered with a 6 ply sheet of ACell MatriStem® Surgical Matrix PSMX ECM (ACell Inc., Columbia, MA). The ECM will be placed and held in position for 14 days (±4 days) using a Boston Scientific WallFlex™ Fully Covered Esophageal Stent (Boston Scientific, Boston, MA)."
223799336|NCT06126354|DRUG|Insulin human|Insulin infusion rate (IIR) will be determined empirically first to maintain mean basal fasting plasma glucose, and then either maintained at the basal rate (MH protocol) or be reduced stepwise toward euinsulinemia (RE protocol).
223799337|NCT06126354|DRUG|Octreotide Acetate|Octreotide will be infused at 30 ng/kg/min to suppress endogenous insulin, glucagon, and growth hormone secretion. Co-administered with glucagon and rhGH.
223799338|NCT06126354|DRUG|Glucagon|Glucagon will be replaced at a constant rate of up to 0.65 ng/kg/min to maintain baseline counterregulatory response. Co-administered with octreotide and rhGH.
223799339|NCT06126354|DRUG|Human Growth Hormone|Recombinant human growth hormone (rhGH) will be replaced at a constant rate of up to 3 ng/kg/min to maintain baseline counterregulatory response. Co-administered with octreotide and glucagon.
223799340|NCT06126354|DRUG|Dexamethasone Oral|Synthetic pure glucocorticoid used to induce temporary insulin resistance, administered orally as seven 1-mg doses over 72 hours.
223799341|NCT06126354|OTHER|[6,6-2H2] D-glucose|"Stable isotope tracer administered to calculate glucose kinetics during pancreatic clamp.~(Non-investigational)"
223799342|NCT06126354|DRUG|20% D-glucose (aq)|"20% D-glucose (aq) (D20W) will be administered to counteract hypoglycemia or strongly downward blood glucose trends, as needed.~(Non-investigational)"
223799343|NCT06126354|DIETARY_SUPPLEMENT|BOOST Plus|"Nutritional supplement will be administered to provide three standardized mixed meals on the day before the pancreatic clamp.~(Non-investigational)"
223799344|NCT06126354|DEVICE|Harvard Apparatus PHD ULTRA CP syringe pump|"Device: Harvard Apparatus PHD ULTRA CP syringe pump Syringe pump used for highly precise administration of insulin, octreotide/glucagon/rhGH, and D20W (as needed) even at low infusion rates.~(Non-investigational)"
223799345|NCT06126354|DEVICE|Yellow Springs Instruments (YSI) 2500 Biochemistry Glucose/Lactate Analyzer|"Glucose oxidase analyzer used to detect plasma glucose levels at the point of care. YSI have been the gold standard in clamp studies for many years. Two machines will run in parallel to ensure accuracy of results.~(Non-investigational)"
223799346|NCT06126354|OTHER|Normal saline|Normal saline (0.9% NaCl, aq), variable rate (as needed)
223799347|NCT06126354|OTHER|Human albumin|Human albumin (5%, aq), 0.4 g per 100 mL of infusion (0.4% (w/v) in insulin and OCT/GCG/GH bags)
223799348|NCT05103020|DRUG|intra-arterial oxaliplatin + Systemic FOLFIRI + target agent (bevacizumab or cetuximab) every 2 weeks|Bevacizumab : 5mg/kg IV over 30min, day 1 or Cetuximab : 500 mg/m2 IV over 2-hr, day 1 Oxaliplatin : HAI 100mg/m2 IV over 2-hr, day 1 Leucovorin : 400mg/m2 IV over 2-hr, day 1 5-Fluorouracil : 2400mg/m2 infusion for 46-h Irinotecan : 180mg/m2 IV over 1.5-hr, day 1
223799349|NCT05103020|DRUG|IV FOLFIRI+ target agent (bevacizumab or cetuximab) every 2 weeks|Bevacizumab : 5mg/kg IV over 30min, day 1 or Cetuximab : 500 mg/m2 IV over 2-hr, day 1 Irinotecan : 180mg/m2 IV over 1.5-hr, day 1 Leucovorin : 400mg/m2, IV over 2-hr, day 1 5-Fluorouracil : 400mg/m2 IV bolus, day 1 5-Fluorouracil : 2400mg/m2, infusion for 46-h
223799350|NCT00956345|DRUG|nonacog beta pegol|Cohort to receive a single dose of 25U/kg nonacog beta pegol administered intravenously (into the vein)
223799351|NCT00956345|DRUG|nonacog beta pegol|Cohort to receive a single dose of 50U/kg nonacog beta pegol administered intravenously (into the vein)
223799352|NCT00956345|DRUG|nonacog beta pegol|Cohort to receive a single dose of 100U/kg nonacog beta pegol administered intravenously (into the vein)
223799353|NCT04766762|PROCEDURE|Acupuncture combined with placebo|This group will include 48 patients. Patients in this group will receive acupuncture combined with placebo. Participants are in the supine position. The bilateral Tianrong (SI 17) acupoints are needled for 1-1.5 inch with the direction tilted back 45±5 degrees. The bilateral Fengchi (GB 20) acupoints are needled for 0.5-1 inch with the direction tilted to nose. The bilateral Neiguan (PC 6) acupoints are also needled for 0.5-1 inch with the straight direction. In addition, 4-6 additional acupoints can be identified according to different syndrome types of patients. The needles are kept for 30 min, the treatment frequency is 3 times per week, and the treatment duration lasts 8 weeks. Meanwhile, the dosage of placebo is 1 capsule twice a day and the treatment duration also lasts 8 weeks.
223799354|NCT04766762|PROCEDURE|Sham acupuncture combined with flunarizine hydrochloride|This group will include 48 patients. Participants in this group will receive sham acupuncture plus flunarizine hydrochloride. Participants are in the supine position and sham acupuncture is conducted. The bilateral Tianrong (SI 17) acupoints, Fengchi (GB 20) acupoints and Neiguan (PC 6) acupoints are selected, and 4-6 additional acupoints can be identified according to the syndrome type of the participants. The needles are kept for 30 min, the treatment frequency is 3 times per week, and the treatment duration lasts 8 weeks. Moreover, the dosage of flunarizine hydrochloride is 5mg twice a day and the treatment duration also lasts 8 weeks.
223799355|NCT01982357|DEVICE|Laser Speckle Imaging and Diffuse Optical Spectroscopy|Laser Speckle Imaging and Diffuse Optical Spectroscopy
223799356|NCT01371214|BEHAVIORAL|PLIÉ (Preventing Loss of Independence through Exercise)|Integrative exercise program that incorporates elements of Eastern and Western exercise traditions to target the muscles and movements needed to help individuals with mild to moderate dementia maintain functional status and independence.
223799357|NCT01970982|OTHER|Tobacco Heating System (THS 2.2)|THS 2.2 ad libitum for 5 days in confinement
223799358|NCT01970982|OTHER|Smoking abstinence (SA)|SA for 5 days in confinement
223799359|NCT01970982|OTHER|Conventional cigarette (CC)|Subject's own preferred brand of CC ad libitum for 5 days in confinement
223799360|NCT01066325|BEHAVIORAL|Neuro Emotional Technique|"NET is considered an alternative stress-reduction technique. Its aim is to remove neurological abnormalities which have a specified physiopathological pattern. The goal of NET is to normalize the aberrant patterns through a physical correction.~During the NET procedure, various psychological components of the anxious state are considered: cognitions, emotions, and behaviours. These various components are explored for a physiological reaction in the participant. Once a physiological reaction is found, the practitioner helps the participant identify the specific emotion. The procedure is concluded when the patient no longer feels distress or discomfort. Following the intervention, patients frequently report feeling subjective relief."
223799361|NCT01066325|OTHER|Stretching Instruction|This arm is the Active Control Arm and will receive two 20-minute sessions of Stretching Instructions. During these instructions, participants will hold stretches for not longer than 5 seconds, which in not likely to have any therapeutic effect.
223799362|NCT02923843|OTHER|Comprehensive Geriatric Assessment|The CGA is person-centered and unique for each patient, but is based on the core elements such as socio-demographic background, social network, health and medical history, medications, functional status, cognitive status, nutritional status, somatic status and psychosocial status including depression, providing a comprehensive assessment tailored for each person.
223799363|NCT04321239|BEHAVIORAL|Positive STEPS|Individuals in the intervention group will meet with a community health worker at an in-person or virtual study orientation session. At this session, they will be introduced to the program, learn how to use the online modules and any associated materials, and choose a day and time for future weekly telephone sessions. Participants will also be given a wearable physical activity tracker at the orientation session to use throughout the course of the program. They can choose to report daily step counts either by automatically syncing to an app or by manual reporting via text message. The program will be delivered over 6 weeks. Each week participants will complete a web-based module and have one telephone session with the community health worker to discuss that module and to set a related goal. Participants will also set weekly goals related to walking, which will be informed and tracked by daily step-counts from the physical activity tracker.
223799364|NCT05032001|DRUG|Biguanide, DPP4 inhibitors, SGLT2 inhibitors|Oral antidiabetic treatment during twelve weeks
223799365|NCT01146496|DEVICE|Ultraviolet light-resistant plastic in-ground pesticide storage container|In-ground pesticide storage container to be supplied to every household that uses pesticides in intervention villages
223799366|NCT03270605|PROCEDURE|Myomectomy|Surgical removal of uterine fibroid
223799367|NCT06165783|OTHER|Therapeutic Exercises and Ultrasound|describe the rationale and methodology for evaluating the effect of using therapeutic exercises and ultrasound in the rehabilitation of partially injured hamstring muscles
223799368|NCT01984684|DRUG|delafloxacin|
223799369|NCT01984684|DRUG|vancomycin|
223799370|NCT01984684|DRUG|aztreonam|
223799371|NCT02599415|DEVICE|TL01 light treatment|Patients received treatment in TL01 cabinet three sessions weekly according to a standard escalating protocol based on minimal erythema dose. Standard dose ranges between 0.55 and 3.13J/cm2.
223799372|NCT06191627|DIAGNOSTIC_TEST|Patch testing|Unlike many different dermatological diseases, a biopsy cannot easily distinguish ACD from irritant contact dermatitis or other forms of chronic dermatitis. Thus, the gold standard for diagnosis is patch testing. During patch testing, allergens are placed on the skin under occlusion using an aluminum disc and tape. When undergoing intensive testing for ACD, as many as 300 patches may be applied to a patient. Therefore, a large area of skin clear of rash is required, most often the back, but patches are frequently applied to the legs as well. Patches are applied by clinic patch technicians. They will proceed with their normal procedures, following the randomization to apply the patches to the appropriate location. Patches will be applied to the skin once, as is the normal standard of care. Patches are applied on day 1 and removed on day 3. Patients continue testing through day 5, though study elements will cease on day 3.
223799373|NCT05718375|DRUG|CU01-1001|CU01-1001
223799374|NCT05718375|DRUG|Placebo|Placebo
223799375|NCT05013450|DRUG|Dupilumab|three q3w cycles
223799376|NCT05013450|DRUG|PD-1/PD-L1 blockade|SOC immunotherapy with PD-1/PD-L1 blockade
223799377|NCT05013450|DRUG|Anakinra|100 mg daily injection for Three q3w cycles
223799378|NCT03148223|DEVICE|auriculotherapy|The participants will be submitted to a session per week with duration of 20 minutes, for three consecutive months, to fix the adhesives. The points selected for stimulation, according to Chinese atrial mapping, are: uterus, endocrine, ovary, pituitary, shen men, sympathetic, and liver. Participants will be advised to remain with the stickers fixed to the auricle for six days.
223799379|NCT04685902|DEVICE|One-way speaking valve|One-way speaking valve is a small device that attaches to the tracheostomy tube, to allows tracheostomy patient to breathe in through his or her trach tube. After the inhalation, the speaking valve closes. Air is breathed out (exhaled) up through the vocal cords, then through the mouth and nose.
223799380|NCT04851483|DRUG|BAY2328065|Solid Form, Oral administration.
223799381|NCT04851483|DRUG|Placebo|Matching placebo of BAY2328065.
223799382|NCT04665635|PROCEDURE|Rectosigmoid resection|Most of the colorectal involvements are observed in the seromuscular layer. In seromuscular infiltration, resection of the rectosigmoid colon or shaving of tumoral implants without resection can be performed.
223799383|NCT05971719|DIAGNOSTIC_TEST|Air Leaks: Aerosol glycerine System|A range of different leak will be done with different needle sizes on the lung. Perform localization on staple lines used surgically during pulmonary surgeries, as they are known to not consistently give an airtight closure. The lung will be put in the ex-vivo model and ask for a surgeon to localize the leaks with our system. The needle incisions will be repeat on another lung and ask the same surgeon to localize the leaks with the submersion test. To perform the submersion test the surgeon will have to submerge the lung in saline solution and to check the presence of air bubbles. The lung is inflated to pressures of 20 to 40 cm H209. The precision of both systems will be compared by the minimal incision the minimal incision the surgeon was able to localize.
223799384|NCT04475549|DRUG|IW-6463 Tablets|IW-6463 tablets administered orally (daily)
223799385|NCT05163418|DEVICE|Foot orthosis for flat feet|Plantar orthotics based on a unique process of footprinting, software design and orthotic printing to create custom 3D printed orthotics.
223799386|NCT05163418|DEVICE|Foot orthoses for high arches feet|Plantar orthotics based on a unique process of footprinting, software design and orthotic printing to create custom 3D printed orthotics.
223799387|NCT05711641|DRUG|Lidocaine 10 MG/ML|Application of 10% topical lidocaine in the external auditory canal of tinnitus patients.
223799388|NCT05711641|DRUG|Distilled water|Application of distilled water in the external auditory canal of tinnitus patients.
223799389|NCT01795430|DRUG|etoposide|Given IV
223799390|NCT01795430|DRUG|ifosfamide|Given IV
223799391|NCT01795430|RADIATION|intensity-modulated radiation therapy|Undergo WB-MRI-guided IMRT
223799392|NCT01795430|DRUG|topotecan hydrochloride|Given IV
223799393|NCT01795430|DRUG|busulfan|Given IV
223799394|NCT01795430|DRUG|melphalan|Given IV
223799395|NCT01795430|PROCEDURE|autologous hematopoietic stem cell transplantation|Undergo autologous peripheral blood stem cell or bone marrow transplant
223799396|NCT01795430|PROCEDURE|peripheral blood stem cell transplantation|Undergo autologous peripheral blood stem cell transplant
223799397|NCT01795430|PROCEDURE|autologous bone marrow transplantation|Undergo autologous bone marrow transplant
223799398|NCT00998608|DRUG|risperidone|risperidone 4mg/d
223799399|NCT04512521|DRUG|Mepolizumab|Mepolizumab therapy
223799400|NCT02503748|OTHER|Online tutorial|website informing about treatment options in localized prostate cancer
223799401|NCT00877331|BEHAVIORAL|Brief intervention using motivational interviewing|One brief, in-person motivational interviewing session (30-45 minutes) in conjunction with the medical appointment. Plus one brief follow-up phone call one week later.
223799402|NCT01698294|OTHER|Clinical Observation|Participants maintain usual diet and undergo clinical observation
223799403|NCT01698294|DIETARY_SUPPLEMENT|Flaxseed|Given PO
223799404|NCT01698294|OTHER|Laboratory Biomarker Analysis|Correlative studies
223799405|NCT01698294|OTHER|Questionnaire Administration|Ancillary studies
223799406|NCT03683485|PROCEDURE|long duration EPBD|An 8-mm dilatation balloon was used for EPBD. Balloons were gradually inflated to maximum pressure for 3 minute, and complete inflation was verified by fluoroscopy.
223799407|NCT03683485|PROCEDURE|EST|After deep cannulation was achieved, a complete sphincterotomy was performed with a 25-mm pull-type sphincterotome (Clever Cut 3; KD-V411M, Olympus, Tokyo, Japan) and the sphincter was divided up to the transverse duodenal fold.
223799408|NCT04303949|OTHER|Behavioral:|Facilitating couples reduce anxiety, depression and grief through e-book education.
223799409|NCT01115257|PROCEDURE|vitrectomy|The surgical technique (Group 1) included vitrectomy, with a combination of delamination and segmentation of gliotic tractional membranes using bimanual technique. Silicone oil tamponade was used in eyes with long-standing tractional retinal detachment, as deemed necessary by the surgeon, or in eyes in which a retinal break occurred during the vitrectomy.
223799410|NCT01115257|PROCEDURE|panretinalphotocoagulation|Panretinal photocoagulation was completed according to guidelines summarized in ETDRS with extensive full subconfluent panretinal photocoagulation.
223799411|NCT03054792|DIAGNOSTIC_TEST|Blood Oxygen Level Dependent [BOLD] MRI|BOLD is a non-invasive T2\*-weighted MRI technique that is sensitive to the microvascular deoxyhemoglobin concentration. BOLD has the potential to monitor changes in tissue oxygenation in response to a gas breathing challenge to induce contrast.
223799412|NCT03054792|DIAGNOSTIC_TEST|Diffusion-Weighted [DW] MRI|DW MRI is a non-invasive technique that provides quantitative biophysical information about the movement of water in tissues and reflects the anisotropy of normal and pathologic cells
223799413|NCT03054792|DIAGNOSTIC_TEST|Magnetic Resonance Spectroscopy [MRS]|MRS is a non-invasive imaging technique that enables the generation of spectral profiles of low molecular weight metabolites that reflect status of a tissue
223799414|NCT04118530|OTHER|HSCT Patients|Prospective, observational review of incidence of AF/AFL through Carelink remote monitoring and safety of implantation of device in this population of patients through review of standard of care follow up visits post HSCT implant
223799415|NCT06297486|GENETIC|SPK-8011|Participants will receive a single dose of SPK-8011, administered by intravenous (IV) infusion, on Day 1.
223799416|NCT03609112|OTHER|The WISC-V|The WISC-V (Weschler, 2016) which is measured with several indices: Verbal Comprehension Index (VCI), Visual Spatial Index (VSI), Working Memory Index (WMI), Fluid Reasoning Index (FRI), Processing Speed Index (PSI), and Full Scale IS (FSIQ).
223799417|NCT03609112|OTHER|The NEPSY-II|The NEPSY-II (Korkman et al., 2012). The Narrative Memory subtest is designed to assess verbal memory using organised language material.
223799418|NCT03609112|OTHER|The Child Executive Function Evaluation Battery CEF|The Child Executive Function Evaluation Battery CEF (Roy et al., 2021), which aims to evaluate the four main components of executive function (inhibition, working memory, flexibility and planning).
223799419|NCT03609112|OTHER|"The CONNERS 3 long version"|"The  CONNERS 3 long version  (Conners, 2008), which assesses attentional skills by means of a questionnaire to be completed by parents."
223799420|NCT03609112|OTHER|"The BRIEF"|The 'BRIEF' (Gioia et al., 2013; parent version, teacher version), which is a behavioural evaluation inventory of executive functions completed by parents and teachers and which makes it possible to determine whether the child has, for example, difficulties with organisation, planning or behavioural regulation.
223799421|NCT03609112|OTHER|"The PEDS-QL quality of life"|"The PEDS-QL quality of life (Tessier et al., 2009) that will be completed by the parents and the patient concerns the day to- day functioning of the child (in school, relationships to others, physical abilities and emotional state)."
223799422|NCT03609112|OTHER|The 'fatigue' version of the PEDS-QL (Tessier et al., 2009: parent and child-adolescent version for the brain tumour cohort)|The 'fatigue' version of the PEDS-QL (Tessier et al., 2009: parent and child-adolescent version for the brain tumour cohort) which assesses fatigue in everyday life.
223799423|NCT03609112|OTHER|The Family Functioning Inventory FAD)|The Family Functioning Inventory FAD (Speranza et al., 2006) is used to assess the family functioning of the child and his/her family. The short version is used as an indicator of general functioning.
223799424|NCT03609112|OTHER|The 'fatigue' version of the PEDS-QL (Tessier et al., 2009: child version for the extra-cerebral tumour cohort)|The 'fatigue' version of the PEDS-QL (Tessier et al., 2009: child version for the extra-cerebral tumour cohort) which assesses fatigue in everyday life.
223799425|NCT04575051|OTHER|Consult Model|The Consult Model (i.e., usual care) is an acute care strategy, relying on a monthly Audiologist visit to the facility.
223799426|NCT04575051|OTHER|Engage Model|The Engage Model is a chronic care approach to supportive hearing loss self-management of ARHL. Engage includes (a) hearing screening for all residents, (b) an individualized communication plan for those with an identified hearing loss (e.g., one-to-one, group, telephone, television plans, hearing aid trouble shooting, communication strategies, etc.), (c) provision of simple, non-custom amplifiers, (d) referral to audiology if needed, and (e) ongoing support provided by trained personnel (Communication Facilitator) under the supervision of the audiologist.
223799427|NCT03488901|OTHER|chemoresistance signature|to study the predictive value of a tissue transcriptomic profile (=chemoresistance signature) in the chemoresistance to single or multiagent chemotherapy
223799428|NCT00465413|DEVICE|Small volume spacer and/or Rinsing the mouth with water|
223799429|NCT04939129|DIAGNOSTIC_TEST|The research is terminated by calculating the percentage of PVI changes with SAB formed by LRM after fluid challenge.|Measurements will begin after a hemodynamically stable period in the supine position.Heart rate, central venous pressure, systolic, diastolic and mean arterial pressure, peripheral oxygen saturation, PVI and BIS baseline values (baseline 1) will be recorded.LRM will be automatically adjusted in the mechanical ventilator(30 cm H2O/30 seconds) and all hemodynamic parameters where the maximum change at the end of 30 seconds, will be recorded(after LRM), and the differences initial baseline values will be calculated and recorded as percentages.After the recording of the second values, the crystalloid infusion at 10ml/kg will be made to the patient through the peripheral venous line within 15minutes, new baseline values will be taken before the test(baseline 2).After fluid replacement, LRM will be repeated in the same way. The values after LRM(Fluid Challenge-FC) will be recorded and differences between basal 2 values will be calculated and recorded as percentages.
223799430|NCT00095524|DRUG|Aripiprazole|
223799431|NCT03624504|DEVICE|Micra Transcatheter Pacing System (TPS)|Treatment of subjects eligible for the single chamber ventricular pacemaker per study requirements
223799432|NCT03341390|DRUG|Aspirin|1 x 325 mg tablet of aspirin administered once daily
223799433|NCT03341390|DRUG|BMS-986177|200 mg of BMS-986177 administered twice daily
223799434|NCT03341390|DRUG|Placebo|200 mg of Placebo administered twice daily
223799435|NCT05579353|OTHER|nothing|nothing
223799436|NCT04822220|OTHER|Fatigue Self-management Programme|Fatigue Self-management Programme
223799437|NCT00611143|DRUG|atorvastatin|atorvastatin 20 mg/d, started 3 days before surgery
223799438|NCT01183676|DRUG|DEPAKOTE® Tablets, 500 MG|1 x 500 mg Tablet, under fed conditions
223799439|NCT01183676|DRUG|DIVALPROEX SODIUM DELAYED-RELEASE TABLETS, USP, 500 MG|1 x 500 mg Tablet, under fed conditions
223799440|NCT01505023|DIETARY_SUPPLEMENT|Partial meal replacement|The PMR was designed to contain sufficient amounts of all vitamins and minerals. Women were instructed to consume 2 servings per day at breakfast and dinner, each consisting of 33 g of powder dissolved in 250 ml of skim milk.
223799441|NCT01505023|DIETARY_SUPPLEMENT|Partial meal replacement with inulin|The PMR was designed to contain sufficient amounts of all vitamins and minerals plus inulin. Women were instructed to consume 2 servings per day at breakfast and dinner, each consisting of 33 g of powder dissolved in 250 ml of skim milk.
223799442|NCT01505023|DIETARY_SUPPLEMENT|Inulin|Women were asked to consume one 5g serving of inulin mixed with any drink at breakfast and same amount at dinner (10 g of inulin/d).
223799443|NCT05441072|DEVICE|BulbiCam|"The multi-test device, BulbiCam (BCAM), is a combined eye tracking; pupil metric; video graphic dual device which include the following 10 tests under development and ready for validation:~1. 26 grids glaucoma screening perimetry~2. 64 grids full perimetry (NeuroField64)~3. Pupil and Relative Afferent Pupil Defect (RAPD) assessment~4. Semi-automatic ptosis (droopy eyelid) grading~5. Video-based nystagmus test~6. Dynamic acuity and contrast sensitivity test~7. Dark adaptation test~8. Smooth pursuit eye movements~9. Saccade movements~10. Eye fixation stability~BCAM is connected to the BulbiHub software where measured data is stored and presented in numbers, diagrams, and graphs."
223799444|NCT02862457|DRUG|Epacadostat 25 mg|Oral administration
223799445|NCT02862457|DRUG|Epacadostat 100 mg|Oral administration
223799446|NCT02862457|BIOLOGICAL|pembrolizumab 200 mg|Intravenous (IV) infusion
223799447|NCT02862457|DRUG|Cisplatin 75 mg/m^2|IV infusion
223799448|NCT02862457|DRUG|Carboplatin Area Under the Curve (AUC) 5|IV infusion
223799449|NCT02862457|DRUG|Pemetrexed 500 mg/m^2|IV infusion
223799450|NCT02862457|DRUG|Paclitaxel 200 mg/m^2|IV infusion
223799451|NCT02862457|DRUG|Carboplatin AUC 6|IV infusion
223799452|NCT02243553|DRUG|Tipranavir capsule|
223799453|NCT02243553|DRUG|Tipranavir solution|
223799454|NCT02243553|DRUG|Ritonavir capsule|
223799455|NCT02243553|DRUG|Caffeine|
223799456|NCT02243553|DRUG|Warfarin sodium|
223799457|NCT02243553|DRUG|Vitamin K|
223799458|NCT02243553|DRUG|Omeprazole|
223799459|NCT02243553|DRUG|Dextromethorphan hydrobromide|
223799460|NCT02243553|DRUG|Midazolam injection|
223799461|NCT02243553|DRUG|Midazolam oral solution|
223799462|NCT02243553|DRUG|Digoxin tablet|
223799463|NCT02243553|DRUG|Digoxin injection|
223799464|NCT01782066|BIOLOGICAL|MEN-ACYW135 reduced-dose intradermal administration|Modified traditional dose escalation rule (TER) in an adaptive design. The study will be performed in duplicate, with 2 vaccines.
223799465|NCT04496219|DEVICE|Acupuncture Therapy|Undergo acupuncture therapy
223799466|NCT04496219|BIOLOGICAL|BCG Solution|Given by intravesical injection
223799467|NCT04496219|OTHER|Best Practice|Receive standard of care symptom management
223799468|NCT04496219|OTHER|Quality-of-Life Assessment|Ancillary studies
223799469|NCT04496219|OTHER|Questionnaire Administration|Ancillary studies
223799470|NCT00507000|DRUG|Cholecalciferol|Drug: Cholecalciferol Drug: Cholecalciferol 60,000 IU sachet and calcium carbonate Oral cholecalciferol (vitamin D)60,000 IU weekly along with daily oral dose of 1 gm calcium carbonate for first two months followed by 1 gm of elemental calcium in form of calcium carbonate daily cholecalciferol (vitamin D)60,000 IU per month for the next four months Arms: A, Cholecalciferol
223799471|NCT00507000|DRUG|Lactose granules|Drug: Lactose placebo Lactose placebo granules in identical sachet given weekly and two lactose tablets for first two months followed one sachet of placebo granules every month and two tablets of lactose containing placebo tablets taken daily for next four months
223799472|NCT02859792|DRUG|Riluzole|Riluzole capsules (25 or 50 mg) will be administered in the four dose level groups (i.e. 25 mg bid; 50 mg bid; 75 mg bid; 100 mg bid).
223799473|NCT02859792|DRUG|Placebo|placebo capsules 25 or 50 mg
223799474|NCT02859792|BIOLOGICAL|Blood Samples|v1;v2;v3;v4
223799475|NCT05590819|DEVICE|repetitive transcranial magnetic stimulation(rTMS)|5 hertz(Hz), 1000 pulses, 90% RMT stimulation; 15 minutes per session; for a total of 10 sessions
223799476|NCT05590819|DEVICE|Intermittent Theta-burst Stimulation(iTBS)|3 pulses of stimulation delivered at 50 Hz and repeated at 5 Hz; 2s train of TBS with repetitive interval of every 10s, 70% RMT; 600 pulses in total; 15 minutes per session; for a total of 10 sessions
223799477|NCT05590819|DEVICE|Sham stimulation|Set-up the coil without true stimulation; 15 minutes per session; for a total of 10 sessions
223799478|NCT03508648|DRUG|GTx-024|Subjects will not be provided with any study treatments and will be off-drug during this extension study. Intervention was administered during study G201002.
223799479|NCT03508648|DRUG|Matching Placebo|Subjects will not be provided with any study treatments and will be off-drug during this extension study. Intervention was administered during study G201002.
223799480|NCT00672074|DRUG|Ipamorelin|IV
223799481|NCT00672074|DRUG|placebo|IV
223799482|NCT03018405|BIOLOGICAL|NKR-2 cells|"In cohorts 1-6, the schedule of administration will be 3 NKR-2 doses administered with a 2-week interval. In absence of progressive disease at the first tumor assessment following NKR-2 administration (on Visit D29 for hematological tumors or on Visit D57 for solid tumors), and according to product availability, the patient will receive a new cycle of 3 administrations maximum with a 2-week interval, at a dose of 1x109 NKR-2 cells per injection, or at the same dose of cycle 1 if it was below 1x109 NKR-2 cells.~Patients in cohorts 8-9 (solid arm) and 10-11 (hematological arm) of first segment will receive 3 treatment doses at 1x109 NKR-2 (cohorts 8 and 10) or 3x109 NKR-2 (cohorts 9 and 11) per injection, with a 1-week interval between each dose. A second cycle of three NKR-2 injections at the same dose as in 1st cycle will be administered 2 weeks after the third NKR-2 injection, and with a 2-week interval between each dose."
223799483|NCT04171466|OTHER|Ciprofloxacin + Metronidazole|Participants will be instructed to take 1 capsule of Ciprofloxacin (500mg) twice daily for 7 days and 1 capsule of Metronidazole (500mg) thrice daily for 7 days. Antibiotics should be taken at least 2 hours before or 6 hours after mineral supplements containing magnesium or aluminum, as well as sucralfate, metal cations such as iron, and multivitamin preparations with zinc.
223799484|NCT04171466|OTHER|SH-DS01|SH-DS01 is a rationally defined microbial consortia consisting of 24 strains across 12 species, with polyphenolic and phenolic prebiotic bioactive compounds. Participants will be instructed to take 2 capsules daily for the duration of the trial.
223799485|NCT04171466|OTHER|Placebo|Placebo capsules for SH-DS01 will contain rice flour matched for color and texture in an identical outer capsule shell. Participants will be instructed to take 2 capsules daily for the duration of the trial.
223799486|NCT06265350|DRUG|Cadonilimab|Cadonilimab, 375mg，Q3W， IV
223799487|NCT06265350|DRUG|Bevacizumab|Bevacizumab, 7.5mg/kg，Q3W， IV
223799488|NCT06265350|PROCEDURE|Cryoablation|Patients accepted Cryoablation of pulmanary metastases
223799489|NCT01039701|DRUG|AZD1446|capsules, oral, 3 times daily
223799490|NCT01039701|DRUG|Placebo|capsules, oral, 3 times daily, 4 weeks
223799491|NCT00210795|DRUG|epoetin alfa|
223799492|NCT05918068|DRUG|Metformin 500 mg/day|Metformin 500 mg/day in addition to non-pharmacological therapy
223799493|NCT05918068|COMBINATION_PRODUCT|Metformin 500 mg/day plus vitamin B6 300 mg/day|Metformin 500 mg/day plus vitamin B6 300 mg/day in addition to non-pharmacological therapy
223799494|NCT05918068|OTHER|non-pharmacological therapy|non-pharmacological therapy (healthy lifestyle modifications)
223799495|NCT02017340|DRUG|Nilvadipine|8mg of Nilvadipine taken once a day at lunch time for 78 weeks
223799496|NCT02017340|DRUG|Placebo|8mg Placebo tablet taken once a day at lunch time for 78 weeks
223799497|NCT00951483|DRUG|Quetiapine-XR|Quetiapine-XR (Seroquel-XR) 50-300mg daily for 12 weeks.
223799498|NCT04973865|OTHER|Validation & reliability|Translated version of IPAQ(SF) validation \& Reliability
223799499|NCT01570829|DRUG|Dietressa|Oral administration.
223799500|NCT01570829|DRUG|Placebo|Oral administration.
223799501|NCT05594979|DIETARY_SUPPLEMENT|TOTUM-070|2.5-g dose of TOTUM-070 diet supplement; Four capsules per day to consume orally in two intakes
223799502|NCT03950765|BEHAVIORAL|Ecological momentary intervention|Content of this intervention is based on pre-established transdiagnostic protocols for addressing the negative emotion associated with suicidal thoughts and behaviors.
223799503|NCT03424824|DRUG|BP1.3656 low dose|Tablet, once daily oral administration at the low dose
223799504|NCT03424824|DRUG|BP1.3656 intermediate dose|Tablet, once daily oral administration at the intermediate dose
223799505|NCT03424824|DRUG|Placebo|Tablet, once daily oral administration
223799506|NCT03424824|DRUG|BP1.3656 high dose|Tablet, once daily oral administration at the high dose
223799507|NCT03291574|PROCEDURE|Electroacupuncture|Acupuncture at Baihui, Nei guan, bilateral Zu sanli and bilateral Tian shu.
223799508|NCT03291574|PROCEDURE|Sham electroacupuncture|Sham acupuncture at Baihui, Nei guan, bilateral Zu sanli and bilateral Tian shu.
223799509|NCT01437748|DRUG|Indacaterol maleate|Dry powder, 300 mcg, only one inhalation with 24 hours duration
223799510|NCT01437748|DRUG|Tiotropium bromide|Dry powder, 18 mcg, only one inhalation with 24 hours duration
223799511|NCT03364751|OTHER|IQOS|Patients will switch from cigarette smoking to ad libitum IQOS use.
223799512|NCT03364751|OTHER|Cigarette|Patients will continue to smoke cigarettes ad libitum.
223799513|NCT00562887|BIOLOGICAL|Placebo|every 4 weeks, IV
223799514|NCT00562887|BIOLOGICAL|ABT-874|400 mg IV every 4 weeks
223799515|NCT00562887|BIOLOGICAL|ABT-874|700 mg IV every 4 weeks
223799516|NCT01937052|OTHER|Sample collection|Participants will be offered the option to consent for blood (preferred) or saliva for DNA pharmacogenetic testing, and for additional samples for banking for future studies.
223799517|NCT01937052|BEHAVIORAL|Patient-reported outcomes|Patient reported outcomes (PROs) will be collected via electronic questionnaires that will be administered to patients at regular intervals per the study calendar; in most cases, this should coincide with medical oncology follow-up.
223799518|NCT01475968|OTHER|Ultrafine Air Pollution Particulate Matter|Ultrafine (particle diameter less than 2.5 microns) Air Pollution Particulate Matter, concentrated from the ambient air outside of the Chapel Hill EPA Human Studies Facility
223799519|NCT01475968|OTHER|Filtered Air|Filtered Air
223799520|NCT02496624|OTHER|Cone Beam CT localization and placement of microcoil|Cone Beam CT localization and placement of microcoil
223799521|NCT06449833|DRUG|Henagliflozein and Metformin|The experimental group will be treated with 10mg Henagliflozein and Metformin.
223799522|NCT06449833|DRUG|Linagliptin and Metformin|The control group will be treated with 5mg Linagliptin and Metformin.
223799523|NCT04468438|DIAGNOSTIC_TEST|serum estrogen and urinary albumin creatinine ratio|serum estrogen and urinary albumin creatinine ratio
223799524|NCT04396067|DRUG|Aerosolized 13 cis retinoic acid|The infected patients will receive Aerosolized 13 cis retinoic acid in gradual in one dose increases froms 0.2 mg/kg/day to 4 mg/kg/day as inhaled 13 cis retinoic acid therapy for 14 days
223799525|NCT04396067|DRUG|Aerosolized All trans retinoic acid|The infected patients will receive Aerosolized All trans retinoic acid in gradual one dose increases froms 0.2 mg/kg/day to 4 mg/kg/day as inhaled all trans retinoic acid therapy for 14 days
223799526|NCT04396067|OTHER|Placebo|Placebo is a pill or tablet that does not contain any study drug.
223799527|NCT04654338|RADIATION|SABR + HDR|One SABR treatment + one HDR brachytherapy treatment
223799528|NCT03923348|DEVICE|Leva device|The leva® Pelvic Digital Health System by Renovia Inc is a novel tool for subjects with urinary incontinence to train and strengthen pelvic floor muscles via directional mechano-transductive feedback on performance in the privacy of their own homes.
223799529|NCT02423187|OTHER|No Intervention|
223799530|NCT03583554|DRUG|Placebo|Single dose of 4 placebo oral capsules
223799531|NCT03583554|DRUG|AV-101 720 mg|Single dose of 2 360 mg AV-101 oral capsules + 2 placebo oral capsules
223799532|NCT03583554|DRUG|AV-101 1440 mg|Single dose of 4 360 mg AV-101 oral capsules
223799533|NCT03178266|DEVICE|Knee Arthroplasty|Standard Knee Arthroplasty will be performed on study subjects. The closure method will be studied at 3 weeks and 6 weeks and patients will be asked about satisfaction with the closure method assigned.
223799534|NCT00223834|BEHAVIORAL|single session of Motivational Interviewing|
223799535|NCT05001100|OTHER|rehabilitation|rehabilitation
223799536|NCT00754026|PROCEDURE|Insertion of interscalene catheter for shoulder surgery|Distance of interscalene catheter: 2cm
223799537|NCT00754026|PROCEDURE|Insertion of interscalene catheter for shoulder surgery|Distance of interscalene catheter: 6cm
223799538|NCT03240848|PROCEDURE|artificial intelligent clinic|Participants in group A assigned to artificial intelligent clinic to get the initial diagnosis after the eye examinations, including images of ocular anterior segment.
223799539|NCT03240848|PROCEDURE|normal clinic|Participants in group B assigned to normal clinic to get the initial diagnosis after the eye examinations, including images of ocular anterior segment.
223799540|NCT03240848|PROCEDURE|experts diagnose|After making the initial diagnosis, participants went to get the final definite diagnosis from experts with more than 10 years of clinical experience.
223799541|NCT04050826|DRUG|Lidocaine 2.5% and Prilocaine 2.5% cream, USP (Actavis Pharma incorporated, USA)|Topical application
223799542|NCT04050826|DRUG|Lidocaine 2.5% and Prilocaine 2.5% cream (E. Fougera & Co. a division of Fougera Pharmaceuticals Inc., USA)|Topical application
223799543|NCT04050826|DRUG|Oraqix Parodontal-Gel (Dentsply Detrey GmbH, Germany)|Topical application
223799544|NCT04050826|DEVICE|Dermal open flow microperfusion|"Dermal open flow microperfusion will be used to collect interstitial fluid in order to assess lidocaine/prilocaine concentration in the dermis.~16 dOFM probes will be implanted per participant (8 test-sites; 2 dOFM probes per test-site).~From each dOFM probe 13 samples will be taken (1 pre-dose, 12 post-dose)."
223799545|NCT04050826|PROCEDURE|Blood sampling|1 sample will be taken pre-dose and 12 samples post-dose.
223799546|NCT00796770|BIOLOGICAL|Dendritic Cell Vaccine|"Biological/Vaccine: Experimental: Dendritic Cell Vaccine Patients will receive 4 doses of the vaccine at weeks 0, 4, 8 and 12. The vaccine will be injected subcutaneously, in 3 separate injection sites in the upper and lower extremities.~At week 24, patients will have HAART treatment interrupted. The HAART treatment will be resumed at week 48 or earlier at any time point if one of the following occur:~1. two consecutive measurements of CD4+ T cell count below 350x10e6 cells/L and/or 25% of total lymphocytes within at least a 2 weeks~2. an opportunistic infection~3. a CDC class C-defining event (defined in appendix 2)~4. a serious non-AIDS defining event.~Patients will have follow-up visits on weeks: 22, 24, 25, 26, 27, 28, 32, 36, 40, 44, and 48."
223799547|NCT04582474|OTHER|Dengue module and rapid diagnostic tests|Digital platform providing clinical decision support for Dengue, Dengue rapid diagnostic tests and training will be deployed at study sites for Dengue screening, diagnosis, case management as well as reporting to surveillance system following local guidelines
223799548|NCT00001926|DRUG|O15|
223799549|NCT00001926|DEVICE|Cadwell rTMS|
223799550|NCT02794376|BEHAVIORAL|Mindfulness Based Cognitive Therapy (MBCT)|
223799551|NCT02794376|BEHAVIORAL|Waiting Period|
223799552|NCT02087631|DRUG|Extended-release quetiapine fumarate|Dosing schedule for RRMS: Group 1: Day 1-3:50 mg Day 4-6:100 mg Day 7-28:150 mg Day 29-30:100mg Day 31-32:50mg; Group 2: Day 1-2:50 mg Day 3-4:150 mg Day 5-6:200 mg Day 7-28:300 mg Day 29-30:250mg Day 31-32:200mg Day 33-34:150mg Day 35-36:100mg Day 37-38:50mg; Group 3: Day 1:50 mg Day 2:100 mg Day 3:200 mg Day 4-28:300 mg Day 29-30:250mg Day 31-32:200mg Day 33-34:150mg Day 35-36:100mg Day 37-38:50mg Dosing schedule for progressive MS: Group 1: Day 1-14: 50 mg Day 15-28: 100 mg Day 29-30: 50mg; Group 2: Day 1-5: 50 mg Day 6-10: 100 mg Day 11-15: 150 mg Day 16-28: 200 mg Day 29-30: 150mg Day 31-32: 100mg Day 33-34: 50mg; Group 3: Day 1-5: 50 mg Day 6-10: 100 mg Day 11-15: 200 mg Day 16-28: 300 mg Day 29-30: 250mg Day 31-32: 200mg Day 33-34: 150mg Day 35-36: 100mg Day 37-38: 50mg
223799553|NCT04080050|DRUG|Single intravenous (IV) dose of human Low Density Lipoprotein Receptor (LDLR) Gene Therapy|No investigational product will be administered in this study. All participants have previously received a one-time intravenous infusion of RGX-501 in a separate clinical trial
223799554|NCT04840810|PROCEDURE|In-plane Axis|"In a long-axis view, the image plane is parallel to the course of the vessel (needle is in-plane). The image shows the course of the vessel across the screen and the shaft and point of the needle as it is advanced. The central venous cannulation was done in in-plane axis."
223799555|NCT04840810|PROCEDURE|Out of plane Axis|"In a short-axis view, the image plane is perpendicular to the course of the vessel and to the needle (needle is out of plane). The vessel appears as an anechoic circle on the screen of ultrasound with the needle visualized as a hyperechoic point in cross-section. The central venous cannulation was done in out of plane axis."
223799556|NCT06136975|DEVICE|Low-level laser therapy|The treatment was once a week for eight weeks. The patient was in a supine position. The gain medium of the laser was Gallium-Aluminum-Arsenide. The laser was introduced into vagina via a silicon vaginal probe inserted by a doctor for 30 minutes (wavelength 660nm, power density 18.17mW/cm2, energy density 0.018J/cm2s, total energy density 32.4J/cm2).
223799557|NCT02471196|DRUG|ORM-12741|ORM-12741 low dose twice a day
223799558|NCT02471196|DRUG|ORM-12741|ORM-12741 high dose twice a day
223799559|NCT02471196|DRUG|Placebo|Placebo twice a day
223799560|NCT00241579|DRUG|Smoked Cannabis|
223799561|NCT05417880|DRUG|Oral Hypoglycemic Agents,Oral|Control group with routine current oral hypoglycemic agents for 3-6 months
223799562|NCT05417880|DRUG|Voreta|Empagliflozin 10 mg oral tablets Once Daily for 3-6 months
223799563|NCT05417880|DRUG|Voreta plus SunnyD PRO|Empagliflozin 10 mg oral tablets + Vitamin D3 ( 2000 IU ) + Vitamin K2 ( 100 mcg) Once Daily for 3-6 months
223799564|NCT06580873|DRUG|DOVATO|HIV-1 medication
223799565|NCT03457519|DEVICE|Children's Automated Respiration Monitor (ChARM)|The Philips CHARM (children's automatic respiratory monitor) is specifically designed to detect pneumonia in low resource areas. The lightweight measuring device sits on a child's or infant's chest, secured by a strap and measures respiration rate (fast breathing) through an ingenious algorithm. In this study ChARM will be used as a self monitoring and teaching aide by the CHWS.
223799566|NCT02853890|OTHER|Questionnaires during hospitalization for delivery|Questionnaires during hospitalization for delivery (one questionnaire completed by doctors about different technic of analgesia and anesthesia and one questionnaire completed by women about pain, and feeling about the different techniques of analgesia and anesthesia used during delivery, eventually caesarean section or uterine revision)
223799567|NCT05970627|DRUG|Toripalimab|Perioperative Toripalimab, 240 mg IV infusion
223799568|NCT05970627|DRUG|Oxaliplatin|Oxaliplatin (130 mg/m2) infusion as perioperative chemotherapy
223799569|NCT05970627|DRUG|S1|S-1 orally intake as perioperative chemotherapy
223799570|NCT06347302|BIOLOGICAL|Blood sampling|Two tubes will be taken, the first tube (Tube 1) for specialised lipid analysis. The second tube (Tube 2) for routine biochemical analysis
223799571|NCT06347302|OTHER|vitreous sampling|Intra-operative vitreous sampling: systematic collection of the vitreous humour during vitrectomy for vitreoretinal surgery such as retinal detachment, epiretinal membranes and macular holes.
223799572|NCT06347302|OTHER|Sub-retinal fluid sampling|Sub-retinal fluid sampling consists of collecting the sub-retinal fluid that is systematically aspirated during retinal detachment surgery in order to dry the detached retina and allow retinopexy to be performed.
223799573|NCT06347302|OTHER|Retinal tissue sampling|cutting and aspiration of the retina using the vitreotome opposite the tear to allow access to the sub-retinal fluid.
223799574|NCT02342886|DRUG|Moxifloxacin|Oral
223799575|NCT02342886|DRUG|PA-824|Oral
223799576|NCT02342886|DRUG|Pyrazinamide|Oral
223799577|NCT02342886|DRUG|HRZE (Rifampicin, Isoniazid, Pyrazinamide, Ethambutol combination)|Oral
223799578|NCT02342886|DRUG|HR (rifampicin plus isoniazid combination tablets)|Oral
223799579|NCT04160325|DIETARY_SUPPLEMENT|postoperative 3-month exclusive enteral nutrition|postoperative 3-month exclusive enteral nutrition after surgery and alter to normal food after 3 months
223799580|NCT04160325|DRUG|azathioprine|azathioprine
223799581|NCT04160325|OTHER|normal diet|normal diet
223799582|NCT01025440|DEVICE|Continuous Positive Airway Pressure|"Continuous Positive Airway Pressure (CPAP) Dose: A flow (35 L/min) or pressure (btw 4 and 20 cmH20 -individual to each subject) is set on the device.~Duration: 1 night - the duration of the subject's sleep period (minimum of 3 hrs of sleep required)~Duration:"
223799583|NCT01319266|DRUG|Hydrocodone Bitartrate extended-release tablet|Hydrocodone bitartrate extended-release oral tablet will be administered at a dose of 45 mg and dosed one time on Day 1. Subjects will also be dosed with naltrexone hydrochloride to block opioid effects.
223799584|NCT00285142|DRUG|rosiglitazone|
223799585|NCT01328080|RADIATION|Targeted UV-B|Daavlin Lumera phototherapy device (290-320 nm), dosed by patients' individual minimal erythema dose (MED)
223799586|NCT00862134|DRUG|PR104|770 mg/m\^2, IV, every 21 days. Number of Cycles: until progression or unacceptable toxicity develops.
223799587|NCT00862134|DRUG|docetaxel|75 mg/m\^2, IV, every 21 days. Number of Cycles: until progression or unacceptable toxicity develops.
223799588|NCT00862134|DRUG|docetaxel|60 mg/m\^2, IV, every 21 days. Number of Cycles: until progression or unacceptable toxicity develops.
223799589|NCT00862134|DRUG|Granulocyte colony-stimulating factor|Subjects randomized to PR104/docetaxel will receive prophylactic G-CSF per package insert administration recommendations. Number of Cycles: until progression or unacceptable toxicity develops.
223799590|NCT06236750|DEVICE|EPIFIX|EPIFIX® is an allograft derived from dehydrated human amnion/chorion membrane. EPIFIX is a medical device in Japan (Generic name: Material using human amniotic membrane for promotion of tissue healing) for use on intractable ulcers that are non-responsive to existing therapies for the purpose of promoting wound healing.
223799591|NCT02414542|DEVICE|MINIMA stem|
223799592|NCT05776173|GENETIC|BD211|Genetically modified CD34+ autologous stem cells were transfused intravenously with single dosing.
223799593|NCT02191267|RADIATION|[F18]-T807|\[F18\]-T807 PET Scan to measure tau deposition in the brain.
223799594|NCT02191267|RADIATION|[F18]-Florbetapir|\[F18\]-Florbetapir PET scan to measure Beta-amyloid deposition in the brain.
223799595|NCT02191267|DEVICE|MRI/MRS|Two scans (structural, diffusion tensor imaging, and susceptibility weighted imaging scanned as part of one MR protocol, and a one-dimensional and two-dimensional spectroscopy examination as part of the other MR protocol.
223799596|NCT02191267|GENETIC|Genetic Analysis for Genetic Risk Score for Tau.|DNA will be extracted from previously acquired and de-identified frozen blood specimens using a standard protocol (Gentra Puregene Kit, Qiagen 158422). Genotyping will be performed using the iPLEX Sequenom MassARRAY platform and samples will be genotyped for single nucleotide polymorphisms (SNPs) associated with the deposition of neurofibrillary tangles.
223799597|NCT04967235|OTHER|Conventional Exercise-based Cardiac Rehabilitation Session|"This session will be composed of:~I.10 minutes of initial rest in the supine position; II. 15 minutes of warm-up through stretching and global exercises; III. 30 minutes of treadmill aerobic exercise at an intensity of 60-80% of the heart rate reserve for those without diabetes Mellitus and 40-70% of the heart rate reserve for those diagnosed with diabetes mellitus; IV. 1 minute passive recovery in orthostatic position; V. 30 minutes of passive recovery in the supine position."
223799598|NCT04967235|OTHER|Dance-based Cardiac Rehabilitation Session|I.10 minutes of initial rest in the supine position; II. 15 minutes of warm-up through stretching and global exercises; III. 30 minutes of dance therapy. The intensity of the choreography will be set at the same range as the conventional exercise-based session. (60-80% of the heart rate reserve for those without diabetes Mellitus and 40-70% of the heart rate reserve for those diagnosed with diabetes mellitus); IV. 1 minute passive recovery in orthostatic position; V. 30 minutes of passive recovery in the supine position.
223799599|NCT01871831|DEVICE|6 blood glucose monitoring systems for self-testing|
223799600|NCT06262568|OTHER|assess the nurse knowledge and practices.|assess the nurse knowledge and practices.
223799601|NCT00765674|DRUG|Aliskiren|150 and 300 mg tablets
223799602|NCT00765674|DRUG|Amlodipine|5 and 10 mg capsules
223799603|NCT00765674|DRUG|Hydrochlorothiazide (HCTZ)|12.5 and 25 mg capsules
223799604|NCT00765674|DRUG|Placebo|tablet
223799605|NCT00765674|DRUG|Placebo|capsules
223799606|NCT02560948|BIOLOGICAL|Placebo solution|4 x 2 injections over 21 days
223799607|NCT02560948|BIOLOGICAL|gpASIT+TM|4 x 2 injections over 21 days
223799608|NCT05072873|DRUG|Topical tranexamic acid|temporary uterine packing with gauze of the dimensions soaked with 2 gm tranexamic diluted in 60ml saline acid
223799609|NCT05072873|OTHER|normal saline|temporary uterine packing with gauze of the dimensions soaked with 2 gm placebo to tranexamic diluted in 60ml saline acid
223799610|NCT00360438|DRUG|Rasburicase|0.15mg/kg intravenously over 30 minutes once per day for 5 consecutive days.
223799611|NCT01813474|DRUG|olaparib|tablet oral
223799612|NCT02186210|DEVICE|prewarming|recovery slope StO2
223799613|NCT00316082|DRUG|Saxagliptin|Coated tablets, Oral, 2.5 mg, QAM, Daily (6 months ST, 12 months LT)
223799614|NCT00316082|DRUG|Saxagliptin|Coated tablets, Oral, 2.5 mg titrated to 5mg, QAM, Daily (6 months ST, 12 months LT)
223799615|NCT00316082|DRUG|Saxagliptin|Coated tablets, Oral, 5mg, QAM, Daily, (6 months ST, 12 months LT)
223799616|NCT00316082|DRUG|Saxagliptin|Coated tablets, Oral, 5mg QPM, Daily (6 months ST, 12 months LT)
223799617|NCT00316082|DRUG|Placebo|Coated tablets, Oral, 0mg, Daily (6 months ST, 12 months LT)
223799618|NCT00316082|DRUG|metformin|Tablets, Oral, 500-2000 mg, as needed (12 months LT)
223799619|NCT01011829|DRUG|Varenicline|Varenicline dosing will follow that which has been shown to be effective for cigarette smoking cessation. Varenicline dose will start at 0.5 mg daily for days 1-3, followed by 0.5 mg twice daily for days 4-7, followed by 1 mg twice daily from day 8 until completion of the medication period (end of week 8).
223799620|NCT01011829|DRUG|Placebo|Placebo dose will start at 0.5 mg (sugar pill) daily for days 1-3, followed by 0.5 mg twice daily for days 4-7, followed by 1 mg twice daily from day 8 until completion of the medication period (end of week 8).
223799621|NCT00528775|DRUG|HPPH|4 mg/m2 IV
223799622|NCT00528775|PROCEDURE|endoscopic procedure|Treatment with 150 joules from laser
223799623|NCT04605796|COMBINATION_PRODUCT|Toripalimab combined with Bevacizumab|"Experimental group:~Toripalimab, 240mg, IV infusion, every 3 weeks (q3w). combined with Lenvatinib 15 mg/kg (IV infusion, every 3 weeks (q3w).. Continuous infusion, in a cycle of 3 weeks (21 days), until occurrence of termination event specified in the protocol."
223799624|NCT05361226|OTHER|Accuracy measurement|"Three months following the implant placement, patients were called back to the implant clinic to record the actual implant position with the digital impression technique. Full mouth scans were done by using the intraoral scanner (Trios 3, 3Shape, Copenhagen, Denmark). The surface scans were then exported as an STL file and were imported to coDiagnostiX software. The Treatment evaluation tool function tool was used to measure the accuracy of the implant placement which measured the amount of deviation of the placed implant from the planned position. The outcomes were generated into three main parameters."
223799625|NCT01121068|OTHER|Blood samplings|About 3.5ml of blood will be drawn from the participants monthly.
223799626|NCT01826812|OTHER|30 minutes sustained reading|The participants will be given a text to read silently in 30 minutes.
223799627|NCT01826812|OTHER|Dry eye exam|Tear break-up time, tear collection, osmolarity, Schirmer test, corneal and conjunctival staining.
223799628|NCT05117138|BIOLOGICAL|AMT-116 CAR-T cells|"1. Classical 3+3 dose escalation will be applied to 9 subjects with moderate or far advanced non-small cell lung carcinoma (NSCLC) enrolled.~2. Classical 3+3 dose escalation will be applied to 9 subjects with moderate or far advanced head and neck Squamous Cell Carcinoma (HNSCC) enrolled."
223799629|NCT05117138|BIOLOGICAL|AMT-253 CAR-T cells|"1.The classic 3 + 3 dose escalation will be applied to 9 selected subjects with moderate or far advanced melanoma by intravenous drip.~2.3 \~ 6 patients with intermediate and advanced melanoma will be injected intratumorally at a dose of ≤ 1 × 10\^8 cells.~3.3 \~ 6 patients with operable advanced melanoma will be treated with postoperative adjuvant treatment at a dose of ≤ 1 × 10\^8 cells ≤ intravenous drip on Day 1 of each 42 days cycle (8 cycle maximum)."
223799630|NCT01955954|DEVICE|Canary Breathing System|The Canary Breathing System is a biofeedback device meant to assist patients in the re-training of abnormal breathing patterns.
223799631|NCT04901650|DIAGNOSTIC_TEST|Survey|A survey will be administered to find out the prevalence of pain in hospitalized patients for any cause and its intensity. The medical history will be reviewed to assess the presence of pain medications and their impact on the pain perception and patients' satisfaction.
223799632|NCT00276640|DRUG|vincristine, carboplatin|"vincristine: 1,5 mg/m² i.v., week 1,2,3,4,5,6,7,8,9,10,13,17,21~carboplatin: 550 mg/m² i.v., week 1,4,7,10,13,17,21"
223799633|NCT00276640|DRUG|vincristine, carboplatin, etoposide|"vincristine: 1,5 mg/m² i.v., week 1,2,3,4,5,6,7,8,9,10,13,17,21~carboplatin: 550 mg/m² i.v., week 1,4,7,10,13,17,21~etoposide: 100 mg/m² i.v., week 1,4,7,10"
223799634|NCT00276640|RADIATION|radiation therapy|"intracranial tumor site: 30 fractions, dose per fraction: 1.8 Gy, total dose: 54 Gy, duration 6 weeks~spinal tumor site: 28 fractions, dose per fraction: 1.8 Gy, total dose: 50.4 Gy duration 5 1/2 weeks"
223799635|NCT05435274|DRUG|HS-10376|HS-10376 will be administered orally once daily in a continuous regimen
223799636|NCT02426788|BEHAVIORAL|Cognitive behavioural therapy (CBT)|Behavioral: Cognitive behavioural therapy (CBT) The CBT intervention used in the trial has been adapted for people with PPS and it is based on a model of understanding PPS (Deary et al 2007). The therapy aims to help the patient develop an understanding of the relationship between cognitive, physiological and behavioural aspects of their problem; to understand factors that may be maintaining the problem and to learn how to modify their behavioural and cognitive responses in order to improve quality of life. The approach is transdiagnostic in that it targets processes and underlying mechanisms that affect disorders similarly, rather than focusing on how they are diagnostically different. The approach is personalised during therapy following a detailed assessment.
223799637|NCT03185533|BEHAVIORAL|Quality improvement (QI) interventions|"1\. The ED admissions exhibited prolonged length of stay.~2\. The Interventions for Reducing Medical Decision Time:~1. The ED director created QI education sessions and reported monthly QI outcomes.~2. The ED nurses reported the current number of ED admission patients twice a day to the director. The director summarized the bed requests to the administrative personnel.~3. The nurses reported the in-scene complicated cases to the ED director. The director would give an assistance in managing these cases.~3\. The Interventions for Reducing Boarding Time~1. The ED patients could be admitted before 8 a.m. if the bed was vacant.~2. The ED director initiated an on-line meeting at 8 a.m. and 4 p.m.~3. Monthly QI outcomes were reported in the hospital affairs meeting."
223799638|NCT01509222|BEHAVIORAL|Personalized nutrition counseling|
223799639|NCT03356379|DIAGNOSTIC_TEST|Transcutaneous oximetry|Measurement of TcpO2 on calves and chests. Calculation of the DROP index (decrease from rest of oxygen pressure)on both calves
223799640|NCT01383733|DRUG|RO5458640|Multiple ascending doses intravenously, weekly or every 2 weeks or every 3 weeks
223799641|NCT00417352|DEVICE|Brace|
223799642|NCT00417352|DEVICE|Added mass|
223799643|NCT05959993|BEHAVIORAL|Human Care Model Based Nursing Interventions|The interviews scheduled for the intervention group were organized in accordance with the sub-dimensions of the PAIS-SR scale, and the content of each interview was informed by the 10 improvement processes of HCT.
223799644|NCT01403896|DRUG|Plerixafor (Mozobil)|They will receive Plerixafor (240 µg/kg/day subcutaneously for 1 dose) on Day 0 at 8 am
223799645|NCT01403896|DRUG|Plerixafor + G-CSF|They will receive G-CSF (5 µg/kg/day) for 4 days (Days -4,-3,-2,-1 at 8 am) followed by Plerixafor (240 µg/kg/day subcutaneously for 1 dose) on Day 0 at 8 am
223799646|NCT00914329|DRUG|Gelsemium Sempervirens|5CH, one dose of globules morning and evening during 2 days plus one dose the morning of the day of the stress-test.
223799647|NCT00914329|DRUG|Gelsemium Sempervirens|15CH, one dose of globules morning and evening during 2 days plus one dose the morning of the day of the stress-test.
223799648|NCT00914329|DRUG|Placebo|placebo, one dose of globules morning and evening during 2 days plus one dose the morning of the day of the stress-test.
223799649|NCT05965687|PROCEDURE|Normobaric Hyperoxia|Within 4.5 hours after stroke onset, patients were randomized into the NBO group and immediately given 100% oxygen inhalation (no more than 30 minutes after randomization) at a ventilation rate of 10L/ min using a sealed non-ventilating oxygen storage mask and keep giving oxygen for 4 hours. If the patient needs to be intubated with a ventilator to maintain ventilation, the FiO2 should be set to 1.0.
223799650|NCT05965687|PROCEDURE|Nasal oxygen|For nasal oxygen group, patients were immediately given oxygen inhalation (no more than 30 minutes after randomization) at a ventilation rate of 1L/min using nasal cannula and keep giving oxygen for 4 hours. If the patient needs to be intubated with a ventilator to maintain, the FiO2 should be set to 0.3 and gradualy incerased if spO2≤94%.
223799651|NCT05965687|DRUG|Intravenous thrombolysis(rt-PA)|10% dose of rt-PA (0.9 mg/kg) is given as bolus and the rest given as an infusion over the remaining 1 hour. Maximum dose 90mg.
223799652|NCT05637840|OTHER|Urine sample|Collection of 36-84 urine samples over a 14 consecutive day period.
223799653|NCT05637840|OTHER|Sleep restriction|Participants will be asked to limit their sleep to 4 hours within a 24-hour period for 2 days in a row.
223799654|NCT00384904|DRUG|Atazanavir/Ritonavir|Capsules/capsules, Oral, 300/100 mg, Once daily, 10 days.
223799655|NCT00384904|DRUG|Atazanavir/Ritonavir + Famotidine|Capsules/capsules + Tablets, Oral, 300/100 mg + 40 mg, Once daily + Twice daily, 7 days.
223799656|NCT00384904|DRUG|Atazanavir/Ritonavir + Famotidine|Capsules/capsules + Tablets, Oral, 300/100 mg + 20 mg, Once daily + Twice daily, 7 days.
223799657|NCT00384904|DRUG|Atazanavir/Ritonavir|Capsules/capsules + Tablets, Oral, 300/100 mg, Once daily, 10 days.
223799658|NCT00384904|DRUG|Atazanavir/Ritonavir + Tenofovir Disproxil Fumrarate + Famotidine|Capsules/capsules + Tablets + Tablets, Oral, 300/100 mg + 300 mg + 40 mg, Once daily + Twice daily, 7 days.
223799659|NCT00384904|DRUG|Atazanavir/Ritonavir + Tenofovir Disproxil Fumrarate + Famotidine|Capsules/capsules + Tablets + Tablets, Oral, 300/100 mg + 300 mg + 20 mg, Once daily + Twice daily, 7 days.
223799660|NCT01245010|OTHER|Water|Water and education will be provided
223799661|NCT01245010|OTHER|Education|Education
223799662|NCT01163097|DRUG|Palifermin|40 µg/kg IV bolus injections for three consecutive days
223799663|NCT01163097|DRUG|Heparin|Heparin continuous IV infusion
223799664|NCT06079905|OTHER|Nonoperative treatment|Nonoperative treatment
223799665|NCT06079905|OTHER|Operative treatment|Operative treatment
223799666|NCT00208143|DRUG|Quetiapine|
223799667|NCT00208143|DRUG|Risperidone|
223799668|NCT01921296|DRUG|Cyclobenzaprine|5 milligrams orally 2 hours before bedtime
223799669|NCT01569438|DRUG|Gefapixant|50 or 300 mg tablets for a total daily dose of 50, 100, 150, 200, 250 or 300 mg BID, orally with food for 4 weeks
223799670|NCT01569438|DRUG|Placebo|Dose matched placebo tablets, BID, orally, with food for 4 weeks
223799671|NCT01429480|PROCEDURE|Preoperative Ultrasound Guided Ilioinguinal/Iliohypogastric Block|
223799672|NCT01429480|PROCEDURE|Preoperative Ultrasound Guided Posterior TAP Block|
223799673|NCT01429480|DRUG|Patient controlled analgesia|
223799674|NCT02959632|BEHAVIORAL|Animal Assisted Therapy|Animal Assisted Therapy is the program where a pet, usually dog will visit and interact with the patients.
223799675|NCT04667312|DRUG|Durvalumab|Durvalumab
223799676|NCT04459390|DIAGNOSTIC_TEST|realtime PCR|Detection of SARS-CoV-2 genes by realtime PCR
223799677|NCT00404365|OTHER|counseling intervention|
223799678|NCT00404365|OTHER|screening questionnaire administration|
223799679|NCT00404365|OTHER|study of socioeconomic and demographic variables|
223799680|NCT00404365|PROCEDURE|psychosocial assessment and care|
223799681|NCT00668902|DRUG|[13C]Pantoprazole|\[13C\]Pantoprazole was administered to EM, IM and PM of CYP2C19 and enzyme activity was measured through breath test and compared among the genotypes
223799682|NCT02316964|DRUG|decitabine|20 mg/m2 Given IV (intravenous) for 5 days over 60 minutes
223799683|NCT02316964|BIOLOGICAL|natural killer cell therapy|Undergo infusion of allogeneic NK cells on day 0
223799684|NCT02316964|BIOLOGICAL|aldesleukin|Given SC
223799685|NCT02316964|OTHER|laboratory biomarker analysis|Correlative studies
223799686|NCT03655769|DEVICE|transcranial direct current stimulation|transcranial direct current stimulation applied at 2 mA over the right parietal region for 20 min
223799687|NCT03655769|DEVICE|sham transcranial direct current stimulation|transcranial direct current stimulation applied at 2 mA over the right parietal region for 30 sec
223799688|NCT04136886|DRUG|Cisplatin|cisplatin is to give from the first Day of radiation therapy D1,D22 Q3W for 2 cycles Radiation: IMRT IMRT is to give 60Gy in 27 fraction
223799689|NCT04136886|RADIATION|IMRT|Radiation: IMRT IMRT is to give 60Gy in 27 fraction
223799690|NCT06216054|DRUG|LPM3770164 sustained release tablet|administrated orally
223799691|NCT06216054|DRUG|LPM3770164 sustained release tablet simulant|administrated orally
223799692|NCT01221987|PROCEDURE|Cervical sampling|Cervical biopsy or excision specimen testing for human papillomavirus deoxyribose nucleic acid types
223799693|NCT01221987|OTHER|Data collection|Questionnaire completion
223799694|NCT04262518|DEVICE|Outcomes4Me Mobile App|A mobile app that provides patient navigation and treatment and clinical trial options to people with breast cancer
223799695|NCT01159054|DRUG|Extended Release Nicotinic Acid (Niaspan)|Subjects will start on 500 mg per day of Niaspan for 4 weeks, then the dose will be increased to 1000 mg per day of Niaspan for 4 weeks, then the dose will be increased to 1500 mg of Niaspan per day for 4 weeks, after this subjects with weight of less than 60 kg will continue at 1500 mg per day of Niaspan for another 12 weeks whereas in subjects with weight of more than 60 kg the dose will be increased to 2000 mg of Niaspan per day which will be continued for 12 weeks.
223799696|NCT00905918|DIETARY_SUPPLEMENT|vitamin E|Given orally
223799697|NCT00905918|OTHER|laboratory biomarker analysis|All patients undergo biomarker analyses
223799698|NCT02382198|DRUG|Glycopyrrolate|Drug to reduce drooling in patients with Parkinson's Decease.
223799699|NCT02382198|DRUG|Placebo|
223799700|NCT00305799|PROCEDURE|management of therapy complications|Patients will complete three self-reported questionnaires including the Peripheral Neuropathy Scale, Hearing Handicap Inventory for Adults, and Dizziness Handicap Inventory. Patients will also be asked a series of questions regarding symptoms or complaints about hearing changes, tinnitus, and dizziness that they may have experienced prior to, during, and after completion of chemotherapy. Patients will also undergo a hearing test.
223799701|NCT05258786|BEHAVIORAL|Pre-labor ultrasound as a visual biofeedback device for maternal pushing education and pelvic floor training|"1. Ultrasound examination with the screen turned to the provider will assess the bladder movements at rest and during contraction of the pelvic floor and fetal head descent at rest and during pushing.~2. The provider will turn the screen to the patient and explain the anatomical landmarks: bladder, fetal head, birth canal direction.~3. A repeat of the first stage (1) with the screen turned to the patient: the biofeedback process. Bladder displacement will serve as a marker of pelvic floor contraction, and the delta in the progression angle will serve as a marker for effective pushing.~4. Finally, the provider will turn the screen again from the patient and repeat the first stage."
223799702|NCT01774513|DEVICE|Procore-Needle|
223799703|NCT01356355|DRUG|Herbmed plus|one capsule of herbmed plus orally twice a day with meals till the ureteral stent is in situ.
223799704|NCT01356355|DRUG|Placebo|One capsule twice a day daily till ureteral stent in situ
223799705|NCT01356355|DRUG|Tolterodine|One capsule twice a day daily till ureteral stent in situ
223799706|NCT03097705|DIAGNOSTIC_TEST|OCT (Optical coherence tomography)|RNFL AND IOP MEASUREMNTS
223799707|NCT01769300|BEHAVIORAL|Clinical decision support for medication titration|Electronic health record-based clinical decision support for ADHD medication titration.
223799708|NCT00990990|DRUG|PNU-100480|100 mg BID for 14 days
223799709|NCT00990990|DRUG|Placebo|to match 100 mg BID for 14 days
223799710|NCT00990990|DRUG|PNU-100480|300 mg BID for 14 days
223799711|NCT00990990|DRUG|Placebo|to match 300 mg BID for 14 days
223799712|NCT00990990|DRUG|PNU-100480|600 mg BID for 14 days
223799713|NCT00990990|DRUG|Placebo|to match 600 mg BID for 14 days
223799714|NCT00990990|DRUG|PNU-100480|1200 mg QD for 14 days
223799715|NCT00990990|DRUG|Placebo|to match 1200 mg QD for 14 days
223799716|NCT00990990|DRUG|PNU-100480|600 mg BID for 28 days with pyrazinamide (25 mg/kg up to 2 g) QD on Days 27-28
223799717|NCT00990990|DRUG|Placebo|placebo to match 600 mg BID for 28 days with pyrazinamide (25 mg/kg up to 2 g) QD on Days 27-28
223799718|NCT00990990|DRUG|PNU-100480|PNU-100480 dose up to total of 1200 mg daily for 28 days with pyrazinamide (25 mg/kg up to 2 g) QD on Days 27-28
223799719|NCT00990990|DRUG|Placebo|placebo to match dose up to total of 1200 mg daily for 28 days with pyrazinamide (25 mg/kg up to 2 g) QD on Days 27-28
223799720|NCT00990990|DRUG|Linezolid|300 mg QD for 4 days (open label)
223799721|NCT01825681|BEHAVIORAL|Positive Affect|Six-session skill-building program designed to raise levels of positive emotion when skills are practiced over the duration of the program.
223799722|NCT02432105|DRUG|EXE844 Sterile Otic Suspension, 0.3%|
223799723|NCT02432105|PROCEDURE|Tympanostomy Tube Insertion|Surgical procedure for treating pediatric cases of recurrent or chronic otitis media
223799724|NCT01947465|BIOLOGICAL|Hepatitis A vaccine and tetanus vaccine|Hepatitis A and/or tetanus vaccination will be given to participants in all group on day 0. All monovalent active hepatitis A vaccinations and all vaccines containing tetanus toxoid available in Switzerland may be used in the study
223799725|NCT04718428|DIAGNOSTIC_TEST|Nail Ultrasonography|The MyLab 60 (Esaote Biomedica Genoa, Italy) device and linear probe were used. Nails were examined in B-mode grayscale and power Doppler.
223799726|NCT00004339|DRUG|tetrathiomolybdate|
223799727|NCT00004339|DRUG|trientine|
223799728|NCT06560047|PROCEDURE|Catheter ablation|Catheter ablation with pulmonary vein isolation will be the study intervention. Patients randomized to the intervention arm will undergo catheter ablation within six weeks of randomization. In the waiting-time for ablation, patients will receive standard treatment for AF and HF, as per current guideline recommendations. Catheter ablation will be performed at one of six high-volume ablation centers in Denmark. Mode of catheter ablation will be at the discretion of the operator. Radiofrequency ablation, cryo-balloon ablation and pulsed-field ablation will be utilized. The treating physician should ensure successful pulmonary vein isolation after ablation with either post-procedural mapping or pacing, as per current standards. Only pulmonary vein isolation will be performed during the ablation procedure.
223799729|NCT01005940|DEVICE|Mandibular advancement device|Mandibular advancement device made to subject specific specifications
223799730|NCT03860857|RADIATION|Amyloid PET scan|Amyloid Positron Emission Tomography scan using radio tracer florbetapir-F18
223799731|NCT03860857|DRUG|Tau PET scan using MK-6240|Tau Positron Emission Tomography scan using radio tracer MK-6240
223799732|NCT03860857|BEHAVIORAL|Neurocognitive testing|A battery of clinical neuropsychological assessments and computerized cognitive tasks will be used to test participants' memory and cognitive abilities.
223799733|NCT03860857|OTHER|MRI|High-resolution structural, functional, and diffusion Magnetic Resonance Imaging scans will be collected during the study.
223799734|NCT05356806|OTHER|Supportive periodontal and periimplant care|"Periodontal and peri-implant maintenance therapy will be carried out at baseline, 3 and 6-month visit. This session will include the removal of biofilm and calculus on teeth and implants (except those that have just been restored) with an ultrasonic device using a plastic tip ( for implants. and a conventional metal tip ( for teeth. At the end, polishing will be done with a rubber cup~Subsequently, patients will be explained that they must continue with their usual oral hygiene technique on their teeth, using the same type of brush (which can be electric or manual), interproximal devices, toothpaste or mouthwash used to date. Finally, they will receive specific instructions for the supragingival biofilm control in the area of the new restoration and will be given interdental brushes that suit to the space"
223799735|NCT03965897|BEHAVIORAL|Acceptance and Committment Therapy (ACT)|Overall, the goal of the ACT intervention is to cultivate psychological flexibility: to help Veterans respond to life events in ways which do not exacerbate difficulties or restrict engagement in meaningful activities. It increases patients' awareness of behaviors that exacerbate the pain (such as struggling with it) and recognition of avoidance strategies that interfere with life engagement.
223799736|NCT03965897|OTHER|Attention Control (AC)|Information on any other coping practices will be omitted. The group facilitators will present one topic at a time, using the Pain Manual, and the participants will discuss and reflect about issues and experiences related to each topic. If necessary, the group facilitators will raise specific discussion questions to facilitate group dialogue and participant involvement.
223799737|NCT06559501|BEHAVIORAL|Integrated case manager care|comprises 8 sessions delivered by case managers. Case managers will provide up to 6 low-intensity sessions in the hospital or the community (if the patient is discharged before completing the required sessions), with content and duration tailored to patient preferences. Post-discharge, patients will receive 2 follow-up sessions with case managers to ensure a smooth transition into the community.
223799738|NCT02228265|OTHER|Cytology Specimen Collection Procedure|Undergo blood and tissue collection
223799739|NCT02228265|DRUG|Enzalutamide|Given PO
223799740|NCT02228265|OTHER|Laboratory Biomarker Analysis|Correlative studies
223799741|NCT06470321|BEHAVIORAL|Flexiquit Computerized Smoking Cessation Program|Flexiquit is an avatar-led, self-directed computerized program delivering evidence-based techniques to assist with smoking cessation. It includes motivational interviewing, psychoeducation on nicotine addiction, cognitive-behavioral strategies for coping with cravings, relapse prevention, and stress/emotion regulation skills training. Participants receive the program over 6 months and their adherence is monitored. The program provides tailored feedback to support abstinence.
223799742|NCT00233922|DEVICE|Osteosheet(r)|
223799743|NCT00000154|PROCEDURE|Vitrectomy|
223799744|NCT05618795|OTHER|minimal gap arthoplasty v/s aggressive gap arthoplasty|Comparative evaluation of aggressive gap arthroplasty with minimal gap arthroplasty in the management of TMJ ankylosis
223799745|NCT01400503|DRUG|Siltuximab|Type=exact number, unit=mg/kg, number=11, form=intravenous solution, route=intravenous. Siltuximab given as a 1-hour infusion every 3 weeks.
223799746|NCT00058123|DRUG|poly ICLC|
223799747|NCT01525732|PROCEDURE|Per Oral Endoscopic Myotomy|
223799748|NCT03494387|DRUG|Oxygen|80% versus 30% inspiratory oxygen concentration
223799749|NCT03494387|DRUG|Antioxidants|Antioxidants versus placebo
223799750|NCT01767740|DEVICE|ULTRABRAID PLUS SUTURE|Rotator Cuff Repair with ULTRABRAID PLUS SUTURE
223799751|NCT01767740|DEVICE|ULTRABRAID SUTURE|Rotator Cuff Repair with ULTRABRAID SUTURE
223799752|NCT01936025|DRUG|Dextromethorphan|
223799753|NCT01936025|DRUG|Sitagliptin|
223799754|NCT01936025|DRUG|Placebo|
223799755|NCT04682496|PROCEDURE|Intratendon vascularization|Ultrasonic exploration by power-Doppler of the intratratendon vascularization, making longitudinal cuts of the patellar tendon and with previously pre-established Doppler optimization parameters for all patients. The optimization parameters of the power-Doppler signal will be set at a Doppler frequency of 6.7 MHz, pulse repetition frequency (PRF) of 0.7 kHz. The lowest wall filter and a standardized gain just below the level that produces random noise will be applied. This examination will be repeated several times with different probe pressures, which will be quantitatively adjusted through the force sensor and maintained with the articulated arm. A 4-second static video will be recorded of the longitudinal section that presents a higher Doppler signal in each of the scans at different probe pressures.
223799756|NCT01212770|DRUG|Apremilast 20mg|Apremilast 20 mg twice daily, orally
223799757|NCT01212770|DRUG|Apremilast 30mg|Apremilast 30 mg twice daily, orally
223799758|NCT01212770|DRUG|Placebo|
223799759|NCT03581812|DIETARY_SUPPLEMENT|Intervention snack 1|To be eaten instead of regular snacks twice a day for 4 weeks.
223799760|NCT03581812|DIETARY_SUPPLEMENT|Intervention snack 2|To be eaten instead of regular snacks twice a day for 4 weeks.
223799761|NCT03581812|DIETARY_SUPPLEMENT|Control snack|To be eaten instead of regular snacks twice a day for 4 weeks.
223799762|NCT01970826|PROCEDURE|Single Dental Implants|place single unit dental implants, 2 mm below crestal bone and follow manufacturer guidelines.
223799763|NCT01970826|PROCEDURE|Sterilized Aseptic|Operatory room will be prepared totally aseptic
223799764|NCT01970826|PROCEDURE|Sterilized Clean|Operatory room will be prepared clean but not aseptic
223799765|NCT01970826|PROCEDURE|Full-Mouth Dental Implants|dental implants for full-mouth implant rehabilitation.
223799766|NCT01970826|PROCEDURE|Partial Rehabilitation|two or more implants to support partial rehabilitation
223799767|NCT01970826|PROCEDURE|Duration of Surgery|it will be measure the amount of time to perform the dental implant surgery. It will be measured from the time that the surgeon does the first incision until the last suture is made.
223799768|NCT03717961|DRUG|BOTOX® solution|Botox solution + Saline serum + lidocaine/prilocaine cream + Nitrous oxide/oxygen (50%/50%)
223799769|NCT03717961|DRUG|Placebo group|Placebo + lidocaine/prilocaine cream + Nitrous oxide/oxygen (50%/50%)
223799770|NCT06285877|PROCEDURE|Conventional therapy sessions|Conventional sessions are neuropsychology, speech therapy, physiotherapy and occupational therapy treatments. They are based on cognitive stimulation, manipulative dexterity, therapeutic exercise.
223799771|NCT06285877|PROCEDURE|Conventional therapy sessions plus Nintendo Switch|Conventional sessions are neuropsychology, speech therapy, physiotherapy and occupational therapy treatments. They are based on cognitive stimulation, manipulative dexterity, therapeutic exercise plus one hour a week of Nintendo Switch.
223799772|NCT04728321|BIOLOGICAL|AK104 lenvatinib|Subjects will receive AK104 and lenvatinib until disease progression or for a maximum of 24 months
223799773|NCT04728321|BIOLOGICAL|AK104|Subjects will receive AK104 until disease progression or for a maximum of 24 months
223799774|NCT02243943|DRUG|Sugammadex|
223799775|NCT02243943|DRUG|Neostigmine|
223799776|NCT05242328|PROCEDURE|Ultrasound-guided erector spinae plane block|Ultrasound-guided erector spinae plane block
223799777|NCT05242328|PROCEDURE|surgical thoracoscopic intercostal nerve block|surgical thoracoscopic intercostal nerve block
223799778|NCT04440566|BIOLOGICAL|blood sample|30 ml whole blood for Peripheral blood mononuclear cell (PBMC) and monocytes isolation
223799779|NCT02339831|DEVICE|CAMOPED|Camoped given after surgery
223799780|NCT02339831|DEVICE|CPM passive motion device|passive motion device given after surgery
223799781|NCT05189730|DRUG|Tirelizumab|Two cycles of Tirelizumab (200mg administered as an intravenous infusion over 30 minutes per 3 weeks), D1.
223799782|NCT05189730|DRUG|Paclitaxel|Two cycles of paclitaxel (135mg/m2 administered as an intravenous infusion per 3 weeks), D1.
223799783|NCT05189730|DRUG|Carboplatin|Two cycles of carboplatin(AUC=5 administered as an intravenous infusion per 3 weeks) D1.
223799784|NCT05189730|RADIATION|Neoadiuvant radiotherapy|Simultaneous radiotherapy would be consecutively performed for 4 weeks with the total dose of 40Gy (40Gy/ 4W /20F), D1.
223799785|NCT01458197|DRUG|Tarafenacin 0.2 mg|Capsule, qd, 12 weeks
223799786|NCT01458197|DRUG|Placebo|Capsule, qd, 12 weeks
223799787|NCT01458197|DRUG|Tarafenacin 0.4 mg|Capsule, qd, 12 weeks
223799788|NCT05777226|DRUG|Epalrestat|Patients in the treatment group are intervened with Epalrestat tablets.
223799789|NCT02297022|DEVICE|Deep Brain Stimulation|Deep Brain Stimulation hypothalamic surgery in patients with Prader-Willi syndrome
223799790|NCT01767558|OTHER|Ablation / MRI|"All subjects will undergo a standard of care ablation procedure for paroxysmal AF with the CE-Marked PVAC GOLD catheter.~MRIs will be performed on all subjects at Enrollment and Pre-Discharge (Post Ablation). Subjects with a positive MRI (cerebral lesion) at Pre-Discharge will undergo another MRI at the 1 month follow-up visit."
223799791|NCT04636970|OTHER|Home training program|Subjects randomized to the IG will participate at home training program that will last 12 weeks and consists of endurance, flexibility, balance and cardiovascular resistance training performed with low to moderate intensity, in 20-60 minutes sessions, five times a week. Study participants will be asked to wear wrist and chest unobtrusive devices during active day time or at least during the training session and two hours before and after.
223799792|NCT01417689|OTHER|Encouragement to attempt eye drop instillation with a specific technique|Encouragement to one of the 2 techniques (open eyes and closed eyes) is accomplished through a standardized educational session designed to take2-5 minutes.
223799793|NCT01944865|OTHER|Interval Training|The interval training group consisted of 7 to 10 repetitions of 4-6 min at the highest intensity sustainable, the active recovery was 4-6 min in intensity from 10 to 15 of scale of perceived exertion CR100.
223799794|NCT01944865|OTHER|Intermittent Training|The riders of intermittent training group completed 8 to 12 repetitions of 30 s all-out with 4 min of active recovery.
223799795|NCT01112579|DEVICE|Medtronic PrimeADVANCED Neurostimulator|Heart failure therapy
223799796|NCT01112579|DEVICE|Medtronic PrimeADVANCED Neurostimulator|Medical management
223799797|NCT04462666|DRUG|Huzhang granule|Empty the content of one sachet into a mug, add 50ml warm water, stir until dissolved, add another 50ml hot water. Consume and complete all 100ml liquid mixture as a single dosage.
223799798|NCT04462666|DRUG|Etoricoxib|take one capsule per day in the morning, at approximately 30 minutes after the meal.
223799799|NCT04462666|DRUG|Huzhang granule Placebo|Empty the content of one sachet into a mug, add 50ml warm water, stir until dissolved, add another 50ml hot water. Consume and complete all 100ml liquid mixture as a single dosage.
223799800|NCT04462666|DRUG|Etoricoxib Placebo|take one capsule per day in the morning, at approximately 30 minutes after the meal.
223799801|NCT01385072|BIOLOGICAL|Double matched sibling transplantation|"Patients with poor risk active acute leukemia and who have 2 matched sibling donors can be included. Patients' conditioning may be myeloablative or non-myeloablative. Both matched donors will be mobilized with G-CSF and their peripheral blood stem cells will be collected on day 0.Equal numbers of CD34+ cells from both donors will be transfused to the patient.~Patients will be followed for engraftment kinetics, chimerism, GVHD rate, severity and response to treatment, relapse rates, DFS and OS."
223799802|NCT05738993|DRUG|BCD-178|A single intravenous (IV) infusion at a dose of 420 mg
223799803|NCT05738993|DRUG|Perjeta|A single intravenous (IV) infusion at a dose of 420 mg
223799804|NCT01963325|DRUG|S-1 plus Abraxane|Patients will receive Abraxane at 100 mg/m2 X 3 doses on Days 1, 8. S-1 chemotherapy was given based on the body surface area, \<1.25 m2: 80mg/day, 1.25\~1.5 m2: 100mg/day, ≧1.5 m2: 120mg/day. Given orally twice daily for 14 days, followed by 7 days without treatment.
223799805|NCT00818753|DRUG|dabigatran 110 mg|comparison of different dabigatran dosages with unfractionated heparin
223799806|NCT00818753|DRUG|dabigatran 150 mg|comparison of different dabigatran dosages with unfractionated heparin
223799807|NCT00818753|DRUG|unfractionated heparin|comparison of different dosages dabigatran with unfractionated heparin
223799808|NCT03703466|DRUG|Abemaciclib|Administered orally.
223799809|NCT06670248|PROCEDURE|Debridement Surgery|Surgical debridement of burn wounds involving ≥ 20% of the TBSA, including debrided and donor sites.
223799810|NCT06670248|DIAGNOSTIC_TEST|Sdc-1 Level Measurement|"Measurement of plasma sdc-1 levels in different situations to assess endothelial glycocalyx damage using an enzyme-linked immunosorbent assay (ELISA):~Preoperatively:~* Upon admission to the Burn Unit.~* 24 hours after admission to the Burn Unit.~* Prior to the start of surgery, after anesthetic induction.~* If surgery is performed after the fifth day following the burn, an additional sdc-1 measurement will be taken on the fifth day of hospital admission.~Postoperatively:~* 6 hours after surgery.~* 24 hours after surgery.~* 48 hours after surgery."
223799811|NCT06668311|OTHER|play dough|"1. Children and families will be informed about the purpose of the study and their verbal and written consent will be obtained.~2. The first part of the Patient Information Form will be completed for children who accept the study.~3. The second part of the Patient Information Form will be completed five minutes before nebulizer treatment.~4. Five minutes before nebulizer treatment, play dough will be given to the child.~5. The child will be allowed to play with the play dough during the nebulizer treatment.~6. The second part of the Patient Information Form will be filled in at the 5th minute of the treatment and after the treatment is over.~7. The application will take approximately 15 minutes."
223799812|NCT06668311|OTHER|picture book reading|"1. Children and families will be informed about the purpose of the study and their verbal and written consent will be obtained.~2. The first part of the Patient Information Form will be completed for children who accept the study.~3. The second part of the Patient Information Form will be completed five minutes before nebulizer treatment.~4. Five minutes before nebulizer treatment, the child will be given a picture book.~5. Picture book will be read to the child during the treatment.~6. The second part of the Patient Information Form will be filled in at the 5th minute of the treatment and after the treatment is over.~7. The application will take approximately 15 minutes."
223799813|NCT02611466|DRUG|ASP7962|Participants receive ASP7962 100 mg orally twice daily, in the morning and evening with or without food (approximately 12 hours).
223799814|NCT02611466|DRUG|Naproxen|Participants receive naproxen 500 mg orally twice daily, in the morning and evening with or without food (approximately 12 hours).
223799815|NCT02611466|DRUG|Placebo|Participants receive matching placebo orally twice daily, in the morning and evening with or without food (approximately 12 hours).
223799816|NCT04427202|BEHAVIORAL|Referral to harm reduction services|Participants are referred to harm reduction services
223799817|NCT06624137|DRUG|Serotonergic Psychedelic|"Any serotonergic or classic psychedelic that exhibits mainly Serotonin 2A receptor (5-HT2AR) agonism and is judged to produce subjectively similar effects."
223799818|NCT06624137|DRUG|Placebo|Matched Placebo
223799819|NCT06120907|OTHER|Data collection|The data include phenotypic data, treatments administered, response to treatment, Three-dimensional total body images, biopsies and blood plasma.
223799820|NCT05399953|OTHER|Myofascial Release Technique|"Sternocleidomastoid, Upper trapezius, Suboccipital region, Scalenes, Pectoral release, Scapular and hyoid mobilization techniques.~Duration: 6 weeks, 1 supervised session per week, and the session lasted 30 minutes."
223799821|NCT05399953|OTHER|Exercise|"Therapeutic exercise: passive and active range of motion, strengthening and postural exercise in order to improve shoulder and cervical mobility, muscle flexibility, strength and endurance, postural control and movement patterns; 2) stretching of pectoral muscles and serratus anterior; 3) scar tissue massage to reduce scar tissue's stiffness.~Duration of the intervention: 6 weeks (1 supervised session and 2 individual per week). Each exercise will be done 1-3 sets and 5-10 repetitions.The session lasted 30 minutes.~Exercise diary will be utilized in order to follow the exercise program."
223799822|NCT05399953|OTHER|Scar Tissue Massage|Circular, Up and Down, Side to Side technique
223799823|NCT04675138|OTHER|No intervention will be provided to the subject|No intervention will be provided to the subject
223799824|NCT01538550|PROCEDURE|Flexible sigmoidoscopy|Flexible sigmoidoscopy screening is offered once only
223799825|NCT01538550|PROCEDURE|iFOBT|Biennial screening with iFOBT
223799826|NCT04508699|OTHER|semantic learning|Experimental semantic learning from linguistic context task
223799827|NCT06701539|DRUG|Liposome bupivacaine group|After standardized anesthesia induction, bilateral scalp nerve block (supprorbital nerve, auriculotemporal nerve, major occipital nerve, minor occipital nerve) was performed with liposome bupivacaine stock solution, and 1-2ml was injected into each block site.
223799828|NCT06701539|DRUG|Ropivacaine group|After standardized anesthesia induction, bilateral scalp nerve block (supraorbital nerve, auriculotemporal nerve, major occipital nerve, minor occipital nerve) was administered with 0.5% ropivacaine, and 1-2ml was injected into each block site.
223799829|NCT06693479|DEVICE|Shoulder watch load (SWL) feedback|During week 2 and 3 after randomization, the experimental group will undergo the intervention using the SWL, designed to monitor workers' physical work demands. During this time, the SWL will provide real-time feedback based on parameters set via Ergowatchapp. A workplace visit by a physiotherapist will be conducted to establish and adjust the feedback thresholds in week 2, after the education intervention. If necessary, a second remote meeting will take place in week 3 to explain how participants can modify the thresholds themselves. The initial feedback thresholds will be set based on the physical work demands measured during week 1 and will be adjusted after one week of feedback use. These thresholds will be collaboratively determined by a physiotherapist and the workers. Only the experimental group will receive feedback from the SWL during the study period.
223799830|NCT06693479|OTHER|Education|Participants will receive an education intervention delivered by a physiotherapist. This intervention will take place preferentially at the participants' workplace at the end of the 2nd week post-randomization. The session will last 30 to 45 minutes, and involve personalized, patient-centered education on their condition. The physiotherapist will use open-ended questions to encourage participants to express their goals and address specific concerns related to their shoulder condition. Given the expected diversity in physical constraints (manual vs. non-manual workers) and individual challenges, the session will be tailored to each worker needs. At the end of the session, workers will receive a booklet summarizing key points, including: understanding shoulder anatomy, function and pain, managing shoulder pain, enhancing movement variability, adjusting work environment, and considering factors such as sleep, stress, coping mechanisms, and psychological factors on pain.
223799831|NCT06732310|BEHAVIORAL|Pregnant Moms' Empowerment Program|Women who receive the PMEP complete a structured set of sessions delivered over the course of 5 weeks, each session lasts 2 hours in duration: (1) becoming a group \& safety planning, (2) identifying and understanding sources of stress, (3) strategies to build resilience and resolve conflict, (4) perinatal health and infant care, and (5) positive parenting.
223799832|NCT06732310|BEHAVIORAL|Reminiscing and Emotion Training|Each of the 5 RET sessions are 1 hour in duration. The program is manualized and each session includes teaching/review of skills, instructions/activity with rationale, reminiscing practice, and immediate video feedback by a family coach.
223799833|NCT06732310|BEHAVIORAL|Pregnancy - Active Control|Women who are not randomized to the PMEP participate in a contact-equivalent, nondirective social support group.
223799834|NCT06732310|BEHAVIORAL|Enhanced Case Management|Families randomized to this attentional control condition will receive enhanced case management. They will be mailed a kit containing 5 packets to be opened weekly. Each packet includes a family activity and a newsletter with parenting materials (e.g., Adventures in Parenting curriculum developed by NICHD) that were selected to not overlap with RET content (e.g., reading together, fitness, etc.). Using mothers' responses regarding access to resources on the Family Resource Scale (Dunst \& Leet, 1987), which is completed during the baseline visit, mothers will also receive referrals to community resources for items rated as inadequate.
223799835|NCT03355326|DRUG|Glycerin Suppository|Glycerin suppository is given once daily beginning after conditions described are met and continued until discontinue conditions are met.
223799836|NCT04915183|OTHER|Placebo|Placebo will be formulated to also contain a white powder such that the atorvastatin and placebo are indistinguishable even if a capsule is opened.
223799837|NCT04915183|DRUG|Atorvastatin|Subjects will be provided with atorvastatin (40 mg) or placebo to be taken daily by mouth or by feeding tube. The tablets may be taken whole or crushed according to patient swallowing capabilities and preference.
223799838|NCT06359769|BEHAVIORAL|Group Cognitive Evolutionary Therapy|In-person therapy group. Delivery method: in-person groups. Number of sessions: 2. Duration of each session: 8 hours. Topics to be covered in the sessions are informed by the answers to the Fitness Evaluation Scale, following an adapted protocol of Cognitive Therapy for Depression.
223799839|NCT06772155|PROCEDURE|Ventriculostomy|Involves inserting a catheter into the brain's ventricular system to drain cerebrospinal fluid (CSF) and reduce intracranial pressure (ICP). This is a common procedure performed in this type of patient. It can be performed by a frontal approach, using a standard point 10cm from the nasion and 3cm lateral to the midline in the skull. A burr hole is performed and then the catheter is inserted in the frontal horn of the ventricular system. Then the catheter is tunneled subcutaneously and connected to an external ventricular drain collection system that allows also ICP measurement.
223799840|NCT06772155|PROCEDURE|Ventriculostomy + Locking Device|Involves inserting a catheter into the brain's ventricular system to drain cerebrospinal fluid (CSF) and reduce intracranial pressure (ICP). This is an alternative procedure performed for this type of patient. It can be performed by a frontal approach, using a standard point 10cm from the nasion and 3cm lateral to the midline in the skull. A burr hole is performed and then the catheter is inserted in the frontal horn of the ventricular system. During the insertion, a locking device is attached and secured at the burr hole defect. Then the catheter is tunneled subcutaneously and connected to an external ventricular drain collection system that allows also ICP measurement.
223799841|NCT05622305|BEHAVIORAL|1-Day Cognitive Behavioural Therapy-Based Workshop|The Online Workshop is a day-long intervention delivered by two trained public health nurses consisting of 6 hours of instruction delivered in 4 modules. The 1st contains information on PPD etiology with a focus on modifiable cognitive risk factors (e.g., negative thoughts, maladaptive core beliefs). The 2nd module focuses on cognitive skills including cognitive restructuring. The 3rd builds behavioural skills such as problem solving, behavioural activation, assertiveness, sleep strategies, and using supports. The final module provides an opportunity for goal setting/action planning. Teaching methods include didactic sections, group exercises, and role-plays. Regular breaks are incorporated. Each participant is given a professionally designed manual to facilitate learning. We also provide a list of region-specific PPD resources and a copy of the Canadian Practice Guidelines for the treatment of PPD.
223799842|NCT05986578|DEVICE|TMS to dmPFC|TMS will be delivered with a MagVenture Mag Pro R30 with the Cool-B70 A/P coil with active liquid cooling and active/sham sides. For dmPFC, approximately 25% of the nasion-inion distance or Talairah coordinates X 0 Y+60 Z+60 will be measured. The first session will begin with the acquisition of the resting motor threshold (rMT) on the contralateral hand. iTBS (triplet 50 Hz bursts, repeated at 5 Hz, 2 sec on and 8 sec off; 600 pulses per session) will be delivered at 110% of the rMT and will last \~3 minutes. The stimulation will start at a lower percentage and ramp up over time to acclimate participant to the feeling of stimulation. The intensity will be lowered in participant cannot tolerate the stimulation. Each participant will receive 3 sessions per visit with a 15-20 minute interval between sessions to increase the likelihood of detecting acute effects.
223799843|NCT05986578|DEVICE|TMS to dlPFC|TMS will be delivered with a MagVenture Mag Pro R30 with the Cool-B70 A/P coil with active liquid cooling and active/sham sides. For dlPFC, position F3 will be measured, using probabilistic EEG placement. The first session will begin with the acquisition of the resting motor threshold on the contralateral hand. iTBS (triplet 50 Hz bursts, repeated at 5 Hz, 2 sec on and 8 sec off; 600 pulses per session) will be delivered at 110% of the rMT and will last 3 minutes. The stimulation will start at a lower percentage and ramp up over time to acclimate participant to the feeling of stimulation. The intensity will be lowered in participant cannot tolerate the stimulation. Each participant will receive 3 sessions per visit with a 15-20 minute interval between sessions to increase the likelihood of detecting acute effects.
223799844|NCT05986578|DEVICE|Sham iTBS|Sham TMS will be delivered with the sham side of the MagVenture Cool B70 A/P coil. The software will be pre-programmed by a staff member that will not be involved in data analysis or collection for blinding purposes. The sham stimulation will match the number of pulses and length of time as the active condition and each participant will receive 3 sessions with a 15-20 min interval between sessions.
223799845|NCT06831864|DRUG|HFrEF Polypill|"The heart failure with reduced ejection fraction (HFrEF) polypill will include 4 guideline recommended medications used to treat HFrEF patients. The dose of initiation and titration will be at the investigator's discretion.~HFrEF polypill strength 1: bisoprolol 2.5 mg + losartan 25 mg + eplerenone 25 mg + dapagliflozin 10 mg; HFrEF polypill strength 2: bisoprolol 5 mg + losartan 50 mg + eplerenone 25 mg + dapagliflozin 10 mg; HFrEF polypill strength 3: bisoprolol 10 mg + losartan 100 + eplerenone 50 mg + dapagliflozin 10 mg"
223799846|NCT06831864|OTHER|Comparator Arm|Participants in the comparator control group will receive usual care by their healthcare providers. Providers will be encouraged to treat all participants according to international and local clinical practice guidelines.
223799847|NCT06902571|DEVICE|Intermittent theta burst stimulation (iTBS)|600 pulses (3 pulses × 10 bursts × 20 trains = 600 pulses) will be delivered each session with reference to a 3-minute protocol developed by Huang, et al. (2005). Before, during and after iTBS, both fNIRS and fMRI measurements will be conducted simultaneously.
223799848|NCT04854291|OTHER|Administration of donor FMT|Intracaecal infusion of FMT
223799849|NCT04854291|OTHER|Administration of placebo|Intracaecal infusion of carrier solution
223799850|NCT06495710|OTHER|Blood pressure treatment algorithm|Single or combination antihypertensive therapy as needed: 1) amlodipine (2.5-10 mg), 2) telmisartan (20-80 mg) or losartan (25-100 mg), 3) chlorthalidone (6.25-25 mg), or 4) spironolactone (12.5-50 mg). a two-drug regimen with either amlodipine + chlorthalidone or telmisartan + chlorthalidone will be initiated following randomization. If a diuretic is contraindicated, amlodipine + telmisartan will be initiated. For those over 75 years, either amlodipine or telmisartan will be initiated at baseline if SBP is \<140 mmHg. In the standard treatment group (SBP goal of \< 140 mmHg), participants will either be prescribed amlodipine or telmisartan/losartan as initial therapy. If \>3 medications are necessary to reach the intensive goal and no first line options remain, potassium sparing diuretics or direct vasodilators will be considered.
223799851|NCT05451251|DEVICE|Deep brain stimulation|Implantation of deep brain stimulation lead within the pontine lesion
223799852|NCT06931262|DRUG|Dichloroacetate (DCA)|Study medication DCA is an oral solution mixed with an artificial sweetener containing aspartame and strawberry extract (50mg/mL) Participants will be genotyped to determine GSTZ1 (glutathione S-transferase Zeta-1) haplotype status, which will stratify this group into 1 of 2 dose regimens: EGT carriers will receive 12 mg/kg/12hr DCA. EGT non-carriers will receive 6 mg/kg/12 hr DCA.
223799853|NCT01602536|BEHAVIORAL|smoking cessation aides|All participants will receive 8 weeks of free nicotine patches, referral to the NCI's online Smokefree.gov Quit Guide, and instruction to set a quit date within 8 days of study start.
223799854|NCT01602536|BEHAVIORAL|Twitter|Twitter quit-smoking group
223799855|NCT05477745|PROCEDURE|total knee arthroplasty|The surgeries were performed under general anesthesia. The medial parepatellar incision was introduced during the TKA. The femoral component size was selected according to the intro-operative measurement. The osteotomy was done according to the intramedullary guide and the cutting guide. After the proximal tibial osteotomy was finished, the cruciate-retaining Total Knee System was used. The lateral rotation of the femoral component was determined by the gap-balancing technique.
223799856|NCT05665699|DRUG|D-0120|increasing dose of D-0120
223799857|NCT05665699|DRUG|Allopurinol|standard dosing
223799858|NCT06952712|DRUG|Aspirin 100mg|Aspirin 100mg qn was started from 12-16 weeks of gestation and discontinued from 36+0-36+6 weeks of gestation
223799859|NCT06952712|DRUG|Aspirin 150mg|Aspirin 150mg qn was started from 12-16 weeks of gestation and discontinued from 36+0-36+6 weeks of gestation
223799860|NCT05892328|OTHER|Watermelon Flesh Dose 1|1 cup watermelon flesh, \~152g, 7 days/week over a 4-week period
223799861|NCT05892328|OTHER|Watermelon Flesh Dose 2|2 cups watermelon flesh, \~304 g, 7 days/week over a 4-week period
223799862|NCT05892328|OTHER|Control|304g italian ice, 0 g watermelon, 7 days/week over a 4-week period
223799863|NCT00608582|DEVICE|Transcranial Magnetic Stimulation, Repetitive|10 rTMS treatments (90% of motor threshold, 20 minutes, at 1 Hz) to specific right hemisphere area of brain cortex; 5 days per week for 2 weeks at the Berenson-Allen Center for Noninvasive Brain Stimulation, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; or at the Neurology Department, Hospital of the University of Pennsylvania, Philadelphia, PA.
223799864|NCT00246116|PROCEDURE|Functional Imaging of Treatment Effects|PET \& VQ Scans
223799865|NCT02464813|DRUG|Pregabalin|Patients will receive pregabalin twice preoperatively and twice daily for 5 days after surgery.
223799866|NCT02464813|DRUG|Sugar pill|Patients will receive placebo twice preoperatively and twice daily for 5 days after surgery.
223799867|NCT02464813|DRUG|Oxycodone|All patients will receive oxycodone as analgetic treatment administered by PCA. Oxycodone consumption will be measured.
223799868|NCT05182567|DRUG|GLS-5310 (Group 1)|GLS-5310 DNA plasmid vaccine
223799869|NCT05182567|DRUG|GLS-5310 (Group 2)|GLS-5310 DNA plasmid vaccine
223799870|NCT05182567|DRUG|GLS-5310 (Group 3)|GLS-5310 DNA plasmid vaccine
223799871|NCT05182567|DRUG|GLS-5310 (Group 4)|GLS-5310 DNA plasmid vaccine
223799872|NCT04649866|DIAGNOSTIC_TEST|plethysmography|"Forearm blood flow (FBF) measurements in both arms will be made using venous occlusion strain-gauge plethysmography prior to the initiation of any intra-arterial infusions. All FBF measurements will be expressed as mL/min per 100-1 mL forearm volume according to prior studies and the Whitney method.1, 2 Resting baseline FBF will be measured at least 30 minutes after venous and arterial catheter placement to ensure that blood flows in the cannulated arms are stabilized. We will measure FBF during the last 2 minutes of each infusion period. Infusions of individual vasoactive medications will occur over a 15-minute interval. There will be a 25-minute washout between vasoactive medications. Cumulative dose response curves will be constructed over 5-minute incremental infusions. We will proceed in the following order:~* SNP 0.8, 1.6 and 3.2 mcg/min~* ACh 7.5, 15 and 30 mcg/min~* Normal saline"
223799873|NCT01196455|DRUG|Capecitabine and Mitomycin C|"* Capecitabine 1000 mg/m2 twice-daily, administered orally on day 1-14, every three weeks~* Mitomycin C 8 mg/m2 i.v. bolus, on day 1, every three weeks"
223799874|NCT00993655|DRUG|carboplatin|Carboplatin AUC 5 if measured GFR or AUC6 if calculated GFR intravenous or intraperitoneal.
223799875|NCT00993655|DRUG|cisplatin|Cisplatin 75 mg/m2 intraperitoneal day 1
223799876|NCT00993655|DRUG|paclitaxel|Paclitaxel 135 mg/m2 intravenous day 1 plus Paclitaxel 60 mg/m2 intraperitoneal or intravenously day 8. Cycles given Q 21 days x 3 cycles
223799877|NCT05595668|BEHAVIORAL|Prism Adaptation - 15-degree prism goggles|Patients in the experimental condition will wear prism goggles while completing an iPad-administered aiming task. The prisms will shift the patients' vision 15 degrees rightward, causing a recalibration of visuo-motor information. Prism adaptation will be carried out for ten sessions for 15 minutes a day, over the span of two weeks.
223799878|NCT05595668|OTHER|Prism Adaptation - 5-degree prism goggles|5-degree goggles are worn instead of the 15-degree prism goggles, while completing the same tasks as those assigned to the 15-degree condition.
223799879|NCT04796441|BIOLOGICAL|CAR-γδT|Biological: CAR-γδT; Drug: Cyclophosphamide,Fludarabine; Procedure: Leukapheresis;
223799880|NCT03775200|DRUG|Psilocybin|Dose-finding
223799881|NCT05100290|DIAGNOSTIC_TEST|Hyperventilation Provocation Test (HPTest)|"During the HPTest, the subject is comfortably seated in a chair with armrests and breathes in a mouthpiece with a salivary collector and a nasal clamp. Parameters of ventilation and gas exchange are analyzed via an Oxycon ProTM (SN808008) with TripleV-Volume Sensor digital(Jaeger).~The HPTest begins with a 3-minutes adaptation phase during which the patient is asked to breathe normally. During the 3-minutes of voluntary hyperventilation phase, the patient is asked to increase his tidal volume and support a breath rate of at least 30/min in order to reduce his PETCO2 by at least 50%. During the recovery phase of the HPTest, the patient is invited to regain a natural breathing for 5 minutes, without guidance on tidal volume or breath rate."
223799882|NCT06385743|OTHER|Neuromuscular Training-based Exercise Program|Neuromuscular training has been accepted as an effective treatment modality to improve the neurophysiological states of the joints for coordinated work. In addition to shoulder strength, stabilization and kinetic chain exercises, this program includes internal and external focus (sound, touch, light, dual task, etc.), sport-specific exercises and plyometric exercises (speed, agility). All athletes with shoulder pain will include in the baseline evaluation at the beginning of the season and all parameters will be followed throughout the season for 8 weeks. All athletes in this group will participate in a total of 24 physiotherapy sessions, 3 days a week, for eight weeks.
223799883|NCT06385743|OTHER|''Thrower's Ten'' Exercise Program|"''Thrower's Ten'' Exercise Program includes 10 different shoulder strengthening and shoulder stabilization exercises in a diagonal pattern. Advanced Thrower's Ten exercises that include kinetic chain exercises (covering more than one joint) in addition to shoulder exercises planned to be used in the late stages of rehabilitation into the program, progression is considered after the 3rd week will be added. All athletes with shoulder pain will include in the baseline evaluation at the beginning of the season and all parameters will be followed throughout the season for 8 weeks. All athletes in this group will participate in a total of 24 physiotherapy sessions, 3 days a week, for eight weeks."
223799884|NCT05941754|DIETARY_SUPPLEMENT|omega-3|supplement in the market
223799885|NCT05941754|DIETARY_SUPPLEMENT|placebo|corn oil
223799886|NCT06182306|PROCEDURE|Biopsy|Patients undergo a biopsy from a lesion, and give 40ml of blood
223799887|NCT03313518|DEVICE|tDCS|15 patients received real anodal tDCS for 20 minutes daily for 10 consecutive days.
223799888|NCT03313518|DEVICE|Sham tDCS|15 patients received sham anodal tDCS for 20 minutes daily for 10 consecutive days.
223799889|NCT04586725|OTHER|Encouragement a one minute intervals|Patients will perform the six exercise tests with encouragement at one minute intervals
223799890|NCT04586725|OTHER|Encouragement a two minute intervals|Patients will perform the six exercise tests with encouragement at two minute intervals
223799891|NCT04605978|DRUG|S95011 concentrate for solution for infusion|IV administration every 2 weeks until week 4 and then every 3 weeks until week 10.
223799892|NCT04605978|DRUG|Placebo concentrate for solution for infusion|IV administration every 2 weeks until week 4 and then every 3 weeks until week 10.
223799893|NCT01855854|DRUG|Icotinib|Icotinib: 250 mg is administered orally three times per day, until disease progression or untolerable toxicity.
223799894|NCT02834156|OTHER|LP in a seated position then LP in a lying position|
223799895|NCT02834156|OTHER|LP in a lying position then LP in a seated position|
223799896|NCT03019354|DEVICE|high-flow nasal oxygen|Using high-flow nasal oxygen 10 L/min before anesthesia induction, then using high-flow nasal oxygen 30-50 L/min during intravenous general anesthesia.
223799897|NCT03019354|DEVICE|Oxygen mask|Using oxygen mask with oxygen flow 10 L/min before and during intravenous general anesthesia.
223799898|NCT01176721|DEVICE|t-VNS verum|Active stimulation of the left auricle by t-VNS
223799899|NCT01176721|DEVICE|t-VNS placebo|Sham stimulation of the left auricle with the t-VNS device
223799900|NCT02484157|DEVICE|Hemochron|Activated coagulation time was checked serially by Hemochron Jr.
223799901|NCT02484157|DEVICE|ACT Plus|Activated coagulation time was checked serially by ACT Plus.
223799902|NCT06956963|OTHER|Partial Sleep Deprivation|30% reduction in habitual time in bed
223799903|NCT03037632|BEHAVIORAL|Family Heart Talk Booklet|
223799904|NCT06788184|DEVICE|Virtual Reality (VR) Game for Auditory Processing|"The Virtual Reality (VR) Game is a novel auditory rehabilitation tool designed to enhance central auditory processing skills in children with cochlear implants. This intervention features a restaurant simulation environment where participants perform auditory tasks such as identifying verbal orders, recognizing speech in noisy environments, and matching auditory cues to visual inputs.~Dosage Form: Virtual reality sessions conducted through a VR headset (Oculus Meta Quest 3).~Frequency: Once per week. Duration per Session: 30 minutes per session. Total Duration: Four weeks (4 sessions). Complexity Levels: Tasks increase in complexity over time, starting with simple auditory cues in quiet environments and progressing to more challenging scenarios involving background noise and multitasking.~The VR game is specifically designed to replicate real-world auditory challenges in a controlled and engaging virtual environment, providing participants with tailored tasks to improve auditory atten"
223799905|NCT06788184|BEHAVIORAL|Traditional Auditory Rehabilitation|"Name: Traditional Auditory Rehabilitation~Description:~Participants will continue the standard auditory rehabilitation program they currently receive at their registered rehabilitation center and will focus on improving auditory processing skills. This program includes:~Session Length: 30 minutes per session Frequency: Once a week Total Duration: 4 weeks (4 sessions total)~Components:~Improve speech understanding in noise"
223799906|NCT06958315|OTHER|Inclisiran|This is an observational study, there is no treatment allocation.
223799907|NCT00292435|DRUG|Read vine leaf extract (AS 195)|
223799908|NCT01484639|OTHER|Liberal transfusion triggers|"Patients allocated to a liberal transfusion strategy will receive red cell transfusion if their hemoglobin concentration is 95 g/L or less intraoperatively and postoperatively in the intensive care unit, and less than 85 g/L on the ward."
223799909|NCT01484639|OTHER|Restrictive transfusion triggers|"Patients allocated to a restrictive transfusion group will receive a red cell transfusion if their hemoglobin is 75 g/L or less intraoperatively and postoperatively."
223799910|NCT05686239|DRUG|RL-007 (Inidascamine)|investigational study drug
223799911|NCT05686239|DRUG|Placebo|placebo capsules matching the appearance and size of the active drug
223799912|NCT06636292|DEVICE|Virtual Reality Distraction and Disassociation (VRDD) Stage 1|Participants wear a VR headset which plays VR content/material pre- endoscopy only.
223799913|NCT06636292|DEVICE|Virtual Reality Distraction and Disassociation (VRDD) Stage 1&2|Participants wear a VR headset which plays VR content/material pre- endoscopy and during endoscopy.
223799914|NCT00005855|DRUG|carmustine|
223799915|NCT00005855|DRUG|efaproxiral|
223799916|NCT02096328|DRUG|POL7080|Intravenous infusion
223799917|NCT04467385|OTHER|VR training + Sensory Integration therapy + conventional therapy|"After the baseline assessment,~* Coconut ShootersVR - 5 min/day~* Ninja flipVR - 5 min/day.~* Sensory integration training include Exercises on BOSU ball and mini-trampoline. It will involve:~* Passive bouncing with child standing with his/her feet shoulder width apart for 2.5 and 2.5 minutes on both.~* Active bouncing (the child bounces and therapist will control the rate) for 2.5 and 2.5 minutes on both.~* Mini-squat exercises with feet apart and feet together for 2.5 and 2.5 minutes on both.~* Conventional exercises include:~  * passive stretching exercises for the hip flexors, hip adductors, hamstring, and calf muscle; stretching will be applied for 30 sec with 30 sec rest for each muscle group within pain limit.~ * Strengthening of abdominal and back muscles, hip abductions and knee joint extensors and ankle dorsiflexors will be performed."
223799918|NCT04467385|OTHER|VR training + conventional therapy|"After the baseline assessment,~* The Your Shape: Fitness Evolved 2012TM game is selected for VR training (walking and walking with obstacles) for 8 min~* Coconut ShootersVR - 8 min/day~* Ninja flipVR - 8 min/day~* Conventional Therapy - 20 min per day~  * Passive stretching exercises for the hip flexors, hip adductors, hamstring, and calf muscle; stretching will be applied for 30 sec with 30 sec rest 3-5 times for each muscle group within pain limit.~ * Strengthening of abdominal and back muscles, hip abductions and knee joint extensors and ankle dorsiflexors will be performed."
223799919|NCT02775292|BIOLOGICAL|Aldesleukin|Given SC
223799920|NCT02775292|DRUG|Cyclophosphamide|Given IV
223799921|NCT02775292|DRUG|Fludarabine Phosphate|Given IV
223799922|NCT02775292|OTHER|Laboratory Biomarker Analysis|Correlative studies
223799923|NCT02775292|BIOLOGICAL|Nivolumab|Given IV
223799924|NCT02775292|BIOLOGICAL|NY-ESO-1 Reactive TCR Retroviral Vector Transduced Autologous PBL|Given IV
223799925|NCT02775292|BIOLOGICAL|NY-ESO-1(157-165) Peptide-pulsed Autologous Dendritic Cell Vaccine|Given ID
223799926|NCT02775292|PROCEDURE|Positron Emission Tomography|Correlative studies
223799927|NCT00199615|PROCEDURE|PET|Intravenous injection of glucose labeled Fluor 18.Le patient remains fasted at least 6 hours before the start of the examination. The review lasted 1 hour, during which the patient should not move.
223799928|NCT03104699|DRUG|AGEN2034|Anti-programmed cell death protein-1 (PD-1) Monoclonal Antibody
223799929|NCT04477642|DRUG|Abatacept|10mg/kg intravenously administered on Day 1
223799930|NCT01690130|DEVICE|Transcranial Magnetic Stimulation (Neuronetics)|Transcranial magnetic stimulation is a noninvasive brain stimulation that can focally stimulate the brain of an awake individual. A TMS pulse focally stimulates the cortex by depolarizing superficial neurons which induces electrical currents in the brain.
223799931|NCT01690130|DEVICE|Sham Transcranial Magnetic Stimulation|The electrical current of the sham system is titrated to a level matching participants' ratings of active TMS.The sham-TMS scalp discomfort will be matched to that of active TMS.
223799932|NCT01644734|DRUG|Spiriva HandiHaler|
223799933|NCT02035800|DRUG|Adalimumab|Patient will received medication as standard of care
223799934|NCT03731273|BEHAVIORAL|portion size|"Smaller than normal portion size - the intervention is the meal size perceived as 'smaller than normal' that participants are provided with during a lunchtime session in the laboratory.~'Small-normal' portion size - the intervention is the meal size perceived as 'small normal' that participants are provided with during a lunchtime session in the laboratory.~'Large normal' portion size - the intervention is the meal size perceived as 'large normal' that participants are provided with during a lunchtime session in the laboratory."
223799935|NCT02073799|PROCEDURE|Laser prostatectomy (Photoselective vaporization of the prostate or Holmium laser enucleation of the prostate)|
223799936|NCT03188848|DRUG|BPI-3016|Single-dose subcutaneous injection of BPI-3016
223799937|NCT03188848|DRUG|Placebo|Single-dose subcutaneous injection of placebo to match BPI-3016
223799938|NCT03436329|PROCEDURE|Vein ligation first|During this procedure, patients undergo lobectomy with the pulmonary vein ligated first.
223799939|NCT03436329|PROCEDURE|Artery ligation first|During this procedure, patients undergo lobectomy with the pulmonary artery ligated first.
223799940|NCT00269490|BEHAVIORAL|Yoga Nidra|
223799941|NCT05271864|DEVICE|Apple Watch|Apple Watch
223799942|NCT01404520|OTHER|Exercise based multimodal intervention|The intervention is initiated early, during treatment (consolidation) in the intra-hospital setting and continues for two successive treatment series (12 weeks). The intervention is a three hour/wk supervised in-hospital programme of aerobic (stationary cycle) and functional muscle training, progressive relaxation training, nutrition supplement (protein and carbohydrate) immediately after training and health-promoting consultation combined with an unsupervised in-home walking and progressive relaxation programme.
223799943|NCT05159622|BEHAVIORAL|Water Up! at Home|1: Addressing physical barriers to replace SSB with water at home: Participants will receive a personal, reusable bottle of water, a National Sanitation Foundation-certified water filter pitcher and one additional filter cartridge 2: Addressing sociocultural barriers to change individual perceptions: The curriculum has 6 topics delivered in 12 sessions: a) water for your health (diabetes/obesity among Latinos); b) health benefits of water vs. SSB, c) sugar content of SSB, d) safety \& affordability of filtered tap water vs. bottled beverages, e) access and promotion of SSB vs. water in your community, f) tips for improving water taste, perceived susceptibility, severity, costs and benefits. 3: Addressing sociocultural barriers to increase skills: During each session, participants will be asked to perform hands-on learning activities (e.g., measure sugar content in SSB, take pictures of themselves explaining to their family members the key messages of various lessons).
223799944|NCT04052672|OTHER|Exercise and Nutritional Supplement|The intervention consists of exercise (a combination of supervised and in home) as well as a nutritional supplement (a combination of whey protein and creatine).
223799945|NCT02368808|BEHAVIORAL|Abangane Support Group|The Abangane support group program consists of 8 sessions for bereaved adolescents with standardized activities and discussion content based the Khululeka Grief Support Program in Cape Town, South Africa. The materials include a resource book that provides training and referral agencies for grief group facilitators as well as exercises and creative activities designed to stimulate group discussions that will help adolescents to deal with loss and grief.
223799946|NCT03646799|DRUG|CKD-387|test drug
223799947|NCT03646799|DRUG|D484|reference drug
223799948|NCT02231827|OTHER|Gait analysis|Subjects, barefoot and standing upright and motionless on a force plate, were instructed to walk for 10 m following a beep delivered by the experimenter. Two experimental conditions were tested: (i) the 'natural' gait condition where subjects walked normally and (ii) the 'fast' gait condition where subjects walked as fast as they could, taking large steps. Each subject performed 10 trials in each condition.
223799949|NCT03318523|DRUG|Placebo|Administered as specified in the treatment arm
223799950|NCT03318523|DRUG|BIIB054|Administered as specified in the treatment arm.
223799951|NCT05632146|PROCEDURE|Continuous suturing|In continuous closure, each bite will be taken 2 cm from the cut edge of linea alba and successive bites taken 1 cm from each other in continuous fashion followed by gentle approximation of the wound
223799952|NCT05632146|PROCEDURE|Interrupted X suturing|In interrupted X closure, large bite will be taken outside-in, 2 cm from the cut edge of linea alba and the needle emerged on the other side from inside out diagonally 2 cm from the edge and 4 cm below the first bite and this strand will be crossed and continued outside-in, diagonally at 90 degree to the first diagonal. The two ends will be tied just tight enough to approximate the edges of linea alba.
223799953|NCT01000168|OTHER|Treadmill therapy and conventional walking therapy.|"The experimental group received 30 sessions of treadmill therapy with body weight support for a time period of 10 weeks.~The conventional group received traditional walking therapy for the same time period."
223799954|NCT05190250|DIAGNOSTIC_TEST|Pipelle biopsy|Ultrasonographically confirmed implantation window. Collection of material with use of Pipelle biopsy. Collection of 5 ml venous blood.
223799955|NCT00361374|DIETARY_SUPPLEMENT|eicosapentaenoic acid|1 gram/day
223799956|NCT00361374|DIETARY_SUPPLEMENT|docosahexaenoic acid|1 gram/day
223799957|NCT00361374|DRUG|Placebo|980 milligram/day
223799958|NCT03581981|BEHAVIORAL|Prolonged Exposure for Primary Care (PE-PC)|Brief version of Prolonged Exposure (PE) provided in 30 minute sessions in primary care (PC)
223799959|NCT03581981|BEHAVIORAL|Treatment as Usual|Veterans assigned to Primary Care (PC) Mental Health Integration (PCMHI)-Treatment as Usual (TAU) will receive standard PCMHI care for PTSD in PC that does not include any PTSD-specific therapy in PCMHI but may include referral for specialty care (including specialty MH), medication management or general supportive contact while awaiting referral. All PTSD care received during the study will be collected and monitored as TAU.
223799960|NCT06106386|OTHER|cryotherapy|Cooling of irrigation
223799961|NCT05263752|DEVICE|ERCP with NvisionVLE® Imaging Low Profile System|Endoscopic Retrograde Cholangio-Pancreatography (ERCP) with NvisionVLE® Imaging Low Profile System
223799962|NCT04326270|DEVICE|Nasal interface|Randomized to initial interface of nCPAP prongs or infant cannula
223799963|NCT01410474|BIOLOGICAL|Meningococcal ACWY conjugate vaccine|All subjects received a single dose of Meningococcal ACWY conjugate vaccine and had blood draw at day 1 and day 29.
223799964|NCT04481295|OTHER|High-flow nasal cannula|The nasal high flow therapy has enabled high flow oxygen to be derived through nasal cannula. This mode not only allows constant FiO2 during peak inspiratory flow but also confers benefits including a low level of continuous positive airway pressure with increased end-expiratory lung volume and reduced work of breathing, partly through intrinsic positive end-expiration pressure compensation and dead space washout. The inspired gases are warmed and humidified, improving comfort and possibly reducing airway inflammation, leading to improved drainage of respiratory secretions.
223799965|NCT04481295|OTHER|Low SpO2|Low SpO2
223799966|NCT06579521|OTHER|Alcohol|A standard dose of alcohol will be administered (volume calculated with regard to age, sex assigned at birth, height, and weight) in the form of vodka and combined with mixer at a 1:4 ratio to reach a target breath alcohol concentration of .08%.
223799967|NCT06579066|DRUG|Probiotic Blend Capsule|Patients will administer (probiotics) Linex® one capsule daily orally along with the standard care of therapy for duration of 4 weeks.
223799968|NCT06579066|DRUG|Activated Charcoal|Patients will administer (activated charcoal) Charclone® 1000MG Tablet three times daily orally along with the standard care of therapy for duration of 4 weeks.
223799969|NCT04525495|DRUG|Dopamine|Dopamine treatment
223799970|NCT04701151|DRUG|Bacillus Calmette Guerin|The same dose of the drug will be given in both arms but the dwell-time will be adjusted for the subjects in the intervention arm according to the grading of side effects given by the study algorithm.
223799971|NCT03105414|DEVICE|Mechanical ventilation|Mechanical ventilation
223799972|NCT03384173|DEVICE|Near Infrared Spectroscopy|Application of regional NIRS sensors to brain and kidney sites in the first 48 hours after birth to monitor regional tissue oxygenation for the first 7 days of age.
223799973|NCT04632602|OTHER|physiological effects of awake prone position in COVID 19 patients|"Study of physiological effects of awake prone position in COVID 19 patients on lung inhomogeneity assessed by Electrical Impedance Tomography (EIT), gas exchange and dyspnea score (Borg Scale).~Measurements will be performed at baseline (on supine position), then patients will be randomized on the order of position, either supine then prone, either prone then supine. Each period will last at least 2 hours. EIT records will be performed during the last 30 minutes of each period, blood gas and dyspnea score at the end of each period."
223799974|NCT00002974|DRUG|carboplatin|
223799975|NCT00002974|DRUG|etoposide|
223799976|NCT00002974|DRUG|ifosfamide|
223799977|NCT00002974|PROCEDURE|hyperthermia treatment|
223799978|NCT05267392|DRUG|Durvalumab|Patients will receive 1500 mg of durvalumab (MEDI4736) via IV infusion
223799979|NCT05267392|OTHER|standard of care RT/RCT|standard of care RT/RCT
223799980|NCT05807243|OTHER|Dietary intervention for healthy weight loss|Balanced and varied dietary plan adjusted to each participant's needs, with an approximate reduction of 500 Kcal from their total metabolic expenditure. The diet will be followed by the subjects during the 4 weeks of the study.
223799981|NCT00446810|DRUG|Benfotiamine|
223799982|NCT00446810|DRUG|Placebo|
223799983|NCT00828984|DRUG|macrogol 3350-based oral osmotic laxative|Given PO
223799984|NCT00828984|OTHER|Placebo|Given PO
223799985|NCT00828984|OTHER|Laboratory Biomarker Analysis|Correlative studies
223799986|NCT05904951|DEVICE|INVADER™ PTCA Balloon Dilatation Catheter|INVADER™ PTCA Balloon Dilatation Catheter is a single use, EO sterilized, monorail rapid exchange (RX) coronary angioplasty balloon dilatation catheter. The INVADER™ PTCA has been designed to dilate the stenotic atherosclerotic lesions in coronary arteries or bypass grafts. The INVADER™ PTCA is an interventional, non-surgical device, and considered minimally invasive.
223799987|NCT03509974|DEVICE|Osseointegrated Steady State Implant|Bone anchored, bone conduction hearing system
223799988|NCT01210833|DEVICE|HandTutor System|Computerized system designed to evaluate and rehabilitate hand function. It is composed of a glove with special sensors detecting the movements of the wrist and the fingers, with a biofeedback software designed to evaluate and then to exercise the hand movements through supplying a variety of computer graphic patterns.
223799989|NCT02230202|OTHER|Flow-mediated dilation|Flow-mediated dilation used to measure vascular function. The test is minimally invasive, with only a slight discomfort due to the inflation of the arm cuff.
223799990|NCT02230202|OTHER|single blood draw|single blood draw of approximately 45 mL.
223799991|NCT00464646|DRUG|Epirubicin|Both Cohorts: Epirubicin 90 mg/m2 IV every 21 days x 4 cycles
223799992|NCT00464646|DRUG|Cyclophosphamide|Both Cohorts: Cyclophosphamide 600 mg/m2 IV every 21 days x 4 cycles
223799993|NCT00464646|DRUG|Docetaxel|Both Cohorts: Docetaxel 100 mg/m2 IV on Day 1 every 21 days x 4 cycles
223799994|NCT00464646|DRUG|Trastuzumab|"Cohort A: Pre-op therapy - 4 mg/kg IV first dose, then subsequent doses at 2 mg/kg IV weekly (16+ weeks) until 1-7 days prior to surgery. Post-operative therapy (beginning no sooner than 28 days after surgery and continuing every 3 weeks x 13 doses) - 8 mg/kg IV first post-op dose, then subsequent doses at 6 mg/kg IV~Cohort B: 4 mg/kg IV first dose, then subsequent doses at 2 mg/kg IV weekly on days 1, 8, and 15. Three (3) weeks after last dose of docetaxel, 6 mg/kg IV and continuing every 3 weeks x 13 doses"
223799995|NCT00464646|DRUG|Bevacizumab|"Cohort A: Cycles 1-4, 15 mg/kg IV on day 1 of cycle 4 only; Cycles 5-7, 15 mg/kg IV on day 1 every 21 days x 3 cycles; post-operative therapy (beginning no sooner than 28 days after surgery), 15 mg/kg IV every 3 weeks x 13 doses~Cohort B: Cycles 5-8, 15 mg/kg IV on day 1 every 21 days x 4 cycles; beginning 3 weeks after last dose of docetaxel, 15 mg/kg IV every 3 weeks x 13 doses"
223799996|NCT01174420|DEVICE|Use of ologen Collagen Matrix in trabeculectomy|After trabeculectomy, place ologen Collagen Matrix on the top of the scleral flap under the conjunctiva before suturing
223799997|NCT01174420|DRUG|Use of Mitomycin-C in trabeculectomy|After creating a scleral flap, a sponge with Mitomycin-C (0.02%) is applied on the scleral surface for 3 minutes. Afterwards, Mitomycin-C was rinsed out with balanced salt solution.
223799998|NCT04043923|DRUG|Norketotifen|Oral capsule
223799999|NCT04043923|DRUG|Placebo|Oral capsule
223800000|NCT03820856|PROCEDURE|acupuncture plus fire needle therapy|The protocol used in this group was the same as that used in the acupuncture alone group except that fire needle therapy was added. The treatments were administered twice weekly for 6 weeks. Fire needle therapy was performed as follows: an acupuncture needle made of tungsten was heated until red-hot over a lighter and then inserted into the two Ah shi points (the tender points on the common extensor tendon, specifically extensor carpi radialis). The red-hot needle was inserted rapidly into the Ah shi point (approximately 5-8 fen deep, 1 cun = 10 fen) for approximately half a second and then removed. Pressure was then applied to the needle hole using a sterilized dry cotton ball.
223800001|NCT03820856|PROCEDURE|acupuncture|We selected acupoints that have often been recommended for the treatment of lateral epicondylitis. Triple needling was performed at the Ah shi point, i.e., the 1-2-cm area encompassing the most painful spot on the humeral epicondyle. We also manipulated acupuncture needles in the following areas: LI10 (Shousanli), LI11 (Quchi), LI12 (Zhouliao) and LU5 (Chize). The treatments were administered twice weekly for 6 weeks.
223800002|NCT05439798|DRUG|Ondansetron+Dexamethasone|"The patients in Group OD (Group ondansetron+dexamethasone) will be given intravenous (iv) ondansetron (0.1 mg.kg-1) + dexamethasone (0.5 mg.kg) The patients in Group PD (Group palonosetron+dexamethasone) will be given intravenous (iv) palonosetron (0.75µg.kg-1) + dexamethasone (0.5 mg.kg-1).~The patients In Group D (Group Dexamethasone) will be given iv only dexamethasone (0.5 mg.kg-1)"
223800003|NCT05439798|DRUG|Palonosetron+Dexamethasone|"The patients in Group OD (Group ondansetron+dexamethasone) will be given intravenous (iv) ondansetron (0.1 mg.kg-1) + dexamethasone (0.5 mg.kg) The patients in Group PD (Group palonosetron+dexamethasone) will be given intravenous (iv) palonosetron (0.75µg.kg-1) + dexamethasone (0.5 mg.kg-1).~The patients In Group D (Group Dexamethasone) will be given iv only dexamethasone (0.5 mg.kg-1)"
223800004|NCT05439798|DRUG|Dexamethasone|Dexamethasone
223800005|NCT00177060|DRUG|hydromorphone|
223800006|NCT01543243|DEVICE|Stochastic resonance whole-body vibration A|"Immediate effects (one minute after intervention): over 5 sets with 6 Hz, Noise 4 and than 1 Hz, Noise 1.~Long term effect: over four weeks, three times a week with 6 Hz, Noise 4 and than over four weeks three times a week with 1 Hz, Noise 1."
223800007|NCT01543243|DEVICE|Stochastic resonance whole-body vibration B|"Immediate effects (one minute after intervention): over 5 sets with 1 Hz, Noise 1 and than 6 Hz, Noise 4.~Long term effect: over four weeks, three times a week with 1 Hz, Noise 1 and than four weeks three times a week with 6 Hz, Noise 4."
223800008|NCT00863655|DRUG|Everolimus|Everolimus was formulated as tablets of 5-mg strength and was packaged into blister packs . Everolimus (two 5 mg tablets daily) were administered in a blinded manner on their respective treatment arms by continuous oral daily dosing.
223800009|NCT00863655|DRUG|Exemestane|Exemestane 25 mg orally daily.
223800010|NCT00863655|DRUG|Everolimus Placebo|Placebo was formulated to be indistinguishable from the everolimus tablets. Matching placebo (two tablets daily) were administered in a blinded manner on their respective treatment arms by continuous oral daily dosing.
223800011|NCT01040858|BEHAVIORAL|Cognitive Strategy Training|Cognitive Strategy Training will consist of weekly 120-minute group sessions for 10 weeks.
223800012|NCT01040858|OTHER|Placebo comparison group|Participants in the experimental group will receive the Cognitive strategy intervention during the first ten weeks of their participation in the study, whereas comparison group participants will continue to receive usual care (no cognitive strategy intervention) during their participation in the study (but will be offered cognitive strategy intervention after the end of the study).
223800013|NCT02976441|RADIATION|Radiation therapy|
223800014|NCT02976441|DRUG|Temozolomide|
223800015|NCT02976441|PROCEDURE|Stem cell collection|
223800016|NCT02976441|PROCEDURE|Stem cell infusion|
223800017|NCT02445313|DEVICE|Nidek MP-3|Nidek MP-3 device to be used to take images which will allow measurement of GA in patients with AMD
223800018|NCT02157779|BEHAVIORAL|Cognitive Behavioral Intervention|Includes individual therapy sessions using cognitive and behavioral strategies addressing problems with anger intensity / frequency / management
223800019|NCT02157779|BEHAVIORAL|Supportive Intervention|Includes individual therapy sessions using supportive and problem-solving strategies.
223800020|NCT04351503|OTHER|Study A|Study A: collection of data of clinical outcomes and features of SARS-CoV-2 infection. Demographical, clinical, microbiological, laboratory, epidemiological and hospital-associated data will be analyzed. For this study part, only patients with a visit at the University Hospital Basel will be included in order to access patient charts.
223800021|NCT04351503|OTHER|Study B|Study B: collection of epidemiological surveillance data to describe the epidemiology of the SARS-CoV-2 outbreak. The epidemic transmission of Influenza viruses in the City of Basel serves as an important reference to identify similarities and differences to the pandemic SARS-CoV-2 situation. In addition data collected during the Influenza projects - in particular data on statistical blocks of the city, e.g. population density, income and living space will be re-used. Already collected and stored samples such as serum and respiratory material (leftover material) will be (re-) used.
223800022|NCT04351503|OTHER|Study C|Study C: data collection for viral evolution. Respiratory materials and matching blood and tissue materials will be used to perform whole genome sequencing to study pathogen evolution between hosts as well as in-host evolution. No additional material will be collected.
223800023|NCT04351503|OTHER|Study D|"Study D: collection of safety and efficacy data of different treatment modalities. Currently the following treatments are considered as part of the treatment:~1. Lopinavir/Ritonavir~2. Hydroxychloroquine~3. Tocilizumab~4. Eculizumab~5. Ruxolitinib~6. Remdesivir~7. Treatment with convalescent plasma blood count, blood chemistry and pulmonary function test (collected on a routine basis during hospitalization and in the outpatient setting)."
223800024|NCT02855307|OTHER|60-minute exercise|Patients will be admitted at the research clinical facility at 6:30. The artificial pancreas intervention will start at 7:00. A standardized breakfast will be served at 8:00. At 9:30, patients will performed a 60-minute exercise on the ergocycle at 60% of VO2 max. At 11:30, patients will be switched to standard insulin pump therapy and a lunch will be served. Patients will be discharged after lunch consumption.
223800025|NCT02855307|DEVICE|Insulin pump|Patient's insulin pump will be used to infuse insulin.
223800026|NCT02855307|DEVICE|Dexcom G4 Platinum glucose sensor|The Dexcom G4 Platinum glucose sensor will be used to measure glucose levels.
223800027|NCT02855307|DRUG|Insulin|Patient's usual fast-acting insulin analog will be used.
223800028|NCT02855307|OTHER|Single-hormone closed-loop strategy|Variable subcutaneous insulin infusion rates will be used to regulate glucose levels. Patient's usual fast acting insulin analog (Lispro, Aspart or Guilisine) will be infused using the patient's pump. The glucose level as measured by the real time sensor (Dexcom G4 Platinum, Dexcom Inc.) will be entered manually into the computer every 10 minutes. The pump's infusion rate will then be changed manually based on the computer generated recommendation infusion rates.
223800029|NCT00778583|DRUG|Nitrofurantoin 100 mg capsules|
223800030|NCT03881306|DRUG|D-TACE|D-TACE with CalliSpheres-Oxaliplatin
223800031|NCT05801211|PROCEDURE|primary tumor resection|"primary surgical tumor resection with a primary colorectal anastomosis (associated or not with a diverting loop ileostomy) or without a primary anastomosis (Hartmann's procedure)"
223800032|NCT00005791|DRUG|cisplatin|
223800033|NCT00005791|DRUG|fluorouracil|
223800034|NCT00005791|DRUG|irinotecan hydrochloride|
223800035|NCT04000841|BEHAVIORAL|Mindful You mobile app|"The CRSR intervention consists of a native mobile application for Android and iOS devices. The mobile app includes:~* Guided meditations of varying length designed to connect the user to the present moment and a place of calm through culturally aligned exercises grounded in spirituality, orality, self-empowerment, and resilience.~* User-customized notifications prompting users to reflect and engage with the app, such as providing African American proverbs and quotes and asking simple questions like What are you grateful for today?~* Scheduled messages on the importance mindfulness as a way increase control over physical and psychological health~* User-customized reminders to do specific meditations and display personally selected images or messages."
223800036|NCT05872373|BEHAVIORAL|Snakebite prevention and first aid|The study will offer a communication strategy to develop an effective narrative by using a mix-media campaign, where IEC materials would be chiefly localized.
223800037|NCT01826227|PROCEDURE|Positron Emission Tomography|
223800038|NCT01826227|RADIATION|18F-Fluoro-2-deoxy-D-lucose|
223800039|NCT01826227|PROCEDURE|Cytoreductive surgery|
223800040|NCT05287555|OTHER|Telemonitoring Care|NIV, Supplies as needed, especially masks, tubes, humidifiers, SpO2 sensor and modems.
223800041|NCT05287555|OTHER|Standard Care|NIV, Supplies as needed, especially masks, tubes, humidifiers, and modems
223800042|NCT03021356|DEVICE|Aortic xenograft|After randomization, the aortic xenograft is implanted in the standard fashion
223800043|NCT01911039|BIOLOGICAL|Regulatory T Cells|
223800044|NCT06532318|BIOLOGICAL|Platelet rich plasma|Freshly prepared autologus platelet rich plasma
223800045|NCT06532318|DRUG|Pfizer Depo-medrol|Methylprednisolone acetate 20mg/ml injection
223800046|NCT02813187|BIOLOGICAL|cellular and tissue based therapy|
223800047|NCT02813187|PROCEDURE|debridement|
223800048|NCT02813187|PROCEDURE|advanced wound therapy|
223800049|NCT02813187|DIETARY_SUPPLEMENT|Nutritional screening|
223800050|NCT06491771|DEVICE|TargetCool|The patients were treated with TargetCool via boosting mode combined with tranexamic acid and normal saline on each side of cheek for 4 times every 1 week
223800051|NCT02944136|BEHAVIORAL|enhanced usual care|usual care from health providers
223800052|NCT02944136|BEHAVIORAL|stepped collaborative care|Using website that was specifically designed for advanced cancer patient, collaborative with treatment from health professional
223800053|NCT02249819|DEVICE|transcranial direct current stimulation|Soterix 1x1 anodal tDCS
223800054|NCT05849779|DRUG|Inhaled sedation with sevoflurane|"In both arms, the management of sedation will be conducted in the broader picture of ICU patient care, as per current standard practice in participating ICUs, and following the current guidelines for Pain, Agitation, Delirium, Immobility, and Sleep Disruption (PADIS) published in 2018 by the Society of Critical Care Medicine.~Among many recommendations, this will include the monitoring and titration of both sedation and analgesia using validated scores such as the Richmond Agitation-Sedation Scale (RASS) for sedation. As a result of the current recommendations, the level, dose, and duration of sedation will vary among patients and will be decided by the treating clinicians. The choice of the analgesic drug(s) will be as per the treating clinicians.~Other aspects of critical care will adhere to standard care, including the use of the Checklist for Lung Injury Prevention (CLIP)."
223800055|NCT05849779|DRUG|Intravenous sedation (current practice)|"In both arms, the management of sedation will be conducted in the broader picture of ICU patient care, as per current standard practice in participating ICUs, and following the current guidelines for Pain, Agitation, Delirium, Immobility, and Sleep Disruption (PADIS) published in 2018 by the Society of Critical Care Medicine.~Among many recommendations, this will include the monitoring and titration of both sedation and analgesia using validated scores such as the Richmond Agitation-Sedation Scale (RASS) for sedation. As a result of the current recommendations, the level, dose, and duration of sedation will vary among patients and will be decided by the treating clinicians. The choice of the analgesic drug(s) will be as per the treating clinicians.~Other aspects of critical care will adhere to standard care, including the use of the Checklist for Lung Injury Prevention (CLIP)."
223800056|NCT00002558|BIOLOGICAL|filgrastim|
223800057|NCT00002558|DRUG|carboplatin|
223800058|NCT00002558|DRUG|etoposide|
223800059|NCT00002558|DRUG|ifosfamide|
223800060|NCT00002558|DRUG|paclitaxel|
223800061|NCT00002558|PROCEDURE|peripheral blood stem cell transplantation|
223800062|NCT06038760|PROCEDURE|Resection|Patients undergo a resection from a lesion, and give 40mL of blood
223800063|NCT04286139|BEHAVIORAL|SHAPE|The SHAPE intervention provides information for carers, and maintains the dignity and autonomy of the person with dementia, supporting them in planning for the future with their family. The person with dementia attends an online 10 week facilitator lead group based course. It is designed to develop self-management skills in areas including decision-making, symptom management and social interaction. It also provides information on the disease process and the development of healthy behaviors in a supportive learning environment to prevent problems that are common in the later stages of the disease. The adjunctive e-learning platform for carers provides the same information that the person with dementia receives plus additional material and signposting to support them in their role. This will empower the whole family to support and enable more effective self-management by the person with dementia, and enhance their ability to plan ahead together and make key decisions jointly.
223800064|NCT03360708|OTHER|Laboratory Biomarker Analysis|Correlative studies
223800065|NCT03360708|BIOLOGICAL|Malignant Glioma Tumor Lysate-Pulsed Autologous Dendritic Cell Vaccine|Given ID
223800066|NCT05571631|OTHER|exercise|Arm ergometer will aplied as an aerobic exercise. Combination of balance training and arm ergometer exerise program will applied.
223800067|NCT06131866|OTHER|Psychoeducation based on Acceptance and Commitment Therapy|Acceptance and Commitment Therapy Based Psychoeducation will be applied to the patients in the intervention group in the form of group education (consisting of 5-7 people), one session per week for eight weeks; no intervention will be applied to the control group.
223800068|NCT04989959|DRUG|[18F]PT2385|\[18F\]PT2385 infusion
223800069|NCT04989959|PROCEDURE|Positron Emission Tomography/Computed Tomography|PET/CT scan after \[18F\]PT2385 infusion
223800070|NCT04989959|PROCEDURE|Biopsy|CT-guided tumor biopsy
223800071|NCT02362529|DRUG|Minocycline|50 mg and 100 mg capsule, oral administration
223800072|NCT02362529|DRUG|Placebo|Lactose monohydrate in identical gel capsules to minocycline, oral administration.
223800073|NCT02362529|DRUG|Celecoxib|100 mg and 200 mg capsules, oral administration.
223800074|NCT02166424|DIETARY_SUPPLEMENT|Omega-3 polyunsaturated fatty acids|
223800075|NCT02166424|DIETARY_SUPPLEMENT|Olive oil|
223800076|NCT02045394|OTHER|Chest X-ray|
223800077|NCT02045394|OTHER|computed tomography of the chest|
223800078|NCT02045394|PROCEDURE|Bronchoscopy|In patients with haemoptysis bronchoscopy will be performed with flexible bronchoscope. A systemic research of bleeding site and causes will be done. Microbiological or pathological sampling will be executed if clinically required. In selected patients, bronchoscopy might be performed with the rigid instrument or the flexible bronchoscope in intubated patients.
223800079|NCT05214274|OTHER|No intervention would be taken|No intervention would be taken
223800080|NCT02660710|DRUG|R-CHOP|maximum of 6-8 cycles of R-CHOP over 18-24 weeks
223800081|NCT02065336|DRUG|ARC-520|
223800082|NCT02065336|DRUG|Placebo|
223800083|NCT02065336|DRUG|entecavir|
223800084|NCT02065336|DRUG|chlorpheniramine|In all cohorts, each participant received an 8 mg dose of oral chlorpheniramine 2 hours prior to each administration of ARC-520 Injection.
223800085|NCT03978234|DRUG|AbobotulinumtoxinA 300 UNT|AbobotulinumtoxinA 300 UNT
223800086|NCT05418036|DRUG|Sotalol Oral Tablet|Dose of sotalol is prescribed by the attending physician. Accepted for this protocol when the dose is no greater than 160 mg/day
223800087|NCT03118583|DIETARY_SUPPLEMENT|300 mg/day of dietary supplement containing carrageenan|300 mg/day of dietary supplement containing carrageenan.
223800088|NCT04315168|DEVICE|FRED and FRED JR|Intracranial aneurysm treatment
223800089|NCT02965950|DRUG|Cyclophosphamide|I.v. infusion
223800090|NCT00626028|DRUG|Nitric Oxide for inhalation|Nitric Oxide (NO) for inhalation, given at 80ppm over 10 minutes using an INOvent® delivery system
223800091|NCT00626028|DRUG|Oxygen|100% oxygen (O2) for inhalation, given at 80ppm over 10 minutes using an INOvent® delivery system
223800092|NCT00626028|DRUG|Nitric Oxide plus Oxygen|Nitric Oxide (NO) for inhalation plus oxygen, given at 80ppm over 10 minutes using an INOvent® delivery system
223800093|NCT03657433|DIETARY_SUPPLEMENT|Ferrous sulfate 325mg|Oral tablets supplied for home use
223800094|NCT03657433|DRUG|Ferumoxytol|Ferumoxytol will be administered in two infusions, one week apart
223800095|NCT01335204|DRUG|Cabazitaxel plus bavituximab|Cabazitaxel (25 mg/m2) will be administered IV on Day 1 of each 21-day treatment cycle, and bavituximab (3 mg/kg) will be administered as an IV infusion on a weekly basis (Cycle 1 Day 2, all other cycles Day 1; day 8; day 15) for 8 cycles.
223800096|NCT04496180|DEVICE|Closed incision negative pressure therapy versus standard dressing after emergency abdominal laparotomies|"Target population is every patient undergoing a laparotomic procedure and responding to inclusion criteria marked in paragraph 3.8 (see forward) A member of the medical surgery team should apply the PREVENA just after the surgical procedure.~A medical member (nurse specialist in wound care) of the surgical team removes the dressing. All other manipulations of the therapy unit, the connector and the cartridge can be carried out by any nurse practitioner in hospital or extra hospital environment but must warn the investigators.~The aspiration will be stopped 24 hours before and the dressing is removed by a nurse at home or in the hospital.~The specialized nurse who will take a photo and assess the condition of the wound in the treatment room.~One of the investigators, non-operators, who will also assess the condition of the wound by photo."
223800097|NCT02144064|DRUG|Heparin|Group A (n = 100) are put on Inj. UFH (Cal-heparin) 5000 U subcutaneous twice daily plusAspirin 81 mg/day (Juspirin) with the ﬁrst positive pregnancy test, Inj. UFH is given either into anterior abdominal wall or anterior aspect of thigh subcutaneously
223800098|NCT04880564|DRUG|CN1, 0.5mg/kg and CN401, 400mg|CN1(0.5mg/kg) will be administered on Day 1 of each cycle (once every three weeks) for up to 12 months and CN401(400mg) will be administered orally twice daily.
223800099|NCT04880564|DRUG|CN1, 1mg/kg and CN401, 600mg|CN1(1mg/kg) will be administered on Day 1 of each cycle (once every three weeks) for up to 12 months and CN401(600mg) will be administered orally twice daily.
223800100|NCT04880564|DRUG|CN1, 1mg/kg and CN401, 800mg|CN1(1mg/kg) will be administered on Day 1 of each cycle (once every three weeks) for up to 12 months and CN401(800mg) will be administered orally twice daily.
223800101|NCT04880564|DRUG|CN1, 3mg/kg and CN401, 800mg|CN1(3mg/kg) will be administered on Day 1 of each cycle (once every three weeks) for up to 12 months and CN401(800mg) will be administered orally twice daily.
223800102|NCT04880564|DRUG|CN1, 10mg/kg and CN401, 800mg|CN1(10mg/kg) will be administered on Day 1 of each cycle (once every three weeks) for up to 12 months and CN401(800mg) will be administered orally twice daily.
223800103|NCT03637946|OTHER|Device: SHOFU beautifil II LS|Restorative system FL-Bond II (self-etching adhesive system)/ beautifil II (composite restorative) were used following manufacturer's instructions
223800104|NCT03886532|OTHER|Medical Marijuana|registry and blood samples
223800105|NCT00104169|DRUG|Epoetin Alfa|
223800106|NCT06381089|DEVICE|Robotic Rehabilitation|Lokomat is an exoskeleton type robotic walking device that can support both extremities symmetrically.
223800107|NCT06381089|DEVICE|Transcutaneous Auricular Vagal Nerve Stimulation|Vagus nerve stimulation is defined as any technique that stimulates the vagus nerve in our body.
223800108|NCT00141427|DRUG|Pregabalin|
223800109|NCT04467554|DEVICE|T-chair|Participants will receive 15 sessions of intervention, four weeks in total with a duration of one hour for each session. The focus of the intervention will be trunk rehabilitation.
223800110|NCT01320007|DRUG|Preset increase in frusemide dose|"All patients in Group 1 will have the Optivol function and alerts switched on. Optivol levels will be downloaded monthly via the Medtronic Carelink Network (for those patients who have it) or during pacemaker follow up appointments.~If the Optivol alarm goes off, all patients will be requested to contact a member of the research team by phone and those with rising Optivol (irrespective of the presence or absence of heart failure symptoms) will be requested to increase the dose of diuretic that they are on by 50% for 1 week then revert to their usual dose after 7 days. A routine renal function check will be performed at the end of the week."
223800111|NCT01320007|OTHER|No intervention|The Optivol data for these patients will be downloaded periodically (at each scheduled device check) and recorded but will not be available at follow up in the heart failure clinic.. These patients will act as controls for group 1 patients. They will undergo baseline investigations and then will undergo routine heart failure treatment and follow-up in the heart failure clinic. These will include a routine clinical evaluation, body weight and blood analysis as per the heart failure clinic protocol. Medications will be reviewed and changed according to clinical needs.
223800112|NCT00831779|DRUG|Dapagliflozin|Tablets, Oral, 5 mg, once daily, 12 weeks
223800113|NCT00831779|DRUG|Placebo|Tablets, Oral, 0 mg, Once daily, 12 weeks
223800114|NCT00511017|DRUG|Doxercalciferol|.05 mcg/kg by mouth daily x 28 Days
223800115|NCT00372281|DRUG|Cliavist|Injection of 0,9 mL (weight \< 60kg) or 1,4 mL (weight \> 60kg) of Cliavist (ferucarbotran) by direct intraveinous way, 48 h following the MRI done with gadolinium.
223800116|NCT04269499|DEVICE|QuiremSpheres®|Radioembolization with QuiremSpheres® under MR imaging
223800117|NCT02235350|OTHER|Action Observation Treatment (AOT)|Participants will be asked to carefully observe at a computer screen videos depicting different daily actions. Each action will consist of 3 to 4 constituent motor acts. Each motor act will be presented for 3 minutes. As a whole, therefore, each video will be 12 minutes long. At the end of each motor act presentation, participants will be required to execute with the affected hand the observed motor sequence for 2 minutes. Each single rehabilitation session based on AOT will last 20 minutes. We will record ten daily actions for a total of ten video-clips. Participants will be presented with each video clips, twice a day, in order of complexity as judged by the experimenter. Participants will undergo 10 sessions a week, each lasting 20 minutes for 2 weeks.
223800118|NCT02235350|OTHER|Observation of videos with no motor content (MNO)|Participants will be asked to observe video clips with no specific motor content. Videos will concern scientific, geographical and historical issues. As for cases, video clips will be divided into three to four parts. At the end of each part, controls will execute the same actions as cases, in the same order. In this way cases and controls will undergo the same amount of motor practice and receive the same amount of visual stimulation, the only difference being the content of visual stimuli.
223800119|NCT06335433|OTHER|Exercise Training (Isometric Handgrip Exercise)|Participants allocated to the exercise groups will complete 6 weeks of isometric handgrip exercise training (IHGT) using an electronic hand dynamometer (Camry EH101, Zhongshan Camry Electronic Co. Ltd, Guangdong) for either 2 or 4 sessions per week. Each exercise session will consist of 4 x 2-minute isometric contractions at 30% MVC with 1 minute rest periods between contractions. The first bout will be performed on the dominant arm and then the arm will be alternated for each subsequent two-minute bout. Participants will be instructed to try keep the contraction tension as close as possible to the set tension of 30% MVC using visual feedback from the dynamometer's electronic display.
223800120|NCT03689335|PROCEDURE|Operative|Open reduction and internal fixation, using a plate and screws (the exact surgical approach and fixation technique utilised will be at the discretion of the treating surgeon)
223800121|NCT03689335|DEVICE|Humeral brace|Immobilisation in a U-slab or hanging cast, followed by application of a lightweight prefabricated humeral brace
223800122|NCT02769286|DRUG|Osimertinib|Treatment efficacy of osimertinib will be assessed in patients with lung cancer harboring EGFR mutations (cohort 1) and those harboring T790M (cohort 2) which were detected from circulating tumor DNA
223800123|NCT00713440|OTHER|Oral glucose test (OGTT); isoglycaemic iv. clamp; liquid meal test; Gastric Emptying Rate; Prednisolone; Paracetamol|"OGTT: The test is performed with 50 g of glucose deluded in 300 ml. of water. Isoglycaemic iv. clamp: Iv glucose infusion mimicking the glucose response curve of the OGTT.~Liquid Meal Test: The test is performed with 100g of formula milk in 300 ml. of water.~Gastric Emptying Rate: Paracetamol absorption test. Adrenocortical Steroids: Use of 37,5 mg./day of prednisolone during 10 days"
223800124|NCT05108792|OTHER|NO INTERVENTION|observational study, no intervention performed
223800125|NCT05895266|DRUG|ABBV-903|Oral Tablet
223800126|NCT05895266|DRUG|Midazolam|Oral Liquid
223800127|NCT04150003|BEHAVIORAL|Pulmonary Rehabilitation program|Structured rehabilitation program of directed exercises
223800128|NCT04150003|OTHER|Usual care|Usual care for patients who had suffered a Pulmonary Embolism
223800129|NCT00096694|DEVICE|Levonorgestrel-releasing intrauterine device (IUD)|
223800130|NCT02436330|BEHAVIORAL|Exergaming|"6 months of weight management programming consisting of 10 weekly sessions:1 hour of session was spent exergaming, which included active video game play and traditional group exercises. Some examples include: Dance, Dance, Revolution, Exerbike, Treadwall, Yoga, Spin class, etc."
223800131|NCT02436330|BEHAVIORAL|Didactic health teaching|6 months of weight management programming consisting of 10 weekly 1-hour sessions of didactic classes teaching behavioral and dietary curricula. Followed by monthly 1 hour didactic health teaching sessions for the remainder of the 6 month period.
223800132|NCT00174525|DRUG|AAB-001|
223800133|NCT04010630|DRUG|Sodium bicarbonate infusion|"Patients randomly assigned to bicarbonate group will receive intravenous 4.2% sodium bicarbonate titrated from 125ml to 250ml in 30min at physician's discretion to target a pH equal or above 7.30. Bicarbonate infusion will be repeated up to 1000ml per 24h. Arterial blood gases will be repeated from 3 to 6 times during the first 24h at physician's discretion.~Bicarbonate infusion recommendations will be as follow: a central line is recommended, infusion will be slow (125-250ml in 30 min, no intravenous push), careful surveillance of metabolic alkalosis, cardiogenic pulmonary edema, kalemia, natremia and calcemia. Repeated arterial blood gases will be suggested to monitor these critically ill patients and physicians will be reinformed of the potential side effects of sodium bicarbonate infusion."
223800134|NCT05830994|PROCEDURE|G-POEM|An Endoscopic submucosal tunnel is formed and extended to the first part of the duodenum, followed by a pyloromyotomy, beginning approximately two centimetres proximal to the pylorus and ending in the first part of duodenum.
223800135|NCT05830994|PROCEDURE|Sham|Endoscopy is performed and tissue samples are collected from fundus and antrum as part of the Sham procedure
223800136|NCT00163579|DRUG|Bryophyllum|
223800137|NCT00163579|OTHER|Placebo|
223800138|NCT03610295|PROCEDURE|PPI group|The patients underwent cataract extraction, posterior capsulotomy, anterior vitrectomy combined with prophylactic peripheral iridectomy.
223800139|NCT03610295|PROCEDURE|cataract extraction|The patients underwent cataract extraction, posterior capsulotomy combined with anterior vitrectomy and leave the iris intact.
223800140|NCT04483310|BEHAVIORAL|MR therapy.|MR therapy is based on 4 steps applied directly during the attack: Step I: Reappraisal of the meaning of the attack; Step II: psychological and emotional distancing; Step III: inward focused-attention meditation; Step IV: Muscle relaxation.
223800141|NCT04483310|BEHAVIORAL|breathing-distraction exercise|The control intervention is based on a breathing exercise, the patients should entail slow deep breaths, while repeatedly counting from 1-10
223800142|NCT03758963|DEVICE|R:GEN Selective Retina Therapy|Selective Retina Therapy (SRT) is the treatment method using innovative laser technology with the wavelength absorbed by melanosomes such as laser photocoagulation, but due to short pulse width (1.7 µs) with 100 Hz repetition rate, Retinal Pigment Epithelium (RPE) cells may be destroyed only through the generation of microbubble around melanosomes (photomechanical action), and no thermal damage of normal cells or tissues may occur in the surrounding tissues. SRT influences the RPE wound healing, including migration and proliferation of RPE cells, which treats CSC in the mechanism of recovering RPE. Once RPE is recovered, the sub-retinal fluid may be pumped out and retinal function again recovered. Moreover, previous studies showed that SRT may stimulate a moderate increase of activated metalloproteinase (MMP), leading to the improvement of Bruch's membrane's transport property.
223800143|NCT00526643|DRUG|gemcitabine|1200 mg/m2 intravenous infusion on days 1 and 8, every 3 weeks for a maximum of 4 cycles
223800144|NCT00526643|DRUG|cisplatin|cisplatin 60 mg/m2 on day 1 for 4 cycles
223800145|NCT02804087|DEVICE|MobiusHD|The MobiusHD device is a self-expanding nitinol implant that is delivered intravascularly to the internal carotid sinus via the delivery catheter.
223800146|NCT02804087|OTHER|Sham Implantation|Sham Implantation
223800147|NCT00768820|DRUG|methylphenidate, fluoxetin, risperidone|first cognitive evaluation without methylphenidate,second cognitive evaluation with methylphenidate
223800148|NCT06525948|DRUG|rhTPO|rhTPO
223800149|NCT06525948|DRUG|Cyclosporin A|cyclosporine A
223800150|NCT03965156|PROCEDURE|1) Ultrasound guided Erector spinae block|In the lateral position, after skin sterilization, erector spinae plane block will be performed at the level of T9. Counting down from the spine of seventh cervical vertebrae, the spine of the nine thoracic vertebrae (T9). A linear low frequency ultrasound transducer (US) (3-5 MHz) will placed sagittal 3cm lateral to midline to visualize the muscles of the back, transverse process and simmering pleura in between transverse processes. A 22-gauge short bevel needle will be inserted in cranial-caudal direction towards transverse process (TP) in plane to the US transducer until needle touched the TP crossing all the muscles. The location of the needle tip will be confirmed by visible normal saline fluid separating erector spinae muscle off the bony shadow of the transverse process on ultrasound imaging. Then 20 ml of bupivacaine 0.375% plus plus 5ug/ml adrenaline (1:200000) will be injected. The procedure will be repeated following the same steps on the other side of the back.
223800151|NCT03965156|PROCEDURE|Ultrasound guided transversus abdominis plane block|in supine position and after skin sterilization. The linear high frequency transducer (6-13 MHz) will be placed in the transverse plane to the the lateral abdominal wall in the midaxillary line, between the lower costal margin and iliac crest. The three abdominal wall muscles (external oblique, internal oblique, and transversus abdominis) are visualized. The needle inserted in plane and advanced anterior to posterior under continual visualization until the tip between the internal oblique and the transversus abdominis muscle. After negative aspiration, a 20 ml of bupivacaine 0.375% plus 5ug/ml adrenaline (1:200000) will be injected. The success of the injection will be confirmed by separation of the internal oblique and transversus abdominis with a distinct pocket of local anesthetic in between. The procedure will be repeated following the same steps on the other side.
223800152|NCT02608398|OTHER|no intervention|NO intervention by the research group - this is an observational study. urine samples simply collected as children lose weight on their diet and exercise camp
223800153|NCT02370433|DRUG|Intravenous Neostigmine and Glycopyrrolate|
223800154|NCT02370433|DRUG|Transdermal Neostigmine and Glycopyrrolate|
223800155|NCT06490562|DRUG|PDCy|Low dose Cy 30 mg/kg/d was administered on the 3rd and 4th day after gDLI to prevent GVHD
223800156|NCT06490562|DRUG|Non Cy|Oral administration of low-dose CNI (CSA 25mg Q12H or FK506 0.25mg Q12H combined with azole fungal drugs) for 2 weeks to prevent GVHD at 0 days after gDLI
223800157|NCT01063101|OTHER|Fucoidan (extract of Laminaria japonica)|Capsule (300 mg/capsule) - oral administration - 5 different dose levels - BID
223800158|NCT01063101|OTHER|Placebo|Cellulose filled capsule - oral administration - 5 different dose levels - BID
223800159|NCT01875380|DRUG|Regorafenib|
223800160|NCT03386201|DRUG|Intravenous Methylene blue|Methylene blue fluorescence cholangiography during laparoscopic cholecystectomy
223800161|NCT00489385|DRUG|Albinterferon|
223800162|NCT00489385|DRUG|Ribavirin|
223800163|NCT00489385|DRUG|Albuferon|
223800164|NCT02133534|DRUG|Atorvastatin|
223800165|NCT04969484|OTHER|Telehealth visit|ImPACTT Telehealth visit with the PC provider
223800166|NCT01786486|DEVICE|Amplatzer Cardiac Plug|
223800167|NCT03994458|BEHAVIORAL|Smartphone Full version application|Android smartphone experimental application include: rehabilitative self-administered evidence-based exercises (Strengthening and stretching), ergonomics, and education related to low back pain. The application includes videos, photos, text, and reminders.
223800168|NCT03994458|BEHAVIORAL|Samartphone limited version application|Android smartphone placebo application include: ineffective content that does not help in treating low back pain. The application includes only five posts in the general instruction and advises section about proper nutrition and few irrelevant reminders.
223800169|NCT01855217|DRUG|Sugammadex|1 mg/kg total BW based sugammadex reversal of deep block
223800170|NCT01855217|DRUG|Sugammadex|1 mg/kg ideal BW based sugammadex reversal of deep block
223800171|NCT01855217|DRUG|Placebo|0,9% NaCl
223800172|NCT01342224|BIOLOGICAL|tadalafil and vaccination|Participants receive a 4-week course of vaccination with telomerase vaccine and GM-CSF by injection, along with a cycle of gemcitabine chemotherapy (IV). This is followed by radiation and gemcitabine given twice weekly then by another dose of vaccine. Four weeks after completion of chemotherapy and radiation, participants able to have surgical treatment will have surgery followed by vaccination and chemotherapy. Participants with stable or responsive disease that cannot be treated by surgery will have vaccination and chemotherapy with 2 cycles of telomerase vaccine with GM-CSF along with gemcitabine. Participants with unresectable and progressive disease after administration of vaccine, chemotherapy and radiation treatment may transition to vaccination and chemotherapy treatment.
223800173|NCT03471663|DRUG|D-0502|oral tablets
223800174|NCT03471663|DRUG|palbociclib|standard dose of palbociclib
223800175|NCT03226964|DEVICE|high flow nasal oxygen|humidified high flow nasal oxygen
223800176|NCT04969237|DIAGNOSTIC_TEST|Vitamine D in blood samples|vitamine D values
223800177|NCT00881491|DRUG|Double Antibiotic Paste|ciprofloxacin and metronidazole powder mixed at a 1:1 ratio used as a intracanal medicament for disinfection.
223800178|NCT00881491|DRUG|Triple Antibiotic Paste|ciprofloxacin, metronidazole \& minocycline mixed to a 1:1:1 powder used as a intracanal medicament for disinfection.
223800179|NCT00881491|DRUG|Mineral Trioxide Aggregate|standard material providing an apical barrier
223800180|NCT01375114|DRUG|Panax Ginseng|400 mg by mouth twice daily from Day 1-29.
223800181|NCT01375114|DIETARY_SUPPLEMENT|Placebo|Placebo by mouth twice daily for 4 weeks.
223800182|NCT01375114|BEHAVIORAL|Questionnaires|Completion of questionnaires taking about 30 minutes on Day 15 (± 3 days), Day 29 (± 3 days), and Day 57 (± 3 days), regarding symptoms such as fatigue, mood, depression, anxiety, nausea, appetite problems, sleep problems, and overall sense of well-being.
223800183|NCT03575325|DRUG|CPX-351|The infusion of CPX-351 (cytarabine:daunorubicin) Liposome Injection will be performed through a central venous catheter, using an infusion pump to ensure that the drug is infused over the specified time period.
223800184|NCT01882322|DRUG|Prograf|oral
223800185|NCT01882322|DRUG|Advagraf|oral
223800186|NCT01368367|OTHER|Intensive exercise|Both groups, stretching exercise monitored once per week Intensive exercise group An aerobic and resisted exercise program for a minimum of three times per week for a total of approximately 60 minutes per session for six weeks. Aerobic exercise will be conducted on a treadmill, exercise bike or arm ergometer at an intensity of 80 % of VO2peak during initial assessment. For resistance exercise, the three repetition maximum (3RM) (maximum weight able to be lifted a maximum of 3 times) will be established and then resisted exercise will be commenced at 60% of the 3RM in the first week. Resisted exercise will then be progressed weekly by 5-10% by increasing the number of repetitions or the weights lifted. All resisted exercises will be done using variable resistance machines or free weights.
223800187|NCT00109616|BEHAVIORAL|Newborn skin cleansing with 0.25% chlorhexidine solution|
223800188|NCT00109616|BEHAVIORAL|Cleansing of umbilical cord with soap and water solution|
223800189|NCT00109616|BEHAVIORAL|Cleansing of umbilical cord with 4% chlorhexidine|
223800190|NCT00146575|DEVICE|Sirolimus-eluting stent (Cypher)|patients have been implanted a Cypher stent
223800191|NCT00146575|DEVICE|Paclitaxel-eluting stent (Taxus)|patients have been implanted a Taxus stent
223800192|NCT04262362|PROCEDURE|Root canal treatment|Incidence of pain that may occur due to sodium hypochlorite extrusion
223800193|NCT00162370|DRUG|Perflutren Lipid Microsphere Injectable Suspension|Activated DEFINITY 10ug/kg by bolus injection
223800194|NCT00606775|DRUG|Carvedilol|2.5-5mg/day
223800195|NCT06579118|OTHER|Laughter yoga|The women in the experimental group were given laughter yoga sessions by the researcher.
223800196|NCT03154216|BEHAVIORAL|Exercise|90 minutes of moderate-intensity walking exercise on a treadmill
223800197|NCT03154216|OTHER|Drink|Beverage to be consumed after exercise
223800198|NCT05431075|DRUG|Amoxicillin|Included in quadruple eradication medication.
223800199|NCT05431075|DRUG|Tetracycline tid|Included in quadruple eradication medication.
223800200|NCT05431075|DRUG|Tetracycline qid|Included in quadruple eradication medication.
223800201|NCT05431075|DRUG|Bismuth Potassium Citrate|Included in quadruple eradication medication.
223800202|NCT05431075|DRUG|Colloidal Bismuth Pectin|Included in quadruple eradication medication.
223800203|NCT05431075|DRUG|Esomeprazole 20mg|Included in quadruple eradication medication.
223800204|NCT04040751|BEHAVIORAL|CARE-CITE|The primary CARE-CITE components will be education via web platform. Carepartners complete 6 online CARE-CITE modules (15-30-minute sessions each). The modules include demonstration videos and instructive content covering following areas: principles of functional task practice (i.e., activities of daily living such as eating, grooming, or leisure/vocational activities), adaptation of tasks, and importance of progression of challenging tasks to drive neuroplasticity (i.e., increasing numbers of practice repetitions or weight of objects lifted). Underpinning the content is the concept of autonomy support, with examples of fostering empathy, problem solving, instruction in the use of non-controlling language with role playing situations and the importance of creating choice in activities.
223800205|NCT04040751|BEHAVIORAL|Standard of care|The carepartner will receive a support brochure with general caregiving information including website resources to mimic web interaction of intervention group (e.g., stroke caregiver resource site).
223800206|NCT03298009|DRUG|Canagliflozin 100mg|2-week intervention
223800207|NCT03298009|DRUG|Placebo oral capsule|2-week intervention
223800208|NCT03298009|RADIATION|PET imaging|1 day postprandial metabolic protocol at the end of treatment: CT scan followed by dynamic and pancorporel imaging
223800209|NCT06066060|DRUG|JMKX000623|JMKX000623, administered orally ;
223800210|NCT06066060|DRUG|Metformin|Metformin,administered orally
223800211|NCT02472964|BIOLOGICAL|Trastuzumab|Trastuzumab 8mg/kg Iv over 90 minutes x 1 then Trastuzumab 6 mg/kg IV over 30 minutes every 3 weeks
223800212|NCT02472964|BIOLOGICAL|MYL- 1401O|MYL-1401O 8mg/kg Iv over 90 minutes x 1 then HERMyl 1401O Trastuzumab 6 mg/kg IV over 30 minutes every 3 weeks
223800213|NCT02472964|DRUG|Paclitaxel|Paclitaxel 80mg/m2 IV over 60 minutes weekly.
223800214|NCT02472964|DRUG|Docetaxel|Docetaxel 75mg/m2 IV over 60 minutes on day 1 of a 3 week cycle
223800215|NCT00403416|DRUG|AEB071|
223800216|NCT00403416|DRUG|Mycophenolic Acid|
223800217|NCT00244296|DRUG|Duloxetine hydrochloride|
223800218|NCT00244296|DRUG|placebo|
223800219|NCT04941040|DRUG|Opioid free anesthetics|"Patients will receive over the 10 minutes prior to induction:~* Acetaminophen 1 gm i.v. infusion in 100ml over 10 minutes.~* Ketorolac 30 mg i.v. infusion in100 ml over 10 minutes.~* Mg SO4 loading dose 30 mg/kg i.v. infusion in 100 ml over 10 minutes.~* Dexmedetomidine loading dose 1 μg/kg i.v. infusion.~* Lidocaine loading dose 1.5 mg/kg i.v. infusion.~* Ketamine loading dose 0.25 mg/kg i.v. infusion.~The weight based doses of dexmedetomidine, lidocaine, ketamine will be prepared on 20 ml syringe and infused over 10 minutes prior to induction. In a dose of 0.1 ml/kg~Then after induction maintenance analgesic infusion will start in a rate that ranges from 0.025 to 0.05 ml/kg/h which is equivalent to:~* Dexmedetomidine 0.25-0.5 μg/kg/h~* Lidocaine 0.375-0.75 mg/kg/h~* Ketamine 0.0625- 0.125 mg/kg/h"
223800220|NCT04941040|DRUG|Opioid Anesthetics|Placebo equivalent to acetaminophen, ketorolac, magnesium sulphate will be infused as 100 ml normal saline each over 10 minutes ,patients will receive fentanyl 2 μg/kg loading dose which will be prepared over 20 ml syringe and infused over 10 minutes prior to induction, Then after induction maintenance of analgesic infusion by fentanyl 0.5-1 μg/kg/h.
223800221|NCT02766569|DEVICE|ASD closure with the Occlutech Flex II ASD closure device|Monitoring of possible device related side effects with a minumum of 1 year follow-up.
223800222|NCT04534374|BEHAVIORAL|Resistance exercise|Barbell back squat, press, and deadlift for three sets of five repetitions with the weight closest to 75% of their estimated 1 repetition max. The participants were instructed to execute the movement with moderate speed (2s eccentric, 2s concentric, no pause in between). The rest period between sets and exercise movements was two to three minutes.
223800223|NCT04534374|BEHAVIORAL|Stretching exercise (sham exercise)|Participants completed a passive stretching exercise session for a similar duration of time as the resistance exercise (≈ 30 min) as sham intervention, which included 15-20 stretching movements twice, holding each for 30 seconds as recommended by ACSM.
223800224|NCT01749982|OTHER|Placebo|
223800225|NCT01749982|DRUG|Choline bitartrate|
223800226|NCT01749982|DRUG|Betaine|
223800227|NCT01749982|DRUG|Choline bitartrate + Betaine|
223800228|NCT02302443|BIOLOGICAL|HM12470|Single dose subcutaneous administration ranging from a very low dose to high dose
223800229|NCT02302443|BIOLOGICAL|Active comparator|Single dose subcutaneous administration of active comparator
223800230|NCT03189017|DRUG|ICP-022|The drug product is a white, round, uncoated tablet.
223800231|NCT03189017|DRUG|Placebos|The placebo is a white, round, uncoated tablet.
223800232|NCT05817851|DRUG|Vitamin C (Laroscorbine) + Vitamin B1 (Bevitine)|in addition of standard post-CA as the control group, patients will receive an IV high-dose vit-C 50mg/kg infusion every 6 hours, started within the hour after randomization, for 3 days. In addition, all patients will receive intravenous thiamine 200 mg twice a day for 3 days to limit the oxalate production.
223800233|NCT05817851|DRUG|standard treatment|no intervention Standard IV vit-C supplementation will be allowed for dosages up to 1000 mg a day from day 4 after randomization, as well as thiamin supplementation.
223800234|NCT04822038|DIETARY_SUPPLEMENT|Vitamin D3|5000 UI Vitamin D3 daily by 4 weeks
223800235|NCT04822038|OTHER|Dietary recommendations|Dietary recommendations based on food rich in 25 (OH) vitamin D
223800236|NCT04950374|OTHER|Moisturizer Body Lotion|The body lotion product is a moisturizing formulation intended for topical use on the whole body and face. It will be applied at least twice daily.
223800237|NCT04950374|OTHER|Lip Moisturizer|The lip product is a moisturizing formulation intended for topical use on the lips. It will be applied at least twice daily.
223800238|NCT01596582|BEHAVIORAL|Risk Assessment|Patients randomized to the experimental arm will be asked a complete the ACNI risk assessment tool after reviewing a web-based colorectal cancer decision aid. The ACNI uses a point based system to stratify patients into low (mean rate of ACN \~3%) versus intermediate/high (\~ 8%) risk groups based on responses to 6 items: age (50-59, 60-69, 70+), sex (male/female), race/ethnicity (non-Hispanic black, other), smoking history (never, \<20 years, 20+ years), daily alcohol intake (\< 2 vs. \>/=2 drinks) and use of non-steroidal anti-inflammatory drugs (ever, never). The index represents a prototype version of the Advanced Colorectal Neoplasia Index (Am J Gastroenterol 2015;110:1062-71).
223800239|NCT05798195|OTHER|conventional western medicine treatment|conventional western medicine treatment only
223800240|NCT05798195|DRUG|Dexamethasone oral tablet|treat with Dexamethasone for 2 weeks
223800241|NCT05798195|OTHER|Traditional Chinese medicine decoction|treat with strengthening spleen and tonifying lung decoction for 2 weeks
223800242|NCT00204048|BEHAVIORAL|Observation (behavior)|Inpatients admitted in GenMed at the University of Chicago will be consented to participate in an inpatient interview that consists of questions related to quality of care and satisfaction. The patient will also be interviewed over the phone 30 days after discharge and will be asked questions related to current health and their satisfaction during their stay at University of Chicago.
223800243|NCT04635553|DRUG|Praziquantel 600 milligram|A single treatment with a dose of 40 milligram/kilogram (mg/kg)
223800244|NCT00006352|BIOLOGICAL|BCG vaccine|
223800245|NCT00006352|BIOLOGICAL|monoclonal antibody BEC2|
223800246|NCT01398150|DIETARY_SUPPLEMENT|Beverage made to look like the cranberry beverage|one 15 ounce bottle of beverage consumed daily
223800247|NCT01398150|DIETARY_SUPPLEMENT|Beverage made from cranberry compounds|one 15 ounce bottle consumed daily for 70 days
223800248|NCT01846182|DRUG|Duloxetine|serotonin norepinephrine reuptake inhibitor
223800249|NCT01846182|DRUG|Pregabalin|alpha-2-alpha subunit calcium channel ligand
223800250|NCT01846182|DRUG|Placebo|Placebo
223800251|NCT03923933|DRUG|Chlorthalidone|Chlorthalidone
223800252|NCT03923933|DRUG|Bumetanide|Bumetanide
223800253|NCT01435538|BEHAVIORAL|Care pathway.|The intervention group will implement a care pathway for PFF or COPD containing three active components: a formative evaluation of the actual teams' performance, a set of evidence based key interventions and a training in pathway-development.
223800254|NCT00419263|DRUG|Peramivir 150 mg|Single dose administered as bilateral 2-mL intramuscular injections in each gluteal muscle (one injection of peramivir 150 mg and one injection of placebo).
223800255|NCT00419263|DRUG|Peramivir 300 mg|Single dose administered as bilateral 2-mL intramuscular injections in each gluteal muscle (2 injections of peramivir 150 mg).
223800256|NCT00419263|DRUG|Placebo|Single dose administered as bilateral 2-mL intramuscular injections in each gluteal muscle (2 injections of placebo).
223800257|NCT05314036|OTHER|Standardized test meal|During this study visit, a standardized test meal will be administered. Blood samples will be collected at baseline and then every 30 minutes for 2 hours after test meal.
223800258|NCT05480475|DRUG|Dabigatran etexilate|On Day 1 (Treatment A1) and on Day 9 (Treatment C1) a single oral dose of 75 mg dabigatran etexilate will be administered under fasted conditions.
223800259|NCT05480475|DRUG|Rosuvastatin|On Day 3 (Treatment A2) and on Day 11 (Treatment C2) a single oral dose of 10 mg rosuvastatin will be administered under fasted conditions.
223800260|NCT05480475|DRUG|Daridorexant|On Day 7 and Day 8 (Treatment B), on Day 9 and Day 10 (Treatment C1), and on Day 11 through 14 (Treatment C2) subjects will receive 50 mg daridorexant o.d. under fasted conditions.
223800261|NCT00343928|OTHER|Branched-chain amino acids|Participants will spend approximately 2 weeks in each phase over a 9-week period, during which they will receive an amino acid mixture and the placebo control condition.
223800262|NCT00400335|DRUG|Nanomilled testosterone|
223800263|NCT00400335|DRUG|commercially available dutasteride|
223800264|NCT00400335|DRUG|Nanomilled dutasteride|
223800265|NCT06246604|DIAGNOSTIC_TEST|Ultrasound screening for lower limbs DVT|Using a linear ultrasound probe (7.5-12 MHz) a compression ultrasound of the lower limbs is performed, from the hip to the ankle. The exam is completed by the use of Doppler.
223800266|NCT06246604|DIAGNOSTIC_TEST|Standard-of-care|Ultrasound examination of lower limbs is performed according to clinical risk of DVT
223800267|NCT01372306|DRUG|Reminyl|Galantamine Hydrobromide Tablets of Dr. Reddy's Laboratories Limited
223800268|NCT00274638|DRUG|Telmisartan & Hydrochlorothiazide|
223800269|NCT00274638|DRUG|Losartan & Hydrochlorothiazide|
223800270|NCT00274638|PROCEDURE|ABPM|
223800271|NCT00002258|DRUG|Interleukin-3|
223800272|NCT06470165|PROCEDURE|Priority-matching correction technique in DLS|"For Type 1 global coronal malalignment (GCM), TL/L curve makes the primary contri- bution on C7PL shifting. First, inserting pedicle screws bilaterally. Second, aggressively decreasing the magnitude of TL/L curve. Third, moderately leveling L4 endplate to pull the fusion segments to the middle line with hand pressure on the convexity of TL/L curve. If the correctability of the key curve was limited, the correction of the minor curve would be con- vergent.~For Type 2 GCM, LS curve makes the primary contribution on C7PL shifting. First, releasing LS curve from the concave side using facetectomy after screws inserted. Second, performing L4-5 or L5-S1 trans- foraminal lumbar interbody fusion (TLIF) from the con- vexity of the fractional curve, with cages inserted at the concave side to assist deformity correction. Third, compressing the convexity of LS to horizontalize L4 endplate, followed by moderate manipulative reduction of TL/L curve to adjust intraoperative coronal balance."
223800273|NCT06470165|PROCEDURE|Traditional correction technique in DLS|"In concave coronal malalignment (CM), the correction of the main curve improves the CM, thus we can talk about convergent corrective objectives. The ability to correct the CM depends on the correctability of the main curve. The need of three-column osteotomies in order to obtain correction of CM depends on the location and flexibility of the main curve.~The correction of convex CM depends on the correction of the lumbosacral curve. The correction strategy will depend on many factors including the driver of the deformity, which should always be fused, but also the degeneration and stiffness of the compensatory curve which can lead to more extended fusion. The need of three-column osteotomies depends mainly on the stiffness of the lumbosacral curve."
223800274|NCT05304169|DRUG|Leuprorelin Acetate (Eligard® 45 mg).|Semiannually Leuprorelin Acetate (Eligard® 45 mg).
223800275|NCT02291731|DRUG|Continuous use of topical autologous serum|Silicone-hydrogel SCLs combined with 20% (v/v) autologous serum eye drops were used until complete re-epithelialization. SCLs were removed after total re-epithelialization and patients were subsequently randomized divided into two groups: (1) with and (2) without continuous use of topical autologous serum for an additional 2 weeks after SCLs removal.
223800276|NCT06010082|BEHAVIORAL|Music Therapy|Music Therapy intervention will be delivered through instructed participants to empty their bladder and then listen to music for 30 min in a semi-fowler's position with their head and shoulders raised 30° in a quiet and dim environment, listening to the music of symphonic music.
223800277|NCT00561210|DIETARY_SUPPLEMENT|Crucial|Treatment between minimum 14 days and maximum 6 months. Apports depend on method of CURRERI.
223800278|NCT00561210|DIETARY_SUPPLEMENT|Sondalis HP|Treatment between minimum 14 days and maximum 6 months. Apports depend on method of CURRERI.
223800279|NCT00156793|PROCEDURE|AI-700 contrast-enhanced echocardiography|
223800280|NCT01732068|DRUG|Triptorelin|Triptorelin 0.1 mg/1 ml solution daily from day 1 or 2 of the cycle onwards
223800281|NCT01732068|DRUG|Corifollitropin alfa|Corifollitropin alfa 150μg (single dose) on day 2 or 3 of the cycle
223800282|NCT01732068|DRUG|hpHMG|300IU hMG daily from day 7 following Corifollitropin alfa until the day of ovulation triggering
223800283|NCT00587964|RADIATION|Stereotactic Radiosurgery|"All patients would undergo craniotomy and the goal of surgery in all cases would be total removal of the metastases. The patient will initially receive premedication with 0.5- 1mg of Ativan orally prior to SRS procedure. Subsequently, the patient will have the stereotactic head ring placement under local anesthesia. A peripheral IV will be placed for administration of the intravenous contrast. Thin-section CT images will be obtained with intravenous contrast with head ring in place for the purpose of treatment planning.~A fusion program will be used to combine the recently obtained MRI images along with the CT scans. The target volume as well as the critical structures will be contoured. SRS would be delivered using either the Brain Lab or Radionics Radiosurgery planning and delivery system. Patients would receive a single treatment ranging from 15-22 GY."
223800284|NCT05321680|OTHER|Treatment withdrawal|Tapering or suspension of antidementia drugs
223800285|NCT02671032|DEVICE|Nucleus CI532 cochlear implant|
223800286|NCT00540124|DRUG|Tadalafil|5 mg once a day
223800287|NCT00540124|DRUG|Placebo|once a day
223800288|NCT00540124|DRUG|Tamsulosin|0.2 mg once a day
223800289|NCT01538732|DRUG|alitretinoin|30mg capsules (Alitretinoin)will be taken peroral once daily with a meal. Study treatment will be given for a total duration of up to 24 weeks
223800290|NCT04508595|DIAGNOSTIC_TEST|RestEaze|Wearable band to detect leg movements of sleep
223800291|NCT01744652|DRUG|Crizotinib|"Arm A Crizotinib dose: 250 mg by mouth twice a day in a 28 day cycle. Crizotinib Expansion dose: 250 mg by mouth twice a day in a 28 day cycle.~Arm B Crizotinib starting dose: 250 mg by mouth every other day in a 28 day cycle. Crizotinib Expansion Dose: MTD from dose escalation group."
223800292|NCT01744652|DRUG|Dasatinib|"Arm A Dasatinib starting dose: 50 mg by mouth daily in a 28 day cycle. Arm A Dasatinib Expansion Dose: MTD from dose escalation group.~Arm B Dasatinib dose: 140 mg by mouth daily in a 28 day cycle. Arm B Dasatinib Expansion Dose: 140 mg by mouth daily in a 28 day cycle."
223800293|NCT02763800|DRUG|BIA 3-202|BIA 3-202 (50, 100 and 200 mg) was administered in the form of oral tablets, given with 200 ml potable water.
223800294|NCT02763800|DRUG|Placebo|Matched placebo was administered in the form of oral tablets, given with 200 ml potable water
223800295|NCT00975312|DRUG|Triple combination cream|The triple combination cream (hydroquinone 4%, tretinoin 0.05%, and fluocinolone acetonide 0.01%) was applied on the whole back of one hand once daily for up 12 weeks.
223800296|NCT00975312|DRUG|Tretinoin 0.05%|Tretinoin 0.05% cream was applied on the whole back of the other hand once daily for up 12 weeks.
223800297|NCT03118024|DRUG|Crystalloid Solutions|crystalloid restrictive anesthesia protocol
223800298|NCT03118024|DRUG|Catecholamines|catecholamine restrictive anesthesia protocol
223800299|NCT03031964|DEVICE|revision multihole acetabular cup|post market study of multi hole revision acetabular cup
223800300|NCT04540874|DRUG|BI 894416|BI 894416
223800301|NCT04540874|DRUG|Placebo|Placebo
223800302|NCT05035472|DRUG|Phenylephrine|An initial prophylactic bolus dose of phenylephrine (37.5μg) simultaneous with spinal anesthesia. If the patient did not respond adequately to the current dose (SBP decreased to \< 80% of baseline), the dose was considered to have failed and the subsequent dose for the following patient was increased to the next higher dose level. The dose administered to subsequent patients varied by increments or decrements of 12.5 μg according to the responses of previous patients according to the up-down sequential allocation.
223800303|NCT05035472|DRUG|Norepinephrine|An initial prophylactic bolus dose of norepinephrine (3μg) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 1 μg according to the responses of previous patients according to the up-down sequential allocation.
223800304|NCT00331643|DRUG|ixabepilone|Given IV
223800305|NCT01207102|DRUG|Abraxane|Abraxane® 100 mg/m2 IV over 30 min days 1,8,15 every 28 days
223800306|NCT01207102|DRUG|Carboplatin|area under curve(AUC)=2 over 15 minutes days 1,8,15 every 28 days
223800307|NCT03115892|DRUG|Green Tea With Aloe Vera mouthwash|measuring Tool/device Smell identification test ( organoleptic score ) (human nose) to measure of malodor which its unit 0-5 score
223800308|NCT03115892|DRUG|Chlorhexidine mouthwash|chlorohexidine mouthwash take two times per day for one week
223800309|NCT01337895|OTHER|Low dairy|No more than 1 serving per day
223800310|NCT01337895|OTHER|High dairy|4 or more servings per day
223800311|NCT00796302|DRUG|Methylphenidate HCl|"For children weighing less than 25 kg, the dose will be titrated at 18 mg for the first 7 days, 36 mg for the next 4 days, and, if needed, 54 mg for the next 4 days. For children weighing more than 25 kg, the dose will be titrated at 18 mg for the first 4 days, 36 mg for the next 3 days, 54 mg for the next 4 days, and 72 mg for the next 3 days.~Once the child's optimal dose is established, he or she will continue on that dose for the rest of the 21-week trial.~One pill is taken once daily."
223800312|NCT00796302|DRUG|Risperidone|"For children weighing less than 45 kg, the dose will start at 0.5 mg at night. After 4 days, the child's dose may be increased to 1 mg a day. On Day 8, the child's dose may be increased to 1.5 mg a day. On Day 16, the child's dose may be increased to 2.0 mg a day. On Day 22, the child's dose may be increased to 2.5 mg a day.~For children weighing more than 45 kg, the dose will start at 0.5 mg at night. After 4 days, the child's dose may be increased to 1.0 mg a day. On Day 8, the child's dose may be increased to 1.5 mg a day. On Day 12, the child's dose may be increased to 2.0 mg a day. On Day 15, the child's dose may be increased to 2.5 mg a day. On Day 18, the child's dose may be increased to 3 mg a day. On Day 23, the child's dose may be increased to 3.5 mg a day."
223800313|NCT00796302|BEHAVIORAL|Parent Management Training (PMT)|PMT will include individual parent sessions held weekly for 9 weeks, with two booster sessions to be completed during the 3-month extension. Sessions will include development of problem-solving skills and behavior management strategies, practice activities, and role-playing with the behavioral therapist.
223800314|NCT00796302|DRUG|Placebo|One pill will be taken once daily for the first 4 days and then twice daily until Week 21.
223800315|NCT00775710|DEVICE|Nocturnal non-invasive ventilation|Prolongation of non-invasive ventilation during 3 nights.
223800316|NCT04629703|DRUG|Fostamatinib|Fostamatinib (150 mg twice daily) for 14 days and Standard of Care
223800317|NCT04629703|DRUG|Placebo|Placebo (twice daily) for 14 days and Standard of Care
223800318|NCT02083016|DEVICE|Ablation guided by conventional mapping.|Substrate mapping and ablation of ventricular tachycardia.
223800319|NCT02083016|DEVICE|Ablation guided by ultra-high density mapping with multielectrode catheter.|Substrate mapping and ablation of ventricular tachycardia.
223800320|NCT05697094|BEHAVIORAL|Meditation to Remove Stress and Create A Proper System in Mind|Meditation to Remove Stress and Create A Proper System in Mind is a guided meditation.
223800321|NCT03651167|OTHER|Survey|Participants will complete a survey online
223800322|NCT01777854|DRUG|Omeprazole|The principal investigator will be contacted and will work with the research pharmacist to obtain the omeprazole (20 mg PO daily for patients \>20kg) and placebo. The placebo does not look like the omeprazole, however this will not be an issue because none of the subjects will have knowledge of how the medications look. The medication will be locked in the designated medication cabinet at each office. It will be prepackaged for a 28 day course. The patient will start the treatment 4 weeks prior to tonsillectomy and stop the day before surgery. The medication will be given to the patient once the consent and assent are signed. This will avoid an unnecessary office visit to improve patient compliance.
223800323|NCT04791501|DEVICE|Mechanical ventilation|Ventilatory support
223800328|NCT03649230|DRUG|300mg netupitant/0.5mg palonosetron hydrochloride|Antiemetic (NK1 receptor antagonist/5-HT3 receptor antagonist)
223800329|NCT06200454|DEVICE|neuromuscular ultrasound of cranial nerves|neuromuscular ultrasound of cranial nerves.
223800330|NCT00452387|DRUG|Mitoxantrone|"Once six patients are accrued at dose level 1, the maximum tolerated dose (MTD) will be assessed by following them through one cycle of treatment. If 2/6 patients experience dose limiting toxicity (DLT) at the 400 mg twice a day (bid) level then the MTD will be defined as 400 mg daily (QD). Additional patients will be enrolled at the MTD for the phase II portion.~Dose Level -2, Mitoxantrone 9mg/m2~Dose Level -1 Mitoxantrone 12mg/m2~Dose Level 1 Mitoxantrone 12mg/m2"
223800331|NCT00452387|DRUG|Prednisone|"Once six patients are accrued at dose level 1, the maximum tolerated dose (MTD) will be assessed by following them through one cycle of treatment. If 2/6 patients experience dose limiting toxicity (DLT) at the 400 mg twice a day (bid) level then the MTD will be defined as 400 mg daily (QD). Additional patients will be enrolled at the MTD for the phase II portion.~Dose Level -2, Prednisone 5mg bid~Dose Level -1 Prednisone 5mg bid~Dose Level 1 Prednisone 5mg bid"
223800332|NCT00452387|DRUG|Sorafenib|"Once six patients are accrued at dose level 1, the maximum tolerated dose (MTD) will be assessed by following them through one cycle of treatment. If 2/6 patients experience dose limiting toxicity (DLT) at the 400 mg twice a day (bid) level then the MTD will be defined as 400 mg daily (QD). Additional patients will be enrolled at the MTD for the phase II portion.~Dose Level -2, Sorafenib 400 mg QD~Dose Level -1 Sorafenib 400 mg QD~Dose Level 1 Sorafenib 400 mg bid"
223800333|NCT01560039|DEVICE|TMS|Transcranial magentic stimulation of the motor cortex. Device Details : Model is Magstim TMS Rapid. Manufacturer : MAGSTIM CO LTD. Spring Gardens, Whitland, Carmarthenshire, Wales, U.K., SA34 0HR
223800334|NCT01560039|OTHER|Neurofeedback|EEG neurofeedback based on the primary motor cortex
223800335|NCT01560039|OTHER|Sham neurofeedback|Sham EEG neurofeedback
223800336|NCT05047198|PROCEDURE|Control - Catheter Ablation for VT|"Currently standard of care involves surgical resection of myocardial scarring in structural heart disease. Imaging is performed to identify culprit areas for ablation, pre procedural imaging involves echocardiography, CT scanning and PET imaging to assess cardiac function, ischemia, inflammation and scarring. Radiofrequency energy is delivered via catheter to the targets and is performed under sedation or anesthesia using multiple catheters placed in the heart while the patient is anticoagulated. A conventional approach will be used advancing multiple catheters via femoral veins and/or arteries under a combination of fluoroscopic, ultrasound and electroanatomic guidance. Ablation targets include an arrhythmogenic focus or the critical isthmus of the VT circuit and/ or substrate identified on preprocedural imaging or low voltage areas, scar, identified during endocardial mapping. CA procedures for VT are often long, averaging approximately 5 hours ."
223800337|NCT05047198|PROCEDURE|Treatment - Non-Invasive Radio Ablation for VT|Patients undergoing a non-invasive RA procedure for VT similarly require medical stabilization and multimodal imaging prior to treatment. A non-invasive electrophysiology study is performed under light sedation using ECGi mapping. This procedure requires only the placement of an IV cannula for light sedation, uses the ICD to stimulate VT which is mapped in real time using the ECGi mapping system. The multimodal imaging data is digitally fused and combined with the ECGi data to identify the VT circuit(s) and to attain the targets for radio-ablation. This analogue process is performed off-line by a physician team. The treatment plan is sent for alignment on a 4D planning CT performed with breath holding in the radiotherapy suite. Final treatment targets are reviewed by the local treating team and discussed with our collaborators remotely. Thereafter the patient is booked for a 15 minute out-patient radiotherapy treatment performed on a standard linear accelerator.
223800338|NCT06405503|OTHER|NO INTERVENTION|NO INTERVENTION - OBSERVATIONAL ONLY
223800339|NCT05140928|OTHER|Dadiah Pudding|Supplementation of Dadiah Pudding to pregnant women. One cup a day for 18-26 weeks of pregnancy
223800340|NCT05140928|OTHER|Pudding without Dadiah|Supplementation of Milk Pudding without dadiah to pregnant women. One cup a day for 18-26 weeks of pregnancy
223800341|NCT02652481|DEVICE|ImageReady MR Conditional Defibrillation System|"ImageReady MR Conditional Defibrillation System Components:~Device Name Device Model Number Pulse Generators Phase I and II Phase II Only \* CRT-D (IS1/DF4/IS4) VR ICD (DF4) DR ( dual chamber) ICD (IS1/DF4) ORIGEN™ MINI ICD ORIGEN EL ICD ORIGEN X4 CRT INOGEN™ MINI ICD INOGEN EL ICD INOGEN X4 CRT DYNAGEN™ MINI ICD DYNAGEN EL ICD DYNAGEN X4 CRT-D AUTOGEN ™ MINI ICD\* AUTOGEN EL ICD\* AUTOGEN X4 CRT-D\* Right Atrial Leads and Accessories FINELINE™ II Sterox FINELINE II Sterox EZ Suture Sleeves for FINELINE II Leads INGEVITY™ MRI\* Suture Sleeve for INGEVITY MRI\* IS-1 Lead Port Plug 7145 Right Ventricular Leads and Accessories RELIANCE 4-FRONT™ (DF4)\* Suture Sleeve for RELIANCE 4-FRONT leads\*; ENDOTAK RELIANCE™ (DF4) Left Ventricular Leads and Accessories ACUITY™ X4 (IS4) Suture Sleeve for ACUITY X4 leads~\* May only be used internationally outside the US"
223800342|NCT00579280|DRUG|quetiapine SR|flexible dosing, 50 mg up to a maximum of 300 mg per day for 8 weeks
223800343|NCT00579280|DRUG|divalproex sodium ER|Flexible dosing, 500 mg up to a maximum of 3000 mg per day for 8 weeks
223800344|NCT00579280|DRUG|placebo|placebo
223800345|NCT01803308|DRUG|SB9200|Part A open-label, single ascending doses of SB9200 from 100mg - 1500mg.
223800346|NCT01803308|DRUG|SB9200|Part B randomised 6:2 (active:placebo) using recommended Part B starting dose, and ascending to up to 1500mg for 7-14 days of dosing.
223800347|NCT01803308|DRUG|Placebo|Part B randomised 6:2 (active:placebo) using anhydrous lactose capsules identical to active comparator, minus active ingredient.
223800348|NCT03407599|DRUG|Faster aspart|An injection of fast-acting insulin aspart 0.2 U/kg body weight under the skin just prior to a standard meal.
223800349|NCT03407599|DRUG|Insulin aspart (NovoRapid®)|An injection of insulin aspart (NovoRapid®) 0.2 U/kg body weight under the skin just prior to a standard meal.
223800350|NCT01693068|DRUG|Pimasertib|Subjects will receive pimasertib orally as monotherapy at a dose of 60 milligram (mg) twice daily continuously. Treatment will consist of repeated 21-day cycles which will continue until progression of the disease, unacceptable toxicity, withdrawal of informed consent, or death, whichever occurs first.
223800351|NCT01693068|DRUG|Dacarbazine|Subjects will receive dacarbazine intravenously at dose of 1000 milligram per square meter (mg/m\^2) of body surface area every 3 weeks on Day 1 of each 21-days cycle until progression of the disease, unacceptable toxicity, withdrawal of informed consent, or death, whichever occurs first. Eligible subjects with documented tumor progression on dacarbazine will offer to switch to pimasertib treatment.
223800352|NCT05478655|OTHER|visual analog scale|VAS was studied: 1) before and after anesthesia - at the stage of the medical and nursing brigade, military mobile hospital, military medical clinical center; 2) at the stage of the medical and nursing team - within 2 days; 3) at the stage of the military mobile hospital - within 5 days; 4) at the stage of the military medical clinical center - within 7 days, at the time of discharge from the hospital and further 1, 3, 6, 12 months after the injury; 5) at the rehabilitation stage. Intervals between analgesia were also studied.
223800353|NCT00811876|OTHER|Data Collection on Depo-Eligard exposure|Retrospective, Non-interventional
223800354|NCT00474695|DRUG|Lucentis|0.05 mg intravitreal injection
223800355|NCT04684121|DRUG|Granexin® gel (200 μM)|Granexin® gel (200 μM) will be topically applied once daily for 10 days in association with standard of care (SOC) wound cleaning and ACTICOAT Flex 3TM dressing.
223800356|NCT04684121|DRUG|Vehicle gel|Vehicle gel will be topically applied once daily for 10 days in association with standard of care (SOC) wound cleaning and ACTICOAT Flex 3TM dressing.
223800357|NCT01624675|DRUG|Risperidone|Subjects weighing less than 20 kilogram (kg) received risperidone 0.25 milligram per day (mg/day) up to Day 4. On Day 4, dose was titrated in increments of 0.25 mg/day (up to a daily dose of 1.0 mg) at the regular study visit thereafter till Week 8. Subjects weighing greater than or equal to (\>=) 20 kg received risperidone 0.5 mg/day up to Day 4. On Day 4, dose was titrated in increments of 0.5 mg per day (up to a daily dose of 2.5 mg) at the regular visit thereafter till Week 8. The maximum daily dose for subjects weighing \>= 45 kg was 3.0 mg. For subjects weighing \>=45 kg, the maximum daily dose was 3.0 mg.
223800358|NCT01624675|DRUG|Placebo|Subjects will receive placebo matching with risperidone orally up to 8 weeks.
223800359|NCT02379182|BEHAVIORAL|standard clinical care|adaptation of fluids, diet and oral hygiene recommendations, and postural and swallowing maneuvers training if necessary
223800360|NCT02379182|DEVICE|transcutaneous electrical stimulation at sensory level|The treatment procedure will consist of the application, at rest, of 80 Hz of transcutaneous electrical stimulus (biphasic, 700 µs) using VitalStim device (Chattanooga Group, Hixson, TN, USA), 2 sessions of 1 hour per day the first week, and 1 hour per day the next week. Sessions will be applied from Monday to Friday for two weeks. Treatment intensity will be set to 75% of motor threshold and electrode placement, thyro-hyoid (placement 3a described in the VitalStim Certification Program). The motor threshold will be determined by triplicate, as the intensity level at which the patient reports a grabbing or pulling sensation and confirmed by the clinician. Every 10 min, the patient will be asked if the initial sensation is maintained and, if necessary, treatment intensity will be re-adjusted.
223800361|NCT02379182|DEVICE|transcutaneous electrical stimulation at motor level|The treatment procedure will consist of the application, at rest, of 80 Hz of transcutaneous electrical stimulus (biphasic, 700 µs) using VitalStim device (Chattanooga Group, Hixson, TN, USA), 2 sessions of 1 hour per day the first week, and 1 hour per day the next week. Sessions will be applied from Monday to Friday for two weeks. Treatment intensity will be set to the motor threshold and electrode placement, supra-hyoid. The motor threshold will be determined by triplicate, as the intensity level at which the patient reports a grabbing or pulling sensation and confirmed by the clinician. Every 10 min, the patient will be asked if the initial sensation is maintained and, if necessary, treatment intensity will be re-adjusted.
223800362|NCT02605629|OTHER|CG428|The experimental group will receive CG428. For each application, the patient should shake the bottle before spraying 10-12 times directly to the dry scalp whole area, with the nozzle, and then gently massage the whole scalp with fingertips in order to spread the lotion evenly until it has completely penetrated the scalp. Hairs should not be washed or shampooed within 1 hour following study treatment administration. Each dose should be spaced out by minimum 4 hours.
223800363|NCT02605629|OTHER|Placebo|The placebo group will received placebo which excluded active ingredients. For each application, the patient should shake the bottle before spraying 10-12 times directly to the dry scalp whole area, with the nozzle, and then gently massage the whole scalp with fingertips in order to spread the lotion evenly until it has completely penetrated the scalp. Hairs should not be washed or shampooed within 1 hour following study treatment administration. Each dose should be spaced out by minimum 4 hours.
223800364|NCT00710138|DIETARY_SUPPLEMENT|Hydroxycobalamin (Vitamin B12 Depot, Nycomed Pharma)|400 µg hydroxycobalamin (Vitamin B12 Depot, Nycomed Pharma), as a single intramuscular injection
223800365|NCT05029765|DIETARY_SUPPLEMENT|Mediterranean diet|"Mediterranean diet:~22% Monounsaturated fat, 6% Polyunsaturated fat, 7% Saturated fat, 15% Protein, 50% Carbohydrates"
223800366|NCT05029765|DIETARY_SUPPLEMENT|Healthy diet (WHO recommendations)|Recommendations according to WHO
223800367|NCT05029765|DIETARY_SUPPLEMENT|Placebo|Placebo
223800368|NCT05029765|DIETARY_SUPPLEMENT|Biopolis-MIX42|Biopolis-MIX42: a capsule containing 10\^9 colony forming units of Lactobacillus rhamnosus and Bifidobacterium longum.
223800369|NCT00956566|BEHAVIORAL|dietary intervention|dietary counseling, group teaching
223800370|NCT03260166|DRUG|nicotinamide|Drug: nicotinamide; Pharmaceutical form: tablet; Route of administration: oral
223800371|NCT02510144|DRUG|Skin Prep Chlorhexidine|3 day preoperative skin prep prior to surgery
223800372|NCT02510144|DRUG|Skin Prep Benzoyl Peroxide|3 day preoperative skin prep prior to surgery
223800373|NCT05604625|DEVICE|Van-Beek activator and a headgear|12 patients will receive Van-Beek activator and a headgear
223800374|NCT05604625|DEVICE|Andresen activator|12 patients will receive Andresen activator.
223800375|NCT03311373|DRUG|Regimen A|2 inhalations BGF MDI; no spacer device; no oral charcoal - reference formulation/total systemic exposure
223800376|NCT03311373|DRUG|Regimen B|2 inhalations BGF MDI; AeroChamber Plus Flow-Vu spacer device; no oral charcoal - test formulation/total systemic exposure
223800377|NCT03311373|DRUG|Regimen C|2 inhalations BGF MDI; no spacer device; with oral charcoal - reference formulation/lung exposure
223800378|NCT03311373|DRUG|Regimen D|2 inhalations BGF MDI; AeroChamber Plus Flow-Vu spacer device; with oral charcoal - test formulation/lung exposure
223800379|NCT02029079|DIETARY_SUPPLEMENT|E+|300 ml E+ per day (525 kcal, 22.5 gram protein) for 35 days.
223800380|NCT04126408|DEVICE|gammaCore|The intervention consists of a transcutaneous non-invasive stimulation of the cervical branch of the vagus nerve (nVNS) using gammaCore, an FDA approved device for the treatment of migraine and cluster headache. This will be compared to the sham device, which is the same device which will not provide stimulation to the nerve. Stimulation frequency will be identical to the frequency used in previous nVNS studies for the treatment of migraine headache.
223800381|NCT04924231|BEHAVIORAL|astigmatism|astigamatism at least 1 month after the cataract surgery
223800382|NCT03208023|PROCEDURE|RESIPI Management Strategy|a structured hemodynamic monitoring and treatment plan: RESIPI includes normalization of vascular resistance, correction of fluid responsiveness, and inotropy, and hemodynamic monitoring with the Starling SV (Cheetah Medical, Inc).
223800383|NCT03208023|OTHER|No intervention|No intervention
223800384|NCT02322008|BIOLOGICAL|infliximab and adalimumab|In this retrospective, observational study, no interventions were undertaken by the researchers.
223800385|NCT02782338|DRUG|Voltaren ophtha 0.1%|All study patients will be treated with Voltaren ophtha 0.1% after cataract surgery
223800386|NCT01922492|PROCEDURE|Autologous islet transplantation|"Islet was isolated from the normal part of resected pancreas with modified Ricordi method.~After purification, the islets were infused into the liver through percutaneous transhepatic portal vein catheterization."
223800387|NCT01922492|DRUG|Oral anti-diabetic drugs|"* Metformin on the diagnosis of postoperative diabetes mellitus. Starting dose of 500mg per day and dose adjustment as needed to control blood glucose.~* Vildagliptin added on the insufficient glycemic control with monotherapy. Starting dose of 50mg per day and dose adjustment as needed to control blood glucose."
223800388|NCT00694005|PROCEDURE|kissing balloon|simultaneous kissing balloon angioplasty during drug-eluting stent implantation for bifurcation coronary lesions
223800389|NCT00694005|PROCEDURE|"without kissing balloon angioplasty leave alone"|simultaneous kissing balloon angioplasty during drug-eluting stent implantation for bifurcation coronary lesions
223800390|NCT00119548|OTHER|Rates of HIV testing and receipt of results|Rates of HIV testing and receipt of results
223800391|NCT00119548|OTHER|Sexual risk reduction; HIV knowledge improvement|Sexual risk reduction; HIV knowledge improvement
223800392|NCT00119548|OTHER|Rates of HIV testing and receipt of results|Rates of HIV testing and receipt of results
223800393|NCT00119548|OTHER|Sexual risk reduction; HIV knowledge improvement|Sexual risk reduction; HIV knowledge improvement
223800394|NCT00119548|OTHER|Rates of HIV testing and receipt of results|Rates of HIV testing and receipt of results
223800395|NCT00119548|OTHER|Sexual risk reduction; HIV knowledge improvement|Sexual risk reduction; HIV knowledge improvement
223800396|NCT03223974|DEVICE|Paclitaxel DCB|Balloon/vessel diameter ratio 0.8-1.0, 8-10 ATM, lasting for \>30 seconds. If quantitative coronary angiography determines residual stenosis ≤ 30% , it is considered to be a successful operation.
223800397|NCT03223974|DEVICE|DES|MB should be sufficiently predilated to facilitate the positioning of the stent and the stent residual stenosis should be ≤10% to be a successful operation.
223800398|NCT02330133|BEHAVIORAL|Women's Reproductive Health|Targeted text and video information on website for women aged 25-55 to avoid unplanned pregnancy and sexually transmitted infections
223800399|NCT02330133|BEHAVIORAL|Online sexual health content|Online general text-based information about reproductive health issues and strategies for preventing sexually transmitted infections
223800400|NCT05012800|BIOLOGICAL|COVID-19 Vaccine|Coronavirus vaccine was inoculated on day 0 and day 21, respectively.
223800401|NCT01931280|BEHAVIORAL|Lifestyle Counseling|Participants receive lifestyle counseling on healthy eating and physical activity through an internet based program or self-directed educational program.
223800402|NCT00406003|DRUG|Paroxetine controlled release tablet|Paroxetine will be given as single dose, controlled release tablet with dosing strengths of 12.5, 25 and 37.5 milligrams in fasted state separated by a wash-out period of 10 days.
223800403|NCT01551199|BEHAVIORAL|Multiple Channel Exposure Therapy- Veterans|Individual therapy design completed over a 12-week period. The treatment will include psychoeducation about panic attacks and trauma and behavioral and cognitive exposure exercises.
223800404|NCT01185444|PROCEDURE|Hya-Joint|The Hya-Joint group received 3 weekly intraarticular injections of 2 ml sodium hyaluronate (Hya-Joint, derived from Streptococcus zooepidemicus and produced by a highly purified biologic fermentation process, molecular weight 650-1200 kDa),into the target knee.
223800405|NCT01185444|PROCEDURE|Hyalgan|The control group received 3 weekly intraarticular injections of 2 ml sodium hyaluronate (Hyalgan, extracted from chicken combs, molecular weight 500-730kDa) into the knee joints.
223800406|NCT01408355|DRUG|PF-06273588|Intravenous, 50 microgram, single dose
223800407|NCT01408355|DRUG|PF-06273588|Oral solution, 50 microgram, single dose
223800408|NCT05161299|PROCEDURE|Surgery (across all specialities)|Surgery performed by a surgeon in an operating theatre during the patient inclusion period
223800409|NCT02624362|BEHAVIORAL|Therapeutic Suggestion|suggestions about potential beneficial effects of the odor are given
223800410|NCT02624362|BEHAVIORAL|Asthmogenic Suggestion|suggestions about potential negative effects of the odor are given
223800411|NCT02624362|OTHER|Phenylethyl Alcohol odor|Over the course of 15 minutes, participants, receive 15 short sniffs of Phenylethyl Alcohol odor
223800412|NCT01239030|DRUG|Methylphenidate Hydrochloride Extended Release Capsules|Biphentin Methylphenidate ER Once-A-Day Capsules
223800413|NCT01239030|DRUG|Placebo|Placebo capsules
223800414|NCT01925833|PROCEDURE|Both insertion and withdrawal|inspection and polypectomy during both insertion and withdrawal of colonoscopy
223800415|NCT01925833|PROCEDURE|Only withdrawal|inspection and polypectomy during only withdrawal of colonoscopy
223800416|NCT04569630|OTHER|Controlled hypoglycaemic state while driving|Participants will drive on a designated circuit with a real car on a test track accompanied by a driving instructor. Driving data will be recorded in 4 subsequent glycemic states using an adapted hypoglycemic clamp protocol: euglycemia (d1, 5-8 mmol/l), progressive hypoglycaemia (d2, declining from 4.5 to 2.5 mmol/l), stable hypoglycemia (d3, 2.0-2.5 mmol/l), and again in euglycaemia (d4, 5-8 mmol/l). Patients will be blinded to their glucose levels.
223800417|NCT03433989|DIAGNOSTIC_TEST|telephone interview|questionnaire PDEQ et IES-R
223800418|NCT02119507|DEVICE|Curodont Repair|Single application on Day 0
223800419|NCT02119507|OTHER|No treatment - control|
223800420|NCT00328432|DRUG|celecoxib 400 mg bid|
223800421|NCT05412641|OTHER|Intervention - Responsible Fatherhood Programming|Participants receive educational programming to include: 24/7 Dad, Couples Communication I, and a comprehensive program targeting financial literacy/money management.
223800422|NCT04733287|OTHER|High Intensity Interval Training of the Knee Extensors|"Subjects will perform intense, single leg knee extension exercise 3 times a week for 6 weeks. Specifically, subjects will be seated in a custom knee extension ergometer and perform single leg, dynamic knee extension (similar to single leg cycling) as they perform the exercise. After a 6 minute warm-up at \~20% of that leg's maximum aerobic power (determined during a graded exercise test of single leg knee extension), subjects will perform 4 bouts of 4 minutes at \~80% of maximum aerobic power. Recovery of 4 minutes at \~40% will occur between each bout of exercise. A cool down will be provided at the end of exercise. In total, subjects will perform 40 minutes of single leg knee extension exercise, 3 times a week for 6 weeks.~Maximum aerobic power (determined by a graded exercise test) will be determined again at 3 weeks to appropriately adjust the training intensity."
223800423|NCT04733287|OTHER|Muscle Heat Therapy|Subjects will receive muscle heat therapy on the knee extensor muscles (short-wave diathermy) for 120 minutes for each visit. Specifically, subjects will lie supine while short-wave diathermy units (Megapulse II) will be placed on the quadriceps femoris and turned on to 800 pulses per second with a pulse duration of 400 microseconds. Our previous research (e.g. Hafen et al 2018- Repeated exposure to heat stress...) has indicated that this treatment raises muscle temperature to \~39C, a similar temperature induced by exercise.
223800424|NCT04733287|OTHER|Muscle Disuse|Subjects will undergo 2 weeks of limb immobilization (a model of muscle disuse). Specifically, a knee brace will be placed on one of the subjects' legs and bent to a flexion of 60 degrees to prevent the foot from touching the ground while standing. Subjects will given a pair of crutches and asked to ambulate on crutches for 2 weeks, avoiding bearing any weight with the immobilized leg.
223800425|NCT04733287|OTHER|Sham Heat Therapy|Specifically, subjects randomly assigned to the sham group will receive the same treatment as the heat group (same number of visits and set up with the heating units applied to leg for 2 hours each visit) except, unbeknownst to either group, the heating units will never be turned on for the sham group.
223800426|NCT05668533|DIAGNOSTIC_TEST|Interscalene versus PENG Block|"1. Interscalene group: Patients received ipsilateral ultrasound-guided interscalene nerve after induction of general anesthesia using bupivacaine 0.25% (0.5 mL/kg).~2. PENG Block: Patients received ultrasound-guided PENG block after induction of general anesthesia using bupivacaine 0.25% (0.5 mL/kg)."
223800427|NCT06457828|PROCEDURE|Non-corticosteroid injection|no infiltration injection of 0.7 ml of dexamethasone lateral to the involved tooth after anesthesia administration.
223800428|NCT06457828|DRUG|Corticosteroid injection|infiltration injection of 0.7 ml of dexamethasone lateral to the involved tooth after anesthesia administration.
223800429|NCT01758354|OTHER|Pompe disease newborn screening|DBS will be tested for acid alpha-glucosidase (GAA)activity. Newborns with low GAA activity will received a confirmatory blood sampling and clinical evaluation for the presence of cardiomyopathy.
223800430|NCT00381069|BEHAVIORAL|Family & Community Recreation Center Intervention|The two year intervention involves changing the environment and policies in community recreation centers to promote physical activity and healthy eating choices. The Recreation Specialist will meet with recreation center staff monthly to create action plans that work towards this goal. Family Health Coaches will be in contact with intervention families twice a month either through a phone consultation, workshop at the recreation center,or home visit. Intervention families will receive a monthly mailing highlighting tips for healthy eating and physical activity. MOVE families will be encouraged to utilize the recreation center as a resource in supporting their child's physical activity and healthy eating behaviors.
223800431|NCT05625191|DIAGNOSTIC_TEST|Acoustic voice analysis|Acoustic recordings will involve the five repetitions of three vowels (/ɑ, i, u/) and a standard reading passage (Rainbow Passage) in different voice conditions. Control participants will produce voice in breathy, typical, and pressed conditions. Patient participants will produce voice in typical production and in a resonant voice production. High-speed videoendoscopy and simultaneous acoustic recording will occur on one repetition of a sustained /i/ in each requested condition. Data will be collected using a head-mounted microphone.
223800432|NCT05625191|DIAGNOSTIC_TEST|High-speed videoendoscopy|High-speed videoendoscopy will occur on one repetition of a sustained /i/ in each requested condition. Exams will be recorded using the Phantom V311 high-speed camera (Vision Research, Wayne, NJ) connected to a Storz 70° rigid laryngoscope using a 400 Watt Xenon light source (Titan 400E).
223800433|NCT04656834|PROCEDURE|hand incision closure using monocryl sutures and skin glue|At the end of surgery, the investigator will close the incision using monocryl sutures and skin glue
223800434|NCT04656834|PROCEDURE|hand incision closure using simple nylon sutures|At the end of surgery, the investigator will close the incision using simple nylon sutures
223800435|NCT04023240|DRUG|68Ga-FAPI|"68Ga-FAPI is quinoline based PET radiopharmaceutical.~68Ga-FAPI is administered intravenously (IV)"
223800436|NCT04023240|PROCEDURE|Computed Tomography (CT) scan|Participants will have a CT scan for attenuation correction and anatomic localization of PET data.
223800437|NCT04023240|PROCEDURE|Positron Emission Tomography (PET) scan|PET images will be acquired.
223800438|NCT01248338|DRUG|metoprolol succinate|once daily 50 or 100 mg for one year
223800439|NCT01248338|DRUG|Nebivolol|once daily 5 mg capsule for one year
223800440|NCT02235948|DRUG|folic acid supplementation|0.8mg folic acid/day
223800441|NCT05675657|OTHER|No Block|The patients will receive general anesthesia.
223800442|NCT05675657|PROCEDURE|Quadratus Lumborum Block Type III|Patients will receive ultrasound-guided quadratus lumborum block type III with 60 ml of bupivacaine 0.25% followed by general anesthesia.
223800443|NCT05675657|PROCEDURE|Erector Spinae Plane Block|Patients will receive ultrasound-guided erector spinae plane block type III with 60 ml of bupivacaine 0.25% followed by general anesthesia.
223800444|NCT02483169|DRUG|cilostazol|Cilostazol 100mg bid
223800445|NCT02483169|DRUG|Probucol|Probucol 250mg bid
223800446|NCT02483169|DRUG|Aspirin|Aspirin 100mg qd
223800447|NCT02483169|DRUG|placebo of cilostazol|same shape and size of active cilostazol
223800448|NCT02483169|DRUG|Placebo of aspirin|same size and shape of active aspirin 100mg
223800449|NCT02483169|DEVICE|Intima-medial thickness|ultrasound measured IMT of both common carotid arteries
223800450|NCT01142206|BEHAVIORAL|Dietary|All participants in the investigation will receive a standard 8-week behavioral obesity intervention with 8 weekly, 1 hour group counseling and education sessions. The intervention will include a reduced caloric prescription (1200-1500 kcal/day) and fat gram prescription (30% or less kcals from fat).
223800451|NCT01142206|BEHAVIORAL|Physical Activity|All participants will receive a physical activity goal of 200 minutes/week of moderate-intense physical activity.
223800452|NCT01142206|BEHAVIORAL|TV Watching + Physical Activity|The TV Watching + physical activity arm will receive a TV watching goal of watching less than 10 hours of TV/week.
223800453|NCT03661411|DRUG|Aspirin|100mg qd
223800454|NCT03661411|DRUG|Clopidogrel 75mg|75mg（after first dose of 300mg）qd
223800455|NCT03661411|DRUG|Alteplase|Iv at 0.9 milligrams per kilogram (mg/kg)
223800456|NCT03526822|BIOLOGICAL|Blood sample|Five blood sample in pre-, post-operative period, before radiotherapy, before adjuvant temozolomide and at relapse in newly diagnosed glioblastoma
223800457|NCT03526822|BIOLOGICAL|Tumor sample|One tumor sample in operative period
223800458|NCT06009341|OTHER|Rehabilitation|The control group will not be trained. Only exercise brochure including muscle strengthening and stretching will be given. In addition, the intervention group will be taught the training program and applications.
223800459|NCT05245344|PROCEDURE|Peripheral blood withdrawal|25 ml of blood for T cell isolation or 40 ml of blood for B cell isolation will be obtained following informed consent as approved by the ethical committees of the MS centers.
223800460|NCT03036163|DRUG|PBTZ169 - 40 mg|40 mg of PBTZ169 (1 capsule) orally once in fasting state
223800461|NCT03036163|DRUG|PBTZ169 - 80 mg|80 mg of PBTZ169 (2 capsules 40 mg) orally once in fasting state
223800462|NCT03036163|DRUG|PBTZ169 - 160 mg|160 mg of PBTZ169 (4 capsules 40 mg) orally once in fasting state
223800463|NCT03036163|DRUG|PBTZ169 - 320 mg|320 mg of PBTZ169 (8 capsules 40 mg) orally once in fasting state
223800464|NCT03036163|DRUG|PBTZ169 - 640 mg|640 mg of PBTZ169 (16 capsules 40 mg) orally once in fasting state
223800465|NCT03036163|DRUG|PBTZ169 - 320 mg (multiple administration)|320 mg of PBTZ169 (8 capsules 40 mg) orally once per day in fasting state for 14 days
223800466|NCT03036163|DRUG|PBTZ169 - 640 mg (multiple administration)|640 mg of PBTZ169 (16 capsules 40 mg) orally once per day in fasting state for 14 days
223800467|NCT05415735|BEHAVIORAL|Stress Management and Resiliency Training Program|This is a multimodal mind-body program designed to teach participants a variety of different strategies to reduce their physiologic stress response.
223800468|NCT02668224|DEVICE|Vibrasens|Transcutaneous vibrations are used. This device allows vibrations from 25 to 150 Hz with an amplitude of 1 mm. In our study the frequency used is 50 Hz.
223800469|NCT02668224|OTHER|Usual activities|The patients will perform their usual activities, to allow the comparison with a vibration programme. They will not have a specific training.
223800470|NCT06089811|DIETARY_SUPPLEMENT|Prebiotic|Group 1 (prebiotic and placebo L-tryptophan): prebiotic (oligofructose, Orafti®P95, 20g/day) and placebo L-tryptophan (microcrystalline cellulose, 3g/day)
223800471|NCT06089811|DIETARY_SUPPLEMENT|L-Tryptophan|Group 2 (placebo prebiotic and L-tryptophan): L-tryptophan (3g/day) and placebo prebiotic (microcrystalline cellulose, 20g/day)
223800472|NCT06089811|DIETARY_SUPPLEMENT|Placebo|Group 3 (placebo prebiotic and placebo L-tryptophan): placebo prebiotic (microcrystalline cellulose, 20g/day) and placebo L-tryptophan (microcrystalline cellulose, 3g/day).
223800473|NCT00572741|DIETARY_SUPPLEMENT|B12|Methylcobalamin Dose: 75 μg/kg every 3 days
223800474|NCT00572741|DIETARY_SUPPLEMENT|Placebo|cellulose
223800475|NCT00572741|DIETARY_SUPPLEMENT|folate|Folinic acid: Dose: 400 µg twice a day (BID)
223800476|NCT00572741|DIETARY_SUPPLEMENT|B complex|B-Complex: B-1 (3 mg); B-2 (3.4 mg); B-352 (20 mg); B-6 (4 mg;) Pantothenic Acid(10 mg); Biotin (300 mcg); pyridoxal (25mg)
223800477|NCT00572741|DIETARY_SUPPLEMENT|vitamin C|Vitamin C 500 mg
223800478|NCT00572741|DIETARY_SUPPLEMENT|cod liver oil|Cod liver oil 1/2 teaspoon
223800479|NCT00572741|DIETARY_SUPPLEMENT|Mineral complex|Magnesium citrate (200 mg); Selenium (50 mcg); Zinc picolinate (25 mg); Molybdenum (50 mcg); Calcium citrate (400 mg)
223800480|NCT00572741|DIETARY_SUPPLEMENT|carnitine|Acetyl L-Carnitine Dose: 250 mg
223800481|NCT00005600|PROCEDURE|management of therapy complications|
223800482|NCT05257096|BEHAVIORAL|Medical clown|The medical clown will meet the children in the waiting room for 15-30 minutes and will accompany them through the whole investigation, up to one hour.
223800483|NCT03356925|DIAGNOSTIC_TEST|Xpert Ultra Point of Care testing|The intervention is the point of care Xpert Ultra TB diagnostic compared to the standard of care centralised TB testing at a centralised facility
223800484|NCT00182754|DRUG|octreotide acetate|Given subcutaneously
223800485|NCT00182754|OTHER|placebo|Given subcutaneously
223800486|NCT01764737|DRUG|VX15/2503|single dose intravenous administration
223800487|NCT01764737|DRUG|Placebo|single dose intravenous administration
223800488|NCT01667601|OTHER|Routine Care|Psychiatric outpatient care provided by the outpatient departments, e.g., medical consultation, brief education by psychiatric nurses and financial advices or referrals by social workers.
223800489|NCT01667601|BEHAVIORAL|Mindfulness-based program|The program was based on the psychoeducation programs by Chien et al and Lehman et al, as well as the 8-session Mindfulness-Based Stress Reduction Program by Kabat-Zinn(1990).
223800490|NCT01667601|BEHAVIORAL|Psychoeducation group|A 5-month patient psychoeducation group program (12 sessions) led by the research team will be provided.
223800491|NCT01763710|DRUG|Paclitaxel 80 mg/m2|Paclitaxel 80 mg/m2 days 1, 8 and 15
223800492|NCT01763710|DRUG|Nab-paclitaxel 100 mg/m2 days 1, 8 and 15|Nab-paclitaxel 100 mg/m2 days 1, 8 and 15
223800493|NCT01763710|DRUG|Nab-paclitaxel 150 mg/m2 days 1, 8 and 15|Nab-paclitaxel 150 mg/m2 days 1, 8 and 15
223800494|NCT01763710|DRUG|Nab-paclitaxel 150 mg/m2 days 1 and 15|Nab-paclitaxel 150 mg/m2 days 1 and 15
223800495|NCT03876405|DEVICE|smartskin non-invasive sensory feedback|"The sensory feedback system used was a simple non-invasive, non-electronic system based on air-mediated pressure. A silicone glove with bulbs (35 mm in length) volar in every fingertip was made and applied on a VariPlus Speed hand (OttoBock), size 7¾.~The sensory feedback system was embedded in the prosthetic socket."
223800496|NCT02535104|DRUG|Ranpirnase|Topical application by subject
223800497|NCT02535104|DRUG|Vehicle|Vehicle control
223800498|NCT04881006|DRUG|Dapagliflozin 10 mg tablets|Manufactured by Jiangsu Hansoh Pharmaceutical Group Co., Ltd.
223800499|NCT04881006|DRUG|Farxiga® 10 mg tablets|Manufactured by AstraZeneca Pharmaceuticals LP
223800500|NCT04364373|PROCEDURE|Left colon resection|"This procedure is performed for tumours in splenic flexure and proximal and descending colon.~Left colic artery is divided at its origin. Sigmoid arteries and superior rectal arteries are preserved. Inferior mesenteric vein is divided at the lower border of the pancreas. The colon is divided about 10 cm proximal and distal to the tumour. Mesocolic fascia is preserved and the length of the vessel trunk of the mesocolon corresponds to the level of lymph node dissection. After removal of the resected colonic segment a handsewn or stapler end-to-end or side-to-side colonic anastomosis is performed."
223800501|NCT04364373|PROCEDURE|Sigmoid colon resection|"This procedure is performed for tumours in sigmoid colon. Corresponding sigmoid arteries are divided at their origin. Left colic artery and superior rectal artery are preserved. Inferior mesenteric vein is divide close to the left colic artery. Proximal and distal margin compose 10 cm from the tumour. Mesocolic fascia is preserved and the length of the vessel trunk of the mesocolon corresponds to the level of lymph nodes dissection. After removal of the resected colonic segment a handsewn end-to-end or side-to-side or stapler colonic anastomosis is performed."
223800502|NCT04364373|PROCEDURE|Distal sigmoid colon resection or anterior resection|"This procedure is performed for tumours in distal sigmoid colon or rectosigmoid junction. Superior rectal artery is divided below the origin of left colic artery. Left colic artery is preserved. Inferior mesenteric vein is divide close to the left colic artery. The colon is divided about 10 cm proximal and 5 cm distal to the tumour. Mesocolic fascia is preserved and the length of the vessel trunk of the mesocolon corresponds to the level of lymph node dissection. After removal of the resected colonic segment handsewn or stapler colo-rectal anastomosis is performed."
223800503|NCT00236873|DRUG|topiramate|
223800504|NCT01053182|PROCEDURE|Ivor-Lewis Esophagectomy|Esophagectomy via Right Side Thoracotomy Plus Midline Laparotomy Approach
223800505|NCT01053182|PROCEDURE|Sweet Esophagectomy|Esophagectomy through Left Side Thoracotomy
223800506|NCT01232608|BEHAVIORAL|Exercise|12 months of exercise training
223800507|NCT01054768|DRUG|alpha-lipoic acid and acetyl-L-carnitine|none to report
223800508|NCT01054768|DRUG|Control|none to report
223800509|NCT06011590|OTHER|No intervention.|No intervention.
223800510|NCT05222282|OTHER|Sexual Health|Prevention of sexual dysfunction
223800511|NCT06100133|DIETARY_SUPPLEMENT|Ketone ester|Up to 100g ketone ester daily for 56 days
223800512|NCT02603081|DRUG|SPI-1005|Ebselen is a small molecule mimic and inducer of glutathione peroxidase (GPx). GPx reduces reactive oxygen species by the binding of free radicals to its selenium moiety. Ebselen has strong anti-inflammatory characteristics.
223800513|NCT05744648|PROCEDURE|Composite resin restoration using Titania nanoparticle reinforced bonding agent|Each group will receive Composite resin restoration for Class-I and Class-II carious lesion. In group A, titania nanoparticle reinforced bonding agent will be used
223800514|NCT05744648|PROCEDURE|Composite resin restoration without Titania nanoparticle incorporated bonding agent|Composite resin restoration without Titania nanoparticle incorporated bonding agent
223800515|NCT02122133|DEVICE|PC 400|
223800516|NCT05627102|OTHER|Experimental Group|Therapeutic Percutaneous Electrolysis an neuromodulation associated with eccentric exercises devices at home.
223800517|NCT05627102|OTHER|Conventional group|Ultrasound pulsatil therapy (US), transcutaneous electric nerve stimulation (TENS) for 20 minutes and associated with eccentric exercises devices at home.
223800518|NCT02575885|OTHER|Electronic Cigarette|Receive different type of ENDS product at each visit
223800519|NCT02575885|OTHER|Electronic Cigarette|Receive BLU e-cigarette ENDS product
223800520|NCT02575885|OTHER|Laboratory Biomarker Analysis|Correlative studies
223800521|NCT02575885|OTHER|Pharmacological Study|Correlative studies
223800522|NCT02575885|OTHER|Questionnaire Administration|Ancillary studies
223800523|NCT02471651|DRUG|Dexamethasone intravitreal implant (0.7 mg)|Subjects with persistent DME who are randomized to this arm may get up to 3 treatments with the implant (0.7 mg dexamethasone).
223800524|NCT02471651|DRUG|Intravitreal anti-VEGF injection|This injection may be ranibizumab, bevacizumab, or aflibercept.
223800525|NCT03758170|DRUG|Dexamethasone|An intravenous bolus dose of dexamethasone given prior to surgery.
223800526|NCT02085252|DRUG|Leuprorelin|Solution for injection
223800527|NCT02085252|DRUG|Bicalutamide|Bicalutamide tablets
223800528|NCT05665933|BEHAVIORAL|ACCEPTANCE AND COMMITMENT THERAPY-BASED PSYCOEDUCATION|Total Duration: 6 Weeks Session Duration: 90 min Frequency: 1 day per week Number of People: 30
223800529|NCT06270654|PROCEDURE|Erector spinae plane block|"After consent was obtained, patients will be randomised into control group and an intervention group. For patients randomized into the interventional group, bilateral erector spinae plane block will be performed under general anaesthesia in prone position before the operation. An experienced anaesthetist performs this under ultrasound guidance (using curvilinear probe) in a sterile method.~After identifying L3 transverse process, 21G Stimuplex needle will be inserted via in-plane method. Once needle placement is confirmed and aspiration is negative, 20ml of ropivacaine 0.375% with adrenaline 1:200,000 dilution will be given on each side."
223800530|NCT06270654|PROCEDURE|Skin infiltration LA|Pre incision of 0.375% ropivacaine 10ml local infiltration will be given to control group
223800531|NCT06323733|OTHER|Exercise Intervention|The exercise intervention will consist of a personalized and supervised program lasting 12 weeks with two sessions per week, held on Tuesdays and Thursdays at the Sports and Medicine Center SPORMED in Rennes, France. Each session will last 1 hour under the supervision of physiotherapists. Each session will combine endurance and resistance training, commencing with a 6-minute cardiovascular warm-up on ergometers (cycling ergometer or treadmill). This will be followed by 20 minutes at moderate intensity (60-70% of
223800532|NCT01460940|DRUG|panobinostat|Administered orally Monday, Wednesday, Friday of every week for 4 weeks. A cycle is define as 28 days.
223800533|NCT01460940|DRUG|lenalidomide|Lenalidomide will be administered orally daily on days 1-21. Lenalidomide will not be given on days 22-28. A cycle is define as 28 days.
223800534|NCT02767258|DEVICE|LACRIBELL®|Hypromellose and dextran based eyedrop, used in the treatment of dry eye.
223800535|NCT02767258|DEVICE|VIDISIC® GEL|Carbomer based gel, used in the treatment of dry eye.
223800536|NCT04477928|DIAGNOSTIC_TEST|Sera and whole blood sampling|"* Study Entry: Single Nucleotide Polymorphism (SNP)-Based Genetic Risk Score at study entry.~* 2 years old: T1D autoantibodies, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) antibodies~* 5 years old: T1D and celiac autoantibodies~* 9-16 year old: one-time T1D and celiac autoantibodies~* Siblings of people with T1D autoimmunity, ages 6-17 years: one-time T1D and celiac autoantibodies"
223800537|NCT04477928|DIAGNOSTIC_TEST|Differential Gene Expression (DGE)|Opt-in: Differential Gene Expression from cord blood at birth and peripheral blood at 12 months of age
223800538|NCT03606330|DIAGNOSTIC_TEST|Cardiac imaging tests|"* 2D transthoracic echocardiography~* 128-multislice CT coronary angiography with the evaluation of: epicardial fat volume, plaque burden, total and local calcium score, markers for lesion severity; morphological plaque characteristics; plaque components evaluated via volumetric and planimetric units; markers of plaque vulnerability (necrotic core, low attenuation plaque, spotty calcification, napkin ring sign, positive remodeling).~* Shear stress evaluation via computational fluid dynamics.~* Intracoronary imaging techniques: IVUS and OCT."
223800539|NCT03606330|DIAGNOSTIC_TEST|Venous blood sample collection|Venous blood sample collection during the acute coronary event for evaluation of serum levels of hsCRP, IL-6, matrixmetalloproteases MMP9, Adhesion molecules (VCAM, ICAM), alfa tumour necrosis factor, hs-cTnI, NTproBNP
223800540|NCT04072510|BEHAVIORAL|Self-esteem group|"The intervention will comprise of 6 sessions of group self-esteem therapy which uses a cognitive behavioural approach. The therapy has been manualised into a 76 page treatment protocol and will be administered by Assistant Psychologists employed at Newbridge House receiving weekly supervision from a Clinical Psychologist. The self-esteem group is based on Melanie Fennel's cognitive behavioural model of low self-esteem addressing thoughts, feeling and behaviours. The group aims to improve self-esteem and build positivity.~The sessions are structured and laid out in the following overview:~Week 1, Session 1: What is self-esteem and an introduction to CBT Week 2, Session 2: How might low self-esteem develop? Week 3, Session 3: Negative automatic thoughts Week 4, Session 4: Challenging negative automatic thoughts Week 5, Session 5: Creating new coping strategies Week 6, Session 6: Building positivity"
223800541|NCT04072510|BEHAVIORAL|Treatment as Usual|Treatment as usual refers to the standard inpatient treatment programme at Newbridge House which includes: individual therapy, occupational therapy, drama therapy, family therapy, dietetic support, nursing support, yoga and medication prescribed by a consultant psychiatrist.
223800542|NCT02616874|DRUG|MVA.HIVconsv vaccine|Dose: 2x10e8 pfu, Interval: weeks 0 and 9.
223800543|NCT02616874|DRUG|Romidepsin|Dose: 5mg/m2 over 4hours, Interval: weeks 3, 4 and 5
223800544|NCT05327881|DIAGNOSTIC_TEST|Plasma renin concentrations will be measured at enrollment and at 24, 48, and 72 hours. Whole blood lactate measurements will be performed according to normal standard of care.|"Measurement of Whole Blood Lactate Concentrations:~Whole blood lactate concentrations were measured using ABL 800 series analyzers. The IRB (Institutional Review Board) protocol specified that lactate concentrations could be obtained as part of routine care, but lactate concentrations were not measured independently for research purposes.~Measurement of Plasma Renin Concentrations:~Discarded whole blood samples (waste blood samples) in EDTA (ethylenediaminetetraacetic acid) (BD Vacutainer, 4 mL) tubes were prospectively collected from each patient at the time of study enrollment and at 24, 48, and 72 hours.~Plasma active renin levels were measured using the active renin enzyme-linked immunosorbent assay kit (DRG International, Township, NJ)"
223800545|NCT02925676|DEVICE|hyposafe H02|hypoglycaemia notification device
223800546|NCT02460692|DRUG|Placebos|Administration of vaporized cannabis plus either dronabinol or placebo pill
223800547|NCT02460692|DRUG|dronabinol|Administration of vaporized cannabis plus either dronabinol or placebo pill
223800548|NCT02460692|DRUG|Vaporized Cannabis 3.7% THC/5.6% CBD|Administration of vaporized cannabis plus either dronabinol or placebo pill
223800549|NCT02417818|DEVICE|Plasma Therapy (PlasmaDerm)|Plasma Therapy (PlasmaDerm)
223800550|NCT02417818|DEVICE|Repetitive Plasma Therapy (repetitive PlasmaDerm)|Repetitive Plasma Therapy (Repetitive PlasmaDerm)
223800551|NCT01249248|DEVICE|PD2i Analyzer|Analysis of heart rate variability from a standard digital ECG for 6-12 minutes
223800552|NCT03260868|DRUG|Insulin glargine, 300 units per milliliter (U/mL)|Self-administered subcutaneous injection using prefilled pen once daily for 24 weeks. Dose titration to achieve fasting self-monitoring of plasma glucose (SMPG) level between 80 and 130 milligram per deciliter (mg/dL).
223800553|NCT03260868|DRUG|Background therapy: Rapid Acting meal time insulin analogs (Humalog, Novolog or Apidra)|Subcutaneous injection.
223800554|NCT04616261|BEHAVIORAL|Training|6 weeks of training
223800555|NCT04616261|DRUG|Formoterol|inhalation of 54 microg formoterol
223800556|NCT04616261|DRUG|Placebo|inhalation of placebo
223800557|NCT04629482|OTHER|Brain networks activity|The brain network activity under different conditions will be evaluated by magnetoencephalography, including resting, listen to different types of music, watch different types of videos, and interacting with cognitive stimulation conditions.
223800558|NCT04405518|DRUG|Fibrinogen Concentrate (Human) 1 MG [RiaSTAP]|The drug used in this study is Riastap, 1g (Fibrinogen). The dose administered will depend on the arm group assigned and in the results of the thromboelastogram during the procedure.
223800559|NCT00541450|DRUG|Comparator: sitagliptin phosphate (sitagliptin)|sitagliptin 100 mg tablet q.d. orally for a 12-wk treatment period
223800560|NCT00541450|DRUG|sitagliptin phosphate (+) metformin hydrochloride|sitagliptin/metformin HCl (Sita/Met) 50/500 mg b.i.d. orally and then 50/1000 mg b.i.d. orally for a 28-wk treatment period
223800561|NCT00541450|DRUG|Comparator: pioglitazone|pioglitazone 15 mg tablet q.d. orally for 6 weeks, followed by 30 mg q.d orally for 6 weeks, followed by 45 mg q.d. orally, up to 40 weeks.
223800562|NCT00541450|DRUG|Matching placebo to pioglitazone|"matching placebo to pioglitazone tablet q.d. orally, for a 40-wk treatment period.~Participants were administered matching placebo the 15 mg pioglitazone q.d. orally for 6 weeks, followed by matching placebo to 30 mg pioglitazone q.d orally for 6 weeks, followed by matching placebo to 45 mg pioglitazone q.d. orally, up to 40 weeks."
223800563|NCT00541450|DRUG|Matching placebo to sitagliptin|matching placebo to sitagliptin q.d., orally for a 12-wk treatment period.
223800564|NCT00541450|DRUG|Matching Placebo to Sita/Met FDC|matching placebo to Sita/Met FDC - 50/500 mg b.i.d. for 4 weeks and then 50/1000 mg b.i.d. orally for a 28-wk treatment period (Week 12 to Week 40).
223800565|NCT01394900|BEHAVIORAL|CNU Intervention|Notions that strengthen the closeness with one's partner, connect with similar couples, and visibly strengthen a community as key to combating dynamics that cause poor communication, isolation, fragmentation of the Black MSM community.
223800566|NCT01394900|BEHAVIORAL|WP Intervention|Attention control condition - WP focuses on nutrition, fitness, healthcare, and stress management. Given the prevalence of health problems among the target population, WP emphasizes adherence to medical guidance and medication regimens.
223800567|NCT01298999|DRUG|YF476|25 mg: one capsule to be taken by mouth once daily for 12 weeks.
223800568|NCT01298999|DRUG|Placebo|Matching placebo: one capsule to be taken by mouth once daily for 12 weeks.
223800569|NCT05929469|BEHAVIORAL|App|Participants will receive an mHealth program.
223800570|NCT05929469|BEHAVIORAL|Fully Automated Kick-Off|As an orientation to the study, participants will receive a fully automated kick-off session.
223800571|NCT05929469|BEHAVIORAL|Human-Enhanced Kick-Off|As an orientation to the study, participants will receive a kick-off session that includes time with a study interventionist.
223800572|NCT05929469|BEHAVIORAL|Check-In|Participants will receive a check-in with a study interventionist.
223800573|NCT05929469|BEHAVIORAL|Counseling|Participants will receive counseling from a study interventionist.
223800574|NCT01975896|BEHAVIORAL|Meditation|The intervention's curriculum will include: 1) the body scan; 2) training in the awareness of the sensations of breathing; 3) training in directing the attention to simple activities of daily life; 4) practice of 'open awareness' in which students will be instructed to just notice which events (physical sensation, sound, visual object, thought) their attention is spontaneously drawn to from moment to moment; 5) mindful movement (standing and walking exercises); and 6) mindful eating. In addition to the weekly training session, students will practice mindfulness techniques for 15 minutes daily in class with the health education teacher and for an additional 15 minutes daily on their own
223800575|NCT02271958|DRUG|Mifepristone|
223800576|NCT02271958|DRUG|PLACEBO|
223800577|NCT01760096|DRUG|Levamisole+cyclosporin A+Glucocorticoids|Levamisole 2.5mg/kg every other day cyclosporin A 3-5mg/kg every other day Glucocorticoids0.25 mg/kg every day(prednisone)
223800578|NCT01760096|DRUG|cyclosporin A+Glucocorticoids|cyclosporin A 3-5mg/kg every day Glucocorticoids0.25mg/kg every day(prednisone)
223800579|NCT01760096|DRUG|Glucocorticoids|Glucocorticoids0.25mg/kg every day(prednisone)
223800580|NCT01254123|DRUG|Exenatide infusion|"On arrival to our cardiac care unit (CCU) and after informed consent patients will be randomized to Exenatide infusion or Placebo infusion. Patients in the Exenatide group will immediately be treated be with Exenatide iv, 5ug bolus in 30 minutes, followed by a continuous Exenatide infusion of 20ug/ 24 hours.~Exenatide preparation: Byetta injection pens containing 1,2 ml (concentration 0,25 mg/ml; 60 doses of 5 μg) will be obtained. 3 doses (15 μg) will be diluted in 49 ml saline and 1 ml Human Serum Albumen (Cealb 200g/L, 10ml) to get a total of 50 ml containing 15 μg exenatide (or 300 ng exenatide / ml). A 50cc syringe will be placed in a pump system that is connected with a cannula in the patient's vein. The infusionrate will be 33,3 ml/hr for the first 30 minutes, followed by an infusion rate of 2,8 ml/hr for 72 hours. New 50cc syringes will be made every 8 hours."
223800581|NCT01254123|DRUG|Placebo infusion.|"On arrival to our cardiac care unit (CCU) and after informed consent patients will be randomized to Exenatide infusion or Placebo infusion. Patients in the placebo group will immediately be treated with placebo infusion.~Placebo preparation: 49ml saline and 1ml Human Serum Albumen (Cealb 200g/L, 10ml) to get a total of 50 ml will be placed in a 50cc syringe and placed in a pump system that is connected with a cannula in the patient's vein. The infusionrate will be 33,3 ml/hr for the first 30 minutes, followed by an infusion rate of 2,8 ml/hr for 72 hours. New 50cc syringes will be made every 8 hours."
223800582|NCT04510805|DEVICE|NextDose (nextdose.org)|"NextDose guided warfarin management taking into consideration covariates (sex, age, weight, height CYP2C9 (rs1057910) and VKORC1 (rs9923231), the dosing and INR history of each patient to predict an individualized dose in accordance with the theory-based warfarin model and target concentration intervention principles.~Initial recommended warfarin dose, up to the first INR, will be the maintenance dose predicted from group values, subsequently the NextDose predicted maintenance dose will be recommended. The treating clinician will also be provided with the NextDose report to inform the choice of the prescribed dose."
223800583|NCT00455065|BEHAVIORAL|Whole Grain Foods|
223800584|NCT05934968|OTHER|Mad Dog cooking class series|This 6-week series consists of a once-weekly cooking class and educational session where a group of individuals with neuromuscular disability can come together to learn about the health benefits of an anti-inflammatory diet, receive instruction on how to cook selected anti-inflammatory recipes, and experiment with various pieces of accessible kitchen equipment that may increase their meal preparation skills. This series will also allow participants to share a meal together once per week.
223800585|NCT03138148|OTHER|Routine mechanical ventilation|Routine mechanical ventilation in PICU amid children with acute respiratory failure
223800586|NCT03993548|BEHAVIORAL|Wellness Element 1 - Exercise|Daily wellness element focusing on Exercise; adherence documented online daily
223800587|NCT03993548|BEHAVIORAL|Wellness Element 2 - Mindfulness|Daily wellness element focusing on Mindfulness Meditation; adherence documented online daily
223800588|NCT03993548|BEHAVIORAL|Wellness Element 3 - Sleep Hygiene|Daily wellness element focusing on sleep hygiene; adherence documented online daily
223800589|NCT03993548|BEHAVIORAL|Wellness Element 4 - Social Connectedness|Daily wellness element focusing on Social Connectedness; adherence documented online daily
223800590|NCT03993548|BEHAVIORAL|Wellness Element 5 - Nutrition|Daily wellness element focusing on Nutrition; adherence documented online daily
223800591|NCT03993548|BEHAVIORAL|Wellness Element 6 - Wellness Exercises|Daily wellness workbook exercises focusing on improving mental wellness; adherence documented online daily
223800592|NCT03993548|BEHAVIORAL|Wellness Element 7 - Motivational Messages|Daily motivational emails offering information on one of the 5 wellness elements each day (Exercise, Mindfulness Meditation, Sleep, Social Connectedness, and Nutrition)
223800593|NCT02151266|BEHAVIORAL|Exercise and Cognitive retraining|Walking 5 times per week at moderate intensity; cognitive retraining one-hour 2 times per week.
223800594|NCT02151266|BEHAVIORAL|Exercise Only|
223800595|NCT02151266|BEHAVIORAL|Stretching and Flexibility|
223800596|NCT01818479|BIOLOGICAL|stem cell transplant|Open label, dose finding trial with two treatment regimens, Busulfan and Total Body Irradiation (TBI) with four dose escalation cohorts, to assess the efficacy of Treg/Tcon addback to partially matched related donor stem cells.
223800597|NCT01818479|PROCEDURE|Stem cell transplant|
223800598|NCT00803452|DRUG|doxycycline|Oral doxycycline 100mg bid
223800599|NCT00803452|DRUG|azithromycin|topical 1% azithromycin daily to eye
223800600|NCT06294496|PROCEDURE|CEA/CAS|carotid endarterectomy (CEA) and carotid artery stenting (CAS)
223800601|NCT05197894|DEVICE|Virtual Reality|The intervention is a Virtual Reality experience within a selected application using an Oculus Quest 2 ©, as previously in the relevant intervention arm.
223800602|NCT04359472|DEVICE|Application of Autologous Amniotic Fluid|Collection and reapplication of amniotic fluid at wound layers during a cesarean section.
223800603|NCT01340469|BIOLOGICAL|probiotics|Daily enteral probiotic supplementation (live Lactobacillus acidophilus and Bifidobacterium infantis) at a dose of 2.5 x 108 CFU of each strain once a day.The supplementation was started on the first day of enteral feeding and continued for at least 28 days or until discharge. The study drug was in liquid form and mixed with breast milk or formula before given to the infants. The preparation was made on a daily basis by one person who was not involved in the care of the infants.
223800604|NCT00936442|DRUG|Anastrozole|(Standard Treatment) 12-month follow-up of anastrozole treatment according to SmPC and current clinical practice.
223800605|NCT00936442|OTHER|Educational materials|Reception of educational material on regular basis.
223800606|NCT05207514|DRUG|Nanoxel M|75 mg/m2, intravenously every 3 weeks for 4 cycles (after treatment cycles of doxorubicin and cyclophosphamide
223800607|NCT05207514|DRUG|Taxotere|75 mg/m2, intravenously every 3 weeks for 4 cycles (after treatment cycles of doxorubicin and cyclophosphamide
223800608|NCT05207514|DRUG|Doxorubicin|60 mg/m2, intravenously every 3 weeks for 4 cycles. Given as first treatment with cyclophosphamide
223800609|NCT05207514|DRUG|Cyclophosphamide|600 mg/m2, intravenously every 3 weeks for 4 cycles. Given as first treatment with doxorubicin.
223800610|NCT00180726|PROCEDURE|Blood sampling, Endoscopic Bronchoscopy, Spirometry|
223800611|NCT04896268|DEVICE|Radiofrequency|Rafaelo's technique consists of delivering a low-temperature 4 MHz radiofrequency wave current into the haemorrhoidal vascular tissue using a large single-use needle with microfibre electrodes at the end.
223800612|NCT04896268|DEVICE|Arterial ligation then recto-anal repair with Doppler|"The aim of arterial ligation is to de-arterialise the haemorrhoids by reducing the arterial flow of the haemorrhoidal plexuses while avoiding obstructing the venous return."
223800613|NCT03829124|DRUG|Propofol|Propofol 10mg/ml IV push slowly 0.5-2mg/kg
223800614|NCT03829124|DRUG|Ketamine|Ketamine 50mg/ml IV push slowly 0.5- 1mg/kg
223800615|NCT01105611|DRUG|Raltegravir|400mg orally twice daily. Number of cycles: unless toxicity or treatment failure occurs, there will be no anticipated treatment discontinuation.
223800616|NCT01105611|DRUG|Atazanavir/Ritonavir|Atazanavir 300mg orally once daily boosted with Ritonavir orally 100mg once daily. Number of cycles: unless toxicity or treatment failure occurs, there will be no anticipated treatment discontinuation.
223800617|NCT01265355|DIETARY_SUPPLEMENT|Anti-rotavirus protein|11mg ARP In 1 Gm Product Daily For 12 Months, given in orange juice
223800618|NCT01265355|DIETARY_SUPPLEMENT|Maltodextrin|Maltodextrin 1 gm daily
223800619|NCT01190696|PROCEDURE|titanium elastic nailing|we inserted titanium nail in femoral fractures retrogradely
223800620|NCT01190696|DEVICE|Hip spica casting|we applied cast for three weeks in patients with femoral shaft fracture
223800621|NCT05166941|BEHAVIORAL|creative drama|In the training program, a total of six games were played about the experiences of psychiatric patients. The program was designed to be two game per week for four weeks.
223800622|NCT02291679|DRUG|Linaclotide|
223800623|NCT02291679|DRUG|Matching Placebo|
223800624|NCT03375983|BIOLOGICAL|Blood-stage infection of P.vivax|The P. vivax infected blood will be confirmed to follow the national standard of blood donation to ensure that only P. vivax is included, excluding the presence of P. falciparum. Exclude other infectious diseases according to the test of national standard of blood donation.
223800625|NCT05081869|OTHER|Exercise Program|An online yoga-based exercise program will be applied for 16 sessions in individuals' own environments. The exercise program will consist of stretching, mobilization, stabilization, strengthening and relaxation exercises.
223800626|NCT05081869|OTHER|Education Program|There will be video training on the subject for both groups.
223800627|NCT04932876|BIOLOGICAL|SARS - COV 2 VACCINE|Vaccination for SARS - COV 2
223800628|NCT05676632|OTHER|Routine Clinical Care|All participants attending the Achilles Tendon Rupture clinic will receive usual clinical care
223800629|NCT00962728|DEVICE|Inspiratory Threshold Device (Res-Q-Gard ITD)|Patient will breathe through this device attached to a mouthpiece during assessment of orthostatic tolerance.
223800630|NCT00962728|DEVICE|Sham Inspiratory Threshold Device|Breathing through a respiratory particulate filter (Model 002850P, Sims Portex Inc, Keene NH) which will have minimal resistance.
223800631|NCT04548063|OTHER|6,000 word consent form|Mock consent form with consistent content in approximately 6,000 word length.
223800632|NCT04548063|OTHER|4,000 word consent form|Mock consent form with consistent content in approximately 4,000 word length.
223800633|NCT04548063|OTHER|2,000 word consent form|Mock consent form with consistent content in approximately 2,000 word length.
223800634|NCT06218017|DEVICE|High flow nasal oxygen fist|Patients in the two study group first underwent a 10-minute session of high-flow nasal oxygen (50 L/min) followed by the utilization of the standard low-flow nasal oxygen (4 L/min) or underwent a 10-minute session of standard low-flow nasal oxygen (4 L/min) followed by the utilization of the high-flow nasal oxygen (50 L/min).
223800635|NCT06218017|DEVICE|High flow nasal oxygen later|Patient in this group underwent a 10-minute session of standard low-flow nasal oxygen (4 L/min) followed by the utilization of the high-flow nasal oxygen (50 L/min)
223800636|NCT00653640|PROCEDURE|body weight supported treadmill training|BWSTT for 12 weeks, 3 times per week
223800637|NCT00653640|PROCEDURE|traditional physical therapy|traditional PT for 12 weeks, 3 times per week
223800638|NCT05432076|DEVICE|Sleep Band and White Noise|"Not taking any sedative or anesthetic drug in the last 12 hours (Such duration of action) An average of 12 hours of sleepiness at the patient's departure and travel hindrance will.)~* Being extubated~* A Glasgow coma scale of 15 (to be investigated by the Glasgow coma scale).~* Baby dreams of boredom~* Besides pain (to the Wong Baker Face Scale used in the Pediatric Intensive Care Unit) evaluation)."
223800639|NCT00725296|BIOLOGICAL|Remicade (Infliximab)|Induction infusions of Remicade will be administered at weeks 0, 2, and 6 given in a dosage due to the decision of the physicians. A maximum of 6 maintenance infusions will be administered with the dosage and interval due to the discretion of the physicians.
223800640|NCT02136940|DRUG|AMA0076|
223800641|NCT02136940|DRUG|Placebo|
223800642|NCT03089437|BEHAVIORAL|Prolonged Standing|Subject will stand for 12 hours and undergo a high fat tolerance test the subsequent day
223800643|NCT03089437|BEHAVIORAL|Prolonged Sitting|Subject will sit for 12 hours and undergo a high fat tolerance test the subsequent day
223800644|NCT03360942|DEVICE|SCC DBS|Deep Brain Stimulator
223800645|NCT05856162|BEHAVIORAL|ENRICH pilot intervention (full intervention)|The full ENRICH pilot intervention will consist of content related to diet, physical activity, stress/mental health, sleep, tobacco cessation, and child health. The investigators will use an adapted version of the Mothers and Babies stress management intervention to address mental health, an adapted version of the HEALTH curriculum to address diet/physical activity, and an adapted version of the INSIGHT curriculum to address child health.
223800646|NCT05856162|BEHAVIORAL|ENRICH pilot intervention (partial intervention: only diet and physical activity)|The partial ENRICH intervention will focus only on diet and physical activity.
223800647|NCT03083899|OTHER|Out-patient clinic on demand (patient-initiated)|Free use of any resources in the out-patient clinic
223800648|NCT03083899|OTHER|Scheduled out-patient clinic|Scheduled use of the out-patient clinic
223800649|NCT02992990|PROCEDURE|Bladder tumor biopsy|Bladder tumor biopsy performed at the time of the preoperative office flexible cystoscopic evaluation.
223800650|NCT06665607|PROCEDURE|Intrinsic Mucle Training|Conventional physiotherapy treatment and the intrinisc foot muscles strengthening program for 8 weeks.
223800651|NCT06597019|DRUG|Inclisiran|Inclisiran (inclisiran sodium 300 mg subcutaneous (s.c.) for participants with body weight ≥23 kg and inclisiran sodium 180 mg s.c. for participants with body weight \<23 kg. The dose level is based on the participant's body weight on Day 1 (for Part 1) and Day 360 (for Part 2), respectively.
223800652|NCT06597019|DRUG|Placebo|Sterile normal saline (0.9% sodium chloride in water for subcutaneous injection)
223800653|NCT06610617|DEVICE|transcranial direct current stimulation (tDCS)|tDCS designed to facilitate the excitability of the left dlPFC or sham stimulation on separate visits separated by at least one week in random order, using a double-blinded, within-subject crossover design. Electrode placement and current parameters will be optimized to each participant with the goal of generating an average electric field of 0.25 V/m within the left dlPFC. The direct current delivered by any one electrode will not exceed 2.0 mA; the total amount of current from all electrodes will not exceed 4 mA using the Stimweaver algorithm. Each 20-minute session will begin and end with a 60-second ramp up/down of current amplitude to maximize comfort
223800654|NCT06610617|DEVICE|Sham tDCS|Active sham in which very low-level currents (0.5 mA total) will be transferred between electrodes in close proximity on the scalp throughout the entire 20-minute session. This intervention delivers currents and mimics the sensations induced by tDCS, but does not significantly influence cortical tissue.
223800655|NCT06669650|OTHER|PGx guided personalized post-operative pain management|Patients in the intervention group will receive post operative opioid therapy based on their pharmacogenomic results. Patients who are poor CYP2D6 metabolizers or rapid CYP2D6 metabolizers with moderate or severe pain, will be prescribed either oral hydromorphone 2mg every 4 hours as needed or oral hydromorphone 4mg every 4 hours as needed, respectively. Patients who are intermediate or normal CYP2D6 metabolizers with moderate or severe pain will receive oxycodone 5mg or oxycodone 10mg every 4 hours as needed respectively similar to the treatment offered to the control subjects. Normal or intermediate CYP2D6 metabolizers who are concomitantly taking a drug which is a strong CYP2D6 inducer will be treated as if they are in the rapid metabolizer group, and normal or intermediate patients that are concomitantly taking a drug which is a strong CYP2D6 inhibitor will be treated as if they were a poor metabolizer.
223800656|NCT06669650|DRUG|Oxycodone|oxycodone
223800657|NCT06669650|DRUG|Hydromorphone|hydromorphone
223800658|NCT06669026|DIETARY_SUPPLEMENT|vitamin D loaded Poly lactic-co-glycolic acid nanoparticles gel|Scaling and root debridement then inject gel in the pocket
223800659|NCT06669026|DIETARY_SUPPLEMENT|vitamin D3 gel (regular non-nanoparticle form)|Scaling and root debridement then inject gel in the pocket
223800660|NCT06669026|OTHER|Poly lactic-co-glycolic acid nanoparticles placebo gel|Scaling and root debridement then inject gel in the pocket
223800661|NCT06669026|PROCEDURE|only mechanical debridement|Scaling and root debridement
223800662|NCT06670950|DRUG|SYT-510|Oral formulation A fasted
223800663|NCT06670950|DRUG|SYT-510|Oral formulation B fasted
223800664|NCT06670950|DRUG|SYT-510|Oral formulation A fed
223800665|NCT06670950|DRUG|Placebo|Oral formulation
223800666|NCT06670209|DRUG|GZR18 and metformin|GZR18: 3 mg-18 mg Metformin: 500 mg
223800667|NCT06670183|OTHER|Dietary patterns|Dietary patterns such as regular meat-eater, occasional meat-eater, pescatarian, and vegetarian; Mediterranean diet.
223800668|NCT06670183|OTHER|Food groups and Nutrients|Dietary components, such as oily fish, dairy product, supplements, fibre, vitamin D supplements.
223800669|NCT06670183|OTHER|Alcohol intake|Frequency and intake of alcoholic beverages was measured by self-reporting the weekly frequency of different types of alcoholic beverages, e.g., the number of pints of beer/cider consumed per week and measures of spirits or liquors consumed per week were collected to assess consumption of beer/cider and spirits.
223800670|NCT06670183|OTHER|Vitamin D status|Serum 25(OH)D was measured once at baseline through a non-fasted blood draw during any season of the year.
223800671|NCT04278287|RADIATION|Radiotherapy|59.92Gy and 2.14Gy in 28 fractions to PGTV and 50.4Gy and 1.8Gy in 28 fractions 5 days every week in 5.5 weeks.
223800672|NCT04278287|DRUG|Albumin-Bound Paclitaxel|100mg/d weekly,repeatedly on the first day,by intravenous infusion in 5-6 weeks.
223800673|NCT04278287|DRUG|Cisplatin|25mg/m2 weekly,by intravenous infusion in 5-6 weeks.
223800674|NCT05505656|DIAGNOSTIC_TEST|hysteroscopic guided endomyometrial biopsy|we will obtain hysteroscopic guided endomyometrial biopsy in cases of adenomyosis
223800675|NCT05073133|GENETIC|OAV101|A single Gene Therapy IV infusion at 1.1e14 vector genome (vg)/kg over approximately 60 minutes
223800676|NCT06414070|BEHAVIORAL|Jenga Dada|Jenga Dada aims to empower women participating in community-based economic groups by training them to recognize inequality, challenge it, and work toward positive changes in their lives related to finances, health, and relationships and increase social support on these issues within the groups. Jenga Dada is expected to include eight modules: 1) overview of the intervention, 2) gender roles, 3) economic control and abuse, 4) intimate partner violence (IPV), 5) reproductive coercion (RC), 6) family planning (FP), 7) financial literacy, and 8) life goals. The Jenga Dada intervention is group discussion-based and draws on two effective interventions: ARCHES (a facility-based contraceptive counseling intervention providing support for RC and IPV) and Girls Invest (a mobile health application with integrated modules on gender, IPV, and financial literacy). The intervention will be facilitated by a local NGO in partnership with group leaders.
223800677|NCT06877078|BEHAVIORAL|Constipation information via Podcast|"The podcast is 30 minutes long, and includes information on constipation explained by a gastroenterologist specialised in defecation disorders, as well as patients' experience with constipation after surgery.~The podcast is developed in collaboration with Silkeborg Regional Hospital and the Central Denmark Region's Centre for Competence Development.~Patients will get access to the podcast after randomisation, and will be able to listen to it throughout the study period."
223800678|NCT06720051|PROCEDURE|Intraosseous dexamethasone injection after 3rd molar surgery|In Group A, patients will receive 4 mg dexamethasone intraosseous injection into the bone distal to the socket of impacted third molar immediately after extraction of the third molar and before suturing
223800679|NCT06720051|PROCEDURE|Submucosal dexamethasone injection after 3rd molar surgery|In Group B, patients will receive 4 mg dexamethasone submucosal injection into the buccal vestibule opposite to the surgical site of impacted third molar immediately after surgery.
223800680|NCT06883162|DRUG|Varenicline|Participants will be randomized 1:1 to varenicline or matched placebo. The standard dose titration schedule will be used, which includes 0.5 mg once per day (q.d.) on Days 1-3, 0.5 mg twice per day (b.i.d.) on Days 4-7, and 1 mg b.i.d. starting on Day 8. Dosing of 2 mg per day will be maintained for the next 11 weeks.
223800681|NCT06883162|BEHAVIORAL|Counseling|Research staff will provide skills-based counseling at weekly visits. Weekly counseling sessions will include discussion of online intervention modules, while providing skills-based strategies focused on enlisting social support, recognizing triggers, managing craving/withdrawal/stress, etc. Staff will use motivational enhancement techniques to address tobacco cessation, cannabis reduction or abstinence, and medication adherence.
223800682|NCT06883162|BEHAVIORAL|Psychosocial modules|Participants will have access to online modules addressing tobacco and cannabis co-use to support cessation and/or reduction. Content includes 12 virtual modules combining cognitive behavioral therapy (CBT) and motivational enhancement (MET) to address tobacco, cannabis, and their co-use.
223800683|NCT04948099|DRUG|VIB1116|VIB1116
223800684|NCT04948099|DRUG|Placebo|Placebo
223800685|NCT06262620|PROCEDURE|EBUS-TBNA|A 22G biopsy needle was insert into the lesion through tracheal-bronchial wall under real-time EBUS guided by bronchoscopist. Needle punctures were performed by using the jabbing method. Once it is confirmed that the puncture needle is within the target lesion, the puncture needle is moved back and forth while suction (An empty 50 ml syringe was connected to the port at the end of the puncture needle and aspirated to 20 ml maintained for 20 seconds.) is applied. Each lymph node was operated 5 times.
223800686|NCT06262620|PROCEDURE|EBUS-TBMC via a tunnel|First a tunnel between airway wall and mediastinal and/or hilar lesion was made by a puncture dilation catheter (BroncTruTM AK-91-55, Bronchus Inc. Hangzhou, China). The 1.1mm cryoprobe (Erbe 20402-401, ERBE, Tübingen, Germany) entered the target lymph node through the tunnel under direct monitoring of EBUS, and the distance between the tip of the cryoprobe and the border of target lymph node was measured using EBUS. After confirming that the distance was \>5 mm, the probe was cooled with liquid carbon dioxide for 5-9 seconds. Then retracted with the bronchoscope and the frozen biopsy tissue. Samples were retrieved by thawing in saline and then fixed in formalin. The same lymph node was operated for 3 times.
223800687|NCT06262620|PROCEDURE|EBUS-TBFB via a tunnel|Firstly, a tunnel to reach the lymph node is established by making use of a puncture dilation catheter, and a 1.5mm biopsy forceps is pushed into the lymph node through the working channel of the ultrasound bronchoscope. After entering the lymph node, the biopsy forceps were opened proximally to the lymph node, the biopsy forceps were advanced, and then the biopsy forceps were closed distally to the lymph node for each specimen. Each lymph node was operated 5 times.
223800688|NCT06724068|OTHER|Diabetes，Insulin resistance，Control|This retrospective study uses medical records and diagnostic data from patients with type 2 diabetes and healthy controls obtained from Qianfoshan Hospital from2019 to 2022
223800689|NCT06722482|DEVICE|FDBA|Twenty five participants will receive FDBA in anterior extraction sockets as part of the alveolar ridge preservation procedure.
223800690|NCT06722482|DEVICE|CEBX|Twenty five participants will receive CEBX in anterior extraction sockets as part of the alveolar ridge preservation procedure.
223800691|NCT06723366|DRUG|Angong Niuhuang Pill (ANP)|Angong Niuhuang Pill (ANP) (3 g/pill, 1 pill/day for 5 days)
223800692|NCT06723366|OTHER|Control (Standard treatment)|Blank control
223800693|NCT06723678|PROCEDURE|Two distally inclined 45-degree angle posterior implants|During the surgery, two axially placed anterior implants and two distally inclined 45-degree angle posterior implants will be placed, after healing period, All on-4 screw-retained prosthesis will be delivered to the patients.
223800694|NCT06723678|PROCEDURE|Two distally inclined 30-degree angle posterior implants|During the surgery, two axially placed anterior implants and two distally inclined 30-degree angle posterior implants will be placed, after healing period, All on-4 screw-retained prosthesis will be delivered to the patients
223800695|NCT06717685|DRUG|Adenosine|Adenosine is a medication belonging to class V antidysrhythmics, used to treat a type of irregular heart rhythm disorder known as paroxysmal supraventricular tachycardia (PSVT)
223800696|NCT06717685|DRUG|Verapamil Injection|Verapamil is in a class of medications called calcium-channel blockers. It works by relaxing the blood vessels so the heart does not have to pump as hard. It also increases the supply of blood and oxygen to the heart and slows electrical activity in the heart to control the heart rate.
223800697|NCT05227833|DRUG|Vonoprazan fumarate (Vonaspire)|Patients assigned to Vonoprazan (vonaspire) tablets will receive a daily dose of 20 mg before breakfast starting from the first day of band ligation.
223800698|NCT05227833|DRUG|Pantoprazole 40mg|Patients assigned to Pantoprazole tablets (Controloc OR Antopral OR Perloc) will receive a daily dose of 40 mg before breakfast starting from the first day of band ligation.
223800699|NCT05227833|OTHER|Placebo|No Intervention
223800700|NCT04219033|OTHER|EEG(Electroencephalogram) change|patients are found to have characteristic EEG change
223800701|NCT06723873|OTHER|Kinesiology Taping|The treatment group received Kinesiology Taping around the trunk extensors, lower and middle trapezius, supraspinatus, deltoid muscle group, and serratus anterior muscle.
223800702|NCT06723873|OTHER|Placebo Kinesio Taping|In the control group, kinesiology tape was applied without tension and in a manner that did not target specific muscle groups or respect the anatomical origin and insertion points.
223800703|NCT03278262|DRUG|Aflibercept (Eylea, BAY86-5321)|Treatment-naïve eyes with neovascularization AMD (Age-related Macular Degeneration), with the indication to be treated with Aflibercept. One and/or two eyes per patient.
223800704|NCT06225167|BEHAVIORAL|To evaluate the effectiveness and safety of a pharmacist-driven protocol to discontinue stress ulcer prophylaxis in ICU patients when it is no longer indicated according to pre-defined criteria.|"To evaluate the effectiveness and safety of a pharmacist-driven protocol to discontinue stress ulcer prophylaxis in ICU patients when it is no longer indicated according to pre-defined criteria.~To compare the incidence of overt GI bleeds (defined as hematemesis, bloody nasogastric tube aspirate, or melena) between patients who were on stress ulcer prophylaxis versus patients whose acid suppression therapy was discontinued through the stress ulcer prophylaxis minimization protocol."
223800705|NCT02142647|BEHAVIORAL|a high-protein complementary diet with meat|infants will consume a high-protein complementary diet with protein mainly from meat
223800706|NCT02142647|BEHAVIORAL|a high-protein complementary diet with dairy|infants will consume a high-protein complementary diet with protein mainly from dairy
223800707|NCT06234293|DEVICE|near-infrared light device|Nurses will have to find the vein for the PIVC using the near-infrared light device.
223800708|NCT06526403|DEVICE|Zero-fluoroscopy ASD closure|Percutaneous ASD closure without fluoroscopy was performed in secundum-type oval-shaped ASD
223800709|NCT02273284|DEVICE|Buzzy|The Buzzy will be applied for 30 seconds over the area that is going to be injected, then during the actual injection the Buzzy will be moved rostrally and continuously used during the injection. When the injection is completed the Buzzy is positioned in the same way over the next injection site.
223800710|NCT04604002|DEVICE|OCT Angiography|OCT Angiography offers clinicians a non-invasive three-dimensional visualization of vasculature in the retina and choroid. The visualization of perfused vasculature in a three-dimensional layout, offers clinicians an aid in the identification of retinal and choroidal pathologies such as retinal ischemia, microaneurysms, retinal neovascularization and choroidal neovascular membranes.
223800711|NCT04604002|DEVICE|Color Fundus Photography|Non-contact white light photography
223800712|NCT04604002|DEVICE|Optical Coherence Tomography|A non-contact test that uses light waves to take cross-sectional pictures of the retina
223800713|NCT02880592|OTHER|Affinity Allograft|fresh hypothermically stored human amniotic membrane
223800714|NCT02880592|OTHER|Standard of care|offloading, debridement, infection management using appropriate dressings
223800715|NCT05584852|OTHER||no intervention
223800716|NCT01518855|DRUG|Nifedipine (Adalat, BAYA1040)|
223800717|NCT01518855|DRUG|Amlodipine (Norvasc)|
223800718|NCT01518855|DRUG|Diovan|
223800719|NCT04333420|DRUG|IFX-1 + BSC|Phase II study part: IFX-1 + BSC
223800720|NCT04333420|DRUG|BSC|Phase II study part: BSC
223800721|NCT04333420|DRUG|IFX-1 + SOC|Phase III study part: IFX-1 + SOC
223800722|NCT04333420|DRUG|Placebo + SOC|Phase III study part: Placebo + SOC
223800723|NCT04318184|PROCEDURE|Aerobic exercise|The aerobic exercise protocol was performed 3 times a week for 3 months on the treadmill. Loading periods were performed according to the heart rate maximum using the Karvonen formula (%60-80 Heart rate maximum)
223800724|NCT06550336|DRUG|Chidamide|20 mg (4 tablets) twice a week, specifically on days 1, 4, 8, 11, 15, 18, 22, and 25.Each 4-week period constitutes one treatment cycle.
223800725|NCT03672773|DRUG|Talazoparib|Given PO
223800726|NCT03672773|DRUG|Temozolomide|Given PO
223800727|NCT03362333|OTHER|Exercise|Exercises were aimed at increasing the endurance and strength of the deep neck flexor and extensor muscles and of the scapular stabilizer muscles.
223800728|NCT03362333|OTHER|Pain neuroscience education|Pain neuroscience education covered the neurophysiology of pain, transition from acute to chronic pain and the nervous system ability to modulate the pain experience.
223800729|NCT02792361|PROCEDURE|Standard Suction Drain|The intervention of the experimental group will be a standard suction drain placed at the surgical site following a Pterional Craniotomy.
223800730|NCT02801994|DEVICE|PAV, Puritan Bennett 980 ventilator|The PAV mode will be delivered by Puritan Bennett 980 ventilator (Covidien, Boulder, USA). Levels of PEEP and FiO2 will be kept constant. The level of assistance in PAV, named %-assistance will be set in order to keep the patient in a respiratory effort zone corresponding to a respiratory muscles pressure time product (PTPmus) between 50 and 150 cm H2O • s / min. As it is not possible to calculate directly the PTPmus at bedside, the investigators will use as a substitute its main component, the pressure peak muscle of the airways according to the previous report from Carteaux et al. This setting has been described extensively and its use has been the subject of a feasibility study in 50 patients. After a 20-minutes stabilization period, a 30-minutes recording will be performed.
223800731|NCT02776332|PROCEDURE|Manual Expression of Breastmilk|Breastfeeding log for 14 days after delivery Video of manual expression for teaching and reinforcement Complete breastfeeding self-efficacy scale at 1 day and 14 days after delivery
223800732|NCT01746693|DEVICE|Dynamic Vessel Analyzer|retinal vessel diameter, retinal oxygen saturation
223800733|NCT01746693|OTHER|Laser Doppler Velocimetry|retinal blood flow velocity, retinal blood flow
223800734|NCT01746693|DEVICE|7-Tesla MRI|High resolution functional and anatomical imaging of the visual pathway
223800735|NCT01746693|OTHER|Pattern electroretinography|inner retinal function
223800736|NCT01746693|OTHER|Fourier domain optical coherence tomography|Blood flow in retina.
223800737|NCT01834755|OTHER|Evaluation of psychological phenotype|
223800738|NCT02525848|DRUG|dexamethasone|dexamethasone 8 mg iv 2 minutes before induction of anesthesia
223800739|NCT02525848|DRUG|Gabapentin|oral gabapentin 600 mg 1 hour before induction of anesthesia
223800740|NCT02525848|DRUG|Aprepitant|oral aprepitan 80mg 1 hour before induction of anesthesia.
223800741|NCT00400907|OTHER|clinical observation|
223800742|NCT00400907|PROCEDURE|management of therapy complications|
223800743|NCT02699502|OTHER|matching an appropriate drug therapy to patients with osteoporotic hip fractures|The process involves reviewing patients characteristics virtually and finding the right drug for them while they are still in the hospital. After matching an appropriate drug, getting it through regulatory authorities to the family physician
223800744|NCT03771014|OTHER|Early mobility|This progressive mobility pathway commenced with passive cycling within 48 hours of intubation and ventilation and progressing through assisted cycling, active cycling, bed exercises, sitting, mobilising out of bed to walking
223800745|NCT06366204|OTHER|Dietary Lysine Intakes|Participants consume 8 hourly meals that contain the assigned test lysine intake. Each meal will provide one-twelfth of the participants' daily energy requirements as estimated by 1.7 x Resting Energy Expenditure (REE) and adequate protein at 1.5 g.kg.d, to maintain a metabolic steady state. The meals are in the form of a crystalline amino acid protein shake, and nitrogenous free cookies.
223800746|NCT03912493|DEVICE|Game Based Virtual Reality Exercises|A game-based virtual reality device named USE-IT will be added to the rehabilitation program. USE-IT is a technological rehabilitation system designed by the Department of Physiotherapy and Rehabilitation at Hacettepe University. It is a smart gaming device which has been used in patients who suffer from movement loss in their upper extremities due to various neurological and orthopedic reasons.
223800747|NCT03912493|OTHER|Conventional Physiotherapy and Rehabilitation|The conventional physiotherapy and rehabilitation program includes the application of Transcutaneous Electrical Nerve Stimulation (TENS), cold pack, therapeutic ultrasound, Codman Exercises, Wand exercises, shoulder wheel exercises, finger ladder exercises, strengthening exercises with elastic band and capsule stretching.
223800748|NCT00289887|DRUG|Comparator: losartan +/- HCTZ|Placebo to losartan once daily for 4 weeks in run-in period. Then, losartan 50 mg for 4 weeks, then titrate to losartan 100 mg at Week 4, then titrate to losartan 100 mg + hydrochlorothiazide (HCTZ) 12.5 mg at Week 8, and finally titrate to losartan 100 mg + HCTZ 25 mg at Week 12. Duration of treatment is approximately 16 weeks.
223800749|NCT00289887|DRUG|Comparator: Placebo|Placebo to losartan once daily for 4 weeks in run-in period. Then, placebo to losartan or losartan/HCTZ once daily for approximately 16 weeks.
223800750|NCT02879266|BIOLOGICAL|TetraVax-DV TV005|Contains 10\^3 plaque-forming units (PFUs) of rDEN1Δ30, 10\^4 PFUs of rDEN2/4Δ30(ME), 10\^3 PFUs of rDEN3Δ30/31-7164, and 10\^3 PFUs of rDEN4Δ30; administered by subcutaneous injection in the deltoid region of the upper arm
223800751|NCT02879266|BIOLOGICAL|Placebo|Administered by subcutaneous injection in the deltoid region of the upper arm
223800752|NCT01266850|BIOLOGICAL|Rotarix®|Each 1-mL dose of Rotarix® contains a suspension of at least 10\^6 median Cell Culture Infective Dose (CCID50) of live, attenuated human G1P rotavirus after reconstitution. The lyophilized vaccine contains amino acids, dextran, Dulbecco's Modified Eagle Medium (DMEM), sorbitol, and sucrose. The liquid diluent contains calcium carbonate, sterile water, and xanthan. The diluent includes an antacid component (calcium carbonate) to protect the vaccine during passage through the acid environment of the stomach. Rotarix® contains no preservatives. Once reconstituted, the vaccine will appear white and turbid.
223800753|NCT01266850|BIOLOGICAL|RotaTeq®|2-mL ready-to-use oral solution of live reassortant rotaviruses, containing G1, G2, G3, G4, and P1A, which contains a minimum of 2.0 to 2.8 x 10\^6 infectious units (IU) per individual reassortant dose, depending on the serotype, and not greater than 116 x 10\^6 IU per aggregate dose. The buffered stabilizer solution contains sucrose, sodium citrate, sodium phosphate monobasic monohydrate, sodium hydroxide, polysorbate 80, cell culture media, and trace amounts of fetal bovine serum. RotaTeq® contains no preservatives. RotaTeq® is a pale yellow clear liquid that may have a pink tint.
223800754|NCT00644462|DEVICE|PulmoTrack® 2010 with WIM-PC™ Technologies|wheeze detection during dynamic bronchial situations in infants
223800755|NCT01584180|DRUG|Cold crystalloid infusions, 0.9%NaCl or Ringer's|Infusion of max. 1L cold crystalloid solution (4°C) over 15 minutes
223800756|NCT01584180|DEVICE|EMCOOLS Brain.Pad|Passive external neck cooling with 1 EMCOOLS Brain.Pad
223800757|NCT05419648|BIOLOGICAL|1 additional tube of blood|For all the patients included, a specific blood sampling will be performed in addition to the classical evaluations that are performed in routine practice
223800758|NCT01695824|DEVICE|LAA occluder|The procedure is performed under transesophageal echocardiographic (TEE) guidance. After a transseptal puncture is performed, a pigtail catheter is maneuvered into the LAA to perform an LAA angiogram. Through the use of a combination of this angiographic and TEE information, a Watchman device, ranging in size between 21 and 33 mm in diameter, is selected. The device comes prepackaged in a catheter-based delivery system that is advanced into the LAA through a 12F transseptal sheath (outer diameter, 14F). Proper positioning and stability of the device are verified by TEE and angiography before device release.
223800759|NCT01695824|PROCEDURE|RFA ablation|The left atrium (LA) and pulmonary veins (PVs) were explored through a transseptal approach. Real-time three-dimensional (3D) LA maps were reconstructed by using a nonfluoroscopic navigation system (CARTO, Biosense-Webster Inc.). The ipsilateral left and right PVs were encircled in 1 lesion line by circumferential PV isolation. Radiofrequency energy was delivered at 43◦C, 35 W, 0.5 cm away from the PV ostia at the anterior wall, and was reduced to 43◦C, 30 W, 1 cm away from the PV ostia at the posterior wall, with a saline irrigation speed of 17 mL/min. Each lesion was ablated continuously until the local potential amplitude decreased by \>80% or RF energy deliveries exceeded 40 seconds. The endpoint of circumferential PV isolation was PV isolation; this was confirmed when Lasso mapping showed the disappearance of all PV potentials or the dissociation of PV potentials from left atrial activity.
223800760|NCT01695824|DRUG|Warfarin|"Warfarin was discontinued in 45 days after procedure in case of no trombus by TE for Watchman group~All patients in Warfarin group continued to receive Warfarin during hole study period with IMR from II to III."
223800761|NCT01862952|OTHER|starting of anti-epileptic drug treatment|
223800762|NCT03115294|DRUG|Theophylline|iv injection
223800763|NCT03115294|PROCEDURE|Ventilator positive end expiratory pressure adjustment|Positive end-expiratory pressure variation
223800764|NCT03115294|DEVICE|Videorecording|Myocardial movement videorecording
223800765|NCT04177680|DRUG|Omega 3 pentaenoic acid|Encapsulated omega-3 pentaenoic acid
223800766|NCT04177680|DRUG|icosapent ethyl|Encapsulated omega-3 acid ethyl esters
223800767|NCT04883307|BEHAVIORAL|Coaching|Professional development coaching based on a curriculum of positive psychology principles and coaching principles.
223800768|NCT04883307|BEHAVIORAL|Wellness resources|Residents in the control group received three emails across the 9 month study period that contained materials related to physician well-being such as personal development and resilience, mindfulness, and work life-integration. Materials included recommended readings, videos, and exercises and were curated by members of the Association of Women Surgeons who were not involved in the coaching program.
223800769|NCT00437645|DRUG|Valsartan 160 mg capsules|
223800770|NCT00437645|DRUG|Amlodipine 5 mg capsules|
223800771|NCT00437645|DRUG|placebo|capsules
223800772|NCT00707265|DEVICE|rhBMP-2/CRM/CD HORIZON® Spinal System|"The rhBMP-2/CRM component of the investigational device consists of recombinant human Bone Morphogenetic Protein-2 (rhBMP-2) and a compression resistant matrix (CRM) carrier consisting of an absorbable collagen sponge imbedded with biphasic calcium phosphate.~The posterior spinal fixation system, the CD HORIZON® Spinal System, is a commercially available rod-based spinal system intended for temporary stabilization of the spine in order to facilitate fusion. The CD HORIZON® Spinal System is available in either titanium or stainless steel. For this study, only titanium implant components will be used."
223800773|NCT00707265|DEVICE|Autograft/CD HORIZON® Spinal System|The control will be autogenous bone taken from the iliac crest of the patient and placed bilaterally across two adjacent transverse processes and used in conjunction with the CD HORIZON® Spinal System. When used as a posterior spine thoracic/lumbar system, the CD HORIZON® CANNULATED M8 MULTI-AXIAL SCREW components are intended for several indications including degenerative disc disease.
223800774|NCT00412048|PROCEDURE|fMRI to detect MCI patients who will convert to Alzheimer's disease|There is a fMRI to be realized in the 3 arms. No drug is administered
223800775|NCT01830114|BEHAVIORAL|Web app|The Checkup and Choices web application
223800776|NCT03254082|OTHER|Glycemic response of F-1000|The intervention was to determine if different flours elicit similar or different (change from baseline) 2 hour glucose responses (e.g., similar to glycemic index) after eating.
223800777|NCT03254082|OTHER|Glycemic response to sumac sorghum flour|The intervention was to determine the two hour change from baseline glucose responses (e.g., similar to glycemic index) after consuming sumac sorghum flour as a gruel.
223800778|NCT03254082|OTHER|Glycemic response to MMR sorghum flour|The intervention was to determine the two hour change from baseline glucose responses (e.g., similar to glycemic index) after consuming MMR sorghum flour as a gruel.
223800779|NCT03254082|OTHER|Glycemic response to wheat flour|The intervention was to determine the two hour change from baseline glucose responses (e.g., similar to glycemic index) after consuming wheat flour as a gruel.
223800780|NCT03254082|OTHER|Glycemic response to sucrose|The intervention was to determine the two hour change from baseline glucose responses (e.g., similar to glycemic index) after consuming sugar (dissolved in water)
223800781|NCT00642512|DRUG|dronabinol|10 - 20 mg
223800782|NCT00642512|DRUG|ondansetron|8 - 16 mg
223800783|NCT00642512|DRUG|dronabinol/ondansetron|10 - 20 mg/8 - 16 mg
223800784|NCT00642512|DRUG|placebo|placebo
223800785|NCT05721131|DEVICE|NC° Thermometer (Gen 3)|The NC° Thermometer (Gen3) is used orally for the intermittent measurement and monitoring of human body temperature. The device can be used by adults and children over the age of 5 years old.
223800786|NCT05164575|BEHAVIORAL|progressive resistance exercise|Progressive resistance exercise program and self-management strategies. Participants will be provided with Theraband to progress exercise intensity, a FitBit to monitor physical activity, an audio-journal to promote self-reflection, and educational materials provided as part of usual OA care.
223800787|NCT05164575|BEHAVIORAL|self-management strategies|Progressive resistance exercise program and self-management strategies. Participants will be provided with Theraband to progress exercise intensity, a FitBit to monitor physical activity, an audio-journal to promote self-reflection, and educational materials provided as part of usual OA care.
223800788|NCT03834233|DRUG|Nivolumab|Nivolumab 3mg/kg IV every 14 days until disease progression, unacceptable toxicity or up to 12 months.
223800789|NCT04336735|OTHER|immunization app|A transplant specific immunization app will be trialed that 1) provides vaccine information and education, 2) stores vaccine records and 3) provides reminders when vaccines are due
223800790|NCT02614495|DRUG|Surufatinib|Patients receive oral Sulfatinib at a dose of 300mg/d within 1 hour after breakfast (once-daily dosing continuously, every 28-day treatment cycle)
223800791|NCT00047476|DRUG|dexmethylphenidate(d-mph)|
223800792|NCT05745142|DRUG|Sunitinib|as provided in real world practice
223800793|NCT05656599|DRUG|Letermovir|Patients received letermovir as prophylaxis or received preemptive therapy for CMV depends on clinical needs and patients' wishes
223800794|NCT05282797|DRUG|ANEB-001|Experimental Treatment
223800795|NCT05282797|DRUG|Placebo|Placebo comparator
223800796|NCT06146491|DRUG|Oral tablet and transdermal patch|oral combination of paracetamol -500mg and ibuprofen - 400mg will be given to group A and transdermal diclofenac patch - 200 mg will be given to group B.
223800797|NCT05011968|DIETARY_SUPPLEMENT|Lettuce with not biofortification|Lettuce without any biofortification was assigned to each participant belonging to the control group which ate 100gr every day for 10 days
223800798|NCT05011968|DIETARY_SUPPLEMENT|Lettuce biofortificated with Iodine|Lettuce with Iodine biofortification was assigned to each participant belonging to the intervention group which ate 100gr every day for 10 days
223800799|NCT02295839|BEHAVIORAL|Sleep Hygiene and Relaxation Education|Intervention group participants receive a nurse-led, one-hour 1:1 educational session including education about sleep in children and a description of what is known about sleep and fatigue issues in children with cancer. The session also includes strategies to improve sleep hygiene in children. Information about relaxation to promote sleep is outlined and two children's books designed to promote relaxation using the principles of deep breathing are given to the parent(s). A handout containing all the information covered is given to the parent(s).
223800800|NCT03350568|OTHER|Total dietary NEAC assessed at baseline|
223800801|NCT02559336|OTHER|Integrated palliative oncology care|Integrated palliative care and oncology care for advanced cancer patients who have an unplanned admission to hospital
223800802|NCT03722927|DRUG|Bupivacaine|While in the operating room,if subject is randomized to bupivacaine, it will be injected into the surgical site. After surgery, oral and IV pain medications will be available to control pain. During the hospital stay, subject will rate pain on pain scales and monitor how much pain medications needed. Once discharged, PI/staff will provide a pain diary to record pain medication use and pain rating (0-10). Subjects will follow up with clinic at regularly scheduled appointment times at 1 week, 3 weeks and 5 weeks postoperatively. At those appointments, PI/staff will have subjects bring pain medication diary and fill out a pain assessment and a disability assessment related to recent surgery.
223800803|NCT03722927|DRUG|Liposomal Bupivacaine|While in the operating room,if subject is randomized to Liposomal Bupivacaine, it will be injected into the surgical site. After surgery, oral and IV pain medications will be available to control pain. During the hospital stay, subject will rate pain on pain scales and monitor how much pain medications needed. Once discharged, PI/staff will provide a pain diary to record pain medication use and pain rating (0-10). Subjects will follow up with clinic at regularly scheduled appointment times at 1 week, 3 weeks and 5 weeks postoperatively. At those appointments, PI/staff will have subjects bring pain medication diary and fill out a pain assessment and a disability assessment related to recent surgery.
223800804|NCT03089684|OTHER|No intervention|No intervention
223800805|NCT04835818|DIAGNOSTIC_TEST|Provide the panel report to the primary care physician|Point-of-care Multiplex PCR Respiratory Panel (BIOFIRE FilmArray) and Pneumonia Panel results (BIOFIRE FilmArray)
223800806|NCT00003617|DRUG|chlorambucil|
223800807|NCT00003617|DRUG|clarithromycin|
223800808|NCT00003617|DRUG|omeprazole|
223800809|NCT00003617|DRUG|tinidazole|
223800810|NCT05858697|OTHER|Declining participation in the Aarhus intervention|Each year a fraction of the children invited into the Aarhus intervention decline to participated.
223800811|NCT05858697|BEHAVIORAL|Participation in the Aarhus intervention|A community-based multicomponent family-centered lifestyle intervention which included visits at home and weekly supervised physical activity. The intervention has a maximum duration of one year.
223800812|NCT03751631|DRUG|Tropicamide 1%-Phenylephrine 2.5% ophthalmic solution (TR/PE)|Fixed combination tropicamide 1%-phenylephrine 2.5% ophthalmic solution administered with the Optejet microdose dispenser
223800813|NCT03751631|DRUG|Tropicamide 1% ophthalmic solution (TR)|Tropicamide 1% ophthalmic solution administered with the Optejet microdose dispenser
223800814|NCT03751631|DRUG|Phenylephrine 2.5% ophthalmic solution (PE)|Phenylephrine 2.5% ophthalmic solution administered with the Optejet microdose dispenser
223800815|NCT04238026|PROCEDURE|Distal radial artery approach|Use of distal radial artery approach in coronary angiography and angioplasty
223800816|NCT02937961|BIOLOGICAL|Early SLED|withing 6 to 12 hours
223800817|NCT02937961|BIOLOGICAL|Late SLED|when absolute indications will meet
223800818|NCT03949166|OTHER|food during labor and delivery|The food that will be allowed during labor and delivery was approved by the anesthesia team. It includes - fruits, energy bars, yogurt,
223800819|NCT03159520|BEHAVIORAL|Advice sheet|Advice on management of post orthodontic pain
223800820|NCT03073148|DEVICE|Tangible Boost|Participants will treat their lenses with Tangible Boost, a kit designed to maintain the wettability of Hydra-PEG treated fluorosilicone acrylate lenses.
223800821|NCT03073148|OTHER|Placebo saline|"Participants will treat their lenses with a placebo Tangible Boost kit, which contains saline in place of the Tangible Boost solution."
223800822|NCT00140504|OTHER|Medcheck message|Participants selected at random will receive one email message asking them questions about their prescription which will be forwarded to their physician
223800823|NCT00370630|DRUG|Avastin (Bevacizumab) and triamcinolone|
223800824|NCT00879138|DRUG|VA106483|
223800825|NCT00879138|DRUG|Sugar pill|
223800826|NCT01610427|PROCEDURE|Blood sample collection|Blood samples will be collected in all subjects at two time points, at the Screening Visit (Day 0) and at the Sample Collection Visit (Day 15)
223800827|NCT02579954|BEHAVIORAL|Rehabilitation|
223800828|NCT00444691|DEVICE|ultra-sonography|"o The ultrasonographic evaluation was performed on 38 joints: the 28 joints included in DAS28 (e.g. shoulderx2, elbowx2, wristx2, metacarpo-phalangeal (MCP)x10, proximal inter phalangeal (PIP)x10, kneex2) and also the metatarso-phalangeal (MTPx10). Systematic multiplanar gray-scale (mode B) and Power Doppler examination was carried out with commercially available real-time scanners using multi-frequency linear transducers (7-12 MHz).~The ultrasonographic evaluation was performed at baseline and 1, 2, 3, and 4 months after baseline."
223800829|NCT02250105|DRUG|ARI-3037MO|Lipid lowering
223800830|NCT02250105|DRUG|Placebo|Inactive
223800831|NCT03382782|BEHAVIORAL|BWLI|"BWLI includes group weight management classes, physical activity classes, individual sessions with a facilitator to address goals and barriers to weight loss, and weigh-ins.~A punch card system will be implemented to incentivize participation for BHL classes. Each participant from the BWLI condition will be given a punch card, each punch card contains 10 spaces of punches, and will receive a punch at the end of each class (either BHL or physical activity) they attend. No punch will be given if they are more than 15 minutes late for BHL class or more than 5 minutes late for physical activity class. Participants can earn $5 per punch for up to $250. They will be allowed to cash in for $50 Visa gift card every 10 punches. They cannot cash in for a partially filled card. They must have the 10 full punches to cash in."
223800832|NCT03382782|BEHAVIORAL|BWLI & Peer Navigator|Participants receive the BWLI condition and partner with a peer navigator. Peer navigators will meet individually and face-to-face with participants to address their health and weight goals (i.e. working on BWLI homework, attending health care appointments, and facilitating diet and exercise activities). A punch card system will be implemented to incentivize participation for BHL classes. Each participant from BWLI \& Peer Navigator will be given a punch card, each punch card contains 10 spaces of punches, and will receive a punch at the end of each class (either BHL or physical activity) they attend. No punch will be given if they are more than 15 minutes late for BHL class or more than 5 minutes late for physical activity class. Participants can earn $5 per punch for up to $250. They will be allowed to cash in for $50 Visa gift card every 10 punches. They cannot cash in for a partially filled card. They must have the 10 full punches to cash in.
223800833|NCT03382782|BEHAVIORAL|Integrated Care|Participants receive integrated physical and mental health care from their usual provider.
223800834|NCT04186013|DRUG|Atezolizumab Injection [Tecentriq]|intravenous infusion of 1.200 mg of Atezolizumab administered intravenously every 3 weeks for a total of 6 doses
223800835|NCT04186013|RADIATION|External Beam Radiation Therapy (EBRT)|60 Gy of radiotherapy in 30 fractions overs 6 weeks at 2 Gy/day
223800836|NCT01316510|DIETARY_SUPPLEMENT|Bifidobacteria infantis|1 billion organisms twice daily either through a feeding tube or by mouth for 6 weeks or until discharge
223800837|NCT01316510|OTHER|Placebo|Dilute Nutramigen formula
223800838|NCT03974620|BEHAVIORAL|Individual Placement and Support|Individual Placement and Support is a vocational support program that was developed in the USA, to facilitate return to employment in individuals with severe and enduring mental illnesses.
223800839|NCT03974620|BEHAVIORAL|Cognitive Remediation Therapy|This is an evidence based intervention that aims to improve cognitive functioning.
223800840|NCT01520740|DEVICE|Emphysematous Lung Sealant|4 Subsegments treated - 2 each bilaterally
223800841|NCT01520740|DEVICE|Emphysematous Lung Sealant|4 Subsegments treated - 2 each bilaterally
223800842|NCT00135369|DRUG|stavudine extended-release, lamivudine, efavirenz|
223800843|NCT04021810|DEVICE|Continuous Positive Airway Pressure (CPAP) and patient education|Mask connected to a pump (CPAP machine) that forces air into the nasal passages at pressures high enough to overcome obstructions in the airways. Plus patient education.
223800844|NCT04021810|DEVICE|Mandibular Advancement Device|Adjustable oral prosthesis which retains the lower mandible in an anterior position, thus limiting sleep apneas
223800845|NCT02377154|DEVICE|Slit lamp|Examination of cornea
223800846|NCT02377154|DEVICE|Autorefractor|Measurement of refraction
223800847|NCT02377154|DEVICE|IOLMaster 500|Measurement of axial length and white-to-white distance; Keratometry; IOL calculation
223800848|NCT02377154|DEVICE|Pentacam HR|Measurement of white-to-white distance; Keratometry
223800849|NCT02377154|DEVICE|LenStar LS900|Measurement of axial length and white-to-white distance; Keratometry; IOL calculation
223800850|NCT02377154|DEVICE|VERION Image Guided System|Measurement of white-to-white distance; Keratometry; IOL calculation with axial length value of IOLMaster 500
223800851|NCT05596370|DIAGNOSTIC_TEST|cell free DNA in blood and urine, metabolite/microbiome in urine and stool|cell free DNA in blood and urine, metabolite/microbiome in urine and stool
223800852|NCT03195868|DEVICE|Realief Therapy|Patients will be treated using class IV laser using a proprietary algorithm developed by REALief neuropathy centers
223800853|NCT03233243|DRUG|Rosuvastatin Oral Tablet|Patients with 18F-NaF-positive plaques will be treated with 20 mg of rosuvastatin daily for six months, except in patients who need a 55% LDL reduction to achieve recommended targets (rosuvastatin 40 mg). A second visit (visit 2) will take place eight weeks after therapy initiation to monitor for compliance and adverse events report: therapy will be discontinued if there is an elevation of creatine kinase over five times the ULN with myalgia or alanine amino-transferase three times the ULN.
223800854|NCT04852874|PROCEDURE|Ultrasound-guided Quadratus Lumborum Block|"Low dose spinal anesthesia will be done at L3-4 lumbar vertebrae with bupivacaine 2.5 mg (0.5 ml Marcaine 0.5%) and fentanyl 25 µgm (0.5 ml) of fentanyl amp (100 µgm/ 2ml) to be added to 1.5 - 2 ml of free water to form total volume of 2.5- 3ml according to the patient height aiming level of T6 sensory level.~Quadratus lumorum block:~After 4 to 5 minutes, ultrasound guided quadratus lumborum block (QL 1,2,3) will be done unilaterally, using low-frequency convex probe, taking into consideration the total volume of injectate not exceeding 0.4 ml /kg of (bupivacaine 0.5%) to avoid local anesthesia systemic toxicity. This is equal to 0.8 ml/kg of (bupivacaine 0.25%).~After confirming the correct position of the needle, 0.2-3 ml/kg of 0.25% bupivacaine plus 1.5 mg dexamethasone and magnesium sulphate of 100 mg will be injected in each site of the QL 1,2,3 using the lean body weight. The lean body weight will be calculated by omni lean body mass online calculator."
223800855|NCT00428090|DRUG|Rosiglitazone|XR (extended release) oral tablets
223800856|NCT03912454|OTHER|Autologous Bone Marrow Aspirate Concentrate (BMAC) Injection|Subjects will undergo bone marrow aspiration from the iliac crest. Bone marrow will be concentrated and injected into the symptomatic lumbar disc.
223800857|NCT00510094|BEHAVIORAL|Friend to Friend program|Friend to Friend arm is a social information processing group treatment to help aggressive girls learn better social problem solving and decision making choices. Participants will learn how to identify signs of physiological arousal, evaluate others' intentions, react to a potential conflict situation, and generate and evaluate alternatives. Treatment sessions are twice per week (30 to 40 minutes per session) for ten weeks.
223800858|NCT00510094|BEHAVIORAL|Psychoeducational attention control intervention|Psychoeducational attention control group also meets two times per week for 10 weeks to control for nonspecific factors of treatment. Participants learn homework, study skills, and organizational skills.
223800859|NCT05374226|BIOLOGICAL|JS019|Four dose levels are preset: 0.3 mg/kg, 1 mg/kg, 3 mg/kg, and 10 mg/kg. The subjects are treated with JS019 by intravenous infusion, once every 3 weeks (Q3W). A treatment cycle is 21 days, and the DLT observation period is 21 days after the first administration.
223800860|NCT04553341|DEVICE|Navigated repetitive transcranial magnetic stimulation|In these patients we will apply the following protocol: after the initial nTMS mapping of the according function, patients will be stimulated on 20 consecutive days by a series of rTMS pulses. The frequencies (1-20 Hz), number of pulses (100-1,000), and stimulation intensities (50-130% resting motor threshold = rMT = individual lowest stimulation intensity that evokes positive muscle responses) will be applied in dependency of the individual patients comfort and the evoked effect. Stimulations will be applied to the eloquent brain region, which is infiltrated by the tumor.
223800861|NCT01380951|DRUG|telbivudine|telbivudine 600mg/d 96 weeks
223800862|NCT01315093|DRUG|Heparin, Low-Molecular-Weight|Heparin from start till hcg test
223800863|NCT01315093|DRUG|no heparin|
223800864|NCT03205397|OTHER|Experimental Group|Preparation for anesthesia (explanations, film, booklet), the presence of a parent in the operating room and the awakening of the child
223800865|NCT03205397|OTHER|usual care|Usual care
223800866|NCT03409666|DEVICE|Taperloc Complete Microplasty stem|Total hip replacement with Taperloc Complete Microplasty stem and G7 acetabular shell with E1 liner
223800867|NCT03409666|DEVICE|Taperloc Complete Reduced Distal stem|Total hip replacement with Taperloc Complete Reduced Distal stem and G7 acetabular shell with E1 liner
223800868|NCT04818294|DEVICE|Pain treatment by electrostatic charge to the whole body|"Study Type is Observational as participants in the study receive therapeutic interventions in the therapy cabin as part of routine medical care and a researcher studies the effect of the intervention.~The study includes all persons who are already receiving therapy in the mentioned facilities, no external, specifically selected persons, but existing patients suffering from chronic pain who meet the specified conditions.~The therapy aims to alleviate chronic pain by applying an electrostatic charge of 50'000 Volt to the whole body in the special, electrically insulated cabin. The treatment is done upon the instructions of a physician. It is done with the patient standing up in the treatment cabin. The person is charged and discharged several times over the course of 2x 4 minutes. The charge can be felt on the skin and it can be seen through bristling of the hairs on the body. This treatment is repeated once a week."
223800869|NCT00733603|OTHER|Global Therapeutic Massages (GTM)|Non-specific somatic treatment with full-body Western massage.
223800870|NCT00733603|OTHER|Myofascial Tissue Manipulation (MTM)|Targeted internal and external Connective Tissue Manipulation focusing on the muscles and connective tissues of the pelvic floor, hip girdle, and abdomen.
223800871|NCT03462732|DEVICE|Endotracheal tube|Nasotracheal intubation will be done with endotracheal tube
223800872|NCT03462732|DEVICE|Nelaton catheter|plus nelaton catheter
223800873|NCT00361140|DRUG|Busulfan|"Bu IV (BusulfexR) over 3 hours on days -6, -5, -4, and -3. Day -6 and -5 doses for patients on Level 1 will be 170mg/m2. This dose is based on the dose used by DeLima (2004) adjusted proportionately to achieve an AUC of 6000uM-min. Subsequent daily doses for patients on Level 1 will be adjusted to achieve an average AUC of 6000uM-min.~Day -6 and -5 doses for patients on Level 2 will be based on the mean dose required on Level 1 to achieve target AUC then adjusted proportionally for new target AUC.~Subsequent daily doses will be adjusted to achieve target AUCs."
223800874|NCT00361140|DRUG|Fludarabine|Fludarabine 40mg/m2 IV over 1 hour on days -6, -5, -4, and -3
223800875|NCT01791725|DRUG|ELND005|
223800876|NCT01791725|DRUG|Placebo|
223800877|NCT05715996|DEVICE|mixed reality guided localization|In this study, MR was utilized to assist in the localization of pulmonary nodule during sublobectomy lung resection in patient to assess the accuracy of the technique.
223800878|NCT06174584|DRUG|Hypertonic saline|Hypertonic saline
223800879|NCT06174584|OTHER|Cow Milk|Cow Milk
223800880|NCT05545982|PROCEDURE|Video laryngoscope with Miller approach|Miller approach indicates lifting epiglottis during laryngoscopy, which is the way of using Miller laryngoscope
223800881|NCT03191487|OTHER|ChimioPal|"Systematic collection of clinical and laboratory toxicities (TXs) during the 2-4 days preceding a chemotherapy (CT) session (48H before a session (D-2 towards the end of the afternoon) and a maximum of 96h before sessions occurring on Mondays (D-4 towards the end of the afternoon). Clinical TX data will be collected via ChimioPal (a self-questionnaire administered by smartphone) and laboratory TX data will be collected via Apicrpyt (secure messaging service) or a fax-to-email service. Data flow management by a nurse dedicated to this activity in each centre will be implemented. If the results of the assessment do not authorize CT, additional assessments may be prescribed. If the experimental data transmission does not occur, the usual pathways will be implemented.~Patient training on how to use a smart phone and the questionnaire will be performed by a nurse before the start of the first chemotherapy session, with reminders at the following sessions if required."
223800882|NCT03191487|OTHER|Usual pathways|In the standard arm, the usual management and logistic pathways will be respected. Only extra data collection is required by this study.
223800883|NCT00512148|DEVICE|Autologous neobladder construct|augmentation cystoplasty with autologous neo-bladder construct
223800884|NCT01686789|DRUG|Pegylated interferon alpha-2a|
223800885|NCT05732441|DRUG|Huange capsule|Huange Capsule was orally administered (Zhejiang Kangenbe Pharmaceutical Co., Ltd., specification: 0.4g×60 tablets/bottle, GuoYaoZhunZi Z20110006). Administration method: 1.6g each time, three times a day, 40min after breakfast, lunch and dinner. The treatment course was four weeks.
223800886|NCT06413836|DEVICE|aPDT|Mechanized endodontic treatment using an endodontic rotatory device (DENTSPLY) will be used to prepare the root canals. Following, it will be applied the methylene blue solution in surfactant medium and after 1 minute a diode laser equipment (DMC THERAPY/EC, Sao Carlos, Brazil) will be used to shine light at a wavelength of 660nm, 100 mW (miliWatts) and irradiation time of 3 min. CaOH (calcium hydroxide) paste will be applied at the root canals canals as a long-term dressing for endodontic treatment..
223800887|NCT06413836|PROCEDURE|Endodontic treatment|Mechanized endodontic treatment using an endodontic rotatory device (DENTSPLY) will be used to prepare the root canals. Following, it will be applied the methylene blue solution in surfactant medium and after 1 minute a diode laser equipment (DMC, THERAPY/EC, Sao Carlos, Brazil) will be used with an aluminium foil at the tip of the equipment to block light and use during 3 min as study group. CaOH (calcium hydroxide) will be applied at the root canals as a long-term dressing for endodontic treatment.
223800888|NCT00221442|DRUG|Zonegran|zonegran (zonisamide)
223800889|NCT00221442|DRUG|sugar pill|fake pill
223800890|NCT02904408|BEHAVIORAL|psychotherapy|Group psychotherapy
223800891|NCT00822133|DRUG|lidocaine|lidocaine 5%
223800892|NCT00822133|DRUG|ketamine|ketamine cream
223800893|NCT00822133|DRUG|non-active drug cream|will be put on the skin
223800894|NCT01223157|BIOLOGICAL|Biological data|Height, Weight, waist circumference and systolic and diastolic blood pressure will be measured in obese and normal subjects. Blood and saliva sampling will be performed after an overnight fast, one hour and just before the beginning of the lunch and one hour after the end of the lunch. This will allow a measurement of fasting glycaemia and insulin, fasting cholesterol and triglycerides, liver profile. Endocannabinoids will be measured both in plasma and saliva at each time point. Gut hormones (Ghrelin and PYY) will be measured before, just before and after lunch in plasma.
223800895|NCT03705208|OTHER|Youth First Curriculum|A 25 session emotional resilience and health curriculum designed for 7th and 8th grade students.
223800896|NCT02926248|DRUG|Colchicine|Colchicine is an anti-fibrotic and anti-inflammatory drug
223800897|NCT02926248|OTHER|Placebo|
223800898|NCT02969720|DIETARY_SUPPLEMENT|Phytosterols|Oral daily consumption of 2 grams of phytosterols (8 ml) per 180 days.
223800899|NCT02969720|DIETARY_SUPPLEMENT|Titanium Dioxide|Oral daily consumption of Titanium Dioxide (8 ml) per 180 days.
223800900|NCT02159131|DRUG|Ethinyl Estadiol|EE is available as a combination of EE 0.03 mg and LNG 0.15mg, a monophasic oral contraceptive tablet to be taken along with 240 mL water
223800901|NCT02159131|DRUG|Levonorgestrel|LNG is available as a combination of EE 0.03 mg and LNG 0.15mg, a monophasic oral contraceptive tablet to be taken along with 240 mL water
223800902|NCT02159131|DRUG|GSK1265744|GSK1265744 is available as 30 mg tablet to be taken along with 240 mL water
223800903|NCT05482048|OTHER|Exercise as Airway Clearance Therapy (ExACT)|"Arm-2 (ExACT): Participants will be advised to replace routine chest physiotherapy sessions with exercise combined with coughs and huffs - also referred to as forced expiratory techniques (FET). The undertaking of ExACT at least once per day is expected.~Written and verbal instruction will be provided on the type, duration, frequency and intensity of exercise that is considered adequate replacement for routine chest physiotherapy. A compendium of allowable activity types, and the required times at different intensities that are considered to replace chest physiotherapy for ACT The research team will support exercise advice in line with standard care if subjects request this. The trial has no other changes to CF care. All medications, nutritional support and other treatments continue."
223800904|NCT06580535|OTHER|blood sample|Blood sample taking from patient for tissue culture
223800905|NCT05065489|OTHER|No intervention|No intervention
223800906|NCT00003780|BIOLOGICAL|tumor infiltrating lymphocyte therapy|
223800907|NCT00003780|DRUG|gemcitabine hydrochloride|
223800908|NCT04051268|BIOLOGICAL|Vi-DT Typhoid Conjugate Vaccine|1 dose of Investigational Product
223800909|NCT04051268|BIOLOGICAL|PQed Typhoid Conjugate Vaccine|1 dose of Active Comparator
223800910|NCT04051268|BIOLOGICAL|Vi Polysaccharide Vaccine|1 dose of Active Comparator
223800911|NCT01444157|OTHER|Palliative homecare nursing|The nurse helps the family assess the identified problems. Written coping strategies according to each problem is produced including actions of the patient, family member, nurse or others. At the same time the nurse keeps attention to the family members specific needs of knowledge and support when handling direct or indirect care, understanding and coping with the disease, treatment, physical, psychosocial and economical problems and the family members own physical and mental health. The nurse provides knowledge to the family on how to prevent and/or cope with problems that may occur or re-occur and/or accepts or adapt to unsolvable problems.
223800912|NCT00780858|DRUG|Ganirelix|Ganirelix 0.25mg s.c every 24 h starting stimulation day 6
223800913|NCT01034267|DRUG|F2695 SR|Drug F2695 SR (flexible dose) to be given orally in capsule form once daily
223800914|NCT02978755|DRUG|GM102|GM102 escalating doses (phase1)
223800915|NCT02978755|DRUG|GM102 escalating doses|GM102 escalating doses combined with paclitaxel and carboplatin
223800916|NCT02978755|DRUG|GM102|GM102 single agent at recommended dose in 3 parallel cohorts (sex cord, epithelial ovarian, cervix cancers)
223800917|NCT00811343|BIOLOGICAL|QFTB-G and T-SPOT.TB tests|QFTB-G and T-SPOT.TB test before TST
223800918|NCT03948750|PROCEDURE|Aqueous humour sampling|Aqueous humour sampling with Goldman-Witmer coefficient and immunoblotting
223800919|NCT03255824|DRUG|Dexmedetomidine and Midazolam|Administration of Dexmedetomidine and Midazolam for sedation during third molar surgery.
223800920|NCT03255824|DRUG|Propofol, Midazolam, and Fentanyl|Administration of Propofol, Midazolam, and Fentanyl for sedation during third molar surgery.
223800921|NCT02975570|DRUG|Delamanid|Delamanid is a medication used to treat tuberculosis. Specifically it is used, along with other antituberculosis medications, for active multidrug-resistant tuberculosis. It is taken by mouth.
223800922|NCT02975570|DRUG|Linezolid|Linezolid is an antibiotic used for the treatment of infections caused by Gram-positive bacteria that are resistant to other antibiotics.
223800923|NCT02975570|DRUG|Levofloxacin|Levoflaxacin is an antibiotic used to treat a number of bacterial infections including acute bacterial sinusitis, pneumonia, urinary tract infections, chronic prostatitis, and some types of gastroenteritis. Along with other antibiotics it may be used to treat tuberculosis.
223800924|NCT02975570|DRUG|Pyrazinamide|Pyrazinamide is a medication used in combination with other drugs such as isoniazid and rifampicin in the treatment of Mycobacterium tuberculosis.
223800925|NCT02975570|DRUG|WHO MDR-TB regimen|The WHO guidelines recommend the following 5-agent treatment regimen for MDR-TB: pyrazinamide; a fluoroquinolone; a parenteral agent (typically amikacin or kanamycin); ethionamide (or prothionamide); and either cycloserine or para-aminosalicylic acid, with preference for cycloserine. Short (9 mos) or longer (20-24 mos) treatment schedules can be used.
223800926|NCT00677833|DRUG|Azithromycin plus Chloroquine|Combination of Azithromycin plus Chloroquine Azithromycin (\~30 mg/kg) + chloroquine (\~10mg base /kg) combination tablet(s) on weight basis, once daily for 3 days (Days 0,1,2) or Artemether-lumefantrine tablet(s) based on weight and labeling for 3 days (Days 0, 1, 2)
223800927|NCT00677833|DRUG|Artemether-lumefantrine|Artemether-lumefantrine tablet(s) based on weight and labeling for 3 days (Days 0, 1, 2)
223800928|NCT03967431|OTHER|Narrative Enhancement and Cognitive Therapy (NECT)|Narrative Enhancement and Cognitive Therapy includes two introduction meetings, three psychoeducation meetings, seven cognitive restructuring meetings, seven narrative enhancement meetings and one summing up meeting.
223800929|NCT01168193|OTHER|No intervention|
223800930|NCT00279292|PROCEDURE|Celiac Plexus Neurolysis|
223800931|NCT05072457|DEVICE|Roger On microphone|Roger On microphone transmitter which is used with Roger receivers and Audeo P hearing aids
223800932|NCT05072457|DEVICE|Roger Select microphone|Roger Select microphone transmitter which is used with Roger receivers and Audeo P hearing aids
223800933|NCT04575168|DIAGNOSTIC_TEST|Spartan COVID-19 Test|A nasopharyngeal sample analyzed on the Spartan COVID-19 System.
223800934|NCT03852563|DRUG|BAY207543 (Bepanthol)|Product is applied to one hemiface.
223800935|NCT03852563|OTHER|Semisolid vaseline|Product is applied to one hemiface.
223800936|NCT06020690|DEVICE|bioabsorbable steroid-releasing stent|The patient after functional endoscopic sinus surgery to treat their chronic sinusitis, the experimental device or active comparator device will be implanted to the sinus to prevent re-intervention (surgery or medicine).
223800937|NCT03515928|OTHER|Ultrasonic noise exposure|Group will be exposed to 40kHz ultrasonic noise at 110-120 dB SPL for 15 minutes.
223800938|NCT03515928|DIAGNOSTIC_TEST|Pure Tone Audiometry|Participants will undergo 2 (pre and post exposure) hearing tests
223800939|NCT02859610|OTHER|research on interactions between portal hypertension and microparticles|
223800940|NCT03500055|PROCEDURE|Abdominal Closure Bundle|Surgeons will re-scrub, change gown and gloves prior to closure of fascia. Will also use new instruments, bovie tip, suction tip, and light handles, for closure of fascia, subcutaneous tissue, and skin
223800941|NCT03075579|DRUG|Medication Other|medication of atomoxetine
223800942|NCT03075579|DEVICE|motor measurement and saliva collection|motor measurement by actometer and saliva collection for measurement of saliva cortisol and saliva alpha amylase
223800943|NCT04299880|DRUG|Napabucasin|Oral
223800944|NCT04299880|DRUG|Nab-paclitaxel|Intravenous
223800945|NCT04299880|DRUG|Gemcitabine|Intravenous
223800946|NCT04299880|DRUG|Nivolumab|Intravenous
223800947|NCT04299880|DRUG|Paclitaxel|Intravenous
223800948|NCT04299880|DRUG|Irinotecan|Intravenous
223800949|NCT04299880|DRUG|Leucovorin|Intravenous
223800950|NCT04299880|DRUG|5Fluorouracil|Intravenous
223800951|NCT04299880|DRUG|Bevacizumab|Intravenous
223800952|NCT06206967|OTHER|Physical Activity Promotion|"This intervention includes a hospital-based and a home-based intervention. During the hospital stay, the patients were provided with a health education which included information about thromboembolism pathophysiology and its management, healthy-lifestyle habits, benefits of early-mobilisation, and any questions patients may have would be answered.~Additionally, an early-mobilization program is provided, which includes resistance and aerobic exercise.~At the end of the hospital stay, a diary is provided to patients for recording the physical activity that performing the following 3 months. This diary is accompanied by phone calls at 15 days, 1 and 2 months of the hospital stay. During the phone calls, patients are motivated to increase their activity levels, and any questions patients may have, are answered."
223800953|NCT06206967|OTHER|Control Intervention|Patients received an informational brochure in a consultation with a health professional. The brochure explained the importance of physical activity to improve the health condition of these patients. Patients had the opportunity to ask any questions to the healthcare professional.
223800954|NCT02001194|BEHAVIORAL|Individual Incentives|
223800955|NCT02001194|BEHAVIORAL|Team Incentives|
223800956|NCT02001194|BEHAVIORAL|Individual plus Team Incentives|
223800957|NCT01579604|PROCEDURE|Nerve reconstruction|Under general anesthetic, the surgeon will make a cut on the back (dorsal) part of the forearm. The radial nerve will be identified and specifically the branches which control the supinator muscle and the remainder of the radial nerve (Posterior interosseous nerve or PIN). . The PIN branch will be stimulated to ensure that it is non-functional. Then, the supinator branch will be stimulated to ensure it is functioning and is appropriate for transfer. If appropriate, the supinator branch will be severed and connected to the EDC branch under the operating room microscope. After the surgery, the patient will be placed into a splint including the forearm and hand for 2-3 weeks.
223800958|NCT01866943|DRUG|Tranexamic Acid|Tranexamic Acid 1.5 g (100 mg/mL)in 100cc normal saline is applied topically to the wound for 5 minutes time then suctioned and the skin closed. The control group receives just normal saline and no drug.
223800959|NCT01866943|DRUG|Normal Saline Solution|
223800960|NCT02037048|DRUG|oxaliplatin|Given IV
223800961|NCT02037048|DRUG|leucovorin calcium|Given IV
223800962|NCT02037048|DRUG|fluorouracil|Given IV
223800963|NCT02037048|PROCEDURE|therapeutic conventional surgery|Undergo therapeutic conventional surgery
223800964|NCT02037048|RADIATION|radiation therapy|Undergo radiation therapy
223800965|NCT02037048|DRUG|carboplatin|Given IV
223800966|NCT02037048|DRUG|paclitaxel|Given IV
223800967|NCT03977090|DRUG|Geptanolimab Injection|GB226 3mg/kg, q2w, iv.
223800968|NCT03977090|DRUG|Fruquintinib|Fruquintinib 3 or 4 or 5mg,qd,po. 3 weeks-on, 1 week-off
223800969|NCT04646239|DIAGNOSTIC_TEST|Heterologous stimuli|In vitro exposure of peripheral blood mononuclear cells to heterologous stimuli
223800970|NCT04646239|DIAGNOSTIC_TEST|Neutralization assay|In vitro measurement of neutralizing antibody activity to wild-type SARS-CoV-2
223800971|NCT02690974|DRUG|LCZ696 (sacubitril/valsartan)|All patients were treated with the LCZ696 (sacubitril and valsartan) tablets
223800972|NCT01091155|DEVICE|ColonRing (Colorectal anastomosis)|Creation of a colorectal compression anastomosis
223800973|NCT03791164|BEHAVIORAL|The Pain Toolkit|the Pain Toolkit is a leaflet that encourages self management techniques for patients with chronic pain
223800974|NCT03791164|BEHAVIORAL|the Back Book|The Back Book is a patient information leaflet that offers information and advice about back pain
223800975|NCT03404492|OTHER|Stress echocardiography|A stress echocardiography will be performed in addition to the traditional patient care
223800976|NCT03925701|DRUG|Vildagliptin|vildagliptin twice daily
223800977|NCT03925701|DRUG|vildagliptin\metformin|vildagliptin\\metformin twice daily
223800978|NCT04401514|DEVICE|Rocking chair therapy|20 min long rocking therapy with music cure. The therapy can be extended if needed
223800979|NCT05025657|BEHAVIORAL|ALLY|ALLY is a universal, school-based prevention program that takes place during the school day with individual students over 6 weeks.
223800980|NCT00678314|DRUG|Ropivacaine 0.2%|10 ml
223800981|NCT00678314|DRUG|Ropivacaine 0.75%|3 ml
223800982|NCT00678314|DRUG|Normal saline|10 ml
223800983|NCT01355588|DRUG|Ketorolac Tromethamine|30 mg Ketorolac Tromethamine intranasal (IN)
223800984|NCT01355588|DRUG|Ketorolac Tromethamine with 4% Lidocaine hydrochloride (HCl)|30 mg Ketorolac Tromethamine with 4% Lidocaine HCl IN
223800985|NCT01355588|DRUG|Ketorolac Tromethamine with 5% Lidocaine HCl|30 mg Ketorolac Tromethamine with 5% Lidocaine HCl IN
223800986|NCT01355588|DRUG|30 mg Ketorolac Tromethamine with 6% Lidocaine HCl|30 mg Ketorolac Tromethamine with 6% Lidocaine HCl IN
223800987|NCT00002481|DRUG|cisplatin|
223800988|NCT00002481|DRUG|cyclophosphamide|
223800989|NCT00002481|DRUG|cytarabine|
223800990|NCT00002481|DRUG|dexamethasone|
223800991|NCT00002481|DRUG|etoposide|
223800992|NCT00002481|PROCEDURE|autologous bone marrow transplantation|
223800993|NCT00002481|RADIATION|radiation therapy|
223800994|NCT03201016|DIAGNOSTIC_TEST|Bone densitometry|Procollagen Type I Propeptides, alkaline phosphatase, Crosslinked Telopeptides of Type I Collagen
223800995|NCT06150651|OTHER|CAR T-cell therapy|1x10\^6 cells/kg CD-19 CAR-T cells
223800996|NCT02126501|OTHER|Gradual pressure wean|NCPAP will be removed by gradually decreasing pressure over 24 hours once the weaning is decided
223800997|NCT02686580|BIOLOGICAL|Collagen paste|Permacol cross-linked collagen paste, 2.5-3.5 mls to be injected into the MRI defined fistula tracts 7-10 days following drainage of the anorectal abscess.
223800998|NCT00522301|DRUG|sorafenib tosylate|
223800999|NCT00522301|OTHER|immunoenzyme technique|
223801000|NCT00522301|OTHER|immunohistochemistry staining method|
223801001|NCT00522301|OTHER|laboratory biomarker analysis|
223801002|NCT00522301|OTHER|pharmacological study|
223801003|NCT02187913|DIETARY_SUPPLEMENT|Resistant starch|Each subject will complete 2 testing days (randomized and crossover design). On each of 2 test days, subjects will arrive at the Purdue Clinical Research Center after a 12-h fast and will consume a snack bar containing resistant starch. The test snack bar will be consumed along with a standard meal provided at the start of the test day. A second standard meal that does not contain the snack bar will be consumed four hours later.
223801004|NCT01666951|DRUG|LCP-Tacro tablets|Tacrolimus
223801005|NCT01666951|DRUG|Prograf|Tacrolimus
223801006|NCT04646655|DRUG|Enoxaparin|subcutaneous injections
223801007|NCT00772785|DRUG|Probuphine (buprenorphine implant)|Implantable formulation of buprenorphine made of buprenorphine HCl/ethylene vinyl acetate, considered a drug. (4 implants 6-month duration)
223801008|NCT04613908|DEVICE|neuro muscular electro stimulation|We used a commercial equipment of electro stimulation with a pulse width of 300 micro seconds, a frequency of 50 Hz, with symmetrical balanced biphasic rectangular wave and with an intensity of up to 80 milliampere.
223801009|NCT04613908|OTHER|Early Mobilization protocol|"The protocol consisted in applying a specific treatment based on different levels of treatment to each subject. Admission to them was carried out according to the maximum capacity of each subject, the conditions of each level being the following:~* Level 1: MRC (shoulder) \<3 + MRC \<3 (hip).~* Level 2: MRC (shoulder) ≥ 3 + MRC (hip) \<3.~* Level 3: MRC (shoulder) ≥ 3 + MRC (hip) ≥ 3 + sitting on the edge of the bed without assistance (minimum 15 minutes).~* Level 4: Standing without assistance and walking with or without assistance."
223801010|NCT04613908|OTHER|standard care or usual rehabilitation|routine, non-protocolized rehabilitation treatment performed by the physiotherapist assigned to intensive care
223801011|NCT00617578|DEVICE|ATP One Shot ON|"The new antitachycardia pacing algorithm ATP One Shot attempts to terminate fast VT by one ATP sequence and thus avoid defibrillation shock delivery"
223801012|NCT00617578|DEVICE|ATP One Shot OFF|Standard defibrillation shock delivery
223801013|NCT02885987|DEVICE|AmplifEYE|AmplifEYE will be attached to the tip of the colonoscope prior to start of procedure.
223801014|NCT05654896|DRUG|Ceftriaxone Sodium|Antibiotic will be administered prophylactically for TACE
223801015|NCT02443948|OTHER|Vena puncture for blood collection|Cf-DNA blood samples will be collected in EDTA tubes (20 ml) during the routine blood test
223801016|NCT05461976|BEHAVIORAL|Home-based self-management exercise program|Session 1 will includes education about stroke. Session 2 will includes feedback on behaviour performance on initial measurement outcomes, health consequences of the physical inactivity, answering an exercise preferences questionnaire, generation of a list of goals, delivering a smartband and a diary to self-monitoring. Session 3 will includes reviewing of goals and strategies to self-monitoring, encouragement, rising barriers to exercise and potential solutions to them, development of a weekly schedule physical exercise, implementation of the physical exercise session with participant and delivering a paper-exercise guide. Session 4 will includes reviewing of goals and weekly schedule physical exercise, encouragement, problem solving/coping planning, reviewing strategies to self-monitoring and showing to participant a video with another stroke survivors which are physically active. Sessions 5 and 6 will be the same as session 4 with exception of vicarious reinforcement.
223801017|NCT06078605|OTHER|Nicotinamide(Mitovita)|Nicotinamide(VitaminB3)
223801018|NCT06078605|OTHER|Placebo|Placebo
223801019|NCT03704155|DRUG|Botulinum toxin type A|Botulinum Toxin type A The intervention with BoNT-A (Dysport®, Ipsen Biopharmaceutical, USA) was performed in the gastrocnemius and soleus muscles, bilaterally for diplegic children and unilaterally for hemiplegic children.
223801020|NCT03704155|OTHER|Physical Therapy|"Physiotherapeutic intervention was performed twice a week, with duration of one hour per session for 4 weeks. To maintain standardization of treatment, physiotherapists received a booklet with instructions on what treatment they should do.~The intervention protocol consisted of:~* Passive stretching of lower limbs,~* Stretching associated with the functionality of the plantar flexor muscles, knee flexors, adductors and hip flexors;~* Strengthening of the antagonist muscles with the application of BoNT-A;~* Static and dynamic balance training;~* Up and down stairs;~* Functional walking training, prioritizing the initial contact of the heel and active and passive dorsiflexion."
223801021|NCT00337272|DRUG|Placebo|Placebo taken 30 minutes before bedtime days 1-28 of treatment period
223801022|NCT00337272|DRUG|Ramelteon|8 mgs daily for days 1-28 of treatment period
223801023|NCT05339048|GENETIC|Genetic risk variants|Exposure: Genetic predisposition to complex diseases.
223801024|NCT05339048|OTHER|Diet|Exposure: dietary intake of unhealthy foods known to be associated with higher prevalence of respiratory and cardiovascular diseases.
223801025|NCT05339048|BEHAVIORAL|Physical activity|Exposure: frequency of moderated or intense physical activity, and daily exposure to sedentary behavior.
223801026|NCT05339048|OTHER|Socio-economic conditions|Exposure: socio-economic vulnerability indexes associated with higher prevalence of respiratory and cardiovascular diseases (including household conditions, accessibility to health care services, among others).
223801027|NCT04272580|DRUG|Control group|No preload was given before spinal anesthesia.
223801028|NCT04272580|DRUG|4 ml/kg group.|4 ml/kg compound sodium chloride (0.85% NaCl, 0.03% KCl, and 0.033% CaCl2) was given before spinal anesthesia.
223801029|NCT04272580|DRUG|8 ml/kg group.|8 ml/kg compound sodium chloride (0.85% NaCl, 0.03% KCl, and 0.033% CaCl2) was given before spinal anesthesia.
223801030|NCT04272580|DRUG|12 ml/kg group.|12 ml/kg compound sodium chloride (0.85% NaCl, 0.03% KCl, and 0.033% CaCl2) was given before spinal anesthesia.
223801031|NCT02430402|OTHER|Rehabilitation in warm climate|
223801032|NCT03043079|DIAGNOSTIC_TEST|Ultrasound Acoustic Radiation Forced Impulse Shear Wave Velocity|Abdominal Ultrasound Acoustic Radiation Forced Impulse Shear Wave Velocity (ARFI-SWV)
223801033|NCT02366910|DEVICE|omafilcon A|Each subject randomized to wear either the test or control in either the left of right eye.
223801034|NCT02366910|DEVICE|delefilcon A|Each subject randomized to wear either the test or control in either the left of right eye.
223801035|NCT03331718|DRUG|PGA felt reinforcement|During pancreaticojejunostomy, 1) a 0.3 mm thick PGA felt (Neoveil®, Gunze, Japan) is pasted on the ventral side and the dorsal side of pancreatic parenchyma, through which suture between pancreatic parenchyma and jejunum is performed. 2) Before abdominal closure (after completion of all reconstruction, after washing in the abdominal cavity), a 0.15 mm thick PGA felt is further covered around the anastomotic site and fibrin glue is sprayed.
223801036|NCT06490757|DRUG|Baricitinib|An ancillary study will be performed in a subgroup of 12 patients to assess the variation of the results of PET-CT with 18FDG from baseline to 3 months. The variation of tumor features assessed by PET-CT with 18FDG after three months of treatment, will be assessed. The median value of the SUV max and tumor to non-tumor ratio of the SUV max value for each HCA lesion between the PET CT with 18FDG performed at baseline and after 3 months of treatment will be assessed.
223801037|NCT01843426|DRUG|Low-volume, low-concentration contrast (iodixanol - Visipaque 270) CT scan|An ECG-synchronized, contrast-medium enhanced CT study of the heart for the evaluation of the aortic root complex and general cardiac morphology will be obtained. This is immediately followed by a CT angiographic study of the chest, abdomen, and pelvis (beyond the femoral heads), which utilizes the same contrast bolus that is injected for evaluating the heart. This latter vascular study serves to evaluate the TAVR deployment catheter access route through the femoral, iliac, and aortic vascular stations. In clinical routine, we have been performing this type of study with total contrast media volumes ranging from 40-120 mL of iodinated contrast material.
223801038|NCT02897713|OTHER|intensive enteral nutrition|After recruitment, patients should be assessed for EN initiation during first 24 hours after ICU admission. 80% of energy target should be reached within 72 hours.
223801039|NCT02897713|OTHER|routine enteral nutrition|Attendings decide when and how EN should be administered according to guidelines from academic organizations, such as ESPEN or ASPEN.
223801040|NCT05276830|DRUG|BXCL501|Sublingual film containing 40 Micrograms BXCL501
223801041|NCT05276830|DRUG|BXCL501|Sublingual film containing 60 Micrograms BXCL501
223801042|NCT05276830|DRUG|Placebo film|Matching Sublingual Placebo film
223801043|NCT05530213|DEVICE|3D gait analysis on the GRAIL|3D gait anlysis performed on an instrumented treadmill (GRAIL, Motek Medical)
223801044|NCT05530213|OTHER|Weight and height|The subject's body weight and height will be assessed
223801045|NCT02623322|DRUG|MHAA4549A|MHAA4549A will be administered as a single dose by IV administration.
223801046|NCT02623322|DRUG|Placebo|Placebo will be administered as a single dose by IV administration.
223801047|NCT06514144|DRUG|BGF|budesonide/glycopyrrolate/formoterol fumarate
223801048|NCT04962555|PROCEDURE|Meniscus Suture|Patients with knee joint meniscus injury undergoing meniscus suture
223801049|NCT04962555|PROCEDURE|Partial meniscus resection|Patients with knee joint meniscus injury undergoing partial meniscus resection
223801050|NCT04962555|PROCEDURE|Subtotal meniscus resection|Patients with knee joint meniscus injury undergoing subtotal meniscus resection
223801051|NCT04962555|PROCEDURE|Complete meniscectomy|Patients with knee joint meniscus injury undergoing complete meniscectomy
223801052|NCT04657744|DRUG|Sphingomod|1 capsule contains 0.5 mg Fingolimod
223801053|NCT04657744|DRUG|Gilenya|1 capsule contains 0.5 mg Fingolimod
223801054|NCT04147039|BEHAVIORAL|MINISTOP 2.0|The MINISTOP 2.0 is a behavioural change program aiming to promote healthier diet and physical activity among 2.5-year-old children. The program consists of features such as information, monitoring and feedback (dietary key variables, physical activity, screen time) and it is built around 13 themes during the 6-month period.
223801055|NCT02313857|BIOLOGICAL|Viralym-C|"Follow-up Assessments: The timing of follow-up visits is based on the date of Viralym-C infusion. If a patient has multiple Viralym-C infusions the schedule resets again at the beginning so follow up relates to the last Viralym-C infusion.~Follow up will occur at 7 days, 14 days, 21 days, 28 days, 35 days, 42 days, 90 days, 180 days, and 365 days post enrollment."
223801056|NCT00743769|DRUG|thymosin beta 4|Single bolus injections of ascending doses of 42 mg, 140 mg, 420 mg or 1,260 QD of thymosin beta 4
223801057|NCT00743769|OTHER|Placebo|Single bolus injections of ascending doses of 0.00 mg QD of thymosin beta 4
223801058|NCT01082094|BIOLOGICAL|ACRX-100|Three cohorts (16 total subjects) will be studied. There will be no concurrent controls. The dose will be escalated by increasing the total amount of ACRX-100 delivered per subject from low dose (n=4 subjects) to middle dose (n=6 subjects) to high dose (n=6 subjects). ACRX-100 will be injected directly into the myocardium as a single dose at multiple sites through a percutaneous, left ventricular approach using a needle injection catheter.
223801059|NCT00969384|BEHAVIORAL|Active awareness/Lifestyle counseling|"Intervention (active awareness):~In the intervention institutions, a detailed feedback of all index measures will be distributed to the patients and the staff. The project leader and a medical specialist in psychiatry will advise on medical aspects and health promotion. In connection with this feedback, guidance on psycho-pharmacological treatment will be provided."
223801060|NCT05795530|PROCEDURE|cochlear implantation|surgery for bilateral hearing loss
223801061|NCT02942602|DRUG|Atorvastatin 20 mg|The patients who meet the 2013 American College of Cardiology/American Heart Association criteria for receiving lipid-lowering therapy will be randomized into 5 groups.
223801062|NCT02942602|DRUG|Cholestyramine 8 g|The patients who meet the 2013 American College of Cardiology/American Heart Association criteria for receiving lipid-lowering therapy will be randomized into 5 groups.
223801063|NCT02942602|DRUG|Omega-3 2g|The patients who meet the 2013 American College of Cardiology/American Heart Association criteria for receiving lipid-lowering therapy will be randomized into 5 groups.
223801064|NCT02942602|DRUG|Concurrent with Atorvastatin 5 mg + Ezetimibe 10 mg|The patients who meet the 2013 American College of Cardiology/American Heart Association criteria for receiving lipid-lowering therapy will be randomized into 5 groups.
223801065|NCT02942602|BEHAVIORAL|Lifestyle modification|The patients who meet the 2013 American College of Cardiology/American Heart Association criteria for receiving lipid-lowering therapy will be randomized into 5 groups.
223801066|NCT04012996|DEVICE|prodisc C SK and/or Vivo|Subjects will be randomized in a 2:1 ratio either to the two-level prodisc C SK or prodisc C Vivo device (investigational group) or to the two-level Mobi-C device (control group).
223801067|NCT04012996|DEVICE|Mobi-C Cervical Disc|Subjects will be randomized in a 2:1 ratio either to the two-level prodisc C SK or prodisc C Vivo device (investigational group) or to the two-level Mobi-C device (control group).
223801068|NCT04984707|DRUG|KX0826|AR antagonist
223801069|NCT04984707|OTHER|Placebo|Placebo of KX-826
223801070|NCT02408575|DEVICE|Notched filtering (verum)|Conventional hearing aid type Carat 7bx with M-Receiver Adjustment by Connexx 7.3 The Hearing aid with notched amplification filters frequences in a specific manner, depending on the individual tinnitus frequency. Through this special filtering the neuronal functional changes of the auditory cortex are supposed to be affected therapeutically.
223801071|NCT02408575|DEVICE|No filtering (placebo)|"Conventional hearing aid type Carat 7bx with M-Receiver Adjustment by Connexx 7.3~No notched filtering"
223801072|NCT04629677|OTHER|Electronic Health Record Review|Review of medical records
223801073|NCT04629677|OTHER|Quality-of-Life Assessment|Ancillary studies
223801074|NCT04629677|OTHER|Questionnaire Administration|Complete questionnaires
223801075|NCT01278355|DEVICE|Ear acupuncture|Ear acupuncture
223801076|NCT03284788|BEHAVIORAL|ABT Weight Loss Intervention|This includes 15 sessions that are each 90 minutes in length. Intervention sessions will be weekly for the first 2 months, bi-weekly for the next 2 months, and monthly for the last 2 months.
223801077|NCT01953393|OTHER|Low-dose TNF-alpha|
223801078|NCT04828564|DRUG|Ribavirin Capsules|Ribavirin 200 mg capsules
223801079|NCT04828564|DRUG|Favipiravir|Favipiravir 200 mg tablets
223801080|NCT05399225|DIAGNOSTIC_TEST|Platelets to lymphocytes ratio and procalcitonin|Platelets to lymphocytes ratio and procalcitonin in sepsis
223801081|NCT01572064|PROCEDURE|Blood sample|1 fasted blood sample taken for metabolomics
223801082|NCT01572064|OTHER|MRI Scan|1 single visit for MRI and MRS
223801083|NCT01828580|DEVICE|active laparoscope positioner (AutoLap)|
223801084|NCT05861362|RADIATION|Curative radiotherapy|Curative radiotherapy as indicated by the patient's disease and prescribed by the treating radiation oncologist
223801085|NCT05861362|BEHAVIORAL|5:2 intermittent fasting|Two nonconsecutive days of fasting per week that could be chosen freely according to the patient's weekly schedule.
223801086|NCT06525844|PROCEDURE|regenerative endodontic therapy using I-PRF|Blood will be taken from medial cubital vein
223801087|NCT06525844|PROCEDURE|blood clot|Other: BC According to the procedures of regenerative endodontics therapy, BC was made by the way of provoking apical bleeding into root canal.
223801088|NCT06459947|PROCEDURE|Free gingival graft procedure|The palatal area is anesthetized using local anesthesia. The free gingival graft (FGG) is taken from the donor site with a scalpel.
223801089|NCT06174311|BEHAVIORAL|Active Cognitive Bias Modification|The intervention comprises three sessions and is provided online. Each session consists of two different tasks. To prevent order effects, these tasks will be presented to each participant in a random sequence. One of the tasks involves uncertain scenarios based on a scenario paradigm. At the end of these scenarios, participants will be asked to complete a missing letter in a word that in the scenario, followed by a comprehension question related to the scenario interpretation. Following each question, feedback will be provided regarding the correctness of the response. The other task is a word-sentence pair paradigm, where participants will be asked to assess whether these pairs are related, and feedback will also be provided.
223801090|NCT03235505|DRUG|Nicotine|Nicotine containing e-cigarettes + placebo-varenicline + Motivational Interview (MI)
223801091|NCT03235505|DRUG|Varenicline Tartrate|Varenicline + Innokin Endura T20S electronic inhaler but without any nicotine content + MI
223801092|NCT03235505|BEHAVIORAL|Motivational Interview|Placebo-varenicline + Innokin ENdura T20S electronic inhaler but without any nicotine content +MI
223801093|NCT02899325|DRUG|Diagnostic PET/CT scans|These PET/CT scans will be performed for diagnostic purposes of hepatocellular carcinoma.
223801094|NCT03958084|DIAGNOSTIC_TEST|Straight Leg Raise|The assessment of the flexibility of the hamstring will be realized through the test of straight leg raise (SLR). The SLR is a passive test performed unilaterally.
223801095|NCT00005041|DRUG|tipifarnib|
223801096|NCT00002611|BIOLOGICAL|dactinomycin|
223801097|NCT00002611|BIOLOGICAL|filgrastim|
223801098|NCT00002611|DRUG|cyclophosphamide|
223801099|NCT00002611|DRUG|doxorubicin hydrochloride|Source and Pharmacology: An anthracycline antibiotic isolated from cultures of Streptomyces peucetius. Binds to DNA and inhibits nucleic acid synthesis, with its major lethal effect occurring during the S phase of the cell cycle. Has some topoisomerase II inhibitory activity. Since it is primarily excreted by the liver, any liver impairment may enhance toxicity. 40% to 50% is excreted in the bile; \<5% in the urine. The drug has a very short initial t½ of \<20 minutes and a terminal t½ of 17 hours. Animal studies indicate cytotoxic levels persist in tissue for as long as 24 hours.
223801100|NCT00002611|DRUG|etoposide|
223801101|NCT00002611|DRUG|vincristine sulfate|
223801102|NCT00002611|PROCEDURE|conventional surgery|
223801103|NCT00002611|RADIATION|radiation therapy|
223801104|NCT05052086|DIAGNOSTIC_TEST|Magnetomotoric ultrasound|Nanoparticles will be injected close to the tumor. Magnetomotoric ultrasound will be performed just before scheduled standard operation, when the patient is anesthetized.
223801105|NCT03026790|OTHER|Medication management|Individualized management of medications for pain
223801106|NCT03026790|OTHER|Non-pharmacological pain management|Individualized management of non-medication pain treatment approaches
223801107|NCT03026790|DRUG|Buprenorphine-Naloxone|Option of using buprenorphine-naloxone to assist with opioid dose reduction or discontinuation
223801108|NCT01568099|BIOLOGICAL|AFFITOPE® PD01A|s.c. injection
223801109|NCT01568099|OTHER|Control|Untreated control
223801110|NCT01169714|DRUG|0.1 mg PF-04995274|0.1 mg PF-04995274, qd, for 14 days or placebo
223801111|NCT01169714|DRUG|1 mg PF-04995274|1 mg PF-04995274, qd, for 14 days or placebo
223801112|NCT01169714|DRUG|10 mg PF-04995274|10 mg PF-04995274, qd, for 14 days or placebo
223801113|NCT01169714|DRUG|15 mg PF-04995274|15 mg PF-04995274, qd, for 14 days or placebo
223801114|NCT01169714|DRUG|1.0 mg PF-04995274|1.0 mg PF-04995274, qd, for 14 days or placebo
223801115|NCT01169714|DRUG|15 mg PF-04995274|15 mg PF-04995274, qd, for 14 days or placebo
223801116|NCT00198484|DRUG|Vitrase|
223801117|NCT04209478|DRUG|Tramadol hydrochloride|The Wong-Baker facial pain scale was used to assess pain (1: no pain, 10: worst possible pain). During monitoring patients with pain score ≥3 had intravenous 1 mg/kg tramadol hydrochloride administered, After 15 minutes following tramadol injection, cases with pain score continuing ≥3 were to be assessed as insufficient analgesia and had 0.1 mg/kg morphine hydrochloride planned for intravenous administration
223801118|NCT04596202|BEHAVIORAL|Supine position|After the infants are treated and fed, they will be given the supine position. After positioning, the residue control will be performed in accordance with the procedure steps guideline at the 30th, 60th and 120th minutes and it will be recorded on residue follow-up form. In addition, the comfort level, heart rate, respiratory rate, and oxygen saturation levels of the infant will be evaluated and recorded at the specified times. At the end of two hours, until the next feeding hour (between 121st-180th minutes), the routine position (supine position) applied in the clinic will be given to the infant and waited in order for physiological parameters and comfort levels to return the period without intervention. The aim here is to ensure for the case to get over the effect of the previous position. No data will be collected within this period.
223801119|NCT04596202|BEHAVIORAL|Prone position|After the infants are treated and fed, they will be given the prone position. After positioning, the residue control will be performed in accordance with the procedure steps guideline at the 30th, 60th and 120th minutes and it will be recorded on residue follow-up form. In addition, the comfort level, heart rate, respiratory rate, and oxygen saturation levels of the infant will be evaluated and recorded at the specified times. At the end of two hours, until the next feeding hour (between 121st-180th minutes), the routine position (supine position) applied in the clinic will be given to the infant and waited in order for physiological parameters and comfort levels to return the period without intervention. The aim here is to ensure for the case to get over the effect of the previous position. No data will be collected within this period.
223801120|NCT04596202|BEHAVIORAL|Lateral position|After the infants are treated and fed, they will be given the left or right position. After positioning, the residue control will be performed in accordance with the procedure steps guideline at the 30th, 60th and 120th minutes and it will be recorded on residue follow-up form. In addition, the comfort level, heart rate, respiratory rate, and oxygen saturation levels of the infant will be evaluated and recorded at the specified times. At the end of two hours, until the next feeding hour (between 121st-180th minutes), the routine position (supine position) applied in the clinic will be given to the infant and waited in order for physiological parameters and comfort levels to return the period without intervention. The aim here is to ensure for the case to get over the effect of the previous position. No data will be collected within this period. These processes will continue until the 4 positions are completed. Infants will stay in each position for 2 hours.
223801121|NCT03182699|DIAGNOSTIC_TEST|cardiac MRI|non contrast heart MRI at baseline and after 1 year of therapy
223801122|NCT03182699|DIAGNOSTIC_TEST|echocardiography with strain|echocardiography at baseline and after 1 year of therapy
223801123|NCT03182699|DIAGNOSTIC_TEST|Laboratory tests|drawing blood from dialysis machine
223801124|NCT03182699|DIAGNOSTIC_TEST|Body composition monitoring|Measurement with BCM (Fresenius) machine
223801125|NCT03182699|DIAGNOSTIC_TEST|lung ultrasound|ultrasound
223801126|NCT02465281|OTHER|Device: 3T scanner with MRI-compatible robot|
223801127|NCT00772590|DRUG|Raltegravir|Tablets, 400mg, twice daily
223801128|NCT00772590|DRUG|Hyper-immune Bovine Colostrum|Tablet, 1800mg, twice daily
223801129|NCT00772590|OTHER|raltegravir placebo|One tablet, twice daily
223801130|NCT00772590|OTHER|Hyper-immune Bovine Colostrum placebo|Three tablets twice daily
223801131|NCT00772590|DRUG|raltegravir and hyper-immune bovine colostrum|400mg twice daily raltegravir and 1800mg twice daily of hyper-immune bovine colostrum
223801132|NCT05100186|DRUG|Dexamethasone 0.4 MG [Dextenza]|Dextenza
223801133|NCT01843998|DRUG|Sirolimus 0.1% Ointment|Sirolimus 0.1% ointment will be applied topically to all affected areas of the skin twice daily for 6 months or until progression or unacceptable toxicity.
223801134|NCT01367028|DRUG|Trastuzumab, Docetaxel|"6 cycles - Day1 (Day22 = Day1): Trastuzumab: 8 mg/kg loading dose (1st cycle) i.v.; 6 mg/kg maintenance dose in subsequent cycles i.v.~Docetaxel: 100 mg/m2 by 60 min i.v. infusion"
223801135|NCT01367028|DRUG|Trastuzumab, Docetaxel, Bevacizumab|"6 cycles - Day1 (Day22 = Day1): Trastuzumab: 8 mg/kg loading dose (1st cycle) i.v.; 6 mg/kg maintenance dose in subsequent cycles i.v.~Docetaxel: 100 mg/m2 by 60 min i.v. infusion Bevacizumab 15 mg/kg"
223801136|NCT01367028|DRUG|Trastuzumab+Docetaxel+NPLD|"6 cycles - Day1 (Day22=Day1): Trastuzumab: 8 mg/kg loading dose (1st cycle) i.v.; 6 mg/kg maintenance dose in subsequent cycles i.v.~Docetaxel: 75 mg/m2 by 60 min IV infusion NPLD 50 mg/m2 by 60 min i.v. infusion"
223801137|NCT01367028|DRUG|Trastuzumab+Docetaxel+NPLD+Bevacizumab|"6 cycles - Day1 (Day22= Day1): Trastuzumab: 8 mg/kg loading dose (1st cycle) i.v.; 6 mg/kg maintenance dose in subsequent cycles i.v.~Docetaxel: 75 mg/m2 by 60 min i.v. infusion NPLD: 50 mg/m2 by 60 min i.v. infusion; Bevacizumab 15 mg/kg"
223801138|NCT02660723|OTHER|Healthy Volunteers|A catheter will be introduced in the arm vein and 14 ml of blood will be drawn in one 4 ml dry tube, one 5 ml heparinized tube for cell count and 5 1 ml TruCulture tubes.
223801139|NCT05562479|BIOLOGICAL|Sars Cov 2 infection|Donors recovered from Sars Cov 2 Infection
223801140|NCT05562479|BIOLOGICAL|Sars Cov 2 vaccination|Egg Donors vaccinated
223801141|NCT02003079|BEHAVIORAL|Cystic Fibrosis Questionnaire (Revised) for Teens/Adults|
223801142|NCT03813238|DRUG|TEV-50717|Dosage ranging from 6 mg to 48 mg.
223801143|NCT03813238|DRUG|Placebo|Dosage ranging from 6 mg to 48 mg.
223801144|NCT02079662|OTHER|Behavioral, Psychological or Informational Intervention|Undergo IO intervention
223801145|NCT02079662|OTHER|Best Practice|Undergo standard of care
223801146|NCT02079662|OTHER|Cognitive Intervention|Undergo IO intervention
223801147|NCT02079662|OTHER|Computer-Assisted Intervention|Undergo IO intervention
223801148|NCT02079662|OTHER|Counseling|Undergo counseling
223801149|NCT02079662|BEHAVIORAL|Exercise Intervention|Undergo IO intervention
223801150|NCT02079662|OTHER|Laboratory Biomarker Analysis|Correlative studies
223801151|NCT02079662|OTHER|Quality-of-Life Assessment|Ancillary studies
223801152|NCT02079662|OTHER|Questionnaire Administration|Ancillary studies
223801153|NCT06057623|OTHER|Evaluation of central and peripheral neuromuscular fatigue|To define peripheral and central component of fatigue, the investigators will test, before, during and after the fatigue task, the force produced during a Maximal Voluntary Contraction (MVC) and the force produced by the electrically evoked Resting Twitch (RT) produced, at rest, 5 seconds after the MVC.
223801154|NCT02623465|DRUG|Insulin Lispro|Administered subcutaneously (SC)
223801155|NCT00687999|DRUG|pegylated interferon alpha and ribavirin|standard pegylated interferon alpha and ribavirin
223801156|NCT06791473|DIAGNOSTIC_TEST|AI-Based Diagnostic and Prognostic Model|This intervention involves an AI system that integrates multimodal data, including patient medical history, laboratory test results, imaging data, and genetic information, to predict the risk of cancer. The system uses deep learning algorithms to provide real-time, accurate predictions, enabling early identification of cancer risks. By analyzing historical health data, the model aims to predict potential cancer developments, improving early detection and treatment outcomes.
223801157|NCT04460144|DIAGNOSTIC_TEST|Mass spectrometry|Proteomic analysis
223801158|NCT04329065|BIOLOGICAL|pUMVC3-IGFBP2-HER2-IGF1R Plasmid DNA Vaccine|Given ID
223801159|NCT04329065|DRUG|Paclitaxel|Given via infusion
223801160|NCT04329065|BIOLOGICAL|Trastuzumab|Given IV
223801161|NCT04329065|BIOLOGICAL|Pertuzumab|Given IV
223801162|NCT04329065|DRUG|Docetaxel|Given IV
223801163|NCT04329065|DRUG|Carboplatin|Given IV
223801164|NCT04329065|PROCEDURE|Ultrasound Imaging|Undergo ultrasound imaging
223801165|NCT04329065|PROCEDURE|Biopsy Procedure|Undergo biopsy
223801166|NCT04329065|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223801167|NCT00378001|DRUG|FSH-IBSA|
223801168|NCT00378001|DRUG|GONAL-F|
223801169|NCT04466748|DRUG|Anaprazole Sodium enteric-coated tablet|Multiple ascendinng dose, anaprazole 20mg QD(20mg QD group), 40mg QD(40mg QD group), 20mg Bid(20mg Bid group) , 6 days, fasting oral administration.
223801170|NCT04466748|DRUG|Placebo|Multiple dose, 1 tablet QD (20mg QD and 40mg QD group), 1 tablet Bid (20mg Bid group), 6 days, fasting oral administration.
223801171|NCT02823951|DRUG|Rebif|
223801172|NCT02823951|DRUG|Tecfidera|
223801173|NCT03338894|BEHAVIORAL|Yoga|1 Hour yoga class
223801174|NCT04465357|DRUG|Erenumab-Aooe 140 MG/ML [Aimovig]|140 mg/mL administered subcutaneously
223801175|NCT02538185|DEVICE|NanoJect device (DebioJect™)|The investigational device used in this study is the NanoJect™ device developed by Debiotech company.
223801176|NCT02538185|DEVICE|Classical syringe (1mL Becton Dickinson (BD) Luer-Lock™) with a 25 Guage (G) needle (Terumo® Neolus)|The comparator device used for standard ID injections is a classical syringe (1mL BD Luer-Lock™) with a 25G needle (Terumo® Neolus)
223801177|NCT02538185|DEVICE|Classical syringe (1mL BD Luer-Lock™) with a 22G needle (Terumo® Neolus)|The comparator device used for standard IM injections is a classical syringe (1mL BD Luer-Lock™) with a 22G needle (Terumo® Neolus)
223801178|NCT02538185|DRUG|Vaccin rabique Pasteur®|
223801179|NCT02538185|DRUG|Placebo|Sodium Chloride (NaCl) 0,9%; B. Braun
223801180|NCT06225856|DRUG|YY201|Oral administration under fasting state.
223801181|NCT00420199|DRUG|Abatacept|Vials (250 mg/vial), intravenous (IV), 10 mg/kg, monthly infusion , 12 months of treatment
223801182|NCT00420199|DRUG|Placebo|Intravenous (IV) bags, IV, 0 mg, monthly infusion, 12 months of treatment
223801183|NCT00001507|DRUG|Monoclonal Antibody 3A1|
223801184|NCT00001507|DRUG|Monoclonal Antibody 95-5-49|
223801185|NCT00001507|DRUG|Monoclonal Antibody 95-6-22|
223801186|NCT00001507|DEVICE|Baxter Isolex 3001 Stem Cell Selection System|
223801187|NCT00001507|DEVICE|Ceprate SC|
223801188|NCT04433364|OTHER|biological samples, questionnaires and interviews|"Biological samples: to study impact of testing positive for SARS-CoV-2 during pregnancy samples taken in routine clinical care, samples from already existing research biobanks and the newly established COPE biobank will be used. Time-points: inclusion, at delivery mother and fetus. Covid-19 positive group only: 48-96 h, 2 months postpartum for mother and fetus.~Questionnaires: Women and partners in both groups will fill out electronical questionnaires at different time points during pregnancy and until 12 months postpartum based on validated instruments to test for differences in Self-Efficacy, Anxiety and Depression, Health-related quality of life, Sense of Coherence, PTSD Symptoms, Postpartum Bonding, Childbirth experiences and Self-Efficacy of Breastfeeding. The child's health will be assessed regarding infection until 6 weeks of age and development until 4 years.~Interviews: 24-40 women and partners in both groups. Interviews will be conducted 3 to 6 months after childbirth."
223801189|NCT05520463|PROCEDURE|Sacral lateral branch radiofrequency ablation under ultrasound guidance|Sacral lateral branch radiofrequency ablation will be performed under ultrasound guided approach.
223801190|NCT05520463|PROCEDURE|Sacral lateral branch radiofrequency ablation under fluoroscopy guidance|Sacral lateral branch radiofrequency ablation will be performed under fluoroscopy guided approach.
223801191|NCT05095272|BIOLOGICAL|HMPBS02-Pv|The blood-stage P. vivax master cell bank HMPBS02-Pv was also produced using blood collected from a consenting patient with naturally acquired malaria infection. The malaria infection was confirmed to be P. vivax by species-specific PCR at Pathology Queensland (accredited by the Australian National Association of Testing Authorities) and further confirmed by deep sequencing at the Sanger Institute. The clinical response to antimalarial chemotherapy was also demonstrated with this donor, who was successfully cured with artemether/lumefantrine.
223801192|NCT01328301|OTHER|Experimental|For SDT training, subjects received short intervals of locomotion training with a treadmill. After walking for 30s, the subjects were given two minutes of rest. If they completed the first walking trial safely and without stumbling, the belt speed was increased by 10% on the next trial. However, if a subject failed to complete the first trial, the belt speed was decreased by 10% on the next trial. The speed of the treadmill was adjusted in each subsequent trial according to the same principle. Subjects usually completed 7-8 walking trials in one session. The belt speed was increased by a maximum of five increments within one training session.
223801193|NCT01328301|OTHER|Speed-stable treadmill training|Subjects in the control group walked on the treadmill with the belt speed adjusted according to their fastest over-ground gait speed. There was no adjustment of the belt speed throughout the 30-minute steady-speed treadmill training session.
223801194|NCT05589870|OTHER|Multi-drug analysis of polypharmacy treatment|Multi-drug analysis to assess and provide insights for lowering the risk of ADRs and increasing the benefit of polypharmacy treatment
223801195|NCT01588626|DRUG|AZD6140|tablet
223801196|NCT04749589|DIAGNOSTIC_TEST|iron deficiency|Its not an intervention. Its an observational study. The groups are defined based on their iron status
223801197|NCT02445040|DEVICE|Babylog VN500 in HFOV Mode|Treatment with high frequency oscillatory ventilation with investigational device for up to 14 days
223801198|NCT00995982|BIOLOGICAL|VRC-FLUDNA056-00VP|
223801199|NCT03536910|OTHER|Copeptin|Level of copeptin in maternal blood and umbilical cord blood
223801200|NCT03676179|PROCEDURE|patella denervation|patella denervation
223801201|NCT03676179|PROCEDURE|patella non-denervation|patella non-denervation
223801202|NCT05122390|OTHER|Contraction Coper|Digital application built on the Birth without fear method, based on four different tools to be used during labour. Breathing, relaxation, voice and mind.
223801203|NCT05122390|OTHER|Contraction Coper Plus|Digital application built on the Birth without fear method, based on four different tools to be used during labour. Breathing, relaxation, voice and mind. Clinical guidance from a midwife during two different occasions is added to the group.
223801204|NCT04285450|DIETARY_SUPPLEMENT|Vitamin K|1mg
223801205|NCT04285450|OTHER|Placebo|Lactose
223801206|NCT01514526|DRUG|Dovitinib|"Dovitinib (TKI-258), gelatin capsule of 100mg, developed and supplied by Novartis Inc. The study regimen consists of the administration of 500 mg / day (5 x 100mg) once daily, taken orally with a large amount of water, preferably one hour prior to a meal or at least two hours following a meal. This dose will be taken once daily according to 5 days on/2 days off schedule.~The patient will continue on treatment until disease progression,unacceptable toxicity, death or premature withdrawal."
223801207|NCT00002402|BIOLOGICAL|MN rgp120/HIV-1 and GNE8 rgp120/HIV-1|
223801208|NCT00002402|BIOLOGICAL|MN rgp120/HIV-1 and A244 rgp120/HIV-1|
223801209|NCT00002402|BIOLOGICAL|Aluminum hydroxide|
223801210|NCT02834702|DEVICE|Sinew acupuncture|The subject is asked to be on sitting posture. The skin around the needling points is disinfected with a 75% alcohol swap. A tube-guided, sterilized, disposal needle is then inserted (at a small angle to the skin) into the acupoint at 0.5-1 cun (depending on point location and body size of the subject). No needle sensation (deqi sensation) is required. A piece of surgical adhesive tape will be applied to the needle immediately after insertion.
223801211|NCT02834702|DEVICE|Sham acupuncture|The procedure in the sham acupuncture group will be as similar to that of the acupuncture group as possible. In the sham acupuncture group, however, a mock plastic needle guiding tube is tapped on the surface of each acupoint (Ashi point and traditional acupoints) to produce some discernible sensation. A piece of adhesive tape is immediately applied to fix the needle on the dermal surface tapped, without needle insertion. In addition, a plastic tube-guided needle is superficially inserted at the sham point at less than 5mm in depth.
223801212|NCT05009108|DIAGNOSTIC_TEST|Purdue Pegboard Test|"At first, each person will be asked to fill in the informed agreement and answer short questionnaire. Than he/she will be tested by the Purdue Pegboard Test according to the Czech version of extended manuals for those tests in only one session. Audio recording of verbal instructions will be used and whole testing process will be video recorded which is necessary for establishing the internal variability and variability of results of the Purdue Pegboard Test.~The results will be used only for establishing of the variability and inter-rater reliability of the Purdue Pegboard Test, not for patients' other interventions."
223801213|NCT04184726|BEHAVIORAL|Mindfulness Based Cognitive Therapy|mindfulness and cognitive behavioural therapy techniques taught in group sessions meeting once weekly for 8 weeks, and home practice between sessions.
223801214|NCT02920697|DRUG|S 55746|S 55746, per os administration, from 50 to 1500 mg, once a day during a 21-day cycle. Participants will receive 21-day cycles of treatment until a discontinuation criterion is met.
223801215|NCT05892315|PROCEDURE|Repeated subgingival instrumentation|Supragingival scaling will be performed at sites with plaque and subgingival scaling will be performed by the use of manual and ultrasonic instruments at pockets ≥ 4 mm with bleeding. Oral hygiene instructions will be reinforced. Patients will be instructed to use interdental brushes with appropriate size interdental brushes or dental floss when interdental embrasures will not allow for interdental brushing.
223801216|NCT05892315|PROCEDURE|Supragingival scaling|Supragingival scaling will be performed at sites with plaque. Oral hygiene instructions will be reinforced. Patients will be instructed to use interdental brushes with appropriate size interdental brushes or dental floss when interdental embrasures will not allow for interdental brushing.
223801217|NCT04497792|DRUG|Empagliflozin 10Mg Tab|Patients from treatment group received empagliflozin 10 mg daily additionally to previously prescribed diabetes medication
223801218|NCT04497792|DRUG|hypoglycemic therapy|hypoglycemic therapy.
223801219|NCT03600584|PROCEDURE|Modified one-layer duct-to-mucosa Pancreaticojejunostomy|After the completion of the preparation of the remnant pancreas for reconstruction was performed. Modified one-layer duct-to-mucosa Pancreaticojejunostomy was performed.
223801220|NCT03600584|PROCEDURE|Invagination pancreaticojejunostomy|After the completion of the preparation of the remnant pancreas for reconstruction was performed. Invagination Pancreaticojejunostomy was performed.
223801221|NCT03887338|OTHER|Transnasal Fiberoptic Laryngoscopy|Use of Transnasal Fiberoptic Laryngoscopy during NIV titration to optimalize the NIV settings to laryngeal responses during the NIV treatment.
223801222|NCT02133599|DRUG|IOHEXOL|Patients receive 5 mL of Iohexol prior to cycle 1 and 4 of HDMTX
223801223|NCT03094780|BEHAVIORAL|Quality of life counseling|Will receive quality of life counseling from PI, social workers, and physical therapists
223801224|NCT03094780|OTHER|Video-conference quality of life counseling|Participants may video-conference to other sites to participate in group session dependent on Florida, Northfield and Arizona enrollment
223801225|NCT00144274|DRUG|Ambroxol Lozenge|
223801226|NCT02311530|DRUG|Felodipine|Extended Release Tablets, 10mg
223801227|NCT02311530|DRUG|Felodipine (Plendil®)|
223801228|NCT05241704|PROCEDURE|Fat grafting|Under general or local anaesthesia, fat will be harvested from either abdomen or lower limb. After harvesting the fat by liposuction, the lipoaspirate will be injected underneath the ulcer under complete aseptic operative setting
223801229|NCT05241704|PROCEDURE|Endovenous ablation of superficial venous reflux|Endovenous ablation of the main truncal venous reflux to the lowest point of incompetence, where possible (routine practice)
223801230|NCT04834791|DRUG|Letrozole 2.5mg|These patients were treated with letrozole (Femara®, Novartis New York, NY, USA) in a dose 2.5 mg (one tablet daily) orally began on the 3rd day to the 7th day of the cycle. If ovulation is not achieved dose is increased by 2.5 mg in next cycle till 3 cycles
223801231|NCT04834791|DRUG|Gonadotropin|These patients were given urofollitropin (fostimon ®, IBSA, Lugano, Switzerland) in a dose of 75 IU/mL I.M from day 3rd to day 7th of the cycle beginning by one ampoule per day and the dose had been modulated according to response.
223801232|NCT03489590|DRUG|PFP|"* Composition: inhaled PFP, a gaseous contrast agent (79% PFP, 21% O2, pre-mixed, medical grade gas)~* Administration: Full-face disposable ventilation mask and a standard Douglas Bag system.~* Dosage: Two controlled breaths of contrast gas followed by a full breath and a 12-second breath-hold and scan for image acquisition.~* Frequency: Repeated 5 times followed by an identical five cycles with room air to ensure PFP gas wash-out has occurred."
223801233|NCT01712100|DRUG|Irbesartan|
223801234|NCT01712100|DRUG|Avapro|
223801235|NCT06803355|DIAGNOSTIC_TEST|complete blood count, CRP, blood smear test, blood culture, chest X- ray|Inflammation markers obtained from all cases will be evaluated and used to differentiate between transient tachypnea of the newborn and congenital pneumonia.
223801236|NCT06052241|DRUG|shampoos and scalp serums|shampoos and scalp serums personalized according to their SPI-AI-defined scalp types
223801237|NCT02618967|BIOLOGICAL|AMG 570|7 dose levels of AMG 570 administered as single dose subcutaneous in healthy volunteers.
223801238|NCT02618967|BIOLOGICAL|AMG 570 Matching Placebo|Placebo administered as single dose subcutaneous in healthy volunteers.
223801239|NCT00533377|DRUG|CP-533, 536|Active study drug
223801240|NCT00533377|DRUG|Placebo|Placebo vehicle
223801241|NCT00533377|PROCEDURE|Standard of Care|Standard surgical procedure
223801242|NCT00533377|DRUG|CP-533,536|Active study drug
223801243|NCT00533377|DRUG|CP-533,536|Active study drug
223801244|NCT00533377|DRUG|CP-533,536|Active study drug
223801245|NCT03368820|OTHER|No intervention|Treatment left at the discretion of the participant
223801246|NCT03225664|BIOLOGICAL|Pembrolizumab|Given IV
223801247|NCT03225664|OTHER|Pharmacokinetic Study|Correlative studies
223801248|NCT03225664|DRUG|Trametinib|Given PO
223801249|NCT02612311|BIOLOGICAL|Obinutuzumab|Obinutuzumab: IV infusion
223801250|NCT02612311|BIOLOGICAL|Ublituximab|Ublituximab: IV infusion
223801251|NCT02612311|DRUG|TGR-1202|TGR-1202: Oral daily dose
223801252|NCT02612311|DRUG|Chlorambucil|Chlorambucil: Oral dose
223801253|NCT04672551|BEHAVIORAL|EMDR Treatment|Eight individual EMDR sessions lasting for 1 hours will be provided over 8 weeks by licensed EMDR therapists from the German-speaking part of Switzerland. Each EMDR session follows a standardized 8-phase protocol.
223801254|NCT06647836|OTHER|Efficacy observation|Observation about the efficacy of sq-NSCLC patients receiving immunotherapy combined with or without chemotherapy as first-line treatment.
223801255|NCT05360056|DEVICE|DexCom G6|Wearable continuous glucose monitor
223801256|NCT02742168|RADIATION|99mTc-3PRGD2|"Diagnostic group：For patients in suspicion of breast cancer, single intravenous bolus injection of nearly 0.3 mCi/kg body weight of 99mTc-3PRGD2 on day one of the treatment period, whole-body planar and lesions SPECT/CT to determine the accumulation of 99mTc-3PRGD2 in the tumors and the other parts of the body.~Efficacy evaluation group：patients firstly diagnose with malignant lesions ,and prepare to chemotherapy(including neoadjuvant chemotherapy) or radiotherapy.the same dose of 99mTc-3PRGD2 will be intravenously injected into the patients before treatment ,the second period,the sixth period( almost three months after the initial treatment)，whole-body planar and lesions SPECT/CT to assess the value of 99mTc-3PRGD2 in evaluation of cancers."
223801257|NCT01859481|DRUG|Placebo|All subjects will receive open label eletriptan 40 mg per attack for the first three attacks in the phase 1 of the study. For the next 4 attacks subjects will be assigned to either eletriptan 40 mg or 80 mg group based on the response in the phase 1 portion of the study. In phase II, in each group subjects will receive eletriptan 40 mg or 80 mg for 3 attacks and placebo for 1 attack. In each group double-blind placebo will be inserted at random.
223801258|NCT01859481|DRUG|Eletriptan HBr 40 mg|All subjects will receive open label eletriptan 40 mg per attack for the first three attacks in the phase 1 of the study. For the next 4 attacks subjects will be assigned to either eletriptan 40 mg or 80 mg group based on the response in the phase 1 portion of the study. In phase II, in each group subjects will receive eletriptan 40 mg or 80 mg for 3 attacks and placebo for 1 attack. In each group double-blind placebo will be inserted at random.
223801259|NCT01859481|DRUG|Eletriptan HBr 80 mg|All subjects will receive open label eletriptan 40 mg per attack for the first three attacks in the phase 1 of the study. For the next 4 attacks subjects will be assigned to either eletriptan 40 mg or 80 mg group based on the response in the phase 1 portion of the study. In phase II, in each group subjects will receive eletriptan 40 mg or 80 mg for 3 attacks and placebo for 1 attack. In each group double-blind placebo will be inserted at random.
223801260|NCT01371331|DRUG|Tacrolimus granules|oral
223801261|NCT03422874|DRUG|MLN9708|MLN9708 is a second-generation reversible proteasome inhibitor which shows greater oral bioavailability, improved pharmacokinetics and enhanced antitumor activity compared with bortezomib (VELCADE®).
223801262|NCT03422874|DRUG|Nelfinavir|Nelfinavir is an oral HIV protease inhibitor approved by FDA in 1997, now available in generic form. It has a well established safety profile in HIV patients when administered at the recommended dose of 1250 mg PO BID. Nelfinavir was shown to induce ER stress in cancer cell lines and xenograft tumors leading to apoptosis and tumor growth inhibition.
223801263|NCT05794542|DEVICE|Cue X|Cue X is used with augmented (mixed) reality glasses. These glasses are similar to virtual reality glasses except you can see the real world around you with digital images overlain. The Cue X software is used on two existing devices, the Microsoft HoloLens and the Magic Leap.
223801264|NCT06359938|DEVICE|Atrial pacing with respiratory sinus arrhythmia (RSA) variability|The intervention in this study is a modification of the pacing output from a standard external pacemaker such that it will approximate the RSA variation found in healthy subjects. A pacemaker (PACE204, Osypka Medical AG), similar to those currently in common use in post-CABG patients, will be adapted to receive an additional input signal based on the respiratory signal (Ceryx device). The respiration signal will be combined with the ECG signal to determine the appropriate pacing interval. The pacing impulse will be delivered by the pacemaker unit.
223801265|NCT06359938|DEVICE|Monotonic right atrial overdrive pacing|Pacing is delivered by a PACE204 pacemaker (Osypka Medical AG) delivering standard monotonic right atrial pacing
223801266|NCT04393441|DRUG|011516X (New Artificial Tear Formulation)|Topical eye drops
223801267|NCT04393441|DRUG|Systane Ultra Multidose|Topical eye drops
223801268|NCT04393441|DRUG|REFRESH PLUS®|Topical eye drops
223801269|NCT01817179|OTHER|FES neuroprosthesis to dorsiflexors on affected leg|
223801270|NCT03756103|DRUG|SPH3127 tablet Dose 1|Oral SPH3127 tablet, a kind of renion inhibitor, 50 mg, once daily for 8 weeks.
223801271|NCT03756103|DRUG|SPH3127 tablet Dose 2|Oral SPH3127 tablet, a kind of renion inhibitor, 100 mg, once daily for 8 weeks.
223801272|NCT03756103|DRUG|SPH3127 tablet Dose 3|Oral SPH3127 tablet, a kind of renion inhibitor, 200 mg, once daily for 8 weeks.
223801273|NCT03756103|DRUG|SPH3127 tablet Placebo|Oral SPH3127 tablet placebo, once daily for 8 weeks.
223801274|NCT02802800|OTHER|Plyometric training|Plyometric exercises
223801275|NCT06097312|OTHER|Data collection|The schedule of office visits and all treatment regimens will be determined by the treating health care provider. No interventions are administered as part of this protocol (observational study).
223801276|NCT01688700|DRUG|Nimotuzumab combined with paclitaxel and cisplatin|"Nimotuzumab: 200mg, IV once a week for 6 weeks during chemotherapy (days 1,8,15,22,29,36).~Cisplatin: 75mg/m2,IV on days 1，22~paclitaxel: 90mg/m2, IV on days 1,8,22,29.~patients will receive radical operation 4-6 weeks after Neoadjuvant therapy."
223801277|NCT01432548|PROCEDURE|ischemic preconditioning|Surgery with ischemic preconditioning in liver resection
223801278|NCT05642481|DIAGNOSTIC_TEST|Therapeutic drug monitoring in plasma of mother and child and in breastmilk|Measurement of drug concentration in plasma of mother and if possible of child and in breastmilk
223801279|NCT03558048|DIAGNOSTIC_TEST|Blood draw|Subjects will have their blood drawn during clinic visits over the course of the study period to measure their serum prostate specific antigen levels.
223801280|NCT02316795|PROCEDURE|Sentinel lymph node biopsy|
223801281|NCT02316795|DEVICE|Goggle-based device with light-emitting diodes (LED)|
223801282|NCT02316795|DRUG|Indocynanine Green|This is a infrared fluorescence imaging contrast agent
223801283|NCT06217328|DEVICE|Revi System Treatment|The Revi System is an implantable neuromodulation device placed in the ankle region that is activated by a battery-operated rechargeable external wearable
223801284|NCT06217328|DEVICE|Revi System - Delayed Activation|The Revi System is an implantable neuromodulation device placed in the ankle region that is activated by a battery-operated rechargeable external wearable. The system will be implanted but it will not be turned on until 4 months post implant procedure.
223801285|NCT05198466|DEVICE|Electrical Stimulation|Subjects will receive an active electrical stimulation device to wear for 1 hour daily for 4 weeks (phase II).
223801286|NCT05198466|DEVICE|Electrical Stimulation - Sham|Subjects will receive a sham electrical stimulation device to wear for 1 hour daily for 4 weeks (phase II).
223801287|NCT01452750|DRUG|TAK-438|TAK-438 10 mg tablets, orally, once daily for up to 24 weeks.
223801288|NCT01452750|DRUG|Placebo|Lansoprazole placebo-matching capsules, orally, once daily for up to 24 weeks.
223801289|NCT01452750|DRUG|TAK-438|TAK-438 20 mg tablets, orally, once daily for up to 24 weeks.
223801290|NCT01452750|DRUG|Placebo|Lansoprazole placebo-matching capsules, orally, once daily for up to 24 weeks.
223801291|NCT01452750|DRUG|Lansoprazole|Lansoprazole 15 mg capsules, orally, once daily for up to 24 weeks.
223801292|NCT01452750|DRUG|Placebo|TAK-438 placebo-matching tablets, orally, once daily for up to 24 weeks.
223801293|NCT01215292|DRUG|Acyline|300 mcg/kg on Day 1
223801294|NCT01215292|DRUG|Testosterone gel|5 gm of 1% T Gel applied transdermally for 10 days
223801295|NCT01215292|DRUG|ketoconazole 400|400 mg PO daily, Days 3-10
223801296|NCT01215292|DRUG|Ketoconazole 800|800 mg PO daily, Day 3-10
223801297|NCT01215292|DRUG|Dutasteride|2.5 mg PO daily, Day 3-10
223801298|NCT01215292|DRUG|Anastrozole|1 mg PO daily, Day 3-10
223801299|NCT01215292|DRUG|Placebo ketoconazole|placebo to mimic ketoconazole
223801300|NCT03390439|DEVICE|Nd-Yap 1340nm laser|Each part of the abdomen will be treated with a therapeutic modality. The ND-yap 1340-nm laser will be used in the following parameters: 90 mtz / cm2 nozzle, 90 mJ / mtz power, 2.5 Hz frequency, 3 ms pulse duration, 1 pass.
223801301|NCT03390439|DEVICE|Microneedling|In the other segment of the abdomen, the dermaroller 2.5 mm will be applied, with ten to fifteen passes in the same direction and at least four crosses in the rolling areas.
223801302|NCT06268158|BEHAVIORAL|Eye patch|The experimental group will fill out the patient introduction form, Richmond Agitation-Sedation Scale, Nursing Delirium Screening Scale and Richard-Campbell Sleep Scale on the first day. On the 4th day of the study, the Nursing Delirium Screening Scale and the Richard-Campbell Sleep Scale will be completed.
223801303|NCT02044185|DRUG|salvage chemotherapy, total body irradiation|there are no direct interventions to our patients.
223801304|NCT01696201|BEHAVIORAL|Exercise group|"Supervised physical conditioning program of three 55-60 minute sessions per week during whole pregnancy (from week 9 to 38). Each session consists of 25-30 minutes of cardiovascular exercise,10 minutes of specific exercises (strength and balance exercises), and 10 minutes of pelvic floor muscles training.~Aerobic activity was prescribed at light to moderate intensity, aiming for 55-60 of maximal heart rate. All subjects wore a heart rate (HR) monitor (Polar FT7) during the training sessions to ensure that exercise intensity was light to moderate."
223801305|NCT02451527|DRUG|Digoxin|Digoxin 0.5mg tablet by mouth on Day 1 and Day 38
223801306|NCT02451527|DRUG|PEX168|PEX168 in subcutaneous injection on Day8，15，22，29 and Day 36
223801307|NCT04407390|DIETARY_SUPPLEMENT|Nicotinamide riboside|The patients will receive 1 g of nicotinamide riboside or placebo orally every morning for 14 days.
223801308|NCT04407390|DIETARY_SUPPLEMENT|Placebo|Placebo
223801309|NCT05046054|DEVICE|transcutaneous electrical nerve stimulation|transcutaneous electrical nerve stimulation group received transcutaneous electrical nerve stimulation via two electrodes on the venous cannulation site 20 min before propofol injection
223801310|NCT05046054|DEVICE|Placebo transcutaneous electrical nerve stimulation|Placebo transcutaneous electrical nerve stimulation group received no transcutaneous electrical nerve stimulation via two electrodes on the venous cannulation site 20 min before propofol injection
223801311|NCT03768258|DRUG|Testosterone Implant|Testosterone implants or combination testosterone + anstrozole implants used to treat symptoms of hormone/androgen deficiency
223801312|NCT05204225|OTHER|Tablet Application|Participants will receive a tablet app (ReHand) along with face-to-face physiotherapy sessions. The ReHand app includes an exercise program based on current scientific evidence for improving funcional ability and dexterity of the hand with neurological affectation. Those exercises are performed making controlled taps and movements while touching the touchscreen and guided by feedbacks. Also, ReHand app includes a prescription and monitoring web-based system for professionals. Along with this intervention, face-to-face physiotherapy sessions will be performed their respective centres.
223801313|NCT05204225|OTHER|Conventional Treatment|Participants of this group will receive a home exercise program on paper and face-to-face physiotherapy sessions. This intervention is the conventional approach usually delivered in their respective centres. Those exercises were specifically developed for the rehabilitation of the hand with neurological affectation.
223801314|NCT00977665|DRUG|rasagiline mesylate|rasagiline 1 mg tablet/day for 48 weeks
223801315|NCT00977665|DRUG|placebo|placebo tablet for 48 weeks
223801316|NCT03156660|BEHAVIORAL|Weight gain prevention (Group 1)|"Participants will be asked to keep their weight stable during the initial 8 weeks of the study.~Intervention Components:~1. Lesson materials adapted from the Small Changes intervention, which will provide guidance for meeting the goals of this intervention (i.e., increasing steps by 2000 steps per day, making one Small dietary Change each day).~2. Daily self-monitoring of steps and number of Small Changes~3. Daily weight self-monitoring on the BodyTraceTM e-scale~4. Fit Bit Alta activity trackers to self-monitor steps"
223801317|NCT03156660|BEHAVIORAL|Weight loss intervention (Group 2)|"Participants will be asked to achieve a weight loss goal of at least 5% of their baseline weight by week 8.~Intervention Components:~1. Tailored calorie and fat goals based on their baseline weight.~2. Daily dietary intake and physical activity self-monitoring using a website or app.~3. Daily weight self-monitoring on the BodyTraceTM e-scale~4. Lesson materials for each session, drawn from the Look AHEAD intensive lifestyle intervention~5. Meal replacements for two meals and one snack for 8 weeks as a method to achieve the study's calorie and fat goals and as a strategy to control portions~6. Graded physical activity goals of 175 minutes of moderate intensity exercise (e.g., brisk walking) per week, or 10,000 steps per day~7. Fit Bit Alta activity trackers to self-monitor steps"
223801318|NCT03156660|BEHAVIORAL|Self-guided intervention (Group 3)|"Participants randomized to Group 3 will wait for 8 weeks before initiating the same smoking cessation intervention as the other two conditions, while they review the provided weight management focused book.~Intervention Components:~1. EatingWell Diet book.~2. Daily weight self-monitoring on the BodyTraceTM e-scale"
223801319|NCT04240366|PROCEDURE|Control intervention|patients treated with balloon-based ablation of AF by PVI
223801320|NCT04240366|PROCEDURE|Experimental intervention|patients treated with balloon-based ablation of AF by PVI
223801321|NCT05725317|DEVICE|LID220365 contact lens|Investigational delefilcon A spherical contact lens made with a modified manufacturing process
223801322|NCT05725317|DEVICE|LID006961 contact lens|Commercially available delefilcon A spherical contact lens
223801323|NCT00327626|DRUG|ISIS 113715|
223801324|NCT01869842|PROCEDURE|percutaneous coronary intervention|the traditional percutaneous coronary intervention by Resolute zotarolimus-eluting stent insertion
223801325|NCT01869842|PROCEDURE|OCT-guided percutaneous coronary intervention|the percutaneous coronary intervention using optical coherence tomography by Resolute zotarolimus-eluting stent insertion
223801326|NCT01869842|PROCEDURE|percutaneous coronary intervention|the traditional percutaneous coronary intervention by Resolute zotarolimus-eluting stent insertion
223801327|NCT01869842|PROCEDURE|OCT-guided percutaneous coronary intervention|the percutaneous coronary intervention using optical coherence tomography by Resolute zotarolimus-eluting stent insertion
223801328|NCT01550458|DRUG|mibefradil|25 mg tablets for oral administration given for 7 days at a total daily dose beginning at 100 mg per day divided into four doses. Doses will be incremented in successive cohorts by 25 mg/day up to 400 mg/day.
223801329|NCT01550458|OTHER|Placebo|1 out of 6 patients per cohort will receive placebo tablets identical in appearance and number to the active mibefradil arm.
223801330|NCT02354664|OTHER|Thoracic MRI|Imaging of the diaphragm will be completed during resting breathing, and then during a maximal voluntary ventilation maneuver.
223801331|NCT02354664|OTHER|Spirometry|Upright forced vital capacity (FVC)
223801332|NCT02354664|OTHER|Inspiratory Load Compensation|A spring-loaded pressure device will resist inspiration. The patient must generate the threshold inspiratory pressure to receive airflow. The changes in breathing timing, flow and volume will be recorded.
223801333|NCT02354664|OTHER|Maximal Inspiratory Pressure|Measure the maximal airflow on inhalation
223801334|NCT02354664|OTHER|Resting Breathing Pattern|The breathing pattern will be assessed when the subject is seated and in a relaxed state.
223801335|NCT02354664|OTHER|Respiratory Muscle Endurance Test|Evaluates the time limit that a participant can maintain ventilation while breathing with a submaximal inspiratory threshold load.
223801336|NCT03987841|BEHAVIORAL|Integrated MBSR/DSME intervention|Integrated mindfulness-based stress reduction/diabetes self-management education intervention. The intervention will comprise components of MBSR and DSME and will be delivered in a group setting with 8 weekly sessions. A trained masters-level interventionist will deliver the integrated intervention.
223801337|NCT02816138|DRUG|Nicotine|Open-label transdermal nicotine patch
223801338|NCT01814969|RADIATION|Hyperfractionated Radiochemotherapy|28 x 1.5Gy 2 times a day; gap between the fractions min. 6-8h - duration of treatment 2.5 weeks + simultaneous bolus 5-Fluorouracil (the each cycle consisted of 5-fluorouracil 325 mg/m2 per day) on 1-3 and 16-18 (last 3 days of radiotherapy).
223801339|NCT01814969|RADIATION|Hyperfractionated Radiotherapy|28 x 1.5Gy 2 times a day; gap between the factions min. 6-8h - duration of treatment 2.5 weeks
223801340|NCT01695564|DEVICE|LARIAT LAA|The LARIAT snare device is an over-the-wire device guided over the LAA to enable ligation of the LAA. The LARIAT can be opened and closed as desired for ideal positioning without risk of suture deployment.
223801341|NCT01695564|DEVICE|WATCHMAN|The WATCHMAN is an expandable device deployed in the LAA via a trans-septal catheter. The implanted device has a self-expanding nitinol frame to secure it in the LAA. The fabric of the WATCHMAN device is permeable to blood.
223801342|NCT00981084|DRUG|armodafinil|Half of the patients will be randomized to receive a single oral dose of placebo prior to the first testing session. After a washout period of one week, they will then receive 250mg of armodafinil prior to a second testing session (P/A group). The other half of patients will be randomized to receive the active drug first. After a washout period of one week, they will receive the placebo prior to a second testing session (A/P group). As plasma levels of armodafinil peak between 2-4 hours after administration, participants will be asked to take a single 250mg capsule 2 hours prior to the scheduled testing sessions.
223801343|NCT05944523|PROCEDURE|Erector Spina Plan Block|Preemptive erector spina plan block and postoperative erector spina plan block were applied to patients undergoing thoracotomy. The effect of the time of application on intraoperative opioid consumption was compared with the Nociception Level Index pain monitor.
223801344|NCT04253327|OTHER|questionnaire|"Patients will be contacted by their physician during regular follow-up in the out-patient clinic or contacted by phone.~The questionnaires will be filled in at the UZBrussel, Laarbeeklaan 101, 1090 Brussels or at the patients home.~Filled-in questionnaires can be hand off immediately at the physician or send by post or email.."
223801345|NCT04530292|BEHAVIORAL|Intervention by a pediatric nurse at the child's home|"The intervention will consist of a coordinated intervention by a pediatric nurse at the child's home to support the parents in the implementation of the theoretical knowledge acquired at the hospital.~Three home visits will be set up by a nurse during the first six months of the discovery of diabetes in the child. These visits will be organized during the first, fourth and sixth months after the discovery of diabetes and last about 2 hours each time. An additional visit may be set up according to the needs of families."
223801346|NCT06113601|OTHER|There is no intervention.|There is no intervention in the study.
223801347|NCT04887025|BIOLOGICAL|RGV004|a genetically-engineered vaccinia virus (encoding CD19/CD3 bispecific antibody)
223801348|NCT05166044|BIOLOGICAL|EV71 Inactivated Vaccine|The EV71 vaccine was manufactured by Sinovac Biotech Co,And inactivated EV71 virus antigen was no less than 3.0EU in 0.5 mL of aluminium hydroxide solution per injection.
223801349|NCT04719091|DEVICE|Lubricity|Oral spray
223801350|NCT00551252|DRUG|Imatinib mesylate plus Gemcitabine|Imatinib (400 mg daily) + Gemcitabine (500 mg/sqm, days 1 and 8 every 21 days) for a maximum of 6 cycles
223801351|NCT02613104|OTHER|emotion recognition modification - sad>happy|Participants must choose whether each face is happy or sad. Based on these responses, an algorithm then estimates each participant's balance point, the threshold point on the morph sequence at which they are equally likely to label the face as happy or sad. During the intervention, the participant receives feedback on their emotion choices designed to train them to identify two additional morphs as happy, rather than sad. The intervention is completed three times.
223801352|NCT02613104|OTHER|emotion recognition modification - sad>happy control|Participants must choose whether each face is happy or sad. Based on these responses, an algorithm then estimates each participant's balance point, the threshold point on the morph sequence at which they are equally likely to label the face as happy or sad. During the placebo intervention, the participant receives feedback on their emotion choices designed to reinforce their initial emotion choices. The placebo intervention is completed three times.
223801353|NCT02613104|OTHER|emotion recognition modification - angry>happy|Participants must choose whether each face is happy or angry. Based on these responses, an algorithm then estimates each participant's balance point, the threshold point on the morph sequence at which they are equally likely to label the face as happy or angry. During the intervention, the participant receives feedback on their emotion choices designed to train them to identify two additional morphs as happy, rather than angry. The intervention is completed three times.
223801354|NCT02613104|OTHER|emotion recognition modification - angry>happy control|Participants must choose whether each face is happy or angry. Based on these responses, an algorithm then estimates each participant's balance point, the threshold point on the morph sequence at which they are equally likely to label the face as happy or angry. During the placebo intervention, the participant receives feedback on their emotion choices designed to reinforce their initial emotion choices. The placebo intervention is completed three times.
223801355|NCT04932629|BIOLOGICAL|Ex-vivo cultivated Allogeneic limbal stromal stem cells|n this prospective intervention study patients with unilateral superficial corneal scars will undergo a surgical procedure and in the second procedure, the eligible patients will undergo corneal transplant surgery, when the central corneal epithelium will be removed using a surgical sponge. 0.1ml of stromal cells in a concentration of 0.5x10\*6 cells/µl diluted in the thrombin component of fibrin glue (TISEEL, Baxter) will be applied to the debrided corneal stroma. A soft bandage contact lens will be placed over the cornea at the end of the procedure. The patient will receive topical antibiotic and steroid eye drops in the post-operative period. Periodic comprehensive ophthalmic evaluation along with anterior segment optical coherence tomography (ASOCT) scanning and slit-lamp photography will be done at Day 1, Day 7, Day 30, Day 90, Day 180 and Day 360 and 720 Days post-surgery
223801356|NCT04852016|BEHAVIORAL|Consent process with the addition of Digital educational platform (DEP)|In-patients being consented for laparoscopic cholecystectomy will be provided with a Digital Educational Platform (DEP), in the form of modules on an iPad. These participants will still undergo the usual standard verbal consent (SVC). Multiple choice questionnaires will be given pre and post consent to determine acquisition and retention of the information provided using DEP.
223801357|NCT04852016|BEHAVIORAL|Consent process using the standard verbal consent (SVC)|In-patients being consented for laparoscopic cholecystectomy will go through the SVC. Multiple choice questionnaires will be given pre and post consent to determine acquisition and retention of the information provided using SVC.
223801358|NCT04717726|DIETARY_SUPPLEMENT|Milk Thistle (MT)|Participants in the MT and EX + MT groups will be provided 900 mg of standardized milk thistle extract daily (300 mg three times per day before meals) over the 12-week regimen. We will use the standardized Jarrow Formulas Milk Thistle Veggie Caps containing 30:1 extract that is standardized to contain 80% total Milk Thistle seed flavonoids (polyphenols), including the critical Silymarin fractions isosilybinins A and B, silybinins A and B, silychristin and silydianin that is active against suppressing the UGT1A1 enzyme increasing plasma bilirubin. The capsules are free of wheat, gluten, soybeans, dairy, egg, fish/shellfish, peanuts/tree nuts, and GMOs. Rationale for using this brand: There have been inconsistencies with previous studies that did not use a standardized silymarin extract, which may have contained low levels of the active polyphenolic flavonoids in the milk thistle plant, which varies in the plant's stems, leaves, roots, and flowers.
223801359|NCT04717726|DIETARY_SUPPLEMENT|Lactobacillus Gasseri (LAC)|Participants in the LAC and LAC + EX groups will receive two doses of 3 billion CFU of lactobacillus gasseri per day for a total of 6 billion CFU, the recommended upper level for supplementation of probiotic cultures. We will use Swanson brand Lactobacillus gasseri, whose capsules are also free of wheat, gluten, soybeans, dairy, egg, fish/shellfish, peanuts/tree nuts, and GMOs. Importantly, this brand uses acid-resistant designed release capsules to improve the viability of the lactobacillus in the human stomach.
223801360|NCT04717726|BEHAVIORAL|Exercise (EX)|Participants in the EX, EX + MT, and EX + LAC groups will complete five weekly exercise sessions on their own, expending roughly 600 kcal per session. Participants will be provided a Polar A-300 heart rate monitor programmed for their individual attributes (height, weight, age, training status, gender), which gives a real-time estimate of energy expenditure during exercise. Participants will report to the lab once per week to download the exercise sessions and verify compliance. If participants are not compliant (defined as completing 85% of their assigned exercise sessions per month), they will be disqualified. This intervention has been successfully used by Dr. Flack in multiple studies to produce significant weight loss without dietary intervention in this population with a retention rate of over 90%
223801361|NCT04717726|DIETARY_SUPPLEMENT|Control (CON)|Participants in the CON and EX group will receive a placebo (maltodextrin) made to look identical to the MT and LAC capsules.
223801362|NCT05711979|BEHAVIORAL|AARC|There will be 10 90min weekly sessions. The first half of each session will consist of health education discussing diet, physical activity and screen time. Participants will set goals for themselves and their families. The investigators will check-in on goals and barriers to achieving goals in each session following the initial session. The second half of the sessions will focus on mindfulness based stress reduction including brief meditation, discussion of mindful eating and mindful parenting. This intervention will adapt an already-existing evidence-based obesity prevention program which has been administered to over 100 families (COACH), and it will add mindfulness-based stress reduction, tailored to African American women.
223801363|NCT02883738|OTHER|tremor|evaluation of the intensity of the tremor
223801364|NCT00618254|DRUG|Granisetron|
223801365|NCT00568048|BIOLOGICAL|bevacizumab|10 mg/kg i.v., on day 1 of every cycle (14 days) until PD or any other event qualifying for stopping treatment
223801366|NCT00568048|DRUG|temozolomide|150 mg/m2 p.o., on days 1-7 of every cycle (14 days) until PD or any other event qualifying for stopping treatment
223801367|NCT03144713|DRUG|Terlipressin|Terlipressin 1mg intravenous bolus at the onset of paracentesis and the remaining as 1 mg doses intravenous at 8 and 16 h after the first dose. ( total -3mg)
223801368|NCT03144713|DRUG|Midodrine|Terlipressin 1mg intravenous bolus at the onset of paracentesis and the remaining as 1 mg doses intravenous at 8 and 16 h after the first dose. ( total -3mg)
223801369|NCT03144713|DRUG|Albumin|Albumin-8g/L of tap- one half of dose at beginning of tap and rest half after 6 hours of tapping.
223801370|NCT00604032|DRUG|Atralin (tretinoin) Gel, 0.05%|Assess potential of tretinoin gel, 0.05% to produce phototoxic reactions, measured 24 and 48 hours after UV radiation of drug on the skin.
223801371|NCT04457557|OTHER|Reduced concentration of local anesthetic (ropivacaine)|Reduced concentration of ropivacaine We usually use 0.5% ropivacaine in our facility. The intervention group used 0.15% ropivacaine 15 ml
223801372|NCT04457557|OTHER|Usual concentration of local anesthetic (ropivacaine)|0.5% ropivacaine 15ml
223801373|NCT03968432|BEHAVIORAL|MIAS&Q|There were two interventions compared in this study: 1) Be Sweet to Babies Videos and Pamphlet; and 2) Be Sweet to Babies Videos, pamphlet, and MIAS\&Q. The Be Sweet to Babies vaccination pain management videos and pamphlet were provided to all participants as this information is publicly available, and demonstrates the effectiveness of the evidence-based recommended vaccination pain management strategies for infants. In addition, a pamphlet was used which was developed in partnership with CHEO and Ottawa Public Health as a knowledge translation tool. Those in the intervention arm were also given MIAS\&Q included five questions and statements based on the MI approach consisted of four scaled questions and two open-ended questions, aimed to present brief informative and affirmative questions and statements to help the parents reflect on their own thoughts and support them to advocate for the use of the recommended pain management strategies during their infant's vaccination.
223801374|NCT03968432|BEHAVIORAL|Be Sweet to Babies Videos and Pamphlet|The Be Sweet to Babies vaccination pain management videos and pamphlet will be provided to all participants. Be Sweet to Babies vaccination pain management videos showing parents how to use breastfeeding, upright secure holding, and a small volume of sweet solution during vaccination, will be used. This pamphlet is a knowledge translation tool previously developed in partnership with the Children Hospital of Eastern Ontario (CHEO) and Ottawa Public Health and has been publicly available on the Ottawa Public Health Website since June 2013. The content presented about pain management for infants during vaccination is the same information as the video.
223801375|NCT03249155|BEHAVIORAL|AO - plus sonification|patients re-learn 8 motor gestures watching video-clips showing an actor performing the same gestures, and then tried to repeat the gesture. Each video-clip is composed by images and sounds of the gestures. The sound of gestures is obtained with the sonification technique, by transforming kinematic data (velocity) recorded during the execution of gesture, into pitch variations (for an example see: bit.ly/sonif\_example)
223801376|NCT03249155|BEHAVIORAL|CUE - visual and auditory|patients re-learned 8 motor gestures practicing a traditional protocol combining visual and auditory cues
223801377|NCT03155789|PROCEDURE|Lumbar Fusion|"Standard Transforaminal Lumbar Interbody Fusion (S TLIF)~Minimally Invasive Transforaminal Lumbar Interbody Fusion (MI TLIF)~AxiaLIF Fusion"
223801378|NCT00842140|DRUG|oral contraceptive|oral contraceptive (0,03mg ethynylestradiol and 2mg chlormadinone acetate)once a day for 12 months
223801379|NCT00842140|DRUG|Oral contraceptive plus spironolactone|The patient will receive an oral contraceptive (0,03mg ethynylestradiol and 2mg chlormadinone acetate) plus 100 mg spironolactone. One pill each once a day for twelve months.
223801380|NCT00842140|DRUG|Oral contraceptive plus metformin|Oral contraceptive (0,03mg ethynylestradiol and 2mg chlormadinone acetate) plus 850 mg of metformin
223801381|NCT01012232|DRUG|20 mL ropivacaine 5 mg/mL|
223801382|NCT01012232|DRUG|10 mL ropivacaine 10 mg/mL|
223801383|NCT02264522|OTHER|Place dialysis chair into position 3.|Upon device notification event 1, place patient in dialysis chair position 3.
223801384|NCT02264522|OTHER|Decrease dialysate temperature.|Upon device notification event 2, decrease dialysate temperature by 0.5 degree centigrade.
223801385|NCT02264522|OTHER|Decrease ultrafiltration rate by 25%.|Upon device notification event 3, decrease ultrafiltration rate by 25% from baseline ultrafiltration rate.
223801386|NCT02264522|OTHER|Decrease ultrafiltration rate by 50%.|Upon device notification event 4, decrease ultrafiltration rate by 50% from baseline ultrafiltration rate.
223801387|NCT03126825|DEVICE|CP910/CP920 with noise reduction on|This intervention uses the approved Nucleus 6 system (CP910/CP920 and accessories) but adds the investigational noise reduction algorithm.
223801388|NCT03126825|DEVICE|CP910/CP920|The approved CP910 or CP920 Sound Processor.
223801389|NCT01873430|DRUG|Melatonin|
223801390|NCT03918746|BEHAVIORAL|internet Attachment-Based Compassion Therapy (iABCT)|"The internet version of Attachment-Based Compassion Therapy (iABCT) will be developed to be totally self-applied over the Internet through the website www.psicologiaytecnologia.com designed by Labpsitec (Laboratory of Psychology and Technology, Universitat Jaume I, and University of Valencia). The iABCT will consist of eight sequential modules: Module 0) Welcome module: approaching to the compassion; Module 1) Preparing ourselves for compassion. Kind attention; Module 2) Discovering our compassionate world; Module 3) Developing our compassionate world; Module 4) Understanding our relationship with compassion; Module 5) Working on ourselves; Module 6) Understanding the importance of forgiveness; Module 7) Consolidating the practice of compassion~The content will present through texts, audios, videos, pictures, vignettes, and interactive exercises. Downloadable PDF files will be available so that users can review them offline."
223801391|NCT05341258|DIAGNOSTIC_TEST|EtCO2|EtCO2
223801392|NCT05341258|DIAGNOSTIC_TEST|PaCO2|PaCO2
223801393|NCT00466882|DEVICE|Inamed Lap-Band System|Patient's will be seen in the physician's office one week post surgery and once a month thereafter. The device can be gradually adjusted by the insertion of a needle into the port and saline is added or removed to inflate or deflate the LAPBAND. This can be conducted in the physician's office setting to enable the patient to lose 1-2 pounds per week over two years.
223801394|NCT02064543|OTHER|GAITRite|mobility test assessing gait parameters
223801395|NCT02064543|OTHER|ADPM|mobility test assessing gait parameters
223801396|NCT04706702|BEHAVIORAL|Tele-EnhanceFitness|Livestream, instructor-led tele-exercise classes, involving balance, endurance, and strength training
223801397|NCT06249932|DRUG|Empagliflozin 25 MG|The medication will be packed in a customized sealed jar and labeled on the exterior of the jar.
223801398|NCT06249932|DRUG|Placebo|The placebo tablet is manufactured by Prince Pharmaceutical Co., Ltd, a leading manufacturer of nutritional supplements with certifications including cGMP, GMP, ISO, and HACCP. The Prince Pharmaceutical also provides Original Equipment Manufacturing (OEM)/Original Design Manufacturing (ODM) services for a wide array of tablet shapes, and post-processing techniques such as film coating and sugar coating.
223801399|NCT02953301|DRUG|resminostat|
223801400|NCT02953301|DRUG|Placebo|
223801401|NCT05477732|DIETARY_SUPPLEMENT|Bifidobacterium longum OLP-01|Bifidobacterium longum OLP-01 is one of probiotics. Subjects in OLP-01 group will supplement with either 2 × 1010 colony-forming unit (CFU) of Bifidobacterium longum OLP-01 powder per day for 12 weeks.
223801402|NCT05477732|OTHER|Placebo|Subjects in placebo group will supplement with placebo powder per day for 12 weeks.
223801403|NCT01430260|DRUG|Ciclesonide|200 ㎍ once daily
223801404|NCT01430260|DRUG|Levocetirizine|5mg once daily
223801405|NCT01430260|DRUG|Ciclesonide & Levocetirizine|"* Omnaris (ciclesonide) 200 ㎍ once daily~* Levocetirizine 5mg once daily"
223801406|NCT03677713|PROCEDURE|No nasal packing.|No nasal packing at the end of the surgery
223801407|NCT03677713|PROCEDURE|Nasal Packing|Patients will have nasal packing at the end of the surgery
223801408|NCT01643590|BIOLOGICAL|JVS-100 15 mg dose Injection|Intramyocardial Injection
223801409|NCT01643590|BIOLOGICAL|Placebo Injection|Intramyocardial Injection
223801410|NCT01643590|BIOLOGICAL|JVS-100 30 mg dose injection|Intramyocardial Injection
223801411|NCT01285583|DRUG|TRO19622|2 capsules of TRO19622 (330mg) once a day with the noon meal as add-on therapy to riluzol 50mg bid
223801412|NCT01543061|DEVICE|OPTIVEtm Plus|1 drop in each eye four times a day for a period of 30 (± 3) days
223801413|NCT01543061|PROCEDURE|No treatment|One month of contact lens wear with no eye drop use
223801414|NCT01543061|DEVICE|Blink Contacts® Eye Drops|1 drop in each eye four times a day for a period of 30 (± 3) days
223801415|NCT01731236|DIETARY_SUPPLEMENT|Carnitine|Group 1: Carnitine supplement for 2 months, No antibiotics, no aspirin for 3 months (1 month prior and during study)
223801416|NCT01731236|DIETARY_SUPPLEMENT|Choline|Group 2: Choline supplement for 2 months, No antibiotics, no aspirin for 3 months (1 month prior and during study)
223801417|NCT01731236|DRUG|Antibiotics|Group 3: Carnitine or Choline for 2 months, antibiotic cocktail (Ciprofloxacin, Flagyl, Vancomycin, and Neomycin) for 1 week
223801418|NCT01731236|DRUG|Choline and Aspirin|Group 4: Choline supplement for 2 months plus aspirin 81 mg for 3 months (1 month prior to starting the study and 2 months during the study).
223801419|NCT01731236|DRUG|Carnitine and Aspirin|Group 5: Carnitine supplement for 2 months plus aspirin 81 mg for 3 months (1 month prior to starting the study and 2 months during the study).
223801420|NCT03752216|DRUG|Niraparib|"Two different doses of Niraparib can be administrated:~For patient who had at baseline (T0) a body weight ≥ 77 kg and a platelet count ≥ 150 000/µL, Niraparib will be administrated at a dose of 300 mg daily. The planned dose of 300 mg daily will be made up of three 100 mg capsules.~For patient who had at baseline (T0) a body weight \< 77 kg or a platelet count \<150 000/µL, Niraparib will be administrated at a dose of 200 mg daily. The planned dose of 200 mg daily will be made up of two 100 mg capsules.~Patient should continue to receive study treatment until disease progression as per RECIST as assessed by the investigator or they do not meet any other discontinuation criteria."
223801421|NCT06679751|BEHAVIORAL|ID-TOUCH|ID TOUCH is a multi-pronged intervention to increase HIV testing and PrEP linkage that includes jail-based HIV care process improvements with post-incarceration outreach and linkage to community services.
223801422|NCT04658667|BIOLOGICAL|IHV01|IHV01 consists of the Full-Length Single Chain (FLSC) gp120-CD4 chimera subunit HIV-1 vaccine formulated in aluminum phosphate adjuvant. It is encoded by a synthetic gene, which contains a human codon-optimized HIV (BaL) gp120 sequence followed by human CD4D1D2, with a flexible 20-amino acid linker.
223801423|NCT04658667|BIOLOGICAL|A244|A244 consists of the gp120 envelope glycoprotein HIV-1 subtype CRF\_01AE A244 derived from the CM244 CRF\_01AE. The A244 gp120 envelope has an 11 amino N-terminal deletion, similar to the A244 protein used in AIDSVAX B/E. The aluminum hydroxide fluid gel (AHFG) adjuvant that is mixed with A244 consists of Rehydragel HPA that is diluted with sterile water for injection to a concentration of 5 + /- 1mg/mL.
223801424|NCT04658667|BIOLOGICAL|ALFQ|ALFQ (Army Liposomal Formulation) is a liposomal adjuvant containing a synthetic monophosphoryl lipid A (MPLA) with the addition of QS-21.
223801425|NCT04658667|OTHER|Placebo|Normal saline (Sodium Chloride for injection USP, 0.9%) will be used as placebo.
223801426|NCT03743649|DRUG|Haloperidol|Given IV
223801427|NCT03743649|DRUG|Lorazepam|Given IV
223801428|NCT03743649|OTHER|Placebo|Given IV
223801429|NCT03743649|OTHER|Quality-of-Life Assessment|Ancillary studies
223801430|NCT03743649|OTHER|Questionnaire Administration|Ancillary studies
223801431|NCT04969263|BIOLOGICAL|BNT162b2 vaccine (Pfizer/BioNTech)|30 microgram dose
223801432|NCT04969263|BIOLOGICAL|mRNA-1273 vaccine (Moderna)|100 microgram dose
223801433|NCT04314557|DEVICE|Renal denervation|Spyral device. Bilateral renal denervation.
223801434|NCT04058652|DEVICE|transcutaneous electrical nerve stimulation (TENS) unit|The transcutaneous electrical nerve stimulation (TENS) unit is a noninvasive, inexpensive, battery-operated device that was originally designed to provide modulation of the afferent nervous system to relieve pain. By providing alternating current through cutaneous electrodes, TENS activates large-diameter afferent fibers of the nervous system (A-delta, A-beta, C fibers), whose ascending signals are subsequently relayed to the central nervous system.
223801435|NCT04450108|DIAGNOSTIC_TEST|Vivatmo pro FeNO Test|Breath gas analysis
223801436|NCT05572138|DIAGNOSTIC_TEST|Body Impedance Analysis|Body Impedance Analysis
223801437|NCT01257906|DRUG|CLIND PHOSPHATE (1.2%) AND TRETINOIN (0.025%) TOPICAL GEL|Topical Gel applied in the evening for 84 days
223801438|NCT01257906|DRUG|ZIANA®|Topical Gel applied in the evening for 84 days
223801439|NCT01257906|DRUG|Vehicle Control|Topical Gel applied in the evening for 84 days.
223801440|NCT01461876|DRUG|antiretroviral therapy|Standard of care antiretroviral therapy
223801441|NCT00772226|DEVICE|music pillow|according to randomisation patients will receive with/without music.
223801442|NCT00772226|DEVICE|pillow without music|According to randomisation patients will receive a pillow with/without music
223801443|NCT02693743|DEVICE|repetitive transcranial magnetic stimulation (rTMS)|A Neurostar TMS Therapy System and Neurostar XPLOR coil system (Neuronetics, Malvern, Pennsylvania) will be used to deliver stimulation.
223801444|NCT02200731|BEHAVIORAL|FAMOS: psychosocial family intervention|The FAMOS intervention consists of a six session manualized psychosocial intervention including videos and tools. Four sessions focus on the parents and two sessions focus on the childhood cancer survivor and its siblings. The intervention is conducted by a psychologist with Cognitive Behavioral Therapy experience
223801445|NCT04339192|PROCEDURE|Minimally Invasive Tricuspid Surgery|minimally invasive tricuspid surgery including endoscopy-assist right minithoracotomy, vacuum-assist single femoral venous drainage without dissecting or snaring vena cava, direct right atriotomy through pericardium and the beating-heart technique.
223801446|NCT01456026|DIETARY_SUPPLEMENT|Glycated beta-lactoglobulins.|oral, 20 g, single administration
223801447|NCT01456026|DIETARY_SUPPLEMENT|Non-glycated beta-lactoglobulins|20 g, oral, single administration,
223801448|NCT01031810|DRUG|tranylcypromine|MAO-Inhibitor 60mg-120mg
223801449|NCT04521855|OTHER|Questionnaire|Questionnaires in French on the quality of life, the burden of caregiving and a screening for depressive symptoms, completed during specific interviews.
223801450|NCT00253669|OTHER|laboratory biomarker analysis|
223801451|NCT00253669|OTHER|physiologic testing|
223801452|NCT00253669|PROCEDURE|management of therapy complications|
223801453|NCT03961789|OTHER|patients undergoing opioid replacement therapy|patients undergoing opioid replacement therapy
223801454|NCT05225064|BEHAVIORAL|Incentives to be vaccinated|Individuals will be provided with a guaranteed cash payment, entry into a cash lottery, or guaranteed gift of food if they are vaccinated
223801455|NCT05225064|DEVICE|Mask|Individuals are given cloth masks
223801456|NCT05225064|BEHAVIORAL|Encouragement to wear a mask|Individuals who are not wearing masks over their mouth and nose are stopped in public places and encouraged to wear a mask
223801457|NCT05225064|BEHAVIORAL|Vaccination made more convenient|Vaccines are conducted at the household-level rather than the village-level
223801458|NCT05225064|BEHAVIORAL|Social mobilization campaign to be vaccinated|Village-level social mobilization campaign to be vaccinated
223801459|NCT04606966|OTHER|Therapeutic Horseback Riding|Horse therapy
223801460|NCT04606966|OTHER|Barn Activity|Horsemanship group
223801461|NCT04606966|OTHER|Hybrid|Ground and riding activities
223801462|NCT02669784|DRUG|Low Dose Contrast (Omnipaque) 40mL|The patient will be administered a low dose, 40mL of intravenous contrast (Omnipaque) at a rate of 5mL/sec based on the area of the body being scanned (chest versus chest and abdomen versus chest, abdomen and pelvis). This will be compared to the patient's prior examination performed with 100mL of intravenous contrast at a rate of 4mL/sec.
223801463|NCT02669784|DRUG|Low Dose Contrast (Omnipaque) 50 mL|The patient will be administered a low dose, 50mL of intravenous contrast (Omnipaque) at a rate of 5mL/sec based on the area of the body being scanned (chest versus chest and abdomen versus chest, abdomen and pelvis). This will be compared to the patient's prior examination performed with 100mL of intravenous contrast at a rate of 4mL/sec.
223801464|NCT01806987|BEHAVIORAL|KITS Program|The KITS Program is a 4-month psychosocial intervention for children at high risk for school difficulties and their caregivers. The intervention begins in the summer before kindergarten and continues across the first two months of kindergarten. The KITS intervention consists of: (a) child school readiness play groups to facilitate the development of self-regulatory, social, and early literacy skills (2 times per week in summer, 1 time per week in the fall); and (b) a 12 session psychoeducational workshop to promote parent involvement in the child's early literacy and schooling and the use of effective parenting techniques (once per week in summer, bi-weekly in the fall).
223801465|NCT03856879|BEHAVIORAL|Proactive E-consult|E-consult recommendations and orders will be developed by a panel of pulmonologists and will address a range of care elements for patients with COPD.
223801466|NCT04648150|DEVICE|Evaluation of a millimeter wave emission bracelet for improving Parkinson's disease symptoms|Evaluation of a millimeter wave emission bracelet -type medical device for improving Parkinson's disease symptoms: multicenter, double-blind randomized controlled trial
223801467|NCT06158698|DRUG|Colchicine|Colchicine 1 mg daily (or 0.5 mg daily il weight \<70 kg) from randomization for 180 days (6 months)
223801468|NCT06158698|OTHER|Placebo|Placebo 1 mg daily (or 0.5 mg daily il weight \<70 kg) from randomization for 180 days (6 months)
223801469|NCT01009268|PROCEDURE|Orthogeriatric intervention|The intervention group will be transferred as soon as possible to the orthogeriatric ward, stabilised there preoperatively, and transferred back to the same ward postoperatively for further treatment and rehabilitation, while the control group will be treated in a traditional orthopaedic ward. Operative and anaesthesiologic procedures will be the same in the two groups.Clinical routines for the orthogeriatric service has been developed during the pilot phase in 2008 and 2009, and are documented in the electronic library of clinical handbooks at Department of Geriatric Medicine.
223801470|NCT01774149|DEVICE|Few Touch Application|Users get access to the regular version of the Few Touch Application for Type 1 Diabetes.
223801471|NCT01774149|DEVICE|Diastat|Users get the Few Touch Application with Diastat module activated.
223801472|NCT06979492|BIOLOGICAL|Prophylactic Transfusion Intervention group: Transfusion|"For participants randomized to the prophylactic transfusion intervention group, the first RBC transfusion will occur within 3 weeks of randomization. All transfusions will be managed per SOC.~SOC prophylactic RBC transfusion management is as follows: transfusions are performed at 3-6 week intervals with the intent to maintain a pre-transfusion hemoglobin S level at \<30%. All participants will have a complete blood count, reticulocyte count, hemoglobin fractionation, complete metabolic profile with LDH, ferritin, and type/screen at baseline and within 3 days of all monthly transfusions. All RBC transfusions must be compatible between the recipient and the donor and antigen matched for Rh (D/Cc/Ee) and Kell antigens at a minimum. For participants with a previous history of RBC alloimmunization, extended matched RBCs will be provided (Rh, Kell, Duffy, Kidd, S/s) per NHLBI/ASH guidelines to minimize further alloimmunization."
223801473|NCT06979492|OTHER|Control group|"Participants randomized to the control group will be followed per SOC. SOC management for pregnant women with SCD includes but is not limited to~* Clinic appointments with an SCD provider every 2 months~* Lab draws - complete blood count, reticulocyte count, hemoglobin fractionation, complete metabolic profile with LDH and ferritin."
223801474|NCT06191913|DEVICE|Near-infrared spectroscop|Before the induction of anesthesia, INVOS pediatric SomaSensor probe (Coviden, Dublin, Ireland) was placed on the patient's forearm and then connected to a monitor, which was used to continuously measure and assess the dynamic changes in the StO2
223801475|NCT03389542|PROCEDURE|Surgery|Early mitral valve repair
223801476|NCT03389542|OTHER|Clinical interview and echocardiography|Clinical interview and echocardiography every 6 months.
223801477|NCT06815640|OTHER|recovery|Fatigue protocol
223801478|NCT06656299|DEVICE|ultrasound guided external oblique intercostal plane block|ultrasound guided external oblique intercostal plane block
223801479|NCT06656299|DRUG|Bupivacaine injection|5 ml local anesthetic for each trocar sides
223801480|NCT06656299|DRUG|paracetamol, tramadol, and ondansetron|"As standard multimodal analgesia, 20 min before the end of the surgery patients will receive 1 g of paracetamol, 1-2 mg/kg of tramadol, and 4 mg of ondansetron via intravenous infusion.~All patients will be recovered in the PACU, and after confirming an Aldrete score of \>9, a PCA (patient-controlled analgesia) device will be installed with morphine prepared at a dose appropriate for the patient's age. Patients will be administered paracetamol 1 gr IV every 8 hours in the postoperative period. When patients have a Numerical Rating Scale (NRS) score is ≥ 4, 1 mg/kg iv tramadol will be administered as a rescue analgesic"
223801481|NCT00642187|DRUG|budesonide|
223801482|NCT00642187|DRUG|Placebo|
223801483|NCT01083251|DRUG|Peginterferon + Vitamin D|180 mcg/week + 400 IUX2/day
223801484|NCT01083251|DRUG|Peginterferon|180 mcg/week
223801485|NCT01083251|DRUG|Sebivo|Telbivudine 600 mg daily
223801486|NCT01083251|DRUG|entecavir+ vitamin d|entecavir 1 mg daily+ vitamin d
223801487|NCT04608487|DRUG|Fludarabine|Intravenous infusion
223801488|NCT04608487|DRUG|Cyclophosphamide|Intravenous infusion
223801489|NCT04608487|BIOLOGICAL|Axicabtagene Ciloleucel|Intravenous infusion
223801490|NCT02444065|BEHAVIORAL|Cognitive Behavior Therapy (CBT)|The CBT intervention is a 4 session (1 hour each) individual psychotherapy intervention that uses a manualized treatment protocol developed by the investigators. It uses standard CBT for eating disorders interventions, including orientation to the CBT model, psychoeducation, commitment and goal setting, behavioral strategies for normalizing eating and reducing bulimic symptoms, planning, and homework. 1-2 sessions are delivered before starting day hospital treatment, and the remaining sessions are delivered in the first weeks of day hospital.
223801491|NCT02444065|BEHAVIORAL|Motivational Interviewing (MI)|The MI intervention is a 4 session (1 hour each) individual psychotherapy intervention that uses a manualized treatment protocol (Carter \& Bewell-Weiss, 2012). It uses standard MI for eating disorders interventions, including decisional balance, exploring values, readiness and confidence rules, and MI communication strategies. 1-2 sessions are delivered before starting day hospital treatment, and the remaining sessions are delivered in the first weeks of day hospital.
223801492|NCT02434133|PROCEDURE|Blood Draw/Data Collection|Participation will involve an extra 8ml tube of blood and a review of their medical records for medications and immunization history.
223801493|NCT00326131|DRUG|Oral Taxane|
223801494|NCT00817362|DRUG|IPI-504|IPI-504 IV infusion 300 mg/m2
223801495|NCT00817362|DRUG|Trastuzumab|Trastuzumab IV infusion 8 mg/kg as the first dose of trastuzumab, followed by trastuzumab 6 mg/kg every 3 weeks. Subjects whose last dose of trastuzumab was \<4 weeks prior to study entry will receive 6 mg/kg as the first dose of trastuzumab. For all additional cycles in Stage 1, trastuzumab will be administered with the first dose of IPI-504.
223801496|NCT03289234|DRUG|MCI-186|30 mg of edaravone will be administered intravenously over 60 minutes
223801497|NCT04247672|DEVICE|Total Knee Arthroplasty (uncemented rotating platform ATTUNE)|All patients receive an uncemented ATTUNE rotating platform knee system.
223801498|NCT04915573|DIAGNOSTIC_TEST|Specimen|Sputum will be collected in clean disposable containers
223801499|NCT00863174|DRUG|SPARC147709|SPARC147709 injection
223801500|NCT00863174|DRUG|Reference147709|Reference147709 injection
223801501|NCT03846648|DRUG|Cypep-1|"Eligible subjects will be randomized to one of the two treatment groups in a ratio of 1:1 (active:placebo).~The treatment groups are:~* CyPep-1 topical formulation 1% (w/w)~* Vehicle topical formulation (placebo) The minimum set of studied warts is 1 treated common wart per subject. The subjects will be randomly assigned to treatment. During the treatment period topical formulation will be applied daily on to a maximum of 3 warts. One selected wart will serve as target wart, i.e. the primary wart, for detailed analysis. Selection of warts will be based on the feasibility to conduct treatment application and pharmacodynamics (including biopsy sampling) on the region of interest."
223801502|NCT02821403|DEVICE|clear lens with regular coating|
223801503|NCT02821403|DEVICE|regular coating lens with yellow tint|
223801504|NCT02821403|DEVICE|clear lens with blue-light blocking coating|
223801505|NCT06722976|OTHER|Multicomponent exercise programs|"The program is organized into three phases: (1) Initial assessment; (2) Multicomponent training sessions; (3) Final assessment.~1. The initial assessment will consist of physical fitness tests (lasting around 1 hour) and Neuropsychological Assessment tests (lasting around 1.5 hours).~2. The multicomponent training sessions will last 3 months, twice a week, 50 minutes each session.~3. The final assessment will be the same as the initial assessment (physical fitness tests (about 1 hour) and Neuropsychological Assessment tests (about 1.5 hours)."
223801506|NCT06733064|DIETARY_SUPPLEMENT|Supplementation of vitamin D3|Supplementation of vitamin d3 at a dose of 4000 iu / day
223801507|NCT06733064|DIETARY_SUPPLEMENT|Placebo|Vegetable oil as a placebo
223801508|NCT06732570|DEVICE|high intensity laser|the patient will be in supine position with shoulder uncovered from clothes and wearing laser protective eye glass to protect eye from laser radiation, the dose will be selected from device pathologies list programs number thirty-four with 30% power, frequency continuous, density 16 j/cm2, time automatically adjusted by the device according to the width of scanning area ( superiorly from the acromioclavicular joint down to end of biceps tendon and medially from the coracoid process to the middle fiber of deltoid laterally) and the infrared will be ON.
223801509|NCT06732570|OTHER|manual therapy|manual therapy (mulligan shoulder abduction, deep transverse friction technique on the supraspinatus tendon, scapular mobilization, caudal and posterior humeral mobilization) three session weekly over 5 weeks.
223801510|NCT06732570|OTHER|exercise therapy|therapeutic exercises (rotator cuff strengthening, cools ex's, serratus punch supine ex, pectoralis minor flexibility (focused and gross stretch) and posterior capsule modified sleeper stretching ex's from side)
223801511|NCT06732765|OTHER|Pilates exercise program|Pilates exercise program Will be treated with WBV with Pilate Exercises. Before applying exercise, hot pack will be applied for 15-20minutes
223801512|NCT06732765|OTHER|Traditional physical therapy program|Traditional physical therapy program in form of stretching, strengthening and postural correction exercises
223801513|NCT06733948|DEVICE|Dental stent|Dental stent is personalised device for tongue depressing and immobilisation during RT. The aims are to reduce unnecessary RT doses to adjacent non-target healthy tissue, including the tongue, adjacent oral mucosa, parotid glands/ submandibular glands, and temporomandibular joints. Dentists will take impression of the teeth on moulds, and measure the height to raise the bite, the stent is then fabricated as methyl methacrylate resin in the dental laboratory. The resin base extends to the tongue and a flat plate depresses the tongue. This device will be placed before each RT fraction.
223801514|NCT06733948|OTHER|No dental stent|No dental stent used during chemoradiation treatment
223801515|NCT06732128|OTHER|nature-based virtual reality applications and videos|Participants will receive nature-based applications available on the Oculus platform, as well as nature-based 360 videos with the same content as the control group however in a 360 format.
223801516|NCT06732128|OTHER|nature-based videos|Participants will receive YouTube links to watch nature-based videos on a device (e.g., a tablet).
223801517|NCT06732934|OTHER|exercise (Basic Body Awareness Therapy|"Body Awareness Therapy is a patient-centered physiotherapy approach that also includes mental health, focusing on movement awareness training. This therapy primarily consists of exercises aimed at improving postural disorders, balance, and muscle tension. It aims to help individuals experience and accept bodily responses while increasing coping strategies.~The therapy includes body scanning, integration of sound and movement, stretching exercises, and exercises focusing on body alignment and midline orientation.~Floor exercises: body scanning, stretching, strength accumulation, sound resonance.~Seated exercises: body alignment, trunk rotation, head and neck movements. Standing exercises: support surface perception, midline elevation and lowering, bilateral arm movements, rotation, one-legged balance, voice exercises, and group movements."
223801518|NCT06732934|OTHER|exercise (aerobic exercise)|"The continuous exercise protocol specified by the American College of Sports Medicine (ACSM) will be applied under supervision on a treadmill. The exercise duration will follow ACSM recommendations, starting at 30 minutes in the first week and increasing to 45 minutes by the 12th week.~Exercise intensity will be assessed using the target heart rate method (220 - age). The intensity of aerobic exercise will be set at a moderate level (64-77% HRmax), according to ACSM guidelines.~During exercise, heart rate will be monitored through a heart rate monitoring device. A 5-minute warm-up and a 5-minute cool-down exercise will be performed before and after each session, with an intensity of 50-60% of the maximum heart rate."
223801519|NCT04506970|DIAGNOSTIC_TEST|Comprehensive Doppler Ultrasound of the Placenta|Ultrasound measures to be collected include uterine artery (UtA) and umbilical artery (UA), systolic/diastolic (S/D) ratio, resistance index (RI), pulsatility index (PI) and presence of early diastolic notch.
223801520|NCT04506970|OTHER|Verasonics Ultrasound scanner (ultra-sensitive Doppler imaging)|In addition, a Verasonics ultrasound scanner will be used for ultra-sensitive Doppler imaging. Data will be collected on vessel density, periphery-to-center vessel density ratio (VDR) and microvessel morphology.
223801521|NCT06732622|DEVICE|Laser acupuncture|"Patients in the laser acupuncture group (LA group) received 12 sessions of laser acupuncture (3 times per week). Laser aucpuncture used a class IV Multiwave Locked System (MLS) laser (Mphi laser, ASA Sri, Vicenza, Italy).~Laser acupuncture used have wavelength of 808 nm and 905nm, 1.2 W power (808nm is 1 W, 905 nm is 200 mW), continuous mode emission (808 nm) and pulsed mode emission (905 nm), 500 Hz, 50% power level, 50% duty cycle, 8.35 J/cm2 dosimetry, 26.22 J for each point, administered for 3 times per week in the first 2 weeks, and 1500 Hz, 50% power level, 50% duty cycle, 8.35 J/cm2 dosimetry, 26.22 J for each point, in the last 2 weeks, 12 times total treatment.~Acupoints:~we chose 5 acupoints on the affected side. This includes ST2 (Si Bai), ST4 (Di Cang), ST6 (Jia Che), GB14 (Yang Bai), GB20 (Feng chi). We choose 6 acupoints bilaterally, including LI4 (He Gu), LI11 (Qu Chi), ST36 (Zu San Li), SP6 (San Yin Jiao), KI3 (Tai Xi), and LR3 (Tai Chong)."
223801522|NCT06732622|DRUG|Steroids|Prednisolone as 5 mg tablets (Tianjin Lisheng Pharmaceutical Co., Ltd., China) were given as a single dose of 30 mg daily for the first 3 days; 15 mg daily for the following 3 days; 10 mg daily for the after 3 days; 5 mg daily for the final 3 days, with a total treatment time of 12 days.
223801523|NCT06732622|DEVICE|Sham laser acupuncture|"Patients in the laser acupuncture group (Sham group) received 12 sessions of laser acupuncture (3 times per week). Laser aucpuncture used a class IV Multiwave Locked System (MLS) laser (Mphi laser, ASA Sri, Vicenza, Italy).~The Sham LA group received the same laser device and the same acupoints. The device showed the same red light but did not emit a laser, administered for 3 times per week in the 4 weeks.~Acupoints:~we chose 5 acupoints on the affected side. This includes ST2 (Si Bai), ST4 (Di Cang), ST6 (Jia Che), GB14 (Yang Bai), GB20 (Feng chi). We choose 6 acupoints bilaterally, including LI4 (He Gu), LI11 (Qu Chi), ST36 (Zu San Li), SP6 (San Yin Jiao), KI3 (Tai Xi), and LR3 (Tai Chong)."
223801524|NCT06733714|DEVICE|Transcranial Alternating Current Stimulation|An alternate eletric current of 1.6mA in theta frequency is applied in the scalp, using two eletrodes (5x5cm). The eletrodes are located aiming for the left dorsolateral prefrontal Cortex area.
223801525|NCT06733714|DEVICE|Digital Cognitive Training|Using a tablet, the participant will do exercises that were designed to stimulate cognitive domains, especially attention and memory. In this case, we use the BrainHQ platform.
223801526|NCT06888986|BEHAVIORAL|VR Dementia Prevention Health Education Module|A virtual reality (VR) cognitive health education program designed to enhance knowledge related to dementia, improve health literacy, boost self-efficacy, and shape attitudes towards dementia. Participants engage with 360-degree immersive VR modules using VR headsets that simulate real-world scenarios related to dementia. The intervention comprises five interactive VR sessions, each addressing important topics in dementia prevention and management. Trained research staff will guide participants to ensure safe and effective interaction with the VR system.
223801527|NCT06891040|DRUG|VC005 Placebo group|VC005 Placebo group with Local topical application
223801528|NCT06891040|DRUG|VC005 groups|VC005 group with Local topical application
223801529|NCT06723275|OTHER|Standardized assessments, guided tumor biopsy and biobanking|"Standardized assessment of Scores~* Guided tumor biopsy in patients listed for hepatocellular carcinoma with active tumor at listing in centers not perfoming tumor biopsy on a routine basis~* Additional blood sampling for biobanking and subsequent analysis of innovative biomarkers and OMICs~* Urine sampling for biobanking and subsequent analysis of innovative biomarkers~* Ascite sampling for biobanking and subsequent analysis~* Tumor sampling for biobanking and subsequent analysis~* Centralized assay for routine biomarkers"
223801530|NCT06723275|OTHER|Standardized assessments and biobanking|"* Standardized assessment of Scores~* Additional blood sampling for biobanking and subsequent analysis of innovative biomarkers and OMICs~* Urine sampling for biobanking and subsequent analysis of innovative biomarkers~* Ascite sampling for biobanking and subsequent analysis~* Tumor sampling for biobanking and subsequent analysis~* Centralized assay for routine biomarkers"
223801531|NCT04711889|DRUG|Ulinastatin|Ulinastatin is taken three times a day.
223801532|NCT04711889|DRUG|Blank control|Blank control
223801533|NCT06750731|DEVICE|Tappt|"Tappt is a web-based system designed to record participants medication taking behavior and bowel symptoms. Participants will be assigned smart labels for their specific vedolizumab regimen, which will be used by participants to record their vedolizumab use. Participants will be shipped smart labels to be affixed to an IV card for the first three infusions and for subsequent infusions or injections. At the time of a vedolizumab dose, participants will scan the smart label by tapping it with their mobile device to verify that they are taking the medication. Each day that vedolizumab is due, patients will receive a reminder through SMS message. If participants fail to scan the label at a given time (as expected by their specific medication regimen), they will receive an end of day text message reminder. Participants will also complete a patient reported outcome assessment at baseline, weekly for 6 weeks, and then monthly for the entire 22 weeks of the study triggered by the system."
223801534|NCT06777758|DRUG|Remimazolam|Remimazolam
223801535|NCT06777758|DRUG|Propofol|Propofol dose reduction ratio
223801536|NCT06535061|OTHER|white noise|The experimental group was exposed to a white noise sound combined from 4 different sounds: ultrasound heartbeat sound, wave sound, vacuum cleaner sound and hair removal machine sound at 50 dBSPL 5 minutes before the procedure. The experimental group was exposed to white noise for a total of 15 minutes before, during and after the procedure. At the same time, the newborn in the experimental group I was given a pacifier.
223801537|NCT07094347|DEVICE|inspiratory muscle training|Powerbreathe® threshold resistance loading device (POWERbreathe, HaB International) will be used for this training program that strengthens the inspiratory muscles. The PowerBreathe® device is a threshold device that creates resistance to inspiration. This resistance is created by the spring tension in the device mechanism. The device has a mechanism that is adjusted according to 9 different levels in its mechanism specific to the individuals using it.
223801538|NCT07093320|OTHER|No intervention|No intervention
223801539|NCT03303612|DEVICE|Pacemaker implant|Patient will be in the electrophysiology laboratory. The doctor will freeze the groin area and a medication may be given to help the patient relax. A catheter will be inserted into the groin up to the heart and the heart's electrical system will be recorded.
223801540|NCT03303612|DEVICE|Transcutaneous cardiac monitor|"Transcutaneous cardiac patches will allow continuous electrocardiographic monitoring for a 30-day period. For the first randomized patients at the Montreal Heart Institute, Icentia was used and then was changed to a m-Health® device which allows continuous cardiac monitoring. The PocketECG from m-Health® is attached to 3 electrodes on the chest and contains a SIM card that transmits to a server located in Burlington, Ontario .The COME-TAVI coordinating center and the associated site will be informed rapidly of any events that occur . These events include:~Ventricular fibrillation; Sustained ventricular tachycardia Any RR interval \>5 sec; Third-degree AV block or Mobitz 2 AV block;"
223801541|NCT03902054|BIOLOGICAL|Three-dose regimen of high dosage investigational sIPV|The investigational vaccines were manufactured by Beijing Minhai Biotechnology Co. Ltd..
223801542|NCT03902054|BIOLOGICAL|Three-dose regimen of medium dosage investigational sIPV|The investigational vaccines were manufactured by Beijing Minhai Biotechnology Co. Ltd..
223801543|NCT03902054|BIOLOGICAL|Three-dose regimen of low dosage investigational sIPV|The investigational vaccines were manufactured by Beijing Minhai Biotechnology Co. Ltd..
223801544|NCT03902054|BIOLOGICAL|Three-dose regimen of commercialized sIPV|The control vaccine was manufactured by Chinese Academy of Medical Sciences.
223801545|NCT03902054|BIOLOGICAL|Three-dose regimen of commercialized IPV|The control vaccine was manufactured by Sanofi Pasteur S.A (IMOVAX POLIO).
223801546|NCT06914167|BEHAVIORAL|Slow Breathing Exercises|Participants will perform slow breathing (6 breaths/min) for 3 minutes daily before bedtime
223801547|NCT06914167|BEHAVIORAL|Lavender Essential Oil Inhalation|inhalation of 3 drops of lavender essential oil on a towel,
223801548|NCT06914167|BEHAVIORAL|linalyl acetate essential oil Inhalation|inhalation of 3 drops of linalyl acetate essential oil on a towel.
223801549|NCT06914167|BEHAVIORAL|linalool essential oil Inhalation|inhalation of 3 drops of linalool essential oil on a towel.
223801550|NCT01516047|DRUG|Cohort 1|125 mg to 2000 mg abiraterone acetate suspension on Day 1
223801551|NCT01516047|DRUG|Cohort 2|2000 mg abiraterone acetate suspension on Day 1
223801552|NCT02651766|PROCEDURE|Cupping massage|Using suction on the skin by means of glass cups, and moving the cups after applying massage oil on the skin
223801553|NCT06388694|OTHER|Pharmacist Care|Pharmacists will provide ADHD medication refill orders in response to secure message requests by parents, under the authorization of appropriate physicians.
223801554|NCT06388694|OTHER|Primary Care Physician Care|Primary care pediatricians will provide ADHD medication refill orders in response to secure message requests by parents. This is usual care.
223801555|NCT06190301|DRUG|Rituximab|Intralesional Rituximab Injection
223801556|NCT06190301|RADIATION|Involved Site Radiation Therapy|Involved Site Radiation Therapy
223801557|NCT05911503|DRUG|2% Ganciclovir Eye Drops|Administration method and dosage adjustment: 2% ganciclovir eye drops, 10 times/day for two weeks, 8 times/day for two weeks, 6 times/day for two weeks, 4 times/day for more than 6 weeks
223801558|NCT01046539|DRUG|RDC-0313 + Buprenorphine|1 and 4 mg (1 dose for each) + 8 mg
223801559|NCT01046539|DRUG|Placebo|0 mg
223801560|NCT06950619|GENETIC|Whole Genome Sequencing|Genetic testing will be performed to find variants in genes involving congenital cataract and/or ocular diseases (keratitis, keratoconus, corneal dystrophies, ectopia lentis, glaucoma, retinitis pigmentosa, coloboma and aniridia) and dental anomalies (tooth agenesis, supernumerary teeth, Hutchinson teeth, mulberry molars). Cutaneous appendage anomalies will be also evaluated in clinical history for ascertaining ectodermal diplasia.
223801561|NCT06950619|OTHER|Cephalometric tracing|Cephalometric tracing will be performed on lateral cephalometric radiographs if present and not taken on purpose for the study
223801562|NCT00230828|DRUG|bifeprunox|
223801563|NCT04514341|OTHER|Short Message Service (SMS)|Patients with FIT orders receive seven messages over 60 days to remind them to return their kits for testing. Patients with colonoscopy orders receive eight messages to remind them to schedule an appointment for a colonoscopy over 90 days. After confirming their colonoscopy appointment, the patient gets educational messages on bowel preparation.
223801564|NCT04514341|OTHER|Remote Patient Navigation|Patient navigators at our partner FQHCs called patients who received a screening order for more than 60 days but failed to complete it or who had a positive stool-based test and needed a follow-up diagnostic colonoscopy.
223801565|NCT04295005|DRUG|Empagliflozin|film coated tablet
223801566|NCT04295005|DRUG|DPP-4i|film coated tablets, specifically Sitagliptin
223801567|NCT04295005|DRUG|GLP-1-RA|subcutaneous injection or tablet
223801568|NCT03169387|BEHAVIORAL|Virtual Reality|For the VRG training, Microsoft's Xbox 360® will be used with Kinect™, which features an infrared camera sensor that recognizes user movements without a controller. The games used will be YourShape™(Fitness Evolved) and Dance Central 3™, which will be played for 25 minutes each; the former will be associated with the use of Velcro weights on the ankles and dumbbells in the hands to provide resistance.
223801569|NCT03169387|BEHAVIORAL|Conventional Training|treadmills (embreex) will be used to perform the aerobic training for a period of 30 minutes and free weights and weight training equipment for the resistance training, which will be carried out in 3 sets of 10 repetitions, with a recovery interval of 1 minute between sets.
223801570|NCT01128803|PROCEDURE|injection of the cell therapy product|Between D-15 and D-30: Cytapheresis D0: 1st injection of the cell therapy product D21: 2nd injection of the cell therapy product D42: 3rd injection of the cell therapy product and 1 injection of dendritic cells not loaded D45: cutaneous biopsies if induration \> 2mm
223801571|NCT06176261|DRUG|Datopotamab Deruxtecan|Antibody-drug conjugate, 100 mg single-use vial, via intravenous infusion per protocol.
223801572|NCT00596843|BEHAVIORAL|Motivational interviewing|6 one-on-one individual sessions lasting from 30 minutes to 1-hour each
223801573|NCT00596843|BEHAVIORAL|Educational intervention|6 1-hour sessions. 2 sessions are delivered by an interventionist and 4 sessions are delivered as videos
223801574|NCT03502486|OTHER|Moderate exercise|20 minutes of cycle ergometry at 50-60% of heart rate max
223801575|NCT03502486|OTHER|Intense exercise|20 minutes of cycle ergometry at 70-80% of heart rate max
223801576|NCT03502486|OTHER|Reading|20 minutes of seated reading
223801577|NCT02259179|DRUG|Reference naltrexone 8 mg SR/bupropion 90 mg SR combination trilayer tablets (2 tablets)|
223801578|NCT02259179|DRUG|Test naltrexone 8 mg SR/bupropion 90 mg SR combination trilayer tablets (2 tablets)|
223801579|NCT02643576|BEHAVIORAL|F&V Bonus|To examine the independent effect of offering an incentive (i.e. bonus dollars for fruit and vegetable purchases) to SNAP-like benefits to encourage the purchase of more healthful foods
223801580|NCT02643576|BEHAVIORAL|Restriction|To examine the independent effect of prohibiting the use of SNAP-like benefits to purchase foods high in discretionary calories (i.e.sugar-sweetened beverages, candy, or sweet baked goods) on food purchases and diet quality
223801581|NCT02643576|BEHAVIORAL|Bonus & Restriction|To examine the joint effects of prohibiting the use of SNAP benefits to purchase foods high in discretionary calories and offering an incentive to encourage the purchase of more healthful foods
223801582|NCT05095805|BEHAVIORAL|additional weight-bearing exercise|Nintendo Wii Balance Board, real-time visual feedback, weight-bearing assessment by center of pressure
223801583|NCT05095805|BEHAVIORAL|standard weight-bearing exercise|conventional training for fitting of initial prosthesis
223801584|NCT01976065|DRUG|Triple Antibiotic Paste|USP antibiotic drugs mixed at a 1:1:1 ratio into a powder that is mixed with sterile saline to a paste-like consistency
223801585|NCT01976065|OTHER|Standard Treatment|Standard Treatment no use of study drug
223801586|NCT05794438|BEHAVIORAL|Static Approach Bias Modification|In the static approach bias modification, users were instructed to swipe upward when they see portrait format images and swipe downward when they see landscape format images. A shrinking animation comes after swiping upward to simulate the visual effect of moving away (approach), and a growing animation comes after swiping downward to simulate the visual effect of moving towards (avoidance). Two types of images, namely drug-related and non-drug-related, were used in the training. The drug-related images were related to methamphetamine (methamphetamine crystals, powders, and paraphernalia), and the non-drug-related images were related to healthy lifestyles (wealth, sports, gourmet, family activities, etc).
223801587|NCT05794438|BEHAVIORAL|Adaptive Approach Bias Modification|In the adaptive approach bias modification, users were instructed to swipe upward when they see portrait format images and swipe downward when they see landscape format images. A shrinking animation comes after swiping upward to simulate the visual effect of moving away (approach), and a growing animation comes after swiping downward to simulate the visual effect of moving towards (avoidance). Two types of images, namely drug-related and non-drug-related, were used in the training. The drug-related images were related to methamphetamine (methamphetamine crystals, powders, and paraphernalia), and the non-drug-related images were related to healthy lifestyles (wealth, sports, gourmet, family activities, etc). An algorithm continuously monitors the performance of the user and adjusts the ratio of congruent and incongruent trials accordingly to attain a desired difficulty curve.
223801588|NCT02218827|DRUG|Loteprednol Etabonate (FML)|a steroid topical treatment used for moderate dry eye symptoms. this drug causes less increase in intra ocular pressure
223801589|NCT04156490|OTHER|No intervention is planned, this will be a purely retrospective trial.|Osmotic Therapy
223801590|NCT00836082|DRUG|PF-04457845, FAAH inhibitor|Oral solution of 0.5mg given once daily for 14 days.
223801591|NCT00836082|DRUG|PF-04457845, FAAH inhibitor|Oral solution of 1mg given once daily for 14 days.
223801592|NCT00836082|DRUG|PF-04457845, FAAH inhibitor|Oral solution of 4mg will be administered as a single dose 7-14 days prior to the multiple dosing phase where 4mg will be administered once daily for 14 days.
223801593|NCT00836082|DRUG|PF-04457845, FAAH inhibitor|A randomized food treatment will be administered 7-14 days prior to and on day 1 of the multiple dosing phase
223801594|NCT00836082|DRUG|PF-04457845, FAAH inhibitor|Oral solution of 8mg will be administered as a single dose 7-14 days prior to the multiple dosing phase where 8mg will be administered once daily for 14 days.
223801595|NCT00836082|DRUG|PF-04457845, FAAH inhibitor|A randomized food treatment will be administered 7-14 days prior to and on day 1 of the multiple dosing phase
223801596|NCT04876794|DEVICE|ABLE Exoskeleton|Participants with SCI will undergo a training programme with the ABLE Exoskeleton device three times a week for four to six weeks for a total of 12 sessions.
223801597|NCT05100264|OTHER|Vaginal washing with 5% acetic acid|Induction of labor (vaginal tablet dinoprostone and vaginal washing with 5% acetic acid)
223801598|NCT05100264|OTHER|Vaginal washing with 0.9% NS|Induction of labor (vaginal tablet dinoprostone and vaginal washing 0.9% NS)
223801599|NCT05981118|DRUG|Betamethasone dipropionate 0.05%|0.05% cream group will be treated once daily on both legs until clear or up to 12 weeks
223801600|NCT05981118|DRUG|Tapinarof|1% tapinarof cream applied once daily to both legs until clear or up to 12 weeks
223801601|NCT01139190|DRUG|PL3100|Oral administration
223801602|NCT01139190|DRUG|Naproxen|Oral administration
223801603|NCT05166538|DRUG|Ticagrelor|direct-acting oral P2Y12-receptor antagonist
223801604|NCT05166538|DRUG|Clopidogrel|platelet aggregation inhibitor
223801605|NCT05618548|BIOLOGICAL|COVID-19 vaccine|COVID-19 vaccine available at the moment of vaccination: either the Comirnaty vaccine (mRNA, Pfizer BioNtech), the Moderna vaccine (mRNA, Moderna), the Vaxzevria vaccine (Viral Vector, Astra Zeneca).
223801606|NCT05049408|DIAGNOSTIC_TEST|MMP-1 Enzyme Linked Immunosorbent assay (ELISA)|The MMP-1 ELISA is to measure salivary MMP-1 levels of participants
223801607|NCT02127372|DRUG|Docetaxel, Cisplatin and STI571|"Treatment will consist of docetaxel plus cisplatin IV every 21days and oral STI571 given on Days -5 to 2 with each chemotherapy cycle. A maximum of 6 cycles will be given.~Phase 1 dose levels are:~* Level 1 Docetaxel/Cisplatin 60 mg/m2, STI571 300mg~* Level 2 Docetaxel/Cisplatin 60 mg/m2, STI571 400mg~* Level 3 Docetaxel/Cisplatin 70 mg/m2, STI571 400mg~* Level 4 Docetaxel/Cisplatin 70 mg/m2, STI571 600mg~* Level 5 Docetaxel/Cisplatin 75 mg/m2, STI571 600mg~* Level 6 Docetaxel/Cisplatin 75 mg/m2, STI571 800mg~Once the MTD level has been established, the previous dose level will be the dosing schedule for Phase II."
223801608|NCT02127372|DRUG|Docetaxel|
223801609|NCT02127372|DRUG|Cisplatin|
223801610|NCT00169000|DRUG|Capecitabine|"Capecitabine at the following dose levels for 14 days every 21 days, beginning with dose level 1~Dose level -2 600 mg/m2 po BID~Dose level -1 700 mg/m2 po BID~Dose level 1 825 mg/m2 po BID~Dose level 2 1000 mg/m2 po BID"
223801611|NCT00169000|DRUG|Docetaxel|75 mg/m2 over one hour on day 8 of each cycle
223801612|NCT04123925|DRUG|Nivolumab|Locally advanced colon cancer must be documented at screening (within 21 days prior to initiation of study treatment) and re-assessed prior surgery by spiral or multidetector computed tomography (CT) scan Postoperatively, standard adjuvant chemotherapy will be administered in pathological III-stage and at investigator discretion in pathological II-stage at high risk
223801613|NCT00498979|BIOLOGICAL|recombinant interferon alfa-2b|recombinant interferon alfa-2b
223801614|NCT00498979|DRUG|cisplatin|recombinant interferon alfa-2b
223801615|NCT00498979|DRUG|sodium stibogluconate|sodium stibogluconate
223801616|NCT00498979|DRUG|dacarbazine|dacarbazine
223801617|NCT00498979|DRUG|vinblastine|vinblastine
223801618|NCT06049264|OTHER|Thoracic spine manual traction with mobilization protocol.|The therapist will perform one 30-second bout of grade I or II central posterior-anterior mobilization at the T3 spinous process as described by Maitland et al. After the 30-second bout, the therapist proceeded to T4 and performed the same technique. This process was continued sequentially in a caudal direction to T8, for an overall intervention time of approximately 3 minutes. In addition to mobilization, thoracic spine traction will be also given in sitting position.
223801619|NCT06049264|OTHER|Thoracic manipulation protocol|To perform the manipulation, the stabilizing hand will be placed at the level immediately caudal to the restricted segment using a ''pistol grip''. Once the pre manipulative position will be achieved the patient will be instructed to take a deep inhalation and exhale. During the exhalation the treating clinician performed a high velocity, small amplitude thrust in a direction to facilitate relative closing or opening of the respective facet joint as indicated by the segmental examination.
223801620|NCT02611739|DEVICE|Medi-Port|Treatment
223801621|NCT02611739|DEVICE|Medi-Port|Control
223801622|NCT03502655|OTHER|Experimental: Intervention message (first phase)|Effect of positive communication on pain during intravenous cannulation in an emergency department delivered by a recorded message
223801623|NCT03502655|OTHER|Placebo Comparator: Control message (first phase)|Effect of usual communication on pain during intravenous cannulation in an emergency department delivered by a recorded message
223801624|NCT03502655|OTHER|Experimental: Intervention message (second phase)|Effect of positive communication on pain during intravenous cannulation in an emergency department delivered by a care provider
223801625|NCT03502655|OTHER|Placebo Comparator: Control message (second phase)|Effect of usual communication on pain during intravenous cannulation in an emergency department delivered by a care provider
223801626|NCT06732739|OTHER|percussions with teach-back breathing exercise|"patient will receive Teach Back Breathing Exercises like pursed lip breathing, DE breathing and diaphragmatic breathing Teach-back breathing exercises refer to a method of instructing individuals in breathing techniques and then having them demonstrate or teach back the instructions to ensure comprehension and mastery. This educational approach is commonly used in healthcare settings, particularly when teaching patients how to perform various breathing exercises for therapeutic purposes. Patients were informed about the importance of regular chest percussion I will use the clapping technique which provided by cupped hand for 3 minutes in 5 positions of drainage (upper lobes-apical and posterior segment, apical and anterior segment, right upper lobe-posterior segment, left upper lobe-posterior segment, lower lobes- apical segment) with assisted suction three times/shift for four days, and then each patient will be observed."
223801627|NCT06732739|OTHER|PERCUSSION|similar to Group A, each patient underwent individual interviews. Patients were educated on the significance of regular chest percussion. The clapping technique, executed with cupped hands, was applied for 3 minutes in five drainage positions (upper lobes - apical and posterior segment, apical and anterior segment, right upper lobe - posterior segment, left upper lobe - posterior segment, lower lobes - apical segment). This procedure, including assisted suction three times per shift, was administered for four consecutive days.
223801628|NCT05452655|BEHAVIORAL|Multidisciplinary Intensive Rehabilitation|"The rehabilitation program will last for 6 consecutive weeks and involves the execution of 30 sessions, 5 days a week lasting 160 '/ day each (80' motor; 40 'cognitive and 40' speech therapy rehabilitation) for 3 days a week and 180'/ day (80 'motor; 60' cognitive and 40 'speech therapy rehabilitation) for 2 days a week. The EXP group will receive 18 sessions (3 times a week) of treadmill (20 min), balance exercises and functional reinforcement (20 min). The remaining motor sessions will be defined based on the patient's therapeutic needs.~The cognitive treatment will be proposed both in traditional mode (3 times a week) and through the support of semi-immersive Virtual Reality Rehabilitation System (VRRS) (2 times/week). The VRRS treatment is structured in 2 sessions per week (60 min) for 6 consecutive weeks.~The speech therapy program will include clinical and instrumental evaluations and innovative techniques will be used for the treatment (biofeedback with Vitalstim)."
223801629|NCT05452655|BEHAVIORAL|Muscle-stretching and active mobilization exercises|The control group subjects will undergo a home-based self-treatment program for 40 '/ day for 6 consecutive weeks consisting of muscle-stretching and active mobilization exercises.
223801630|NCT02221401|DRUG|Linagliptin/Metformin FDC|
223801631|NCT02221401|DRUG|Linagliptin|
223801632|NCT02221401|DRUG|Metformin|
223801633|NCT01708330|DRUG|Lidocaine|2% Lidocaine gel
223801634|NCT01708330|DRUG|Placebo gel|odorless, colorless gel will be used as a placebo
223801635|NCT02546830|DEVICE|FreeO2 v2.2 active|"* Automatic adjustment of oxygen through the Free O2 device.~* FreeO2 device in mode medical data collecting(SpO2,EtCO2...)."
223801636|NCT02546830|DEVICE|FreeO2 v2.2 with manual oxygenation|"* Manual adjustment of oxygen without the assistance of the FreeO2 device.~* Only FreeO2 device in mode medical data collecting(SpO2,EtCO2...)."
223801637|NCT05179967|DEVICE|WeFlow-JAAA Stent Graft System|WeFlow-JAAA Stent Graft System consists of abdominal main body of inner embedded stent graft , abdominal main bifurcation stent graft, extension stent graft and branch stent graft. The abdominal main body of inner embedded stent graft is composed of abdominal main embedded covered stent and conveyor, the abdominal main bifurcated stent graft is composed of abdominal main bifurcated stent and conveyor, the extended stent is composed of extended stent graft and conveyor, and the branch vascular stent graft is composed of branch vascular stent and conveyor. The abdominal main body of inner embedded stent graft, abdominal main bifurcation stent graft, extension stent graft and branch vascular stent graft are pre-installed in the corresponding conveyor respectively.
223801638|NCT00538551|OTHER|Database|Database
223801639|NCT00770107|DRUG|Thiamine|Supplementation of thiamine (vitamin b1) 300 mg per day, once daily, for a duration of 4 weeks
223801640|NCT00770107|DRUG|Placebo|Placebo, once daily, for a duration of 4 weeks
223801641|NCT00900874|DRUG|salbutamol|two puffs (100 microgram each of salbutamol) by MDI and spacer
223801642|NCT00900874|DRUG|Formoterol|Formoterol 2 puffs (6 µg /puff) by MDI and spacer
223801643|NCT02808936|PROCEDURE|Remote ischemic preconditioning|three cycles of ischemia (5 min) / reperfusion (5 min) of available upper or lower limb with an automated machine using blood pressure cuff
223801644|NCT02808936|PROCEDURE|Sham control|The patients had the same pneumatic cuff around the upper arm and similar maneuvers were performed, but pressure was not applied to the cuff.
223801645|NCT02281448|DRUG|BIA 2-093|
223801646|NCT02281448|DRUG|Contraceptives, Oral, Combined|
223801647|NCT03983187|DEVICE|Rotating Magnetic Therapy|Rotating Magnetic Therapy 30min/ Bid for 1 month
223801648|NCT03320018|DRUG|Hydrogen|Hydrogen will be infused into bags of normal saline solution and administered intravenously, or hydrogen generating tablets will be dissolved into water for the patient to drink, as the patient's condition permits. This will be administered TID for 3 days.
223801649|NCT03320018|DRUG|Minocycline|"Minocycline 200 mg will be mixed with normal saline and given by i.v. administration, or provided as capsules for the patient to swallow, q 24 hours for 5 days.~Once patients regain the ability to swallow capsules, minocycline will be given orally in capsule form (2 capsules of 100 mg each), administered once daily for the remainder of the 5 day period."
223801650|NCT03320018|OTHER|Placebo Hydrogen|"Normal saline solution will be administered intravenously, in place of hydrogen solution.~Placebo tablets will be dissolved into water for the patient to drink, as the patient's condition permits. This will be administered TID for 3 days."
223801651|NCT03320018|OTHER|Placebo Minocycline|Normal saline solution or placebo capsule will be administered i.v. or p.o. respectively, in place of minocycline.
223801652|NCT05365321|DRUG|WP1122|Doses from 8 mg/kg will be increased in doubling increments up to 64 mg/kg in the dose escalation Phase 1 portion of the study, administered orally (PO) for 10 days q12h ±1h. The dose in Phase 2 will utilize the Maximum Tolerated Dose (MTD) established in Phase 1 and also administered PO q12h ± 1h for 10 days.
223801653|NCT05687968|BEHAVIORAL|Real-Time Personalized Dietary Feedback (via AI and Nutritionist)|"* Behavioral: 3D/AR MetaFood Portion Size and Nutrition Education~* Behavioral: Nutrition and Physical Activity Educational Videos"
223801654|NCT05687968|BEHAVIORAL|conventional nutrition education by dietitian|The participants receive conventional health and nutrition education from state registered dietitian.
223801655|NCT02398929|DRUG|Bisoprolol 2.5 mg|Bisoprolol 2.5 mg will be given once daily
223801656|NCT02398929|DRUG|Placebo|Placebo tablets will be given once daily for 2 weeks during the run-in period.
223801657|NCT00616187|DRUG|interferon beta treatment to add-on atorvastatin treatment|IFN-β-1a 22 µg s.c. 3 times weekly or IFN-β-1b s.c. every other day (3 months baseline) and add on oral daily 80 mg atorvastatin (9 months add on treatment)
223801658|NCT00616187|DRUG|untreated to atorvastatin treatment|no treatment(3 months baseline)and oral daily 80 mg atorvastatin (9 months add on treatment)
223801659|NCT03440749|OTHER|luminous stimuli|The child is placed in front of a screen on which 4 luminous stimuli are presented on a horizontal plane. Four buzzers are placed in front of him, each buzzer corresponds to the position of a stimulus. Child had to push the buzzer corresponding to the place of the luminous stimuli.
223801660|NCT05360082|OTHER|[11C]UCB-J PET|11C-labeled SV2A binding PET radioligand
223801661|NCT05360082|OTHER|[18F]SynVest-1 PET|18F-labeled SV2A binding PET radioligand
223801662|NCT01977300|DRUG|Valproate|serum level of 50 to 125 ug/L
223801663|NCT01977300|DRUG|Lithium|serum levels of 0.6 to 1.2 mmol/L
223801664|NCT01977300|DRUG|Risperidone|1 to 6 mg/day
223801665|NCT01977300|DRUG|Olanzapine|5 to 25 mg/day
223801666|NCT01977300|OTHER|Placebo|manufactured to mimic risperidone and olanzapine
223801667|NCT06048731|DEVICE|Defibrillation using EV-ICD|Device: Defibrillation using the Extravascular ICD (EV-ICD)
223801668|NCT01487317|DRUG|Rivastigmine transdermal patch|One transdermal patch of Rivastigmine (equivalent to 4.6 mg/24h per os) per day from randomization to day 14 before day 14: end od treatment, if DRS R-98 severity \< 10 during 2 consecutive days At day 14, if DRS R-98 severity ≥ 10: one transdermal patch of Rivastigmine 9.5 mg/24h per day from day 14 to day 30 if DRS R-98 severity \< 10, the active treatment will be stopped
223801669|NCT01487317|DRUG|placebo patch|One transdermal patch of placebo per day from randomization to day 14 Before day 14: end of treatment if DRS R-98 severity \< 10 during 2 consecutive days, At day 14 if DRS R-98 severity ≥ 10: One transdermal patch of placebo per day from day 14 to day 30 if DRS R-98 severity \< 10, the placebo treatment will be stopped
223801670|NCT04653402|DEVICE|Hydrocelectomy surgery|The standardized hydrocelectomy operation i.e. Eversion of the TVT sac
223801671|NCT01973660|DRUG|Lapatinib|
223801672|NCT01973660|DRUG|Trastuzumab|
223801673|NCT01973660|DRUG|Endocrine Therapy|Letrozole or tamoxifen will be prescribed according to patient's menopausal status
223801674|NCT01973660|DRUG|Paclitaxel|Only administrated if tumor progression is observed by US on week 6
223801675|NCT03300791|OTHER|Admitted|Readmitted patients in the next months after an episode of aute heart failure will be recruited. Controls will be selected between those who were admitted in the baseline but not readmitted in this month.
223801676|NCT04434807|PROCEDURE|Minimally invasive hematoma evacuation|Neurosurgery performed via burr hole or minicraniotomy and using the Aurora surgiscope and evacuator (Integra Lifesciences)
223801677|NCT05736562|DIETARY_SUPPLEMENT|Ritual Epre Multimineral-Vitamin Supplement|The Ritual Epre supplement is a commercially available multivitamin-mineral supplement designed for pregnant and lactating women.
223801678|NCT05736562|DIETARY_SUPPLEMENT|Placebo Control|This is a customarily designed blank placebo provided by Ritual.
223801679|NCT01939704|OTHER|Pediatric Primary Care Intervention|30 minute on-site intervention with biweekly follow up phone calls to address social needs and health care status.
223801680|NCT01939704|OTHER|Pediatric Urgent Care Intervention|3 months of intervention protocol, including a 30 minute on-site intervention and twice monthly phone calls to address social needs and health care status.
223801681|NCT00717639|PROCEDURE|Diagnostic MR-Angiography|Single MR-Angiography of the lower extremity after the bolus injection 0.03mmol/kg BW Vasovist
223801682|NCT03608280|PROCEDURE|Bone autograft|The principle of this surgery is based on the removal of a portion of the outer bone layer from the vault of the skull in order to have a flat and solid bone element (cortical bone), which can be carved freehand to better replace the defective bone wall.
223801683|NCT03608280|PROCEDURE|Orbital reconstruction by 3D-printed porous titanium implant|"From data of a patient's CT-scan, it is possible to perform a mirroring. The unaffected orbit is mirrored onto the affected orbit, via a virtual treatment planning, in order to rely on facial symmetry to virtually restore healthy anatomy. From this simulation, the implant is 3D-printed by Selective Laser Melted (SLM) technique using titanium powder. This technique enabling the creation of custom-made implants is called computer-aided design and computer-aided manufacturing (CAD-CAM).~After sterilization, the implant is ready to be placed during a surgical procedure."
223801684|NCT03754179|DRUG|Dabrafenib|"Upfront treatment with dabrafenib, trametinib and hydroxychloroquine in phase 1 and Arm A phase 2.~Upfront treatment with dabrafenib and trametinib in Arm B phase 2 with add-on of hydroxychloroquine at progression of disease"
223801685|NCT03754179|DRUG|Trametinib|"Upfront treatment with dabrafenib, trametinib and hydroxychloroquine in phase 1 and Arm A phase 2.~Upfront treatment with dabrafenib and trametinib in Arm B phase 2 with add-on of hydroxychloroquine at progression of disease"
223801686|NCT03754179|DRUG|Hydroxychloroquine|Upfront treatment with dabrafenib, trametinib and hydroxychloroquine in phase 1 and Arm A phase 2. Add-on at progression of disease in Arm B phase 2
223801687|NCT03311412|DRUG|Sym021|Sym021 is a humanized antibody that binds PD-1 with sub-nanomolar affinity and blocks binding of the inhibitory ligands PD-L1 and PD-L2, thus releasing PD-1-mediated inhibition of the immune response.
223801688|NCT03311412|DRUG|Sym022|Sym022 is a recombinant, fully human antibody that binds LAG-3 and blocks the LAG-3/major histocompatibility complex class II (MHC-II) interaction, thus allowing for increased T-cell proliferation and cytokine production.
223801689|NCT03311412|DRUG|Sym023|Sym023 is a recombinant, fully human antibody that binds TIM-3 and induces activation of immune cells.
223801690|NCT04208516|PROCEDURE|Continuous Erector Spinae Plane Nerve Block|To be administered to subjects in the active comparator group receiving primary unilateral thoracic surgery.
223801691|NCT04208516|PROCEDURE|Continuous Quadratus Lumborum Nerve Block|To be administered to subjects in the active comparator group receiving primary major abdominal surgery.
223801692|NCT04208516|PROCEDURE|Single Erector Spinae Plane Nerve Block|To be administered to subjects in the experimental group receiving primary unilateral thoracic surgery.
223801693|NCT04208516|PROCEDURE|Single Quadratus Lumborum Nerve Block|To be administered to subjects in the experimental group receiving primary major abdominal surgery.
223801694|NCT04208516|DRUG|Lidocaine IV|To be given postoperatively as a continuous infusion at a dose of 50 mg/hr in the experimental group.
223801695|NCT04208516|DRUG|Ropivacaine 0.5% Injectable Solution|To be used in both treatment arms as nerve block initial bolus injection.
223801696|NCT04208516|DRUG|Dexamethasone|To be used in the experimental arm as a nerve block adjuvant to promote prolonged single block duration, as is standard of care in this institution.
223801697|NCT04208516|DRUG|Dexmedetomidine|To be used in the experimental arm as a nerve block adjuvant to promote prolonged single block duration, as is standard of care in this institution.
223801698|NCT04208516|DRUG|Lidocaine|To be used perineurally as a 0.25% solution in the active comparator group at a rate of 10 ml/hr per perineural catheter.
223801699|NCT04020341|DRUG|Gepotidacin|Gepotidacin will be available as tablets containing 750 mg gepotidacin. Each dose should be taken with water after consumption of food.
223801700|NCT04020341|DRUG|Placebo matching nitrofurantoin|Placebo matching nitrofurantoin will be available as over-encapsulated unit-dose capsules. Each dose should be taken with water after consumption of food.
223801701|NCT04020341|DRUG|Nitrofurantoin|Nitrofurantoin will be available as over-encapsulated capsules containing 25 mg nitrofurantoin macrocrystals and 75 mg nitrofurantoin. Each dose should be taken with water after consumption of food.
223801702|NCT04020341|DRUG|Placebo matching gepotidacin|Placebo matching gepotidacin will be available as unit-dose gepotidacin placebo-to-match tablet. Each dose should be taken with water after consumption of food.
223801703|NCT05763628|DEVICE|Control Lens (stenfilcon A)|Daily Disposable Multifocal Contact Lens for 2 weeks
223801704|NCT05763628|DEVICE|Test Lens (senofilcon A)|Daily Disposable Multifocal Contact Lens for 2 weeks
223801705|NCT05574725|DEVICE|Smartphone|review of the smartphone video on patients phone by general neurologist and epileptogist each separately with comment on onquality of video using videoquality scale(10), semiology, seizure diagnosis
223801706|NCT02351219|DRUG|FOLFOXIRI|
223801707|NCT02098980|DIETARY_SUPPLEMENT|Vitamin D|
223801708|NCT04683926|DRUG|Desmetramadol|Analgesic
223801709|NCT00346021|BEHAVIORAL|Increasing hat use|Sun protection intervention that address sun protection knowledge, attitudes, social norms, and perceived behavioral controls. Intervention also provides free wide brimmed hats
223801710|NCT06015867|DIETARY_SUPPLEMENT|Dietary Intervention with Wholemeal Bread with Yeast|Single administration of 150g wholemeal long-time processed bread with baker's yeast, with no lactic acid (control).
223801711|NCT06015867|DIETARY_SUPPLEMENT|Dietary Intervention with Wholemeal Sourdough Bread|Single administration of 150g wholemeal long-time processed sourdough bread (with alternative lactic acid bacteria and yeast) high in lactic acid concentration.
223801712|NCT00003796|DRUG|irofulven|
223801713|NCT00617981|DRUG|ThermoDox|Thermally Sensitive Liposomal Doxorubicin 50 mg/m2 Single 30 minute intravenous infusion
223801714|NCT00617981|DRUG|5% Dextrose Solution|Single 30 minute intravenous infusion
223801715|NCT02281669|DRUG|Pentostam|Intralesional injection of Pentostam
223801716|NCT02241122|PROCEDURE|prostate biopsy|
223801717|NCT02123108|DRUG|Basiliximab|Peri-operative 40 mg IV dose within 4 hours of OLT Postoperative 20mg IV dose Day 4
223801718|NCT02123108|DRUG|Tacrolimus|Day #7 post-transplant or when serum creatinine (SCr) \< 1.8 mg/dl 6 months to 1 year: 0.03-0.1 mg.kg q12h po to maintain whole blood trough concentration of 3-5ng/mL
223801719|NCT02123108|DRUG|Tacrolimus|Day #1 post-transplant to 6 months: 0.03-0.1mg/kg q12h po to maintain whole blood trough concentration of 7-10 ng/mL + 6 months to 1 year: maintain whole blood trough concentration of 5-8ng/mL
223801720|NCT02123108|DRUG|Mycophenolic Acid|Enteric coated mycophenolic acid 360-720 mg po bid
223801721|NCT05039372|BEHAVIORAL|TRAINING AND CONSULTANCY|TRAINING AND CONSULTANCY
223801722|NCT00716092|DRUG|Placebo (linagliptin)|once daily for 28 days
223801723|NCT00716092|DRUG|Placebo (linagliptin)|once daily for 28 days
223801724|NCT00716092|DRUG|Sitagliptin|100 mg once daily for 28 days
223801725|NCT00716092|DRUG|Placebo (sitagliptin)|once daily for 28 days
223801726|NCT00716092|DRUG|Placebo (sitagliptin)|once daily for 28 days
223801727|NCT00716092|DRUG|Linagliptin|5mg once daily for 28 days
223801728|NCT03956472|PROCEDURE|Osteopathic protocol for improving drainage of LCS|Osteopathic intervention improving drainage of LCS and cerebral blood flow through opitmizing veinous circulation
223801729|NCT03956472|DEVICE|PEEP 10cmH2O|Breathing through a 10 cmH2O expiratory resistance for 10 min every 2 hours during 10h at 3842m high
223801730|NCT03956472|OTHER|Fake Osteopathic protocol|Placebo intervention
223801731|NCT03956472|OTHER|PEEP-Sham|PEEP 0 cmH2O (hidden)
223801732|NCT00578955|DRUG|1% Azithromycin and 0.1% Dexamethasone|Subjects will dose topically to the eye and eyelid BID at approximately 12 hour intervals for 14 days in both eyes.
223801733|NCT00578955|DRUG|1% Azithromycin|Subjects will dose topically to the eye and eyelid BID at approximately 12 hour intervals for 14 days in both eyes.
223801734|NCT00578955|DRUG|0.1% Dexamethasone|Subjects will dose topically to the eye and eyelid BID at approximately 12 hour intervals for 14 days in both eyes.
223801735|NCT00122226|DRUG|Lopinavir/ritonavir + zidovudine + lamivudine|
223801736|NCT00122226|DRUG|Lopinavir/ritonavir + nevirapine|
223801737|NCT02713802|DRUG|Cudafol(R) (propofol, 1% [10 mg/mL])|Test product Cudafol(R) to be administered via 1 mg/kg bolus injection, then continuous infusion at 50 ug/kg/min for 15 minutes
223801738|NCT02713802|DRUG|Diprivan(R) (propofol, 1% [10 mg/mL])|Reference product Diprivan(R) to be administered via 1 mg/kg bolus injection, then continuous infusion at 50 ug/kg/min for 15 minutes
223801739|NCT01132326|DRUG|Droxidopa|Oral, 100, 200, 300, 400, 500, 600 mg TID, 12 months
223801740|NCT03888664|DRUG|gamma interferon|1st two weeks: gIFN 100 ugr/three times a week from the 3rd week: gIFN 200 ugr/ three times a week for the following 22 weeks From the 25th week: no treatment for the following 24 weeks
223801741|NCT05933759|BEHAVIORAL|Telemedical coaching|Individual telemedical coaching delivered by a nutritional consultant
223801742|NCT05933759|BEHAVIORAL|Low-Insulin-Method|Lifestyle intervention with education via the Low-Insulin-App, low-carb diet, self-monitoring of weight and steps
223801743|NCT00677235|DEVICE|FLAIR Endovascular Stent Graft|Treatment of stenoses with primary PTA and placement of the FLAIR Endovascular Stent Graft
223801744|NCT00677235|PROCEDURE|PTA|Treatment of stenoses with PTA only
223801745|NCT00952367|OTHER|Nasopharyngeal swab|Nasopharyngeal swab
223801746|NCT03521726|DRUG|Amoxicillin|Twenty patients receive Intraluminal Amoxicillin eradication for H. pylori.
223801747|NCT03521726|DRUG|Rabeprazole, Amoxicillin|Patients fail to achieve intraluminal eradication of H. pylori will be assigned to the oral antibiotic rescue therapies with high dose dual therapy (Rabeprazole, Amoxicillin) for 14 days.
223801748|NCT03016767|PROCEDURE|Manual oral stimulation protocol|
223801749|NCT03414801|OTHER|Allergen Exposure|Subjects will undergo two exposure sessions, one week apart, of up to 1 hour depending on the subject's symptom severity and pulmonary function. During the exposure, subjects will be exposed to cat dander and levels of cat allergen, Fel d1, will be measured using sampling pumps with attached filters.
223801750|NCT01040260|OTHER|Counseling|Smoking cessation counseling
223801751|NCT01040260|BEHAVIORAL|Contingency management|Use of tangible rewards for abstinence from smoking
223801752|NCT01040260|DRUG|Nicotine patches|Nicotine patches
223801753|NCT00264420|DRUG|zoledronic acid|At baseline 4 mg IV zoledronic acid over 15 min. every 4 weeks for 6 months plus radiation therapy 30 Gy in 10 fractions (5 times per week for first two weeks)
223801754|NCT06215014|OTHER|Isometric handgrip training|Participants will train three days per week at home for 1 month using a reliable and validated digital handgrip dynamometer (DynX, MD System, Inc., Westerville, USA) in a seated position. The isometric handgrip training protocol will consist of four sets (2 for each hand) of two-min sustained contractions starting at 30% of maximum voluntary contraction (MVC) interspersed by 1-min resting periods (a total of 12-min). All training sessions will be remotely supervised via Zoom or phone call by a research team member to ensure compliance with the exercise prescription. Before each training session, MVCs will be re-assessed over three repetitions, each separated by 30-s, to ensure an accurate exercise prescription. The highest value will be used to determine the target intensity of the session
223801755|NCT04504331|DRUG|Infigratinib|Oral dose
223801756|NCT04504331|DRUG|Tamoxifen|Oral Dose
223801757|NCT04504331|DRUG|Omnipaque 350|IV contrast agent
223801758|NCT04504331|DRUG|Iopamidol|IV contrast agent
223801759|NCT04504331|DIAGNOSTIC_TEST|Computed tomography (CT)|Computed tomography (CT) to assess disease state using Iopamidol and/or Omnipaque 350.
223801760|NCT05741684|BEHAVIORAL|Internet-delivered Cognitive Behavioral Therapy|iCBT was administered in an unguided fashion without human therapeutic support. Participants were instructed to progress through the eight core modules over an 8-week period. The modules comprised psychoeducational content centered around CBT, aimed at promoting the development of skills such as self-monitoring of emotions, cognitive distancing, cognitive reframing/restructuring, problem-solving, and mindfulness. In the event of technical difficulties during the intervention, participants were able to seek assistance.
223801761|NCT05741684|BEHAVIORAL|Attention Bias Modification|The Dot-Probe Paradigm was utilized within the Attention Bias Modification procedure. The training sessions were comprised of 96 trials, which included facial expression photos depicting happiness, neutrality, and sadness, sourced from four male and four female actors. A fixed cross (+) was presented on the computer screen's center for a duration of 500 milliseconds before each stimulus display, followed by the presentation of two images portraying distinct emotional expressions, which persisted for 500 milliseconds. After the disappearance of the images, an arrow appeared in the location where they had been displayed, and participants were instructed to select the arrow that corresponded with the presented arrow. In the ABM procedure, the arrow was consistently presented following the display of a more positive facial expression, such that in the instance of a sad-neutral face pair, the arrow would always appear in the location of the neutral facial expression image.
223801762|NCT02753855|DRUG|Telavancin|A single dose of telavancin as a 1-hour intravenous infusion
223801763|NCT01732848|DRUG|BMS-986094/INX-08189|
223801764|NCT01732848|DRUG|Placebo matching BMS-986094/INX-08189|
223801765|NCT04759690|BEHAVIORAL|Action observation|Action observation group: The participants will first watch the conventional balance exercises with the action observation method on video for 15 minutes.After watching of conventional balance exercise for 45 minutes in 5-10 repetitions.
223801766|NCT04759690|BEHAVIORAL|Exercise group|Exercise group is the control group.TheParticipants will only do the conventional balance exercise without action observation for 45 minutes in 5-10 repetitions.
223801767|NCT05018884|PROCEDURE|Observation of surgical site infections|No intervention is done, only observation of routine clinical practice
223801768|NCT01451879|DRUG|Rituximab|Clinically prescribed immune modulation regimen dosage determined by local medical provider.
223801769|NCT01451879|DRUG|Miglustat|Clinically prescribed immune modulation regimen dosage determined by local medical provider.
223801770|NCT01509781|PROCEDURE|Insertion of suction drain(s) following mastectomy|One suction drain (16 Ch Redon drain) following simple mastectomy and two following modified radical mastectomy.
223801771|NCT01509781|PROCEDURE|Adaptive skin sutures.|Subcutis of skin flaps of the axilla and the wound edges are adapted to the chest wall and pectoralis major muscle by 8 to 24 stitches (depending on the wound surface of the breast and axilla) using 3.0 absorbable sutures, in a distance of 4-5 cm from each other in a chessboard pattern. The wound is then closed with 3.0 running subcutaneous sutures and 4.0 intracutaneous stitches. Compressive dressing is applied on the chest in the first 12-24 hours after surgery.
223801772|NCT03659448|DRUG|SGM-101|A fluorochrome-labeled anti-carcinoembryonic antigen (CEA) monoclonal antibody intraoperative imaging agent.
223801773|NCT00228072|PROCEDURE|Suction-curettage|
223801774|NCT03129854|DEVICE|prostate cryotherapy|prostate cryotherapy added to experimental group within 6 months of ADT
223801775|NCT04570436|DRUG|gabapentin 600 mg|participants will receive an oral dose of gabapentin 600 mg
223801776|NCT04570436|DRUG|gabapentin 1200 mg|participants will receive an oral dose of gabapentin 1200 mg
223801777|NCT04570436|DRUG|gabapentin 1800 mg|participants will receive an oral dose of gabapentin 1800 mg
223801778|NCT04570436|DRUG|diazepam 20 mg|participants will receive an oral dose of 20 mg dose of diazepam
223801779|NCT04570436|OTHER|placebo|participants will receive an oral dose of placebo
223801780|NCT00023153|DRUG|Adefovir Dipivoxil|
223801781|NCT05727410|DRUG|nivolumab, docetaxel, cisplatin Group|Patients will be treated with nivolumab 360mg and plus docetaxel 60mg/m2 and cisplatin 60mg/m2 every 3 weeks for 3 cycles and will be evaluated for the operability. Patients with R0 resection will receive radiation 59.4 Gy in 27 fractions. Boost RT of 6.6 Gy in 3 fractions to tumor bed and/or gross tumor will be optional in patients who had R1-R2 resection. If tumors are regarded inoperable after neoadjuvant therapy (due to high risk of post-operative complication, or metastatic disease), they will be off from this study and receive the appropriate treatment, though they will be also included in the efficacy and safety analyses.
223801782|NCT01635257|OTHER|Ultrasound scan|A multiorgan ultrasound was performed by an emergency physician sonographer before MCTPA. Pulmonary embolism was considered echographically present if compression ultrasound was positive for deep vein thrombosis or transthoracic-echocardiography was positive for right ventricular dysfunction or at least one pulmonary subpleural infarct was detected with thoracic ultrasound.
223801783|NCT00781391|DRUG|warfarin tablets|Warfarin tablets plus Edoxaban placebo tablets each taken once daily for 24 months
223801784|NCT00781391|DRUG|Edoxaban tablets (high dose regimen-60mg)|Edoxaban tablets plus warfarin placebo tablets each taken once daily for 24 months
223801785|NCT00781391|DRUG|Edoxaban tablets (low dose regimen-30mg)|Edoxaban tablets plus warfarin placebo tablets each taken once daily for 24 months
223801786|NCT00781391|DRUG|placebo warfarin|placebo warfarin
223801787|NCT00781391|DRUG|placebo edoxaban|placebo edoxaban
223801788|NCT05817448|DIAGNOSTIC_TEST|HIF 1α and LC3B expression and MMP-9 level|"5ml of venous blood samples will be taken from all participants at 28-40 weeks of gestation for detcetion of MMP-9 level by Enzyme-Linked Immune Sorbent Assay (ELISA) kit.~Placental tissue sample in the maternal surface will be taken during CS in placenta previa group and similar location in maternal surface will be sampled after placental delivery in control group for histopathology and immunohistochemistry for detection of HIF 1α and LC3B expression"
223801789|NCT04745481|DEVICE|Trunk stabilization training device|"Conventional rehabilitation 30min daily, 20times 4weeks~+Trunk stabilization training device 30min daily, 20time 4weeks"
223801790|NCT04745481|DEVICE|Conventional rehabilitation|"Conventional rehabilitation 30min daily, 20times 4weeks~+Conventional rehabilitation 30min daily, 20times 4weeks"
223801791|NCT04444167|BIOLOGICAL|AK104|Subjects will receive AK104 and lenvatinib until disease progression or for a maximum of 24 months
223801792|NCT04444167|DRUG|Lenvatinib|Subjects will receive AK104 and lenvatinib until disease progression for a maximum of 24 months
223801793|NCT03574064|OTHER|Glucagon-Like Peptide-2 (GLP-2)|Glucagon-Like Peptide-2 (GLP-2) injection.
223801794|NCT03574064|OTHER|Glucose-dependent insulinotropic polypeptide (GIP)|Glucose-dependent insulinotropic polypeptide (GIP) injection.
223801795|NCT03574064|OTHER|GLP-2+GIP|GLP-2+GIP injection.
223801796|NCT03574064|OTHER|Placebo|Placebo injection.
223801797|NCT03616184|DRUG|Ruxolitinib|Patients with sclerotic chronic graft-versus-host disease (GVHD) will receive oral ruxolitinib at a dose of 10 mg twice daily. Doses may not exceed 10 mg twice daily. Ruxolitinib will be continued for 6 months. Patients who continue to have stable disease, mixed responses or partial/complete responses at the end of 6 months may continue the drug for a total of 12 months.
223801798|NCT06439355|BIOLOGICAL|Fasting blood test|metabolic assays determination of food intake hormones oxidative stress and neurodegeneration marker assays
223801799|NCT06439355|OTHER|Subject interview|socio-demographic data, medical and family history, treatment taken
223801800|NCT06439355|OTHER|Motor assessment|MDS-UPDRS scale PART III
223801801|NCT06439355|OTHER|Neurocognitive assessment|MoCA and MMSE scales
223801802|NCT06439355|OTHER|Nutritional assessment|anthropometric data (weight, height, BMI, waist circumference, hip circumference, android/gynoid ratio, triceps skin fold, brachial circumference), bioelectrical impedancemetry (fat mass, lean mass, water mass and bone mass)
223801803|NCT06439355|OTHER|Taste tests|Recording of PEGs in response to a sucrose solution and a free fatty acid solution (prepared beforehand)
223801804|NCT03458455|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|Vessel Architectural Imaging is an MRI-based tumor diagnostic framework providing a powerful tool for non-invasive, in vivo assessment of diagnostic biomarkers relevant for these new therapy forms; microvascular function and tumor oxygenation.
223801805|NCT03458455|RADIATION|Stereotactic Radiosurgery|A non-surgical radiation therapy used to treat tumors of the brain. It can deliver precisely-targeted radiation in fewer high-dose treatments than traditional therapy, which can help preserve healthy tissue.
223801806|NCT03458455|DRUG|Ipilimumab, nivolumab or pembrolizumab|A type of therapy that uses substances to stimulate the immune system to help the body fight cancer by blocking inhibitory receptors on lymphocytes to overcome immune tolerance.
223801807|NCT04413630|OTHER|family workshop|The family workshop with 5 courses, with 6 families in one course The intervention of one course; 2 hours per session, one time per week, for a total of 6 weeks
223801808|NCT04111757|DEVICE|Technolas® TENEO 317 Model 2|LASIK eye surgery
223801809|NCT03533426|PROCEDURE|Serratus anterior plane catheter block|Ultrasonographic guided placement of a catheter under the serratus anterior muscle in cases of open thoracotomies for chest malignancies in an attempt to reduce the emergence of postthoracotomy pain syndrome.
223801810|NCT03533426|PROCEDURE|Patient controlled analgesia|The use of patient controlled analgesia through a pump aiming to reduce the development of postthoracotomy pain syndrome
223801811|NCT03371810|BEHAVIORAL|Bright light therapy|Mobile therapeutic light (10.000 LUX, white light without UV light), daily (except Sunday) for 30 min in the morning or evening for 10 weeks in total at home provided by a bright light therapy device (Philips EnergyLight HF 3419). Monitoring and feedback will be realized with the m-Health system comprising of a smartphone equipped with the m-Health App, and an activity sensor equipped with a light sensor to monitor the light exposure of the participant.
223801812|NCT03371810|BEHAVIORAL|Physical exercise|"During 10 weeks participants perform three days of aerobic activities proposed and in two of these days also do muscle-strengthening exercise. Specifically, a training day consists of: (i) a 5-min warm-up period, (ii) a 10-35 min of muscle-strength training on two of the three days, (iii) a 20-40 min of aerobic training, (iii), and a 5-min of flexibility/stretching cool-down. During the course of the 10 weeks, the duration and intensity of the exercises will increase gradually.~Instruction, monitoring, and feedback will be realised by the m-Health system including a smartphone equipped with the m-Health app and Secure Digital Memory cards to store the exercise videos as well as an activity sensor equipped with a mobile sensor for the acquisition of physical activity."
223801813|NCT04594031|BIOLOGICAL|ECT-001-CB (UM171-Expanded Cord Blood Transplant)|Single ECT-001-CB transplant (CD34+: 2 to 5.75x10E5/kg, CD3+ \>1x10E6/kg)
223801814|NCT05569746|DRUG|INM004|Two 4 mg/kg doses of INM004, 24 h (±2 h) apart, will be assessed. Each dose will be administered as an intravenous infusion during 50 min.
223801815|NCT05569746|OTHER|SoC|Standard of care
223801816|NCT03132428|DRUG|INOmax|Nitric oxide gas for inhalation provided via mechanical ventilation or non invasive ventilation
223801817|NCT03879746|DRUG|Tamsulosin|drug will be used in treatment of premature ejaculation
223801818|NCT03879746|DRUG|Paroxetine Hydrochloride|drug will be used in treatment of premature ejaculation
223801819|NCT03879746|OTHER|placebo|tablets without active substance will be given to patients suffering from premature ejaculation
223801820|NCT01510275|DEVICE|Combined use of RESPIVOL® and RESPILIFT®|Active devices (combined) for 14 consecutive session, bid, for 15 minutes.
223801821|NCT01510275|DEVICE|Combined use of RESPIVOL® and RESPILIFT®|Sham devices (combined) (without resistive load)for 14 consecutive session, bid, for 15 minutes.
223801822|NCT02200796|OTHER|Control Meal|High carbohydrate meal
223801823|NCT02200796|OTHER|Low Protein Meal|Omelet with 15 g of protein
223801824|NCT02200796|OTHER|Moderate Protein Meal|Omelet with 30 g of protein
223801825|NCT02200796|OTHER|High Protein Meal|Omelet with 45 g of protein
223801826|NCT04195308|DEVICE|Active TBS-DLPFC|"Participants in the active stimulation group will receive intermittent TBS to left DLPFC. The L-DLPFC will be targeted utilizing the Localite neuronavigation system. Stimulation intensity will be standardized at 90% of RMT and adjusted to the skull to cortical surface distance (see Nahas 2004).~Stimulation will be delivered to the L-DLPFC using a MagPro stimulator."
223801827|NCT04195308|DEVICE|Sham TBS-DLPFC|The parameters in the active arms will be as above with the internal randomization of the device internally switching to sham in a blinded fashion.
223801828|NCT04195308|DEVICE|Open label TBS-DLPFC|"Patients will have the option of receiving active, open label aTBS treatment following sham.~Stimulation will be delivered to the L-DLPFC using a MagPro stimulator or Nexstim TMS device."
223801829|NCT02483897|DRUG|Tetracaine 0.5% ophthalmic drops|0.8 mls. drops provided to be used hourly p.r.n. for pain control
223801830|NCT02483897|DRUG|Normal Saline placebo drops|0.8 mls. drops provided to be used hourly p.r.n. for pain control
223801831|NCT04563468|PROCEDURE|Strength inspiratory muscle training|Two training sessions per day consisting of 30 breaths (against external load of \~50% Pi,max; 4-5 minutes per session), 7 days/week (once/month supervised at the research center), for 6 months will be performed using an electronic tapered flow resistive loading (TFRL) device (POWERbreathe®KH1, HaB International Ltd., Southam, UK) according to an established method. Measurements of Pi,max will be performed every week and training loads will be increased continuously to maintain external load at \~50% of Pi,max values. Ratings of perceived inspiratory effort on a modified Borg scale (4-5 out of 10) will also be used to support decisions on increasing training load.
223801832|NCT04563468|PROCEDURE|Endurance inspiratory muscle training|Two daily sessions of 30 breaths using TFRL device (POWERbreathe®KH1, HaB International Ltd., Southam, UK) and will train at an inspiratory load of no more than 10% of their initial Pi,max. This training load will not be changed during the entire study period. Participants in the control group will be offered the active treatment upon completion of the study.
223801833|NCT01358695|BIOLOGICAL|ANT-1207|The interventions differ by dose of investigational product applied.
223801834|NCT01358695|BIOLOGICAL|Botulinum Toxin, Type A|The interventions differ by dose of investigational product applied.
223801835|NCT01358695|BIOLOGICAL|Botulinum Toxin Type A|The interventions differ by dose of investigational product applied.
223801836|NCT05263466|DIAGNOSTIC_TEST|PET-MRI|For the diagnostic imaging aspect included in this pilot study, \[68Ga\]PSMA-11 will be used. This is a peptidomimetic agent with a covalently bound chelator (HBED-CC) that is FDA-approved in prostate cancer imaging. We will use PET-MRI to visualise a) the concentration and b) the distribution of this tracer to establish a functional map of primary brain tumour activity
223801837|NCT05263466|PROCEDURE|Brain tumour biopsy|All patients included in our study will undergo stereotactic surgery for biopsy/resection of the tumour as part of the standard of care at KCH. During this study we will not vary from the surgical standard of care for primary brain tumours and will only extend the surgery time due to additional stereotactic biopsies (an additional 3 biopsies increasing the time of the operation by \~30 minutes). Professor Ashkan (KCH) has defined the additional surgical risk of performing these biopsies to be \~0%, since targeted biopsies will only be taken within the tumour just before resection. The stereotactic biopsy may be targeted to areas of high \[68Ga\]PSMA SUV within the tumour as defined by the PET MRI scan.
223801838|NCT02470130|BEHAVIORAL|relaxation|5 min of conversational relaxation red by one of the instructor between simulation and debriefing
223801839|NCT05011474|BIOLOGICAL|administered an autologous adipose-derived mesenchymal stem cell spheroid pretreated with matrillin 3|Adipose-derived mesenchymal stem cells isolated from subject's adipose tissue are pretreated with matrillin 3 and produced in spheroid form.
223801840|NCT01265602|DRUG|LAS41007|Topical gel, to be applied twice daily (mornings and evenings), for up to 90 days. Generally 0.5 g gel (pea-sized amount of gel) per application will be sufficient to cover an overall area of 25 cm².
223801841|NCT01265602|DRUG|LASW1510|Topical gel, to be applied twice daily (mornings and evenings), for up to 90 days. Generally 0.5 g gel (pea-sized amount of gel) per application will be sufficient to cover an overall area of 25 cm².
223801842|NCT01265602|DRUG|vehicle of LAS41007|Topical gel, to be applied twice daily (mornings and evenings), for up to 90 days. Generally 0.5 g gel (pea-sized amount of gel) per application will be sufficient to cover an overall area of 25 cm².
223801843|NCT04322604|DRUG|lirentelimab (AK002)|Lirentelimab (AK002) is a humanized non-fucosylated immunoglobulin G1 (IgG1) monoclonal antibody directed against Siglec-8.
223801844|NCT04322604|OTHER|Placebo|Placebo
223801845|NCT05543850|DEVICE|Bi-hormonal closed-loop control|During bi-hormonal closed-loop control insulin and glucagon are administered to the developed closed-loop algorithm. Aditionally, patients will wear a blinded Dexcom G6 for data collection during the closed loop period.
223801846|NCT05543850|DEVICE|Open-loop control|During open-loop control the patients will use their usual diabetes therapy. Aditionally, patients will wear a blinded Dexcom G6 for data collection during the open loop period.
223801847|NCT01238055|DRUG|Docetaxel + Sunitinib|"Docetaxel 60 mg/m2 iv, every 3 weeks~Sunitinib 37.5 mg qd daily, every 3 weeks"
223801848|NCT01238055|DRUG|Docetaxel only|Docetaxel 60 mg/m2 iv
223801849|NCT00850889|DEVICE|Hyaluronic acid gel (24 mg/mL) with 0.3% lidocaine|Day 0, maximum total volume (dosage) allowed for each NLF is 1.6 mL
223801850|NCT00850889|DEVICE|A gel of hyaluronic acid (concentration of 20 mg/mL)|Day 0, maximum total volume (dosage) allowed for each NLF is 1.6 mL
223801851|NCT02456402|DEVICE|Drug Coated Balloon|If post balloon angioplasty FFR is more than 0.80, either DCB treatment or BMS implantation will be carried out based on randomization of 1:1. DCB (SeQuent Please paclitaxel-coated balloon catheter, B. Braun, Melsungen, Germany) will be applied at the predilated lesions. PCB will be delivered rapidly and inflated for 60 seconds with nominal pressure.
223801852|NCT02456402|DEVICE|Bare Metal Stent|BMS (Vision®) will be applied at the predilated lesions after angiographic confirmation of the target lesion.
223801853|NCT05038280|BEHAVIORAL|Let's Talk about Children intervention|The LTC -intervention includes two steps: Let´s Talk about Children discussion and Let´s Talk about Children network meeting. Students, students´ parents, and a teacher take part in the LTC -discussion. The LTC logbook is used as the framework for the discussions. The LTC discussion depicts the child's ordinary day in all developmental contexts and an action plan is made with parents to enhance the identified strengths and to give support in vulnerabilities. When the action plan is difficult to carry out without further participants, the LTC-Network meeting is planned with parents (and sometimes also the child). LTC-Network meeting provides a forum for case-based cross-sectoral collaboration, including also the families and their social network.
223801854|NCT00740961|BEHAVIORAL|compliance monitoring|Patients complete the Vulnerable Elders Survey (VES-13) and a Comprehensive Geriatric Assessment at baseline and 12 months later. Variables collected include sociodemographics; cognitive, nutritional, psychosocial, and emotional status; tumor characteristics; therapy; and mortality.
223801855|NCT00740961|DRUG|systemic chemotherapy|Learning about changes over time in older patients' ability to function after receiving chemotherapy for breast or colon cancer
223801856|NCT00740961|OTHER|medical chart review|A limited review of medical records for the sole purpose of evaluating patients for study eligibility will be undertaken by the research team.
223801857|NCT00740961|OTHER|study of socioeconomic and demographic variables|Patients complete the Vulnerable Elders Survey (VES-13) and a Comprehensive Geriatric Assessment at baseline and 12 months later. Variables collected include sociodemographics; cognitive, nutritional, psychosocial, and emotional status; tumor characteristics; therapy; and mortality.
223801858|NCT00740961|OTHER|survey administration|Patients complete the Vulnerable Elders Survey (VES-13) and a Comprehensive Geriatric Assessment at baseline and 12 months later. Variables collected include sociodemographics; cognitive, nutritional, psychosocial, and emotional status; tumor characteristics; therapy; and mortality.
223801859|NCT00740961|PROCEDURE|cognitive assessment|Patients complete the Vulnerable Elders Survey (VES-13) and a Comprehensive Geriatric Assessment at baseline and 12 months later. Variables collected include sociodemographics; cognitive, nutritional, psychosocial, and emotional status; tumor characteristics; therapy; and mortality.
223801860|NCT00740961|PROCEDURE|psychosocial assessment and care|Patients complete the Vulnerable Elders Survey (VES-13) and a Comprehensive Geriatric Assessment at baseline and 12 months later. Variables collected include sociodemographics; cognitive, nutritional, psychosocial, and emotional status; tumor characteristics; therapy; and mortality.
223801861|NCT05767684|BIOLOGICAL|Dendritic Cell Vaccine|Approximately 1.5 x 10\^6±20% cells will be subcutaneously injected to the patient's inguinal area (either left side or right side can be injected, only one area will be injected each time) on day 1, 8, 15, 29, 85, 141, 197, 253 and 309.
223801862|NCT05767684|DRUG|Lenvatinib|Lenvatinib 10mg/day on day 43-77
223801863|NCT05767684|DRUG|Nivolumab|Nivolumab 3mg/kg on day 43, 57 and 71.
223801864|NCT00825422|DRUG|Ropivacaine / Placebo|Wound infiltration with local anesthesics/placebo through a parietal paravertebral catheter
223801865|NCT03105284|PROCEDURE|Liposuction|Fat harvest by liposuction (Colemans method)
223801866|NCT05908214|OTHER|wide pulse high frequency neuromuscular electrical stimulation training|Plantar flexors will be stimulated with wide pulse high frequency neuromuscular electrical stimulation 3 times a week for 6 weeks
223801867|NCT01969019|DRUG|methylprednisolone, prednisone|
223801868|NCT03261128|OTHER|Self-questionnaire|Filling of a self-questionnaire before each chemotherapy cure
223801869|NCT00053989|BIOLOGICAL|anti-thymocyte globulin|iv
223801870|NCT00053989|BIOLOGICAL|graft-versus-tumor induction therapy|iv
223801871|NCT00053989|BIOLOGICAL|sargramostim|iv
223801872|NCT00053989|BIOLOGICAL|therapeutic allogeneic lymphocytes|iv
223801873|NCT00053989|DRUG|cyclophosphamide|injection
223801874|NCT00053989|DRUG|fludarabine phosphate|iv
223801875|NCT00053989|DRUG|methylprednisolone|oral
223801876|NCT00053989|DRUG|mycophenolate mofetil|oral
223801877|NCT00053989|DRUG|tacrolimus|oral
223801878|NCT00053989|PROCEDURE|allogeneic bone marrow transplantation|iv
223801879|NCT00053989|PROCEDURE|peripheral blood stem cell transplantation|iv
223801880|NCT00053989|PROCEDURE|umbilical cord blood transplantation|iv
223801881|NCT05094401|DEVICE|BT-001|BT-001 is a software program intended to help patients with type 2 diabetes, under the guidance of their physician, improve glycemic control.
223801882|NCT02679040|PROCEDURE|Immediate mammary reconstruction|Chemotherapy administration then radiotherapy and then surgery : mastectomy and immediate mammary reconstruction.
223801883|NCT02679040|DRUG|Chemotherapy|Chemotherapy treatment
223801884|NCT02679040|RADIATION|Radiation therapy|Radiation therapy
223801885|NCT03114280|DRUG|TPF2|Combination drugs : docetaxel (T), cisplatin (P), 5 Fluorouracil (F) and pembrolizumab every 21 days
223801886|NCT03114280|OTHER|Radiotherapy with carboplatin|Radiotherapy (RT) combined with carboplatin
223801887|NCT01137188|DIETARY_SUPPLEMENT|Low calorie diet|Low calorie diet containing 800-1000 kcal/day
223801888|NCT03205371|BIOLOGICAL|MenACYW conjugate vaccine|Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine; 0.5 milliliter (mL), Intramuscular
223801889|NCT03205371|BIOLOGICAL|MMR|Measles, Mumps, and Rubella Virus Vaccine Live; 0.5 mL, Subcutaneous
223801890|NCT03205371|BIOLOGICAL|Varicella|Varicella Virus Vaccine Live; 0.5 mL, Subcutaneous
223801891|NCT03205371|BIOLOGICAL|DTaP-IPV-HB-Hib|Diphtheria, Tetanus, Pertussis (acellular component), Hepatitis B, Poliomyelitis (inactivated), and Haemophilus influenzae type-b conjugate vaccine (adsorbed); 0.5 mL, Intramuscular
223801892|NCT03205371|BIOLOGICAL|PCV13|Pneumococcal 13-valent Conjugate Vaccine; 0.5 mL, Intramuscular
223801893|NCT02486601|DRUG|nab-paclitaxel|nab-paclitaxel : 150 mg/m2 D1 every 2 weeks
223801894|NCT02486601|DRUG|FOLFOX|Leucovorin: 400 mg/m2 D1 every 2 weeks Oxaliplatin: 85 mg/m2 D1 every 2 weeks Fluorouracil (5-FU) infusion: 2400mg/m2 48h infusion every 2 weeks
223801895|NCT01851174|DRUG|Gemcitabine|Patients will receive Gemcitabine (1,000 mg/m\^2) IV over 30 minutes after nab-paclitaxel infusion
223801896|NCT01851174|DRUG|nab-Paclitaxel|Patients will receive nab-Paclitaxel (125 mg/m\^2) IV over 30 minutes before Gemcitabine infusion
223801897|NCT00298922|DRUG|Azithromycin|500 mg tablets orally thrice weekly for 24 weeks
223801898|NCT00298922|DRUG|Placebo|tablet orally thrice weekly for 24 weeks
223801899|NCT00959543|OTHER|MRI|MRI and clinical investigation
223801900|NCT03142048|OTHER|Schools of Health for the Elderly|"The intervention School of Health for the Elderly  consists of 22 weekly group sessions of 1.5 hours each. In addition to helping participants learn about different health issues, the intervention encourages interaction among participants and works on personal skills. Furthermore, most sessions are led by professionals who are experts on the topic covered and work in the neighborhood (professionals from the health services, social services, markets or neighborhood associations), making it easier to inform participants of the neighborhood's available resources. The aim of the intervention is to decrease social isolation and loneliness and, therefore, to improve mental health, self-perceived health and wellbeing"
223801901|NCT05414591|DRUG|DWP16001 drug A|1 tablet, Oral, once daily single dose
223801902|NCT05414591|DRUG|DWP16001 drug B|3 tablet, Oral, once daily single dose
223801903|NCT04777812|DIAGNOSTIC_TEST|Rectal and buccal swabs|The oral and intestinal flora is collected from buccal and rectal swabs.
223801904|NCT00435279|DRUG|Eszopiclone|Eszopiclone 3 mg
223801905|NCT00435279|DRUG|Placebo|Placebo
223801906|NCT00435279|DRUG|Venlafaxine|Venlafaxine 75 mcg Weeks 1, 2, 29, and 30 Venlafaxine 150 mcg Weeks 3 through 28
223801907|NCT02947347|DRUG|ibrutinib|ibrutinib 560mg administered orally
223801908|NCT02947347|DRUG|placebo to match ibrutinib|placebo capsules to match ibrutinib administered orally
223801909|NCT02947347|DRUG|rituximab|rituximab 375mg/m\^2 IV
223801910|NCT04341623|OTHER|Cetaphil Pro Eczema moisturizer|All 30 patients to receive
223801911|NCT04341623|BEHAVIORAL|Electronic interaction|10 patients to electronic surveys about moisturizer use
223801912|NCT04341623|BEHAVIORAL|GPSkin|Measuring moisture in the skin
223801913|NCT06488664|BIOLOGICAL|GNR-068|GNR-068 was administered subcutaneously at weeks 0 and 4 weeks then every 12 weeks thereafter until week 52.
223801914|NCT06488664|BIOLOGICAL|Stelara®|Stelara® was administered subcutaneously at weeks 0 and 4 weeks then every 12 weeks thereafter until week 28 and then all patients receive GNR-068 45 mg until week 52.
223801915|NCT03227354|DEVICE|Vittamed 205|non-invasive Intracranial Pressure measurement
223801916|NCT05934812|DRUG|Oxytocin nasal spray|24IU oxytocin liquid delivered with a pump-actuated nasal spray device, administered twice-daily
223801917|NCT05934812|DRUG|Placebo|Placebo liquid nasal spray administered twice-daily
223801918|NCT05166967|DRUG|Individual Antithymocyte globulin|Individual dose of ATG was Intravenous infused every day from day -5 to day -2 (total ATG dose was calculated based on pharmacokinetic index, within a range of 6 mg/kg to 13mg/kg). Prophylaxis against graft versus-host disease (GVHD) was performed with cyclosporine A (CsA), mycophenolate mofetil (MMF) and short-term methotrexate.
223801919|NCT05166967|DRUG|Antithymocyte globulin|A 10mg/kg total dose of antithymocyte globulin (ATG) was added to conditioning regimens for 4 days (from day -5 to day -2). Prophylaxis against graft versus-host disease (GVHD) was performed with cyclosporine A (CsA), mycophenolate mofetil (MMF) and short-term methotrexate.
223801920|NCT06959992|BEHAVIORAL|Metaverse group|The activities will be conducted in a Metaverse platform with immersive features. Each session is divided into two parts (\~2 hours duration). First, a specific social context will be represented (environmental features and static avatars) and a microaggression scenario (adapted for the chosen context) will be described. Participants are engaged in the conversation by the moderator in order to identify various psychological manifestations regarding the context (according to the SORC model) and to come up with solutions for the main, model avatar (part of the research team). Second, the debriefing part of the session will allow participants to talk about their own experiences alongside specific self-compassionate exercises. Repeated measurements will be required: pre-intervention, mid-intervention, post-intervention and at follow-up (after 3 months).
223801921|NCT06959992|BEHAVIORAL|Online asynchronously|The activities will be conducted asynchronously in an online platform where participants will be guided by the moderator through the same type of activities. First, a social context with specific microaggressions will be presented in a text format followed by the same requirements for participants (identifying various psychological manifestations regarding the context and coming up with solutions for the problematic situation). Second, participants will have the transcripts of several self-compassionate exercises to be done independently. A discussion forum will also require their active engagement. Repeated measurements will be required pre-interventions, mid-intervention, post-intervention and at follow-up (3 months).
223801922|NCT03453398|OTHER|Shifts working hours with different schedules|"Workers in Group 1, 2, and 3 will undergo three different shift work modalities presenting different schedules.~Importantly, as an inclusion criteria, workers have to be involved in the same shift modality for at least one year at the time at the beginning of the study."
223801923|NCT05508503|DIAGNOSTIC_TEST|Test of methylated NTMT1 and MAP3K14-AS1|A dual-target test kit to detect methylated NTMT1 and MAP3K14-AS1 in blood samples.
223801924|NCT05508503|DIAGNOSTIC_TEST|FIT|Fecal immunochemical test（optional）
223801925|NCT00742092|DRUG|miglustat|Oral miglustat capsules 200 mg t.i.d. (three times a day) for 7 days and a single 200 mg dose on Day 8
223801926|NCT00742092|DRUG|placebo|Oral placebo capsules matching in appearance miglustat capsules given t.i.d. (three times a day) for 7 days and a single dose on Day 8
223801927|NCT04310995|DRUG|Nicorandil 5mg tid|oral Nicorandil Tablets 5mg (5mg per tablet) three times daily for 24 weeks
223801928|NCT04310995|DRUG|Diltiazem 180mg qd|oral Diltiazem Sustained-release Tables180mg (90 mg per tablet) once daily for 24 weeks
223801929|NCT04310995|DRUG|Isosorbide Mononitrate 50mg qd|oral Isosorbide Mononitrate Sustained-release Capsules 50 mg (50mg per capsule) once daily for 24 weeks
223801930|NCT04632927|BIOLOGICAL|Secukinumab|Eligible subjects are randomized to one of two treatment arms in a 1:1 ratio
223801931|NCT04632927|BIOLOGICAL|Ustekinumab|Eligible subjects are randomized to one of two treatment arms in a 1:1 ratio
223801932|NCT06433908|DRUG|Salbutamol HFA-152a|100 µg (ex-valve), given at 20-second intervals.
223801933|NCT06433908|DRUG|Salbutamol HFA-134a|100 µg (ex-valve), given at 20-second intervals.
223801934|NCT05522725|OTHER|Single-use wipes installed at the bedside|
223801935|NCT03878810|BEHAVIORAL|Exergaming|A video game-based physical activity training applied using a commercial game console.
223801936|NCT06142136|DIETARY_SUPPLEMENT|Vitamin D substitution with sublingual sprayable microemulsion.|Participants received sublingual sprayable microemulsion of vitamin D3 4000 IU daily for 30 days.
223801937|NCT06142136|DIETARY_SUPPLEMENT|Vitamin D substitution with oil droplets|Participants received oil droplets of vitamin D3 4000 IU daily for 30 days.
223801938|NCT06142136|DIETARY_SUPPLEMENT|Vitamin D substitution with capsules|Participants received capsules of vitamin D3 4000 IU daily for 30 days.
223801939|NCT00673972|RADIATION|gastric scintigraphy|"All tests start after overnight fast. Test meals consists of 120g scrambled egg, two slices of toasted bread, 30g of strawberry jam and 120ml of water. 12MBg (0.33mCi) of 99mTc sulfur colloid is mixed with egg thoroughly before the mixture cooked in a microwave oven for 2 minutes. All meals are prepared on the morning of examination and consumed within 20 minutes.~Anterior and posterior images of the gastric region are taken within one minute after completion of test meals. Subsequent images are taken every 2 minutes in the first 60 minutes and at 120 minutes and 180 minutes. One-min images of gastric region at upright position are taken in the 140keV 99mTc peak with a 20% window."
223801940|NCT02413580|BIOLOGICAL|IGIV-C|An IV dose of 2 g/kg of IGIV-C was administered over 2 consecutive days at a dose of 1 g/kg per day.
223801941|NCT04542018|OTHER|a low FODMAP diet for 4 weeks|low FODMAP diet for 4 weeks
223801942|NCT00538135|BEHAVIORAL|Cognitive Behavioural Therapy|
223801943|NCT00538135|OTHER|Treatment as usual|Standard National Health Service treatment as usual for borderline personality disorder
223801944|NCT03141320|OTHER|Interview/observation of social media comments|Interview with pregnant or postnatal women and observation of relevant social media comments
223801945|NCT04357262|OTHER|StreaMD|Patients who are randomized to the intervention arm will be signed up for the automated text messaging program. Patients will receive automated text messages related to their surgery during the study period and can also ask questions through the text messages program, where automated messages will be sent based on the questions asked.
223801946|NCT03399032|DRUG|Caspofungin|"Each patient will receive: caspofungin i.v. once daily ( 70 mg on the first day, 50 mg on the 2 and 3 day~Blood samples (3 mL) will be collected 2, 4, 8, 12 and 24 hours after each dose of caspofungin for 3 consecutive days."
223801947|NCT01725828|DEVICE|Ultrasound|Using the Ultrasound to determine the location of the CTM.
223801948|NCT01725828|OTHER|External Palpation|Using External Palpation to identify cricothyoid membrane
223801949|NCT02543034|DEVICE|Betafoam Wound Dressing|Foam dressing including Betadine iodine
223801950|NCT02543034|DEVICE|Petrolatum Gauze|Gauze dressing
223801951|NCT02543034|DEVICE|Allevyn Wound Dressing|Foam dressing
223801952|NCT04217681|BEHAVIORAL|Self-hypnosis/self-care|It is a 7-months 2 hours-session (1 session per month) of self-hypnosis/self-care learning. Participants are given strategies to learn self-care (knowing their needs, self-respect, communication etc.), each strategy is discussed for participant to understand them and thus apply them correctly in daily life. An hypnosis exercise is conducted at the end of each session. A CD with the audiotaped hypnosis exercise is given to each patient so that they can practice also every day.
223801953|NCT04217681|BEHAVIORAL|Music/self-care|It is a 7-months 2 hours-session (1 session per month) of music/self-care learning. Participants are given strategies to learn self-care (knowing their needs, self-respect, communication etc.), each strategy is discussed for participant to understand them and thus apply them correctly in daily life. At the end of each session, patients are invited to listen to a relaxing melody of 15 minutes. This melody was composed by a professional musico-therapist. A CD with the audiotaped melody is given to each patient so that they can practice also every day.
223801954|NCT04217681|BEHAVIORAL|Self-hypnosis/self-care motivation|It is a 7-months 2 hours-session (1 session per month) of self-hypnosis/self-care learning. Participants are given strategies to learn self-care (knowing their needs, self-respect, communication etc.), each strategy is discussed for participant to understand them and thus apply them correctly in daily life. An hypnosis exercise is conducted at the end of each session. A CD with the audiotaped hypnosis exercise is given to each patient so that they can practice also every day.
223801955|NCT04217681|BEHAVIORAL|Self-hypnosis/self-care malignant pain|It is a 7-months 2 hours-session (1 session per month) of self-hypnosis/self-care learning. Participants are given strategies to learn self-care (knowing their needs, self-respect, communication etc.), each strategy is discussed for participant to understand them and thus apply them correctly in daily life. An hypnosis exercise is conducted at the end of each session. A CD with the audiotaped hypnosis exercise is given to each patient so that they can practice also every day.
223801956|NCT04099108|COMBINATION_PRODUCT|Combined cycle ergometry and bolus amino acid supplementation|A 4-hour bolus amino acid supplement administered within 30 minutes after a 30-minute in-bed cycling session.
223801957|NCT03963908|BEHAVIORAL|AtEase|AtEase is a tailored pain self-management mobile app that tailors participant's feedback based on readiness to engage in pain self-management and preference for self-management strategies.
223801958|NCT03963908|BEHAVIORAL|Chronic Pain Education|CBT-based Education on Pain Self-Management for Veterans
223801959|NCT00689221|DRUG|Cilengitide|Cilengitide 2000 milligram (mg) will be administered intravenously twice weekly over 1 hour infusion from Weeks -1 to 77 or until occurrence of progressive disease, unacceptable toxicity, or withdrawal for any other reason. If considered beneficial in the opinion of the Investigator, continuation of cilengitide treatment will be optional in subjects without disease progression and after Week 77 since start of treatment.
223801960|NCT00689221|DRUG|Temozolomide|Temozolomide (TMZ) 75 milligram per square meter \[mg/m\^2\] will be administered intravenously once daily from Weeks 1 to 6. From Week 11 onwards, TMZ will be given as maintenance treatment at a dose of 150-200 mg/m\^2 for consecutive 5 days every 4 weeks until Week 34 or until disease progression.
223801961|NCT00689221|RADIATION|Radiotherapy|Radiotherapy (RTX) at a dose of 2 gray (Gy) per fraction will be given once daily, 5 days per week from Weeks 1 to 6, total dose 60 Gy.
223801962|NCT04355351|OTHER|blood sampling|blood sampling done on hospital staff without sars-coV-2 symptoms
223801963|NCT04355351|OTHER|additional blood tubes|Additionnal blood tube taken during the classical blood sampling in hospital
223801964|NCT01311960|DRUG|bevacizumab eye drop 0.05%|bevacizumab eye drop 0.05% will apply 4 times a day for 3 months
223801965|NCT01311960|DRUG|normal saline 0.9%|normal saline eye drop 0.9% will apply 4 times a day for 3 months.
223801966|NCT02610348|BIOLOGICAL|DTaP-IPV-HB-PRP~T and Pneumococcal polysaccharide vaccines|Original Vaccine in Study A3L12 (NCT00401531). No vaccination will be administered as part of this study
223801967|NCT02610348|BIOLOGICAL|DTaP-HB-IPV and Pneumococcal polysaccharide vaccines|Original Vaccine in Study A3L12 (NCT00401531). No vaccination will be administered as part of this study
223801968|NCT06171542|DEVICE|CTM Injection|All glenohumeral joint injections will be performed by a physician under the guidance of either ultrasound or fluoroscopy to ensure and document intra-articular needle placement. 2cc of CTM Flow will be injected. The glenohumeral joint will be injected with the medication under the discretion of the treating surgeon.
223801969|NCT04994834|DIETARY_SUPPLEMENT|Probiotics|Once a day daily intake of probiotics for at least 28 consecutive starting within 24 hours after birth
223801970|NCT05554952|COMBINATION_PRODUCT|MTA|Mineral trioxide aggregate (MTA) is composed of Portland cement, with 4:1 addition of bismuth oxide added so that the material can be detected on a radiograph. The cement is made up of calcium, silicon and aluminium. The main constituent phases are tricalcium and dicalcium silicate and tricalcium aluminate.
223801971|NCT02444455|BIOLOGICAL|UCMSC group|Human umbilical cord MSCs are transplanted by intravenous infusion(5×10\^5/kg) once a day,a total of three times.
223801972|NCT01812655|DEVICE|Virtual Reality|
223801973|NCT01812655|OTHER|Passive Distraction|
223801974|NCT04647149|BEHAVIORAL|Dietary Approach|Dietary approaches with energy restriction performed at different times of the day.
223801975|NCT00036569|PROCEDURE|adjuvant therapy|
223801976|NCT00036569|BIOLOGICAL|pegylated interferon alfa|0.3 mg/kg subcutaneously once a week for 4 weeks beginning 2-10 weeks after completion of radiation therapy and continued until disease progression or one of the other off study criteria.
223801977|NCT03608930|DEVICE|Disposable Polypectomy Snare,JHY-SD-23-230-30-A1|The technique is hot snare resection of the polyp with electrocautery. Details are as follows: (1) insert the snare into the colonoscopy; (2) connect the snare with the high-frequency device;(3) advance sliding handle to open the loop; (4) adjust the direction of the snare by rotating the handle as required, rotate the loop until the loop reaches target polyp; (6) encircle the target polyp with loop; (7) pull the sliding handle, lasso the target polyp;(8) resect the polyp with electrocautery, then inhaling the transected polyp into a trap followed by submission to the histological evaluation.
223801978|NCT01187693|OTHER|shoe lift|shoe lift for balancing the heights of bilateral pelvis of participants with leg length discrepancy during standing
223801979|NCT05242991|DEVICE|Photobiomodulation therapy|Light therapy for the management of oral side effects related to radiotherapy, mainly in the decrease of oral mucositis (OM) rates and OM severity, healing of OM ulcers and pain relief.
223801980|NCT00442143|PROCEDURE|Stem cell implantation|
223801981|NCT04814329|OTHER|genetic characteristic|the underlying genetic characteristics that prodicting response
223801982|NCT01274195|DRUG|Busulfan|First dose: busulfan (120 mg/m2 ivs once daily) (if age\<1 yr: 80 mg/ m2) Second to forth dose: according to the daily pharmacokinetic study
223801983|NCT01986465|DRUG|Depomedrol|
223801984|NCT01986465|DRUG|Placebo|
223801985|NCT06191718|DEVICE|Mitral Valve Replacement|Foldax Mitral Valve Replacement
223801986|NCT02615574|BIOLOGICAL|αDC1 vaccine|Subjects will receive one cycle of CKM alone followed by three cycles of vaccine + CKM.
223801987|NCT02615574|DRUG|CKM|Subjects will receive one cycle of CKM alone followed by three cycles of vaccine + CKM.
223801988|NCT01896570|PROCEDURE|Catheter ablation of subsequent atrial tachycardia|
223801989|NCT04808804|DIAGNOSTIC_TEST|Optical Coherence Tomography (OCT)|a noninvasive imaging technology used to obtain high resolution cross-sectional images of the retina
223801990|NCT04210206|OTHER|PHE-diet|phenylalanine-restricted diet with phenylalanine free supplements for 8 weeks
223801991|NCT05356858|DRUG|zanubrutinib|zanubrutinib orally, 80mg bid for 1 year
223801992|NCT04435665|DRUG|NFX-179 Gel|gel for topical administration
223801993|NCT04435665|DRUG|Vehicle Gel|vehicle gel for topical administration
223801994|NCT04672941|DRUG|Tiotropium bromide plus Olodaterol|Tiotropium bromide plus Olodaterol
223801995|NCT01263834|DRUG|Bevacizumab|Bevacizumab injection of 1.25m/0.05 cc + Mitomycin C soaked cellulose dose 0.4 mg/ml with 3 minutes of application
223801996|NCT01263834|DRUG|Mitomycin C|Mitomycin C soaked cellulose dose 0.4 mg/ml with 3 minutes of application
223801997|NCT00765388|DEVICE|SenSura Uro|The test product is a CE-marked non-sterile one-piece urostomy multi-chamber bag with the SenSura adhesive.
223801998|NCT00765388|DEVICE|Hollister|The comparator product is CE-marked and non-sterile and produced for urostomy operated. It is a flat one-piece urostomy product, Hollister Moderma Flex Urostomy beige, Cut-to-Fit Bag, flat adhesive.
223801999|NCT00194558|BEHAVIORAL|Internet co-management module|
223802000|NCT04073238|DEVICE|Low-level Red-light Therapy|In addition to wearing single vision spectacle lens with power for correcting distance refraction, low-level red-light therapy is performed twice per school day at home with an interval of at least 4 hours, each treatment lasting 3 minutes.
223802001|NCT00349479|BEHAVIORAL|Barrier assessment / interactive educational intervention|"Intervention hospitals received a barrier assessment - interactive educational intervention (BA-IEI) which included: on-site barrier assessment, annual stroke champions meetings, stroke center telephone access, quarterly mock stroke codes, and ongoing feedback and education."
223802002|NCT06122740|OTHER|Turkish Validity and Reliability of The MAM-36 Scale|The aim of this study is to adapt the Manual Ability Measure-36 (MAM-36) scale to Turkish society and to make its validity and reliability in Turkish.
223802003|NCT03917368|OTHER|Ultrasound scan of the internal jugular veins|Participants, lying at their hospital bed, will maintain their head in a fixed position on the longitudinal axis, while an operator gently places a linear probe L12-RS (7.5-11 MHz), smeared with gel, on one side of the neck, at the middle level. A 15-sec video clip of the ultrasound images will be recorded. This procedure will be repeated on the other side of the neck. In addition, three electrodes will be placed on participants' chests and connected to the ultrasound system for simultaneously measuring the ECG signal.
223802004|NCT02115633|DEVICE|Walkasins ON|Subjects will be wearing a device that works as intended and provides real-time vibrotactile feedback that reflects center of pressure sway.
223802005|NCT02115633|DEVICE|Walkasins OFF|Subjects will be wearing a device that is turned off.
223802006|NCT01786967|DRUG|Fesoterodine Fumarate|FDA approved anticholinergic medication used for treatment of urge urinary incontinence
223802007|NCT05536362|DRUG|TCI Propofol Injection|To decrease postoperative pain after cancer colon surgery
223802008|NCT04653766|DRUG|Ir-CPI - Dose 1|6 participants received a single intravenous dose of 1.5 mg/kg of Ir-CPI during 6 hours
223802009|NCT04653766|DRUG|Ir-CPI - Dose 2|6 participants received a single intravenous dose of 3.0 mg/kg of Ir-CPI during 6 hours
223802010|NCT04653766|DRUG|Ir-CPI - Dose 3|6 participants received a single intravenous dose of 6.0 mg/kg of Ir-CPI during 6 hours
223802011|NCT04653766|DRUG|Ir-CPI - Dose 4|6 participants received a single intravenous dose of 9.0 mg/kg of Ir-CPI during 6 hours
223802012|NCT04653766|DRUG|Placebo|For each dose group, 2 additional participants received a single intravenous dose of placebo during 6 hours (8 in total).
223802013|NCT01563536|DRUG|ABT-267|Tablet
223802014|NCT01563536|DRUG|ABT-450|Tablet
223802015|NCT01563536|DRUG|ABT-333|Tablet
223802016|NCT01563536|DRUG|Ritonavir|Capsule
223802017|NCT01563536|DRUG|Ribavirin|Tablet
223802018|NCT04560257|DEVICE|High flow nasal cannula HFNC|High flow nasal cannula HFNC is a device that delivered the warmed and humid air on high flow rate through nose. It is used to treat severe respiratory distress in COVID-19 patients, a non-invasive ventilatory approach which is relative comfortable by using humidified and pre-heated air containing large concentration of oxygen.
223802019|NCT00808275|DIETARY_SUPPLEMENT|Dietary calcium|Dairy and non-dairy calcium provided as a part of diet in the amounts of 500 mg/day and 1500 mg/day. Diet contained 70% of daily caloric requirements.
223802020|NCT02036489|DRUG|Vincristine|
223802021|NCT02036489|DRUG|Daunorubicin|
223802022|NCT02036489|DRUG|Prednisone|
223802023|NCT02036489|DRUG|L-asparaginase|
223802024|NCT02036489|DRUG|Ciclophosphamide|
223802025|NCT02036489|DRUG|Metotrexate|
223802026|NCT02036489|DRUG|ARA-C|
223802027|NCT02036489|DRUG|Hidrocortisone|
223802028|NCT02036489|DRUG|Mercaptopurine|
223802029|NCT02036489|DRUG|VP-16|
223802030|NCT02036489|DRUG|Dexametasone|
223802031|NCT05232695|DIAGNOSTIC_TEST|metabolically healthy obese|Obese individuals will be divided into 2 groups as metabolic healthy and unhealthy obese, and their batokine concentrations will be compared.
223802032|NCT01270126|DEVICE|Repetitive transorbital alternating current stimulation|Repetitive, transorbital alternating current stimulation (rtACS) was applied with a multi-channel device generating weak current pulses in predetermined firing bursts of 2 to 9 pulses. The amplitude of each current pulse was below 1000µA. Current intensity was individually adjusted according to how well patients perceived phosphenes, i.e. any sensation of flickering light in response to the rtACS stimulation.
223802033|NCT02158676|DIETARY_SUPPLEMENT|Prebiotic|Fructooligosaccharides
223802034|NCT02158676|DIETARY_SUPPLEMENT|Synbiotic|Fructooligosaccharides + Lactobacillus paracasei LPC-37 + Lactobacillus rhamnosus HN001 + Lactobacillus acidophilus NCFM + Bifidobacterium lactis HN019
223802035|NCT02158676|OTHER|Placebo|Maltodextrin
223802036|NCT05902832|BEHAVIORAL|EmotiPlay|EmotiPlay is a computer-based intervention program, designed to enhance emotion recognition (ER) by addressing multiple modalities of emotional cues (facial expressions, tone of voice, body language),
223802037|NCT00112879|DRUG|arsenic trioxide|
223802038|NCT00112879|DRUG|ascorbic acid|
223802039|NCT00112879|DRUG|dexamethasone|
223802040|NCT00112879|DRUG|thalidomide|
223802041|NCT00112879|PROCEDURE|anti-cytokine therapy|
223802042|NCT00112879|PROCEDURE|antiangiogenesis therapy|
223802043|NCT00112879|PROCEDURE|biological therapy|
223802044|NCT00112879|PROCEDURE|chemotherapy|
223802045|NCT00112879|PROCEDURE|drug resistance inhibition|
223802046|NCT00112879|PROCEDURE|growth factor antagonist therapy|
223802047|NCT00112879|PROCEDURE|non-specific immune-modulator therapy|
223802048|NCT00538590|DEVICE|Collagen Matrix in Glaucoma Filtering Surgery|Collagen Matrix implantation in Glaucoma Filtering Surgery
223802049|NCT00538590|DRUG|Mitomycin-C(MMC) and glaucoma filtering surgery|If mitomycin -C is applied, a single cellulose sponge soaked with Mitomycin-C(MMC) (0.2mg/ml - 0.4mg/ml) is fashioned into an approximate 2.0 × 4.0 mm rectangular shape and applied to the scleral bed and subconjunctival space taking care to avoid exposure to the conjunctival wound edge. Application time is 2 minutes for MMC. Then, the area treated is copiously irrigated with balanced salt solution. After operation, appropriate anti-inflammatory and antibiotic eye-drops will be prescribed.
223802050|NCT06059222|DRUG|Romosozumab|Romosozumab 210 mg/2.34 ml from baseline to month 11
223802051|NCT06059222|DRUG|Zoledronate|5 mg/100 ml at month 12
223802052|NCT06059222|DRUG|Romosozumab|210 mg/2.34 ml from baseline to month 5 and from month 18 to month 23
223802053|NCT06059222|DRUG|Zoledronate|5 mg/100 ml at month 6
223802054|NCT06059222|DRUG|Romosozumab|210 mg/2.34 ml from baseline to month 5
223802055|NCT06059222|DRUG|Zoledronate|5 mg/100 ml at month 5 and month 18
223802056|NCT01256567|BIOLOGICAL|Ramucirumab|Ramucirumab administered as an intravenous (I.V.) infusion at a dose of 10 milligrams per kilogram (mg/kg) every 3 weeks.
223802057|NCT01256567|DRUG|Docetaxel|Docetaxel administered by intravenous (I.V.) infusion at a dose of 75 milligrams per square meter (mg/m\^2) every 3 weeks.
223802058|NCT02563496|DRUG|Tafenoquine|Tafenoquine tablet is supplied as film-coated tablet (100 mg, 150 mg, 200 mg and 300 mg) and fast-dispersing film coated tablet (50 mg).
223802059|NCT02563496|DRUG|Chloroquine|Subjects may receive chloroquine according to local/national treatment guidelines.
223802060|NCT03275025|DRUG|YRA-1909 low dose|A low dose of YRA-1909; daily oral intake for 12 weeks
223802061|NCT03275025|DRUG|YRA-1909 mid dose|A mid dose of YRA-1909; daily oral intake for 12 weeks
223802062|NCT03275025|DRUG|YRA-1909 high dose|A high dose of YRA-1909; daily oral intake for 12 weeks
223802063|NCT03275025|DRUG|Placebo|Matching placebo dosing with daily oral intake for 12 weeks
223802064|NCT02515760|PROCEDURE|Bone marrow aspiration from the iliac crest|
223802065|NCT02515760|DEVICE|Illinois bone marrow aspiration neddle|
223802066|NCT06333587|PROCEDURE|image-guided thermal ablation|image-guided thermal ablation in patients with diagnosis of micropapillary thyroid carcinoma
223802067|NCT00567190|DRUG|Pertuzumab|Pertuzumab was administered as an intravenous (IV) loading dose of 840 milligrams (mg) q3w on Day 1 of Cycle 1 (1 Cycle length = 21 days), and 420 mg q3w on Day 1 of subsequent cycles until investigator-assessed radiographic or clinical progressive disease, unmanageable toxicity, or study termination.
223802068|NCT00567190|DRUG|Placebo|Placebo (matching pertuzumab) was administered intravenously.
223802069|NCT00567190|DRUG|Trastuzumab|Trastuzumab was administered as an IV loading dose of 8 milligrams per kilogram (mg/kg) q3w on Day 2 of Cycle 1 (1 Cycle length = 21 days), and 6 mg/kg q3w on Day 1 of subsequent cycles until investigator-assessed radiographic or clinical progressive disease, unmanageable toxicity, or study termination.
223802070|NCT00567190|DRUG|Docetaxel|Docetaxel was administered as an IV dose of 75 milligrams per square meter of body surface area (mg/m\^2) q3w on Day 2 of Cycle 1 (1 Cycle length = 21 days), and 75 mg/m\^2 (up to 100 mg/m\^2 as per treating physician discretion) q3w on Day 1 of subsequent cycles until investigator-assessed radiographic or clinical progressive disease, unmanageable toxicity, or study termination. On or prior to Cycle 6, docetaxel was only to be discontinued for progressive disease or unmanageable toxicity. After Cycle 6, continuation of docetaxel treatment was at the discretion of the participant and treating physician.
223802071|NCT06075108|OTHER|P-KIDs CARE|The P-KIDs CARE intervention will include two components: 1) the World Health Organization (WHO) Basic Emergency Care Course for training on patient assessment and stabilization, and 2) a decision support tool which integrates adaptation of two evidence-based tools: a) the Pediatric Resuscitation and Trauma Outcome model for mortality risk assessment, and 3) the Field Triage Decision Scheme to assist with timely referral decisions. WHO Basic Emergency Care Course includes modules delivered via PowerPoint with hands-on training components. The decision support tool will be online with checkboxes that healthcare providers can cross as they fill it out in real time. The team will adapt the tool for use in Northern Tanzania, with particular attention to local contextual and cultural factors.
223802072|NCT02674893|DRUG|Liraglutide|
223802073|NCT02674893|OTHER|Observation alone|
223802074|NCT06031883|DRUG|Ketamine|Total intravenous anesthesia in craniotomy
223802075|NCT06136221|BEHAVIORAL|LiverWatch Intervention|The LiverWatch Intervention will include standard cirrhosis care and include additional components utilizing the W2H system. Details on this intervention are included in the study arm description.
223802076|NCT03136445|DRUG|Tranexamic acid (TXA).|IV or oral preparation. IV tranexamic acid or Oral tablet of tranexamic acid.
223802077|NCT03136445|DRUG|Placebo|IV (saline) or oral placebo tablets
223802078|NCT04526795|DRUG|Cytarabine|Given IV
223802079|NCT04526795|DRUG|Fludarabine|Given IV
223802080|NCT04526795|DRUG|Pegcrisantaspase|Given IV
223802081|NCT05850091|DRUG|Rosuvastatin|Pharmacotherapy for reduction in LDL cholesterol level
223802082|NCT05850091|DRUG|Colchicine|Pharmacotherapy for inflammation inhibition
223802083|NCT05850091|DRUG|Placebo|Capsule with sugar pill that mimics active study drugs
223802084|NCT06030414|BIOLOGICAL|LMN-301|Intranasally administered powder.
223802085|NCT06019117|DIETARY_SUPPLEMENT|Probiotic K10|clinical trial using 90 days of probiotic K10
223802086|NCT06019117|DRUG|Placebo|clinical trial using 90 days of placebo controlled
223802087|NCT04288505|DIAGNOSTIC_TEST|VIRTUAL REALITY application|application on virtual reality headset
223802088|NCT05411965|DRUG|BR3003(T)|"Test drug (T):BR3003 Boryung Pharmaceutical Co., Ltd."
223802089|NCT05411965|DRUG|BR3003B(R1)|"Reference drug 1 (R1): BR3003B of Celltrion Pharm, Inc."
223802090|NCT05411965|DRUG|BR3003C(R2)|"Reference drug 2 (R2): BR3003C of AstraZeneca Korea"
223802091|NCT03772067|DEVICE|Continuous glucose monitoring CGM|The effect of the two diets (MBdiet and OBdiet) will be compared on the efficacy on changing the overall glucose levels measured with CGM installed in the arm during 14 days at baseline before diet intervention and after 14 days of the beginning of diet intervention
223802092|NCT03772067|DIAGNOSTIC_TEST|Clock Genes m RNA expression|The effect of the two diets (MBdiet and OBdiet) will be compared on the efficacy on changing the blood levels of Clock Genes measured at baseline and after 14 days of diet intervention
223802093|NCT03772067|DIAGNOSTIC_TEST|Postprandial Glucose|The effect of the two diets (MBdiet and OBdiet) will be compared on the efficacy on changing the postprandial plasma Glucose measured at meal test after 14 days of diet intervention
223802094|NCT03772067|DIAGNOSTIC_TEST|Postprandial Insulin|The effect of the two diets (MBdiet and OBdiet) will be compared on the efficacy on changing the postprandial plasma Insulin measured at meal test after 14 days of diet intervention
223802095|NCT03772067|DIAGNOSTIC_TEST|Plasma GLP-1|The effect of the two diets (MBdiet and OBdiet) will be compared on the efficacy on changing the postprandial plasma GLP-1 measured at meal test after 14 days of diet intervention
223802096|NCT03772067|DIAGNOSTIC_TEST|DPP4 plasma activity|The effect of the two diets (MBdiet and OBdiet) will be compared on the efficacy on changing the postprandial DPP4 plasma activity measured at meal test after 14 days of diet intervention
223802097|NCT03772067|DIAGNOSTIC_TEST|Ghrelin|The effect of the two diets (MBdiet and OBdiet) will be compared on the efficacy on changing the postprandial plasma Ghrelin measured at meal test after 14 days of diet intervention
223802098|NCT03772067|DIAGNOSTIC_TEST|Plasma CCK|The effect of the two diets (MBdiet and OBdiet) will be compared on the efficacy on changing the postprandial plasma CCK measured at meal test after 14 days of diet intervention
223802099|NCT03772067|DIAGNOSTIC_TEST|Plasma PYY|The effect of the two diets (MBdiet and OBdiet) will be compared on the efficacy on changing the postprandial plasma PYY measured at meal test after 14 days of diet intervention
223802100|NCT03772067|OTHER|Body Weight|The effect of the two diets (MBdiet and OBdiet) will be compared on the efficacy on changing the body weight at baseline and every weeks of diet intervention
223802101|NCT03772067|DIAGNOSTIC_TEST|Blood levels of HbA1c|The effect of the two diets (MBdiet and OBdiet) will be compared on the efficacy on changing blood HbA1c measured at baseline and after 90 days of diet intervention diet intervention
223802102|NCT05258162|OTHER|Mobilization|"Hot pack for ten minutes.~Active and active-assisted exercises for the:~* Elbow flexion and extension~* Wrist flexion and extension~* Forearm supination and pronation~* Lock and key exercises.~* Shoulder flexion, extension, abduction, adduction, and rotation (10 repetitions x 1sets) Low-intensity isometric resistance exercises for;~* Elbow flexion and extension~* Forearm supination and pronation (10 sec hold) (10 repetitions x 1 set) Resistance will be provided manually by the therapist. Along all these exercises Mobilisations are performed with minimum 6 seconds distraction stretch followed by partial release then followed by slow intermittent stretch at 3-4 seconds intervals.~  3 days per week for 3 weeks. Oscillations for 2 minutes at 2-3 oscillations per second."
223802103|NCT05258162|OTHER|Muscle Energy Technique|"Hot pack for ten minutes.~Active and active-assisted exercises for the:~* Elbow flexion and extension~* Wrist flexion and extension~* Forearm supination and pronation~* Lock and key exercises.~* Shoulder flexion, extension, abduction, adduction, and rotation (10 repetitions x 1sets) Low-intensity isometric resistance exercises for;~* Elbow flexion and extension~* Forearm supination and pronation (10 sec hold) (10 repetitions x 1 set) Resistance will be provided manually by the therapist. Along all these exercises Muscle Energy Technique is given in the form of post isometric relaxation with 5-7 sec hold for 8-10 repetitions followed by a gentle passive stretch. Only 20% resistance is offered to the isometric contraction.~  3 days per week for 3 weeks."
223802104|NCT03491761|BIOLOGICAL|PRP Treatment|PRP will be prepared using an Arthrex ACP® kit (a low-leukocyte Autologous Conditioned Plasma system). This is a single-spin system that concentrates platelets and separates red blood cells (RBCs) as well as white blood cells (WBCs) from the treatment product.
223802105|NCT03491761|BIOLOGICAL|HA Treatment|Euflexxa will be used for treatment. It will be prepared according to the package insert.
223802106|NCT00680511|BEHAVIORAL|Adolescent Methamphetamine Treament (AMT)|AMT Group Therapy plus Functional Family Therapy (FFT)
223802107|NCT00680511|BEHAVIORAL|Functional Family Therapy (FFT)|FFT
223802108|NCT01522417|DRUG|Short Tirofiban|25 mcg/kg i.v. bolus followed by a 0.15 mcg/kg/min i.v. infusion during a PCI plus 1 to 2 hours post-PCI.
223802109|NCT01522417|DRUG|Eptifibatide|180 mcg/kg bolus followed by a 2.0 mcg/kg/min infusion for 12 to 18 hours, with a second 180 mcg/kg bolus 10 min after the first.
223802110|NCT01522417|DRUG|Long Tirofiban|25 mcg/kg i.v. bolus followed by a 0.15 mcg/kg/min i.v. infusion for 12 to 18 hours post-PCI.
223802111|NCT06200766|DRUG|Mometasone furoate as a nasal spray|Subjects received 2 presses in each side nostrils at the same time point (± 1h).
223802112|NCT04406493|DIAGNOSTIC_TEST|Lung impedance technique|"COVID 19 patients are admitted to the Infectious Diseases Unit; they will undergo examination using a lung impedance device. The first value that has been measured will be set as BASAL.~During the hospitalization, each patient will undergo this examination twice a day until discharge.~Changes in impedance values during admission will be evaluated as POSITIVE AND NEGATIVE PREDICTIVE values for clinical deterioration and improvement of COVID 19 patients and as a factor which predicts mechanical ventilation.~The time between lung impedance started to decrease (expression of the lung fluids accumulation), and the need for mechanical ventilation will be measured."
223802113|NCT01894295|DIETARY_SUPPLEMENT|Placebo|Corn oil pearl Capsules 1 gram; were given to the intervention group once a day for 8 weeks
223802114|NCT01894295|DIETARY_SUPPLEMENT|Vitamin D analogue|1-α hydroxyvitamin D3 dose 0.25, 0.5 and 1 microgram were given to the intervention group once a day for 8 weeks
223802115|NCT05040451|DEVICE|Carillon Mitral Contour System|"The Carillon Mitral Contour System (XE2) consists of the following components:~* An implant intended for permanent placement in the coronary sinus (CS)/great cardiac vein (GCV)~* A delivery system which consists of a custom 9F delivery catheter and a handle assembly."
223802116|NCT03292250|DRUG|BYL719|Patients will be instructed to take BYL719 orally at a dose of 100 mg with a glass of water once daily, in a fasting state or with a light fat-free meal, and as close as possible to the same time each day.
223802117|NCT03292250|DRUG|Poziotinib|Patients will be instructed to take BYL719 orally at a dose of 12 mg once daily, in a fasting state or with a light fat-free meal, and as close as possible to the same time each day.
223802118|NCT03292250|DRUG|Nintedanib|Initial dose 200 mg twice per day orally according to study protocol.
223802119|NCT03292250|DRUG|Abemaciclib|Patients will be instructed to take Abemaciclib orally at a dose of 200mg bid with a glass of water twice daily, in a fasting state or with a light fat-free meal, and as close as possible to the same time each day.
223802120|NCT03292250|DRUG|Durvalumab,Tremelimumab|Durvalumab: 1.5g Q4W plusTremelimumab: 75mg Q4W up to 4cycle then Durvalumab 750mg Q2W, till PD or unacceptable toxicity.
223802121|NCT04801550|DEVICE|Millimeter waves local exposure|several blocks of somatosensory evoked potentials with or without Millimeter waves local exposure
223802122|NCT05308329|DEVICE|Intra-coronary imaging device|Culprit/nonculprit lesions are accessed by intra-coronary imaging device including intravascular ultrasound and optical coherence tomography.
223802123|NCT05308329|BEHAVIORAL|PCI procedural characteristics|Procedural characteristics include the information about angiographical characteristics, type of stent, pre/post POBA, and thrombectomy.
223802124|NCT05330065|DRUG|bevacizumab and camrelizumab|"Stage 1 was classical 3+3 dose escalation with pts assigned to one of the following 3 cohorts, Cohort A:Avastin 5mg/kg once every 2 weeks and camrelizumab 100mg once every 2 weeks;Cohort B:Avastin 7.5mg/kg once every 2 weeks and camrelizumab 100mg once every 2 weeks;Cohort C:Avastin 7.5mg/kg once every 2 weeks and camrelizumab 200mg once every 2 weeks.DLT was observed for 28 days."
223802125|NCT01657058|DIETARY_SUPPLEMENT|Soluble viscous fibre blend powder in hydrophobic matrix|5g soluble viscous fibre blend pre-mixed into margarine (hydrophobic matrix) + white bread + jello
223802126|NCT01657058|DIETARY_SUPPLEMENT|Soluble viscous fibre blend in pre hydrated form|0g soluble viscous fibre blend margarine + white bread +5g Konjac fibre prehydrated in jello
223802127|NCT01657058|DIETARY_SUPPLEMENT|No soluble viscous fibre blend|0g soluble viscous fibre blend margarine + white bread + jello
223802128|NCT01657058|DIETARY_SUPPLEMENT|Soluble viscous fibre blend premixed with ½ carbohydrate gel|Margarine + white bread (1/2 carbohydrate) +5g soluble viscous fibre blend hydrated in jello with glucose
223802129|NCT01657058|DIETARY_SUPPLEMENT|No soluble viscous fibre blend, ½ carbohydrate jello|Margarine + white bread (1/2 carbohydrate) +5g soluble viscous fibre blend hydrated in jello with glucose
223802130|NCT01352598|RADIATION|stereotactic body radiotherapy|Patients will receive 30 - 40 Gy in 4 - 5 fractions. For high risk patients who also receive external beam radiotherapy, the SBRT will be given as 19 - 21 Gy in 2 - 3 fractions.
223802131|NCT00091481|DRUG|Zemplar|
223802132|NCT02450318|OTHER|Slow-paced walking|Subjects will walk on a treadmill at a slow pace for 47 minutes
223802133|NCT04788550|COMBINATION_PRODUCT|Fluoridated toothpaste|Group 1 will act as control group. Participants will be advised to brush twice daily using fluoridated toothpaste during the follow up periods. No other fluorides supplements will be allowed to use.
223802134|NCT04788550|COMBINATION_PRODUCT|fluoride varnish (5% sodium fluoride)|Approximately 0.5-1.0ml fluoride varnish will be applied on the tooth surface (labially) with the paint-on method fom canines to canines. No other fluorides supplements will be allowed to use.
223802135|NCT04788550|COMBINATION_PRODUCT|CPP-ACP plus crème group|Pea size CPP-ACP plus crème on the tooth surfaces using a clean fingers twice daily after brushing their teeth with fluoridated toothpaste. No other fluorides supplements will be allowed to use.
223802136|NCT00093834|BIOLOGICAL|allogeneic GM-CSF-secreting breast cancer vaccine|The first three patients will receive a dose of 5 X 107 cells, and the next three will receive a dose of 5 X 108 cells. Then, if these two doses of vaccine alone are found to be safe, a fixed vaccine dose of 5 X 108 cells will be tested in combination with chemotherapy based on the safety of the allogeneic breast vaccine alone and the safety and bioactivity of a dose of 5 X 108 cells in the allogeneic pancreatic vaccine trial
223802137|NCT00093834|DRUG|cyclophosphamide|This trial will be a dose ranging study of a fixed sequence of drug doses in a three by three factorial matrix modeled after the theories of Plackett and Burman (Plackett et al., 1946), and is designed to determine the doses of CY and DOX that maximize the immunologic response to vaccination
223802138|NCT00093834|DRUG|doxorubicin hydrochloride|This trial will be a dose ranging study of a fixed sequence of drug doses in a three by three factorial matrix modeled after the theories of Plackett and Burman (Plackett et al., 1946), and is designed to determine the doses of CY and DOX that maximize the immunologic response to vaccination
223802139|NCT06152653|DRUG|n-acetylcystine (NAC)+ albuterol|NAC is a mucolytic drug and Albuterol is a bronchodilator.
223802140|NCT06152653|DEVICE|AeroEclipse-VersaPAP System|The AeroEclipse-VersaPAP System combine continuous positive inspiratory pressure and nebulizer in one system.
223802141|NCT02434380|DIETARY_SUPPLEMENT|Euro D|Vitamin D3 Euro D 10,000 IU (1 tablet) plus Euro D Placebo (1 tablet) weekly, alternating with Euro D Placebo (2 tablets) weekly, starting at the second trimester and continued until delivery.
223802142|NCT02434380|DIETARY_SUPPLEMENT|Euro D|Vitamin D3 Euro D 10,000 IU (2 tablets, equivalent to 20,000 IU) weekly, starting at the second trimester and continued until delivery.
223802143|NCT03538470|OTHER|Spa Treatment|"* Bath with immersion shower~* Overall penetrating shower~* Multiple local application cataplasm~* Individual physiotherapy~* Mobilisation pool"
223802144|NCT05279170|OTHER|MAVEPPIC: MAsk VEntilation with Paratracheal Pressure In Children|"Pressure will be applied with two fingers in the area located between the trachea and the sternal head of the sternocleidomastoid muscle on the left side to compress the cervical esophagus.~The force applied (after measuring the equivalent force applied on a precision scale) will be about 10 - 15 N. This force will be adapted according to the child's body weight : 10 N below 20 kgs and 15 N between 20 kgs and 40 kgs"
223802145|NCT05979909|DRUG|Mitomycin C|Mitomycin (40 mg in 40 mL of sterile water) will be administered through a Foley catheter, which will be clamped for two hours.
223802146|NCT02732366|BEHAVIORAL|Group-based exercise and peer coaching|Group-based exercise and peer coaching will take place over 6 weeks plus one booster visit after 3 months, and include physical therapist-led 1 hour sessions 2 times per week for 2 weeks followed by once per week for 4 weeks (8 sessions) to include: progressive strengthening, balance and mobility exercises; patient goal setting; peer coaching training activities to teach group members ways to help each other to meet their exercise goals during and after classes are over. There will be an individualized home program including flexibility, strengthening, walking, and balance, as well as activity monitoring.
223802147|NCT02732366|OTHER|Usual PT and attention control grp class|The usual PT and attention control group class will receive standard one-on-one PT strength, balance, gait and education intervention, and group classes to provide valuable information about healthy living, including nutrition, relaxation, and stress management. The attention control - healthy living group classes will take place over 6 weeks plus one booster visit after 3 months, and include 1 hour sessions 2 times per week for 2 weeks followed by once per week for 4 weeks (8 sessions).
223802148|NCT04524468|DIAGNOSTIC_TEST|Transthoracic echocardiography|Conventional 2-D transthoracic echocardiography was performed to all patients
223802149|NCT05228600|DRUG|YL-13027|"YL-13027 is a novel small molecule TGF-βR1 inhibitor. 1.1.1. Chemical Properties~Chemical Name:~6-(5-fluoro-2-(6-methylpyridin-2-yl)phenyl)imidazo\[1,2-a\]pyridine-3-carboxamide Molecular Formula C20H15FN4O Molecular Weight 346.36 Formulation YL-13027 is provided as pink film coated tablets for oral administration in two strengths, 30 mg and 120 mg.~Packaging and Storage YL-13027 tablets are packaged (30 tablets/bottle) in the 45 mL opaque HDPE bottles with child resistant polypropylene caps, induction-sealed inner polypropylene liners. YL-13027 tablets should be protected from light in a closed container and stored at room temperature.~Stability The shelf-life of YL-13027 oral tablets is tentatively set at 24 months when stored at room temperature."
223802150|NCT04609033|DRUG|Bupivacaine|instillation of local anaesthetic in the abdominal cavity at the end of the procedure
223802151|NCT04609033|DRUG|isotonic saline|instillation of local anaesthetic in the abdominal cavity at the end of the procedure
223802152|NCT04609033|DRUG|Bupivacaine + morphine|instillation of local anaesthetic + morphine sulfate in the abdominal cavity at the end of the procedure
223802153|NCT04609033|DRUG|Bupivacaine + morphine + ketamine|instillation of local anaesthetic + morphine sulfate + ketamine in the abdominal cavity at the end of the procedure
223802154|NCT03131557|DEVICE|Line extension of the Phonak Audéo B product family|The line extension of the Phonak Audéo B product family will be fitted to the participants individual hearing loss.
223802155|NCT03131557|DEVICE|Phonak Audéo B|Phonak Audéo B will be fitted to the participants individual hearing loss.
223802156|NCT05525273|DRUG|Oral dabrafenib and trametinib|Neoadjuvant or postoperative treatment of patients with verified BRAF mutated papillary craniopharyngioma
223802157|NCT03062969|PROCEDURE|Cleavage stage biopsy group|"* intracytoplasmatic sperm injection (ICSI)- (Invitro Fertilization)IVF~* Time lapse embryo culture~* Cleavage stage biopsy~* aCGH analysis~* Fresh euploid embryo transfer"
223802158|NCT03062969|PROCEDURE|Trophectoderm biopsy group|"* ICSI-IVF~* Time lapse embryo culture~* Day 3 zona pellucida opening~* Trophectoderm biopsy~* aCGH analysis~* Frozen-thawed euploid embryo transfer"
223802159|NCT05579418|DRUG|Evolocumab|Evolocumab is an injection for management of dyslipidemia
223802160|NCT00000727|DRUG|Pentamidine isethionate|
223802161|NCT00000727|DRUG|Pyrimethamine|
223802162|NCT00000727|DRUG|Sulfamethoxazole/Trimethoprim|
223802163|NCT00000727|DRUG|Sulfadoxine/Pyrimethamine|
223802164|NCT00000727|DRUG|Zidovudine|
223802165|NCT03520764|DIETARY_SUPPLEMENT|New infant formula with synbiotics|Infants are fed with synbiotics formula for 17 weeks from the date of enrollment.
223802166|NCT03520764|DIETARY_SUPPLEMENT|Standard infant formula with prebiotics|Infants are fed with prebiotics formula for 17 weeks from the date of enrollment.
223802167|NCT03781752|DRUG|Methylphenidate|study to determine dose
223802168|NCT05568433|DIAGNOSTIC_TEST|Endoscopic ultrasound fine needle aspiration (EUS-FNA)|Patients with pancreatic cysts who underwent endoscopic ultrasound and endoscopic fine needle aspiration for diagnostic and therapeutic purpose. A sample of the cyst fluid and frozen serum was collected from the patients and stored at minus 80 degrees.
223802169|NCT01839929|DRUG|Prograf|oral
223802170|NCT01839929|DRUG|Advagraf|oral
223802171|NCT00344461|DRUG|Nevirapine, FTC, and Tenofovir|One arm only - Open label using FTC 200 mg p.o. qd, and Tenofovir 300 mg p.o. qd, and Nevirapine 200 mg b.i.d.
223802172|NCT04189562|OTHER|SMS Intervention|Delivery of text messages will use the text messaging program Simple Online Family Intervention for ADHD (SOFIA).
223802173|NCT02096523|OTHER|Blood collection for platelet protein samples|
223802174|NCT01229930|DRUG|carboplatin|
223802175|NCT01229930|DRUG|cediranib maleate|
223802176|NCT01229930|DRUG|paclitaxel|
223802177|NCT01229930|OTHER|laboratory biomarker analysis|
223802178|NCT01229930|OTHER|pharmacological study|
223802179|NCT01229930|PROCEDURE|quality-of-life assessment|
223802180|NCT06171607|PROCEDURE|Contrast-Enhanced Ultrasound|Undergo CEUS
223802181|NCT06171607|DRUG|Perflutren Lipid Microspheres|Given IV
223802182|NCT06171607|DRUG|Sulfur Hexafluoride Lipid Microspheres|Given IV
223802183|NCT05945433|DEVICE|anovo™ Surgical System|The anovo Surgical System is an endoscopic instrument control system that is intended to assist in the accurate control of the Instrument ARMS during single site, natural orifice laparoscopic-assisted transvaginal benign surgical procedures.
223802184|NCT00142441|DEVICE|Pulsed dye laser|
223802185|NCT02660632|OTHER|Thoracic epidural analgesia (TEA)|Epidural catheter will be inserted at T9-T11. Then, epidural analgesia will be activated with administering bolus of 10 mls 0.25% bupivacaine in conjunction with100 mcg fentanyl to establish a block. This will be followed by an infusion of 0.125% bupivacaine in conjunction with 2 mcg/ ml fentanyl at a rate of 10 mls /hour and then titrated to effect for up to 48 hour postoperative
223802186|NCT02660632|OTHER|Rectus sheath catheter block|Following insertion of bilateral rectus sheath catheters, 20 ml of 0.25% bupivacaine will be injected through each one. Then continuous infusion pumps will be connected to the catheters and set to deliver boluses of 20 mL of 0.25% bupivacaine, with a 4-hour lockout for up to 48 h postoperatively.
223802187|NCT05230173|OTHER|Pragmatic|"Patients randomized to a strategy of switching TIM will be switched to one of the preferred agents recommended by clinical guidelines and covered by the patients' insurance formulary as part of routine care, and at the discretion of the site investigator and treating provider. No study-related medications will be provided.~Patients (and their providers) in either treatment arm will be allowed to stop or start new TIMs and other IBD-directed therapies in case of symptomatic relapse or intolerance to therapies, at the discretion of the treating provider-patient team."
223802188|NCT04414267|BIOLOGICAL|BCG vaccine|Patients susceptible to SARS-CoV-2 infection will be vaccinated with one intradermal injection of 0.1ml of BCG vaccine
223802189|NCT04414267|BIOLOGICAL|Placebo|Patients susceptible to SARS-CoV-2 infection will be vaccinated with one intradermal injection of 0.1ml of sodium chloride 0.9%
223802190|NCT00636610|DRUG|Vismodegib 150 mg|Vismodegib 150 mg was provided in hard gelatin capsules in 3 different strengths, 25 mg, 125 mg, and 150 mg.
223802191|NCT00636610|DRUG|Placebo to vismodegib|Placebo to vismodegib consisted of the excipients for vismodegib without the active molecule in hard gelatin capsules matching the active drug product in color and size.
223802192|NCT00636610|DRUG|Bevacizumab|Bevacizumab 5 mg/kg was administered intravenously (IV) over 90 minutes for the first infusion, shortening to 60 and 30 minutes for subsequent infusions.
223802193|NCT00636610|DRUG|Modified FOLFOX|Following administration of bevacizumab, patients received oxaliplatin 85 mg/m\^2 IV administered over 90 minutes concurrently with folinic acid 400 mg/m\^2 (d,I-racemic form, or 200 mg/m\^2 I-isomer form) IV administered over 120 minutes, then fluorouracil 400 mg/m\^2 administered as an IV bolus, then 2400 mg/m\^2 administered as a continuous IV infusion over 46 hours.
223802194|NCT00636610|DRUG|FOLFIRI|Following administration of bevacizumab, patients received irinotecan 180 mg/m\^2 IV administered over 90 minutes concurrently with folinic acid 400 mg/m\^2 (d,I-racemic form, or 200 mg/m\^2 I-isomer form) administered IV over 120 minutes, then fluorouracil 400 mg/m\^2 administered as an IV bolus, then fluorouracil 2400 mg/m\^2 administered as a continuous IV infusion over 46 hours.
223802195|NCT02063126|DIETARY_SUPPLEMENT|ReConnect (NADH plus CoQ10)|"ReConnect supplementation (NADH: 20 mg/day plus CoQ10: 200mg/day) divided into two daily dose ( 2 tablets/ before breakfast and 2 tablets/ before lunch)~Placebo supplementation divided into two daily dose ( 2 tablets/ before breakfast and 2 tablets/ before lunch)"
223802196|NCT02063126|DIETARY_SUPPLEMENT|placebo|placebo (phosphoserine/serine plus vitamin C) supplementation divided in two daily doses (2 tablets/before brekfast and 2 tablets/before lunch)
223802197|NCT06313580|OTHER|Yogurt with added Spices|Consumption of twice daily yogurt with added spices for four weeks.
223802198|NCT06313580|OTHER|Yogurt without added Spices|Consumption of twice daily yogurt without added spices for four weeks.
223802199|NCT03691116|BEHAVIORAL|Digital Health Profile|Screening, health check-up and automatic feedback in the areas tobacco, alcohol, exercise and diet, used on a National digital platform (Stöd och Behandlingsplattformen, SoB)
223802200|NCT03691116|BEHAVIORAL|Treatment as usual|Ordinary psychological assessment and counseling.
223802201|NCT02910648|BEHAVIORAL|Modified Go/No-Go Task|Participants in the experimental group and control sham sound cues group will complete a computerized training task to facilitate learning to respond (press a computer key) to healthy food stimuli and to inhibit responses (not press a computer key) to unhealthy food stimuli. Participants in the control sham go/no-go group will complete a similar task with common office supplies (approach) and tools (inhibit). All participants will also complete a 24 hour dietary recall as described below.
223802202|NCT02112981|DEVICE|Sirolimus Eluting Coronary Stent|BioMimeTM Sirolimus Eluting Stent (CE Marked) has cobalt chromium NexGenTM platform (CE Marked) with Tamarin BlueTM balloon Delivery System (CE marked and with FDA clearance under 510k). Stent is coated with combination of Sirolimus drug and Biodegradable PLLA and PDLG polymers.
223802203|NCT02112981|DEVICE|Everolimus-eluting Coronary stent|Xience V/Xience Xpedition/Xience Prime stent is MULTI-LINK MINI VISION or MULTI-LINK VISION platform Cobalt chromium stent with Everolimus (active ingredient) embedded in a non-erodible polymer (inactive ingredient).
223802204|NCT00291967|BIOLOGICAL|DTPw-HBV/Hib-MenAC conjugate vaccine|
223802205|NCT05081453|DEVICE|pavlik harness|The application of a pavlik harness will be carried out in the intervention group. It will follow a protocol similar to that of the treatment of hip dysplasia in terms of follow-up and safety
223802206|NCT02889653|DRUG|Any oral antithrombotics (antiplatelets or anticoagulants)|
223802207|NCT01494168|PROCEDURE|Bariatric surgery (Roux-en-y bypass or sleeve gastrectomy)|Bariatric surgery
223802208|NCT04115111|DRUG|Durvalumab|Durvalumab in monotherapy as second line treatment
223802209|NCT03610126|PROCEDURE|volume controlled ventilation|the patients will be ventilated by volume controlled ventilation after insertion of the BASKA laryngeal mask airway
223802210|NCT03610126|PROCEDURE|pressure controlled ventilation|the patients will be ventilated by pressure controlled ventilation after insertion of the BASKA laryngeal mask airway
223802211|NCT01235468|BIOLOGICAL|ex vivo expansion|ex-vivo expansion of cord blood for transplantation
223802212|NCT03682718|DEVICE|Transcervical Foley catheter|combined methods of induction of labor Floey Catheter with misoprstol
223802213|NCT03682718|DRUG|Misoprostol|Misoprstol inserted vaginally for induction of labor
223802214|NCT00501254|DRUG|Slow release acetyl salicylic acid|
223802215|NCT00501254|BEHAVIORAL|Antithrombotic effect|
223802216|NCT03337646|DRUG|Lisdexamfetamine Dimesylate|Medication to treat ADHD
223802217|NCT00671931|DRUG|low dexmedetomidine, low propofol|Dexmedetomidine loading dose 0.6 MCG/KG,Propofol infusion 100 MCG/KG/M
223802218|NCT00671931|DRUG|high dexmedetomidine, low propofol|Dexmedetomidine loading dose 1.1 MCG/KG ,Propofol infusion 100 MCG/KG/M
223802219|NCT00671931|DRUG|Dexmedetomidine|Dexmedetomidine loading dose 0.6 MCG/KG,Propofol infusion 200 MCG/KG/M
223802220|NCT00671931|DRUG|Dexmedetomidin|Dexmedetomidine loading dose 1.1 MCG/KG.Propofol infusion 200 MCG/KG/M
223802221|NCT00671931|DRUG|Dexmedetomidine|Dexmedetomidine loading dose 0.9 mcg/kg,Propofol infusion 140 mcg/kg/min
223802222|NCT04419948|OTHER|White bread|White bread (120g) containing 54 g CHO
223802223|NCT04419948|OTHER|Butter|Butter 39 g
223802224|NCT04419948|OTHER|Refined olive oil|Refined olive oil (40 ml).
223802225|NCT04419948|OTHER|EVOO with 250 mg/kg oleocanthal|Extra virgin olive oil containing 250 mg/kg oleocanthal.
223802226|NCT04419948|OTHER|EVOO with 500 mg/kg oleocanthal|Extra virgin olive oil containing 500 mg/kg oleocanthal.
223802227|NCT04419948|OTHER|Ibuprofen|Ibuprofen 400 mg
223802228|NCT04369014|DRUG|etomidate anesthesia|etomidate is used for induction and maintenance of general anesthesia
223802229|NCT04369014|DRUG|propofol anesthesia|propofol is used for induction and maintenance of general anesthesia
223802230|NCT02251327|DEVICE|Investigational Xpert DST test|One investigational test performed directly on the same sputum specimen.
223802231|NCT00816881|DEVICE|flutter mucus clearance device|five minutes every session, four sessions per day
223802232|NCT02118129|BEHAVIORAL|an educational video|
223802233|NCT02118129|OTHER|wait listed|
223802234|NCT04437940|DIAGNOSTIC_TEST|Vaginal fluid Covid-19 PCR test|Vaginal fluid samples are tested for Covid-19
223802235|NCT03619460|PROCEDURE|piezoelectric extraction|Only Piezoelectric device will be used for surgical wisdom teeth extraction
223802236|NCT03619460|PROCEDURE|conventional extraction|Only manual instruments and burs on straight handpick will be used for wisdom teeth extraction
223802237|NCT03084926|DRUG|MP0274|Intravenous infusion of MP0274 as single agent at four planned dose levels, every three weeks until progressive disease, unacceptable toxicity or patient withdrawal for other reasons
223802238|NCT00003500|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Refractory or Recurrent Intermediate-Grade Stage II - IV Non-Hodgkin's Lymphoma will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
223802239|NCT00826306|OTHER|Patient Educational Materials|In the experimental arm, the intervention is the video-based patient educational material on sunscreen. In the active comparison arm (control arm), the comparison intervention is written patient educational material on sunscreen.
223802240|NCT06217367|DRUG|50 mg Diphenhydramine|Participants ingest 50mg of diphenhydramine orally \~2 hours prior to a passive heating protocol. Participants then don a water-perfusion heat suited and lay supine on assessment table while 49℃ is circulated throughout the garment. Heating persists until participants reach a 1.5℃ increase in core temperature from baseline.
223802241|NCT06217367|DRUG|10 mg Loratadine|Participants ingest 10 mg of loratadine orally \~2 hours prior to a passive heating protocol. Participants then don a water-perfusion heat suited and lay supine on assessment table while 49℃ is circulated throughout the garment. Heating persists until participants reach a 1.5℃ increase in core temperature from baseline.
223802242|NCT06217367|DRUG|5 mg Desloratadine|Participants ingest 5 mg of desloratadine orally \~2 hours prior to a passive heating protocol. Participants then don a water-perfusion heat suited and lay supine on assessment table while 49℃ is circulated throughout the garment. Heating persists until participants reach a 1.5℃ increase in core temperature from baseline.
223802243|NCT06217367|OTHER|Placebo (Sugar Pill)|Participants ingest placebo pill orally \~2 hours prior to a passive heating protocol. Participants then don a water-perfusion heat suited and lay supine on assessment table while 49℃ is circulated throughout the garment. Heating persists until participants reach a 1.5℃ increase in core temperature from baseline.
223802244|NCT02507648|DRUG|Oseltamivir|1 tablet contains 75 mg oseltamivir
223802245|NCT02507648|DRUG|Tamiflu®|1 tablet contains 75 mg oseltamivir
223802246|NCT04845048|BIOLOGICAL|Adsorbed COVID-19 (Inactivated) Vaccine|Adsorbed COVID-19 (inactivated) Vaccine manufactured by Sinovac/Butantan Institute
223802247|NCT03757000|DRUG|YY-20394|YY-20394 is a new type of PI3K-δ selective inhibitor which differs structurally from idelalisib and its analogs, showing high potency against PI3Kδ, but with markedly improved selectivity (\>1,000-fold selectivity for PI3K-δ versus PI3Kγ). This higher selectivity for PI3Kδ may decrease the risk of serious infection seen with idelalisib and especially with duvelisib due to strong immune suppression.Preclinical evaluation has demonstrated improved efficacy and safety for YY-20394 compared to idelalisib.
223802248|NCT04719689|OTHER|Dry needling|Experimental group 1 got this intervention containing Dry needling for 10 mins, followed by conventional physiotherapy treatment (hot pack and stretching) for 15 mins. Participants were treated 6 times over a 3 week period with 2 treatment sessions per week per patient. Pre and Post treatment readings were taken in 1st and 6th session over a 3 week period respectively. A follow up reading was also taken after 1 month for checking prolonged post treatment effects. Assessment was done via Pressure pain threshold Scale, Pelvic goniometer and Measuring tape for assessing functional positional fault of pelvis and muscle length of Quadratus lumborum
223802249|NCT04719689|OTHER|Dry cupping|Experimental group 2 got this intervention containing Dry cupping for 10 mins, followed by conventional physiotherapy treatment (hot pack and stretching) for 15 mins. Participants were treated 6 times over a 3 week period with 2 treatment sessions per week per patient. Pre and Post treatment readings were taken in 1st and 6th session over a 3 week period respectively. A follow up reading was also taken after 1 month for checking prolonged post treatment effects. Assessment was done via Pressure pain threshold Scale, Pelvic goniometer and Measuring tape for assessing functional positional fault of pelvis and muscle length of Quadratus Lumborum
223802250|NCT01723722|DRUG|Methadone|Concentration is 1mg/mL administered every 12 hours given on sliding scale in response to last NAS score.
223802251|NCT01723722|DRUG|Diluted Deodorized Tincture of Opium|Concentration is 1:24 dilution for a concentration of 0.4%
223802252|NCT03511755|DEVICE|Transdermal Electrical Neuromodulator (TEN)|Thync TEN is a portable, battery-powered, electrical neuromodulation device connected to single-use gel electrode pads that are applied to the base of the neck (C3 to C7).
223802253|NCT02771743|DRUG|Cisplatin|
223802254|NCT02771743|DRUG|Doxorubicin|
223802255|NCT02771743|DRUG|Etoposide|
223802256|NCT02771743|DRUG|Cyclophosphamide|
223802257|NCT02771743|DRUG|Ifosfamide|
223802258|NCT02771743|DRUG|Carboplatin|
223802259|NCT02771743|PROCEDURE|Tandem HDCT/auto-SCT|
223802260|NCT02771743|RADIATION|Radiotherapy|
223802261|NCT02771743|DRUG|Interleukin-2|
223802262|NCT02771743|DRUG|Isotretinoin|
223802263|NCT02771743|RADIATION|MIBG|
223802264|NCT01381796|DRUG|NP101|comparison of NP101 with minor patch modifications
223802265|NCT01381796|DRUG|sumatriptan succinate|tablet, 100 mg
223802266|NCT03816774|DRUG|PEG split-dose and simethicone|Patients in active comparator arm are instructed to take 250mg simethicone pill 15 minutes before PEG dose on the previous evening plus 250mg simethicone pill 15 minutes before PEG dose ending 3 hours before colonoscopy
223802267|NCT02262533|DRUG|Apixaban|
223802268|NCT02262533|DRUG|Atenolol|
223802269|NCT01169675|DRUG|BIBW 2992 low dose|patient receives low dose BIBW 2992 po daily on day 1 of 21 day cycle
223802270|NCT01169675|DRUG|BIBW 2992 high dose|patient receives high dose BIBW 2992 po daily on day 1 of 21 day cycle
223802271|NCT01169675|DRUG|pemetrexed|given intravenously on day 1 of a 21 day cycle
223802272|NCT01169675|DRUG|pemetrexed|given intravenously on day 1 of a 21 day cycle
223802273|NCT01169675|DRUG|BIBW 2992 high dose 6 day|patient receives high dose BIBW 2992 po daily on days 1-6 on 1 of 21 day cycle
223802274|NCT01169675|DRUG|pemetrexed|given intravenously on day 1 of a 21 day cycle
223802275|NCT01169675|DRUG|pemetrexed|given intravenously on day 1 of a 21 day cycle
223802276|NCT01169675|DRUG|pemetrexed|given intravenously on day 1 of a 21 day cycle
223802277|NCT01169675|DRUG|pemetrexed|given intravenously on day 1 of a 21 day cycle
223802278|NCT01169675|DRUG|BIBW 2992 low dose 6 day|patient receives low dose BIBW 2992 po daily on days 1-6 on day 1 of 21 day cycle
223802279|NCT01169675|DRUG|BIBW 2992 medium dose 6 day|patient receives medium dose BIBW 2992 po daily on day1 to 6 of a 21 day cycle
223802280|NCT01169675|DRUG|BIBW 2992 medium dose|patient receives medium dose BIBW 2992 po daily on day 1 of 21 day cycle
223802281|NCT03439774|DEVICE|Topcon CT-800|tonometer
223802282|NCT03439774|DEVICE|Topcon TRK-2P|tonometer, pachymeter
223802283|NCT03123965|DRUG|glecaprevir|Glecaprevir will be administered orally.
223802284|NCT03123965|DRUG|pibrentasvir|Pibrentasvir will be administered orally.
223802285|NCT06304766|PROCEDURE|Laparoscopic ablation|Heat-based ablation modality performed by laparoscopy. Centers may use either radiofrequency or microwave ablation. The modality should be the same in both groups.
223802286|NCT06304766|PROCEDURE|Open ablation|Heat-based ablation modality performed by laparotomy. Centers may use either radiofrequency or microwave ablation. The modality should be the same in both groups.
223802287|NCT03011632|DRUG|Mometasone Nasal|a group of children who will receive a nasal mometasone in an atomiser for three months (one application, once per day) and supplemental 3ml 0.9% Sodium chloride (NaCl) solution in a nasal nebuliser once a day for 3 months
223802288|NCT03011632|DRUG|placebo mometasone|a group of children without IgE-dependent hypersensitivity who will receive nasal mometasone placebo in an atomiser for three months (one application, once per day) and supplemental 3ml 0.9% NaCl solution in a nasal nebuliser once a day for 3 months,
223802289|NCT05812001|BEHAVIORAL|Exergames-acceptance and commitment therapy (e-ACT)|In the e-ACT training program, participants will perform a 30-minute per session Nintendo-program on TV for three days per week and a 50-minute ACT session per week for 8 weeks which will take place in the psychology labs of AMDI, USM. The ACT session will be held after 30 minutes break following the completion of the final exergame session of the week. Hence, the total duration of each weekly e-ACT training session will be approximately 2 hours. In addition, each weekly e-ACT training session will be held at the same time (± 2 hours) and at the same venue.
223802290|NCT05812001|BEHAVIORAL|Acceptance and commitment therapy (ACT)|As for the ACT intervention, each ACT session will run for 50 minutes, one session per week for 8 weeks. Each weekly ACT session will be held at the same time (± 2 hours) and at the same venue (in the psychology lab).
223802291|NCT01763879|OTHER|The PCV-VCV group|During the PCV period, the inspiratory pressure will be adjusted to deliver a TV of 6 mL/kg (predicted body weight) to the patient's dependent lung. During the VCV period, the patient's dependent lung will be ventilated with a TV of 6 mL/kg (PBW). Whereas FiO2, I: E ratio, PEEP, frequency, Ppk, and a FGF will be maintained as during two-lung ventilation (TLV) and the lumen of the nondependent lung will be left open to air. Dependent lung recruitment maneuvers will be repeated at 30-minute intervals by raising the inspiratory pressure up to 35 cmH2O for 10 seconds.
223802292|NCT01763879|OTHER|The VCV-PCV group|During the PCV period, the inspiratory pressure will be adjusted to deliver a TV of 6 mL/kg (predicted body weight) to the patient's dependent lung. During the VCV period, the patient's dependent lung will be ventilated with a TV of 6 mL/kg (PBW). Whereas FiO2, I: E ratio, PEEP, frequency, Ppk, and a FGF will be maintained as during two-lung ventilation (TLV) and the lumen of the nondependent lung will be left open to air. Dependent lung recruitment maneuvers will be repeated at 30-minute intervals by raising the inspiratory pressure up to 35 cmH2O for 10 seconds.
223802293|NCT00098969|DRUG|resveratrol|
223802294|NCT03875027|PROCEDURE|proximal femur replacement|patient with proximal femur fracture or those in whom previous surgery on hip is failed and treated with replacement of proximal femur implant
223802295|NCT03757221|COMBINATION_PRODUCT|Ixazomib and Daratumumab|"Daratumumab will be administrated every week for the first 2 cycles. For cycle 3 to 6, it will be administrated every two weeks at day 1 and day 15. From cycle 7 until progression Daratumumab will be administrated every 4 weeks.~Ixazomib will be administrated every week three weeks on one week off at D1, D8 and D15 on a 28-d cycle basis.~Dexamethasone will not be given except one series of 4 days of dexamethasone, 20 mg/day or a maximum of 80 mg, for emergencies and complications at initiation of treatment."
223802296|NCT04839965|BIOLOGICAL|Ampion|Ampion administered via intravenous infusion
223802297|NCT04839965|OTHER|Saline|Placebo administered via intravenous infusion
223802298|NCT00137566|DRUG|acetaminophen (paracetamol)|Paracetamol tablets, 50 mg/kg/day for 3 days.
223802299|NCT00137566|OTHER|Placebo|
223802300|NCT05268679|OTHER|Biospecimen Collection|A blood of a sample of 2 x 7 mL will be collected for the analysis of the anti-SARS-CoV-2 T-cell response during a scheduled check-up as part of their routine follow-up
223802301|NCT05268679|OTHER|Questionnaire|Patients who have received SARS-CoV-2 vaccination will be asked to complete the Vaccine tolerance questionnaire
223802302|NCT05268679|OTHER|Electronic Health Record Review|For heart transplant recipients who were offered vaccination against SARS-CoV-2 medical records will be reviewed retrospectively.
223802303|NCT02365519|BIOLOGICAL|LME636 ophthalmic solution|
223802304|NCT02365519|BIOLOGICAL|LME636 Vehicle|Inactive ingredients used as a placebo comparator
223802305|NCT04398212|DIAGNOSTIC_TEST|mfERG (multifocal-retinogram)|mfERG will be performed for the students to document the effect of CVS on retina
223802306|NCT05387941|DRUG|Dexamethasone Ophthalmic|one drop daily in each eye with retinopathy of prematurity of a predefined stage.
223802307|NCT04064879|OTHER|AD-SVF|Intravenous, intra-articular, and soft tissue injection delivery of SVF. Target regions include forehead, temporal, and suboccipital regions.
223802308|NCT03004794|OTHER|medical records review|
223802309|NCT00737555|DRUG|CHR-2797|Oral once daily administration of capsules of CHR-2797, to determine safety and tolerability in patients being treated with paclitaxel infusion every 3 weeks for up to 18 weeks.
223802310|NCT03994068|DIAGNOSTIC_TEST|VIVO non invasive mapping|non invasive pre-procedural localization of PVC / VT origin
223802311|NCT00331981|DRUG|Amisulpride|
223802312|NCT04011774|OTHER|PLANI-REV|Cognitive remediation program.
223802313|NCT04011774|OTHER|RELAXATION|Stimulation with no cognitive remediation.
223802314|NCT02635802|DRUG|Remifentanil|"a loading dose 1.0-2.0μg/kg remifentanil,intravenous injection slowly,time \>1min,then 5μg/kg·h pumping if the operation can not be done in 5 minutes.~Critical-Care Observation Tool(CPOT) and Richmond Agitation-Sedation Scale(RASS) are assessed before and after the loading.We should maintain the CPOT≤2 and RASS 0～2,if it is not up to the standard,increasing the pumping rate 0.5 μg/kg·h every 2-5min."
223802315|NCT02635802|DRUG|Lidocaine|lidocaine 100-400mg,local anesthesia.Critical-Care Observation Tool(CPOT) and Richmond Agitation-Sedation Scale(RASS) are assessed before and after local anesthesia.We should maintain the CPOT≤2 and RASS 0～2.
223802316|NCT02635802|DRUG|Remifentanil+Lidocaine|a loading dose 1.0-2.0μg/kg remifentanil,intravenous injection slowly,time \>1min,then 5μg/kg·h remifentanil pumping immediately if the operation can not be done in 5 minutes.then local anesthesia with lidocaine 100-400mg.Critical-Care Observation Tool(CPOT) and Richmond Agitation-Sedation Scale(RASS) are assessed before and after anesthesia.We should maintain the CPOT≤2 and RASS 0～2,if it is not up to the standard,increasing the pumping rate 0.5μg/kg·h every 2-5min.
223802317|NCT02635802|DRUG|Midazolam|midazolam is an adjuvant drug.we should maintain the CPOT≤2 and RASS 0～2,if lidocaine is already used up to 400mg or the pumping rate of remifentanil is already 7.5μg/kg·h,then we should use midazolam 3mg, intravenous injection slowly.
223802318|NCT02048072|DRUG|Gilenya|Autonomic testing during first dose administration of Gilenya.
223802319|NCT03583749|DRUG|Subcutaneous (SC) route for antibiotic treatment|Patients receiving one of the three antibiotics by SC route without any randomization because the route will be chosen before inclusion by the physician in charge.
223802320|NCT03583749|DRUG|Intravenous (IV) route for antibiotic treatment|Patients receiving one of the three antibiotics by IV route without any randomization because the route will be chosen before inclusion by the physician in charge.
223802321|NCT00363519|DRUG|Placebo|Double-blind period (12 wk); placebo QD The double-blind period will be followed by a 40 wk open-label extension period where MK-0431/ONO-5435 could be titrated from 50 mg QD to 100 mg QD
223802322|NCT00363519|DRUG|Sitagliptin phosphate|Double-blind period (12 wk); 50 mg QD The double-blind period will be followed by a 40 wk open-label extension period where MK-0431/ONO-5435 could be titrated from 50 mg QD to 100 mg QD
223802323|NCT04823260|DRUG|Nicotinamide Mononucleotide|Nicotinamide adenine dinucleotide (NAD+) is an essential cofactor in all living cells involved in fundamental biological processes. Depletion in the levels of NAD+ is associated with traits of aging, many age-related diseases like cancer, metabolic disorders and neurological disorders. Evidence stemming from recent studies have unveiled numerous roles of NAD+ metabolism on aging and longevity and delaying the progression of age-related diseases
223802324|NCT04823260|OTHER|Placebo|Rice flour in white capsule resembling NMN
223802325|NCT02355028|DRUG|LHA510 ophthalmic suspension|
223802326|NCT02355028|DRUG|LHA510 vehicle|Inactive ingredients used as a placebo comparator
223802327|NCT02355028|DRUG|Ranibizumab ophthalmic solution|For intravitreal (IVT) injection
223802328|NCT03830593|PROCEDURE|Laparoscopic Adrenalectomy|minimally invasive lateral transperitoneal adrenalectomy
223802329|NCT03948191|DRUG|Methylprednisolone|500mg i.v. infusion once a week for 6 weeks followed by 250mg i.v. once a week for 6 weeks.
223802330|NCT03948191|DRUG|99Tc-MDP(99Technetium-Methylenediphosphonate Injection)|15mg i.v. infusion once a day for 10 days, 20 days apart, received 3 courses of infusions.
223802331|NCT02276222|DRUG|SUN-101 50 mcg BID eFlow (CS) nebulizer|SUN-101 (Glycopyrrolate) 50 mcg twice daily (BID) via eFlow Closed System (CS) nebulizer
223802332|NCT02276222|DRUG|Spiriva® 18 mcg QD Handihaler|Spiriva (tiotropium) 18 mcg once daily (QD) via Handihaler
223802333|NCT05290831|DEVICE|VitalPatch|The VitalPatch continuously monitors skin temperature, activity, and electrocardiography.
223802334|NCT03668587|OTHER|Troponin Protocol|Feasibility and security of a rapid rule-out and rule-in troponin protocol in the management of NSTEMI in an Emergency Departement.
223802335|NCT06324266|DRUG|Cyclophosphamide|Standard risk group MM patients who achieve VGPR or above after initial induction and consolidation therapy and are not suitable transplantation, are maintained with Cyclophosphamide monotherapy for 2 years.
223802336|NCT06324266|DRUG|Lenalidomide|Standard risk group MM patients who achieve VGPR or above after initial induction and consolidation therapy and are not suitable transplantation, are maintained with Lenalidomide monotherapy for 2 years.
223802337|NCT03655795|BIOLOGICAL|Bronchial basal cells|Autologous transplantation of bronchial basal cells
223802338|NCT05982457|BEHAVIORAL|virtual reality group|"Before the training, the Descriptive Information Form and the State and Trait Anxiety Inventory as a pre-test will be applied by face interview method. They will study for two hours. After the introduction and information, the lens and pupil distances of the virtual reality Glasses will be adjusted according to each student and students are expected to wear their vision. The application is the same for every student. Students will be introduced through the images projected to the computer simultaneously while in the application. Cervical dilation and effacement application will be monitored using virtual reality glasses. Next, the students will be asked to touch the woman's perineum with their hands to make her image transparent and we ask them to watch the cervix structures again. After the application, Learning Satisfaction and Self-Confidence in Learning Scale and State and Trait Anxiety Inventory will be applied as a post-test."
223802339|NCT02115880|BEHAVIORAL|Prevention programme|Based on a group- and family-based cognitive behavioural manual developed by Bruce Compas and colleagues in the USA, and adapted for a German sample. The programme is for parents and children and consists of 8 weekly sessions and 4 monthly booster sessions.
223802340|NCT03909126|BIOLOGICAL|Boostrix administered during gestational diabetes screening|Boostrix administered during gestational diabetes screening
223802341|NCT03909126|BIOLOGICAL|Boostrix administered in high volume obstetric clinic|Boostrix administered in high volume obstetric clinic
223802342|NCT04107922|DIETARY_SUPPLEMENT|Glicoset|Patients will take a nutraceutical containing Ilex Paraguariensis, White Mulberry and Chromium Picolinate
223802343|NCT04107922|OTHER|Placebo|Patients will take placebo
223802344|NCT06495931|DRUG|HRS-1780 tablets|HRS-1780 tablets, three times
223802345|NCT06495931|DRUG|HR20033 tablets|HR20033 tablets, nine times
223802346|NCT06495931|DRUG|HRS-7535 tablets|HRS-7535 tablets ，three times or nine times
223802347|NCT03285139|BEHAVIORAL|Cognitive Behavioural Therapy|Cognitive Behavioral Therapy 9 weekly 2-hour group CBT sessions delivered by trained lay peers.
223802348|NCT01168284|BEHAVIORAL|Coping Effectiveness Training|
223802349|NCT01024426|PROCEDURE|Enhanced health facility-based care|The intervention is designed to address barriers to delivering quality care at health centers and will focus on three components: (1) training in-charges in health center management, (2) providing training to health workers in fever case management and patient-centered services, and (3) ensuring adequate supplies of artemether-lumefantrine and RDTs.
223802350|NCT01024426|OTHER|Standard care|In the clusters randomized to standard care, standard care will include services typically provided by government-run facilities; we will not provide any additional support to these facilities. Health care will be provided to patients attending these facilities according to the usual standards; in-charges will continue to manage the facilities using their standard approach, no additional training will be provided to the health workers stationed at these facilities; and no support for staffing or supplies will be provided beyond what is supplied by the district and MoH.
223802351|NCT02650050|RADIATION|Micropulsed laser photocoagulation|Micropulsed laser photocoagulation after 3 anti-VEGF injections
223802352|NCT03076099|DRUG|Dexmedetomidine|1.2 μg/kg Dexmedetomidine was administered intravenously constantly after tracheal extubation.
223802353|NCT03076099|OTHER|normal saline|equal volume of normal saline was administered intravenously constantly after tracheal extubation.
223802354|NCT02323984|OTHER|miRNA Testing, Microemboli Monitoring, Delirium Assessment|Delirium assessment questionnaire and blood testing for miRNA will be done for all patients postoperatively, as well as BIS monitoring during surgery. The three arms of the study indicate the allocation of each patient based on their delirium presentation (hypoactive, hyperactive, or none).
223802355|NCT05056779|DRUG|Nemolizumab|Participants will receive loading dose of 60 milligram (2×30 mg) subcutaneous (SC) injection of nemolizumab at baseline. Thereafter 30 mg nemolizumab will be administered via single SC injection once in 4 week (Q4W) up to week 12.
223802356|NCT05056779|DRUG|CD14152 placebo|Participants will receive loading dose of 60 mg (2×30 mg) SC injection of placebo at baseline. Thereafter 30 mg placebo will be administered via single SC injection Q4W up to week 12.
223802357|NCT00002155|DRUG|Indinavir sulfate|
223802358|NCT00002155|DRUG|Lamivudine|
223802359|NCT00002155|DRUG|Zidovudine|
223802360|NCT01971723|OTHER|T+ Supplement|Randomized, placebo-controlled, double blind protocol with two treatment groups (matched by lean body mass). Group 1 will receive the recommended serving of one scoop (11g) of T+ supplement. This serving will be taken 45 minutes before the beginning of working out on an empty stomach (\>1 hour after meal). On non-training days, the participants will also take a serving at the same time as on training days. This will continue for four weeks (28 days).
223802361|NCT01971723|OTHER|Placebo|The placebo group will consume a calorie-match placebo in the same manner as the supplement group (one serving 45 minutes prior to work outs on an empty stomach). The placebo group will also follow the same supplementation patterns and workout as their counterparts in the supplement group.
223802362|NCT05038384|OTHER|Survey Administration|Complete survey
223802363|NCT02840357|OTHER|Purple Wheat Convenience Bars|Whole grain convenience bars manufactured with purple wheat
223802364|NCT02840357|OTHER|Control Wheat Convenience Bars|Whole grain convenience bars manufactured with ordinary wheat
223802365|NCT00002292|DRUG|Pentamidine isethionate|
223802366|NCT00377325|DRUG|Cyclosporine|4 mg/Kg/day; daily; liquid form; 6 months
223802367|NCT05539092|OTHER|changing angle of bed|Before the cardiac catheterization procedure: patients' demographic characteristics and health relevant data will be collected on the first day of admission. the researcher will change angle of bed from 15° to 45°.
223802368|NCT04028986|DRUG|Ulipristal Acetate 5 MG Oral Tablet|use of ulipristalacetate OR surgery before fertility treatment
223802369|NCT04639674|DRUG|AST-120|If no other medicines are taken usually, take AST-120 one hour after each meal with a frequency of three doses a day and one dose every administration. The drug will be taken for four weeks.
223802370|NCT03900702|BEHAVIORAL|Gaze-driven training games|Training games are played on a PC with attached eye-tracker. Games include embedded training principles to improve attentional control including resistance to distraction and inhibitory control.
223802371|NCT02716948|OTHER|Laboratory Biomarker Analysis|Correlative studies
223802372|NCT02716948|BIOLOGICAL|Nivolumab|Given IV
223802373|NCT02716948|RADIATION|Stereotactic Radiosurgery|Undergo stereotactic radiosurgery
223802374|NCT03645759|BEHAVIORAL|I'm Whole|I'm whole will provide 6 behavioral health treatment sessions that focus on stroke self-management, psychological distress and social re-integration.
223802375|NCT03645759|OTHER|Education + usual care|Will receive the standard usual care for stroke self-management provided by the Michael E. Debakey VA Medical facility and will receive 6 brief health education calls unrelated to stroke or psychological distress.
223802376|NCT03285425|OTHER|Natural history|Parent interview
223802377|NCT04109014|OTHER|FASTLANE II|"The intervention will consist of nine weekly hour-long individual counseling sessions. The FL II sessions utilize a combination of Cognitive Behavioral Therapy (CBT) and Motivational Interviewing (MI) to reduce sexual risk behaviors and mental health symptoms. Thus, individuals develop a toolbox for mood self-management to improve emotional self-regulation and reduce maladaptive coping mechanisms to minimize drug and sex risk behavior. Participants will be considered as completing the FASTLANE Intervention upon completion of the nine weeks of sessions."
223802378|NCT05751122|OTHER|Dynamic flex cast with neurodevelopmental treatment|"Neurodevelopmental therapy in combination with dynamic flex cast to treat experimental group.~Three times a week, 1 hour session per day.~Dynamic flex casting is casting which manipulate bone alignment and maintains range of motion or sustained stretch. Casting will be changed weekly for 3 months.~Neuro developmental approach is individualized treatment which is attuned to each child's specific problems, aims and goals.~Key elements in NDT are: facilitation (using sensory inputs to improve motor performance), management of compensatory motor behavior, and an overall management strategy (a 24-hour interdisciplinary management approach) NDT involves task specific postures and movements."
223802379|NCT05751122|OTHER|Rigid Ankle foot Orthosis with neurodevelopmental treatment|"Rigid ankle foot orthosis will be applied to ankle joint at the start of intervention.~Neurodevelopmental treatment will be applied to both groups with protocol; Three times a week, 1 hour session per day.~Assessment on 1st day,6th week and 12th week"
223802380|NCT03652974|DRUG|sodium valproate with Clozapine|sodium valproate may be used as a synergistic agent of clozapine in the treatment of treatment-refractory schizophrenia
223802381|NCT03652974|DEVICE|modified electroconvulsive therapy(MECT) with Clozapine|modified electroconvulsive therapy(MECT) may be used as a synergistic agent of clozapine in the treatment of treatment-refractory schizophrenia
223802382|NCT03652974|DRUG|amisulpride with Clozapine|amisulpride may be used as a synergistic agent of clozapine in the treatment of treatment-refractory schizophrenia
223802383|NCT03652974|DRUG|placebo with Clozapine|placebo may be used as a synergistic agent of clozapine in the treatment of treatment-refractory schizophrenia
223802384|NCT01648270|DRUG|buprenorphine|Session 1 Intravenous buprenorphine: 0.2 mg over 1 hr Session 2 Sublingual buprenorphine: 2 mg Session 3 Intravenous buprenorphine 0.2 mg over 1 hr beginning 1 hr after starting cyclosporine Session 4 Sublingual buprenorphine: 2 mg after cyclosporine.
223802385|NCT01389193|DRUG|Ibudilast|Ibudilast 40 mg twice daily oral capsules for a duration of 8 weeks
223802386|NCT01389193|DRUG|Placebo|Placebo 40 mg twice daily oral capsules for a duration of 8 weeks
223802387|NCT02199236|RADIATION|endorectal brachytherapy|Patients will receive 3 fractions of endorectal brachytherapy, each spaced apart by 7 days (+/- 1 day). The three dose tiers will be 1500cGy (500cGy per fraction), 1800cGy (600cGy per fraction), and 2100cGy (700cGy per fraction).
223802388|NCT02199236|DRUG|concurrent capecitabine or 5-FU|"Patients will receive 500 mg and 150 mg oral tablets of capecitabine for the prescribed dose of 825 mg/m2 BID, morning and evening (total daily dose of 1650 mg/m2 ). Dosages will be rounded to the nearest 150 mg or 500 mg. Tablets should be swallowed with water within 30 minutes after a meal. Capecitabine will be started on the Monday of the first week of brachytherapy (day 1) and taken on weekdays (Monday through Friday) during weeks of brachytherapy only.~Administration of 5-FU should be only by the intravenous route taking care to avoid extravasation. Patients will receive 225 mg/m2/day, as a continuous venous infusion by a portable pump for the 3 weeks of treatment. The infusional 5-FU will be exchanged every 7 days."
223802389|NCT02199236|BEHAVIORAL|Questionnaires|Patients should complete the 2 quality of life questionnaires during their follow-up appointments. If they are unable to be seen in follow-up, they may complete the questionnaires at home and email or mail them back to the investigator. Should there be any incomplete or ambiguous answers, a follow-up phone call will be made by a member of the research team for clarification. Additionally, if the questionnaires have not been returned within 3 weeks after the time when they are due, a member of the research team will call the patient, and the questions will be completed over the phone.
223802390|NCT03994302|DRUG|Drug inducing antiphospholipid syndrome|Drugs susceptible to induce immune toxicities such as antiphospholipid syndrome
223802391|NCT05570955|BEHAVIORAL|Text reminder|weekly text to remind use of drug
223802392|NCT06276595|BEHAVIORAL|Nowhi Isdza bit Nadagoldi: Telling Our Daughters Our Story (TODOS)|The TODOS program consists of 11 weekly sessions conducted with girls ages 8-11 and their female caregivers. Five of the 11 sessions will be taught to small groups, and 6 of the Each of the sessions (group and individual) will be 60-90 minutes in duration and delivered by a trained Family Health Coach (FHC). Group sessions will take place at a local community center in a private room.
223802393|NCT06276595|BEHAVIORAL|Control condition - 3 Monthly Group Activities in the Community|The control condition consists of 3 group sessions delivered monthly for three months. The first group session will occur at a community center and will consist of a meal and ice breaker activities. The second group session will consist of going to a movie at the local movie theatre The third group session will consist of going bowling at the local bowling alley.
223802394|NCT00902694|BEHAVIORAL|ACHIEVE Intervention|Group and individual weight loss counseling and group physical activity classes for 18 months
223802395|NCT00902694|OTHER|Control|group health classes quarterly with topics not related to weight
223802396|NCT06566131|BEHAVIORAL|Gamified mobile health app|Participants will receive visualized instructions about the PW use (e.g., search and download the app on App Store, navigate and understand key features, play puzzle games, and track step counts). During the 6-week intervention period, participants will receive reminders on wearing the accelerometer, using the app for potential incentives, and engaging in regular physical activities for health promotion.
223802397|NCT04625712|PROCEDURE|Cholecystectomy|Cholecystectomy within the first week after a mild acute biliary pancreatitis
223802398|NCT04431466|DRUG|Ivermectin|SOC plus different dosing regimens of Ivermectin
223802399|NCT04431466|OTHER|Standard of Care|Standard treatment for COVID-19
223802400|NCT01394393|BEHAVIORAL|Experiential-Cognitive Therapy for Obesity|Is a relatively short-term, integrated, patient oriented approach that focuses on individual discovery (Riva, Bacchetta, Baruffi, Rinaldi, \& Molinari, 1998, 1999; Riva et al., 2000). It shares with the cognitive-behavioral approach proposed by Cooper and colleagues the use of a combination of cognitive and behavioral procedures to help the patient identify and change the maintaining mechanisms (Cooper et al., 2003). However, it considers morbid obesity as a peculiar form of addiction. So, as in the cognitive-behavioral treatment of addictions (Carroll et al., 1994) the two main goals are the functional analysis of the maintaining mechanisms and the required skill training (relapse prevention).
223802401|NCT01394393|BEHAVIORAL|Behavioral cognitive Treatment|Therapists will follow a detailed manual that outlined the content of each session. This manual was based on the cognitive-behavioral treatment approach described by Cooper and colleagues (Cooper \& Fairburn, 2002; Cooper et al., 2003). It was developed during a year of intensive pilot work and adapted to the in-patient setting. Patients will be taught to self-monitor their food intake and eating patterns and thoughts, as well as the circumstances and environment surrounding eating (e.g. whether eating alone or with others, speed of eating, and place of eating). Patients will also be taught to identify problems in eating, mood, and thinking patterns and to gradually develop alternative patterns.
223802402|NCT01394393|DIETARY_SUPPLEMENT|Nutritional groups (NT)|5 weekly nutritional treatment based on the LEARN manual (Brownell, 1985), whose goal will be to provide practical guidelines for the self-monitoring of eating and lessons on nutrition (e.g stressing gradual weight loss with the caloric restriction achieved largely by reductions in fat intake), plus a low-calorie diet (1,200 kcal/day) and physical training (30 min of walking two times a week as a minimum).
223802403|NCT01024608|DRUG|Beclomethasone dipropionate|Total daily dose of 320 micrograms per day of beclomethasone dipropionate (BDP) hydrofluoroalkane (HFA) applied as a nasal aerosol each morning for two weeks.
223802404|NCT01024608|DRUG|Placebo Nasal Aerosol|Placebo nasal aerosol administered each morning for two weeks.
223802405|NCT04549363|DRUG|Belantamab mafodotin|Belantamab mafodotin is a first-in-class immunoconjugate that targets B cell maturation antigen (BCMA), which is highly expressed on malignant plasma cells.
223802406|NCT04110405|BEHAVIORAL|Stepped Care|This stepped care model involves three steps. Step 1 is a peer and nurse co-led 8-session group based upon BRIDGES. Step 2 is peer or nurse led 6-session individual meetings based upon Interpersonal Psychotherapy. Step 3 is primary care physician led medication treatment with Amitriptyline.
223802407|NCT04110405|BEHAVIORAL|Standard of Care plus Healthy Lifestyle|Standard outpatient care supplemented with literature on healthy lifestyles will serve as an enhanced control condition. In each clinic, non-specialty mental health care is available in the form of counseling from doctors or nurses along with psychiatric medication management. Given the difficulties faced by women in Tajikistan, ethical responsibility compels us to enhance the control condition by having nurses distribute written materials on healthy eating, physical fitness, and personal hygiene, at a reading level which will be widely accessible.
223802408|NCT01880723|DRUG|Albuterol|2.5 mg diluted in 3mL normal saline nebulized using a Power Neb2 nebulizer
223802409|NCT01880723|DRUG|Placebo saline|nebulized 3mL normal saline) using a Power Neb2 nebulizer
223802410|NCT04680455|OTHER|Online home-based strength training|Body weight exercises (i.e., squats, tricep dips, lunges, and push-ups) delivered online through Teams
223802411|NCT03862157|DRUG|Azacitidine|Given IV or SC
223802412|NCT03862157|DRUG|Pevonedistat|Given IV
223802413|NCT03862157|DRUG|Venetoclax|Given PO
223802414|NCT06085430|DEVICE|Kubota Glass|Kubota Glass employs white light producing micro-LEDs covered by masks which create a patterned target. The patterned images are defocused by micro-lenslets and projected to the retinal periphery by a central mirror. Parameters of interest to evaluate in this investigation include but are not limited to dioptric amount of defocus, brightness (cd/m2), spectrum of illumination, and shape of the target mask. In each scenario, right eyes will be exposed to the stimulus, whereas left eyes serve as controls. The order of exposures to the various stimuli will be randomized to participant and investigator.
223802415|NCT01592370|BIOLOGICAL|Nivolumab|Administered by intravenous (IV) infusion
223802416|NCT01592370|BIOLOGICAL|Ipilimumab|Administered by IV infusion
223802417|NCT01592370|BIOLOGICAL|Lirilumab|Administered by IV infusion
223802418|NCT01592370|BIOLOGICAL|Daratumumab|Administered by IV infusion
223802419|NCT01592370|DRUG|Pomalidomide|Administered PO
223802420|NCT01592370|DRUG|Dexamethasone|Administered PO and by IV infusion
223802421|NCT06820658|DIAGNOSTIC_TEST|Neuromuscular Test|"To measure neuromuscular connectivity, Transcranial Magnetic Stimulation (TMS) will be used to stimulate regions of the cerebral cortex known to control specific muscles.~Electromyography (EMG) activity will then be measured from the following muscle groups: deltoid, biceps, extensor digitorum communis, abductor pollicis brevis, abductor digiti minimi, and first dorsal interosseous muscle."
223802422|NCT06820658|DIAGNOSTIC_TEST|DEXA|The DEXA test uses X-rays to measure how many grams of calcium and other bone minerals are packed into a segment of bone. The test also measures the amount of fat-free mass, and fat mass.
223802423|NCT06820658|DIAGNOSTIC_TEST|Mixed Meal Tolerance Test|Fasting blood will be collected for glucose, insulin, and c-peptide. Participants will be provided with a milkshake with a fixed amount of protein, carbohydrates, and fat. Glucose, insulin, and c-peptide will be measured at multiple time points (every 10 minutes) until four hours after consumption (50% Fat, 30% Carbohydrate HO, 20% Protein). Approximately 70mls of blood will be drawn during this time
223802424|NCT06820658|DIAGNOSTIC_TEST|Strength Test|Knee extensor strength will be tested by gradually increasing the workload on a pneumatic Keiser knee extension machine. The test will begin with a warm-up of 4-5 reps with one leg at 30-50 psi. Then the participant will increase the workload at self-selected intervals ranging from 5-20psi until a maximum effort is achieved. If a rep is failed, then the workload will be reduced by 5psi until a successful rep is performed or a workload is reached in which a successful rep had been previously achieved. Handgrip strength will be tested using a handheld dynamometer (Baseline® standard hydraulic hand dynamometer). The test is performed with the participant seated with the elbow unsupported and flexed at 90 degrees, forearm neutral, wrist held between 0-15 degrees of ulnar deviation (Horowitz, 1997). Maximum grip is the average of three 3-5 second trials.
223802425|NCT01775228|BEHAVIORAL|Peer Support|Support (informational, emotional and appraisal) in the form of like persons (i.e. age, gender) who have undergone CABG surgery with successful outcomes (post-recovery at least one year); peer support was provided by telephone for 6 weeks post cardiac surgery recovery.
223802426|NCT06668246|DEVICE|Vision-S™ 700, an immersive and compact phoropter with a tunable-focus lens, and Vision-R™ 800, a phoropter with a tunable-focus lens without immersion, with cycloplegic refraction serving as the gold|As of today, no published clinical studies have been conducted with the Vision-S™ 700 neither Vision R 800
223802427|NCT06172972|BEHAVIORAL|Atraumatic nursing care|Children in the intervention group were allowed to choose a distracting method (foam balloons, stress balls, musical books) to be occupied with during the procedure
223802428|NCT06669195|DEVICE|Intravascular lithotripsy group|20 subjects with stent under-expansion in calcified coronary lesions who met the inclusion/exclusion criteria were enrolled; subjects were assigned to the treatment group of Intravascular lithotripsy group.
223802429|NCT06669195|DEVICE|high-pressure balloon group|20 subjects with stent under-expansion in calcified coronary lesions who met the inclusion/exclusion criteria were enrolled; subjects were assigned to the treatment group of high-pressure balloon group.
223802430|NCT06670235|BEHAVIORAL|Upright Birthing Position|This intervention involves encouraging participants to use an upright position during labor and delivery, which may include : squatting, based on their preference and comfort level. Healthcare staff will support the participants in maintaining an upright position throughout labor as much as possible to evaluate its effects on maternal and newborn outcomes.
223802431|NCT06670235|BEHAVIORAL|Lithotomy Birthing Position|Participants in this arm will be positioned in the lithotomy position during labor and delivery, which is a common practice in clinical settings. In this position, the mother lies on her back with her legs supported in stirrups. This intervention serves as the control condition to provide a baseline comparison for evaluating outcomes against the upright birthing position.
223802432|NCT06669741|DEVICE|Placebo|One group will receive placebo therapy (identical shoulder brace and arm sleeve absent of semiconductor fabric)
223802433|NCT06669741|DEVICE|Shoulder Sleeve|One group will receive active therapy (active semiconductor embedded shoulder brace and arm sleeve)
223802434|NCT06669169|DRUG|Jia Shen Tablet Placebo|Jia Shen Tablet Placebo contains 4 placebo tablets (0.47 g per placebo tablet),take orally, 2 times a day for 12 weeks
223802435|NCT06669169|DRUG|Low dose Jia Shen Tablet|Low dose Jia Shen Tablet contains 2 tablets (0.47 g per tablet) and 2 placebo tablets (0.47 g per placebo tablet),take orally, 2 times a day for 12 weeks
223802436|NCT06669169|DRUG|High dose Jia Shen Tablet|High dose Jia Shen Tablet contains 4 tablets (0.47 g per tablet),take orally, 2 times a day for 12 weeks
223802437|NCT03915782|DEVICE|Remote ischemic conditioning|Remote ischemic conditioning (RIC): Four cycles of \[5 minutes of brachial cuff inflation at 200 millimeters (mm) of mercury (Hg) followed by 5 minutes of cuff deflation\] started as soon as possible after Magnetic Resonance Imaging (MRI).
223802438|NCT03915782|DEVICE|Patients with a sham procedure of remote ischemic conditioning|Sham procedure: Four cycles of \[5 minutes of brachial cuff inflation at 30 millimeters (mm) of mercury (Hg) followed by 5 minutes of cuff deflation\] started as soon as possible after Magnetic Resonance Imaging (MRI).
223802439|NCT06516289|DRUG|HRS-1167|a highly selective PARP1 inhibitor
223802440|NCT06516289|DRUG|Famitinib|a tyrosine kinase inhibitor targeting VEGFR2, PDGFR, and c-kit
223802441|NCT06516289|DRUG|Camrelizumab|a humanised anti-programmed death-1 (anti PD-1) antibody
223802442|NCT06586255|RADIATION|Concurrent Immunotherapy and Radiation Therapy|Radiation therapy will begin between 12 to 18 weeks from the start of adjuvant nivolumab. Patients will receive radiation therapy for about 6 weeks.
223802443|NCT06595108|RADIATION|Stereotactic body radiotherapy|Patients with advanced hepatocellular carcinoma who are indicated for the first-line atezolizumab-bevacizumab combination therapy are the primary subjects, and they should begin stereotactic radiotherapy to one or more but not more than five sites for primary cancer and/or metastatic lesions within two month before and after the start date of atezolizumab-bevacizumab combination therapy.
223802444|NCT06140199|PROCEDURE|Pit-picking surgery|Patients are placed in left-side position. After shaving, cleaning and scrubbing of the skin with alcoholic chlorhexidine, double strong tape is placed on the right buttock in order to increase exposure. Local anaesthesia is administered before incision with 20 ml xylocaine or lidocaine 1-2%. In principle, all sinusoidal pits are cut out with a margin of at least 1 mm with a biopsy core punch (4 mm, 6 mm or 8 mm depending on pit size) or an oval excision of the pits is performed. Hair and debris is removed from the sinus tracts with a small surgical spoon or mosquito clamp. Rigorous de-epithelialisation of the underlying sinus is performed with the spoon through every pit, whilst removing even more debris and hairs. At the end of the procedure a debris washout is performed with saline solution, the wounds are left open for secondary healing and sterile dressings are applied.
223802445|NCT06140199|PROCEDURE|Pit-picking surgery with Sinus Laser assisted Closure|The pit picking procedure is described above. Subsequently, a radial diode laser probe at 1470 nm wavelength is used for delivering homogeneous (360 degrees) energy to the surrounding epithelium. The laser energy is 13 Joule, given continuously. First, a 'preparatory laser treatment' is performed to extract any missed hairs or debris, after which the sinus tracts are cleansed with a surgical spoon again. During the following definitive procedure, the probe is withdrawn at an approximate speed of 1 cm per three seconds, causing the small sinus tracts to shrink and close. Large sinus tracts remain open because very large sinus tracts or cavities cannot be closed with the 3mm laser fibre. The injury to the endothelium will cause granulation and create oedema for collapsing of the tract. The remaining open wounds are left open for secondary healing and sterile dressings are applied.
223802446|NCT06670703|DIAGNOSTIC_TEST|Obesity|diagnosis as obese patients
223802447|NCT06672471|OTHER|No Post Operative Antibiotics for intervention group|No Post Operative Antibiotics in patients going clean contaminated head and neck surgery
223802448|NCT06672471|OTHER|Post Operative Antibiotics for one day|Control group will receive perioperative as well as post operative antibiotics for one day
223802449|NCT05460325|DRUG|Lanadelumab|Lanadelumab subcutaneous injection
223802450|NCT03800823|BEHAVIORAL|Parent group|In group sessions parents will learn how to use positive parenting practices (e.g., encouragement and limit setting) instead of ineffective practices (e.g., coercive behaviour, negative reciprocity). Using a parent group approach, each of the 10 sessions consist of introduction to effective parenting practices followed by a discussion and practice using role play and home practice assignments.
223802451|NCT03800823|BEHAVIORAL|mHealth component|After the group sessions, parents will receive a 6-month mHealth program (MINISTOP app) based on social cognitive theory with strategies to change unhealthy diet/physical activity behaviours. The program includes information, advice, and strategies to change unhealthy behaviours and the possibility to register the child's intake of fruit, vegetables, candy, sweetened beverages, and sedentary time.
223802452|NCT03800823|BEHAVIORAL|Standard care|Standard care for overweight and obesity.
223802453|NCT05261178|OTHER|Evaluation of satisfaction and the level of daily living activities using the prosthesis|Evaluation of satisfaction with using the prosthesis with TAPES (Trinity Amputation and Prosthesis Experience Scale) and the level of daily living activities using the prosthesis with SF-36 (Short Form-36)
223802454|NCT06669286|PROCEDURE|implant placement using navigated surgery near alveolar nerve|Dental implant placement in proximity of alveolar nerve (within 2 mm) using navigated surgery.
223802455|NCT06670300|DRUG|cardonilimab|Subjects will receive cardonilimab 10mg/kg once every three weeks; The maximum duration of administration is 2 years until disease progression or death, toxicity becomes intolerable, subject voluntarily requests withdrawal, or investigator determines that subject needs to withdraw from the study.
223802456|NCT06678178|BEHAVIORAL|Control (QR) Labels|Participants will view a fast-food restaurant menu including main, side, dessert, and drink items. Each menu item will be displayed with an image of the item, name, price, and total calories. For main items only, Control (QR) labels will be displayed beneath each item. Participants will be instructed to select up to 4 menu items for a hypothetical meal order.
223802457|NCT06678178|BEHAVIORAL|Warning High Climate Impact Labels|Participants will view a fast-food restaurant menu including main, side, dessert, and drink items. Each menu item will be displayed with an image of the item, name, price, and total calories. For main items only, Warning High Climate Impact labels will be displayed beneath select items. Participants will be instructed to select up to 4 menu items for a hypothetical meal order.
223802458|NCT06678178|BEHAVIORAL|Traffic Light Labels|Participants will view a fast-food restaurant menu including main, side, dessert, and drink items. Each menu item will be displayed with an image of the item, name, price, and total calories. For main items only, Traffic Light labels will be displayed beneath each item. Participants will be instructed to select up to 4 menu items for a hypothetical meal order.
223802459|NCT06678178|BEHAVIORAL|Climate Grade Labels|Participants will view a fast-food restaurant menu including main, side, dessert, and drink items. Each menu item will be displayed with an image of the item, name, price, and total calories. For main items only, Climate Grade labels will be displayed beneath each item. Participants will be instructed to select up to 4 menu items for a hypothetical meal order.
223802460|NCT06678178|BEHAVIORAL|Numeric Carbon Footprint Labels|Participants will view a fast-food restaurant menu including main, side, dessert, and drink items. Each menu item will be displayed with an image of the item, name, price, and total calories. For main items only, Numeric Carbon Footprint labels will be displayed beneath each item. Participants will be instructed to select up to 4 menu items for a hypothetical meal order.
223802461|NCT01356875|DRUG|BSC|The support group will be receive transfusional BSC, erythropoietin and / or G-CSF as determined by the physician.
223802462|NCT01356875|DRUG|HIDRA/VPA|In each cycle (30 days), Hydralazine 50mg tablets every 12 hours and Valproic 500mg tablets every 8 hours will be administrated orally to HYDRA / VPA group.Each patient will receive 6 cycle.
223802463|NCT06669143|DRUG|Zanubrutinib|160 mg bid, po, day 1-21, a maximum of 2 years.
223802464|NCT06669143|DRUG|Lenalidomide|25 mg qd, po, day 1-10, a maximum of 2 years.
223802465|NCT02434809|PROCEDURE|Bronchoscopic Implantation|Calypso transponders
223802466|NCT02434809|DEVICE|Cone-Beam CT-Guided|
223802467|NCT02434809|RADIATION|stereotactic body radiation treatments|
223802468|NCT05878197|BEHAVIORAL|Straw phonation|"The two experimental groups will receive either straw phonation therapy or resonant voice therapy. The hierarchical structure of the therapy sessions will be equal for the three programs. In each session, vocal rest pauses will be foreseen by playing games, performing drawing assignments, etc. This will make the therapy more pleasant and less intensive. All voice therapy programs will be guided by the same experienced voice therapist.~Content:~Day 1: counseling (anatomy and physiology of the voice and vocal fold nodules), vocal hygiene recommendations (water intake, avoiding vocal misuse and abuse) Day 2: breathing exercises, vocal hygiene recommendations, straw phonation on vowel and syllable level, pitch variations Day 3: breathing exercises, vocal hygiene recommendations, straw phonation on word and sentence level, pitch variations Day 4: straw phonation in spontaneous speech, combination exercises"
223802469|NCT05878197|BEHAVIORAL|Resonant voice therapy|"The two experimental groups will receive either straw phonation therapy or resonant voice therapy. The hierarchical structure of the therapy sessions will be equal for the three programs. In each session, vocal rest pauses will be foreseen by playing games, performing drawing assignments, etc. This will make the therapy more pleasant and less intensive. All voice therapy programs will be guided by the same experienced voice therapist.~Content:~Day 1: counseling (anatomy and physiology of the voice and vocal fold nodules), vocal hygiene recommendations (water intake, avoiding vocal misuse and abuse) Day 2: breathing exercises, vocal hygiene recommendations, resonant voice therapy on vowel and syllable level, pitch variations Day 3: breathing exercises, vocal hygiene recommendations, resonant voice therapy on word and sentence level, pitch variations Day 4: resonant voice therapy in spontaneous speech, combination exercises"
223802470|NCT05878197|BEHAVIORAL|Vocal Hygiene|"Participants of the control group will receive a sham treatment, including the exact same games, drawing assignments, etc. as in the experimental groups. However, no SOVT or other active vocal techniques will be practiced. Vocal hygiene guidelines (e.g. avoid screaming, imitating voices, sufficient hydration etc.) will be kept equally in the four groups. All voice therapy programs will be guided by the same experienced voice therapist.~Content:~Day 1: counseling (anatomy and physiology of the voice and vocal fold nodules), vocal hygiene recommendations (water intake, avoiding vocal misuse and abuse) Day 2: breathing exercises, vocal hygiene recommendations Day 3: breathing exercises, vocal hygiene recommendations Day 4: combination exercises"
223802471|NCT04491448|BEHAVIORAL|Social needs screening|Interview and referral for non-medical health-related social needs
223802472|NCT05092191|DRUG|Cannabis oil vs placebo|"Eligibility, Screening and Baseline (T0):~Candidates will be seen by both research staff and a neurologist. Full written informed consent will be obtained before completing questionnaires and administering physical and medical evaluations. If eligibility is confirmed, a blood sample will be collected followed by participant randomisation .~Follow-up visits:~Randomized participants come back after 4 weeks (T1) for the same assessments administered at T0. Only participants who had a decrease in their level of spasticity can continue their participation in the same allocated arm for an additional period of 12 weeks.~At the end of the additional period of 12 weeks (T2), another visit is scheduled for a last assessments which are the same as T0 and T1.~Throughout study, courtesy calls will be scheduled and standard care for MS will also be offered to ensure participants 'safety and well-being."
223802473|NCT06626412|DIAGNOSTIC_TEST|Diagnostic Test: 18F-SynVesT-1 PET|Positron Emission Tomography (PET) of synaptic vesicle protein 2A (SV2A) using the radioligand 18F-SynVesT-1.
223802474|NCT06626412|DIAGNOSTIC_TEST|Volumetric MRI|Magnetic resonance imaging of brain volume.
223802475|NCT06320860|DEVICE|Kidney Stone Retrieval|Using FlexStone Basket aimability to retrieve kidney stones
223802476|NCT05937724|OTHER|Family Caregiving|Family caregiving and sibling inclusive
223802477|NCT05487664|DEVICE|Transcutaneous Auricular Neruostimulation (tAN)|The intervention we are studying is called transcutaneous auricular neurostimulation (tAN). tAN is simply electrical nerve stimulation administered at the ear which targets both the auricular branch of the vagus nerve (ABVN) and the auriculotemporal nerve (ATN, a branch of the trigeminal nerve).
223802478|NCT02412137|OTHER|Counseled cohort|This group will be counseled after brace temperature/date/time data is logged at each visit.
223802479|NCT06698887|DRUG|Idecabtagene vicleucel|As per CA089-1043 study protocol
223802480|NCT04913363|OTHER|Green space|Green space in which activities take place
223802481|NCT03577587|DIETARY_SUPPLEMENT|Silitidil for 21 days|daily ingestion of herbal galactagogue Silitidil over time period of 3 weeks
223802482|NCT03577587|DIETARY_SUPPLEMENT|Placebo for 21 days|daily ingestion of Placebo preparation over time period of 3 weeks
223802483|NCT06732700|OTHER|Integrated Neuromuscular Inhibition Technique and Posture Corrective Exercises.|INIT will be performed for experimental group and then posture corrective exercises will be performed and for control group only posture corrective exercises will be performed
223802484|NCT07064824|BEHAVIORAL|Adaptive Cell Phone Support|Mobile health adherence promotion based on the supportive accountability model
223802485|NCT07064824|BEHAVIORAL|Computer-Delivered Cell Phone Support|Mobile health adherence promotion based on the supportive accountability model
223802486|NCT07064824|BEHAVIORAL|Automated Text Reminders|Scheduled text reminder to take medication
223802487|NCT07081984|BIOLOGICAL|therapeutic tumor vaccine|TI-0093 injection will be administered intramuscularly on Day1, Day8, Day15, Day29 and Day43.
223802488|NCT07092787|BEHAVIORAL|Smartphone-based behavioral intervention|The proposed study will use a behavioral smartphone-based intervention in a 12-week RCT among clinically diagnosed ADHD adolescents in Hong Kong. Guided by a conceptual framework on SO in ADHD, we will implement specific strategies that counter the potentially addictive qualities of smartphones using built-in smartphone functions that have been previously shown to be effective.
223802489|NCT07092787|OTHER|Self-monitoring of smartphone use|Participants will receive information about the known benefits and risks of SO and activate their smartphones' screentime monitoring setting. They will receive weekly reminders to submit their smartphone usage data.
223802490|NCT01323530|DRUG|Eribulin mesylate|Intravenous (IV) bolus or infusion.
223802491|NCT01323530|DRUG|Capecitabine|Oral film-coated tablets.
223802492|NCT03716310|DIAGNOSTIC_TEST|platelet responsiveness evaluation|Blood samples were anticoagulated with 0.129 mmol/L of sodium citrate and then centrifugated for 10 min at 200 rpm; platelets aggregation was assessed with an AggRAM Advanced Modular System light transmittance aggregometer (Helena Laboratories, Beaumont, Texas, USA). Low-molecular-weight heparin (LMWH) was given at least 8 hours before any blood aggregation sample. Agonist used to initiate aggregation test were: -Adenosine diphosphate (ADP) to assess P2Y12-dependent platelet aggregation; (20 ng) - Arachidonic acid (AA) to assess cyclooxygenase-dependent platelet Adenosine diphosphate aggregation (1 mcg) - thrombin receptor-activating peptide-6 (TRAP-6) to assess protease-activated receptor 1-dependent platelet aggregation. Max aggregation reached (Aggmax), the slope of the curve (slope) and the latency time (lat) were analyzed for each agonist.
223802493|NCT05604924|OTHER|virtual reality training for cesarean section|Participants who received virtual reality training for cesarean section can learn the surgical procedures as if they were in a real field.
223802494|NCT04608175|OTHER|Acupuncture|Treatment of disease by inserting needles along specific pathways or meridians. The placement varies with the disease being treated. It is sometimes used in conjunction with heat, moxibustion, acupressure, or electric stimulation.
223802495|NCT02929355|OTHER|carotid assesment by duplex ultrasonography|
223802496|NCT02532179|BIOLOGICAL|Mouse Allergenic Extract|Subjects will receive escalating doses of glycerinated mouse allergenic extract administered subcutaneously up to a maximum study dose (MSD) of 0.4 mL of extract at a concentration of 1:10 wt/vol., per protocol.
223802497|NCT03648112|DIETARY_SUPPLEMENT|Intervention 1|The study participants receive recipes for breakfast for 21 days. The recipes imply 80 g of crude oat flakes per day.
224264123|NCT03371186|OTHER|Balanced Post-Partum Contraceptive Counseling|Research on interventions to improve postpartum contraception suggest strategies that bridge the continuum of reproductive health care-antenatal care, labor and delivery, postnatal care, and infant care-are more effective than short term, stand-alone counseling sessions. The structured counseling module incorporated in the intervention will be partially adapted from the Balanced Counseling Strategy, an interactive contraceptive counseling method developed by the Population Council in accordance with the World Health Organization's tiered effectiveness guidelines. Prior studies in clinical settings in Nepal have demonstrated increased uptake of modern contraceptive methods, especially of long-acting reversible contraceptives with use of balanced counseling.
223802498|NCT03648112|DIETARY_SUPPLEMENT|Intervention 2|The study participants receive recipes for breakfast for 21 days. The recipes imply 80 g of roasted oat flakes per day.
223802499|NCT03648112|DIETARY_SUPPLEMENT|Intervention 3|The study participants receive recipes for breakfast for 21 days. The recipes imply 80 g of crude barley flakes per day.
223802500|NCT03648112|DIETARY_SUPPLEMENT|Intervention 4|The study participants receive recipes for breakfast for 21 days. The recipes imply 80 g of roasted barley flakes per day.
223802501|NCT03648112|DIETARY_SUPPLEMENT|Control|"White toastbread (control) (dietary supplement) White toastbread was chosen because of its low fibre content. To achieve the same energy value (kcal) as 80 g cereal flakes the participants have to consume four slices of white toastbread.~The study participants receive recipes for breakfast for 21 days. The recipes imply four slices of white toastbread."
223802502|NCT02681848|DRUG|Varenicline|Smoking cessation medication
223802503|NCT02681848|DRUG|Nicotine replacement therapy|
223802504|NCT04715516|BEHAVIORAL|alcohol brief intervention|Nested within the lifestyle health promotion provided in both conditions, participants randomised to the experimental condition will receive an alcohol brief intervention. The strong evidence-base for alcohol brief intervention, amplified by Co-Investigators' Smith and Bragge's (BehaviourWorks) approaches to applied behaviour change, has provided the framework for the development of the alcohol brief intervention used in this study. This intervention comprises personalised feedback on alcohol consumption levels, comparison to gender/age drinking norms, and information and behaviour-change content regarding alcohol consumption (i.e. negative-framed messaging around alcohol risks and harms, positive-framed messaging on the health benefits of reducing alcohol intake, alcohol harm reduction strategies).
223802505|NCT04715516|BEHAVIORAL|lifestyle health promotion|Lifestyle health promotion specific to physical activity and maintaining a healthy weight, developed to be relevant to women attending breast screening services, will be provided.
224264124|NCT04180969|DRUG|yohimbine + hydrocortisone|yohimbine 54mg + hydrocortisone 20mg oral
224264125|NCT04180969|DEVICE|medial prefrontal cortex rTMS|1 Hz mPFC rTMS
224264126|NCT04180969|DRUG|Placebo oral tablet|placebo stressor
223802506|NCT03646032|BEHAVIORAL|SAAFE|After completing the pre-game assessment, participants will be asked to play the SAAFE game for at least 30 minutes and up to 1 hour . At the conclusion of the game, participants will be provided with a post-game assessment about their perception of risk, knowledge of specific protective behaviors, and whether they plan to change behaviors.
223802507|NCT03646032|BEHAVIORAL|Control|This group will receive dating sim game (called Choices). They will also receive pamphlets that provide information on the testing location and care if they have HIV/STI.
223802508|NCT03348072|PROCEDURE|Cardiac surgery|Cardiac surgery
223802509|NCT05639179|BIOLOGICAL|UCAR-T Cells|"UCAR-T Cellswill be administered by vein. The trial includes two portions. The first portion is a3+3dose escalation study, in which three dose groups are set:Dose level one:1×10\^6 cells/kg;Dose level two:2×10\^6 cells/kg;Dose level three:5×10\^6 cells/kg. Each dose group requires at least three subjects. The trial will start from dose level one. The second portion includes a dosage extended cohort and will start after the finish of the3+3dose escalation study. Twelve subjects will get infusion of UCAR-T Cells at the best dose verified in the first portion."
223802510|NCT02395861|OTHER|neuro-electrophysiologic analyses|mismatch negativity (MMN) cognitive evoked potentials (CEP) auditory evoked potentials (AEP)
223802511|NCT04386434|BEHAVIORAL|Active for Life: Assisted Living|"Each intervention session will take place within the assisted living facility twice a week for 12 weeks.~Sessions will begin with 5-10 minutes of walking in the hallway. Participants will be encouraged to walk at their own pace and allowed to take breaks if needed.~Next, behavioral strategies based on the construct of self-efficacy from social cognitive theory and education about physical activity will be delivered. This component is scheduled between the walking and circuit training, lasts 15-20 minutes, and serves as a rest period.~Circuit training will focus on strength and balance. Approximately 8 exercise stations will be set up, and the exercises performed at each station will be changed approximately every 4 weeks. The circuit training will last \~30-40 minutes, with participants moving from one station to the next at their own pace and taking breaks in between."
223802512|NCT01314989|DRUG|Cyproheptadine|0,25mg/kg/day orally in 2 doses per day (2mg/5 ml)for 1 month
223802513|NCT01314989|DRUG|Sugar pill|liquid placebo
223802514|NCT00253344|DRUG|docetaxel|Docetaxel IV over 1 hour on day 1. Courses repeat every 21 days until disease progression or unacceptable toxicity.
223802515|NCT00253344|DRUG|lenalidomide|Oral lenalidomide on days 1-14. Courses repeat every 21 days until disease progression or unacceptable toxicity.
223802516|NCT00889057|DRUG|sorafenib|400 mg bid until progression or inacceptable toxicity
223802517|NCT00953134|DIETARY_SUPPLEMENT|Ferrous fumarate (iron)|60 mg of ferrous fumarate
223802518|NCT00953134|DIETARY_SUPPLEMENT|folic acid|400 mcg folic acid
223802519|NCT05961852|DEVICE|Angioplasty|Angioplasty with cutting and drug-coated balloon
223802520|NCT00876915|DRUG|dalteparin injection|Potency is described in international anti-Xa units (IU). One unit (anti-Xa) of dalteparin sodium, average molecular weight 5,000, corresponds to the activity of one unit of the 1st International Standard for Low Molecular Weight Heparin (LMWH)with respect to inhibition of coagulation Factor Xa in plasma utilizing the chromogenic peptide substrate S-2765 (N-alpha-Benzyloxycarbonyl-D-arginyl-glycyl-arginine-pNA.2HCl).
223802521|NCT02138045|DRUG|Placebo treatment|Treatment continues at highest tolereable dose (minimum 1.2 mg/day). Intervention time 26 weeks at target dose.
223802522|NCT02138045|DRUG|Liraglutide treatment|Treatment continues at highest tolereable dose (minimum 1.2 mg/day). Intervention time 26 weeks at target dose.
223802523|NCT05600049|DEVICE|Prototypes (815-v1 001) to (815-v1 050)|"Application on brown spots located on the face and/or the hand (6 treatments during the study).~An operator previously trained by the dermatologist will apply the study device to the patient's face or/and hand.~Subjects will be lying down, and the prototypes will be administered upside down for the applications on the face and sitting for the applications on the hands. For the application on the hands, the hands will be placed flat on the table and the prototypes will be applied upside down. During applications on the face, subjects will wear diving goggles protecting the eyes from cryogenic gas."
223802524|NCT05600049|DEVICE|Prototype (815-v1 051) to (815-v1 100)|"Application on brown spots located on the face and/or the hand (6 treatments during the study.~An operator previously trained by the dermatologist will apply the study device to the patient's face or/and hand.~Subjects will be lying down, and the prototypes will be administered upside down for the applications on the face and sitting for the applications on the hands. For the application on the hands, the hands will be placed flat on the table and the prototypes will be applied upside down. During applications on the face, subjects will wear diving goggles protecting the eyes from cryogenic gas."
224264127|NCT04180969|DEVICE|sham rTMS|sham mPFC rTMS
224264128|NCT05415891|BEHAVIORAL|Modified Health Policy Project (HPP) HIV-Stigma and Discrimination Reduction Training Curriculum|The Health Policy Project (HPP) training curriculum provides participatory training modules that address three key actionable drivers of HIV-stigma. The HPP curriculum was adapted through participatory workshops with the study's community collaborative board, including representatives from the HIV care and advocacy communities as well as community members. The training is a whole-site training to address stigma as a barrier to accessing substance use and mental health services by persons living with HIV. Consequently, staff at all levels (clinical and nonclinical) will be trained on stigma and discrimination as it relates to persons living with HIV in order to reduce stigma-related barriers to mental health and substance use healthcare in Positive Impact Health Centers and increase retention in healthcare services for persons living with HIV.
224264129|NCT05415891|DEVICE|You℞ Decision prescribing platform|The You℞ Decision prescribing platform is a mobile application that serves as a reference to quickly inform providers about the medications recommended for serious mental health disorders and naltrexone to treat AUD; the appropriate dosing regimen; and potential contraindications or interactions related to antiretroviral therapy medications or other psychiatric medication. Information for the platform is adapted from the Department of Veteran Affairs' Manual for HIV Care in Primary Care settings.
224264130|NCT02270697|DEVICE|Array|Applications of oligonucleotide array in diagnosis.
224264131|NCT01487720|DRUG|GEMOX|Gemcitabine 1000 mg/m2 IV on day 1 every 2 weeks (fixed-dose rate 10 mg/m2/min) Oxaliplatin 100 mg/m2 IV on day 1 every 2 weeks Prednisolone 5 mg twice a day orally daily
223802525|NCT05600049|DEVICE|Prototypes (815-v1 101) to (815-v1 150)|"Application on brown spots located on the face and/or the hand (6 treatments during the study.~An operator previously trained by the dermatologist will apply the study device to the patient's face or/and hand.~Subjects will be lying down, and the prototypes will be administered upside down for the applications on the face and sitting for the applications on the hands. For the application on the hands, the hands will be placed flat on the table and the prototypes will be applied upside down. During applications on the face, subjects will wear diving goggles protecting the eyes from cryogenic gas."
223802526|NCT05600049|DEVICE|Prototypes (815-v1 151) to (815-v1 200)|"Application on brown spots located on the face and/or the hand (6 treatments during the study.~An operator previously trained by the dermatologist will apply the study device to the patient's face or/and hand.~Subjects will be lying down, and the prototypes will be administered upside down for the applications on the face and sitting for the applications on the hands. For the application on the hands, the hands will be placed flat on the table and the prototypes will be applied upside down. During applications on the face, subjects will wear diving goggles protecting the eyes from cryogenic gas."
223802527|NCT03046615|DEVICE|EEG Electrode Patch|The additional electrodes are modified EEG electrodes (used in clinical practice on the head already) placed in a silicone molding. These are placed lateral to the eye with the patient asleep. These are then wired to the same recording apparatus that we would commonly use for recording.
223802528|NCT03046615|DEVICE|Standard Needles|Needles are placed in the muscles surrounding the eye to measure eye movements.
223802529|NCT01615874|DRUG|MF/F Metered Dose Inhaler (MDI) 25/5 mcg|MF/F MDI 25/5 mcg, 2 inhalations twice a day (BID)
223802530|NCT01615874|DRUG|MF/F MDI 50/5 mcg|MF/F MDI 50/5 mcg, 2 inhalations BID
223802531|NCT01615874|DRUG|MF/F MDI 100/5 mcg|MF/F MDI 100/5 mcg, 2 inhalations BID
223802532|NCT01615874|DRUG|BDP hydrofluoroalkane (HFA) 80 mcg|BDP HFA 80 mcg, 2 inhalations BID
223802533|NCT01615874|DRUG|Montelukast tablets 5 mg (4 mg for children 5 years of age)|"Montelukast chewable tablets 5 mg once daily (QD) for children 6-11 years of age~OR~Montelukast chewable tablets 4 mg QD for children 5 years of age"
223802534|NCT01615874|DRUG|Rescue medication: short-acting beta-2 agonist (SABA) MDI|albuterol MDI 90 mcg OR or salbutamol HFA MDI 100 mcg for rescue medication, taken as directed
223802535|NCT01615874|DRUG|Rescue medication: Prednisone/Prednisolone|Prednisone/Prednisolone for rescue medication, taken as directed
223802536|NCT05519280|BEHAVIORAL|the Biopsychosocial-Spiritual Group Intervention|The Experimental group received 8 sessions of weekly BPS-S group therapy for 80 minutes each.
223802537|NCT01885728|DIETARY_SUPPLEMENT|An arginine rich nutritional supplement|Impact is a nutritional supplement formulated with 18 grams of protein per serving and 24 essential nutrients including arginine.
223802538|NCT06308679|DRUG|Empagliflozin 10 mg tablets|Empagliflozin 10 mg tablets (test drug)
223802539|NCT06308679|DRUG|JARDIANCE®|Empagliflozin 10 mg tablets (reference drug)
223802540|NCT01865708|DRUG|Ethanol Lock|Ethanol lock, utilizing 74% ethanol, will begin within 24 hours of urinary catheter placement. The lock will be done every 24 hours for 1 hour. The volume that will be instilled depends upon the fill volume of the catheter, which is imprinted by the manufacturer on each catheter. Once the alcohol is in the catheter, the proximal end of the catheter will be clamped for 1 hour. After the 1 hour dwell time, the clamp will be removed and the alcohol in the lumen of the catheter will be flushed out by the patient's own urine output.
223802541|NCT01735201|DRUG|AGN-199201 Dose A|AGN-199201 Dose A applied once or twice daily to the face for 28 days.
223802542|NCT01735201|DRUG|AGN-199201 Dose B|AGN-199201 Dose B applied once or twice daily to the face for 28 days.
223802543|NCT01735201|DRUG|AGN-199201 Dose C|AGN-199201 Dose C applied once or twice daily to the face for 28 days.
223802544|NCT01735201|DRUG|AGN-199201 Vehicle|AGN-199201 Vehicle applied once or twice daily to the face for 28 days.
223802545|NCT01553318|DRUG|Ketotifen|After meeting the full eligibility requirement, participants will be randomized. From week 1 to 2, subjects will receive either ketotifen 1 mg by mouth, twice a day or the equivalent placebo. Thereafter, subjects will take ketotifen to 2 mg by mouth twice a day or the equivalent placebo.
223802546|NCT01553318|DRUG|Placebo (Sugar Pill)|After meeting the full eligibility requirement, participants will be randomized. From week 1 to 2, subjects will receive either ketotifen 1 mg BID or the equivalent placebo. Thereafter, subjects will take ketotifen to 2 mg BID or the equivalent placebo.
223802547|NCT00892502|DRUG|Bismuth tablets|1000 mg x 2 for five days prior to chemotherapy/radiotherapy 500 mg x 2 for ten days during and after chemotherapy/radiotherapy
223802548|NCT00892502|DRUG|Placebo tablets|1000 mg x 2 for five days prior to chemotherapy/radiotherapy 500 mg x 2 for ten days during and after chemotherapy/radiotherapy
223802549|NCT04219852|OTHER|data collection|data collection
223802550|NCT03362463|OTHER|Non-Interventional Study|Non-Interventional Study
223802551|NCT00176163|BEHAVIORAL|Operant behavioral treatment; Drug: THC|
223802552|NCT03499522|OTHER|Observational group|"The dependent variables (pain, quality of life, anxiety and coping strategies) and the outcome measures used to measure these variables will be:~* Numerical scale of pain~* Short Form 36 Health Survey \[SF-36\].~* State-Trait Anxiety Inventory \[STAI\].~* Tampa Scale of Kinesiophofia \[TSK-11SV\].~* Pain catastrophizing scale \[PCS\].~* Coping Strategies Questionnaire \[CSQ\]."
223802553|NCT00209573|DRUG|fospropofol disodium|
223802554|NCT02357004|DRUG|Carvedilol|CR 40 mg daily in addition to normal BP medications
223802555|NCT02357004|DRUG|Chlorthalidone|12.5 mg daily in addition to normal BP medications
223802556|NCT02042079|PROCEDURE|EFTR with LA|(Endoscopic full-thickness resection with laparoscopic assistance)
223802557|NCT04563221|DEVICE|Prostatic artery embolization|Prostatic artery embolization is performed using LC Bead LUMI, which is the investigational device. The particles are administered to the prostatic arteries using either a balloon occlusion or standard microcatheter. Follow-up is performed at 1 month, 6 months, 12 months, and 24 months after intervention.
223802558|NCT06165406|PROCEDURE|Distal radial access|Distal radial access for coronary procedures
223802559|NCT02318043|DRUG|inhaled corticosteroids (usually budesonide/fomorterol 160/4.5mcg; fluticasone/salmeterol 250/50mcg)|Patients with uncontrolled and partly controlled asthma, following accomplishment of study 1, were invited to participate in observational study (study 2), which sought to determine usefulness of both BPTs in reflecting improvement of asthmatic symptoms following 3 and 6 months of moderate-dose ICSs treatment (400\~800μg budesonide or equivalent). Patient continued to administer their original ICS during follow-up. During two follow-up visits (3 months apart), AMP-BPT, His-BPT and Hogg's symptom scores were reassessed.
223802560|NCT00154206|DRUG|Enteric-Coated Mycophenolate Sodium (EC-MPS)|
223802561|NCT04547088|DRUG|Camrelizumab|Anti-PD-1 targeted immunotherapy
223802562|NCT04547088|DRUG|Apatinib|A small-molecule vascular endothelial growth factors receptor (VEGFR) tyrosine kinase inhibitor
223802563|NCT04128293|DRUG|GSK3640254 Tablet|GSK3640254 tablets will contain mesylate salt with a unit dose of 100 mg (2x100 mg) and will be administered orally.
223802564|NCT04128293|DRUG|GSK3640254 Capsule|GSK3640254 capsules will contain mesylate salt with a unit dose of 100 mg (2x100 mg) and will be administered orally.
223802565|NCT02965222|DEVICE|the time-lapse videography|The all oocytes will be placed in the Time-Lapes .The third day the top-grade embryo will be selected by time-lapse imaging (TLI) .
223802566|NCT03603223|BIOLOGICAL|Pembrolizumab|Given IV
223802567|NCT04446611|DIAGNOSTIC_TEST|First antenatal care + test-of-cure|Single point-in-time molecular point-of-care diagnostic screening and treatment for Chlamydia trachomatis, Neisseria gonorrhoeae and Trichomonas vaginalis at first antenatal care visit and infection-specific test-of-cure 3 weeks post-treatment. Women with a positive test-of-cure will be re-treated. As CT/NG is a combined Xpert test, women who present with an incident infection (newly diagnosed infection) will be treated and managed accordingly.
223802568|NCT04446611|DIAGNOSTIC_TEST|First antenatal care + week 30-34 gestation (no test-of-cure)|Repeated molecular point-of-care diagnostic screening and treatment for Chlamydia trachomatis, Neisseria gonorrhoeae and Trichomonas vaginalis at first antenatal care visit and at week 30-34 gestation. No test-of-cure will be conducted for women with positive test results; however, additional treatment will be provided to women with persistent/recurrent vaginal discharge.
223802569|NCT03019510|BEHAVIORAL|No exercise|No exercise will be done on the day of the study night to be tested
223802570|NCT03019510|BEHAVIORAL|Morning exercise|Early morning exercise will be done on the day of the study night to be tested
223802571|NCT03019510|BEHAVIORAL|Evening exercise|Evening exercise will be done on the day of the study night to be tested
223802572|NCT03178786|BEHAVIORAL|PAT sessions|PD subjects will be tested twice, that is, within four weeks before (Baseline) and after the completion of 9 PAT projects (Follow up).
223802573|NCT03496779|DRUG|Brentuximab Vedotin - induction|Brentuximab vedotin 1.8 mg/kg at D8 of a 28-day cycle - 4 cycles = 16 weeks for combined chemotherapy
223802574|NCT03496779|DRUG|Gemcitabine|Gemcitabine 1000 mg/m² at D1 and D15 of a 28-day cycle - 4 cycles = 16 weeks for combined chemotherapy
223802575|NCT03496779|DRUG|Brentuximab Vedotin - maintenance|"Patients who will obtain partial or complete response and who will not be eligible for transplant will receive maintenance therapy with brentuximab vedotin every 3 weeks for 12 infusions.~Brentuximab vedotin 1.8 mg/kg at D1 of a 21-day cycle - 12 cycles = 36 weeks for maintenance therapy"
223802576|NCT03496779|PROCEDURE|autologous or allogeneic stem cell transplantation|Patients who will obtain partial or complete response and who will be eligible for transplant will receive autologous or allogeneic stem cell transplantation
224264132|NCT05366582|DEVICE|Macintosh Laryngoscope|"After the induction, laryngoscopy will be performed with a Macintosh laryngoscope after 2 minutes of manual ventilation after muscle relaxant by an anesthesiologist with at least 4 years of experience. Patients will be intubated with the Medtronic Xomed Nerve Integrity Monitor Standard Reinforced ElectromyographyEndotracheal Tube (size 6.0, 7.0 or 8.0). The cuff of the intubation tube will be connected to a manometer and inflated at a pressure of 20-30 mmHg until there is no air leak. Intubation will be confirmed by the appearance of end-tidal carbon dioxide (CO2). Failed intubation will be considered if not achieved within 2 minutes"
224264133|NCT05366582|DEVICE|Video Laryngoscope|"After the induction, laryngoscopy will be performed with a Video laryngoscope after 2 minutes of manual ventilation after muscle relaxant by an anesthesiologist with at least 4 years of experience. Patients will be intubated with the Medtronic Xomed Nerve Integrity Monitor Standard Reinforced ElectromyographyEndotracheal Tube (size 6.0, 7.0 or 8.0). The cuff of the intubation tube will be connected to a manometer and inflated at a pressure of 20-30 mmHg until there is no air leak. Intubation will be confirmed by the appearance of end-tidal CO2. Failed intubation will be considered if not achieved within 2 minutes"
224264134|NCT00942838|DRUG|Cisplatin|PLATINOL®-AQ (cisplatin injection) is a clear, colorless, sterile aqueous solution, each mL containing 1 mg cisplatin and 9 mg Sodium Chloride, USP. HCl and/or Sodium Hydroxide is added to adjust pH of the solution. The active ingredient, cisplatin, is a yellow to orange crystalline powder with the molecular formula PtCl2H6N2, and a molecular weight of 300.1. Cisplatin is a heavy metal complex containing a central atom of platinum surrounded by two chloride atoms and two ammonia molecules in the cis position. It is soluble in water or saline at 1 mg/mL and in dimethylformamide at 24 mg/mL. It has a melting point of 207°C.
224264135|NCT00942838|RADIATION|Whole Abdomen Radiotherapy|Whole abdominal radiotherapy will be delivered with an open-field anterior-posterior/posterior-anterior technique. Radiation will be administered in a dose escalating fashion to determine toxicity. The maximal dose of radiation will be defined as a mean midplane dose to the abdomen of 3,000 Gy through parallel-opposed single ports with a 1-cm margin that will cover the entire abdomen including the diaphragm.
224264136|NCT00491738|DRUG|bevacizumab|Intravenous repeating dose
224264137|NCT00491738|DRUG|sunitinib|Oral repeating dose
224264138|NCT00491738|DRUG|placebo|Intravenous repeating dose
224264139|NCT05285865|OTHER|Conventional Treatment|Thrice a day for complete length of stay. This is Conventional treatment The total duration of session will be of 15-20 mins.
224264140|NCT05285865|OTHER|Scapular Mobilization|Thrice a day for complete length of stay including two sets of repetitions with a rest interval of 30 seconds between sets. Grade 1-3 As reported in a study Scapular mobilization (SM) i.e., Scapular superior, inferior glides, upward and downward rotations and scapular distraction, along with Conventional treatment according to American Heart Association Guidelines i.e., Incentive spirometer, chest clearance, expectoration of the sputum (suctioning if needed), mobilizing the patient out of bed, AAROM and AROM exercises.
224264141|NCT02043392|DEVICE|Magnamosis|Single-use, sterile device enables creation of a circular compression intestinal anastomosis. Device is comprised of matched pair of self-centering rare earth magnets encased in medical grade polycarbonate. Geometry of magnets' mating surfaces applies force on inside of mated rings to produce compression necrosis of intervening intestinal walls. Lesser force on outside of mated rings produces inflammatory healing of the two co-apted intestinal walls. Internal lumen creates patency of the anastomosis to prevent intestinal obstruction during compression anastomosis creation. In 5-10 days, mated rings with necrotic tissue falls into intestinal lumen and is naturally expelled with stool, leaving a well-healed anastomosis.
224264142|NCT00664196|BIOLOGICAL|Gene Modified T Cells|One time infusion Modified T-Cells given through a vein in the arm or a catheter over a 30-60 minute period.
223802577|NCT05924542|BEHAVIORAL|Kelaa Mental Resilience App|"Users can track their stress, wellbeing, and resilience via short in-app questionnaires. The app uses inbuilt sensors in smartphones to measure sleep quality and quantity. Personalized feedback on questionnaire scores and on sleep data are given. Users access structured science-based content on factors contributing to reduced stress and improved well-being. Kelaa provides the user with evidence-based interventions grounded in current research, e.g., from sleep science and psychology. Users can choose from a variety of topics, based on their results from the tracking module and personal interest, and then journey through the self-selected goals. Each goal includes six to seven daily sessions, aiming to increase personal resources by providing information, exercises, and reflection. During each daily session, relevant research and expected benefits are outlined, before users are instructed, e.g., in specific stress management and resilience techniques, to encourage behavior change."
223802578|NCT00000192|DRUG|Lamotrigine|
223802579|NCT01037842|DRUG|Mitiglinide|"mitiglinide 10 mg three times a day added to metformin 500 mg three times a day~for 16 weeks"
223802580|NCT01037842|DRUG|Placebo|placebo three times a day added to metformin 500 mg three times a day for 16 weeks
223802581|NCT03008967|OTHER|Arthroplasty and postoperative rehabilitation.|Patients undergoing total knee or total hip arthroplasty and their response to postoperative rehabilitation.
223802582|NCT04618874|DIAGNOSTIC_TEST|Rapid on-site evaluation|Rapid on site evaluation performed with an MGG quick stain (Bio-Optica, Milano, Italy).
223802583|NCT03728829|DRUG|Trastuzumab+TP|Trastuzumab (4 mg/kg loading dose, then 2 mg/kg I.V., every week, totally 17 weeks (6 cycles)) combined with TC neoadjuvant chemotherapy (Docetaxel 75 mg/m2 I.V., day 1, Carboplatin 400 mg/kg, I.V., day 2, every 3 weeks, totally 6 cycles).
223802584|NCT01357616|DRUG|Brinzolamide 1% / Timolol 0.5% fixed combination ophthalmic suspension|
223802585|NCT01357616|DRUG|Brinzolamide 1% ophthalmic suspension|
223802586|NCT01357616|DRUG|Timolol 0.5% ophthalmic solution|
223802587|NCT01799564|PROCEDURE|Micropulse|Between 1 and 3 sessions of micropulse laser will be applied in the inferior hemiretina of the randomly selected eye
223802588|NCT01418274|DRUG|danoprevir|oral doses of danoprevir
223802589|NCT01418274|DRUG|escitalopram|oral doses of escitalopram
223802590|NCT01418274|DRUG|ritonavir|oral doses of ritonavir
223802591|NCT05399745|OTHER|Neurocognitive monitoring|Neurocognitive tests and MRI of the brain
223802592|NCT03247790|DRUG|Lasmiditan|Administered orally
223802593|NCT00726206|OTHER|Electroencephalogram, recording the movements|Electroencephalogram, recording the movements of the child, RMI, Transfontanel Imaging
223802594|NCT01730885|OTHER|Comparison of different Blood Glucose Meters|
223802595|NCT03432364|GENETIC|ST-400 Investigational product|Single dose of ST-400 following chemotherapy conditioning with busulfan
223802596|NCT03288610|DIAGNOSTIC_TEST|Preoperative copeptin level|Measure of plasmatic copeptin from preoperative samples retained in a biorepository. Physicians are blinded to the result.
223802597|NCT03544346|OTHER|Exploratory brain and general health assessment|Exploratory brain and general health assessment
223802598|NCT01490502|DRUG|Vitamin D3|Patients will be assigned to low dose (600 IU/day) versus high-dose (5000 IU/day) of vitamin D3 as an add-on therapy to glatiramer acetate (Copaxone).
223802599|NCT01199484|OTHER|Cow's milk|
223802600|NCT02858141|OTHER|Data collection|
223802601|NCT04186780|OTHER|Shiitake cereal bar|patients with borderline cholesterol exposed to bars with Shiitake
223802602|NCT01699022|DRUG|Injection Cyclofem|"Injection Cyclofem contains 25 mg medroxyprogesterone acetate (MPA) and 5 mg estradiol cypionate as a microcrystalline suspension in 0.5ml aqueous solution and is supplied in vials.~Women were administered three consecutive monthly injections of Cyclofem for prevention of ovulation, and were followed until the 92nd day from the last (third) injection."
223802603|NCT04827485|OTHER|Gluteal squeeze|During procedure, the doctor performing colonoscopy will ask for gluteal pressure. The technician will perform the maneuver, but the doctor will be blinded as the arms of the technician along with the patients behind are covered by a towel.
223802604|NCT04827485|OTHER|No squeeze|During procedure, the doctor performing colonoscopy will ask for gluteal pressure. The technician will not perform the maneuver, but the doctor will be blinded as the arms of the technician along with the patients behind are covered by a towel.
223802605|NCT02002026|PROCEDURE|Uterine artery ligation|Uterine artery ligation during cesarean section before delivery of the baby
224264143|NCT05282693|DIETARY_SUPPLEMENT|ReMag|300 mg of ReMag dissolved in lemon flavor liquid
224264144|NCT05282693|DIETARY_SUPPLEMENT|Placebo|Lemon flavored liquid
224264145|NCT02727192|DEVICE|PAP (CPAP or ASV)|Patients will be randomized to treatment of Sleep Apnea with a CPAP or control
224264146|NCT02316457|BIOLOGICAL|IVAC_W_bre1_uID|vaccination
224264147|NCT02316457|BIOLOGICAL|IVAC_W_bre1_uID/IVAC_M_uID|vaccination
224264148|NCT00595140|DRUG|pegvisomant|growth hormone receptor antagonist pegvisomant in patients´ individual dose
224264149|NCT00595140|DRUG|combination with somatostatin analogue octreotide|s.c., 100µg, one time
224264150|NCT00595140|DRUG|combination with dopamine agonist cabergoline|oral, 0.5mg, one time
224264151|NCT03050866|DRUG|Cabazitaxel|25mg/m2 q3w
224264152|NCT03050866|OTHER|Antihistamine|As intravenous premedication (dexchlorpheniramine 5 mg, diphenhydramine 25 mg, or equivalent)
224264153|NCT03050866|OTHER|Corticosteroid|As intravenous premedication (dexamethasone 8 mg or equivalent)
224264154|NCT03050866|OTHER|H2 antagonist|As intravenous premedication (ranitidine or equivalent)
224264155|NCT03050866|OTHER|Antiemetic|Antiemetic prophylaxis is recommended and can be given orally or intravenously if necessary
224264156|NCT00928057|DEVICE|4mm x 32G pen needle|For 3 weeks, subjects used this pen needle with their own pen device for all daily insulin injections they usually administered themselves with a pen device. Subjects followed their usual insulin regimen and there was no upper limit on total daily insulin dosage or number of injections. Subjects were advised to inject straight in when using the 4mm PN, with no pinch up.
223802606|NCT05465057|BEHAVIORAL|High intensity interval training (HIIT) + lifestyle intervention (TCOCT)|"The participants randomized for HIIT will perform supervised training sessions three times a week for 3 months. All HIIT programs consist of activities that involve 4 x 4 min. intervals at 90-95% of HRmax.~The lifestyle intervention (TCOCT) comprises a lifestyle intervention targeting all aspects of everyday life, incl. guidance on diet, physical activity, sleep, screen time, and social problems. The participant will be scheduled for follow up in the out-patient clinic or municipal obesity clinic by a trained pediatric nurse and dietician after 6-12 weeks."
223802607|NCT05465057|BEHAVIORAL|Lifestyle intervention (TCOCT)|The lifestyle intervention (TCOCT) comprises a lifestyle intervention targeting all aspects of everyday life, incl. guidance on diet, physical activity, sleep, screen time, and social problems. The participant will be scheduled for follow up in the out-patient clinic or municipal obesity clinic by a trained pediatric nurse and dietician after 6-12 weeks.
223802608|NCT04469647|DIAGNOSTIC_TEST|Serology Test|"Participants will be seen at T0 (baseline),T2 (2 months after T0), and T4 (2 months after T2).~at every visit, participants will be asked to complete a general surveillance survey and a blood sample will be taken for the serology test."
223802609|NCT02650219|GENETIC|genetic analyses|
223802610|NCT02066402|DRUG|Tedizolid (BAY119-2631)|50 % of the participants will be randomized to this arm and will receive 200 mg Tedizolid once daily i.v to oral from 1-6 days
223802611|NCT02066402|DRUG|Placebo Tedizolid (BAY119-2631)|50 % of the participants will be randomized to this arm and will receive 200 mg Placebo Tedizolid once daily i.v to oral from 7-10 days
223802612|NCT02066402|DRUG|Linezolid|50 % of the participants will be randomized to this arm and will receive 600 mg Linezolid twice daily i.v. to oral from 1-10 days
223802613|NCT02066402|DRUG|Placebo Linezolid|50 % of the participants will be randomized to this arm and will receive 600 mg Placebo Linezolid twice daily i.v. to oral from 1-10 days
223802614|NCT00003163|BIOLOGICAL|filgrastim|
223802615|NCT00003163|BIOLOGICAL|sargramostim|
223802616|NCT00003163|DRUG|cyclophosphamide|
223802617|NCT00003163|DRUG|melphalan|
223802618|NCT00003163|PROCEDURE|autologous bone marrow transplantation|
223802619|NCT00003163|PROCEDURE|peripheral blood stem cell transplantation|
223802620|NCT00003163|RADIATION|radiation therapy|
223802621|NCT00152464|DRUG|Placebo|Pharmaceutical form: Oral drops Route of administration: Oral use
223802622|NCT00152464|DRUG|Levocetirizine|Pharmaceutical form: Oral drops Concentration: 5 mg/ml Route of administration: Oral use
223802623|NCT06845046|DIETARY_SUPPLEMENT|w-3 fatty acid|omega-3 fatty acid supplement
223802624|NCT06845046|DIETARY_SUPPLEMENT|L-carnitine|L-carnitine supplement
223802625|NCT06845046|OTHER|Control Diet|Control Diet high in unsaturated fat
223802626|NCT05098470|DRUG|Metformin|1500-2000 mg per day for 8 weeks
223802627|NCT05098470|DRUG|Insulin Glargine|Long-acting insulin for 8 weeks
223802628|NCT05098470|DRUG|Dorzagliatin|Oral Glucokinase Activator 75 mg twice daily for 8 weeks
223802629|NCT01088139|DIETARY_SUPPLEMENT|Protein supplementation|Ready made protein supplement drinks with approximate protein content of 18-24g per 500ml per day. Caloric content is 490 to 530Kcal depending on the brand of drink.
223802630|NCT06201338|PROCEDURE|Screening of preoperative frailty|"The day before the surgery, a multimodal evaluation is performed regarding :~Cognitive assessment: Mini mental State evaluation (MMSE) test Physical functional assessment: Chair raising Addiction assessment: Fagerstrom Assessment of the social environment: environmental assessment Nutritional assessment: Grip test Quality of life: completion of SF 36 scale and QOR15 scale"
223802631|NCT03001297|BIOLOGICAL|Placebo|Participants will receive single dose of placebo matched MEDI5884 injection SC on Day 1
223802632|NCT03001297|BIOLOGICAL|MEDI5884 Dose 1|Participants will receive single dose MEDI5884 Dose 1 injection SC on Day 1.
223802633|NCT03001297|BIOLOGICAL|MEDI5884 Dose 2|Participants will receive single dose MEDI5884 Dose 2 injection SC on Day 1
223802634|NCT03001297|BIOLOGICAL|MEDI5884 Dose 3|Participants will receive single dose MEDI5884 Dose 3 injection SC on Day 1
223802635|NCT03001297|BIOLOGICAL|MEDI5884 Dose 4|Participants will receive single dose MEDI5884 Dose 4 injection SC on Day 1
223802636|NCT01312870|DIETARY_SUPPLEMENT|Ensure, Abbott Nutrition|Enteral feeding Ensure, Abbott Nutrition 400 ml per day for seven postoperative days
223802637|NCT01312870|OTHER|standard hospital diet|standard hospital diet
223802638|NCT01421433|DRUG|Tandrilax|Tandrilax (caffeine, carisoprodol, sodium diclofenac, paracetamol). Tablets, administered 3 times a day, for 7 consecutive days.
223802639|NCT01421433|DRUG|Dolamin Flex|Dolamin Flex (lysine clonixinate and cyclobenzaprine). Tablets, administered 3 times a day, for 7 consecutive days.
223802640|NCT02203240|OTHER|Cocoa|
223802641|NCT02203240|OTHER|Placebo|
223802642|NCT00501176|PROCEDURE|Plastic and metalic stent inserion|Patient randomizes to metal or plastic insertion prior to Whipple procedure
223802643|NCT02258139|DEVICE|B&L Investigational Contact Lens|The lens used in this study will be supplied by the Sponsor. All subjects will wear a -3.00D lens.
223802644|NCT04493931|DRUG|Gepotidacin|Gepotidacin tablets will be available as unit dose strength 750 mg and will be administered orally.
223802645|NCT04493931|DRUG|Cimetidine|Cimetidine tablets will be available as unit dose strength 400 mg and will be administered orally.
223802646|NCT04493931|DRUG|Rifampicin|Rifampicin Capsules will be available as unit dose strength 300 mg and will be administered orally.
223802647|NCT04493931|DRUG|Midazolam|Midazolam oral syrup 2 milligrams per milliliter (mg/mL) will be available to be administered orally.
223802648|NCT04493931|DRUG|Digoxin|Digoxin tablets will be available as unit dose strength 0.25 mg and will be administered orally.
223802649|NCT04493931|OTHER|Placebo matching to gepotidacin|Placebo matching to gepotidacin tablets will be administered orally.
223802650|NCT00123032|BEHAVIORAL|Diet|Increase the availability of fruits and vegetables, serve recommended portion sizes and reduce availability of excessive energy-dense foods at school cafeterias to improve the diet of participants at school breakfast, lunch and snacks.
223802651|NCT00123032|PROCEDURE|Exercise|Increase active recess time, implement classroom action breaks and increase school PE class time to increase physical activity among participants.
223802652|NCT00236301|DRUG|CLIMASTON (drug)|CLIMASTON(drug)
223802653|NCT00236301|DRUG|17 Beta-estradiol (2mg/day)and (1mg/day)|17 Beta-estradiol (2mg/day)and (1mg/day)
223802654|NCT00236301|DRUG|placebo|placebo
223802655|NCT00814424|DEVICE|monitored using currently marketed smart biteblock o2|oral nasal CO2 monitoring and oxygen delivery
223802656|NCT00814424|DEVICE|monitored using investigational smart biteblock|monitored during ERCP procedure with nasal CO2 sampling and oral oxygen delivery at a flow rate up to 10 lit/min
223802657|NCT04750967|DRUG|Lidocaine 1% Injectable Solution|Repeated injections of lidocaine to greater occipital nerve and supraorbital nerve once a week for first four weeks then once a month for five months
223802658|NCT04750967|DRUG|Amitriptyline|Amitriptyline 25 mg daily
223802659|NCT03211364|OTHER|Glenohumeral mobilization|Comparing the effect of angular mobilization in frontal or scapular plane and of providing soft tissue techniques on hemiplegic shoulder range of motion and pain.
223802660|NCT03211364|OTHER|Scapular mobilization|
223802661|NCT00919074|PROCEDURE|Pancreatic duct stent|Placement of a pancreatic duct stent to facilitate bile duct cannulation
223802662|NCT00919074|PROCEDURE|Pancreatic wire placement|Placement of a pancreatic wire to facilitate bile duct cannulation
223802663|NCT03610464|DRUG|Amphetamine Extended Release Suspension [Dyanavel]|1 mL of study drug (AMPH EROS, 2.5 mg/mL), pharmacokinetic analysis
223802664|NCT06449131|DRUG|Platelet-Rich Plasma and Fibrin Glue|"Allogenic platelet-rich plasma with fibrin glue (PRP-FG) was derived from blood obtained from a blood bank. Peripheral blood (400 ml) was collected from a donor with a matching ABO blood type, and rigorous viral safety tests were conducted. Concentrated PRP (10 ml) was obtained by subjecting the sample to centrifugation at 4000 g for 15 min to separate the plasma from the sedimented platelets.~Fibrinogen was extracted from the separated plasma using cryoprecipitation. After freezing at -70°C followed by thawing at 4°C, fibrinogen concentrate (20 ml) was prepared by centrifugation at 6500 × g for 5 min. The concentrated PRP was combined with fibrinogen (30 ml).~Thrombin was generated from the plasma isolated during the second centrifugation step. The ionic strength and pH were adjusted to precipitate prothrombin. The resulting precipitate was separated by centrifugation and dissolved in a calcium ion solution, resulting in a final volume of 5 ml of thrombin solution."
223802665|NCT01873170|DRUG|levonorgestrel exposure|
223802666|NCT01873170|DRUG|DMPA exposure|
223802667|NCT01873170|DRUG|etonogestrel exposure|
223802668|NCT01873170|DEVICE|IUD insertion|
223802669|NCT01873170|DEVICE|subdermal contraceptive implant insertion|
223802670|NCT05672979|DRUG|Brolucizumab Injection [Beovu]|brolucizumab 6mg intravitreal injection
223802671|NCT00430248|DRUG|Febuxostat|Febuxostat 40 mg, capsules, orally, once daily for up to 6 months.
223802672|NCT00430248|DRUG|Febuxostat|Febuxostat 80 mg, capsules, orally, once daily for up to 6 months.
223802673|NCT00430248|DRUG|Allopurinol|"Allopurinol 200 mg or 300 mg, capsules, orally, once daily for up to 6 months.~Dose is dependent on the subject's renal function. Subjects with normal renal function or mild renal impairment received 300 mg once daily; subjects with moderate renal impairment received 200 mg once daily."
223802674|NCT06397599|OTHER|denture adhesive|use of adhesive for completely edentulous
223802675|NCT05775588|PROCEDURE|Lung volume reduction surgery with endobronchial valve implantation|the patient would undergo Lung volume reduction surgery with endobronchial valve implantation
223802676|NCT03351855|BIOLOGICAL|HPV-CTLs|2 to 4 infusions, once a week, for 1x10\^5\~4x10\^6 CTLs/kg by IV each time
223802677|NCT01557387|OTHER|Endoscopic techniques|All patients will undergo non-invasive endoscopic techniques considered standard of care in surveillance for dysplasia
223802678|NCT03695302|BEHAVIORAL|questionnaire|KAP questionnaire for fifth year undergraduate dental students.
223802679|NCT01291914|DRUG|FX005|Single Ascending Dose (SAD) Phase Cohorts: 1, 10 or 45 mg intra-articular injection; Proof of Concept Phase: Maximum, well-tolerated dose intra-articular injection (determined during SAD Phase)
223802680|NCT01291914|DRUG|Placebo 1 (Carrier)|Single intra-articular injection
223802681|NCT01291914|DRUG|Placebo 2 (Diluent)|Single intra-articular injection
223802682|NCT00822081|DRUG|brimonidine tartrate 0.2%/timolol maleate 0.5% fixed combination|1 drop BID in each eye
223802683|NCT00822081|DRUG|dorzolamide hcl 2%/ timolol maleate 0.5% fixed combination|1 drop BID in each eye
223802684|NCT00822081|DRUG|brimonidine tartrate 0.2%/timolol maleate 0.5% fixed combination as adjunctive to current prostaglandin therapy.|1 drop BID in each eye
223802685|NCT00822081|DRUG|dorzolamide hcl 2%/timolol maleate 0.5% fixed combinatin as adjunctive to current prostaglandin therapy.|1 drop BID in each eye
223802686|NCT01624948|DRUG|Everolimus|Everolimus will be administered orally at a starting dose of 0.75 mg PO b.i.d. (1.5 mg/day). Everolimus whole blood trough levels will be monitored at pre-specified time points to achieve a range of 3-8 ng/mL. Group 1 patients will continue on prednisone and tacrolimus with a target whole blood trough level of 3-6 ng/mL.
223802687|NCT01624948|DRUG|Mycophenolic acid dose reduction|Group 2 patients will undergo a 50% reduction of the mycophenolic acid (MPA) dose, and continue with tacrolimus (target trough level of 6-10 ng/mL), and prednisone.
223802688|NCT03748290|DRUG|Pregabalin|Pregabalin 75 mg for 12 weeks
223802689|NCT03748290|DRUG|Placebo Oral Tablet|Placebo Oral Tablet
223802690|NCT00372008|DRUG|Testosterone|
223802691|NCT04237805|DRUG|SAF-189s|20mg，40mg，80mg，120mg，160mg，210mg，once daily
223802692|NCT01629914|BEHAVIORAL|Mindfulness Meditation|8-week, group-based mindfulness meditation intervention
223802693|NCT05592795|OTHER|Whether ERCP or EST is carried out|This project systematically studies the physiological characteristics of biliary microecology in normal people, and explores the impact of ERCP and EST duodenal papillary incision on biliary microecology.
223802694|NCT04069598|DIAGNOSTIC_TEST|Statin intolerance test|Statin intolerance test
223802695|NCT03918863|OTHER|Neuromuscular electrical stimulation|Exercise protocol associated with neuromuscular electrical stimulation on vastus medialis and gluteus medius. Parameters: rectangular pulse shape, biphasic, symmetrical, pulse duration of 200μs, interbust interval of 10ms and frequency of 2.500Hz modulated in 50 bursts.
223802696|NCT03918863|OTHER|Exercise|Same protocol of exercises of the other group, without association of electrical stimulation.
223802697|NCT03980444|DEVICE|Basket of wire|(using a basket of wires3F) the helical type was passed through the four wires of the working channel of the orthoscope and routed to the proximal part of the rock, and the stone was routed to the bowl, then the stone was ducted The gasket was kept, and the probe of the pneumatic crusher also passed through the working channel and proceeded to break it down. Conditions were observed during the stomach as control group. Urethroscopic crushing was performed by a urologist in both groups under similar technical conditions. Findings during and after the completion of crushing include the success, stone retropulsion or parts larger than 3 mm, which requires secondary measures (SWL - ureter stenting, resection ureteroscopy), the duration of stone breakdown and traumatic ureteric complications in both groups it is registered
223802698|NCT03980444|PROCEDURE|control group, no basket|"In each group, ureteroscopy was performed using a standard F9.5 ureteroscope. After reaching the rock in group A (control), the probe of the pneumatic crusher was passed through the working channel of the ureteroscope and began crushing the rock.~During the crushing process, the minimum flow of water, flattening and the single-shot impact was used to minimize the stone's retropulsion."
223802699|NCT02745821|DEVICE|Pressure Wire Certus, St. Jude Medical, USA|FFR. CFR and IMR will be measured using the Pressure Wire Certus, St. Jude Medical, USA in target and non-target vessels. Changes in FFR, CFR and IMR post PCI of target vessels will also be recorded.
223802700|NCT03387579|DRUG|Smoflipid 20% Lipid Emulsion for Injection|Intravenous lipid containing soy, MCT, olive, and fish oils at goal doses of 3 g/kg/day
223802701|NCT03387579|DRUG|Intralipid, 20% Intravenous Emulsion|Intravenous lipid emulsion of 20% soy oil at goal doses of 1 g/kg/day
223802702|NCT03387579|DRUG|Intralipid, 20% Intravenous Emulsion|Intravenous lipid emulsion of 20% soy oil at goal doses of 2-3 g/kg/day
223802703|NCT01546961|DRUG|Chloroquine|"Chloroquine phosphate GPO® (Government Pharmaceutical Organization, Thailand) 250 mg (equivalent to chloroquine base 150 mg).~Dosing will be at 0, 24, 48 hrs with 10 mg/kg on day 0 and day 1, and 5 mg/kg on day 2."
223802704|NCT04769726|DIETARY_SUPPLEMENT|almonds|almond intervention (20 g) before three major meals (60g per day) for 3 days in subacute phase, before OGTT in the acute phase ad for 3 months in chronic phase
223802705|NCT04295954|OTHER|Yoga Intervention|"It is an intervention based on Hatha yoga designed specifically to improve dysmenorrhea. This intervention consists of physical postures, also called asanas; meditation and breathing. It begins with a progression of various asanas until reaching the three central postures: cat, cobra and fish. The compensation asanas of these central postures are then performed, and it is closed with a relaxation. The program and Yoga Intervention have been triangulated by experts and piloted afterwards."
223802706|NCT03605433|DRUG|Rivaroxaban|Rivaroxaban 2.5 mg or Rivaroxaban 20 mg or no oral anticoagulation
223802707|NCT00314925|DRUG|Seneca Valley Virus (biological agent)|Dose escalation (starting at 1 × 10\^7 vp/kg), IV (in the vein) over 1 hour in a single administration
223802708|NCT04550962|DRUG|Dupilumab SAR231893|"Pharmaceutical form:solution Route of administration: subcutaneous~Dose regimen:"
223802709|NCT06019195|OTHER|Time restricted eating|not more than 10 hrs. eating window daily goal for 6 months
223802710|NCT03039595|OTHER|Ploidy and tumour:stromal ratio measurements|Ploidy and tumour:stromal ratio measurements will be made on specimens of early rectal cancer removed by transanal endoscopic microsurgery (TEM)
223802711|NCT04921631|BEHAVIORAL|Early Integration of Specialty Palliative Care with Critical Care|The PC team will visit the patient within 24 hours of randomization and the consultation will address the following domains of PC: illness understanding and goals of care conversations with patients/surrogates; symptom assessment and management; spiritual needs; patient and family coping and support; and care coordination and transitions. The initial family meeting will be scheduled to occur within two days of randomization. Follow-up visits will be conducted by the PC MD/APP every weekday. During this time, the ICU and PC team will be in daily communication. The PC team will continue to follow the patient in the hospital once discharged from ICU. Prior to discharge, the PC team will document patient goals and preferences for future treatment, coordinate appropriate PC services in the home and/or outpatient clinic settings and contact the patient's primary physician to provide an update on the patient's hospital stay.
223802712|NCT01682980|OTHER|Strength training|The strength training will be delivered 2-3 times per week for 12 weeks, 5-8 repetitions maximum in 3 series. The patients must warm up 5 minutes on an ergometer cycle. The following muscle groups will be trained: Quadriceps and hamstrings, hip muscles (abductors and extensors), calf muscles. A home exercise program will be delivered including one leg exercises and balance exercises. Progression will follow a 2+ principle. For instance, when the study participant is able to perform 2 more repetitions, more loads are required.
223802713|NCT01682980|OTHER|Aerobic exercise|The aerobic exercise program include ergometer cycling for at least 45 minutes 2-3 times a week on 75-80% of max heart rate will be required.
223802714|NCT05851859|OTHER|Cardiac coherence|Use of Cardiac coherence (complementary respiratory training) during 6 month
224264157|NCT00928057|DEVICE|8mm x 31G pen needle|For 3 weeks, subjects used this pen needle with their own pen device for all daily insulin injections they usually administered themselves with a pen device. Subjects followed their usual insulin regimen and there was no upper limit on total daily insulin dosage or number of injections. Subjects were directed to use pinch-up when injecting in the abdomen or thigh with the 8mm PN, and no pinch-up at other injection sites.
224264158|NCT00928057|DEVICE|5mm x 31G pen needle|For 3 weeks, subjects used this pen needle with their own pen device for all daily insulin injections they usually administered themselves with a pen device. Subjects followed their usual insulin regimen and there was no upper limit on total daily insulin dosage or number of injections. Subjects were advised to inject straight in when using the 5mm PN, with no pinch up.
223802715|NCT04852653|PROCEDURE|Supplementary blood samples collection during the normal follow up of the patients|Supplementary blood samples collection during the normal follow up of the patients
223802716|NCT01821742|OTHER|Ultrasound cardiac output measurement|
223802717|NCT05143827|OTHER|Pasta manufactured with traditional wheat varieties (Senatore Cappelli, Korasan)|A single meal composed of a portion of pasta (with standardized dressing) manufactured with different wheat varieties
223802718|NCT05143827|OTHER|Pasta manufactured with current wheat varieties (Claudio)|A single meal composed of a portion of pasta (with standardized dressing) manufactured with different wheat varieties
223802719|NCT05410938|DRUG|Chemotherapy|Triweekly chemotherapy with bevacizumab versus intraperitoneal chemotherapy without bevacizumab
223802720|NCT00027001|BEHAVIORAL|Aerobic and Resistance Exercises|
223802721|NCT00027001|BEHAVIORAL|Qigong|
224264159|NCT03543735|BEHAVIORAL|Wisepill+SMS|This will include: 1) an in-person Wisepill orientation session to introduce the pillbox and generate relapse prevention messages that can be later delivered during non-adherent windows; 2) use of the Wisepill device during the intensive treatment program and after discharge; and 3) three forms of tailored SMS messages paired with Wisepill device use: a) supportive messages with medication compliance, b) reminder messages for early non-adherence (e.g., 1 hour late) and c) relapse-prevention messages after longer periods of non-adherence (e.g., several hours).
224264160|NCT03543735|OTHER|Wisepill-only|This will include: 1) an in-person Wisepill orientation session to introduce the pillbox; 2) use of the Wisepill during the intensive treatment program and after discharge.
224264161|NCT03461341|OTHER|High intensity postoperative oncologic surveillance|High intensity surveillance protocol using routine cross-sectional imaging (computed tomography or positron emission tomography with computed tomography).
224264162|NCT01897064|BEHAVIORAL|Aerobic Exercise|36 sessions of aerobic exercise (12 weeks of 3 times/week, 60-minute exercise sessions) in small groups (3-5 individuals), in addition to standard psychiatric care.
224264163|NCT01897064|OTHER|Standard Psychiatric Treatment|Standard psychiatric treatment.
224264164|NCT06000579|OTHER|EFT|Each student will be asked to voluntarily give their phone number and last menstrual cycle date, and the day will be determined for the first session. Then, the first EFT session will be made by the researchers by calling 14 days before the menstruation date. In the 2nd and 3rd sessions, a total of 3 sessions of EFT will be applied face-to-face by the researchers 14 days before menstruation. After each student completes three menstrual cycles, the researchers will meet with the student and PMSS will be applied as a post-test.
224264165|NCT05497557|DRUG|Omeprazole|Omeprazole will be administered as an oral capsule.
224264166|NCT05497557|DRUG|Sotorasib|Sotorasib will be administered as an oral tablet.
224264167|NCT00845130|BIOLOGICAL|ascorbic acid (Vitamin C)|ascorbic acid IV 1 g/kg
224264168|NCT04292691|DRUG|40ml of Ropivacaine 0.5% Injectable Solution|already outlined in the arm/group description
224264169|NCT04292691|DRUG|40ml of Ringer's Lactate|already outlined in the arm/group description
224264170|NCT05274724|DIAGNOSTIC_TEST|No teleconsultation during the ambulance journey|Standard will be met according to the current institutional protocol, which does not include teleconsultation. Therefore, the call will be interrupted after guidance from the telemedicine on duty
224264171|NCT05274724|DIAGNOSTIC_TEST|Teleconsultation during the ambulance journey|"teleconsultation will receive a video call using the free WhatsApp application, made by one of the emergency workers of the Telemedicine Center, using an institutional smartphone. The teleconsultation can be done directly to the patient and/or with the companion who made the call. The telemedicine on-duty officer will then assess the condition during the time the ambulance travels. The ambulance team will contact the Telemedicine Center and inform the on-call person when the ambulance geolocation application informs 2 minutes of estimated time of arrival at the place of care. At this point, the on-call doctor will interrupt the teleconsultation and pass the information on to the ambulance team. The video call will be turned off upon arrival of the ambulance team."
224264172|NCT04425096|OTHER|Skin to skin contact|Skin to skin contact
224264173|NCT03513224|OTHER|eDosette|The eDosette is an internet-enabled, medication administration monitoring unit that has been previously tested for feasibility in older adults. The eDosette was designed to be compatible with different types of weekly medication blister packs and dosettes, and monitors medication-taking behaviour in a patient's home. The eDosette securely transmits this information to a secure server where the information is converted to individual medication administration records. Patients can also use the eDosette to notify their primary care team of potential medication side effects.
224264174|NCT03151824|OTHER|quality of life|Quality of life which was measured by the Korean version of the 36-item short-form health survey (SF-36)
224264175|NCT05762458|DRUG|Ammoxetine|Ammoxetine hydrochloride enteric-coated tablets
224264176|NCT05762458|DRUG|Placebo|placebo to Ammoxetine.
224264177|NCT06316336|DRUG|Alfuzosin Hydrochloride 10 mg|Alfuzosin Hydrochloride 10 mg (test durg)
224264178|NCT06316336|DRUG|Xatral® XL 10 mg|Xatral® XL 10 mg (reference drug)
223802722|NCT03062722|PROCEDURE|keyhole approach|The surgical procedure was a direct microsurgical approach with a 1.5 cm incision in the thenar sulcus, under local anesthesia (3cc, 2% lidocaine) administered with an insulin needle. The keyhole approach applied to this anatomical region is based on a 1.5 cm skin incision from where the 0.5 cm dissection is completed in the subcutaneous plane in the side borders and 1cm in the distal and proximal borders. Thus, the subcutaneous phase of the dissection is completed with separation of the carpal ligament and resection of its borders. Once the transverse fibers are open, the perineural micro adhesions of the median nerve are resected and 3mm of the free borders of the carpal fibers found on the nerve are removed to avoid fibrosis. The wound is checked for hemostasis and closed in apposition with Vicryl 3-0 and a single subdermal 3-0 Nylon stitch.
223802723|NCT05100888|DEVICE|repetitive Transcranial Magnetic Stimulation (rTMS)|Theta-burst stimulation
223802724|NCT05979753|OTHER|EFFECTS OF HIGH INTENSITY INTERVAL TRAINING IN SPRINTERS|EFFECTS OF HIGH INTENSITY INTERVAL TRAINING ON SPEED AND EXPLOSIVE STRENGTH IN SPRINTER
223802725|NCT02363556|PROCEDURE|Misoprostol administered vaginally|
223802726|NCT02363556|PROCEDURE|Misoprostol administered buccally|
223802727|NCT02363556|PROCEDURE|Misoprostol administered vaginally with Dilapan|
223802728|NCT02363556|PROCEDURE|Misoprostol administered buccally with Dilapan|
223802729|NCT01067170|DEVICE|Pneumatic Compression Stockings|Thigh-high pneumatic compression stockings
223802730|NCT03351972|DRUG|Klean Prep|Participants randomised to use polyethylene glycol will follow either routine guidance of taking the bowel prep the night before their capsule endoscopy or receive guidance that they should split their dose between the night before and the morning of the procedure
223802731|NCT03351972|OTHER|Clear liquids only|Participants randomised to clear liquids only will receive guidance to only drink clear liquids before their procedure
223802732|NCT03912844|PROCEDURE|SIRT followed by liver resection or liver transplantation|The ESSURE registry is a prospective observational study. Patients are only asked to be enrolled when they are treated with SIR-Spheres microspheres followed by liver resection/liver transplantation or when SIRT has been performed with the intention to downsize/ downstage the tumor, to induce hypertrophy of the contralateral lobe, making the patient eligible for a future liver resection/transplantation. In no way will participation in the registry influence the way in which the patient is treated according to the treating clinician, or will it influence the quality of the treatment. If a patient is included in the registry, a documented decision of a multidisciplinary tumour board for the treatment algorithm including SIRT must be available. The follow-up periods depend on the treating clinician and local practice and guidelines. Typically, the follow ups are done every three months. So data of a single patient will be included over two years after the treatment.
223802733|NCT02104622|DEVICE|ReWalk Rehabilitation 2.0|
223802734|NCT02979938|OTHER|Semen analysis and semen PCR for Zika virus|Every two weeks subjects provide a semen sample which is analysed and then frozen for RT-PCR and viral load. Semen sample testing for the presence of ZIKV (Institute of Tropical Medicine, Belgium) will be performed using both a ZIKV-specific, in-house duplex real-time RT-PCR, targeting a 102bp and 121bp sequence of the NS5 gene and the RealStar® Zika Virus RT-PCR Kit (Altona). Quantitative viral load RNA measurements will be expressed utilizing threshold cycle values because a standardized viral load reference method is not available. To test for infectivity of ZIKV in semen, ZIKV isolation will be attempted in semen samples with a high viral ZIKV load (i.e. positive ZIKV PCR result and Ct-values below 30) by inoculation in Vero cells.
223802735|NCT01754467|BEHAVIORAL|NEAT!|Participants will wear the accelerometer and use the NEAT! application during waking hours for 1 month. The NEAT! app will prompt participants to stand up when they have been sitting for a prolonged period.
223802736|NCT02154633|BEHAVIORAL|Family Gene Toolkit|Psychosocial educational presentations over the Internet (Webinars) Two Webinars lasting 1 hour each One follow-up phone call lasting 20 minutes Webinars and phone calls are delivered to one mutation carrier and one non-tested relative Genetic counselors and nurses with master's degree and experienced in oncology deliver the content of the intervention
223802737|NCT02154633|BEHAVIORAL|Delayed Family Gene Toolkit|Psychosocial educational presentations over the Internet (Webinars) Two Webinars lasting 1 hour each One follow-up phone call lasting 20 minutes Webinars and phone calls are delivered to one mutation carrier and one non-tested relative Genetic counselors and nurses with master's degree and experienced in oncology deliver the content of the intervention
223802738|NCT00335218|DRUG|Climodien / Lafamme (BAY86-5027)|1 tablet daily (2 mg EV + 2 mg DNG)
223802739|NCT00335218|DRUG|Placebo|1 tablet daily
223802740|NCT00049374|BIOLOGICAL|oblimersen sodium|
223802741|NCT00049374|DRUG|dexamethasone|
223802742|NCT00049374|DRUG|thalidomide|
223802743|NCT03078348|OTHER|Fecal Immunochemical Test (FIT) Kit|Free FIT Kits distributed at study entry.
223802744|NCT03078348|BEHAVIORAL|Culturally targeted Photo Novella Booklet|Culturally targeted Photo Novella Booklet + culturally targeted reminders. Print materials developed by the Centers for Disease Control and Prevention (CDC)) to provide information about CRC, importance of screening and available screening tests. Timed reminder letters and/or emails intended as a cue to action and as educational boost to facilitate participant screening decision making and screening uptake.
223802745|NCT03078348|BEHAVIORAL|Screen for Life Brochure|Screen for Life Brochure + standard reminders. Print materials developed by the Centers for Disease Control and Prevention (CDC)) to provide information about CRC, importance of screening and available screening tests. Timed reminder letters and/or emails intended as a cue to action and as educational boost to facilitate participant screening decision making and screening uptake.
223802746|NCT01970462|DRUG|Sitagliptin|Sitagliptin prior to hospital discharge and 6 weeks following discharge.
223802747|NCT01970462|DRUG|Placebo|Patients are reandomized to Sitagliptin or placebo for 6 weeks post-operatively
223802748|NCT05439902|DRUG|Tamsulosin|One 0.4mg Tamsulosin capsule taken per day for 30 days
223802749|NCT05439902|DRUG|Placebo|one placebo capsule per day for 30 days. with identical appearance (color and size) to the experimental drug, composed of microcrystalline cellulose
223802750|NCT04538326|BEHAVIORAL|Exercise|Participants performed stepping movements that were either cued by the investigator or interacted with a video game. There were three video game exercises that all involved stepping in either a repeated or a random pattern that was either self-paced or game paced.
223802751|NCT03964597|DIAGNOSTIC_TEST|Measurement of lens opacification|Measurement of OSI and ALD at inclusion and during post-IVT follow-up visits to M3, M6, and M12, +/- M18, +/- M24 and +/- M30.
223802752|NCT04746573|DEVICE|Natrox Topical Oxygen Therapy|Device delivering humidified oxygen directly to the wound bed
223802753|NCT00754338|DRUG|Alcon Opti-Free® RepleniSH® with Supraclens®|Marketed Multipurpose Disinfecting Care System + Marketed contact lens protein remover
223802754|NCT00754338|DRUG|Alcon Opti-Free® RepleniSH®|Marketed Multipurpose Disinfecting Care System
223802755|NCT00754338|DRUG|B&L ReNu MultiPlus™|Marketed Multipurpose Disinfecting Care Systems
223802756|NCT05724979|OTHER|ZP-binding|The ZP is selective with regard to binding and can bind to normally functioning sperm, especially those with a normal acrosomal region
223802757|NCT03756792|BEHAVIORAL|Normal Education Material|Patients will receive standard educational material about Mohs micrographic surgery.
223802758|NCT03756792|BEHAVIORAL|Vignette|Patients will receive standard educational material about Mohs micrographic surgery and read a vignette detailing the typical experience of a Mohs patient.
223802759|NCT00932776|DEVICE|TBA care device|Tracheal suction maneuvers are performed according to the indications provided by the TBA care device or to clinical parameters whichever occurs first.
223802760|NCT00932776|DEVICE|Control|In this group suction maneuvers are performed according to clinical indications or on a fixed schedule whichever comes first.
223802761|NCT03339323|OTHER|Exercise|TKA patients do the exercise intervention
223802762|NCT02361320|PROCEDURE|Computed Tomography (CT)|Participants to receive 2 CT scans. One scan performed before the start of chemotherapy, and the other at first restaging visit with oncologist.
223802763|NCT02361320|BEHAVIORAL|Questionnaire|Participant to complete the MD Anderson Symptom Inventory for Gastrointestinal cancer (MDASI-GI) questionnaire at baseline visit, and follow up visit. Questionnaires should take about 10 minutes to complete.
223802764|NCT04830826|PROCEDURE|Surgeries|Surgeries
223802765|NCT02200913|OTHER|core stabilization exercise|core stabilization exercise, 2 times/week, 10 weeks
223802766|NCT02200913|OTHER|general trunk strengthening exercise|general trunk strengthening exercise, 2 times/week, 10 weeks
223802767|NCT04385368|DRUG|Durvalumab + SoC chemotherapy|Experimental Treatment
223802768|NCT04385368|OTHER|Placebo + SoC chemotherapy|Placebo Comparator
223802769|NCT02753049|BEHAVIORAL|Peer led mHelath behavioral intervention|A trained peer adherence coach will schedule five, weekly-60 minute, 'ACCESS' sessions, delivered to participants via remote videoconferencing, using smartphones. Cognitive behavioral strategies will be employed to target beliefs about antiretroviral treatment (ART), knowledge of ART, and adherence self-efficacy.
223802770|NCT01631084|OTHER|JADE|"Patients are booked for reviews led by the doctor-nurse-HCA team every 2-4 months, preferably in a setting different from the busy clinics in order to facilitate group education and promote peer support.~Between each follow-up visit, the nurse or HCA will contact the patient by phone or email to remind them of the appointments (e.g. medical FU visit or laboratory tests), adhere to medications and healthy lifestyles, perform self glucose monitoring and provide psychosocial support, as appropriate."
223802771|NCT01631084|OTHER|DIAMOND|Patients randomized to the DIAMOND group will receive usual care after the initial baseline comprehensive assessment (CA), with repeat CA at 12 and 24 months.
223802772|NCT04620291|BIOLOGICAL|UB-421 SC|The UB-421 SC (dB4C7C22-6 mAb) will be supplied at a concentration of 125 mg/mL after reconstitution. Subjects will receive weekly UB-421 SC injections during the 4-week Treatment Period.
223802773|NCT00412100|DRUG|Oxycodone naloxone prolonged release tablets (OXN)|
223802774|NCT00306982|BIOLOGICAL|Fluarix|
223802775|NCT01179204|PROCEDURE|Preoperative heat stimulation|Preoperative short and long tonic heat stimulation
223802776|NCT03116048|OTHER|Chronic pain evaluation|Chronic pain assessment with study questionnaire
223802777|NCT00134550|DRUG|Atorvastatin (10 mg or 80 mg)|
223802778|NCT03443882|DIETARY_SUPPLEMENT|Astaxanthin|an oral dose form
223802779|NCT06579456|OTHER|Surgical Training Intervention|Validation of a Formaldehyde-Free embalmed cadavers for recreate with more precision the experience of learning surgical endoscopy
223802780|NCT06579456|OTHER|Positive Control|training in models that emulate the rigidity, structure, dimensions, and haptic feedback of the anatomical structures to be treated.
223802781|NCT06579456|OTHER|Negative Control|Training proceeded in the rigid described skills acquisition platform, adding suture training using a perforable MMA-type woven fabric
223802782|NCT06580977|BEHAVIORAL|cardiovascular training|Cardiovascular training will be performed in supervised sessions and in small groups of 2-5 persons at the study site. The training is performed on a cycle ergometer at 60% of peak power output (Wmax) for 30 min (i.e., 5 min warm-up, 20 min at 60% Wmax, 5 min cool-down) three times a week for twelve weeks. The exercise program will be increased by 5 min (max. 55 min) and 5% of intensity (in Watt) every two weeks. If participants report a too low (i.e., Borg scale ≤ 11) or too high (i.e., Borg scale ≥ 16) subjective rate of perceived exertion (RPE; Borg scale 6-20) intensity will be increased or decreased until the target levels are met (i.e., Borg scale 12-15). During training, heart rate, intensity (in Watt) and RPE will be monitored. Participants missing training sessions will be offered an additional week to perform up to three training sessions.
223802783|NCT06580977|BEHAVIORAL|stretching|The stretching training will be performed in supervised sessions and in small groups of 2-5 persons at the study site. Stretching training consists of lying, seated, and standing flexibility exercises (according to the recommendations of the American Parkinson´s Disease Foundation and the Parkinson Society Canada) for 30 min (i.e., 5 min warm-up, 20 min main part, 5 min cool-down) three times a week for twelve weeks. The exercise program will be increased by 5 min (i.e., adding additional repetitions and exercises; max. 55 min) every two weeks. Intensity of stretching exercises will be assessed by subjective rate of perceived muscle tension on a visual analog scale (VAS) from 0 to 10 and will be moderate defined as 5 to 7 on the VAS. During training VAS, heart rate, and RPE will be monitored. Participants missing training sessions will be offered an additional week to perform up to three training sessions.
223802784|NCT00758238|OTHER|myBP facilitated e-health self-management|MyOSCAR, a web-based patient-controlled personal health record, provides a mechanism for patients to enter/track health information and can encourage longitudinal patient engagement, better interaction between patients and health care providers, and patient self management. The intervention will provide access via MyOSCAR to a cardiovascular risk profile and BP tracker with sharing to providers enabled. Patients can receive general information about hypertension management; tailored messages related to their modifiable risk factors; and secure messaging with multiple providers. Providers can draw on a 'menu' of links/resources to share with patients. A lifestyle changes planner/checklist and an enhanced medication diary are additional components.
223802785|NCT02450266|DEVICE|Systematic transrectal ultrasound-guided prostate biopsy|12-18 systematic biopsy cores
223802786|NCT02450266|DEVICE|MRI/ultrasound fusion-guided prostate biopsy|2 targeted biopsy cores from each prostate lesion
223802787|NCT03985891|DRUG|Anti-PD-1 Monoclonal Antibody JS001|Anti-PD-1 monoclonal antibody combined with chemotherapy in patients with locally advanced colon cancer (perioperative treatment)
223802788|NCT03985891|DRUG|Chemotherapy|Folfox
223802789|NCT02270151|DEVICE|MyDiagnostick|Diagnostick strategy with MyDiagnostick
223802790|NCT01208948|DRUG|1,2 dithiolane 3 valeric acid|600 mg alpha lipoic acid per day
223802791|NCT04334265|DRUG|Anluohuaxian|6g each time, twice a day
223802792|NCT04905615|OTHER|Data-driven and teacher led school based strategies.|The intervention is individualised to each school, depending on the teacher led strategies which are data-informed
223802793|NCT01659190|OTHER|Oiled-limestone liniment|
223802794|NCT00954148|PROCEDURE|PET/CT|5 visits with PET/CT as only testing
223802795|NCT00954148|PROCEDURE|NCCN recommendations for solid tumor post treatment|12-14 visits with exams, blood tests, CTs and PET/CT
223802796|NCT03532802|DRUG|Metoprolol Succinate|"1. week: uptitration with 50 mg capsules per day, until maximum dosage of 150 mg´s/day.~2. week: steady state treatment with the maximum tolerated dose of the 1.week."
223802797|NCT03532802|DRUG|Placebo oral capsule|"1. week: uptitration with 1 capsule per day, until maximum tolerated dosage of 3 capsules/day.~2. week: steady state treatment with the maximum tolerated dose of the 1. week"
223802798|NCT02228070|DEVICE|strabismus video goggles|
223802799|NCT03324893|DIAGNOSTIC_TEST|[F-18]-FCH PET/MRI|Subjects will undergo the \[F-18\]-FCH PET/MRI within three months prior to scheduled parathyroidectomy.
223802800|NCT02054806|BIOLOGICAL|Pembrolizumab|IV infusion
223802801|NCT01474096|OTHER|implementation strategy of Breastfeeding|implementation strategy (including training session, information distribution, an opinion leader) of Breastfeeding
223802802|NCT04721925|BEHAVIORAL|Social media messaging|A motivational interviewing-based intervention delivered via private health coaching on social media for 8 weeks.
223802803|NCT01443819|OTHER|Lumbar Transforaminal Epidural Corticosteroid Injection|"Injection: Anesthetic/corticosteroid (per randomization); repeat 1-3 times if clinically indicated.~The following drugs will be used for this procedure: 80mg Depo-Medrol and 1% lidocaine. These drugs used for the epidural injections are local anesthetic numbing medicines and cortisone/steroid anti-inflammatory medicines."
223802804|NCT01443819|OTHER|Physical Therapy|"Physical therapy carried out per protocol; 2-3 times per week for a total of 12 treatment sessions (excluding initial evaluation, including exit evaluation, minimum attendance 8/12) to be completed by 6 weeks from initiation of care (within study).~Please note: There will be another PT evaluation at the end of 6 weeks."
223802805|NCT01443819|OTHER|Observation|If subject declines then inquire about enrolment in the observational cohort. Participants in this group (Cohort) will chose their treatment (per-protocol physical therapy, injections, or both) after consulting with their physicians.
223802806|NCT01463722|OTHER|Amniotic fluid Lamellar Body Counting|fluid samples were obtained by amniocentesis during normal delivery or before rupturing the membrane in cesarean. The samples were sent to the lab as soon as possible and after centrifuging with 500 round per minute for 3 minutes, they were placed in the cell counter machine (STKR coulter).
223802807|NCT05025969|OTHER|Glioma data collection|Glioma data collection
223802808|NCT05025969|OTHER|Brain metastasis data collection|Brain metastasis data collection
223802809|NCT05373355|DRUG|TLL018 tablets|Oral tablets administered at different doses BID daily for 12 weeks.
223802810|NCT04437238|OTHER|KeepWell tool|KeepWell is standalone eHealth application aimed at supporting the self-management of older adults with multimorbidity, and it has the following features: (i) lifestyle advice for any combination of the top 10 chronic conditions affecting older adults); (ii) an avatar health coach that walks users through a health prioritization and goal setting exercise; (iii) a health risk questionnaire (HRQ) covering health (chronic diseases), lifestyle (physical activity, diet, smoking, alcohol, caffeine, bladder health), and social and emotional well-being (social frailty, isolation, loneliness) dimensions; (iv) an evidence-based, customized Action plan; (v) an interactive lifestyle tracker; (vi) journaling; (vii) and a health resources library. A health coach avatar leads users through a health priority and goal setting exercise that allows them to create a customized action plan based on guideline recommendations for lifestyle changes.
223802811|NCT04437238|OTHER|Control - Usual care|Participants allocated to the control condition will receive care as usual.
223802812|NCT04550988|OTHER|feasibility study|The aim of this study is to evaluate the possibility of establishing a patient-based ultrasound monitoring of the knee (representing a target joint accessible with any hand) with a handheld device.
223802813|NCT00034255|DRUG|INGAP Peptide|
223802814|NCT01926730|OTHER|Restriction diet|Selected food items will be limited in the participants diet
223802815|NCT01016080|DRUG|glutathione|250 mg capsules, twice daily, orally
223802816|NCT01016080|DRUG|placebo|250 mg capsules, twice daily, orally
223802817|NCT02781402|PROCEDURE|4 weeks of Aerobic Training|The duration of aerobic training was 40 minutes for each session and 3 days per week with the intensity of 75-80% of their maximum heart rate. The participants were needed to walk or jog on treadmill during the first 10 minutes at the intensity of 50-60% of maximal heart rate (HR max). The aerobic training was followed by 4 x 4 minutes intervals at 75-80% HR max. The participants were given 3 minutes active breaks in between the intervals in which they can either walk or jog at 50-60% of maximal heart rate.
223802818|NCT05288010|COMBINATION_PRODUCT|Cannabis|The provision of whole flower cannabis via an inhalation device in addition to standard of care chronic pain treatment.
223802819|NCT04949659|PROCEDURE|Laparoscopic appendectomy|Laparoscopic appendectomy performed with defined, randomized to level of pressure for pneumoperitoneum
223802820|NCT05120115|OTHER|Weight belt|Wearing belt around waist with various weights attached.
223802821|NCT02456766|DEVICE|FibroTouch|
223802822|NCT02456766|PROCEDURE|Liver Biopsy|
223802823|NCT03627884|DRUG|Sodium Bicarbonate Catheter Lock Solution|Using Sodium Bicarbonate Catheter Lock Solution
223802824|NCT03627884|DRUG|Normal Saline Catheter Lock Solution|Using Sodium Bicarbonate Catheter Lock Solution
223802825|NCT04679181|OTHER|Telemedecine|telemedical consultation
223802826|NCT00480701|DRUG|[123I]-IBVM|Subjects will be asked to undergo an injection of 123-I IBVM followed by up to three approximately thirty minute SPECT scans during the next 24 hours.
223802827|NCT01113502|DRUG|Eltrombopag|Oral formulation taken daily
223802828|NCT04782557|DIAGNOSTIC_TEST|EUS-guided portal vein and hepatic vein aspiration|EUS-guided portal vein and hepatic vein aspiration
223802829|NCT04620967|DRUG|Insulin aspart|Insulin aspart (Iasp) in insulin pump
223802830|NCT04620967|DRUG|Fast-acting insulin aspart|Fast-acting insulin aspart (Fiasp) in insulin pump
223802831|NCT06313801|DRUG|Docetaxel|Docetaxel 50 mg/m2 intravenously on day 1
223802832|NCT06313801|DRUG|Oxaliplatin|Oxaliplatin 85 mg/m2 on Day 1
223802833|NCT06313801|DRUG|Calcium folinate|200 mg/m2 2-hour intravenous infusion on day 1
223802834|NCT06313801|DRUG|Fluorouracil|2600 mg/m2 x intravenous infusion 24-hours (infusion of the samee of the total dose of fluorouracil for 48 hours) on day 1.
223802835|NCT06313801|PROCEDURE|Diagnostic laparoscopy|Access to the abdominal cavity by Hassen (3 trocars). Carboxyperitoneum - 12 mm of water column - stable pressure maintenance throughout the operation. Revision. Photo recording of 4 quadrants of the abdominal cavity from the paraumbilical port. The evaluation of the PCI index. The evaluation of other distant dissemination. Standard peritoneal lavage of 300 ml Sol. NaCl 0.9 % (37 ºС), with the exposure of 3-5 minutes (with Trendelenburg and Fowler position alternately) and the lavage aspiration, the transfer of the lavage for the cytological examination. Biopsy of perioneal lessions if needed.The operation is completed as standard with the extraction of laparoports and suturing of laparoport wounds.
223802836|NCT06313801|COMBINATION_PRODUCT|dPIPAC ( The description of the standard diagnostic laparoscopy procedure and the session of PIPAC (dPIPAC)).|Diagnostic laparoscopy described earlier and PIPAC session. The drugs for PIPAC - Docetaxel 50 mg/ m2 diluted with saline sodium chloride to a total volume of 200 ml. The rate of administration is 30 ml per minute. The maximum pressure in the injector system is 250 PSI. After the spray stage, the exposure is 30 minutes while maintaining the declared intraperitoneal pressure. After the exposure stage, only gas is removed from the abdominal cavity. The operation is completed as standard with the extraction of laparoports and suturing of laparoport wounds.
223802837|NCT03466424|RADIATION|preoperative short-course radiotherapy|Patients will be enrolled into Group 1 to 3 according to the time order of entering the study to receive dose from 6Gy×5F to 8Gy×5F using the traditional 3+3 dose escalation design.
223802838|NCT00325364|DRUG|Human Insulin Inhalation Powder|patient specific dose, inhaled, before meals, 24 months
223802839|NCT00325364|DRUG|Injectable insulin|patient specific dose, injectable, before meals, 24 months
223802840|NCT04557072|DRUG|Selective alpha-1-antagonist|Patients treated with selective alpha-blockade (prazosin, terazosin, doxazosin)
223802841|NCT04557072|DRUG|Non-selective alpha-1-antagonist|Patients treated with non-selective alpha-blockade (phenoxybenzamine)
223802842|NCT04843787|DRUG|SLV213|SLV213 oral capsule (200mg) BID
223802843|NCT04843787|DRUG|SLV213|SLV213 oral capsule (400mg) BID
223802844|NCT04843787|DRUG|SLV213|SLV213 oral capsule (800mg) QD
223802845|NCT04843787|DRUG|Placebo|Placebo oral capsule (200mg) BID
223802846|NCT04843787|DRUG|Placebo|Placebo oral capsule (400mg) BID
223802847|NCT04843787|DRUG|Placebo|Placebo oral capsule (800mg) QD
223802848|NCT01144026|BIOLOGICAL|TUTI-16 (0.2mg)|Two subcutaneous injections of 0.2 mg at Day 0, and Week 5.
223802849|NCT01144026|BIOLOGICAL|TUTI-16 (1.0 mg)|Two subcutaneous injections of 1.0 mg at Day 0, and Week 5.
223802850|NCT06370026|BIOLOGICAL|KSD-101|Patients will receive approximately 5x10\^6 DC vaccine via subcutaneous injections bi-weekly,total 3-5 times.
223802851|NCT04010240|OTHER|Retrospective cohort|Tumor material tested positive will be analyzed by next-generation sequencing to identify NTRK1, NTRK2 or NTRK3 gene fusions.
223802852|NCT02238002|PROCEDURE|cataract surgery|The patients of both groups underwent cataract surgery
223802853|NCT03913598|OTHER|patient questionnaire|self-administered patient questionnaire regarding the different aspects of internet and social media use in dermatology patients
223802854|NCT01429636|BEHAVIORAL|Modified Relaxation (MR)|The MR technique is modified from the AR technique that will require participants to attend only 1 session, lasting 60 minutes. After the training session, participants will be given a hand-out on MR. They will continue to practice MR at home once a day for 15-20 minutes during their leisure times, at least 5 days a week for the whole 12 weeks of the follow-up period.
223802855|NCT01429636|BEHAVIORAL|Applied Relaxation (AR)|Participants will receive 12 sessions AR training. After that they will asked to practice at home once a day for 15-20 minutes during their leisure times, at least 5 days a week for the whole 12 weeks of the follow-up period.
223802856|NCT00107250|DRUG|capecitabine|1000 mg/m2 orally twice daily (total of 2000 mg/m2 per day) for the first 14 days of a 21 day cycle for a maximum of 6-8 cycles.
223802857|NCT00107250|DRUG|carboplatin|AUC 6; IV; 30 minutes; Every 21 days for a maximum of 6-8 cycles
223802858|NCT00107250|DRUG|cediranib maleate|Given daily; orally with approximately 240 ml of water whilst in an upright position
223802859|NCT00107250|DRUG|paclitaxel|200mg/m2; IV; 3 hours; Every 21 days for a maximum of 6-8 cycles
223802860|NCT00929162|DRUG|ZD4054 Zibotentan|10 mg oral tablets once daily
223802861|NCT00929162|DRUG|Paclitaxel|175mg/m2 IV on day 1 every 3 weeks
223802862|NCT00929162|DRUG|Carboplatin|Carboplatin AUC of 5.0 IV on day 1 every 3 weeks
223802863|NCT00929162|DRUG|Placebo|matching placebo for ZD4054 10 mg
223802864|NCT04506957|DEVICE|Pulse CO-Oximetry Hemoglobin measurement transcutaneous|this is an observational Investigation, in which transcutaneous continuous hemoglobin detection using Pulse-CO-Oximetry is compared with co-oximetrically measured Hemoglobin using a blood gas analyzer device
223802865|NCT05079022|DRUG|Furmonertinib|Furmonertinib at 80mg dose will be administered orally once daily.
223802866|NCT02891720|DEVICE|Proteus Sensor System|The Proteus Sensor System (PSS) intervention includes 12 weeks of daily FTC/TDF with a weekly text messages transmitted to participants with estimated HIV risk reduction based upon the DBS algorithm.
223802867|NCT01535820|DRUG|Treatment A: ORTHO EVRA patch (NGMN + EE) with an adhesive overlay|NGMN: type= exact number, unit= mg, number= 6, form= transdermal patch, route= transdermal use. EE: type= exact number, unit= mg, number= 0.75, form= transdermal patch, route= transdermal use. A single patch is applied to the buttock with an adhesive overlay applied over the transdermal contraceptive system for 7 days.
223802868|NCT01535820|DRUG|Treatment B: ORTHO EVRA patch (NGMN + EE) without an overlay|NGMN: type= exact number, unit= mg, number= 6, form= transdermal patch, route= transdermal use. EE: type= exact number, unit= mg, number= 0.75, form= transdermal patch, route= transdermal use. A single patch is applied to the buttock without an overlay for 7 days.
223802869|NCT00762944|DEVICE|Biomet TMJ Replacement System|Total replacement of the temporomandibular joint with a Biomet TMJ Replacement System
223802870|NCT05508230|OTHER|Hyaluronic Nasal Spray|Health care product - nasal application
223802871|NCT04202939|OTHER|nutrition|type and amount of food eaten or type of oral nutritional supplements as well as enteral or parenteral nutrition
223802872|NCT02495480|DEVICE|A novel disposable sheath|a new sheath will be placed on the endoscope in sheathed group
223802873|NCT05353998|OTHER|CDS with Sleep Navigation|The Sleep Navigation program will involve 1-3 meetings between the Sleep Navigator (SN) and the participating family. Participants will also complete baseline and post-intervention assessments, and about 10 to 15 caregivers will be randomly invited to participate in an interview on the acceptability and feasibility of the program. The SN will provide: SDB and sleep health psychoeducation using Patient-Family Education handouts and videos that are currently part of usual care practices; Care coordination for scheduling of specialty care referral(s) for clinical SDB evaluation; Problem-solving for family-identified barriers to accessing specialty care; and Motivational interviewing to enhance family engagement, communication, and collaboration with the family's medical team.
223802874|NCT05353998|OTHER|CDS-only|Participants will complete baseline and post-intervention assessments. Participants will be able to follow-up with their primary care clinician as needed.
223802875|NCT01822587|DRUG|Propranolol, 40 mg|
223802876|NCT01822587|DRUG|Propranolol, 80 mg|
223802877|NCT01822587|DRUG|Placebo|
224264179|NCT03081897|DRUG|SPRANC Block group|General anaesthesia with Propofol (2mg/kgKG) and Remifentanil (0,1-0,4 µg/kg/min); additional regional anaesthesia (cervical plexus block) with an long acting local anesthetic according to clinical estimation of the treating anesthetist (about 15 ml Ropivacaine 0,75% around the carotid bifurcation, 5 ml Ropivacaine in the region of Erb´s Point of the superficial cervical plexus and 10 ml Ropivacaine at the area of skin incision on the tumor side); unilateral neck dissection.
224264180|NCT03081897|DRUG|SPRANC Control group|General anaesthesia with Propofol (2mg/kgKG) and Remifentanil (0,1-0,4 µg/kg/min); additional regional Patient Control Group (no Intervention planned), general anaesthesia with Propofol (2mg/kgKG) and Remifentanil (0,1-0,4 µg/kg/min); unilateral neck dissection.
224264181|NCT03681977|DEVICE|Zimmer MP Persona|The medial pivot Persona® knee implant with a Medial Congruent™ Bearing
224264182|NCT03681977|DEVICE|Zimmer Persona Knee-PS|Persona the personalized knee system
224264183|NCT03013036|DEVICE|Ultrasonography|
224264184|NCT03013036|DRUG|Sevoflurane|
224264185|NCT03013036|DRUG|intravenous midazolam|
224264186|NCT03013036|DRUG|Propofol|
224264187|NCT03013036|DRUG|fentanyl and rocuronium|
224264188|NCT03531450|BEHAVIORAL|Cognitive Behavioral Therapy|Treatment sessions will use active, structured techniques to alter distorted thoughts, with a focus on acquiring and practicing cognitive and emotional modulatory skills. In particular, cognitive restructuring is used to help patients recognize the relationships between thoughts, feelings, and behaviors. Patients learn to identify, evaluate, and challenge negative thoughts. Patients will also learn behavioral strategies to decrease avoidance behavior and increase toleration of physical sensations.
223802878|NCT01274182|BIOLOGICAL|GP2013|1000 mg iv infusion on two separate occasions, two weeks apart (i.e. on Day 1 and on Day 15)
223802879|NCT01274182|BIOLOGICAL|MabThera|1000 mg iv infusion on two separate occasions, two weeks apart (i.e. on Day 1 and on Day 15)
223802880|NCT01274182|BIOLOGICAL|Rituxan|1000 mg iv infusion on two separate occasions, two weeks apart (i.e. on Day 1 and on Day 15)
223802881|NCT02355002|DEVICE|Transcranial Magnetic Stimulation|Transcranial magnetic stimulation uses a rapidly changing magnetic field to induce current in brain tissue non-invasively. It is common procedure in both clinical and research settings, and it has well established guidelines for safe an ethical use which maximize safety for all subjects.
223802882|NCT00708916|DRUG|CC-10004|20 mg twice daily by mouth for 12 weeks, followed by a 4 week washout period and final assessment
223802883|NCT02444390|PROCEDURE|Biopsy|biopsy of a metastasis
223802884|NCT04020848|OTHER|Review of past medical history, clinical exam, and electroencephalogram, polysomnography and urine samples of melatonin and pupillometry.|Review of past medical history; review of paroxysmal events; identification of presence of seizures \& epilepsy \& epilepsy classification; characterization of the non-paroxysmal features; degree of paroxysmal, non-paroxysmal disability indices; Vineland II adaptive behavior scales scoring; behavioral evaluation; presence of a genetic mutation; pharmacological treatments already used; AHC paroxysmal events assessement during the time of study; patient calendar for the follow up of events, for the follow up of epileptic seizures; whether, or not, there was occurrence of a serious or potentially life-threatening event (status epilepticus, apnea requiring intervention, or death) during time of study; growth and somatic complaints; further information concerning family history \& comorbidities; past instrumental \& biochemical investigations (ECG, cardiac ultrasound results if done as part of patient's follow-up); electroencephalogram; polysomnography; urine samples of melatonin ; pupillometry
223802885|NCT04020848|OTHER|The patients' parents have to complete the VINELAND II adaptive behavior scales scoring, The Sleep Disturbance Scale for Children (SDSC) and Horne & Ostberg Circadian Typology Questionnaire|Sleep Disturbance Scale for Children ; Horne \& Ostberg Circadian Typology Questionnaire
223802886|NCT04934579|DRUG|Rituximab|375mg/m2 intravenous infusion d1, every 3 weeks for 1 cycle, 6 cycles will be prescribed for induction therapy. 375mg/m2 intravenous infusion d1, every 8 weeks for 1 cycle, 4 cycles will be prescribed for maintenance therapy.
223802887|NCT04934579|DRUG|Lenalidomide|25mg orally d1-10 every 3 weeks for 1 cycle, 6 cycles will be prescribed for induction therapy. 25mg orally d1-14,d29-42 every 8 weeks for 1 cycle, 4 cycles will be prescribed for maintenance therapy.
223802888|NCT04934579|DRUG|Methotrexate|3.5g/m2 intravenous infusion for 4 hours in d1, every 21 days for 1 cycle, 6 cycles will be prescribed.
223802889|NCT04899050|DRUG|Cannabidiol (Epidiolex)|Use of Epidiolex to control absence seizures.
223802890|NCT00047775|DRUG|BiDil|
223802891|NCT02934152|DRUG|H pylori eradication|H pylori eradication
223802892|NCT02934152|OTHER|H pylori eradication timing|Early or late eradication
223802893|NCT00679328|DEVICE|Surgical implantation of OP-1 device or autograft bone graft material|Surgical implantation of OP-1 device or autograft bone graft material
223802894|NCT01269996|DRUG|Janumet, Lantus|"In this multicentre, randomized, open-label prospective study. Recruited patients will be randomized to one of the two treatment groups. Treatment efficacy and safety in terms of HbA1c control and hypoglycemic events will be evaluated.~Treatment groups:~Group 1 - Metformin followed by Sulfonylurea (Gliclazide) and supplementary intermediate-acting insulin (Protaphane) injection.~Group 2 - Janumet followed by Lantus insulin injection."
223802895|NCT01269996|DRUG|metformin, gliclazide, protaphane|"In this multicentre, randomized, open-label prospective study. Recruited patients will be randomized to one of the two treatment groups. Treatment efficacy and safety in terms of HbA1c control and hypoglycemic events will be evaluated.~Treatment groups:~Group 1 - Metformin followed by Sulfonylurea (Gliclazide) and supplementary intermediate-acting insulin (Protaphane) injection.~Group 2 - Janumet followed by Lantus insulin injection."
223802896|NCT01758835|OTHER|Splint 3 weeks|A removable orthosis/splint. Dynacast/Ortho-Glass AS (BSN Medical). Splint is used for 3 weeks and no additional support is used after splint removal.
223802897|NCT01758835|OTHER|Cast 3 weeks|A standard short boot cast from proximal tibia to MTP I-V joint line. Cast is made from 3M Scotchcast. Cast is removed after 3 weeks and no additional support is used after cast removal.
223802898|NCT01758835|OTHER|Cast 6 weeks|standard short boot cast from proximal tibia to MTP I-V joint line. Cast is made from 3M Scotchcast. Cast is changed after 3 weeks and removed after 6 weeks. No additional support is used after cast removal.
223802899|NCT01133158|DRUG|Rituximab, Bendamustine, Mitoxantrone, Dexamethasone|Bendamustine: 90 mg/m2/day, days 1 and 2 of each cycle, iv Mitoxantrone: 6 mg/m2/day, day 1 of each cycle, iv Dexamethasone 20 mg / day, days 1 through 5 of each cycle, od Rituximab: 375 mg / m 2 / day, day 1 of each cycle, iv
223802900|NCT00115141|DRUG|Resiquimod|
223802901|NCT04890535|DRUG|TBAJ-587|oral suspension
223802902|NCT04890535|DRUG|Placebo|matching placebo oral suspension for TBAJ-587
223802903|NCT00658567|DRUG|Pimavanserin tartrate (ACP-103)|10 mg, tablet, once daily by mouth, for six weeks
223802904|NCT00658567|DRUG|Pimavanserin tartrate (ACP-103)|20 mg, tablet, once daily by mouth, for six weeks
223802905|NCT00658567|DRUG|Pimavanserin tartrate (ACP-103)|Placebo, tablet, once daily by mouth, for six weeks
223802906|NCT00831064|PROCEDURE|colonoscopy bowel prep|PEG, bisacodyl, NaP, PSMC and Mg-citrate
223802907|NCT04031482|OTHER|No intervention, only standard care|"The aim of this registry is to expand on previous findings in the field of diagnostic and therapeutic pathways for patients with Crohn's disease, ulcerative colitis and indeterminate colitis undergoing routine administration of a targeted therapy (biologics or another targeted therapy such as Janus kinase therapy) and various different treatment approaches. A data pool is to be generated for this purpose, in order to~* analyse disease progression~* systematize findings about treatment processes~* identify potential influencing factors~* review any new diagnostic procedures~* identify potential test subjects for further study~* evaluate the safety of various treatment concepts"
223802908|NCT02403882|BEHAVIORAL|Order|In the order intervention, the investigators place the targeted product at the front of the line for the treatment. For the control, the investigators place the targeted product at the end of the line.
223802909|NCT02403882|BEHAVIORAL|Packaging|In the packaging intervention, the investigator present the targeted product in the original package. In the control, the investigator repackage the targeted product in clear, plastic bags.
223802910|NCT02403882|BEHAVIORAL|Pricing|In the pricing intervention, the investigators price all or targeted products in the treatment. In the control, the investigators do not price the products.
223802911|NCT02403882|BEHAVIORAL|Relative Proportions|The investigators adjust the amount of the targeted good available relative to the other products. In the treatment, the targeted good is a larger proportion of the total goods offered in the section, while in the control the shares of the targeted and other goods are equal.
223802912|NCT02403882|BEHAVIORAL|Default Option|In an early site, the investigators offer a targeted product without an alternative. The subjects can accept or reject the offer. The subjects are told that an alternative product is available later. At the site where the alternative product is available, investigators offer subjects the opportunity to exchanged the targeted product for the alternative product.
223802913|NCT02915848|DEVICE|PC+S group|PC+S group: participants in the study will also receive a specific stimulation device (Activa PC+S, Medtronic) that is capable of recording the local field potentials (LFP). Approximately 10 participants are expected to take part in this study at UHN.
223802914|NCT03945838|OTHER|Complete Decongestion Therapy|"It is given in two phases. First phase includes intensive therapy which aims to reduce the volume of the extremity. Second phase aims to preserve these reductions of volume.~All patients were prescribed lymphedema specific exercises and were advised to walk (for 30 minutes everyday) daywhile taking complete decongestive therapy. They were specifically informed that exercise does not aggravate the severity of their lymphedema.~Short stretch bandages were applied to the patients with self manual lymphatic drainage. Intensive phase was given 5 days a week, and short stretch bandages applied for 23 hours a day with 1 hour interval. To increase the local pressure on the areas required, foams were added. Patients were screened with arm circumferential measurements once a week. After gaining a plateau in the volumes, patients were prescribed compression garments."
223802915|NCT00420992|DRUG|ALO-01 (Morphine Sulfate Plus Naltrexone Hydrochloride Extended Release)|capsules, up to 80 mg bid
223802916|NCT00420992|DRUG|Placebo|capsules, bid
223802917|NCT03234153|DRUG|Durvalumab (Imfinzi)|Durvalumab 1500 mg i.v. every 4 weeks in combination with Tremelimumab 75 mg i.v. every 4 weeks for a total of 4 cycles before surgery.
223802918|NCT03234153|DRUG|Tremelimumab|Tremelimumab 75 mg i.v. in combination with Durvalumab 1500 mg i.v. every 4 weeks every 4 weeks for a total of 4 cycles before surgery.
223802919|NCT03249610|BEHAVIORAL|Lifestyle intervention|Intervention Trial with Multi-Component Lifestyle Intervention for reduction of body weight and cardio-metabolic risk factors
223802920|NCT05769738|DRUG|Furosemide|40mg (4ml) of furosemide to be nebulized 3 times daily for 3 days
223802921|NCT05769738|DRUG|Normal saline|4ml of normal saline to be nebulized 3 times daily for 3 days
223802922|NCT00382824|DIETARY_SUPPLEMENT|Coenzyme Q10|active drug
223802923|NCT00382824|OTHER|Placebo|Placebo
223802924|NCT02850432|PROCEDURE|Invasive treatment|Endovascular therapy or surgery with medical therapy according to Trans-Atlantic Inter-Society Consensus II scoring system (TASC II)) as described in the main study protocol
223802925|NCT02850432|OTHER|Conservative treatment|rehabilitation with medical therapy
223802926|NCT01146301|DRUG|Clopidogrel|All patients will receive a loading dose of 600mg of study medication. The first group will receive 300 mg of clopidogrel and 300 mg placebo, the second group will receive 600mg of clopidogrel at least 24h before carotid stenting
223802927|NCT03732118|DEVICE|Eye-tracker Mobile EBT|Use of the eye-tracker for the diagnosis of minimal HE by studying the characteristics of saccades and anti-saccades during a day hospitalization.
223802928|NCT04038528|BEHAVIORAL|telemonitoring of T2DM|"Baseline record of:~* Weight~* Height~* BMI~* Abdominal circumference~* Winsor Index~* ECG~* Retinography~* Blood level of (fasting values): total cholesterol, HDL cholesterol, LDL cholesterol, blood sugar, triglycerides, glycated hemoglobin These parameters will be checked again at 3, 6 and 18 months in the two groups.~Telemedicine group (intervention):~* Blood sugar (two measurements per week).~* Body weight (weekly)~* Blood pressure (weekly) Use of devices that allow the automatic upload of data via wi-fi or web is allowed~Control group (control):~Routine appointments scheduled by their GPs and specialists in outpatient clinics to record blood sugar levels as per standard GP or specialist physician's indications.~Blood sugar level is measured in mg/dl in a drop of capillary blood with the use of standard glucose meter"
223802929|NCT03882879|BEHAVIORAL|Karate Classes|Eligible subjects will engage in twice-weekly karate classes for 6 months, specifically designed for individuals with early to middle stage PD, focused on incorporating upper and lower limb movements in multiple directions, increasing awareness throughout the body, shifting body weight and rotation, relaxation of the muscles, improving reaction time, using complex repetitive actions to improve coordination, footwork training and centered weight shifts to help with fall prevention, and striking shields for self-defense and stress relief
223802930|NCT03882879|BEHAVIORAL|Pre-Intervention Study Visit|At the pre-intervention study visit, the study logistics will be reviewed, informed consent process will occur, the subject will complete a battery of pre-intervention assessments focused on overall mobility, gait, balance, mood, cognition, and quality of life, and the subjects will be prompted to share their expectations of and goals for the karate classes.
223802931|NCT03882879|BEHAVIORAL|Bimonthly Online Survey|All participants in both arms will receive a personalized email every two months directing them to indicate how frequently they have attended karate classes, how frequently they have engaged in exercise, how frequently they have fallen, whether their PD medication regimen has changed, and they will complete brief surveys about mood, camaraderie, and overall quality of life.
223802932|NCT03882879|BEHAVIORAL|6-month Study Visit|All participants in both arms will complete questionnaires and assessments of their PD symptoms, cognition, mood, camaraderie, and quality of life. Subjects will meet with a member of the study team to complete a series of physical and cognitive assessments. At this visit, subjects will review the initial expectations they shared at the pre-intervention visit and indicate if they thought their goals were achieved for the class.
223802933|NCT03882879|BEHAVIORAL|12-month Study Visit|At the 12-month study visit, the assessments from the baseline and 6-month study visit will be readministered, along with an assessment of the subject's global impression of change. Subjects will be prompted to share their thoughts on how the intervention impacted their overall wellbeing, balance, and mindfulness; whether the intervention achieved their expectations; and they will be asked to provide feedback for improvements.
223802934|NCT01641393|DRUG|EUR-1008 25,000 Units|EUR-1008 25,000 Units is a PEP with pancreas powder as the active ingredient.18 Pancreas powder contains various enzymes having proteolytic, lipolytic, and amylolytic activity. Each capsule contains approximately 25,000 Ph. Eur. lipase units. EUR-1008 25,000 consists of orally administered capsules containing enteric-coated beads.
223802935|NCT01641393|DRUG|Kreon 25,000 Units|Kreon 25,000 is a PEP consisting of porcine-derived pancreatic enzymes.18 Each capsule contains approximately 25,000 Ph. Eur. lipase units. Kreon 25,000 consists of orally administered capsules containing enteric-coated spheres.
223802936|NCT04426643|BIOLOGICAL|Autologous adipose-derived mesenchymal stem cells|Autologous adipose-derived mesenchymal stem cells mixed with collagen solution injected in submucosal space
223802937|NCT04426643|OTHER|Standard treatment according to the Clinical protocols|Standard treatment according to the Clinical protocols
223802938|NCT06068621|DRUG|Azacytidine;Cytarabine;Aclacinomycin;Chidamide;Venetoclax;Granulocyte colony-stimulating factor|"1. Azacytidine (75 mg/m2/day, days 1 to 7).~2. Cytarabine (75-100 mg/m2 bid, days 1 to 5).~3. Aclacinomycin(20 mg/day, days 1,3,5).~4. Chidamide (30 mg/day , days 1,4,8,11).~5. Venetoclax (400 mg/day, days 1 to 14,Combined with posaconazole reduced to 100 mg/day,Combined with voriconazole reduced to 200 mg/day ).~6. Granulocyte colony-stimulating factor (300 μg/day, day 0 until agranulocytosis recovery)"
223802939|NCT06068621|DRUG|"3+7"|"IA regimen:~1. Idarubicin (8-10 mg/m2) for 3 days .~2. Cytarabine (75-100mg/m2, every 12 hrs) for 7 days.~DA regimen:~1. Daunorubicin(60 mg/m2) for 3 days.~2. Cytarabine (75-100mg/m2, every 12 hrs) for 7 days."
223802940|NCT05493592|BIOLOGICAL|Standardized physical activity protocol associated with the consumption of Cajanus cajan (EXACAJAN)|"Supervised re-training by an Adapted Physical Activity (APA) professional combined 100 g of pigeon peas 3 times a week~Physical activity protocol is standardized. It's the same than in the control arm.~The preparation of pigeon peas and their consumption will be standardized in terms of species cultivated, geographical origin and culinary preparation.~A follow-up of the food intakes standardized plus follow-up logbook, recording the weekly pigeon pea intake, will also be filled out by the participant. The addition of 100 grams of pigeon peas to the diet corresponds to an intake of about 980 mg of polyphenols, 360 mg of carotenoids and 570 mg of vitamin C (24). Thus, the patient's diet will be fortified with approximately 420 mg of polyphenols per day. This level of polyphenol supplementation is known to have beneficial effects on human health."
223802941|NCT03404570|DRUG|Dexmecamylamine HCl|Investigational drug
223802942|NCT03404570|OTHER|Placebo|Oral tablet containing no active drug.
223802943|NCT01175603|BEHAVIORAL|Mothers and Babies Course (Adapted for Baltimore Home Visiting Programs)|6 weekly 2-hour cognitive-behavioral intervention sessions held in group format
223802944|NCT02448251|DRUG|AC0010MA|Following Phase I, a protocol amendment will be submitted to the IND to specify the selected dose and dose justification to be used in Phase II.
223802945|NCT03227679|OTHER|Nicotine Metabolite Ratio|This intervention used information from a genetically-informed biomarker (Nicotine Metabolite Ratio, NMR) to assign one of 3 FDA-approved smoking cessation pharmacotherapies (varenicline, bupropion, or NRT) to participants.
223802946|NCT03227679|DRUG|Varenicline|FDA-approved smoking cessation pharmacotherapy
223802947|NCT03227679|DRUG|Bupropion|FDA-approved smoking cessation pharmacotherapy
223802948|NCT03227679|DRUG|Nicotine patch|FDA-approved smoking cessation pharmacotherapy
223802949|NCT04584164|DEVICE|sialendoscopy|The patients applying the hygiene rule and benifiting in addition a sialendoscopy treatment with a local injection of corticostéroïdes (at the end of the procedure) in the treatment for Xerostomia.
223802950|NCT03143725|DRUG|GLPG1972|Oral administration of GLPG1972 in four different treatment conditions (Treatments A throug D)
223802951|NCT03340402|RADIATION|Accelerated Partial Breast Irradiation|Proton radiation
223802952|NCT03340402|DEVICE|AlignRT|AlignRTTM uses infrared imaging to capture the 3D data of the patient's position to ensure accuracy of treatment delivery
223802953|NCT01463956|DRUG|Boceprevir|Boceprevir 200 mg capsules at 2400mg/day (800mg 3 times a day) from week 4 until week 48 or until liver transplant (can be performed from week 16)
223802954|NCT01463956|BIOLOGICAL|Peg-Interferon α-2b or Peg-Interferon α-2a|Peg-Interferon α-2b by subcutaneous injection, 1.5µg/kg/week, from day 0 until week 48 or until liver transplantation, or Peg-Interferon α-2a by subcutaneous injection, 180 µg, once weekly, from day 0 until week 48 or until liver transplantation
223802955|NCT01463956|DRUG|Ribavirin|Ribavirin: capsules 200 mg (weight-based daily dose: \<65kg, 800 mg; 65-80kg, 1000mg; 81-105kg: 1200mg; \>105kg: 1400mg), from day 0 until week 48 or until liver transplantation or, Ribavirin: Tablet Oral, weight-based dose, 1000 mg for subjects weighing below 75 kg or 1200 mg for subjects weighing equal or over75 kg, once daily, from day 0 until week 48 or until liver transplantation
223802956|NCT02835339|DRUG|Magnesium sulfate 4g loading dose, 1g/hr infusion|
223802957|NCT02835339|DRUG|Magnesium sulfate 6g loading dose, 2g/hr infusion|
223802958|NCT01498432|DRUG|Heliox21|For Heliox21 the percentage of O2 will match the percentage of O2 prior to extubation, and Helium will make up the remainder (e.g. Helium 65% + O2 35%), and the O2 concentration will be titrated as their clinical condition indicates (as O2 increases Helium will decrease and vice versa).
223802959|NCT01498432|DRUG|Air O2|For Air-O2 the percentage of O2 delivered will match the patient's percentage of O2 prior to extubation, and will be titrated as their clinical condition indicates.
223802960|NCT02401581|OTHER|Catheter|The effectiveness of this model of management is defined by absence of a need for re-catheterization in the post -operative period of 24 hours, indications for resondage being cases of acute urinary retention (AUR ) or macroscopic hematuria necessitating a washes with drainage . Patients are followed for a period of 3 months with a post-operative visit at 30 days and a last follow-up visit at 90 days during which the effectiveness is evaluated by conventional means of clinical indicators ( flowmetry , postvoid residue, volumetry of the prostate , IPSS scores , QoL , EVA, IIEF ... ).
223802961|NCT06629363|OTHER|biobank|"The following samples will be collected :~* Serum samples and plasma sample: inclusion visit and follow up visit~* Urines samples : inclusion visit and follow up visit~* blood DNA: inclusion visit~* Blood RNA: inclusion visit and follow up visit"
223802962|NCT00508443|RADIATION|Radiation Therapy|Three radiation treatments guided by the CT-on-Rails or Trilogy procedure over a period of 2 weeks. Participants prescribed to receive 9 Gy x 3 so that a peripheral dose of 27 Gy is given to the tumor.
223802963|NCT05968651|DRUG|Oxytocin nasal spray|Single acute administration of 24 international units (IU) oxytocin
223802964|NCT01077544|DRUG|Nilotinib|"Nilotinib capsules were delivered in bottles with dose strengths of 50mg, 150mg and 200mg.~Patients were administered nilotinib 230 mg/m2 (per BSA) bid, orally, rounded to the nearest 50 mg (max single dose 400 mg) for 28 days (1 cycle) for up to 12 cycles prior to protocol amendment 3 and up to 24 cycles post amendment 3. Capsules were to be swallowed whole with water. Apple sauce (puréed apple) may have been used as a vehicle for dosing where capsules were not able to be swallowed whole with water."
223802965|NCT06087510|DRUG|Esketamine|Different doses of esketamine in the esketamine-dexmedetomidine combination as a supplement to sufentanil for postoperative analgesia.
223802966|NCT03923959|DRUG|Tranexamic Acid Injectable Solution|100 cc normal saline mixed with 1g of tranexamic acid in solution
223802967|NCT03923959|OTHER|Placebo|100 cc normal saline
223802968|NCT04918147|DRUG|elotuzumab|Elotuzumab is a humanized recombinant monoclonal antibody (mAb) targeted against SLAMF7, a cell surface glycoprotein.
223802969|NCT04918147|DRUG|placebo for elotuzumab|The placebo for elotuzumab is 0.9% sterile normal saline for injection.
223802970|NCT04918147|DRUG|methylprednisolone|Premedication administered intravenously, 45 to 90 minutes prior to each elotuzumab/placebo infusion, per protocol. Dosage in milligrams (mg).
223802971|NCT04918147|DRUG|diphenhydramine|Premedication administered orally or intravenously, 45 to 90 minutes prior to each elotuzumab/placebo infusion, per protocol. Dosage in milligrams (mg).
223802972|NCT04918147|DRUG|acetaminophen|Premedication administered orally, 45 to 90 minutes prior to each elotuzumab/placebo infusion, per protocol. Dosage in milligrams (mg).
223802973|NCT04918147|DRUG|famotidine|Premedication administered orally or intravenously, 45 to 90 minutes prior to each elotuzumab/placebo infusion, per protocol. Dosage in milligrams (mg).
223802974|NCT04918147|DRUG|prednisone|Prescribed dosing with prednisone begins on the day of the first elotuzumab/placebo infusion, administered orally. The ten-week dosing taper proceeds, per protocol. Dosage in milligrams (mg).
223802975|NCT04409119|DEVICE|HIS/LBB pacing|3830 lead to HIS or LBB
223802976|NCT04409119|DEVICE|LV pacing|LV lead in a CS branch
223802977|NCT00664937|DRUG|montelukast sodium|single oral dose, before exercise challenge, of montelukast 10mg; 7 week duration.
223802978|NCT00664937|DRUG|Comparator: placebo (unspecified)|single oral dose, before exercise challenge, of Pbo; 7 week duration.
223802979|NCT06488521|BIOLOGICAL|Complarate|Complarate solution, a subcutaneous injection at a single dose of 162 mg.
223802980|NCT06488521|BIOLOGICAL|Actemra®|Actemra® solution, subcutaneous injection at a single dose of 162 mg.
223802981|NCT05806229|PROCEDURE|Mid transverse process to pleura block (MTP)|After marking the level of the incision by surgeon (commonly T11 -T12) The patient will be situated in modified lateral position with flank region over kidney elevated to wide the space between iliac crest and subcostal margin, the block area will be sterilized with povidine-iodine, and high -frequency linear ultrasound probe will be placed oblique parasagittally lateral to the spinous process of T11 or T 12 and scanning till appearance of transverse process, 100-mm short bevel echogenic needle (Vygon) will be inserted in plane from cranial to caudal direction. The desired end point of the needle tip will be the midpoint of the line between the posterior border of transverse process and the pleura.After negative aspiration to avoid intravascular injection levobupivacaine 0.5% and dexamethazone 4mg total volume 21ml will be injected
223802982|NCT05806229|PROCEDURE|Mid transverse process to pleura Sham block|After marking the level of the incision by surgeon (commonly T11 -T12) The patient will be situated in modified lateral position with flank region over kidney elevated to wide the space between iliac crest and subcostal margin, the block area will be sterilized with povidine-iodine, and high -frequency linear ultrasound probe will be placed oblique parasagittally lateral to the spinous process of T11 or T 12 and scanning till appearance of transverse process, 100-mm short bevel echogenic needle (Vygon) will be inserted in plane from cranial to caudal direction. The desired end point of the needle tip will be the midpoint of the line between the posterior border of transverse process and the pleura. with 2ml normal saline subcutaneously will be injected
223802983|NCT04273139|DRUG|IBRUTINIB|Ibrutinib Cycle 1-24 will be administered at a predetermined dose, once daily for 28 days
223802984|NCT04273139|DRUG|Venetoclax|Venetoclax Cycle 2-24 will be administered daily for 28 days. Predetermined dosage ramp up schedule during cycle 2.
223802985|NCT04496726|OTHER|Pacran and Sapnov P quillaja|Cranberry (450 mg) and quillaja (50 mg) capsules taken orally twice daily (morning and evening) for a total daily dose of 900 mg cranberry and 100 mg quillaja for 14 days. Nitrofurantoin 100 mg taken orally twice daily for five days as a rescue medication if symptoms do not subside.
223802986|NCT05391854|DIETARY_SUPPLEMENT|Pep2dia|700 mg Pep2Dia® 15 min prior to breakfast and 700 mg Pep2Dia® 15 min prior to dinner
223802987|NCT05391854|DIETARY_SUPPLEMENT|Placebo|700 mg placebo 15 min prior to breakfast and 700 mg placebo 15 min prior to dinner
223802988|NCT01525316|DIETARY_SUPPLEMENT|Bovine Lactoferrin|Infants will receive oral bovine lactoferrin (200 mg/Kg/day divided in three dosis) for 8 weeks. Lactoferrin will be dissolved in human milk or infant formula or in a 5% glucose solution. Each dose will be dissolved in a small volume so the maximum lactoferrin concentration will be 25mg/mL.
223802989|NCT01525316|DIETARY_SUPPLEMENT|Maltodextrin|Infants will receive oral maltodextrin (200mg/Kg/day in three divided dosis) for 8 weeks. Maltodextrin will be dissolved in human milk or infant formula or in a 5% glucose solution. Each dose will be dissolved in a small volume so the maximum maltodextrin concentration will be 25mg/mL.
223802990|NCT02954354|DRUG|Baloxavir Marboxil|2 to4 X 20-mg tablets taken orally
223802991|NCT02954354|DRUG|Placebo to Baloxavir Marboxil|2 to4 X 20-mg tablets taken orally
223802992|NCT02954354|DRUG|Oseltamivir|75 mg capsules taken orally
223802993|NCT02954354|DRUG|Placebo to Oseltamivir|Placebo capsules matching oseltamivir 75 mg capsules
223802994|NCT05208281|DRUG|GNR-055 1.0-2.0-3.0 mg/kg|Weekly IV infusion (lyophilized powder) 1.0-2.0-3.0 mg/kg
223802995|NCT05208281|DRUG|GNR-055 2.0 mg/kg|Weekly IV infusion (lyophilized powder) 2.0 mg/kg
223802996|NCT05208281|DRUG|GNR-055 3.0 mg/kg|Weekly IV infusion (lyophilized powder) 3.0 mg/kg
223802997|NCT05590247|BEHAVIORAL|Intermittent Fasting Diet|Patients will follow the 16: 8 traditional intermittent fasting model, where they may only consume calories during 1 continuous 8-hour period of the day. Water may be consumed during fasting.
223802998|NCT02760849|OTHER|Laboratory Biomarker Analysis|Correlative studies
223802999|NCT02760849|PROCEDURE|Oophorectomy|Undergo ISDO
223803000|NCT02760849|OTHER|Quality-of-Life Assessment|Ancillary studies
223803001|NCT02760849|PROCEDURE|Salpingectomy|Undergo ISDO
223803002|NCT02760849|PROCEDURE|Salpingo-Oophorectomy|Undergo RRSO
223803003|NCT04377555|DRUG|Ocrelizumab|Ocrelizumab will be administered intravenously (IV) at a dose of 600 mg every 24 weeks. The first dose of ocrelizumab will be administered as two 300 mg IV infusions given 14 days apart. For the subsequent dose, ocrelizumab will be administered as a single 600 mg IV infusion every 24 weeks.
223803004|NCT04219670|DIAGNOSTIC_TEST|Wearable sensors|Utilizing wireless wearable sensors, to capture quantitative biometric and movement-based data.
223803005|NCT04426448|BEHAVIORAL|Brief Relaxation, Education And Trauma HEaling|A three-week psychological intervention for PTSD which comprise psychoeducation and breathing retraining to manage anxiety symptoms
223803006|NCT04697576|BIOLOGICAL|Ipilimumab|immune checkpoint inhibitor
223803007|NCT04697576|BIOLOGICAL|Nivolumab|immune checkpoint inhibitor
223803008|NCT04697576|BIOLOGICAL|Pembrolizumab|immune checkpoint inhibitor
223803009|NCT04697576|BIOLOGICAL|Quadrivalent Inactivated Influenza Vaccine|Given IM and intratumorally. For this protocol the U.S. F.D.A recently approved the use of recently expired influenza vaccine (only until new seasonal vaccine is available anticipated Sept 1). Use of expired vaccine will not exceed 4 months past June 30th expiry date (October 30th).
223803010|NCT04697576|PROCEDURE|Resection|Undergo surgical resection
223803011|NCT04697576|BIOLOGICAL|Nivolumab + Relatlimab|immune checkpoint inhibitor
223803012|NCT06411288|DRUG|AOC 1001 (del-desiran)|Del-desiran will be administered by intravenous (IV) infusion.
223803013|NCT06411288|DRUG|Placebo|Placebo will be administered by intravenous (IV) infusion.
223803014|NCT03716609|DIETARY_SUPPLEMENT|Magnesium Citrate|Pure Magnesium citrate powder 2.07 gram from NOW FOODS (Bloomingdale, IL, USA)
223803015|NCT03716609|OTHER|Food grade citrate acid|Food grade citrate acid 0.1 gram from San Fu Chemical Co., Ltd (Taipei, Taiwan)
223803016|NCT03716609|OTHER|Splenda(Sucralose)|Splenda 1.0 gram from Splenda(Carmel, Indiana, USA)
223803017|NCT03556111|PROCEDURE|Sticky bone augmentation|"1. Autogenous sticky bone augmentation for the first group~2. Autogenous sticky bone preparation with xenograft usage~3. After 5-month of bone grafting; esthetic implant placement"
223803018|NCT05867654|DRUG|Amoxicillin-clavulanate 875mg/125mg q12hrs|Oral antibiotic used based on indication
223803019|NCT05867654|DRUG|oral clindamycin 300mg q6hrs|Oral antibiotic used based on indication
223803020|NCT05867654|DRUG|Levofloxacin 750mg QID|Oral antibiotic used based on indication
223803021|NCT03892993|OTHER|Decision Aid|Use decision aid
223803022|NCT03892993|OTHER|Questionnaire Administration|Ancillary studies
223803023|NCT05092321|BEHAVIORAL|Aquatic Occupational Therapy|Group of 4-8 children, paired with a swim buddy. Intervention techniques including discrete teaching, motor shaping, behavioral management, therapeutic relationship and individualized goals.
223803024|NCT03065387|DRUG|Everolimus|Given PO
223803025|NCT03065387|DRUG|Neratinib|Given PO
223803026|NCT03065387|DRUG|Palbociclib|Given PO
223803027|NCT03065387|DRUG|Trametinib|Given PO
223803028|NCT06393322|OTHER|Depression e-Learning A|"Participants in Depression e-Learning A will be provided e-learning about depression, consisting of following components:~1. One multimedia e-learning lesson on depression;~2. A series of 4 'micro-learning' emails (2 emails/week) with small segments of content to reinforce the material from the lesson.~1\. One multimedia e-learning lesson on depression; 2. A series of 4 'micro-learning' emails (2 emails/week) with small segments of content to reinforce the material from the lesson."
223803029|NCT06393322|OTHER|Depression e-Learning B|"Participants in Depression e-Learning B will be provided e-learning about depression, consisting of following components:~1. One multimedia e-learning lesson on depression;~2. A series of 4 'micro-learning' emails (2 emails/week) with small segments of content to reinforce the material from the lesson.~1\. One multimedia e-learning lesson on depression; 2. A series of 4 'micro-learning' emails (2 emails/week) with small segments of content to reinforce the material from the lesson."
223803030|NCT06393322|OTHER|Anxiety e-Learning A|"Participants in Anxiety e-Learning A will be provided e-learning about anxiety, consisting of following components:~1. One multimedia e-learning lesson on anxiety;~2. A series of 4 'micro-learning' emails (2 emails/week) with small segments of content to reinforce the material from the lesson."
223803031|NCT06393322|OTHER|Anxiety e-Learning B|"Participants in Anxiety e-Learning B will be provided e-learning about anxiety, consisting of following components:~1. One multimedia e-learning lesson on anxiety;~2. A series of 4 'micro-learning' emails (2 emails/week) with small segments of content to reinforce the material from the lesson."
223803032|NCT03721939|DEVICE|FLEX Scoring Catheter|Vessel preparation with the FLEX Scoring Catheter® with a 30° rotation between each passage is performed, followed by a DEB angioplasty.
223803033|NCT05338658|DRUG|Peptide Alarm Therapy (PAT)|PAT is given on Day 1 by IT injection after the 1st anti PD-1/PD-L1 infusion and again 36-48 hours later on Day 3.
223803034|NCT05280301|DEVICE|Sous Vide Device (SVD)|A basin will be filled to the marked line with water from jugs at room temperature, for each frozen extremity. The sous vide device (SVD) will be attached to the distal edge of the basin. The SVD will be turned on and set to maintain the bath at a constant 38 degrees celsius for 30 minutes duration. The thermometers will be powered on continuously and the researcher will record temperatures simultaneously from each thermometer and the SVD every 2 minutes. At the end of the 30 minute treatment, the extremity assessed by the researcher for warmth and pliability. If the extremity still feels cold or frozen, an additional 30 minutes in the water bath will commence, with subsequent reassessment. Rewarming will be considered complete when the affected tissue becomes red or purple, soft, and pliable.
223803035|NCT06496048|DRUG|Lurbinectedin|Lurbinectedin 3.2 mg/m2 administered by infusion on Day 1 of each cycle (q3wk)
223803036|NCT06496048|DRUG|Irinotecan|Irinotecan 75 mg/m² intravenously Days 1 \& 8 q3wk
223803037|NCT06496048|DRUG|Lurbinectedin|Lurbinectedin 2.0 mg/m2 administered by infusion on Day 1 of each cycle (q3wk)
223803038|NCT06496048|DRUG|Topotecan|Topotecan 1.2 mg/m² intravenously Days 1-5 q3wk
223803039|NCT03131908|DRUG|GSK2636771|"Phase I Starting Dose of GSK2636771: 300 mg by mouth given for 21 days.~Phase II Dose of GSK2636771: Maximum tolerated dose from Phase I."
223803040|NCT03131908|DRUG|Pembrolizumab|Phase I and II Dose of Pembrolizumab: 200 mg given by vein every 3 weeks.
223803041|NCT04798664|BEHAVIORAL|Removal of Financial Barriers|Free access to nicotine replacement therapies and/or reimbursement for smoking cessation prescription medications
223803042|NCT04798664|BEHAVIORAL|Financial Incentives|Financial incentive plan of up to $600 for biochemically-confirmed, sustained abstinence for 6 months.
223803043|NCT04798664|BEHAVIORAL|Mobile Health Application|Episodic future thinking tool to overcome temporal discounting of future
223803044|NCT06126783|DRUG|IBI311|The first dose was 10 mg/kg, followed by 7 maintenance doses of 20 mg/kg, Q3W
223803045|NCT04576091|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223803046|NCT04576091|PROCEDURE|Computed Tomography|Undergo CT and/or PET-CT scan
223803047|NCT04576091|DRUG|Elimusertib|Given PO
223803048|NCT04576091|BIOLOGICAL|Pembrolizumab|Given IV
223803049|NCT04576091|PROCEDURE|Positron Emission Tomography|Undergo PET-CT scan
223803050|NCT04576091|OTHER|Quality-of-Life Assessment|Ancillary studies
223803051|NCT04576091|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
223803052|NCT00959933|DRUG|Ribavirin 200 Capsules (Geneva Pharmaceutical, U.S.A.)|
223803053|NCT00959933|DRUG|Rebetol 200 Capsules (Schering Corporation, U.S.A.)|
223803054|NCT00135005|DRUG|AMN107, STI571|
223803055|NCT04658147|DRUG|Nivolumab|Nivolumab 480mg will be administered as a 30 minute IV infusion (-/+15min) at cycle 1 day 1 and at cycle 2 day 1 (28 days) then every month for up to 12 months. Intravenous administration of Nivolumab (480 mg) will occur on Cycle 1 and 2 of the study then every 28 days up to a year. Nivolumab will be administered on Day 1 of each cycle for 10 doses/ months (whichever occurs first) for adjuvant.
223803056|NCT04658147|DRUG|Relatlimab|Patients will receive 480 mg Relatlimab intravenously (-/+15min) on cycle 1 day 1 and at cycle 2 day 1 (every 28 days) for up to 1 year co-administered with Nivolumab.
223803057|NCT03602118|DRUG|Phenobarbital Sodium Injection|Phenobarbitone Inj, Phenobarbitone SOD, Phenobarbitone Sodium
223803058|NCT02328885|DRUG|DLI of the 20 fraction of the UCBT|Administration of 20 fraction of the UCBT
223803059|NCT03804710|DRUG|Developmental moisturizing cream 1|Participants will topically apply developmental moisturizing cream 1
223803060|NCT03804710|DRUG|Developmental moisturizing cream 2|Participants will topically apply developmental moisturizing cream 2
223803061|NCT03804710|OTHER|Standard cleanser soap|Participants will cleanse the entire face and both lower legs (between the knees and the ankles)with simple pure soap
223803062|NCT01834131|BEHAVIORAL|Comprehensive Intervention|The comprehensive intervention includes physician education, a community health worker home intervention and a mobile health intervention. Please see Arm Description for details.
224264189|NCT02791958|DRUG|Cardiovascular Fixed Dose Combination Pill AAR|A once daily oral dose of the Cardiovascular Fixed Dose Combination Pill AAR (acetylsalicylic acid 100 mg, atorvastatin 40 mg and ramipril 10 mg) for 4 weeks.
224264190|NCT02791958|DRUG|Atorvastatin 40 mg|A once daily oral dose of atorvastatin 40 mg (Lipitor®) for 4 weeks
224264191|NCT02791958|DRUG|Ramipril 10 mg|A once daily oral dose of ramipril 10 mg (Altace®) for 4 weeks
223803063|NCT04088019|DRUG|Fixed drug combination (FDC) of ATT and Oral steroid|"In the first two week, patients receive FDC of ATT only. Oral steroid start to be given in week three.~The ATT regiment is continued for up to 6 months or more, in accordance with WHO guidelines. In the first two months the antibiotic combination given consisted of isoniazid (INH), rifampicin, pyrazinamide, and ethambutol. The next four months or continuation phases, the ATT given is rifampicin and isoniazid.~The following dosage and administration of oral steroids will be given to patients, according to guidelines from the American Journal of Ophthalmologists (Douglas A. Jabs et al, 2000):~Initial dose: 1mg/kg/day, with maximum adult oral dose 60-80 mg/kg and maintenance dose less than or equal to 10 mg/day. The tapering schedule: Over 40 mg/day, decrease by 10 mg/day every 1-2 weeks, 40-20 mg/day, decrease by 5 mg/day every 1-2 weeks, 20-10 mg/day, decrease by 2.5 mg/day every 1-2 weeks, 10-0 mg/day, decrease by 1 to 2.5 mg/day every 1-4 weeks."
223803064|NCT01064232|DRUG|Risperidone|Risperidone Tablets 1 mg
223803065|NCT04351867|DRUG|docetaxel plus oxaliplatin and capecitabine|docetaxel 50mg/㎡ ivgtt. d1+oxaliplatin 100mg/㎡ ivgtt. d1+capecitabine 1000mg/㎡ bid p.o. d1-d14 q21d
223803066|NCT04351867|DRUG|oxaliplatin plus capecitabine|oxaliplatin 130mg/㎡ ivgtt. d1+capecitabine 1000mg/㎡ bid p.o. d1-d14 q21d
223803067|NCT04688242|OTHER|Anal dilatation per anus|Digital anal dilatation through anastomosis, with concomitant administration of probiotics per anus
223803068|NCT04688242|DRUG|administration of probiotics (Clostridium butyricum TO-A; Bacillus mesentericus TO-A; Streptococcus faecalisT-110) per anus|Digital anal dilatation through anastomosis, with concomitant administration of probiotics per anus
223803069|NCT03167307|DRUG|Omega 3 fatty acid|Omega-3 fatty acids in addition to standard treatment for depression in children and adolescents according to the German S3 Guidelines
223803070|NCT03167307|DRUG|Placebo oil|medium chain triglycerides in addition to standard treatment for depression in children and adolescents according to the German S3 Guidelines
223803071|NCT02454101|PROCEDURE|cord milking|milking of the cord 5 times toward the neonate
223803072|NCT02454101|PROCEDURE|delayed cord clamping|delay clamping of the cord for 120 seconds
223803073|NCT05307848|OTHER|No intervention|No intervention
223803074|NCT04602312|OTHER|Meditation (1 x 20-minute guided audio training)|Participants will complete a single session of 20-minutes online guided audio-delivered training session of one of the four conditions.
223803075|NCT05031546|DRUG|Difelikefalin|IV Difelikefalin 0.5 mcg/kg administered after each dialysis session (3 times/week)
223803076|NCT03467867|DRUG|Venetoclax|Venetoclax will be administered as described in the reporting arm.
223803077|NCT03467867|DRUG|Rituximab|Rituximab (IV) will be administered as described in the reporting arm.
223803078|NCT03467867|DRUG|Rituximab/Hyaluronidase Human|Rituximab/Hyaluronidase Human (SC) ill be administered as described in the reporting arm.
223803079|NCT06134830|DRUG|RAI|Radioactive iodine
223803080|NCT02930733|DRUG|Bupivacaine|30 ml %0,25 bupivacaine bilaterally
223803081|NCT02930733|DRUG|Saline|2 ml saline subcutaneously bilaterally
223803082|NCT01395381|DRUG|Placebo|placebo given once
223803083|NCT01395381|DRUG|Albendazole|single dose albendazole given at the time of enrollment
223803084|NCT03037450|PROCEDURE|Miniinvasive corneal neurotization|Neurotization of a neurotrophic cornea
223803085|NCT05969171|DRUG|Surufatinib, gemcitabine, nab-paclitaxel|Nab-paclitaxel: 125mg/m2 intravenously, d1, 8; every 3 weeks for a treatment cycle, did not exceed a maximum of 6 treatment cycles. Gemcitabine: 1000mg/m2, intravenous infusion greater than 30min, d1, 8, every 3 weeks for a treatment cycle. Surufatinib: 250mg, qd, po, every 3 weeks for a treatment cycle. Surufatinib and gemcitabine was continued until disease progression (PD, RECIST 1.1) or death (while the patient was on treatment) or toxicity became intolerant or other criteria for discontinuation of study therapy were met in the protocol. Allow adjustment of dosage according to protocol requirements, including suspension, lowering of dosage or permanent discontinuation.
223803086|NCT05969171|DRUG|Nab-paclitaxel, gemcitabine|Nab-paclitaxel: 125mg/m2 intravenously, d1, 8; every 3 weeks as a treatment cycle, should not exceed a maximum of 6 treatment cycles. Gemcitabine: 1000mg/m2, intravenous infusion greater than 30min, d1, 8, every 3 weeks as a treatment cycle, treatment until toxicity intolerance or disease progression, death, or other criteria for termination of study therapy as specified in the protocol. Allow adjustment of dosage according to protocol requirements, including suspension, lowering of dosage or permanent discontinuation.
223803087|NCT06524466|DRUG|Neoadjuvant SBRT combined with Lenvatinib and Pucotenlimab|"SBRT: SBRT will be performed within 2-4 weeks after enrollment. The total radiation dose will be 24 Gy, delivered in 3 fractions on alternate days, to be completed within one week.~Lenvatinib: 8mg/day, begin immediately after enrollment. Lenvatinib should be discontinued one week before surgery.~Pucotenlimab: 200mg，3-week interval between cycles, begin immediately after enrollment, a total of four cycles of Puco treatment must be completed before surgery.~Surgical resection will be performed within 10-16 weeks after the completion of SBRT."
223803088|NCT01270269|BEHAVIORAL|Behavioral: Physical and functional rehabilitation|A multi-component program of physical rehabilitation interventions (without cognitive rehabilitation) will be delivered to patients beginning in the ICU and continue throughout the hospitalization.
223803089|NCT01270269|BEHAVIORAL|Behavioral: Cognitive, physical, & functional rehabilitation|A multi-component program of cognitive, physical, and functional rehabilitation interventions will be delivered to patients beginning in the ICU with continued cognitive rehabilitation in their home environments over a focused 12-week period.
223803090|NCT04474743|OTHER|No intervention - cross-sectional observational only|No intervention - cross-sectional observational only
223803091|NCT04266379|DEVICE|Closed-loop insulin infusion driven by continuous glucose monitoring through an algorithm, in free-life conditions|Continuous subcutaneous insulin infusion according to an automated algorithm from continuous glucose monitoring data
223803092|NCT04266379|DEVICE|Continuous Subcutaneous Insulin Infusion and Continuous Glucose Monitoring|Insulin delivered subcutaneously by a pump and manage by the patient with the help of a CGM sensor
223803093|NCT00303199|DRUG|ZIO-101 (Darinaparsin)|IV zio-101 (Darinaparsin) give for 5 consecutive days to be repeated every 28 days for up to 6 months
223803094|NCT00353587|DRUG|MBX-102|MBX-102 200 mg once daily for 16 weeks
223803095|NCT00353587|DRUG|MBX-102|MBX-102 400 mg once daily for 16 weeks
223803096|NCT00353587|DRUG|MBX-102|MBX-102 600 mg once daily for 16 weeks
223803097|NCT00353587|DRUG|Placebo|MBX-102 Placebo once daily for 16 weeks
223803098|NCT00353587|DRUG|Actos|Actos 30 mg once daily for 16 weeks
223803099|NCT02361515|RADIATION|Moderate hypofractionated radiotherapy|Moderate hypofractionated radiotherapy of 62Gy in 20 fraction of 3.1Gy.
223803100|NCT02361515|RADIATION|Stereotactic radiotherapy|Stereotactic radiotherapy of 37.5Gy in 5 fraction of 7.5Gy.
223803101|NCT04132843|DRUG|Gadobenate Dimeglumine|Given IV
223803102|NCT04132843|DRUG|Gadobutrol|Given IV
223803103|NCT04132843|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223803104|NCT05613738|DRUG|1.11 GBq (30 mCi) of 177Lu-PSMA-EB-01|All patients were intravenous injected with single dose 1.11 GBq (30 mCi) of 177Lu-PSMA-EB-01 then monitored at 3 hours, 24 hours, 48 hours, 72 hours, and 168 hours post-injection.
223803105|NCT05613738|DRUG|1.85 GBq (50 mCi) of 177Lu-PSMA-EB-01|All patients were intravenous injected with single dose 1.85 GBq (50 mCi) of 177Lu-PSMA-EB-01 then monitored at 3 hours, 24 hours, 48 hours, 72 hours, and 168 hours post-injection.
223803106|NCT05613738|DRUG|2.59 GBq (70 mCi) of 177Lu-PSMA-EB-01|All patients were intravenous injected with single dose 2.59 GBq (70 mCi) of 177Lu-PSMA-EB-01 then monitored at 3 hours, 24 hours, 48 hours, 72 hours, and 168 hours post-injection.
223803107|NCT04805255|RADIATION|Hypofractionated Stereotactic Radiotherapy|A course of hypofractionated stereotactic radiotherapy (HF-SRT) is delivered within 2 weeks with a cumulative dose of 3000 - 3500 cGy in 5 fractions.
223803108|NCT04510675|DEVICE|Test Article|Omeza Collagen Matrix
223803109|NCT04510675|OTHER|Negative Control|Occlusive Patch of 0.9% sodium chloride, NaCl
223803110|NCT04501510|DIAGNOSTIC_TEST|Ultrasonographic examination validation and testing|X-ray imaging as well as the ultrasonographic examination of the fracture and healing process in children will be performed. The validation of an usg will be done.
223803111|NCT05217342|DRUG|Diuretic therapy|Standard diuretic therapy according to the current guidelines
223803112|NCT05204810|OTHER|Anticoagulation strategy|For each session of this cross-over study, a different anticoagulation therapy is used: either 1 dose of anticoagulant or 2 doses of anticoagulant
223803113|NCT05204810|OTHER|Blood sampling|During the study sessions, blood sampling is performed from the arterial blood line at different time points (5min, 60min, 240min and at the dialysis end)
223803114|NCT05204810|OTHER|Scanning of hemodialyzer with micro-computed tomography|After the study sessions, the used hemodialyzers are scanned using a gold standard micro computed tomography technique.
223803115|NCT05310474|DEVICE|Knee Glider|The purpose of this study is to study the efficacy of a remote range of motion monitor, the Knee Glider, alongside a patient engagement platform, Force Therapeutics, on clinical improvements and cost following primary TKA.
223803116|NCT01479387|DRUG|[111]In-ibritumomab tiuxetan (Zevalin, BAY86-5128)|Patients who have received In-111 Zevalin.
223803117|NCT03034616|DEVICE|OLIVA device|"OLIVA device is a laparoscopic device with a standard handle and a tip built of 5 parallel razor blades enclosed by protective cap opened by a separate button.~This device will enable to perform shallow slashes on the ovarian cortex following the grasping of the ovary without damaging other abdominal and pelvic organs"
223803118|NCT02317393|OTHER|K5-RGD PET|Both PET examinations will be performed within 4-6 weeks after the end of chemotherapy
223803119|NCT02317393|OTHER|FDG|Both PET examinations will be performed within 4-6 weeks after the end of chemotherapy
223803120|NCT06217757|RADIATION|Low-dose radiotherapy|The LDRT deals with primary tumour in a 15 Gy of 5fractions over five days, starting from Day 1 in the first cycle.
223803121|NCT06217757|DRUG|Etoposide|Etoposide will be administered intravenously at a dose of 100 mg/m\^2 on Days 1, 2 and 3 of each 21-day cycle during the induction phase (Cycles 1-4).
223803122|NCT06217757|DRUG|Cisplatin|Cisplatin will be administered as intravenous infusion at a dose of 25 mg/m\^2 on Days 1, 2 and 3 of each 21-day cycle during the induction phase (Cycles 1-4).
223803123|NCT06217757|DRUG|Sugemalimab|Sugemalimab will be administered by intravenous infusion at a dose of 1200mg on Day 1 of each 21-day cycle for a maximum of 2 years or progressive disease or intolerable toxicity.
223803124|NCT06217757|DRUG|Olaparib|Olaparib will be administered orally at a dose of 150mg qod Day 1,3,5,7 or 150 mg qd/150 mg bid/300mg in the morning and 150mg in the evening/300 mg bid on Day 1-7 of each 21-day cycle for a maximum of 2 years or progressive disease or intolerable toxicity.
223803125|NCT05177458|BEHAVIORAL|Experimental|Behavioral: Moderate Intensity Exercise The moderate-intensity aerobic exercise session will consist of walking or running at a moderate intensity (i.e., between 70-75% maximum heart rate) for 30 minutes on a treadmill.
223803126|NCT05177458|BEHAVIORAL|Active Control|Behavioral: Low Intensity Exercise Control participants will maintain light-intensity activity (i.e., walking at 40-50% of maximum heart rate) for 30 minutes.
223803127|NCT04198805|DIETARY_SUPPLEMENT|Vitamin E [(all-rac)-α-tocopheryl acetate]|Vitamin E (1000 mg) once daily for 6 months (1 capsule) and matching placebos (2 matched capsules) for 6 months
223803128|NCT04198805|DIETARY_SUPPLEMENT|Omega-3 fatty acid (DHA EE)|DHA EE (1.89 g) once daily for 6 months (2 capsules) and matching placebo for DHA EE (1 matched capsule for 6 months)
223803129|NCT04198805|COMBINATION_PRODUCT|Omega-3 fatty acid (DHA EE) & Vitamin E [(all-rac)-α-tocopheryl acetate]|DHA EE (1.89 g) once daily for 6 months and Vitamin E (1000 mg) once daily for 6 months
223803130|NCT04198805|OTHER|Placebo|Matching soybean placebo (3 capsules) of all arms daily for 6 months.
223803131|NCT01330433|DEVICE|CoSeal Surgical Spray Group|"A patient randomized to the CoSeal treatment group will have CoSeal Surgical Spray applied at the end of their first staged procedure.~The dose regimen is as follows:~* Patients weighing \< 3kg will receive 1ml of CoSeal~* Patients weighing 3-10kg will receive 1-2ml of CoSeal~* Patients weighing \>10kg will receive 2-4ml of CoSeal"
223803132|NCT01494584|DRUG|ezogabine/retigabine|ezogabine dose escalation
223803133|NCT06378892|DRUG|Lorlatinib|Platinum-pemetrexed based chemotherapy plus Lorlatinib will be administered for an induction phase of four cycles. The choice between Carboplatin or Cisplatin is entrusted to the clinician. Subsequently, patients with response or stability of disease at radiological assessment will start the maintenance phase with pemetrexed-Lorlatinib in 21-day cycles until progression, unacceptable toxicity, death, or withdrawal of consent.
223803134|NCT02624544|DRUG|esomeprazole|esomex 40 mg twice daily
223803135|NCT02624544|DRUG|desonide|topical corticosteroid desonid 0,1% b.i.d
223803136|NCT01499082|DRUG|HOE901-U300 (new formulation of insulin glargine)|HOE901-U300 (new insulin glargine 300 units per milliliter \[U/mL\]) subcutaneous (SC) injection once daily (evening) for 12 months on top of mealtime insulin analogue. Dose titration seeking fasting plasma glucose 4.4-5.6 millimole per liter (mmol/L) (80 - 100 milligram per deciliter \[mg/dL\]). After 6 months participants were proposed to participate to the administration substudy and to receive either HOE901-U300 once daily at intervals of 24 +/- 3 hours (adaptable dosing intervals) or to continue once daily injections of HOE901-U300 every 24 hours (fixed dosing intervals) up to Month 9.
223803137|NCT01499082|DRUG|Lantus (insulin glargine)|Lantus (HOE901-U100, insulin glargine 100 U/mL) SC injection once daily (evening) for 12 months on top of mealtime insulin analogue. Dose titration seeking fasting plasma glucose 4.4-5.6 mmol/L (80 - 100 mg/dL).
223803138|NCT05686005|DRUG|Oral tranexamic acid|4 tablets of tranexamic acid 500mg (equal 2gm) 2 hours before surgery in the ward.
223803139|NCT05686005|DRUG|Intravenous tranexamic acid|15mg/kg of tranexamic acid in a 20ml syringe slowly intravenous during induction.
223803140|NCT01457911|DRUG|Glimepiride and Metformin hydrochloride combination (HOE490)|Pharmaceutical form:tablet Route of administration: oral
223803141|NCT01457911|DRUG|Glimepiride (HOE490)|Pharmaceutical form:tablet Route of administration: oral
223803142|NCT03176836|DIAGNOSTIC_TEST|Whole body STIR MRI|Standard technique that detects abnormalities related to excess of water in tissues (edema).
223803143|NCT03176836|DIAGNOSTIC_TEST|DW-MRI|MRI technique that analyzes areas of dead cells within tissues, present in some types of tumor.
223803144|NCT03176836|DIAGNOSTIC_TEST|PET-MRI|MRI technique that detect's the cells' use of glucose, more intensely in harmful cells.
223803145|NCT03599349|DEVICE|Microfocused ultrasound w/ visualization|
223803146|NCT00586911|DRUG|Cystadane|Betaine 20 mg a day or identical placebo for 1 year.
223803147|NCT00586911|DRUG|Identical Placebo|Placebo
223803148|NCT06439563|DRUG|JP-1366 10 mg|JP-1366 10 mg, tablet, orally once a day for up to 24 weeks
223803149|NCT06439563|DRUG|Lanston Capsule 15 mg|Lanston Capsule 15 mg orally once a day for up to 24 weeks
223803150|NCT06439563|DRUG|JP-1366 10 mg placebo|JP-1366 10 mg placebo, tablet, orally once a day for up to 24 weeks
223803151|NCT06439563|DRUG|Lanston Capsule 15 mg placebo|Lanston Capsule 15 mg placebo, orally once a day for up to 24 weeks
223803152|NCT05617755|BIOLOGICAL|AB-1015|autologous T cell therapy
223803153|NCT01527929|DRUG|Cabazitaxel XRP6258|Pharmaceutical form: solution for infusion Route of administration: intravenous
223803154|NCT06047626|OTHER|Fatigue Reduction Diet|Sessions will be \~15 minutes for 8 sessions. The FRD maintains participants on a diet with their typical caloric intake as assessed at baseline, and replaces some of their calories with the following foods on a daily basis: at least 50% of servings grains to be whole grains (these would replace non-whole grain foods); 5 servings of vegetables (1 leafy green, 1 tomato, and 1 yellow/orange); 2 servings of fruit (1 high in vitamin C), both fruit and vegetables would replace some of the carbohydrates from non-fruit and vegetable sources; 1 serving of fatty fish and or 1 serving of nuts and/or seeds (2 servings of nuts and/or seeds for vegetarians), both the fish, the nuts, and seeds will replace existing sources of fats and proteins in the diet.
223803155|NCT06047626|OTHER|General Health Curriculum|These sessions will be matched counseling method, time spent (\~15 minutes per session), for 8 sessions. Registered Dietitians will discuss general health topics with the participant, excluding topics of diet and food.
223803156|NCT03640650|COMBINATION_PRODUCT|Dropless Therapy|The Dropless will be injected, as a single administration, into the vitreous cavity during the cataract surgery.
223803157|NCT03640650|DRUG|Usual Care|In order to reflect real-world clinical practice, the choice of topical ophthalmic medications as well as dosage, posology, and duration of treatment will be left to the discretion of the treating ophthalmologist.
223803158|NCT02380547|OTHER|Sonographic diaphragmatic measurements|
223803159|NCT02549469|DRUG|Naproxen Sodium ER (BAY117031), 20% HPMC|1 tablet 660 mg administered orally once daily
223803160|NCT02549469|DRUG|Naproxen Sodium ER (BAY117031), 30% HPMC|1 tablet 660 mg administered orally once daily
223803161|NCT02549469|DRUG|Naproxen Sodium ER (BAY117031), 40% HPMC|1 tablet 660 mg administered orally once daily
223803162|NCT02549469|DRUG|Aleve (Naproxen Sodium, BAY117031)|1 tablet 220 mg administered orally three times daily
223803163|NCT00222833|DRUG|Aripiprazole|
223803164|NCT04197843|DEVICE|NaviCam (ANKON)|The NaviCam (ANKON) is a miniaturised wireless endoscope in a single use capsule. It can be remotely controlled with the patient in a magnetic console. The operator to the magnetic-driven NaviCam sits in a computer workstation and manipulates the capsule suspended in a waterfilled stomach. After careful examination of the stomach, the capsule is then allowed to passed through the pylorus into duodenum and small bowel. The patient wears harness with small bowel imaging capabilities.
223803165|NCT01830127|DRUG|Ribavirin|24 Weeks
223803166|NCT01830127|DRUG|BI 207127 high dose|24 Weeks
223803167|NCT01830127|DRUG|Faldaprevir|24 Weeks
223803168|NCT01830127|DRUG|Ribavirin|24 Weeks
223803169|NCT01830127|DRUG|BI 207127 low dose|24 Weeks
223803170|NCT01830127|DRUG|Faldaprevir|24 Weeks
223803171|NCT04557930|BEHAVIORAL|Hopewell Hospitalist Video Game|Hopewell Hospitalist is a customized theory-based adventure video game that uses narrative engagement to educate physician players on advance care planning to increase physicians' likelihood of engaging in and billing for ACP conversations.
223803172|NCT01584765|DRUG|Prescription drugs with known hepatotoxicity|14 prescription drugs with known hepatotoxicity : Amoxicillin/clavulanate, nitrofurantoin, isoniazid, trimethoprim-sulfamethoxazole, duloxetine, valproate, interferon-beta, ciprofloxacin, lamotrigine, phenytoin, diclofenac, terbinafine, levofloxacin, aripiprazole
223803173|NCT02899494|OTHER|Antenatal classes|
223803174|NCT02899494|OTHER|Physical and psychic preparation|
223803175|NCT05840432|DEVICE|Postoperative hypotension prediction index|Performance of the hypotension prediction index (HPI) in predicting hypotension episodes in the first 12 h of cardiac surgery postoperative
223803176|NCT04216030|OTHER|High Fe IP meal labelled with Fe-58|500 gram steamed, mashed OFSP high Fe with 0.33 mg FeSO4-58 daily for 10 days
223803177|NCT04216030|OTHER|Control OFSP meal labelled with Fe-57|500 gram steamed, mashed OFSP control with 0.33 mg FeSO5-57 daily for 10 days
223803178|NCT00844025|BEHAVIORAL|Pharmacist intervention|Medication review, medication reconciliation, and pharmacotherapy recommendation.
223803179|NCT03717896|DRUG|200mg IV thiamine in 50mL 0.9% saline|Thiamine 200mg IV every 12 hours for 2 days
223803180|NCT03717896|DRUG|Placebo|50mL 0.9% saline
223803181|NCT06264479|PROCEDURE|Biopsy|Patients undergo a biopsy from a lesion, and give 40ml of blood
223803182|NCT02693990|RADIATION|Intensity Modulated Proton Therapy (IMPT)|Radiation Therapy - Intensity Modulated Proton Therapy (IMPT)
223803183|NCT00233558|DRUG|adalimumab (up to 9 months exposure)|
223803184|NCT00233558|DRUG|methotrexate|
223803185|NCT05238233|DRUG|Tropicamide|One drop will be given to participants
223803186|NCT05238233|DRUG|1% Pilocarpine|One drop will be given to participants
223803187|NCT05238233|DRUG|Proparacaine Hydrochloride|One drop will be given to participants
223803188|NCT05238233|DEVICE|Tono pen AVIA|Participant intraocular pressures measured
223803189|NCT05238233|DEVICE|VG4 Gonio|Participant iridocorneal angle measured
223803190|NCT05238233|DEVICE|Reichert phoropter|Participant screened for hyperopia \>+1 diopter
223803191|NCT01972958|OTHER|comprehensive care|comprehensice assessment,physical activity training, community resources referral, health education.
223803192|NCT00003334|DRUG|paclitaxel|
223803193|NCT00003334|DRUG|pegylated liposomal doxorubicin hydrochloride|
223803194|NCT01345721|BIOLOGICAL|MenACWY-CRM|
223803195|NCT04337814|DRUG|EMLA Cream|Topical anaesthetic cream
223803196|NCT04337814|DRUG|Ibuprofen|Oral analgesic syrup (non-steroidal anti inflammatory drug)
223803197|NCT04337814|DRUG|Placebo syrup|Placebo syrup similar to Ibuprofen
223803198|NCT04337814|DRUG|Placebo cream|Placebo cream similar to EMLA
223803199|NCT02190539|OTHER|Homeopathic treatment|Remedies are sold over the counter without a physician prescription (approved by the Israeli Ministry of Health). No toxicity or side effects are expected to be observed, potencies (dilutions) of substances beyond 7C (7 dilutions, each 1:100) do not contain a sufficient number of molecules of the original material to be pharmacologically active. Since the remedies being used in this trial are diluted at 30c and 200c, levels that are way beyond Avogrado's number, so no original material is expected to be found. This fact was verified utilizing high pressure liquid chromatography (HPLC) method. Due to those facts, most scientists do not accept that these remedies have any biological effects and consign any positive response to the placebo effect.
223803200|NCT00506064|DRUG|Melatonin|0.15 mg/kg by mouth (PO) Daily
223803201|NCT00506064|DRUG|Placebo|Two, three, or four starch tablet or capsules before bed
223803202|NCT00506064|BEHAVIORAL|Questionnaire|Sleep study surveys, two per day completed each evening, lasting 10 minutes
223803203|NCT00553696|DRUG|Cisplatin|Cisplatin 60 mg/m2 on day 1 of each 28 day cycle
223803204|NCT00553696|DRUG|S-1|S-1 80 mg/m2 on days 1-21 of each 28 day cycle
223803205|NCT00553696|DRUG|Sunitinib|Sunitinib 25 mg, 37.5 mg and 50 mg daily S-1 80 mg/m2 on days 1-21 of each 28 day cycle Cisplatin 60 mg/m2 on day 1 of each 28 day cycle
223803206|NCT01507805|DEVICE|EA preconditioning|EA preconditioning group was treated at bilateral Neiguan(PC 6)，Lieque(LU 7)and Yunmen(LU 2)with electrical stimulation(5-30 Hz，2．34-6．24 mA，30 min)for 5 consecutive days before surgery
223803207|NCT01507805|DEVICE|sham EA preconditioning|Patients in Sham EA preconditioning group was treated at bilateral Neiguan(PC 6)，Lieque(LU 7)and Yunmen(LU 2)without electrical stimulation(5-30 Hz，2．34-6．24 mA，30 min)for 5 consecutive days before surgery
223803208|NCT05382182|DRUG|androgen deprivation therapy|outcome of hormonal treatment as androgen deprivation therapy on prostate cancer patient on survival and relapse
223803209|NCT05382182|RADIATION|external beam radiotherapy|outcome of radiotherapy as external beam radiotherapy on prostate cancer patient on survival and relapse
223803210|NCT00686881|BIOLOGICAL|Peginterferon alfa-2b (PegIFN-2b)|PegIFN-2b administered at a dose of 0.5 ug/kg SC once a week for 156 weeks
223803211|NCT00686881|DRUG|Comparator: Stronger neo minophagen C (SNMC)|SNMC (as glycyrrhizin-containing compound) administered at 40 mL by intravenous (IV) injection or IV infusion 3 times weekly for 156 weeks .
223803212|NCT00243880|DRUG|lovastatin|investigators will treat the patients within 24 hours of symptom onset with short term high-dose lovastatin at escalating dosage. The escalating dosage levels will be 1, 3, 6, 8, and 10 mg/kg per day for 3 days.
223803213|NCT03303157|OTHER|no intervention|not relevant
223803214|NCT06221579|OTHER|No intervention, interviews with MCI patients as part of the development phase|No intervention, interviews with MCI patients as part of the development phase
223803215|NCT04846452|DRUG|Sintilimab + Anlotinib + Pemetrexed + Cisplatin or Carboplatin|Patients with non-squamous NSCLC will receive sintilimab, anlotinib hydrochloride, pemetrexed, and cisplatin or carboplatin.
223803216|NCT04846452|DRUG|Sintilimab + Anlotinib + Albumin Paclitaxel + Carboplatin|Patients with squamous NSCLC will receive sintilimab, anlotinib hydrochloride, albumin paclitaxel, and carboplatin.
223803217|NCT02908373|OTHER|Implementation of the coaching model|20 hours methodological help for each nursing home and an implementation kit
223803218|NCT05845320|OTHER|ICIQ-UI SF questionnaire|validated arabic short form of ICIQ on urinary incontinence
223803219|NCT03511833|DRUG|Morphine|IV morphine -0.1 mg/kg: Morphine vial contains 10 mg/10 ml = 1mg/ml ----\> 0.1 ml/kg
223803220|NCT03511833|DRUG|Ketamine|IN ketamine: 1 mg/kg: Ketamine vial contains 100 mg/2 ml = 50mg/ml ---\> 0.02ml/kg
223803221|NCT04292249|OTHER|Blood sampling|Analysis will be performed using commercially available analyses (suPARnostic® kit (validated to measure suPAR concentrations between 0.6 and 22 ng/mL) (ViroGates)). HsCRP will be measured by high sensitivity CRP assays (Tina-quant hs-CRP latex assay (validated to measure CRP concentrations between 0.3 - 20 mg/L) (Roche/Hitachi)). In patients with CRP\>20 mg/L a regular CRP-measurement will be performed.
223803222|NCT05085925|BEHAVIORAL|Cognitive behavioral mindfulness intervention|The group that receives mindfulness-based stress reduction at their entry into the study will have 7 sequential sessions during 3 months, and later have a booster session in month 5
223803223|NCT05085925|BEHAVIORAL|Cognitive behavioral mindfulness intervention after 3-month wait list|Wait-list control patients will get no intervention at the start of the study and instead will be contacted by study personal 7 times to care for the patient in order to control for the 7 sessions performed in the intervention group. After three months they will be offered mindfulness-based stress reduction as 8 sequential sessions.
223803224|NCT02680548|DRUG|0.9% saline|
223803225|NCT02680548|DRUG|0.25% bupivacaine hydrochloride injectable suspension USP|
223803226|NCT02680548|DRUG|4mg/cc methylprednisolone acetate injectable suspension USP|
223803227|NCT00838955|DRUG|Temsirolimus|Temsirolimus 25 mg IV infusion on Days 1, 8, 15, and 22 of a 28 day cycle
223803228|NCT01180348|DRUG|Botulift|Application of 90 U of Botulift divided in 3 applications on each side of the face in fifteen predetermined sites in three regions of the face (front, glabellar, periocular).
223803229|NCT01180348|DRUG|Botox|Application of 90 U of Botox divided in 3 applications on each side of the face in fifteen predetermined sites in three regions of the face (front, glabellar, periocular).
223803230|NCT01826474|DRUG|PRO045, 0.15 mg/kg/week|Subcutaneous injection
223803231|NCT01826474|DRUG|PRO045, 1.0 mg/kg/week|Subcutaneous injection
223803232|NCT01826474|DRUG|PRO045, 3.0 mg/kg/week|Subcutaneous injection
223803233|NCT01826474|DRUG|PRO045, 6.0 mg/kg/week|Subcutaneous injection
223803234|NCT01826474|DRUG|PRO045, 9.0 mg/kg/week|Subcutaneous injection
223803235|NCT01826474|DRUG|PRO045, selected dose|Subcutaneous injection
223803236|NCT05899686|DEVICE|Tetanic Stimulus|5 second 100 Hz 70 mA tetanic stimulus will be applied to three different anatomical locations in each subject.
223803237|NCT00551798|PROCEDURE|TEP au MIBI|Intravenous injection of MIBI.The review lasted 30 min, during which the patient should not move.
223803238|NCT05176275|DIAGNOSTIC_TEST|68Ga-NOTA-RP25|The proliferation and distribution of CD19 CAR-T cells in lymphoma patients were investigated by PET / CT after injection of 68Ga-NOTA-RP25
223803239|NCT06128668|BEHAVIORAL|Yoga|Yoga will be applied
223803240|NCT00255957|DRUG|HES administration|
223803241|NCT00255957|DRUG|Hydroxy Ethyl Starch administration to stroke patients|
223803242|NCT02170025|DRUG|Riociguat (Adempas, BAY63-2521)|Participants received 0.5 mg BAY63-2521 three times daily (tid) for 14 days. The dose would be increased to 1 mg BAY63-2521 for an additional 14 days, if this was considered safe and tolerable on the basis of the available data for a given patient.
223803243|NCT02170025|DRUG|Placebo|Participants received matching placebo tid.
223803244|NCT00572195|DEVICE|RNS® System|The previously implanted RNS® System is programmed to provide responsive stimulation. Upon detecting electrographic patterns, previously identified by the neurologist or neurosurgeon as abnormal, the Neurostimulator provides brief pulses of electrical stimulation through the Leads to interrupt those patterns. Patients with epilepsy treated with responsive direct-brain stimulation with the RNS System typically receive less than 6 minutes of stimulation a day.
223803245|NCT04858919|DIAGNOSTIC_TEST|3D transabdominal ultrasound|Initially 3D pelvic ultrasound will be performed on all patients. The transabdominal probes used will be those of the ultrasound scanner using a convex probe (multiple frequency 1-6 MHz).
223803246|NCT04858919|DIAGNOSTIC_TEST|transrectal ultrasound|The vaginal probe will be covered with the customary plastic sheath and richly lubricated with lubricating gel. The probe will then be slowly advanced into the rectum. The transvaginal probes used will be those of the ultrasound scanner using a vaginal probe (multiple frequency 1-8 MHz). The scanning technique will be similar to that of Transvaginal ultrasound.
223803247|NCT04858919|DIAGNOSTIC_TEST|vaginoscopy|It is the final procedure in the study to reach the accurate diagnosis. A rigid hysteroscope will be used. The sheath has a 5-mm outer diameter, with 2.9 mm rod lens. A high intensity light source and fiberoptic cable will be used to illuminate the uterine cavity. A solution of 0.9% normal saline will be used as the distention medium. The pressure will be kept at 100-120 mmHg using a pressure adjustable cuff system with the aim of maintaining the lowest pressure required to distend the uterine cavity.
223803248|NCT03677011|DIAGNOSTIC_TEST|Andrositol® Test|The intervention consists in the addiction of myo-inositol directly to the semen identifying the quality of sperm prior ICSI procedure
223803249|NCT01959724|OTHER|Vitrectomy|
223803250|NCT03657277|DEVICE|Micropatch|Each micropatch contains 50 tiny projections (800 um in length)
223803251|NCT04960865|OTHER|Kinesio Taping under tension.|Kinesio tape will be applied to participants under tension.
223803252|NCT04960865|OTHER|Kinesio Tape without tension|Kinesio tape will be applied to participants without any tension.
223803253|NCT04960865|OTHER|Rigid Taping|Rigid Taping will be applied.
223803254|NCT04349280|DRUG|Bintrafusp alfa|Participants will receive bintrafusp alfa.
223803255|NCT03794622|OTHER|intramedullary nail fixation with bone marrow concentration|intramedullary nail fixation with bone marrow concentration
223803256|NCT03794622|OTHER|intramedullary nail fixation|intramedullary nail fixation only
223803257|NCT00657618|DRUG|Sodium Stibogluconate (SSG)|100 mg/ml/vial. Treatment for laboratory-confirmed leishmaniasis with SSG 20mg/kg/d intravenously (IV) for 10 days or 20 days; visceral leishmaniasis will be treated with SSG 20mg/kg/d IV for 28 days as a second line of therapy for those failing or intolerant of Ambisome; and mucosal leishmaniasis will be treated with SSG 20mg/kg/d IV for 28 days.
223803258|NCT02610738|BEHAVIORAL|Junior KICk-OFF education programme|The Junior KICk-OFF course is an age appropriate eduction course which aims to improve the understanding and knowledge of children with type 1 diabetes. It has been designed with school teachers and educationalists to meet the learning needs of children aged 4-11yrs
223803259|NCT06977802|BEHAVIORAL|Digital Nutrition Education Mobile App for Healthy and Sustainable Eating|"This intervention is uniquely characterized by:~Dual Health-Sustainability Focus - Unlike most nutrition apps targeting weight loss, this integrates planetary health metrics (e.g., carbon/water footprints) alongside dietary guidance.~Psychobehavioral Personalization - Content is tailored to four predefined user profiles (e.g., Convenience-Seeker, Health-Conscious) identified through baseline questionnaires, adapting messaging strategies (e.g., time-saving tips vs. environmental appeals).~Biomarker-Validated Outcomes - Unlike apps relying solely on self-reports, efficacy is assessed via objective measures (urinary LC-MS metabolomics, fecal microbiota analysis).~Academic Development - Designed by nutrition scientists + AI engineers (University of Parma), with recipes aligned to Mediterranean/Planetary Diet standards"
223803260|NCT06485076|OTHER|Early Palliative Care|see previous description
223803261|NCT06700915|DIETARY_SUPPLEMENT|Diaberine|Participants will take one capsule three times daily, 15 minutes prior to meals, over a 24-week period.
223803262|NCT06700915|DIETARY_SUPPLEMENT|Placebo Capsule|Participants will take one capsule three times daily, 15 minutes prior to meals, over a 24-week period.
223803263|NCT04981678|DRUG|Buprenorphine|Patients randomized to this group will reduce their buprenorphine dose prior to surgery.
223803264|NCT04981678|DRUG|Buprenorphine|Patients randomized to this group will continue their buprenorphine at the full prescribed dose.
223803265|NCT06719505|OTHER|ME|Exercises selected with a focus on the major muscle groups. There will be one protocol for the first 3 months and a second protocol for months 4-6, with the number of repetitions for each exercise varying from 3 sets of 8 to 10 repetitions, totaling 18 exercises.
223803266|NCT06719505|OTHER|PE|The stretching and strengthening exercises will target the major muscle groups, and at the end of each session (lasting approximately 60 minutes), the instructor will guide the participant through a relaxation exercise using an EVA foam roller. The exercises were selected to improve overall muscle strength, as traditionally applied in Pilates. There will be one protocol for the first 3 months and a second protocol for months 4-6, with 17 exercises in each protocol, varying from 3 sets of 8 to 10 repetitions.
223803267|NCT06721026|OTHER|Continuous intravenous stable isotope amino acid tracer infusion|During the single 12 h trial day, a primed continuous stable isotope infusion will run in order to assess muscle protein synthesis in the basal (4 h) and post-prandial (8 h) state.
223803268|NCT06721026|OTHER|Amino acid infusion|In order to assess muscle protein synthesis rates during continuous elevated plasma amino acid availability, the amino acid infusion solution Vamin®14 EF will be used. Vamin® 14EF contains 85g amino acids per liter and will be administered in the post-prandial period for 8 hours to ensure a constant rate of amino acid infusion over the full assessment period of the primary outcome measure.
223803269|NCT06720662|DIETARY_SUPPLEMENT|Icosapent-ethyl ester capsules|Icosapent-ethyl ester (4.0 g of EPA) taken twice a day (2.0 g/day x 2) for six months.
223803270|NCT06720662|DIETARY_SUPPLEMENT|Corn oil Control|Corn oil twice a day (2.0 g/day x 2) for six months.
223803271|NCT06722222|PROCEDURE|Gao's triple eversion carotid endarterectomy|The carotid sheath is dissected in front of the sternocleidomastoid muscle to expose sufficient lengths of the CCA, ECA, and ICA. After raising the systolic blood pressure to 180 mmHg and intravenously injecting 1 mg/kg heparin, the superior thyroid artery is lapped and severed, and the CCA is occluded proximally to the CCA plaque, based on the plaque location shown by preoperative CTA and by intraoperative arterial exploration. Subsequently, the ECA and ICA are blocked individually. The ICA is cut diagonally at the CCA fork and the ECA is transected approximately 5 mm above its beginning. The plaque is removed with tweezers after eversion of the ICA. This process is repeated for the ECA. Finally, the long segment of plaque in the CCA is stripped proximally, followed by thorough removal of the debris on the peeling surface using heparin irrigation.
223803272|NCT06732661|PROCEDURE|Preserve pre-cardial fat pad|For this group, a sleeve was fashioned starting 4 cm proximal to the pylorus using serial applications of an 60 stapler over a 36Fr oro-gastric bougie. A security distance of 10 mm lateral to the esophagus is respected without dissection of pre-cardial fat pad.
223803273|NCT06732661|PROCEDURE|Dissect pre-cardial fat pad|For this group, a sleeve was fashioned starting 4 cm proximal to the pylorus using serial applications of an 60 stapler over a 36Fr oro-gastric bougie. Dissect the pre-cardial fat pad, and a security distance of 10 mm lateral to the esophagus is respected.
223803274|NCT06732492|DRUG|RD13-02 cell infusion|CAR-T cells
223803275|NCT06731959|DRUG|Flexlamose|Fexlamose solution via nebulizer for 28 days
223803276|NCT06731959|DRUG|Placebo|Placebo solution via nebulizer for 28 days
223803277|NCT06732973|DRUG|JS005|JS005：The drug was administered by a single subcutaneous injection
223803278|NCT06733883|OTHER|psychotherapy|Music therapy
223803279|NCT00478712|OTHER|Identification of genetic causes of Hirschsprung Disease|Blood, saliva, or DNA samples are requested from all study participants. The blood or saliva samples are used to isolate DNA in all participants. Blood samples are also used to establish cell lines in some participants.
223803280|NCT07087665|DEVICE|Wavelight Plus|"The WaveLight EX500 laser system, in conjunction with INNOVEYES Sightmap, is indicated for use in INNOVEYES Laser Assisted In-Situ Keratomileusis (wavelight plus1 LASIK) treatments:~* or the reduction or elimination of myopia or myopia with astigmatism, in eyes with spherical equivalent (SE) more than -1.00 and up to -9.00 diopters (D), with up to -8.00 D of spherical component (in minus cylinder format) and up to -3.00 D of astigmatic component at the spectacle plane, based on the INNOVEYES Sightmap Measured Refraction,~* in patients with magnitude of the spherical equivalent (SE) difference between the Manifest Refraction (MRSE) and the Sightmap measured refraction SE being less than 0.75D,~* in patients who are 18 years of age or older, and~* for patients with documentation of a stable manifest refraction defined as 0.5 D preoperative spherical equivalent shift over one year prior to surgery."
223803281|NCT07089186|DRUG|Meropenem and Pralurbactam|3g，q8h，180min infusion，Dose adjustments are available for participants with eGFR(mL/min)
223803282|NCT07089186|DRUG|Best Available Therapy (e.g., colistin, meropenem, tegecycline, amikacinceftezidime-avibatam)|The main therapeutic agents anticipated for use, either in combination or as monotherapy, commonly include colistin, meropenem, tigecycline, amikacin, and ceftazidime-avibactam.
223803283|NCT06058832|DEVICE|Low-intensity Shockwave Therapy|patients will receive 6 sessions, once per week of low-intensity extracorporeal shock wave with the following parameters: - 3000 SWs (energy intensity of 0.09 mJ/mm2) to each of five different sites: three along the penile shaft and two at the crural level plus Sildenafil 25mg of daily dose and 50mg on-demand dose one hour before intercourse for 6 weeks.
223803284|NCT06058832|OTHER|Kegel Exercises|"* The patient was asked to perform short (1 second) and long-lasting (6-10 seconds) contractions of the target muscles. Later, the exercises will do with the patient sitting or standing.~* Patient asked to repeat the contractions daily. Each patient performed 15 short and 15 long-lasting contractions in a prone, sitting, or standing position. Patients asked to do 30 contractions in the morning 30 contractions in the evening"
223803285|NCT06940232|DIAGNOSTIC_TEST|Blood Test for Glial Fibrillary Acidic Protein (GFAP) and Ubiquitin C-terminal Hydrolase L1 (UCH-L1) Acute Biomarkers|All groups will have blood drawn per standard of care. Blood samples will be analyzed using Traumatic Brain Injury (TBI) cartridges for iSTAT Alinity device.
223803286|NCT04168554|DEVICE|Telemedicine|Patient is examined using telemedicine
223803287|NCT06944704|DRUG|Pentoxifylline|Patients will receive oral Pentoxifylline 400 mg twice daily in addition to supportive treatment, for 3 months.
223803288|NCT04922554|DRUG|Omadacycline Oral Tablet|omadacycline 300 mg orally, once daily (150 mg tablets x 2)
223803289|NCT04922554|DRUG|Placebo|placebo tablets resembling omadacycline orally, once daily (x 2 tablets)
223803290|NCT02644590|DRUG|Melatonin|Detailed in arm description
223803291|NCT03139422|DRUG|Tranexamic Acid 500 MG|oral tablets
223803292|NCT03139422|DRUG|Calcium Dobesilate|oral tablets
223803293|NCT01007864|DRUG|piribedil|Oral application of piribedil at an equivalent dose of pramipexole or ropinirole according to a defined equivalence scheme (dose range 100 - 300 mg per day) for 11 weeks.
223803294|NCT01007864|DRUG|pramipexole or ropinirole|continuation of pre-study treatment regimen
223803295|NCT02673398|OTHER|Comprehensive Geriatric Assessment|Ancillary studies
223803296|NCT02673398|OTHER|Laboratory Biomarker Analysis|Correlative studies
223803297|NCT02673398|DRUG|Neratinib|Given PO
223803298|NCT02673398|OTHER|Pharmacological Study|Correlative studies
223803299|NCT03790995|PROCEDURE|Robot assisted laparoscopic prostatectomy|
223803300|NCT03952702|PROCEDURE|Myopic overcorrection|Myopic overcorrection
223803301|NCT05181852|DRUG|IP2015, dose 1|Active
223803302|NCT05181852|DRUG|IP2015, dose 2|Active
223803303|NCT05181852|DRUG|Placebo|Placebo
223803304|NCT05181852|DRUG|Pregabalin|Comparator
223803305|NCT01236079|BEHAVIORAL|Assisted referral & IVR|includes assistance in enrolling in outpatient cessation services, pharmacy orders for cessation medication, interactive voice recognition follow-up
223803306|NCT02368106|RADIATION|Radiation Therapy|targeted radiation treatment
223803307|NCT04679402|OTHER|Carbon monoxide 200 ppm in air|Low dose carbon monoxide
223803308|NCT03917940|DIETARY_SUPPLEMENT|Omega 3 fatty acids 1000 mg per day + glimepiride 2 mg or 3 mg oral|Omega 3 fatty acids 1000 mg per day oral
223803309|NCT03917940|DRUG|Glimepiride|glimepiride 2 mg or 3 mg per day oral
223803310|NCT01906684|DRUG|Acthar Gel|Patients who present with MS relapse within 72 hours of onset will be recruited for study. Upon consent they will be administered Achtar Gel for 5-14 days as clinically appropriate.
223803311|NCT00048230|DRUG|bortezomib|
223803312|NCT05308550|DIAGNOSTIC_TEST|rapid RT-LAMP test to detect SARS-COV-2 RNA|rapid RT-LAMP test to detect SARS-COV-2 RNA
223803313|NCT01321554|DRUG|Lenvatinib|Lenvatinib 24 mg (two 10-mg and one 4-mg lenvatinib matched capsules) taken orally once daily, continuously. Dose interruptions or reductions were allowed for subjects who experienced treatment-related toxicity.
223803314|NCT01321554|DRUG|Placebo|Matching placebo (two 10-mg and one 4-mg lenvatinib matched capsules) taken orally once daily, continuously.
223803315|NCT01321554|DRUG|Lenvatinib|"Lenvatinib 20 mg (two 10-mg capsules) taken orally once daily, continuously. Dose interruptions or reductions were allowed for subjects who experienced treatment-related toxicity.~The dose of lenvatinib during the OOL Lenvatinib Treatment Period was 24 mg once daily from 03 Oct 2011 until 15 Feb 2013. The dose was lowered at the request of the Data Monitoring Committee to 20 mg on 16 Feb 2013. Thus, more subjects were treated with 24 mg starting dose and the treatment duration was longer for these participants than those whose starting dose was 20 mg."
223803316|NCT06070402|DEVICE|DIAL, a voice-controlled virtual assistant|Participants in the experimental group will test in their homes a device called DIAL, a voice-controlled virtual assistant designed to communicate with the elderly and help them in different contexts. They will use it for four weeks. They will receive an individual training session on how to use the device, an instruction sheet for its use and, in addition, they will receive telephone technical support throughout the study. Finally, the device will be uninstalled and all participants will be called back to answer the same survey they answered before the intervention.
223803317|NCT00962351|PROCEDURE|Total Hip Replacement|
223803318|NCT01111123|DRUG|Lac-Hydrin lotion (ammonium lactate lotion 12%) ; UItravate ointment (halobetasol propionate ointment 0.05%)|Steroid on weekends only group
223803319|NCT01111123|DRUG|Lac-Hydrin lotion (ammonium lactate lotion 12%); placebo ointment|Placebo on weekends only group
223803320|NCT06119984|BEHAVIORAL|Community mobilization|The intervention focused on creating awareness, challenging social norms, and promoting actions against violence. To achieve these, the following activities were undertaken: introductory meetings, selection and training of model couples, structured workshops and small group meetings.
223803321|NCT03033654|OTHER|Sunscreen, Actinica|Two Consecutive Sunscreen Applications
223803322|NCT05593757|DRUG|Quinidine|Oral quinidine
223803323|NCT05593757|DRUG|Verapamil|Oral verapamil
223803324|NCT00432874|PROCEDURE|wound hydration method|Anterior vs lateral wound hydration
223803325|NCT00908492|BEHAVIORAL|Education Control|Caregiver participants are provided with information about caregiver stress and discuss it individually with an interventionist who visits the home. The control intervention involves 5 visits over 6 months.
223803326|NCT00908492|BEHAVIORAL|Environmental Skill Building|The ESP intervention addresses home modifications and training in their use, instruction in strategies of problem-solving, energy conservation, safe task performance, fall recovery techniques, and balance and muscle strength training. Intervention is individualized for target areas identified in the initial client assessment and caregiver interview. The intervention involves using a problem solving approach and client-centred focus and the intervention assessment tools are individualized measures which determine the goals identified by the caregiver. It involves 5 visits over 6 months.
223803327|NCT06013943|DRUG|Envafolimab+Gemox|"All of drugs were used for 6-8 cycles at the combined treatment stage, then Envafolimab and Gemcitabine continued at maintenance treatment stage until disease progression as defined by RECIST1.1, unacceptable toxicity, withdrawal from the study or death, or no more than 1 years.~Combined treatment stage: Envafolimab(150mg, iH, Q1W, Day1)+Gemcitabine(1000mg/m2, iv, Q3W, Day1 and Day8)+Cisplatin(1000mg/m2, iv, Q3W, Day1 and Day8);~Caintenance treatment stage: Envafolimab(400mg, iH, Day1, Q3W)+Gemcitabine(1000mg/m2, po, Day1-14, Q3W)."
223803328|NCT05810246|DIAGNOSTIC_TEST|68Ga-NY104 PET/CT Contrast-enhanced MRI of the brain and contrast-enhanced CT of abdomen and pelvis) 68Ga-NODAGA-LM3 PET/CT (exploratory)|"68Ga-NY104 PET/CT is expected to be completed within 21 days following screening. Participants will be administered a single, intravenous bolus of 68Ga-NY104 (1.8-2.2 MBq per kilogram bodyweight). PET/CT scanning will occur at 45 -75 minutes following injection of 68Ga-NY104.~Conventional imaging should be performed within one month from 68Ga-NY104 PET/CT. It includes contrast-enhanced MRI of brain and contrast-enhanced CT of abdomen and pelvis.~68Ga-NODAGA-LM3 PET/CT is optional in patients with evidence of or in suspicion of pheochromocytoma, paraganglioma, or pancreatic neuroendocrine tumor. They are encouraged to undergo exploratory 68Ga-NODAGA-LM3 PET/CT for better evaluation of neuroendocrine tumors. The decision, however, is up to the participants. 68Ga-NODAGA-LM3 PET/CT should be performed within one month after 68Ga-NY104 PET/CT. The details of 68Ga-NODAGA-LM3 PET/CT are similar to 68Ga-NY104 PET/CT."
223803329|NCT04968691|OTHER|Telerehabilitation based exercise treatment|The telerehabilitation group will be shown how to do the exercises online by the researcher before each session, 3 sessions a week for 6 weeks, with mobile telecommunication applications, and it will be ensured that the patients do the exercises correctly and are followed up. In addition, at the beginning of each week, videos with the exercise content of that week will also be sent.
223803330|NCT04968691|OTHER|Home based exercise treatment|n the study, exercise cards were given to the control group and the exercise treatment they were asked to do at home 3 sessions a week for 6 weeks
223803331|NCT00752843|DRUG|mifepristone + fluvastatin|Subjects will receive a single oral dose of 40 mg PO of fluvastatin on three occasions: alone (Day 1), at the same time as a single dose of CORLUX 1200 mg (Day 8) and during concomitant administration of CORLUX 1200 mg/day (CORLUX on Days 8-14, fluvastatin on Day 14).
223803332|NCT02943850|BIOLOGICAL|Stem cell (HPC) implantation|All patients will received unilateral lumbar spinal cord injections of CNS10-NPC-GDNF cells.
223803333|NCT02943850|DEVICE|Stereotactic surgical device|A newly developed stereotactic frame is being evaluated as a part of this trial
223803334|NCT01308606|DRUG|TMC435 HPMC capsule|Single intake of one 150-mg capsule without food
223803335|NCT01308606|DRUG|TMC435 HPMC or gelatin capsule|Single intake of one 150-mg capsule after high-fat breakfast
223803336|NCT01308606|DRUG|TMC435 HPMC or gelatin capsule|Single intake of one 150-mg capsule without food
223803337|NCT01308606|DRUG|TMC435 HPMC or gelatin capsule|Single intake of one 150-mg capsule after standardized breakfast
223803338|NCT01308606|DRUG|TMC435 gelatin capsule|Single intake of one 150-mg capsule without food
223803339|NCT02355067|BEHAVIORAL|Social Media Intervention|These women will participate in the intervention through the online Facebook group.
223803340|NCT02355067|BEHAVIORAL|Traditional In-Person Intervention|These women will participate in the intervention through a traditional weekly meeting of a group in-person.
223803341|NCT02063230|DRUG|Selumetinib 50mg|HV and hepatic impaired patients with mild and moderat severity will recived selumetinib 50mg orally on day 1
223803342|NCT02063230|DRUG|Selumetinib 25mg|Severe (Child Pugh C) hepatic impaired patients will receive selumetinib 25mg orally on Day 1
223803343|NCT05797922|DRUG|DWP16001|DWP16001 0.3mg
223803344|NCT00800839|DRUG|Busulfan|Starting dose of 32 mg/m\^2 by vein over 3 hours each day. Test dose day -8 (inpatient) or test dose day -30 to day -8 (outpatient) and then, days -6,-5,-4, and -3.
223803345|NCT00800839|DRUG|Fludarabine|Dose of 40 mg/m\^2 by vein over 1 hour each day on Day -6 through Day -3 before receiving Busulfan.
223803346|NCT00800839|DRUG|Cyclophosphamide|Dose of 50 mg/kg by vein over 3 hours on Days 3 and 4.
223803347|NCT04676425|DRUG|MK-8189|Administered at a dose of 4 mg via oral tablet
223803348|NCT02350712|DRUG|Patritumab|Patritumab initial loading dose is 18 mg/kg IV over 60 minutes, followed in Cycle 2 and beyond with a maintenance dose of 9 mg/kg IV over 60 minutes (+/- 10 minutes) every 3 weeks. Infusion time can be extended to a maximum of 120 minutes for participants unable to tolerate the 60-minute infusion.
223803349|NCT02350712|DRUG|Cetuximab|Cetuximab initial dose at 400 mg/m2 IV as a 2-hour infusion, followed by 250 mg/m2 IV over 60 minutes weekly.
223803350|NCT02350712|DRUG|Cisplatin|Cisplatin is given as an IV infusion, over 1 hour, 1 hour after the cetuximab infusion, every 3 weeks up to a maximum of 6 cycles (with standard pre- or post-treatment therapies at the investigator's discretion).
223803351|NCT02350712|DRUG|Carboplatin|Carboplatin is given as an IV-bolus, over 30-60 minutes, every 3 weeks, for a maximum of 6 cycles (with standard pre- or post-treatment therapies at the investigator's discretion).
223803352|NCT03391609|DRUG|placebo infusion|Caesarian section will be performed under standard general anesthesia plus pre and intra operative saline infusion (placebo) in the same rate as dexmedetomedine starting 15 minutes before induction of general anesthesia and continue till peritoneum closure.
223803353|NCT03391609|DRUG|Dexmedetomidine infusion|Caesarian section will be performed under standard general anesthesia plus pre and intra operative Dexmedetomidine infusion in a dose of 0.5mic/kg/hour starting 15 minutes before induction of general anesthesia and continue till peritoneum closure.
223803354|NCT02238925|DRUG|CPX-351|
223803355|NCT03340480|DRUG|NVP-1402|Oral
223803356|NCT06366191|OTHER|prevention algorithm|a health watch adapted to stress and dissociative symptoms
223803357|NCT06366191|OTHER|Standard care|Standard care for post traumatic stress disorder
223803358|NCT02130934|PROCEDURE|Cardiac 3D MRI|
223803359|NCT04036071|DEVICE|Total Hip Arthroplasty|Total Hip Arthroplasty using the SL-PLUS™ MIA cement free hip stem
223803360|NCT05217186|DIAGNOSTIC_TEST|Measurements|All infants wirth high risk of cp will be assessed by neuroimaging and Hammersmith Neonatal Neurological Examination (HNNE) at term age, Prechtl's General movements (GMs) assessments form birth up to 3-5 months, and will be assesed by Hammersmith Infant Neurological Examination (HINE) at 2,3,6,9 and 12th months, also BAYLEY-III Infant and Toddler Development Assessment Scale (BAYLEY-III) at the 3rd, 6th, and 12th months.
224264192|NCT02684331|OTHER|Cardiac Magnetic Resonance Imaging (CMR)|An extensive explorative CMR protocol, including time/volume curves of LV and LA, rest and stress perfusion (with Adenosin) and time/volume curve of LA after chronotropic stress with Glycopyrrolate, further flow measurements and T1 mapping.
223803361|NCT01410058|DIETARY_SUPPLEMENT|Moringa oleifera|leaf powder, 1.85g once daily, hard gelatin capsules
223803362|NCT01410058|DRUG|Efavirenz 600mg|Efavirenz 600mg based regimen
223803363|NCT01410058|DRUG|Nevirapine 200Mg Oral Tablet|Nevirapine 200mg based regimen
223803364|NCT00389883|DRUG|Comparison of two anesthetics protocol|Comparison of two anesthetics protocol
223803365|NCT01957917|OTHER|NAC (Nutritional Assessment and Counseling)|
223803366|NCT01957917|OTHER|Cash Transfer|
223803367|NCT01957917|OTHER|Food Assistance|
223803368|NCT02607982|DRUG|Paclitaxel|PTX 135 mg/m2 was administered intravenously over 3 hours on Day 1 and Day 29 with standard premedications.
223803369|NCT02607982|DRUG|Oxaliplatin|oxaliplatin (125mg/ m²) was given as a 2 hours infusion. Chemotherapy was started concurrently with radiation on day 1.
223803370|NCT02607982|RADIATION|Radiotherapy|Radiotherapy was given concurrently on the first day of the first cycle of chemotherapy. The GTV received 60Gy (30 fractions at 2Gy per fraction) and CTV was 40 Gy (20 fractions at 2Gy per fraction). Radiotherapy was delivered in three-dimensional conformal technique (3D-CRT) and no intensity-modulated radiotherapy was used.
224264193|NCT02684331|OTHER|Echocardiography|Standard measurements and strain.
224264194|NCT02684331|OTHER|Bood samples|HbA1c, Glucose, Hgb, Creatinin, Sodium, Potassium, Total cholesterol, LDL cholesterol, HDL cholesterol, Free fatty acids, ALAT, Urinary albumin, NT-proBNP, ANP, suPAR, Copeptin, Proendothelin, proCNP, Soluble ST2, Galectin-3
224264195|NCT01566851|OTHER|Cardiovascular check-up|Cardiovascular check-up once a year in patients with rheumatoid arthritis
224264196|NCT01049282|BIOLOGICAL|Antigen (Ag85B-ESAT-6)|Solution for injection, 0.5 mL, 50 ug antigen, 2 vaccinations with 2 months interval
224264197|NCT01049282|BIOLOGICAL|Antigen (Ag85B-ESAT-6) with adjuvant (IC31)|Suspension for injection, 0.5 mL, 50 ug antigen, 2 vaccinations with 2 months interval
224264198|NCT02659462|OTHER|Cardio Pulmonary Exercise Testing|Cardio Pulmonary Exercise Testing
223803371|NCT02153801|PROCEDURE|During the surgical procedure of Laparoscopic Low Anterior Resection with Total mesorectal Excision .|"For High Ligation The opening of the peritoneum proceeds cephalad towards the duodenojejunal angle of Treitz, and the mesenteric root is incised 1 cm below the inferior margin of the pancreas. The aortomesenteric window is opened wide and the inferior mesenteric vessels are exposed. The inferior mesenteric artery (IMA) is ligated and divided at 2 cm from its origin. The inferior mesenteric vein is ligated and divided below the pancreatic margin.~For Low Ligation The opening of peritoneum proceeds upward and then laterally towards the sigmoid colon. Left colic artery is identified and preserved while low ligation of the inferior mesenteric artery (superior hemorrhoidal artery) is performed. Lymphadenectomy is carried on medially along the inferior mesenteric artery until 2 cm from the aorta.~For both groups dissection is then carried on windowing Toldt and Gerota fascias till the parietocolic gutter."
223803372|NCT06414486|DIETARY_SUPPLEMENT|Dietary supplement group|One tablet per day for 3 weeks consumed for subjects randomized in the Dietary supplementation group. This will lead to an intake of 200mg per day of Red Panax Ginseng (corresponding to 22.4mg of ginsenosides and 20.2mg of rare ginsenosides).
223803373|NCT06414486|OTHER|Placebo group|One tablet per day consumed for 3 weeks for subjects randomized in the Control group. The product is composed of rice flour (50mg) and brown sugar (150mg).
223803374|NCT00402701|BEHAVIORAL|Walking School Bus Program|Schoolwide promotion of walk to school. Facilitation of parent-led walking school bus routes.
223803375|NCT05808738|BEHAVIORAL|therapeutic play|therapeutic game will be played to prepare children for hydrotherapy treatment
223803376|NCT02737800|PROCEDURE|endometrioma aspiration|Transvaginal ultrasound guided aspiration
223803377|NCT02737800|DRUG|GnRh agonist ( Decapeptyl )|3 monthly doses of Decapeptyl 7.5mg intramuscular
223803378|NCT02737800|PROCEDURE|standard long stimulation protocol|Decapeptyl 3.75mg in the mid luteal phase followed by human menopausal gonadotropins(HMG);fostimon, or merional injections after bleeding, doses are individualization according to each patient, monitored by follicular size \&serum estradiol.
223803379|NCT01953614|OTHER|Chiropractic adjustment|
223803380|NCT01953614|OTHER|Sham adjustment|
223803381|NCT05559502|DEVICE|HFNO group|HFNO therapy make possible to perform tubeless anesthesia, providing perfect exposure of structure of the vocal cords.
223803382|NCT05559502|DEVICE|ET group|Endotracheal tube is a plain tube, which is most commonly used in general anesthesia.
223803383|NCT03019146|OTHER|HIIT|
223803384|NCT03019146|OTHER|HOLD|
223803385|NCT03019146|OTHER|HUG|
223803386|NCT02565901|DRUG|Carboplatin|Given IV
223803387|NCT02565901|DRUG|Docetaxel|Given IV
223803388|NCT02565901|OTHER|Laboratory Biomarker Analysis|Correlative studies
223803389|NCT02565901|DRUG|Sirolimus|Given PO
223803390|NCT03177668|DRUG|YS110|Intravenous administration
223803391|NCT01946022|DRUG|randomization between the two GnRH analogues (agonist and antagonist)|
223803392|NCT00718822|OTHER|oxygen concentration in the culture atmosphere|
223803393|NCT03896009|DRUG|AXS-07 (MoSEIC meloxicam and rizatriptan)|AXS-07 taken once upon onset of a qualifying migraine.
223803394|NCT03896009|DRUG|Meloxicam|Meloxicam taken once upon onset of a qualifying migraine.
223803395|NCT03896009|DRUG|Rizatriptan|Rizatriptan taken once upon onset of a qualifying migraine.
223803396|NCT03896009|DRUG|Placebo|Placebo taken once upon onset of a qualifying migraine.
223803397|NCT05542940|OTHER|p 53 immunohistochemistry positive staining and relation to stages ,pathological types and grading|p 53 immunohistochemistry positive staining and relation to stages ,pathological types and grading
223803398|NCT05596643|DIAGNOSTIC_TEST|Composite Autonomic Symptom Score-31|Standardized questionnaire to determine the level of autonomic dysfunction
223803399|NCT05596643|DIAGNOSTIC_TEST|r-r interval variability with normal breathing|electrophysiological test to detect parasympathetic dysfunction
223803400|NCT05596643|DIAGNOSTIC_TEST|r-r interval variability with deep breathing|electrophysiological test to detect parasympathetic dysfunction
223803401|NCT05596643|DIAGNOSTIC_TEST|Valsalva ratio|electrophysiological test to detect parasympathetic dysfunction
223803402|NCT05596643|DIAGNOSTIC_TEST|30:15 ratio|electrophysiological test to detect parasympathetic dysfunction
223803403|NCT05596643|DIAGNOSTIC_TEST|sympathetic skin response|electrophysiological test to detect sympathetic dysfunction
223803404|NCT05596643|DIAGNOSTIC_TEST|blood pressure response to standing|clinical test to detect sympathetic dysfunction
223803405|NCT05596643|DIAGNOSTIC_TEST|blood pressure response to sustained handgrip test|clinical test to detect sympathetic dysfunction
223803406|NCT05596643|OTHER|Hospital anxiety and depression scale|Standardized questionnaire to investigate the depression and anxiety
223803407|NCT05596643|DIAGNOSTIC_TEST|Fibromyalgia rapid screening tool|Standardized questionnaire to determine the presence of fibromyalgia
223803408|NCT05596643|OTHER|Familial Mediterranean Fever Quality of life scale|Standardized questionnaire to investigate the quality of life in Familial Mediterranean Fever patients
223803409|NCT05596643|OTHER|Jenkins Sleep Evaluation Scale|Standardized questionnaire to investigate the sleep quality and disturbance
223803410|NCT05596643|OTHER|The Fatigue Severity Scale|Standardized questionnaire to investigate the fatigue severity
223803411|NCT04444037|DEVICE|OCT-guided PCI|using optical coherence tomography imaging to help PCI procedure
223803412|NCT03597568|DIETARY_SUPPLEMENT|Resveratrol|Oral supplementation for 6 weeks
223803413|NCT03597568|OTHER|Placebo|Oral supplementation for 6 weeks
223803414|NCT03488368|OTHER|observation|Observation of renal outcome parameters and adverse events in the follow-up beyond the 3-year trial phase of the original STOP-IgAN trial.
223803415|NCT05194904|DRUG|Dexmedetomidine|This is a prospective randomised clinical study designed to assess the effect of intravenous ketorolac versus intravenous dexmedetomidin on postoperative pain after hypospadias repair in children
223803416|NCT04439643|DEVICE|vascuCAP|time to event and phenotype classification model
223803417|NCT05148325|DRUG|BAT4706|The administration cycle was proposed to be 3 weeks (Q3W), i.e., 21 days in a cycle, and the first 4 cycles were administered on the first day of each cycle.
223803418|NCT02052310|DRUG|Roxadustat|Roxadustat will be administered per dose and schedule specified in the arm.
223803419|NCT02052310|DRUG|Epoetin Alfa|Epoetin alfa will be administered TIW according to the epoetin alfa USPI or SmPC, or local SOC.
223803420|NCT05531279|DRUG|PEG-rhG-CSF|PEG-rhG-CSF group A(q7d):6mg d1,8,subcutaneously injected; PEG-rhG-CSF group B(q10d):6mg d1,11,subcutaneously injected; RhG-CSF group(short-acting ): 480ug d1-14(daily for 14days),subcutaneously injected.
223803421|NCT04635579|DEVICE|Blood flow restriction|Intervention restricts blood flow to the lower limb as a percentage of the limb occlusion pressure
223803422|NCT03075384|PROCEDURE|computer-assisted navigation system|The computer-assisted navigation system was applied in treatment of unilateral complicated zygomatic fractures
223803423|NCT00845884|DRUG|Docetaxel, Cisplatin, Capecitabine, Bevacizumab|"* Docetaxel 30-35 mg/m2 IV, on Days 1 and 8, Q:21 days.~* Cisplatin 30-35 mg/m2 IV, on Days 1 and 8, Q:21 days.~* Capecitabine 1,600 mg/m2/d PO, divided into two daily doses, on Days 1-14, Q:21 days.~* Bevacizumab 7.5 mg/kg IV, on Day 1, Q:21 days."
223803424|NCT04839263|PROCEDURE|"FAST TRACK protocol"|"Preoperative evaluation and information~Patient general health state optimization proposal prior to hospitalization:~Preoperative strategy:~* Hospitalization on surgery day~* No prolonged fasting~Perioperative strategy:~* Pain control based on limited systemic opioid therapy use~* Anti-nausea prophylaxis~* Anaesthesia via IV propofol / remifentanyl~* Bladder catheter removal postoperative~Postoperative strategy:~* Pain control using balanced analgesia~* Gum chewing~* Early oral refeeding and rapid mobilization~* Venflon removal 6 hours post-op"
223803425|NCT05035914|DRUG|Anlotinib Hydrochloride|Anlotinib Hydrochloride is a capsule in the form of 8 mg ,10 mg and 12 mg, orally, once daily, 2 weeks on/1 week off.
223803426|NCT02380625|DRUG|Azithromycin|Adults (\>18 yrs): 3 x 500mg tablets daily for 5 days; Children (6 months to \<18 yrs): 30mg/kg (oral suspension) daily for 5 days
223803427|NCT02380625|DRUG|Sunitinib and Erlotinib|Sunitinib - Adults (\>18 yrs): 1 x 50mg tablet daily for 7 days; Children (6 months to \<18 yrs): 0.83 mg/kg (oral suspension) daily for 7 days. Erlotinib - Adults (\>18 yrs): 1 x 150mg tablet daily for 7 days; Children (8kg to \<20kg): 3.5 mg/kg daily for 7 days; Children (\>20kg to \<30kg): 3.0 mg/kg daily for 7 days; Children (\>30kg to \< 18 yrs): 25 mg/kg daily for 7 days
223803428|NCT02380625|DRUG|Atorvastatin and Irbesartan|Atorvastatin - Adults (\>18 yrs): 1 x 40mg tablet daily until discharge; Children (6 years to \<18 yrs): 1 x 40mg tablet daily until discharge; Irbesartan - Adults (\>18 yrs): 1 x 150mg tablets daily until discharge; Children (6 years to \<18 yrs): 1 x 75mg tablet daily until discharge.
223803429|NCT02380625|OTHER|IV fluids and laboratory testing|All arms will receive aggressive IV fluid rehydration and frequent laboratory tests to assist with medical management as indicated.
223803430|NCT05703100|OTHER|Incremental exercise test|Maximal incremental exercise test on a cycle ergometer (5 min warm-up at 30W, and subsequent steps of 3 min with power increases of 30W)
223803431|NCT05703100|OTHER|Incremental exercise test under hyperthermia|Maximal incremental exercise test on a cycle ergometer (5 min warm-up at 30W, and subsequent steps of 3 min with power increases of 30W) performed at a room temperature of 35-38ºC (degrees Celsius).
223803432|NCT05703100|OTHER|Incremental exercise test under glycogen depletion|Maximal incremental exercise test on a cycle ergometer (5 min warm-up at 30W, and subsequent steps of 3 min with power increases of 30W) under glycogen depletion by performing an exercise protocol to deplete glycogen stores plus a low-carbohydrate diet 24 h before incremental testing
223803433|NCT02565914|DRUG|TEZ/IVA|Fixed dose tablet for oral administration.
223803434|NCT02565914|DRUG|IVA|Tablet for oral administration.
223803435|NCT03434327|OTHER|Strength Training|Eleven resistance training exercises performed on pneumatic resistance training machines using 2 second concentric and 3 second eccentric contractions at 75-80% of each subjects maximal strength. Subjects will perform 3 sets per exercise, two times per week for 12 weeks.
223803436|NCT03434327|OTHER|Power Training|Eleven resistance training exercises performed on pneumatic resistance training machines using maximum speed concentric and 3 second eccentric contractions at the load that produces the highest power for the individual. Subjects will perform 3 sets per exercise, two times per week for 12 weeks.
223803437|NCT05154383|BIOLOGICAL|Experimental arm : High-Dose Quadrivalent Influenza Vaccine (Efluelda)|Patient will received one dose of High Dose Quadrivalent Influenza Vaccine according to marketing authorization.
223803438|NCT05154383|BIOLOGICAL|Active Comparator: Standard-Dose Quadrivalent Influenza Vaccine|Patient will received one dose of Standard Dose Quadrivalent Influenza Vaccine according to marketing authorization.
223803439|NCT06578910|DIAGNOSTIC_TEST|Standard of care|12 months after the IOL implantation: measurement of intraocular pressure, slitlamp and fundus examination, visual acuity, manifest refraction.
223803440|NCT06578910|OTHER|Patient satisfaction questionnare|VFQ- 25 (Visual Function Questionnare) to be completed during 12 month visit.
223803441|NCT02656810|DRUG|Teriparatide|Single subcutaneous injection
223803442|NCT01505387|DIETARY_SUPPLEMENT|Litramine|Fibre complex of plant origin in tablet form 2 tablets 3 times daily (oral consumption, after meal)
223803443|NCT01505387|DIETARY_SUPPLEMENT|Placebo|Identical to Litramine tablets 2 tablets 3 times daily (oral consumption, after meal)
223803444|NCT00663325|DRUG|Lactic acid (Dermacid)|Liquid soup to be applied in the external genital area, in a small quantity, with abundantly rinse after use, during 21 days.
223803445|NCT01941732|DRUG|Sildenafil|
223803446|NCT04669730|OTHER|usual care|Routine care
223803447|NCT04669730|BEHAVIORAL|Walk|Walk 30mins
223803448|NCT04669730|BEHAVIORAL|Baduanjin|Baduanjin exercise is moderate in intensity and short in duration (a set of Baduanjin takes about 12 minutes). Baduanjin consists of the sitting and standing practicing form. The sitting Baduanjin exercise conforms to the aspects of low-intensity and long-term aerobic activity, which is suitable for the rehabilitation training of patients who are in stable condition during hospitalization. The standing Baduanjin is more suitable for patients with sequential rehabilitation after discharge and can be adjusted based on the patient's condition
223803449|NCT04669730|BEHAVIORAL|Baduanjin plus walk|Walk 30mins then Baduanjin 12mins per day, 5 times per week.
223803450|NCT04756557|OTHER|Experimental.|Tooth Brushing HAP 2x daily repeated cleaning of all teeth 3 min. using a standardized electric tooth brush Electric (powered) toothbrushes (Oral-B; P\&G, Schwalbach, Germany), brushing head: medium; will be changed every 2 months and a non-fluoridated tooth paste containing microcrystalline hydroxyapatite . HAP-toothpaste (Karex toothpaste with 10 % hydroxyapatite) If a subject shows multiple carious lesions during the course of the study, the study dentist will decide whether the subject must be excluded from the study. In this case the subject will receive additional intensive caries prophylactic measures (e.g. chlorhexi-dine gel application, dietary counselling, etc.). Caries preventive treatment (removing caries and placing a restoration) by the study centers is offered.
223803451|NCT04756557|OTHER|Active comparator|Tooth Brushing F 2x daily repeated cleaning of all teeth 3min.using a standardized electric tooth brush ((Oral-B; P\&G, Schwalbach, Germany) and a fluoridated toothpaste (Karex Base with sodium fluoride 1450 F-), brushing head: medium; will be changed every 2 months If a subject shows multiple carious lesions during the course of the study, the study dentist will decide whether the subject must be excluded from the study. In this case the subject will receive additional intensive caries prophylactic measures (e.g. chlorhexidine gel application, dietary counselling, etc.). Caries preventive treatment (removing caries and placing a restoration) by the study centers is offered.
223803452|NCT04290351|PROCEDURE|band ligation|"Rubber band ligation will be applied to patients, and then phlebotonic will be prescribed.~(Note: The researcher has no contribution or intervention to the treatment method. Patients receiving this treatment will be observed.)"
223803453|NCT04290351|DRUG|oral 450 mg diosmin+50 mg hesperidin|"450 mg diosmin + 50 mg hesperidin will be prescribed to patients undergoing band ligation.~(Note: The researcher has no contribution or intervention to the treatment method. Patients receiving this treatment will be observed.)"
223803454|NCT04749732|BEHAVIORAL|WalkingPad plus Psychological Intervention - PsyWPad Group|The 24-week walking program will be monitored by the WalkingPAD application that will accompany the patient on their walks and record their adherence to the previously defined individual program. Motivational support for a behavioral intervention will include two face-to-face sessions and the following contacts will be made over the phone. The behavioral motivational intervention will follow the principles of 1) motivational interview, will be based on 2) Theory of self-determination, taking into account 3) components of the Transtheoretical Model of Change and the Theory of Planned Behavior.
223803455|NCT04749732|BEHAVIORAL|WalkingPad plus Virtual Assistant - CyberWPad Group|The 24-week walking program will be monitored by the WalkingPAD application, which will accompany the patient on their walks and record their adherence to the previously defined individual program. Motivational support will be provided by a virtual assistant through daily and on-the-spot interactions and through support and motivational messages.
223803456|NCT04749732|BEHAVIORAL|WalkingPad group - Paper WPad Group|The 24-week walking program will be supported by a printed prescription of an individualized HbET previously defined on the WalkingPAD platform. However, this group of patients will not have the support of an application to monitor and record adherence to the program. Motivational support for a behavioral intervention will include two face-to-face sessions and the following contacts will be made over the phone. The behavioral motivational intervention will follow the principles of 1) motivational interview, will be based on 2) Theory of self-determination, taking into account 3) components of the Trans-Theoretical Model of Change and the Theory of Planned Behavior.
223803457|NCT02138630|DIETARY_SUPPLEMENT|Capsaicin|
223803458|NCT02138630|DIETARY_SUPPLEMENT|Placebo|Sugar capsule
223803459|NCT01391520|DRUG|deferiprone|3 tablets (treatment arm assigned in double-blind, randomized manner) will be given every 12 hours for a total of 8 days, beginning 1-3 hours prior to angiography
223803460|NCT01391520|DRUG|Placebo|3 tablets (treatment arm assigned in double-blind, randomized manner) will be given every 12 hours for a total of 8 days, beginning 1-3 hours prior to angiography
223803461|NCT06296095|BIOLOGICAL|Cell therapy|Subjects were placed sequentially into three different dose groups, 5.0×107 cells/time (low-dose group), 1.5×108 cells/time (medium-dose group), and 5.0×108 cells/time (high-dose group) for dose escalation
223803462|NCT00892112|DRUG|Intravenous Immunoglobulins|2 gr/kg body weight of intravenous immunoglobulin product Nanogam® administered as 0.5 gr/kg IV over a period of 6 hours on each of 4 consecutive days
223803463|NCT00892112|DRUG|plasma volume expander|10 ml/kg BW will be administrated on four consecutive days.
224264199|NCT02752074|DRUG|pembrolizumab + epacadostat|"* Pembrolizumab will be administered intravenously every 3 weeks starting at Day 1 (Week 1)~* Epacadostat will be administered orally daily starting at Day 1 (Week 1)"
224264200|NCT02752074|DRUG|pembrolizumab + placebo|"* Pembrolizumab will be administered intravenously every 3 weeks starting at Day 1 (Week 1)~* Placebo will be administered orally daily starting at Day 1 (Week 1)"
224264201|NCT05101382|OTHER|Observation|Retrospective Observation of standard clinical practice
224264202|NCT06160804|PROCEDURE|Skeletal traction|A pin through the bone with weights attached
224264203|NCT06160804|PROCEDURE|Femoral shaft splinting|A splint of the broken thigh bone
224264204|NCT04662476|DIETARY_SUPPLEMENT|Vitamin D3|Vitamin D3 supplement
224264205|NCT04125394|DEVICE|hypertonic Sodium chloride (NaCl 5%) eye drops solution in single-dose|Ophthalmic solution of hypertonic sodium chloride (NaCl 5%) without preservatives in single-dose container
224264206|NCT04017494|DIAGNOSTIC_TEST|Cardiac Magnetic Resonance Imaging|Cardiac Magnetic Resonance Imaging (non-invasive, with i.v. application of contrast), awake or (if clinically indicated) in general anesthesia
223803464|NCT04372836|PROCEDURE|Vasopressin injection|The intervention consists of five steps: rupture the ovarian endometrial cyst and remove the ''chocolate fluid;'' inject diluted vasopressin solution into the interface between endometrioma and ovarian parenchyma; stop injecting until the solution overflow; separate the endometrioma away from the ovarian parenchyma; and coagulate bleeding spots and suture the ovary.
223803465|NCT02015494|BIOLOGICAL|VAX2012Q|Recombinant influenza HA vaccine delivered IM
223803466|NCT05838807|DEVICE|Thermal Ultrasound|Participants in this group will receive thermal ultrasound treatment using a gel-coupled ultrasound probe that delivers continuous ultrasound waves at a frequency of 1 Mega Hertz. The ultrasound probe will be moved continuously over the affected wrist and hand region for 5 minutes per session, three times per week, for four weeks. The intensity of the ultrasound wave will be set at 1.0 W/cm2 applied for 5 minutes. The treatment will be administered three times per week, for four weeks.
223803467|NCT05838807|DEVICE|Pulsed Ultrasound|Participants in this group will receive pulsed ultrasound treatment using a gel-coupled ultrasound probe that delivers pulsed ultrasound waves at a frequency of 1 Mega Hertz. The ultrasound probe will be moved continuously over the affected wrist and hand region for 15 minutes with 25% duty cycle and intensity of 1.0 W/cm2.The treatment will be administered three times per week, for four weeks.
223803468|NCT05838807|DEVICE|Combined Ultrasound|Participants in this group will receive a combination of thermal and pulsed ultrasound treatments. The thermal ultrasound treatment will be administered first for 5 minutes, followed by the pulsed ultrasound treatment for another 15 minutes. The same parameters as described above will be used for each treatment modality. The combination treatment will be administered three times per week, for four weeks.
223803469|NCT05838807|DEVICE|Placebo Ultrasound|Participants in this group will receive a placebo ultrasound treatment that looks and feels identical to the active ultrasound treatments, but does not deliver any therapeutic effects. The placebo treatment will be administered using the same gel-coupled ultrasound probe for 15 minutes per session, three times per week, for four weeks, with the intensity set at 0 W/cm² and the temperature maintained at room temperature.
223803470|NCT04111003|PROCEDURE|local anesthesia|administering local anesthesia in the region of the planned restorative procedure
223803471|NCT04111003|PROCEDURE|Tooth restored using SFRC filling|Restoration of an endodontivally treated molar using a shor-fiber base filling and veneering composite
223803472|NCT04111003|PROCEDURE|Tooth restored using Ceramic indirect endocrown|Restoration of an endodontically treated molar using a ceramic indirect restoration
223803473|NCT02857530|DRUG|rhTPO|rhTPO
223803474|NCT02857530|DRUG|placebo|without rhTPO
224264207|NCT04017494|DIAGNOSTIC_TEST|Blood draw for hematocrit and heart failure biomarkers|Approximately 10 ml of blood will be drawn before administration of contrast medium.
224264208|NCT04017494|DIAGNOSTIC_TEST|Cardiopulmonary exercise test|In patients 8 years of age or older: on a cycle ergometer with breath-by-breath analysis, continuous ECG and SpO2 monitoring during exercise, after a baseline spirometry and bodyplethysmography
224264209|NCT04017494|DIAGNOSTIC_TEST|Exhalomics|Measurement of exhaled molecules by mass spectrometry; patients breathe into a mouthpiece for 15 seconds 6 times (total time requirement: about 5 minutes)
224264210|NCT04017494|DIAGNOSTIC_TEST|Quality of life questionnaire|Questionnaire to be filled out by the Patient regarding quality of life perception
224264211|NCT02169063|RADIATION|carbon-11 acetate|Given IV
224264212|NCT02169063|RADIATION|fluorine F 18 sodium fluoride|Given IV
224264213|NCT02169063|PROCEDURE|positron emission tomography|Undergo 11C-acetate and 18F-fluoride PET
224264214|NCT02169063|OTHER|laboratory biomarker analysis|Correlative studies
224264215|NCT03692663|DRUG|TABP EIC|A single dose of 0.5, 10, and 30 million TABP EIC will be iv administered at D0, D7, and D14.
224264216|NCT03692663|BIOLOGICAL|Cyclophosphamide|Cyclophosphamide will be iv administered with 250 mg/m\^2 at D-3, D-2, and D-1 before TABP EIC infusion.
224264217|NCT03692663|BIOLOGICAL|fludarabine|Fludarabine will be iv administered with 25 mg/m\^2 at D-3, D-2, and D-1 before TABP EIC infusion.
224264218|NCT00041392|DRUG|Magnesium|100 mg/kg
224264219|NCT00041392|DRUG|0.9% saline|Placebo
224264220|NCT04908852|OTHER|Blood Sample Collection - Observational Study|Blood samples will be collected at enrollment and week 4 and used in analyses to understand associations between metabolic function and symptom experiences.
224264221|NCT04908852|OTHER|Symptom questionnaires - Observational Study|Symptom questionnaires at baseline, 1-, 2-, 3- and 4-weeks.
224264222|NCT05262985|DRUG|Durvalumab|In patients with advanced treatment naive LCNEC, treatment with Durvalumab+ Cisplatin/Carboplatin+Etoposide
224264223|NCT02574377|DRUG|A: myDC vaccination|
224264224|NCT02574377|DRUG|B: pDC vaccination|
224264225|NCT02574377|DRUG|C: combined myDC/pDC vaccination|
224264226|NCT03266380|DIAGNOSTIC_TEST|observational|All patients do an emergency brain computed tomography scan. Intracranial hypertension is treated with mannitol with or without a craniotomy. A third generation cephalosporin (ceftriaxone) and metronidazole are administered as antibiotic prophylaxis for accompanying wound injuries (skin and soft tissue). VAP preventive strategies that are performed in the ICU include daily interruption of sedation and a readiness to extubate assessment, early facilitation of mobility, elevating the head of the bed to 30- 45 degree, change of the ventilator circuit if visibly soiled or malfunctioning, stress ulcer prophylaxis, residual gastric volume monitoring, early parenteral nutrition, and deep venous thrombosis prophylaxis. An infusion of midazolam and propofol is to be used for sedation.
224264227|NCT01369927|BIOLOGICAL|Shigella Sonnei O-SPC/rBRU|
224264228|NCT00170729|DRUG|Prednisolone acetate|
224264229|NCT01160796|DRUG|placebo|1x14-day course of treatment during 4 cycles
224264230|NCT01160796|DRUG|Lcr35®|1x14-day course of treatment during 4 cycles
224264231|NCT02392195|OTHER|Non-interventional|Observational
224264232|NCT00907907|DRUG|Mycophenolate Mofetil|Mycophenolate Mofetil Tablet 500 mg
224264233|NCT00907907|DRUG|CellCept® Tablets|CellCept® Tablets, 500 mg
224264234|NCT05898607|OTHER|continuous Thoracic paravertebral block|continuous infusion U/S-Guided TPVB of 5 ml/hr of 0.125% bupivacaine started through the catheter before the surgical procedure intraoperative.
224264235|NCT05898607|OTHER|continuous Erector spinae plane block|continuous U/S-Guided ESPB of 5 ml/hr of 0.125% bupivacaine started through the catheter before the surgical procedure
223803475|NCT04721379|BEHAVIORAL|Meditation|"1. Group 1 participants with unguided session simply close their eyes for 10 minutes while EEG and EKG recordings are performed. Following 10 minutes, after briefly opening their eyes, they will be asked to relax with eyes closed for 30 minutes. After finishing the session, they fill out meditation depth questionnaire.~2. Group 2 participants with guided sessions close their eyes for 10 minutes while EEG and EKG recordings are performed. Following 10 minutes, after briefly opening their eyes, they will be guided through relaxation and meditation session for 30 minutes with a Heartfulness trainer with continued recording. After finishing the session, they also fill out meditation depth questionnaire."
223803476|NCT00378352|DRUG|Epoetin alfa|Randomized
223803477|NCT02864225|DEVICE|Scalp electrode,|the parturient will be connected to the routine fetal Doppler and to the EUM. and When necessary to the scalp electrode will be connected. Tracings will be recorded simultaneously from all three devices until delivery. three separate outputs will be processed Output of the scalp electrode recording. Output of the fetal doppler. Output of the EUM. Three noncontinuous segments of 30 minutes each with two segments occurring during the first stage of labor and the third occurring during the second stage of labor, will be randomly picked from the scalp electrode recording with 3 matching segments in time from the EUM100pro and the fetal doppler
223803478|NCT02864225|DEVICE|Fetal doppler|the parturient will be connected to the routine fetal Doppler and to the EUM. and When necessary to the scalp electrode will be connected. Tracings will be recorded simultaneously from all three devices until delivery. three separate outputs will be processed Output of the scalp electrode recording. Output of the fetal doppler. Output of the EUM. Three noncontinuous segments of 30 minutes each with two segments occurring during the first stage of labor and the third occurring during the second stage of labor, will be randomly picked from the scalp electrode recording with 3 matching segments in time from the EUM100pro and the fetal doppler
223803479|NCT02864225|DEVICE|EUM|the parturient will be connected to the routine fetal Doppler and to the EUM. and When necessary to the scalp electrode will be connected. Tracings will be recorded simultaneously from all three devices until delivery. three separate outputs will be processed Output of the scalp electrode recording. Output of the fetal doppler. Output of the EUM. Three noncontinuous segments of 30 minutes each with two segments occurring during the first stage of labor and the third occurring during the second stage of labor, will be randomly picked from the scalp electrode recording with 3 matching segments in time from the EUM100pro and the fetal doppler
223803480|NCT01738620|BEHAVIORAL|psychological counseling|
223803481|NCT01738620|BEHAVIORAL|prevention of sleep disorders in ICU|
223803482|NCT04317508|DRUG|Topicale GelPatch (Benzocaine 18%)|Intervention group
223803483|NCT04317508|DRUG|Benzocaine oral gel 20%|control group
223803484|NCT05032365|DEVICE|Close-loop FiO2 controller|Close-loop FiO2 controller software option provides automated adjustment of the ventilator Oxygen setting to maintain the patient's SpO2 in a defined target range. When using the software option, the user defines the SpO2 target range, as well as the SpO2 emergency limits, and the device adjusts the FiO2 setting to keep the patient's SpO2 in the target range.
223803485|NCT05032365|DEVICE|Conventional|Conventional FiO2 adjustment by the clinician according to SpO2 values
223803486|NCT04419090|OTHER|web-based centralized service and message|Perform three cycles of cascade screening through several generation of family members of an index case. The contact of relatives will be initiated by the index case and supported by a web-based centralized service. The index case will be provided with a prepared email or Whatsapp message that the index case can further forward to his first-degree relatives. The email/message will contain a link to a secured web application with a code for the connection. By clicking on the link, the relative will connect to a specifically designed app. The app will provide information about the transmission mode of FH, the cardiovascular risk associated with FH and the way how to reduce this risk. The relative can then fill out information and provide agreement to be contacted for the study. The nearest specialized clinic will then contact the relative to organize further screening with similar processes.
223803487|NCT01197508|DRUG|TC-5214|Twice daily for 8 weeks.
223803488|NCT01197508|DRUG|Placebo|Twice daily for 8 weeks.
223803489|NCT02264184|DRUG|Tamsulosin|
223803490|NCT02264184|DRUG|Paroxetine|
223803491|NCT05200130|OTHER|Home Exercise Group|The home exercise program includes an educational training program and posture correction exercises. The program includes stretching and strengthening exercises of the neck and shoulder complex.
223803492|NCT05200130|OTHER|Manual Therapy Group|"Manual Therapy includes deep friction massage and myofascial relaxation techniques to shoulder and neck complex, active and resistant shoulder complex movements, shoulder complex mobilization, mobilization cervical joints.~The home exercise program includes an educational training program and posture correction exercises. The program includes stretching and strengthening exercises of the neck and shoulder complex."
223803493|NCT05200130|OTHER|Telerehabilitation Group|The telerehabilitation program applied to the same home exercise group. In addition, to the home exercises, these patients will apply active mobilization called self-mobilization. Self-myofascial release, active glenohumeral joint mobilization, thoracic mobilization, and active cervical mobilization.
223803494|NCT05477758|BEHAVIORAL|Collaborative care|Participants in the intervention group were allocated a receive a low-intensity programme of behavioural activation specifically designed for adults ≥65 with subthreshold depression. An allocated case manager (primary care mental health worker/ Improving Access to Psychological Therapy) delivered collaborative care for an intended 8-10 weeks. This ran alongside general practitioner (GP) usual care. Collaborative care in both CASPER and CASPER+ trial included weakly telephone/ face-to-face support, active surveillance and symptom monitoring
223803495|NCT05477758|OTHER|Usual General Practitioner (GP) care|Participants allocated to the control group received usual GP care. Participants did not receive any additional care to their usual primary care management for subthreshold (CASPER) or Major (CASPER+) depression in line with National Institute for Health and Care Excellence (NICE) guidelines as implemented in their GP and local service provision.
223803496|NCT05477758|BEHAVIORAL|Behavioral Activation Self-Help guide|Participants in the intervention arm were provided with a self-help booklet based on clear principles of BA for depression. The purpose of the booklet was to introduce simple behavioural strategies for improving mood. Participants were encouraged to (1) re-establish their daily routine, (2) increase meaningful activities and (3) reduce avoidance behaviours. Participants also received 3 phone calls at week 1, 3 and 6 designed to check the booklet had arrived and to encourage the use of the materials. All participants received their usual GP care
223803497|NCT03170011|BEHAVIORAL|Exercise using the Biodex Sit2Stand Trainer|Week 1-2 - Focused on lower intensity, higher volume, comfortable/self-selected velocity Week 3-4 - Focus on higher intensity, lower volume, comfortable/self-selected velocity Week 5 - Focus on moderate intensity, moderate volume, transitioning to higher velocity Week 6 - Focus on moderate intensity, moderate volume, high velocity
223803498|NCT00266825|DRUG|DHA|600 mg DHA
223803499|NCT00266825|OTHER|Placebo capsule|Placebo capsule
223803500|NCT04688424|DEVICE|FES|FES will be applied via surface electrodes placed over bilateral quadriceps muscles. FES-stimulation will be ramped from sensory level (the level at which the individual feels a cutaneous sensation from the stimulation) to the maximum-tolerated level using a closed loop system controlled by computer software Subjects will exercise at home, three times per week, with FES on for 8 weeks with a goal of attaining 30 minutes of continuous cycling per session. If the individuals are unable to cycle for 30 continuous minutes, rest breaks will be provided with a goal of cycling for a total of 30 minutes. The length of each session will be approximately 45 minutes, with 15 minutes of set-up and 30 minutes of cycling.
223803501|NCT04688424|OTHER|Cycling|Subjects will exercise at home, three times per week, without FES for 8 weeks with a goal of attaining 30 minutes of continuous cycling per session. If the individuals are unable to cycle for 30 continuous minutes, rest breaks will be provided with a goal of cycling for a total of 30 minutes. The length of each session will be approximately 45 minutes, with 15 minutes of set-up and 30 minutes of cycling.
223803502|NCT04452292|OTHER|Treatment Specific for Non-Small Cell Carcinoma/Adenocarcinoma|Treatment assigned to targetable mutation. Or, for tumors that are by and large without any targetable mutation follow Large-Cell Neuroendocrine Carcinoma (NCCN) guideline-directed best front-line treatment for specific non-small cell carcinoma/adenocarcinoma.
223803503|NCT04452292|OTHER|Treatment for Small Cell Lung Cancer|Treatment assigned to a targetable mutation or the current standard-of-care regimen for the treatment of small cell lung cancer.
223803504|NCT01301391|DRUG|Milciclib Maleate|"150 mg/day once daily, for 7 consecutive days (days 1 to 7) followed by 7 days of rest (days 8 to 14) in a 2-week cycle.~Number of cycles: until disease progression or unacceptable toxicity."
223803505|NCT01782443|DRUG|Ziv-aflibercept|
223803506|NCT00153998|DRUG|Cetuximab|
223803507|NCT00153998|PROCEDURE|Liver resection|
223803508|NCT00153998|DRUG|Cetuximab and FOLFIRI|"Cetuximab 400 mg/m² (2.0 h i.v.) (first dose only), followed by:~Cetuximab 250 mg/m² (1.0 h i.v.) weekly~Irinotecan 180 mg/m² (2.0 h i.v.) all compounds day 1, repeated at day 15 Folinic acid (D,L) 400 mg/m² (2.0 h i.v.) 5-FU 400 mg/m² (bolus i.v.) 5-FU 2400 (-3000) mg/m² (46 h i.v.)"
223803509|NCT00153998|DRUG|Cetuximab and FOLFOX|"Cetuximab 400 mg/m² (2.0 h i.v.) (first dose only), followed by:~Cetuximab 250 mg/m² (1.0 h i.v.) weekly~Oxaliplatin 100 mg/m² (2.0 h i.v.) all compounds day 1, repeated at day 15 Folinic acid (D,L) 400 mg/m² (2.0 h i.v.) 5-FU 400 mg/m² (bolus i.v.) 5-FU 2400 (-3000) mg/m² (46 h i.v.)"
223803510|NCT03671174|DRUG|Prednisone|10mg once daily orally
223803511|NCT03671174|DRUG|Hydroxychloroquine|100mg to 200mg twice daily orally
223803512|NCT03671174|DRUG|Aspirin|50mg once daily orally
223803513|NCT03671174|DRUG|low molecular weight heparin|Enoxaparin 40mg once daily subcutaneous or dalteparin 5000IU once daily subcutaneous or nadroparin calcium 4100U once daily subcutaneous
223803514|NCT02448940|DIETARY_SUPPLEMENT|Species of Lactobacillus|2 capsule a day Lactofem probiotics containing Species of Lactobacillus
223803515|NCT02448940|DIETARY_SUPPLEMENT|lactose|2 capsule a day containing lactose
223803516|NCT02430467|BEHAVIORAL|Caregiver-guided pain management training (CG-PMT)|Patient-caregiver dyads in the CG-PM arm of the study will receive 3 50-minute sessions via Skype with a masters-level therapist over a 3-week period. The intervention integrates educational information about cancer pain and its management with a behavioral training program to teach patients and caregivers pain coping skills including relaxation, imagery, and activity pacing, and to teach caregivers how to guide and coach the patient in the practice and application of these pain control techniques.
223803517|NCT02430467|BEHAVIORAL|Enhanced treatment-as-usual (TAU)|Patient-caregiver dyads in the Enhanced TAU condition will receive the same educational video and booklet on cancer pain and its management that is used as part of the CG-PMT intervention. They will also receive iPads with icons linked to reputable websites that provide educational information on cancer including cancer pain (e.g., ACS, NCI) and will be encouraged to utilize them for information and support. However, they will not meet with a study interventionist nor receive any training in behavioral pain coping skills.
223803518|NCT04128644|BEHAVIORAL|Thoughts & health|12 sessions of Thoughts \& Health. Baseline questionaires and follow up assessments
224264236|NCT05351892|DRUG|Elinzanetant (BAY3427080)|Soft gel capsule, oral
224264237|NCT05026294|OTHER|plyometric exercises|Exercises for strength and flexibility
224264238|NCT05026294|OTHER|Exercises for flat feet rehabilitation|Exercises for intrinsic muscles strength
224264239|NCT06164860|OTHER|Meditteranean Diet|The MD provided 20% proteins, 40% fat and 40% carbohydrates. Each participant received a brochure with a template of a daily five course (breakfast, lunch, dinner and two snacks) diet plan that provided several options for each meal and was advised to use it as a guide for the 8-week period
224264240|NCT06164860|OTHER|Ketogenic Diet|The KD provided approximately 34% proteins, 55% fat and 11% carbohydrates. The macronutrient targets were successfully met by replacing breakfast and two daily snacks with specifically selected food products provided by Evivios Med. Lunch and dinner were natural protein-rich dishes. Each participant received accurate teaching and a brochure that incorporated a template of a weekly diet plan from an expert dietitian.
224264241|NCT01561391|DRUG|activated recombinant human factor VII|Infused continuously at 50 mcg/kg/hr through Day 5 then at 25 mcg/kg/hr on Days 6 to10.
224264242|NCT01561391|DRUG|activated recombinant human factor VII|Injected every 2 hours during surgery through Day 5, then every 4 hours for Days 6 to 10.
224264243|NCT01561391|OTHER|factor IX|Patients with haemophilia A or B without inhibitors undergoing similar surgery were treated in accordance with local standard of care per physician's orders.
224264244|NCT01561391|DRUG|factor VIII|Patients with haemophilia A or B without inhibitors undergoing similar surgery were treated in accordance with local standard of care per physician's orders.
224264245|NCT01783366|DEVICE|TUBE EXCHANGER|
224264246|NCT00545792|DRUG|Avastin|Avastin will be administered intravenously (vein) at 10mg/kg every two weeks starting day 1 for a total of 3 doses.
223803519|NCT04128644|OTHER|Treatment as Usual|Baseline questionnaires and follow up assessments, intervention as usual, Student Health
223803520|NCT03088592|DEVICE|Deep Brain Stimulation|Subjects will have awake or asleep DBS surgery with STN or GPi placement. Microelectrode recordings will define the electrophysiological target prior to lead implantation. Cortical recordings will be done using µECoG grids (2.0 x 0.8 cm) placed over the cortex through the same burr hole used for lead implantation. Neural recordings will be made continuously throughout the procedure: before, during, and after DBS, and at all levels of anesthesia. A pulse generator will be connected and implanted either during the operation or within 7-10 days post-operatively. Subjects will be admitted overnight for observation with anticipated discharge the next morning. The researchers will also be collecting other routine data points (length of surgery, stereotactic accuracy, length of hospital stay, and post-operative complications).
223803521|NCT02629991|DRUG|Intranasal Oxytocin (IN-OXT)|Participants were instructed to take 16 IU/per day everyday (2 puffs per nostril, 4 IU each puff).
223803522|NCT02629991|OTHER|Matched Placebo|Participants were instructed to take 16 IU/per day everyday (2 puffs per nostril, 4 IU each puff).
223803523|NCT00306033|DRUG|Intravenous ImmuneGlobulin|
223803524|NCT03718689|DEVICE|Laser etching|Acid etching
223803525|NCT01122082|BEHAVIORAL|food preloads|Subjects will eat in the morning during breakfast 300g cottage cheese (627kJ - 147kcal; 13.2g carbohydrate, 0.3g fat, 23g protein) plus, according to the situations, either: 90g sucrose, HCB); 6g aspartame; 40g vegetable oil; 40g paraffin oil. Therefore two breakfast will have the same energy content (2072kJ - 495kcal), as did the other two(565 kJ - 135kcal).
223803526|NCT01257776|DRUG|Autologous adipose derived mesenchymal stem cells|Intra-arterial administration through a selective cannulation of target common femoral artery
223803527|NCT02799784|DRUG|UMEC/VI|ELLIPTA dry powder inhaler (DPI) will contain a total of 30 doses. Each DPI will be comprised of two double-foil, laminate blister strips. Each blister of one strip will consist of 62.5 mcg of UMEC blended with lactose and magnesium stearate while each blister of other strip will consist of 25 mcg of VI blended with lactose and magnesium stearate. Each actuation of the DPI will deliver the contents of one blister from each strip simultaneously
223803528|NCT02799784|DRUG|TIO/OLO|TIO/OLO inhalation spray will be supplied as an inhalation spray delivered using a RESPIMAT inhaler. Each actuation from the RESPIMAT inhaler delivers 3.124 mcg tiotropium bromide monohydrate (equivalent to 2.5 mcg tiotropium) and 2.736 mcg olodaterol hydrochloride (equivalent to 2.5 mcg olodaterol)
223803529|NCT02799784|DRUG|Albuterol/salbutamol|Albuterol/salbutamol will be supplied as an inhalation spray via metered dose inhaler and will be issued for reversibility testing at Visit 1. Albuterol/salbutamol will be permitted throughout the study for use as-needed
223803530|NCT04636372|DEVICE|Intense pulsed light therapy|Patients with xerophthalmia were treated with intense pulsed light of meibomian gland.
223803531|NCT04636372|OTHER|Hot compress massage|Patients with xerophthalmia were treated with hot compress massage of meibomian gland.
223803532|NCT00003835|DRUG|leucovorin calcium|Given IV
223803533|NCT00003835|DRUG|fluorouracil|Given IV
223803534|NCT00003835|DRUG|irinotecan hydrochloride|Given IV
223803535|NCT00003835|OTHER|laboratory biomarker analysis|Correlative studies
223803536|NCT05635578|BEHAVIORAL|sleep|reiki
223803537|NCT03769402|DRUG|Citric acid|Citric acid ph1, 50% concentration solution
223803538|NCT03769402|DRUG|Control Test|Control group, xenograft was used to fill infrabony defects without treating bone surface
223803539|NCT04068350|OTHER|Pain questionnaire|Pain questionnaire, 3 months after surgery
223803540|NCT03458884|OTHER|Cardiorespiratory interval training|A structured cardiorespiratory interval training program on an ergometer cycle 3 days a week for 8 weeks.
223803541|NCT02098213|OTHER|Immediate spa treatment|soon after randomization: Spa treatment of 3 weeks. Spa treatment : that best adapted to the concerned pathology and common to all participating of spa resorts (walk in a specially pool, whirlpool bath with automatic air and water massages cycles, massaging shower etc)
223803542|NCT02098213|OTHER|Late Spa treatment|soon after 4,5 months visit: Spa treatment of 3 weeks. Spa treatment : that best adapted to the concerned pathology and common to all of spa resorts (walk in a specially pool, whirlpool bath with automatic air and water massages cycles, massaging shower etc)
223803543|NCT03447080|OTHER|Control|White Bread containing 50g carbohydrate
223803544|NCT03447080|OTHER|Control|White Bread containing 50g carbohydrate
223803545|NCT03447080|OTHER|Ricebran soybean milk|White Bread with rice bran soybean milk
223803546|NCT03447080|OTHER|Soybean milk|White Bread with soybean milk
223803547|NCT06086379|BEHAVIORAL|Compensatory Cognitive Training for COVID-19|CCT-C is a manualized group-based behavioral intervention (10 weeks, 2 hours per week, 20 hours total) designed to improve cognition and everyday functioning in patients with prolonged COVID-19 symptoms
223803548|NCT06086379|BEHAVIORAL|Holistic Cognitive Education|HCE provides the same frequency and amount of therapist and other group member contact as CCT-C, but does not provide training in cognitive or lifestyle strategies addressed in CCT-C. The HCE intervention provides information and discussion regarding common causes of and treatments for cognitive impairment.
223803549|NCT01291784|BIOLOGICAL|monoclonal antibody to TGF-beta|starting dose of 1mg/kg intravenous over approximately 1 hour every 4 weeks for a total of 6 doses
223803550|NCT00075062|PROCEDURE|Flexible Sigmoidoscopy|
223803551|NCT00075062|PROCEDURE|Rectal Biopsy|
223803552|NCT00345449|BEHAVIORAL|Decision Aid|
223803553|NCT01292954|DIETARY_SUPPLEMENT|Blueberries|low dose: 31.4 g of freeze dried blueberry reconstituted in water medium dose: 57 g of freeze dried blueberry reconstituted in water high dose: 80 g of freeze dried blueberry reconstituted in water Placebo: sugars and vitamin c match control in water Frequency:1 single time Total Duration: 3 days study over 3 weeks period
223803554|NCT03475550|OTHER|Standard of Care|The intervention involves clinician-provided information to patients receiving a new medication as part of their standard medical care. Intervention 1 includes more detailed information compared to Intervention 2.
223803555|NCT02570126|BIOLOGICAL|Varilrix HSA-free|2 doses will be administered, one at Day 0 and the other at Day 42
223803556|NCT02570126|BIOLOGICAL|Varilrix™|2 doses will be administered, one at Day 0 and the other at Day 42
223803557|NCT00048464|PROCEDURE|Infusion of Activated & Expanded Autologous T Cells|
223803558|NCT00917579|DRUG|Atorvastatin|A single 10 mg dose of marketed 10 mg atorvastatin tablets
223803559|NCT00917579|DRUG|Atorvastatin|A single 10 mg dose of new formulation of 10 mg atorvastatin
223803560|NCT05311800|OTHER|Physical activity|Comparison of HIIT mode (running vs cycling)
223803561|NCT02351804|DRUG|Ropivacaine + dexamethasone|Adductor canal block, single bolus
223803562|NCT02351804|DRUG|Ropivacaine + placebo|Adductor canal block, single bolus
223803563|NCT02892812|BIOLOGICAL|Pneumococcal conjugate vaccine|
223803564|NCT04329754|DEVICE|Cataract surgery|Cataract surgery with implantation of an intraocular lens (IOL)
223803565|NCT02872701|DRUG|OTL38 for Injection|Folate analog ligand conjugated with an indole cyanine-like green dye as a solution in vials containing 3 mL at 2 mg/mL
223803566|NCT02872701|DEVICE|Near infrared camera imaging system|Near infrared camera imaging system
223803567|NCT02872701|PROCEDURE|Endoscopic or Thoracic Surgery|Endoscopic or Thoracic Surgery
223803568|NCT03594565|DRUG|Fluticasone Propionate|Local Fluticasone Propionate use prior to continuous glucose monitoring system insertion
223803569|NCT00187226|PROCEDURE|Radiation Therapy|External Beam Radiation Therapy: 54Gy administered at 1.8Gy per day for low-grade glioma, craniopharyngioma and selected ependymoma.
223803570|NCT00187226|PROCEDURE|Radiation Therapy|External Beam Radiation Therapy: 59.4Gy administered at 1.8Gy per day for high-grade glioma and selected ependymoma.
223803571|NCT03963674|OTHER|Diacutaneous fibrolysis|Diacutaneous fibrolysis over the gastrocnemious muscles
223803572|NCT00941993|DEVICE|Iontophoresis System (Acclarent)|Iontophoresis system will deliver iontophoresis simultaneously to both ears. Active elements of this drug delivery system are lidocaine and epinephrine.
223803573|NCT01235546|DRUG|Azithromycin and standard of care|500 mg in 250 cc normal saline 1 time dose plus standard of care (cephazolin or clindamycin)
223803574|NCT01235546|DRUG|Placebo and standard of care|250 cc normal saline, plus standard of care (cephazolin or clindamycin)
223803575|NCT00885196|DRUG|Placebo|
223803576|NCT00885196|DRUG|AEB071|
223803577|NCT06087341|OTHER|NKG2D-CAR memory T cell|Patients will be allocated in two groups: Arm A and Arm B. Both groups will receive an intravenous infusion of NKG2D-CAR memory T cells. Additionally, patients on Arm B will receive an intratumoral dose of NKG2D-CAR memory T cells (in accessible primary tumor and metastases). The distribution of patients on one arm or other will depend on their clinical characteristics described in the inclusion/ exclusion criteria. All patients will receive lymphodepleting chemotherapy prior to the infusion of NKG2D-CAR memory T cells according to the usual clinical practice in our center. Some patients will also receive low dose radiotherapy prior to infusion.
223803578|NCT05886400|OTHER|SCAT6|The SCAT6 is a standardized assessment tool to diagnose a concussion. This tool will be used for the experiment utilizing the 6th edition to recreate the methods used in an athletic situation. The SCAT6 is broken down into multiple subtests to focus on specific aspects of a person's wellbeing that could be affected by a possible concussion. The assessments are created to measure an athlete's subjectively experienced symptoms, cognitive functioning and balance and postural stability (mBESS).
223803579|NCT05886400|OTHER|Visual/ Auditory Distraction|The purpose of this study is to examine the effect of environmental distractions on one's ability to complete the SCAT6. The environmental distractions will be visual and auditory by playing a sports event or sports clips during the completion of the assessment. The goal of this is to simulate the distraction of a sideline like a SCAT6 is typically used within athletic training.
223803580|NCT00319748|DRUG|852A|0.2% 852a subcutaneous injection, 2 times per week for 12 weeks (24 doses) starting at 0.6 mg/m2; subsequent dose escalation for additional courses may be increased by 0.2 mg/m2 not to exceed 1.2 mg/m2.
223803581|NCT04354987|DRUG|CKD-391 10/10mg|Drug T: CKD-391 10/10mg(Other Name: Test Drug)
223803582|NCT04354987|DRUG|D090, D337|D090 and D337 co-administration(Other Name: Reference drug)
223803583|NCT01256411|DRUG|LCZ696|Participants received LCZ696 200 mg as the starting dose with optional down titration to 100 mg for tolerance and optional up titration to 400 mg for adequate blood pressure control.
223803584|NCT01256411|DRUG|Amlodipine|Optional add-on of amlodipine (5-10 mg) was allowed (as applicable per local country regulations) for adequate blood pressure control.
223803585|NCT01256411|DRUG|Hydrochlorothiazide (HCTZ)|Optional add-on of hydrochlorothiazide (HCTZ) (12.5-25 mg) was allowed (as applicable per local country regulations) for adequate blood pressure control.
223803586|NCT02740049|DRUG|VR588|Evaluation of the efficacy of a novel JAK/STAT inhibitor, VR588, in isolated epithelial cells from asthma patients
223803587|NCT01989026|BIOLOGICAL|BCG|
223803588|NCT05305287|DRUG|Pioglitazone|An insulin sensitizer and anti-diabetic agent. Participants will be started on 15 mg/day, increased to 30 mg/day at week 2 and then to 45 mg/day at week 4.
223803589|NCT05305287|OTHER|Placebo|Placebo for pioglitazone
223803590|NCT04042155|DRUG|dabigatran, rivaroxaban, apixaban or edoxaban|Record of all serious complications associated with any of the drugs and the clinical changes that occurred during prospective follow-up.
223803591|NCT04102202|DRUG|BOL-DP-o-05|BOL-DP-o-05
223803592|NCT04102202|DRUG|Placebo|Placebo
223803593|NCT06580522|OTHER|Prone Position Group|After the children in the prone position group were weaned from noninvasive mechanical ventilation according and started to breathe spontaneously, they were prone positioned and monitored for 120 minutes (2 hours) every 20 minutes (0.min, 20.min, 40.min, 60.min, 80.min, 100.min, 120.min) with a head-monitor for peak heart rate, oxygen saturation, respiratory rate and blood pressure.
223803594|NCT06580522|OTHER|Supine Position Group|After the children in the supine position group were weaned from noninvasive mechanical ventilation according and started to breathe spontaneously, they were supine positioned and monitored for 120 minutes (2 hours) every 20 minutes (0.min, 20.min, 40.min, 60.min, 80.min, 100.min, 120.min) with a head-monitor for peak heart rate, oxygen saturation, respiratory rate and blood pressure.
223803595|NCT04431193|DRUG|Oxytocin|Oxytocin infused to maintain serum concentrations of 4, 16, 64, and 256 picogram/millilitre
223803596|NCT03087565|PROCEDURE|subtotal hystrectomy|"A transverse lower abdominal incision (Pfannenstiel incision) The corpus is amputated just below the level of the isthmus and then the endocervical canal is electrocoagulated using monopolar electrocautery. The cervical stump is closed using vicryl 0 sutures.~Revision of all pedicles to ensure hemostasis. Intraoperative antibiotics . The abdomen is closed in layers; the wound is covered with a sterile dressing."
223803597|NCT03087565|PROCEDURE|Total hystrectomy|"A transverse lower abdominal incision (Pfannenstiel incision) The urinary bladder is dissected off the lower uterine segment of the uterus and cervix by blunt or sharp dissection. Revision of all pedicles to ensure hemostasis.~The abdomen is closed in layers; the wound is covered with a sterile dressing."
223803598|NCT06579924|PROCEDURE|Disposable mini-PCNL|Mini-PCNL carried out using disposable scope
223803599|NCT06579924|PROCEDURE|Re-usable mini-PCNL|Mini-PCNL carried out using re-usable scope
223803600|NCT05338099|DRUG|EN001|"EN001 intravenously (IV) in the treatment of Duchenne Muscular Dystrophy (DMD) Dosage for each group is as follows.~Dose group A (Low dose): 5.0x10\^5 cells/kg"
223803601|NCT05338099|DRUG|EN001|"EN001 intravenously (IV) in the treatment of Duchenne Muscular Dystrophy (DMD) Dosage for each group is as follows.~Dose group B (High dose): 2.5x10\^6 cells/kg"
223803602|NCT02310529|BEHAVIORAL|Interpersonal Psychotherapy|"Interpersonal Psychotherapy will be delivered to Intervention group. The intervention group will be further divided into 3 groups (8 depressed mothers in each group).IPT is 12-16 week treatment, contains a supportive element, an educational element, parenting element and an interpersonal relationship element. Its goals include helping mothers feel supportive, empowered and confident about their parenting abilities, which will directly influence in reducing their depressive symptoms as well as resolution of interpersonal conflicts. Groups will assist people who have become withdrawn, isolated and disconnected.~Intervention will be delivered by trained clinical psychologists."
223803603|NCT02545777|DRUG|diclofenac sodium enteric-coated|
223803604|NCT02545777|DRUG|Oral medicine of tonifying spleen and descending turbid|Ingredient:cortex phellodendrine, rhizoma atractylodis, radix cyathula, coix seed, cotton Bi Xie,rhizoma smilacis glabrae
223803605|NCT02545777|DRUG|Steeping and washing medicine of descending turbid and clearing heat|Ingredient: turmeric, rhubarb, cortex phellodendrine, rhizoma atractylodis, rhizoma arisaema, angelica dahurica,garden balsam stem, pseudobulbus cremastrae seu pleiones
223803606|NCT02545777|DRUG|Wet wrapping medicine of descending turbid and clearing heat|Ingredient:turmeric, rhubarb, cortex phellodendrine, rhizoma atractylodis, rhizoma arisaema, angelica dahurica, pseudobulbus cremastrae seu pleiones.
223803607|NCT05088070|DRUG|SPH 3348|2 tablets of 8mg SPH3348 will be orally administered once a day with empty stomach
223803608|NCT05088070|DRUG|SPH 3348|1 tablet of 40mg SPH3348 will be orally administered once a day with empty stomach
223803609|NCT05088070|DRUG|SPH 3348|2 tablets of 40mg SPH3348 will be orally administered once a day with empty stomach
223803610|NCT05088070|DRUG|SPH 3348|4 tablets of 40mg SPH3348 will be orally administered once a day with empty stomach
223803611|NCT05088070|DRUG|SPH 3348|6 tablets of 40mg SPH3348 will be orally administered once a day with empty stomach
223803612|NCT05088070|DRUG|SPH 3348|8 tablets of 40mg SPH3348 will be orally administered once a day with empty stomach
223803613|NCT06374446|OTHER|Classical Treatment|This group in our study exercises 2 days a week, 2 repetitions a day, 3 sets of 15 repetitions for 6 weeks. Upper and lower extremity exercises are available, including shoulder flexion and abduction, hip and knee exercises. Active breathing cycle is used as breathing exercises. Active respiratory cycle; Includes breathing control, thoracic expansion exercises and huffing. These are done for 6 weeks, along with upper and lower extremity exercises. All evaluations are made at the beginning and end of the groups.
223803614|NCT06374446|OTHER|Virtual Reality Combined with Classical Treatment|This group in our study exercises 2 days a week, 2 repetitions a day, 3 sets of 15 repetitions for 6 weeks. Upper and lower extremity exercises are available, including shoulder flexion and abduction, hip and knee exercises. Active breathing cycle is used as breathing exercises. Active respiratory cycle; Includes breathing control, thoracic expansion exercises and huffing. These are done for 6 weeks, along with upper and lower extremity exercises. In addition, individuals can take a 30-minute walk in the forest, do yoga, etc. with virtual reality glasses. Videos for relaxation will be shown. All evaluations will be made at the beginning and end of the groups.
223803615|NCT06374446|OTHER|Virtual Reality|Individuals in this group are given 30-minute walks in the forest, yoga, etc. with virtual reality glasses, 2 days a week, 2 times a day for 6 weeks. Videos for relaxation will be shown. All evaluations will be made at the beginning and end of the groups.
223803616|NCT06374446|OTHER|Control Group|This group will be given a handbook explaining the importance of exercise in individuals with long-term symptoms after Covid.
223803617|NCT00189215|DEVICE|cardiac stabilizer instead of cardiopulmonary bypass|
223803618|NCT02316769|PROCEDURE|King Vision video laryngoscope|Patient intubated with the King Vision Video Laryngoscope
223803619|NCT02316769|PROCEDURE|McGrath MAC video laryngoscope|Intubation with the McGrath MAC video laryngoscope
223803620|NCT00500877|BEHAVIORAL|Mood Management Phone Counseling for Smoking Cessation|Phone counseling addressed mood management and smoking cessation
223803621|NCT00885092|DEVICE|FID 114675A Multi-Purpose Disinfecting Solution (MPDS)|Investigational solution intended for use as a cleaning, rinsing, conditioning, disinfecting, and storage solution for silicone hydrogel (SiH) contact lenses.
223803622|NCT00885092|DEVICE|RepleniSH Multi-Purpose Disinfecting Solution (MPDS) (OPTI-FREE® RepleniSH®)|Commercially marketed solution intended for use as a cleaning, conditioning, rinsing, disinfecting, and storage solution for all silicone hydrogel and soft (hydrophilic) contact lenses.
223803623|NCT00885092|DEVICE|Senofilcon A contact lens (ACUVUE® Oasys™)|Commercially marketed silicone hydrogel contact lens for daily wear use
223803624|NCT00885092|DEVICE|Balafilcon A contact lens (PureVision®)|Commercially marketed silicone hydrogel contact lens for daily wear use
223803625|NCT00946439|DEVICE|Wheel assisted running training|'Race-Runner' uses the principle of body weight reduction and wheel assisted running training. This is a three-wheel device specifically designed in the 1990s for athletic purposes. The participant is walking or running with the feet on the ground while using a triangular frame equipped with three large bicycle wheels. Support to the participant's body is provided by a regular cycle saddle, a frontal body support plate, and the steering handlebars. The vertical and horizontal distance of the saddle and frontal support from the steering handlebars are adaptable to the participant's body dimension and comfort. This equipment is commonly used in competition in Scandinavia and Central Europe
223803626|NCT06525493|PROCEDURE|Regional Anesthesia|The interventions are three different regional anesthesia techniques: Proximal Adductor Canal Block (ACB), iPACK (Interspace between the Popliteal Artery and the Capsule of the Posterior Knee), and Large-Volume Distal Adductor Canal Block (Large ACB distal). all three interventions were administered using ropivacaine 0.2%. However, there were differences in the volumes injected for each regional anesthesia technique. Proximal ACB: 15 mL of ropivacaine 0.2%. iPACK: 20 mL of ropivacaine 0.2%. Large ACB distal: 35 mL of ropivacaine 0.2%
223803627|NCT01911728|DRUG|MDV3100|Oral
223803628|NCT01911728|DRUG|Pioglitazone|Oral
223803629|NCT01911728|DRUG|Warfarin|Oral
223803630|NCT01911728|DRUG|Omeprazole|Oral
223803631|NCT01911728|DRUG|Midazolam|Oral
223803632|NCT06103214|OTHER|acute normovolemic hemodilution (ANH)|Acute normovolemic hemodilution (ANH) is a medical procedure that involves removing a certain volume of blood from a patient before surgery and replacing it with a volume expander or blood substitute. The goal of ANH is to reduce the need for blood transfusions during or after surgery. During the ANH procedure, a patient's blood is typically withdrawn and replaced with a crystalloid or colloid solution. This dilutes the patient's blood, reducing the concentration of red blood cells. The withdrawn blood is then stored and can be reinfused back into the patient after the surgical procedure is completed.
223803633|NCT06103214|OTHER|acute hypervolemic hemodilution (AHH)|The purpose of diluting the blood with fluids and removing some of the red blood cells is to decrease the viscosity of the blood. This can improve blood flow and oxygen delivery to tissues, especially in cases of decreased blood flow or oxygenation.
223803634|NCT02213562|DIETARY_SUPPLEMENT|200 mg of chrysanthemum flower oil|
223803635|NCT02213562|DIETARY_SUPPLEMENT|300 mg of chrysanthemum flower oil|
223803636|NCT02213562|DIETARY_SUPPLEMENT|400 mg of chrysanthemum flower oil|
223803637|NCT00212381|DRUG|di indolylmethane (DIM)|This is the agent being studies. Similar agents have been reported to have potential activity.
223803638|NCT00212381|DIETARY_SUPPLEMENT|Red rice bran|"this will act as the active comparator. The sponsor provided this as the placebo arm since it is a filler component of their DIM capsules"
223803639|NCT03520595|DRUG|Arnica 200 drug 3 pills,3 times daily for 3 days|CLP with ostectomy done in patients whose biologic width and crown height is insufficient
223803640|NCT03520595|DRUG|Diclofenac Sodium 50mg twice daily|CLP with ostectomy done in patients whose biologic width and crown height is insufficient
223803641|NCT03520595|DRUG|Placebo pills and distilled water 3 pills,3 times daily|CLP with ostectomy done in patients whose biologic width and crown height is insufficient
223803642|NCT04996615|OTHER|no intervention|no intervention
223803643|NCT03388749|DRUG|Liposomal Annamycin|2-hour intravenous infusion liposomal annamycin daily for 3 consecutive days followed by 18 days off study drug (i.e., one treatment cycle = 21 days).
223803644|NCT02613819|RADIATION|SABR|"Renal cell carcinoma (RCC) is conventionally considered radioresistant to fully fractionated EBRT. In an effort to overcome the perceived radioresistance of RCC, severely hypofractionated External beam radiation therapy (EBRT) in the form of stereotactic radiotherapy will be used in the management of renal cell carcinoma with radiotherapy."
223803645|NCT00288483|DRUG|Policosanol|
223803646|NCT04032665|DIAGNOSTIC_TEST|Rivaroxaban|In stable CAD/PAD patients with previous PCI and DES-implantation treated with DAPT (ASA+clopidogrel) platelet rich plasma (PRP) and washed platelets as well as serum/plasma/urinary samples will be collected between 2 and 4 weeks before switching from DAPT to ASA + rivaroxaban (2,5 mg b.i.d.), between 2 and 4 weeks under monotherapy with ASA 100mg o.d., and between 2 and 4 weeks under therapy with ASA 100mg o.d. + rivaroxaban (2,5 mg b.i.d.) and treated ex vivo with rivaroxaban to asses platelet activation and function, platelet-triggered thrombin generation and platelet-dependent vascular inflammation.
223803647|NCT03390699|DIAGNOSTIC_TEST|Microbial profile|microbiological testing
223803648|NCT01161979|DRUG|Zonisamide|Zonisamide capsules 100 mg
223803649|NCT01161979|DRUG|Zonegran|Zonegran Capsules 100 mg of EISAI INC
223803650|NCT04535947|DRUG|Vehicle|Investigational product (IP) will be administered via topical ocular instillation, one drop per eye, twice daily (BID) for 8 weeks (56 days). Both eyes will be treated.
223803651|NCT04535947|DRUG|SDP-4 Ophthalmic Solution (1.0%)|Investigational product (IP) will be administered via topical ocular instillation, one drop per eye, twice daily (BID) for 8 weeks (56 days). Both eyes will be treated.
223803652|NCT04309045|BEHAVIORAL|DBT|Today, the most well-known and established treatment for borderline personality disorder is Dialectical Behavior Therapy (DBT) that developed by Marsha Linhan in the 1990s. DBT is currently used in other disorders such as: eating disorders, addictions, impulse control problems and bipolar disorder. Various studies have found a beneficial effect for this treatment in various areas: decreased suicidal thoughts and attempts and self-harm behaviors, improvements in suicide attempts, anger levels, impulsive behaviors, depressive symptoms, The use of drugs, the percentage of dropouts from treatment, number Hospitalization and general function.
223803653|NCT04309045|BEHAVIORAL|DDP|DDP treatment is part of a trend of dynamic therapies to treat borderline personality disorder. The DDP focuses on deficiencies in the emotional experience processing and is performed in the form of weekly, individual sessions with a trained therapist over a 12-18 month period. Treatment is based on the need to correct three neurocognitive functions responsible for adaptive processing of emotional experiences: association (the ability to recognize, understand their existence, and experience a sequence of emotional experiences), attribution (the ability to make complex attributions about the self and others), and the ability to make realistic attribution, about the self and the other. Interventions that activate these three functions are the basis for DDP treatment.
223803654|NCT04309045|OTHER|control group|Patients on the waiting list for treatment, or patients in the hospital under routine care.
223803655|NCT00995501|DRUG|Dexamethasone Sodium Sulfate|8 mg given 1-2 hours before surgery (incision time), 4 mg on the first postoperative morning, and 2 mg on the second postoperative morning
223803656|NCT00995501|DRUG|Insulin|Insulin to maintain blood glucose 80-110 mg/dl.
223803657|NCT00995501|DRUG|anesthesia management|Light anesthesia to maintain BIS about 55
223803658|NCT00995501|OTHER|Dexamethasone - placebo|8 mg given 1-2 hours before surgery (incision time), 4 mg on the first postoperative morning, and 2 mg on the second postoperative morning
223803659|NCT00995501|OTHER|Insulin - Placebo|Insulin to maintain blood glucose 180-200 mg/dl.
223803660|NCT00995501|OTHER|Anesthesia management -Placebo|Deep anesthesia to maintain BIS about 35
223803661|NCT05241964|BIOLOGICAL|PRP|4\~6ml autologous platelet rich plasma injection every 14±2 days for a total of 5 injections.
223803662|NCT06063798|OTHER|General anesthesia for laryngotracheal surgery|Patients undergoing general anesthesia and mechanical ventilation.
223803663|NCT06063798|OTHER|Mechanical ventilation by FCV|Mechanical ventilation is assured by Flow-controlled ventilation mode.
223803664|NCT06063798|OTHER|Mechanical ventilation by HFJV|Mechanical ventilation is assured by High frequency jet ventilation mode.
223803665|NCT03002610|OTHER|Pls|Text format with simple explanation of the survey topic main findings and is intended for lay audience.
223803666|NCT03002610|OTHER|Infographics|Cochrane started developing infographics, where short textual information about research is supported by visual representations of the main findings and is also aimed at the lay public The investigators will examine whether this format is better in information uptake than standard PLS.
223803667|NCT03002610|OTHER|Scientific abstract|Scientific abstract the text written for the academic population and practitioners, with scientific abbreviations which enables experts to go into more detail about the topic.
223803668|NCT01017354|DRUG|Hidroferol® (ES)|24000 IU vitamin D3 orally and once per month plus 300 mcg 25(OH)D orally and once per month
223803669|NCT01017354|DIETARY_SUPPLEMENT|ViDe3 (CH)|60000 vitamin D3 orally and once per month
223803670|NCT01017354|DIETARY_SUPPLEMENT|ViDe3 (CH)|24000 Vitamin D3 orally and once per month
223803671|NCT05416957|DRUG|Vortioxetine Hemihydrobromide Orally Disintegrating Tablets|Vortioxetine Hemihydrobromide Orally Disintegrating Tablets 20mg administration under fasting condition
223803672|NCT01185626|OTHER|SCP care|
223803673|NCT06229002|PROCEDURE|Transcranial alternative current stimulation (tACS) at alpha frequency|Single session of tACS
223803674|NCT06229002|PROCEDURE|Sham stimulation|Single session of tACS sham stimulation
223803675|NCT03802123|DRUG|⁸⁹Zr-Df-IAB22M2C|⁸⁹Zr-Df-IAB22M2C CD8 T cell tracer for Positron Emission Tomography (PET)
223803676|NCT04878835|BIOLOGICAL|intralesional ranibizumab|Lucentis; Genentech, Inc, San Francisco, California, USA 0.5mg/ 0.05mL
223803677|NCT01730898|OTHER|Study product containing lutein|delivered in capsule form
223803678|NCT01730898|OTHER|Study product containing lutein|delivered in capsule form
223803679|NCT02454192|BEHAVIORAL|CHAMPS|
223803680|NCT06291610|BEHAVIORAL|Clinical trial decision support intervention|"1. a patient decision aid tailored to clinical trial participation~2. decision coaching consultations carried out by trained healthcare professionals.~3. a training program in decision coaching will be an integrated part of the intervention."
223803681|NCT04636658|OTHER|Incentive spirometer training|Incentive spirometer training 5 sessions a week, each session of 15 minutes, for 4 weeks
223803682|NCT04636658|OTHER|diaphragmatic resistance exercises|"Incentive spirometer with diaphragmatic resistance exercises. Resistance is applied through the different Thera bands and then performing the pursed lip breathing exercise. Resistance increased weekly as per tolerance by the patient.~Digital spirometer training for 15 minutes. diaphragm breathing exercises with resistance for 30 minutes. 5 sessions a week, for 4 weeks"
223803683|NCT02253355|DEVICE|Deep Brain Stimulation|
223803684|NCT05521425|DEVICE|"Helping Hands for CAPD bag exchange procedures"|"Training served as Treatment As Usual (TAU) for all participants; The difference between two groups was whether Helping hands were provided to participants for CAPD bag exchange procedures at home."
223803685|NCT03865602|BEHAVIORAL|Sepsis Transition And Recovery (STAR)|In the STAR program intervention, a centrally located nurse navigator facilitates the application of four evidence-based core components of post-sepsis care (i.e., review of medications, new impairments, comorbidities, and palliative care) to patients prior to and during the 30 days after hospital discharge. The STAR navigator will provide telephone and EHR-based support within the hospitalization and to patients across all discharge settings with remote monitoring at specified intervals following hospital discharge. Patients will continue to receive STAR directed services for 30 days following their discharge and then will be transitioned back to the next appropriate care location.
223803686|NCT03865602|BEHAVIORAL|Usual care|Patients and their providers will not have access to the STAR program. Patients will continue to receive usual care throughout their stay and discharge, consisting of: patient education and follow-up instructions at discharge, which are not specific to sepsis; routine recommendations for follow-up visits with primary care providers; arrangements for home health services or care management follow-up based on each patient's needs but not specifically tailored to the sepsis population; discharge to post-acute setting with no sepsis-specific follow-up. All aspects of usual care will be determined by treating clinicians independent of trial assignment.
223803687|NCT04225533|DRUG|SP16|All patients will receive a single dose of SP16
223803688|NCT06579560|DIAGNOSTIC_TEST|Audiovestibular assessment in Patients with Fibromyalgia|Audiovestibular assessment in Patients with Fibromyalgia
223803689|NCT03911648|DRUG|0.5 ml.kg-1 bupivacaine 0.25%|Caudally
223803690|NCT03911648|DRUG|0.5 ml.kg-1 bupivacaine 0.25% with the addition of 3 mg/kg lidocaine 1%|Caudally
223803691|NCT05280418|BIOLOGICAL|Tezepelumab|Monoclonal antibody designed for the treatment asthma.
223803692|NCT05280418|BIOLOGICAL|Placebo|Matched placebo.
223803693|NCT03617744|PROCEDURE|Sleeve gastrectomy|Open sleeve gastrectomy
223803694|NCT01701414|DRUG|Femoral nerve block: 25 mL of 0.5% bupivacaine|25ml of 0.5% bupivacaine will be injected along the nerve sheath. The nerve block will be administered by one of the physician co- investigators all of whom are emergency physicians and all of whom have been trained in the use of ultrasound and ultrasound guided nerve blocks.
223803695|NCT01701414|DRUG|Placebo: 3cc of 0.9% Normal Saline|1cm lateral to the ultrasound probe, a 27 gauge needle and syringe will be used to inject 3cc of 0.9% NS subcutaneously. The SC group will then be cared for by the Emergency Department physicians according to their regular clinical practice
223803696|NCT00149305|OTHER|Genetic analyses|
223803697|NCT00149305|OTHER|Genetic analyses|
223803698|NCT05514912|DRUG|Cisplatin|Given IV
223803699|NCT05514912|DRUG|Gemcitabine Hydrochloride|Given IV
223803700|NCT05514912|DRUG|Infigratinib Phosphate|Given PO
223803701|NCT05514912|DRUG|Nab-paclitaxel|Given IV
223803702|NCT01232010|DRUG|Mirodenafil|50mg Single Oral Dose of
223803703|NCT01290406|DRUG|BEZ235|
223803704|NCT04052464|OTHER|endometrium biopsy|All patients will have endometrium biopsy.
223803705|NCT04052464|OTHER|endometrium lavage|In some selected cases biopsy is preceded by endometrium lavage.
223803706|NCT04052464|OTHER|repeated endometrium lavage|Endometrium lavage is repeated during the same cycle.
223803707|NCT01531166|DRUG|pegylated Interferon-alpha 2a|Pegasys 180mcg/PFS/ subcutaneous injection / Once a week
223803708|NCT06029101|PROCEDURE|posterior fossa craniectomy with or without duraplasty|craniectomy of occipital bone and duroplasty with graft to expand the shallow posterior fossa and reposition the cerebellar tonsils.
223803709|NCT01362439|DRUG|Paliperidone ER|Participants will be administered paliperidone extended release (ER) tablets orally (taken by mouth; to be swallowed) once daily in the dose range of 3 to 12 milligram (mg) for 13 weeks. Dose will be increased or decreased as per Investigator's discretion.
223803710|NCT04547374|OTHER|GaH Intervention|"Patients in this cohort will be referred for management/intervention with GaH.~However, the purpose of this program is not to define, control, or evaluate the specific details of the GaH process or procedure, but to evaluate its effectiveness as an alternative clinical care path in this setting. As such, the specific details and actions of the GaH care team in each patient interaction are left to their medical discretion."
223803711|NCT03233802|BEHAVIORAL|Individualized Assess & Treatment (IATP)|See previous description
223803712|NCT03233802|BEHAVIORAL|Packaged Cognitive-Behavioral (PCBT)|See previous description
223803713|NCT03233802|BEHAVIORAL|Case Management (CaseM)|See previous description
223803714|NCT00114179|DRUG|capecitabine|Given orally
223803715|NCT00114179|RADIATION|radiation therapy|Undergo radiotherapy
223803716|NCT00114179|BIOLOGICAL|bevacizumab|Given IV
223803717|NCT00114179|PROCEDURE|therapeutic conventional surgery|Undergo surgery
223803718|NCT00114179|DRUG|gemcitabine hydrochloride|Given IV
223803719|NCT04108455|OTHER|Specimens Collected|Serum will be collected from patients at multiple times during pregnancy for later analysis.
223803720|NCT05273632|DRUG|Oxytocin|trial of reduction of losing blood intra operative or post operative during Cesarean Delivery
223803721|NCT04710745|DIAGNOSTIC_TEST|Peripheral blood samples for routine analysis including NT-proBNP and plasmatic biomarkers.|Sampling of peripheral venous blood for analysis of plasma concentration of plasmatic markers (Apelin, microRNA, FGF-23, IGF-1, IGFBP-1) and routine analysis (laboratory parameters: NT-proBNP, D-dimer, Creatinine Clearance, CRP, Hs-troponin).
223803722|NCT04710745|DIAGNOSTIC_TEST|Echocardiography|"ECHO parameters:~* E/e´~* Mean e' septal and lateral wall~* LA volume (Biplane Area-Length Method)~* Left atrial volume index~* Diameter of left atrium in PLAX~* Severe aortic stenosis~* Severe mitral regurgitation~* Severe tricuspid regurgitation~* Left ventricular end-diastolic diameter~* Interventricular septum~* Posterior wall~* LV Mass~* Left ventricular mass index"
223803723|NCT04710745|DIAGNOSTIC_TEST|ECG Holter monitor|Patient receives an ECG Holter for a 7-day monitoring.
223803724|NCT04710745|DIAGNOSTIC_TEST|Standardized Mini-Mental Status Exam (SMMSE)|A screening test for evaluating cognitive performance of patients done in the clinician's office.
223803725|NCT02216266|DRUG|Physostigmine|
223803726|NCT02216266|OTHER|Sodium Chloride solution|
223803727|NCT00063284|DEVICE|Magstim Rapid Magnetic Stimulator|
223803728|NCT00777374|DRUG|Patch|epicutaneous application of allergen patch
223803729|NCT00777374|DRUG|Placebo patch|epicutanoeus application of a placebo patch
223803730|NCT04609267|DIAGNOSTIC_TEST|PHQ-9 - Mirror format|The intervention we will be using is a new delivery system of the PHQ-9 using an Amazon Alexa equipped Mirror device. This Mirror device is similar to a smart television with a mirror interface. The device records auditory responses to the PHQ-9. We will be comparing the responses from the Mirror device to those given on the clinically established paper format.
223803731|NCT03116984|PROCEDURE|Transcatheter arterial chemoembolization|Transcatheter arterial chemoembolization (TACE) is performed via an injection into the hepatic artery of agents by puncturing the common femoral artery.Adriamycin(30 to 60 mg) is considered as basic chemotherapy drugs in the process of transcatheter endovascular perfusion. The dose of lipiodol was determined by diameter and blood supply type of HCC, generally 5-20ml, and no more than 30ml once.
223803732|NCT03116984|RADIATION|External- beam radiotherapy|We have reported a series of retrospective clinical trials in which transarterial chemoembolization (TACE) combined with external- beam radiotherapy (EBRT) was a better treatment method than TACE alone for unresectable HCC in the same period and organization, no matter in aspects of the regression rate of carcinoma or survival.Patients who were randomized to the EBRT 3-5 weeks after the completion 2 times TACE.
223803733|NCT05777798|DEVICE|Hyalistil Bio PF|Moisturizing and lubricating ophthalmic solution
223803734|NCT04851548|PROCEDURE|hyaluronic acid|after flap refection, the furcation area will be debrided then add hyaluronic acid 8% and cover it with a collagen membrane
223803735|NCT05127525|DRUG|IRX-101|IRX-101 to prevent infectious endophthalmitis following intravitreal injection therapy (IVT)
223803736|NCT05127525|DRUG|Control|Providone-Iodine Betadine to prevent infectious endophthalmitis following intravitreal injection therapy (IVT)
223803737|NCT01127282|DRUG|Vitamin (vitamin A 15 mg,C 500 mg, E 400IU)|Vitamin (vitamin A 15 mg,C 500 mg, E 400IU) 1T po for 5 days in addition to anti-viral agent and antipyretics
223803738|NCT01127282|DRUG|Placebo (digestive tablet)|Placebo (digestive tablet) 1T po for 5 days in addition to anti-viral agent and antipyretics
223803739|NCT01281644|DEVICE|Diode Laser|810 nm diode laser
223803740|NCT02732379|PROCEDURE|Lavender Aromatherapy|the two drops of lavender essential oil will be dropped into the gauze and the patient will inhale it for 5 minutes.
223803741|NCT02732379|PROCEDURE|Rose Aromatherapy|the two drops of rose essential oil will be dropped into the gauze and the patient will inhale it for 5 minutes.
223803742|NCT02732379|PROCEDURE|Ginger Aromatherapy|the two drops of ginger essential oil will be dropped into the gauze and the patient will inhale it for 5 minutes.
223803743|NCT02732379|PROCEDURE|Placebo Aromatherapy|the two drops of pure water will be dropped into the gauze and the patient will inhale it for 5 minutes
223803744|NCT05333354|OTHER|education strategy|The educational course of the experimental group will last for 6 weeks, including classroom teaching and simulated situational teaching. The classroom teaching will be divided into 3 times, a course of about 2 hours at a time; after the class, simulated situational teaching is also arranged for 4 hours at a time/ Caring for many patients with delirium, and performing related research. The simulated scenario lesson plan plans to design 3 major themes (delirium assessment, delirium risk factors, delirium prevention, each major theme will have 2 scenarios, each The simulation teaching exercise starts with pre-briefing, and after the end, debriefing reflection and discussion with the students.
223803745|NCT03404310|DIETARY_SUPPLEMENT|Zinc Sulfate|Participant will take one 220mg tablet twice daily for three months.
223803746|NCT03404310|OTHER|Placebo (Gelatin Tablet)|Participant will take one tablet twice daily for three months.
223803747|NCT00065585|PROCEDURE|Accupuncture|
223803748|NCT04879290|OTHER|FiO2 0.5|Ten minutes before emergence from general anesthesia, the amount of oxygen delivered from the mechanical ventilator called fractional inspired oxygen (FiO2) is set to 0.5 (50%)
223803749|NCT04879290|OTHER|FiO2 1|Ten minutes before emergence from general anesthesia, the amount of oxygen delivered from the mechanical ventilator called fractional inspired oxygen (FiO2) is set to 1 (100%)
223803750|NCT06259422|DRUG|Iohexol|Subjects will receive a single bolus of 5 mL of Omnipaque 300 (containing 3235 mg iohexol)
223803751|NCT06259422|DIAGNOSTIC_TEST|125I-iothalamate and 131I-hippuran|Subjects will receive 125I-iothalamate and 131I-hippuran as part of their routine clinical care.
223803752|NCT00614081|DEVICE|Contrast-enhanced dynamic MRI|
223803753|NCT04920357|DRUG|Vaccination|Persons that are vaccinated within the national and regional vaccine program are invited to participate in the follow-up study.
223803754|NCT01755702|DRUG|Placebo|Placebo
223803755|NCT01755702|DRUG|Experimental paracetamol + caffeine formulation|experimental paracetamol + caffeine formulation
223803756|NCT01755702|DRUG|ibuprofen marketed formulation|ibuprofen marketed formulation
223803757|NCT01755702|DRUG|Paracetamol marketed formulation|Paracetamol marketed formulation
223803758|NCT03083314|PROCEDURE|SELECTIVE AXILLARY LYMPH NODE DISSECTION (SAD)|
223803759|NCT03083314|PROCEDURE|COMPLETE AXILLARY DISSECTION (ALND)|
223803760|NCT00877279|DEVICE|CosmoDerm1|CosmoDerm1 is a single use syringe, injected into the mid dermal layer.
223803761|NCT00877279|DEVICE|Belotero Soft|Dermal Filler
223803762|NCT03006484|OTHER|No intervention|No intervention will be needed.
223803763|NCT05294796|COMBINATION_PRODUCT|Short course of antibiotherapy|Short duration of authorized antibiotic therapy according to its data sheet in infections associated with osteosynthesis material
223803764|NCT05294796|COMBINATION_PRODUCT|Long course of antibiotherapy|Long duration of authorized antibiotic therapy according to its data sheet in infections associated with osteosynthesis material
223803765|NCT03638206|BIOLOGICAL|CAR-T cell immunotherapy|According to tumor burden and other conditions, patients will be treated with cyclophosphamide or fludarabine,then,CAR-T cells will be infused 48-72 hours later.
223803766|NCT01325285|DEVICE|RespirAct|"Participants will breathe through a mask connected to a sequential rebreathing circuit and gas blender. The following seven gas stages will be targeted for about 10 minutes each:~1. Baseline, measured in eye A (PETCO2=38mmHg and PETO2=100mmHg)~2. 10% hypercapnic increase, measured in eye A (PETCO2=42mmHg and PETO2=100mmHg)~3. 20% hypercapnic increase, measured in eye A (PETCO2=46mmHg and PETO2=100mmHg)~4. Baseline, measured in both eyes (PETCO2=38mmHg and PETO2=100mmHg)~5. 250% hyperoxic increase, measured in eye B (PETCO2=38mmHg and PETO2=250mmHg)~6. 500% hyperoxic increase, measured in eye B (PETCO2=38mmHg and PETO2=500mmHg)~7. Baseline, measured in eye B (PETCO2=38mmHg and PETO2=100mmHg)"
223803767|NCT02598986|DIETARY_SUPPLEMENT|Macronutrient supplementation|adding of phosphorus, potassium and magnesium
223803768|NCT06016010|DRUG|USL|500mg of Achyranthis Radix Extract
223803769|NCT06016010|DRUG|USL Placebo|USL Placebo
223803770|NCT04519086|RADIATION|Low-dose CT|Low-dose computed tomography for suspected acute uncomplicated appendicitis in patients with BMI \>30
223803771|NCT04519086|PROCEDURE|Laparoscopic appendectomy|All patients with BMI \>30, who are diagnosed with an uncomplicated acute appendicitis on low-dose CT-scan will undergo laparoscopic appendectomy to evaluate the sensitivity and specificity of the CT diagnosis
223803772|NCT03692338|BEHAVIORAL|Exercise|Patients will be asked to complete 3 x 30 minute exercise sessions each week.
223803773|NCT00541918|DRUG|Diprivan (propofol, Astra Zeneca)|Total intravenous anesthesia with propofol
223803774|NCT00541918|DRUG|Sevorane (sevoflurane, Abbott)|inhaled anesthesia with sevoflurane
223803775|NCT02960399|BIOLOGICAL|Zostavax®|Zostavax® immunization
223803776|NCT05088369|DRUG|HM201|HM201 will be administered intravenously.
223803777|NCT05088369|DRUG|Placebo|Placebo will be administered intravenously.
223803778|NCT05088369|DRUG|HM201|HM201 will be administered intravenously.
223803779|NCT05088369|DRUG|Placebo|Placebo will be administered intravenously.
223803780|NCT02392325|BIOLOGICAL|rDEN1Δ30|Administered subcutaneously in 0.5 mL containing 10\^3.0 plaque-forming units (PFU)
223803781|NCT02392325|BIOLOGICAL|Placebo|Administered subcutaneously in 0.5 mL
223803782|NCT02392325|BIOLOGICAL|rDEN2Δ30-7169|Administered subcutaneously in 0.5 mL containing 10\^3.0 PFU
223803783|NCT02361125|DRUG|Methylphenidate|5 mg tablet by mouth as needed every 2 hours for participant described significant fatigue. Participants to take a maximum of 20 mg/day, for total of 28 tablets for 7 days.
223803784|NCT02361125|BEHAVIORAL|Fatigue Evaluations|Participants to have evaluation of their fatigue, ability to sleep, and will answer a set of general symptom questions at baseline visit, daily while on study drug, and on seventh day of treatment.
223803785|NCT04735744|OTHER|Patients recovering from COVID19 receive usual care by allied health professionals|We will not develop specific interventions for this prospective observational cohort study. The care provided by allied health professionals in daily practice are based on recommendations published by the professional bodies of allied health professionals and on the interdisciplinary guidance developed by the LAN. All allied health professionals are working according to these recommendations. Dissemination of these recommendations is done by the professional bodies of the allied health professionals. Given the observational nature of our study, no additional implementation strategies will be employed to stimulate this care by the research group.
223803786|NCT01260844|DRUG|briakinumab|single dose briakinumab and 2 doses of CYP substrates
223803787|NCT03536286|BEHAVIORAL|Encouragement|Households will be visited and encouraged to enroll in Asili
223803788|NCT04732091|PROCEDURE|Therapeutic ultrasound with 20 usec|A custom designed high mechanical index (MI) impulses at 4-20 usec and \>1.0 mechanical index designed for the 1.8 MHz S5-1 transducer
223803789|NCT06201130|DIAGNOSTIC_TEST|Suctioning of artificial airway|Collection of tracheal aspirates in either the PICU or NICU will occur. We will instill 1 mL of normal saline, then perform bag ventilation, and then suction out aspirate. Suctioning is routinely performed for tracheostomy and endotracheal tube hygiene - for instance, it is performed on tracheostomies by caregivers at home. The aspirates that will be collected will be clinically indicated and otherwise would be discarded. If the patients weren't enrolled in this research, the aspirates would have been collected anyways.
223803790|NCT03144414|PROCEDURE|Laparoscopic hysterectomy|Laparoscopic hysterectomy
223803791|NCT03172702|DRUG|Zirconium Cyclosilicate|Correction Phase Dosing: Sodium Zirconium Cyclosilicate 10 g three times daily (TID) from 24 to 72 Extended Dosing: Sodium Zirconium Cyclosilicate 5 g once daily (QD). Sodium Zirconium Cyclosilicate dose increased or decreased in increments/decrements of 5 g QD up to a maximum of 15 g QD or a minimum of 5 g every other day (QOD) (or 2.5 g QD) based on i-STAT potassium measurements up to 12 months.
223803792|NCT03309839|OTHER|Blood collection|A sample of an additional blood tube will be taken in parallel with the blood test carried out for the treatment.
223803793|NCT05343416|PROCEDURE|Open abdomen procedure|All patients underwent to open abdomen procedure
223803794|NCT02246335|DEVICE|Cemented total hip arthroplasty|
223803795|NCT02246335|DEVICE|Cemented hemiarthroplasty|
223803796|NCT05458375|DRUG|Estradiol vaginal cream|Insert pea-sized amount of vaginal estradiol cream into vagina nightly for first two weeks and then twice weekly thereafter.
223803797|NCT03118921|DEVICE|Virtual reality|The first session aims to present the virtual reality material that will be used. The second session will take place 2 weeks after the first session and will consist of the use of the immersion software.
223803798|NCT05807581|OTHER|physical activity|treadmill running 3 times weekly
223803799|NCT05807581|OTHER|iTBS|repetitive TMS stimulation 5 days weekly for two weeks
223803800|NCT02967614|DRUG|[A]|One eye drop(about 40ul) / Day1 \~ Day8 / BID
223803801|NCT02967614|DRUG|[B]|One eye drop(about 40ul) / Day1 \~ Day92 / BID
223803802|NCT02967614|DRUG|[A]+[B](1)|One eye drop(about 40ul) / Day9 \~ Day100 / BID
223803803|NCT02967614|DRUG|[A]+[B](2)|One eye drop(about 40ul) / Day93 \~ Day100 / BID
223803804|NCT03786952|BEHAVIORAL|Stress immediately before learning in males|Male participants will be exposed to the socially evaluated cold pressor test immediately prior to fear learning. Participants will place their dominant hand in a bath of ice cold water for up to 3 minutes. The participants will also be informed that they are being videotaped for analysis of facial expressions and be asked to stare at a camera throughout the manipulation. Immediately following the acute stressor, participants will undergo the acquisition phase of fear conditioning.
223803805|NCT03786952|BEHAVIORAL|Sham control immediately before learning in males|Male participants will be exposed to the sham control condition (no stress) immediately prior to fear learning. Participants will place their dominant hand in a bath of lukewarm water for up to 3 minutes. Immediately following the sham control condition, participants will undergo the acquisition phase of fear conditioning.
223803806|NCT03786952|BEHAVIORAL|Stress 30 minutes before learning in males|Male participants will be exposed to the socially evaluated cold pressor test 30 minutes prior to fear learning. Participants will place their dominant hand in a bath of ice cold water for up to 3 minutes. The participants will also be informed that they are being videotaped for analysis of facial expressions and be asked to stare at a camera throughout the manipulation. Thirty minutes following the acute stressor, participants will undergo the acquisition phase of fear conditioning.
224264247|NCT03265574|DRUG|Enalapril|Enalapril is an Angiotensin Converting Enzyme (ACE) inhibitor which supresses the reninangiotensin-aldosterone system resulting in increased plasma renin activity and decreased aldosterone secretion
223803807|NCT03786952|BEHAVIORAL|Sham control 30 minutes before learning in males|Male participants will be exposed to the sham control condition (no stress) 30 minutes prior to fear learning. Participants will place their dominant hand in a bath of lukewarm water for up to 3 minutes. Thirty minutes following the sham control condition, participants will undergo the acquisition phase of fear conditioning.
223803808|NCT03786952|BEHAVIORAL|Stress immediately before learning in females|Female participants will be exposed to the socially evaluated cold pressor test immediately prior to fear learning. Participants will place their dominant hand in a bath of ice cold water for up to 3 minutes. The participants will also be informed that they are being videotaped for analysis of facial expressions and be asked to stare at a camera throughout the manipulation. Immediately following the acute stressor, participants will undergo the acquisition phase of fear conditioning.
223803809|NCT03786952|BEHAVIORAL|Sham control immediately before learning in females|Female participants will be exposed to the sham control condition (no stress) immediately prior to fear learning. Participants will place their dominant hand in a bath of lukewarm water for up to 3 minutes. Immediately following the sham control condition, participants will undergo the acquisition phase of fear conditioning.
224264248|NCT04991610|RADIATION|computed tomography|CT scans will be obtained from patients lying in a supine position using 120 kV tube voltage, 150 effective mA and 1 mm slice thickness parameters.
224264249|NCT04550702|DRUG|Mirabegron 25mg|Mirabegron 25 mg per day
224264250|NCT03057210|OTHER|Stress Protocol|Participants will be submitted to an exercise protocol consisting of a jumping program and a maximum short cycle test (ALMEIDAetal). The jumping program consists of 10 sets of 10 jumps with one minute interval between sets. The participants will then perform the Wingate Anaerobic Test protocol, which will be performed on a Biotec 2100 cycle ergometer (Cefise, Nova Odessa, Brazil). A 5-minute warm-up will be carried out where the participant will pedal at a speed of 60 to 90 rpm with a fixed load of 1.0 kg and perform sprints in the 2nd and 4th minute and the test itself, which consists of a maximum of pedals In 30 seconds with a stipulated load of 0.075 kP · kg-1 of the participant's body mass.
224264251|NCT03057210|OTHER|Massage Protocol|"the present protocol will have a total of 12 minutes duration, being six minutes in the anterior region of the thigh (three minutes for each limb) and six minutes in the posterior region of the trunk.~Surface and deep sliding techniques will be used, the latter being presented in two intensities, moderate or intense, gradually increased. The massage will be performed towards the muscle fibers, from distal to proximal and following the lymphatic flow. In addition to the standardization of the intensity of the massage performed by the physiotherapist, in order to avoid causing discomfort and possible variations in the application of the technique, participants should report their level of comfort from a scale that considers the technique light, moderate or Intense, corresponding respectively to surface slip, Deep Slip 1 and Deep Slip 2."
224264252|NCT02812121|DRUG|umbilical cord blood mesenchymal stem cells|
224264253|NCT04244630|COMBINATION_PRODUCT|Antioxidants|Over-the-counter anti-oxidants, namely vitamin E, NAc cysteine, L-cystine, Nicotinamide and Taurursodiol at defined doses
224264254|NCT05437848|DRUG|Experimental: Cotadutide|Cotadutide: subcutaneous (SC) injection
224264255|NCT05437848|OTHER|Placebo|Placebo subcutaneous injection
224264256|NCT00629122|DRUG|Tacrolimus (Arm B)|Study day 1 (9a): Initiate sublingual (SL) tacrolimus and clotrimazole troche x 5 doses; Study day 3 (9a): Collection of pharmacokinetic parameters around the 5th SL tacrolimus dose; Study day 3 (9p): Start washout period, no drug administration (tacrolimus, clotrimazole); Study day 5 (9p): End washout period; Study day 6 (9a): Initiate oral tacrolimus and clotrimazole troche x 5 doses; Study day 8 (9a): Collection of pharmacokinetic parameters around the 5th oral tacrolimus dose; Study day 15: Contact subject by telephone to assess for any adverse effects. To ensure that dietary intake does not affect the absorption profile of tacrolimus we will ensure that breakfast is given 15 minutes prior to drug administration on the days of pharmacokinetic assessment (study day 3 and 8).
223803810|NCT03786952|BEHAVIORAL|Stress 30 minutes before learning in females|Female participants will be exposed to the socially evaluated cold pressor test 30 minutes prior to fear learning. Participants will place their dominant hand in a bath of ice cold water for up to 3 minutes. The participants will also be informed that they are being videotaped for analysis of facial expressions and be asked to stare at a camera throughout the manipulation. Thirty minutes following the acute stressor, participants will undergo the acquisition phase of fear conditioning.
223803811|NCT03786952|BEHAVIORAL|Sham control 30 minutes before learning in females|Female participants will be exposed to the sham control condition (no stress) 30 minutes prior to fear learning. Participants will place their dominant hand in a bath of lukewarm water for up to 3 minutes. Thirty minutes following the sham control condition, participants will undergo the acquisition phase of fear conditioning.
223803812|NCT03320616|DRUG|EYP001a|Oral EYP001a capsules - 100 mg strength
223803813|NCT03113123|DRUG|PrEP with Truvada®|"Associated with:~* STD screening/treatment for syphilis, gonorrhoea and chlamydiae~* HIV screening/therapy~* Questionnaire~* Addiction, social or psychological follow-up care if needed~* Peer interactive counselling (peer counselors/nurses/physicians experienced with therapeutic education) at the baseline visit and at every follow-up visit up to 6 months. After 6 months, counselling will be provided at the request of participants if they need it. Counselors will remain in contact with the participants between visit to answer any questions relative to PrEP, treatment and prevention, and to facilitate participants interactions with study sites."
223803814|NCT05290857|OTHER|Restart DOAC within 7 days of clinical hemostasis after GI bleeding|"In patients at high thrombotic risk, DOACs will be resumed within 7 days of clinical hemostasis (as judged by the clinical team).~High thrombotic risk includes the following:~(i) Atrial fibrillation or atrial flutter with CHA2DS2VASc score of 5 or higher (ii) Atrial fibrillation or atrial flutter with CHA2DS2VASc score or 3 to 4 with recent ischemic stroke, TIA or systemic embolism (within 6 months) (iii) VTE (proximal DVT or PE) within 3 months (iv) Recurrent VTE (proximal DVT or PE) (v) VTE (proximal DVT or PE) associated with antiphospholipid syndrome (if eligible for DOAC) (vi) VTE (proximal DVT or PE) associated with active non-GI cancer (vii) None of the above but considered high thrombotic risk as per investigator"
223803815|NCT05290857|OTHER|Restart DOAC between 7 to 14 days of clinical hemostasis after GI bleeding|"In patients at moderate thrombotic risk, DOACs will be resumed between 7 and 14 days of clinical hemostasis (as judged by the clinical team).~Moderate thrombotic risk includes the following:~(i) Atrial fibrillation or atrial flutter with CHA2DS2VASc score of 3 to 4 (ii) VTE (proximal DVT or PE) beyond 3 months~The type and dose of DOAC will be according to patient and physician choice and will be prescribed by the clinical care team."
223803816|NCT01682993|OTHER|Topography guided Excimer Laser treatment and Corneal Cross Linking|A topography guided excimer laser treatment will be performed prior to CCL in one session.
223803817|NCT01682993|OTHER|Corneal Cross Linking|A standard corneal cross linking procedure will be performed in this arm.
223803818|NCT02084459|BEHAVIORAL|Autonomy-supportive counselling (GSD)|GSD, an educational method, comprising 32 semi-structured reflection sheets inviting the patients in groups of 4 through 8 sessions of 150 minutes' duration to reflect on the patient's own situation and to be active in co-operation with the nurses.
223803819|NCT03683147|OTHER|Laboratory Biomarker Analysis|Correlative studies
223803820|NCT03683147|BEHAVIORAL|Meditation-Based Stress Reduction Program|Participate in 6-week online program
223803821|NCT03683147|OTHER|Quality-of-Life Assessment|Ancillary studies
223803822|NCT03683147|OTHER|Questionnaire Administration|Ancillary studies
223803823|NCT05518383|DRUG|Cyclophosphamide, Cytarabine, Dexamethasone, Etoposide, Ifosfamide, Methotrexate|For patients with very limited disease (R1- stage I/II СR), the addition of rituximab might allow the omission of anthracyclines and vincristine without jeopardizing survival rates but reducing acute and long term toxicities. In this treatment arm, it is tested whether the event-free survival is similar to that of the historical control
223803824|NCT05518383|DRUG|Cyclophosphamide, Cytarabine, Dexamethasone, Etoposide, Ifosfamide, Methotrexate, Vincristine|R2: Drug: Rituximab 2 doses of Rituximab (375 mg/m²) before the start of the first chemotherapy cycle, 2 doses of Rituximab before the start of the second chemotherapy cycle
223803825|NCT05518383|DRUG|Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin hydrochloride, Etoposide, Ifosfamide, Methotrexate, vincristine|2 doses of Rituximab (375 mg/m²) before the start of the first chemotherapy cycle, 2 doses of Rituximab before the start of the second
223803826|NCT05518383|DRUG|Cyclophosphamide , Cytarabine, Dexamethasone, Doxorubicin hydrochloride, Etoposide, Ifosfamide, Methotrexate, Vincristine, Сarboplatine, CCNU/ BCNU, Melphalan, Idarubicin|Rituximab 4 doses of Rituximab (375 mg/m²) before the start of the first chemotherapy cycle, Further
223803827|NCT03468933|DRUG|tissue plasminogen activator (tPA) and human recombinant deoxyribonuclease (DNase)|Patients will receive intrapleural combination of TPA (10 mg) and DNAse (5 mg). Therapy will be given twice daily for a maximum of 6 dose
223803828|NCT03468933|PROCEDURE|Medical Thoracoscopy|Medical thoracoscopy will be performed as per standard protocols.
223803829|NCT05534022|DEVICE|Test myopia control lenses (BSL)|Myopia control spectacle lenses (test lenses) will be given to subjects throughout the 24 months trial.
223803830|NCT06433531|DRUG|TQH2929 Injection|TQH2929 injection is a humanized monoclonal antibody that interfering with the signal cascade.
223803831|NCT05088889|DRUG|Nivolumab|Nivolumab administered IV over 30 minutes at a dose of 360mg every 3 weeks
223803832|NCT05088889|DRUG|ipilimumab|Ipilimumab administered IV over 30 minutes at 1 mg/kg every 6 weeks
223803833|NCT05088889|RADIATION|Stereotactic body radiation therapy|Three fractions of 8 Gy, treated on alternate days
223803834|NCT05088889|RADIATION|Low dose irradiation|a single fraction of 2Gy will be given to the metastatic lesions at first progression
223803835|NCT01186029|DRUG|aprepitant|Emend 40mg by mouth 30 minutes before procedure x 1
223803836|NCT05275192|DEVICE|Videoscope-assisted periodontal regeneration minimally invasive surgery|Use of a videoscope to improve visualization of periodontal defect during minimally invasive surgery
223803837|NCT05275192|PROCEDURE|Periodontal regeneration minimally invasive surgery|Conventional periodontal regeneration minimally invasive surgery without use of a videoscope
223803838|NCT05275192|PROCEDURE|Guided tissue regeneration surgery|Conventional guided tissue regeneration surgery for periodontal regeneration without use of a videoscope
223803839|NCT03341078|DRUG|Ibudilast|Ibudilast capsules will be orally ingested twice daily for 6 weeks.
223803840|NCT03341078|DRUG|Placebo Oral Tablet|Placebo capsules will be orally ingested twice daily for 6 weeks.
223803841|NCT06134180|BEHAVIORAL|CONFIDENCE-AI|Multicomponent psychoeducational intervention focused on financial wellbeing
223803842|NCT06254469|DRUG|[F-18]Flornaptitril|All participants will receive a single dose of F-18 FNT during an imaging visit.
223803843|NCT06543056|DRUG|ES014|ES014 is administered via intravenous infusion, once every 14 days, every 28 days as a treatment cycle for a maximum treatment duration per patient of 24 months.
223803844|NCT02152982|OTHER|Laboratory Biomarker Analysis|Correlative studies
223803845|NCT02152982|OTHER|Placebo Administration|Given PO
223803846|NCT02152982|OTHER|Quality-of-Life Assessment|Ancillary studies
223803847|NCT02152982|DRUG|Temozolomide|Given PO
223803848|NCT02152982|DRUG|Veliparib|Given PO
223803849|NCT05771337|DIAGNOSTIC_TEST|blood sample|blood sample
223803850|NCT02470650|DRUG|elvitegravir/cobicistat/emtricitabine/tenofovir|1 recovered tablet once Per day ● Specify total dose (number and unit): 150 mg de elvitegravir, 150 mg cobicistat, 200 mg emtricitabine , 245 mg tenofovir disoprox milligram(s)
223803851|NCT02470650|DRUG|Darunavir|Darunavir 800 mg (Prezista®) 1 recovered tablet 800 mg once a day
223803852|NCT02470650|DRUG|abacavir/lamivudine|Abacavir 600 mg /lamivudine 300 mg recovered tablet once a day
223803853|NCT02470650|DRUG|Ritonavir|Ritonavir 100 mg recovered tablet once a day
223803854|NCT02470650|DRUG|Lamivudine|lamivudine 300mg (Epivir) 1 recovered tablet
223803855|NCT02470650|DRUG|rilpivirine|rilpivirine (Edurant®) 1 recovered tablet 25 mg. once a day
223803856|NCT06412653|DRUG|Zinc Acetate Dihydrate|In this single arm trial, all participants will be receive the trial drug zinc acetate dihydrate orally. The Investigational medicinal product (IMP) will be given one hour after meal in a dosage which is recommended in Wilson Disease and has been given in this condition without observing severe adverse effects. If oral administration is not possible due to the disability level of the patient, the IMP can be mortared and suspended and can then be given as suspension orally or via the Percutaneous endoscopic gastrostomy. The total treatment duration in each patient is 6 months with stable dosage over the duration of the trial. If the therapy shows effects, the parents and participants may continue medication after the end of the trial. If not, they will stop the medication after the last visit at the trial site.
223803857|NCT03586661|DRUG|Copanlisib|Given IV
223803858|NCT03586661|DRUG|Niraparib|Given PO
223803859|NCT03338829|BEHAVIORAL|Positive incentive|Compensation is paid for each glucose test completed
223803860|NCT03338829|BEHAVIORAL|Loss aversion|Fixed compensation is offered to patients and they can earn a range of compensation at the completion of pregnancy depending on overall glucose testing adherence
223803861|NCT05917652|BEHAVIORAL|Tool kit|The study team will develop and design key elements of the implementation intervention (toolkit) among a small group of burn and non-burn clinician stakeholders (4-6 total). The study team will use in-person interviews with stakeholders and a semi-structured interview guide to elicit feedback and assess face and content validity of the toolkit elements prior to deployment across the study hospitals. For those who consent to participation, the study team will conduct virtual teleconference interviews in-person using a secure videoconferencing platform while the person is not working, at a time convenient for them. Interviews will last between 45 and 60 minutes. The study team anticipates conducting 4-6 interviews to finalize toolkit elements prior to implementation.
223803862|NCT05115825|BEHAVIORAL|Behavioral Intervention|Attend Mobile Pain Coping Skills Training
223803863|NCT05115825|OTHER|Quality-of-Life Assessment|Ancillary studies
223803864|NCT05115825|OTHER|Questionnaire Administration|Ancillary studies
223803865|NCT06032559|BEHAVIORAL|MORE|MORE plus TAU
223803866|NCT06032559|BEHAVIORAL|SMP|SMP plus TAU
223803867|NCT06032559|OTHER|TAU|TAU only
223803868|NCT04026295|BEHAVIORAL|Short Burst Interval Treadmill Training (SBLTT)|SBLTT will consist of short-bursts (30 seconds) of high speed walking alternating with 30 seconds of low/moderate speed walking. Total duration of walking per session will be up to 30 minutes of the 30 second alternating intervals (30sec high / 30sec low/moderate) with rests as needed. Both groups will receive 40 sessions delivered 5x/week for 8 weeks. Initial speeds for high speed walking will be 75-80% of each participant's over ground baseline fast walking speed, and low/moderate speed will be 75-80% of self-selected speed calculated from the 10-Meter Walk Test.
223803869|NCT04026295|BEHAVIORAL|Traditional Locomotor Treadmill Training (TLTT)|TLTT group will receive the same number of sessions (40) delivered 5x/week for 8 weeks with a total duration of walking per session up to 30 minutes with rests as needed. TLTT will consist of walking at steady-state speeds. Initial treadmill speed will be 75-80% of over ground self-selected walking speed. The overall goal will be to achieve 30 minutes of walking at a steady-state walking speed within each session. Speed will be increased on the next session by .1 to .4mph when the subject can walk for 30 minutes on the treadmill at the current speed with an OMNI score of \< 6/10.
223803871|NCT06118372|DRUG|Recombinant von Willebrand Factor|Recombinant von Willebrand Factor is a drug that is currently FDA approved to treat patients with certain types of von Willebrand Disease. In the current trial it will be used to treat ECMO patients who have acquired von Willebrand syndrome.
223803872|NCT05535478|BEHAVIORAL|STRIDE|a. Targeted providers for STRIDE program: i. Clinical staff at the LTCF who participate in deprescribing at the facilities (physicians (MDs), physician's assistants (PAs), nurse practitioners (NPs), clinical pharmacists): clinical staff members caring for LTCF residents with ADRD and diabetes at 6 LTCFs in the Ohio and Michigan areas will be invited via email from the LTCF leadership to participate in the STRIDE education program. The STRIDE program consist of practical algorithms and educational material, which they are free to view at any time, and participation in 2 webinars and monthly telementoring calls
223803873|NCT04345393|BEHAVIORAL|Digital Transformation Network (DTN) Program|Patients will be screened based on ePRO and online assessment tool results to be identified to be eligible for enrollment into the DTN program. The results of ePROs and online assessments will be used to precision match patients to in-person care at the IBD home or to IBDTx care pathways. RxUniverse platform allows the creation of adaptive pathways based on feedback loops that provide relevant on-demand resources based on patient care touch-points. For example, a patient with mild depression or anxiety, maybe offered an online DTx and if not useful, link to telepsychiatry or in-person psychiatry consultation. Patients will transition into the intervention DTN arm at set intervals by site.
223803874|NCT04889573|GENETIC|Blood sample|The blood samples will be collected from healthy volunteers : 7 tubes of 7 ml with anti-coagulant Héparine Lithium and 1 tube of 7ml with anti-coagulant EDTA
223803875|NCT06231355|DRUG|Performing paravertebral nerve block with lipo-bupivacaine|Paravertebral block is performed using liposomal bupivacaine.
223803876|NCT06231355|DRUG|Performing paravertebral nerve block with bupivacaine|Paravertebral block is performed using bupivacaine.
223803877|NCT01409161|DRUG|Arsenic Trioxide|Given IV
223803878|NCT01409161|DRUG|Gemtuzumab Ozogamicin|Given IV
223803879|NCT01409161|OTHER|Laboratory Biomarker Analysis|Correlative studies
223803880|NCT01409161|DRUG|Tretinoin|Given PO
223803881|NCT05617313|DRUG|Pembrolizumab|200 mg intravenously on Day 1 of cycle.
223803882|NCT05617313|DRUG|GT103|10mg/kg taken intravenously on Day 1 of cycle.
223803883|NCT05934370|OTHER|Home-Based Environmental Interventions (HEI)|"Housing Specialist will conduct an environmental home assessment to identify asthma triggers.~• The participant will receive the following Breath Easy at Home Kit Products:~* HEPA filtered upright vacuum cleaner~* HEPA-filtered air purifier~* Hypoallergenic latex free mattress and pillow covers~* Healthier household cleaners~* Non-toxic pest control devices for rodent control~* Safe products to locate and kill roaches."
223803884|NCT06464653|DEVICE|Forel's Field H-DBS ON|The surgical intervention named deep brain stimulation is a well-established neurosurgical treatment for drug-resistant epilepsy. The targets used in this study is Forel's Field H. The devices used for intervention have been approved by Chinese National Medical Products Administration (CFDA). The postoperative drug dosage adjustment depends on the efficacy of DBS and the judgment of the epilepsy specialist.
223803885|NCT05046301|PROCEDURE|Biospecimen Collection|Correlative studies
223803886|NCT05046301|OTHER|Contrast Agent|Given IV
223803887|NCT05046301|PROCEDURE|Contrast-Enhanced Mammography|Undergo contrast-enhanced mammography
223803888|NCT05046301|OTHER|Questionnaire Administration|Ancillary studies
223803889|NCT03854071|OTHER|intravenous fluid challenge|Patients will undergo a receive a pre-load increasing stress test with intravenous fluids depending on tolerability
223803890|NCT06013878|OTHER|Transfer Training with clinician|Participants will undergo transfer training with a clinician who is an expert on assisted transfer techniques if they are found to have skill deficits during the study. After training, a transfer assessment will be conducted to examine if the transfer skills of the caregiver have improved
223803891|NCT05809635|OTHER|Natural History Study|Longitudinal assessment of participants with BEST1 Vitelliform Macular Dystrophy
223803892|NCT03844620|OTHER|Best Practice|Receive SOC
223803893|NCT03844620|OTHER|Laboratory Procedure|Undergo ctDNA testing
223803894|NCT03844620|OTHER|Quality-of-Life Assessment|Ancillary studies
223803895|NCT03844620|OTHER|Questionnaire Administration|Ancillary studies
223803896|NCT03844620|DRUG|Regorafenib|Given by mouth
223803897|NCT03844620|DRUG|Trifluridine and Tipiracil Hydrochloride|Given by mouth
223803898|NCT03452007|DEVICE|Epidural Stimulation|Spinal cord epidural stimulation will be administered through a multi-electrode array implanted in the epidural space over the dorsum of the spinal cord. An implanted package containing stimulating circuits, rechargeable battery, and wireless communication activates the electrodes (16 platinum electrodes arranged in three columns of \[5-6-5\]). The pattern of electrically active electrodes, as well as electrode voltage, stimulating frequency, and stimulating pulse width will be varied to facilitate effects toward bladder function.
223803899|NCT05910385|PROCEDURE|laparoscopy|tubal ligation by laparoscopy or vnotes technique
223803900|NCT05910385|PROCEDURE|vnotes|tubal ligation by laparoscopy or vnotes technique
223803901|NCT04895475|BEHAVIORAL|SARS-CoV-2 vaccine|Baseline demographics, baseline breast milk samples, and blood collection will be obtained at the initial visit. Serial collections of breastmilk and blood as well as weekly self-administered monthly surveys will occur
223803902|NCT06542458|BEHAVIORAL|Assessments|Participants will undergo a standard battery of neuropsychological measures, behavioral questionnaire, and functional assessment to monitor cognition and function over time. Clinical data obtained as part of standard of care will be collected from the medical record
223803903|NCT06542458|OTHER|Neuroimaging volumetric measures|Neuroimaging volumetric measures will be obtained from already conducted standard of care neuroimaging.
223803904|NCT06542458|OTHER|Biofluid samples|Biofluid sampling data will be obtained through another protocol. All participants will be required to sign that consent to participate in this trial.
223803905|NCT03703856|DRUG|Memantine|"Phase 1 will test the acute effects of memantine (20 mg po) vs. placebo (PBO) on early auditory information processing measures in 32 carefully characterized patients with mild-to-moderate severity AD who are not currently taking AD medications. From this challenge test, a set of early auditory information processing memantine sensitivity measures will be derived for each patient. In Phase 2, all patients will begin an open-label trial of memantine, titrated to 10 mg bid, with outcome measures collected after 8, 16 and 24 weeks of treatment. Medication adjustments are not restricted, and response heterogeneity is anticipated."
223803906|NCT03703856|DRUG|Placebo|"Phase 1 will test the acute effects of memantine (20 mg po) vs. placebo (PBO) on early auditory information processing measures in 32 carefully characterized patients with mild-to-moderate severity AD who are not currently taking AD medications. From this challenge test, a set of Early auditory information processing P memantine sensitivity measures will be derived for each patient. In Phase 2, all patients will begin an open-label trial of memantine, titrated to 10 mg bid, with outcome measures collected after 8, 16 and 24 weeks of treatment. Medication adjustments are not restricted, and response heterogeneity is anticipated."
223803907|NCT05493774|OTHER|Multi-person virtual reality simulation scenario training|Using multi-person virtual reality simulation scenario training to evaluate the learning effectiveness of nursing care for emergency burn and scald patients.
223803908|NCT05493774|OTHER|Multi-person high-fidelity simulation scenario training|Using multi-person high-fidelity simulation scenario training to evaluate the learning effectiveness of nursing care for emergency burn and scald patients.
223803909|NCT00812786|DRUG|cyclosporine, tacrolimus, mycophenolate mofetil and everolimus (immunosuppressive drugs)|
223803910|NCT06430424|BIOLOGICAL|Relapsed glioblastoma|Paired tumor samples diagnosis/relapse
223803911|NCT02727296|DRUG|sevoflurane|General anesthesia with sevoflurane
223803912|NCT02727296|DRUG|propofol|General anesthesia with propofol
223803913|NCT02684006|DRUG|Avelumab (MSB0010718C)|IV treatment Avelumab administered at 10 mg/kg IV every two weeks
223803914|NCT02684006|DRUG|Axitinib (AG-013736)|Oral treatment Axitinib given 5 mg PO BID
223803915|NCT02684006|DRUG|Sunitinib|Oral treatment Sunitinib given at 50 mg PO QD on schedule 4/2
223803916|NCT02650648|DRUG|cyclophosphamide|chemotherapy with intravenous (IV) cyclophosphamide 50mg/kg/day (for patients with body weight\<70kg) or 1500mg/m\^2/day (for patients with body weight ≥70kg) for two days (days -6 and -5).
223803917|NCT02650648|BIOLOGICAL|NK cells|Day 0: NK cell infusion. NK cells are resuspended in Normasol at a concentration no less than 5 x 10\^6cells/mL. The patient is pre-medicated as per standard cell product infusion. The cell product is infused through a central venous catheter. Patients will be evaluated clinically by vital signs pre- and approximately 30 minutes post infusion of NK cells and thereafter at approximately 1 hour intervals for 4 hours.
223803918|NCT02650648|BIOLOGICAL|hu3F8|On Days -1, +1, +5, +7 and +9 hu3F8 is administered at 1.68 mg/kg/day and infused over \~30-90 minutes
223803919|NCT02650648|DRUG|rIL-2|On day 0, daily from +2 through +4, day +6, and day +8, rIL-2 is administered subcutaneously at 6 x 10\^5 U/m\^2/day.
223803920|NCT03589079|GENETIC|Sanger and/or Next Generation Sequencing (NGS)|NGS panel, whole exome / genome sequencing (WES/WGS)
223803921|NCT06024538|PROCEDURE|Tumor samples|Tumor samples will be collected by the pathologist at the reception of the tumor removed during surgery
223803922|NCT04112641|DRUG|Nicotinamide riboside|Daily oral ingestion of 1 g/day NIAGEN in capsule form for 84 days; two capsules in the a.m. and two capsules in the p.m.
223803923|NCT04112641|DRUG|Placebo capsules|Daily oral ingestion of placebo in capsule form for 84 days; two capsules in the a.m. and two capsules in the p.m.
223803924|NCT05073757|DEVICE|Custom-made guides and plates|Patients will be included in the study and then followed clinically according to the routine care of orthognathic surgery with custom-made guides and plates. The only specific act this study is the completion of an OQLQ quality of life questionnaire by patients preoperatively and between 8 to 12 months postoperatively.
223803925|NCT05676255|BEHAVIORAL|Cognitively-Based Compassion Training for Survivors|"CBCT-S is a secular adaptation of techniques derived from traditional Tibetan Buddhist methods for cultivating compassion known as lo-jong. CBCT-S will be administered to breast cancer survivors and will not including supportive partners.~Module 1 (Week 1): Overview and Connecting to A Moment of Nurturance~Module 2 (Week 2) Developing Stable and Clear Attention~Module 3 (Week 3): Enhancing Self Awareness~Module 4 (Week 4): Cultivating Self compassion Part 1: Accepting our Suffering~Module 5 (Week 5): Self Compassion Part 2: Finding Meaning in Suffering.~Module 6(Week 6): Expanding our Circle of Concern~Module 7 (Week 7): Deepening Gratitude and Tenderness~Module 8 (Week 8): Harnessing the Power of Compassion"
223803926|NCT05676255|BEHAVIORAL|Cognitively-Based Compassion Training for Dyads|"CBCT-D is a secular adaptation of techniques derived from traditional Tibetan Buddhist methods for cultivating compassion known as lo-jong. CBCT-D will be administered to breast cancer survivors and supportive partners together.~Module 1 (Week 1): Overview and Connecting to A Moment of Nurturance~Module 2 (Week 2) Developing Stable and Clear Attention~Module 3 (Week 3): Enhancing Self Awareness~Module 4 (Week 4): Cultivating Self compassion Part 1: Accepting our Suffering~Module 5 (Week 5): Self Compassion Part 2: Finding Meaning in Suffering.~Module 6(Week 6): Expanding our Circle of Concern~Module 7 (Week 7): Deepening Gratitude and Tenderness~Module 8 (Week 8): Harnessing the Power of Compassion"
223803927|NCT05676255|BEHAVIORAL|Health Education|"HE focuses on topics relevant to health and cancer, but is also intended for individuals who are not cancer survivors themselves.~HE will be administered to both breast cancer survivors and supportive partners together.~Module I (Week 1): Cancer Advocacy.~Module II (Week 2): Health Through the Lifespan.~Module III (Week 3): Nutrition.~Module III (Week 4): Nutrition.~Module IV (Week 5): Physical Activity.~Module V (Week 6): Sleep.~Module VI (Week 7): Stress.~Module VII (Week 8): Mental Health and Social Support."
223803928|NCT01952184|DEVICE|CBSvit HS device|closed vitrification with closed storage
223803929|NCT01952184|DEVICE|Cryotop SC device|open vitrification with closed storage
223803930|NCT04495179|DRUG|AZD4635|Subjects will receive AZD4635 orally daily
223803931|NCT04495179|DRUG|Durvalumab|Subjects will receive intravenous durvalumab every 4 weeks for Arm A and every 3 weeks for Arm B.
223803932|NCT04495179|DRUG|Cabazitaxel|Subjects will receive intravenous cabazitaxel every 3 weeks
223803933|NCT05323539|OTHER|Evaluating Thyroid Volumes by ultrasonography|The inclusion criteria are ; having a prediagnosis of surgically planned endometrioma and to undergo gynecological surgery for a reason other than endometriosis (control group). Among the patients with pre-diagnosis of endometriosis, who applied to our clinic during the study period and accepted to participate in the study, thyroid volumes will be measured by ultrasonography during the preoperative hospitalization. The pathological diagnosis of the patients will be confirmed and patients with different results will be excluded from the study (such as malignancy, endometriosis prediagnosis but different pathology detected etc.) In the same period, gynecological surgery was planned for another reason and patients without endometriosis will form the control group.
223803934|NCT06236165|DRUG|N-acetylcysteine|Patients will receive oral N-acetylcysteine 600 mg twice daily in addition to supportive treatment, for 3 months.
223803935|NCT00146835|BIOLOGICAL|Pediarix|1 or more injections
223803936|NCT00146835|BIOLOGICAL|Licensed DTPa containing vaccine|1 or more injections
223803937|NCT00146835|BIOLOGICAL|Prevnar®: (Wyeth)|Concomitant vaccination
223803938|NCT02968420|BIOLOGICAL|Human Papillomavirus 9-valent Vaccine, Recombinant|All groups will receive a single dose of the Gardasil9 vaccine at Visit 1/Day 0 of the study.
223803939|NCT03465280|PROCEDURE|Microdebrider|Removal of lesions via microdebrider
223803940|NCT03465280|PROCEDURE|Cold-steel surgery (forceps)|Removal of lesions via forceps
223803941|NCT03465280|PROCEDURE|Carbon dioxide laser|Removal of lesions via carbon dioxide laser
223803942|NCT03465280|PROCEDURE|Potassium titanyl phosphate (KTP) laser|Removal of lesions via KTP laser
223803943|NCT03465280|PROCEDURE|Pulsed dye laser|Removal of lesions via pulsed dye laser
223803944|NCT03465280|PROCEDURE|Radiofrequency ablation|Removal of lesions via radiofrequency ablation
223803945|NCT03465280|PROCEDURE|Monopolar suction diathermy|Removal of lesions via monopolar suction diathermy
223803946|NCT03465280|PROCEDURE|Plasma coagulation|Removal of lesions via plasma coagulation
223803947|NCT03465280|PROCEDURE|Other|Removal of lesions via other methods
223803948|NCT03465280|OTHER|Adjuvant therapies|All adjuvant therapies
223803949|NCT01368965|DEVICE|Ulthera® System treatment|Ulthera® System treatment delivering focused ultrasound energy
223803950|NCT02625896|BEHAVIORAL|Intervention|Standard skydive from 4 000 m above mean sea level (AMSL) following standard safety recommendations and procedures including, if necessary, standard reserve parachute activation procedures. If necessary for safety, participants are asked to immediately leave the study at will. At 1 500 m AMSL, the participant is asked to begin to slow down the fall rate by increasing the body surface area to the relative wind. At no lower than 1 200 m AMSL, the participant is asked to deploy the main parachute. At main parachute deployment, while maintaining a stable body position with shoulders level to the horizon and unaltered heading, the participant is asked to increase the pitch angle of the long body axis attitude, raising the head, shoulders, and upper body up from the flat belly-to-relative-wind plane to a head-high body position, using any free fall technique the participant is comfortable with - as long as there is NO RISK for an unintentional backflip.
223803951|NCT03328299|DRUG|Dexmedetomidine|20 ml of 0.5 % bupivacaine plus dexmedetomidine 1 μg•kg-1
223803952|NCT03328299|DRUG|bupivacaine|20 ml of 0.5 % bupivacaine
223803953|NCT00673309|PROCEDURE|Stable Isotope Infusion study|Stable isotope infusion study to be done following each surgery. Tagged isotopes to assess uptake into blood and tissues. Includes collection of blood and tissues (muscle)
223803954|NCT00673309|DRUG|Insulin High Dose|Insulin IV administered continuously throughout hospitalization until wounds are 95% healed.
223803955|NCT00673309|DRUG|oxandrolone|Oxandrolone given daily throughout hospitalization until 95% wound healing.
223803956|NCT00673309|DRUG|Propranolol|Propranolol to be given daily throughout hospitalization until 95% wound healing.
223803957|NCT00673309|DRUG|Growth Hormone|Recombinant Human Growth hormone to be administered daily until 95% wound healing.
223803958|NCT00673309|DRUG|Insulin Low Dose|Insulin administered IV until 95% wound healing
223803959|NCT00673309|DRUG|IGF-1/IGFBP-3|Insulin Like Growth Factor-1/Insulin like Growth Factor Binding Protein 3 administered until 95% wound healing
223803960|NCT00673309|DRUG|Itraconazole|Itraconazole administered until 95% wound healing
223803961|NCT00673309|DRUG|Growth Hormone and Propranolol|Growth Hormone and Propranolol given until 95% wound healing
223803962|NCT00673309|DRUG|Oxandrolone and Propranolol|Oxandrolone and Propranolol
223803963|NCT00673309|DRUG|Placebo or Control|Administration of Placebo or Control until 95% wound healing
223803964|NCT01512901|DRUG|Betamethasone Microsphere (DE-102） Low Dose|
223803965|NCT01512901|DRUG|Betamethasone Microsphere (DE-102） High Dose|
223803966|NCT01512901|DRUG|Sham|
223803967|NCT02355743|DRUG|rtPA lock therapy|"rtPA 2 mg/2 ml, or 110% of the volume of the catheter lumen if less than 2 mL, administered locally in a volume to fill the lumen (dead space) of the CVAD, once weekly for a total of 24 weeks. rtPA will be given as research intervention as lock therapy in that it will dwell within the catheter of the CVAD for a specified duration of time and then be removed (aspirated); in this setting the medication is not given to the patient as a flush, i.e. in systemic fashion."
223803968|NCT04131608|DIAGNOSTIC_TEST|CBC ,Serum ferritin ,HBA1C|Diabetic patients will be applied to CBC, HBA1C and serum ferritin
223803969|NCT02007642|PROCEDURE|Blood sampling / Body fluid sampling|"During the hospitalization of the patient, when a sampling is done for classic follow-up and diagnosis, additionnal blood sampling will be done, for the PATHOQUEST method.~Other body fluids might be taken (if the sampling is done for the classic follow-up), such as cerebrospinal fluid, ascite..."
223803970|NCT06041984|DRUG|Glycopyrrolate|Intravenous injection of glycopyrrolate 0.2mg
223803971|NCT06041984|OTHER|Placebo|Intravenous injection of saline 1ml
223803972|NCT00502255|DEVICE|Health Buddy system|Patients are followed on distance by the Health Buddy system.
223803973|NCT00502255|DEVICE|Telemonitoring in patients with heart failure|Health Buddy in patients home situation.
223803974|NCT04212091|BIOLOGICAL|PGT121.414.LS|Administered via IV infusion or SC infusion, depending on the arm
223803975|NCT04212091|BIOLOGICAL|VRC07-523LS|Administered via IV infusion or SC infusion, depending on the arm
223803976|NCT05560048|DIETARY_SUPPLEMENT|rice protein RP-80N|rice protein RP-80NY were dried beige powder. It can be stored at room temperature, but it must be exposed to direct sunlight
223803977|NCT05560048|DIETARY_SUPPLEMENT|placebo|placebo were dried beige powder. It can be stored at room temperature, but it must be exposed to direct sunlight
223803978|NCT02563457|OTHER|periodontal manual treatment|periodontal manual treatment
223803979|NCT02563457|OTHER|no periodontal manual treatment|blood sampling
223803980|NCT05770999|OTHER|Lavender application|Lavender application
223803981|NCT03300947|DRUG|Psilocybin 100 mcg/kg|"Psilocybin belongs to the class of hallucinogen or psychedelic drugs. It is one of the major psychoactive components in mushrooms of the Psilocybe genus (magic mushrooms)."
223803982|NCT03300947|DRUG|Psilocybin 300 mcg/kg|"Psilocybin belongs to the class of hallucinogen or psychedelic drugs. It is one of the major psychoactive components in mushrooms of the Psilocybe genus (magic mushrooms)."
223803983|NCT03300947|DRUG|Lorazepam 1 mg|A medication used to treat anxiety belonging to a class of drugs known as benzodiazepines, which act on the central nervous system to produce a calming effect. This drug works by enhancing the effects of a certain natural chemical in the body (GABA).
223803984|NCT04796818|PROCEDURE|Diffusion Weighted Imaging|Undergo IVIM DWI
223803985|NCT06506578|RADIATION|Radiation|Radiation
223803986|NCT05339529|DRUG|Thymosin Alpha1, 28A-Glycine-28B-L-Arginine-28C-L-Glutamic Acid-28D-L-Alanine-28E-L-Proline-28F-L-Alanine-28G-L-Asparagine-|Thymosin alpha 1, 1.6mg injection hypodermic (I.H), every 12 hours for 5 days at least during the ICU admission. The administration will be terminated any day during the treatment when the patient is deemed as qualified for ICU discharge or dead.
223803987|NCT05339529|DRUG|Blank control|Blank control
223803988|NCT05315349|OTHER|Complete ophthalmological check-up|Preoperatively, 3 to 7 days after surgery and 1 to 2 months after surgery: fundus, optical coherence tomography angiography (OCT-A)
223803989|NCT05315349|BIOLOGICAL|Blood sampling|Preoperatively and on Day 1 of surgery: 6 tubes of approximately 5 ml each, i.e. 30 ml
223803990|NCT05341349|BIOLOGICAL|Ipilimumab|Given IV
223803991|NCT05341349|BIOLOGICAL|Nivolumab|Given IV
223803992|NCT05341349|BIOLOGICAL|Pembrolizumab|Given IV
223803993|NCT05341349|RADIATION|Stereotactic Radiosurgery|Undergo SRS
223803994|NCT05341349|PROCEDURE|Tumor Treating Fields Therapy|Undergo TTFields
223803995|NCT04865627|DEVICE|activity monitor|Both groups will wear three different activity monitors for one week. There is one observation moment which consists of four minutes lying, sitting, standing, walking and taking stairs. Participants will be filmed during this moment.
223803996|NCT05773768|DEVICE|EHRA-PATHS software tool|Newly developed care pathways integrated into a care-management software tool
223803999|NCT00715429|DRUG|vitamin d|After a two-week wash-in, subjects will take a vitamin D capsule (50,000 units) once daily for 10 days, followed by a once weekly vitamin D (50,000 units) maintenance dose for 7 weeks.
223804000|NCT00715429|DRUG|placebo|After a two-week wash-in, subjects will take a placebo capsule once daily for 10 days, followed by a once weekly maintenance dose for 7 weeks.
223804001|NCT03681158|DRUG|sodium valproate|Pharmaceutical form:Powder for oral solution reconstituted with water Route of administration: Oral
223835389|NCT04243161|OTHER|Control|"The study variables PIM, PEM, FVC, PEF and EQ-5D quality of life questionnaire will be measured on the first day when patient incorporated into the seating position in the patient's bed. Reassessments will be performed every two week till patient discharge from hospital. After that patient will be assessed after 4 month and 1 year after the SCI.~SCIM III will be administered at discharge, 4 month later and 1 year after the injury.~Common clinical practice (pulmonary expansion exercises,drainage of secretions and training of inspiratory muscles) + expiratory muscle training at 30% load after MIP measurement.~The intensity of the treatment will be 30% of the PIM value (increasing the load in 2 cmH2O weekly). Three sets of 10 reps will be performed, with one total of 30 repetitions, resting 1 minute between each series.~The sessions will be held once per day, from monday to friday, during the entire hospital admission."
223804002|NCT05616988|OTHER|psychological-clinical intervention with three days of expressive writing by Pennebaker|"The psychological-clinical intervention involves five interviews with three days of expressive writing by Pennebaker. During the psychological-clinical interviews the following aspects will be explored:~* Emotions and expectations related to the breast reconstruction process.~* Feelings related to the perception of one's own body image to promote an integration between the image of one's body and the aspects related to one's own identity and femininity.~* Thoughts and feelings related to one's relational and social life.~Expressive writing is a technique devised by Pennebaker (1986), who states that expressing deeper thoughts and feelings through writing can improve the physical and psychological health of the individual. The writing task consists of writing about a traumatic experience or a significant event for the person, for a controlled period (usually 15-30 minutes) and on consecutive days (from 2 to 3 days)."
223804003|NCT01409538|OTHER|Placebo Instructions|There is no intervention in this study. It is not a Clinical Trial. The study is an investigation of the neural basis of placebo analgesia.
223804004|NCT01409538|OTHER|Control condition|"This protocol represents an investigation of the neural mechanisms of placebo analgesia. As such, it does not represent the traditional clinical trial design. Instead the active intervention is a placebo, and the comparison condition is a no-intervention control."
223804005|NCT04772625|DEVICE|Patellofemoral arthroplasty|Insertion of an artificial joint between the front of the femur and the back of the patella. The femoral component consists of a metal implant, and the patellar component is a polyethylene implant. The two components replace the original articular cartilage of the patellofemoral joint.
223804006|NCT03543930|DEVICE|Postoperative preventive CPAP|Administration of a course of 2 hours of CPAP with 7.5 cmH2O pressure and 0.30 FIO2
223804007|NCT00618553|OTHER|Questionnaire|Questionnaire regarding quality-of-life that lasts about 30 minutes.
223804008|NCT00618553|BEHAVIORAL|Pulmonary Rehabilitation|Rehabilitation treatment given over about 3-4 weeks.
223804009|NCT00957476|DIETARY_SUPPLEMENT|Omega-3 Fish Oil|800mg DHA and 1200mg EPA or the equivalent of a placebo PO (by mouth) once a day from enrollment (prior to 16 weeks gestation) until delivery.
223804010|NCT03845153|DRUG|Metformin Retard 850 mg|tablet
223804011|NCT03845153|OTHER|Placebo|placebo tablet
223804012|NCT00185185|DRUG|Olmesartan medoxomil|
223804013|NCT00185185|DRUG|Atenolol|
223804014|NCT00185185|DRUG|Hydrochlorothiazide|tablets
223804015|NCT00185185|DRUG|olmesartan medoxomil|tablets
223804016|NCT00185185|DRUG|atenolol|tablets
223804017|NCT06537154|PROCEDURE|Active Surveillance|Participant found to have a cCR will be randomized to either standard of care or investigational active surveillance.
223804018|NCT06537154|PROCEDURE|Control arm - Definitive bladder treatment|Standard of care, consisting of radical cystectomy or chemo-radiation of the bladder
223804019|NCT02998073|BEHAVIORAL|Stop, Now and Plan|SNAP program was developed to target justice-involved youth (6 years and older) who have problems with aggression, CD, and/or gang affiliation. SNAP focuses on engaging youth in interesting and creative learning modules by providing real life scenarios designed to improve self-control, impulsive behaviors, decision-making skills, and pro-social skills. SNAP treatment is delivered over a 13-week period.
223804020|NCT04085328|DEVICE|LID015385 soft contact lenses|Investigational silicone hydrogel contact lenses for up to 6 nights/7 days of continuous wear
223804021|NCT04085328|DEVICE|Comfilcon A soft contact lenses|Silicone hydrogel contact lenses for up to 6 nights/7 days of continuous wear
223804022|NCT04041362|BIOLOGICAL|UB-421|Monoclonal antibody by IV infusion plus standard ART
223804023|NCT04041362|OTHER|Antiretroviral Therapy (ART)|Standard ART
223804024|NCT04518878|DRUG|Eltrombopag|Fixed dose of eltrombopag oral 25mg daily
223804025|NCT04518878|DRUG|rhTPO|Rh-TPO 300U/kg subcutaneous injection once daily for 7 consecutive days, followed by a tapering dose in maintenance therapy.
223804026|NCT05304338|DRUG|Chlorhexidine|Gargling with 10 mL 0.2% Chlorhexidine
223804027|NCT05304338|OTHER|Oil Pulling|In oil pulling therapy, a tablespoon of edible oil is placed in the mouth and swirled between the teeth for 15 to 20 minutes
223804028|NCT05304338|OTHER|Distilled Water|Gargling with 10 mL distilled water
223804029|NCT00330083|BIOLOGICAL|ALK Ragweed Tablet|
223804030|NCT00744484|BEHAVIORAL|Training in water|45 minutes interval training in water, submaximal intensity, twice a week
223804031|NCT00744484|BEHAVIORAL|Training on land|45 minutes interval training on land, submaximal intensity, twice a week
223804032|NCT03768492|DRUG|Caffeine anhydrous 5% added to Lipoderm Cream Base.|Caffeine USP Anhydrous 5 gm Ethoxy Digylco Reagent 10 ml Professional Compounding Centers of America (PCCA) Lipoderm Base 85 gm
223804033|NCT03768492|OTHER|Lipoderm Cream Base|Professional Compounding Centers of America (PCCA) Lipoderm Base 85 gm
223804034|NCT00514735|PROCEDURE|Medtronic Cardiac Ablation System|Arm 1 (Ablation Management): Ablation procedures using investigational catheters in left atrium. Cardioversion could be used to restore sinus rhythm if needed.
223804035|NCT00514735|DRUG|Class I or III Antiarrhythmic Medications|Arm 2 (Medical Management): Class I or III antiarrhythmic drugs. Changes in dosing, antiarrhythmic drugs or combinations of antiarrhythmic drugs were allowed. Direct current cardioversions were also allowed at the discretion of the investigator.
223804036|NCT05591339|BIOLOGICAL|BCG vaccine (two doses, 4 weeks apart)|BCG vaccine provided intradermally at the upper arm.
223804037|NCT05591339|BIOLOGICAL|Saline placebo (Two doses, 4 weeks apart)|Participants randomized to the control group (placebo) will receive one 0.1 ml dose sterile 0.9 % NaCl by intradermal injection in the left deltoid region.
223804038|NCT01920451|BEHAVIORAL|Cognitive-Behavioral Therapy for Insomnia (CBTI)|See arm description.
223804039|NCT05417620|BEHAVIORAL|Social Media Campaign|PrEP social influence campaign, which will use online approaches to promote PrEP within communities in addition to the standard of care activities. Messaging crafted with community input will be geographically targeted to women, parents/mentors, and male partners on Facebook, Instagram, and Whatsapp, all with the intention to promote PrEP for women at high risk of HIV infection and change community norms and influence around PrEP. A combination of static imagery and brief videos will be used to engage these groups via social media platforms. A Facebook page will be created and maintained that can be accessed by anyone anywhere, but will only be advertised/promoted in the intervention districts.
223804040|NCT05417620|BEHAVIORAL|PrEP Champions|Within venues served by the FSW and AGYW programs, the team will identify and train 1 venue-based PrEP champion per venue who will receive supplies (e.g. a hat, pin and posters, flyers, IEC material) to wear to promote PrEP, facilitate linkage between women interested in PrEP and the TB HIV Care PrEP programme. PrEP champions will be either peers with experience taking PrEP, venue managers or local influencers (e.g. women running shops next to the mobile serving AGYW) that have repeated contact with the women the programme is intended to serve. The final selection of PrEP champions will be made in consultation with the Community Advisory Groups, venues and by the programme who works closely with each of the sites.
223804041|NCT05417620|BEHAVIORAL|Community Mobilization|A PrEP community mobilization team (2 peers, including one woman and one man) will be recruited within each ward to promote PrEP. The team will present information about PrEP and the PrEP programme at the ward councilors meeting, at Learning Support Agent meetings with parents/guardians, at local events/fairs, community meetings and through engaging men, women and parents across the community through informal conversations. Teams will be wearing branded material and will focus on presenting factual information and decreasing PrEP stigma. Each team will focus on promoting PrEP within their own ward over the 6-month period.
223804042|NCT05417620|OTHER|Standard of Care|"Full-time peer educators employed by the TB HIV Care programme to engage women, layer PrEP promotion across prevention programs, and implement refer a friend strategies, information, education and communication (IEC) materials, service user testimonials, risk reduction posters to increase young women's perception of risk, working after hours/weekends to reach young women, working with school governing bodies, and door-to-door outreach."
223804043|NCT03821168|DRUG|injection of bevacizumab and erythropoietin|injection of bevacizumab and erythropoietin
223804044|NCT03821168|DRUG|injection of bevacizumab|under gone 3 intravitreal injection of bevacizumab monthly and examine monthly for Visual acuity and central macular thickness
223804045|NCT05989100|BEHAVIORAL|Favourate taste stimulation|The taste stimulaiton for swallowing is completed with long swab. Taste solution will be prepared with sugar, salt, citric acid, or paprika mixed with water. And the swab will be immersed in the solution and freezed in -18℃ circumstances. Bilateral buccal mucosa，palate and tounge will be brushed. Four swabs will be used in a training session.
223804046|NCT05989100|BEHAVIORAL|Sour taste stimulation|Using sour swab to brush oral cavity and tounge.
223804047|NCT05989100|BEHAVIORAL|Thermal stimulation group|Only ice-water swab to brush oral cavity and tounge.
223804048|NCT01786928|OTHER|Resistance training|Resistance training group received training program for upper (shoulder flexion and abduction and biceps) and lower limbs (knee extension and flexion and hip flexion). Daily exercise for every muscle was performed with free weights at 80% of an maximal repetition test and a 4 minutes rest was allowed between each step.
223804049|NCT03969862|DEVICE|NOVEOS® system|"The NOVEOS® System is a fully automated, high-throughput immunoassay platform that uses magnetic microbeads as a solid phase.~This is a partially closed system that is primarily intended for the determination of specific IgE with NOVEOS® Hycor allergens. It has the CE mark."
223835390|NCT05315219|PROCEDURE|Endoscopic Thyroidectomy Bilateral Areola Approach|The endoscopic thyroidectomy achieves better cosmetic effects than open thyroidectomy, and is one of the most widely applied approach in China, meanwhile its safety and effectiveness has been broadly discussed since being introduced.
223804050|NCT03346629|DRUG|Mifepristone + Misoprostol|A single dose of 200 mg mifepristone (one tablet) to be taken orally either at home or at the hospital, followed 24-48 hours later with 400mcg misoprostol (buccal) at home. The participant will return to the hospital one to two hours after taking the initial dose of misoprostol to receive repeated doses of 400 mcg misoprostol until the abortion occurs.
223804051|NCT03560427|DRUG|Duloxetine 60mg|"Patients will receive duloxetine, 60 mg tablet 2 hour before operation and will be anesthetized by combined spinal-general anesthesia that includes: spinal anesthesia with morphine 0.3 mg delivered in L4-5 inter spinous space.~General anethseia: Induction of anesthesia was done by intravenous fentanyl, 2 µg / kg and propofol 1 - 2 mg / kg. Endotracheal intubation was achieved by cis-atracurium, 0.15 mg / kg. Maintenance of anesthesia was done by isoflurane and cis-atracurium, 0.03 mg / kg on demand. Additional intraoperative analgesia was consisted of administration of intravenous boluses of fentanyl, 50 µg according to the attending anesthesiologist's decision. At the end of surgery, muscle relaxation was reversed using neostigmine 0.05 mg / kg and atropine 0.01 mg / kg."
223804052|NCT03560427|DRUG|placebo|"Patients will receive placebo tablet 2 hour before operation and will be anesthetized by combined spinal-general anesthesia that includes: spinal anesthesia with morphine 0.3 mg delivered in L4-5 inter spinous space.~General anethseia: Induction of anesthesia was done by intravenous fentanyl, 2 µg / kg and propofol 1 - 2 mg / kg. Endotracheal intubation was achieved by cis-atracurium, 0.15 mg / kg. Maintenance of anesthesia was done by isoflurane and cis-atracurium, 0.03 mg / kg on demand. Additional intraoperative analgesia was consisted of administration of intravenous boluses of fentanyl, 50 µg according to the attending anesthesiologist's decision. At the end of surgery, muscle relaxation was reversed using neostigmine 0.05 mg / kg and atropine 0.01 mg / kg."
223804053|NCT01559298|DRUG|Aspirin (80 mg/d) + clopidogrel (75 mg/d)|Aspirin (80 mg/d) + clopidogrel (75 mg/d) Aspirin therapy will start at least 24 hrs before the TAVI procedure and continued for at least 6 months. Clopidogrel therapy will start within 24 hrs before the TAVI procedure in cases where a transfemoral approach is used and within 24 hrs after the TAVI procedure in cases where a transapical approach is used. The initial dose of clopidogrel will be of 300 mg followed by 75 mg/die. The duration of clopidogrel treatment will be of 3 months. Patients will be followed either by phone contact or clinical visits at 1- and 12-month follow-up.
223804054|NCT01559298|DRUG|Aspirin|Aspirin (80 mg/d) Aspirin therapy will start at least 24 hrs before the TAVI procedure and continued for at least 6 months.
223804055|NCT00579566|OTHER|Specimen protocol|The research specimen will be obtained from the residual specimen that would otherwise be discarded per usual hospital procedure.
223804056|NCT02106988|RADIATION|Radiation Therapy|Radiation therapy delivered for a total dose of 50.4 to 54 Gy 5 days a week for 28 to 30 treatments.
223804057|NCT02106988|DRUG|Dexamethasone|40 mg by vein Days 1-3 in a 21 day cycle.
223804058|NCT02106988|DRUG|Etoposide phosphate|67 mg/m2 by vein on Days 1-3 of a 21 day cycle.
223804059|NCT02106988|DRUG|Ifosfamide|1 g/m2 by vein on Days 1-3 of a 21 day cycle.
223804060|NCT02106988|DRUG|Mesna|0.4 g/m2 by vein on Days 1-3 with Ifosfamide, 0.6 g/m2 by vein over 24 hours daily on Days 1-3 via ambulatory pump.
223804061|NCT02106988|DRUG|Carboplatin|200 mg/m2 by vein on Day 1 of a 21 day cycle.
223804062|NCT02347020|BEHAVIORAL|Normal Sleep/ Normal Meal|The subject will be inpatient for 5 days, and sleep between the hours of 0000-0800 h, with meals at 1, 5, 11, and 12.5 (snack) h after awakening every day for 5 days. On night 3, we will insert a catheter in the participant's arm to facilitate multiple blood sampling overnight and the next day. On d 4, a frequently sampled i.v. glucose tolerance test (FSIVGTT) will be performed. A MTT will be performed at the scheduled lunch. At 1 h before dinner, participants will undergo fMRI scanning to assess neuronal responses to food stimuli and to examine functional connectivity with reward circuitry. On d 5, participants will be allowed to determine their own food intake at the scheduled meal and snack times. Participants will be discharged upon awakening on day 6.
223804063|NCT02347020|BEHAVIORAL|Normal Sleep/ Late Meal|The subject will be inpatient for 5 days and sleep between the hours of 0000-0800 h,with controlled meals at 4.5, 8.5, 14.5, and 16 (snack) h after awakening. On night 3, we will insert a catheter in the participant's arm to facilitate multiple blood sampling overnight and the next day. On d 4, at the scheduled breakfast time, a frequently sampled i.v. glucose tolerance test (FSIVGTT) will be performed. A MTT will be performed at the scheduled lunch. At 1 h before dinner, participants will undergo fMRI scanning to assess neuronal responses to food stimuli and to examine functional connectivity with reward circuitry. On d 5, participants will be allowed to determine their own food intake at the scheduled meal and snack times. Participants will be discharged upon awakening on day 6.
223804064|NCT02347020|BEHAVIORAL|Late Sleep/ Normal Meal|The subject will be inpatient for 5 days, and sleep between the hours of 0330-1130 h, with controlled meals at 1, 5, 11, and 12.5 (snack) h after awakening. On night 3, we will insert a catheter in the participant's arm to facilitate multiple blood sampling overnight and the next day. On d 4, at the scheduled breakfast time, a frequently sampled i.v. glucose tolerance test (FSIVGTT) will be performed. A MTT will be performed at the scheduled lunch. At 1 h before dinner, participants will undergo fMRI scanning to assess neuronal responses to food stimuli and to examine functional connectivity with reward circuitry. On d 5, participants will be allowed to determine their own food intake at the scheduled meal and snack times. Participants will be discharged upon awakening on day 6.
223804065|NCT02347020|BEHAVIORAL|Late Sleep/ Late Meal|The subject will be inpatient for 5 days, and sleep between the hours o 0330-1130 h, with controlled meals at 4.5, 8.5, 14.5, and 16 (snack) h after awakening. On night 3, we will insert a catheter in the participant's arm to facilitate multiple blood sampling overnight and the next day. On d 4, at the scheduled breakfast time, a frequently sampled i.v. glucose tolerance test (FSIVGTT) will be performed. A MTT will be performed at the scheduled lunch. At 1 h before dinner, participants will undergo fMRI scanning to assess neuronal responses to food stimuli and to examine functional connectivity with reward circuitry. On d 5, participants will be allowed to determine their own food intake at the scheduled meal and snack times. Participants will be discharged upon awakening on day 6.
223804066|NCT00067015|DRUG|bicalutamide|
223804067|NCT00067015|DRUG|goserelin acetate|
223804068|NCT00067015|PROCEDURE|assessment of therapy complications|
223804069|NCT00067015|PROCEDURE|quality-of-life assessment|
223804070|NCT00067015|RADIATION|radiation therapy|
223804071|NCT04591522|OTHER|Healthy fecal bacteria liquid|Fecal bacteria liquid were obtained from healthy people by a feces processor, and perfused into the patient's intestine.
223804072|NCT00765232|DRUG|Ketorolac|90 mg ketorolac in 1 L of normal saline infused at 40-120 mL/hr for 18.5-23 hours beginning 0.5 hours after the end of surgery.
223804073|NCT00765232|DRUG|Placebo|1 L of normal saline infused at 40-120 mL/hr for 18.5-23 hours beginning 0.5 hours after the end of surgery.
223804074|NCT06639061|DEVICE|Hippocampal stimulation using repetitive transcranial magnetic stimulation (rTMS)|"We will use fMRI resting state data to personalize a TMS inhibitory stimulation to a cortical location that is the most strongly connected to a deeper left hippocampal target.~5 once a week sessions of rTMS will be delivered at 1-Hz stimulation frequency for 15 minutes following trauma memory reactivation."
223804075|NCT06639061|DEVICE|Sham stimulation using repetitive transcranial magnetic stimulation (rTMS)|We will use fMRI resting state data to personalize a TMS sham stimulation to a cortical location with near zero connectivity to a deeper left hippocampal target. 5 once a week sessions of rTMS will be delivered at 1-Hz stimulation frequency for 15 minutes following trauma memory reactivation.
223804076|NCT01268748|PROCEDURE|Conventional laparoscopic procedure|Patients allocated to this group will undergo laparoscopic cholecystectomy using two 12 mm ports and two 5 mm ports
223804077|NCT01268748|PROCEDURE|Experimental laparoscopic procedure|Patients allocated to this group will undergo laparoscopic cholecystectomy using only a transumbilical SILS port
223804078|NCT01273454|DRUG|OROS Hydromorphone|8,16, 32 mg once a day for 4 weeks
223804079|NCT04358003|DEVICE|Marker Therapeutics D2000 Cartridge (D2000) for use with the Spectra Optia® Apheresis System (Optia SPD Protocol)|"Subjects will receive one treatment per day with the D2000 Cartridge for up to 4 hours (treatment cycle) for up to seven (7) days. Treatment may extend beyond 7 days, up to 14 days total, if deemed necessary and useful by the principal investigator (PI). Additional cartridges may be used, if needed, to achieve the maximum daily treatment duration of 4 hours. Each day, before initiating the treatment cycle, pre-treatment chemistry and hematology, coagulation status, and disease severity scores (SOFA, APACHE II) will be collected. Then, immediately following the therapy on each treatment day, post-therapy measurements will also be collected.~Study Exit. Subjects will be exited from the study after the Day 28 follow-up visit which will occur 28 days after Study Day 1. Subjects will be included in the study for a total of 28 days. Subjects may also choose to discontinue at any time or conclude participation at the discretion of the PI or the subject's treating physician."
223804080|NCT04787601|OTHER|Exercise|Cognıtıve-based neuromuscular exercıses will be applied.
223804081|NCT04787601|OTHER|Classic Training|Classic match preparation training
223804082|NCT06372821|DRUG|NIO752|Antisense oligonucleotide
223804083|NCT06372821|OTHER|Placebo|Saline
223804084|NCT00421551|DRUG|Darunavir|during the 48 first weeks of the trial, (2x300mg) twice a day between W48 and W96, (2x400mg) once a day
223804085|NCT00421551|DRUG|ritonavir|during the first 48 weeks, 100mg twice a day between W48 and W96, 100mg once a day
223804086|NCT03869398|DIETARY_SUPPLEMENT|Tums|start their calcitriol 0.25mcg PO BID and Tums 1,500mg PO TID 5 days before surgery. The five days is determined due to the time it takes vitamin D to have an effect on the guts reabsorption of calcium.
223804087|NCT03869398|DIETARY_SUPPLEMENT|Calcitriol|start their calcitriol 0.25mcg PO BID and Tums 1,500mg PO TID 5 days before surgery. The five days is determined due to the time it takes vitamin D to have an effect on the guts reabsorption of calcium.
223804088|NCT02264704|OTHER|High intensity exericse|Participants will exercise at high intensity (70% VO2 peak) intermittently (30 seconds on, 30 seconds off) for 15 minutes, twice weekly for 15 weeks. Workload may increase as the study progresses based on heart rate response.
223804089|NCT02264704|OTHER|Moderate intensity exericse|Participants exercise at moderate intensity (35% VO2 peak) continuously for 15 minutes, twice weekly for 15 weeks. Workload may increase as the study progresses based on heart rate response.
223804090|NCT01029054|DRUG|carfilzomib, lenalidomide plus dexamethasone|"Phase I: Carfilzomib will be administered at the dosage assigned for the subject's cohort as an IV infusion on Days 1, 2, 8, 9, 15, and 16 of a 28-day cycle for Cycles 1 - 8 (induction) and on Days 1, 2, 15, and 16 of a 28-day cycle for Cycles 9+ (maintenance).~Lenalidomide will be administered PO daily at 25 mg on Days 1- 21 of the 28-day cycle for Cycles 1 - 8+.~Dexamethasone 40 mg will be administered PO or IV between 30 minutes and 4 hours preceding the carfilzomib push."
223804091|NCT01029054|DRUG|carfilzomib, lenalidomide plus dexamethasone|"Phase II: Carfilzomib will be administered at the Maximum Tolerated Dose (MTD) established in Phase I as an IV infusion on Days 1, 2, 8, 9, 15, and 16 of a 28-day cycle for Cycles 1 - 8 (induction) and on Days 1, 2, 15, and 16 of a 28-day cycle for Cycles 9+ (maintenance).~Lenalidomide will be administered PO daily at 25 mg on Days 1- 21 of the 28-day cycle for Cycles 1 - 8+.~Dexamethasone will be administered PO or IV between 30 minutes and 4 hours preceding the carfilzomib push on Days 1, 8, 15, and 22 as follows: Cycles 1-4: 40 mg; Cycles 5-8: 20 mg; and Cycles 9 and higher: 10 mg."
223804092|NCT05748912|PROCEDURE|Therapeutic bronchoscopy for removal of mucus plugs|Research participants that meet the study inclusion criteria will undergo a research bronchoscopy to remove airway mucus plugs from 1 lung for the first 5 participants, and, if single lung mucus removal is well tolerated, on both lungs for the next 5 participants.
223804093|NCT06307015|RADIATION|De-escalation|Surgical resection of primary oropharyngeal tumour followed by de-escalated radiation therapy (30Gy) with concurrent platinum-based chemotherapy to oropharynx + neck, followed by surgical neck dissection
223804094|NCT06307015|RADIATION|Standard of care|Radiation therapy (70Gy) with concurrent platinum-based chemotherapy to oropharynx + neck
223804095|NCT05916326|BIOLOGICAL|Human Norovirus Bivalent (GⅠ.1/GⅡ.4)Vaccine，Recombinant (Hansenula polymorpha)|Intramuscular injection of Human Norovirus Bivalent (GⅠ.1/GⅡ.4)Vaccine，Recombinant (Hansenula polymorpha) in the deltoid muscle of the upper arm
223804096|NCT05916326|BIOLOGICAL|placebo|Intramuscular injection of placebo in the deltoid muscle of the upper arm
223804097|NCT02652988|OTHER|Active-tDCS|Active home-based tDCS applied at home.
223804098|NCT02652988|OTHER|Sham-tDCS|Sham home-based tDCS applied at home.
223804099|NCT01428076|DRUG|Polidocanol Endovenous Microfoam (PEM)|Pharmacokinetic comparison of different doses of drug
223804100|NCT01087892|DIETARY_SUPPLEMENT|Probiotic drink containing the live strain|Probiotic drink contains no strain
223804101|NCT01087892|DIETARY_SUPPLEMENT|placebo probiotic|Placebo product is a sweetened flavoured, non fermented, acidified dairy drink
223804102|NCT04598724|OTHER|Surveys|Survey will be administered involving questions regarding knowledge and perception of palliative care.
223804103|NCT03907995|BEHAVIORAL|Cognitive Behavioral Therapy|The form of treatment will involve 6 group sessions every two weeks about an hour each. Sessions consist of teaching a different coping technique in each session to help cope with disaster or other events.
223804104|NCT02216773|PROCEDURE|Radiofrequency assisted liver partition with portal vein ligation (RALPP)|
223804105|NCT02216773|PROCEDURE|Portal vein embolization (PVE)|
223804106|NCT04274894|DRUG|AndroGel 1.62%|AndroGel 1.62% was packaged in pump bottles with quantities sufficient to accommodate study design and could have been dose adjusted between a minimum of 20.25 mg of T (1 pump actuation) and a maximum of 81.0 mg of testosterone (4 pump actuations). For the first study drug administration at the Day 1 Visit, and also at Week 2, Week 4, Week 16 ambulatory blood pressure monitoring (ABPM,) and End of Treatment Visits, participants applied the study drug while on site so that the site staff could observe the proper administration of study drug. If participants forgot to apply their AndroGel 1.62% dose at their regularly scheduled dosing time, they were to take the next dose at the next dosing time.
223804107|NCT03061565|DRUG|erythropoietin|Patients were given erythropoietin during the EPO-TBI study in 2010-2014. In the current follow-up we will evaluate any possible long term differences between patients treated with etrythropoietin compared to placebo.
223804108|NCT03061565|DRUG|Placebos|Patients were given placebo during the EPO-TBI study in 2010-2014. In the current follow-up we will evaluate any possible long term differences between patients treated with etrythropoietin compared to placebo.
223804109|NCT06309108|OTHER|Education Booklet|The education group was given training with a education booklet
223804110|NCT06309108|OTHER|Augmented Reality Group|The second of the intervention group was trained with augmented reality. Patients were able to see the augmented reality element with the 3DQR application.
223804111|NCT05491148|OTHER|work conditions|an increased degree of responsibility for the life of newborns, high psycho-emotional stress, intellectual stress, an irrational work and rest regime, in connection with the COVID-19 pandemic, also using personal protective equipment against biological factors
223804112|NCT02164877|DRUG|pectin|Patients allocated to experiment group will receive 15g pectin each day
223804113|NCT04763902|BEHAVIORAL|Time Restricted Eating (TRE) Schedule|\[See arm/group descriptions\]
223804114|NCT01936857|DRUG|Buprenorphine/naloxone|Buprenorphine/naloxone induction begins with a 2-4mg test dose followed by additional doses on the day of induction to relieve withdrawal symptoms, and then titrated to a maintenance dose between 8-24 mg/day over 1 to 3 days. Doses will be directly observed and occur daily. After a minimum of 2 weeks, dosing may be changed to 3 or 4 times per week, as determined clinically appropriate by the HIV clinic study physician. Dosing will remain flexible to a maximum dose of 24mg for daily dosing and 32mg for every other day dosing, as deemed clinically appropriate by the study physician.
223804115|NCT01936857|DRUG|Methadone Maintenance Therapy|Subjects randomized to methadone maintenance therapy (MMT) referral will meet with an HIV clinic case manager who will facilitate referral to MMT. Methadone dosing will be managed by MMT staff, who dispense methadone according to Ministry of Health guidelines for MMT.
223804116|NCT00134290|DRUG|metformin|
223804117|NCT00134290|BEHAVIORAL|"standard diet advice"|
223804118|NCT00134290|BEHAVIORAL|"personal diet advice"|
223804119|NCT02279043|BEHAVIORAL|Interaction with users of IUC and non-IUC users|"Birth Control Connect is an online community where women will be invited to share their personal experiences with birth control. Birth Control Connect group sessions will last for twelve days. Each day, participants will be prompted to respond to questions in the group (e.g. If you're using a birth control method right now, how did you choose it?). Participants will also be able to pose questions to other members of the group and respond to other members' questions. Half of participants in Birth Control Connect intervention groups will be current IUC users."
223804120|NCT02279043|BEHAVIORAL|Interaction with non-IUC users only|"Birth Control Connect is an online community where women will be invited to share their personal experiences with birth control. Birth Control Connect group sessions will last for twelve days. Each day, participants will be prompted to respond to questions in the group (e.g. If you're using a birth control method right now, how did you choose it?). Participants will also be able to pose questions to other members of the group and respond to other members' questions."
223804121|NCT05303779|OTHER|Exercise Interventions of Eye Muscles|Application of eye exercise for improving eye control post strabismus surgery
223804122|NCT05303779|DRUG|Medication and eye glasses|medication and eye glasses used post strabismus surgery
223804123|NCT01278134|DRUG|Copegus placebo|1000 mg or 1200 mg daily orally in split doses (morning/evening), up to 24 weeks
223804124|NCT01278134|DRUG|RO5024048|1000 mg bid orally, up to 24 weeks
223804125|NCT01278134|DRUG|danoprevir|100 mg bid orally, up to 24 weeks
223804126|NCT01278134|DRUG|peginterferon alfa-2a [Pegasys]|180 mcg sc weekly, 24 weeks
223804127|NCT01278134|DRUG|ribavirin [Copegus]|1000 mg or 1200 mg daily orally in split doses (morning/evening), up to 24 weeks
223804128|NCT01278134|DRUG|ritonavir|100 mg bid orally, up to 24 weeks
223804129|NCT02124265|DRUG|CeraLyte 90|"1. This is a prospective pilot study of patients with moderate-major burn wounds (20-65% TBSA).~2. Patients who meet inclusion/exclusion criteria will be enrolled in the study upon admission to the Burn Unit.~3. Fluid requirements will be calculated according to the Parkland Formula (4 cc/kg/% Total Body Surface Area) administered over 24 hours since time of injury.~5\. Patients will be monitored according to standard of care.~a. If gastric residuals are \>300cc, ORT will be stopped and only IV fluid resuscitation will be used."
223804130|NCT01795365|OTHER|Active surveillance|
223804131|NCT02067260|DEVICE|X5 HairLaser|Treatment consists of three, 10-15 minute, at-home treatments per week (on nonconcurrent days) for 26 weeks.
223804132|NCT02067260|DEVICE|X5 Hair Laser Sham Device|Treatment consists of three, 10-15 minute, at-home treatments per week (on nonconcurrent days) for 26 weeks.
223804133|NCT06524674|DIETARY_SUPPLEMENT|Hydration Multiplier + Energy|Participants will be administered one oral serving of an oral rehydration solution containing caffeine and l-theanine
223804134|NCT06524674|DIETARY_SUPPLEMENT|Hydration Multiplier + Sleep|Participants will be administered one oral serving of an oral rehydration solution containing melatonin and l-theanine
223804135|NCT06524674|DIETARY_SUPPLEMENT|Energy Comp|Participants will be administered one oral serving of a comparator oral rehydration solution containing caffeine and l-theanine
223804136|NCT06524674|OTHER|Sleep Comp|Participants will be administered one oral serving of a comparator oral rehydration solution containing melatonin and l-theanine
223804137|NCT05608850|OTHER|Exercise Then Stretch|This arm (sequence) will perform an anti-gravity kinetic chain intervention and then a passive, partner-assisted stretching intervention, separated by a one-week washout period.
223804138|NCT05608850|OTHER|Stretch Then Exercise|This arm (sequence) will perform a passive, partner-assisted stretching intervention and then an anti-gravity kinetic chain intervention , separated by a one-week washout period.
223804139|NCT00490282|RADIATION|Intensity Modulated Radiation Therapy|IMRT Treatment Over 6-7 Weeks
223804140|NCT00490282|RADIATION|Adaptive Radiotherapy|ART Treatment Over 6-7 Weeks
223804141|NCT03220243|DRUG|MSC-AFP|Eligible patients will be treated with a fistula plug that has been coated with autologous mesenchymal stromal cells.
223804142|NCT01666808|DRUG|FACBC|FACBC is given intravenously prior to PET scan, radiotherapy decisions and treatment guided by PET findings
223804143|NCT01666808|RADIATION|Radiation therapy|External beam radiotherapy to prostate bed +/- pelvic lymph nodes; final dose of 66.6 Gy.
223804144|NCT05087381|DRUG|FluvoxaMINE Maleate 50 MG|"The subjects received fluvoxamine (immediate release) 50 mg, 1 tablet in the morning and 50 mg 2 tablets before bedtime, orally after meals. For a total of 14 days, the first two days and the last two days, 50 mg 1 tablet in the morning and 50 mg 1 tablet at bedtime.~All enrolled patients will be provided a thermometer as well as a fingertip probe pulse oximeter, with the specific instructions to monitor both temperature at oxygen saturation at the time of daily oral administration of drug. In addition, Oropharyngeal swab samples will be collected for viral shedding as measured by PCR on days 0, 7 and 14. Fecal and blood samples will be collected for viral shedding as measured by PCR on days 0,7 and 14. A baseline fecal and oropharyngeal sample will be obtained on Day 0 prior to starting dosing of drugs."
223804145|NCT05087381|COMBINATION_PRODUCT|Fluvoxamine, Bromhexine|"The subjects received fluvoxamine (immediate release) 50 mg, 1 tablet in the morning and 50 mg 2 tablets before bedtime, orally after meals. For a total of 14 days, the first two days and the last two days, 50 mg 1 tablet in the morning and 50 mg 1 tablet at bedtime. Co- administration with bromhexine 8 mg, 1 tablet twice taken after meals and taken at least 8 hours apart, for 10 days.~All enrolled patients will be provided a thermometer as well as a fingertip probe pulse oximeter, with the specific instructions to monitor both temperature at oxygen saturation at the time of daily oral administration of drug. In addition, Oropharyngeal swab samples will be collected for viral shedding as measured by PCR on days 0, 7 and 14. Fecal and blood samples will be collected for viral shedding as measured by PCR on days 0,7 and 14. A baseline fecal and oropharyngeal sample will be obtained on Day 0 prior to starting dosing of drugs."
223804146|NCT05087381|COMBINATION_PRODUCT|Fluvoxamine, Cyproheptadine|"The subjects received fluvoxamine (immediate release) 50 mg, 1 tablet in the morning and 50 mg 2 tablets before bedtime, orally after meals. For a total of 14 days, the first two days and the last two days, 50 mg 1 tablet in the morning and 50 mg 1 tablet at bedtime. Co- administration with cyproheptadine 4 mg, 1 tablet, three times, orally after meals and should be taken every 8 hours apart, for 14 days.~All enrolled patients will be provided a thermometer as well as a fingertip probe pulse oximeter, with the specific instructions to monitor both temperature at oxygen saturation at the time of daily oral administration of drug. In addition, Oropharyngeal swab samples will be collected for viral shedding as measured by PCR on days 0, 7 and 14. Fecal and blood samples will be collected for viral shedding as measured by PCR on days 0,7 and 14. A baseline fecal and oropharyngeal sample will be obtained on Day 0 prior to starting dosing of drugs."
223804147|NCT05087381|DRUG|Niclosamide Pill|"The subjects received 1 tablet of niclosamide 1000 mg orally in divided doses twice a day. After meals in the morning and evening for a total of 14 days.~All enrolled patients will be provided a thermometer as well as a fingertip probe pulse oximeter, with the specific instructions to monitor both temperature at oxygen saturation at the time of daily oral administration of drug. In addition, Oropharyngeal swab samples will be collected for viral shedding as measured by PCR on days 0, 7 and 14. Fecal and blood samples will be collected for viral shedding as measured by PCR on days 0,7 and 14. A baseline fecal and oropharyngeal sample will be obtained on Day 0 prior to starting dosing of drugs."
223804148|NCT05087381|COMBINATION_PRODUCT|Niclosamide, Bromhexine|"The subjects received 1 tablet of niclosamide 1000 mg orally in divided doses twice a day. After meals in the morning and evening for a total of 14 days. Co-administration with bromhexine 8 mg, 1 tablet twice taken after meals and taken at least 8 hours apart, for 10 days.~All enrolled patients will be provided a thermometer as well as a fingertip probe pulse oximeter, with the specific instructions to monitor both temperature at oxygen saturation at the time of daily oral administration of drug. In addition, Oropharyngeal swab samples will be collected for viral shedding as measured by PCR on days 0, 7 and 14. Fecal and blood samples will be collected for viral shedding as measured by PCR on days 0,7 and 14. A baseline fecal and oropharyngeal sample will be obtained on Day 0 prior to starting dosing of drugs."
223804149|NCT05350943|PROCEDURE|HAIC|After successful percutaneous hepatic artery cannulation, superior mesenteric arteriogram and hepatic arteriogram were performed, and after confirming that the subjects were eligible for enrollment according to the results, the hepatic artery was cannulated to the predetermined position. The catheter was connected to a syringe pump in the ward for continuous pumping of drugs.
223804150|NCT05350943|DRUG|Gemcitabine|1000 mg/m\^2 in 100ml saline solution IV, d1, Q3W
223804151|NCT05350943|DRUG|Oxaliplatin|85 mg/m\^2 in 500ml 5% glucose solution over 2 hours IV, d1, Q3W
223804152|NCT05350943|DRUG|Toripalimab|3mg/kg (body weight \< 60kg) or 240 mg（body weight\>= 60kg）in 250 saline soluation, IV, Q3W
223804153|NCT05350943|DRUG|Donafenib|0.2mg. P.O, BID, continuously
223804154|NCT02185625|DEVICE|Safe Delivery smartphone application|The intervention is the use of a smartphone application called Safe Delivery, designed by University of Copenhagen, Denmark and Maternity Foundation Denmark. The application contains animated videos aimed to train midwives in the prevention and management of postpartum hemorrhage and the treatment of neonatal resuscitation. The instructions in the videos are based on WHO recommendations, and the application is designed to be an on-going tool for midwives, so that they can drill themselves in the emergencies of postpartum hemorrhage and neonatal resuscitation.
223804155|NCT04021303|DIETARY_SUPPLEMENT|Experimental cereal|Cereal containing probiotics, prebiotic fiber and low carbohydrates
223804156|NCT04021303|DIETARY_SUPPLEMENT|Conventional cereal|Gluten free conventional cereal (from 4 to 6 months old) and conventional cereal with gluten (from 7 to 12 months old)
223804157|NCT01901107|DRUG|Kiklin capsules|oral
223804158|NCT01407081|BEHAVIORAL|Telerehabilitation Cognitive Strategy Training|The strategy intervention is a 16-week program during which a trained rehabilitation coach speaks by telephone to the stroke participant and their caregiver twice a week (one approximately 45-minute 'training' call and one approximately 15-minute 'update' call). Rehabilitation discussions during the training calls will follow a detailed protocol and focus each week on the stroke education and cognitive strategy training information provided in each section of the manual provided to the participants.
223804159|NCT04668196|DEVICE|High-flow nasal cannula treatment|Standard operating procedures represented by hihg-flow nasal cannula oxygen therapy
223804160|NCT04668196|DEVICE|Continuous positive airway pressure (CPAP) treatment|Standard operating procedures represented by continuous positive airway pressure (CPAP) therapy
223804161|NCT04668196|DEVICE|Noninvasive ventilation treatment|Standard operating procedures represented by noninvasive ventilation treatment
223804162|NCT01525602|DRUG|PLX3397|PLX3397 tablets, 200mg
223804163|NCT01525602|DRUG|Paclitaxel|Paclitaxel IV
223804164|NCT01638325|DRUG|Insulin Lispro|Administered SC
223804165|NCT01638325|DRUG|BC106 insulin lispro|Administered SC
223804166|NCT06124040|BEHAVIORAL|psychological assessment evaluation|"A prospective data collection will be performed with self-administered psychological measures, with the aim to compare two different groups of patients with cervical cancer neo diagnosis, candidates for non conservative surgery or radio-chemotherapy treatment, based on FIGO Gynecologic Oncology Committee Guidelines.~Test will be repeated at Time 0 (firs access in radiotherapy Day Hospital, or first access in hospital ward for surgery), and Time 1 (after 6 months)."
223804167|NCT05316441|BEHAVIORAL|psychoeducation|Positive Psychotherapy is a recently emerged therapy method that works on talents. In the study, success skill development psychoeducation based on positive psychotherapy will be applied.
223804168|NCT05684406|GENETIC|Genotyping|Genotyping by Real Time PCR
223804169|NCT05655026|DEVICE|NIV, HFNO|Arterial blood pressure and saturation will be measured. Arterial blood gases will be collected to qualify patients to one of the three groups. After qualification, patient will be randomly assigned to a given respiratory support method during FB.
223804170|NCT05970822|DRUG|BC3402|Escalating of BC3402 will be administered IV(intravenous)
223804171|NCT05970822|DRUG|Azacitidine|Azacitidine will be administered daily
223804172|NCT00824096|PROCEDURE|Bronchoscopy|The patients in our ICU intubated for \> 24h and met weaning criteria, will be examined by bronchoscopy. Five ㏄ blood will be collected for checking CRP and cytokines before performing bronchoscopy. The proposed grading of post-extubation vocal cord finding were shown (Figure 1). The patients will be classified to two groups (Figure 2). The first group is these patients without swelling or swelling area ≦50% who will be extubated after bronchoscopic examination. These patients will be followed for 48 hours to monitor the incidence of PES. The second group is those patients who develop laryngeal edema with swelling area ≧50% or swelling in the whole vocal cord. Bosmin 2 ml local injection and Solu-medrol 40 mg I.V. Q6h for 1\~4 days will be given. Bronchoscopy will be done if CLV ≧24% or after treatments for 3\~4 days even with CLV \<24%. The above treatments will be applied again if stridor develops. Extubation will be performed if no presence of laryngeal edema.
223804173|NCT04413591|BEHAVIORAL|Community based combination HIV prevention package|The intervention compares the efficacy of a community-based comprehensive HIV/STI prevention package compared to standard of care (HIV testing, counseling, and referrals) among Female Sex Workers.
223804174|NCT05887505|OTHER|Vitamin D|Oral supplementation of 576,000IU/day vitamin D3 in 3 consecutive days
223804175|NCT05887505|OTHER|Placebo|Oral supplementation of placebo in 3 consecutive days.
223804176|NCT01105026|DEVICE|Alveolar Bone Defect Regeneration Following Tooth Extraction|"Patients underwent surgery under local anesthesia and minimally invasive periotomy was carried out with a surgical blade. Atraumatic extraction with forceps was performed. The extraction socket was carefully curetted to remove the granulation tissue and was rinsed with a physiologic solution. To evaluate the eligibility of the surgical site, the alveolar walls integrity was checked clinically and by means of extemporaneous peri-apical radiography.~Then, the socket was filled to the bone margin with Inion BioRestore™ (granules size 1 to 2 millimetres). Finally, single interrupted (5-0) sutures were tightened to promote the stability of grafted particles. Ten days after the surgery, sutures were removed."
223804177|NCT02335008|DIETARY_SUPPLEMENT|Sucralose|2 packets per 12 fl oz
223804178|NCT02335008|DIETARY_SUPPLEMENT|Sucrose|equisweet to sucralose
223804179|NCT01452997|DRUG|NSAI treatment|Ibuprofen 5% gel
223804180|NCT01452997|DRUG|Steroid treatment|Steroid intervention with 0.05% w/w clobetasone butyrate.
223804181|NCT00656279|BEHAVIORAL|Intensive dietary phosphorus education|Intensive dietary phosphorus education will be completed using the Phosphorus Point System Tool, a booklet listing phosphorus points for food items based on the phosphorus content. Patients will be allotted a maximum of 32-40 phosphorus points daily. Points consumed will be tracked by the patients via daily tracking sheets which require patients to list the phosphorus food items consumed, the number of points, and the time and amount of phosphate binders. Patients in this group will also receive intensive education about phosphorus additives. As a part of the program that supports the tool, patients will receive weekly telephone calls for the first 6 weeks to address any questions about the tool and find phosphorus point values of foods not listed within the tool.
223804182|NCT00965926|DRUG|YM178|oral
223804183|NCT04469686|COMBINATION_PRODUCT|Twice daily 90 mg hydrocortisone acetate suppository administered with Sephure applicator|Twice daily 90 mg hydrocortisone acetate suppository administered with Sephure applicator
223804184|NCT04469686|COMBINATION_PRODUCT|Once daily 90 mg hydrocortisone acetate or placebo suppository administered with Sephure applicator|Once daily 90 mg hydrocortisone acetate or placebo suppository administered with Sephure applicator
223804185|NCT04469686|COMBINATION_PRODUCT|Twice daily placebo suppository administered with Sephure applicator|Twice daily placebo suppository administered with Sephure applicator
223804186|NCT03577067|PROCEDURE|Liver resection for primary and secondary disease|Liver resection in parenchyma-sparing setting for primary and secondary disease
223804187|NCT00129922|DRUG|paclitaxel|
223804188|NCT00129922|DRUG|Fluorouracil|
223804189|NCT00129922|DRUG|Epirubicin|
223804190|NCT00129922|DRUG|Cyclophosphamide|
223804191|NCT05351996|DEVICE|Kinesiotape|The participants received kinesiotape application three times with one-week intervals. Y strip tape was used. The interventionist applied the band to the rectus femoris muscle with facilitation technique.
223804192|NCT05351996|DEVICE|Sham-kinesiotape|"The participants received sham-kinesiotape application three times with one-week intervals.~In the sham group, the interventionist adhered KT to the rectus femoris transversely, without stretching."
223804193|NCT05351996|OTHER|Home-based exercise program|Participants were taught exercise program training. The exercise intervention was based on quadriceps and knee flexor muscle group strengthening, and knee joint range of motion exercises, in their home.
223804194|NCT05139667|DRUG|Corticosteroid Topical|topical tacrolimus and corticosteroids
223804195|NCT04904770|DEVICE|Scoop stretcher|Already included in arm/group description
223804196|NCT04904770|DEVICE|Vacuum mattress|Already included in arm/group description
223804197|NCT01194570|DRUG|Ocrelizumab|Two IV infusions of 300 mg in each treatment cycle of double blind treatment period; two IV infusions of ocrelizumab 300 mg for Cycle 1 and single IV infusion of ocrelizumab 600 mg for subsequent cycles in OLE phase.
223804198|NCT01194570|OTHER|Placebo|Two IV infusions of placebo matched to ocrelizumab in each treatment cycle of double blind treatment period.
223804199|NCT03060655|BIOLOGICAL|PLGA-Mg material|The PLGA-Mg material was used to accomplish the fixation of fragments. Then, the clinical outcome was assessed.
223804200|NCT03060655|BIOLOGICAL|titanium alloy|Traditional fixation was titanium alloy. the clinical outcome was assessed.
223804201|NCT00806234|DRUG|Aripiprazole or Perphenazine|Baseline second generation antipsychotic (SGA) treatment will be gradually decreased and discontinued over 8 weeks while treatment with aripiprazole or perphenazine will be increased to effective levels.
223804202|NCT00806234|DRUG|Metformin|Metformin treatment will be added to current SGA treatment, with dosing based on participant weight and increased according to a preset titration schedule unless side effects interfere.
223804203|NCT00806234|DRUG|Olanzapine, quetiapine, risperidone, ziprasidone, aripiprazole, asenapine, iloperidone, lurasidone, paliperidone, or olanzapine/fluoxetine|Current antipsychotic medication will be continued throughout the treatment period, with changes in dose only made as clinically indicated
223804204|NCT06009601|DIAGNOSTIC_TEST|Pectus Study Form|"Pectus study forms consisting of clinical and radiological measurements of patients aged 3-18 years who applied to the outpatient clinic with chest deformity will be filled in in detail.~In addition, this study form includes 'Quality of Life Evaluation Form in Pectus Deformity', 'Social Comparison Scale', 'Sleep Disorder Scale for Children', 'Anxiety Disorders Screening Scale in Children', 'Pediatric Quality of Life Questionnaire' designed for patients and their relatives. PedsQL)', 'SRS-22 Patient Questionnaire', 'Beck Anxiety Scale' and 'Informed Consent Form' designed for patients and their relatives."
223804205|NCT06009601|DIAGNOSTIC_TEST|Adams Test|Adams test (forward bending test) (+) was measured by Bunnell scoliometer (scoliosis assessment tool) and ATR (angle of trunk rotation angle) values were 7 degrees in patients who meet the inclusion criteria will be included in the study by filling out an informed consent form
223804206|NCT06009601|DIAGNOSTIC_TEST|Scoliosis Graphy|"ATR (angle of trunk rotation) values above 7 degrees on bunnell scoliometer were determined. Afterwards, patients who meet the inclusion criteria will be included in the study by filling out an informed consent form and a scoliosis graphy will be requested.~Coronal, sagittal balance; coronal and sagittal cobb angles will be measured from posterior-anterior (PA) (posterior-anterior) and lateral (lateral) scoliosis radiographs."
223804207|NCT06009601|DIAGNOSTIC_TEST|Pulmonary function test|"Pulmonary function tests (PFTs) are noninvasive tests that show how well the lungs are working. The tests measure lung volume, capacity, rates of flow, and gas exchange. This information can help your healthcare provider diagnose and decide the treatment of certain lung disorders.~There are 2 types of disorders that cause problems with air moving in and out of the lungs:~Obstructive. This is when air has trouble flowing out of the lungs due to airway resistance. This causes a decreased flow of air.~Restrictive. This is when the lung tissue and/or chest muscles can't expand enough. This creates problems with air flow, mostly due to lower lung volumes."
223804208|NCT03662932|OTHER|Early intensive mobilization|"Early mobilization: mobilization with the hospital staff begins already on the day of surgery, and includes mobilization in and out of bed, rise up from a chair, standing and walking.~Intensive mobilization: mobilization more than 4 times a day in the first postoperative week."
223804209|NCT00006364|DRUG|omacetaxine mepesuccinate|Given IV or SC
223804210|NCT00006364|OTHER|pharmacological study|Correlative studies
223804211|NCT00006364|OTHER|laboratory biomarker analysis|Correlative studies
223804212|NCT04922151|DRUG|601|intravitreal recombinant humanized anti-VEGF monoclonal antibody
223804213|NCT04922151|DRUG|Ranibizumab|intravitreal recombinant humanized anti-VEGF monoclonal antibody
223804214|NCT04123678|DEVICE|Deep Ensemble for the Recognition of Malignancy (DERM)|AI-based decision support tool
223804215|NCT00003979|DRUG|CHS 828|
223804216|NCT05347264|OTHER|gun massager|15 to 20 minutes along with hot pack.
223804217|NCT05347264|OTHER|transverse friction massage|15 to 20 minutes along with hot pack.
223804218|NCT03076970|DRUG|lasmiditan 200 mg|drug including single placebo tablet
223804219|NCT03076970|DRUG|Sumatriptan|drug including single placebo tablet
223804220|NCT03076970|DRUG|matching placebo|single oral tablet -given with single lasmiditan tablet and with single sumatriptan tablet.
223804221|NCT03893721|DIAGNOSTIC_TEST|arsenic exposure|analysis of hair samples for Arsenic using Agilent graphite tube atomizer 120
223804222|NCT04805060|DRUG|TQB2858 injection|TQB2858 administered intravenously (IV) on Day 1 of each 21-day. The established dose of TQB2858 is diluted with normal saline \[0.9% (w/v) sodium chloride solution\], and the infusion time is 60 ± 10 min.
223804223|NCT02697279|PROCEDURE|Traditional Incision and Drainage.|Control Group- Standard treatment of a simple cutaneous abscess with traditional I\&D technique with or without packing utilizing a standard I\&D kit.
223804224|NCT02697279|PROCEDURE|Loop drainage|Study Group- Treatment of a simple cutaneous abscess with the loop drainage technique utilizing an standard I\&D kit and the cuff of a sterile glove for a loop device.
223804225|NCT00503022|DRUG|ACZ885|
223804226|NCT04649502|COMBINATION_PRODUCT|Metformin|Metformin in combination with doxycycline
223804227|NCT05654792|DEVICE|Transcatheter aortic valve implantation|Transcatheter aortic valve implantation in cases of severe aortic stenosis
223804228|NCT03866941|BEHAVIORAL|causes of abuse synthetic cannibinoids|Epidemiological data (age, sex, residence, occupation, route of abuse, the cause of abuse and smoking) (2) Symptoms and signs (seizures, psychosis, hallucinations) (3) Injuries and their relation to violence (type of wound, type of instrument, number of injuries, external or internal injuries and assailant or victim).
223804229|NCT04556994|OTHER|Phase 1 Cardiac Rehabilitation|"Step 1:Breathing exercises, 3 sets of 10 repetitions. Active upper and lower extremity exercises, 3 sets of 10 repetitions; bed inclined at 45°.~Step 2:Active exercises as in step 1. Stay in the upright position and perform walking on the spot for three series of 1 min.~Step 3:Active exercises as in step 2. Ambulation within the inpatient wards (7 min). Transfer to an allocated chair beside the bed (at least 30 min).~Step 4:Same exercises as in step 3. Ambulation within the inpatient wards (10 min). Transfer to an allocated chair beside the bed (at least 1 h).~Step 5:Same exercises as in step 4. Ambulation within the inpatient wards (15 min). Transfer to an allocated chair beside the bed (at least 2 h).~Step 6:Active exercises from the previous day. Ambulation within the inpatient wards (20 min). Step training (3 times continuously, 20 cm standardized step).~Step 7:Exercises from the previous day. Step training (6 times continuously, 20 cm standardized step)."
223804230|NCT04556994|OTHER|Phase 1 Cardiac Rehabilitation with Lower Limb Paddling|Step 1 to step 6 of Phase 1 Cardiac Rehabilitation given to the patients along with Lower limb exercise on Paddler lasting 20 min (5-min warm-up, 10 min of low-intensity exercise, and 5-min recovery), 30 rpm ( rotation per minute)
223804231|NCT02543658|DRUG|Neostigmine Methylsulfate 1 MG/ML|The initial dose was 1mg, intramuscular injection(IM) once every 12 hours. If there is no defecation after 12 hours, the dose is increased to 1mg IM once every 8 hours; if there is no defecation after 24 hours, the dose is increased to 1mg IM once every 6 hours. If the abdominal pressure drops below 12mmhg, neostigmine will be stopped, otherwise it will be used continuously for 7 days.
223804232|NCT02543658|COMBINATION_PRODUCT|Conservative treatment|Intragastric administration of paraffin oil, 50ml,once every 8 hours；gastrointestinal decompression with nasogastric tube and rectal tub; lycerin enema promotes defecation; patients with ascites undergo percutaneous puncture drainage. Other conservative medical treatment recommended by the guidelines.
223804233|NCT03688984|BEHAVIORAL|Cognitive Behavioural Therapy for Insomnia|Cognitive Behavioural Therapy for Insomnia (CBT-I) consists of six individual therapy sessions that last approximately one hour each. The sessions include psychoeducation about insomnia, goal setting, relaxation training, stimulus control, sleep consolidation and medication review. Additional components include cognitive therapy, sleep hygiene and mindfulness and relapse prevention.
223804234|NCT05807113|OTHER|Atopi intensive care BNO 3731|Crem twice daily
223804235|NCT05807113|OTHER|Benchmark product|Crem twice daily
223804236|NCT05980208|DRUG|Inetetamab|Inetetamab-based treatment for first-line treatment of HER2-positive MBC
223804237|NCT03552133|DEVICE|Smart CO2|A lightweight, cylindrical reservoir attached to a face mask which monitors breathing breath-by-breath and automatically adjusts the level of dead space rebreathe volume so that CO2 will be increased and sleep apnea treated.
223804238|NCT00789815|DEVICE|Bispectral index guide propofol infusion|"Induction:~Alfentanil: 5μg/kg slowly push. Propofol: 0.5-1.5mg/kg slowly push till BIS value 70.~Maintenance:~Propofol infusion (3\~12 mg/kg/hour) to maintain BIS around 65\~75. Alfentanil: 5μg/kg slowly push Q15min prn if severe cough."
223804239|NCT00789815|DRUG|Clinical-judged midazolam administration|"Induction:~Alfentanil: 5μg/kg slowly push. Midazolam: 2 mg slowly push followed by increments of 2 mg/ 2min till OAA/S\* 2\~3.~Maintenance:~Midazolam: 2 mg/ 2min prn to keep OAA/S\* 2\~3 or if intolerance of procedure. Alfentanil as study arm.~\*Observer's assessment of alertness/sedation (OAA/S):~Class 5: Responds readily to name spoken in normal tone.~Class 4: Lethargic response to name called in normal tone.~Class 3: Responds only to name called loudly.~Class 2: Responds only to shaking.~Class 1: No response to shaking."
223804240|NCT05189626|OTHER|Muscle energy technique|Post Isometric relaxation(muscle energy technique) 3 days/ week for 4 weeks
223804241|NCT05189626|OTHER|Kaltonborn mobilizations|Kaltonborn mobilizations grade II and III will be performed on Glenohumeral joints 3 days/ week for 4 weeks.
223804242|NCT05074355|DRUG|Azacitidine|Azacitidine is a hypomethylating agent that works by activating certain genes in the body to help cells mature and to kill abnormal bone marrow cells.
223804243|NCT05074355|DRUG|Venetoclax|Venetoclax is a drug that blocks a protein called B-cell lymphoma (BCL2) protein from working. BCL2 is a protein that helps control whether a cell lives or dies and is thought to help cancer cells to live. Blocking BCL2 is believed to help kill cancer cells.
223835391|NCT03713814|OTHER|Exercise|"8-week exercise program, three times a week, during 45 minutes each section. Exercises for strength, endurance and mobility of the spine using pilates´ball and mat.~The researcher will explain, demonstrate and supervise the participants. It will start with 10 minutes of warming-up using a ergometer bicycle, followed by the mat exercises. Some of these will require motor control with mobility, others will require isometry, or concentric and eccentric phases with progression of eccentric phase timing."
223804244|NCT03963661|BEHAVIORAL|c-SIGHT (computorized spatial innatention grasping home-based therapy)|C-SIGHT will be self-administered at people's homes. c-SIGHT is a computerized therapy administered via people's television. The therapy involves performing repeated rod lifts with the less impaired arm in response to auditory and visual instructions presented on the television screen connected to a laptop. A small motion-tracking camera monitors rod lifts during therapy sessions. People will be asked to self-administer c-SIGHT for 1 hour a day (30min after breakfast and 30min after lunch) for 7 consecutive days. The first day of therapy will be performed with a therapist there for training purposes.
223804245|NCT02035332|DEVICE|Aurora Endometrial Ablation System|Ablation of the endometrial lining of the uterus using the Aurora System
223804246|NCT03554993|DRUG|CC-99677|CC-99677
223804247|NCT03554993|OTHER|Placebo|Placebo
223804248|NCT04465279|DEVICE|Trifocal diffractive intraocular lens|Trifocal IOL having foldable single-piece fully diffractive pupil dependent aspheric IOL. Which have been made of hydrophilic acrylic with an ultraviolet (UV) and blue light inhibitor. It has an optic diameter of 6.15 mm and an overall diameter of 10.75 mm; it has +3.5D additional power for near vision and +1.75 D additional power for intermediate vision, consisting of 26 diffractive steps.
223804249|NCT05994144|OTHER|VIDEO OBSERVED THERAPY|Video-observed therapy is the usage of teleconferencing to observe anti-TB medication ingestion.
223804250|NCT00662857|DRUG|Technosphere® Insulin Inhalation Powder|TI Inhalation Powder, two 15 U cartridges
223804251|NCT00662857|DRUG|Technosphere Insulin® Inhalation Powder|TI Inhalation Powder, one 30 U cartridge
223804252|NCT00662857|DRUG|RAA Population|RAA Population: All subjects received a single 10 IU sc injection of insulin lispro.
223804253|NCT05995314|DIETARY_SUPPLEMENT|PLACEBO|3 mg/kg of cellulose (0 mg/kg of caffeine)
223804254|NCT05995314|DIETARY_SUPPLEMENT|3 mg/kg of caffeine|Ingestion of 3 mg/kg of body mass of caffeine
223804255|NCT05995314|DIETARY_SUPPLEMENT|6 mg/kg of caffeine|Ingestion of 6 mg/kg of body mass of caffeine
223804256|NCT01539876|PROCEDURE|Fine needle aspiration assessing tumour TNFa levels|Fine Needle aspiration will be done X5: 1 hr pre-treatment, 1hr post treatment,24 hrs post treatment, 48 hrs post treatment, and following last chemotherapy cycle
223804257|NCT01861886|DEVICE|ESS505 (BAY1454033)|Bilateral hysteroscopic placement of the permanent birth control system, Model ESS505 in the proximal portion of the fallopian tubes using a transvaginal approach. Subsequent transvaginal ultrasound (TVU) or hysterosalpingogram (HSG) was performed approximately ≤ 3 hours and 90 days following insert placement.
223804258|NCT01827826|BEHAVIORAL|Telephonic intervention to prevent Diabetes Mellitus, Type 2|Participants assigned to the intervention group received a total of 16 phone calls from the study interventionist over 24 weeks. The first 12 weeks was the intervention phase and calls were made weekly. The second 12 weeks was the maintenance phase and calls were made every 3 weeks. After 24 weeks, the investigators continued to follow this group for 52 weeks post-randomization, allowing half of the group to continue to receive monthly maintenance calls while the other half received no further calls. The study interventionist used behavior modification techniques to encourage intervention group participants to adopt healthy eating and exercise habits so that improvement might be seen in fasting glucose, glycated hemoglobin (HbA1c), weight, and waist/hip measurements.
223804259|NCT03966053|DRUG|Trifluoperazine|Trifluoperazine (TFP)1mg, 2mg, 5mg, or 10mg will be given once daily by mouth for 21 days
223804260|NCT04407013|OTHER|Enhanced supportive care based on standardized care pathway|Enhanced supportive care based on standard care pathway is consisted of 1) symptom management (symptom assessment and according management) and 2) coping enhancement (nurse-led counseling). The enhanced supportive care will be provided 5 times, according to the standardized care pathway.
223804261|NCT04407013|OTHER|Control group with usual care|Control group will receive usual care (symptom monitoring only)
223804262|NCT00005954|DRUG|temozolomide|
223804263|NCT02026856|DRUG|sodium selenite pentahydrate|
223804264|NCT02026856|OTHER|placebo - continuous saline NaCl 50 ml|
223804265|NCT04793919|DRUG|Mylotarg|See the protocol
223804266|NCT04793919|DRUG|Arsenic Trioxide|See the protocol
223804267|NCT04793919|DRUG|All-trans retinoic acid|See the protocol
223804268|NCT05750186|OTHER|Abdominal Massage|Abdominal massage is a noninvasive application that stimulates bowel movements by applying patting, kneading and vibration movements over the abdominal wall to the area where the intestines are located. It increases peristalsis, creates a mechanical and reflex effect on the intestines, reducing the individual's feeling of pain and discomfort.
223804269|NCT01756664|OTHER|Sunscreen|
223804270|NCT01756664|OTHER|Vaseline|
223804271|NCT01487278|DRUG|misprostol|600 mcg misoprostol oral
223804272|NCT01487278|DEVICE|UnijectTM|10 IU oxytocin delivered intramuscularly with UnijectTM
223804273|NCT00003578|DRUG|CHOP regimen|
223804274|NCT00003578|DRUG|carmustine|
223804275|NCT00003578|DRUG|cyclophosphamide|
223804276|NCT00003578|DRUG|cytarabine|
223804277|NCT00003578|DRUG|doxorubicin hydrochloride|
223804278|NCT00003578|DRUG|etoposide|
223804279|NCT00003578|DRUG|melphalan|
223804280|NCT00003578|DRUG|prednisone|
223804281|NCT00003578|DRUG|vincristine sulfate|
223804282|NCT00003578|PROCEDURE|autologous bone marrow transplantation|
223804283|NCT00003578|PROCEDURE|peripheral blood stem cell transplantation|
223804284|NCT00823784|PROCEDURE|Transanal doppler hemorrhoidal ligation|THD technique involves identification and ligation of the terminal hemorrhoid arteries (about 6) followed by mucopexy
223804285|NCT00823784|PROCEDURE|stapled hemorrhoidopexy|Staple hemorrhoidopexy involves resection of a ring of low rectal mucosa an lifting the hemorrhoids up in the anal canal with a stapled suture
223804286|NCT00003092|DRUG|paclitaxel|
223804287|NCT03895164|BEHAVIORAL|Enhanced NE|Standard nutrition education package from primary health care enhanced with local specific food-based complementary feeding recommendation
223804288|NCT03895164|BEHAVIORAL|Standard NE|Standard nutrition education package from primary health care
223804289|NCT06184711|DEVICE|Transcranial Magnetic Stimulation+McNeill Dysphagia Therapy Programme|The McNeill Dysphagia Therapy programme (MDTP) combined with Transcranial Magnetic Stimulation (TMS) will be applied to the first experimental group.
223804290|NCT06184711|DEVICE|Sham Transcranial Magnetic Stimulation +McNeill Dysphagia Therapy Programme|The McNeill Dysphagia Therapy programme (MDTP) combined with sham Transcranial Magnetic Stimulation (TMS) will be applied to the sham comparator group.
223804291|NCT06184711|DEVICE|Transcranial Magnetic Stimulation|Only Transcranial Magnetic Stimulation (TMS) will be applied to the second experimental group.
223804292|NCT06200337|PROCEDURE|Fine needle acupuncture|All participants underwent three 24-hour apart sessions. In each session, the acupuncturist inserted two sterile needles into the left and right acupoints with a 90-degree angle and 0.5 to 1 cun in depth for TB3, 0.3 to 0.5 cun for BL65, and 0.3 to 0.5 cun for SP3. The acupuncturist rotated the needle at an angle of 180-270 degrees within 1 minute, with a frequency of 60 - 120 times/minute for stimulation.
223804293|NCT02104362|RADIATION|exclusive single-fraction irradiation|
223804294|NCT01175915|OTHER|Western therapy|"1. Adopting physical cooling therapy, including physical cooling paste or warm bathing, when patient's body temperature is lower than 38.5 degree Celsius;~2. Using Ibuprofen suspension when patient's temperature higher than 38.5 degree Celsius lasting for more than 2 hours;~3. No specific treatment for tetter and ulcer, but Bingpeng powder, Watermelon tablet or frost for oral herpes.~Intervention time: 3-7 days; Follow-up time: 3 days."
223804295|NCT01175915|OTHER|Reduning Injection|"1. Lifestyle counseling, vitamin supplementation if necessary, and non-use of antibiotics;~2. Reduning Injection, 0.5\~15ml, depending on patient's condition, IV per day, or according to the instruction;~3. Using Ibuprofen suspension when patient's temperature higher than 39 degree Celsius lasting for more than 2 hours.~Intervention time: 3-7 days; Follow-up time: 3 days."
223804296|NCT01175915|OTHER|Reduning Injection plus western therapy|"1. General treatment including lifestyle counseling, vitamin supplementation if necessary, non-use of antibiotics, and symptomatic treatment as follows;~2. Symptomatic treatment by western therapy adopting the same plan in western therapy comparator group;~3. Symptomatic treatment by Reduning Injection adopting the same plan in Reduning Injection experimental group.~Intervention time: 3-7 days; Follow-up time: 3 days."
223804297|NCT03675451|DRUG|89ZR-DF-IAB2M|injection of 10 milligrams of radioactive 89Zr-Df-IAB2M followed by PET/CT scan
223804298|NCT03675451|DRUG|68Ga-PSMA-HBED-CC|Optional but recommended 68Ga-PSMA-HBED-CC (5±2mCi) injection and PET/CT scan (1 to 3 hours after the injection) will also be performed prior to radical prostatectomy depending on subject's availability and compliance.
223804299|NCT03817892|OTHER|Guidance of the External Chest Compression|The CPRmeter® device is positioned on the patient's chest with a disposable adhesive. In the situation of guidance of the External Chest Compression the rescuers have access in real time on the screen to visual feedback on the quality of the External Chest Compression performed and indications of possible corrections to improve the quality of the External Chest Compression . In the case of non-guidance of the External Chest Compression , a mask is position on the screen in order to hide the feedback information.
223804300|NCT03817892|OTHER|Rhythm of a relay 4 minutes|The duration or rhythm of a relay is the time during which a rescuer performs External Chest Compression before being relayed by another rescuer. This time is 2 minutes in non intervention group according to the current guidelines and 4 minutes in experimental group.
223804301|NCT02385734|OTHER|Concentrated Growth Factor Membrane|Concentrated growth factor membrane is produced by the centrifugation of venous blood and platelets are concentrated in a gel layer containing fibrin matrix
223804302|NCT02385734|PROCEDURE|Coronally Advanced Flap|Periodontal plastic surgery technique
223804303|NCT06110884|BEHAVIORAL|music therapy, speech therapy|receive group music therapy in addition to traditional language therapy
223804304|NCT06110884|BEHAVIORAL|speech therapy|receive only traditional language therapy
223804305|NCT05888506|DIETARY_SUPPLEMENT|Ketone Ester|Participants will consume the ketone ester beverage produced by KetoneAid prior to bedtime. Participants will consume 60 mL (30 grams ketones) of the ketone beverage.
223804306|NCT05888506|DIETARY_SUPPLEMENT|Placebo|Participants will consume the placebo supplement prior to bedtime. The placebo supplement will be a ketone ester-free, taste and viscosity-matched, beverage produced by KetoneAid.
223804307|NCT03329898|PROCEDURE|dried biological amnion graft|dried biological amnion graft. The amnion grafts were spread on the balloon end of disposable balloon uterine stent .
223804308|NCT03329898|DEVICE|disposable balloon uterine stent|the disposable balloon uterine stent is heart-shaped that resembled the shape of the uterine cavity and could fully separate the two sides of the uterine wall and the corners of the uterus.
223804309|NCT03329898|DRUG|estradiol valerate tablets|oral estradiol valerate tablets, which can promote endometrial growth after operation.
223804310|NCT03329898|DRUG|dydrogesterone Tablets|oral dydrogesterone Tablets
223804311|NCT02191072|DRUG|omalizumab|a recombinant DNA-derived humanized IgG1k monoclonal antibody that specifically binds to free human immunoglobulin E (IgE)
223804312|NCT06574009|BEHAVIORAL|Multimodal pain care|Behavioral therapy (as below), physical therapy, assistive devices (e.g. TENS, bracing), referrals to VA specialists (e.g. interventional pain), and complementary and integrative therapies (e.g. acupuncture or massage
223804313|NCT06574009|DRUG|Medication optimization|Medications will be optimized following an algorithm the investigators created based upon NCCN's Survivorship Guidelines and AHRQ's comprehensive review of non-opioid treatments for chronic pain.
223804314|NCT06574009|DEVICE|Buprenorphine rotation|Subjects randomized to this arm at 6 months will be offered the chance to rotate from their full mu agonist opioid to buprenorphine using a standardized protocol
223804315|NCT06574009|OTHER|Opioid tapering|Subjects randomized to tapering will receive recommendations based upon the VA PBM's opioid tapering reference guide
223804316|NCT03274635|BEHAVIORAL|Desk-based pedaling device and pedaling incentives provided|Varying types of incentives, equivalent in monetary value, will be randomly assigned across the 6 arms to promote regular desk-based pedaling. A free desk-based pedaling device will be provided. Effects on amount of desk-based pedaling and work productivity will be evaluated.
223804317|NCT01132625|DRUG|AUY922|
223804318|NCT06815497|DRUG|Telmisartan|Telmisartan will be introduced as a 40 mg tablet to be taken orally once daily. In participants not experiencing telmisartan dose limiting toxicity, the dose will be escalated to a maximum of 80 mg
223804319|NCT05100225|BIOLOGICAL|PTP-001|Allogeneic human placental tissue particulate (PTP-001) is administered as a single intra-articular injection to the target knee after resuspension with saline.
223804320|NCT05100225|OTHER|Placebo control|The placebo control, physiological saline (0.9% sodium chloride injection, USP), is administered as an intra-articular injection to the target knee.
223804321|NCT02886806|OTHER|BIS XP, Covidien, Ireland|Closed loop for propofol and remifentanil using BIS XP TM, Covidien, Ireland
223804322|NCT02886806|OTHER|EV-1000 TM, Edwards Lifesciences, Irvine, California, USA|Closed loop for fluid perfusion using EV-1000 TM, Edwards Lifesciences, Irvine, CA, USA
223804323|NCT02088151|DEVICE|Selective retinal pigment epithelium laser therapy using the R:GEN Laser System|Patients receive selective retinal pigment epithelium laser treatment using the R:GEN Laser System by Lutronic Corporation, Korea.
223804324|NCT04271943|BEHAVIORAL|Computer Based Exercises|For 8 weeks 3 days a week for 45 minutes See-ME Virtual Rehabilitation system with the physical therapist will perform cognitive and physical activity exercises
223804325|NCT04271943|DIETARY_SUPPLEMENT|Aerobic Exercises|For 8 weeks 3 days a week exercise bike with 5 min warm-up 35 min constant speed exercise 5 min cooling, a total of 45 min prescribed by the physiotherapist to the maximum heart rate will do aerobic exercise work. Cardiac values will also be monitored throughout the session
223804326|NCT03962244|DEVICE|EsoSponge|Endoscopically placed an EsoSponge for Negative pressure wound therapy in the area of the esophagogastric anastomotic leaks
223804327|NCT03962244|DEVICE|Self-Expanding Metal Stent|Endoscopically placed self-expanding-metal-stent (SEMS) for negative pressure wound therapy in the area of the esophagogastric anastomotic leaks
223804328|NCT05194306|DRUG|Perla® Cold Preservation solution|Perla® must be cooled to 2° to 6 °C prior to use. The cold Preservation Solution is used to flush the isolated organ immediately before removal from the donor and/or immediately after removal from the donor. The solution is then left in the organ vasculature during hypothermic storage and transportation.
223804329|NCT01332227|DRUG|Atazanavir|Capsules, Oral, 300mg, Once daily, 48 weeks
223804330|NCT01332227|DRUG|Ritonavir (heat-stable)|Tablets, Oral, 100 mg, Once daily, 48 weeks
223804331|NCT01332227|DRUG|Raltegravir|Tablets, Oral, 400 mg, Twice daily, 48 weeks
223804332|NCT01332227|DRUG|Tenofovir/Emtricitabine|Tablets, Oral, 300/200 mg, Once daily, 48 weeks
223804333|NCT00514943|DRUG|BIBW 2992|experimental drug taken once daily orally
223804334|NCT00514943|DRUG|Cetuximab|active comparator administered weekly intravenously
223804335|NCT03764449|DRUG|Oral Balovaptan|"In Period 1, balovaptan was administered as a single oral dose.~In Period 2, balovaptan was administered as an oral dose once daily on Day 1 to Day 14."
223804336|NCT03764449|DRUG|IV Balovaptan|"In Period 1, IV infusion of balovaptan was administered after the balovaptan oral dose.~In Period 2, IV infusion of balovaptan was administered after the final oral dose of balovaptan."
223804337|NCT01100255|DRUG|Ketamine infusion|0.5mg/kg IV over 40 minutes
223804338|NCT01100255|OTHER|Saline|saline infusion
223804339|NCT05538195|BIOLOGICAL|CEA-targeted CAR-T cells|Administration method: intravenous infusion； Subjects will receive conditioning therapy by Fludarabine and Cyclophosphamide before cell infusion.
223804340|NCT05538195|BIOLOGICAL|CEA-targeted CAR-T cells|Administration method: intraperitoneal injection；Subjects will receive conditioning therapy by Fludarabine and Cyclophosphamide before cell infusion.
223804341|NCT00150579|DRUG|Neutral salts of dextroamphetamine sulfate, USP, amphetamine sulfate, USP, d-amphetamine saccharate, d, l-amphetamine aspartate monohydrate|
223804342|NCT05782543|PROCEDURE|Normothermic machine perfusion|To determine whether a 4-6 hour period of normothermic machine perfusion, following standard hypothermic machine perfusion, results in better graft function after transplantation, compared to hypothermic machine perfusion preservation alone of kidneys recovered from deceased donors aged 50 years or older
223804343|NCT02662725|DRUG|IPILIMUMAB|
223804344|NCT02662725|RADIATION|Stereotactic radiosurgery|
223804345|NCT01075932|DIETARY_SUPPLEMENT|DHA-rich fish oil|Either 1 g or 2 g DHA-rich fish oil taken daily for 12 weeks. Participants in the 1 g group will also consume 1 g olive oil placebo capsules per day to maintain double blind.
223804346|NCT01075932|DIETARY_SUPPLEMENT|Placebo|2 g placebo (olive oil) taken daily for 12 weeks
223804347|NCT03705195|DRUG|Gliclazide|Low dose liquid gliclazide will be used with the second matched clamp (OGTT/IGII) in visits 4 \& 5.
223804348|NCT02278068|DEVICE|Metabolic Neuromodulation System (MNS)|Prospective, First-in-Human (FIH), multi-center, non-randomized trial to evaluate the initial safety and performance of hepatic sympathetic denervation to aid in glycemic control.
223804349|NCT00800969|PROCEDURE|FDG-PET-CT|Radiologic standard procedure
223804350|NCT01783418|BEHAVIORAL|Mindfulness Intervention|Mindfulness-based intervention adapted for teenagers
223804351|NCT06228521|OTHER|Liquid nitrogen sprayed|Liquid nitrogen sprayed on each wart using a standardised technique. Freeze-thaw cycle repeated up to 3 times per wart per session. 4 sessions at weekly intervals.
223804352|NCT06228521|OTHER|980nm diode laser applied|980nm diode laser applied to each wart for 5 seconds at 2W power and 1mm spot size. 4 sessions at weekly intervals.
223804353|NCT00687570|DIETARY_SUPPLEMENT|Fresubin Energy Drink|Fresubin energy drink 30 kcal/kg\*dag-1, seven days before surgery
223804354|NCT00687570|DRUG|Laxabon®|Laxabon® 4 litres starting the day before surgery
223804355|NCT03548207|BIOLOGICAL|JNJ-68284528|JNJ-68284528 consist of autologous T lymphocytes transduced with LCAR-B38M, a lentiviral vector to express a chimeric antigen receptor targeting the human B cell maturation antigen (anti-BCMA CAR).
223804356|NCT01613638|OTHER|meconium samples + maternal self-questionnaire|meconium samples + maternal self-questionnaire
223804357|NCT06048510|DIAGNOSTIC_TEST|Pregnant women|"Gestational Diabetes Mellitus increases the risk of adverse pregnancy outcomes (such as macrosomia).~The lack of early clinical symptoms leads to screen pregnant women for GDM, and the strategies of screening are a matter of debate.~Interventions to control glucose levels in women with GDM have demonstrated efficacy in terms of macrosomia. However, macrosomia may start before the time of screening, suggesting that markers of glycation may have interest : skin autofluorescence, glycated albumin."
223804358|NCT01184365|BEHAVIORAL|Energy Management Program|The program content over the four sessions is structured as follows: Session 1 is an introduction to the group, important concepts, and upcoming session topics; Session 2 further elaborates on the concepts introduced in session 1 and encourages self-reflection; Session 3 is the peer to peer contact by phone or in person to assist with problems and share tips that really worked; and Session 4 concludes the program and serves to consolidate information learned.
223804359|NCT01184365|BEHAVIORAL|Energy Management Program|The goal of the EnMP-2 is to control for group effects
223804360|NCT00945464|OTHER|Blood/saliva samples, historic breast imaging|Subjects are required only to provide a blood or saliva sample, relevant personal and family history (if available), and 5 years of historic breast imaging reports.
223804361|NCT00792896|BEHAVIORAL|family conference|family conference
223804362|NCT00999466|DRUG|AZD8848|Nasal spray, solution 0.6mg/ mL. Once weekly for 7 weeks, 8 doses in total.
223804363|NCT00999466|DRUG|Placebo|Nasal spray, solution. Once weekly for 7 weeks, 8 doses in total.
223804364|NCT05700500|PROCEDURE|shockwave therapy, barbotage and infiltration|ultrasound guided interventions
223804365|NCT02961023|OTHER|Exercise therapy|"3-week residential phase and 12-week outpatient phase.~Residential phase~* Exercise will be supervised by a physiotherapist and prescribed based on cardiopulmonary exercise testing.~* A monitored daily program of exercise involving bicycle ergometry, walking, breathing exercises, dumbbell exercises 5 days per week.~* 1.5 to 2 hours of exercise will be performed daily, with rest intervals.~* At weekends, lower intensity, unsupervised exercise mirroring the outpatient phase~* Ongoing exercise prescription will be based on tolerability, progress and HR~Outpatient phase~* A training manual will be compiled based on the subjects exercise performance during the residential program and tailored specifically to their needs~* Participants will be provided with a cycle ergometer, weights and a HR monitor~* Weekly telephone contact will be made by the study doctor or physiotherapist, with adjustments made to training prescription as necessary"
223804366|NCT01389830|BEHAVIORAL|Telephone Survey|Telephone interviews (survey) at baseline taking approximately 30-40 minutes to complete; follow-up monthly surveys for cancer patients take 20-30 minutes to complete, follow ups until 12 months or death.
223804367|NCT03658564|DIETARY_SUPPLEMENT|Preoperative Oral Carbohydrate Drink|Patients in Oral carbohydrate group consumed 400 ml Preoperative Oral Carbohydrate Drink Nutricia preOp® (12.5% carbohydrates, 0.5kcal/ml, 240 mOsm, pH 4.9, Nutricia Zoetermeer, the Netherlands) 3 hours prior to induction of anesthesia and finished the ingestion within 20 minutes.
223804368|NCT02609880|BEHAVIORAL|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy is used to optimize sleep, pain, and mood in women with gynecologic cancers and will be provided 2 hours once a week for six weeks.
223804369|NCT02609880|BEHAVIORAL|Psychoeducation|Psychoeducation is used to provide information, resources, and non-specific support related to adapting well to cancer. Sessions will be provided 2 hours once a week for 6 weeks.
223804370|NCT03205540|PROCEDURE|Continuous epidural block|Continuous epidural block at level L2-3 or L3-4 with 0.0625% bupivacaine + fentanyl 2 mcg/ml infusion epidurally 5 ml/hr for 48 hours postoperatively.
223804371|NCT03205540|PROCEDURE|Bilateral single-shot bilateral adductor canal blocks|Bilateral single-shot adductor canal blocks, ultrasound guidance, with 0.33% bupivacaine 15 ml on each side.
223804372|NCT03040713|DRUG|Flortaucipir F18|370 megabecquerel (MBq)(10 millicurie \[mCi\]) injection, single dose
223804373|NCT03040713|PROCEDURE|Brain PET scan|positron emission tomography (PET) scan of the brain
223804374|NCT03263884|DEVICE|Repetitive trancranial magnetic stimulation (rTMS) group|Repetitive trancranial magnetic stimulation is applied on the dorsolateral prefrontal cortex. The protocol consists on 20 minutes of 10Hz stimulation, 5 seconds on, 10 seconds off, at 110% RMT, for a total of 4000 pulses.
223804375|NCT03263884|DEVICE|Sham group|A sham coil is used to mimic the clicking sound of the trancranial magnetic coil and skin stimulation.
223804376|NCT04789265|OTHER|instrumented- assisted soft tissue mobilization (IASTM)|IASTM is a new, non-invasive, conservative therapeutic approach. Instead of the therapist's hands and fingers in treatment, these devices are used to provide contact mobilization power. AYDM intervention, such as friction, rubbing massage treatments, requires the therapist to apply a significant amount of pressure. The main purpose of IASTM is to eliminate scar tissue and to restore the normal function of the tissue following soft tissue regeneration.
223804377|NCT01788865|DEVICE|cSEMS(Covered self-expandable dual-layered metal stent) implant|
223804378|NCT01519531|DRUG|Placebo|Oral, daily-dosing for 14 days; matching number of placebo capsule(s) with active arm
223804379|NCT01519531|DRUG|VIA-3196|Oral, daily dosing for 14 days
223804380|NCT04116749|OTHER|Water|Drink water freely until 2 hours before anesthesia.
223804381|NCT04897984|BIOLOGICAL|Liver-enriched antimicrobial peptide 2|IV infusion of LEAP2, 2 hours
223804382|NCT01694784|BEHAVIORAL|Quantitative Information Sheet|Patients will read an information sheet about one of the three exemplar services in one of four presentations: quantitative, qualitative, narrative, or framed. In the quantitative information sheet, harms will be communicated in absolute risks with accompanying fact box (i.e. box containing key facts and rates). In addition to information about harms, the information sheet will include the following information: a description of the disease to be detected and the screening test, a description of the possible benefits of the service, and a statement encouraging decision. As an adjunct to numerical information in paragraph form, fact boxes engage individuals to process information and improve understanding.
223804383|NCT01694784|BEHAVIORAL|Qualitative Information Sheet|Patients will read an information sheet about one of the three exemplar services in one of four presentations: quantitative, qualitative, narrative, or framed. In the qualitative information sheet, harms will be communicated using verbal descriptors. In addition to information about harms, the information sheet will include the following information: a description of the disease to be detected and screening test, a description of the possible benefits of the service, and a statement encouraging decision.
223804384|NCT01694784|BEHAVIORAL|Narrative Information Sheet|Patients will read an information sheet about one of the three exemplar services in one of four presentations: quantitative, qualitative, narrative, or framed. In the narrative information sheet, harms will be communicated using patient narratives with accompanying fact box. In addition to information about harms, the information sheet will include the following information: a description of the disease to be detected and screening test, a description of the possible benefits of the service, and a statement encouraging decision.
223804385|NCT01694784|BEHAVIORAL|Framed Information Sheet|Patients will read an information sheet about one of the three exemplar services in one of four presentations: quantitative, qualitative, narrative, or framed. In the framed information sheet, harms will be communicated using a gain frame (as described in the arm section above) with accompanying fact box. In addition to information about harms, the information sheet will include the following information: a description of the disease to be detected and screening test, a description of the possible benefits of the service, and a statement encouraging decision.
223804386|NCT01053195|BEHAVIORAL|Lifestyle counseling|Non-diabetic high-risk subjects enrolled will be eligible for individual and/or group lifestyle counseling. The intervals of the counseling sessions depend on the glucose levels of the high-risk individuals, every three months for those having prediabetes and every six months for those with normal glucose levels but high risk score.
223804387|NCT02531178|BIOLOGICAL|ABBV-257|subcutaneous injection
223804388|NCT02531178|BIOLOGICAL|Placebo|Placebo for ABBV-257
223804389|NCT04122248|OTHER|standard radiographic imaging|standard radiographic imaging
223804390|NCT04122248|DEVICE|cervical total disc replacement|Artificial disc replacement (ADR) in the cervical spine is a minimally invasive procedure that involves removing diseased disc tissue and replacing it with an artificial disc. The artificial disc is designed to preserve the spine\&#39;s natural motion while remaining securely attached to the surrounding vertebral bones. The goal of ADR is to help preserve the motion of the cervical spine or spinal segment after surgery, which can improve the quality of life for patients.
223804391|NCT02563002|DRUG|mFOLFOX6|Regimen consists of oxaliplatin 85 mg/m\^2 IV on Day 1, leucovorin 400 mg/m\^2 or levoleucovorin 200 mg/m\^2 IV on Day 1, 5-fluorouracil (5-FU) 400 mg/m\^2 IV bolus on Day 1 and then 1200 mg/m\^2/day IV over 2 days for total dose of 2400 mg/m\^2 in each 2-week cycle
223804392|NCT02563002|DRUG|FOLFIRI|Regimen consists of irinotecan 180 mg/m\^2 IV on Day 1, leucovorin 400 mg/m\^2 or levoleucovorin 200 mg/m\^2 IV on Day 1, 5-FU 400 mg/m\^2 IV bolus on Day 1 and then 1200 mg/m\^2/day IV over 2 days for total dose of 2400 mg/m\^2 in each 2-week cycle
223804393|NCT02563002|BIOLOGICAL|Pembrolizumab|IV infusion
223804394|NCT02563002|BIOLOGICAL|Bevacizumab|IV infusion
223804395|NCT02563002|BIOLOGICAL|Cetuximab|IV infusion
223804396|NCT06839092|PROCEDURE|oxaliplatin-based PIPAC|"Patients operated for pT4 pN0-2 cM0 pMMR colorectal cancer (of the colon, colorectal junction or high rectum) or patients operated for pT3-4 pN0-2 cM0 pMMR colorectal cancer with positive cytology or in patients with pT3-4 pN0-2 M1c pMMR colorectal cancer with limited peritoneal carcinomatosis which is limited to one abdominal quadrant and was resected during index surgery and no other distant lesion, will undergo 6 months of adjuvant systemic chemotherapy associated with 3 cycles of oxaliplatin-based PIPAC (4-6 weeks apart).~Each PIPAC session will include exploration laparoscopy (with PCI score), peritoneal lavage for cytology and biopsies of healthy peritoneum of the four quadrants + Douglas + omentum), and oxaliplatin-based PIPAC."
223804397|NCT06839092|PROCEDURE|Control (Standard treatment)|Patients operated for pT4 pN0-2 cM0 pMMR colorectal cancer (of the colon, colorectal junction or high rectum) or patients operated for pT3-4 pN0-2 cM0 pMMR colorectal cancer with positive cytology or in patients with pT3-4 pN0-2 M1c pMMR colorectal cancer with limited peritoneal carcinomatosis which is limited to one abdominal quadrant and was resected during index surgery and no other distant lesion, will undergo 6 months of adjuvant systemic chemotherapy, followed by exploration laparoscopy (including 300ml peritoneal lavage for cytology and seven punch peritoneal biopsies in the four quadrants of the abdomen, Douglas and omentum, as well as peritonectomy of 1 cm2) at 6 months after index surgery before entering a standard surveillance program.
223804398|NCT05008029|PROCEDURE|In situ immobilization|Immobilization with an above-elbow cast. A 2, 3, or 4-year orthopedic resident or pediatric orthopedic fellow supervised by a pediatric orthopedic surgeon will perform the procedure without reduction, sedation, or anesthesia. Analgesia will be administered with paracetamol at doses of 10-15 mg/kg/dose or tramadol 0.5-1mg/kg/dose. Supposing immobilization is not satisfactory, or the patient or family member does not authorize the procedure to be carried out by staff in training. In that case, the procedure will be supported or carried out by the pediatric orthopedic surgeon.
223804399|NCT05008029|PROCEDURE|Reduction under general anesthesia|The participants will receive paracetamol at 10-15 mg/kg/dose or tramadol 0.5-1 mg/kg/dose for pain control until the time of surgery. Under general anesthesia, radius closed reduction, and above-elbow casting will be performed. After the reduction maneuvers, the radius reduction is satisfactory if the translation in the coronal and sagittal planes of less than 50% and angulation in the same planes is less than 10 °. If the radius does not remain reduced, it is unstable. Unstable fractures require percutaneous fixation with K-wires, a sugar tong splint immobilization, and a nerve block. The procedures will be carried out by a 2, 3, or 4-year orthopedic resident or pediatric orthopedic fellow under the supervision of a child orthopedist. Suppose reduction is not satisfactory or the patient or parent doesn´t authorize the procedure performed by personnel in training. In that case, the procedure will be supported or carried out by the pediatric orthopedic surgeon.
223804400|NCT01800773|BEHAVIORAL|Written Exposure Therapy|Written exposure therapy is a 5 session, weekly treatment in which individuals write about their trauma event in a specified manner.
223804401|NCT01800773|BEHAVIORAL|Cognitive Processing Therapy|Cognitive Processing Therapy (CPT) is an evidence-based treatment for PTSD. CPT consists of 12, weekly sessions.
223804402|NCT02123602|OTHER|core stabilization|
223804403|NCT02123602|OTHER|lower extremity training only|
223804404|NCT05362981|OTHER|CAT|2 group programs, led by trained speakers, addressing specific ED topics through written, verbal and/or behavioral exercises,
223804405|NCT05682911|DRUG|Zingiber officinale L. tablets|Zingiber officinale L. tablets 500mg twice daily
223804406|NCT05682911|DRUG|Simvastatin 20mg|Simvastatin 20mg once a day for 2 months
223804407|NCT00676286|PROCEDURE|3T MR Imaging|3TR Imaging
223804408|NCT00676286|PROCEDURE|C-Choline PET Scanning|C-Choline PET Scanning
223804409|NCT00676286|PROCEDURE|Gene Rearrangement|Gene Rearrangement
223804410|NCT05852132|PROCEDURE|pars plana vitrectomy(PPV)|Vitrectomy was performed for severe non-proliferative diabetic retinopathy, but panretinal photocoagulation(PRP) was not performed
223804411|NCT05852132|PROCEDURE|Pars plana vitrectomy(PPV) +Panretinal photocoagulation(PRP)|PPV was performed for severe non-proliferative diabetic retinopathy with PRP.
223804412|NCT05852132|PROCEDURE|Panretinal photocoagulation(PRP)|Only PRP was used for severe non-proliferative diabetic retinopathy.
223804413|NCT04874402|PROCEDURE|Prepectoral approach|Two sheets of contour, fenestrated ADM sutured together are trimmed in accordance with the measurement of the expander/implant and fixed to the pectoralis major muscle (superiorly, medially, and inferiorly) and serratus fascia (laterally), covering the entire anterior surface of the device
223804414|NCT04874402|PROCEDURE|Partial Subpectoral approach|The leading edge of the pectoral muscle is elevated and a subpectoral pocket is fashioned. The lower medial origin muscle fibers are released for anatomical expander seating. An ADM sling is sutured from the leading edge of the pectoralis muscle to the inframammary fold (over the expander) and laterally to close the expander pocket. In both groups, the size of the expander and the intraoperative filling volume will be decided by the attending surgeon based on the pocket dimension and volume capabilities.
223804415|NCT02745665|OTHER|flow mediated dilation (endothelial function)|
223804416|NCT02745665|OTHER|ABPI|
223804417|NCT02745665|OTHER|Pulse wave velocity and augmentation index|
223804418|NCT02745665|OTHER|blood pressure|
223804419|NCT02745665|OTHER|ramp test|
223804420|NCT04748081|PROCEDURE|hepatectomy|hepatectomy (ICD-9-CM procedure code: 50.2, 50.22, 50.3 and 50.4)
223804421|NCT05700084|DRUG|Utidelone Capsule (Part 1)|"At least 3 dose cohorts are planned, and 14-26 cases are expected. Cohort 1: 2 cases are planned, and the subjects will receive Utidelone Capsule at a dose of 50 mg/m2/d for 5 days.~Other dose-escalation cohorts: 3-6 cases are planned in each cohort, following the 3 + 3 design. The subjects in these cohorts will receive Utidelone Capsule at 75 mg/m2/d for 5 days, 100 mg/m2/d for 5 days, 100 mg/m2/d for 7 days, and 120 mg/m2/d for 7 days, in a 21-day cycle respectively."
223804422|NCT05700084|DRUG|Drug A Utidelone Capsule (Part 2: Group A-B)|"Utidelone Capsule at Part 2 in Group A-B will be administered at 60 mg/m2/d.~At Cycle 0, on day 1, all patients will receive the drug in fasted status with a glass (approximately 240 ml) of warm water (2 h of fasting before administration; 2 h of fasting after administration).~At Cycle 2, subjects will receive the drug after meals on days 1-5 (high-fat meal, drug taken 30 min after the meal; 2 h fasting after administration). Subjects will receive the drug on day 1-5 with 21 days as a cycle.~For the subsequent treatment period, there is no special requirements for food. Subjects will receive the drug on day 1-5 with 21 days as a cycle."
223804423|NCT05700084|DRUG|Drug A Utidelone Capsule (Part 2: Group B-A)|"Utidelone Capsule at Part 2 in Group B-A will be administered at 60 mg/m2/d.~At Cycle 1, on day 1-5, all patients will receive the drug in fasted status with a glass (approximately 240 ml) of warm water (2 h of fasting before administration; 2 h of fasting after administration), with 21 days as a cycle.~At Cycle 2, subjects will receive the drug after meals on days 1-5 (high-fat meal, drug taken 30 min after the meal; 2 h fasting after administration), with 21 days as a cycle.~For the subsequent treatment period, there is no special requirements for food. Subjects will receive the drug on day 1-5 with 21 days as a cycle."
223804424|NCT05700084|DRUG|Drug B Utidelone Injection (Part 2: Group A-B)|"Utidelone Injection at Part 2 in Group A-B will be administered at 30 mg/m2/d in 250 mL normal saline, intravenous drip over1.5 h.~For Cycle 1, subjects will be administered Utidelone Injection on day 1-5 with 21 days as a cycle."
223804425|NCT05700084|DRUG|Drug B Utidelone Injection (Part 2: Group B-A)|"Utidelone Injection at Part 2 in Group B-A will be administered at 30 mg/m2/d in 250 mL normal saline, intravenous drip over1.5 h.~For Cycle 0, all patients will be administered Utidelone Injection on day 1, with 21 days as a cycle."
223804426|NCT05700084|DRUG|Capecitabine|1000mg/m2, twice a day (daily dose 2000mg/m2), once in the morning and once in the evening, taken orally within 30 minutes after meals. It is administered continuously for 14 days from day 1 to day 14, with a 21 day treatment cycle.
223804427|NCT05700084|DRUG|Utidelone Capsule (Part 3)|Utidelone capsule: 60 mg/m2/d, administered once a day on an empty stomach, continuously for 5 days from day 1 to day 5, with a treatment cycle of 21 days.
223804428|NCT01889173|DRUG|TNX-102 SL Tablets at 2.8 mg|1 x TNX-102 SL Tablet (with potassium phosphate) at 2.8 mg held under the tongue until dissolution, without swallowing or chewing it.
223804429|NCT01889173|DRUG|TNX-102-B SL Tablets at 2.8 mg|1 x TNX-102-B SL Tablet (with sodium phosphate) at 2.8 mg held under the tongue until dissolution, without swallowing or chewing it.
223804430|NCT01889173|DRUG|TNX-102-C SL Tablets at 2.8 mg|1 x TNX-102-C SL Tablet (with trisodium citrate) at 2.8 mg held under the tongue until dissolution, without swallowing or chewing it.
223804431|NCT01889173|DRUG|Cyclobenzaprine tablets|1 x 5 mg cyclobenzaprine tablet, swallowed with 240 mL of room-temperature water
223804432|NCT06423755|OTHER|Swimming programme|A session plan will be followed, which included aims, objectives, learning outcomes and suggested core aquatic skills and swimming activities under each section. The session will consist of a session brief, a warmup, core aquatic skills, swimming strokes (front crawl, backstroke, breaststroke, and hybrid strokes), a cool down and a session debrief; following the guidance developed in study three.
223804433|NCT06423755|OTHER|Standard Physiotherapy care|Treatment delivered by the physiotherapist could include exercise, advice, education, and manual therapy; they will be offered up to 6 sessions.
223804434|NCT03191695|OTHER|Assessment via questionnaire|All the children will be assessed via assessment questionnaires.
223804435|NCT01649830|RADIATION|Radiotherapy|External beam radiation: 54.0 Gy in 27 - 30 fractions over 6 - 7 weeks.
223804436|NCT01649830|DRUG|Temozolomide|dosed at 200 mg/m2 (150 mg/m2 for the first cycle) daily for 5 consecutive days, repeated every 28 days.
223804437|NCT02139098|DRUG|Amitriptyline|50 mg capsule amitriptyline before going to bed on 8 out of 17 nights
223804438|NCT02139098|DRUG|Zolpidem|5 mg capsule zolpidem before going to bed on 8 out of 17 nights
223804439|NCT02139098|DRUG|Amitriptyline|50 mg capsule amitriptyline before going to bed on 13 out of 17 nights
223804440|NCT02139098|DRUG|Placebo|Placebo
223804441|NCT05273125|BEHAVIORAL|Gait disorders and falls risk assessment|Implementation of a standardized assessment of the fall risk and gait disorders in the memory clinic in addition to usual care.
223804442|NCT06491849|OTHER|Peri-implant Condition Evaluation|This intervention involves a detailed clinical evaluation of peri-implant conditions in patients who have received orthodontic mini implants. The assessments include measuring periodontal parameters such as probing depth, bleeding on probing, mucosal redness, plaque index, gingival index, and implant stability. The evaluations are conducted at specified intervals during and after orthodontic anchorage treatment to monitor changes and ensure the health of peri-implant tissues.
223804443|NCT00466635|DRUG|GT267-004 (tolevamer potassium sodium)|
223804444|NCT01129388|DRUG|clopidogrel|"Pharmaceutical form: tablet~Route of administration: oral"
223804445|NCT01129388|DRUG|Placebo|"Pharmaceutical form: matching tablet~Route of administration: oral"
223804446|NCT01129388|DRUG|omeprazole|"Pharmaceutical form: delayed-release capsule~Route of administration:oral"
223804447|NCT05873374|BIOLOGICAL|50 μg Baiya SARS-CoV-2 Vax 2|Intramuscular injection in the deltoid region of 0.5 mL/dose of 50 μg Baiya SARS-CoV-2 Vax 2
223804448|NCT05873374|OTHER|Placebo|Intramuscular injection in the deltoid region of 0.5 mL/dose of 0.9% Sodium Chloride
223804449|NCT03426202|DRUG|Modafinil Oral Tablet|modafinil 200mg
223804450|NCT03426202|DRUG|Placebo Oral Tablet|placebo 200mg
223804451|NCT04077619|BEHAVIORAL|Modern pain neuroscience approach|Modern pain neuroscience approach. The modern pain neuroscience approach includes 3 sessions (1 group and 2 individual sessions) of therapeutic pain neuroscience education followed by 15 individual sessions of dynamic and functional cognition-targeted exercise therapy and stress management techniques. In addition, participants will be instructed to perform a daily set of home exercises. The exercises will be performed in a time-contingent way. The 18 sessions will be spread over a period of 16 weeks.
223804452|NCT04077619|BEHAVIORAL|Usual care physiotherapy|Usual care evidence-based physiotherapy The usual care evidence-based physiotherapy includes 3 sessions (1 group and 2 individual sessions) of neck school followed by 15 individual sessions of graded and active exercise therapy focusing on strength, flexibility, endurance, and ergonomic principles. In addition, participants will be instructed to perform a daily set of home exercises. The exercises will be performed in a symptom-contingent way. The 18 sessions will be spread over a period of 16 weeks.
223804453|NCT03042455|DEVICE|Armeo and rTMS|"The Armeo, a robot with a spring mechanism allowing adjustable arm weight support, can generate assistive forces of up to 66N in flexion/extension and up to 30N for the arm and forearm respectively. This robot integrates seven angle sensors and one pressure sensor that allow direct interaction between the motion of the patient's arm and the associated therapy software. rTMS is a magnetic method used to stimulate small regions of the brain.~The Robot and rTMS group will receive the robot-assisted upper arm training and rTMS for 5 times per week, for 4 weeks. And all patients of three groups will receive the additional conventional occupational therapy for 30 minutes daily 5 times per week, for 4 weeks."
223804454|NCT03042455|DEVICE|Armeo|The Armeo, a robot with a spring mechanism allowing adjustable arm weight support, can generate assistive forces of up to 66N in flexion/extension and up to 30N for the arm and forearm respectively. This robot integrates seven angle sensors and one pressure sensor that allow direct interaction between the motion of the patient's arm and the associated therapy software. The Robot group will receive the robot-assisted upper arm training for 30 minutes daily 5 times per week, for 4 weeks. And all patients of three groups will receive the additional conventional occupational therapy for 30 minutes daily 5 times per week, for 4 weeks.
223804455|NCT03042455|OTHER|Control group|The conventional group will receive occupational therapy for 30 minutes daily 5 times per week, for 4 weeks instead of Robot or rTMS. And all patients of three groups will receive the additional conventional occupational therapy for 30 minutes daily 5 times per week, for 4 weeks.
223804456|NCT03909984|DEVICE|Nightwatch|Nocturnal monitoring for 2 months with three different seizure detection devices.
223804457|NCT03466086|DEVICE|Test Eye Drops|blink® intensive TRIPLE ACTION 3 in 1 eye drops
223804458|NCT03466086|DEVICE|Control Eye Drops|Systane® BALANCE eye drops
223804459|NCT00595504|DRUG|Ramelteon|Two week supply of ramelteon 8mg/day first dispensed at baseline. New two week supply of study medication dispensed at each biweekly visit for 8 consecutive weeks.
223804460|NCT00595504|DRUG|Placebo|Two week supply of placebo tablets first dispensed at baseline. New two week supply of placebo dispensed at each biweekly visit for 8 consecutive weeks.
223804461|NCT05097846|DRUG|Group1 Vonoprazan Fumarate + amoxicillin + doxycycline|Vonoprazan Fumarate + amoxicillin + doxycycline
223804462|NCT05097846|DRUG|Group2 Vonoprazan Fumarate + furazolidone + doxycycline|Vonoprazan Fumarate + furazolidone + doxycycline
223804463|NCT05097846|DRUG|Group3 esomeprazole + colloidal bismuth tartrate + amoxicillin + doxycycline|esomeprazole + colloidal bismuth tartrate + amoxicillin + doxycycline
223804464|NCT05097846|DRUG|Group4 esomeprazole + colloidal bismuth tartrate + furazolidone + doxycycline|esomeprazole + colloidal bismuth tartrate + furazolidone + doxycycline
223804465|NCT02235246|DRUG|Magnesium Sulfate|magnesium sulfate 50 mg/kg will be administrated during 10 min before anesthetic induction in patients undergoing endoscopic submucosal dissection.
223804466|NCT02235246|DRUG|Normal saline|Normal saline will be administrated during 10 min before anesethetic induction in patients undergoing endoscopic submucosal dissection.
223804467|NCT01862822|OTHER|upright position|
223804468|NCT02994914|OTHER|Onco Geriatric Evaluation|"Seven tests will be performed by an onco geriatrician : Activities of Daily Living, Instrumental Activities Of Daily Living, Mini Mental State Examination, mini Geriatric Depression Scale, Mini Nutritional Assessment, Cumulative Illness Rating Scale-Geriatric, and  timed get up and go  tests. Those tests lead to a score, and this score will determine the scheme of patients radiotherapy."
223804469|NCT01949870|DRUG|Cisplatin|day1 and day8 at each cycle
223804470|NCT01949870|DRUG|Gemcitabine|day1 and day8 at each cycle
223804471|NCT01949870|DRUG|Selumetinib|25mg/day, 50mg/day and 75mg/day
223804472|NCT03953235|BIOLOGICAL|GRT-C903|a shared neoantigen cancer vaccine prime
223804473|NCT03953235|BIOLOGICAL|GRT-R904|a shared neoantigen cancer vaccine boost
223804474|NCT03953235|BIOLOGICAL|nivolumab|anti-PD-1 monoclonal antibody
223804475|NCT03953235|BIOLOGICAL|ipilimumab|anti-CTLA-4 monoclonal antibody
223804476|NCT05649111|DRUG|Difluprednate Eye Drops|post-operative cataract surgery medication regimen. but different dosages between the 2 groups.
223804477|NCT06202326|DEVICE|renal artery doppler|doppler ultrasound follow up
223804478|NCT01379872|OTHER|Non-Interventional Study|This is a non-interventional study
223804479|NCT00677352|DRUG|sertraline|dosage : 25mg , 50mg , placebo; dosage form : tablet; frequency : once daily after dinner; duration : 14 weeks
223804480|NCT00677352|DRUG|Paroxetine|dosage : 10mg, placebo; dosage form : capsule; frequency : once daily after dinner; duration : 14 weeks
223804481|NCT01841346|PROCEDURE|Procedure: PCI|
223804482|NCT04791280|PROCEDURE|Faeces collection|"* faeces collection at inclusion~* follow-up visit 6 months after inclusion"
223804483|NCT04465019|DEVICE|Exoskeleton Rehabilitation|The EKSO GT® was operated by a Licensed Physical Therapist who was certified to control the device. We followed a strictly established protocol for operating the device during the rehabilitation process as established by the company.
223804484|NCT02182973|DIETARY_SUPPLEMENT|donor human milk|"Infants with NAS requiring pharmacologic management will be fed donor human milk instead of formula for 2 weeks.~GI-subscores from the Finnegan NAS Scoring system will be computed."
223804485|NCT03854968|OTHER|Quality control|The performance of the home mechanical ventilator of all patients in the study will be evaluated with a portable device
223804486|NCT01197196|BEHAVIORAL|Behavioral Weight Loss Intervention|Participants assigned to this condition will receive an intensive group-based lifestyle program modeled after the DPP and Look AHEAD trials. Participants will attend 16 weekly sessions involving provision of behavioral goals and strategies to modify diet and exercise behaviors in order to achieve a weight loss of at least 7% of initial body weight.
223804487|NCT01197196|OTHER|Migraine Education|Participants assigned to this condition (Healthy Living for Migraine Relief \[HLMR\]) will receive basic education and didactic instruction in migraine headaches and treatments that are the standard of care. Participants will attend 4 months of weekly group lectures focused on 3 different major topic areas: 1) migraine symptomatology and pathophysiology, 2) standard abortive and preventive pharmacological treatment options, and 3) standard and alternative non-pharmacological treatment options.
223804488|NCT01123382|DEVICE|Intramuscular Electrical Stimulator|A sterile percutaneous IM electrode is implanted in the shoulder using a 20-gauge hypodermic needle and connected to an external cable. The exit site and electrode are covered by a bandage, but the cable extends out. After a one week stabilization period, the cable is connected to a stimulator. A self-adhesive surface electrode serves as the indifferent electrode. Stimulation intensity is set by the investigator. The prescription for daily stimulation treatment will be 6 hrs. The duty cycle and daily dose will remain constant throughout the treatment, but stimulus parameters may be adjusted by the research staff as deemed appropriate. The treatment period will be 3 weeks, after which the electrode will be removed. Total time of electrode implantation is no more than 29 days.
223804489|NCT01123382|OTHER|Outpatient Therapy|Subjects will receive 8 hrs of outpatient therapy over a four week period from a treating therapist, coupled with prescribed daily home exercises. The therapist will implement an individualized treatment plan consistent with the needs of the participant.
223804490|NCT04704518|DRUG|Sodium Hyaluronate Ophthalmic 0.4%|Topical ophthalmic administration of one drop of Lagricel® Ofteno PF QID.
223804491|NCT04704518|DRUG|Trehalose 3% / Sodium Hyaluronate Ophthalmic 0.15%|Topical ophthalmic administration of one drop of Thealoz® Duo QID.
223804492|NCT01497522|DRUG|Vildagliptin|vildagliptin 50 mg twice daily
223804493|NCT01497522|DRUG|Placebo|Matching Placebo of vildagliptin 50 mg twice daily
223804494|NCT04006561|RADIATION|A treatment protocol of combined chemoradiation delivered in the manner of hyperfractionated conformal whole-brain radiation therapy|Each freshly-diagnosed patient with primary CNS lymphoma will be treated with combined chemoradiation in a sandwiched way, in which 2 cycles of induction chemotherapy with intravenous methotrexate (MTX in a conventional dose of 1g/m2) and intrathecal MTX are followed by a complete course of hyperfractionated WBRT and then high-dose cytarabine for 2 cycles.
223804495|NCT00594854|DRUG|PN400 (VIMOVO)|PN400 tablet (500 mg delayed-release naproxen/20 mg immediate-release esomeprazole) given by mouth twice daily (bid).
223804496|NCT00594854|DRUG|Diclofenac/Misoprostol|Over-encapsulated ARTHROTEC® 75 (75 mg diclofenac sodium/200 mcg misoprostol) capsules given by mouth bid.
223804497|NCT01187979|BEHAVIORAL|Cash incentives|Cash incentives paid to learners for reaching pre-determined milestones
223804498|NCT01187979|BEHAVIORAL|Life skills curriculum|Standard department of education lifeskills curriculum
223804499|NCT02141763|DRUG|UCB4940 40 mg|"* Active Substance: UCB4940~* Pharmaceutical Form: solution~* Concentration: vials at 80 mg/mL will be diluted with 0.9 % sodium chloride to a final concentration calculated to achieve the correct dose~* Route of Administration: intravenous"
223804500|NCT02141763|DRUG|UCB4940 80 mg|"* Active Substance: UCB4940~* Pharmaceutical Form: solution~* Concentration: vials at 80 mg/mL will be diluted with 0.9 % sodium chloride to a final concentration calculated to achieve the correct dose~* Route of Administration: intravenous"
223804501|NCT02141763|DRUG|UCB4940 160 mg|"* Active Substance: UCB4940~* Pharmaceutical Form: solution~* Concentration: vials at 80 mg/mL will be diluted with 0.9 % sodium chloride to a final concentration calculated to achieve the correct dose~* Route of Administration: intravenous"
223804502|NCT02141763|DRUG|UCB4940 240 mg|"* Active Substance: UCB4940~* Pharmaceutical Form: solution~* Concentration: vials at 80 mg/mL will be diluted with 0.9 % sodium chloride to a final concentration calculated to achieve the correct dose~* Route of Administration: intravenous"
223804503|NCT02141763|DRUG|UCB4940 320 mg|"* Active Substance: UCB4940~* Pharmaceutical Form: solution~* Concentration: vials at 80 mg/mL will be diluted with 0.9 % sodium chloride to a final concentration calculated to achieve the correct dose~* Route of Administration: intravenous"
223804504|NCT02141763|DRUG|UCB4940 560 mg|"* Active Substance: UCB4940~* Pharmaceutical Form: solution~* Concentration: vials at 80 mg/mL will be diluted with 0.9 % sodium chloride to a final concentration calculated to achieve the correct dose~* Route of Administration: intravenous"
223804505|NCT02141763|OTHER|Placebo|"* Pharmaceutical Form: solution~* Concentration: 0.9 % sodium chloride~* Route of Administration: intravenous"
223804506|NCT01870193|DIETARY_SUPPLEMENT|Glycine, cysteine (as n-acetylcysteine), alanine|"Young controls will receive cysteine plus glycine for 2 weeks~The elderly subjects will be randomized in a double-blinded design to receive either cysteine plus glycine OR alanine for a period of 4 months"
223804507|NCT05374954|BIOLOGICAL|Omicron COVID-19 Vaccine (Vero Cell), Inactivated|intramuscular injection in the deltoid muscle
223804508|NCT05374954|BIOLOGICAL|COVID-19 Vaccine (Vero Cell), Inactivated|intramuscular injection in the deltoid muscle
223804509|NCT06191419|OTHER|Odorants|Each smoker is assigned a CPAP nose mask. Odor sample bags are attached to the mask. Smokers open the valve, inhale once through the nose, close the valve, remove the bag from the mask and report on the odor.
223804510|NCT00432250|PROCEDURE|Cervical length ultrasound|
223804511|NCT06561178|DIAGNOSTIC_TEST|molecular residual disease detection|ctDNA detection
223804512|NCT06250270|DIETARY_SUPPLEMENT|protein or placebo|casein protein (30g) or placebo (maltodextrin, 30g)
223804513|NCT04628442|PROCEDURE|Sinonasal Debridement Procedure|This is a medical procedure prescribed by the participant's physician that has been deemed necessary for patient care in order to address their chronic rhinosinusitis.
223804514|NCT04628442|PROCEDURE|Nasal Polyp Removal|This is a surgical procedure prescribed by the participant's physician that has been deemed necessary for patient care in order to address their chronic rhinosinusitis.
223804515|NCT04628442|PROCEDURE|Biopsy|A biopsy is optional and will remove a sample of inferior turbinate tissue from the nasal passage. It will be performed during a nasal polyp removal surgery already scheduled for patient care.
223804516|NCT04153227|DIAGNOSTIC_TEST|Bone mineral density (BMD)|Bone mineral density (BMD) is measured by Dual-energy X-ray absorptiometry (DXA). BMD provides a measure of bone mass.
223804517|NCT04153227|DIAGNOSTIC_TEST|Trabecular bone score (TBS)|The Trabecular Bone Score (TBS) is a novel gray-level texture measurement that can be extracted from DXA images. TBS provides a measure of bone quality (bone microarchitecture).
223804518|NCT04153227|DIAGNOSTIC_TEST|Fracture risk Assessment Tool (FRAX)|The Fracture risk Assessment Tool (FRAX) is a fracture risk calculator that estimates an individual's 10-year probability of incurring a hip or other major osteoporotic fracture.
223804519|NCT06577623|BEHAVIORAL|MINDful TIME|Group-based psychoeducational mindfulness-based intervention.
223804520|NCT03482479|DRUG|Naltrexone Hydrochloride|Naltrexone Hydrochloride will be taken daily (dose 4.5 mg) for six weeks
223804521|NCT03482479|OTHER|Placebo Comparator|A placebo tablet which matches the drug will be taken daily for 6 weeks.
223804522|NCT04671784|OTHER|EUS-E|EUS-E
223804523|NCT06335719|PROCEDURE|BES|Nerve biopsies during surgery + brief electrical stimulation therapy
223804524|NCT06335719|PROCEDURE|Standard of Care surgery|Nerve biopsies during surgery - no brief electrical stimulation therapy
223804525|NCT03579316|DRUG|Adavosertib|Given PO
223804526|NCT03579316|DRUG|Olaparib|Given PO
223804527|NCT03579316|DRUG|Ceralasertib|Given PO
223804528|NCT06162741|BEHAVIORAL|Primary Care Brief Mindfulness Training (PCBMT)|PCBMT is a manualized intervention that is a brief adaptation of MBSR Mindfulness Based Stress Reduction (MBSR). It was developed by Dr. Scott Treatman and Dr. Dessa Bergen-Cico (Co-I). PCBMT consists of four 90-minute classes (360 total minutes of classes). Instruction encompasses sitting meditation, body scan, moving meditation, gentle yoga, and group discussion on topics such as non-judging, patience, trust, non-striving, acceptance, and letting go. In-class meditations are followed by a group process of the experience. At-home practice between sessions is encouraged and is guided by simple checklists asking students to check the meditation they practiced and write a few comments about what the experience was like.
223804529|NCT06162741|BEHAVIORAL|Moving Forward (MF)|"Moving Forward (MF) is a transdiagnostic class that seeks to build resilience and reduce emotional distress by teaching step-by-step problem-solving skills such as stop, slow down, think and act. The format that will be used as the comparison is manualized, group-delivered, primary care-based, often co-delivered by MH providers and peers, and considered a usual care practice in many VHA PCMHI programs. MF content is derived from problem solving therapy, which has clear effectiveness in reducing depression and other types of psychological distress. While the MF manual consists of four 60-minutes classes, for this study the 4 classes will be 90-minutes long to equate the length of both conditions. No new content will be added rather the additional time will be used to allow Veterans to complete worksheets in class and allow more group discussion."
223804530|NCT06258018|DRUG|Temodal|given orally for 7 consecutive days, followed by 7 days OFF, in a cycle of 28 days
223804531|NCT06258018|DRUG|Niraparib|given orally in continous
223804532|NCT06199258|DIAGNOSTIC_TEST|pulmonary function test|pulmonary function testing
223804533|NCT05756387|DEVICE|Non-invasive ventilation|NIV as in standard care
223804534|NCT01146509|DRUG|Aricept (donepezil hydrochloride)|Donepezil hydrochloride tablet: initial 5 mg/day dose was taken orally, once a day. At Week 4 visit, the dose was increased to 10 mg/day at the discretion of the investigator.
223804535|NCT06304818|DRUG|SCTB14|SCTB14,IV
223804536|NCT00853814|BEHAVIORAL|Access to sedentary behaviors|Access to sedentary behaviors: Reduced access - reduce access to sedentary behaviors by 50% using TV Allowance technology. Usual access - monitoring only, no change in access to sedentary behaviors. Access to neighborhood parks: High access - large amount of park land very near to the child's home. Low access - little to no park land near the child's home.
223804537|NCT06198465|DRUG|adebrelimab,Paclitaxel,Lobaplatin,Fluorouracil|adebrelimab: 1200mg，D1，q3w; Paclitaxel: 50mg/m2 D1/8/15； Lobaplatin: 50mg，iv 2h，d1; Fluorouracil: 400mg/m2，bolus iv，600mg/m2，iv 22h，d1-3；
223804538|NCT04189718|PROCEDURE|osseodensification protocol|Local anaesthesia was administered and mucoperiosteal flap was reflected. Implant osteotomies was performed with sequential drilling with osseodensification protocol at 1100 rpm. The pilot drill was used in clockwise direction and the other sequential drills were used in counter clockwise direction under copious irrigation. Flap closure was achieved using 3-0 silk sutures to protect the implant site.
223804539|NCT04189718|PROCEDURE|conventional implant site preparation protocol|Local anaesthesia was administered and mucoperiosteal flap was reflected. Implant osteotomies was performed with sequential drilling with conventional implant site preparation protocol at 1100 rpm. The pilot drill was used in clockwise direction and the other sequential drills were used in clockwise direction under copious irrigation. Flap closure was achieved using 3-0 silk sutures to protect the implant site.
223804540|NCT00569582|DRUG|mifepristone|Patients take mifepristone by mouth once a day. The dose is increased during scheduled timepoints during the study or until symptoms improve or the highest dosage allowed is reached. Dose escalation will be based upon weight. During clinic visits, blood pressure, glucose tolerance and blood chemistries are measured and EKG and urinalysis will be performed.
223804541|NCT05586152|DRUG|INV-102|INV-102 Ophthalmic Solution
223804542|NCT05586152|DRUG|Vehicle|Vehicle Ophthalmic Solution
223804543|NCT04674241|DRUG|Dexmedetomidine|Ten minutes after anesthesia induction and endotracheal intubation, patients assigned to dexmedetomidine group were given a loading dose of dexmedetomidine 0.6 μg/kg over 10 minutes, followed by continuous infusion at a rate of 0.4 μg/kg/h until the start of dural closure.
223804544|NCT04674241|DRUG|0.9% saline|0.9% saline is administered with the same volume at the same speed as the other group.
223804545|NCT02676375|DRUG|Combination Bupropion + NRTs|
223804546|NCT02676375|OTHER|Extended Treatment|
223804547|NCT02676375|OTHER|Home Visits & Calls|
223804548|NCT02676375|DRUG|Monotherapy|
223804549|NCT00487617|PROCEDURE|Fruit juice or placebo absorption|absorption of 300 ml of fruit juice ; 24 hours later, absorption of 300 ml of placebo.
223804550|NCT00464802|DRUG|MOA-728|
223804551|NCT05688748|OTHER|Dengue self-monitoring system|The system has a symptom monitoring algorithm whereby patient would be asked to report their symptoms thrice daily (9am, 2pm and 8pm). The algorithm is developed by the researchers which consist of primary care doctors, emergency physician and infectious disease specialists. If the patient reports warning symptoms (persistent vomiting, persistent diarrhoea, abdominal pain, bleeding, difficulty breathing, feel like fainting, difficulty carrying out usual activities, drowsiness, reduced urine output and reduced urine output), the system will advise patients to seek earlier medical care instead of waiting for the scheduled appointment the next day/other days.
223804552|NCT00762450|DRUG|Triclosan, Fluoride|Rinse 3 times daily with assigned toothpaste slurry
223804553|NCT00762450|DRUG|fluoride|Rinse 3 times daily with assigned toothpaste slurry
223804554|NCT00762450|DRUG|Fluoride, triclosan, amino acid|Rinse 3 times daily with assigned toothpaste slurry
223804555|NCT03230773|DEVICE|Defibrillator model|Comparison of the performance of different public access defibrillators
223804556|NCT01011621|DRUG|0.5% prednisolone acetate cream|Small amount applied over the lesion twice a day for 14 days.
223804557|NCT01011621|DRUG|0.1% betamethasone valerate cream|Small amount applied over the lesion twice a day for 14 days.
223804558|NCT03905330|DRUG|Maralixibat|Maralixibat oral solution (up to 600 mcg/kg) orally twice daily for 26 weeks.
223804559|NCT03905330|OTHER|Placebo|Placebo matching to maralixibat orally twice daily for 26 weeks.
223804560|NCT04329962|OTHER|Blueberry Powder Food Product|Consume blueberry powder confection
223804561|NCT04329962|OTHER|Dietary Intervention|Consume blueberry extract confection
223804562|NCT04329962|OTHER|Questionnaire Administration|Ancillary studies
223804563|NCT04433884|DEVICE|Endotracheal intubation using a laryngoscope|Patients will undergo intubation using 2 different types of laryngoscopes and their hemodynamic response would be recorded
223804564|NCT02502201|OTHER|six-minute walk study indoors|Performance of a six-minute walk test according to American Thoracic Society standard.
223804565|NCT02502201|OTHER|six-minute walk study outdoors|Performance of a six-minute walk test.
223804566|NCT03077490|DEVICE|Transvaginal mesh Uphold TM Vaginal Support System|
223804567|NCT03077490|DEVICE|Transvaginal mesh Uphold TM Vaginal Support System.|
223804568|NCT06491472|DRUG|Ivonescimab|20mg/kg,IV,d1,Q3W
223804569|NCT06491472|DRUG|Gemcitabine|1000mg/m2, IV, d1/8, Q3W
223804570|NCT06491472|DRUG|Nab paclitaxel|125mg/m2, IV, d1/8, Q3W
223804571|NCT06491472|RADIATION|SBRT|5Gy \*5 F
223804572|NCT02001766|BEHAVIORAL|Exercise training|
223804573|NCT06024226|PROCEDURE|Tumor samples|Tumor samples will be collected by the pathologist at the reception of the tumor removed during surgery
223804574|NCT05989178|OTHER|Data Registry|Follow-up questionnaires sent every year for the 5 years following the patient's initial visit.
223804575|NCT05694741|DRUG|AZD0186|Subjects will receive AZD0186 orally.
223804576|NCT05694741|DRUG|Placebo|Subjects will receive placebo orally.
223804577|NCT04989075|OTHER|Oral prophylactic intervention|The oral prophylactic intervention will consist of the provision of specific package including a soft-bristled manual toothbrush, toothpaste, and a kit of calibrated interdental brushes (IDBs)(Curaprox CPS; Curaden) of sizes corresponding to the diameter of their interdental spaces. The participants will be instructed to brush their teeeth twice-daily and to realise a daily interdental brushing until delivery. The instructions for the use of the toothbrush and IDBs comprised verbal instructions supported by practical demonstration. The first use of the material will be conducted under the supervision of a qualified public health professor.
223804578|NCT05759078|DRUG|Ferinject|The first dose of either FCM will be administered during the first visit on the day of randomisation (V1). Then, the participants will be reassessed at 4, 8, 12, 18, 24 and 30 months (visits V2, V3, V4, V5, V6, V7). If safety criteria are not fulfilled, a patient in the active study arm will receive i.v. NaCl 0.9% during the particular visit.
223804579|NCT05759078|DRUG|Sodium Chloride 0.9% Inj|The first dose of placebo will be administered during the first visit on the day of randomisation (V1). Then, the participants will be reassessed at 4, 8, 12, 18, 24 and 30 months (visits V2, V3, V4, V5, V6, V7).
223804580|NCT05261152|DRUG|drug product: capsules are containing S. boulardii, administered twice daily (250 mg)|Randomisation: 1:1 Capsules containing S. boulardii twice daily (250 mg) or indistinguishable capsules containing placebo twice daily.
223804581|NCT01508429|OTHER|placebo|4 placebo tablets (resembling misoprostol) administered sublingually
223804582|NCT01508429|DRUG|Misoprostol|800mcg misoprostol (4 200mcg tablets administered sublingually)
223804583|NCT06078462|OTHER|job related activities|Different types of effort offered by female physiotherapist and female dentist during clinical practicing with patients in internship year
223804584|NCT03087071|OTHER|Laboratory Biomarker Analysis|Correlative studies
223804585|NCT03087071|BIOLOGICAL|Panitumumab|Given IV
223804586|NCT03087071|DRUG|Trametinib|Given PO
223804587|NCT02652741|DRUG|Enalapril Orodispersible Minitablet|8-weeks treatment, open, uncontrolled, PK/PD, acceptability and palatability assessments and safety assessments after Enalapril intake in form of 0.25 mg or 1 mg ODMTs
223804588|NCT02782169|DRUG|Pregabalin|Pregabalin 300 mg capsule (over encapsulated to maintain blinding)
223804589|NCT02782169|DRUG|Placebo|Matching placebo capsule with excipient to match Pregabalin
223804590|NCT02975973|DEVICE|transcranial direct current stimulation|transcranial direct current stimulation (tDCS) is a safe, noninvasive, weak electrical current delivery that stimulates brain function. It is a novel therapeutic for cognition in schizophrenia.
223804591|NCT00771810|DRUG|TXA127|Once daily subcutaneous injection of 100 ug/kg
223804592|NCT00771810|DRUG|TXA127|Once daily subcutaneous injection of 300 ug/kg
223804593|NCT00771810|DRUG|Placebo|Once daily subcutaneous injection of placebo
223804594|NCT04220177|DEVICE|SETA LATECBA Stent Grafts|ABK model is a bifurcated polyester graft partially corrugated which is sutured at the proximal end (renal) to a balloon expandable 316 L stainless steel stent. The proximal half part of the stent is uncovered by polyester graft providing the anchoring to the healthy aorta wall when the device is implanted, as well as the perfusion of the renal arteries. The remaining half part is covered by polyester graft providing sealing of the aneurysm when it is expanded upon on the graft fabric and aneurysm neck. The distal end of each branch has the anchorage site for sealing after the connection with the iliac extensions RIK. The diameter of the anchorage site varies with the different ABK codes. The end of one branch is cone-shaped after the anchoring diameter with the purpose of promoting insertion of iliac extension RIK. The connection to iliac arteries is achieved by completing the aortic trunk ABK with 2 iliac extensions RIK.
223804595|NCT00989248|OTHER|Aerobic and anaerobic capacity use aquatic exercises|Improve aerobic capacity use aquatic exercises in patients with Congestive Heart Failure
223804596|NCT05524974|DRUG|Camrelizumab|Camrelizumab One course will last 21 days. Given once every 3 weeks at a dose of 200 mg.
223804597|NCT05524974|DRUG|Oxaliplatin|Oxaliplatin for Injection 135mg/m2 /per day，ivgtt，in day1. Given once every 3 weeks.
223804598|NCT05524974|DRUG|S1|S-1 was calculated according to body surface area , P.O., bid, d1-d14. And the dosage according body surface area:\<1.25m2, 40mg every time;1.25-1.5m2,50mg every time; \>1.5m2, 60mg every time
223804599|NCT05524974|DRUG|Apatinib Mesylate|Apatinib One course will last 21 days.Oral administration at a dose of 250 mg everyday.
223804600|NCT05524974|DRUG|Nab paclitaxel|nab-paclitaxel One course will last 21 days. Given twice every 3 weeks at a dose of 260 mg/m2 in day 1 and day 8.
223804601|NCT02942108|PROCEDURE|piezo surgery|
223804602|NCT02942108|PROCEDURE|conventional surgery|
223804603|NCT01900782|BIOLOGICAL|Intervention A|Prefilled syringe.
223804604|NCT01900782|BIOLOGICAL|Intervention B|Prefilled syringe.
223804605|NCT01900782|BIOLOGICAL|Placebo|Prefilled syringe to match experimental drug and active comparator.
223804606|NCT04640532|DRUG|KRT-232|KRT-232, administered by mouth
223804607|NCT04640532|DRUG|TL-895|TL-895, administered by mouth
223804608|NCT01953848|DRUG|EC905|Oral
223804609|NCT01489995|DRUG|A (migalastat)|150 mg migalastat HCl in the fasting state (reference arm)
223804610|NCT01489995|DRUG|B (migalastat)|150 mg migalastat HCl with simultaneous consumption of a glucose drink
223804611|NCT01489995|DRUG|C (migalastat)|150 mg migalastat HCl 1 hour before consumption of a high fat meal
223804612|NCT01489995|DRUG|D (migalastat)|150 mg migalastat HCl 1 hour before consumption of a light meal
223804613|NCT01489995|DRUG|E (migalastat)|150 mg migalastat HCl 1 hour after consumption of a light meal
223804614|NCT01832116|DRUG|89Zr-MMOT0530A|Injection of 89Zr-MMOT0530A followed by 2 or 3 PET scans at different time points
223804615|NCT05916651|BEHAVIORAL|Learning to Offset Stress (LOS) (in Dutch: Leren Omgaan met Stress) training|The investigational treatment is the LOS training, which is an adaptation of two previously validated mindfulness-based programs: Mindfulness-Based Cognitive Therapy (MBCT) developed by Segal, Williams, and Teasdale (2002) and the Mindful2Work (M2W) program developed by de Bruin, Formsma, and Bögels (2018). The M2W program combines mindful physical activity, yoga, and mindfulness meditation to target stress symptoms and burn-out in adults. The LOS training was adapted from these programs to meet the needs of youth with internalizing problems. The training consists of 8 weekly 2-hour sessions that each comprise three elements: mindful physical activity (15-20 minutes), yoga (15-20 minutes), and mindfulness meditation exercises (80-90 minutes). In addition to attending group sessions, participants are invited to practice at home on a daily basis. Home practice consists of daily mindfulness practices comprising mindfulness exercises, yoga and mindful physical activity.
223804616|NCT05916651|BEHAVIORAL|Care as usual|"Youth who seek help for internalizing problems from a primary mental health practitioner, including student psychologists or mental health nurse practioners, but do not (yet) meet criteria for (major) mental illness are typically offered supportive counselling, aimed primarily at helping people feel understood and supported. Supportive counselling may also include instructions on behavioral activation, particularly when individuals report reduced activity and behavioral avoidance including social withdrawal. In addition, mental health practitioners commonly employ a watchful waiting policy for people with symptoms in the milder range, where they check-in with clients on a regular basis and refer for more intensive treatment if and when symptoms worsen."
223804617|NCT01727739|DEVICE|Linvatec PLLA+TCP|Linvatec PLLA+TCP tibial interference screw fixation will be used in ACL reconstruction.
223804618|NCT01727739|DEVICE|Linvatec PLLA|Linvatec PLLA tibial interference screw fixation will be used in ACL reconstruction.
223804619|NCT04802941|DEVICE|Neoadjuvant Chemotherapy by CDSS (MedicBK)|CDSS (MedicBK) captures the patient-specific data required to determine appropriate care decisions from the EMR and then presents relevant data alongside treatment suggestions to clinicians. MedicBK uses algorithms for presenting treatment suggestions framed by guideline-based therapy and personalized personalized evidence-based therapy. MedicBK consists of three main blocks: database, network meta-analysis, and heterogeneity of treatment effects assessment.
223804620|NCT04802941|DRUG|General practice|General practice
223804621|NCT05275257|DEVICE|Use of Uricap Female, a New Urine Collecting Device|The uridome is changed daily by trained staff
223804622|NCT03043508|OTHER|Chart Review|Database reviewed to obtain patient and disease characteristics, laboratory values, imaging results, hormone parameters (menopausal status, bioidentical hormone use, oral contraception use, gestational status and diagnosis of a prolactinoma) and vital status.
223804623|NCT03043508|BEHAVIORAL|Questionnaire|Participants sent an email questionnaire to complete regarding their pregnancy and hormone use history.
223804624|NCT04779138|BEHAVIORAL|Increasing Willingness and Uptake of COVID-19 Vaccination|Provide/enhance knowledge, modify attitudes, motivate and provide skills and resources to reduce COVID-19 vaccine hesitancy and increase willingness and uptake in COVID-19 vaccination.
223804625|NCT06104033|DEVICE|drug-coated balloon|For the procedure, the drug-coated balloon (Agent®, Boston Scientific, USA) that can be used for both de-novo coronary lesions and in-stent restenosis lesions is used.
223804626|NCT06104033|DEVICE|drug-eluting stent|When using drug-eluting stents, the latest 2nd generation drug-eluting stent (Synergy®, Boston Scientific, USA) should be used in accordance with the latest guidelines.
223804627|NCT05721534|OTHER|Medication review|"Annual consultation focusing on pharmacological treatment. This specific consultation constituted the intervention. It included a structured review of the patient's health state, in addition to a structured medication review with a focus on appropriate medication and deprescribing."
223804628|NCT00255931|BEHAVIORAL|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy and Relaxation/biofeedback
223804629|NCT00255931|BEHAVIORAL|Attention Placebo|Untrained relaxation
223804630|NCT01127867|DIETARY_SUPPLEMENT|dietary intervention|dietary intervention
223804631|NCT01579734|DRUG|Tamoxifen|1 tablet, 5 mg / day for 5 years
223804632|NCT01579734|DRUG|Placebo|1 tablet day for 5 years
223804633|NCT04637334|PROCEDURE|Superior vena cava reconstruction|Endovascular therapy with percutaneous transluminal angioplasty (PTA) and, in recent years, with stenting of the SVC, has been performed with increasing frequency. An endovascular approach is the current standard of care to relieve SVC obstruction due to malignancy to obtain prompt relief of the rapidly emerging symptoms and improve quality of life,3 keeping in mind the short life expectancy of these patients. The role of endovascular therapy in SVC syndrome of nonmalignant etiology is undecided because long-term durability of this treatment method remains to be assessed.
223804634|NCT03577639|OTHER||
223804635|NCT00491803|DRUG|Sildenafil|sildenafil 20 mg orally
223804636|NCT00491803|DRUG|Sildenafil|sildenafil 40 mg orally
223804637|NCT00387673|BEHAVIORAL|Somatosensory Stimulation and Massed Practice Training|a) somatosensory stimulation of the median, ulnar and radial nerves at the level of the wrist (2 hours/session); SS group b) somatosensory stimulation of the median, ulnar and radial nerves at the wrist (2 hours/session) followed by an activity-based upper extremity training program (1 hour/session); SS+ABT group and c) sham somatosensory stimulation of the median, ulnar and radial nerves at the wrist (2 hours/session) followed by an activity-based upper extremity training program (1 hour/session); ABT group then carry out training in the 3 subject groups simultaneously, each group consisting of 2 subjects at a time, with 2 sets of subjects/year over a 2-year period, yielding a target sample of 36 subjects.
223804638|NCT03158883|DRUG|Avelumab|Avelumab: 10 mg/kg administered by IV infusion q2w (1 cycle = 14 \[±2\] days).
223804639|NCT03158883|RADIATION|Stereotactic ablative radiotherapy (SAR)|SAR: the prescription dose will be 50 Gy over 5 fractions of 10 Gy each on an every 2 day basis (i.e., 2-3 treatments per week, with a minimum of 40 hours and a maximum of 96 hours between treatments) and completed within 1.5-2 weeks. SAR treatment will not be repeated.
223804640|NCT03065270|OTHER|Use unstable shoes Masai Barefoot Technology (MBT)|Use of unstable shoes during 9 weeks, at least four hours per day.
223804641|NCT03065270|OTHER|Use conventional sport shoes|Use of conventional sport shoes during 9 weeks, at least four hours per day.
223804642|NCT03326531|OTHER|Not applicable for this study|Not applicable for this study
223804643|NCT05125575|DRUG|Metformin 1000 mg Prolonged Release Tablets (JSC Farmak, Ukraine)|One tablet of the Test (T) product was administered orally with 240 mL of water.
223804644|NCT05125575|DRUG|Glucophage® XR 1000 mg Prolonged Release Tablets|One tablet of the Reference (R) product was administered orally with 240 mL of water.
223804645|NCT00045305|DRUG|Cyclosporine|Immunosuppressant
223804646|NCT00045305|DRUG|Methotrexate|Antimetabolite
223804647|NCT00045305|DRUG|Photopheresis|Psoralens
223804648|NCT00045305|DRUG|Mycofenolate mofetil|an antibiotic with immunosuppressamt properties isolated from Penicillium spp
223804649|NCT00045305|DRUG|Pentostatin|Purine analogue
223804650|NCT00045305|PROCEDURE|allogeneic bone marrow|Unmanipulated allogeneic bone marrow
223804651|NCT00045305|PROCEDURE|peripheral blood stem cell|G-CSF mobilized peripheral blood stem cell
223804652|NCT00045305|RADIATION|Total body irradiation|a total of 600 cGy given in 3 200 cGy fractionated doses
223804653|NCT01033357|DEVICE|Graft, Vascular Wrap|Lifespan® ePTFE Vascular Graft and Vascular Wrap Paclitaxel-Eluting Mesh (0.9 µg/mm2 paclitaxel)
223804654|NCT01033357|DEVICE|Lifespan® ePTFE Vascular Graft Only|Vascular Graft only
223804655|NCT01440491|OTHER|Physiotherapy exercise|once a day, during 15 minutes, for 12 weeks
223804656|NCT00910442|DIETARY_SUPPLEMENT|Glutathione precursors|HIV+ patients were assigned to 7 day diets containing either NAC or Gln
223804657|NCT04492579|OTHER|Gentle-UHT donor human milk supplementation|Providers referred mothers with newborns that fit the following criteria: exhibited insufficient milk supply, an infant with early weight loss born \>36 weeks gestation. Mother was given Gentle-UHT donor milk for supplementation, in addition to mother's own milk for the first week of the infant's life after hospital discharge.
223804658|NCT02763514|DIETARY_SUPPLEMENT|3 g PronovaPure 150:500 EE EU|
223804659|NCT02763514|DIETARY_SUPPLEMENT|3 g PronovaPure 500:200 EE EU|
223804660|NCT02763514|DIETARY_SUPPLEMENT|3 g Placebo|
223804661|NCT00955669|BIOLOGICAL|Symptoms and Objective Examination|5.0\*108\~5.0\*109 MSCs and MNCs were transplant into impaired lower limbs by intramuscular injection
223804662|NCT02635048|PROCEDURE|Mini Percutaneous Nephrolithotomy|patients undergo PNCL with 18Fr nephrostomy tract
223804663|NCT02635048|PROCEDURE|Percutaneous Nephrolithotomy|patients undergo PNCL with 24Fr nephrostomy tract
223804664|NCT00005810|BIOLOGICAL|filgrastim|
223804665|NCT00005810|DRUG|carboplatin|
223804666|NCT00005810|DRUG|docetaxel|
223804667|NCT00005810|DRUG|estramustine phosphate sodium|
223804668|NCT03323333|BEHAVIORAL|psychosocial counseling|A problem-solving and psychosocial skill-building intervention.
223804669|NCT03138096|BIOLOGICAL|Pb(PfCS@UIS4)-infected mosquitoes|Pb(PfCS@UIS4)-infected mosquitoes
223804670|NCT03138096|OTHER|Challenge infection P. falciparum|Challenge infection with bites of five infected Pf mosquitoes
223804671|NCT04830072|BEHAVIORAL|Brief AWARD advice and active referral to somking cessation services|The AWARD advice includes: (1) Ask about smoking history; (2) Warn about the high risk of smoking; (3) Advise to quit or reduce smoking as soon as possible; (4) Refer smokers to smoking cessation services (with a referral card); (5) Do it again: to repeat the intervention.
223804672|NCT04830072|BEHAVIORAL|Chat-based support through Instant Messaging apps|Participants in the intervention group will receive 3 months of chat-based support through Instant Messaging apps (e.g., WhatsApp, WeChat). The support mainly includes (1) regular messages on health warnings, benefits and methods of quitting, coping craving approach, and promotion to use the SC services; (2) real-time, personalized, and interactive behavioral and psychosocial support through Instant Messaging apps.
223804673|NCT04830072|OTHER|Leaflet|Leaflet on harms of smoking
223804674|NCT04830072|BEHAVIORAL|AR images|AR images of the harms of smoking and the benefit of abstinence.
223804675|NCT03977038|DEVICE|repetitive transcranial magnetic stimulation|Repetitive transcranial magnetic stimulation (rTMS) is prescribed as first-line treatment for TRD patients (4). rTMS is safe, tolerable and non-invasive neurostimulation procedure where powerful magnetic pulses are transmitted through the skull into the underlying cortical cortex with the aim of electrical current induction within the neural tissue. This study administers a standard dose of rTMS treatment to the TRD patient sample consisting of high frequency deep TMS (HF-dTMS) stimulation over left dorsolateral prefrontal cortex (L-DLPFC), at the frequency of 18Hz, at 120% value of the individual's motor threshold, in 5 daily sessions per week, taking place each weekday, over the course of 6 weeks. The technology of dTMS, which will be used in this study, is an adaptation of the therapeutic intervention of rTMS with the advancement of possessing higher efficacy in targeting deeper brain regions of interest.
223804676|NCT02536365|BEHAVIORAL|Sensory Integration Therapy|Children in the SIT treatment group will receive a manualized SIT intervention that follows the principles of sensory integration.
223804677|NCT02536365|BEHAVIORAL|Applied Behavioral Analysis|Children in the ABA treatment group will receive intervention that follows the principles of Applied Behavioral Analysis.
223804678|NCT02159599|DRUG|Darunavir/Ritonavir|Darunavir/ritonavir (800/100 mg): QD (quaque die )
223804679|NCT02159599|DRUG|Lamivudine|Lamivudine (300mg) : QD
223804680|NCT02159599|DRUG|Emtricitabine/tenofovir or abacavir/lamivudine|Emtricitabine/tenofovir (300/200 mg) or abacavir/lamivudine (600/300 mg): QD
223804681|NCT02475122|OTHER|azygos blood flow measurements by MRI|
223804682|NCT05011994|BEHAVIORAL|Maintenance intervention|"The intervention consists of action planning, text messages, and coordinator support.~At onset, each participant creates an action plan for physical activity with the help of a health professional:~* What types of physical activities?~* When and how often?~* Where and with who?~  2 auto-generated text messages are sent weekly for a duration of 12 weeks. The first prompts physical activity. The second asks if plans were reached. If yes, an automatic reply with positive reinforcement is generated. If no, an automatic reply asks if the participant wants to be contacted.~Participants are contacted by a coordinator either by answering text messages or if not answering the texts for a period of 2 weeks or more. Coordinator functions:~* Call participants replying to texts that they wish to be contacted~* Help participants establish contact to local activities involving physical activity~* Follow-up on and adjustment of action plan~* Offer guidance in physical activity"
223804683|NCT03848403|BIOLOGICAL|Ixekizumab|Administered SC
223804684|NCT01939548|DRUG|PF-02545920|PF-02545920 2 mg BID x 7 days, then 5 mg BID until the Week 12 visit
223804685|NCT01939548|DRUG|Placebo|Placebo BID until the Week 12 visit
223804686|NCT01939548|DRUG|PF-02545920|PF-02545920 5 mg BID x 7 days, then 10 mg BID x 7 days, then 15 mg BID until the Week 12 visit
223804687|NCT00534131|PROCEDURE|Standard abdominal approach for rectal excision|Standard abdominal approach for rectal excision
223804688|NCT00534131|PROCEDURE|APPEAR Procedure|Perineal incision to reach the distal rectum
223804689|NCT00534131|PROCEDURE|Proctectomy|standard rectal excision which does not preserve the anal canal
223804690|NCT00760149|DRUG|Rifampicin in higher doses|Rifampicin 900 mg (study arm 2), and rifampicin 1200 mg (study arm 3)
223804691|NCT02386995|DEVICE|BIS monitor|Both types of depth of anesthesia monitoring (BIS and entropy- electrodes) are applied on patients together with standard monitoring (heart rate, blood pressure, respiratory rate). The two different types of depth of anesthesia monitoring are then compared.
223804692|NCT02386995|DEVICE|Entropy monitor|Both types of depth of anesthesia monitoring (BIS and entropy- electrodes) are applied on patients together with standard monitoring (heart rate, blood pressure, respiratory rate). The two different types of depth of anesthesia
223804693|NCT00101933|DEVICE|Medtronic DBS Therapy for epilepsy|Stimulation On
223804694|NCT00101933|DEVICE|Medtronic DBS Therapy for epilepsy|Stimulation Off
223804695|NCT01414621|OTHER|atrial tissue sample|atrial tissue sample from CABG patient
223804696|NCT00877825|PROCEDURE|dairy food control diet and high- and low- isoflavone soyfood diets|
223804697|NCT03234205|DEVICE|MRI scan|"MRI standard protocol with addition of:~* a second clinical respiratory belt besides belt usually installed for clinical examination~* a second clinical electrocardiogram sensor besides sensor usually installed for clinical examination~* 12 sequences during free respiration are added lasting supplementary 15 minutes~* Use of cardiac antennae usually used for cardiac MRI scans"
223804698|NCT02601989|DRUG|Tadalafil|
223804699|NCT02601989|DRUG|Placebo|Per oral intake of placebo for six weeks
223804700|NCT05316285|OTHER|Yoga exercise|Yoga lesson practices will be designed and implemented by instructors physiotherapists who have completed 200 hours of yoga instructor training (RYT-200). The yoga program, which will consist of one-hour sessions once a week, is planned to last 14 weeks. 4 weeks of classes will be theoretical lessons related to yoga philosophy, 10 weeks of yoga sessions will be applied every week on different concepts such as upper extremity and / or lower extremity focused strengthening and / or flexibility and breathing exercises. In addition to this training, students will be advised to repeat the practices once a week. Sessions will begin with breathing practices called pranayama, followed by yoga postures called asanas, and the sequence will be finished with savasana pose. In this pose, guided meditations will be performed on subjects such as body awareness and self-compassion.
223804701|NCT06562361|DRUG|[68Ga]Ga-DOTA-Cys-ATH001|Target dose of 200MBq \[68Ga\]Ga-DOTA-Cys-ATH001 corresponding to a maximum mass dose of 100 µg, administered as an intravenous bolus dose.
223804702|NCT00976352|DRUG|rAAV1-CMV-GAA (study agent) Administration|rAAV1-CMV-GAA via intramuscular injection into the diaphragm. Dose selection for cohort 1: 1.0 x 10e12 vector genomes Cohort 1 will have a total of 3 participants enrolled. Dose selection for cohort 2 and 3: 5.0 x 10e12 vector genomes rAAV1-CMV-GAA. Cohort 2 = 6 subjects.
223804703|NCT00976352|OTHER|RMST|After enrollment and screening visit, the subject will be given a RMST prescription and will complete RMST for a minimum of 4 weeks prior to study agent administration. RMST prescription will be adjusted as needed at Day 14, 90, 180, and 270.
223804704|NCT00500942|BEHAVIORAL|Questionnaire|Questionnaires about the pain level experienced during and after standard procedures are performed in the IR.
223804705|NCT02114151|DRUG|Simeprevir|100 participants will receive 1 capsule of 150 mg orally once daily for 12 weeks.
223804706|NCT02114151|DRUG|Sofosbuvir|100 participants will receive 1 tablet of 400 mg sofosbuvir orally once daily for 12 weeks.
223804707|NCT04738526|OTHER|lithium disilicate (IPS e-max) ceramic crown|monolithic lithium disilicate ceramic crown
223804708|NCT04738526|OTHER|New gradient technology zirconia (5Y-TZP\ 3Y-TZP) IPS e.max ZirCad Prime ceramic crown|conjunction with the two zirconium oxide raw materials 3Y-TZP and 5Y-TZP is responsible for producing a continuous, seamless progression of the shade and translucency within the material
223804709|NCT04738526|OTHER|natural tooth|natural tooth is composed of enamel. Enamel is on the surface of every tooth and it has a natural hue of white. However, the underlying dentin layer has a slightly yellowish color. This yellowish hue shows through the enamel in almost everyone
223804710|NCT03179644|OTHER|Measurement of oesophageal pressure and pleural pressure|Measurement of oesophageal pressure by a nasogastric tube with an esophageal balloon (also enabling the patient to be fed) and pleural pressure measurement by means of several pleurocath-type catheters (Prodimed Inc, France) which the thoracic surgeon will have previously Positioned at the end of the surgery without any additional skin intrusion
223804711|NCT00859079|DRUG|GLP-1|Patients received GLP-1 intravenously at a dose of 1.2 pmol/kg/min for at maximum 8 hours.
223804712|NCT00859079|DRUG|Human regular insulin intravenously|Human regular insulin intravenously according to the Munich-registry.
223804713|NCT05678205|DRUG|AB-201|NK Cell Therapy
223804714|NCT05678205|DRUG|Cyclophosphamide|Lymphodepleting chemotherapy
223804715|NCT05678205|DRUG|Fludarabine|Lymphodepleting chemotherapy
223804716|NCT00009802|DIETARY_SUPPLEMENT|calcitriol|
223804717|NCT00009802|DRUG|paclitaxel|
223804718|NCT03442712|OTHER|Auricular acupressure plus smartphone App|Semen Vaccaria laccaria will be kept in place by a piece of adhesive patch. Seeds will be applied on one ear only, and seed plasters will be changed every 3 days to 4 days to the opposite ear, that is, we will meet the subjects twice per week. Subjects will be requested to apply pressure on the acupoints thrice per day, preferably within 30 min before eating, pressing for 20 times using a constant rhythm to each point. Coaching on how to self-administer AA on the acupoints will be given to the subjects, and a return demonstration from the subjects will be required to ensure the skills are performed properly. The subjects will install the smartphone App specifically designed for this study. The App will send out regular AA reminders to the subjects. In addition, the subjects will be asked to input the number of bowel open and compliance with AA performance per day into the App. The total treatment period will be 8 weeks.
223804719|NCT03442712|OTHER|Auricular acupressure|The participants will receive AA treatment and are required to perform daily self-administered seeds pressing, but no smartphone App will be provided, but a booklet containing relevant information will be provided to the subjects.
223804720|NCT04528836|DRUG|BBP-398 (Formerly known as IACS-15509)|oral capsules
223804721|NCT04861987|DRUG|PCS6422 and capecitabine|PCS6422 is an experimental drug that, when combined with capecitabine, may make the immune response more active against cancer. Capecitabine is a commonly used oral fluoropyrimidine.
223804722|NCT05378581|DEVICE|Virtual reality mask|virtual reality mask Deepsen® with age-appropriate software Birdy®
223804723|NCT05378581|OTHER|control arm|usual process
223804724|NCT06437990|PROCEDURE|Arteriovenous loop graft|Using saphenous vein graft to create an arteriovenous loop from the common carotid artery to the external jugular vein, providing vascular supply for a free functional gracilis muscle flap in patients with late-onset brachial plexus injury with concomitant subclavian or axillary artery injury.
223804725|NCT05000957|DEVICE|Laser Treatment|"Laser radiation is emitted by a series of pulses following each other through a pause. The duration of one pulse is 20-200 ns, the pause between pulses is 30 us. The energy of one pulse is about 1.5 mJ.~General laser radiation parameters for 1st and 2nd stages are: beam with diameter of 4 millimeters (mm) scans treatment area by 4 circles with step of 2 mm (50 percentage (%) overlap), average power of 10-25 Watt (W), treatment time in one point of 1-10 seconds (s), treatment step of 5 mm, from 1 to 5 repetitions of total vagina treatment. General laser radiation parameters for 3d stage are: beam diameter of 6 mm, average power of 15-30 W, duration of ns-pulses packet of 50-100 milliseconds (ms), pause between packets of 50-100 ms, treatment duration up to 65 s, treatment in permanent motion with speed of 10-50 mm/s.~The procedure is performed without anesthesia. The doctor always focuses on the participant's feeling of warmth."
223804726|NCT05000957|DIAGNOSTIC_TEST|Blood analysis|Taking blood from a vein for clinical blood analysis, glucose test, hepatitis B, C viruses, human immunodeficiency viruses and syphilis test, blood clotting tests, blood type and rhesus factor determination (to include the participant in the study).
223804727|NCT05000957|DIAGNOSTIC_TEST|Сlinical urine test|Urine sampling for Clinical urine test (to include the participant in the study).
223804728|NCT05000957|DIAGNOSTIC_TEST|Electrocardiography|Electrocardiography investigation to determine cardiac abnormalities (to include the participant in the study).
223804729|NCT05000957|DIAGNOSTIC_TEST|Vaginal smear|Vaginal smear for flora investigation, oncocytology (to include the participant in the study).
223804730|NCT05000957|DIAGNOSTIC_TEST|Colposcopy|Colposcopy investigation to determine pre-malignant and malignant lesions of cervix, vagina or vulva (to include the participant in the study).
223804731|NCT05000957|DIAGNOSTIC_TEST|Pelvic ultrasound|Pelvic ultrasound investigation to determine pathologies of the pelvic through a gynecological probe (to include the participant in the study).
223804732|NCT05000957|DIAGNOSTIC_TEST|Doppler ultrasonography|Ultrasound investigation for assessing blood flow in the tissues of vulva region (to evaluate procedure efficiency).
223804733|NCT05000957|DIAGNOSTIC_TEST|Vaginal Health Index|Vaginal Health Index will be investigated by clinical examination for vaginal elasticity, vaginal secretions, epithelial mucous membrane, vaginal hydration. Potential of hydrogen (pH) will be investigated by test-lines paper (to evaluate procedure efficiency).
223804734|NCT05000957|DIAGNOSTIC_TEST|Biopsy of the vaginal wall|Sampling of the vaginal wall material in the posterior fornix area including the mucous membrane and muscle layer will be performed during colporrhaphy or any pelvic surgical procedure for histological, immunohistochemical studies, and optical coherence tomography (elastography) (to evaluate procedure efficiency)
223804735|NCT05000957|DIAGNOSTIC_TEST|The Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire|The Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire will be used to collect feedback on changes in the participants' life quality (to evaluate procedure efficiency).
223804736|NCT05000957|DIAGNOSTIC_TEST|Pelvic Floor Distress Inventory Questionnaire|Pelvic Floor Distress Inventory Questionnaire will be used to collect feedback on changes in the participants' life quality (to evaluate procedure efficiency).
223804737|NCT05000957|DIAGNOSTIC_TEST|International Consultation on Incontinence Questionnaire - Short Form|International Consultation on Incontinence Questionnaire will be used to collect feedback on changes in the participants' life quality (to evaluate procedure efficiency).
223804738|NCT05000957|DIAGNOSTIC_TEST|Pelvic Floor Impact Questionnaire|Pelvic Floor Impact Questionnaire will be used to collect feedback on changes in the participants' life quality (to evaluate procedure efficiency).
223804739|NCT05000957|PROCEDURE|Anterior and/or posterior colporrhaphy|Surgical procedure to repair pelvic organ prolapse followed by biopsy for histological, immunohistochemical studies, and optical coherence tomography (elastography).
223804740|NCT05000957|PROCEDURE|Pelvic surgical procedure|Any pelvic surgical procedure which do not affect condition of vagina, vulva and paraurethral region followed by biopsy for histological, immunohistochemical studies, and optical coherence tomography (elastography).
223804741|NCT05000957|OTHER|Physical examination|Pelvic examination (to include the participant in the study and observe throughout the study)
223804742|NCT05000957|OTHER|Сonsultation|Сonsultation of a therapist about the absence of contraindications for surgical treatment (to include the participant in the study)
223804743|NCT05000957|GENETIC|Buccal smear|"Buccal smear to performing genetic testing.~The following markers will be analyzed:~ESR1 rs2234693, ESR1 rs2228480, COL3A1 rs1800255, COL14A1 rs4870723, MMP9 rs3918253, MMP10 rs17435959, LOXL1 rs2304719, WNT4 rs3820282, MMP2 rs243865, TIMP2 rs2277698, CD31 / PECAM1 rs1131012, Ki67 rs11016076."
223804744|NCT01832948|DRUG|Endostar|
223804745|NCT01832948|DRUG|Oxaliplatin|
223804746|NCT01832948|DRUG|Folinic acid|
223804747|NCT01832948|DRUG|5-FU|
223804748|NCT04209075|DIETARY_SUPPLEMENT|Biomebliss|BiomeBliss is a commercially available powder containing prebiotic fiber (inulin and beta glucan), along with blueberry extract providing polyphenols.
223804749|NCT04209075|DRUG|Metformin|Metformin is a commonly used antidiabetic medication, and the only oral medication approved for children and adolescents under 18 years old. Though reasonably effective, gastro-intestinal side effects are common (80% at initiation, and 10-30% after long term use). Metformin dosing at clinically recommended doses will be titrated per protocol during the study.
223804750|NCT04209075|DIETARY_SUPPLEMENT|Placebo|Placebo Comparator
223804751|NCT02149251|GENETIC|Pre-genetic diagnosis|
223804752|NCT02638948|DRUG|BMS-986142|BMS986142 specific dose on specific days
223804753|NCT02638948|DRUG|Placebo|Placebo of BMS-986142 specific dose on specific days
223804754|NCT02638948|DRUG|Methotrexate|Methotrexate specific dose on specific days
223804755|NCT02271256|DEVICE|Functional Intimate Apparel|The design of functional intimate apparel will incorporate different mechanisms, such as a) compression and pulling forces through a close fit of the intimate apparel, b) lumbar flexion by using a supporting belt, c) transverse forces applied by inserting pads inside the pocket lining with the application of 3-point pressure system, d) axial rotation or coupled motion by using uneven straps, and e) an active mechanism that aims to shift the trunk away from areas of pressure.
223804756|NCT00141154|DRUG|Celecoxib|
223804757|NCT00141154|DRUG|Placebo|
223804758|NCT00141154|DRUG|Loxoprofen|
223804759|NCT06472466|BEHAVIORAL|Sleep/eating virtual reality self-help exposure-based intervention|"Participants will receive one of two possible interventions:~1. A virtual reality kitchen with foods with different caloric contents. Participants will be invited to explore the environment and interact with the stimuli they feel most comfortable with. Depending on their preference, they will be able to access the virtual kitchen in one of three different conditions: alone, accompanied by a pink elephant (designed to induce positive mood), or accompanied by a reassuring voice that will encourage them to interact with the food and face their fears.~2. A virtual reality bedroom with several objects, some of which will have a neutral valence for people with sleep difficulties, and others that will be related to insomnia, such as a mobile phone, electronic devices and a clock marking 3:00. Participants will be first told to move in the environment and they could not fall asleep. Then, they will receive specific instructions to cope with sleeping difficulties."
223804760|NCT06472466|BEHAVIORAL|Sleep/eating self-help written materials.|Participants allocated to the control condition will be invited to download self-help written materials about eating and sleep difficulties and helpful ways to cope with these.
223804761|NCT00764920|DEVICE|non-invasive imaging modalities for assessment of skin|skin imaging
223804762|NCT06116916|DRUG|KHK4951|KHK4951 eye drop for 36 weeks until end of the trial
223804763|NCT06116916|DRUG|Aflibercept Injection|Intravitreal injection (IVT) of aflibercept will be given as specified in the protocol
223804764|NCT06052384|OTHER|Standard pain management combined with sleep disorder management|Standard pain management combined with sleep disorder management at M6, and M12
223804765|NCT02411565|DRUG|Fermented Wheat Germ Extract (FWGE)|5.53 grams of FWGE combined with natural orange flavor and stevia Reb-A sweetener to create an instant drink mix, dissolved in 150 mL of water, orally once-daily, for 2 to 4 weeks.
223804766|NCT02411565|DRUG|Placebo|Dried and pulverized, white and black rice, 5.53 grams, combined with natural orange flavor and stevia Reb-A sweetener, to create an instant drink mix, dissolved in 150 mL of water, orally once-daily, for 2 to 4 weeks.
223804767|NCT02411565|OTHER|Standard of Care: Planned Surgery|Participants will undergo their planned surgery during the 2nd to 4th week after entry into the study. However, if there are delays, patients can continue to take drug/placebo for a time period no greater than 2 months. If surgery has not occurred after this 2-month period, the patient will be removed from the study. Participants will take the study drug up until the day prior to surgery. The minimum amount of time on study drug is 2 weeks. A separate consent form will be obtained for the surgical procedure.
223804768|NCT02411565|OTHER|Quality of Life (QoL) Surveys: FACT-O|Quality of life questionnaire (FACT-O) at the time of enrollment, then weekly and the day of surgery.
223804769|NCT02963974|DEVICE|Cochlear implant|Implantation
223804770|NCT00810264|DEVICE|CRT Therapy - LV Lead Registry|Collecting long-term safety and efficacy data on a market-released left ventricular lead.
223804771|NCT04814836|PROCEDURE|Total-etch mode with 35% phosphoric acid (K-ETCHANT) (TE-A group)|35% phosphoric acid was applied to enamel and dentin for 10 s, washed and dried for 5 s. The universal adhesive, Clearfil Universal Bond Quick (CBQ) was applied to enamel and dentin surfaces with a single-use applicator, then gently air-dried for 5 s without waiting, and light-cured for 10 s.
223804772|NCT04814836|PROCEDURE|Selective-etch mode with 35% phosphoric acid (K-ETCHANT) (SE-A group)|35% phosphoric acid was used only on enamel for 10 s, then washed and dried for 5 seconds. Subsequently, the adhesive was applied in a similar manner to the TE-A group.
223804773|NCT04814836|PROCEDURE|Total-etch mode with Er, Cr: YSGG laser (Waterlase MD) (TE-L group)|the enamel margin and dentin surfaces of lesions were irradiated with an Er,Cr:YSGG laser (2780 nm, Waterlase MD, BioLase Technology, Inc., San Clemente, CA). Then the adhesive was applied in a similar manner to the TE-A group.
223804774|NCT04814836|PROCEDURE|Selective-etch mode with Er, Cr: YSGG laser (Waterlase MD) (SE-L group).|The laser system was applied in the same way as described in the TE-L group only on enamel surface. Subsequently, the adhesive was applied in the same way as described in the TE-A group.
223804775|NCT04814836|PROCEDURE|Self-etch mode Clearfil Universal Bond Quick (Kuraray, Japan) (SE group)|Universal adhesive system (CBQ) was applied to enamel and dentin surfaces without any previous etching. Then gently air-dried for 5 s without waiting, and light-cured for 10 s.
223804776|NCT00778479|DEVICE|Sepraspray|Max. 10g of Sepraspray
223804777|NCT02569580|DEVICE|Topically|"use the No More medical device as anti lice treatment"
223804778|NCT06030674|OTHER|Secondhand cannabis emissions/smoke exposure|This is an environmental exposure performed in public places where people are consuming cannabis.
223804779|NCT02131779|BEHAVIORAL|Men's Workshops|Two male Community Health Advisors will be trained using traditional/classroom methods and provided with technical assistance/support to implement the 4 part workshop series.
223804780|NCT02131779|BEHAVIORAL|Co-Educational Workshops|One male and one female Community Health Advisor will be trained using traditional/classroom methods and provided with technical assistance/support to implement the 4 part workshop series. Two break out sessions will occur in the Health Partner condition with separate discussion sessions for men and female health partners.
223804781|NCT06213701|DEVICE|Healthy Minds Program|HMP is a 4-week mobile health (mHealth) meditation training program.
223804782|NCT06213701|OTHER|Psychoeducation app|Psychoeducation app
223804783|NCT06388499|OTHER|TECC (Telerehabilitation and Exercise for Chronic Conditions)|"Exercise: Synchronous group exercise sessions will be delivered weekly via videoconferencing by a physiotherapist. Recordings of exercise sessions will be made available. Participants will be advised to perform additional exercise sessions at their own convenience to supplement the synchronous exercise sessions and facilitate adherence to physical activity guidelines.~Education: A synchronous educational webinar will be delivered each week. These will be delivered by relevant healthcare professionals and explore various aspects of self-management of health and well-being. Recordings of the webinars will be made available to participants.~Social component: At the end of each weekly synchronous group exercise session, participants will have the opportunity to engage in a 10-15-minute synchronous online social interaction with other participants in their exercise group via videoconferencing."
223804784|NCT05914064|DEVICE|Gravitas FT and Gravitas FT Monitor guidance|FT placed with guidance from the Gravitas FT system
223804785|NCT05914064|DEVICE|Gravitas FT System without placement guidance|SOC placement
223804786|NCT06576726|OTHER|This study involves no intervention.|This study involves no intervention.
223804787|NCT03266783|DRUG|Apixaban|Refer to Apixaban group
223804788|NCT03266783|DRUG|Rivaroxaban|Refer to Rivaroxaban group
223804789|NCT00995072|DRUG|nebivolol and metoprolol succinate|Subjects randomized to treatment Arm A will receive nebivolol 5 mg once daily for 12 weeks. After 12 weeks, double blind therapy will be discontinued and patients will undergo a wash-out period of study therapy over 2 weeks. Subjects randomized to treatment Arm A will then receive metoprolol succinate 100 mg once daily. Subjects will continue double blind therapy for a total duration of 12 weeks.
223804790|NCT00995072|DRUG|metoprolol succinate and nebivolol|Subjects randomized to treatment Arm B will receive metoprolol succinate 100mg once daily for 12 weeks. After 12 weeks, double blind therapy will be discontinued and patients will undergo a wash-out period of study therapy over 2 weeks. Subjects randomized to treatment Arm B will then receive nebivolol 5 mg once daily. Subjects will continue double blind therapy for a total duration of 12 weeks.
223804791|NCT02226913|DRUG|2% lidocaine with 1:80,000 epinephrine|2% lidocaine with 1:80,000 epinephrine
223804792|NCT02226913|DRUG|sodium bicarbonate|8.4% sodium bicarbonate
223804793|NCT02226913|DRUG|placebo|sterile distilled water (Samen Pharmaceutical Co, Iran)
223804794|NCT04696666|DEVICE|INSTYLAN (Sodium Hyaluronate 80mg/50ml)|The bladder instillation with INSTYLAN is a treatment involving a sterile solution of Sodium Hyaluronate (80mg/50ml) inserted into the bladder through a catheter and released after a short period of time.
223804795|NCT02658864|DRUG|lafutidine|comparison of different doses, sex and medication conditions
223804796|NCT01037348|DRUG|ranibizumab 0.5mg|
223804797|NCT04776980|DIAGNOSTIC_TEST|Post Feraheme Infusion MRI|All participants will receive a ferumoxtyol (Feraheme) infusion 20-28 hours prior to a head MRI. In addition, a blood draw for liquid biopsy targeted tissue sampling during surgery and special iron and macrophage staining on the tumor tissue.
223804798|NCT05911204|OTHER|Questionnaire about intense noises exposure during pregnancy|Response to questionnaire given within 3 days after delivery about noise exposure
223804799|NCT01751828|DRUG|Sertraline|
223804800|NCT02306759|DRUG|Ketamine|Ketamine 0.3mg/kg in 50ml normal saline, administered over 15 minutes
223804801|NCT02306759|DRUG|Placebo|Normal saline 50ml, administered over 15 minutes
223804802|NCT04760418|BEHAVIORAL|Concurrent Treatment of PTSD and Substance Use Disorders Using Prolonged Exposure (COPE)|A 12-session integrated cognitive behavioral therapy for posttraumatic stress disorder and substance use
223804803|NCT00000126|PROCEDURE|Surgery|
223804804|NCT00624299|DRUG|Botox|Botox injection (100 ius) per muscle
223804805|NCT00624299|OTHER|Saline|Saline injection
223804806|NCT04584229|OTHER|Intervention|Intervention: comprehensive individual or collective interview, recorded and transcribed
223804807|NCT03063294|OTHER|Online Toolkit|The online toolkit provides a set of tools that clinics can use to improve their care coordination processes.
223804808|NCT03063294|OTHER|Distance-based coaching|The distance-based coach supports included clinics in carrying out a quality improvement project focused on care coordination, either using the online toolkit or other resources determined by the clinic.
223804809|NCT05646667|OTHER|interscalene with Erector spinae plane block group|patients will receive interscalene brachial plexus block using 10 ml of bupivacaine 0.5% and US guided Erector spinae plane block at T2 using 10 ml of bupivacaine 0.5%.
223804810|NCT05646667|OTHER|Interscalene group|patients will receive interscalene brachial plexus block using 15 ml of bupivacaine 0.5%.
223804811|NCT00646477|DEVICE|titration night|"Each subject undergo 1 night of full polysomnography split into 2 consecutives and randomized sequences, using the Sandman device into two different modes:~in APAP mode - Data analysis of this sequence will be used to evaluate the therapeutic effectiveness of the CPAP/autoCPAP Sandman in APAP mode compared both to the polysomnography registration and the diagnosis night for each enrolled patient. The type of respiratory events and their index/hour of sleep and the total arousal index will be appraised as markers of the efficacy of OSAS treatment, constituting the primary outcomes.~in CPAP mode for manual titration sequence.During the manual titration, 5 constant pressure levels settings were studied for equal periods of 30 minutes gradually increasing the pressure. The aim of this sequence is to determine the sensitivity and the specificity of the CPAP/autoCPAP Sandman in detecting respiratory events."
223804812|NCT02666547|DRUG|68Ga-NODAGA-RGD PET/CT|200 MBq 68 Ga-NODAGA-RGD will be administered i.v. and images acquired on all body . For glioma, images acquired centred on the skull
223804813|NCT02666547|RADIATION|18F-FDG PET/CT|3.5 MBq/kg 18F-FDG will be administered i.v. and images acquired on all body
223804814|NCT02666547|RADIATION|18F-FET PET/CT|200 MBq 18F-FET will be administered i.v. and images acquired centred on the skull
223804815|NCT05420103|OTHER|Accelerated Stroke Ambulation Program|Stroke Rehabilitation Program
223804816|NCT04830475|DEVICE|Non invasive ventilation (NIV)|Patients allocated in NIV Group fulfilled a 120-minute cycle of PSV + PEEP with full-face mask. Ventilation was performed with a Draeger Ventilator with the following basic settings: DeltaPInsp 10 mmHg + PEEP 5 mmHg + Fio2 60%.
223804817|NCT04830475|DEVICE|Conventional Venturi Mask|Patients were offered VenturiMask with Fio2 60% at 15 l / m.
223804818|NCT02329054|DRUG|Favipiravir|"Group A1: Day-0 (inclusion), h0: 2400 mg; h8: 2400 mg; h16: 1200 mg. Day-1 to Day-9: 1200 mg bid.~Group A2: Day-0 (inclusion), h0: 2400 mg; h8: 2400 mg; h16: 1200 mg. Day-1 to Day-9: 1200 mg bid.~Group C: daily dosages will be adapted to their body weight."
223804819|NCT02183987|OTHER|Active Knowledge Translation Intervention|"1. Access to CSN guidelines, \& provider- \& patient-directed infographics recommending an intent-to-defer dialysis initiation strategy will be displayed in prominent clinic wall space \& disseminated to patients.~2. Educational whiteboard video will be made available as a resource for clinic staff \& patients.~3. Each clinic will receive reports from the Canadian Organ Replacement Register (CORR) outlining the proportion of patients followed by a Nephrologist (\>3 months) starting dialysis early (eGFR \>10.5 ml/min), for all incident dialysis patients from the clinic, with provincial \& national average comparisons. These reports, \& the CSN guideline on timing of dialysis initiation recommendation, will be delivered to the medical lead for each CKD clinic.~4. Each clinic will receive an in-person visit from one of the study investigators/collaborators highlighting the clinical practice guidelines \& evidence supporting an intent-to-defer strategy, \& will receive follow-up."
223804820|NCT00512395|DRUG|epidural analgesia (Duracain/Fentanyl/Naropin)|naropin 0.3% or duracain 0.125% + Fentanyl via epidural catheter 4-12 ml/h
223804821|NCT02170740|DRUG|BIBR 1048 MS - low dose|
223804822|NCT02170740|DRUG|BIBR 1048 MS - high dose|
223804823|NCT02170740|DRUG|BIBR 1048 MS + Pantoprazole|
223804824|NCT04753372|DRUG|Rivaroxaban 2.5 MG [Xarelto]|rivaroxaban 2.5mg bid on top of ASA for CAD and/or PAD
223804825|NCT02535910|DIETARY_SUPPLEMENT|vitamin D3|Subjects are asked to consume a breakfast rich in 20 µg vitamin D3
223804826|NCT02535910|DIETARY_SUPPLEMENT|25(OH) D3|Subjects are asked to consume a breakfast rich in 20 µg 25(OH)D3
223804827|NCT02535910|DIETARY_SUPPLEMENT|Control|Subjects are asked to consume a breakfast without vitamin D
223804828|NCT02495025|BEHAVIORAL|Telephone-based developmental screening and care coordination|
223804829|NCT03818672|DRUG|Rifaximin|Rifaximin 550 MG BID
223835392|NCT03291600|BEHAVIORAL|Virtual Psychiatric Care|Virtual psychiatric care for perinatal depression will be offered to participants, in addition to care as usual, for a 12-week period by their treating perinatal psychiatrist. Virtual care will be delivered by video-based visits through the Ontario Telemedicine Network (OTN). The treating psychiatrist may request that an intervention group participant present for in-person care at any visit, and this may include need for behavioural activation, or another health-related indication at the discretion of the treating psychiatrist.
223835393|NCT01473420|BIOLOGICAL|Epoetin Hospira|Variable dose
223804830|NCT03505112|OTHER|Goal-directed therapy|"The patients in GDT group will receive intravenous crystalloid fluid or vasopressor or inotropic agent according to the goal-directed therapy protocol utilizing FloTrac / EV1000 clinical platform (Edwards Lifesciences, Irvine, CA, USA).~After induction of anesthesia, the baseline stroke volume index (SVI) is measured and then 200-250 ml of crystalloid is administered over 5-10 minutes. If SVI increase by ≥10%, 200-250 ml of crystalloid is given repeatedly until the increase in SVI \<10%. If SVI does not increase by ≥10% and there is no decrease in mean arterial pressure (MAP), revaluate SVI every 10 minutes. Despite an increase in SVI of \<10% after fluid challenge, if a decrease in MAP is accompanied by cardiac index (CI) ≤ 2.5 L/min/m2, dobutamine is administered by continuous infusion. If there is a decrease in MAP but no decrease in CI, start low dose norepinephrine continuous infusion."
223804831|NCT03341793|DIAGNOSTIC_TEST|Muscle biopsy and blood test|Characterize the changes in muscle secretion induced by bariatric surgery and determine their role in improving the insulin sensitivity of skeletal muscle and insulin secretion by B cell responsible for the remission of diabetes mellitus.
223804832|NCT05646186|DIETARY_SUPPLEMENT|Personalized dietary intervention based on microbiome analysis|Personalized dietary intervention based on individual microbiome analysis
223804833|NCT05646186|DIETARY_SUPPLEMENT|Low-FODMAP diet|Low fermentable oligosaccharides, disaccharides, monosaccharides, and polyols diet
223804834|NCT03248258|OTHER|Qualitative Interview or Focus group discussions|"The purpose of this study is to identify factors that influence decision-making in treatment selection and the optimal approach for sharing information about prognosis and guideline-based care.~Secondly, to further understand patient perspective on the concept of de-escalation, in which patients reduce the amount of chemotherapy to avoid side effects and (2) consider how prognosis would impact their decision-making about reducing chemotherapy (as standard or care or within a clinical trial)."
223804835|NCT02721082|BEHAVIORAL|Opt Out Treatment Program|Tobacco Treatment (UKanQuit) staff will complete a treatment plan for all participants.
223804836|NCT02721082|DRUG|Nicotine Replacement Therapy|Unless they Opt Out all participants will be provided with a 14 day supply of the nicotine patch and nicotine mini-lozenges or nicotine gum, depending on study related criteria.
223804837|NCT02721082|BEHAVIORAL|Opt In Treatment Program|Tobacco Treatment (UKanQuit) staff will complete a treatment plan for participant's who are ready to quit smoking. For patient's not ready to quit, motivational counseling will be provided to participants based on principles of Motivational Interviewing.
223804838|NCT02721082|DRUG|Nicotine Replacement Therapy|Participants ready to quit will be provided with a 14 day supply of the nicotine patch and nicotine mini-lozenges or nicotine gum, depending on study related criteria.
223804839|NCT01751438|OTHER|Best Systemic Therapy (BST)|Group 1 will continue to receive best systemic therapy (BST).
223804840|NCT01751438|OTHER|Best Systemic Therapy (BST) + Surgery or Radiation Therapy|Group 2 will receive best systemic therapy in addition to surgery to remove prostate or radiation therapy to the prostate. Treating physician will decide if surgery or radiation therapy is the best choice.
223804841|NCT01751438|BEHAVIORAL|Questionnaires|Questionnaire completion at 60 days, 12 weeks, and at end of treatment visit. It should take about 15 minutes to complete.
223804842|NCT01751438|OTHER|Phone Call/Email|Every 6 months after end-of-treatment visit, patient contacted by phone or e-mail and asked questions about how they are feeling. Each phone call should last about 5 minutes.
223804843|NCT04373876|DEVICE|Subcutaneous Implantable Cardioverter Defibrillator|Patients implanted with a totally subcutaneous defibrillator system
223804844|NCT02134587|OTHER|Multifaceted educational intervention|"1. Application of questionnaire of knowledge, attitudes and skills in pharmacovigilance.~2. Lecture regarding the theoretical framework and importance of pharmacovigilance, and distribution of educational material~3. Distribution of educational material~4. Practical class to explain the correct fill of adverse drug events form~5. Reapplication of questionnaire of knowledge, attitudes and skills in pharmacovigilance."
223804845|NCT00265889|BIOLOGICAL|filgrastim|480 mcg beginning day +5
223804846|NCT00265889|DRUG|busulfan|11.2 mg/kg; 0.8 mg/kg IV q6h X 14 doses
223804847|NCT00265889|DRUG|cyclophosphamide|60 mg/kg IV over 2 hours x 2 days
223804848|NCT00265889|DRUG|etoposide|60 mg/kg, IV
223804849|NCT00265889|DRUG|melphalan|150mg/m2 in NS at a concentration of 0.4mg/cc infused over 60 minutes.
223804850|NCT00265889|PROCEDURE|autologous-autologous tandem hematopoietic stem cell transplantation|autologous-autologous tandem hematopoietic stem cell transplantation
223804851|NCT00265889|RADIATION|radiation therapy|radiation therapy
223804852|NCT03503266|DRUG|[14C] MT-7117|14-C MT-7117
223804853|NCT03133026|DEVICE|Single operator cholangioscopy, Endoscopic biliary RFA|Single operator cholangioscopy will be done to acess the cause of occluded SEMS, if tumour ingrowth or overgrowth seen then endoscopic biliary RFA will be done
223804854|NCT01625351|DRUG|alemtuzumab|Patients receive alemtuzumab on days -14 through -12 (Day 0 = stem cell transplantation).
223804855|NCT01625351|DRUG|fludarabine|Patients receive fludarabine phosphate on days -11 through -7. (Day 0 = stem cell transplantation.)
223804856|NCT01625351|DRUG|sirolimus|"Patients receive sirolimus beginning on day -1 with taper beginning on day 90. (Day 0 = stem cell transplantation.)~Participants treated after activation of protocol revision 2.3 on 06/05/2014 have not and will not receive sirolimus as part of their therapy."
223804857|NCT01625351|DRUG|Busulfan|Patients receive busulfan on days -6 through -3. (Day 0 = stem cell transplantation.)
223804858|NCT01625351|DRUG|melphalan|Patients receive melphalan on days -2 and -1. (Day 0 = stem cell transplantation.)
223804859|NCT01625351|BIOLOGICAL|stem cells|Patients undergo CD3 depleted haploidentical hematopoietic stem cell transplant (HSCT) on day 0. Patients also undergo CD45RA depleted HSCT infusion on day 1. (Day 0 = stem cell transplantation.)
223804860|NCT01625351|DEVICE|CliniMACS|The mechanism of action of the CliniMACS Cell Selection System is based on magnetic-activated cell sorting (MACS). The CliniMACS device is a powerful tool for the isolation of many cell types from heterogeneous cell mixtures, (e.g. apheresis products). These can then be separated in a magnetic field using an immunomagnetic label specific for the cell type of interest, such as CD3+ human T cells.
223804861|NCT00860379|DRUG|Selenium1|2 ug/kg
223804862|NCT00860379|DRUG|Selenium2|4 ug/kg
223804863|NCT00860379|DRUG|Placebo|IV saline as placebo
223804864|NCT01831622|DRUG|Ritalin|On one of the two test-dates the patient participant is administered methylphenidate, in the dose prescribed by the patients doctor.
223804865|NCT01831622|DRUG|Placebo|On one of the test-dates the patient participants are administered a sugar pill, matching their prescribes medical dose.
223804866|NCT03096405|DIAGNOSTIC_TEST|Polymerase Chain Reaction of Methicillin Resistant Staphyloccus Aureus|Polymerase Chain Reaction of Methicillin Resistant Staphyloccus Aureus
223804867|NCT01515748|DRUG|Docetaxel (XRP6976)|Pharmaceutical form:solution for infusion Route of administration: intravenous
223804868|NCT01515748|DRUG|Oxaliplatin (SR96669)|Pharmaceutical form:solution for infusion Route of administration: intravenous
223804869|NCT01515748|DRUG|S-1 (1-(2-tetrahydrofuryl)-5-fluorouracil + 5-chloro-2, 4-dihydroxypyridine (CDHP) (Gimeracil) + Oxo (Oteracil)|Pharmaceutical form:Tablet Route of administration: Oral
223804870|NCT03345498|DRUG|Entecavir|Entecavir is the antiviral drug of choice recommended for hepatitis B virus treatment in presence of decompensated cirrhosis
223804871|NCT02215122|DRUG|MGR001|Fluticasone Propionate is an inhaled corticosteroid (ICS) Salmeterol is a long acting β2 agonist (LABA)
223804872|NCT02215122|DRUG|Advair® Diskus®|Fluticasone Propionate is an inhaled corticosteroid (ICS) Salmeterol is a long acting β2 agonist (LABA)
223804873|NCT02215122|DRUG|Seretide™ Accuhaler™|Fluticasone Propionate is an inhaled corticosteroid (ICS) Salmeterol is a long acting β2 agonist (LABA)
223804874|NCT03917667|DIAGNOSTIC_TEST|EWGSOP2|EWGSOP2 criteria (Writing Group for the European Working Group on Sarcopenia in Older People 2) will be followed to determine the diagnosis of sarcopenia, considered as a dichotomous variable -yes/no- in presence of low grip strength + low muscle mass + low gait speed.
223804875|NCT03535935|DRUG|Astragalus Powder|"3 grams of water soluble astragalus sachets (equivalent to 15g raw herbs) administrated orally on top of standard medical care for 48 weeks.~Patients will have 5 days of medicine per week and will be advised to take the medicine once daily dissolved in boiling water in the first 5 days of the week."
223804876|NCT03535935|OTHER|Routine medical care (active comparator)|Angiotensin converting enzyme inhibitor or angiotensin receptor blocker
223804877|NCT04873570|DRUG|Moxifloxacin 400mg|Moxifloxacin 400mg IR tablet
223804878|NCT00006231|PROCEDURE|quality-of-life assessment|
223804879|NCT00006231|PROCEDURE|standard follow-up care|
223804880|NCT00006231|RADIATION|radiation therapy|
223804881|NCT03371875|BEHAVIORAL|Automated transition care reminders|The CHICA system will gather the elements of the TRAQ questionnaire and report the specific areas of deficiency to the physician. If a patient reaches the point of care transition (18 years), then an automated email is sent to a clinic nurse.
223804882|NCT02400138|OTHER|Respiratory training|Respiratory training will include training of the inspiratory and expiratory muscle seven times per week over eight weeks, during 40 minutes, divided into two 20-min sessions (morning and afternoon). Each 20-min session comprised 4-min sets of respiratory training, followed by 1-min rest between the sets. The training program will be carried-out with the Orygen Dual Valve regulated at 50% of the subjects' maximal inspiratory and expiratory pressure values. Once a week, the treating physiotherapist performed a home visit, measured the current values of inspiratory and expiratory strength, and progressed the load to 50% of the new values.
223804883|NCT02400138|OTHER|Control|The control/sham group will underwent exactly the same protocol and weekly monitoring at home, but the participants will receive the devices without resistance of the spring.
223804884|NCT01711203|OTHER|Motor Control|Exercises and verbal cues to facilitate deep abdominal control and contraction for muscular stabilization/re-training.
223804885|NCT01711203|OTHER|General Strengthening|General abdominal and lower quarter musculature strengthening
223804886|NCT00416182|DRUG|Pulmozyme (dornase alfa)|2.5 mg/2.5 mL of Pulmozyme (dornase alfa) delivered via Sinustar nasal nebulizer device
223804887|NCT00416182|DRUG|Placebo|2.5 mL of placebo delivered via Sinustar nebulizer device
223804888|NCT05185531|COMBINATION_PRODUCT|PD-1 plus stereotactic body radiotherapy|neoadjuvant PD-1(Tislelizumab) plus stereotactic body radiotherapy (8 Gy × 3 fractions) in resectable HCC
223804889|NCT04952506|DRUG|CKD-349 F1 Tab.|1T Single does
223804890|NCT04952506|DRUG|CKD-349 F2 Tab.|1T Single does
223804891|NCT04952506|DRUG|D113 Tab.|1T Single does
223804892|NCT06289075|OTHER|Intensive Care Unit (ICU) treatment|ICU treatment
223804893|NCT00071617|BEHAVIORAL|Youth-Nominated Support Team|
223804894|NCT00460187|DEVICE|Percutaneous intervention of the carotid artery|
223804895|NCT03288116|DIAGNOSTIC_TEST|Scheimplug imaging and contrast and sensitivity test|examination of the patients using the schemiplug imaging with evaluation of keratometric parametres ,pachymetric parametres ,elevation parameters.
223804896|NCT00014638|DRUG|letrozole|
223804897|NCT03001284|OTHER|NO intervention|
223804898|NCT05917639|DEVICE|Vitruvian plot|Visual (magnitude, uncertainty) and written (magnitude) communication tool / interventional decision-making aid tool
223804899|NCT05917639|DEVICE|Kilim plot|Visual (uncertainty) and written (magnitude) communication tool / interventional decision-making aid tool
223804900|NCT05917639|DEVICE|Summary of findings table|Written (magnitude, uncertainty) communication tool / interventional decision-making aid tool
223804901|NCT03352791|BEHAVIORAL|DSM-H Hospice Edition performance improvement program|Patients in the performance improvement group will receive care from a care team who has received the DSM-H Hospice Edition performance improvement program
223804902|NCT03352791|BEHAVIORAL|Usual Care|control will receive usual care from a care team who has not received the performance improvement program.
223804903|NCT02571517|DRUG|Glucocorticoids|Patients assigned to experimental group (group 1) will receive iv methylprednisolone 2 mg/kg/day (divided in two doses) doses and/or oral prednisolone 2,5 mg/kg/day (divided in two doses) during 7 days.
223835394|NCT01473420|BIOLOGICAL|Epogen Amgen|Variable dose
223804904|NCT02571517|OTHER|Placebo|Patients assigned to control group (group 2) will receive iv/oral glucose 5% solution as placebo, 2 mg/kg/day (divided in two doses) during 7 days.
223804905|NCT03221387|DEVICE|Humidified nasal high flow with oxygen|The AIRVO 2 is for the treatment of spontaneously breathing patients who would benefit from receiving high flow warmed and humidified respiratory gases.
223804906|NCT04944641|BEHAVIORAL|education on epilepsy|education on epilepsy, including epilepsy diary, pamphlet，discussion between patients and phone visits and so on
223804907|NCT04944641|DRUG|routine and proper antiepileptic drugs|routine and proper antiepileptic drugs
223804908|NCT02622854|PROCEDURE|plasma exchange|see arm description
223804909|NCT02622854|DRUG|conservative treatment|see arm description
223804910|NCT01474733|OTHER|educational intervention|series of lectures and workshops on health literacy
223804911|NCT01811082|DRUG|Coenzyme A|Coenzyme A 400mg per day.
223804912|NCT01811082|DRUG|Pantethine|Pantethine 600mg per day.
223804913|NCT04127838|BEHAVIORAL|Low Vision Occupational Therapy|Occupational therapy may include methods to effectively modify environments (such as addition of task lighting), training in the use of assistive technology (such as voice activated devices), teaching new skills (such as sensory substitution) and prevention of accidents and injury (such as home safety modifications).
223804914|NCT03959462|DEVICE|real anodal transcranial direct current stimulation|A neuroConn DC-Stimulator PLUS (neuroCare Group, Ilmenau, Germany) will be used.
223804915|NCT03959462|DEVICE|sham transcranial direct current stimulation|A neuroConn DC-Stimulator PLUS (neuroCare Group, Ilmenau, Germany) will be used.
223804916|NCT04979975|OTHER|Placebo|PBO- placebo matching to UB-621
223804917|NCT04979975|BIOLOGICAL|UB-621 low-dose|fully human anti-HSV mAb
223804918|NCT04979975|BIOLOGICAL|UB-621 high-dose|fully human anti-HSV mAb
223804919|NCT00059358|DRUG|Ribavirin plus interferon alfa-2b|Oral tablets taken daily
223804920|NCT00059358|DRUG|Ribavirin|Oral tablet taken daily
223804921|NCT00059358|DRUG|Peginterferon alfa-2b|Subcutaneous injection
223804922|NCT01485042|DRUG|Pazopanib and TH-302|Pazopanib 800 mg daily TH-302 IV on Days 1, 8, 15 at MTD Subjects will receive this regimen until disease progression.
223804923|NCT03406728|OTHER|PDSAFEX|PDSAFEX is a week by week, progressive, exercise protocol that is followed. It lasts 12 weeks.
223804924|NCT03406728|OTHER|CONTROL|Participants will be asked to maintain their day to day life as consistently as possible for the 12 week duration of the study.
223804925|NCT03406728|DEVICE|VIRTUAL REALITY|WorldViz Oculus Rift Move package (headset and software).
223804926|NCT00990080|BIOLOGICAL|Pediacel® and Infanrix™-IPV/Hib|0.5 mL IM at 2,4 and 6 months of age
223804927|NCT03407794|OTHER|Fermented vegetable|The intervention is to consume 1/2 cup fermented vegetables every day for 6 weeks
223804928|NCT03407794|OTHER|Non-fermented vegetable|The intervention is to consume 1/2 cup of non-fermented vegetables every day for 6 weeks
223804929|NCT00790283|DEVICE|PTCA with stent implantation|"Eligible patients will be randomly assigned to the implantation of one (or more) Numen or Vision/Mini Vision stent.~Each patient will undergo a 1-month follow-up and a clinical visit at 6 months from the procedure."
223804930|NCT03213275|OTHER|Microbiome Sequencing, Neurophysiologic Assessment, Immunological test|Stool sampling, aEEG, VEP, NIRS, ydTCR, Treg, biomarker
223804931|NCT01529125|DRUG|zidovudine, lamivudine, nevirapine|
223804932|NCT02075879|BEHAVIORAL|Nurse-led interviewing|Participants in experimental arm received regular face-to-face interviews during dialysis sessions conducted by the designated case managers every week for 6 weeks and biweekly for another 6 weeks.
223804933|NCT02075879|OTHER|Brief group exercise|Participants in this arm only participated in the brief in-center exercise training. They received usual care from the nurse without the interviews and mutual goals developed.
223804934|NCT04558255|DIAGNOSTIC_TEST|A machine-learning method which can robustly discriminate early-stage lung cancer patients from controls|In our study, we intend to integrate molecular features obtained through liquid biopsy and clinical data of lung cancer patients, and develop and prospectively validate a machine-learning method which can robustly discriminate early-stage lung cancer patients from controls.
223804935|NCT04102579|DRUG|Valbenazine|vesicular monoamine transporter 2 (VMAT2) inhibitor
223804936|NCT04102579|DRUG|Placebo|non-active dosage form
223804937|NCT01269879|DEVICE|Flexi-Bar vibration device only|daily vibration training 10min twice
223804938|NCT01269879|DEVICE|Flexi-Bar + XCO-Trainer|"XCO-Trainer is a way to overload the cardiovascular system and the core muscles during running. An oscillating mass inside the XCO-Trainer is activated when the XCO is propelled forward and backward with force. The movement of the mass triggers a series of responses from the runners' body.~In addition Flexi-Bar vibration training as in the referred active comparator group"
223804939|NCT05725928|BEHAVIORAL|Mobility technician|Designated mobility technicians (MT) will ambulate hospitalized medical patients up to 3 times daily, 7 days per week, until discharge or a maximum of 10 days. Each day, the MT will visit the patient 4 times or until the patient successfully ambulates 3 times that day. In cases where a PT has provided a recommendation in the patient's chart, the MT will follow the recommendation, if feasible. Otherwise, the MT will execute the standard mobility protocol. The mobility protocol will allow the MT to assist a patient with an appropriate out-of-bed activity based on their 6-clicks score from the immediately preceding session.
223804940|NCT05248100|BEHAVIORAL|Conditional Cash Transfer|The intervention is a one-time cash transfer of 22,500 Tanzanian Shillings (\~$10), with half (11,250 TSH) delivered upon enrollment in the study and half delivered after confirmation of the completion of a clinical visit if within 90 days of study enrollment.
223804941|NCT01165775|DEVICE|Dexcom Seven Plus Continuous Glucose Monitoring System|Soft sensor for continuous glucose monitoring inserted for up to 24 hours prior to administration of betamethasone. Device to be worn for duration of hospitalization or up to 7 days total, whichever time period is shorter.
223804942|NCT07030595|DRUG|AP301|Three times a day, administered orally with three meals at a daily dose level from 2.1g to 9.1g
223804943|NCT07030595|DRUG|Sevelamer carbonate (Renvela®)|Three times a day, administered orally with three meals at a daily dose level from 2.4g to 9.6g
223804944|NCT07030595|DRUG|AP301 Low Dose|Three times a day, administered orally with three meals at a daily dose level of 0.375g.
223804945|NCT07031518|DEVICE|Syde|Actimyo/Syde is an innovative device intended to be used in a home-based environment. It is composed of two watch-like sensors, each containing a magneto-inertial sensors that record the linear acceleration, the angular velocity, the magnetic field of the movement in all directions.The two watches can be worn as wristwatch or placed near the ankle.
223804946|NCT07031518|DIAGNOSTIC_TEST|The Self-Paced 40-meter Walk Test (SPWT)|Assesses walking speed over a fixed distance by having participants walk as quickly and safely as possible, but without running, along a 40-meter course.
223804947|NCT07031518|DIAGNOSTIC_TEST|30-second chair stand test (30s-CST)|It is a simple assessment of lower body strength and endurance. Participants are instructed to stand up and sit down from a chair as many times as possible in 30 seconds.
223804948|NCT07031518|DIAGNOSTIC_TEST|The Timed up and go test (TUG)|During this standardized test, the subject is observed and timed while he/she rises from a chair, walks 3 meters, performs a 180° turn, walk back toward the chair and sits down.
223804949|NCT07031518|DIAGNOSTIC_TEST|Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC 3.1)|The WOMAC is a widely used self-administered health status measure for evaluating pain, stiffness, and function in patients with osteoarthritis of the hip or knee. The WOMAC measures three separate dimensions: pain (5 questions), stiffness (2 questions) and function (17 questions).
223804950|NCT07031518|DIAGNOSTIC_TEST|Patient global impression of severity (PGI-S)|"The PGI-S is a patient-reported measure that evaluates the perceived severity of a condition based on a standardized scale, ranging from none to very severe."
223804951|NCT07031518|OTHER|Pain Level Diary|Patients will record their specific OAK average pain level during the day using the VAS scale of 0-10 points for one week at the beginning of each month of recording.
223804952|NCT07031518|OTHER|Qualitative Interview|This interview is designed to better understand the patient's perspective on the impact of osteoarthritis of the knee on their motor function and to inform the selection of digital tools in upcoming clinical studies.
223804953|NCT06269757|BEHAVIORAL|Individualized Exercise Program|"The individualized exercise program involves an initial 2D individual running evaluation designed for runners of all ages and abilities, to help improve performance and prevent injury. During the assessment patients receive a one-on-one evaluation with an exercise physiologist that includes:~* Running analysis;~* Training program review;~* Strength and flexibility assessment;~* Review of running video;~* Personalized final report."
223804954|NCT06269757|BEHAVIORAL|Standard Physical Therapy|Standard of care physical therapy for ITB band syndrome involves exercises designed to target structural weaknesses such as hip abductor weakness. Typical exercises include but are not limited to hip flexor stretches, side lying hip abduction, figure 4 bridges, lateral walks with exercise bands, and side planks.
223804955|NCT07034183|DRUG|PRD001|PRD001 capsules will be provided for oral administration
223804956|NCT07034183|DRUG|Placebo|Placebo capsules will be provided for oral administration
223804957|NCT06711770|BIOLOGICAL|Blood sample|Four tubes of 7 mL collected at baseline, 3 weeks, 6 weeks, 12 weeks, 6 months, 12 months and 24 months (end of chemo-immunotherapy) or in case of relapse
223804958|NCT06732908|DIETARY_SUPPLEMENT|LipoMicel Berberine|Berberine powder in a LipoMicel matrix encapsulated in soft gel.
223804959|NCT06732908|OTHER|Placebo|microcrystalline cellulose
223804960|NCT07093762|DRUG|Atezolizumab+Bevacizumab+Carboplatin+Paclitaxel|Atezolizumab: 1200 mg IV every 3 weeks; Bevacizumab: 15 mg/kg IV every 3 weeks; Carboplatin: AUC 5 IV every 3 weeks; Paclitaxel: 175 mg/m² IV every 3 weeks. Treatment cycles: After 4-6 cycles, continue Atezolizumab + Bevacizumab as maintenance therapy until disease progression or unacceptable toxicity.
223804961|NCT07093944|DRUG|N-Acetylcysteine (NAC) Treatment|Parkinson's disease patients receive NAC (1200 mg/day) for one year.
223804962|NCT07093944|DRUG|Placebo|Parkinson's disease patients receive Placebo similar to the real drug, with no active ingredient
223835395|NCT06483412|BEHAVIORAL|Healthy Futures: Alternative-to-Suspension Curriculum|Healthy Futures: Alternative-to-Suspension Curriculum uses a trauma-informed and restorative practice lens and uses principles of motivational interviewing (MI) and cognitive-behavioral therapy (CBT) to help students understand the harms of nicotine, reduce stress, increase positive coping, and provide resources to quit.
223804963|NCT07093450|OTHER|Educational Quality Improvement Intervention|The intervention will be delivered at the cluster level. It will include an initiation visit, when educational sessions and an operations manual will be delivered to the ICU. These will consist of cognitive aids for antimicrobial initiation and duration decision-making, based on recent recommendations from guidelines, societies and regulatory authorities. In this visit, an assessment of barriers and facilitators for implementation of the behavioral change will be done, so that local adaptations can be done by the clinicians championing the implementation. Additionally, monthly, one-day audits will be done, which will be used to provide feedback to the ICU during the intervention phase regarding the suggested recommendations for antimicrobial decision-making.
223804964|NCT07093112|DIETARY_SUPPLEMENT|Psychobiotic supplement|"The psychobiotic supplement consists of Bifidobacterium lactis CCT 7858 and Lactobacillus rhamnosus CCT 7863, at a final concentration of 1 x 10\^10 CFU/g (GABBIA® Biotechnology, Santa Catarina, Brazil).~The intervention will be administered once daily for 90 days, spanning the pre-season and start-season phases with an interval and restarting for 90 days until the end-season phase."
223804965|NCT07093112|DIETARY_SUPPLEMENT|Placebo|The placebo consists of maltodextrin. The intervention will be administered once daily for 90 days, spanning the pre-season and start-season phases with an interval and restarting for 90 days until the end-season phase.
223804966|NCT07093229|OTHER|Ultrasound exam of quadriceps muscles (left/right) and gait analysis|"Ultrasound exam (initial and after 3 months) - with SonoScape S9Pro; the investigators exam the thickness of the quadriceps muscle group between the superficial fat-muscle interface and the cortex of the femur and calculate the quadriceps muscle index as sum of both muscle thickness RT and LT cm/height2 (m2). The exam is conducted by a qualified sonographer. The examination is carried out on a one-on-one basis in a private setting where only the participant and the sonographer are present.~Gait analysis with wireless system - BTS G-WALK; the investigators consider four gait parameters: Timed Up-and-Go (TUG) test, Symmetry index, Six Minutes Walking Test (6 MWT), and Walk cadence or average cadence (steps/min)."
223804967|NCT07093229|OTHER|Electrotherapy measures: transcutaneous nerve stimulation, ultrasound and low intensity laser; each one daily , applied on both lower limbs, for 10 days. Kinetic measures daily|The gait training is the distinguish aspect in rehabilitation program. Usually, KOA training include only kinetic measures, without gait control training
223804968|NCT07093229|OTHER|Gait training|This type of special kinetic training includes Frenkel exercises for lower limb muscles and virtual / mirror exercises for different types of gait
223804969|NCT07094581|DIAGNOSTIC_TEST|USG|Masseter Muscle Thickness and Internal Echogenic Bands Assessed by Ultrasonography
223804970|NCT07093788|DEVICE|super high-pressure balloon|preparation strategy for calcified lesions after unsatisfactory dilation
223804971|NCT07093788|DEVICE|intravascular lithotripsy (IVL)|preparation strategy for calcified lesions after unsatisfactory dilation
223804972|NCT07093645|DEVICE|SEL4@ll|SEL4@ll is a school-based digital intervention targeting students aged 10-16 (Primary and Secondary Education). It combines: (1) a serious game with five missions promoting SEL skills (1/week), playable online at home or school; (2) a digital teacher handbook with classroom activities used 1-2 times per week; and (3) online surveys to assess impact. The program lasts 8 weeks: 2 weeks for pre/post assessments and 6 weeks of gameplay and classroom sessions. Surveys are administered online (3 waves), and optional focus groups are conducted with a subsample of students. Teachers complete an online evaluation after implementation.
223804973|NCT07093671|OTHER|MBT + NBCI|The MBT for CHR-P intervention consists of 24 weekly individual psychotherapy sessions, supplemented by monthly mentalization-based family therapy sessions. Both patient and family sessions will last 50 minutes. These psychotherapeutic sessions will complement those received though NBCI by strengthening mentalizing abilities aiming to reduce or prevent detrimental outcomes, by prohibiting or restricting some usual techniques in NBCI treatment (e.g., interpretation, cognitive challenge and Socratic dialogue) and by emphasizing certain techniques (e.g., empathic validation, active management of emotional arousal) which are only sporadically and irregularly used during NBCI treatment. Overall, the program is designed to improve patients' capacity to understand their own and others' mental states and, within interpersonal settings, how these patterns contribute to conflict and psychological distress.
223804974|NCT07092891|PROCEDURE|Ultrasound-Guided Supraclavicular Block|Ultrasound-guided supraclavicular brachial plexus block using a high-frequency linear ultrasound probe-real-time visualization of the brachial plexus for precise anesthetic delivery.
223804975|NCT07092891|DRUG|Bupivacaine Hydrochloride 0.5 % Injectable Solution|30 mL used for supraclavicular brachial plexus block
223804976|NCT07092891|DEVICE|Ultrasound|Imaging for block placement
223804977|NCT07092891|DEVICE|Infrared Thermography Camera|Skin temperature monitoring
223804978|NCT07092891|DEVICE|Pulse Oximeter|Perfusion Index monitoring
223804979|NCT07094867|OTHER|customized Z shaped miniplate|Planning was done using Mimics Innovation Suite 15.0 software for surgical planning, surgical simulation, and modeling of a custom-made Z-pattern plate installed on a standard personal computer system. The milling of a plate design on a titanium block was be done.
223804980|NCT07094867|OTHER|conventional two miniplates|Mobilization of the fracture, removal of any soft tissue entrapped within the fracture line, and management of teeth in the fracture line, either by extraction or preservation. Followed by bone reduction into proper anatomical occlusion. Then conventional two miniplates was used according to Champy's osteosynthesis lines
223804981|NCT07092774|DEVICE|Ablation|Ablation procedure using the Thermocool Smarttouch SF
223804982|NCT07094165|DRUG|Dexmedetomidine|Following 2 hours of bilateral muscle compression, rats in the dexmedetomidine group underwent a 1-hour period including both laparotomy and continuous intravenous dexmedetomidine infusion.
223804983|NCT07094165|DRUG|Remifentanil|Following 2 hours of bilateral muscle compression, rats in the remifentanil group underwent a 1-hour period including both laparotomy and continuous intravenous remifentanil infusion.
223804984|NCT07094165|PROCEDURE|Laparotomy|A standardized laparotomy was carried out for 1 hour, during which the abdominal cavity was opened and subsequently closed. This procedure aimed to mimic the physiological impact of a one-hour surgical operation.
223804985|NCT07094165|PROCEDURE|Compression|Bilateral compression was applied to the gastrocnemius muscles for a duration of 2 hours.
223804986|NCT01901068|DEVICE|MonoMax|Abdominal wall will be closed with MonoMax after an elective primary laparotomy.
223804987|NCT07092605|DRUG|GLP-1|Sublingual GLP1 (weekly), Subcutaneous GLP1 (weekly), Sublingual Placebo (weekly) for up to 6 months.
223804988|NCT07092605|DRUG|Placebo|Sublingual Placebo (weekly) for up to 6 months
223804989|NCT07093710|DRUG|Golidocitinib|"Cohort1: 150mg, po, qd;~Cohort2: 150mg, po, qod and 150mg, po, qd (phase Ib); RP2D (II study)"
223804990|NCT07093710|DRUG|Mitoxantrone Hydrochloride Liposome|Cohort 1: 15 mg/m2, IV, D1 and 18 mg/m2, IV, D1 (phase Ib); RP2D (II study)
223804991|NCT07093710|DRUG|GemOx|Cohort 2: Gemcitabine：1g/m2，IV，D1; Oxaliplatin：100mg/m2, IV，D1
223804992|NCT07092618|DRUG|Metformin|Increasing doses from 500mg/d to 2000mg/d metformin
223804993|NCT07092618|DRUG|Rapamycin|Increasing doses from 1mg/wk to 6mg/wk rapamycin
223804994|NCT07092618|DRUG|Naltrexone|Increasing doses from 1.5mg b.i.d. to 4.5mg b.i.d. low-dose naltrexone
223804995|NCT07092618|DIETARY_SUPPLEMENT|Vitamin C|Placebo control - increasing doses from 250mg/d to 1000mg/d vitamin C (ascorbic acid)
223804996|NCT07094633|PROCEDURE|Kegel Exercise Group|The patient was positioned in a supine lying position, with the therapist standing beside them for guidance. They were instructed to engage and contract their pelvic floor muscles for 3 to 5 seconds, followed by a relaxation phase of 3 to 5 seconds.
223804997|NCT07094633|PROCEDURE|Clamshell Exercise Group|The patient was positioned in a side-lying posture with both knees flexed at 90 degrees. One hand was placed on the hip for stability, while the other supported the head. The therapist, standing nearby, instructed the patient to lift the top knee as high as comfortably possible while keeping the feet together. The position was held for 3 to 5 seconds, after which the knee was slowly lowered back to the starting position.
223804998|NCT05514210|BEHAVIORAL|heart team meeting and discussion|When the patient is eligible for the study, the interventional cardiologist will invite a cardiac surgeon to conduct a heart team discussion. Both specialists will assess the patient comprehensively and make an optimal decision for the patient, with consideration patient's preference.
223804999|NCT07093047|OTHER|Questionnaire administration|Participants are required to complete a survey collecting anonymous data
223805000|NCT06944509|DEVICE|treatment with the Azurion system with Xres5|treatment with the Azurion system with Xres5
223805001|NCT06944509|OTHER|Azurion with Clairy IQ|Azurion system with the standard of care (ClarityIQ/Xres4)
223805002|NCT06942494|DRUG|conventional medical treatment (TAU)|In this study, the investigators use selective serotonin reuptake inhibitors (SSRIs, i.e., sertraline, fluoxetine and fluvoxamine)and tricyclic drugs(i.e., clomipramine) approved by the State Food and Drug Administration (CFDA) for the treatment of OCD in children and adolescents. The drugs used in this study are commonly used in clinical practice and have a good safety profile. The maximum dosage shall not exceed the maximum dosage prescribed in the instruction manual, or the maximum dosage tolerated by the patients.
223805003|NCT06942494|BEHAVIORAL|Family-Based Self-help Book for Adolescents with Obsessive-Compulsive Disorder|The self-help book used in this study was independently developed by members of our research team. Its content is based on Exposure and Response Prevention (ERP). Adolescent patients with OCD will be instructed to read one chapter of the self-help book each week and complete the corresponding exercises. This 12-week intervention will involve self-guided practice conducted by the adolescent and their family members.Throughout the intervention period, adolescents and their caregivers may contact the therapist via WeChat to ask questions and upload records of their completed exercises. The therapist will respond to any questions within 48 hours by sending written messages via WeChat, with each family receiving no more than 30 minutes of such written guidance per week. All therapists will be required to keep a weekly log of the time spent providing guidance to each participating family.If a participating family does not initiate contact, the therapist will not provide proactive guidance.
223805004|NCT03698565|OTHER|Nerve stimulation of the ulnar nerve|"The intervention is the nerve stimulation of the ulnar nerve for evaluation / realization of PPI by videopupillometry.~The realization of PPI and ANI measurements is carried out at the end of the surgical procedure, it implies a maintenance of the anesthesia for approximately 5 additional minutes."
223805005|NCT05062486|DRUG|Resveratrol, Quercetin, Curcumin (RQC)|100 mg resveratrol, 120 mg quercetin, 1000 mg curcumin BID
223805006|NCT05062486|DRUG|Curcumin|1000 mg curcumin BID
223805007|NCT05673070|DIETARY_SUPPLEMENT|Ritual Epre Multivitamin-mineral supplement|The Ritual Epre supplement uses methyl folate instead of folic acid and has higher vitamin D and biotin contents compared to the control supplement.
223805008|NCT05673070|DIETARY_SUPPLEMENT|control MVI|The control MVI supplement is a commercially available product from another brand. Since this MVI doesn't contain DHA, a pill of DHA will also be provided to participants in this group.
223805009|NCT01337674|DRUG|MK-4618|Once daily oral dose of MK-4618 100 mg (two 50 mg tablets) on Days 1 through 7
223805010|NCT01337674|DRUG|Placebo for MK-4618|Once daily oral dose of placebo for MK-4618 100 mg (two 50 mg tablets) on Days 1 through 7
223805011|NCT01337674|DRUG|Metoprolol|Previously prescribed daily dose of open-label metoprolol for the duration of the study
223805012|NCT01337674|DRUG|Amlodipine|Previously prescribed daily dose of open-label amlodipine for the duration of the study
223805013|NCT05265663|RADIATION|stereotactic ablative radiotherapy|SABR will be delivered in an image-guided hypofractionated scheme of 5 fractions of 8 Gy (total 40 Gy), prescribed to 95% of the planning target volume (PTV). Treatment is delivered on alternate days within a maximum overall treatment duration of 14 days.
223805014|NCT03753451|PROCEDURE|treatment of periodontal disease|Patients with periodontal disease received treatment of periodontal disease through ultrasound or manual scaling of dental calculations. In addition to receiving instructions to improve oral health, such as the correct use of dental floss, adequate time and the correct way to brush.
223805015|NCT06524076|PROCEDURE|Partial Pulpotomy|After removing caries high-speed handpiece with water coolant using a round diamond bur. Once there is an exposure, the bur is changed with another sterile one with which the superficially inflamed pulp tissue will be gently removed to a depth of 1-3 mm beneath the pinpoint pulp exposure that occurred at the end of caries removal. A sterile cotton pellet with saline will be placed with light pressure for 2-3 minutes to achieve hemostasis.
223805016|NCT06524076|PROCEDURE|Complete pulpotomy|After removing caries with a large round bur, the access cavity will be opened. Excavation of inflamed coronal pulp tissues will be done using a sharp excavator. A sterile cotton pellet with saline will be placed with light pressure for 2-3 minutes to achieve hemostasis.
223805017|NCT04829721|OTHER|Educational Intervention with video|Women randomized to an educational video workshop group.
223805018|NCT02497898|BIOLOGICAL|Cytokine-induced killer cells (CIK)|Cytokine-induced killer (CIK) cells are able to eradicate lymphomas and other malignancies. CIK cells are generated by incubation of peripheral blood lymphocytes with an anti-cluster of differentiation 3 (anti-CD3) monoclonal antibody, interleukin-2 (IL-2), interleukin-1 (IL-1) and interferon-gamma.
223805019|NCT06448325|OTHER|Hip arthroplasty|Surgical treatment of the hip after osteoporosis fracture. The focus of the study is the prediction of further fractures (and therefore further surgical procedures) after the first one.
223805020|NCT05256030|OTHER|Speed-based relearning training|Spasticity, balance and gait exercises will be started at slow speeds, at muscle level, and in the following sessions, movement speed will be increased in relation to the patient's compliance, and global balance and gait exercises will be performed.
223805021|NCT05256030|OTHER|Neurodevelopmental Therapy|Neurodevelopmental Therapy
223805022|NCT03857503|DIAGNOSTIC_TEST|iFR|"Patients will undergo standard of care diagnostic coronary angiography using established invasive physiological criteria for iFR and FFR to aid in clinical decision making for coronary revascularization.~Angiograms will be made in at least two projections, and the treating physician will record his/her estimation of stenosis severity.~Resting iFR and Pd/Pa measures will then be made distal to the target lesion; adenosine will be administered, and the FFR measures will be made without moving the wire. An iFR pullback will then be made after hyperemia as abated. Patients will be treated or deferred from treatment based on physician decision aided by the iFR measures."
223805023|NCT01645826|DRUG|Diltiazem Hydrochloride|The study agent will be diltiazem and will start at 60 mg po BID then titrated up very two weeks until at a maximum maintenance dose of 180mg po BID for six weeks.
223805024|NCT01645826|DRUG|Sugar Pill|The placebo group of patients will be treated with sugar pill PO bid and return every two weeks for next titration dose (actually will be an unchanged concentration).
223805025|NCT01203930|DRUG|Idelalisib|Idelalisib 150 mg tablets administered orally twice daily
223805026|NCT01203930|DRUG|Rituximab|Rituximab 375 mg/m\^2 administered intravenously once weekly x 8 weeks
223805027|NCT02178059|DRUG|terbutaline sulphate delivered dose|0.4 mg terbutaline sulphate (delivered dose) per inhalation
223805028|NCT02178059|DRUG|terbutaline sulphate metered dose|0.5 mg terbutaline sulphate (metered dose) per inhalation
223805029|NCT05988021|DRUG|CCX168|Administered orally.
223805030|NCT04957017|BEHAVIORAL|Training|"After the data was collected, the women in the intervention group were trained on Hand-Washing and Nutrition during the COVID-19 period. The training on hand-washing and nutrition was given using the Hand-Washing and Nutrition Training Guide prepared by the researchers, and the Hand-Washing and Nutrition Training Manual covering the content of the training, was distributed to the women at the end of the training"
223805031|NCT05178121|BEHAVIORAL|eLearning Training in Suicide Safety Planning|The training includes a web-based didactic in suicide safety planning, interactive practice in counseling microskills with a chat bot, role-playing safety planning with a standardized patient, and reviewing automated feedback on safety planning counseling skills generated from a computer coding system.
223805032|NCT04569110|OTHER|Not applicable. Observational study. Retrospective analysis of samples.|Not applicable. Observational study. Retrospective analysis of samples.
223805033|NCT01835262|DRUG|Morphine|Morphine: 0.1 mg /kg given as IVP
223805034|NCT01835262|DRUG|Ketamine|Ketamine:0.3 mg/given as IVP
223805035|NCT04495439|DEVICE|Augmentation with the ISS Study System|Augmentation with the ISS Study System
223805036|NCT04495439|OTHER|Augmentation with PMMA|Augmentation with PMMA (standard)
223805037|NCT03324438|BEHAVIORAL|Home Telehealth T1D C2oYoT1-HR|1\) assessment of physical and behavioral health characteristics associated with high-risk status; 2) delivery of home telehealth that incorporates: 2a) medical and behavioral health care delivered with the endocrinologist and behavioral health specialist working together with high-risk youth; 2b) personalized intervention to improve T1D adherence and T1D clinical health outcomes; 2c) personalized intervention to improve mental health comorbidities and T1D clinical health outcomes; and 3) an underused methodological approach for optimizing intervention components to be delivered at point of care.
223805038|NCT03324438|BEHAVIORAL|Personalized Behavioral Health|1\) assessment of physical and behavioral health characteristics associated with high-risk status; 2) delivery of home telehealth that incorporates: 2a) medical and behavioral health care delivered with the endocrinologist and behavioral health specialist working together with high-risk youth; 2b) personalized intervention to improve T1D adherence and T1D clinical health outcomes; 2c) personalized intervention to improve mental health comorbidities and T1D clinical health outcomes; and 3) an underused methodological approach for optimizing intervention components to be delivered at point of care.
223805039|NCT03324438|BEHAVIORAL|Personalized Adherence Feedback|1\) assessment of physical and behavioral health characteristics associated with high-risk status; 2) delivery of home telehealth that incorporates: 2a) medical and behavioral health care delivered with the endocrinologist and behavioral health specialist working together with high-risk youth; 2b) personalized intervention to improve T1D adherence and T1D clinical health outcomes; 2c) personalized intervention to improve mental health comorbidities and T1D clinical health outcomes; and 3) an underused methodological approach for optimizing intervention components to be delivered at point of care.
223805040|NCT01718002|BEHAVIORAL|Educational video|The patient was asked to execute the technique used daily oral hygiene that, with the sequence, movements and technical procedures for its implementation evaluated and recorded an instrument to analyze the steps of oral hygiene. Subsequently, patients watched the video prepared individually in the ward where they were interned. After this step, the patient demonstrated again the procedure for oral hygiene. At this point the researcher also observed the sequence, movements and technical procedures used to analyze the steps of oral hygiene, using the same instrument for such employee initially.
223805041|NCT03717402|BEHAVIORAL|Intervention Participants|Patients with advances cancer using opioids for chronic pain will be enrolled and asked to use the STAMP cancer pain management app for 4 weeks.
223805042|NCT04395573|DEVICE|Accuro|ultrasound device (Accuro, Rivanna Medical, Charlottesville, VA) with automated pattern recognition software programmed (SpineNav3DTM technology) to calculate the depth to epidural space and identify bony landmarks
223805043|NCT04395573|DEVICE|standard ultrasound device|standard ultrasound device (o calculate the depth to epidural space and identify bony landmarks
223805044|NCT02244801|DRUG|darTreg infusion|"The first subject in each dosing cohort will be monitored for 4 weeks after darTreg infusion. Following the 4 week observation period, the study team will conduct a thorough review of all available data to ensure that there are no safety signals and to make a determination about proceeding with additional patients. sBc production for darTreg manufacturing for the second subject in each cohort may be initiated but the second subject may not undergo leukapheresis until the safety review is complete.~Once the last subject in the first cohort reaches week 4 post-infusion, the DSMB will conduct a thorough review of all available data to make a determination about proceeding with additional patients at the lower dose or proceeding to the second dosing cohort. sBc production for darTreg manufacturing for the subsequent subject may be initiated but the patient may not undergo leukapheresis until the DSMB( Data Safety and Monitoring Board ) has approved enrollment of subsequent subjects."
223805045|NCT01704625|PROCEDURE|Osteopathic Manipulative Treatment|The investigators wish to see if emergency medicine physicians can use osteopathic evaluation and OMT to reliably treat headaches. The results of the examination and treatment will be recorded, but will not be used to change treatment or to change additional tests.
223805046|NCT01704625|PROCEDURE|Sham Osteopathic Manipulative Treatment|The sham group will receive 3 sham treatments.
223805047|NCT01900262|OTHER|Strengthening|Participants will be asked to complete 8 weeks of isolated ankle strengthening at home.
223805048|NCT01900262|OTHER|Balance Training|Participants will be asked to compete 8 weeks of functional balance training at home.
223805049|NCT01900262|OTHER|Stretching|Participants will be asked to complete a standard of practice static and dynamic stretching warm-up for 8 weeks at home.
223805050|NCT03147235|BEHAVIORAL|vitrectomy with music listening|Those randomized to music listening will be exposed to a standardized playlist of previously validated relaxation music.
223805051|NCT02909348|DRUG|Pembrolizumab|3mg/kg, intravenous and on day1 of each 21 day cycle until progression or unacceptable toxicity develops.
223805052|NCT01914094|BEHAVIORAL|Prehab|
223805053|NCT04550325|BIOLOGICAL|Kamada Anti-SARS-CoV-2|Anti-SARS-CoV-2 is a preparation of immune gamma globulin manufactured from convalescent plasma of COVID-19 recovered patients, using Kamada's proprietary purification methods
223805054|NCT03362450|OTHER|Fetal ultrasound during the second or third trimester/ Postnatal surgery / Post mortem examination|Fetal ultrasound during the second or third trimester Postnatal surgery Post mortem examination
223805055|NCT05239988|OTHER|no experimental intervention|There will not be any experimental intervention. The study will be conducted according with normal clinical practice
223805056|NCT04494438|DRUG|Rituximab|
223805057|NCT00242528|DRUG|Zoledronic acid|
223805058|NCT03287739|BEHAVIORAL|Assessment of behavioral biometric impairments|Assessment of behavioral biometric impairments
223805059|NCT02000739|GENETIC|Genetically Informed Therapy|If there is a genetic mutation that can be identified with current DNA sequencing and a drug has been developed for this mutation, participants may be able to receive that drug. If there is more than one drug available, the participant and his/her oncologist will decide which is the best one for the participant.
223805060|NCT06342089|OTHER|Type I diabetes milletus|the exposure is type I diabetes milletus
223805061|NCT05646394|DRUG|Dual antiplatelet therapy|Aspirin plus any of clopidogrel, ticagrelor or prasugrel
223805062|NCT05646394|DRUG|Combined antithrombotic therapy|Combination of a vitamin K antagonist, such as warfarin, acenocoumarol, phenprocoumon, phenindione etc, with low-dose aspirin.
223805063|NCT05646394|DRUG|Vitamin K antagonist standard intensity|vitamin K antagonist, such as warfarin, acenocoumarol, phenprocoumon, phenindione etc, with therapeutic range, international normalized ratio 2.0-3.0
223805064|NCT05646394|DRUG|Vitamin K antagonist high intensity|vitamin K antagonist, such as warfarin, acenocoumarol, phenprocoumon, phenindione etc, with therapeutic range, international normalized ratio 3.0-4.0
223805065|NCT03109821|OTHER|Home-based exercise|"The intervention reflects the standard rehabilitation practice at Elective Surgery Centre. 3 weeks after surgery the patients will receive a thorough instruction and supervision in the strength training exercises that they are to perform without supervision at their own homes the following 7 weeks. The instruction is conducted one-to-one by physiotherapists and supported by an instruction booklet with written and illustrated exercise descriptions. The exercises included are: hip abduction, flexion and extension with elastic band resistance and sit-to-stand and one-legged stance. The prescribed training load will be two sets with repetitions to failure and a relative load of 10 to 20 RM (Repetition Maximum), performed every second day (3-4 times a week).~Exposure: Performed exercise dose will be quantified as the total physiological exercise stimulus (Time under tension summary dose) recorded by a sensor (BandCizer) attached to the elastic exercise band."
223805066|NCT00233441|DRUG|CELIVARONE (SSR149744C)|
223805067|NCT03227016|DRUG|veliparib|Topotecan at increasing doses (1x or 2x per day) will be administered in each cycle.
223805068|NCT03227016|DRUG|Topotecan|Topotecan at dose 1.25 mg/m2 will be administered in each cycle.
223805069|NCT00231673|DRUG|Topiramate|Increasing dosing of topiramate gradually to 200 mg daily by mouth, dose maintenance for 12 weeks, then decreasing dose until stopped over 12 weeks
223805070|NCT01436968|BIOLOGICAL|Aglatimagene besadenovec + valacyclovir|"Patients will receive three courses of ProstAtak® each consisting of aglatimagene besadenovec injection + oral valacyclovir. AdV-tk injection will be delivered to the prostate via trans-rectal ultrasound guided injection as follows:~1. The first injection will be given at least 15 days and not more than 8 weeks before starting radiation.~2. The second injection will be 0-3 days before initiation of radiation therapy.~3. The third injection will be 15-22 days after the 2nd injection.~The prodrug, valacyclovir, will be administered at a fixed dose for 14 days after each AdV-tk injection.~Standard external beam radiation therapy will be delivered to the prostate. Short-term androgen deprivation therapy (maximum of 6 months) is optional but must be decided before enrollment to allow for stratification."
223805071|NCT01436968|BIOLOGICAL|Placebo + valacyclovir|"Patients will receive three courses each consisting of placebo injection + oral valacyclovir. Placebo injection will be delivered to the prostate via trans-rectal ultrasound guided injection as follows:~1. The first injection will be given at least 15 days and not more than 8 weeks before starting radiation.~2. The second injection will be 0-3 days before initiation of radiation therapy.~3. The third injection will be 15-22 days after the 2nd injection.~The prodrug, valacyclovir, will be administered at a fixed dose for 14 days after each placebo injection.~Standard external beam radiation therapy will be delivered to the prostate. Short-term androgen deprivation therapy (maximum of 6 months) is optional but must be decided before enrollment to allow for stratification."
223805072|NCT03760601|BEHAVIORAL|Brief cognitive intervention|A one-session intervention with a researcher including a simple cognitive task (a memory cue, 10 minutes time gap and ca. 20 minutes of Tetris game play) with instructions to engage in the task self-guided in the subsequent week.
223805073|NCT02687321|OTHER|Determination of CA 125 and HE4, Computed tomography|Blood sample collection to determinate tumor marker found in blood elevated by the presence of cancer recurrence.In case of one or both of tumor markers are elevated, computed tomography examination with intravenous contrast agent of chest and abdomen is performed to detect the recurrence of the disease.
223805074|NCT03540511|DIAGNOSTIC_TEST|postoperative troponin|assess postoperative troponin levels after cardiac surgery in patients with renal dysfunction
223805075|NCT06453122|OTHER|Oral care|The intervention group procedure will be carried out in the same way and frequency of the control group, however, replacing the chlorhexidine solution 0.12% for mineral water. Oral hygiene will be carried out by the nursing team, which will be blind to the indices to be evaluated. The team will be previously trained to carry out hygiene procedures by the team of ICU dental surgeons.
223805076|NCT02452684|DRUG|Eszopiclone|The usual dosage of eszopiclone is 2 mg per dose for adults and 1 mg per dose for elderly participants, taken orally before bedtime. The dosage may be adjusted according to the participant's symptoms, but a single dose should not exceed 3 mg in adults and 2 mg in elderly participants.
223805077|NCT04418934|DEVICE|Hemanext One|Leukoreduced red blood cell product from donors in the Investigational Product arm will be processed in the Hemanext Oxygen Reduction Bag for 3 hours and then transferred to the Hemanext Storage Bag and stored for 56 days at 1-6°C.
223805078|NCT06510452|DRUG|2000 mg of Cefazolin|receive 2000 mg of Cefazolin and 500 mg of Metronidazole IV dissolved in 100 ml NACL0.9%.
223805079|NCT06510452|DRUG|500 mg of Metronidazole IV|receive 2000 mg of Cefazolin and 500 mg of Metronidazole IV dissolved in 100 ml NACL0.9%.
223805080|NCT06510452|DRUG|NACL 0.9% 100 ml|receive 100 ml NACL0.9% without any antibiotics in it.
223805081|NCT04202926|DEVICE|real coil|active 10Hz with a train of 3s on / 17s off, 50 trains, a total of 1500 pulses
223805082|NCT04202926|DEVICE|sham coil|sham 10Hz with a train of 3s on / 17s off, 50 trains, a total of 1500 pulses
223805083|NCT03248765|OTHER|post-surgical opioid use measured at 1 day and 1 week.|"Evaluation of intra-hospital perioperative opioid administration (including intraoperative opioids and Patient Controlled Analgesia (PCA) use). This endpoint is calculated as the total amount of morphine equivalents administered intraoperatively and in the first 24 hours after the end surgery (measured on postoperative day 1).~2\) Opioid utilization after discharge from hospital (prescription refills and pills count at subsequent hospital visits). This endpoint is calculated as the total amount of morphine equivalents consumed in the first week after the surgery (measured at 1 week after surgery by electronic questionnaire and verified by direct pill count performed on occasion of the patient's postsurgical visit )."
223805084|NCT03456037|OTHER|hepatitis viruses|There are 5 main hepatitis viruses, referred to as types A, B, C, D and E. These 5 types are of greatest concern because of the burden of illness and death they cause and the potential for outbreaks and epidemic spread. In particular, types B and C lead to chronic disease in hundreds of millions of people and, together, are the most common cause of liver cirrhosis and cancer.The aim is to investigate incidence of HBsAg, anti-HCV in serum samples and evaluation of biomarkers taken from patients who were followed the intensive care unit of Sakarya University Training and Research Hospital.
223805085|NCT00082394|DRUG|Trizivir|
223805086|NCT00082394|DRUG|atazanavir|
223805087|NCT00082394|DRUG|Combivir|
223805088|NCT02544464|DRUG|ferric carboxymaltose 1000 mg|Ferric carboxymaltose is administered after anesthesia induction
223805089|NCT02544464|DRUG|placebo|placebo (normal saline) is administered after anesthesia induction
223805090|NCT00838682|DRUG|omeprazole sodium IV|Intravenous Omeprazole (brand name: Losec® injection 40 mg) 80 mg as a bolus injection followed by continuous infusion at 8 mg per hour for 3 days. From Day 4, oral Rabeprazole 10 mg once daily for 6 weeks as maintenance therapy.
223805091|NCT00838682|DRUG|Rabeprazole|Oral Rabeprazole 20 mg twice daily for 3 days. From Day 4, oral Rabeprazole 10 mg once daily for 6 weeks as maintenance therapy.
223835396|NCT04895787|BEHAVIORAL|Gait + aerobic exercise|Following skill-based gait training, the participants in the AEX group will engage in 20 minutes of moderate to high intensity aerobic exercise on a recumbent bicycle. The participants will first perform a brief warm-up, followed by 20 minutes of moderate to high intensity aerobic exercise pedaling at 60-80 rpm with a target heart rate range between 60-70% of heart rate reserve (HRR). Given the potential of having autonomic dysfunction in this population, it has been suggested that a RPE scale between 14-17 is appropriate.
223805092|NCT04524143|OTHER|cervical mobilization|"Cervical mobilization techniques were applied in the study. Within the scope of application; rotation with traction, lateral gliding, anterior-posterior gliding with traction, bridging and stroking techniques to the paravertebral muscles were used. Mobilization were performed at grade A (mobilization in painless joint range) and grade B (continuous stretching at the end of the joint range). The mobilization were applied during 10 minutes.~At the end of study all patients were received home-based exercise tailored to each individual's needs which include stretching, strengthening, balance and gait exercise and posture exercise"
223805093|NCT04524143|OTHER|control|There was no intervention in the control group during study. At the end of study all patients were received home-based exercise tailored to each individual's needs which include stretching, strengthening, balance and gait exercise and posture exercise
223805094|NCT03966222|DEVICE|Endoscopic vein harvest|An endoscope is introduced adjacent to the vein, allowing its dissection under direct vision via a small incision.
223805095|NCT03966222|OTHER|Open vein harvest|Open vein harvest
223805096|NCT03397680|DIAGNOSTIC_TEST|13C Urea Breath Test|After the H.pylori eradication treatment course completed, participants then was tested with 13C Urea Breath Test to confirm treatment effectiveness at least after ceasing PPI and antibiotics for 4 weeks.
223805097|NCT02124889|BEHAVIORAL|Weekly Internet surveys|Subjects will receive weekly Internet surveys asking them how their treatment is working, how often they took the medication, and how easy it was to use the medication.
223805098|NCT03166943|PROCEDURE|Systolic function by echocardiography|"Echocardiography for evaluation of systolic function:~* by biplane Simpson's method.~* by speckle tracking:"
223805099|NCT03166943|PROCEDURE|Diastolic function by echocardiography|"Echocardiography for evaluation of diastolic function:~* Left atrial Volume~* Mitral Inflow Patterns~  * Pulsed wave Doppler~ * Mitral inflow patterns include normal, impaired left ventricular relaxation, pseudonormal, and restrictive left ventricular filling patterns.~* Tissue Doppler Annular Early and Late Diastolic Velocities~  * Pulsed wave tissue doppler imaging~ * Primary measurements include the systolic , early diastolic, and late diastolic velocities."
223805100|NCT00989092|BIOLOGICAL|darbepoetin alfa|Administered subcutaneously.
223805101|NCT04684225|OTHER|Hand Therapy via Telerehabilitation|Hand Therapy via Telerehabilitation
223805102|NCT04684225|OTHER|Hand Therapy via home-exercises|Hand Therapy via home-exercises
223805103|NCT00292175|PROCEDURE|Narrow Band Imaging|
223805104|NCT00292175|PROCEDURE|colonoscopy|
223805105|NCT00002864|DRUG|octreotide acetate|Octreotide LAR (SMS 201-995 pa LAR) 90 mg depot injection monthly for 2 years (plus Tamoxifen 20 mg PO daily for 5 years)
223805106|NCT00002864|DRUG|tamoxifen citrate|20 mg PO for 5 years
223805107|NCT02565238|DEVICE|BioMonitor 2|Implantation of BioMonitor 2
223805108|NCT01010425|DRUG|ACP-001 (TransCon PEG hGH)|ACP-001, dose-level 1, s.c., single-dose
223805109|NCT01010425|DRUG|ACP-001 (TransCon PEG hGH)|ACP-001, dose-level 2, s.c., single-dose
223805110|NCT01010425|DRUG|ACP-001 (TransCon PEG hGH)|ACP-001, dose-level 3, s.c., single-dose
223805111|NCT01010425|DRUG|ACP-001 (TransCon PEG hGH)|ACP-001, dose-level 4, s.c., single-dose
223805112|NCT01010425|DRUG|Placebo|Placebo, s.c., single-dose
223805113|NCT01010425|DRUG|Human Growth Hormone|Human Growth Hormone, s.c., daily for 7 days
223805114|NCT05850039|OTHER|Sampling|Sample collection: a small fragment of atrial wall will be collected
223805115|NCT01869790|OTHER|Different fat types|Saturated, monounsaturated fats
223805116|NCT00990964|DEVICE|Attain Success Lead|Attain Success Lead
223805117|NCT01667913|OTHER|6 minutes walking test|
223805118|NCT00375362|DRUG|Nitroderm patch|
223805119|NCT04932499|OTHER|Standard of Care|Participants randomly assigned to this intervention will receive standard of care given to all patients undergoing total knee arthroplasty at our institution as outlined in the Common Care Pathway for Total Joint Replacement. Outcome assessments will be completed pre-operatively, each day while in hospital and 7 and 14 days postoperative.
223805120|NCT04932499|OTHER|Mindfulness Meditation|"In addition to standard of care, participants randomly assigned to the treatment group will be given a 45-60 minute teaching session on mindfulness meditation. Upon completion of this session, participants will be given homework recordings of a body scan exercise and asked to listen to the recording daily for the two-week period prior to surgery. Participants will be asked to listen to their recording immediately prior to their surgery and daily while in hospital. In addition, participants assigned to mindfulness intervention will receive standard of care as outlined in the control group. Outcome assessments will be completed pre-operatively, each day while in hospital and 7 and 14 days postoperative."
223805121|NCT04551599|DRUG|Danicopan|A single dose of danicopan (200 milligrams) will be administered orally.
223805122|NCT05103683|DRUG|TORL-1-23|antibody drug conjugate (ADC)
223805123|NCT04344041|DRUG|cholecalciferol 200,000 IU|Patients receive a vitamin D supplementation of 400,000 IU in a single oral dose.
223805124|NCT04344041|DRUG|cholecalciferol 50,000 IU|Patients receive a vitamin D supplementation of 50,000 IU in a single oral dose
223805125|NCT03202472|DEVICE|Implanted Medical Device|Radiofrequency tag
223805126|NCT03202472|PROCEDURE|Mammography|Undergo mammogram for image-guided placement of radiofrequency tag
223805127|NCT03202472|OTHER|Questionnaire Administration|Ancillary studies
223805128|NCT03202472|PROCEDURE|Radiofrequency (RFID) -Guided Localization|Undergo radiofrequency-guided localization
223805129|NCT03202472|PROCEDURE|Ultrasonography|Undergo ultrasound for image-guided placement of radiofrequency tag
223805130|NCT04098406|DRUG|CNM-Au8|CNM-Au8 is a dark red/purple-colored liquid formulation consisting of a stable suspension of faceted clean surfaced elemental gold nanocrystals in buffered deionized water with a nominal concentration of 0.5 mg/mL of gold. The formulation is buffered by sodium bicarbonate present at a concentration of 0.546 mg/mL. There are no other excipients. The drug product is formulated to be taken orally and will be provided in single dose 60 mL HDPE containers.
223805131|NCT04098406|DRUG|Placebo|Placebo was liquid with identical color and taste
223805132|NCT04199780|DEVICE|Transcranial Direct Current Stimulation|Transcranial direct current stimulation (tDCS), stimulates specific areas of the brain via electric current passed through electrodes placed on the scalp. During tDCS, low amplitude direct currents penetrates the skull to enter the brain and modulates neuronal activity.
223805133|NCT04199780|BEHAVIORAL|Cognitive-Behavioral (CB) intervention|CBI generally consist of cognitive coping strategies (e.g., distraction, relabeling, reducing pain-catastrophizing) and self-management (e.g., relaxation strategies, guided imagery) designed to enhance perceived control and reduce sympathetic nervous system tone.
223805134|NCT03974659|COMBINATION_PRODUCT|Transcranial magnetic stimulation|1.Patients were given 10 consecutive days bilateral cerebellar VIIa lobules Theta Burst Stimulation which was a special mode of Transcranial magnetic stimulation from one week after surgery Intermittent Theta Burst Stimulation(Positive stimulation) is used in right cerebellar VIIa lobule.Each stimulus had three 50 Hz monopulses, which were repeated every 200 ms. Each stimulation continued for 2 seconds and rested for 8 seconds. The total intervention time was 200s (600 pulses) Continuous Theta Burst Stimulation(Negative stimulation) is used in left cerebellar VIIa lobule,three 50 Hz monopulses in each stimulus, each with an interval of 200 ms, and each intervention lasted 40s (600 pulses).
223805135|NCT01590290|OTHER|financial compensation|financial monetary reimbursement
223805136|NCT04378192|DEVICE|Laryngeal mask airway|Insertion of laryngeal mask airway before intubation of a morbidly obese patient
223805137|NCT04378192|DEVICE|face mask|use of face mask before intubation of a morbidly obese patient
223805138|NCT06519994|DRUG|Artesunate vaginal inserts|Subjects will self-administer 200 mg of Artesunate vaginal insert daily for 5 days, on weeks 1, 3, 5.
223805139|NCT06519994|DRUG|Placebo vaginal inserts|Subjects will self-administer a placebo vaginal insert daily for 5 days, on weeks 1, 3, 5.
223805140|NCT04422613|DIAGNOSTIC_TEST|pulmonary anomalies 4 months after documented COVID-19 pneumonia|Characterization of pulmonary damage with a complete pulmonary assessment 4 months after COVID-19 pneumonia,
223805141|NCT04636554|OTHER|Phage Therapy|Personalized intravenous phage therapy in Covid-19 patients along with anti-microbial treatment for pneumonia, bacteremia or septicemia due to A. baumannii, P. aeruginosa or S. aureus.
223805142|NCT04839029|PROCEDURE|Bipolar En bloc TURBT|patients subjected to Bipolar resection of bladder tumor by Collins loop
223805143|NCT04839029|PROCEDURE|Monopolar En bloc TURBT|patients subjected to Monopolar resection of bladder tumor by Collins loop (hot Knife)
223805144|NCT03406819|DRUG|Nitroprusside Sodium|Intracoronary infusion 50\~100μg each time (repeated)
223805145|NCT03406819|DRUG|Tirofiban Hydrochloride|Intracoronary infusion 10μg/kg for single time
223805146|NCT03406819|DRUG|Heparinized saline|Intracoronary infusion 2ml for single time
223805147|NCT06956417|BEHAVIORAL|Cognitive behavioral therapy|Cognitive behavioral therapy (CBT) is delivered by a psychologist over 10 individual (1:1) manualized videoconference sessions. The goal of this therapy is for participants to use their memory more normally (i.e., reduce avoidance and safety behaviors) and view memory lapses as less threatening.
223805148|NCT06956417|BEHAVIORAL|Cognitive rehabilitation|Cognitive compensatory strategy training (CCST), a traditional cognitive rehabilitation intervention, is delivered by a Occupational Therapist over 10 individual (1:1) manualized videoconference sessions. Participants optimize their use of current compensatory strategies and/or learn new ones suited to their needs and lifestyle. The goal is to minimize memory lapses in daily life.
223805149|NCT02878174|PROCEDURE|internal jugular vein catheterization|internal jugular vein catheterization using ultrasound (US) or US-based prelocation techniques
223805150|NCT03010839|PROCEDURE|Modified Remote Ischemic Preconditioning|mRIPC will be induced at 24 h, 12 h and 1 h before surgery and once before induction of anesthesia by 3 cycles of 5-min upper limb ischemia and 5-min reperfusion using a blood-pressure cuff inflated to a pressure 200mmHg
223805151|NCT03010839|PROCEDURE|Control|Control group witnout remote ischemic preconditioning
223805152|NCT05284825|RADIATION|12 Gy in 6 daily fractions|12 Gy in 6 daily fractions
223805153|NCT02073916|DRUG|T-DM1|antibody-drug conjugate of trastuzumab and emtansine
223805154|NCT02073916|DRUG|Lapatinib|Dual tyrosine kinase inhibitor (HER2 and EGFR)
223805155|NCT02073916|DRUG|Abraxane|albumin-bound paclitaxel. Chemotherapy - microtubule inhibitor
223805156|NCT02173548|DRUG|Anakinra|
223805157|NCT02173548|DRUG|Placebo|
223805158|NCT01580072|OTHER|self-monitoring for patients with severe COPD|Intervention Group entering vital parameters via Web Portal or automatic call center.
223805159|NCT01580072|OTHER|nurse-monitoring for patients with severe COPD|Nurses are entering vital parameters of the patient with mobile devices.
223805160|NCT04535674|BIOLOGICAL|Asunercept|Asunercept (APG101) will be administered once per week as an i.v. infusion
223805161|NCT06393348|DRUG|HRS-7535|HRS-7535
223805162|NCT06393348|DRUG|Placebo|Placebo
223805163|NCT06267456|DIAGNOSTIC_TEST|Upper Limb Rotation Test|The athlete is positioned with the shoulder, elbow lateral epicondyle, greater trochanter, and ankle lateral malleolus in contact with the wall. In the push-up position, the elbows are started at shoulder height with a 90° bend, and the feet are placed in a shoulder-width apart position. Athletes are instructed to perform a rotation of the shoulder and trunk by touching a vertically placed band on the wall for 15 seconds in the position of 90° abduction and 90° external rotation of the shoulder. The tested side is the upper extremity where the closed kinetic chain position is maintained.
223805164|NCT06267456|DIAGNOSTIC_TEST|Closed Kinetic Chain Upper Extremity Stability Test|Athletes were placed in a push-up position with a distance of 91.44 centimeters (cm) (3 feet) between their hands for the test position. Subsequently, they were instructed to touch one hand to the other as quickly as possible. The total number of touches within a 15-second period was recorded. Modified push-up position was used for women, and regular push-up position for men during this time. Prior to the test, a familiarization trial consisting of 5 repetitions was performed. The test was then repeated 3 times, and the average of these repetitions was recorded as the score. Individuals were given a 45-second rest period between repetitions. The normalized score, representing the touch count per individual's height, was calculated. The power score was obtained by multiplying the touch count by 68% of the individual's body weight in kilograms.
223805165|NCT06267456|DIAGNOSTIC_TEST|Upper Quarter Y Balance Test|The Upper Extremity Y Balance Test was created using three rulers placed on the ground in the medial, inferolateral, and superolateral directions. The rulers in the superolateral and inferolateral directions were positioned at a 90° angle to each other, while the ruler in the medial direction was placed at a 135° angle with respect to these two directions. In this test, both arms started in a push-up position with shoulder-width apart. The athlete was then instructed to touch, using their non-dominant hand, the maximum reachable point in the medial, inferolateral, and superolateral directions.
223805166|NCT01886911|OTHER|Attention Training Intervention Game|
223805167|NCT01886911|OTHER|Prosocial Training Intervention Game|
223805168|NCT01886911|OTHER|Control for Attention Intervention|
223805169|NCT01886911|OTHER|Control for Prosocial Intervention|
223805170|NCT05599009|PROCEDURE|remote ischemic conditioning|Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min re-perfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 200 mmHg. All patients underwent dynamic cerebral autoregulation before treatment, immediately after treatment, 6 hours after treatment and 24 hours after treatment.
223805171|NCT05599009|PROCEDURE|sham remote ischemic conditioning|Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min re-perfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 60 mmHg. All patients underwent dynamic cerebral autoregulation before treatment, immediately after treatment, 6 hours after treatment and 24 hours after treatment.
223805172|NCT05270681|OTHER|Movement to Music|Participants will be educated on how to access prerecorded Move to Improve classes conducted by a professional dance instructor which will be accessible by computer or tablet 24/7 via a hyperlink. Classes last 45 minutes, and participants will be instructed to participate in the activity at least twice weekly, for 12 weeks. Each class uses movement to music combinations across different dance genres that build in intensity and sequence complexity, accompanied by music with faster beats, to encourage participants to achieve a moderate-vigorous level of physical and cognitive activity. Care partners will be present during each class to ensure safety and will also participate in the Move to Improve exercise program. The care partner and participant will be instructed to stand at a counter or behind a chair for safety during exercise.
223805173|NCT00415610|DRUG|nicardipine|"Intravenous (IV) nicardipine infusion. It is expected that the treatment duration will vary between 18 and 24 hours.~* Started at 5mg/h~* Titrated by 2.5mg/hour every 15 minutes to bring systolic blood pressure in target range for the applicable Tier. Max dose 15mg/hour \*Once target systolic blood pressure reached, dose decreased by 2.5mg/hour every 15 minutes until systolic blood pressure maintained in the target range or the medication is discontinued."
223805174|NCT01295645|DRUG|Cidofovir|0.5 mg/kg by vein (IV) 3 times a week for 4 weeks.
223805175|NCT01295645|OTHER|No Cidofovir|Standard of Care: Pharmacologic management of pain, spasms, and urinary urgency with medications, hyper-hydration, or continuous bladder irrigation.
223805176|NCT02239393|BIOLOGICAL|Mesenchymal Stem Cells|"Mesenchymal Stem Cells in Plasma-Lyte A (Baxter) suspension media, containing 5% Human Albumin and 10% dimethylsulfoxide (DMSO, total volume of 5mL DMSO in final cell product) and autologous MSCs at a dose of 1 to 2 x 106 MSC/Kg participant's body weight at randomization.~Matching placebo Plasma-Lyte A (Baxter) suspension media, containing 5% Human Albumin and 10% DMSO (total volume of 5mL DMSO in final cell product)."
223805177|NCT00455975|DRUG|Bevacizumab|Bevacizumab
223805178|NCT04350710|OTHER|PEEP trial|Measurement of Recruitment-to-Inflation Ratio
223805179|NCT01086748|DRUG|Risperidone|Administered orally.
223805180|NCT01086748|DRUG|Placebo|Administered orally.
223805181|NCT01086748|DRUG|LY2140023|Administered orally.
223805182|NCT01494337|PROCEDURE|HOLEP|USING HOLMIUM LASER, the prostate adenoma will be enucleated and removed into small pieces
223805183|NCT01494337|PROCEDURE|PVEP-XPS|Greenlight laser will be used with high power setting for selective vaporization of the prostate adenoma, using 180 watt XPS laser machine
223805184|NCT04424862|DRUG|Prednisone, ciclosporin and mycophenolate mofetil|Multitarget Therapy
223805185|NCT04424862|DRUG|Ponticelli Regimen|Month 1: i.v. methylprednisolone (0.5 g) daily for three doses, then oral prednison (0.5 mg/kg/d, maximum dose 30mg/d) for 27 days Month 2: Oral cyclophosphamide (2.0 mg/kg/d, maximum dose 100mg/d) for 30 days Month 3: Repeat Month 1 Month 4: Repeat Month 2 Month 5: Repeat Month 1 Month 6: Repeat Month 2
223805186|NCT03982602|OTHER|Ketogenic diet|Subjects will be provided with the Ketogenic diet in the form of tube feeds once the decision is made to start the patient on diet.
223805187|NCT00810836|DRUG|BG00012|oral
223805188|NCT00810836|DRUG|BG00012|Oral
223805189|NCT00810836|DRUG|placebo|oral placebo
223805190|NCT04285008|DEVICE|Pure-Vu System|The Pure-Vu System is Food and Drug Administration (FDA) approved device (K191220), intended to connect to standard colonoscopes to help facilitate intra-procedural cleaning of a poorly prepared colon by irrigating or cleaning the colon and evacuating the irrigation fluid (water), feces and other bodily fluids and matter, e.g. blood.
223805191|NCT06075797|BEHAVIORAL|PediQUEST ResPOND|"PPC teams will have access to feedback reports and the PQ-ResPOND checklist (standardized framework to diagnosis and treatment of recurrent pain behaviors in children with severe neurologic impairment).~Integration of the PPC team into care will be achieved through (i) initial consultation (goals: identify treatment goals, and address recurrent pain), and (ii) follow-up: the team will contact or visit the family in response to feedback reports or for treatment monitoring purposes."
223805192|NCT02723942|BIOLOGICAL|CAR-T cell immunotherapy|This CAR-T cell immunotherapy with a novel specific Chimeric antigen receptor aiming at GPC3 antigen.
223805193|NCT01224301|BEHAVIORAL|School based flu vaccine: Low intensity|Interventions: Parents of children in Low Intensity Notification schools got less than 3 communications from schools describing influenza vaccine and the clinics, and consent forms sent home one.
223805194|NCT01224301|BEHAVIORAL|School based flu vaccine: High intensity|Interventions: Parents in high intensity schools have 3 or more communications from schools about influenza illness, influenza vaccine, and school based clinics.
223805195|NCT05134766|OTHER|Observation only|Based on type of SOC applied and the type of CAM products by subject's own decison
223805196|NCT05021510|OTHER|Simultaneous Cervical Traction & Neural Mobilization|Simultaneously Mechanical Cervical traction with Neural Mobilization of the upper limb for 3 times a week, 45 minutes per day for 4 weeks
223805197|NCT05021510|OTHER|consecutive Cervical Traction & Neural Mobilization|consecutive Mechanical Cervical traction with Neural Mobilization of the upper limb for 3 times a week, 45 minutes per day for 4 weeks
223805198|NCT03895411|DRUG|sotalol|Oral sotalol 2.5mg/kg/time, per 12h
223805199|NCT03895411|DRUG|Propafenone|Oral Propafenone 5mg/kg/time, pre 8h
223805200|NCT03895411|DRUG|betaloc|Oral betaloc 0.5mg/kg/time ,pre 12h
223805201|NCT03613311|DIAGNOSTIC_TEST|Urodynamic study|Urodynamic study: including uroflowmetry, filling cystometry, voiding cystometry, and urethral pressure profile
223805202|NCT04042857|DEVICE|Next Science Treatment Gel|Next Science Treatment Gel will be applied after nail surface nail-filing and/or debridement.
223805203|NCT01055730|OTHER|Pulmonary rehabilitation|Structured education and supervised exercise program, lasting between 6 and 9 weeks.
223805204|NCT04737564|BEHAVIORAL|Attachment and Biobehavioral Catch-up (ABC10)|"The ABC parenting targets include: nurturing children when they are distressed (Sessions 1 and 2), following the child's lead in play (Sessions 3 and 4), and avoiding harsh or frightening behavior (Sessions 5 and 6). Sessions 7 and 8 help parents consider how their own experiences of being parented affect their sensitivity, and Sessions 9 and 10 consolidate gains with additional practice. Session content focusing on parenting targets is guided by a manual. Additionally, parent coaches make frequent in-the-moment comments (at least once per minute) about parent-child interactions as they occur in session, and use video feedback."
223805205|NCT04737564|BEHAVIORAL|Attachment and Biobehavioral Catch-up, Brief (ABC3)|The 3-session Attachment and Biobehavioral Catch-up intervention (ABC 3) is a brief version of the standard protocol. Parents who receive ABC 3 will receive the first 3 sessions of the ABC intervention, which focus on enhancing parental sensitivity (i.e., nurturance to distress, following the child's lead) by providing in-the-moment feedback on parent-child interactions, video feedback, and discussion of manualized content. ABC 3 was adapted from the standard protocol based on modeling of session-by-session data that demonstrated that, on average, most of the change in parental sensitivity happens in the first several sessions of the intervention.
223805206|NCT04737564|BEHAVIORAL|Safe Environment for Every Kid (SEEK)|Safe Environment for Every Kid (SEEK) is an evidence-based screening and referral system to facilitate parents' access to services for risk factors for maltreatment, including: mental health, substance abuse, intimate partner violence, harsh parenting, major parental stress, and food insecurity. Parents first complete the SEEK Parent Questionnaire with the help of an outreach worker. Following the SEEK protocol, handouts will be provided that address the identified problems and parents will be referred to partnering organizations in the community. Any additional work is completed by phone. The developer of the intervention, Howard Dubowitz, is a consultant on this application and will provide support around effective implementation.
223805207|NCT00778128|DRUG|CP-4126|Step 1: Dose escalation oral CP-4126 until maximum tolerated dose. Step 2: Oral CP-4126 day 1 and 15 + IV Gemcitabine 1000 mg/m2 day 8 in a 4 week schedule until complete response or disease worsening / progression
223805208|NCT00778128|DRUG|Gemcitabine|Step 1: Dose escalation oral CP-4126 until maximum tolerated dose Step 2: Oral CP-4126 day 8 and 15 + IV Gemcitabine 1000 mg/m2 day 1 in a 4 week schedule until complete response or disease worsening / progression
223805209|NCT03448445|OTHER|Usual care setting|usual care settings without any intervention
223805210|NCT04178057|BIOLOGICAL|GB222 3mg/kg|Injection, strength 100mg/bottle, intravenous infusion, 3mg/kg, dose escalation; After it is tolerated, 2 weeks/per time, combines use of chemotherapeutic agents is allowed after 3 months until disease progression, death, intolerable toxic reactions, withdrawal of informed consent form, loss to follow-up, death or study conclusion; low dose group.
223805211|NCT04178057|BIOLOGICAL|GB222 5mg/kg|Injection, strength 100mg/bottle, intravenous infusion,5mg/kg, dose escalation; After it is tolerated, 2 weeks/per time, combines use of chemotherapeutic agents is allowed after 3 months until disease progression, death, intolerable toxic reactions, withdrawal of informed consent form, loss to follow-up, death or study conclusion; intermediate dose group 1.
223805212|NCT04178057|BIOLOGICAL|GB222 7.5mg/kg|Injection, strength 100mg/bottle, intravenous infusion,7.5mg/kg, dose escalation; After it is tolerated, 2 weeks/per time, combines use of chemotherapeutic agents is allowed after 3 months until disease progression, death, intolerable toxic reactions, withdrawal of informed consent form, loss to follow-up, death or study conclusion; intermediate dose group 2.
223805213|NCT04178057|BIOLOGICAL|GB222 10mg/kg|Injection, strength 100mg/bottle, intravenous infusion,10mg/kg, dose escalation; After it is tolerated, 2 weeks/per time, combines use of chemotherapeutic agents is allowed after 3 months until disease progression, death, intolerable toxic reactions, withdrawal of informed consent form, loss to follow-up, death or study conclusion; high dose group.
223805214|NCT00006048|DRUG|cisplatin|
223805215|NCT00006048|DRUG|gefitinib|
223805216|NCT00006048|DRUG|gemcitabine hydrochloride|
223805217|NCT04539821|OTHER|VCPM|VCPM is a multi-component intervention consisting of already-established care processes and materials.
223805218|NCT01720290|DRUG|repaglinide|Dose individually adjusted
223805219|NCT01720290|DRUG|metformin|Dose individually adjusted
223805220|NCT01720290|DRUG|metformin|Dose at 1000 mg/day
223805221|NCT04980664|OTHER|Integrated intervention strategies|Implementation of integrated intervention strategies to reduce the proportion of indicated-but-not-treated CHB patients.
223805222|NCT01439607|OTHER|Bone marrow and blood sampling|Bone marrow and blood sampling
223805223|NCT05078151|DIAGNOSTIC_TEST|Whole-Body Diffusion Weighted MRI|MRI at baseline, after four and eight weeks of treatment and at disease progression or treatment discontinuation.
223805224|NCT02641392|DRUG|GED-0301|Mongersen
223805225|NCT02641392|OTHER|Placebo|Placebo
223805226|NCT03859414|DRUG|Therapeutic Dose 1|CHF 5993 100/6/12.5 µg pMDI, fixed combination of BDP 100 µg + FF 6 µg + GB 12.5 µg.
223805227|NCT03859414|DRUG|Therapeutic Dose 2|CHF 5993 200/6/12.5 µg pMDI, fixed combination of BDP 200 µg + FF 6 µg + GB 12.5 µg.
223805228|NCT03859414|DRUG|Supra-therapeutic Dose|CHF 5993 200/6/12.5 µg pMDI, fixed combination of BDP 200 µg + FF 6 µg + GB 12.5 µg.
223805229|NCT03859414|DRUG|Placebo|CHF 5993 placebo pMDI
223805230|NCT00309530|DRUG|5-fluorouracil, levamisol, interferon|
223805231|NCT01840553|DRUG|oral sodium phosphate tablets|
223805232|NCT01840553|DRUG|polyethylene glycol|
223805233|NCT00168545|BIOLOGICAL|Measles vaccine|
223805234|NCT00402480|DRUG|Hydroxyurea|
223805235|NCT02691182|DRUG|SPN-810|
223805236|NCT04167241|DIAGNOSTIC_TEST|Echocardiography|Before and after right pneumonectomy or bi-lobectomy patients will receive echocardiography
223805237|NCT03197012|DRUG|90Y-DOTA-TOC|Starting 30 minutes prior to the administration of 90Y-DOTA-TOC, amino acid solution will be administered via IV, and will continue through the PRRT procedure. An angiographic catheter will be inserted under fluoroscopic guidance to the appropriate location in the hepatic artery. 90Y-DOTA-TOC will be administered via the hepatic arterial catheter.
223805238|NCT03197012|DRUG|68Ga-DOTA-TOC|In the sub-study, 10 patients will receive 68Ga-DOTA-TOC concurrent with the 90Y-DOTA-TOC dose and 90 minutes after treatment, these patients will be imaged using a PET/CT. The following day, patients enrolled in the sub-study will undergo a PET/MRI.
223805239|NCT02333214|OTHER|Exergames and conventional physiotherapy|The protocol of conventional physiotherapy will be customized and will include exercises to improve strength and muscle power, flexibility, mobility, balance, and aerobic conditioning exercises. In particular cases, when necessary analgesia will be used to relive pain. The progression of the exercises will be individualized according to the treatment plan established in the initial functional assessment and will be target to meet patient's improvement during treatment. Conventional physiotherapy will be conducted in pairs. In this group exercises that are best accomplished using virtual scenarios, such as dual task exercises, anticipatory adjustments exercises and inter limb coordination exercises will be performed using video games.
223805240|NCT02333214|OTHER|Conventional physiotherapy|The protocol of conventional physiotherapy will be customized and will include exercises to improve strength and muscle power, flexibility, mobility, balance, and aerobic conditioning exercises. In particular cases, when necessary analgesia will be used to relive pain. The progression of the exercises will be individualized according to the treatment plan established in the initial functional assessment and will be target to meet patient's improvement during treatment. Conventional physiotherapy will be conducted in pairs. In this group dual task exercises, anticipatory adjustments exercises and inter limb coordination exercises will be performed without the virtual environment.
223805241|NCT02525757|DRUG|MPDL3280A|"1200 mg by vein every 3 weeks up to 1 year after completing consolidation chemotherapy.~Group 1: MPDL3280A given after receiving standard chemotherapy and radiation for 6-7 weeks, followed by a 3-4 week rest period.~Group 2: MPDL3280A given with standard chemotherapy, and radiation therapy for 6-7 weeks followed by a rest period of 3-4 weeks, during which time participants receive 1 dose of MPDL3280A but no chemotherapy or radiation."
223805242|NCT02525757|DRUG|Carboplatin|AUC 2 by vein once a week on Day 1 during radiation therapy. During consolidation chemotherapy, Carboplatin given at AUC 6 by vein on Days 1 and 22 for 2 cycles.
223805243|NCT02525757|DRUG|Paclitaxel|50 mg/m2 by vein once a week on Day 1 during radiation therapy. During consolidation chemotherapy, Paclitaxel given at 200 mg/m2 on Days 1 and 22 for 2 cycles.
223805244|NCT02525757|RADIATION|Radiation Therapy|60-66 Gy in 30-33 fractions administered once-daily on Day 1, 5 days a week, for 6 to 7 weeks.
223805245|NCT01550198|DEVICE|Advanced hemodynamic monitoring|Comprehensive advanced hemodynamic monitoring
223805246|NCT02434094|BEHAVIORAL|eDAPT on-line training program|A series of modules used to train on the web based training system for the artificial pancreas (AP) prototype, DiAs.
223805247|NCT04152902|OTHER|Objective outcome|The final outcome of surgical therapy was assessed according to a semi-quantitative scale graded as excellent, good, fair and poor, according to quantitative grades for dysphagia, reflux symptoms and oesophagitis
223805248|NCT04152902|OTHER|Quality of life|SF-36 Questionnaire
223805249|NCT02256670|BEHAVIORAL|Text Message Application|Two-way text messaging application addressing adherence with adjuvant endocrine therapy
223805250|NCT03120962|DRUG|Oxycodone|Oxycodone 20mg/day, for 4 weeks
223805251|NCT03120962|DRUG|Gabapentin|Gabapentin 900mg/day, titrated up to max tolerated dose or 1800mg/day, for 4-12 weeks
223805252|NCT03120962|DRUG|Famciclovir|Famciclovir 500mg three-times daily for 7 days
223805253|NCT05120089|OTHER|muscle energy technique and myofacial release (physiotherapy techniques)|Each technique will be applied for three month (3 session/week)
223805254|NCT03036358|OTHER|teledermatology consult|Information from the dermatologic assessment will be entered into the patients chart.
223805255|NCT03036358|OTHER|Routine Care|The dermatologic assessment will occur but not added to the patients medical record. Dermatology may still be consulted but will be at the prerogative of the treating hospitalist.
223805256|NCT06579976|OTHER|No intervention|This is an observational study, no intervention will be implemented.
223805257|NCT01944202|BEHAVIORAL|Educational intervention|Educational and feedback intervention, as described in the Arm Description.
223805258|NCT03814798|BIOLOGICAL|IGSC 20% daily push versus every 2 weeks pump|IGSC 20% syringe daily push dosing for 16 weeks followed by every 2 weeks pump dosing for 16 weeks or the reverse sequence
223805259|NCT03814798|BIOLOGICAL|IGSC 20% daily push versus once a week pump|IGSC 20% syringe daily push dosing for 16 weeks followed by once weekly ambulatory pump administration dosing for 16 weeks or the reverse sequence
223805260|NCT03814798|BIOLOGICAL|IGSC 20% daily push versus 2 times per week pump|IGSC 20% syringe daily push dosing for 16 weeks followed by 2 times/week ambulatory pump administration on preselected days (eg, Monday and Thursday) not less than 3 days apart for 16 weeks or the reverse sequence
223805261|NCT03814798|BIOLOGICAL|IGSC 20% 150 mg/kg|loading dose of IGSC 20% consisting of 5 consecutive daily doses of 150 mg/kg/day (Week 0, Days 1-5) followed by weekly infusions of IGSC 20% 150 mg/kg starting Week 1 (Day 8) through Week 32 using an infusion SC pump
223805262|NCT00835848|DRUG|Exenatide|Following arrival at the catheter laboratory informed consent is obtained and the patient randomised to placebo or exenatid treatment. 25 μg Byetta (Lilly, Exenatide) and 0.1% human albumine are added to 250 ml isotonic NaCl. Infusion is started immediately at 72ml/hour for 15 min, followed by 26ml/hour to be contoinued for 6 hours.
223805263|NCT00835848|DRUG|Saline|Following arrival at the catheter laboratory informed consent is obtained and the patient randomised to placebo or exenatid treatment. 0.1% human albumine is added to 250 ml isotonic NaCl. Infusion is started immediately at 72ml/hour for 15 min, followed by 26ml/hour to be contoinued for 6 hours.
223805264|NCT03258216|DIAGNOSTIC_TEST|panendoscopy|panendoscopy
223805265|NCT03258216|DIAGNOSTIC_TEST|tongue image|capture tongue images by Automatic Tongue Diagnosis System
223805266|NCT03013023|BEHAVIORAL|BS|NNS, FT, positional support, and oral sucrose feeding
223805267|NCT03013023|BEHAVIORAL|Routine care|Routine NICU care
223805268|NCT03013023|BEHAVIORAL|PITP|Parents will learn to regulate infant responses while implementing caregiving activities.
223805269|NCT03013023|BEHAVIORAL|BS+PITP|Parents will learn to regulate infant responses while implementing caregiving activities. Supportive interventions, i.e., NNS, FT, positional support, and oral sucrose feeding, will be provided while infants are undergoing painful procedures.
223805270|NCT06509256|DRUG|Tranexamic acid injection|work aims to evaluate the role of tranexamic acid in bleeding control in gynecomastia surgery
223805271|NCT06193265|PROCEDURE|Discectomy|Discectomy is total or more often partial intervertebral disc surgical removal
223805272|NCT00645164|OTHER|Ointment Vehicle|Subject acts as own control. 20 mg under Finn chambers
223805273|NCT00645164|DRUG|Xenaderm|20 mg under Finn chambers
223805274|NCT05245578|DRUG|KX01 ointment 1%|A total of 4 application sites (2 cm x 2 cm each) will be marked on each subject's back, placing 2 sites for KX01 ointment 1% and 2 sites for Placebo ointment. One set (KX01 ointment 1% and Placebo ointment patches) will be designated for irradiation and the other set will remain non-irradiated under open conditions.
223805275|NCT05245578|DRUG|Placebo ointment|A total of 4 application sites (2 cm x 2 cm each) will be marked on each subject's back, placing 2 sites for KX01 ointment 1% and 2 sites for Placebo ointment. One set (KX01 ointment 1% and Placebo ointment patches) will be designated for irradiation and the other set will remain non-irradiated under open conditions.
223805276|NCT05413980|OTHER|Moxifloxacin hydrochloride ophthalmic solution|Prospective observational study. There is no treatment allocation. Patients prescribed with 0.5% Moxifloxacin hydrochloride ophthalmic solution during the perioperative period of ophthalmic surgery are eligible to enroll into this study.
223805277|NCT02346396|DEVICE|tDCS (use at home)|During 4 weeks (every week : 20 minutes / day during 5 days)
223805278|NCT01744886|PROCEDURE|maintain oxygenation during one lung ventilation|"All study patients will be placed on a volume controlled mode of ventilation with the following settings: tidal volume between 5 and 10 ml/kg and FIO2 at 50% and 4 cm H2O PEEP. Respiratory frequency and tidal volume will be adjusted to maintain ETCO2 between 30 and 40 mmHg. ETCO2 levels and SpO2 will be monitored continuously.~If SpO2 declines below 90% the ventilator settings will be adapted according to the following protocol: First the FIO2 is increased to 80%. If this is insufficient FIO2 is increased to 100%. If this remains insufficient 5 cm H2O of CPAP is applied to the non-ventilated lung. If this is still insufficient the surgeon will be asked to allow for temporary recruitment of the non-ventilated lung."
223805279|NCT02240433|DRUG|LY2157299|LY2157299 administered orally
223805280|NCT02240433|DRUG|Sorafenib|Sorafenib administered orally
223805281|NCT03343223|BEHAVIORAL|Intervention Group|"The goal of this research study is to evaluate the preliminary impact of a public-health-partnered tele-pharmacist model for pre-exposure prophylaxis (PrEP) delivery in a rural state (TelePrEP). In brief, PrEP involves daily use of a medication (i.e. Truvada) to prevent HIV infection among people at risk for infection due to sexual exposure or needle sharing."
223805282|NCT04110002|BEHAVIORAL|Injury Prevention Program|
223805283|NCT04906525|BEHAVIORAL|Resistance training|Participants will undergo 6 weeks of supervised resistance training
223805284|NCT04906525|OTHER|Conventional physical activity guidelines|Participants are given recommendations on physical activity guidelines
223805285|NCT01019538|OTHER|Pre-flight test with supplemental oxygen|The Hypoxia-altitude simulation test, which is established in clinical practice, is compared to the gold standard of hypobaric chamber while giving supplemental gaseous oxygen without and with oxygen conserving device, and with oxygen concentrator.
223805286|NCT02718703|DEVICE|Blood Glucose Monitoring System.|In vitro diagnostic medical device
223805287|NCT00117676|DRUG|TDF|300 mg tablet administered orally once daily
223805288|NCT00117676|DRUG|ADV|10 mg tablet administered orally once daily
223805289|NCT00117676|DRUG|TDF placebo|Tablet administered orally once daily
223805290|NCT00117676|DRUG|ADV placebo|Tablet administered orally once daily
223805291|NCT00117676|DRUG|FTC/TDF|200/300 mg fixed-dose combination (FDC) tablet administered orally once daily
223805292|NCT00952822|BIOLOGICAL|Antihemophilic factor, recombinant, manufactured protein-free (rAHF-PFM). (Antihemophilic factor is also known as Factor VIII)|Subjects are randomized to receive an infusion of rAHF-PFM reconstituted in 2 mL sterile water for infusion (SWFI) followed (after a wash-out period) by rAHF-PFM reconstituted in 5 mL SWFI or in 5 mL then 2 mL SWFI(cross-over design). Each subject will receive 2 infusions.
223805293|NCT01715974|DRUG|GM-CSF group|30 micrograms/day of GM-CSF from the day of embryo transfer through the day of beta HCG test
223805294|NCT01715974|DRUG|CONTROL|saline infusion every day from the day of embryo transfer through the day of beta HCG test
223805295|NCT02643862|DRUG|Xolair|Xolair is a monoclonal antibody approved by the FDA for asthma and chronic urticaria
223805296|NCT02643862|DRUG|Placebo|Placebo
223805297|NCT03721575|PROCEDURE|Scarpa's preserving hernio-abdominoplasty|Scarpa's fascia is preserved during hernio-abdominoplasty
223805298|NCT03721575|PROCEDURE|Classical hernio-abdominoplasty|Scarpa's fascia is removed during hernio-abdominoplasty
223805299|NCT00195026|DEVICE|Infrared Breast Scan|Patients already scheduled for breast biopsies will receive an additional infrared scan
223805300|NCT00975845|OTHER|BioCleanse Tibialis tendon|Outcomes of anterior cruciate replacement will be evaluated
223805301|NCT03264651|DRUG|enobosarm|Oral combination therapy of enobosarm and anastrozole
223805302|NCT06222216|OTHER|Chilled Needle|Before subcutaneous injection, 26G sterile disposable needles will be kept in the refrigerated compartment of the refrigerator for at least 24 hours. Immediately before SC injection, the needle will be removed from the refrigerator, placed in the ice box and placed next to the patient's bed. The needle temperature will be kept at 0-2 degrees Celsius in the ice box and controlled using an LCD digital thermometer. If Enoxaparin Sodium is in the ready injector, the drug in the injector will be drawn into the injector suitable for 1 cc SC injection application without loss of dose. The needle of the prepared syringe will be replaced with a cooled needle. Afterwards, the injection will be made in the designated area (outer side of the upper arm) in accordance with the SC injection procedure steps. After the injection, the patient's pain assessment will be made and marked on the ILC, and ecchymosis assessment will be made after 24, 48 and 72 hours.
223805303|NCT06222216|OTHER|Control Group|SC injection will be administered to the control group in accordance with the clinical routine. No different action will be applied. The injection will be made in accordance with the SC injection protocol with a needle at room temperature, without applying any tools or procedures. After the injection, the patient's pain will be evaluated and marked on the VAS, and ecchymosis will be evaluated after 24, 48 and 72 hours.
223805304|NCT04284449|OTHER|Whole-practice cognitive optimization|This intervention is a whole-practice intervention that may include nutritional assessment \& supplementation, determination of food sensitivities and dietary changes, natural products such as herbal anti-inflammatories, assessment of whole body-burden of toxicants (such as heavy metals and fungal toxins) and steps to reduce exposures, and behavioral changes such as exercise, meditation, and sleep hygiene optimization.
223805305|NCT05809206|OTHER|Glutes maximus strength protocol|"The subjects attended physical therapy two times. Per week for a total of 10 visits. Each session lasted approximately 30 minutes. In the first five sessions, subjects performed the following exercises to strengthen the gluteus maximus: bilateral bridge, unilateral bridge, and non-weight-bearing hip extension in prone with the knee flexed at 90 degrees. In the next five sessions, abduction and external rotation in a quadruped (fire hydrant exercise) and weight-bearing hip extension (known as deadlift exercise) were added. Each exercise was performed for 10 repetitions. Elastic resistance was added to the fire hydrant, hip extension in prone and dead lift exercises to allow each subject to perform at a 10-repetition maximum. The resistance for each subject was adjusted weekly as needed. The exercise program was performed under direct supervision only during the physical therapy sessions."
223805306|NCT05809206|OTHER|Gluteus medius strength program|"Strengthening exercises for Gluteus Medius subdivisions:~The anterior GMED exercise: side lying abduction exercise The middle GMED exercise: wall press Exercise The posterior GMED exercise: was the pelvic drop exercise"
223805307|NCT05809206|OTHER|Corrective Exercises|"The following low back corrective exercises were given:~To stretch the tight lower back muscles: Seated Forward Bend and Full Squat held for 5 sec and Repeated for 3 times, once a day.~To strengthen the weak lower abdomen: Draw in and Reverse Crunch 3 seconds, repeated 5 times, once a day.~To stretch the tight hip flexors: held for 10-15 seconds repeated 5 times on both legs, once a day.~To stretch the tight quadriceps: held for 3 seconds, repeated 5 times on each side, once a day.~To strengthen weak hamstrings: Kick Butts 2 sec, repeated 8 times, once a day."
223805308|NCT05809206|DEVICE|Ultrasound|US was administered in continuous mode at PSIS with patient in prone lying position, with a frequency of 1 MHz and intensity of 0.8 W/cm2 for 5 minutes every alternating day
223805309|NCT00000379|DRUG|Fluoxetine|
223805310|NCT00000379|BEHAVIORAL|EMDR|
223805311|NCT05742828|BEHAVIORAL|Virtual Seating Coach|Power wheelchair intervention
223805312|NCT02577055|PROCEDURE|myomectomy|Surgical ablation of all fibroids
223805313|NCT02577055|PROCEDURE|embolisation|Embolisation of the peri-myoma vascular network, with non-resorbable particles of \>500 µm diameter, using an ultra thin catheter introduced through the vascular network up to the uterine arteries under radioscopic control.
223805314|NCT02621580|DEVICE|Pan-Retinal Photocoagulation|"Diabetic retinopathy does not usually impair sight until the development of long-term complications, including proliferative retinopathy, a condition in which abnormal new blood vessels may rupture and bleed inside the eye. When this advanced stage of retinopathy occurs, pan-retinal photocoagulation is usually recommended.~During this procedure, a special laser is used to make tiny burns that seal the retina and stop vessels from growing and leaking. Hundreds of tiny spots of laser are placed in the retina to reduce the risk of vitreous haemorrhage and retinal detachment."
223805315|NCT03072940|OTHER|Clinical investigations|Clinical examination, motor, cognitive, autonomous, psychological, olfactory and color vision tests, and rapid eye movement sleep characterization using video-polysomnography and 3 T magnetic resonance imaging
223805316|NCT02132845|OTHER|cytology specimen collection procedure|Undergo collection of tissue and blood samples
223805317|NCT02132845|DRUG|targeted therapy|Receive target-directed therapy
223805318|NCT02132845|PROCEDURE|therapeutic procedure|Receive standard of care therapy
223805319|NCT02132845|OTHER|laboratory biomarker analysis|Correlative studies
223805320|NCT01296022|DEVICE|Implantation of subcutaneous ICD|Implantation of subcutaneous ICD
223805321|NCT01296022|DEVICE|Implantation of transvenous ICD|Implantation of transvenous ICD
223805322|NCT04332510|OTHER|Intact formula|600 ml of infant formula with intact protein
223805323|NCT04332510|OTHER|Partially hydrolyzed formula|600 ml of infant formula with partially hydrolyzed protein
223805324|NCT04332510|OTHER|High protein formula|600 ml of infant formula with high protein level
223805325|NCT04332510|OTHER|Human breast milk|600 ml of breast milk, safe for human consumption
223805326|NCT05547425|DEVICE|Blur Obfuscation|Blurring is applied to objects and people in the background of images.
223805327|NCT05547425|DEVICE|Edge Obfuscation|Objects and people in the background of images are replaced with an outline of the object.
223805328|NCT05547425|DEVICE|Cartoon Obfuscation|Blurring is applied to objects and people in the background of images and the wearer's face is concealed with cartoon faces.
223805329|NCT05547425|DEVICE|Raw images|No editing is performed on images.
223835397|NCT04895787|BEHAVIORAL|Gait + resistance exercises|Following skill-based gait training, the participants in the REX group will engage in resistance training, which will target major muscle groups important for daily activities. The resistance training will be provided with free weights or therabands at an intensity of 8-12 repetition maximum (RM). Each muscle group should be trained with 8-12 repetitions ranging from 1 to 3 sets with resting intervals provided between each set. The target RPE scale will be set between 14-17, and the training load will be progressively increased as the participants improved.
223805330|NCT03514602|BEHAVIORAL|Multicomponent behavioral intervention|Pregnant patients in the intervention group will receive multicomponent interventions consisting of education, feedback, contingent financial incentives, and peer support. At initial intervention visit, they will choose a quit date within the next 14 days and sign a no-smoking pledge and a no-smoking contract. The contract lists the intervention components, the patient's and the counselor's responsibilities, importance of keeping scheduled visits, and rules on contingent incentives. After the quit date, pregnant women will meet with counselors daily for 5 consecutive days (Monday to Friday) for abstinence monitoring in weeks 1-2. The frequency of abstinence monitoring will decrease to twice a week (Monday and Thursday) in weeks 3-8, weekly in weeks 9-12, and biweekly in weeks 13 until delivery.
223805331|NCT03514602|BEHAVIORAL|Education only control|"The control group will receive one 60-minute counseling mainly based on a pregnancy-tailored self-help booklet entitled Need Help Putting Out That Cigarette? distributed by the American College of Obstetricians and Gynecologists."
223805332|NCT00691938|DRUG|LBH589|
223805333|NCT00691938|DRUG|Decitabine|
223805334|NCT02681614|DEVICE|Uronav guided biopsy|"All biopsies will be completed in the outpatient setting in the ambulatory operating room prior to routine prostate brachytherapy under general anesthesia.~Patients will be prepped in a dorsal lithotomy position with insertion of a Foley catheter. The perineum will be shaved as needed, and cleansed with antiseptic solution, and the scrotum will be elevated with a towel roll to expose the perineum."
223805335|NCT02681614|DEVICE|Magnetic resonance imaging|An MRI (magnetic resonance imaging) is a scan that uses radio waves and a strong magnetic field to provide images of internal organs and tissues. This is not part of the study but will have been done per standard treatment. An MRI will occur at the screening visit and last visit of the study.
223805336|NCT00428558|DRUG|Chemotherapy (DAUNORUBICINE-CYTARABINE)|A Phase 3 Trial of Systematic versus Response-adapted Timed-SEQUENTIAL Induction in Patients with Core Binding Factor (CBF) Acute Myeloid Leukemia (AML)
223805337|NCT00428558|DRUG|Chemotherapy (DAUNORUBICINE-CYTARABINE)|Chemotherapy induction sequential
223805338|NCT01319799|OTHER|Open heart surgery|TCD count of microembolic signals during surgical aortic valve replacement
223805339|NCT04667299|DRUG|Rabeprazole|20mg bid
223805340|NCT04667299|DRUG|Bismuth potassium citrate|0.6g bid
223805341|NCT04667299|DRUG|Metronidazole|0.4g qid
223805342|NCT04667299|DRUG|Amoxicillin|1g bid
223805343|NCT04842578|OTHER|Cross- Section of CT Guided Anatomic Segmentectomy|The anatomic segmentectomy is base on the reading and comprehension of Cross- Section of CT.
223805344|NCT04842578|OTHER|3D simulation Guided Anatomic Segmentectomy|The anatomic segmentectomy is base on the overview of 3D simulation of pulmonary structure.
223805345|NCT00783380|BIOLOGICAL|Virosomal influenza vaccine|Influvacplus 2005/2006, Solvay Pharma AG, Bern, Switzerland Assigned to all 4 groups if immunocompromized patients
223805346|NCT00783380|BIOLOGICAL|Subunit influenza vaccine|Influvac 2005/2006, Solvay Pharma AG, Bern, Switzerland Assigned to all 4 groups if immunocompromized patients
223805347|NCT04390984|DRUG|Apatinib Mesylate, Gefitinib|Subjects will be administrated with 500mg apatinib on day 1 and day 12-15, and administrated with gefitinib on day 4-15.
223805348|NCT02003352|PROCEDURE|Functional Neurological Rehabilitation|Functional Neurological Rehabilitation Includes vestibular rehabilitation and physical rehabilitation. Vestibular rehabilitation utilizes strategies that involves movement of the head and eyes at various speeds and directions while the subject looks at a target. Physical rehabilitation involves exercises to increase mobility and increase strength.
223805349|NCT04860518|DRUG|IFN beta-1a|Treated daily with IFN beta-1a 10 μg as an IV bolus for 6 days while hospitalised
223805350|NCT04860518|DRUG|Dexamethasone|Treated daily with dexamethasone 6 mg as an IV bolus for 6 days while hospitalised
223805351|NCT00452686|BIOLOGICAL|Boostrix|
223805352|NCT00452686|BIOLOGICAL|Chinese DT vaccine|
223805353|NCT04807985|DEVICE|JVPHome and ultrasound|Remote clinician assessment of JVP height using the JVPHome, and ultrasound based assessment of JVP height in the same patients.
223805354|NCT01473693|OTHER|MRI Screening Form, MRI, Demographic / Medical Data form|"MRI Screening Form: MRI screening form will be administered twice at baseline and follow up visits. Administration time: 5 minutes. MRI data: at both time points (pre- and post-treatment only) Administration time: 30 minutes.~Demographic / Medical Data: Administration time: 5 minutes."
223805355|NCT01473693|OTHER|MRI Screening Form, MRI. Demographic / Medical Data|"MRI Screening Form: MRI screening form will be administered twice at baseline and follow up visits Administration time: 5 minutes.~MRI data: at both time points (pre- and post-treatment only) Administration time: 30 minutes.~Demographic / Medical Data: Administration time: 5 minutes"
223805356|NCT04886479|OTHER|Control|No lens
223805357|NCT04886479|DEVICE|Test Lens|Low Dk HEMA contact lens worn for 3 hours
223805358|NCT00186316|BIOLOGICAL|Idiotype-pulsed allogeneic dendritic cells|
223805359|NCT01673763|DEVICE|Stent insertion into the main pancreatic duct|Stent insertion into the main pancreatic duct
223805360|NCT05227755|DIETARY_SUPPLEMENT|Soy protein isolate|Participants will receive 120 mls of soy protein isolate (total of 20 g protein) to consume 3x/week after dialysis treatment for 4 weeks.
223805361|NCT05227755|DIETARY_SUPPLEMENT|Whey protein isolate|Participants will receive 120 mls of whey protein isolate (total of 20 g protein) to consume 3x/week after dialysis treatment for 4 weeks.
223805362|NCT03776825|DEVICE|Permacol Paste|Permacol Paste Injection
223805363|NCT01250535|DRUG|Warfarin|10 mg, po, single dose on day 7
223805364|NCT01250535|DRUG|Placebo|po, once a day, days 1 through 14
223805365|NCT01250535|DRUG|Lovastatin|40 mg, po, once a day, days 1 through 14
223805366|NCT01965782|DRUG|[^14C]-LY3023703|Administered orally
223805367|NCT02753309|DRUG|Sirolimus|
223805368|NCT05322070|DRUG|Fluocinolone Acetonide Intravitreal Implant 0.18 mg|YUTIQ® 0.18 mg as an intravitreal injection in the designated study eye.
223805369|NCT02028026|DRUG|Vilazodone|10mg/day for 1 week, 20 mg/day for 1 week, and then 40 mg/day for 6 weeks.
223805370|NCT02028026|DRUG|Citalopram|20 mg/day for 2 weeks and then 40 mg/day for 6 weeks
223805371|NCT02756754|DEVICE|Radiofrequency ablation|The radiofrequency system will be used as the RFA generator device standard cycle of ablation will be applied in the patient. During RFA, blood pressure, pulse and oxygen saturation will be continuously monitored.
223805372|NCT01534325|DEVICE|SD|"The participants in the study receive basic nutrition guidance by MD and clinical dietician and make daily use of the device under study (called SD). During the 13 weeks study period, the participants get to meet clinical dietician/MD once in every 2 weeks for guidance and supervision and for on -going monitoring of physical parameters such as body weight and waist circumference.~The use of the SD device is done by study participants during the day every day throughout the study period. The device under study can be easily used by the participants themselves in their regular environment and does not require professional assistance.~The device under study is expected to affects the satiety, energy homeostasis and metabolic control centers in the brain and by that to reduce food intake and lead to weight loss.~The device under study is a device- not a medication and not a surgical procedure, and it does not involve any of such elements."
223805373|NCT01534325|DEVICE|Control|"The participants in the Control arm of the study receive basic nutrition guidance by MD and clinical dietician and make daily use of the placebo. During the 13 weeks study period, the participants get to meet clinical dietician/MD once in every 2 weeks for guidance and supervision and for on -going monitoring of physical parameters such as body weight and waist circumference.~The use of the placebo is done by the control study participants during the day every day throughout the study period. The placebo can be easily used by the participants themselves in their regular environment and does not require professional assistance."
223805374|NCT01534325|DEVICE|SD|"The participants in the study receive basic nutrition guidance by MD and clinical dietician and make daily use of the device under study (called SD). During the 13 weeks study period, the participants get to meet clinical dietician/MD once in every 2 weeks for guidance and supervision and for on -going monitoring of physical parameters such as body weight and waist circumference.~The use of the SD device is done by study participants during the day every day throughout the study period. The device under study can be easily used by the participants themselves in their regular environment and does not require professional assistance.~The device under study is expected to affects the satiety, energy homeostasis and metabolic control centers in the brain and by that to reduce food intake and lead to weight loss.~The device under study is a device- not a medication and not a surgical procedure, and it does not involve any of such elements."
223805375|NCT04623073|PROCEDURE|Total Hip arthroplasty via a Direct Anterior Approach|Total Hip arthroplasty via a Direct Anterior Approach
223805376|NCT05003102|DRUG|Dexmedetomidine Hydrochloride - Cycling|Dexmedetomidine Hydrochloride infusion at 0.5 mcg/kg titrated to 0.3 mcg/kg/hr up to a max drip rate of 2 mcg/kg/hr.
223805377|NCT05003102|DRUG|Fentanyl - PICU Standard|fentanyl infusion at 1 mcg/kg/hr up to a max drip rate of 5 mcg/kg/hr
223805378|NCT05003102|DRUG|Dexmedetomidine Hydrochloride - PICU Standard|Dexmedetomidine Hydrochloride infusion at 0.3 mcg/kg titrated to 0.5 mcg/kg/hr up to a max drip rate of 2 mcg/kg/hr
223805379|NCT03017430|DRUG|Pregabalin|Pregabalin 600 mg a day for six-seven days along with symptomatic therapy: Doxylamin 30 mg/day, Ketorolac, Loperamide, Metoclopramide, Nefazolin and Phenazepam (benzodiazepine).
223805380|NCT03017430|DRUG|Clonidine|Clonidine 600 micrograms a day for six-seven days along with symptomatic therapy: Doxylamin 30 mg/day, Ketorolac, Loperamide, Metoclopramide, Nefazolin and Phenazepam (benzodiazepine)
223805381|NCT03017430|DRUG|Doxylamin|
223805382|NCT03017430|DRUG|Ketorolac, Loperamide, Metoclopramide, Nefazolin and Phenazepam (benzodiazepine)|
223805383|NCT04555096|DRUG|GC4419|180 Minute IV Infusion
223805384|NCT04555096|DRUG|Placebo|180 Minute IV Infusion
223805385|NCT04701463|DIETARY_SUPPLEMENT|L-glutamine, L-arginine and calcium beta-hydroxy-beta-methylbutyrate|2 daily sachets (mid morning and mid afternoon) of an oral dietary supplement with L-glutamine and L-arginine and calcium beta-hydroxy-beta-methylbutyrate
223805386|NCT04701463|COMBINATION_PRODUCT|Placebo|Isocaloric formula
223805387|NCT03951038|PROCEDURE|PCIA group|The formula of the PCIA included tramadol 800 mg, flurbiprofen axetil 100mg with saline added up to a volume of 80 ml in total. The PCIA pump was set up with a 5 ml loading dose, a 2 ml bolus dose, a 15 min lockout interval and background infusion at a rate of 1 ml/h.
223805388|NCT03951038|PROCEDURE|Lateral TLIPB group|"both sides of the spine, a single injection of ropivacaine by nerve stimulating needle under ultrasound-guided between the longissimus and iliocostalis muscles .~The regimen of Lateral TLIPB group is0.2% 20ml ropivacaine and the regimen of PCIA is same with PCIA group."
223805389|NCT00295763|DRUG|Thyrogen (thyrotropin alfa for injection)|"No reference therapy was given. All patients in this follow-up study received Thyrogen. Thyrogen 0.9 mg was administered intramuscularly (IM) in the buttock on 2 consecutive days.~For WBS and static neck imaging, each patient received 4 mCi (148 MBq) ± 0.4 mCi 131I PO."
223805390|NCT04344639|OTHER|the incidence, risk factors, treatment, prognosis of necrotizing enterocolitis in newborn infants born in newborn intensive care units in our country|With this project, which is planned as a national multicenter prospective study, the incidence of necrotizing enterocolitis in newborn infants born in newborn intensive care units in our country and the risk factors associated with the disease, especially the detailed feeding history of the patient (when the first feeding is nourished, antibiotics and other treatments that are being used). Most epidemiological data such as the most common stage of the disease, treatment, prognosis, comparison with the data of other countries will provide important information for the neonatal health of our country.
223805391|NCT04496102|DEVICE|Triathlon|Modern TKA design (Triathlon) with patellar resurfacing
223805392|NCT01250990|DRUG|Niacin|Niacin taken orally for 12 weeks at the highest tolerated dose (up to 6 grams), and at least 2 grams daily and up to the maximum approved dose. Subjects will initiate therapy with Niaspan and will advance to Niacor as tolerated.
223805393|NCT01250990|OTHER|Placebo|Placebo
223805394|NCT04995679|PROCEDURE|Implant of metaphyseal sleeves in Total knee arthroplasty|Implant of metaphyseal sleeves in Primary and revision TKA
223805395|NCT05321355|DEVICE|Implantation of vagus nerve stimulation according to clinical indication|no interventions, only observation
223805396|NCT02341001|OTHER|Daily text message of support|
223805397|NCT00004670|PROCEDURE|pallidotomy|
223805398|NCT00942617|DRUG|Aspirin|40 mg non-enteric coated ASA once daily for 21 + or - 2 days
223805399|NCT01468298|OTHER|Isostretching|All of patients were accompanied by an individual treatment program composed by 12 sessions of 45 minutes, twice a week. The Isostretching method includes therapeutic different postures, lying, sitting or standing, and the positions were selected according to the postural changes of each patient, identified in the assessment. The Isostretching protocol involves nine positions held for a period of nine breaths, and every three cycles, the patient should rest for a period. The physical therapist used verbal commands to emphasize pursed lip breathing, self growth, curvatures correction and isometric of abdominal, paravertebral, quadriceps and gluteal muscles with the aim of optimizing the stretching and discouraging compensatory movements.
223835398|NCT04895787|BEHAVIORAL|Gait + conventional physical therapy|Following skill-based gait training, the participants in the CPT group will receive conventional physical therapy, which may include stretching exercise, balance training, or practice over-ground walking based on the participant's need.
223805400|NCT01468298|OTHER|Global Posture Reeducation|All patients were accompanied by an individual treatment program composed by 12 sessions of 45 minutes, twice a week, involving a series of active gentle movements and postures aimed at realigning joints, stretching shortened muscles and enhancing the contraction of antagonist muscles, thus avoiding postural asymmetry. The positions were selected according to the postural changes of each patient, identified in the assessment and these therapeutic postures imply an active involvement of the patient. The protocol includes three therapeutic postures, lying, sitting or standing, to be held for 15 minutes each. The physical therapist used verbal commands and manual contact to maintain the alignment and make the necessary postural corrections, with the aim of discouraging compensatory movements.
223805401|NCT00046501|DRUG|Lantus (insulin glargine [rDNA origin] injection)|
223805402|NCT00046501|DRUG|Humulin N|
223805403|NCT00046501|DRUG|Humulin L|
223805404|NCT00046501|DRUG|Lispro|
223805405|NCT03814733|DRUG|Rapastinel|Participants will be administered single IV doses of rapastinel, ketamine, rapastinel matched placebo, and ketamine matched placebo, and single oral doses of alprazolam and alprazolam matched placebo in a randomized crossover manner.
223805406|NCT03814733|DRUG|Alprazolam|Participants will be administered single IV doses of rapastinel, ketamine, rapastinel matched placebo, and ketamine matched placebo, and single oral doses of alprazolam and alprazolam matched placebo in a randomized crossover manner.
223805407|NCT03814733|DRUG|Ketamine|Participants will be administered single IV doses of rapastinel, ketamine, rapastinel matched placebo, and ketamine matched placebo, and single oral doses of alprazolam and alprazolam matched placebo in a randomized crossover manner.
223805408|NCT03814733|DRUG|Rapastinel Matched Placebo|Participants will be administered single IV doses of rapastinel, ketamine, rapastinel matched placebo, and ketamine matched placebo, and single oral doses of alprazolam and alprazolam matched placebo in a randomized crossover manner.
223805409|NCT03814733|DRUG|Alprazolam Matched Placebo|Participants will be administered single IV doses of rapastinel, ketamine, rapastinel matched placebo, and ketamine matched placebo, and single oral doses of alprazolam and alprazolam matched placebo in a randomized crossover manner.
223805410|NCT03814733|DRUG|Ketamine Matched Placebo|Participants will be administered single IV doses of rapastinel, ketamine, rapastinel matched placebo, and ketamine matched placebo, and single oral doses of alprazolam and alprazolam matched placebo in a randomized crossover manner.
223805411|NCT00523159|DRUG|Endoxana, IMA901, Leukine|a single i.v. infusion of Cyclophosphamid and then patients received vaccination therapy with intradermal (i.d.) injections of GM-CSF followed by i.d. injections of IMA901
223805412|NCT00523159|DRUG|IMA901 and Leukine|Intradermal injection of GM-CSF followed by intradermal injection of IMA901
223805413|NCT05642468|DRUG|Ritivixibat|10mg tablet A3907 administered orally
223805414|NCT03641313|DRUG|Berzosertib|Given IV
223805415|NCT03641313|PROCEDURE|Computed Tomography Assisted Biopsy|Undergo CT assisted biopsy
223805416|NCT03641313|PROCEDURE|Endoscopic Biopsy|Undergo endoscopic biopsy
223805417|NCT03641313|DRUG|Irinotecan|Given IV
223805418|NCT03641313|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223805419|NCT04642898|BEHAVIORAL|Standard UP Treatment|Participants will receive treatment modules sequenced in accordance with the Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders (UP; Barlow et al 2011; 2018).
223805420|NCT04642898|BEHAVIORAL|Capitalization UP Treatment|Participants will receive Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders (UP) treatment modules organized to prioritize skills that capitalize on patient strengths.
223805421|NCT04642898|BEHAVIORAL|Compensation UP Treatment|Participants will receive Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders (UP) treatment modules organized to prioritize skills that compensate for patient weaknesses.
223835399|NCT04895787|BEHAVIORAL|Gait + rest|Following skill-based gait training, the participants will sit and rest on a chair.
223805422|NCT03574597|DRUG|Semaglutide|Semaglutide will be injected into a skin fold, in the stomach, thigh or upper arm once a week at the same day of the week (to the extent possible) throughout the trial. Subjects will start semaglutide treatment at 0.24 mg; dose will gradually be increased every 4 weeks up to 2.4 mg.
223805423|NCT03574597|DRUG|Placebo (semaglutide)|Placebo will be injected into a skin fold, in the stomach, thigh or upper arm once a week at the same day of the week (to the extent possible) throughout the trial. Participants will receive placebo at an equivalent dose to semaglutide.
223805424|NCT01952223|DRUG|Cabazitaxel|Cabazitaxel administered at 25 mg/m² as a 1 hour intravenous infusion every 3 weeks (1 cycle = 21 days) for 4 cycles
223805425|NCT01952223|RADIATION|Pelvic radiotherapy|"Prostate+pelvic RT (2 Gy fractions, 5 times per week):~* Phase 1: pelvic radiotherapy (prostate, seminal vesicles, ilio-obturator, presacral lymph nodes) (46 or 50 Gy according to the center)~* Phase 2: prostate-only boost (EBRT) up to 74-78 Gy"
223805426|NCT01952223|RADIATION|prostate radiotherapy|"Prostate-only RT (2 Gy fractions, 5 times per week):~* Phase 1: prostate + seminal vesicle radiotherapy (46 or 50 Gy according to the center)~* Phase 2: prostate-only boost (EBRT) up to 74-78 Gy"
223805427|NCT03434678|DRUG|Propofol+ Rocuronium+ Fentanyl 2 mcg/kg+ Inhalational Agent, Bupivacaine 0.125% + Fentanyl 5 mcg/ml|Patient will have their epidural started at the beginning of the surgery and receive fewer opioid drugs. The epidural is continued into the recovery room.
223805428|NCT03434678|DRUG|Propofol+ Rocuronium+ Fentanyl + Inhalational|Patient will have the standard intraoperative management during surgery and have the epidural started just before being taken to the recovery room.
223805429|NCT03434678|PROCEDURE|Open Pancreaticoduodenectomy|Whipple' Procedure
223805430|NCT04654377|OTHER|Personalised education|Patients will be explained about their disease and possible outcomes based on clinical, biochemical and imaging data.
223805431|NCT05735587|OTHER|Freeze-dried Blueberry Powder|Participants will be asked to consume 48 grams of freeze-dried blueberry powder (\~ equivalent to 2 cups of fresh blueberries) daily for 12 weeks. Participants will be asked to save any powder packet wrappers as a means to measure compliance. They will also be instructed to avoid consumption of foods/beverages that are high in anthocyanins and/or fiber.
223805432|NCT05735587|OTHER|Placebo Powder|Participants will be asked to consume 48 grams of a nutritionally matched placebo powder (that does not contain fiber or anthocyanins) daily for 12 weeks. Participants will be asked to save any powder packet wrappers as a means to measure compliance. They will also be instructed to avoid consumption of foods/beverages that are high in anthocyanins and/or fiber.
223805433|NCT03744793|DRUG|Avelumab|Given IV
223805434|NCT03744793|DRUG|Pemetrexed|Given IV
223805435|NCT00994981|DRUG|magnesium|Thirty minutes after the beginning of the anhepatic phase, the patients were received a magnesium solution (MgSO4 25 mg•kg-1 mixed in 100 ml of normal saline) over 20 minutes. A resident anesthesiologist, who was blinded to the group assignment, performed intravenous administration of the study solution and assessed study outcomes.
223805436|NCT00994981|DRUG|normal saline|Thirty minutes after the beginning of the anhepatic phase, the patients were received 100 ml of normal saline over 20 minutes. A resident anesthesiologist, who was blinded to the group assignment, performed intravenous administration of the study solution and assessed study outcomes.
223805437|NCT06462508|DRUG|[18F]F-PSMA-N5|Each subject receive a single intravenous injection of \[18F\]F-PSMA-N5, and undergo PET/CT imaging within the specificed time.
223805438|NCT06462508|DRUG|[68Ga]Ga-PSMA-11|Each subject receive a single intravenous injection of \[68Ga\]Ga-PSMA-11, and undergo PET/CT imaging within the specificed time.
223805439|NCT06017024|DEVICE|microprocessor-controlled knee (MPK) assessment|The subject will wear the microprocessor-controlled knee prosthesis for 4 weeks, and then reply questionnaires and achieve functional tests
223805440|NCT01446081|BEHAVIORAL|Exercise|Patients will receive an individualized, supervised mixed-modality exercise program created by a CSEP-Certified Exercise Physiologist (CEP). They will perform 30 minutes of light to moderate intensity exercise 4-5 times/week tailored to ability. Aerobic exercise will primarily consist of walking and/or stationary cycling. Resistance exercises will target large muscle groups using dumbbells, resistance bands, and stability balls. The CEP will monitor and document details of each exercise session as well as patient tolerance and symptoms, and make appropriate adaptations to ensure program safety and progression. Exercise intensity and duration will vary based on patient tolerance, symptoms and blood parameters. Exercise equipment will be carefully sanitized between each use.
223805441|NCT03798938|OTHER|plant-based diet|subjects will be placed in plant-based diet and the effect of plant-based diet to the endothelial function will be monitored
223805442|NCT06060457|BIOLOGICAL|Placebo|0.9% sodium chloride (normal saline) injection
223805443|NCT06060457|BIOLOGICAL|mRNA-1345|Suspension for injection
223805444|NCT06060457|BIOLOGICAL|Fluzone HD|Suspension for injection
223805445|NCT03468010|RADIATION|chemoradiation|radiation with concurrent ciplatin
223805446|NCT03468010|DRUG|Paclitaxel, Cisplatin|The regimen of additional adjuvant chemotherapy following radiation is Paclitaxel, Cisplatin once 3 weeks.
223805447|NCT06220955|OTHER|centric relation registration|centric relation registration using conventional and digital methods
223805448|NCT06220955|OTHER|maximum intercuspation registration|maximum intercuspation registration
223805449|NCT01743079|DRUG|Telbivudine|LdT 600mg QD
223805450|NCT01743079|DRUG|Lamivudine|LAM 100mg QD
223805451|NCT03755830|OTHER|Skin biopsy|Two skin biopsies (lesional and non-lesional) will be taken from every patient. Also a skin biopsy will be taken from each control subject.
223805452|NCT02061202|DRUG|Mometasone Furoate|inhaled cortico-steroid (ICS) with a dosage of 220mcg once daily for 16 weeks
223805453|NCT02061202|DRUG|Placebo|placebo training inhaler with the same instructions as the experimental group.
223805454|NCT03224013|PROCEDURE|LASIK|LASIK with concurrent prophylactic high fluence crosslinking in right eye ( After the excimer laser ablation, and with the flap folded onto itself and protected with a dry sponge, one drop of Vibex Rapid™ , consisting of 0.10% saline-diluted riboflavin (a very slightly hypotonic solution, mixed with hydroxypropyl methylcellulose, a dextran substitute), was placed on the exposed stromal bed afforded by the open LASIK flap and carefully spread over the bed area with an irrigating cannula for 60 seconds and LASIK only in left eye
223805455|NCT04832828|DIAGNOSTIC_TEST|Roth´s Test|Subjets must count from 1 to 30 in their languages, and health professional will count seconds that last in take breath during the count.
223805456|NCT01533493|DRUG|Placebo|Memantine-matched placebo will be prescribed following approved FDA dosing guidelines for Alzheimer's dementia, beginning at 5mg in AM and increasing in BID doses by 5mg weekly to a maximum dose of 10mg BID.
223805457|NCT01533493|DRUG|Memantine Hydrochloride|Memantine will be prescribed following approved FDA dosing guidelines for Alzheimer's dementia, beginning at 5mg in AM and increasing in BID doses by 5mg weekly to a maximum dose of 10mg BID.
223805458|NCT01533493|DRUG|OROS-Methylphenidate|OROS-Methylphenidate will be openly prescribed, starting with an initial dose of 36mg/day and titrated to optimal response to a maximum daily dose of 1.3mg/kg or 108mg/day, whichever is lower, according to clinician judgment. During titration, dose will be increased on a weekly basis in 36mg/day increments. The dose may be reduced by 18 or 36mg/day increments if adverse effects occur or if the subject discontinues treatment.
223805459|NCT04803981|OTHER|SpoonfulONE|SpoonfulONE is a line of nutritional food products designed to help improve diet diversity starting in early infancy. SpoonfulONE covers a wide range of food proteins. Each product contains 30 mg of peanuts, milk, shellfish (shrimp), tree nuts (almond, cashew, hazelnut, pecan, pistachio, and walnut), egg, fish (cod and salmon), grains (wheat and oat), soy, and sesame.
223805460|NCT03509740|DRUG|tramadol|100 mg tramadol in 100 ml saline with slow infusion
223805461|NCT03509740|DRUG|paracetamol|Intravenous 1 gm paracetamol in 100 ml saline with slow infusion
223805462|NCT01528384|DRUG|ADI-PEG 20|4.5, 9 and 18 mg/m2 dosage weekly dosing intramuscular until progressive disease
223805463|NCT02433743|DIETARY_SUPPLEMENT|Ready-to-use therapeutic food (RUTF)|HIV-infected patients were randomly allocated to receive standard hospital diet (Control: n=33), or this diet combined with 100 g/day of RUTF (RUTF: n=32). All patients was follow-up during hospitalisation and 9 week after discharge at home
223805464|NCT01136122|DEVICE|CPAP Treatment|Effective CPAP treatment for one month
223805465|NCT01992679|BEHAVIORAL|Exercise group|The BWSTT program will consist of biweekly training sessions for 20 weeks. Per neurorecovery network guidelines, each training session will include a minimum of 20 minutes of locomotor training and 20 minutes of balance training. Training will take place on a Therastride which consists of a treadmill with an air pressure powered pulley system connected to a harness system. The locomotor training strategy focuses on proper gait mechanics, including weight bearing, shifting and maintaining body positioning. Manipulating the participant's legs is done in such a way as to provide appropriate sensory-motor cues that facilitate the development and refinement of walking pattern.
223805466|NCT02863484|OTHER|surgery|pealing of the outer layer of the cavernous sinus
223805467|NCT06239870|DRUG|Envafolimab combined with chemoradiotherapy in the whole course of neoadjuvant therapy|Each enrolled patient was given 2 cycles of induction chemotherapy combined with immunization, followed by immunization combined with chemoradiotherapy, and finally 2 cycles of consolidation chemotherapy combined immunization
223805468|NCT00525525|DRUG|Bevacizumab|Patients are given 10 mg/kg IV Q2 weeks.
223805469|NCT00525525|DRUG|Tarceva|Patients receive 150 mg PO daily. If patients are not experiencing intolerable toxicity, they may escalate their dose to 200 mg PO daily. If patients are experiencing intolerable toxicity, their dose will be held until the toxicity improves or resolves, then re-treated at a lower dose level, i.e. 100 mg PO daily.
223805470|NCT00525525|DRUG|Temozolomide|Patients receive 200 mg/m2 for Days 1-5 of every 28 day cycle. Although the calendar days may be slightly altered, the patient should always receive this dose for 5 days within a treatment cycle. If the patient experiences certain toxicities specified in the protocol, Temodar will be held then given at a reduced dose, i.e. 150 mg/m2 Days 1-5.
223805471|NCT06350253|DIAGNOSTIC_TEST|Metabolic cart|RMR measurement via metabolic cart
223805472|NCT06350253|DIAGNOSTIC_TEST|MedGem|RMR measurement via MedGem
223805473|NCT06350253|DIAGNOSTIC_TEST|BIA|RMR estimation from BIA analysis
223805474|NCT05163522|DRUG|VH4004280|VH4004280 will be administered.
223805475|NCT05163522|DRUG|Placebo|Placebo will be administered.
223805476|NCT05163522|DRUG|Midazolam|Midazolam will be administered
223805477|NCT05019261|OTHER|Multi-component Family Support Intervention|The multi-component intervention is designed to enhance the quality of clinician-family communication and help families manage the emotional and cognitive complexities of surrogate decision-making. It involves: 1) proactive clinician-family meetings; 2) use by surrogates of an interactive web-based tool throughout the ICU stay which is narrated by family members of ICU patients and includes stories and experiences from other families, self-care strategies, brief videos explaining what to expect during family meetings, a question prompt list, an interactive values clarification exercise, and an explanation of different treatment pathways for critically ill patients. 3. Prior to the proactive family meetings, the ICU team is provided with a summary of the family's main questions/concerns, their prognostic expectations, a summary of the patient's values and preferences, and surrogates' current ratings of the extent to which their psychosocial needs are being addressed in the ICU.
223805478|NCT05365490|PROCEDURE|Transcarotid Artery Revascularization (TCAR)|Carotid artery revascularization treated with the FDA-cleared ENROUTE Transcarotid NPS in conjunction with the FDA-approved ENROUTE Transcarotid Stent
223805479|NCT01853891|OTHER|dim light at night|
223805480|NCT05994703|DRUG|d-cycloserine|d-cycloserine (DCS) 100 mg taken orally, once a day for six weeks.
223805481|NCT05994703|OTHER|Juul e-cigarette|Juul use as often as the participant likes for 12 weeks.
223805482|NCT05094466|BEHAVIORAL|Behavioral Intervention|Receive peer support sessions
223805483|NCT05094466|OTHER|Counseling|Receive health coaching sessions
223805484|NCT05094466|PROCEDURE|Discussion|Attend focus groups
223805485|NCT05094466|OTHER|Educational Intervention|Receive handbook
223805486|NCT05094466|OTHER|Informational Intervention|Receive navigation sessions
223805487|NCT05094466|OTHER|Interview|Participate in interview
223805488|NCT04532606|DRUG|Remimazolam|Remimazolam is administered intravenously for anesthesia induction and maintenance. The dose and infusion rate is adjusted to maintain BIS value between 40 and 60. Analgesia is maintained with remifentanil and/or sufentanil. Muscle relaxation is maintained with rocuronium and/or cisatracurium. Sevoflurane inhalation is provided when considered necessary.
223805489|NCT04532606|DRUG|Propofol|Propofol is administered intravenously for anesthesia induction and maintenance. The dose and infusion rate is adjusted to maintain BIS value between 40 and 60. Analgesia is maintained with remifentanil and/or sufentanil. Muscle relaxation is maintained with rocuronium and/or cisatracurium. Sevoflurane is provided when considered necessary.
223805490|NCT06492278|BEHAVIORAL|SMART-3RP|The adapted program incorporates the three prongs of the 3RP: RR elicitation, stress awareness, and adaptive strategies.
223805491|NCT06492278|BEHAVIORAL|Health Education Program|This is a multiple behavior change program that addresses sleep, exercise, nutrition, substance use, and working with one's healthcare team.
223805492|NCT06058624|BEHAVIORAL|Veteran ACT for Chronic Pain (VACT-CP)|"Participants receive 7 online modules, provided as weekly sessions that feature Coach Anne as a virtual, animated treatment guide. All content is presented interactively, through text-based conversations with Coach Anne. Veterans will hear what Coach Anne says and respond to her using text-based dialogue options that will trigger different responses from Coach Anne as the conversation progresses, to allow the system to responsively interact in a personalized manner with the Veteran. Veterans will also be presented with videos (e.g., Veteran narratives, metaphors), in-module assessments (e.g., values assessments), and interactive opportunities for goal setting."
223805493|NCT06058624|BEHAVIORAL|Online Pain School|"Participants will receive 7 modules (15 to 20 minutes each) of content based on a common non-ACT based VA treatment option, Pain School. The adaptation used for this study, Online Pain School, will support Veterans' self-management of their chronic pain by providing informational videos on chronic pain and its health impacts, short behavioral exercises to help with pain management, and psychoeducation on different wellness techniques for their pain management toolbox."
223805494|NCT00030693|BIOLOGICAL|recombinant fowlpox-B7.1 vaccine|Given intratumorally
223805495|NCT00030693|BIOLOGICAL|recombinant fowlpox-TRICOM vaccine|Given intratumorally
223805496|NCT00030693|OTHER|laboratory biomarker analysis|Correlative studies
223805497|NCT00030693|PROCEDURE|quality-of-life assessment|Ancillary studies
223805498|NCT01124760|DRUG|AZD9742|Sterile solution, 620 mg (20 mg/mL) in 50 mL vial with a fill volume of 31 mL; On Day 7, a single 150 mg IV dose, coadministered after the morning dose of ketoconazole
223805499|NCT01124760|DRUG|Diltiazem|Orally, daily beginning on Day 4 for 14 consecutive days
223805500|NCT01124760|DRUG|ketoconazole|200 mg, orally, every 12 hours starting on Day 4 for 10 consecutive days in which on Day 13 only the morning dose will be administered
223805501|NCT04732455|DRUG|Lidocaine in Saline|Lidocaine IV infusion (2 mg/kg) in 200 ml saline over forty minutes with a maximum upper limit of 200 mg pre each chemotherapy session until end of the cycle.
223805502|NCT04732455|DRUG|Duloxetine 30 MG|Oral Duloxetine tablet 30 mg once per day starting from the night pre chemotherapy during the whole period of chemotherapy cycle which expected to be three month
223805503|NCT04732455|DRUG|Normal saline|200 ml normal saline over forty minutes pre each chemotherapy session until end of the cycle.
223805504|NCT00100451|PROCEDURE|exercise|
223805505|NCT02660827|DEVICE|Insulin Pump|Closed Loop Algorithm
223805506|NCT01792180|BEHAVIORAL|Mobility feedback device with use of instruction book|Weekly use of the mobility feedback device to measure gait speed. Two infrared sensors will be placed in the line of walking, a photo frame containing a display, symbols and lights will tell the participant when and how to perform the test. Gait speed is shown on the display and will serve as feedback to the participant. Participant can use their gait speed to decide which exercises from the instruction book he performs. Participants will be asked to keep an activity diary.
223805507|NCT01833338|DEVICE|Imaging|All patients undergo non-invasive (MSCT) and invasive (IVUS, OCT) imaging
223805508|NCT03071055|DRUG|Ranibizumab Injection [Lucentis]|intravitreal injection
223805509|NCT02679261|DRUG|Atorvastatin|Oral administration atorvastatin 20 mg per day
223805510|NCT02679261|DRUG|Placebo|Oral administration placebo
223805511|NCT05938985|DIAGNOSTIC_TEST|Questionnaires and dry eye tests|Ocular Surface Disease Index (OSDI), National Eye Institute Visual Functioning Questionnaire (NEI VFQ-25), best visual acuity (BCVA) measuring, intraocular pressure, corneal fluorescein staining, lissamine green staining, Schirmer test type I and II, tear breakup time (TBUT) and noninvasive tear breakup time (NIBUT).
223805512|NCT02373800|DEVICE|Cervical ultrasound with elastography|Following routine vaginal exam with determination of Bishop's score, cervical ultrasound with elastography will be used to determine a cervical hardness score varying from 1 to 10. Patients are then hospitalized and labor induced 12 to 48 hours after the elastography.
223805513|NCT01832428|OTHER|Intra thecal transplantation of Autologous Stem Cells|Intra thecal transplantation of Autologous Stem Cells
223805514|NCT00520858|OTHER|Resistance Exercise (RE)|
223805515|NCT00520858|OTHER|Aerobic Exercise (AE)|
223805516|NCT00520858|OTHER|Resistance and Aerobic Exercise (RAE)|
223805517|NCT01647490|PROCEDURE|Permanent Cardiac Pacemaker Implantation|
223805518|NCT05566600|BIOLOGICAL|Human (allogeneic) iPS-cell-derived cardiomyocyte|10-20 epicardial injections (0.25 mL each) of iPSC-CMs will be delivered in the border zone of the infarcted myocardium
223805519|NCT02336334|DEVICE|Positioning measurement|Logging of posturing informations
223805520|NCT02336334|DEVICE|Patient feedback|Evaluation of patients questionary
223805521|NCT02336334|PROCEDURE|Usefulness of a sketch|Helping the patients to understand posturing positions by randomized allocation of sketches
223805522|NCT02336334|DEVICE|Closure rate of macular holes|closure rates of macular holes in the group with macular holes. Measurement using SD-OCT (spectral domain optical coherence tomography=
223805523|NCT02953938|BIOLOGICAL|Ranibizumab|"Ranibizumab is a biologic and known anti-VEGF (vascular endothelial growth factor) medication approved for treatment of ME (Macular Edema) due to RVO (Retinal Vein occlusion)~0.5 mg ranibizumab applied one + PRN as intravitreal injection of 0.05 mL, with or without laser treatment"
223805524|NCT02953938|RADIATION|Grid&Direct short pulse laser photocoagulation|Grid\&Direct short pulse laser photocoagulation is a kind of laser treatment to retina within vascular arcades and used to suppress macular edema
223805525|NCT00611000|DIETARY_SUPPLEMENT|folic acid|
223805526|NCT00611000|GENETIC|DNA methylation analysis|
223805527|NCT00611000|GENETIC|gene expression analysis|
223805528|NCT00611000|GENETIC|microarray analysis|
223805529|NCT00611000|GENETIC|polymorphism analysis|
223805530|NCT00611000|OTHER|laboratory biomarker analysis|
223805531|NCT05735574|OTHER|IPG infections|Infected IPGs
223805532|NCT04137692|OTHER|Red Blood Cell Transfusion|The procedure will be performed as an outpatient according to protocols established for sickle cell anemia patients. Two IVs are placed for the purposes of transfusion, one for draw and one for return. Patients will undergo isovolemic hemodilution-red cell exchange (IHD- RBCx) with up to 10 units of red cell antigens (Rh group, Kell, Duffy, Kidd blood group antigens) matched normal donor red cells to replace a target of 70% of the patient's red cells with donor red cells.Total time of procedure: approximately 150 minutes.
223805533|NCT02142933|OTHER|vagino-perineal swab|
223805534|NCT01220700|OTHER|Triclosane|Triclosane coated suture material
223805535|NCT01220700|OTHER|Control|Ordinary suture material
223805536|NCT05810168|OTHER|Dietary modifications|TDA and low FODMAP diet
223805537|NCT01903850|DEVICE|spray cryotherapy|spray cryotherapy
223805538|NCT02038894|DRUG|Intubated with Sevoflurane (IS)|Anesthesia will be maintained with sevoflurane 3% in oxygen at 2 L/min. The endoscopist will begin the procedure. The sevoflurane inspired concentration will be adjusted between 1 to 2 times the minimum alveolar concentration (MAC) by the attending anesthesiologist to maintain an appropriate level of anesthesia.
223805539|NCT02038894|DRUG|Intubated with Propofol (IP)|Anesthetic maintenance will be with 2 L/min flow of oxygen through the endotracheal tube and a continuous propofol infusion at a rate of 250 mcg/kg/min. A maximum of two bolus doses of propofol 0.5 to 1 mg/kg and an increase in the continuous infusion to 300 mcg/kg/min may be given at the discretion of the anesthetist if necessary to provide adequate anesthesia.
223805540|NCT02038894|DRUG|Zofran - no intubation|A nasal cannula will be placed with oxygen administered at a rate of 3 L/min, and a bite block will be inserted. Zofran will be administered. Anesthesia will be maintained with a continuous propofol infusion at a rate of 250 mcg/kg/min. A maximum of two bolus doses of propofol 0.5 to 1 mg/kg, and an increase of the continuous infusion to 300 mcg/kg/min may be given at the discretion of the anesthetist.
223805541|NCT02038894|DRUG|Propofol|
223805542|NCT00262587|DRUG|Seretide|Combination of inhaled corticosteroids (250 microgr) and inhaled long-acting beta2-agonists (25 microgr)
223805543|NCT00262587|DRUG|Placebo|Inhaled sugar powder in a placebo inhaler
223805544|NCT01492023|BEHAVIORAL|neuropsychological rehabilitation|attention retraining and teaching compensatory strategies as well as offering psychological support to better cope with cognitive impairments (13 times 60 minutes, once per week during 13 weeks)
223805545|NCT05828966|DRUG|human chorionic gonadotropin (hCG)|H.C.G. will be given in Group A and in a dose of 5000units intramuscular injection followed by a drip of 10,000 units in 500ml of dextrose 5%, at the rate of 20 drops per minute.
223805546|NCT05828966|DRUG|Magnesium sulfate|4gm of MgSO4 will be given in Group B as intravenously as continuous dose followed by 2gm/hr till uterine quiescence is achieved.
223805547|NCT03613675|DEVICE|Video games|"The 4 videos games consists of:~* Asthmonaut, a desktop game in which the child navigates through different scenarios and interacts with nine characters to learn about asthma symptoms and management (30 minutes)~* Lung Launcher, a mobile game in which the character encounters different asthma triggers (customizable to the child) and the child has to find the correct preventive method to address each trigger (4 minutes)~* Asthma Heroes, a desktop game where the player interacts with several characters to learn about their symptoms, treatment and context, and collects objects to help them manage their asthma (30 minutes)~* Bloïd, a mobile game where the player uses a pressure sensor as an input device to guide a spacecraft and destroy meteorites in its path (4 minutes)."
223805548|NCT03381755|DRUG|half-dose ticagrelor|To observe the effectiveness and safety of ticagrelor 45mg bidpo. in Chinese ACS patients undergoing PCI.
223805549|NCT03381755|DRUG|standard-dose ticagrelor|To observe the effectiveness and safety of ticagrelor 90mg bidpo. in Chinese ACS patients undergoing PCI.
223805550|NCT00665574|OTHER|ActaVisc and ActaVisc Mx Intra-articular Injection|ActaVisc is a hyaluronan based device intended to alleviate the pain associated with osteoarthritis of the knee with a single injection and ActaVisc Mx is the same material combined with a corticosteroid.
223805551|NCT00549588|OTHER|After-sun-lotion with DNA repair enzymes|2 mg/cm2 immediately after UV exposure
223805552|NCT00549588|OTHER|SPF30 sunscreen|2 mg/cm2 2o min before UV exposure
223805553|NCT00549588|OTHER|Placebo after-sun-lotion|2mg/cm2 immediately after UV exposure
223805554|NCT00549588|OTHER|Intervention: none (only UV)|
223805555|NCT02980055|PROCEDURE|collagen matrix|Surgical procedure for root coverage using collagen matrix
223805556|NCT02980055|PROCEDURE|connective tissue graft|Surgical procedure for root coverage using connective tissue graft
223805557|NCT04920864|DEVICE|rTMS|Repetitive transcranial magnetic stimulation
223805558|NCT00365443|BIOLOGICAL|V502|
223805559|NCT02395939|PROCEDURE|CT guided core biopsy|CT guided biopsy will be performed by a trained interventional radiologist using core biopsy.
223805560|NCT02395939|PROCEDURE|Cryo-biopsy via Radial EBUS navigation|Cryo-biopsy will be performed via R-EBUS guidance. Cryo biopsy probe will be applied for 4 seconds for each biopsy and a minimum of 3 biopsies will be performed . Each patient will also have 3 forceps biopsies. The order of forceps biopsy or cryo biopsy will be randomly allocated.
223805561|NCT06442150|COMBINATION_PRODUCT|Low-Calorie Medicine Diet|Low-Calorie Medicine Diet meals which are 815-835 kcal/day (approximately 43% carbohydrate, 29% protein, and 29% fat), combined with physical activity.
223805562|NCT06442150|COMBINATION_PRODUCT|Low-Calorie Diet|Low-Calorie Diet meals which are 815-835 kcal/day (approximately 43% carbohydrate, 29% protein, and 29% fat), combined with physical activity.
223805563|NCT02275676|OTHER|bioelectrical impedance analysis|
223805564|NCT02275676|OTHER|indirect calorimetry|
223805565|NCT05917795|PROCEDURE|Endoscopic Sleeve Gastroplasty (ESG)|ESG will be performed under general anaesthesia with orotracheal intubation. The Endomina® suturing system (EndoTools Therapeutics S.A., Gosselies, Belgium) mounted on a single channel endoscope (GIF-H190/GIF-HQ190; Olympus Medical Systems Corp., Tokyo, Japan) will be used. This system allows to obtain full thickness gastric sutures through the gastric wall of the gastric body, leaving the antrum and the gastric fundus free. The ESG starts with the reduction of the gastric body, suturing from distal to proximal and starting from the notch of the angulus and ending at the level of the fundus. 4-8 full thickness stitches will be placed, with 2 passes per stitch. The final effect of ESG is the creation of a gastric tubule thus reducing the volume of the stomach. After the procedure, the final shape will be evaluated, to examine any gaps that would require additional closure, and to exclude bleedings and/or other complications.
223805566|NCT00313820|DRUG|Pregabalin|Eligible subjects with post-stroke central pain will be randomized to receive double blinded treatment using pregabalin or matched placebo. The effects of pregabalin as compared to placebo on pain pain symptoms will be compared over the 13 week clinical trial. At baseline following pain ratings and clinical measures, subjects randomized to pregabalin receive instructions to take 75mg twice a day for 7days. The dosing of pregabalin or matching placebo will be titrated over the first 4 weeks (based on tolerability and pain scores). (Range 150-600mg) After the 4th week, the dose of medication will be maintained until week 12 (when tapering of medication begins) Ratings of Pain severity, review of pain/sleep diaries as well as medication tolerance occur bi-weekly throughout the study. Tapering off med occurs from week 12-13.
223805567|NCT00313820|DRUG|Placebo|Eligible subjects with post-stroke central pain will be randomized to receive double blinded treatment using pregabalin or matched placebo. The effects of pregabalin as compared to placebo on pain pain symptoms will be compared over the 13 week clinical trial. At baseline following pain ratings and clinical measures, subjects randomized to pregabalin receive instructions to take 75mg twice a day for 7days. The dosing of pregabalin or matching placebo will be titrated over the first 4 weeks (based on tolerability and pain scores). (Range 150-600mg) After the 4th week, the dose of medication will be maintained until week 12 (when tapering of medication begins) Ratings of Pain severity, review of pain/sleep diaries as well as medication tolerance occur bi-weekly throughout the study. Tapering off med occurs from week 12-13.
223805568|NCT00336674|BIOLOGICAL|Intranasal insulin|440IU Insulin
223805569|NCT00336674|OTHER|Placebo|Placebo insulin carrier solution containing benzalkonium chloride and glycerol
223805570|NCT04072094|PROCEDURE|Minimally Invasive Locking Plate Fixation|Patients randomized to the Minimally Invasive Locking Plate Fixation arm will be treated with plate fixation. The plate may be applied in a percutaneous fashion. Any combination of locked and/or non-locked screws may be used.
223805571|NCT04072094|PROCEDURE|Intramedullary Nail Fixation|Patients randomized to the Intramedullary Nail Fixation arm will be receive a standard locked intramedullary nail fixation. The nail must use at least one static interlock proximal to and one static interlock distal to the fracture site. The nail may be placed with a reamed technique.
223805572|NCT00211705|BEHAVIORAL|Diet|
223805573|NCT00211705|DRUG|Diet+pravastatin|
223805574|NCT01952626|DRUG|Ondansetron|intravenous injection
223805575|NCT01952626|DRUG|Palonosetron|intravenous injection
223805576|NCT00522626|DEVICE|Maternal fetal monitoring|Simultaneous monitoring of maternal and fetal physiology
223805577|NCT03295487|PROCEDURE|TVT-O|transobturator tape has been applied to all the patients in the study,and local estrogen vaginal cream is only applied to patients in group A
223805578|NCT00147680|DRUG|Paclitaxel, Carboplatin|
223805579|NCT05437081|BEHAVIORAL|Latino Emerging Adults (LEA)|The LEA program involves two components, one for emerging adults (aged 18-23 years old) focused on identity development linked to cultural and familial strengths, and a parent component focused on support for emerging adult children. Each session is 4 sessions.
223805580|NCT04848428|BEHAVIORAL|Online mindfulness-based cognitive therapy|The first session will first focus on providing feedback regarding post-surgical pain. The second session will focus on teaching mindfulness strategies. The third session will focus on practicing one of the two strategies. Of note, sessions 2 and 3 will start with cognitive restructuring strategies for the moderate-high risk profile patients. The 4th session consists in a booster providing feedback and reminders about cognitive reactions to pain and mindfulness meditation. The participants will be asked to practice meditation 5 days a week, for a total of 4 weeks
223805581|NCT04848428|BEHAVIORAL|Online standardized education|One 15-minute educational session on postoperative pain, the relationship between pain, thoughts and emotions and brief overview of strategies.
223805582|NCT06184672|OTHER|dry needling|"the area is disinfected by the use of 0.5% chlorhexidine digluconate alcohol solution. The physiotherapist in charge of the intervention uses sterile nitrile gloves, using dry needling needles with dimensions of 0.30 x 50 mm is used. This technique, designed by Hong, applies speed both at the entrance, in order to provoke the local spasm response and at the exit. The inputs and outputs are performed until the REL disappears or until the tolerance threshold of the patient is reached.~Immediately after performing the puncture, ischemic compression is performed on the treated muscle, in order to decrease the duration and intensity of post-puncture pain. For this, a digital pressure is made to the point where the patient's sensation ceases to be pressure and becomes pain. Once the patient is noted that pain is repeated again the art up to a total of 2 minutes"
223805583|NCT03479697|DEVICE|HIRREM|Technology
223805584|NCT03479697|OTHER|Continued Current Care|Continue their current clinical care.
223805585|NCT04560491|DIAGNOSTIC_TEST|Intraoperative examination of sentinel node|Intraoperative examination of sentinel node by either frozen section or scrape cytology to detect metastasis and decide for further lymphadenectomy.
223805586|NCT00553930|DRUG|Pegylated interferon alfa-2a and Ribavirin|All patients will be treated with the combination of pegIFN-α 2a (135 μg per week)plus oral Ribavirin at a dose of 800 mg per day. The treatment will be continued up to 20 weeks after reaching an undetectable plasma RNA-HCV. Treatment will be discontinued for patients who did not achieve a reduction of al least 2 log10 IU/ml in plasma HCV RNA levels with respect to baseline at week 12 and will be considered as viral failures.
223805587|NCT00553930|DRUG|Pegylated interferon alfa 2a and Ribavirin|Pegylated interferon alfa 2a (135 ug/week)and Ribavirin (800 mg/day). Duration: 20 weeks after reaching an undetectable plasma RNA\_HCV. Treatment will be discontinued for patients who did not achieve a decrease of \>= 2 log10 IU/ml in plasma HCV RNA levels with respect to baseline at week 12 of treatment or earlier and will be considered as viral failures.
223805588|NCT00066482|BIOLOGICAL|bleomycin sulfate|Given IV over 10 minutes. Children ≥ 12 months: 15 units/m2/dose Children \< 12 months: 0.5 units/kg/dose Day 1 (Week 1, 4, 7, 10)
223805589|NCT00066482|BIOLOGICAL|filgrastim|Given SQ once daily 5 micrograms/kg/dose Starting on Day 6 (Week 1, 4, 7, 10) Daily until ANC \> 5,000/uL
223805590|NCT00066482|DRUG|cisplatin|Children ≥ 12 months: Given IV over one hour Dose: 20 mg/m2/dose Days 1-5 (Week 1,4,7,10) Children \< 12 months: Given IV over 4 hours, 0.67 mg/kg/dose Days 1-5 (Week 1,4,7,10)
223805591|NCT00066482|DRUG|cyclophosphamide|Given IV over 1 hour. Children ≥ 12 months: Level 1: 1.2 g/m2/dose Level 2: 1.8 g/m2/dose Level 3: 2.4 g/m2/dose Children \< 12 months: Level 1: 40 mg/kg/dose Level 2: 60 mg/kg/dose Level 3: 80 mg/kg/dose Day 1 (Week 1, 4, 7, 10)
223805592|NCT00066482|DRUG|etoposide|Given IV over 1 hour. Children ≥ 12 months: 100 mg/m2/dose Children \< 12 months: 3.3 mg/kg/dose Day 1-5 (Week 1, 4, 7, 10)
223805593|NCT00066482|PROCEDURE|conventional surgery|Stage III/IV extragonadal tumors: biopsy followed by a definitive surgical excision after maximal chemotherapy effect, likely after 4 cycles of therapy
223805594|NCT00066482|BIOLOGICAL|MESNA|Given IV or oral. The total daily MESNA dose is equal to at least 80% of the daily CPM dose. The oral dose of MESNA is 2x the IV dose. Day 1 (Week 1,4,7,10) To be given with CPM.
223805595|NCT04697277|DRUG|Antibiotic prophylaxis timing (before skin incision and after cord clamping) for caesarean section|
223805596|NCT05941130|DRUG|Combination of corticosteroid (methylprednisolone - Medrol, 16mg Pfizer Laboratories) therapy and non-steroidal anti-inflammatory (Ibuprofen 600mg Mylan) therapy|"Facial swelling assessment with a tridimensional method, pain and patient's quality of life will be evaluated after impacted third molar surgery, when NSAID are prescribed either alone (group A) or in combination with a corticosteroid (group B).Patients will be randomized before surgery into two groups regarding postoperative anti-inflammatory prescription.~Half will receive postoperative steroid anti-inflammatory"
223805597|NCT05941130|DRUG|Non-steroidal anti-inflammatory therapy (Ibuprofen 600mg Mylan)|"Facial swelling assessment with a tridimensional method, pain and patient's quality of life will be evaluated after impacted third molar surgery, when NSAID are prescribed either alone (group A) or in combination with a corticosteroid (group B).Patients will be randomized before surgery into two groups regarding postoperative anti-inflammatory prescription.~Half will receive postoperative non-steroid anti-inflammatory"
223805598|NCT04503525|OTHER|Nutritional assessment|Nutritional assessment in COVID patients
223805599|NCT06328530|OTHER|Cowhage|25 spicules will be inserted in the center of the predefined skin area on the mandibular area. The spicules will be gently rubbed for 15-20 seconds in circular motion to facilitate epidermal penetration.
223805600|NCT06328530|OTHER|Histamine|Histaminergic itch will be evoked by a 1% histamine solution. A droplet of histamine solution will be placed on the predetermined area on the forearm, and the SPT lancet will be pierced through the histamine with 120 g of pressure for 1-2 seconds.
223805601|NCT01534026|DRUG|Aspirin|Current dose
223805602|NCT01534026|OTHER|withdrawal of aspirin|Stopping current dose of aspirin
223805603|NCT00413270|DRUG|nilotinib|
223805604|NCT02317926|DRUG|Levothyroxine|
223805605|NCT02317926|DRUG|Levothyroxine Plus Liothyronine|
223805606|NCT02317926|DRUG|Desiccated Thyroid Extract|
223805607|NCT02432872|DRUG|Daunorubicin|defferent doses of daunorubicin,that is 60mg/m2 for 3 doses compared with 45mg/m2 for 3 doses
223805608|NCT02432872|DRUG|Cytarabine|medium dosage cytarabine（1 g/m2 q12h for 3 days) compared with standard dosage cytarabine(100mg/m2 per day for 6 days)combinated with aclacinomycin（20mg per day for 6 days）for consolidation therapy.
223805609|NCT05189951|OTHER|circular motion|The phlebotomy site was wiped in a circular motion from the center outwards, approximately 5x5 cm wide.
223805610|NCT05189951|OTHER|vertical motion|The phlebotomy site was wiped vertically from top to bottom with a single maneuver.
223805611|NCT05189951|OTHER|circular+vertical motion|The phlebotomy site was first vertically wiped from top to bottom with a single maneuver, and then it was wiped in a circular motion from the center to the outside.
223805612|NCT03055143|DRUG|SPARC-08-038|2 mg/ml intravenous infusion
223805613|NCT03055143|DRUG|Ref-08-038|2 mg/ml intravenous infusion
223805614|NCT04322123|DRUG|Hydroxychloroquine Oral Product|Hydroxychloroquine 400 mg BID
223805615|NCT04322123|DRUG|Hydroxychloroquine + azithromycin|Hydroxychloroquine 400 mg BID + azithromycin 500 mg once a day
223805616|NCT03322280|PROCEDURE|TACE combined with iodine-125 seeds implantation|Conventional TACE with lipiodol was performed. Then Iodine-125 seed implantation into PVTT is conducted 7-10 days after TACE when liver function tests demonstrated values comparable to those obtained before TACE.
223805617|NCT03322280|PROCEDURE|TACE|Only conventional TACE with lipiodol and chemotherapy drugs was performed.
223805618|NCT05288426|OTHER|No intervention|This is an observational study, with no intervention.
223805619|NCT01547897|DRUG|NOX-E36|0.5 mg/kg study drug or placebo as SC injections twice a week
223805620|NCT04885556|DEVICE|Tampon-like device for absorption of sexual fluids|Subjects will insert a tampon-like device to absorb sexual fluids after intercourse
223805621|NCT03740308|DEVICE|Locally Made Zirconia Crowns|Occlusal reduction by decreasing the occlusal surface to less than the natural occlusal profile by about 1-1.5 mm roughly. Proximal reduction by unfastening the interproximal contacts. The tooth should be trimmed down circumferentially by around 0.5-1.25 mm as needed. Subgingival reduction, leaving no undercuts or subgingival ridges, about 1-2 mm subgingivally on every area should be prepared. Completion of the preparation by eliminating sharp lines and pointed angles to allow all prepared areas to be marginally rounded and smoothed. Locally Made Zirconia Crowns are fixed using Glass Ionomer cement (Fuji- Jaban).
223805622|NCT03740308|DEVICE|ZR Zirconia Crwons NuSmile ® Crowns|Occlusal reduction by decreasing the occlusal surface to less than the natural occlusal profile by about 1-1.5 mm roughly. Proximal reduction by unfastening the interproximal contacts. The tooth should be trimmed down circumferentially by around 0.5-1.25 mm as needed. Subgingival reduction, leaving no undercuts or subgingival ridges, about 1-2 mm subgingivally on every area should be prepared. Completion of the preparation by eliminating sharp lines and pointed angles to allow all prepared areas to be marginally rounded and smoothed. ZR Zirconia Crwons NuSmile ® Crowns are fixed using Glass Ionomer cement (Fuji- Jaban).
223805623|NCT01367509|DRUG|Methylnaltrexone (MNTX)|
223805624|NCT05925933|OTHER|Intervention|high protein diet (carbohydrates 45%, protein 29%, and fat 26%) over 8-week periods.
223805625|NCT03419364|DRUG|nicotinamide|2.5 gm nicotinamide given orally in 3 divided doses: 1000 mg in morning and evening, 500 mg at noon/midday
223805626|NCT02475785|DEVICE|FFRD and mini plates group|FFRD direct loading over mini plates inserted in the mandibular symphysis
223805627|NCT02475785|DEVICE|Conventional FFRD|FFRD inserted between maxillary and mandibular arches with the pushrods placed distal to mandibular canines
223805628|NCT03403322|OTHER|Kinesio taping|An experienced physiotherapist placed the base of the Kinesio taping strip, over rectus femoris muscle, 3cm bellow the anterior iliac spine, without tension. From this point, the Kinesio taping was placed up to the upper edge of the patella and stretched to 100% tension. It was, then, bi-sectioned, circled the patella and ended in the tuberosity of the femur, without tension. In order to avoid interference in the electromyography signals, a section was held at Kinesio taping at the point where the electrode was placed.
223805629|NCT03403322|OTHER|Without taping|Children performed functional activities without tape
223805630|NCT05576584|DRUG|GST-HG121 tablets|This trial includes single-dose studies and multiple-dose studies, The single-dose study included 5 dose groups of 5 mg, 15 mg, 30 mg, 60 mg, 100 mg（Alternative groups include 150mg and 200mg）. Based on the results of a single dose, select 1 to 3 doses which are tolerated in SAD to conduct multiple dose studies.
223805631|NCT05576584|DRUG|Placebo|This trial includes single-dose studies and multiple-dose studies, The single-dose study included 5 dose groups of 5 mg, 15 mg, 30 mg, 60 mg, 100 mg（Alternative groups include 150mg and 200mg）. Based on the results of a single dose, select 1 to 3 doses which are tolerated in SAD to conduct multiple dose studies.
223805632|NCT00988403|DIETARY_SUPPLEMENT|Fructan - 7.5|Subjects will consume 7.5 grams of fructan
223805633|NCT00988403|DIETARY_SUPPLEMENT|Fructan - 10|Subjects will consume 10 grams of fructan
223805634|NCT00988403|DIETARY_SUPPLEMENT|Fructan - 12.5|Subjects will consume 12.5 grams of fructan
223805635|NCT00988403|DIETARY_SUPPLEMENT|Fructan -- 5 grams|Subjects will consume 5 grams fructan.
223805636|NCT06423326|PROCEDURE|Biopsy|Undergo biopsy
223805637|NCT06423326|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223805638|NCT06423326|DRUG|Cisplatin|Given IV
223805639|NCT06423326|PROCEDURE|Computed Tomography|Undergo CT
223805640|NCT06423326|DRUG|Gemcitabine|Given IV
223805641|NCT06423326|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223805642|NCT06423326|DRUG|Nab-paclitaxel|Given IV
223805643|NCT06423326|PROCEDURE|Pancreatic Surgical Procedure|Undergo surgical resection
223805644|NCT06602193|DRUG|BIIB122 225 mg|Administered as specified in the treatment arm
223805645|NCT06602193|OTHER|BIIB122-Matching Placebo|Administered as specified in the treatment arm
223805646|NCT03175770|PROCEDURE|transoral radiofrequency Resection in Oropharyngeal Tumor Surgery|Patient of 18 years and older with benign or malign tumor in the oropharynx. The resection is done transorally by radiofrequency
223805647|NCT06233279|DEVICE|Charge-Balanced, Symmetric Nerve Stimulation|Charge-Balanced, Symmetric Nerve Stimulation device is used during night sleep for eight hours each day for 4 weeks (28 days).
223805648|NCT06233279|DEVICE|Sham Stimulation|Sham Stimulation device is used during night sleep for eight hours each day for 4 weeks (28 days).
223805649|NCT06989164|OTHER|Post prandial testing|A variety of foods, supplements, and short prescriptive exercise will be tested to see which one helps mitigate the rise is postprandial glucose after eating carbohydrate containing foods.
223805650|NCT05614947|DIETARY_SUPPLEMENT|Powdered tart cherry|500 mg freeze-dried tart cherry per capsule
223805651|NCT05614947|DIETARY_SUPPLEMENT|Placebo|500 mg colored cornstarch per capsule
223805652|NCT05571280|DIETARY_SUPPLEMENT|Nutritional Supplementation|"The Small-quantity lipid-based nutrient supplementation (SQ-LNS) consists of micronutrients delivered in a lipid-based vehicle. All pregnant women (as of 12 weeks self-referred) within households who were randomly included in the study in the nutritional supplementation arm and their children as of 6 months of age will receive the SQ-LNS.~● Pregnant women: 20-g sachets, 20 g (1 sachet) dose per day. Nutritional composition and caloric intake.~Total = 12/13 months approximately.~● Children from 6 months of age: 20-g sachets, 20 g (1 sachet) dose per day. Nutritional composition and caloric intake. Total = 18 months.~The distribution will be made by ADECOS on a fortnightly basis.~A family ration will be distributed: family supplementation is presented in a basket of locally produced basic foods that complement the usual diet. The caloric distribution of the basket will be 45% of cereals, 30% of pulses, and 25% in oil, and 1 kg of iodized salt."
223805653|NCT05571280|BEHAVIORAL|Money transfers|The distribution of the amounts will be made through the corresponding financial providers, together with the Municipal or Communal Administration authorities, the Assistants of Community Activities, the Investigator's personnel, and the ADECOS. The distribution frequency will be every 3 months until the end of the study.
223805654|NCT05571280|BEHAVIORAL|Standard intervention|"The activities included are the following:~1. Community interventions against malnutrition and promotion of adequate nutrition: raise awareness of malnutrition and training mothers to recognize signs of malnutrition.~2. Community interventions in promoting hygiene and proper sanitation: a) Promotion of Community-Led Total Sanitation approach (CLTS)strategy: community awareness of the entire population included in the cluster about the dangers of open defecation, and the direct link to malnutrition; b) Promotion of Baby-Wash strategy: to make the community aware of the problems and consequences of unsafe water consumption.~3. Biannual supplementation with vitamin A for children from 6 to 24 months of age.~4. Biannual deworming (albendazole/mebendazole) for children from 12 months to 24 months of age and pregnant women as of 2nd quarter.~5. Malaria prophylaxis with sulfadoxine-pyrimethamine (SP) in pregnant women as of 13 weeks of pregnancy."
223805655|NCT06671548|DRUG|Relugolix|"* Relugolix (40 mg) tablet administered orally once daily；~* megestrol acetate (1 mg) administered orally once daily；~* medroxyprogesterone acetate (2 mg) administered orally once daily"
223805656|NCT06671548|DRUG|Relugolix placebo|"Relugolix (0 mg) tablet administered orally once daily and manufactured to match the relugolix tablet in size, shape, color, and odor.~megestrol acetate (0 mg) administered orally once daily and manufactured to match the relugolix tablet in size, shape, color, and odor.~medroxyprogesterone acetate (0 mg) administered orally once daily and manufactured to match the relugolix tablet in size, shape, color, and odor."
223805657|NCT01387139|DRUG|Ketamine|1.0 milligrams/kilogram (mg/kg) ketamine with additional doses of 0.5 mg/kg ketamine as needed (maximum single dose based on 100 kilogram (kg) person)
223805658|NCT01387139|DRUG|Ketamine Co-administered with Propofol|0.5 mg/kg ketamine and 0.5 mg/kg propofol with additional doses of 0.25 mg/kg ketamine and 0.25 mg/kg propofol as needed (maximum single dose based on 100 kg person)
223805659|NCT05610852|PROCEDURE|Transvesical Single Port Robotic Partial Prostatectomy|A foley catheter is inserted on the sterile field. A suprapubic midline incision is made and the da Vinci SP surgical system is docked percutaneously directly to the bladder. Prior to the operation, a radiologist identifies and segments tumors and the urethra. A transrectal ultrasound probe is inserted and secured into a fixed position. The Koelis software is utilized to fuse MRI and ultrasound images to identify the target lesion in real-time, allowing for intraoperative guidance. The ultrasound probe rotates automatically, allowing for localization of the tumor intraoperatively. Then depending on the area of the tumor, a Hemi or quadrant resection is completed while preserving the nerves, vas deferens, and seminal vesicles. The urethrovesical anastomosis is then performed.
223805660|NCT05610852|PROCEDURE|High-intensity focused ultrasound (HIFU)|Three contoured measurements are required for the MR fusion system to reproduce the volume of the prostate. Following this, the area to be targeted will be selected in graded fashion from the anterior to posterior of the prostate. Once planning of ROI (region of interest) is complete, the HIFU treatment may begin. Quadrant or hemi ablation will be performed based on the size and complexity of the tumor. The distal margin of the ablation will be kept at least 4 mm away from the external sphincter. The rectal temperature and its distance from the probe will be carefully monitored throughout the procedure.
223805661|NCT05251454|PROCEDURE|Brain Stimulation|Participants will receive brief electrical brain stimulation as they perform the study tasks. This will be linked to events occurring on screen and/or to specific changes in their brain activity. The stimulation parameters will be individualized for each participant, but will never exceed safe limits for charge density (30 µC/phase).
223805662|NCT07009171|DRUG|KDS2010|KDS2010 will be administered orally once daily, three tablets per day, for 12 weeks. Dosage will be either 120 mg or 180 mg depending on the assigned group.
223805663|NCT07009171|DRUG|Placebo|Placebo matching the investigational product in appearance but containing no active ingredient, administered orally once daily, three tablets per day, for 12 weeks.
223805664|NCT01999166|RADIATION|radiography (X-ray)|
223805665|NCT01999166|GENETIC|DNA sampling|
223805666|NCT06676280|DRUG|Aspirin|Patients will take aspirin 100 mg/day.
223805667|NCT06676280|DRUG|High-intensity statin|Statin intensity is defined as 2018 Cholesterol Clinical Practice Guidelines.
223805668|NCT06676280|DRUG|Guideline-directed statin therapy|as 2018 Cholesterol Clinical Practice Guidelines.
223805669|NCT05420636|DRUG|Iadademstat|Patients will be treated with iadademstat given at a dose of 150 microgram PO administered on a 5 day on-2 day off schedule every week (days 1 through 21)
223805670|NCT05420636|DRUG|Paclitaxel|Patients will be treated with Paclitaxel given at a dose of 80 mg/m2 intravenous administration weekly day 1, 8 and 15 (days 1 through 21).
223805671|NCT06623396|BIOLOGICAL|M28z1XXPD1DNR CAR|Participants with esophagastric adenocarcinoma will be treated with an intraperitoneal infusion of different doses of autologous T cells that have been genetically modified ex vivo to express the M28z1XXPD1DNR CAR. The CAR T cells will be manufactured in MSK's Center for Cell Engineering.
223805672|NCT06122727|PROCEDURE|total knee arthroplasty|In detail, in the STANDARD group, patients will undergo a primary TKR by implanting a prosthetic model of the same standard design for all using the usual surgical technique and instrumentation (based on the use of guide intramedullary of femur and extramedullary of tibia); in the PERSONALIZED group, patients will undergo a primary TKA by implanting a prosthetic model (YourKnee, Rejoint) with design based specifically on each patient's actual knee morphology and using PSI surgical technique and instrumentation. In both groups, the approach of the basic prosthetic design base will be of the Cruciate-Retaining (CR) type with congruent polyethylene (PE), with standard and customized for the STANDARD and CUSTOM group, respectively.
223805673|NCT07010289|OTHER|Prepared Meals|Participants will receive the intervention of weekly home meal delivery, consecutively for 4 weeks, delivered to their home. The meals will be provided by Providence Community Kitchen, which is a program of Second Harvest Food Bank of Northwest NC. During the 4 weeks of meal provisions, participants will receive 7 family style frozen dinners delivered to the participant's home weekly. Meals are frozen, have minimal preparation time, and can be heated by oven.
223805674|NCT07010289|OTHER|Grocery Gift Cards|Participants will receive weekly grocery store gift cards, consecutively for 4 weeks. During the 4 weeks of gift card provisions, participants will receive (1) $40.00 grocery store gift card weekly, mailed to participants' home address by study staff.
223805675|NCT07010289|OTHER|Standard of Care|Participants will receive the current standard for care for families endorsing inpatient food insecurity during a hospitalization, which include provision of printed and electronic food access resources. Currently, all families with positive food insecurity screening are met by a community health worker in the hospital who reviews current food access status with families (including enrollment in federal nutrition programs) and provides them with printed and electronic resources of nearby food pantries and other food access resources available to them at time of discharge from the hospital.
223805676|NCT06209320|DRUG|Lower dose atropine sulfate eye drops|administer to eyes
223805677|NCT06209320|DRUG|Low dose atropine sulfate eye drops|administer to eyes
223805678|NCT06209320|DRUG|placebo|administer to eyes
223805679|NCT07014020|GENETIC|RB001|The study will enroll up to 2 cohorts, evaluating a starting dose plus a higher or lower dose
223805680|NCT07014202|COMBINATION_PRODUCT|Immunotherapy (with or without chemotherapy) maintenance therapy combined with radiotherapy|Immunotherapy (with or without chemotherapy) maintenance therapy combined with radiotherapy in patients with advanced NSCLC who have not progressed after 4-6 cycles of first-line platinum-containing chemotherapy combined with immunotherapy and who have an oligo-residual status confirmed by PETCT.
223805681|NCT07014202|DRUG|Immunotherapy (with or without chemotherapy) maintenance therapy|Immunotherapy (with or without chemotherapy) maintenance therapy in patients with advanced NSCLC who have not progressed after 4-6 cycles of first-line platinum-containing chemotherapy combined with immunotherapy and who have an oligo-residual status confirmed by PETCT.
223805682|NCT04120233|DRUG|Placebo|Matched placebo administered orally
223805683|NCT04120233|DRUG|MW151, 10mg|10 mg MW151, 1 x 10mg capsule administered orally
223805684|NCT04120233|DRUG|MW151, 20mg|20 mg MW151, 1 x 20mg capsule administered orally
223805685|NCT04120233|DRUG|MW151, 40mg|40 mg MW151, 2 x 20mg capsule administered orally
223805686|NCT04120233|DRUG|MW151, 80mg|80 mg MW151, 1 x 80mg capsule administered orally
223805687|NCT04120233|DRUG|MW151, 160mg|160 mg MW151, 2 x 80mg capsule administered orally
223805688|NCT06689553|DEVICE|Automated Continual Fluid Removal System|The intraperitoneal device is percutaneously implanted via mini laparotomy, under local anaesthesia and sedation, and connected to the wearable rechargeable pump through extracorporeal tubing. The device aims to remove excess fluids in heart failure patients with diuretic resistance
223805689|NCT06688578|DEVICE|Subperceptual Stimulus|For each test participants will be stimulated using a subperceptual electric signal that is optimized to improve their gait.
223805690|NCT06688578|DEVICE|Sham Comparator|During intervention trial, sham comparator will consist of same stimulation device but no actual electrical stimulation will be provided by device during intervention trial.
223805691|NCT07016815|DEVICE|Wearable wrist heart rate and activity monitor|A commercially available smart watch capable of continuous monitoring of heart rate and activities including daily steps count and daily activity level, detection of arrythmia using a proprietary FDA approved algorithm14, and measuring peripheral capillary oxygen saturation will be provided to the patient. Patients will be encouraged to wear the watch as often as possible during daytime and during sleep. Data gathered will be automatically transmitted wirelessly to a cloud-based platform provided by the manufacturer accessible only by the research team and the patient.
223805692|NCT07016815|DEVICE|Bluetooth enabled body weight scale with bioimpedance analysis|An electronic scale which measures bioimpedance using bioelectrical analysis from foot-to-foot impedance and body fluid percentage (BF%) using a proprietary equation15,16 will be provided to the patients. Patient will be encouraged to measure their bodyweight (BW) and bioimpedance twice per day, one in the morning, and one before bath, with minimal clothing. Both data will be automatically transmitted wirelessly to a cloud-based platform provided by the manufacturer accessible only by the research team and the patients.
223805693|NCT07016815|DEVICE|Bluetooth enabled electronic blood pressure device|An electronic cuffed arm blood pressure monitor will be provided to the patient with instruction on how to perform proper blood pressure measurement at home16. Patients are encouraged to take at least 2 blood pressure reading daily, one in the morning and one in the evening. Blood pressure reading will be transmitted wirelessly to an online platform provided by the manufacturer accessible only by the research team and the patients.
223805694|NCT07016815|DEVICE|mobile application|a mobile Application through which data from remote monitoring and wearables will be incorporated, and instruction for medication titration and education on heart failure management will be provided to the patients.
223805695|NCT00099892|DRUG|vildagliptin|
223805696|NCT05047185|DRUG|Deucrictibant low dose|Deucrictibant softgel capsules for oral use (PHVS416)
223805697|NCT05047185|DRUG|Deucrictibant high dose|Deucrictibant softgel capsules for oral use (PHVS416)
223805698|NCT05047185|DRUG|Placebo|Matching placebo capsules for oral use
223805699|NCT06627270|DRUG|Metronidazole|Participants will receive metronidazole (500 mg t.i.d. x 10 days)
223805700|NCT06627270|OTHER|Chlorhexidine|Mouth rinse chlorhexidine (10 ml t.i.d. x 10 days)
223805701|NCT06627933|OTHER|No intervention|No intervention
223805702|NCT01750138|DRUG|Glutamine|
223805703|NCT01750138|DRUG|Dextrose powder|
223805704|NCT06877026|DEVICE|FibroScan|Day 1 = 5 FibroScan examinations Day 2 = 4 FibroScan examinations
223805705|NCT06877026|OTHER|Liver Enzymes|Day = 1 blood collection for liver enzymes. Day 2= 1 blood collection for liver enzymes.
223805706|NCT03779906|DRUG|Isovue|Isovue will be given to all subjects per the standard of clinical care.
223805707|NCT04909970|OTHER|Self-hypnosis|Self-hypnosis training during 8 weeks and one daily self-hypnosis session during 8 weeks
223805708|NCT04909970|OTHER|Control (Waiting list)|Usual practice during the first 16 weeks. At the end of study, the participant will practice Self-hypnosis training during 8 weeks and one daily self-hypnosis session during 8 weeks
223805709|NCT06717191|DRUG|biosimilar insulin glargine|Switched to once daily injection of biosimilar insulin glargine via reusable pen and three mealtime bolus insulin injections of short-acting human insulin via needle and syringe
223805710|NCT06733402|DRUG|Trifarotene Cream 0.005%|A thin layer of the investigational product will be self-applied to the affected areas of the face once daily at bedtime.
223805711|NCT06733402|DRUG|AKLIEF® Cream (Trifarotene 0.005%) US REFERENCE LISTED DRUG|A thin layer of the investigational product will be self-applied to the affected areas of the face once daily at bedtime.
223805712|NCT06733402|DRUG|AKLIEF® Cream (Trifarotene 50 mcg/g) CANADIAN REFERENCE PRODUCT|A thin layer of the investigational product will be self-applied to the affected areas of the face once daily at bedtime.
223805713|NCT06733402|DRUG|Placebo|A thin layer of the investigational product will be self-applied to the affected areas of the face once daily at bedtime.
223805714|NCT06732544|OTHER|snoezelen room|During the travail, projectors, starry ceiling visuals and blue light LEDs will be used for visual stimuli, speakers will be used as auditory stimuli, diffusers will be used for olfactory stimuli, and therapy dough will be used for touch stimuli.
223805715|NCT06732544|OTHER|routine delivery room|General practice
223805716|NCT06722053|OTHER|virtual reality and digital education|Breastfeeding education through virtual reality and digital education
223805717|NCT06722053|OTHER|virtual reality and digital education and lemon scent|virtual reality and digital education and lemon scent inhalation
223805718|NCT06732076|BEHAVIORAL|web based education|web based education
223805719|NCT06733818|OTHER|Functional assessment of physical performance|Functional assessment of physical performance was performed with the Alusti test. This 10-question test was developed to assess physical performance in the geriatric population 13 and has been validated in Turkish 14. This test evaluates limb range of motion and muscle strength, ability to move from supine to sitting position, sitting balance, ability to stand up from sitting position, standing, walking, walking distance, ability to stand on tandem and single leg with eyes closed. The results of this test, which is scored out of 100, indicate the level of activity. 0-30, interpreted as totally dependent; 31-40, highly dependent; 41-50, moderately dependent; 51-60, slightly dependent; 61-75, good activity; 76-90, very good activity; and 91-100, excellent activity.
223805720|NCT06732063|DEVICE|endodontic retreatment|Re-treatment of previously failed root canal treatments
223805721|NCT06732297|BEHAVIORAL|dyadic art therapy intervention for parent-child relationship in vulnerable families|The Stronger Family Through Art Therapy (SFAT) is a dyadic art therapy intervention developed to improve the parent-child relationship in vulnerable families. Service users of the SFAT programme will receive a progressive support from workshops, dyad art therapy, and an innovative art-based self-care tool developed with a multidisciplinary team to meet the needs of enhancing family communication and strengthening emotional bonding.
223805722|NCT06733688|DRUG|Tedizolid Phosphate Oral Formulation 1 (Reference)|Oral administration
223805723|NCT06733688|DRUG|Tedizolid Phosphate Oral Formulation 2 (Test)|Oral administration
223805724|NCT06733662|BEHAVIORAL|Experimental: Education-based motivational interviewing Group|The Effect of Motivational Interviewing-Based Education on Treatment Adherence and Self-Care Agency in COPD Patients
223805725|NCT06732583|BIOLOGICAL|Tuberculosis (TB) vaccine (Ad5-105K)|1 doses of Ad5-105K vaccine (1 x 10\^8 vp)) on Day 0, Nebulized Inhalation (IH) through mouth
223805726|NCT06732583|BIOLOGICAL|Placebo|1 doses of placebo on Day 0, IH
223805727|NCT06732583|BIOLOGICAL|Ad5-105K|1 doses of Ad5-105K vaccine (2 x 10\^8 vp)) on Day 0, IH
223805728|NCT06732583|BIOLOGICAL|Placebo|1 doses of placebo on Day 0, IH
223805729|NCT07050238|BEHAVIORAL|Life Force|5-session, group-based, skills training program tailored specifically for active-duty Soldiers aimed at mitigating harmful and high-risk behaviors and promote Mental Toughness
223805730|NCT03520322|DEVICE|Mastoid Oscillator|The oscillator will be placed over the mastoid of their involved ear and secured via an elastic/Velcro headband. The subject is positioned so as to place the endolymphatic duct into a gravitationally dependent orientation (the subject lying on their contralateral side with the face slightly tilted towards the floor). The device is turned on and operated for 30 minutes.
223805731|NCT03520322|DEVICE|Control Device|The control device will be placed over the mastoid of their involved ear and secured via an elastic/Velcro headband. The subject is positioned so as to place the endolymphatic duct into a gravitationally dependent orientation (the subject lying on their contralateral side with the face slightly tilted towards the floor). The device is turned on and operated for 30 minutes.
223805732|NCT06733246|DEVICE|Aspiration 0|Ceretrieve is a neuro-thrombectomy aspiration catheter deigned for clot removal in AIS patients.
223805733|NCT06732635|PROCEDURE|Enhanced recovery after surgery (ERAS)|Enhanced recovery after surgery (ERAS) programs are designed to achieve early recovery after surgery and a shorter length of stay (LOS) at hospital.
223805734|NCT06733805|BEHAVIORAL|Portrait + Therapeutics Letter|"In the context of audit and feedback interventions, Portrait is a document produced by the physician organization Therapeutics Initiative that provides personalized prescribing feedback for BC clinicians. Portraits are used as a practice resource tool for reflection on prescribing patterns. Each Portrait topic provides data of individual prescriber's prescribing practice, benchmarks or targets, a succinct review of the best-available evidence on the topic, and recommendations for future action.~The Therapeutics Letter is a standalone publication that details identified problematic therapeutic issues in a brief, simple and practical manner. Therapeutics letters include a systematic literature review on a clinical topic, and provide reference for the data presented in the Portraits."
223805735|NCT06732050|DEVICE|nociception guided treatment|For the nociception level-guided group the same standard narcosis will be applied whilst ensuring that the NOL® level value will be maintained between 10 and 25.
223805736|NCT06732869|BEHAVIORAL|eHealth physical activity coaching intervention|Patients will attend a PR program and in week 5 of PR will receive an eHealth PA coaching intervention until 6 months after end of PR. The PA goals will be prescribed through a phone call and the personalisation of goal prescription will be based on an algorithm considering patient's performance in the previous week, perceived easiness of achieving the previous goal and confidence to change it. If patient does not achieve the goal, reasons, barriers to PA and strategies to overcome them will be identified. Patients will receive a daily notification about their goal achievements, at 6PM every day, giving them the possibility to increase their PA to achieve the goal, if they have not reached it yet. Patients will also receive personalized notifications sent manually by the researcher whenever appropriate. PA goals will be prescribed on a weekly basis.
223805737|NCT06732869|BEHAVIORAL|pulmonary rehabilitation|Patients will attend pulmonary rehabilitation program for 10 weeks. Pulmonary rehabilitation is evidence-based multidisciplinary intervention based on thorough patient assessment followed by patient-tailored therapies that include, but are not limited to exercise training, education, self-management intervention aiming at behaviour change, known to improve health status and psychological well-being, reducing dyspnoea and healthcare utilization and hospitalization. In this study, pulmonary rehabilitation programs will have 20 sessions, twice a week, including exercise training (aerobic and strength training), educational sessions about topics as medication, smoking cessation, energy conservation techniques, physical activity, stress and anxiety management, breathing control, inhaled therapy and nutrition; nutritional and psychosocial counselling. Education session about PA importance and recommendations will be also provided in both arms.
223805738|NCT07051187|DRUG|WGc0201|Wgc0201 will be administered by intramuscular route, with a total of 9 doses.
223805739|NCT02553460|DRUG|ITMHA|Given intrathecally (IT).
223805740|NCT02553460|DRUG|Dexamethasone|Given orally (PO) or naso-gastrically (NG) or intravenously (IV).
223805741|NCT02553460|DRUG|Mitoxantrone|Given IV.
223805742|NCT02553460|DRUG|Pegaspargase|Given IV. If participant is allergic to pegaspargase, Asparaginase Erwinia Chrysanthemi will be used.
223805743|NCT02553460|DRUG|Asparaginase Erwinia Chrysanthemi|Asparaginase Erwinia Chrysanthemi will be used in case of allergy or intolerance of participant to PEG-asparaginase. Given IV (preferred) or intramuscularly (IM).
223805744|NCT02553460|DRUG|Bortezomib|Given IV.
223805745|NCT02553460|DRUG|Vorinostat|Taken PO or NG.
223805746|NCT02553460|DRUG|Cyclophosphamide|Given IV.
223805747|NCT02553460|DRUG|Mercaptopurine|Given PO or NG.
223805748|NCT02553460|DRUG|Methotrexate|Given IV, IM or PO.
223805749|NCT02553460|DRUG|Leucovorin Calcium|Leucovorin rescue PO or IV.
223805750|NCT02553460|DRUG|Cytarabine|Given IV.
223805751|NCT02553460|DRUG|Etoposide|Given IV. In case of participant allergy, etoposide phosphate (Etopophos®) will be given.
223805752|NCT02553460|DRUG|Vincristine|Given IV.
223805753|NCT06865651|DRUG|Remibrutinib|tablets
223805754|NCT06865651|DRUG|Placebo|tablets
223805755|NCT07059546|DRUG|Adrenomedullin|The participants will receive continuous intravenous infusion of 20 mL of 19.9 pmol/kg/min adrenomedullin over 20 minutes.
223805756|NCT07059546|DRUG|Placebo|The participants will receive a continuous intravenous infusion of 20 mL of placebo (isotonic saline) over 20 minutes.
223805757|NCT07057037|DRUG|NEMO-103 Injection|15mL(at least 12mL), solution for Intravenous injection, single dose
223805767|NCT06838832|BIOLOGICAL|Allogenic CD19-CAR-γδT cell|Phase 1 dose escalation (3+3) : dose 1 (1 × 10\^6 cells/kg) , dose 2 (3 × 10\^6 cells/kg), dose 3 (6× 10\^6 cells/kg); Phase 2 : dose of RP2D.
223805768|NCT06838832|DRUG|Fludarabine|"Intravenous fludarabine 30\~50 mg/m\^2/day on days~-5, -4, and -3."
223805769|NCT06838832|DRUG|Cyclophosphamide|Intravenous cyclophosphamide 500\~1000 mg/m\^2/ day on days -5, -4, and -3.
223805770|NCT03830151|DRUG|Hyperpolarized Carbon C 13 Pyruvate|Given IV
223805771|NCT03830151|PROCEDURE|Magnetic Resonance Spectroscopic Imaging|Undergo MRSI
223805772|NCT06865521|DIETARY_SUPPLEMENT|Akkermansia Probiotics|After enrollment, patients will receive anti-PD-1 monoclonal antibody + Tyrosine kinase inhibitor (TKI, e.g., regorafenib, fruquintinib) treatment or anti-PD-1 monoclonal antibody ± chemotherapy (etc., CAPEOX \[oxaliplatin+capecitabine \], XELIRI \[irinotecan+capecitabine \]) ± Bevacizumab treatment (anti-PD-1 monoclonal antibody, chemotherapy, and bevacizumab every 3 weeks, TKI every 4 weeks), along with daily continuous administration of Akkermansia probiotics (Songke, dose: 1 capsule/day, taken with breakfast), until disease progression, intolerable toxicity, or patient withdrawal from the study.
223805773|NCT07065448|OTHER|physical performance tests|All participants underwent the 4-meter Gait Speed Test, the Short Physical Performance Battery (SPPB), the Timed Up and Go (TUG) test, and the Elbow Performance Test twice, with a 7-10-day interval between sessions. In the Elbow Performance Test, a 1-kilogram sandbag was fixed to the distal forearm of the dominant arm, and participants were asked to perform 30 consecutive elbow flexion-extension movements.
223805774|NCT06829862|OTHER|Own Doctor Education|The self-applied online program will comprise a 3-month behavioural intervention seeking to develop gradually achieving the goals of changing eating and physical activity habits, supported by audiovisual instructions. This group will receive access to the internet-based lifestyle intervention (exercise and nutritional education), supported by audiovisual instructions given by their specialist doctor.
223805775|NCT06829862|OTHER|Unknown Doctor Education|The self-applied online program will comprise a 3-month behavioural intervention seeking to develop gradually achieving the goals of changing eating and physical activity habits, supported by audiovisual instructions. This group will receive the same intervention, but in this case supported by audiovisual instructions given by a doctor outside the patient.
223805776|NCT06646835|BEHAVIORAL|Stress Ball Intervention|The stress ball is a simple and effective tool for reducing anxiety and relaxation as a non-pharmacological method (Yanes et al., 2018). Due to the limited pharmacological options available for pregnant women to reduce anxiety during cesarean section, alternative, complementary or supportive non-pharmacological methods and low-risk approaches are needed (Baltacı \& Başer, 2020). It is thought that squeezing the stress ball may be advantageous in reducing anxiety.
223805777|NCT07068763|RADIATION|Lymph-node-sparing short-course radiotherapy|Three-dimensional conformal or intensity-modulated radiotherapy targeting only the primary tumor bed (no regional lymph nodes), delivering a total dose of 25 Gy in 5 Gy fractions over five consecutive days.
223805778|NCT07068763|DRUG|Capecitabine|Oral capecitabine 1,000 mg/m² administered twice daily on Days 1-14 of each 21-day cycle, for a total of four cycles.
223805779|NCT07068763|DRUG|PD-1/CTLA-4 inhibitor (Aiparolitoworixureli injection)|Intravenous PD-1/CTLA-4 bispecific monoclonal antibody at 5 mg/kg every 3 weeks for four cycles, starting on Day 8 after completion of radiotherapy.
223805780|NCT06901193|BEHAVIORAL|Virtual Reality Mindfulness intervention|Mindfulness will be offered via a virtual reality headset; participants will use the virtual reality mindfulness program 3 times per week (15 minutes at a time) for 8 weeks.
223805781|NCT06812143|BEHAVIORAL|Strength training|This intervention involves strength training with lighter loads and higher repetitions.
223805782|NCT06812143|BEHAVIORAL|Strength training|This intervention involves conventional strength training with higher loads and moderate repetitions.
223805783|NCT06854419|DIETARY_SUPPLEMENT|Placebo Drink|Take one bottle of the product every morning on an empty stomach
223805784|NCT06854419|DIETARY_SUPPLEMENT|Blood Peach Extract Drink|Take one bottle of the product every morning on an empty stomach
223805785|NCT06854419|DIETARY_SUPPLEMENT|Rose Apple Extract Drink|Take one bottle of the product every morning on an empty stomach
223805786|NCT06866925|DEVICE|Transcranial stimulation|A randomized, 2-arm, sham-controlled study, patients with Down syndrome presenting with major depressive episode (DSM5) with catatonic features will be randomly allocated to receive 15 sessions of either active (20 min, 2mA, ramp up/down 30 sec) or sham tDCS (20 min, ramp up/down 30 sec at the beginning and at the end of each stimulation session), thrice daily. Each stimulation session will be spaced at least two hours apart. The anode will be placed over the left DLPFC, the cathode over the right DLPFC using the Beam F3 algorithm in order to individualize target location based on head circumference, tragus to tragus and inion to nasion distances.
223805787|NCT06848244|BEHAVIORAL|Appetite Awareness Training (AAT)|Partcipants will receive the AAT delivered as 16 core sessions over six months as well as six maintenance sessions over the course of 12 months.
223805788|NCT06848244|BEHAVIORAL|Diabetes Prevention Program (DPP)|Partcipants will receive the DPP delivered as 16 core sessions over six months as well as six maintenance sessions over the course of 12 months.
223805789|NCT07075068|DIAGNOSTIC_TEST|Behavioral and Functional Performance Assessment Battery|This study will include only observational functional assessments. No active intervention will be performed.This observational protocol will involve standardized assessments of lower extremity coordination (LEMOCOT), movement speed (30-meter sprint), and smoking-related behavioral patterns (Fagerström Test for Nicotine Dependence). These tools will be used to evaluate the potential impact of cigarette addiction on physical performance in young adults. No therapeutic or pharmacological intervention will be applied.
223805790|NCT07078045|OTHER|Arterial pressure monitoring|We will perform oscillometric arterial pressure measurements at different limb sites.
223805791|NCT07076446|BIOLOGICAL|IgPro|IgPro20 is a solution for infusion for subcutaneous administration.
223805792|NCT07081386|OTHER|Laparoscopic Training using the LAPARO Analytic simulator|Participants in the experimental group will undergo a 3-hour in-person laparoscopic training session using the LAPARO Analytic simulator. The session will be supervised by an experienced General Surgery tutor and will include real-time performance analytics to guide skill acquisition relevant to laparoscopic appendicectomy.
223805793|NCT07081386|OTHER|Laparoscopic Training using a classic Box Trainer|Participants will receive a single, 3-hour in-person laparoscopic training session using a Classic Box Trainer. Training will be supervised by an experienced General Surgery tutor and focused on key technical skills required for laparoscopic appendicectomy.
223805794|NCT07081672|PROCEDURE|Ultrasound-guided interscalene brachial plexus block (ISB)|The intervention consisted of an ultrasound-guided interscalene brachial plexus block (ISB) administered to patients in Group B prior to general anesthesia. The block was performed using a posterior in-plane approach with real-time ultrasound visualization. A total of 20 mL of 0.125% bupivacaine was injected around the C5-C6 nerve roots under sterile conditions by experienced anesthesiologists.
223805795|NCT07081672|PROCEDURE|General Anesthesia (control group)|General anesthesia without regional block
223805796|NCT07080255|PROCEDURE|Adams-Berger Reconstruction|The Adams-Berger procedure involves anatomical reconstruction of the distal radioulnar joint (DRUJ) ligaments using a palmaris longus tendon graft. Bone tunnels are drilled in the radius and ulna, and the graft is passed through these tunnels to reconstruct the dorsal and palmar radioulnar ligaments. This technique is designed to restore stability in patients with chronic post-traumatic DRUJ instability.
223805797|NCT07080255|DEVICE|TightRope®-Augmented Adams-Berger Reconstruction|This intervention combines the standard Adams-Berger procedure with the addition of the TightRope® (Double Loop Lift System) device to provide dynamic stabilization of the DRUJ. The TightRope® system consists of a FiberWire suture passed through 2.7 mm bone tunnels in the radius and ulna and secured with cortical metal buttons. It allows for early mobilization and enhanced postoperative joint stability.
223805798|NCT07079761|BEHAVIORAL|Experiment 1: Three-day aversive conditioning, extinction, and extinction retention testing paradigm|Day 1: Aversive conditioning will involve the pairing of a brief, noxious but not painful air blast to the neck (unconditioned stimulus; US) to a colored shape appearing on a computer monitor (conditioned stimulus). An auditory stimulus will serve as the startle probe. Day 2: Extinction training will occur followed by IV Allo administration. Day 3: The effects of IV Allo (administered on Day 2) on extinction retention as well as reinstatement of conditioned psychophysiological reactions will be assessed.
223805799|NCT07079761|DRUG|Allopregnanolone (Allo) with 6% USP Dexolve (sulfobutyl ether-beta-cyclodextrin sodium salt) in 0.9% saline for IV infusion will be provided by the University of California, Davis, GMP manufacturer.|On Day 2 of Experiment 1, a 1.7 mcg/kg dose of IV Allo will be administered over 5 minutes at the completion of extinction training to raise resting plasma Allo plus pregnanolone (PA) levels by 1500 pg/ml. This will be followed by a 4-5-hour continuous infusion of IV Allo at 2.6 mcg/kg/hr to maintain resting plasma Allo levels at the target level.
223805800|NCT07079761|BEHAVIORAL|Experiment 1. Three-day aversive conditioning, extinction, and extinction retention testing paradigm|Day 1: Aversive conditioning will involve the pairing of a brief, noxious but not painful air blast to the neck (unconditioned stimulus; US) to a colored shape appearing on a computer monitor (conditioned stimulus). An auditory stimulus will serve as the startle probe. Day 2: Extinction training will occur followed by IV Allo administration. Day 3: The effects of IV Allo (administered on Day 2) on extinction retention as well as reinstatement of conditioned psychophysiological reactions will be assessed.
223805801|NCT07079761|OTHER|Matching IV Placebo|On Day 2 of Experiment 1, participants randomized to placebo will receive IV matching placebo over 5 minutes at the completion of extinction training followed by a continuous infusion of matching placebo over the next 4-5 hours. The matching IV placebo will be administered according to the same per kg dosing regimen as that for active drug.
223805802|NCT07079761|BEHAVIORAL|Experiment 2. Three-day aversive conditioning, reconsolidation blockade, and testing paradigm|Day 1: Aversive conditioning will involve the pairing of a brief, noxious but not painful air blast to the neck (unconditioned stimulus; US) to a colored shape appearing on a computer monitor (conditioned stimulus). An auditory stimulus will serve as the startle probe. Day 2: Brief exposure to the conditioned stimulus will be followed by IV Allo administration. Day 3: The effects of IV Allo (administered on Day 2) on reconsolidation blockade and reinstatement of conditioned psychophysiological reactions will be assessed.
223805803|NCT07079761|DRUG|Allopregnanolone (Allo) with 6% USP Dexolve (sulfobutyl ether-beta-cyclodextrin sodium salt) in 0.9% saline for IV infusion will be provided by the University of California, Davis, GMP manufacturer.|On Day 2 of Experiment 2, a 28 mcg/kg dose of IV Allo will be infused over 30 minutes following brief reactivation of aversively conditioned psychophysiological reactions, after which IV fluid only (0.9% normal saline) will be administered over 4-5 hours.
223805804|NCT07079761|BEHAVIORAL|Experiment 2. Three-day aversive conditioning, reconsolidation blockade, and testing paradigm|Day 1: Aversive conditioning will involve the pairing of a brief, noxious but not painful air blast to the neck (unconditioned stimulus; US) to a colored shape appearing on a computer monitor (conditioned stimulus). An auditory stimulus will serve as the startle probe. Day 2: Brief exposure to the conditioned stimulus will be followed by IV Allo administration. Day 3: The effects of IV Allo (administered on Day 2) on reconsolidation blockade and reinstatement of conditioned psychophysiological reactions will be assessed.
223805805|NCT07079761|OTHER|Matching IV Placebo|On Day 2 of Experiment 2, matching IV placebo will be infused over 30 minutes following brief reactivation of aversively conditioned psychophysiological reactions, after which IV fluid only (0.9% normal saline) will be administered over the 4-5 hours. The matching IV placebo will be administered according to the same per kg dosing regimen as that for active drug.
223805806|NCT07080151|OTHER|Cardiac imaging|Patients who underwent CTA or CAG, with or without other cardiac imaging modelities (OCT, IVUS, or CMR) will be enrolled in this registry.
223805807|NCT04458610|BIOLOGICAL|Rituximab|Given IV
223805808|NCT04458610|DRUG|Zanubrutinib|Given PO
223805809|NCT06767800|DRUG|TQB2102 for injection (7.5 mg) +Benmelstobart+Chemotherapy|TQB2102 for injection is an antibody-coupled drug Benmelstobart is a Programmed cell death -Ligand 1 (PD-L1) Antibody
223805810|NCT06767800|DRUG|TQB2102 for injection (6 mg/7.5 mg) +Benmelstobart+Chemotherapy|TQB2102 for injection is an antibody-coupled drug Benmelstobart is a PD-L1 Antibody
223805811|NCT06767800|DRUG|TQB2102 for injection (6 mg/7.5 mg) +Penpulimab+Chemotherapy|TQB2102 for injection is an antibody-coupled drug
223805812|NCT07082673|DIETARY_SUPPLEMENT|Sea Buckthorn (Hippophae rhamnoides L.) botanical extract 500 mg.|Dietary supplement based on sea buckthorn extract (Hippophae rhamnoides L.) at a dose of 500 mg - DOSE A (1 capsule of supplement + 2 capsules of placebo).
223805813|NCT07082673|DIETARY_SUPPLEMENT|Sea buckthorn (Hippophae rhamnoides L.) 1500 mg.|Dietary supplement based on sea buckthorn (Hippophae rhamnoides L.), at a dose of 1500 mg - DOSE B (3 capsules of supplement).
223805814|NCT07082673|DIETARY_SUPPLEMENT|Placebo|Placebo (3 capsules of placebo).
223805815|NCT07076706|DRUG|minoxidil + finasteride|topical foam: 5%minoxidil+0.075%finasteride
223805816|NCT07076706|DRUG|minoxidil + finasteride|topical foam: 5%minoxidil+0.1%finasteride
223805817|NCT07076706|DRUG|Placebo foam|Topical placebo foam
223805818|NCT04312867|BEHAVIORAL|Project STRONG|Project STRONG is a 6-module web-based, dyadic intervention for middle school boys and their parents to complete. Its goal is primary prevention of adolescent dating violence by targeting parent-child communication and emotion regulation ability.
223805819|NCT04312867|BEHAVIORAL|Health Promotion|Health promotion is a 6 module web-based, health information program designed to provide health content similar to that provided in a middle school health class. This program is designed to mirror Project STRONG for time and delivery method.
223805820|NCT07087171|OTHER|Artificial intelligence-Machine learning report with accurate personalized probabilities of having a live birth rate|Patients included in the prospective arm will receive the Univfy® PreIVF Report with their accurate personalized probabilities of having a live birth rate (Univfy®) together with a medical explanation by their physician
223805821|NCT07085637|OTHER|intravenous infusion of hydrogen nanobubbles (HNB) administered twice weekly over a 5-week period|"This study investigated a novel intervention using intravenous hydrogen nanobubbles (HNBs), which are microscopic hydrogen gas bubbles encapsulated in liquid, offering enhanced stability, deep tissue penetration, and sustained antioxidant and anti-inflammatory effects. Unlike other hydrogen therapies (such as inhalation or hydrogen-rich water), this method delivers HNBs directly into the bloodstream.~Participants were randomized into six groups: one control group receiving saline and five intervention groups receiving escalating doses of HNBs (5-25 mL) over 10 intravenous infusions in 5 weeks. This intervention is distinct for its dose-response design, intravenous delivery, and combined evaluation of cardiovascular function and quality of life (SF-36)-a patient-centered approach not commonly found in similar studies."
223805822|NCT07086885|BEHAVIORAL|Resistance band training|Four-week resistance band training intervention (15 mins 3x per week). Written and video instructions on the exercises were provided inlcuding guidance on increasing resistance over the weeks.
223805823|NCT06905652|DRUG|R-3,4-methylenedioxymethamphetamine|A dose of 300mg enantiomeric R-MDMA will be administered.
223805824|NCT06905652|DRUG|S-3,4-methylenedioxymethamphetamine|A dose of 100mg enantiomeric S-MDMA will be administered.
223805825|NCT06905652|OTHER|Placebo|Placebo (Mannitol)
223805826|NCT06777316|DRUG|CGT4859|CGT4859 is a selective FGFR2/3 inhibitor
223805827|NCT07089056|PROCEDURE|transcranial direct current stimulation|The intervention will be conducted using a battery-powered stimulator (TCS-E2000, Shenzhen Yingchi Technology Co., Ltd) through a pair of saline-soaked sponge electrodes (5 cm × 5 cm).The stimulation intensity will be set at 2 mA. The stimulation will last for 20 minutes, with a 10 s fade-in period at the start and a 10-s fade-out period at the end of stimulation. The anodal electrode will be placed over the primary motor cortex (M1), and the reference electrode will be positioned at the center of the forehead.
223805828|NCT07089056|DEVICE|sham transcranial direct current stimulation|The intervention will be conducted using a battery-powered stimulator (TCS-E2000, Shenzhen Yingchi Technology Co., Ltd) through a pair of saline-soaked sponge electrodes (5 cm × 5 cm).The stimulation intensity will be set at 2 mA. The anodal electrode will be placed over the primary motor cortex (M1), and the reference electrode will be positioned at the center of the forehead for 20 minutes. However, there will be current only during the first 10 seconds and the last 10 seconds.
223805829|NCT07089056|PROCEDURE|immobilization|The researchers will use an upper limb fixation splint to fix the right upper limb of the participants, with the elbow joint flexed at 90 degrees, to ensure that all movements of the wrist, metacarpophalangeal joints, proximal interphalangeal joints, and interphalangeal joints are completely restricted. To avoid discomfort caused by the splint, soft bandages will be wrapped around the hand, and the splint will be adjusted to fit the shape of the hand. Ensure that the fingertips are visible to ensure good blood circulation. The subjects need to wear the upper limb fixation splint for 16 hours. Instruct the subjects to minimize movement and use of the right upper limb as much as possible. During the immobilization process, pay attention to checking if the participants have numbness or other discomfort, as well as whether the blood flow is good. If any adverse symptoms occur, the immobilization will be immediately terminated.
223805830|NCT07088419|DRUG|Tinidazole|2 grams orally on day one followed by 500mg orally twice daily on days 2-10
223805831|NCT07088276|PROCEDURE|microneedling with topical crisaborole|From each patient 3 patches will be selected The first will have microneedling and topical crisaborole and NB UVB sessions The second will have microneedling and NB UVB sessions The third will be exposed only to NB UVB sessions The microneedling sessions will be every 2 weeks for 6 sessions
223805832|NCT07088601|DRUG|Oral ondansetron strips|In the anesthesia preparation room and before the insertion of the peripheral IV cannula, patients in group O will receive oral ondansetron in the form of an oral soluble film 4 mg strip.
223805833|NCT07088601|OTHER|Placebo (oral peppermint strip)|In the anesthesia preparation room and before the insertion of the peripheral IV cannula, patients in group C will receive a placebo in the form of an oral peppermint strip.
223805834|NCT07088510|PROCEDURE|Hysteroscopic resection|Participants will undergo a hysteroscopy where a camera is placed on the inside of the uterus. Then a resector will be used to remove the pregnancy loss under direct visualization.
223805835|NCT07088510|PROCEDURE|Manual Vacuum Aspiration|Participants will undergo a manual vacuum aspiration with ultrasound guidance for treatment of early pregnancy loss. This is when pregnancy loss is suctioned by a machine from the uterus.
223805836|NCT02047591|OTHER|Relaxing-touch method|
223805837|NCT04814368|BIOLOGICAL|canakinumab|Canakinumab 600 mg single intra-articular injection (into the knee) on Day 1
223805838|NCT04814368|BIOLOGICAL|LNA043|LNA043 40 mg intra-articular injection (into the knee) every 4 weeks, on Days 15, 43 and 71
223805839|NCT04814368|OTHER|Placebo to canakinumab|Placebo to canakinumab single intra-articular injection (into the knee) on Day 1
223805840|NCT07081971|OTHER|Bioheat Patch|Bioheat Patch for pain relif
223805841|NCT07081971|OTHER|Placebo Patch|placebo Patch
223805842|NCT04021017|DRUG|Estradiol Hemihydrate Transdermal System|Participants who have had their first period or have a bone age greater than or equal to 14 years will receive PrClimara® 25 (estradiol hemihydrate transdermal system - 25 mcg/day) as a weekly patch, for 24 months. Participants who have not yet had their first period and have a bone age below 14 years will receive an increasing dose of estrogen. These participants will be initiated on graduated dose of transdermal 17-β estradiol patches: 3.1 mcg/day (1/8 patch) for first six-months, 6.2 mcg/day (1/4 patch) for second six-months, 12.5 mcg/day (1/2 patch) for third six-months and 25 mcg/day (full patch) for final six-months.
223805843|NCT06370364|OTHER|Nurses' Practice of Safe Blood Transfusion|Nurses' Practice of Safe Blood Transfusion
223805844|NCT05151068|BEHAVIORAL|traditional nursing method|"①Preoperative education, informing patients of the importance of the tube and the adverse effects of unauthorised extubation after the operation on the recovery of the disease. ②Pipe care: The nose wing is fixed with modified human elastic tape, and the same side cheek bridge is fixed to keep the duct unobstructed and pour gastric juice in time. ③Oral care: routinely brush teeth and gargle with mouthwash daily. ④Skin care: Observe the condition of the nose, cheek skin and oral and nasal mucosa. Replace the tape as needed, and clean the skin before fixing. ⑤ Pain care: assess the degree of pain, follow the doctor's prescription for medication, and observe the efficacy of medication. ⑥Psychological care: pay attention to the emotional changes of patients and provide psychological support."
223805845|NCT05151068|BEHAVIORAL|Precise acupoint application combined with ear acupoint embedding nursing program|On the basis of conventional nursing, the experimental group adopted a precision nursing program of acupoint application combined with ear acupoint embedding.
223805846|NCT03571958|BEHAVIORAL|BMI|A derivative of motivational interviewing (MI), which is a patient-centered, collaborative counseling approach to strengthen an individual's intrinsic motivation towards a positive behavior change. BMI is intended for healthcare providers with limited time (5-10 minutes) to support a positive behavior change.
223805847|NCT05838261|PROCEDURE|Pharyngeal flap|Children with combined or isolated cleft palate with velopharyngeal insufficiency undergoing surgical treatment with pharyngeal flap will be evaluated with patient- and parent reported outcome measures before and after the surgery.
223805848|NCT00034957|DRUG|Investigational drug|
223805849|NCT01343602|BEHAVIORAL|mod. Constraint-Induced Movement Therapy|"Therapists of the intervention group are trained in CIMT at home. During an initial home visit the therapist determines together with the patient an individually tailored home training program focussing on everyday practice and instructs the non-professional coach. For four weeks the patients will perform 2 hours of daily training at home together with an instructed non-professional coach (e.g. family member) applying shaping techniques (i.e. 20 consecutive days). Patients are supposed to wear a resting hand splint for the entire treatment period for 4 to 6 hours daily. During the four weeks the therapist will provide 5 weekly visits at the patients' home to instruct and supervise the training."
223805850|NCT01343602|OTHER|Therapy as usual|Therapy as usual consists of the therapy, which is usually provided by the occupational or physical therapist. Therapy will be applied at the patients home or at the therapists' practice.
223805851|NCT04436263|BEHAVIORAL|Supplement|A sufficient quantity of the winery by-products will be extracted on an industrial scale and capsules will be produced, each one containing 110mg of phenolic compounds (gallic acid equivalents).Volunteers will consume 6 capsules along with a standardized meal (1131 kcal, 19.7% carbohydrates, 11.2% protein, 66.7% fat) and blood will be drown before the meal consumption and at specific time points for the next 6h
223805852|NCT04436263|BEHAVIORAL|Placebo|A look-alike placebo containing maltodextrin will be prepared.Volunteers will consume 6 capsules along with a standardized meal (1131 kcal, 19.7% carbohydrates, 11.2% protein, 66.7% fat) and blood will be drown before the meal consumption and at specific time points for the next 6h
223805853|NCT05115344|DRUG|flonoltinib 25mg|1 case,The starting dose,Take the medicine once on D1,D 5-21.
223805854|NCT05115344|DRUG|flonoltinib 50mg|6 case,Increasing dose,Take the medicine once on D1,D5 -21.
223805855|NCT05115344|DRUG|flonoltinib 100mg|6 case,Increasing dose,Take the medicine once on D1,D5 -21.
223805856|NCT05115344|DRUG|flonoltinib 150mg|6 case,Increasing dose,Take the medicine once on D1,D5 -21.
223805857|NCT05115344|DRUG|flonoltinib 225mg|6 case,Increasing dose,Take the medicine once on D1,D5 -21.
223805858|NCT05115344|DRUG|flonoltinib 325mg|6 case,Increasing dose,Take the medicine once on D1,D5 -21.
223805859|NCT02617875|OTHER|conventional EMS physician|A physically present conventional EMS physician on scene, will treat the patients according to the standard operating procedures.
223805860|NCT02617875|OTHER|tele-EMS physician|The patients will be treated by the paramedics, which are concurrently instructed by the tele-EMS physicians of the tele consultation center according to the software-based guideline conform algorithms for diagnosis and treatment.
223805861|NCT02758353|DRUG|Community distribution of SP|SP delivered at both the community and facility level by trained CBHVs in three LGAs.
223805862|NCT03190551|OTHER|retroclavicular approach|Retroclavicular approach for ultrasound guided infraclavicular brachial plexus block
223805863|NCT03190551|OTHER|costoclavicular approach|costoclavicular approach for ultrasound guided infraclavicular brachial plexus block
223805864|NCT02802163|DRUG|Panobinostat|"Induction Phase: Panobinostat (dose escalation beginning at 10 mg) will be administered 3 times a week (TIW) by mouth every other week starting on day 1 of each cycle.~Maintenance Phase: Panobinostat will be administered TIW by mouth every other week starting on day 1 of each cycle. The dose of panobinostat during maintenance phase will be the same dose taken during cyce 8 of induction phase."
223805865|NCT02802163|DRUG|Carfilzomib|Induction Phase: Carfilzomib will be administered at 20 mg/m\^2 on Cycle 1 Day 1. Beginning on Cycle 1 Day 2 the carfilzomib dose will be according to the assigned level of 27 mg/m\^2 or 36 mg/m\^2. Carfilzomib will be administered twice weekly IV on Days 1,2, 8,9,15, and 16.
223805866|NCT02802163|DRUG|Lenalidomide|"Induction Phase: Lenalidomide (25 mg) will be administered once-daily by mouth on Days 1-21, 25.~Maintenance Phase: Lenalidomide (10 mg) will be administered once-daily by mouth on days 1-21."
223805867|NCT02802163|DRUG|Dexamethasone|Induction Phase: Dexamethasone (20 mg) will be administered twice weekly by mouth or by IV on Days 1,2, 8, 9, 15, and 16.
223805868|NCT02119143|DIETARY_SUPPLEMENT|vitamines and minerals|given for 24 weeks, after 4 week wash out of all supplements and dietetic products
223805869|NCT02119143|DIETARY_SUPPLEMENT|placebo|given for 24 weeks, after 4 weeks wash out of all supplements and dietetic products
223805870|NCT04846088|OTHER|Product A|A 4mg nicotine pouch product
223805871|NCT04846088|OTHER|Product B|A 7mg nicotine pouch product
223805872|NCT04846088|OTHER|Product C|A 7mg nicotine pouch product
223805873|NCT04846088|OTHER|Product D|A 7mg nicotine pouch product
223805874|NCT04846088|OTHER|Product E|A 7mg nicotine pouch product
223805875|NCT04846088|OTHER|Product F|A 7mg nicotine pouch product
223805876|NCT04846088|OTHER|Product G|A 7mg nicotine pouch product
223805877|NCT04846088|OTHER|Product H|A 7mg nicotine pouch product
223805878|NCT04846088|OTHER|Product I|A 7mg nicotine pouch product
223805879|NCT02489786|DRUG|patients take 0.25 mg of digoxin daily except friday|
223805880|NCT02489786|DRUG|patients take 0.25 mg of digoxin daily except thursday and friday|
223805881|NCT02489786|DRUG|patients take 0.125 mg of digoxin daily|
223805882|NCT02489786|DRUG|digoxin dose is calculated using Jusko-Koup method and given daily|
223805883|NCT01184599|DRUG|aliskiren|150 mg/day p.o.
223805884|NCT00939484|OTHER|Pharmacological Study|Correlative studies
223805885|NCT00939484|DRUG|Vismodegib|Given PO
223805886|NCT05947214|OTHER|Myofascial Decompression Therapy|Group A will be given myofascial decompression therapy.15 minute's moist heat will be given first. Patient was lied prone on couch with their upper torso unclothed, covered with massage oil than placed cup on skin and suction will created by pump. Than drawn over skin along the spine from cervical to thoracic up to lateral border maintain the suction within skin throughout the procedure. The cup massage will conducted for approximately 10 minutes. Patients were informed that the treatment area may become patchy and there are chances of ecchymosis on the same area.
223805887|NCT05947214|OTHER|positional Release Therapy|Group B will be given Positional Release technique (PRT) after application of moist heat pack for 15 minute. The subjects received PRT will be in supine lying with the therapist sitting on the affected side, tender points were located along with the upper fibers of trapezius muscle. The subject's head was laterally flexed towards the side of tender point, then therapist grasps the subject's forearm and abducts shoulder to approximately 90 degree and adds slight flexion or extension to fine-tune. The ideal position of comfort achieved was held for a period of 90 sec and followed by passive return of body part to an anatomically neutral position continued for 5 minutes. Treatment duration was 3 sessions per week for 4 weeks.
223805888|NCT06398483|PROCEDURE|surgical fixation of acute bony mallet finger|"surgical fixation of acute bony mallet finger by micro plate will be performed under either Infraclavicular nerve blockage or digital block will be performed in all patients .fracture fragment will be reduced, The legs of the plate will be embedded in the terminal tendon to grasp the fragment. The plate will be fixed to the distal phalanx with a 1.3-mm screw.~surgical fixation of acute bony mallet finger by blocking K.wire will be performed under either infraclavicular nerve block or digital block. The injury will be surgically intervened with an extensor blocking k.wire. the distal phalanx was extended to maximum flexion and (K.wire) will be placed in the cephalic direction through the terminal band at an angle of 45 degrees to the mid-phalanx. Reduction of the fracture fragment will be achieved by bringing the distal phalanx to extension . the DIP will be transfixed with a second K-wire"
223805889|NCT05217095|DEVICE|Convergence Dialyzer|The Convergence dialyzer with design changes made to FX Coral 600 dialyzer will be tested together with Sidecar. In the dialyzer is integrated centrifugal-flow blood pump.The centrifugal-flow blood pump replaces the peristaltic roller pump of the extracorporeal circuit which pumps blood from patient to the dialyzer and from dialyzer to the patient. The centrifugal-flow blood pump is designed to transport blood from the patient to the dialyzer, and after purification, return the blood to patient.
223805890|NCT01224925|PROCEDURE|Direct pulp capping with Dycal|Capping over carious exposure with Dycal. Dycal: covered with Fuji IX. After one week, part of the temporary filling was left under the permanent filling
223805891|NCT01224925|PROCEDURE|Direct pulp capping|WMTA capping over exposed pulp, wet pellet, Fuji IX. After one week, the entire temporary filling was removed,the cavity was permanently restored with a composite resin material used at the study clinic.
223805892|NCT03122561|DRUG|Paracetamol 500 mg tablet at morning|Single dose oral paracetamol will be administered at 8.00 am
223805893|NCT03122561|DRUG|Paracetamol 500 mg tablet at midday|Single dose oral paracetamol will be administered at 2.00 pm
223805894|NCT03122561|DRUG|Paracetamol 500 mg tablet at night|Single dose oral paracetamol will be administered at 8.00 pm
223805895|NCT03381001|PROCEDURE|embryo transfer after thaw and culture|embryos will be kept in culture after thawing for one day before transfer for the uterus
223805896|NCT03381001|PROCEDURE|embryo transfer with no culture|embryos will be transfer with no culture after thaw
223805897|NCT00791843|DRUG|Growth hormone releasing hormone/ placebo|12 weeks of drug at max dose of 2mg/day administered in 4 pulses at 11pm, 1am, 3am, and 5am, followed by 6 weeks of washout period, then 12 weeks of placebo or vise versa- 12 weeks of placebo, 6 weeks washout, 12 weeks of drug.
223805898|NCT00647101|DRUG|Latanoprost|Latanoprost 0.005% drops: 1 drop in the diseased eye(s) in the evening for 3 months
223805899|NCT01720732|BEHAVIORAL|Lifeline NET|Short Version of Narrative Exposure Therapy
223805900|NCT06170775|OTHER|Pulp therapy|Pulp capping material
223805901|NCT06170775|DRUG|Sodiumhexametaphosphate|Sodiumhexametaphosphate
223805902|NCT06170775|OTHER|MTA|MTA
223805903|NCT01439061|DEVICE|Device: easypod™|Saizen (Somatotropin) as per Summary of Product Characteristics administered by easypod™
223805904|NCT02309437|DRUG|Oxycodone|Use oxycodone to treat patients with mild pain caused by radiation mucositis.
223805905|NCT02309437|DRUG|Oxycodone|Use oxycodone to treat patients with moderate/severe pain caused by radiation mucositis.
223805906|NCT03329287|BEHAVIORAL|SCBT|SCBT, one hour per session.
223805907|NCT03329287|DRUG|SSRIs and/or SNRIs|SSRIs and/or SNRIs at a recommended dosage.
223805908|NCT03329287|BEHAVIORAL|Psychological Placebo|Supportive and relaxation therapy, one our per session.
223805909|NCT03014765|OTHER|EDOP|no intervention
223805910|NCT00621608|PROCEDURE|Hyperbaric Oxygen Therapy|Hyperbaric Oxygen Therapy (HBOT) will be provided 5 days per week for 6 weeks for a total of 30 treatments on average. Subjects will be placed into the hyperbaric chamber for approximately 90 minutes of HBOT at 2.4 ATA (partial pressure of oxygen = 1,800 mmHg) when inside the chamber. Subjects will receive dressing changes as required per standard of care.
223805911|NCT00621608|PROCEDURE|Placebo Hyperbaric Oxygen Chamber|Patients will receive HBOT placebo 5 days per week for 6 weeks for a total of 30 treatments. Each patient will be placed into the hyperbaric chamber and will receive 90 minutes of room air while inside the chamber and the initial flow of air into the chamber will produce a small increase in pressure (0.3 ATA partial pressure of oxygen = 210 mmHg) which will then be released over a period of 10 minutes. Subjects will receive dressings changes as required per standard of care.
223805912|NCT05848921|DEVICE|magnetic resonance image|Imaging data were collected in a strong magnetic field
223805913|NCT05848921|DIAGNOSTIC_TEST|Neuropsychological scale|Multi dimensional neuropsychological test
223805914|NCT00245102|DRUG|sorafenib tosylate|Given orally
223805915|NCT01788696|RADIATION|Group A - Early Imaging|Total of 3 scans
223805916|NCT01788696|RADIATION|Group B - Delayed Imaging|Total of 2 scans
223805917|NCT04806295|OTHER|any/all treatments for blood cancer|Following people undergoing any/all treatments for blood cancer.
223805918|NCT01371773|PROCEDURE|repositioning method for left-sided double lumen tubes|When a left-sided double lumen tube were placed in right mainstem bronchus, after withdrawing the tube into mid-trachea, it was re-advanced with patient's head turned right and counterclockwise rotation of the tube.
223805919|NCT03501433|DIETARY_SUPPLEMENT|Nicotinamide riboside chloride (Niagen)|250 mg capsules 2x/day for 7 days
223805920|NCT03501433|DIETARY_SUPPLEMENT|Placebo|2x/day for 7 days
223805921|NCT06216522|OTHER|Topical Sesame Oil|5 drops/0.25mls of sesame oil applied to the IV cannula site at 12 hourly intervals for 72 hours
223805922|NCT06216522|OTHER|Liquid paraffin oil|5 drops/0.25mls of liquid paraffin oil applied to the IV cannula site at 12 hourly intervals for 72 hours
223805923|NCT01231529|DRUG|GSK1349572|All subjects will receive a single dose of GSK1349572 50 mg. GSK1349572 is an experimental drug in the integrase inhibitor class being developed for the treatment of HIV infection. GSK1349572 is not approved by the FDA.
223805924|NCT03310073|BIOLOGICAL|bOPV|Batch Number: 2042015
223805925|NCT03310073|BIOLOGICAL|Pentabio|Batch number: 5050115 The vaccine shall be given intramuscularly.
223805926|NCT03310073|BIOLOGICAL|IPV|The vaccine shall be given intramuscularly.
223805927|NCT04000867|DEVICE|Transcutaneous Magnetic Stimulation (TCMS)|The study will evaluate whether an experimental medical device that emits a series of brief, intense magnetic pulse called TCMS will relieve foot pain from Diabetic Neuropathy (DN) when compared to the same device giving a sham treatment without magnetic pulses. Participants will be blindly randomized into either the TCMS treatment group or the sham treatment group according to the number 1-20 that they draw. This is necessary to further investigate this TCMS treatment and to determine how to obtain statistically significant data as to whether this therapy reduces the foot pain caused by diabetic neuropathy.
223805928|NCT02512679|DRUG|Cyclophosphamide Dose Level 1|given by IV at a total dose of 105 mg/kg, to be divided into three doses of one 35 mg/kg dose per day, for 3 days on the first level. After ten patients the de-escalation will begin if the stopping rule is not met.
223805929|NCT02512679|DRUG|Cyclophosphamide Dose Level 2|Level 2 will be 70mg/kg in 2 divided given once a day for 2 days;
223805930|NCT02512679|DRUG|Cyclophosphamide Dose Level 3|Level 3 will be 35mg/kg as a one-time dose.
223805931|NCT02512679|DRUG|Cyclophosphamide Dose Level 4|Level 4 will be no cytoxan.
223805932|NCT05307770|DIETARY_SUPPLEMENT|Immediate Release Melatonin|5 mg orally every night at 9 pm for 4 weeks
223805933|NCT05307770|DIETARY_SUPPLEMENT|Extended Release Melatonin|5 mg orally every night at 9 pm for 4 weeks
223805934|NCT04392466|OTHER|walking on the treadmill|Participants will walk on the treadmill under single task, cognitive dual task and motor dual task conditions.
223805935|NCT03503539|PROCEDURE|Mini percutaneous nephrolithotomy|
223805936|NCT03503539|PROCEDURE|Retrograde intrarenal surgery|
223805937|NCT00253201|DRUG|galantamine hydrobromide|
223805938|NCT01716143|PROCEDURE|radiofrequency catheter ablation|
223805939|NCT06065878|PROCEDURE|IPACK + Genicular Nerve Block|IPACK and Genicular Nerve block were applied with the same total volume of local anesthetic as the control group.
223805940|NCT02424084|DEVICE|Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)|Extracorporeal Shock Wave Therapy
223805941|NCT00580658|DEVICE|Medtronic Activa Gpi|Activa Therapy, Gpi
223805942|NCT05698134|DIAGNOSTIC_TEST|ROTEM|ROTEM is a commercially available whole blood Viscoelastic-Haemostatic Assay(VHA) point-of-care, global and dynamic haemostasis assessment tests that measures the viscoelastic changes occurring during the haemostatic process. They provide real-time, comprehensive reflection of the interaction between plasma, blood cells and platelets. It display hypo or hyper-coagulable features in patients with cirrhosis. It is widely used prior to cardiac, obstetric, trauma and liver transplant surgery to assess and correct for coagulation defects.
223805943|NCT05698134|OTHER|Standard of care|Standard of care
223805944|NCT03511911|DIAGNOSTIC_TEST|evaluation of pelvic floor muscle function through the PHENIX instrument|the PHENIX instrument was designed and produced for sensing muscle activity with surface electrodes, pressure probes and external captors,so it could test biological signals of pelvic floor muscle in human body.
223805945|NCT03511911|DIAGNOSTIC_TEST|vaginal palpation|vaginal palpation is based on modified Oxford Grading Scale(MOS) and Levator ani testing(LAT) to test patients' pelvic muscle strength
223805946|NCT06511336|DRUG|Alkaline water (FLO water- Bottled drinking water- the Egyption Saudi Company for natural water- made in Egypt|children will use Alkaline water as mouthwash daily for 3 weeks. each time they will use 10 ml of their mouthwash for 30 seconds
223805947|NCT00604838|DEVICE|AL-SENSE Diagnostic Absorbent Panty liner|worn for 12 hours
223805948|NCT00604838|DEVICE|AL-SENSE Diagnostic Absorbent Panty liner|Diagnostic Absorbent Panty liner (AL-SENSE Amniotic Leak Test Kit), developed by Common Sense Ltd worn for 12 hours
223805949|NCT00192062|DRUG|gemcitabine|
223805950|NCT00192062|DRUG|vinorelbine|
223805951|NCT01756352|DRUG|18F-FET|Radiotracer, surrogate marker for protein synthesis
223805952|NCT00010855|BEHAVIORAL|Self-hypnotic relaxation|
223805953|NCT06093906|BEHAVIORAL|Positive Processes and Transition to Health|See arm/group description for details regarding this intervention
223805954|NCT06093906|BEHAVIORAL|Progressive Muscle Relaxation|See arm/group description for details regarding this intervention
223805955|NCT01728519|DRUG|AllerT SC|AllerT subcutaneous injections on days 1, 7, 14, 21 and 56 - cumulative dose 440 microgram)
223805956|NCT01728519|DRUG|AllerT ID|AllerT intra-dermal injections on days 1, 7, 14, 21 and 56 - cumulative dose 440 microgram)
223805957|NCT01728519|DRUG|Placebo SC|Placebo subcutaneous injections on days 1, 7, 14, 21 and 56
223805958|NCT01728519|DRUG|Placebo ID|Placebo intra-dermal injections on days 1, 7, 14, 21 and 56
223805959|NCT00310232|DRUG|Epoetin Alfa|
223805960|NCT01256853|DRUG|MVA Vaccine|The starting dose will be 5 x 107 plaque forming units (pfu) given by intradermal vaccination. Cohorts of three patients will receive escalating doses of the vaccine (100%, 100%, 67% and 50%). The dose escalation scheme is 5 x 107 pfu, 1 x 108 pfu, 2 x 108 pfu, 3.3 x 108 pfu, 5 x 108pfu. This will be dependant on toxicity.
223805961|NCT05473754|BEHAVIORAL|SUPER digital platform|SUPER digital platform was implemented to ensure synergy between ASD families, health services, and schools through different tools to share rehabilitative and educational objectives and strategies. It was designed following the ASD International Guidelines and the recommendations of the ICF-CY and was organized into two areas: General (to promote scientific knowledge on ASD) and Personalized (restricted virtual space for groups of users following an individual with ASD).
223805962|NCT02529826|PROCEDURE|Testicular Biopsy|An open testicular biopsy will be performed by an attending urologist under general anesthesia.
223805963|NCT02555540|BIOLOGICAL|Boostrix|Randomised assignment
223805964|NCT02555540|BIOLOGICAL|Placebo (Saline)|Randomised assignment
223805965|NCT05199779|BEHAVIORAL|Single Session Intervention Leveraging an Ultra-Brief Self-Compassion Exercise|This 20-second contemplative exercise includes draws from the science of habit formation and includes elements of self-soothing touch, somatic experiencing, and mindful self-compassion.
223805966|NCT05199779|BEHAVIORAL|Finger-Tapping Active Control|This 20-second finger tapping exercise involves touching each finger to the thumb on one hand and repeating for twenty seconds. This intervention was designed to control for the potential effect of assessment on outcomes, the effect of having an activity to do for the duration of the intervention (4 weeks), regression to the mean, time, or other nonspecific factors.
223805967|NCT06490107|DRUG|Durvalumab combined with S-1|"The treatment regimen for this study is as follows:~First 8 cycles of adjuvant therapy: Durvalumab 1500mg, (Day 1, IV, Q3W) and S-1 40mg/m2 (Day1-14, BID, Q3W), up to 8 cycles.~Maintenance therapy stage(6 cycles)：If the patients do not experience disease recurrence or intolerance after first 8 cycles of adjuvant therapy, then, Durvalumab 1500mg, (IV, Q4W), up to 6 cycles"
223805968|NCT00877084|OTHER|Resistance training|Resistance training: series of 3x8 repetitions will be performed for the quadriceps muscle at 70% of the 1 Repetition Maximum determined as the weight the patient can lift once over the full range of motion. The weight can be applied using free weights or using a classical multi-gym device or a quadriceps chair.
223805969|NCT00877084|OTHER|Usual care|usual care according to clinical pathway for COPD, No training
223805970|NCT03315143|DRUG|Sotagliflozin|Sotagliflozin was administered as a tablet(s), orally once daily.
223805971|NCT03315143|DRUG|Placebo|Placebo was administered as a tablet(s) (identical to the sotagliflozin tablet in appearance), orally once daily.
223805972|NCT01280838|BEHAVIORAL|Hombre Seguro|A theory-based intervention that uses principles of behavior change derived from Social Cognitive Theory (SCT), Cognitive Behavioral Therapy (CBT), Theory of Reasoned Action (TRA), and MI to increase clients' use of condoms with FSWs.
223805973|NCT01280838|BEHAVIORAL|Didactic attention-control condition|The didactic control condition is a modified version of the CDC's revised guidelines for HIV counseling, testing, and referral and materials from Mexico's National Center for AIDS Studies (CENSIDA). The one-session, 60-minute counseling intervention focuses on HIV and STI prevention, risk appraisal, and the development of a risk reduction plan.
223805974|NCT00111670|DRUG|DPP-IV Inhibitor|Escalating doses po bid or qd
223805975|NCT00111670|DRUG|Placebo|po bid or qd
223805976|NCT00549757|DRUG|Aliskiren|Aliskiren 150 mg film-coated tablets
223805977|NCT00549757|DRUG|Placebo|Placebo to match aliskiren 150 mg film-coated tablets
223805978|NCT04547725|OTHER|CRS followed by IP and systemic chemotherapies|Complete cytoreductive surgery (CRS) + normothermic intraperitoneal chemotherapy (N-IPEC) + systemic chemotherapy
223805979|NCT01346319|DRUG|ABT-SLV361|For dose groups 1, 2 and 3 medication is taken 1 time per day the first day followed by 2 times per day for 14 days. For dose groups 4 and 5, medication is taken 1 time per day for the first day followed by 2 times per day for 28 days.
223805980|NCT01346319|DRUG|placebo|For dose groups 1, 2 and 3 medication is taken 1 time per day the first day followed by 2 times per day for 14 days. For dose groups 4 and 5, medication is taken 1 time per day for the first day followed by 2 times per day for 28 days.
223805981|NCT05651854|OTHER|pranayama breathing|Bhramari and sheetali pranayama breathing
223805982|NCT04591028|DRUG|Indocyanine green|A one time injection of IDC prior to the day of scheduled surgery.
223805983|NCT01843543|OTHER|Mindfulness Based Stress Reduction Course|The MBSR course developed by Jon Kabat-Zinn is a mind-body intervention that incorporates mindfulness techniques. This is an eight week MBSR course at OHSU. Class instruction will be augmented by daily home practices of listening to audiotapes, diary reflections, and reading preloaded on itouch devices provided to participants. Adherence will be assessed through in-house iMINDr tracking program loaded on the itouch.
223805984|NCT02423681|DEVICE|ThermoSmart|Heated humidification as first intention (HH1st) with ThermoSmart
223805985|NCT02423681|DEVICE|Without ThermoSmart|ThermoSmart is switched off
223805986|NCT04432701|BEHAVIORAL|proactive extubation|when children is breathing spontaneously and adequately in PACU,endotracheal tube was removed directly
223805987|NCT05002205|OTHER|Questionnaires|Participants will be followed up by means of online surveys and 2 study visits.
223805988|NCT05002205|OTHER|spirometry|During two study visits, the lung function will be measured (FVC, FEV1)
223805989|NCT05002205|OTHER|ECG|During two study visits, the presence of arrhythmia will be explored.
223805990|NCT05002205|OTHER|1 minute sit to stand test|Physical endurance is tested during 2 study visits.
223805991|NCT05002205|OTHER|Vital parameters|blood pressure, pulse, weight
223805992|NCT00908401|OTHER|Breastmilk|Breastmilk: 0.2 ml
223805993|NCT00908401|OTHER|Oral Sucrose|oral sucrose: 0.2 ml one time 1 minute before the painful procedure with a pacifier
223805994|NCT06214286|DEVICE|Shockwave|Shockwave therapy
223805995|NCT06214286|OTHER|Kinesio taping|Kinesio taping application
223805996|NCT06214286|OTHER|conventional physical therapy|conventional physical therapy
223805997|NCT03737201|OTHER|ozone|In the two-visit indirect pulp therapy, due to reduce the number of bacteria remaining in the cavity, the antimicrobial agents can be used as cavity disinfectants such as ozone.
223805998|NCT03737201|OTHER|chlorhexidine digluconate|In the two-visit indirect pulp therapy, due to reduce the number of bacteria remaining in the cavity, the antimicrobial agents can be used as cavity disinfectants such as chlorhexidine digluconate.
223805999|NCT03737201|OTHER|Control|without any cavity disinfectant
223806000|NCT01127646|DRUG|Atomoxetine|25-80 milligrams (mg) administered orally, once daily.
223806001|NCT01127646|DRUG|Osmotic-release oral system methylphenidate|18-54 mg administered orally, once daily.
223806002|NCT01127646|DRUG|Placebo|Administered orally, once daily for random nonconsecutive 6 days during 4-week treatment period.
223806003|NCT02887430|OTHER|foot reflexology therapy|standard care and foot reflexology
223806004|NCT00714376|DRUG|Docetaxel|75 mg/m2 iv every 3 weeks for 8 cycles
223806005|NCT03924778|BEHAVIORAL|DASH diet|brief description
223806006|NCT03924778|BEHAVIORAL|standard American diet|describe
223806007|NCT03566459|OTHER|CBOC offering Tele-MOUD to Veterans|CBOC offering medications for opioid use disorder (MOUD) using telemedicine
223806008|NCT03566459|OTHER|CBOC not offering Tele-MOUD to Veterans|CBOC not offering medications for opioid use disorder (MOUD) using telemedicine
223806009|NCT04963205|DEVICE|Adjustable bed backrest|The adjustable bed backrest facilitates for the individual high lying with a fowler (90 degrees raised head and trunk) and/or semi fowler position (30-45 degrees raised head and trunk) which enables patient's lung expansion. The diaphragm is pulled downwards by the gravity allowing for lung expansion and improved ventilation. In addition, the upper airways are stretched in order to prevent upper airway narrowing during sleep (flow limitation, snoring, obstructive sleep apnea). The position relaxes the tension of the abdominal muscles, allowing for improved breathing. Patients can define their own most comfortable position during the night. Elevated body position over 30 degrees from supine position is a requirement for the intervention group. No sleeping time restrictions will be applied. One week washout period between the interventions will be used.
223806010|NCT04963205|OTHER|Standard bed|Sleeping in a standard bed, in a position below 30 degrees from supine position. No sleeping time restrictions will be applied. One week washout period between the interventions will be used.
223806011|NCT01725269|DRUG|AIR001|All doses specified are the amount loaded into the I-neb AAD System nebulizer.
223806012|NCT03454165|COMBINATION_PRODUCT|BNC105P|BNC105P is the phosphate ester of BNC105, a small molecule tubulin polymerization inhibitor.
223806013|NCT03454165|COMBINATION_PRODUCT|Ibrutinib|A novel BTK inhibitor.
223806014|NCT03793725|DRUG|SHR1210|Anti-PD-1 Antibody
223806015|NCT03793725|DRUG|Apatinib|Anti-angiogenic drugs
223806016|NCT01914835|BEHAVIORAL|Motivational Chess|"The Motivational Chess (MC) combines Motivational Interviewing with chess game. Volunteers are submitted to 10 sessions of 90 minutes, over three weeks (total 15 hours: 10 hours of chess practice and 5 hours of motivational interviewing).~The Active Control (AC) group consists of ten structured activities using cardboard, paper, crayons, among others. Volunteers are submitted to 10 sessions of 90 minutes, over three weeks (total 15 hours: 10 hours of recreational activities and 5 hours of information about basic cognitive functions)."
223806017|NCT04067401|BEHAVIORAL|Wingman Connect|Wingman-Connect combines group and individual skill training. Group exercises build cohesion, belonging and shared purpose, and promote value of healthy unit, giving and receiving support. Individual skills promote the ability to thrive during transitions, manage stressors and meet career goals, and decrease barriers to utilizing organizational resources (family, health). The training has a total of 22 modules comprised of specific learning objectives and activities. Six months of text messages (1-2 per week) to reinforce and extend program concepts and skills.
223806018|NCT04067401|BEHAVIORAL|Stress Management|Stress management training reviews the basics of the hypothalamic-pituitary-adrenal axis stress-response system; common experiences of stress (physiological, cognitive, emotional); the impact of chronic stress on the brain and other domains of health; how exercise reduces harmful effects of stress; and relaxation techniques that have been shown to reduce stress and adverse effects of stress on health. Additional modules review the physiological stress response and effects of stress on health; introduces how cognition influences stress responses; common cognitive distortions/attributions are reviewed that affect stress including strategies to strengthen protective cognitive responses. Six months of text messages (1-2 per week) to reinforce and extend program concepts and skills.
223806019|NCT02579876|DRUG|Viaskin Milk 500 mcg|Biological: Viaskin Milk 500 mcg Subjects epicutaneously administered daily (up to 24 hours application per day) with a patch containing 500 mcg cow's milk proteins.
223806020|NCT02579876|DRUG|Viaskin Placebo|Biological: Viaskin Placebo Subjects epicutaneously administered daily (up to 24 hours application per day) with a patch containing a matching placebo formulation.
223806021|NCT05226182|OTHER|visualisation of a digital care path|The implementation and visualisation of a digital care path, specifically designed for patients with type 2 diabetes and their care team. The digital care path wil include: 1) a timeline with appointments, messages and questionnaires 2) Diabetes related articles 3) a page for monitoring clinical parameters and goals 4) a section displaying information on their care team and personal health records. The aim of this intervention is to evaluate whether providing a central platform for all data will increase patient empowerment and involvement. Secondly it will also evaluate whether the communication between healthcare professionals improves when selected data is readily available for the entire care team.
223806022|NCT04077957|DRUG|Methotrexate|Methotrexate 10mg per week will be the background therapy in participants in Group 1. Experimental.
223806023|NCT04077957|DRUG|Sulfasalazine|Sulfasalazine 2.25g per day will be the background therapy in participants in Group 1. Experimental.
223806024|NCT04077957|DRUG|Hydroxychloroquine|Hydroxychloroquine 0.2g per day will be the background therapy in participants in Group 1. Experimental.
223806025|NCT04077957|DRUG|Etanercept (50mg per week, for 4 weeks)|Participants in Group 1. Experimental who satisfied the criteria for high disease activity (ASDAS≥2.1) at every follow-up point will receive etanercept (50mg per week, for 4 weeks) in the next 4 weeks.
223806026|NCT04077957|DRUG|Etanercept (50mg per week, for 2 weeks)|Participants in Group 1. Experimental who satisfied the criteria for low disease activity (2.1\>ASDAS≥1.3) at every follow-up point will receive etanercept (50mg per week, for 4 weeks) in the next 2 weeks.
223806027|NCT04077957|DRUG|Etanercept (50mg per week)|Participants in Group 2. Positive Control will receive etanercept (50mg per week, for 12 weeks) for 48 weeks.
223806028|NCT01933035|OTHER|Immune Thrombocytopenics|Full blood count with extended platelet parameters
223806029|NCT01933035|OTHER|Hypo-proliferative thrombocytopenics|Full blood count with extended platelet parameters
223806030|NCT01933035|OTHER|Control Population|Full blood count with extended platelet parameters
223806031|NCT00738686|DEVICE|Intracoronary stent implantation|Taxus stent implantation in patients with multivessel coronary artery disease
223806032|NCT01555788|DEVICE|Artificial Pancreas for DiaPort system with Zone-MPC algorithm|Artificial pancreas system uses the intraperitoneal route to deliver insulin (through DiaPort) in type 1 diabetic patients treated by basal-bolus insulin and external pumps.
223806033|NCT06448429|OTHER|Usual care|Participants will have the usual diabetes care at the Grady Diabetes Clinic.
223806034|NCT06448429|OTHER|Collaborative care model (CoCM)|"Collaborative care will include:~* Care with a behavioral health consultant (BHC)~* Measurement-based mental health care~* Systematic caseload reviews~* Medical management of depression~The BHC will monitor depression and anxiety severity, promote behavioral change with patients through Behavioral Activation, and support the medical management of depression through participation in caseload reviews (I.e., Mental health care plans for individual patients will be reviewed monthly by a multi-disciplinary T1D clinical team and BHC). Depression treatment initiation (if warranted) by a clinician and engagement in mental health care."
223806035|NCT03577860|DRUG|Bupivacaine 4 mL|The interscalene brachial plexus block is performed with 4ml of bupivacaine-epinephrine 0,5%- 1:200,000
223806036|NCT03577860|DRUG|Bupivacaine 15 mL|The interscalene brachial plexus block is performed with 15ml of bupivacaine-epinephrine 0,5%- 1:200,000
223806037|NCT00548730|PROCEDURE|Bronchoscopy|The endoscopic examination of the bronchial tree will be performed using a commercially available flexible fluorescence bronchoscope and the flexible white light video-bronchoscope. Biopsies are taken of a normal region and all abnormal regions.
223806038|NCT00227526|BEHAVIORAL|Prehabilitation|
223806039|NCT01547026|BEHAVIORAL|Implementation Intentions|In a 10 minute structured therapy session patients are assisted to build up implementation intentions to participate in the sports program.
223806040|NCT01662063|DRUG|Tocilizumab|TCZ will be given as 162 mg SC QW or Q2W for up to 96 weeks.
223806041|NCT02496338|OTHER|Training program about menopausal health isues|A three sessions raining program about health issues during menopause for spouses of 45-60 years old
223806042|NCT04782934|DEVICE|The YANG SENSOR is an active implantable device, for Real Time Continuous Glucose, Lactate and Ketone Measurement|The YANG SENSOR is an active implantable device, that is intended to be implanted in the subcutaneous abdominal tissue, approximately 10mm below the skin. The SENSOR is battery powered. The battery is wirelessly recharged through the skin by the YANGEXD, using a charging coil ('Donut') applied to the skin with an adhesive patch at the level of the SENSOR. The 'Donut' also receives data from the sensor.
223806043|NCT03487536|OTHER|Nutritional assessment|BMI and cholesterol levels evaluation
223806044|NCT01681108|BEHAVIORAL|Lifestyle counseling|Individualized meal planning and exercise regimen sessions will be developed for each participant
223806045|NCT02897479|DRUG|Savolitinib|Enrolled patients will be treated with Savolitinib 600mg or 400mg once per day(QD), till disease progression, death or unacceptable toxicity, whichever comes first. A cycle of study treatment will be defined as 21 days of continuous dosing.
223806046|NCT01905930|DEVICE|PCM Cervical Disc|Patients enrolled in the IDE clinical study and treated with the PCM Cervical Disc to treat degenerated cervical discs and neurological symptoms at one level from C3 to T1
223806047|NCT01905930|DEVICE|Anterior Cervical Discectomy and Fusion (ACDF)|Patients enrolled in the IDE clinical study and treated with an anterior cervical discectomy and fusion (ACDF) using a cervical plate and bone graft in patients with degenerated cervical discs and neurological symptoms at one level from C3 to T1
223806048|NCT04791072|OTHER|Exercise|Breathing exercise training Use of incentive spirometry Aerobic exercise training Strengthening exercises
223806049|NCT00048672|DRUG|Gleevec|Starting dose of 400 mg orally daily.
223806050|NCT01359670|DRUG|Tadalafil|Escalating dose (0.25 mg/kg, 0.5 mg/kg, 1.0 mg/kg; once daily) over 2 weeks
223806051|NCT01359670|DRUG|Sildenafil|Escalating dose (0.25 mg/kg, 0.5 mg/kg, 1.0 mg/kg; four times daily) over 2 weeks
223806052|NCT01981525|DRUG|Metformin|Treatment will be administered primarily on an outpatient basis. Patients will be instructed to take 500 mg metformin by mouth 1, 2 or 3 times a day or 1000 mg twice per day depending on dose level. Patients will receive metformin at level 1 dose for 2 weeks. If dose is tolerated, patient will receive level 2 dose for 2 weeks and if tolerated will escalate to level 3 dose, and if tolerated will escalate to level 4 dose. Metformin will be taken for 14 weeks.
223806053|NCT04860960|DRUG|Hydroxypropyl-beta-cyclodextrin|Dose is 2000 mg/kg body weight provided every 2 weeks intravenously
223806054|NCT04860960|DRUG|Placebo|0.5N saline provided every 2 weeks intravenously
223806055|NCT03891121|DEVICE|Occlusal Splint|Occlusal splints are appliances that were usually applied to the upper jaw and covering all teeth and they are made of autopolymerizing acrylic resin. It is produced by using 2 mm thick hard acrylic between the maxilla and mandible as defined by the Okeson.
223806056|NCT03891121|DRUG|Botulinum toxin type A|We diluted 100-U freeze-dried BTX-A with 1.0 milliliters of sodium chloride, resulting in a dose of 1.0 U per 0.1 mL. We administered all skin injections by using a 1-inch 30-gauge needle. Patients were placed with the Frankfurt horizontal plane parallel to the floor.
223806057|NCT00250913|BEHAVIORAL|Telephone-based physical activity counseling program|
223806058|NCT01431001|DEVICE|Cervel Neurotech Deep Shaped-Field repetitive transcranial magnetic stimulator (DSF-rTMS)|The Cervel Neurotech Deep Shaped-Field repetitive transcranial magnetic stimulator is an investigational rTMS device
223806059|NCT02676401|DRUG|MT-3995 Low|
223806060|NCT02676401|DRUG|MT-3995 Middle|
223806061|NCT02676401|DRUG|MT-3995 High|
223806062|NCT06495567|DIETARY_SUPPLEMENT|Creatine|For 7 days, participants will take a 20mg creatine supplement each day.
223806063|NCT06495567|DIETARY_SUPPLEMENT|Dietary methionine tracer and protein intake|On the study days participants will ingest 8 hourly meals of controlled amino acid intake, fortified with the necessary macronutrients. Each meal will provide one-twelfth of the participants' daily energy requirements as estimated by 1.5 x Resting Energy Expenditure (REE) and adequate protein at 1.0 g/kg/d, to maintain a metabolic steady state. The meals are in the form of a crystalline amino acid protein shake, and protein-free cookies.
223806064|NCT01501708|DRUG|Caspofugin based combination therapy|"Caspofungin: 70 mg on the ﬁrst day of therapy, followed by 50 mg q.d.~* All patients received azoles as prophylaxis (fluconazole as prophylaxis and itraconazole or voriconazole as secondary prophylaxis), combination with liposomal amphotericin B at a dosage 3mg/kg q.d will be given.~* In case of renal function damage, combination with voriconazole 6mg/kg followed by 4 mg/kg b.i.d. will be given."
223806065|NCT02150018|OTHER|non invasive ventilation|
223806066|NCT04203043|DRUG|Pycnogenol Oral Product|pycnogenol use to prevent hyper pigmentation after foam sclerotherapy
223806067|NCT04203043|OTHER|Placebo|Placebo
223806068|NCT01686555|DRUG|ABT-199|Tablet
223806069|NCT01686555|OTHER|Placebo|Tablet
223806070|NCT00293267|DRUG|raltegravir potassium|Raltegravir 400 mg twice daily (b.i.d.) by mouth (p.o.) with optimized background therapy. Treatment period of 48 weeks.
223806071|NCT00293267|DRUG|Comparator: Placebo|Placebo b.i.d. p.o. with optimized background therapy. Treatment period of 48 weeks.
223806072|NCT05195931|DIAGNOSTIC_TEST|preload challenge|reduction in preload by head-up tilt and increase in preload with saline infusion
223806073|NCT05195931|DIAGNOSTIC_TEST|afterload challenge|reduction in afterload with nitroprusside and increase in afterload with phenylephrine
223806074|NCT05195931|DIAGNOSTIC_TEST|contractility assessment|heart rate changes will be made by increasing heart rate with external pacemaker/defibrillator. Contractility will be adjusted by dobutamine infusion. Patients will exercise at a constant pump speed and also with pump speed increases.
223806075|NCT00602056|OTHER|Redesigned immunization card|A low cost nad simplified redesigned immunization card
223806076|NCT00602056|OTHER|Center based education to mothers/caregivers|A 2-3 minute center based education to mothers/caregivers
223806077|NCT00602056|OTHER|Redesigned immunization card with center based education to mother/caregivers|Redesigned immunization card with center based education to mother/caregivers
223806078|NCT00994357|DEVICE|Real-time CGM|See previous description.
223806079|NCT00994357|OTHER|Standard care|See text.
223806080|NCT01477853|DRUG|Sitagliptin|Sitagliptin 100 mg tablet orally daily
223806081|NCT01477853|DRUG|Atorvastatin|Atorvastatin 80 mg tablet orally daily
223806082|NCT01477853|OTHER|Placebo to sitagliptin|Placebo to sitagliptin tablet orally daily
223806083|NCT01477853|OTHER|Placebo to atorvastatin|Placebo to atorvastatin tablet orally daily.
223806084|NCT01477853|DRUG|Metformin (open-label)|Participant will remain on prestudy dose of metformin tablets (at least 1500 mg daily) throughout entire study.
223806085|NCT01477853|DRUG|Glimepiride (open-label)|Phase A: Glimepiride 1 or 2 mg tablet once daily with breakfast or the first main meal of the day (titrated up to 6 mg/day) for 16 weeks as rescue therapy for randomized participants not meeting specific glycemic goals.
223806086|NCT01477853|DRUG|Glimepiride (double-blind)|Phase B: glimepiride up to 6 mg daily for participants not rescued with open-label glimepiride during Phase A.
223806087|NCT01477853|DRUG|Placebo to glimepiride|Phase B: placebo to glimepiride tablet orally daily.
223806088|NCT02331862|DRUG|Methylprednisolone|Add methylprednisolone in addition to the experience antibiotics in children with urinary tract infection to see if the frequency of the renal scar formation could be decreased
223806089|NCT03659604|BEHAVIORAL|'SmartLife' with tailored feedback|'SmartLife' game with tailored feedback: mobile exergame with tailored feedback. Feedback will be based on accelerometer data from a sensor that is integrated in a T-shirt. The sensor captures individually calibrated accelerometer data and is paired with the mobile exergame. Depending on the physical activity intensity of the player, the game challenge and feedback adapts individually in real-time.
223806090|NCT03659604|BEHAVIORAL|'SmartLife' without tailored feedback|'SmartLife' without tailored feedback: mobile exergame without tailored feedback. The mobile exergame will not be paired to any sensor. The participant can play the mobile game, yet, will not receive any real-time feedback or adjustment in the game on physical activity intensity.
223806091|NCT03659604|BEHAVIORAL|No game|Passive control: School classes will be asked to continue their daily life as usual.
223806092|NCT01050816|PROCEDURE|Chondron(autologous chondrocyte) Implantation|"* Test drug: Chondron (more than 12 million chondrocytes in 0.4ml, i.e. 1 vial)~* Directions and dosage:~Suspend the cells in the vial sufficiently, and implant them in the defective part, making sure that sufficient amounts are injected.~\*30 subjects participated in this open clinical trial. Those who agreed to participate voluntarily went through screening to confirm the appropriateness for the clinical trial, and then received Gel type CHONDRON (fibrin mixed autologous chondrocytes) transplantation."
223806093|NCT04009369|OTHER|Direct access to a PT|Direct access to a PT in the ED immediately after triage and prior to physician assessment.
223806094|NCT03086330|DRUG|Semaglutide|Semaglutide, gradually increased to 1.0 mg, injected once weekly under the skin (subcutaneously, s.c.) for 30 weeks
223806095|NCT03086330|DRUG|Placebo|Semaglutide placebo, gradually increased to 1.0 mg, injected once weekly under the skin (subcutaneously, s.c.) for 30 weeks
223806096|NCT00248781|DEVICE|Telecommunications system|
223806097|NCT00248781|DEVICE|attention control|health education
223806098|NCT01102244|DRUG|Tobradex ST|tobramycin / dexamethasone ophthalmic suspension 0.3%/0.05% 1 drop 4 times daily for 14 days
223806099|NCT01102244|DRUG|Azasite|azithromycin 1% 1 drop twice daily for 2 days, then once daily for 12 days
223806100|NCT05454150|DEVICE|balloon-expandable valve|Sapien 3/Ultra, Edwards Lifesciences©
223806101|NCT05454150|DEVICE|self-expanding valve|Evolut R/Pro, Medtronic©
223806102|NCT01107860|DEVICE|Computed Tomography|In Group I, fifty CBCT studies will be performed. The objectives will be to illustrate the capacity of CBCT to image the breast in its entirety as compared with the gold standard mammographic exam.
223806103|NCT01107860|DEVICE|Computed Tomography|In Group II , at least three hundred and fifty (350) study participants, who require diagnostic evaluation of the breast will undergo a breast CBCT . These subjects may be referred for biopsy as a result of a finding from a mammogram, ultrasound, MRI, or clinical exam.
223806104|NCT02360319|DRUG|Any FDA approved antipsychotic agent|Investigators are free to choose the most appropriate treatment for their clients
223806105|NCT02360319|DRUG|aripiprazole long acting injectable formulation|
223806106|NCT05410600|OTHER|Arm ergometer smart trainer cycling program|Arm ergometer exercise training using the smart trainer.
223806107|NCT02132364|OTHER|optimised follow-up|optimised follow-up will be done by nursing personnel associated with a caregiving member of his social circle.
223806108|NCT03074227|OTHER|Allogeneic faecal transplantation|"Patients will get bowel lavage through a nasoduodenal tube. This bowel lavage consists of 2-3 litres of macrogol electrolytes (Klean-Prep) solution. After that, patients will be treated with allogeneic faecal microbiota transplantation via the nasoduodenal tube.~Faeces will be collected from a donor."
223806109|NCT03074227|OTHER|Autologous faecal transplantation|Patients will get bowel lavage through a nasoduodenal tube at our centre. This bowel lavage consists of 2-3 litres of macrogol electrolytes (Klean-Prep) solution. After that, patients will be treated with autologous faecal microbiota transplantation via the nasoduodenal tube.Faeces will be collected from the patient him/herself, in which their own faeces (autologous) will be used as a placebo.
223806110|NCT04387630|DRUG|Metformin|Oral hypoglycemic drug. Initial dose 500-850 mg/d. incrementally increased to a maximum daily dose of 2550 mg in three divided doses.
223806111|NCT04387630|DRUG|Placebo oral tablet|Simethicone 60 mg three times daily.
223806112|NCT05165342|DEVICE|Rexon-eye|a technique in which low-intensity, high-frequency (a spectrum of frequencies ranging from 4 MHz to 64 MHz) electric currents are administered to a biological tissue through contact electrodes
223806113|NCT02036203|DEVICE|SCu300A IUB|Spherical copper contraceptive
223806114|NCT02036203|DEVICE|TCu380A IUD|T-shaped copper IUD
223806115|NCT01186445|DRUG|morphine chlorhydrate|1mg of morphine chlorhydrate dilute in 3ml of saline solution, intracoronary injection, just before reperfusion
223806116|NCT01186445|DRUG|saline solution|3 ml of saline solution , intracoronary injection during reperfusion
223806117|NCT01532128|DRUG|rasagiline|1 mg rasagiline (single-dose)
223806118|NCT01532128|DRUG|BIA 9-1067|50 mg BIA 9-1067 (single-dose)
223806119|NCT04992351|PROCEDURE|WALANT|WALANT as anesthesia method for upper and lower limb palstic surgery operations
223806120|NCT05375474|DRUG|Oral anticoagulation therapy|Vitamin-K antagonists (warfarin)
223806121|NCT05375474|DRUG|Single antiplatelet therapy|Aspirin
223806122|NCT05016154|BEHAVIORAL|Online Group CBT intervention|Group of participants complete 10 weeks of Online Group CBT intervention
223806123|NCT05016154|BEHAVIORAL|SilverCloud guided|Group of participants make use of the SilverCloud guided app
223806124|NCT05016154|BEHAVIORAL|SilverCloud Unguided|Group of participants make use of the SilverCloud Unguided app
223806125|NCT05016154|BEHAVIORAL|Mood Flow|Group of participants make use of the Mood Flow app
223806126|NCT05085119|PROCEDURE|Stepwise modifications of FiO2|FiO2 will be increased stepwise from 30 to 100% (40, 60 and 80%), and then decreased with the same FiO2 reverse steps.
223806127|NCT03627039|DRUG|SGLT2|All SGLT2 medications approved prior to 2017 will be included (Canagliflozin, empagliflozin, dapagliflozin (all doses, all of the medications are oral)
223806128|NCT03627039|DRUG|Metformin|Metformin is the main comparator of interest. In a secondary analysis GLP1 will be the comparator
223806129|NCT04983758|OTHER|Oral Rehabilitation with dental implants|Patients have been treated with oral dental implants supporting fixed dental prostheses
223806130|NCT04218448|OTHER|Hypnorelaxation|"Hypno-relaxation is induced by following VAKOG: external sensory identification, fixation of attention, bodily sensation, breathing, sensory perceptions, closing of the eyes.~The work phase follows induction and allows deepening of the hypnotic trance. It corresponds to a metaphorical narrative associated with post-hypnotic suggestions and is fueled by the construction of adapted suggestions and metaphors, adapted to each patient. The investigator who remains present throughout the duration of the examination, maintains a hypnotic, empathetic, attentive attitude, and makes it possible to recover this material. Using the elements previously supplied by the patient, the investigator tells a story which allows the patient to focus his attention on something other than the performance of the somatosensory evoked potentials examination. The investigator, thanks to hypnosis, allows the development"
223806131|NCT01825668|OTHER|Plant Sterols|
223806132|NCT01825668|OTHER|High cholesterol|
223806133|NCT01825668|OTHER|Placebo|
223806134|NCT02695030|DEVICE|Low Profile Visualized Intraluminal Support Device|LVIS device is intended for use with bare platinum embolic coils for the treatment of unruptured, wide neck, intracranial, saccular aneurysms.
223806135|NCT02548767|OTHER|high fructose corn syrup|High fructose corn syrup provided as 15% HFCS/85% water (weight/weight) fruit-flavored beverage
223806136|NCT02548767|OTHER|aspartame|Aspartame provided as 0.04% aspartame/99.96% water (weight/weight), fruit-flavored beverage
223806137|NCT02548767|OTHER|Energy-balanced diet|Provided in quantities that equal energy requirement. Formulated such that the overall macronutrient intake; including beverage; equal 45%/5% energy requirement at complex/simple carbohydrate, 35% energy requirement as fat, 15% energy requirement as protein.
223806138|NCT02548767|OTHER|Ad libitum diet|Provided in quantities that exceed energy requirement by approximately 25%. Formulated such that the overall macronutrient intake; including beverage; equals approximately 45%/5% energy requirement at complex/simple carbohydrate, 35% energy requirement as fat, 15% energy requirement as protein.
223806139|NCT06579729|BEHAVIORAL|Dietary intervention for low free sugars|After baseline data collection, the intervention group received a 30-60 minute educational session with a dietitian and clinicians, including a health education prescription. Interventions occurred at weeks 1, 12 and 24, with routine evaluations of disease, diet, physical activity, and adherence. Follow-ups at 48 weeks assessed NAFLD extent, dietary profile, and health knowledge for both subjects and guardians.
223806140|NCT03520166|OTHER|Medium frequency electrotherapy (interferential currents)|Treatment with medium frequency electrotherapy, interferential currents between 5500 Hz and 8500 Hz (Combi-200®, Gymna®), was performed using transvaginal application. The frequency was increased progressively over the first six sessions (twice a week), starting with a frequency of 5500 Hz until reaching a frequency of 8500 Hz, which remained until the end of treatment.
223806141|NCT03520166|OTHER|No treatment|No treatment
223806142|NCT02274389|DRUG|No Intervention|This is an observational study and participants did not receive any intervention in this study. Participants initiating bedaquiline (BDQ) treatment as decided by healthcare provider, will be prospectively observed.
223806143|NCT01814748|DRUG|Omarigliptin|Omarigliptin 25 mg capsule administered orally once weekly
223806144|NCT01814748|DRUG|Placebo to omarigliptin|Matching placebo to omarigliptin 25 mg capsule administered orally once weekly
223806145|NCT01814748|DRUG|Metformin|Open-label metformin (dosed daily according to the country-specific product label) was to be initiated for participants meeting protocol-specified glycemic criteria, but was otherwise prohibited.
223806146|NCT05854225|DRUG|Thiotepa|Thiotepa is an alkylating agent that is routinely used in solid tumors, but it is able to cross the blood-brain barrier into the center.
223806147|NCT05019664|DEVICE|Affixus Natural Nail System|Intramedullary nailing designed for fixation and stabilization of fractures or osteotomies of the humerus. Nails are comprised of proximal and antegrade/retrograde.
223806148|NCT06578975|DIAGNOSTIC_TEST|HT-ENDO-MOS-A13|Mutli-Omics based biomarker to diagnose primary hypertension or endocrine forms of hypertension; primary aldosteronism, pheochromocytoma/functional paraganglioma or Cushing syndrome.
223806149|NCT06578975|OTHER|Normal diagnosis|Standard diagnosis for endocrine hypertension
223806150|NCT06580379|PROCEDURE|Spine surgery|Spine surgery, such as fusion requiring the need for precise intraoperative registration and navigation
223806151|NCT06579274|DRUG|Parecoxib|Parecoxib (Dynastat) 40 mg solution for injection is for intravenous administration. Parecoxib may be given as an intravenous injection for 30 minutes directly into a vein or through an intravenous infusion set.
223806152|NCT06579274|DRUG|Placebo|Placebo intravenous injection can be administered quickly and directly into a vein or through an intravenous infusion set.
223806153|NCT03901196|DIAGNOSTIC_TEST|Elemental analysis|LIBS multi elemental analysis of the specimen
223806154|NCT04044456|BEHAVIORAL|Goal Management Training|"GMT: is a 10-session intervention to improve planning and problem solving. Interactive Power Point modules are administered by a cognitive therapist. Each session builds on the steps of a five-stage planning and problem-solving strategy. Veterans will be taught to generate and verbalize the following five-steps: stop-what am I doing?, define the goal, list the steps, learn the steps; then, check-am I doing what I planned? The five-stage strategy is then incorporated into a variety of activities in the laboratory and in-home assignments."
223806155|NCT04044456|BEHAVIORAL|Attention Training|"Attention Process Training (APT-III) will be administered for a second weekly session in addition to the GMT session. Each session will be 2 hours/ week for 10 weeks. Veterans will also engage in BrainHQTM attention training at home for one-hour, five days/ week comprised of selected components of BrainHQ from Posit Science Corporation. This web-based computerized CRT modality of cognitive training is a restorative or bottom-up approach that targets basic cognitive skills such as arousal and vigilance processes, attention and information processing, and directly engages fundamental attention-control skills through repetitive graded exercises."
223806156|NCT04044456|BEHAVIORAL|Brain Health Workshop|. BHW was developed specifically for consistency with GMT session length and contact with the facilitator49. BHW is an education presentation on brain function and cognitive principles of learning with homework and quizzes on information covered. To match time and contact of attention training, control participants will meet with the therapist for a separate two-hour session from BHW
223806157|NCT04044456|BEHAVIORAL|National geographic movies|participants will select movies to watch and answer a few questions about to equate the time and therapist interaction to attention training in arm 1.
223806158|NCT01972529|DRUG|avatrombopag (lower baseline platelet count)|60 mg avatrombopag (3 x 20 mg tablets)
223806159|NCT01972529|DRUG|placebo (lower baseline platelet count)|60 mg placebo (3 x 20 mg matching placebo tablets)
223806160|NCT01972529|DRUG|avatrombopag (higher baseline platelet count)|40 mg avatrombopag (2 x 20 mg tablets)
223806161|NCT01972529|DRUG|placebo (higher baseline platelet count)|40 mg placebo (2 x 20 mg matching placebo tablets)
223806162|NCT01344668|OTHER|Enhanced Diabetes Education|Provide enhanced diabetes education
223806163|NCT01344668|OTHER|Standard Diabetes Education|Provide Standard Diabetes Education
223806164|NCT01844271|DEVICE|Low Level Laser (LLL)|"Comparison of different dosages of a Low Level Laser applied in six different locations of the knee extensor muscles of the lower limb non-dominant before a strenuous exercise.~We performed stretching and warming up of the muscles involved, assessment of muscle pain, withdrawal of blood sample, test muscle function (MVC), application of dose of low level laser designated for each volunteer (0, 2, 6 or 10), performing eccentric contractions protocol in isokinetic dynamometer . After the protocol we evaluated muscle function, the DOMS, and blood analyzes in 1 minute, 1 hour, 24 hours, 48 hours 72 hours and 96 hours.~In a second stage, the optimal dose defined by the first part of the study will be tested in two different powers, 100 and 400mW. The study was repeated in two experimental groups using the optimal dose established and the powers of 100 and 400mW that was randomly distributed in groups."
223806165|NCT01872533|OTHER|Hypoxia Exposure|Participants spent 10 consecutive nights (approximately 100 hours of exposure) in a hypoxic tent at \~ 15% O2 (ca. 2400 m elevation).
223806166|NCT00268827|DRUG|Kaletra soft-gel capsules switched to Kaletra tablets|
223806167|NCT00268827|DEVICE|MOS-HIV Health and Medication Satisfaction Survey, Global Conditioning Improvement and Therapy Preference Questionnaire|
223806168|NCT03262610|DRUG|Setmelanotide|daily subcutaneous injection
223806169|NCT00783731|DRUG|Low dose midazolam|
223806170|NCT03393195|BEHAVIORAL|Time-restricted Eating plan|Research team will prescribe an eating plan for the participant to follow for the 12 week study. The eating plan will consist of eating during a specified 8 hour window and fasting for the remaining 16 hours of the day.
223806171|NCT03393195|BEHAVIORAL|Consistent Meal timing plan|Research team will prescribe an eating plan for the participant to follow for the 12 week study.The eating plan will consist of eating three structured meals each day during three specified meal windows.
223806172|NCT02274857|PROCEDURE|Standard PVI Ablation|Standard PVI procedure without FIRMap.
223806173|NCT02274857|PROCEDURE|FIRM-Guided Procedure and PVI|FIRM-guided procedure followed by conventional ablation including PVI.
223806174|NCT01606527|DRUG|Ibuprofen 600mg orally three times daily|Ibuprofen is taken 600mg orally three times daily
223806175|NCT00948298|DRUG|Vitamin D|Two 50,000 IU tablets of oral Vitamin D3 will be given every 4 weeks.
223806176|NCT00948298|DRUG|Placebo|Two tablets of oral placebo (microcrystalline cellulose),matching in appearance to the Vitamin D3, will be given every 4 weeks.
223806177|NCT04894201|RADIATION|Dental Panoramic Radiographs|Exposure to dental panoramic radiographs
223806178|NCT06072534|DRUG|"Mivacurium Chloride"|emergence modified sequence intubation
223806179|NCT03871179|DIAGNOSTIC_TEST|ASD Diagnostic Device|"The ASD Diagnostic Device is a machine learning algorithm-based software as a medical device that is incorporated into a parent/caregiver-facing mobile application, the Cognoa App, used outside of a clinical setting"
223806180|NCT00330174|DRUG|Acamprosate|2 333mg tablets three times daily
223806181|NCT05199610|DRUG|aumolertinib|A single dose of 55-mg EQ143 tablet will be administered in the morning on Day 1, and participants will remain for 5 days (4 nights) in the study center for collection of blood samples and safety monitoring. Participants will attend outpatient follow-up visits on Days 5, 6, 8, and 9 for additional blood sampling and safety assessments.
223806182|NCT05019833|DEVICE|Signals collection|A non-CE marked embedded software will be temporarily uploaded in the implanted device, in order to enable the collection of sensors signals.
223806183|NCT01520818|DRUG|biphasic insulin aspart 50|Administered subcutaneously (s.c., under the skin) at breakfast, lunch and dinner. Randomised subjects being obese with a body mass index (BMI) exceeding 30 kg/m\^2 will receive BIAsp 50
223806184|NCT01520818|DRUG|biphasic insulin aspart 70|Administered subcutaneously (s.c., under the skin) at breakfast, lunch and dinner. Randomised subjects being lean and overweight with a body mass index (BMI) of maximum 30 kg/m\^2 will receive BIAsp 70
223806185|NCT01520818|DRUG|biphasic human insulin 30|Administered subcutaneously (s.c., under the skin), twice a day
223806186|NCT04606277|OTHER|Smartphone addiction scale, physical activity scale and depression questionnaire|Telephone addiction of the subjects was measured. Then, physical activity levels were questioned, and finally depression scale was applied.
223806187|NCT00546780|DRUG|Tanespimycin|Solution, IV, 340mg/m2, twice weekly for 2 weeks (3 week cycle), 60 minutes infusion
223806188|NCT00546780|DRUG|Bortezomib|Solution, IV, 1.3 mg/m2, twice weekly for 2 weeks (3 weeks cycle), 3-5 minute bolus
223806189|NCT01595893|DRUG|Oral Vitamin D 3|40,000 IE vitamin D3 per 70 kg body weight, given twice (2 weeks apart)
223806190|NCT01595893|DRUG|Miglyol 812 N|Neutral oil of esters extracted from coconut and palm kernel
223806191|NCT01506895|DRUG|darapladib|Experimental compound 160 mg dose
223806192|NCT01506895|DRUG|placebo|Placebo to match
223806193|NCT00428467|PROCEDURE|LV Apex Compression|
223806194|NCT03831243|RADIATION|Stereotactic body radiotherapy|Treatment will be prescribed to the periphery of the target, i.e. 80% of the dose should cover 95% of the PTV. The organ at risk (OAR) dose constraints will be in accordance with the recommendations from the report of the American Association of Physicists in Medicine (AAPM) task group 101. Image-guidance will consist of cone-beam CT in combination with 6 degrees of freedom corrections using robotic couch.
223806195|NCT03831243|RADIATION|3D-conformal radiotherapy|In the standard setting, 95% of the PTV should receive 95% of the prescribed dose while near maximum dose (Dnear-max) in the PTV should not exceed 107%. Image-guidance will consist of portal images showing the relevant bony anatomy.
223806196|NCT02526043|PROCEDURE|laparoscopic hepatectomy|The HCC patients who meet the Louisville consensus will underwent liver resection by laparoscopy
223806197|NCT02526043|PROCEDURE|Open hepatectomy|The HCC patients who meet the Louisville consensus will underwent liver resection by open surgery
223806198|NCT02845401|OTHER|Stop NA therapy|Cases will stop antiviral therapy
223806199|NCT04194567|OTHER|Black Ragi|Pancakes made out of the dark ragi
223806200|NCT04194567|OTHER|White Ragi|Pancakes made out of the white ragi
223806201|NCT02708875|OTHER|Mixed Meal Challenge|Liquid mixed meal (300 calories - fat, carbohydrate, and protein).
223806202|NCT02708875|OTHER|Glucose Challenge|Glucose drink (50g glucose)
223806203|NCT00004408|DRUG|poloxamer 188|
223806204|NCT02521662|DRUG|Nicotine patch|A transdermal patch that slowly releases nicotine into the body through the skin.
223806205|NCT02521662|DEVICE|e-cigarette|A electronically powered device that delivers to the user an aerosol of propylene glycol and/or glycerine, with or without flavourings and nicotine.
223806206|NCT02521662|DRUG|Nicotine|Nicotine contained in e-liquid (e-juice) used in e-cigarettes
223806207|NCT02521662|BEHAVIORAL|Behavioural support|Withdrawal-oriented behavioural support
223806208|NCT01372657|OTHER|biometry calculation|
223806209|NCT05306366|DRUG|[11C]-Lu AF90103|PET ligand administrated as a single intravenous bolus injection
223806210|NCT00611858|DRUG|Cetuximab|
223806211|NCT00611858|DRUG|5-Fluorouracil|
223806212|NCT00611858|RADIATION|Radiation|
223806213|NCT01844284|DEVICE|XIENCE PRIME®/XIENCE Xpedition™|Subjects receiving XIENCE PRIME®/XIENCE Xpedition™
223806214|NCT01844284|DEVICE|Absorb™ BVS|Subjects receiving Absorb™ BVS
223806215|NCT04085302|DEVICE|Digital Behaviour Change Intervention|14 days
223806216|NCT01058304|OTHER|Group Physical Therapy for Knee OA|The group PT arm will include 6 1 to 1 hour visits (every other week) led by a physical therapist and exercise physiologist or PT Assistant, with 8 participants per group. The group PT sessions will include group instruction in joint care (activity pacing and joint projection), group discussion of exercise successes and barriers, group exercise, and scheduled individual consultations with the physical therapist (2 per participant, 15-20 minutes each) to address specific functional and therapeutic needs. Participants will also be given instructions for a home exercise program.
223806217|NCT01058304|OTHER|Individual Physical Therapy for Knee OA|The individual PT arm, modeled after typical PT care for knee OA at the Durham VAMC and other health care settings, will include 2 1-hour visits with a physical therapist, 2-3 weeks apart. While the individual PT sessions will differ in structure from the group PT sessions they will include the same informational, assessment, and therapeutic content as the group sessions. Participants in this group will also be given instructions for the same home exercise program.
223806218|NCT04175795|BEHAVIORAL|My Personal Brain Health Dashboard|"The intervention of this study is grounded in the knowledge-to-action framework (Graham et al., 2006) and consists of providing feedback by sending participants their personalized health outcome profiles. As mentioned above, the context of our study is the BHN cohort. For all participants enrolled in the parent study, data on wide spectrum of health outcomes have been gathered. As part of the knowledge translation plan, a personalized profile of specific modifiable health outcomes called as My Personalized Brain Health Profile has been created for each participant (Appendix B). The profile covers information on brain health outcomes, health and quality of life ratings, and lifestyle factors."
223806219|NCT01820559|DRUG|Placebo|Tablets
223806220|NCT01820559|DRUG|ESL 1200 mg|Eslicarbazepine acetate was supplied in 400-mg and 600-mg tablets and was administered with a dose of 800 or 1200 mg QD in the evening by the oral route.
223806221|NCT01820559|DRUG|ESL 800 mg|Eslicarbazepine acetate was supplied in 400-mg and 600-mg tablets and was administered with a dose of 800 or 1200 mg QD in the evening by the oral route.
223806222|NCT03263832|DIAGNOSTIC_TEST|Antibiofilmogramme|An Antibiofilmogramme (BioFilm Control) evaluates the capacity of a series of antibiotics to inhibit the growth of bacterial biofilms for a given bacterial isolate.
223806223|NCT02317939|OTHER|instruction|online instruction tutorials at followup visits
223806224|NCT02317939|OTHER|standard baseline instruction|self-guidance at followup visits
223806225|NCT02755597|DRUG|Venetoclax|Participants self-administered venetoclax tablets by mouth QD in combination with bortezomib. Venetoclax was to be given before other agents administered on the same day, if applicable. Each venetoclax dose was to be taken all at one time with approximately 240 mL of water within 30 minutes after completion of breakfast or the subject's first meal of the day. Tablets were to be swallowed whole and must not have been broken, chewed, or crushed. On days that pre-dose PK sampling was required, dosing occurred at the clinic to facilitate PK sampling.
223806226|NCT02755597|DRUG|Bortezomib|Bortezomib (subcutaneous injection \[preferred\] or IV) was given following administration of venetoclax or placebo in Cycles 1 -8 on Days 1, 4, 8 and 11, and for Cycles 9 and beyond, on Days 1, 8, 15 and 22 and was to be administered per the prescribing information. The route of administration was to stay the same during the study.
223806227|NCT02755597|DRUG|Dexamethasone|Dexamethasone was to be given orally, administered per the prescribing information, the day of bortezomib dosing and the following day, given the protocol-defined dosing window (bortezomib dosing window is ± 1 day) is maintained. If bortezomib was interrupted or a dose is skipped, dexamethasone was to be administered as scheduled per protocol (unless dexamethasone was interrupted due to toxicity).
223806228|NCT02755597|DRUG|Placebo for venetoclax|Participants self-administered placebo tablets by mouth QD in combination with bortezomib. Placebo was to be given before other agents administered on the same day, if applicable. Each placebo dose was to be taken all at one time with approximately 240 mL of water within 30 minutes after completion of breakfast or the subject's first meal of the day. Tablets were to be swallowed whole and must not have been broken, chewed, or crushed. On days that pre-dose PK sampling was required, dosing occurred at the clinic to facilitate PK sampling.
223806229|NCT05782725|OTHER|Comparison of laboratory test results in women in the 4 study arms|Comparison of AMH, FSH, LH, estradiol, AFC/ ovarian volume on ultrasound in women in the 4 study arms
223806230|NCT01069354|DEVICE|Radiesse® Injectable Dermal Filler with Lidocaine|Calcium hydroxylapatite particles suspended in an aqueous-based gel carrier with 3% lidocaine hydrochloride (HCl)
223806231|NCT01069354|DEVICE|Radiesse® Injectable Dermal Filler without Lidocaine|Calcium hydroxylapatite particles suspended in an aqueous-based gel carrier without 3% lidocaine hydrochloride (HCl)
223806232|NCT00904514|GENETIC|gene expression analysis|
223806233|NCT00904514|GENETIC|microarray analysis|
223806234|NCT00904514|GENETIC|mutation analysis|
223806235|NCT00904514|GENETIC|polymerase chain reaction|
223806236|NCT00904514|OTHER|flow cytometry|
223806237|NCT00904514|OTHER|immunoenzyme technique|
223806238|NCT00904514|OTHER|laboratory biomarker analysis|
223806239|NCT05608096|DEVICE|Hemoperfusion|Commercial membrane for extracorporeal blood purification (hemoperfusion)
223806240|NCT02685644|PROCEDURE|Laparoscopic removal of cysts|Women with endometrioma lesions will undergo laparoscopic removal. Cysts will be enucleated with blunt dissection of the cyst capsule and following traction, counter traction maneuver. Bipolar coagulation will be used sparsely and suturing will be the predominant choice for achieving bleeding control.
223806241|NCT04182763|OTHER|CoA-Z|People with PKAN lack a chemical to process or metabolize a certain vitamin in the brain. CoA-Z is designed to bypass this metabolic defect that causes PKAN.
223806242|NCT04182763|OTHER|Placebo|The placebo is a strawberry-flavored syrup that looks and tastes like CoA-Z but has no active CoA-Z in it.
223806243|NCT06579339|OTHER|xylitol chewing gum|Chewing gum with xylitol was chewed 3 times a day for 15 minutes. A new chewing gum was chewed by the researcher in each chewing period, chewing gum was stopped at the end of 15 minutes and each quadrant was listened for 15 seconds. The onset of bowel movement was evaluated and all information was recorded in the patient information form and follow-up form. Patients who were discharged without stool output were telephoned and their stool output was questioned. Gum chewing was performed at the 2nd hour, 4th hour and 6th hour postoperatively (due to the opening of the oral cavity at 6 hours) and the collection of patient data was continued by telephone until discharge and afterwards.
223806244|NCT02393287|OTHER|Eribulin (ReProLine)|this is an observational trial ; there is no intervention
223806245|NCT03402256|BEHAVIORAL|Text Message|In addition to the SC interventions, participants in the Text Message condition received text messages. Participants received 3 text messages per day for the first four weeks of the study and 3 messages per week for the last four weeks. Participants will receive messages targeting known predictors of alcohol abstinence and relapse, including (1) craving, (2) identification of high-risk situations, (3) identification of triggers, (4) stress level, (5) coping skills, and (5) quality of life. The text messages will include motivational messages and behavior-change techniques (e.g. coping with cravings and urges to drink, trigger identification, high-risk situation identification). Messages will encourage participants to continue with sobriety and focus on the success they have achieved so far.
223806246|NCT02790723|DRUG|sc-rAAV2.5IL-1Ra|Self-complementing, recombinant AAV carrying IL-1Ra cDNA produced by the Research Institute at Nationwide Children's Hospital.
223806247|NCT06141330|DIETARY_SUPPLEMENT|D Max Drops|Vitamin D
223806248|NCT06141330|DRUG|Azithromycin 250 milligram Oral Capsule|Anti Biotic
223806249|NCT06141330|DRUG|Adapalene|Retinoid
223806250|NCT06508047|DEVICE|Informed Vital Core App|Informed Vital Core App will be initiated by the study staff to take a measurement, which takes 60 seconds to calculate and report a breathing rate value.
223806251|NCT05292859|BIOLOGICAL|Neoantigen specific TCR-T cell drug product|No study drug is administered in this study. Patients who have received Neoantigen specific TCR-T cell drug product will be evaluated in this trial for long-term safety and efficacy
223806252|NCT05108649|OTHER|Nicotine Messaging|After completing a 7-day baseline period, participants will be randomized to a 28-day experimental period and will view nicotine corrective messaging at each in-person session or delayed control messaging at the final study session.
223806253|NCT05108649|OTHER|Cigarette Condition|After completing a 7-day period of smoking own brand cigarettes, participants will be randomized to a 28-day experimental period and will receive reduced nicotine content (RNC) cigarettes or normal nicotine content (NNC) cigarettes.
223806254|NCT03673306|OTHER|Clinical outcomes|Clinical outcomes
223806255|NCT02202746|DRUG|Lucitanib|Lucitanib is a potent, orally available selective inhibitor of the tyrosine kinase activity of fibroblast growth factor receptors (FGFR1-3), vascular endothelial growth factor receptors (VEGFR1-3), and platelet-derived growth factor receptors alpha and beta (PDGFR alpha and beta)
223806256|NCT05728255|DIAGNOSTIC_TEST|ABPM plys SCAFB|24-hour ambulatory blood pressure monitoring (ABPM) and of tilt-table Short Cardiovascular Autonomic Function Battery (SCAFB) which consists in carotid sinus massage (CSM) and head-up tilt test (HUT) performed one after the other in an uninterrupted sequence as a single procedure on a tilt table
223806257|NCT05384028|OTHER|Nurse -led case management|This study would apply case management to the whole course management of AMI patients from admission to 6 months after discharge. Pharmacists, nutritionists, rehabilitation specialists and psychiatrists led by nurse would take the initiative to conduct individualized assessment and health guidance, and case managers would participate in the whole process of inpatient diagnosis and treatment. Coordinating multidisciplinary medical resources to jointly implement diagnosis and treatment and rehabilitation for patients can improve the quality of care.
223806258|NCT05384028|OTHER|Routine inpatient care and post-discharge follow-up management|Patients in the control group will receive routine inpatient care and post-discharge follow-up management
223806259|NCT01842113|DRUG|Rifaximin|Rifaximin 550mg by mouth twice a day
223806260|NCT01842113|DRUG|Lactulose|Lactulose 30ml by mouth three times a day
223806261|NCT01842113|DRUG|Lactulose Placebo|Lactulose Placebo 30ml three times a day
223806262|NCT01842113|DRUG|Rifaximin Placebo|Rifaximin Placebo twice a day
223806263|NCT04426864|OTHER|Supervised Aerobic Plus Stretching Exercises|An exercise prescription was developed for each woman based on the data acquired from the baseline treadmill exercise test. Target HR corresponding to values of 50-70 % ergospirometric VO2max (moderate-intensity) was determined by the submaximal treadmill test. The participants were instructed to perform their exercises at 50 % of VO2max for six weeks. At seventh their exercise intensity was increased to target HR corresponding to 70 % of VO2max. HR was monitored by a Polar HR monitor (Polar Beat, Port Washington, NY). Stretching exercises were performed at the beginning and end of each exercise session. Each muscle group exercise was performed 3-4 times and each repeat was 30 seconds long. The muscle groups which were involved in stretching exercises were upper trapezius, rhomboid, hip flexor, hamstring, pectoral, piriformis, quadriceps, gastrocnemius, soleus, levator scapulae, hip adductor and tensor fasciae late muscles. The exercise program was applied 3 days a week for 12 weeks.
223806264|NCT04426864|OTHER|Supervised Resistance Plus Stretching Exercises Group|According to the data obtained from 1-RM tests, an exercise prescription was developed for each woman. The participants were instructed to perform their exercises with 50% of 1-RM for six weeks. In the 7. week, weights were increased to 70-80% of 1-RM. The number of sets increased progressively (10 repetitions per set; 1 set in the first two weeks; 2 sets in the 3rd and 4th week; 3 sets in the 5th and 6th week). The muscle groups which were involved in resistance exercises were bilateral biceps, deltoid, trapezius, pectorals, serratus anterior, latissimus dorsi, levator scapulae, rhomboid, gluteal, quadriceps, hip adductor and abductor, hamstring, gastrocnemius and abdominal muscles. Stretching exercises were performed at the beginning and end of each exercise session. Each muscle group exercise was performed 3-4 times and each repeat was 30 seconds long. Stretching exercises were given for the muscle groups they worked on. The exercise program was applied 3 days a week for 12 weeks.
223806265|NCT04426864|OTHER|Home-based Stretching Exercises Group|Each exercise was described to the patient by visually. For each muscle group exercise was performed for 3-4 times and each repeat was 30 seconds long. The muscle groups which were involved in stretching exercises were upper trapezius, rhomboid, hip flexor, hamstring, pectoral, piriformis, quadriceps, gastrocnemius, soleus, levator scapulae, hip adductor and tensor fasciae late muscles. Exercise program was applied 3 days in a week during 12 weeks. Each participant was called every 2 weeks to maintain compliance.
223806266|NCT03210662|RADIATION|External Beam Radiation Therapy|Undergo EBRT
223806267|NCT03210662|BIOLOGICAL|Pembrolizumab|Given IV
223806268|NCT03773393|BIOLOGICAL|CK0801|CK0801 (a Cord blood-derived T-regulatory cell product)
223806269|NCT05298150|OTHER|Dynamic cycling|The dynamic cycling involves smart bike that changes according to participants' performance.
223806270|NCT05298150|OTHER|Forced cycling|The same smart bike as used for dynamic cycling, but its adaptive capacity will be disabled. In this case, the bike will behave as standard exercise stationary bike. It will not change its performance according to participants' response.
223806271|NCT06211660|BEHAVIORAL|AI-based AR training system|Participants will use the AI-empowered AR training system to get individualized assessments of their hand wash performance. They will not be informed about the hand scanner results.
223806272|NCT06211660|BEHAVIORAL|Hand scanner and Video training|Participants will use an existing education program that has been demonstrated effective in our previous study (unpublished). In brief, the participants will be informed about their hand scanner results during the first HW attempt. They will also watch a training video about the 7 steps of hand washing.
223806273|NCT00501826|DRUG|Cyclophosphamide|Given IV
223806274|NCT00501826|DRUG|Cytarabine|Given IV
223806275|NCT00501826|DRUG|Dexamethasone|Given IV or PO
223806276|NCT00501826|DRUG|Doxorubicin Hydrochloride|Given IV
223806277|NCT00501826|DRUG|Mercaptopurine|Given PO
223806278|NCT00501826|DRUG|Methotrexate|Given IV and PO
223806279|NCT00501826|DRUG|Nelarabine|Given IV
223806280|NCT00501826|DRUG|Pegaspargase|Given IV
223806281|NCT00501826|DRUG|Prednisone|Given PO
223806282|NCT00501826|DRUG|Venetoclax|Given PO
223806283|NCT00501826|DRUG|Vincristine Sulfate|Given IV
223806284|NCT05139875|DRUG|Betamethasone Dipropionate / Betamethasone Sodium Phosphate|Single intra-articular Betamethasone Dipropionate / Betamethasone Sodium Phosphate (Diprospan) injections to affected knee
223806285|NCT05139875|DRUG|Triamcinolone Acetonide 40mg/mL|Single intra-articular Triamcinolone Acetonide injections to affected knee
223806286|NCT04723823|OTHER|Motor or sensory imagery with fMRI|Brain activity will be measured using fMRI while participants imagine different movements or sensations in order to assess the organization of sensorimotor cortical activity after injury
223806287|NCT06441565|DRUG|Fruquintinib|A treatment cycle of 4 weeks, with 5 mg orally once daily for 3 weeks, followed by a 1-week break
223806288|NCT06441565|DRUG|Fluorouracil|2.8 g/m² (400mg bolus + 2.4g/m² continuous infusion) given every 2 weeks through hepatic arterial infusion
223806289|NCT06441565|DRUG|Oxaliplatin|85 mg/m² given every 2 weeks through hepatic arterial infusion
223806290|NCT02288754|DIAGNOSTIC_TEST|Blood test|No intervention except to collect blood for diagnostic test development
223806291|NCT02744833|DRUG|GMI-1271|
223806292|NCT02744833|DRUG|Enoxaparin Sodium (Lovenox®)|
223806293|NCT00423384|DRUG|Placebo|Placebo
223806294|NCT00423384|DRUG|Ibandronate|I.v.
223806295|NCT05917977|BEHAVIORAL|Collective Motivational Interviewing plus Education Materials|The participants in the intervention group will receive IGD educational materials as well as four counseling sessions of CMI intervention.
223806296|NCT05917977|OTHER|Control group (Education Materials)|The participants in the control group will receive IGD educational materials.
223806297|NCT05864781|BEHAVIORAL|Jigsaw Technique|Jigsaw technique is one of the cooperative learning methods. A topic planned to be learned in the lesson is divided into sections and these sections are distributed to the students in the main group. Students who are responsible for the same sections in the groups combine to form expert groups and specialize by working on the subject. They then return to their main group to share their knowledge and make a presentation on the topic.
223806298|NCT04064489|OTHER|TRIPscore|TRIPcast score calculation
223806299|NCT01510431|DRUG|PROCHYMAL (remestemcel-L)|intravenous administration of 200 million cells on days 0, 3, 7, and 14, and then, at investigator discretion, periodically thereafter
223806300|NCT03897257|DRUG|UHE-103A1 cream|Investigational mono-therapy cream (containing drug A \[low dose\]). Drug A is an antifungal agent.
223806301|NCT03897257|DRUG|UHE-103A2 cream|Investigational mono-therapy cream (containing drug A \[low dose\]). Drug A is an antifungal agent.
223806302|NCT03897257|DRUG|UHE-103B cream|Comparator mono-therapy cream (containing drug B). Drug B is a keratolytic agent.
223806303|NCT03897257|DRUG|UHE-103A1B cream|Investigational combination-therapy cream (containing drug A \[low dose antifungal\] + drug B \[keratolytic\]).
223806304|NCT03897257|DRUG|UHE-103A2B cream|Investigational combination-therapy cream (containing drug A \[high dose antifungal\] + drug B \[keratolytic\]).
223806305|NCT04348305|DRUG|Hydrocortisone|Continuous infusion: 200 mg (104 ml) every 24 hours, Bolus injections: 50 mg (10 ml) every 6 hours, Total treatment duration: 7 days
223806306|NCT04348305|DRUG|Sodium Chloride 9mg/mL|Continuous infusion: 104 ml every 24 hours, Bolus injections: 10 ml every 6 hours, Total treatment duration: 7 days
223806307|NCT05349825|DIAGNOSTIC_TEST|Genetic analysis and Losartan plazma level measurement|20 ml of blood was collected from the enrolled patients. 10 ml of blood was stored in the tubes with ethylene diamine tetraacetic acid (EDTA) until Deoxyribonucleic acid (DNA) isolation was performed at -20 degrees and plasma level was identified. The remaining 10 ml was centrifuged at 3500 rpm for 10 min, and the plasma was separated. The resulting plasmas were stored in the eppendorf tubes at -20°C until the tandem mass spectrometry measurement. The blood samples in EDTA tubes were then transferred for DNA analysis. . To measure plasma losartan concentration, after the frozen plasma samples stored in the eppendorfs were thawed and brought to room temperature, plasma losartan and EXP3174 levels of the patients were calculated using tandem mass spectrometry
223806308|NCT01868295|BEHAVIORAL|Sleeping with denture|Sleeping with denture at night
223806309|NCT04999878|DRUG|Ruxolitinib, Etoposide, Dexamethasone, Gemcitabine, Pegaspargase, cis-platinum|"All enrolled patients will receive a regimen containing Ruxilitinib, Etoposide, Dexamethasone, Gemcitabine, Pasparase and Platinum for 28 days. The specific medication is as follows:~Ruxilitinib 10 mg, bid, d1-28, P.O. Etoposide 100mg per week, two weeks, ivgtt Dexamethasone, 15mg/(m²·d)，d1-12，10 mg/ (m²·d) ，d13-14，5 mg/ (m²·d) ，d15-21，2.5mg/(m²·d)，d22-28，ivgtt or P.O.~Gemcitabine, 0.5 g/m², d8, ivgtt Pegaspargase, 2500IU/m², d9, im Platinum, 20mg/m² d10 d11, ivgtt After the treatment, patients will be given disease specific chemotherapy regimen to treat lymphoma according to patient's different lymphoma subtype."
223806310|NCT02961530|OTHER|Isokinetic eccentric exercises|"The individuals of both groups will be submitted to the same physiotherapeutic protocol with objectives of analgesia, reduction of edema, recovery of range of motion, proprioception and functionality.~15 days after partial menisectomy, subjects randomly allocated to this arm will be submitted to a muscle rehabilitation program based on isokinetic eccentric exercise lasting six weeks, with training frequency of two sessions per week, separated by a minimum interval of 72 hours."
223806311|NCT02961530|OTHER|Isotonic eccentric exercises|"The individuals of both groups will be submitted to the same physiotherapeutic protocol with objectives of analgesia, reduction of edema, recovery of range of motion, proprioception and functionality.~15 days after partial menisectomy, subjects randomly allocated to this arm will be submitted to a muscle rehabilitation program based on isotonic eccentric exercise lasting six weeks, with training frequency of two sessions per week, separated by a minimum interval of 72 hours."
223806312|NCT02020525|PROCEDURE|restrictive transfusion strategy|Patients allocated to the restrictive transfusion strategy were transfused only when their hemoglobin concentration decreased below 7.7 g d dL-1 and were then maintained at hemoglobin concentrations between 7.7 and 9.9 g d dL-1.
223806313|NCT02020525|PROCEDURE|liberal transfusion strategy|Patients assigned to the liberal strategy were transfused when their hemoglobin concentration fell below 9.9 g dL-1, aiming at maintaining hemoglobin at or above 10 g dL-1.
223806314|NCT05571293|DRUG|Botensilimab|Botensilimab, a CTLA-4 inhibitor, will be administered prior to surgical resection as described in the arm description.
223806315|NCT05571293|DRUG|Balstilimab|Balstilimab, a PD-1 inhibitor, will be administered prior to surgical resection as described in the arm description.
223806316|NCT06205342|DRUG|Mesenchymal Stem Cells|Autologous bone marrow derived MSCs
223806317|NCT06205342|OTHER|Other: Placebo|Control
223806318|NCT04639388|BEHAVIORAL|neuropsychological testing, questionnaires and experimental tasks|Neuropsychological testing (the Sky Search subtest from the Test of Everyday Attention for Children (TEA-Ch); the Overlapping lines task of Rey; auditory attention of NEPSY II battery); questionnaires completed by the children's legal representatives to assess behavior; experimental tasks evaluating gaze direction and facial expression recognition
223806319|NCT03628287|OTHER|Revised Care Coordination Program|Greater focusing, tailoring and cues for delivery of key components of Care Coordination
223806320|NCT03628287|OTHER|Original Care Coordination Program|Original Care Coordination
223806321|NCT04880395|DRUG|Intervention Arm: dolutegravir/lamivudine|1 pill QD
223806322|NCT04880395|DRUG|Comparator ARM: TDF/XTC plus Dolutegravir (XTC stand for lamivudine OR emtricitabine)|1 pill of each QD
223806323|NCT05082090|PROCEDURE|Spinal Surgery|Implanted with Orthofix Spinal products
223806324|NCT03744273|PROCEDURE|breast capsule biopsy|
223806325|NCT01895972|DRUG|Latanoprostene bunod|
223806326|NCT06523530|DRUG|Goserelin Acetate 3.6 mg inj, implant|3.6 mg (1ml) administered subcutaneously once every month for 6 months (totally 6 injections)
223806327|NCT04278118|RADIATION|Hypofractionated Radiation Therapy|Undergo hypofractionated proton or photon radiation therapy
223806328|NCT04278118|RADIATION|Photon Beam Radiation Therapy|Undergo hypofractionated proton or photon radiation therapy
223806329|NCT04278118|RADIATION|Proton Beam Radiation Therapy|Undergo hypofractionated proton or photon radiation therapy
223806330|NCT04278118|OTHER|Quality-of-Life Assessment|Ancillary studies
223806331|NCT04278118|OTHER|Questionnaire Administration|Ancillary studies
223806332|NCT06450834|DEVICE|Ostene|Soluble Bone Hemostasis Implant Material
223806333|NCT05893927|OTHER|Diabetes education web site application|The Diabetes education website application will contain informational videos for this protocol. The videos will include a welcome video and the categorical topics of Healthy Coping, Healthy Eating, Staying Active, Medications (Use and Safety), Problem Solving in Diabetes, and Disease Pathophysiology. Each category contains several videos providing education about a different component of diabetes care.
223806334|NCT06061497|OTHER|Abdomino-diaphragmatic breathing|Breathing should be done twice a day for 10 minutes.
223806335|NCT06061497|BEHAVIORAL|Usual Care|Health education Review of inhaler technique Check adherence to treatment; Presence of comorbidities; Smoking; Other environmental factors; Promotion of physical activity
223806336|NCT05750628|DRUG|INE963|oral INE963
223806337|NCT05750628|DRUG|KAE609 (Cipargamin)|oral KAE609 (Cipargamin)
223806338|NCT05750628|DRUG|SoC (Coartem)|SoC (Coartem)
223806339|NCT05750628|DRUG|KLU156|oral sachet KLU156 (KAF156 + lumefantrine)
223806340|NCT04631263|DEVICE|Hyaluronic Acid|Injectable gel. Chin correction and augmentation for retrusion
223806341|NCT03057353|DEVICE|lumbar CT imaging|Collecting lumbar CT imaging data of 104 patients with lumbar spinal stenosis to observed the incidence of ligamentum flavum hypertrophy of patients with different nationalities, sexes, heights, ages, and weights and explored risk factors affecting ligamentum flavum hypertrophy.
223806342|NCT02753595|DRUG|Eribulin mesylate|Eribulin mesylate will be administered at 1.4 mg/m\^2 or 1.1 mg/m\^2 as intravenous (IV) infusion on Day 1 and 8 of 21-day cycle
223806343|NCT02753595|DRUG|Eribulin mesylate|Eribulin mesylate will be administered at 1.4 mg/m\^2 or 1.1 mg/m\^2, depending on RP2D, as IV infusion on Day 1 and 8 of each 21-day cycle
223806344|NCT02753595|DRUG|Eribulin mesylate|Eribulin mesylate will be administered at 1.4 mg/m\^2 as IV infusion on Day 1 and 8 of 21-day cycle
223806345|NCT02753595|OTHER|Biologic: PEGylated recombinant human hyaluronidase (PEGPH20)|PEGPH20 will be administered at 3.0 mcg/kg or 1.6 mcg/kg as IV infusion on Day -1 and 7 of 21-day cycle
223806346|NCT02753595|OTHER|Biologic: PEGylated recombinant human hyaluronidase|PEGPH20 will be administered at 3.0 mcg/kg or 1.6 mcg/kg, depending on RP2D, as IV infusion on Day -1 and 7 of each 21-day cycle
223806347|NCT04414449|OTHER|ICT-enabled Social-emotional Learning|ICT-enabled Social-emotional Learning
223806348|NCT01570868|DRUG|Ponatinib|Starting dose: 45 mg by mouth once daily.
223806349|NCT04181203|DRUG|Apalutamide|"240 mg PO daily should start the same day as the first LHRHa administration for 6 months.~months."
223806350|NCT04181203|RADIATION|Salvage radiotherapy (SRT)|"The SRT treatment will be administered to a total dose of 66 Gy (in 33 fractions of 2 Gy) directed at the prostate bed with an additional 56.1 Gy (in 33 fractions of 1.7 Gy) directed at the pelvis region. The pelvis will be irradiated in all patients.~An additional simultaneously integrated boost of 69.3 Gy (in 33 fractions of 2.1 Gy) can be delivered to a local relapse based on Positron Emission Tomography - Computed Tomography (PET/CT) and Magnetic Resonance Imaging (MRI) images."
223806351|NCT04181203|DRUG|Luteinising Hormone Releasing Hormone agonist (LHRHa)|Doses of LHRHa may vary due to availability of different brand names and pharmaceutical forms. It will be left to the discretion of the investigator.
223806352|NCT02453581|DRUG|OZ439|OZ439 Powder for Oral Suspension
223806353|NCT04856722|PROCEDURE|mini-PNL|PCNL using miniature nephroscope. The procedure will be performed under general or regional anaesthesia under fluoroscopy guidance.
223806354|NCT04856722|PROCEDURE|RIRS|RIRS using flexible ureteroscope. The procedure will be performed under general or regional anaesthesia under fluoroscopy guidance. Holmium Laser lithotripter will be used for stone fragmentation.
223806355|NCT04856722|PROCEDURE|SWL|SWL using Dornier SII lithotripter. the procedure will be performed under sedoanalgesia, and fluoroscopy will be used for stone localization; for a maximum of 3 SWL session.
223806356|NCT04885062|DEVICE|Belun Ring|The Belun Ring sensor will be applied to the proximal phalanx of the index finger in the non-dominant hand of the participating individuals prior to their sleep onset in the sleep lab and will be removed upon awakening at the end of the sleep period on the following morning. The attended in-lab sleep study will be performed simultaneously in a standard fashion.
223806357|NCT04885062|DIAGNOSTIC_TEST|PSG|All patients scheduled for attended overnight in-lab polysomnography (PSG) in our 2 sleep labs will undergo PSG testing. On the same night of the PSG testing, these same patients will also wear the Belun Ring device. After the study, we will compare results of the Belun Ring device vis-à-vis with the results of the PSG on the same patient.
223806358|NCT06231862|DIAGNOSTIC_TEST|SeptiCyte (various)|mRNA expression scores
223806359|NCT03899753|DEVICE|2-Octyl Cyanoacrylate and Mesh|2-Octyl Cyanoacrylate and a mesh will be applied to final closure of wounds after undergoing a Total Shoulder Arthroplasty
223806360|NCT03899753|DEVICE|2-Octyl Cyanoacrylate|Incisions will be closed with 2-Octyl Cyanoacrylate after undergoing a Total shoulder arthroplasty
223806361|NCT03585582|OTHER|Prospective follow-up|This is a prospective follow-up study to assess of outcomes at 1 year following the discharge from the hospitalization during which PARDS was diagnosed
223806362|NCT01217931|DRUG|Pazopanib|800 mg by mouth once daily for 28 days. A cycle consists of 4 weeks.
223806363|NCT01217931|DRUG|Bevacizumab|10 mg/kg by vein every two weeks. A cycle consists of 4 weeks.
223806364|NCT01217931|DRUG|Everolimus|10 mg by mouth once daily. A cycle consists of 4 weeks.
223806365|NCT02021838|OTHER|Lethality Assessment Program|Law enforcement officers conduct risk screen of domestic violence victims, if high risk victims are referred to domestic violence services.
223806366|NCT02021838|OTHER|Domestic Violence High Risk Team|Law enforcement officers conduct risk screen of domestic violence victims, if high risk victims are referred to domestic violence services and a team who monitors the clinical and criminal justice progress.
223806367|NCT05872568|DRUG|Enteric-Coated Mycophenolate Sodium (EC-MPS)|The recommended dose range is 360 to 720mg,bid
223806368|NCT04895865|BEHAVIORAL|RPE-based load and repetition number selection|Providing trainees with choices regarding the load and the number of repetitions to be performed per set and exercise
223806369|NCT04895865|BEHAVIORAL|Predetermined load and number of repetitions|Trainees predetermine the load and perform ten repetitions per set and exercise
223806370|NCT04862182|DIAGNOSTIC_TEST|Trans-perineal ultrasound|Intrapartum trans-perineal ultrasound in predicting the mode of delivery.
223806371|NCT04321226|DEVICE|Femtosecond Laser guided Arcuate Keratotomy|Astigmatism will be reduced in cataract surgery using a low energy Femtosecond Laser device
223806372|NCT05822115|DEVICE|Reduction of breast hypertrophy by means of laparoscopic|"The research procedure is a breast reduction performed by means of laparoscopic surgery.~The project consists of removing a disc from the breast at the level of the base, thus causing peripheral skin slackening of 2 to 3 cm but circular. Both breasts are usually operated on at the same time. In case of asymmetry, only one side will be treated."
223806373|NCT01156948|DRUG|misoprostol|400ug vaginally the day before surgery
223806374|NCT01156948|DRUG|oral misoprostol|400ug misoprostol orally the day before the surgery
223806375|NCT00003532|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Stage III or IV Ovarian Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
223806376|NCT01072461|BEHAVIORAL|HAS Training|Robotically measured and facilitated training of the hemiparetic hand and arm in isolation, in a three dimensional haptically rendered virtual environment.
223806377|NCT01072461|BEHAVIORAL|HAT training|Robotically measured and facilitated training of the hemiparetic hand and arm as an integrated functional unit, in a three dimensional haptically rendered virtual environment
223806378|NCT01072461|BEHAVIORAL|Bimanual Training|Robotically measured and facilitated training of the hemiparetic hand and non-hemiparetic hand together, in a three dimensional haptically rendered virtual environment
223806379|NCT00063050|BEHAVIORAL|Physical activity and nutrition intervention|
223806380|NCT00623090|BEHAVIORAL|educational internet site on prostate cancer screening|Healthy men between 45-70 receive the login information to access our educational internet site on prostate cancer screening.
223806381|NCT00623090|BEHAVIORAL|Educational print booklet|Healthy men between 45-70 receive a copy of our educational print booklet in the mail.
223806382|NCT00623090|BEHAVIORAL|Usual care|Healthy men aged 45-70 receive no intervention and are followed for one year, along with the men in the two intervention arms.
223806383|NCT02515279|DRUG|Peginterferon alfa-2a|180 micrograms subcutaneous weekly for 48 weeks.
223806384|NCT02515279|DRUG|Ribavirin|1000-1600 mg day orally for 48 weeks.
223806385|NCT02429765|DRUG|ACL/FOR|
223806386|NCT02429765|DRUG|Placebo|
223806387|NCT01417429|DRUG|Galantamine|8mg/a day or placebo
223806388|NCT01417429|DRUG|IV Nicotine|1.0 mg/70 kg of nicotine against saline
223806389|NCT03528018|DEVICE|REACt system|The REACt system is a virtual reality-based paradigm for upper limb rehabilitation that allows for interaction of individuals with restricted movements from active responses triggered when they attempt to perform a movement. The experimental system also provides multisensory stimulation in the visual, auditory, and tactile channels, and transcranial direct current stimulation coherent to the observed movements
223806390|NCT03528018|OTHER|Physical therapy|Physical therapy included passive and active mobilization of the paretic upper limb. Passive range of motion exercises were provided in those segments where no active movement was detected to meticulously reproduce a range of articular movements and muscle and soft tissue elongation. In case of residual active movement capability, participants were encouraged to perform the movements with the assistance of the therapists
223806391|NCT00226239|DRUG|Docetaxel|Docetaxel 75 mg/m\^2 IV over 1 hour, day 1
223806392|NCT00226239|DRUG|Cisplatin|Cisplatin 75 mg/m\^2 IV over 1-2 hours, day 1, 1 hour following completion of cetuximab infusion.
223806393|NCT00226239|DRUG|Cetuximab|Cetuximab dose will be 250 mg/m\^2 IV over 60 minutes weekly on ALL subsequent administrations (days 8 and 15 of cycle 1 and days 1,8,15 of cycles 2 and 3).
223806394|NCT00226239|PROCEDURE|Radiation Therapy|Photon energies of 1.25 to 6 MV and/or appropriate electron energies for boosting the nodes are allowed. Photon energies\>6 MV may be utilized when appropriate to boost target localized centrally.
223806395|NCT02808624|DRUG|L-CARNOSINE|L-CARNOSINE is a supplement given with chemotherapy to prevent peripheral neuropathy.
223806396|NCT03756428|PROCEDURE|Deep dry needling in tibialis posterior|The inspector, with gloves, disinfects the area to be treated with 70º alcohol. Once the alcohol is applied, the intervenor locates and takes the myofascial trigger point and places the needle with the guide tube resting on the skin of the patient. The inspector holds the guide tube between the index and middle fingers lightly touch the needle with the index finger of the other hand to insert the needle perpendicularly into the skin, directing it towards the inspector's thumb. Once the needle is inserted subcutaneously, the guide tube is removed. The controller deepens the needle to myofascial trigger point, and makes fast inputs and outputs into it. The rapid exit is made to the subcutaneous cellular tissue, outside the muscle, but not outside the skin. Next, hemostasis is performed in the area. Once this hemostasis is completed, the patient is incorporated and dressed.
223806397|NCT03756428|PROCEDURE|Sham technique in tibialis posterior|The patient lies on the stretcher without the trousers. The interventor, with the guide tube, simulates the technique of puncture in the right twin of the subject. The comptroller cleans the area with 70º alcohol. Once the alcohol is applied, he performs the simulated dry needling technique in a plane with his index and middle fingers with the guide tube. It is important that the subject has his head stuck in the hollow of the head of the stretcher throughout the technique to make a correct masking.
223806398|NCT01800968|DRUG|Liraglutide|Active Drug
223806399|NCT01800968|DRUG|Placebo|Placebo
223806400|NCT02865720|DRUG|CINRYZE 500 U|IV infusion administered twice weekly
223806401|NCT02865720|DRUG|CINRYZE 1000 U|IV infusion administered twice weekly
223806402|NCT05362565|BIOLOGICAL|Salivary Sampling|"The DNA study will be carried out from saliva sample~1 saliva sample per patient will be performed at the inclusion visit"
223806403|NCT03144895|PROCEDURE|Laying a radial or femoral arterial catheter|Laying a radial or femoral arterial catheter
223806404|NCT03403868|DIAGNOSTIC_TEST|conductance catheter|pressure volume loops are assessed via a special catheter (Conductance catheter)
223806405|NCT00257140|DRUG|levofloxacin|
223806406|NCT03749564|BEHAVIORAL|SMT|"The subject is supine. The clinician stands opposite the side to be manipulated and side-bends the subject away from the side to manipulate. The side to be manipulated is the more painful. If the subject cannot identify a more painful side the clinician selects a side. The clinician rotates the subject, and delivers a high-velocity, low-amplitude (HVLA) thrust to the pelvis in a posterior/inferior direction. The clinician notes if a cavitation (ie, a pop) occurred. If it does, SMT treatment is complete. If no cavitation occurs, the subject is repositioned and SMT is performed again. If no cavitation occurs on the second attempt, the clinician manipulates the opposite side. A maximum of 2 attempts per side is permitted. If no cavitation is noted by that time, SMT treatment is complete. Substitution with a side-posture HVLA technique is allowed if the preferred technique is not possible due to subject preference or comfort."
223806407|NCT03749564|BEHAVIORAL|Activation Exercises|Activation exercises are designed to facilitate use of the lumbar multifidus muscle. Exercises will begin with isometric multifidus contractions in different positions with clinician feedback and exercises to isometrically co-contract the multifidus and deep abdominal muscles. Subjects will also perform lumbar extensor strengthening exercises shown to produce 20%-50% of multifidus maximum voluntary contraction. Subjects will continue to perform isometric exercises throughout treatment. Subjects will perform their prescribed exercises at treatment sessions and will be instructed to perform the exercises daily on other days.
223806408|NCT03749564|BEHAVIORAL|Mobilizing Exercises|Mobilizing exercises include a program of repeated movements progressing into end-ranges of spinal flexion and/or extension shown in past studies to improve ROM and reduce spinal stiffness. Patients will be instructed in mid-range exercises and will be further assessed for a directional preference. A directional preference is present if movement in a particular direction decreases LBP intensity or causes symptoms to centralize towards the midline. If a subject has a directional preference he or she will be prescribed exercises specifically in that direction along with mid-range exercise. Otherwise the subject will be assigned exercises moving into either flexion or extension based on the clinician's discretion. Subjects will perform their prescribed exercises at treatment sessions and will be instructed to perform the exercises daily on other days.
223806409|NCT03749564|BEHAVIORAL|Extended SMT|Additional 6 SMT sessions provided
223806410|NCT04834466|BEHAVIORAL|Pain Level experience during orthodontic treatment|A questionnaire was given to patients who have started their orthodontic treatment to assess their pain level experience
223806411|NCT05502705|DRUG|Lidocaine|Intravenous bolus of 1.5 mg/kg of lidocaine followed by a continuous infusion of 3.0 mg/kg for the frst hour, 1.5 mg/kg for the second hour, 0.7 mg/kg until the end of the surgery
223806412|NCT05502705|OTHER|Normal saline (NS)|Patients are received equal volumes of saline intravenously until the end of the surgery
223806413|NCT06057376|OTHER|Low-FODMAP diet group (LFD)|Each participant will be following a low-FODMAP diet group for 3 weeks, followed by 3 week break prior to second diet intervention.
223806414|NCT06057376|OTHER|Low Sugar diet group (LAS)|Each participant will be following a low added sugar diet group for 3 weeks, after 3 week break.
223806415|NCT06496217|DRUG|MBX 2109|Group 1: Subjects with mild renal impairment (eGFR ≥ 60 and \< 90 mL/min)
223806416|NCT06496217|DRUG|MBX 2109|Group 2: Subjects with moderate renal impairment (eGFR ≥ 30 and \< 60 mL/min)
223806417|NCT06496217|DRUG|MBX 2109|Group 3: Subjects with severe renal impairment (eGFR \< 30 mL/min), or kidney failure and not receiving dialysis
223806418|NCT06496217|DRUG|MBX 2109|Group 4: Matched healthy subjects with normal renal function (eGFR ≥ 90 mL/min)
223806419|NCT02085148|DRUG|Regorafenib (BAY73-4506)|Regorafenib will be given orally once a day, across cycles of 21 days each. During each cycle regorafenib is taken for 2 weeks followed by one week off the drug. Doses of the study drug used in this study are age-dependent and the children's dose will been adjusted based on the age and the body surface area and given either as tablets or granulate.
223806420|NCT02085148|DRUG|Vincristine (Cellcristin®)|Vincristine will be given at a dose of 1.5 mg/m2 (0.05 mg/kg for subjects ≤ 10 kg, maximum 2.0 mg) on Day 1 and Day 8 in 21-day cycles.
223806421|NCT02085148|DRUG|Irinotecan (Irinotecan Cell pharm®)|Irinotecan will be administered at a starting dose of 50 mg/m2/day from Day 1 to Day 5, in 21 day cycles.
223806422|NCT04864574|OTHER|Garden installation|"Garden installation: 6 raised planting beds (4x6x16) configured in a single line with direct sun at least 6 hrs./day, close to hose bib, sufficient distances to allow working from most sides, vegetable vines spill over space, and storage unit for tools.~Planting beds constructed from a standard kit. Beds filled with high quality growing medium.~Plants selection criteria: a) documented harvest success in NC Piedmont; b) able to be eaten raw, c) harvest times at the same time (except strawberries).~Designated beds and plants: Bed 1: 4 pepper, 2 tomato; Bed 2: 20 bean on 2 mini-teepees, 2 cucumber (trellised); Bed 3: 1 yellow squash, 1 zucchini; Bed 4: 2 blueberry bushes, 12 strawberry; Bed 5: 2 cantaloupe. Bed 6: 2 watermelon. 2 Blackberries planted at ground level on trellis."
223806423|NCT05808049|OTHER|MXP22 (Probiotic and antioxidant capsule)|Dose: NLT 4 Billion CFU/Capsule Route: Oral Administration Regimen: 1 capsule to be taken once daily after lunch for 120 days
223806424|NCT05808049|OTHER|Placebo (Microcrystalline Cellulose)|Dose: NLT 4 Billion CFU/Capsule Route: Oral Administration Regimen: 1 capsule to be taken once daily after lunch for 120 days
223806425|NCT02899780|DEVICE|Ultraviolet light emitting optical fiber|A ultraviolet light emitting optical fiber will be threaded through the existing catheter and withdrawn.
223806426|NCT05440370|DEVICE|MegaCarti®|MegaCarti® application after microfracture through athroscopic or incision surgery
223806427|NCT05440370|PROCEDURE|Microfracture|Microfracture through athroscopic or incision surgery
223806428|NCT03019926|BIOLOGICAL|Hydroxychloroquine dosage|Blood sample from a 6 ml tube, performed in the common practice.
223806429|NCT03044964|DRUG|Ranolazine|Patients will be started on 500mg twice daily and may be increased to 1000mg twice daily after 1 week. Patients will or may remain on the 1000mg for 5 weeks.
223806430|NCT03044964|DRUG|Placebo|Patients will be started on 500mg twice daily and may be increased to 1000mg twice daily after 1 week. Patients will or may remain on the 1000mg for 5 weeks.
223806431|NCT01422408|DRUG|Fluocinonide Cream|Given topically
223806432|NCT01422408|PROCEDURE|Management of Therapy Complications|Receive fluocinonide cream
223806433|NCT01422408|OTHER|Questionnaire Administration|Ancillary studies
223806434|NCT03185481|DRUG|1 mg QD to 15 mg QD PF-06649751|Up titration from 1 mg QD to 15 mg QD PF-06649751
223806435|NCT03185481|DRUG|3 mg QD to 15 mg QD PF-06649751|Up titration from 3 mg QD to 15 mg QD PF-06649751
223806436|NCT03185481|DRUG|7 mg QD to 15 mg QD PF-06649751|Up titration from 7 mg QD to 15 mg QD PF-06649751
223806437|NCT03185481|DRUG|15 mg QD PF-06649751|15 mg QD PF-06649751 remaining at 15 mg QD PF-06649751
223806438|NCT03185481|DRUG|1 mg QD to 7 mg QD PF-06649751 (if de-escalated in parent study)|Up titration from 1 mg QD to 7 mg QD PF-06649751 for subject at 1 mg QD who were blindly de-escalated in the parent study
223806439|NCT03185481|DRUG|3 mg QD to 7 mg QD PF-06649751 (de-escalated in parent study)|Up titration from 3 mg QD to 7 mg QD PF-06649751 for 3 mg QD subjects who were blindly de-escalated in parent study
223806440|NCT03185481|DRUG|7 mg QD to 7 mg QD PF-06649751 (de-escalated in parent study)|7 mg QD to remain at 7 mg QD PF-06649751 for subjects who were blindly de-escalated in parent study
223806441|NCT03185481|DRUG|15 mg QD de-escalated to 7 mg QD PF-06649751 in parent study remain at 7 mg QD|7mg QD PF-06649751 for subjects assigned to 15 mg QD who were blindly de-escalated to 7 mg QD PF-06649751 in parent study
223806442|NCT06383585|DEVICE|oZTEo|An FDA approved MRI pulse sequence, oZTEo, will be added to a standard of care MRI examination. The oZTEo pulse sequence will be anonymized and sent to GE Healthcare for the application of a deep learning algorithm, 3D DL.
223806443|NCT04735549|DEVICE|Laser Treatment|"Laser radiation is emitted by a series of pulses following each other through a pause. The duration of one pulse is 20-200 ns, the pause between pulses is 30 us. The energy of one pulse is about 1 mJ.~General laser radiation parameters for 1st and 2nd stages are: beam with diameter of 4 millimeters (mm) scans treatment area by 4 circles with step of 2 mm (50 percentage (%) overlap), average power of 10-25 Watt (W), treatment time in one point of 1-10 seconds (s), treatment step of 5 mm, from 1 to 5 repetitions of total vagina treatment. General laser radiation parameters for 3d stage are: beam diameter of 6 mm, average power of 15-30 W, duration of ns-pulses packet of 50-100 milliseconds (ms), pause between packets of 50-100 ms, treatment duration up to 65 s, treatment in permanent motion with speed of 10-50 mm/s.~The procedure is performed without anesthesia. The doctor always focuses on the participant's feeling of warmth."
223806444|NCT04735549|DRUG|Topical hormone estriol|Estriol ((17 beta)-estra-1,3,5 (10)-trien-3,17-diol). Daily dose will be 0.5 gram daily for 2 weeks, later 0.5 gram twice a week for 12 months.
223806445|NCT04735549|DIAGNOSTIC_TEST|Сlinical blood analysis|Taking blood from a vein for Clinical blood analysis, Wassermann reaction (WR), human immunodeficiency viruses (HIV), hepatitis B infection (HBsAg), hepatitis C infection (HCVAg) determination, glucose test (to include the participant in the study).
223806446|NCT04735549|DIAGNOSTIC_TEST|Сlinical urine test|Urine sampling for Clinical urine test (to include the participant in the study).
223806447|NCT04735549|DIAGNOSTIC_TEST|Vaginal smear|Vaginal smear for flora investigation (to include the participant in the study), cytology, microbiological analysis with Gram staining (to evaluate procedure efficiency).
223806448|NCT04735549|DIAGNOSTIC_TEST|Pelvic ultrasound|Pelvic ultrasound investigation to determine pathologies of the pelvic through a gynecological probe (to include the participant in the study).
223806449|NCT04735549|OTHER|Female Sexual Function Index|Female Sexual Function Index will be used to collect feedback on changes in the participants life quality (to evaluate procedure efficiency).
223806450|NCT04735549|OTHER|The Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire|The Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire will be used to collect feedback on changes in the participants life quality (to evaluate procedure efficiency).
223806451|NCT04735549|OTHER|Vulvovaginal Symptoms Questionnaire|Vulvovaginal Symptoms Questionnaire will be used to collect feedback on changes in the participants life quality (to evaluate procedure efficiency).
223806452|NCT04735549|DIAGNOSTIC_TEST|Vaginal Health Index|Vaginal Health Index will be investigated by clinical examination for vaginal elasticity, vaginal secretions, epithelial mucous membrane, vaginal hydration. Potential of hydrogen (pH) will be investigated by test-lines paper (to evaluate procedure efficiency).
223806453|NCT04735549|DIAGNOSTIC_TEST|Elastography (ultrasound investigation)|Ultrasound investigation for assessing elasticity / stiffness of tissues of vulva region with Mindray device (head L14-6WU) (to evaluate procedure efficiency).
223806454|NCT04735549|DIAGNOSTIC_TEST|Perineometry|Pressure force of vaginal walls measurement with EmbaGYN device (to evaluate procedure efficiency).
223806455|NCT04735549|OTHER|Visual Analogue Scale (VAS)|Visual Analogue Scale will be used to collect feedback on changes in the participants life quality (to evaluate procedure efficiency).
223806456|NCT04492527|BEHAVIORAL|Telehealth coaching sessions|Participants will be receiving a 2-month coaching session intervention that will be delivered via telephone or video-conferencing. Each of the 6 sessions will be 30-45minutes long and one-on-one with a student coach. In each session, coaches will review the participants' health behaviours and assess their knowledge about behavioural risks factors for chronic diseases and their current behaviours. The coaches will then provide information about the health risks of poor health behaviours, and benefits of change. Health behavioural goals will be established through a collaborative process. The coaches will then assist participants to develop readily achievable action plans that participants will follow in between coaching sessions as a means to realize their health goals. Adherence and modifications to the action plans will be discussed at the follow-up coaching session to promote health accountability.
223806457|NCT04540705|BIOLOGICAL|Nivolumab|Specified dose on specified days
223806458|NCT04540705|DRUG|Axitinib|Specified dose on specified days
223806459|NCT04540705|DRUG|Cabozantinib|Specified dose on specified days
223806460|NCT03051971|DEVICE|Vibrating Mesh Nebulizer|short-acting bronchodilator medication delivered with a vibrating mesh nebulizer via mouthpiece, valved facemask or non-invasive ventilation mask
223806461|NCT03051971|DEVICE|Jet Nebulizer|short-acting bronchodilator medication delivered with a jet nebulizer via mouthpiece, valved facemask or non-invasive ventilation mask
223806462|NCT03598413|DIETARY_SUPPLEMENT|Omega-3|200ml, pre-mixed oral nutritional supplement supplying 1.42g per bottle of EPA and DHA.
223806463|NCT05684627|DIETARY_SUPPLEMENT|Fast mimicking diet group|Test group will be assigned to follow one cycle of a fasting mimicking diet the same day after receiving the full mouth non surgical periodontal treatment. The FMD program is a plant-based diet program designed to attain fasting-like effects while providing both macro- and micronutrients to minimize the burden of fasting and adverse effects. The FMD consist 5 days regimen that provides approximately 1.100 kilocalories for the first day ; approximately 750 kilocalories per day for the second to the fifth day. FMD group will need 5 visits.
223806464|NCT05684627|PROCEDURE|Normal diet group|Normal diet (control) group after receiving the non surgical periodontal treatment (with periodontal Gracey curettes and ultrasonic scaler) will continue with their current diet.Normal diet group will need 5 visits.
223806465|NCT01950949|OTHER|300 ml Hydroxyethyl Starch 130/0.4 and Sodium Chloride Injection infusing in 15 minutes if PPV under VT 8 ml/kg was larger than 13% in the initial investigation|
223806466|NCT05099042|OTHER|Recommendations and re-orientation towards appropriate physical, mental, and social health ressources|Resources recommendations and interventions curated to the needs of the EP such as refering them to a social activity for socially isolated EP.
223806467|NCT04823429|BEHAVIORAL|High intensity-interval training (HIIT)|"Subjects performed HIIT (3-min intervals at 40% and 80%VO2peak) on a bicycle ergometer for 30 min/day, 5 days/week for 6 weeks.~Without any exercise training"
223806468|NCT04823429|BEHAVIORAL|Moderate intensity-continuous (MICT)|Subjects performed MICT (sustained 60%VO 2max) on a bicycle ergometer for 30 min/day, 5 days/week for 6 weeks.
223806469|NCT00566683|DRUG|diazemuls, pethidine|5mg Diazemuls and 25mg Pethidine one min. before procedure followed by bolus doses of 2.5mg Diazemuls / 12.5mg Pethidine at the discretion of endoscopists Maximal dose of 0.2mg/kg Diazemuls and 1mg/kg Pethidine
223806470|NCT00566683|DRUG|Propofol and Alfentanil|Loading dose of 40-60mg or 0.8mg/kg Propofol one min. before procedure Propofol 200mg + Alfentanil 0.5mg, 1.5ml per bolus (bolus dose of 14.3mg Propofol + 35ug Alfentanil) via PCA pump No maximal dose Zero lockout time
223806471|NCT04274673|DEVICE|measuring cotinine level|Measuring of the cotinine levels
223806472|NCT00276692|DRUG|irinotecan hydrochloride|
223806473|NCT04928105|BIOLOGICAL|Senl-T7|Patients will be treated with CD7 CAR-T cells
223806474|NCT01426971|DRUG|IBUPROFEN + CAFFEINE|Pharmaceutical form: capsule Route of administration: oral
223806475|NCT01426971|DRUG|IBUPROFEN|Pharmaceutical form: capsule Route of administration: oral
223806476|NCT00050180|DRUG|Midazolam|
223806477|NCT00050180|DRUG|Indinavir|
223806478|NCT00050180|DRUG|Saquinavir|
223806479|NCT04371146|DRUG|Methylphenidate|35 mg methylphenidate (Ritalin®) is administered once using a randomized placebo-controlled between subject's design
223806480|NCT04371146|DRUG|Reboxetine|8 mg Reboxetine (Edronax®) is administered once using a randomized placebo-controlled between subject's design
223806481|NCT04371146|DRUG|Placebos|A placebo pill is administered once using a randomized placebo-controlled between subject's design
223806482|NCT00227617|BIOLOGICAL|bevacizumab|5mg/kg IV q 2 wk on day 1. Initial study drug dose will be delivered over 90 +/- 15 minutes x1. If the first infusion is tolerated without fever/chills, the second infusion may be delivered over 60 +/- 10 minutes. If 60 minutes infusion is well tolerated, all subsequent infusions maybe be delivered over 30 +/- 10 minutes.
223806483|NCT00227617|DRUG|5-fluorouracil|2400mg/m2 CIV over 46-48 hours D1-2 q2 weeks.
223806484|NCT00227617|DRUG|leucovorin|200mg/m2 IV q2 wk on day 1 over a 2-hour period.
223806485|NCT00227617|DRUG|oxaliplatin|200mg/m2 IV q 2 wk on day 1 over a 2-hour period
223806486|NCT06451900|DRUG|Fenofibrate|full-term (37 to 41 weeks), Appropriate for gestational age weight between 2500 to 3500 gm infants and with neonatal hyperbilirubinemia not reaching the level of phototherapy were randomised to receive the drug in different doses or in the control group
223806487|NCT06451900|OTHER|placebo|ull-term (37 to 41 weeks), Appropriate for gestational age weight between 2500 to 3500 gm infants and with neonatal hyperbilirubinemia not reaching the level of phototherapy were randomised to receive the drug in different doses or in the control group
223806488|NCT05089617|DRUG|YG1699|"YG1699 is a novel investigational dual inhibitor of sodium-dependent glucose cotransporters, SGLT1 and SGLT2, indicated as an adjunct to diet and exercise to improve glycemic control and weight loss in adults with T2DM. A subsequent indication will be developed for YG1699 to improve glycemic control in adults with T1DM.~Drug: Placebo~Placebo is the same appearance as YG1699."
223806489|NCT01753921|OTHER|this is not an intervention study|Subjects will wear the headband/helmet-like device for approximately 10 minutes on four different occasions: t=0, t=1week, t=1month, t=3months. Of note, part of the device also involves electrodes that are worn to obtain an electrocardiogram or EKG.
223806490|NCT01753921|OTHER|this is not an intervention study|Subjects will be asked to participate in both computerized and non-computerized tests to assess subjects' cognitive (learning, language and memory) abilities, developmental level, and behavior. Tests will take place at t=0, t=1week, t=1month, t=3months.
223806491|NCT01753921|DEVICE|MRI|MRI study of the brain will be performed at t=3months.
223806492|NCT03266770|DEVICE|RELIEF Stent|The RELIEF stent will be placed under cystoscopy. The stent with pusher will be placed over the guidewire and inserted. The pusher will be positioned, the guidewire will be removed, and the pusher will be retracted. The position of the stent will be confirmed by x-ray (C-arm).
223806493|NCT06393621|DIETARY_SUPPLEMENT|KEFPEP®|Twice daily (one pack before breakfast and the other before dinner)
223806494|NCT06393621|OTHER|Placebo|Twice daily (one pack before breakfast and the other before dinner)
223806495|NCT01085838|DRUG|Erlotinib|Erlotinib oral capsule, 100, 150, or 300 mg/day during 12 weeks at study start
223806496|NCT04370925|PROCEDURE|Radical colectomy|Patients undergo radical resection of the primary colorectal cancer(open or laparoscopic/robotic)
223806497|NCT04370925|PROCEDURE|HIPEC|HIPEC(simultaneously or within 2days after resection) with mitomycin c (30 mg/m2) at 43°C for 90 minutes.
223806498|NCT04370925|DRUG|Systemic chemotherapy|"Systemic chemotherapy regimens: CapeOx and mFOLFOX6 are preferred for stage Ⅲ patients.~CapeOx:oxaliplatin 130 mg/m2 IV d1 + capecitabine 1000mg/m2 po bid d1-14. Repeat every three weeks for eight cycles.~mFOLFOX6:oxaliplatin 85 mg/m2 IV d1 + leucovorin calcium 400 mg/m2 IV d1 + 5-FU 400 mg/m2 IV bolus d1 + 5-FU 2400 mg/m2 continuous IV over 46-48 hours d1-2. Repeat every two weeks for twelve cycles.~For stageⅡpatiens, regimens recommend by NCCN guide line(2019 v1) are acceptable."
223806499|NCT01751555|DRUG|Regimen:TDF+3TC+EFV|TDF+3TC+EFV for HIV/HBV co-infection
223806500|NCT02080429|PROCEDURE|Passive Descent|
223806501|NCT02080429|PROCEDURE|Pushing|
223806502|NCT03069092|BEHAVIORAL|aerobic exercise|AE training will consist of 60 min of treadmill, elliptical, or bike exercise at a moderate to vigorous intensity (50-80% of heart rate reserve). Intensity of the exercise sessions will be built up gradually. Sessions will occur 3 times per week for the duration of the 1 year trial.
223806503|NCT03069092|BEHAVIORAL|resistance exercise|RE will consist of 3 sets of 8-15 repetitions at 50-80% of 1 rep-max of each exercise for 12 exercises (chest press, shoulder press, pull-down, back extension, abdominal crunch, torso rotation, biceps curl, triceps extension, leg press, leg extension, leg curl, and calf raise). Weight loads will be increased gradually. With one minute of rest between sets, this plan is estimated to take approximately 60 minutes per session. Sessions will occur 3 times per week for the duration of the 1 year trial
223806504|NCT03069092|BEHAVIORAL|Combined resistance and aerobic exercise|Participants will perform exactly the same AE and RE exercises as listed previously; however, the time of AE and RE will each be reduced to 30 min (for 60 min/session total). For the RE aspect, participants will perform 2 sets of 8-15 repetitions of 9 exercises (excluding biceps curl, triceps extension, and calf raise, as these are minor muscle groups). Exercise intensity and resistance will be increased gradually. Combined AE and RE sessions will take place 3 times per week for the duration of the trial.
223806505|NCT04137848|PROCEDURE|Osteopathic Manipulative Treatment (OMT)+ Multidisciplinary Intensive Rehabilitation Treatment (MIRT)|OMT: 4-week manual therapeutic program with a weekly session of osteopathic examination and manipulation of somatic disfunctions in ambulatory setting. MIRT: 4-week physical therapy with 4 daily sessions (1 hour each), 5days/week, in a hospital setting. The first session comprises cardiovascular warm-up activities, relaxation, muscle stretching, exercises to improve the range of motion of different joints, exercises to improve the functionality of the abdominal muscles, and postural changes in the supine position. The second session includes exercises to improve balance and gait using stabilometric platform,treadmill plus, crossover and cycloergometer. The third and fourth pertain occupational and speech therapy.
223806506|NCT04137848|PROCEDURE|Sham Osteopathic Manipulative Treatment (SOMT)+ Multidisciplinary Intensive Rehabilitation Treatment (MIRT)|"SOMT: 4-week of sham osteopathic therapeutic program with a weekly session of osteopathic examination and manipulation in ambulatory setting.~MIRT: 4-week physical therapy with 4 daily sessions (1 hour each), 5days/week, in a hospital setting. The first session comprises cardiovascular warm-up activities, relaxation, muscle stretching, exercises to improve the range of motion of different joints, exercises to improve the functionality of the abdominal muscles, and postural changes in the supine position. The second session includes exercises to improve balance and gait using stabilometric platform,treadmill plus, crossover and cycloergometer. The third and fourth pertain occupational and speech therapy."
223806507|NCT00796692|DRUG|Nadroparin|LMWH is given with a weight adjusted dose of 86 international anti-factor Xa units of nadroparin (Fraxiparine) per kilogram of body weight(86 anti-factor Xa IU/kg) subcutaneously every 12 hours,which will be used at least 5-7 days.
223806508|NCT00796692|DRUG|Unfractionated heparin(UFH)|UFH is received with an initial bolus dose of 80 IU per kilogram, followed by a continuous intravenous infusion at an initial rate of 18 IU per kilogram per hour. The dose is subsequently adjusted so that the activated partial thromboplastin time (APTT) would be 1.5 to 2.5 times the control value in normal subjects. The tests are performed 4 hours after the start of treatment, whenever a sub-therapeutic APTT had been measured after a dose adjustment, and otherwise daily.UFH will be used at least 5-7 days.
223806509|NCT02657031|DRUG|Prochlorperazine|prochlorperazine 10 mg IV
223806510|NCT02657031|DRUG|Ketamine|Ketamine 0.3 mg/kg IV
223806511|NCT02657031|DRUG|Diphenhydramine|Diphenhydromine 25 mg IV
223806512|NCT02657031|DRUG|Ondansetron|Ondansetron 4 mg IV
223806513|NCT02657031|DRUG|Normal Saline|Normal Saline 500 cc IV Bolus
223806514|NCT01561001|DEVICE|SENSIMED Triggerfish®|Portable investigational device using a contact lens sensor that monitors the IOP fluctuation continuously over 24-hours.
223806515|NCT01245946|PROCEDURE|Photodynamic therapy|Photodynamic therapy: 2 sessions separated by 2 weeks of TDF with topical ALA20% for 1.5 hrs, then irradiated with red light (Waldmann lamp) at a fluence of 37 J/cm2 for 7-9 minutes. From the sixth week will begin adapalene 0.1% gel until 12 weeks
223806516|NCT01245946|DRUG|Conventional therapy|Conventional therapy: Topical adapalene gel 0.1% at night for 12 weeks plus doxycycline 100 mg / day for 6 weeks.
223806517|NCT00512512|PROCEDURE|Transoral Endoscopic Liver Biopsy|Liver will be biopsied with transoral endoscope instead of the laparoscopic instruments during laparoscopic gastric bypass
223806518|NCT03912558|PROCEDURE|Butterfly device implantation|The Butterfly device will be positioned and deployed with cystoscopy guidance
223806519|NCT04118244|DIAGNOSTIC_TEST|lung recruitment maneuver|The ventilator was switched to pressure control ventilation, inspiratory time was increased to 50%, the peak inspiratory pressure gradient (above PEEP) was set at 15cm H2O, and PEEP was progressively increased to obtain a stepwise increase of peak inspiratory to 20, 25, and 30 cm H2O every three breaths. The final recruiting pressure of 30 cm H2O was applied for six breaths.
223806520|NCT02748187|OTHER|CBASP|Interpersonal psychotherapy for chronic depression
223806521|NCT05114655|OTHER|Herbaceous Essential Oil Blend|Participants are given a diluted proprietary oil blend of aromatic extracts from resins, bark, and flowers to apply three times daily for the purposes of inhalation.
223806522|NCT05114655|OTHER|Citrus Essential Oil Blend|Participants are given a diluted proprietary oil blend of aromatic extracts from citrus peel, and flowers to apply three times daily for the purposes of inhalation.
223806523|NCT05114655|OTHER|Inert Oil|Participants are given an inert vegetable based oil blend to apply three times daily for the purposes of inhalation.
223806524|NCT03797521|DRUG|SXC-2023|SXC-2023 oral capsules
223806525|NCT03797521|DRUG|Placebo|Matching Placebo oral capsules
223806526|NCT03953339|PROCEDURE|Release or no release of the suprascapular nerve|
223806527|NCT00543595|DRUG|MK0916|
223806528|NCT05766917|BEHAVIORAL|peer education group|Patients in this group will receive the routine hospital care, in addition to the proposed peer education by trained peer
223806529|NCT04450602|DIETARY_SUPPLEMENT|ALRV5XR|"ALRV5XR oral supplement. Dose/Route/Schedule: 1 capsule/oral twice daily. Take one capsule in the morning and one capsule in the evening. Take 30-60 minutes before food. If stomach upset occurs, subjects will be instructed to take the capsule at the beginning of a meal.~There should be no deviation from the daily nutriment regimen (although in the event a capsule or day is missed, subject should continue with regimen the following day.)"
223806530|NCT04450602|OTHER|ALRV5XR Shampoo|"ALRV5XR Shampoo. Dose/Route/Schedule: 3-7 ml, topical, daily. The amount of shampoo used will vary by subject, based on length of hair. Short hair will use approximately 3ml of shampoo per wash and long hair as much as 7 ml. For short hair, an amount equivalent to a quarter in the palm of a hand, and for long hair a half-dollar size.~There should be no deviation from the daily nutriment regimen (although in the event a day is missed, subject should continue with regimen the following day"
223806531|NCT04450602|OTHER|ALRV5XR Conditioner|"ALRV5XR Conditioner. Dose/Route/Schedule: 3-7 ml, topical, daily. The amount of conditioner used will vary by subject based on length of hair. Short hair will use approximately 3ml of conditioner per wash and long hair as much as 7 ml. For short hair, an amount equivalent to a quarter in the palm of a hand, and for long hair a half-dollar size.~There should be no deviation from the daily nutriment regimen (although in the event a day is missed, subject should continue with regimen the following day"
223806532|NCT04450602|OTHER|ALRV5XR Hair Follicle Serum (Nutriment)|"ALRV5XR topical Hair Follicle serum (Nutriment), sealed in an airless pump dispensing bottle, metered at 0.2ml per depression. Dose/Route/Schedule: 1ml, topical, daily, applied at night.~Topical serum (referred to as the Nutriment) dosage is metered as 5 x depressions of plunger per day to cover areas of thinning scalp and adjacent scalp areas. Care should be taken to limit the Nutriment in hair. Each depression is metered at 0.2ml for a daily dose of 1.0 ml. Each container has 30ml of Nutriment. Nutriment will dry within a few minutes and any on the hair will also dry. The dried effect in the hair should not cause oiliness or dryness on scalp or hair. There should be no deviation from the daily nutriment regimen (although in the event a day is missed, subject should continue with regimen the following day.)"
223806533|NCT04450602|DIETARY_SUPPLEMENT|Placebo|"Placebo oral supplement. Dose/Route/Schedule: 1 capsule/oral twice daily. Take one capsule in the morning and one capsule in the evening. Take 30-60 minutes before food. If stomach upset occurs, subjects will be instructed to take the capsule at the beginning of a meal.~There should be no deviation from the daily nutriment regimen (although in the event a capsule or day is missed, subject should continue with regimen the following day.)"
223806534|NCT04450602|OTHER|Placebo Shampoo|"Placebo Shampoo. Dose/Route/Schedule: 3-7 ml, topical, daily. The amount of shampoo used will vary by subject, based on length of hair. Short hair will use approximately 3ml of shampoo per wash and long hair as much as 7 ml. For short hair, an amount equivalent to a quarter in the palm of a hand, and for long hair a half-dollar size.~There should be no deviation from the daily nutriment regimen (although in the event a day is missed, subject should continue with regimen the following day"
223806535|NCT04450602|OTHER|Placebo Conditioner|"Placebo Conditioner. Dose/Route/Schedule: 3-7 ml, topical, daily. The amount of conditioner used will vary by subject based on length of hair. Short hair will use approximately 3ml of conditioner per wash and long hair as much as 7 ml. For short hair, an amount equivalent to a quarter in the palm of a hand, and for long hair a half-dollar size.~There should be no deviation from the daily nutriment regimen (although in the event a day is missed, subject should continue with regimen the following day"
223806536|NCT04450602|OTHER|Placebo Hair Follicle Serum (Nutriment)|"Placebo topical Hair Follicle serum (Nutriment), sealed in an airless pump dispensing bottle, metered at 0.2ml per depression. Dose/Route/Schedule: 1ml, topical, daily, applied at night.~Topical serum (referred to as the Nutriment) dosage is metered as 5 x depressions of plunger per day to cover areas of thinning scalp and adjacent scalp areas. Care should be taken to limit the Nutriment in hair. Each depression is metered at 0.2ml for a daily dose of 1.0 ml. Each container has 30ml of Nutriment. Nutriment will dry within a few minutes and any on the hair will also dry. The dried effect in the hair should not cause oiliness or dryness on scalp or hair. There should be no deviation from the daily nutriment regimen (although in the event a day is missed, subject should continue with regimen the following day.)"
223806537|NCT04766268|OTHER|Prostate artery embolization|Prostate artery embolization (PAE) is a safe and effective minimally invasive interventional radiology procedure in which intraprostatic vessels are embolized to shrink the size of the prostate gland. LUTS is mainly categorized into irritative, obstructive, and mixed types. This has a variable impact on patients' quality of life by interfering with sleep, activities of daily living, anxiety, mobility, leisure, and effect on sexual activities. This trial aims to determine safety and effectiveness of prostate artery embolization and determine factors associated with improved procedure outcome.
223806538|NCT05899842|DRUG|Protein pump inhibitor therapy systematically|Lansoprazole 30mg once per day
223806539|NCT05724355|DRUG|Dalpiciclib Isetionate Tablets, Camrelizumab|Dalpiciclib, D1-21, po, 150mg, qd, Q4W. Camrelizumab, iv, 200mg, D1, Q3W.
223806540|NCT05977426|OTHER|Reiki|In the study, women received four Reiki sessions once a week for four weeks from the researchers with Usuı Shiki Ryoho Reiki 1
223806541|NCT02375295|DRUG|ciprofloxacin, cotrimoxazole-trimethoprim, macrodantin|Approved antibiotics used routinely will be given at the physician's discretion with the patient: ciprofloxacin, cotrimoxazole-trimethoprim, or macrodantin
223806542|NCT00669786|DRUG|Human Menopausal Gonadotropin (HMG) & - Recombinant Follicle Stimulating Hormone (r-FSH)|
223806543|NCT03325543|OTHER|Visual observation|Verbal instructions about the anatomy, function and how to perform the pelvic floor muscle contraction
223806544|NCT03325543|OTHER|Vaginal palpation (bidigital touch)|The physiotherapist touched the patients' perineal region (vulva, tendinous centre of the perineum and external region of the anal canal) with a spatula and asked them to identify the pointed region; and with the digital palpation, the physiotherapist touched the tendinous centre of the perineum, pressing it in the cranial direction, and instructed the patients to contract the pelvic floor muscle
223806545|NCT04410068|DEVICE|WARMTAC|Randomization to one of the arms previous to surgery.
223806546|NCT04410068|DEVICE|3M Bair Hugger|Randomization to one of the arms previous to surgery.
223806547|NCT00603577|DRUG|Placebo|Xaliproden matching placebo. 1 capsule per day for 6 months or until resolution of PSN (whichever comes first).
223806548|NCT00603577|DRUG|Xaliproden|1.0 mg capsule. 1 capsule per day for 6 months or until resolution of PSN (whichever comes first).
223806549|NCT05505474|DEVICE|IVF with the Neria™ Guard Subcutaneous Catheter|Use of the Neria™ Guard subcutaneous catheter for administration of subcutaneous medication in an IVF cycle.
223806550|NCT00293683|DEVICE|Insorb absorbable skin staple|
223806551|NCT03777267|DEVICE|Active CR|The upgraded platform for medical research using the HIRREM technology has been rebranded as Cereset Research® (CR). This system uses the same core technology and algorithms to echo brainwaves in real-time using audible tones, as with HIRREM. The CR system also includes 64-bit processing architecture for faster feedback, the use of 4 sensors, and the use of standard protocols (with flexibility regarding the length and sequencing of the standard protocols), all done with eyes closed. Four sensors are applied to the scalp at a time. However, only two sensors are actively echoing feedback. The software automatically switches from one sensor pair to the other when needed. This reduces the number of sensor placement changes needed, resulting in shorter session time and fewer interruptions.
223806552|NCT05129943|DEVICE|active distraction|The subject receives the injection of local anesthesia while playing a game on a mobile phone mounted on the VR device using a PS4 controller.
223806553|NCT05129943|DEVICE|passive distraction|The subject receives the injection of local anesthesia while watching a cartoon on a mobile phone mounted on the VR device.
223806554|NCT04679090|OTHER|Exercise Program|Participants will exercise twice a week for twelve weeks total.
223806555|NCT02707835|OTHER|self massage|self massage, skin care education, manual lymph drainage exercise, compression garment
223806556|NCT02707835|OTHER|manual lymph drainage|manual lymph drainage by a physical therapist, skin care education, manual lymph drainage exercise, compression garment
223806557|NCT02707835|OTHER|epidermis fascia taping|epidermis fascia taping by a physical therapist, skin care education, manual lymph drainage exercise, compression garment
223806558|NCT04305314|OTHER|PRI (Enhanced Recovery after surgery protocol)|Standard use of Spanish perioperative guidelines (PRI)
223806559|NCT04300894|DEVICE|Mamma Mia|"Users of the Mamma Mia program progress through the intervention in a sequence of modules.~Every day that a module should be completed, you will receive a notification with a reminder to access the program. By clicking on the reminder, you can access that particular day's session content. Modules involve a variety of information and activities; for example, there are guided mindfulness practices, information on breastfeeding, instructional videos on how to interpret your baby's cries, and discussions on how to have effective discussions with your partner or healthcare provider about your needs."
223806560|NCT04300894|OTHER|Mamma Mia Plus|Participants will use the Mamma Mia program, plus receive contact (phone calls or emails or texts) from study staff every few months.
223806561|NCT02768363|BIOLOGICAL|aglatimagene besadenovec|Aglatimagene besadenovec will be delivered to the prostate via trans-rectal ultrasound guided injection followed by 14 days of oral prodrug, valacyclovir. The second aglatimagene besadenovec injection will be 2-3 weeks after the first followed by 14 days of valacyclovir.
223806562|NCT02768363|BIOLOGICAL|placebo|Placebo will be delivered to the prostate via trans-rectal ultrasound guided injection followed by 14 days of oral prodrug, valacyclovir. The second placebo injection will be 2-3 weeks after the first followed by 14 days of valacyclovir.
223806563|NCT02768363|DRUG|valacyclovir|Oral prodrug to be given for 14 days starting the day after each aglatimagene besadenovec or placebo injection.
223806564|NCT04016090|DIETARY_SUPPLEMENT|Folic Acid|Folic acid (5 mg)
223806565|NCT04016090|OTHER|Placebo|Placebo capsule
223806566|NCT06095297|BEHAVIORAL|Processing Speed Training|"Speed of processing training involves trainer-guided practice of computer-based video games. The games require the player to rapidly distinguish targets from decoys, which trains how rapidly the player processes information received through their senses."
223806567|NCT06095297|BEHAVIORAL|In-lab Instrumental Activities of Daily Living Training|Participant will receive shaping on IADLS. Participants will receive training on everyday tasks with important cognitive components, in which the difficulty is increased in small steps over the course of treatment.
223806568|NCT06095297|BEHAVIORAL|In-lab Brain Health Training|Participants will receive training on healthy eating, sleeping, and relaxation techniques that have been shown to improve brain health.
223806569|NCT06095297|BEHAVIORAL|Transfer Package|"The Transfer Package was designed to try and bridge the gap between what is trained in the lab and what the participant does outside of the treatment setting. This components includes negotiation of a behavioral contract with participants at the outset of treatment regarding the responsibilities of the participant, family caregivers, if available, and the treatment team, self-monitoring, assignment of homework, review of homework by the trainer, and support of problem-solving by the participant."
223806570|NCT06095297|BEHAVIORAL|Follow Up Phone Calls|After completing training, participants will receive four follow up phone calls in the first month of training. Each call will separated by about a week. The focus of the calls will incorporating the lessons learnt during treatment into daily life.
223806571|NCT06095297|BEHAVIORAL|Vocational Rehabilitation|In partnership with the Alabama Department of Rehabilitation Services (ADRS), participants who are eligible may receive vocational rehabilitation. Participants will receive typical services offered by the ADRS. These could include career counseling, guidance regarding job retention or return-to-work, and guidance regarding workplace accommodations.
223806572|NCT06095297|BEHAVIORAL|Peer Mentoring|Participants who are eligible for vocational rehabilitation, and agree will also have a peer mentor, a co-worker that will be trained by our team, to reinforce strategies the participant learned during training, and to help the participant problem solve issues that may arise on the job during the first month after treatment. Peer mentors will meet with trainers during the month after treatment to make sure procedures are being followed and address any issues that may arise.
223806573|NCT06095297|BEHAVIORAL|Reaction Time Training|"Reaction time training involves trainer-guided practice of computer-based video games. Several different games will be featured that train how rapidly players react to threats and train eye-hand coordination."
223806574|NCT06095297|PROCEDURE|Trans-auricular Vagus Nerve Stimulation: High Intensity|The vagus nerve run from the brain to the external ear, throat, chest, and abdomen and controls, among other functions, the rest and relax response, which supports learning and turns down inflammatory processes. The rest and relax response can be turned on by electrically stimulating the vagus nerve. We will place electrodes on the external part of each ear and safely apply a microcurrent of at least 4 milliamps. Stimulation will administered for 10 minutes near the start and midway point of each treatment session.
223806575|NCT06095297|PROCEDURE|Trans-auricular Vagus Nerve Stimulation: Low Intensity|The vagus nerve run from the brain to the external ear, throat, chest, and abdomen and controls, among other functions, the rest and relax response, which supports learning and turns down inflammatory processes. The rest and relax response can be turned on by electrically stimulating the vagus nerve. We will place electrodes on the external part of each ear and safely apply a microcurrent of less than 4 milliamps. Stimulation will administered for 10 minutes near the start and midway point of each treatment session.
223806576|NCT05007392|DRUG|Dotinurad|Dotinurad oral tablets.
223806577|NCT05007392|DRUG|Febuxostat|Febuxostat oral tablets.
223806578|NCT05007392|OTHER|Dotinurad Matched Placebo|Dotinurad matched placebo oral tablets.
223806579|NCT05007392|OTHER|Febuxostat Matched Placebo|Febuxostat matched placebo oral tablets.
223806580|NCT06559163|DRUG|Obexelimab|Obexelimab is a monoclonal antibody that simultaneously binds CD19 and FcyRllb, resulting in down regulation of B cell activity.
223806581|NCT06559163|DRUG|Placebo|Placebo
223806582|NCT06024616|BEHAVIORAL|TARANG|"TARANG is aimed to empower young women to navigate newly formed relationships, improve women's awareness of sexual reproductive health, and challenge inequitable gender norms, with an aim to reduce unintended pregnancies and increase use of family planning. The TARANG intervention for newly married women will include 14 group sessions delivered by trained moderators from Vikalp. It will cover three overarching themes, including norms, empowerment, and sexual and reproductive health and wellbeing.~Four light-touch sessions for mothers-in-law and one in-person session for husbands of newly married women will be conducted. For husbands, TARANG will include one 2-hour group session within the first month of the intervention, followed by regular and moderated content delivery via videos and take-home exercises over WhatsApp groups. Vikalp will conduct door-to-door listing, and a research team from NEERMAN will recruit households into the study depending on the eligibility criteria."
223806583|NCT01218126|DRUG|losmapimod|comparison of different dosages of drug 2.5 mg, 7.5 mg or 15 mg
223806584|NCT01218126|DRUG|placebo|placebo comparison with active
223806585|NCT04835155|PROCEDURE|Premature Infant Oral Motor Intervention (PIOMI)|The Premature Infant Oral Motor Intervention (PIOMI), developed by Dr. Brenda Lessen Knoll, was chosen for this study because it is the only oral motor program designed specifically for preterm babies as young as 29 weeks post menstrual age (PMA) and is the only program with a standardized training method and published intervention fidelity. The 5 minute therapy offers assisted movement to activate muscle contraction and movement against resistance to build strength in the perioral structures. The PIOMI has 8 steps where a provider uses a pinky finger to provide gentle stroking and pressure on the cheeks, lips, tongue, gums and palate to strengthen the oral sensory-motor functions and improve feeding efficiency. PIOMI ends with 2 minutes of NNS. NNS and oral stimulation have been found to mature the oral motor sensory system, and improve not only bottle feeding, but also breastfeeding.
223806586|NCT00913484|DRUG|Disulfiram|Disulfiram 250 mg per day
223806587|NCT00913484|DRUG|Placebo|Placebo daily
223806588|NCT00980070|DEVICE|Pediatric Restraint for Lumbar Puncture|Restraint for children 1-90 days of age that allows physician to position pt for optimal lumbar puncture procedure.
223806589|NCT00980070|DEVICE|Lumbar Puncture Device|Lumbar Puncture positioner
223806590|NCT00980070|OTHER|Standard of Care|Lumbar Puncture positioner
223806591|NCT03732183|BEHAVIORAL|Podcast SMART-3RP|28 daily podcasts, each 15 minutes.
223806592|NCT02254447|DRUG|Candesartan Cilexetil in formulation 1|Round, biconvex white tablets containing Candesartan cilexetil 16 mg for oral administration
223806593|NCT02254447|DRUG|Candesartan Cilexetil in formulation 2|Round, biconvex white tablets containing Candesartan cilexetil 16 mg for oral administration
223806594|NCT02254447|DRUG|ATACAND|Round, biconvex pink tablets containing Candesartan cilexetil 16 mg for oral administration
223806595|NCT02241941|DRUG|Daptomycin|
223806596|NCT00942214|DRUG|Natalizumab|300mg, IV, every 4 weeks
223806597|NCT06584864|DIAGNOSTIC_TEST|bedside ultrasound examination of the lumbar spinal canal|The ultrasound examination will be performed using a Lumify linear probe (frequency range 4-12 MHz). In the longitudinal projection, the doctor will assess the spinal cord endings by marking them with a sterile marker - a horizontal line on the patient's back. In the same projection, the doctor will designate a safe and optimal place (the greatest width of the dural sac) for performing a lumbar puncture by marking it with a sterile marker. Additionally, in the longitudinal projection, the researcher will measure the depth from the skin surface to the dura mater. Then, in the transverse projection, the doctor will confirm the absence of the spinal cord at the planned puncture site and the optimal amount of cerebrospinal fluid in the selected space. This information will be passed on to the operator, who will ultimately decide on the lumbar puncture site.
223806598|NCT01860703|DRUG|Deferiprone|Ferriprox 500 mg tablets
223806599|NCT01860703|DRUG|deferiprone matching placebo tablets|deferiprone matching placebo tablets
223806600|NCT01860703|DRUG|moxifloxacin|Active control
223806601|NCT01860703|DRUG|placebo|moxifloxacin-matching placebo
223806602|NCT04064151|BEHAVIORAL|My Guide|12-week long health promotion Smartphone application
223806603|NCT06580639|OTHER|No intervention.|Blood sampling for analysis of mycobacterial growth inhibition assay (MGIA) analysis.
223806604|NCT01019044|PROCEDURE|Rectal mucosa biopsy|Collection of a maximum of 15 rectal mucosa samples in the high portion of the rectum near the rectosigmoidal junction
223806605|NCT03825783|BIOLOGICAL|RP-L201|CD34+ enriched hematopoietic stem cells from subjects with severe LAD-I transduced ex vivo with lentiviral vector carrying the ITGB2 gene, Chim-CD18-WPRE.
223806606|NCT03726255|PROCEDURE|Mesenchymal Stem Cell injection|curettage, closure of the internal opening (IO) and cell injection in IO (50%) and fistula tract (50%)
223806607|NCT01188109|DRUG|Gemcitabine|"Standard of care chemotherapy and dosage~Dose - 1000 mg/m²~Schedule - Days 1 and 15; Q 28 days"
223806608|NCT01188109|DRUG|Cisplatin|"Dose - 50 mg/m²~Schedule - Days 1 and 15; Q 28 days"
223806609|NCT00530595|DRUG|candesartan or valsartan or losartan|
223806610|NCT01494844|DEVICE|Respiratory monitor patient interface.|Wear each interface for 20 minutes
223806611|NCT05405959|DEVICE|Kinesio tape|The Kinesio Tex Gold FP (Kinesio Tex Tape, Kinesio Holding Corporation, Albuquerque, NM, USA) was used. It was waterproof, porous and adhesive, had a width of 5 cm and a thickness of 0.5 mm. The same brand of tape was used in both groups.
223806612|NCT05405959|DEVICE|Sham Kinesio Tape|The Kinesio Tex Gold FP (Kinesio Tex Tape, Kinesio Holding Corporation, Albuquerque, NM, USA) was used. It was waterproof, porous and adhesive, had a width of 5 cm and a thickness of 0.5 mm. The same brand of tape was used in both groups.
223806613|NCT05168826|DEVICE|SAPIEN 3 Transcatheter Heart Valve|Implantation of the SAPIEN 3 valve
223806614|NCT06296576|PROCEDURE|arterial ultrasound scan|An arterial ultrasound scan of the lower limbs with pulsed Doppler analysis of arterial flow spectra over the abdominal aorta, dorsal artery of the foot and lateral plantar artery, bilaterally
223806615|NCT06050226|DRUG|MY008211A tablets|The first 10 participants will be received low-dose MY008211A tablets, and the next 30 participants will be randomized to low-dose or high-dose treatment arms in a 1:2 ratio.
223806616|NCT06467331|OTHER|Hippotherapy|Hippotherapy, also known as horse-assisted therapy, is a form of animal-assisted therapy. It consists of regularly scheduled sessions designed to enhance functionality in individuals' lives and contribute to their overall health improvement.
223806617|NCT06227247|BEHAVIORAL|Meals4Moms Intervention|A community-based, healthy living program including continued gestational diabetes (GDM) education, physical activity level monitoring, and delivery of medically-tailored GDM meals for the management of gestational diabetes in pregnant people.
223806618|NCT04188977|OTHER|Usual Practice|OTP Directors are able to ask their state health officials permission to use interim methadone treatment. The state officials are in turn able to ask officials from the Center of Substance Abuse Treatment for permission to provide interim methadone treatment.
223806619|NCT04188977|OTHER|Implementation Facilitation|Implementation Facilitation (IF) will consist of educational outreach to OTP staff, identification of local champions, training, performance feedback, and learning collaborative for OTP staff and state health department officials.
223806620|NCT02446158|DRUG|Chlorhexidine gluconate|The intervention group received daily cleaning of the exit site and application of 4% chlorhexidine (Antigerm Solution, Shining BioMedical Com. Ltd) with a swab. The chlorhexidine was rinsed off after 3 min of air drying and then gauze was applied.
223806621|NCT02815462|OTHER|FAMFACESG|\- PNs will receive the FAM-FACE-SG FA risk scores for frequent admitters admitted to their ward.
223806622|NCT02815462|OTHER|Control|\- Usual hospital Care
223806623|NCT02815462|OTHER|FAMFACESG|\- PNs will be instructed to prioritize intervention of frequent admitters for intervention based on the FA risk score.
223806624|NCT02815462|OTHER|FAMFACESG|"* For high and moderate risk patients who do not require transitional home care (THC), PN will do the case management and follow up.~* For high and moderate risk patients \& have complex nursing and / or high functional needs, PNs will refer these patients for THC.~* For mild risk patients, PNs will refer them to care coordinator."
223806625|NCT02815462|OTHER|FAMFACESG|\- For low risk patients, PNs will continue usual hospital care.
223806626|NCT01417572|DRUG|lidocaine|to evaluate the effect of lidocaine on oculocardiac reflex during the surgery
223806627|NCT05977231|PROCEDURE|BT|A program of BT (including exercise and muscle training)
223806628|NCT05977231|PROCEDURE|bPFMT|A bPFMT program at home
223806629|NCT05977231|PROCEDURE|iVES|An iVES program at home
223806630|NCT05977231|PROCEDURE|BT + bPFMT|Combination of BT and bPFMT
223806631|NCT05977231|PROCEDURE|BT + iVES|Combination of BT and iVES
223806632|NCT05977231|PROCEDURE|bPFMT + iVES|Combination of bPFMT and iVES
223806633|NCT03827122|DRUG|onabotulinumtoxinA|Experimental group we will use BTX-A administration group. All patients (Male/Female) with bruxism associated with chronic pain in masseter muscles bilaterally Patients will have treatment with 20 units of BOTOX, (Allergan Inc.) per side will be injected at three points into masseter muscle bilaterally.
223806634|NCT06379919|PROCEDURE|Irrisept Irrigation|Irrisept Antimicrobial Wound Lavage is a single-use, manual, self-contained irrigation device. Irrisept contains 0.05% Chlorhexidine Gluconate (CHG) in 99.95% Sterile Water for Irrigation, United Staes Pharmacopeia (USP). The solution is aseptically filled in a Blow-Fill-Seal (BFS) bottle.
223806635|NCT06379919|PROCEDURE|Saline Irrigation Solution Delivery|Normal saline is isotonic and the most commonly used wound irrigation solution due to safety (lowest toxicity) and physiologic factors.
223806636|NCT00251862|BEHAVIORAL|Web-based decision aid plus personalized risk assessment|Patients review a computer-based decision aid that discuss the pros and cons of of 5 recommended CRC screening options and provides personalized 10-year estimates of CRC risk prior to meeting with their provider to discuss CRC screening.
223806637|NCT00251862|BEHAVIORAL|Web-based decision aid alone|Patients review a computer-based decision aid that discuss the pros and cons of the 5 recommended CRC screening options prior to meeting with their provider to discuss CRC screening.
223806638|NCT00251862|BEHAVIORAL|Generic website|Patients review a generic website that discuss ways to reduce overall cancer risk.
223806639|NCT02453685|DRUG|biphasic insulin aspart 30|Injected s.c./subcutaneously once daily with the largest meal Subjects should continue their pre-trial metformin and sulfonylurea dosages all throughout the trial while other oral antidiabetic drugs will be discontinued.
223806640|NCT02453685|DRUG|insulin glargine|Injected s.c./subcutaneously once daily at the same time every day, with the possibility of treatment intensification with insulin aspart (Basal-bolus arm) Subjects should continue their pre-trial metformin and sulfonylurea dosages all throughout the trial while other oral antidiabetic drugs will be discontinued.
223806641|NCT02453685|DRUG|insulin aspart|Injected s.c./subcutaneously once daily.
223806642|NCT00453986|BIOLOGICAL|Meningococcal vaccine GSK134612|One intramuscular dose
223806643|NCT00453986|BIOLOGICAL|Mencevax™ACWY|One subcutaneous dose
223806644|NCT00453986|BIOLOGICAL|Fluarix™|One intramuscular dose
223806645|NCT02622165|BEHAVIORAL|The REWARD serious game intervention|The REWARD intervention is based on the dual process model incorporating strategies to influence both the automatic pathway (i.e., operant learning theory) and the conscious pathway (i.e., a focus on certain determinants). The central idea of the intervention will be that participants will earn credits in the game when scanning healthy (rather than unhealthy) snacks which will influence the advancement of the players in the game. This credit system will be related to the dietary quality index of the consumed snacks.
223806646|NCT02925611|DRUG|Isoflurane|
223806647|NCT02925611|DRUG|Desflurane|
223806648|NCT01001052|DRUG|Colcrys™ (colchicine)|0.6 mg taken by mouth on day 1
223806649|NCT02778100|DRUG|Nasal Glucagon|Administered intranasally.
223806650|NCT02778100|DRUG|Oxymetazoline|Administered intranasally.
223806651|NCT00825266|DRUG|bosentan|Bosentan 62.5 mg BID for 4 weeks, then 125mg BID for duration of study.
223806652|NCT00825266|DRUG|Pioglitazone|Pioglitazone 15 mg a day for 4 weeks then Pioglitazone 30 mg a day for the duration fo the study.
223806653|NCT03152383|BEHAVIORAL|Training trials|"A highly preferred edible item will be selected to teach the contingencies for the assessment. Materials to engage in the work response (i.e., button press) will be placed within arm's reach of the child, and the edible item will be in sight. The therapist will deliver a vocal prompt for the child to engage in the work response (e.g., press the button and you can have some candy). If the child engages in the response, the therapist immediately delivers the edible item. The therapist will guide the child to engage in the instrumental response, and will then gradually begin to fade the prompt level. If the child makes an error at any level of prompting, the therapist will guide the participant to emit a correct response. The edible item will be delivered to the child each time that the child responds correctly at any prompt level."
223806654|NCT03152383|BEHAVIORAL|Progressive Ratio Session|The child will be guided to engage in the instrumental response then the stimulus will be immediately delivered for 30 seconds. The leisure item or the individual who will provide attention will be directly outside of the session room. If the child emits the work response, they will be allowed access to either a leisure item or to attention (depending on the condition) for 30 seconds. The child is initially required to respond one time, then they will be required to respond two times to gain access to the item or attention (then 4, then 8, and so on) such that the response requirement progressively increases according to a pre-determined schedule. A minimum of 3 sessions will be conducted for each condition. The amount of time required for participation depends on the child's responding, and caregiver availability. Participation may take as little as a couple hours, or as long as 3-4 hours per day for approximately one week.
223806655|NCT03152383|BEHAVIORAL|Re-test|10 children with ASD will return to repeat the progressive ratio (PR) assessment one week after completing it the first time to examine the reliability of the measure.
223806656|NCT03152383|BEHAVIORAL|Pairing Protocol|15 children with ASD will receive an intervention designed to increase social approach after completing the PR assessment. Participants will attend 2 hour appointments 3-5 days per week in which a therapist will deliver highly preferred items, play with the child, work on teaching communication skills, and teach the child to comply with demands. After completing the intervention (once the child is willingly staying near and interacting with the therapist and complying with instructions), the PR assessment will be repeated to measure change due to the intervention.
223806657|NCT03610087|BEHAVIORAL|Low Intensity Intervention|Participants will have access via the online platform to the NAVIGATE self-help modules for physical activity, nutrition and quitting smoking with a list of community resources. Subjects will be sent a standard reminder emails once per week to complete their modules and connect with their main provider for any assistance.
223806658|NCT03610087|BEHAVIORAL|High Intensity Intervention|Participants will receive individualized treatment planning, in collaboration with a Care Coordinator, and the Virtual Care Team (VCT). Interactive modules on physical activity, nutrition and quitting smoking will be provided via the online platform. the virtual team will be engaged to provide treatment and/or recommendations regarding the following: increasing physical activity, improving nutrition and diet, smoking cessation (psychosocial support plus medications), and medication adherence. Participants in this arm will have weekly check-ins with their assigned Care Coordinator where they will be able to discuss VCT recommendations, and progress on their goals.
223806659|NCT06244277|DRUG|Suanzaoren Decoction and Huanglian Wendan Decoction|Twice daily. Chinese herbal medicine includes: includes: 25 grams of Suanzaoren, 10 grams of chuanxiong, 30 grams of fushen, 10 grams of Polygala tenuifolia, 10 grams of Pinellia ternata, 12 grams of tangerine peel, 15 grams of Zhuru, 30 grams of forged keel, 30 grams of forged oyster,10 grams of aurantii fructus, 6 grams of coptis chinensis, 30 grams of Albizzia bark.Add or subtract Chinese herbal medicine according to the different clinical manifestations of each patient.
223806660|NCT06244277|DRUG|Zolpidem|Zolpidem 10Mg Tab 10mg tablet once daily
223806661|NCT02073461|DRUG|CD1579 2.5%|
223806662|NCT02073461|DRUG|CD1579 5%|
223806663|NCT02073461|DRUG|Vehicle|
223806664|NCT03120754|PROCEDURE|Place the peritoneal drainage|In the experimental group, the abdominal drainage was not placed
223806665|NCT03120754|PROCEDURE|No peritoneal drainage|Intraoperative placement of peritoneal drainage as control group.
223806666|NCT04900623|DEVICE|NavDx HPV ctDNA Testing|Blood will be collected and shared with an outside lab for analysis. This test will be done at Week 4 and at End of Treatment. This test will be done at at End of Treatment and in follow-up at 3, 6, 9, and 12 months after completing the study treatment. In years 2 and 3 after treatment, the test will be collected every 6 months or twice a year. The specimens will be identifiable. The specimens will be banked for future use.
223806667|NCT04900623|RADIATION|Radiotherapy|Radiation Therapy (administered daily, Monday-Friday). Higher risk participants will receive standard radiation dose for up to 7-8 weeks. Lower risk participants will receive a lower dose and treatment will only last 5-6 weeks.
223806668|NCT04900623|DRUG|Chemotherapy drug|"Chemotherapy and radiation therapy are both considered standard treatments~* Bolus Cisplatin: Infused every 21 days for up to 2 or 3 doses.~* Weekly Cisplatin or Carboplatin with Paclitaxel: Infused weekly during radiation therapy."
223806669|NCT05484388|DEVICE|SN2|Investigational device absorption level Normal
223806670|NCT05484388|DEVICE|SP3|Investigational device absorption level Plus
223806671|NCT05435352|PROCEDURE|Core needle biopsy|An additional core needle biopsy is taken to run the Pear Bio test. Test results are not used to inform treatment. Approved neoadjuvant therapy regimens are given to the patient as per standard of care to observe response.
223806672|NCT01338025|DRUG|HAART regimen|The study participant continued their non-suppressive HAART regimen as prescribed by their primary provider.
223806673|NCT01338025|DRUG|3TC or FTC monotherapy|The study participant was assigned to either 3TC or FTC monotherapy (the choice of 3TC or FTC was left to the provider.
223806674|NCT05474274|OTHER|Machine learning algorithms|Machine learning techniques to rank order physiologic variables obtained via the wearable and handheld devices as well as remove low-importance and redundant variables to accurately determine postoperative pain intensity in outpatients
223806675|NCT06022328|BIOLOGICAL|Assessment of the epigenetic age|Retrospective assessment of the epigenetic age on DNA samples obtained at diagnosis
223806676|NCT02381522|OTHER|Remote Ischemic Pre-conditioning|
223806677|NCT02381522|OTHER|Sham RIPC|
223806678|NCT05884216|DEVICE|Entarik Feeding Tube System|"Entarik Feeding Tube:~The Entarik Feeding Tube is intended for the administration of nutrition, fluids and medications by the nasoenteric route for patients who have an intact gastrointestinal tract but are physically unable to manage nutritional intake through normal mastication and deglutition.~Entarik Feeding Tube System:~The Entarik Feeding Tube System is designed to aid qualified operators in the placement of the Entarik Feeding Tube (Entarik FT) into the stomach of patients requiring enteral feeding. The Entarik FT is equipped with sensors designed to provide information about the location of the tube tip relative to the stomach, thus assisting in reducing the incidence of misplacement during first positioning. The Entarik Monitor also monitors the feeding tube position continuously during the course of feeding and automatically and in real-time alerts of tube migration."
223806679|NCT05884216|DEVICE|Entarik Feeding Tube System without monitoring|"Entarik Feeding Tube:~The Entarik Feeding Tube is intended for the administration of nutrition, fluids and medications by the nasoenteric route for patients who have an intact gastrointestinal tract but are physically unable to manage nutritional intake through normal mastication and deglutition.~Entarik Feeding Tube System:~The Entarik Feeding Tube System will collect data from the Entarik Feeding Tube. There will be no monitoring or dislodgement alerts, and no placement guidance."
223806680|NCT05547295|OTHER|Numeric prevention|Numeric information for prevention of pressure sores thgrough digital tool MEDIASCREEN
223806681|NCT05547295|OTHER|Paper prevention|Information for prevention of pressure sores in classic way with paper
223806682|NCT06088277|BEHAVIORAL|TM HIV|Participants will receive 5 intervention text messages (TM) about HIV risk and testing per week for the first 3 months and 3 messages per week for the last 3 months of the intervention.
223806683|NCT06088277|BEHAVIORAL|TM HL|Participants will receive 5 intervention text messages (TM) about promoting healthy living (HL) per week for the first 3 months and 3 messages per week for the last 3 months of the intervention.
223806684|NCT06653855|OTHER|Dry Static Cupping|A myofascial decompression cupping set with a precision pressure pump will be used to perform dry static cupping to the adductor and hamstring muscle groups of the affected limb, using a negative pressure of 300mmHg for eight minutes each.
223806685|NCT06653855|OTHER|Placebo cupping|The same protocol will be used as stated for the Dry static cupping intervention, with the only difference being that the cup will be pumped to 50mmHg instead of 300mmHg.
223835400|NCT01564719|BEHAVIORAL|Holistic health|The investigators conceptualize this as a holistic health intervention because it has components involving the mind, body, and spirit. The stress reduction program Williams LifeSkills, adapted for clergy; the 10-session online weight loss program Naturally Slim Foundations plus its 7-session online booster program, Naturally Slim Advanced; monthly phone conversations with Wellness Advocates who function as health coaches; $500 small grants to use to promote health; and three in-person workshops that cover the theology of the body and incarnation and provide the religious rationale for caring for the mind and body.
223806686|NCT06653855|OTHER|Standard physical therapy treatment|"Treatment will consist of typical physical therapy interventions performed for patients with spasticity of the lower extremity after stroke. These may include, but not be limited to:~* Balance exercise~* Therapeutic exercise~* Neuromuscular/muscular coordination exercise~* Manual (hands on) therapy~* Gait training~The treating physical therapist is left with the autonomy of the standard physical therapy treatment (within the above stated groups of interventions) because patients with the diagnosis of stroke do not all present with the same type or level of impairment. Furthermore co-morbidities (e.g., hypertension) and/or functional level (wheelchair bound vs. independent ambulator) may necessitate different treatment strategies. Therefore, while the general categories of treatment will remain the same across all study patients, it is expected that the treating physical therapist provides patient-specific interventions."
223806687|NCT06981299|DRUG|PROT-001|Orally bioavailable small molecule kinetic stabilizer of lambda light chains (λLCs).
223806688|NCT06439914|DRUG|[89Zr]Zr-DFO-emapalumab|Radiotracer \[89Zr\]Zr-DFO-emapalumab administration followed by 3 PET Scans (day 0, day 1 and day 3-5) within 14 days of starting immunotherapy and repeated once 25-45 days after immunotherapy started
223806689|NCT05365776|BEHAVIORAL|Graded Exposure Therapy|Graded exposure therapy is delivered by a psychologist over 12 individual (1:1) secure videoconference sessions. The core active ingredient is graded situational exposure to foster habituation and challenge beliefs that the avoided activities are dangerous. Homework exercises involve planned exposure exercises in the home and community to support generalization.
223806690|NCT05365776|BEHAVIORAL|Prescribed aerobic exercise|Participants will be asked to complete 30 minutes of aerobic exercise on 5 days/week for a 12-week period. Participants select the mode (e.g., swimming, jogging, bicycling) and location of exercise (e.g., outdoors, a gym or community centre, at home). The initial exercise intensity target will be based on the Buffalo Concussion Bike Test. The target progression will be 3-5 beats per minute every two weeks.
223806691|NCT05365776|OTHER|Enhanced usual care|Usual care (education about concussion from the website: concussion.vch.ca/) will be enhanced through email message support.
223806692|NCT06859541|BEHAVIORAL|Culturally Adapted Play-Based Behavioural Intervention|The Culturally Adapted Play-Based Behavioural Intervention (PPBI) integrates traditional Tamil games and folk storytelling to enhance social, emotional, and communication skills in children with Autism Spectrum Disorder (ASD). This 12-week structured program focuses on engagement, motor development, language, emotional regulation, social interaction, and real-world skill application, making it a culturally relevant and accessible intervention for improving adaptive behaviours.
223806693|NCT06859541|BEHAVIORAL|Applied Behaviour Analysis|The ABA-based program utilized structured techniques focused on positive reinforcement, imitation training, guided communication, and step-by-step skill-building. The primary goal was to reduce problem behaviors while reinforcing desirable social and communication skills. Parents and teachers were provided with structured training on how to apply ABA strategies consistently at home and school.
223806694|NCT06669624|BEHAVIORAL|Attachment and Biobehavioral Catch-up (ABC)|10-session home visiting intervention designed to increase parental sensitivity and nurturance and decrease parental frightening behavior.
223806695|NCT06669624|OTHER|Waitlist with 4-month delay, then ABC|A 4-month waitlist period, after which they will also receive the home-based ABC program (same as Intervention group).
223806696|NCT06993064|DIETARY_SUPPLEMENT|4000 IU of Vitamin D3|Vitamin D supplementation in Mexican subjects with Type 2 Diabetes Mellitus
223806697|NCT00684437|BEHAVIORAL|Focus Group|Focus group discussion and evaluation of various smoking risk informational messages. The focus group session should last about 1 hour and 30 minutes.
223806698|NCT00684437|BEHAVIORAL|Questionnaire|Questionnaires taking 15-30 minutes to complete.
223806699|NCT07022886|PROCEDURE|achalasia treatments|esophageal achalasia treatments
223806700|NCT05631730|DRUG|Flecainide|Flecainide is mainly used for pharmacological conversion in patients with atrial tachyarrhythmias and to suppress ventricular arrhythmias in patients with structurally normal hearts.
223806701|NCT05631730|DRUG|Metoprolol|Metoprolol is a beta-blocker and class II antiarrhythmic drug considered standard care in most cardiac diseases predisposing to ventricular arrhythmias, including arrhythmic mitral valve prolapse.
223806702|NCT06105021|DRUG|AFNT-211|Engineered TCR T-Cell
223806703|NCT07093424|OTHER|scoring|magnesium depletion score calculation
223806704|NCT07093216|BEHAVIORAL|Exercise|6 month exercise intervention
223806705|NCT07094880|DRUG|Tab. Methotrexate 25mg/week|Tab. Methotrexate will be given orally in one arm at a dose of 25 mg/week
223806706|NCT07094880|DRUG|Inj. Methotrexate 25mg/week|Inj. Methotrexate 25 mg/week will be given subcutaneously in another arm
223806707|NCT07092644|DEVICE|UltraSonic Cardiac Output Monitor (USCOM®)|Using USCOM, the haemodynamic evaluation will be performed at the time of diagnosis of congenital heart desease and then every two weeks until delivery. A further evaluation will be performed immediately after delivery (within 72 hours).
223806708|NCT07092943|DEVICE|Lung protective ventilation|The patient in this group will receive tidal volume at 6-8 ml/kg of ideal body weight with PEEP of 5 cm of H2O and plateau pressure will be kept less than 30cm of H2O.
223806709|NCT07092943|DEVICE|Driving pressure guided ventilation|They will receive tidal volume of 6-8 ml/kg of ideal body weight and initial PEEP of 5 cm of water. Principal investigator will then incrementally increase PEEP by 2 cm of water till a value 15 cm of water PEEP is reached or Plateau pressure becomes equal to 30 cm of water or driving pressure starts to increase or there is change in any hemodynamics. Each incremental PEEP will last for 3 respiratory cycles before moving on to next value. PEEP value with lowest driving pressure will then be selected for the duration of surgical procedure
223806710|NCT07094529|BEHAVIORAL|Recumbent Exercise Bike to induce mild hypoglycemia|"The participant rides the recumbent exercise bike at their preferred speed and records the distance travelled until there is onset of mild hypoglycemia, determined by capillary blood glucose test result 3.0 to 3.8 mmmol/L.~Based on each participant's own experience with hypoglycemia treatment or their preferences, the participant can choose one of 4 simple carbohydrate treatment quantities: 8 grams, 16 grams, 20 grams, 32 grams~The participant can choose one of 4 capillary blood glucose recheck times: 15 minutes, 20 minutes, 25 minutes, 30 minutes."
223806711|NCT07094529|BEHAVIORAL|Delaying food to induce mild hypoglycemia,|"At the study visit, in front of the study nurse, the participant takes their usual clinical care dose of sulfonylurea or basal insulin. If the participant's usual clinical care includes insulin with a rapid-acting component, then its dose is reduced based on the study protocol.~No food intake (water is allowed) until there is onset of mild hypoglycemia, determined by a capillary blood glucose test result 3.0 to 3.8 mmol/L.~Based on each participant's own experience with hypoglycemia treatment or their preferences, the participant can choose one of 4 simple carbohydrate treatment quantities: 8 grams, 16 grams, 20 grams, 32 grams~The participant can choose one of 4 capillary blood glucose recheck times: 15 minutes, 20 minutes, 25 minutes, 30 minutes."
223806712|NCT07094295|OTHER|perioperative blood transfusion|The PBT group received the red blood cell concentrate units during surgery and up to one month postoperatively.
223806713|NCT07093086|DRUG|Triple-targeted CAR-T Therapy|Lymphodepletion preconditioning is required prior to CAR-T cell therapy. Lymphodepletion will be performed using a regimen of cyclophosphamide (250-500 mg/m²) and fludarabine (25-30 mg/m²), each administered for 3 consecutive days.
223806714|NCT03205657|PROCEDURE|auto transplant followed by allo transplant|patients who got MAC conditioning with auto SCT followed by RIC followed by alloSCT for mature B-NHL
223806715|NCT01878929|DRUG|Allergen(Tree, Grass, Weeds)|Greer is manufacture of all allergen extract used in this study.
223806716|NCT02785640|BEHAVIORAL|Hourly prompts to stand delivered by Microsoft Outlook|Prompt group
223806717|NCT05271058|OTHER|Control group|23 eyes that didn't receive any intraoperative steroids
223806718|NCT05271058|DRUG|Dexamethasone group|23 eyes each received intracameral dexamethasone at the conclusion of phacoemulsification Received intracameral 0.4 mg in / 0.1 ml dexamethasone (8mg/2ml®; Amriya or Epico) at the end of phacoemulsification.
223806719|NCT05271058|DRUG|Triamcinolone (TA) group|23 eyes each received intracameral triamcinolone (TA) at the conclusion of phacoemulsification Received intracameral 2 mg/0.05 ml triamcinolone (TA) (Kenacort-A®; Bristol-Myers Squibb) at the end of phacoemulsification.
223806720|NCT00089089|DRUG|decitabine|Given IV
223806721|NCT00089089|OTHER|pharmacological study|Correlative studies
223806722|NCT00089089|OTHER|laboratory biomarker analysis|Correlative studies
223806723|NCT00501189|BIOLOGICAL|human papillomavirus vaccine L1, type 6,11,16,18|Subjects are those getting gradasil vaccination already. This is really not an intervention
223806724|NCT01592903|GENETIC|Laparoscopic myomectomy. Following analysis and proliferation of cells isolated from removed human leiomyoma.|"* Obtention of one part of removed human leiomyoma after surgery and maintained in 4ºC until procedures.~* Sample digestion through controlled enzymes.~* Isolated the Side Population from leiomyoma cell suspension by Flow cytometry .~* Culture of these cells.~* Morphological and genetic characterization.~* Assessment of pluripotent potential from isolated cells.~* Analysis of the degree of functionality."
223806725|NCT05395988|DEVICE|Digital hand washing instructions|Tablet displaying animated hand washing instructions
223806726|NCT05395988|DEVICE|Digital hand washing reward|Tablet displaying animated hand washing instructions and animated animals as reward
223806727|NCT01561859|BEHAVIORAL|Cognitive Enhancement Therapy|Cognitive Enhancement Therapy (CET) consists of approximately 60 hours of computer-assisted neurocognitive training in attention, memory, and problem-solving; and 45 social-cognitive group sessions that employ in vivo learning experiences to foster the development of social wisdom and success in interpersonal interactions. CET begins with 3 months of weekly 1-hour neurocognitive training in attention, after which patients begin the weekly 1.5-hour social-cognitive groups. Neurocognitive training then proceeds concurrently with the socialcognitive groups.
223806728|NCT01561859|BEHAVIORAL|Enriched Supportive Therapy|"Enriched Supportive Therapy is an individual approach that includes the established principles of supportive therapy previously tested by our group, which are enriched by selected practice principles from the effective Personal Therapy. These manualized supportive therapeutic practices include active listening, correct empathy, appropriate reassurance, basic psychoeducation, including computer-based educational programs, reinforcement of health-promoting initiatives, the provision of case management, and reliance on the advocacy and advice of the therapist in times of crisis."
223806729|NCT05385458|BEHAVIORAL|ACT Intervention|Acceptance and Commitment Therapy
223806730|NCT05385458|OTHER|Usual Care|Usual Care Services
223806731|NCT05897567|OTHER|resistance training|All participants perform a four-day resistance training aimed to stimulate a hypertrophic response.
223806732|NCT05897567|OTHER|ketogenic diet|Subjects allocated to the ketogenic diet arm (KD group) consume less than 50 g of carbohydrates per day.
223806733|NCT05897567|OTHER|western diet|Subjects allocated to the western diet arm (WD group) consume a standard diet based on 55% of their daily calories from carbohydrates.
223806734|NCT05284864|PROCEDURE|Stoma closure|Stoma closure after rectal surgery
223806735|NCT00780650|DRUG|Atomoxetine|80 mg oral dose, once per day for 6 weeks
223806736|NCT00780650|DRUG|Placebo|80 mg dose once per day for 6 weeks
223806737|NCT06116838|DEVICE|Spinal motor evoked responses (sMERs)|Spinally Evoked Motor Responses (sMERs) will be obtained while stimulating with single pulses using various stimulation parameters. sMERs are the electromyograph (EMG) responses of the peripheral muscles to electrical stimulation of the spinal cord. sEMP will be used to test the integrity of the motor pathways of the spinal cord. This will be measuring by assessing the EMG responses in the lower limb muscles.
223806738|NCT06116838|DEVICE|Continuous stimulation tolerance|Participants may receive up to 45 min of locomotion training (treadmill or overground training) with transcutaneous spinal cord stimulation. The goal will be for the investigators to determine what amount of intensity at each stimulation site the individual finds to be comfortable enough that they would be able to receive without pain or discomfort
223806739|NCT06053814|DRUG|NS-050/NCNP-03|NS-050/NCNP-03 solution for IV infusion.
223806740|NCT06053814|DRUG|Placebo|NS-050/NCNP-03 placebo-matching solution for IV infusion.
223806741|NCT06470074|DEVICE|Transcranial electrical stimulation|Transcranial electrical stimulation can modulate the brain functional network through weak transcranial current
223806742|NCT01257464|DRUG|Sitagliptin|100mg po one dose
223806743|NCT01257464|DRUG|Placebo|Sugar pill po one dose
223806744|NCT00819364|BEHAVIORAL|BCRI intervention program|"Phase 1: The parents will receive a two-day lecture about autism to get the basic knowledge about autism intervention.~Phase 2: BCRI model intervention.Parents and children will take part in a 24-halfday workshop to learn practical teaching skills in BCRI model. Then Home-based intervention using BCRI model for 11 months. At least 28 hours of BCRI intervention per week is acquired. Doctors or therapists will meet the parents and children once per month, each for 30 minutes, totally 10 times, to monitor and give advice on the interventions."
223806745|NCT00819364|BEHAVIORAL|Standard community care|"Phase 1: the parents will receive a two-day lecture about autism to get the basic knowledge about autism intervention.~Phase 2:Any treatment and interventions available chosen by families for children with autism and ASD, for at least one and a half years.~Phase 3:One and a half years after enrollment, parents and children will be free to take part in the BCRI model intervention which is the same as Phase 2 for experimental group lasting for one year."
223806746|NCT02018445|PROCEDURE|Posterolateral Fusion|
223806747|NCT06325137|DIAGNOSTIC_TEST|Transcriptome analyses|A sample of peripheral whole blood cells will be collected at the onset before the initiation of steroid treatment (time 0, t0) and after 6 weeks at the definition of steroid sensitivity/unresponsiveness (time 1, t1).
223806748|NCT02888717|PROCEDURE|'OSNA stadification during surgery'|"The para-aortic dissection surgery is performed in the usual way. The lymph nodes are isolated from fat tissue during surgery, and cut into 4 slices sterile.~* Slices A and C are sent OSNA analysis~* Slices B and D are sent ultimately histological analysis (1 cup HES or 5 cup HES + IHC) The nodes of less than 5 mm will be sent in final histological analysis due to the inability to cut into 4.~After the analysis, the report indicates whether the node is:~* Free (-): \<250 copies~* Micrometastatic (+): 250 ≤ - \<5,000 copies,~* Macrometastatic (++): ≥ 5000 copies."
223806749|NCT06147518|DRUG|Metformin|Metformin: 1.5g/d CTPA,1g/d CTPB
223806750|NCT06147518|DRUG|Sitagliptin|Sitagliptin: Assess HbA1c/HBSG at 8 weeks, increase sitagliptin to 100 mg if HbA1c\>7%
223806751|NCT06147518|DRUG|Dapagliflozin|Assess HbA1c/HBSG at 8 weeks, increase Dapagliflozin to 10 mg if HbA1c\>7%
223806752|NCT00949884|DRUG|olmesartan medoxomil|Oral tablets, once daily, at either 20mg or 40mg daily.
223806753|NCT00949884|DRUG|Placebo|placebo oral tablets once daily for two weeks
223806754|NCT00949884|DRUG|losartan potassium|losartan potassium oral tablet at either 50mg or 100 mg daily dose.
223806755|NCT02463201|BEHAVIORAL|Weight loss|
223806756|NCT04083716|DRUG|ABI-H2158 Reference Formulation|ABI-H2158 tablets Reference Formulation
223806757|NCT04083716|DRUG|ABI-H2158 Test Formulation|ABI-H2158 tablets Test Formulation
223806758|NCT02733809|DRUG|Sorafenib|Liver lesion biopsy (HCC) and blood samples will be taken from the subjects before starting the treatment course, and another biopsy and blood samples when they devolve a resistance.
223806759|NCT01953003|DRUG|vinflunine|intravenous administration day 1 once every 3 weeks, 280 mg/m²
223806760|NCT01953003|DRUG|Capecitabine|Arm A : 1650 mg/m² Arm B : 2500 mg/m²
223806761|NCT06230458|DIAGNOSTIC_TEST|FeNO-test|Fractional Exhaled Nitric Oxide (FeNO)- test
223806762|NCT02681575|BEHAVIORAL|Cog-Fun - A|Meta-cognitive functional intervention for improved self management in adults with ADHD
223806763|NCT04099602|OTHER|Baby Massage|Received baby massage and bilirubin levels were measured twice daily by the transcutaneous bilirubin meter for 5 days
223806764|NCT00979823|OTHER|Early SimCare Diabetes Group|Residents in the early learning program group will participate in the learning cases before undergoing a knowledge and performance assessment. They will complete 18 learning cases, 4 assessment cases, knowledge survey, and a satisfaction survey.
223806765|NCT00979823|OTHER|Delayed SimCare Diabetes Group|Residents in the delayed learning program group will receive their usual diabetes training through their residency program for 8 months before completing the knowledge and performance assessment, and then will subsequently be offered the learning program. They will receive 4 assessment cases, knowledge survey, and satisfaction survey
223806766|NCT02243644|DRUG|7 days of albendazole 15 mg/kg/day|group A will receive 7 days of oral albendazole 15 mg/kg/day
223806767|NCT02243644|DRUG|28 days of albendazole 15 mg/kg/day|group B will receive 28 days of oral albendazole 15 mg/kg/day
223806768|NCT03092375|DRUG|Glecaprevir/Pibrentasvir (G/P) 300mg/120mg|daily
223806769|NCT03092375|DRUG|Ribavirin 200Mg Tablet|Weight-based 1000-1200 mg
223806770|NCT01043016|PROCEDURE|Photodynamic therapy|patient undergo Photocyanine Injection via venous infusion followed by photodynamic therapy with 670nm diobe laser 24 hours later
223806771|NCT00291759|DRUG|Tamoxifen|
223806772|NCT00291759|DRUG|Anastrozole|
223806773|NCT04945421|DRUG|Sintilimab|(IBI310 3 mg/kg IV d1, Q3W combined with sintilimab 100 mg IV d1, Q3W) or( IBI310 1 mg/kg IV d1, Q3W combined with sintilimab 200 mg IV d1, Q3W) for up to 4 cycles, and then sintilimab 200 mg IV d1, Q3W until progressive disease, intolerable toxicity, start of a new antitumor treatment, withdrawal of informed consent, loss to follow-up, death or other situations requiring termination of treatment specified in the protocol, whichever occurs first.
223806774|NCT04945421|DRUG|IBI310|(IBI310 3 mg/kg IV d1, Q3W combined with sintilimab 100 mg IV d1, Q3W) or( IBI310 1 mg/kg IV d1, Q3W combined with sintilimab 200 mg IV d1, Q3W) for up to 4 cycles, and then sintilimab 200 mg IV d1, Q3W until progressive disease, intolerable toxicity, start of a new antitumor treatment, withdrawal of informed consent, loss to follow-up, death or other situations requiring termination of treatment specified in the protocol, whichever occurs first.
223806775|NCT01857882|OTHER|Decision Support Workshop|"Incorporates the key components of shared decision-making and decision support with the philosophy of delivering supportive care to cancer patients.~* Surgeon (30 mins): treatment options for breast reconstruction with indications/ contraindications, advantages / disadvantages, expected post-operative course, aesthetic result and complications with probabilities~* Registered nurse (30 mins): preparing for surgery, postoperative recovery and how to navigate the health care system~* Social worker (30 mins): values clarification exercise~* Breast reconstruction patient volunteer (30 mins) questions and answers about her personal experience"
223806776|NCT04190628|DRUG|ABM-1310|"Part A: Starting dose at 25 mg by mouth twice daily.~Part B: Starting dose at a dose below the MTD( Maximum Tolerated Dose) that has been demonstrated to be safe in Part A.~Part C-1 and C-2: Continuous twice daily oral doses of ABM-1310 at the recommended phase 2 dose (RP2D) from Part A until disease progression, unacceptable toxicity, or a clinical observation satisfying another withdrawal criterion is met.~Part C-3 and C-4: Continuous twice daily oral doses of ABM-1310 at the recommended phase 2 dose (RP2D) from Part B until disease progression, unacceptable toxicity, or a clinical observation satisfying another withdrawal criterion is met."
223806777|NCT04190628|DRUG|Cobimetinib|"Part B: orally administered once daily.~Part C-3 and C-4: Continuous once daily oral dose from Part B, administered the first 21 days of each 28-day treatment cycle until disease progression, unacceptable toxicity, or a clinical observation satisfying another withdrawal criterion is met.~Dose formulation is 60 mg capsules."
223806778|NCT02558582|BEHAVIORAL|respiratory and exercise therapy|The PH specific rehabilitation consists of: bicycle ergometer training, respiratory training, dumbbell-training and (mental) gait training.
223806779|NCT02558582|BEHAVIORAL|respiratory and exercise therapy with supplemental oxygen|"The PH specific rehabilitation consists of: bicycle ergometer training, respiratory training, dumbbell-training and (mental) gait training.~Patients who are not already under long-term oxygen therapy (LTOT) due to daytime hypoxemia will additionally be randomized to receive standardized supplemental oxygen therapy (SSOT) during training and nights."
223806780|NCT05312567|DRUG|FP-101|daily oral tablet administration (b.i.d.)
223806781|NCT01104740|OTHER|Biological sample collection|Blood (serum) sample collection
223806782|NCT01599390|OTHER|Data collection|"The study will use multiple primary data sources: the Nationwide Inpatient Sample (for hospitalisations) and the US National Vital Statistics System (for mortality), and weekly virology data from the Centers for Disease Control and Prevention (CDC) influenza surveillance program supplemented with literature data.~Weekly time series of the rates of various severe influenza-related health outcomes will be constructed. Statistical models, guided by weekly numbers of cases of laboratory-confirmed influenza and respiratory syncytial virus (RSV) contained in the CDC virology data, will be constructed to estimate the portions of the various outcomes that can be attributed to influenza. Next, the seasonal impact of influenza by age, risk status, and influenza subtype will be assessed. Finally, the potential burden that a quadrivalent vaccine could have prevented over the 12 year study period will be predicted."
223806783|NCT02898779|DRUG|Primaquine, R-Primaquine, S-Primaquine, SR Primaquine|"Cohort 1: Eighteen individuals (6 per group) Cohort 2: Eighteen individuals (6 per group)~Group 1-15 mg of S-Primaquine followed by one-week washout, 15 mg of R-Primaquine followed by one week washout, and 30 mg of RS-Primaquine.~Group 2- 15 mg of R-Primaquine followed by one-week washout, 30 mg of RSPQ followed by one week washout, and 15 mg of SPQ.~Group 3- 30 mg of RS-Primaquine followed by one week washout,15 mg of SPQ followed by a one week washout, and 15 mg of RPQ."
223806784|NCT00004401|DRUG|botulism immune globulin|
223806785|NCT00940238|DRUG|Citalopram Hydrobromide|
223806786|NCT03701295|DRUG|Azacitidine|Given IV or SC
223806787|NCT03701295|DRUG|Pinometostat|Given IV
223806788|NCT05751174|OTHER|pediatric patients affected by severe burns|All patients admitted to the pediatric intensive care unit affected by severe burns involving more than 10% of the body surface will be enrolled.
223806789|NCT04947371|DRUG|Anlotinib Hydrochloride|Oral anlotinib hydrochloride 12 mg/d
223806790|NCT00403897|DRUG|Polyethylene glycol 3350 Na bicarbonate NaCl KCl|6.9g sachet, oral
223806791|NCT04639193|DRUG|Acetazolamide|Acetazolamide tablet (encapsulated)
223806792|NCT04639193|DRUG|Eszopiclone|Eszopiclone tablet (encapsulated)
223806793|NCT04639193|DRUG|Placebo|Sugar capsule manufactured to match encapsulated Acetazolamide/Eszopiclone
223806794|NCT04639193|DRUG|Venlafaxine|Venlafaxine capsule
223806795|NCT01023568|DEVICE|Macintosh blade|Intubation with Macintosh blade laryngoscope
223806796|NCT01023568|DEVICE|Glidescope|Intubation with Glidescope laryngoscope.
223806797|NCT01023568|DEVICE|Truview PCD|Intubation with Truview PCD laryngoscope.
223806798|NCT04331535|DIAGNOSTIC_TEST|Polygenic risk score (PRS)|Polygenic risk score report from a Clinical Laboratory Improvement Amendment (CLIA)-certified laboratory for coronary artery disease, atrial fibrillation, type 2 diabetes, colorectal cancer, breast cancer (for women only), and prostate cancer (for men only), delivered along with patient- and provider-level educational material.
223806799|NCT00224770|DRUG|MIS+Cathflo Activase (drug)|MIS+Cathflo Activase (drug): The intervention is a comparison of the safety and preliminary effectiveness of investigational minimally invasive surgery to place a catheter into an intracerebral hemorrhage blood clot and subsequent administration in sequential tiers of 0.3 or 1.0mg of rt-PA, CathFlo® through the catheter once every eight hours for up to 72 hours, in addition to best medical care.
223806800|NCT00224770|PROCEDURE|Intraoperative stereotactic CT-Guided Endoscopic Surgery|Mechanical intracerebral hemorrhage removal via an endoscope utilizing the same operative targeting arm as MISTIE arm. No rt-PA administered, and in addition to best medical care.
223806801|NCT01106430|DRUG|Lisdexamfetamine Dimesylate|Oral 30, 50, or 70mg once-daily for 9 weeks
223806802|NCT01106430|DRUG|Atomoxetine Hydrochloride|Oral 10mg to 100mg once-daily for 9 weeks
223806803|NCT03175627|DEVICE|Filtek One|Restoring a posterior permanent tooth in need of a filling applying Filtek One using bulk fill technique.
223806804|NCT03175627|DEVICE|Filtek Z250|Restoring a posterior permanent tooth in need of a filling applying Filtek Z250 using incremental filling technique.
223806805|NCT01341977|DEVICE|Alcon MPDS|Multi-Purpose Solution intended for use with silicone hydrogel and soft contact lenses
223806806|NCT01341977|DEVICE|ReNu Fresh MPS|ReNu Fresh MPS is a marketed product indicated for cleaning, removing protein deposits, rinsing, disinfecting and storage of soft contact lenses.
223806807|NCT01985620|BEHAVIORAL|Educational intervention|
223806808|NCT05458596|BEHAVIORAL|Screen-based simulation|In the research, training will be given to the sample group on intimate partner violence against women through screen-based simulation.
223806809|NCT04557839|OTHER|Traditional physical therapy balance exercise|"first phase : stepping forward, backward, and sideways on the exercise step stepping over blocks of various heights standing up from a chair, walking four steps forward,)A performing a range of motion and balance exercises (forward and backward rolling of the arms; bending the trunk forward and side to side);on a swiss ball. performed In a normal condition In first 20 m of each session 2nd phase Performing double-legged stance tandem walking forward and backward~• Dosage of exercise was twice a week for 6 week each session comprise of 60 mints. Each set consisted of 4 periods of 11 exercises and rest of 40 sec .many exercise over time will turn into circuit training"
223806810|NCT04557839|OTHER|proprioception based balance training|"first phase : stepping forward, backward, and sideways on the exercise step stepping over blocks of various heights standing up from a chair, walking four steps forward,)A performing a range of motion and balance exercises (forward and backward rolling of the arms; bending the trunk forward and side to side);on a swiss ball. performed In a normal condition In first 20 m of each session 2nd phase Performing double-legged stance tandem walking forward and backward all exercise done under following condition.~* eyes open firm surfaces~* Eyes open soft surfaces~* Eyes closed firm surfaces~* Eyes closed soft surfaces (the soft surfaces will be a foam mate with 2.5 cm thick )~* These exercise will perform with turning the head side to side ad up and down~* Dosage of exercise was twice a week for 6 week each session comprise of 60 mints. Each set consisted of 4 periods of 11 exercises and rest of 40 sec .many exercise over time will turn into circuit training"
223806811|NCT05083195|OTHER|Home-based Telerehabilitation|Balance, walking, strengthening exercise videos etc. taken in different positions will be uploaded to the telerehabilitation system. A personalized exercise program will be created from these exercises. This program will be defined to the account of the patient and the follow-up of the person will be carried out through the system.
223806812|NCT05083195|OTHER|Exercise Brochure|Photos and explanations of exercises taken in different positions such as balance, walking, strengthening etc. will be uploaded to the telerehabilitation system. A personalized exercise brochure will be created from these exercises. This program will be defined for the patient's account and the patient will be asked to follow the exercises with this brochure.
223806813|NCT04227080|DRUG|BH4|oral administration of 20 mg/kg KUVAN (BH4)
223806814|NCT04426396|DIAGNOSTIC_TEST|FFR|FFR measured by pressure wire, CT-FFR computed by coronary CT angiography
223806815|NCT02331797|DEVICE|Endoscopic Technique|Endoscopic Technique; endoscopic transcanal lateral graft tympanoplasty using An endoscope (Karl Storz, Tuttlingen, Germany) and A microdrill (Skeeter Otologic Drill System; Medtronic Xom ed Surgical Products, Inc., Jacksonville, FL, USA)
223806816|NCT02331797|DEVICE|Microscopic Technique|Microsopic surgical approach using a Zeiss Opmi 111 (Carl Zeiss, Jena, Germany) operating microscope
223806817|NCT01255592|DRUG|AZD5069|Oral dose bid
223806818|NCT01255592|DRUG|Placebo|Oral dose bid
223806819|NCT00551070|OTHER|Laboratory Biomarker Analysis|Correlative studies
223806820|NCT00551070|OTHER|Pharmacological Study|Correlative studies
223806821|NCT00551070|DRUG|Selumetinib|Given PO
223806822|NCT00551070|DRUG|Selumetinib Sulfate|Given PO
223806823|NCT05324969|BEHAVIORAL|MM-based MI|9 remote mindful-based MI sessions will be delivered to promote participating parents' mindful eating, mindful movements, and mindful family interactions. Parents will be encouraged to act as changing agents for their families.
223806824|NCT05324969|OTHER|healthy education|9 health education emails will be sent to participating parents in the control group
223806825|NCT02782390|OTHER|Dental Restoration with Stainless Crown|Lesions allocated to this group will be treated with stainless dental crowns according to the Hall Technique protocol (Evans \& Innes, 2010).
223806826|NCT02782390|OTHER|Dental Restoration with Composite Resin|"Surfaces allocated to this group will be treated with composite resin (Z250, 3M ESPE, USA) according to the manufacturer's instructions.~Initially, local anesthesia and rubber dam adaptation will be performed. Then, 37% phosphoric acid will be applied on the surface for 15 seconds, followed by spray of water/air for at least 15 seconds. Then, the adhesive system (Single Bond, 3M ESPE, USA) will be applied and light cured according to the manufacturer's instructions. Finally, composite resin (Z250, 3M ESPE, USA) will be applied and light cured according to the manufacturer's instructions."
223806827|NCT00113282|DRUG|Interleukin-2 (IL-2)|
223806828|NCT00622011|DRUG|Risperidone and Zotepine for delirium|try risperidone or zotepine in the treatment of delirium
223806829|NCT00845338|DRUG|Darifenacin (BAY79-4998)|Darifenacin 7,5mg tablets once daily for 14 days, darifenacin 7,5mg or 15mg once daily for 14 consecutive days
223806830|NCT06347094|OTHER|Personalized Dietary Plan|Prescription of dietary plans increasing the intake of (poly)phenols through consumption of foods rich in these compounds, in the context of a balanced, personalised diet
223806831|NCT06347094|DIETARY_SUPPLEMENT|Oral (Poly)phenol Challenge Test (OPCT)|Nutritional challenge with standardized (poly)phenol-rich tablets
223806832|NCT06347094|OTHER|General Dietary Advice|Prescription of balanced dietary plans
223806833|NCT02020122|DRUG|Duloxetine|duloxetine 60mg
223806834|NCT02020122|DRUG|Pregabalin|pregabalin 150mg
223806835|NCT02020122|DRUG|Placebo|non active placebo
223806836|NCT03704584|DRUG|Treatment Group: Corticosteroid injection|Subjects will receive a corticosteroid injection that is 40 mg/mL injection of Methylprednisolone or 40mg/mL injection of methylacetate injectable suspension or 40 mg/mL triamcinolone.
223806837|NCT03704584|DRUG|Control Group (corticosteroid alone)|Control Group (corticosteroid alone) subjects will receive (40 mg/mL injection of Methylprednisolone acetate injectable suspension or 40 mg/mL triamcinolone) .
223806838|NCT03704584|DRUG|Treatment Group: Lidocaine|Subjects will receive an injection of lidocaine (1% lidocaine HCl).
223806839|NCT03987126|DIETARY_SUPPLEMENT|Human Milk Oligosaccharides (HMO)|Sachet containing 10 grams of HMO
223806840|NCT03987126|OTHER|Placebo|Sachet manufactured to mimic 10g of HMO
223806841|NCT03439189|COMBINATION_PRODUCT|Methacetin Breath Test|A breath analyzer will be used to measure changes in carbon-12 to carbon-13 ratio as a result of metabolism of the Methacetin substrate before and after treatment.
223806842|NCT03439189|DRUG|Emricasan|Investigational drug for NASH treatment in Main Conatus protocol
223806843|NCT03439189|DRUG|Placebo oral capsule|Placebo versus emricasan in Conatus NASH treatment trial
223806844|NCT01777321|BIOLOGICAL|Herpes zoster vaccine GSK1437173A|HZ/su vaccine administered either into the subcutaneous tissue of the upper arm (deltoid region) of the non-dominant arm or intramuscularly in the deltoid region of non-dominant arm on a 0,2-month schedule.
223806845|NCT04670133|DIETARY_SUPPLEMENT|Inulin|Supplementation with a prebiotic, specifically inulin.
223806846|NCT04670133|DIETARY_SUPPLEMENT|Maltodextrin|Supplementation with maltodextrin (placebo)
223806847|NCT04483154|DEVICE|Coala Heart Monitor|The Coala Heart Monitor (Coala Life AB, Sweden) is a CE and FDA-cleared device for real-time, remote monitoring of 2-lead ECG as well as heart and lung sounds. The Coala Heart Monitor automatically detects for 9 of the most common arrhythmias and has an integrated stethoscope for remote auscultation. It is paired wirelessly with the patient's smartphone and results are provided instantly both to patient and to connected provider in the cloud-based Coala Care portal.
224264257|NCT00629122|DRUG|Clotrimazole Troche|Study day 1 (9a): Initiate sublingual (SL) tacrolimus and clotrimazole troche x 5 doses; Study day 3 (9a): Collection of pharmacokinetic parameters around the 5th SL tacrolimus dose; Study day 3 (9p): Start washout period, no drug administration (tacrolimus, clotrimazole); Study day 5 (9p): End washout period; Study day 6 (9a): Initiate oral tacrolimus and clotrimazole troche x 5 doses; Study day 8 (9a): Collection of pharmacokinetic parameters around the 5th oral tacrolimus dose; Study day 15: Contact subject by telephone to assess for any adverse effects. To ensure that dietary intake does not affect the absorption profile of tacrolimus we will ensure that breakfast is given 15 minutes prior to drug administration on the days of pharmacokinetic assessment (study day 3 and 8).
223806848|NCT02579564|DRUG|Gemcitabine|
223806849|NCT02579564|DRUG|Vinorelbine|
223806850|NCT02579564|DRUG|Paclitaxel|
223806851|NCT02579564|DRUG|Pemetrexed|
223806852|NCT02579564|DRUG|Oncorine|
223806853|NCT02579564|DRUG|Endostar|
223806854|NCT02579564|DRUG|Cisplatin|
223806855|NCT01641796|DRUG|Paromomycin|Paromomycin Topical Cream applied to all lesions once a day for 20 days
223806856|NCT05274932|OTHER|BFR resistance exercise|4 sets (30, 15, 15, 15 reps).
223806857|NCT01924611|PROCEDURE|Atraumatic Restorative Technique using cotton rolls|Atraumatic Restorative Technique using cotton rolls.
223806858|NCT01924611|PROCEDURE|Atraumatic Restorative Technique|"Atraumatic Restorative Technique is typically used in Minimally invasive Dentistry.~This restoration technique is made using only hand instruments and is possible to be carried out in children in schools.~This particular time, the isolation of the surgical/tooth area was made using rubber dam as saliva barrier."
223806859|NCT02032160|BIOLOGICAL|Engerix B IM injection - 20ug|Engerix B IM injection - 20ug At 0, 1 and 6 months
223806860|NCT02032160|BIOLOGICAL|Fendrix IM injection - 20ug|Fendrix IM injection - 20ug At 0, 1 and 6 months
223806861|NCT04069325|DRUG|simiaowan|pills, 6g twice daily (BID), oral, 12 weeks
223806862|NCT04069325|DRUG|placebo|pills, 6g twice daily (BID), oral, 12 weeks
223806863|NCT04069325|DRUG|febuxostat|tablets, 40 mg once daily (QD), oral, 12 weeks
223806864|NCT05850780|DEVICE|Photobiomodulation|"A diode laser (Sirolaser blue laser system, Sirona Dental Systems GmbH, Fabrikstraße 31, 64625 Bensheim, Germany) Wavelength 660 nm will be used, and the laser parameters will be set as follows: Power 0.1 W, energy 6 J, Continuous wave; energy Tip area 0.5 cm2, fluence 12 J/cm2 will be applied to the surface of the pulp stumps for 60 seconds. The pulp chamber will then be filled with reinforced zinc oxide-eugenol (IRM, Dentsply, Mount Waverley, Australia) to ensure proper sealing.~Then, each tooth in both groups will finally be restored with a stainless-steel crown (SSC)40 (3M/ESPE, St. Paul, Minn., USA) in the same visit, which will be cemented onto the tooth using glass ionomer cement.~Finally, reapplication of laser with the same parameters will be done around inserted crowns to promote tissue healing and decrease post operative pain."
223806865|NCT05850780|DRUG|MTA|Three parts of MTA powder will be mixed with one part of distilled water to obtain paste. This mixture will then be placed on the radicular pulp stumps and condensed lightly with a moistened cotton pellet. then the access cavities will be sealed with glass ionomer cement
223806866|NCT01519388|OTHER|Spontaneous breathing|study of the swallowing of boluses of water and yogurt under spontaneous breathing
223806867|NCT01519388|DEVICE|Elysée 150®|Study of the swallowing of boluses of water and yogurt while under mechanical ventilation
223806868|NCT01450722|PROCEDURE|bypass surgery, stent placement|bypass surgery, stent placement
223806869|NCT01450722|PROCEDURE|stent placement|placement of paclitaxel eluting stent in long superficial femoral artery obstruction
223806870|NCT00485225|DRUG|EN3270|Transdermal Therapeutic System
223806871|NCT04372628|DRUG|Lopinavir/Ritonavir 400 mg/100 mg|Lopinavir/Ritonavir tablets
223806872|NCT04372628|OTHER|Placebo|Unmatched placebo
223806873|NCT00194688|DRUG|H. pylori treatment|
223806874|NCT01512771|OTHER|CPAP|6 weeks of CPAP
223806875|NCT05767528|DIAGNOSTIC_TEST|Patient-derived tumor-like cell clusters (PTC) drug sensitivity testing|Conducting the neoadjuvant therapy of FDA-approved drugs for patients with muscle-invasive bladder carcinoma, culturing the patient-derived tumor-like cell clusters for drug sensitivity testing simultaneously, then assess the accuracy of the diagnostic test by combination and analysis of these results
223806876|NCT05445154|DRUG|SKLB1028 Dose Escalation|Drug :SKLB1028 ;Drug: Cytarabine ;Drug: Daunorubicin
223806877|NCT02088203|DIETARY_SUPPLEMENT|Dose 1|Russian Tarragon Nutrasorb 0.3 g
223806878|NCT02088203|DIETARY_SUPPLEMENT|Dose 2|Russian Tarragon Nutrasorb 1 g
223806879|NCT02088203|DIETARY_SUPPLEMENT|Dose 0|Placebo
223806880|NCT02088203|DIETARY_SUPPLEMENT|Dose 3|Russian Tarragon Nutrasorb 3 g
223806881|NCT02088203|DIETARY_SUPPLEMENT|Dose 4|Russian Tarragon Nutrasorb 10 g
223806882|NCT02088203|DIETARY_SUPPLEMENT|Dose 5|Russian Tarragon Nutrasorb 20 g
223806883|NCT02088203|DIETARY_SUPPLEMENT|Dose 6|Russian Tarragon Nutrasorb 30 g
223806884|NCT00751764|DRUG|Moxidectin|
223806885|NCT03362359|DRUG|Ga-68-PSMA-11|Single administration of 150 MBq (± 50 MBq), corresponding to a mass dose of ≤ 6 µg. A 2nd administration of 150 MBq (± 50 MBq), corresponding to a mass dose of ≤ 6 µg is possible in the unlikely case of a negative histological result (i.e. no prostate-specific membrane antigen (PSMA) expression in dissected lymph nodes) to verify if PSMA PET-positive tissue as seen on day 1 has not been removed during RP with EPLND.
223806886|NCT05709990|DRUG|Solifenacin Succinate 5 MG Oral Tablet [Vesicare]|These patients will receive solifenacin 5-10 MG daily (combined with standard urotherapy) for 8 weeks.
223806887|NCT05709990|DRUG|Vitamin D3|These patients will receive high dose vitamin D supplementation (more than 2000IU daily) (combined with standard urotherapy) for 8 weeks.
223806888|NCT05709990|BEHAVIORAL|Standard urotherapy|These patients will receive standard urotherapyfor 8 weeks.
223806889|NCT04791761|DRUG|Oxycodone|Oxycodone will be prescribed at a dose in the range of 0.025 mg/kg to 0.10 mg/kg every four hours or as needed for adequate pain management. The total supply will be limited to seven days. It will be prescribed in liquid suspension form for ease of use in pediatric populations. Subjects or parents will purchase this medication and dosage will be given to subjects in easy-to-understand language.
223806890|NCT04791761|DRUG|Ibuprofen|Ibuprofen will be prescribed at 10 mg/kg to be taken every 6 hours for the first three post-operative days. After the first three days, the subject should take the ibuprofen every 6 hours as needed for pain control. The daily dose of ibuprofen is not to exceed 1200mg or more than 4 individual doses. It will be prescribed in liquid suspension form for ease of use in pediatric populations. Subjects or parents will purchase this medication and dosage will be given to subjects in easy-to-understand language.
223806891|NCT04791761|DRUG|Acetaminophen|Acetaminophen will be prescribed at 15mg/kg to be taken every 4 hours for the first three days, except when sleeping. After the first three days, the subject should take the acetaminophen every 4 hours as needed for pain control. The daily dose of acetaminophen is not to exceed 5 doses in 24 hours. It will be prescribed in liquid suspension form for ease of use in pediatric populations. Subjects or parents will purchase this medication and dosage will be given to subjects in easy-to-understand language.
223806892|NCT04791761|OTHER|Opioid disposal pouch|Half of the opioid group will be randomized assigned to an opioid disposal pouch arm. This pouch is a drug deactivation system that can be disposed in the trash in a household.
223806893|NCT04791761|OTHER|Opioid disposal education|An opioid disposal education document will be provided to all families in the opioid group. This education document has information on unused or expired prescription medication disposal and specific information about permanent collection sites within our health system, drug take-back locations, drug take back day, and disposing at home.
223806894|NCT00107055|DRUG|REN-1654|
223806895|NCT04224324|PROCEDURE|Tonsillectomy and Adeniodectomy|pediatric patients undergoing tonsillectomy and adenoidectomy
223806896|NCT01972633|PROCEDURE|Laser|Endovenous Laser (1470nm) ablation of great or small saphenous vein
223806897|NCT01972633|PROCEDURE|Radiofrequency|Endovenous Radiofrequency (VNUS Closure Fast) of great or small saphenous vein
223806898|NCT00089141|DRUG|mycophenolate mofetil|Given orally
223806899|NCT00089141|DRUG|placebo|Given orally
223806900|NCT05435222|BEHAVIORAL|Male-specific psychotherapeutic program (MSPP)|The MSPP for MDD is designed to be used for the acute treatment of depression in men in 18 sessions over a period of 18 weeks. Therapy is delivered weekly with homework bridging every session. Central CBT elements (e.g. behavioral activation, cognitive restructuring) will be retained in MSPP. During implementation of typical CBT techniques, masculine role norms will be considered. One underlying topic will be the potential of multiple masculinities to coexist, being fluid and relational within one man, emphasizing positive aspects of masculinities compatible with psychotherapy for MDD.
223806901|NCT05435222|BEHAVIORAL|Cognitive beahvioral therapy (CBT)|This intervention consists of 18 sessions of manualized, standard cognitive behavioral therapy for major depression. Therapy is delivered weekly with homework bridging every session.
223806902|NCT04030858|BEHAVIORAL|Plant-based diet + nutrition education|The intervention group will adopt a nutrient-dense dietary pattern and receive nutrition education sessions specific to that lifestyle. The diet protocol is comprised of minimally-processed plant foods such as fruits, vegetables, legumes, beans, nuts and seeds. No refined sugars, added salt, or oil will be included. Dietary fat intake limited to 20% of total calories or less per day. Animal products will be eliminated. This dietary pattern is expected to improve resilience, mood, inflammation, microbiome, spirituality, and overall general health (as measured by weight, cholesterol, blood pressure). The treatment group will also receive weekly nutrition education sessions to support the diet.
223806903|NCT05428605|OTHER|Blood sample|10 mL on lithium heparinate tubes, 10 mL on EDTA tubes.
223806904|NCT05455905|DIAGNOSTIC_TEST|Patient Health Questionnaire-9|The Patient Health Questionnaire-9 is a nine question self-administered examination in which the patient indicates how often they have experienced different feelings and sensations in the past two weeks. The Patient Health Questionnaire-9 is scored from 0 to 27 where higher scores are associated with more severe depression.
223806905|NCT05455905|DIAGNOSTIC_TEST|Generalized Anxiety Disorder-7|The Generalized Anxiety Disorder-7 is a seven question self-administered examination in which the patient indicates how often they have experienced different feelings and sensations in the past two weeks. The Generalized Anxiety Disorder-7 is scored from 0 to 21 where higher scores are associated with more severe anxiety.
223806906|NCT05455905|DIAGNOSTIC_TEST|Hamilton Depression Rating Scale|The Hamilton Depression Rating Scale is administered by a mental health profession and includes twenty-one questions asking about how the participant has been feeling in the past week. The Hamilton Depression Rating Scale is scored from 0 to 45 where higher scores are associated with more severe depression.
223806907|NCT05455905|DIAGNOSTIC_TEST|Hamilton Anxiety Rating Scale|The Hamilton Anxiety Rating Scale is administered by a mental health profession and includes fourteen questions asking about how the participant has been feeling in the past week. The Hamilton Anxiety Rating Scale is scored from 0 to 56 where higher scores are associated with more severe anxiety.
223806908|NCT03026218|OTHER|GlucoseMama application with blood sugar monitoring and carb monitoring.|We will use the Glucosemama application to review glucose and carb logs on a weekly basis. This will be reviewed with the patient in order to adjust dietary and medicals.
223806909|NCT03026218|OTHER|Group prenatal care for GDM.|group prenatal care is a group based intervention where individuals with GDM will meet together to learn about pregnancy and diabetes.
223806910|NCT03373526|OTHER|Inspiratory Muscle Training|The Inspiratory Muscle Training will be perform using using the Power Breathe® device, during 20 minutes daily, five times a week. The protocol will be performed in the sitting position with an established load of 40% of maximal inspiratory pressure.
223806911|NCT03373526|OTHER|Aerobic Training|The aerobic physical training will be perform using a cycle ergometer, during 20 minutes daily, five times a week, with moderate intensity (50-70% of reserve heart rate).
223806912|NCT03418116|DEVICE|Argus II Retinal Prosthesis|The Argus II System is designed to provide visual function to individuals with severe to profound vision loss due to outer retinal degeneration. It consists of implanted and external components. The implant is an epiretinal prosthesis that is surgically implanted in and around the eye. The external equipment includes glasses and a video processing unit (VPU). The glasses include a miniature video camera, which captures video images, and a coil that sends data and stimulation commands to the implant. The VPU converts the video images into stimulation commands and is body-worn. The Argus II System operates by converting video images into electrical energy that activates retinal cells, delivering the signal through the optic nerve to the brain where it is perceived as light.
223806913|NCT06496191|BIOLOGICAL|FMT|\- Single dose (30gm/90ml) of FMT will be given via upper GI gastroduodenoscope at D4
223806914|NCT06496191|OTHER|SMT|Baclofen + AUD counselling
223806915|NCT06496191|OTHER|Placebo|Placebo identical to the FMT arm.
223806916|NCT06083870|DRUG|Oba01|Oba01 0.15, 0.5, 0.75, 1.0 mg/kg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle
223806917|NCT01888393|DRUG|lumacaftor 200 mg q12h + ivacaftor 250 mg q12h|
223806918|NCT05279781|PROCEDURE|Non surgical root canal treatment|Complete root canal treatment will be performed followed by direct restoration
223806919|NCT05279781|PROCEDURE|Pulpotomy|Full pulpotomy followed by direct restoration
223806920|NCT05936931|BEHAVIORAL|Changes in CRC screening awareness and intentions|Using a single arm, open-label, pre-test post-test design (n=15 adult child/parent dyads), assess the impact of a young adult-mediated intervention to increase CRC screening among a paired age-eligible family member (e.g., parent/grandparent). The focus of the intervention will be on changes in CRC screening awareness and intentions among the age-eligible adult, but we hypothesize that the young adult could benefit as well. Thus, in addition to assessing feasibility and acceptability, we will assess changes in 1) CRC screening intentions among the age-eligible adults and 2) CRC health literacy and awareness of screening guidelines among the younger adult participant.
223806921|NCT01559948|BEHAVIORAL|Lumbopelvic stabilization exercise|The objective of this exercise program is to recruit and train the primary stabilizing muscles of the spine in order for them to more appropriately support the spine. Participants will complete 4 different exercises daily: one in supine, one in standing, one in quadruped, and one in a side-bridge position. The dosage for each exercise is 20 reps with an 8 second hold. In supine, the first exercise is the abdominal drawing-in maneuver. In standing, the first exercise is the abdominal drawing-in maneuver. In quadruped, the first exercise is alternating arm lifts. The final exercise is the side-bridge hold. Participants will then be asked to attend supervised physical therapy sessions twice a week for 2 weeks and once a week for another 2 weeks. They will be instructed to perform the exercises at home daily for a total of 12 weeks as well as complete a compliance log. Progression of the stabilization program will be determined by the physical therapist based on pre-established criteria.
223806922|NCT01559948|DEVICE|Sacroiliac joint belt|The belt should be worn low around the pelvis just above the greater trochanter and instructed to wear the belt during all waking hours of the first four weeks of the study. The treating physical therapist will monitor the placement of belts during each exercise session. Belt usage logs will be given to each participant to assess compliance with wearing the belt.
223806923|NCT00508261|BIOLOGICAL|Meningococcal vaccine GSK134612|Single dose intramuscular injection
223806924|NCT00508261|BIOLOGICAL|Infanrix™ hexa|Single dose intramuscular injection
223806925|NCT00508261|BIOLOGICAL|Meningitec™|Single dose intramuscular injection
223806926|NCT00873418|BEHAVIORAL|Coping skills training|16 weekly telephone session using to teach heart failure patients self-management skills and how to cope more effectively with psychological distress associated with heart failure.
223806927|NCT02231866|BIOLOGICAL|VRC-EBOADC069-00-VP|cAd3-EBO Ebola Chimpanzee Adenovirus Vector Vaccine GP Zaire + GP Sudan
223806928|NCT02231866|BIOLOGICAL|VRC-EBOADC076-00-VP|cAd3-EBO Ebola Chimpanzee Adenovirus Vector Vaccine GP Zaire
223806929|NCT00972348|OTHER|Online access to a personal health record|Patients in the intervention arm have full access to their online personal health record
223806930|NCT00972348|OTHER|No access to the PHR|Patients will not be given access to their PHR but will complete online surveys.
223806931|NCT00180479|DEVICE|XIENCE V® Everolimus Eluting Coronary Stent|Drug eluting stent implantation stent in the treatment of coronary artery disease.
223806932|NCT00180479|DEVICE|TAXUS® EXPRESS2™ Paclitaxel Eluting Coronary Stent|Drug eluting stent implantation stent in the treatment of coronary artery disease.
223806933|NCT01423682|BEHAVIORAL|Eccentric exercise|Patients and healthy subjects will perform an eccentric exercise during which a weight is lifted along the body and lowered with an extended arm at a slow speed. Weight is determined, based on pain in patients and based on force in healthy subjects.
223806934|NCT06181864|OTHER|NAO intervention|The subjects will undergo a pre-intervention assessment phase that will consist of administering the Test of Emotional Vocabulary (TLE) and the Test of emotion comprehension (TEC). The tests will be re-submitted at the end of the intervention. Having ascertained the presence of the inclusion criteria and following randomization of the sample, the Experimental Group constituted of 20 children, will be administered the research task, which involves 15 sessions, one per week lasting one hour and thirty minutes. the children are guided by the voice of the robot Nao. The robot guides them in carrying out practical and relaxation activities. Consequently, audio visual feedback will be provided, via the robot, to return information to the subject about the accuracy of the response.
223806935|NCT06181864|OTHER|Traditional intervention|The subjects will undergo a pre-intervention assessment phase that will consist of administering the Test of Emotional Vocabulary (TLE) and the Test of emotion comprehension (TEC). The tests will be re-submitted at the end of the intervention. Having ascertained the presence of the inclusion criteria and following randomization of the sample, the Experimental Group constituted of 20 children, will be administered the research task, which involves 15 sessions, one per week lasting one hour and thirty minutes. The children are guided by the instructions of the operator who guides them in carrying out practical and relaxation activities. Consequently, the operator will provide feedback, to return information to the subject regarding the accuracy of the response.
223806936|NCT04577677|DEVICE|brain stimulation|tDCS and peripheral nerve stimulation
223806937|NCT03056482|DRUG|Ondansetron 8mg|Ondansetron 8 MG prepared in a 100 mL normal saline min-bag
223806938|NCT03056482|DRUG|Haloperidol 0.05mg/kg|Haloperidol 0.05 mg/kg prepared in a 100 mL normal saline min-bag
223806939|NCT03056482|DRUG|Haloperidol 0.1mg/kg|Haloperidol 0.1 mg/kg prepared in a 100 mL normal saline min-bag
223806940|NCT02336243|DIETARY_SUPPLEMENT|Docosahexaenoic acid (DHA)|Docosahexaenoic acid (DHA), 600 mg per day. Each woman will take three DHA capsules per day (200 mg each), as early in gestation as possible and until the end of pregnancy.
223806941|NCT02336243|DIETARY_SUPPLEMENT|Placebo (for Docosahexaenoic acid (DHA))|Each women allocated to the placebo group, will receive three placebo capsules per day. The placebo capsules will have same size, aspect and flavor than the DHA capsules.
223806942|NCT02780232|BEHAVIORAL|Cuida tu animo / Care for your mood|"CUIDA TU ÁNIMO is an online program to adolescents that provides information, education and support related to the care of the mood.~Adolescents interact with the program via a monitoring e-mail that they receive every two weeks (Monitoring) and a website which allows them to access a number of links. The website have the following modules:~1. What is 'CUIDA TU ÁNIMO': Description and definition of the program~2. Psycho-educational information: Information about depression, its treatment, and opportunities for prevention~3. How is your mood? (Monitoring): a) Online assessment of symptoms every two weeks during three months with the PHQ-3. b) Feedback~4. Forums.~5. Blog.~6. Appointment (Chat or Phone call).~7. Contact."
223806943|NCT02391636|DRUG|Carbetocin|at delivery of anterior shoulder
223806944|NCT02391636|DRUG|Oxytocin|at delivery of anterior shoulder
223806945|NCT05346003|PROCEDURE|TCSP|In the pre-test, all students will be given a BLS information form, followed by blended e-learning with theory and video in a virtual environment. The BLS knowledge post-test will be administered immediately after class.T-shirts and standard pillows (550 g silicon fiber pillow 50x70 cm size) with a simulation of an adult human size (approximately) sternum, rib and heart drawing (printed as picture) will be given to the intervention group only after the pretest. In the study, the BLS will be simulated for adult patients only. To simulate a half-body human BLS mock-up, a pre-made simulation t-shirt will be fitted on a standard pillow to create a BLS mock-up in a home environment, and after blended e-learning, they will be able to perform BLS iteratively on a T-shirt-clad simulation pillow (TCSP) model. In this way, autonomous learning will be supported. All students will practice BLS in a real simulation model two weeks after the blended e-learning.
223806946|NCT01479998|OTHER|standard care|standard care plus nicotine replacement therapy
223806947|NCT01479998|OTHER|standard care plus contingency management|standard care is 4 counseling sessions and nicotine replacement therapy plus 3 weekly meetings with positive reinforcers
223806948|NCT02984657|PROCEDURE|Surgical patients in 2012 with anesthesia and nursing staff less attuned to intraoperative RTP.|RTP, reverse Trendelenburg positioning
223806949|NCT02984657|PROCEDURE|Surgical patients in 2015 with enhanced anesthesia and nursing staff awareness and use of intraoperative RTP.|RTP, reverse Trendelenburg positioning
223806950|NCT01222169|DRUG|NaCl 0,9%|Propofol 3micrgr/ml (TCI plasma concentration) and NaCl 0,9% 2min. and 10min. application
223806951|NCT05131165|BEHAVIORAL|Daily Text Messages|Participants will receive daily text message reminders to use their routine behavior to trigger medication adherence.
223806952|NCT05131165|BEHAVIORAL|Incentivization based on timely ART adherence|Participants will be eligible to draw a prize if they take their medication within +/- one hour of the stated existing routine to which pill-taking is anchored on at least 70% of days between recruitment and the 3-month study visit.
223806953|NCT03652779|DRUG|Tecarfarin 10mg|Tecarfarin 10mg tablets
223806954|NCT03652779|DRUG|Tecarfarin 20mg|two tecarfarin 10mg tablets
223806955|NCT03652779|DRUG|Tecarfarin 30mg|three tecarfarin 10mg tablets
223806956|NCT03652779|DRUG|Tecarfarin 40mg|four tecarfarin 10mg tablets
224264258|NCT00629122|DRUG|Tacrolimus (Arm A)|Study day 1 (9a): Initiate sublingual (SL) tacrolimus and nystatin suspension x 5 doses; Study day 3 (9a): Collection of pharmacokinetic parameters around the 5th SL tacrolimus dose; Study day 3 (9p): Start washout period, no drug administration (tacrolimus, nystatin); Study day 5 (9p): End washout period; Study day 6 (9a): Initiate oral tacrolimus and nystatin suspension x 5 doses; Study day 8 (9a): Collection of pharmacokinetic parameters around the 5th oral tacrolimus dose; Study day 15: Contact subjects by telephone to assess for any adverse effects. To ensure that dietary intake does not affect the absorption profile of tacrolimus we will ensure that breakfast is given 15 minutes prior to drug administration on the days of pharmacokinetic assessment (study day 3 and 8).
223806957|NCT04930692|DIAGNOSTIC_TEST|Contrast-enhanced CT lymphography with the periareolar injection of iopamidol|"Patients who meet the inclusion/exclusion criteria will undergo the CT lymphography with periaoreolar injection of a mixture of 4 mL iopamidol and 2 mL of 1% lidocaine hydrochloride. Computed tomographic images will be obtained 1, 3, 5, and 10 minutes after administration of the iopamidol. Following enhancement of the lymphatic duct, the first lymph node to show enhancement will be defined as the SLN.~No later than 10 days after the CT lymphography patients will receive surgical treatment. During breast cancer surgery identification of the SLN using the ICG-fluorescence method with injection of 2 ml indocyanine green into the skin of the areola and the biopsy of identified SLN will be performed. The comparison of the results of CT lymphography and SLN biopsy will be administrated by the investigator."
223806958|NCT03626779|OTHER|Prf|Take 10cc blood from patient and gain prf blug
223806959|NCT03960229|OTHER|MicroFluidic Sperm Sorting Chips|sperm selection of IVF treatment
223806960|NCT03960229|OTHER|Gradient-Density Centrifugation|sperm selection of IVF treatment
223806961|NCT01267292|DRUG|Buspirone|\[week 1: Buspirone 30 mg twice a day (9am and 6pm) on Monday through Sunday\] \[weeks 2-3: Buspirone 45 mg twice a day (9am and 6pm) on Monday through Sunday\]
224264259|NCT00629122|DRUG|Nystatin Suspension|Study day 1 (9a): Initiate sublingual (SL) tacrolimus and nystatin suspension x 5 doses; Study day 3 (9a): Collection of pharmacokinetic parameters around the 5th SL tacrolimus dose; Study day 3 (9p): Start washout period, no drug administration (tacrolimus, nystatin); Study day 5 (9p): End washout period; Study day 6 (9a): Initiate oral tacrolimus and nystatin suspension x 5 doses; Study day 8 (9a): Collection of pharmacokinetic parameters around the 5th oral tacrolimus dose; Study day 15: Contact subjects by telephone to assess for any adverse effects. To ensure that dietary intake does not affect the absorption profile of tacrolimus we will ensure that breakfast is given 15 minutes prior to drug administration on the days of pharmacokinetic assessment (study day 3 and 8).
224264260|NCT06395246|BEHAVIORAL|Active Comparator: Continuous calorie restriction|Individualized continuous calorie restriction diet based on healthy Mediterranean diet recommendations aiming to achieve at least a 5% weight loss at the end of the intervention
224264261|NCT06395246|BEHAVIORAL|eTRE|early (morning) time-restricted eating pluss individualized continuous calorie restriction diet based on healthy Mediterranean diet recommendations aiming to achieve at least a 5% weight loss at the end of the intervention
224264262|NCT05467111|OTHER|Acute Exercise|Patients will perform an acute bout of exercise (different types of exercise for each cycle of anthracyclines, as aerobic exercise, strength training or combined training) 24-48 hours prior to each cycle of anthracyclines.
224264263|NCT06078501|DRUG|Misoprostol 400mcg buccal|Misoprostol 400mcg buccal administration 2-3 hours prior to procedure
224264264|NCT06078501|DRUG|Placebo|Placebo buccal administration 2-3 hours prior to procedure
224264265|NCT04728542|DEVICE|ORIGIN PS System|70 surgeries with the ORIGIN PS System
224264266|NCT04728542|DEVICE|VANGUARD PS System|70 surgeries with the VANGUARD System
224264267|NCT00197353|DRUG|Epidural bupivacaine (dose/concentration/volume ranging)|
224264268|NCT03155503|DRUG|SUVN-911|Oral Tablet
224264269|NCT03155503|DRUG|Placebo|Oral Tablet
224264270|NCT01380782|DRUG|BIBF 1120|200 mg BID oral for 28 day cycle
224264271|NCT01839344|DIETARY_SUPPLEMENT|Quercetin|Quercetin 250 mg capsules; oral single dose of 2000 mg
224264272|NCT01839344|DRUG|Acarbose|Acarbose 100 mg tablet; oral single dose of 100 mg
224264273|NCT01839344|DRUG|placebo|An oral single dose of a solid, colored empty capsule.
224264274|NCT05747469|DRUG|local anaesthetic injection|Subcutaneous local anesthesia with 1% lidocaine without epinephrine is administered to the skin overlying the joint.
224264275|NCT05747469|PROCEDURE|Human Adipose Allograft|Light axial traction of the digit is used to open the joint space when introducing the 18-gauge needle. Fluoroscopy is used to assist with visualization 1 cc of Leneva is injected into the CMC joint and 0.5 cc in the IP, PIP and DIP joints. The puncture is dressed with a band-aid and coban wrap, which will be worn for 48 hours. Return to work and normal use of the hand is recommended at 48 hours. No narcotics are prescribed.
224264276|NCT03676946|DRUG|ZKAB001 5mg/kg|5mg/kg/times bi-week IV administration of ZKAB001
224264277|NCT03676946|DRUG|ZKAB001 10mg/kg|10mg/kg/times bi-week IV administration of ZKAB001
224264278|NCT03676946|DRUG|ZKAB001 15mg/kg|15mg/kg/times bi-week IV administration of ZKAB001
224264279|NCT06627868|DIETARY_SUPPLEMENT|NAD+ precursor|NAD+ precursor supplementation (Nicotinamide, Nicotinamide Riboside, or Nicotinamide Mononucleotide)
224264280|NCT06627868|OTHER|Placebo|Oral placebo daily intake for 6 months
224264281|NCT02369822|DIETARY_SUPPLEMENT|Vitamin C|those who are 2-3 years will receive 400 mg/day, 4-8 years will receive 500 mg/day, those who are 9-13 years will receive 1000 mg/day, and from 14-16 years will receive 1500 mg/day
224264282|NCT03125447|OTHER|speed and accuracy answer to visual stimuli|A yellow fish swimming over a blue-green background will appear on the screen of virtual glasses. The child will have to give as fast as possible the direction of the fish pushing the left or right button of a computer mouse
224264283|NCT06556849|DEVICE|Defocus Incorporated Multiple Segments (DIMS)|To evaluate the effectiveness of Defocus Incorporated Multiple Segments (DIMS) in slowing myopia progression as a function of age in pediatric patients.
224264284|NCT04580784|RADIATION|Weekly hypofractionation for early breast cancer|Testing the feasibility of a hypofractionated adjuvant radiotherapy regimen after breast surgery on a-once-weekly basis for a total dose of 28.5Gy in 5 fractions over 5 weeks
224264285|NCT05967286|DRUG|Alpelisib|Given PO
224264286|NCT05967286|PROCEDURE|Biopsy|Undergo biopsy
224264287|NCT05967286|PROCEDURE|Biospecimen Collection|Undergo collection of blood
224264288|NCT05967286|PROCEDURE|Bone Scan|Undergo bone scans
224264289|NCT05967286|PROCEDURE|Computed Tomography|Undergo CT
224264290|NCT05967286|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
224264291|NCT05967286|DRUG|Olaparib|Given PO
224264292|NCT05967286|PROCEDURE|Positron Emission Tomography|Undergo PET
224264293|NCT03965286|DRUG|DAAs|Daily fixed-dose combination of ledipasvir (90 mg)/sofosbuvir (400 mg) 12 weeks Daily simeprevir (150 mg) plus sofosbuvir (400 mg) 12 weeks Daily daclatasvir (60 mg) plus sofosbuvir (400 mg) 12 weeks Daily fixed-dose combination of paritaprevir (150 mg)/ritonavir (100 mg)/ombitasvir (25 mg) with dasabuvir (600 mg) 12weeks
223806962|NCT01267292|DRUG|Placebo for Buspirone|\[week 1: Placebo for Buspirone twice a day (9am and 6pm) on Monday through Sunday\] \[weeks 2-3: Placebo for Buspirone twice a day (9am and 6pm) on Monday through Sunday\]
223806963|NCT01267292|DRUG|Methylphenidate|Methylphenidate serves as an acute stimulant challenge. \[week 1: no Methylphenidate or Methylphenidate placebo\] \[week 2: 0mg Methylphenidate (placebo for Methylphenidate) on Monday at 10am; Methylphenidate once a day (10am) on Wednesday and Friday, and on each of these 2 days the Methylphenidate dose will be different (15 mg, 30mg, 60 mg, or 0mg)\] \[week 3: Methylphenidate once a day (10am) on Monday and Wednesday, and on each of these 2 days the Methylphenidate dose will be different (15 mg, 30mg, 60 mg, or 0mg)\]
223806964|NCT01267292|DRUG|Placebo for Methylphenidate|\[week 1: no Methylphenidate or Methylphenidate placebo\] \[week 2: 0mg Methylphenidate (placebo for Methylphenidate) on Monday at 10am; Methylphenidate once a day (10am) on Wednesday and Friday, and on each of these 2 days the Methylphenidate dose will be different (15 mg, 30mg, 60 mg, or 0mg)\] \[week 3: Methylphenidate once a day (10am) on Monday and Wednesday, and on each of these 2 days the Methylphenidate dose will be different (15 mg, 30mg, 60 mg, or 0mg)\]
223806965|NCT05897723|DEVICE|Fractional Radiofrequency|Fractional Radiofrequency (RF) delivering nano-fractional RF energy, causing fractional ablation and coagulation at the treatment site.
223806966|NCT01103310|DRUG|BAY94-9392|
223806967|NCT03238898|DRUG|Botulinum toxin type A|"botulinum toxin type A injections~Botulinum toxin type A (100 or 30 units) was injected for each side into the gastrocnemious or the small flexor foot muscles, respectively, according to the predominance of leg or foot cramps."
223806968|NCT03238898|OTHER|Normal saline|"Normal saline injections~The same dosage as the active group, but with normal saline alone were injected into the gastrocnemious or the small flexor foot muscles, respectively, according to the predominance of leg or foot cramps."
223806969|NCT01945905|OTHER|Intramural|Under this alternative, the patients will receive treatment with direct observation from health team. Treatment will be provided for free
223806970|NCT01945905|OTHER|Extramural|In this form the medication will be given by a health worker in the place chosen by patients. This option will be delivered to patients with newly diagnosed pulmonary TB without hospitalization criteria
223806971|NCT01478009|DIETARY_SUPPLEMENT|Korean red ginseng|Korean red ginseng(3.0g/day) for 12 weeks
223806972|NCT01478009|DIETARY_SUPPLEMENT|Placebo|Placebo (3.0g/day) for 12 weeks
223806973|NCT04074421|DRUG|Rifaximin|A non-aminoglycoside intestinal antibiotic, 400mg, twice one day for 2 weeks.
223806974|NCT04074421|DRUG|Probiotic Formula|A probiotic called Enterococcus faecium, 500mg, triple one day for 4 weeks.
223806975|NCT04074421|DRUG|Placebo oral tablet|Placebo oral tablet that has no therapeutic effect
223806976|NCT02298361|OTHER|Health insurance outreach IT tools|"IT tools that support Community Health Centers in children's health insurance outreach efforts (insurance outreach IT tools), adapted from tools proven to support chronic disease management."
223806977|NCT00598026|OTHER|Tele- follow-up|Remote transmission to the implantation centre every 3 months
223806978|NCT00598026|OTHER|Conventional follow-up|Visits at the implantation centre every 3 months
223806979|NCT01798394|DRUG|Progesterone|Take micronized natural progesterone capsule by mouth, twice daily (approximately at 8 am and 8 pm) for four weeks beginning on postpartum day 4.
223806980|NCT01798394|OTHER|Placebo|Take placebo capsule by mouth, twice daily (approximately at 8 am and 8 pm) for 4 weeks beginning on postpartum day 4.
223806981|NCT00766233|OTHER|Hyperthermal treatment|Hyperthermal treatment one or three times per week for 60 minutes
223806982|NCT03026023|DRUG|Combindation treatment with Grazoprevir and Elbasvir fixed dose combination tablet, with or without ribavirin|HCV treatment for 12 to 16 weeks. Treatment length and addition of ribavirin based upon presence of baseline resistance associated variant in the HCV virus. Medications given concurrently.
223806983|NCT05758831|DRUG|Perfusion of treatment Rituximab|Perfusion of treatment (Mabthera®, Truxima®, Rixathon®, Ruxience®)
223806984|NCT05758831|DRUG|Perfusion of treatment Ocrelizumab|Perfusion of treatment (Ocrevus®)
223806985|NCT00440869|DIETARY_SUPPLEMENT|N-acetylcysteine|600 mg po bid
223806986|NCT00440869|DIETARY_SUPPLEMENT|placebo|bid oral dosing
223806987|NCT05541055|DEVICE|digital CBT-I|A fully-automated and personalized digital intervention based on principles from cognitive behavioral therapy for insomnia.
223806988|NCT05541055|OTHER|Sleep hygiene education|Participants will be provided with sleep hygiene advice which will be delivered digitally all at once upon allocation to the SHE arm. Participants will be able to revisit content during the trial as they wish.
223806989|NCT01711762|DRUG|GDC-0973|Single oral dose of \[14C\]-GDC-0973
223806990|NCT01746095|DRUG|Vancomycin hydrochloride inhalation powder|There will be two treatment cohorts in this study, each comprised of 40 randomized (1:1 active to placebo) and treated patients (adults ≥18 and children ≥12 years of age). In Cohort 1, patients will be enrolled and randomized to receive the 32 mg dose of AeroVanc bid or placebo bid. Prior to starting enrollment in Cohort 2, a safety evaluation will be carried out by the Data Monitoring Committee (DMC) based on treatment data from the first 20 patients in Cohort 1. Subject to the Sponsor's written communication of the DMC's opinion of acceptable safety, the dose for the active arm in Cohort 2 will be escalated to 64 mg bid. Optionally, the active arm for Cohort 2 may also be kept the same (32 mg bid), or reduced to 16 mg bid, depending on the outcome of the DMC's safety evaluation.
223806991|NCT01746095|DRUG|Placebo inhalation powder|
223806992|NCT05388721|OTHER|Clinical data and specimen collection|"Questionnaire survey and clinical data was conducted when pregnant women were enrolled in the first trimester, and blood and urine were collected. Furthermore, we will follow up the pregnant women until delivery, blood and urine were collected during the third trimester (after 28 weeks), and clinical information was collected.~Umbilical cord blood and placental tissue will be collected if possible."
223806993|NCT00526630|DRUG|Methylphenidate (MPD)|Participants will be given 1 mg/kg of MPD divided in three doses (at 8 am, 12 noon, and 4 pm). A four-week titration period will be used, using 0.25-mg/kg increments per week until achieving the weight-adjusted target dosage, which may range from five to eight 10-mg tablets per day. The maximum daily dose will be 80 mg/day.
223806994|NCT00526630|DRUG|Placebo|Participants will be given placebo instead of active MPD.
223806995|NCT02520167|BEHAVIORAL|Dietary and Lifestyle Counseling|Dietary and lifestyle education; Peer group support.
223806996|NCT03012464|OTHER|Pathologic and functional assessment|Random biopsies will be taken from the pelvic floor muscles, external anal sphincter, and the lateral supportive ligaments of the rectum during surgical treatment of rectal prolapse whether via the abdominal or perineal approach. Tissue samples will be subjected to immunohistochemistry to calculate the ratio between collagen type I and type III, and to reveal any myopathic or degenerative changes
223806997|NCT02944084|DIETARY_SUPPLEMENT|Rice bran extract|
223806998|NCT02944084|DIETARY_SUPPLEMENT|Porridge in water|
223806999|NCT02944084|DIETARY_SUPPLEMENT|Porridge in milk|
223807000|NCT05845268|COMBINATION_PRODUCT|Long-course chemoradiation, with Tislelizumab (PD-1 inhibitor)|Tislelizumab was added to long-course chemoradiotherapy (CRT) in LARC patients, CRT + concurrent tislelizumab was used in the Experimental arm, and CRT was used in the Active Comparator arm.
223807001|NCT05845268|COMBINATION_PRODUCT|Long-course chemoradiation, without Tislelizumab (PD-1 inhibitor)|Tislelizumab was added to long-course chemoradiotherapy (CRT) in LARC patients, CRT + concurrent tislelizumab was used in the Experimental arm, and CRT was used in the Active Comparator arm.
223807002|NCT04088201|DEVICE|Glucose measurements|We will not conduct an intervention, but will obtain measurements from a continuous, non-invasive glucose sensor, and compare with those from a glucometer.
223807003|NCT06187740|RADIATION|thoracic radiotherapy|"Thoracic radiotherapy should begin within 42 days after the end of the last chemotherapy at an initial dose of 30 Gy in 10 fractions (3 patients).~Dose escalation will start after acceptable safety was observed, first at: 35 Gy/10 Fx(3 patients), then to the next dose group: 40 Gy/10 Fx(22 patients). Radiotherapy was administered between two immunotherapy doses (3 weeks interval) to avoid thoracic radiotherapy on the same day with immunotherapy."
223807004|NCT03979196|OTHER|Inpatient Management|"Admission for a minimum of three days, administration of betamethasone, and clinical reassessment by obstetrician after three days. After the initial three day admission, further management will be at the discretion of their obstetrician who will continue their care and decide if further admissions are needed.~Weekly cervical length assessment will be performed until 28 weeks and patient readmission will be decided by their Obstetrician.~Post-intervention, women in both arms will receive the same standard of care (weekly clinic or inpatient follow-up appointments) and will be followed to delivery. Prior to delivery, participants will complete a patient Quality of Life survey and at delivery, primary and secondary outcomes will be collected."
223807005|NCT03979196|OTHER|Outpatient Management|"Avoid heavy lifting and core exercise, avoid intercourse, weekly assessment of cervical length by ultrasound and administration of betamethasone. Patients will continue with outpatient management for the remainder of their pregnancy with no admission unless the patient develops contractions, PPROM, bleeding, or the cervix is dilated to ≥1cm.~Post-intervention, women in both arms will receive the same standard of care (weekly clinic or inpatient follow-up appointments) and will be followed to delivery. Prior to delivery, participants will complete a patient Quality of Life survey and at delivery, primary and secondary outcomes will be collected."
223807006|NCT06185998|DEVICE|low pressure tracheostomy cannulas|"The tracheostomy tube is changed according to the randomization sequence, a filter is connected for 5 minutes; then baseline data will be assessed. The tracheostomy tube is then connected to the four interfaces for 30 minutes each. Parameters is measured after each 30-minute period. The cuff of the tracheostomy tube will be deflated using a syringe when the interface is a filter, phonation valve, or cap. In contrast, the cuff will be inflated when the interface is the ventilator.~The cuff is inflated with a manometer for the low-pressure balloon tracheostomy tube and with the minimum and sufficient amount of injectable water for the plated balloon tracheostomy tube to avoid overpressure"
223807007|NCT06185998|DEVICE|plated balloon tracheostomy cannulas|"The tracheostomy tube is changed according to the randomization sequence, a filter is connected for 5 minutes; then baseline data will be assessed. The tracheostomy tube is then connected to the four interfaces for 30 minutes each. Parameters is measured after each 30-minute period. The cuff of the tracheostomy tube will be deflated using a syringe when the interface is a filter, phonation valve, or cap. In contrast, the cuff will be inflated when the interface is the ventilator.~The cuff is inflated with a manometer for the low-pressure balloon tracheostomy tube and with the minimum and sufficient amount of injectable water for the plated balloon tracheostomy tube to avoid overpressure"
223807008|NCT01656330|DRUG|Rivaroxaban 20 mg twice daily|One rivaroxaban 20 mg tablet administered twice a day (b.i.d.) for 4 days (Days 1-4). Interpretation by CTRL: Concentration type = Exact; Number = 20; unit=mg; route: oral use for 4 days.
223807009|NCT01656330|DRUG|Rivaroxaban 20 mg once daily|One rivaroxaban 20 mg tablet administered once daily on Day 5. Interpretation by CTRL: Concentration type = Exact; Number = 20; unit=mg; route: oral use for 1 day.
223807010|NCT01656330|DRUG|Profilnine SD|Single bolus dose of Profilnine SD 50 IU/kg administered by intravenous (IV) injection on Day 5. Interpretation by CTRL: Concentration type = Exact; Number = 50; unit=IU/kg; route: intraveous use.
223807011|NCT01656330|DRUG|Beriplex P/N|Single bolus dose of Beriplex P/N 50 IU/kg administered by intravenous (IV) injection on Day 5 Interpretation by CTRL: Concentration type = Exact ; Number = 50; unit=IU/kg; route : intravenous use
224264294|NCT05264363|DEVICE|VIPUN Gastric Monitoring System prototype|The Investigational Medical Device (IMD) is used simultaneously with the reference device (solid state high-resolution manometry) to record gastric intraluminal pressure for approximately 2.5 hours.
224264295|NCT05039996|BEHAVIORAL|education and relaxation program|randomized controlled trial
224264296|NCT00003035|BIOLOGICAL|filgrastim|
224264297|NCT00003035|DRUG|doxorubicin hydrochloride|
224264298|NCT00003035|DRUG|paclitaxel|
224264299|NCT00003035|DRUG|tamoxifen citrate|
224264300|NCT00003035|PROCEDURE|surgical procedure|
224264301|NCT00003035|RADIATION|radiation therapy|
223807012|NCT01656330|OTHER|Saline|Single 100 cc bolus of saline administered by intravenous (IV) injection on Day 5. Interpretation by CTRL: Concentration type = Exact ; Number = 100; unit=cc; route : intravenous use use.
223807013|NCT02459262|BIOLOGICAL|GBS-NN vaccine|Three dose levels will be administered, with and without Alhydrogel®
223807014|NCT00181571|DRUG|methylphenidate HCl (Concerta)|up to a maximum dose of 1.3 mg Concerta/kg/day, and not more than 144 mg/day for any subject regardless of weight.
223807015|NCT00181571|DRUG|Placebo|up to a maximum dose of 1.3 mg Placebo /kg/day, and not more than 144 mg/day for any subject regardless of weight.
223807016|NCT03107078|DRUG|Glucocorticoids|Intravenous Glucocorticoids (GCs)
223807017|NCT00303056|DRUG|HOE140 Icatibant|
223807018|NCT01094132|DEVICE|Multispectral Digital Colposcope (MDC)|"The MDC has 2 components: an optical probe \& a multispectral colposcope. The optical wand makes use of fluorescence \& reflectance spectroscopy; a light is shone on the cervix and the wand reports what it sees to a computer. Since cancer \& healthy cells interact differently with light, a computer can detect abnormalities. The multispectral colposcope is based on a conventional colposcope, which is already widely used. However, it is also able to produce fluorescence \& polarized reflectance images of the entire cervix. Computer analysis of these images can detect abnormalities on the cervix, defining their location and shape.~This trial involves combined analysis of MDC data. This may lead to more effective diagnosis of cervical abnormalities. The MDC will be used with standard care for patients presenting with cervical abnormalities (as detected by a Pap test). The MDC will not be used to guide patient management decisions.~All study subjects will receive this same intervention."
223807019|NCT01242748|DRUG|Degarelix|The degarelix doses were administered by subcutaneous (s.c.) injections into the abdominal wall. In the main CS35 trial, a starting dose of 240 mg degarelix was administered on Day 0. One month later a maintenance dose of 480 mg was administered. This was repeated after 4, 7, and 10 months (ie a total of 5 administrations in the main trial). In the CS35A extension trial, the participants received the same treatment as in the main trial ie the degarelix treated participants continued to receive degarelix 480 mg s.c. treatment every three months.
223807020|NCT01242748|DRUG|Goserelin acetate|The goserelin doses were administered by subcutaneous (s.c.) implants into the abdominal wall. In the main CS35 trial, an initial dose of 3.6 mg goserelin was administered on Day 0. One month later a subsequent dose of 10.8 mg was administered and this was repeated after 4, 7, and 10 months (ie a total of 5 implants in the main trial). In the CS35A extension trial, the participants received the same treatment as in the main trial ie the goserelin treated participants continued to receive goserelin acetate 10.8 mg s.c. implants every three months.
223807021|NCT00840801|BIOLOGICAL|Tick-Borne Encephalitis (TBE) Vaccine (Inactivated)|Subjects receive three vaccinations with FSME-IMMUN 0.25ml Junior on days 0, 28 and 360
223807022|NCT00840801|BIOLOGICAL|Tick-Borne Encephalitis (TBE) Vaccine (Inactivated)|Subjects receive two vaccinations with Encepur 0.25ml Children on days 0 and 28 and a third vaccination with FSME-IMMUN 0.25ml Junior on day 360.
223807023|NCT02031367|DRUG|Triamcinolone Acetonide|Corticosteroid arm
223807024|NCT02031367|OTHER|Platelet Rich Plasma|Platelet Rich Plasma
223807025|NCT05542810|COMBINATION_PRODUCT|Use sports drinks as polyethylene glycol solvents|Using sports drinks as a polyethylene glycol solvent and water as a polyethylene glycol solvent in the control group, the effectiveness of intestinal preparation in the two groups was compared, and the adverse reactions, the acceptability of the solution taste, the timing of oral laxatives, and the willingness to repeat the same intestinal preparation or the willingness to recommend the same intestinal preparation to others were compared.
223807026|NCT03933475|DEVICE|Virtual reality game|Use of virtual reality games on television screens
223807027|NCT05386667|DRUG|Majezik %0.25 oral spray|"Free gingival graft was taken from the palatal mucosa of the patients in order to increase the attached gingiva.~After FGG, the patients were asked to apply this spray to the palatal mucosa 3 times a day."
223807028|NCT05386667|OTHER|Aftamed oral spray|"Free gingival graft was taken from the palatal mucosa of the patients in order to increase the attached gingiva.~After FGG, the patients were asked to apply this spray to the palatal mucosa 3 times a day."
223807029|NCT05386667|OTHER|Crystalin oral spray|"Free gingival graft was taken from the palatal mucosa of the patients in order to increase the attached gingiva.~After FGG, the patients were asked to apply this spray to the palatal mucosa 3 times a day."
223807030|NCT05386667|PROCEDURE|Free gingival graft harvesting|Free gingival graft was taken from the palatal mucosa of the patients in order to increase the attached gingiva.
223807031|NCT01152775|OTHER|This group of patients will be exposed to multimedia|This group of patients will be exposed to multimedia
223807032|NCT01152775|OTHER|No Media|This group will not be exposed to multimedia
223807033|NCT03880630|OTHER|Inspiratory muscle training|Patients will perform 3 inspiratory loading tests (15%, 30%, and 50% of maximum inspiratory pressures) on 3 separate days with the sequence will be randomized. Patient will then be trained with individualized IMT program based on the results of 3 inspiratory loading tests.
223807034|NCT05272891|OTHER|experimental group|audio book app
223807035|NCT01719107|DIETARY_SUPPLEMENT|L. reuteri DSM 17938 chewable tablets|2 chewable tablets with breakfast for 4 weeks
223807036|NCT01719107|DIETARY_SUPPLEMENT|Placebo chewable tablets|2 chewable tablets with breakfast for 4 weeks
223807037|NCT00691808|DRUG|LX6171 High Dose|A high dose of LX6171, using an oral suspension; daily oral intake for 28 days in the morning at approximately the same time.
223807038|NCT00691808|DRUG|LX6171 Low Dose|A low dose of LX6171, using an oral suspension; daily oral intake for 28 days in the morning at approximately the same time.
223807039|NCT00691808|DRUG|Placebo|Matching placebo dosing with daily oral intake for 28 days in the morning at approximately the same time.
223807040|NCT03767166|DEVICE|Biodegradable biliary and pancreatic stents placement|Biodegradable biliary and pancreatic stents placement
223807041|NCT03724487|BEHAVIORAL|Coachman|Coachman is comprised of: TBI and nurse counseling. TBI is comprised of: 1) web-based education modules on hypertension knowledge and skills as well as behavioral lifestyle guidance, (2) Medisafe, a smartphone medication management app to support medication adherence to antihypertensives, and (3) self-monitoring blood pressure. Participants will be exposed to nurse counseling, by registered nurses from the community, affiliated with a local nurse organization that will serve as community health workers (CHWs). The CHWs will provide informal counseling, social support, as well as follow-up phone sessions on medication adherence and monitoring blood pressure.
223807042|NCT03724487|BEHAVIORAL|Enhanced Usual Care (EUC)|Standard printed education materials on hypertension management, including content on lifestyle modification and medication-taking will be provided; plus access to one web-based education (video) with information on how to self-monitoring blood pressure.
223807043|NCT01007656|DIETARY_SUPPLEMENT|GD Antrodia camphorata|Three 500mg capsules per oral dose, twice daily with an interval of 12 hours for 90 days
223807044|NCT00464451|DRUG|Dexmedetomidine|Dexmedetomidine 3 micrograms per kilogram per os; subsequent dose of 1 microgram per kilogram per os if necessary to treat inadequate sedation 30 minutes following initial dosing.
223807045|NCT00464451|DRUG|Chloral hydrate|Chloral hydrate 75 milligrams per kilogram per os; subsequent dose of 25 milligrams per kilogram per os if necessary to treat inadequate sedation 30 minutes following initial dosing.
223807046|NCT05008952|OTHER|High-fat shake|All participants will be given a high-fat test meal to examine their postprandial triglyceride response.
223807047|NCT04696913|DIAGNOSTIC_TEST|Exposure: Positive COVID-19 infection|Exposure: Positive COVID-19 infection as determined by RT-PCR
224264302|NCT01447017|DRUG|DPK-060|DPK-060 2% ear drops were administered as 3 applications per day into the outer ear by use of a single-dose pipette (0.3 mL/pipette) for 7 days. In case clinical symptoms remained after 7 days of treatment, the treatment period was extended by another 3 days with 3 applications per day.
223807048|NCT04696913|DIAGNOSTIC_TEST|Exposure: Negative COVID-19 infection|Exposure: Negative COVID-19 infection as determined by RT-PCR
223807049|NCT04111068|DEVICE|anodal tDCS Active Stimulation|a weak electric current is applied to the head through electrodes to affect the cortical excitability of the targeted cells in the brain.
223807050|NCT04111068|DEVICE|anodal tDCS Sham/Placebo Stimulation|The tDCS machine will be used as in active stimulation, except the electrical current will not be applied.
223807051|NCT02714855|DRUG|Apixaban|
224264303|NCT01447017|DRUG|Placebo for DPK-060 ear drops|Placebo for DPK-060 ear drops were administered as 3 applications per day into the outer ear by use of a single-dose pipette (0.3 mL/pipette) for 7 days. In case clinical symptoms remained after 7 days of treatment, the treatment period was extended by another 3 days with 3 applications per day.
224264304|NCT02695472|DRUG|80 Milligrams NSI-189|Orally Administered
223807052|NCT02115867|DIETARY_SUPPLEMENT|Probiotic|Symprove probiotic
223807053|NCT03168568|DRUG|Valsartan/Sacubitril or placebo|tablet (double dummy)
223807054|NCT03168568|DRUG|Valsartan or placebo|tablet (double dummy)
223807055|NCT01928966|OTHER|Pumpkin Seeds|Participants will be asked to consume 1.5 ounces of raw, unsalted pumpkin seeds per day. The 1.5 ounces will be split in to two servings (each 0.75 ounces).
224264305|NCT02695472|DRUG|Placebo|Orally administered
224264306|NCT02695472|DRUG|40 Milligrams NSI-189|Orally Administered
224264307|NCT04701216|DRUG|SHR8735|SHR8735 is an thrombopoietin receptor agonist to promote platelet production.
224264308|NCT03458845|DIAGNOSTIC_TEST|Computed Tomography Scan|The results of the CT scan and the hand-grip test will be used for diagnosis of sarcopenia. The Royal Free Hospital-Global Assessment (RFH-GA) results will classify the nutritional status of the patient.
224264309|NCT03534076|OTHER|Cohort Observational study|Cohort Observational study - there is no intervention
224264310|NCT00000330|DRUG|Opioid-Related Disorders|
223807056|NCT00715650|BEHAVIORAL|Benefits Counseling|Benefits counseling is designed to improve the quality of life of disability applicants by accomplishing two functions: 1) Providing information concerning what vocational rehabilitation services are available and how they will affect receipt of disability payments, 2) Amplifying applicants' existing motivation to engage in work and related-activities, using a Motivational Interviewing approach.
223807057|NCT00715650|BEHAVIORAL|VA Orientation|VA Orientation is designed to provide the Veteran with information regarding the services available, how to access the services and where the service is located on the VA campus.
223807058|NCT01750879|DRUG|Peanut Flour|Peanut Flour
223807059|NCT01750879|DRUG|Oat Flour|Oat Flour
223807060|NCT05993702|DRUG|regorafenib|(TAS102): Trifluridine tepipiridine tablets 35 mg/m2 twice a day, D1-5, D15-D19, 28 days as a cycle; (TKI: regorafenib: regorafenib capsules administered at a dose of 80 mg (2 tablets, each containing 40 mg regorafenib) once daily for a 28-day cycle)
223807061|NCT05993702|DRUG|fruquintinib|TAS102: Trifluridine tepipiridine tablets 35 mg/m2 twice a day, D1-5, D15-D19, 28 days as a cycle; or Fruquintinib: a dose of 3mg/dose administered orally once daily, continuously for 28 days as a cycle.
223807062|NCT01548430|DRUG|TTP4000|
223807063|NCT01548430|DRUG|Placebo|
223807064|NCT00001785|DRUG|Recombinant human interferon beta-1a|
223807065|NCT00320775|DRUG|VEGF Trap|"Part A: Six successive cohorts of 3-6 patients each with neovascular AMD will receive a single intravitreal (ITV) injection of 0.05, 0.15, 0.5, 1.0, 2.0, or 4.0 mg of VEGF Trap into the study eye.~Part B: Up to 30 subjects will be randomly assigned in a 1:1 ratio to receive a single of 2.0 mg/eye VEGF Trap followed by 1 sham injection six weeks later, or an initial dose of 0.3 mg pegaptanib sodium into the study eye, followed by a second dose six weeks later.~Part C: Approximately 30 subjects will be randomly assigned in a 1:1 ratio to receive up to two ITV injections of either 0.15 or 4.0 mg/eye VEGF Trap.~After completion of Visit 8 (Day 57), patients from all parts of the study, may be eligible to continue in Open-label Extension and will receive 4.0 mg of VEGF Trap."
223807066|NCT00455585|DRUG|nevirapine, stavudine, lamivudine|
223807067|NCT05987306|BEHAVIORAL|Weight loss plus self-compassion|A novel weight loss approach combining a standard weight loss based on the Diabetes Prevention Program and internalized weight bias intervention with self-compassion exercises.
223807068|NCT04647032|DEVICE|Transcranial alternating current stimulation|Transcranial alternating current stimulation (tACS) will be applied across the prefrontal cortex near electrodes coordinates AF3/AF4
223807069|NCT04955834|DRUG|Insulin degludec injection|long-acting insulin
223807070|NCT04955834|DRUG|Tresiba®|long-acting insulin
223807071|NCT03674554|PROCEDURE|titanium bases using intra oral luting cement technique|a full-arch screw-retained implant prosthesis on titanium bases using intra oral luting cement technique
223807072|NCT03674554|PROCEDURE|transmucosal abutment|a full-arch screw-retained implant prosthesis with transmucosal abutment
223807073|NCT01041014|BEHAVIORAL|Professional medical interpreter|All treatment interpreters were certified bilingual in Spanish and English and had completed (1) at least 40 hours of training in medical terminology, ethics, patient privacy, and basic interpreting skills; and (2) an online course in protection of human subjects.
223807074|NCT02437656|DRUG|Metformin|"J3 - J10 (7 days minimum) : 850 mg 2 times / day~J10 - 48h before surgery : 850 mg 3 times / day"
223807075|NCT01934803|DIETARY_SUPPLEMENT|Zinc gluconate|Study participants will be randomly assigned to a zinc gluconate or placebo group and will be instructed to take one pill of study medication orally daily for 18 months.
223807076|NCT01934803|DIETARY_SUPPLEMENT|Placebo|
223807077|NCT05130125|DRUG|rFSH|rFSH or HP-hMG or rFSH and HP-hMG
223807078|NCT03320798|OTHER|Data record|
223807079|NCT06370910|OTHER|Low-Level Laser Therapy|The patient will be submitted to evaluation through a questionnaire, which will be the patient's evaluation form, which will be elaborated by the researcher (Appendix A). Next, pain and edema will be evaluated, using the VAS scales, Mc Gill scale and REEDA scale, after this process, the therapy will be applied, and the patient will be randomly selected for cryotherapy or LLLT. After application, the patient will be evaluated immediately and the scales applied again and after 24 hours.
223807080|NCT03962296|DRUG|Vitis vinifera extract|Three daily oral doses of 50mg tablets of Vitis vinifera extract(Entelon®, Hanlim Pharm, Seoul, South Korea) were administered to patients in this group
223807081|NCT03962296|DRUG|Calcium Dobesilate|Three daily oral doses of 50mg tablets of Calcium Dobesilate(Doxium®, Ilsung Pharm, Seoul, South Korea) were administered to patients in this group
223807082|NCT03962296|DRUG|Placebo|Placebo tablets lacked Vitis vinifera extract or calcium dobesilate, but their appearance was identical to those of the study group tablets.
223807083|NCT02856425|DRUG|Nintedanib|Nintedanib oral tablets. An angiokinase inhibitor targeting VEGFR 1-3, FGFR 1-3, and PDGFR α/β as well as RET. Refer to current IB for product details
223807084|NCT02856425|DRUG|Pembrolizumab|Pembrolizumab, Intravenous. An IgG4 anti-PD-1 blocking monoclonal antibody. Refer to current IB for product details
223807085|NCT04500496|DRUG|INH|3 tablet of INH inserted by the patient 12 hours before the scheduled office hysteroscopy
223807086|NCT04500496|DRUG|dinoprostone|1 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia \& Upjohn, Puurs, Belgium) inserted by the patient 12 hours before the scheduled office hysteroscopy.
223807087|NCT03708588|DRUG|Ticagrelor|Chewed
223807088|NCT03708588|DRUG|Ticagrelor|Integral
223807089|NCT03518125|BIOLOGICAL|BioThrax|"Other Names:~Anthrax Vaccine Adsorbed (AVA)"
223807090|NCT03518125|BIOLOGICAL|AV7909|Anthrax Vaccine Absorbed plus CPG 7909 Adjuvant
223807091|NCT03518125|DRUG|Sodium chloride injection USP, 0.9% (placebo)|"Other Names:~Saline Solution"
223807092|NCT06491836|DIETARY_SUPPLEMENT|oligoantigenic diet|Oligoantigenic diet that will cover recommended daily allowance (RDA) of macronutrients and micronutrients according patients' ages according to our available sources of food in our culture and the diet consists typically of meat (e.g. chicken and lamb), carbohydrate sources (e.g., potatoes and rice), fruits (e.g., bananas, pears and apples), vegetables (e.g., cucumbers, carrot, lettuce, cauliflower, turnips, cabbage and broccoli)
223807093|NCT06491836|OTHER|Food regimen without food restrictions.|Food regimen that will cover recommended daily allowance (RDA) for macronutrients and micronutrients according patients' ages without any food restriction
223807094|NCT03311282|DEVICE|infants bottles|"* angled/inclined teat that remains full of milk throughout the feeding to prevent the risk of air ingestion, gassy colic, hiccups and regurgitation and to keep the infant's neck in the right position;~* extra-large, soft and rounded base to ensure maximum simulation of the maternal breast and a wide latch on for a correct suckling motion~* flexors at the base to enhance elasticity and flexibility of the teat"
223807095|NCT03311282|DEVICE|Infants Bottles|"* large, rounded and soft teat to ensure maximum simulation of the maternal breast and a wide latch on for a correct suckling motion~* non-inclined shape of the teat ideal from 4 months onwards, when the colic episodes have subsided and infant has more control of the neck.~* flexors at the base to enhance elasticity and flexibility of the teat"
223807096|NCT03311282|DEVICE|Infants Bottles|"* teat with less rounded base to guarantee tighter lip support, which helps the sucking motion.~* flexors at the base to enhance elasticity and flexibility of the teat"
223807097|NCT02416492|BIOLOGICAL|SB623 cells|SB623 cells will be implanted in the peri-infarct area using stereotactic surgery.
223807098|NCT02416492|PROCEDURE|Sham Control|Sham Surgery
223807099|NCT02093663|DRUG|MMX Mesalamine/Mesalazine (Low Dose)|Once daily, tablets - the amount depends on the participants weight; 900 milligram per day (mg/day) for participants weighing 18 kg to less than or equal to (\<=) 23 kilograms (kg); 1200 mg/day for participants weighing greater than (\>) 23 kg to \<= 35 kg; 1800 mg/day for participants weighing \> 35 kg to \<= 50 kg; 2400 mg/day for participants weighing \> 50 kg to \<= 90 kg.
223807100|NCT02093663|DRUG|MMX Mesalamine/Mesalazine (High Dose)|Once daily, tablets - the amount depends on the participants weight;1800 mg/day for participants weighing 18 kg to \<= 23 kg; 2400 mg/day for participants weighing \> 23 kg to \<= 35 kg; 3600 mg/day for participants weighing \> 35 kg to \<= 50 kg; 4800 mg/day for participants weighing \> 50 kg to \<= 90 kg.
223807101|NCT03730285|DEVICE|Telemedicine|Installation of videotelephone with broadband in patient's home
223807102|NCT04626739|DRUG|CD19 CAR-T|CD19 CAR-T for CD19 positive R/R non-Hodgkin lymphoma
223807103|NCT04626739|DRUG|CD22 CAR-T|CD22 CAR-T for CD22 positive R/R non-Hodgkin lymphoma
223807104|NCT04626739|DRUG|CD19+CD22 CAR-T|CD19+CD22 CAR-T for CD19 positive and CD22 positive R/R non-Hodgkin lymphoma
223807105|NCT04626739|DRUG|Fludarabine|25mg/㎡ for D-4、D-3 and D-2
223807106|NCT04626739|DRUG|Cyclophosphamide|500mg/㎡ for D-3 and D-2
223807107|NCT05747963|DEVICE|software-delivered CBT-I|The automated software called 'resleep' incorporates all core elements of CBT-I: sleep restriction, stimulus control, cognitive therapy, relaxation techniques, and sleep hygiene and education, tailoring content based on each participant's reported baseline sleep function and sleep progress. The 6-week treatment includes 42 times of intervention.
223807108|NCT05747963|OTHER|online PE|Subjects in the control group will receive non-tailored information about insomnia and sleep health education content using the Wechat Official Account.
223807109|NCT06233643|DRUG|Phloroglucinol|The active comparators will be treated with 40 mg of Phloroglucinol in the form of a single intramuscular injection.
223807110|NCT06233643|COMBINATION_PRODUCT|Acupuncture Combined Intradermal Sterile Water|Acupuncture was applied to a seated patient using the urinary bladder meridian points and combianed Intradermal Sterile Water in costovertebral area where the patient's pain was located (Sterile water of 0.5 ml was injected as intradermal into 4 points at a depth of 1-3 mm to form papules)
223807111|NCT02094443|DRUG|Alisporivir|ALV 100 and 200 mg soft gel capsules administered orally
223807112|NCT02094443|DRUG|Ribavirin|RBV 200 mg tablets (weight-based dose: \< 75 mg = 1000 mg/day; ≥ 75 kg = 1200 mg/day) administered orally in a divided daily dose
223807113|NCT06130878|OTHER|Rhythmic exercise|"A multicomponent rhythmic physical training will be carried out, with a predominance of QMT, following the principles of Animal Flow \[46\] and including the following components: wrist mobilizations; activations; specific stretching positions; special locomotor movements or traveling forms; interruptions and transitions with dynamic movements and choreographic sequences of Flow. Aspects related to the control of intensity, volume and progression strategy have yet to be defined."
223807114|NCT05280769|OTHER|oral nicotine pouch - 2 mg|"On brand oral nicotine pouch with 2 mg of protonated nicotine in original flavor"
223807115|NCT05280769|OTHER|oral nicotine pouch - 4 mg|"On brand oral nicotine pouch with 4 mg of protonated nicotine in original flavor"
223807116|NCT05280769|OTHER|oral nicotine pouch - 8 mg|"On brand oral nicotine pouch with 8 mg of protonated nicotine in original flavor"
223807117|NCT05280769|OTHER|Smokeless tobacco|Participant's typical brand of smokeless tobacco
223807118|NCT05605470|BIOLOGICAL|ChulaCov19 BNA159 vaccine (50 mcg)|Single dose of ChulaCov19 BNA159 vaccine 0.5 ml will be given by IM at Day 1
223807119|NCT05605470|BIOLOGICAL|Pfizer/BNT vaccine (30 mcg)|Single dose of Pfizer/BNT vaccine 0.3 ml will be given by IM at Day 1
223807120|NCT05605470|BIOLOGICAL|COMVIGEN (ChulaCov19 BNA159.2) vaccine (50 mcg)|Single dose of COMVIGEN vaccine 0.5 ml will be given by IM at Day 1
223807121|NCT00508404|DRUG|Panitumumab|Administered by intravenous infusion
223807122|NCT00508404|DRUG|FOLFIRI|FOLFIRI chemotherapy was initiated on Day 1 of each treatment cycle at the following starting doses: irinotecan 180 mg/m², leucovorin 400 mg/m², 5-fluorouracil bolus 400 mg/m², 5-fluorouracil infusion 2400 mg/m².
223807123|NCT02514018|BIOLOGICAL|Live-attenuated varicella-zoster virus vaccine|Commercial vaccine used to prevent shingles
223807124|NCT03662074|DRUG|Gemcitabine|Given IV
223807125|NCT03662074|BIOLOGICAL|Nivolumab|Given IV
223807126|NCT02781948|DEVICE|Optical Coherence Tomography|
224264311|NCT05668689|OTHER|Preliminary testing|The pilot test will be administered by local investigators via a computer-based application to 35-50 trainees and consultants. The cohorts will include an equal number of trainees and consultants of varying experience, based on the new RCOA curriculum and the extent of their regional experience (stage 1 (CT1-3); stage 2 (ST4-5); stage 3 (ST6-7); stage 3 + regional fellowship trained; consultant; consultant with special interest in regional; consultant + regional fellowship trained). The pilot test will contain short video clips and images of ultrasound guided regional anaesthesia with questions in a constructed response question (CRQ) format to identify relevant structures, anatomy and clinical knowledge.
223807127|NCT06276933|DRUG|Camrelizumab + chemotherapy+Thalidomide|"Camrelizumab + chemotherapy+Thalidomide Drug: Camrelizumab Camrelizumab 200mg intravenous (IV) on Day 1 of each 21-day cycle，until progression or unacceptable toxicity Other Name: SHR-1210~Drug: Thalidomide Thalidomide 100mg，po qd； Other Name: Thalidomide~Drug: Chemotherapy~Platinum-based chemotherapy:~Non-small cell lung cancer (non-squamous cell carcinoma): pemetrexed plus carboplatin/cisplatin on Day 1 of each 21-day cycle for 4-6 cycles，pemetrexed every three weeks (Q3W) maintenance for the remainder of the study or until documented PD; Non-small cell lung cancer (squamous cell carcinoma) : paclitaxel/albumin-bound paclitaxel + carboplatin/cisplatin on Day 1 of each 21-day cycle for 4-6 cycles.~Other Name: Platinum-based chemotherapy"
223807128|NCT06276933|DRUG|Camrelizumab + chemotherapy+placebo|"Drug: Camrelizumab Camrelizumab 200mg intravenous (IV) on Day 1 of each 21-day cycle，until progression or unacceptable toxicity Other Name: SHR-1210~Drug: placebo 100mg placebo 100mg，po qd；~Drug: Chemotherapy~Platinum-based chemotherapy:~Non-small cell lung cancer (non-squamous cell carcinoma): pemetrexed plus carboplatin/cisplatin on Day 1 of each 21-day cycle for 4-6 cycles，pemetrexed every three weeks (Q3W) maintenance for the remainder of the study or until documented PD; Non-small cell lung cancer (squamous cell carcinoma) : paclitaxel/albumin-bound paclitaxel + carboplatin/cisplatin on Day 1 of each 21-day cycle for 4-6 cycles.~Other Name: Platinum-based chemotherapy"
223807129|NCT02754102|OTHER|Sunscreen Spray- Liquid (BAY987516)|50 μl/cm\*2 of each test product is applied to duplicate skin sites (approximately 2 x 2 cm each) on the lower or mid-back.
223807130|NCT00260143|DRUG|Testosterone enanthate|
223807131|NCT00260143|DRUG|Placebo|
223807132|NCT05197361|DIAGNOSTIC_TEST|Invasive coronary physiology|Estimation of guide-wire coronary physiology parameters
223807133|NCT01791920|DRUG|Botulinum toxin type A(Botulax®)|Single administration, Day 0, 20 units
223807134|NCT01791920|DRUG|Botulinum toxin type A(Botox®)|Single administration, Day 0, 20units
223807135|NCT02417779|DEVICE|Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)|Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)
223807136|NCT02417779|DEVICE|Repetitive Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)|Repetitive Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)
223807137|NCT00426608|DRUG|metyrapone|Metyrapone will be available as 250 mg dose capsule.
223807138|NCT00426608|DRUG|alprazolam|Alprazolam capsules will be available with dose strength of 0.25mg
223807139|NCT00426608|DRUG|placebo|GSK561679 placebo tablets visually match the active GSK561679 tablets. Placebo to match Alprazolam is a hard gelatine capsule that visually matches active Alprazolam capsules.
223807140|NCT00426608|DRUG|GSK561679|GSK561679 tablets will be available with dose strength of 50, 10 and 200 mg.
223807141|NCT03286751|DRUG|LY900014|Administered SC
223807142|NCT03286751|DRUG|Insulin Lispro|Administered SC
223807143|NCT03261284|DIAGNOSTIC_TEST|D-dimer-guided adjustment stratege|D-dimer-guided adjustment stratege
223807144|NCT03261284|DIAGNOSTIC_TEST|Thepeautic-heparin therapy|0.3-0.7U/ml of anti-Xa activity or APTT 1.5-2.5 times of control
223807145|NCT01573936|OTHER|Physical therapy, occupational therapy, psycotherapy, medical consultations|The mean duration of the RP was 7.47 ± 4.45 months, but it was not standardized because this factor was not one of the parameters of interest for this study
223807146|NCT00626730|PROCEDURE|adjuvant therapy|
223807147|NCT00626730|RADIATION|radiation therapy|
223807148|NCT00648128|DRUG|Clarithromycin|Single-dose 500 mg immediate-release oral tablet
223807149|NCT00648128|DRUG|Clarithromycin|single-dose 500 mg immediate-release oral dose'
223807150|NCT03154489|OTHER|acenocoumarol|medication review with follow-up in acenocoumarol treatment
223807151|NCT03154489|OTHER|control|group
223807152|NCT01839006|PROCEDURE|dismembered pyeloplasty|Using a flank approach, as the patient was placed in the lateral decubitus position, and an anterior subcostal incision was made. The narrow segment of UPJ was identified and resected, and then the proximal edge of the ureter was spatulated to allow a wide anastomosis between the ureter and the most dependent part of the renal pelvis. The extent of renal pelvis reduction was decided by the surgeon.
223807153|NCT04406480|GENETIC|CGH-array and exome sequencing|A blood sample will be used for CGH-array and exome sequencing
223807154|NCT03220399|DRUG|NVP-1603-1 (P)|1capsule, single oral dosing
223807155|NCT03220399|DRUG|NVP-1603-2 (T)|1tablet, single oral dosing
223807156|NCT03220399|DRUG|NVP-1603-1 and NVP-1603-2 (P+T)|1capsule and 1tablet co-administration, oral single dosing
223807157|NCT01438125|OTHER|MF-4181|Surgical procedure will be performed as per the standard of care. Scar halves randomized to treatment with device (MF-4181), opposite side treated per standard of care.
223807158|NCT01438125|OTHER|Standard surgical wound closure|Surgical procedure will be performed as per the standard of care. Scar halves randomized to treatment with device (MF-4181), opposite side treated per standard of care.
223807159|NCT02389257|DEVICE|MINIMAG / MEG|
223807160|NCT02389257|DEVICE|MINIMAG / ECG|
223807161|NCT03559101|OTHER|Distilled water|"Commercially available beverage~Subjects collect all morning urine and drink 500 milliliters of water. Baseline vital measurements (heart rate, blood pressure, oral temperature) and body weight collected Baseline blood samples and urine collected Beverage pretreatment consumed (1 liter over 30 minutes) Body weight measured and blood and urine collected at 5 minutes, 10 minutes, 15 minutes, and then every 30 minutes for 4 hours post beverage consumption"
223807162|NCT03559101|OTHER|Medical Food 1|"Commercially available beverage~Subjects collect all morning urine and drink 500 milliliters of water. Baseline vital measurements (heart rate, blood pressure, oral temperature) and body weight collected Baseline blood samples and urine collected Beverage pretreatment consumed (1 liter over 30 minutes) Body weight measured and blood and urine collected at 5 minutes, 10 minutes, 15 minutes, and then every 30 minutes for 4 hours post beverage consumption"
223807163|NCT03559101|OTHER|Medical Food 2|"Commercially available beverage~Subjects collect all morning urine and drink 500 milliliters of water. Baseline vital measurements (heart rate, blood pressure, oral temperature) and body weight collected Baseline blood samples and urine collected Beverage pretreatment consumed (1 liter over 30 minutes) Body weight measured and blood and urine collected at 5 minutes, 10 minutes, 15 minutes, and then every 30 minutes for 4 hours post beverage consumption"
223807164|NCT03559101|OTHER|Pedialyte|"Commercially available beverage~Subjects collect all morning urine and drink 500 milliliters of water. Baseline vital measurements (heart rate, blood pressure, oral temperature) and body weight collected Baseline blood samples and urine collected Beverage pretreatment consumed (1 liter over 30 minutes) Body weight measured and blood and urine collected at 5 minutes, 10 minutes, 15 minutes, and then every 30 minutes for 4 hours post beverage consumption"
223807165|NCT03559101|OTHER|Gatorade|"Commercially available beverage~Subjects collect all morning urine and drink 500 milliliters of water. Baseline vital measurements (heart rate, blood pressure, oral temperature) and body weight collected Baseline blood samples and urine collected Beverage pretreatment consumed (1 liter over 30 minutes) Body weight measured and blood and urine collected at 5 minutes, 10 minutes, 15 minutes, and then every 30 minutes for 4 hours post beverage consumption"
223807166|NCT02116348|DRUG|Cerebrolysin (Nerve growth factor)|Cerebrolysin will be given to the intervention group
223807167|NCT03717090|OTHER|No intervention|Sample collection study Sample collection and collection of laboratory values
223807168|NCT05195073|BIOLOGICAL|Laparoscopy|3 D laparoscopy
223807169|NCT06472401|OTHER|Integrated Learning Support System|"Students will receive simulation preparation with an Integrated Learning Support System consisting of:~* Educational technology in comic book format~* Virtual monitoring system with tutors~* Psychological follow-up~* Music listening and relaxation session"
223807170|NCT06472401|OTHER|Standard Learning Model|"Students will receive standard simulation preparation consisting of:~\- Expository and dialogued theoretical class."
223807171|NCT05471648|DRUG|420 mg EG1206A EirGenix Pertuzumab in 14 mL Injection|Healthy volunteers receive pertuzumab (EG1206A, 420 mg, single dose)
223807172|NCT05471648|DRUG|Perjeta (EU origin) 420 mg in 14 mL Injection|Healthy volunteers receive pertuzumab (Perjeta (EU origin) 420 mg, single dose)
223807173|NCT05471648|DRUG|Perjeta (US origin) 420 mg in 14 mL Injection|Healthy volunteers receive pertuzumab (Perjeta (US origin), 420 mg, single dose)
223807174|NCT03940820|BIOLOGICAL|ROBO1 CAR-NK cells|The subject will be observed for any side effects during this time and all the adverse events will be recorded.
223807175|NCT03941275|DIAGNOSTIC_TEST|Bi-plane fluoroscopy|In vivo acquisition of biplane cine radiographic images of the market released Medtronic SelectSecure 3830 pacing lead
223807176|NCT04886882|OTHER|placebo comparator|solution containing 0.9 % sodium chlorine
223807177|NCT04886882|OTHER|sham comparator|vaseline, beeswax,polyglyceryl-3 diisostearate, sorbitan caprylate, propandiol,benzoic acid, glycerin, water
223807178|NCT04886882|OTHER|Experimental drug 1|A cream containing 10 % MgSO4.vaseline, beeswaxpolyglyceryl-3 diisostearate, sorbitan caprylate, propandiol,benzoic acid, glycerin, water
223807179|NCT04886882|OTHER|Experimental drug 2|A cream containing 10 % MgSO4.vaseline, beeswax,polyglyceryl-3 diisostearate, sorbitan caprylate, propandiol,benzoic acid, glycerin, water
223807180|NCT04886882|DRUG|Centella asiatica|A cream containing Centella asiatica
223807181|NCT01742377|PROCEDURE|Patients with GerdQ positive|Patients done GerdQ questionnaire, then undergone EGD. The distal esophagus was examined by HD and followed by SE with a preset TE mode for esophagus ( TE-e mode ). All patients had pH monitoring study within 1 week after the endoscopy.
223807182|NCT01742377|PROCEDURE|Patients with GerdQ negative|Patients done GerdQ questionnaire, then undergone EGD. The distal esophagus was examined by HD and followed by SE with a preset TE mode for esophagus ( TE-e mode ). All patients had pH monitoring study within 1 week after the endoscopy.
223807183|NCT01742377|PROCEDURE|Normal volunteers|Normal volunteers undergone EGD.The distal esophagus was examined by HD and followed by SE with a preset TE mode for esophagus ( TE-e mode ).
223807184|NCT00386503|DRUG|Artesunate + Amodiaquine|
223807185|NCT01394354|DRUG|Vorinostat|"Vorinostat 100 mg/d p.o., on day 1-4, 8-11, and 15-18 /28 day treatment cycle in combination with BDD.~The dose level of Vorinostat will be escalated in each new cohort:~if no dose limiting toxicity (DLT) has been observed in the previous dose level in 3 patient, the second cohort of 3 new patients will be treated with Vorinostat 200 mg/d p.o. and the third cohort will be given Vorinostat with 300 mg/d p.o."
223807186|NCT01394354|DRUG|Bortezomib|1.3mg/m2 (days 1,8,15)/28 day treatment cycle, i.v., for max. 6 treatment cycles
223807187|NCT01394354|DRUG|Doxorubicin|18mg/m2 i.v. (days 1 and 8)/ 28 day treatment cycle, max. 6 treatment cycles
223807188|NCT01394354|DRUG|Dexamethasone|40mg abs. p.o. (days 1,8,15,22) 1st treatment cycle, 20mg abs. p.o.(days 1,8,15,22) 2-6 treatment cycles
223807189|NCT00238433|BIOLOGICAL|filgrastim|5mcg/kg IVPB will be administered beginning on day +5 and continued until ANC\> 1500 for 2 consecutive days.
223807190|NCT00238433|DRUG|busulfan|3.2mg/kg/day for 3 days starting on day -8. Each dose of intravenous busulfan will be mixed in a concentration of 0.54 mg/ml of 0.9% saline and infused over 3 hours.
223807191|NCT00238433|DRUG|melphalan|50mg/m2/day/iv, infused over 30 minutes on days -5 and -4. The reconstituted melphalan is diluted in 250cc normal saline to a concentration not greater than 0.4 mg/ml.
223807192|NCT00238433|DRUG|thiotepa|250 mg/m2/day/iv on days -3 and -2
223807193|NCT00238433|PROCEDURE|bone marrow ablation with stem cell support|The transplant therapy should begin within 2 weeks of registration, but no sooner then 30 days after the last dose of chemotherapy.
223807194|NCT00238433|PROCEDURE|peripheral blood stem cell transplantation|Performed 36-48 hours following last chemotherapy dose.
223807195|NCT00580814|DRUG|Experimental: methylphenidate treatment|subjects received mehtylphenidate treatment for 12 months
223807196|NCT06579703|DRUG|Ketorolac|"Randomized to a single dose of:~Arm A: 15 mg/mL (per mL) Arm B: 30 mg/mL (per mL)"
223807197|NCT06462911|BEHAVIORAL|HOme-Based Self-management and COgnitive Training CHanges lives (HOBSCOTCH) - Spanish/Espanol|HOBSCOTCH is a home-based self-management program to treat cognitive symptoms and improve quality of life, while minimizing the barriers of access to care. The program is based on Problem Solving Therapy (PST) and teaches problem solving strategies and compensatory mechanisms to help manage cognitive dysfunction and enhance quality of life. The entire HOBSCOTCH program has been translated into Spanish for people with epilepsy who speak Spanish.
223807198|NCT02999828|BIOLOGICAL|inactivated EV71 vaccine (KMB-17)|3.0EU of inactivated enterovirus 71 vaccine (KMB-17) on day 0, 28.
223807199|NCT00939874|DRUG|Raltegravir|Raltegravir tablet 400mg is taken orally, twice daily with or without food for 48 weeks.
223807200|NCT05295966|OTHER|Cognitive therapy|Cognitive therapy
223807201|NCT05295966|BEHAVIORAL|Physiocognitive Integration|Physiocognitive Integration
223807202|NCT02749357|DEVICE|30 minutes Lokomat|"30 training sessions in robotic orthosis with duration of 30 or 60 minutes during 6 weeks, duration of 30 minutes.~The initial training speed will be the comfortable one for each patient, as assessed by Swinnen (20). The training progression will consist in a 10% weekly increase in speed, and a 5% weekly reduction of partial weight support."
223807203|NCT02749357|DEVICE|60 minutes Lokomat|30 training sessions in robotic orthosis with duration of 30 or 60 minutes during 6 weeks, duration of 60 minutes.
223807204|NCT03470779|OTHER|Physiotherapy|Treatment group participants will participate in weekly group physiotherapy and psychotherapy sessions as part of the standard program procedure.
223807205|NCT03470779|OTHER|Psychotherapy|Treatment group participants will participate in weekly group physiotherapy and psychotherapy sessions as part of the standard program procedure.
223807206|NCT01032733|BEHAVIORAL|Lifestyle Counseling|In the WL+E group, participants attended a group-based weight management session plus three supervised exercise sessions each week.
223807207|NCT01032733|OTHER|Educational Control|Participants in the educational control group attended monthly health education lectures on topics unrelated to weight loss (e.g., skin protection).
223807208|NCT06116565|BIOLOGICAL|CM310|CM310, subcutaneous injection
223807209|NCT00627484|PROCEDURE|Gastric bypass|NOTE: the surgery is not paid for by the study
223807210|NCT00627484|PROCEDURE|Gastric banding|NOTE: the surgery is not paid for by the study
223807211|NCT00627484|PROCEDURE|Sleeve gastrectomy|NOTE: the surgery is not paid for by the study
223807212|NCT00627484|BEHAVIORAL|Very low calorie diet|Weight loss with calorie restricted liquid diet. Subject will be asked to stay in our in-patient research unit for 2-3 weeks and consume only those foods supplied by our bionutrition unit. Expected weight loss should be between 7-10% of body weight. Subjects will receive the diet at no cost and will be compensated for their time.
223807213|NCT03810625|DRUG|D-0502|D-0502 oral tablets
223807214|NCT05421455|DRUG|Group A|treat participants with biologics
223807215|NCT05421455|PROCEDURE|Group B|treat participants with surgery
223807216|NCT02726802|OTHER|physical therapy vs. primary care interventions|Subjects with acute (\< 3 months onset) will be randomized to see either a physical therapist or a primary care provider as their initial entry into the healthcare system
223807217|NCT01567332|DEVICE|SHAM - MagproR30 - DGM-512 - 9016E0741 - Tonika elektronics A/S - Active coil|"For each patient, stimulation inactive (sham) and 1 Hz stimulation activates the healthy motor cortex (randomization). Active or sham session: Each session includes a series of 5 sessions of 20 'weekly (daily for 5 d) evaluation and pre-rTMS (T0 within 6 h before the procedure) and 1h post-rTMS (T1), at J8 (T2) and J21 (T3).~6-week interval between two sessions."
223807218|NCT01567332|DEVICE|SHAM inactive - MagproR30 - DGM-512 - 9016E0741 - Tonika elektronics A/S - Inactive coil|"For each patient, stimulation inactive (sham) and 1 Hz stimulation activates the healthy motor cortex (randomization). Active or sham session: Each session includes a series of 5 sessions of 20 'weekly (daily for 5 d) evaluation and pre-rTMS (T0 within 6 h before the procedure) and 1h post-rTMS (T1), at J8 (T2) and J21 (T3).~6-week interval between two sessions."
223807219|NCT05950425|OTHER|Aspiration training|"Pre-test application; All mothers whose children are hospitalized in the PICU will be filled in the questionnaires after verbally expressing and signing the informed consent before being admitted to the intensive care unit and starting the education.~In practice; The mother of the child who is planned to be discharged from the intensive care unit is given training a week before. Aspiration training will be given to the Experimental I group with the video method, and to the Experimental II group with the picture training booklet method. The materials of these trainings will be given to the mothers and they will be asked to look after them when they come to the next care.~Final test application; scales will be filled in the mother on the day of the child's discharge."
223807220|NCT04469881|BEHAVIORAL|VR|"Participants will be asked to do the following things:~1. Wear VR goggles for the duration of the surgery~2. Answer questions about their experience with the VR goggles~3. Give permission for the researchers to collect information about the anesthesia medications used, pain medications used, and reported pain scores during the surgery and during recovery in the hospital"
223807221|NCT00200304|BEHAVIORAL|Internet weight loss with SlimFast and human counseling|
223807222|NCT00200304|BEHAVIORAL|Internet weight loss with SlimFast and computer counseling|
223807223|NCT00200304|BEHAVIORAL|Internet weight loss program with SlimFast|
223807224|NCT06276270|DEVICE|Mucopad HA|The product is a Class III Medical Device incorporating a medicinal substance (antiseptics-octenidine) within the composition made of sodium hyaluronate polysacharide stabilised by calcium chloride. Device is administered directly onto the area affected by mucositis.
223807225|NCT04867356|OTHER|Spinal Stabilization Exercises (SSE)|"Spinal stabilization exercises (SSE) including bridging, planks and tummy tuck-in will be performed. Each participant received a total 7 session thrice a week sessions in two weeks, . Each session had lasted for 30-40 minutes. Spinal stabilization exercises were repeated 5-15 times depending on the endurance of patients.~Home exercise plan will also be given e.g. postural care, precautions in lifting and carrying weights etc."
223807226|NCT04867356|OTHER|Spinal Stabilization Exercises (SSE) & Latissimus Dorsi Stretching (LDS)|In experimental group in addition SSE group interventions, participants will receive the latissimus dorsi stretching (LDS). Each participant received a total 7 session thrice a week sessions in two weeks. Each session had lasted for 30-40 minutes. each stretch of latissimus dorsi was of 20-30 seconds with 10-20 repetitions in each session.
223807227|NCT01241695|DIETARY_SUPPLEMENT|Oral nutritional supplement, food for special medical purposes|2 servings of 200 ml per day, treatment period: 12 weeks
223807228|NCT01241695|DIETARY_SUPPLEMENT|Oral nutritional supplement, food for special medical purposes|2 servings of 200 ml per day, treatment period: 12 weeks
223807229|NCT02782702|DRUG|Botulism Toxin Treatment|Injection of 50 UI of botulism toxin for treated zone
223807230|NCT02403180|DEVICE|DACP MF|Nelfilcon A multifocal contact lenses
223807231|NCT02403180|DEVICE|PROCLEAR 1D MF|Omafilcon A multifocal contact lenses
223807232|NCT01876290|DRUG|Dexamethasone and Ondansetron|Comparison between Dexamethasone and Ondansetron and placebo in the prevention of postoperative Nausea and Vomiting
223807233|NCT01876290|DRUG|Placebo|Placebo
223807234|NCT01876316|DRUG|Moxifloxacin|single oral administration of 400mg of moxifloxacin
223807235|NCT01876316|DRUG|Placebo|single oral administration of 400mg of placebo
223807236|NCT03399643|DRUG|Atezolizumab|Atezolizumab is administered via IV 1200 mg every 3 weeks
223807237|NCT00834106|BIOLOGICAL|Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine|Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine injection at Day 1, Month 2, and Month 6.
223807238|NCT00834106|BIOLOGICAL|Comparator: placebo (unspecified)|Aluminum-containing Vaccine placebo injection at Day 1, Month 2, and Month 6.
223807239|NCT00122642|PROCEDURE|Alcohol-lock|The intervention is the instillation of ethanol 70% solution in the catheter lumen (or lumina) for 15minutes per day during hospital stay and for 15minutes per week for patients not in the hospital.
223807240|NCT00122642|DRUG|placebo-lock|The intervention is the instillation of placebo solution in the catheter lumen (or lumina) for 15minutes per day during hospital stay and for 15minutes per week for patients not in the hospital.
223807241|NCT02158117|DRUG|nasal naloxone|one puff in one nostril with the subject is lying down
223807242|NCT03364855|OTHER|Star excursion balance test|Star excursion balance test,
223807243|NCT03364855|OTHER|Kinesthetic Ability Trainer 2000|Kinesthetic Ability Trainer 2000
223807244|NCT03364855|OTHER|SEBT and KAT 2000|Star excursion balance test and Kinesthetic Ability Trainer 2000
223807245|NCT01980238|DEVICE|cannula ileostomy|
223807246|NCT01980238|DEVICE|loop ileostomy|
223807247|NCT01980238|DEVICE|LAR|
223807248|NCT05001360|DRUG|XBI-302 + Nivolumab|After gut preparation, a single dose of FMT will be performed via oral administration. Subsequently, nine combined treatment cycles that composed of anti-PD-1 infusions (Nivolumab at 240 mg, q2w) and additional FMT capsules, and 3 single treatment cycles of anti-PD-1 infusions will be administered.
223807249|NCT00330915|DRUG|pemetrexed|500 mg/m2, intravenous (IV), every 21 days x 3 cycles
223807250|NCT03022201|DRUG|DA-9701|Following 2-week screening period, study participants in this group will be given a standard dose of DA-9701 (30 mg t.i.d). Concomitant anti-PD medication will be continued without modification during the trial. The investigators will evaluate dyspepsia and constipation symptoms, gastric emptying by MRI, UPDRS and clinical variables at baseline and at the end of the study.
223807251|NCT03022201|DRUG|Domperidone|Following 2-week screening period, study participants in this group will be given a standard dose of domperidone (10 mg t.i.d). Concomitant anti-PD medication will be continued without modification during the trial. The investigators will evaluate dyspepsia and constipation symptoms, gastric emptying by MRI, UPDRS and clinical variables at baseline and at the end of the study.
223807252|NCT03022201|DRUG|Placebo domperidone|
223807253|NCT03022201|DRUG|Placebo DA-9701|
223807254|NCT01916005|DEVICE|18F-FDG PET/CT|
223807255|NCT03665844|DEVICE|SmartSleep Boost On|"SmartSleep device can be configured to two different settings. SmartSleep Boost On setting provides soft audio tones during the night.~It's a non-invasive portable light weight device designed to stimulate deep slow wave sleep (SWS)."
223807256|NCT03665844|DEVICE|SmartSleep Boost Off|SmartSleep device can be configured to two different settings. SmartSleep Boost Off provides no audio tones.
223807257|NCT01445652|DEVICE|nelfilcon A contact lens|Commercially marketed, single vision, soft contact lens for daily disposable wear
223807258|NCT01445652|OTHER|Spectacles|Spectacles per current prescription
223807259|NCT06097754|DIETARY_SUPPLEMENT|Ketone ester|"Ketone ester: A total of 300g ketone ester supplementation will be provided in one of the 72h experimental sessions in order to establish intermittent exogenous ketosis. Sucralose (5% w/w) is added to the ketone ester (R)-3-hydroxybutyl (R)-3-hydroxybutyrate~Hypobaric hypoxia: 72 hours experimental protocol conducted at terrestrial altitude"
223807260|NCT06097754|DIETARY_SUPPLEMENT|Placebo|"Placebo: Water, 5% sucralose (w/w), octaacetate (1 mM)~Hypobaric hypoxia: 72 hours experimental protocol conducted at terrestrial altitude"
223807261|NCT05374902|OTHER|Providing procedural informational animation video|Children and parents have watched procedural informational animation before venipuncture. Afterward, the children and their parents entered the blood drawn unit, and the procedure was performed as in standard care.
223807262|NCT05374902|DEVICE|Buzzy|Buzzy® was placed on the injection site and it was turned on 60 s before the procedure. Then, the nurse moved Buzzy® about 3-5 cm above the injection site. The procedure was performed with buzzy®. The Buzzy® intervention and phlebotomy were terminated at the same time.
223807263|NCT05374902|COMBINATION_PRODUCT|Multiple interventions|Watching procedural informational animation video prior to venipuncture, and Buzzy application during venipuncture
223807264|NCT03059901|OTHER|Caminamos App|Mobile phone that encourages Latina women to walk together through social support.
223807265|NCT02493400|OTHER|No intervention in the follow up study.|
223807266|NCT03595332|OTHER|Summer activity program|Children receive a summer scorecard to facilitate access to local facilities for exercise.
223807267|NCT02227875|DRUG|Mylan's insulin glargine|Patients who are randomized to receive Mylan's insulin glargine during the comparative phase will receive the same dose as the dose of Lantus® received during the screening period. The recommended starting dose of Mylan's insulin glargine or Lantus®, in patients with T2DM who are not currently treated with insulin is 10 units (or 0.2 Units/kg) once daily, which should subsequently be adjusted every week if essential.
223807268|NCT02227875|DRUG|Lantus®|For patients who are randomized to receive Lantus® during the comparative phase the dose of Lantus® will be equal to the dose received during the screening period.
223807269|NCT00656604|GENETIC|proteomic profiling|at the time of each procedure.
223807270|NCT00656604|PROCEDURE|lumpectomy or mastectomy|removal of breast tumor or removal of the entire breast in which the tumor is located
223807271|NCT00656604|PROCEDURE|dynamic contrast-enhanced magnetic resonance imaging|Prior to initiation of treatment
223807272|NCT00656604|PROCEDURE|histopathologic examination|After the breast tumor has been removed, examination of the tumor under a microscope to determine the type and grade of breast cancer
223807273|NCT00656604|PROCEDURE|magnetic resonance spectroscopy|Prior to initiation of treatment
223807274|NCT04209725|DRUG|CPX-351|Given during the induction and consildation phase and will consist of 44 mg/m\^2 daunorubicin with 100 mg/m\^2 cytarabine administered intravenously on Days 1, 3, and 5 during induction phase and Days 1 and 3 of consolidation phase.
223807275|NCT04209725|DRUG|Quizartinib|Given during induction, consolidation, and maintenance phases and will be taken orally at a dose of 30mg on Days 8-21 of induction phase, Days 6-21 of consolidation phase, and daily in maintenance phase.
223807276|NCT04833764|DRUG|Rosuvastatin|Oral administration of 20 mg rosuvastatin for at least 3 months
223807277|NCT01804101|OTHER|Laboratory Biomarker Analysis|Correlative studies
223807278|NCT01804101|DRUG|Liposomal Cytarabine-Daunorubicin CPX-351|Given IV
223807279|NCT03257332|PROCEDURE|Low Anterior Resection for Rectum Cancer|Subjects should have received curative surgery for rectal cancer (low anterior resection) with/with-out adjuvant (radiation/chemo) therapy.
223807280|NCT03786861|PROCEDURE|corneal WFG group|TransPRK using ESIRIS flying spot excimer laser system (SCHWIND AMARIS®500E, SCHWIND eye-tech-solutions, Kleinhostheim, Germany), with 500 Hz repetition rate for faster treatments and scanning spots and with smart pulse technology. Eye-tracking during laser ablation was achieved using a 1050 Hz infrared eye tracker centered on the pupil. Static cyclotorsion control (SCC) compensation was obtained for all patients in corneal WFG group.
223807281|NCT03786861|PROCEDURE|aberration free group|TransPRK was performed to eligible myopic patients with or without astigmatism with corneal HOAs ≥ 0.35 µ utilizing aberration free patterns provided by ORKCAM software (SCHWIND eye-tech-solutions, Kleinostheim, Germany)
223807282|NCT01040702|DRUG|methylphenidate|a single doses of 10-20 mg in each one of two visits
223807283|NCT01040702|DIETARY_SUPPLEMENT|sweetener pill|a capsule containing a sweetener pill
223807284|NCT02604290|DEVICE|Kinesio Taping method|"The tape is applied depending on the physical examination:~* Muscular technique is placed along paravertebral muscles if back pain in flexion or extension improves when skin/fascial mobilisation is applied in the direction of paravertebral muscle fibers; the base is placed up or down if the mobilisation direction is up or down respectively.~* Space technique is placed horizontally over the painful spinal segmental level if back pain in flexion or extension improves when skin/fascial mobilisation is applied approaching to a central point.~* Fascia technique is placed horizontally over the painful area in paravertebral muscles if back pain in flexion or extension improves when skin/fascial mobilisation is applied transverse to the paravertebral muscle fibers."
223807285|NCT02604290|DEVICE|Kinesio Taping sham|The tape is applied with 0% tension, horizontally over two non-tender to palpation spinal segmental levels. The patient is kept in neutral position.
223807286|NCT00166296|DRUG|Escitalopram|15 mg/day starting 2 weeks before and 12 weeks during interferon therapy
223807287|NCT00166296|DRUG|Placebo|Placebo, 15 mg/day, starting 2 weeks before and for 12 weeks during interferon therapy.
223807288|NCT03477279|BEHAVIORAL|Enhanced Couple HIV Testing and Counseling|"Participants are provided study-specific partner referral cards and encouraged to bring male partners to antenatal care for a male engagement intervention. Those who do not present on their own are then traced.~Couples will receive three enhanced couple counseling sessions that include: pre-test counseling, return of joint results, and post-test counseling. HIV-infected men will be able to initiate cART at the antenatal clinic and the couple will be offered condoms from the HTC counselor. Between sessions, couple members can pick up condoms and cART for one another."
223807289|NCT04304352|DRUG|Vinorelbine|Metronomic Vinorelbine 40 mg orally thrice a week
223807290|NCT04304352|DRUG|Capecitabine|Metronomic Capecitabine 500 mg, thrice daily
223807291|NCT04304352|DRUG|Cyclophosphamide|Metronomic Cyclophosphamide 50 mg daily
223807292|NCT03721640|OTHER|electrocardiogram|Autonomic and hemodynamic evaluation with different indices (LF, heart rate, Systolic, diastolic and mean arterial blood pressure, SaO2) during a sedation protocol for intubation and surfactant administration according the INSURE or LISA technique.
223807293|NCT02019628|DIETARY_SUPPLEMENT|Rice Bran Arabinoxylan Compound (RBAC)|Participants enrolled in the study will receive BRM4 at a dosage level of either 1 gram/day or 3 gram/day for the 60-day period. Subjects will be instructed to not consume any known immune-active pharmaceutical agents, nutritional supplements containing vitamins C and D, and/or any mushroom products for two weeks prior to having the baseline assessments and until the conclusion of the 60-day period. According to the company's literature, RBAC is a water soluble extract of rice bran that has been acted upon by an enzyme complex extracted from Shiitake mushroom. BRM4 contains: microcrystalline cellulose, hypromellose, sucrose fatty acid ester, gellan gum, and potassium acetate.
223807294|NCT03741101|DRUG|Trametinib|treatment
223807295|NCT04176341|OTHER|a systematic proposal for non pharmacological interventions targeting the subject's empowerment among slackline, mindfulness, adapted physical activity, self-hypnosis, and Qi Gong|chronic pain patient consulting in Grenoble Alps University Hospital, and Hospital Mutualist Group who will one non pharmacological intervention between slackline, mindfulness, adapted physical activity, self-hypnosis, Qi Gong during 6 to 8 weeks.
223807296|NCT01097252|RADIATION|radiation|radiation with cisplatin 40mg/m2, 6 cycles, every week
223807297|NCT01097252|DRUG|weekly cisplatin|weekly cisplatin 40mg/m2, 6 cycles
223807298|NCT01097252|DRUG|tri-weekly cisplatin|cisplatin 75mg/m2, 3cycles, every 3 weeks
223807299|NCT05003050|OTHER|Meditation|Holistic natural therapy
223807300|NCT05003050|OTHER|Pranic Healing|Energy therapy
223807301|NCT03128996|DRUG|RIC regimen|Days -60 to -21: hydroxyurea (30mg/kg/day po) \>6hrs prior to 1st dose: alemtuzumab (3mg IV) Day -21: alemtuzumab (10mg IV or S/C) Day -20: alemtuzumab (15mg IV or S/C) (10mg if \< 10kg) Day -19: alemtuzumab (20mg IV or S/C) (10mg if \< 10kg) Days -8 to -4: fludarabine (30mg/m2/day IV) Day -4: thiotepa (8mg/kg IV) Day -3: melphalan (140mg/m2) Days -2 to -1: rest days/no therapy Day 0: bone marrow transplant
223807302|NCT03128996|DRUG|GVHD prophylaxis regimen|Day +3 to +4: cyclophosphamide (50mg/kg/day IV) Day +5: Start of tacrolimus \& Start of mycophenolate mofetil (MMF) Days +5, +14, +30, +60, +90: abatacept (IND) (10mg/kg/day IV) Days +120 to +390: abatacept (IND) monthly (5mg/kg/day IV)
223807303|NCT01105923|OTHER|MAPLE|MAPLE is a CDS intervention within the EHR that will alert providers to problem lists gaps and present an opportunity to correct them.
223807304|NCT01071564|DRUG|Gamma-Secretase Inhibitor RO4929097|Given PO
223807305|NCT01071564|OTHER|Laboratory Biomarker Analysis|Correlative studies
223807306|NCT01071564|OTHER|Pharmacogenomic Study|Correlative studies
223807307|NCT01071564|OTHER|Pharmacological Study|Correlative studies
223807308|NCT01071564|DRUG|Vismodegib|Given PO
223807309|NCT03569384|COMBINATION_PRODUCT|Tele Rehab|The intervention group will obtain telerehabilitation
223807310|NCT01456299|DRUG|Remifentanil 1|"Remifentanil 1: The R1 group, which received a target effect-site remifentanil concentration of 1 ng/ml."
223807311|NCT01456299|DRUG|Control|The control group, which received an infusion of normal saline
223807312|NCT01456299|DRUG|Remifentanil 2|"Remifentanil 2: The R2group, which received a target effect-site remifentanil concentration of 2 ng/ml."
223807313|NCT02913664|DRUG|Angiotensin II receptor blocker (ARB, losartan) and calcium channel blocker (CCB, amlodipine)|"Angiotensin II receptor blocker (ARB, losartan) and calcium channel blocker (CCB, amlodipine) will be used to reduce SBP\<130 mmHg; atorvastatin 80 mg daily will be administered to reduce blood lipid level. Additional antihypertensives may be used if needed.~Intensive Reduction of Vascular Risk Factors (IRVR)"
223807314|NCT02913664|BEHAVIORAL|Aerobic Exercise Training|Participants will take part in a supervised, moderate to vigorous aerobic exercise training program for approximately 24 months. This program consists of exercising 3 times per week for about 30 minutes per session at the beginning, and will increase to 4-5 times per week, 40-50 minutes per session over a period of 4-5 months. Exercise frequency, intensity and duration will be maintained at this level during the rest of the study period.
223807315|NCT02913664|OTHER|Usual Care|Participants will follow their regular doctor's recommendations for blood pressure and lipid control.
223807316|NCT02913664|BEHAVIORAL|Stretching Exercise|Participants will perform home-based stretching exercise 3 times per week, gradually increased to 4-5 times per week over a period of 4-5 months, and maintained at this level during the rest of the study period. They will be encouraged to attend monthly stretching exercise classes, which will be led by study staff or exercise trainers.
223807317|NCT03877458|OTHER|L. acidophilus TYCA06, B. longum BLI-02 and B. bifidum VDD088|Taking 1 mix probiotics capsule at bed time everyday for three months.
223807318|NCT03877458|OTHER|L. reuteri GL-104|Taking 1 probiotic capsule at bed time everyday for three months.
223807319|NCT03877458|OTHER|Placebo|Taking 1 placebo capsule at bed time everyday for three months.
223807320|NCT06213532|BEHAVIORAL|Smoking Cessation Intervention|Multimedia program administered either remotely or in person
224264312|NCT05668689|OTHER|Psychometric main study testing (Phase 5)|The main study assessment tool will be administered to trainees of all levels and consultants, aiming to recruit an equal number across different stages of the RCoA curriculum and of varying regional anaesthesia experience (stage 1; stage 2; stage 3; stage 3 + regional fellowship trained; consultant; consultant with special interest in regional; consultant + regional fellowship trained). The exam will consist of constructed response questions (CRQs), which will require the participant to write free-text responses to questions, in line with RCoA examinations.
223807321|NCT06213532|OTHER|Saliva Collection|Saliva samples will be collected from each participant
223807322|NCT06213532|OTHER|Survey Administration|Ancillary studies
223807323|NCT04237753|BEHAVIORAL|VA Video Connect|Remote telehealth visits with continence care provider who will provide education on bladder anatomy and function, pelvic floor muscle exercises with behavioral strategies, and self-monitoring tools for urine leakage
223807324|NCT04237753|BEHAVIORAL|MyHealtheBladder|Daily mobile health education with information on bladder anatomy and function, pelvic floor muscle exercises with behavioral strategies, and self-monitoring tools for urine leakage
223807325|NCT05130359|DIETARY_SUPPLEMENT|Placebo|take 2 tablets 2 hours before bedtime for 4 consecutive weeks
223807326|NCT05130359|DIETARY_SUPPLEMENT|Banana peel extract|take 2 tablets 2 hours before bedtime for 4 consecutive weeks
223807327|NCT05905302|OTHER|Forced and Voluntary Exercise|Participants will complete a forced exercise (FE) and voluntary exercise (VE) session. Forced exercise is a mode of high intensity exercise in which voluntary exercise rate is augmented, but not replaced. Voluntary exercise is standard stationary cycling. FE and VE exercise sessions will be Off antiparkinsonian medication. The order in which exercise session is conducted first will be randomized. Bilateral neural activity of the STN will be continuously recorded for 130 minutes (pre, during FE or VE and post-exercise).
223807328|NCT06246396|DRUG|Minocycline Hydrochloride|Minocycline Hydrochloride 100 mg twice daily
223807329|NCT06246396|DRUG|Placebo|Placebo
223807330|NCT05830162|DRUG|Placebo|We will evaluate how many women gets an infection and/or wound dehiscence after a second degree obstetric tear or episiotomy
223807331|NCT05830162|DRUG|Bioclavid (Amoxicillin and Clavulanic acid)|We will evaluate how many women gets an infection and/or wound dehiscence after a second degree obstetric tear or episiotomy
223807332|NCT00934284|OTHER|Lumbar injection|Patients are instructed to resume normal activity as tolerated.
223807333|NCT00934284|OTHER|Rehabilitation following lumbar injection|Participants are referred to an average of four weeks of physical therapy after receiving a lumbar injection. Physical therapy designed to include end-range directional preference exercises and/or mechanical traction to reduce lower extremity symptoms and progress activity tolerance.
223807334|NCT03587662|DRUG|Doxorubicin|Given IV
223807335|NCT03587662|DRUG|Doxorubicin Hydrochloride|Given IV
223807336|NCT03587662|DRUG|Gemcitabine|Given IV
223807337|NCT03587662|DRUG|Gemcitabine Hydrochloride|Given IV
223807338|NCT03587662|DRUG|Ixazomib|Given PO
223807339|NCT03587662|DRUG|Ixazomib Citrate|Given PO
223807340|NCT05842408|DRUG|DA-5212|Test drug: DA-5212
223807341|NCT05842408|DRUG|DA-5212-R|Control drug: DA-5212-R
223807342|NCT03599752|DRUG|Chemotherapy|Receive chemotherapy
223807343|NCT03599752|PROCEDURE|Metastasectomy|Undergo pulmonary metastasectomy
223807344|NCT03627013|DRUG|Custodiol-N Solution|Perfusion
223807345|NCT03627013|DRUG|Custodiol HTK Solution|Perfusion
223807346|NCT05047120|BEHAVIORAL|Hypnosis enhanced cognitive behavioral therapy|This therapy entails subjects being induced into a state of relaxation and the receiving cognitive behavioral therapy for pain associated with a new spinal cord injury.
223807347|NCT05047120|BEHAVIORAL|Pain Education|This therapy entails subjects learning about the causes, mechanisms, and ways to reduce pain associated with a new spinal cord injury.
223807348|NCT06256614|OTHER|WMT|Washed microbiota transplantation refers to the infusion of washed microbiota from healthy donor into patients' gastrointestinal tract. Participants will receive three doses of WMT for T1DM.
223807349|NCT05091268|BEHAVIORAL|Exercise|"All participants will attend a four-hour pain education session including gynecologist, psychologist, sexologist, and physiotherapist at Akershus University Hospital.~The education will be held twice, with half of the participants at the time. The training group will then attend a 60 minutes weekly group training session led by a physiotherapist with specialist training in women's health over a period of four months. In addition, participants will perform a progressive home exercise program performed daily over the same period. The focus will be general strength training using own body weight and cardiovascular fitness (walking, low-impact aerobic exercise), stretching, and relaxation"
223807350|NCT06017219|DIETARY_SUPPLEMENT|spermidine|spermidine
223807351|NCT06437782|OTHER|Questionnaire completion|HLQ (Health Literacy questionnaire) will be completed by all included patients once.
223807352|NCT03818087|BEHAVIORAL|Observational cohort|Patients will be followed by collecting clinical data, biospecimens, and quality of life assessments over a period of five years from registration.
223807353|NCT03412396|DRUG|Apalutamide|Given PO
223807354|NCT03412396|OTHER|Quality-of-Life Assessment|Ancillary studies
223807355|NCT03412396|PROCEDURE|Radical Prostatectomy|Undergo radical prostatectomy
223807356|NCT06164639|BEHAVIORAL|aspiration|Based on whether the patient meets the diagnosis of aspiration pneumonia.
223807357|NCT06164639|DIAGNOSTIC_TEST|bronchial alveolar fluid|Performing bronchoscopy.
223807358|NCT06164639|DEVICE|EIT V/Q test|Local pulmonary ventilation and perfusion are measured by electrical impedance tomography (EIT). For perfusion imaging, 10 ml of 5% saline is injected as a central venous bolus. The matching of ventilation and perfusion reveals intrapulmonary shunting.
223807359|NCT06164639|OTHER|Nitric oxide inhalation|According to the physician's judgment and the family members' consent, the patient is administered nitric oxide inhalation at a dosage of 20-30 parts per million (ppm).
223807360|NCT05950646|DRUG|Dexmedetomidine|Dexmedetomidine will be infused at a rate of 0.01 ml/ kg/h (0.02 μg/kg/h) from 8 pm in the night before surgery until 8 am in the third morning after surgery.
223807361|NCT05950646|DRUG|Esketamine|Esketamine will be infused at a rate of 0.01 ml/ kg/h (5 μg/kg/h) from 8 pm in the night before surgery until 8 am in the third morning after surgery.
223807362|NCT05950646|DRUG|Normal saline|Normal saline will be infused at a rate of 0.01 ml/ kg/h from 8 pm in the night before surgery until 8 am in the third morning after surgery.
223807363|NCT05921227|BEHAVIORAL|VAULT Phase 6|VAULT is an input-based word learning intervention based on principles of statistical learning.
223807364|NCT05166304|DRUG|Rebamipide|patients will receive the standard therapy plus 100 mg Rebamipide three times daily
223807365|NCT05166304|DRUG|Placebo|patients will receive the standard therapy (methotrexate) plus placebo tablets
223807366|NCT02992951|DEVICE|DACC-Coated Post Operative Dressing|Leukomed Sorbact is a non-active coated wound dressing, containing Dialkylcarbomoylchloride. This is a bacteria-binding compound that adheres bacteria via hydrophobic interaction and removes them from the wound bed at dressing change.
223807367|NCT02272049|DRUG|Hyperpolarized 129 Xenon|During the scans, subject will inhale hyperpolarized Xenon gas for up to 16 seconds per scan, for up to 4 separate MR scans
223807368|NCT06142656|DRUG|Metformin Hydrochloride tablet|Metformin Hydrochloride 850 mg oral tablet
223807369|NCT06142656|DRUG|Vildagliptin 50 MG|Vildagliptin 50 MG oral tablets
223807370|NCT05488626|DEVICE|Adaptive Radiotherapy|Standard fractionation external beam radiotherapy (60-66 Gy in 2 Gy/fraction) with daily online adaptation.
223807371|NCT05488626|DEVICE|Non-Adaptive Radiotherapy|Standard fractionation external beam radiotherapy (60-66 Gy in 2 Gy/fraction) with daily image guidance.
223807372|NCT05488626|DRUG|Chemotherapy|Concomitant chemotherapy per NCCN or other national guidelines.
223807373|NCT05488626|DRUG|Immunotherapy|Adjuvant immunotherapy per national or institutional guidelines.
223807374|NCT00542438|BEHAVIORAL|Physical Activity Recall|Hand-held computers will be used to record information for 7 days about physical activity. Assessments will be completed either 3 times a day or once a day.
223807375|NCT00542438|BEHAVIORAL|Environmental Assessments|Hand-held computer programs will be used to collect information about the community. Some factors will be assessed only once (e.g., availability of facilities) while other information will be collected over the course of 7 days (e.g., perceptions of neighborhood safety).
223807376|NCT01371630|BIOLOGICAL|Blinatumomab|Given CIVI
223807377|NCT01371630|DRUG|Cyclophosphamide|Given IV
223807378|NCT01371630|DRUG|Cytarabine|Given IT and IV
223807379|NCT01371630|DRUG|Dexamethasone|Given IV or PO
223807380|NCT01371630|BIOLOGICAL|Inotuzumab Ozogamicin|Given IV
223807381|NCT01371630|OTHER|Laboratory Biomarker Analysis|Correlative studies
223807382|NCT01371630|DRUG|Mercaptopurine|Given PO
223807383|NCT01371630|DRUG|Methotrexate|Given IT, IV, and PO
223807384|NCT01371630|DRUG|Prednisone|Given PO
223807385|NCT01371630|BIOLOGICAL|Rituximab|Given IV
223807386|NCT01371630|DRUG|Vincristine|Given IV
223807387|NCT00796380|DRUG|Xingnaojing|injection
223807388|NCT05288660|DRUG|ALXN1210|All doses of ALXN1210 were administered by IV infusion, using programmable IV infusion pump and IV sets with in-line filters, at a fixed rate of 686 mg/hour (equivalent to 137 milliliters \[mL\]/hour), excluding interruption for safety or technical reason.
223807389|NCT05288660|DRUG|Placebo|All doses of placebo were administered by IV infusion, using programmable IV infusion pump and IV sets with in-line filters, at a fixed rate of 686 mg/hour (equivalent to 137 mL/hour), excluding interruption for safety or technical reason.
223807390|NCT00406133|DEVICE|Continuous glucose monitor|Daily use of a continuous glucose monitor
223807391|NCT04899245|DIAGNOSTIC_TEST|BinaxNOW Rapid Antigen System|"BinaxNOW Rapid Antigen System (Abbott) is a point-of-care, lateral flow immunoassay intended for the qualitative detection of nucleocapsid protein antigen from SARS-CoV-2 in direct anterior nasal (nares) swabs. Internal controls are built into the testing system and results are available in 15 minutes.~The use of the BinaxNOW system is authorized under the Food and Drug Administration's Emergency Use Authorization. The test is allowed for over-the-counter, non-prescription use with or without symptoms. The test may be used with children two years and older with the help of sample collection by an adult, and the test may be self-administered by anyone aged 15 years or more."
223807392|NCT01087554|DRUG|Sirolimus|"Escalation Phase: Sirolimus starting dose1 mg by mouth on Days 1 - 28.~Expansion Phase starting dose: MTD from Escalation Phase."
223807393|NCT01087554|DRUG|Vorinostat|"Arm A - Escalation Phase: Vorinostat starting dose 100 mg by mouth on Days 7 - 28 of Cycle 1; For all other cycles, dose of 100 mg Days 1-28.~Expansion Phase starting dose: MTD from Escalation Phase.~Arm B + Arm C - Escalation and Expansion Phase: Vorinostat dose 300 mg by mouth on Days 7 - 28. Rest of cycles: 300 mg by mouth on Days 1 - 28."
223807394|NCT01087554|DRUG|Everolimus|"Escalation Phase: Everolimus starting dose 5 mg by mouth on Days 1 - 28.~Expansion Phase: MTD from Escalation Phase."
223807395|NCT01087554|DRUG|Temsirolimus|"Escalation Phase: Temsirolimus starting dose 12.5 mg by vein on Days 1, 8, 15, 22.~Expansion Phase: MTD from Escalation Phase."
223807396|NCT03088267|DRUG|amphetamine extended-release oral suspension, 2.5 mg/mL|5 mL1 (5 mg), 7 mL (17.5 mg) or 8 mL (20 mg) PO
223807397|NCT03088267|DRUG|Placebo extended-release oral suspension|6, 7 or 8 mL PO
223807398|NCT05718544|DRUG|Esketamine|Esketamine 50 mg is included in the mixture for patient-controlled analgesia.
223807399|NCT05718544|DRUG|Dexmedetomidine|Dexmedetomidine 200 microgram is included in the mixture for patient-controlled analgesia.
223807400|NCT05718544|DRUG|Sufentanil|Sufentanil 4 microgram/kg (maximum 250 microgram) is included in the mixture for patient-controlled analgesia.
223807401|NCT03664869|DRUG|BCG instillation therapy|Induction period of six weekly instillations of BCG followed by maintenance period of ten monthly instillations of BCG
223807402|NCT03664869|DRUG|Sequential BCG and EMDA mitomycin C|"Induction period includes nine weekly instillations of sequential BCG and EMDA-MMC instillations applied as three cycles of BCG, BCG and EMDA-MMC. Induction period is followed by maintenance period of nine monthly instillations of sequential EMDA-MMC and BCG applied with three cycles of EMDA-MMC, EMDA-MMC and BCG.~BCG instillation is performed as a standard instillation.~Mitomycin C is administered with electromotive drug administration (EMDA) device (Instillation: 40 mg mitomycin C with 960 mg of excipient sodium chloride dissolved in 100 ml sterile water, EMDA settings: current rise rate 30-50 microamperes per second, max 25 milliamperes, treatment duration 30 min)"
223807403|NCT02561494|DRUG|Nefopam|
224264313|NCT03058614|DRUG|CEUS|In subjects randomized into the CEUS arm, 2 mL of Lumason will be injected as a single dose via a nephrostomy tube at the time of postoperative renal ultrasound, following by 5 mL of normal saline flush. Subjects will be given up to one additional dose injected in the same fashion as indicated during the imaging study to confirm opacification of the ureter.
224264314|NCT03058614|DIAGNOSTIC_TEST|Non-contrast CT scan|The CT scan performed in this study arm is regularly performed to evaluate the kidney and look for residual stones after surgery both at UCSF and around the world. It does not require contrast injection, so risks from contrast allergy or any injection are absent. A low dose protocol will be used, and therefore, subjects will be exposed to a very small amount of ionizing radiation as low as 1-2 mSv if randomized into this arm.
223807404|NCT02561494|DRUG|Saline|
223807405|NCT03023592|DRUG|Iguratimod|Iguratimod 25 mg orally twice a day for 24 weeks
223807406|NCT01398280|DRUG|Topical aminocaproic acid (ACA) mixed with Vanicream|25% Aminocaproic acid cream twice daily for up to 12 weeks.
223807407|NCT01398280|DRUG|Vehicle cream|Vehicle cream moisturizer twice daily for up to 12 weeks
223807408|NCT05170165|OTHER|Using a clinical decision software to provide specific recommendation of a medication at a certain dosage|During routine follow-up, clinicians, cardiologists, and NPs who have a scheduled visit with an enrolled patient will be offered a medication recommendation. The medication recommendation will be generated by the clinical decision support tool. The software will advise the cardiologist whether an HF medication should be initiated, discontinued, or the dosage titrated and if the patient requires labs. In addition, the software, or decision engine (DE), will be run once weekly and every time the patient has new basic metabolic panel results. If the patient is admitted to the hospital, skilled nursing facility, or inpatient rehabilitation unit, the use of DE will be placed on hold until the patient is discharged and at home.
223807409|NCT00801008|BEHAVIORAL|Exercise and relaxation intervention|Comparison of an exercise and relaxation intervention to a wait-list control condition
223807410|NCT00057551|BEHAVIORAL|Brief Supportive Psychotherapy|brief supportive psychotherapy
223807411|NCT00057551|BEHAVIORAL|CBASP|psychotherapy developed for chronic depression
223807412|NCT00057551|DRUG|Medication Only|antidepressant medication
223807413|NCT04037501|OTHER|Care Management|A computerized Care Management System (CMS) will identify unmet needs of the informal caregiver of PwD and generates suggestions for interventions. Based on these, the treating physician develops an individualized treatment and care plan and assigns specific tasks to the care manager. Upon a home visit in the caregivers' home the care manager evaluates the need for additional tasks. Based on the complete list of tasks, the care manager initiates the implementation of respective actions. Via monthly telephone calls and optional home visits the care manager monitors the status of implementation and actively coordinates the support and care for the informal caregiver recommended intervention
223807414|NCT01222325|PROCEDURE|extracorporeal shockwave lithotripsy (SWL)|patients were submitted to one session SWL at a Dornier Compact Delta lithotripter under general anesthesia under supervision of an anesthesiologist and an urologist.
223807415|NCT00204295|DRUG|O-(2-[F-18]Fluorethyl)-L-Tyrosin (FET) - PET|
223807416|NCT00960180|DRUG|MR1817|
223807417|NCT00960180|DRUG|Placebo|
223807418|NCT03209323|DEVICE|electroencephalography (EEG)|Four EEG channels were recorded using electrode positions as defined in the International 10-20 System with Ag/AgCl2 cup electrodes (Spes Medica) attached to the scalp with EC2 Electrode Cream (Grass Technologies). The impedance was set below 1 k, and the electrodes were attached to module S/5 E-EEG of the anaesthetic monitor S/5 (GE Healthcare).
223807419|NCT03209323|DEVICE|bispectral index (BIS)|The BIS score was derived from a sensor (Aspect Medical Systems) positioned diagonally on the patients' foreheads according to producer's instructions.
223807420|NCT03209323|DEVICE|response and state entropy (RE and SE)|The respone and state entropy (RE and SE) score was derived from a sensor (Aspect Medical Systems) positioned diagonally on the patients' foreheads according to producer's instructions.
223807421|NCT03209323|DEVICE|middle latency auditory evoked potentials (MLAEP)|value of A-line Auto Regressive Index (AAI) derived from middle latency auditory evoked potentials (MLAEP) (A-line Monitor, Danmeter A/S, Odense, Denmark) was observed which measures the central nervous system responsiveness to a specific auditory stimulus
223807422|NCT02680873|OTHER|SASI bypass|he operation was done under general anesthesia. The technique commences with the devascularization of the greater curvature of the stomach with the harmonic scalpel.junction. The stomach is then tubularized over a 36 French calibration tube, with a linear stapler charged with a green cartridge, commencing 6 cm proximal to the pylorus. The ileocecal junction is identified and 250 cm is measured upwards. The selected loop is ascended antecolic without division of the greater omentum, and a stapled isoperistaltic side-to-side to the anterior wall of the antrum of the stomach just cranial 3 cm away from the pylorus with a linear stapler charged with a green cartridge.
223807423|NCT03371940|BEHAVIORAL|Program ACTIVE Exercise|Please see the Exercise arm description above.
223807424|NCT03371940|BEHAVIORAL|Program ACTIVE CBT|Please see the Talk Therapy arm description above.
223807425|NCT03371940|BEHAVIORAL|Program ACTIVE|Please see the Talk Therapy + Exercise arm description above.
223807426|NCT03371940|BEHAVIORAL|Usual Care - No intervention|Please see the Usual Care arm description above.
223807427|NCT03221621|PROCEDURE|Wide Excision|Wide excision is performed under general anaesthesia or procedural sedation and analgesia (PSA). All lesional tissue, including fibrosis, is electrosurgically removed until the area is clear. The subcutaneous fat and epithelised sinus floors are left intact where possible. The wounds are left open to heal by secondary intention.
223807428|NCT03221621|DRUG|Adalimumab Injection|Adalimumab will be administered through subcutaneous injections in weekly dose of 40mg from week 4 up to 24 months (V8), after an initial dose of 160mg at week 0 and a 80mg dose at week 2 until end of study or last surgery.
223807429|NCT01201148|DEVICE|tDCS (Eldith DC-Stimulator (CE certified))|For participants receiving intermittent tDCS or oscillating TES, one electrode will be placed over the left pF3 electrode site (overlying the left dorsolateral prefrontal cortex and identified on the scalp using an EEG cap based on the 10/20 system) and the other over the right temporal area.
223807430|NCT03330223|DEVICE|Clopidogrel group;Ticagrelor group|A total of 60 patients with ESRD and under dual-antiplatelet treatmen for at least 5 days will be enrolled and divided into the Clopidogrel group (clopidogrel 75mg qd;aspirin 100mg qd, n=30) and the Ticagrelor group (ticagrelor 90mg bid; aspirin 100mg qd, n=30). All included patients will receive haemodialysis by two different types of dialysis membrane.Platelet aggregation of venous blood from all patients will be detected by LTA and VerifyNow immediately before and after haemodialysis.
223807431|NCT02813837|BIOLOGICAL|CD19CART|Patients will be given infusions of CD19CART cells into the vein over a period of 1 to 3 days. The target dose range administered in this study is 1x10e5-1x10e7 CD19CART cells/kg. Patients will be monitored for a response, toxic effects, and the expansion and persistence of circulating CD19CART cells.
223807432|NCT04502576|DEVICE|Noninvasive respiratory support|"In both arms, the treatment according to the assigned protocol will be continued until the patient requires endotracheal intubation or (in case of no intubation) up to ICU discharge.~Patients will have to undergo the allocated treatment within 1 hour from the moment of randomization and within 24 hours from admission in the intensive care unit"
223807433|NCT00279669|PROCEDURE|Ultrasound examination|contact ultrasound examination
223807434|NCT04605562|DRUG|GP+DDP|Gemcitabine as induction chemotherapy, 1000 mg/m2 day 1, 8 per cycle, every 3 weeks for 3 cycles; induction cisplatin 80mg/m2, every 3 weeks for 3 cycles before radiation; concurrent cisplatin 100mg/m2, every 3 weeks for 2 cycles during radiation
223807435|NCT04605562|DRUG|Palbociclib|Administered orally
223807436|NCT04605562|RADIATION|Intensity-modulated radiotherapy|Definitive IMRT of 70 Gy, 33 fractions, 5 fractions/week, 1 fraction/day
223807437|NCT04605562|DRUG|PD-1 blocking antibody|Administered every 3 weeks
223807438|NCT04605562|DRUG|Galunisertib|Administered orally
223807439|NCT00729404|DRUG|Ethinylestradiol/Gestodene (BAY86-5016)|transdermal patch: 0.55mg EE+2.1mg GSD; 3x7 days patch- wearing phase and a patch-free interval of 7 days (1 pre-treatment cycle, 3 treatment cycles)
223807440|NCT00729404|DRUG|Ethinylestradiol/Gestodene (BAY86-5016)|transdermal patch: 0.55mg EE+1.05 mg GSD; 3x7 days patch- wearing phase and a patch-free interval of 7 days (1 pre-treatment cycle, 3 treatment cycles
223807441|NCT03531320|DRUG|D07001-softgel capsules|Active Ingredient:Gemcitabine hydrochloride
224264315|NCT03058614|DIAGNOSTIC_TEST|Capping trial|Subjects who are randomized into this study arm will undergo both nephrostomy tube capping and a low dose non-contrast CT scan on the first day after surgery. Successfully passing a capping trial is defined as the absence of fever, worsened flank pain, and leakage around the nephrostomy tube within 4 hours after capping the tube.
224264316|NCT00027664|BIOLOGICAL|recombinant interferon alfa|
224264317|NCT00027664|DRUG|thalidomide|
224264318|NCT02554877|DRUG|PF-06291874|study drug to be given as an oral tablet at 30, 60 or 100 mg
224264319|NCT02554877|DRUG|Placebo|oral tablet
224264320|NCT04474405|DRUG|Flortaucipir F18|IV injection, 370 MBq (10 mCi), single dose
224264321|NCT04474405|PROCEDURE|Brain PET Scan|positron emission tomography (PET) scan of the brain starting immediately after administration (60 minute dynamic imaging plus 4 frames x 5 minutes at approximately 80 minutes post-dose).
224264322|NCT04474405|PROCEDURE|Whole body PET scan|positron emission tomography (PET) scan of the body from the vertex of the head to the thighs starting immediately following injection and repeated over 6 hours
224264323|NCT04474405|DRUG|Florbetapir F 18|IV injection, 370 MBq (10 mCi), single dose
224264324|NCT04474405|PROCEDURE|Brain MRI|Volume-based T1-weighted Magnetic Resonance Imaging (MRI) of the brain
224264325|NCT00274651|DRUG|belinostat|
224264326|NCT01601405|DRUG|YF476|Each subject took one capsule of YF476 100 mg twice daily on Days 1-6 and once on Day 7. Each capsule taken with water 150 mL.
224264327|NCT01601405|DRUG|Placebo|On Days 0 and 14, each subject took a placebo capsule. Each capsule taken with water 150 mL.
224264328|NCT04150133|OTHER|Low Residue Diet|Variable cohort will eat 3 low residue meals on the day prior to their planned colonoscopy
224264329|NCT01468623|OTHER|Pharmacokinetic 5-FU dose adjustment using OnDose® assay|OnDose is a commercially available assay to measure concentration of 5-FU exposure.
224264330|NCT01468623|OTHER|Standard of care|Patients' dose of 5-FU will be based on Body Surface Area (BSA).
224264331|NCT02157974|DRUG|Byetta 5Mcg Pen Injection|10 participants will receive 2 doses of Byetta, one at 7 PM the night prior to metabolic study and the second 30 min before ingestion of glucola
224264332|NCT03356691|OTHER|Complementary Spiritist Therapy|"Complementary Spiritist Therapy:~1. Prayer: for 1 to 2 minutes.~2. Spiritual education: reading and commentary of the Gospel according to Spiritism, about 7 minutes.~3. Spiritist passe, for 2-min.~4. Fluid therapy."
224264333|NCT03356691|OTHER|Prayer|Individuals will receive prayer during 1 to 2 minutes.
224264334|NCT03356691|OTHER|"Spiritist passe"|"Individuals will receive Spiritist passe during 5 to 10 minutes."
224264335|NCT03356691|OTHER|laying on of hands with intent to heal|Individuals will receive laying on of hands with intent to heal during 5 to 10 minutes.
224264336|NCT03356691|OTHER|Fluid therapy.|Individuals will receive fluid therapy.
224264337|NCT03356691|OTHER|No-fluid therapy.|Individuals will receive no-fluid therapy.
224264338|NCT02922569|OTHER|Computerized Plasticity-Based Adaptive Cognitive Training|Thirty minutes of training on computerized exercises that targets processing speed, memory and attention.
223807442|NCT01846793|DRUG|NX-1207|2.5 mg NX-1207 in 10 mL saline vehicle
223807443|NCT01496833|DEVICE|Ankura Branched/Fenestrated Stent Graft|Ankura Branched/Fenestrated Stent Graft（Lifetech Scientific Co.,LTD.，Shenzhen, China）
223807444|NCT02362048|DRUG|ACP-196|
223807445|NCT02362048|DRUG|ACP-196 in combination with pembrolizumab|
223807446|NCT05099926|BEHAVIORAL|Reducing Exercise Sensitivity with Exposure Training|"Participants complete 2, home-based intervention visits on a secure video visit platform. Video visits include psychoeducation, interoceptive exposure, and interoceptive counseling. For homework, participants are asked to document their weekly physical activity and exercise sensations in a journal.~Psychoeducation: Participants are educated about the benefits and safety of exercise and cardiac rehabilitation, the role of fear and anxiety in exercise avoidance, and the concept of interoceptive exposure.~Interoceptive Exposure: A gradual six-minute walk (G6MW) serves as a low-risk form of interoceptive exposure. Exercise sensations and ratings of perceived intensity and distress are collected before and after the G6MW.~Interoceptive Counseling: Participants review and reflect upon their pre-walking and post-walking physical sensations and ratings (intensity and distress) with a research team member. Homework is also reviewed."
223807447|NCT03353064|OTHER|Vivify|A telemedicine kit will (Vivify) which will obtain daily biometrics (vital signs) and care plans. These are all monitored by the Pulmonary team remotely via an online portal. The telemedicine system has a set-up for alerts whenever there are clinical concerns (vital signs out of parameters), or non-use of the Non-invasive positive pressure ventilation (NIPPV). This system allows for video conferencing between the Pulmonary team (physician, respiratory therapist, nurse) to troubleshoot issues, and increase NIPPV compliance.
223807448|NCT03353064|OTHER|EMS|Emergency medical service scheduled home visits for face to face troubleshooting of the NIPPV, environmental check and end-tidal CO2.
223807449|NCT00644397|DEVICE|95-degree Angled Blade Plate|
223807450|NCT00644397|DEVICE|4.5mm Condylar Locking Plate|
223807451|NCT03609567|OTHER|Aromatherapy|Aromatherapy using essential oils
223807452|NCT03609567|OTHER|Placebo|Aromatherapy using odorless placebo oil
223807453|NCT00269035|DRUG|SB773812|SB-773812 tablets will be available with dose strength of 60 mg
223807454|NCT00269035|DRUG|Risperidone|Risperidone tablets will be available with dose strength of 3 and 6 mg
223807455|NCT01636180|DRUG|Clopidogrel|repeated loading dose of clopidogrel (600 mg) in addition to high dose of clopidogrel continuous therapy for 30 days (150 mg/day)
223807456|NCT01636180|DRUG|Clopidogrel|no repeated loading dose of clopidogrel with clopidogrel continuous therapy for 30 days (75 mg/day)
223807457|NCT04983381|OTHER|Multimedia education video|The multimedia education video was a 30 minutes information-based patient education program and contained information about pelvic anatomy and how to practice vaginal examination. The same gynecologist (M.S.) (male) who 15 years of experience explained details of vaginal examination, who told about vaginal examination in this video to the study participants, also did the gynecologic examination. The gynecologic examination which contained pelvic ultrasound scan and vaginal examination lasted approximately 20 minutes practice.
223807458|NCT03365154|DEVICE|Cardio Flow FreedomFlow™ Orbital Atherectomy System treatment|Occlusive lesions will be treated using atherectomy with or without adjunctive low pressure balloon angioplasty.
223807459|NCT03365154|DEVICE|Balloon Angioplasty|Low pressure balloon angioplasty may be used following atherectomy
223807460|NCT03209804|PROCEDURE|hybrid operating techniques|A one-stage cooperation of existing endovascular interventional techniques and microsurgical techniques, including microsurgical resection, endovascular embolization, balloon occlusion.
223807461|NCT01896882|OTHER|Sodium restriction|
223807462|NCT04365595|OTHER|Questionnaires, spirometry|Questionnaires targeting health-related quality-of-life, symptoms, anxiety and depression
223807463|NCT04523896|RADIATION|Real time High-Dose-Rate prostate brachytherapy in combination with stereotactic prostate radiotherapy|"\- Brachytherapy: Real time HDR prostate brachytherapy using a MRI-trans-rectal ultrasound image fusion protocol: single fraction of 15 Gy.~Planning software: Oncentra prostate (Nucletron)~\- External beam radiotherapy: Stereotactic ablative radiation therapy (SABR): 5 session in 5 consecutive days, 5 Gy per fraction to the prostate.~Intra-fraction gold seeds monitoring using Auto beam Hold solution (Varian) Planning software: Eclipse (Varian)."
223807464|NCT00790010|DRUG|Bevacizumab Plus Ipilimumab Cohort 1|Cohort 1: Ipilimumab 10 mg/kg IV every 3 weeks x 4 doses(induction), then every 3 months (maintenance); Bevacizumab 7.5 mg/kg IV every 3 weeks (continuous)
223807465|NCT00790010|DRUG|Bevacizumab Plus Ipilimumab Cohort 2|Cohort 2: Ipilimumab 10 mg/kg IV every 3 weeks x 4 doses(induction), then every 3 months (maintenance); Bevacizumab 15 mg/kg IV every 3 weeks (continuous)
223807466|NCT00790010|DRUG|Bevacizumab Plus Ipilimumab Cohort 3|Cohort 3: Ipilimumab 3 mg/kg IV every 3 weeks x 4 doses (induction), then every 3 months (maintenance); Bevacizumab 7.5 mg/kg IV every 3 weeks (continuous)
223807467|NCT00790010|DRUG|Bevacizumab Plus Ipilimumab Cohort 4|Cohort 4: Ipilimumab 3 mg/kg IV every 3 weeks x 4 doses (induction), then every 3 months (maintenance); Bevacizumab 15 mg/kg IV every 3 weeks (continuous)
223807468|NCT00724152|BEHAVIORAL|Cognitive Behavioral Therapy|A psychotherapeutic approach to tinnitus management which includes tinnitus education
223807469|NCT00724152|BEHAVIORAL|Tinnitus Education|An audiologic rehabilitative approach to tinnitus education.
223807470|NCT03124979|DEVICE|LNCS DBI Sensor|Noninvasive Measurement of SpO2
223807471|NCT00386022|DRUG|GnRH|GnRH doses of 25, 75, 250 and 750 ng/kg will be given IV every 4 hr at baseline and after transdermal estradiol
223807472|NCT00386022|DRUG|NAL-GLU GnRH antagonist|A single subcutaneous injection of the NAL-GLU GnRH antagonist at a dose of 150 mcg/kg before and after transdermal estradiol
223807473|NCT00386022|DRUG|Estrogen patch|transdermal estrogen patches 0.05mg/day, changing the patch every 86 hr in second part of sequential study
223807474|NCT01417507|PROCEDURE|cognitive assessment|Undergo neurocognitive assessment
223807475|NCT01417507|PROCEDURE|magnetic resonance imaging|Undergo MRI
223807476|NCT01417507|OTHER|laboratory biomarker analysis|Correlative studies
223807477|NCT01417507|OTHER|questionnaire administration|Ancillary studies
223807478|NCT01417507|PROCEDURE|quality-of-life assessment|Ancillary studies
223807479|NCT04590534|DRUG|Chromax|Treatment of BPH by Chromax for 3 Months
223807480|NCT04590534|DRUG|Sildosin Group|patients will receive one capsule of Sidosin 8 mg once daily for 12 weeks
223807481|NCT04590534|OTHER|Placebo Group|patients will receive placebo 3 times daily for 12 weeks
223807482|NCT06070155|OTHER|Aerobic Exercise three time a week|The participants will receive mild to moderate aerobic exercise for three weeks for 12 sessions.
223807483|NCT00329329|DRUG|satraplatin and capecitabine|satraplatin and capecitabine dose escalated per the dosing scheme
223807484|NCT02493296|OTHER|This observational study will not entail an intervention.|This study will entail measurement of central aortic haemodynamics before and after (clinically indicated) abdominal aortic aneurysm repair
223807485|NCT02440633|DRUG|14C-OPS-2071|Subjects will swallow Single 25 mL of suspension containing 50 mg of 14C-OPS-2071 directly.
223807486|NCT03346603|OTHER|urine culture and susceptibility testing|All patients will have a urine culture and susceptibility test ordered per standard care. Results of tests will identify which patients have antimicrobial-resistant organisms.
223807487|NCT00404664|BEHAVIORAL|influenza vaccine, reminders letters, raffle prize|
223807488|NCT05660200|DIETARY_SUPPLEMENT|IBSA Iron ODF|IBSA Iron ODF is a food supplement based on ferric pyrophosphate and folic acid in orodispersible film. IBSA Iron ODF appears as a yellow, opaque, homogeneous film, without visible particles. Once taken, it dissolves on the tongue and can be swallowed without adding water.
223807489|NCT05660200|DIETARY_SUPPLEMENT|SiderAL® FORTE|Sideral® r.m. contained in SiderAL® FORTE is an iron protected with Sucrosomial® Technology which passes through the gastric environment intact and is absorbed in the intestine, thus preventing any irritation and discomfort to the stomach. The presence of Vitamin C facilitates the absorption of iron.
223807490|NCT02764034|DEVICE|Low level Laser diode machine|wavelength 635 Low level diode laser power control time control Continuous mode
223807491|NCT01160848|DRUG|Area cleaned with saline water and occluded with Tegaderm|
223807492|NCT01160848|DRUG|Area cleaned with saline water|
223807493|NCT01160848|DRUG|Area cleaned with Ethyl alcohol solution|
223807494|NCT01160848|DRUG|Visonac left on the skin for 24 hours in facial area one|
223807495|NCT01160848|DRUG|Visonac wiped off after one hour|
223807496|NCT01160848|DRUG|Visonac left on the skin 24 hours in facial area two|
223807497|NCT03859882|OTHER|Sleep deprivation|40 hours of continuous awaking in the sleep laboratory in order to compare before and after sleep deprivation for each treatment (Caffeine vs. placebo).
223807498|NCT06442618|OTHER|Extracorporeal Shockwave Treatment (Group A)|Each session involved a 1:1 ratio of patient to physiatrist. The treatment modality was explained to the patient preliminarily, and before each session, the patients were clinically evaluated and the location of pain was identified.; so patients were asked to assume a comfortable position, and treatment with focal ESWTs was started as per the ISMST protocol
223807499|NCT06442618|OTHER|Nutraceutical Supplementation (Group B)|Participants in Group B performed home therapy with nutraceutical supplementation containing: hyaluronic acid (200 mg), collagen (5,000 mg), manganese (10 mg) and vitamin C (250 mg), daily for 30 days. Patients were advised to shake the compound, before taking, and to store it at room temperature not exceeding 25 °C, in a cool, dry place, away from light and heat sources. The compound is also free of gluten and lactose, so it can be safely administered.
223807500|NCT06442618|OTHER|Combined Treatment (Group C)|Participants in group C were invited to come to our department\&#39;s outpatient clinics to perform treatment with focal ESWT; they had one session every six days for a total of 5 sessions lasting about 20 minutes each. Patients in this group took also additional nutraceutical therapy; they took a daily supplemental treatment of hyaluronic acid, collagen, vitamin C and manganese for 30 days.
223807501|NCT02240095|BEHAVIORAL|Intervention A - Online Clinical Questions Recorder|Students allocated to this intervention will receive access to an online recorder for the clinical questions at the point of care. The recorder is accessible across a wide range of devices including phones, tablets, and desktop computers.
223807502|NCT02240095|BEHAVIORAL|Intervention B - Online Evidence Retrieval Coach|Students allocated to this intervention will receive online guidance, embedded in the MPFS search engine, in the form of short videos, animations, demos and tips and tricks regarding evidence retrieval.
223807503|NCT02240095|BEHAVIORAL|Intervention C - Online Audit and Feedback|Students allocated to this intervention will receive feedback on their current search performance compared to their peers, both online when using MPFS as well as by e-mail.
223807504|NCT00637208|PROCEDURE|venographic occlusion of spermatic veins|Through the femoral vein a catheter is inserted into the spermatic veins in succession and the veins are occluded.
223807505|NCT00031486|DRUG|Valacyclovir|Valacyclovir is a L-valyl ester of acyclovir. Valacyclovir is provided in 500 mg tablets, 4 tablets (500 mg tablets) 3 times a day (every 8 hours) for 90 days.
223807506|NCT00031486|DRUG|Placebo|Placebo (identical to active drug in appearance) 500 mg tablets, 4 tablets 3 times daily for 90 days.
223807507|NCT03663686|DRUG|Litapiprant Tablet|Small molecules inhibitors of the chemoattractant receptor homologous molecule expressed on Th2 cells
223807508|NCT03440684|OTHER|Exercise|"At the beginning of the training, participants were informed about the anatomy and biomechanics of core muscles and the effectiveness core stabilization exercises.~In all sessions, 5 minutes warm-up exercises and 5 minutes cool-down exercises were done before training. The exercises were first shown by the physiotherapist 2 to 3 repetitions and then the participants performed the exercise 10 to 12 repetitions.~Participants were included clinical pilates exercises for 6 weeks, which would be 3 days per week. Exercise programme were managed by one and the same physiotherapist. Each week the level of difficulty of the exercises was increased according to the tolerance of the participants and new exercises were added to the program."
223807509|NCT02609165|DRUG|rhNGF 180 µg/ml eye drops solution|eye drops
223807510|NCT02609165|DRUG|vehicle eye drops|placebo
223807511|NCT05741216|OTHER|OTF Ocular Lubricant|Ocular lubricant in 1 of 3 test formulations
223807512|NCT05741216|OTHER|Ocular Lubricant|Commercially available ocular lubricant
223807513|NCT04716348|PROCEDURE|muscle energy technique|muscle energy technique for suboccipital muscles
223807514|NCT04997954|DRUG|MediCabilis CBD oil|"The investigational product (MediCabilis 5% (50mg/ml) CBD Oil) will be supplied by BOD Australia, an Australian licensed manufacturer of medical grade cannabis.~The main components of MediCabilis 5% (50 mg/mL) CBD extract in MCT Oil are:~* Cannabis sativa L. dry extract~* Medium chain triglycerides (Ph Eur 0868) which are added in order to adjust the active constituent (cannabidiol) to the target content.~Each mL of MediCabilis provides:~* 50 mg of Cannabidiol (CBD+CBDA)~* Less than 2 mg tetrahydrocannabinol (THC)~* Non-active ingredient: Medium Chain Triglycerides (MCT) oil sourced from coconut"
223807515|NCT03078816|DEVICE|Activa PC Primary Cell Neurostimulator - (Model 37601)|Deep Brain Stimulator system will be implanted using standard neurosurgical techniques. The device will deliver constant stimulation to the thalamus using settings programmed by study team.
223807516|NCT03078816|DEVICE|Activa RC Rechargeable Neurostimulator - (Model 37612)|Deep Brain Stimulator system will be implanted using standard neurosurgical techniques. The device will deliver constant stimulation to the thalamus using settings programmed by study team.
223807517|NCT03078816|DEVICE|Activa SC Single Cell Neurostimulator (Models 37602/37603)|Deep Brain Stimulator system will be implanted using standard neurosurgical techniques. The device will deliver constant stimulation to the thalamus using settings programmed by study team.
223807518|NCT03078816|DEVICE|DBS Lead - (Model 3387|Deep Brain Stimulator system will be implanted using standard neurosurgical techniques. The device will deliver constant stimulation to the thalamus using settings programmed by study team.
223807519|NCT03078816|DEVICE|DBS Extension - (Models 37085/6)|Deep Brain Stimulator system will be implanted using standard neurosurgical techniques. The device will deliver constant stimulation to the thalamus using settings programmed by study team.
223807520|NCT03078816|DEVICE|Patient Programmer - (Model 37642)|Deep Brain Stimulator system will be implanted using standard neurosurgical techniques. The device will deliver constant stimulation to the thalamus using settings programmed by study team.
223807521|NCT03078816|DEVICE|Test Stimulator - (Model 3625)|Deep Brain Stimulator system will be implanted using standard neurosurgical techniques. The device will deliver constant stimulation to the thalamus using settings programmed by study team.
223807522|NCT03078816|DEVICE|N'Vision Clinician Programmer - (Model 8840)|Deep Brain Stimulator system will be implanted using standard neurosurgical techniques. The device will deliver constant stimulation to the thalamus using settings programmed by study team.
223807523|NCT03078816|DEVICE|N'Vision Software Application Card - (Model 8870)|Deep Brain Stimulator system will be implanted using standard neurosurgical techniques. The device will deliver constant stimulation to the thalamus using settings programmed by study team.
223807524|NCT00180635|DRUG|Aminoguanidine|500mg
223807525|NCT00180635|DRUG|Placebos|2ml
223807526|NCT00145015|BEHAVIORAL|Increased dietary intake of salmon or cod|
223807527|NCT05373095|BEHAVIORAL|PKC (adapted adherence counseling) and Conditional Cash Transfers|The intervention includes up to 3 cash transfers of 22,500 Tanzanian Shillings (\~$10) paired with attendance at each of the three adapted enhanced adherence counseling sessions (PKC sessions). The first cash transfer will occur at enrollment; the next two cash transfers are payable upon visit attendance and attendance of the two remaining PKC sessions. The cash transfers will include extra funds for transaction fees, typically \<$1.
223807528|NCT02706860|DRUG|Atorvastatin|
223807529|NCT06472596|DIAGNOSTIC_TEST|CBC, CRP ,ESR, ABG , interleukin 6, tumor necrotic factor alpha|compare results of investigations in asthmatics and non asthmatics
223807530|NCT00145093|DRUG|Baker's yeast (Bio Chromium)|
223807531|NCT01889433|DRUG|Algeron|1.5 µg/kg of body weight subcutaneously, once a week
223807532|NCT01889433|DRUG|Pegasys|180 µg subcutaneously, once a week
223807533|NCT00103766|DRUG|Alteplase|
223807534|NCT02935361|DRUG|Atezolizumab|Given IV
223807535|NCT02935361|DRUG|Guadecitabine|Given SC
223807536|NCT02525965|PROCEDURE|Wide resection margin >1cm|Surgical removal of lesions choosing the method of wide resection margin \>1cm
223807537|NCT02525965|PROCEDURE|Narrow resection margin <1cm|Surgical removal of lesions choosing the method of wide resection margin \<1cm
223807538|NCT00818116|DEVICE|AcrySof ReSTOR Aspheric IOL|Bilateral implantation with the AcrySof ReSTOR Aspheric Intraocular Lens (IOL) for the replacement of cataract in the natural lens of the eye.
223835401|NCT06458387|DIETARY_SUPPLEMENT|Active protein supplementation|The participants in active nutritional supplementation arm received consultation from the nutritional support team (NST) upon ICU admission, and nutritional supplementation was initiated on the same day. NST is a multidisciplinary support team comprised of physicians, nurses, dietitians, and pharmacists, which assesses the nutritional status of patients, and provides recommendations for nutritional therapy. Targets in the participants in active protein supplementation arm were protein supplementation at over 1.5 g/kg/day during first 3 days after ICU admission. Actual body weight was used as the body weight for patients with a percent of ideal body weight (PIBW) of less than 120%, while adjusted body weight was used for patients with a PIBW greater than or equal to 120%.
223807539|NCT06969456|PROCEDURE|Exercise|Structured treatment sessions, each lasting 30 minutes, will be organized into distinct blocks. In the initial phases, participants will engage in exercises emphasizing core stabilization and general strength training, with a particular focus on forced expiration as a technique to ensure the proper activation of the transversus abdominis muscle. This methodology aims to mitigate adverse effects associated with increased intra-abdominal pressure. To optimize the activation of the transversus abdominis, patients will be instructed to perform a forced expiration while concurrently drawing the navel inward and upward toward the spine, maintaining the lumbar spine in a neutral position. During the initial exercises, ultrasound imaging of the transversus abdominis will be employed as visual feedback, enabling patients to observe muscle thickening during forced expiration. This visual feedback enhances the accuracy of muscle activation and exercise technique. Exercises will be progressively s
223807540|NCT06969456|PROCEDURE|TDCS|The transcranial direct current stimulation (tDCS) protocol will involve the application of a continuous current for 30 minutes, with an intensity ranging from 1 to 1.5 mA, targeting the left dorsolateral prefrontal cortex (DLPFC) during each session. Two saline-soaked sponge electrodes, each measuring 35 cm², will be employed to ensure adequate skin contact. In accordance with the international 10-20 EEG electrode placement system, the anodal electrode will be positioned at the F3 location, specifically targeting the left DLPFC. The reference electrode will be placed above the left eye to facilitate efficient current flow through the prefrontal region of the brain. To enhance both safety and efficacy, a 30-second ramp-up and ramp-down period will be incorporated at the commencement and conclusion of the stimulation session. This methodology is intended to minimize potential adverse effects and ensure an optimal stimulation experience for participants.
223807541|NCT06969456|PROCEDURE|ShamTDCS|The device will be configured to produce an upward gradient for 30 seconds, identical to that used in the experimental group, followed by a downward gradient for another 30 seconds. Consequently, the control group will feel a similar tingling on their scalp as the experimental group. This stimulation will occur for a total of 60 seconds, which is insufficient to induce changes in cortical excitability. Studies have demonstrated that this approach effectively ensures patient blinding.
223807542|NCT06971588|OTHER|Music intervention|The intervention will involve patient-chosen music.
223807543|NCT04180657|GENETIC|Protein C deficiency|The effect of protein C deficiency on ghrelin levels are investigated.
223807544|NCT05340855|BEHAVIORAL|Wiidookaage'win Facebook Group|A 30-day Facebook group prototype that is moderated by two women who will post various forms of media addressing opioid recovery, mindfulness, stress management, and resiliency.
223807545|NCT00303862|DRUG|cediranib maleate|Given orally
223807546|NCT00303862|OTHER|laboratory biomarker analysis|Correlative studies
223807547|NCT01459861|PROCEDURE|Canal Block and Capsular Injection|Continuous Adductor canal block with 15ml of ropivacaine 0.2% with epinephrine 1:400,000 followed by an infusion of ropivacaine 0.2% at 6ml per hour for 2 days post operatively. This is combined with ultrasound guided posterior capsular knee injection with 30ml ropivacaine 0.2% with epinephrine 1:400,000.
223807548|NCT01459861|PROCEDURE|Femoral Nerve Block with Tibial Nerve Block|Continuous femoral nerve block with 15ml of ropivacaine 0.2% followed by an infusion of ropivacaine 0.2% at 6ml per hour for 2 days after surgery combined with tibial nerve block in the popliteal fossa with ropivacaine 0.5% up to 15ml.
223807549|NCT00033358|DRUG|medroxyprogesterone|Given intramuscularly
223807550|NCT00033358|DRUG|ethinyl estradiol|Given orally
223807551|NCT00033358|DRUG|norgestrel|Given orally
223807552|NCT00033358|OTHER|laboratory biomarker analysis|Correlative studies
223807553|NCT01811212|DRUG|Cabozantinib S-malate|Given PO
223807554|NCT01811212|OTHER|Laboratory Biomarker Analysis|Correlative studies
223807555|NCT05900726|DIAGNOSTIC_TEST|High Resolution Anorectal Manometry|A test used to measure the strength of the muscles in the anal canal
223807556|NCT05900726|DIAGNOSTIC_TEST|Endoanal Ultrasound|An examination of the anal canal (back passage) that allows us to see the muscles involved in passing stool and the tissues that surround these.
223807557|NCT05900726|OTHER|Bowel diary|A daily diary to assess episodes of faecal incontinence
223807558|NCT05900726|OTHER|MYMOP2|Questionnaire to assess individual symptoms, general wellbeing and activity in faecal incontinence
223807559|NCT05900726|OTHER|FIQOL|Questionnaire to assess the quality of life with faecal incontinence
223807560|NCT05900726|OTHER|FISI|Questionnaire to assess the severity of faecal incontinence
223807561|NCT05900726|OTHER|Follow up call|At 28 days and 3 months post final pelvipower or sham session to assess faecal incontience after study period
223807562|NCT05900726|OTHER|St Mark's incontinence score|A score of incontinence
224264339|NCT02922569|OTHER|Commercially available computerized training|Thirty minutes of training on computerized, casual video games.
224264340|NCT02922569|OTHER|Mindfulness Training|Ten minutes of using an online training course that teaches skills to help overcome ongoing life stressors.
224264341|NCT02922569|OTHER|Traumatic Brain Injury Information Session|Ten minutes of viewing traumatic brain injury related news, information, and programs.
224264342|NCT01410227|BIOLOGICAL|Recombinant von Willebrand factor (rVWF)|Intravenous administration
224264343|NCT01410227|DRUG|Placebo|Syringe supplied with physiologic saline solution for infusion
224264344|NCT01410227|BIOLOGICAL|Recombinant factor VIIII (rFVIII)|Intravenous administration
224264345|NCT04411576|DIAGNOSTIC_TEST|Throat swab sample for measuring current infection with SARS-CoV-2|Throat sample taken by the study participant to be analyzed with RT PCR for the presence of SARS-CoV-2 viral nucleic acids.
224264346|NCT04411576|DIAGNOSTIC_TEST|Blood sample for serology to measure past infection with SARS-CoV-2|Blood samples for serology to be analyzed for the presence of SARS-CoV-2 antibodies.
224264347|NCT01665495|PROCEDURE|Extended pericardial drainage by catheter|Extended pericardial drainage will be done after pericardiocentesis by the insertion of a catheter to intermittently drain pericardial fluid till daily fluid return\<30 ml.
224264348|NCT03407963|PROCEDURE|Embolization|Embolization by microparticles (300-500 microns)
224264349|NCT04862039|DEVICE|Virtual Reality (VR) devices|Virtual Reality (VR) devices. Subjects receiving the experimental treatment will be given a VR headset, headphones and wristband and the Philips wireless fetal-maternal monitoring system, after the necessary preparation of the abdominal skin.
223807563|NCT04648540|DRUG|Dexmedetomidine 0.5 mic/kg/h|"In Group I (OFA) the following drugs will be administered preoperatively:~Acetaminophen 1 gm and Ketorolac 30 mg in 100 mL i.v. over 10 minutes Dexmedetomidine loading dose of 0.5 mic/kg i.v. over 10 minutes Lidocaine loading dose of 1.5 mg/kg i.v. over 10 minutes~The following drugs will be administered as a continuous infusion throughout the operation:~* Dexmedetomidine 0.5 mic/kg/h~* Lidocaine 0.5 mg/kg/h~The following drugs will be administered postoperatively:~Acetaminophen 1 gm/6h ketorolac 30 mg/8h Pregabalin 150 mg once at night Celecoxib 200 mg/24 hours"
223807564|NCT04648540|DRUG|Fentanyl 1 mic/kg/hr|In Group II (OA) patients will receive a continuous infusion of Fentanyl (1 mic/kg/h) Morphine 0.1 mg/kg PRN will be administered every 8 hours for postoperative analgesia
223807565|NCT02542839|DEVICE|NeuroStar TMS therapy|Application of repetitious transcranial magnetic stimulation (TMS) pulses using NeuroStar device to a specific brain target at predefined stimulation parameters.
223807566|NCT02542839|DEVICE|Sham NeuroStar TMS therapy|Same procedure as real rTMS without stimulating the cerebral cortex.
223807567|NCT02542839|OTHER|Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS)|All participants will receive a clinical assessment of dystonia severity by using the TWSTRS test.
223807568|NCT02542839|OTHER|Craniocervical Dystonia Questionnaire (CDQ-24)|All participants will fill out the Craniocervical Dystonia Questionnaire (CDQ-24) quality of life questionnaire.
223807569|NCT02542839|OTHER|Cerebellar-brain Inhibition (CBI)|All participants will have a measure of the cerebellar-brain inhibition(CBI) which will be conducted by using a TMS device determining the ability of the coil to activate the cerebellum.
223807570|NCT02542839|PROCEDURE|Botulinum toxin injections|All participants will receive Botulinum toxin(BoNT) injections as part of their standard of care
223807571|NCT06247202|OTHER|Smart Phone Education (mhealth)|Nutrition and Health Education module delivered through m-health approach (smart phones)
223807572|NCT06247202|OTHER|Paper Education (conventional)|Nutrition and Health Education module delivered through conventional approach (paper)
223807573|NCT06063122|DEVICE|smallTalk NICU Active|The novel smallTalk NICU Active product design allows a disposable pacifier (equipped with the smallTalk sensor) to act as an infant-controlled mechanism for administration of developmentally appropriate parental voice, delivered by the NICU-safe speaker contingent upon the infant suck strength meeting an individually calibrated threshold.
223807574|NCT04500860|DRUG|Low dose tadalafil 5 mg|Efficacy of daily low dose tadalafil 5mg for treatment of female overactive bladder syndrome or urgency with or without urgency urinary incontinence
223807575|NCT04500860|DRUG|Tolterodine 4 Mg Oral Capsule, Extended Release|To compare efficacy of low dose tadalafil 5 mg to tolterodine 4 mg extended release in treatment of female overactive bladder
223807576|NCT04500860|DRUG|Placebo|Placebo drugs
223807577|NCT02300857|BEHAVIORAL|Low carbohydrate diet|Feeding study. Composition (by proportion of calories): 20% carbohydrate, 60% fat, 20% protein
223807578|NCT02300857|BEHAVIORAL|Moderate carbohydrate diet|Feeding study. Composition (by proportion of calories): 40% carbohydrate, 40% fat, 20% protein
223807579|NCT02300857|BEHAVIORAL|High carbohydrate diet|Feeding study. Composition (by proportion of calories): 60% carbohydrate, 20% fat, 20% protein
223807580|NCT06282614|DEVICE|Mucogyne Ovule|At inclusion visit (V0), the Investigator will ask the subject to use MUCOGYNE® Ovule 2 times a week until symptoms improve during 5 weeks (D35± 3) preferably at bedtime
223807581|NCT05001724|BIOLOGICAL|KN046|KN046 is 5 milligram per kilogram, every 3 weeks.
223807582|NCT05001724|DRUG|Lenvatinib|Lenvatinib is RP3D milligram per day, every day.
224264350|NCT01112722|BIOLOGICAL|Apitox, purified honeybee toxin, lyophilized in saline|intradermal injections of 0.1mg apitox in 0.1ml WFI over 12 weeks treatment period, injections twice weekly range from 1 to 20 injections
224264351|NCT01112722|BIOLOGICAL|histamine|imitates pain and erythema of honeybee venom
224264352|NCT03694015|RADIATION|SUPR|simple unplanned palliative radiotherapy-(either 8 Gy in 1 fraction or 20 Gy in 5 fractions), chosen pre-randomization at ROs or centres discretion
224264353|NCT03694015|RADIATION|VMAT|volumetric modulated arc therapy--(either 8 Gy in 1 fraction or 20 Gy in 5 fractions), chosen pre-randomization at ROs or centres discretion
224264354|NCT04130022|DEVICE|Point-of-Care Ultrasound|Portable ultrasonography done at the bedside.
224264355|NCT05515796|DRUG|Terelizumab (aka Tislelizumab)|q3w Terelizumab (aka Tislelizumab) 200mg on day 1 of each cycle
224264356|NCT05515796|DRUG|CapeOx|Oxaliplatin(130mg/m2) on day 1 of each cycle and Capecitabine:Dose of 1000mg/m2,14days
224264357|NCT05515796|DRUG|Trastuzumab|q3w Trastuzumab (6 mg/kg following an initial loading dose of 8 mg/kg) on day 1 of each cycle
224264358|NCT05515796|RADIATION|Radiotherapy|25 Gy/5 fractions
223807583|NCT05001724|DRUG|Docetaxel|Docetaxel is 75 milligram per Square meter, every 3 weeks.
223807584|NCT03631446|DRUG|Sodium Picosulfate, Magnesium Oxide and Citric Acid|Combination powder for oral solution
223807585|NCT02234544|DRUG|Ezetimibe|The groups will be randomized to ezetimibe 10 mg for 5 days or placebo. On the fifth day, they should came after an overnight fast for blood tests collection \[25(OH)D, PTH, calcium, albumin\]. Next, all participants will receive orally a cholecalciferol 50,000 IU capsule and a snack containing 15g of fat. Participants will return 14 days after that for a second blood test.
223807586|NCT02234544|DRUG|Cholecalciferol|All participants will receive orally a cholecalciferol 50,000 IU capsule and a snack containing 15g of fat. Participants will return 14 days after that for a second blood test.
223807587|NCT02234544|OTHER|Placebo|The groups will be randomized to ezetimibe 10 mg for 5 days or placebo. On the fifth day, they should came after an overnight fast for blood tests collection \[25(OH)D, PTH, calcium, albumin\]. Next, all participants will receive orally a cholecalciferol 50,000 IU capsule and a snack containing 15g of fat. Participants will return 14 days after that for a second blood test.
224264359|NCT04676529|DRUG|PXS-5505|PXS-5505 is a hard capsule (size 0) with the additional excipients mannitol and magnesium stearate.
224264360|NCT02143258|PROCEDURE|Stenting of the venous sinus|Patients with medically refractory idiopathic intracranial hypertension who meet the eligibility criteria will be offered stenting of their venous sinus in effort to reduce their intracranial pressure and improve their visual capabilities.
224264361|NCT02147379|DRUG|Lurasidone|
223807588|NCT03372330|DRUG|Standard care for sepsis and PAD|The standard medications care for the patient with PAD included antiplatelet agents.
223807589|NCT03372330|DRUG|Standard care for sepsis|The standard care for the patient with sepsis.
223807590|NCT01302431|OTHER|Manualised nurse-led telephone support|The manualised nurse-led telephone support intervention is designed to provide proactive support and enable caregivers of people with multiple sclerosis manage problems encountered with caregiving
223807591|NCT05168579|BEHAVIORAL|Deliberate practice|As above
223807592|NCT01969422|PROCEDURE|observation|intervention is the contact with online question answering serice ad subseudd
223807593|NCT03960632|DIAGNOSTIC_TEST|Abbott SD Bioline Malaria Pf Plus (05FK150) and Abbott SD Bioline Malaria Pf/Pv Plus (05FK160))|Qualitative in vitro tests for the detection of Plasmodium antigens
223807594|NCT00019058|DRUG|chemotherapy|
223807595|NCT00019058|DRUG|hydroxyurea|
223807596|NCT00019058|DRUG|pentoxifylline|
223807597|NCT00019058|RADIATION|radiation therapy|
223807598|NCT06497218|DIAGNOSTIC_TEST|Blinklab diagnostic device|Blinklab is a non-invasive diagnostic device for Autism Spectrum Disorder
223807599|NCT02107794|OTHER|Decision Aid|Paper based decision aid will be utilized to facilitate treatment option conversation between clinician and patient.
223807600|NCT00317889|PROCEDURE|Bone preparation technique: compaction|
223807601|NCT00317889|PROCEDURE|Bone preparation technique: broaching|
223807602|NCT04424784|BIOLOGICAL|5% O2|5% oxygen will be used during oocyte retrieval, fertilization check and embryo grading
223807603|NCT00239564|DRUG|IPX054 100 mg|IPX054 containing 25 mg carbidopa and 100 mg levodopa
223807604|NCT00239564|DRUG|IPX054 150 mg|IPX054 containing 37.5 mg carbidopa and 150 mg levodopa
223807605|NCT00239564|DRUG|IPX054 200 mg|CD-LD CR containing 50 mg carbidopa and 200 mg levodopa
223807606|NCT00239564|DRUG|IPX054 250 mg|CD-LD CR containing 62.5 mg carbidopa and 250 mg levodopa
223807607|NCT00239564|DRUG|IPX054 300 mg|CD-LD CR containing 75 mg carbidopa and 300 mg levodopa
223807608|NCT02167763|DEVICE|VeraCept Intrauterine Copper Contraceptive|
223807609|NCT02167763|DEVICE|TCu380 IUD|
223807610|NCT06386003|DRUG|Psilocybin|Participants will receive a single dose of psilocybin 25mg combined with 12 sessions of massed CPT, and 2 psychotherapy sessions related to psilocybin over 7 days.
223807611|NCT05692622|OTHER|Whole-body exercise and respiratory exercise|The study involves an 8-week intervention involving whole-body and respiratory exercises. The whole-body exercise component will involve doing exercises while watching a total of 32 Comic Kids yoga movies. These movies have been adapted to suit the needs and abilities of the target population. For the first 7 weeks of intervention, children will be provided with 4 yoga movies for each week, providing around 67 minutes of exercise in each week. In the last week of intervention, children will have the choice to practice any 4 exercises of their choice from the 28 movies. The respiratory exercise component will involve watching a 10-minute-long movie that involves practicing different styles of breathing and breath holding. Participants will be provided a respiratory trainer to use while practicing these breathing exercises. Children will be asked to practice these breathing exercises by watching the movie at least 2 days each week.
223807612|NCT03156933|OTHER|Assessment of splicing variants|This is a biological study with primary samples without any intervention on patients.
223807613|NCT01424930|DRUG|Abiraterone|Participants will receive abiraterone acetate at a starting dose of 1,000 mg once daily for 7 days post 30-minutes of a standardized low-fat meal and high-fat meal from Cycle 1 Day 8 to Cycle 1 Day 14.
223807614|NCT01424930|DRUG|Prednisone|Prednisone will be administered as 5 mg oral tablet twice daily during Cycle 1 Day 8 to Cycle 1 Day 14.
223835402|NCT06458387|DIETARY_SUPPLEMENT|Conventional protein supplementation|The participants in conventional protein supplementation arm received conservative nutritional management without specific protein targets.
223835403|NCT01811017|DEVICE|755nm Alexandrite Laser|755nm Alexandrite Laser
223807615|NCT02449668|DEVICE|Acupuncture|Acupuncture techniques with a plastic insertion tube was used to introduce every needle. The needles were perpendicularly inserted to a depth of 2-3 cm. The needles were applied to the area of the injured shoulder while the patient was lying in a lateral decubitus position on the stretcher. The skin was prepared with clorhexidine and the needles were sterile. They measured 40 mm long and 0.25 mm in diameter. The sessions lasted 20 minutes and the Qi sensation was sought by consistent manipulations, with rotation of the needles in both senses and scratching of the handle.
223807616|NCT02449668|DEVICE|Sham Acupuncture|
223807617|NCT00872040|OTHER|Ultrasound assessment of pelvic floor|Sample of women will undergo ultrasound examination of their pelvic floor before and after delivery. The assessment will be performed by transperineal probe.
223807618|NCT00161590|DRUG|CHOP and alemtuzumab|
223807619|NCT04119895|OTHER|Neuromuscular electrical stimulation and core stabilization exercise|"In NMES group, the amplitude of the electrical current will be set at the highest level subject can tolerate.~The lumbar stabilization mode of the device will be used. This mode consists of three phases; warming, contraction and recovery phases. The duration will be set to 35 minutes. In the first 2 minutes (warming phase), frequency is 6 Hz. Contraction phase includes consecutive cycles of contractile frequency of 40 Hz for 6 seconds and the rest frequency of 4 Hz for 12 seconds, lasting a total of 30 minutes. The last 3 minutes (recovery phase) frequency is 3 Hz. The ramp up time is 2 seconds and the ramp down time is 1 second"
223807620|NCT04119895|OTHER|Sham neuromuscular electrical stimulation and core stabilization exercise|In sham NMES group, the amplitude of the electrical current will be set at a minimum level which does not stimulate any contraction.
223807621|NCT02608866|RADIATION|SF-SSRS|Spine stereotactic radiosurgery/ablative radiotherapy (SSRS) with 16 Gy in single fraction to the defined target volume using intensity modulated radiotherapy or volumetric modulated arc therapy (VMAT or RapidArc).
223807622|NCT02608866|RADIATION|MF-SSRS|SSRS with 24 Gy in three fractions to the defined target volume using intensity modulated radiotherapy or volumetric modulated arc therapy (VMAT or RapidArc). Treatment should be given on every other day. Treatment on the consecutive days to the same target volume is not allowed.
223807623|NCT02913066|OTHER|S-1 concurrent radiotherapy|Radiotherapy 60\~66 Gray/28\~33 times (50.4\~60 Gray /28\~33 planning target volume times, 60\~66 Gray/28\~33 Gross tumor volume of primary tumor), synchronous chemotherapy S-1 70 mg/m2 5 to 1 per week, to the end of radiotherapy. Two weeks after radiotherapy finish, two cycle adjuvant chemotherapy with S-1, 70 mg/m2, 1\~ 14 days, 21 days for a cycle.
223807624|NCT02913066|OTHER|S-1 plus Cisplatin concurrent radiotherapy|Radiotherapy 60\~66 Gray/28\~33 times (50.4\~60 Gray /28\~30 planning target volume times, Gross tumor volume of primary tumor60\~66 Gray/28\~33), synchronous chemotherapy S-1 70 mg/m2 1\~ 14 days and 29 to 42 days, plus cisplatin 25mg/m2 1\~ 4 days and 29 to 33 days. Two weeks after radiotherapy finish, two cycle adjuvant chemotherapy with S-1 70 mg/m2 1\~ 14 days, plus cisplatin 25mg/m2 1\~ 4 days, 21 days for a cycle.
223807625|NCT02982525|DIETARY_SUPPLEMENT|No Mussels|Habitual diet only
223807626|NCT02982525|DIETARY_SUPPLEMENT|One mussel portion|1 x 75g mussel portions provided per week
223807627|NCT02982525|DIETARY_SUPPLEMENT|Two mussel portions|2 x 75g mussel portions provided per week
223807628|NCT02982525|DIETARY_SUPPLEMENT|Three mussel portions|3 x 75g mussel portions provided per week
223807629|NCT02157480|DEVICE|electrostimulation (with Compex® Compex2* (DJO, Vista, CA, USA)) 3 days per week .|outpatient biquadricipital electrostimulation 3 days per week with an electrostimulator Compex2\* (DJO, Vista, CA, USA)
223807630|NCT02157480|DEVICE|electrostimulation (with Compex® Compex2* (DJO, Vista, CA, USA)) 5 days per week|outpatient biquadricipital electrostimulation 5 days per week with an electrostimulator Compex2\* (DJO, Vista, CA, USA)
223807631|NCT01621880|DRUG|bevacizumab|Patients receive bevacizumab 5mg/kg intravenously over 30-90 minutes on day1. Treatment repeats every 2 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity.
223807632|NCT01621880|DRUG|Corticosteroid|Patients in the corticosteroid group were treated with intravenous pulsed-steroid therapy: methylprednisolone 500 mg daily intravenously for three consecutive days followed by oral prednisone 60 mg for five days and gradually tapered 15mg every 5 days. When the prednisone dose reached 30mg per day, it was tapered down more slowly (tapered 5mg every week), until a maintenance dose of 10mg per day was reached. The entire intervention lasted two months. At 2 months, prednisone was stopped.
223807633|NCT03921814|DEVICE|Treatment with IPL device|Exposure of body parts to the IPL device
223807634|NCT01568268|DRUG|Palonosetron|palonosetron 0.075 mg intravenous injection over 10 seconds when nausea with NRS \>= 4, or developement of retching or vomiting more than one time within three hour after the end of surgery.
223807635|NCT01568268|DRUG|placebo control group|placebo intravenous injection over 10 seconds when nausea with NRS \>= 4, or developement of retching or vomiting more than one time within three hour after the end of surgery.
223807636|NCT00582257|BEHAVIORAL|questionnaires|Participation in the registry will consist of adequately completing the family history questionnaire (one per family) the gastric cancer risk factor questionnaire and providing a blood sample for future correlative studies. Registry participants (both Patient/Relative and Control cohorts) will be required to submit tissue (both normal and/or tumor) to create a Tissue and DNA repository. Select participants will be invited to undergo Genetic Counseling, eg. those participants who meet clinical criteria for HDGC.
223807637|NCT04675450|DRUG|Placebo|Take 4 capsules BID on an empty stomach at least 1 hour before food intake, and remain fasting at least 1 hour after dosing
223835404|NCT04172987|DRUG|Tirzepatide|Administered SC
223807638|NCT04675450|DRUG|NBP Softgel Capsules|Take 4 capsules BID on an empty stomach at least 1 hour before food intake, and remain fasting at least 1 hour after dosing.
223807639|NCT06108401|DIETARY_SUPPLEMENT|Goat milk-based infant formula|Goat milk-based infant formula exclusively for 4 weeks at a volume depending on the infant.
223807640|NCT06108401|DIETARY_SUPPLEMENT|Cow milk-based infant formula|Regular cow milk-based infant formula that is similar in color, smell, and taste to the formula received by the experimental group.
223807641|NCT02081625|DRUG|NS-065/NCNP-01|"NS-065/NCNP-01 for Infusion is packaged as 25 mg/mL in phosphate buffered saline with 1 mL per vial. Study dosages will be infused over a 1 hour period with Normal saline as follows:~Cohort 1: 1.25mg/kg once weekly for 12 weeks; Cohort 2: 5.0mg/kg once weekly for 12 weeks; Cohort 3: 20.0mg/kg once weekly for 12 weeks"
223807642|NCT05080062|BEHAVIORAL|Requirements and functional Schedule|An interview with the employee and the employer where the occupational worker is leading the interview and a pain rehabilitation-program
223807643|NCT05080062|BEHAVIORAL|No intervention|a pain rehabilitation-program
223807644|NCT05287308|DRUG|doxorubicin|doxorubicin 50\~60mg/m2, i.v., d1, q3w or q2w.
223807645|NCT05287308|DRUG|epirubicin|epirubicin 80\~100mg/m2, i.v., d1, q3w or q2w.
223807646|NCT05287308|DRUG|pirarubicin|pirarubicin 40\~50mg/m2, i.v., d1, q3w or q2w.
223807647|NCT05287308|DRUG|cyclophosphamide|cyclophosphamide 600mg/m2, i.v., d1, q3w or q2w.
223807648|NCT05287308|DRUG|albumin-bound paclitaxel|albumin-bound paclitaxel 260mg/m2, i.v., d1, q3w; 260mg/m2, i.v., d1, q2w; or 125mg/m2, i.v., d1, qw.
223807649|NCT05287308|DRUG|paclitaxel|paclitaxel 175mg/m2, i.v., d1, q3w; 175mg/m2, i.v., d1, q2w; or 80mg/m2, i.v., d1, qw.
223807650|NCT05287308|DRUG|docetaxel|docetaxel 80\~100mg/m2, i.v., d1, q3w.
223807651|NCT06319417|DIETARY_SUPPLEMENT|HT treatment|Total consumption of 60 mg/day of HT
223807652|NCT06319417|DIETARY_SUPPLEMENT|Placebo treatment|Consumption of placebo treatment of 4 caramels/day
223807653|NCT01551602|DRUG|AK159|transdermal administration of teriparatide acetate
223807654|NCT01551602|DRUG|MN-10-T|subcutaneous administration of teriparatide acetate
223807655|NCT01551602|DRUG|Placebo|Multiple administration of placebo AK159
223807656|NCT00639730|DIETARY_SUPPLEMENT|modified Atkins diet|High fat, low carbohydrate diet
223807657|NCT03917004|DRUG|Nitroglycerin|"The starting rate of nitroglycerin was 0.25 μg / kg / min and the mean arterial pressure (MAP) decreased to 80% of the baseline but not less than 70%.The drug infusion rate was adjusted so that the MAP was maintained in the range to the suture, and the administration was stopped and the blood pressure was gradually returned to the pre-depressurization level."
223807658|NCT02877602|DEVICE|MRI|
223807659|NCT02877602|DEVICE|Transient Elastography|
223807660|NCT03369275|BIOLOGICAL|Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells|Cryopreserved Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells will be administered intravenously.
223807661|NCT03369275|OTHER|Placebo|Placebo, with excipients, will be administered intravenously.
223807662|NCT00969397|DRUG|Topical Antiangiogenic|Topical Antiangiogenic
223807663|NCT00969397|DEVICE|Pulsed Dye Laser|Pulsed Dye Laser
223807664|NCT01293058|DRUG|Intranasal naloxone|spray naloxone, 0.4 mg/ each 4 minutes till increasing patient level of consciousness
223807665|NCT01293058|DRUG|Intravenous|Amp naloxone, 0.4 mg / each 4 minutes till increasing patient level of consciousness
223807666|NCT06425380|OTHER|Resistant Potato Starch|Participants will receive 4 weeks of resistant potato starch 20 grams (g) twice daily. Bob's Red Mill® potato starch will be used. Every patient will receive the same dose and there are no dose titrations.
223807667|NCT01537302|DEVICE|CTO crossing in femoropopliteal arteries CONNECT II|CTO crossing in femoropopliteal arteries using the Ocelot System
223807668|NCT00760539|DRUG|Travoprost 0.004%/Timolol 0.5% BAC-free ophthalmic solution|
223807669|NCT00760539|DRUG|Travoprost 0.004%/Timolol 0.5% ophthalmic solution|
224264362|NCT05922306|DRUG|PEGylated recombinant human interferon alpha-2b injection|Continuous combination therapy: pegylated interferon alpha-2b 180µg, subcutaneously once a week for 96 weeks, combined with NAs throughout the treatment period.
224264363|NCT05922306|DRUG|PEGylated recombinant human interferon alpha-2b injection|Pulsed combination therapy: pegylated interferon alpha-2b 180µg once weekly by subcutaneous injection for 8 weeks with 4 weeks off for a total treatment duration of 96 weeks, combined with NAs throughout the treatment period.
223807670|NCT04543006|DIAGNOSTIC_TEST|serology|blood sample of 10 ml twice (6 and 12 months after the Covid-19)
223807671|NCT00106184|DRUG|Rituximab|Treatment Group A - intravenous rituximab 750mg/m2 BSA (Body Surface Area) up to a maximum dose of 1 gram at Weeks 0 and 1 Group B - intravenous rituximab 750mg/m2 BSA (Body Surface Area) up to a maximum does of 1 gram at Weeks 8 and 9
223807672|NCT00106184|DRUG|Placebo|"Treatment Group A: placebo infusion at Weeks 8 and 9~Treatment Group B: placebo infusion at Weeks 0 and 1"
223807673|NCT02313909|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|15 mg, once daily, orally, tablet
223807674|NCT02313909|DRUG|Acetylsalicylic acid (Aspirin, BAY1019036)|100 mg, once daily, orally, tablet
223807675|NCT02313909|OTHER|Rivaroxaban-Placebo|Matching placebo, once daily, orally, tablet
223807676|NCT02313909|OTHER|Aspirin-Placebo|Matching placebo, once daily, orally, tablet
223807677|NCT02082925|OTHER|Patient has to get up his hand when he defined his dyspnea threshold during 6MWT|
223807678|NCT02799615|DRUG|Infliximab|No standard dosing regimen will be used and the dose of infliximab will be determined by the treating physician
223835405|NCT04172987|DRUG|EE/NGM|Combination oral contraceptive administered orally
223835406|NCT02308501|DRUG|Lastacaft ®|
223835407|NCT02308501|DRUG|Tears Naturale ® (Placebo)|
223835408|NCT00712855|BIOLOGICAL|mapatumumab|3, 10, or 30 mg/kg IV (in the vein), on day 1 of each 21 day cycle
223835409|NCT00712855|DRUG|sorafenib|400 mg orally, twice a day continuously in each cycle
223835410|NCT00030875|DRUG|bortezomib|
223835411|NCT03020095|DRUG|Ravidasvir|Ravidasvir 200mg tablet administered orally once daily
223807679|NCT05180266|OTHER|Therapeutic Touch|Each of the women will be informed about the purpose and content of the study at the first meeting, and informed consent will be obtained from the women who meet the conditions for participation and agree to participate. The pre-test data in the research will be obtained with the Participant Identification Form, PSQI,MRS and MENQOL. After pre-test data collection, women will be given an appointment for therapeutic administration.The therapeutic touch group will be applied to the therapeutic touch group once a week for four weeks in a suitable room in the Faculty of Nursing and on the specified day and time by the researcher.At the end of the fourth week, post-test data will be obtained by filling in PSQI, MRS and MENQOL again.
223807680|NCT05180266|OTHER|Music Listening Group|Each of the women was informed about the purpose and content of the study at the first meeting, and informed consent was obtained from the women who met the conditions for participation and accepted to participate.The pre-test data in the research will be obtained with the Participant Identification Form, PSQI, MRS and MENQOL. Music stream, music will be uploaded to mobile phones. He will be asked to listen to music (relaxation music in the relaxation exercises CD prepared by the Turkish Psychological Association) for 30 minutes before going to sleep every day for four weeks. At the end of the fourth week, post-test data will be obtained by filling in PSQI, MRS and MENQOL again
223807681|NCT05180266|OTHER|Control Group|Each of the women will be informed about the purpose and content of the study at the first meeting, and informed consent will be obtained from the women who meet the conditions for participation and agree to participate.The pre-test data in the research will be obtained with the Participant Identification Form, PSQI, MRS and MENQOL. No action will be taken on the control group for four weeks. At the end of the fourth week, post-test data will be obtained by filling in PSQI, MRS and MENQOL again.
223807682|NCT00314561|DRUG|Pioglitazone, Rosiglitazone|
223807683|NCT00169559|DRUG|GW590735|1µg to 20µg daily doses of GW590735
223807684|NCT00169559|DRUG|fenofibrate|Marketed Drug
223807685|NCT04325113|DRUG|levobupivacaine|Patient satisfaction and pain score using a visual anagogic scale (VAS)
223807686|NCT06063720|DEVICE|Endoscreen QC|Artificial intelligence monitoring of effective withdrawal time
223807687|NCT02789384|OTHER|Procedure/Surgery|"Procedure/Surgery: Newly obtained biopsy if applicable and Blood samples collection.~For each patient:~* Frozen and paraffin embedded tumor material (archival or new biopsy) will be obtained for genetic profiling~* Blood samples will be obtained for genetic profiling and assessment of markers.~The classification as CINSARC will be performed for each patient. Patients should be treated by neoadjuvant anthracycline-based chemotherapy. Chemotherapy regimen must contain at least doxorubicin (dose range: 60 -75 mg/m²) and ifosfamide (dose range: 2.5-3g/m²) to be delivered on a 21-days cycle basis up to 6 cycles prior surgery. After neoadjuvant chemotherapy completion, patients will be treated by surgery followed or not by radiotherapy.~All patients should be managed according to the usual medical practices."
223807688|NCT01583686|DRUG|Fludarabine|Days -5 to Day -1: Fludarabine 25 mg/m\^2/day intravenous piggyback (IVPB) daily over 30 minutes for 5 days.
223807689|NCT01583686|BIOLOGICAL|Anti-mesothelin chimeric T cell receptor (CAR) transduced peripheral blood lymphocytes (PBL)|Day 0: Cells will be infused intravenously (IV) on the Patient Care Unit over 20 to 30 minutes.
223807690|NCT01583686|DRUG|Cyclophosphamide|Days -7 and -6: Cyclophosphamide 60 mg/kg/day X 2 days intravenous (IV) in 250 ml 5% dextrose in water (D5W) with Mesna 15 mg/kg/day X 2 days over 1 hr.
223807691|NCT01583686|DRUG|Aldesleukin|Aldesleukin 72,000 IU/kg intravenous (IV) (based on total body weight) over 15 minutes every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses).
223807692|NCT03859258|DEVICE|Transvaginal sonography|Niche is assessed using TVS, SIS (cases only) and office hysteroscopy
223807693|NCT02560662|BEHAVIORAL|Physical activity|"Preoperative intervention - takes place from randomization until surgery (4 weeks +/-2 w):~• 30 minutes of exercise daily added to the existing daily exercise routine. The level of exercise should produce shortness of breath but the patient should be able to talk without much effort.~Postoperative intervention - takes place from discharge from the hospital until 4 weeks postoperatively:~• 30 minutes of exercise daily added to the existing daily exercise routine. The level of exercise should produce shortness of breath but the patient should be able to talk without much effort.~Participants randomized to intervention will receive a visit to a physiotherapist for personally adjusted information regarding the intervention, later followed up with a telephone call."
223807694|NCT05016726|DEVICE|Intravascular Lithotripsy|Intravascular Lithotripsy and/or Rotational Atherectomy and/or Orbital Atherectomy to the target vessel prior to placing a coronary stent.
223835412|NCT03020095|DRUG|Danoprevir|Danoprevir 100mg tablet administered orally twice daily
224264364|NCT04257838|DRUG|Piperacillin/tazobactam or Meropenem|"The plasmatic levels determinations will always be made in state of equilibrium (after the fourth dose) and two samples will be collected:~1. Just before the antibiotic infusion (T0)~2. In the midpoint of time (T50). If the antibiotic is administered every 8 hours this determination will be made at 4 hours. If the antibiotic is administered every 6 hours, the determination will be made at 3 hours.~A second complete determination will be made (before the infusion, in the midpoint of time and before the next dose) after the administration of 4 doses as long as a posology modification is made as a consequence of the information received from the plasmatic levels."
224264365|NCT01484912|DRUG|STA-2|"After 1 week of screening and washout, patients who met the entry criteria were randomly assigned either to the treatment or control group. The regimen of STA-2 was:~STA-2 250 mg capsule, each containing 100 mg green tea polyphenols, 2 capsules t.i.d. (three times a day) for 6 weeks, to be administered in a non-fasting state."
224264366|NCT01484912|DRUG|Placebo|"After 1 week of screening and washout, patients who met the entry criteria were randomly assigned either to the treatment or control group. The regimen of Placebo was:~Placebo 250 mg capsule, 2 capsules t.i.d. (three times a day) for 6 weeks, to be administered in a non-fasting state."
224264367|NCT00796341|PROCEDURE|PIPELLE ENDOMETRIAL SAMPLING|Pipelle endometrial sampling will be done twice between 7th to 10th day and 24th to 26th d in the cycle prior to IVF.
224264368|NCT00773149|DRUG|Alemtuzumab (CAMPATH 1H) associated to G-CSF|"All patients receive Alemtuzumab in 3 successive phases:~Phase A: Test week: 3mg, then 10mg, then 30mg every other day for one week to test for tolerance.~Phase B: 30mg 3 times a week for 12 to 18 administrations until response or progression/failure has been documented.~Phase C: in patients in CR, maintenance with Alemtuzumab: 3 injections one week every 2 months."
223807695|NCT04005534|DRUG|Standard group|Ultrasound examination of the brachial plexus 2 days before the surgery. Ultrasound guided brachial plexus blockade and sedation on the day of surgery.
223807696|NCT04005534|DRUG|Preemptive group|Ultrasound guided brachial plexus blockade 2 days before the surgery. Ultrasound guided brachial plexus blockade and sedation on the day of surgery.
223807697|NCT01249469|OTHER|skin whitening cosmetic product|Product application: twice a day in the morning and before sleep for 8 weeks; from D1 to D55, but no application on D27 at night/ D28 in the morning and D55 at night/ D56 in the morning before visit. The product is applied on one side of the hand
223807698|NCT00637130|DRUG|Travoprost ophthalmic solution, 0.0008%|
223807699|NCT00637130|DRUG|Travoprost ophthalmic solution, 0.001%|
223807700|NCT00637130|DRUG|Travoprost ophthalmic solution, 0.0012%|
223807701|NCT00637130|DRUG|TRAVATAN|
223807702|NCT00637130|OTHER|Vehicle|
223807703|NCT01218880|DRUG|M2ES 7.5mg|M2ES Dosage：7.5mg/m2
223807704|NCT01218880|DRUG|M2ES 15mg|M2ES Dosage：15mg/m2
223807705|NCT01218880|DRUG|M2ES 30mg|M2ES Dosage：30mg/m2
223807706|NCT01218880|DRUG|M2ES 45mg|M2ES Dosage：45mg/m2
223807707|NCT04367558|PROCEDURE|Minimally invasive, in-office, RF reduction of the affected area|Usage of RF needle to treat one or more of the affected areas
223807708|NCT03629418|DRUG|Targeted blood-pressure management|Prophylactic norepinephrine infusion is started before anesthetic induction and maintained throughout surgery. The target is to maintain systolic blood pressure at 110 mmHg or higher.
223807709|NCT03629418|DRUG|Routine blood-pressure management|Phenylephrine (25-50 ug) is injected or vasopressors is infused only when necessary. The target is to maintain systolic blood pressure at 90 mmHg or higher during surgery.
223807710|NCT03472456|DRUG|Implementation of a pulp medication in compliance with the dental emergency management protocol: articaïne|Implementation of a pulp medication in compliance with the dental emergency management protocol: articaïne
223807711|NCT03472456|DRUG|Implementation of a pulp medication in compliance with the dental emergency management protocol: eugenol|Implementation of a pulp medication in compliance with the dental emergency management protocol: eugenol
223807712|NCT04667364|DEVICE|Transcutaneous electrical nerve stimulation (TENS)|Conventional TENS will be performed using two electrodes placed on the involved extremity and with the following stimulation parameters; a frequency of 100 Hz, pulse duration 50-100 ms, and at an intensity gradually increased until the patient feels a strong, tolerable and non-painful sensation (18, 19). The intensity is incrementally increased based on patient feedback. Patients will receive guidelines on how to use the TENS device at home and will over a period of 30 days self-administer TENS as needed. Patients is to fill out a predefined schedule on paper each day to monitor dose.
223807713|NCT06156722|PROCEDURE|Sperm selection by IMSI|Intracytoplasmic morphologically selected sperm injection (IMSI) is a sperm selection method used in intracytoplasmic sperm injection (ICSI)
223807714|NCT06156722|PROCEDURE|Sperm selection by IMSI and spermslow|Intracytoplasmic morphologically selected sperm injection (IMSI) is a sperm selection method used in intracytoplasmic sperm injection (ICSI) + spermslow
223807715|NCT03919786|PROCEDURE|topical local anesthesia of pulmonary vein combined with vagus nerve block|"Injecting 1% lidocaine 1.5ml+0.375% ropivacaine 1.5ml into vascular sheaths of all pulmonary vein of the surgery side at the beginning of surgery operation.~Wrapping all pulmonary vein of the surgery side with cotton sheet infiltrated with 1% lidocaine+0.375% ropivacaine at the end of surgery operation.~Blocking vagus nerve above the aortic vein on the right side of the trachea with 1% lidocaine 1ml+0.375% ropivacaine 1ml after exposing the pleural apex."
223807716|NCT03293576|BEHAVIORAL|Volitional Help Sheet|"This brief intervention will last around 20 minutes. The participants and the researcher will read through the list of real-life solutions the participants might find applicable to them. They will then read through the list of situations one by one. The participant will draw a coloured line between the situation and the solution which seems more appropriate to them. The volitional help sheet helps create implementation intentions, which are self-regulatory strategies taking the form of if-then plans (i.e. situation-solution plan)."
223807717|NCT05083325|DRUG|Oseltamivir 75mg Test Drug capsules|Investigational Medicinal Product
223807718|NCT05083325|DRUG|Oseltamivir 75mg capsules Reference Product capsules|Tamiflu (Roche Pharma (Switzerland) AG, Basel)
223807719|NCT04751201|BEHAVIORAL|Mindfulness open and circular program|"At the end of the first and the last cycle, as well as 3 weeks after the last cycle, the patient will be invited to answer different questionnaires evaluating his or her quality of life (HADS, QLQC30, FA12). This is why the observation period is 3 months (3 cycles of 3 weeks + 3 weeks).~Similarly, some of the patients included in the study will be asked to complete a semi-structured interview at the end of the MAEva programme.~Patients and nursing staff participating in the study will be asked to complete a satisfaction questionnaire"
223807720|NCT06384950|BEHAVIORAL|ChatGPT|Patients receive additional education using a GPT-3.5-based educational robot on top of the traditional education.
223807721|NCT06384950|BEHAVIORAL|patient education with traditional methods.|Patients receive standard traditional education procedures.
223807722|NCT03202043|OTHER|High dose vegetable juice|High dose (13 fl oz) vegetable juice
223807723|NCT03202043|OTHER|Medium dose vegetable juice|Medium dose (10 fl oz) vegetable juice
223807724|NCT03202043|OTHER|Low dose vegetable juice|Low dose (5.5 fl oz) vegetable juice
223807725|NCT03202043|OTHER|Control bottled water|Control (12 fl oz) bottled water
223807726|NCT01718327|DRUG|Sunitinib|sunitinib dose :37.5mg/day
223807727|NCT04866615|DIAGNOSTIC_TEST|Optvue OCT|Optical coherence tomography
224264369|NCT04165252|DIAGNOSTIC_TEST|Collection of vaginal, neonatal buccal and placental samples|Analysis of microbiome and mycobiota of vaginal, neonatal buccal and placental
224264370|NCT03129685|PROCEDURE|HALED|This is attained via a laparotomy involves isolation of the arterial blood supply of the tumor-containing liver lobe (the ipsilateral hepatic artery as well as the extrahepatic arterial collaterals) while preserving the feeding veins.
224264371|NCT03089983|DRUG|Methadone|Participants will receive daily or weekly doses of oral methadone.
224264372|NCT03089983|DRUG|Isoniazid|Participants will be randomized to receive standard INH as TB treatment in prison for 26 weeks.
224264373|NCT03089983|DRUG|Rifapentine|Participants will be randomized to receive short course INH + RIF as TB treatment in prison for 12 weeks.
223807728|NCT02953743|DRUG|Lenvatinib|Lenvatinib 4 mg capsules will be administered orally, once daily continuously 28-day cycles until disease progression, development of unacceptable toxicity or withdrawal of consent.
223807729|NCT04230057|DIETARY_SUPPLEMENT|Antitumor B|Single dose 2400 mg
223807730|NCT06427655|DEVICE|SALAD intubation|SALAD suction during intubation
223807731|NCT00948974|BEHAVIORAL|Cognitive Therapy|"Cognitive therapy (CT) highlights the identification and reappraisal of distorted or dysfunctional cognitions in the treatment of psychopathology. For example, socially anxious patients are taught to identify the thoughts and underlying beliefs that trigger strong emotional reactions (e.g., if I attempt to initiate a conversation I'll humiliate myself), and then replace these with more accurate, functional thoughts. There is a large body of research supporting the efficacy of CT for mood and anxiety disorders, and for social anxiety disorder in particular (Beck, 2005)."
223807732|NCT00948974|BEHAVIORAL|Acceptance and Commitment Therapy|ACT does not attempt to modify cognitions directly, but rather seeks to foster a mindful acceptance of whatever thoughts or feelings arise, while still pursuing specific behavioral goals. For example, the individual would be taught simply to notice the thoughts as if from a distance without attempting to modify them, and initiate a conversation. Like other newer mindfulness and acceptance-based models of CBT, ACT also expands the traditional focus on symptom reduction to include an emphasis on broader life goals. The scientific literature on ACT has expanded rapidly over the past ten years. Recent reviews conclude that it appears to be at least as effective as CT, and may work at least in part via distinct treatment mechanisms (Powers, Zum Vörde Sive Vörding, \& Emmelkamp, 2009).
223807733|NCT04069000|BEHAVIORAL|Mindfulness-based social-emotional learning program|Grade 3 teachers implement MindUP in their classrooms over the academic year. MindUP is a manualized program informed by cognitive-developmental neuroscience, contemplative science, positive psychology, and social-emotional learning. The curriculum consists of 15 sequential lessons taught in 10-15 minute chunks and cross-curricular extension activities. There are four lesson units: Getting Focused (introduction to brain structure and function, the core practice, and how focused awareness affects brains and feelings), Sharpening Your Senses (focus on internal experiences such as mindful smelling and tasting), It's All About Attitude (focus on cognitive experiences such as positive mindset, perspective-taking, and practicing gratitude), and Taking Action Mindfully (performing acts of kindness to others and building positive relationships). An essential component is the core practice, a focused breathing exercise and mindfulness practice that is implemented three times daily.
223807734|NCT04069000|BEHAVIORAL|Regular grade 3 program|Grade 3 teachers are expected to implement activities to achieve a number of pre-specified social-emotional learning outcomes that are identified by the Ministry of Education. Educators have leeway over how they achieve these curriculum expectations and they will report on a weekly basis regarding their implementation of social-emotional learning activities.
223807735|NCT03833297|DRUG|Drugs inducing hepatological toxicity|Drugs susceptible to induce hepatological toxicities
223807736|NCT01302470|PROCEDURE|Primary epicardial placement of left ventricular lead|Epicardial leads will be placed on the left ventricle in the area of the most dyssynchrony . the leads will be attached to a Medtronic Cardiac resynchronization/ AICD/ device
223807737|NCT01302470|PROCEDURE|Transvenous placement of left ventricular lead|Conventional placement of left ventricular leads performed in the electrophysiology department.
223807738|NCT03440931|DIAGNOSTIC_TEST|Ultrasound scan|Transvaginal ultrasound scan to assess ovaries
223807739|NCT02481544|BEHAVIORAL|Gratitude Journaling Plus SOC|
224264374|NCT04403347|DIETARY_SUPPLEMENT|Innovative Dietary Formulation (Patent ID: CN110250417A)|In addition to regular diets and usual care of hypertension, additional innovative natural dietary formulation derived from tartary buckwheat will be orally taken 3 times per day.
224264375|NCT04403347|DRUG|Losartan 50mg per day|In addition to regular diets and usual care of hypertension, antihypertensive medication will be orally taken (Losartan 50mg per day).
224264376|NCT06097819|OTHER|Mobile app-based game group|Mobile app based game therapy+Occupational therapy+Sensor-based game therapy
224264377|NCT06097819|OTHER|Supervised combined sensor-based game group|Occupational therapy+Sensor-based game therapy
224264378|NCT06097819|OTHER|Individualized occupational therapy group|Occupational therapy
224264379|NCT03125408|DIAGNOSTIC_TEST|HCV Assay|Molecular diagnostic test to detect Hepatitus C
224264380|NCT03158727|BIOLOGICAL|Cx611|Two intravenous infusions, one on day 1 and another one on day 3.
224264381|NCT03158727|OTHER|Placebo|Two intravenous infusions, one on day 1 and another one on day 3.
224264382|NCT00223457|BEHAVIORAL|Factors that influence compliance|
224264383|NCT00127985|DRUG|6-methyl-prednisolone|iv, 2 mg/kg/day, qid
224264384|NCT00985439|DRUG|Diclofenac Test (lower dose)|18-mg Single dose
224264385|NCT00985439|DRUG|Diclofenac Test (upper dose)|35-mg Single dose
224264386|NCT00985439|DRUG|Celecoxib 400 mg|Capsules 2 x 200 mg Single-dose
224264387|NCT00985439|DRUG|Placebo|Capsules 2 Single-dose
224264388|NCT00110604|BEHAVIORAL|folic acid (0.8 mg)|
224264389|NCT06469645|DRUG|Empagliflozin 10 MG|Participants allocated in the Intervention Group will be taking empagliflozin 10mg once a day on top of their regular medications.
224264390|NCT04879537|OTHER|Telemedical support|The nursing homes participating in the project will be equipped with telemedical equipment. This will allow teleconsultations to take place when needed. In addition, an early warning system will be introduced and, within the framework of the teleconsultation, a trained medical assistant can be sent to the care facility if necessary, who can carry out medical activities on site under a physician's delegated instructions. In addition, an electronic patient file will be introduced which can be accessed by the telemedicine physician and the general practitioner.
224264391|NCT01043952|DRUG|Propofol|Propofol is used as an anesthetic drug on all patients, with the dosing depending on patient age, weight, body mass index, general status, the hemodynamic and neurophysiological response to the previously administered dose and the degree of surgical stimulation, and in the Bispectral Index Monitor arm, depending on the BIS values.
224264392|NCT01043952|DRUG|Remifentanil|Remifentanil is used as analgesic drug, as a part of the total intravenous anaesthesia, on all patients, with the dosing depending on patient age, weight, body mass index, general status, the hemodynamic and neurophysiological response to the previously administered dose and the degree of surgical stimulation, and in the Bispectral Index Monitor arm, depending on the BIS values.
223807740|NCT02481544|BEHAVIORAL|Memorable Events Journaling Plus SOC|
223807741|NCT06580366|DRUG|Sennosid A+B|Bowel Preparation
223807742|NCT06580366|DRUG|Sodium Picosulfate/Magnesium Oxide/Citric Acid|Bowel Preparation
223807743|NCT06579352|BIOLOGICAL|Human Umbilical Cord Mesenchymal Stem Cells (UC-MSC)|Umbilical cord-derived mesenchymal stem cells administered intravenously.
223807744|NCT05408806|OTHER|Exercise Interventions|Rehabilitation methods and exercise practices to improve postural control in children with cerebral palsy. In addition to neurodevelopmental treatment, one group is treated with virtual reality games and the other group is treated with a hippotherapy simulator.
223807745|NCT04334473|PROCEDURE|phacoemulsification and Intraocular lens implantation|Standartd surgical procedure with small incision to remove catarct using ultrasound waves. it can be done by topica, local or general anaesthesia acoording to patients general fitness and preference.
223807746|NCT04334473|DIAGNOSTIC_TEST|Ultrasound Biomicrosopy (UBM)|A diagnostic test using ultrasound waves to evaluate the anterior chamber depth, angle and lens vault.
223807747|NCT05860127|BEHAVIORAL|Referral for Cognitive Stimulation Therapy|Physician will review participant eligibility for CST treatment and offer referral based on clinical judgement
223807748|NCT05860127|OTHER|No change to Standard of Care|Participants will not receive referral from a physician. They will continue with standard of care at their site.
223807749|NCT05347979|DRUG|Dabigatran Etexilate|Dabigatran will be administered orally as a 75 mg capsule on Day 1 and Day 12.
223807750|NCT05347979|DRUG|Relacorilant|Relacorilant will be administered orally as 4 X 100 mg capsules (400 mg) on Days 3 through 13.
223807751|NCT04667975|DRUG|CKD-702|In principle, based on 1 cycle of 28 days (4 weeks), administer CKD-702 Inj. once every 2 weeks over 4 weeks.
223807752|NCT02231177|DRUG|BI 1744 CL|
223807753|NCT02231177|DRUG|BI 1744 CL/Tiotropium FDC|
223807754|NCT02231177|DRUG|Tiotropium|
223807755|NCT02955472|DRUG|GLA5PR GLARS-NF3 tablet 150mg|A new formulation(3rd.) of Pregabalin CR tablet
223807756|NCT02955472|DRUG|GLA5PR GLARS-NF1 tablet 150mg|A new formulation(1st.) of Pregabalin CR tablet
223807757|NCT06274814|PROCEDURE|U/S guided Type 2 Pectoral Nerve Block|20 mL separates the pectoralis major and minor muscles, while 10 mL separates the serratus and pectoralis major muscles
223807758|NCT06274814|PROCEDURE|U/S guided RIB combined with the sub-serratus plane block (RISS)|he ipsilateral arm was abducted. RISS was performed. Using a 6-13 MHz linear ultrasound probe was placed medial to the medial border of the scapula in the oblique sagittal plane.. A 100-mm 21-gauge needle was inserted at the level of T5-6 in the ultrasound view. A single dose of 20-mL 0.25% bupivacaine was injected in the interfascial plane between the rhomboid major and intercostal muscles. The spread of the local anesthetic solution under the rhomboid muscle was visualized by ultrasonography. Thereafter, the ultrasound probe was moved caudally and laterally to identify the tissue plane between the serratus anterior and external intercostal muscles for the sub-serratus block at the T8-9 level. The needle was advanced from its previous position, and an additional 20 mL of 0.25% bupivacaine was injected.
223807759|NCT00087958|DRUG|XRP9881|
223807760|NCT04731779|DRUG|cannabidiol|Cannabidiol oral product formulated in MCT (medium chain triglyceride) oil
223807761|NCT04731779|DRUG|Placebo|Placebo oral product formulated in MCT (medium chain triglyceride) oil
223807762|NCT05718843|DRUG|BI 425809|BI 425809
223807763|NCT04995185|RADIATION|(18)F-fluoromisonidazole (FMISO)|Patients do not need to be fasted prior to intravenous injection of 370MBq ± 10% (18)F-fluoromisonidazole. Scanning will be performed two hours after the injection. Patients will be scanned with their thermoplastic shell used in routine radiotherapy treatment for 10 minutes, followed by approximately 5 minutes scan of the upper chest.
223807764|NCT02413060|OTHER|Resistance training|This training consists 4 exercises and every exercises lasts 5 seconds.
223807765|NCT02413060|BEHAVIORAL|Lifestyle counselling|Lifestyle counselling mainly indicates dietary instruction.
223807766|NCT00409682|BIOLOGICAL|Adalimumab|All subjects received an open-label adalimumab induction regimen. Subjects weighing greater than or equal to 40 kg at Baseline received 160 mg at Week 0 and 80 mg at Week 2. Subjects weighing less than 40 kg at Baseline received 80 mg at Week 0 and 40mg at Week 2.
223807767|NCT00409682|BIOLOGICAL|Adalimumab|Subjects randomized to the Low-Dose treatment group received either 20 mg adalimumab every other week (eow) (if Week 4 body weight \[BW\] was greater than or equal to 40 kg) or 10 mg adalimumab eow (if Week 4 BW less than 40 kg). Starting at the Week 12 study visit, subjects who experienced a disease flare or were non-responders could be switched from blinded eow dosing to blinded every week (ew) dosing, continuing with the same blinded dose. If a subject continued to experience a flare or met the definition of non-response following an 8-week course of double-blind (DB) ew therapy they could be switched to open-label ew therapy.
223807768|NCT00409682|BIOLOGICAL|Adalimumab|Subjects randomized to the High-Dose treatment group received either 40 mg adalimumab every other week (eow) (if Week 4 body weight \[BW\] was greater than or equal to 40 kg) or 20 mg adalimumab eow (if Week 4 BW less than 40 kg). Starting at the Week 12 study visit, subjects who experienced a disease flare or were non-responders could be switched from blinded eow dosing to blinded every week (ew) dosing, continuing with the same blinded dose. If a subject continued to experience a flare or met the definition of non-response following an 8-week course of double-blinded (DB) ew therapy they could be switched to open-label ew therapy.
223835413|NCT03020095|DRUG|Ritonavir|Ritonavir 100mg tablet administered orally twice daily
223835414|NCT03020095|DRUG|Ribavirin|Ribavirin(RBV)1000/1200 mg/day (bodyweight\<75/≥75 kg)administered orally
223807769|NCT05807659|DRUG|fractionated busulfan-based conditioning regimen|"Drug: Chidamide 30 mg oral twice weekly for 2 weeks Drug: Fludarabine 35 mg/m2 intravenously daily for 5 days in the 2nd week Drug: Cytarabine~1 g/m2 intravenously for 5 days in the 2nd week Drug: Busulfan 3.2 mg/kg intravenously daily for 2 days in the 1st week, 1.6 mg/kg intravenously daily for 4 days in the 2nd week Procedure/Surgery: allogeneic hematopoietic stem cell transplantation"
223807770|NCT01954355|DRUG|LDE225|400, 600 and 800 mg OD
223807771|NCT01954355|DRUG|Paclitaxel|80 mg/m2 (days 1, 8, 15)
223807772|NCT01361425|DRUG|methildopa|methildopa, 1,5g/day (500mg 8/8 hours, orally)
223807773|NCT01361425|DRUG|placebo|placebo 500mg 8/8h, orally
223807774|NCT03581084|DRUG|N-acetylcysteine|Research participants that meet the study inclusion criteria will be admitted to a medical-surgical ward in Moffitt-Long Hospital (UCSF Medical Center) for 6 days and 5 nights and treated with an inhaled mixture of NAC and albuterol four times per day spaced at 4 to 6 hours apart.
223807775|NCT00990717|BIOLOGICAL|NK-92 cells|"Cells are administered as an intravenous infusion over one hour on days 1, 3 and 5 of each cycle of treatment. Patients can receive up to 6 cycles, which are administered monthly. Cell dosage is as follows:~* Level I: 1x10\^9 cells/m\^2~* Level II: 3x10\^9 cells/m\^2~* Level III: 5x10\^9 cells/m\^2"
223807776|NCT00462215|BIOLOGICAL|Whole virion, Vero cell-derived influenza vaccine containing H5N1 HA antigen|Vaccination on Day 0 and Day 21 with the whole virion, Vero cell-derived influenza vaccine containing 7.5 µg H5N1 hemagglutinin (HA) antigen (without adjuvant) of the A/Vietnam/1203/2004 strain + 6-month booster vaccination with the H5N1 vaccine containing 3.75 mg HA antigen strain A/Vietnam/1203/2004
223807777|NCT00462215|BIOLOGICAL|Whole virion, Vero cell-derived influenza vaccine containing H5N1 HA antigen|Vaccination on Day 0 and Day 21 with the whole virion, Vero cell-derived influenza vaccine containing 7.5 µg H5N1 hemagglutinin (HA) antigen (without adjuvant) of the A/Vietnam/1203/2004 strain + 6-month booster vaccination with the H5N1 vaccine containing 7.5 mg HA antigen strain A/Vietnam/1203/2004
223807778|NCT00462215|BIOLOGICAL|Whole virion, Vero cell-derived influenza vaccine containing H5N1 HA antigen|Vaccination on Day 0 and Day 21 with the whole virion, Vero cell-derived influenza vaccine containing 7.5 µg H5N1 hemagglutinin (HA) antigen (without adjuvant) of the A/Vietnam/1203/2004 strain + 6-month booster vaccination with the H5N1 vaccine containing 3.75 mg HA antigen strain A/Indonesia/05/2005
223807779|NCT00462215|BIOLOGICAL|Whole virion, Vero cell-derived influenza vaccine containing H5N1 HA antigen|Vaccination on Day 0 and Day 21 with the whole virion, Vero cell-derived influenza vaccine containing 7.5 µg H5N1 hemagglutinin (HA) antigen (without adjuvant) of the A/Vietnam/1203/2004 strain + 6-month booster vaccination with the H5N1 vaccine containing 7.5 mg HA antigen strain A/Indonesia/05/2005
223807780|NCT00462215|BIOLOGICAL|Whole virion, Vero cell-derived influenza vaccine containing H5N1 HA antigen|Vaccination on Day 0 and Day 21 with the whole virion, Vero cell-derived influenza vaccine containing 7.5 µg H5N1 hemagglutinin (HA) antigen (without adjuvant) of the A/Vietnam/1203/2004 strain + 12-month booster vaccination with the H5N1 vaccine containing 3.75 mg HA antigen of the A/Indonesia/05/2005 strain
223807781|NCT00462215|BIOLOGICAL|Whole virion, Vero cell-derived influenza vaccine containing H5N1 HA antigen|Vaccination on Day 0 and Day 21 with the whole virion, Vero cell-derived influenza vaccine containing 7.5 µg H5N1 hemagglutinin (HA) antigen (without adjuvant) of the A/Vietnam/1203/2004 strain + 24-month booster vaccination with the H5N1 vaccine containing 3.75 mg HA antigen of the A/Indonesia/05/2005 strain
223807782|NCT06379191|BEHAVIORAL|Nutrition intervention model based on WeChat applets|"We recorded the full nutritional management plan for ovarian cancer chemotherapy patients obtained through evidence-based in the previous period into the applet developed by our team - Good Nutrition. At the first chemotherapy admission assessment, patients were instructed to search for the applet on WeChat and add it to My applet. The patient was introduced to the main functional sections of the applet and the content settings for each section. The patient was instructed to turn on the applet notification permission and set it to receive new content alerts. Patients were invited to join our nutrition management group chat. They were informed that throughout the intervention phase, we would be sending evidence-based scientific articles to the group chat for independent study, and that they were allowed to ask questions, share personal experiences, and discuss lifestyles within the group."
223807783|NCT03475082|DEVICE|Transcutaneous Electrical Nerve Stimulation|Transcutaneous electrical nerve stimulation (TENS) is utilized clinically by a variety of health care professionals for the reduction of pain. The mechanisms by which TENS produces analgesia or reduces pain are only recently being elucidated. TENS is a non-invasive modality that is inexpensive, safe and easy to use with relatively few contraindications. Frequency of stimulation is broadly classified as high frequency (\>50Hz), low frequency (\<10Hz) TENS. Intensity is determined by the response of the patient as either sensory level (low-intensity) TENS strong but comfortable. With sensory level TENS, the voltage (i.e. amplitude) is increased only until the patient feels a comfortable tingling (perceived with high frequency) or tapping (perceived with low frequency) sensation without motor contraction. With strong but comfortable TENS the intensity is increased to a strong but comfortable level which may include muscle contraction.
223807784|NCT03358056|BEHAVIORAL|Mindfulness-Based Cognitive Therapy|Mindfulness-based cognitive therapy (MBCT) is a manualized, 8 weeks-group-based training derived from mindfulness-based stress reduction (MBSR) and cognitive-behavioral therapy (CBT). In MBCT participants are trained in how to be more aware of their bodily sensations, thoughts and feelings associated with negative emotional states. Mindfulness exercises and cognitive-behavioral skills are practiced both during the sessions and through homework assignments. The program is structured in 2.30 h group sessions over 8 consecutive weeks.
223807785|NCT00041782|DRUG|Dalteparin (Fragmin)|200 IU/kg subcutaneously daily (based on actual body weight with a maximum dose of 18,000 IU).
223807786|NCT03375281|PROCEDURE|RFA|thermal ablation using radiofrequency for HCC
223807787|NCT05711537|DEVICE|Auricular Acupressure with Vaccaria 600t ear seeds|Auricular Acupressure utilizing vaccaria 600 t ear seeds applied to 5 designated sites to each ear. Both ears will have seeds applied. Participants will be asked if they consent to having their intervention session photographed and audio recorded in collaboration with the BAA press training and intervention fidelity study.
223807788|NCT01087268|OTHER|questionnaire administration|
223807789|NCT01087268|PROCEDURE|gastrointestinal complications management/prevention|
223807790|NCT01087268|PROCEDURE|quality-of-life assessment|
223807791|NCT01896869|DRUG|Ipilimumab|3 mg/kg administered IV (10mg/kg if treatment started prior to protocol v 6.3)
223807792|NCT01896869|BIOLOGICAL|Vaccine|5x10\^8 cells administered in 6 intradermal injections
223807793|NCT01896869|DRUG|FOLFIRINOX|Standard of care FOLFIRINOX may be modified according to the patient's known tolerability. Acceptable modified options could include 5-FU alone, capecitabine, FOLFOX, FOLFIRI, or FOLFIRINOX on a 21 day cycle.
223807794|NCT05461703|BEHAVIORAL|Planet Nutrition Program|It is a 6-month school-based obesity prevention program that includes: nutrition education sessions, physical activity and family participation.
223807795|NCT02367755|DRUG|Propofol|Propofol use during therapeutic hypothermia
223807796|NCT02367755|DRUG|Lorazepam|Lorazepam use during therapeutic hypothermia
223807797|NCT04670692|OTHER|5G-MCE examination|The endoscopist (W.Z.) manipulated the two joysticks on the remote console (based in Shanghai). Then the remote control software and remote connection software takes the endoscopist's input and translates it into a control signal. After network transmission, the patient side cart (based in Yinchuan) translates the control signal into actual instrument manipulation and mobilize the robotic magnetic arm, and simultaneously driving the precise movement and rotation of the capsule to perform the gastric and duodenum examination. Meanwhile, the images captured by the capsule are simultaneously sent back to the screen of the remote console, and thus provide guidance for better control of the capsule.
223807798|NCT04670692|OTHER|MCE examination|The endoscopist (W.Z.) performs the MCE examination procedure conventionally. And communicate with the volunteer face to face in the same examination room.
223807799|NCT02260453|OTHER|Preoperative coronary angiography|If coronary disease is detected percutaneous intervention (PCI) or coronary artery bypass grafting (CABG) is applied
223807800|NCT02260453|OTHER|Standard cardiac workup|EKG, transthoracic cardiac echocardiogram
223807801|NCT01919203|DRUG|Remifentanil|The starting dose of remifentanil is 0.5μg/kg and a step size is 0.05μg/kg. If LMA insertion is successful or failed in previous patient, an decrement or increment of 0.05μg/kg remifentanil is injected to next patient, respectively.
223807802|NCT03058341|DRUG|propofol|Monitoring and other anaesthetic procedures including the management of hypertension and hypotension will be the same as group S. The only difference is that induction and maintenance of general anaesthesia will be conducted using total intravenous infusion of propofol. Sevoflurane will not be used, and oxygen and air would be given to provide a FiO2 of 30-50%.
223807803|NCT03058341|DRUG|Sevoflurane|Propofol 1.5-3mg/kg, remifentanil 0.5-1mcg/kg, and rocuronium 0.6-1mg/kg or atracurium 0.5mg/kg will be used intravenously (IV) for induction of general anaesthesia. Otrivin can be applied nasally at the discretion of the anaesthetist. Intubation would be performed after induction of general anaesthesia. General anaesthesia monitoring will be used. Sevoflurane, air and oxygen will be used for maintenance of general anaesthesia. FiO2 will be kept between 35-50%. BIS monitoring will be applied and level of anaesthetia will be titrated to keep a BIS value of 40-60. Intravenous remifentanil infusion between 0.1-0.25mcg/kg/min will be given and this will be titrated to optimal haemodynamic parameters. Muscle relaxants can be given during the operation as required.
223807804|NCT05291780|RADIATION|Stereotactic Ablative Radiotherapy in Unresectable Locally Advanced Non-Small Cell Lung Cancer|"The prescribed dose of stereotactic ablative radiotherapy (SABR) will be of at least 35-40 Gy in 5 fractions. The dose of SABR will be increased, case by case, respecting the maximum tolerance dose of the healthy structures.~Participants will SABR once a day for 5 days, Monday through Friday (around 1 week)."
223807805|NCT02221167|OTHER|Donor Milk|"breastfeeding plus 10 ml of donor milk by syringe after each breastfeeding until mother's milk comes in."
223807806|NCT01287130|DRUG|Cetuximab|Day 1 administer cetuximab 400 mg/m2 IV loading dose over 120 minutes. On days 8, 15 and 22 administer cetuximab 250 mg/m2 IV loading dose over 60 minutes
223807807|NCT01287130|DRUG|AZD6244|Given orally once or twice a day depending on dose level.On days 1, 8, 15 and 22. Repeat every 28 days
223807808|NCT00232830|DEVICE|drug-eluting stent|Cypher Sirolimus-eluting Coronary Stent
223807809|NCT00232830|DEVICE|bare-metal stent|any bare-metal stent brand
223807810|NCT01304030|BEHAVIORAL|Empathy Training Modules|The Empathy Training Modules utilize translational research in emotion expression basic science, physiology of emotions, decoding facial expressions and self-regulation skills as pertaining to management of medical and surgical patients.
223807811|NCT01304030|BEHAVIORAL|Residency Training as usual|Residents will receive their typical didactic and clinical education
223807812|NCT04235335|BEHAVIORAL|Indigenous Mother's Empowerment Program & Indigenous Kid's Club Program|Weekly groups administered to mothers and children simultaneously but separately for 10 weeks
223807813|NCT06437379|BEHAVIORAL|Infection control|To evaluate the effect of implementing teaching protocol on nurse's knowledge and practice regarding infection control measures for patients undergoing Percutaneous Nephrolithotomy.
223807814|NCT00286117|DRUG|Anastrozole|oral
223807815|NCT00286117|DRUG|Tamoxifen|oral
223807816|NCT05135416|PROCEDURE|chewing gum Group|control of consciousness chewing gum listening to bowel sounds assessment of pain
223807817|NCT05135416|PROCEDURE|Control group|control of consciousness listening to bowel sounds assessment of pain
223807818|NCT01387555|BIOLOGICAL|JX-594 recombinant vaccina GM-CSF|Patients will be randomised 2:1 to Arm A or Arm B and will receive 6 treatments on days 1, 8, 22, week 6, week 12, and week 18 plus best supportive care as needed.
223807819|NCT01387555|OTHER|Best Supportive Care|Patients will be randomised 2:1 to Arm A or Arm B and will receive best supportive care as needed.
223807820|NCT04857203|DIAGNOSTIC_TEST|Vitamin D|Vitamin D levels will be measured for the patients undergoing neoadjuvant therapy in patients with locally advanced rectal cancer
223807821|NCT01691833|DIETARY_SUPPLEMENT|Vitamin D|Patients that are Vitamin D deficient and randomized to the treatment group will receive a 10,000 IU dose of Vitamin D.
223807822|NCT01691833|DIETARY_SUPPLEMENT|Placebo|Patients that are Vitamin D deficient maybe randomized to the placebo group D.
223807823|NCT06089356|DRUG|zolmitriptanee|zolmitriptane tablet daily
223807824|NCT06089356|DRUG|topiramate|topiramate once daily
223807825|NCT06089356|DRUG|Valproate|valproate once daily
223835415|NCT04033991|DRUG|Sunitinib|Tyrosine kinase inhibitor, licensed for use in treatment of renal cell carcinoma.
223807826|NCT03496519|DRUG|Dose Escalation of Durvalumab and Trabectedin|"There will be a fixed dosage of Durvalumab, 1125mg, given intravenously over 60 minutes on Day 2 every 21 days. There will be an increase in Trabectedin for each cohort, given through intravenous infusion over a 24 hour period on Day 1 every 21 days as an outpatient.~* Cohort -1: Durvalumab 1125mg with Trabectedin 0.5mg/m2~* Cohort 1: Durvalumab 1125mg with Trabectedin 0.75mg/m2~* Cohort 2: Durvalumab 1125mg with Trabectedin 1.0mg/m2~* Cohort 3: Durvalumab 1125mg with Trabectedin 1.2mg/m2~* Cohort 4: Durvalumab 1125mg with Trabectedin 1.5mg/m2"
223807827|NCT03496519|DRUG|Dose Expansion of Durvalumab and Trabectedin|There will be a fixed dosage of Durvalumab, 1125mg, given intravenously over 60 minutes on Day 2 every 21 days. There will be a fixed dosage of Trabectedin for each cohort, whatever was determined to be the safest dose during the Dose Escalation Phase, and it will be given through intravenous infusion over a 24 hour period on Day 1 every 21 days as an outpatient.
223807828|NCT02826200|DRUG|Acenocoumarol|Standard of care plus oral anticoagulant therapy (acenocoumarol)
223807829|NCT02826200|OTHER|Standard of care|Standard of care
223807830|NCT01080222|DRUG|telaprevir|tablet, 1125-mg, twice daily
223807831|NCT01080222|DRUG|VX-222|capsule, 100-mg, twice daily
223807832|NCT01080222|DRUG|ribavirin|tablet, 1000-mg for subjects weighing \<75-kg or 1200-mg for subjects weighing ≥75-kg, twice daily
223807833|NCT01080222|BIOLOGICAL|peginterferon-alfa-2a|subcutaneous injection, 180-mcg, once weekly
223807834|NCT01080222|DRUG|VX-222|capsule, 400-mg, twice daily
223807835|NCT03019874|DIETARY_SUPPLEMENT|Cranberry Extract|3 x Cystorenal Cranberry plus daily for 6 months (contains 300 mg Cranberry-Extract, 100 mg Pumpkin seeds-Extract, 20 mg Vitamin C und 0,47 mg Riboflavin)
223807836|NCT03462615|DIAGNOSTIC_TEST|HS-RDT|A single finger-prick blood sample will be collected and used to test participants with the HS-RDT. The results of the results of the test will not be used for treatment purposes nor used to inform patient care.
223807837|NCT04951674|OTHER|High fiber diet|30 grams of fiber per day
223807838|NCT04951674|OTHER|Control diet|No diet education and change in diet
223807839|NCT03956290|BEHAVIORAL|TREAT pilot intervention|Participants will be asked to use the app and take pictures of everything they eat and drink, from the time they get up to the time they go to bed, regardless of size of meal/snacks/drink, for 2 weeks. This will generate data on their eating pattern and eating duration. Participants will be reminded through app, call or text by study staff based on personalized eating schedule. The sleep schedule will also be recorded.
223807840|NCT02365675|DEVICE|Cotton gauze with petrolatum|
223807841|NCT02365675|DEVICE|Cellulose acetate with petrolatum|
223807842|NCT02365675|DEVICE|Nanocrystalline silver (Acticoat)|
223807843|NCT02365675|DEVICE|Carboxymethylcellulose with ionic silver (Aquacel Ag)|
223807844|NCT01450748|DRUG|Sodium alginate|oral suspension, 50 mg/ml, 20 ml three times daily, 8 weeks
223807845|NCT01450748|DRUG|Placebo|matching placebo oral suspension, 50 mg/ml, 20 ml three times daily, 8 weeks
223807846|NCT03865966|OTHER||No intervention
223807847|NCT00430053|GENETIC|gene rearrangement analysis|
223807848|NCT00430053|GENETIC|polymerase chain reaction|
223807849|NCT00430053|GENETIC|proteomic profiling|
223807850|NCT00430053|OTHER|flow cytometry|
223807851|NCT00430053|OTHER|immunohistochemistry staining method|
223807852|NCT00430053|PROCEDURE|biopsy|
223807853|NCT02958592|OTHER|two-dimensional shear-wave elastography (SWE)|performa two-dimensional shear-wave elastography (SWE) for staging hepatic fibrosis in the background liver parenchyma in patients with liver tumors before hepatic resection
223807854|NCT00314314|DRUG|Intranasal Insulin|Intranasal spray; 40 IU qid; 8 weeks
223807855|NCT00314314|DRUG|Diluent|Intranasal spray; 8 weeks
223807856|NCT00846105|OTHER|Rapid MRSA PCR test for screening carriers|In the rapid test intervention arm, all patients admitted to study wards will be sampled within 24 h after admission. To ensure comparison of like with like, sample taking will include: (1) a swab from the anterior nares for PCR testing according to the test manufacturer's instructions; (2) the swab of anterior nares, and swabs from throat, perineum and of any wounds, bladder catheter or intravenous catheter exit site will be processed by conventional testing.
223807857|NCT02826122|DEVICE|Pai APP|Prescription: Target 100 PAI Points per week
223807858|NCT02826122|DEVICE|FitBit APP|Prescription: Target daily 10.000 steps
223807859|NCT02428322|DIETARY_SUPPLEMENT|Placebo|Soft gel capsules will be identical to the vitamin D intervention but contain no vitamin D.
223807860|NCT02428322|DIETARY_SUPPLEMENT|VItamin D3|Soft gel capsules will contain 2,000IU vitamin D.
223807861|NCT00779389|DRUG|Erlotinib|Erlotinib 150mg will be taken once a day for 14-21days.
223807862|NCT00779389|DRUG|Dasatinib + Placebo|Dasatinib (100 mg) once a day for 14-21 days.
223807863|NCT00779389|DRUG|Erlotinib plus Dasatinib|Erlotinib (150 mg PO qD) plus Dasatinib (100 mg PO qD) 14-21 days
223807864|NCT00779389|DRUG|Placebo|Placebo for 14-21 days.
223807865|NCT00779389|DRUG|Erlotinib|Erlotinib 150 mg for 14-21 days.
223807866|NCT00146250|DRUG|Nitrous oxide|Substitution of Nitrous oxide for Nitrogen as balance gas in inspired gas mixture
223807867|NCT00024492|DRUG|Liposome Encapsulated Mitoxantrone (LEM)|
223807868|NCT00801801|DRUG|Docetaxel + Sorafenib|Subjects will be treated with metronomic chemotherapy with low dose docetaxel weekly for 3 out of 4 weeks, and sorafenib will be administered continuously 400 mg bid on a 28 day cycle. Treatment with metronomic chemotherapy will be expressed as a 4-week cycle. Tumor response to treatment will be evaluated after every 8 weeks. Treatment with metronomic chemotherapy and sorafenib will continue for a total of 6 cycles unless there is evidence of disease progression, intolerable toxicity, or withdrawal of consent. Maintenance therapy with sorafenib will then continue until disease progression, intolerable toxicity or withdrawal of consent.
223807869|NCT00118716|DRUG|Fluticasone propionate/salmeterol|Fluticasone propionate/salmeterol
223807870|NCT00118716|DRUG|Fluticasone Propionate|Fluticasone Propionate
223807871|NCT04436666|DEVICE|motivational video production through virtual reality glasses|Music-funded, park, nature and seaside walks, submarine, museum, with virtual reality glasses (Bobo VR Z4 Binocular Glasses and 5.7 inch 1440x2560 pixel display resolution, China) for 10 minutes to diabetic patients before blood glucose measurement and insulin injection The videos that the patient wants to watch will be watched from videos such as his trip Studies have indicated that these videos are relaxing environments, and motion videos should not be watched to reduce nausea and vomiting.
223807872|NCT04436666|OTHER|Ice Application|Before the blood glucose measurement and insulin injection, patients with diabetes will be given ice for 5 minutes. It is planned to apply ice cubes in liquid-proof ice bags.
223807873|NCT05725252|DRUG|NVP-2203|NVP-2203(Combination of NVP-2203-R1 and NVP-2203-R2)
223807874|NCT05725252|DRUG|NVP-2203-R|administration of active comparator
223807875|NCT01410955|DIETARY_SUPPLEMENT|Probiotic formula|Probiotic formula Colon DophilusTM , will be administered at a dose of 3x1 cps per day orally for 12 weeks. In the first cycle the starting dose is 3x1 cps per day. In other cycles the starting dose is 3x1 cps per day, or the dose according to dose adjustments from the previous treatment cycle.
223807876|NCT01410955|DIETARY_SUPPLEMENT|Placebo|Placebo capsules will be administered at a dose of 3x1 cps per day orally for 12 weeks. In the first cycle the starting dose is 3x1 cps per day. In other cycles the starting dose is 3x1 cps per day, or the dose according to dose adjustments from the previous treatment cycle.
223807877|NCT02708979|OTHER|University exam-period|This visit takes place one week prior to an exam at the university assuming that students will be stressed in this period.
223807878|NCT02708979|OTHER|University non-exam-period|This visit takes place several weeks post and prior to an exam at the university assuming that students will not be stressed in this period.
223807879|NCT00454571|DRUG|pazopanib hydrochloride|Given PO
223807880|NCT00454571|DRUG|leuprolide acetate|
223807881|NCT00454571|DRUG|goserelin acetate|
223807882|NCT01273025|DIETARY_SUPPLEMENT|Lime powder regime|1 sachet of lime powder regimen with 200 ml of water
223807883|NCT01398670|BIOLOGICAL|Insulin Lispro|"a. Lispro and Lispro Mix® 75/25 / Lispro Mix 50/50~The drugs would be administered subcutaneously"
223807884|NCT01398670|BIOLOGICAL|Insulin Lispro|"Humalog® and Humalog® Mix75/25 /Humalog® Mix 50/50~The drugs would be administered subcutaneously"
223807885|NCT03431402|DRUG|Hyperbaric oxygen|\- HBOT group will receive 10 sessions of HBOT at 2.0 Atmosphere absolute (ATA) for one hour in a hyperbaric chamber pressured with compressed air, whereby patients will breath 100% oxygen to 2 ATA started within 3-5days after the onset of stoke plus conventional therapy as antiplatelets therapy, correction of hypovolaemia , hypoxia and adequate nutrition
223807886|NCT02436811|BEHAVIORAL|Written form instruction|60 women aged between 12 and 50 and gestational period of up to 32nd weeks. Participants in writing intervention will receive a brochure containing information on diet and oral health. This leaflet was produced in accordance with the recommendations of the Ministry of Health regarding eating habits for children under two years (BRAZIL, 2002) and according to the Health Book of the Child: Growth and Development (BRAZIL, 2012).
223807887|NCT02436811|BEHAVIORAL|Standardized oral instruction|60 women aged between 12 and 50 and gestational period of up to 32nd weeks. A trained individual will present the same information arranged in the educational brochure in the intervention group on standardized oral form. This examiner will be trained in a unified way in relation to the instructions available in the form of written guidance. Thus, the only difference between the two measures is the interaction between the participant and researcher orally.
223807888|NCT02436811|BEHAVIORAL|Control|60 women aged between 12 and 50 and gestational period until 32nd weeks.The control group will receive a leaflet on oral cancer.
223807889|NCT02471092|OTHER|Skim milk products|Milk treatments will be served with 58g of breakfast cereal.
223807890|NCT04150991|OTHER|Fiber intervention|Each subject will supplement his/her normal dietary intake with 35 grams of dietary fiber daily for three consecutive weeks.
223807891|NCT04150991|OTHER|Placebo treatment|Each subject will supplement his/her normal dietary intake with an 18.53-g maltodextrin placebo daily for three consecutive weeks.
223807892|NCT03389152|DEVICE|Elastography|liver stiffness measurements by shear wave-based elastography
223807893|NCT05939921|DRUG|Metformin|T2DM patients will be provided with metformin in a specified dose
223835416|NCT04033991|DRUG|Axitinib|Tyrosine kinase inhibitor, licensed for use in treatment of renal cell carcinoma.
223807894|NCT04770064|DRUG|High-dose/short-duration Fisetin|Fisetin is a plant flavanol senolytic found in strawberries, persimmons, and cucumbers. It has senolytic properties that may provide therapeutic benefit for those with knee osteoarthritis. Participants will be asked to take approximately 20 mg/kg of body mass for 2 consecutive days, followed by a 28-day washout period, and then another 2-day administration.
223807895|NCT04770064|DRUG|Low-dose/sustained-duration Fisetin|Fisetin is a plant flavanol senolytic found in strawberries, persimmons, and cucumbers. It has senolytic properties that may provide therapeutic benefit for those with knee osteoarthritis. Participants will be asked to take one, 100 mg capsule of fisetin daily for 90 days.
223807896|NCT04770064|OTHER|Oral placebo capsule|Participants will be asked to take one, 100 mg oral placebo capsule (corn starch) daily for 90 days.
223807897|NCT04336748|DRUG|Hydroxychloroquine|low dose (200mg) Hydroxychloroquine once daily for 4 weeks
223807898|NCT04336748|DRUG|Placebo|Placebo
223807899|NCT06320886|DIAGNOSTIC_TEST|Diagnostic Test|Use both ultrasonography and Computed tomography scan to diagnose the causes of Acute Abdominal Pain in Adults.
223807900|NCT00816465|DIETARY_SUPPLEMENT|Hoodia gordonii|PO administration of 1 Tab Hoodia gordoni extract per day.
223807901|NCT00816465|OTHER|Placebo|PO Placebo pill
223807902|NCT00218881|PROCEDURE|HIV educational video|
223807903|NCT00983632|PROCEDURE|Selective vagus nerve stimulation|"Stimulus will be combination of quasi-trapezoidal cathodic and rectangular anodic current pulses. Precisely, the resulting current, biphasic and charge balanced combination will be composed of a quasi-trapezoidal cathodic phase with a square leading edge with different intensity ic , a plateau tc of 300 μs, and exponentially decaying phase texp of 500 μs, followed by a wide rectangular anodic phase ta of allow current magnitude ia. Anodic phase ia will be one-tenth of the magnitude in the cathodic phase. However, the width of the anodic phase ta will be dependent upon the charge injected in the cathodic phase: the greater the charge, the wider the anodic phase.~For details see detailed study description"
223807904|NCT00983632|DEVICE|selective vagus nerve stimulation|electrical vagus stimulation
223807905|NCT05691257|DRUG|Roxadustat|"The initial dose of roxadustat was given according to body weight, which was more than 60kg: 100mg (three times a week); Weight less than 60kg: 70mg (three times a week); 2 weeks later, the corresponding indexes were rechecked and medication was adjusted according to hemoglobin. The target is hemoglobin 100-120g/L.~Reference for medication Method: The use of roxadustat is the same as the RCT study of roxadustat in the treatment of anemia and the drug instructions of roxadustat published by N Engl J Med in 2019."
223807906|NCT05691257|DRUG|Recombinant human eythropoietin and/or Iron agents|Other drugs to treat anemia include: Recombinant human eythropoietin (RH-EPO), iron agents (ferrous succinate, polysaccharide iron complex, iron sucrose, etc.)
223807907|NCT01201811|DRUG|Azacitidine|Subjects will receive azacitidine 75 mg/m2/day SC for 7 days every 28 days for up to 6 cycles, unless they are discontinued from the treatment. In addition, subjects may receive best supportive care as needed, including antibiotics and transfusions, per Investigator discretion.
223807908|NCT01092403|DRUG|ASM-024|ASM-024 50 mg of ASM-024 or 200 mg once daily by inhalation
223807909|NCT01092403|DRUG|Placebo|Placebo once daily by inhalation
223807910|NCT01089374|RADIATION|Partial breast radiation after lumpectomy|Radiation therapy will be administered in the vicinity of the center where the surgical resection was performed. Adjuvant radiation must start within 12 weeks of breast excision or re-excision. The radiation oncologist can choose between two methods of partial breast irradiation (PBI): external beam partial breast radiation or Mammosite® brachytherapy, based on radiation oncologist and patient preference. Radiation will be administered per guidelines used in the NSABP B-39/RTOG 0413 protocol.
223807911|NCT02657317|BEHAVIORAL|FORT-A|FORT-A is based on a functional restoration paradigm of pain management in which treatment is interdisciplinary and designed to achieve a functional goal (often specified by the patient; e.g., doing more with family, returning to work). FORT-A includes intensive functional rehabilitation, group-based pain management intervention, and individual interventions tailored to the patient's specific needs (e.g., biofeedback for stress, individual psychotherapy for mood or trauma symptoms).
223807912|NCT02657317|OTHER|VA Treatment as Usual|VA TAU includes referrals for specialty intervention, rehabilitation, and behavioral health intervention within the VA medical system. Some participants may be referred for care outside of the VA system. The South Texas Veterans Health Care System offers a wide range of pain management services.
223807913|NCT00311038|DRUG|ONO-1101|
223807914|NCT02856113|DRUG|Alogliptin Benzoate|Alogliptin benzoate tablets.
223807915|NCT02856113|DRUG|Placebo|Alogliptin placebo-matching tablets.
223807916|NCT04367038|OTHER|Warm Acupressure, Cold Acupressure , Conventional Acupressure|Acupressure is non-invasive, safe and effective.
223807917|NCT06579495|OTHER|Peer involvement in Two player mode(peer involvement) in Competitive Exergame play|Device: Nintendo Wii sports competitive versus. The duration of the study was 8 weeks and the frequency was 45 minutes, three times per week. In the first two weeks, three games of bowling, tennis and fencing will be selected for experimentation at the beginner and intermediate levels respectively. In the three weeks from week 3 to week 5, golf, tennis and cycling were selected for the beginner, intermediate and advanced levels of the experiment. In the last three weeks, basketball, boxing and dancing will be selected for experimentation at beginner, intermediate and advanced levels respectively. The control group did not participate in any intervention and maintained daily physical activity behavior.
223835417|NCT00134524|PROCEDURE|MME procedure|
223835418|NCT02410161|DIETARY_SUPPLEMENT|alpha-linolenic acid-rich supplement|each participant consumed one 1000 mg capsule of flaxseed oil four times per day for 4 weeks, providing a total of 2 g/d of ALA. The capsules used were a commercially available flaxseed oil supplement containing ALA at 56% of total fatty acids (Jamieson, Toronto, ON, Canada). The other main fatty acids present in flaxseed oil include linoleic acid (18%), oleic acid (16%), palmitic and stearic acid (10% combined).
223807918|NCT06579495|OTHER|Single player mode in Competitive Exergame play|Device: Nintendo Wii sports competitive versus. The duration of the study was 8 weeks and the frequency was 45 minutes, three times per week. In the first two weeks, three games of bowling, tennis and fencing will be selected for experimentation at the beginner and intermediate levels respectively. In the three weeks from week 3 to week 5, golf, tennis and cycling were selected for the beginner, intermediate and advanced levels of the experiment. In the last three weeks, basketball, boxing and dancing will be selected for experimentation at beginner, intermediate and advanced levels respectively. The control group did not participate in any intervention and maintained daily physical activity behavior.
223807919|NCT06579495|OTHER|Children did not engage in any Competitive Exergame play|Device: Nintendo Wii sports competitive versus. The duration of the study was 8 weeks and the frequency was 45 minutes, three times per week. In the first two weeks, three games of bowling, tennis and fencing will be selected for experimentation at the beginner and intermediate levels respectively. In the three weeks from week 3 to week 5, golf, tennis and cycling were selected for the beginner, intermediate and advanced levels of the experiment. In the last three weeks, basketball, boxing and dancing will be selected for experimentation at beginner, intermediate and advanced levels respectively. The control group did not participate in any intervention and maintained daily physical activity behavior.
223807920|NCT03494166|BEHAVIORAL|Start with SMSH+TIPC|See arm/group descriptions
223807921|NCT03494166|BEHAVIORAL|Start with SMSH alone|See arm/group descriptions
223807922|NCT01694732|DRUG|Varenicline|
223807923|NCT01694732|DRUG|placebo|
223807924|NCT03376815|DIAGNOSTIC_TEST|landscape sample method|200 cases of different tumor tissues will be compared by traditional sample method and landscape sample method to testify the clinical value and significance of tumor landscape pathological diagnosis .
223807925|NCT01645748|DRUG|S-1|S-1 is an oral fluoropyrimidine derivative, based on the concept of biochemical modulation. It consists in a molar ratio of 1:0.4:1: tegafur, a prodrug that is slowly metabolized to 5-fluorouracil; gimeracil, which reversibly inhibits dihydropyrimidine dehydrogenase. In patients with advanced gastric cancer, phase I study of S-1, docetaxel and cisplatin combination chemotherapy was reported and the recommended doses were 40mg/m2 bid (D1-D14), 60mg/m2 (D1) and 60mg/m2 (D1), respectively.
223835419|NCT01470378|PROCEDURE|Thigh Surgery|Circumferential thigh surgery post bariatric surgery
223807926|NCT01645748|DRUG|S-1|Chemotherapy was comprised of docetaxel 30 mg/m2 on days 1 and 8, cisplatin 60 mg/m2 on day 1, and S-1 70 mg/m2 on days 1 to 14, with the regimen repeated every 21 days
223807927|NCT01645748|DRUG|S-1|In patients with advanced gastric cancer, phase I study of S-1, docetaxel and cisplatin combination chemotherapy was reported and the recommended doses were 40mg/m2 bid (D1-D14), 60mg/m2 (D1) and 60mg/m2 (D1), respectively. Another phase II study of TPS as induction chemotherapy for locally advanced HNSCC was determined to be 70/70/60 mg∙m2/d every 3 weeks. However, the rate of grade 3-4 neutropenia was 75% at this recommended dose. To reduce the hematologic toxicities, we used the docetaxel weekly. Therefore following regimen was evaluated in this study; docetaxel 30 mg/m2 (D1, D8), cisplatin 60mg/m2 (D1), S-1 70mg/m2 (D1-D14) every 3 weeks.
223807928|NCT02857426|DRUG|Nivolumab|
223807929|NCT03782311|BEHAVIORAL|motivation and and oral hygiene instructions|Motivation and oral hygiene instructions were received OHSE-high and OHSE-low groups. After showing the modified-Bass tooth brushing technique and interdental cleaning on the model, patients were followed up while brushing and flossing their teeth to correct misapplications. It was advised to brush teeth twice a day and use the interdental cleaning devices once a day.
223807930|NCT01733108|DRUG|Glyburide|One 1.25 mg tablet taken orally (by mouth) on Day 1 and Day 9.
223807931|NCT01733108|DRUG|Canagliflozin (JNJ-28431754)|One 200 mg tablet taken orally (by mouth) on Days 4 through 9.
223807932|NCT01155154|DRUG|cephalexin|500 mg (two 250 mg capsules) every 6 hours for 7 days
223807933|NCT01155154|DRUG|clindamycin|300 mg of clindamycin (two 150 mg capsules) every 6 hours for 7 days
223807934|NCT01155154|DRUG|placebo|Two placebo capsules every 6 hours for 7 days
223807935|NCT05462535|DRUG|Amosartan Plus Tab.|Amosartan Plus Tab., Once daily administered per the locally approved product information
223807936|NCT05602051|DEVICE|virtual reality device|mindfulness combined with virtual reality
223807937|NCT03761303|DEVICE|active rTMS|The rTMS coil is applied tangentially to the head surface above the left DLPF (corresponding to position F3 of the international 10-20 system). For the stimulation intensity, the motor rest threshold of the patient is determined. The motor rest threshold is defined as the minimum intensity that triggers an EMG response with an amplitude\> 50 μV in the first right interosseus dorsalis muscle in at least 5 out of 10 cases. The stimulation intensity within the rTMS therapy is 80 percent of the motor rest threshold. In one session, 1,000 pulses are applied in 10 trains at a frequency of 10 Hz (1 train = 100 pulses in 10 s). Between the individual trains there is an inter-train interval of 28 seconds. The total duration of a session is 5:52 minutes. In total, the patient recieve 20 sessions.
223807938|NCT03761303|DEVICE|sham rTMS|Patients in the intervetion group (active rTMS stimulation) receive active 10 Hz rTMS stimulation over the left dorsolateral prefrontal cortex (DLPFC) over a period of 20 days, seven days a week (20 sessions).
223807939|NCT04093674|PROCEDURE|de-epithelized (DE) SCTG|subepithelial connective tissue grafts
223807940|NCT04788901|OTHER|REThink therapeutic game|REThink is a online therapeutic game developed by David and collaborators (2018), proved to be an efficient intervention to reduce emotional symptoms of children and adolescents.
223807941|NCT05453968|DRUG|Berotralstat|Administered orally once daily at a weight-based dose in up to 4 cohorts
223807942|NCT05634044|DEVICE|eNose Device|Participants will place the e-Nose device in their bathroom to record VOCs from the ambient air after they have a bowel movement. In addition to this, all participants will complete 2 blood draws 3 stool collections and questionnaires over the course of 4 visits during a 3-week period.
223807943|NCT02522143|BEHAVIORAL|Informational sessions describing BPD characteristics|Control intervention consists of informational sessions describing BPD characteristics/ treatment and time- / stress-management skills
223807944|NCT02522143|BEHAVIORAL|Condensed-DBT treatment intervention|The Intervention consists of an 8-week manual based psychoeducational group utilizing modified condensed-DBT Treatment manual previously used in a treatment study (Moen et al, 2012).
223807945|NCT06173375|DIAGNOSTIC_TEST|Cologuard|Multi-target stool DNA test for colorectal cancer screening implemented by Exact Sciences. Cologuard has 94% sensitivity and 87% specificity to detect colorectal cancer.
223807946|NCT06173375|DIAGNOSTIC_TEST|Fecal Immunochemical Test|Stool blood test for colorectal cancer screening. FIT has 75% sensitivity and 90% specificity to detect colorectal cancer.
223807947|NCT05103163|OTHER|Foot Reflexology|Reflexology application is an energy balancing system with its own pressure technique that provides recovery by rubbing the reflex (nerve endings) points, stroking and applying pressure during squeezing movements. Thanks to the pressure and massage applie
223807948|NCT00326586|DRUG|AR Antagonist (BMS-641988)|Tablets, Oral, 6 Patients will be randomized in a 1:1 ratio and in a double-blinded fashion to achieve a single dose of the study drug or Placebo on C1D1. Once daily, at least 3 cycles until the disease progresses
223807949|NCT06347510|DIAGNOSTIC_TEST|Suppression of tumorigenicity 2 (ST2)|Suppression of tumorigenicity 2 (ST2) is a member of the interleukin-1 (IL-1) receptor family. The ligand and soluble versions are its two isoforms. It was first isolated in 1989. It was found to function as an IL-33 ligand in 2005. The IL-33-ST2L ligand complex\&#39;s creation offers protection against heart fibrosis and hypertrophy. The formation of this complex is inhibited by soluble ST2, which removes the cardioprotective effect. Unlike NT pro BNP, it is unaffected by age, body mass index, creatinine, hemoglobin, and albumin levels, according to studies performed on individuals. with heart failure.
223807950|NCT02223884|DRUG|docetaxel 35mg/m2|D1, 8 docetaxel 35 mg/m2 D1, 8 carboplatin AUC 3 every 3 weeks
223807951|NCT02223884|DRUG|Carboplatin AUC3|D1, 8 docetaxel 35 mg/m2 D1, 8 carboplatin AUC 3 every 3 weeks
223807952|NCT00408148|DRUG|Placebo|Undistinguishable placebo tablets
223807953|NCT00408148|DRUG|Rimonabant|White film-coated, for oral administration containing 20 mg of active rimonabant
223807954|NCT02831257|DRUG|AZD2014|
223807955|NCT01780935|DRUG|Ranibizumab|Intravitreal injections of 0.5 mg Ranibizumab
223807956|NCT00855595|DRUG|Azelaic acid (Finacea, BAY39-6251)|Participants received topical azelaic acid gel 15% twice daily for 12 weeks
223807957|NCT00855595|DRUG|Metronidazole (Metrogel)|Participants received topical metronidazole 1% gel once daily for 12 weeks
223807958|NCT00855595|DRUG|Doxycycline (Oracea)|Participants received systemic doxycycline 40 mg once daily for 12 week
223807959|NCT03792854|OTHER|EORTC QLQ C30|standardized questionaire
223807960|NCT03792854|OTHER|EORTC QLQ CR29|standardized questionaire
223807961|NCT00615186|DRUG|Neuradiab + Radiotherapy + Temozolomide|"Prior Surgery~Rickham Catheter placement 99mTc-DTPA Flow Study~Neuradiab Dosimetry Study~Neuradiab Therapeutic Dose Administration~Radiation Therapy (XRT) + Temozolomide:~XRT 5 days/week + temozolomide (75 mg/m2/day) over 6.5 weeks.~Post-Radiation Temozolomide Therapy:~Temozolomide 150-200 mg/m2/day × 5 days, every 28 days until patient's death, confirmed disease progression, unacceptable toxicity, non-compliance with the protocol, withdrawal of consent, and/or other factor that in the opinion of the consulting oncologist precludes continued study treatment."
223807962|NCT00615186|DRUG|Radiation Therapy + Temozolomide|"Prior Surgery: Gross total resection (\< 1 cm. enhancing rim)~Radiation Therapy (XRT) + Temozolomide:~XRT 5 days/week + 42 days of temozolomide (75 mg/m2/day) over 6.5 weeks~Post-Radiation Temozolomide Therapy:~Temozolomide 150-200 mg/m2/day × 5 days, every 28 days until patient's death, confirmed disease progression, unacceptable toxicity, non-compliance with the protocol, withdrawal of consent, and/or other factor that in the opinion of the consulting oncologist precludes continued study treatment."
223807963|NCT03962725|DRUG|Neuromuscular Blocking Agents|Use of non depolarizing neuromuscular blocking agents for maintenance of general anesthesia.
223807964|NCT03962725|DRUG|Anesthetic Adjuncts|Use of deeper plane of inhaled anesthetics or adjuncts (opioids, propofol, dexmedetomidine or ketamine for maintenance of general anesthesia.
223807965|NCT02621346|BEHAVIORAL|Imagery|Prior to exercising participants will be given an imagery script. Afterwards, participants will imagine completing the leg press.
223807966|NCT02621346|BEHAVIORAL|Muscle Maintenance|Participants complete the leg press exercises at an intensity that promotes muscle maintenance but not muscle growth
223807967|NCT02621346|BEHAVIORAL|Bicep Curls|Control group participants will complete a bicep exercise at a maintenance training intensity.
223807968|NCT01824615|DRUG|Sunitinib|37.5mg everyday from D1-D28
223807969|NCT05163613|OTHER|magnetostimulation|Treatment parameters: 12 minutes M2P2 program, with increasing intensity from 1 to 8. The authors applied magnetic field with a frequency of 180 - 190 Hz, pulse packet frequencies between 12.5 and 29 Hz, packet groups 2.8 - 7.6 Hz, series 0.08 - 0.3 Hz, with magnetic induction B= 3.2 µT (on average) and B = 40 µT at a pulse peak.
223807970|NCT05163613|OTHER|standard therapy|Standard therapy used in all patients consisted of the use of pharmacological agents necessary to treat the viral infection (antiviral drugs, antibiotics, dexamethasone) and the inclusion of proper care, education, occupational therapy, self-service learning, breathing exercises and motor mobilization.
223807971|NCT02666287|DRUG|BAT/FF|BAT/FF is available in DPI form and will be administered via the ELLIPTA inhaler. Each first strip contains 300 mcg per blister of BAT blended with lactose and its physical appearance is dry white powder. Second strip contains 100 mcg per blister of FF blended with lactose and its physical appearance is dry white powder.
223807972|NCT02666287|DRUG|BAT|BAT is available in DPI form and will be administered via the ELLIPTA inhaler. Each first strip contains 300 mcg per blister of BAT blended with lactose appear as dry white powder. Second strip contains lactose which appear as a dry white powder.
223807973|NCT02666287|DRUG|FF|FF is available in DPI form and will be administered via the ELLIPTA inhaler. Each first strip contains 100 mcg per blister of FF blended with lactose appear as dry white powder and second strip contains lactose which appear as dry white powder.
223807974|NCT02666287|DRUG|FF (MgSt)|FF magnesium stearate is available in DPI form and will be administered via the ELLIPTA inhaler. Each first strip contains 100 mcg per blister of FF blended with lactose appear as dry white powder and second strip contains lactose with magnesium stearate which appear as dry white powder.
223807975|NCT02666287|DRUG|FF/Vilanterol|FF/Vilanterol is available in DPI form and will be administered via the ELLIPTA inhaler. Each first strip contains 25 mcg per blister of vilanterol blended with lactose and magnesium stearate appear as dry white powder and second strip contains 100 mcg per blister of FF blended with lactose which appear as dry white powder.
223807976|NCT06162143|DEVICE|Gelsectan®|Gelsectan® is a CE-marked class II device containing xyloglucans, xylo-oligosaccharides, pea proteins, and tannins from grape seeds extract, already used in Irritable Bowel Syndrome (IBS).
223807977|NCT02571270|OTHER|Combined aerobic and resistance physical training program|
223807978|NCT00571766|DRUG|L-Arginine|Oral L-Arginine 2g, twice a day for 14 weeks
223807979|NCT00571766|DRUG|Placebo|Placebo 2 g twice a day for 14 weeks
223807980|NCT00156143|PROCEDURE|Blood sample|
223807981|NCT00156143|PROCEDURE|Radiography|
223807982|NCT04035200|DRUG|V117957 tablets|V117957 tablets taken orally at bedtime
223807983|NCT04035200|DRUG|Placebo|Tablets to match V117957
223807984|NCT04994158|COMBINATION_PRODUCT|Drugs, procedures|standard of care only. non interventional registry.
223807985|NCT04471155|PROCEDURE|Holep|laser enucleation of the gland versus open enucleation
223807986|NCT05685459|OTHER|Standard patient simulation model|Nursing students were trained with a standard patient simulation model for position and communication skills education.
223807987|NCT03033225|PROCEDURE|Endoscopic Ultrasound|Undergo EUS-guided PDT
223807988|NCT03033225|PROCEDURE|Fluorescence Imaging|Undergo fluorescence imaging
223807989|NCT03033225|DRUG|Photodynamic Therapy|Undergo EUS-guided PDT
223807990|NCT03033225|OTHER|Quality-of-Life Assessment|Ancillary studies
223807991|NCT03033225|OTHER|Questionnaire Administration|Ancillary studies
223807992|NCT03033225|DRUG|Verteporfin|Given IV
223807993|NCT04481737|BEHAVIORAL|Peer-delivered and Technology Support Integrated Illness Management and Recovery|PDTA-IIMR is delivered by a peer support specialist with the use of guided IIMR eModules and a smartphone application designed to complement in-person eModule sessions. The eModules are designed to be reviewed with a peer support specialist and consumer during one-hour, weekly, telephonic sessions in a community setting. Each eModule includes videos and experiential learning tasks on psychoeducation and coping skills training.
223807994|NCT04481737|BEHAVIORAL|Peer support|Peer support is a non-manualized form of social support, frequently coupled with instrumental support, that is mutually offered or provided by persons having a mental health condition to others sharing a similar mental health condition to bring about a desired social or personal change. Peer support specialists are provided with 1-hour of supervision each week
223807995|NCT05780489|DIAGNOSTIC_TEST|Determination of progesterone and oestradiol|Blood and saliva samples will be taken for determination of progesterone and oestradiol hormones.
223807996|NCT03611348|DRUG|Latanoprost|"Topical application of latanoprost 0.005% eye drops solution only twice daily for 3 months.~* To apply latanoprost solution, one drop of the solution will be distributed over 1cm2 of depigmented skin. Side effects will be recorded."
223807997|NCT03611348|DEVICE|Microneedling|A superficial micro-needling technique will be done in millimeters according to depth of skin. The vitiliginous area and a thin surrounding rim (about 2 mm) will be subjected to micro-needling with dermapen. The depth of abrasion will be guided by the depth adjustor according to depth of skin on the affected area. This will be followed by the appearance of multiple, tiny, punctate, bleeding points
223807998|NCT05095610|DEVICE|Flash|Use of the device FreeStyle Libre, only commercialized system for intermitent continuous glucose monitoring.
223807999|NCT03670667|OTHER|Non-Interventional|Non-Interventional
223808000|NCT03670667|OTHER|Non-Interventional|Non-Interventional
223808001|NCT03670667|OTHER|Non-Interventional|Non-Interventional
223808002|NCT05078931|DRUG|Pembrolizumab|Pembrolizumab 200 mg will be administered as a 30-minute IV infusion every 3 weeks for up to 35 cycles
223808003|NCT05078931|DRUG|Lenvatinib|Lenvatinib 20mg will be administered orally daily.
223808004|NCT04086329|DEVICE|Nanosensor|"The purpose of the study is to test a device called a nanosensor, which measures oxygen levels (a proxy of mitochondrial function) in muscle. The nanosensor has not been tested in humans nor has it been approved by the FDA.~The study nanosensor measures 1.8 mm width x 6 mm length x 0.3 mm depth. Placement of the sterilized nanosensor involves a small incision for manual placement of the nanosensor in muscle forearm tissue."
223808005|NCT06368115|OTHER|Educational Materials|Educational materials on inappropriate prescribing and deprescribing.
223808006|NCT02303184|DRUG|4 mg CLS-TA|40 mg/mL CLS-TA, Clearside's formulation of TA (CLS-TA, triamcinolone acetonide injectable suspension)
223808007|NCT02303184|DRUG|Sham|suprachoroidal sham procedure
223808008|NCT02303184|DRUG|IVT aflibercept|2 mg intravitreal injection of aflibercept
223808009|NCT03427684|RADIATION|Hypo-fractionated radiotherapy|Hypo-fractionated radiotherapy with fraction \>2Gy .
223808010|NCT03427684|DRUG|S1|S-1 80mg/m2/day, orally intake on radiotherapy days.
223808011|NCT05753150|DRUG|Tafenoquine|Tafenoquine 300 mg (2x150 mg tablets)
223808012|NCT05753150|DRUG|Primaquine|Daily primaquine adjusted by weight (0.25 mg/kg/day for 14 days)
223808013|NCT05753150|DRUG|Primaquine|Weekly primaquine adjusted by weight (0.75mg/kg/week for 8 weeks)
223808014|NCT00095706|DRUG|Bevacizumab (drug), Herceptin (drug)|
223808015|NCT04029129|OTHER|Air filtration and building envelop modifications|Air filters and closing and sealing of windows and doors was used to reduce infiltration of air pollution from outdoors in rooms next to major highways at rush hour.
223808016|NCT03403348|DRUG|JNJ-64417184|Participants will receive JNJ-64417184 in Parts 1, 2A, 2B, 3, 4, 5 and 6.
223808017|NCT03403348|DRUG|Placebo|Participants will receive matching placebo to JNJ-64417184 in Parts 1, 2A, 2B, 3, 4, 5 and 6.
223808018|NCT02296554|PROCEDURE|SLAP Repair|SLAP repair for SLAP tear
223808019|NCT02296554|PROCEDURE|Biceps Tenodesis|Biceps tenodesis for SLAP tear
223808020|NCT03685591|DRUG|PF-06952229|Oral 7 days on / 7 days off - 28 day cycles (Part 1)
223808021|NCT03685591|DRUG|Enzalutamide|Prostate Cancer (Part 2). 160mg, capsules, orally, daily
223808022|NCT00281710|DRUG|Methylprednisolone|
223808023|NCT02021175|BEHAVIORAL|Tailored CBME Therapy via Technology|6 Sessions of tailored interactive Cognitive-Behavioral Motivational Enhancement Therapy delivered through internet and cell phones
223808024|NCT02021175|OTHER|Standard of Care|Referral to currently available resources for 6 sessions of a standard smoking cessation approach
223808025|NCT00168038|BIOLOGICAL|Immunoglobulin Intravenous (Human)|A dose of 1 g IgG per kg body weight (bw) administered on two consecutive days resulting in the total treatment dosage of 2 g IgG per kg bw.
223808026|NCT01637103|BEHAVIORAL|Cognitive therapy of depression|Cognitive therapy will involve eight individual weekly sessions of 50 minutes with a Ph.D. student in psychology.
223808027|NCT01637103|BEHAVIORAL|Bright light therapy|Bright light therapy will consist of a 30-min daily morning exposition to a 10 000-lux BLT lamp during 8 weeks.
223808028|NCT01172002|DRUG|Leflunomide|"Leflunomide, 20 mg/d, ORAL ,each day. Number of Cycles: until progression or unacceptable toxicity develops.~Predonine, 10 mg/d, ORAL, each day. If extra renal flare occurs, the dose of predonine may be increased to 1mg/kg/day for not more than 2 weeks."
223808029|NCT01172002|DRUG|Azathioprine|"Azathioprine,50-100 mg/d, ORAL ,each day . Number of Cycles: until progression or unacceptable toxicity develops.~Predonine, 10 mg/d, ORAL, each day. If extra renal flare occurs, the dose of predonine may be increased to 1mg/kg/day for not more than 2 weeks."
223808030|NCT04130568|DIAGNOSTIC_TEST|INO survey|Garvin's Learning organisation tool
223808031|NCT05085626|DRUG|fluzoparib+chidamide|Arms A will be treated with fluzoparib in combination with cedaramide
223808032|NCT05085626|DRUG|fluzoparib+camrelizumab|Arms B will be treated with fluzoparib in combination with camrelizumab
223808033|NCT01274052|OTHER|Meal test|Liquid meal test
223808034|NCT01685138|DRUG|LDK378|LDK378/Ceritinib was supplied as 150 mg hard gelatin capsules and administered orally
223808035|NCT02855931|PROCEDURE|Middle turbinate resection|
223808036|NCT01938248|DRUG|Apixaban|apixaban at a dose of 5 mg twice daily (2.5 mg twice daily if 2 or more of: age \> 80, weight ≤ 60 kg or serum creatinine ≥ 133 mmol/L)
223808037|NCT01938248|DRUG|aspirin|aspirin 81 mg once daily
223808038|NCT01210430|DRUG|Losartan|Subjects will receive placebo or losartan for 4 weeks. Days 1-7, subjects will receive 12.5mg of Losartan or placebo. Days 7-14, subjects will receive 25mg of Losartan or placebo. Days 14-28, subjects will receive 50mg of Losartan or placebo.
223808039|NCT01210430|DRUG|Ascorbic Acid (Vitamin C)|Subjects will receive 60mg/kg of Ascorbic Acid over 20 minutes followed by a maintenance infusion of 20mg/kg.
223808040|NCT01210430|DRUG|Normal Saline|Subjects will receive 60mg/kg of normal saline over 20 minutes followed by a maintenance infusion of 20mg/kg of normal saline.
223808041|NCT00490256|PROCEDURE|Modified Selective Cerebral Perfusion|Modified Selective perfusion is a cardiopulmonary bypass circuit that has been modified to allow blood flow to the lower body as well as the upper body while the surgery is being performed.
223808042|NCT02472210|DRUG|Botulinum Toxin|An individualized dose will be injected in the painful limbs: up to 200 units in the upper limbs or up to 300 units in the lower limbs according to the average doses that subjects with PD pain in the limbs received in our clinic, as per our retrospective study. Each injection will contain 25 Units of Botulinum Toxin this way the number of injections will be from 1 to 8 for the upper limbs and from 1 to 12 in the lower limbs. The pattern of injections will be decided by the study investigator according to the localization. The involved muscles will be targeted using EMG guidance. of pain and will be the same at visit 2 and 3.
223808043|NCT02827006|PROCEDURE|corrective osteotomy distal radius|Opening wedge corrective osteotomy on dorsal malunions of the distal radius. Distraction and correction of deformity.
223808044|NCT01542957|BEHAVIORAL|Combined Cognitive Behavioral and Dilemma-Focused Therapy|7 2-hour sessions of Group Cognitive Behavioral Therapy for Depression + 8 individual sessions of a Dilemma-Focused Intervention + 1 3-hour final group session. Manualized.
223808045|NCT01542957|BEHAVIORAL|Cognitive Behavioral Therapy for Depression|Cognitive Behavioral Therapy for Depression. Format: 7 2-hour sessions in group + 8 individual sessions + 1 3-hour final group session. Manualized.
223808046|NCT05938257|PROCEDURE|TMJ discopexy|Arthroscopic versus open TMJ discopexy
223808047|NCT05559957|BEHAVIORAL|observation of delivery and neonatal outcomes|MONITORING THE DELIVERY MODE EITHER CESAREAN OR VAGINAL, BESIDE THE NEONATAL OUTCOME AND MORBIDITIES IN BOTH GROUPS
223835420|NCT03574701|DIETARY_SUPPLEMENT|Vitamin A|The use of Vitamin A , in the treatment of olfactory loss has been previously studied in both animals and humans. These studies have shown promising results in the treatment of olfactory loss.
223808048|NCT03076268|BEHAVIORAL|Treinta Millones de Palabras - Visitas al Hogar|TMP-Visitas al Hogar is a cultural and linguistic adaptation of the TMW-Home Visiting curriculum into Spanish. The 12-module curriculum has been translated into Spanish and adapted to address concerns that are vital to mono- and bilingual Spanish-speaking families, including the broadening research base for when to introduce a second language to a child and the benefits of bilingualism.
223808049|NCT05554601|BEHAVIORAL|gamification with collaboration|participants receive a FitBit and set goals, then are assigned to a group of other participants who will play a game to gain points based on collaboration
223808050|NCT05554601|BEHAVIORAL|gamification with competition|participants receive a FitBit and set goals, then are assigned to a group of other participants who will play a game to gain points based on competition with each other
223808051|NCT06214845|PROCEDURE|Red blood cell EXchange (REX)|A single automated REX will be performed, as soon as possible after randomization.
223808052|NCT01600664|BEHAVIORAL|Interactive computer game|Participants will use the interactive computer game installed on a convertible PC
223808053|NCT01600664|BEHAVIORAL|Convertible PC|Participants will be using the convertible PC without the interactive computer game
223808054|NCT04360525|OTHER|Reasons|Causes of sigmoid volvulus
223808055|NCT05609084|PROCEDURE|Speech therapy|Patients will connect on an interface to pratice speech therapy
223808056|NCT05609084|PROCEDURE|Speech therapy assessment|Patients will be followed by an speech therapist
223808057|NCT00308256|BEHAVIORAL|nurse-counselling|Phone calls performed by nurse 15 days after each monthly visit
223808058|NCT04726020|OTHER|Intensive monitoring|periodic and planned monitoring nurse intervention with phone call
223808059|NCT04726020|OTHER|Standard monitoring|standard monitoring of adverse event reaction
223808060|NCT04767867|OTHER|Pre-oxygenation|"Induction of anaesthesia after 2mins 45 seconds of pre-oxygenation with 1-1.5mcg/kg remifentanil plus 2-3mg/kg propofol. Propofol (10mg/kg/hr) and remifentanil (0.15mcg/kg/min) infusions commenced until study conclusion.~Positive pressure ventilation commenced at Sp02 92%. Failure to intubate the patient during the first minute of apnoea results in withdrawal from the study.~Blood samples obtained from an arterial catheter immediately prior to commencing pre-oxygenation, after 90 and 180 seconds of pre-oxygenation, after one minute of apnoea, and every two minutes during the apnoeic period."
223808061|NCT02220894|BIOLOGICAL|pembrolizumab|
223808062|NCT02220894|DRUG|carboplatin|
223808063|NCT02220894|DRUG|paclitaxel|
223808064|NCT02220894|DRUG|pemetrexed|
223808065|NCT03419481|DRUG|pembrolizumab|200mg every 3 weeks infusion
223808066|NCT02870140|DEVICE|SUPRAFLEX|Percutaneous Coronary Intervention
223808067|NCT02870140|DEVICE|XIENCE|Percutaneous Coronary Intervention
223808068|NCT04639128|DEVICE|Adductor Canal Catheter|The adductor canal catheter is a medical device that consists of a tunneled catheter connected to an analgesic solution-containing reservoir that slowly infuses the anesthetic over the first 2-3 postoperative days
223808069|NCT06850987|PROCEDURE|non surgical periodontal therapy|All participants will have their non-surgical periodontal treatments completed after samples are taken and periodontal measurements are taken at the beginning.
223808070|NCT06850987|OTHER|measurement of periodontal clinical parameters|Periodontal measurements will be taken from all participants at baseline, 1 month, 3 months and 6 months
223808071|NCT06850987|OTHER|Gingival crevicular fluid samples will be collected|Gingival crevicular fluid samples will be collected from all participants at baseline, 1 month, 3 months and 6 months
223808072|NCT04062890|DRUG|Vigabatrin Pill|Oral Vigabatrin Pill
223808073|NCT04062890|DRUG|Placebo oral tablet|Oral Placebo Pill
223808074|NCT05708755|DEVICE|Cytomegalovirus T Cell Immunity Panel (CMV-TCIP)|Whole blood assay that evaluates T cell (CD4 and CD8) responses to cytomegalovirus (CMV) antigens via intracellular cytokine staining (ICS).
223808075|NCT05708755|DIAGNOSTIC_TEST|Donor-Derived Cell-Free DNA (dd-cfDNA) Assay|Determines the percentage of circulating cell-free DNA (cfDNA) in transplant recipients derived from donor grafts.
223808076|NCT05708755|DRUG|Valganciclovir|Delivered as standard of care for post-lung transplant immunosuppression and infection prophylaxis. Started on the first day post-transplant at a standard dose of 900 mg daily and continued for 12 months. Dose adjustments may be necessary based on renal function and/or adverse effects (e.g. neutropenia). Dose adjustments are standard based on package insert recommendations.
223808077|NCT02698254|BIOLOGICAL|Bevacizumab|
223808078|NCT02698254|OTHER|Quality-of-Life Assessment|Ancillary studies
223808079|NCT02698254|RADIATION|Radiation Therapy|Undergo radiation therapy with conventional fractionation
223808080|NCT05390970|PROCEDURE|Platelet-rich plasma injection|Injection of autologous platelet-rich plasma into the anterior vaginal wall
224264393|NCT01043952|DEVICE|Bispectral Index Monitor|Bispectral Index Monitor (BIS monitor integrated in the IntelliVue Patient monitor MP70, Philips) is used to monitor the depth of anesthesia. The values this monitor reports are used as an aid in evaluating the response of the single patient to the administered anesthetics, and as a guide in adjusting the dosing of anesthetics. We follow the algorithm from: http://www.biseducation.com/assets.aspx?ac=1 (ASA Practice Advisory White Paper)
223808081|NCT04226027|BEHAVIORAL|T2.coach|"T2.coach is a smartphone app for low-burden capture of diet and blood glucose (BG) levels and for reviewing past records, integrated with FitBit for captured of physical activity and sleep. All captured data are sent to the computational inference engine that uses machine learning methods and expert system to formulate personalized behavioral goals. Examples of behavioral goals include the following: For high carbohydrate breakfasts, reduce your carbs to be about 1 carb choice. Examples of 1 carb choice are 1 slice of whole wheat toast, 1 cup of oatmeal, or 1 apple. The T2.coach chatbot companion uses text messages to help individuals set goals that are consistent with evidence based guidelines for diabetes self-management, inferences on data captured with T2.coach, and their own preferences, as well as send individuals goal reminders and prompts for reflection on goal achievement."
223808082|NCT03927469|OTHER|age, sex, hemiplegic side, stroke duration, First hospitalisation duration (day)|This is a retrospiective descriptive study
224264394|NCT03475251|BIOLOGICAL|CS1003|In the dose escalation part, the dose levels will be escalated following a modified 3+3 dose escalation scheme. In the dose expansion part, patients will be assigned to different groups based on their tumor type.
224264395|NCT03475251|BIOLOGICAL|CS1003|CS1003 to be intravenously administered at the dose level determined during the dose escalation part
223808083|NCT01752673|OTHER|Visualized pulmonary embolism computer task model|This group of participants was presented and trained to use a visual representation of diagnostic pathway for pulmonary embolism. The design of this visual representation is based on Bayes theorem and cognition enhancing visual design principles.
224264396|NCT03475251|DRUG|Regorafenib|Regorafenib to be orally administered at the protocol-specified dose level, once daily for the first 21 days of each 28-day cycle
224264397|NCT05143801|DEVICE|High-intensity interval exercise with surgical face mask in a temperate environment|Participants performed high-intensity interval exercise in a temperate environmental condition while wearing surgical face mask
224264398|NCT05143801|DEVICE|High-intensity interval exercise with surgical face mask in a hot environment|Participants performed high-intensity interval exercise in a hot environmental condition while wearing surgical face mask
223808084|NCT01752673|OTHER|Didactic review lecture|This group of participants was presented with a didactic lecture covering the diagnostic approach of pulmonary embolism.
223808085|NCT03856710|DEVICE|self-gripping mesh|The initial laparoscopic approach will be the same for both groups until the process of selection and placement of the mesh (ProGripTM self-gripping mesh versus standard 'lightweight' (large pore) polypropylene mesh fixed with SecurestrapTM) which would be decided by randomization by sealed envelope into one of the 2 intervention groups: Group 1 (Self-gripping Mesh), Group 2 (Stapled Mesh).
223808086|NCT03856710|DEVICE|Stapled mesh|The initial laparoscopic approach will be the same for both groups until the process of selection and placement of the mesh (ProGripTM self-gripping mesh versus standard 'lightweight' (large pore) polypropylene mesh fixed with SecurestrapTM) which would be decided by randomization by sealed envelope into one of the 2 intervention groups: Group 1 (Self-gripping Mesh), Group 2 (Stapled Mesh).
223808087|NCT02108379|DEVICE|Rhinix Nasal Filters|
223808088|NCT04716179|DIAGNOSTIC_TEST|Sperm test|The semen sample will be collected and analyzed within an hour after collection.
223808089|NCT04716179|DIAGNOSTIC_TEST|hormone levels (testosterone, FSH, LH, prolactin)|Hormone levels (testosterone, FSH, LH, prolactin) will be assessed on 5-7 days after symptom onset until the end of hospital stay.
223808090|NCT04716179|DIAGNOSTIC_TEST|SARS-CoV-2 Ig G levels|SARS-CoV-2 Ig G levels will be assessed on 3 months after discharge
223808091|NCT04716179|OTHER|Testis pathology samples|Postmortem examination of the testes of patients deceased as a result of COVID-19 infection will be carried out using immunohistochemistry analysis.
223808092|NCT06578988|PROCEDURE|Mammography Images|Ultrasound and / or mammography are typically performed and reported by the imaging team at the same visit, with biopsy performed when indicated. This service is an important part of cancer care provision, with approximately half of the breast cancers diagnosed presenting via the symptomatic service rather than identified at screening.
223808093|NCT03365076|OTHER|Physical activity|Aerobic physical activity as stated in Arm A
223808094|NCT04780373|OTHER|data collection|clinical data collection
223808095|NCT03230708|OTHER|Erythrocytes derived MPs containing MTX|General conventional treatment and peritoneal drainage, additional peritoneal perfusion with erythrocytes derived MPs containing MTX
223808096|NCT03230708|DRUG|convention drugs|according to usage method of drugs
224264399|NCT05143801|OTHER|High-intensity interval exercise without using a surgical face mask in a hot environment|Participants performed high-intensity interval exercise in a hot environmental condition without wearing a surgical face mask
224264400|NCT05143801|OTHER|High-intensity interval exercise without using a surgical face mask in a temperate environment|Participants performed high-intensity interval exercise in a temperate environmental condition without wearing a surgical face mask
224264401|NCT05347953|DEVICE|Single night downgraded home polygraphy|All patients will be outfitted with the ambulatory downgraded polygraphy device (Nox A1, Nox Medical Global, Reykjavik) for 24 hour monitoring. The data exported by the polygraphy device is in European Data Format and will be filtered and annotated using custom MATLAB-software.
224264402|NCT01534845|DRUG|Temozolomide (Temodal)|RT with daily temozolomide (75 mg/m2/day, 7 days/week) from the first to the last day of radiotherapy) and adjuvant TMZ chemotherapy (150-200 mg/m2 po qd for 5 days q 28 days for 6 cycles)
224264403|NCT05074745|DIAGNOSTIC_TEST|ELISA POCT vs RT-PCR|3 swabs taken, buccal for RT-PCR and ELISA POCT, nasopharyngeal for RT-PCR
224264404|NCT02945618|DEVICE|Neurocryostimulation|"CRYOFOS will be applied on the ankle at the end of each of the 8 sessions (in accordance to the protocol established). The treatment time with the CRYOFOS will take between 1 and 2 minutes, and will be pain-free.~Both groups will also receive the same conventional program consisting of: compression, bracing, early mobilization (including manual therapy), strengthening (isometric and isotonic using elastic bands) and proprioception (using proprioception boards) exercises, according to the grade of the sprain and the stage of biological ligament healing."
224264405|NCT02945618|OTHER|Ice|The control group will receive the same conventional program (as the experimental group) consisting of: compression, bracing, early mobilization (including manual therapy), strengthening (isometric and isotonic using elastic bands) and proprioception (using proprioception boards) exercises, according to the grade of the sprain and the stage of biological ligament healing. Ice will be applied to the ankle for 15 minutes at the end of each of the 8 sessions.
224264406|NCT02729987|BEHAVIORAL|WorkGuru|A multi-modal stress management intervention accessed over 8 weeks, incorporates CBT, positive psychology and Mindfulness. Delivered via the internet.
224264407|NCT01669460|OTHER|Red Bull™ Sugar-Free Drink|Red Bull™ Sugar-Free Drink two (250mL) cans per day for 28 days
224264408|NCT05450107|PROCEDURE|Open Reduction Internal Fixation|Surgical intervention by lag screw or plate fixation
224264409|NCT05450107|PROCEDURE|Cast immobilisation|Cast immobilsation for a total of 6 weeks with gradual increase in weight bearing after 2 weeks
223808097|NCT00500903|DRUG|Alisertib|Alisertib (MLN8237) will be supplied in capsules of 5 or 25 mg and will be given on an empty stomach, with patients remaining nothing by mouth except for water and prescribed medications for 2 hours before and 1 hour after each dose. Each dose will be given by mouth with 8 ounces of water for 7 to 21 consecutive days. A 14-day recovery period will follow each dosing period regardless of its duration.
223808098|NCT00529490|DRUG|Hypertonic lactate|Parenteral solution administered to a maximal volume of 10 ml/kg BW over the first 12 hours post-CABG
223808099|NCT00529490|DRUG|Ringer's lactate|Parenteral solution administered to a maximal dose of 30 ml/kg BW over the first 12 hours post-CABG
223808100|NCT02447822|DRUG|Thymoglobulin|6.0 mg/kg vs 4.5 mg/kg Thymoglobulin
223808101|NCT04211064|DIAGNOSTIC_TEST|Ultrasonographic measurement of optic nerve sheath diameter|Optic nerve sheath diameter will be measured at both neuromuscular blocks level.
223808102|NCT04211064|PROCEDURE|Deep neuromuscular block|Deep neuromuscular block will be obtained via appropriate dose of rocuronium.
223808103|NCT04211064|PROCEDURE|Moderate neuromuscular block|Moderate neuromuscular block will be obtained via appropriate dose of rocuronium.
223808104|NCT04373538|BEHAVIORAL|Trans-C for sleep and circadian function + Memory Support|The Memory Support Intervention will be delivered interwoven with Trans-C. The Memory Support Intervention is designed to improve patient memory for treatment and involves a series of specific procedures that support the encoding and retrieval stages of episodic memory. The memory support strategies are proactively, strategically and intensively integrated into treatment-as-usual to support encoding. Memory support is delivered alongside each 'treatment point', defined as a main idea, principle, or experience that the treatment provider wants the patient to remember or implement as part of the treatment.
223808105|NCT05096156|DEVICE|Precision1® Daily Disposable Contact Lens|Soft, spherical contact lens used to correct distance vision.
223808106|NCT02452723|BIOLOGICAL|ISC-hpNSC|
223808107|NCT02510430|BEHAVIORAL|Re-Patterning Sitting Time Group|This is a behavioral intervention to help women interrupt long bouts of sitting time by incorporating standing breaks into their lifestyle.
223808108|NCT02510430|BEHAVIORAL|Reducing Sitting Time Group|This is a behavioral intervention to help women reduce their overall accumulated sitting time by 2 hours per day.
223808109|NCT02510430|BEHAVIORAL|Usual Care|This intervention consists solely of follow-up contact to control for attention effects and reduce attrition.
223808110|NCT00529750|DRUG|IRBESARTAN|Tablets
223808111|NCT00529750|DRUG|Atenolol|Tablets
223808112|NCT04445636|DRUG|Dexmedetomidine|Caudal block with Dexametomedine as an adjuvant to bupivacaine.
223808113|NCT04445636|DRUG|Morphine|Addition of morphine as adjuvant to bupivacaine during caudal block.
223808114|NCT00072761|PROCEDURE|transfusion therapy|Those in the blood transfusion group will receive at least monthly blood transfusion therapy.
223808115|NCT02532556|DEVICE|Electrical stimulation (Digitimer)|Stimulation with Digitimer (DS7A HV, Digitimer Ltd, UK) over motor point of muscle in protocol. 1Hz, pulse duration 1ms, maximum compliance voltage 200V. Current set to twice motor threshold
223808116|NCT01648348|BIOLOGICAL|Anti-Endoglin Chimeric Monoclonal Antibody TRC105|Given IV
223808117|NCT01648348|BIOLOGICAL|Bevacizumab|Given IV
223808118|NCT01648348|OTHER|Laboratory Biomarker Analysis|Correlative studies
223808119|NCT01648348|OTHER|Pharmacological Study|Correlative studies
223808120|NCT01648348|OTHER|Quality-of-Life Assessment|Ancillary studies
223808121|NCT01423630|DIETARY_SUPPLEMENT|Probiotics and fruit fibre|probiotics and fruit fibre
223808122|NCT00696410|DRUG|Zinc Acetate|Zinc acetate 50 mg po TID for 10 months. Dose will be titrated to achieve ceruloplasmin levels \~10-12.
223808123|NCT01844752|DRUG|NVN1000 1% Gel|Twice daily NVN1000 1% Gel for 12 weeks
223808124|NCT01844752|DRUG|NVN1000 4% Gel|Twice daily NVN1000 4% Gel for 12 weeks
223808125|NCT01844752|DRUG|Vehicle Gel|Twice daily Vehicle Gel for 12 weeks
223808126|NCT06048770|BIOLOGICAL|RBI-4000|RBI-4000 intramuscular injection.
223808127|NCT06048770|BIOLOGICAL|RabAvert|RabAvert intramuscular injection.
223808128|NCT03344224|DIAGNOSTIC_TEST|laboratory test|laboratory test
223808129|NCT04791982|BEHAVIORAL|Educational sessions|Firstly, the literature was scanned and a education booklet prepared after the opinions of 5 academic nurses, who are experts in the field of oncology, was used. The booklet was included colorectal cancer treatment, symptoms that may develop due to chemotherapy and information on their control, psychosocial support of caregiving family members. Interviews and educational sessions with family members who agreed to participate in the study were held in one-on-one and face-to-face meeting room. These interviews lasted approximately 45 to 60 minutes for each family member. In the interviews, a educational booklet containing information on nutrition, exercise, symptom management, physical aspects of care and disease-specific care was used to present information to caregivers. All of educational sessions were performed by the single researcher.
223808130|NCT06350890|DRUG|HTD1801|HTD1801 1000 mg administered orally BID as four capsules
223808131|NCT06350890|DRUG|Placebo|Matching placebo administered orally BID as four capsules
223808132|NCT00002538|PROCEDURE|laparoscopic surgery|
223808133|NCT01951638|DRUG|Vericiguat (BAY1021189) (1.25 mg)|1.25 mg BAY1021189 tablets
223808134|NCT01951638|DRUG|Vericiguat (BAY1021189) (5 mg)|5 mg BAY1021189 tablets
223808135|NCT01951638|DRUG|Placebo|
223808136|NCT03460028|BEHAVIORAL|Yoga Condition|Participants randomized to the Yoga Condition will participate in an integrated yoga program consisting of yoga postures, breathing exercises, and concentration/meditation practices.
223808137|NCT03684486|BEHAVIORAL|rehabilitation by effort|
223808138|NCT01942681|DRUG|Propiverine Hydrochloride|Administrate Propiverine Hydrochloride for 12 weeks
223808139|NCT00421720|DRUG|Sufentanil|
223808140|NCT00421720|DRUG|Remifentanil|
223808141|NCT03634124|BIOLOGICAL|Blood test|Additional blood test of 4,5 ml of venous blood
223808142|NCT03634124|OTHER|Doppler ultrasound|Vascular ultrasonic vascular exploration of the lower limbs
223808143|NCT03163355|OTHER|a gelling agent|Pureed rice containing a gelling agent (Softia U, Nutri Co., Ltd., Yokkaichi, Japan) is compared with the standard purred rice in the condition of swallowing.
223808144|NCT00032279|DRUG|Visilizumab|
223808145|NCT03375502|DRUG|Varicella Vaccine|The subject will receive investigational product or comparator.
223808146|NCT01080508|OTHER|tracheal ventilation with regular tube|Description of the pressure waveforms during tracheal ventilation
223808147|NCT01080508|OTHER|ventilation after intubation with special tube|Description of the pressure waveforms during esophageal ventilation
223808148|NCT04523155|DIETARY_SUPPLEMENT|Medically tailored meals|10 meals per week for 3 months
223808149|NCT00451165|PROCEDURE|laparoscopic colorectal surgery|laparoscopic colorectal surgery
223808150|NCT04923113|DIAGNOSTIC_TEST|Histology，13C urea breath test，Stool antigen test，Serological antibody test for H.pylori and Serologic test with a current infection marker of H.pylori|The above 5 detection methods will be performed in patients who meet the inclusion criteria to detect H. pylori infection
223808151|NCT04923113|DRUG|Rabeprazole，Minocycline，Amoxicillin and Colloidal bismuth pectin|Helicobacter pylori positive patients will be treated with rabeprazole10mg,minocycline 100mg,amoxicillin1000mg,and colloidal bismuth pectin 200mg,all twice daily for 10 days
223808152|NCT00282893|PROCEDURE|transluminal ballooning|
223808153|NCT00282893|OTHER|currently existing therapies for the treatment of vasospasm|
223808154|NCT04451122|OTHER|cleansing the eyelid margins|using eyelid cleaning wipes to cleansing the eyelid margins
223808155|NCT03642041|BEHAVIORAL|smoking|smoking behavior
223808156|NCT06336616|BEHAVIORAL|Behavior Activation|Participants will be taught to identify meaningful activities, set goals, use environmental cues, self-reward, to identify barriers and facilitators, and learn new skills to support them to develop self-management skills and new habits.
223808157|NCT05563194|DEVICE|Heating prototype (Prototype 1)|A wearable that heats and vibrates to help distract from pain. It can be wrapped around any joint with temperature and vibration settings allowing CYP to set the device to their needs.
223808158|NCT05563194|DEVICE|Physio tool (Prototype 2)|A motivational physiotherapy tool that incrementally lights up as the CYP do their prescribed stretches, emphasising a sense of progression and making it a more engaging activity.
223808159|NCT05563194|DEVICE|Communication tool (Prototype 3)|A wearable to help communication in the classroom between the teacher and pupil. The child can alert the teacher if they need help, through vibration, without attracting the attention of their classmates, reducing embarrassment.
223808160|NCT04417686|PROCEDURE|arterial embolization|arterial embolization of the geniculated arteries for reduction of pain after installation of total knee prosthesis
223808161|NCT01298505|DRUG|PF-03654764 2.5mg plus fexofenadine 60mg|PF-03654764 2.5mg plus fexofenadine 60mg twice daily for 7 days
223808162|NCT01298505|DRUG|PF-03654764 5mg plus fexofenadine 60mg|PF-03654764 5mg plus fexofenadine 60mg twice daily for 7 days
223808163|NCT01298505|DRUG|placebo|placebo given twice daily for 7 days
223808164|NCT04962425|DRUG|Trastuzumab|Trastuzumab \[Herceptin\] is a recombinant DNA-humanized monoclonal antibody that selectively targets the HER-2 receptor on the surface of tumor cells.
223808165|NCT05667467|PROCEDURE|Care Bundle Implementation|"In this study, the control group received standard care. The nurse group was given training on the implementation of the care bundle. A cardiac surgery care bundle was applied to the study group by clinical nurses."
223808166|NCT00459342|DRUG|dasatinib|Given orally
223808167|NCT02686034|DEVICE|gammaCore-S|At onset of migraine pain, the subject self-administers a bilateral treatment with the gammaCore nVNS device (2 minutes on the right side, and 2 minutes on the left side). If their headache pain has not improved after 15 minutes, they administer another bilateral treatment. If they are not pain-free at 2 hours, they have the option to administer a third bilateral treatment, or take their usual rescue medication.
223808168|NCT02686034|DEVICE|gammaCore-S Sham|At onset of migraine pain, the subject self-administers a bilateral treatment with the gammaCore nVNS Sham device (2 minutes on the right side, and 2 minutes on the left side). If their headache pain has not improved after 15 minutes, they administer another bilateral treatment with the Sham device. If they are not pain-free at 2 hours, they have the option to administer a third bilateral treatment with the Sham device, or take their usual rescue medication.
223808169|NCT01118364|OTHER|Cannabis|"a cigarette tobacco trade mark Drum with the addition of 250 mg of cannabis resin with 8% of D9THC (20 mg per cigarette)45 minutes before simulating or real driving"
224264410|NCT01403363|DRUG|use of fentanyl patch that was halved|A sample of 95 patients will be recruited. Once consent form is signed, blood samples will be collected twice: 1. At the time of the visit; 2. After 144 hours (about 6 days) from the first sample, and at least 36 hours after replacing the cut patch. Pain management will be evaluated at both visits using the Brief Pain Inventory (Hebrew version) - BPI questionnaire, and rescue doses used before and after the cutting of the patch. The blood samples will be transferred to the laboratory for testing of fentanyl concentration levels.
224264411|NCT02281539|DEVICE|Neuromotus|
224264412|NCT02462837|DRUG|Mirabegron|
223808170|NCT01118364|OTHER|tobacco|"a cigarette tobacco trade mark Drum 45 minutes before simulating or real driving"
223808171|NCT02659761|DRUG|dolutegravir/abacavir/lamivudine|600 mg abacavir, 50 mg dolutegravir and 300 mg lamivudine single tablet taken orally, once daily, during 96 weeks
223808172|NCT02464800|PROCEDURE|Vitrectomy for proliferative diabetic retinopathy|25-gauge vitrectomy
223808173|NCT00468221|DRUG|Ozone Exposure|Low dose ozone exposure in chamber
223808174|NCT01440426|PROCEDURE|Autologous connective tissue graft with rotated papilla flap|Subepithelial connective tissue graft harvested from hard palate
223808175|NCT01440426|DEVICE|Collagen matrix construct (Mucograft)|Mucograft Collagen Matrix combined with rotated papilla flap
223808176|NCT03256825|DIAGNOSTIC_TEST|Rapid diagnostics alone|Urine samples present at the laboratory at opening on weekdays will be screened using urine flow cytometry and microscopy of centrifuged gram stained urine. Samples found positive for significant mono microbial bacteriuria will be investigated further by using direct automated phenotypic identification and antimicrobial susceptibility determination.
223808177|NCT03256825|OTHER|Real-time antimicrobial stewardship decision support|"A clinical microbiologist will be give RADS by phone to a designated clinician with the aim of:~1. Switch to active treatment if non-working empirical treatment~2. De-escalate broad spectrum empiric treatment when feasible~3. Promote early intravenous to per oral switch~4. Shorten treatment duration"
223808178|NCT02154984|BEHAVIORAL|behavioral dietary intervention|Follow tRD
223808179|NCT02154984|BEHAVIORAL|telephone-based intervention|Receive coaching calls
223808180|NCT02154984|OTHER|laboratory biomarker analysis|Correlative studies
223808181|NCT03846102|DRUG|Levobupivacaine|Levobupivacaïne for injection 7.5 mg/kg diluted with Sodium Chloride 0,9%
223808182|NCT03846102|DRUG|Placebo|Sodium Chloride 0,9% for injection/infusion.
223808183|NCT03846102|DRUG|Acetaminophen|Acetaminophen 500 milligram tablet
223808184|NCT03846102|DRUG|Morphine|Morphine 1 mg/ml solution for infusion.
223808185|NCT03846102|PROCEDURE|Fascia Iliaca Compartment Block with Levobupivacaine|Ultrasound guided Fascia Iliaca Compartment Block with levobupivacaine placed in the emergency department by an emergency physician.
223808186|NCT03846102|PROCEDURE|Fascia Iliaca Compartment Block with placebo|Ultrasound guided Fascia Iliaca Compartment Block with placebo placed in the emergency department by an emergency physician.
223808187|NCT01216930|OTHER|Observation|Observation
223808188|NCT02775955|DRUG|RX0041|Active
223808189|NCT04578327|DEVICE|Prosthetic hand|Different types of conventional prosthetic limbs will be used by subjects.
223808190|NCT04578327|PROCEDURE|Peripheral Nerve Interface|Different types of peripheral nerve stimulation will take place
223808191|NCT05140330|BEHAVIORAL|ALAPAGE workshop|7 weekly group sessions over 2 months (1 introduction session, 2 physical activity sessions and 4 nutrition sessions) and 1 evaluation session at 3 months
223808192|NCT05140330|BEHAVIORAL|control workshop|3 evaluation group sessions over 2 months and 1 session at 3 months. After those 4 sessions, the participants will benefit from an ALAPAGE workshop
223808193|NCT03659422|OTHER|Modified Paleolithic diet|The diet eliminates legumes, grains and nightshades (as opposed to the Paleolithic diet) and is higher in vegetable and fruit intake and in omega-3 fatty rich foods.
223808194|NCT00552084|DRUG|Fish oil|Fish oil supplements 4 gms will be taken daily for 24 weeks.
223808195|NCT00552084|DRUG|Placebo|Placebo supplements will be taken daily for 24 weeks.
223808196|NCT00316810|DRUG|Alemtuzumab|Day 0: Campath 30 mg i.v. infusion over 3-6 hours
223808197|NCT00316810|DRUG|Rabbit Anti-Human Thymocyte Globulin|Day O: Single shot of a polyclonal antilymphocyte preparation (ATG-Fresenius - 8 mg/kg, or IMTIX-Sangstat ATG 4 mg/kg/day).
223808198|NCT00489333|DRUG|ProAlgaZyme|
223808199|NCT00820937|PROCEDURE|Single photon emission computed tomography and Magnetic Resonance Imaging|
223808200|NCT05159089|BEHAVIORAL|Socioecological model apply to reduce physical activity drop out in type 2 diabetes patients|"To implement this model this intervention aims to address three key elements: 1) prepare the user; 2) structure the action; and 3) design the context.~These goals will be worked in each session of Nordic Walking during the warm-up and cool-down and, if necessary, during the session (as long as it's non-stop or slowing down)."
223808201|NCT05159089|BEHAVIORAL|Nordic Walking|Sessions will be progressive: the first month will long 30 minutes, the second month 35 minutes, and the third month 40 minutes (without 10 minutes warm-up and 10 minutes cool-down each session). The track will not have more than 100 accumulate high and will allow doing 5 kilometers without stopping. The meeting point will be between the Biomedical Research Park (Barcelona) and Hospital del Mar (nearby CAP Sant Joan). All sessions will be conducted by an instructor of nordic walking physiotherapists.
223808202|NCT06456632|OTHER|Intervention Su Jok Therapy|Su Jok Therapy
223808203|NCT03017079|DIETARY_SUPPLEMENT|semi-solid agent with standard enteral feeding|after infusion of semi-solid agent, Intermittent enteral feeding is applied less than 60 minutes
223808204|NCT03017079|OTHER|standard enteral feeding|Intermittent enteral feeding is applied less than 60 minutes
223808205|NCT04490746|OTHER|with no intervention, Collect samples|only with observation,there is no need to intervene
223808206|NCT03512652|DEVICE|Patello|The Patello is a new intervention device which mobilizes the Patella passively and continuously in cranial-caudal direction to increase Patella mobility.
223808207|NCT00566579|PROCEDURE|Cryotherapy|Double freezing technique
223808208|NCT06220357|DIAGNOSTIC_TEST|Indocyanine Green|The patients were split into three different groups, the patient were given ICG with three different concentrations in a double-blind randomized manner postoperatively. The fluorescence emitted was quantitatively analyzed using the ImageJ software to ascertain the mean gray values, providing a robust measure of the ICGA concentration. The imaging was captured using a FLUORO 4000XL type NIR camera, positioned at a distance of 15-20 cm perpendicular to the flap.
223808209|NCT02863679|DRUG|Tetracaine hydrochloride gel|Tetracaine hydrochloride gel contains 1% tetracaine hydrochloride, and a fair dose of fungicide, lubricants, remove foam agent, as the long-term local anesthetics.
223808210|NCT04504656|OTHER|observation of postoperative leak, stenosis, mortality|detect complications in both groups
223808211|NCT02964676|PROCEDURE|ab interno trabeculectomy with Trabectome|123 PACG will be recruited to receive ab interno trabeculectomy with Trabectome and before this surgery, laser peripheral iridectomy will be performed firstly
223808212|NCT02964676|PROCEDURE|trabeculectomy|123 PACG will be recruited to receive trabeculectomy to reduce IOP
223808213|NCT06545981|OTHER|Lumbar puncture and administration of medication|Patients with idiopathic intracranial hypertension will receive lumbar puncture and will be given medication to reduce intracranial pressure by neurologists. The lumbar puncture and the administration of medication are not part of this study, patients would also receive these without participating in the study.
223808214|NCT02781129|OTHER|electrical stimulation|Stimulation applied will be within parameters commonly used for the treatment of epilepsy during periods of encoding, recall, and memory maintenance .
223808215|NCT01439659|BEHAVIORAL|Nutritional Counseling|Initial interview and subsequent telephone contact once per week for two months, once every other week for the following two months, and once per month for the remaining two months.
223808216|NCT01439659|DIETARY_SUPPLEMENT|Daily Supplements|Two capsules daily in the morning and two capsules daily in the evening of Juice Plus+ in addition to regular meal. Also a beverage, Juice Plus+ Complete (a powder mixture to be added to one cup of fluid) daily in the evening.
223808217|NCT05391828|DEVICE|Zimmer-Biomet Persona Medial Congruent (MC) Bearing Design|TKA will be performed using the MC Bearing Design. The MC bearing provides medial stability and lateral mobility to facilitate more natural motion.
223808218|NCT05391828|DEVICE|Zimmer-Biomet Persona Posterior-Stabilized (PS) Bearing Design|TKA will be performed using the PS Bearing Design. The PS bearings are designed to provide ±1.5 degrees varus/valgus constraint and ± 5.5 degrees internal/external rotation constraint.
224264413|NCT02462837|DRUG|Placebo|
224264414|NCT00159458|DRUG|Gemcitabine and oxaliplatin|
223808219|NCT04549155|DEVICE|Transcranial Magnetic Stimulation|Transcranial magnetic stimulation (TMS) is a noninvasive procedure that uses magnetic fields to stimulate nerve cells in the brain to improve a variety of cognitive conditions, and to probe the dynamics of normal brain function.
223808220|NCT03678935|OTHER|Low FODMAP diet|The intervention group follows the low FODMAP diet for 4 weeks.
223808221|NCT04964219|DRUG|S-ketamine|"After anesthesia induction, a bolus of 0.15 mg/kg S-ketamine is injected intravenously about 30 min before incision; this is followed by a continuous infusion at a rate of 0.15 mg/kg/h until 1 hour before the end of surgery.~After surgery, patient-controlled analgesia is provided. The pump is established with S-ketamine 25 mg, dexmedetomidine 100 microgram, and sufentanil 100 microgram, diluted with normal saline to 100 ml. The pump is programmed to deliver 2-ml boluses with a background infusion rate at 1 ml /h and a 10-min lockout interval."
223808222|NCT04964219|DRUG|Placebo|"After anesthesia induction, a bolus of placebo (normal saline) in the same volume is injected intravenously about 30 min before incision; this is followed by a continuous infusion of placebo at the same rate until 1 hour before the end of surgery.~After surgery, patient-controlled analgesia is provided. The pump is established with placebo, dexmedetomidine 100 microgram and sufentanil 100 microgram, diluted with normal saline to 100 ml. The pump is programmed to deliver 2-ml boluses with a background infusion rate at 1 ml /h and a 10-min lockout interval."
223808223|NCT04350892|PROCEDURE|Roux-en-Y Gastric Bypass (RYGB)|"This surgery is often called gastric bypass. It is a weight-loss surgery that involves creating a small stomach pouch and bypassing part of the small intestine.~If you decide with your doctor to have gastric bypass, you can be enrolled on this arm of the study. A surgery date should be pending before the investigators screen you for the study. The study does not cover the cost of the Roux-en-Y gastric bypass."
223808224|NCT04350892|PROCEDURE|Sleeve Gastrectomy (SG)|"Sleeve gastrectomy, is a weight-loss surgery that involves removing about 80% of the stomach.~If you decide with your doctor to have sleeve gastrectomy, you can be enrolled on this arm of the study. A surgery date should be pending before the investigators screen you for the study. The study does not cover the cost of the sleeve gastrectomy."
223808225|NCT04350892|BEHAVIORAL|Very Low Calorie Diet (VLCD)|Weight loss with calorie restricted liquid diet. Participants will be placed on a 800 kcal/day diet for meal replacement (Optifast) provided by the investigator for 12 weeks. Participants will be monitored weekly by the study dietician and medical staff.
223808226|NCT04114734|BEHAVIORAL|Park Rx|Participants will be advised to visit a specific park at a specific frequency and duration
223808227|NCT06665386|PROCEDURE|hypothermia|"Patients who meet the inclusion criteria and do not meet the exclusion criteria will be randomly assigned to either the control group or the IA-SCI group. Control group patients will receive BMM and EVT. IA-SCI group patients will receive BMM and EVT, and additionally a selective intraarterial cooling infusion. The specific method is as follows:~* Pre-recanalization: During the procedure, a micro-catheter used to deploy the stent retriever is threaded coaxially into the common femoral artery through the guide catheter. The microcatheter is advanced over a microguide wire, traveling up through the neck until it reaches beyond the clot. A 50 mL cold 0.9% saline (4℃) is infused into the ischemic territory at a rate of 10 mL/min via the microcatheter. This enables the cold solution to infuse into the ischemic territory prior to revascularization.~* Post-recanalization: Following vessel recanalization, cold 0.9% saline (4 ℃) is reinfused into the vessel via the catheter at a rate of 22 mL"
223808228|NCT05963607|OTHER|Weighted blanket|A blanket sewn with extra weight in it.
223808229|NCT06599567|OTHER|Traditional therapy|Cold - Hot pack applications, TENS device application, which is a pain-relieving electrotherapy agent, therapeutic exercises
223808230|NCT06599567|OTHER|Graded motor imagery|Cold-Hot pack applications, TENS device application, which is a pain-relieving electrotherapy agent, therapeutic exercises, graded motor imagery training (body right-left discrimination exercise, imagining the movement and exercising the opposite limb in front of the mirror).
223808231|NCT06599567|OTHER|Nintendo Wİİ|Cold - Hot pack applications, TENS device application, which is a pain-relieving electrotherapy agent, therapeutic exercises, games involving your relevant shoulder such as boxing and bowling on the Nintendo Wii game console.
223808232|NCT04838041|DRUG|Asciminib 40 MG|40 mg by mouth (PO) when used with imatinib.
223808233|NCT04838041|DRUG|Asciminib 40 MG Twice Daily|40 mg twice daily when used with nilotinib.
223808234|NCT04838041|DRUG|Asciminib 80 MG daily|80 mg daily when used with dasatinib or taken alone.
223808235|NCT04838041|DRUG|Imatinib|Maximum dose of 400 mg PO once daily.
223808236|NCT04838041|DRUG|Nilotinib|Maximum dose of 300 mg twice daily.
223808237|NCT04838041|DRUG|Dasatinib|Maximum dose of 100 mg PO once daily.
223835421|NCT03862482|DEVICE|Brånemark® 2, Swede-Vent® 2, Screw-Vent® 1 (Configuration 1)|Brånemark® implant placed at sites 2 (left medial) and 5 (right distal), Swede-Vent® implant placed at sites 1 (left distal) and 4 (right medial), Screw-Vent® implant placed at site 3 (para symphysis)
223835422|NCT03862482|DEVICE|Brånemark® 1, Swede-Vent® 2, Screw-Vent® 2 (Configuration 2)|Brånemark® implant placed at site 3 (para symphysis), Swede-Vent® implant placed at sites 2 (left medial) and 5 (right distal), Screw-Vent® implant placed at sites 1 (left distal) and 4 (right medial)
223835423|NCT03862482|DEVICE|Brånemark® 2, Swede-Vent® 1, Screw-Vent® 2 (Configuration 3)|Brånemark® implant placed at sites 1 (left distal) and 4 (right medial), Swede-Vent® implant placed at site 3 (para symphysis), Screw-Vent® implant placed at sites 2 (left medial) and 5 (right distal)
224264415|NCT02266407|PROCEDURE|Aquamantys System|The use of the saline-coupled bipolar sealing technology (Aquamantys® System, Medtronic Advanced Energy, LLC, Portsmouth, NH, USA) uses bipolar radiofrequency energy combined with a continuous-flow saline at the electrode tip to prevent tissue temperatures from exceeding 100 °C thus minimizing tissue charring. The temperature achieved is sufficient to induce a process called Transcollation(TM) which shrinks the collagen fibers in the walls of blood vessels, effectively sealing the blood vessels up to 1mm in diameter, resulting in the reduction of bleeding from soft tissue.
223808238|NCT06606574|OTHER|Titration protocol|A standardized titration protocol for ITB will be used and the ITB dose will be increased to the next step if 1) there is persistent hypertonia identified on the dystonia screener or ASAS total spasticity, or 2) there is room for improvement on the D-FIS, and 3) there are no detrimental side effects (e.g., worsening head control). This will be continued until 1) dystonia and spasticity have been eliminated or no longer deemed as functionally impairing by the medical team, 2) side effects prevent further titration, or 3) a maximum dose of 2000 mcg/day has been reached. Once steady state is reached, this new dose becomes the maintenance dose for the rest of the trial. If there are detrimental side effects, the child will be seen weekly to confirm resolution of side effects. If side effects persist, the child will be reduced at each visit to the previous step. Once side effects are controlled, this new dose becomes the child's maintenance dose for the rest of the trial.
223808239|NCT06984003|OTHER|stretching exercises|a brief explanation, by a trained physical therapist, of stretching exercise program and of how to practice these active stretching exercises as a home program 3 times per week for 4 weeks.
223808240|NCT04823884|PROCEDURE|open distal chevron osteotomy|Through a 4-cm-long dorsomedial skin incision the V-shaped osteotomy with the apex 1-2 mm superior to the center of the metatarsal head is performed. The angle of the chevron is 60° to 90°. The direction of the osteotomy is angled toward the center of the third metatarsal head. After shifting the metatarsal head laterally, fixation is achieved by usage of one cannulated screw (3.0 mm or 2.5mm). Prominent bone ridges are resected with a saw. A distal soft tissue procedure is performed in every case through the same skin incision. The adductor hallucis tendon is detached from its insertion at the phalangeal bone and from the lateral border of the fibular sesamoid. The transverse intermetatarsal ligament is released and a T-shaped capsulotomy is performed to allow reposition of the sesamoids. Sesamoid position is controlled by sight. After closing of the medial capsula skin is closed with nylon sutures.
223808241|NCT04823884|PROCEDURE|minimally invasive distal chevron osteotomy|The osteotomy is performed percutaneously through a dorsomedial incision of 3-5 mm. An electric motor-driven machine used for the osteotomy. To prevent overheating the reamer is frequently rinsed with sterile saline. The medial eminence is excised and the V-shaped osteotomy is performed. The apex of the osteotomy is identified by fluoroscopy and centered 1-2 mm superior to the center of the metatarsal head. The angle of the osteotomy amounts to 60-90 degrees as well. Bone debris is washed out with sterile saline. A lateral soft-tissue release is undertaken through a separate lateral incision of 3-5 mm. The distal fragment is shifted laterally and fixed with a canulated screw of 3.5mm. Residual bone ridges are reamed. Position of the metatarsal head and the K-wire is controlled by fluoroscopy. The skin is closed with a nylon sutures.
223808242|NCT05560854|BEHAVIORAL|Internet delivered prolonged exposure|Internet delivered prolonged exposure for ten weeks with therapist support.
223808243|NCT01855776|DEVICE|Fitbit|Fitbit Zip is a wireless pedometer that tracks steps of participants, and will be offered in conjunction with a tailored website with customized information for participants, employers, and/or charities.
223808244|NCT01855776|BEHAVIORAL|Cash Incentives|Incentives will be awarded to participants for meeting specified weekly step goals as measured by a pedometer.
223808245|NCT01855776|BEHAVIORAL|Charitable Incentives|Incentives will be awarded to charities selected by participants should the latter meet specified weekly step goals measured by a pedometer.
223808246|NCT01855776|OTHER|Usual Care|"The usual care programme consists of educational materials designed by the Singapore Health Promotion Board. It includes material on how to stay active, walking programmes, and healthy eating."
223808247|NCT04704063|DRUG|Tocotrienols / Vitamin E|Palm Tocotrienols complex
223808248|NCT04704063|DRUG|Placebo control|Placebo matching Tocovid Suprabio
223808249|NCT03736603|BEHAVIORAL|PIPA Intervention Bundle 1|"The PIPA intervention bundle 1 includes:~1. Pathway Implementation Toolkit~2. Local Multidisciplinary Champions~3. Audit and Feedback~4. Educational Seminars/Webinars~5. Practice Facilitation"
223808250|NCT03736603|BEHAVIORAL|PIPA Intervention Bundle 2|"The PIPA intervention bundle 2 includes:~1. Pathway Implementation Toolkit~2. Local Multidisciplinary Champions~3. Audit and Feedback~4. Educational Seminars/Webinars~5. Practice Facilitation~6. Mobile App"
223808251|NCT05601869|DEVICE|RECOVER Prosthetic Ankle-Feet System|The RECOVER prosthetic ankle-feet system includes a single prosthetic ankle joint that can be easily attached to 3D printed feet. The feet are designed to fit specifically within different footwear.
223808252|NCT06670664|OTHER|No intervention|No intervention. This is a single-group study.
223808253|NCT06999213|OTHER|Assist|The device will provide assistive torques to support either ankle, knee, and/or hip movements.
223808254|NCT06999213|OTHER|Resist|The device will apply resistive torques to exaggerate gait asymmetries, facilitating error augmentation.
223808255|NCT06999213|OTHER|Slack|The device will be worn but will not generate any torque.
223808256|NCT06670872|DRUG|Eravacycline combination therapy group|"Physicians determine the combination regimen of eravacycline, which may include sulbactam or compound preparations containing sulbactam, polymyxin B, beta-lactam antibiotics, etc., based on the pathogen identification and susceptibility results, and the China Guidelines for Diagnosis, Treatment, and Prevention of Infections Caused by Carbapenem-Resistant Gram-Negative Bacteria. The combined drugs are used according to their instructions for use or clinical practice guidelines."
223808257|NCT02697851|DRUG|Microgynon 30®|
223808258|NCT02697851|DRUG|Evotaz®|
223808259|NCT07002762|DIETARY_SUPPLEMENT|Burdock ( Arctium lappa L.) root extract in a form of a nutritional additive|Gastric soluble capsules each containing: 750 mg of burdock ( Arctium lappa L.) root extract in the form of a nutritional additive
223808260|NCT07002762|OTHER|Placebo|Gastric soluble capsules each containing: Maltodextrin, silicon dioxide, calcium stearate, food colourants
223808261|NCT06621238|BEHAVIORAL|Music|Listen to Music
223808262|NCT02630134|OTHER|These patients receive the Baeta device and take it home|
223808263|NCT04839354|DRUG|L-Arginine Hydrochloride|A one-time L-arginine hydrochloride loading dose of 200 mg/kg will be administered intravenously (IV) followed by a standard dose of 100 mg/kg given by IV three times per day (TID).
223808264|NCT04839354|OTHER|Normal saline|A placebo of normal saline will be administered by IV with a loading dose of 2ml/kg followed by 1ml/kg given by IV three times per day (TID).
223808265|NCT05879627|DRUG|BAT8007 for injection|Intravenous infusion: once every three weeks.The infusion time in the first cycle is recommended to be ≥ 90 minutes. If no infusion reaction occurs, the subsequent cycle can be completed within 30\~120 minutes.
223808266|NCT04665154|DRUG|MAS825|single dose i.v. and s.c.
223808267|NCT04665154|DRUG|Placebo|single dose i.v. and s.c.
223808268|NCT06733090|DRUG|0.12% chlorhexidine glucanate solution|The superiority of two different solutions over each other will be examined with a standard maintenance.
223808269|NCT06733090|DRUG|0.2% chlorhexidine glucanate solution|0.2% chlorhexidine glucanate solution
223808270|NCT06724276|PROCEDURE|balloon angioplasty and stenting of lower extremity vessels + fibroblasts|A balloon or a stent of the required size (according to the intrinsic diameter of the affected vessel) is delivered to the affected area, sequential balloon dilatation with exposure of up to 5 minutes or stenting of the vessel is performed. After completion, control angiography is performed with evaluation of the result. Instruments, introdjuncer are removed. Manual compression haemostasis (up to 20 minutes over the puncture site) followed by aseptic pressure dressing on the puncture site for 12 hours with bed rest. After surgery, fibroblasts will be applied to the wound for 24 hours.
223808271|NCT06724276|PROCEDURE|balloon angioplasty and stenting of lower extremity vessels|A balloon or a stent of the required size (according to the intrinsic diameter of the affected vessel) is delivered to the affected area, sequential balloon dilatation with exposure of up to 5 minutes or stenting of the vessel is performed. After completion, control angiography is performed with evaluation of the result. Instruments, introdjuncer are removed. Manual compression haemostasis (up to 20 minutes over the puncture site) followed by aseptic pressure dressing on the puncture site for 12 hours with bed rest.
223808272|NCT06731972|OTHER|Exercises|Classical massage, stretching, functional exercises, electrical modalities, thermal agents, home exercises, etc., plus home exercises.
223808273|NCT06731972|DEVICE|Mobile game|mobile application games (such as Temple Run, Flappy Bird, Angry Birds, etc., or games the patient is already playing) as part of their home exercise program.
223808274|NCT06733857|BEHAVIORAL|VEG2|Participants were provided with a caloric target to place them in a ∼0 to 10% energy surplus, and a protein target of 2 g·kg bm-1·d-1. Participants were instructed to avoid animal products for ≥6 d per wk, focusing their intake on protein-rich non-animal-derived foods (for example, mycoprotein-containing products, pulses, soy). To facilitate reaching protein intake targets, the research team provided participants with mycoprotein-containing vegan products (∼1-2 products per day) to be used as the main protein source for some meals. This group also received 105-g mycoprotein (46-g protein, 10-g carbohydrate, 13-g fat, 348 kcal), 35-g post-training, and 70-g before bed.
223808275|NCT06733857|BEHAVIORAL|OMNI2|Participants were provided with a caloric target to place them in a ∼0 to 10% energy surplus, and a protein target of 2 g·kg bm-1·d-1. Participants in OMNI2 were instructed to consume an omnivorous diet, focusing their intake on high-quality animal-derived proteins (that is, meat, milk, yogurt, cheese). To facilitate reaching protein intake targets, the research team provided participants with a weekly supply (∼1-2 products per day) of chicken or beef to be used as the main protein source for some meals. This group also received 59-g supplemental milk protein daily (47-g protein, 2-g carbohydrate, \<1-g fat, 198 kcal) 19.5-g to drink post-training and 39-g to drink before sleep.
223808276|NCT06733961|DIAGNOSTIC_TEST|SCUBE-1 and VAP-1|There is no other study comparing these biomarkers with healthy volunteers in the diagnosis of pulmonary embolism.
223808277|NCT06732206|OTHER|Short Solution Focused Approach Program|It will be a psychoeducational approach aimed at developing preventive and protective properties against addiction.
223808278|NCT06209281|DRUG|Lower dose atropine sulfate eye drops|Administer to eyes
223808279|NCT06209281|DRUG|Low dose atropine sulfate eye drops|Administer to eyes
223808280|NCT06209281|DRUG|placebo|Administer to eyes
223808281|NCT06473584|DIAGNOSTIC_TEST|Diabetes detection|Fasting glycemia on blood sample
223808282|NCT06901388|PROCEDURE|Non-surgical peri-implant therapy|Standardized non-surgical therapy consisting of mechanical debridement of peri-implant sites using ultrasonic instruments, combined with personalized oral hygiene instruction. The intervention is delivered in a single session. No adjunctive antimicrobials are used. Follow-up is scheduled 3 months after therapy for clinical and psychometric re-evaluation.
223808283|NCT07093164|BEHAVIORAL|Virtual visit|Patients will be provided an initial virtual health or telehealth visit instead of an in person visit.
223808284|NCT07093190|DIETARY_SUPPLEMENT|exercise following Rg1 consumption|The effect of Rg1 on exercised skeletal muscle in older women
223808285|NCT07093190|DIETARY_SUPPLEMENT|Placebo|Resistance exercise performed 1 hour following placebo consumption
223808286|NCT07092722|DIETARY_SUPPLEMENT|LN18178|400 mg, One capsule to be consumed in the morning after breakfast with water for 12 Weeks
223808287|NCT07092722|DIETARY_SUPPLEMENT|Placebo|One capsule to be consumed in the morning after breakfast with water for 12 Weeks
223808288|NCT07094659|BEHAVIORAL|Task-Specific Balance Training|Participants in the intervention groups will receive 8 weeks of task-specific balance training that includes both functional tasks and predictable perturbations specific to slips and trips. Sessions will be completed 2x per week for 8 weeks (16 sessions total).
223808289|NCT07094659|BEHAVIORAL|Treadmill Perturbation Training|Participants in the treadmill perturbation training group will receive 8 weeks of training that includes exposure to slip-like and trip-like perturbations delivered via motorized treadmill. Sessions will be completed 2x per week for 8 weeks (16 sessions total).
223808290|NCT07094659|BEHAVIORAL|Conventional Balance Training|Participants in the conventional balance training group will receive 8 weeks of training that includes conventional exercises designed to improve balance control. Sessions will be completed 2x per week for 8 weeks (16 sessions total).
223808291|NCT07094178|PROCEDURE|Corticosteroid Injection|This intervention consists of a single injection of corticosteroids administered directly into the affected tendon of the shoulder. Corticosteroids are anti-inflammatory drugs used to rapidly reduce inflammation and pain associated with tendinopathy. The injection is performed under aseptic conditions by a trained physician. The aim is to provide quick pain relief and improve shoulder function, although effects may be temporary.
223808292|NCT07094178|PROCEDURE|platelet-rich plasma injection|This intervention involves a single injection of Platelet-Rich Plasma (PRP), which is prepared from the patient's own blood through a process of centrifugation to concentrate platelets. PRP contains growth factors that may promote tissue healing and regeneration. The injection is administered under aseptic conditions into the affected shoulder tendon by a trained physician. The goal is to enhance long-term recovery of tendon function and reduce pain.
223808293|NCT07093840|DEVICE|AmblyoPlay Digital Visual Therapy|AmblyoPlay is a home-based, app-delivered multimodal visual therapy program designed for children with amblyopia. The therapy consisted of 30-minute sessions, performed 5 days per week over a 6-month period. Exercises included gamified visual tasks targeting oculomotor control, visual acuity, stereopsis, visual-motor integration, and postural coordination. The software automatically adjusted task difficulty based on individual performance. Therapy was performed on a tablet or computer with red-green anaglyph glasses provided to participants
223808294|NCT07093840|OTHER|control group|Participants in this group were healthy children who did not receive any therapeutic intervention during the 6-month study period. They were age- and gender-matched with participants in the intervention group to ensure baseline comparability. Assessments were performed only at baseline and at the 6-month follow-up and included measurements of visual acuity, oculomotor function, stereopsis, visual-motor integration, and postural control.
223808295|NCT07093970|DRUG|MRG006A|Administrated intravenously
223808296|NCT07093632|PROCEDURE|Graft dysfunction will be assessed through clinical examination and imaging follow-up to detect occlusion, pseudoaneurysm, aneurysm rupture, infection, or major amputation of the treated limb.|This study concerns adult subjects with symptomatic lower limb arterial disease who have undergone arterial bypass surgery and are included in the study cohort. Graft dysfunction will be assessed through clinical examination and imaging follow-up to detect occlusion, pseudoaneurysm, aneurysm rupture, infection, or major amputation of the treated limb.
223808297|NCT07092813|DRUG|sulopenem etzadroxil and probenecid|single dose of 500 mg of sulopenem etzadroxil and 500 mg of probenecid given orally as a bilayer tablet.
223808298|NCT07093736|DEVICE|FW-200|Non-invasive, home-use neurostimulation device delivering transcranial fixed output, alternating current stimulation
223808299|NCT07093515|OTHER|No intervention|No intervention
223808300|NCT07094464|DRUG|Maintenance Therapy with Selinexor and Azacitidine|"1. Selinexor: Oral administration in 4 cycles:~   \- Dose Escalation Phase: Cohort 1: Selinexor, 20 mg, twice a week for 2 weeks Cohort 2: Selinexor, 40 mg, twice a week for 2 weeks Cohort 3: Selinexor, 60 mg, twice a week for 2 weeks~   \- Dose Expansion: MTD/RP2D will be determined based on safety.~2. Azacitidine: 35 mg/m² for 5 days."
223808301|NCT07089836|DEVICE|ALPCO Syphilis-T|Detection of antibodies to Treponema pallidum in human serum and plasma
223808302|NCT07089836|DEVICE|ALPCO Syphilis-NT CLIA Kits|Detection of antibodies to lipoidal antigens in human serum and plasma
223808303|NCT07093723|DIAGNOSTIC_TEST|S100B Protein|Serum level of S100B Protein was measured on the first and third days of seizure activity by ELISA.
223808304|NCT07093723|DIAGNOSTIC_TEST|Neutrophils to Lymphocytes ratio|Neutrophils to Lymphocytes ratio was measured on the first and third day of seizure activity obtained by complete blood count.
223808305|NCT07092982|PROCEDURE|Ultrasound Guided Suprainguinal Fascia Iliaca Block|Ultrasound Guided Suprainguinal Fascia Iliaca Block, 30 ml Bupivacain %0,25
223808306|NCT07092982|PROCEDURE|Ultrasound Guided Adductor Canal Block|Ultrasound Guided Adductor Canal Block, 15ml Bupivacain %0,25
223808307|NCT07092982|PROCEDURE|Ultrasound Guided iPACK Block|Ultrasound Guided iPACK Block, 15ml Bupivacain %0,25
223808308|NCT07093060|DRUG|Oxytocin lower dose (24IU)|Oxytocin (24IU) will be administered as a lingual spray (6, 0.1 puffs (4IU per puff) of spray on and under the tongue)
223808309|NCT07093060|DRUG|Oxytocin higher dose (48IU)|48IU oxytocin administered as a lingual spray (6, 0.1ml sprays (8IU per puff) on or under the tongue)
223808310|NCT07093060|DRUG|Atosiban|150ug atosiban administered by lingual sprays (6, 0.1ml sprays on and under the tongue)
223808311|NCT07093060|DRUG|Placebo|Placebo administered as a lingual spray (6, 0.1 ml sprays one and under the tongue. Placebo has the same composition of 0.9% saline and glycerol as for oxytocin and atosiban interventions
223808312|NCT07093372|DEVICE|Laryngeal Mask Airway|A supraglottic airway device (i-gel) used to deliver oxygen and assist ventilation during electroconvulsive therapy (ECT) in obese patients. The device is inserted after induction of general anesthesia and removed after spontaneous respiration is restored.
223808313|NCT07093372|DEVICE|High-Flow Nasal Cannula|A heated and humidified oxygen delivery system that provides high flow oxygen through nasal prongs. In this study, it is used throughout the ECT procedure to maintain oxygenation in obese patients without the need for invasive airway insertion.
223835424|NCT01121640|PROCEDURE|CA125 assay on Abbott Architect i1000SR platform|Bead-based sandwich ELISA style assay
223835425|NCT01121640|PROCEDURE|HE4 assay on Architect i1000SR platform|Bead-based sandwich ELISA style assay
223835426|NCT01121640|PROCEDURE|Transvaginal Ultrasound|Sonogram will be obtained only if confirmatory markers are elevated. Exam is restricted to ovarian evaluation.
223835427|NCT05607966|DEVICE|ORIGIN® CR devices|It is planned to include consecutive eligible subjects which will be treated with the ORIGIN® CR devices.
223808314|NCT07092839|OTHER|transcranial electric stimulation|tTIS is an innovative non-invasive brain stimulation approach, in which two or more independent stimulation channels deliver high-frequency currents in the kHz range (oscillating at f1 and f1 + Δf). These high-frequency currents are assumed to be too high to effectively modulate neuronal activity. Still, by applying a small shift in frequency, they result in a modulated electric field with the envelope oscillating at the low-frequency Δf (target frequency) where the two currents overlap. The peak of the modulated envelope amplitude can be steered towards specific areas located deep in the brain, by tuning the positions of the electrodes and the current ratio across stimulation channels. Here, we applied tTIS via surface electrodes applying a low-intensity (2mA baseline to peak), sub-threshold protocol following the safety guidelines for low-intensity transcranial electric stimulation in humans.
223808315|NCT07093385|DRUG|Faricimab Injection|Faricimab (6 mg/0.05 mL) for three months (loading dose) in a sterile environment,
223808316|NCT07094841|DEVICE|3D PRINTED herbst appliance|participants will receive treatment with herbst appliance for 4 to 5 months
223808317|NCT07094841|DEVICE|3d printed mara|participants will receive treatment with mara appliance for 4 to 5 months
223808318|NCT07093242|BEHAVIORAL|Personalized Nutritional Follow-Up|Participants in the experimental arm will receive a individual nutritional follow-up based on their epigenetic hair analysis results. This includes dietary guidance, recommendations tailored to genetic markers, and periodic consultations with a nutritionist over 4 weeks and continuous availability to clarify doubts via email . The aim is to evaluate changes in genetic expression or health biomarkers after the intervention period.
223808319|NCT06924788|BEHAVIORAL|Video-Conferenced Stress Management and Relaxation Training (VSMART)|10 week stress management group discussions
223808320|NCT06941831|OTHER|Digital Dashboard-Supported Sugira Muryango Implementation|Arm investigating technology-supported delivery of Sugira Muryango, specifically, the use of a Digital Dashboard tool developed in partnership with the University of Rwanda. Developed using co-design and user interface/user experience techniques, the Dashboard (a) streamlines collection of data on evidence-based intervention quality and reach; (b) improves visibility and searchability of implementation data by region; (c) facilitates caregiver mental health and social services referrals and follow up, and (d) serves as a training platform with resources to enhance lay worker fidelity (content-specific skills) and competence (cross-cutting skills) in evidence-based intervention delivery.
223808321|NCT06941831|OTHER|Usual Care - Sugira Muryango Implementation|Sugira Muryango intervention is delivered using traditional supervision, data entry, and quality monitoring tools.
223808322|NCT01797679|OTHER|Strength Training|
223808323|NCT01797679|OTHER|Aerobic Exercise|
223808324|NCT00791323|DRUG|Ketorolac 0.4%|One drop 4 times a day in the pre-operative eye beginning day 0 for 4 days
223808325|NCT00791323|DRUG|Lubricating Eye Drop|One drop 4 times a day in the operative eye beginning one day prior to the peripheral iridotomy and continuing until the day of IOL implantation
223808326|NCT00207584|DRUG|Doxycycline treatment|
223808327|NCT02235545|DEVICE|St. Jude Medical Optisure Lead|Patients implanted with St. Jude Medical Optisure Lead
223808328|NCT04073563|DEVICE|Infuse™ Bone Graft (Infuse™)|(Recombinant human bone morphogenetic protein-2 (rhBMP-2)/absorbable collagen sponge (ACS))
223808329|NCT04073563|DEVICE|Intervertebral body fusion device and Medtronic posterior Fixation Systems|Adaptix™Interbody System, Capstone™ Spinal System, Catalyft™ PL Interbody System
223808330|NCT06431503|OTHER|Tok-Sen Massage|Press the wedge and tapping: the strength for pressing the wedge is 1000g±50g, the height for mallet free fall(instead of beating by arm)10cm±2cm. For Pressure massage, the strength for pressing the wedge is 1500g±50g.
223808331|NCT06431503|OTHER|Pressure Massage|Press the wedge: the strength for pressing the wedge is 1500g±50g,
223808332|NCT01546467|BEHAVIORAL|Cognitive remediation|Cognitive remediation including feedback from neurocognitive assessment, psychoeducation about cognitive deficits, 30 hours of computer based drill and practise and strategy coaching based cognitive remediation, 1-3 collaborative meetings with cognitive specialist, participant, therapist and teacher, occupational therapist or other therapist (depending on participants rehabilitation situation) to enhance transfer of skills to daily functioning
223808333|NCT03502863|DEVICE|Digital refraction|A web-based application for obtaining the refractive error and visual acuity of each eye, using a computer and a smart phone.
223808334|NCT03502863|OTHER|Manual Refraction|Manual refraction and ETDRS chart
223808335|NCT00914004|DRUG|Desipramine HCl 50 mg Tablets Cord Laboratories|
223808336|NCT00914004|DRUG|Norpramin 50 mg Tablets Merrell Dow Pharmaceuticals, Inc|
223808337|NCT05030779|BIOLOGICAL|Assigned Interventions CD19/BCMA CAR T-cells|Drug: CD19/BCMA CAR T-cells Each subject receive CD19/BCMA CAR T-cells by intravenous infusion Other Name: CD19/BCMA CAR T-cells injection
223808338|NCT03389568|BEHAVIORAL|singing-based music therapy program|A single 1-hour singing-based intervention is conducted with each primary caregiver of an ICU patient. The intervention is composed of three steps: 1) listening to a participant's preferred music and identifying his and her emotional states (15 minutes), (2) singing for emotional changes (30 minutes), and (3) discussing what he or she experiences during singing and identifying how they apply such experience to their personal use of music for emotional changes in his or her everyday life (15 minutes).
223808339|NCT05613790|DEVICE|Active High-Definition Transcranial Direct Current Stimulation (HD-tDCS)|Portable multi-channel tES stimulation (Starstim 8, Neuroelectric, Barcelona, Spain) will be used.
223808340|NCT05613790|DEVICE|Sham High-Definition Transcranial Direct Current Stimulation (HD-tDCS)|Portable multi-channel tES stimulation (Starstim 8, Neuroelectric, Barcelona, Spain) will be used.
223808341|NCT01747564|DRUG|YM178 (mirabegron)|oral
223808342|NCT05467579|DEVICE|Device: orthodontic - mandibular advancement clear aligner|Intervention orthodontic - mandibular advancement: mandibular retrognathia correction with a mandibular advancement using a step-wise approach with clear aligner.
223808343|NCT00969475|DEVICE|Lumenis fractional carbon dioxide laser|intra-operative laser resurfacing at time of wound closure
223808344|NCT00385411|DRUG|valproate microgranules|20 to 30 mg/kg/day
223808345|NCT04606784|BIOLOGICAL|Ampion|Ampion, nebulized for inhalation
223808346|NCT04606784|OTHER|Standard of Care|Standard of Care
223808347|NCT04700501|OTHER|Enjoy Your Bump - CBT life skills learning programme|Antenatal use of an online Cognitive Behavioural Therapy life skills learning programme to improve maternal feelings of anxiety and low mood.
223808348|NCT00820274|PROCEDURE|amniotic membranes|The amniotic membrane is taken with a sterile crowbar then applied side foetal face against the ulcer and displayed in a homogeneous way
223808349|NCT05323617|DRUG|Romiplostim|Administered as a subcutaneous injection.
223808350|NCT05323617|DRUG|Antithymocyte Globulin|Horse or rabbit antithymocyte globulin administered as an intravenous infusion.
223808351|NCT05323617|DRUG|Cyclosporine A|Administered orally.
223808352|NCT05773560|DEVICE|virtual reality rehabilitation|All patients will receive VR-assisted rehabilitation. The VR-assisted rehabilitation is proceed with SyncVR® (Padualaan, Netherlands ) equipment, which is composed of a head set (PICO NEO 3) and one dashboard (TABLET), enabling the patients to receive stepwise rehabilitation program with 360° videos activities (SyncVR Medical Platform). The VR-assisted rehabilitation will be performed two times per day, 30 minutes per training. The first training will start on the second post-operative day.
223808353|NCT02044627|DRUG|[14C-ETC-1002]|
223808354|NCT01048892|BIOLOGICAL|Seneca Valley virus-001|
223808355|NCT01048892|DRUG|cyclophosphamide|
223808356|NCT01048892|OTHER|laboratory biomarker analysis|
223808357|NCT01048892|OTHER|pharmacological study|
223808358|NCT01331460|BEHAVIORAL|RBT|"Intervention for Injection Drug Using Women:~Incorporates elements of Reinforcement-Based Treatment and Women's Health CoOp to help prevent drug abuse (and promote drug abstinence) and lower risk of Human Immunodeficiency Virus, violence, and high-risk sexual behaviors."
223808359|NCT01331460|OTHER|Case-Management|"Standard Intervention:~Incorporates standard practice elements like accessing resources, service linkage, monitoring the success of patient-service linkages, and advocating for the patient to help her meet her needs"
223808360|NCT03610763|DEVICE|Transcranial Direct Current Stimulation|Transcranial direct current stimulation (tDCS) is a portable neurostimulation method that modulates cortical excitability. The technique involves placing two saline-soaked electrodes (anode and cathode) on the scalp and passing a small direct current (1.5 milliamps; mA) between them. Cortex underlying the anode is more easily excited due to lowered thresholds for depolarization of glutamatergic neurons, while thresholds are increased in neurons beneath the cathode, making them less excitable. Sham stimulation is easily implemented, and the technique can be effectively double-blinded.
223808361|NCT03610763|BEHAVIORAL|Modified Constraint Induced Movement Therapy|In CIMT, patients are required to wear a mitt that restricts use of the unaffected limb while they practice structured tasks and also engage in activities of daily living.
223808362|NCT05513326|OTHER|Exercises and education|"Exercises: 3 training sessions per week that will last for 30 minutes. Sessions will start with 5 minutes of activation (walking on a treadmill or cycling). Then, participants will be asked to complete 5 exercises targeting lower limb strengthening (time: 18 minutes) followed by 2 exercises designed to improve balance and 3 stretching exercises for the lower limb (time: 7 minutes).~Education: Two one-on-one sessions (during week 2 and week 4 assessments) during which participants will receive information directly related to LSS and NC using illustration and videos. Participants will also be invited to ask their questions."
223808363|NCT05513326|OTHER|Education alone|Education: Two one-on-one sessions (during week 2 and week 4 assessments) during which participants will receive information directly related to LSS and NC using illustration and videos. Participants will also be invited to ask their questions.
223808364|NCT06325423|COMBINATION_PRODUCT|neoadjuvant chemotherapy|platinum-based chemotherapy before radical cystectomy or bladder preservation
223808365|NCT06495203|DRUG|anti-VEGF treatment|Follow clinical practice/administration
223808366|NCT06038955|BEHAVIORAL|Virtual reality Based Cognitive Remediation|The main component of the intervention is a virtual reality training platform in 360° Oculus Quest 2-software in which participants train their cognitive abilities guided by the therapist. The platform includes four immersive daily-life scenarios in which patients have consistently reported that they often experience cognitive difficulties: (1) a kitchen scenario focusing on planning and cooking a meal, (2) a supermarket scenario focusing on grocery shopping, (3) a restaurant scenario focusing on remembering names and personal information and (4) an office scenario focusing on planning, initiating, and completing work assignments. The virtual reality training is supported by a psychoeducation program that focuses on application of learned cognitive strategies in daily life.
223835428|NCT01224561|BEHAVIORAL|Lipid overnutrition|During 4 months, the daily caloric intake will be increased by about 70 g fat as butter 20 grams, 100 grams of cheese (Emmental) and 40 grams of almonds. This overnutrition corresponds to an excess of 760 kcal / day or 21,280 calories for the period and then taken to a theoretical 2.4 kg of fat (1 kg fat = 9000 kcal).
223835429|NCT00738530|DRUG|Bevacizumab [Avastin]|10 mg/kg IV every 2 weeks
223808367|NCT06038955|BEHAVIORAL|Virtual reality control training|The virtual reality control training involves completing different virtual reality games that are available through the Oculus Quest games store.The chosen games involve no direct training of cognitive abilities such as planning skills og strategic learning, but merely involves simple reaction time and interaction with an entertaining environment that is meaningful to the participant and gives the impression of training cognitive skills.
223808368|NCT04813380|OTHER|Sublingual immunotherapy|Sublingual immunotherapy give to allergic rhinitis patients for treatment
223808369|NCT02240108|DRUG|Rifaximin EIR|Rifaximin EIR tablets will be administered per the dose and schedule specified in the arm.
223808370|NCT02240108|DRUG|Placebo|Placebo matching to rifaximin EIR tablets will be administered per the dose and schedule specified in the arm.
223808371|NCT04799379|DRUG|microporous polysaccharide hemospheres (MPH) agent in rectal surgery|Use of microporous polysaccharide hemospheres (MPH) agent in patients after rectal surgery to avoid pelvic collections and the use of any drain
223808372|NCT01345630|DRUG|Maraviroc|Maraviroc tablet 150 mg once daily for 96 weeks.
223808373|NCT01345630|DRUG|Emtricitabine/tenofovir|Emtricitabine/tenofovir tablet 200/300 mg once daily for 96 weeks.
223808374|NCT01345630|DRUG|darunavir/ritonavir 800/100 mg|darunavir/ritonavir 800/100 mg
223808375|NCT01345630|DRUG|placebo for emtricitabine/tenofovir|placebo for emtricitabine/tenofovir
223808376|NCT01345630|DRUG|placebo for maraviroc|placebo for maraviroc
223808377|NCT04414579|DRUG|Faster Insulin Aspart (Fiasp®)|Subjects will be randomized either to use Fiasp or conventional insulin aspart in CSII. CSII settings (basal, bolus, and correction factors) will be optimized using a meal challenge for a 2-week run in period followed by a 10-week period of CSII use with the assigned insulin. After a 12-week maintenance period, each group will cross over to the other insulin (conventional insulin aspart or Fiasp) by CSII for a second 2-week optimization period followed by a 10-week treatment period.
223808378|NCT01573806|DRUG|Exenatide|Exenatide, dosed subcutaneously every 12 hours for 4 doses
223808379|NCT01573806|DRUG|Exenatide vehicle|Exenatide vehicle, dosed subcutaneously every 12 hours for 4 doses
223808380|NCT02310555|PROCEDURE|Gastric bypass|
223808381|NCT02310555|PROCEDURE|Modified gastric bypass.|
223808382|NCT02310555|PROCEDURE|Slevee Gastrectomy|
223808383|NCT03041779|DRUG|Diclofenac Sodium 50Mg Suppository|
223808384|NCT03041779|DRUG|Paracetamol 500Mg Suppository|
223808385|NCT03808779|PROCEDURE|Radiofrequency Ablation|Patients were supine with the neck exposure completely during the procedure. Local anesthesia with 1% lidocaine was injected at the subcutaneous puncture site and the thyroid anterior capsule. If the distance between the tumor and critical cervical structures was less than 5 mm, normal saline was injected to form at least 1 cm distance between the tumor and the critical structure to prevent the unwilling thermal injury. RFA was performed using the moving-shot technique and RFA power was 5 W, if a transient hyperechoic zone did not form at the electrode tip within 5-10 seconds. The RFA extent exceeded the tumor edge to prevent marginal residue and recurrence. The ablation was terminated when all portions of the target ablation area had changed to hyperechoic zones.
223808386|NCT03808779|PROCEDURE|Conventional Surgery|Patient is performed total thyroidectomy or thyroid lobectomy depending on the intraoperative situation, disease condition and comprehensive judge by surgeon. Patients are routinely disinfected and spread the drapes after general anesthesia. Neck skin, fat and placenta muscle are incised and separated successively. The flap is separated to the upper edge of thyroid cartilage, neck white line is incised and anterior muscle group is separated. Then both sides thyroid lobes are exposed. Cut off the isthmus, ligature the thyroid artery, cut off the upper pole. Ligature and cut off the ipsilateral thyroid vein. Reveal and protect the ipsilateral recurrent laryngeal nerve and the parathyroid gland during the entire process.
223808387|NCT00533104|PROCEDURE|BM-MNC preparation|"For autologous bone marrow - mononuclear cells preparation, 500ml of bone marrow are collected under general anaesthesia; mononuclear cells are separated using a blood-cells separator (COBE SPECTRA, GAMBRO BCT) and concentrated to produce a final volume of 40ml.~Cells are implanted 1 to 3 hours after preparation by multiple intramuscular injections into the gastrocnemius of the ischemic leg.(30 injection sites, 1 to 1.5 cm deep, spaced 1 cm apart,1 ml per injection)."
223808388|NCT00533104|PROCEDURE|PB-MNC preparation|"Peripheral blood - mononuclear cells are collected through cytapheresis with the same blood-cells separator which is adjusted to obtain a 40 mL cell product. No previous mobilization with hematopoïetic growth-factor is administered.~Cells are implanted 1 to 3 hours after preparation by multiple intramuscular injections into the gastrocnemius of the ischemic leg.(30 injection sites, 1 to 1.5 cm deep, spaced 1 cm apart,1 ml per injection)."
223808389|NCT03994042|DEVICE|Mental imagery neurofeedback training|Mental Imagery (MI)-neurofeedback training, 2-3 hours, 3 times/week for 4 weeks.
223808390|NCT04585659|OTHER|Qigong|Mind-body movement art that includes specific movements, breath exercises, stretching and meditation.
223808391|NCT00744094|DIETARY_SUPPLEMENT|protein drink|250 ml protein hydrolysate solution
223808392|NCT00744094|BEHAVIORAL|Resistance training|12 weeks resistance training, 3 days per week
223808393|NCT01201603|DIETARY_SUPPLEMENT|orange juice|250ml of orange juice or a sugars matched orange drink
223808394|NCT00148226|BEHAVIORAL|Decision Aid|
223808395|NCT00000822|DRUG|Ritonavir|
223808396|NCT00000822|BIOLOGICAL|gp160 Vaccine (Immuno-AG)|
223808397|NCT00000822|DRUG|Stavudine|
223808398|NCT00000822|DRUG|Didanosine|
223808399|NCT04960605|PROCEDURE|Dental implants|Treatment of the toothless regions with dental implants
223808400|NCT04112225|BEHAVIORAL|Happify|An online platform for conveying techniques from positive psychology, cognitive-behavioral therapy, and mindfulness-based stress reduction.
223808401|NCT05739669|DEVICE|EEG recording with the comparator device Micromed Brain Quick|Each patient will undergo a visit in a clinic, during which a 15 minutes long EEG trace with a CE-certified wet electrode EEG Device (Micromed Brain Quick) will be recorded by specialized staff.
223808402|NCT05739669|DEVICE|"EEG recording with the investigational device Atlas with dry electrodes clinic/specialized staff"|"During the same visit when the wet electrode EEG is recorded, the patient will be subjected to a second 15 minutes long EEG recording with the investigational device Atlas with dry electrodes, which will be conducted by specialized staff"
223808403|NCT05739669|DEVICE|"EEG recording with the investigational device Atlas with dry electrodes home/lay people"|"The patients will record their own EEGs at home daily for 14 days, using the investigational device Atlas with dry electrodes"
223808404|NCT00463827|DRUG|Atorvastatin|
223808405|NCT00463827|DRUG|atorvastatin|atorvastatin 40mg
223808406|NCT00463827|DRUG|matched placebo|Matched placebo
223808407|NCT02222480|DRUG|Fimasartan|
223808408|NCT02222480|DRUG|Hydrochlorothiazide|
223808409|NCT02222480|DRUG|Placebo|
223808410|NCT04612855|OTHER|Groupwise comparison of primary and secondary outcomes|Statistical comparison of cohorts. Cfr supporting information on statistical plan.
223808411|NCT06303154|DEVICE|Mobiderm Intimate Bra group|At the conclusion of the surgical operation, MOBIDERM Intimate bra will be placed on the patient by the medical team. It will be recommended for the patients to wear MOBIDERM Intimate Bra during day and night for 3 weeks after the surgery, and as much time as the patients tolerate the device during the rest of the study, until 6 months after radiotherapy
223808412|NCT02573480|BEHAVIORAL|Wraparound care|Wraparound care starts by linking an individual with a support worker who works with them to address risk factors and empower the individual to make positive choices. It not only includes connecting the youth with existing community resources such as education, employment, cultural services and substance counselling, it also helps build problem-solving skills, coping skills, and self-efficacy of the youth and family members. The support worker provides mentorship to the youth. Mentorship both teaches and emulates appropriate behaviours with respect to attitudes and behaviours associated with violence.
223808413|NCT01641263|BEHAVIORAL|Sleep Education Therapy|Each 2-hour session, held once a week for 8 weeks, consists of a 60-minute video presentation followed by a 60-minute question-and-answer discussion
223808414|NCT01641263|BEHAVIORAL|Cognitve Behavioral Therapy for Insomnia|For each 2-hour session held once a week for 8 weeks, the CBT treatment manual will outline objectives, patient skills, and treatment activities. Therapists will direct role-playing and other skill-development exercises that will be designed to increase patients' self-efficacy in managing their insomnia. Homework assignments will be planned weekly to ensure practice and skill application.
223808415|NCT00048880|DRUG|HeFi-1 Monoclonal Antibody|
223808416|NCT00673062|DRUG|SCH 900538|(4X50mg Capsules)
223808417|NCT00673062|DRUG|Pseudoephedrine|Encapsulated pseudoephedrine (2X30 mg immediate release tablets)
223808418|NCT00673062|DRUG|Placebo Capsules|Placebo
223808419|NCT04437420|DRUG|injection of BEP 800|injection of BEP 800
223808420|NCT04437420|OTHER|Control|no injection of BEP 800
223808421|NCT02481284|DEVICE|Laser Doppler perfusion imaging|LDPI is an extension of laser Doppler flowmetry (LDF) and was developed to generate a colour-coded perfusion image in a large area of skin.
223808422|NCT04233372|DRUG|Delstrigo|"Doravirine / lamivudine / tenofovir disoproxil fumarate (Delstrigo®) 100 mg doravirine, 300 mg lamivudine,300 mg tenofovir disoproxil fumarate equivalent to 245 mg de tenofovir disoproxil.~1 covered tablet for day .( will be administered 28 days maximum)"
223808423|NCT05450263|BEHAVIORAL|Interoceptive exposure|A pilot study addressing the efficacy and feasibility of an interoceptive exposure technique.
223808424|NCT05776927|DRUG|QVM149|QVM149: Indacaterol as acetate 150 µg / glycopyrronium as bromide 50 µg / mometasone furoate 160 µg od delivered via Breezhaler®
223808425|NCT05776927|DRUG|Salmeterol Xinafoate / Fluticasone Propionate|Salmeterol Xinafoate 50 μg / Fluticasone Propionate 500 μg bid delivered via Girohaler®
223808426|NCT05776927|DRUG|Placebo to QVM149|Placebo to QVM149: 150 μg Indacaterol Acetate / 50 μg Glycopyrronium Bromide / 160 μg Mometasone Furoate od delivered via Breezhaler®
223808427|NCT05776927|DRUG|Placebo to Salmeterol Xinafoate / Fluticasone Propionate|Placebo to Salmeterol Xinafoate 50 μg / Fluticasone Propionate 500 μg bid delivered via Girohaler®
223808428|NCT05776927|DRUG|Run-In Medication|Salmeterol Xinafoate 50 μg / Fluticasone Propionate 250μg bid delivered via Girohaler® or equivalent DPI device
223808429|NCT05776927|DRUG|Rescue Medication|Salbutamol 100μg / Albuterol 90μg
223808430|NCT05776927|DEVICE|Concept 1 Device|Concept1 (Breezhaler) used for QVM149 and placebo delivery
223808431|NCT05776927|DEVICE|Girohaler|Girohaler for Comparator and Placebo delivery.
223808432|NCT03938454|DRUG|Crizanlizumab|Crizanlizumab is a concentrate for solution for infusion, IV use. Supplied in single use 10 mL vials at a concentration of 10 mg/mL. One vial contains 100 mg of crizanlizumab.
223808433|NCT06196736|DRUG|9MW2821|1.25mg/kg of 9MW2821 by intravenous infusion on days 1, 8 and 15 of every 28-day cycle
223808434|NCT06196736|DRUG|Chemotherapy|75mg/m\^2 docetaxel by intravenous infusion or 175 mg/m\^2 paclitaxel by intravenous infusion on day 1 of every 21-day cycle.
223808435|NCT05438030|DIAGNOSTIC_TEST|Cardiac MRI scan|Undertaken at the radiology department at Hammersmith Hospital. The scan will be performed by the MRI radiographers, under the supervision of a consultant radiologist or cardiologist.
223808436|NCT05438030|DIAGNOSTIC_TEST|Echocardiogram scan|Undertaken at the Peart Rose research unit, by a British Society of Echocardiography accredited sonographer.
223808437|NCT01090310|DRUG|AIN457|AIN457 150 mg powder for solution was provided in glass vials each containing 150 mg AIN457 as a lyophilized cake
223808438|NCT01090310|DRUG|Placebo|Matching placebo to AIN457
223808439|NCT06326710|BEHAVIORAL|mHealth|"Participants receive 4 sessions of face-to-face or online delivered workshop on how to use the mobile app Outdoor Rehab-Fit to support their daily PA level. In addition to the workshop, participants have to go to public parks to practice what they have learnt from the mobile app."
223808440|NCT06326710|BEHAVIORAL|Health Talk|Participants receive 4 sessions of face-to-face or online delivered health talks on the benefits different types of modified exercises for frail older adults (chair yoga, seated eight-section brocades, Otago and seated multi-component exercise). Each talk has an experiential session.
223808441|NCT01142388|BIOLOGICAL|Cixutumumab|Given IV
223808442|NCT01142388|OTHER|Laboratory Biomarker Analysis|Correlative studies
223808443|NCT01142388|DRUG|Paclitaxel|Given IV
223808444|NCT01142388|OTHER|Pharmacological Study|Correlative studies
223808445|NCT06051539|DEVICE|MR-001|MR-001 is an autonomous neurorehabilitation system based on the principles of Rhythmic Auditory Stimulation intended to improve walking and ambulation in adult chronic stroke patients. MR-001 is intended to be a prescription use only device for use at home/community. The user operates the MR-001 System autonomously and the therapy progresses automatically once a user engages in a session. The MR-001 system consists of two foot sensors that measure walking, a touchscreen device preloaded solely with a proprietary software application, a headset, and charging equipment. The electronic components are powered by lithium-ion rechargeable batteries. Participants are asked to walk with the device for 3 times per week for 12 weeks. Each walking session is 30 minutes in length.
223808446|NCT00877578|DIETARY_SUPPLEMENT|Nutri-Energie ®, Aliscience society|Nutri-Energie ® is a new cake of high caloric density and palatability, enriched in different specific pharmaco nutrients.
223808447|NCT00877578|DIETARY_SUPPLEMENT|Clinutren 1.5 ®, Nestlé Clinical Nutrition|Clinutren 1.5 ®, isocaloric commercially available supplement, twice a day for 4 weeks, in addition to an enriched diet
223808448|NCT00695786|DRUG|Lenalidomide|Given PO
223808449|NCT00695786|BIOLOGICAL|Rituximab|Given IV
223808450|NCT06492980|PROCEDURE|triple-branched stent graft|a triple-branched stent graft for aortic arch repairement during surgery
223808451|NCT01471132|DRUG|Oxaliplatin|Oxaliplatin 345mg/m2,43℃，30mins
223808452|NCT01471132|DRUG|Paclitaxel|Paclitaxel 260mg/m2,43℃，30mins
223808453|NCT01960595|PROCEDURE|IV fentanyl PCA|
223808454|NCT01960595|PROCEDURE|local bupivacaine infiltration and post-OP IV fentanyl PCA|
223808455|NCT01960595|PROCEDURE|Nerve Blocks and post-OP IV fentanyl PCA|
223808456|NCT03027414|DRUG|Transcranial Magnetic Stimulation Sham|TMS device is used to determine the effect of non-invasive brain stimulation on anxiety and anxiety-cognition interactions in healthy subjects.
223808457|NCT03027414|DEVICE|Transcranial Magnetic Stimulation|TMS device is used to determine the effect of non-invasive brain stimulation on anxiety and anxiety-cognition interactions in healthy subjects.
223808458|NCT01364922|DRUG|hydrocodone/acetaminophen extended release|
223808459|NCT01364922|DRUG|Placebo|
223808460|NCT02200263|DIETARY_SUPPLEMENT|Lutein plus Zeaxanthin|dose: two softgels once a day with a meal
223808461|NCT02200263|DIETARY_SUPPLEMENT|Placebo|two softgels once-daily with a meal
223808462|NCT05064787|BEHAVIORAL|Digital Health Coaching|The digital health coaching program consists of weekly calls and delivery of evidence-based content across health and wellness domains (e.g. nutrition, exercise, physical, emotional and financial health) up to 4 times weekly via text, email or mobile application. The program is 6-months in duration and designed for engagement following CAR T cell infusion.
223808463|NCT00651235|DRUG|Losartan and Atenolol or Propranolol|"50 mg of Atenolol once daily, 20 mg of Propranolol twice daily for adult and 1 mg/Kg/day for children.~Losartan is 100 mg/day for adult and 50 mg/day for children."
223808464|NCT00651235|DRUG|Atenolol or Propranolol|The maximal dose of Atenolol or Propranolol is 150 mg/day for adult and 2 mg/Kg/day for children.
223808465|NCT03727009|OTHER|Blood Sample Collection|Subjects participating in the study will have blood drawn at enrollment.
223808466|NCT04244396|DEVICE|TactiCath™ Contact Force Ablation Catheter, Sensor Enabled™ (TactiCath SE)|TactiCath SE is indicated for use in cardiac electrophysiological mapping (stimulation and recording), and, when used in conjunction with a radiofrequency generator, for cardiac ablation of supraventricular arrhythmias in the right and left atrium, including atrial fibrillation.
223808467|NCT04133103|PROCEDURE|first ambulation at 4 hour after operation|Two groups were conducted for first ambulation at 4 or 24 hours aftër operation
223808468|NCT02775318|PROCEDURE|Stellate Ganglion Block|Under aseptic conditions, transducer is placed on the surface of the neck at the level of C6 vertebrae. The internal jugular vein, carotid artery, thyroid gland, trachea, C6 vertebrae, transverse process of C6, esophagus , longus colli with its covering prevertebral fascia and esophagus are visualized. A 25-gauge Quincke spinal needle was inserted paratracheal towards the middle of the longus colli muscle. The endpoint of the injection was the ultrasound image of the tip of the needle as it penetrates the prevertebral fascia covering the longus colli muscle. The drug is then injected and spread of drug is visualized in real time.
223808469|NCT02775318|DRUG|Bupivacaine|10 ml of 0.5% injection bupivacaine is used for giving stellate ganglion block on the side of cerebral vasospasm
223808470|NCT02775318|PROCEDURE|Transcranial Doppler|The principle on which the TCD works is that with arterial narrowing, the blood flow velocity within the vessel increases. A good correlation has been found between the TCD blood flow velocities and vasospasm. The MCA velocity greater than 120 cm/sec indicates mild vasospasm , velocity greater than 130 cm/sec indicates moderate vasospasm and velocity greater than 200 cm/sec indicates severe vasospasm.
223808471|NCT02775318|PROCEDURE|Digital Subtraction Angiography|Digital subtraction angiography is a direct method for the assessment of vessel caliber. It generates high resolution, high contrast and low artifact images using digital subtraction technology. Direct visualization using DSA is the gold standard for the radiographic diagnosis of cerebral vasospasm
223808472|NCT01787097|DRUG|Symbicort® total dose 400ug/12ug|Symbicort® is combination of formoterol 400ug and budesonide 12ug. Single dose
223808473|NCT01787097|DRUG|Symbicort® total dose 800ug/24ug|Symbicort® is combination of formoterol 800ug and budesonide 24ug. Single dose
223808474|NCT01787097|DRUG|Formoterol 24ug|Turbuhaler
223808475|NCT01787097|DRUG|BUD total dose 800ug|Turbuhaler
223835430|NCT00738530|DRUG|Interferon alfa 2a [Roferon]|9 MIU SC 3 times/week
223835431|NCT00738530|DRUG|Placebo|IV every 2 weeks
223835432|NCT04101864|PROCEDURE|Electromagnetic navigation|Acetabular component placement in total hip arthroplasty will be performed wit the help of electromagnetic image-less navigation system.
223808476|NCT03810534|BEHAVIORAL|Connect-Home|Connect-Home will introduce organizational structure to support delivery of transitional care processes. New elements of structure include:electronic health record (EHR) template, Connect-Home Toolkit, and Staff Training. After structural elements are added, SNF staff will use Connect-Home care processes to deliver the 2-step transitional care intervention.In Step 1, SNF nurses, therapists, and social workers will develop a Transition Plan of Care and prepare the patient and caregiver to manage the patient's serious illness and functional needs. In Step 2, the Connect-Home Activation RN will visit the patient's home within 24 hours of discharge; the nurse will activate the Transition Plan of Care at home. Both intervention steps focus on 6 key care needs to optimize patient and caregiver outcomes: 1) home safety and level of assistance; 2) advance care planning; 3) symptom management; 4) medication reconciliation; 5) function and activity; and 6) coordination of follow-up medical care.
223808477|NCT02629835|OTHER|intravenous 8 mg dexamethasone and perineural 0.8 ml of saline solution|
223808478|NCT02629835|OTHER|intravenous 0,8 ml of saline solution and perineural 8 mg of dexamethasone|
223808479|NCT05614414|PROCEDURE|tracheal intubation by Videolaryngoscope|The investigators performed laryngoscopy using a McGrath video-laryngoscope with a number 4 blade.
223808480|NCT05614414|PROCEDURE|tracheal intubation by direct laryngoscope|The investigators performed laryngoscopy using either a Macintosh laryngoscope using a number 4 blade.
223808481|NCT05286944|OTHER|Mobile phone alarm reminder|Patients are reminded to take their INCS using a mobile phone alarm set to ring daily
223808482|NCT02448667|DIETARY_SUPPLEMENT|FAXE Kondi|Sucrose and glucose containing softdrink
223808483|NCT02448667|DIETARY_SUPPLEMENT|Faxe Kondi Free|Diet softdrink with artificial sweeteners aspartame and acesulfame potassium. Both sweeteners are approved for use as food additives in the European Union and by the FDA. Aspartame metabolism is well understood and normal doses does not affect plasma concentrations of lipids, amino acids, glucose levels, key regulatory hormones or skeletal muscle metabolism. Acesulfame Potassium is not metabolized in humans and is excreted as the parent compound in urine. Since the two artificial sweeteners does not affect skeletal muscle metabolism or blood glucose levels, and both compounds have a well documented safety profiles, FAXE Kondi Free is considered to be an ideal placebo soft drink in this study.
223808484|NCT05009524|DEVICE|iPACES (interactive Physical and Cognitive Exercise System)|"iPACES involves a pedal-to-play neuro-exergame in which physical and mental exercise are combined in an interactive way. In this condition a person will pedal to control forward motion in a tablet-based game, such as when pedaling along a virtual path and steering to different assigned errand locations."
223808485|NCT05009524|DEVICE|PACE (Physical and Cognitive Exercise)|"PACE involves a pedal-while-play experience in which physical and mental exercise are combined in a simultaneous, but not fully interactive way. In this condition a person will pedal while also separately steering in a tablet-based game, such as when pedaling while automatically progressing along a virtual path to different assigned errand locations."
223808486|NCT00553501|BIOLOGICAL|epratuzumab|Days 1, 8, 15, 22 and weeks 12, 20, 28, \& 36: 360mg/sq m IV
223808487|NCT00553501|BIOLOGICAL|rituximab|Day 3, 8, 15, 22 and weeks 12, 20, 28, \& 36: 375mg/sq m IV
223808488|NCT05794555|BEHAVIORAL|Enhanced Usual Care|Patients will be provided and counseled on two methods which will enhance care. The first is a handout on nutrition recommendations and protein supplementation. This will include the recommendation of both high protein snacks during the daytime (e.g., protein bars) and a high-protein night-time snack (e.g., peanut butter and crackers). The second will be to counsel participants on falls prevention methods that can be enacted in day-to-day life. All participants will be provided with a standard hand-out of Centers for Disease Control and Prevention (CDC)-endorsed fall-risk reduction measures.
223808489|NCT05794555|DRUG|Lactulose|"Patients will be prescribed lactulose and will also receive enhanced usual care. Lactulose will be taken on a specific schedule based on the average number of bowel movements on average per day. It will be started at 15 milliliter (mL) dose and will be instructed to slowly increase the lactulose dose over the course of the first week of Stage 1 participation. The prescribed maximum dose will be 30 mL (20g) twice daily. The dose will slowly increase toward the maximum or until participants reach 2-3 soft bowel movements daily.~Participants that receive Lactulose during stage 1 will continue this in stage 2."
223808490|NCT05794555|BEHAVIORAL|Investigator recommended exercise|Participants randomized to enhanced usual care will be reminded of standard fall precautions outlined in the Fall Prevention Primer that were provided in Stage 1 and will receive exercise recommendations.
223808491|NCT05794555|BEHAVIORAL|TeleTai-Chi (virtual)|TeleTai-Chi will be taught remotely via live Zoom classes of up to 15 patients by a certified TeleTai-Chi instructor three times per week (for approximately 12 weeks). Classes will be conducted via a HIPAA-compliant Zoom server through the University of Michigan. Participants will be instructed to use Zoom by smartphone, tablet, or computer. High-Definition Multimedia Interface (HDMI) cables and other device specific equipment to connect devices to televisions will be provided.
223808492|NCT02293395|DRUG|Acetylsalicylic acid|ASA 100 mg enteric-coated tablet once daily orally.
223808493|NCT02293395|DRUG|Rivaroxaban|Rivaroxaban 2.5 mg tablet twice daily orally.
223808494|NCT02293395|DRUG|Clopidogrel|Clopidogrel 75 mg once daily orally.
223808495|NCT02293395|DRUG|Ticagrelor|Ticagrelor 90 mg twice daily orally.
223808496|NCT02597907|DRUG|aprepitant|aprepitant 80 mg is given to all patients before surgery
223808497|NCT02597907|DRUG|palonosetron|palonosetron 0.075 mg is given to patients in the aprepitant plus palonosetron group after induction of general anesthesia
223808498|NCT02597907|DRUG|Ramosetron|ramosetron 0.3 mg is given to patients in the aprepitant plus ramosetron group after induction of general anesthesia
223808499|NCT03305874|OTHER|Exposure to CBCIN risk score|The computer-based contrast induced nephropathy (CBCIN) risk score and associated standard hydration strategy will be displayed on a monitor in front of the treating interventional cardiologist during the entirety of the PCI case. Since this scoring system and hydration strategy are both available in the peer-reviewed literature, clinical use of these data and implementation of a CIN-avoidance strategy is not experimental; however, the display of these data to interventional cardiologists is experimental. Based on exposure to these data, the treating interventional cardiologist may use the information as clinically appropriate (i.e. it is not the basis for clinical decisions).
223808500|NCT01677221|DEVICE|Acleara Acne Treatment System|
223808501|NCT02816034|BEHAVIORAL|Visuo-motor rotation|Participant moves a cursor on a screen by sliding a pen over a digital tablet. Participants perform a center-out movement, aiming to a target that appears over one of a set of eight markers radially distributed. In several block of trials, the mapping of the pen position to the cursor is rotated.
223808502|NCT02816034|BEHAVIORAL|Explicit strategy|Participant is provided with an explicit instruction as to how counteract the effects of the visuo-motor rotation via aiming to a marker adjacent target
223808503|NCT01303120|DRUG|Femoral Nerve Block|Preoperative Bupivacaine 0.5%, perineurally as single shot
223808504|NCT01303120|DRUG|Combined nerve blocks|Preoperative Bupivacaine 0.5%, perineurally as single shot
223808505|NCT01303120|DRUG|Patient-controlled analgesia|Patient controlled analgesia with morphine
223808506|NCT02300012|PROCEDURE|Surgeons knowledge of pre-operative PBIs|Surgeon performing ACL repair will have prior knowledge of patients pre-operative PBIs to inform surgical practice
223808507|NCT06175585|OTHER|narrative nursing|"The narrative nursing process is based on the practice of two-line system proposed by Jiang, which is carried out in a separate classroom, office or ward with sufficient space and good lighting. The environment is set to the right temperature and humidity for comfortable face-to-face conversation. This process is done in stages, depending on how often the patient is dialysis three or more times a week.~Each session lasts about 30 minutes and the whole process lasts four weeks. Adjust to the specific needs of each patient ."
223808508|NCT06175585|OTHER|traditional nursing|Patients undergoing MHD received traditional nursing interventions, encompassing various aspects such as dietary advice, instructions on medication usage, health education, emphasis on precautions during dialysis, and guidelines for vascular access care. Additionally, the nurses proactively inquired about patients' emotional well-being during the nursing shift change, actively engaged and uplifted patients experiencing low spirits, and encouraged family members to provide emotional support.
223808509|NCT01478711|OTHER|Clinical Decision Support Tool|A clinical decision support tool embedded within Epic will appear for children with a history of prematurity at the intervention sites.
223808510|NCT02060591|DRUG|Exparel|
223808511|NCT02060591|DRUG|Marcaine|
223808512|NCT01879423|DRUG|Lamotrigine Dispersible/Chewable tablets 5mg*5|Single dose of lamotrigine dispersible/chewable 5mg\*5 tablets at Day1 and Single dose of Lamotrigine Compressed 25mg\*1 tablet at Day15
223808513|NCT01879423|DRUG|Lamotrigine Compressed tablet 25mg|Single dose of lamotrigine compressed 25mg\*1 tablet at Day1 and Single dose of lamotrigine dispersible/chewable 5mg\*5 tablets at Day15
223808514|NCT00861614|DRUG|Ipilimumab|5 mg/ml solution, Intravenous, 10 mg/kg, Every 3 weeks for up to 4 doses in the Induction Phase. Every 12 weeks in the Maintenance Phase, Up to 24 weeks in Induction, 48+ weeks in the Maintenance Phase, or until Treatment Stopping Criteria are met, withdrawal of consent, lost to follow-up, death, study closure
223808515|NCT00861614|DRUG|Placebo|Solution, Intravenous, 0 mg, Every 3 weeks for up to 4 doses in the Induction Phase. Every 12 weeks in the Maintenance Phase, up to 24 weeks in Induction, 48+ weeks in the Maintenance Phase, or until Treatment Stopping Criteria are met, withdrawal of consent, lost to follow-up, death, study closure
223808516|NCT03391765|DRUG|ABBV-8E12|Participants with 44-49 kg body weight (BW) had an intravenous infusion rate of 3.5 mL/min or 210 mL/hr; those with 50-58 kg BW, 4.0 mL/min or 240 mL/hr; and those with a BW \>59 kg, 4.7 mL/min or 282 mL/hr.
223808517|NCT03391765|DRUG|Placebo solution for IV infusion on Day 15|0.9% NaCl injection/solution for infusion 500 mL; participants with 44-49 kg body weight (BW) had an intravenous infusion rate of 3.5 mL/min or 210 mL/hr; those with 50-58 kg BW, 4.0 mL/min or 240 mL/hr; and those with a BW \>59 kg, 4.7 mL/min or 282 mL/hr.
223808518|NCT02212444|DEVICE|Dynamic elastomeric fabric orthoses (DEFO)|A patient customised dynamic elastomeric fabric orthoses (DEFO)
223808519|NCT02212444|DEVICE|Off -the-shelf triplanar orthoses|
223808520|NCT01056588|BEHAVIORAL|CO-Contingent|In this 42 day condition, participants will receive monetary reinforcements contingent on submitting breath samples at CO levels indicating reductions or abstinence from smoking (4ppm).
223808521|NCT01056588|BEHAVIORAL|Control condition|In this condition, participants will receive monetary reinforcement for timely breath samples with no contingency for a specific breath CO level
223808522|NCT00944658|DRUG|Apremilast|10mg twice a day, dose was titrated by 20mg every 2 days until the maximum dose 30mg twice a day for 12weeks
223808523|NCT00944658|DRUG|Placebo (sugar pill)|twice a day
223808524|NCT01272960|DEVICE|Post-Placenta Mirena Insertion|Mirena(R) intrauterine device will be inserted within 10 minutes of delivery of the placenta
223808525|NCT01272960|DEVICE|Interval Insertion|Insertion of Mirena 4-8 weeks post partum after vaginal delivery
223808526|NCT01837329|DRUG|Tetrathiomolybdate|"Dose Escalation - Dose level -1: 20 mg TM orally 3 x daily x 21 days in combination with carboplatin IV area under the curve (AUC) = 6 and pemetrexed IV 500/mgm2 day 1 x 1 cycle.~Dose level 1: 40 mg TM orally 3 x daily x 21 days in combination with carboplatin IV AUC = 6 and pemetrexed IV 500 mg/m2 day 1 x 1 cycle.~Dose level 2: 60 mg TM orally 3 x daily x 21 days in combination with carboplatin IV AUC = 6 and pemetrexed IV 500 mg/m2 day 1 x 1 cycle.~Patients in the dose-expansion cohort will continue on carboplatin and pemetrexed (without TM) at the discretion of the treating physician.~Dose Expansion - Maximum tolerated dose of TM determined from the dose-escalation cohorts combined with carboplatin IV AUC = 6 and pemetrexed IV 500 mg/m2 day 1 x 4 cycles."
223808527|NCT05297474|OTHER|MRI|No intervention was performed in this study.
223808528|NCT03312153|DRUG|Neem|A natural irrigant solution act as anti-inflammatory and anti bacterial
223808529|NCT03312153|DRUG|2.5% sodium hypochlorite|anti bacterial root canal irrigant solution
223808530|NCT04698317|PROCEDURE|open flap debridement|Open flap for removal of diseased periodontal tissues and necrotic cementum
223808531|NCT04698317|OTHER|use of Biodegradable Gelatin Sponge loaded with Beta-tricalcium Phosphate plus concentrated growth factors|use of Biodegradable Gelatin Sponge loaded with Beta-tricalcium Phosphate incorporating Concentrated Growth Factors in Periodontal Defect
223808532|NCT04698317|OTHER|use of Biodegradable Gelatin Sponge loaded with Beta-tricalcium Phosphate alone|use of Biodegradable Gelatin Sponge loaded with Beta-tricalcium Phosphate alone in the Intrabony Periodontal Defect
223808533|NCT00963911|OTHER|Geriatric screening tests|"The G-8 consists of eight items: patient age (\>85, 80-85, \<80), and seven items from the original 18-item MNA (Mini Nutritional Assessment: appetite changes, weight loss, mobility, neuropsychological problems, body mass index, medication, and self-rated health). The total score ranges from 0 to 17, with lower scores indicating a higher risk of impairments. The cut-off value for an 'impaired' reference test score was \<=14 and the time taken to complete the test was recorded.~VES-13 is a self-administered questionnaire that was completed during the first visit after enrollment. For three pre-identified centers, patients also filled in the questionnaire at the following geriatric visit. VES-13 consisted of four groups of questions: age, self-perceived health, difficulties to perform six specific activities, and difficulties to perform daily living tasks due to health concerns. The score ranged from 0 to 10 and a score \>=3 was considered to show impairment."
223808534|NCT00963911|OTHER|Multidimensional geriatric assessment|Patients underwent a geriatric evaluation in the month following the completion of G8 and VES-13 (+/- seven days) before treatment began. The nurse completed six of the seven instruments of the MGA (MNA, Timed Get up and Go (TUG), Activities of Daily Living (ADL), Instrumental ADL (IADL), Mini Mental State Examination (MMSE), and Geriatric Depression Scale (GDS-15)), and the geriatrician rated comorbidity on the Cumulative Illness Rating Scale (CIRS-G), recorded the time required for the consultation, identified patients who needed personalized geriatric interventions, and, if necessary, proposed further geriatric evaluation (outside of the scope of this study).
223808535|NCT02357030|DRUG|Methyl-P plus GWI Nutrient Formula|"Week 1:~* One tablet of Methyl-P (5mg) twice daily~* Four tablets of GWI Nutrient Formula twice daily~Week 2 to Week 12 :~* Two tablets of Methyl-P (10mg) twice daily~* Four tablets of GWI Nutrient Formula twice daily"
223808536|NCT00926510|BEHAVIORAL|Language toolkit|Simple toolkit of interactive things to stimulate language.
223808537|NCT00926510|BEHAVIORAL|Safety counseling|Smoke detector and general safety counseling
223808538|NCT03496974|DRUG|Bermekimab Monoclonal Antibody 200 mg|200 mg subcutaneous injection
223808539|NCT03496974|DRUG|Bermekimab Monoclonal Antibody 400 mg|400 mg subcutaneous injection
223808540|NCT05616364|DRUG|Dexmedetomidine injection|Dexmedetomidine intravenous
223808541|NCT05616364|DRUG|Tramadol|Tramadol intravenous
223808542|NCT00992953|BEHAVIORAL|Treatment as Usual|10 weeks of therapy and/or psychiatric medication as available
223808543|NCT00992953|BEHAVIORAL|Virtual Reality Exposure with Stimulus Control|10 weeks of therapy, up to twice a week, 90 min sessions involving Virtual Reality Exposure with Stimulus Control
223808544|NCT00101127|BIOLOGICAL|filgrastim|
223808545|NCT00101127|BIOLOGICAL|pegfilgrastim|
223808546|NCT00101127|DRUG|docetaxel|
223808547|NCT00101127|DRUG|gemcitabine hydrochloride|
223808548|NCT01038258|PROCEDURE|PET scan after course 1 and surgery after 8 courses|PET scan and surgery
223808549|NCT00297115|DRUG|Roflumilast|500 mcg, once daily, oral administration in the morning
223808550|NCT00297115|DRUG|Placebo|once daily
223808551|NCT05381298|PROCEDURE|Deep Margin Elevation using resin composite|After completion of the root canal treatment of the offended tooth and comprehensive evaluation of the obtained treatment, the randomly allocated patients will undergo deep margin elevation procedure where rubber dam isolation will be accomplished Followed by proper matricing and wedging ) followed by selective enamel etching for 10 seconds then universal adhesive application following the manufacturer instructions followed by application of flowable resin composite for the first 1 mm and light cured for 20 seconds according to the manufacturer recommendations followed by application of packable bulk fill composite to elevate the margins and light cured following the manufacturer instructions.
223835433|NCT04101864|PROCEDURE|Freehand|In the control group acetabular components in total hip arthroplasty will be placed with the help of the freehand technique.
223808552|NCT05381298|PROCEDURE|Surgical Crown Lengthening|Participants in this group will undergo surgical crown lengthening in which an internal bevel incision will be done buccally and lingually followed by full thickness flap reflection using mucoperiosteal elevator, then interproximal bone removal will be done using end cutting bur to the planned position away from the margins by 3 mm. The flap will be displaced apically with apically positioned sutures. Postoperative instructions will be given to the patient aiming to control postsurgical complications including pain and swelling. Suture removal and assessment of the surgical site will be done after two weeks
223808553|NCT02235467|BEHAVIORAL|ABA parent training|A parent training based on Applied Behavior Analysis that is going to be delivered by video modeling in 21 weeks
223808554|NCT02427789|OTHER|Physical Exercise|physical exercise
223808555|NCT03586583|DEVICE|FBP|Old processing
223808556|NCT03586583|DEVICE|ISR|New processing
223808557|NCT02352597|DRUG|phytoestrogen|20mg of cimifuga racemosa from day 1- 12
223808558|NCT02352597|DRUG|estradiol valerate|2mg from cycle day 7 to day 11
223808559|NCT02352597|DRUG|clomiphene citrate|50 mg orally every 8 hours started from cycle day 3 for 5 days
223808560|NCT00336739|DRUG|cinacalcet|
223808561|NCT02832622|DEVICE|MPP|MPP ON within 1 month post implant and then continuously programmed ON until 12 months (i.e., MPP ON for months 1-12 continuously)
223808562|NCT02832622|DEVICE|BiV/MPP|MPP ON at the 12-month study visit and for at least 3 continuous months prior to 12-month assessment (i.e., BiV pacing ON at some point in months 1-9 and MPP ON for months 10-12)
223808563|NCT01558310|DRUG|Ustekinumab|Subjects will be randomized into one of two groups. Group A will receive ustekinumab at week 0, 4, 16, 28, and week 40 and placebo at week 12 and 52. Group B will receive placebo at Week 0 and 4, and ustekinumab at weeks 12, 16, 28, 40 and 52. The subjects when assigned to ustekinumab, depending on body weight, will receive either 45mg or 90mg ustekinumab doses
223808564|NCT01558310|DRUG|Placebo|Subjects will be randomized into one of two groups. Group A will receive ustekinumab at week 0, 4, 16, 28, and week 40 and placebo at week 12 and 52. The subjects when assigned to ustekinumab, depending on body weight, will receive either 45mg or 90mg ustekinumab doses
223808565|NCT05011643|OTHER|Moderate-intensity exercise|Participants will walk either 30km, 40km or 50km for four consecutive days during the Nijmegen Four Days Marches. Measurements will be performed after the finish of the first, second and third walking day.
223808566|NCT04607655|DRUG|GB1211|GB1211 is a galectin-3 inhibitor an orally available small molecule anti-fibrotic. It is administered orally twice a day.
223808567|NCT04607655|DRUG|Placebo|Placebo is administered as inhalation once a day
223808568|NCT01058538|DRUG|L19IL2|Route: i.v. infusion (60 min) Patients will receive a minimum of 2 cycles of treatment. Each cycle is comprised of treatment on Days 1, 3 and 5 followed by a 16 days rest (1 cycle= 21 days). Patients may receive up to 4 further cycles of treatment (max. of 6 cycles in total). Patients will be initially recruited into the study in cohorts of 3 and the starting dose of L19IL2 will be 5 Mio IU IL2 equivalent. Five steps of dose escalation are planned: 5, 10, 20, 30 and 40 Mio IU IL2 equivalent). After the MTD has been established, the RD will be determined. A further 12 patients (with RCC) will receive the RD dose for a minimum of 2 cycles. For patients in the RD part of the study, patients can switch to maintenance therapy. Maintenance therapy consists of 15 Mio IU IL2 every 2 weeks. The maximum duration of the study for a patient is 12 months.
223808569|NCT05001438|PROCEDURE|Hidro|Guided by ultrasonography under anesthetic blockage of the circumflex nerve and the supraescapular nerve. The hidrodilatation is achieved by insuflating the articulation with 2 cc of trigon depot + 10 cc 1% mepivacain + 11 cc saline serum.
223808570|NCT05001438|PROCEDURE|MUA|Movilization under anesthesia
223808571|NCT02472652|DRUG|Abilify Maintena|For subjects who meet inclusion/exclusion criteria for this study a switch from Palliperidone Palmitate or Risperidone injectable will be made to Abilify Maintena for a 3 month period to determine if there are changes in sexual dysfunction ratings over this time period
223808572|NCT01053260|BEHAVIORAL|LEARN Program|Participants will receive weekly counseling based on the LEARN Program for Weight Management
223808573|NCT01053260|BEHAVIORAL|Contingency Management|Participants can earn chances to win prizes for losing weight and completing activities that promote weight loss.
223808574|NCT02713711|RADIATION|phototherapy|Twelve sessions of phototherapy (UV-B) according to individual initial evaluation of Minimal Erythema Dose (MED).
223808575|NCT02713711|PROCEDURE|balneotherapy|Twelve sessions of 15 minutes of balneotherapy (warm water, 32 °C and natural sea salt, 250 g/L).
223808576|NCT02713711|PROCEDURE|balneophototherapy|Twelve sessions of both balneotherapy and phototherapy treatments.
223808577|NCT00001790|DRUG|FK463|
223808578|NCT00998400|BEHAVIORAL|CBT in combination with WBT and life style modification|CBT involves several essential features: identifying and correcting inaccurate thoughts associated with depressed feelings (cognitive restructuring); helping patients to engage more often in enjoyable activities (behavioral activation); enhancing problem-solving skills; providing instruction and guidance in specific strategies for solving problems. The techniques included in WBT may be used in overcoming impairments in environmental mastery, purpose in life, personal growth, autonomy, self-acceptance and positive relations with others. CM will consist of reviewing the patients' clinical status, and providing the patient with support and advice if necessary.
223808579|NCT03185832|DEVICE|CRT-D|This subject cohort is made by all patients enrolled and implanted with defibrillator with CRT capabilities
223808580|NCT03185832|DEVICE|ICD|This subject cohort is made by all patients enrolled and implanted with defibrillator capabilities
223808581|NCT03185832|DEVICE|PM / CRT-P|This subject cohort is made by all patients enrolled and implanted with pacemakers with or without CRT capabilities
223808582|NCT03185832|OTHER|Non-device|Patient enrolled but not implanted with a Defibrillator or Pacemaker
223808583|NCT02127619|DEVICE|Total knee replacement with the ROCC® knee prosthesis|replacement of an osteoarthritic knee with a total knee prosthesis operation may be for a single knee ( unilateral) or both knees of a patient ( bilateral)
223808584|NCT04563325|DRUG|Oral co-amoxiclav or oral dicloxacillin only|High dose oral treatment followed by standard dose oral treatment
223808585|NCT04563325|DRUG|IV ceftriaxon followed by oral co-amoxiclav or oral dicloxacillin|IV treatment followed by standard dose oral treatment
223808586|NCT03133104|OTHER|Antenatal corticosteroids|Women and neonates with PPROM who received a repeat dose of antenatal corticosteroids, compared to women with PPROM who did not received a repeat course of antenatal corticosteriods
223808587|NCT01083641|DRUG|Estradiol|10mg oral three times daily
223808588|NCT01528449|BIOLOGICAL|B.microti diagnostic blood tests|the interventions/procedures are investigational diagnostic tests for B.microti (PCR and IFA).
223808589|NCT01528449|BIOLOGICAL|B.microti diagnostic blood tests|the interventions/procedures are investigational diagnostic tests for B.microti (PCR and IFA).
223808590|NCT05233202|DRUG|Levosimendan|Levosimendan administered as a continuous infusion over a 24-hour period at the rate of 0.2μg/kg/min, with no bolus administration. The infusion will begin 24H to 48H before anesthetic induction.
223808591|NCT05233202|DRUG|PLACEBO|Placebo (isotonic sodium) administered as a continuous infusion over a 24-hour period at the rate of 0.2μg/kg/min, with no bolus administration. The infusion will begin \<48H before anesthetic induction.
223808592|NCT03881280|BEHAVIORAL|Parenting education program|"Parenting education program through the app Fammeal. It includes educational content, tailored to parents and centered on positive parenting child-feeding practices. The app will also include a virtual-pet game for children, in order to help them self-regulate their intake.~Through the app, parents will:~* Fill in a registration questionnaire, which will tailor recommendations.~* Receive information and video content recommendations.~* Set goals related to their child's lifestyle and tracking progress.~* Earn points by watching the contents.~* Invite children to play a serious game.~* Exchange messages with other users.~The investigators created a support website that connects to the main server to get data gathered from the mobile app and game."
223808593|NCT04234724|OTHER|Kinetics test, oral fat tolerance test, and an oral glucose tolerance test.|Subjects will participate in a kinetics test, oral fat tolerance test, and an oral glucose tolerance test.
223808594|NCT02352441|OTHER|Implementation Intentions(II)|"Implementation Intention training will include:~Demonstration and practice using examples and personal goals identified at first session. Worksheets will be provided to practice IF-THEN statements to set Implementation Intentions. Additionally, at the end of each session, the participant will be instructed to perform and event based or time based task. The objective is to see if those receiving II training are more likely to carry out the assigned task than those who do not receive II training. They will also be expected to practice II at least 5 days/week using personal goals."
223808595|NCT00003084|DRUG|Doxorubicin Hydrochloride|Doxorubicin IV on days 1, 15, and 29.
223808596|NCT00003084|DRUG|Estramustine phosphate sodium|"Arm I: Oral estramustine three times a day for 21 day cycle.~Arm II: Oral estramustine three times a day on days 8-14, 22-28, and 36-42 in 8 week cycle."
223808597|NCT00003084|DRUG|Etoposide|Oral etoposide twice daily on days 1-14.
223808598|NCT00003084|DRUG|Ketoconazole|Oral ketoconazole three times a day on days 1-7, 15-21, and 29-35.
223808599|NCT00003084|DRUG|Paclitaxel|IV over 1 hour on day 2.
223808600|NCT00003084|DRUG|Vinblastine|IV on days 8, 22, and 36.
223808601|NCT02421562|PROCEDURE|training in hypnoanalgesia|training nurses in hypnoanalgesia techniques to perform painful procedures in children followed in the outpatient hematology oncology clinic
223808602|NCT04995562|DRUG|129Xe|Inhaled contrast for MRI
223808603|NCT00087360|OTHER|counseling intervention|
223808604|NCT00087360|OTHER|physiologic testing|
223808605|NCT00087360|PROCEDURE|evaluation of cancer risk factors|
223808606|NCT01329354|BIOLOGICAL|Autologous effector lymphocytes expanded ex-vivo|Maintenance therapy with Rituximab every two months is the standard of care for patients with follicular lymphoma after induction therapy. The intervention consists on the administration of autologous effector lymphocytes expanded ex-vivo every two Rituximab administrations.
223808607|NCT03386032|DRUG|Investigational OTC Cream|Investigational Over the Counter (OTC) Cream applied topically, twice daily, for 8 weeks, once in the morning and once in the evening, to atopic dermatitis lesions and whole body as moisturizer.
223808608|NCT03386032|DRUG|0.05% Desonide|"Rx Steroid applied topically, twice daily, once in the morning and once in the evening, for 8 weeks to all atopic dermatitis lesions.~Placebo Cream applied topically, twice daily, for 8 weeks, once in the morning and once in the evening, to whole body as body moisturizer, except atopic dermatitis lesions."
223808609|NCT03386032|OTHER|Placebo Cream|Placebo Cream applied topically, twice daily, for 8 weeks, once in the morning and once in the evening, to atopic dermatitis lesions and whole body as body moisturizer.
223808610|NCT01003457|OTHER|ultrasonography|transvaginal ultrasonography of bladder wall thickness
223808611|NCT03753295|DIAGNOSTIC_TEST|Hand Grip Force|"For measuring the grip strength, the subjects will be asked to sit on a chair with their hip joint flexed at 90 degree, and shoulder joint in a neutral position.~The elbow is fixed at 90 degree flexion, forearm in a neutral position, and wrist at 0 to 15 degree radial deviation.~The test will be performed twice, and the higher value between the two measurements will be selected.~The subjects will be allowed a rest time of more than 5 minutes after the first measurement to avoid examiner bias and to decrease physical stress"
223808612|NCT01807156|DRUG|Tivozanib|Oral medication given daily. No placebo.
223808613|NCT03364348|DRUG|Utomilumab|Given IV
223808614|NCT03364348|DRUG|Trastuzumab|Given IV
223808615|NCT03364348|DRUG|Ado-Trastuzumab Emtansine|Given IV
223808616|NCT05753865|DRUG|SYHX2011|IV infusion, 260 mg/m\^2
223808617|NCT05753865|DRUG|Paclitaxel for injection (albumin-bound)|IV infusion, 260 mg/m\^2
223808618|NCT05412888|DIETARY_SUPPLEMENT|CoQ10 supplementation|Young men training endurance running will be supplemented with CoQ10
223808619|NCT05412888|PROCEDURE|Ischemic preconditioning training|Young men training endurance running will undergo IPC training
223808620|NCT05412888|DIETARY_SUPPLEMENT|IPC training combined with CoQ10 supplementation|Young men training endurance running will undergo IPC training combined with CoQ10 supplementation
223808621|NCT05412888|DIETARY_SUPPLEMENT|Sham IPC combined with placebo|Young men training endurance running will undergo sham IPC training combined with placebo supplementation
223808622|NCT01480947|DRUG|Bio-three|oral Bio-three three times daily for 7 days, Bio-three dosage plan: 1) patients aged 6 years old, 1 tablet t.i.d.; 2) patients aged between 6 and 12 years old, 2 tablets t.i.d.; 3) patients aged 12 years old, 3 tablets t.i.d.
223808623|NCT04377230|PROCEDURE|biliopancreatic limb length of 60cm.|Roux-en- Y gastric bypass will be performed with a biliopancreatic limb length of 60cm.
223808624|NCT04377230|PROCEDURE|biliopancreatic limb length of 100cm.|Roux-en- Y gastric bypass will be performed with a biliopancreatic limb length of 100cm.
223808625|NCT03276637|GENETIC|Whole exome sequencing|Whole exome sequencing at 125x coverage (i.e., at least 125 sequencing reads covering each position within the exome region of interest) performed at the Laboratory of Molecular Medicine's Clinical Laboratory Improvement Amendments (CLIA) certified laboratory on 75 enrolled individuals
223808626|NCT03484676|DEVICE|Titinium|custom made plate at one point after 3D virtual simulation and reduction of the complex using Mimics software.
223808627|NCT03464279|BEHAVIORAL|Nudge using Behavioral Economic Interventions|
223808628|NCT03464279|BEHAVIORAL|Standard Practices to Reduce Health System Antibiotic Prescription|
224264416|NCT05199064|OTHER|Ultrasound guided greater occipital nerve (GON) radiofrequency|After identifying the GON with ultrasound guidance, a catheter needle (22-gauge 5 cm 5 mm active tip hybrid electrode) is inserted with an in-plane technique from lateral to medial.After visualizing the electrode tip placed close to the right or left GON, a sensory stimulation test is performed using an RF generator (URF-3AP Diros Tecnology Inc.). After the patient reports dysesthesia and a tingling sensation at the occipital area with less than 0.2 V, the PRF treatment is administered at 5 Hz and 5 milliseconds pulsed width for 360 seconds at 45 V under the constraint that the temperature of the electrode tips does not exceed 42°C
224264417|NCT05351567|OTHER|EDUCATIONAL PROGRAM CREATED ACCORDING TO TRANSFORMATIONAL LEARNING THEORY|EDUCATIONAL PROGRAM CREATED ACCORDING TO TRANSFORMATIONAL LEARNING THEORY FOR INFERTILITY FEMALES
223808629|NCT04680325|DIETARY_SUPPLEMENT|Juice daily consumption|Single-service bottles of juice were provided for 15 days of daily consumption in each arm
223808630|NCT04508452|DRUG|Capecitabine-Oxaliplatin-Irinotecan-Bevacizumab Combination|CAP 1,600 mg/sq.m /day (p.o. day1-10) D1-10; Oxaliplatin (OX): 68 mg/sq.m (d.i.v.) D1; Irinotecan (IRI):135 mg/sq.m (d.i.v.) D1; BEV: 5mg/kg (d.i.v.) D1; Administered every 2 weeks.
223808631|NCT06329726|DIAGNOSTIC_TEST|Clinical examinations and clinical scales administration|Psychometric assessment of cognitive and behavioral outcomes
223808632|NCT01731743|DEVICE|AT LISA tri 839MP|
223808633|NCT00005993|DRUG|aldesleukin|
223808634|NCT00005993|DRUG|filgrastim|
223808635|NCT00005993|DRUG|recombinant human stem cell factor|
223808636|NCT00005993|PROCEDURE|peripheral blood stem cell transplantation|
223808637|NCT02056860|PROCEDURE|Group 1 will receive 15 Hz|Group 1 (n=30), these subjects will receive 10 minutes of High Frequency Oscillation at 15 Hz at .75 cm on day 1. Then will have a 24 hour washout. On day 2 will receive 10 minutes of low Frequency Oscillation at 15 Hz at 1.25 cm.
223808638|NCT02056860|PROCEDURE|Group 2 will receive 30 Hz|Group 2 (n=30), these subjects will receive 10 minutes of High Frequency Oscillation at 30 Hz at .75 cm on day 1. Then will have a 24 hour washout. On day 2 will receive 10 minutes of low Frequency Oscillation at 30 Hz 1.25 cm.
223808639|NCT02056860|PROCEDURE|Group 3 will receive 60 Hz|Group 3 (n=30), these subjects will receive 10 minutes of High Frequency Oscillation at 60 Hz .75 cm on day 1. Then will have a 24 hour washout. On day 2 will receive 10 minutes of low Frequency Oscillation at 60 Hz at 1.25 cm.
223808640|NCT02056860|PROCEDURE|Group 4 will receive 100 Hz|Group 4 (n=30), these subjects will receive 10 minutes of High Frequency Oscillation at 100 Hz at .75 cm on day 1. Then will have a 24 hour washout. On day 2 will receive 10 minutes of low Frequency Oscillation at 100 Hz at 1.25 cm.
223808641|NCT02056860|PROCEDURE|Phase II Optimal Frequency|Participants in Phase II will undergo 10 minutes of HFO at the optimal frequency as determined during Phase I.
223808642|NCT04158414|DIAGNOSTIC_TEST|PET/MR scan|500 cancer patients referred to PET-CT assessment will undergo PET/MR scan as well, and the net data will be compared. The overall data will be investigated in groups and subgroups of patients that share similar clinical characteristics and represent cancer patients in different time points during the natural history of their disease. Data analysis will be performed both visually and quantitatively using different MR and PET parameters according to the patient group. Specific populations will be detailed in the next sections per malignancy.
223808643|NCT00122590|DRUG|nelfinavir|
223808644|NCT00122590|DRUG|lopinavir/r|
223808645|NCT00122590|DRUG|indinavir|
223808646|NCT00122590|DRUG|ritonavir|
223808647|NCT05596084|PROCEDURE|maxillary sinus augmentation and implant placement|For maxillary sinus augmentation, the area will be prepared by lifting a full-thickness flap. The sinus membrane will be carefully elevated by opening a window through the lateral wall of the sinus on both sides.platelet-rich fibrin prepared with titanium on the other side will be placed in the space prepared in the sinus region by random selection. For Platelet-rich fibrin prepared with titanium (T-PRF), the blood taken from the patient to a 20 cc injektor was put into titanium tubes and prepared by centrifugation at 2700 rpm for 14 minutes according to the standard protocol. Then, 6 months after the surgery, histological sample will be taken with a trephine bur in both groups and the implant will be placed in accordance with the standard protocol. The stability value (ISQ) of the placed implant will be measured with the Ostell device at the time the implant is placed and 3 months after it is placed.
223808648|NCT05596084|PROCEDURE|Maxillary sinus augmentation with bovine bone graft|For maxillary sinus augmentation, the area will be prepared by lifting a full-thickness flap. The sinus membrane will be carefully elevated by opening a window through the lateral wall of the sinus on both sides. Bio-oss bovine bone graft on one side will be placed in the space prepared in the sinus region by random selection. For Platelet-rich fibrin prepared, the blood taken from the patient to a 20 cc injektor was put into titanium tubes and prepared by centrifugation at 2700 rpm for 13 minutes according to the standard protocol. Then, 6 months after the surgery, histological sample will be taken with a trephine bur in both groups and the implant will be placed in accordance with the standard protocol. The stability value (ISQ) of the placed implant will be measured with the Ostell device at the time the implant is placed and 3 months after it is placed.
223808649|NCT04332523|DRUG|JNJ-53718678|Participants will receive a single oral dose of JNJ-53718678 suspension on Day 1.
223808650|NCT05655676|DRUG|89Zr-NY008|Patients will receive a tracer (5-10mg, IV) dose of 89Zr (2-3mCi) labelled NY008
223835434|NCT04501458|OTHER|Training of youth, community health assistants and community health workers.|Training of youth, community health assistants, and community health workers in the screening, detection, contact tracing, prevention, and management of COVID-19 with concurrent maintenance of essential health services.
223808651|NCT05742425|DRUG|Serplulimab Combined With FOLFIRI and Bevacizumab|For patients with confirmed failure to reach CC0/1, they should be treated with sullizumab combined with FOLFIRI+bevacizumab for 4-8 cycles within 3 weeks after the exploration operation. After the end of the 4th and 8th cycles, they should be evaluated with imaging and MDT. If the conversion is successful, they should be treated with a second exploration operation within 3-4 weeks, The patients with CC0/1 can be evaluated for tumor reduction surgery (CRS) combined with intraperitoneal hyperthermic perfusion chemotherapy (HIPEC), and the follow-up treatment plan will be selected according to the clinical situation of the patients after surgery; If CC0/1 cannot be evaluated after the second exploration surgery and CC0/1 cannot be performed after the imaging evaluation, other chemotherapy and optimal supportive treatment will be performed according to the situation.
223808652|NCT02552290|OTHER|Upper Trapezius Stretch|Sustained stretch of upper trapezius muscle
223808653|NCT02552290|OTHER|Cervicothoracic manipulation|Manipulation to the cervicothoracic spine
223808654|NCT02552290|OTHER|No intervention|Wait
223808655|NCT04970199|DEVICE|laser application on acupoints|laser acupuncture
223808656|NCT01631890|PROCEDURE|Endoscopic Ultrasound assisted endoscopic glue injection|N Butyl cyanoacrylate will be used for achieving initial hemostasis during active gastric variceal bleed and during follow up gastric variceal obturation. Endoscopic injection will be performed intravariceally using a therapeutic endoscope and a steel hubbed catheter, with N-butyl-2-cyanoacrylate. The cyanoacrylate will be injected without dilution with lipiodol. The tip of the endoscope will be coated with lipiodol to prevent sticking of glue to the endoscope. The injection catheter is primed with saline solution followed by injection of glue in 1ml aliquot to fill the dead space followed by injection of sterile water to flush the glue into the varix. The needle is withdrawn immediately after the glue injection to prevent tissue adherence.
223808657|NCT01631890|PROCEDURE|Standard Endotherapy|Patients will be stabilized by giving i/v fluids, blood and blood products. Injection terlipressin will be given to all patients in a bolus dose of 2mg within 30 minutes of admission to the hospital. This would be followed by 1mg i/v 6hrly and will be continued for 5 days. If terlipressin cannot given then inj.somatostatin 500mcg IV bolus followed by 250mcg/hr continuous infusion for 5days.
223808658|NCT05566808|OTHER|Autologous Costal Cartilage Graft|Subjects undergoing either reconstructive or cosmetic rhinoplasty will choose which graft will be used in their intervention.
223808659|NCT05566808|OTHER|Costal Cartilage Allograft.|Subjects undergoing either reconstructive or cosmetic rhinoplasty will choose which graft will be used in their intervention.
223808660|NCT03181802|DRUG|Botox|single injection of 200 International Unit of BoNT-A in 10 bilateral paravertebral intramuscular points for treating chronic LBP
223808661|NCT03181802|DRUG|Placebos|4 ml of physiological serum injected intramuscularly into the lumbar paravertebral muscles.
223808662|NCT04070625|OTHER|Communication book group|Communication book
223808663|NCT04070625|OTHER|Control group|Simple speech therapy
223808664|NCT01003522|OTHER|Arterial puncture|Patients will undergo arterial blood gas sampling from the radial artery. This will be done by experienced doctors who are highly skilled in this procedure.
223808665|NCT01003522|OTHER|Venepuncture|Blood samples for baseline biochemistry, full blood count, and clotting screen will be taken. In patients additionally providing optional consent blood will be taken for laboratory based basic science research into lung cancer carcinogenesis and pharmacogenetics. Blood will be taken by qualified and experienced nurses, doctors and phlebotomists.
223808666|NCT01003522|PROCEDURE|General anaesthetic|Patients randomised into the stenting arm will undergo rigid bronchoscopy under general anaesthetic.
223808667|NCT01003522|PROCEDURE|Inpatient stays|Patients randomised into the stenting arm will be admitted overnight for the procedure
223808668|NCT01003522|OTHER|Walking test|All patients will be asked to complete a 6 minute walking test at baseline and on day 15. Patients randomised into the stent arm (Arm A) will complete a further 6 minute walking test at 24 hours post-stent
223808669|NCT01003522|OTHER|Spirometry & flow volume loop assessment|All patients will undergo spirometry and flow volume loop assessments at baseline and on day 15.
223808670|NCT01003522|OTHER|Biopsy material|For patients randomised to stenting and giving additional voluntary consent, 2 pairs of biopsies of tumour tissue, and 1 pair of biopsies of normal airways tissue will be taken for basic scientific research into lung cancer carcinogenesis, and pharmacogenetics.
223808671|NCT00131339|BEHAVIORAL|Cognitive behavioral therapy|
223808672|NCT00131339|DRUG|D-cycloserine|
223808673|NCT05716230|OTHER|bowel function score questionnaire survey|Bowel function score(BFS, total 20 points) was approved by Rintala in 1995, and patients with a score ≥ 17 were considered to have normal bowel habits. 7 items were in BFS, including the ability to hold back defecation, feeling/reporting the urge to defecate, frequency of defecation, soiling, accidents, constipation. In December 2022, BFS questionnaire surveys were conducted on children with ARM who underwent surgical repair between January 2017 and December 2019 at Children's Hospital of Nanjing Medical University.
223808674|NCT01500330|PROCEDURE|cupping massage|the upper back is covered in massage oil the cupping glass is drawn along the back muscles
223808675|NCT01500330|PROCEDURE|Progressive muscle relaxation|standardized programme on muscle relaxation according to Jacobson
223808676|NCT06789484|OTHER|Probiotic|Given daily from enrollement to 28 days of life
223808677|NCT06789484|DIETARY_SUPPLEMENT|Placebo|Given daily from enrollement to 28 days of life
223808678|NCT06446505|OTHER|Deep Brain Stimulation Decision Aid|An online decision support tool that provides education about deep brain stimulation and the alternatives, and includes value clarification exercise.
223808679|NCT05127148|OTHER|Evaluation of survival and toxicities in AYA Ph-negative ALL patients treating in first line depending on risk category.|Evaluation of survival (event free survival and overall survival) and toxicities in AYA Ph-negative ALL patients treating in first line with argentinian pediatric-like protocol depending on risk category.
223808680|NCT01493687|DRUG|CD5024|CD5024 1% Cream, once daily
223808681|NCT01493687|DRUG|Azelaic acid 15% Gel|Topical Gel applied twice daily
223808682|NCT02282397|DEVICE|Continuous Glucose Monitor|RT-CGM are adjunctive devices with glucose trend graphs and user-configurable low and high glucose alerts.
223808683|NCT05067439|DRUG|Abrocitinib|200 mg once daily (QD)
223808684|NCT05067439|DRUG|Omeprazole|single doses of 10 mg
223808685|NCT05067439|DRUG|Caffeine|single dose of 100 mg
223808686|NCT05067439|DRUG|Efavirenz|single doses of 50 mg
223808687|NCT05809713|OTHER|Technology-enabled Team Care|Patients randomized to the TTC arm will receive telehealth-enabled team-based care. The team will include a physician and/or advanced practice provider, a pharmacist with Certified Pharmacist Practitioner (CPP) status or similar skills in NC, and will incorporate brief nutritionist-directed lifestyle behaviors counseling (DASH diet; exercise) initially delivered every other week by phone for two months, followed by monthly calls (once SBP values achieve individualized goal and remain stable for 14 days) over 12 months supported by cellular enabled home BP monitoring.
223808688|NCT05809713|OTHER|Enhanced Usual Care|Patients randomized to the enhanced usual care (EUC) arm will receive telehealth enabled home BP monitoring equipment including set-up and instruction and basic hypertension-specific lifestyle (diet, exercise) instruction and materials at baseline, but will not receive telehealth-enabled team-based care, active home BP monitoring by a pharmacist, or detailed DASH intensive lifestyle counseling.
223808689|NCT04121884|BEHAVIORAL|Accelerated Resolution Therapy|"The ART protocol first uses the technique of imaginal exposure to elicit physiological reactions associated with patient recall from beginning to end (verbally or non-verbally) of a traumatic/distressing experience. As physiological reactions emerge, the participant is directed to focus their attention on the specific body-centric reactions while laterally performing smooth pursuit eye movements which are achieved by tracking the clinician's hand which oscillates from left-to-right at a short distance from the participant's eyes. Then the participant is directed to imagine a positive way in which they prefer to recall their experience(s), including emphasis on replacing negative images in the brain with positive images. This technique is based on the process of memory reconsolidation, which allows for adding of positive material to the recall of negative, highly emotional past experiences."
223808690|NCT06373484|BEHAVIORAL|Behavioral Parent Training|Two 15-session multi-component cognitive-behavioral group treatments for children with disruptive behavior and their parents (i.e., one program for children aged 6-8 years and their parents and another for children aged 9-12 years and their parents. The programs have a child and parent group that are implemented concurrently).
223808691|NCT04368650|DRUG|BMP-2|lyophilized Human Bone Morphogenetic Protein-2 was used as an active drug.
223808692|NCT04368650|PROCEDURE|PRF|For the preparation of sticky bone, the patient's venous blood is collected and centrifuged at 2400rpm for 2min which leads to two different layers in the vacutainer the upper autologous fibrin glue (AFG) and the lower RBC portion, the upper AFG is mixed with a particulate bone graft (hydroxyapatite). Within 5-10 min fibrin meshwork was formed
223808693|NCT00705133|DRUG|Treprostinil|For both SQ and IV routes, treprostinil will be started in the hospital at 1ng/kg/min and titrated up by 1ng/kg/min every 1-3 days as tolerated
223808694|NCT00453011|DEVICE|posterior chamber intraocular lens|
223808695|NCT00453011|DEVICE|anterior chamber intraocular lens|
223808696|NCT02857439|OTHER|Standard diagnostic item list|All consecutive patients are assessed by both examiners, according to a standardized physical examination item list.
223808697|NCT03135535|DEVICE|Avex Footbeat|Subjects will receive diabetic shoes equipped with Boa Technology shoelace system and Footbeat compression insoles, which for simplicity will be named intervention shoes. All participants will be asked to wear the intervention shoes for duration of 4-weeks on daily basis (minimum 4 hours per day). Daily use of the intervention shoes will be assumed to improve balance, mobility, plantar sensation, lower extremity edema, and lower extremity skin perfusion.
223808698|NCT02364180|DIAGNOSTIC_TEST|Electromyography (EMG)|
223808699|NCT01903421|DRUG|Spinal anesthesia group: bupivacaine 10-15mg|
223808700|NCT01903421|DRUG|General anesthesia group: induction propofol 1.5-2mg/kg and fentanyl 1-3g/kg, maintained with isoflurane or sevoflurane|
223808701|NCT01903421|GENETIC|Blood test|DNA will be tested for the presence of ε4 allele of the apolipoprotein E gene
223808702|NCT01903421|OTHER|Lumbar spinal tap|1ml of cerebrospinal fluid (CSF) removed and stored for further analysis of amyloid tau protein after completion of the study
223808703|NCT01903421|BEHAVIORAL|Montreal Cognitive Assessment (MOCA) and MMSE|
223808704|NCT02755064|DRUG|Erythromycin lactobionate|In Phase 1 of the study, during the second visit, erythromycin was given as an initial bolus of 0.5 mg/kg over 10 min immediately before the meal. Thereafter, an infusion of 1.5 or 2.5 mg/kg was given over the next 50 min with the same infusion pump. The goal of testing 2 different doses was not to assess dose-related effects but to compare glycemic indices against a spectrum of gastric emptying rates.
223808705|NCT02755064|DRUG|Placebo IV|In Phase 1 of the study, during the second visit, saline was given as an initial bolus over 10 min immediately before the meal. Thereafter, an infusion of saline was given over the next 50 min with the same infusion pump.
223808706|NCT02755064|DRUG|[13C]-Spirulina|The subject consumed the test meal containing 13C-Spirulina in no more than 10 minutes. Breath samples were collected at baseline obtained upon completion of the meal and at 15, 30, 45, 60, 90, 120, 150, 180, and 240 minute time points.
223808707|NCT02755064|DRUG|Erythromycin Ethylsuccinate Suspension|In Phase 2 of the study, subjects randomized to this arm will receive Erythromycin Ethylsuccinate Suspension 250 mg tid orally for a total period of 7 days.
223808708|NCT02755064|DRUG|Placebo Suspension|In Phase 2 of the study, subjects randomized to this arm will receive an oral placebo prepared to mimic the Erythromycin Ethylsuccinate Suspension for a total period of 7 days.
223808709|NCT02323646|DRUG|Placebo|Matching placebo, vaginally, once daily for 18 weeks (Course 1) and repeated for an additional 18 weeks (Course 2) following the ODI.
223808710|NCT02323646|DRUG|Telapristone Acetate|Telapristone acetate, vaginally, once daily for 18 weeks (Course 1) and repeated for an additional 18 weeks (Course 2) following the ODI.
223808711|NCT02731664|BIOLOGICAL|GLP-1|Intravenous infusion of GLP-1
223808712|NCT02731664|BIOLOGICAL|Intravenous saline|Control
223808713|NCT05810207|PROCEDURE|Colorectal resection|Patients undergoing a colorectal resection with the construction of a primary anastomosis
223808714|NCT01299155|DEVICE|ReSTOR +3|Bilateral implantation of an Alcon AcrySof ReSTOR +3 Intraocular Lens (IOL) Model SN6AD1 following cataract extraction.
223808715|NCT01299155|DEVICE|LENTIS MPlus|Bilateral implantation of a LENTIS MPlus Intraocular Lens (IOL) following cataract extraction.
223808716|NCT03073564|DIAGNOSTIC_TEST|Endurance test for upper limbs|Subjects will initially perform maximal incremental cardiopulmnar test of upper limbs to assess the suggestion of dynamic hyperinflation (DH). After that, it will be randomized, for those who presented DH, to perform the endurance test with and without the use of positive expiratory pressure mask.
223808717|NCT03073564|DIAGNOSTIC_TEST|Functional test|The 6-min pegboard and ring test (6PBRT) will be performed under usual breathing and during application of the EPAP mask. In this condition will be evaluated the presence of dynamic hyperinflation, perception of effort and dipnea, in addition to exercise capacity.
223808718|NCT02106130|DRUG|Rebamipide|oral administration, 3 times/day
223808719|NCT02106130|DRUG|Mosapride citrate|oral administration, 3 times/day
223808720|NCT03263689|DRUG|Intrathecal morphine|ITM group were given 100 micrograms of preservative-free morphine in addition to the local anaesthesia (plain hyperbaric bupivacaine 10mgs) intrathecally during the spinal anaesthesia
223808721|NCT00521144|DRUG|obatoclax mesylate|Given IV
223808722|NCT00521144|DRUG|topotecan hydrochloride|Given IV
223808723|NCT00521144|OTHER|laboratory biomarker analysis|Correlative studies
223808724|NCT01592149|OTHER|No Drug|No intervention will be given to subjects, survey of loss of appetite in patients suffering from various healthcare disorders.
223808725|NCT01037439|DEVICE|Adaptive Servo-controlled Ventilation (ASV)|Pressure support ventilation adapts to meet a target ventilation level that is constantly being assessed
223808726|NCT01370525|DRUG|Esomeprazole|Nexium 20 mg administered as 22.3 mg of esomeprasole magnesium hydrate, capsule, oral dose
223808727|NCT04664725|DRUG|Repaglinide, Bupropion and SHR3680|Single dose of oral administration of Repaglinide and Bupropion, Multiple dose of oral of SHR3680
223808728|NCT02614443|OTHER|Space from Depression|Delivered through the online SilverCloud platform, the program for the treatment of depression employs several innovative engagement strategies for improving the user experience. These are divided into several categories: personal, interactive, supportive, and social.
223808729|NCT02614443|OTHER|Space from Anxiety|Delivered through the online SilverCloud platform, the program for the treatment of anxiety employs several innovative engagement strategies for improving the user experience. These are divided into several categories: personal, interactive, supportive, and social.
223808730|NCT02614443|OTHER|Space from Stress|Delivered through the online SilverCloud platform, the program for the treatment of stress employs several innovative engagement strategies for improving the user experience. These are divided into several categories: personal, interactive, supportive, and social.
223808731|NCT00804492|BEHAVIORAL|Multifaceted intervention|consulted, educated, referred or receive an exercise training for their fitness, strength and balance
223808732|NCT05799326|DRUG|Levofloxacin|Levofloxacin is a quinolone antibiotics and newly identified neuro-protective agent.
223808733|NCT05799326|DRUG|Levofloxacin simulant|Levofloxacin simulant is placebo.
223808734|NCT01207570|PROCEDURE|Endermotherapy|The subjects will receive a single session of endermotherapy applied to the gastrocnemius/soleus muscle on the more affected side for 5 minutes. The treatment will be conducted by a qualified physiotherapist.
223808735|NCT01207570|PROCEDURE|Passive manual stretching|The subjects will receive a single session of passive manual stretching of the gastrocnemius/soleus muscle on the more affected side. The treatment will be given by a qualified physiotherapist.
223808736|NCT04416893|DIAGNOSTIC_TEST|RT-PCR SARS-Cov2|nasopharyngeal swab will be taken for detection of SARS-CoV-2 by RT-PCR
223808737|NCT04416893|DIAGNOSTIC_TEST|Sars-Cov2 serology|A microsample of blood will be taken for serology
223808738|NCT03844022|DIAGNOSTIC_TEST|MRI|magnetic resonance imaging
223808739|NCT03376867|OTHER|Conditioned pain modulation|Conditioned pain modulation (CPM) protocol consist of evaluating pain during two stimuli test (heat and pressure point), before and after one conditioning stimulus (cold water bath); Blood analyses for biochemistry and genes polymorphisms.
223808740|NCT03128424|DEVICE|PQ Bypass Stent Graft System|The PQ Bypass™ Stent Graft System is indicated to improve luminal diameter in the treatment of patients with symptomatic de novo or restenotic native lesions or occlusions of the superficial femoral artery (SFA) and/or proximal popliteal artery, with reference vessel diameters of 5.0 to 6.7 mm and lesion lengths up to 180 mm.
223808741|NCT00214305|BEHAVIORAL|Range of Motion Therapy Program|The program involves exercises and maneuvers that include voluntary maximal movements of the tongue, pitch range exercises, head lifting (Shaker exercise), resistance to laryngeal excursion (Mendelsohn Maneuver), breath holding after swallow and cough, thermal-tactile stimulation (ice), suck-swallow, optimal posturing, and dietary changes.
223808742|NCT00214305|BEHAVIORAL|Postural Sensory Therapy Program|The program involves all of the above, except that range of motion exercises (voluntary maximal movements of the tongue, pitch range exercises, head lifting, resistance to laryngeal excursion, breath holding after swallow and cough) are not performed.
223808743|NCT01705496|RADIATION|[124I]FIAU|This is a single dose study of 5 mCi \[124I\]FIAU in subjects presenting with pain in a prosthetic knee or hip joint. Subject will receive two PET-CT scans after \[124I\]FIAU injection.
223808744|NCT05033782|OTHER|questionnaire|"Each included patient will be given a paper questionnaire, with the following questions:~* Zip code of patient's iterative residences since 2018, as well as the zip code of residence at the time of the 2 confinements~* Occupational status~* Occurrence of COVID infection/date needed for hospitalization~* During the COVID-19 outbreak, did the patient: avoid seeing a doctor, avoid going to health care facilities, stop background treatment for MS. If yes to any of the questions, the reason, date and duration of the cessation will be asked.~Other sources of data will be used together:~Clinical data from the OFSEP registry Pollution data from approved air quality monitoring associations Data on the circulation of influenza and gastroenteritis, produced by Santé Publique France"
223808745|NCT03653455|BEHAVIORAL|Email reminders|Patients will receive email reminders until their PROs are completed.
223808746|NCT03653455|BEHAVIORAL|Pre- and Post-operative discussion|Patients will discuss with their provider the importance of PROs pre-operatively, as well as their post-operative progression in comparison to established norms.
223808747|NCT03653455|BEHAVIORAL|Incentive|Patients will receive up to $30 in amazon gift cards upon the completion of their PROs.
223808748|NCT04280653|DEVICE|NDE L68 StableFit® Punctal Plug|Tear lake evaluation of the planned study eye, prior to insertion of the Punctal Plug and then tear lake evaluation at days 7 and 28 after punctal plug insertion.
223808749|NCT00314548|DRUG|PGE1 (prostacyclin)|alprostadil nebulization
223808750|NCT00314548|DRUG|normal saline|nebulize for 30 mins
223808751|NCT03087344|DEVICE|Fibroscan and Acoustic Radiation Force Impulse|Liver stiffness and spleen stiffness will be measured before and after a standard meal is administered by Fibroscan and Acoustic Radiation Force Impulse
223808752|NCT03087344|DEVICE|Fibroscan|Liver stiffness will be measured before and after a standard meal is administered
223808753|NCT03087344|DEVICE|Acoustic Radiation Force Impulse|Liver stiffness and spleen stiffness will be measured before and after a standard meal is administered by Fibroscan and Acoustic Radiation Force Impulse
223808754|NCT06395610|DRUG|CHF6001 DPI|Single dose of CHF6001
223808755|NCT06395610|DRUG|Erythromycin|Repeated doses of oral Erythromycin
223808756|NCT06171334|DEVICE|Remote ischemic conditioning|The intervention consists in Remote Ischemic conditioning (RIC), one session of 40-minutes duration per day for 12 months. The procedure will be performed by using an electric auto-control device by SnapDx Inc (Calgary, Canada) with a blood pressure cuff that inflates up to a pressure of 200 mmHg during the ischemic period. Participant will self-administer the RIC procedure at their home. The device records and documents each RIC cycle.
223808757|NCT06219564|PROCEDURE|Peripartum total abdominal hysterectomy (p-TAH)|"Peripartum total abdominal hysterectomy (cesarean hysterectomy) refers to a surgical procedure in which a woman undergoes both a cesarean section (C-section) and a hysterectomy simultaneously.~Placenta Accreta, Increta, or Percreta: These are conditions where the placenta attaches too deeply to the uterine wall. In cases of severe attachment, it may be difficult to remove the placenta without causing excessive bleeding, and a hysterectomy may be required.~Cesarean hysterectomy is a major surgical procedure involving significant medical expertise and coordination among healthcare professionals, including obstetricians and surgeons. The decision to perform a cesarean hysterectomy is usually made in emergency situations to address life-threatening complications."
223808758|NCT06219564|PROCEDURE|Cesarean Section (C/S)|"A cesarean section (C/S) involves making an incision in the abdominal wall and uterus to deliver a baby when a vaginal delivery is not feasible or safe.~Total placenta previa refers to a condition where the placenta completely covers the opening of the cervix in the uterus. This condition can pose significant risks during pregnancy and childbirth, and it often necessitates a planned cesarean section (C/S) for delivery."
223808759|NCT06219564|OTHER|Neonatal mortality|"Neonatal mortality refers to the death of a newborn within the first 28 days of life. This period is divided into early neonatal mortality, which covers the first seven days of life, and late neonatal mortality, which extends from the eighth to the 28th day. Neonatal mortality is a critical measure of the health and well-being of infants and is often used to assess a population's overall health and healthcare systems.~To reduce neonatal mortality, efforts are made to improve maternal healthcare, access to prenatal care, skilled attendance during childbirth, and the availability of neonatal healthcare services. Tracking and addressing factors contributing to neonatal mortality are crucial for improving the chances of survival of newborns and overall health outcomes."
223808760|NCT01719822|DEVICE|Yamax Digi-Walker CW-700|A pedometer with a daily step count target set by a physiotherapist.
223808761|NCT04028349|DRUG|Ad26.ZEBOV/MVA-BN-Filo|Candidate Ebola Vaccine
223808762|NCT00964834|DRUG|Doxycycline and Valortim|Days 1-5 100mg IV Doxycycline BID over 60 minutes. Day 6 20mg/kg Valortim IV over 60 minutes.
223808763|NCT00964834|DRUG|Placebo Antibiotic and Valortim|Days 1-5 20mg/kg IV Normal Saline BID over 60 minutes. Day 6 20mg/kg IV Valortim over 60 minutes.
223808764|NCT00964834|DRUG|Placebo Antibiotic and Placebo Valortim|Days 1-5 200mL IV Normal Saline for Placebo Antibiotic BID over 60 minutes. Day 6 20mg/kg IV Normal Saline for Placebo Valortim over 60 minutes.
223808765|NCT03067454|PROCEDURE|Early mobilisation|"Conservative treatment with early mobilisation~The patient is instructed to do a fist and is not allowed to leave the clinic before. Active mobilisation under control (doctor or physiotherapist) is performed until healing of the fracture is documented."
223808766|NCT03067454|PROCEDURE|Operation|Operation of the fracture. Usually open reduction and internal fixation with plates and screws or just screws within 2 weeks of injury. Immobilisation in a cast for two weeks followed by physiotherapy.
223808767|NCT03948984|BEHAVIORAL|Therapeutic Music Session|The 20 minute therapeutic music session will consist of classical music performed by a pianist with or without flute accompaniment with an individual patient's ICU room.
223808768|NCT04692402|DEVICE|Solitaire™ thrombus retrieval device|After consent has been obtained, interventional cardiologist selects the proper solitaire device size per device-specific instructions for use. Adjunctive intervention with Solitaire will be done with a maximum of 2 device deployments. Do not perform more than three recovery attempts in the same vessel using the devices (Maximum of 2 attempts per device per subject). Do not reposition each device more than two times. TIMI flow, thrombus grade and myocardial blush grade will be assessed immediately upon completion of procedure. If recanalization is deemed inadequate by the interventional cardiologist, rescue treatment will follow as per current clinical practice. All other procedures followed will be as clinically indicated.
223808769|NCT02101229|DRUG|Insulin, Asp(B28)-|"the insulin dose is calculated by the Diabeloop algorithm and then administered to the patient"
223808770|NCT02546934|DRUG|ABX, cisplatin|ABX 125 mg/m2, IV drip 30 minutes, D1, D8 Cisplatin 75 mg/m2, IV drip 120 minutes, D1
223808771|NCT02546934|DRUG|Gemcitabine, Cisplatin|Gemcitabine 1250 mg/m2, IV drip 30 minutes, D1, D8 Cisplatin 75 mg/m2, IV drip 120 minutes, D1
223808772|NCT04302831|BEHAVIORAL|Strength training|weight lifting to increase muscle strength
223808773|NCT04302831|BEHAVIORAL|Endurance training|treadmill walking to increase endurance
223808774|NCT04302831|BEHAVIORAL|Flexibility training|stretches to improve flexibility
223808775|NCT04302831|BEHAVIORAL|Physical activity behavioral intervention|Intervention to encourage participants to be more physically active
223808776|NCT04302831|BEHAVIORAL|Task Specific timing and coordination training|stepping and walking patterns to improve timing and coordination of gait
223808777|NCT05181293|BEHAVIORAL|Mobile Gaming App for Nutrition Intervention|A mobile gaming app (BabyThrive) will be disseminated to teenage mothers to help them learn about exclusive breastfeeding, introduction to solid/semi-solid foods, meal frequency and dietary diversity. BabyThrive will also demonstrate how to prepare 30 nutritious recipes for complementary feeding; create a calendar and set reminders to prompt mothers to access child health services; and plot growth patterns of the baby to facilitate growth monitoring.
223808778|NCT00116896|DRUG|OSI-7904L|
223808779|NCT00116896|DRUG|Cisplatin|
223808780|NCT04107831|OTHER|Pulmonary rehabilitation|Pre-post test design
223808781|NCT03183102|DIETARY_SUPPLEMENT|Flaxseed|2 months of dietary flaxseed supplementation
223808782|NCT01402596|DRUG|Midazolam|0,4 mg per kg - intranasal midazolam - once
223808783|NCT01402596|DRUG|Chloral Hydrate|50 mg per kg, rectal
223808784|NCT00654810|BEHAVIORAL|Walking Exercise|Intermittent treadmill walking to near maximal claudication pain three days per week
223808785|NCT06171230|OTHER|Eye Movement Desensitization and Reprocessing|Using the LEC and PCL-5, emotionally charged images are selected at the onset of the EMDR intervention. Initially, events meeting the criteria for PTSD (A-criterion worthy events) are processed. Subsequently, pain-related experiences, including any distressing images, are addressed. If the emotional charge of the events diminishes (SUD=0) before the completion of the six EMDR sessions, the participant is categorized as an 'early completer,' and the post-assessment is conducted immediately. The duration of each EMDR session is 90 minutes.
223808786|NCT06171230|OTHER|Attention control phase|Prior to EMDR, there is a two-week attention control phase. During this phase, the participant is asked to daily record their activities, emotions, and thoughts when experiencing pain. This information is further explored and evaluated in two sessions lasting 45 minutes each, involving in-depth discussions with the participant.
223808787|NCT02301351|OTHER|Graphic Warning Label|All packs provided will include FDA-approved graphic warning labels
223808788|NCT02301351|OTHER|Text Warning Label|All packs provided will include standard text warning labels
223808789|NCT05333406|DRUG|EN001|"EN001 intravenously (IV) in the treatment of Charcot-Marie-Tooth disease (CMT) type 1A Dosage for each group is as follows.~Dose group A (Low dose): 5.0x10\^5 cells/kg"
223808790|NCT05333406|DRUG|EN001|"EN001 intravenously (IV) in the treatment of Charcot-Marie-Tooth disease (CMT) type 1A Dosage for each group is as follows.~Dose group B (High dose): 2.5x10\^6 cells/kg"
223808791|NCT05273970|OTHER|Behavioral testing under intracranial monitoring|After standard of care surgery to implant the electrodes is complete and patients have have recovered satisfactorily from the procedure, they will be asked to perform some computer based tasks to answer questions about pretend financial decisions, pay attention to certain images, watch videos, look at images, listen to sounds, or move a joystick.
223808792|NCT01774747|DRUG|DSP-1053|DSP-1053 10, 15, 20, 30, 45, 60, 90 mg once daily for 14 days
223808793|NCT01774747|DRUG|Placebo|Placebo 10, 15, 20, 30, 45, 60, 90 mg once daily for 14 days
223808794|NCT00832767|PROCEDURE|SILS™ port laparoscopic cholecystectomy|This interventional arm will have a single incision laparoscopic cholecystectomy procedure.
223808795|NCT00832767|PROCEDURE|Four Port Laparoscopic Cholecystectomy|This interventional arm will have a traditional four port laparoscopic cholecystectomy procedure.
223808796|NCT02940574|DRUG|Syntocinon (Oxytocin)|Syntocinon nasal spray. A single dose (24IU) of nasal spray (3 puffs of 4IU per nostril), followed by 4 weeks of a daily single dose (24IU; 3 puffs of 4IU per nostril) of nasal spray
223808797|NCT02940574|OTHER|Placebo (Physiological water (solution of sodium chloride (NaCl) in water))|Placebo nasal spray. A single dose (24IU) of nasal spray (3 puffs of 4IU per nostril), followed by 4 weeks of a daily single dose (24IU; 3 puffs of 4IU per nostril) of nasal spray
223808798|NCT02798510|RADIATION|Concurrent Chemoradiotherapy|
223808799|NCT02798510|DRUG|capecitabine|
223808800|NCT02798510|DRUG|gemcitabine|
223808801|NCT06132555|OTHER|Online questionnaire survey|"The investigators have made an electronic questionnaire through the questionnaire star, and send the link or two-dimensional code of the electronic questionnaire to the subjects through WeChat or SMS to remind them to fill in the answer on the mobile phone or computer.~The questionnaire consisted of four parts: (1) basic information of the interviewees, (2) drug abuse of the interviewees, (3) drug treatment interventions received by the interviewees, and (4) problems encountered by the interviewees when they return to society."
223835435|NCT04501458|OTHER|Training clinicians in basic critical care and the management of severe COVID-19 cases|Training clinicians in basic critical care and the management of severe COVID-19 cases with concurrent maintenance of essential health services.
223835436|NCT01628510|DEVICE|Dandle Roo/Dandle Wrap|Infant remains in the Dandle Roo/Dandle Wrap throughout the NICU stay when the infant is lying in the isolette or crib, but is taken out for hands on care times or when held.
223808802|NCT06132555|OTHER|In-depth personal interview|The in-depth personal interview was conducted in a semi-structured way. The outline of the interview was formulated from seven aspects: drug use history, drug abstinence history, relapse situation, living conditions, physical and mental health status, return to society status, and active drug abstinence willingness of the drug abstinence personnel. The aim was to understand the needs of drug addicts in terms of family relationship, peer relationship, history of drug use, history of drug withdrawal, employment, economy, social support network, psychology, and assistance.
223808803|NCT06132555|OTHER|Colloquia|"The colloquia were carried out in the form of group interviews, 1-2 people from each different institution were selected to participate, and the number of people in each colloquium was controlled to be between 6 and 12.~The colloquia mainly focused on: ① The status quo of the implementation of the local drug drug treatment policy, ② the status quo of the compulsory isolation drug treatment work, ③ the status quo of the work of social workers for drug drug treatment, ④ the status quo of the work of community health centers, ⑤ the operation of various mechanisms in the work of various units, and ⑥ what content in the drug control work needs assistance from other departments and what external resources are needed."
223808804|NCT00387894|DRUG|erlotinib hydrochloride|Tarceva will be self-administered in an open-label, unblinded manner to all patients enrolled in the study. During the treatment period, patients who are not receiving EIAED (Group A) will receive single-agent Tarceva, 150 mg/day. Patients on EIAED (Group B) will receive single-agent Tarceva, 600 mg/day. Tablets should be taken at the same time each day with 200 mL of water at least 1 hour before or 2 hours after a meal. Patients who are unable to swallow tablets may dissolve the tablets in distilled water for administration. The dose of Tarceva will be escalated after 14 days to 200 mg/day (Group A) or 650 mg/day (Group B) assuming no intolerable grade 2 rash, any grade 3 rash, or grade 2 diarrhea despite loperamide.
223808805|NCT03687190|BEHAVIORAL|Tai chi|participants were required to receive hospital-based Tai chi training at least once a month, and home-based Tai chi exercise at least three times a week over the next 9 months
223808806|NCT03687190|DRUG|conventional medicine|participants without Tai chi training still received routine conventional medicine
223808807|NCT05516277|BEHAVIORAL|Behavioral Sleep Education Intervention|Manual-based education program focusing on behavioral sleep techniques provided in individual 60-minute sessions for 5 weekly sessions.
223808808|NCT03685838|OTHER|Compression Stockings|Class II above knee compression stockings
223808809|NCT00809692|PROCEDURE|validated techniques for histamine response|the prick test and iontophoresis technique (serial assessment of blood flow using validated Doppler technique)
223808810|NCT00809692|PROCEDURE|new technique for histamine response|laser Dopper technique and genotyping
223808811|NCT05318924|DRUG|Ghrelin|Participants will receive an infusion that is intended to raise ghrelin level up to a steady plateau.
223808812|NCT05318924|OTHER|Placebo|Participants will receive a saline infusion as the placebo control condition.
223808813|NCT02421666|BEHAVIORAL|PNMI|Eligible patients received patient navigator led plus mobile phone text messaging intervention (PNMI) or standard care. Bilingually trained patient navigators were recruited from our existing patient navigator training network, received intensive training on HBV prevention, diagnosis and treatment management, and served as a liaison with respective clinical partners. The PNMI intervention offered three education sessions on HBV management and weekly CHB patient-designed educational phone-based text messages for five weeks.
223808814|NCT03268239|DEVICE|Additional MRI sequences|"Due to the participation in the study, the following sequences are added to the imaging protocol:~* 3D T1 GRE after injection (Gradient-Recalled Echo)~* 3D T1 TSE before injection (Turbo Spin Echo)~* 3D fGATIR PSIR after injection (fast Gray Matter Acquisition T1 Inversion Recovery Phase-Sensitive Inversion Recovery)~Sequences will be performed in a random order to avoid the bias induced by different time intervals between injection and acquisition."
223808815|NCT01230255|PROCEDURE|Percutaneous catheter drainage|Ultrasound guided insertion of a 14 French pigtail catheter to drain free intra-peritoneal fluid or blood and thereby reduce elevated intra-abdominal pressure
223808816|NCT00001444|DRUG|7-hydroxystaurosporine (UCN-01)|
223808817|NCT04976803|OTHER|Determination of ATM alteration status.|ATM alterations identified using NGS profiles with ATM protein expression levels from tumor tissue assessed by IHC.
223808818|NCT05877950|DEVICE|Smartphone-based speech therapy|Participants will be instructed to use the speech therapy app for 1 hour per day (5 days for 1 week) over a 4-week period.
223808819|NCT05877950|OTHER|Home-based speech therapy|Participants will receive treatment maintaining the same frequency as the intervention group.
223808820|NCT06153043|OTHER|Women patients with classical congenital adrenal hyperplasia|The Easily and Médifirst medical files of these patients will be studied in order to collect the desired variables. If the files are incomplete, and if data concerning fertility, pregnancy, and the characteristics of the newborn are missing, patients will be contacted to ask them to answer the questionnaire to obtain this information.
223808821|NCT00290602|DRUG|Methylprednisolone sodium succinate|
223808822|NCT05968222|OTHER|Vibration exercise|Each training session on the vibrating platform is composed of 6 exercises with a duration of 60 seconds with 60-second pauses between exercises and a warm-up exercise
223808823|NCT01288339|DRUG|Panitumumab + FOLFOX (DP)|Panitumumab and FOLFOX will be administered to patients with DP once every 14 days until 6 months of treatment or until disease progression (PD) or unacceptable toxicity. If patients have not progressed after 6 months of treatment with panitumumab and FOLFOX they will continue with panitumumab monotherapy until disease progression.
223835437|NCT01628510|OTHER|Traditional NICU Positioning|These methods aim at providing containment and flexion and may consist of interventions such as swaddling, use of boundaries around the infant, rolled blankets, Snuggly®, or Bendy Bumper®
224264418|NCT04428307|OTHER|Conditional artemisinin combination therapy subsidy|An additional discount on WHO-approved quality assured ACTs will be offered to individuals with a positive RDT.
224264419|NCT04428307|OTHER|Testing incentive|A small incentive will be paid to the provider each time they perform a malaria rapid diagnostic test.
224264420|NCT02163382|DEVICE|Neurovent Monitor XIII|Nasogastric tiube installation to monitor EAdi
224264421|NCT02163382|DEVICE|Neurovent Monitor XIII|RIP jacket installation
224264422|NCT02163382|DEVICE|Neurovent Monitor XIII|Ventilator change (if a different ventilator was used prior to the study).
224264423|NCT02163382|DEVICE|Neurovent Monitor XIII|Determination of NAVA parametersVentilator
223808824|NCT01288339|DRUG|Panitumumab + FOLFOX (no-DP)|Panitumumab and FOLFOX will be administered to patients with no-DP (MMP7+/p-IGF-IR-, MMP7-/p-IGF-IR+ or MMP7-/p-IGF-IR) once every 14 days until 6 months of treatment or until disease progression (PD) or unacceptable toxicity. If patients have not progressed after 6 months of treatment with panitumumab and FOLFOX they will continue with panitumumab monotherapy until disease progression.
223808825|NCT02946840|DEVICE|FNA with 25 G Beacon needle|
223808826|NCT01722760|PROCEDURE|measurements|
223808827|NCT01936701|PROCEDURE|bilateral cataract surgery|same-day bilateral cataract surgery with implantation of intraocular lens
223808828|NCT04009590|OTHER|Educational Intervention|Read educational booklet
223808829|NCT04009590|OTHER|Questionnaire Administration|Ancillary studies
223808830|NCT04009590|BEHAVIORAL|Smoking Cessation Intervention|Utilize Quit4Health
223808831|NCT04204369|OTHER|Ultrasound education curriculum|"Participants were enrolled in a musculoskeletal ultrasound course including 2 components:~* An online course (1-2 hours) to be done before the practical session. The videos were made available one (1) month prior to the practical course. This component reviewed the basics of ultrasonography, as well as the normal and abnormal appearance of relevant musculoskeletal structures (bone, tendon, ligaments, muscles, bursas, and nerves), and the ultrasound anatomy of high yield regions of the musculoskeletal system (shoulder, elbow, knee, ankle)~* A practical session (4-6 hours) done during one of the usual academic days of the orthopedic residency program. This session covered the use of the ultrasound; the examination of the shoulder, elbow, knee, and ankle; ultrasound-guided musculoskeletal injections and aspirations; and ultrasound-guided distal radius fracture reductions. Ample practice time was given to the residents using means such as phantom models, cadavers, and real patients."
223808832|NCT04034108|PROCEDURE|Surgical intervention combined with weight-supported ambulation training|"Surgeries were performed between 12 hours to 30 days after trauma. Internal fixation was implemented once instability of the injured spinal column was confirmed by radiology and exploration during operation. At 15 days after surgery, the patients were encouraged to start weight-supported ambulation training under careful protection by the trainers, the patients were encouraged to start weight-supported ambulation training under careful protection by the trainers. The training program was named Kunming Locomotor Training Program (KLTP)formulated by actively walking for a duration of 6 hours per day, 6 days per week for a minimum of 6 months."
223808833|NCT06330584|DRUG|Placebo Nasal Spray 0 mg/spray|"A unit-dose nasal spray will be used for the intervention.~1 spray (= 0.1 μl = 0 mg midazolam/spray) in each nostril, i.e., no active compound"
223808834|NCT06330584|DRUG|Midazolam Nasal Spray 0.45 mg/spray|"A unit-dose nasal spray will be used for the intervention.~1 spray (= 0.1 μl = 0.45 mg midazolam/spray) in each nostril, i.e., total dose of midazolam 0.9 mg"
223808835|NCT06330584|DRUG|Midazolam Nasal Spray 0.9 mg/spray|"A unit-dose nasal spray will be used for the intervention.~1 spray (= 0.1 μl = 0.9 mg midazolam/spray) in each nostril, i.e., total dose of midazolam 1.8 mg"
223808836|NCT05639543|DRUG|INT-787|Blinded Study Drug
223808837|NCT05639543|DRUG|Placebo|Placebo
223808838|NCT06335420|DIETARY_SUPPLEMENT|Carrot juice from Yellowstone carrots cultivars|Consumption of 100 ml of carrot juice daily for 1 year
223808839|NCT06335420|DIETARY_SUPPLEMENT|Placebo juice|Consumption of 100 ml of placebo juice daily for 1 year
223808840|NCT00846638|BEHAVIORAL|Brief Intervention|Diagnostic assessment followed by a single session Brief Intervention with 3, 6, and 12 month follow-up
223808841|NCT00846638|BEHAVIORAL|Diagnostic assessment|Single session diagnostic assessment with 12 month followup
223808842|NCT01566331|DEVICE|Baby-guardTM|Baby-guardTM system, through its ergonomic, three chamber, inflatable abdominal belt, engineered after studies of biomechanics and biophysics, that follows obstetric semiotics, that applies fundal pressure during the second stage of labor in the direction of the pelvic outlet, may be of maternal and fetus aid for a safe natural childbirth for their better outcomes
223808843|NCT06246500|OTHER|No intervention|No intervention
223808844|NCT02908308|PROCEDURE|Targeted temperature management to 33°C|Rapid cooling to below 33°C, followed by temperature control at 33°C for up to 28h.
224264424|NCT02163382|DEVICE|Neurovent Monitor XIII|Second period with conventional NIV settings
223808845|NCT02908308|PROCEDURE|Standard care with early treatment of fever|Normothermia and standard care - use of a device for temperature control if temperature is greater than or equal to 37.8°C
223808846|NCT05029752|DEVICE|Vendys II Device|Using the device
223808847|NCT03090867|OTHER|Relatives or surrogates are encouraged to perform care|"The relative or surrogate will perform at least two cares a week among feeding, mouth care, hair wash, shaving, eye care, hand, foot and face massage.~All care are planned and perform under the supervision or/and in collaboration with a caregiver.~The relative or surrogate will give his opinion by completing the study questionnaires."
223808848|NCT03090867|OTHER|Conventional ,care|The relative or surrogate will not be encouraged to perform care. The management of the relative or surrogate wi ll not changed from the regular standard of the ICU.
223808849|NCT01597830|OTHER|Mobility shoe|flat, specialized shoe
223808850|NCT01597830|OTHER|control shoe|control shoe
223808851|NCT06378853|OTHER|no intervention|no intervention
223808852|NCT06362980|DRUG|BPI-1178|200 or 300 mg, oral, QD
223808853|NCT06362980|DRUG|Osimertinib|80mg, oral, QD
223808854|NCT00797979|DEVICE|Skull Grip bone fixation|Skull Grip bone fixation
223808855|NCT00797979|DEVICE|sutures|Standard skull bon flap fixation, sutures
224264425|NCT05291195|DEVICE|Laser-device group|"After each instrumentation, the root canals were irrigated with 1.5 % sodium hypochlorite (NaOCl).~Depending on allocations, in the laser-device groups, the adjuvant treatment approaches were performed either by means of photodynamic therapy (HELBO, Photodynamic Systems GmbH) or high power diode laser (940nm, Biolase ® Technology, CA, USA). Performing photodynamic therapy the root canals were filled with the phenothiazine chloride (HELBO® Endo Blue, Bredent, Germany) for 2 min following irradiation of diode laser (HELBO® TheraLite Laser (λ = 660 nm, power = 100 mW)) for 60 s. Performing only diode laser the root canals were be irrigated with a diode laser (λ = 940 maximal power 10W) for 60 s."
224264426|NCT05291195|DRUG|Essential Oil|"After each instrumentation, the root canals were irrigated with 1.5 % sodium hypochlorite (NaOCl).~Depending on allocations, in the EO group, the adjuvant treatment approaches were performed either by means of essential oil (Cymbopogon martinii and Thymus vulgaris, Herba oils, Herba d.o.o, Belgrade, Serbia)"
223808856|NCT03685396|BIOLOGICAL|Platelet rich fibrin ( PRF)|"Venous blood was collected with a butterfly needle in two 10 mL tubes without anticoagulants or other chemicals. The tubes were immediately centrifuged at 3000 rpm for 10 minutes.~At the end of centrifugation a fibrin clot (PRF) was obtained in the middle of the tube, just between the red corpuscles at the bottom and acellular plasma at the top. The PRF clot was taken from the tube and the red cells portion at the base of the clot was eliminated with sterile scissors Then the PRF was enveloped in sterile gauzes and positioned between two glass plates: the compression drove out the serum from the clot obtaining PRF membranes that were ready to be used in the surgical site."
223808857|NCT03685396|DRUG|hemostatic agents with oxidized and regenerated cellulosa|In the Control Group hemostatic agents with oxidized and regenerated cellulosa were sutured to the palatal wound with mattress suture ( silk 5/0).
223808858|NCT03325244|OTHER|EEG monitor|sleep patterns will be monitored using EEG monitor
223808859|NCT03325244|OTHER|FitBit|activity levels will be monitored
223808860|NCT02157025|DEVICE|Cartoon video fixation target and cartoon character voice audio instructions during Humphrey perimetry|
223808861|NCT02157025|OTHER|Usual Care procedures during Humphrey perimetry for children|
223808862|NCT05340959|DEVICE|Devices: Osstell®, Periotest® and AnyCheck®.|"1. Osstell®: is a device that measure implant stability and based on resonance frequency analysis (RFA). Due to stiffness in the interface between the implant surface and the bone smart peg will vibrates accordingly. the more dense bone the higher stability, the higher frequency and higher Implant Stability Quotient (ISQ) value which is from 1-100.~2. Periotest®: is a device used to assess osseointegration of dental implants, so it measure implant stability . it is based on damping effect of implant. Showing the measurement digitally on a scale from -8 (low mobility) to 50 (high mobility) PTV units.~3. AnyCheck®: this is an implant stability meter that measures the stiffness of alveolar bone-implant interface through a tapping motion. Showing the measurement on a scale from 30 (low stability) to 85 (high stability)."
223808863|NCT05177445|COMBINATION_PRODUCT|Phototherapy|"Prior to the beginning of the procedure the patient will be administered a nasal decongestant. Second to this, the patient will be advised to blow his/her nose. This step allows the physician a better view and allows the light exposure to reach the majority of the nasal mucosa(9).~To start the intervention the physician will introduce the phototherapy device inside the patient's nasal cavity as the patient sits in an upright condition. As the procedure is ongoing the physician will slightly rotate the device in order to minimize dryness and to irradiate all the nasal cavity. After the intervention the patient will be administered an emollient/moisturizing drug to further hydrate the nasal mucosa(9).~The intervention will have a crescent duration, the first one will be only two minutes and the following ones will increase 15 seconds each until a plateau is reached at 3 minutes in the 5th intervention."
223808864|NCT05177445|COMBINATION_PRODUCT|OT+Corticosteroids|Patients that present loss of smell 4 weeks after their coronavirus-19 infection and that have had a real-time polymerase chain reaction (reverse transcriptase polymerase chain reaction )and both oral corticosteroids (prednisone 40mg) and olfactory training will be applied, in the intervals of daily for 10 days and daily for the duration of the study respectively.
223808865|NCT01493505|DRUG|AMG 386|AMG 386 15mg/kg IV QW (until progression or unacceptable toxicity develops)
223808866|NCT01493505|DRUG|Paclitaxel|Paclitaxel 175 mg/m2 3 hour IV Q3W (6 cycles)
223808867|NCT01493505|DRUG|AMG 386 Placebo|AMG 386 Placebo IV QW (until progression or unacceptable toxicity develops)
223808868|NCT01493505|DRUG|Carboplatin|Carboplatin AUC 5 or 6 IV Q3W (6 cycles)
223808869|NCT06221423|DRUG|Fruquintinib Combined With TAS-102|Fruquintinib Combined With TAS-102
223808870|NCT00794638|DRUG|SyB L-0501|The administration of SyB L-0501 90 mg/m2 or 120 mg/m2/day on Day 2 and Day 3 will be followed by 18 days of observation. In the absence of adverse events or progressive disease, treatment will be repeated up to a maximum of 6 cycles, where 1 cycle is the 21-day treatment period (3 days of administration and 18 days of observation).
223808871|NCT00794638|DRUG|Rituximab|The administration of rituximab 375 mg/m2 on Day 1 of each cycle will be followed by 18 days of observation. In the absence of adverse events or progressive disease, treatment will be repeated up to a maximum of 6 cycles, where 1 cycle is the 21-day treatment period (3 days of administration and 18 days of observation).
223808872|NCT05057689|DRUG|Intranasal Dexmedetomidine (4 mcg/kg)|Dexmedetomidine 100 mcg/mL (concentration of 200 mcg/2 mL) will be atomized for intranasal administration at a dose of 4 mcg/kg (0.04 mL/kg) according to a weight-based dosing chart prior to laceration repair. The maximum dose will be 200 mcg.
223808873|NCT05057689|DRUG|Intranasal Fentanyl (2 mcg/kg)|Fentanyl 50 mcg/mL (concentration of 100 mcg/2 mL) will be atomized for intranasal administration at a dose of 2 mcg/kg (0.04 mL/kg) according to a weight-based dosing chart prior to laceration repair. The maximum dose will be 100 mcg.
223808874|NCT05057689|DRUG|Intranasal Midazolam (5 mg/kg)|Midazolam 5 mg/mL (concentration of 10 mg/2 mL) will be atomized for intranasal administration at a dose of 0.3 mg/kg (0.06 mL/kg) according to a weight-based dosing chart prior to laceration repair. The maximum dose will be 10 mg.
223808875|NCT01119768|DRUG|Esomeprazole|20mg Esomeprazole once daily, 8 weeks and 24 weeks on-demand treatment
223808876|NCT01119768|DRUG|Esomeprazole|20mg Esomeprazole once daily, 2 weeks and 24 weeks follow up
223808877|NCT00714922|PROCEDURE|PRK|Laser refractive surgery
223808878|NCT00714922|PROCEDURE|SBK|Laser refractive surgery
223808879|NCT04360850|BEHAVIORAL|online survey|A brief survey for therapists to fill out
223808880|NCT01059643|DRUG|LY2523355|Dose determined by participant body surface area: 5 milligrams/square meter(mg/m²) or 6 mg/m², administered intravenously as a 1-hour infusion on Days 1, 2 and 3 of a 21 day cycle; for up to 2 cycles (4 cycles for prostate cancer patients). Additional cycles administered based on patient response assessment.
223808881|NCT01059643|DRUG|pegfilgrastim|6 milligrams (mg), administered subcutaneously approximately 24 hours after third dose of LY2523355 on Day 4 of each 21-day cycle, for up to 2 cycles of LY2523355 administration (4 cycles for prostate cancer patients). Additional cycles of LY2523355 administered based on patient response assessment.
223808882|NCT00886028|DRUG|Liposomal doxorubicin|"Liposomal doxorubicin 60 mg/m2 every 4 weeks for 6 cycles.~Thirty patients with epithelial, sarcomatoid or biphasic histological confirmed diagnosis of MPM from the Instituto Nacional de Cancerología and the Instituto Nacional de Enfermedades Respiratorias were included to receive LD 60mg/m2 plus cisplatin 80 mg/m2 every 4 weeks for 6 cycles."
223808883|NCT00886028|DRUG|Cisplatin|"Cisplatin 80 mg/m2 every 4 weeks for 6 cycles.~Thirty patients with epithelial, sarcomatoid or biphasic histological confirmed diagnosis of MPM from the Instituto Nacional de Cancerología and the Instituto Nacional de Enfermedades Respiratorias were included to receive LD 60mg/m2 plus cisplatin 80 mg/m2 every 4 weeks for 6 cycles."
223808884|NCT06425731|OTHER|Fasting|Participants (Dance for PD, in-person only) will engage in one of their routine weekly dance sessions while a portable indirect calorimeter is used for energy expenditure analysis. Before this session, participants will be asked to fast for at least 4-hours. In this way, participants in this study arm will engage in a self-controlled study design wherein they complete a 4-hour fast before engaging in an oxygen uptake assessment during their routine dance classes. During the 4-hour fasting period, participants will be asked to refrain from eating any food and drinking any beverages except for water.
223808885|NCT06425731|OTHER|No Intervention|No Intervention
223808886|NCT03525548|DRUG|VX-445/TEZ/IVA|Participants received VX-445/TEZ/IVA orally once daily in the morning.
223808887|NCT03525548|DRUG|TEZ/IVA|Participants received TEZ/IVA orally once daily in the morning.
223808888|NCT03525548|DRUG|IVA|Participants received IVA orally once daily in the evening.
223808889|NCT03525548|DRUG|Placebo|Participants received placebo matched to VX-445/TEZ/IVA orally once daily in the morning.
223808890|NCT03525548|DRUG|Placebo|Participants received placebo matched TEZ/IVA orally once daily in the morning.
223808891|NCT05246449|OTHER|individualised treatment plan (VitalCare) and associated remote medical monitoring|VitalCare is a treatment plan to help in the personalisation of patient care.
223808892|NCT06770491|DRUG|Y-3 for injection|"The investigational drug (Y-3) consists of two parts: Y-3 for injection (lyophilized powder) and Solvent for Y-3 for injection (concentrated solution).~Name: Y-3 for injection Strength: 20 mg Dosage Form: Lyophilized powder for injection Storage Condition: 2-8°C Supplier: Neurodawn Pharmaceutical Co., Ltd. Name: Reconstitution diluent for Y-3 for injection Strength: 3ml (containing 0.6 g propylene glycol) Dosage Form: Concentrated solution for injection Storage Condition: 2-8°C Supplier: Neurodawn Pharmaceutical Co., Ltd."
223808893|NCT06770491|DRUG|Placebo|"The placebo consists of two parts: placebo (lyophilized powder) and Solvent for Y-3 for injection(concentrated solution).~Name: Placebo Strength: 0 mg Dosage Form: Lyophilized powder for injection Storage Condition: 2-8°C Supplier: Neurodawn Pharmaceutical Co., Ltd. Name: Solvent for Y-3 for injection Strength: 3 mL (containing 0.6 g propylene glycol) Dosage Form: Concentrated solution for injection Storage Condition: 2-8°C Supplier: Neurodawn Pharmaceutical Co., Ltd."
223808894|NCT04441281|PROCEDURE|Traction of the cervix for IUD insertion|Limited mobility of the uterine cervix and alignment with the vaginal canal is often required during insertion of an intrauterine contraceptive device (IUD).
223808895|NCT02032212|OTHER|EVP unflavoured|
223808896|NCT02032212|OTHER|EVP flavoured|
223808897|NCT02032212|OTHER|Nicotine inhalator|15 mg nicotine Nicorette
223808898|NCT02032212|OTHER|Conventional cigarette|
223808899|NCT03404102|DEVICE|Cu-IUD|Copper Intra-uterine device used as contraceptive method
223808900|NCT06443242|DEVICE|Low-Dose Laser Acupuncture (LLA)|The intervention utilizes the xS-998D06 semiconductor laser acupoint therapeutic device specifically designed for targeted acupoint therapy. This device is critical in delivering precise low-dose laser therapy at a controlled wavelength and power. The laser treatment is directed towards enhancing neurological function and potentially alleviating symptoms of insomnia and depression by stimulating specific acupoints associated with mental health and sleep.
223808901|NCT06443242|DEVICE|Sham Laser Acupuncture (SLA)|Sham laser acupuncture serves as a control to assess the placebo effect of the laser treatment. It involves the same procedure as LLA but uses a non-emitting laser probe. This intervention is designed to mimic the LLA setup without delivering actual laser therapy, allowing for an evaluation of the psychological and physiological effects of the placebo compared to the active laser treatment.
223808902|NCT00148382|DRUG|ATL-962|
223808903|NCT02295566|DRUG|Nitric Oxide|Not required
223808904|NCT02295566|DRUG|Control|Not required
223808905|NCT01422135|DRUG|AG200-15|A transdermal contraceptive delivery system for levonorgestrel (LNG) and ethinyl estradiol (EE). . A total of 3 patches will be worn during the study. Each patch will be worn for 1 week followed by a patch free week.
223808906|NCT06162832|COMBINATION_PRODUCT|Allograft and rHPDGF-BB|At this intervention the periodontal defect will be treated with allograft and rHPDGF-BB (GEM21)
223808907|NCT06162832|COMBINATION_PRODUCT|Allograft and Saline solution|This will be used as the control group
223808908|NCT02162680|DRUG|1% lidocaine|
223808909|NCT02162680|DRUG|bacteriostatic normal saline (BNS)|
223808910|NCT04836221|BEHAVIORAL|Support|"Community Health Workers will conduct weekly phone calls to monitor blood pressure or blood glucose, to check in on patient need for social, practical or emotional supports, and to encourage healthy lifestyle modification.~Participants will also have access to a mobile app to support chronic disease management (Either diabetes or hypertension)."
223808911|NCT03379623|OTHER|ESCAPE-pain Programme|The Enabling Self-management and Coping with Arthritic (knee) Pain using Exercise (ESCAPE-pain) is a programme of rehabilitation that integrates educational self-management and coping strategies for people with joint pain with an individualised exercise regimen for each participant. The implementation of the programme will be conducted by the researcher as a certified facilitator by using Clinician's training manual for the ESCAPE-pain programme.
223808912|NCT02819102|DRUG|BCX7353 and probes|
223808913|NCT02600884|BEHAVIORAL|Families Talking Together Plus (FTT+HPV)|Intervention parents will attend a 1-hour intervention session and receive program materials to use with youth at home and 2 booster phone calls post intervention. Content of the experimental intervention includes parent child sexual health communication and HPV vaccination navigation.
223808914|NCT02600884|BEHAVIORAL|Brief motivational interviewing (BMI)|Control parents will attend a 1-hour intervention session and receive program materials to use with youth at home and 2 booster phone calls post intervention. Content of the control intervention includes obesity prevention strategies using motivational interviewing.
223808915|NCT06437236|DRUG|ondansetron|"Group A will receive ondansetron 4mg diluted in normal saline,The total volume of the solution infused will kept at 10 mL.~After preloading, patients in the respective group will receive the infusion of the study drug over 1 minute just 5 minutes before performing the subarachnoid block"
223808916|NCT06437236|DRUG|granisetron|"Group B will receive granisetron 1mg diluted in normal saline.The total volume of the solution infused will kept at 10 mL.~After preloading, patients in the respective group will receive the infusion of the study drug over 1 minute just 5 minutes before performing the subarachnoid block"
223808917|NCT00705302|BEHAVIORAL|Group training with self-help group|Combined educational and exercise program for pulmonary rehabilitation, with (1) or without(2 a self-help group. The educational part consists firstly of two days with group meetings with information from medical doctor, pharmacist, psychologist, ergonomist, nurse, social worker, physiotherapist and a clinical nutritional physiologist. One more day will be held after 3 months and it is the participants themselves who decide on the content of these days. An experienced patient will participate throughout the course. The exercise part consists of group training twice a week for 3 months with 10-15 participants in each group. Patients will instead of five of the group training sessions, participate in a self-help group.
223808918|NCT00705302|BEHAVIORAL|Group training|Combined educational and exercise program for pulmonary rehabilitation. The educational part consists firstly of two days with group meetings with information from medical doctor, pharmacist, psychologist, ergonomist, nurse, social worker, physiotherapist and a clinical nutritional physiologist. One more day will be held after 3 months and it is the participants themselves who decide on the content of these days. An experienced patient will participate throughout the course. The exercise part consists of group training twice a week for 3 months with 10-15 participants in each group.
223808919|NCT00643123|DRUG|Allopurinol|300-600 mg/day over a 6 week period
223808920|NCT00643123|OTHER|Placebo|Inactive substance
223808921|NCT03631225|DIAGNOSTIC_TEST|Vectra|Each arm will have the Vectra test however, scores will not be provided for the Usual Care Arm until end of study (12 month time point)
223808922|NCT05929443|OTHER|END-IT intervention for nursing homes|Complex intervention, as described in the arm/group descriptions
223808923|NCT03819582|DEVICE|EyeCee One intraocular lens|Hydrophobic aspheric monofocal intraocular lens
223808924|NCT06328166|PROCEDURE|Sono-guided injection with ES135|Sono-guided injection with ES135 between carpal tunnel and median nerve
224264427|NCT05291195|DRUG|Sodium hypochlorite group|Mechanico-chemical root canal preparation and root canal disinfection were be performed by means of mechanic-chemical methods including hand instruments followed by 1.5% sodium hypochlorite (pH 12), at room temperature (21 degrees Celsius).
223808925|NCT06328166|PROCEDURE|Sono-guided injection with placebo|Sono-guided injection with placebo between carpal tunnel and median nerve
223808926|NCT02923739|BIOLOGICAL|Bevacizumab|Given IV
223808927|NCT02923739|BIOLOGICAL|Emactuzumab|Given IV
223808928|NCT02923739|OTHER|Laboratory Biomarker Analysis|Correlative studies
223808929|NCT02923739|DRUG|Paclitaxel|Given IV
223808930|NCT02923739|OTHER|Pharmacological Study|Correlative studies
223808931|NCT02701335|DEVICE|Neural mobilization|The first 6 exercises consist of active range of motion movements of the hand designed to improve joint flexibility. The remaining 3 exercises are designed to strengthen grip and pinch by using a non-latex polymer ball: the Thera-Band Hand Exerciser (The Hygenic Corporation, Akron, OH) Subjects began with 10 repetitions the first 4 sessions, progressed to 12 repetitions the next 2 sessions, then 15 (2 sessions), and finally 20, if able, during the last sessions.
223808932|NCT02701335|DEVICE|Gloreha device|Robotic assisted passive mobilization.
223808933|NCT02701335|DEVICE|Standardized exercise|9 exercises: active range of motion, strengthen grip and pinch
223808934|NCT06094556|DRUG|SHR-1826|dose is calculated based on the subjects' baseline weight.
223808935|NCT03471169|DRUG|Desirable TEG|"Change the type and dose of antithrombotic therapy and obtain desirable TEG results.~Antithrombotic drugs inclued Bayaspirin®，Plavix ® and Cilostazol."
223808936|NCT03471169|DRUG|Undesirable TEG|Don't change the type and dose of antithrombotic therapy and obtain undesirable TEG results. Antithrombotic drugs inclued Bayaspirin®，Plavix ® and Cilostazol.
224264428|NCT05025527|DIAGNOSTIC_TEST|biparametric MRI (bpMRI)|Men go for the bpMRI for PCa (prostate cancer) screening, those who had a suspicious result will go for the next confirmation test
224264429|NCT05025527|DIAGNOSTIC_TEST|Prostate cancer antigen (PSA)|Men go for the PSA test for PCa screening, those who had a suspicious result will go for the next confirmation test
224264430|NCT03899935|PROCEDURE|Laparoscopy|Laparoscopy for endometriosis
224264431|NCT06345235|DIAGNOSTIC_TEST|blood test|Assessment of the association of new biomarkers (GDF15, ST2, galectin-3, TIMP-1, MMP-9, NfL) and plasma prothrombotic potential in groups 1, 2, 3
224264432|NCT02623257|OTHER|mutation detection|
224264433|NCT02623257|OTHER|ARMS|
224264434|NCT02623257|GENETIC|ctDNA analysis|
223808937|NCT03297203|BEHAVIORAL|Blood sample|The investigators will take two kits of blood samples for the group 1, one during the early stage of the septic shock (48 first hours of care) and one during the late stage of the disease (between the fourth and the sixth day). We'll take only one kit of blood samples for the group 2. One kit includes one EDTA tube (5 mL) and five Lithium Heparin tubes (25 mL). The immune mapping will be made by Julien Carvelli, a gold medalist resident, in the framework of a Master 2. The analyses will be made in the laboratory of immunology in the Conception Hospital (Pr Vivier's team).
223808938|NCT02623855|BEHAVIORAL|Family outings|Participants will be invited to three weekly outings to local parks, case management and support in getting to nature. Participants will be offered transportation to the outings and s meal at local nature destinations. Programming at the park will include a picnic and walk with nature exploration, and will be facilitated by park and clinic staff.
223808939|NCT02623855|BEHAVIORAL|Park prescription|Participants will receive a map of local parks, and the recommendation to be physically active outdoors three days a week in nature.
223808940|NCT02623855|DEVICE|Pedometry|Participants will record their daily pedometry.
223808941|NCT02623855|BEHAVIORAL|Case Management|Participants will receive a phone call to list potential barriers to participating in nature outings, and will talk through solutions with an investigator. Participants will be offered assistance with transportation if necessary.
223808942|NCT00796250|BIOLOGICAL|Infliximab|Patients in this group were treated with azathioprine (AZA), infliximab, and placebo prednisolone. Infliximab was to be administered at a dose of 5 mg/kg at Visit 2 (Week 0), and at Weeks 2, 6, and 14 (total of four infusions). Infliximab infusions were administered by the investigators in the hospital during the patient's visit, usually in the morning.
223808943|NCT00796250|DRUG|AZA|Patients in this group were treated with AZA, infliximab, and placebo prednisolone. All patients were treated with AZA, by oral use, with a 2 mgkg dose a day until the end of the study (30 weeks).
223808944|NCT00796250|DRUG|Placebo Prednisolone|Patients in this group were treated with AZA, infliximab, and placebo prednisolone. Placebo prednisolone was to be administered by oral use.
223808945|NCT00796250|DRUG|Prednisolone|Patients in this group were treated with AZA, prednisolone, and placebo infliximab. Prednisolone was to be administered by oral use, with the decreasing dose of 40 mg a day, 35 mg a day, 30 mg a day and 25 mg a day every week for each dosage, respectively; 20 mg a day for five weeks; 15 mg a day, 10 mg a day and 5 mg a day for one week for each dosage respectively, until discontinuation.
223808946|NCT00796250|DRUG|AZA|Patients in this group were treated with AZA, prednisolone, and placebo infliximab. All patients were treated with AZA, by oral use, with a 2 mgkg dose a day until the end of the study (30 weeks).
223808947|NCT00796250|BIOLOGICAL|Placebo Infliximab|Patients in this group were treated with AZA, prednisolone, and placebo infliximab. Placebo infliximab was to be administered at Visit 2 (Week 0), and at Weeks 2, 6, and 14 (total of four infusions). Infliximab infusions were administered by the investigators in the hospital during the patient's visit, usually in the morning.
223808948|NCT05147610|DIAGNOSTIC_TEST|Intraocular pression|"First, measurement of the eye pressure by air-puff tonometry and estimation of the pachymetries with the TONOREF III.~Secondly, measurement of the eye pressure by GAT. Thirdly, measurement of the eye pressure by Icare 200."
223808949|NCT05633875|OTHER|MRI|Patients will undergo MRI without contrast agent
223808950|NCT03996057|DRUG|Methenamine Hippurate 1000 MG|Discussed in arm/group description
223808951|NCT03996057|DRUG|Vaginal estrogen|Any form of low dose vaginal estrogen, whether ring, cream, tablet, or capsule. Depends on what patient is already using.
223808952|NCT03996057|DIETARY_SUPPLEMENT|D-mannose|Powder or tablet, depending on what patient is already using.
223808953|NCT01591382|DRUG|Ketamine|Intravenous (IV) ketamine 0.2 mg/kg/hr for 24-48 hours postoperatively.
223808954|NCT01591382|DRUG|Placebo|Patients who received ketamine-matching placebo were given saline infusions
223808955|NCT01591382|DRUG|Hydromorphone PCA|Intravenous hydromorphone PCA
223808956|NCT03319537|DRUG|pevonedistat|Pevonedistat will be administered as an IV infusion at a dose of 50 mg/m2 days 1, 3, and 5 of a 21-day cycle.Treatment will be administered as an outpatient.
223808957|NCT03319537|DRUG|Pemetrexed and cisplatin|Pemetrexed, 500 mg/m2 and cisplatin, 75 mg/m2, will be given at fixed doses on day 1 of each cycle.
223808958|NCT04307706|BEHAVIORAL|Acceptance and Commitment Therapy|The Acceptance and Commitment Therapy Based Intervention Program was applied to the intervention group in six sessions. The duration of each session lasted on average 60-90 minutes. A session was held for each parent once a week.
223808959|NCT02787707|DRUG|Persumac|2.7 grams Persumac powder (Iranian traditional medicine remedy composed from sumac and Bunium Persicum) every 8 hour
223808960|NCT02787707|DRUG|lactose|2.7 grams Lactose every 8 hour
223808961|NCT04413292|DIAGNOSTIC_TEST|ELISA assays and Westren blot analysis of survivin and fibulin-3 expression|expression analysis of biomarkers
223808962|NCT03357614|DRUG|Sulopenem|Antibiotic therapy for complicated UTI
223808963|NCT03357614|DRUG|Sulopenem-Etzadroxil/Probenecid|Antibiotic therapy for complicated UTI
223808964|NCT03357614|DRUG|Ertapenem|Antibiotic therapy for complicated UTI
223808965|NCT03357614|DRUG|Ciprofloxacin|Antibiotic therapy for complicated UTI
223808966|NCT03357614|DRUG|Amoxicillin-clavulanate|Antibiotic therapy for complicated UTI
223808967|NCT01116492|OTHER|Single incision laparoscopic cholecystectomy|One port placed through the umbilicus
223808968|NCT01116492|OTHER|Laparoscopic cholecystectomy|Standard 4 port laparoscopic cholecystectomy
223808969|NCT02695355|DRUG|Methylphenidate (MPH)|Test 1: No medication. Registration of ERPs and behavioral data during an attention task. Test 2: Test repeated on a single dose of MPH. Outcome measure: Classification as responders or non-responders after a four weeks medication trial, based on rating scales from parents and Teachers.
224264435|NCT04405479|BEHAVIORAL|Examination of tremor and upper hand functions|Participants will be only examined. They will not undergo any intervention.
224264436|NCT03701945|OTHER|Pulmonary rehabilitation|Pulmonary rehabilitation will be provided to patients presenting an acute exacerbation. The intervention will be composed of exercise training, education and psychosocial support.
223808970|NCT03738202|BEHAVIORAL|Multifaceted intervention package|"Multifaceted intervention package will comprise following strategies:~1. Initial training for all workers and managers on occupational health and safety (OHS)~2. Follow-up refresher sessions every three months~3. Formation of workplace committees (including worker representatives) to draw up, agree and promote a health and safety plan that includes wet mopping, safe disposal of cotton dust, and the use of simple face masks, as well as further publicity about the risks from cotton dust.~4. Provision of adequate supplies of face masks to support the health and safety plan"
223808971|NCT03474302|BEHAVIORAL|Physical Activity|Aerobic, strength training, balance, flexibility
223808972|NCT03474302|OTHER|Successful Aging|Healthy aging education
223808973|NCT01893385|DRUG|Vitamin D (drug)|
223808974|NCT00868465|DRUG|Artemether-Lumefantrine|Treatment with artemether-lumefantrine (AL; Coartem; Novartis Pharma), administered as half a tablet (20 mg of artemether and 120 mg of lumefantrine) per 5 kg of body weight in a 6-dose regimen (at enrolment and 8, 20, 32, 44, and 56 h \[+/-90 min\] after the initiation of treatment). AL is currently the first line treatment in Tanzania
223808975|NCT00868465|DRUG|Dihydroartemisinin-piperaquine|Dihydroartemisinin-piperaquine (DP; Artekin; Duocotexin, Holley Pharm, 40 mg dihydroartemisinin/320 mg piperaquine tablets), with a dihydroartemisinin dose of 2.5 mg per kilogram and a piperaquine phosphate dose of 20 mg per kilogram daily for 3 days. DH is registered in Tanzania as Artekin and has been tested extensively in Asia and recently in clinical trials in Uganda and Rwanda
223808976|NCT03991117|BEHAVIORAL|resistance exercise|unilateral knee extensions until fatigue with varying load and speeds of contraction
223808977|NCT02277990|DEVICE|TYRX™ Absorbable Antibacterial Envelope|
223808978|NCT00405457|DRUG|Restasis, Optive Tears|Restasis and Optive Tears use twice daily more frequently if needed
223808979|NCT03203109|BEHAVIORAL|Postural Assessment Scale for Stroke (PASS)|Postural Assessment Scale for Stroke (PASS)
223808980|NCT05541510|BIOLOGICAL|AD17002 + Formulation buffer|Intranasal innate immune modulator
223808981|NCT05541510|BIOLOGICAL|Placebo|Formulation buffer
223808982|NCT03997513|BEHAVIORAL|Pulmonary Telerehabilitation|The intervention will consist of an eight-week, three sessions per week, home-based pulmonary telerehabilitation program that will incorporate both lower extremity endurance exercise and upper and lower extremity resistance training. Subjects randomized to the study intervention will also participate in a one hour, twice-monthly support group via group video conferencing consisting of an educational topic (i.e. inhaler use, understanding COPD) and group discussion.
223808983|NCT06488092|OTHER|Cesarean Risk Calculator|The cesarean risk calculator will be incorporated into routine care at the site
224264437|NCT03783663|BEHAVIORAL|Misfit Shine 2|The intervention group was given a Misfit Shine 2 to monitor sleep throughout the 12-week intervention period. Participants were instructed to wear the device on the wrist, which is better for capturing sleep than the other wear locations. Participants were instructed on how to self-monitor total sleep time and select a goal for that behavior. Further, participants were asked to view feedback on their sleep time daily on the Misfit smartphone app, which they used to monitor their progress toward achieving their behavioral goals.
224264438|NCT04332445|OTHER|Hyaluronic Acid Gel|Health care product - to be apllied on the subject's skin
223808984|NCT06238141|OTHER|Expressive writing|"According to the writing prompts, online expressive writing focuses on stressful events and will be conducted twice a week (every Monday and Thursday) for 15 minutes each time, lasting for ten weeks.~Writing prompts are developed based on Emotional Processing Theory (EPT) and Cognitive Adaptation Theory (CAT)."
223808985|NCT06238141|OTHER|Neutral writing|According to the writing prompts, online neutral writing focuses on immediate surroundings and will be conducted twice a week (every Monday and Thursday) for 15 minutes each time, lasting for ten weeks.
223808986|NCT02260128|OTHER|Chewing gum|The intervention group will receive chewing gum four times daily following surgery.
223808987|NCT03723343|DRUG|GP+IMRT|Gemcitabine 1000 mg/m2 intravenously, d1\&d8 +Cisplatin 80 mg/m2 intravenously, d1 21\~28 days/cycle, 4 patients with oligometastasis, 6 cycles with multiple metastases
223808988|NCT03723343|DRUG|TPF+IMRT|Docetaxel: 75mg/m2 intravenous drip, d1+Cisplatin75mg/m2 intravenous drip, d1\~d5+5-fluorouracil 750mg/m2/d intravenous drip, d1\~d521\~28 days/cycle, patients with oligometastasis take 4 cycles, moreTransfer patients for 6 cycles
223808989|NCT06834113|PROCEDURE|Dorsogluteal intramuscular injection|"The injection is carried out on the dorsogluteal intramuscular site, without virtual reality headset~The injection is carried out on the ventrogluteal intramuscular site, without virtual reality headset~The injection is carried out on the dorsogluteal intramuscular site, with virtual reality headset~The injection is carried out on the ventrogluteal intramuscular site, with virtual reality headset"
223808990|NCT03138733|DRUG|Ceftobiprole medocaril|Ceftobiprole 500 mg (as 667 mg ceftobiprole medocaril) as a 2 h infusion
223808991|NCT03138733|DRUG|Daptomycin|Daptomycin 6 mg/kg (up to 10 mg/kg based on institutional standards) as a 0.5 h infusion, with or without aztreonam
223808992|NCT06048081|DRUG|zolbetuximab|"intravenous infusion~mFOLFOX6 or CAPOX (used at physician discretion) will be used in combination with zolbetuximab"
223808993|NCT04026529|OTHER|walking on incline or walking at increasing speed|"Subjects will be prepared for data collection by wearing a form-fitting suit (i.e., wrestling singlet) and obtaining height and body weight. Retro-reflective markers will be placed bilaterally on anatomical locations of the feet, legs, and hips.~Subjects will be outfitted with the portable metabolic cart and oximeter as in the previous visit. One of two treadmill trials will be performed: 1) at the speed and 2) at the slope +speed determined in the previous visit. Trial order will be randomized among subjects and across visits 3 \& 4. For each trial, subjects will be asked to walk on a treadmill for up to 6 minutes. Speed or slope will be increased every 30 seconds and they will be asked to walk for one minute at that speed or slope."
223808994|NCT04938817|BIOLOGICAL|coformulation pembrolizumab/quavonlimab|Intravenous (IV) infusion
223808995|NCT04938817|DRUG|lenvatinib|Oral administration
223808996|NCT04938817|BIOLOGICAL|MK-4830|IV infusion
223808997|NCT04938817|BIOLOGICAL|coformulation favezelimab/pembrolizumab|IV infusion
223808998|NCT04938817|BIOLOGICAL|R-DXd|IV Infusion
223808999|NCT02969837|DRUG|Elotuzumab|Elotuzumab will be given on Cycles 1-2 on days 1, 8, 15, 22, Cycles 3 and Beyond on days 1 and 15
223809000|NCT02969837|DRUG|Carfilzomib|Carfilzomib will be given on Day 1 and 8 of Cycle 1, Days 1, 8, and 15 of Cycles 2-8, and Days 1 and 15 of Cycles 9 and beyond
223809001|NCT02969837|DRUG|Lenalidomide|Lenalidomide will be given on days 1-21 for all cycles.
223809002|NCT02969837|DRUG|Dexamethasone|"Dexamethasone will be given as follows:~Cycle 1 and 2: Days 1, 2, 8, 9, 15, 16, and 22 Cycles 3 and Beyond: Days 1, 8, 15, and 22"
223809003|NCT02098538|DRUG|Regorafenib|All eligible patients will receive a starting regorafenib dose of 120 mg daily taken orally for 3 weeks in a 4-week cycle. Patients for whom regorafenib dose reduction was not performed or required may have their treatment dose increased to the FDA-approved dose of 160 mg daily orally for 3 weeks in a 4-week cycle in cycle #2 or beyond (this is not mandatory). RECIST v1.1 tumor assessments will be made at baseline (CT or MRI) and then approximately every 2 cycles (or every 8 weeks (+/- 1 week)). After 10 months, imaging will be done every 3 cycles (or every 12 weeks (+/- 1 week)). Patients may remain on study until progression of disease or unacceptable toxicity
223809004|NCT04252742|DRUG|Erenumab|140 mg, 2 consecutive injections of 70 mg
223809005|NCT04252742|DRUG|Placebo|2 consecutive injections
223809006|NCT06180304|OTHER|Exercise training|The indoor physical exercise program was carried out in a gym with weight machines. The physical exercise program was divided into four parts. Part I: playful game or shuttle run (5 to 7 minutes). Part II: aerobic training (treadmill; 10 minutes; 40% to 80% of Heart Rate Reserve; between 12 to 17 according to the Borg Rating Of Perceived Exertion Scale; between 5 to 8 according to the Borg Category-Ratio 10 Scale. Part III: strength training (more or less 25 minutes; Leg Press + Chest Press + Leg Extension + Lat Pull Down + Leg Curl + Shoulder Press; 40-80% of 3 maximum repetitions; 10-15 reps; 2-3 sets). Part IV: 4 static stretches (30 to 60 seconds each).
223809007|NCT05016583|OTHER|Paula Method|12 weeks of Paula Method of Exercises
224264439|NCT03302832|OTHER|Physical Therapy|Physical therapy includes both the in-person and home-based interventions prescribed for each individual participant in order to maximize overall patient outcomes including: ambulation, range of motion, strength, functional activities, pain, swelling, balance, patient safety, and other items within the scope of physical therapy practice.
223809008|NCT01151800|OTHER|Using IVR to maintain ACS patients on best practice guidelines|
223809009|NCT04499651|BEHAVIORAL|Navigation|Trained study navigators will provide one-on-one learning sessions and accompaniments to criminal-justice involved people to help link them to HIV/Hepatitis C care
223809010|NCT05586594|DIAGNOSTIC_TEST|Genetic testing for 4 MODY genes (GCK, HNF1A, HNF4A, HNF1B)|Genetic testing for 4 MODY genes (GCK, HNF1A, HNF4A, HNF1B) to look for common non-syndromic MODY in Emirati population
223809011|NCT01714804|DEVICE|Accell Evo3 Prospective Use|
223809012|NCT02283281|DRUG|Tetrahydrocannabinol|1:1 THC to CBD standardized extract from cannabis plant
223809013|NCT02283281|DRUG|Dummy oromucosal|drops containing only Olive oil vehicle without the active compound (i.e.: without Cannabis oil)
223809014|NCT04841941|DEVICE|G4 Multifocal soft contact lens with a 54% water content for presbyopia|"The participants must agree to wear lenses from a trial set with the fit assessed according to the Fitting Guide. Prescription lenses will then be ordered from the manufacturer."
223809015|NCT00975910|DRUG|lidocaine|Lidocaine arm: lidocaine (2%) as an intravenous bolus (1.5 mg/kg) during induction followed by an intravenous infusion (2 mg. kg(-1).h(-1)) after induction until at the end of surgery
223809016|NCT00975910|DRUG|saline|Saline arm: infused at the same rate as lidocaine
223809017|NCT06218225|DIETARY_SUPPLEMENT|Verum|1st cycle - 30 days continuous use Cycle 2 - first 15 days washout, remaining 15 days use of study product Cycle 3 - first 15 days washout, remaining 15 days use of study product 4th cycle - 30-day washout
223809018|NCT06218225|DIETARY_SUPPLEMENT|Placebo|1st cycle - 30 days continuous use Cycle 2 - first 15 days washout, remaining 15 days use of placebo Cycle 3 - first 15 days washout, remaining 15 days use of placebo 4th cycle - 30-day washout
223809019|NCT00018135|DRUG|calcium acetate|
223809020|NCT00018135|DRUG|aluminum hydroxide|
223809021|NCT00018135|DRUG|Sevelamer|
224264440|NCT03302832|OTHER|In-home Exercise Equipment|The in-home exercise component of the study will supplement physical therapy services. This exercise equipment will be utilized daily for up to 90 minutes as guided by the healthcare team
224264441|NCT03556813|OTHER|survey|non-inferiority study, randomized, blind, excluding health product, with no risk or constraint, in which all the acts are performed in the usual way and do not modify the patient's management.
223809022|NCT02693938|DEVICE|Follicular Euglycemic clamp|Follicular Euglycemic clamp during follicular phase
223809023|NCT02693938|DEVICE|Luteal Euglycemic clamp|Luteal Euglycemic clamp during luteal phase
223809024|NCT01299519|BEHAVIORAL|Weight Maintenance|Subjects in the weight maintenance arm will maintain a steady body weight (plus or minus 2% of initial body weight) for six months.
223809025|NCT01299519|BEHAVIORAL|Weight Loss|Half of the subjects in the weight loss arm will lose 5% of their weight through a low-calorie diet, and half will also lose 10% and 15% body weight.
223809026|NCT00689026|DRUG|Lubiprostone|Two 24 mcg lubiprostone capsules, which will be taken orally the morning and evening of the day of the 4L PEG prep (before and after the 4L PEG prep).
223809027|NCT00689026|OTHER|Polyethylene glycol with electrolytes|Standard oral dosing of 4L Polyethylene glycol colonoscopy preparation the day prior to their scheduled colonoscopy.
223809028|NCT01383265|PROCEDURE|Water method and chromoendoscopy|Study method will employ a 0.008% IC solution used with the water method for screening colonoscopy
223809029|NCT01383265|PROCEDURE|Water method|Control method will use plain water with water method for screening colonoscopy
223809030|NCT01819246|PROCEDURE|Aphersis Treatment Arm|
223809031|NCT01819246|OTHER|Control Arm|
223809032|NCT00892489|DRUG|ER OROS Paliperidone|
223809033|NCT00006257|DRUG|paclitaxel|
223809034|NCT00006257|DRUG|semaxanib|
223809035|NCT00944502|DRUG|Dexamethasone|"Group A: Vitatonus DEXA injectable:~1 ampoule intramuscularly every 3 days for 10 days.~Group B: Vitatonus DEXA tablets:~1 tablet orally every 8 hours for 10 days.~Group C: Dexamethasone Injectable:~1 ampoule intramuscularly every 3 days for 10 days.~Group D: Dexamethasone tablets:~1 tablet orally every 8 hours for 10 days."
223809036|NCT00114010|DRUG|AMA1/Alhydrogel|
223809037|NCT04838990|OTHER|EDSS|Neurological Exam - EDSS (Expanded Disability Status Scale)
223809038|NCT04838990|OTHER|Discussion of symptoms, Patient reported outcome (MSIS)|Patients will be asked about their wellbeing
223809039|NCT04671979|DIAGNOSTIC_TEST|Lactate Dehydrogenase|All the patients that arrived at the hospital with symptoms of mesenteric ischemia, had a registered lactate dehydrogenase. We compared the value with the patient's outcomes.
223809040|NCT00394355|DRUG|mometasone furoate dry powder inhaler|400 mcg MF DPI via a breath-actuated, dry-powder inhaler and a placebo tablet given by mouth once daily in the evening for 1 year.
223809041|NCT00394355|DRUG|mometasone furoate dry powder inhaler|200 mcg MF DPI via a breath-actuated, dry-powder inhaler and a placebo tablet given by mouth once daily in the evening for 1 year.
223809042|NCT00394355|DRUG|fluticasone propionate hydrofluoroalkane (HFA)|250 mcg FP HFA given twice a day via a metered-dose inhaler and a placebo tablet given once daily in the evening for 1 year
223809043|NCT00394355|DRUG|montelukast|10 mg given once daily in the evening by mouth for 1 year.
223809044|NCT00575926|DRUG|LingZhi capsule|LingZhi or Placebo 300 mg x 4 or 300 mg x 6 capsules daily according to age group
223809045|NCT01527734|DRUG|Tetrodotoxin|15ug and 30ug once or twice a day for 1 or 2 days.
223809046|NCT01527734|DRUG|placebo|1ml once or twice a day for 1 or 2 days.
223809047|NCT04141527|PROCEDURE|Spinal analgesia|Spinal analgesia (SA) was provided by a resident or specialist anaesthesiologist with the patient in a sitting or a recumbent position. A pencil-point needle, primarily 27 G (0.4 mm), otherwise 25 G (0.5 mm), was used for transdermal intrathecal administration of 2.0 ml of sufentanil 5 µg/ml (Sufenta®, Janssen-Cilag AB, Solna, Sweden) at low-lumbar level. Blood pressure was recorded before, immediately after, and at five-minute intervals for 20 minutes after the block. Any decrease in systolic pressure to \<100 mmHg or a decrease \>20% from the baseline level despite infusion of crystalloid was defined to indicate maternal hypotension.
223809048|NCT02119910|BEHAVIORAL|Technology Supported Manual|
223809049|NCT02813148|DRUG|Naloxegol|Non-interventional study of drug utilization
223809050|NCT02731248|OTHER|Prospective screening study|Prospective screening study in newborns
223809051|NCT01892059|PROCEDURE|Segmental artery clamping|Laparoscopic partial nephrectomy with segmental artery clamping will be performed for patients enrolled in this group.
223809052|NCT01892059|PROCEDURE|Main renal artery clamping|Laparoscopic partial nephrectomy with main renal artery clamping technique will be performed for patients enrolled in this group.
223809053|NCT00753792|DRUG|methylprednisolone|methylprednisolone 1.000 mg/day intravenous administration during three days
223809054|NCT00753792|DRUG|methylprednisolone|methylprednisolone 1.250 mg/day orally administered during three days
223809055|NCT00753792|DRUG|Placebo|Placebo of methylprednisolone administered intravenously (Arm 2) or orally (Arm 1)
223809056|NCT01595568|BEHAVIORAL|Personality-targeted interventions|Motivational and cognitive behavioural interventions targeting four personality profiles. 2 90 minute group sessions with personality-matched peers facilitated by a trained therapist and co-facilitator
223809057|NCT01595568|BEHAVIORAL|Personality-targeted interventions|Motivational and cognitive behavioural interventions targeting four personality profiles. 2 90 minute group sessions with personality-matched peers facilitated by a trained therapist and co-facilitator
223809058|NCT01595568|BEHAVIORAL|Personality-targeted interventions|Motivational and cognitive behavioural interventions targeting four personality profiles. 2 90 minute group sessions with personality-matched peers facilitated by a trained therapist and co-facilitator
223809059|NCT01595568|BEHAVIORAL|Personality-targeted interventions|Motivational and cognitive behavioural interventions targeting four personality profiles. 2 90 minute group sessions with personality-matched peers facilitated by a trained therapist and co-facilitator
223809060|NCT04230421|DEVICE|The Monsenso system with feedback|See description under intervention
223809061|NCT04230421|DEVICE|The Monsenso system without feedback|See description under intervention
223809062|NCT04230421|DEVICE|CAG Bipola and mood monitoring only|See description under intervention
223809063|NCT03249051|OTHER|Indirect Calorimetry|Energy need is being determined using indirect Calorimetry
223809064|NCT01445405|DRUG|Bortezomib (Velcade, PS-341)|
223809065|NCT01445405|DRUG|Cetuximab|
223809066|NCT01445405|DRUG|Cisplatin|
223809067|NCT01445405|PROCEDURE|Radiation Therapy|
223809068|NCT06084858|OTHER|Dialysate bicarbonate modification|Dialysate bicarbonate prescription will be modified from low (27 mmol/l) to high (37 mmol/l) in a step-wise fashion
223809069|NCT02414191|BEHAVIORAL|Benchmarked Feedback|Participants receive data, during the 6 month intervention phase, regarding their monthly temperature management performance in the form of benchmarked feedback, which is the measure of their performance in comparison the standard set by the hospital.
223809070|NCT02414191|BEHAVIORAL|Ranked Feedback|Participants receive data, during the 6 month intervention phase, regarding their monthly temperature management performance in the form of ranked feedback, which is the measure of their performance in comparison to their peers.
223809071|NCT05550142|BIOLOGICAL|SARS-CoV-2 Variant (Omicron BA.5) mRNA vaccine Low dose|50μg/dose
223809072|NCT05550142|BIOLOGICAL|SARS-CoV-2 Variant (Omicron BA.5) mRNA vaccine High dose|100μg/dose
223809073|NCT05550142|DRUG|Placebo|Saline solution
223809074|NCT03651648|DEVICE|SENSITACT System|the activated stimulation (ON period of 6 hours) will be hidden from the care team, who will continue the care according to the usual procedures (blind treatment).
223809075|NCT03651648|DEVICE|SENSITACT System|the desactivated stimulation (OFF period of 6 hours) will be hidden from the care team, who will continue the care according to the usual procedures (blind treatment).
223809076|NCT04196426|BEHAVIORAL|Nutrition education intervention about osteoporosis and calcium|The intervention is designed and developed based on the Intervention Mapping Process and the Health Belief Model. Topics of the intervention include: the importance of osteoporosis and risk factors, role of calcium in bone health and controlling the disease, calcium recommendations and sources, role of vitamin D and physical activity in calcium absorption and bone health, and how to identify calcium-rich foods in the locality and prepare meals with local calcium-rich foods. A recipe booklet containing recipes using local calcium-rich foods will be given to the participants after the end of the two nutrition lessons. Interactive activities are incorporated in each lesson to encourage the participation of participants.
223809077|NCT01531452|DRUG|Oxaliplatin|130mg/m2 d1,repeated q21d
223809078|NCT01531452|DRUG|s1|80mg/m2/d, d1-14,repeated q21d
223809079|NCT00680927|OTHER|46 hrs Holter ECG recording|Maximum of 2 46 hrs external Holter ECG recordings are required.
223809080|NCT03497455|DEVICE|Barco NV Digital Dermatoscope device images|Images taken by Clinician in consultation OR in Dermatology department theatres OR images taken in medical photography suite - in the latter case, images can be taken by medical photographer or Research nurse or Dermatologist
223809081|NCT03497455|DEVICE|Standard medical photographs including dermoscopy images|Images taken by medical photographer as part of standard care in the medical photography suite.
223809082|NCT03497455|OTHER|Clinic proforma completion|This is part of standard care and will be undertaken by the clinician who is responsible for the patient
223809083|NCT00221910|PROCEDURE|Ultrasound|
223809084|NCT03861910|DIETARY_SUPPLEMENT|hypoallergenic formulas|hypoallergenic formulas used for cow milk allergy treatment
223809085|NCT02618616|DRUG|ZPL-3893787|
223809086|NCT02618616|DRUG|Placebo|
223809087|NCT01349920|DRUG|Infliximab|Infliximab administered intravenously at a dose of 5 mg/kg at study Weeks 0, 2, 6, 14, and 22.
223809088|NCT01185067|DRUG|grape seed extract (MegaNatural BP, Polyphenolics, Inc.)|Subjects will be randomized in double-blind fashion to either grape seed extract (GSE) or maltodextrin placebo capsules for for 6 weeks. Patient will take 300 mg GSE/placebo twice a day for 6 weeks. Patient will have a 2 week washout period and then cross over to the opposite group for an additional 6 weeks.
223809089|NCT02080780|DRUG|Clarithromycin XL|Clarithromycin XL administered once daily on Days 4 through 9 as 2 x 500 mg tablets, 1000 mg per day, for a total of 6000 mg
223809090|NCT02080780|DRUG|2% Diltiazem|2% Diltiazem Hydrochloride Cream applied on Day 1 \& Day 8 to the perianal area (\~2.5 cm \[1 inch\]; \~8.5 mg)
223809091|NCT06139757|DEVICE|Oura ring|Patient will wear Oura ring before and after embryo transfer. They will be blinded to sleep data during this period. Thus the intervention of wearing the ring to track sleep will not affect outcomes, but rather track the outcome of sleep.
223809092|NCT02382068|DRUG|Dexamethasone|Given via intratympanic injection
223809093|NCT02382068|OTHER|Placebo|Given via intratympanic injection
223809094|NCT02382068|DRUG|Cisplatin|"Standard of care treatment with the following treatment course criteria:~1. Dose: \> 50 mg/m2~2. Frequency: q3 -q4 weeks~3. Cycles: 7 maximum"
223809095|NCT05606757|DRUG|BOTOX Dose A|Injection; intramuscular
223809096|NCT05606757|DRUG|Placebo for BOTOX|Placebo
223809097|NCT05606757|DRUG|BOTOX Dose B|Injection; intramuscular
223809098|NCT05606757|DRUG|BOTOX Dose C|Injection; intramuscular
223809099|NCT00724581|DRUG|Amiodarone|intravenous bolus of 300 mg oral treatment og 600 mg twice a day for five days
223809100|NCT00002892|BIOLOGICAL|recombinant interferon alfa|
223809101|NCT02832206|PROCEDURE|hybrid ablation|Surgical thoracoscopic epicardial ablation (box-lesion) and left atrial appendage occlusion , followed (after 2-3months) by electrophysiological examination, and catheter ablation (completion of the box-lesion, cavotricuspid isthmus ablation and other ablation if indicated)
223809102|NCT05369715|OTHER|Exercise|Aerobic exercise
223809103|NCT01989143|DRUG|PF-06480605|Subjects will receive single intravenous doses of 1, 3, 10, 30, 100, 300, 600 or 800 mg of PF-06480605 solution in a dose escalation format.
223809104|NCT01989143|DRUG|Placebo|Subjects will receive single intravenous doses of PF-06480605 matching placebo solution in a dose escalation format.
223809105|NCT01989143|DRUG|PF-06480605|Subjects will receive three subcutaneous doses of 30, 100, or 300 mg of PF-06480605 solution in a dose escalation format of one dose every 2 weeks (q2wk).
223809106|NCT01989143|DRUG|Placebo|Subjects will receive three subcutaneous doses of PF-06480605 matching placebo solution in a dose escalation format of one dose every 2 weeks (q2wk).
223809107|NCT01989143|DRUG|PF-06480605|Subjects will receive three intravenous doses of 500 mg of PF-06480605 solution in a dose escalation format of one dose every 2 weeks (q2wk).
223809108|NCT01989143|DRUG|Placebo|Subjects will receive three intravenous doses of PF-06480605 matching placebo solution in a dose escalation format of one dose every 2 weeks (q2wk).
223809109|NCT03613805|DEVICE|Dexcom G5-Eversense|Patients will wear sensor for 3 months, monitor blood capillary values 4 times/day. At the beginning and at the end of the period HbA1c will be measured and questionnaires will be administered
223809110|NCT03613805|DEVICE|Eversense-Dexcom G5|"Patients will wear sensor for 3 months, monitor blood capillary values 4 times/day. At the beginning and at the end of the period HbA1c will be measured and questionnaires will be administered.~After 30-50 days of sensor implantation patients will wear also Dexcom G5 for a week to compare accuracy simultaneously"
223809111|NCT00256958|PROCEDURE|total knee replacement|
223809112|NCT03637244|BEHAVIORAL|Decision Support Aid and PrEP for Black Canadians|Ottawa Decision Support Framework Adaptation.Investigators will use the inputs from the qualitative findings, CDC public health guidance and the tenofovir + emtricitabine product monograph to tailor the ODSF for use in the C5TM PrEP decision support web-app.
223809113|NCT04327141|BEHAVIORAL|P-IF|Protein pacing and intermittent fasting
223809114|NCT04327141|BEHAVIORAL|HH|Heart Healthy
223809115|NCT04225988|DRUG|Extended-release tacrolimus|Patients will receive the extended-release formulation of tacrolimus for maintenance immunosuppression.
223809116|NCT04225988|DRUG|Immediate-release tacrolimus|Patients will receive the immediate-release formulation of tacrolimus for maintenance immunosuppression.
223809117|NCT05403099|OTHER|Hyaluronic acid|immediate placement of dental implant after topical application of hyaluronic acid on implant surface
223809118|NCT05403099|OTHER|conventional implant placement|immediate placement of dental implant without application of hyaluronic acid on implant surface
223809119|NCT02624739|DEVICE|Reassure Non-Contact Respiration Monitor|Reassure uses a specially-designed, non-contact motion sensor to monitor body movement and continuous respiratory rate (CRR) during sleep. Reassure is used to monitor, over a prolonged period, the sleep patterns and respiration rate while the patient is asleep.
223809120|NCT04602884|DIAGNOSTIC_TEST|Breath biopsy sampling using the ReCIVA Breath Sampler|Breath biopsy sampling using the ReCIVA Breath Sampler
223809121|NCT06634225|DIAGNOSTIC_TEST|Usual care (as recommended by the Haute Authorité de Santé (HAS)) and medical device test|Patients will receive the care they need, in line with HAS recommendations. They will be asked to perform two gait analysis tests on a three-dimensional platform, equipped with sensors (medical device).
223809122|NCT06634225|DIAGNOSTIC_TEST|Usual care (as recommended by the Haute Authorité de Santé (HAS)) and medical device test|They will be asked to perform two gait analysis tests on a three-dimensional platform, equipped with sensors (medical device).
223809123|NCT00419822|PROCEDURE|Acupuncture|6 Acupuncture visits
223809124|NCT00419822|PROCEDURE|Sham Acupuncture|6 Acupuncture visits with sham procedure
223809125|NCT00419822|OTHER|Patient to receive standard care without Acupuncture or Sham Acupuncture.|Standard care
223809126|NCT00158665|BIOLOGICAL|2 0.5 ml doses of '04-05 Trivalent Influenza Vaccine|2 0.5 ml doses of '04-05 Trivalent Influenza Vaccine
223809127|NCT05361655|DRUG|Palbociclib + an aromatase inhibitor|Palbociclib + an aromatase inhibitor therapy
223809128|NCT05361655|DRUG|Aromatase inhibitor|Aromatase inhibitor therapy
223809129|NCT04119388|OTHER|Adapted sports practices|Adapted sports practices for 30 minutes twice a week
223809130|NCT03538951|DRUG|10% VDA-1102|200 mg twice-daily for 12 weeks
223809131|NCT03538951|DRUG|20% VDA-1102|200 mg once-daily for 12 weeks
223809132|NCT06668376|DEVICE|Leg Sleeve|Once the informed consent has occurred, the patient will be invited to enroll in the study. The patient will be shown the Incrediwear product (Leg Sleeve) and given instructions. Participants will randomly be assigned treatment type in addition to the standard of care procedure they will be instructed to follow (active vs. placebo vs standard of care alone) based on surgery type. An equal number of patients from each primary condition type (ACL or ACL+MCL) will be assigned to each treatment type. The study will be double blinded as to the active vs placebo groups.
223809133|NCT06668376|DEVICE|Placebo|Once the informed consent has occurred, the patient will be invited to enroll in the study. The patient will be shown the Incrediwear product (Leg Sleeve) and given instructions. Participants will randomly be assigned treatment type in addition to the standard of care procedure they will be instructed to follow (active vs. placebo vs standard of care alone) based on surgery type. An equal number of patients from each primary condition type (ACL or ACL+MCL) will be assigned to each treatment type. The study will be double blinded as to the active vs placebo groups.
223809134|NCT06987786|OTHER|Massage|"Soft tissue mobilization (STM), also known as massage, is a form of manual therapy. STM consists of many different categories of treatment, but all involve a hand's on application. During the session, the Dr. Cook will use techniques such as kneading, stretching, and deep tissue manipulation to target the affected areas. The total time of application will be 30 minutes. This hands-on approach is theorized to reduce muscle tension, improve blood circulation, and promote relaxation. STM stimulates the release of endorphins and serotonin, which are natural painkillers and mood enhancers."
223809135|NCT06987786|OTHER|Talk-based therapy|Talk based therapy includes an innovative, evidence-based psychosocial therapy designed to provide rapid and effective pain management for individuals suffering from chronic pain. This single-session, intervention equips patients with essential pain relief skills through a combination of cognitive behavioral therapy (CBT) techniques, mindfulness principles, and pain neuroscience education. The program focuses on teaching patients how to identify and reframe distressing thoughts, practice relaxation techniques, and develop personalized pain management plans.
223809136|NCT01582191|DRUG|Everolimus|Given PO
223809137|NCT01582191|OTHER|Laboratory Biomarker Analysis|Optional correlative studies
223809138|NCT01582191|OTHER|Pharmacological Study|Optional correlative studies
223809139|NCT01582191|DRUG|Vandetanib|Given PO
223809140|NCT06991101|DRUG|Ruxolitinib|"During Radiation Therapy phase: 20 mg ruxolitinib will be self-administered orally (PO) twice every day (BID), starting on Day 1 for 6 weeks. Then there will be a 4-week break after radiotherapy is complete.~Maintenance phase: Occurs thirty days (4 weeks) after receiving the last dose of radiotherapy. Ruxolitinib 20 mg will be self-administered PO BID, starting on Day 1 in consecutive 28-day cycles.~Either phase:~Aside from the 30-day break, ruxolitinib will be continued daily until disease progression or treatment intolerance. Ruxolitinib should be administered at approximately the same time each day. The tablets should be swallowed whole with water and should not be opened, broken, or chewed. The dose may be reduced in the case of certain adverse events."
223809141|NCT06991101|DRUG|Temozolomide|"During Radiation Therapy phase: 75 mg/m\^2 will be self-administered PO once every day, starting on Day 1, for 6 weeks. Then there will be a 4-week break after radiotherapy is complete.~Maintenance phase: Occurs thirty days (4 weeks) after receiving the last dose of radiotherapy. Temozolomide 150-200 mg/m\^2 will be self-administered PO BID, starting on Day 1 to Day 5 of each cycle for six cycles.~Either phase:~The dose may be reduced in the case of certain adverse events."
223809142|NCT06991101|RADIATION|Radiation Therapy|Radiation will be administered every weekday (Monday to Friday) in 2 Gy fractions for 30 fractions during a 6-week period (60 Gy total).
223809143|NCT06732557|OTHER|Traditional treatments|Isometric exercise for deep neck flexors and sub occipital release
223809144|NCT06732557|OTHER|muscle energy technique|Muscle energy technique for upper trapezius, elevator scapulae and sternocleidomastoid
223809145|NCT06732557|OTHER|Mulligan Mobilization|Mulligan mobilization in the form of SNAGS for rotation, lateral flexion, extension and flexion
223809146|NCT06733168|DEVICE|electrical impedance tomography|"Before initiating recruitment maneuver, all patients were placed on mechanical ventilation set according to the ARDSnetwork strategy for 10 minutes, ensuring SpO2 of 88-95%, PaO2 of 55-80 mmHg, and a mean arterial pressure (MAP) ≥ 65 mmHg.~* PEEP was incrementally increased by 5 cmH2O every minute: from 10 to 15, to 20, and finally to 25 cmH2O, with a maximum pressure limit of 40 cmH2O.~* Following recruitment maneuver at the final PEEP level, the process of identifying the optimal PEEP was initiated.~* Then, PEEP will be set to 20 cmH2O and was gradually decreased by 2 cmH2O every 30 seconds until it reached 6 cmH2O or SpO2 dropped to ≤ 80%.~* Selection of optimal PEEP: The optimal PEEP was defined as the intersection point between the alveolar overdistension and collapse curves as measured by the EIT system."
223809147|NCT06733168|OTHER|Non-EIT|Patients will have PEEP set using the low FiO2-PEEP table, based on the ARDSnet protocol
223809148|NCT06733909|OTHER|Restoration of Pulpotomized Primary Molars using NuSmile Zirconia crowns|Prefabricated pediatric Zirconia crowns offer an excellent alternative to full-coverage crowns when restoring deciduous teeth with a sizeable carious defect. These crowns have high flexural strength, allowing them to resist crack propagation. The additional benefits of these crowns are the ability to replace metals due to extremely high strength and toughness, higher resistance to chemicals, and superior erosion resistance
223809149|NCT06733909|OTHER|Restoration of Pulpotomized Primary Molars using BioFlx crowns|The Bioflex crown has been introduced in pediatric practice as a synthetic crown that will provide better adaptation, durability, and ease of handling with improved aesthetic properties compared to conventional crowns. The Bioflex crown may provide a promising result in terms of the clinician's and parental satisfaction as aesthetic is a prime concern for parents and children in this era. The limitations of the studies on this type of crowns will require more studies with more detailed clinical observation and larger sample size to provide more rigorous results.
223809150|NCT06733909|OTHER|Restoration of Pulpotomized Primary Molars using Digital VITA ENAMIC crowns (CAD/CAM blanks)|is a hybrid ceramic with a dual network structure that combines the best characteristics of ceramic and composite. Fast and efficient CAM fabrication; for minimally invasive reconstructions, tooth-like material properties.
223809151|NCT06733870|PROCEDURE|guided immediate implant surgery|fully guided immediate implant placement and loading
223809152|NCT06735651|DIETARY_SUPPLEMENT|Wild Blueberry|Daily consumption of 22 g of freeze-dried wild blueberry freeze-dried powder for 6 weeks
223809153|NCT06735651|DIETARY_SUPPLEMENT|Placebo|Daily consumption of 22 g of freeze-dried macronutrient-matched placebo powder for 6 weeks
223809154|NCT01265199|DRUG|AT-406 in combination with daunorubicin and cytarabine|Oral AT-406 (capsule) given once daily on days 1-5 of induction therapy with daunorubicin 90 mg/m2 I.v. on days 1-3 and cytarabine 100 mg/m2 i.v. by continuous infusion on days 107 of induction therapy.
223809155|NCT07073521|BEHAVIORAL|Integrated Cognitive Behavioral Therapy (CBT) & Mindfulness Group Intervention for Adjustment to Vision Loss|The intervention will be an 8-week integrated group therapy curriculum combining cognitive behavioral therapy (CBT) with mindfulness practices designed for individuals adjusting to vision loss.
223809156|NCT07066228|DEVICE|tissue-engineered bone|Commercial decalcified bone scaffolds were combined with autologous bone marrow mesenchymal stem cells to form tissue engineered bone in vitro
223809157|NCT07076797|OTHER|EXERCISE TRAINING|PHYSIOTHERAPY PROGRAM
223809158|NCT07076797|OTHER|NMES|PHYSIOTHERAPY PROGRAM
223809159|NCT07093346|DIETARY_SUPPLEMENT|Pectin|15g of pectin with 10g of cocoa powder added as flavour were randomly allocated to eligible participants.
223809160|NCT07093346|OTHER|Cocoa Powder|10g of cocoa powder served as the control/ placebo to compare the effects observed with pectin.
223809161|NCT07093346|DIAGNOSTIC_TEST|Magnetic Resonance Imaging with Contrast|To validate MRI scans as a tool to assess intestinal wall thickness to indicate gut permeability on MASLD patients, the investigators will scan 15 healthy volunteers twice, at baseline and after 6 weeks, and then compare their results with MASLD participant results at baseline and after 6 weeks.
223809162|NCT07093138|COMBINATION_PRODUCT|Canvert-M (Produced by Alasht Pharmed co. Iran)|Canvert-M is a topical roll-on formulation that contains cannabidiol, peppermint, lavender, rosemary, eucalyptus, wintergreen, basil oil, etc. At the onset of a migraine attack, an adequate amount of Canvert-M roll-on should be applied to the areas of the forehead, temporal, behind the ears, and the base of the neck. If the patient's headache persists after 30 minutes, a second dose can be used.
223809163|NCT07093879|OTHER|STATIC HAMSTRING STRETCH|For the static stretching technique, individuals lay supine in a straight posture on the treatment table and relaxed. Then, the pelvis and thighs opposite to the lower limb to which the stretching technique was to be applied were tied with Velcro straps. With the knees extended, the foot in neutral position and the hip joint bent as much as possible within its range, the hip joints were bent more until the hamstring muscle was stretched with light, tolerable pain, and kept there for 30 seconds
223809164|NCT07092878|DIETARY_SUPPLEMENT|Chamomile (Matricaria recutita)|Participants in the intervention group will consume the chamomile with L-theanine (CTT) beverage, which contains 480 mg of chamomile extract and 200 mg of L-theanine.
223809165|NCT07092878|DIETARY_SUPPLEMENT|Chamomile|A chamomile-flavored beverage
223809166|NCT07092488|PROCEDURE|Advanced Platelet-Rich Fibrin Plus (A-PRF+) Revascularization Procedure|The intervention consists of the advanced platelet-rich fibrin plus (A-PRF+) revascularization protocol. It includes minimal mechanical instrumentation of the root canal, disinfection using sodium hypochlorite irrigation, and intracanal medicaments-initially calcium hydroxide followed by triple antibiotic paste. Peripheral venous blood was drawn from each participant into anticoagulant-free sterile tubes. The blood was immediately centrifuged at 1300 rpm for 8 minutes to obtain the A-PRF+ clot, which was then used as the scaffold material, extending through the root canal into the coronal cavity. The cavity was permanently sealed with glass ionomer cement. This protocol aims to promote regenerative healing and continued root development in necrotic immature permanent teeth.
223809167|NCT07093658|OTHER|High fall injury group|High fall injury group
223809168|NCT07093697|DRUG|DW5121|Participants receive DW5121, 2 tablets orally, DW51211 Placebo, 2 tablets orally, DW51212 Placebo, 1 tablets orally, 3 times a day after meals for 7 days
223809169|NCT07093697|DRUG|DW51211|Participants receive DW5121 placebo, 2 tablets orally, DW51211, 2 tablets orally, DW51212 Placebo, 1 tablets orally, 3 times a day after meals for 7 days
223809170|NCT07093697|DRUG|DW51212|Participants receive DW5121 placebo, 2 tablets orally, DW51211 placebo, 2 tablets orally, DW51212 , 1 tablets orally, 3 times a day after meals for 7 days
224264442|NCT03641001|BEHAVIORAL|Child feeding counselling, food voucher, micronutrient powder, WASH|Child feeding counselling will be assisted by food voucher, micronutrient powder and WASH messages
224264443|NCT04432636|OTHER|Data collection of environmental factors|\- Data collection of environmental factors (including maternal nutrition and social level, mode of delivery, birth weight, mode of infant feeding, antibiotic treatments) at the recruitment
224264444|NCT04432636|OTHER|Collection of maternal feces|\- Collection of maternal feces: the first sample after delivery and once a week during the period of hospitalization of their infant (i.e. 5 to 8 samples per mother)
224264445|NCT04432636|OTHER|Collection of infant feces|\- Collection of infant feces: the first sample after birth and once a week during the period of hospitalization of the baby (i.e. 5 to 8 samples per mother) and a sample collected at the corrected age of 1 year and 2 years (i.e. 8 to 10 samples per infant)
224264446|NCT04432636|OTHER|food questionnaire|\- A food questionnaire completed by the mother the week after delivery,
224264447|NCT04432636|OTHER|a food questionnaire on the infant alimentation and food behavior during the period of 2 and 10 months of age|a food questionnaire on the infant alimentation and food behavior during the period of 2 and 10 months of age, completed by the parents and given to the pediatrician at the medical check-up at the corrected age of 1 year
224264448|NCT04432636|OTHER|a food questionnaire on the infant alimentation and food behavior during the period of 12 and 24 months of age|a food questionnaire on the infant alimentation and food behavior during the period of 12 and 24 months of age, completed by the parents and given to the pediatrician at the medical check-up at the corrected age of 2 years
224264449|NCT04432636|OTHER|Sample of milk|A sample of 15 mL of milk drunk by the preterm at the 7th postnatal day (if not possible between the 7th and the 10th postnatal days).
224264450|NCT04432636|OTHER|The 'Ages and Stages Questionnaire' ASQ|\- The 'Ages and Stages Questionnaire' ASQ survey completed by the parents and given to the pediatrician at the corrected age of 2 years medical check-up
224264451|NCT01439620|DEVICE|MGH Optical Frequency Domain Imaging (OFDI)|Imaging of biliary tract with OFDI system using MGH Optical Frequency Domain Imaging (OFDI) System
224264452|NCT03922555|DRUG|ASTX727|ASTX727 is made up of the 2 study drugs cedazuridine and decitabine. Cedazuridine is believed to work by slowing down how fast decitabine is broken down by the body. Decitabine is believed to work by blocking abnormal cells or cancer cells from growing.
224264453|NCT02010463|OTHER|Exercise|
224264454|NCT02182713|DRUG|Salbutamol sulfate/Ipratropium bromide|Salbutamol sulfate 120 mcg + Ipratropium bromide 20 mcg per puff
224264455|NCT02182713|DRUG|Salbutamol|Salbutamol 100 mcg per puff
224264456|NCT01080703|OTHER|Exercise|Lower extremity resistance exercises and aerobic exercises 3 times a week in 10 week pulmonary rehabilitation program prior to lung transplant.
224264457|NCT03616379|BEHAVIORAL|Psychoeducational Control|The Psychoeducational Control condition will consist of a brief script describing the body's response to stress and will not discuss cognition or the role of interpretation or affect labeling during stress.
224264458|NCT03616379|BEHAVIORAL|Affect Regulation|In the Affect Regulation Condition, participants will be provided instructions for how to reappraise negative thoughts in the context of stress by developing statements consistent with more benign interpretations of stress (e.g., This won't last forever.).
224264459|NCT03616379|BEHAVIORAL|Affect Labelling|In the Affect Labeling Condition, participants will be provided with instructions for how to verbalize their emotional response during the stressor.
224264460|NCT00293878|DRUG|Disodium Ascorbyl Phytostanol Phosphate (FM-VP4)|
224264461|NCT01325909|BEHAVIORAL|Exercise programme|
224264462|NCT06560671|OTHER|novel type of health education|animation video based health education
224264463|NCT03999645|PROCEDURE|Early laparoscopic cholecystectomy|within 72h from symptom onset
223809171|NCT07093827|PROCEDURE|Posterior decompression surgery|\*\*Posterior decompression for thoracolumbar fractures involves a midline incision and subperiosteal exposure of the posterior spinal elements, followed by laminectomy or laminotomy to relieve neural compression. Pedicle screw-rod instrumentation is then applied above and below the fractured level under fluoroscopic guidance to restore stability, often supplemented by posterolateral fusion using bone graft. The procedure concludes with layered wound closure, providing direct neural decompression, rigid fixation for early mobilization, and reduced morbidity compared to anterior approaches in select cases. This technique is indicated for unstable fractures (e.g., AO Type B/C) or neurological deficits with posterior canal compromise, with variations based on fracture severity and surgical judgment.\*\*
223809172|NCT07093827|PROCEDURE|unilateral open-door laminoplasty|Posterior cervical expansive open-door laminoplasty (also known as unilateral open-door laminoplasty) is a surgical technique used to decompress the spinal cord in cervical myelopathy or spinal cord injury. The procedure involves a midline posterior cervical incision, followed by exposure of the laminae. A high-speed burr is used to create a hinged trough on one side (preserving the inner cortex) and a complete trough on the contralateral side, allowing the lamina to be gently elevated like an opening door. The opened lamina is then stabilized using sutures, miniplates, or spacers to maintain the expanded canal diameter. This approach effectively increases spinal canal space while preserving posterior elements, reducing cord compression while minimizing instability risks compared to laminectomy. It is particularly indicated for multilevel cervical stenosis with preserved cervical alignment.
223809173|NCT07093827|PROCEDURE|Posterior lumbar discectomy with fusion|Posterior lumbar discectomy with fusion (PLDF) is a standard surgical treatment for lumbar disc herniation with instability or recurrent symptoms. The procedure involves a midline posterior approach to expose the affected vertebral level, followed by laminotomy or partial laminectomy to access the neural elements. The herniated disc material is carefully removed to decompress the nerve roots, after which pedicle screws and rods are inserted for segmental stabilization. Interbody fusion (via posterior lumbar interbody fusion \[PLIF\] or transforaminal lumbar interbody fusion \[TLIF\]) is often performed by placing a bone graft or cage in the disc space to promote bony union. The combination of neural decompression, rigid instrumentation, and interbody fusion aims to relieve radicular pain while restoring spinal stability and alignment.
223809174|NCT07093827|PROCEDURE|Surgical resection of spinal tumors|Surgical resection of spinal tumors involves a tailored approach based on tumor location, type (primary/metastatic), and spinal stability. For posteriorly accessible lesions, a midline incision exposes the affected vertebrae, followed by laminectomy to access the epidural space and decompress neural elements. Tumor resection is performed using meticulous dissection, with intraoperative neuromonitoring to minimize neurological risk. In cases requiring vertebral body involvement, a posterolateral (costotransversectomy) or combined anterior-posterior approach may be used for en bloc or piecemeal excision. Reconstruction typically involves spinal instrumentation (pedicle screws/rods) and structural support (cages/allografts) to restore stability. The goal is maximal safe resection while preserving neurological function, often supplemented by adjuvant therapies (radiation/chemotherapy) for malignant tumors.
223809175|NCT07093827|DRUG|Conservative management of ankylosing spondylitis|Conservative management of ankylosing spondylitis (AS) focuses on symptom relief, functional preservation, and slowing disease progression through a multidisciplinary approach. First-line pharmacotherapy includes NSAIDs (e.g., celecoxib) for pain and inflammation control, supplemented by TNF-α inhibitors (e.g., adalimumab) or IL-17 inhibitors for refractory cases. Physical therapy emphasizes daily spinal extension exercises, postural training, and deep breathing to maintain mobility and prevent kyphotic deformity. Patient education on ergonomic adjustments (sleeping positions, workplace modifications) and low-impact aerobic exercise (swimming, yoga) is integral. Smoking cessation is strongly advocated due to its association with worse outcomes. Regular monitoring with inflammatory markers (CRP/ESR) and imaging (MRI for early sacroiliitis) guides therapeutic adjustments, while comorbidities (uveitis, osteoporosis) require coordinated care.
223809176|NCT07093827|PROCEDURE|anterior cervical discectomy/fusion|Surgical management of cervical spondylotic myelopathy (CSM) aims to decompress the spinal cord and stabilize the spine, with the approach tailored to pathology and spinal alignment. For multilevel anterior compression, anterior cervical discectomy/fusion (ACDF) or corpectomy with plating is preferred, utilizing structural grafts or cages to restore lordosis. Posterior approaches (laminoplasty or laminectomy with fusion) are indicated for multilevel stenosis with preserved cervical curvature, employing lateral mass or pedicle screws for fixation. Hybrid strategies (e.g., ACDF combined with laminoplasty) address complex cases. Intraoperative neuromonitoring (SSEPs/MEPs) minimizes neurological risks, while emerging techniques like cervical disc arthroplasty are considered in select patients to preserve motion. Surgical timing is critical, with earlier intervention correlating to better neurological recovery in progressive myelopathy.
223809177|NCT07093827|PROCEDURE|anterior cervical corpectomy/fusion|Surgical management of cervical spondylotic myelopathy (CSM) aims to decompress the spinal cord and stabilize the spine, with the approach tailored to pathology and spinal alignment. For multilevel anterior compression, anterior cervical discectomy/fusion (ACDF) or corpectomy with plating is preferred, utilizing structural grafts or cages to restore lordosis. Posterior approaches (laminoplasty or laminectomy with fusion) are indicated for multilevel stenosis with preserved cervical curvature, employing lateral mass or pedicle screws for fixation. Hybrid strategies (e.g., ACDF combined with laminoplasty) address complex cases. Intraoperative neuromonitoring (SSEPs/MEPs) minimizes neurological risks, while emerging techniques like cervical disc arthroplasty are considered in select patients to preserve motion. Surgical timing is critical, with earlier intervention correlating to better neurological recovery in progressive myelopathy.
223809178|NCT07093827|DRUG|Conservative management of lumbar spinal stenosis|Conservative management of lumbar spinal stenosis (LSS) focuses on symptom alleviation and functional improvement through a multimodal approach. First-line interventions include NSAIDs or acetaminophen for neurogenic claudication pain, with consideration of epidural steroid injections for refractory radicular symptoms. Supervised physical therapy emphasizes flexion-based exercises, core stabilization, and aquatic therapy to reduce mechanical stress on neural structures. Activity modification strategies (e.g., avoiding prolonged standing) combined with assistive devices (walking frames) improve mobility. Adjuvant therapies such as gabapentinoids may be trialed for neuropathic pain, while cardiovascular conditioning (stationary cycling) counters deconditioning. Patient education on weight management and posture optimization is integral, with surgical evaluation reserved for progressive neurological deficits or failure of 3-6 months structured conservative care.
223809179|NCT07093827|PROCEDURE|decompression surgery for caudal plexus disorder|Surgical intervention for caudal plexus disorders is indicated in cases of structural compression, trauma, or refractory symptoms unresponsive to conservative measures. The approach involves meticulous exposure of the lumbosacral plexus through a retroperitoneal or transabdominal route, depending on lesion location. For compressive pathologies, microsurgical decompression with intraoperative neurophysiological monitoring (IONM) is performed to minimize iatrogenic injury. In traumatic avulsions or sharp injuries, direct nerve repair, grafting, or neurolysis may be attempted to restore function. For chronic pain syndromes, dorsal root entry zone (DREZ) ablation or nerve decompression may be considered. Surgical success depends on etiology, timing of intervention, and extent of neural damage, with optimal outcomes achieved in early decompression of compressive lesions or precise repair of focal injuries.
223809180|NCT03592225|BEHAVIORAL|Educational workshop|the intervention is a 3 hours educational workshop designed to address all the potential questions that the general practitioners (GP) and their patients might have regarding HPV vaccination.
223809181|NCT04614883|DEVICE|Volatile Organic Compounds analysis|VOC analysis in exhaled air with e-noses and mass spectrometry. VOC analysis in sweat with mass spectrometry.
223809182|NCT04614883|OTHER|Canine odor detection of Volatile Organic Compounds|VOC analysis in sweat by trained dogs.
223809183|NCT00286000|DRUG|Administration of high dose simplified folfiri|
223809184|NCT03007784|DEVICE|transcranial direct current stimulation (tDCS) / Comparison of current intensities|
223809185|NCT02359643|DRUG|Aspirin|"This study was conduct to investigate the role of high dose aspirin in acute stage of KD via a multi-center randomized control trail, and we plan to achieve the followings in the coming 4 years:~1. Enroll 300 KD patients from multiple medical centers of Taiwan and China in 4 years. Randomize group patients as group 1: with high dose aspirin (more than 30/mg/kd/day) until fever subsided and shift to low dose aspirin (3-5mg/kg/day, N=150); and group 2: without high dose aspirin during acute febrile stage, only use low dose aspirin (N=150).~2. Compare data including fever days, admission duration, laboratory data (CBC/DC, GOT/GPT, BUN/Cr, Alb, ESR, CRP, 2D echo), IVIG treatment response and CAL formation rate (followed at least 1 year)."
223809186|NCT02962856|DRUG|BAY987517|50 μl/cm\*2 of each test product is applied to duplicate skin sites (approximately 2 x 2 cm each) on the lower or mid-back. (Formulation: Z43-078)
223809187|NCT02962856|OTHER|Untreated Skin|This site is patched without treatment as irradiated control
223809188|NCT02294825|PROCEDURE|various surgical procedures in endometriosis|Shaving, disc excision and colorectal resection; ureterolysis or ureter resection; bladder resection; ablation of endometriomas using plasma energy; excision and ablation of deep and superficial lesions
223809189|NCT04117269|DEVICE|External shoe lift|Height compensation will be made with cork or EVA (polyurethane + Ethylene Vinyl Acetate) depending the characteristics of the shoe. It will be made by the same orthophaedic technician. The prescription of the heigh of the lift will be made with the patient in a barefoot standing position, a calibre will be used to mark the femoro-tibial joint in both lower limbs in order to rule out the asymmetry. After this, the patient will shod the offloading device in the ulcerated feet and their conventional footwear in the other foot (with the use of their own foot orthosis). 5 millimeters splints will be added under the non affected footwear until the previous mark in both limbs been balanced. The difference in the heigh between limbs will be assessed measuring all the splints used previously
223809190|NCT06178783|DRUG|Brensocatib|Brensocatib oral solutions will be expectorated following the tasting.
223809191|NCT01936896|DRUG|Alpha 1-Antitrypsin|
223809192|NCT04959630|BEHAVIORAL|Clinical decision making based on visualizing liver 3D models in Virtual Reality (VR) environment or via a Desktop Interface (DI)|Visualizing 3D models of livers for preoperative surgical planning via two different environment: DI and VR in sequential order
223809193|NCT00949715|DEVICE|Medtronic or Vitatron Dual-Chamber Pacemaker|A Medtronic or Vitatron market-approved dual-chamber implantable pulse generator (IPG) with atrial tachycardia/atrial fibrillation (AT/AF) trending ability
223809194|NCT00949715|DEVICE|Medtronic SelectSecure 3830 Lead|Medtronic market-approved SelectSecure Model 3830 bipolar pacing lead
223809195|NCT00844740|DRUG|Cinacalcet|Stable patients with XLH already treated with Phosphate and calcitriol will add Cinacalcet to their treatment regimen. Sequential monitoring of blood nand urine biochemical variables will follow, based on which adjustments to the doses of the 3 medications will be done.
223809196|NCT03853356|DEVICE|Orthoss|Orthoss® granules. Orthoss® granules mixed with local bone and pedicle bone marrow aspirate.
223809197|NCT01166490|DRUG|ASG-5ME|0.3-3.0 mg/kg IV on Days 1, 8, and 15 of 28-day cycles
223809198|NCT05699122|OTHER|Gentle intimate hygiene and skin protective barrier application - Persistent erythema with intact epidermis|"Follow-up will be for 4 days, current treatment will be carried out with:~Perform intimate hygiene with warm water (to remove excess feces and urine), apply skin cleanser without rinsing to finish cleaning, apply a thin layer of Dexpanthenol (with each diaper change), apply polymeric spray solution once a day."
223809199|NCT05699122|OTHER|Gentle intimate hygiene and skin protective barrier application - Erythema with signs of epidermis loss|"Follow-up will be for 4 days, current treatment will be carried out with:~Perform intimate hygiene with warm water (to remove excess feces and urine), applying a leave-in skin cleanser to finish cleaning, applying powdered hydrocolloid powder and removing excess. Afterwards, apply a polymeric spray solution."
223835438|NCT05503680|BEHAVIORAL|Yoga|In this study, the researcher will provide participants with two month of Hatha yoga as an experimental intervention for managing stress. All participants who belong to the intervention group will be required to complete 120 minutes per week of home-based, online streaming yoga for eight weeks with our certified yoga instructor. The intervention will be conducted online by Zoom video; participants will be sent a link to join a scheduled live online yoga session twice every week. The data collection will be undertaken in three times: baseline (before the intervention begins), posttest one ( after two month intervention), and posttest two (one month after yoga intervention finish) to evaluate the lasting effect of yoga.
223809200|NCT05699122|OTHER|Low Level Laser Therapy - Persistent erythema with intact epidermis|"Follow-up will be for 4 days, current treatment will be carried out with:~Perform intimate hygiene with warm water (to remove excess feces and urine), apply skin cleanser without rinsing to finish cleaning, apply a thin layer of Dexpanthenol (with each diaper change), apply polymeric spray solution once a day.~It will be associated with the application of Low Intensity Laser Therapy. The entire area affected by DAI will be irradiated with LBI at 1 Joule (J) of energy and with a wavelength of 660nm and 1J with a wavelength of 808nm, which will be applied simultaneously, with a radiance of 20J/cm2 per point, the distance between the stitches will be 1cm long and the application of LLLT will be performed every 24 hours."
223835439|NCT00200421|DRUG|Nebivolol and Atenolol|
223835440|NCT05685680|PROCEDURE|total mesorectal excision in rectal carcinoma|total mesorectal excision laparoscopic versus open technique in management of rectal carcinoma
223835441|NCT06445920|OTHER|No Intervention|No Intervention
223835442|NCT04179461|DRUG|Cholecalciferol|Oral administration
223809201|NCT05699122|OTHER|Low Level Laser Therapy - Erythema with signs of epidermis loss|"Follow-up will be for 4 days, current treatment will be carried out with:~Perform intimate hygiene with warm water (to remove excess feces and urine), applying a leave-in skin cleanser to finish cleaning, applying powdered hydrocolloid powder and removing excess. Afterwards, apply a polymeric spray solution.~It will be associated with the application of Low Intensity Laser Therapy. The entire area affected by DAI will be irradiated with LBI at 1 Joule (J) of energy and with a wavelength of 660nm and 1J with a wavelength of 808nm, which will be applied simultaneously, with a radiance of 20J/cm2 per point, the distance between the stitches will be 1cm long and the application of LLLT will be performed every 24 hours."
223809202|NCT06397274|BIOLOGICAL|Stemchymal|Patients will receive Stemchymal® through intravenous infusion
223809203|NCT06397274|BIOLOGICAL|Placebo|Patients will receive Placebo through intravenous infusion
223809204|NCT05194189|DRUG|Vitamin C|12 g vitamin C (48 ml) will be intravenously injected by a infusion pump every 12 h for 4 days or at ICU discharge
223809205|NCT05194189|DRUG|5% glucose injection|5% glucose solution 48 ml every 12 h for 4 days or at ICU discharge.
223809206|NCT04872244|DEVICE|usage of mirena ( levonorgestrel releasing intrauterine device) in isthmocele|usage of mirena ( levonorgestrel releasing intrauterine device) in isthmocele for postmenstrual spotting and do not have desire for fertility
223809207|NCT04872244|DRUG|Levonorgestrel Drug Implant Product|intrauterine administration
223809208|NCT02063100|DRUG|Shenyankangfu tablets|Shenyankangfu tablets 2.4g, po, 3/day and Losartan potassium placebo 2 tab, po, 1/day,all drugs and placebo are taken for 48 weeks.
223809209|NCT02063100|DRUG|Losartan potassium 50mg|Shenyankangfu tablets placebo 5 tab, po, 3/day and losartan potassium 50mg,po, 1/day and losartan potassium placebo1 tab,po, 1/day, all drugs and placebo are taken for 48 weeks.
223809210|NCT02063100|DRUG|Shenyankangfu tablets and Losartan potassium 50mg|Shenyankangfu tablets 2.4g, po, 3/day and losartan potassium 50mg,po, 1/day and losartan potassium placebo1 tab, po, 1/day, all drugs and placebo are taken for 48 weeks.
223809211|NCT02063100|DRUG|Shenyankangfu tablets and Losartan potassium 100mg|Shenyankangfu tablets 2.4g, po, 3/day and losartan potassium 50mg×2,po, 1/day, all drugs and placebo are taken for 48 weeks.
223809212|NCT02063100|DRUG|Losartan potassium 100mg|Shenyankangfu tablets placebo 5 tab, po, 3/day and losartan potassium 50mg×2,po, 1/day, all drugs and placebo are taken for 48 weeks.
223809213|NCT04458584|PROCEDURE|Trapeziectomy with ligament reconstruction (I; LRTI)|Thumb basal joint arthroplasty (surgical) using Trapeziectomy with ligament reconstruction (I; LRTI)
223809214|NCT04458584|PROCEDURE|Trapeziectomy with suture suspensionplasty (II; SS)|Thumb basal joint arthroplasty (surgical) using Trapeziectomy with suture suspension-lastly (II; SS)
223809215|NCT04458584|PROCEDURE|Arthroscopic Trapeziectomy (III; AT)|Thumb basal joint arthroplasty (surgical) using Arthroscopic Trapeziectomy (III; AT)
223809216|NCT06259565|DRUG|Dexmedetomidine|Dexmedetomidine (Dex) is an α2-adrenergic agonist sedative commonly used in invasive mechanical ventilation (IMV) that promotes patient wakefulness, has no effect on respiratory drive, has important analgesic properties, and reduces delirium
223809217|NCT06259565|OTHER|Placebo Control|Those in the control group will receive a placebo that is identical in colour and packaging and at equal volume to the intervention group. Each bag of placebo contains 100mL of 0.9% sodium chloride and labeled as per Health Canada guidance for labelling pharmaceutical drugs for use in humans
223809218|NCT02198495|DRUG|Supplementation of ferric carboxymaltose|
223809219|NCT02198495|DRUG|Supplementation of iron sucrose|
223809220|NCT05464381|DRUG|allo-APZ2-OTS|Allogeneic dermal ABCB5-positive Mesenchymal Stromal Cells (ABCB5+ MSCs)
223809221|NCT05464381|DRUG|Placebo|Placebo
223809222|NCT05890625|OTHER|On going treatment|No additional attempts will be made by the investigator on the cases in the control group. These cases will only benefit from the services in the clinic.
223809223|NCT05890625|OTHER|InT-mAp|InT-mAp, the content of which will be created as a result of the evaluation of the nursing needs of infertile women, consists of a web-based training and online consultancy platform. The treatment plan specific to each participant will be entered into the web base individually, and the participants will be able to follow and manage the treatment protocols and appointments under their own control. InT-mAp is a guide that helps breakers about the intended use, effects, side effects of the drugs under treatment and how to self-administer, especially for women.
223809224|NCT01807806|BEHAVIORAL|Role-playing game|Eligible participants will be invited to engage with a role-playing game for 30 minutes. The role play presents situations where a service member/veteran interacts with family or friends.
223809225|NCT03897062|DRUG|Suvorexant 20 mg|Placebo controlled double blind suvorexant vs placebo
223809226|NCT03897062|OTHER|placebo|Placebo controlled double blind suvorexant vs placebo
223809227|NCT02540694|DEVICE|Endosonography|
223809228|NCT04962399|DIAGNOSTIC_TEST|Enzyme linked immunosorbent assay|Serum N / OFQ and IL-6 levels were detected，and the genotype and allele frequencies of rs1800796 in IL-6 gene were determined.
223809229|NCT01352585|DRUG|Anagrelide hydrochloride|0.5 mg hard capsules, dosing decisions will be made by the treating physician
223809230|NCT00605202|DRUG|Hydrochlorothiazide|Hydrochlorothiazide 25 mg a day for 14 days.
223809231|NCT00605202|DIETARY_SUPPLEMENT|Licorice|Licorice candy 32 grams a day for 14 days.
223809232|NCT06491251|PROCEDURE|Bilateral Subinguinal microscopic varicocelectomy|Using Leica® Microsystems , Germany. the patient was placed in a supine position after spinal anesthesia administration , The left external inguinal ring was located near the pubic tubercle by palpation, and the incision site was marked below the annulus of the left external ring. A 1.5- to 3-cm oblique incision was made along the skin line. After the tissues were dissected layer by layer, the incision was exposed until the spermatic cord became visible. the spermatic cord was lifted out with Babcock clamp and delivered though the incision and followed by the placement of a nelaton catheter 20 fr below the spermatic cord. The external spermatic vein was located and ligated. The microscopic operation was performed at 10× to 20× magnification.
223835443|NCT04179461|DRUG|antihistamine|Oral administration
223835444|NCT04179461|DRUG|Azithromycin|Oral administration
223835445|NCT04179461|DRUG|emollient cream|Topical
223835446|NCT04179461|DRUG|Fluticasone Propionate|Nasal spray
224264464|NCT03999645|PROCEDURE|Late laparoscopic cholecystectomy|after 72h up to seven days from symptom onset
223809233|NCT06452056|DEVICE|Rapid Antigen Screening Test|A point-of-care Rapid Antigen Screening Test (RAST) using a lateral flow immunoassay platform with our partner, BioMedomics Inc. The BioMedomics RAST is a lateral flow immunoassay that detects the nucleocapsid protein (NP) antigen of SARS-CoV-2 using a double antibody sandwich assay. The test cassette contains one detection line (T) fixed with anti-SARS-CoV-2 NP antibody and one quality control line (C) fixed with control antibody. When the test sample is treated with lysis buffer and added to the sample well of the test cassette, the fluid will move forward along the test strip via capillary action. If the sample contains NP antigen at levels higher than the limit of detection, the antigen will bind to the NP capture antibody as well as the immobilized detection antibody on the membrane forming a red T line, indicating a positive result. A positive signal at C line provides assurance that the fluid containing the sample material has moved laterally in an appropriate fashion.
223809234|NCT03784690|OTHER|Individualized intraoperative BP management|"In the treatment group, the nurse will measure resting blood pressure three times in the ward one day before surgery (after a 5-min rest while lying supine). Average measurement will be used to calculate mean arterial pressure (MAP).~Before and after CPB patients will receive continuous infusion of norepinephrine to maintain MAP within ± 10% of patients resting MAP. If targeted MAP during CPB could not be achieved after increasing pump-flow (not more than 130%), infusion of norepinephrine will used. After CPB, the choice of vasopressors/inotropes to maintain predefined MAP will be left on attending anesthesiologists based on patient status."
223809235|NCT03784690|OTHER|Standard intraoperative BP management|Standard treatment strategy will be used aiming to maintain pre-bypass and post-bypass MAP at 65-75 mm Hg. MAP during CPB will be maintained at 50-60 mm Hg. If MAP of 50-60 mm Hg during CPB could not be achieved after increasing pump-flow (not more than 130%), infusion of norepinephrine will be started. No vasodilators will be used if MAP will exceed predefined range.
223809236|NCT05153460|DEVICE|Telemetry and manual monitoring vs Contactless monitoring devices|"All participants will be on standard telemetry monitoring for Heart Rate, Respiration Rate and movements using the gold standard (Electrocardiography and Capnography respectively).~In addition, two contactless monitoring devices will be placed on the patient bed to measure data simultaneously. These devices include EarlySense (USFDA approved ballistocardiography device) and Dozee VS (Investigational Device)."
223809237|NCT04916119|DRUG|IBI323|In phase Ia study, seven dose levels of IBI323 (0.03, 0.1, 0.3, 1, 3, 10 and 20mg/kg) will be evaluated. The DLT observation period is 28 days. IBI323 is administered by iv infusion day 1 of every 14 days. After dose escalation stage completed, two dose levels (10mg/kg and 20mg/kg) will be expanded to 20 patients each. In Phase Ib study, IBI323 is administered RP2D by iv infusion day 1 of every 14 days. IBI323 and chemotherapy will be administrated in cohort C and cohort K
223809238|NCT03644901|PROCEDURE|nonsurgical periodontal treatment|patients will undergo nonsurgical periodontal treatment to reduce the relative attachment level and improve the probing depth. An initial session will be conducted to remove supra gingival plaque and calculus. another appointment is set to perform full moth scalling and root planing.
223809239|NCT02789683|OTHER|Fine emulsion|Emulsion is made up of distilled water, olive oil and emulsifier. Emulsion will be flavored, sweetened (sucralose) and served in a portion of 300ml and approximately 3 slices of white bread (50g of available carbohydrate). Additional glass of plain water will be provided with every treatment.
223809240|NCT02789683|OTHER|Coarse emulsion|Emulsion is made up of distilled water, olive oil and emulsifier. Emulsion will be flavored, sweetened (sucralose) and served in a portion of 300ml and approximately 3 slices of white bread (50g of available carbohydrate). Additional glass of plain water will be provided with every treatment.
223809241|NCT02789683|OTHER|Control|Beverage is made up of distilled water and olive oil. Beverage will be flavored, sweetened (sucralose) and served in a portion of 300ml and approximately 3 slices of white bread (50g of available carbohydrate). Additional glass of plain water will be provided with every treatment.
223809242|NCT01560325|DRUG|CKD-516 inj.|CKD-516: 3.3\~13mg/m2/day
223809243|NCT04978974|BEHAVIORAL|Stress Management Program|Stress management program includes different techniques such as relaxation technique, psycho-education, laughing, emotional freedom technique, referenting, cognitive restructuring, rational emotive imagery, time management, anger management, assertiveness and social support
223809244|NCT01073670|DRUG|Indomethacin|Indomethacin was given via suppository at time of induction for anesthesia (2 x 50 mg) followed by one 50 mg suppository at 6, 12, 18 and 24 hours following cardiac bypass surgery.
223809245|NCT01073670|DRUG|Acetaminophen & Indomethacin|Subjects were given a loading dose of acetaminophen (1300 mg) and indomethacin (50 mg)by suppository at the time of induction for anesthesia and then given 650mg acetaminophen + 25 mg indomethacin at 6, 12, 18 and 24 hours following cardiac bypass surgery.
223809246|NCT01073670|DRUG|Acetaminophen|Subjects were given a loading dose of 2600 mg of acetaminophen (via suppository) at time of induction for anesthesia then given 1300mg at 6, 12, 18 and 24 hours following cardiac bypass surgery.
223809247|NCT04479033|OTHER|Multidisciplinary collaborative model of community care management|An individualised care plan is developed for PLWDs-caregiver dyads who meet/communicate weekly with various members of the HMDCS team depending on the nature of their needs. Each dyad's care plan involves the diagnosis of problems (eg: memory problems, family conflicts, poor nutrition, fall risk, medication compliance, lack of long-term care arrangements), establishment of treatment goals (eg: caregiver education, awareness of long-term care planning, stabilising medical care at home, improving emotional support), and indicating specific interventions (eg: referrals to counsellors, specialist doctors, day rehabilitation centres; consultations at GP clinic; coordination of advanced care planning; installation of home safety devices; training caregivers to detect acute deterioration in PLWDs). Monitoring of the dyads' statuses and updating of care plans are performed throughout the duration of the programme.
224264465|NCT01889407|DRUG|Idarubicin|8 mg/m2, iv drip on days 1-3
224264466|NCT06058845|DIETARY_SUPPLEMENT|Tamarindus indica fruit juice_A|The participants will be exposed to 10% Tamarind pulp juice
224264467|NCT06058845|DIETARY_SUPPLEMENT|Tamarindus indica fruit juice_B|The participants will be exposed to 30% Tamarind pulp juice
224264468|NCT02966782|DRUG|venetoclax|Tablet
224264469|NCT02966782|DRUG|azacitidine|Powder for injection, subcutaneously or intravenous
224264470|NCT05562011|DEVICE|Caretaker Device placement|a continuous non-invasive blood pressure and vital signs monitor that is worn on the wrist
224264471|NCT02491853|DEVICE|Implantable Cardioverter Defibrillator|Implantable Cardioverter Defibrillator
223809248|NCT05050578|DEVICE|Lehfilcon A contact lenses|Commercially available, silicone hydrogel, spherical contact lenses used as indicated
223809249|NCT05050578|DEVICE|Senofilcon A contact lenses|Commercially available, silicone hydrogel, spherical contact lenses used as indicated
223809250|NCT05050578|DEVICE|CLEAR CARE|Hydrogen peroxide-based contact lens cleaning and disinfecting solution
223809251|NCT02816190|PROCEDURE|prone position|
223809252|NCT03401892|DEVICE|Dynamic Vessel Analyzer (DVA)|Retinal vessel diameters and oxygen saturation will be measured with the DVA device.
223809253|NCT03401892|DEVICE|Fourier Domain Doppler Optical Coherence Tomography (FDOCT)|Retinal blood flow will be assessed using FDOCT.
223809254|NCT03401892|DEVICE|Optical coherence tomography (OCT)|Nerve fiber layer thickness and central retinal thickness will be measured using OCT.
223809255|NCT02243280|DRUG|ABT-493|Tablet
223809256|NCT02243280|DRUG|ABT-530|Tablet
223809257|NCT00172354|DRUG|Hydrocortisone|
223809258|NCT05519384|DRUG|JK500 cell injection，cyclophosphamide，Fludarabine|After enrollment, patients received JK500 cell injection infusion after reinduction therapy. Pretreatment regimen before cell infusion: intravenous infusion of cyclophosphamide 60mg/kg day -7, intravenous infusion of fludarabine 25mg/㎡/day day -6 to -2 days. In order to activate and expand circulating NK cells, on the day of each infusion of JK500 cells, the patients were first subcutaneously injected with 100WU/ m2 of interleukin (IL)-2 0.5h-1h in advance, for a total of 6 doses.
223809259|NCT03766841|BEHAVIORAL|Facilitated Enrollment|Research coordinator will assist patients in account creation and usage of the tool.
223809260|NCT00004935|DRUG|Herceptin™ (Her)|Herceptin™ (Her) loading dose 4 mg/kg iv, followed by 2 mg/kg iv weekly or loading dose 8 mg/kg iv, followed by 6 mg/kg iv every 3 weeks; at time of progression add chemotherapy
223809261|NCT00004935|DRUG|Herceptin™ (Her) + chemo|Herceptin™ (Her) loading dose 4 mg/kg iv, followed by 2 mg/kg iv weekly or loading dose 8 mg/kg iv, followed by 6 mg/kg iv every 3 weeks, and chemotherapy
223809262|NCT03928028|BEHAVIORAL|Cognitive Remediation Therapy|Cognitive Remediation Therapy (CRT) is an adjunctive treatment focused on increasing set-shifting ability and developing meta-cognition.
223809263|NCT03928028|BEHAVIORAL|Family Based Treatment|Family Based Treatment (FBT) is an evidence based treatment in which parents are responsible for adolescent re-nourishment. They play an active role in treatment and their self-efficacy to make decisions regarding their child's treatment is empowered.
223809264|NCT04379193|BEHAVIORAL|Neuroproprioceptive facilitation and inhibition physical therapy|All groups underwent two months' therapy, 16 face-to-face sessions (1 hour, twice a week for two months).
223809265|NCT05022095|OTHER|Questionnaires|Diverse questionnaires have to be filled in.
223809266|NCT02239497|PROCEDURE|Femoral block by ultrasound and neurostimulation|
223809267|NCT02239497|DRUG|Intravenous analgesia|Intravenous analgesia with ketoprofen, dipyrone and dexamethasone. IV morphine to rescue analgesia
223809268|NCT03895554|PROCEDURE|cardiac PET stress test|Volunteers will undergo cardiac PET stress testing
223809269|NCT02016404|OTHER|Low-sodium, high-potassium salt|Iodized low-sodium, high-potassium botcanh (a traditional mixture of salt, MSG, sugar and herbs) plus and iodized low-sodium, high-potassium salt for home food preparation
223809270|NCT02016404|OTHER|Regular salt|Regular iodized high-sodium botcanh (a traditional mixture of salt, MSG, sugar and herbs) and high-sodium salt
223809271|NCT03594539|OTHER|Withholding standard phosphate binder|In this trial, placebo represents the intervention and not the control. Standard therapy for hyperphosphatemia in end-stage renal disease includes treatment with a phosphate binder. In this trial the intervention will be to withhold the phosphate binder and use placebo instead. In this way the effect of a higher serum phosphate can be evaluated.
223809272|NCT05748210|OTHER|Symptom management mobile health application with personalised support|"Child-caregiver dyads in the intervention group will use the mHealth app for 12 weeks with personalised nurse support via interactive communication technologies. The design of the app will be guided by the theory of unpleasant symptoms.~The app will comprise several interactive elements to provide children and their caregivers with real-time symptom management support. Comprehensive educational materials regarding cancer and its treatment side effects, including possible symptoms, functional limitations, and psychological responses, will be provided in the app for the children and their caregivers to gain a thorough understanding of the potential symptom burden that they may experience."
223809273|NCT05748210|OTHER|Wait-list Symptom management mobile health application with personalised support|To ensure the equity of access to a potentially desirable and effective intervention (i.e., mHeath app for symptom management), participants in the wait-list control group will be invited to receive the same intervention as participants in the intervention group after the completion of all assessments on a voluntary basis.
223809274|NCT05485363|DIAGNOSTIC_TEST|ultrasonographic measurement of the optic nerve sheath diameter|Assessing the optic nerve sheath diameter as an indicator of intracranial pressure during different positions and on specific time intervals in patients undergoing laparoscopic sleeve gastrectomy
223809275|NCT04525547|DRUG|Nintedanib|Nintedanib
223809276|NCT02628002|DEVICE|Antigravity treadmill (Alter-G)|Test arm subjects will exercise according to the Bruce protocol unweighted to 75% of their body weight with additional unweighting to 50% during the test if unable to reach target at 75% weight. Once these subjects have reached their target heart rate on the Bruce protocol, patients will receive the Tc-99m injection as per standard clinical protocol and maintain target heart rate for 1 minute following the injection.
223835447|NCT04179461|DRUG|Asthma Controller Medication|Study participants asthma controller medication may be increased based off of their asthma control and the recommendation of the personalized plan.
223835448|NCT06276413|DEVICE|GORE TAG Thoracic Branch Endoprosthesis|deployment of the GORE TAG Thoracic Branch Endoprosthesis fro thoraci aorta pathologies
224264472|NCT04352205|DRUG|Bortezomib|Given SC
224264473|NCT04352205|BIOLOGICAL|Daratumumab|Given IV
224264474|NCT04352205|DRUG|Dexamethasone|Given PO and IV
224264475|NCT04352205|DRUG|Lenalidomide|Given PO
224264476|NCT04352205|DRUG|Thalidomide|Given PO
224264477|NCT06271005|DIETARY_SUPPLEMENT|NeuroTears|Over-the-counter supplement
224264478|NCT06271005|DIETARY_SUPPLEMENT|Placebo|Oral placebo pill
223809277|NCT02628002|DEVICE|Conventional treadmill/regadenoson|Subjects randomized to the control arm will proceed with the clinical standard regadenoson pharmacological stress SPECT study with adjunctive low-intensity walk on conventional treadmill during regadenoson and Tc-99m injections if tolerated. If they are unable to tolerate any treadmill exercise, they will receive regadenoson and Tc-99m injections at rest. Study patients will have stable systemic blood pressure with readings equal to or greater than 90 mmHg systolic. Other inclusion and exclusion criteria are described in detail below.
223809278|NCT06395155|DRUG|DHP2306R1|100mg per capsule, BID
223809279|NCT06395155|DRUG|DHP2306R2|75mg per Tab, BID
223809280|NCT03117283|PROCEDURE|Laparoscopic D2 radical total gastrectomy with bursectomy using a left outside bursa omentalis approach|Patients with advanced posterior gastric wall cancer including in the laparoscopic total gastrectomy (LTG) with bursectomy group will undergo laparoscopic D2 radical total gastrectomy with bursectomy using a left outside bursa omentalis approach.
223809281|NCT03117283|PROCEDURE|Laparoscopic D2 radical total gastrectomy without bursectomy|Patients who are included in the laparoscopic total gastrectomy (LTG) without bursectomy group will undergo laparoscopic D2 radical total gastrectomy without bursectomy in a conventional manner.
223809282|NCT03122119|DRUG|Platelet Rich Plasma Joint Injection|30 to 50 milliliters of venous blood will be drawn from the patients arm with a 19 gauge ¾ inch needle using universal precautions. The venous blood will be mixed with 8 milliliters of anticoagulant citrate dextrose solution-A (ACD-A). The anti-coagulated blood will then be centrifuged for 15 minutes at 3200 revolutions per minute in the office centrifuge. This will allow plasma to separate from blood cells. The portion of centrifuged blood deficient in platelets will be extracted and discarded. Once the needle is visualized entering the joint capsule via ultrasound guidance and the physician feels resistance provided by the capsule and ligaments, 3 milliliters of PRP extract will be injected (3 inch, 22 gauge needle) into the sacroiliac joint. The needles will be properly disposed.
223809283|NCT06100302|OTHER|no-intervention|no-intervention
223809284|NCT02531763|BEHAVIORAL|Social incentive intervention|Participant sign a pre-commitment pledge to try to achieve their goal. They are entered into a game with their teammate in which they have the chance to earn points and advance through levels (bronze, silver, gold, platinum). At the end, those in gold or platinum will receive a coffee mug as a reward
223809285|NCT00023647|BIOLOGICAL|Synchrotope TA2M|Cancer Vaccine, Immunotherapy
223809286|NCT00023647|BIOLOGICAL|Synchrotope TA2M|Cancer Vaccine, Immunotherapy
223809287|NCT00023647|BIOLOGICAL|Synchrotope TA2M|Cancer Vaccine, Immunotherapy
223809288|NCT00518635|DRUG|Nutropin|Nutropin 0.1 mg/day self-administered once a day
223809289|NCT00699439|OTHER|Paper-based asthma flow diagram|If a patient is identified as having an asthma exacerbation by the Bayesian Network, the patients will be randomized to either arm A or B. If in A, the paper-based flow-chart will be printed out to place on the chart.
223809290|NCT05411432|DRUG|68Ga labeled HER2 Affibody|inject the tracer to subjects and perform PET/CT scans
223809291|NCT04803448|BEHAVIORAL|Benefit statement|"The participant reads this statement after asked one of eight health questions~1. What is your height in inches?~2. What is your weight in pounds?~3. How many days out of the last 2 weeks did you drink alcohol?~4. How often a month do you use other substance such as marijuana, cocaine, ecstasy, or other drugs~5. How often a month do you use Rx or non-Rx medications to excessive amounts?~6. When was the last time you smoked a cigarette?~7. How many days in the last 2 weeks did you engage in more than 30 min exercise?~8. How many times did you engage in sexual activity in the last month with another individual? . The statement reads: Accurately answering this will increase the likelihood of a correct diagnosis.~An example of this with one of the 8 health questions is... What number of days in the last 2 weeks you engaged in \>30 minutes of exercise? Accurately answering this will increase the likelihood of a correct diagnosis."
223809292|NCT04803448|BEHAVIORAL|Risk Statement|"The participant reads this statement after being asked one of eight health questions.~The statement reads: Inaccurately answering this will increase the likelihood of an incorrect diagnosis."
223809293|NCT04803448|BEHAVIORAL|Privacy Statement|"The participant reads this statement after being asked one of eight health question for example. We will not share or sell this personal health information with anyone. We will comply with all HIPPA regulations regarding the protection of your data."
223809294|NCT04803448|BEHAVIORAL|Benefit + Privacy|"The statement reads Accurately answering this will increase the likelihood of a correct diagnosis. We will not share or sell this personal health information with anyone. We will comply with all HIPPA regulations regarding the protection of your data."
223809295|NCT04803448|BEHAVIORAL|Risk + Privacy|"The statement reads Inaccurately answering this will increase the likelihood of an incorrect diagnosis. We will not share or sell this personal health information with anyone. We will comply with all HIPPA regulations regarding the protection of your data."
223809296|NCT00800202|DRUG|bevacizumab [Avastin]|15mg/kg iv every 3 weeks
223809297|NCT00800202|DRUG|carboplatin|AUC6 iv every 3 weeks for 6 cycles
223809298|NCT00800202|DRUG|erlotinib [Tarceva]|150mg/day po
223809299|NCT00800202|DRUG|paclitaxel|200mg/m2 iv every 3 weeks for 6 cycles
223809300|NCT04425902|DRUG|GSK3640254 200 mg|GSK3640254 will be available as oral tablets at unit dose strength of 100 mg.
223809301|NCT04425902|DRUG|Caffeine 200 mg|Caffeine will be available as oral tablets at unit dose strength of 200 mg.
223809302|NCT04425902|DRUG|Metoprolol 100 mg|Metoprolol will be available as oral tablets at unit dose strength of 100 mg.
223809303|NCT04425902|DRUG|Montelukast 10 mg|Montelukast will be available as oral tablets at unit dose strength of 10 mg.
223809304|NCT04425902|DRUG|Flurbiprofen 100 mg|Flurbiprofen will be available as oral tablets at unit dose strength of 100 mg.
223809305|NCT04425902|DRUG|Omeprazole 40 mg|Omeprazole will be available as oral capsules at unit dose strength of 40 mg.
223809306|NCT04425902|DRUG|Midazolam 5 mg (2.5 mL)|Midazolam will be available as syrup for oral administration at unit dose strength of 2 milligram per milliliter (mg/mL).
223809307|NCT04425902|DRUG|Digoxin 0.25 mg|Digoxin will be available as oral tablet at unit dose strength of 0.25 mg.
223809308|NCT04425902|DRUG|Pravastatin 40 mg|Pravastatin will be available as oral tablet at unit dose strength of 40 mg.
223809309|NCT04728308|DRUG|Bupivacain|Before closing the skin incision,Infiltration of 20ml of 0.5% bupivacaine around incision site will be done in the patients of experimental group and 20 ml of distill water will be infiltrated in the pateints of the placebo group
223809310|NCT00970216|DRUG|Telbivudine|Post-marketing observation for chronic hepatitis B patients receiving Telbivudine treatment
223809311|NCT02966145|OTHER|Observational Study|
223809312|NCT02803125|BEHAVIORAL|Psychosocial intervention|This intervention is to be developed during the study. It will likely include modules that provide anger management strategies, communication skills, and education about interpersonal relationships and social support. In addition, psychoeducation about behavioral activation and stress management will likely be included
223809313|NCT02803125|BEHAVIORAL|Support group control|The support groups will be process-oriented in nature with core elements manualized to facilitate consistency of the intervention. In particular, group leaders will facilitate a check-in with the group, and the agenda will be open to topics brought in by group members
223809314|NCT00027924|DRUG|busulfan|
223809315|NCT00027924|DRUG|cyclosporine|
223809316|NCT00027924|DRUG|fludarabine phosphate|
223809317|NCT00027924|DRUG|methotrexate|
223809318|NCT00027924|PROCEDURE|peripheral blood stem cell transplantation|
223809319|NCT02916602|DRUG|HCP1401|amlodipine, Losartan, Chlorthalidone FDC
223809320|NCT02916602|DRUG|HCP0605|amlodipine, Losartan FDC
223809321|NCT02584348|DEVICE|Gastric ultrasound|Preoperative qualitative ultrasound assessment of gastric contents will be performed for each children admitted for emergency surgery
223809322|NCT04361344|BIOLOGICAL|blood samples|Clinical examination and blood samples will be done at inclusion (day 0), at day 7 (between day 4 and exit from intensive care) and at day 60.
223809323|NCT04943198|DRUG|Vemurafenib|20 mg/kg/day
223809324|NCT02564679|PROCEDURE|Laparoscopic Sleeve gastrectomy (LSG)|"These patients (no. 20) are assessed by clinical and psychological evaluation (auxological parameters, blood pressure and personal and family history), blood tests (liver function test's (LFT's), uric acid, lipid and gluco-insulinemic profile with oral glucose tolerance test (OGTT)), abdominal ultrasound at time of enrollment.~They are treated with laparoscopic sleeve gastrectomy associated to lifestyle intervention. Concomitantly to surgical intervention, liver biopsy is performed.~At 6 and 12 months after LSG the patients are evaluated with laboratory, clinical and echographic assessment. Moreover, one year after LSG liver biopsy is repeated."
223809325|NCT02564679|BEHAVIORAL|Lifestyle Intervention|"These patients (no. 20) are assessed by clinical and psychological evaluation (auxological parameters, blood pressure and personal and family history), blood tests (liver function test's (LFT's), uric acid, lipid and gluco-insulinemic profile with oral glucose tolerance test (OGTT)), abdominal ultrasound at time of enrollment.~They are treated with lifestyle intervention. At 6 and 12 months after enrollment the patients are evaluated with laboratory, clinical and echographic assessment."
223809326|NCT05917704|OTHER|Guitar then physical therapy|See arm/group descriptions
223809327|NCT05917704|OTHER|Physical therapy then guitar|See arm/group descriptions
223809328|NCT00336843|DRUG|Zevalin-BuCyE|rituximab (IV, 250 mg/m2 on days -21 and -14) single dose of 90Y-ibritumomab (IV, 0.4 mCi/kg on day -14) Busulfan (IV, 0.8 mg/kg every 6 h from day -7 to day -5) Cyclophosphamide (IV, 50 mg/kg on days -3 and -2) Etoposide (IV, 200 mg/m2 every 12 h on days -5 and -4) Autologous stem cells infusion on day 0
223809329|NCT03710525|OTHER|Own-Price Elasticity|The price of vegetables will be 75%, 100%, or 125% of the reference price, but the price of other foods will remain the same.
223809330|NCT03710525|OTHER|Cross-Price Elasticity|The price of vegetables will remain the same, but the price of other foods will be 75%, 100%, or 125% of the reference price.
223809331|NCT01461382|OTHER|Treadmill Desks|Treadmill Desk were installed in subjects personal workspace.
223809332|NCT01461382|OTHER|Treadmill Desks|Treadmill desks were installed in subjects personal workspace six months after phase I started.
224264479|NCT06196554|DRUG|Oxaliplatin|"According to the first-line drugs provided by the NCCN guidelines, the concentration of each drug was added to the organoid culture medium after setting 5-6 concentration gradients according to literature reports. Chemo-sensitive and drug-resistant.~Construction of gastric cancer organoid T cell co-culture system to screen sensitive immunotherapy drugs."
224264480|NCT03097445|DRUG|Nicotine patch|mailed 5-week course of Habitrol® transdermal nicotine patches
224264481|NCT03119077|DRUG|BAY1161116|Escalating doses of BAY1161116; single dose administration; redosing of BAY1161116 at dose group 1 together with itraconazole; redosing of BAY1161116 at dose group 2 as liquid service formulation, redosing of BAY1161116 at dose group 3 together with food
223809333|NCT01875354|DIETARY_SUPPLEMENT|Dietary Supplements and TR90 Eating Plan|Supplements to maintain muscle, assist in utilization of body fat, curb appetite, support positive willpower along with TR90 Eating plan. TR90 Eating Plan will consist of approximately 30 g high quality protein along with fruit, vegetables and complex carbohydrates
223809334|NCT01875354|DIETARY_SUPPLEMENT|Placebo and Low Fat Eating Plan|
223809335|NCT03559088|OTHER|Migraine App|Smart phone app used to report migraine burden to the EHR.
223809336|NCT00204984|DRUG|oral hydralazine and intravenous nesiritide|vasodilators
223809337|NCT03326960|DRUG|Sevoflurane|Anesthesia maintenance with sevoflurane guided by Narcrotrend index monitoring.
223809338|NCT03326960|DRUG|Propofol|Anesthesia maintenance with propofol guided by Narcrotrend index monitoring.
223809339|NCT03326960|DRUG|Desflurane|Anesthesia maintenance with desflurane guided by Narcrotrend index monitoring.
223809340|NCT00462254|DRUG|ROZEREM|8 mg tablet orally 30 minutes before bedtime for 8 days (Days 4-11).
223809341|NCT00462254|DRUG|Ramelteon|8 mg tablet orally 30 minutes before bedtime for 8 days (Days 15-22).
224264482|NCT03119077|DRUG|Placebo|Escalating doses of respective placebos; single dose administration; redosing of placebo at dose group 1 together with itraconazole; redosing of placebo at dose group 2 as liquid service formulation, redosing of placebo at dose group 3 together with food
224264483|NCT03119077|DRUG|Itraconazole|Redosing of BAY1161116/placebo at dose group 1 together with itraconazole
224264484|NCT05751447|DIAGNOSTIC_TEST|Lymph node puncture, bronchoscopy|Included patients will undergo an extra lympn node punction through oesophagus and/ or an extra bronchoscopy.
224264485|NCT03811145|BIOLOGICAL|Tendoncel|Platelet lysate gel
224264486|NCT03811145|OTHER|Placebo control gel|Placebo control gel
224264487|NCT01446770|DEVICE|Hydrogel scaffold (MF-4181)|Following surgical removal of the ear keloid, the incision will be treated with MF-4181.
224264488|NCT03296956|DIETARY_SUPPLEMENT|Motherwell|The interventions involves a dietary supplement called Motherwell, at current stage, to reduce the intensity of sadness in day-5 postpartum women.
223809342|NCT02581332|BEHAVIORAL|Mindfulness Meditation Training|Training will be held in groups of up to five participants. All of the participants within this group will receive up to 6 days (20m/d) of meditation training to be administered over 15 days. This is a paradigm similar to one employed in previous studies.
224264489|NCT03296956|OTHER|Placebo|Matching placebo for appearance, taste
224264490|NCT03046550|DRUG|NTM-1634|NTM-1634 drug product is a mixture of four human monoclonal IgG1 antibodies. Three dose cohorts (A: 0.33 mg/kg B: 0.66 mg/kg, and C: 1 mg/kg).
224264491|NCT03046550|DRUG|Placebo|placebo
224264492|NCT01956318|BEHAVIORAL|Crenobalneotherapy|18 days of balneotherapy session in 3 weeks. Each day, the treatment associates 4 techniques: Kneipp Therapy, walking pool, underwater massage, bath tub and finishing with 20 minutes of rest in the Trendelendburg position. Kneipp Therapy is an alternating warm (28°C) and cold (14°C) shower on the legs during 10 minutes. Walking pool is a 60 cm deep pool at 23°C with underwater shower where patients are walking without stopping during 10 minutes. Underwater massage is realized by a senior physiotherapist. It starts at the feet and gradually rises to the thighs during 10 minutes. Bath tub is underwater shower at 30°C. It also starts at the feet and gradually rises to the thighs during 20 minutes. The interventions are standardized by timers. Adherence to each technique is supervised before each session in the usual manner for each patient treated in the spa center.
224264493|NCT03221049|DIAGNOSTIC_TEST|radiomics|
224264494|NCT04800718|OTHER|Intervention Arm|Intervention includes door-to-door screening and awareness generation in 8-12 villages surrounding the Vision Centres
224264495|NCT03921918|DEVICE|Breast Pump|Hydraulic Breast pump
224264496|NCT06563219|OTHER|Glasgow coma scale|The levels of response in the components of the Glasgow Coma Scale are 'scored' from 1, for no response, up to normal values of 4 (Eye-opening response) 5 ( Verbal response) and 6 (Motor response) The total Coma Score thus has values between three and 15, three being the worst and 15 being the highest.
224264497|NCT06563219|OTHER|Hunt-Hess scale|"The Hunt-Hess scale was used to assess SAH severity according to the clinical presentation and the visible neurological deficits. The Grades run from 1 to 5:~* Grade 1: Asymptomatic or minimal headache, slight neck stiffness.~* Grade 2: Moderate to severe headache, and neck stiffness, but no neurological deficit except cranial nerve palsy.~* Grade 3: Drowsiness, confusion, or a mild focal deficit.~* Grade 4: Stupor, moderate to severe hemiparesis, early decerebrate rigidity, and vegetative disturbance.~* Grade 5: Deep coma, decerebrate rigidity, and a moribund appearance."
224264498|NCT06563219|OTHER|World Federation of Neurological Surgeons (WFNS) scale|"The World Federation of Neurological Surgeons (WFNS) scale, introduced in 1988, is used to evaluate the clinical severity of patients with SAH. This scale is derived from the GCS score and considers the presence of motor deficits:~* Grade 1: GCS score of 15, no motor deficit~* Grade 2: GCS score of 13 to 14, no motor deficit~* Grade 3: GCS score of 13 to 14, with motor deficit~* Grade 4: GCS score of 7 to 12, with or without motor deficit~* Grade 5: GCS score of 3 to 6, with or without motor deficit"
224264499|NCT06563219|OTHER|modified Fisher scale|"The modified Fisher scale was used to evaluate SAH severity by reference to the extent of hemorrhage as revealed by CT of the brain. Four grades are depending on the degree of bleeding observed:~* Grade 0: No hemorrhage apparent in CT.~* Grade 1: Minimal hemorrhage without intraventricular hemorrhage (IVH).~* Grade 2: Thin or diffusely thin (\<1mm) hemorrhage with bilateral IVH.~* Grade 3: Thick (\> 1 mm) hemorrhage without bilateral IVH.~* Grade 4: Thick (\> 1 mm) hemorrhage with bilateral IVH."
224264500|NCT06563219|OTHER|VASOGRADE scale|"The VASOGRADE scale was established to estimate the risk of delayed cerebral ischemia following SAH. This scale is based on the WFNS and the modified Fisher scales at admission. There are three categories:~* Green: WFNS score of 1 or 2 and modified Fisher scale of 1 or 2.~* Yellow: WFNS score of 1 or 3 and modified Fisher scale of 3 or 4.~* Red: WFNS score of 4 or 5 and any modified Fisher scale score."
224264501|NCT06563219|OTHER|Ogilvy and Carter scale|"The Ogilvy and Carter scale is a grading system used to predict the outcomes of surgical treatment in patients with SAH due to a ruptured aneurysm. The scale considers multiple factors, including age, Hunt and Hess grade, Fisher grade, and aneurysm size, with a score assigned to each of these variables:~* Age greater than 50~* Hunt and Hess grade of 4 to 5~* Fisher grade scores of 3 to 4~* Aneurysm size \>10 mm~* An additional point is added for a giant posterior circulation aneurysm (≥25 mm)"
224264502|NCT00675779|DRUG|oral contraceptive (Mercilon)|oral contraceptive (20ug EE, 150ug DSG) 1 tablet a day p.o. for 21 days with 7 day break for 6 months
224264503|NCT00675779|DRUG|atorvastatin + oral contraceptive|atorvastatin 20mg po a day for 6 months + oral contraceptive (20ug EE, 150ug DSG) 1 tablet po a day for 21 days with 7 day break for 6 months
224264504|NCT04026243|PROCEDURE|QL block|U/S guided Transmuscular Quadratus Lumborum Block
224264505|NCT04026243|PROCEDURE|TF block|U/S guided Transversalis Fascia Plane Block
223809343|NCT03319511|OTHER|spinal group|plain bupivacaine 0.5%,1.5 ml plus dexmedetomidine 5 μg. once injection.
223809344|NCT03319511|OTHER|paravertebral group|plain bupivacaine 0.5%, 0.3 ml (1.5 mg)/kg plus dexmedetomidine 0.5 μg /kg divided between the T2 and T4 levels.
223809345|NCT02145325|DRUG|Expanded Tregs|
223809346|NCT01124721|BEHAVIORAL|Cognitive training|Cognitive computerized training for several days per week.
223809347|NCT01124721|BEHAVIORAL|Cognitive training-placebo|Cognitive training that only minimally increases in difficulty
223809348|NCT03117725|DRUG|Melatonin adminstration|The drug, melatonin will be taken every night from the time of COH to the date of oocyte retrieval. The method of administration is as follows: Melatonin 2mg once a day, 1 to 2 hours before bedtime for about 2 weeks until the date of oocyte retrieval.
223809349|NCT03117725|DRUG|placebo administration|the drug, placebo pill will be taken every night from the time of COH to the date of oocyte retrieval. The method of administration is as follows: placebo pill once a day, 1 to 2 hours before bedtime for about 2 weeks until the date of oocyte retrieval.
223809350|NCT00327002|DRUG|LY518674|
223809351|NCT03323619|PROCEDURE|anesthesia type|No intervention. General anesthesia or local anesthesia with sedation are decided by the physicien according to his usual practice
223809352|NCT03873220|DEVICE|Wrist Actigraphy Devices|A watch-like wearable sensor
223809353|NCT03873220|DEVICE|Sleep Monitor|Remote Sensor
223809354|NCT03873220|DEVICE|Polysomnography|Sleep Monitor
223809355|NCT03873220|DEVICE|Videography|Thermal Camera
223809356|NCT01170338|DRUG|Varenicline 100 mg by mouth twice daily|this is an active drug to help smoking cessation
223809357|NCT01170338|DRUG|control|this is the placebo that will help us maintain a blinded study
223809358|NCT00958763|BEHAVIORAL|Motivational Interviewing, Single - MIS|The Motivational Interviewing Single Arm is delivered individually to participants in 3 separate sessions to address a specific concept (alcohol use, cravings and what to do with them, and concomitant behaviors and/or consequences of alcohol use). Participants will be encouraged to explore the pros and cons for each of these topics with the facilitator, who will remain non-judgmental. Participants who are eligible for the Hepatitis A/B vaccine are also offered the vaccine in conjunction with each session.
223809359|NCT00958763|BEHAVIORAL|Motivational Interviewing Group|The Motivational Interviewing Group Arm is delivered to participants in groups in 3 separate sessions to address a specific concept (alcohol use, cravings and what to do with them, and concomitant behaviors and/or consequences of alcohol use). Participants will be encouraged to explore the pros and cons for each of these topics with the facilitator and with the group, who will remain non-judgmental. Participants who are eligible for the Hepatitis A/B vaccine are also offered the vaccine in conjunction with each session.
223809360|NCT00958763|OTHER|Usual Care Group - UCG|The Usual Care Arm is delivered to participants in three brief time-equivalent health promotion sessions. Each session focuses on health promoting activities such as the importance of diet and exercise, need for physical and mental health assessment and enhanced coping for those afflicted with a history of drug and alcohol addiction. In addition participants receive liver health promotion education. Participants are also provided referrals to alcohol treatment programs in the community and offered the 3 series hepatitis A/B vaccine
223809361|NCT06043986|DEVICE|novel nurse call system|"Inavya Ventures Ltd (Inavya) has developed a medical-grade artificial intelligence enabled mobile system (AVATR) to support out-of-hospital healthcare. AVATR is approved as a UK Government official supplier of healthcare technology on the UK Digital Marketplace for cloud-based solutions (G Cloud). AVATR in hospital, will connect to the existing AVATR outpatient service building on existing AVATR technology, which is regulated CE-mark Grade 1 (EU/UK). The research team will create, deploy and test a novel ward-based AI technology innovation to transform current nurse call systems to patient-centred mobile technology assets at bedside, thus reducing the need for unproductive visits by nurses to the bedside, which takes away time and attention where it is otherwise best served.~Having mobile connection to the patients, would improve patient experience and saving nursing staff time, thereby improving quality of care, and saving money."
223809362|NCT01533363|PROCEDURE|Stapled hemorrhoidopexy|
223809363|NCT01533363|PROCEDURE|Milligan Morgan|
223809364|NCT01910623|OTHER|Health Related Quality of Life (HRQOL) measures|
223809365|NCT04358692|DEVICE|Aixplorer Mach30|To measure myocardial stiffness by ShearWave elastography on not beating heart
223809366|NCT00146614|DRUG|Sirolimus|
223809367|NCT00146614|DRUG|Tacrolimus|
223809368|NCT00146614|DRUG|Methotrexate|
223809369|NCT00146614|PROCEDURE|Stem Cell Transplantation|
223809370|NCT06075563|RADIATION|Total lymphoid irradiation|Total lymphoid irradiation (TLI) 6Gy by tomotherapy as part of conditioning treatment before haploidentical hematopoietic stem cell transplant
223809371|NCT06835725|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|prostate stereotactic ablative radiotherapy
223809372|NCT05918302|DRUG|177Lu-edotreotide|6 cycles of 7.5 ± 0.7 Giga becquerel (GBq) 177Lu-edotreotide
223809373|NCT05918302|DRUG|Everolimus|10 mg orally once daily (QD)
223809374|NCT03622788|BIOLOGICAL|Anti-Thymocyte Globulin|Given IV
223809375|NCT03622788|DRUG|Cyclophosphamide|Given IV
223809376|NCT03622788|BIOLOGICAL|Cytokine-treated Veto Cells|Given IV
223809377|NCT03622788|DRUG|Fludarabine|Given IV
223809378|NCT03622788|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo PBSCT
223809379|NCT03622788|RADIATION|Total-Body Irradiation|Undergo TBI
223809380|NCT00122564|BIOLOGICAL|HIV-1 gp 160|
223809381|NCT00122564|BIOLOGICAL|DC-Chol|
223809382|NCT04669600|DRUG|SAR445088 (BIVV020)|Pharmaceutical form:solution for injection
223809383|NCT04589468|OTHER|Exercise|Exercise therapy in both phases will consist of individualized walking delivered 3 to 6 times weekly (over a 7-day period). Exercise treatment will be delivered for up to 18 months, or until progression of disease or withdrawal of consent, whichever comes first. The phase 1a trial will assess five doses of exercise therapy (i.e., 90, 150, 225, 300, and 375 mins/wk) delivered following a non-linear (i.e., exercise dose is continually altered and progressed in conjunction with appropriate rest/recovery sessions across the entire intervention period) dosing schedule. The phase 1b trial will only test one dose of exercise therapy - the RP2D identified in the phase 1a trial.
223809384|NCT06423963|BEHAVIORAL|Physical Activity|Each participant will receive a Fitbit device with instruction and encouragement to self-monitor physical activity using step counts.
223809385|NCT06423963|BEHAVIORAL|Nutrition Counseling|Participants will receive nutritional counseling with a registered dietician.
223809386|NCT06423963|BEHAVIORAL|Resistance Training|Participants will engage in progressive, full-body resistance training based on American College of Sports Medicine (ACSM) guidelines.
223809387|NCT06802601|OTHER|Manual Therapy and Exercise|Manual Therapy and Exercise
223809388|NCT06802601|OTHER|Manual Therapy, Exercise and Visio-Vestibular Exercise|Manual Therapy, Exercise and Visio-Vestibular Exercise
223809389|NCT05435924|OTHER|Turkish validity and reliability|"1. Explanation of the Turkish version of the scale.~2. Translating the Turkish version of the scale into English to ensure consistency with the original scale.~3. First application of scales to participants by two examiners separately.~4. Second application of the scales to the participants by one examiner.~5. Statistical analysis and scaling"
223809390|NCT06029855|OTHER|Kabat Therapy|The participants of group A will receive Kabat Rehabilitation with routine physical therapy. The protocol will be given to the participants for three sessions/week for six weeks. Each session will be of 30 minutes.
223809391|NCT06029855|OTHER|Mime Therapy|The participants of group B will receive Mime Therapy in addition to routine physical therapy. The protocol will be given to the participants once a week for six weeks, while physical therapy will be given on alternate days. Each session will be of 30 minutes.
223809392|NCT01544998|DRUG|Nesiritide|10 ug/kg
223809393|NCT01544998|DRUG|Tadalafil|5 mg
223809394|NCT01544998|DRUG|Placebo|The pharmacy will create a placebo subcutaneous injection volume to match the volume of Nesiritide dose.
223809395|NCT01544998|DRUG|Saline load|Normal saline 0.9% 0.25 ml/kg/min for 60 minutes
223809396|NCT05842213|BIOLOGICAL|AVT05 (proposed biosimilar to golimumab)|AVT05 is a recombinant human IgG1қ mAb developed as a subcutaneous injection
224264506|NCT05458687|OTHER|Chinese herbal medicine decoction、Acupuncture or Laser acupuncture pen treatment、Acupoint Tuina massage、Acupoint application、Nursing/Diet and health education and guidance|"* Chinese herbal medicine decoction: prescribed three times a day, seven days a week, and lasts for up to one weeks.~* Acupuncture or Laser acupuncture pen treatment: twice a week, once for 20 minutes,up to a total of one week.~* Acupoint Tuina massage: once a day for up to 20 minutes each time, for up to a week.~* Acupoint application of traditional Chinese herbal medicinal cake: Apply warm navel ointment in our hospital to CV 4 (Guanyuan) point every day, and remove after getting up the next day, seven days a week for up to one week.~* Nursing and health education and guidance: teach the patients and their family members the matters needing attention in daily life.~* Diet and health education:give personalized Traditional Chinese Medicine diet guidance and recommendations in accordance with Traditional Chinese Medicine physique syndrome."
224264507|NCT05836311|DEVICE|One Perclose Proglide Suture|One Perclose Proglide Suture
224264508|NCT05836311|DEVICE|Two Perclose Proglide Suture|One Perclose Proglide Suture
224264509|NCT03810937|OTHER|head position|head positioning in sniffing or flat position
224264510|NCT02054715|BEHAVIORAL|print educational intervention|print educational intervention
224264511|NCT02054715|BEHAVIORAL|multimedia psychoeducational intervention|multimedia psychoeducational intervention
224264512|NCT02331511|DRUG|placebo|placebo administration for 3 months after device(PPM,ICD,CRT) implantation
223809397|NCT05842213|BIOLOGICAL|Simponi (Golimumab)|Simponi (Golimumab) is a recombinant human IgG1қ mAb developed as a subcutaneous injection
223809398|NCT01713543|OTHER|physical therapy|Tailored physical therapy sessions to modify impairments in balance and/or gait and to transition high-risk participants to an evidence-based group exercise program.
223809399|NCT05320055|PROCEDURE|robotic repair|robotic assisted retromuscular hernia repair
223809400|NCT00182962|BEHAVIORAL|Geriatric Resources for Assessment & Care of Elders (GRACE)|
223809401|NCT06782919|OTHER|Trunk control training|Four sessions of biofeedback trunk movement training, provided once per week.
223809402|NCT05236946|RADIATION|Stereotactic radiosurgery/whole brain radiotherapy|SRS/ WBRT for asymptomatic brain metastases depending on the number of brain metastases
223809403|NCT05236946|DRUG|Tyrosine kinase inhibitor|TKI
224264513|NCT02331511|DRUG|Aspirin 80 mg daily|Aspirin 80 mg daily administration for 3 months after device(PPM,ICD,CRT) implantation
224264514|NCT02331511|DRUG|Clopidogrel 75 mg daily|Clopidogrel administration for 3 months after device(PPM,ICD,CRT) implantation
224264515|NCT04207528|BEHAVIORAL|Writing|After completing the baseline questionnaire, participants will be randomized to one of two conditions-a peer helping condition or a facts-only writing control. Participants will receive general instructions for completing the writing sessions and will be asked to write for at least 5 minutes per session. Topics covered in each session will vary and are related to common themes relating to life as a first-year university student (e.g., academics, adjusting to university, etc.). Participants will be instructed not to worry about grammar, spelling, or sentence structure and reminded that their responses will remain anonymous. Writing sessions (four in total) will be spaced 1 day apart and take place all within the same week.
224264516|NCT01780051|DRUG|Repaglinide/Metformin combination, Repaglinide, Metformin|"Co-administration of Repaglinide 2mg and Metformin HCl 500mg at once in period 1.~Administration of the Combination tablet of Repaglinide 2mg/Metformin HCl 500mg) in period 2."
224264517|NCT01780051|DRUG|Repaglinide/Metformin combination, Repaglinide, Metformin|"Administration of the Combination tablet of Repaglinide 2mg/Metformin HCl 500mg) in period 1.~Co-administration of Repaglinide 2mg and Metformin HCl 500mg at once in period 2."
224264518|NCT05730920|DRUG|Methadone|IV Methadone
224264519|NCT05730920|DRUG|Liposomal bupivacaine (LB, Exparel)|LB and bupivacaine hydrochloride via erector spinae plane blocks
224264520|NCT05492032|DEVICE|Active-tDCS|For active-tDCS condition, participants will receive stimulation on the dorsolateral prefrontal cortex with ramp up and ramp down mode for 10 seconds, eliciting a tingling sensation on the scalp that fades over seconds. Following that, a twenty-minute executive functional training task will be initiated five minutes subsequent to the stimulation mode, and the stimulation will be terminated when the training task ends.
224264521|NCT05492032|DEVICE|Sham-tDCS|For sham-tDCS condition, participants will receive initial stimulation with ramp up and ramp down mode for 30 seconds, eliciting a tingling sensation on the scalp then it will be discontinued. Participants will also receive the twenty-minute executive functional training task five minutes subsequent to the stimulation mode.
224264522|NCT05492032|BEHAVIORAL|Cognitive training|Participants will complete an online cognitive training program consisting of 10 consecutive daily weekday training sessions while they receive either the active or sham tDCS stimulation. Each training session will last for 20 minutes. The online cognitive training program will comprise five exercises assessing information processing speed and executive function capacities. Each exercise will take approximately 4 minutes to complete. Given many studies, across different neurological/neuropsychiatric diagnoses, especially for people with autism, it has long been established that social skills and functioning are closely related, and multiple studies have shown that executive function training can improve social functioning in autism or vice versa (i.e. social skills training improves executive functioning in autism), it is reasonable to include cognitive training in this tDCS protocol.
224264523|NCT03612154|DRUG|Lorlatinib|Subjects will be treated with lorlatinib 100mg PO daily. A cycle will be defined as 28-days for the convenience of analysis.
223809404|NCT02671201|OTHER|Education|Different methods in education of emergency ultrasound
223809405|NCT04538365|DRUG|Triclosan 0.5 % Topical Solution|Hand antisepsis by scrub Surgical Hand scrubbing using triclosan 0.5% solution both hands using a sterile disposable surgical scrub brush with plastic bristles on one side and a foam sponge on the other side
223809406|NCT04538365|DRUG|propanolol|Hand antisepsis by scrub Surgical Hand scrubbing using Propanolol 60% solution both hands using a sterile disposable surgical scrub brush with plastic bristles on one side and a foam sponge on the other side
223809407|NCT02809144|PROCEDURE|Nerve block|Nerve block: 31 ml ropivacaine 7.5 mg/ml (Lateral sagittal infraclavicular brachial plexus block) + 4 ml ropivacaine 5 mg/ml (suprascapular nerve block) + 5 ml ropivacaine 5 mg/ml (superficial cervical plexus block)
223809408|NCT03762343|DRUG|ultrasound guided Greater occipital nerve block|ultrasound guided Greater occipital nerve block with 2 ml of bupivacaine 0.5% (up to a maximum of 2 mg/kg) subcutaneous under ultrasound guidance in the greater occipital nerve region bilaterally.
223809409|NCT03762343|DRUG|control group C|Patient in this group will receive the intraoperative standard of care(intraoperative intravenous fentanyl and paracetamol)
223809410|NCT03889626|DRUG|Apatinib|Apatinib: 500mg qd po, q4w
223809411|NCT03889626|DRUG|Capecitabine|Capecitabine: 1000mg/m2 bid po, d1-14, q3w
223809412|NCT02834637|DRUG|bivalent HPV vaccine|head to head comparisons of different dose schedules and HPV vaccine types
223809413|NCT02834637|DRUG|nonavalent HPV vaccine|head to head comparisons of different dose schedules and HPV vaccine types
223809414|NCT05627063|DRUG|ABSK121-NX|In the escalation part, patients will receive a single dose of oral ABSK121-NX on Day -7 followed by a 7-day washout (Day -7 dosing day as 1st day of wash out) as a run-in period to access the safety and PK of ABSK121-NX. Then, patients will continuously receive ABSK121-NX once daily (QD) starting at C1D1 and continuing in subsequent cycles (28-day cycles). The starting dose is 3mg QD. In the expansion part, patients will each receive oral ABSK121-NX at the RDE in repeated 28-day cycles.
223809415|NCT05343338|DRUG|Sivelestat sodium|After dissolving sivelestat sodium with 0.9% sodium chloride injection, dilute the 1-day dose (4.8 mg/kg) with 50 mL of 0.9% sodium chloride injection and continue intravenously at a rate of 0.2 mg/kg/h for administration. The start time of administration was after induction of anesthesia, and at the same time, the extracorporeal circulation circuit is prefilled with 100 mg. The end time is 48 hours after admission to the ICU.
223809416|NCT05889806|OTHER|Observational Study Only. NO Intervention.|Observational Study Only. NO Intervention.
223809417|NCT04387981|DRUG|[14C]-orvepitant|Oral solution of \[14C\]-orvepitant
223809418|NCT02291523|BIOLOGICAL|Fecal Microbial Transplant|Fecal Transplant via Colonoscopy.
223809419|NCT05046496|DIAGNOSTIC_TEST|Intra-arterial digital subtraction angiography|Invasive intra-arterial angiography, with intra-arterial stent placement if a stenosis is confirmed
223809420|NCT04800419|BEHAVIORAL|Mindfulness-based Stress Reduction (MBSR)|The term 'mindfulness' refers to mindful awareness as a way of being - a knowing and experiencing of feelings, thoughts, and perceptions as they arise and pass away each moment. It is a way of relating to all experiences in an open, receptive way, without judging experiences as good or bad (grasping at them or pushing them away). Mindfulness employed two styles of meditations: concentrative meditation involves intentionally focusing attention on a chosen object (e.g. the sensations of breathing) in a sustained way, while receptive meditation involves monitoring the content of experience (e.g. sensations, emotions, thoughts, sounds, etc.) in a non-reactive and non-judgmental way, from moment to moment, with the goal being to recognize the nature of emotional and cognitive patterns. Mindfulness-based stress reduction (MBSR) is an 8-week, standardized group intervention consisting of mindfulness meditation and gentle yoga that is designed to have applications for stress, pain, and illness
223809421|NCT01403025|DRUG|liraglutide|Once daily at a fixed timing, and subcutaneously (under the skin) in the abdomen, in the thigh or in the upper arm
223809422|NCT02150720|DRUG|Tranexamic Acid|1g intra-articular before closing the wound surgery
223809423|NCT02150720|DRUG|Fibrin glue|5mL intra-articular before closing the wound surgery
223809424|NCT02150720|PROCEDURE|Electrocauterization|Coagulation blood from vessels by means of a electrocautery.
223809425|NCT06381323|DRUG|Finerenone|All eligible subjects enter a 2-week enrollment phase and only take stable doses of controlled-release nifedipine. After completing baseline examinations, subjects with SBP \<180 and ≥140 mmHg and DBP \<120 and ≥90 mmHg enter the follow-up phase of the treatment period. Eligible subjects receive a starting dose of 20 mg qd of Finerenone. If the blood pressure is still ≥140/90 mmHg at week 4, serum potassium is \<5.0 mmol/L, and eGFR has decreased \<30% compared to baseline, the Finerenone dose is adjusted to 40 mg qd.
223809426|NCT06177158|BEHAVIORAL|oral hygiene instructions|"Standardized motivation and oral hygiene instructions regarding the tooth brushing will be demonstrated to all three groups using modified bass technique and a standardized brush, medium bristled brush with toothpaste, the patients will be instructed to brush their teeth for 2 minutes with a pea- size amount of dentifrice twice daily. For interdental cleaning aids each patient will be instructed to use the suitable methods regarding the space between teeth.~clinically for each patient to ensure that the patients understood the instruction sessions. Before receiving oral hygiene instructions and motivation, the salivary sample will be collected and clinical periodontal parameters will be measured at a base line visit then, after 3 weeks, saliva will be collected and the same clinical measurements will be taken."
223809427|NCT04323956|DRUG|Cyclophosphamide|Given IV
223809428|NCT04323956|DRUG|Doxorubicin Hydrochloride|Given IV
223809429|NCT04323956|DRUG|Parsaclisib|Given PO
223809430|NCT04323956|BIOLOGICAL|Pegfilgrastim|Given SC
223809431|NCT04323956|DRUG|Polatuzumab Vedotin|Given IV
223809432|NCT04323956|DRUG|Prednisone|Given PO
223809433|NCT04323956|BIOLOGICAL|Rituximab|Given IV
223809434|NCT04323956|DRUG|Vincristine Sulfate|Given IV
223809435|NCT05184322|DRUG|T2026|Once daily for 15 days.
223809436|NCT05184322|DRUG|Placebo|Once daily for 15 days.
223809437|NCT05184322|DRUG|Oral ecnoglutide tablet|Once daily for 6 weeks.
223809438|NCT05184322|DRUG|Oral ecnoglutide tablet|Once daily and titrated up in concentration to once every week during maintenance period.
223809439|NCT05184322|DRUG|Oral ecnoglutide tablet|Once daily for 15 days.
223809440|NCT05184322|DRUG|Oral ecnoglutide tablet|Once daily for 15 days.
223809441|NCT05184322|DRUG|Oral ecnoglutide tablet|Once daily for 15 days.
223809442|NCT05184322|DRUG|Oral ecnoglutide tablet|Once daily for 15 days.
223809443|NCT05184322|DRUG|T2026|Once daily for 6 weeks.
223809444|NCT05184322|DRUG|Placebo|Once daily for 6 weeks.
223809445|NCT05184322|DRUG|T2026|Once daily to once weekly for 12 weeks.
223809446|NCT05184322|DRUG|Placebo|Once daily to once weekly for 12 weeks.
223809447|NCT04313959|DRUG|Ropivacaine 0.2% Injectable Solution|Single-shot ultrasound-guided erector spine plane block of 0.2% ropivacaine
223809448|NCT04313959|DRUG|Ropivacaine 0.2% + Dexamethasone|Addiction of 5 mg/ml dexamethasone in 0.2% ropivacaine solution
223809449|NCT06152042|DRUG|BMF-219|BMF-219 is an orally bioavailable, covalent small-molecule menin inhibitor.
223809450|NCT02179502|DRUG|GLPG1690 single ascending doses|Single dose, oral suspension or solid formulation, starting dose of 20mg escalating up to 1500mg
223809451|NCT02179502|DRUG|Placebo single ascending doses|Single dose, oral suspension or solid formulation matching placebo
223809452|NCT02179502|DRUG|GLPG1690, multiple ascending doses, oral suspension|Multiple doses, daily for 14 days, oral suspension, anticipated doses: 300mg to 1000mg
223809453|NCT02179502|DRUG|Placebo, multiple ascending doses, oral suspension|Multiple doses, daily for 14 days, oral suspension matching placebo
223809454|NCT02929433|OTHER|Cycloergometer|Daily training of the RCT patients was provided by the use of a cycloergometer at home. Educational support once a month was guaranteed by a nurse of the telemedicine service
223809455|NCT06412627|PROCEDURE|4°C frozen normal saline gauze|Soak two 4x4 gauze pads in 15 ml of normal saline, refrigerate at 4°C, and then apply in the oral cavity for 15 minutes before removal.
223809456|NCT03526601|DIAGNOSTIC_TEST|NT-proBNP, echocardiography|screening
223809457|NCT00243542|DRUG|ACZONE Gel, 5%|
223809458|NCT00243542|DRUG|Vehicle|
223809459|NCT02573402|DEVICE|Transcutaneous Tibial Nerve Stimulation|10 sessions over a 2 week period of TTNS for 30 minutes. Electrodes will be placed 2 inch by 4 inch according to anatomic landmarks, with the negative electrode behind the internal malleolus and the positive electrode 10cm superior to the negative electrode, verified with rhythmic flexion of the toes secondary to stimulation of the flexor digitorum and hallicus brevis. Current intensity may vary from patient to patient and will be documented and used in the analysis.
223809460|NCT02573402|DEVICE|Control|10 sessions over a 2 week period of TTNS sham stimulation for 30 minutes. Electrodes will be placed 2 inch by 4 inch according to anatomic landmarks, with the negative electrode behind the internal malleolus and the positive electrode 10cm superior to the negative electrode. Current intensity will be set to zero.
223809461|NCT01416870|DRUG|ICI176,334-1|Subject will receive single dose of ICI176,334-1
223809462|NCT01416870|DRUG|Casodex 80 mg tablet|Subject will receive single dose of Casodex 80 mg tablet
223809463|NCT02009670|DIETARY_SUPPLEMENT|13C inulin|Oral 13C inulin
223809464|NCT02009670|OTHER|Placebo|Oral maltodextrin
223809465|NCT02153138|DEVICE|Endo-pat 2000|"The endo peripheral arterial tonometry (PAT) provides an index of endothelial function in two forms:~1. The reactive hyperemia index (RHI) is the post-to-preocclusion PAT signal ratio in the occluded side, normalized to the control side and further corrected for baseline vascular tone.~2. The logarithm RHI (LnRHI) is s similar index as RHI after natural log transformation with a matched cutoff. LnRHI provides better double-sided distribution than RHI and one that is closer to normal distribution"
223809466|NCT02153138|DEVICE|carotid intima media thickness Ultrasound|cIMT is the distance between the intimal-luminal interface and the medial-adventitial interface. It will be studied by B-mode ultrasonography of the extracranial carotid arteries. A duplex system with a 7-10 megahertz (MHz) linear array multi-frequency transducer will be used.
223809467|NCT02153138|DEVICE|Dexa- Bone densitometer & Bone ultrasonometer System|A means of measuring bone mineral density and body composition by a dual energy X-ray absorptiometry (DEXA) machine
223809468|NCT00883038|OTHER|diabetic diet following the DNSG guidelines|The DNSG diet consists of 15-20% protein, ≤7% saturated fat, 60-70% carbohydrate and monounsaturated fats, cholesterol ≤200 mg/day, fiber content 20-30g/day.
223809469|NCT00883038|OTHER|low-fat vegetarian diet|The low-fat vegetarian diet (\~10% of energy from fat, 15% protein, and 75% carbohydrate, fiber content 40-50 g/day) consists of vegetables, fruits, grains, legumes and small amounts of nuts. Participants will be asked to avoid animal products and added fats and to favor low-glycemic index foods, such as beans and green vegetables.
223809470|NCT06579053|DRUG|Spironolactone Tablets (Test)|Take one test tablet each period
223809471|NCT06579053|DRUG|Spironolactone Tablets (Reference)|Take one reference tablet each period
223809472|NCT06578884|DEVICE|877PTY|IOL implantation with 6-month follow-up period Monocular UDVA/CDVA Manifest Refraction (SPH, CYL, SEQ) Optical Biometry, Keratometry (K1, K2, AXL, ACD) IOL axis orientation determination Visual function questionnaire Glistening evaluation Tonometry Slit-Lamp examination Fundus visualization
223809473|NCT00369538|DRUG|losartan, hydrochlorothiazide|Two administrations of losartan per day,up to 100mg per day, during 2 months, followed by a wash-out during 1 month, and then one administration of hydrochlorothiazide, 25 mg per day during 2 months
223809474|NCT00369538|DRUG|hydrochlorothiazide, losartan|One administration of hydrochlorothiazide, 25 mg per day during 2 months, followed by a wash-out during 1 month, and then, two administrations of losartan per day,up to 100mg per day, during 2 months
223809475|NCT05506748|OTHER|pantients undergoing pancreaticoduodenectomy|The study includes all the cases who underwent pancreaticoduodenectomy for carcinoma head of the pancreas, distal cholangiocarcinoma, periampullary and duodenal cancer.
223809476|NCT00053495|BIOLOGICAL|Vaccinia virus: ACAM2000 smallpox vaccine|Group 1 dose: 1.0x10-8th PFU/ml Group 2 dose: 2.0x10-8th PFU/ml Group 3 dose: 1.0x10-7th PFU/ml Group 4 dose: 5.0x10-6th PFU/ml
223809477|NCT00053495|BIOLOGICAL|vaccinia virus (calf lymph): Dryvax|Group 5 dose: 1.0x10-8th PFU/ml
223809478|NCT03550833|BEHAVIORAL|Questionnaire|Questionnaire
223809479|NCT03550833|BIOLOGICAL|blood sample|7 ml whole blood for Peripheral blood
223809480|NCT01670981|BIOLOGICAL|ixmyelocel-T|12-20 transendocardial injections of 0.4 mL of ixmyelocel-T per injection into the left ventricle.
223809481|NCT01670981|OTHER|Placebo|12-20 transendocardial injections of 0.4 mL of vehicle control per injection into the left ventricle.
223809482|NCT01166516|DEVICE|Treatment with HUD IBV Valve System|Treatment involves placing one or more valves in the airways of the lung to control a prolonged air leak.
223809483|NCT03483987|DRUG|Sof+Ledi+R arm|Fixed dose combination of sofosbuvir 400 mg plus ledipasvir 90 mg once daily plus ribavirin 1000 mg (body weight \<75 kg) or 1200 mg (body weight =\>75 kg) daily in two divided doses
223809484|NCT03483987|DRUG|Sof+Ledi+R+Peg-IFN arm|Fixed dose combination of sofosbuvir 400 mg plus ledipasvir 90 mg once daily plus ribavirin 1000 mg (body weight \<75 kg) or 1200 mg (body weight =\>75 kg) daily in two divided doses plus pegylated interferon alpha 2b @ 1.5 microgram/kg subcutaneously once in a week
223809485|NCT03483987|DRUG|Sof+Dacla+R arm|Sofosbuvir 400 mg once daily plus daclatasvir 100 mg once daily plus ribavirin 1000 mg (body weight \<75 kg) or 1200 mg (body weight =\>75 kg) daily in two divided doses
223809486|NCT03483987|DRUG|Sof+Dacla+R+Peg-IFN arm|Sofosbuvir 400 mg once daily plus daclatasvir 100 mg once daily plus ribavirin 1000 mg (body weight \<75 kg) or 1200 mg (body weight =\>75 kg) daily in two divided doses plus pegylated interferon alpha 2b @ 1.5 microgram/kg subcutaneously once in a week
223809487|NCT03483987|DRUG|Sof+Velpa+R arm|Fixed dose combination of sofosbuvir 400 mg plus velpatasvir 100 mg once daily plus ribavirin 1000 mg (body weight \<75 kg) or 1200 mg (body weight =\>75 kg) daily in two divided doses
223809488|NCT03483987|DRUG|Sof+Velpa+R+Peg-IFN arm|Fixed dose combination of sofosbuvir 400 mg plus velpatasvir 100 mg once daily plus ribavirin 1000 mg (body weight \<75 kg) or 1200 mg (body weight =\>75 kg) daily in two divided doses plus pegylated interferon alpha 2b @ 1.5 microgram/kg subcutaneously once in a week
223809489|NCT03630822|BEHAVIORAL|Psychiatric Advanced Directive|The patient completes a questionnaire to express in advance his wishes regarding his future care in psychiatry.
223809490|NCT03630822|BEHAVIORAL|Standard care|standardized maintenance with the patient
223809491|NCT03262740|DRUG|BMS-986195|Oral administration of specified dose on specified days
223809492|NCT03262740|DRUG|Loestrin 1.5/30 (1.5 mg norethindrone acetate/30 μg ethinyl estradiol)|Oral Contraceptive
223809493|NCT06384248|DRUG|LTC004|LTC004,45μg/kg,IV,Day 1,Q3W;
223809494|NCT05354843|DRUG|ET0038|ET0038 for oral administration
223809495|NCT03513406|DRUG|Sugammadex|Sugammadex is indicated for the reversal of neuromuscular blockade.
223809496|NCT03513406|DRUG|Neostigmine|Neostigmine is indicated for the reversal of neuromuscular blockade.
223809497|NCT03513406|DRUG|Glycopyrrolate|Glycopyrrolate is used in conjunction with neostigmine to prevent neostigmine's muscarinic effects.
223809498|NCT00109044|DRUG|Escitalopram|
223809499|NCT06403579|DEVICE|virtula reality goggles|no intervention
223809500|NCT04610931|BEHAVIORAL|Virtual Reality-Enhanced Cognitive Behavioral Therapy (VR-CBT)|"Participants are smokers seeking treatment. Patients will be randomized into one of the 2 intervention groups.~In all cases, patients will receive nicotine replacement therapy. The second physician in charge of the usual tobacco monitoring will adjust the dosage.~Subjects in the usual treatment group will receive 6 weekly individual cognitive behavior therapy sessions lead by a psychologist. The content of CBT is similar in both groups. Subjects in the Virtual Reality group will receive 6 weekly individual CBT sessions followed by 6 virtual therapy sessions. Virtual therapy consists of exposing the patient to 3D situations considered to cause a high risk of smoking relapse and aiming to reduce signal reactivity by extinction. At each session, a neutral exposure will be given at the beginning to facilitate immersion and emergence of the session with a duration determined according to the sensitivity of each patient. Exposure is stopped when the craving approaches the baseline level."
223809501|NCT04610931|BEHAVIORAL|cognitive behavior therapy|"Participants are smokers seeking treatment. Patients will be randomized into one of the 2 intervention groups. In all cases, patients will receive nicotine replacement therapy. The second physician in charge of the usual tobacco monitoring will adjust the dosage.~Subjects in the usual treatment group will receive 6 weekly individual cognitive behavior therapy sessions lead by a psychologist. The content of CBT is similar in both groups."
223809502|NCT02091479|DRUG|UFH Early group|"Either curative dose, intravenous unfractionated heparin (UFH) so as to reach an anti-Xa activity between 0.3 and 0.7 IU/mL, lengthening the activated prothrombin time as determined by each centre according to the treatment area (depending on the coagulometer and reactants).~Or low-molecular-weight, curative dose, subcutaneous heparin (LMWH) so as to reach an anti-Xa activity corresponding to treatment areas as determined for each type of molecule (about 0.5 to 1 anti-Xa IU for most LMWHs, administered via 2 daily injections, and about 0.5 to 1.5 anti-Xa IU for tinzaparin, 1 injection daily)."
223809503|NCT02091479|DRUG|UFH Late group|"Either curative dose, intravenous unfractionated heparin (UFH) so as to reach an anti-Xa activity between 0.3 and 0.7 IU/mL, lengthening the activated prothrombin time as determined by each centre according to the treatment area (depending on the coagulometer and reactants).~Or low-molecular-weight, curative dose, subcutaneous heparin (LMWH) so as to reach an anti-Xa activity corresponding to treatment areas as determined for each type of molecule (about 0.5 to 1 anti-Xa IU for most LMWHs, administered via 2 daily injections, and about 0.5 to 1.5 anti-Xa IU for tinzaparin, 1 injection daily)."
223809504|NCT05515419|BIOLOGICAL|Allogeneic cord blood treatment|Allogeneic cord blood treatment
223835449|NCT06285526|PROCEDURE|Cytoreduction surgery with Hyperthermic Intraperitoneal Chemotherapy|Cytoreduction surgery with Hyperthermic Intraperitoneal Chemotherapy
223835450|NCT06285526|PROCEDURE|Cephalic DuodenoPancreatectomy|Cephalic DuodenoPancreatectomy
223835451|NCT01474408|BEHAVIORAL|interval training day 1|
223835452|NCT01474408|BEHAVIORAL|Moderate exercise day 2|
223809505|NCT03883815|OTHER|Active Video Games Therapy|"Interventions were completed in 1-week periods, after 3 clinical visits. All individuals underwent both neurodevelopmental therapy and active video games therapy. Demographic data of individuals were recorded and muscle tone and gross motor functions were evaluated at the first visit. The games determined by the physiotherapist were explained and experienced by individuals. During the second visit, individuals played 4 games that were previously determined and experienced for about 45 minutes. On the last visit, individuals underwent neurodevelopmental therapy. During both treatment sessions, the accelerometer was fitted on a flexible belt by attaching it to the dominant wrist. Individuals were instructed not to remove the device during both treatment sessions.~One session individuals treated with exercises which weight transfer and postural reactions were facilitated.~Other session they played Nintendo Wii games in accordance with their current level and skills."
223809506|NCT00855062|DRUG|minocycline|100 mg capsule every 12 hours by mouth
223809507|NCT00855062|DRUG|minocycline placebo capsule|1 capsule every 12 hours by mouth
223809508|NCT03050502|DEVICE|Chest tube drain|This group will have an intra-pleural catheter placed with the intent of draining all intra-pleural blood (HTX). The size and nature of the catheter, manner of placement, and timing of removal will be at the discretion of the attending clinician.
223809509|NCT03050502|OTHER|Expectant management|This group will not have an intra-pleural catheter placed on the basis of the HTX, but will undergo standard observation/conservative management by the trauma service. Intra-pleural catheters may be placed after enrollment at the attending clinician's discretion.
223809510|NCT03406546|DRUG|Dexmedetomidine|Dexmedetomidine was used as a sedation agent with less side effect on respiratory system.
223809511|NCT03406546|DRUG|Remifentanil|Remifentanil was used to prevent cough induced by bronchoscopy.
223809512|NCT03406546|DEVICE|Laryngeal mask|Laryngeal mask was used to ensure respiration function during general anesthesia.
223809513|NCT01258192|DRUG|albumin-bound paclitaxel plus cisplatin|neo-chemotherapy program:Albumin-bound paclitaxel:100 mg/m2, IV (in the vein) on days 1,8 of each 21 day cycle. Cisplatin 75mg/m2,IV DRIP on day 1 of each 21 day cycle.Number of Cycles: 2 cycles before operation.If it is effective ,2 cycles will be given in 6 weeks after radical resection.
223809514|NCT00433303|BEHAVIORAL|Correlation between early delivery and coital activity|
223809515|NCT05580848|PROCEDURE|Wrist arthroscopy|"Wrist arthroscopy is a minimally invasive endoscopic method that enables the diagnosis and treatment of certain diseases and injuries of the radiocarpal, mediocarpal and distal radioulnar joints.~Wrist arthroscopy enables a direct view of the articular surface of the wrist and the assessment and adequate treatment of articular fractures The wrist arthroscopy procedure also enables the detection and necessary treatment of associated soft tissue injuries (scapho-lunate and/or luno-triquetral ligament, i.e. triangular fibrocartilaginous complex) and/or cartilage lesions in extra-articular and articular fractures."
223809516|NCT04601558|BEHAVIORAL|The letters with the Cochrane abstracts in the form of blog-shots|"The active intervention were letters with the remainder on participant's own cardiovascular risk factors, a participant's own count of 10-year risk of cardiovascular disease, and Cochrane abstract in the form of blog-shots and personal advice in reducing cardiovascular disease risk.~There were three Cochrane blog-shots. The first was about calcium in prevention of high blood pressure, the second was about the effect of reducing saturated fat acids in eating habits and the third consisted evidence of green and black tea for the prevention of cardiovascular diseases.~The letters were sent three times, every two months after the participants received first letter about cardiovascular disease risk."
223809517|NCT04601558|BEHAVIORAL|The letters with remainder on cardiovascular risk factors|"The passive intervention were letters with the remainder on participant's own cardiovascular risk factors and participant's own count of 10-year risk of cardiovascular disease.~The letters were sent three times, every two months after the participants received first letter about cardiovascular disease risk."
223809518|NCT02605564|OTHER|Gluten Free Diet|Gluten Free Diet
223809519|NCT02605564|OTHER|Placebo|Placebo No intervention, standard T1DM diet
223809520|NCT05969457|DRUG|Naropeine|Local anesthesia with injection of Ropivacaine (20mL of ropivacaine 7.5 mg/mL, i.e. 150mg)
223809521|NCT05969457|OTHER|questionnaires|Numerical Rating scale Questionnaire FSFI Qustionnaire SF12 Questionnaire DN4
223809522|NCT05969457|OTHER|Placebo|Injection of 20 mL of NaCl
223809523|NCT04605848|DIAGNOSTIC_TEST|Infrared themrography|measurement of temperature and microcirculation of the skin overlaying BAT depots in the region of FDG-uptake detected by 18F-FDG PET/CT before and after a cold test
223809524|NCT06006988|COMBINATION_PRODUCT|myoton pro|MyotonPRO is a mobile, removable handheld myotonometer. This tool is noninvasive and provides a quantitative assessment of a muscle's viscoelastic properties. These properties are characterized by various parameters such as hardness, tone and elasticity. The probe of MyotonPRO delivers a short (15 ms), low intensity (0.58 N) mechanical impact/impact on the skin on the muscle. The response of the touch then generates a recorded signal and an internal software program generates an acceleration graph. Measurements of various viscoelastic muscle properties such as stiffness, tone and elasticity are then extracted from this graph.
223809525|NCT02390726|BIOLOGICAL|Fecal Microbiota Transplant|
223809526|NCT02390726|BIOLOGICAL|Placebo|
223809527|NCT02551523|DRUG|Dolutegravir|92 patients will be simplified to once daily dolutegravir monotherapy
223809528|NCT02551523|DRUG|Standard of care combinational antiretroviral therapy|
223809529|NCT01487980|PROCEDURE|Cord clamping|Early vs Delayed
223809530|NCT01960725|BIOLOGICAL|RV5 (Pentavalent Rotavirus Vaccine)|
223809531|NCT00487058|DRUG|Gimatecan|
223809532|NCT02770651|DEVICE|Everolimus-Eluting stent|Everolimus-Eluting stent with bioabsorbable polymer
223835453|NCT01474408|BEHAVIORAL|Control day 3|
223809533|NCT02770651|DEVICE|Zotarolimus-Eluting stent|Zotarolimus-Eluting stent with permanent polymer
223809534|NCT03098940|DRUG|Chewing Gum|During the study healthy subjects will receive single doses of the various strengths of dronabinol
223809535|NCT03771430|BEHAVIORAL|Osteoarthritis education, exercise and CBT|"Osteoarthritis Education~1. 60-min session by AktivA trained PT)~   * Signs/symptoms, risk factors, weight control, treatment~  * Importance of physical activity~  * Appropriate activity \& training modalities~   Exercise and CBT Support~2. 60-min sessions/week for 12 weeks (a total of 24 sessions) led by AktivA and CBT trained PT)~   * Warm-up session~  * Strengthening exercises~  * Functional exercises~  * Stretching~  * Monitoring of CBT progress~  * Review of CBT lessons learned~  * Integration of CBT skills~  * Enhance motivation to continue~Online CBT (iCBT) (10 modules completed at home)~* Pain causes \& prevention~* Pain management~* Health promotion \& stress reduction at home \& work~* Adapting for leisure \& work~* Controlling flare-ups~* Maintaining \& improving results"
223809536|NCT03771430|PROCEDURE|Total Knee Arthroplasty|Standard total knee arthroplasty will be performed.
223809537|NCT02387892|DIETARY_SUPPLEMENT|Cheese & yogurt + Vitamin D|cheese \& yogurt with added 420 IU cholecalciferol
223809538|NCT02387892|DIETARY_SUPPLEMENT|Cheese & yogurt|Cheese \& yogurt without added vitamin D
223809539|NCT06273943|DRUG|Cabotegravir Tablets, for oral use.|Participants randomly assigned to the cabotegravir arm will be instructed to take by mouth a single tablet of cabotegavir 30mg once daily for four weeks.
223809540|NCT06273943|DRUG|Cabotegravir Extended-Release Injectable Suspension, for intramuscular use.|Participants will receive 600mg (3mL) CAB LA injections intramuscularly at Month 1, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22 and 24. The injections will be performed in the gluteal muscle by trained healthcare providers at study sites.
223809541|NCT06273943|DRUG|Tenofovir disoproxil/Emtricitabine 300mg/200mg fixed-dose combination tablets, for oral use|"* Daily regimen: a single tablet of TDF/FTC every 24 hours, regardless of sexual activity. If PrEP was stopped, resume with two pills of TDF/FTC followed by one pill every 24 hours.~* On-demand regimen: a loading dose of two pills of TDF/FTC 2 to 24 hours before sexual intercourse, a third pill 24 hours after the first drug intake and a fourth pill 24 hours later. In case of daily sexual intercourse, participants will be instructed to take one pill per day until the last sexual intercourse, then to take the two post-exposure pills. If the last dose of TDF/FTC was taken less than one week prior, a leading dose with a single pill of TDF/FTC is sufficient."
223809542|NCT06273943|PROCEDURE|Rectal Biopsies|"This intervention concerns only participants involved in the rectal tissue HIV-1 permissibility sub-study.~The proctologist collects ten rectal biopsies at different time points before and after PrEP initiation according to the randomization arm."
223809543|NCT01945749|DRUG|Intraarticular steroid|1 ml methylprednisolon corticosteroid (40 mg Depo-Medrol®) mixed with 4 ml Lidocain (10 mg/ml) without adrenalin. Injections are done ultrasound guided.
223809544|NCT01945749|DRUG|Intraarticular saline|1 ml isotonic saline mixed with 4 ml Lidocain (10 mg/ml) without adrenalin. Injections are done ultrasound guided
223809545|NCT01945749|OTHER|Exercise therapy|"The exercise is commenced 2 weeks after injection.~The exercise includes a 10 minute warm up phase (ergometer bicycling) followed by strengthening and coordination exercises focusing on trunk, hip and knees.~In case of pain or symptom exacerbation, a rescue exercise program is administered, excluding weight bearing activities."
223809546|NCT03367507|BEHAVIORAL|Sub-symptom aerobic exercise|Both groups will be instructed to perform their respective aerobic exercise program the following day after completing their first treadmill test. Participants will be instructed to exercise at their prescribed intensity for a maximum of 30 minutes a day, 4-5 days a week. They will be asked to postpone the exercise until the next day if they experience significant increases in symptoms from usual resting levels. Exercise type will be the participant's choice, however we will ask the participant refrain from contact/high risk activities including any modalities that might induce rapid and aggressive head movements.
223809547|NCT00365586|DRUG|Ketoprofen Topical Patch , 20%|
223809548|NCT04995848|OTHER|Telepalliation|Telepalliation platform Telepal.dk
224264524|NCT04298151|DRUG|Zirconomer Improved|glass ionomer restoration reinforced with nano-zirconia particles to improve strength and esthetics
224264525|NCT04298151|DRUG|Ketac Molar quick Aplicap|highly viscous glass ionomer with improved mechanical properties than the conventional GI
224264526|NCT04138251|DRUG|Empagliflozin|oral administration of Empagliflozin
224264527|NCT01293097|DRUG|Atorvastatin|Atorvastatin 80mg/d ×2d before PCI. After PCI, atorvastatin 40mg/d until 30 days later, and then followed by usual care
224264528|NCT01293097|DRUG|Statin|Usual care, but statin dose should not be higher than that described in exclusion criteria
224264529|NCT05913245|DIETARY_SUPPLEMENT|Maltodextrin 12.5%|Preoperative Maltodextrin 12.5%
224264530|NCT05913245|OTHER|Water|Preoperative water
224264531|NCT06319625|BEHAVIORAL|Rehabilitation therapy|"The study lasted 10d for each patient. During the treatment, All the participants were provided with the rehabilitation therapy, which included routine rehabilitation, cognitive training, swallowing function training and nutrition support.~Particularly, due to dysphagia, the patients enrolled might face difficulty in eating. For patients who were able to finish intake via mouth by compensatory means, the consistency, type, and size of food bolus was arranged. For those who cannot acquire sufficient nutrition through oral intake, the nasogastric tube feeding (NGT) was provided."
224264532|NCT06319625|PROCEDURE|Stellate ganglion block|Based on the invention above, the patients in the observation group were provided with Stellate ganglion block , using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate ganglion block . The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
223809549|NCT02524392|OTHER|Independent medical evaluation|The independent medical evaluation (IME) will be performed by specialists in general medicine, temporarily hired by the county welfare service. The independent medical evaluation (IME) procedure is developed by the Research Unit for General Practice at Uni Research Health in Norway.
223809550|NCT05009303|DEVICE|OneStep Smartphone App and C-Mill Treadmill|OneStep technology is a smartphone application that utilizes smartphone sensors to provide ongoing gait diagnostics. Each participant will have two sessions, during which, they will walk on a C-Mill smart treadmill for up to 15 minutes (with a minimum of 2 minutes), while carrying 2 smartphones and being recorded via two video cameras. The second walking session, conducted under similar conditions, will be used for test-retest reliability.
223809551|NCT04889001|OTHER|Simulation enhanced HBB training|Simulation enhanced HBB is a one-day course delivered using a format of Explain, Demonstrate and Facilitate practice. Compared to the standard HBB training, the simulation enhanced HBB course is designed with increased peer-to-peer feedback and scripted expert facilitator feedback at HBB practice exercises.
223809552|NCT05392023|OTHER|Relaxation Exercises and Scapular Stabilization exercise program|Scapular Stabilization Program (3 sets of 10 reps each/day). This exercise program is for muscles affecting scapular alignment due to chronic neck pain. A specialized program of non-resistive scapular upward rotation, wall facing arm lift, backward rolling arm lift, overhead arm raise, shoulder abduction in scapular plane above 120˚, shoulder shrugs, levator scapulae and pectoralis minor stretching. Hot pack (10 min) and relaxation exercises including myofascial release and stretching of neck and scapular region muscles. A total of 45 minutes session three times a week on alternate days for 3 weeks. Assessment will be done at baseline, on the end of 3rd week and for long-term effects at the end of 6th week.
223809553|NCT05392023|OTHER|Relaxation Exercises of cervico- scapular region|Relaxation exercises of the cervico-scapular region including neck stretches of scapular muscles and myofascial release will be given to patients three times a week on alternate days for 3 weeks. Assessment will be done at baseline, at the end of the 3rd week, and for long-term effects at the end of the 6th week.
223809554|NCT00448890|DRUG|GSK729327|Tablets
223809555|NCT00448890|DRUG|Placebo|GSK729327 Matching placebo - Tablets
223809556|NCT05024669|COMBINATION_PRODUCT|Gluma desensitiser|Gluma desensitiser was used before restoration.
223809557|NCT05024669|COMBINATION_PRODUCT|Sheildforce Plus desensitiser|Sheildforce Plus desensitiser was used before restoration.
223809558|NCT05024669|COMBINATION_PRODUCT|Telio CS desensitiser|Telio CS desensitiser was used before restoration.
223809559|NCT02110901|DRUG|PRT-201|
223809560|NCT02110901|DRUG|Placebo|
223809561|NCT02634788|DRUG|Buprenorphine|Buprenorphine sublingual spray delivered via single 100 μL spray
223809562|NCT02634788|DRUG|Placebo|Placebo-matching buprenorphine sublingual spray delivered via single 100 μL spray
223809563|NCT05414539|OTHER|OptiCogs Online|A multicomponent intervention to rehabilitate cognitive deficits in people post-stroke
223809564|NCT00758459|DRUG|AZD1236|oral tablet, 75 mg, twice daily during 6 weeks
223809565|NCT00758459|DRUG|Placebo|Dosing to match AZD1236
223809566|NCT02464683|DIETARY_SUPPLEMENT|VitaminD|200 International Units (oral dose) daily of 60 days
223809567|NCT04069780|PROCEDURE|Intravitreal injection (4mg/0.1ml)|"Injection will be performed in the operating room under complete sterile conditions Under topical anaesthesia. Intravitreal injection (4mg/0.1ml) of triamicinolone acetonide will be done using a 30-31 gauge needle at a distance of 3.5 mm from the limbus in aphakic or pseudophakic patients, and 4 mm in phakic patients. The needle will be then removed with application of cotton tipped applicator over the entry site.~-IOP monitoring will be done at 15, 30 and 60 minutes following injection in all groups."
223809568|NCT04069780|PROCEDURE|Superachoroidal injection (4 mg/0.1ml)|"Injection will be performed in the operating room under complete sterile conditions Under topical anaesthesia. Suprachoroidal injection (4mg/0.1ml) of triamcinolone acetonide will be done using a custom-made 30-31 gauge needle with a sleeve to prevent further penetration of the needle into the vitreous cavity. Injection will be done at approximately 4 mm from the limbus.~* IOP monitoring will be done at 15, 30 and 60 minutes following injection in all groups.~* UBM assessment will be done 24 hours following injection to confirm targeting of the suprachoroidal space."
223809569|NCT04069780|PROCEDURE|Suprachoroidal injection (2mg/0.1ml)|"njection will be performed in the operating room under complete sterile conditions Under topical anaesthesia. Suprachoroidal injection (2mg/0.1ml) of triamcinolone acetonide will be done using a custom-made 30-31 gauge needle with a sleeve to prevent further penetration of the needle into the vitreous cavity. Injection will be done at approximately 4 mm from the limbus.~* IOP monitoring will be done at 15, 30 and 60 minutes following injection in all groups.~* UBM assessment will be done 24 hours following injection to confirm targeting of the suprachoroidal space."
223809570|NCT02489110|BEHAVIORAL|Webnovela|
223809571|NCT02489110|BEHAVIORAL|Information|
223809572|NCT01238640|DRUG|Code STD|"2 mg Single-dose of experimental nicotine product coded STD"
223809573|NCT01238640|DRUG|Code STE|"2 mg Single-dose of experimental nicotine product coded STE"
223809574|NCT01238640|DRUG|Nicorette Microtab|A comparative 2 mg Single-dose of marketed tablet
223809575|NCT02415699|DRUG|Fluorouracil|
223809576|NCT02415699|DRUG|Oxaliplatin|
223809577|NCT02415699|DRUG|Leucovorin|
223809578|NCT02415699|BIOLOGICAL|DC-CIK|
223809579|NCT03076372|DRUG|MM-310|MM-310
223809580|NCT00892125|DRUG|paliperidone ER; Carbamazepine|
223809581|NCT03057743|DEVICE|Positron emission tomography (PET/CT) imaging|
223809582|NCT03057743|DEVICE|radiotracer [18F]ISO-1|
223809583|NCT02415348|DEVICE|Fibroscan|
223809584|NCT03760770|PROCEDURE|corneal collagen crosslinking|Crosslinking in patients with progressive keratoconus.
223809585|NCT04402463|OTHER|Global Postural Reeducation|"The participants will receive treatment along 4 weeks, 2 sessions per week, and 40-45 minutes each session.~In the treatment 3 of the therapeutic postures of GPR method to will carry out following Souchard's principles of Global Postural Reeducation"
223809586|NCT04402463|OTHER|Exercise Therapeutic|"The participants will receive treatment along 4 weeks, 2 sessions per week, and 40-45 minutes each session.~The treatment will be divided into 3 phases, where it initially starts with phase 1 (3 treatments) and progresses to phase 2 (3 treatments) until reaching stage 3 (2 treatments)."
223809587|NCT03467932|DRUG|Cohort A: ORMD-0801|"Part 1 In the first two weeks of active treatment (Part 1) subjects will receive double-blind therapy according to their randomized regimen (placebo or ORMD-0801) to be taken QHS, BID or TID. Subjects will undergo a step-wise dose escalation from a starting dose of 16 mg (Visit 3), to 24 mg (Visit 4), to a top dose of 32 mg (Visit 5 onward). Subjects will then enter Part 2.~Part 2:~During Part 2, subjects will remain on fixed doses of ORMD-0801 (or matched placebo) for 10 weeks. Doses will not be adjusted unless clinically indicated for adverse events or hypoglycemia."
223809588|NCT03467932|DRUG|Placebo oral capsule|Placebo provided QHS, BID, TID
223809589|NCT03467932|DRUG|Cohort B: ORMD-0801|"Part 1 In the first two weeks of active treatment, subjects will receive double-blind therapy according to their randomized regimen (ORMD 0801 8 mg or 16 mg, or matched placebo) to be taken QHS or BID. Subjects will then enter Part 2 at the same dose and regimen administered in Part 1.~Part 2 Subjects will remain on fixed doses of ORMD-0801 (or matched placebo) for 10 weeks. Doses will not be adjusted unless clinically indicated for adverse events or hypoglycemia."
223809590|NCT00004410|DRUG|tauroursodeoxycholic acid|
223809591|NCT05999786|BEHAVIORAL|early rehabiliation swallowing program|not receiving early rehabilitation swallowing program from before and after surgery
223809592|NCT05999786|BEHAVIORAL|not receiving early rehabilitation swallowing program|the Taiwan Dysphagia Society's publicly shared swallowing exercises for dysphagia, which is from before and after surgery
223809593|NCT05685992|OTHER|no intervention|no intervention
223809594|NCT05863130|DRUG|BI 764198 (C-14) (approach 1)|BI 764198 (C-14) (approach 1)
223809595|NCT05863130|DRUG|BI 764198 (C-14) (approach 2)|BI 764198 (C-14) (approach 2)
223835454|NCT01653847|DRUG|Tacrolimus with MMF|Standard dose Tacrolimus and MMF. This will follow standard of care procedures at Northwestern Memorial Hospital's Comprehensive Transplant Center. MMF trough or area under the concentration time curve (AUC) shall not be used to adjust dosing. In this group, Tacrolimus will be initiated according to our practice. The Tacrolimus dose will be adjusted from day 3 on to achieve a target whole blood trough concentration of 8 ng/mL to 10 ng/mL. From month 2 until Month 6, the target Tacrolimus trough level will be reduced to 6 ng/mL to 8 ng/mL. After month 6, the target level of Tacrolimus will be reduced to 4 ng/mL to 8 ng/mL.
223809596|NCT02788630|BEHAVIORAL|Sleep hygiene counseling|The mothers of the eligible infants will be visited at home and will be invited to participate at the study. To those who sign the Consent Form (CF) a following visit will be scheduled to within 5 days. Between CF signature and the 5-day visit, the enrolled children will use an actigraph-device in the leg and the mothers will fill out a sleep diary registering the times of the day the child is asleep, awake, napping, and feeding. At the 5-day visit the child allocation in the trial (intervention or control group) will be uncovered and the sleep recommendations will be delivered to mothers in the intervention group. Phone calls on days 6 and 7 and a home visit on day 8 will be paid to support mothers for possible difficulties in implementing the recommendations.
223809597|NCT06306014|DRUG|EXL01|"Following a at least 10-days vancomycin treatment :~Oral EXL01 including:~* 10 capsules per day in week 1 and 2~* 4 capsules per day, in weeks 3 and 4~* 1 capsule per day in weeks 5 to 8 Phase I : EXL01 during a 8 weeks open-label period"
223809598|NCT06306014|DRUG|EXL01|"Following a at least 10-days vancomycin treatment :~Oral EXL01 including:~* 10 capsules per day in week 1 and 2~* 4 capsules per day, in weeks 3 and 4~* 1 capsule per day in weeks 5 to 8 Phase II: EXL01 during a 8 weeks double blind placebo-controlled period"
223809599|NCT06306014|DRUG|Placebo|"Following a at least 10-days vancomycin treatment:~Oral placebo including:~* 10 capsules per day in week 1 and 2~* 4 capsules per day, in weeks 3 and 4~* 1 capsule per day in weeks 5 to 8 Phase II : Placebo during a 8 weeks double blind placebo-controlled period"
223809600|NCT03360630|BIOLOGICAL|Anti-PD-1 plus DC-CIK|Patients will receive pembrolizumab 100mg every three weeks until disease progression, unacceptable toxicity or patient refusal. DC-CIK Immunotherapy: Mononuclear cells were collected aseptically with blood cell separator composition apheresis, and cultured DC-CIK cells for 10-14 days. Cells were infused back to the patients in 3 times via intravenous infusion .Patients will received at least 2 cycles of DC-CIK Immunotherapy along with 4 dosage of anti-PD-1 antibody treatment. If the evaluation of the treatment is partial response or stable disease, additional cycles were eligible.
223809601|NCT03360630|BIOLOGICAL|Anti-PD-1 alone|Patients will receive pembrolizumab 100mg every three weeks until disease progression, unacceptable toxicity or patient refusal.
223809602|NCT03140501|DEVICE|"Mobile application (app)"|"The self-management app has 3 main features: 1) SCI-specific education modules; 2) a circle-of-care in which the users select health allies (formal and informal caregivers); and 3) a variety of tools to assist with goal identification, symptom/behaviour tracking, etc. The intervention will involve 5-6 contacts that occur over a 3-month period and ongoing use of the app. There will be 1 to 2 in-person sessions, where the principles of self-management are reviewed, self-management goals are identified, and features of the app are explained. Over the next month, there will be 2 follow-up contacts to review any questions/issues participants have. Participants can set additional goals during this time. Over the last 2 months, there will be monthly contacts to address the same issues."
223809603|NCT00723099|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo umbilical cord blood transplant
223809604|NCT00723099|DRUG|Cyclophosphamide|Given IV
223809605|NCT00723099|DRUG|Cyclosporine|Given IV
223809606|NCT00723099|DRUG|Fludarabine Phosphate|Given IV
223809607|NCT00723099|OTHER|Laboratory Biomarker Analysis|Correlative studies
223809608|NCT00723099|DRUG|Mycophenolate Mofetil|Given IV or PO
223809609|NCT00723099|RADIATION|Total-Body Irradiation|Undergo TBI
223809610|NCT00723099|PROCEDURE|Umbilical Cord Blood Transplantation|Undergo umbilical cord blood transplant
223809611|NCT03163914|DRUG|Epinephrine|Epinephrine infusion rate will adjust 30 ml/h (5µg/ ml )
223809612|NCT03163914|DRUG|Norepinephrine|Norepinephrine infusion rate will adjust 30 ml/h (5µg/ ml )
223809613|NCT03163914|DRUG|Phenylephrine|Phenylephrine infusion rate will adjust 30 ml/h (100µg/ ml )
223809614|NCT03163914|DRUG|Saline|saline infusion will apply till the end of the surgery
223809615|NCT02533869|RADIATION|Low-dose CT|Low-dose computed tomography for suspected acute uncomplicated appendicitis
223809616|NCT02533869|PROCEDURE|Laparoscopic appendectomy|All patients diagnosed with an uncomplicated acute appendicitis on low-dose CT-scan will undergo laparoscopic appendectomy to evaluate the sensitivity and specificity of the CT diagnosis
223809617|NCT01069081|DRUG|Arm C|Docetaxel and cisplatin chemotherapy combined with high dose PPI. Docetaxel 75mg/m2 intravenous d1, cisplatin 75mg/m2 intravenous d1,repeated every 3 weeks.Each patient is designed to receive no more than 6 cycles of chemotherapy.PPI 200mg p.o. d1-3 every week for 66 weeks.
223809618|NCT01069081|DRUG|Arm B|Docetaxel and cisplatin chemotherapy combined with lower dose PPI. Docetaxel 75mg/m2 intravenous d1, cisplatin 75mg/m2 intravenous d1,repeated every 3 weeks.Each patient is designed to receive no more than 6 cycles of chemotherapy.PPI 160mg p.o. d1-3 every week for 66 weeks.
223809619|NCT01069081|DRUG|Arm A|Docetaxel and cisplatin chemotherapy. Docetaxel 75mg/m2 intravenous d1, cisplatin 75mg/m2 intravenous d1,repeated every 3 weeks.Each patient is designed to receive no more than 6 cycles of chemotherapy.
223809620|NCT05326763|DRUG|Platelet Rich Plasma|Preparing 2 mL of PRP with concentration of 4-6 times the average normal values, 20mL of blood will be first collected from the patient's upper limb cubital vein using an 18G needle. A local subcutaneous anesthesia (2 ml of 1% lidocaine) will be finished by the orthopedist.
223809621|NCT05326763|DRUG|Dextrose 50%|The group will use 4 ml of PRP + 4 ml of 0.9% saline -h 2 ml of 1% lidocaine (10-ml syringe).
223809622|NCT00500721|DRUG|HCV-796|HCV-796 500mg BID x 14 days
223809623|NCT00500721|DRUG|Desipramine|"Period 1: Single oral dose of desipramine (50 mg) on day 1. No test article administration on days 2 to 6.~Period 2: Multiple oral doses of HCV-796 (500 mg) every 12 hours on days 1 to 9.~Period 3: Multiple oral doses of HCV-796 (500 mg) every 12 hours on days 10 to 14 and a single oral dose of desipramine (50 mg) on day 10."
223809624|NCT04018248|DRUG|BR101801 (Phase Ia)|Phase Ia (dose escalation):25 mg capsules and 100 mg capsules Planned doses are 50, 100, 200, 325, and 450 mg.
223809625|NCT04018248|DRUG|BR101801 (Phase Ib)|Phase Ib (dose expansion):25 and 100 mg capsules Doses administered will be determined from Phase Ia data.
223809626|NCT02693821|DRUG|Gabapentin|gabapentin 300 mg per day, orally during 30 days
223809627|NCT02693821|DRUG|Placebo|Placebo 300 mg per day, orally during 30 days
223809628|NCT00262795|DRUG|Fludarabine|Fludarabine i.v. (25 mg/m2/d, d1-5) q28d; max 6 cycles
223809629|NCT00262795|DRUG|Chlorambucil|Chlorambucil p.o. (0,4 mg - max. 0,8 mg/kg/d, d1) q15d, max. 12 month
223809630|NCT01726855|PROCEDURE|vascularized finger dorsal fascial flap|
223809631|NCT00916461|DRUG|Minocycline|Minocycline + treatment as usual. 50 mg twice daily increasing to 200 mgs per day, increments of 50 mgs every 2 weeks.
223809632|NCT00916461|DRUG|Placebo|Placebo + treatment as usual.
223809633|NCT02496767|DRUG|Tirasemtiv|
223809634|NCT02496767|DRUG|Placebo tablets|
223809635|NCT02203708|OTHER|Supportive Program for Mother with BPD (SuPMother-B).|"The development of the program is based on several principles: group process, groupware, mentalization, parental values, behavioral strategies and information on the child's needs, knowledge of the BPD and the strategies of get better. The program will last 10 sessions of group of about 2h.~Minimal intervention. All study participants receive an individual interview about 45 minutes with a psychiatrist for three objectives: information on the diagnosis of BPD, information on resources for health care and educational aids."
223809636|NCT01860469|PROCEDURE|vancomycin-soaked mesh|
223809637|NCT01860469|PROCEDURE|plain mesh|
223809638|NCT05374044|DIAGNOSTIC_TEST|pelvic MRI for establishing new mrTRG method|they will received two pelvic MR examinations before and after neoadjvant therapy. The MRI before neoadjvant therapy is considered as baseline MRI, which is usually taken within 3 weeks before NAT. The MRI after neoadjvant therapy is considered as preoperative MRI, which is usually taken within 3-8 weeks before NAT.
223809639|NCT03041844|DEVICE|Low Frequency, Low Intensity Ultrasound|Therapeutic ultrasound (20 kHz, \<100 mW/cm2 spatial peak-temporal peak)
223809640|NCT03041844|DEVICE|Sham Applicator|Sham ultrasound applicator
223809641|NCT01939886|DRUG|Mefloquine - Artesunate|
223809642|NCT01939886|DRUG|Artemether-lumefantrine combination|
223809643|NCT02252432|DRUG|Ketamine|A bolus of intravenous (IV) ketamine during induction (0.5mg/kg), and an IV infusion of ketamine intraoperatively (5 mcg/kg/min)
223809644|NCT02252432|DRUG|Methadone|A single dose of IV methadone (0.2 mg/kg) preinduction.
223809645|NCT02252432|DRUG|Ketamine + methadone|Methadone (0.2 mg/kg) preinduction, a bolus of IV ketamine (0.5 mg/kg) during induction and IV ketamine infusion intraoperatively (5 mcg/kg/min)
223809646|NCT04513613|DEVICE|Procedure/Surgery: Robotic-PVI|Robotic-assisted (CorPath GRX System) percutaneous vascular interventions.
223809647|NCT04345159|OTHER|Questionnaire by phone call|"2 questionnaires : at inclusion and 4 months later. The exposure to hydroxychloroquine and the history of autoimmune disease is determined during the phone call along with other exposure factors. The symptoms presented by the patient are classified in Suggestive of a COVID-19 infection or Not suggestive of COVID-19 infection by a team of internists and infectious diseases specialists, by studying the questionnaires after the completion in a blind-manner regarding the hydroxychloroquine intake."
223809648|NCT01281202|DRUG|Vigabatrin|Tablets
223809649|NCT01281202|DRUG|Matching Placebo|Tablets
223809650|NCT05680454|BIOLOGICAL|Recombinant Nonavalent (Types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (HPV) Vaccine (Escherichia Coli)|For Low-dosage group, a 3-dose regimen administered at months 0, 2 and 6. For Mid-dosage group, a 3-dose regimen administered at months 0, 2 and 6. For High-dosage group, a 3-dose regimen administered at months 0, 2 and 6.
223809651|NCT05680454|BIOLOGICAL|Recombinant nonavalent Human Papillomavirus (Types 6,11,16,18,31,33,45,52,58) Vaccine|A 3-dose regimen administered at months 0, 2 and 6.
223809652|NCT00894673|BIOLOGICAL|Heparin sodium Hipolabor|Heparin sodium Hipolabor 5.000 UI/mL
223809653|NCT00894673|BIOLOGICAL|Heparin sodium APP|Heparin sodium APP 5.000 USP
223809654|NCT03224221|DRUG|Apatinib|Patients will receive Apatinib at 500mg/times,oral one times daily for 28 days
223809655|NCT03224221|DRUG|fluorouracil and platinum|the dosage of the fluorouracil and platinum need to be determined by the doctors according to the actual condition of the patients
223809656|NCT05174481|OTHER|Early warning system for emergency department overcrowding|In this study, no interventions are performed.
223809657|NCT06082245|PROCEDURE|TLIP Block For Perioperative Analgesia In Patients With Lumbar Spine Fusion Surgery|"* Patients were placed in a prone position;~* ultrasound-guided TLIP block: (1) The transducer was positioned in a transverse midline position at the level of the L3 vertebra. After the identification of the spinous process and interspinous muscles. (2) The probe was moved laterally to identify the multifidus (MF) and longissimus (LG) muscles. (3) the TLIP block was performed under real-time ultrasound guidance using an insulated 100-mm 22G echogenic needle which was inserted in-plane lateral to the medial direction. (4) After negative aspiration, 20-mL 0.25% ropivacaine was injected in each side bilaterally in the interface between the MF and LG muscles.~* patients received general anesthesia"
223809658|NCT06082245|PROCEDURE|ESP Block For Perioperative Analgesia In Patients With Lumbar Spine Fusion Surgery|"* Patients were placed in a prone position;~* ultrasound-guided ESP block: (1) The 12th rib was identified in the parasagittal plane, and with probe shifted caudad and medial, the L3 transverse process (TP) was identified. (2) Insulated 100-mm 22G echogenic needle was inserted from cranial to caudal direction. (3) The needle tip was identified between the L2 and L3, and 20 mL of 0.25% ropivacaine was injected in each side bilaterally in ESP.~* patients received general anesthesia"
223809659|NCT06082245|PROCEDURE|Lidocaine injection|"* patients received general anesthesia~* the expected incision was anesthetized with 15ml of 1% lidocaine mixed with 1/200,000 adrenaline on each side before surgery."
223809660|NCT00357721|DRUG|Atazanavir Sulphate|Capsules, Oral, 200 mg, twice daily, 7 days.
223809661|NCT00357721|DRUG|Atazanavir Sulphate|Capsules, Oral, 300 mg, twice daily, 8 days.
223809662|NCT00357721|DRUG|Atazanavir Sulphate|Capsules, Oral, 400 mg, twice daily, 9 days.
223809663|NCT02712125|DRUG|isosorbide mononitrate|20 mg isosorbide mononitrate (IMN) tablet applied vaginally once daily until delivery .
223809664|NCT02712125|DRUG|Placebo|placebo vaginal tablets once daily until delivery
223809665|NCT01984580|DRUG|zinc gluconate|26.6 mg zinc BID (as zinc gluconate)
223809666|NCT05207930|DEVICE|GAmified HOme-based COgnitive-Nutrition training (GAHOCON)|"A home-based tablet game training, in which participants are expected to apply the nutrition knowledge they learn from the centre-based nutritional education and their cognitive functions.~Participants in the intervention group are expected to engage in the home-based training regularly during those 8 weeks. A team of registered social workers working in the elderly community centre will monitor the progress, remind, set goals, and provide supports to the participant remotely on WhatsApp."
223809667|NCT05207930|DEVICE|Centre-based online open-source cognitive games|During the 8 weeks in which the intervention group receives GAHOCON treatment, the control group will be introduced to some online open-source cognitive games (e.g. CogniFit) and are encouraged to play those games at the elderly community centre. However, the content of these games are unrelated to nutrition and the training is gamified to a less extent compared to GAHOCON. They will have free access to these online open-source cognitive games at the elderly community centre.
223809668|NCT02889133|DRUG|Iron-dextran|Approved for clinical use: 1-gram dose IV - diluted in 500 mL, one pint normal saline.
223809669|NCT02889133|DRUG|Saline|Salt water IV - 500 mL, one pint normal saline.
223809670|NCT02889133|PROCEDURE|Blood Donation|Standard process of collecting and storing blood and blood components (approximately 450 mL, or a pint of blood). Following donation, the blood will be leukoreduced, packed, and stored in AS-3 solution.
223809671|NCT02889133|PROCEDURE|24-hour PTR|"The way the FDA determines how good blood is for transfusion is called a radioactive 51-Chromium 24-hour post-transfusion red cell recovery study. The purpose is to measure how many of the transfused red cells are still in circulation (being pumped by the heart through blood vessels) 24 hours after transfusion. In order to measure the percent of red cells that are still in circulation, a small amount of the donated blood will be radioactively labeled. This will be infused in one arm and then blood will be collected from the other arm at different time points to measure how much of the transfused red cells are still in circulation."
223809672|NCT00521703|DRUG|Lidocaine|oral cavity and throat were sprayed with lidocaine 10% two to three puffs before propofol infusing
223809673|NCT00521703|DRUG|Tannic acid|oral cavity and throat were sprayed with placebo (tannic acid 0.5%) two to three puffs before propofol infusing
223809674|NCT02265614|GENETIC|PGS|
223809675|NCT00133536|BIOLOGICAL|Influenza A/H5N1 Vaccine|Monovalent inactivated subvirion influenza H5N1 vaccine (derived from A/Vietnam/1203/04). Packaged in single-dose vials of 90 mcg/mL (0.7 mL/vial). Dosage 45 mcg/0.5 mL administered intramuscularly.
223809676|NCT00133536|DRUG|Placebo|Normal saline administered intramuscularly.
223809677|NCT01555801|DEVICE|submucosal injection needle ; EUS|The patients will accepted submucosal injection of 5ml saline followed by ordinary endosonography(EUS) before surgery or endoscopic dissection.
223809678|NCT01555801|DEVICE|ordinary endosonography(EUS)|These patients will be accepted ordinary EUS followed by surgery or endoscopic dissection.
223809679|NCT02481492|DEVICE|No flip technique of Shang Ring circumcision|Measure the diameter of the penis with a scale plate of holes, the diameter of the ring was accordance with the glands, inner ring is placed into foreskin cavity, apply the outer ring on the skin covering inner ring, clamp the out ring and cut the redundant foreskin; Ring is detached spontaneously.
223809680|NCT02481492|DEVICE|Flip technique of Shang Ring circumcision|Measure the diameter of the penis with a scale plate of holes, the diameter of the ring was accordance with the penis, inner ring is placed around the penis, flip foreskin over the inner ring, apply the outer ring on the skin covering inner ring, clamp the out ring and cut the redundant foreskin; Remove the ring 7days postoperatively.
223809681|NCT01154478|OTHER|Diet rich in omega-3 fatty acids|fish at least 3 times per week, large leaf vegetables
223809682|NCT01154478|OTHER|Diet rich in polyphenols|extra virgin olive oil, green tea, berries,fruits rich in polyphenols, dark chocolate, decaffenated coffee
223809683|NCT01154478|OTHER|Control diet|low content of omega-3 fatty acids and polyphenols (low intake of fish, nuts and legumes,oil rich in monounsaturated fatty acids, vegetables and fruits poor in polyphenols)
223809684|NCT01154478|OTHER|diet rich in omega-3 and polyphenols|Fish at least 3 times x week,large leaf vegetables + extra virgin olive oil, green tea, berries,fruits rich in polyphenols, dark chocolate, decaffenated coffee
223809685|NCT01440686|DRUG|Somatropin|A single dose 5.0mg administered subcutaneously(under the skin) via Genotropin
223809686|NCT01440686|DRUG|Placebo|Tablets, oral administrations
223809687|NCT00170222|DRUG|doxycycline|
223809688|NCT04711603|DRUG|MR13A9|Intravenous administration
223809689|NCT04711603|DRUG|Placebo|Intravenous administration
223809690|NCT02124148|DRUG|Prexasertib|Administered IV
223809691|NCT02124148|DRUG|Cisplatin|Administered IV
223809692|NCT02124148|DRUG|Cetuximab|Administered IV
223809693|NCT02124148|DRUG|G-CSF|Administered SC
223809694|NCT02124148|DRUG|Pemetrexed|Administered IV
223809695|NCT02124148|DRUG|Fluorouracil|Administered IV
223809696|NCT02124148|DRUG|LY3023414|Administered PO
223809697|NCT02124148|DRUG|Leucovorin|Administered IV
223809698|NCT01587352|OTHER|Laboratory Biomarker Analysis|Correlative studies
223809699|NCT01587352|DRUG|Vorinostat|Given PO
223809700|NCT04191447|DRUG|Flamboyant 200/12|Flamboyant 200/12 capsule
223809701|NCT04191447|DRUG|Budesonide / Formoterol 400/12|Budesonide / Formoterol 400/12 capsule
223809702|NCT04191447|OTHER|Flamboyant 200/12 Placebo|Flamboyant 200/12 Placebo capsule
223809703|NCT04191447|OTHER|Budesonide / Formoterol 400/12 Placebo|Budesonide / Formoterol 400/12 Placebo capsule
223809704|NCT06499285|BIOLOGICAL|KER-050|KER-050 administered subcutaneously every 4 weeks
223809705|NCT06499285|DRUG|Placebo|Placebo administered subcutaneously every 4 weeks
223809706|NCT03821337|DEVICE|repetitive Trans Magnetic Stimulation|Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive brain stimulation technique that is able to alter cortical excitability and is FDA-approved to treat Major Depressive Disorder. Magnetic fields pass unimpeded through the scalp, skull and meninges, and can directly excite cortical areas.
223809707|NCT03821337|DEVICE|Sham TMS|Sham sessions will be delivered using an electronic sham system consisting of a coil that mimics the appearance and sound of TMS, combined with a TENS device which produces a small electric shock mimicking the feeling of real rTMS. This type of sham has been demonstrated to be indistinguishable from real rTMS, has been well tolerated (George et al., 2010; George et al., 2014) and successfully used in other clinical trials (Borckardt et al., 2008; Arana et al., 2008). During each session of rTMS the investigators will present a series of opioid related images, including those utilized in previous studies (Garland et al., 2015; Garland \& Howard, 2014).
223809708|NCT01750736|OTHER|Augmented Exercise and Manual Therapy|Session 1 will include the manual therapy intervention to cervical and or thoracic regions. Subjects will perform the augmented exercise at home and at each data collection session.
223809709|NCT01750736|OTHER|General Exercise and Manual Therapy|Session 1 will include the manual therapy intervention to cervical and or thoracic regions. Subjects will perform general range of motion exercises for the neck at home and at each data collection session.
223809710|NCT01351909|DRUG|Cyclophosphamide|Given PO
223809711|NCT01351909|OTHER|Laboratory Biomarker Analysis|Correlative studies
223809712|NCT01351909|DRUG|Veliparib|Given PO
223809713|NCT06319846|DRUG|Tirofiban|Initial infusion of tirofiban 0.4μg/kg body weight/minute for 30 minutes (a maximum dose of 1mg) within 24 hours of symptom onset, followed by a continuous infusion of tirofiban 0.1μg/kg body weight/minute for 48 hours.
223809714|NCT06319846|DRUG|Placebo|Initial infusion of saline placebo for 30 minutes within 24 hours of symptom onset, followed by a continuous infusion of placebo for 48 hours.
223809715|NCT05479604|DEVICE|SinuSonic|Handheld device that utilizes sound and pressure combined with normal breathing to relieve nasal congestion. The device is held over the nose and creates vibrations similar to humming.
223809716|NCT05479604|DEVICE|Sham Device|Device looks exactly like study device but does not emit the same pressure or make the same noise as the study device
223809717|NCT05108207|OTHER|Prevention software|The software is installed on an Alcatel OneTouch Pixi-3 10 tablet and is delivered every day to each patient between 9:00 am and 8:00 pm, with nighttime pickup (8:00 pm to 09:00 am), so the patient can rest and to charge the device. The first day, a previously trained health professional delivers the tablet and trains the older adults in its use, taking 10 to 15 minutes. The day after the tablet is delivered, the same person goes to the patient's room to check if he or she has any doubts or problems with its use. Both groups are advised to use the tablet 3 times a day, at least 10 minutes each time.
223809718|NCT05108207|OTHER|Placebo|All patients will have a tablet without the software PREVEDEL between 09:00-19:00 hrs.
223809719|NCT05108207|OTHER|Implement a program of non-pharmacological interventions to prevent delirium|Three months before the start of the clinical trial, an intervention is carried out in the Internal Medicine, Geriatrics and Intermediate Care Unit services of the 4 participating centers in order to establish a homogeneous plan of nPPD and assess adherence. The implementation methodology in the first stage will be according to the Consolidated Framework for Advancing Implementation Science (CFIR) model, used in a local pilot study.
223809720|NCT05539729|DRUG|Vancomycin|A marketed antibiotic (Study Drug) supplied by Amerisource Bergen, by the Mount Sinai Investigational Drug Services (IDS), and encapsulated in red coating to match the placebo.
223809721|NCT05539729|DRUG|Placebo|Placebo created by the IDS and encapsulated in red coating to match the Study Drug.
223809722|NCT05646485|DIAGNOSTIC_TEST|Urinalysis|"Urine analysis (every 6 months for 2 years); Patients with \<3 red blood cells (RBCs) per high-powered field (HPF) will repeat screening at 6-month intervals for an average of 2 years.~If RBCs are 3-25 RBSc/HPF- subjects will undergo- \[cystoscopy + Upper tract imaging\] or \[urine marker cancer testing with Cxbladder triage + Upper tract imaging\].~If \>25 RBCs, subjects will get - \[cystoscopy + Upper tract imaging\]."
223809723|NCT06135727|DEVICE|Maestro2 OCT|3D Wide (12mmx9mm) OCT scan using the Maestro (Topcon, Japan)
223809724|NCT02956499|DRUG|APX001 single dose 1|
223809725|NCT02956499|DRUG|APX001 single dose 2|
223809726|NCT02956499|DRUG|APX001 single dose 3|
223809727|NCT02956499|DRUG|APX001 single dose 4|
223809728|NCT02956499|DRUG|APX001 single dose 5|
223809729|NCT02956499|DRUG|APX001 single dose 6|
223809730|NCT02956499|DRUG|APX001 multiple dose 1|
223809731|NCT02956499|DRUG|APX001 multiple dose 2|
223809732|NCT02956499|DRUG|APX001 multiple dose 3|
223809733|NCT02956499|DRUG|APX001 multiple dose 4|
223809734|NCT02956499|DRUG|Matching Placebo|
223809735|NCT06200155|DRUG|Psilocybin|Given by PO
223809736|NCT06200155|OTHER|Niacin|Given by PO
223809737|NCT05400005|OTHER|Dietary protein|"Intervention of the study include consuming a higher protein diet. Depending on the group allocation, this is done by asking the subjects to follow My Healthy Plate diet and consumption of 20g of protein isolates (casein or soy)."
223809738|NCT05887947|DEVICE|Electronic Cigarette with 5% Nicotine Concentration|Electronic cigarette in 5% nicotine concentration (Vuse Alto), provided for free.
223809739|NCT05887947|DEVICE|Electronic Cigarette with 1.8% Nicotine Concentration|Electronic cigarette in 1.8% nicotine concentration (Vuse Alto), provided for free.
223809740|NCT06527183|DIAGNOSTIC_TEST|Skin punch biopsy to demonstrate small fiber neuropathy|Skin punch biopsy to assess intrapidermal nerve fiber density
223809741|NCT05867160|OTHER|ASM as adjunctive therapy|ASM approved as adjunctive therapy
223809742|NCT01364051|DRUG|Cediranib|Given PO
223809743|NCT01364051|DRUG|Cediranib Maleate|Given PO
223809744|NCT01364051|OTHER|Laboratory Biomarker Analysis|Correlative studies
223809745|NCT01364051|OTHER|Pharmacological Study|Correlative studies
223809746|NCT01364051|DRUG|Selumetinib|Given PO
223809747|NCT01364051|DRUG|Selumetinib Sulfate|Given PO
223809748|NCT06304389|OTHER|electroencephalography, electrocardiogram, pupillometry, evoked potentials, light administration|Recording of the electrical activity of the brain, of the heart. Pupil size will be analyzed. The effect of blue light administration will be assessed on those parameters.
223809749|NCT06304389|OTHER|transcutaneous vagus nerve stimulation, electroencephalography, pupillometry, electrocardiogram, light administration|Transcutaneous vagus nerve stimulation will be performed in helathy subjects, as well as the recording of the electrical activity of the brain, and of the heart. Pupil size will be analyzed. The effect of blue light administration will be assessed on those parameters.
223809750|NCT01861314|DRUG|Bortezomib|Given SC
223809751|NCT01861314|DRUG|Decitabine|Given IV
223809752|NCT01861314|OTHER|Laboratory Biomarker Analysis|Correlative studies
223809753|NCT01861314|OTHER|Pharmacological Study|Correlative studies
223809754|NCT01861314|DRUG|Sorafenib Tosylate|Given PO
223809755|NCT05297448|DRUG|Rifaximin SSD|Rifaximin Solid Soluble Dispersion Immediate Release Twice Daily
223809756|NCT05297448|DRUG|Placebo|Placebo Twice Daily
223809757|NCT06644560|BEHAVIORAL|Prehabilitation Intervention|The intervention involves a 3-week prehabilitation program during the participant's preoperative window before cancer surgery. During the intervention, patients will be asked to consume 60 grams of walnuts daily, participate in two 60-minute individualized supervised physical activity training sessions per week, meet with a nutritionist for a 30-60 minute session, and conduct 30 minutes of independent walking per day. The participants will be given pre-portioned walnuts for daily consumption, a pedometer, and educational materials. The participants will track their completion of tasks with a daily log and the study coordinator will also track their attendance at scheduled nutrition and fitness sessions. In addition, the study coordinator will check-in with participants twice weekly and send text reminders about their required activities.
223809758|NCT05572944|OTHER|LDCT lung cancer screen, immediately|"Participants will receive the following things in sequence~1. Non-smoker lung cancer prediction model among Taiwanese population by questionnaire~2. Check autoantibodies against p53, NY-ESO-1, CAGE, GBU4-5, HuD, MAGE A4 and SOX2 in the blood of recruited patients and detect 133 SNPs and 11 mitochondrial mutations which are highly correlated with never-smoking lung cancer in our preliminary data~3. Check total bilirubin, urinary heavy metals, serum tumor marker, including CEA, alpha-fetal protein, etc.~4. Check pulmonary function test and chest X ray~5. Arrenge chest CT right away, and detection, classification, prediction of lung cancer risk in CT using deep learning and radiomics~6. Optimization and validation of lung cancer risk and probability prediction model: prospective multicenter clinical study."
223809759|NCT05572944|OTHER|LDCT lung cancer screen, later|"Participants will receive the following things in sequence~1. Non-smoker lung cancer prediction model among Taiwanese population by questionnaire~2. Check autoantibodies against p53, NY-ESO-1, CAGE, GBU4-5, HuD, MAGE A4 and SOX2 in the blood of recruited patients and detect 133 SNPs and 11 mitochondrial mutations which are highly correlated with never-smoking lung cancer in our preliminary data~3. Check total bilirubin, urinary heavy metals, serum tumor marker, including CEA, alpha-fetal protein, etc.~4. Check pulmonary function test.~5. Arrange AI-asisted chest X-ray right away.~6. Arrange chest CT three years later, and detection, classification, prediction of lung cancer risk in CT using deep learning and radiomics~7. Optimization and validation of lung cancer risk and probability prediction model: prospective multicenter clinical study."
223809760|NCT06517563|DRUG|VMX-C001|VMX-C001 is human factor X engineered to be insensitive to factor Xa DOACs
223809761|NCT06517563|DRUG|Rivaroxaban|FXa Inhibitor
223809762|NCT06517563|DRUG|UFH|Unfractionated Heparin
223809763|NCT06517563|DRUG|Enoxaparin|Low Molecular Weight Heparin
223809764|NCT05107960|DRUG|Azilsartan (TAK-536)|Azilsartan Tablets, Azilsartan Granules
223809765|NCT05370781|BEHAVIORAL|Peer Led Diabetes Self-Management Support|While the effectiveness of peer-led interventions delivering diabetes-related education and support for short-term clinical, psychosocial, and behavioral improvements is well-established, older Black men in particular are less likely to participate and are at a higher risk of drop-out from these studies. This intervention aims to determine if using older Black men as peer leaders to other older Black men will improve retention rates for this population.
223809766|NCT05370781|BEHAVIORAL|Diabetes Self-Management Education|Participants will attend 10 hours of virtual group diabetes self-management education classes led by a certified diabetes care and education specialist through the online HIPPA compliant Zoom platform.
223809767|NCT06262997|OTHER|Pilates|Pilates training will be given to groups of 3 people for 8 weeks, 2 days a week. Exercises will start with 10-12 repetitions and the number of repetitions will be increased to 20 starting from the 4th week. Before the Pilates training, basic principles such as breathing, concentration, focusing on the center, control, precision and fluid movement will be taught in a special session to inform individuals about the training principles and exercises. Each exercise will be demonstrated by the physiotherapist and cues such as tactile, verbal and imagery will be used to control the participants throughout the training. The difficulty level of Pilates training will be progressed by changing body positions, exercise ball and band use according to the performance of the patients and Pilates principles. The exercise program will start with warm-up exercises and end with 40 minutes of basic Pilates exercises followed by cooling exercises.
223809768|NCT06262997|OTHER|Pilates and Kinesiotape|Patients in the Pilates and Kinesiotape group will receive exactly the same Pilates training as in the Pilates group. At the end of each exercise session, Kinesio Tex Gold FP elastic tape (5 cm) will be applied with mechanical correction technique for postural correction and the tape will be renewed in each session. Waterproof, porous, adhesive, 0.5 mm thick tape will be applied to the upper trapezius.
223809769|NCT05585684|OTHER|Non-invasive Comprehensive Genomic Profiling for Cancer Treatment Selection|Use of liquid biopsy to evaluate the clinical utility of non-invasive comprehensive genomic profiling for cancer treatment selection.
223809770|NCT04417595|DRUG|Fish Oil (Containing Omega-3 Acids)|Fish Oil Supplement
223809771|NCT04417595|DRUG|Olive Oil|Olive Oil Supplement
223809772|NCT06199934|BIOLOGICAL|Vaccination|BNT162b2 vaccination
223809773|NCT03182075|BEHAVIORAL|Computerized Training|OCD and hoarding disorder participants will receive 14 sessions of training via computer within 3 weeks.
223809774|NCT04270747|DRUG|ABP 938|Subject will receive ABP 938 2 mg (0.05 mL) IVT injection every 4 weeks for the first 3 doses, followed by once every 8 weeks
223809775|NCT04270747|DRUG|Aflibercept|Subject will receive aflibercept 2 mg (0.05 mL) IVT injection every 4 weeks for the first 3 doses, followed by once every 8 weeks
223809776|NCT06239519|BEHAVIORAL|Usual Practice + JoyPop|Participants will be asked to use the app at least twice daily but will otherwise not be provided with requirements related to feature or total usage.
223809777|NCT04862676|DRUG|Hyperbaric oxygen|The treatment consists of exposure to hyperbaric oxygen at 2.5 atmospheric absolutes (ATA) for a total of 90 minutes after compression to 2.5 atmosphere absolutes (ATA) in a monoplace hyperbaric chamber breathing 100% oxygen. The subjects will be in the chamber for a total of 120 minutes as approximately 10-15 minutes are spent during the compression and decompression phases and subjects have 5-10 minute room air breaks every 30 minutes of hyperbaric oxygen treatment.
223809778|NCT06771388|DIETARY_SUPPLEMENT|Liposomal collagen drink|consume 50 g liquid drink daily for 8 consecutive weeks
223809779|NCT06771388|DIETARY_SUPPLEMENT|Non-liposomal collagen drink|consume 50 g liquid drink daily for 8 consecutive weeks
223809780|NCT06771388|DIETARY_SUPPLEMENT|Placebo drink|consume 50 g liquid drink daily for 8 consecutive weeks
223809781|NCT03672539|DRUG|Gemtuzumab Ozogamicin|Given IV
223809782|NCT03672539|DRUG|Liposome-encapsulated Daunorubicin-Cytarabine|Given IV
223809783|NCT03672539|OTHER|Quality-of-Life Assessment|Ancillary studies
223809784|NCT06289192|BEHAVIORAL|C-Raven Virtual Tobacco Cessation Counseling|A two-module tobacco cessation intervention that involves interaction with a virtual counselor and includes instruction about addiction and the use of pharmacotherapy for cessation. Each module takes approximately 20 minutes to complete.
223809785|NCT06289192|DRUG|Nicotine Replacement Product|Participants will be offered a 12-week supply of nicotine patches and either nicotine gum or lozenges.
223809786|NCT06289192|OTHER|Community Health Worker|A community health worker will meet with each participant throughout the study period to teach appropriate NRT usage, discuss barriers/facilitators to NRT use and cessation, conduct shared decision-making about lung cancer screening, and provide health system navigation when needed.
223809787|NCT06289192|OTHER|Lung Cancer Screening|Eligible participants will be referred to their primary care physician or existing specialist to complete lung cancer screening.
223809788|NCT06636565|OTHER|No intervention|No intervention
223809789|NCT06207630|DEVICE|Dressing Device|Use of a dress at the end of surgery in the operating room, making sure not to stick it on the openings of the chest drains.
223809790|NCT04578678|OTHER|Steering|Fine tuning of the STN-DBS settings
223809791|NCT06796764|DEVICE|the COMBO Endoscopy Oropharyngeal Airway Group|Using the COMBO Endoscopy Oropharyngeal Airway for oxygenation.
223809792|NCT06796764|DEVICE|Regular Nasal Cannula|Using regular nasal cannula for oxygenation.
223809793|NCT04138277|DRUG|AT2221|Participants received ATB200 co-administered with AT2221 (Miglustat)
223809794|NCT04138277|BIOLOGICAL|ATB200|Enzyme Replacement Therapy via intravenous infusion
223809795|NCT03459287|DEVICE|INTERCEPT|Pathogen reduced RBCs
223809796|NCT03459287|DEVICE|Control|Conventional RBCs
223809797|NCT04189354|DEVICE|Transcranial direct current stimulation (t-DCS) device|t-DCS is a brain electrostimulation technique that consists of applying a current of low intensity (between 1 and 2 mA) on the scalp via two electrodes, in order to modify the cerebral activity of the stimulated zones. The investigators use the Soterix Medical t-DCS devices of the mini-CT 1x1 type.
223809798|NCT02417584|DEVICE|positive airway pressure (PAP)|Positive Airway Pressure (PAP) is a non-invasive machine providing air pressure f to prevent the collapse of the oropharyngeal walls and the obstruction of airflow during sleep, which occurs in obstructive sleep apnea hypopnea syndrome.
223809799|NCT01784068|DRUG|Nilotinib followed by treatment-free|Nilotinib is being used as commercial available capsules (except in Japan where clinical supplies is used) of 150 mg and 200 mg strength. Treatment occurs during consolidation, continuation, prolonged continuation, re-initiation and re-initiation-2 phases of the study.
223809800|NCT04685590|DRUG|Dasatinib + Quercetin|D+Q will be administered once daily (1st dose of each cycle will be given, supervised, at the clinic visit; the 2nd dose will be taken at home) for 2 consecutive days followed by a 13-day (+/- 2 day) no-drug period for 12 consecutive weeks for 6 rounds of administration.
223809801|NCT04685590|OTHER|Placebo Capsules|Matching placebo capsules following the same administration protocol as the experimental treatment - administered once daily (1st dose of each cycle will be given, supervised, at the clinic visit; the 2nd dose will be taken at home) for 2 consecutive days followed by a 13-day (+/- 2 day) no-drug period for 12 consecutive weeks for 6 rounds of administration.
223809802|NCT03178552|DRUG|Alectinib|Participants will receive 600 mg BID (Cohort A); 900, 1200, or 750 mg BID (Cohort B) or RP2D BID; orally until disease progression, unacceptable toxicity, withdrawal of consent or death.
223809803|NCT03178552|DRUG|Atezolizumab|Participants will receive atezolizumab 1200 mg IV infusion Q21D (Cohorts C and F) or 1680 mg IV infusion Q4W starting on Day 29 (Cohort E).
223809804|NCT03178552|DRUG|Pemetrexed|Participants will receive pemetrexed 500 mg/m\^2 IV infusion on Day 1 Q21D.
223809805|NCT03178552|DRUG|Cisplatin|Participants will receive cisplatin 75 mg/m\^2 IV on Day 1 Q21D.
223809806|NCT03178552|DRUG|Carboplatin|Participants will receive carboplatin of AUC 5 or 6 IV on Day 1 Q21D.
223809807|NCT03178552|DRUG|Gemcitabine|Participants will receive gemcitabine 1000 or 1250 mg/m\^2 on Days 1 and 8 of every cycle (1 Cycle=21 days).
223809808|NCT03178552|DRUG|Entrectinib|Participants will receive entrectinib 600 mg orally QD.
223809809|NCT03178552|DRUG|Cobimetinib|Participants will receive 60 mg PO QD on Days 1-21 of the initial run-in and triple-combination periods.
223809810|NCT03178552|DRUG|Vemurafenib|Participants will receive 960 mg PO BID on Days 1-21 of the initial run-in period, and 720 mg PO BID on Days 22-28 of the initial run-in period and on Days 1-28 of each cycle during the triple-combination period.
223809811|NCT03178552|DRUG|Bevacizumab|Participants will receive 15 mg/kg of IV bevacizumab on Day 1 of each 21-day cycle during the induction and maintenance periods.
223809812|NCT03178552|DRUG|Divarasib|Participants will receive divarasib PO QD until disease progression or unacceptable toxicity.
223809813|NCT03178552|DRUG|Docetaxel|Participants will receive IV docetaxel Q3W (75 mg/m\^2) until disease progression or unacceptable toxicity
223809814|NCT06079203|BEHAVIORAL|Emergency Care Redesign (ECR)|"Care Process Redesign: Care process redesign with a shared structured worksheet for data gathering, standardized assessment and referral. Education of all providers (Physician, Nurse, and Social Work Champion) on new processes at huddles and via on-line training, smart phone-compatible animated videos, faculty meetings, e-mail and from ED champions on shift~CDS System: Alerts and new workflow to refer the dyad to social work or care manager. Continued use throughout study period and beyond~Follow up: Within 72 hours of ED visit if discharged home Social Work Champion will have a single phone call. Triadic telephone encounter to ensure understanding of discharge plan, medication management and connection to community services"
223809815|NCT06079203|BEHAVIORAL|Nurse-led Telephonic Care (NLTC)|Telephonic support for dyad for safe ED to home care transition, and to enhance knowledge and management of AD/ADRD and co-morbid conditions. First call to dyad within 72 hours of index ED visit from Registered nurses. Each call \~30 minutes depending on needs and willingness of dyad. Calls also occur at 14 days, and at least monthly thereafter for 6 months. Dyad or nurse can initiate additional as-needed calls and coordinate care and care needs with other providers
223809816|NCT06079203|BEHAVIORAL|Community Paramedic-led Transitions Intervention (CPTI)|Community paramedics to provide coaching with dyad to improve medication management, outpatient follow up, understanding of red flags necessitating medical care. Home visit within \~5 days of index ED visit. One home visit and three telephone encounters over 30 days
223809817|NCT02974725|DRUG|LXH254|LXH254 will be supplied as tablet for oral use.
223809818|NCT02974725|DRUG|LTT462|LTT462 will be supplied as hard gelatin capsule for oral use.
223809819|NCT02974725|DRUG|Trametinib|Trametinib will be supplied as film-coated tablet for oral use
223809820|NCT02974725|DRUG|Ribociclib|Ribociclib will be supplied in tablets and hard gelatin capsules.
223809821|NCT00520390|DRUG|EZN-2208|
223809822|NCT05845814|BIOLOGICAL|Coformulated favezelimab/pembrolizumab|Coformulated favezelimab/pembrolizumab (800 mg/200 mg) IV infusion
223809823|NCT05845814|BIOLOGICAL|Coformulated vibostolimab/pembrolizumab|Coformulated vibostolimab/pembrolizumab (200 mg/200 mg) IV infusion
223809824|NCT05845814|COMBINATION_PRODUCT|EV|1.25 mg/kg IV infusion
223809825|NCT05845814|BIOLOGICAL|Pembrolizumab|200 mg IV infusion
223809826|NCT00743561|DEVICE|Polysomnography|Simultaneous recording of electro-encephalography, tibial and submental electro-myography, electro-oculography, nasal air flow, oxygen saturation, as well as the thoracic and abdominal respiratory effort
223809827|NCT00743561|DEVICE|ambulatory polygraphy|Simultaneous recording of nasal air flow, oxygen saturation, as well as the abdominal and thoracic respiratory effort.
223809828|NCT04108052|RADIATION|Low CT scanner without injection dose|CT scan acquisition will be performed at 140 kVp (kilovolt peak), 10 mAs(milliampere), CTDI 1.3 mGy with an irradiation dose 0.51 mSv (milliSievert). The CT image will be reconstructed and analyzed in parenchyma window. The CT images will be blinded and re-read by two independent senior radiologists 3 to 6 weeks apart between each re-reading.
223809829|NCT04108052|RADIATION|Ultra-low dose CT scanner without injection|CT acquisition will be performed at 80 kVp for patient with a body mass index\<30, and 100 kVp with a body mass index\>30, 10 mAs, CTDI 0.3 and 0.6 mGy with an irradiation dose 0.15-0.30 mSv. The CT images will be reconstructed and analyzed in mediastinal window. The CT images will be blinded and re-read by two independent senior radiologists 3 to 6 weeks apart between each re-reading.
223809830|NCT05133050|DRUG|Ramipril|We use ACEI: ramipril, in this prospective, randomized, controlled and multicenter clinical trial to access the safety and efficacy in Alport syndrome patients carried COL4A3/COL4A4/COL4A5 variants.
223809831|NCT01908465|DRUG|Ebastine|
223809832|NCT01908465|DRUG|Placebo|
223809833|NCT00946296|DRUG|Potassium Iodide|8 drops of Potassium Iodide in a glass of water taken daily for 7 days prior to thyroidectomy. This is the current standard of care.
223809834|NCT06455371|OTHER|Decision support tool|Patients in the intervention groups are given the option to use the decision support tool when adjusting the levothyroxine dose after total thyroidectomy. Levothyroxine therapy is not a part of the intervention, as all patients receive this therapy regardless of study participation.
223809835|NCT04283448|BEHAVIORAL|Dietary Lentil|Participants in the Lentil arm of the study will consume midday meals containing 0.66 cups of lentils seven days per week for 12 weeks.
223809836|NCT04283448|BEHAVIORAL|Control|Participants in the Control arm of the study will consume midday meals containing 0.00 cups of lentils seven days per week for 12 weeks.
223809837|NCT03726788|DRUG|Botulinum Toxin Type A 100U|one intra-articular injection of 100 U of botulinum toxin type A, diluted in 2 ml of 0.9% SSI
223809838|NCT03726788|DRUG|Botulinum Toxin Type A 200U|one intra-articular injection of 200 U of botulinum toxin type A, diluted in 4 ml of 0.9% SSI
223809839|NCT03726788|DRUG|Triamcinolone Hexacetonide Inj Susp 20 MG/ML|one intra-articular injection of 2 ml Triamcinolone Hexacetonide
223809840|NCT00344058|DRUG|abbreviation of magnesium sulfate therapy (12 hours versus the traditional 24 hours after delivery)|
223809841|NCT05902234|BEHAVIORAL|interdiciplinary treatment|Normal interdiciplinary treatment path
223809842|NCT05434858|OTHER|Dual-energy CT (DECT) and ultrasound|DECT and ultrasound will be performed to clarify the pathological mechanisms responsible for the transition from asymptomatic crystalline deposition to gout, and the mechanisms involved in the transition from hyperuricemia to de novo crystalline deposition.
223809843|NCT06571448|DRUG|SR750 tablet|SR750 high dose BID orally for 6 weeks
223809844|NCT06571448|DRUG|SR750 tablet|SR750 low dose BID orally for 6 weeks
223809845|NCT06571448|DRUG|Placebo|Placebo
223809846|NCT06100419|PROCEDURE|serratus posterior superior intercostal plane block|With this newly introduced procedure added to the literature, patients undergoing breast surgeries are expected to experience reduced pain.
223809847|NCT05535049|PROCEDURE|Non-surgical periodontal treatment|Full month non-surgical periodontal treatment procedure was applied to the periodontitis group.
223809848|NCT05810493|OTHER|Observation|Follow-up of disease, therapeutics and evolution
223809849|NCT00209924|DRUG|Gaboxadol|
223809850|NCT01864239|OTHER|Medicines Advice Service|"The intervention consists of:~1. Telephone consultations with a pharmacist~2. Follow-up tailored written information~3. A medicine reminder chart"
223809851|NCT02137525|DRUG|Morphine 6 mg|Intravenous infusion - delivering morphine 6 mg
223809852|NCT02137525|DRUG|Fentanyl 100 µg|Fentanyl sublingual spray - single unit delivering 100 µg fentanyl
223809853|NCT02137525|DRUG|Fentanyl 200 µg|Fentanyl sublingual spray - single unit delivering 200 µg fentanyl
223809854|NCT02137525|DRUG|Fentanyl 400 µg|Fentanyl sublingual spray - single unit delivering 400 µg fentanyl
223809855|NCT02137525|DRUG|Placebo Sublingual Spray|Matching sublingual spray - single unit delivering 0 µg fentanyl
223809856|NCT02137525|DRUG|Intravenous Placebo|Matching intravenous infusion - delivering 0 mg morphine
223809857|NCT01704469|PROCEDURE|The local anesthetic injection|
223809858|NCT06190795|OTHER|AMPLIFY Smartphone Application|AMPLIFY Smartphone Application enables prescription and progression of exercises/functional activities, while offering immediate feedback on upper limb movement performed, real-time logging and monitoring of adherence through virtual platform
223809859|NCT06190795|OTHER|Hardcopy Manual|Hardcopy Manual
223809860|NCT06432686|DEVICE|Transcutaneous Electrical Nerve Stimulation|Transcutaneous electrical nerve stimulation (TENS) is a safe, relatively cheap, and non-painful stimulation of the peripheral sensory and motor nerves. The stimulator is easy to operate and pwMS can apply the stimulation themselves at home. This makes TENS an interesting tool to augment sensory input. A high frequency and long pulse duration is used.
223809861|NCT06432686|BEHAVIORAL|Movement|Participants are instructed to perform plantar- and dorsi-flexion contraction in a relatively slow tempo. The movement of the ankle is measured by an MRI-compatible potentiometer and participants receive feedback of this movement on the screen inside the scanner.
223809862|NCT05038930|DEVICE|Mobilisation using the Sara Combilizer|The mobilisation with the Sara Combilizer, will be done one time either 24 or 48 hours after stable intracranial pressure
223809863|NCT04273542|OTHER|liquid biopsy|Blood sample collection during follow-up of the three cohorts of patients
223809864|NCT05861674|BIOLOGICAL|HH-003(20mg/kg)|20 mg/kg Q2W intravenously for 48 weeks
223809865|NCT05861674|BIOLOGICAL|HH-003(10mg/kg)|10 mg/kg Q2W intravenously for 48 weeks
223809866|NCT05861674|DRUG|TAF|TAF 25 mg QD orally during 48-week treatment period and 24-week follow-up period
223809867|NCT05995821|OTHER|Collection of biological specimens|Collection of tumor, blood, lymph nodes, white blood cells, mouth cells (buccal smears) scraped from the inside of your cheek, urine, saliva, or other tissue samples.
223809868|NCT03652259|GENETIC|SRP-9003|SRP-9003 will be administered through a single systemic injection.
223809869|NCT01849263|DRUG|Ibrutinib|Given PO
223809870|NCT01849263|OTHER|Laboratory Biomarker Analysis|Correlative studies
223809871|NCT05721235|DRUG|Serdexmethylphenidate (SDX) and dexmethylphenidate (d-MPH)|Serdexmethylphenidate (SDX) and dexmethylphenidate (d-MPH)
223809872|NCT00038051|DRUG|Hum-195/rGel|Starting Dose = 3 mg/m\^2 twice weekly for 2 weeks.
223809873|NCT00473070|DRUG|Tobradex AF|
223809874|NCT03873948|OTHER|Evaluation of arginine serum level|correlation of serum arginine level with periodontal and cardiovascular disease
223809875|NCT04547608|OTHER|The difference of the timing of rocuronium administration after propofol injection|The difference of the timing was rocuronium was administered immediately after propofol injection or when BIS score became below 60 after propofol administration.
223809876|NCT05000567|OTHER|12 week nordic hamstring exercise program|12 weeks progressive eccentric strength training program targetting the hamstring muscles.
223809877|NCT02469948|DRUG|Botulinum toxin type A|To inject Botulinum toxin type A on the spasticity lower extremity for stroke patients by Ultrasonography direct-guidance, Electric stimulation and Surface anatomy landmark.
223809878|NCT06542536|DRUG|Monlunabant|Oral monlunabant
223809879|NCT06542536|DRUG|Placebo (monlunabant)|Oral placebo (monlunabant)
223809880|NCT01295450|DRUG|Apevinat BC|"Apevinat BC presents in its formula the cyproheptadine hydrochloride (0,800 mg), tiamin hydrochloride(0,120 mg), Riboflavin sodium phosphate (0,200 mg), nicotinamide (1,334 mg, piridoxin hydrochloride (0,134 mg), ascorbic acid (4,334 mg).~Administer the recommended dosage for children 7 to 14, preferably one hour before meals: 5 ml three times daily."
223809881|NCT01295450|DRUG|Vitamin Complex|A vitamin complex contains: B1, B2, B3, B3 and C vitamins. Administer the recommended dosage preferably one hour before meals: 5 ml three times daily.
223809882|NCT01292551|DRUG|Bosentan|tablets Bosentan 62,5 mg x 2 daily for two weeks, then 125 mg x 2 daily for 12 weeks
223809883|NCT01292551|DRUG|Placebo|Placebo tablets 2 x daily for 2 weeks, then change to different placebo tablets to match Bosentan group, 2 x daily for 12 weeks
223809884|NCT06579131|BEHAVIORAL|sitting position|The participants' seating positions will be assessed, and evaluations will be made based on this.
223809885|NCT06580431|OTHER|Saliva and serum sampling|Saliva were collected to analyze the selected markers as unstimulated samples during the early hours of the day. The saliva was centrifuged and then transferred into Eppendorf tubes. Venous puncture was performed after saliva collection and 10 mL of blood samples were collected by qualified staff from each participant. Saliva and serum were then stored at -80 °C until analysis.
223809886|NCT06144866|DRUG|Dabigatran, rivaroxaban, apixaban, edoxaban|For patients who received direct oral anticoagulants (DOAC) before ischemic stroke or intracranial hemorrhage, the DOAC level upon hospital arrival will be measured.
223809887|NCT06579898|OTHER|Progressive resistance exercise training|A 24-week progressive strength training programme (PRET). Divided into 4 mesocycles in which the intensity of training is built up from 60% 1RM- 80% 1RM. Training is carried out twice a week under the guidance of a physiotherapist or exercise instructor.
223809888|NCT01229631|DIETARY_SUPPLEMENT|Juice plus+|Subjects in active group will be supplemented with Juice plus+ capsules (3 in the morning and 3 in the evening, for 3 months)
223809889|NCT01229631|DIETARY_SUPPLEMENT|Placebo non active capsules|Subjects will take non-active placebo capsules (3 in the morning and 3 in the evening, for 3 months)
223809890|NCT01722942|PROCEDURE|ICD implantation|ventricular ICD implantation
223809891|NCT01722942|DRUG|amiodarone hydrochloride|amiodarone prescription
223809892|NCT02803554|OTHER|Plasma|Blood plasma from donors aged 25 years or younger
223809893|NCT02615964|RADIATION|Nova Flow Procedure|Evaluation of the diagnosis, and stratification of the severity of Raynaud's disorder in patients with scleroderma based on clinical and imaging data will allow creation of more precise diagnostic criteria as well as disease classification which may guide treatment practices. The study results will likely have no immediate benefit to the patients participating in the study, however may have a future impact diagnosis, stratification and ultimately treatment of patients with Raynaud's disorder. In addition, data collected in this study may provide insight into disease process and leading to future research endeavors.
223809894|NCT00986076|DRUG|Enoxaparin|Enoxaparin 40 mg / 500 ml in Balanced Salt Solution
224264533|NCT06319625|DRUG|Lidocaine hydrochloride|Based on the invention above, the patients in the observation group were provided with Stellate ganglion block , using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate ganglion block . The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
224264534|NCT06319625|PROCEDURE|Placebo injection|1 milliliter of normal saline will be used for injection. The percutaneous approach via the paratracheal route was used for Stellate ganglion block . The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
224264535|NCT06102850|BEHAVIORAL|Critical Time Intervention for Young Adults with Mental Health conditions|SIx month supportive intervention involving CTI phased based casemanagement, support from a peer support specialist, and support from a mental health liaison
224264536|NCT00205686|DRUG|DHEA|
224264537|NCT00205686|BEHAVIORAL|exercise|
224264538|NCT04890418|DRUG|Ketalar, 5 mg/mL Injectable Solution|The patients will receive (slow intravenous injection) 0.3 mg/kg intravenous ketamine diluted by the pharmacy department into 10mL saline after the realization of PNB but before tourniquet set up and before start of surgery.
224264539|NCT04890418|OTHER|Placebo|The patients will receive 10 mL of 0.9% saline. This injection is also performed after the realization of PNB but before tourniquet set up and before start of surgery.
223809895|NCT00986076|DRUG|Balanced Salt Solution|Intraocular infusion of Balanced Salt solution
223809896|NCT02578979|DEVICE|Electrocardiogram|Patients will receive electrocardiogram for detecting atrial fibrillation - a 5-day routine ECG.
223809897|NCT02578979|DEVICE|Holter|Patients will receive electrocardiogram for detecting atrial fibrillation - a 24-h Holter.
223809898|NCT01276925|DRUG|Ropivacaine|7,5 mg/ml. 10 ml for the femoral nerve, 10 ml for the anterior division of the obturator nerve, 5 ml for the lateral femoral cutaneous nerve.
223809899|NCT01276925|DRUG|Ropivacaine|7,5 mg/ml. 10 ml for the anterior division of the obturator nerve, 5 ml for the lateral femoral cutaneous nerve.
223809900|NCT01276925|DEVICE|Ultrasound|All nerve blockades will be performed with ultrasound guidance.
223809901|NCT01276925|PROCEDURE|Peripheral nerve blockade|All patients will receive injections around the three nerves before surgery.
223809902|NCT01276925|DRUG|Saline|Isotonic. 10 ml for the femoral nerve.
223809903|NCT01276925|PROCEDURE|Total hip arthroplasty|All patients undergoes total hip arthroplasty.
223809904|NCT01276925|DRUG|Bupivacaine|5 mg/ml. 3 ml for spinal anaesthesia.
223809905|NCT02428465|BEHAVIORAL|Purposeful Parenting|Purposeful Parenting reinforces responsive interactions that help promote emerging developmental skills. This information is presented over the course of a child's first 12 months, such that core lessons are the same but specific skills are designed to be developmentally appropriate. This repetitiveness, along with the provision of age-appropriate behavioral guidance, will allow parents to successfully engage in responsive interactions with their children.
223809906|NCT03189784|OTHER|mobilization with movement techniques|patient will receive an anteroposterior stimuli in the talus in order to restore the range of motion
223809907|NCT05741957|BEHAVIORAL|Once-a-week Exercise|Participants in this group will participate in a supervised treadmill exercise program delivered by certified fitness instructors. The prescribed program will involve one session weekly for 4 months, and the duration of vigorous-intensity treadmill exercise per session will be 75 min. Participants will exercise with an exercising heart rate at 6-7 metabolic equivalents (METs). Health information provided to the usual care control group will be made available to the participants in this group.
223809908|NCT05741957|BEHAVIORAL|Thrice-a-week Exercise|Participants in this group will participate in a supervised treadmill exercise program delivered by certified fitness instructors. The prescribed program will involve three sessions weekly for 4 months, and the duration of vigorous-intensity treadmill exercise per session will be 25 min. Participants will exercise with an exercising heart rate at 6-7 METs. Health information provided to the usual care control group will be made available to the participants in this group.
223809909|NCT05741957|OTHER|Usual Care Control|Participants in this group will receive health education delivered by research personnel. This program will consist of eight two-hour bi-weekly sessions covering major health issues relating to general health and NAFLD, such as non-communicable diseases, infectious diseases, and a healthy lifestyle.
223809910|NCT01353781|DRUG|AZD5363|Patients will be given AZD5363 capsules administered orally as a single dose, and then multiple twice-daily dosing following 3 to 7 days washout.
224264540|NCT02627235|BEHAVIORAL|DIAL|The physical activity intervention is based on Social Cognitive Theory and includes feedback on physical activity progress via IVR system and monthly graphic-based feedback letters delivered in the mail. Messages will encourage incremental increases until national PA guidelines are reached and provide specific information on cancer risk reduction.
224264541|NCT02627235|BEHAVIORAL|Wait List Control|Access to DIAL intervention 12 weeks following baseline assessment.
224264542|NCT00151489|DRUG|pregabalin|
224264543|NCT00151489|DRUG|placebo|
224264544|NCT00680277|DIETARY_SUPPLEMENT|spirulina ß-carotene|an acute dose of spirulina up to 5 g
224264545|NCT00680277|DIETARY_SUPPLEMENT|spirulina ß-carotene|vitamin A value of spirulina ß-carotene
224264546|NCT02463981|DEVICE|real-time fMRI neurofeedback training running on Turbo Brain voyager (TBV) 3.2 (Brain Innovation, Maastricht, The Netherlands)|
224264547|NCT04296994|BIOLOGICAL|QL1706|QL1706（PSB205） is a bi-functional product that has been engineered to contain two unique monoclonal antibodies.
224264548|NCT00568672|DRUG|Olanzapine|Olanzapine 5 mg / day for 6 months
224264549|NCT06056414|OTHER|Energy Resonance by Cutaneous Stimulation|Energy Resonance by Cutaneous Stimulation session
224264550|NCT05748535|DEVICE|Auricular Vagus Nerve Stimulation|First of all, the application will be explained to the participants and a signed consent form for the application will be obtained from the individuals. Groups; It will be in the form of Right Ear Stimulation, Left Ear Stimulation and Bilateral Ear Stimulation group. Non-invasive auricular vagus nerve stimulation will be applied to all participants with a VAGUSTIM device, biphasic, frequency 10 Hz, pulse width 300 μs in Modulation mode, and current intensity for 20 minutes for 10 sessions, keeping the current constant at the point where the participant feels the current comfortably. Before and after each application, pulse variability (rmssd, LF/HF, pNN50, LF, HF) and blood pressure measurements will be taken from both the right index finger and left index finger. Before the first session and after the 10th session, pain level will be evaluated with the Numerical Pain Rating Scale, and disability level related to headache will be evaluated with the Headache Impact Test.
224264551|NCT02355418|PROCEDURE|Mitral valve repair|Standard mitral valve repair surgery
224264552|NCT00883233|DRUG|Adapalene BPO Gel standard daily overnight application|Adapalene 0.1% /Benzoyl Peroxide 2.5% Gel standard daily overnight application for 12 week
224264553|NCT00883233|DRUG|Adapalene-BPO 3-hour daily application before bedtime|Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel 3-hour daily application before bedtime for first 4 weeks and then standard overnight daily application for the following 8 weeks
224264554|NCT00883233|DRUG|Adapalene-BPO Gel every other day application|Adapalene 0.1% /Benzoyl Peroxide 2.5% Gel every other day application for the first 4 weeks and then standard overnight daily application for the following 8 weeks
224264555|NCT00883233|DRUG|Adapalene-BPO Gel standard+Cetaphil® Moisturizing Lotion|Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel standard daily overnight application with Cetaphil® Moisturizing Lotion application at wake-up time for the first 4 weeks and then standard daily overnight application for the following 8 weeks
223809911|NCT05947929|OTHER|Aerobic excise|the treadmill exercises three times a week for 12 weeks) based on the Following protocol: Intensity exercise: determined by karvonen formula: Exercise heart rate = \[(A-B) × desired intensity\] + B \[A represents maximum heart rate (220-age) and B for resting heart rate (average of three measurements)\]. The desired intensity will be at 50- 70%. Heart rate was measured by pulse-meter to detect pulse rate before exercise (Resting HR)\].
223809912|NCT05947929|OTHER|acupuncture|the acupuncture needles will be inserted through the adhesive pads. The acupuncture needles used in the study are 40 mm in length and 0.30 mm in diameter and manufactured by Suzhou Hwato Medical Instruments Co. Ltd (Suzhou, China). The following acupoints will be used: DU20 (Baihui), ST36 (Zusanli), ST37 (Shangjuxu), SP6 (Sanyinjiao), ST25 (Tianshu), and LR3 (Taichong).
223809913|NCT02701894|DIETARY_SUPPLEMENT|Alpha-Linolenic Acid|Meta-Analysis of Randomized Controlled Trials
223809914|NCT05773118|DEVICE|orthokeratology lens|Subjects will wear orthokeratology lens at night. Axial length elongation over a period of 12-month will be recorded.
223809915|NCT05773118|DEVICE|multifocal soft contact lens|Subjects will wear multifocal soft contact lens during the day time. Axial length elongation over a period of 12-month will be recorded.
223809916|NCT05773118|DEVICE|Single vision spectacles|Subjects will wear single vision spectacles during the day. Axial length elongation over a period of 12-month will be recorded.
223809917|NCT01303081|BEHAVIORAL|Individual Rewards|If participants quit smoking by their target quit date, and that is confirmed by cotinine/anabasine tests, they will receive a monetary award from the study investigators.
223809918|NCT01303081|BEHAVIORAL|Fixed Deposits|Participants will have to deposit a certain monetary amount of their own money as an incentive to quit smoking. If they quit smoking by their target quit date, and that is confirmed by cotinine/anabasine tests, participants will receive their deposit back. If participants do not quit, their money will be used to support future research studies designed to help people stop smoking.
223809919|NCT01303081|BEHAVIORAL|Chosen Deposits|Participants will choose their deposit amount (XX = chosen deposit); this same amount will be returned upon success (that is, quit smoking by the target quit date, and having this confirmed by cotinine/anabasine tests). If participants do not quit, their money will be used to support future research studies designed to help people stop smoking. The default deposit will be set to a certain monetary amount for consistency with other arms, and participants can increase or decrease this amount until they reach the amount they want to deposit.
223809920|NCT01303081|BEHAVIORAL|Competitive Deposits (Pari-Mutuel)|"Groups (or cohorts) of 6 smokers each will be formed on a rolling basis, linking individuals with target quit dates (day 0's) near each other. Participants will deposit a certain monetary amount (Y) in an account, and the payout for quitting on this arm will be Y x 6/Q , where Q is the number of quits in the cohort. Again, success will be confirmed by cotinine or anabasine tests, and if participants do not quit, their money will be used to support future research studies designed to help people stop smoking."
223809921|NCT01303081|BEHAVIORAL|Usual Care|Participants will receive reimbursements for completing the surveys that are part of the Way To Quit program and for submitting saliva or urine samples at 14 days and 3 months (among those eligible).
223809922|NCT03687801|BEHAVIORAL|Online hearing support|The intervention group will follow an online hearing support for five weeks
223809923|NCT03687801|BEHAVIORAL|Standard care|The control group will follow standard care during the time the intervention group receives online haring support
223809924|NCT06435104|OTHER|neoadjuvant chemotherapy|The neoadjuvant chemotherapy plan will be selected according to the recommendations of the NCCN guidelines and the Chinese CSCO guidelines for early breast cancer.The neoadjuvant chemotherapy plans include:AC-T(HP),TCb(HP),AC-TCb, in which A represents anthracycline, C represents cyclophosphamide, T represents taxane, Cb represents carboplatin, H represents trastuzumab, and P represents pertuzumab.
223809925|NCT06435104|OTHER|aromatherapy|Patients will inhale essential oils during the neoadjuvant chemotherapy courses.
223809926|NCT04430751|BEHAVIORAL|Medical QiGong training|"The study intervention consisted of a 12-week training program that introduced students to a progressive series of 10 QiGong forms that are designed to build upon each other to restore balance and function and to enhance well-being. These forms involve both physical movement and visualization."
223809927|NCT05385120|PROCEDURE|Temporary Portocaval Shunt|In Temorary Portocaval Shunt Group (TPCS group), Hilar dissection( division of Hepatic artery, Bileduct) is followed by temporary portocaval shunt formation during recipient Hepatectomy.
223809928|NCT02432989|BEHAVIORAL|Exercise|Light-moderate exercise on a stationary bike and leisurely walks.
223809929|NCT00438880|DRUG|Agatolimod Sodium|Given IV
223809930|NCT00438880|RADIATION|Indium In-111 Ibritumomab Tiuxetan|Given IV
223809931|NCT00438880|OTHER|Laboratory Biomarker Analysis|Correlative study
223809932|NCT00438880|PROCEDURE|Radionuclide Imaging|Undergo imaging scans
223809933|NCT00438880|BIOLOGICAL|Rituximab|Given IV
223809934|NCT00438880|PROCEDURE|Single Photon Emission Computed Tomography|Undergo imaging scans
223809935|NCT00438880|RADIATION|Yttrium Y-90 Ibritumomab Tiuxetan|Given IV
223809936|NCT04461743|OTHER|No intervention|No intervention, regular therapy
223809937|NCT05582005|DEVICE|noninvasive blood pressure, 3 lead ECG, peripheral oxygen saturation|Children 3 year old and younger, scheduled for elective MRI, that are not intubated or require higher oxygen support and with no parents/guardians refusal will be placed on an electrocardiogram during post-anesthesia recovery. The NIPE monitor will be connected to the patients monitor in the PACU. Values will be recorded from the time of patient awaking until the patient meets the discharge criteria from PACU not before 1 hour.
223809938|NCT02068495|DRUG|Candesartan cilexetil/Amlodipine besilate|Candesartan cilexetil/Amlodipine besilate tablets
223809939|NCT05365243|DEVICE|AMMA Portalbe Scalp Cooling System|AMMA is indicated for use in chemotherapy infusion centers, during transit from the infusion center and at home and is intended for use by patients who are undergoing chemotherapy treatment and who want to reduce the likelihood of chemotherapy-induced alopecia.
223809940|NCT01032655|DRUG|susceptibility test guided sequential therapy|"susceptibility test driven sequential therapy D1- D7 Nexium ,40mg, bid Amolin, 1gm bid D8-14 Nexium ,, 40mg, bid Flagyl, 500mg, bid~plus either one of the following~1. Klaricid, 500 mg, bid~2. Cravit, 250 mg, bid~3. Tetracycline, 500 mg, bid"
223809941|NCT00736307|PROCEDURE|Cultured limbal stem cells Transplantation|Transplantation of cultivated limbal epithelium on amniotic membrane
223809942|NCT05547243|BIOLOGICAL|SARS-CoV-2 mRNA Vaccine, Bivalent Low dose|50μg/dose
223809943|NCT05547243|BIOLOGICAL|SARS-CoV-2 mRNA Vaccine, Bivalent High dose|100μg/dose
223809944|NCT05547243|DRUG|Placebo|Saline solution
223809945|NCT06252103|DRUG|Ferrous Gluconate 300 MG|iron salt one tab 300 mg contain 35 mg of elemental iron given 2 doses 600 mg per day
223809946|NCT06252103|DRUG|ferrous gluconate with lactoferrin|Lactoferrin is a glycoprotein from the transferrin family consist of 691 amino acids,Lactoferrin is a protein found in cow milk and human milk
223809947|NCT05815654|DEVICE|Warm Palace Analgesic Point Sticker|The Warm Palace Analgesic Point Sticker is developed by Changchun University of Traditional Chinese Medicine
223809948|NCT02475252|PROCEDURE|hysteroscopy on a training model|Diagnostic hysteroscopy on a diagnostic hysteroscopy training model using a pelvic dummy and all surgical instruments also used in the original procedure. The performance of all participants will be scored using an OSATS scoring sheet developed for assessing surgical proficiency.
223809949|NCT03733405|BEHAVIORAL|Postpartum Visit at 6 Weeks|The patient will be scheduled for a routine postpartum visit at the standard time interval. Each postpartum visit will consist of the standard interview and physical examination. The purpose of this visit is for routine postpartum care. If she has a medical complication during delivery, she may be recommended to schedule an additional earlier visit.
223809950|NCT03733405|BEHAVIORAL|Postpartum Visit at 2 Weeks|The patient will be scheduled for an earlier postpartum visit in addition to the standard time interval. Each postpartum visit will consist of the standard interview and physical examination. The purpose of this visit is for routine postpartum care. If she has a medical complication during delivery, she may be recommended to schedule an additional earlier visit.
223809951|NCT04663451|RADIATION|radioacive iodine therapy|Hyperthyroid patients who have undergone radioactive iodine treatment to cure them from their hyperthyroidism.
223809952|NCT03819140|DRUG|Yasmin|Participants in each treatment arm will receive the medication Yasmin. However only the Cyclical OCP Therapy arm will take the sugar pills designated each month in the pill packs and the Continuous OCP Therapy arm will not.
223809953|NCT00929825|DEVICE|mechanical stimulation (Elastomers)|The instrument of mastication, sialogogue should be used 4 times a day for 10 minutes each time always after meals
223809954|NCT00929825|PROCEDURE|TENS|transcutaneous electrical stimulation
223809955|NCT01155752|DRUG|Pulmozyme single use ampule|• Each Pulmozyme single use ampule delivers 2.5 mL (2.5 mg) of the sterile solution to the nebulizer bowl. The aqueous solution contains 1.0 mg/mL dornase alfa, 0.15 mg/mL calcium chloride dihydrate, and 8.77 mg/mL sodium chloride.
223809956|NCT01155752|DRUG|placebo|identical placebo
223809957|NCT05311202|BEHAVIORAL|low-volume moderate-intensity group|The interventional program will include (1) 5 minutes of warm-up and aerobic exercise from light to moderate intensity; (2) 20 minutes of two sets of moderate intensity resistance exercise with 10 repetitions; (3) 5 minutes of cool down
223809958|NCT05311202|BEHAVIORAL|moderate-volume moderate-intensity group|The interventional program will include (1) 5 minutes of warm-up and aerobic exercise from light to moderate intensity; (2) 30 minutes of three sets of moderate intensity resistance exercise with 10 repetitions; (3) 5 minutes of cool down
223809959|NCT05311202|BEHAVIORAL|high-volume moderate-intensity group|The interventional program will include (1) 5 minutes of warm-up and aerobic exercise from light to moderate intensity; (2) 40 minutes of four sets of moderate intensity resistance exercise with 10 repetitions; (3) 5 minutes of cool down
223809960|NCT05311202|BEHAVIORAL|moderate-volume low-intensity group|The interventional program will include (1) 5 minutes of warm-up and aerobic exercise from light to moderate intensity; (2) 35 minutes of four sets of low intensity resistance exercise with 20 repetitions; (3) 5 minutes of cool down
223809961|NCT05311202|BEHAVIORAL|Control group|Reading a book related to cognitive function \& exercise for 40 minutes
223809962|NCT01038388|DRUG|Bortezomib|1.3mg/m² given IV or subcutaneously
223809963|NCT01038388|DRUG|Lenalidomide|25 mg given PO
223809964|NCT01038388|DRUG|Dexamethasone|20 mg given PO
223809965|NCT01038388|DRUG|Vorinostat|100, 200, or 300 mg given PO
223809966|NCT00136786|DRUG|Memantine|
223809967|NCT05794048|BIOLOGICAL|Hepatocellular carcinoma|Tumor and liver biopsy
223809968|NCT05794048|BIOLOGICAL|Pancreatic adenocarcinoma|Tumor and pancreatic biopsy
223809969|NCT05794048|BIOLOGICAL|Pancreatic neuroendocrine tumor|Tumor and pancreatic biopsy
223809970|NCT00041730|BIOLOGICAL|Id-KLH|
223809971|NCT00944047|DRUG|nab-paclitaxel|100 MG/M2 IV over 30 minutes once a week for 12 weeks
223809972|NCT00944047|DRUG|trastuzumab|4 MG loading dose followed by 2 MG/KG every week for a total of 12 weeks
223809973|NCT00944047|DRUG|Doxorubicin|60 MG/M2 every two weeks for a total of 4 cycles
223809974|NCT00944047|DRUG|cyclophosphamide|600 MG/M2 every 2 weeks for 4 cycles (administered with Doxorubicin above)
223809975|NCT00944047|BIOLOGICAL|Growth Factor Support|"* All patients will receive pegfilgrastim 6.0 mg sc on Day #2 of each doxorubicin/cyclophosphamide neoadjuvant treatment cycle.~* Erythropoetic growth factor support for fatigue/anemia will be allowed at the discretion of the treating physician."
223809976|NCT00944047|PROCEDURE|Surgery|"* After completion of neoadjuvant therapy, patients will proceed with either modified radical mastectomy or lumpectomy.~* All patients with pretreatment lymph node positive disease and positive sentinel lymph node will undergo complete axillary lymph node dissection."
223809977|NCT04069130|DRUG|400 mg of BIA 5-1058|1 x 400 mg capsule Oral, Fasted
223809978|NCT02415179|DRUG|Inhaled Mometasone/formoterol|Inhaled Mometasone/formoterol (100/5 microgram) 2 puffs twice daily via metered dose inhaler for 6 weeks
223809979|NCT02415179|DRUG|Inhaled Fluticasone/Salmeterol|Inhaled Fluticasone/Salmeterol (125/25 microgram) 2 puffs twice daily delivered by using metered dose inhaler for 6 weeks
223809980|NCT05734963|GENETIC|DNA sequencing, RNA gene expression analysis, molecular profiling|Growth of organoids from tissue samples, collection of tissue, blood and saliva samples for DNA sequencing, RNA gene expression analysis, molecular profiling
223809981|NCT03258749|DRUG|Tiotropium|inhaled Tiotropium(18μg, qd)
223809982|NCT03258749|DRUG|Formoterol|inhaled formoterol(4.5μg, bid)
223809983|NCT03701984|DRUG|Lidocaine|The lidocaine group will be administered a 1,000 ml distention medium containing 5 ml lidocaine per 250 ml (DEBOCAINE (LIDOCAINE) 2% 1 VIAL 50 ML, Sigma-Tec pharmaceutical Industry. Co. Egypt) and oral placebo similar to tramadol(given 1 hour before the procedure).
223809984|NCT03701984|DRUG|Tramadol|an oral tramadol tablet (Tramal®, Memphis, Giza, Egypt) 1 h before the procedure and with a 1,000 ml distention medium containing 5 ml serum physiologic per 250 ml.
223809985|NCT03701984|DRUG|placebo|a 1,000 ml distention medium containing 5 ml serum physiologic per 250 ml and oral placebo(1 h before the procedure).
223809986|NCT01273948|DRUG|Bavituximab|"1. Bavituximab 3 mg/kg given by intravenous (IV) infusion once weekly, plus oral ribavirin 1000 mg (weight \<75 kg) or 1200 mg (weight greater than or equal to 75 kg) divided into twice-daily doses, for 12 weeks or~2. Bavituximab 0.3 mg/kg given by IV infusion once weekly, plus oral ribavirin 1000 mg (weight \<75 kg) or 1200 mg (weight greater than or equal to 75 kg) divided into twice-daily doses, for 12 weeks or"
223809987|NCT01273948|DRUG|Pegylated interferon (PEG-IFN)|Pegylated interferon (PEG-IFN) alpha-2a 180 micrograms given by subcutaneous (SC) injection once weekly, plus oral ribavirin 1000 mg (weight \<75 kg) or 1200 mg (weight greater than or equal 75 kg) divided into twice-daily doses, for 12 weeks
223809988|NCT01857401|OTHER|No intervention, observational study only|No intervention. We are collecting blood for an ex vivo study
223809989|NCT06448923|DRUG|Cannabidiol|25 mg of CBD tablets twice daily
223809990|NCT06448923|DRUG|Cannabidiol|50 mg of CBD tablets twice daily
223809991|NCT06448923|DRUG|Placebo|Matching placebo tablets twice daily
223809992|NCT04992546|DRUG|PRN473 (SAR444727)|White to off-white gel suspension
223809993|NCT04992546|DRUG|Placebo|White to off-white gel suspension
223809994|NCT06228001|DEVICE|Actimyo|Actimyo is an innovative device intended to be used in a home-based environment. It is composed of two watch-like sensors, each containing a magneto-inertial sensors that record the linear acceleration, the angular velocity, the magnetic field of the movement in all directions.The two watches can be worn as wristwatch or placed near the ankle.
223835455|NCT01653847|DRUG|Group 2: Tacrolimus with Everolimus.|From day 5 on, the starting dose of Everolimus (0.75 mg bid) will be increased if the trough level is \< 3 ng/mL, or reduced if the trough level is \> 8 ng/mL. Tacrolimus will be initiated according to our practice. In this treatment arm, the Tacrolimus dose will be adjusted from day 3 on, to a target whole blood trough concentration of 4 ng/mL to 7 ng/mL. From month 2 until Month 6, the target Tacrolimus trough level will be 3 ng/mL to 6 ng/mL. After month 6, the Tacrolimus dose should be adjusted in order to achieve a target trough level of 2 ng/mL to 5 ng/mL. MMF dose will be initiated as 1 g b.i.d. (2 g/day). Adjustments should be made for adverse events including but not limited to gastrointestinal intolerance and a decrease in white blood cell (WBC).
223809995|NCT06577571|OTHER|CKM-EMPOWER|CKM-EMPOWER is a series of 11 just-in-time educational videos on topics related to caring for patients who opt for CKM: CKM overview, dysgeusia, fatigue, restless leg syndrome, uremic pruiritis, cramping, pain, volume overload, electrolyte abnormalities, anticipatory grief, and actively dying patient. Videos are approximately 5-10 minutes in length and intended to provide learners with a brief overiew on the definition of each issue, impact of the issue on a patient, assessment of the issue, and approaches to addressing the issue. Videos conclude with references to additional resources on each topic for more in-depth self-study. CKM-EMPOWER was created by a team comprised of a health educator, the principal investigator (nephrologist), a geriatrician and a physician dually trained in nephrology and palliative care and with feedback from a geriatric pharmacist and members of a national professional interest workgroup in kidney palliative care.
223809996|NCT06821997|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223809997|NCT06821997|PROCEDURE|Computed Tomography|Undergo CT
223809998|NCT06821997|DRUG|Fluorouracil|Given IV
223809999|NCT06821997|DRUG|Irinotecan Sucrosofate|Given IV
223810000|NCT06821997|DRUG|Leucovorin Calcium|Given IV
223810001|NCT06821997|DRUG|Oxaliplatin|Given IV
223810002|NCT06821997|PROCEDURE|Surgical Procedure|Undergo surgical resection
223810003|NCT02703922|OTHER|color Doppler ultrasound and TAB in case of CDU negative|Screening with color Doppler ultrasound followed by TAB in case of CDU negative
223810004|NCT03157518|DIETARY_SUPPLEMENT|Seeking Health Probiota Bifido|• This is a proof of concept study to demonstrate that oral probiotic use can modulate the airway microbiome. After informed consent has been obtained, this study will consist of 2 visits over a four week time period. Each visit will include a blood draw (30ml) and a research bronchoscopy/ bronchoalveolar lavage (BAL) (200ml) visit . A urine pregnancy test will be done on all females of childbearing potential prior to the first BAL as well as a CBC, BMP, and blood clotting tests in all participants. Following the first BAL, subjects will be asked to take an over the counter probiotic supplement (Seeking Health Probiota Bifido) nightly which will be provided to the participant by the study coordinator until the 2nd BAL is performed 4 weeks after the first BAL.
223810005|NCT03934736|DRUG|HEPLISAV-B®|HEPLISAV-B®, a licensed, commercially-available hepatitis B vaccine for adults 18 years of age and older, consisting of the adjuvant cytidine phosphoguanosine (CpG) 1018 combined with the antigen recombinant hepatitis B surface antigen (rHBsAg).
223810006|NCT03868865|BEHAVIORAL|Integrative mind-body-medicine group program|The mind-body-medicine group program focuses on support in coping with the disease, in lifestyle modification and in reduction of chemotherapy induced side effects. The self-contained modules of the mind-body-medicine group program can be followed in an individual order, to allow adoption to different chemotherapy concepts and continued access is possible. Patients can join in the group program eleven times for six hours each visit. They participate in every one of the eleven modules once.
223810007|NCT02053818|DRUG|Remifentanil|Randomization to receive Remifentanil (ultrashort acting opioid) as basic opioid in anaesthesia
223810008|NCT02053818|DRUG|Sufentanil|Randomization to receive Sufentanil (medium/long acting opioid) as basic opioid in anaesthesia
223810009|NCT00627380|BEHAVIORAL|Yoga lifestyle intervention|Sixteen weeks of 2-3 yoga sessions per week, 1.5 hrs per session administered by a certified yoga instructor. Sessions include breathing exercises and yoga postures/positions.
223810010|NCT00627380|OTHER|Standard of care|Participants are observed/followed for 16 weeks during which lifestyle and medication changes are discouraged, unless medically necessary.
223810011|NCT00070902|PROCEDURE|Lumbar side-posture spinal adjusting|
223810012|NCT04284527|OTHER|Observational study|a reliability - validity study
223810013|NCT04642508|PROCEDURE|Prepectoral reconstruction|Immediate prepectoral breast reconstruction in women requiring a mastectomy
223810014|NCT07094360|OTHER|Land-based exercise program|Land-based exercise program
223810015|NCT07094360|OTHER|Hydrotherapy besides Land-based exercise program|Hydrotherapy besides Land-based exercise program
223810016|NCT07094191|DIETARY_SUPPLEMENT|Chicory Coffee (Caffeine-free, polyphenol-rich beverage from roasted chicory root)|"A single oral dose of 180 mL chicory coffee prepared by steeping 20 grams of roasted and ground chicory root in hot water (approximately 90°C) for 5 minutes. The beverage was administered once, exactly 45 minutes before exercise, as part of a single session within a randomized crossover design. Chicory coffee is naturally caffeine-free, and rich in inulin and polyphenols, which are standardized in each preparation. No additional ingredients (milk, sugar, or flavoring) were added.~Blood lactate, glucose, blood pressure, and oxygen saturation (SpO₂) levels were measured both before and after the exercise. In addition, venous blood samples were collected post-exercise to assess serum levels of adiponectin, interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-α) and LPL."
223810017|NCT07094191|DIETARY_SUPPLEMENT|arabica coffee|A single oral dose of 180 mL Arabica coffee prepared by steeping 20 grams of roasted and ground chicory root in hot water (approximately 90°C) for 5 minutes. The beverage was administered once, exactly 45 minutes before exercise, as part of a single session within a randomized crossover design. Chicory coffee is naturally caffeine-free, and rich in inulin and polyphenols, which are standardized in each preparation. No additional ingredients (milk, sugar, or flavoring) were added. Blood lactate, glucose, blood pressure, and oxygen saturation (SpO₂) levels were measured both before and after the exercise. In addition, venous blood samples were collected post-exercise to assess serum levels of adiponectin, interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-α) and LPL.
223810018|NCT07094191|DIETARY_SUPPLEMENT|no beverage control|Participants underwent the shuttle run exercise protocol in a fasted state, without consuming any food or beverages prior to the test. Blood lactate, glucose, blood pressure, and oxygen saturation (SpO₂) levels were measured both before and after the exercise. In addition, venous blood samples were collected post-exercise to assess serum levels of adiponectin, interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-α) and LPL.
223810019|NCT07094009|PROCEDURE|received transverse needling|received transverse needling of high-frequency microneedles
223810020|NCT07094009|PROCEDURE|received vertical needling|received vertical needling of high-frequency microneedles
223810021|NCT07094009|PROCEDURE|received mixed needling|received mixed needling of high-frequency microneedles
223810022|NCT07093775|OTHER|Tumor grade (I or II vs. III)|We compared the prognosis according to the tumor grade stratified by 21-gene recurrence score
223810023|NCT07094750|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223810024|NCT07094750|PROCEDURE|Bone Marrow Collection|Undergo bone marrow assessment
223810025|NCT07094750|OTHER|Electronic Health Record Review|Ancillary studies
223810026|NCT07094750|OTHER|Questionnaire Administration|Ancillary studies
223810027|NCT07094802|DRUG|Intrathecal morphine with bupivacaine|Participants will receive 100 mcg intrathecal morphine along with 2.2ml of 0.5% hyperbaric bupivacaine
223810028|NCT07094802|DRUG|Hyperbaric Bupivicaine|0.5% hyperbaric Bupivacaine 2.2 ml
223810029|NCT07092748|DRUG|HS387|HS387 tablets will be given orally
223810030|NCT07093853|OTHER|Four Locator Attachments, Four Bar Attachment System|"This study retrospectively evaluated two types of implant-retained mandibular overdenture attachment systems placed in edentulous patients over a 10-year period. All patients received four dental implants placed in the interforaminal region (lateral incisor and first premolar areas).~In the Locator group, each implant was restored with an individual Locator attachment, allowing for independent retention and easier hygiene access.~In the Bar group, the four implants were splinted together with a rigid metal bar, and the overdenture was attached using clips that engaged the bar, offering splinted support and enhanced load distribution.~Both interventions were designed to support mandibular overdentures and were compared in terms of their long-term effects on posterior mandibular ridge resorption, marginal bone loss around implants, and anterior maxillary ridge resorption."
223810031|NCT07092657|OTHER|Nursing Education Intervention|Four standardized sessions. With a duration of 40 to 60 minutes each session, once a week for a period of one month and a follow-up one month after the end of the intervention. Interventions are carried out at different times depending on the availability of the nursing professionals.
223810032|NCT07094438|PROCEDURE|Deep Brain Stimulation, DBS|Deep brain stimulation (DBS) is performed after preoperative MRI and CT images are fused in a planning system to determine the target and trajectory. Under general anesthesia, electrodes are precisely implanted into the fornix or nucleus basalis of Meynert using a stereotactic frame or neurosurgical robot. The electrodes are inserted through a burr hole in the patient's skull and connected to a pulse generator placed subcutaneously in the chest. Optimal stimulation parameters for Alzheimer's disease are not yet established. For fornix targets, settings are typically 3-3.5 V, \~130 Hz, 90 μs; for nucleus basalis targets, 2-4.5 V, 10-20 Hz, 90-150 μs, adjusted according to anatomical features and intraoperative responses.
223810033|NCT07094438|PROCEDURE|Deep cervical lymphatic-venous anastomosis, LVA|Cervical deep lymphaticovenous anastomosis (LVA) microsurgically connects deep cervical lymphatic vessels to adjacent veins, promoting drainage of brain-derived amyloid-β and tau into the venous system and potentially alleviating Alzheimer's disease symptoms. The minimally invasive neck procedure involves small incisions and high-magnification suturing of lymphatics and veins with ultra-fine (11-0 or 12-0) sutures, creating multiple anastomoses to enhance brain lymphatic outflow.
223810034|NCT07094438|DRUG|Recognized pharmacological treatments for AD.|Patients in the medication group received only the currently recognized pharmacological treatments for AD, including Memantine Hydrochloride and Donepezil.
223810035|NCT07094763|DRUG|TNK plus standard medical treatment|Patients in the TNK treatment group will receive TNK intravenous thrombolysis and the usual dosage for TNK intravenous thrombolysis is 0.25mg/Kg, with a maximum of 25mg.
223810036|NCT07094763|DRUG|standard medical management|standard medical management
223810037|NCT07093866|DRUG|Disitamab Vedotin (RC48)|Disitamab Vedotin 2mg/kg is administered intravenously once every 2 weeks (1 cycle)
223810038|NCT07093866|DRUG|Abiraterone + prednisone|Abiraterone 1000mg is administered orally once a day，and prednisone 5mg is administered orally twice a day.
223810039|NCT07092956|BEHAVIORAL|Financial Literacy Education|A structured financial literacy training program delivered by an expert in economics. The training includes topics such as budgeting, saving, opportunity cost, financial planning, and investment tools. It was provided to the experimental group over a single session, and outcomes were assessed three weeks later.
223810040|NCT07092709|DRUG|Tenecteplase (TNK) (0.25 mg/kg, to maximum of 25mg)|Tenecteplase is administered as a single intravenous bolus at a dose of 0.25 mg/kg, with a maximum of 25 mg, administered as soon as possible after the randomization, and within 24 hours of stroke onset.
223810041|NCT07092709|DRUG|Placebo|Matched placebo is administered as a single intravenous bolus at a dose of 0.25 mg/kg, with a maximum of 25 mg, administered as soon as possible after the randomization, and within 24 hours of stroke onset.
223810042|NCT07092930|DIETARY_SUPPLEMENT|BA and SB supplementation|"Assigned Interventions:~* Beta-alanine (BA)~* Sodium bicarbonate (SB)~Description:~• Participants receive beta-alanine and sodium bicarbonate~Intervention list \& supplementation details:~1. Beta-alanine (BA)~   * Form: Gelatin capsules~  * Substance: Pure beta-alanine~  * Daily dose: 6.4 g/day~  * Dosing schedule: Four equal servings taken with meals (breakfast, lunch, snack, dinner)~  * Supplementation period: days 1 to 28~2. Sodium bicarbonate (SB)~   * Form: Gelatin capsules~  * Substance: Pure sodium bicarbonate~  * Daily dose: 0.3 g/kg body mass per day~  * Dosing schedule: Three equal servings taken with meals (breakfast, lunch, dinner)~  * Supplementation period: days 21 to 28 of BA or PL1 supplementation~Rationale:~• This group tests the combined effects of BA and SB"
223810043|NCT07092930|DIETARY_SUPPLEMENT|BA and PL2 supplementation|"Participants in this intervention group will undergo chronic supplementation with beta-alanine (BA) and an inert placebo (PL2) matched to the sodium bicarbonate (SB) protocol.~* Beta-alanine (pure, in gelatin capsules) will be administered at a total daily dose of 6.4 g, divided into four servings taken with meals, over a period of 28 consecutive days.~* PL2 (placebo matched to SB, in gelatin capsules) will be administered from Day 21 to Day 28 of beta-alanine supplementation, at a daily dose of 0.3 g per kg of body mass, divided into three equal servings taken with meals.~This group allows for evaluation of the isolated effects of BA supplementation when combined with a placebo comparator to SB"
223835456|NCT01889160|DRUG|AZD4721 Solution|1-9 mg/mL liquid solution
223835457|NCT01889160|DRUG|AZD4721 Placebo|Liquid solution
223835458|NCT01889160|DRUG|AZD4721 Suspension|9 mg/g liquid suspension
223835459|NCT00915070|DRUG|BQ-123|60 mcg/min, infusion period: 60 min
223810044|NCT07092930|DIETARY_SUPPLEMENT|PL1 and SB supplementation|"Assigned Interventions:~* Placebo matched to BA (PL1)~* Sodium bicarbonate (SB)~Description:~• Participants receive only sodium bicarbonate as the active compound and placebo capsules matching the BA protocol.~Intervention list \& supplementation details:~1. Placebo matched to BA (PL1)~   * Form: Gelatin capsules~  * Substance: Inert substance matched in appearance and dosing schedule to BA~  * Daily dose: 6.4 g/day~  * Dosing schedule: Four equal servings taken with meals (breakfast, lunch, snack, dinner)~  * Supplementation period: days 1 to 28~2. Sodium bicarbonate (SB)~   * Form: Gelatin capsules~  * Substance: Pure sodium bicarbonate~  * Daily dose: 0.3 g/kg body mass per day~  * Dosing schedule: Three equal servings taken with meals (breakfast, lunch, dinner)~  * Supplementation period: days 21 to 28 of BA or PL1 supplementation~Rationale:~• This group tests the isolated effects of SB"
223810045|NCT07092930|DIETARY_SUPPLEMENT|PL1 and PL2 supplementation|"Assigned Interventions:~* Placebo matched to BA (PL1)~* Placebo matched to SB (PL2)~Description:~• Participants receive two matched placebos.~Intervention list \& supplementation details:~1. Placebo matched to BA (PL1)~   * Form: Gelatin capsules~  * Substance: Inert substance matched in appearance and dosing schedule to BA~  * Daily dose: 6.4 g/day~  * Dosing schedule: Four equal servings taken with meals (breakfast, lunch, snack, dinner)~  * Supplementation period: days 1 to 28~2. Placebo matched to SB (PL2)~   * Form: Gelatin capsules~  * Substance: Inert substance matched in appearance and timing to SB~  * Daily dose: 0.3 g/kg body mass per day~  * Dosing schedule: Three equal servings taken with meals (breakfast, lunch, dinner)~  * Supplementation period: days 21 to 28 of BA or PL1 supplementation~Rationale:~• This serves as the control group for comparison with all active intervention arms."
223810046|NCT07094516|BIOLOGICAL|VHB937|VHB937 solution for infusion
223810047|NCT07094516|BIOLOGICAL|VHB937|VHB937 solution for infusion
223810048|NCT07094516|OTHER|Placebo|Solution for infusion
223810049|NCT07092852|OTHER|Cheek swab for PGx testing|Pharmacogenetic test kits will be provided to each CPU residence. An order will be issued to obtain samples for the study - a cheek swab - to be collected by residence direct care providers or nursing staff, trained in the procedure for obtaining the sample, and preparing and submitting it for transport. Failures to collect and submit valid samples, the number of samples submitted that cannot be processed, and the reasons for failure, will be recorded. If a submitted sample cannot be processed, another sample can be obtained and submitted.
223810050|NCT07092852|OTHER|Medication safety review|A medication reconciliation will be performed by a GalenusRx pharmacist on all included residents. Medication data for enrolled participants will be collected by the GalenusRx pharmacist from the unique pharmacy provider and/or the medication records from the facility and a medication reconciliation will be conducted with the nurse of the residents' facility. GalenusRx pharmacists will apply a CDSS to patients' medication regimens, screening for drug interactions, assess medication related risks, and consider pharmacogenomic type and phenoconversion results in recommending appropriate drug selection and dosage to prescribing clinicians.
223810051|NCT07093177|BEHAVIORAL|Telerehabilitation Unit|Telerehabilitation is the use of information and communication technology (ICT) to deliver rehabilitation services remotely in participants' homes or other settings. A telerehab unit consists of a touchscreen tablet, a portable bike, elastic bands, and a pulse oximeter. A mobile Wi-Fi hotspot device will be provided for participants who have limited or no internet connection for the duration of the study. The telerehab unit is designed to work in areas with limited internet connectivity as all multimedia materials are stored locally on the tablet.
223810052|NCT07094854|OTHER|Cention Forte alkasite bioactive restorative material|Cention forte material will be used as a final restoration for pulpotomized second primary molars
223810053|NCT07094854|OTHER|Stainless steel crown|The control group using the gold standard stainless steel crown (SSC) as a final restoration for pulpotomized second primary molars
223810054|NCT07094451|DEVICE|Virtual Reality|Meta Quest 2 virtual reality headset. The VR experience includes an interactive, immersive environment with classical music and wrist-controlled movement to match floating visual cues to a beat. The experience is designed to be soothing and require minimal movement.
223810055|NCT07094451|PROCEDURE|Ultrasound|Ultrasound-guided (US-Guided) procedure
223810056|NCT07094477|DRUG|CD22/CD19 CAR-T cell immunotherapy|targeted CD22/CD19 CAR-T cell immunotherapy
223810057|NCT07093554|DRUG|Talquetamab|Talquetamab will be administered subcutaneously.
223810058|NCT07093554|DRUG|Ciltacabtagene Autoleucel|Ciltacabtagene Autoleucel will be administered intravenously.
223810059|NCT06931652|DRUG|Epcoritamab|Epcoritamab Investigational Medicinal Product (IMP): Epcoritamab will be used during induction phase and Maintenance phase.
223810060|NCT06443346|OTHER|Eosinophilic Esophagitis|Eosinophilic Esophagitis patients with a proper diagnosis
223810061|NCT05797103|DEVICE|A novel electrolyzed water spray reduces numbers of bacteria E-coli and an attenuated human flu virus on human hands|Electrolyzed water spray group will use the novel electrolyzed water spray to flush the hands that daub E. coli and attenuated human influenza virus H1N1 for 6 seconds per hand, and then use 4 seconds to collect a sample of the water flowing from the sprayed hand and apply it to the plate. Untreated tap water group will use the untreated tap water spray to flush the hands that daub E. coli and attenuated human influenza virus H1N1 for 6 seconds per hand, and then use 4 seconds to collect a sample of the water flowing from the sprayed hand and apply it to the plate.
223810062|NCT00766675|DRUG|Tramadol hydrochloride|Tramadol hydrochloride oral tablet will be administered at a dose of 37.5 milligram as, once daily for Day 1-3, twice daily for Day 4-6 and thrice daily for Day 7-56.
223810063|NCT00766675|DRUG|Acetaminophen|Acetaminophen oral tablet will be administered at a dose of 325 milligram as, once daily for Day 1-3, twice daily for Day 4-6 and thrice daily for Day 7-56.
223810064|NCT05795413|PROCEDURE|Mastectomy with PECS blocks|Approximately half of patients recruited will receive a PECS block with Liposomal bupivacaine and half will not receive a block.
223810065|NCT05795413|DRUG|Liposomal bupivacaine|All of the PECS blocks performed at this institution have liposomal lupivacaine as the anesthetic. Investigators will examine quality of recovery and pain control in patients who receive a PECS block versus those who do not receive one.
223810066|NCT05673239|DRUG|Levocarnitine Injection|The patients in the test group were injected with 1-2g (10-20mg/kg) levocarnitine on each dialysis day
223810067|NCT03099330|DRUG|TQ-B3139|TQ-B3139 p.o. qd
223810068|NCT01974115|DEVICE|Radial extracorporeal shock wave therapy|All patients were treated with radial extracorporeal shock waves using the Swiss Dolorclast (Electro Medical Systems S.A., Nyon, Switzerland) and the Power+ handpiece with the 36-mm applicator. Patients were treated unilaterally with two weekly treatments for four weeks on a randomly selected leg (left or right), totaling eight treatments on the selected side. After the application of coupling gel, treatment was performed at 3.5 to 4 bar, with 15,000 impulses per session, and applied at 15 Hz. Impulses were applied homogeneously over the posterior thigh and buttock area. One patient was treated on both legs, with each leg considered an independent treatment.
223810069|NCT01837160|PROCEDURE|Cardiac MRI scan|Cardiac MRI scan with assessment of late gadolinium enhancement and T1 mapping.
223810070|NCT01837160|RADIATION|CT-PET scan|Computed Tomography / Positron Emission Tomography scan with 18F-fluciclatide tracer.
223810071|NCT01837160|PROCEDURE|Echocardiogram|Echocardiography.
223810072|NCT01837160|RADIATION|CT-coronary angiogram scan|CT-coronary angiogram following CT-PET scan. Standard protocol.
223810073|NCT01837160|PROCEDURE|Aortic Valve Replacement|For AVR (already scheduled prior to enrollment)
223810074|NCT01984697|BIOLOGICAL|V503 (9-valent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] vaccine)|V503, a 9-valent HPV (Types 6, 11, 16, 18, 31, 33, 45, 52, 58) administered as a 0.5-mL intramuscular injection
223810075|NCT03178279|OTHER|Physical Health Plan|Use of a Physical Health Plan by service users
223810076|NCT01313143|DRUG|AOP200704|Comparison of AOP200704 with Esmolol
223810077|NCT01313143|DRUG|Esmolol hydrochloride, infusion|Comparison of AOP200704 with Esmolol
223810078|NCT06096545|PROCEDURE|Axillary sentinal lymph node biopsy|"For SLNB evaluation, multiple sections of the excised lymph node were stained with hematoxylin and eosin (H\&E) at a thickness greater than 2 mm. Lymph nodes with metastasis greater than 2 mm were defined as positive SLNB. Macroscopic metastasis was considered positive in the evaluation for the axilla, while benign histological characteristics were considered negative. The presence of micrometastasis and isolated tumor cells was also noted. The size and diameter of the metastatic lymph node were considered in the evaluation.~SLNB technique using isosulfan blue dye was performed for axillary evaluation, and all patients had the clipped lymph node excised under ultrasound guidance with a guide wire placed preoperatively."
223810079|NCT06320626|OTHER|Emicizumab - PK-guided dose reduction|PK-guided dose reduction emicizumab targeted at a Ctrough of 30μg/mL.
223810080|NCT06320626|OTHER|Emicizumab - Dosis continuation group|Continue on their current dose regimen
223810081|NCT06320626|OTHER|Emicizumab - Dose adjustment group|Adjusted in dosing regimen according to local protocol
223810082|NCT04660422|OTHER|VitalTalk communication skills training|Clinicians will receive VitalTalk intensive communication skills training via highly structured Zoom conference. They will learn skills relevant to discussions about ACP and COVID-19 including delivering serious news, eliciting goals of care, and managing difficult conversations via telehealth platforms.
223810083|NCT04660422|OTHER|ACP Decisions Video Program|All clinicians will also be trained remotely on the ACP Decisions Video Program using the ACP app. Training will instruct clinicians on how to: 1. Introduce the COVID-19 videos to patients and caregivers; 2. Select the appropriate video(s) from the entire suite according to patients' needs; and, 3. Prescribe videos for patients and caregivers using the electronic platform. The suite of ACP videos is designed to address common ACP decisions confronting patients at risk or with COVID-19 and the caregivers.
223810084|NCT04660422|OTHER|Intervention training:|Training will instruct the clinicians on how to: i. more effectively communicate with patients regarding COVID- 19, ii. have ACP conversations with patients, iii. introduce the videos to patients and families, iv. use the videos as an adjunct to ACP counseling by clinicians, v. select the appropriate video(s) from the entire suite as according to patients' needs, and, vi. use the app or electronic platform for prescribing videos to be seen at home (telehealth visits), or to be viewed in clinic with an iPad.
223810085|NCT04660422|OTHER|Medical Record Review|13,000 (total) patients aged 65 or older for our primary (completed advance care plans) outcome. ACP can include designating a health care proxy, discussion of advance directives, goals-of-care discussions, CPR discussions, palliative care discussions and referrals, as well as hospice. Each of these ACP outcomes will also be compared in secondary analyses using NLP. These data will be obtained from the EHR. All patient participants will only be included for medical record review.
223810086|NCT00150774|DRUG|Levetiracetam|
223810087|NCT02163590|OTHER|2Hz mobilisation|This intervention will be applied for 3 sets of 1 minute, with 1 minute rest period in between each set.
223810088|NCT02163590|OTHER|0,5Hz mobilisation|This intervention will be applied for 3 sets of 1 minute, with 1 minute rest period in between each set.
223810089|NCT02163590|OTHER|Placebo|Intervention that mimics the experimental procedures
223810090|NCT03265054|BIOLOGICAL|Analysis of plasma samples|Measuring microparticles (MPs) in Human Plasma Samples
223810091|NCT01514214|DEVICE|WInged perimeter biliary stent insertion (Viaduct)|Insertion of a winged perimeter stent. Size to be determined during the ERCP based on findings.
223810092|NCT01514214|DEVICE|traditional polyethylene stent insertion (Cotton Huibregtse)|insertion of a traditional polyethylene stent during ERCP, size to be determined depending on findings during ERCP
223810093|NCT06240052|BEHAVIORAL|Conditioning and active avoidance paradigm (CAAP)|On day 1 subjects will undergo image viewing, fear conditioning, and avoidance learning. Subjects will be instructed to passively view the images from 3 categories on the screen, with 2 of the 3 categories being paired with a mild shock to the subjects' foot. Then they will see a picture of a button on the screen together with all three categories. If they press the button, they may prevent the shock from occurring. Pressing the button for one of the conditioned categories will prevent the shock from happening. Pressing the button to the other conditioned cue will not prevent the shock .Pressing the button to the third category does nothing. On day 2, subjects will be given $5 and will be told that they can press a button to avoid a shock. The number of times the button was pressed will be counted and if it is less than the number by another randomly selected participant then the participant will get to keep the money.
223810094|NCT06219889|BEHAVIORAL|Frequency of neurochecks|the frequency with which a patient is awakened to perform serial examinations
223810095|NCT05177510|DRUG|Mifepristone|Progestin Antagonist
223810096|NCT05177510|DRUG|Placebo|Placebo
223810097|NCT06229457|BEHAVIORAL|Girls PLAY program|Girls PLAY program (8-12 weeks) will include 1) a series of in-person sessions, led by Boys and Girls Clubs staff at the Boys and Girls Club sites, and 2) take-home activities. In-person sessions (60-75 min; 2-3x/week) will center around a different developmentally appropriate sport each week. Lesson plans will outline games/activities in which youth engage in fundamental, sport-specific movement skills. Lesson plans will be delivered by Boys and Girls Club leaders using acts of instruction derived from Self-Determination Theory. Take home activities will 1) summarize and add on to the week's in-person sessions and 2) be adapted for delivery by parents and/or self-guided participation by youth. Take-home activities will provide information for engaging in the past week's activities as well as additional activities that parents and youth can participate in together.
223810098|NCT06487091|DIAGNOSTIC_TEST|Analysis of platelet function|Blood withdrawal, platelet separation and analysis of the expression levels of markers of platelet function
223810099|NCT05954156|OTHER|Injectable restorative resin composite|The introduction of injectable composites, according to available literature, offers a simple and efficient solution for the cementation of veneers. This versatile, injectable restorative composite unites easy handling, high physical properties and excellent aesthetics. Generally used as a restorative material, it can also be used for the cementation of veneers and some inlays/onlays, thus considered as good alternative to preheated composite. (Alajrash MM et al., 2020)
223835460|NCT00915070|DRUG|Physiological saline solution|infusion period 60 minutes
223810100|NCT05954156|OTHER|Dual cured resin cement|Resin cements are widely used due to their strong adhesion, and compatibility with various restorative materials, including ceramics and zirconia. They bond to enamel and dentin through functional monomers such as MDP, and 4-META, forming a stable hybrid layer. Based on their bonding mechanism, resin cements are classified as adhesive or self-adhesive, while their polymerization method -chemical, light, or dual-cure-allows for versatility in clinical applications
223810101|NCT01332396|DRUG|Lapatinib|
223810102|NCT00847405|DRUG|Sumatriptan Succinate|100 mg Tablets
223810103|NCT00847405|DRUG|Imitrex®|100 mg Tablet
223810104|NCT05963152|BEHAVIORAL|Habitual Physical Activity|Participants will be asked to maintain their normal activity levels
223810105|NCT05963152|BEHAVIORAL|Morning Exercise|Between 6-10am participants will attend the gym and perform 10 min of warm up exercise, 3 sets of 7 resistance exercises ( leg press, calf press, leg curl, chest press, lateral raise, seated row and plank)
223810106|NCT05963152|BEHAVIORAL|Afternoon Exercise|Between 4-8pm participants will attend the gym and perform 10 min of warm up exercise, 3 sets of 7 resistance exercises ( leg press, calf press, leg curl, chest press, lateral raise, seated row and plank)
223810107|NCT00605514|DRUG|VRC-EBODNA023-00-VP|
223810108|NCT00605514|DRUG|VRC-MARDNA025-00-VP|
223810109|NCT01870752|PROCEDURE|Transplantation of previously cryopreserved ovarian tissu|
223810110|NCT03460457|DRUG|TQB2450|Pharmacokinetics/Dynamics Study
223810111|NCT05502419|PROCEDURE|Neural slump mobilization|Slump stretching will be performed with the patient in the long sitting position with the patient's feet against the wall to assure the ankle remained in 0 degree dorsiflexion. The therapist will apply over pressure to the cervical spine flexion to the point where the patient's symptoms will be reproduced. The position will be held for 30 s. A total of 5 repetitions will be completed.
223810112|NCT05502419|PROCEDURE|Conventional Physical Therapy|Moist heat with hydro collator pack, Maitland Mobilization for Lumbar spine, Therapeutic exercise: Core stability exercises
223810113|NCT06070584|PROCEDURE|aerobic exercises with electrical treadmill for 30 min and inspiratory muscle training for 10 minutes.,|aerobic exercises with moderate intensity in the form of walking on electrical treadmill
223810114|NCT04682119|DRUG|LY3526318|Administered orally.
223810115|NCT04682119|DRUG|Placebo|Administered orally.
223810116|NCT01750762|DRUG|Lenalidomide|
223810117|NCT02955030|BIOLOGICAL|NSV0001|sublingual
223810118|NCT02955030|BIOLOGICAL|"Influenza HA vaccine Biken HA"|subcutaneous
223810119|NCT02955030|BIOLOGICAL|Placebo|sublingual
223810120|NCT01073904|DRUG|Levonorgestrel Emergency Pill (BAY86-5028)|Single dose of 1.5 mg coated tablet
223810121|NCT01073904|DRUG|Postinor 2|Single dose of 1.5 mg tablet
223810122|NCT01900600|OTHER|Cardiopulmonary exercise test|All patients will undergo a first CPX prior to initiation of treatment, a second one after 3 months, and a third one after 12 months of treatment.
223810123|NCT01900600|OTHER|Echocardiogram|An echocardiogram (ultrasound of the heart) will be performed prior to initiation of treatment and then again 12 months later.
223810124|NCT05362552|OTHER|Urban Afforestation Program|An afforestation program based on land cultivation and transplantation of several plants for 90 minutes will be implemented.
223810125|NCT00004884|DRUG|cisplatin|
223810126|NCT00004884|DRUG|docetaxel|
223810127|NCT00004884|DRUG|gemcitabine hydrochloride|
223810128|NCT02483286|BEHAVIORAL|ICG|"Core 2-hour education course including practice of study home exercise program. Weekly professional led exercise program for 90 mins at NTUHBB site with reinforcement on osteoporosis related educations and care managements from study educational booklet and CD-rom for 3-month.~The exercise program included 15 minutes warm up with 10 minute brisk walks followed by gentle stretching. Resistance training (20-30 minutes) was provided with rubber band and bottled water (0.6-1L) as weight for major muscles of upper and lower limbs. Balance training were also provided for 10 minutes with tandem gaits and one leg standing, step up and down stairs, toe walking and heel walking.~Subjects are encouraged to practice study home exercise program at least twice weekly."
223810129|NCT02483286|BEHAVIORAL|MTG|MTG group subjects were invited to NTUHBB site to receive 2 sessions of 45-minute training using isotonic strength training machines on major muscle groups each week. The intensity is set at 60-80% of 1 repetition maximum (RM). Evaluation of the exercise protocol are repeated every 2 weeks for individualized adjustments by trained physical therapist
223810130|NCT02483286|BEHAVIORAL|XBG|XBG group subjects were invited to LCGMH site to receive 2 sessions of 45-minute training using x-box machine with combination programs selected from existing commercial programs with a exercise training specialist.
223810131|NCT06212648|DRUG|SPC1001 High|"Drugs for clinical trials are orally administered once a day after breakfast.~After randomization, the drug for clinical trials is taken once a day (total of 4 tablets) for 8 weeks."
223810132|NCT06212648|DRUG|SPC1001 Mid1|"Drugs for clinical trials are orally administered once a day after breakfast.~After randomization, the drug for clinical trials is taken once a day (total of 4 tablets) for 8 weeks."
223810133|NCT06212648|DRUG|SPC1001 Mid2|"Drugs for clinical trials are orally administered once a day after breakfast.~After randomization, the drug for clinical trials is taken once a day (total of 4 tablets) for 8 weeks."
223810134|NCT06212648|DRUG|SPC1001 Low|"Drugs for clinical trials are orally administered once a day after breakfast.~After randomization, the drug for clinical trials is taken once a day (total of 4 tablets) for 8 weeks."
223810135|NCT06212648|DRUG|SPC3001|"Drugs for clinical trials are orally administered once a day after breakfast.~After randomization, the drug for clinical trials is taken once a day (total of 4 tablets) for 8 weeks."
223810136|NCT06212648|DRUG|SPC4001|"Drugs for clinical trials are orally administered once a day after breakfast.~After randomization, the drug for clinical trials is taken once a day (total of 4 tablets) for 8 weeks."
223810137|NCT06212648|DRUG|SPC4002|"Drugs for clinical trials are orally administered once a day after breakfast.~After randomization, the drug for clinical trials is taken once a day (total of 4 tablets) for 8 weeks."
223810138|NCT06212648|DRUG|Placebo|"Drugs for clinical trials are orally administered once a day after breakfast.~After randomization, the drug for clinical trials is taken once a day (total of 4 tablets) for 8 weeks."
223810139|NCT04532723|DEVICE|ExoAtlet II|ExoAtlet II is the second version of an exoskeleton that ExoAtlet has manufactured
223810140|NCT06138249|DIETARY_SUPPLEMENT|Vitamin D|Vitamin D
223810141|NCT02710292|DEVICE|Delefilcon A contact lenses|
223810142|NCT02710292|DEVICE|Narafilcon A contact lenses|
223810143|NCT01074892|DRUG|Provera (medroxyprogesterone/progestin)|10 mg tablet, 1 tablet per day taken 10 days per month Duration is 6 months
223810144|NCT01074892|DRUG|Provera (medroxyprogesterone)|10 mg per oral tablet. One tablet per day for 6 months
223810145|NCT01074892|DEVICE|Mirena (levonorgestrel)|Inserted in the uterine cavity and kept in situ for 6 months
223810146|NCT01920282|DRUG|Nebivolol|
223810147|NCT01920282|OTHER|Lifestyle Modification|
223810148|NCT01920282|OTHER|Nebivolol plus Lifestyle Modification|
223810149|NCT01768832|BEHAVIORAL|Treadmill|
223810150|NCT01768832|BEHAVIORAL|Tango|
223810151|NCT01768832|BEHAVIORAL|Stretching|
223810152|NCT03852238|OTHER|Blood test and self-administrated questionnaires|
223810153|NCT00710606|DRUG|NuvaRing|Obese subjects (BMI 30-39.9) will receive two contraceptive hormonal rings. During the second cycle of ring use, subjects will return to the study site for serial serum hormone measurements and transvaginal ultrasound twice weekly during four weeks of continuous use.
223810154|NCT00710606|DRUG|NuvaRing|Normal weight subjects will also receive two contraceptive hormonal rings. During the second cycle of ring use, subjects will return to the study site for serial serum hormone measurements and transvaginal ultrasound twice weekly during four weeks of continuous use.
223810155|NCT00022230|BIOLOGICAL|aldesleukin|
223810156|NCT00022230|BIOLOGICAL|filgrastim|
223810157|NCT00022230|BIOLOGICAL|sargramostim|
223810158|NCT00022230|BIOLOGICAL|therapeutic autologous lymphocytes|
223810159|NCT00022230|DRUG|cyclophosphamide|
223810160|NCT00022230|DRUG|doxorubicin hydrochloride|
223810161|NCT00022230|DRUG|paclitaxel|
223810162|NCT05891769|DRUG|18Fluorocholine|18F Fluorocholine 5 mCi ± 20% administered intravenously.
223810163|NCT05316129|DRUG|Follicle Stimulating Hormone Receptor T Cells|Participants will receive an infusion of autologous t cells genetically modified ex vivo to express the FSHR-specific 4-1BB/CD3ζ CER.
223810164|NCT02128646|DRUG|EXPAREL|
223810165|NCT02128646|DRUG|Ketorolac|
223810166|NCT02128646|PROCEDURE|laparoscopic abdominal hernia repair|
223810167|NCT02128646|PROCEDURE|an open surgery for abdominal hernia repair|
223810168|NCT06679010|OTHER|Online group counseling|The program progresses as one weekly group session over 10 weeks, each with its own topic. The core components of the program include psychoeducation, training self-compassion and acceptance, cognitive restructuring, interpersonal skills training, systems and management of daily life activities, prevention of conflicts, and the mother-baby relation. Participants will meet online as a group together with the instructor, a consultant from the ADHD Association, who will lead and facilitate the sessions. Before each session, there is a podcast episode that covers the topic of each session. The 10 podcasts feature interviews with clinicians, researchers, and women with ADHD, focusing on the themes from the program's sessions.
223810169|NCT03462329|DRUG|Antibiotics (preferentially oral doxycycline 100 mg bid)|Patients will be treated with antibiotics for Lyme disease.
223810170|NCT06472076|BIOLOGICAL|Dostarlimab|Dostarlimab will be administered.
223810171|NCT06472076|BIOLOGICAL|Belrestotug|Belrestotug will be administered.
223810172|NCT06472076|BIOLOGICAL|Pembrolizumab|Pembrolizumab will be administered.
223810173|NCT06472076|DRUG|Placebo|Placebo will be administered.
223810174|NCT04903314|DRUG|Xcopri|Xcopri will be administered orally not to exceed 400mg/day adult equivalent
223810175|NCT03339479|DIAGNOSTIC_TEST|dielectric property test|Test the dielectric property of resected lung nodules/mass through a touching probe after the lung tissue with nodules/mass has been resected and cut open, which usually takes only 1-5 minutes.
223810176|NCT03339479|DIAGNOSTIC_TEST|frozen pathological examination|And after the dielectric property test, the lung tissue will be sent for frozen pathological examination.
223810177|NCT03339479|DIAGNOSTIC_TEST|final pathological examination|All of the lung nodules/mass will be diagnosed by final pathological examination and recognized as the final diagnosis after surgery.
223810178|NCT00953264|BEHAVIORAL|lifestyle|lifestyle intervention, including diet, physical activity and behavioral changes
223835461|NCT00915070|DEVICE|Laser Doppler Flowmetry|blood flow measurements at the temporal neuroretinal rim to assess optic nerve head blood flow
223810179|NCT02347644|BEHAVIORAL|Brief Motivational Interview|"Motivational interviewing is a technique which aims to be both non-judgmental and non-confrontational. Its success depends largely on the presentation of objective feedback based on information provided by an individual. The technique involves acknowledgement that individuals who attend a counselling session, assessment or prevention program may be at different levels of readiness to change their alcohol consumption patterns, including:~* No perception of any alcohol consumption problem~* Realization of alcohol consumption problem with no corresponding action"
223810180|NCT02560870|DRUG|Active Comparator:Aloe Vera mouthwash|mouthwash( Aloe Vera),10 ml by patients routinely washed two times in one day for about 30 seconds for two weeks.
223810181|NCT02560870|DRUG|Active Comparator:Chlorhexidine mouthwash|mouthwash( Chlorhexidine ),10 ml by patients routinely washed two times in one day for about 30 seconds for two weeks.
223810182|NCT04536246|PROCEDURE|Bone Quadriceps Tendon (BQT) arthroscopic-assisted ACL reconstruction|New intervention method deployed in Indonesia to gain better clinical outcome for ACL--deficient patients requiring surgical treatment
223810183|NCT04536246|PROCEDURE|Single-Bundle Hamstring Tendon (SBHT) arthroscopic-assisted ACL reconstruction|Comparator for New Reconstruction Technique
223810184|NCT04029701|DRUG|Ruyizhenbao Pill|Ruyizhenbao Pills are provided by Jinhe Tibetan Pharmaceutical Co., Ltd. Chinese national medicine permission number:Z63020289、Z63020064. Medication method: oral 4 pills once, twice a day, 4 weeks in a row.
223810185|NCT04029701|DRUG|Placebo of Ruyizhenbao Pill|Placebo is provided by Jinhe Tibetan Pharmaceutical Co., Ltd.，which is made of malt dextrin as a matrix, similar shape and same color to the Ruyizhenbao Pill. Medication method: oral 4 pills once, twice a day, 4 weeks in a row.
223810186|NCT04978714|PROCEDURE|Cystocele repair|Fascial repair for endopelvic fascia and anterior colporrhaphy
223810187|NCT04292782|PROCEDURE|anterior Quadratus lumborum block|ultrasound anterior quadratum lumborum block with 1 ml/kg 0.2% ropivacaine
223810188|NCT04292782|PROCEDURE|caudal block|ultrasound guided caudal block with 1 ml/kg 0.2% ropivacaine
223810189|NCT03233568|DIAGNOSTIC_TEST|Indirect calorimetry|"Indirect calorimetry will be performed by using an open-circuit calorimeter (Sensor Medics, Italy). Indirect calorimetry is the reference method for energy expenditure determination. A canopy hood covered the patient's head and expired air is extracted by a pump to be analyzed by metabolic cart sensors; flow rate is directly measured with a digital turbine flowmeter. After an overnight fast, patients will asked to lay supine in complete physical rest, not sleeping or talking for approximately 20-25 minutes, at a room temperature ranged between 22 and 24°C. The mean REE for each participant considers the last 15-20 minutes of measurements corresponding to steady state.~Software of calorimeter will be set for minute-by-minute reading report of VO2 (Oxygen flow) and VCO2 (Carbon dioxide flow) measurement.~Parameters obtained by Indirect Calorimetry will be the Resting Energy Expenditure and the Respiratory Quotient (RQ)"
223810190|NCT00514683|DRUG|low dose BIBF1120 once daily|low dose BIBF1120 once daily
223810191|NCT00514683|DRUG|low dose BIBF 1120 twice daily|low dose BIBF 1120 twice daily
223810192|NCT00514683|DRUG|intermediate dose BIBF 1120 twice daily|intermediate dose BIBF 1120 twice daily
223810193|NCT00514683|DRUG|high dose BIBF 1120 twice daily|high dose BIBF 1120 twice daily
223810194|NCT00514683|DRUG|placebo|placebo
223810195|NCT00664898|DRUG|bortezomib|Escalating intravenous repeating dose
223810196|NCT00664898|DRUG|SGN-40|Escalating intravenous repeating dose
223810197|NCT06363422|PROCEDURE|Epicanthoplasty|Patients with unsatisfied blepharoplasty underwent epicanthoplasty in our center
223810198|NCT04894526|OTHER|Alternating Energy Intake|To alternate between caloric overconsumption (130% of usual total energy needs) and caloric underconsumption (70% of usual total energy needs) on a daily basis for 6 days/week followed by one ad libitum day for 4 weeks.
223810199|NCT04894526|OTHER|Regular Energy Intake|To consume the usual energy intake (100% of total energy needs) on a daily basis for 6 days/week, also followed by one ad libitum day for 4 weeks.
223810200|NCT02417103|DRUG|GLP-1 (Liraglutide)|GLP-1 Analogon
223810201|NCT02417103|DRUG|Placebo|Placebo
223810202|NCT05760157|OTHER|Possible risk factors of heart failure|Demographic data, previous medical history data, physical examination, ECG examination, blood routine, blood biochemistry, the peak value of myocardial injury markers, serum markers of heart failure, high-sensitivity C-reactive protein Coronary angiography, interventional treatment, microcirculation resistance index caIMR calculation based on coronary angiography Doppler echocardiography, medication during hospitalization, NYHA cardiac function grading before discharge, and 6-minute walk test before discharge.
223810203|NCT00335452|DRUG|Clopidogrel|oral administration
223810204|NCT00335452|DRUG|acetylsalicyclic acid (ASA)|oral administration
223810205|NCT01410370|RADIATION|6MV-X ray|3Gy/time, 5 times/week, a total of 10 times
223810206|NCT01410370|DRUG|Endostar|7.5mg/m2/d, continuous infusion, in parallel with radiotherapy
223810207|NCT06096480|PROCEDURE|gabapentin + bilateral spine erector block|preoperative, ultrasound-guided, bilateral ESP block (administration of a local anesthetic mixture of ropivacaine 0.375% and lidocaine 1%) and a 100mg dose of oral gabapentin 4 nights daily before surgery and 2 weeks postoperatively.
223810208|NCT05868915|BIOLOGICAL|HV-101|"Biological: HV-101~HV-101 is autologous tumor-infiltrating lymphocyte cells without genetic modification.~Drug: IL-2~Following cell infusion, the patient receives intravenous IL-2.~Drug: Fludarabine~Part of the non-myeloablative lymphocyte-depleting preparative regimen.~Drug: Cyclophosphamide~Part of the non-myeloablative lymphocyte-depleting preparative regimen."
223810209|NCT02943941|OTHER|Reveal LINQ ICM Cardiac Monitor, taped on the subject's chest rather than inserted in the body.|Cardiac Monitor with LINQ™ HF Investigational RAMware download
223810210|NCT02736825|DEVICE|Ulthera System with standard transducer|Focused ultrasound energy delivered below the surface of the skin using commercially available transducer to deliver one line of treatment at a time
223810211|NCT02736825|DEVICE|Ulthera System with prototype 2 simulines transducer|Focused ultrasound energy delivered below the surface of the skin using new transducer to deliver two lines of treatment simultaneously
223810212|NCT03486028|OTHER|Adherence to ASAM protocols|ASAM Counties. These counties are requiring their providers to use ASAM criteria to assess patients and to determine level of care. These counties also use ASAM to determine the ongoing need for high-intensity services, such as residential, and approve those services for Medicaid payment.
223835462|NCT00915070|DEVICE|Goldmann Applanation Tonometer|intraocular pressure measurements
223810213|NCT03486028|OTHER|Non-adherence to ASAM protocols|These counties are not implementing the ASAM criteria to assess patients and determine the level of care.
223810214|NCT02103621|BEHAVIORAL|Unified Protocol (UP)|
223810215|NCT02103621|BEHAVIORAL|Taper and Monitoring (TAP-M)|
223810216|NCT03088709|DRUG|Cyclophosphamide|IV medication given for prevention of graft versus host disease.
223810217|NCT03088709|DRUG|Tacrolimus|IV medication given for prevention of graft versus host disease.
223810218|NCT03088709|DRUG|Mycophenolate mofetil|IV medication given for prevention of graft versus host disease.
223810219|NCT03088709|OTHER|Haploidentical Stem Cell Transplantation|A stem cell transplant that involves matching a patient's tissue type, specifically their human leukocyte antigen (HLA) tissue type, with that of a related donor.
223810220|NCT05199363|OTHER|Information leaflet|"Before examination study participant will obtain an information leaflet which includes descriptive and illustrative sections Information for young patients and their caregivers. What is Magnetic Resonance Imaging and what is the examination like?"
223810221|NCT05199363|OTHER|Educational movie|"Before examination study participant will be shown educational video with an radiology technologist and actors who role play the examination What is MRI and what is the examination like?"
223810222|NCT05199363|OTHER|Demonstration|"Before examination study participant will take a part in scenario-based demonstration with the use of props such as the scanner model and a multimedia presentation Scenario for a demonstration before a Magnetic Resonance examination for young patients and their caregivers"
223810223|NCT01904864|DRUG|elemental iron (NovaFerrum®)|single daily dose (3mg/kg) of a 15 mg/ml elemental iron preparation, NovaFerrum®, for 12 weeks
223810224|NCT01904864|DRUG|elemental iron (Ferrous Sulfate)|single daily dose (3mg/kg) of a 15 mg/ml elemental iron preparation, Ferrous Sulfate, for 12 weeks
223810225|NCT00267410|BEHAVIORAL|Healthy Relationships|"Healthy Relationships, grounded in the social cognitive theory, is a five-session, group-level intervention originally designed for HIV-positive heterosexual individuals seeking skills-building and support around risk reduction, as well as disclosure of status and sexual preference. Through clip media and active role-plays, the intervention promotes the development of decision-making and problem-solving tools, empowering participants to make voluntary and informed decisions around disclosure and safer sex practices. This model was formally disseminated to AIDS Service Organizations as part of CDC's strategic plan - Advancing HIV Prevention, New Strategies for a Changing Epidemic - which focused on innovative strategies to recruit individuals into HIV testing, as well as a movement towards secondary prevention efforts."
223810226|NCT00650195|DRUG|Metolazone Tablets 10 mg|10mg, single dose fasting
223810227|NCT00650195|DRUG|Zaroloxyn® Tablets 10 mg|10mg, single dose fasting
223810228|NCT04563650|BIOLOGICAL|blood sample|Sample collection of 4 to 10 tubes of whole blood will be done according to centre Saint-Victor's protocol.
223810229|NCT05905250|BEHAVIORAL|an empirically supported protocol, further refined with evidence-based strategies|The intervention utilizes an empirically supported protocol, further refined with evidence-based strategies targeting the needs of young adult (YA) survivors. Its long-term goal is to promote hopeful thinking, and ultimately enhance other long-term markers of quality of life (QOL) (including mental health and health behaviors). The intervention follows 8 weekly curricula, reinforced through psychoeducation and skill-building, homework/practical application, and self-monitoring. Its 8-week design was informed by cognitive behavioral therapy and positive psychology intervention literature.
223810230|NCT05905250|BEHAVIORAL|Health education|Health education regarding maintaining a healthy weight, physical activity, and nutrition, based on American Cancer Society and NCI guidelines/recommendations.
223810231|NCT03536364|BEHAVIORAL|Food Order|carbohydrate (ciabatta bread ) first, followed 10 minutes later by protein (grilled chicken) and vegetables
223810232|NCT03536364|BEHAVIORAL|Carbohydrate Last|protein and vegetables first, followed 10 minutes later by carbohydrate
223810233|NCT03536364|BEHAVIORAL|Vegetables first|vegetables first, followed 10 mins later by protein and carbohydrate.
223810234|NCT01163643|DRUG|0.3% BOL-303242-X ophthalmic suspension|0.3% BOL-303242-X ophthalmic suspension BID for 12 weeks.
223810235|NCT01163643|DRUG|2% BOL-303242-X ophthalmic suspension|2% BOL-303242-X ophthalmic suspension BID for 12 weeks.
223810236|NCT01163643|DRUG|Placebo Comparator: Vehicle|Placebo Comparator: Vehicle BID for 12 weeks.
223810237|NCT01163643|DRUG|1% BOL-303242-X ophthalmic suspension|1% BOL-303242-X ophthalmic suspension BID for 12 weeks.
223810238|NCT01163643|DRUG|2% BOL-303242-X ophthalmic suspension AM|2% BOL-303242-X ophthalmic suspension once daily (QD) AM and vehicle QD in PM for 12 weeks.
223810239|NCT01163643|DRUG|2% BOL-303242-X ophthalmic suspension PM|Vehicle QD AM and 2% BOL-303242-X ophthalmic suspension QD in PM for 12 weeks.
223810240|NCT00959101|DRUG|repaglinide and metformin combination tablet|Combination tablet of repaglinide (1.0 mg)/metformin (500 mg) given just prior to a standard normal breakfast
223810241|NCT00959101|DRUG|repaglinide and metformin combination tablet|Combination tablet of repaglinide (2.0 mg)/metformin (500 mg) given just prior to a standard normal breakfast
223810242|NCT00959101|DRUG|repaglinide|Co-administration of metformin 500 mg tablet and repaglinide 2 mg tablet given just prior to a standard normal breakfast
223810243|NCT00959101|DRUG|metformin|Concomitant administration: Metformin 500 mg tablet and Repaglinide 2 mg tablet
223810244|NCT04035837|DRUG|pegylated interferon-alfa|All the patients in this study will receive pegylated interferon for all course.
223835463|NCT00915070|OTHER|squatting|subjects will perform squatting for 6 minutes while blood flow measurements
223810245|NCT05408728|PROCEDURE|Endoscopic biopsy|Upper small intestinal biopsies from patients undergoing BS will be collected during routine standard of care screening EGD and again from the same patients at 1 year during routine standard of care surveillance EGD (esophageal reflux screening/surveillance). Biopsy-derived enteroid cultures and tissue samples from pre- and one-year post BS will be examined for expression level of sugar transporters and gluconeogenic enzymes; glucose and fructose absorption
223810246|NCT01564368|PROCEDURE|diffusion-weighted magnetic resonance imaging|diffusion-weighted magnetic resonance imaging examination and subsequent radiologist interpretation
223810247|NCT04035213|BEHAVIORAL|Behavior of Sleep Course|The current study will evaluate whether a semester-long course focused on sleep improves college students' sleep patterns over one semester compared to students completing a similar-level course in the same department (Psychology) at the same university.
223810248|NCT00500864|DRUG|Magnesium Sulfate 2 grams|
223810249|NCT03021135|PROCEDURE|Conventional Endoscopic Mucosal Resection|Conventional Endoscopic Mucosal Resection
223810250|NCT03021135|PROCEDURE|Underwater Endoscopic Mucosal Resection|Underwater Endoscopic Mucosal Resection
223810251|NCT02901626|DEVICE|Arabin Cervical Pessary|"The Arabin cervical pessary is a soft, flexible silicone pessary and fits high around the cervix with no rigid metal framework or inflexible edges that put increase pressure on the vaginal wall. It is available in a variety of sizes however three sizes will be used in this study:~Pessary Size upper diameter, lower diameter~1. Nulliparous 65 mm, 32 mm~2. Multiparous 70 mm, 32 mm~3. Alternative 70 mm, 35 mm"
223810252|NCT06738368|DRUG|Asparaginase Erwinia chrysanthemi|Given IM
223810253|NCT06738368|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223810254|NCT06738368|PROCEDURE|Bone Marrow Collection|Undergo bone marrow sample collection
223810255|NCT06738368|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
223810256|NCT06738368|DRUG|Cyclophosphamide|Given IV
223810257|NCT06738368|DRUG|Doxorubicin|Given CIV
223810258|NCT06738368|DRUG|Etoposide|Given CIV
223810259|NCT06738368|BIOLOGICAL|Filgrastim|Given SC
223810260|NCT06738368|BIOLOGICAL|Pegfilgrastim|Given SC
223810261|NCT06738368|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
223810262|NCT06738368|DRUG|Prednisone|Given PO
223810263|NCT06738368|BIOLOGICAL|Rituximab|Given IV
223810264|NCT06738368|DRUG|Vincristine|Given CIV
223810265|NCT05751031|DRUG|Raltegravir|Raltegravir exposure in pregnant women living with HIV in routine clinical care. No study intervention administrated.
223810266|NCT00111748|DRUG|Velcade, Thalidomide, Dexamethasone|"Dosage and Administration Schedule Each cycle will consist of 3 weeks (21 days). AGENT DOSE ROUTE DAYS Velcade 1.0 mg/m2 IV 1, 4, 8, and 11 Thalidomide 100 mg PO Daily, hs Dexamethasone 20 mg PO Days 1, 2, 4,5, 8, 9, 11, 12 Lovenox 40 mg SQ Days 1-14~This 21-day period will be considered one treatment cycle; Cycle 2 would commence on Day 22 (Cycle 2, Day 1). The next cycle of treatment may be delayed up to day 29 due to non-toxicity reasons. Patients may continue to receive treatment every 21 days, provided there is no evidence of disease progression or no unacceptable toxicity for a maximum of eight cycles. At the discretion of the treating physician, patients may be eligible to receive treatment at their local physician after completion of the 1st cycle. These patients will need to return to MIRT prior to every cycle for cycles 2-4, cycles 6 and 8, and final visit."
223810267|NCT04794426|DRUG|Silver diamine fluoride|Previous studies have recommended that Silver diamine fluoride (SDF) solution would exert a preventive result in managing early childhood caries ECC. However, no well-designed clinical trials have yet been performed to study the effect of SDF on caries prevention. the objective is useful in arresting early childhood caries (ECC)
223810268|NCT04794426|DEVICE|Hall Technique|The first report on the Hall Technique published in 2007 by a general dental practitioner from Aberdeen/Scotland, Dr. Norna Hall. Dr. Hall used PMCs to restore carious primary molars rather than using the standard technique, placed them using a simplified method.
223810269|NCT03504098|BEHAVIORAL|nutrition consult|Post-lung cancer operation diet pattern
223810270|NCT04562961|OTHER|Schizophrenia caregivers qualitative interview|"The semi-structured qualitative interview will be carried out in a focus group or individually for a period of 1 hour. Focus groups are a group interview technique, moderated by a neutral facilitator in the presence of an observer, which aims to collect information on a limited number of pre-defined questions. In this study we foresee groups of 4 to 5 subjects. Focus groups will be privileged because they allow a better elaboration of the participants and therefore a better collection of data. If the focus group is not possible, the visit will be done individually. This interview will be framework-guided and recorded in their entirety and anonymously using a dictaphone and then transcribed the objective verbatim on a computer using word processing software. These transcriptions will be called the verbatims. The source data recorded using a dictaphone will be stored in secure, locked cabinets located within the investigation center."
223810271|NCT00331344|DRUG|mitoxantrone hydrochloride|Given IV
223810272|NCT00331344|DRUG|ixabepilone|Given IV
223810273|NCT00331344|DRUG|prednisone|Given orally
223810274|NCT01945151|OTHER|Group 2 (G2) NMES is applied in the spastic muscle (gastrocnemius).|The G2 apply NMES in the gastrocnemius motor point and the rest will be done during stretching of the gastrocnemius muscle (autogenic inhibition). Five consecutive sessions will be held in the morning and afternoon in the laboratory of Sensory Motor Rehabilitation Engineering.
223810275|NCT03396029|BEHAVIORAL|Individually tailored lifestyle feedback|The written, standardized individually tailored lifestyle feedback includes feedback on consumption of fruit, berries and vegetables and alcohol, physical activity, smoking and body mass index.
223810276|NCT03396029|BEHAVIORAL|Standard leaflet|The leaflet is The Norwegian Cancer Society's one-page information brochure on healthy lifestyle behaviours for low cancer risk, including non-smoking, healthy body weight, physical activity, diet, moderate alcohol consumption, moderate sun exposure etc.
223810277|NCT05378984|OTHER|before - hypertonic saline 5%|pain was induced by intramuscular injections of hypertonic saline (5%)
223810278|NCT05378984|OTHER|after - hypertonic saline 5%|pain was induced by intramuscular injections of hypertonic saline (5%)
223810279|NCT04565171|DRUG|Yimitasvir Phosphate Capsule|DAG181 100 mg (100 mg Capsule) administered orally
223810280|NCT02462902|DRUG|5% albumin Infusion|colloid, 5% albumin (250 ml over 15 to 30 minutes).
223810281|NCT02462902|DRUG|0.9% sodium chloride solution|0.9% sodium chloride solution (total of 30ml/kg over 15 to 30 minutes)
223810282|NCT03366922|DIETARY_SUPPLEMENT|Artemisia Annua, Moringa oleifera|As described above
223810283|NCT05177406|OTHER|Aimovig|patients newly initiating Aimovig therapy
223810284|NCT01373931|DRUG|LY2216684|Administered orally
223810285|NCT01373931|DRUG|Ortho Cyclen|35 micrograms (mcg) ethinyl estradiol and 250 mcg norgestimate administered orally
223810286|NCT01373931|DRUG|Placebo|Administered orally
223810287|NCT05747456|DEVICE|IPN-21-SENSE|"Up to 2.0 mL will be injected in the zygomaticomalar region and optionally up to 2.0 mL in the anteromedial cheek at the first session, on each side of the face.~Up to 1.0 mL in the zygomaticomalar region and optionally up to 1.0 mL in the anteromedial cheek for the optional touch-up session, on each side of the face."
223810288|NCT05747456|DEVICE|IPN-21-SENSE|"Up to 2.0 mL will be injected in the zygomaticomalar region and optionally up to 2.0 mL in the anteromedial cheek at the first session, on each side of the face.~Up to 1.0 mL in the zygomaticomalar region and optionally up to 1.0 mL in the anteromedial cheek for the optional touch-up session, on each side of the face."
223810289|NCT04857034|DRUG|Deucravacitinib|Specified dose on specified days
223810290|NCT04857034|DRUG|Placebo|Specified dose on specified days
223810291|NCT03580590|DRUG|oral Diltiazem|Diltiazem, a calcium channel blocker reduced arteriolar tone and fall in blood pressure
223810292|NCT03580590|DRUG|IV Tranexamic Acid|Tranexamic acid inhibits fibrinolysis, which reduces blood loss
223810293|NCT03580590|DRUG|Placebo Oral Tablet|Placebo Oral Tablet
223810294|NCT01556126|DEVICE|Amphilimus Eluting Stent (CRE8)|Sirolimus formulated coronary eluting stent
223810295|NCT02014818|DEVICE|CoCr-EES|
223810296|NCT06785181|DIAGNOSTIC_TEST|Active standing|a session at resting state in supine position, a session during autonomic challenge obtained via active standing evoking reflex sympathetic activation, and a session of emotional elicitation via the administration of videos
223810297|NCT04235907|OTHER|Telerehabilitation|Internet-guided rehabilitation with weekly phone calls from a physical therapist.
223810298|NCT04235907|OTHER|Standard rehabilitation|Prescription for physical therapy and a printed list of exercises to complete.
223810299|NCT00659490|DRUG|AZD1940|800ug oral administration
223810300|NCT00659490|DRUG|Naproxen|500mg oral administration
223810301|NCT00659490|DRUG|Placebo|Placebo given pre-surgery
223810302|NCT01887470|DRUG|Full dose preparation|
223810303|NCT01887470|DRUG|Split dose preparation|
223810304|NCT02341508|BIOLOGICAL|0.5 mg/kg Lpathomab|
223810305|NCT02341508|BIOLOGICAL|1.0 mg/kg Lpathomab|
223810306|NCT02341508|BIOLOGICAL|3.0 mg/kg Lpathomab|
223810307|NCT02341508|BIOLOGICAL|10 mg/kg Lpathomab|
223810308|NCT02341508|BIOLOGICAL|20 mg/kg Lpathomab|
223810309|NCT02341508|OTHER|Saline solution for intravenous infusion|
223810310|NCT04196998|DRUG|Entecavir|Patients would receive treatment of oral entecavir (ETV) 0.5 mg once per day.
223810311|NCT04196998|DRUG|Tenofovir Disoproxil Fumarate|Patients would receive treatment of oral tenofovir disoproxil fumarate (TDF) 300 mg once per day.
223810312|NCT04196998|DRUG|Tenofovir alafenamide|Patients would receive treatment of oral tenofovir alafenamide (TAF) 25 mg once per day.
223810313|NCT04137354|OTHER|Intermittent placebo iron supplement|Placebo iron supplements are also three tablets containing the same ingredients as for iron tablets and will be given to the children on a weekly basis for the whole duration of the intervention (i.e. the school year of 9 months)
223810314|NCT04137354|OTHER|Intermittent iron supplement|Three iron tablets containing 42 mg of elemental iron will be provided to the children on a weekly basis for the whole duration of the intervention (i.e. the school year of 9 months)
223810315|NCT04137354|OTHER|Placebo Vitamin A|Children will receive in a colorful Eppendorf tube 400 micro-liter of corn oil stabilized with vitamin A twice during the intervention period of 9 months, at baseline (after enrollment) and at mid-line (4.5 months).
223810316|NCT04137354|OTHER|High-dose Vitamin A supplement|Children will receive in a colorful Eppendorf tube 400 micro-liter of oil-based preparation of retinyl palmitate that contains the equivalent of 100,000 IU (110μmol) of vitamin A and stabilized with 20IU of vitamin E twice during the intervention period of 9 months, at baseline (after enrollment) and at mid-line (4.5 months).
223810317|NCT05674890|DIAGNOSTIC_TEST|SmartSystem VR Headset perimeter|Patients will undergo visual field testing with the head-mounted SmartSystem VR Headset perimeter.
223810318|NCT04719039|BEHAVIORAL|Restorative Yoga Internvention|Participants in the intervention group will receive links to two 60-min videos per week for 8 consecutive weeks. Each video will include a yoga practice guided by a certified yoga instructor. The intervention group is required to perform the yoga practice at least two times per week. If preferred, they can do additional sessions with the videos and record their total hours of self-practice.
223810319|NCT01171092|DRUG|bortezomib and G-CSF|"Bortezomib injection:~1.3mg/m2 11 days before and 8 days before the stem cell collection~G-CSF injection:~10mcg/kg on days -4 to day -1 once daily"
223810320|NCT04294992|DRUG|Ondansetron 8mg|Study drugs will be prepared, diluted to a volume of 10 mL using saline 0.9%
223810321|NCT00827541|DRUG|Tigecycline|Tigecycline 50 or 100 mg intravenously. Therapy conducted according to the package leaflet of Tygacil and to international treatment guidelines. Tygacil will be dosed according to labeling. The administration and duration of the therapy will be determined by the treating physician to meet the patient individual needs for treatment.
223810322|NCT01649232|DEVICE|Active tDCS|tDCS applied to left dorsolateral prefrontal scalp area through a saline-soaked pair of surface sponge electrodes (35 cm2). The anode electrode was placed over F3 (based on the 10-20 International EEG System) of each subject. The cathode was placed over the contralateral mastoid area. A constant current of 1.1 mA was applied for 25 min/day (administered for 12 alternated days).
223810323|NCT02228967|BEHAVIORAL|SBIRT|"SBIRT is an opportunistic approach whereby patients are screened by Health Educators for their alcohol use, and then, taking advantage of a teachable moment, are delivered a brief, motivational intervention matched to their level of risk."
223810324|NCT05891626|BEHAVIORAL|Group intervention|"An enhanced electronic reminder mechanism specialized on vaccines and actively highlight vaccine standing orders in the system.~Set up a data benchmarks, so clinic managers or providers are able to aggregate immunization data, red flag missed opportunities, and facilitate modifying vaccine promotion plans.~Other components:~1. missed opportunities and doubts/hesitancy about immunization as a whole;~2. specific questions with regard to specific vaccines;~3. health conditions and socioeconomic/demographic vulnerabilities (insufficient resources in health literacy, linguistic or cultural considerations); and~4. challenges in patient-clinician interactions. These components will be addressed through team training/meetings, pamphlets, physician-led speech in online videos, and group messages via MyChart on the clinic level."
223810325|NCT06294119|PROCEDURE|Major Cardiac surgery|From a clinical perspective, MANCAVA will especially target neuro-cardiovascular health and mood disorders such as depression
223810326|NCT01713725|BIOLOGICAL|Omalizumab|"* Two injections will be administered the first two weeks~* The following three injections will be administered every four weeks Consequently, we will administer 5 doses within 14 weeks"
223810327|NCT01713725|BIOLOGICAL|Placebo|"* Two injections will be administered the first two weeks~* The following three injections will be administered every four weeks Consequently, we will administer 5 doses within 14 weeks"
223810328|NCT04141631|DRUG|EPO (600UI/Kg, sub-cutaneous) and Ferric Carboxymaltose (FCM) (20 mg/kg in 250 mL of saline solution 0.9% over 15 min)|"EPO (600UI/Kg, sub-cutaneous) and Ferric Carboxymaltose (FCM) (20 mg/kg in 250 mL of saline solution 0.9% over 15 min) will be administered if~* Hb \< 13g/dL the day before surgery~* Hb ≥ 7g/dL AND ScvO2 \> 65% in postoperative ICU stay~Postoperative Transfusion will be guided by ScvO2 values :~if Hb ≤ 8 g/dL AND ScvO2 ≤ 65% or if Hb \< 7g/dL independently of ScVO2 value"
223810329|NCT05715203|DEVICE|Pulsotonometry|Evaluation of arterial stiffness
223810330|NCT00520975|BIOLOGICAL|Bevacizumab|Given IV
223810331|NCT00520975|DRUG|Carboplatin|Given IV
223810332|NCT00520975|DRUG|Paclitaxel|Given IV
223810333|NCT00520975|OTHER|Placebo|Given IV
223810334|NCT00520975|BIOLOGICAL|Trastuzumab|Given IV
223810335|NCT03384264|OTHER|Physical activity|The suspension device was securely attached to a fixed beam. The suspension programme included an initial 10 min warm-up with very low-intensity joint mobility exercises. The central part of the program had a duration of 40 min and included six exercises in which the level of intensity was based on the inclination of the body. The exercises were performed in a split routine, alternating by segment to prevent joint overload. Finally, participants performed 10 minutes of stretching.
223810336|NCT05476055|GENETIC|NGS|In the conbentional NBS+/NICU/premature infants, NGS was conducted to investigate whether NGS can accelerate diagnosis and improve prognosis in these children
223810337|NCT03707288|BEHAVIORAL|Clinical Control Group (Group A)|The participants who reported the presence of neck or low back pain and were assigned to the clinical control group (Group A) after randomisation will not receive the intervention of an exercise program. The interventional group (Group B) will be asked to keep the standardised exercise program confidential and not share with the control group (Group A). After eight (8) weeks, Group A participants will receive: the Cornell Musculoskeletal Discomfort Questionnaires (CMDQ) to assess for changes in the frequency, discomfort and interference with work due to musculoskeletal pain; a Questionnaire B, to ascertain any changes in their pain level using the Numeric Rating Scale (NRS); as well as their knowledge, attitude and practice towards musculoskeletal problems of the neck and low back pain, without having received any intervention.
223810338|NCT03707288|BEHAVIORAL|Spine Exercise Program (Group B)|The standardised spine exercise program will be provided in a handout and given only to the intervention group (Group B), and will include simple basic neck or low back exercises to be done three (3) times per week, as well as brief stretching exercises, to be done during periods of sitting for greater than sixty (60) minutes. The selected participants will be asked to comply with instructions on the handout. Participants who experience worsening of their symptoms, or who develop new symptoms will be assessed as having an adverse outcome and will be withdrawn from the study.
223810339|NCT04810221|OTHER|Controlled desaturation study|Measure of SpO2 and Heart Rate by BrOxy M device and reference device in a controlled desaturation study.
223810340|NCT03017417|OTHER|Exercise Intervention|Various exercise tests
223810341|NCT03017417|OTHER|standard of care|standard treatment
223810342|NCT00264979|PROCEDURE|Simultaneous surgery|Simultaneous surgery of colorectal cancer and synchronous liver metastases
223810343|NCT00264979|PROCEDURE|Sequential surgery|Sequential surgeries of colorectal cancer and synchronous liver metastases: the metastases surgery will be programmed 12 to 14 weeks after the primary tumour exeresis.
223810344|NCT03642938|BEHAVIORAL|Walking Exercise|Exercise groups will perform moderate intensity treadmill walking at a speed of 3.5 mph at a 0% incline for 30 minutes.
223810345|NCT03642938|BEHAVIORAL|Control|The Control group will perform 30 minutes of quiet rest.
223810346|NCT04643925|DRUG|Ovitrelle|Ovitrelle 260 IE once daily for 8 weeks prior to IVF/ICSI
223810347|NCT01042028|DRUG|Everolimus, Cetuximab, Irinotecan|Cetuximab 500 mg/m² iv biweekly Irinotecan 180 mg/m² iv biweekly Everolimus in daily MDT dosage
223810348|NCT01042028|DRUG|Capecitabine, Oxaliplatine|Capecitabine 1250 mg/m² bid. Oxaliplatin 70 mg/m² biweekly
223810349|NCT00407199|DRUG|quetiapine|
223810350|NCT05374499|DRUG|Liposomal bupivacaine|Dosage: 3 mL Frequency: Administer via buccal infiltration technique immediately following mandibular third molar extraction surgery and at least twenty minutes following most recent lidocaine injection.
223810351|NCT05374499|DRUG|0.5% bupivacaine with 1:100,000 epinephrine|Dosage: 3 mL of diluted 0.5% bupivacaine with 1:200,000 epinephrine (2:1 ratio of saline to standard bupivacaine) Frequency: Administer via buccal infiltration technique immediately following mandibular third molar extraction surgery and at least twenty minutes following most recent lidocaine injection.
223810352|NCT04570917|BEHAVIORAL|Online educational intervention to reduce ageism|Participants in this group will go over multiple short videos covering the following content:1). Myths about aging, 2). Ageism and its negative effects, 3). Distorted views about aging among young adults, 4). Ageism during the COVID-19 pandemic, and 5). importance of reducing ageism among healthcare professionals. These will be multiple videos posted on the LMS (Blackboard). At the end of the lesson, they will be asked to briefly write what they learned on Blackboard as an assignment.
223810353|NCT04570917|BEHAVIORAL|Online educational intervention to enhance cultural competance|Participants in the control group will go over multiple short videos covering the following content: 1). Myths about cultural competence, 2) Cultural competence for health care professionals including dietitians, 3). Connecting culture and food, and 4). Importance of cultural competence in sports dietitians. At the end of the lesson, they will be asked to briefly write what they learned. These will be multiple videos posted on the LMS (Blackboard). At the end of the lesson, they will be asked to briefly write what they learned on Blackboard as an assignment.
223810354|NCT03600675|OTHER|No intervention element, observational study.|No intervention will be applied to any group. It is an observational study and all measurements are collected during one visit.
223810355|NCT06273111|DRUG|5% simvastatin ointment|5% simvastatin ointment will be applied directly on IH lesion twice per day for 24 weeks
223810356|NCT06775834|DRUG|HRS-1893|HRS-1893 tablets.
223810357|NCT00105235|DRUG|Alemtuzumab|T-cell depleting monoclonal antibody; two doses by intravenous infusion on Days 0 and 4
223810358|NCT00105235|DRUG|Cyclosporine|Oral immunosuppressant
223810359|NCT00105235|DRUG|Mycophenolate mofetil|Oral immunosuppressant
223810360|NCT00105235|DRUG|Tacrolimus|Oral immunosuppressant
223810361|NCT00105235|PROCEDURE|Liver transplant|Occurs at study entry
223810362|NCT00105235|PROCEDURE|Immunosuppression withdrawal|Beginning no earlier than Year 1
223810363|NCT00361959|DRUG|Tiotropium bromide 18mcg|
223810364|NCT00361959|DRUG|Fluticasone propionate/ salmeterol combination 50/500mcg|
223810365|NCT01956422|DEVICE|Continuous Positive Airway Pressure(CPAP)|
223810366|NCT01956422|DEVICE|Venturi Mask FiO2 40%|
223810367|NCT03440502|PROCEDURE|spinal anaesthesia|Intrathecal block under strict aseptic conditions will be performed by median approach (L3-4 or L4-5) under sitting position by anesthesiologists . 25 Gauge sprotte spinal needles and 2-3 mLof 0.5% hyperbaric bupivacaine
223810368|NCT03826290|OTHER|EHR-integrated diabetes dashboard|The diabetes dashboard is available as a tab in the electronic health record (EHR) system and enables clinicians to confirm relevant patient parameters, select treatment goals, and review likely outcomes from alternative treatment strategies through an interactive graphical user interface.
223810369|NCT04340310|DIAGNOSTIC_TEST|Home respiratory polygraphy|Home respiratory polygraphy or Polysomnography to stablish a therapeutic decission
223810370|NCT01964326|DRUG|Atorvastatin calcium 10 mg|Atorvastatin calcium 10 mg tablet to be administered orally every day
223810371|NCT02347657|DRUG|VX-661 Plus Ivacaftor Combination|FDC tablet, oral use
223810372|NCT02347657|DRUG|Ivacaftor|Tablet, oral use
223810373|NCT02347657|DRUG|VX-661 Plus Ivacaftor Combination Placebo|FDC tablet, oral use
223810374|NCT02347657|DRUG|Ivacaftor placebo|Tablet, oral use
223810375|NCT01995539|BEHAVIORAL|therapy regimen|Subjects will be recommend changes in therapy regimens.
223810376|NCT05764343|OTHER|Immediate smoking cessation support|Smoker patients with chronic airway diseases (asthma and/or COPD and/or bronchiectasis) will be evaluated for the inclusion criteria. Afterwards they will be randomized as routine support arm (as the current procedure of the care) and immediate support arm (intensive brief cessation advices following by the immediate arrangement of the appointment from the same clinic's smoking cessation service). Both arms will be followed remotely at first week and third months of the randomization regarding their quit status as well as their use of evidence based cessation treatments.
223810377|NCT02564302|DEVICE|MUSE Headband|MUSE Headband will help patients with mindfulness.
223810378|NCT05356754|DEVICE|The Vital Labs Digital Blood Pressure Monitor|The Vital Labs Digital Blood Pressure monitor is a software-as-a-medical device (SaMD) that is capable of determining blood pressure, after calibration, using waveform changes observed in photoplethysmogram signals.
223810379|NCT06452953|DRUG|suanzaoren decoction|The Suanzaoren decoction is a Chinese herbal formula known for nourishing the blood, calming the mind, and nourishing the heart and liver
223810380|NCT06452953|DRUG|Eszopiclone 1 mg|Eszopiclone is used in the treatment of various types of insomnia.
223810381|NCT03417947|DIETARY_SUPPLEMENT|Vitamin D bolus|One single oral liquid vitamin D3 supplement of 300 000 IU
223810382|NCT03417947|DIETARY_SUPPLEMENT|Placebo|Placebo identical in taste and appearance to the vitamin D bolus
223810383|NCT06072222|DRUG|Meropenem|all patients in both groups receive meropenam and put on the ventilators for 2 weeks
223810384|NCT06072222|PROCEDURE|bronchoscopy|Only patients of group B had three times bronchoscopy according to our protocol one at the end of first 5 days, second bronchoscopy at the end of the second 5 days and last one at the end of the studied period
223810385|NCT06072222|DEVICE|ventilator|ventilator
223810386|NCT05886491|DRUG|GDX012|GDX012 suspension for IV infusion.
223810387|NCT05886491|DRUG|Chemotherapy Agents|Chemotherapy agents (fludarabine/cyclophosphamide) as per standard of care.
223810388|NCT04864002|OTHER|No intervention. only observational cross sectional study|No intervention done. only observational cross sectional study
223810389|NCT06573671|DIAGNOSTIC_TEST|Chitotriosidase|The amount of patients with increased chitotriosidase, and the extent of elevation of chitotriosidase
223810390|NCT06573671|DIAGNOSTIC_TEST|Mass spectrometry|to show polyvinylpyrrolidone presence in histiocytes of injecting drug users compared to controls
223810391|NCT06573671|DIAGNOSTIC_TEST|scanning electron microscope with energy-dispersive X-ray spectroscopy|to show polyvinylpyrrolidone presence in histiocytes of injecting drug users compared to controls
223810392|NCT06573671|DIAGNOSTIC_TEST|Fluorescence microscopy|to show polyvinylpyrrolidone presence in histiocytes of injecting drug users compared to controls
223810393|NCT06573671|DIAGNOSTIC_TEST|Transcriptomics|To describe pathologic signals of polyvinylpyrrolidone-exposed in vitro histiocytes of injecting drug users compared to control samples
223810394|NCT06831136|DRUG|Neoadjuvant Chemotherapy (NAC)|Participant will undergo 8 weeks of NAC (treating physician's choice). Possible regimens are either mFOLFIRINOX or NALIRIFOX or Gemcitabine Nab-Paclitaxel ± Cisplatin (GA+/-Cisplatin) or Capecitabine (Xeloda).
223810395|NCT06831136|DRUG|Immunotherapy (pembrolizumab)|2-12 weeks after initial chemotherapy and after the first EUS-RFA treatment, patients will receive 400 mg every 6 weeks of pembrolizumab via infusion. Participants will be administered standard of care chemotherapy and pembrolizumab every 6 weeks.
223810396|NCT06831136|DEVICE|Endoscopic ultrasound (EUS)-guided radiofrequency ablation (RFA)|After 2-12 weeks of chemotherapy, patients will undergo EUS-RFA treatment 1 session every 6 weeks. Each RFA treatment will be for up to 5 cycles at 30W for 20 seconds or until there is an increase in measured impedance. After the 5th EUS-RFA, if there is clinical benefit, then patients will continue with EUS-RFA treatments until no active tumor is seen. During each session, the therapeutic gastroenterologist will evaluate if there is any tumor to undergo RFA. If no active tumor seen, then will abort RFA
223810397|NCT05751512|DRUG|MRG003|Administered intravenously
223810398|NCT05751512|DRUG|Cetuximab injection|Administered intravenously
223810399|NCT05751512|DRUG|Methotrexate Injection|Administered intravenously
223810400|NCT00261495|DRUG|OROS hydromorphone HCl|8 to 32 mg once daily for 52 weeks (flexible dosing)
223810401|NCT00261495|DRUG|Oxycodone|10, 20, or 40 mg twice a day for 52 weeks (flexible dosing)
223810402|NCT01036308|DIETARY_SUPPLEMENT|pure fibre-product|The subjects consumed 25 g pure fibre-product per day over two weeks. One half a portion of the fibres was stirred into a selected milk product and the other half in juice.
223810403|NCT01036308|DIETARY_SUPPLEMENT|reference fibre|The subjects consumed 25 g reference fibre (citrus fibre: Herbacel AQ Plus; Herbafood Ingredients) per day over two weeks. One half a portion of the fibres was stirred into a selected milk product and the other half in juice.
223810404|NCT03446014|DEVICE|Fitbit Sub-Study|
223810405|NCT05409989|DEVICE|FRED™ X™|The FRED™ X™ System is indicated for use in the internal carotid artery from the petrous segment to the terminus for the endovascular treatment.
223810406|NCT01968525|BIOLOGICAL|pre-oxygen|3 min of preoxygenation before anesthesia induction.
223810407|NCT06226766|DRUG|JSKN033 Injection|JSKN033 is a combination drug product comprised of JSKN003 and envafolimab for subcutaneous injection.
223810408|NCT04969835|DRUG|AVA6000|AVA6000 is a FAP-activated doxorubicin.
223810409|NCT05934747|DEVICE|DBS|Deep Brain Stimulation
223810410|NCT06250491|DEVICE|Deep active rTMS with Hesed coil|This brain neurostimulation method targets the motor cortex bilaterally
223810411|NCT06250491|DEVICE|Sham rTMS with Hesed coil|This brain sham neurostimulation method targets the motor cortex bilaterally
223810412|NCT03822572|OTHER|endurance exercise|defined exercise program
223810413|NCT03822572|OTHER|control|habitual physical activity before the diagnosis
223810414|NCT05181553|OTHER|Whole-food plant based diet (WFPB diet)|28-day fully controlled dietary intervention during which participants will receive a whole food plant-based diet that reflects the recommendations of Canada's Food Guide.
223810415|NCT05181553|OTHER|Standard North American diet (SAD diet)|28-day fully controlled dietary intervention during which participants will receive a diet that reflects the eating habits of Canadians.
223810416|NCT04023864|DIETARY_SUPPLEMENT|Platycodon Grandiflorus Extract(GCWB107)|Once-daily, once a tablet, after meals, for 12 week
223810417|NCT04023864|DIETARY_SUPPLEMENT|Placebo|Placebo for 12 week
223810418|NCT05073042|BEHAVIORAL|Morning exercise goal|Participants will be instructed to walk at a moderate intensity for at least 15 continuous minutes between 5 AM and 10 AM each day.
223810419|NCT05073042|BEHAVIORAL|Evening exercise goal|Participants will be instructed to walk at a moderate intensity for at least 15 continuous minutes between 5 PM and 10 PM each day.
223810420|NCT05073042|BEHAVIORAL|Time of choice exercise goal|Participants will be instructed to walk at a moderate intensity for at least 15 continuous minutes at a time of their choice each day. This time can change day-to-day.
223810421|NCT03649555|DRUG|[18F]-FTC-146|Two 5 mCi \[18F\]-FTC-146 doses will be administered intravenously on two separate scan days at least one week apart (total per study = 10 mCi) Participants who complete both test days will receive 10 mCi total dose; however, if a participant is unable to return for a second test day due to unforeseen circumstances, they will receive 5 mCi total dose.
223810422|NCT05911568|PROCEDURE|Endovascular Stroke Treatment|Patients who receive endovascular stroke treatment when they are admitted into the hospital, as determined by their clinical care team. Endovascular stroke treatment consist of catheter-based treatment for the blood clot causing the acute ischemic stroke
223810423|NCT05911568|OTHER|Medical Management|Patients who receive MMM when they are admitted into the hospital, as determined by their clinical care team. MMM may involve any combination of the following: intravenous thrombolysis, antiplatelets, anti-hypertensives, cholesterol-lowering medications, and rehabilitative care. Specifically, this treatment does not involve endovascular stroke treatment.
223810424|NCT05254184|DRUG|Pooled Mutant KRAS-Targeted Long Peptide Vaccine 0.3mg each; 1.8mg total peptides|administering the KRAS peptide vaccine with poly-ICLC adjuvant in combination with nivolumab and ipilimumab
223810425|NCT03117595|DRUG|Bupivacaine-fentanyl|Dosages as previously written
223810426|NCT03117595|DRUG|Bupivacaine-fentanyl morphine|Dosage as previously written
223810427|NCT06409221|OTHER|Non-interventional study, Observational only|Observational study only, there are no planned interventions.
223810428|NCT03683797|OTHER|Post-discharge call|Patients will receive a call 1-3 days after they were discharged from the hospital to make sure their healthcare needs are being met.
223810429|NCT01059630|DRUG|Obinutuzumab|IV infusion.
223810430|NCT01059630|DRUG|Bendamustine|IV infusion.
223810431|NCT06029556|OTHER|Mobility out of Bed|Active upper limb exercises will be conducted (flexion-extension and adduction-abduction) of large joints (shoulder, elbow and wrist) Associated with upper limb exercises, patients will undergo a series of exercises ergometer with lower limb (LL). The mobilization will be conduct on a cycle ergometer in an active, lasting 20 minutes, divided into three steps: heat 5 minutes; 10 minutes of low-intensity exercise, with a speed of 30 revolutions per minute (rpm); and 5 minutes recovery. The patient remains in the supine position with the head of the bed elevated to 45 degrees, while the lower limbs will remain planned
223810432|NCT06029556|OTHER|Ergometry in Bed|Ankle pumps (5\*2), knee extension (5\*2), breathing exercises with elbow flexion and extension(5\*2), spirometry and progressive early ambulation (from bed to wheelchair and wheelchair to standing and from standing to few steps), and conventional chest physical activity (5 minutes on precursor)
223810433|NCT01572025|DRUG|Dehydroepiandrosterone|"Dehydroepiandrosterone (DHEA)(St Mary's Pharmaceutical Unit Cardiff and Vale) DHEA 75 mg capsule. 1 capsule taken once daily for at least 12 weeks prior commencing ovarian stimulation protocol~: Stimulation protocol standard long down-regulation protocol, using human menopausal gonadotropin (HMG)"
223810434|NCT01572025|DRUG|Placebo|"Matched Placebo containing no active ingredient. 1 capsule taken once daily for at least 12 weeks prior commencing ovarian stimulation protocol~: Stimulation protocol standard long down-regulation protocol, using human menopausal gonadotropin (HMG)"
223810435|NCT00052676|DRUG|patent blue V dye|
223810436|NCT00052676|PROCEDURE|radionuclide imaging|
223810437|NCT00052676|PROCEDURE|sentinel lymph node biopsy|
223810438|NCT00052676|RADIATION|technetium Tc 99m sulfur colloid|
223810439|NCT04045821|DRUG|AMD3100|Subjects in this arm will have AMD3100 administered per the standard dosing regimen of 0.24 mg/kg actual body weight subcutaneous x1 dose
223810440|NCT04045821|DRUG|Normal saline|Subjects in this arm will have a placebo of normal saline administered subcutaneously x1 dose
223810441|NCT04045821|PROCEDURE|dilation and curettage|all participants will undergo routine D\&C procedure
223810442|NCT04988802|DIETARY_SUPPLEMENT|Prenatal Nutrients Solgar|Patients will take dietary supplement Prenatal Nutrients from Solgar
223810443|NCT04988802|OTHER|Placebo|Placebo capsules based on starch.
223810444|NCT00325325|DRUG|everolimus and tacrolimus|
223810445|NCT01241383|DRUG|Bosentan|Bosentan 62.5mg bid x 4 weeks; up-titrated to 125mg bid x 20 weeks
223810446|NCT02450630|BEHAVIORAL|Strenghtened referral of children|Community awareness on referral+ trained private providers in using RDTs/ICCM to treat and refer sick children + supervision and regular meetings between the private and public sector.All health workers in the intervention arm will be trained on how to recognize and distinguish uncomplicated \& severe malaria, supplying unit-dose packaged Coartem® to customers with uncomplicated malaria, and administration of rectal artesunate pre-referral treatment and referral for sick children with severe and complicated malaria, diarrhoea and pneumonia.Private outlets in intervention arm will be trained to improve diagnosis, treatment and referral of children. The intervention will thus contribute to better health seeking practices at a community level and improved quality of care in the private sector
223810447|NCT04888091|PROCEDURE|Cotton swab|Removal of the cervical mucus with a cotton swab before embryo transfer.
223810448|NCT04888091|PROCEDURE|Cannula|Removal of the cervical mucus with a cannula before embryo transfer.
223810449|NCT01488565|DRUG|Azacitidine and eltrombopag|Standard: azacitidine D1-5, 8\&9, until loss of clinical benefit. Experimental: eltrombopag at a dose ranging from 50-300mg for 6 months, continuing only in those deriving clinical benefit.
223810450|NCT06296823|BEHAVIORAL|Simulated jetlag protocol|16 hours of wakefulness and an 8 hour scheduled sleep opportunity in a simulated jetlag protocol where you will go to bed and awaken earlier than usual.
223810451|NCT03044522|OTHER|Opioid Education|
223810452|NCT06222372|DRUG|Rifampin|antibiotic
223810453|NCT06500559|PROCEDURE|PRP injection|PRP (0.7 ml = 70 unit) will be injected submucosal disto-buccal and disto-palatal to the maxillary canine like the local anesthesia injection in group I experimental sides
223810454|NCT06500559|PROCEDURE|Combined decortication and PRP injection|Experimental sides will receive PRP injection after performing decortication. After administration of local anesthesia, two-line flap will be performed from the mesial surface of the maxillary second premolar to the distal surface of the maxillary canine Mucoperiosteal flap will be reflected in the buccal side. Two millimeters of marginal crestal bone will be held intact and using a high-speed drill and a round carbide bur (1mm diameter) under copious saline irrigation, the cortical wall will be penetrated to reach marrow spaces. Multiple perforations (10 holes for standardization) in the cortical bone will be created. The surgical site will then rinsed, and the flap will be repositioned and sutured.
223810455|NCT03351738|DRUG|MEDI5884|Participants will receive SC dose of MEDI5884 50 mg or 100 mg or 200 mg or 350 mg or 500 mg on Days 1, 31, and 61.
223810456|NCT03351738|DRUG|Placebo|Participants will receive SC dose of placebo (volume matched to MEDI5884) on Days 1, 31, and 61.
223810457|NCT06427122|BEHAVIORAL|EMD Protocol for Urge|During the EMD-U sessions, the patient is asked to focus on the spot on his/her skin where the urge to scratch is highest. The patient is asked to rate the level of urge to scratch this spot on a 10-point scale and to imagine that they scratch this spot as they would like. At the same time eye movements are offered for 30 seconds. This procedure is repeated until the level of urge to scratch has become nihil. This procedure is repeated for all other skin parts where the patient experiences an urge to scratch, until there are no skin parts left. As a homework assignment straight after the first session, the patient is instructed and encouraged to practice the same intervention at home. The two EMD-U sessions and two phone calls, take place in the first three weeks of the study. In the five following weeks, patients are phoned twice to ask for their experiences with the practicing at home.
223810458|NCT06427122|OTHER|Care as Usual|Patients in the control group receive care as usual (CAU), which is the standard care of the dermatologist. In addition to completing the questionnaires at T0, 1, 2, 3, and 4 these patients are not offered any additional treatment or support aimed at their scratching behaviour.
223810459|NCT01375205|OTHER|Cetaphil Restoraderm|Subjects will apply Cetaphil Restoraderm moisturizer once daily to infant's skin. They will bathe their infant with Cetaphil Restoraderm cleanser.
223810460|NCT01375205|OTHER|Standard of Care|Subjects will apply Johnson\&Johnson moisturizer to their infant's skin as often as they wish. They will also use the Johnson\&Johnson cleanser.
223810461|NCT06251739|DRUG|Ivermectin 6 Mg Oral Tablet|A cumulative dose of 60 mg Oral Ivermectin monotherapy (12 mg/day) on five consecutive days (day 1 - day 5) for three consecutive months (180 mg in total)
223810462|NCT06251739|DRUG|Miltefosine Oral Capsule|Oral Miltefosine monotherapy for 12 weeks. 50 mg in the morning and 50 mg in the evening with meal x 84 days (Total 100 mg/day)
223810463|NCT01120158|DRUG|Bevacizumab|Bevacizumab (IV) 10 mg/kg on day 1 and day 15. Treatment repeats every 28 days. Therapy will continue until maximum response, disease progression or unacceptable toxicity.
223810464|NCT01120158|DRUG|Paclitaxel|Paclitaxel (IV) 120 mg/m2,on day 1 and day 15. Treatment repeats every 28 days Therapy will continue until maximum response, disease progression or unacceptable toxicity.
223810465|NCT04024631|OTHER|75g glucose beverage (Glucola, Trutol, or similar brand)|Subjects will present fasting to the study day and ingest the glucose beverage during the oral glucose tolerance test.
223810466|NCT04024631|OTHER|DXA, whole body|Subjects will undergo a whole body DXA scan for assessment of adiposity index and body fat distribution.
223810467|NCT05995717|DIETARY_SUPPLEMENT|PKU UP|"PKU UP is a food for special medical purposes (FSMP). This product is for use in the dietary management of Phenylketonuria (PKU) in children aged from one (1) to ten (10) years.~PKU UP is a neutral-flavoured, ready-to-drink, low-phenylalanine protein substitute containing a blend of glycomacropeptide (GMP) isolate, essential and non-essential amino acids, fat, carbohydrate, vitamins, minerals and docosahexaenoic acid (DHA)."
223810468|NCT05687032|DRUG|inotuzumab ozogamicin|Given IV
223810469|NCT05239741|BIOLOGICAL|Pembrolizumab|Intravenous (IV) infusion
223810470|NCT05239741|DRUG|Oxaliplatin|85 mg/m\^2 given as an intravenous infusion (IV) on Day 1 in each 14-day cycle (Q2W) as part of the mFOLFOX6 regimen
223810471|NCT05239741|DRUG|Leucovorin|400 mg/m\^2 given as an IV on Day 1 Q2W as part of the mFOLFOX6 and FOLFIRI regimens
223810472|NCT05239741|DRUG|5-fluorouracil|400 mg/m\^2 given as an IV bolus on Day 1 and then 1200 mg/m\^2/day IV over 2 days for a total dose of 2400 mg/m\^2 Q2W as part of the mFOLFOX6 and FOLFIRI regimens
223810473|NCT05239741|DRUG|Irinotecan|180 mg/m\^2 IV on Day 1 Q2W as part of the FOLFIRI regimen
223810474|NCT05239741|BIOLOGICAL|Bevacizumab|IV infusion
223810475|NCT05239741|BIOLOGICAL|Cetuximab|IV infusion
223810476|NCT05464121|BEHAVIORAL|• Blended treatment for AjD combining a self-applied Internet-based program (TAO) with face-to-face sessions via videoconference.|"The self-applied Internet-based program called TAO is accessible online from the platform https://psicologiaytecnologia.labpsitec.es. It is organised into 7 sequential modules of approximately 60 minutes. The patient will do a treatment module every 10-12 days, plus an individual session via videoconference with a therapist (approximately 20-30 minutes long). During these sessions, the therapist will explain the main contents of each module, resolve doubts and motivate the patient to continue with the therapy. It takes about 12 weeks to complete the intervention.~TAO is the optimised version of the original intervention protocol for AjD developed by Botella et al. by Botella et al. (2008) and includes the following therapeutic components: psychoeducation, emotion regulation techniques, exposure, problem-solving techniques, Mindfulness, acceptance and elaboration of the stressful event, positive psychology strategies and relapse prevention."
223810477|NCT05887908|DRUG|co-administration of cefepime and nacubactam|2 g cefepime and 1 g nacubactam
223810478|NCT05887908|DRUG|co-administration of aztreonam and nacubactam|2 g aztreonama and 1 g nacubactam
223810479|NCT05887908|DRUG|imipenem/cilastatin|1 g imipenem/1 g cilastatin
223810480|NCT05369052|DRUG|contezolid acefosamil (IV)/contezolid (PO)|Contezolid acefosamil (IV)/contezolid (PO) administered for a total of 14 to 28 days (28 to 56 doses)
223810481|NCT05369052|DRUG|Linezolid (IV and PO)|Linezolid (IV and PO) administered for a total of 14 to 28 days (28 to 56 doses)
223810482|NCT06384261|DRUG|Cusatuzumab|CD70 monoclonal antibody
223810483|NCT06384261|DRUG|Venetoclax|BCL-2 inhibitor
223810484|NCT06384261|DRUG|Azacitidine|Hypomethylating agent
223810485|NCT02729922|DEVICE|Cardiomems|Eligible patients will undergo implantation of a pulmonary artery sensor (CardioMEMS), a wireless implantable hemodynamic monitoring system in the cardiac catheterization laboratory. This system has a passive wireless, radiofrequency sensor without batteries or leads. Patients transmit data through a device in their home that interacts wirelessly with the sensor. Clinicians retrieve this data via a web interface to use in making management decisions for patients.
223810486|NCT03604406|BIOLOGICAL|Varicella Zoster Vaccine|live-attenuated vaccine to prevent herpes zoster
223810487|NCT03604406|OTHER|Placebo Injection|Saline solution injection
223810488|NCT03604406|BIOLOGICAL|Varicella Zoster Vaccine|non-live vaccine to prevent herpes zoster
223810489|NCT03871088|DIETARY_SUPPLEMENT|Omega-3 fatty acids|12-week double-blind, randomized controlled trial
223810490|NCT02557490|DRUG|oxaliplatin and raltitrexed|"TACE methods: use of epirubicin 20-40mg emulsifier lipiodol embolization target vessel, with gelatin sponge particles or PVA particles or microspheres embolization supplement.~Hepatic arterial chemotherapy: Bi embolization catheter in the hepatic artery or left hepatic artery branch within the right, chemotherapy, for the experimental group (A group): OXA 130mg / m2 artery 0-4 hours pumped Raltitrexed 3mg/m2 4-5 hours pumped into the arteries; the control group (group B)"
223810491|NCT05889689|BEHAVIORAL|Relationship Smarts Plus & Mind Matters|18.5 hours long intervention that combines the Relationship Smarts Plus teen pregnancy prevention curriculum with lessons from the Mind Matters trauma-coping skills curriculum
223810492|NCT05889689|BEHAVIORAL|Relationship Smarts Plus alone|14-hour-long curriculum that addresses pregnancy prevention within the context of teaching relationship skills for young teens.
223810493|NCT05889689|BEHAVIORAL|Preparing Adolescents for Young Adulthood (PAYA).|A financial literacy curriculum
223810494|NCT03653546|DRUG|AZD3759|AZD3759 200mg PO BID.
223810495|NCT03653546|DRUG|Erlotinib|SoC EGFRTKI Erlotinib 150 mg PO Q.D
223810496|NCT03653546|DRUG|Gefitinib|SoC EGFRTKI Gefitinib 250 mg PO Q.D
223810497|NCT06376760|OTHER|No interventions, it is a observational study|No interventions, this study is to compare the dosage requirement of intravenous anesthetic drug during digestive endoscopy between insomnia group and normal sleep group.
223810498|NCT06960070|DEVICE|Saremco print resin|The teeth were restored with Saremco print resin via Asiga Max printer according to the manufacturer's instructions.
223810499|NCT06960070|DEVICE|Varseosmile Crownplus resin|The teeth were restored with Varseosmile Crownplus resin via Asiga Max printer according to the manufacturer's instructions.
223810500|NCT06960070|DEVICE|Varseosmile TriniQ resin|The teeth were restored with Varseosmile TriniQ resin via Asiga MAx printer according to the manufacturer' instructions
223810501|NCT06160986|BEHAVIORAL|Horizons Group Intervention|The Horizons Group intervention in English or Spanish language (per participant preference) contains 8 weekly group sessions delivered via video conference by a bone marrow transplant clinician and behavioral health specialist, over approximately 8 weeks, approximately 1.5 hours per session every week. The intervention pairs state-of-the-science information about survivorship and chronic graft versus host disease with self-management strategies. Intervention sessions will be delivered via video conference (Zoom), which participants may access by computer, laptop, tablet, or smart phone. As part of the intervention, participants will have access to an intervention manual and audio-recorded relaxation exercises to support learning and skills practice.
223810502|NCT06502665|OTHER|Women having had second ovulation induction after failed oocyte pick-up|IVF success is defined by the number of retrieved oocytes. Identifying women at risk of failed oocyte pick-up at the first oocyte pick-up and optimizing their ovulation induction could enhance outcomes
223810503|NCT05335928|DRUG|Abatacept plus|"Up to 4 study drug infusions at 10 mg/kg, IV~Drug: Standard of care Local standard of care per written policies or guidelines Other Name: SoC"
223810504|NCT05335928|DRUG|Placebo|Drug: Standard of care Local standard of care per written policies or guidelines Other Name: SoC
223810505|NCT05688059|OTHER|Absorbable Suture and Permanent Suture|Absorbable Suture and Permanent Suture
223810506|NCT05982873|DRUG|Telisotuzumab Adizutecan|Intravenous (IV) Infusion
223810507|NCT02514681|DRUG|Trastuzumab|
223810508|NCT02514681|DRUG|Pertuzumab|
223810509|NCT02514681|DRUG|Docetaxel|
223810510|NCT02514681|DRUG|Paclitaxel|
223810511|NCT02514681|DRUG|Nab-paclitaxel|
223810512|NCT02514681|DRUG|Vinorelbine|
223810513|NCT02514681|DRUG|Eribulin|
223810514|NCT02514681|DRUG|Capecitabine|
223810515|NCT02514681|DRUG|Gemcitabine|
223810516|NCT05950945|DRUG|Trastuzumab Deruxtecan|Intravenous administration, 5.4 mg/kg on Day 1 of each 21-day cycle until radiographic disease progression as assessed by the investigator, unacceptable toxicity, other discontinuation criteria are met, or 2 years after first dose of study drug
223810517|NCT05997407|BEHAVIORAL|Organic Conceptions mindset management program|"Organic Conceptions is a theoretical model and corresponding 9-step cognitive-based therapy program that enables people to understand where they are in their fertility journey, and provides them with coping strategies to reframe the painful emotional side effects of infertility. In addition to the 9-step program, there are mini-classes on the key triggers that people face when dealing with infertility.~The intervention consists of a series of assignments that participants in the intervention group will complete for a ten-week period. These assignments will take approximately three hours per week to complete. In addition, participants will complete biweekly live support group sessions led by certified coaches and will have the option to join a Facebook support group."
223810518|NCT06398652|BIOLOGICAL|CMAB015|Patients would receive 300 mg CMAB007 subcutaneous injections at week 0, 1, 2, 3, 4, 8 as induction therapy. Patients who obtain a 75% improvement relative to baseline in PASI scores would receive 300 mg CMAB007 subcutaneous injections every 4 weeks as maintain therapy, until the last treatment at week 48.
223810519|NCT06398652|BIOLOGICAL|Secukinumab|Patients would receive 300 mg secukinumab subcutaneous injections at week 0, 1, 2, 3, 4, 8 as induction therapy. Patients who obtain a 75% improvement relative to baseline in PASI scores would receive 300 mg secukinumab subcutaneous injections every 4 weeks as maintain therapy, until the last treatment at week 48.
223810520|NCT05800743|DEVICE|GORE® Ascending Stent Graft (ASG device)|Endovascular aortic repair of the ascending aorta
223810521|NCT05800743|DEVICE|GORE® Thoracic Aortic Graft Thoracic Branch Endoprosthesis (TBE Device)|Endovascular aortic repair of the ascending aorta/aortic arch
223810522|NCT05800743|PROCEDURE|Surgery|Open surgical repair of the ascending aorta and/or the aortic arch
223810523|NCT04121026|OTHER|External validation of the PAANTHER TB treatment decision algorithm|"The PAANTHER algorithm will be used for a TB treatment decision by site clinicians in all children enrolled in the study. The PAANTHER algorithm and prediction score was designed as a guiding tool for empirical TB treatment decision in HIV-infected children with presumptive TB. The proposed score includes:~* history of contact~* suggestive TB symptoms~* tachycardia~* chest radiography~* abdominal ultrasound~* Xpert MTB/RIF Ultra.~A score of \>100 is highly predictive of TB. In children with a score \>100, anti-TB treatment will be initiated immediately. In children with a score of \<100, TB treatment will not be initiated except in those with severe/life-threatening conditions for whom TB treatment decision could be made at the discretion of the site clinician. TB could be definitely ruled out after further assessment and decision made as to what treatment the children should receive in accordance with existing national protocols, along with clinical follow-up."
223810524|NCT04367584|OTHER|Clinical and laboratory examination|Clinical and laboratory examination (follicular content of acne lesions were obtained for fungal microscopic examination and fungal culture)
223810525|NCT01348750|OTHER|Healing Touch & Guided Imagery|"Healing Touch (HT) is an energy based approach to health and healing. It uses light touch to influence the energy field that surrounds the body, and the energy centers which control the flow of energy to the physical body.~HT complements traditional health care and is used together with other approaches to health and healing.~Guided Imagery (GI) is a form of focused relaxation used to create harmony between the mind and body. Positive mental imagery can promote relaxation, reduce stress and improve mood as well as alter heart rate, blood pressure and breathing."
223810526|NCT05855226|OTHER|OTHER-intervention (Occupational Therapy at Home E-Rehabilitation)|The occupational therapist will use activity monitoring and coaching techniques with videoconference during OTHER.
223810527|NCT05034432|PROCEDURE|Intra-Op Prophylactic VT ablation|For surgical intra-operative ablation, efforts will be made to identify scarred myocardium based on methods such as cardiac magnetic resonance imaging, nuclear scans, and/or echocardiogram. Electrophysiological mapping may be obtained either pre-surgery or intra-operation. Mapping and ablation will be performed with the currently approved and updated mapping and ablation systems available at each center. Voltage mapping of the ventricle(s) to delineate scars will be carried out through electroanatomic mapping
223810528|NCT05034432|OTHER|Conventional Management|To ensure uniformity in control arm, a standardized AAD regimen is recommended among subjects randomized to the medical management control arm. Subjects who are already on a stable AAD regimen, such as amiodarone, sotalol or dofetilide, these should be continued
223810529|NCT04290130|OTHER|Measurement of brain activity using electrodes.|We will present audiovisual speech and record neural responses.
223810530|NCT04605731|BIOLOGICAL|Durvalumab|Given IV
223810531|NCT04605731|BIOLOGICAL|Tremelimumab|Given IV
223835464|NCT04400708|PROCEDURE|adductor canal block|After the end of the surgery, at the arrival of PACU, the patient's leg is prepared and draped in a sterile manner. Assisted by the high-frequency linear ultrasound transducer, we target the mid-thigh level and the 22-gauge/8cm needle is introduced in plain through the sartorius muscle. the correct position for the tip of the needle in the adductor canal is checked and a bolus injection of 0.5% ropivacaine 15ml is given.
223810532|NCT05614089|DRUG|Insulin Glargine|"Formulation: Available as a clear liquid in a glass cartridge (1 cartridge =3ml=300 units).~Route: Reusable pen~Amount of each dose: varies depending on baseline basal insulin needs~Dose escalation scheme: Participants randomly assigned to glargine will start with a dose that is generally equal to 80% of their total basal human insulin dose prior to the switch (per ISPAD guidelines and the switching guide developed by Life for a Child with the guidance of Dr. Ragnar Hanas and two other ISPAD members familiar with less-resourced settings).~Frequency of dose: once per day (usually administered before bedtime)~Duration of therapy: 12 months"
223810533|NCT05614089|DRUG|NPH or premixed 70/30 (human insulin)|"Formulation: Available as a liquid in a glass cartridge (3ml=300IU) or as liquid in a prefilled, disposable pen (3ml=300IU).~Route: Bangladesh = reusable pens; Tanzania = disposable pens~Amount of each dose: varies depending on baseline basal insulin needs (per usual care or treating clinician)~Frequency of dose: once or twice per day (per usual care or treating clinician)~Duration of therapy: 12 months"
223810534|NCT03809273|DRUG|Yangxinshi|Yangxinshi pill 3 pills /tid
223810535|NCT03809273|DRUG|Trimetazidine|Trimetazidine 20mg/tid
223810536|NCT03809273|DRUG|Yangxinshi mimic|Yangxinshi mimic tablets 3 pills /tid
223810537|NCT03809273|DRUG|Trimetazidine mimic|Trimetazidine mimic tablets 20mg/tid
223810538|NCT05656040|BIOLOGICAL|MK-2060|MK-2060 lyophilized powder diluted in normal saline and administered subcutaneously
223810539|NCT05656040|DRUG|Placebo|Normal saline administered subcutaneously
223810540|NCT06356220|OTHER|Gluten-Free Diet Education|The two groups will receive different gluten free diet education interventions. Currently, virtual GFD education classes are the standard of care for educating children with CeD and their families about GFD at Boston Children's Hospital. Thus, all diet education (including GFFG intervention) will be provided virtually by Registered Dietitians with expertise in GFDs. .
223810541|NCT01712477|DRUG|Intravenous sedation using propofol|Patients will be given intravenous sedation for treatment of traumatic brain injury requiring mechanical ventilation
223810542|NCT01712477|DRUG|Intravenous sedation with midazolam|patients with severe traumatic brain injury requiring mechanical ventilation and sedation will be sedated with midazolam
223810543|NCT04875286|OTHER|Electronic Health Record Review|Medical records reviewed
223810544|NCT04875286|OTHER|Questionnaire Administration|Complete questionnaires
223810545|NCT06370481|OTHER|Telemedicine|Routine care administered via telemedicine
223810546|NCT06370481|OTHER|Standard of care|Standard of care, as received in HIV clinic settings
223810547|NCT05183672|PROCEDURE|Telecare consultation|Using Zoom to communicate with patients
223810548|NCT05183672|PROCEDURE|Usual face-to-face consultation|Face-to-face communication with patients
223810549|NCT05470101|DRUG|ITI-333|ITI-333 oral solution
223810550|NCT05543616|BIOLOGICAL|Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 3 microgram dose|Injection in the muscle
223810551|NCT05543616|BIOLOGICAL|Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 6 microgram dose|Injection in the muscle
223810552|NCT05543616|BIOLOGICAL|Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 10 microgram dose|Injection in the muscle
223810553|NCT05543616|BIOLOGICAL|Variant-adapted BNT162b2 (Omicron XBB.1.5) 3 microgram dose|Injection in the muscle
223810554|NCT05543616|BIOLOGICAL|Variant-adapted BNT162b2 (Omicron XBB.1.5) 6 microgram dose|Injection in the muscle
223810555|NCT05543616|BIOLOGICAL|Variant-adapted BNT162b2 (Omicron XBB.1.5) 10 microgram dose|injection in the muscle
223810556|NCT05543616|BIOLOGICAL|Variant-adapted BNT162b2 (Omicron KP.2) 10 microgram dose|Injection in the muscle
223810557|NCT05750654|DEVICE|Small Phlebotomy Tube Group|"In the small tubes group, the recommended blood volumes are 0.5 mL for hematology and single chemistry tests, and 1 mL when multiple chemistry tests are needed. A, a non-formulary medication order will be placed in the electronic medical record to alert nurses to collect blood in small tubes. Participants will continue to use small tubes anytime they are in the ICU or IMU."
223810558|NCT05750654|DEVICE|Standard Phlebotomy Tube Group|In the standard tubes group, the recommended blood volumes are 4.0 mL for hematology and 3.0 for chemistry tests.
223810559|NCT06340217|OTHER|washed microbiota transplantation|Washed microbiota transplantation refers to the infusion of washed microbiota from healthy donor into patients' gastrointestinal tract. Participants will receive two doses of WMT for DGP.
223810560|NCT06340217|OTHER|placebo|A carrier fluid with matching volume and consistent appearance to the infusion of washed microbiota.
223810561|NCT04130802|DRUG|OCS-01 - Dexamethasone Cyclodextrin Nanoparticle Ophthalmic Suspension 1.5% mg/mL|OCS-01 eye drops
223810562|NCT04130802|DRUG|Placebo|Vehicle eye drops
223810563|NCT04073745|OTHER|Quality-of-Life Assessment|Ancillary studies
223810564|NCT04073745|OTHER|Questionnaire Administration|Ancillary studies
223810565|NCT04073745|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
223810566|NCT03083288|DRUG|[18F]FluorThanatrace|\[18F\]FluorThanatrace is a radiotracer for PET/CT
223810567|NCT06156423|OTHER|Motor control exercise|Motor control exercises include stabilization exercises for the scapula with external focus by activating the correct alignment and kinetic chain by providing verbal feedback and visual feedback.
223810568|NCT06156423|OTHER|Standard exercise|The standard rehabilitation group received a rehabilitation program via video call 3 days a week for 12 weeks.
223810569|NCT06851481|DEVICE|Ladera LBC System|Use of the Ladera LBC System to close the femoral arteriotomy
223810570|NCT02718274|DEVICE|OraQuick ADVANCE HIV I/II test kits, packaged for self-use (manufactured in Thailand)|Community based distribution of self-tests
223810571|NCT02718274|OTHER|Home-based initiation of ARVs|Home-based initiation of ARVs by study nurse linked to follow-up at clinic
223810572|NCT03401684|BEHAVIORAL|Resilient Minds|The program is designed: 1) to decrease the risk of developing a stress disorder or other mental illnesses due to workplace incidents and/or unhealthy stress; 2) to mitigate the negative impacts of mental illness and trauma through early recognition and early intervention; 3) to support the public while on the frontline; and 4) to improve the psychological health of fire staff while cultivating resilience and enhancing quality of life.
223810573|NCT02044991|DRUG|Corticosteroid|40mg of a non-fluorinated injectable glucocorticoid, methylprednisolone acetate (1cc) combined with 1cc of 1% Lidocaine
223810574|NCT02044991|DRUG|Placebo Injection|A placebo injection
223810575|NCT00701038|DEVICE|auto adjusting bi-level positive airway pressure device|auto adjusting bi-level positive airway pressure device is provided for treatment of obstructive sleep apnea.
223810576|NCT02954523|DRUG|Dasatinib|oral every day
223810577|NCT02954523|DRUG|Osimertinib|oral every day
223810578|NCT00439712|DRUG|Levocetirizine|1 tablet of Levocetirizine 5 mg OD in the morning for 29+/-4 days
223810579|NCT00439712|DRUG|Placebo|1 placebo tablet OD in the morning for 29+/-4 days
223810580|NCT03079154|OTHER|Teacher-led MBCT course|9 x 2 hour group sessions following national guidelines for mindfulness-based cognitive therapy
223810581|NCT03079154|OTHER|Self-guided MBCT course|9 weeks of self-guided mindfulness-based cognitive therapy, following an audiobook covering the same material and exercises as the teacher-led intervention
223810582|NCT00685958|DRUG|enoxaparin (XRP4563)|14 days of treatment
223810583|NCT06011941|PROCEDURE|Modified laparoscopic transcystic biliary drainage|First, a needle was passed through a separate skin puncture wound 3 cm below the costal margin on the midaxillary line/posterior axillary line. Second, a lateral incision into the cystic duct was performed medially to allow insertion and embedding of the catheter. Third, a 7-Fr catheter was introduced through the abdominal wall via the cystic duct into the CBD. Fourth, if the position of the catheter inside the CBD was correct (the end of the tube reached the distal CBD but did not pass the papilla), the lateral incision of the cystic duct was closed by a V-Loc closure device using a single-layered, continuous suture in a circling manner to simultaneously cover and anchor the C-tube. After the procedure, an artificial fistula of 3 to 5 mm in length was formed.
223810584|NCT03633942|DEVICE|LMA Supreme|Placement of the LMA Supreme supraglottic airway device for patients undergoing outpatient spine surgery in the prone position.
223810585|NCT03094260|DEVICE|High intensity bright light therapy|"Treatment with light therapy in high intensity (10,000 lux), daily for 30 days between 6 am and 9 am for 30 minutes.~Le device is placed at arm's length (at approximately 50-75cm from the eyes) within the field of vision. The light must bathe the face To ensure the light reaches your eyes, this appliance has a stand that can be set to a variable angle. If subject is sitting higher or standing and the top edge of the appliance is below eye level, the appliance will be placed in a tilted position so that its light points further upwards and reaches the eyes. If subject is sitting at a table or desk and the top edge of the appliance is above eye level. The appliance can be placed in a more upright position."
223835465|NCT04400708|PROCEDURE|control group|After the end of the surgery, at the arrival of PACU, the patient's leg is prepared and draped in a sterile manner. Assisted by the high-frequency linear ultrasound transducer, we target the mid-thigh level and the 22-gauge/8cm needle is introduced in plain through the sartorius muscle. the correct position for the tip of the needle in the adductor canal is checked and a bolus injection of normal saline15ml is given.
223835466|NCT00136903|DRUG|Prochymal® - 2 Million cells/kg|2 million hMSCs/kg actual body weight, IV on study Days 1 and 4
223810586|NCT03094260|DEVICE|Low intensity light therapy|"Treatment with light therapy in low intensity (\<500 lux), daily for 30 days between 6 am and 9 am for 30 minutes.~Le device is placed at arm's length (at approximately 50-75cm from the eyes) within the field of vision. The light must bathe the face To ensure the light reaches your eyes, this appliance has a stand that can be set to a variable angle. If subjectis sitting higher or standing and the top edge of the appliance is below eye level, the appliance will be placed in a tilted position so that its light points further upwards and reaches the eyes. If subject is sitting at a table or desk and the top edge of the appliance is above eye level. The appliance can be placed in a more upright position."
223810587|NCT03246282|DEVICE|UVL1000 Treatment Station|"Non-coherent light source administered 365 nm, 630 nm, and 530 nm at an output intensity of 0.1 mW directly into an existing intravascular 20 gauge 1.0 catheter"
223810588|NCT03246282|DRUG|Normal Saline 0.9% Infusion Solution Bag|250 ml of 0.9% Sodium Chloride Solution
223810589|NCT03246282|DEVICE|Peripheral Catheterization|"20-gauge 1.0 catheter"
223810590|NCT03737838|DEVICE|Atrial fibrillation ablation|High density mapping of left atrium using Rhythmia mapping system to identify gaps in conduction and wavefront discontinuities (deceleration zones)
223810591|NCT03661138|DRUG|Upadacitinib|Upadacitinib is administered orally.
223810592|NCT03661138|DRUG|Placebo for upadacitinib|Placebo is administered orally.
223810593|NCT03661138|DRUG|Topical Corticosteroids (TCS)|It is administered concomitantly with upadacitinib or placebo.
223810594|NCT05488132|DRUG|anti-siglec-6 CAR-T cell therapy|Enrolled patients will receive prespecified dose of autologous CAR-T cells.
223810595|NCT03818282|DRUG|Paclitaxel for injection (albumin-bound)|Paclitaxel for injection (albumin-bound) 260 mg/m2, i.v., d1; AUC = 5 for carboplatin injection, i.v., infusion completed on day 1-3; Repeated every 3-4 weeks for 6-8 cycles.
223810596|NCT03371082|BIOLOGICAL|Gan & Lee Insulin Glargine Injection|Route of administration: subcutaneous injection
223810597|NCT03371082|BIOLOGICAL|Lantus®|Route of administration: subcutaneous injection
223810598|NCT01064297|DRUG|Lamotrigine monotherapy|Lamotrigine monotherapy
223810599|NCT01064297|DRUG|Lamotrigine polytherapy including valproate|Lamotrigine polytherapy including valproate
223810600|NCT01064297|DRUG|Lamotrigine polytherapy without valproate|Lamotrigine polytherapy without valproate
223810601|NCT04549610|DIETARY_SUPPLEMENT|HMB supplementation|Group taking oral HMB supplementation in a blinded capsule form.
223810602|NCT04549610|DIETARY_SUPPLEMENT|Placebo treatment|Group taking oral supplementation with placebo (corn starch) in a blinded capsule form.
223810603|NCT03027648|PROCEDURE|Placement of levonorgestrel-releasing intrauterine system|All the patients accepted treatment of levonorgestrel-releasing intrauterine system
223810604|NCT06185933|DRUG|Lidocaine Spray|Pharyngeal anesthesia using a topical lidocaine spray was administered in the preprocedure room, in the absence of the endoscopist or the research assistant. 5 minute before the UGE without any sedation
223810605|NCT06185933|DRUG|Lidocaine Viscous+Lidocane spray|Pharyngeal anesthesia using topical viscous lidocaine solution + lidocaine spray were administered in the preprocedure room, in the absence of the endoscopist or the research assistant. 5 minute before the UGE without any sedation
223810606|NCT02259738|DRUG|Human Urinary Kallidinogenase|
223810607|NCT02259738|DRUG|Shuxuening injection|
223810608|NCT02161302|DEVICE|transcranial direct current stimulation (tDCS)|The stimulation will be administered with a pair of surface electrodes, sponge coated, soaked in saline. A battery-powered constant current stimulator will be used for this purpose (tDCS device Soterix 1X1). The stimulation is performed by placing the anodal electrode in the primary motor cortex (M1) and the cathodal one in the contralateral supraorbital area and it will use a 2 mA current.
223810609|NCT02161302|DEVICE|Sham Transcranial Direct Current Stimulation|The sham tDCS consists of the same montage of the active tDCS, but the device is turned off 30 seconds after initiating stimulation (without letting the patient notice it). Rest of the montage is kept identical as the active one during the 20 minutes that the session lasts.
223810610|NCT03943784|PROCEDURE|Endoscopic Variceal Ligation|Endoscopic varices ligation was performed with a six-shooter multiband ligator (Cook Medical, Limerick, Ireland) if medium to large varices or reddish spots, regardless of the grade of the varix, were observed. Each varix was ligated 1-2 cm above the gastro-esophageal junction, with 1 or 2 rubber bands and using no more than 5 rubber bands per session.
223810611|NCT03943784|DRUG|Non-Selective Beta-Blocking Agent|Patients of the Propranolol group that presented medium to large esophageal varices without contraindication to Non-Selective Beta-Blockers, received propranolol, 1 mg/Kg/day every 8 hours, titrated to reduce the basal heart rate in 25% and not exceeding 5 mg/Kg/day. Patients were evaluated monthly until this reduction in heart rate was achieved, and every three to six months thereafter.
223810612|NCT05964608|BEHAVIORAL|Behavioral Therapy|"Structured interviews, consisting of a total of 6 sessions, were held once every two weeks for men with premature ejaculation problems. Behavioral therapy took place once every two weeks for a total of six 45-minute sessions. The stop-start technique was the therapy used. Behavioral therapy interviews were conducted at the urology outpatient clinic of the hospital. Post-tests were administered to men with premature ejaculation (PEDT) and their spouses (FSFI and SQOL-F) immediately after the 6th session was completed."
223810613|NCT00032474|DRUG|Ginkgo biloba extract|
223810614|NCT01134146|RADIATION|IMRT|Delivery of whole-pleura radiation doses beginning with 1) 45 Gy to low-risk region and 60-66 Gy to high-risk region; then 2) the same dosing regimen as above with a third dosing level, 50 Gy to an intermediate-dosing region. Every weekday (Monday-Friday) for up to 5 weeks, lasting about 45-60 minutes.
223810615|NCT04475432|DRUG|TP-03, 0.25%|TP-03, lotilaner ophthalmic solution, 0.25%, administered twice a day
223810616|NCT04475432|DRUG|TP-03 Vehicle|Vehicle of TP-03 ophthalmic solution, administered twice a day
223810617|NCT03369379|DRUG|D3 Vitamin|Subjects will receive a capsule of 50,000 units of vitamin D3 echa week for 12 weeks, basal levels of vitamin D will be taken and again at week 12.
223810618|NCT03369379|OTHER|Placebo|Placebo pill
223810619|NCT03872479|DRUG|EDIT-101|Participants will receive a single dose of EDIT-101 administered via subretinal injection in the study eye. Up to 5 cohorts across 3 doses will be enrolled in this study.
223810620|NCT06517667|DRUG|Icross tear substitute|Patients were instructed to instill 1 drop of 0.20% Cross-linked hyaluronic acid substitute into each eye 3 times per day for 3 months.
223810621|NCT06517667|DRUG|Hyabak tear substitute|Patients were instructed to instill 1 drop of 0.15% hyaluronic acid substitute into each eye 3 times per day for 3 months.
223810622|NCT04050774|DEVICE|Balance boards|The unstable surface will be created with a balance board consisting of a wooden board mounted on a section of a cylinder, creating an unstable support in the sagittal plane or in the frontal plane. The participants will stand on three balance boards, varying the height of the surface of the board above the point of contact (15, 17 and 19 cm respectively). The radius of the cylinder will kept constant at 24 cm. The standing surface will be 48cm x 48 cm
223810623|NCT02168530|DRUG|placebo|matching placebo administered daily orally
223810624|NCT02168530|DRUG|vismodegib|vismodegib 150 mg administered daily orally
223810625|NCT00228605|DRUG|OraVescent Fentanyl|
223810626|NCT00992680|DEVICE|ROX Anastomotic Coupler System (ACS)|The ACS will be used to create an arteriovenous fistula in the iliac region (between the iliac artery and vein)
223810627|NCT00002180|DRUG|Tenofovir|
223810628|NCT03059758|OTHER|fMRI|All participants are scanned while evaluating deductive reasoning problems. Their math skill is also assessed.
223810629|NCT05203484|DEVICE|Multielecotrde Mapping|Multielectrode Mapping with Pentaray/Octaray
223810630|NCT05203484|DEVICE|Point-by-point mapping|Point-by-point mapping with QDot
223810631|NCT01756911|DEVICE|MFM|Implantation of the MFM
223810632|NCT04876079|OTHER|Test to induce a decline in plasma glucose|Participants will be admitted at the research center at 7:00 after an overnight fast. A venous catheter will be inserted into an arm vein for blood sampling purposes. A subcutaneous insulin bolus will be administered to bring plasma glucose to the glycemic threshold. Oral carbohydrates (16g) will be given when plasma glucose levels are at the target threshold. Sixty minutes after carbohydrates consumption, a standardized meal will be provided and participants will be discharged 90 minutes after the meal.
223810633|NCT04876079|DEVICE|Dexcom G6|Participants will have to wear a Dexcom G6 during study interventions
223810634|NCT04876079|OTHER|Dex4|When the glycemic threshold is reach, participants will be given 16g of Dex4
223810635|NCT04876079|DRUG|Insulin|A subcutaneous insulin bolus will be given to induce a decline in plasma glucose and reach the glycemic threshold.
223810636|NCT03763162|DRUG|Bortezomib|Given SC
223810637|NCT03763162|BIOLOGICAL|Daratumumab|Given IV
223810638|NCT03763162|DRUG|Dexamethasone|Given IV or PO
223810639|NCT03763162|DRUG|Ixazomib|Given PO
223810640|NCT03763162|OTHER|Quality-of-Life Assessment|Ancillary studies
223810641|NCT04506775|DEVICE|ViTrack|ViTrack is a continuous non-invasive wearable blood pressure cuff.
223810642|NCT04506775|PROCEDURE|Radial artery catheterization|Radial artery catheterization is the standard of care for measuring blood pressure continuously throughout surgery.
223810643|NCT05989698|DEVICE|C-mo System|Patients will use C-mo System for a period of 24h, to assess cough characteristics.
223810644|NCT02175355|DRUG|Low dose of Micardis®|
223810645|NCT02175355|DRUG|Medium dose of Micardis®|
223810646|NCT02175355|DRUG|High dose of Micardis®|
223810647|NCT02175355|DRUG|Hydrochlorothiazide|
223810648|NCT02175355|DRUG|Placebo|
223810649|NCT04540432|OTHER|Stool collection at the patient's home.|Stool samples will be taken from each patient to look for changes in intestinal microbiota. These collections will be made on Day 0 +24h, 24 hours before the 1st follow-up visit after 1 month of treatment with non-steroidal anti-inflammatory drugs, 24 hours after the second follow-up visit (between months 3 and 4) and finally, at the end of treatment.
223810650|NCT04540432|DIAGNOSTIC_TEST|Blood test|7 ml of blood will be taken from each patient before treatment i.e. at the inclusion visit and at the end of treatment.
223810651|NCT04255628|DIAGNOSTIC_TEST|FDG PET|Cancer patients who scheduled whole body FDG-PET image scan for clinically indicated.
223810652|NCT06066437|DRUG|Arm A: 177Lu rhPSMA-10.1|Participants will receive 177Lu rhPSMA-10.1 alone.
223810653|NCT06066437|DRUG|Arm B: 177Lu rhPSMA-10.1 plus Degarelix|Participants will receive 177Lu rhPSMA-10.1 alone. Participants will receive 177Lu rhPSMA-10.1 with Degarelix
223835467|NCT00136903|DRUG|Prochymal®- 8 Million cells/kg|8 million hMSCs/kg actual body weight IV on study Days 1 and 4
223835468|NCT00136903|DRUG|Methylprednisolone|Methylprednisolone 2 mg/kg administered intravenously.
223810654|NCT04589533|OTHER|educational program|The educational program will be based on: a outreach visit (a 3-h face-to-face meeting between a trained diabetes specialist from outside the Center and the staff of the Center itself) and a distance learning (FAD).The educational programme will be focused on current Diabetes Guidelines recommendations and based on possible deviations from the best clinical practice observed during phase1
223810655|NCT02254226|DRUG|Salmeterol Diskus low|
223810656|NCT02254226|DRUG|Salmeterol Diskus high|
223810657|NCT02254226|DRUG|Salmeterol MDI low|
223810658|NCT02254226|DRUG|Salmeterol MDI high|
223810659|NCT06161311|DEVICE|DIMS lenses|Defocus incorporated multiple segments lenses, which use induce peripheral myopic defocus to control for myopia development in children
223810660|NCT04044222|BIOLOGICAL|Sintilimab|IV
223810661|NCT04044222|DRUG|Carboplatin|IV
223810662|NCT04044222|DRUG|Etoposide|IV
223810663|NCT04044222|DRUG|Ifosfamide|IV
223810664|NCT04044222|DRUG|Placebo|IV
223810665|NCT04044222|DRUG|Carboplatin|IV
223810666|NCT04044222|DRUG|Etoposide|IV
223810667|NCT04044222|DRUG|Ifosfamide|IV
223810668|NCT00286845|DRUG|Standard Chemotherapy|physician determined
223810669|NCT04060875|DEVICE|Karuna Labs Virtual Reality Software|The subjects will engage in the three therapeutic modules: laterality, motor imagery, and 'mirroring.' The decision of which module to employ will be based on the subject's readiness and comfort on a case-by-case basis. A subject visit can be expected to last 40 minutes, with enough time to complete PHQ-9, and to accustom to the virtual reality setup by playing in a non-therapeutic virtual environment should they choose to do so. Time in the virtual reality is expected to last approximately 20 minutes per session.
223810670|NCT00269802|DRUG|OROS methylphenidate HCl|
223810671|NCT00269802|DRUG|Ritalin|
223810672|NCT00269802|DRUG|Placebo|
223810673|NCT04716699|PROCEDURE|Biospecimen Collection|Undergo collection of blood and tumor samples
223810674|NCT04716699|DRUG|Lidocaine|Given IV
223810675|NCT04716699|PROCEDURE|Resection|Undergo surgical resection per standard of care
223810676|NCT02674217|PROCEDURE|Hematopoietic stem cell transplantation|autologous transplant using non-frozen peripheral blood stem cells
223810677|NCT06256289|DRUG|Canagliflozin 100mg Tab|Canagliflozin 100mg once daily combined Metformin 1000mg twice daily
223810678|NCT06256289|DRUG|Metformin Hydrochloride|Metformin 1000mg twice daily
223810679|NCT05278130|OTHER|Additional vaginal swabs|Every 2 weeks from 16 weeks gestational age to 34 weeks gestational age
223810680|NCT04914611|OTHER|No intervention|No intervention
223810681|NCT01865916|DRUG|Polyethylene Glycol (PEG) and 15 mg Bisacodyl|Subjects will be asked to take split dose of 2L PEG and 3 tablets of 5 mg Bisacodyl
223810682|NCT01865916|DRUG|Polyethylene Glycol (PEG) + ascorbic acid|Subjects will be asked to take split dose of 2L PEG and vitamin C
223810683|NCT06558929|BEHAVIORAL|Occupational Therapy|Participants will redesign their daily routine with support from occupational therapists and an online health management platform.
223810684|NCT06558929|OTHER|Conventional Treatment|Participants will receive conventional treatment and education on sleep hygiene.
223810685|NCT06068218|OTHER|Biopsy for the patient group|The investigator will perform a 4mm skin biopsy will be performed on 5 body sites: neck, trunk, elbows, wrist and feet. For vitiligo patients, the biopsies will be taken on a non-depigmented skin.
223810686|NCT06068218|OTHER|biopsy for the volunteer group|A publicity in the hospital will announce the study, and will be use to recruit the healthy volunteers. The investigator will perform a 4mm skin biopsy will be performed on 5 body sites: neck, trunk, elbows, wrist and feet.
223810687|NCT06251375|DRUG|Dexmedetomidine|Dexmedetomidine is an α2-adrenergic agonist sedative commonly used in invasive mechanical ventilation that promotes patient wakefulness, has no effect on respiratory drive, has important analgesic properties, and when compared to γ-aminobutyric acid receptor agonists like benzodiazepines, reduces delirium.
223810688|NCT06251375|OTHER|Placebo|Normal saline placebo will be given as continuous infusion.
223810689|NCT05458648|PROCEDURE|Cardiac Ablation for the treatment of persistent Atrial Fibrillation|Patients participating in the study will undergo a cardiac ablation for the treatment of persistent atrial fibrillation.
223810690|NCT06576128|DEVICE|ultrasound|In additional to local anesthesia, 10 ml lidocaine (2%) (Lidon, Onfarma, Turkey ), TAPB will be performed under ultrasound imaging..
223810691|NCT06576128|PROCEDURE|parenteral local anesthesia|As routine procedure; the cardiologist will palpate the right or left femoral artery under sterile conditions and apply approximately 10 ml lidocaine (2%) to this area as local anesthesia (Lidon, Onfarma, Turkey ). Then, a puncture will be made on the anterior wall of the femoral artery with an 18 G needle . Approximately 3-4 mm skin incision will be made with the number 11 scalpel tip and the Seldinger technique will be continued. 6F femoral sheath to be placed, cardiac The catheterization process will begin.
223810692|NCT05311033|OTHER|Exacyl|Healthy males with at risk of post-inflammatory hyperpigmentation have a skin samples for evaluate the activity of tranexamic acid.
223810693|NCT02958852|DRUG|Letrozole|Daily orally
223810694|NCT02958852|DRUG|Letrozole and atorvastatin|Daily orally
223810695|NCT02958852|DRUG|Fulvestrant|Fulvestrant will be used as second line treatment upon progression on first line treatment with letrozole +/- atorvastatin.
223810696|NCT00717860|DRUG|caspofungin acetate|Caspofungin acetate (50 mg/day for participants with esophageal candidiasis and 50 mg/day for participants with invasive candidiasis or aspergillosis after a 70 mg loading dose on Day 1), once daily intravenously (IV) for 1-4 weeks for esophageal candidiasis, 2-8 weeks for invasive candidiasis, 2-12 weeks for aspergillosis.
223810697|NCT00717860|DRUG|Comparator: Micafungin sodium|Micafungin sodium 150 mg/day, once daily IV, for 1-4 weeks for esophageal candidiasis, 2-8 weeks for invasive candidiasis, 2-12 weeks for aspergillosis.
223810698|NCT02917707|OTHER|normal colorectal tissues|The investigators will extract total protein, DNA and RNA from these groups.
223810699|NCT03538015|DRUG|Carvedilol 3.125 mg|Participants will receive a 3.125 mg oral dose of carvedilol twice daily during the 4-week treatment period
223810700|NCT03538015|DRUG|Carvedilol 2.5 mg|Participants will receive a 2.5 mg oral dose of carvedilol twice daily during the 4-week treatment period
223810701|NCT03538015|DRUG|Placebo capsule|Participants will receive a matching oral dose of placebo capsule twice daily during the 4-week treatment period
223810702|NCT04058353|DRUG|ELX/TEZ/IVA|FDC tablet for oral administration.
223810703|NCT04058353|DRUG|IVA|Mono-tablet for oral administration.
223810704|NCT04058353|DRUG|TEZ/IVA|Fixed-dose combination (FDC) tablet for oral administration.
223810705|NCT05663424|OTHER|rTMS-PTi|10 daily sessions of rTMS (1Hz, 1200 short, for totally 20 minutes) plus immediate rehabilitation programs
223810706|NCT05663424|OTHER|rTMS-PTd|10 daily sessions of rTMS (1Hz, 1200 short, for totally 20 minutes) plus delayed rehabilitation programs (\>2hr)
223810707|NCT05663424|OTHER|rTMSs-PT|10 daily sessions of sham rTMS (to vertex) plus rehabilitation programs
223810708|NCT00698646|DRUG|Valsartan + HCTZ|At week 0 patients received V+HCTZ 160+12.5 mg capsules. Subjects not at BP goal \<140/90 mmHg were uptitrated to V+HCTZ 320+12.5 mg at week 4 and if needed to V+HCTZ 320+25 mg at week 8 or 12.
223810709|NCT00698646|DRUG|Valsartan|At week 0 patients received Valsartan(V) 160 mg capsule. Subjects not at BP goal \<140/90 mmHg were uptitrated to V+HCTZ 160+12.5 mg at week 4 and if needed to V+HCTZ 320+12.5 mg at week 8, and V+HCTZ 320+25 mg at week 12.
223810710|NCT00698646|DRUG|HCTZ|At week 0 patients received HCTZ 12.5 mg capsule. Subjects not at BP goal \<140/90 mmHg were uptitrated to V+HCTZ 160+12.5 mg at week 4 and if needed to V+HCTZ 320+12.5 mg at week 8, and V+HCTZ 320+25 mg at week 12.
223810711|NCT05844813|DRUG|Doxorubicin+Ifosfamide+Anlotinib(AI+A)|Doxorubicin（PLD） 40mg/㎡ d1, Ifosfamide（I） 1g/㎡ d1-5, Anlotinib（A）10mg d1-14 Q3weeks \* 3 Circles
223810712|NCT05844813|PROCEDURE|Radical Surgery|Radical sarcoma resectional surgery
223810713|NCT00554918|DRUG|docetaxel|
223810714|NCT00554918|DRUG|prednisolone|
223810715|NCT00554918|DRUG|zoledronic acid|
223810716|NCT00554918|PROCEDURE|quality-of-life assessment|
223810717|NCT00554918|RADIATION|strontium chloride Sr 89|
223810718|NCT01814592|PROCEDURE|coronally partial thickness flap plus connective tissue|The design of the flap will be performed according to the technique described by de Sanctis and Zucchelli 2007.
223810719|NCT01814592|PROCEDURE|coronally mucosal thickness flap|The design of the flap will be performed according to the technique described by Greenwell H, Vance G, Munninger B and Johnston H.
223810720|NCT05907824|OTHER|Histopathological review, long-term prognosis and quality of life follow-up|Histopathological review, long-term prognosis and quality of life follow-up
223810721|NCT02739282|OTHER|Systematic therapeutic drug monitoring|Blood samples with antiepileptic drug level measurement
223810722|NCT04956302|DRUG|Bortezomib|Given SC
223810723|NCT04956302|DRUG|Daratumumab and Hyaluronidase-fihj|Given SC
223810724|NCT04956302|DRUG|Dexamethasone|Given PO or IV
223810725|NCT04956302|DRUG|Panobinostat Lactate|Given PO
223810726|NCT02808364|BIOLOGICAL|Personalized cellular vaccine|Patients with recurrent glioblastoma will undergo tumor resection and receive tumor antigen pulsed cellular vaccines.
223810727|NCT03381768|BIOLOGICAL|PD-L2 peptide|100 ug PD-L2 peptide dissolved in DMSO and water mixed with 500ul montanide.
223810728|NCT03381768|BIOLOGICAL|PD-L2 and PD-L1 peptide|100 ug PD-L2 peptide and 100ug PD-L1 peptide dissolved in DMSO and water mixed with 500ul montanide.
223810729|NCT00319540|BEHAVIORAL|Control with depression course (CWD)|
223810730|NCT04000295|DRUG|Apatinib|Subjects receive Apatinib orally, Dosage form: tablet, Strength: 375 mg/d
223810731|NCT04000295|DRUG|Etoposide|Subjects receive Etoposide capsule orally, d1-14, q3w, Dosage form: capsule, Strength: 50 mg/d
223810732|NCT04000295|DRUG|Paclitaxel|Subjects receive Weekly Paclitaxel, intravenously, d1, d8, d15, q3w, Dosage form: injectable, Strength: 80 mg/m2
223810733|NCT04663022|OTHER|Dunn's sensory profile questionnaire|all children will complete the Dunn Sensory Profile questionnaire
223810734|NCT00279201|DRUG|Insulin glargine|Subcutaneous injection daily
223810735|NCT00279201|DRUG|Lispro Low Mix|Subcutaneous injection twice daily.
223810736|NCT00279201|DRUG|Lispro Mid Mix|Lispro Mid Mix subcutaneous injection 3 times daily.
223810737|NCT00279201|DRUG|Lispro|Lispro subcutaneous injection 3 times daily.
223810738|NCT01391221|DRUG|Duloxetine|Subjects with major depression will be entered into the trial and treated with duloxetine 30 mg for one week, followed by 60 mg for 8 weeks. The option of increasing the dose as clinically indicated to 120mg is possible for the last 4 weeks of the study intervention
223810739|NCT02413164|OTHER|A multimodal physiotherapy programme|"Intervention: individualised Multimodal Physiotherapy Programme of therapeutic exercises with education healthy-style-of-life based.~Groupal sessions two times per week during 12 weeks. Each session 60 minutes: 10 minutes of warm up, 20 minutes of strength and muscular endurance, 20 minuts of aerobic training, 10 minutes of cold-down.~Intensity aerobic training: The training heart rate will be calculated according to recommendations of the American College of Sport Medicine (ACSM), it must oscillate between 55/65% and 90% of the HRmax. Initial four weeks: moderate intensity (55-69% HRmax); Following weeks according to each response, to higher level of training (70-89% HRmax). Strength training: individualised working with the principal muscular groups. 3 sessions using a weight which can repeat the exercise 10-15 times, increasing to a weight at which they can repeat the exercise 8-12 times."
223810740|NCT01444859|DIETARY_SUPPLEMENT|Trenev Trio®/Healthy Trinity®|Trenev Trio®/Healthy Trinity® (1 capsule, 2x/day for 10 weeks), which offers a daily dose of: a) Lactobacillus acidophilus NAS strain (10 billion CFU), b) Bifidobacterium bifidum Malyoth strain (40 billion CFU), and c) Lactobacillus delbrueckii subspecies bulgaricus LB-51 strain (10 billion CFU)
223810741|NCT01444859|DIETARY_SUPPLEMENT|Placebo|Daily placebo for 10 weeks
223810742|NCT01717781|PROCEDURE|Thunderbeat technology|
223810743|NCT01717781|PROCEDURE|Standard bipolar electrosurgery|
223810744|NCT04598867|DRUG|CD-008-0045|CD-008-0045 20 mg capsules
223810745|NCT04598867|DRUG|Placebo|Placebo capsules
223810746|NCT04598867|DRUG|Afobazol|Afobazol 10 mg tabletes
223810747|NCT03281473|OTHER|Strategy 1|PEEP titration according to transpulmonary-end-expiratory pressure
223810748|NCT03281473|OTHER|Strategy 2|PEEP titration according to chest wall elastance measurement
223810749|NCT04980118|BEHAVIORAL|Control group|A nutritional intervention program that consisted of two individual nutritional consults.
223810750|NCT04980118|BEHAVIORAL|Nutrition and physical activity group|A nutritional and physical activity intervention program that consisted of two individual nutritional consults and five nutritional group lectures.
223810751|NCT00162695|DRUG|Ifosfamide, oncovin, actinomycine D, epirubicine, carboplatinum, etoposide|
223810752|NCT03113474|OTHER|Food palatability|Food palatability is modulated
223810753|NCT02792465|DRUG|CFI-402257|
223810754|NCT02792465|DRUG|Fulvestrant|
223810755|NCT04207827|BEHAVIORAL|xSmoker app|xSmoker - mHealth intervention consisted of using the app xSmoker
223810756|NCT04207827|BEHAVIORAL|SMS|Text messages with content based on the Motivation and Problem Solving approach and informed by our prior work.
223810757|NCT04207827|OTHER|Usual Care|Usual postnatal care
223810758|NCT05260996|OTHER|Pilot Group|12 Weeks, 1-1 Hour Session Per Week for 10 Total Curriculum Sessions,including 1 Week of Orientation and 1 Week of Debriefing/Program Graduation.
223810759|NCT01172769|BIOLOGICAL|Temsirolimus|"After dissolving and dilution 25 mg of temsirolimus will be administered i.v. once a week by 30 minute infusion.~Study treatment will continue until tumor progression or unless unacceptable toxicity is encountered."
223810760|NCT01911377|DRUG|Botulinum Toxin Type A|
223810761|NCT01911377|DRUG|Normal Saline for Injection|
223810762|NCT02390531|DRUG|Bevacizumab|Varying dosages in 10µl
223810763|NCT00511875|DRUG|doxycycline monohydrate|50mg once daily for 24 months
223810764|NCT00511875|DRUG|placebo|placebo taken once daily for 24 months
223810765|NCT01536132|DRUG|Levosimendan|0.2 micrograms/kg/min is administered intravenously without bolus for 6 hours every two weeks.
223810766|NCT01536132|DRUG|Placebo|Placebo (same appearance than active drug) is administered with the same dosing regime
223810767|NCT05322148|DRUG|Klarity CL, Cylcosporine 0.1%/Loteprednol Etabonate 0.2% Preservative Free|A number of studies have shown the benefit of both cyclosporine and steroids in managing dry eye. However, existing formulations of these products are challenged by either limited tolerability, a high out-of-pocket cost or both. Combination therapy with these agents in an advanced, more tolerable formulation have the potential to improve both tolerability and cost. However, the available formulation of preservative free Klarity CL (cyclosporine 0.1% and loteprednol 0.2% in a chondroitin sulfate vehicle) has not been studied rigorously.
223810768|NCT00784394|DRUG|diindolylmethane|Given PO
223810769|NCT00784394|OTHER|placebo|Given PO
223810770|NCT00784394|OTHER|pharmacological study|Correlative studies
223810771|NCT00784394|OTHER|laboratory biomarker analysis|Correlative studies
223810772|NCT00784394|OTHER|quality-of-life assessment|Ancillary studies
223810773|NCT06272422|PROCEDURE|hip arthroplasty|resurfacing procedures (HRP), THA and Minihip-type neck-preserving total hip arthroplasty.
223810774|NCT05089838|BIOLOGICAL|CMV-TCR-T cells|Patients who developed refractory CMV infection after allo-HSCT will be enrolled, and donor derived CMV-TCR-T(HLA-A\*1101\\0201\\2402) cells will be intravenously infused with a escalated dose of 0.3-1×10E7CMV-TCR-T cells. The CMV DNA copies and CMV-TCR-T cell proliferation will be monitored in the scheduled time (day 0, day 4, day 7, day 10, day 14,day 28).
223810775|NCT04167605|OTHER|Bone metastasis|Collection of waste tissue samples during surgery and immediate immersion of the same in 10% Neutral buffered formalin. The samples will be send to the laboratory where they will be processed (decalcification, inclusion in paraffin, sectioning etc.) for subsequent analyzes.
223810776|NCT04167605|OTHER|Breast cancer metastatic to bone|Patients will be assisted in the recovery of samples (slides) related to surgery on primary tumor (breast cancer responsible for metastatic disease).
223810777|NCT01458470|DRUG|Memantine|oral tablet, 1 BID, 24 weeks
223810778|NCT01458470|OTHER|Placebo|oral tablet, 1 BID, 24 weeks
223810779|NCT04049318|OTHER|Education+ exercise (delivered digitally)|The intervention consisted of a digital, structured and individualized treatment program for people with hip or knee OA (Joint Academy®; www.jointacademy.com). The program consists of neuromuscular exercises appropriately adjusted to each patient in regard to degrees of complexity and difficulty, continuous access to and dialogue with a physiotherapist through a chat function, and/or telephone , and information in the form of text or video lessons (with quizzes on the material after each episode) on subjects related to OA, OA symptoms and its management.
223810780|NCT04656379|PROCEDURE|spine surgery|Risk factors for postoperative delirium in elderly patients underwent spine surgery will be evaluated.
223810781|NCT00637286|DRUG|Zolmitriptan|5mg Nasal Spray
223810782|NCT04445480|PROCEDURE|Popliteal block|Sciatic nerve block at popliteal fossa would perform before the participant undergoing angioplasty in experimental arm.
223810783|NCT04445480|OTHER|Control|Sciatic nerve at popliteal fossa would be scanned with the ultrasound. The toothpick would be applied to simulate the procedure of nerve block.
223810784|NCT01552564|PROCEDURE|Index of microvascular resistance|
223810785|NCT01552564|OTHER|Cardiac magnetic resonance|
223810786|NCT01552564|OTHER|Blood markers|
223810787|NCT02568631|OTHER|serious game JeStiMulE|The objective of JeStiMulE players will be ending the game after a learning period and two playing periods (with emotional words and idioms, which include three modules each). The session ends when the module is completed, which is approximately one hour per module, or 6 sessions of play.
223810788|NCT02568631|OTHER|control video game|The patients will play 6 sessions of one hour with the control video game
223810789|NCT01996579|DIETARY_SUPPLEMENT|Lactoferrin|Lactoferrin is an 80 kilodalton (kD) naturally occurring multifunctional glycoprotein of the transferrin family which is an important component of the human innate immune system. Lactoferrin is distributed widely in humans with the main sources of production being exocrine glands and specific granules of neutrophils. It is present in virtually all human secretions. The highest concentrations are found in milk and colostrum. Lactoferrin has multiple biological functions which make it of interest as a therapeutic agent in the critically ill. These include the ability to bind iron, antimicrobial activity including antibacterial, antifungal, antiviral properties, the ability to bind endotoxin, promotion of beneficial bacteria in the gastro-intestinal tract and immunomodulatory activity.
223810790|NCT01996579|OTHER|Placebo|Sterile water will be utilized as the placebo control in this double blind randomized-controlled trial.
223810791|NCT01005342|OTHER|Oat bran|82 g oat bran was added to 250 ml blackcurrant beverage with pulp to give 5 g soluble fiber (12.6 g total fiber).
223810792|NCT01005342|OTHER|Spray-dried oat drink|62 g spray-dried oat drink was added to 250 ml blackcurrant beverage with pulp to give 2.7 g soluble fiber (3.3 g total fiber).
223810793|NCT01005342|OTHER|Rye bran|31 g rye bran was added to 250 ml blackcurrant beverage with pulp to give 1.7 g soluble fiber (12 g total fiber).
223810794|NCT01005342|OTHER|Sugar beet fiber|19 g sugar beet fiber was added to 250 ml blackcurrant beverage with pulp to give 5 g soluble fiber (12 g total fiber).
223810795|NCT01005342|OTHER|Mixture of fiber|38 g spray-dried oat drink, 30 g rye bran and 6 g sugar beet fiber were added to 250 ml blackcurrant beverage with pulp to give 5 g soluble fiber (18 g total fiber).
223810796|NCT01005342|OTHER|Control|No fiber was added to control meal (250 g black-currant beverage)
223810797|NCT04272502|DRUG|CKD-348 F1, CKD-348 F2, CKD-828, D326, D337|Each arm has a different order for taking IP
223810798|NCT06358157|DEVICE|Ladera LBC System|Use of the Ladera LBC System to close the femoral arteriotomy
223810799|NCT06344390|DRUG|Pentoxifylline|Take pentoxifylline 0.4 g twice daily
223810800|NCT00895986|BEHAVIORAL|Conversation Maps Diabetes Education|The Conversation Maps program is a set of innovative, interactive diabetes education tools developed by the Healthy Interactions, Inc (Healthy I) and endorsed by the American Diabetes Association. It consists of four conversation maps covering: 1) Diabetes Overview, 2) Diabetes and Healthy Eating, 3) Blood Glucose and Monitoring, and 4) The Natural Course of Diabetes (a fifth map covering gestational diabetes will not be used in this study), and a program manual to help educators successfully implement the program.
223810801|NCT00895986|BEHAVIORAL|Heart Healthy Living Diabetes Education|The Joslin Clinic offers a series of two 120-minute classes specifically for people with diabetes that address dyslipidemia and blood pressure problems. A registered nurse and/or a registered dietitian teach the classes, which have a formal written curriculum, including PowerPoint slides.
223810802|NCT04636489|DIETARY_SUPPLEMENT|Highland barley β-glucan dietary supplement|100 mL oral liquid mainly containing highland barley β-glucan once daily for 8 weeks
223810803|NCT04636489|OTHER|Placebo controls|Placebo with a similar appearance and taste to highland barley β-glucan supplement
223810804|NCT00002832|BIOLOGICAL|Filgrastim|Subcutaneously (SQ) daily every 12 hours starting 2-4 days prior to first PBSC collection then daily starting 1 day after PBSC infusion until blood counts recover.
223810805|NCT00002832|DRUG|Cyclosporine|IV daily on day -2, then orally once dose is tolerable, dose may be escalated.
223810806|NCT00002832|DRUG|Decitabine|IV for 6 hours every 12 hr for 5 days.
223810807|NCT00002832|PROCEDURE|Allogeneic Bone Marrow Transplantation|Stem cell infusion on Day 0.
223810808|NCT00002832|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Peripheral blood stem cells (PBSC) are administered 5 days after last dose of decitabine.
223810809|NCT03660579|OTHER|HIIT-AB Group|Group that performed HIIT and consumed 330 ml (women) or 2x300 ml (men) of beer with 5.4% alcohol.
223810810|NCT03660579|OTHER|HIIT-NAB Group|Group that performed HIIT and consumed 330 ml (women) or 2x300 ml (men) of beer without alcohol (0.0%).
223810811|NCT03660579|OTHER|HIIT-SW Group|Group that performed HIIT and consumed the same amount of sparkling water (0.0%).
223810812|NCT03660579|OTHER|HIIT-ASW Group|Group that performed HIIT and consumed sparkling water with the same amount of alcohol than the pre-established beer (5.4%).
223810813|NCT04063774|DIAGNOSTIC_TEST|Dengue calculator|Clinical diagnostic algorithms of dengue generated by discrete and continuos Bayes formulas installed in a mobile device
223810814|NCT00653458|DRUG|Ondansetron|ODT, 8 mg, single-dose, fed conditions
223810815|NCT00653458|DRUG|Zofran|ODT, 8 mg, single-dose, under fed conditions
223810816|NCT03034343|BEHAVIORAL|Mindfulness|
223810817|NCT04849286|DRUG|HTL0016878|Oral solution
223810818|NCT00026143|BIOLOGICAL|recombinant interleukin-12|Given IV
223810819|NCT00026143|BIOLOGICAL|recombinant interferon alfa|Given SC
223810820|NCT00026143|OTHER|laboratory biomarker analysis|Correlative studies
223810821|NCT00542880|DRUG|Symbicort Turbuhaler (budesonide/formoterol) 320/9 μg|
223810822|NCT00542880|DRUG|Seretide Diskus (salmeterol/fluticasone) 50/500 μg|
223810823|NCT04310553|PROCEDURE|Irreversible electroporation|Patients with locally advanced pancreatic cancer diagnosed by cell / histopathology will receive nano knife treatment if the target lesion is not suitable for surgical resection or the target lesion is suitable for surgical resection but patients give up surgery and choose nano knife combined with chemotherapy. Patients who have not previously received first-line chemotherapy will receive systemic chemotherapy for 4-6 cycles of treatment. Imaging evaluation will be performed every 6-8 weeks (± 7 days) during chemotherapy.
223810824|NCT01778348|DEVICE|Overnight closed-loop|The closed-loop system is purpose-built and comprises a hand-held computer containing a model predictive control (MPC) based glucose control algorithm and communicating with the CGM device and the insulin pump.
223810825|NCT01778348|DEVICE|Real-time CGM alone|Subject glucose level controlled by usual insulin pump therapy in conjunction with real time continuous glucose monitoring (CGM)
223810826|NCT03497650|DEVICE|Mirror Therapy|Mirror Therapy involved the patient sitting on a chair with a standard mirror placed between both legs with the reflective side of the mirror facing the non-affected leg. The patient is instructed to observe the reflection of the non-affected limb during the sessions. The patient was not given any instruction on the use of the affected limb.
223810827|NCT03497650|OTHER|Cross-Education of Strengthening.|Cross-education of strengthening involves training one side of the body with the intention of producing strengthening gains on both sides of the body. In this case the strengthening was done on the non-affected leg of each stroke patient.
223810828|NCT01690091|DRUG|Metformini hydrochloridum (Siofor 1000 tbl, Berlin)|"Patients will be randomized into 2 groups (A succession: MET-placebo, B succession: placebo-MET. After 3 months the treatment will be switched.~Titration:~500 mg per day(1/2 tbl 1000 mg once a day - in the morning) after a week increase the dose to 1 tbl á 1000 mg after two weeks increase the dose to 2 x tbl 1000 mg (in the morning and in the evening)"
223810829|NCT01690091|DRUG|placebo|Patients will be randomized into 2 groups (A succession: MET-placebo, B succession: placebo-MET. After 3 months the treatment will be switched.
223810830|NCT05101525|PROCEDURE|Ultrasound|Ultrasound to visualize the intra tendinous marker. If this is in place, healing is effective. On the other hand, if it has migrated, there is no scarring.
223810831|NCT02642198|DEVICE|Surveyor S12 and S19 patient monitor|Non-invasive blood pressure measurement
223810832|NCT00696384|DRUG|Azilsartan medoxomil|"All subjects initiated azilsartan medoxomil 40 mg, tablets, orally, once daily for four weeks, force-titrated to 80 mg, tablets, orally, once daily. After Week 8, chlorthalidone, 25 mg, tablets, orally, once daily as needed and other antihypertensive medications as needed to achieve target blood pressure (defined as \<140/90 mm Hg for participants without diabetes or chronic kidney disease (CKD) and \<130/80 mm Hg for participants with diabetes or CKD) for up to 26 weeks.~Study medication could have been up-titrated only after the subject had been at the previous dose level for a minimum of 2 weeks. Study medication could only have been up- or down-titrated by 1 dose level per scheduled or unscheduled visit."
223810833|NCT00696384|DRUG|Azilsartan medoxomil, with or without chlorthalidone and other non-angiotensin II receptor blocker antihypertensive medications.|Azilsartan medoxomil at the final dose received during the open-label phase: (20 mg, 40 mg or 80 mg), tablets, orally, once daily with or without chlorthalidone 25 mg, tablets, orally once daily and other non-ARB antihypertensive medications (if currently taking), for 6 weeks/Week 32.
223810834|NCT00696384|DRUG|Placebo|Azilsartan medoxomil placebo-matching tablets, orally, once daily with or without chlorthalidone 25 mg or other non-ARB antihypertensive (if currently taking), tablets, orally, once daily for 6 weeks/Week 32.
223810835|NCT01445808|BEHAVIORAL|Psychodynamic Motivation and Training Program (PMT)|The Psychodynamic Motivation and Training Program (PMT) is a psychodynamic stepped care approach. Depending on the individual needs PMT consists of 3 to 8 sessions of individual psychodynamic psychotherapy. If appropriate session 4 - 8 may be conducted by a nurse. PMT targets the mental and external barriers to improve physical activity by focusing on affects, interpersonal relations and maladaptive self- and other representations. PMT will be offered in addition to +Ex.
223810836|NCT01445808|BEHAVIORAL|Advice in Exercise Training (+Ex)|Advice in Exercise Training consists of one individual session of advice in exercise training based on the results of the spiroergometry.
223810837|NCT01445808|OTHER|Treatment as usual (TAU)|Usual care by family doctor, cardiologist
223810838|NCT01678131|DRUG|Vaniprevir 600 mg|Vaniprevir capsules, were administered orally, twice per day (BID) to achieve a final daily dose of 600 mg on Days 1 through 6; and a single dose of 600 mg, orally, on Day 7.
223810839|NCT01678131|BIOLOGICAL|Peg-IFN alfa-2b|Peg-IFN alfa-2b was administered at 1.5 µg/kg per week by subcutaneous injections on Days 1, 8, 15 and 21
223810840|NCT01678131|BIOLOGICAL|Ribavirin|Ribavirin capsules were administered on Days 1-21, orally, twice daily for a total daily dose of 600 - 1400 mg, depending on the participant's weight
223810841|NCT01678131|PROCEDURE|Liver samples from FNA|Liver samples were collected from Day 7 up to Day 10 by FNA at 3 of 5 specified postdose timepoints.
223810842|NCT01678131|DRUG|Vaniprevir 300 mg|Vaniprevir capsules were administered orally, twice per day to achieve a final daily dose of 300 mg on Days 1 through 6; and a single dose of 300 mg, orally, on Day 7.
223835469|NCT00136903|DRUG|Prednisone|Prednisone 2.5 mg/kg administered orally.
223810843|NCT01678131|PROCEDURE|Liver samples from CNB|Liver samples were collected from Day 8 up to Day 10 by CNB at 1 of 3 specified postdose timepoints.
223810844|NCT04984057|DRUG|PS is stopped when the pressure is equal between bPDA and aPDA.|PS is given and stopped when the pressure is equal between bPDA and aPDA. the pressure is measured using ultrasound
223810845|NCT04984057|DRUG|PS is given according to the 2019 European RDS management guideline|PS is given according to the 2019 European RDS management guideline
223810846|NCT03117348|OTHER|Enteral nutrition|Patients in Gradual Goal-dose EN group will receive increased calories gradually by EN and will reach the 80% of target energy by EN at day 8 while patients in immediate Goal-dose EN group will receive 100% of target energy by EN at day 3 after abdominal surgery. Both of the two group will receive EN for 5 days except 80% of target energy delivered by oral feeding or patients are discharged from hospital, whichever arrives first.
223810847|NCT04552743|DRUG|MGTA-145|A chemokine receptor type 2 (CXCR2) agonist protein, administered via intravenous (IV) infusion over 3 to 10 minutes.
223810848|NCT04552743|DRUG|Plerixafor|An azamacrocycle CXCR4 chemokine receptor antagonist, administered at 0.24 mg/kg subcutaneously, reduced to 0.16 mg/kg in patients with renal dysfunction (per package insert).
223810849|NCT03544892|OTHER|Low carbohydrate diet|60-80 g total carbohydrate per day
223810850|NCT03544892|OTHER|Standard of care diet|\> 150 g total carbohydrate per day
223810851|NCT02129101|DRUG|Azacitidine|Given SC or IV
223810852|NCT02129101|DRUG|Decitabine|Given IV
223810853|NCT02129101|OTHER|Laboratory Biomarker Analysis|Correlative studies
223810854|NCT02129101|OTHER|Quality-of-Life Assessment|Ancillary studies
223810855|NCT02129101|DRUG|Sonidegib|Given PO
223810856|NCT05692505|DIAGNOSTIC_TEST|QuadQuik|Invitro diagnostic device
223810857|NCT02027402|PROCEDURE|Laparoscopic cholecystectomy with drain insertion|In the drain insertion group, investigators use the closed suction drain through a lateral 5-mm trocar and placed it in right subhepatic space
223810858|NCT01767168|OTHER|comprehensive preoperative testing for risk factors of persistent postoperative pain|nociceptive reflex threshold, pain threshold, CPM-effect of hot water bath, pain sensitivity questionnaire, STAI, BDI, fear of surgical consequences
223810859|NCT02513069|OTHER|Nicotine gum|"Participants will be prescribed one form of nicotine replacement rescue treatment (i.e., gum, lozenge), and may choose nicotine gum as the preferred rescue treatment. Participants will be instructed to use the rescue method as needed during the post-quit phase of the study to reduce cigarette cravings."
223810860|NCT02513069|BEHAVIORAL|mobile contingency management|Participants will be asked to provide video recordings of themselves taking carbon monoxide readings in order to confirm smoking abstinence. Participants are asked to upload these videos to the study's secured server, and are provided reinforcement for videos that suggest smoking abstinence.
223810861|NCT02513069|BEHAVIORAL|Telephone counseling|Participants receive five sessions of cognitive-behavioral telephone counseling, and a participant manual. The telephone counseling protocol included in this application is based on standard cognitive-behavioral therapy techniques shown to be efficacious for smoking cessation and is informed by behavioral treatment principles .
223810862|NCT02513069|OTHER|Nicotine patch|Participants will be prescribed nicotine patches to be used during the post-quit phase of the study.
223810863|NCT02513069|OTHER|Nicotine lozenge|"Participants will be prescribed one form of nicotine replacement rescue treatment (i.e., gum, lozenge), and may choose nicotine lozenge as the preferred rescue treatment. Participants will be instructed to use the rescue method as needed during the post-quit phase of the study to reduce cigarette cravings."
223810864|NCT02513069|OTHER|Smart phone|Participants in the experimental condition will be loaned a smart phone to use during the mobile contingency management intervention period. The phone will be used to record videos of carbon monoxide readings to determine smoking abstinence.
223810865|NCT02513069|OTHER|Carbon monoxide monitor|Participants in the experimental condition will be loaned a CO monitor to use during the mobile contingency management intervention period. The monitor will be used to determine carbon monoxide content in the breath as a measurement of smoking.
223810866|NCT04945148|DRUG|Metformin|Metformin 2000 to 3000mg/day daily will be started by 6 weeks after histological diagnosis and 7 days before the start of RT-TMZ and will continue until progression.
223835470|NCT00136903|DRUG|Cyclosporine|Administered as prescribed by the caregiver.
223810867|NCT04945148|RADIATION|Radiation IMRT|2 Gy x 5 days for 6 weeks to be started 7 days after first administration of Metformin and by 7 weeks after histological diagnosis
223810868|NCT04945148|DRUG|Temozolomide|75 mg/m² daily from first to last day of radiation (IMRT) and then 150 to 200 mg/m² x 5 days every 28 days cycle for 12 cycles
223810869|NCT03513757|DRUG|propofol|propofol 2 mg/kg at start of procedure; 2 mg/kg for movement, 150-300 mcg/kg/minute propofol infusion if movement persists
223810870|NCT03513757|DRUG|Dexmedetomidine|single dose dexmedetomidine administered at start of sedation in the propofol-dexmedetomidine group. Dosing is based upon anticipated duration of scan from 30 - 75 minutes and will range from 0.5 mic/kg to 1.25 mcg/kg
223810871|NCT03513757|DRUG|Glycopyrrolate|4 mcg/kg glycopyrrolate will be administered at the start of sedation in the propofol-dexmedetomidine group
223810872|NCT03513757|DRUG|Lidocaine 1% Injectable Solution|1 mg/kg intravenous administration prior to propofol administration
223810873|NCT03513757|DRUG|Nitrous Oxide|Inhalation of nitrous oxide may be used for IV placement
223810874|NCT03513757|DRUG|Sevoflurane|Inhalation of sevoflurane may be used for IV placement
223810875|NCT05354232|DEVICE|2 mA transcranial direct current stimulation (tDCS)|tDCS is a non-invasive neuromodulatory technique that has previously demonstrated the ability to transiently modulate cognitive domains in both healthy and psychiatric populations. In the 2mA condition, the investigators will assist the administration of a 2mA current stimulation from the device.
223810876|NCT05354232|DEVICE|1 mA transcranial direct current stimulation (tDCS)|tDCS is a non-invasive neuromodulatory technique that has previously demonstrated the ability to transiently modulate cognitive domains in both healthy and psychiatric populations. In the 1mA condition, the investigators will assist the administration of a 1mA current stimulation from the device.
223810877|NCT05354232|DEVICE|Sham transcranial direct current stimulation (tDCS)|tDCS is a non-invasive neuromodulatory technique that has previously demonstrated the ability to transiently modulate cognitive domains in both healthy and psychiatric populations. In the sham condition, the investigators will assist the administration of a sham stimulation from the device.
223810878|NCT01949779|DEVICE|TransForm™ Occlusion Balloon Catheter|TransForm™ Occlusion Balloon Catheter
223810879|NCT01048814|OTHER|ChemoFx|Chemoresponse Marker Assay
223810880|NCT02252419|DRUG|Dexamethasone|Dexamethasone will be administered.
223810881|NCT02252419|DRUG|Paracetamol|Paracetamol will be administered.
223810882|NCT03169218|OTHER|Mirror therapy|The treatment proposed for the mirror group consisted of 8 weeks of treatment, performing a series of exercises 2 times a day / 4 times a week. The first 4 weeks the treatment was done in the hospital next to the physiotherapist for 2-3 days a week, and the next 4 weeks the patient performed the exercises following the same guidelines at home.
223810883|NCT03169218|OTHER|Placebo group|The treatment was the same than proposed in inference group but with a mirror covered to avoid the reflexion on the hand and looking at the hand that did not remain hidden.
223810884|NCT00941798|DRUG|QMF149 Twisthaler®|Once daily via multi-dose dry-powder inhaler
223810885|NCT00941798|DRUG|Mometasone Twisthaler®|Once daily via multi-dose dry-powder inhaler
223810886|NCT03018964|PROCEDURE|Solo surgery|Solo surgery using a camera scope holder in single incision laparoscopic cholecystectomy
223810887|NCT03018964|PROCEDURE|operation with a camera operator in SILC|conventional single incision laparoscopic cholecystectomy with a scopist
223810888|NCT01865955|PROCEDURE|Ultrasound|Ultrasound applied to the lumbar region to determine spinal needle placement.
223810889|NCT01865955|DEVICE|The spinal needle|
223810890|NCT03688061|BIOLOGICAL|ChAd3-hliNSmut|Attenuated chimpanzee adenovirus (ChAd) vectored vaccine against HCV
223810891|NCT03688061|BIOLOGICAL|MVA-hliNSmut|Modified Vaccinia Ankara (MVA) vectored vaccine against HCV
223810892|NCT03450902|COMBINATION_PRODUCT|Chinese herb & acupuncture|Participants will take Chinese herbal formula, Yiqi Suoquan granule, which is composed of Radix Astragali 30 g, Radix Codonopsis pilosula 10g, Radix Angelica sinensis 10g, Radix Atractylodis Macrocephalae 10g, Fructus Alpiniae Oxyphyllae 10g, Radix Lindera aggregata 6g, Rhizoma Dioscoreae 10g, pericarpium citri reticulatae 10g, Rhizoma Cimicifuga 10g, Radix Bupleuri 10g, Fructus Rubi 15g, and Semen raphani 10g and prepared by the Department of Pharmacy, Guang'anmen Hospital, China Academy of Chinese Medical Sciences. Besides, Participants will receive acupuncture, three times a week. The selected acupoints include bilateral BL33, BL35, SP6, and ST36.
223810893|NCT03450902|COMBINATION_PRODUCT|Chinese herb & sham acupuncture|Participants will take Chinese herbal formula, Yiqi Suoquan granule, which is composed of Radix Astragali 30 g, Radix Codonopsis pilosula 10g, Radix Angelica sinensis 10g, Radix Atractylodis Macrocephalae 10g, Fructus Alpiniae Oxyphyllae 10g, Radix Lindera aggregata 6g, Rhizoma Dioscoreae 10g, pericarpium citri reticulatae 10g, Rhizoma Cimicifuga 10g, Radix Bupleuri 10g, Fructus Rubi 15g, and Semen raphani 10g and prepared by the Department of Pharmacy, Guang'anmen Hospital, China Academy of Chinese Medical Sciences. Besides, Participants will receive sham acupuncture, three times a week. The sham BL33, BL35, SP6, and ST36, which are 25 mm outward to BL33, BL35, SP6, and ST36, will be inserted with a depth of 2 to 3 mm.
223810894|NCT03450902|COMBINATION_PRODUCT|Placebo & acupuncture|Participants will take Chinese herbal placebo which is prepared by the Department of Pharmacy, Guang'anmen Hospital, China Academy of Chinese Medical Sciences. Besides, Participants will receive acupuncture, three times a week. The selected acupoints include bilateral BL33, BL35, SP6, and ST36.
223810895|NCT03450902|OTHER|Placebo & sham acupuncture|Participants will take Chinese herbal placebo which is prepared by the Department of Pharmacy, Guang'anmen Hospital, China Academy of Chinese Medical Sciences. Besides, Participants will receive sham acupuncture, three times a week. The sham BL33, BL35, SP6, and ST36, which are 25 mm outward to BL33, BL35, SP6, and ST36, will be inserted with a depth of 2 to 3 mm.
223810896|NCT02660814|OTHER|Non-surgical periodontal treatment|"1. SRP under local anaesthesia, in a total of 2-3 clinical visits.~2. Oral hygiene instructions including the modified Bass technique, regular toothpaste, and an appropriate interdental cleaning device with dental floss and interdental brush."
223810897|NCT02660814|OTHER|Gingival crevicular fluid collection|GCF collection with filter paper (Periopaper) using the intracrevicular method.
223810898|NCT04251884|PROCEDURE|Local anesthetic (ropivacaine)|Patients randomized in the treatment arm will receive a sonography-guided pudendal nerve block
223810899|NCT05752799|DRUG|Opioid Free Anaesthesia|"* 40 mg/kg magnesium sulfate in 100 ml N/S infusion~* 0.4 mcg/kg dexmedetomidine, max total dose 50mcg in 50 ml N/S infusion~* 0.3 mg/kg ketamine in 10 ml volume~* 0.2 ml/kg of the Multimix regimen in 100 ml N/S infusion as a bolus (The Multimix regimen consists of 50mcg dexmedetomidine, 500 mg lidocaine and 50mg ketamine).~* 0.2 ml/kg/h of the Multimix regimen in 100 ml N/S infusion as a continuous infusion. Except for standard analgesic strategies, both groups will receive fentanyl as a rescue dose (1mcg/kg) based on a nociceptive level value \> 25 or elevation of Heart Rate and/or Blood Pressure \>20%.~Placebo infusions of normal saline will be prepared to enable blinding."
223810900|NCT05752799|DRUG|Opioid based anesthesia|"* 2 mcg/kg fentanyl in 10 ml volume~* 0.2 mL/kg/h remifentanil infusion~* 0.1 mg/kg morphine. Except for standard analgesic strategies, both groups will receive fentanyl as a rescue dose (1mcg/kg) based on a nociceptive level value \> 25 or elevation of Heart Rate and/or Blood Pressure \>20%.~Placebo infusions of normal saline will be prepared to enable blinding."
223810901|NCT00265135|DRUG|CNTO 328|Patients will receive CNTO 328 at dose levels ranging from 1, 3, 6, and 12 mg/kg in Part 1 of the study to determine the maximum tolerated dose for Part 2 of the study. Patients will receive 2 well tolerated dose levels of CNTO 328 from Part 1 of the study every 3 weeks in Part 2 of the study. Patients will receive 6 mg/kg of CNTO 328 every 2 weeks in Part 3 of the study.
223810902|NCT00693251|PROCEDURE|Crush technique|Crush technique
223810903|NCT00693251|PROCEDURE|provisional T stenting|Provisional T stenting
223810904|NCT04058795|BEHAVIORAL|Cancer Distress Coach (CaDC) App|an app that provides participants with tools to manage their stress in the moment they experience it.
223810905|NCT04058795|BEHAVIORAL|CaDC + mCoaching|The CaDC app plus weekly clinician support which provides support in navigating the app, encouraging adherence to the use of the CaDC, and providing guidance in choosing treatment strategies.
223810906|NCT04058795|BEHAVIORAL|mCBT|8 mobile sessions with a therapist to receive cognitive behavioral therapy.
223810907|NCT00379132|DRUG|131-I-TM-601 (chlorotoxin)|"Patients will be administered 1 - 3 (Test Doses A, B, and Dose C) escalating doses of 131I-TM601 by intravenous (IV) administration. Each dose will be administered as a single administration, scheduled at one-week intervals.~Test Dose A - 10 mCi (+/- 20%)/0.2 mg TM601 (131I-TM601) Test Dose B - 20 mCi (+/- 20%)/0.4 mg TM601 (131I-TM601) Dose C - 30 mCi (+/- 10%)/0.6 mg TM601 (131I-TM601)"
223810908|NCT05901038|DEVICE|Wearing heart rate monitors|Participants will use 2 consumer wearable heart rate monitors: Polar H10 chest strap and Fitbit Inspire 2 fitness tracker.
223810909|NCT00811382|DEVICE|Home Monitoring (Cardiac resynchronization therapy and atrial fibrillation therapy, with Home Monitoring feature)|Cardiac resynchronization therapy and atrial fibrillation therapy according to medical guidelines, where the physician receives relevant daily data from the implant via Home Monitoring
223810910|NCT00811382|DEVICE|Home Monitoring (Cardiac resynchronization therapy and atrial fibrillation therapy, without Home Monitoring)|Cardiac resynchronization therapy and atrial fibrillation therapy according to medical guidelines, without daily data transmission from the implant via Home Monitoring (except for the safety data on device integrity)
223835471|NCT00136903|DRUG|Tacrolimus|Administered as prescribed by the caregiver.
223810911|NCT06673394|DRUG|Complement protein C5 inhibitor|Investigational arm: eculizumab (900 mg) will be administered intravenously once per week for a total of four doses (days 1, 8, 15, and 22) in conjunction with IVMP and oral prednisone (60mg, 5mg weekly decline). Terminal complement complex inhibition by eculizumab predisposes patients to infections by encapsulated bacteria, especially N meningitidis. Meningococcal vaccination will not be effective in this timeframe; instead, all enrolled patients will receive antibiotic prophylaxis against N meningitidis from the time of the first dose of the study drug to 8 weeks after the last administration.
223810912|NCT06673394|DRUG|IVMP|IVMP arm: 1000mg methylprednisolone x5d, oral prednisone 60mg, 5mg weekly decline + antibiotics
223810913|NCT03444376|DRUG|GX-188E|GX-188E (1.0mg/0.5ml/vial), Intramuscular administration using electroporator, Ichor TDS-IM device
223810914|NCT03444376|DRUG|KEYTRUDA®|pembrolizumab(100mg/4mL/vial), Intravenous administration
223810915|NCT07061080|DRUG|Tarlatamab|Tarlatamab as a standalone treatment through intravenous infusion at 10 mg dose every 14 days (i.e. 2 weeks)
223810916|NCT07061080|DRUG|standard of care second-line chemotherapy (FOLFIRI)|FOLFIRI:: irinotecan intravenously 180 mg/m2 on day 1, followed by 400 mg/m2 folinic acid or 200 mg/m² levofolinate in a 2-h infusion, a 10-min bolus of 400 mg/m2 5-FU, and 2400 mg/m2 5-FU over 46 hours; every 14 days).
223810917|NCT07061509|OTHER|Battery of Physical and Psychological Assessments|Participants in this observational study will not receive any therapeutic intervention. Instead, all individuals will undergo a series of standardized non-invasive assessments for data collection purposes. These include the Exercise Dependence Scale-21 (EDS-21) to classify exercise addiction status, the Drive for Muscularity Scale (DMS) to evaluate body image and muscle-related attitudes, and the Extended Nordic Musculoskeletal Questionnaire to determine the presence and severity of musculoskeletal symptoms. Cardiovascular risk will be assessed using the SCORE Risk Assessment System, which incorporates blood pressure, cholesterol, blood glucose, smoking status, and demographic data. Additional measurements will include oxygen saturation and heart rate using pulse oximetry, and blood pressure using a sphygmomanometer. These evaluations are intended solely for comparative analysis between exercise-dependent and non-dependent groups.
223810918|NCT07094620|RADIATION|Non-surgical rhinoplasty|Non-surgical rhinoplasty using hyaluronic acid at baseline consultation.
223810919|NCT07093905|PROCEDURE|arthroscopy of the shoulder rotator cuff|minimally invasive surgical procedure in which a camera (arthroscope) is inserted into the shoulder joint
223810920|NCT07094698|OTHER|sacral stimulation|A low-frequency (2-10 Hz) current with a pulse duration of 200 μs will be applied for 30 minutes, 5 days a week, under the supervision of a physiotherapist for 6 weeks.
223810921|NCT07093151|OTHER|Target SBP <160mmHg|For subjects assigned to the SBP \<160 mmHg group, an SBP target order will be placed to guide the neuro-intensive care team to treat the patient with antihypertensive medications as needed to achieve an SBP \<160 mmHg. Selection of the antihypertensive medication and administration route is at the discretion of the treating team. Patients will undergo regular and frequent blood pressure measurements using the arterial line placed during surgery, or through a non-invasive blood pressure measurement method if no arterial line is present.
223810922|NCT07093151|OTHER|Target SBP <140 mmHg|For subjects assigned to the SBP \<140 mmHg group, an SBP target order will be placed to guide the neuro-intensive care team to treat the patient with antihypertensive medications as needed to achieve an SBP \<140 mmHg. Selection of the antihypertensive medication and administration route is at the discretion of the treating team. Patients will undergo regular and frequent blood pressure measurements using the arterial line placed during surgery, or through a non-invasive blood pressure measurement method if no arterial line is present.
223810923|NCT07094828|OTHER|AOMI with D-Wall|"The intervention group will follow routine rehabilitative activity in the morning and will perform one hour of Action Observation and Motor Imagery training with augmented visual feedback (D-Wall) in the afternoon, three times a week.~Each session will be conducted as follows: first AO (Action Observation), then MI (Motor Imagery). During the MI phase, participants will be asked to imagine the motor tasks and then perform them, receiving real-time augmented visual feedback provided by the digital mirror."
223810924|NCT07094828|OTHER|Routine physiotherapy with D-Wall|The control group will also follow routine rehabilitative activity in the morning, while in the afternoon they will perform motor training of the same duration, without Action Observation and Motor Imagery, but solely with augmented visual feedback (D-Wall), with the same weekly frequency.
223810925|NCT07094048|DRUG|Target trough IgG level of 8-10 g/L|Target trough IgG level of 8-10 g/L
223810926|NCT07094048|DRUG|Target trough IgG level 4-6 g/L|Target trough IgG level of 4-6 g/L
223810927|NCT07094048|DRUG|No history of recurrent or severe infections and total IgG level higher or equal at 4 g/L|If, during follow-up, the patient presents recurrent or severe infections and/or total IgG level less 4 g/L, crossover to group A or B
223810928|NCT07088315|DEVICE|TECAR therapy|TECAR therapy was applied to the lower limbs of patients diagnosed with lipedema using the BTL-6000 TR-Therapy PRO device (BTL, Turkiye). All treatment sessions were performed by a physiotherapist with specific experience in TECAR therapy. The device operated at a frequency of approximately 500 kHz and employed three types of electrodes: active, neutral, and static application electrodes. Two types of active electrodes -capacitive and resistive- were utilized and applied directly to the treatment area. The neutral electrode, serving as a reference point, was placed in proximity to the target region to ensure effective energy transfer.
223810929|NCT07088315|OTHER|compression|All participants were provided with individually fitted compression garments (either pantyhose-type or thigh-high models, in class I \[18-21 mmHg\] or class II \[23-32mmHg\] depending on symptom severity and tolerance), and were instructed to wear them during waking hours for a minimum of 8 hours per day. Adherence to garment usage was monitored through patient diaries and reinforced at follow-up visits.
223810930|NCT07088315|OTHER|Exercise|All patients were advised to engage in a structured walking program, consisting of moderate-intensity walking (perceived exertion level 11-13 on the Borg scale), for at least 20 minutes per session, three times per week.
223810931|NCT07087990|DEVICE|Virtual Reality Glasses|articipants in the VR group used virtual reality glasses during coronary angiography to reduce anxiety and pain and improve satisfaction.
223810932|NCT07087990|OTHER|Stress Ball|articipants in the stress ball group used a stress ball during coronary angiography to evaluate its effects on anxiety, pain, and satisfaction.
223810933|NCT07094282|OTHER|Acupuncture|Integrative Medicine: Acupuncture treatment
223810934|NCT07094282|OTHER|myofascial therapy|Integrative Medicine: myofascial therapy to include transverse abdominus teaching, rectus abdominus release, functional neuromyofascial techniques, cupping, gua sha, active needling.
223810935|NCT07094282|OTHER|microcurrent therapy|Integrative Medicine: Microcurrent
223810936|NCT07094282|OTHER|LASER|Integrative Medicine: LASER
223810937|NCT07094282|OTHER|extracorporeal shockwave therapy|Integrative Medicine: Extracorporeal shockwave therapy
223810938|NCT07094282|OTHER|Pulsed electromagnetic therapies|Integrative Medicine: Pulsed electromagnetic therapies
223810939|NCT07094282|OTHER|Miscellaneous integrative medicine|other integrative medicine modalities
223810940|NCT07093931|DRUG|lobaplatin|30mg / m2 i.v. q3w
223810941|NCT07093931|DRUG|carboplatin|AUC 5-6 i.v. q3w
223810942|NCT07093931|DRUG|Docetaxel or albumin paclitaxel|Docetaxel ( 75 mg / m2 i.v. d1, q3w ) or albumin paclitaxel ( 260 mg / m2 i.v. d1, q3w )
223810943|NCT07093931|DRUG|Trastuzumab|6 cycles of treatment, according to the instructions recommended dosage.
223810944|NCT07093931|DRUG|pertuzumab|6 cycles of treatment, according to the instructions recommended dosage.
223810945|NCT07093099|BEHAVIORAL|Enhanced Education Package for Bowel Preparation|"a multifaceted intervention was designed to improve mechanical bowel preparation (MBP) in patients undergoing colonoscopy. It included:~Structured face-to-face counseling on the importance of bowel prep, potential complications of poor prep, and how to follow instructions.~A 6-minute instructional video explaining step-by-step dietary and medication instructions.~A printed booklet with visual aids summarizing key steps.~A mobile phone app delivering interactive reminders, tracking tools, and preparation guidance.~All participants used the same polyethylene glycol-based bowel cleansing agent."
223835472|NCT00136903|DRUG|Mycophenolate Mofetil|Administered as prescribed by the caregiver.
223810946|NCT07093099|OTHER|Standard Education Leaflet|Participants in this arm received a standard hospital-issued bowel preparation instruction leaflet. The document provided written instructions on dietary modifications, timing and dosage of the bowel cleansing agent, and day-of-procedure guidance. No personalized counseling, video support, or reminder tools were provided. This reflects the routine care practice at the study hospitals.
223810947|NCT07093918|OTHER|V-echo|Imaging system
223810948|NCT07093918|OTHER|L-echo|Imaging system
223810949|NCT07094100|DEVICE|Tissue engineered cartilage|Cartilage constructed by autologous bone marrow mesenchymal stem cells
223810950|NCT07093996|PROCEDURE|Endoscopic pancreatic duct stent placement|Endoscopic pancreatic duct stent placement will be performed with a 5Fr Boston Scientific pancreatic stent (3-4 cm in length) within 24 hours from the randomization procedure. The stent will be removed on the 5th day after installation.
223810951|NCT07093996|DRUG|Conventional treatment of acute pancreatitis in early phase|Infusion therapy, pain relief, nutritional support and surgical procedure if needed
223810952|NCT07092696|DRUG|Toripalimab|"Induction chemo-immunotherapy (platinum-based tri-weekly regimen)~* Paclitaxel 175 mg/m² IV on day 1~* Cisplatin 50 mg/m² IV on day 1 or carboplatin AUC 4-5 IV on day 1~* Toripalimab 240 mg IV on day 1, administered immediately before each chemotherapy infusion Cycle length: every 3 weeks Number of cycles: 2 Concurrent chemoradiotherapy (weekly regimen)~* Radiation therapy delivered according to institutional protocol~* Cisplatin 40 mg/m² IV once weekly~* Toripalimab 240 mg IV on day 1 of every 3-week cycle, given before chemotherapy Cycle length: every 3 weeks during radiotherapy~Maintenance immunotherapy~• Toripalimab 240 mg IV on day 1 every 3 weeks (Q3W) Duration: 1 year (total 13 cycles)"
223810953|NCT07092696|RADIATION|Pelvic External-Beam Radiotherapy (EBRT)|"* PTV: 6 MV photons, 1.80 Gy per fraction × 28 fractions = 50.4 Gy.~* PGTVnd: 6 MV photons, 2.14 Gy per fraction × 28 fractions = 59.92 Gy. Brachytherapy:Dose prescriptions~* Dose: 7.00 Gy per fraction × 4 fractions = 28.0 Gy."
223810954|NCT07093255|DRUG|FLQ-101|"The invervention comprises 3 Groups:~* Group 1: Low Dose~* Group 2: Middle Dose~* Group 3: High Dose"
223810955|NCT06008496|PROCEDURE|Day case surgery|Operation, surgical group, magnitude of surgery, anaesthetic type.
223810956|NCT05471102|PROCEDURE|Study group: lower segment resection with ligation of the anterior division of the internal iliac artery|Cases managed by uterine lower segment resection with ligation ((suturing)) of the anterior division of the internal iliac artery (4 cm distal to the bifurcation of the common iliac artery); in addition to the bilateral uterine artery ligation at 2 levels; bilateral ligation at a level below the lower most placental part followed by bilateral uterine artery ligation at the level of the hysterotomy incision.
223810957|NCT05471102|PROCEDURE|Control group: lower segment resection without ligation of the anterior division of the internal iliac artery|Cases managed by uterine lower segment resection without ligation of the anterior division of the internal iliac artery. (i.e., only bilateral ligation at a level below the lower most placental part followed by bilateral uterine artery ligation at the level of the hysterotomy incision).
223810958|NCT07092683|OTHER|anemia|preoperative anemia
223810959|NCT07092683|OTHER|nonanemia|preoperative nonanemia
223810960|NCT05303493|BIOLOGICAL|Camu Camu Capsules (Camu Camu powder encapsulated (500mg each) + ICI|Evaluate the safety and tolerability of CC prebiotic in addition to ICI in patients with NSCLC and melanoma
223810961|NCT06920186|PROCEDURE|Analgesia|1-Adductor canal block + surgical infiltration
223810962|NCT06920186|PROCEDURE|Analgesia|2-Adductor canal block + femoral-cutaneous block + obturator block + IPACK block
223810963|NCT05550064|OTHER|Structured contraceptive counseling|"1. Educational video - healthcare providers (Medical doctors and nurse-midwives)present available contraceptives that could be used after delivery, with emphasis on effectiveness, how they should be used, mechanism of action and health benefits.~2. The four key questions are to be asked to all pregnant women to make them reflect on factors that highly affects choice of contraceptives.~3. A tiered effectiveness chart will be used to visualize the effectiveness of different contraceptives, and guide the prospective user in her choice depending on the answers to the key questions~4. The box of contraceptive models are used for the prospective user to inspect, hold, feel the different contraceptives, as this has been shown to decrease fear regarding specific methods."
223810964|NCT06932783|DEVICE|Transcutaneous Electrical Acustimulation (TEA)|"Participant will apply TEA at home twice a day (approximately 45 minutes am/pm) for 8 weeks. The top electrode will be placed at ST36 (via acupuncture point) and the electrode patch will be placed vertically.~Additionally, participants will agree to allow medical records to be collected, complete various surveys and have follow-up after treatment (approximately 9-10 weeks)."
223810965|NCT06932783|DEVICE|Sham Transcutaneous Electrical Acustimulation (TEA)|"Participant will apply sham TEA at home twice a day (approximately 45 minutes am/pm) for 8 weeks. Sham TEA will be performed via one point on the leg and not on any meridian or acupoints that were used in previous gastrointestinal studies and did not yield any significant effects.~Additionally, participants will agree to allow medical records to be collected, complete various surveys and have follow-up after treatment (approximately 9-10 weeks)"
223810966|NCT06104956|DRUG|HFNO weaning protocol|Algorithm based on SpO2 values and respiratory rate: a decrease of FiO2 and of the flow will be done
223810967|NCT06104956|DRUG|HFNO Standard of care|Weaning methods will be left to the free choice of the practitioner.
223810968|NCT06932809|DRUG|18F-JSS20-183A PET|2 hour Positron Emission Tomography (PET) scan using new radiotracer 18F-JSS20-183A.
223810969|NCT06932809|DIAGNOSTIC_TEST|Brain MRI|MRI scan of the brain.
223810970|NCT06932809|DIAGNOSTIC_TEST|Amyloid PET|PET scan with Florbetaben F18 or 11C-PiB.
223810971|NCT06932809|BEHAVIORAL|Neurological Assessments|Neurological assessments, including a video interview.
223810972|NCT06936241|OTHER|Circuit weight training|"The Circuit Training protocol will be performed as follows:~wall push-up, bridge on floor, single leg bridge, bird dog, windshield wiper, march in place, ball squat, squat with an overhead press, reverse pendulum, jumping rope, and spinal twist, 30-35 minutes, 3 times a week for 8 weeks"
223810973|NCT06936241|OTHER|Traditional physical therapy program|The participants will receive traditional physical therapy program in the form of therapeutic exercises to keep daily living activity by restoring the strength of flexors and abductors of the shoulder joint using the shoulder wheel and ladder. It will be performed 3 times per week for eight weeks
223810974|NCT07092761|DEVICE|GS3 CGM|Wearing CGM for a consecutive 14 days
223810975|NCT07094308|BEHAVIORAL|Learn Intestinal Failure Tele-ECHO Program|LIFT-ECHO (Learn Intestinal Failure Tele-ECHO) is a virtual tele-education program designed to improve the knowledge and clinical decision-making of non-specialist clinicians managing patients with chronic intestinal failure (CIF) on parenteral nutrition (PN). The intervention consists of eight 60-90-minute sessions delivered over 2-4 months. Each session includes the presentation of anonymized real-world CIF cases and a didactic lecture by an expert in intestinal rehabilitation. Participating physicians may also complete baseline and follow-up surveys, and optionally participate in focus groups or appreciative inquiry workshops.
223810976|NCT07094308|BEHAVIORAL|Standard of Care|Participants will receive routine clinical care for chronic intestinal failure from their usual providers. No additional educational programming or intervention is delivered during this period.
223810977|NCT07093593|OTHER|Mandatory biological samples (blood and sell)|"At cycle 1 and Cycle 3 :~* Stool sample collection~* Blood sample collection (5 EDTA tubes)"
223810978|NCT07146893|DRUG|Selpercatinib|"Patients will be instructed to take selpercatinib orally (PO) twice daily (BID), approximately every 12 hours. While on study, they will undergo weight measurements and regular blood draws every 4 weeks. At the 16-week post-treatment follow-up, patients will return to the clinic for a weight assessment to evaluate potential changes in body weight.~Patients will be administered assessments including, Functional Assessment of Anorexia Cachexia Therapy (FAACT), administered at screening, at 12 weeks post-discontinuation of the study drug, and again at the 16-week follow-up."
223810979|NCT07146893|OTHER|Strength Assessment|Several strength assessment will be conducted at baseline and at 12 weeks end-of-treatment, which will include measurements such as grip strength, hallux strength, timed chair stands, leg press, and localized ultrasound of the quadriceps.
223810980|NCT04499859|DRUG|Ezetimibe 10mg + Rosuvastatin 5mg|Initial use of 10mg of ezetimibe combined with 5 mg of rosuvastatin
223810981|NCT04499859|DRUG|Rosuvastatin 20mg|20mg of Rosuvastatin as a standard treatment for AMI patients
223810982|NCT07164235|OTHER|Patients diagnosed with spondylodiscitis|Patients admitted to the Infectious Diseases Department of the University Hospital of Alessandria between January 1, 2017, and December 31, 2024, who were diagnosed with spondylodiscitis
223810983|NCT06211296|DEVICE|Shortcut|Splitting bioprosthetic aortic valve leaflets
223810984|NCT06249828|DEVICE|MegaCarti^®|MegaCarti® application after microfracture through athroscopic or incision surgery
223810985|NCT06249828|PROCEDURE|Microfracture|Microfracture through athroscopic or incision surgery
223810986|NCT06052904|BEHAVIORAL|mHealth-delivered music breathing therapy|"Parental caregivers in the intervention group will receive individual home-based music breathing therapy comprising eight 1-hour weekly sessions for 2 months delivered through Zoom, by a qualified music therapist based on a standardized and validated music breathing instruction manual. The music breathing therapy comprises four breathing phases, namely Discovery Breathing, Triangular Breathing, Silent Breathing, and Music Breathing. In each session, participants will practice breathing for approximately 20-25 minutes in silence or with music in a sitting position. Thereafter, the participants will be instructed to create a Mandala drawing to visualize the effects of breathing on their mental body image, emotions, and thoughts. Each session will end with a debriefing session, which will serve to verbally integrate and reflect the participants' experiences and mental states."
223810987|NCT06052904|BEHAVIORAL|Online educational modules|Participants in the control group will receive eight weekly online educational modules via email for 2 months. The content of the online educational modules will include medical information and advice about caring for a child who has been newly diagnosed with cancer.
223810988|NCT01980407|DRUG|S-1, leucovorin, oxaliplatin|S-1 (20mg), capsule, 40-60mg, bid, p.o., day1-14； Leucovorin (15 mg), tablet, 30mg,Bid, p.o., day1-14; Oxaliplatin (50 mg), injection 85mg/m2, day1.
223810989|NCT06115330|DEVICE|Press Needle Acupuncture|Ear acupuncture using Pyonex press needles were installed with a diameter of 0.17mm, 0.9mm deep. The needles were retained for three days and stimulated at the installation site of the patch needle by means of pressure on the acupuncture point ears that have been attached needles on both sides, 1 minute at each point, four times a day, for 3 consecutive days and the patch was removed on the 3rd day
223810990|NCT00175344|PROCEDURE|Scar massage.|To objectively evaluate the effects of scar massage, those who agree to participate will be randomly assigned to one of two groups. One group will be taught to perform self-massage of the scars as soon as the scars have adequately healed. The massage should be done about 10 minutes each day for a total of 6 months. The other group will not be taught self-massage and will be asked to not massage their breast scars.
223810991|NCT00658437|DRUG|CY-503|solution for subcutaneous injection, 350 ng twice weekly
223810992|NCT04215016|BIOLOGICAL|Autologous humanized anti-CD19 and anti-CD20 dual specific CAR-T Cells|Humanized anti-CD19 and CD20 bispecific autologous CAR-T cells injection: the first dose is 1.0×106 /kg, the second dose is 3.0×106 /kg, and the third dose is 8.0×106 /kg. Patients will receive lymphodepleting chemotherapy at least 1 week before CAR-T cell infusion.
223810993|NCT00209807|DRUG|escitalopram|escitalopram 10 mg/d for 6 weeks
223810994|NCT00209807|DRUG|Reboxetine|Reboxetine 8 mg/d for 6 weeks
223810995|NCT00209807|OTHER|No intervention|This group of healthy volonteers will receive no drug and will be a healthy comparator.
223810996|NCT03070496|BIOLOGICAL|Blood sampling|Blood sampling will be performed at 6 months after myocardial infarction to analyse diagnostic and prognostic biomarkers
223810997|NCT03070496|PROCEDURE|ECG|ECG will be performed at 6 months after myocardial infarction
223810998|NCT03070496|DEVICE|MRI|MRI will be performed at 1month after myocardial infarction to analyse ventricular remodeling and reperfusion.
223810999|NCT03070496|OTHER|Quality of life questionnaire|Patients will pass a quality of life questionnaire at 12 months after myocardial infarction
223811000|NCT03350334|DRUG|Duloxetine|Peri-operative Duloxetine administration
223811001|NCT03350334|DRUG|placebo|Placebo administration
223811002|NCT03308825|BIOLOGICAL|Fluzone Quadrivalent vaccine|0.25 mL, Intramuscular
223811003|NCT03308825|BIOLOGICAL|Fluzone Quadrivalent vaccine|0.5 mL, Intramuscular
223811004|NCT03308825|BIOLOGICAL|Fluzone High-Dose vaccine|0.5 mL, Intramuscular
223811005|NCT02384564|DEVICE|Ambu King Vision Video Laryngoscope aBlade|At time of tracheal intubation, the subject will be intubated using the Ambu King Vision Video Laryngoscope with the appropriately sized Ambu aBlade System based on manufacturer guidelines and clinical judgement. The first attempt to successful intubation will be assessed. The Cormack Lehane and Percentage of Glottic Opening scores will be recorded via direct vision. Information on subsequent attempts, time to successful intubation, and ease of tracheal tube insertion will be assessed.
223811006|NCT02384564|DEVICE|Direct Laryngoscopy via Miller Straight Blade|At time of tracheal intubation, the subject will be intubated via direct laryngoscopy using a straight laryngoscope blade, based on manufacturer guidelines and clinical judgement. The first attempt to successful intubation will be assessed. The Cormack Lehane and Percentage of Glottic Opening scores will be recorded via direct vision. Information on subsequent attempts, time to successful intubation, and ease of tracheal tube insertion will be assessed.
223811007|NCT05763641|PROCEDURE|Target Axillary Dissection|TAD after neoadjuvant chemotherapy and subsequent axillary lymph node dissection
223811008|NCT00001579|DRUG|5-Fluorouracil|
223811009|NCT00001579|DRUG|Ethynyluracil|
223811010|NCT00001579|DRUG|Leucovorin|
223811011|NCT01755442|OTHER|Placebo|Eligible subjects will be randomly assigned (1:1) to receive AMG 151 and matching placebo in 1 of 2 sequences over 2 treatment periods.
223811012|NCT01755442|DRUG|AMG 151|Eligible subjects will be randomly assigned (1:1) to receive AMG 151 and matching placebo in 1 of 2 sequences over 2 treatment periods.
223811013|NCT04384016|BIOLOGICAL|Skyvaricella Injection|"The main target is evaluating the safety of SKYVaricella injection in healthy Vietnamese children from 12 months to 12 years, with a single injection.~The secondary target is to Assess the immunogenicity of SKYVaricella inj. in a small group of healthy Vietnamese children from 12 months to 12 years, with a single injection."
223811014|NCT00768508|DRUG|Ondansetron 4 ug/kg b.i.d. + Cognitive Behavioral Therapy|Ondansetron 4 ug/kg b.i.d.for 12 weeks
223811015|NCT00768508|DRUG|Naltrexone 50 mg/day + Cognitive Behavioral Therapy|Naltrexone 50 mg/day for 12 weeks
223811016|NCT00768508|DRUG|Ondansetron 4 ug/kg b.i.d.+ Naltrexone 50 mg/day + Cognitive Behavioral Therapy|Combination of ondansetron 4 ug/kg b.i.d. and naltrexone 50 mg/day for 12 weeks
223811017|NCT00768508|OTHER|Placebo + Cognitive Behavioral Therapy|Placebo comparator
223811018|NCT04236193|DIAGNOSTIC_TEST|Ultrasound Shoulder and Immunological Phenotyping by FACS|Cross-sectional Ultrasound exam of the affected shoulder. Peripheral blood measurements of the T and B cell subsets. Anti-Influenza Antibody measurements
223811019|NCT00000844|DRUG|Interferon alfa-n3|
223811020|NCT00000844|DRUG|Interferon alfa-n1|
223811021|NCT02024672|OTHER|Immediate postpartum placement of IUD|pelvic exam, transvaginal ultrasound (3 during the course of the study), bleeding and symptom diary
223811022|NCT00685945|DRUG|Control (bradykinin)|Graded doses of bradykinin (Clinalfa AG, Läufelfingen, Switzerland) will be infused at 50, 100, and 200ng/min. Each dose will be infused for 5 minutes and FBF will measured during the last 2 minutes of infusion. Arterial and venous blood samples will be obtained for measurement of net t-PA release after each dose.
223811023|NCT00685945|DRUG|L-NMMA + bradykinin|Thirty minutes after administration of bradykinin a continuous intra-arterial infusion of L-NMMA at 12 micromol/min will be started started. While continuing the infusion of L-NMMA, baseline measurements and infusion of bradykinin will be repeated.
223811024|NCT00685945|DRUG|Isosorbide + L-NMMA + bradykinin|Following the second bradykinin infusion, 12 subjects will receive 5mg isosorbide dinitrate (an exogenous NO donor; Major Pharmaceuticals Inc, Livonia MI). Sixty minutes after the administration of isosorbide the continuous intra-arterial infusion of L-NMMA at 12 micromol/min will be restarted and baseline measurements and bradykinin infusion will be repeated.
223811025|NCT00685945|DRUG|Sildenafil + L-NMMA + bradykinin|Following the second bradykinin infusion, 12 subjects will receive 50mg sildenafil (phosphodiesterase type 5 (PDE5) inhibitor to increase cGMP without increasing NO; Pfizer, NY). Sixty minutes after the administration of sildenafil the continuous intra-arterial infusion of L-NMMA at 12 micromol/min will be restarted and baseline measurements and bradykinin infusion will be repeated.
223811026|NCT03183388|BEHAVIORAL|BE-SMART|Participants will take part in 12 therapy sessions, at a rate of about 1 session every one to two weeks. Sessions are anticipated to last about 1 hour each. Sessions may be focused on teaching skills to regulate emotions or regularize sleep and activity. These therapy sessions may be videotaped and audiotaped (only with the expressed written consent of the participant, and when appropriate, the participant's parent or guardian). Participants will be asked to complete worksheets and practice the skills learned from these sessions and will be asked questions about feelings. There will be an interview, assessments and scanning performed prior to treatment and at the midpoint and end to assess progress. The intervening 9 sessions may be by video telecommunication. Participants may be given devices to track actigraphy and ecological momentary assessments.
223811027|NCT02772003|BIOLOGICAL|Electroporation-Mediated Plasmid DNA Vaccine Therapy|Undergo electroporation
223811028|NCT02772003|BIOLOGICAL|HCV DNA Vaccine INO-8000|Given IM
223811029|NCT02772003|OTHER|Laboratory Biomarker Analysis|Correlative studies
223811030|NCT02772003|OTHER|Quality-of-Life Assessment|Ancillary studies
223811031|NCT02772003|BIOLOGICAL|Rocakinogene Sifuplasmid|Given IM
223811032|NCT02820805|OTHER|Meal Skipping|No meal
223811033|NCT02820805|OTHER|French fries|50g of available carbohydrates meal
223811034|NCT02820805|OTHER|Mashed potatoes|50g of available carbohydrates meal
223811035|NCT02820805|OTHER|Hash browns|50g of available carbohydrates meal
223811036|NCT02820805|OTHER|Rice|50g of available carbohydrates meal
223811037|NCT02820805|OTHER|Beans|50g of available carbohydrates meal
223811038|NCT06788444|PROCEDURE|The colonoscopy|"Both groups continued to receive the usual standard of gastroenterology care throughout the study period. The patients undergo preoperative preparation according to the requirements of colonoscopy. After entering the endoscopy room, the routine monitoring including electrocardiogram, heart rate, noninvasive blood pressure (BP), respiratory rate, and oxygen saturation (SpO2) are applied for patients. All monitoring data including HR, BP and SpO2 will be recorded at intervals of 3min. Safety assessments will be performed throughout the the research process. As a risk mitigation measure, esketamine should not be administered in patients with systolic blood pressure (SBP) \> 140 mmHg or diastolic blood pressure (DBP) \>90 mmHg prior to administration.~After the right upper limb venous access is opened, the patients is placed in the left lateral position. The oxygen mask is placed near the patients' nose and oxygen is provided by the mask for 6L/min during the colonoscopy."
223811039|NCT06788444|DRUG|Esketamine|The propofol is administered until the patients loss of consciousness (loss of the eyelash refex). The 0.2 mg/kg esketamine is then administered by the anesthesiologist, but should be discontinued if the SBP ≥200 mmHg or the DBP ≥110 mmHg. After the administration of the 0.2 mg/kg esketamine is completed, the endoscopist will begin the colonoscopic procedure.
223811040|NCT01728792|BIOLOGICAL|TDV|TDV IM or SC injection
223811041|NCT02080182|DRUG|Acetylcysteine|
223811042|NCT02080182|DRUG|placebo acetylcysteine|
223811043|NCT00071721|DRUG|Valproate|250mg tablets beginning with one daily for one week, then two daily for one week, then titrated according to body weight and tolerability to achieve 10-12 mg/kg daily for 2 years, followed by a 2-month washout
223811044|NCT00071721|DRUG|Placebo|Placebo tablets beginning with one daily and increasing according to weight and perceived tolerability concerns for two years, followed by a 2-month washout
223811045|NCT04277455|DEVICE|Laser ablation of benign thyroid nodule|Ablating symptomatic benign thyroid nodules using laser
223811046|NCT00546325|DRUG|Rimonabant|White opaque film-coated, for oral administration containing 20 mg of active rimonabant. Once daily before breakfast
223811047|NCT00546325|DRUG|Placebo|Matching placebo tablets. Once daily before breakfast
223811048|NCT05432908|BEHAVIORAL|Orofacial exercises and oropharyngeal functions|Oropharyngeal exercises (derived from speech-language pathology) to the tongue and facial muscles exercises as well stomatognathic functions.
223811049|NCT04834700|OTHER|online group|In terms of teaching ultrasound, video lectures will be conducted rather than hands-on, which is the traditional method.
223811050|NCT04581421|OTHER|High Carb Low Fat Diet|The participants will be randomized to a diet of low carb/ high fat og high carb/low fat
223811051|NCT04581421|OTHER|Low Carb High Fat Diet|The participants will be randomized to a diet of low carb/ high fat og high carb/low fat
223811052|NCT06285669|OTHER|kinesiotaping application|kinesiotaping application
223811053|NCT02422719|DRUG|Radotinib|Radotinib 400mg bid
223811054|NCT06155383|DRUG|Capecitabine|1000 mg/m2, Bid orally, D1-14, every 3 weeks
223811055|NCT06155383|DRUG|oxaliplatin|130 mg/m2, intravenous infusion, D1, every 3 weeks
223811056|NCT06155383|DRUG|Disitamab Vedotin|2.5 mg/kg, intravenous infusion, D1, every 2 weeks
223811057|NCT06155383|DRUG|Toripalimab|3.0 mg/kg, intravenous infusion, D1, every 2 weeks
223811058|NCT03244722|DIETARY_SUPPLEMENT|Very-low energy Diet (VLED)|Structured, intensive dietary intervention using liquid meal replacements aimed at providing 800 kcal/day with a weight loss goal of 15% from baseline
223811059|NCT03244722|OTHER|Standard of care (SOC)|Standard consultation with registered dietitian to determine appropriate caloric deficit for a low calorie diet, education and advice to achieve weight loss in obese women. Standard of care for normal weight women
223811060|NCT04737109|DRUG|Ipatasertib|Ipatasertib
223811061|NCT04737109|DRUG|Darolutamide|Darolutamide
223811062|NCT04737109|DRUG|Androgen Deprivation Therapy|ADT per institutional standards
223811063|NCT06832683|DRUG|Sevoflurane|For Group S, 8% sevoflurane was administered for induction via the procedural oxygen mask for 2 minutes through the external output of the anesthesia machine. The concentration was then reduced to 2%. If any undesired movements occurred, they were recorded, and the sevoflurane concentration was increased by 0.5%.
223811064|NCT06832683|DRUG|Propofol|In Group P, 1.0 mg/kg propofol as a bolus. In the event of undesired movements, an additional 0.5 mg/kg of propofol was administered, and all additional doses were recorded.
223811065|NCT06832683|DRUG|Ketamine|In Group P, 1 mg/kg, single dose ketamine was administered intravenously and all additional doses were recorded.
223835473|NCT05676073|DRUG|SHEN26 dose 1|Specification: 200mg/capsule. Subjects will receive 10 oral doses twice daily (after breakfast and dinner; Q12h±2h) from Day 1 to Day 5 (or Day 1 to Day 6).
223811066|NCT03135561|BEHAVIORAL|pedometer-plus-email|After randomisation, participants will receive a pedometer and will be instructed to wear the pedometer daily for the next four months, check the step count every evening and gradually increase their daily number of steps to at least 10,000. They will also be required to upload data to a website at least once a week. During the intervention period, patients will receive 8 counselling emails based on behavioural techniques.
223811067|NCT03135561|BEHAVIORAL|pedometer-only|After randomisation, participants will receive a pedometer and will be instructed to wear the pedometer daily for the next four months, check the step count every evening and gradually increase their daily number of steps to at least 10,000. They will also be required to upload data to a website at least once a week. There will be no further interaction during the intervention period unless they fail to upload data, in which case they will be offered technical support.
223811068|NCT04672096|DEVICE|Neuronoff BASMATI Injectrode|The 28 day temporary placement of a Basmati Injectrode does not result in unexpected levels of inflammation or encapsulation.
223811069|NCT03090581|PROCEDURE|Biopsies CP|Transbronchial biopsies will be obtained with a flexible bronchoscope, using a cryoprobe.
223811070|NCT03090581|PROCEDURE|Biopsies FC|Transbronchial biopsies will be obtained with a flexible bronchoscope, using a forceps.
223811071|NCT06349018|OTHER|Dietary Supplement: High nitrate isotonic drink|High nitrate (12.9 mmol) drink with carbohydrate and minerals
223811072|NCT06349018|OTHER|Dietary Supplement: No nitrate isotonic drink|Carbohydrate and mineral isotonic drink
223811073|NCT01950065|DEVICE|iovera|
223811074|NCT05385094|DIAGNOSTIC_TEST|S Creatinine concentration|
223811075|NCT05385094|DIAGNOSTIC_TEST|Serum Cystatin C concentration|
223811076|NCT05385094|DIAGNOSTIC_TEST|Urinary Creatinine Clearance|
223811077|NCT01799460|DRUG|The Comprehensive Treatment Regimen of Traditional Chinese Medicine|"①ShenQiMoShen Decoction: which plays vital therapeutic effect in the CTR,the dosage is 150ml per serving and two services per day.Dosage and administration:150ml per time,twice per day~②HuoXueTongMai Capsule : which plays a vital role of promoting blood circulation and removing blood stasis. Its main components are the leeches. Dosage and administration: 4 capsules 3 times daily.~③HeiLiaoDou Particle: which will be prescribed when hypoproteinemia (serum albumin concentration≤30g/L)occurred and should be stopped taking until the serum albumin is above 30g/L. Dosage and administration: 2 packages 3 times daily."
223811078|NCT01799460|DRUG|The immunosuppressive agents|According to Kidney Disease Improving Global Outcomes (KDIGO) clinical practice guideline for glomerulonephritis
223811079|NCT05677932|DEVICE|Bright light therapy|Exposure to bright light therapy for 30mins a day for two weeks
223811080|NCT05677932|DEVICE|Dim red light therapy|Exposure to 50lux dim red light therapy for 30mins a day for two weeks
223811081|NCT02287350|DRUG|diclofenac potassium oral solution|Administration of diclofenac potassium oral solution, taken by mouth, as needed for mild to moderate acute pain.
223811082|NCT00615862|OTHER|Observational study; no interventions|Validated questionnaires will be administered. Blood samples will be analyzed for levels of immune markers as well as cortisol. This is an observational study and patients will not undergo any treatment as part of study participation. Patients will not receive medications or other interventions if they participate in the study. Blood samples analyzed are from samples remaining in the hospital laboratory that were collected as part of routine patient care and destined to be discarded.
223811083|NCT01934413|BEHAVIORAL|Technology-Enhanced Transitional Palliative Care|The Transitional Care intervention will be initiated within 24 hours after enrollment, and will include initial transitional care planning, daily hospital visits, crisis prevention planning by an experienced Palliative Care nurse. The intervention will continue after the patient is discharged to home or short term skilled nursing facility, and it will involve an in-person visit between 24-48 hours post discharge, weekly virtual visits via iPad and video conference technology, and additional home visits as needed. Care plans established during initial planning will be implemented and adjusted under the guidance of the palliative care nurse delivering the intervention.
223811084|NCT01934413|OTHER|Usual Standard of Care|Usual care includes routine hospital discharge planning and usual physician care in primary and specialty outpatient clinics post hospital discharge. The PC consulting service provides consulting services in the inpatient setting. There are no standardized, intentional services provided to outpatients by the PC consulting team. Services provided to outpatients may occur sporadically as initiated by the patient. The majority of PC follow-up if any is a single phone call to the patient/caregiver. To account for the time spent and number of contacts made with the intervention group, the control group will be contacted by phone weekly by a non-nurse member of the study team not involved with the intervention, asked to relate what, if any, medically-related events occurred.
223811085|NCT03091673|DRUG|Glucagon|0.5 or 1.0 mg of pre-mixed liquid Xeris glucagon delivered via auto-injector
223811086|NCT01332890|OTHER|Sequence 1|Period1(A) Period2(B) Period3(C) A : Revaprazan 200mg/Day (multiple dose for 7days) B : Itopride 50mg/Day (multiple dose for 7days) C : Revaprazan 200mg plus Itopride 50mg(multiple dose for 7days)
223811087|NCT01332890|OTHER|Sequence 2|Period1(C) Period2(A) Period3(B) A : Revaprazan 200mg/Day (multiple dose for 7days) B : Itopride 50mg/Day (multiple dose for 7days) C : Revaprazan 200mg plus Itopride 50mg(multiple dose for 7days)
223811088|NCT01332890|OTHER|Sequence 3|Period1(B) Period2(C) Period3(A) A : Revaprazan 200mg/Day (multiple dose for 7days) B : Itopride 50mg/Day (multiple dose for 7days) C : Revaprazan 200mg plus Itopride 50mg(multiple dose for 7days)
223811089|NCT01332890|OTHER|Sequence 4|Period1(C) Period2(B) Period3(A) A : Revaprazan 200mg/Day (multiple dose for 7days) B : Itopride 50mg/Day (multiple dose for 7days) C : Revaprazan 200mg plus Itopride 50mg(multiple dose for 7days)
223811090|NCT01332890|OTHER|Sequence 5|Period1(B) Period2(A) Period3(C) A : Revaprazan 200mg/Day (multiple dose for 7days) B : Itopride 50mg/Day (multiple dose for 7days) C : Revaprazan 200mg plus Itopride 50mg(multiple dose for 7days)
223811091|NCT01332890|OTHER|Sequence 6|Period1(A) Period2(C) Period3(B) A : Revaprazan 200mg/Day (multiple dose for 7days) B : Itopride 50mg/Day (multiple dose for 7days) C : Revaprazan 200mg plus Itopride 50mg(multiple dose for 7days)
223835474|NCT05676073|DRUG|SHEN26 dose 2|Specification: 400mg/capsule. Subjects will receive 10 oral doses twice daily (after breakfast and dinner; Q12h±2h) from Day 1 to Day 5 (or Day 1 to Day 6).
223835475|NCT05676073|DRUG|SHEN26 placebo|Placebo matching the SHEN26 capsule. Subjects will receive 10 oral doses twice daily (after breakfast and dinner; Q12h±2h) from Day 1 to Day 5 (or Day 1 to Day 6).
223811092|NCT05636150|DRUG|Fruquintinib in Combination with S-1|"Cohort A: Fruquintinib 3 mg QD, oral dosing, 2 weeks on/1 weeks off+ S-1 40-60mg/time bid po d1-14 q3w.~Cohort B: Fruquintinib 4 mg QD, oral dosing, 2 weeks on/1 weeks off+ S-1 40-60mg/time bid po d1-14 q3w.~Cohort C: Fruquintinib 5 mg QD, oral dosing, 2 weeks on/1 weeks off+ S-1 40-60mg/time bid po d1-14 q3w.~Patients will be treated until disease progression, death, unacceptable toxicity, loss of follow-up, withdrawal of consent or other conditions meet the end of treatment criteria."
223811093|NCT01582789|DEVICE|enfilcon A|enfilcon A daily wear soft contact lens
223811094|NCT01582789|DEVICE|senofilcon A|senofilcon A daily wear soft contact lens
223811095|NCT00610974|BEHAVIORAL|Body-weight supported treadmill training|BWSTT for 3 times/week for 12 weeks. Each session, subjects will first complete a 10-minute warm-up period followed by 45 minutes of the assigned therapy. Rest breaks will be provided as needed, but subjects must complete 45 minutes of walking per session.
223811096|NCT00610974|BEHAVIORAL|Body-weight supported treadmill training|BWSTT for 3 times/week for 12 weeks. Each session, subjects will first complete a 10-minute warm-up period followed by 45 minutes of the assigned therapy. Rest breaks will be provided as needed, but subjects must complete 45 minutes of walking per session.
223811097|NCT03812211|DIETARY_SUPPLEMENT|Active Supplement|Examine the effects of a multi-faceted supplement comprised of vitamins, minerals and naturally occurring and plant extracts approved for consumption of in overweight/obese men and women
223811098|NCT03812211|DIETARY_SUPPLEMENT|Placebo supplement|Examine the effects of a placebo supplement in overweight/obese men and women, compare to the active supplement
223811099|NCT01784432|DEVICE|Low-level laser therapy and training|
223811100|NCT01784432|OTHER|Training|
223811101|NCT00771303|OTHER|Pregnant patients with suspected PE will undergo a strategy based on clinical probability assessment, D-dimer, lower limb vein ultrasonography and MSCT.|
223811102|NCT02675478|DRUG|AC220|
223811103|NCT02259517|DRUG|Guanfacine|Participants will meet with the study doctor on a weekly basis during the treatment phase of the study. In the first few weeks, the daily dose of the medication will be individually adjusted by the study doctor according to participants' clinical response to and tolerability of the medication. The optimal dose will then be maintained for the remainder of the treatment period.
223811104|NCT02259517|DRUG|Lisdexamfetamine|Participants will meet with the study doctor on a weekly basis during the treatment phase of the study. In the first few weeks, the daily dose of the medication will be individually adjusted by the study doctor according to participants' clinical response to and tolerability of the medication. The optimal dose will then be maintained for the remainder of the treatment period.
223811105|NCT06197555|OTHER|Sodium Monofluorophosphate|Test toothpaste, participants will brush selected sensitive teeth each for 30 seconds followed by the whole mouth thoroughly for at least one minute. The method of application of these agents will be the fingertip method. Patients continued to use the paste twice daily, morning and evening, for 16 weeks.
223811106|NCT06197555|OTHER|Stannous Fluoride|Test toothpaste, participants will brush selected sensitive teeth each for 30 seconds followed by the whole mouth thoroughly for at least one minute. The method of application of these agents will be the fingertip method. Patients continued to use the paste twice daily, morning and evening, for 16 weeks.
223811107|NCT06197555|OTHER|Nano-Hydroxyapatite|Test toothpaste, participants will brush selected sensitive teeth each for 30 seconds followed by the whole mouth thoroughly for at least one minute. The method of application of these agents will be the fingertip method. Patients continued to use the paste twice daily, morning and evening, for 16 weeks.
223811108|NCT06197555|OTHER|8% Arginine & Calcium Carbonate|Test toothpaste, participants will brush selected sensitive teeth each for 30 seconds followed by the whole mouth thoroughly for at least one minute. The method of application of these agents will be the fingertip method. Patients continued to use the paste twice daily, morning and evening, for 16 weeks.
223811109|NCT03657498|PROCEDURE|Combined orthodontic-orthognathic treatment|combined treatment including orthodontics and orthognathic surgery
223811110|NCT03657498|PROCEDURE|Standard orthodontic treatment|treatment with standard orthodontic procedures
223811111|NCT01126827|BEHAVIORAL|Mindfulness-Based Cognitive Behavioral Therapy or Supportive Psychotherapy|12 weekly group therapy sessions
223811112|NCT02276066|DIAGNOSTIC_TEST|GFR by Iohexol|Participants may receive a normal saline dilution of Iohexol 0.5-1 ml given by IV push. Blood or urine will be collected and measured to determine glomerular filtration rate measurements. This test will be repeated in one year.
223811113|NCT02276066|DIAGNOSTIC_TEST|Urine Collection|Both groups of sepsis participants will have urine collected for at least 4 hours to as long as 24 hours or more. The urine volume determined and a sample sent to the lab for determination of creatinine and urea concentration. This test will be repeated in one year.
223811114|NCT02276066|DIAGNOSTIC_TEST|Blood samples|Both groups of sepsis participants will provide peripheral blood samples to the research staff. The samples will be sent to the laboratory for serum creatinine results. This test will be repeated in one year.
223811115|NCT04148014|BEHAVIORAL|An Adjunctive Emotion Regulation Skills Training|The adjunctive emotion regulation skills training is delivered in a group format once a week during 5 weeks to young adults with eating disorders together with treatment as usual
223811116|NCT02691195|DRUG|Ropivacaine|patients were received an ultrasound-guided serratus plane block, the serratus plane was injected with 0.5% ropivacaine 0.4ml/Kg.
223811117|NCT02691195|DRUG|0.9% Nacl|patients were received an ultrasound-guided serratus plane block, the serratus plane was injected with 0.9% Nacl 0.4ml/Kg.
223811118|NCT05377359|DEVICE|Recordings of Hearing Aids with Open Domes|Receiver-in-the-Canal hearing aids will be used which are programmed to the participant's hearing loss and will be coupled to open domes. Recordings will be made of hearing aid output on a head and torso simulator and played back to participants over headphones.
223811119|NCT05377359|DEVICE|Recordings of Hearing Aids with Closed Domes|Receiver-in-the-Canal hearing aids will be used which are programmed to the participant's hearing loss and will be coupled with closed domes. Recordings will be made of hearing aid output on a head and torso simulator and played back to participants over headphones.
223811120|NCT05377359|DEVICE|Recordings of Hearing Aids with Novel State 1|Receiver-in-the-Canal hearing aids will be used which are programmed to the participant's hearing loss and will be coupled with the new coupling method in its first state. Recordings will be made of hearing aid output on a head and torso simulator and played back to participants over headphones.
223811121|NCT05377359|DEVICE|Recordings of Hearing Aids with Novel State 2|Receiver-in-the-Canal hearing aids will be used which are programmed to the participant's hearing loss and will be coupled with the new coupling method in its second state. Recordings will be made of hearing aid output on a head and torso simulator and played back to participants over headphones.
223811122|NCT01808625|OTHER|HYPERBARIC OXYGEN STIMULATION|30 daily sessions, 6 days a week of 90 min exposure to 100% oxygen at 2 ATA.
223811123|NCT01772784|OTHER|Phenolic acids|Phenolic acids
223811124|NCT04425343|GENETIC|16s RNA Metagenomics sequencing|The subgingival plaque was collected using a sterile curette from the buccal aspect of maxillary molars and lingual aspect of mandibular incisors, in a vial containing 200µl of Buffer CL.
223811125|NCT05966402|OTHER|Virtual Reality|Immersion in Virtual Reality
223811126|NCT01031901|DRUG|Skincerity|Study subjects will apply a study product containing polyvinylidene fluoride coating alone to either facial angiofibromas or cutaneous neurofibromas
223811127|NCT01031901|DRUG|Skincerity plus sirolimus/rapamycin|Study subjects will apply a study product containing polyvinylidene fluoride coating plus 1 mg of sirolimus/rapamycin to either facial angiofibromas or cutaneous neurofibromas
223811128|NCT01031901|DRUG|Skinercity plus sirolimus/rapamycin|Study subjects will apply a study product containing polyvinylidene fluoride coating plus 5 mg of sirolimus/rapamycin to either facial angiofibromas or cutaneous neurofibromas
223811129|NCT06182566|PROCEDURE|Convergent ablation|Staged hybrid ablation with CONVERGENT epicardial ablation with ablation of the ligament of Marshall and left atrial appendage clip, followed in second stage by endocardial catheter ablation including pulmonary vein isolation and posterior wall ablation with roof and inferior posterior lines in addition to targeting and touching up any areas with signals at the posterior wall
223811130|NCT06182566|PROCEDURE|Catheter ablation|Pulmonary vein isolation using commercially available catheters; including pulmonary vein isolation and posterior wall ablation with roof and inferior posterior lines in addition to targeting and touching up any areas with signals at the posterior wall
223811131|NCT05673590|DRUG|Utidelone Injection|"Pretreatment: diphenhydramine 40 mg by intramuscular injection or oral administration, and dexamethasone10 mg and cimetidine 300 mg by intravenous injection 30 minutes prior to Utidelone iv drip at the first day of each cycle. The dose of dexamethasone and diphenhydramine can be halved by the physician based on patient's condition in the following day through the fifth day in each cycle, as detailed in the protocol.~Dexamethasone 8 mg per oral, bid, one day prior to docetaxel iv drip for 3 days.~The treatment group will be treated with Utidelone Injection at 40 mg/m2/d intravenously once daily on days 1-5 in a 21-day cycle until disease progression or an occurrence of intolerable toxicities."
223811132|NCT05673590|DRUG|Docetaxel Injection|"Pretreatment: Dexamethasone should be administered orally for 3 days at 16 mg per day (8 mg twice daily), starting one day before the start of Docetaxel.~The control group will be treated with Docetaxel Injection at 75 mg/m2/d, administered intravenously once on day 1. Patients in this group will be treated in 21-day cycles until disease progression or intolerable toxicities occurs."
223811133|NCT01042509|DRUG|Alemtuzumab and rituximab|Alemtuzumab at 10mg subcutaneously daily for 3 doses (days 1, 2 and 3) Rituximab at 100mg intravenously weekly for 4 doses (days 4, 11, 18 and 25
223811134|NCT02802501|DRUG|Tafenoquine|This intervention is provided as tablet containing 150 mg of tafenoquine. Two tablets of this formulation will be administered orally with water as a single dose after a meal. Dose will be taken at least 3 hours after DHA-PQP.
223811135|NCT02802501|DRUG|Matched-Placebo for Tafenoquine|This intervention contains tafenoquine matched-placebo. Two tablets of this formulation will be administered orally with water as a single dose after a meal. Dose will be taken at least 3 hours after DHA-PQP.
223811136|NCT02802501|DRUG|Primaquine|This intervention is provided as over-encapsulated tablet containing 15 mg of primaquine. One capsule of this formulation will be administered orally with water as a single dose after a meal for 14 days. Dose will be taken at least 3 hours after DHA-PQP (Days 1, 2 and 3).
223811137|NCT02802501|DRUG|Matched-Placebo for Primaquine|This intervention contains primaquine matched-placebo. One capsule of this formulation will be administered orally with water as a single dose after a meal for 14 days. Dose will be taken at least 3 hours after DHA-PQP (Days 1, 2 and 3).
223811138|NCT02802501|DRUG|Dihydroartemisinin-piperaquine (DHA-PQP)|This formulation is provided as tablet containing 320 mg of piperaquine tetrasphosphate (as the tetrahydrate; PQP) and 40 mg dihydroartemisinin (DHA). This tablet will be administered orally as single dose for 3 days. For subjects weighing \<75 kg, 3 tablets will be administered per day. For subjects weighing \>=75 kg, 4 tablets will be administered per day. Dose will be taken at least 3 hours after last food intake. No food will be allowed for at least 3 hours after dosing.
223811139|NCT02802501|DRUG|ACT plus PQ (Rescue medication)|Subjects with relapse during the 180 day follow up period will be given an ACT plus PQ 0.5 mg/kg for 14 days as rescue medication.
223811140|NCT02802501|DRUG|PQ (End of study treatment)|Subjects who do not relapse during the study will receive PQ 0.5mg/kg for 14 days at the end of the study.
223811141|NCT02012192|DRUG|Ganetespib|
223811142|NCT02012192|DRUG|Paclitaxel|
223811143|NCT01670448|PROCEDURE|PECBLOCK under echoguidance|Performance of block under echography
223811144|NCT02376621|DIETARY_SUPPLEMENT|PronovaPure 150:500 triglycerides|Subjects will receive 5 single doses with at least 4 treatment-free days between each treatment period. The order of treatments will be in accordance with the randomisation schedule. Using a Williams design, 2 subjects will be randomly assigned to receive 1 of the following 10 treatment sequences:ABECD,BCADE, CDBEA, DECAB, EADBC, DCEBA, EDACB, AEBDC, BACED, CBDAE
223811145|NCT02376621|DIETARY_SUPPLEMENT|Pronovum PRF-048|Subjects will receive 5 single doses with at least 4 treatment-free days between each treatment period. The order of treatments will be in accordance with the randomisation schedule. Using a Williams design, 2 subjects will be randomly assigned to receive 1 of the following 10 treatment sequences:ABECD,BCADE, CDBEA, DECAB, EADBC, DCEBA, EDACB, AEBDC, BACED, CBDAE
223811146|NCT02376621|DIETARY_SUPPLEMENT|Pronovum PRF-037|Subjects will receive 5 single doses with at least 4 treatment-free days between each treatment period. The order of treatments will be in accordance with the randomisation schedule. Using a Williams design, 2 subjects will be randomly assigned to receive 1 of the following 10 treatment sequences:ABECD,BCADE, CDBEA, DECAB, EADBC, DCEBA, EDACB, AEBDC, BACED, CBDAE
223811147|NCT02376621|DIETARY_SUPPLEMENT|PronovaPure 500:200 TG|Subjects will receive 5 single doses with at least 4 treatment-free days between each treatment period. The order of treatments will be in accordance with the randomisation schedule. Using a Williams design, 2 subjects will be randomly assigned to receive 1 of the following 10 treatment sequences:ABECD,BCADE, CDBEA, DECAB, EADBC, DCEBA, EDACB, AEBDC, BACED, CBDAE
223811148|NCT02376621|DIETARY_SUPPLEMENT|Pronovum PRF-047|Subjects will receive 5 single doses with at least 4 treatment-free days between each treatment period. The order of treatments will be in accordance with the randomisation schedule. Using a Williams design, 2 subjects will be randomly assigned to receive 1 of the following 10 treatment sequences:ABECD,BCADE, CDBEA, DECAB, EADBC, DCEBA, EDACB, AEBDC, BACED, CBDAE
223811149|NCT01055925|DEVICE|modified polyurethane film dressing (OpSite, Smith&Nephew, London, UK)|
223811150|NCT01055925|DEVICE|Aquacel® (ConvaTec, Skillman, NJ, USA), sodium carboxy-methylcellulose hydrocolloid polymer dressing|
223811151|NCT06833476|OTHER|EVOQUE|This is a retrospective, non-randomized study. The decision to intervene by TTVR with the EVOQUE device is made by the heart team.
223811152|NCT00959062|DRUG|clonidine|5 mcg/kg (maximum 200 mcg) enterally every 6 hours
223811153|NCT00959062|DRUG|placebo|Preparation visually identical to clonidine.
223811154|NCT01191840|DRUG|Vancomycin|Duration
223811155|NCT01191840|DRUG|Vancomycin|Duration
223811156|NCT03271476|BEHAVIORAL|EMDR psychotherapy|Visit 0 : patient inclusion (questionnaires and interview) Visit 1 : anamnesis Visit 2 : patient supporting Visit 3 : EMDR psychotherapy care Visit 4 : EMDR psychotherapy care Visit 5 : EMDR psychotherapy care and questionnaires Visit 6 : EMDR psychotherapy care Visit 7 : EMDR psychotherapy care Visit 8 : EMDR psychotherapy care ans questionnaires Visit 9 (one month after) : semi-directive interview and data recovery (questionnaires)
223811157|NCT05912140|OTHER|TRACE 2|"The first version of TRACE2 will be retrospectively verified through its application by experts on 150 photos of scoliosis patients who agreed to use the material produced for clinical use for retrospective research. Both intra-operator and inter-operator repeatability will be evaluated and a first Rasch analysis will be performed.~The new version of TRACE2 (TRACE2.2) obtained following the retrospective validation on the photos will be verified prospectively through its application by the experts on 150 patients in specialist medical examination. Both intra-operator and inter-operator repeatability will be evaluated and further Rasch analysis will follow. On the basis of the results obtained from the analysis, the new TRACE2 scale (TRACE2.3) will then be applied to a further 150 patients, its intra- and inter-operator repeatability will be calculated and a final Rasch analysis will be performed to arrive at the final version of the scale (TRACE2.4)."
223811158|NCT04143984|DRUG|Induction chemotherapy|Induction chemotherapy with the regimen of gemcitabine plus nedaplatin.
223811159|NCT04143984|RADIATION|Carbon-ion radiotherapy|Accelerated carbon-ion beam with pencil beam scanning technique.
223811160|NCT04143984|DRUG|Camrelizumab|An anti-PD-1 antibody.
223811161|NCT02923063|BEHAVIORAL|Combined Aerobic and Resistance Exercise via videoconferencing|Combined aerobic and resistance exercise session thrice weekly for 12 weeks
223811162|NCT06783374|PROCEDURE|Neuromodulation|A protocol of posterior tibial nerve electrostimulation will be implemented, inducing retrograde electrostimulation through the pelvic nerves, which are connected to the spinal cord via the sacral plexus at segments S2 and S3. It is recommended to conduct an average of 10 sessions to evaluate the efficacy of the treatment, within a range of 6 to 16 sessions, each lasting 30 minutes, completing a treatment period of 3 months.
223811163|NCT06783374|PROCEDURE|Exercise|Participants will engage in a 60-minute exercise session, divided into two blocks: Block 1 will comprise 10 to 12 repetitions per set, aiming to achieve a perceived exertion level of 7 to 10 on the rating of perceived exertion (RPE). Block 2 will utilize the 5P® LOGSURF Method, termed Proprioceptive Perineal Postural Reeducation, which employs unstable positions to promote postural adjustment and continuous balance. This approach facilitates the activation of the abdominopelvic muscles, enhancing control and strengthening of the pelvic-perineal region.
223811164|NCT06783374|PROCEDURE|Exercise control group|Exercise The control group engages in specific pelvic floor exercises, which are less complex in terms of neuromuscular processing, such as Kegel's exercise. The protocol for these exercises is standardized and conducted individually, comprising 8 to 12 sessions of 20-40 minutes each, performed twice weekly.
223811165|NCT06783374|PROCEDURE|Sham Neuromodulation|A needle with a retractable handle will be used, commonly employed in experimental research with Streitberger and Kleinhenz placebo needles. This creates the appearance of insertion without penetrating the skin and allows the needles to remain in place for the duration of the intervention.
223811166|NCT05234307|DRUG|Adenosine A2B Receptor Antagonist PBF-1129|Given PO
223811167|NCT05234307|PROCEDURE|Biospecimen Collection|Correlative studies
223811168|NCT05234307|BIOLOGICAL|Nivolumab|Given IV
223835476|NCT02509351|DRUG|misoprostol|400 microgram of misoprostol is given preoperatively in patients undergoing elective cesarean section
223811169|NCT06254183|DRUG|Gabapentin|"Gabapentin is a drug that is commonly used to treat neuropathic pain, epilepsy, and other neurological disorders. According to some studies, gabapentin may affect the Wnt signaling pathway.~In this study Gabapentin will be given by a dose of 1200 mg 1 hour before a laparoscopic sleeve gastrectomy(LSG) to decrease postoperative pain and opioid consumption. As acute kidney injury is a common condition following LSG , and as gabapentin has a positive effect on decreasing AKI induced in animal studies, we assess the effect of gabapentin on the AKI status following LSG"
223811170|NCT06254183|DRUG|Placebo|A placebo is a sham medical treatment that appears to be a real medical intervention but has no therapeutic effect. It is often used in clinical trials to compare the effects of a new treatment to those of a placebo. Common examples of placebos include inert tablets (like sugar pills), inert injections (like saline), and even sham surgery or other procedures. Placebos are typically made of inactive substances such as starch or sugar and are designed to be indistinguishable from the actual treatment
223811171|NCT04808505|BIOLOGICAL|Cipaglucosidase alfa|Sterile lyophilized powder intravenous (IV) infusion
223811172|NCT04808505|DRUG|Miglustat|65 mg oral capsules
223811173|NCT03379194|BEHAVIORAL|Antibiotic stewardship program|Routine feedback on antibiotic prescriptions in addition to evidence based guidelines for the management of acute respiratory and urinary tract infection and patient leaflets for using antibiotics wisely
223811174|NCT01341002|PROCEDURE|Transfusion|Red Blood Cells (RBC) Transfusion if SCVO2 \< 70% and guidelines
223811175|NCT01341002|PROCEDURE|Transfusion|transfusion based on guidelines
223811176|NCT00790452|DRUG|Aspirin|325 mg daily by mouth
223811177|NCT00790452|DRUG|Placebo|Tablet daily by mouth
223811178|NCT00980317|PROCEDURE|Restored Kidney Transplant Between Third Parties|Tumor part of the donor kidney is surgically removed and the kidney is restored and transplanted to a third party recipient
223811179|NCT01802437|DRUG|Fluoxetine|If Hamilton Rating Scale for Depression scores do not meet target reductions (20% reduction for 4-week decision point or 40% reduction for 8-week decision point), adolescents will be further randomized to an increase in therapy (4 extra therapy sessions) or fluoxetine therapy. Adolescents who receive pharmacotherapy will be prescribed fluoxetine for 12 weeks. The dosage schedule will be 10 mg per day for the first week and 20 mg per day for the following 5 weeks. If no treatment response is observed by week 6, the dosage can be increased to 40 mg per day. Pharmacotherapy sessions will be scheduled weekly for the first 4 weeks and every other week thereafter. If no treatment response was observed by the sixth week, the dosage could be increased to 40 mg per day.
223811180|NCT01802437|BEHAVIORAL|Increased Dose of Interpersonal Psychotherapy|If Hamilton Rating Scale for Depression scores do not meet target reductions (20% reduction for 4-week decision point or 40% reduction for 8-week decision point), adolescents will be further randomized to an increased dose of interpersonal psychotherapy (4 extra therapy sessions) or fluoxetine.
223811181|NCT01802437|BEHAVIORAL|Continue to Receive Initial Dose of Interpersonal Psychotherapy|If Hamilton Rating Scale for Depression scores meet target reductions (20% reduction for 4-week decision point or 40% reduction for 8-week decision point), adolescents will be assigned to continue initial dose of interpersonal psychotherapy.
223811182|NCT06176599|DRUG|Shenxiao Yuning decoction|Astragalus 30g, Radix Pseudostellariae 15g, Rehmannia glutinosa 15g, Rhodiola rosea 12g，Cimicifuga 15g，Cuttlebone 15g，Poria 15g，Cicada degeneration 9g，Rheum palmatum 6g.
223811183|NCT06176599|DRUG|Symptomatic treatment|(i) Diabetes education: all study participants were given dietary guidance for diabetic nephropathy, low-fat, high-quality, low-protein diet, and restricted sodium intake; maintain emotional stability, quit smoking and alcohol, and exercise appropriately; (ii) control of blood glucose: all study participants routinely received hypoglycaemic treatment, hypoglycaemic measures are not limited (including oral hypoglycaemic drugs or insulin injection); (iii) Control of lipids: study participants with substandard lipids routinely receive lipid-lowering treatment; (iv) Control of blood pressure: those with blood pressure \&gt;140/90 mmHg should be treated with antihypertensive drugs to control blood pressure, and antihypertensive measures are not limited (CCB class, ACEI or ARB class, α, β-blockers, diuretics, etc.); ⑤ Other symptomatic treatment.
223811184|NCT02582346|PROCEDURE|MRI acquisition - no contrast agent|No surgery. Volunteers will have an MRI with a 3T clinical system. Installation will be performed according to standard protocols. Different neurography and tractography sequences will be acquired in order to get different contrasts.
223811185|NCT06426017|OTHER|High Protein Low Calorie Dietary Intervention|High Protein Diet: Diet consisting of 40-60% total energy from proteins, \<20% total energy from carbohydrates and \<30% total energy from fats.
223811186|NCT04082884|BEHAVIORAL|Very Low Carbohydrate Diet|A very low carbohydrate diet (VLCD), is defined as limiting carbohydrate intake to 11% of total daily caloric intake.
223811187|NCT04025151|BEHAVIORAL|Alcohol brief intervention|At baseline, subjects will receive face-to-face or online alcohol brief intervention developed based on the guideline by the World Health Organisation in 5-10 minutes
223811188|NCT04025151|BEHAVIORAL|12-page health warning leaflet|Nurses will provide information about the consequences of drinking using a 12-page health warning booklet. Benefits of reducing and quit drinking will be emphasized by focusing on improving their perception towards the impacts on health, social problems, risky behaviors, academic performance and financial issues.
223811189|NCT04025151|BEHAVIORAL|Regular messages through Instant Messaging (IM)|A total of 26 e-messages will be scheduled: once daily for the first week, 3 time/week for subsequent 4 weeks and 1 time/week for the remaining 7 weeks. The frequency will be adjusted according to IM Apps conversation and subject's requests.
223811190|NCT04025151|BEHAVIORAL|Real-time chat-based support through IM Apps|The chat-based IM support is the extension of baseline ABI and regular e-messages, which aims to provide real-time behavioral and psychosocial support to reduce or quit drinking. It will be personalized according to the subjects' characteristics (gender, drinking pattern and alcoholic drinks preferences), intention to drink and specific questions regarding drinking. Through real-time chatting (text and/or voice), drinkers can acquire information on consequences of drinking and gain social support immediately to reduce intention to drink and alcohol consumption.
223811191|NCT04025151|BEHAVIORAL|General health through SMS|After baseline, they will receive regular e-message through SMS with similar frequency to Intervention group with content on general health and the reminding the importance of participating in the follow-up surveys.
223811192|NCT04025151|BEHAVIORAL|AUDIT score interpretation sheet adapted from the Department of Health of Hong Kong|"a diagram explaining drinking behaviour and potential health risks, definitions of alcohol unit and binge drinking, and advise on limiting daily drinking to 2 alcohol units for men and 1 unit for women"
223811193|NCT05801731|OTHER|Intervention|"The low GI snack is a biscuit with a Glycemic Index of 23.8 ± 3.3. The low GI snack contains plain flour, fibre, plant-based protein, vegetable oil and a low GI sweetener.~The interventional snacks (control, experimental) are matched for caloric content."
223811194|NCT05801731|OTHER|Control|The normal GI snack is a biscuit with a Glycemic Index of 54.4 ± 6.3. The control snack is formulated using basic ingredients for a biscuit recipe consisting of all-purpose flour, butter, sugar, vanilla flavour, baking soda, egg and salt.
223811195|NCT02427659|BEHAVIORAL|Virtual Reality Distraction|The subjects will receive a 20-minute Virtual Reality Distraction (VRD) during their wound care procedure. The nurse will be doing their wound care.
223811196|NCT02427659|BEHAVIORAL|Audio (sound of nature)|"The subjects will listen to an audio recording called Sounds of Nature during their wound care."
223811197|NCT02427659|BEHAVIORAL|Control standard nurse wound care|The subjects will receive their standard care during wound care. The nurse will be doing the wound care.
223811198|NCT03168295|DRUG|Dapagliflozin 10mg then Placebo Oral Tablet|SGLT2 inhibitor - Dapagliflozin then Placebo
223811199|NCT03168295|DRUG|Placebo Oral Tablet then Dapagliflozin 10mg|Placebo then SGLT2 inhibitor - Dapagliflozin
223811200|NCT04131270|BEHAVIORAL|Planning + Education|"Planning: Participants will fill in the planning forms that efer to replacing sedentary behavior with physical activity.~The following behavior change techniques are included in the planning intervention protocol: action planning, barrier identification, prompting self-talk, relapse prevention/coping planning. Applications of all behavior change techniques would include references to planning."
223811201|NCT04131270|BEHAVIORAL|Education|The education would include extended sedentary behavior and physical activity education, delivered face-to-face by the experimenters. The education includes: (1) the behavioral guidelines, tailored to age and health status of the participants, (2) the examples of exercises and their metabolic equivalent, and (3) the education about ways to break sedentary behavior with active breaks.
223811202|NCT01519492|DRUG|AFN-12520000|Two tablets taken in both the morning and evening on an empty stomach for a total daily dose 400 mg
223811203|NCT04709172|DRUG|Cefditoren pivoxil 400mg|Cefditoren pivoxil 400mg bid for 7 days
223811204|NCT02945332|BEHAVIORAL|Required supervised walking|The intervention will include meeting at an agreed upon community center location and time convenient for both the participant and the researcher. During these meetings, the participants will engage in indoor walking under the supervision of the researcher. This is to ensure accurate walking distance recording and also to monitor the participants for any potential adverse events. The participants will have the option of walking as long or short as they please, so long that it is less than 20 miles per week. This is to protect the participants from exhaustion or overexertion. Overall activity of this group will be recorded using Fitbit Flexes, worn at all time for the duration of the study.
223811205|NCT02945332|BEHAVIORAL|Non-required supervised walking|The intervention will include meeting at an agreed upon community center location and time convenient for both the participant and the researcher. During these meetings, the participants will engage in indoor walking under the supervision of the researcher. This is to ensure accurate walking distance recording and also to monitor the participants for any potential adverse events. The participants will have the option of walking as long or short as they please, so long that it is less than 20 miles per week. This is to protect the participants from exhaustion or overexertion. Overall activity of this group will be recorded using Fitbit Flexes, worn at all time for the duration of the study.
223811206|NCT02945332|DEVICE|Fitbit Flex|
223811207|NCT00002420|DRUG|Emivirine|
223811208|NCT00002420|DRUG|Hydroxyurea|
223811209|NCT00002420|DRUG|Delavirdine mesylate|
223811210|NCT00002420|DRUG|Stavudine|
223811211|NCT00002420|DRUG|Didanosine|
223811212|NCT02742298|DEVICE|Muscle ultrasound|Ultrasound images of limb muscles will be collected.
223811213|NCT02742298|OTHER|Electrical Impedance Myography|A painless current passes through the skin and surface electrodes are used to record the impedance through muscle.
223811214|NCT03850652|DIETARY_SUPPLEMENT|Prebiotic (Synergy-1) + Iron supplement|In addition, participants will be required to take one 7 g sachet of prebiotic food supplement daily. In addition, participants will be required to take one daily tablet of a generic, iron supplement (200 mg FeSO4 equivalent to 65 mg iron) (provided by pharmacy).
223811215|NCT03850652|DIETARY_SUPPLEMENT|Placebo (Maltodextrin) + Iron Supplement|participants will be required to take one 7 g sachet of placebo (maltodextrin) daily. In addition, participants will be required to take an iron supplement (200 mg FeSO4 equivalent to 65 mg iron) (provided by pharmacy).
223811216|NCT00813852|BEHAVIORAL|exercise training, IMT|Each exercise session includes graded treadmill walking and resisted exercises. The graded treadmill walking exercise begins with a 5 minute warm-up period with the intensity of about 40% of maximal oxygen consumption (VO2max) follows by a 30 minutes training phase. The training intensity is set at about 70%-85% of VO2max and ends with a 5-minute cool-down period with the intensity of about 40% of VO2max. The resisted exercise program includes 20 minutes of weight training with rest after the first 5 minutes.
223811217|NCT04573543|DIAGNOSTIC_TEST|Evaluation of the degree of fibrosis and steatosis|The degree of steatosis will be estimated using the controlled attenuation parameter (CAP), a method for grading steatosis by measuring the degree of ultrasound attenuation by hepatic fat using a process based on simultaneous transient elastography (TE) which measures the degree of fibrosis.
223811218|NCT04573543|DIAGNOSTIC_TEST|Screening for the components of metabolic syndrome|"Anthropometric measures including body mass index (BMI), waist circumference (WC), waist hip ratio (WHR), and waist height ratio (WHtR) will be measured in all patients.~Results of the routine laboratory tests as part of the standard diagnostic procedure will be collected: bilirubin, AST, ALT, GGT, ALP, albumins, WBC, neutrophil-to-lymphocyte ratio, hemoglobin, platelet count, fasting glucose, triglycerides, cholesterol, HDL and LDL. Non-invasive scores of steatosis/fibrosis will be calculated (APRI, FIB4, NAFLD score). Patients will be screened for the components of metabolic syndrome."
223811219|NCT04573543|DIAGNOSTIC_TEST|Measurement of serum semaphorin concentrations|Semaphorin concentration will be measured in patient sera by ELISA.
223811220|NCT04573543|DIAGNOSTIC_TEST|Identification of semaphorin gene polymorphisms|Semaphorin genes will be sequenced to identify semaphorin gene polymorphisms associated with NAFLD.
223811221|NCT01375270|PROCEDURE|Glucotoxicity|Glucose will be infused intravenously for a 24 hour period to raise blood glucose concentrations 5 mM above basal.
223811222|NCT01375270|PROCEDURE|Lipotoxicity|Intralipid and heparin will be infused intravenously for a 24 hour period to raise blood free fatty acid concentrations to approximately 1 mM.
223811223|NCT06448338|BEHAVIORAL|MyDiaMate|MyDiaMate program
223811224|NCT03200106|DEVICE|Alfapump|Alfapump implant
223811225|NCT01927679|DRUG|Vitamin E|
223811226|NCT01927679|DRUG|Eucerin|Control
223811227|NCT03517592|OTHER|EMDR|The EMDR SUD Protocol consists of a detailed interview with respect to traumatic events, the treatment of those with the EMDR standard protocol and a further specific protocol for SUD that is focused on the concept of addiction memory.
223811228|NCT03517592|OTHER|Treatment as Usual|The TAU condition includes follow-up visits with the psychiatry, psychology and with the nursing service. Visits with the psychiatrist consist to evaluate clinical status and readjust the pharmacological treatment if necessary while visits with the psychologist consist to assess and detect risk situations and to prevent relapses using a cognitive behavioral approach. Finally, the nursing service will provide health and care habits and will carry out the abstinence controls.
223835477|NCT02509351|DRUG|placeboo|women will recive 2 identical tablets as placeboo
223835478|NCT02011308|DEVICE|Green light Laser|Laser vs TURP
223835479|NCT02011308|DEVICE|Transurethral Resection of the Prostate (TURP)|Laser vs TURP
223811229|NCT03114202|OTHER|intensive nutritional counseling|Individualised nutrition intervention in the form of regular and intensive nutrition counselling by a dietitian, following a predetermined standard nutrition protocol, the Medical Nutrition Therapy (Cancer/Radiation Oncology) protocol of the American Dietetic Association (ADA) every week during radiotherapy. Individually tailored sample meal plans, recipe suggestions and hints to minimise the side effects of the tumour and therapy will be provided.
223811230|NCT03114202|OTHER|Standard care|Nutritional counseling / education performed by hospital nurses and nutritional care performed by the hospital nutritionist.
223811231|NCT04699955|BEHAVIORAL|Deviance Regulation Theory|In the negative message condition, participants received information on the negative aspects of individuals that did not used protective strategies and were encouraged to report why these individuals were viewed so much more negatively. In the positive message condition, participants received information on the positive aspects of individuals that used protective strategies and were encouraged to report why these individuals were viewed so much more positively.
223811232|NCT01383889|OTHER|Physical exercise|Two modalities of exercise will be compared: treading mill and stationary bicycle. Pregnant women enrolled in the study will perform exercise during 20 minutes and will be monitored 20 minutes before, during and 20 minutes after exercise.
223811233|NCT01925625|BIOLOGICAL|Early CDT Lung blood test|The EarlyCDT-Lung Test is an early detection test designed to assist in lung cancer risk assessment and detection in the earliest stages of the disease.
223811234|NCT01271569|DRUG|Fospropofol disodium|Fospropofol disodium： 0.5g
223811235|NCT02331602|DRUG|Rivaroxaban|Patients are assigned to receive rivaroxaban 15mg once daily for 12 months. Patients with creatinine clearance 30-49 mL/min receive rivaroxaban 10mg once daily.
223811236|NCT02331602|DRUG|Dabigatran|Patients are assigned to receive dabigatran 150mg twice daily for 12 months. Patients at a high risk of bleeding receive dabigatran 110mg twice daily.
223811237|NCT03756584|DEVICE|Theta-burst stimulation|iTBS comprises 3-pulse 50-Hz bursts, applied every 200 ms (at 5 Hz) as described previously (Huang, Edwards et al. 2005) and consists of 2-second trains with an inter-train-interval of 8 seconds. We will repeat trains (30 pulses; 10 bursts) for 20 times to reach a total number of 600 pulses per session (3x10x20)
223811238|NCT04194203|DRUG|Atezolizumab|Atezolizumab will be administered by IV infusion at a fixed dose of 1200 milligrams (mg) on Day 1 of each 21-day cycle until unacceptable toxicity or loss of clinical benefit.
223811239|NCT04194203|DRUG|Placebo|Placebo matching to atezolizumab will be administered by IV infusion at a fixed dose of 1200 milligrams (mg) on Day 1 of each 21-day cycle until unacceptable toxicity or loss of clinical benefit.
223811240|NCT04194203|DRUG|Bevacizumab|Bevacizumab will be administered by IV infusion at a dose of 15 mg/kg on Day 1 of each 21-day cycle.
223811241|NCT04194203|DRUG|Paclitaxel|Paclitaxel will be administered by IV infusion at a dose of 175 mg/m2.
223811242|NCT04194203|DRUG|Pemetrexed|Pemetrexed will be administered by IV infusion at a dose of 500 mg/m2.
223811243|NCT04194203|DRUG|Carboplatin|Carboplatin will be administered by IV infusion to achieve an initial target AUC of 6 mg/mL/min.
223811244|NCT01342458|OTHER|Flexible footwear|The patients of the Intervention Group (IG) will be use over 6 month a flexible and non-heeled footwear (Moleca; Calçados Beira Rio S.A., Novo Hamburgo, Rio Grande do Sul, Brazil) is a women's flexible flat walking shoe, without heels, with an anti-slip rubber sole, 5-mm thin, with a 3 mm internal wedge of ethylene vinyl acetate, made out of dubbed canvas. It had a mean weight of 172 ± 19.6 g, ranging from 142 to 193 g depending upon the size.
223811245|NCT03083938|PROCEDURE|Omental Roll-up|Using omentum roll-up pancreato-jejunal anastomosis
223811246|NCT00642902|DRUG|Atacicept|Atacicept will be administered subcutaneously at a dose of 25 milligram (mg) twice a week for initial 4 weeks as loading dose, followed by 25 mg once a week for subsequent 32 weeks.
223835480|NCT01944943|DRUG|Vismodegib|150 mg (1 capsule) of Vismodegib per day orally in continue during 12 months
223811247|NCT00642902|DRUG|Atacicept|Atacicept will be administered subcutaneously at a dose of 75 mg twice a week for initial 4 weeks as loading dose, followed by 75 mg once a week for subsequent 32 weeks.
223811248|NCT00642902|DRUG|Atacicept|Atacicept will be administered subcutaneously at a dose of 150 mg twice a week for initial 4 weeks as loading dose, followed by 150 mg once a week for subsequent 32 weeks.
223811249|NCT00642902|DRUG|Placebo matched to atacicept|Placebo matched to atacicept will be administered subcutaneously twice a week for initial 4 weeks, followed by once a week for subsequent 32 weeks.
223811250|NCT00901888|DRUG|Apelin infusion|Infusion of up to 10picmol/min will be administered intra-arterially to induce vasoconstriction. Thereafter infusions of apelin (0.1, 1.0, 3.0nmol/min) will be given for 6mins each. During the same study, sodium nitroprusside will given (1.0, 2.0, 4.0 microg/min) for 6mins.
223811251|NCT00901888|DRUG|Sodium nitroprusside infusion|Infusion of up to 150-600picmol/min will be administered intra-arterially to induce vasoconstriction. Thereafter infusions of apelin (0.1, 1.0, 3.0nmol/min) will be given for 6mins each. During the same study, sodium nitroprusside will given (1.0, 2.0, 4.0 microg/min) for 6mins.
223811252|NCT03953898|PROCEDURE|Biospecimen Collection|Undergo collection of blood
223811253|NCT03953898|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
223811254|NCT03953898|DRUG|Olaparib|Given PO
223811255|NCT06388889|DRUG|Dexpramipexole Dihydrochloride|Oral administration of dexpramipexole tablet
223811256|NCT01963338|DEVICE|Intradermal injection in the forearm (0,1cc NaCl 0,9%)|This injection is conducted by the newly developed device.
223811257|NCT01963338|DEVICE|Intradermal injection in the upper arm (0,1cc NaCl 0,9%)|This injection is conducted by the newly developed device in the upper arm (deltoid region).
223811258|NCT01963338|DRUG|Intramuscular injection in the upper arm (0,5cc NaCl 0,9%)|This injection is conducted by needle and syringe in the upper arm (deltoid region).
223811259|NCT04226222|DIAGNOSTIC_TEST|TEP-TDM FDG|Semi-quantitative PET-TDM FDG Data and Texture Analysis
223811260|NCT06202222|OTHER|rehabilitation|The patient undergoes a daily session on the cycloergometer (Am3i Ergometer). The patient is instructed to pedal at a heart rate ranging from 60% to 80% of their maximum heart rate (calculated as 220 minus their age) for a duration of 20 minutes. These sessions can be conducted with oxygen therapy for patients dependent on oxygen. The sessions are maintained until the patient is discharged from the department.
223811261|NCT04575935|DRUG|Chemotherapy|Receive standard of care chemotherapy
223811262|NCT04575935|PROCEDURE|Laparotomy|Undergo laparotomy
223811263|NCT04575935|PROCEDURE|Minimally Invasive Surgery|Undergo MIS
223811264|NCT04575935|OTHER|Quality-of-Life Assessment|Ancillary studies
223811265|NCT04575935|OTHER|Questionnaire Administration|Ancillary studies
223811266|NCT05064852|DRUG|Surufatinib|The study is a real-world study. According to the actual medical history of patients, the usage of Surufatinib was collected.
223811267|NCT00234650|PROCEDURE|Colonoscopy|
223811268|NCT01271998|DRUG|TR-701 FA|200 mg, oral, once daily for 3 days.
223811269|NCT00808574|BEHAVIORAL|Obstructive sleep apnea screening intervention|Brief, theory-based, online assessment of OSA risk followed by risk-tailed OSA presentation.
223811270|NCT00816179|PROCEDURE|Transgastric diagnostic endoscopic peritoneoscopy|Endoscopic abdominal exploration utilizing an endoscopically created gastrotomy.
223811271|NCT04617548|COMBINATION_PRODUCT|tDCS and CO-OP Group|Transcranial direct current stimulation modulates the excitability of targeted brain regions, and is thought to facilitate or inhibit neuroplasticity. Participants will receive anodal tDCS (1.5 mA) to the dorsolateral prefrontal cortex (dlPFC) for 20 minutes at the beginning of each session. CO-OP focuses on learning of a global problem-solving strategy, Goal-Plan-Do-Check (GPDC), within the performance of participant-chosen goals. Use of a broadly applicable strategy and meaningful activity ensures the intervention is salient to the participant and increases likelihood of transfer. Uniquely, therapists applying CO-OP use guided discovery methods to support participants in analyzing their own performance of a given task and generating potential solutions for improving performance. Participants become equipped with these skills through repetitive application of the Goal-Plan-Do-Check process.The intervention focuses on learning GPDC with gradual withdrawal of guided discovery methods.
223811272|NCT06181110|BEHAVIORAL|Transdiagnostic Intervention for Sleep and Circadian Dysfunction|This intervention is a non-pharmacological approach that targets various factors contributing to sleep and circadian problems. It incorporates evidence-based elements such as CBT for insomnia, IPSRT, chronotherapy, and motivation enhancement. The treatment consists of 8 sessions with 4 cross-cutting modules: case formulation, sleep and circadian education, motivational interviewing, and goal setting. Participants also receive 4 core modules addressing sleep-wake regularity, daytime functioning, correcting beliefs, and maintaining behavioral change. Additionally, 6 optional modules cater to specific sleep-wake patterns, addressing sleep efficiency, excessive time in bed, delayed/advanced sleep phase, sleep-related worry, complex sleep environments, and nightmares. Modules are delivered based on individual needs. Sessions include agenda setting, homework review, treatment content delivery, goal assignment, and session summarization.
223811273|NCT05777148|DEVICE|super high-flux hemodialysis|Super high-flux hemodialysis (SHF-HD) is hemodialysis using Super high-flux dialyzer for 24 week then crossover to post dilution online HDF (wash out period 4 weeks)
223811274|NCT05777148|DEVICE|postdilution online hemodiafiltration|hemodialysis by post dilution online HDF technique for 24 week then crossover to super high-flux HD (wash out period 4 weeks)
223811275|NCT03128866|PROCEDURE|Hemipelvectomy|Undergo hemipelvectomy
223811276|NCT03128866|DRUG|Tranexamic Acid|Given IV
223811277|NCT04837872|OTHER|Multimodal Physical Therapy (MPT)|Individualized physical therapy and static progressive splint (flexion with or without extension splint).
223811278|NCT00335582|DRUG|clonidine hydrochloride|One hour prior to surgery, patients randomized to the treatment arm will receive clonidine as both a 0.2 mg oral tablet and 0.2 mg/day transdermal patch patch will be removed on postoperative day 4 (or hospital discharge, whichever is earlier)
223811279|NCT01222195|DRUG|Lenalidomide|10 mg/day by mouth on days 1-21 of every 28 day cycle.
223811280|NCT01222195|DRUG|Darbepoetin alfa|200 mcg subcutaneously every 2 weeks of a 28 cycle.
223811281|NCT00402571|DRUG|acetaminophen|
223835481|NCT01627847|DRUG|Ropinirole|
223811282|NCT03077984|COMBINATION_PRODUCT|Chinese medicine treatment|The cohort of Chinese medicine treatment uses its comprehensive program of TCM on the basis of treatment with western medicine, including Chinese Herbs, acupuncture and acupoint application therapies.
223811283|NCT03885037|DRUG|Infliximab [infliximab biosimilar 3]|\<Rheumatoid arthritis\> The usual dose is 3 mg as Infliximab \[Infliximab Biosimilar 3\] for every kg of body weight given as an intravenous infusion. After an initial dose is given, the subsequent doses are given at Weeks 2 and 6, and every 8 weeks thereafter. After a dose at Week 6 is given, the dose may be increased or the dosing interval may be reduced for patients who have an incomplete response or reduced effects. These adjustments should be made in a stepwise manner. The maximum dose is 10 mg for every kg of body weight at the dosing interval of 8 weeks and 6 mg for every kg of body weight at a reduced dosing interval. The minimum dosing interval is 4 weeks. This drug should be given in combination with methotrexate.
223811284|NCT00032890|DRUG|glucosamine|
223811285|NCT00032890|DRUG|chondroitin sulfate|
223811286|NCT00032890|DRUG|glucosamine and chondroitin sulfate combined|
223811287|NCT00032890|DRUG|celecoxib|
223811288|NCT01499225|DRUG|YH14642 500mg Tab|YH14642 500mg per day(once a day)
223811289|NCT01499225|DRUG|YH14642 500mg Tab|YH14642 1000mg per day(twice a day)
223811290|NCT01499225|DRUG|YH14642 500mg Tab|YH14642 2000mg per day(three times a day)
223811291|NCT01499225|DRUG|INSADOL[Zea mays L. extract] 35mg Tab|"\[Initiation dose : 4weeks after administraion\] INSADOL\[Zea mays L. extract\] 210mg TAB per day~\[Maintain dose : Between 4weeks and 8weeks after administraion\] INSADOL\[Zea mays L. extract\] 105mg TAB per day~\[Maintain dose : Between 8weeks and 12weeks after administraion\] INSADOL\[Zea mays L. extract\] 105mg TAB per day"
223811292|NCT01499225|DRUG|DENTISTA[Doxycycline hyclate] 20mg Cap|DENTISTA\[Doxycycline hyclate\] Cap 40mg per day
223811293|NCT01499225|DRUG|Placebo|Placebo
223811294|NCT06464588|BIOLOGICAL|Allogeneic Neonatal mesenchymal stromal cells (nMSCs)|nMSCs will be administered intravenously in the predefined dose per each group. The rate of infusion will be approximately 30- 60 minutes at 0, 15 and 30 days, with escalating dose levels.
223811295|NCT05285384|BIOLOGICAL|SARS-CoV-2 recombinant spike protein + Advax-SM adjuvant|SARS-CoV-2 recombinant spike protein (25 μg) with Advax-SM adjuvant (15 mg); a single intramuscular injection into the deltoid muscle of the non-dominant arm
223811296|NCT05865613|DEVICE|Pulsed electromagnetic field|Participants were randomized into either the PEMF group or sham treatment group by a computer-generated random number. The participants were treated using PEMF (20 G ,7H for 10min) and sham treatment. treatment was delivered for one month.
223811297|NCT00291902|DRUG|SB-681323|
223811298|NCT02878928|GENETIC|IDgenetix Neuropsychiatric Test Panel|The IDgenetix Neuropsychiatric Test Panel is used to make recommendations on the medication therapy that might be impacted by the genetic background of the patient.
223811299|NCT04786314|OTHER|Hot Water Application|Pregnant women will apply hot water to their legs before going to sleep for a week.
223811300|NCT04786314|OTHER|Cold Water Application|Pregnant women will apply cold water to their legs before going to sleep for a week.
223811301|NCT00079638|DRUG|Niacin|
223811302|NCT00079638|DRUG|Atorvastatin|
223811303|NCT00079638|DRUG|Simvastatin|
223811304|NCT00079638|DRUG|Ezetimibe|
223811305|NCT00079638|DRUG|Rosuvastatin|
223811306|NCT03823222|DIETARY_SUPPLEMENT|Duckweed protein|20 grams isolated protein
223811307|NCT03823222|DIETARY_SUPPLEMENT|Whey protein|20 grams isolated protein
223811308|NCT01027975|PROCEDURE|laparoscopic Nissen/laparoscopic Thal|
223811309|NCT00947726|DRUG|CeraVe|Using OTC cream on foot twice daily for two weeks.
223811310|NCT06474897|OTHER|Ozone therapy|Ozone therapy will be practiced to study group. Inject 10 ml of ozone gas (O2-O3) at a concentration of 10 µg/ml 3 times at one week intervals. All injections will be performed by the same experienced specialist doctor.
223811311|NCT06474897|OTHER|Mulligan Mobilization|Mulligan mobilization will be practiced to control group. Mobilizations will be performed once a week for 3 consecutive weeks. The first one is a seated position with the patient's arm in approximately 90° abduction. The patient will be asked to abduct the arm and at the same time the physiotherapist will perform posterio/lateral gliding of the shoulder head with the left hand.
223811312|NCT02871960|PROCEDURE|Robotic and Laparoscopic Colectomy|
223811313|NCT00704301|DRUG|Rivastigmine|Rivastigmine, two times 1,5 mg a day. The dosage will be increased every three days with 3 mg a day, until the CAM-ICU is negative or until the occurrence of presumed severe adverse effects or until a maximum of 12 mg a day.
223811314|NCT00704301|DRUG|Placebo|Placebo, 2 times a day
223811315|NCT02893306|BIOLOGICAL|MSCs|origin: bone marrow of healthy donor; manipulation: ex vivo expanded; via: intravenous; vehicle: 5% human recombinant albumin in physiological serum; dose: 2-3 millions/Kg; dosage: single
223811316|NCT05951088|PROCEDURE|Cardio2U follow-up|During the follow-up period, participants will have access to the application and will be able to explore the different modules. At fixed time points, the application will allow them to fill in questionnaires about the application's usability and patient satisfaction. App user data will track how long and how often patients visit the application and which aspects are mostly used. In addition, at different time points during the study, patients will be asked to complete clinical questionnaires regarding e.g. patients' knowledge and self-care abilities. The results of these questionnaires can be used in a more clinical way as they will be accessible to doctors and nurses in the healthcare provider dashboard and can support targeted patient follow-up and guidance
223811317|NCT04116697|OTHER|Acupuncture|Acupuncture is a form of alternative medicine in which thin needles are inserted into the body.
223811318|NCT04116697|OTHER|Aromatherapy|Aromatherapy is a form of alternative medicine in which you will inhale aromatic plant extracts and essential oils.
223811319|NCT01538472|DRUG|Y Zevalin|Starting dose: 0.4 mCi/kg by vein after Rituxan infusion on Day -14.
223811320|NCT01538472|DRUG|In Zevalin|Imaging dose: 5 mCi by vein following Rituxan infusion on Day -21.
223811321|NCT01538472|DRUG|Rituxan|"250 mg/m2 by vein on Day -21 and on Day -14.~1000 mg/m2 by vein on Days +1 and +8."
223811322|NCT01538472|DRUG|BCNU|300 mg/m2 by vein on Day -6.
223811323|NCT01538472|DRUG|VP -16|200 mg/m2 by vein every 12 hours on Days -5, -4, -3, and -2.
223811324|NCT01538472|DRUG|Ara-C|200 mg/m2 by vein every 12 hours on Days -5, -4, -3,and -2.
223811325|NCT01538472|DRUG|Melphalan|140 mg/m2 by vein on Day -1.
223811326|NCT01538472|PROCEDURE|Stem Cell Infusion|Autologous stem cell infusion on Day 0.
223811327|NCT01538472|DRUG|G-CSF|5 mg/kg by vein daily starting Day 0 till recovery of granulocytes of 4.0 x 109/L.
223811328|NCT05596890|DRUG|Paclitaxel-albumin|260mg/m2, ivdrip, d1
223811329|NCT05596890|DRUG|Cisplatin|60mg/m2, ivdrip, d1
223811330|NCT05596890|DRUG|Carboplatin|AUC=4-6, ivdrip, d1
223811331|NCT05596890|DRUG|Tislelizumab|200mg, ivdrip, d1
223811332|NCT05596890|RADIATION|VMAT or IMRT|15Gy/5F (d43-d50, d57-d64), 5 times a week
223811333|NCT05596890|PROCEDURE|Esophagectomy|Minimally-invasive or open McKeown and Ivor-Lewis esophagectomy
223811334|NCT04918368|BEHAVIORAL|Behavioral scales were used|Women's Health Initiative Sleeplessness Scale (WHISS) and State Anxiety Scale (SAS), were applied.
223811335|NCT02309112|OTHER|Yoga|A mind-body therapy that includes specified breathing, meditation and physical postures.
223811336|NCT02539836|DIETARY_SUPPLEMENT|Dietary nutrition based on plant fermentation extract|The main ingredient of dietary nutrition is plant fermentation extraction which is from many fruit and vegetable fermented by probiotics.
223811337|NCT02539836|DIAGNOSTIC_TEST|MRI in quantifying liver fat with MRS|To investigate the accuracy of MRI in quantifying liver fat with magnetic resonance spectroscopy (MRS) as a reference.
223811338|NCT02732613|DEVICE|Laryngeal Mask Airway|If there were any conflicts of the Laryngeal Mask Airway classic size selection in slim patients by the actual or ideal body weight, size selection will based on actual body weight in Actual weight Group while ideal body weight in Ideal weight Group.
223811339|NCT06529666|BEHAVIORAL|Didatic Session 1: Core Foundation Course|A 45-minute foundational presentation covering key Weight Management Counseling (WMC) concepts, obesity bias, and cultural humility facilitated by a trained clinician-educator at the residency program delivered at baseline.
223811340|NCT06529666|BEHAVIORAL|The 3Ps Program|"6 email modules delivered over months 2-8). Each 3P module will allow the resident to:~(1) Prepare: Review relevant concepts and demonstration videos sent via an email to prepare for completing the VCA vignettes; (2) Practice: Respond to brief vignettes of various 5As WMC challenging scenarios by audio recording their spoken response on the VCA tool; and (3) Process: Reflect on actionable expert and crowdsourced analogue patient feedback on the quality of their responses to each VCA vignette."
223811341|NCT06529666|BEHAVIORAL|Didactic session 2|(months 8-10): This 45-minute session will discuss key barriers to WMC adoption in clinical practice using real-world cases captured from residents facilitated by a trained clinician-educator at the residency program.
223811342|NCT06529666|BEHAVIORAL|Email reinforcement|2 emails in months 10-12 covering key concepts in the preceding components.
223811343|NCT06529666|BEHAVIORAL|PowerPoint of the foundational course|Residents will receive a core foundation slides on weight management counselling
223811344|NCT02017054|OTHER|Cath|No intervention - registry
223811345|NCT03221855|DRUG|Domperidone|Capsules 10mg orally each 8 hours for 7 days.
223811346|NCT03221855|DRUG|Placebo|Capsules 10mg orally each 8 hours for 7 days.
223811347|NCT01572779|DEVICE|BSM device with bio-feedback|A postural bio-feedback device worn by subjects for 4-10hours a day for 6 days spread across 6 weeks for the sub acute low back pain group and for 8 days spread across 10 weeks for the chronic group. The device records movement and muscle activity data relating to the lower back. Bio-feedback is delivered to the subject as an audible tone, visual cue or vibration and aims to prompt the subject to alter their posture or position in line with recommendations given by the treating practitioner. Four small sensors are adhered to the lower back and send data wirelessly to a data logger carried in the pocket by the subject (the size of a small mobile phone).
223811348|NCT01572779|DEVICE|BSM device with no bio-feedback|The BSM device is worn as a placebo with no bio-feedback given to the subject. The subjects in the control group wear the device for 4-10 hours a day for 6 days spread across 6 weeks for the sub acute low back pain group and for 8 days spread across 10 weeks for the chronic group.
223811349|NCT00307749|DRUG|Placebo|once daily for 24 weeks
223811350|NCT00307749|DRUG|MCC-257|20mg, once daily for 24 weeks
223811351|NCT00307749|DRUG|MCC-257|40mg, once daily for 24 weeks
223811352|NCT00307749|DRUG|MCC-257|80mg, once daily for 24 weeks
223811353|NCT01227603|DRUG|Nifedipine-candesartan FDC (BAY 98-7106)|Single dose of 1 FDC tablet consisting of 60 mg nifedipine GITS and 32 mg candesartan
223811354|NCT01227603|DRUG|Nifedipine GITS (Adalat LA, BAYA1040)|Single oral dose of 1 tablet of nifedipine GITS 60 mg
223811355|NCT01227603|DRUG|Candesartan (Atacand)|Single oral dose of 32 mg (2 x 16 mg tablet) candesartan
223811356|NCT02637934|DRUG|[18F]FluorThanatrace|
223811357|NCT02637934|RADIATION|PET/CT imaging sessions|
223811358|NCT03203655|BEHAVIORAL|CareMessage™|Adult Obesity texting program, which sends a text message 3 to 5 times a week, encouraging lifestyle modifications (diet and exercise education, and behavioral strategies) that can lead to healthy weight loss.
223811359|NCT03203655|BEHAVIORAL|Control Condition|Control condition will receive an initial talk about weight loss but will not be enrolled in any program or intervention.
223811360|NCT03043001|DRUG|Memantine|All the subjects will receive add-on memantine for 12 week
223811361|NCT01522534|DRUG|Mepivacaine|mepivacaine 1% 20 ml corresponding to 200 mg
223811362|NCT01522534|DRUG|Morphine|Morphine alone with a placebo nerve block
223811363|NCT00530062|DRUG|Albuterol-HFA-MDI|Inhalation Aerosols, 90 mcg, 1 dose per treatment period
223811364|NCT00530062|DRUG|Albuterol-HFA-BAI|Inhalation Aerosol (Breath-Actuated), 90 mcg, 1 dose per treatment period.
223811365|NCT01376323|DRUG|GSK256073 1mg|GSK256073 1mg capsule
223811366|NCT01376323|DRUG|GSK256073 5mg|GSK256073 5mg capsule
223811367|NCT01376323|DRUG|GSK256073 10mg|GSK256073 10mg capsule
223811368|NCT01376323|DRUG|GSK256073 25mg|GSK256073 25mg capsule
223811369|NCT01376323|DRUG|Placebo|placebo capsule
223811370|NCT01376323|DRUG|Sitagliptin 100mg|Sitagliptin 100mg capsule
223811371|NCT04681729|DRUG|Dupilumab SAR231893|Pharmaceutical form: Injection solution Route of administration: Subcutaneous
223811372|NCT04681729|DRUG|Placebo|Pharmaceutical form: Injection solution Route of administration: Subcutaneous
223811373|NCT04681729|DRUG|Non sedating H1-antihistamine|Pharmaceutical form: Tablet Route of administration: Oral
223811374|NCT01874457|BIOLOGICAL|MMR (Mumps, Measles and Rubella)|MMR (Mumps, Measles and Rubella)
223811375|NCT00006825|BIOLOGICAL|trastuzumab|
223811376|NCT00006825|DRUG|pegylated liposomal doxorubicin hydrochloride|
223811377|NCT03306901|PROCEDURE|Esophagectomy|Ivor Lewis esophagectomy or McKeown esophagectomy and systematic lymphadenectomy
223811378|NCT03306901|DRUG|5-fluorouracil|3,200 \~ 4,000mg/m2 intravenously for 4 to 5 days.
223811379|NCT03306901|DRUG|Cisplatin|45\~60mg intravenously over 1 hour on day 1
223811380|NCT03306901|RADIATION|Radiation therapy|45 Gy irradiation (5 days a week for 5 weeks)
223811381|NCT03834103|BEHAVIORAL|Self-rehabilitation program and protein supplement|"Participants follow a home-based self-rehabilitation program consisting of the realisation of a set of physical exercises using an elastic band. The exercises have to be performed 3 times a week, and are associated with a protein supplementation.~The rehabilitation follow-up by the physician is planned once a week, by phone, and with face-to-face appointments at inclusion, 6 weeks and 3 months follow-up."
223811382|NCT02470494|DEVICE|Sound amplification provided via the EarLens CHD|Subjects with mild to severe hearing impairment receiving sound amplification treatment with EarLens CHD.
223811383|NCT00499863|DRUG|methylphenidate transdermal system|dose optimization of 4 doses of the MTS transdermal patch over the same duration of wear
223811384|NCT00499863|DRUG|Placebo|Placebo patch
223811385|NCT04792125|BEHAVIORAL|External electrical stimulation (EES) added to pelvic floor muscle training (PFMT)|"Patients will be treated with the Innovo device using eight external electrodes with a combined stimulator. Electrodes will be applied to the buttocks, outer hips and anterior and posterior proximal thighs 3 days a week for 30 minutes each session.~While explaining the exercise to the patients, it was stated that 1 set of exercise consisted of 10 fast contractions and 10 slow contractions. For the first 2 weeks, they were asked to exercise 2 sets a day, every day. Thus, in the first 2 weeks, 20 fast contractions and 20 slow contractions were performed. Then, 2 sets were increased every two weeks and the exercise was ended as 8 sets (80 fast and 80 slow contractions) at the end of the 8th week."
223811386|NCT04792125|BEHAVIORAL|External electrical stimulation|Patients will be treated with the Innovo device using eight external electrodes with a combined stimulator. Electrodes will be applied to the buttocks, outer hips and anterior and posterior proximal thighs 3 days a week for 30 minutes each session.
223811387|NCT04792125|BEHAVIORAL|Pelvic floor muscle training (PFMT)|While explaining the exercise to the patients, it was stated that 1 set of exercise consisted of 10 fast contractions and 10 slow contractions. For the first 2 weeks, they were asked to exercise 2 sets a day, every day. Thus, in the first 2 weeks, 20 fast contractions and 20 slow contractions were performed. Then, 2 sets were increased every two weeks and the exercise was ended as 8 sets (80 fast and 80 slow contractions) at the end of the 8th week.
223811388|NCT02121678|OTHER|Resistance training|"Participants do resistance training of selected muscle groups. Resistance are predefined from 1-repetition max (1-RM) and increased during the 12 weeks of training:~* Week 0-4: 70-80 % of 1-RM~* Week 5-8: 75-86 % of 1-RM~* Week 9-12: 80-92% of 1-RM~Participants trains unilateral, the opposite site serves as reference.~* MMN patients train elbow (flexion/extension) and wrist (flexion/extension)~* CIDP patients train knee (flexion/extension) and elbow (flexion/extension)"
223811389|NCT02121678|OTHER|Aerobic training|"Participants train on ergometer bicycle 2 times weekly increasing during the first weeks to 3 times weekly. Workload is measured before initiation and VO2-max, heart rate and blood pressure will be measured as well.~Patients train with 60-75 % of VO2-max for 30 minutes per training session. They use heart rate monitor to store data."
223811390|NCT03184584|DRUG|PBI-4050|Four 200 mg capsules (800 mg total) administered orally, once daily
223811391|NCT00284063|PROCEDURE|Low back adjustment and MRI|Subjects received a 15 minutes MRI in neutral position, a chiropractic low back spinal manipulation, and a second 15 minute MRI in neutral position.
223811392|NCT00284063|PROCEDURE|Low back adjustment and MRI|Subjects received a 15 minutes MRI in neutral position, a chiropractic spinal manipulation to the low back, and a second 15 minute MRI in a side posture position.
223811393|NCT00284063|PROCEDURE|MRI|Subjects received a 15 minute MRI in neutral position and a second 15 minute MRI in neutral position.
223811394|NCT03737786|OTHER|Tight control of end-tidal CO2 levels|The desired end-tidal PCO2 levels will be achieved by endotracheal intubation and controlled ventilation
223811395|NCT03540875|DEVICE|Closed loop anesthesia|"Propofol and Remifentanil are administered automatically using a closed-loop system.~The goal of this study is to compare manual titration versus automated titration of propofol and remifentanil in adult patients undergoing surgery guided by the electro-cortical activity. The aim in both group is to maintain the qCon in the range 40-60 during induction and maintenance of general anesthesia using the propofol in TCI mode. But also the qNox in the range 40-60 using remifentanil. The controller is based on a Proportional-Integral-derivative algorithm which steers a target to the pumps during induction and maintenance of general anesthesia."
223811396|NCT03540875|DRUG|Propofol|The dosage is modified automatically by the device or according to the new medical prescription.
223811397|NCT03540875|DRUG|Remifentanil|The dosage is modified automatically by the device or according to the new medical prescription.
223811398|NCT03279835|OTHER|Classic evaluation of neurocognitive functions|Symbol Digit Modalities Test (SDMT)
223811399|NCT03279835|OTHER|New evaluation of neurocognitive functions|Cognitive Speed Computerized Test (CSCT)
223811400|NCT04580563|DRUG|OctaplasLG®|Patient receive 12 ml/kg of OctaplasLG® at day 1, within the 2 hours after randomization (i.e. within the 8 hours after coagulopathy diagnosis). A new identical dose will be infused at day 2 according to coagulation parameters.
223811401|NCT04580563|DRUG|0.9% NaCl|Patient receive 12 ml/kg of placebo (0.9% NaCl) at day 1, within the 2 hours after randomization (i.e. within the 8 hours after coagulopathy diagnosis). A new identical dose will be infused at day 2 according to coagulation parameters.
223811402|NCT02293746|DEVICE|Inspire® Upper Airway Stimulation (UAS) System|This is a single-arm study; all participants will be implanted with the Inspire® Upper Airway Stimulation (UAS) System is a permanent, implantable therapy device, which consists of three implantable components: an IPG, a stimulation lead, and a sensing lead. In addition, the patient receives a remove to activate the therapy.
223811403|NCT05285462|BEHAVIORAL|VR Pain Education|pain education delivered via VR headset, up to 12 sessions
223811404|NCT05285462|BEHAVIORAL|Usual Care Physical Therapy|Normal course of PT without influence by study team on frequency or duration
223811405|NCT05892666|OTHER|On-site recruitment (information and consent) following a random sampling recruitment schedule|A trained research assistant in collaboration with local clerks at each site will screen eligible patients after on-site registration or online scheduling, but prior to assessment by a physician, based on included presenting complaints. The research assistant or member of the care team, depending on the local rules, will approach the potentially eligible participants and present them the research project and information consent form. If the patient agrees to participate and is eligible, they will sign the information and consent form and the research assistant will take their vital signs (for onsite participants only).
223811406|NCT05892666|OTHER|First phone call 1-3 days after the initial visit|Once the patient has been discharged, a research assistant will call the patient within 72 hours following the initial visit. This phone call will allow to i) ensure that gender, ethnicity, comorbidities and disposition plans are fully documented; and ii) use our patient-reported experience measure tool and administer a questionnaire on motivation for choosing one care setting over the other. Motivation will be classified in the 6 domains of the Conceptual Model of Emergency Department Use (Uscher-Pines et al. 2019). Participants will be asked to specify whether their choice of care setting was based on accessibility, convenience, their perception of the severity of illness, their beliefs and knowledge regarding these care settings, referral/advice from a care professional or an acquaintance, or on costs.
223811407|NCT05892666|OTHER|Second phone call 8-14 days after the initial visit|A follow-up phone call will be made to all participants 8 days after the initial visit to evaluate primary and secondary outcome metrics. Patient-reported outcome (primary) and cost measures will be completed by the participants at this moment.
223811408|NCT00000986|DRUG|Zidovudine|
223811409|NCT00000986|DRUG|Aldesleukin|
223811410|NCT02565719|DRUG|REP 2139-Mg|REP 2139-Mg = magnesium chelate complex of REP 2139
223811411|NCT02565719|DRUG|Pegasys|immunotherapy
223811412|NCT02565719|DRUG|Viread|HBV RT polymerase inhibitor
223811413|NCT02565719|DRUG|REP 2165-Mg|REP 2165-Mg = magnesium chelate complex of REP 2165
223811414|NCT02087436|DEVICE|Taperloc Complete Microplasty|Taperloc Complete Microplsty cementless stem is designed to transmit load to the proximal femur, thereby preserving bone density, and preventing long term instability and loosening secondary to proximal bone resorption.
223811415|NCT02087436|DEVICE|Taperloc Complete Standard|Taperloc Complete Standard is designed after the philosophy of a flat tapered wedge. It has evolved to incorporate the Reduced Distal and Microplasty stems to better address all patient anatomies, and facilitate multiple surgical techniques.
223811416|NCT02276924|DEVICE|Laser confocal microscopy|Patients undergoing a reno-ureteroscopy for diagnosis or treatment indication will receive an intra-vesical instillation of fluorescein (0.1%) for 5 minutes, followed by the laser confocal microscopy procedure.
223811417|NCT02659917|OTHER|Glass ionomer|Application of preventive agent
223811418|NCT02659917|OTHER|Glass ionomer cement|Application of preventive agent
223811419|NCT02659917|OTHER|-Glass ionomer-|Atraumatic Restorative Treatment
223811420|NCT02659917|OTHER|-Glass ionomer cement-|Atraumatic Restorative Treatment
223811421|NCT05278052|RADIATION|Local consolidative radiation therapy|Local consolidative radiation therapy (LCRT) to all oligo-metastatic sites in addition to primary disease site
223811422|NCT05278052|DRUG|Standard maintenance therapy as decided by the treating medical oncologist|Standard maintenance therapy/Observation
223811423|NCT05024474|OTHER|Inspiratory muscle training (IMT)|Inspiratory muscle training (IMT) at 20-50 % of maximal inspiratory pressure (MIP), 2 x 30 repetitions, twice a day for 8 weeks.
223811424|NCT05024474|OTHER|Physical exercise|A physical exercise program at least two times a week for 8 weeks. Including strength, aerobic and mobility exercises.
223811425|NCT00179790|PROCEDURE|Extracorporeal Photopheresis|Patient will undergo ECP treatment pre and post stem cell transplant infusion
223811426|NCT03488693|RADIATION|Radiation|Radiotherapy given
223811427|NCT03488693|OTHER|No Radiation|No radiotherapy given
223811428|NCT03763643|DRUG|Rituximab|Rituximab 375mg/m2 intravenous on day 0 or -1 prior to kidney transplant
223811429|NCT03763643|PROCEDURE|Plasmapheresis|1.5 volume exchange plasmapheresis with fresh frozen plasma replacement
223811430|NCT05451004|OTHER|Lymphatic Mapping with SPECT-CT|Radiation: Ipsilateral Neck Radiotherapy and SPECT-CT Guided Contralateral Neck Radiotherapy
223811431|NCT05451004|RADIATION|Ipsilateral and Contralateral Neck|Radiotherapy
223811432|NCT02322541|OTHER|Garlic Intervention|Participants will consume an Allium-free controlled diet for 3 days. On the 4th day, they will consume a test meal containing garlic followed by blood and urine collections for 10 hours. On the 5th day, participants will have a fasting blood and urine collection.
223811433|NCT02747888|GENETIC|•Referral to Genetic Counselor, if indicated|
223811434|NCT04490785|PROCEDURE|MRI|1 MRI 5 days after surgery (-1; +4 days), with intravenous administration of gadolinium
223811435|NCT04490785|BIOLOGICAL|Postoperative dosage of released troponin|Dosage of troponin I Hs H4, H8, H12, H24, H48, and H72 after the aortic cross-unclamping.
223811436|NCT06461338|PROCEDURE|acupuncture|Acupuncture at Neiguan(PC6), Zhongwan (CV12), Guanyuan (CV 4), Baihui (DU20), Yintang (GV29), combined with electro-acupuncture at Zusanli(ST36), and Sanyinjiao (SP-6).
223811437|NCT06461338|PROCEDURE|Sham acupuncture|Sham acupuncture at Neiguan(PC6), Zhongwan (CV12), Guanyuan (CV 4), Baihui (DU20), Yintang (GV29), combined with sham electro-acupuncture at Zusanli(ST36), and Sanyinjiao (SP-6).
223811438|NCT00210171|PROCEDURE|Toxicity : Time to progression, 1 and 2 years survival|
223811439|NCT06014502|DRUG|IMGS-001|Every 2 weeks
223811440|NCT03896568|BIOLOGICAL|Oncolytic Adenovirus Ad5-DNX-2401|Given IA
223811441|NCT03896568|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
223811442|NCT04327973|BIOLOGICAL|ATB200|Participants received ATB200 co-administered with AT2221 capsule (Miglustat)
223811443|NCT04327973|DRUG|AT2221|Participants received ATB200 co-administered with AT2221 capsule (Miglustat)
223811444|NCT05544708|BEHAVIORAL|Wellness Engagement Intervention|Train for, recruit participants into, and lead a 12-week lifestyle intervention delivered via weekly group meetings
223811445|NCT05911451|PROCEDURE|Arteriovenous fistula creation|It is recommended to create the arteriovenous fistula 3 to 6 months before the expected start of hemodialysis treatment using locoregional anesthesia. It is recommended to use minimal venous and arterial diameters of 2mm for radiocephalic fistulas and 3mm for brachiocephalic and brachiobasilic fistulas. It is recommended to avoid creating an arteriovenous fistula at the same side as a pacemaker, central venous catheter, or arterial stenosis. It is recommended to use the following order of preference for arteriovenous fistula creation: radiocephalic fistula as first choice, brachiocephalic fistula as second choice, and brachiobasilic fistula as third choice.
223811446|NCT05911451|PROCEDURE|Arteriovenous graft placement|It is recommended to implant the arteriovenous graft 2 weeks before the expected start of hemodialysis treatment under antibiotic prophylaxis. Implantation of an early-cannulation graft is recommended for patients who require more urgent start of hemodialysis to avoid the use of a temporary central venous catheter. It is recommended to use minimal arterial and venous diameters of 3mm and 4mm, respectively. It is recommended to avoid placing an arteriovenous graft at the same side as a pacemaker, central venous catheter, or arterial stenosis.
223811447|NCT05911451|PROCEDURE|Central venous catheter placement|It is recommended to place a tunneled central venous catheter just before the start of hemodialysis treatment under local anesthesia, with conscious sedation if preferred by the patient. The catheter should preferably be placed in the right internal jugular vein with ultrasound-guided puncture and fluoroscopy control under sterile conditions. According to usual practice at the trial center, catheters may be implanted by surgeons, interventional radiologists, or nephrologists.
223811448|NCT06796647|DIAGNOSTIC_TEST|ESAT6/CFP10 skin test|Each recruited participant would be offered standard tuberculin skin test (TST) and ESAT6/CFP10 (C-TST) skin test on the same day or setting of clinical visit. TST and C-TST would be performed by the Mantoux technique with intradermal injection of 2U purified protein derivative-RT23 on one forearm and 5U (1.0µg/0.1 ml) of recombinant fusion protein ESAT6-CFP10 on the other forearm respectively.
223811449|NCT03961971|DRUG|MBG453|Patients receive MBG453 and spartalizumab IV over 30 minutes on Day 1. Patients then undergo stereotactic radiosurgery on Day 8. Courses with MBG453 and spartalizumab repeat every 28 days in the absence of disease progression or unacceptable toxicity.
223811450|NCT05463692|BEHAVIORAL|Camelia Cohort|Through the HealthMpowerment (HMP) app tailored for women, we will be able to provide informational content, access to resources, PrEP locators and additional gamification features to optimally engage and retain our cohort, which may support linkage to PrEP care.
223811451|NCT05495737|BEHAVIORAL|Meaning-Centered Psychotherapy/MCP-PC Training|Two-Day MCP-PC Training for Nurses (including mock patient/simulation with actor) with a Pre- and Post-Training Assessment
223811452|NCT05495737|BEHAVIORAL|Meaning-Centered Psychotherapy/MCP-PC|3 sessions, completed over the course of 3-6 weeks in the participant's home
223811453|NCT05495737|BEHAVIORAL|Treatment As Usual/TAU|"Research team will provide:~1. feedback about level of distress at time of screening~2. local referral for psychological care"
223811454|NCT00948779|OTHER|antibiotic education for children in an emergency care unit|Educational, Behavioral, and Organizational intervention to improve the use of oral antibiotics in children under 6 years
223811455|NCT00948779|OTHER|antibiotic education for children in an emergency care unit|Educational, Behavioral and Organizational intervention to improve the antipyretic therapy in children under 6 years.
223811456|NCT05319249|BIOLOGICAL|NK cells|NK cells will be given as a single intravenous infusion.
223811457|NCT05319249|DRUG|Talazoparib 1 MG [Talzenna]|Subjects will receive treatment with Talazoparib capsules 1 mg/day (4 days) with subsequent intravenous NK cell infusion.
223811458|NCT06191809|PROCEDURE|Controlled Ovarian Stimulation Protocol|"Ovarian Stimulation Process:~* Stimulate ovaries with FSH \& hMG (150-375 IU) starting day 2-3 of menstruation.~* Monitor response with ultrasound \& hormones (E2, LH, P4).~* GnRH-ant arm: Prevent LH surge with Cetrorelix (0.25mg) starting day 5.~* PPOS arm: Suppress LH with Dydrogesterone (10mg x 3/day) from day 1.~* Trigger ovulation when ≥2 follicles \>17mm (Triptorelin, hCG, or rhCG).~* Oocyte retrieval 36-38 hours later (\>10mm follicles aspirated).~Embryo Culture \& Monitoring:~* Fertilize with ICSI.~* Culture \& evaluate embryos (43-45 hours, day 3/5).~* Freeze all embryos."
223811459|NCT05221931|PROCEDURE|Percutaneous coronary intervention|1:1 randomization to DES (Ultimaster Tansei) or DCB (Agent \[Boston Scientific, USA\], Prevail \[Medtronic, USA\], or SeQuent Please, SeQuent Please NEO \[B-Braun, Germany\])
223811460|NCT05827237|DIAGNOSTIC_TEST|Clinical decision rule|Clinical decision rule for acute chest pain, consisting of the Marburg Heart Score (5 questions) combined with a high-sensitive troponin I point of care test
223811461|NCT03759834|DEVICE|Cochlear promontory stimulation|Promontory stimulation is an established otologic procedure that was initially developed as a diagnostic tool to assess patient candidacy for cochlear implantation. Promontory stimulation is most commonly performed in the outpatient setting on an awake patient by placing a single insulated probe through a topically anesthetized tympanic membrane and applying monopolar current for several seconds to minutes. The initial session of promontory stimulation will define optimal stimulation parameters (i.e., location, current level, pulse-width, phase polarity), where maximal tinnitus suppression occurs with minimal or no auditory percept. Additional stimulation testing visits will confirm these findings.
223811462|NCT05387603|DRUG|177Lu-DOTATOC|"The investigational medicinal product (IMP) is 177Lu-DOTATOC which is registered as an orphan drug by the EMA ( European Medicines Agency) for the treatment of GEP-NEN (gastro-entero-pancreatic neuroendocrine tumor).~The IMP will be administered to participants both in the control arm and the experimental arms, but with different intervals, but the same activity; 7.5 Gbq per dosing."
223811463|NCT05387603|DRUG|Capecitabine|Will be given orally with a dose of 825/m2 twice daily, starting on day 1 of each of the 4 first treatment cycles, cycle length 3 weeks.
223811464|NCT05701995|DRUG|Deucravacitinib|Specified dose on specified days.
223811465|NCT05701995|OTHER|Placebo|Specified dose on specified days.
223811466|NCT05753774|BIOLOGICAL|FMT|FMT is a technique in which intestinal microbiota are transferred from a healthy screened donor to a patient, with the goal being to introduce or restore a stable microbial community in the gut. FMT was given 1-3courses, 3-6 times per courses
223811467|NCT05753774|DRUG|Conventional drugs|Conventional drugs include probiotics and omeprazole, and cyproheptadine and moxapride
223811468|NCT06064890|PROCEDURE|Intrathalamic AAV.PGRN administration|One-time MRI-guided stereotaxic infusion of AAV.PGRN into the brain
223811469|NCT06064890|GENETIC|Intrathalamic AVB-101|AVB-101 is made from an adeno-associated virus, serotype 9 (AAV9). AAVs are small viruses that are naturally occurring and do not cause illness or infection on their own. AVB-101 has been modified to contain a copy of the correct (non-mutated) GRN gene, plus some other genetic material to enable the GRN gene to function inside neurons (cells within the brain). AVB-101 has also been modified so that it cannot divide and make new copies of itself (known as 'replication'), which means that it cannot cause disease or a large immune response in your body.
223811470|NCT01042015|COMBINATION_PRODUCT|Emergency preservation and resuscitation|This involves the induction of profound hypothermia using a flush of ice-cold saline into the aorta. Once hypothermia is achieved, the subject would undergo rapid operative interventions to control bleeding followed by resuscitation/rewarming with cardiopulmonary bypass.
223811471|NCT01042015|OTHER|Standard resuscitation|Standard resuscitation includes an emergency department thoracotomy, open cardiac massage, and fluid resuscitation.
223811472|NCT04858269|DRUG|Pembrolizumab|Pembrolizumab 200 mg intravenously (IV) on day 1 of each 3-week cycle
223811473|NCT04858269|DRUG|Carboplatin|Carboplatin dosed for area under the curve (AUC) 1.5 IV on days 1, 8, 15 of each 3-week cycle
223811474|NCT04858269|DRUG|Paclitaxel|Paclitaxel 45 mg/m2 on days 1, 8, 15 of 3-week cycle.
223811475|NCT03004287|DRUG|Carfilzomib|Given by vein: days 1 and 2 of Induction; days 1, 8, 15, and 22 of Consolidation 1; and days 1, 8, 15, and 22 of alternating 3-month blocks during Maintenance.
223811476|NCT03004287|DRUG|Thalidomide|Given by mouth at bedtime: days 1-4 of Induction
223811477|NCT03004287|DRUG|Dexamethasone|Given by mouth or by vein: days 1-4 of Induction; days -4 - -1 of Transplant(s); and days 1, 8, 15, and 22 of every cycle during Maintenance
223811478|NCT03004287|DRUG|Daratumumab|Given by vein: day -1 of induction; days 1 and 8 of Immunological Consolidations; and day 1 of each Maintenance cycle
223811479|NCT03004287|DRUG|Cisplatin|Given by vein: days 1-4 (continuous infusion) of Induction
223811480|NCT03004287|DRUG|Adriamycin|Given by vein: days 1-4 (continuous infusion) of Induction
223811481|NCT03004287|DRUG|Cyclophosphamide|Given by vein: days 1-4 (continuous infusion) of Induction
223811482|NCT03004287|DRUG|Etoposide|Given by vein: days 1-4 (continuous infusion) of Induction
223811483|NCT03004287|DRUG|Melphalan|Given by vein: days -4 - -1 of Transplant(s)
223811484|NCT03004287|PROCEDURE|ASCT|day 0 of Transplant(s)
223811485|NCT03004287|DRUG|Lenalidomide|Given by mouth: days 1-21 of alternating 3-month blocks during Maintenance
223811486|NCT03004287|DRUG|Bortezomib|Given by vein or subcutaneous injection: may be substituted for carfilzomib throughout the study regimen at the discretion of the treating physician
223811487|NCT06577337|BIOLOGICAL|M5542|Participants will receive single ascending dose of M5542 subcutaneously on Day 1 in Part A. Participants will receive loading dose of M5542 followed by maintenance doses in Part B.
223811488|NCT06577337|BIOLOGICAL|Placebo|Participants will receive placebo matched to M5542 in Part A and Part B.
223811489|NCT06205485|DRUG|Leucovorin|400 mg/m2
223811490|NCT06205485|DRUG|Oxaliplatin|85 mg/m2 or 130 mg/m2 on day 1
223811491|NCT06205485|DRUG|Fluoruracil|bolus fluoruracil (optional) 400 mg, infusional fluorouracil 2,400 mg/m2
223811492|NCT06205485|DRUG|Capecitabine|1,000 mg/m2 twice daily for 14 days
223811493|NCT06205485|RADIATION|Radiation|54 Gy (27-30 fractions)
223811494|NCT04494945|PROCEDURE|Biospecimen Collection|Undergo collection of saliva sample
223811495|NCT04494945|OTHER|Genetic Counseling|Receive genetic counseling if testing results are positive
223811496|NCT04494945|OTHER|Genetic Testing|Undergo genetic testing
223811497|NCT04494945|OTHER|Survey Administration|Complete a survey
223811498|NCT05303532|DRUG|Durvalumab|Fixed dose of 1500 mg via IV infusion upon enrollment visit and every 4 weeks thereafter.
223811499|NCT03483038|DRUG|Liposomal Irinotecan|Subjects will receive 60 mg/m2 intravenously on Day 1 of each 14 day cycle.
223811500|NCT03483038|DRUG|FOLFOX regimen|Subjects will receive FOLFOX (oxaliplatin 60 mg/m2 IV, leucovorin 400 mg/m2 IV, and 5-fluorouracil 2400 mg/m2 IV) on Day 1 of each 14 day cycle.
223811501|NCT05411029|DIAGNOSTIC_TEST|24 hour blood pressure (BP) monitoring|24-hour ambulatory BP measuring device and blood pressures will be measured every 20 minutes to half hour
223811502|NCT05411029|DIAGNOSTIC_TEST|Polysomnography|Measurements will include electroencephalogram, electromyogram, electrooculogram, electrocardiogram, breathing patterns of chest and abdomen, nasal and oral airflow and oxygen saturation. Sleep stages and apneas will be scored in accordance with validated American Academy of Sleep Medicine standards.
223811503|NCT06216821|DRUG|standard DAPT|standard DAPT with aspirin and a P2Y12 inhibitor for 12 months after DES implantation.
223811504|NCT06216821|DRUG|OPT-CAD score guided DAPT de-escalation|De-escalation DAPT at 3 months for moderate to high risk patients and de-escalation DAPT at 1 month for low risk patients.
223811505|NCT01760850|OTHER|educational intervention|Engage in the Esperanza y Vida educational information session for breast and cervical cancer
223811506|NCT01760850|OTHER|educational intervention|Engage in an educational information session for diabetes
223811507|NCT01760850|OTHER|questionnaire administration|Ancillary studies
223811508|NCT00242372|DRUG|Tesaglitazar 0.5|
223811509|NCT00242372|DRUG|Insulin at least 30 units/day|
223811510|NCT06279325|BEHAVIORAL|Computerized cognitive stimulation program|"* The cognitive stimulation (CS) program, for the IG, will be previously designed by 2 Occupational Therapy (OT) of the team, and adapted to the computerized format through a platform specialized in cognitive neurorehabilitation. The activities will be designed under OT models: human occupation model and cognitive-perceptual model, so that the different professions, interests and roles are represented, and allow to express different levels of complexity, according to the level of Cognitive Reserve (CR).~* The cognitive aspects to be worked on are: memory, orientation, language, praxis, gnosis, calculation, perception, logical reasoning, attention-concentration and executive functions.~* In addition, reinforcement, EF, episodic memory, attention and information processing speed activities will be designed, also according to the CR level."
223811511|NCT06279325|BEHAVIORAL|Face-to-face training-explanatory session|The CG will undergo a group and face-to-face training-explanatory session, where the importance of maintaining the usual level of cognitive activity will be emphasized.
223811512|NCT05763069|OTHER|Home surveillance of pregnancies at risk|Offer women with pregnancies at risk home surveillance instaed of more frequent hospital out-patient visits and/or hospitalisation: cardiotocographia (CTG), patient measurements of CRP, temperature, blood pressure, and clinical signs of infection or severe forms of preeclampsia.
223811513|NCT03508739|DRUG|Sacubitril/Valsartan 200mg (blinded)|study day 2 for AB and study day 3 for BA
223811514|NCT03508739|DRUG|Valsartan 160mg (blinded)|study day 3 for AB and study day 2 for BA
223811515|NCT06170164|DIAGNOSTIC_TEST|Diagnostic accuracy|The aim of the study is to evaluate whether the pathological stage of the disease, Gleason score, age at diagnosis, serum PSA value and PET parameters (SUV, MTV) are predictive factors of choline PET examination.
223811516|NCT03483974|DIAGNOSTIC_TEST|hyperspectral imaging|using hyperspectral detector for evaluation excreta pattern
223811517|NCT05842226|OTHER|Micro-teaching enriched with standard patient|The practice group will be shared the 4 most common symptoms in palliative care nursing: pain, fatigue, respiratory distress and loss of appetite. The practice group will be 5 groups and there will be 4 students in each group. During the practice, each student will provide patient education about only one symptom. The standard patient will participate in the intervention in the application laboratory and the students will participate in the intervention in the computer environment. Video recordings will be taken while the students are giving education. After watching the experts, peers and their own video with the micro-teaching group evaluation form, the student himself/herself will make an evaluation. At the same time, a lecturer from outside the research will fill in the Standard Patient Check-List Evaluation Form. The application will be repeated one week later.
223811518|NCT04162093|PROCEDURE|uretero ileal anastomosis in single trough|
223811519|NCT01659892|DRUG|Montelukast|5 mg Chewable Tablet
223811520|NCT01659892|DRUG|Singulair|5 mg Chewable Tablet
223811521|NCT00504426|DRUG|OPC-249|1 pugh/day for 4 weeks (30 IU, 60IU, or 90IU)
223811522|NCT02524041|DEVICE|HR-pQCT|The Xtrem CT scanco device is a HR-pQCT used for 3D bone measurements at the tibia and the radius levels in humans
223811523|NCT02524041|OTHER|blood specimen|blood specimen
223811524|NCT03349164|DIAGNOSTIC_TEST|acute PE survivors|Patients from this group will be assessed by cardiologist, echocardiography and VQ scanning
223811525|NCT05659225|DEVICE|Electronic Stethoscope|Subjects diagnosed as pediatric asthma at Shanghai Children's Medical Center will be consecutively screened and eligible patients will be recruited (enrolment visit, V1). The subject will be assigned to the control group and the electronic stethoscope group and complete their future onsite visits (V2-V5) at Shanghai Children's Medical Center. The patient's caregiver who was assigned to the electronic stethoscope group will be instructed to install the electronic stethoscope developed by our team and its accessories, then they will be trained by investigators on how to use the electronic stethoscope.
223811526|NCT05659225|OTHER|Standard treatment according to GINA(2019)|Subjects diagnosed as pediatric asthma at Shanghai Children's Medical Center will be consecutively screened and eligible patients will be recruited (enrolment visit, V1). The subject will be assigned to the control group and the electronic stethoscope group and complete their future onsite visits (V2-V5) at Shanghai Children's Medical Center. The patient's caregiver who was assigned to the control group will receieve standard treatment according to GINA(2019).
223811527|NCT03984370|DRUG|ZP4207|Abdominal SC administration
223811528|NCT03984370|OTHER|Placebo (saline)|Abdominal SC administration
223811529|NCT03210155|DEVICE|Alpha-Stim AID CES (Active Comparator)|The Alpha-Stim® AID CES device delivers a mild electrical current (100-500 µA) to the brain via ear clips electrodes. The treatment regimen is one daily 60 minutes Alpha-Stim® CES treatment using ear clip electrodes for 6 weeks at 0.5 Hz. 50% duty cycle with a fixed current of 100 µA (subsensory level).
223811530|NCT03210155|DEVICE|Alpha-Stim AID CES (Sham Comparator)|The Alpha-Stim® AID CES sham device is inactive and does not emit electrical current to the brain via ear clip electrodes. The sham treatment regimen is one daily 60 minutes Alpha-Stim® CES treatment using ear clip electrodes for 6 weeks.
223811531|NCT01602406|DRUG|LJM716|LJM716
223811532|NCT01602406|DRUG|Trastuzumab|Trastuzumab
223835482|NCT01013220|OTHER|Depression Product Detailing|"1. two hour academic detailing of depression management products to employees with responsibility for purchasing health care benefits~2. technical assistance in purchasing high quality depression management products"
223811533|NCT05794633|OTHER|Acupuncture|"The patients will be recieved two days a week for 8 sessions with sterile 25\*40 mm needles.Selected points are as local points, 2 painful points (ahshi point) in the shoulder region, Large intestine 4, 15, Gallbladder 21, Triple warmer 5, 14 Small intestine 9; as distant points Gallbladder 34 and Stomach 38.~Patients will recieve also exercise treatment for 8 weeks and coldpack for 4 weeks"
223811534|NCT05794633|OTHER|Placebo acupuncture|"The patients will be recieved two days a week for 8 sessions with placebo needle. Selected points are Large intestine 15 Triple warmer 14 gallbladder 21 and small intestine 9. We will use the placebo needle (blunt needle, tip obtuse, when acupuncture the feeling is similar to acupuncture needles into the skin, but it retracts instead of piercing the skin) to conduct acupuncture treatment. The retention time will be the same as those in the acupuncture group. The specialist will give the subjects verbal cues before and during the acupuncture manipulation, which further reduces the subjects' doubts about the authenticity of acupuncture in the this group. To ensure the implementation of the blinding method, all patients will be treated independently and avoid contacting with each other.~Patients will recieve also exercise treatment for 8 weeks and coldpack for 4 weeks"
223811535|NCT02605226|PROCEDURE|Cryoablation therapy|Cryoablation therapy
223811536|NCT02605226|RADIATION|External beam radiation therapy|External beam radiation therapy
223811537|NCT02605226|DRUG|bicalutamide|bicalutamide
223811538|NCT02605226|DRUG|luteinizing-hormone releasing-hormone (LHRH) agonist|luteinizing-hormone releasing-hormone (LHRH) agonist
223811539|NCT04436315|DEVICE|Motor-cognitive training device|Motor-cognitive training device
223811540|NCT04436315|OTHER|Active control condition|Physical activity program
223811541|NCT01395108|DRUG|Nemonoxacin|oral once daily
223811542|NCT03988166|PROCEDURE|Chronic Total Occlusion Revascularization|Teleflex's series of study guidewires and catheters will be used to facilitate the safe and effective crossing of de novo CTOs and placement of conventional guidewires beyond the lesion via either a true lumen or subintimal pathway.
223811543|NCT03988166|DEVICE|GuideLiner® V3 catheter, TrapLiner® catheter, Turnpike® catheter|GuideLiner® V3 catheter, TrapLiner® catheter, Turnpike® catheter
223811544|NCT02459730|PROCEDURE|ART with GIC containing 1.25% CHX.|Carious lesions were prepared by removing infected dentin with hand instruments. No local anesthesia was administered. Then, the cavities were filled with the press finger technique using GIC KetacMolar Easymix® containing 1.25% chlorhexidine digluconate (n= 41 tooth surfaces).
223811545|NCT02459730|PROCEDURE|ART with GIC.|Carious lesions were prepared by removing infected dentin with hand instruments. No local anesthesia was administered. Then, the cavities were filled with the press finger technique using KetacMolar Easymix® (n = 66 tooth surfaces).
223811546|NCT05960825|COMBINATION_PRODUCT|injectable platelet rich fibrin versus microosteoperforation|injectable platelet rich fibrin which is second product of blood versus microosteoperforation which is surgical procedure
223811547|NCT05488275|PROCEDURE|Surgery|MPFL reconstruction
223811548|NCT01068808|PROCEDURE|skin prick test|skin prick test to aeroallergen
223811549|NCT06170671|DRUG|Non interventional study|CLL patients routinely initiated on acalabrutinib by their physician between January 2023 -December 2024. Retrospective secondary data collection
223811550|NCT06007690|DRUG|Bel-sar|Bel-sar via suprachoroidal administration followed by laser application.
223811551|NCT06007690|DEVICE|Suprachoroidal Microinjector|Suprachoroidal injection device
223811552|NCT06007690|DEVICE|Infrared Laser|Laser application
223811553|NCT06007690|DEVICE|Sham Infrared Laser|Sham laser application
223811554|NCT06007690|DEVICE|Sham Microinjector|Sham injection device
223811555|NCT02957929|DRUG|APX001 single IV dose|
223811556|NCT02957929|DRUG|APX001 single oral dose 1|
223811557|NCT02957929|DRUG|APX001 single oral dose 2|
223811558|NCT02957929|DRUG|APX001 single oral dose 3|
223811559|NCT02957929|DRUG|APX001 single oral dose fasted|
223811560|NCT02957929|DRUG|APX001 single oral dose fed|
223811561|NCT02957929|DRUG|APX001 multiple oral doses 1|
223811562|NCT02957929|DRUG|APX001 multiple oral doses 2|
223811563|NCT02957929|DRUG|APX001 multiple oral doses 3|
223811564|NCT02957929|DRUG|Cytochrome P450 substrates|
223811565|NCT02957929|DRUG|Matching placebo control|
223811566|NCT05125471|DRUG|Cobimetinib|Adult dosing (\>/= 18 years old) will be 60 mg orally once daily (tablet formulation); Pediatric dosing (\<18 years old) will be 1 mg/kg/dose (maximum 60 mg per dose) orally once daily (oral suspension formulation).
223811567|NCT06566326|DRUG|Propofol and ketamine|Patients received IV sedation using prepared mixture of propofol and ketamine in ratio (4:1). It is prepared by mixing 0.8 mg/kg propofol with 0.2 mg/kg ketamine (4:1) in an IV bolus, followed by half of the initial dose every 3 minutes as needed for sedation. The desired level of sedation was achieved (more than score 4) using Modified Ramsay sedation score) before allowing endoscopiest to start the procedure, then the score was assessed every 3 minutes before giving of top up doses of ketofol 4:1 (half of the initial dose) if needed, then the range and median of modified Ramsay sedation score was calculated.
223811568|NCT06566326|DEVICE|Modified Oropharyngeo-esophygeal Topical Anesthesia by OPETA Prototype tool|Topicalization was done for anterior tonsillar pillar on both sides and posterior 1/3 of tongue and posterior pharyngeal wall using xylocain gel 5 % on tip of his index or middle finger then after 5-7 min. patient inserted his middle finger deeply into his mouth as a test for tolerability before insertion of OPETA tool. While head tilted forward, Lubricated OPETA device, soaked with 10 ml lidocaine 2 % mixed with adrenaline 1/200000 was gradually placed by patient with assistance from anesthetist \& patients swallowing into esophagus. To ensure effective topical anesthesia and patient tolerance, pack was left in place for 3-5 min. before being moved up, down, clockwise \& anti-clockwise.. If necessary, increments of 5 ml of 2% lidocaine/adrenaline mixture was injected through device until patient is comfortable. Maximum LA dose was kept at 5 mg/kg.
223811569|NCT06579820|COMBINATION_PRODUCT|tubular bandage|The experimental group consisted of the group in which a tubular bandage was applied over the PIC, which was routinely applied.
223811570|NCT03760536|BEHAVIORAL|16-week Exercise Rehabilitation Program for Breast Cancer Survivors|Interested patients will attend a group meeting where they will be screened and consented to the study. During weeks 1 and 2 patients will complete pre-intervention baseline assessments and blood draws followed by a 16-week supervised exercise program at Get REEL and HEAL facility. Study participants will complete progressive aerobic and resistance exercise training. Post-intervention weeks 1 and 2 participants will complete assessments, questionnaires and blood draws. Participants will be followed up at 6 and 12 months post intervention with physical assessments, questionnaires and blood draws. Annual follow-up will occur at year 2,3,4 and 5 post intervention with questionnaires only.
223811571|NCT03248375|RADIATION|Radiation Segmentectomy|The administration of radioactivity in a branch of an artery of the liver
223811572|NCT06275893|BIOLOGICAL|IC14|recombinant monoclonal antibody directed against cluster of differentiation 14 (CD14) antigen
223811573|NCT04419649|DRUG|KER-050|KER-050 administered subcutaneously every 4 weeks for up to 24 cycles. Eligible participants may be able to continue to receive subcutaneously administered KER-050 after completing 24 cycles in a Long-Term Extension.
223811574|NCT04996758|DRUG|Toripalimab and Anlotinib|Toripalimab 240 mg iv.drip d1; Anlotinib 12mg po qd d1-14.
223811575|NCT05759988|DEVICE|Outpatient Foley catheter|Outpatient Foley catheter placement for induction of labor
223811576|NCT05901610|BEHAVIORAL|Episodic Future Thinking|Participants will generate descriptions of vivid positive future events.
223811577|NCT05901610|BEHAVIORAL|Control Episodic Thinking|Participants will generate descriptions of vivid positive past events.
223811578|NCT05901610|DEVICE|Low-intensity Focused Ultrasound|A transducer device will use focused ultrasound energy to neuromodulate the insular cortex. The participant's brain will be mapped based on information from the CT and MRI scans, and the transducer will deliver brief ultrasound pulses to the insular cortex.
223811579|NCT05901610|DEVICE|Sham Low-intensity Focused Ultrasound|All of the same actions done during LIFU will be performed, but the device will be inactive.
223811580|NCT04683848|BIOLOGICAL|MT-3921|Solution for infusion; Intravenous (IV)
223811581|NCT04683848|BIOLOGICAL|Placebo|Solution for infusion; Intravenous (IV)
223811582|NCT06968741|DEVICE|Artificial Urinary Sphincter (AUS)|AUS implant
223811583|NCT06082960|DRUG|GS-9911|Tablets administered orally
223811584|NCT06082960|DRUG|Zimberelimab|Administered intravenously
223811585|NCT06822400|PROCEDURE|corrective surgery within 28 days of birth|"Participants will be randomized into two groups with a 1:1 allocation:~Intervention Group: Neonates undergoing surgical correction of TOF within 28 days of birth."
223811586|NCT06822400|PROCEDURE|corrective surgery between 3-6 months of age|"Participants will be randomized into two groups with a 1:1 allocation:~Control Group: Infants undergoing surgical correction of TOF between 3-6 months of age"
223811587|NCT03794076|DRUG|Cromoglycate|Cromoglycate will be administered intranasally (nasal spray) (1 spray each nostril 4 times a day, 5.2 mg/spray
223811588|NCT03794076|DRUG|Placebo|Normal saline nasal spray will be administered intranasally (nasal spray) (1 spray each nostril 4 times a day, 5.2 mg/spray)
223811589|NCT00633464|DRUG|ixabepilone|"injection, intravenous (IV), until unacceptable toxicity or progression or 15 months after the Last Subject First Visit (LSFV), whichever comes first.~Ixabepilone 40 mg/m\^2 was administered as a 3-hour IV continuous infusion on Day 1 in a 21-day cycle provided the participant met the re-treatment criteria."
223811590|NCT00633464|DRUG|ixabepilone + cetuximab|"Ixabepilone: injection, IV, until unacceptable toxicity or progression or 15 months after the LSFV, whichever comes first.~Ixabepilone 40 mg/m\^2 was administered as a 3-hour IV continuous infusion on Day 1 in a 21-day cycle provided the participant meets the re-treatment criteria.~Cetuximab: injection, IV, until unacceptable toxicity or progression or 15 months after the LSFV, whichever comes first.~Cetuximab 400 mg/m\^2 was administered as a 2-hour IV loading dose via in-line filtration with an infusion pump, gravity drip, or a syringe pump on Day 1 of first cycle then 250 mg/m\^2 1-hour IV once a week, i.e. on Days 1, 8, and 15 of each cycle provided the participant meets the re-treatment criteria."
223811591|NCT04754412|OTHER|Behavioral, Psychological or Informational Intervention|Write about stress and coping, emotional disclosure, and benefit finding
223811592|NCT04754412|OTHER|Behavioral, Psychological or Informational Intervention|Write about positive thoughts and feelings regarding their breast cancer experience
223811593|NCT04754412|OTHER|Best Practice|Write about facts regarding their cancer diagnosis and treatment
223811594|NCT04754412|OTHER|Quality-of-Life Assessment|Ancillary studies
223811595|NCT04754412|OTHER|Questionnaire Administration|Ancillary studies
223811596|NCT02612064|DEVICE|Stannous Fluoride dentifice|Experimental dentifrice containing 0.454% w/w stannous fluoride (1100ppm)
223811597|NCT02612064|OTHER|Sodium Monofluorophosphate dentifrice|Dentifrice containing 0.76% sodium monofluorophosphate (1000ppm fluoride)
223811598|NCT03580889|DRUG|Atropine|Comparison between atropine, glycopyrrolate and Normal Saline
223811599|NCT03580889|DRUG|Glycopyrrolate|Comparison between glycopyrrolate, atropine and Normal saline
223811600|NCT03580889|DRUG|Normal Saline Flush, 0.9% Injectable Solution|Comparison between Normal saline, atropine and glycopyrrolate
223811601|NCT05674760|DEVICE|Trancutaneous CO2 monitoring (using TCM5 device)|Patients in the Transcutaneous arm will undergo Trancutaneous CO2 monitoring (using TCM5 device)
223811602|NCT05674760|OTHER|Arterial Blood Gas (ABG) sampling|Arterial Blood Gas (ABG) sampling to monitor CO2 - as per standard practice.
223811603|NCT03245138|PROCEDURE|Endoscopic Third Ventriculostomy|patients receive an endoscopic third ventriculotomy as surgical procedure
223811604|NCT03245138|PROCEDURE|Ventriculo-Peritoneal Shunting|patients receive an ventriculo-peritoneal shunt as surgical procedure
223811605|NCT00482820|BEHAVIORAL|attention-bias training|one group recive an attention training away from threat. The second group, the controll group, recive a placebo training
223811606|NCT01669798|DRUG|BIBF 1120|PO 200mg BID
223811607|NCT02080975|OTHER|Data Collection During Atrial Flutter Ablation|All enrolled patients are clinically indicated for an atrial flutter ablation. The patients who consent for this study will have additional electrocardiograms taken during their procedure for future review, as well as ultrasound images form inside their heart. This will lengthen the ablation by approximately 10 minutes, but is not a separate procedure.
223811608|NCT03125005|DEVICE|Rainbow Universal Pulse Oximeter Sensor|
223811609|NCT04876040|DEVICE|SSO2 Downstream System|60-min adjunctive reperfusion of hyperoxemic blood into target coronary artery, immediately following revascularization by means of PCI with stenting.
223811610|NCT04876040|PROCEDURE|PCI + Impella|Standard of Care Intervention
223811611|NCT03367039|PROCEDURE|ProDisc-C vivo|Total Disc Replacement using ProDisc-C vivo.
223811612|NCT03367039|PROCEDURE|Anterior cervical discectomy fusion|Anterior Cervical Discectomy and Fusion
223811613|NCT05632939|DRUG|ASKB589 +CAPOX+Sintilimab/Tislelizumab|"Oxaliplatin: intravenous infusion, 130mg/m2, infusion for more than 3h, every 3 weeks for a cycle, infusion 6 cycles; Capecitabine: oral administration, 1000mg/m2, 2 times, 14 days, 7 days rest, every 3 weeks for a cycle; Sintilimab/Tislelizumab was administered intravenously at 200mg. The drug was administered once every 3 weeks, and the longest cumulative duration was 2 years.~ASKB589 is administered intravenously at a fixed dose. The drug was given once every 3 weeks for a cycle, with the longest cumulative duration of 2 years."
223811614|NCT04387864|DEVICE|Whole-body Vibration Device|Power Plate® (pro5TM; Power Plate North America, Inc., Northbrook, IL, USA)
223811615|NCT03675152|OTHER|Soft spinal brace|Soft thoracolumbar brace worn 23 hours a day.
223811616|NCT03675152|OTHER|thoracolumbar orthosis|Hard thoracolumbar orthosis done individually molded, Worn 23 hours a day.
223811617|NCT03675152|OTHER|Excersice restriction|Patients are only allowed to do isometrical excersices adviced by a physiotherapist.
223811618|NCT05381935|DRUG|ES014|ES014 is administered via intravenous infusion, once every 14 days, every 28 days as a treatment cycle for a maximum treatment duration per patient of 2 years.
223811619|NCT05381935|DRUG|ES014|ES014 is administered via intravenous infusion, once every 14 days, every 28 days as a treatment cycle for a maximum treatment duration per patient of 2 years.
223811620|NCT03205228|DRUG|Omeprazole|A capsule of Omeprazole 20 mg \& 1 capsule of placebo will be given in individual subject, once daily for 4 weeks. Both drugs will be presented in the same appearance (white capsule).
223811621|NCT03205228|BEHAVIORAL|psychoeducation|Psychoeducation will be given by psychologists at the Day 1 and Day 15 of the study period.One white capsule of placebo will be given once daily for 4 weeks of the study period.
223811622|NCT03205228|DRUG|Flupentixol +Melitracen|A capsule containing of a tablet of melitracen 10 mg + flupentixol 0.5 mg \& a capsule of placebo will be given once daily, for 4 weeks. Both would be presented in the same appearance (white capsule)
223811623|NCT06501014|OTHER|Action Observation Therapy-Experimental Group|Patients will be asked to watch the exercises before doing them.For each exercise, patients will first watch the relevant video and do the exercise after the video ends.
223811624|NCT06501014|OTHER|Conventional Exercises-Control Group|Patients will be asked to perform exercises that are described verbally and/or shown through pictures.
223811625|NCT06558851|BEHAVIORAL|High intensity endurance training|12 weeks of high intensity endurance training three times a week. Two of the weekly sessions are supervised.
223811626|NCT02565563|OTHER|Eye Movement Desensitisation Reprocessing|The purpose of this study is not to assess the device itself. The new device will seek to measure heart rate variabilty during the administration of the treatment EMDR. It will measure the patients sympathetic nervous systems (anxiety arousal). Previous reseach studies have used Electrocardiography (ECG) and the purpose of this study is to determine whether or not this device will obtain similar findings as ECG has done.
223811627|NCT02565563|DEVICE|HeartMath measuring Heart Rate Variability (HRV)|This small device will be attached to the patients finger to allow their heart rate variability to be measured.
223811628|NCT06102057|RADIATION|standard Radiotherapy|standard FDG-PET-based radiotherapy
223811629|NCT06102057|DRUG|Chemotherapy|concurrent standard of care chemotherapy
223811630|NCT06102057|DRUG|Immunotherapy|standard of care consolidation therapy with durvalumab (fixed dose of 1500 mg q4w) for up to 12 months or until progression of disease, unacceptable toxicity, patient´s wish, or investigator´s decision, whichever comes first.
223811631|NCT06102057|RADIATION|Experimental Radiotherapy|FDG-PET-based small volume accelerated radiotherapy
223811632|NCT05271786|OTHER|Decannulation|retrospective evaluation of decannulation
223811633|NCT05831696|OTHER|Powered Microprocessor-controlled Knee (PMPK)|A microprocessor-controlled Knee with standardized commercial prosthetic foot
223811634|NCT02987257|DRUG|Harmonized supportive care|Harmonized supportive care with and etanercept placebo days 1 and 4
223811635|NCT02987257|DRUG|Etanercept 50 mg sc day 1 and day 4|Harmonized supportive care with placebo
223811636|NCT06033274|DEVICE|Transcatheter Tricuspid Valve Replacement|All patients undergoing Transcatheter Tricuspid Valve Replacement for native tricuspid valve disease
223811637|NCT03094624|OTHER|Neuropsychological and neurophysiological tests|Neuropsychological tests consist in listening to sounds in various contexts and providing behavioral responses with response-buttons. Neurophysiological tests consist in the recording of EEG and/or MEG signals or MRI images while realizing the neuropsychological tests, as well as anatomical MRI scanning to characterize the participants' brain anatomy and reconstruct the brain sources of surface EEG/MEG signals.
223811638|NCT03094624|OTHER|Experiment 1|Experiment 1 are interested in perception and musical memory vs. Language and contribute to our understanding of the functional and structural organization of the brain to perceive and memorize music and language.
223811639|NCT03094624|OTHER|Experiment 2|Experiment 2 focuses on perception and musical memory vs. Language and contribute to our understanding of the functional and structural organization of the brain to perceive and memorize music and language. The second experiment will also study short-term memory networks for musical and verbal materials, but the specificity will be the inclusion of a verbal material sung, thus representing the combination of both information. Experiment 2 is divided into two sub-parts. Indeed, the investigators will develop the musical and verbal materials during a first experimental part in experiment (experiment 2a) and then apply them in experimentation MEG (experiment 2b). Experiment 2a will allow us to test new equipment in a short term memory task under conditions that are less restrictive for the participants. Then the investigators will apply the optimal material that emerges for the MEG experiment.
223811640|NCT03094624|OTHER|Experiment 3|Experiment 3 will use Discordant Negativity (MMN; Mismatch Negativity) protocols in coupled EEG-MEG (experiment 3a) and EEG alone (experiment 3b) to investigate memory traces of sensory information. The MMN is used to probe auditory sensory memory (pre-requisite for short- or long-term storage), and has the advantage of being measured without requiring an active task from the participant.
223811641|NCT03094624|OTHER|Experiment 4|"Experiment 4 will study the neural correlates of long-term memory for musical and verbal material with fMRI. The testimonies of the amusicians suggest a deficit of the musical lexicon which contrasts with that the musical lexicon elaborated of the non-musician listeners."
223811642|NCT04374630|DRUG|Paclitaxel|Commercially available paclitaxel for IV administration will be obtained by clinical sites in US.
223811643|NCT04374630|DRUG|Afuresertib|"Each afuresertib 50 mg tablet, intended for oral administration, contains afuresertib (hydrochloride salt) equivalent to 50 mg of afuresertib (free base).~Each afuresertib 75 mg tablet, intended for oral administration, contains afuresertib (hydrochloride salt) equivalent to 75 mg of afuresertib (free base)"
223811644|NCT06576219|BEHAVIORAL|Group Music Therapy|My Life Is Music group therapy model
223811645|NCT03948074|DRUG|Cannabis|Medicinal Cannabis Oil
223811646|NCT05278156|DRUG|CPL500036 - low dose|CPL500036 is to be oral administered. Each patient is to take 2 capsules with active substance and 2 capsules of placebo daily.
223811647|NCT05278156|DRUG|CPL500036 - high dose|CPL500036 is to be oral administered. Each patient is to take 4 capsules with active substance daily.
223811648|NCT05278156|DRUG|Placebo|Placebo is to be oral administered. Each patient is to take 4 capsules of placebo daily.
223811649|NCT06650761|DRUG|CDX-622|Up to 4 infusions of one of seven dosages of CDX-622 or up to 1 dose by subcutaneous injection of one of three dosages of CDX-622
223811650|NCT06650761|DRUG|Normal Saline|Up to 4 infusions or 6 SC injections of normal saline
223811651|NCT06013254|DIETARY_SUPPLEMENT|sour liquid|applying lemon juice
223811652|NCT01375829|DRUG|Ixabepilone|Given IV
223811653|NCT01375829|OTHER|Pharmacological Study|Correlative studies
223811654|NCT01375829|DRUG|Temsirolimus|Given IV
223811655|NCT04866212|BEHAVIORAL|Beery- Buktenica Developmental Test of Visual Motor Integration|Investigation of visual motor integration, motor coordination and visual perception by Beery- Buktenica Developmental Test of Visual Motor Integration.
223811656|NCT04866212|BEHAVIORAL|Jebsen Taylor Hand Function Test|Investigation of hand skills by Jebsen Taylor Hand Function Test
223811657|NCT04866212|DIAGNOSTIC_TEST|Participation and Environment Measure - Children and Youth|Investigation of participation by Participation and Environment Measure - Children and Youth
223811658|NCT00916032|BIOLOGICAL|Octocog alfa (recombinant human coagulation factor VIII) [ADVATE]|Participants will receive 3000 IU Advate using one 3000 IU potency vial dissolved in 5 mL diluent followed by two 1500 IU potency vials dissolved in 5 mL diluent each (administered in 10 mL diluent in total) or the alternate sequence
223811659|NCT06069050|PROCEDURE|sequential adolesent left lateral lobe liver transplantation (SALT)|Hemihepatectomy combined with left lateral lobe liver transplantation was performed first, and residual liver resection was performed after the graft grew to a sufficient functional liver volume.
223811660|NCT05174663|OTHER|Almond-enriched diet - 1.5 oz|Participants will receive 1.5 oz of almonds consumed as a snack daily for 16 weeks.
223811661|NCT05174663|OTHER|Almond-enriched diet - 2.5 oz|Participants will receive 2.5 oz of almonds consumed as a snack daily for 16 weeks.
223811662|NCT05174663|OTHER|Control snack|Participants will receive a control snack daily for 16 weeks.
223811663|NCT02859402|DRUG|Busulfan|intravenous, 3.2 mg/kg + 5% DW (the diluent quantity should be 10 times the volume of Busulfan, so that the final concentration of busulfan becomes approximately 0.5 mg/mL), once daily for 3 hours for 3 days (days -7 to -5)
223811664|NCT02859402|DRUG|Fludarabine|intravenous, 30 mg/m2 + 5% DW 100㎖, over 1 hour once daily for 6 days (days -8 to -3)
223811665|NCT00661739|DRUG|Bendamustine|Dose-level Bendamustine(mg/m²): I:50; II:60; III:60; IV:70; V:70 Dose-level Paclitaxel (mg/m²): I:60; II:60; III:80; IV:80; V:90 Treatment will be given on day 1,8,15 and repeated on day 29. When the recommended dose has been determined a total of 48 pts will be treated at this dose level.
223811666|NCT04092725|DRUG|DAB|Single oral 150-mg dose of DAB on Day 1 AM.
223811667|NCT04092725|DRUG|SCY-078 plus DAB|Twice daily (BID), every 12 hours (Q12H) oral doses of SCY-078 750 mg on Day 1 and Day 2; and single oral AM doses of SCY-078 750 mg on Day 3 and Day 4. On Day 3 a single 150-mg dose of DAB will be administered one hour after the AM dose of SCY-078.
223811668|NCT05582187|DRUG|Fosmanogepix|a single dose of fosmanogepix administered by mouth under fasted conditions
223811669|NCT04179721|BEHAVIORAL|PES-4-BPSD Model|"Staff Training: Dementia Care Education and Training. The PI, with the support of the research team, will spend 12 weeks training the PES/NA staff. Based on the Try This: Best Practices in Nursing Care for Persons with Dementia, the PES staff will receive weekly 20 minute sessions. This study aims to capture the impact of dementia care training on the experience of PES (intervention unit) and NA (control unit) staff to care for patients with dementia. Measures will be completed at baseline, prior to dementia training (T1: baseline), immediately after completion of the training program (T2: 3 months post-baseline) and following the completion of the 1-year intervention period (T3: 12 months post-training)."
223811670|NCT04179721|BEHAVIORAL|The attention control condition|"Staff Training: Dementia Care Education and Training. The PI, with the support of the research team, will spend 12 weeks to train the PES/NA staff. Based on the Try This: Best Practices in Nursing Care for Persons with Dementia, the PES staff will receive weekly 20 minute sessions. This study aims to capture the impact of dementia care training on the experience of PES (intervention unit) and NA (control unit) staff to care for patients with dementia. Measures will be completed at baseline, prior to dementia training (T1: baseline), immediately after completion of the training program (T2: 3 months post-baseline) and following the completion of the 1-year intervention period (T3: 12 months post-training)."
223811671|NCT02268695|DRUG|Cisplatin|
223811672|NCT02268695|DRUG|5-Fluorouracile|
223811673|NCT02268695|DRUG|Docetaxel|
223811674|NCT02268695|DRUG|Cetuximab|
223811675|NCT02268695|DRUG|granulocyte colony-stimulating factor (G-CSF)|
223811676|NCT01405625|OTHER|Pictogram-based asthma action plan|Asthma action plan using plain language, pictograms, and photographs
223811677|NCT01405625|OTHER|AAAAI standard of care written action plan|
223811678|NCT01696448|DIETARY_SUPPLEMENT|CAR-191|Patients will be randomized to the CAR-191 intervention group in a 3:1, CAR0-191:placebo ratio. There will be 30 patients in the CAR-191 treatment group.
223811679|NCT01696448|OTHER|Placebo|Patients will be randomised in a 3:1 ratio. There will be 10 patients in the placebo group.
223811680|NCT01738880|DRUG|SVV|During the surgery, patients in group S receive additional fluids (400 ml of normal saline or 200 ml of colloid) when SVV is less than 13.
223811681|NCT01738880|DRUG|CVP|Patients in group C receive additional fluids (400 ml of normal saline or 200 ml of colloid) when CVP is less 8 during the surgery.
223811682|NCT00112580|BIOLOGICAL|ipilimumab|
223811683|NCT02651935|DEVICE|Intellivent ASV|Automated Invasive mechanical ventilation and weaning strategy
223811684|NCT01058317|DRUG|Propranolol|Propranolol 2mg/kg divided twice daily
223811685|NCT06681857|PROCEDURE|Sinus lifting|The implant osteotomy will be initiated by pilot drill entries followed by sequential drills via the radiographic stent's sleeves to position the fixtures precisely into the pre-determined recipient sites. The Implant stability quotient (ISQ) will then be measured using an Osstell device after attaching intelligent implant pigs. Finally, the mucoperiosteal flaps will be sutured in place with 4-0 Prolene.
223811686|NCT05009082|DRUG|Carboplatin|Area under curve (AUC) 5, intravenous, on day 1 every 3 weeks for 6 cycles
223811687|NCT05009082|DRUG|Paclitaxel|175 mg/m², intravenous, on day 1 every 3 weeks for 6 cycles
223811688|NCT05009082|DRUG|Bevacizumab|7.5 mg/kg or 15 mg/kg (according to local standard), intravenous, on day 1 every 3 weeks starting from cycle 2 in combination with chemotherapy and thereafter for up to 1 year starting from Cycle 7 Day 1
223811689|NCT05009082|DRUG|Niraparib|200 or 300 mg capsules once daily for up to a total of 3 years starting from Cycle 7 Day 1
223811690|NCT01969110|DIETARY_SUPPLEMENT|Oral IMPACT|Oral IMPACT enriched with arginine, omega-3 fatty acids, and RNA by enteral feeding after surgery
223811691|NCT01665664|OTHER|Hypocaloric feeding|Daily calorimetry for the first 6 days will be performed with determination of REE and the required amount of calories needed for the next 24 hours. In this group only 20% of REE will be provided but not less than 300 kcal/day.
223811692|NCT00652782|DRUG|rolofyline|rolofyline 2.5 mg IV QD; 15 mg IV QD; 30 mg IV QD; 60 mg IV QD; 3 days
223811693|NCT00652782|DRUG|Comparator Placebo (unspecified)|Matching placebo for rolofyline IV QD; 3 days
223811694|NCT03424434|OTHER|Survey diffusion|The study consists in a survey diffusion during several weeks by emailing each practitioner and resident and inviting them to participate to a questionnaire about occupational blood exposure. This survey is strictly anonymous. No identity data is required, only age, gender, function, surgical or medical specialty, work quota and hospital group they belong. This survey is diffused in four UHC (Lyon, Grenoble, Clermont-Ferrand and Saint-Etienne) in France.
223811695|NCT00983086|DRUG|Flavanones of orange juice|The main objective of this study is to evaluate, in healthy volunteers with young children (50 and 65) and slightly overweight according to their usual diet, the effects of single dose (in postprandial period) and made repeated orange juice or orange flavanones purified on vascular function. The selection criteria for age and weight should, within a healthy population to select individuals who exhibit cardiovascular risk factors, and thus for which it should be a priori easier to identify a beneficial effect of dietary factors on the parameters associated with cardiovascular risk.
223811696|NCT02036957|PROCEDURE|BALM ARM|The product will be applied throughout the body in abundant quantity to achieve that the skin be perfectly hydrated. The product will be applied twice a day (after showering in the morning and at night), massaging the area until completely absorption. Treatment will last three months, and at this time, We will measure toxicologic toxicity in both arms.
223811697|NCT02036957|PROCEDURE|PLACEBO ARM|The product will be applied throughout the body in abundant quantity to achieve that the skin be perfectly hydrated. The product will be applied twice a day (after showering in the morning and at night), massaging the area until completely absorption. Treatment will last three months, and at this time, We will measure toxicologic toxicity in both arms.
223811698|NCT04781738|DIAGNOSTIC_TEST|Cardiopulmonary exercise test|"CPET using a cycle ergometer (COSMED, Rome, Italy) beginning with no resistance warmup lasting 1-3 minutes followed with an incrementing resistance adapted to the patient's functional capacities according to the examiner's free judgment by successive stages~Six minute walk test - patients will be instructed to walk as far as possible for six minutes in a 30-meter long enclosed corridor with a flat and hard surface, marked at every meter. Meters will be calculated at the end of the test.~SF-36 is a questionnaire that contains eight domains - physical functioning (10 items); role limitations due to physical functioning (4 items); role limitations due to emotional problems (3 items); energy and vitality (4 items); mental health (5 items); social functioning (2 items); bodily pain (2 items); and general health perceptions (5 items).~Scores are summed for each domain and were transformed into scores of between 0 (worst possible health state) to 100 (best possible health state)."
223811699|NCT04723095|OTHER|Follow-Up|Receive follow up
223811700|NCT04723095|OTHER|Medical Chart Review|Review of medical records
223811701|NCT06083415|OTHER|Environmental health measures|MRI will be used to confirm the presence of breast buds, to measure the size of the ovaries and uterus, as well as the fraction of fat mass (abdominal, subcutaneous, liver and bone marrow). The bood and urine tests will allow to measure different biological and metabolic parameters. The presence of endocrine disruptors will be determined in the hair. The bone age x ray will be estimate the maturity of the child's skeletal system. Photographs of the teeth will also be taken to be studied by pediatric odontology researchers on the on molar and incisor hypomineralization, known as MIH.
223811702|NCT04500548|PROCEDURE|Biospecimen Collection|Undergo collection of tissue samples
223811703|NCT04500548|BIOLOGICAL|Ipilimumab|Given IV
223811704|NCT04500548|BIOLOGICAL|Nivolumab|Given IV
223811705|NCT06820593|BEHAVIORAL|Digital Asthma Intervention|The intervention consists of two main components-the mHealth app and sensors that is part of the Adherium's Hailie® Solution-and the remote patient monitoring (RPM), conducted in this intervention by an asthma coordinator.
223811706|NCT06820593|BEHAVIORAL|Comparison Group|Participants in the comparison group will receive the sensors for their ICS inhalers and a limited version of the app that only collects the sensor information by Bluetooth, without app features, and sends the information to the Hailie web portal. This passive adherence data collection will allow for comparison of the two groups' adherence rates without the mHealth app self-management support or RPM.
223811707|NCT04979312|DEVICE|LabClasp|Subjects will complete up to 10 measurements per day with potentially more before and during their OGTT using the LabClasp
223811708|NCT05619003|DEVICE|Biatain Silicone Sacral dressing|Biatain Silicone Sacral dressing will be applied over the bony prominence of the sacral area as part of a PIP (Pressure Injury Prevention) protocol in patients at risk
223811709|NCT05366764|DRUG|SAR443765|solution for injection
223811710|NCT05366764|DRUG|Placebo|solution for injection
223811711|NCT05366764|DRUG|Salbutamol or levosalbutamol|metered dose inhaler
223811712|NCT05320731|PROCEDURE|Nebulization with lidocaine|A face mask nebulizer with oxygen flow rate of 8 L/min will be used to deliver 10 mL of 2% lidocaine. Patients will be encouraged to inhale deeply to facilitate entrainment of nebulized LA into their airway. Adequate topical anesthesia will be confirmed by heaviness or numbness of the tongue.
223811713|NCT05320731|PROCEDURE|Atomization with lidocaine|A simple atomization device as a modification of the McKenzie technique will be used. One end of oxygen bubble tubing will be cut to fit into the barrel of 1 mL syringe and attached to one connector of a 3-way tap. A 10-mL syringe filled with 2% lidocaine will be attached to the other connector of the 3-way tap. A 6 Fr suction catheter, with its colored end cut and its distal blind end cut open, will be attached to oxygen bubble tubing via the male Luer connector of the 3-way tap. The other end of bubble tubing will be then attached to an oxygen source turned on to deliver a flow of 6 L/min. As LA is slowly atomized as a jet-like spray, the catheter will be directed towards the soft palate and posterior pharynx in a controlled fashion during patients' inspiration to topicalize the airway. Patients will be asked to take full vital capacity breaths of atomized LA contained oxygen. Adequate topical anesthesia will be confirmed by tongue heaviness or numbness
223811714|NCT03901235|BIOLOGICAL|Mesenchymal Stromal Cells|Suspension of mesenchymal stromal cells for intratissular injection
223811715|NCT06865339|DRUG|Cemiplimab|Human IgG anti-PD-1 monoclonal antibody approved for treatment of advanced NSCLC with PD-L1 TPS ≥ 50% as monotherapy and in combination with chemotherapy
223811716|NCT06865339|DRUG|Fianlimab|Human IgG anti-lymphocyte activation gene 3 (LAG-3) monoclonal antibody, which is expressed by various immune cells, and regulates effector T-cell activation and responses. LAG-3 inhibition restores the effector function of exhausted T cells, enhancing their ability to attack tumor cells. Fianlimab is currently under investigation in several clinical studies involving NSCLC (NCT05800015, NCT03916627, NCT05785767).
223811717|NCT06865339|RADIATION|Radiotherapy|Thoracic radiotherapy. Conventionally fractionated 1.8-2.0 Gray (Gy) per day. Adaptive radiotherapy will not be performed unless difficulty with patient setup or changes in internal patient anatomy require repeating the CT simulation procedure
223811718|NCT06865339|DRUG|Platinum Doublet Chemotherapy (PDC)|Acceptable histology-specific PDC regimens include carboplatin plus paclitaxel or nab-paclitaxel (any histology), carboplatin/cisplatin plus pemetrexed (nonsquamous), carboplatin/cisplatin plus etoposide (any histology), and carboplatin/cisplatin plus docetaxel or gemcitabine (squamous). Carboplatin can be used instead of cisplatin after cycle 1 in cases of cisplatin-induced neuro-/oto-/nephrotoxicity as long as the patient remains eligible for chemoradiotherapy. Weekly radiosensitizing PDC will be recommended for PD-L1 TPS \<50% patients during RT but is not required.
223811719|NCT07001150|DRUG|levodopa-carbidopa|Carbidopa/levodopa is a combination of two medications: carbidopa and levodopa. It is primarily used to manage the symptoms of Parkinson's disease. The main and most effective treatment strategy for motor symptoms in Parkinson's disease relies on replenishing dopamine levels through the use of L-dopa.
223811720|NCT07001150|DRUG|Silymarin|Silymarin, a polyphenolic flavonoid renowned for its potent antioxidant properties, is employed clinically for managing hepatic disorders. Its antioxidant effects are primarily attributed to its ability to scavenge free radicals.
223811721|NCT06998628|DRUG|Methotrexate|Methotrexate (MTX) is a chemotherapy agent and immune-system suppressant. It is used to treat cancer, autoimmune diseases, and ectopic pregnancies. Types of cancers it is used for including breast cancer, leukemia, lung cancer, lymphoma, gestational trophoblastic disease, and osteosarcoma. Methotrexate is also used to treat rheumatoid arthritis and other inflammatory conditions.
223811722|NCT06998628|DRUG|Pentoxifylline|Pentoxifylline (also known as oxpentifylline) is a methylxanthine derivative with strong hemorrheologic effects. In the United States, it is primarily used to treat intermittent claudication. Studies in both humans and animals have demonstrated that pentoxifylline therapy induces various physiological changes at the cellular level
223811723|NCT07001371|BEHAVIORAL|Emotional Brain Training|Emotional Brain Training (EBT) is a structured, neuroscience-based behavioral intervention that focuses on rewiring the brain's stress-related circuits to promote emotional resilience, self-regulation, and lasting behavioral change. This behavioral intervention has not been implemented in addiction treatments in the past. Unlike traditional therapies that primarily target cognitive processes or symptom management, EBT directly addresses the physiological and emotional root causes of maladaptive behaviors by engaging the brain's natural neuroplasticity mechanisms. EBT integrates rapid emotional processing tools, peer-to-peer support, clinician-facilitated sessions, and mobile app-based self-care to systematically transition brain circuits from stress-reactive to stress-resilient states.
223811724|NCT07001371|OTHER|Standard addiction counseling and medical therapy|Participants will receive standard counseling (including but not limited to cognitive behavioral therapy, motivational interviewing, etc.), which does not include EBT, in addition to medications for addiction treatment (including but not limited to buprenorphine, naltrexone, bupropion, etc.).
223811725|NCT04817007|DRUG|BMS-986158|Specified dose on specified days
223811726|NCT04817007|DRUG|Ruxolitinib|Specified dose on specified days
223811727|NCT04817007|DRUG|Fedratinib|Specified dose on specified days
223811728|NCT06606340|DRUG|Eteplirsen|No study medication will be provided by the Sponsor as a condition to participate in this observational study, and all decisions concerning each participant's treatment are at the discretion of the participant's treating physician. Participants will receive treatment as prescribed by the treating physician as part of standard of care.
223811729|NCT06606340|DRUG|Golodirsen|No study medication will be provided by the Sponsor as a condition to participate in this observational study, and all decisions concerning each participant's treatment are at the discretion of the participant's treating physician. Participants will receive treatment as prescribed by the treating physician as part of standard of care.
223811730|NCT06606340|DRUG|Casimersen|No study medication will be provided by the Sponsor as a condition to participate in this observational study, and all decisions concerning each participant's treatment are at the discretion of the participant's treating physician. Participants will receive treatment as prescribed by the treating physician as part of standard of care.
223811731|NCT06871943|OTHER|Incremental Shuttle Walk Tests|The participants will walk on the flat around cones placed 9 meters apart inline with the procedure for the incremental shuttle walk test. They will also walk at a matched speed to the incremental shuttle walk test on a treadmill. This will be performed in a counter balanced procedure to reduce any benefit of a learning effect.
223811732|NCT05037760|DRUG|KER-050 monotherapy|KER-050 administered (SC) for up to 13 cycles. Participants who may have potential benefit from continued treatment, in the opinion of their investigator, may continue in the Long Term Extension after completing 13 cycles.
223811733|NCT05037760|DRUG|KER-050 in combination with ruxolitinib|KER-050 administered (SC) for up to 13 cycles in combination with standard of care ruxolitinib. Participants who may have potential benefit from continued treatment, in the opinion of their investigator, may continue in the Long Term Extension after completing 13 cycles.
223811734|NCT07006818|DEVICE|Direct current stimulation|Direct current stimulation will be applied at 2 mA for 20 minutes.
223811735|NCT07016880|BEHAVIORAL|Virtual Reality Relaxation Session|A 20 minute virtual reality session using visual and auditory stimuli for relaxation before surgery. Delivered via VR headset.
223811736|NCT07025577|DRUG|Immunoglobulin G|Participants will receive SC administrations of IgG
223811737|NCT06701435|DEVICE|Cold Compression|Cold compression was applied to the athletes with the Game Ready (Game Ready; Global, UK) device. The Game Ready (GR) device applies cooling to the tissue by continuous circulation of ice water with intermittent pneumatic compression. The GR consists of a sleeve that surrounds the affected tissue, a tank containing the ice water and a hose connecting the two. There are chambers inside the sleeve and the air pumped through these chambers and the broken ice pieces and water surround the tissue. The pressure settings are no compression (0 mmHg), low compression (5 to 15 mmHg), medium compression (5 to 50 mmHg) and high compression (5 to 75 mmHg). The ice water passes through the sleeve in 3-minute inflation and deflation cycles. The temperature of the water inside the device can be adjusted by adding ice and water. The temperature to be applied to the tissue is set with the screen on the device.
223811738|NCT07021963|DRUG|HRS-1893 Tablet|HRS-1893 tablet.
223811739|NCT06685861|DEVICE|a digital product based on CBT|The digital cognitive behavioral therapy in this study is conducted based on a self-developed mobile applet. The therapy is developed by psychotherapists, which is conducted for a total of 8 weeks, with weekly sessions including Al-guided course work and homework.
223811740|NCT00199719|DRUG|Ribavirine|
223811741|NCT07032688|DRUG|SHR-3167 Injection|SHR-3167 injection.
223811742|NCT07032688|DRUG|Insulin Degludec Injection|Insulin Degludec injection.
223811743|NCT06724757|OTHER|Health questionnaire|The intervention involves the completion and analysis of an online questionnaire designed to assess the health (mental, physical, social) of caregivers aged 50 and over in Quebec. This assessment is based on a combination of questionnaires (CARE, 4-item Zarit scale, 4-item GDS, 3-item UCLA loneliness scale, etc.).
223811744|NCT06724991|PROCEDURE|Lower Dose Therapy|The group receiving the lower-dose therapy consists of 5 units of Actrapid (insulin) with 25cc of Dextrose 50%. This intervention is the focus of the clinical trial and is being investigated to determine if it achieves a comparable reduction in potassium levels with fewer potential complications. The aim is to establish it as a non-inferior alternative to conventional-dose therapy in the management of mild and moderate hyperkalemia.
223811745|NCT06724991|PROCEDURE|Conventional Dose Therapy|The group receiving the conventional-dose therapy, consisting of 10 units of Actrapid (insulin) with 50cc of Dextrose 50%, which is currently in use as a standard practice in emergency departments for managing mild and moderate hyperkalemia. This dosing regimen aligns with established clinical guidelines and is widely accepted as an effective approach in controlling potassium levels.
223811746|NCT07050758|BEHAVIORAL|Pain Reprocessing Therapy|"Each PRT session will take 45-60 minutes and includes psychoeducation about the association between pain and the brain, mindfulness, and exposure- and acceptance-based concepts. Through PRT, participants will learn about how pain can emerge from 'stuck patterns' in neural circuits in the brain. Through reflections of their own pain experiences, the patient explores evidence for whether this applies to their own pain. Patients will acquire corrective experiences in which their brain learns not to respond with pain (false alarm) in situations that are safe. One central reprocessing exercise is 'somatic tracking', in which participants explore their pain sensations in a context of safety. This includes interoceptive exposures and situational exposures to activities they fear will trigger pain. Exploring these sensations and situations through a lens of safety and curiosity allows the participants to reinterpret bodily sensations previously associated with threat or pain, as safe."
223811747|NCT06701812|DRUG|Digoxin|2.5-10 mcg/kg/day orally divided twice daily or once daily based on age on a continuous dosing schedule.
223811748|NCT04803201|DRUG|Cyclophosphamide|Given IV
223811749|NCT04803201|DRUG|Doxorubicin|Given IV
223811750|NCT04803201|DRUG|Vincristine|Given IV
223811751|NCT04803201|DRUG|Prednisone|Given PO
223811752|NCT04803201|DRUG|Etoposide|Given IV or PO
223811753|NCT04803201|DRUG|Duvelisib|Given PO
223811754|NCT04803201|DRUG|Oral azacitidine|Given PO
223811755|NCT04081220|DRUG|IMG-7289|Single starting dose with individualized dose titrations throughout
223811756|NCT07092475|DRUG|Methadon|A long-acting synthetic opioid with a pharmacologic profile that potentially offers more stable and longer-lasting pain relief.
223811757|NCT07094022|DIETARY_SUPPLEMENT|Nutrilite Protein MetX Pro|A total of 4 cans (460 g/can) of study products (Nutrilite Protein MetX Pro) are distributed to each participant. Participants need to take 16g each time, twice a day, for 4 weeks.
223811758|NCT07094022|DIETARY_SUPPLEMENT|Placebo Product|A total of 4 cans (460 g/can) of placebo products are distributed to each participant. Participants need to take 16g each time, twice a day, for 4 weeks.
223811759|NCT07092969|DEVICE|Treadmill Exercise|Participants in this group will perform an aerobic exercise using the Bruce Protocol on a treadmill. The test involves walking or running with gradually increasing speed and incline in predefined stages to assess cardiovascular endurance. Heart rate, blood pressure, and fatigue levels will be recorded at each stage. The session will conclude with a low-intensity cool-down phase.
223811760|NCT07092969|DEVICE|Bicycle Exercise|The Wingate Anaerobic Test will be conducted using an ergometer bike. After a standardized warm-up, participants will pedal all-out for 30 seconds against a preset resistance, aiming to evaluate their anaerobic performance. Physiological parameters including power output, heart rate, and oxygen saturation will be monitored throughout the test.
223811761|NCT07094074|OTHER|Walk tests|"* 200 m walk test~* 2-minute walk test~* 6-minute walk test"
223811762|NCT07094074|OTHER|Functional testing|Timed Up and Go test (TUG), Berg Balance Test (BBT), Choice Stepping Reaction Time (CSRT), Functional Reach Test (FRT)
223811763|NCT07094074|OTHER|Balance analysis|Balance analysis
223811764|NCT07094074|OTHER|Quantified analysis of walking|On flat ground, even on slopes and stairs
223811765|NCT07094074|OTHER|Questionnaires|Houghton, Prosthetic Profile of the Amputees-Locomotion Capabilities Index (PPA-LCI), Activities-specific Balance Confidence scale (ABC), quality of life assessed by the SF-12
223811766|NCT07093606|DRUG|Eltrombopag|ITP patients will receive Eltrombopag and evulate occurance of liver disordres .
223811767|NCT07093333|DRUG|ART5803|A monovalent (one-armed) antibody, that binds to the NTD of the NMDAR NR1 subunit without causing NMDAR inhibition, activation, or receptor internalization, while simultaneously blocking the ability of the pathogenic anti-NMDAR autoantibodies to bind to the receptor.
223811768|NCT04776278|BEHAVIORAL|Brief Alcohol Intervention (BAI)|This session includes a discussion related to harm reduction and the participant's autonomy to make decisions about the information provided in the session; an alcohol use decisional balance exercise; personalized alcohol-related feedback, and goal-setting. Elements included in the feedback are: (a) comparison of the participant's perception of how much he or she drinks and actual norms, (b) a comparison of the participant's alcohol consumption vs. norms, (c) an estimate of the participant's peak blood alcohol content in the past month, (d) alcohol-related problems experienced, (e) money spent on alcohol, and (f) calories consumed from alcohol. Participants discuss the personalized feedback with the clinician and review protective behavioral strategies if he or she indicates interest.
223811769|NCT04776278|BEHAVIORAL|Substance-free Activity Session (SFAS)|The SFAS session includes : a) discussion of life goals, b) discussion of associations between alcohol and drug use, goals, and substance-free activities; c) a graph depicting the participant's ratings of the relative importance of various aspects of their life and how their actions in the past week have been consistent with these priorities; d) personalized feedback on recent time allocation to activities across life domains, and a discussion of any changes the participant would like to make; e) feedback on symptoms of stress, anxiety and discussion of adaptive coping strategies; f) discussion of enjoyable substance-free activities and hobbies and substance-free recreational activity suggestions tailored to individual's interests and neighborhood; g) a goal setting exercise for specific behavior change plans; h) a Future Thinking Writing Exercise. Participants will receive weekly text-message based booster prompts for four weeks after their SFAS session.
223811770|NCT04776278|BEHAVIORAL|Relaxation Training (RT)|The clinician will begin by establishing the credibility of the session by providing the participant with the rationale that developing relaxation or mindfulness training strategies can reduce stress and enhance wellness. The clinician will then lead the participant through a diaphragmatic breathing exercise, followed by a progressive muscle RT protocol, and then a brief breath-counting (mindfulness) exercise. The session will conclude with a brief discussion of additional stress and anxiety management strategies (e.g., apps to monitor heartrate and breathing). Participants will be asked about their reaction to the techniques and, if interested, encouraged to commit to a specific plan for practicing these techniques.
223811771|NCT04776278|OTHER|Education Control|This condition will not include any clinical contact other than a brief (2-3 minute) discussion with the research assistant (RA) who completed the assessment session and who will describe the educational handout. This condition is meant to approximate a low-threshold public health-level approach to providing referral information and some of the content included in the BAI+SFAS condition but without any of the personalized information or MI/clinical contact. Thus, participants will receive information on risks associated with alcohol and drug misuse, strategies for reducing use/problems, and strategies for managing stress and setting and follow-through with achievable goals. The handout will also include links to hotlines, websites, and apps related to these domains. This condition will not include booster contact.
223811772|NCT06239545|BEHAVIORAL|Usual Practice + JoyPop|Participants will be asked to use the app at least twice daily but will otherwise not be provided with requirements related to feature or total usage.
223811773|NCT07111039|OTHER|Airway Pressure Release Ventilation|APRV
223811774|NCT07111039|OTHER|Conventional Mechanical Ventilation|CMV
223811775|NCT06921720|DIAGNOSTIC_TEST|intra-muscular ATP values in phosphate diabetes|intra-muscular ATP values \[ATPi\] (measured by 31P-MRS / Phosphorus-31 nuclear magnetic resonance) at rest and during standardized exercise in patients with phosphate diabetes.
223811776|NCT06921720|DIAGNOSTIC_TEST|intra-muscular phosphate values in phosphate diabetes|intra-muscular phosphate values (measured by 31P-MRS) at rest and during standardized exercise in patients with phosphate diabetes.
223811777|NCT07118072|BEHAVIORAL|Internet-Delivered Skills Training in Affective and Interpersonal Regulation|Internet-Delivered Skills Training in Affective and Interpersonal Regulation (i-STAIR) is a psychological intervention that is focused on applying skills to improve emotion regulation difficulties and reduce interpersonal problems over two months (eight sessions; one session per week). i-STAIR also significantly reduces PTSD symptoms without direct discussion of the trauma and may be used alone or adjunctively to boost the effects of trauma-focused therapies.
223811778|NCT07118072|BEHAVIORAL|Online general psychoeducation|Online general psychoeducation will focus on the teaching the link between adverse childhood experiences and depression, as well as teaching healthy lifestyle changes involving diet, exercise, and sleep. The online general psychoeducation will involve engaging presentations, active discussions, and self-directed homework activities.
223811779|NCT06923592|COMBINATION_PRODUCT|PvSeroTAT|Two rounds (month 0 and month 6) of serological screening for antibodies against P. vivax in the blood of all eligible cluster inhabitants. In the clusters in the PvSeroTAT arm, participants with a positive P. vivax serology at baseline or month 6 will be treated with 7 days of primaquine 0.5mg/kg/day and a three-day course of either chloroquine (Ethiopia) or artesunate-amodiaquine (Madagascar).
223811780|NCT06923592|DIAGNOSTIC_TEST|Control|Two rounds (month 0 and month 6) of serological screening for antibodies against P. vivax in the blood of a subset of eligible cluster inhabitants. Serological status will be assessed at a later stage (months later) and will not lead to treatment of sero-positive individuals.
223811781|NCT06522971|BEHAVIORAL|High-intensiy interval training|All participants undergo physical capacity tests before the onset of NAC and after the last course of NAC but before the breast cancer surgery. A treadmill protocol consisting of twenty-one 1-minute stages, with speed and/or grade increments at each stage, is used to obtain VO2 peak (the highest amount of oxygen consumed at peak exercise) data. The HIIT intervention consists of 2 to 3 exercise sessions per week for 6 months. The HIIT session starts with a 6-minute warm-up period at about 65-70% of maximal heart rate (HRmax) followed by 4 X 4-min high-intensity intervals (85%-95% of HRmax) combined with 3 min period of active recovery (55-70% of HRmax).
223811782|NCT06932614|PROCEDURE|Lyophilized self growth factor|Knee Intraarticular injection with Lyophilized self growth factor
223811783|NCT06932614|PROCEDURE|Platelet-Rich Plasma(PRP)|Knee Intraarticular injection with Lyophilized self growth factor
223811784|NCT06932614|PROCEDURE|Placebo|Knee Intraarticular injection with normal saline
223811785|NCT07129382|DRUG|CS32582 capsule（low dose） or matched placebo|CS32582 capsule（low dose） or matched placebo，4 weeks
223811786|NCT07129382|DRUG|CS32582 capsule（high dose） or matched placebo|CS32582 capsule（high dose） or matched placebo，4 weeks
223811787|NCT07129382|DRUG|CS32582 capsule（low dose）|CS32582 capsule（low dose），12 weeks
223811788|NCT07129382|DRUG|CS32582 capsule（medium dose）|CS32582 capsule（medium dose），12 weeks
223811789|NCT07129382|DRUG|CS32582 capsule（high dose）|CS32582 capsule（high dose），12 weeks
223811790|NCT07139587|DRUG|Iparomlimab/Tuvonralimab (anti PD-1/CTLA-4) combined with albumin-bound paclitaxel|Iparomlimab/Tuvonralimab : 5.0mg/kg, D1, Q3W Albumin-bound paclitaxel: 260mg/m², D1, Q3W
223811791|NCT05528133|RADIATION|Genomically Guided Radiation Therapy|Participants will receive treatment 5 days per week, in once daily fractions. The total dose will be 50 Gy in 25 fractions or 42.56 Gy in 16 fractions with or without a boost of 10 Gy in 5 fractions to the cavity.
223811792|NCT05528133|RADIATION|Genomically Guided Radiation Therapy|Participants will receive treatment 5 days per week, in once daily fractions. The total dose will be 50 Gy in 25 fractions or 42.56 Gy in 16 fractions with a boost of 10 Gy in 5 fractions to the cavity.
223811793|NCT05748314|OTHER|Questionnaire|KINDL-R; Morisky Medication Adherence Scale;
223811794|NCT06940336|DRUG|Tafamidis Meglumine Soft Capsules|20 mg orally once daily for 72 weeks
223811795|NCT06747715|PROCEDURE|Serial Fat Grafting Fresh followed by Cryopreserved Fat|The therapeutic intervention is a two stage surgical procedure (with a third stage biopsy for research purposes in this trial) in which a primary traumatic or post-surgical craniofacial deformity is treated first with autologous fat grafting using freshly harvested adipose tissue. A second fat grafting procedure is performed at 3.0 months after the first procedure using autologous adipose tissue that had been cryopreserved during the first procedure.
223811796|NCT06945120|BEHAVIORAL|ACT Lung Health Intervention|An Asian culture-tailored lung health intervention, which includes individual counseling sessions, family coaching, provision of nicotine replacement therapy (NRT) in the form of patches, lozenges, or chewing gum, and educational materials about low-dose computed tomography (LDCT) for lung cancer screening. The eight weekly, counseling sessions with study staff will be conducted via phone call or the Zoom web-conferencing platform.
223811797|NCT06940154|COMBINATION_PRODUCT|Rademikibart in prefilled syringe|Participants receive 600 mg (4mL) of rademikibart administered subcutaneously.
223811798|NCT06940154|DRUG|Matching placebo in prefilled syringe|Participants receive 4mL of placebo matched to rademikibart administered subcutaneously.
223811799|NCT07145437|DIAGNOSTIC_TEST|Radio-induced Lymphocyte Apoptosis (RILA) Assay|peripheral blood sample processed via the RILA assay to quantify apoptotic CD8+/CD4+ T cells following ex vivo irradiation.
223811800|NCT07145437|RADIATION|Stereotactic body radiotherapy (SBRT)|SBRT delivered to the prostate with image guidance, respecting dose constraints for organs at risk;
223811801|NCT06949631|DIETARY_SUPPLEMENT|Resistant Potato Starch|Active Ingredients: 3.5 g potato starch Inactive ingredients: 3.5 g corn starch
223811802|NCT06949631|OTHER|Placebo|Active Ingredients: N/A Inactive Ingredients: 7 g corn starch
223835483|NCT01013220|OTHER|Depression HEDIS detailing|"1. academic detailing to employees responsible for purchasing health care benefits on how to use HEDIS indicators for depression to assure their depressed employees receive high quality care for the condition~2. technical assistance"
223835484|NCT01198925|DRUG|piperacillin continuous infusion|piperacillin continuous infusion
223835485|NCT01198925|DRUG|piperacillin extended infusion|piperacillin extended infusion
223811803|NCT07143383|BEHAVIORAL|Social Prescribing|SP is a person-centered approach to wellbeing involving the co-development of a non-clinical prescription, between an individual (i.e. young person) and Link Workers (LWs), based on the perceived difficulties for the referral and the YPs values, needs and preferences. LWs have a good knowledge of their local areas, via community asset mapping and networking, allowing them to connect individuals with different types of available support and activities. Typically, SP ranges from 6-12 sessions (average 8 sessions: unpublished data from sites) with a LW over an 8-week period. Sessions may take place online, via phone call, or in person. As part of this process, LWs draw on psychological skills such as motivational interviewing and behavioral activation as well as employ problem solving and goal setting. Following the identification of issues and preferences, the LW will discuss with the YP what the available local activities and support structures are that match their preferences.
223811804|NCT07143383|BEHAVIORAL|Signposting|Those in the control group will receive signposting to activities and local sources of support in their communities. This will consist of a CAMHS clinician or researcher meeting with YP identified and providing them with a leaflet detailing the same local sources of support identified by the LW from asset mapping.
223811805|NCT06952803|DRUG|Saruparib|Saruparib will be administered orally.
223811806|NCT06952803|DRUG|Placebo|Matching placebo to saruparib will be administered orally.
223811807|NCT06952803|DRUG|Abiraterone + Prednisolone/Prednisone|Abiraterone will be administered orally in combination with prednisone/prednisolone.
223811808|NCT06952803|DRUG|Androgen Deprivation Therapy (ADT)|Standard of care ADT will be administered.
223811809|NCT07147946|DRUG|TQC3721 Suspension for inhalation|TQC3721 suspension for inhalation is a Phosphodiesterase3/4 (PDE3/4) inhibitor
223811810|NCT07147946|DRUG|Placebo of TQC3721 Suspension for Inhalation|Placebo without drug substance
223811811|NCT07145099|OTHER|PT Group|Exercise, Manual Therapy, and education
223811812|NCT07145099|OTHER|Usual Care|Education
223811813|NCT07144956|BIOLOGICAL|Cilostazol (Pletal®) 100 mg Tablets|100 mg orally or via feeding tube twice daily for 14 days, starting within 96 hours after aneurysmal subarachnoid hemorrhage onset. Tablets may be crushed for enteral administration.
223811814|NCT07144956|DRUG|Placebo|Oral or enteral placebo, visually identical to cilostazol, twice daily for 14 days, starting within 96 hours after hemorrhage onset.
223811815|NCT07144956|DRUG|Nimodipine group|Administered orally, enterally, or intravenously for 21 days as part of standard of care. Dose, route, and duration determined by treating physician according to clinical condition and guidelines.
223811816|NCT07154953|DIAGNOSTIC_TEST|Serum Surfactant Protein-D|Several studies support the use of SP-D as a marker of systemic inflammation and lung tissue damage in COPD.Measuring serum SP-D could provide a valuable tool for early detection, monitoring progression, and personalizing management of COPD patients.Surfactant protein D (SP D) as a prognostic biomarker needs further studies to validate its clinical applicability
223811817|NCT07153237|DEVICE|STYLAGE® HydroMax|3 injection sessions : Group A: at week 0 (V1a), week 3 (V2a), and week 24 (V5a). Group B: at week 6 (V3b), week 3 from V3b (V4b), and week 24 from V3b (V7b)
223811818|NCT07153107|OTHER|Local Heat Therapy|"This will use a simple device provided to participants named jaw bra, which is a head wrap with straps that goes around the chin and head that holds heated gel packs over the cheeks area"
223811819|NCT07152847|OTHER|Psychosexual education app with artificial intelligence|"Development of the App will contain the following features:~1. A basic Mac for iphone Operating System development~2. General Data Protection Regulation compliance legal certification~3. Hosting and cloud services~4. Security Features: for encryption and secure authentication user sign in~5. Analytics Integration: for integrating app analytics tools~6. Push Notifications: incorporated into the app~7. Legal and Compliance additional General Data Protection Regulation certified~8. Custom Artificial Intelligence Models Interactive Learning Tools Artificial Intelligence will create interactive educational materials on sexual function and dysfunction~9. Artificial Intelligence cloud services~10. Natural Language Processing. Artificial Intelligence will process textual data from the feedback questions to identify emerging topics and concerns in sexual function and participants' experiences using the app."
223811820|NCT02977559|DEVICE|Laryngeal Tube Suction Disposable|Device for ventilation
223811821|NCT02977559|DEVICE|Laryngeal Mask Airway AuraGain|Ventilation device
223811822|NCT07165457|DIETARY_SUPPLEMENT|Probiotic group|Daily consumption of one capsule containing a probiotic for 15 days
223811823|NCT07166757|DRUG|human allogeneic induced pluripotent stem cell (iPSC)-derived dopaminergic neural progenitor cell injection|5.0×10\^7 cells/mL, injection, once, 12 months
223811824|NCT07166172|DEVICE|Fetal Treatment Arm (FETO Group)|Participants will undergo FETO surgery between 27 weeks 0 days to 29 weeks 6 days gestation. The FETO intervention involves two procedures: (1) inserting a balloon into the fetal trachea, and (2) removing the balloon before delivery. After the first FETO procedure, participants will be monitored weekly by ultrasound. Removal of the balloon will be performed at 34 weeks 0 days to 34 weeks 6 days. Planned delivery will occur after 37 weeks. The follow-up phase will be conducted from birth to 24 months of age.
223811825|NCT07166406|BIOLOGICAL|Atezolizumab|Given IV
223811826|NCT07166406|BIOLOGICAL|Bevacizumab|Given IV
223811827|NCT07166406|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223811828|NCT07166406|PROCEDURE|Computed Tomography|Undergo CT and PET/CT
223811829|NCT07166406|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223811830|NCT07166406|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
223811831|NCT07166406|OTHER|Questionnaire Administration|Ancillary studies
223811832|NCT07166406|BIOLOGICAL|Tremelimumab|Given IV
223811833|NCT07166406|BIOLOGICAL|Durvalumab|Given IV
223811834|NCT07166406|BIOLOGICAL|Nivolumab|Given IV
223811835|NCT07166406|DRUG|Ipilimumab|Given IV
223811836|NCT07166406|RADIATION|Stereotactic Body Radiation Therapy|Undergo liver SBRT
223811837|NCT07166406|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
223811838|NCT07164703|DRUG|Targeted drugs or immunotherapies for cholangiocarcinoma based on targetable gene mutations.|Targeted drugs or immunotherapies for cholangiocarcinoma based on targetable gene mutations.
223811839|NCT07164716|OTHER|plantar fascia recovery training group|plantar fascia recovery training group: Gliding massage,Soft tissue mobilization,Metatarsophalangeal Joint Stretching,Foam roller
223811840|NCT07164690|RADIATION|Low Dose Radiation Therapy|"A dose of 2 Gy/1Fx will be delivered to all currently visible lesions. Lesions in different anatomic sites may be irradiated separately, but the entire course must be completed within one week.~* Esophageal primary tumor management: If the investigator judges there is a risk of fistula or bleeding from the esophageal lesion, palliative radiotherapy at 40-50 Gy may be added.~* Immunotherapy: The original PD-1/PD-L1 inhibitor regimen will be resumed immediately after LDRT is completed and continued as maintenance therapy.~* Chemotherapy: At the investigator's discretion, standard second-line chemotherapy per the current CSCO guidelines for esophageal cancer may be administered."
223811841|NCT07166536|OTHER|Provocation Test for Symptoms Using Mental Imagery|"• The mental imagery task will be guided by the examiner through continuous verbal instruction (the examiner will provide ongoing instructions throughout the entire task, not just at the beginning). During the instruction, the examiner will direct the participant's attention to visual, auditory, and proprioceptive aspects of the imagined movement or scenario. Example: Close your eyes, and without moving your head or body at all, try to imagine that you are moving your head from side to side quickly and easily, while noticing the sensation of motion, seeing the rotation through your eyes, and feeling the acceleration of your head as it moves from side to side..."
223811842|NCT07164586|DIAGNOSTIC_TEST|Respiratory Pattern Monitoring|Respiratory pattern assessment and continuous monitoring will be conducted utilizing the Respiratory Diagnostic Assistant, a device capable of providing comprehensive quantitative evaluation of respiratory variables including frequency, volume, flow rates, inspiratory/expiratory timing parameters, and respiratory entropy analysis, as well as qualitative analysis of respiratory pattern curves for volume and flow dynamics, incorporating entropy measurements for assessment of respiratory pattern complexity and variability.
223811843|NCT07164586|DIAGNOSTIC_TEST|Diaphragmatic Excursion|"Diaphragmatic mobility assessment will be conducted using diaphragmatic ultrasonography, a method capable of providing comprehensive quantitative evaluation of diaphragmatic excursion parameters including range of motion, contraction velocity, muscle thickening during inspiration and expiration, as well as qualitative analysis of diaphragm muscle morphology and echogenicity, incorporating craniocaudal displacement measurements for assessment of contractile function and early detection of diaphragmatic dysfunction."
223811844|NCT07164586|DIAGNOSTIC_TEST|Respiratory muscle electrical activity|espiratory muscle electrical activity assessment will be conducted using surface electromyography, a method capable of providing comprehensive quantitative evaluation of muscle activation parameters including electrical signal amplitude, firing frequency, muscle recruitment patterns during inspiration and expiration, as well as qualitative analysis of synchronization and coordination between respiratory muscles, incorporating Root Mean Square (RMS) measurements and spectral analysis for assessment of respiratory neuromuscular function and detection of muscle fatigue.
223811845|NCT07164586|DIAGNOSTIC_TEST|Respiratory Muscle Strength|Respiratory muscle strength assessment will be conducted using manovacuometry, a method capable of providing comprehensive quantitative evaluation of respiratory muscle force parameters including maximal inspiratory pressure (MIP) and maximal expiratory pressure (MEP), as well as qualitative analysis of contractile capacity and muscle endurance, incorporating peak pressure measurements and performance indices for assessment of global respiratory muscle function and early detection of muscle weakness
223811846|NCT07164586|DIAGNOSTIC_TEST|Pulmonary Function Assessment|"Pulmonary function assessment will be conducted using spirometry, a method capable of providing comprehensive quantitative evaluation of respiratory function parameters including forced vital capacity (FVC), forced expiratory volume in one second (FEV1), FEV1/FVC ratio, and forced expiratory flow 25-75% (FEF25-75%), as well as qualitative analysis of flow-volume and volume-time curves, incorporating lung capacity and volume measurements for assessment of respiratory mechanics and early detection of obstructive and restrictive ventilatory disorders."
223811847|NCT07164586|OTHER|Data Acquisition System|The PowerLab C is a biomedical data acquisition system used as an auxiliary tool for physiological monitoring. In this study, it will be employed to collect respiratory signals and diaphragmatic excursion data through specific sensors, integrated with LabChart software for data visualization and analysis. The device is not considered an investigational intervention, but a supporting tool for data collection.
223811848|NCT07164586|OTHER|Nijmegen Questionnaire|The Nijmegen Questionnaire is a standardized self-report instrument designed to assess symptoms related to dysfunctional breathing and hyperventilation. In this study, it will be administered to evaluate respiratory symptoms and their impact on participants' daily life. The questionnaire is used solely for data collection and is not considered a therapeutic intervention.
223811849|NCT07164586|OTHER|System Usability Scale (SUS)|The System Usability Scale (SUS) is a standardized questionnaire used to evaluate the usability and user experience of systems and devices. In this study, it will be applied to assess participants' perceptions of the usability of an intelligent respiratory monitoring system. The SUS will be used solely as a data collection tool and does not constitute a therapeutic intervention.
223811850|NCT07164586|OTHER|Borg Scale|The Borg Scale is a standardized self-report instrument used to assess perceived exertion and breathlessness during physical activity. In this study, it will be applied to evaluate participants' perception of respiratory effort. The scale is used solely for data collection and is not considered a therapeutic intervention.
223811851|NCT07164586|OTHER|Patient Identification Questionnaire|The Patient Identification Questionnaire is a standardized form used to collect sociodemographic and basic clinical information from participants, such as age, sex, and medical history. In this study, it will serve solely for data collection and will not constitute a therapeutic intervention.
223811852|NCT07164586|DIAGNOSTIC_TEST|Peak Expiratory Flow (PEF) Measurement|Peak Expiratory Flow (PEF) measurement is a rapid and noninvasive method to assess the maximum expiratory volume a participant can achieve after a full inhalation. In this study, participants will be seated upright and use a mouthpiece connected to a peak flow meter. After a deep inspiration, they will exhale forcefully, and three measurements will be taken with at least one minute between attempts; the highest value will be recorded. PEF values provide an objective measure of airflow limitation, correlate with asthma symptoms, and will be used solely for data collection, not as a therapeutic intervention
223811853|NCT07165665|OTHER|Bobath (Neurodevelopmental Treatment) approach|The control group will receive only the standard Bobath (Neurodevelopmental Treatment, NDT) approach.
223811854|NCT07165665|DEVICE|Non-invasive transcutaneous auricular vagus nerve stimulation (taVNS)|The intervention group will receive the standard Bobath (Neurodevelopmental Treatment, NDT) approach combined with non-invasive transcutaneous auricular vagus nerve stimulation (taVNS).
223811855|NCT07165574|OTHER|No intervention as the study is observational|As this is an observation study, participants are not assigned an intervention as part of the study
223811856|NCT07164885|RADIATION|Radiosensitivity-Assisted Personalized Adaptive Radiotherapy Technology（RAPART)）|RAPART technology is a special combination of ART and RAPRT, with a total course limit of no more than 30 exposures. The entire course of treatment can be divided into two stages: the first stage is completely the same as the conventional radiotherapy group, with a total of 23 doses of 2 Gy per session. The second stage is the combination of ART and PAPRT. ART uses a CT or PET/CT localization simulation to be performed again during the course of treatment (usually after completing the first part of 17-19 exposures) to generate a new adaptive plan, and after completing the first stage of 23 exposures, treatment is carried out according to the new adaptive plan. RAPAT uses ERCC1/2 biomarkers to predict the patient's radiation sensitivity and determine individualized radiation dose accordingly. ERCC1/2 biomarkers divided patients into 5 different radiosensitivity groups, corresponding to 5 different radiation doses (74, 66, 62, 54, and 50 Gy).
223811857|NCT07164885|RADIATION|Conventional radiotherapy|conventional radiotherapy
223811858|NCT07165067|DRUG|AP601|AP601 is a fully human bispecific antibody designed for the treatment of CD73-expressing solid tumours. Participants will receive a single infusion of AP601 once every 2 weeks (14 days) (Q2W) for up to 12 months. All doses of AP601 will be admistered intraveneously. The infusion time for all doses of AP601 in each patient will be approximately 60 to 120 minutes.
223811859|NCT07165080|DEVICE|smART+ REE|The two study devices will be used simultaneously: the patient's respiratory equipment will be connected directly to the smART+ REE module, and then the COSMED Q-NRG+ will be connected just downstream of that. See the diagram and key below:
223811860|NCT07166055|OTHER|Therapeutic dance|The protocol includes two sessions per week of therapeutic dance, during the months of October to May.
223811861|NCT07165184|OTHER|no intervention was applied as observation study|no intervention was applied as observation study
223811862|NCT07165834|BEHAVIORAL|"Treatment group. Take your sexuality back"|The intervention is trauma-sensitive and focus both on traumatized sexuality and positive sexuality. It incorporates regulatory skills to prevent re-traumatization when addressing sex-positive themes, thus accommodating a wide range of trauma-related symptoms, sexual shame, sexual dysfunctions, and regulation difficulties. The intervention integrates psychoeducation, exercises, reflections and sharing.
223811863|NCT07166419|BIOLOGICAL|Autologous Anti-CD19/CD20/CD22 CAR T-cells|Given IV
223811864|NCT07166419|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223811865|NCT07166419|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow biopsy and aspiration
223811866|NCT07166419|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy and aspiration
223811867|NCT07166419|PROCEDURE|Computed Tomography|Undergo PET/CT
223811868|NCT07166419|DRUG|Cyclophosphamide|Given IV
223811869|NCT07166419|PROCEDURE|Echocardiography Test|Undergo echocardiography
223811870|NCT07166419|DRUG|Fludarabine|Given IV
223811871|NCT07166419|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
223811872|NCT07166419|PROCEDURE|Pheresis|Undergo apheresis
223811873|NCT07166419|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
223835486|NCT06247085|DRUG|Pegtibatinase|Full Target Dose of pegtibatinase BIW
223835487|NCT06247085|OTHER|Placebo|volume-matched saline SC BIW
223835488|NCT03750773|DRUG|Gabapentin 600mg|Subject is given Gabapentin 600mg every 8 hours x 48 hours postoperatively for pain control.
223835489|NCT03750773|DRUG|Placebo oral capsule|Subject is given a Placebo capsule every 8 hours x 48 hours postoperatively for pain control.
223811874|NCT07164794|DRUG|Memantine Hydrochloride|"Memantine Hydrochloride is administered orally, once daily, in combination with the patient's ongoing standard of care treatment for metastatic castration-resistant prostate cancer (mCRPC).~The dosing follows a weekly titration schedule for the first three weeks to reach the maintenance dose.~Week 1: 5 mg once daily. Week 2: 10 mg once daily. Week 3: 15 mg once daily. Week 4 and onwards: 20 mg once daily. This intervention is being studied to evaluate its potential to reduce neuroendocrine differentiation and correct castration resistance in advanced prostate cancer."
223811875|NCT07165964|BEHAVIORAL|Personal interventions in Climateric|"The intervention group (IG) will participate in the climacteric care program. Each participant will receive a personal access code to a Moodle-based virtual campus, where they will find specially designed podcasts and videos, provided in addition to standard care. These digital pills have been developed by subject matter experts to support self-care during the climacteric stage and to promote positive mental health (PMH). Each resource is followed by a short quiz to assess engagement, knowledge acquisition, and adherence. A final satisfaction survey will also be included. IG participants will have two months of access to explore the content, complete the quizzes, and interact with the platform.~The intervention includes the following modules:~MODULE 1: INTRODUCTION TO THE CLIMACTERIC/MENOPAUSE MODULE 2: DIETARY HABITS AND PHYSICAL ACTIVITY MODULE 3: PSYCHOEMOTIONAL MANAGEMENT"
223811876|NCT07165821|BEHAVIORAL|Interpersonal Communication Skills Training Program|This program was developed based on DeVito's communication theory and integrated with the positive reinforcement-based interpersonal communication training developed by Thiengwiriyakul et al.(11) This program was evaluated by a panel of three experts-a psychiatrist, a psychiatric nurse, and a psychiatric nursing academic-who assessed content relevance, appropriateness, and language clarity. After revisions based on their feedback, the program achieved a Content Validity Index (CVI) of 0.93, exceeding the acceptable threshold.
223811877|NCT07165821|BEHAVIORAL|Usual care|Received routine psychiatric nursing care
223811878|NCT07164274|OTHER|Questionnaire|An online questionnaire that will be shared via online platforms for medical students and interns in the Middle East countries to fill.
223811879|NCT07166146|OTHER|Surgical interventions|By leveraging a wide array of surgical interventions - including endoscopic surgery, minimally invasive surgery combined with urokinase, and craniotomy - the TORCH registry intends to provide a granular view of early hematoma evacuation surgical interventions and their impact on patient recovery and quality of life.
223811880|NCT07165054|OTHER|atheroma plaque|Before the endarterectomy procedure, samples will be collected for study from some of the atheroma plaques routinely taken for pathology from patients.
223811881|NCT07165054|OTHER|Dental plaque|Subgingival plaque samples will be collected from patients before the endarterectomy procedure.
223811882|NCT07165548|DIETARY_SUPPLEMENT|Experimental Bar (Formulation 1) + Hypocaloric diet (10% energy restriction)|Participants will consume three satiating compound-enriched bars (formulation 1) daily, 30 minutes before breakfast, lunch, and dinner, as part of a 10% energy-restricted hypocaloric diet for 12 weeks.
223811883|NCT07165548|DIETARY_SUPPLEMENT|Experimental Bar (Formulation 2) + Hypocaloric diet (10% energy restriction)|Participants will consume three satiating compound-enriched bars (formulation 2) daily, 30 minutes before breakfast, lunch, and dinner, as part of a 10% energy-restricted hypocaloric diet for 12 weeks.
223811884|NCT07165548|DIETARY_SUPPLEMENT|Experimental Bar (Formulation 3) + Hypocaloric diet (10% energy restriction)|Participants will consume three satiating compound-enriched bars (formulation 3) daily, 30 minutes before breakfast, lunch, and dinner, as part of a 10% energy-restricted hypocaloric diet for 12 weeks.
223811885|NCT07165548|DIETARY_SUPPLEMENT|Placebo Bar + Hypocaloric diet (10% energy restriction)|Participants will consume three placebo bars daily, 30 minutes before breakfast, lunch, and dinner, as part of a 10% energy-restricted hypocaloric diet for 12 weeks.
223811886|NCT07165990|BEHAVIORAL|Food is Medicine (FIM) Intervention|"Intensive intervention phase - this phase starts at enrollment (\<=14 weeks) through 28 weeks of gestation (or at the time of GDM diagnostic test) and women i) receive a bi-weekly home delivery of a mixed box consisting of fresh produce, lean protein, and whole grains combined with culinary medicine-based nutrition education available in English and Spanish.~Maintenance phase - this phase starts at 29 weeks through 12 weeks postpartum, and women will receive biweekly deliveries of about 10-15 pounds of fresh produce (8-10 different kinds of produce) plus standard nutrition education. The box will be curated for prenatal nutrients needs and following American Diabetes Association guidelines."
223811887|NCT07165990|BEHAVIORAL|Standard of Care|Standard medical care provided at Harris Health for high-risk pregnant women, plus a voucher equal to the value of the produce and meals provided in the Food is Medicine (FIM) Intervention.
223811888|NCT07166744|OTHER|Biological : blood sampling|will be collected from the patient
223811889|NCT07166744|OTHER|nasopharyngeal swab|will be collected from the patient
223811890|NCT07166744|OTHER|Procedure : Lumbar puncture|will be collected from the patient
223811891|NCT07166744|OTHER|Behavioral : clinical, functional, cognitive and psychiatric evaluations|will be collected from the patient
223811892|NCT07166744|OTHER|MRI|will be done on the patient
223811893|NCT07166783|DRUG|Tolvaptan|single dose oral administration of 7.5mg Tolvaptan
223811894|NCT07164781|BIOLOGICAL|Bacillus clausii|The (Test group) will receive bacillus clausii (Enterogermina) 4 billion every 12h.
223811895|NCT07164781|OTHER|Sugar tablets|The (Control group) will receive placebo (sugar tablets).
223811896|NCT07165366|DIAGNOSTIC_TEST|Hydrogen Peroxide|
223811897|NCT07165132|DRUG|RYZ401|Ac-225
223811898|NCT07166796|DRUG|singe dose 15mg|succesfule screened subject, take single dose of 15mg Tolvaptan tablet with no feeding.
223811899|NCT07166796|DRUG|single dose 30mg|succesfule screened subject, take single dose of 30mg Tolvaptan tablet with no feeding.
223811900|NCT07166796|DRUG|single dose 60mg|succesfule screened subject, take single dose of 60mg Tolvaptan tablet with no feeding.
223811901|NCT07166796|DRUG|single dose 120mg|succesfule screened subject, take single dose of 120mg Tolvaptan tablet with no feeding.
223811902|NCT07166796|DRUG|multi dose 30mg|radomize 24 healthy adult male to 2 groups, 12 subjects each. One group take 30mg Tolvaptan. First day, with no feeding, take single 30mg dose, then start from day 3rd, take medication for 7 days. 8 days treatment in total.
223811903|NCT07166796|DRUG|multi dose 60mg|radomize 24 healthy adult male to 2 groups, 12 subjects each. One group take 60mg Tolvaptan. First day, with no feeding, take single 60mg dose, then start from day 3rd, take medication for 7 days. 8 days treatment in total.
223811904|NCT05836571|PROCEDURE|Biopsy Procedure|Undergo biopsy
223811905|NCT05836571|PROCEDURE|Biospecimen Collection|Undergo collection of blood and urine sample
223811906|NCT05836571|DRUG|Cabozantinib|Given PO
223811907|NCT05836571|PROCEDURE|Computed Tomography|Undergo CT
223811908|NCT05836571|BIOLOGICAL|Ipilimumab|Given IV
223811909|NCT05836571|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223811910|NCT05836571|BIOLOGICAL|Nivolumab|Given IV
223811911|NCT06321575|DEVICE|Golazo® Peripheral Atherectomy System (Golazo® Peripheral AS)|Golazo® Peripheral AS is a sterile, single-use percutaneous device that has two main components: 1) the Golazo® Accustrike atherectomy catheter, and 2) the Golazo® motorized drive unit (MDU) and is intended for use in atherectomy of the peripheral vasculature.
223811912|NCT06336980|BEHAVIORAL|Increasing Inclusionary Practices in Faith Communities|Congregational inclusion committees will participate in monthly training meetings for approximately 1 year. Each month a new inclusion practice will be introduced and then the committee will be asked to implement it in their congregation. The 11 practice areas are:1) assessing inclusion needs of members, 2) providing opportunities for members with serious mental illness (SMI) to take on roles and responsibilities, 3) creating an inclusion committee, 4) ensuring that members with SMI are welcomed to all events, 5) creating sensory friendly spaces, 6) offer participation opportunities in multiple formats, 7) adopt policies and practices to support inclusion, 8) using inclusive language, 9) ensure that external communications indicate the congregation is welcoming to all, 10) providing support to family members of individuals with SMI, and 11) conducing outreach to mental health support systems. Goals may vary per congregation based on their current practices, needs, and preferences.
223811913|NCT03993236|DRUG|Experimental: Rosuvastatin/Ezetimibe 10|"* Rosuvastatin/Ezetimibe 10/10mg~* orally administered once daily for 90 days"
223811914|NCT03993236|DRUG|Active Comparator: Rosuvastatin 20mg|"* Rosuvastatin 20mg~* orally administered once daily for 90 days"
223811915|NCT05192772|DEVICE|NPi200|Digital pupillometry performed during cardiopulmonary resuscutation (CPR) every CPR cycle end in case of not intubated patient, or every 2 minutes in case of intubated patient
223811916|NCT02935049|PROCEDURE|Endoscopic resection|Endoscopic resection with technique EMR piecemeal or hybrid technique EMR/ESD
223811917|NCT01369238|DEVICE|Bee Venom Acupuncture Therapy|1:4000, SC 1cc/day, 2\~3days/wk, for 1 month
223811918|NCT01369238|DRUG|zaltoprofen|80mg/Tab, per os 1Tab tid, for 2 months
223811919|NCT06203652|OTHER|Real-world regimen|The final personalized management strategy is determined based on current conventional treatment options, physician and patient preferences.The following protocols: chemotherapy, immunochemotherapy,Anti-cd20 monoclonal antibody, BTKi and so on
223811920|NCT01475695|DRUG|14C GSK2251052|1500 mg iv dose GSK2251052
223811921|NCT03812861|OTHER|CAMDS bundle|Cognitive aids for the assessment and management of deteriorating surgical patients (CAMDS). This bundle contains instructions for doctors and nursing staff to assess, manage and escalate care of deteriorating surgical patients. These management instructions will be derived from best practices that are linked with improved mortality and morbidity in surgical patients.
223811922|NCT02090335|BEHAVIORAL|In SHAPE|In SHAPE is a health promotion intervention consisting of a fitness club membership and a health promotion coach with basic certification as a fitness trainer, instruction on principles of healthy eating and nutrition, and training in tailoring individual wellness plans to the needs of persons with serious mental illness.
223811923|NCT02090335|BEHAVIORAL|Fitness Club Membership|Fitness club membership with education in using the exercise equipment.
223811924|NCT01679301|DEVICE|Pulse Dose (Sleep Mode)|SimplyGo Portable Oxygen Concentrator has two different modes of use 'Sleep Mode', or pulsed oxygen and continuous dose.
223811925|NCT01679301|DEVICE|Continuous Dose|SimplyGo Portable Oxygen Concentrator has two different modes of use 'Sleep Mode', or pulsed oxygen and continuous dose.
223811926|NCT02852122|DRUG|C-11 choline|This is an uncontrolled, open-labeled, non-randomized, prospective study. The study duration is expected to be completed in a period of 2 years. Up to 54 patients with primary prostate cancer and stratified as high risk group (PSA \> 20 ng/mL, or Gleason score 8-10, or clinical stage \>T2c) would be included.
223811927|NCT02646215|DEVICE|Threshold inspiratory muscle training|Inspiratory muscle training
223811928|NCT00110253|DRUG|S-Caine™ Peel (lidocaine and tetracaine cream 7%/7%)|S-Caine Peel is composed of a 1:1 eutectic mixture of 7% lidocaine, and 7% tetracaine, which was applied topically. The S Caine Peel was applied at approximately 1 mm in thickness and remained on the treatment area for 30 or 60 minutes
223811929|NCT02827318|DIETARY_SUPPLEMENT|Isomaltulose|75g Isomaltulose (low glycaemic load intervention)
223811930|NCT02827318|DIETARY_SUPPLEMENT|Glucose|75g Glucose (high glycaemic load intervention)
223811931|NCT02827318|DIETARY_SUPPLEMENT|Sweetened water|Sweetened water will be used as a control
223811932|NCT01529008|DRUG|Core decompression/PREOB® implantation|All patients will undergo a core decompression under general anesthesia combined with the implantation of PREOB® into the necrotic lesion (single administration).
223811933|NCT01529008|DRUG|Core decompression/placebo implantation|All patients will undergo a core decompression under general anesthesia combined with the implantation of placebo into the necrotic lesion (single administration).
223811934|NCT03077464|BEHAVIORAL|Behavioral nutrition education|Education aimed at improving knowledge, attitudes, and practices related to dietary intake, with a focus on impacting theorized mediators of nutrition-related behavior.
223811935|NCT01382602|BIOLOGICAL|AMDC-USR|AMDC-USR Treatment
223811936|NCT01382602|BIOLOGICAL|Placebo|Placebo treatment
223811937|NCT04191070|DEVICE|infrazygomatic miniscrew|class II correction by distalization using infrazygomatic crest miniscrew
223811938|NCT04191070|DEVICE|zygomatic miniplate|class II correction by distalization using zygomatic miniplate
223811939|NCT05079815|DIAGNOSTIC_TEST|CBC and serum ferritin|take blood sample for CBC and serum ferritin
223811940|NCT03813342|BEHAVIORAL|Gait training with visual feedback of joint kinematics|Gait training will be accomplished using a Woodway treadmill. The visual feedback will contain information about the real-time lower-limb joint angles. We will instruct participants to use the feedback to reach a target walking pattern.
223811941|NCT03601455|BIOLOGICAL|Durvalumab|Given IV
223811942|NCT03601455|RADIATION|External Beam Radiation Therapy|Undergo EBRT
223811943|NCT03601455|BIOLOGICAL|Tremelimumab|Given IV
223811944|NCT00007280|DEVICE|Bioengineered skin|
223811945|NCT02401373|BIOLOGICAL|Ad5-EBOV|intramuscular injection
223811946|NCT05537480|DEVICE|Continuous glucose monitoring device|Continuous glucose monitoring device will be worn by participants during several periods.
223811947|NCT05968040|PROCEDURE|Inferior vena cava diameter measurement by ultrasonography|The diameter of the inferior vena cava will be measured at 2 cm close to the entrance of the right atrium. Ultrasound images will be taken at the end of inspiration (Dmax) and at the end expiration (Dmin) to calculate the inferior vena cava dispensability index (dIVC), and will be recorded before and after fluid challenge test of 5 ml/kg crystalloid within 15 min. The IVC distensibility index (IVC-DI) will be calculated using the formula: IVC-DI = IVCmax - IVCmin/ IVCmin. The indices will be expressed as a percentage.
223811948|NCT05968040|PROCEDURE|difference between peak velocities of carotid artery by ultrasound|"Carotid ultrasound images will be obtained from the left CCA in both short-axis and long-axis views by experienced sonographers. The patient will be in supine position, with the head rotated slightly to the right. A broadband linear array transducer 12-4 MHz and the short-axis view will be used for orientation and identification of the CCA. Next, in the long-axis view, Peak Waveform Doppler signals will be acquired by placing a 0.5 mm calliper at the center of the vessel and parallel to the vessel walls, approximately 2 cm proximal from the carotid bifurcation. Insonation-angles between the ultrasound beam and blood flow will be maintained.~ΔVpeakCCA = (MaxCDPV-MinCDPV)+(MaxCDPV+MinCDPV)x100"
223811949|NCT05968040|PROCEDURE|cardiac output be transthoracic echocardiography|"CO will be recorded as baseline measure and after fluid administration. If CO increased more than 15%, it will be considered fluid responder. Increase in cardiac output = (cardiac output after first fluid challenge - cardiac output before)/cardiac output before) X 100.~TTE will be used to measure LTOT and VTI x HR."
223811950|NCT00685321|DEVICE|H1 deep TMS coil|20 daily deep rTMS treatment
223811951|NCT00685321|DEVICE|Sham|inactive treatment
223811952|NCT05942755|OTHER|Concurrent evaluation of blood and CSF ionograms to determine if there is a correlation between CSF change and the development of hyoponatremia between day 0 and day 14.|"Blood samples are taken as part of routine care on arrival of patients and then every 24 hours if an arterial catheter is in place; otherwise, every Monday, Wednesday and Friday. Samples from the EVD will be taken on Day 0 and then every 24 hours. A urine ionogram is also performed every 24 hours as part of the usual management to regulate water, sodium and potassium intake by enteral or parenteral routine.~The ionic composition of CSF from patients with SAH will be compared with a control population of patients hospitalized with normal pressure hydrocephalus. A lumbar puncture is performed in the operating room to evacuate the chronic CSF effusion in the ventricles (hydrocephalus), before performing an intrathecal perfusion test. 1ml of the CSF thus collected will be analyzed to determine its ionic composition"
223811953|NCT02225379|DEVICE|Hypo-Sense (non invasive sensor)|Parallel measurements of capillary blood glucose using reference methods (both capillary glucometer and continuous sensor) and data generated by the non- invasive study device during approximately 4 hours, in which a hypoglycemic event will be induced.
223811954|NCT00199498|DEVICE|Apical RV lead placement|RV lead implanted ( according to randomization )at the apex
223811955|NCT00199498|DEVICE|Septal RV lead placement|RV lead is implanted (according to randomization), on septum
223811956|NCT02571322|DEVICE|HyperVibe Whole Body Vibration training device|Standing on the HyperVibe platform during WBV training will cause repetitive upward movements of platform to be felt by participant.Thus the participant will feel a whole body vibration, as the name of training implies. Each session will last approximately fifteen minutes.
223811957|NCT02571322|OTHER|Aerobic Exercise|Aerobic exercise session will last approximately thirty minutes. Starting training intensity will be specific to each participant based on his/her baseline fitness level.
223811958|NCT00006008|DRUG|arsenic trioxide|
223811959|NCT00657514|DRUG|Ranolazine|500mg tablet po bid up to 1000mg (2 500mg tablets) po bid
223811960|NCT00657514|DRUG|Placebo|1 tablet po bid up to 2 tablets po bid if tolerated
223811961|NCT03921346|DEVICE|Mobile device app (PedAMINES™) 1st drug|To prepare 0.01 mg/kg epinephrine (0.1 mL/kg of 0.1 mg/mL concentration)
223811962|NCT03921346|DEVICE|Mobile device app (PedAMINES™) 2nd drug|To prepare 0.1 mg/kg midazolam (of 5 mg/mL concentration ad 10 mL sodium chloride 0.9%)
223811963|NCT03921346|DEVICE|Mobile device app (PedAMINES™) 3rd drug|To prepare 4 mL/kg dextrose 10%
223811964|NCT03921346|DEVICE|Mobile device app (PedAMINES™) 4th drug|To prepare 1 mmol/kg sodium bicarbonate (of 4.2% = 0.5 mmol/L concentration)
223811965|NCT03921346|DEVICE|Conventional method 1st drug|To prepare 0.01 mg/kg epinephrine (0.1 mL/kg of 0.1 mg/mL concentration)
223811966|NCT03921346|DEVICE|Conventional method 2nd drug|To prepare 0.1 mg/kg midazolam (of 5 mg/mL concentration ad 10 mL sodium chloride 0.9%)
223811967|NCT03921346|DEVICE|Conventional method 3rd drug|To prepare 4 mL/kg dextrose 10%
223811968|NCT03921346|DEVICE|Conventional method 4th drug|To prepare 1 mmol/kg sodium bicarbonate (of 4.2% = 0.5 mmol/L concentration)
223811969|NCT02964455|DRUG|Docetaxel|5 mg/m², 10 mg/m², or 15 mg/m² given intravenously twice weekly (depending on dose under investigation at time of registration) on days 1,4 (depending on allocation of treatment schedule) for 4-6 weeks during chest radiation
223811970|NCT02964455|DRUG|Nedaplatin|5 mg/m², 10 mg/m², or 15 mg/m² given intravenously twice weekly (depending on dose under investigation at time of registration) on days 1,4 (depending on allocation of treatment schedule) for 4-6 weeks during chest radiation
223811971|NCT02964455|RADIATION|chest radiation|continuous chest radiation at 64 Gy/32f
223811972|NCT01177514|DRUG|Gabapentin|Gabapentin PO. (300MG) 1 capsule the night before surgery, q12hrs the day of surgery and q8hrs for the firt 3 postoperative days.
223811973|NCT01177514|DRUG|Sugar pill|Sugar pill. One capsule given the night before surgery, q12hrs on the day of surgery and q8hrs for the first 3 postoperative days.
223811974|NCT01682213|DRUG|Dabrafenib|Following definitive surgical resection, eligible patients will receive dabrafenib at 150 mg twice a day by mouth for 4 cycles (± 5 days). One cycle is 28 days.
223811975|NCT05838001|PROCEDURE|Wire-guided localization and marker clip localization|Positioning guide wire and marker clip in the center of the breast lesion
223811976|NCT05838001|PROCEDURE|marker clip localization|Positioning marker clip in the center of the breast lesion
223811977|NCT05138445|BEHAVIORAL|FAME-W self-management intervention|FAME-W is an occupational therapy led, four-week group based self-management intervention. It focuses on providing people with IA skills and confidence to manage demands of their employment and daily life through education on IA, self-management techniques, managing symptoms of fatigue, pain and stress and managing physical and mental health.
223811978|NCT05138445|BEHAVIORAL|FAME-W Handbook|Individuals in this arm receive a self-guided FAME-W handbook containing the same information as that covered in the four week FAME-W program
223811979|NCT05570643|DRUG|LPS|This is a non-investigational product. LPS is used as challenge agent to achieve a controlled inflammatory state.
223811980|NCT05570643|DRUG|Placebo|Injection of NaCl 0.9%.
223811981|NCT01035164|DRUG|F-18 FEDAA1106 (BAY85-8101)|Alzheimer Disease patients: Single intravenous bolus injection of 250 MBq BAY85-8101 on day one of the treatment period, PET
223811982|NCT01035164|DRUG|F-18 FEDAA1106 (BAY85-8101)|Healthy volunteers for brain imaging: Single intravenous bolus injection of 250 MBq BAY85-8101 on day one of the treatment period, PET
223811983|NCT01035164|DRUG|F-18 FEDAA1106 (BAY85-8101)|Healthy volunteers for whole body imaging: Single intravenous bolus injection of 185 MBq BAY85-8101, whole body PET for evaluation of effective dose, kinetics of BAY85-8101 in blood
223811984|NCT02388503|DIETARY_SUPPLEMENT|no added fruit extract|
223811985|NCT02388503|DIETARY_SUPPLEMENT|fruit extract|
223811986|NCT02388503|DIETARY_SUPPLEMENT|fruit extract|
223811987|NCT02388503|DIETARY_SUPPLEMENT|fruit extract|
223811988|NCT02388503|DIETARY_SUPPLEMENT|fruit extract|
223811989|NCT00742079|DRUG|D-cycloserine|Single, fixed 50-mg dose of D-cycloserine administered 1 hour prior to a CBT session
223811990|NCT00742079|BEHAVIORAL|Cognitive Behavioral Therapy|One-hour talk therapy session with a trained clinician aimed at increasing cognitive flexibility by examining alternative explanations to everyday situations
223811991|NCT05687955|OTHER|Hip Exercise Program|The exercise intervention is being implemented 3 times per week. Two sessions can be completed at home by the participant, and one session per week will be attended by a physiotherapist that will monitor exercise technique and progress the exercise program for each participant. The exercise protocol has been specifically designed to focus on hip rehabilitation appropriate for circus performance. The exercise program will involve hip strength exercises in the sagittal, coronal and transverse planes using weights and elastic bands (Theraband). It will also include trunk strength and postural correction exercises to address swayback posture which is a common clinical presentation in those with hip dysplasia.
223811992|NCT03767179|DIAGNOSTIC_TEST|study|procalcitonin, sedimentation, CRP, leukocyte identification
223811993|NCT02267005|DIETARY_SUPPLEMENT|Creapure|Patients will be prescribed a creapure supplement by weight, to be taken 3x/day for the duration of the trial. They will be randomized to an active product start time using a multiple baseline design.
223811994|NCT02267005|DIETARY_SUPPLEMENT|Glucose Tablet|Patients will be prescribed the placebo supplement by weight, to be taken 3x/day for the duration of the trial. They will be randomized to an active product start time using a multiple baseline design.
223811995|NCT06257368|DEVICE|Coloplast TFL Drive|Thulium Fiber laser
223811996|NCT01264380|DRUG|RO5185426|Single oral dose, fasted
223811997|NCT01264380|DRUG|RO5185426|Single oral dose, with high fat meal
223811998|NCT01264380|DRUG|RO5185426|Continuous administration, orally twice daily
223811999|NCT04269018|BEHAVIORAL|Cancer specific Mobile text message|The intervention is cancer specific lifestyle mobile text messages daily for 2 months
223812000|NCT04269018|BEHAVIORAL|General health messages|Daily text related with general health message
223812001|NCT01147822|DRUG|Pazopanib|800 mg administered once daily orally continuous dosing
223812002|NCT01147822|DRUG|Sunitinib|50 mg sunitinib to be administered in 6-week cycle: 50 mg orally daily for 4 weeks followed by 2 weeks off treatment
223812003|NCT04762329|OTHER|Manage My Pain (MMP) digital pain app group|To evaluate the extent of patient engagement with the Manage My Pain (MMP) digital application when used in a clinical setting
223812004|NCT03592472|DRUG|Pazopanib|All patients will receive pazopanib at a starting dose of 800 mg by mouth (p.o.) daily on Days 1 to 28 of each treatment cycle. Patients should be instructed to take their once- daily oral dose of pazopanib at the same time each morning. Each dose of pazopanib should be taken with an 8 oz/240 mL glass of water either 1 hour before or 2 hours after a meal. Patients should be instructed to swallow the tablets whole and not chew them.
223812005|NCT03592472|DRUG|Abexinostat|The starting dose and schedule of abexinostat will be 80 mg p.o. BID on Days 1 to 4, 8 to 11, and 15 to 18 of every 28-day cycle, 2 doses 4 hours apart. Each dose of abexinostat should be taken with an 8 oz/240 mL glass of water at least half an hour before meals or more than 2 hours after a meal and must be 4 hours apart. Patients should be instructed to swallow the tablets whole and not chew them.
223812006|NCT03592472|OTHER|Placebo|The starting dose and schedule of abexinostat matching placebo will be 80 mg p.o. BID on Days 1 to 4, 8 to 11, and 15 to 18 of every 28-day cycle, 2 doses 4 hours apart. Each dose of placebo should be taken with an 8 oz/240 mL glass of water at least half an hour before meals or more than 2 hours after a meal and must be 4 hours apart. Patients should be instructed to swallow the tablets whole and not chew them.
223812007|NCT06214078|DIETARY_SUPPLEMENT|nicotinamide mononucleotide|Nicotinamide mononucleotide (NMN), a bioactive substance found in a variety of foods, is a precursor for the synthesis of nicotinamide adenine dinucleotide (NAD+). NAD+ plays a crucial role in a variety of biological processes including cell death, senescence, gene expression, neuroinflammation, and DNA repair.
223812008|NCT06214078|OTHER|placebo|The placebo mimicked the appearance and properties of nicotinamide mononucleotide(NMN) enteric-coated capsules. The specifications, usage and dosage of placebo were the same as those of NMN.
223812009|NCT01683760|DRUG|Fluconazole|Prophylactic fluconazole administration in VLBW infants
223812010|NCT00530803|DRUG|EMLA Cream|60 minutes x1
223812011|NCT00530803|COMBINATION_PRODUCT|Synera Patch|20 minutes x1
223812012|NCT04210414|OTHER|Embryo transfer|Transfer of only one embryo
223812013|NCT05356598|OTHER|Authority-delivered Health promotion video|A video delivered by a US Army Lieutenant Colonel (authority figure) encouraging participants to seek help for musculoskeletal injuries experienced while in ROTC.
223812014|NCT05356598|OTHER|Peer-delivered Health Promotion Video|A video delivered by a US Army ROTC cadet (peer) encouraging participants to seek help for musculoskeletal injuries experienced while in ROTC.
223812015|NCT05356598|OTHER|Control Group Video|Video of a US Army First Lieutenant squatting, bench pressing, and deadlifting with voiceover. No mention of musculoskeletal injuries or help-seeking behavior.
223812016|NCT06235658|BEHAVIORAL|Gentle Yoga|Participants will attend two virtual 60-minute gentle yoga sessions per week for 12 weeks. Each session will be conducted via videoconference using the Zoom platform, with participants joining from their homes.
223812017|NCT00429663|DEVICE|reamed, interlocking intramedullary nail|Standard of care device for femur fracture repair
223812018|NCT00429663|DEVICE|locking periarticular plate|Standard of care device for femur fractures
223812019|NCT03590600|DRUG|BTZ-043|Powder and solvent for oral suspension
223812020|NCT03590600|DRUG|Placebo|Matching placebo: powder and solvent for oral suspension
223812021|NCT05383417|DEVICE|EndoClip|Clip attached to mid portion of the endotracheal tube.
223812022|NCT02466646|DRUG|Klorhex® Gel, rinse and spray|Initial periodontal treatment was performed in 2 sessions with application of chlorhexidine to the intra-oral niches within 24 hours (Klorhex® Gel 1% for 10 minutes, Klorhex® Spray 0,2% and Klorhex® rinse 0,2% for 3 weeks).
223812023|NCT02466646|PROCEDURE|Conventional IPT|Initial periodontal treatment was performed in a quadrant-wise manner at 1-week intervals.
223812024|NCT02466646|PROCEDURE|Full-mouth IPT|Initial periodontal treatment was performed in 2 sessions within 24 hours.
223812025|NCT00624611|PROCEDURE|Residual pump blood management post aortic cannula removal|Residual pump blood will be maximally hemoconcentrated by further ultrafiltation within the CPB machine. Resulting hematocrit will be approximately 0.4. The total residual pump blood volume, approximately 300ml, will be reinfused over one hour, beginning 15 minutes after removal of the aortic cross clamp. Additional protamine sulfate will be given every 30 minutes during the infusion, .03 mg/ml of residual pump blood. Procedures in this group do not deviate from current standard practice.
223812026|NCT00624611|PROCEDURE|Residual pump blood management post aortic cannula removal|All residual pump blood will be processed with a bedside red cell washing device (Cell Saver). The resulting total volume of concentrated red cells will be infused over one hour, beginning 15 minutes after removal of the aortic cross clamp. Administration of additional protamine is not required due to the low concentrations of heparin in the resulting product.
223812027|NCT06537011|DRUG|AK112|"1. The patients are given AK112 combined with AP regimen every 3 weeks for 3 cycles before operation.~2. After the neoadjuvant therapy ,the patients will be assessed and be commanded surgery.~3.4-6 weeks after the surgery, the patients will be given chemoradiotherapy or radiotherapy alone decided on the conditon after surgery.~4.The participants will receive AK112 for 14 cycles after surgery."
223812028|NCT03261271|BEHAVIORAL|Weight Loss Program|Program involves one-on-one coaching, diet meal plan, and physical activity plan.
223812029|NCT03261271|BEHAVIORAL|Standardized educational flyer|"The American Institute for Cancer Research handout Nutrition and the Cancer Survivor will be provided to participants."
223812030|NCT03261271|BEHAVIORAL|Weight Maintenance Program|Post-surgery program involves group support sessions, phone check-ins, and diet and exercise monitoring.
223812031|NCT05440513|DEVICE|Renal Pelvic Denervation (bilateral)|Using the natural orifice of the urethra, the ureters are accessed (bilaterally and in sequence), to allow for an ablation device to be placed into the renal pelvis where RF energy is delivered to ablate renal nerves.
223812032|NCT01373216|DRUG|Exenatide|Perioperative continuous i.v. administration of exenatide lasting for 72 hours - 40 ng/min for initial 30 min, 20 ng/min for remaining 71.5 hours
223812033|NCT04897425|DEVICE|Mindful SensoriMotor Therapy Enhanced with Brain Modulation|"Hardware and software for myoelectric pattern recognition and sensory training developed at the Center for Bionics and Pain Research.~tES by Neuroelectrics"
223812034|NCT05856214|BEHAVIORAL|Couple-Based Violence Prevention education(CBVPE)|Couples in the intervention group will receive training on violence against women including intimate partner violence, types, and consequences of intimate partner violence during pregnancy, managing triggers of intimate partner violence, healthy relationships, the role of male partners during pregnancy, and couples communication and problem-solving skills. Training will be provided every fourth week by trained health extension workers for consecutive six months.
223812035|NCT06843512|OTHER|GLP-1 Medication Initiation|One visit before starting GLP-1 medication and one visit 3 months after. No other changes administered between visits.
223812036|NCT03911505|BIOLOGICAL|Cipaglucosidase Alfa|Enzyme Replacement Therapy via intravenous infusion
223812037|NCT03911505|DRUG|Miglustat|Participants received Cipaglucosidase Alfa (ATB200) co-administered with Miglustat(AT2221)
223812038|NCT00147940|PROCEDURE|Acoustic rhinometry (procedure)|
223812039|NCT01932697|DRUG|Docetaxel|Given IV
223812040|NCT01932697|RADIATION|Hyperfractionation|Undergo hyperfractionated IMRT
223812041|NCT01932697|RADIATION|Intensity-Modulated Radiation Therapy|Undergo hyperfractionated IMRT
223812042|NCT01932697|OTHER|Laboratory Biomarker Analysis|Correlative studies
223812043|NCT01932697|OTHER|Quality-of-Life Assessment|Ancillary studies
223812044|NCT01815788|DEVICE|Use of a personal sound amplifying device = TeoFirst|
223812045|NCT02274454|DRUG|Oxytocin|Experiments will be conducted with some myometrial strips pretreated with oxytocin, and others without any oxytocin pretreatment
223812046|NCT02274454|DRUG|Calcium|Calcium will be applied to the myometrial strips in 3 concentrations; 1.25mM (low), 2.5mM (normal) and 5.0mM (high). Myometrial strips will be either oxytocin pretreated, or non-oxytocin pretreated.
223812047|NCT01079559|DEVICE|Simplex™ P with Tobramycin|All patients will receive preoperative antibiotics administered within the hour prior to surgery.All patients will undergo a cemented total knee replacement (both femoral and tibial components) with the type of implant left to the discretion of the surgeon. The patella may or may not be resurfaced depending on indication and preference. All patients will receive one of the two study cements (Simplex™ P with Tobramycin or Simplex™ P) in a blinded fashion; all cement vials will be similar in size and shape and the cement will be similar in odour, color and texture. No additional antibiotics will be added to the cement. Surgeons can use their preferred cement preparation technique (i.e. manual or vacuum mixing). The use of a suction drain will depend on surgical indication and preference.
223812048|NCT01079559|DEVICE|Simplex™ P|All patients will receive preoperative antibiotics administered within the hour prior to surgery.All patients will undergo a cemented total knee replacement (both femoral and tibial components) with the type of implant left to the discretion of the surgeon. The patella may or may not be resurfaced depending on indication and preference. All patients will receive one of the two study cements (Simplex™ P with Tobramycin or Simplex™ P) in a blinded fashion; all cement vials will be similar in size and shape and the cement will be similar in odour, color and texture. No additional antibiotics will be added to the cement. Surgeons can use their preferred cement preparation technique (i.e. manual or vacuum mixing). The use of a suction drain will depend on surgical indication and preference.
223812049|NCT03967769|DEVICE|High Flow nasal Cannula|Apnoeic Oxygenation by High Flow Nasal Cannulae
223812050|NCT01674309|DRUG|FOLFORINOX|INTRAVENOUS administration
223812051|NCT01939873|BEHAVIORAL|KRISTELLER|
223812052|NCT02609217|OTHER|Questionnaires and interviews|
223812053|NCT03298230|BEHAVIORAL|REmotely SuPervised Exercise Training|As described in the Arms section.
223812054|NCT03298230|BEHAVIORAL|Supervised Exercise Training|As described in the Arms section.
223812055|NCT06304350|DRUG|Combination of pembrolizumab and platinum containing dual drugs|After 2 courses of treatment with a combination of pembrolizumab and platinum containing dual drugs (albumin paclitaxel+carboplatin), surgery was performed and pembrolizumab immunomaintenance therapy continued after surgery
223812056|NCT03065296|BEHAVIORAL|Musculoskeletal (MSK) Prescription Didactic Lectures|In between phase 1 and phase 2 there will be a series of didactic lectures to educate resident on home exercise prescription and get them familiarized with the handouts.
223812057|NCT03065296|OTHER|Musculoskeletal (MSK) home exercise hand-outs|In between phase 1 and phase 2, residents will use home exercise hand-outs readily available and educate their patients in regards to those.
223812058|NCT05771779|BIOLOGICAL|Oral Cholera Vaccine (OCV)|Bivalent, Killed, Whole Cell Oral Cholera Vaccine
223812059|NCT05771779|BIOLOGICAL|Typhoid Conjugate Vaccine (TCV)|Vi-polysaccharide conjugated to tetanus toxoid, Vi-TT
223812060|NCT05771779|BIOLOGICAL|Measles and Rubella (MR)|Live attenuated vaccine
223812061|NCT04156165|DIETARY_SUPPLEMENT|VLCD-Active|Lighter life formula products supplied to subjects, four sachets pr day. Dietetic advise given regularly.
223812062|NCT04156165|OTHER|Maintenance-Active|Weight loss maintenance diet with high protein and low glycemic index and load, high in fiber and whole grain, daily including 150 g minced beef.
223812063|NCT04156165|DIETARY_SUPPLEMENT|VLCD-Control|Lighter life VLCD products
223812064|NCT04156165|OTHER|Maintenance-Control|Weight loss maintenance diet with moderate protein and low glycemic index and load, high in fiber and whole grain, daily including 25 g minced beef.
223812065|NCT03716375|DRUG|Intrapleural Medications|urokinase
223812066|NCT02311205|PROCEDURE|Conventional Transarterial Chemoembolization (TACE)|On demand conventional TACE will be performed in all the patients after enrollment and can be continued until intrahepatic CR, TACE failure or consent withdrawal. Sorafenib will be started 3-7 days after the first and each subsequent TACE and stopped one day before next TACE and will be continued until sorafenib failure, consent withdrawal or condition worsening by clinical decision.
223812067|NCT02311205|DRUG|sorafenib|Sorafenib will be started 3-7 days after the first and each subsequent TACE and stopped one day before next TACE and will be continued until sorafenib failure, consent withdrawal or condition worsening by clinical decision.
223812068|NCT03420781|DRUG|Placebo|Placebo injected twice daily
223812069|NCT03420781|DRUG|Relamorelin|Relamorelin 10 μg injected twice daily
223812070|NCT00489710|DRUG|talabostat mesylate|
223812071|NCT00489710|BIOLOGICAL|enzyme inhibitor therapy|
223812072|NCT00489710|DIAGNOSTIC_TEST|flow cytometry|
223812073|NCT00489710|DIAGNOSTIC_TEST|laboratory biomarker analysis|
223812074|NCT00489710|BIOLOGICAL|non-specific immune-modulator therapy|
223812075|NCT00246337|DRUG|Comparator: Placebo|Placebo to match assigned treatment arm; one orally-administered dose
223812076|NCT00246337|DRUG|MK0974|MK0974 25 mg; one orally-administered dose
223812077|NCT00246337|DRUG|MK0974|MK0974 50 mg; one orally-administered dose
223812078|NCT00246337|DRUG|MK0974|MK0974 100 mg; one orally-administered dose
223812079|NCT00246337|DRUG|MK0974|MK0974 200 mg; one orally-administered dose
223812080|NCT00246337|DRUG|MK0974|MK0974 300 mg; one orally-administered dose
223812081|NCT00246337|DRUG|MK0974|MK0974 400 mg; one orally-administered dose
223812082|NCT00246337|DRUG|MK0974|MK0974 600 mg; one orally-administered dose
223812083|NCT00246337|DRUG|Rizatriptan|Rizatriptan 10 mg; one orally-administered dose
223812084|NCT03831984|DRUG|0,09% Bromfenac|topical 0,09% Bromfenac, one drop twice daily 3 days before surgery
223812085|NCT03831984|DRUG|0,1% sodium hyaluronate|topical 0,1% sodium hyaluronate, one drop twice daily 3 days before surgery
223812086|NCT02319226|OTHER|Transplantation from an HLA-identical sibling donor|The study will include a cohort of 60 patients transplanted from an HLA-identical sibling donor.
223812087|NCT04567264|DEVICE|StimRouter®, Self-activated and self-controlled neuromodulation device (Bioness Inc, CE0086).|"Regimen 1 (weeks 0-12): one stimulation every 2 days, for a duration of 30 minutes each.~Regimen 2 (weeks 12-24): Three stimulation treatments per week, for a duration of 30 minutes each."
223812088|NCT02731625|OTHER|Kettlebell training|Kettlebell training will be performed in 30 second work:rest intervals. Total training time will progress from 10 minutes at the beginning of the study to 20 minutes at the end.
223812089|NCT02731625|OTHER|Army Physical Readiness Training|Army Physical Readiness Training per Army Field Manual 7-22
223812090|NCT00229957|BEHAVIORAL|Occupational therapy|
223812091|NCT00229957|BEHAVIORAL|Physiotherapy|
223812092|NCT00229957|BEHAVIORAL|Self-management|
223812093|NCT00338598|DRUG|Glycine|Glycine, 0.8 gr per kg given in two daily doses
223812094|NCT00338598|DRUG|placebo|
223812095|NCT05983159|DRUG|Alpelisib|Oral alpha-specific PI3-kinase inhibitor
223812096|NCT05983159|DRUG|Mirdametinib|An investigational oral MEK inhibitor
223812097|NCT04447430|DEVICE|bright light|treat patients with bright light, 30 min per day, 7 times per week, over 6 weeks
223812098|NCT04447430|DEVICE|dim red light|treat patients with dim red light, 30 min per day, 7 times per week, over 6 weeks
223812099|NCT01226511|DRUG|Duloxetine|Administered orally
223812100|NCT01226511|DRUG|Placebo|Administered orally
223812101|NCT04177225|PROCEDURE|Trans thoracic Ultrasound Examination|Ultrasound examination of cardiac function before and after induction of general anesthesia.
223812102|NCT04177225|OTHER|Intravenous fluid administration|Intravenous fluids will be administered as a bolus in response to standard clinical indications
223812103|NCT03424590|DEVICE|Clearblue Connected Ovulation Test System|Urinary LH test to predict ovulation
223812104|NCT05605210|DEVICE|Electric stimulation|Neuromuscular electrical stimulation will be applied at two sites to induce fatigue with stimulation frequency specified at the Arm/Group Descriptions. The electrical stimulation parameters to generate the fatigue protocol will be: biphasic pulsed current, pulse duration of 2 ms, and on:off times of 5:10s. The fatigue protocol will be applied with a current intensity sufficient to generate an evoked torque at a level of 20% of the MVIC, which will be maintained throughout the protocol. NMES will be maintained until reaching an intervention time of 20 minutes, generating 80 evoked contractions.
223812105|NCT05777967|BIOLOGICAL|human autologous synovial stem cells|A single injection of 1.5 to 9.0 x 10\^7 human autologous synovial stem cells under arthroscopy
223812106|NCT03620422|OTHER|Mannitol|Mannitol-Induced Cough Challenge
223812107|NCT03620422|DRUG|Salbutamol 5mg/mL|Nebulized salbutamol given prior to Mannitol-Induced Cough Challenge
223812108|NCT03620422|OTHER|Sodium Chloride 0.9% Inhl 3Ml|Nebulized 0.9% saline given prior to Mannitol-Induced Cough Challenge
223812109|NCT02696564|DRUG|Losartan|50mg once per day for two weeks,followed by 100mg once per day for 46 weeks if increased dose tolerated
223812110|NCT02696564|DRUG|Placebo|one capsule per day for two weeks, followed by two capsules per day for 46 weeks
223812111|NCT01840384|DIETARY_SUPPLEMENT|Multi-micronutrients|
223812112|NCT01840384|DIETARY_SUPPLEMENT|Maltodextrin and Lactose|
223812113|NCT04302376|DIAGNOSTIC_TEST|Cather-related thrombosis ultrasonography|Doppler and compression ultrasound to detect catheter-related thrombosis
223812114|NCT02850822|DRUG|Demethylation drug|Demethylation drug,such as Decitabine
223812115|NCT02850822|DRUG|Chemotherapy regimen|Chemotherapy regimen,such as CAG, G-CSF 5-10ug/kg/day on days 4 and 17；Aclacinomycin 7mg/m2/day on days 4 and 11；Cytarabine 20mg/m2/day on days 4 and 17.
223812116|NCT01337986|DRUG|Dalfampridine/Placebo|Weeks 1-3: Dalfampridine 10mg (1 tablet) every 12 hours for 3 weeks. Weeks 4-5: 2 weeks of wash-out. Weeks 5-8: Placebo (sugar pill) 1 tablet every 12 hours for 3 weeks.
223812117|NCT01337986|DRUG|Placebo/Dalfampridine|Weeks 1-3: Placebo (sugar pill) 1 tablet every 12 hours for 3 weeks. Weeks 4-5: 2 weeks of wash-out. Weeks 6-8: Dalfampridine 10mg (1 tablet) every 12 hours for 3 weeks.
223812118|NCT02835872|OTHER|dietary fiber|Fiber containing drink mixes and crackers to be consumed with meals (1g fiber/serving) three times per day for a total of 3 g fiber.
223812119|NCT01815528|DRUG|Catumaxomab|"Catumaxomab dosing comprises the following four intraperitoneal (i.p.) infusions via an i.p.-port or an indwelling catheter:~1. 10 µg on day 0~2. 20 µg on day 3~3. 50 µg on day 7~4. 150 µg on day 10"
223812120|NCT06449092|DIAGNOSTIC_TEST|Lipid profile|carotid intima media thickness
223812121|NCT02344446|OTHER|Skilled Therapy|Active physical therapy treatment
223812122|NCT03113084|BIOLOGICAL|Sodium Heparin UQ subcutaneous drug administration|The participants will be hospitalized one day to receive the Sodium heparin UQ experimental medication or Sodium heparin FK comparator medication. They will receive the Subcutaneous medication and start the blood collection at the programmed time. After 7 days, the participants will return to receive the other medication and have their blood collected. The last visit will be to collect safety datas
223812123|NCT03113084|BIOLOGICAL|Sodium Heparin FK subcutaneous drug administration|The participants will be hospitalized one day to receive the Sodium heparin FK comparator medication or Sodium heparin UQ experimental medication. They will receive the subcutaneous medication and start the blood collection at the programmed time. After 7 days, the participants will return to receive the other medication and have their blood collected. The last visit will be to collect safety datas
223812124|NCT00970125|BEHAVIORAL|video|outline of the goals of care
223812125|NCT02127086|OTHER|Intervention Group|The PAIN Algorithm and analgesic order sets to be used by nurses to assess and reassess pain and opioid-related side effects will include orders for: 1) managing pain based on MOPAT Behavioral Dimension cut scores, 2) pre-medication before painful procedures, 3) titration of drugs, and 4) managing major opioid side effects. The order sets will start with small doses of opioids that will be titrated upwards for peak analgesic effect and allow for adjustment for patient characteristics and type of pain while simultaneously monitoring for and treating side effects.
223812126|NCT03830203|DRUG|BAT1806|8 mg/kg
223812127|NCT03830203|DRUG|Actemra(EU-licensed)|8 mg/kg
223812128|NCT00273702|DRUG|N-Acetyl Cysteine|
223812129|NCT04061590|DRUG|Cisplatin|Given IV
223812130|NCT04061590|BIOLOGICAL|Pembrolizumab|Given IV
223812131|NCT04061590|DRUG|Pemetrexed|Given IV
223812132|NCT04061590|DRUG|Pemetrexed Disodium|Given IV
223812133|NCT04061590|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
223812134|NCT03707639|DRUG|Apatinib|Apatinib (500 mg qd p.o.) until disease progression or intolerable toxicity or refused by the patients.
223812135|NCT03707639|DRUG|POF|The POF regimen consisted of a 3-hour infusion of paclitaxel (135 mg/m2) followed by oxaliplatin (85 mg/m2) and Calcium Levofolinate (200 mg/m2).Subsequently, a 46-hour infusion of fluorouracil (2400 mg/m2) was administered using an ambulatory pump, repeating the cycle every 14 days.
223812136|NCT01839422|BEHAVIORAL|Memory assessment|Cognitive assessment : Neuropsycological tests, learning sessions of new stimuli.
223812137|NCT01839422|OTHER|Brain imaging examination MRI|Brain imaging examination : Structural and functional MRI to compare differences between each sample.
223812138|NCT01520402|DRUG|Warfarin|Enrolled subjects on a fixed vitamin K diet followed a standard warfarin dosing algorithm with daily point-of-care INR checks to goal INR ≥ 2 for two consecutive days, then to baseline INR≤1.2 off warfarin. Genotyping for common and rare polymorphisms in CYP2C9, VKORC1, and CYP4F2 performed at study entry and unblinded at completion. Plasma Vitamin K and S-warfarin levels are obtained at goal INR ≥ 2 and study exit (INR ≤1.2 off warfarin).
223812139|NCT06030401|DEVICE|Transthoracic Ultrasound|Sonar of The Chest
223812140|NCT04078737|DRUG|Ticagrelor and Aspirin|"Day of randomization:~Day1:Ticagrelor 180mg; placebo of clopidogrel 300mg; aspirin 75-300mg (open label) Day2-21st: Ticagrelor 90mg bid/day; placebo of clopidogrel 75mg; aspirin 75mg (open label) Day 22nd-3 months:Ticagrelor 90mg bid/day; placebo of clopidogrel 75mg"
223812141|NCT04078737|DRUG|Clopidogrel and Aspirin|"Day of randomization:~Day 1: Clopidogrel 300mg; placebo of ticagrelor 180mg; aspirin 75-300mg (open label) Day2-21st: Clopidogrel 75mg/day; placebo of ticagrelor 90mg bid/day; aspirin 75mg (open label) Day 22nd-3 months:Clopidogrel 75mg; placebo of ticagrelor 90mg bid/day"
223812142|NCT00873236|BIOLOGICAL|bevacizumab|Given IV
223812143|NCT00873236|BIOLOGICAL|recombinant interferon alpha-2a|Given SC
223812144|NCT05358678|DIAGNOSTIC_TEST|cs niche group|"A niche is formally defined by the European Niche Taskforce as an indentation of the uterine myometrium of at least 2 mm at the site of the CS scars. A niche can be sub classified as follows:~1. Simple niche~2. Simple niche with one branch~3. Complex niche (with more than one branch).~The following measurements will be taken:~* Length.~* Depth.~* Width.~* RMT (residual myometrium thickness).~* AMT (adjacent myometrium thickness).~* Distance between the niche and the VV (vesico-vaginal) fold.~* Distance between the niche and the external os. We will also comment on the position of the uterus (AVF or RVF), presence or absence of intra cavitary fluid and its thickness."
223812145|NCT00925405|PROCEDURE|Breast MRI|Magnetic resonance imaging (MRI) scans of the breasts once per year
223812146|NCT00925405|PROCEDURE|Mammogram|Breast x-ray used to detect breast cancer and look for abnormalities in the breast.
223812147|NCT03773458|DEVICE|An artificial system for the screening of scoliosis|An artificial intelligence to make evaluation of scoliosis using back images
223812148|NCT04711356|DRUG|Ad26.ZEBOV booster vaccination, given at a dose of 5x10^10 vp, via IM injection|Ad26.ZEBOV is a monovalent, replication-incompetent adenovirus serotype 26-based vector that expresses the full-length Ebola virus Mayinga glycoprotein
223812149|NCT05404425|PROCEDURE|Visioconference: live visual injury evaluation|For patients randomized in the intervention group, a live visual evaluation of the injury is performed by the Emergency Medical Call Center physician using a dedicated, secure smartphone app
223812150|NCT05404425|PROCEDURE|Control|For patients randomized in the control group, the evaluation is performed by the Emergency Medical Call Center physician only by pone call
223812151|NCT00805090|DRUG|Sporanox|200 mg
223812152|NCT00805090|DRUG|Diclofenac Sodium|37.5 mg
223812153|NCT05181514|OTHER|20% Intralipid|Participants will receive a 5 h primed (375 mL/m2)-continuous (25 mL h-1 m-2) i.v. infusion of 20% fat emulsion (Intralipid 20%), together with a 5 h primed (28 µmol/kg)-continuous (0.28 µmol min-1 kg-1) infusion of 6,6-\[2H2\]glucose. After 2 h, participants will consume within 5 min an oral glucose drink consisting of 147 mL of 50% dextrose solution (wt/vol) enriched with 1.5 g of \[U-13C\] glucose.
223812154|NCT05181514|OTHER|Normal Saline|Participants will receive a 5 h primed (375 mL/m2)-continuous (25 mL h-1 m-2) i.v. infusion of normal saline (Sodium Chloride 0.9%), together with a 5 h primed (28 µmol/kg)-continuous (0.28 µmol min-1 kg-1) infusion of 6,6-\[2H2\]glucose. After 2 h, participants will consume within 5 min an oral glucose drink consisting of 147 mL of 50% dextrose solution (wt/vol) enriched with 1.5 g of \[U-13C\] glucose.
223812155|NCT03258424|DRUG|PTI-428|PTI-428 or placebo will be given QD for 14 days.
223812156|NCT03258424|DRUG|Placebo|PTI-428 or placebo will be given QD for 14 days.
223812157|NCT06284863|DIETARY_SUPPLEMENT|Natritional Education Program In Hemodialysis Patients|Impact Of Natritional Education Program In Hemodialysis Patients Interventional Study
223812158|NCT01722162|DRUG|Bevacizumab|
223812159|NCT01722162|DRUG|Capecitabine|
223812160|NCT01722162|DRUG|Levocetirizine|
223812161|NCT04215263|OTHER|Questionaire|Patient was assessed using mini international neuropsychiatric interview
223812162|NCT03124199|DRUG|Rifaximin|Rifaximin 400 mg/8 h added to the standard triple therapy
223812163|NCT06569875|DEVICE|iCARE|iCARE is an internet-based cognitive behavioral therapy program designed for women experiencing symptoms of postpartum depression, including anxiety, irritability, and sadness. The program offers digital therapy through an online platform tailored to mothers with mild to moderate postpartum depression. The program consists of 7 modules, each with its own theme, incorporating cognitive behavioral therapy, a well-established therapeutic approach for depression. The content includes text, images, audio files, and short films, supplemented with small tasks to provide knowledge and tools to understand and manage one's situation. The treatment course is self-directed, allowing participants to engage with the content at their own pace and at times that are most convenient for them
223812164|NCT02873130|BEHAVIORAL|Telepractice Global Voice Prevention Model|
223812165|NCT02873130|BEHAVIORAL|In-person Global Voice Prevention Model|
223812166|NCT02873130|BEHAVIORAL|Telepractice, Vocal Hygiene and Vocal Education|
223812167|NCT03223103|DRUG|Poly-ICLC|Poly-ICLC 100mcg per peptide per dose
223812168|NCT03223103|DEVICE|Tumor Treating Fields|an FDA approved treatment for patients with recurrent GBM and newly diagnosed GBM
223812169|NCT03223103|BIOLOGICAL|Peptides|synthetic long peptides (SLP) as vaccine substrate
223812170|NCT03881319|DRUG|Conventional gynecologic treatment|Taking NSAIDs or oral contraceptives.NSAIDs include Ibuprofen, Naproxen, Diclofenac, and Piroxicam. Oral contraceptives include Yasmin.
223812171|NCT03881319|DEVICE|Low dose acupuncture|Six acupoints: Three Yin Intersection( SP6)、Grandfather Grandson(SP4)、 Sea of Blood(SP10) 、Sea of Qi(RN6)、Origin Pass(RN4) 、Inner Pass(PC6)
223812172|NCT03881319|DEVICE|High dose acupuncture|Twelve acupoints: Three Yin Intersection( SP6)、Grandfather Grandson(SP4)、 Sea of Blood(SP10) 、Sea of Qi(RN6)、Origin Pass(RN4) 、Middle Extremity(RN3)、Inner Pass(PC6) 、Supreme Rush(LR3) 、Joining Valley(LI4) 、Supreme Stream(KI3) 、Uterus(EX-CA1) 、Leg Three Miles(ST36)
223812173|NCT02905383|OTHER|Exercise|A multi-component exercise program that consists of endurance training, progressive strength exercises and balance exercises.
223812174|NCT02922894|PROCEDURE|Acute episodic hypoxia|The subjects will undergo 30 minutes of baseline monitoring followed by 15 episodes of one minute of episodic hypoxia with supplemental CO2 to maintain isocapnia. This is followed by a 45 minute recovery period.
223812175|NCT02922894|PROCEDURE|Supplemental oxygen|Supplemental oxygen therapy for 6 weeks
223812176|NCT02922894|DRUG|Trazodone|100mg before bedtime
223812177|NCT02922894|DRUG|Placebo|One placebo pill before-bedtime
223812178|NCT02922894|PROCEDURE|Sham|Room air will be administered instead of episodic hypoxia or supplemental oxygen..
223812179|NCT04412044|DRUG|Mepolizumab Injection [Nucala]|Patients receive monthly injection with 100 mg mepolizumab
223812180|NCT01760421|DRUG|Hydroxychloroquine|Hydroxychloroquine (200mg/tab) 1 tab twice daily orally for 6 months
223812181|NCT03170375|BEHAVIORAL|Performance of WHEELS-I in promoting DASH/SRD adoption|All participants will receive motivational interviewing (MI) based counseling. Participants in the MI + WHEELS-I arm will also receive the WHEELS-I electronically-delivered tailored messaging.
223812182|NCT03587246|DIAGNOSTIC_TEST|3DTVUS : Uterine peristaltic frequencies|Perform three-dimensional transvaginal ultrasonography To observe uterine peristaltic frequencies in embryo transfer cycles
223812183|NCT01291979|DRUG|Intravenous lidocaine injection|Patients in Group I (intravenous lidocaine injection group) received an intravenous bolus injection of 1.5 mg/kg lidocaine followed by a continuous lidocaine infusion of 2 mg/kg/hr.
223812184|NCT01291979|DRUG|Intravenous normal saline injection|The patients in Group C (placebo control group) received normal saline intravenous injection
223812185|NCT04040309|BIOLOGICAL|PRGF injection|Plasma rich in growth factors will be prepared following the protocol described by E. Anitua. 9 ml of patients venous blood will be taken into one tube with 3,8% sodium citrate used as an anticoagulant. The blood then will be centrifuged (PRGF Centrifuge System, Biotechnology Institute, Vitoria, Spain) at room temperature for 8 min at 1800 rpm. After centrifugation 1 ml of 2nd plasma fraction will be collected by using a pipet. To activate plasma 10% calcium chloride will be used immediately before injecting plasma into the trigger point in the masseter muscle.
223812186|NCT04040309|DRUG|Lidocaine injection|1 ml 2 % Lidocaine will be injected into the trigger point in the patient's masseter muscle.
223812187|NCT03797482|PROCEDURE|Intra-operative Tumor Tissue Biopsy|The changing pattern of gene expression during surgery has never been studied. This could be an effect of acute hypoxia that sets in the tumour during surgery or could be a surgical response. To study these changes happening in the tumour during surgery, we are taking serial biopsies during surgery, one at the beginning, one midway during surgery and one at the end of surgery. These samples will be snap frozen and stored at -80 deg celsius in biorepository for future analysis.
223812188|NCT02740322|PROCEDURE|Hum Test|The subject will be brought into an exam room. The subject will then be asked to hum for a few seconds in a low pitch. They will then be asked if the nose was heard more so in one ear compared to the other. The subject will then be asked to hum for a few seconds in a high pitch. They will then be asked again if the noise was heard more so in one ear compared to the other.
223812189|NCT02740322|PROCEDURE|Weber Test|Using a 512 Hz tuning fork, the tuning fork will be vibrated and placed on the subject's glabella (forehead landmark). The subject will then be asked if the vibration was heard more so in one ear compared to the other.
223812190|NCT02740322|DEVICE|Audiogram|A standard audiogram will be administered by an audiologist.
223812191|NCT02146313|DRUG|DMUC4064A|Participants will receive escalated DMUC4064A dose or RP2D, as a single agent by intravenous (IV) infusion q3w on Day 1 of each cycle (21 days).
223812192|NCT02206217|DEVICE|Multiple-Segment spectacle lens|A multifocal spectacle lens that corrects distance refraction and provides myopic defocus images simultaneously. The myopic defocus aims at slowing down myopia progression.
223812193|NCT01550484|DRUG|18F-AV-133|222 MBq (6 mCi)
223812194|NCT00763958|DRUG|Placebo|Placebo to match buprenorphine administered for 3 months
223812195|NCT00763958|DRUG|Buprenorphine|Buprenorphine provided for 3 months; dosing was as clinically indicated up to 32 mg daily.
223812196|NCT04504201|OTHER|Focus Group|Breast cancer patients and oncology clinicians will participate in separate focus groups discussing patient-centered communication about healthy weight.
223812197|NCT01355458|DRUG|CD07805/47 gel|applied topically once daily
223812198|NCT01355458|DRUG|Placebo|applied topically once daily
223812199|NCT00908089|DRUG|Trexan+Salazopyrin+Oxiklorin+prednisolone + infliximab|methotrexate 10-25 mg/week, sulfasalazine 1-2 g/day, hydroxychloroquine 35 mg/kg/week, prednisolone 7.5 mg/day, and infliximab 3 mg/kg during first 6 months
223812200|NCT00908089|DRUG|Trexan+Salazopyrin+Oxiklorin+prednisolone + placebo|methotrexate 10-25 mg/week, sulfasalazine 1-2 g/day, hydroxychloroquine 35 mg/kg/week, prednisolone 7.5 mg/day, and placebo infusion during first 6 months
223812201|NCT01320332|DRUG|ASP3291|Oral tablets
223812202|NCT01320332|DRUG|Placebo|Oral tablets
223835490|NCT00169741|OTHER|Renogram|Subjects who enroll in this study will undergo a nuclear scan called a renogram to assess renal function prior to surgery (baseline), approximately one hour after surgery (to assess percutaneous effects on renal function) and finally approximately 6 weeks post-operatively (to assess return to baseline).
223812203|NCT05769036|DEVICE|Implantation of Cardioverter-defibrillator with a Resynchronization Function Using Biventricular Pacing|The local anesthesia will be performed on the left/right subclavian area after prepping the skin. A horizontal incision will be performed. The cephalic and subclavian veins will be used to leads deliver. The active-fixation defibrillation lead will be placed to the apex/interventricular septum. The atrial active-fixation lead will be implanted to the right atrial appendage/interatrial septum. The implantation of the left ventricular pacing lead will be performed by cannulating one of the tributaries of the coronary sinus using delivery system. Leads will be fixated, connected with CRT-D device and placed in subcutaneous (subfascial prepectoral)/submuscular pocket. The pocket will be closed by separate stitches (2-4 suffice) using the resorbable braided suture. Cardioverter-defibrillator with a resynchronization function will be programmed for biventricular pacing.
223812204|NCT05769036|DEVICE|Implantation of Cardioverter-defibrillator with a Resynchronization Function Using Left Bundle Branch Pacing|The local anesthesia will be performed on the left/right subclavian area after prepping the skin. A horizontal incision will be performed. The cephalic and subclavian veins will be used to leads deliver. The active-fixation defibrillation lead will be placed to the apex/interventricular septum. The atrial active-fixation lead will be implanted to the right atrial appendage/interatrial septum. The implantation to the left bundle branch will be performed by using special delivery system. Leads will be fixated, connected with CRT-D device and placed in subcutaneous (subfascial prepectoral)/submuscular pocket. The pocket will be closed by separate stitches (2-4 suffice) using the resorbable braided suture. Cardioverter-defibrillator with a resynchronization function will be programmed left bundle branch pacing.
223812205|NCT06303076|DRUG|Tizanidine Hcl 4Mg Tab|"Initial Dose Administration:~Patients will start by taking an initial dose of 2 mg of Tizanidine at bedtime (HS).~Dose Titration Process:~Every 4 days, the dose of Tizanidine will be increased by 2 mg. This titration is based on the patient's response to the medication and their tolerability of it.~Maximum Dose Limit:~The dose titration will continue until reaching the maximum dose of 0.1 mg/kg/HS, or until the maximum tolerated dose is identified, whichever comes first.~Monitoring and Adjustment:~Throughout the titration process, patients will be closely monitored for any adverse effects and for the effectiveness of the medication.~Adjustments to the dosing schedule may be made based on the clinician's assessment of tolerability and therapeutic response."
223812206|NCT06303076|DRUG|Zolpidem Tartrate 10 mg|"nitial Dose Administration:~Participants will start by taking an initial dose of Zolpidem 5 mg orally at home before bedtime (HS).~Response Evaluation and Dose Adjustment:~If there is no response to the initial 5 mg dose and it is tolerated well by the participant, the dose will be increased to 10 mg.~Monitoring and Adjustment:~Participants will be monitored for their response to the medication as well as for any adverse effects.~The decision to increase the dose to 10 mg will be based on the absence of a therapeutic response to the initial dose and the participant's tolerability of Zolpidem.~Dose Maximization and Safety:~The increase to a 10 mg dose is aimed at maximizing therapeutic efficacy while ensuring the safety and tolerability of the medication in participants who do not respond to the lower dose."
223812207|NCT01209637|BEHAVIORAL|exercise training|exercise training min. 4 times a day for at least 30 min
223812208|NCT01209637|BEHAVIORAL|Intensive exercise training|Intensive exercise training for 4 times / day incl. interval training at 95% individual threshold
223812209|NCT01567358|BIOLOGICAL|Infliximab|100mg/vial
223812210|NCT01567358|BIOLOGICAL|Infliximab|100mg/vial
223812211|NCT00828308|DRUG|Ixabepilone|Ixabepilone, 16 mg/m2 or 20mg/m2, weekly x 3, in 4 week cycles, x 4 cycles.
223812212|NCT00828308|PROCEDURE|Prostatectomy|Prostatectomy 2-8 weeks after completion \*\*\*this was standard of care and not a part of the study\*\*
223812213|NCT05671640|DEVICE|DragonFly-T Transcatheter Tricuspid Valve Repair System|To conduct edge-to-edge repair with DragonFly-T System under the guidance of transesophageal echocardiography.
223812214|NCT04307433|BEHAVIORAL|Storytelling narrative videos on tablets|The storytelling narrative episodes in the application will feature video clips of the multiple stories of women living with HIV infection, HIV support group leaders, community leaders, and health care professionals and a Learn More video of physician discussing cervical cancer.
223812215|NCT03532308|DRUG|Fermented Soy|Two 12.5g packets/day) (\~1 ounce/day) taken between the time of enrollment and radical prostatectomy (RP). Time can be between 4 and 10 weeks.
223812216|NCT03532308|OTHER|Placebo|A placebo compliment to the active intervention with identical packaging and labeling will be used.
223812217|NCT02767063|DRUG|Pioglitazone|PIOGLITAZONE (Actos®): 30 mg per day for 12 months. The dose will be increased to 45 mg per day after 2 months in the absence of grade \>1 related AE.
223812218|NCT02767063|DRUG|Avelumab|10mg/kg every 2 weeks, for a maximum of 8 IV infusions over a 4 months' period. (If MR4.5 is acheived by the first 3 months the 7th and 8th infusions will be omitted)
223812219|NCT03720938|OTHER|Active Video Games|Nintendo Wii® AVGs from sports, balance, aerobics, resort and training categories.
223812220|NCT03522805|DEVICE|High-intensity non-invasive ventilation|Single night of high-intensity non-invasive ventilation
223812221|NCT03960671|DRUG|Midazolam/diazepam/propofol|Therapeutic drug monitoring of anxiolytics
223812222|NCT00206557|DRUG|Raloxifene|
223812223|NCT00206557|DRUG|Estradiol/dyhydroprogestrone|
223812224|NCT01630720|DIETARY_SUPPLEMENT|vitamin C or vitamin D|vitamin C 500 mg twice daily versus vitamin D 5000 IU daily for 7 to 10 days
223812225|NCT03978325|OTHER|Control|The control group will receive standard pre-operative care. This involves standard pre-operative advice and a moderate intensity preoperative exercise programme.
223812226|NCT03978325|OTHER|Exercise - HIIT Intervention|"The HIIT intervention will take the form of a supervised programme, completed for at least two weeks, up to 5 days per week preoperatively. The HIIT intervention will be performed on a cycle ergometer. Exercise sessions will be individually supervised and scheduled at a time of convenience for each participant. Each exercise session will last 40 minutes and will include warm-up, exercise training and cool-down components. Lactate threshold, measured during the baseline CPT, will be used to determine the exercise intensity.~The training protocol will prescribe 15 second intervals of exercise and passive recovery. The highest resistance reached during the baseline CPET (measured in watts) will be recorded as the peak power output (PPO). During training, participants will undergo a 5-minute warm-up at 50% PPO, followed by up to 30 minutes of HIIT with intervals of 15 seconds at 100% PPO with 15 second recovery periods at 0 watts."
223812227|NCT04772846|DRUG|Oral tablet|Oral 250mg chloroquine tablets
223812228|NCT04772846|DRUG|Placebo|Oral placebo tablets
223812229|NCT03839654|DEVICE|continuous positive airway pressure|The CPAP treatment group received both baseline medicine and CPAP treatment for 7 days preoperatively.
223812230|NCT00006422|PROCEDURE|current standard of care treatments|
223812231|NCT04850404|PROCEDURE|abdominal nerve block|All Patients of group A-M will be administered with rectus abdominis block combined with TAPB after anesthesia. Rocuronium was infused continuously (concentration: 1 mg/ml) when TOF recovered to 1. The starting rate was 0.3mg/kg/h, and the TOF count was maintained between 1\~3 (moderate NMB) and recorded during the operation. Whether and how to add rocuronium was based on TOF count and request of surgeons. When TOF Watch- SX showed 4 or ratio, the investigators increased the speed of rocuronium pump infusion and record the score at the time of shallow NMB. When the chief surgeon thought the vision could not satisfy the needs of the operation, rocuronium 0.1mg/kg in bolus was added as a rescue. Then, the pump speed was lowered or even decreased to 0 to make the TOF count recover to 1\~3 as soon as possible.
223812232|NCT03092284|BIOLOGICAL|Cardiology Stem Cell Centre Adipose Stem Cell (CSCC_ASC)|Direct intramyocardial injection of CSCC\_ASC
223812233|NCT03092284|BIOLOGICAL|Placebo|Saline
223812234|NCT02535364|BIOLOGICAL|JCAR015 (CD19-targeted CAR T cells)|"Part A: Following leukapheresis and concurrent with generation of JCAR015, participants received, at the Investigator's discretion, cytoreductive chemotherapy based on the Investigator's choice of regimens and/or supportive care.~Part B: Participants who were eligible for treatment in Part B received two IV doses of JCAR015 CAR T cells separated by 14 to 28 days. JCAR015 infusion was preceded by lymphodepleting chemotherapy with cyclophosphamide alone or cyclophosphamide + fludarabine."
223812235|NCT03715400|BEHAVIORAL|Positive Virtual Reality Training|Participants will undergo 7 45 minute sessions of positive virtual reality training over the course of four weeks. All assessments will be completed online at home following initial orientation to the program.
223812236|NCT06484270|OTHER|Simulation based safety mobilization program|"Nurse participants experienced safe patient mobilization with a simulation-based learning method with a standardized patient for 4 weeks.~Patient participants were mobilized safely under the supervision of a nurse and the care results were measured."
223812237|NCT03949790|PROCEDURE|ESPB and Intercostal nerve block|Erector spinae plane block + Intercostal nerve block
223812238|NCT03949790|PROCEDURE|Intercostal nerve block|Intercostal nerve block
223812239|NCT02346019|PROCEDURE|Medial thighplasty with or without thigh liposuction|Perform a standard medial thighplasty with or without additional thigh liposuction on up to three obese transfemoral amputee subjects. The subjects will be transfemoral amputees who are successful ambulators and have a body mass index (BMI) of 30 or greater with excessive adipose tissue in their residual limb. The surgery will consist of medial excision of excess adipose and cutaneous tissue with circumferential liposuction.
223812240|NCT04299516|PROCEDURE|Two-team simultaneous bilateral total knee arthroplasty|Bilateral total knee arthroplasty can be performed in three different ways: single-stage, two-team simultaneous bilateral total knee arthroplasty; single-stage, one-surgeon, and two-stage bilateral total knee arthroplasty. Two surgeons will operate simultaneously on one side for two-team SBA.
223812241|NCT04299516|PROCEDURE|Single-team simultaneous bilateral total knee arthroplasty|One surgeon will operate sequentially on both sides for one-surgeon SBA
223812242|NCT02138643|PROCEDURE|Endoscopic surgery|These will be treated with Endoscopic surgery - Peroral endoscopic myotomy (POEM)
223812243|NCT02138643|PROCEDURE|Laparoscopic surgery|These will be treated with Laparoscopic surgery - Laparoscopic Heller myotomy.
223812244|NCT00571701|DRUG|celebrex (celecoxib)|Adults: 400 mg celebrex (celecoxib) daily Pediatrics: 100 mg celebrex (celecoxib) daily for weight between 12-25 kg or 200 mg Celebrex (celecoxib) daily for weight \>25 kg
223812245|NCT00571701|DRUG|placebo|similar appearing capsules containing inert ingredients
223812246|NCT05357014|DIAGNOSTIC_TEST|echocardiography|evaluation of cardiac function hn children on regular heamodialysis by echocardiography
223812247|NCT01078857|OTHER|Skin biopsy|A 3-mm-diameter skin biopsy punch was taken at the lateral side of the distal leg and fixed in 4% paraformaldehyde overnight. Sections of 50 m perpendicular to the dermis were cut on a sliding microtome, quenched with 1% H2O2 in methanol, and blocked with 5% normal goat serum. Sections were incubated with rabbit antiserum to protein gene product 9.5 (PGP 9.5, UltraClone, Isle of Wight, UK, 1:1000) overnight. PGP 9.5 is a ubiquitin carboxyl hydrolase, which labels myelinated and unmyelinated nerve fibers in the peripheral nervous system. Sections were then incubated with biotinylated goat anti-rabbit immunoglobulin G (Vector, Burlingame, CA) for 1 h and the avidin-biotin complex (Vector) for another hour. The reaction product was demonstrated using chromogen SG (Vector).
223812248|NCT01119430|DRUG|DU125530|20mg/twice a day
223812249|NCT01119430|DRUG|Placebo|Similar pill as active comparator twice a day
223812250|NCT01112228|PROCEDURE|Bariatric surgery|Bariatric surgery: Gastric bypass, Sleeve gastrectomy, or Gastric banding
223812251|NCT05927974|DIAGNOSTIC_TEST|Passive testing|Passive testing includes baseline recordings or behavioral tasks without stimulation. Examples include language tasks, cognitive, and motor tasks. Passive testing typically takes 30-60 minutes and does not require presence of an epileptologist as the tasks are of minimal or no risk.
223812252|NCT05927974|DIAGNOSTIC_TEST|Active testing|"Active testing includes any study activity in which stimulation occurs. The most frequent paradigm consists of delivering small amounts of electrical stimulation through the implanted grid/strip/depth electrodes. This will be either continuous stimulation or patterned stimulation such as intermittent theta-burst . Stimulation will range between 1-8 mAmp. The duration of these pulses will last between 2-5 seconds.~Subjects may be asked to rest quietly or to perform behavioral tasks during stimulation. Since there is a risk of evoking seizure activity with active testing, presence of an epileptologist is required. Active testing will only occur once the PI/staff has communicated with the epileptologist regarding safety, feasibility, and timing of active testing. Active testing will typically take 60-90 minutes and is only performed once patients are back on their anti-seizure medications."
223812253|NCT06479616|GENETIC|CS-101|Autologous CD34+ hematopoietic stem cell suspension modified by in vitro base editing technique
223812254|NCT01846000|PROCEDURE|low-level laser treatment|A gallium-aluminum-arsenide laser will be employed for the LLLT and placebo treatment. The device will be calibrated with a wavelength of 780 nm, energy density of 25 J/cm2, power of 50 mW and power density of 1.25 W/cm2. Exposure time will be 20 seconds per point, resulting in a total energy of 1 J per point. The spot application method will be used in contact with the skin and with a conventional tip, covering an area of 0.04 cm2.
223812255|NCT01210521|DRUG|Vitamin D|Vitamin D, (2000IU) will be administered orally, once a day, for one month.
223812256|NCT01452646|OTHER|Risk-adapted, MRD-directed therapy|The general objective of this study is that of setting up a multicentre, risk-adapted study that relies on pre-treatment cytogenetic/genetic features and post-consolidation assessment of MRD to establish the final risk assignment and treatment of younger (≤ 60 years) patients with AML. Aim of this clinical trial is to verify whether the delivery of a post remission therapy whose intensity is risk-driven will improve the outcome in terms of both increased anti-leukemic efficacy and reduced therapy-related toxicity.
223812257|NCT02660801|PROCEDURE|Spinal manipulation|A high-velocity and low-amplitude thrust delivered posteroanteriorly to a thoracic vertebra
223812258|NCT02660801|PROCEDURE|Spinal mobilization|Three repetitions of a low-velocity and low-amplitude nonthrust movement delivered posteroanteriorly to a thoracic vertebra
223812259|NCT00735865|PROCEDURE|Punctal plugs, punctal cautery|25 subjects(20 silicone punctal plugs, 5 punctal cautery) The procedure will be based on clinical indication. Randomized one eye for study. Baseline cultures of lid margin \& tarsal/inferior fornix conjunctiva obtained \& plated according to protocol
223812260|NCT00735865|PROCEDURE|Punctal Plug, Punctal thermocauterization|"Up to 5 subjects. Subjects in need of punctal occlusion(No preference for punctal thermocauterization or punctal occlusion by silicone plug). Randomize one eye to silicone punctal plug occlusion, the other eye to punctal thermocauterization.~This group ONLY, cultures will be obtained of the lid margin \& conjunctiva/inferior fornix of BOTH eyes"
223812261|NCT00735865|PROCEDURE|Silicone plug or thermodynamic hydrophobic acrylic plug|"Up to 5 subjects. Subjects in need of punctal occlusion(not preference for punctal occlusion by silicone plug or by the thermodynamic hydrophobic acrylic plug). Randomize one eye to silicone punctal plug occlusion, the other eye to acrylic punctal plug occlusion.~In this group ONLY cultures will be obtained of the lid margin and conjunctiva/inferior fornix of BOTH eyes"
223812262|NCT00735865|OTHER|Previous subjects with Punctal occlusion|"Up to 20 subjects(15 subjects with silicone punctal plug closure and 5 subjects with punctal closure by thermocauterization)Subjects who have previously had punctal occlusion who have symptoms and/or signs thought to be secondary to punctal occlusion.~Lid margin and conjunctiva/inferior fornix of eye with greatest sign or symptoms will be cultured/plated according to standard protocol."
223812263|NCT04766086|BIOLOGICAL|Multivalent Group B streptococcus vaccine|Multivalent Group B streptococcus vaccine
223812264|NCT04766086|BIOLOGICAL|Tetanus, diphtheria, and acellular pertussis vaccine|Tetanus, diphtheria, and acellular pertussis vaccine
223812265|NCT04766086|BIOLOGICAL|Placebo|Saline control
223812266|NCT03390530|DRUG|Thyroxine|8 µg/kg/day divided into two doses intravenous every 12 hours
223812267|NCT03390530|DRUG|Placebo|Placebo
223812268|NCT04903171|OTHER|INCENTIVE VISITING A GARDEN : ENRICHED OR CONVENTIONAL SENSORY GARDEN|Carers invites every the participants of group 2 and 3 visiting their respective gardens (enriched or conventional sensory garden)
223812269|NCT00021814|DRUG|Doxazosin|
223812270|NCT00021814|DRUG|Finasteride|
223812271|NCT00021814|DRUG|Doxazosin placebo|
223812272|NCT00021814|DRUG|Finasteride placebo|
223812273|NCT04072341|DRUG|Propolis Period (Green Propolis 250mg/day)|Randomized, cross-over, open-label. Patients will go through two 4 week periods with 1 week washout between them. During the intervention period will use 250mg of green Propolis per day. In the control period they will only follow standard treatment for their comorbidities.
223812274|NCT04072341|OTHER|Control Period|In the control period they will only follow standard treatment for their comorbidities.
223812275|NCT04692792|DIETARY_SUPPLEMENT|Placebo drink|consume 1 bottle (50 mL) per day for 8 weeks
223812276|NCT04692792|DIETARY_SUPPLEMENT|Dai Dai flower drink|consume 1 bottle (50 mL) per day for 8 weeks
223812277|NCT03281122|DRUG|Placebo|Specified dose on specified days
223812278|NCT03281122|DRUG|BMS-986224|Specified dose on specified days
223812279|NCT02475135|DRUG|Darunavir/Cobicistat/Emtricitabine/Tenofovir alafenamide FDC|A tablet containing DRV 800 mg, COBI 150 mg, FTC 200 mg and TAF 10 mg as FDC will be administered.
223812280|NCT02475135|DRUG|Elvitegravir /Cobicistat/Emtricitabine/Tenofovir alafenamide FDC|A tablet containing EVG 150 mg, COBI 150 mg, FTC 200 mg and TAF 10 mg as FDC will be administered.
223812281|NCT02475135|DRUG|Darunavir|A tablet containing Darunavir (DRV) 800 mg will be administered.
223812282|NCT02475135|DRUG|Emtricitabine/Tenofovir alafenamide (FTC/TAF)|A tablet containing Emtricitabine (FTC) 200 mg and Tenofovir alafenamide (TAF) 10 mg will be administered.
223812283|NCT02475135|DRUG|Cobicistat|A tablet containing cobicistat (COBI) 150 mg will be administered.
223812284|NCT02475135|OTHER|High-fat Breakfast|High-fat breakfast will be administered.
223812285|NCT02475135|OTHER|Standardized Regular Breakfast|Standardized regular breakfast will administered.
223812286|NCT02872948|GENETIC|Diagnostic|
223812287|NCT03180671|DEVICE|Deprogramer Sliding Guide|Use of the intraoral device.
223812288|NCT03180671|DEVICE|Deprogrammer Dawson B-Splint|Use of the intraoral device.
223812289|NCT03180671|DEVICE|Deprogrammer Kois|Use of the intraoral device.
223812290|NCT00466102|DRUG|RAD001|Tablet of 5 mg, 2 tablets (10 mg) are taken once daily during study therapy
223812291|NCT00466102|DRUG|Placebo|2 tablets are taken once daily during study therapy
223812292|NCT04748016|OTHER|3D printed (3DP) bone models + CT imaging|In addition to CT-MPR and CT-3DR, 3DP models will be used for surgical planning and intraoperative visualization.
223812293|NCT04748016|OTHER|CT imaging|CT-MPR and CT-3DR used for surgical planning and intraoperative visualization.
223812294|NCT01494428|DEVICE|rhBMP-2/ACS/allograft bone dowel|The rhBMP-2/ACS will be used in conjunction with an allograft bone dowel.
223812295|NCT01494428|DEVICE|Autogenous bone/allograft bone dowel|An allograft bone dowel contains autogenous bone taken from the patient's iliac crest.
223812296|NCT01644201|DIETARY_SUPPLEMENT|PolyGlycopleX® - PGX®|15g or 20g total daily dose, 5g pre-mixed with liquid meal replacement and consumed twice daily, 5g supplement granules sprinkled on food and consumed once of twice daily
223812297|NCT01644201|DIETARY_SUPPLEMENT|Rice Flour (placebo)|15g or 20g total daily dose, 5g pre-mixed with liquid meal replacement and consumed twice daily, 5g supplement granules sprinkled on food and consumed once of twice daily
223812298|NCT00339690|OTHER|MITE-T-FASTtest kit|The primary objective of this randomized intervention trial is to determine if the use of an inhome test kit, as an adjunct to education, results in greater reductions in dust mite allergen levels than the use of educational materials alone.
223812299|NCT02143037|BEHAVIORAL|prize contingency management for attending treatment|
223812300|NCT02143037|BEHAVIORAL|usual care|
223812301|NCT01163890|BEHAVIORAL|Work and Health Initiative|Telephone-based multi-modal intervention, consisting of: vocational coaching, cognitive-behavioral therapy strategies and care coordination strategies provided by specially-trained EAP counselors
223812302|NCT01163890|BEHAVIORAL|Usual Medical or Behavioral Intervention|Referral to treatment as usual through personal physician, mental health professional, behavioral health program, and/or Employee Assistance Program
223812303|NCT05449691|PROCEDURE|One-stage immediate breast reconstruction|One-stage mesh assisted implant breast reconstruction
223812304|NCT06849050|BEHAVIORAL|Acute continuous exercise|Exercise, which will involve 60 minutes of brisk walking, or jogging, at 60% of peak oxygen uptake. Participants will be asked to wear a face mask, which will measure their oxygen consumption during the exercise session.
223835491|NCT02471508|DEVICE|Body-mapping Tank-top Embedded with Biofeedback System|In this study, the eligible subjects will be given tailor-made tank-top embedded with biofeedback system to wear it 8 hours daily. Monitor, observation and additional posture training sessions will be provided during the 6 months wearing period. The effectiveness of the biofeedback tank-top will be evaluated by pre-and post- treatment ultrasonic imaging device (measuring the angle of the spine) and electromyography muscle signal
223812305|NCT04941664|DRUG|0.5% levobupivacaine|"This study adopts a Modified Narayana rule (MNR), a sequential up-and-down pharmacodynamics method (UDM) to estimate the minimum effective local anesthetic volume of 90% (MELVA90) of cases of the aforementioned local anesthetic (LA), in order to produce the surgical anesthesia of the patients scheduled for shoulder surgeries. Based on the principal investigator's clinical experience, the initial volume of 8ml will be used. Depending on the success or failure of the superior trunk block, which is defined as the readiness for surgery at 30 minutes after the block, the volume for the next patient will be adjusted up or down by 2ml. The upper dose limit of the study to minimize the potential for local anesthetic systemic toxicity will be 16ml and the lower dose limit will be 4ml, which will be of no clinical importance."
223812306|NCT05264870|DRUG|Norepinephrine|treatment of postspinal hypotension
223812307|NCT05264870|DRUG|Norepinephrine|treatment of postspinal hypotension
223812308|NCT03815019|DRUG|Megestrol Acetate|The proposed study will use megestrol 6 mg/kg/day in two doses because this dose has been effective and safe in two previous studies using megestrol to stimulate appetite in children transitioning from tube to oral feedings. The megestrol will be dosed at full dose weeks 10-11, at 66% dose week 12, at 33% dose week 14, and fully tapered at the end of week 14. Megestrol is absorbed from the small bowel, so feeding it through the tube will be acceptable.
223812309|NCT03815019|BEHAVIORAL|iKanEat Behavioral Intervention|"The 24 week iKanEat intervention is composed of 4 clinic visits and a series of 12 tele-visits. All visits (clinic and tele-visits) will focus directly on the oral-motor and behavioral skills necessary for oral eating.~Tele-visits will begin by building rapport and asking for a summary of all relevant information since the last point of contact, including parent perception of changes in weight, feeding habits, progress, stress of parent/child, and illness. The majority of the time left in the 30 minute session will be spent dealing with parent concerns, which our previous project indicates may include questions about measures, questions about implementation of the iKanEat protocol, and ensuring that children/families adhere to the oral-motor and behavioral guidelines for feeding."
223812310|NCT05952856|DRUG|Enlicitide Decanoate|Oral tablet
223812311|NCT05952856|DRUG|Placebo|Oral tablet
223812312|NCT05373342|DEVICE|iCount system assembled with swabs|Designed as single use. Intended purpose - To be used to count swabs and tampons after childbirth in an objective manner. This is intended to be used in women during and after childbirth.
223812313|NCT04462419|RADIATION|Dynamic Contrast-Enhanced Magnetic Resonance Imaging with Positron Emission Tomography|Undergo PET-MRI imaging
223812314|NCT04462419|OTHER|Fluciclovine F18|Given IV
223812315|NCT03775460|DRUG|Methotrexate|Participants in the intervention group will receive methotrexate along side prednisolone
223812316|NCT03775460|DRUG|Placebo|Participants in the control arm will receive placebo along side prednisolone
223812317|NCT03775460|DRUG|Prednisolone|Participants in both arm will receive prednisolone, which will be the same dosage: 40 mg (initial dose) decreasing dosage for 20 weeks
223812318|NCT03305523|DEVICE|Thermocautery|In the thermocautery method, a digital thermocautery device (Thermo-Med TM 802-B, Thermo Medical, Adana, Turkey) with 6 different temperature settings was used. Circumcision was performed in the same way as the surgical circumcision. Only cutting and bleeding intervention was done by using a thermocautery device. Cutting was performed by making the appropriate heat adjustment according to the age of the child and the thickness of the glans. Hemorrhage control was performed with a thermocautery device and then the skin-mucosa integrity was ensured by using a 5/0 absorbable suture
223812319|NCT01320943|DRUG|TDF|Tenofovir disoproxil fumarate (TDF) 300 mg tablet administered orally once daily
223812320|NCT01320943|OTHER|Stop TDF|Participants will stop TDF therapy
223812321|NCT04096612|PROCEDURE|Orbital decompression combined with MPT|Orbital decompression combined with MPT
223812322|NCT01881503|BIOLOGICAL|HBOC-201|HBOC-201 is purified, cross-linked, acellular bovine hemoglobin (Hb) in a modified lactated Ringer's solution.
223812323|NCT03056794|OTHER|No intervention|This is an observational study. The investigators will collect data about exposure to responses to dietary supplements, medications, and the ketogenic diet.
223812324|NCT05277844|RADIATION|Local Consolidative Radiation Therapy|Local consolidative radiation therapy to loco-regional disease and all Oligometastatic sites in addition to TKI
223812325|NCT05277844|DRUG|TKI|TKI
223812326|NCT03654742|PROCEDURE|tonsillectomy|removal of tonsil tissue as described in the study arms
223812327|NCT05557487|DIAGNOSTIC_TEST|Low dose computed tomography|"1. Participants belonging to modified Lung RADS category 1 and 2 at baseline screening will undergo the LDCT next year after the discussion with the physicians in charge.~2. Participants with nodules belonging to modified Lung RADS category 3 and 4, growing nodules, or new nodules found on follow-up LDCT scans will undergo repeat CT every 3 to 6 months or be referred for diagnostic workup depending on the size and characteristics of the nodules as the regular clinical practice.~3. Volume doubling time (VDT) will be performed in the special groups with Lung RADS category 3 or 4, but the nodules with solid components ≧ 6mm and \< 9mm. A repeat LDCT scan will be performed around 3 months after the baseline screening.~4. Check total bilirubin, urinary heavy metals,CRP, serum tumor marker, including CEA, alpha-fetal protein, etc.~5. Check pulmonary function test."
223812328|NCT06822426|DRUG|(taurolidine and heparin) catheter lock solution|for central venous catheter installation use
223812329|NCT06822426|DRUG|Heparin|Heparin
223812330|NCT06721065|OTHER|Remote Simultaneous Medical Interpreting/RSMI|"Remote Simultaneous Medical Interpreting (RSMI), UN-style simultaneous interpreting applied to the medical encounter, which holds tremendous promise for closely approximating a same language encounter, decreasing interpreting errors, and improving outcomes."
223812331|NCT06721065|OTHER|Remote Consecutive Medical Interpreting/RCMI|"Remote Consecutive Medical Interpreting (RCMI; audio consecutive), is the most commonly utilized remote interpreting"
223812332|NCT06721065|OTHER|Remote Consecutive Video Medical Interpreting/RCVI|"Remote Simultaneous Medical Interpreting (RSMI), UN-style simultaneous interpreting applied to the medical encounter"
223835492|NCT00669747|DRUG|Carboplatin i.d. Days 1 & 15|Carboplatin, 10 mg/ml, 10 ml (100 mg) infused into DCIS-involved duct on Days 1 \& 15
223835493|NCT00669747|DRUG|Carboplatin i.d. Day 1; Normal Saline i.d. Day 15|Carboplatin 10 mg/ml, 10 ml (100 mg) i.d. DCIS duct on Day 1 Normal Saline, 10 ml i.d. DCIS duct on Day 15
223835494|NCT00669747|DRUG|Normal Saline|Normal Saline, 10 ml, i.d. on Days 1 and 15
223812333|NCT03484598|DEVICE|SPEAC System|A lightweight, non-invasive monitor that is placed on the belly of the biceps muscles to analyze surface electromyography (sEMG) signals that may be associated with generalized tonic-clonic (GTC) seizures. It provides an alarm to alert caregivers of unilateral, appendicular, tonic extension that could be associated with a GTC seizure. The System records and stores sEMG data for subsequent review by a trained healthcare professional.
223812334|NCT06348199|DRUG|SB27|Will be administered intravenously at a fixed dose of 200 mg every 3 weeks
223812335|NCT06348199|DRUG|Keytruda|Will be administered intravenously at a fixed dose of 200 mg every 3 weeks
223812336|NCT06521502|OTHER|Blood collection|"Blood will be collected from a catheter (IV) that is already in place or using a needle stick into a vein.~Blood will be collected in hospital (Cohorts A, B) and at visits 3, 6, and 12 months following hospitalization for (Long-term Outcomes Cohort)."
223812337|NCT06521502|OTHER|Urine Collection|"Urine will be collected through a urinary catheter that is already in place or by urinating into a cup.~Urine will be collected in hospital only (Cohorts A, B)"
223812338|NCT06521502|OTHER|Nasal, oral, and rectal swabs|"Nasal, oral, and rectal swabs inserted into the nose, mouth, and rectum, respectively. The swabs will be rubbed inside the cavity and then removed the swab.~Oral and nasal swabs will also be collected in hospital (Cohort A, B) and at visits 3, 6, and 12 months following hospitalization for (Long-term Outcomes Cohort). Rectal swabs will be collected in hospital only (Cohorts A, B)."
223812339|NCT06521502|OTHER|Stool collection|"Stool will be collected either in a cup after defecation or by collecting it from a tube or bag that may already be in place that is catching stool.~Stool will be collected in hospital (Cohorts A, B) and at visits 3, 6, and 12 months following hospitalization (Long Term Outcomes Cohort)."
223812340|NCT06521502|OTHER|Heat Moisture Exchange Filter collection|"An HME filter is a sponge that is placed in the tubing between a patient and breathing machine. It reduces the amount of heat and moisture a patient loses when on a breathing machine. Moisture from breath is collected in this filter. The filter is changed every few hours. When the filter is changed, it will be saved to collect the moisture that it contains and run tests on it.~HME filters will be collected in hospital on intubated patients only (Cohorts A, B)."
223812341|NCT06521502|OTHER|Tracheal Aspirate sample collection|"Patients on a breathing machine have a breathing tube in their trachea that connects their lungs to the breathing machine. A smaller tube, called a suction catheter, will be placed through the larger tube and fluid will be gently sucked out.~Tracheal aspirate will be collected in hospital on intubated patients only (Cohorts A, B)"
223812342|NCT06521502|PROCEDURE|Non-bronchoscopic bronchoalveolar lavage (NBBAL)|"The NBBAL procedure involves putting a flexible rubber tube through the breathing tube into the airway of one of the lungs. A small amount of fluid is injected into the lung and then a gentle suction is used to collect fluid. Only patients who pass a safety screen showing that they are not at high risk for complications will have the NBBAL procedure performed.~NBBAL will be performed in hospital on intubated patients only (Cohort A)"
223812343|NCT06521502|OTHER|Surveys|Participants will be contacted by email, text, and /or phone to give updates about their health. These surveys will ask questions about quality of life, mental health, return to work, and re-admission to the hospital. (Cohort A)
223812344|NCT06521502|OTHER|Short physical performance battery|"At visits 3, 6, and 12 months following hospitalization (Long-term Outcomes Cohort)~Chair Stand Test: For this test the participant will sit in a chair. They will then stand as quickly as possible without using their upper body to assist them.~Balance Test: For this test the participant will stand unsupported for 10 seconds with their feet in 3 different positions.~4-meter walk: For this test the participant will walk 4 meters as quickly as possible."
223812345|NCT06521502|OTHER|Hand grip strength|"At visits 3, 6, and 12 months following hospitalization (Long-term Outcomes Cohort):~The participant will squeeze a machine called a hand-held dynamometer 3 times with all their strength."
223812346|NCT06521502|OTHER|CNS Vital Signs|"At visits 3, 6, and 12 months following hospitalization (Cohort A - Long-term Outcomes Cohort):~The participant will sit at a computer and follow the prompts on the screen. This test takes about 45 minutes."
223812347|NCT06521502|OTHER|Muscle Ultrasound|"At visits 3, 6, and 12 months following hospitalization (Long-term Outcomes Cohort):~The participant will undergo ultrasound on the quadriceps muscle on the dominant side of their body."
223812348|NCT06521502|OTHER|Muscle Strength|"At visits 3, 6, and 12 months following hospitalization (Long-term Outcomes Cohort):~A dynamometer will be used to measure muscle strength in the dominant leg."
223812349|NCT06521502|OTHER|Spirometry|"At a visit 12 months following hospitalization (Long-term Outcomes Cohort):~The participant will have a clip placed on their nose and will be given a plastic mouthpiece that is connected to a machine called a spirometer. They will place their lips tightly around the mouthpiece and take in as big and deep of a breath as possible and then blow out as hard and fast as they can."
223812350|NCT06521502|OTHER|Lung Diffusion Testing (DLCO)|"At a visit 12 months following hospitalization (Long-term Outcomes Cohort):~The participant will have a clip on their nose. They will put their mouth over a mouthpiece that is attached to a machine. This machine will deliver a small amount of carbon dioxide when they breathe in and will also record the results of the test. They will then take a few normal breaths. Next they will inhale deeply and exhale completely. They will breathe in quickly through their mouth and hold their breath for 10 seconds or as long as they can. Then they will breathe out."
223812351|NCT06521502|RADIATION|Chest CT Scan|"At a visit 12 months following hospitalization (Long-term Outcomes Cohort):~The participant will undergo a Chest Computed Tomography (CT) scan which uses special X-ray equipment to take detailed pictures of the lungs."
223812352|NCT06515821|DIAGNOSTIC_TEST|ONCOSCREEN|Subjects samples will be tested with diagnostic tests.
223812353|NCT02886065|DRUG|Hiltonol|Intramuscular injection of Hiltonol (1 mg) administered Biweekly at the time of PVX-410 administration
223812354|NCT02886065|DRUG|Citarinostat|Citarinostat (180 mg) administered orally once daily on days 1-21 every 28 day cycle.
223812355|NCT02886065|DRUG|Lenalidomide|Lenalidomide (25 mg) administered orally once daily on days 1-21 every 28 day cycle.
223812356|NCT02886065|BIOLOGICAL|PVX-410|PVX-410 Biweekly (0.8 mg) via subcutaneous injection
223812357|NCT03937219|DRUG|Cabozantinib|Specified dose on specified days.
223812358|NCT03937219|BIOLOGICAL|Nivolumab|Specified dose on specified days.
223812359|NCT03937219|BIOLOGICAL|Ipilimumab|Specified dose on specified days.
223812360|NCT03937219|DRUG|Cabozantinib-matched placebo|Specified dose on specified days.
223812361|NCT01887080|OTHER|Exercise|"This group had the exercise program, thrice a week for eight weeks.~The exercise protocol consists of 10 exercises: aerobic and resistance exercises. It was used a moderate intensity (60% of maximum heart rate of stress test with progression until 80%). Subjects were taught to monitor exercise intensity by measuring the manual heart rate, by using the scale of perceived exertion Borg (11-13), and by observation of signs.~The exercise protocol was done with supervision from a distance, using information technologies (SMS, phone, email ...), and when necessary it was resorted to routine meetings."
223812362|NCT01887080|DEVICE|Microcurrent|"This group had the exercise program after electrolipolysis, thrice a week for eight weeks.~The electrolipolysis consisted of 30-minute sessions: the first 15 minutes with a frequency of 30 Hz and the final 15 minutes with a frequency of 10 Hz; with a pulse time of 10 ms; and an intensity below the threshold of sensitivity (with a maximum of 750 μA). There were used 4 transcutaneous electrodes in the abdominal region (parallel position).~Microcurrent was done with supervision from a distance, using information technologies (SMS, phone, email ...), and when necessary it was resorted to routine meetings."
223812363|NCT01887080|OTHER|Cardiovascular Risk Factors|It was handed flyers on major cardiovascular risk factors: cholesterol, obesity, diabetes, smoking and hypertension.
223812364|NCT00532155|DRUG|Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)|6 mg/kg Aflibercept administered intravenously (IV) over 1 hour once on Day 1, every 3 weeks.
223812365|NCT00532155|DRUG|Placebo|Matching placebo to Aflibercept administered intravenously (IV) over 1 hour once on Day 1, every 3 weeks.
223812366|NCT00532155|DRUG|Docetaxel (Taxotere®)|75 mg/m² docetaxel in 250 mL dextrose 5% or NaCl 0.9% administered intravenously (IV) over 1 hour, on Day 1 every 3 weeks.
223812367|NCT00532155|DRUG|Dexamethasone (pre- and post-medication for docetaxel)|As a pre- and post-medication for docetaxel, 8 mg dexamethasone was administered orally, the evening before Day 1, on Day 1 (early morning, 1 hour before docetaxel treatment, and evening) and on Day 2 (morning and evening).
223812368|NCT04953130|BIOLOGICAL|Gardasil® HPV vaccine|Single dose 4-valent HPV vaccine in males. Gardasil®, manufactured by MSD, consists of a licensed prophylactic virus-like particle (VLP) vaccine that protects against 4 HPV genotypes (HPV 6, 11, 16, 18).
223812369|NCT04987268|GENETIC|clonal hematopoiesis of indeterminate potential|Whole-exome sequencing is performed to detect the presence of clonal hematopoiesis of indeterminate potential (CHIP)
223812370|NCT02134925|OTHER|Laboratory Biomarker Analysis|Correlative studies
223812371|NCT02134925|BIOLOGICAL|MUC1 Peptide-Poly-ICLC Vaccine|Given SC
223812372|NCT02134925|OTHER|Quality-of-Life Assessment|Ancillary studies
223812373|NCT02134925|OTHER|Saline|Given SC
223812374|NCT04545762|DRUG|Fludarabine|Given intravenously (IV)
223812375|NCT04545762|DRUG|Cyclophosphamide|Given intravenously (IV)
223812376|NCT04545762|BIOLOGICAL|anti-CD19 CAR-T cells|Single infusion
223812377|NCT03006770|BIOLOGICAL|PLX-PAD|Local intramuscular (IM) injections of PLX-PAD in the index leg.
223812378|NCT03006770|BIOLOGICAL|Placebo|Local intramuscular (IM) injections of Placebo in the index leg.
223812379|NCT06848231|DRUG|YA-101|"Drug: YA-101~• YA-101 taken BID"
223812380|NCT06848231|DRUG|Placebo|Placebo taken BID
223812381|NCT04987762|DRUG|Adhansia XR|Methylphenidate extended-release capsules taken once daily (12.5 mg, 25 mg, 35 mg, 45 mg, 55 mg, and 70 mg)
223812382|NCT05631795|DRUG|Alpelisib|Film coated tablet for oral use. Participants will be treated with 300 mg of alpelisib once daily starting on Cycle 1 Day 1
223812383|NCT05631795|DRUG|Fulvestrant|Injection for intramuscular administration. Participants will be treated with fulvestrant 500 mg on Cycle 1 Day 1 and Day 15, and Day 1 of every cycle thereafter in a 28-day cycle.
223812384|NCT02492854|DEVICE|PICO Single-Use Negative Pressure Dressings|Negative pressure wound therapy (NPWT), over the past several years, has provided a way to post-operatively manage complex wounds. This is a therapy with potential to decrease rates of SSIs post-LE bypass. Unlike standard gauze dressings, negative pressure wound therapy provides a sealed, moist environment and shuttles fluid away from the wound. A suctioning unit applies even, negative pressure (typically -80 to -120 mmHg) and exudate is suctioned and collected in a control unit. The investigators would like to investigate the efficacy of PICO (Smith\&Nephew), a single-use one-step wound dressing which is effective for 7 days. It is lightweight and uses a small hand-held vacuum pump, both of which allow for ease of use. PICO has been FDA-approved.
223812385|NCT02492854|OTHER|Sterile Gauze Dressings|Current standard-of-care dressings used to cover surgical wounds post-operatively.
223812386|NCT06067633|OTHER|Triple-Masked|Eligible manuscripts in the triple-masked editorial process arm will be masked electronically before being entered in the trial by the editorial assistant
223812387|NCT06067633|OTHER|Usual Procedures|Articles will be processed by the editors with identifiable/unmasking content of cover page and letters.
223812388|NCT05167266|BEHAVIORAL|Psychoeducation|Psychoeducation refers to the process of providing education and information to those seeking or receiving mental health services.
223812389|NCT01091948|DEVICE|Intubation with Fiberoptic laryngoscope|Subjects will be intubated with the Fiberoptic laryngoscope.
223812390|NCT01091948|DEVICE|GlideScope® Video Laryngoscope|Patients will be intubated with the GlideScope® Video Laryngoscope.
223812391|NCT03681574|DRUG|Placebo Group|Patients will be submitted to either myelogram or lumbar puncture procedure. Before that they will receive placebo concentrate.
223812392|NCT03681574|DRUG|GABA 15mg/kg Group|Patients will be submitted to either myelogram or lumbar puncture procedure. Before that they will receive gabapentin at 15mg/kg.
223812393|NCT03681574|DRUG|GABA 30mg/kg Group|Patients will be submitted to either myelogram or lumbar puncture procedure. Before that they will receive gabapentin at 30mg/kg.
223812394|NCT06131580|DRUG|Intervention/Treatment|"Drug: osilodrostat~\- osilodrostat, in the form of film coated tablets for oral administration, in the following tablet strengths: 1mg, 5mg, 10mg. Each strength has unique tablet size, colour and imprint."
223812395|NCT01326858|DRUG|Olopatadine hydrochloride ophthalmic solution, 0.7%|Treatment A
223812396|NCT01326858|DRUG|Olopatadine hydrochloride ophthalmic solution vehicle|Treatment B, inactive ingredients used as placebo
223812397|NCT01326858|DRUG|Ketotifen fumarate ophthalmic solution, 0.025%|Treatment C
223812398|NCT02158884|DEVICE|IDEO brace|All participants will receive the IDEO brace.
223812399|NCT03970239|DRUG|Positron Emission Tomography using [11 Carbon]-3-amino-4-(2-dimethylaminomethylphenylsulfanyl)-benzonitrile ([11C]-DASB) and [18 Fluorine]-altanserin ([18F]-altanserin)|"Imaging of the serotoninergic system with Positron Emission Tomography using \[11 Carbon\]-3-amino-4-(2-dimethylaminomethylphenylsulfanyl)-benzonitrile (\[11C\]-DASB) and \[18 Fluorine\]-altanserin (\[18F\]-altanserin). During this study, subjects will receive a single intravenous administration of approximately 4 Megabecquerel/kilogram (MBq/kg) of \[11C\]-DASB immediately prior to imaging using Positron Emission Tomography (PET). The effective dose in human body is about 2.1 milliSievert (mSv).~On a separate day, subjects will receive a single intravenous administration of approximately 3.7 MBq/kg of \[18F\]-altanserin for 120 minutes prior to imaging using Positron Emission Tomography (PET). The effective dose in human body is about 8.4 mSv."
223812400|NCT03970239|DRUG|Positron Emission Tomography using [18 Fluorine]-altanserin ([18F]-altanserin)|Imaging of the serotoninergic system with Positron Emission Tomography using \[18 Fluorine\]-altanserin (\[18F\]-altanserin). During this study, subjects will receive a single intravenous administration of approximately 3.7 Megabecquerel/kilogram (MBq/kg) of \[18F\]-altanserin 120 minutes prior to imaging using Positron Emission Tomography. The effective dose in human body is about 8.4 mSv.
223812401|NCT00770926|BEHAVIORAL|Live Well, Be Well|Lifestyle change program using personal contact and telephone counseling
223812402|NCT03872752|BEHAVIORAL|FL lay leader training and workshop implementation|Intervention components will include a training course for community lay leaders, enabling them to acquire the skills to lead food literacy workshops. This includes raising their knowledge about nutrition recommendations and food labels, raisin self efficacy, and improving nutrition related organization and preparation skills.
223812403|NCT05802368|OTHER|virtual reality group|a 30-minute VR-based training session utilizing Kinect Xbox after the session of traditional physical therapy.
223812404|NCT05802368|OTHER|exercise group|Traditional physical therapy, 30-minutes physical therapy exercise program each week with 48-hour intervals at least
223812405|NCT04484974|OTHER|Pecan snack|Under this condition, each participant will consume a mid morning snack of pecans followed by an ad libitum lunch.
223812406|NCT04484974|OTHER|Tortilla chip snack|Under this condition, each participant will consume a mid morning snack consisting of an iso-caloric (equal to the pecan snack) snack of tortilla chips followed by an ad libitum lunch.
223812407|NCT01530230|DRUG|oxytocin|Intravenous bolus dose given during 1 minute after clamping of the umbilical cord
223812408|NCT00446069|DRUG|Morphine Sulphate|Egalet® morphine, Controlled Release 30 mg Oral tablet once daily for 2 weeks and MST Continus® 15 mg twice daily for 2 weeks
223812409|NCT00079001|DRUG|zoledronic acid|Given IV
223812410|NCT00079001|OTHER|placebo|Given IV
223812411|NCT00079001|DRUG|androgen deprivation therapy|Patients concurrently enrolled on the Phase III study of intermittent androgen deprivation in patients with stage D2 prostate cancer will receive androgen deprivation therapy per SWOG-9346. All other patients will receive androgen deprivation therapy at a standard dose and schedule throughout the study.
223812412|NCT00079001|DRUG|GnRH agonist|Patients concurrently enrolled on the Phase III study of intermittent androgen deprivation in patients with stage D2 prostate cancer will receive the GnRH agonist per SWOG-9346. All other patients will receive GnRH agonist at a standard dose and schedule throughout the study.
223812413|NCT00079001|DIETARY_SUPPLEMENT|Calcium supplement|Patients will receive 500 mg by mouth daily of a calcium supplement or a combination tablet containing approximately 500 mg elemental calcium and 400-500 IU vitamin D by mouth daily.
223812414|NCT00079001|DIETARY_SUPPLEMENT|Vitamin D|Patients will receive a multivitamin tablet containing 400-500 IU vitamin D by mouth daily or a combination tablet containing approximately 500 mg elemental calcium and 400-500 IU vitamin D by mouth daily.
223812415|NCT01274091|OTHER|PUFA-diet|Diets will contain 30% of energy as fat, 18% as protein and 52% as carbohydrates: polyunsaturated fatty acid diet (PUFA) will have P/S ratio 1.0.
223812416|NCT01274091|OTHER|SAFA-diet|Diets will contain 30% of energy as fat, 18% as protein and 52% as carbohydrates: Saturated fatty acid diet (SAFA) will polyunsaturated/saturated (P/S) ratio of 0.3.
223812417|NCT06976736|OTHER|Observational|Long Term Follow-Up for participants treated with TSC-100 or TSC-101 TCR-T products
223812418|NCT06166693|DEVICE|"MINDLiNG Digital Mental Health Intervention"|The intervention was delivered on an online platform set up separately for the study, which was accessible via the web browser and application. The psychological intervention program for maladaptive personality traits (Mindling) is based on the principles of CBT, psychological schema therapy, acceptance-commitment therapy, and mindfulness-based cognitive therapy, and is aimed primarily at adults to prevent and overcome psychological difficulties
223812419|NCT00316173|DRUG|topotecan|HYCAMTIN at a dose of 2.0 mg/m2 on Days 1 and 8 every 21 days followed by carboplatin at AUC 5 on Day 1
223812420|NCT00316173|DRUG|CARBOPLATIN|HYCAMTIN at a dose of 2.0 mg/m2 on Days 1 and 8 every 21 days followed by carboplatin at AUC 5 on Day 1
223812421|NCT05857787|DEVICE|Ultrasound with nerve track function|The nerve track function installed in some ultrasound devices is software that accumulates ultrasound data obtained from humans and uses ultrasound to identify the target nerve through deep learning. Well-trained pain physicians use this feature to educate subjects before seeking brachial plexus and median nerve.
223812422|NCT05857787|DEVICE|Ultrasound without nerve track function|The nerve track function installed in some ultrasound devices is software that accumulates ultrasound data obtained from humans and uses ultrasound to identify the target nerve through deep learning. Well-trained pain physicians use ultrasound alone without this feature to educate subjects before seeking brachial plexus and median nerve.
223812423|NCT00769548|DRUG|flutamide|Drug used for TAS.
223812424|NCT00769548|DRUG|goserelin acetate|Drug used for TAS.
223812425|NCT00769548|RADIATION|low-LET photon therapy|radiation therapy
223812426|NCT00583986|DRUG|Levalbuterol HFA MDI with top mounted actuation indicator|Levalbuterol HFA MDA with top mounted actuation indicator
223812427|NCT04511754|BEHAVIORAL|Experiential Psychotherapy Skill Training|The Experiential Training intervention will include components of training not usually included in standard clinical training experiences; such components include opportunities for deliberate practice of the skills trained, live supervision and feedback, and discussion with a trainer focused on the skills taught and the trainees' performance.
223812428|NCT04511754|BEHAVIORAL|Standard Psychotherapy Skill Training|Standard didactic training with research support, examples, and opportunities to ask questions.
223812429|NCT03951454|BEHAVIORAL|Conexiones|5 Conexiones telephone sessions
223812430|NCT03951454|BEHAVIORAL|Taking Time|1 Taking Time telephone session
223812431|NCT04022967|DRUG|dolutegravir|One daily tablet (50mg) during 96 weeks
223812432|NCT04022967|DRUG|atazanavir boosted with ritonavir|One daily tablet with atazanavir (300 mg) boosted with ritonavir (100 mg) during 96 weeks
223812433|NCT04022967|DRUG|tenofovir + lamivudine +efavirenz or dolutegravir + lamivudine + tenofovir|One daily tablet with tenofovir 245 mg + lamivudine (300 mg) + efavirenz (400 mg) during 96 weeks OR One daily tablet with dolutegravir 50 mg + lamivudine (300 mg) + tenofovir (300 mg) during 96 weeks
223812434|NCT04022967|DRUG|Lamivudine|One daily tablet (300mg) during 96 weeks
223812435|NCT00812279|OTHER|Distillation based smoking article (SMAR cigarette)|Subjects randomised to the SMAR arm will be trained by the site staff on the usage of SMAR and the corresponding lighter prior to smoking the first SMAR. Subjects will be allowed to smoke SMAR without any limit on consumption during the designated smoking times but have to request each SMAR from the site staff when they wish to smoke.
223812436|NCT00812279|OTHER|conventional cigarette|Subjects randomised to the CC arm will continue to smoke their preferred CC brand during the exposure period. Subjects will be allowed to smoke without any limit on consumption during the designated smoking times but will have to request each CC from the site staff when they wish to smoke.
223812437|NCT00812279|OTHER|smoking cessation|Subjects will not be allowed to smoke any cigarettes or to use any other nicotine/tobacco-containing products during the 5 days following randomisation.
223812438|NCT01111357|BIOLOGICAL|Collect of 10 ml of peripheric blood for DNA extraction|After signed written consent, all patients have a clinic exam in order to assess the presence of eligibility criteria (Patient with Rheumatoid Arthritis that fulfil the ACR criteria of diagnosis)
223812439|NCT00000431|DRUG|PDGF-B/Ad5|This is a dose finding study to evaluate the safety of a single injection of PDGF dna in an adenoviral vector.
223812440|NCT03764072|DRUG|VX-150|Capsules for oral administration.
223812441|NCT03764072|DRUG|Placebo|Capsules for oral administration.
223812442|NCT01975155|OTHER|food questionnaire|
223812443|NCT01975155|OTHER|Urinary mycotoxin test|
223812444|NCT03390387|DRUG|Dexamethasone continuous|6 mg/m2, per os, in two divided doses per day q12 hours. 1-28 day (dose in the first few days is depending on the total tumor mass). From day 29 the dose of dexamethasone is reducing: days 29-31 - 3 mg/m2, days 32-34 - 1.5 mg/m2, days 35-36 - 0.75 mg/m2; then dexamethasone is discontinued completely.
223812445|NCT03390387|DRUG|Dexamethasone intermittent|6 mg/m2, per os, in two divided doses per day q12 hours. Days: 1-14 (dose in the first few days is depending on the total tumor mass) and 22-28; days 15-21 - pause. From day 29 the dose of dexamethasone is reducing: days 29-30 - 3 mg/m2, days 31-32 - 1.5 mg/m2, then dexamethasone is discontinued completely.
223812446|NCT03390387|DRUG|Dexamethasone|"Induction: 6 mg/m2, per os, in two divided doses per day q12 hours. 1-28 day (dose in the first few days is depending on the total tumor mass). From day 29 the dose of dexamethasone is reducing: days 29-31 - 3 mg/m2, days 32-34 - 1.5 mg/m2, days 35-36 - 0.75 mg/m2; then dexamethasone is discontinued completely.~Consolidation: 6 mg/m2 per os, in two divided doses per day q12 hours. Weeks 13-14 (days 85-98), weeks 21-22 (days 141-154), weeks 29-30 (days 197-210), weeks 37-38 (days 253-260), weeks 45-46 (days 309-316), weeks 53-54 (days 365-372).~Maintenance therapy: 6 mg/m2, per os, in two divided doses per day q12 hours, for 10 days followed by quick discontinuation during 3 days. Weeks 61-62, 69-70, 77-78, 85-86, 93-94."
223835495|NCT02264392|PROCEDURE|Ultrasound Guided Incision and Drainage|Ultrasound guidance of the abscess drainage
223835496|NCT02264392|PROCEDURE|Blind Incision and Drainage|Incision and drainage of abscess guided by physical exam alone
223835497|NCT00632528|DRUG|MEOPA|Administration of MEOPA gaz during postoperative physical therapy
223812447|NCT03390387|DRUG|Methylprednisolone|"Induction: 60 mg/m2, per os, in two divided doses per day q12 hours. 1-28 day (dose in the first few days is depending on the total tumor mass). From day 29 the dose of dexamethasone is reducing: days 29-31 - 30 mg/m2, days 32-34 - 15 mg/m2, days 35-36 - 8 mg/m2; then methylprednisolone is discontinued completely.~Consolidation: 60 mg/m2 per os, in two divided doses per day q12 hours. Weeks 13-14 (days 85-98), weeks 21-22 (days 141-154), weeks 29-30 (days 197-210), weeks 37-38 (days 253-260), weeks 45-46 (days 309-316), weeks 53-54 (days 365-372).~Maintenance therapy: 60 mg/m2, per os, in two divided doses per day q12 hours, for 10 days followed by quick discontinuation during 3 days. Weeks 61-62, 69-70, 77-78, 85-86, 93-94."
223812448|NCT03390387|DRUG|Daunorubicin|Induction: 45 mg/m2, intravenously, for 6 hours on days 8 and 22. Consolidation: 30 mg/m2, intravenously, for 6 hours on days 44, 65 (consolidation S1); 107, 121 (consolidation S2); and 163 (consolidation S3).
223812449|NCT03390387|DRUG|Idarubicin|Induction: 10 mg/m2, intravenously, for 6 hours on days 8 and 22. Consolidation: 8 mg/m2, intravenously, for 6 hours on days 44, 65 (consolidation S1); 107, 121 (consolidation S2); and 163 (consolidation S3).
223812450|NCT03390387|DRUG|Bortezomib|1.3 mg/м2, intravenously, bolus injection. Days 85, 89, 92, 96 (consolidation S1); 141, 145, 148, 152 (consolidation S2) and 197, 201, 204, 208 (consolidation S3).
223812451|NCT03390387|DRUG|Second phase of induction|Cyclophosphamide (1,000 mg/m2, intravenously, for 1 hour - days 43 and 71); Cytarabine (75 mg/m2/day, intravenously, bolus injection. Four blocks of 4 days each, days 46-48, 52-55, 59-62, and 66-69); 6-mercaptopurine (60 mg/m2/day, per os, days 43-71); Triple intrathecal therapy (days 52 and 66)
223812452|NCT03390387|DRUG|Standard induction therapy|Dexamethasone (6 mg/m2, p/o; 1-29 days); Daunorubicin (45 mg/m2, i.v.; day 8 and 22); Vincristine (1.5 mg/m2, i.v.; days 8, 15, 22, 29 and 36); Triple intrathecal therapy (Methotrexate/Cytarabine/Prednisone; days 0/1, 8, 15, 22, 29 and 36)
223812453|NCT03390387|DRUG|Standard consolidation therapy|Consolidation consists of 3 phases: S1, S2 and S3. Each phase is a 6-week therapy with 6-mercaptopurine (50 mg/m2 per day, daily, orally), methotrexate (30 мг/м2, i.m., weekly) and L-asparaginase (10 000 U/m2, i.m., weekly), followed by 2 weeks of re-induction with Vincristine (1.5 mg/m2, i.v., days 1 and 8 of reinduction) plus Dexamethasone (6 mg/m2, p/o, daily, for 10 days followed by quick discontinuation during 3 days). Daunorubicin (30 mg/м2, i.v., N2 during S1, N2 during S2 and N1 during S3). Triple intrathecal therapy (Methotrexate/Cytarabine/Prednisone) N12 (4 injections per each phase)
223812454|NCT01342705|PROCEDURE|phlebotomy|Procedure: Phlebotomy of 4 ml / kg to obtain (1 phlebotomy every 14 days) and maintain (1 phlebotomy every 3 months) a serum ferritin below 50 µg / l.
223812455|NCT01592331|DRUG|Placebo|Single oral dose
223812456|NCT01592331|DRUG|RO5508887|Single oral dose
223812457|NCT05438654|DIAGNOSTIC_TEST|Point of care ultrasound|"Abdominal PoCUS use according to the following protocol:~PoCUS assessment of the right lung base PoCUS assessment of Morrison's pouch PoCUS assessment of gallbladder PoCUS assessment of right kidney (comparison to left kidney acceptable) PoCUS assessment of small bowel"
223812458|NCT00333164|DRUG|Asprin, Cilostazol|
223812459|NCT01965210|OTHER|Rye + high dose inulin + low dose gluten|In a randomized cross-over design each subject receive one of six iso-caloric breakfasts on six different occasions, separated by 1 w wash-out.
223812460|NCT01965210|OTHER|Rye + equal doses of inulin & gluten|In a randomized cross-over design each subject receive one of six iso-caloric breakfasts on six different occasions, separated by 1 w wash-out.
223812461|NCT01965210|OTHER|Rye + low dose inulin + high dose gluten|In a randomized cross-over design each subject receive one of six iso-caloric breakfasts on six different occasions, separated by 1 w wash-out.
223812462|NCT01965210|OTHER|Large non-supplemented rye|In a randomized cross-over design each subject receive one of six iso-caloric breakfasts on six different occasions, separated by 1 w wash-out.
223812463|NCT01965210|OTHER|Small non-supplemented rye|In a randomized cross-over design each subject receive one of six iso-caloric breakfasts on six different occasions, separated by 1 w wash-out.
223812464|NCT01965210|OTHER|Refined wheat bread|In a randomized cross-over design each subject receive one of six iso-caloric breakfasts on six different occasions, separated by 1 w wash-out.
223812465|NCT00084370|DRUG|celecoxib|Patients receive ora celecoxib twice daily for 3 months prior to prophylactic oophorectomy.
223812466|NCT00084370|PROCEDURE|oophorectomy|
223835498|NCT00632528|DRUG|Medicinal air|Administration of medical air during postoperative physical therapy
223812467|NCT04534257|DEVICE|SELUTION Sirolimus DCB|Suitable lesions will be treated with SELUTION Sirolimus DCB
223812468|NCT04725344|OTHER|ACTIV'DOS group|ACTIV'DOS group use ACTIV'DOS application (with smartphone) to do the self rehabilitation each day (15 minutes per day) during 6 weeks. There are 7 exercices.
223812469|NCT04725344|OTHER|Usual practise|Control group uses a standard sheet of paper to do the self-rehabilitation (15 minutes per day) during 6 weeks. There are 7 exercises.
223812470|NCT01637779|BEHAVIORAL|Fact sheet|fact sheet about pain management during immunization
223812471|NCT06088524|OTHER|Social Media Fatigue|Mental Fatigue creation protocol: It has been reported that at least 30 minutes of social media use causes mental fatigue and impairs lower extremity and decision-making performance (Fortes et al., 2021). For mental fatigue with social media, participants will be created with 45 minutes of continuous use of social media (instagram, facebook, twitter, youtube) on smartphones by concentrating with headphones.
223812472|NCT00606190|PROCEDURE|Retrograde brain perfusion|observational
223812473|NCT00606190|PROCEDURE|Antegrade brain perfusion|observational
223812474|NCT04794231|OTHER|Standard dressing|a standard breathable, hypoallergenic, transparent dressing (TegadermTM 1635 \[8.5 x 10.5cm\] or 1633 \[7 × 8.5 cm\] depending on patient size; 3M, Neuss, Germany)
223812475|NCT04794231|OTHER|Chlorhexidine gluconate -impregnated dressing group|A chlorhexidine gluconate -gel impregnated transparent dressing (TegadermTM CHG 1660R \[7 x 8.5 cm\] or \[11.5 x 8.5 cm\] depending on patient size; 3M, Neuss, Germany).
223812476|NCT04467957|DRUG|Initiation of CFTR Modulator|Inhaled contrast for MRI occurring at each visit
223812477|NCT04467957|DRUG|Hyperpolarized Xenon 129|Inhaled contrast for MRI occurring at each visit
223812478|NCT01896401|DEVICE|InSeal's Vascular Closure Device|
223812479|NCT00161239|DRUG|Doxil, Methotrexate, L-Asparaginase, Prednisone|
223812480|NCT03323879|RADIATION|LDR/HDR|Focal LDR to dominant lesion with whole gland 19 Gy HDR
223812481|NCT00652223|BIOLOGICAL|CYT005-AllQbG10|Immunomodulator CYT003-QbG10 in combination with commercial house dust mite extract as used for routine SIT
223812482|NCT02919722|BEHAVIORAL|Music Therapy|The majority of each study session will be spent engaging in music therapy: playing live music with a music therapist with the help of an occupational therapist. At the beginning and end of each session subjects will complete 2 assessments.
223812483|NCT05208684|OTHER|Breast stimulation|Breast stimulation by the Elvie Pump to trigger prolactin release.
223812484|NCT05897255|DEVICE|Surface EMG Biofeedback|Surface EMG activity will be recorded from the left and right abdominal muscles while the exercises will be performed in different positions. Electrical signals in the muscle are measured and displayed on the screen and are amplified into sounds that the patient can hear. This feedback increases patient effort and participation and provides the data and documentation required to measure patient outcomes and quantify progress. Electrical activity from Rectus Abdominis muscle, External Oblique muscle and Transversus Abdominis muscle will be recorded with their specific exercises. SEMG Biofeedback protocol of a series of ten second contractions, each contraction preceded by a ten second rest period will be followed. Starting with shorter work/rest periods as needed to build-up to these intervals are acceptable; for example, starting with 3-second contractions and 6-second rest periods, and then gradually increasing the duration of each.
223812485|NCT05959343|BEHAVIORAL|Enhanced Recovery After Surgery program for Oblique Lumbar Interbody Fusion|In the ERAS CP group, the components of the ERAS are protocolized and implemented as a clinical pathway
223812486|NCT06328764|GENETIC|CS-101|Autologous CD34+ hematopoietic stem cell suspension modified by in vitro base editing technique
223812487|NCT04618666|PROCEDURE|laparoscopic and open surgery intervention|laparoscopic and open surgery to remove an inflammed appendix in chronic appendicitis
223812488|NCT00558064|DRUG|telmisartan+amlodipine|
223812489|NCT00558064|DRUG|amlodipine|
223812490|NCT02801539|DEVICE|RMT therapy using modified RMT device|The exercises provided by the RMT device is intended to strengthen breathing muscles.
223812491|NCT02801539|DEVICE|Sham-RMT therapy using modified RMT device|The exercises provided by the Sham-RMT modified device is not intended to strengthen breathing muscles.
223812492|NCT06081764|OTHER|Exercise|Doing Otago Exercise Program, which lasting 3 days a week and an average of 30 minutes per day under the supervision of a physiotherapist. Also doing walking exercise for 30 minutes a day, 2 days a week for total of 12 weeks.
223812493|NCT01834508|DRUG|oral entecavir 0.5mg daily and adefovir 10mg daily for 144 weeks|
223812494|NCT03152084|DRUG|Dapagliflozin|The study consists of a 2-week, open label, dapagliflozin (10mg) treatment period.
223812495|NCT05696210|OTHER|Transfusion rate of red blood cells|Transfusion rate of red blood cells greater than 7
223812496|NCT04284345|PROCEDURE|Saline Pd/Pa|"Use of a ≥6F guiding catheter and the Verrata pressure guidewire. Administration of intracoronary nitroglycerin.~Verrata normalisation and placement of the Verrata sensor ≥3 vessel-diameter beyond the stenosis.~Whole cycle resting Pd/Pa and resting iFR measurements.~Measurement of contrast FFR: record 5 baseline heart beats, injection of contrast media, 10 ml in the left coronary system, 8 ml in the right coronary system, measure minimal Pd/Pa under stable hyperaemia.~Adenosine FFR: measurement: record 5 baseline heart beats, injection of intracoronary adenosine, 200 mcg in the left coronary system, 100 mcg in the right coronary system, measure minimal Pd/Pa under stable hyperaemia.~Saline-induced Pd/Pa measurement: record 5 baseline heart beats, injection of saline using the ACIST system during 5 heart beats, measure minimal Pd/Pa under stable hyperaemia.~Perform pressure guidewire pullback and check for drift: drift ±0.02 is accepted, if ≥0.03, repeat measurement."
223812497|NCT00765596|OTHER|Liquid diet for 3 days|The control group were given a 3 -day liquid diet similar to the RYGB post-op diet
223812498|NCT00982930|DRUG|Tobramycin inhalation powder|Tobramycin inhalation powder, 112 mg (4 capsules of 28 mg), inhalation capsules, b.i.d.
223812499|NCT03915639|PROCEDURE|Peri-incisional injection|The surgeons are planned to inject the cocktail mixture or ropivacaine to muscles and the subcutaneous tissue beneath the fixation sites and incision site using a 22-gauge needle in a sterile fashion prior to skin incision.
223835499|NCT04707391|COMBINATION_PRODUCT|MenABCWY vaccine|2 doses of MenABCWY vaccine administered intramuscularly on Day 1 and Day 181 to participants in ABCWY group.
223812500|NCT02764710|DRUG|Amoxicillin-Potassium Clavulanate Combination|"Short course of postoperative treatment: amoxicillin-clavulanate 875mg, one tab twice daily for a total of 2 doses.~Long course of postoperative treatment: amoxicillin-clavulanate 875mg, one tab twice daily up until and including postoperative day 7."
223812501|NCT05788302|BEHAVIORAL|Prolonged Exposure|\- Participation will occur throughout 17 weeks over 15 separate visits during which 10, 60-minute sessions of PE will take place. Session 1 of PE will focus on psychoeducation. Session 2 of PE will involve a continuation of psychoeducation and rationale for exposure as well as the collaborative construction of the in vivo exposure hierarchy. After session 2, participants will begin homework where they are instructed to confront situations on their hierarchy. Starting in session 3 of PE, participants will begin imaginal exposures to their worst trauma memory. This involves the participant recounting and visualizing the trauma memory aloud with the clinician in the room for 30-40 minutes. The session will end with 15-20 minutes of processing the imaginal exposure. Participants will continue in-session imaginal exposures until the end of treatment. Throughout the treatment, participants will listen to a recording of their imaginal exposure and engage in in vivo exposures daily.
223812502|NCT06492798|DRUG|umbilical cord mesenchymal stem cell|intravenous infusion of umbilical cord mesenchymal stem cell
223812503|NCT04484025|DRUG|Ebselen|Glutathione peroxidase mimetic
223812504|NCT04484025|DRUG|Placebo|Matching placebo containing excipients
223812505|NCT04539314|DRUG|Bupivacain|We will carry out the TAP block using 0.5 ml/ kg bupivacaine 0.25%
223812506|NCT04539314|DRUG|Dexmedetomidine o.5 μg|We will carry out the TAP block using using 0.5 ml/ kg bupivacaine 0.25% with dexmedetomidine 0.5 μg / kg
223812507|NCT04539314|DRUG|Dexmedetomidine 1 μg|We will carry out the TAP block using using 0.5 ml/ kg bupivacaine 0.25% with dexmedetomidine 1 μg / kg
223812508|NCT02236065|PROCEDURE|Umbilical cord blood therapy|
223812509|NCT02236065|BIOLOGICAL|Filgrastim|
223812510|NCT05749848|DRUG|[¹⁴C]-LY3372689|Administered orally.
223812511|NCT06425848|DEVICE|Observational|We are collecting information for both retrospective and prospective arm to further understand the utility of PA pressure sensors.
223812512|NCT01356680|DRUG|BEACOPPescalated (Bleomycin, Etoposide, Adriamycin, Cyclophosphamide, Vincristine, Procarbazine, Prednisone)|
223812513|NCT01356680|DRUG|ABVD (Adriamycin, Bleomycin, Vinblastine, Dacarbazine)|
223812514|NCT01356680|RADIATION|30Gy IF-RT (Involved-Field Radiotherapy)|
223812515|NCT01356680|RADIATION|30Gy IN-RT (Involved-Node Radiotherapy)|
223812516|NCT02537639|DEVICE|Transesophageal echocardiography simulator|
223812517|NCT01489189|OTHER|Prompt Panretinal Photocoagulation|Panretinal photocoagulation alone at baseline (full session completed within 56 days).
223812518|NCT01489189|DRUG|0.5-mg Ranibizumab|Intravitreal injection of 0.5 mg ranibizumab (Lucentis™) at baseline and up to every 4 weeks using defined retreatment criteria.
223812519|NCT01489189|OTHER|Deferred panretinal photocoagulation|PRP is deferred until failure/futility criteria for intravitreal injection are met.
223812520|NCT02699879|DRUG|Pirfenidone|Pirfenidone will be administered according to the physician discretion as part of standard care.
223812521|NCT00426725|DEVICE|EasyLabour|According to the trial protocol
223812522|NCT01521962|DRUG|Alogliptin|Alogliptin tablets
223812523|NCT01521962|DRUG|Insulin|Insulin injection
223812524|NCT02822625|DRUG|QUTENZA®|
223812525|NCT02822625|OTHER|hypnotic message|
223812526|NCT02822625|OTHER|music therapy|
223812527|NCT03062462|DRUG|Clopidogrel|double standard-dose clopidogrel treatment (300 mg loading dose, then 75 mg twice daily) for 5-7 days
223812528|NCT03062462|DRUG|ticagrelor|half-dose ticagrelor treatment (90 mg loading dose, then 45 mg twice daily) for 5-7 days
223812529|NCT05597722|BEHAVIORAL|Digital cognitive behavioral intervention-RxWell|RxWell is a coach enhanced digital behavioral health intervention that teaches techniques to help manage emotional distress, which may improve cognitive fog and/or depression. Participants will have access to this app for three months.
223812530|NCT05597722|DRUG|Amphetamine-Dextroamphetamine|Participants randomized to this arm will be prescribed 10mg of amphetamine-dextroamphetamine to take as needed to help with cognitive fog. Participants in this arm will be contacted at 2 and 6 weeks to assess for any side effects from taking the medication.
223812531|NCT06477640|BEHAVIORAL|Exercise|The intervention group will receive daily activity messages sent through SMS text message or email.The messages will provide daily exercises with heart rate guidance.
223812532|NCT06477640|BEHAVIORAL|Standard of Care|"The control group will receive daily non-descript messages to help with blinding and to eliminate the confounding variable of daily contact. The messages will not include activity tasks and will include phrases such as I hope you have a good day."
223812533|NCT05660590|OTHER|complex decongestive physiotherapy with low pressure compression bandage|both group received complex decongestive physiotherapy consist of manual lymph dranaige, skin care, exercise and compression bandage. Every component except compression bandage applied exacly the same to both group. Compression bandage applied with low bandage interface pressure (20-30 mmHg)
223812534|NCT05660590|OTHER|complex decongestive physiotherapy with high pressure compression bandage|complex decongestive physiotherapy consist of manual lymph dranaige, skin care, exercise and compression bandage. Every component except compression bandage applied exacly the same to both group. Compression bandage applied with high bandage interface pressure (45-55 mmHg)
223812535|NCT03588793|OTHER|Two Point Discrimination|Validity of mechanism in phantom limb pain i.e. cortical reorganisation to be tested using comparison of data from interventions above
223835500|NCT04707391|COMBINATION_PRODUCT|Placebo|1 dose of placebo administered intramuscularly on Day 211 to participants in ABCWY group
223812536|NCT03675932|OTHER|Rapid Cadence Cycling on a Solo-Rider Spin Bicycle|Individuals with Parkinson's Disease will participate in 60 minute spin-classes during which they will follow the Pedaling for Parkinson's(TM) Foundation recommended protocol to achieve a cadence of 80-90 during the 40 minute main set.
223812537|NCT01489943|DRUG|GSK1605786 500 mg|Subjects will receive 500 milligram (mg) (2 doses of 250 mg) GSK1605786 hard gelatin capsules twice daily orally on Days 5 to 14. GSK1605786 will be administered with 240 milliliter (mL) of water.
223812538|NCT01489943|DRUG|Midazolam 3 mg|Subjects will receive 3 mg oral syrup of Midazolam once daily on Day 1 and Day 11. Midazolam will be administered with 240 mL of water.
223812539|NCT01489943|DRUG|Pioglitazone 15 mg|Subjects will receive 15 mg tablet of pioglitazone orally once daily on Day 2 and Day 12. Pioglitazone will be administered with 240 mL of water.
223812540|NCT01489943|DRUG|Omeprazole 40 mg|Subjects will receive 40 mg hard gelatin capsules of Omeprazole once daily on Days 3 and 13. Omeprazole will be administered with 240 mL of water.
223812541|NCT01489943|DRUG|Rosuvastatin 10 mg|Subjects will receive 10 mg tablet of Rosuvastatin orally once daily on Days 4 and 14. Rosuvastatin will be administered with 240 mL of water.
223812542|NCT00404495|DRUG|Irinotecan|Irinotecan 10 mg/m\^2 per day on days 1-5 and days 8-12 in repeated 3 week cycles
223812543|NCT00404495|DRUG|Temozolomide|Temozolomide 100-125 mg/m\^2 daily on days 1-5 in repeated 3 week cycles
223812544|NCT02013310|DRUG|HT-0712|
223812545|NCT02013310|DRUG|Placebo|
223812546|NCT01018225|DRUG|darifenacin|7.5 or 15 mg darifenacin, once a day for 6 weeks
223812547|NCT01018225|DRUG|Placebo|Placebo pill, once a day, for six weeks
223812548|NCT04987125|BEHAVIORAL|Dyspnea Neuroscience education|"Patients will follow an online therapeutic education course about dyspnea. Education about the cognitive and emotional aspects of dyspnea processing, with the goal of changing maladaptive cognitions and behaviors.~The course will be group-based (5 participants). The frequency will be of 1 session per week for 4 weeks, each session will have a duration of 1 hour."
223812549|NCT04987125|BEHAVIORAL|Usual care|General health advice, physiotherapy treatment. The frequency will be of 1 session per week for 4 weeks, each session will have a duration of 1 hour.
223812550|NCT02026323|OTHER|acupuncture|acupuncture
223812551|NCT04108000|BEHAVIORAL|SPIRIT-Dementia|"The interventionist will begin the SPIRIT-dementia session by assessing the patient's and surrogate's cognitive, emotional, and spiritual/religious representations of the patient's illness, prognosis, and end-of-life care. Individualized information will be provided about the effectiveness of life-sustaining treatment for people with end-organ failure, and the patient will examine their values about life-sustaining treatment at the end of life. The interventionist will help the surrogate prepare for end-of-life decision-making and for the emotional burden of decision-making. A Goals-of-Care document will be completed at the end of the session. The delivery of SPIRIT-dementia incorporates enhanced consent techniques, such as reducing information load by proceeding in manageable segments, offering repetition of material, opportunity for rehearsal, and using targeted questioning to verify adequate comprehension prior to eliciting preferences for goals of care."
223812552|NCT04108000|BEHAVIORAL|Usual Care|As required by Centers for Medicare and Medicaid Services (CMS) written information on advance directives is provided to a patient on the first day of dialysis, and a social worker reviews this information with patients and encourages them to complete an advance directive.
223812553|NCT04166825|DIAGNOSTIC_TEST|fibrin clot properties|Assessment of thrombin generation and efficiency of fibrinolysis.
223812554|NCT02765919|RADIATION|HDR Brachytherapy of 9 Gy in 2 fractions|Two fractions of HDR brachytherapy following standard dose CCRT in locally advanced carcinoma cervix
223812555|NCT02765919|RADIATION|HDR Brachytherapy of 7 Gy in 3 fractions|Three fractions of HDR Brachytherapy following standard dose CCRT in locally advanced carcinoma cervix
223812556|NCT06253845|BIOLOGICAL|CG0070|CG0070 will be administered at a dose of 1x10\^12 vp intravesically following a sequence of bladder washes with DDM and normal saline.
223812557|NCT02536014|DRUG|Dexmedetomidine|Dexmedetomidine infusion (0.3㎍/kg/hr) from anesthetic induction to the end of pneumoperitoneum
223812558|NCT02536014|DRUG|Saline|Saline infusion during the same time period
223812559|NCT05632835|OTHER|3D printing guide plate|3D-printed customized guide plate will be used to guide the puncture in endoscopic spinal surgeries to help to reduce intra-operative radiation, puncture time, etc..
223812560|NCT05632835|OTHER|Conventional guidance|The surgeons would place the needle according to his/her previous experience under the guidance of C-arm fluoroscopy or CT.
223812561|NCT01330810|DRUG|curcumin|standardized curcumin supplements containing curcumin, demethoxycurcumin and bisdemethoxycurcumin
223812562|NCT00876538|DRUG|Olesoxime (TRO19622)|2 capsules of TRO19622 (330 mg) once day with the noon meal
223812563|NCT00876538|DRUG|Placebo Control|Placebo Control 2 capsules once day with the noon meal
223812564|NCT03243162|BEHAVIORAL|CBPT-ACLR|The CBPT-ACLR program focuses on improving sports function and return to sport. CBPT-ACLR sessions cover realistic expectations, relaxation strategies, problem-solving training, cognitive restructuring, and behavioral self-management (i.e., graded activity, goal setting, managing setbacks and symptom management plans). Each session builds upon the content of the previous session using an action plan and weekly homework is personally tailored based on patient goals. The program consists of one preoperative telephone session and six postoperative telephone sessions with a physical therapist. Each patient randomized into the CBPT-ACLR program will receive a manual to follow along with the study therapist.
223835501|NCT04707391|BIOLOGICAL|MenACWY vaccine|1 dose of MenACWY vaccine administered intramuscularly on Day 1 to participants in ACWY group
223812565|NCT03243162|OTHER|Education|The education program focuses on postoperative ACLR recovery. Sessions address benefits of physical therapy, proper biomechanics during sports and other functional activity, importance of early exercise after surgery, and ways to promote healing. Education on stress reduction, sleep hygiene, energy management, communication with health providers, and preventing future injury are also provided. The Education program is matched to the CBPT-ACLR treatment in terms of session frequency, length and contact with the study therapist. Each patient randomized into the Education program will receive a manual to follow along with the study therapist.
223812566|NCT06624644|BIOLOGICAL|LNS8801|G protein-coupled estrogen receptor (GPER) agonist
223812567|NCT06624644|BIOLOGICAL|Pembrolizumab|Recombinant monoclonal antibody (anti-PD1)
223812568|NCT06624644|DRUG|Chemotherapy (dacarbazine or temozolomide)|chemotherapy (dacarbazine, temozolomide)
223812569|NCT06624644|BIOLOGICAL|Immunotherapy (Pembrolizumab)|pembrolizumab
223812570|NCT06624644|BIOLOGICAL|Immunotherapy (nivolumab and relatlimab)|nivolumab and relatlimab
223812571|NCT06624644|BIOLOGICAL|Immunotherapy (ipilimumab and nivolumab)|ipilimumab and nivolumab
223812572|NCT05211323|BIOLOGICAL|Atezolizumab|Given IV
223812573|NCT05211323|BIOLOGICAL|Bevacizumab|Given IV
223812574|NCT05211323|PROCEDURE|Biospecimen Collection|Undergo blood specimen collection
223812575|NCT05211323|DRUG|Cisplatin|Given IV
223812576|NCT05211323|PROCEDURE|Computed Tomography|Undergo CT
223812577|NCT05211323|PROCEDURE|Conventional Magnetic Resonance Imaging|Undergo MRI
223812578|NCT05211323|DRUG|Gemcitabine Hydrochloride|Given IV
223812579|NCT05524571|DRUG|Batoclimab|Batoclimab is a fully human anti-neonatal fragment crystallizable receptor (FcRn) monoclonal antibody
223812580|NCT05524571|DRUG|Placebo|Matching Placebo
223812581|NCT03466918|DEVICE|SAPIEN 3 THV with the Commander delivery system|Edwards SAPIEN 3 Transcatheter Heart Valve is implanted using the Commander delivery system
223812582|NCT06172582|BEHAVIORAL|12-week lifestyle intervention|A 12-week lifestyle intervention delivered via weekly group meetings in the House Chat Leaders (HCL's) homes
223812583|NCT06638398|PROCEDURE|Computed Tomography|Undergo standard of care Computed Tomography
223812584|NCT06638398|DEVICE|Diagnostic Procedure|Receive a Virtual Nodule Clinic radiomic prediction score obtained in Optellum software.
223812585|NCT06638398|OTHER|Best Practice|Receive standard of care lung nodule management
223812586|NCT06638398|OTHER|Electronic Health Record Review|Ancillary Studies
223812587|NCT06284564|DRUG|Evolocumab|Given by SC
223812588|NCT06284564|DRUG|Nivolumab|Given by IV
223812589|NCT06036238|BEHAVIORAL|Healthy Living Intervention (HLI)|The Healthy Living Intervention (HLI) is a brief alcohol counseling intervention developed using the Information, Motivation, and Behavioral skills (IMB) model, a framework in which information, motivation, and behavioral skills are key determinants of health behavior. Participants initiating PrEP will be randomized to either HLI or standard of care alcohol counseling.
223812590|NCT06036238|BEHAVIORAL|Standard of Care|Participants who are randomized to the control arm will receive basic alcohol counseling through the Ministry of Health if it is provided as standard of care.
223812591|NCT04579523|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo HCT
223812592|NCT04579523|BIOLOGICAL|Astatine At 211 Anti-CD38 Monoclonal Antibody OKT10-B10|Given IV
223812593|NCT04579523|DRUG|Cyclophosphamide|Given IV
223812594|NCT04579523|DRUG|Fludarabine Phosphate|Given IV
223812595|NCT04579523|RADIATION|Total-Body Irradiation|Undergo TBI
223812596|NCT04579523|PROCEDURE|Biospecimen Collection|Undergo blood collection
223812597|NCT04579523|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspirate
223812598|NCT04579523|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
223812599|NCT04579523|PROCEDURE|X-Ray Imaging|Undergo chest x-rays
223812600|NCT04649385|DRUG|BGB-15025|Administered orally once or twice daily (QD or BID)
223812601|NCT04649385|DRUG|Tislelizumab|Administered 200 mg intravenous (IV) infusion
223812602|NCT01676337|OTHER|Text message appointment reminder|Patients randomized to the intervention arm will receive text message appointment reminders including date, time, and location seven, three and one day prior to their scheduled clinic appointments. All appointment reminders will then be delivered automatically.
223812603|NCT06457633|BEHAVIORAL|Experiential FW|Traditional Fibrowalk based on Pain Science Education (30 min.) - Cognitive restructuring (30 min.) - Mindfulness techniques (30 min.) - Physical exercise in a natural environment / nature exposure (30 min.) carried out experientially.
223812604|NCT06457633|BEHAVIORAL|Traditional FW|Traditional Fibrowalk based on Pain Science Education (30 min.) - Cognitive restructuring (30 min.) - Mindfulness techniques (30 min.) - Physical exercise in a natural environment / nature exposure (30 min.)
223812605|NCT06457633|BEHAVIORAL|Online FW|Traditional Fibrowalk based on Pain Science Education (30 min.) - Cognitive restructuring (30 min.) - Mindfulness techniques (30 min.) - Physical exercise in a natural environment / nature exposure (30 min.) performed virtually.
223812606|NCT00486421|BIOLOGICAL|Rituximab|375mg/m2 IV weekly times 4 (days 1, 8, 15, 22)
223812607|NCT00486421|DRUG|Prednisone|1mg/kg/d PO, taper to off by 8 weeks
223812608|NCT06361901|DEVICE|Zenicog;language rehabilitation program|This program is an AI-based computerized cognitive and language training program.
223812609|NCT06361901|PROCEDURE|Conventional language rehabilitation|Conventional language rahabilitation therapy will apply for all participants with speech impairement
223812610|NCT04386525|DIETARY_SUPPLEMENT|Omega-3 fish oil|soft gels,1000gm, 84% of DHA and EPA
223812611|NCT05110196|DRUG|Capmatinib 150 mg|Capmatinib film-coated tablet 150 mg administered BID with or without food for 24 weeks. It should be swallowed whole and should not be broken, chewed, or crushed.
223812612|NCT05110196|DRUG|Capmatinib 200 mg|Capmatinib film-coated tablet 200 mg administered BID with or without food for 24 weeks. It should be swallowed whole and should not be broken, chewed, or crushed.
223812613|NCT05874804|DEVICE|Carry Life UF|A 5-hour treatment with the Carry Life UF used with a 1.36% glucose PD fill.
223812614|NCT05874804|DRUG|2.27% glucose peritoneal dialysis dwell|A 5-hour CAPD dwell with a 2.27% glucose PD fluid.
223812615|NCT06337370|BEHAVIORAL|Chronic Disease Self Management Program|"Experimental Intervention (Self-Management Program):~In addition to standard care from a rheumatology specialist, the intervention group will receive the Chronic Disease Self-Management Program (CDSMP). This program is a group intervention that provides education on self-managing chronic diseases. The program consists of six weekly sessions, each lasting two and a half hours (including time for breaks and refreshments), for a total of six weeks. Each group will consist of 12 to 16 participants, and the sessions will follow a standardized, scripted format. Two group leaders, who have received training from a Master Trainer certified by Stanford University in how to implement the program, will lead the activities. For this study, the principal investigator and a nurse experienced in health education will undergo training from a CDSMP Master Trainer to ensure fidelity to the intervention."
223812616|NCT06337370|BEHAVIORAL|Conventional Intervention- Standard care|"Conventional intervention (standard care):~The control group will receive standard care provided by a rheumatology specialist. This approach emphasizes clinical and clinimetric evaluations of rheumatoid arthritis. It includes applying validated disease activity indices (e.g., DAS28, CDAI, or SDAI), making therapeutic decisions, and adjusting medications according to current clinical practice guidelines. It also includes the standard clinical counseling provided during routine medical consultations. No additional self-management strategies or structured interventions beyond those already incorporated into routine healthcare practice will be included."
223812617|NCT04411849|OTHER|Best Practice|Receive usual care
223812618|NCT04411849|PROCEDURE|HPV Self-Collection|Receive HPV self-testing intervention
223812619|NCT04411849|OTHER|Informational Intervention|Receive information about cervical cancer
223812620|NCT04411849|BEHAVIORAL|Patient Navigation Program|Receive telephone-based patient navigation
223812621|NCT06365346|BEHAVIORAL|Dyadic video-assisted gamified group-based music breathing therapy|Dyadic video-assisted gamified music breathing therapy comprising six 75-min weekly sessions delivered in a group size of 6-8 (first sessions: parents only; reminding 5 sessions: parent-child dyads).
223812622|NCT06365346|BEHAVIORAL|Online educational modules|Six weekly educational modules on ADHD and its management via email.
223812623|NCT03091257|DRUG|Dabrafenib|Administered Orally BID
223812624|NCT03091257|DRUG|Trametinib|Administered Orally once daily
223812625|NCT07128303|DRUG|GS-5319|Administered orally
223812626|NCT06655324|BIOLOGICAL|V350A|Vaccination administered via intramuscular injection
223812627|NCT06655324|BIOLOGICAL|V350B|Vaccination administered via intramuscular injection
223812628|NCT06655324|BIOLOGICAL|Placebo|Vaccination administered via intramuscular injection
223812629|NCT06979401|OTHER|Exercise|After obtaining informed consent to participate in the study, all participants will be evaluated by an experienced physiotherapist before group allocation. All participants will receive diabetic foot training. Then, the experimental group and the control group will be formed by a sequential random method. Foot sensory training will be applied to the experimental group and no intervention will be made to the control group. However, after the study is completed, sensory training will be provided to the participants in the control group who wish to do so. Foot sensory training will be performed by the researcher physiotherapist. Foot sensory training sessions will be planned for 6 weeks, 3 days a week. An initial assessment will be made before the sessions begin and a final assessment will be made after the 6-week foot sensory training program.
223812630|NCT04296487|OTHER|autologous chondrocytes|autologous chondrocytes implantation (ACI)
223812631|NCT06884176|DEVICE|Ultrasound Guided Central Venous Catheter|Patients randomized to this arm will receive an ultrasound guided central venous catheter. The catheter is 20cm in length.
223812632|NCT06884176|DEVICE|Ultrasound Guided Midline Catheter|Patients randomized to this arm will receive an ultrasound guided midline catheter. The catheter is 8-10cm in length.
223812633|NCT06491953|DRUG|SGLT-2 inhibitors|SGLT-2 inhibitors use or not use； the duration of SGLT-2 inhibitors use
223812634|NCT06979154|DEVICE|tACS (aperiodic)|Individualized tACS waveform based on aperiodic EEG activity will be delivered.
223812635|NCT03750006|BEHAVIORAL|Short session HIIT|Individually tailored short session high intensity interval training session 3 times per week for 12 weeks on a recumbent exercise cycle.
223812636|NCT04722445|DIAGNOSTIC_TEST|Early ultrasound measurement of quadriceps shortening during neuromuscular electrical stimulation (NMES)|NMES will be applied to the quadriceps muscle to generate muscle contraction. Ultrasound measurement of the quadriceps thickness will be provided during contraction and rest, and the shortening of the quadriceps muscle will be measured. A second measurement using Shear-wave elastography measurement will also be undertaken. The measures will be undertaken at day 1 of neuromuscular blockers liberation (if any) as well as at day 3 and day 7 for the patients that will still be received mechanical ventilation at that time.
223812637|NCT06816901|DRUG|Depo Medroxyprogesterone acetate|Initiation of injectable depo medroxyprogesterone acetate (DMPA) contraception within 48 hours after birth
223812638|NCT06658730|DEVICE|Endovascular|TEVAR - thoracic endovascular aortic repair
223812639|NCT06610526|DRUG|Dapagliflozin|Dapagliflozin by oral administration
223812640|NCT04932564|DRUG|Leflunomide tablet|"Leflunomide will be given at standard dose (100 mg OD x 3 days followed by 20 mg OD) in adults and weight based dose in children.~The dosing for children will be as follows:~1. \<20 kg - 100 mg x 1 day followed by 10 mg every alternate day~2. 20-40 kg - 100 mg x 2 days, followed by 10 mg daily~3. \>40 kg - Usual adult dose.~This is scheduled to be continued for 1 year from the time of attaining complete response of musculoskeletal GVHD."
223812641|NCT04105231|DRUG|Cannabidiol|Cannabidiol oral suspension
223812642|NCT04105231|DRUG|Risperidone|Risperidone, encapsulated tablet.
223812643|NCT05596448|PROCEDURE|Coccygeal nerve radiofrequency ablation|During the procedure, after imaging the sacral and coccygeal corns with ultrasonography, a radiofrequency ablation needle is inserted at the level of the coccygeal horn and radiofrequency ablation is applied at 90 degrees for 60 seconds.
223812644|NCT06999694|RADIATION|Proton radiotherapy|"* 72.6 CGE in 22 fractions for tumors ≤1 cm from the hepatic hilum, bowel, and heart.~* 66 CGE in 10 fractions for tumors \>1 cm from the hepatic hilum, bowel, and heart."
223812645|NCT06999694|DRUG|Tremelimumab|Tremelimumab 300 mg will be administered as an IV infusion for one dose
223812646|NCT06999694|DRUG|Durvalumab|"Durvalumab 1500 mg will be administered as an IV infusion every 4 weeks.~Treatment Duration Guidelines:~* Complete Response (CR): Patients who achieve a CR within one year of treatment will continue durvalumab for a total duration of two years.~* Partial Response (PR): Patients who achieve a PR should continue durvalumab until achieving CR, disease progression (PD), or for a total duration of two years.~* Stable Disease (SD): Patients with SD will receive duvalumab for a total of 6 doses."
223812647|NCT06066333|RADIATION|Ablative Radiotherapy|All participants will first undergo ablative RT
223812648|NCT06066333|DRUG|Pembrolizumab|After completion of ablative RT, all subjects may begin pembrolizumab treatment
223812649|NCT06013748|BEHAVIORAL|VR-VOICES|7-10 individual VR assisted therapy for voice-hearing session and two booster sessions, in addition to TAU.
223812650|NCT06013748|OTHER|Treatment as usual|Treatment as usual as provided by the mental health centers
223812651|NCT05072548|BEHAVIORAL|The ABCs of SLEEPING|"The intervention is comprised of three components. The first is a sleep check-in which is a questionnaire that is evidence based and evaluates what areas of sleep parents can work on. The second component is the sleep report which summarizes to the parent what areas they're doing well in (i.e., within the ABCs of SLEEPING mnemonic described above) and what areas they can improve on. The third component of this intervention are the sleep tips which are sleep recommendations that are customized based on the identified areas of sleep the parents are suggested to work on."
223812652|NCT06868108|DEVICE|Flexible Suturing System with Anchors (FSSA)|Surgically repaired full-thickness rotator cuff tendon tears with the Flexible Suturing System with Anchors (FSSA).
223812653|NCT06770738|OTHER|There is no intervention in this study.|This study is planned as a retrospective cross sectional cohort study. Only the information of the patients will be used.
223812654|NCT06624202|BEHAVIORAL|COmmunities Aligned to reduce Concussion and Head impact exposure (COACH) Intervention|COmmunities Aligned to reduce Concussion and Head impact exposure (COACH) includes use of practice plans and a resource booklet aligned with the National Federation for High School guidelines for contact in practice. Coaches will also attend a pre-season coaches' clinic and be paired with a peer mentor during the season.
223812655|NCT07015918|DRUG|[14C] PF-07976016|\[14C\] PF-07976016 liquid (oral) formulation
223812656|NCT07015918|DRUG|PF-07976016|PF-07976016 liquid (oral) formulation
223812657|NCT07015918|DRUG|[14C] PF-07976016|\[14C\] PF-07976016 intravenous (IV) formulation
223812658|NCT04884334|DEVICE|VAC-Stent®|treatment with the VAC-Stent®
223812659|NCT07021742|DEVICE|BioHealx|Subjects will have their anal fistula treated with the BioHealx Anal Fistula Device, a bioabsorbable implant designed to securely close the fistula internal opening, preventing reinfection, while allowing for drainage through the external opening during healing.
223812660|NCT06059105|DEVICE|Immediate Implant Surgery|Inverted Co-Axis 12º Southern Implants
223812661|NCT06059105|DEVICE|Immediate Implant Surgery|Internal Conical (Deep Tapered Conical) South Implants
223812662|NCT07138040|BEHAVIORAL|Stage 1 Written Information|Stage 1 WI: consists of a letter from the survivorship care team with information about long-term follow-up care and relevant contacts to schedule an appointment.
223812663|NCT07138040|BEHAVIORAL|Stage 1 Low Touch Intervention|Stage 1 LTI: consists of the WI stage 1 letter, a copy of their treatment summary with instructions for creating their own survivorship care plan, and one text message per week with information to schedule a follow-up care appointment.
223812664|NCT07138040|BEHAVIORAL|Stage 2 Written Information|Stage 2 WI: consists of a letter from the survivorship care team with information about what to expect at a long-term follow-up care appointment.
223812665|NCT07138040|BEHAVIORAL|Stage 2 Low Touch Intervention|Stage 2 LTI: consists of the WI stage 2 letter, a copy of their treatment summary with instructions for creating their own survivorship care plan, and two to three non-tailored (generic) text messages per week related to scheduling an appointment, overcoming barriers to follow-up care, and health self-management.
223812666|NCT07138040|BEHAVIORAL|Stage 2 High Touch Intervention|Stage 2 HTI: consists of personalized mobile-friendly dashboard containing the WI letters, their treatment summary, survivorship care plan, and a growing discover section with helpful tailored resources. They will also receive four to six text messages per week with personalized messages related to their chosen health goal, personal barriers to attending cancer-related follow-up care, treatment-related risks, information about scheduling their long-term follow-up appointments, health self-management, and fun texts consisting of celebrity quotes, memes, and altruistic messages.
223812667|NCT07122843|DEVICE|VR Guided Meditation|Patients will wear a VR headset for approximately 15 minutes. The headset fully covers the eyes, immersing users in a calming, 3D virtual environment. Once the headset is on, patients will engage in a guided meditation experience, set in a nature-themed scene of their choice; options include a lake, beach, mountains, desert, forest, space, and more. An AI-powered guide will lead the meditation, offering real-time, personalized support based on the patient's age and the pain-related information provided during the hospital intake process. The AI is designed to promote relaxation by helping patients focus, breathe deeply, and feel more at ease. The intervention will be standardized for all participants, with each receiving the same duration of exposure in the VR headset and access to an identical selection of nature scenes. The patients will fill our pre and post intervention pain and anxiety surveys. The pre and post surveys will take between 5-10 minutes each to complete.
223812668|NCT06880770|DRUG|Plozasiran|ARO-APOC3 injection
223812669|NCT06880770|DRUG|Placebo|sterile normal saline (0.9% NaCl)
223812670|NCT06733610|BIOLOGICAL|universal allogeneic anti-CD19/BCMA CAR T-cells|A single injection of UCAR T-cells, referred to as universal allogeneic anti-CD19/BCMA CAR T-cells.
223812671|NCT06886477|OTHER|Mediterranean Diet|Mediterranean Diet foods will be provided for 4 weeks.
223812672|NCT06886477|OTHER|Usual Diet|Participants will consume their typical at home-diet.
223812673|NCT06734611|DIETARY_SUPPLEMENT|Fortified Iodized Salt with Folic Acid (FISFA)|Addition of folic acid to iodized salt for daily consumption to assess folate levels.
223812674|NCT07050082|PROCEDURE|Bladder dissection after filling with 200 cc saline solution|Bladder filling after entering peritoneal cavity, then bladder dissection done to avoid bladder injury
223812675|NCT07050082|OTHER|Bladder dissection with empty bladder|After entering peritoneal cavity, bladder dissection done with empty bladder
223812676|NCT06746285|DIETARY_SUPPLEMENT|Synbiotic Supplement|Participants will be given 1g of a synbiotic product each day, containing 4 microbial strains isolated from an infant gut (total of 1 billion cfu) and a mixture of 4 human milk oligosaccharides. Parents will administer the product by dissolving in breast milk, formula, or water, or mixing with food.
223812677|NCT06746285|DIETARY_SUPPLEMENT|Lactose (inactive placebo)|Participants will be given 1g of lactose as a placebo. Parents will administer the product by dissolving in breast milk, formula, or water, or mixing with food.
223812678|NCT07052214|DRUG|68Ga-PSMA-11|The radioconjugate 68Ga-PSMA-11 is composed of a human PSMA-targeting ligand peptide conjugated via the acyclic radiometal chelator, N, N'-bis \[2-hydroxy-5-(carboxyethyl)benzyl\] ethylenediamine-N, N'-diacetic acid (HBED-CC) to the radioisotope Gallium68 ( 68Ga); which binds to PSMA on the surface of cells expressing PSMA, including malignant prostate cancer cells, which usually overexpress PSMA. 68Ga is a β+ (beta) ray emitting radionuclide that allows precise imaging via PET.
223812679|NCT07051577|OTHER|Exercise Group|"Participants in the neuromuscular exercise group will undergo a training program supervised by the researcher, conducted twice a week for 6 weeks. This group will receive gaze stabilization training, core stabilization training, scapular stabilization training, balance training, and NeuroTracker training.~The exercises provided to the neuromuscular exercise group are structured in three phases and progressively intensified based on phase transition criteria."
223812680|NCT07051577|OTHER|control group|There are standard exercise programs consisting of scapular stabilization and balance exercises.These exercises are commonly used in clinical rehabilitation and will not include any additional neurosensory or visual components.
223812681|NCT06465199|DRUG|Eflornithine (DFMO)|Oral DFMO capsules
223812682|NCT06465199|DRUG|AMXT 1501 Dicaprate|Capsule
223812683|NCT06897007|OTHER|No interventions, it is a observational study|No interventions, this study is to compare the dosage requirement of ciprofol during digestive endoscopy between insomnia group and normal sleep group.
223812684|NCT05019248|BIOLOGICAL|Most recent vaccine to seasonal influenza|Seasonal Influenza vaccine: according to the latest SmPC and according to national guidelines (published by the Standing Committee on Vaccination (STIKO)).
223812685|NCT07058311|OTHER|Manual Therapy|Various soft tissue and joint mobilizations, intramuscular stretches, trigger point treatments, and intraoral applications for the temporomandibular joint were performed in 15 randomly selected bruxism patients. Manual therapy was applied twice weekly over eight weeks, each session lasting approximately 45 minutes. Techniques included trigger point therapy, myofascial release, intraoral mobilizations to the masseter, medial and lateral pterygoid, and temporalis tendons, post-isometric relaxation for masticatory muscles, cervical traction, and suboccipital and cervical fascial release. The manual therapy procedure, which was applied in the supine position and lasted approximately 40 minutes for 8 weeks
223812686|NCT07058311|OTHER|Home Exercise Therapy|The exercise group consisted of 15 randomly selected bruxist individuals and aimed to reduce pain, decrease involuntary contractions of masticatory muscles, increase their nutrition, flexibility and coordination, and strengthen weak muscles with exercise therapy. The exercise program included Rocabado exercises, stretching of the platysma, masticatory and cervical muscles, resistance training (mouth opening, protrusion, and lateral mandibular movements), and postural exercises. Exercises were performed while sitting in a chair with back support in front of a mirror. Each exercise was repeated 10 times. The duration of each session was 25-30 minutes. repeat the home exercises three times a week for 8 weeks. Weekly phone calls were made to encourage compliance. In addition, a video explaining the exercises in detail was shared with all participants in the group in order to ensure that the exercises were not forgotten and to achieve accuracy and standardization among the participants.
223812687|NCT03707574|PROCEDURE|Biospecimen Collection|Undergo collection of blood and tissue
223812688|NCT03881696|DRUG|Omalizumab|Omalizumab will be supplied in pre-filled syringes (PFS). PFS of omalizumab will be provided to the clinical research units as 75 mg and 150 mg dosage forms.
223812689|NCT03881696|DRUG|Placebo for Omalizumab|Placebo contains the same ingredients as the omalizumab formulation, excluding omalizumab. Placebo will be supplied in pre-filled syringes (PFS). PFS of placebo will be provided to the clinical research units as 75 mg and 150 mg dosage forms.
223835502|NCT04707391|COMBINATION_PRODUCT|MenB vaccine|2 doses of MenB vaccine administered intramuscularly on Day 181 and Day 211 to participants in ACWY group. MenB vaccine is a non-investigational medical product (NIMP) in this study and is administered only in compliance with standard of care.
223835503|NCT01019356|DRUG|Rosiglitazone|4 mg twice daily for 8 weeks orally
223835504|NCT01019356|DRUG|Acarbose|100 mg three times daily for 8 weeks orally
223812690|NCT03881696|DRUG|Multi-Allergen Oral Immunotherapy|"Multi-allergen OIT will be any of the following drug products: peanut, milk, egg, wheat, cashew, hazelnut, and walnut (all food protein flours).~A prescription for each participant for the appropriate dose of each of the allergens will be prepared. The pharmacist will compound the appropriate allergens and dispense the Multi-allergen OIT dose in a blinded (masked) fashion. The Clinical Research Unit (CRU) staff will administer food flour to the participant orally in an age-appropriate food vehicle (e.g., applesauce, pudding, etc.). Dosage will be administered according to the study protocol."
223812691|NCT03881696|DRUG|Placebo for Multi-Allergen Oral Immunotherapy|Oat flour will be used for placebo for Multi-allergen OIT. Route: by mouth/oral. Dosage will be administered according to the study protocol.
223812692|NCT03881696|OTHER|Double-Blind Placebo-Controlled Food Challenge Based Treatment|"Each participant will receive a separate treatment plan for peanut and each of the two other participant-specific foods. A treatment plan will include instructions for one of the following:~* Long-term follow-up with dietary consumption of a food; or~* Long-term follow-up with avoidance of a food; or~* Rescue OIT for a food. The treatment plan for each food may change depending on a participant's response to prescribed treatment over time."
223812693|NCT06100822|DRUG|Metformin|500 mg capsules of Metformin Extended Release
223812694|NCT06100822|DRUG|Placebo|500 mg capsules of placebo pills
223812695|NCT06772285|OTHER|Albert Health app|Test an existing digital health app, called Albert Health, designed to support patients with a newly inserted feeding tube to use and manage their tube care, in a feasibility study.
223812696|NCT07071532|DRUG|ABBV-932|Oral Capsule
223812697|NCT07071532|DRUG|Itraconazole|Oral Capsule
223812698|NCT07064330|DRUG|Cemiplimab|350 mg IV every 3 weeks as per standard of care. Patients are observed prospectively for biomarkers of response and toxicity during cemiplimab treatment.
223812699|NCT06773013|DEVICE|Acoustic Resonance (Sound) Therapy|Sonu consists of an acoustic Vibrational Headband worn circumferentially at the level of the forehead; and a Smartphone App, paired to the Headband. The App determines acoustic resonant frequencies of the subject's nasal cavity (using the facial image) and delivers treatment through bone conduction transducers in the headband
223812700|NCT04584905|DIETARY_SUPPLEMENT|dietary supplements for CKD patients|follow up and assessment of nutritional status of CKD patients
223812701|NCT06746597|OTHER|Walking intervention on plantar skin thickness and stiffness|Walking intervention in three different air-insole pressures (80 mmHg, 160 mmHg, 240 mmHg) in two different walking durations (10 and 20 minutes).
223812702|NCT06750094|BIOLOGICAL|Amivantamab|Amivantamab will be administered.
223812703|NCT06750094|BIOLOGICAL|Cetuximab|Cetuximab will be administered.
223812704|NCT06750094|BIOLOGICAL|Bevacizumab|Bevacizumab will be administered.
223812705|NCT06750094|DRUG|5-fluorouracil|5-fluorouracil will be administered as chemotherapy regimen.
223812706|NCT06750094|DRUG|Leucovorin calcium/Levoleucovorin|Leucovorin calcium/Levoleucovorin will be administered as chemotherapy regimen.
223812707|NCT06750094|DRUG|Irinotecan|Irinotecan will be administered as chemotherapy regimen.
223812708|NCT06008756|DRUG|Enlicitide Decanoate|Enlicitide Decanoate 20 mg tablet taken by mouth.
223812709|NCT06008756|DRUG|Placebo|Placebo tablet matched to enlicitide decanoate taken by mouth.
223812710|NCT04729387|DRUG|Alpelisib|Alpelisib will be administered at 200 mg orally once daily following food on a continuous dosing schedule starting on Cycle 1 Day 1 in a 28-day cycle
223812711|NCT04729387|DRUG|Olaparib|Olaparib will be administered at 200 mg orally twice daily irrespective of meals on a continuous dosing schedule starting on Cycle 1 Day 1 in a 28-day cycle.
223812712|NCT04729387|DRUG|Paclitaxel|Paclitaxel will be administered at 80 mg/m2 as an intravenous infusion weekly during a 28-day treatment cycle, starting on Cycle 1 Day 1, and on Day 8, Day 15 and Day 22 of every cycle thereafter
223812713|NCT04729387|DRUG|Pegylated liposomal doxorubicin (PLD)|PLD will be administered at 40-50 mg/m2 (physician discretion) as an intravenous infusion once every 28-days in a 28 day treatment cycle, starting on Cycle 1 Day 1
223812714|NCT06388421|OTHER|Prospective study assessments|Patients will complete prospective assessments at 6- and 12-month intervals for up to 5 years. There will be 1 check in at the first 3 months of enrollment. Follow up visits will include a ±45 day visit window. If an assessment is performed within 45 days of the visit window as part of the patient's standard of care, those values will be used in place of a prospective assessment.
223812715|NCT04852562|PROCEDURE|Modified radical endoscopic sinus surgery|Modified radical endoscopic sinus surgery was performed to remove the mucosa including ethmoid sinus and maxillary sinus, as well as a completly middle turbinate.
223812716|NCT04852562|PROCEDURE|functional endoscopic sinus surgery|Full maxillary antrostomy, ethmoidectomy, sphenoidotomy and frontal sinusotomy, but with the middle turbinate preservation.
223812717|NCT05885659|OTHER|Control group (waiting list)|T2DM in the control group will receive brief psychoeducation advice about smoking cessation as well as a general smoking cessation brochure/ booklet. Participants assigned to this control group will participate in the scheduled assessments (pre- and post-treatment, 1-month, 6-months and 12-months follow-ups) but without receiving any of the intensive treatments previously described (CBT vs. CBT+DiME-SALUD2 protocol).
223812718|NCT05885659|BEHAVIORAL|Cognitive Behavioral Treatment (CBT) for smoking cessation|CBT for smoking cessation will be implemented in group-based sessions of four to six patients, once a week over an eight-week period (Becoña, 2007), and includes three different components: (1) Motivational interviewing to stop smoking; (2) Smoking cessation, focused on nicotine fading from the first to the fourth session; (3) Maintenance of abstinence and relapse prevention strategies from the fifth session onwards. This modality of treatment also includes the following components, among others: Therapeutic contract, self-monitoring and graphical representation of tobacco consumption, psychoeducation about tobacco and specific characteristics of smoking behavior, stimulus control, strategies for coping with nicotine withdrawal symptoms, physiological feedback of consumption (using CO and cotinine in urine levels), social reinforcement when meeting nicotine reduction and abstinence goals, training in alternative behaviors to consumption and strategies for the prevention of relapses.
223812719|NCT05885659|BEHAVIORAL|CBT for smoking cessation + DiMeSALUD2 protocol|In this group, a training protocol on healthy lifestyle habits and self-management of T2DM will be carried out added to usual care (CBT for smoking cessation). CBT plus DiMe-SALUD2 protocol will be developed as in the precedent group, but with the addition of a psychoeducational protocol for monitoring nicotine fading and abstinence specifically designed to address the particular needs of T2DM smokers. The main components of this protocol will be focused on strengthening healthy lifestyle habits as well as structured around the following core elements: dietary control and healthy nutrition, physical exercise, and glycemic control through daily self-registration of both glycemic variability and nicotine fading or abstinence. If necessary, the therapist will adapt these guidelines according to the established medical advice that the smokers receive from their own endocrinologist, so that this program is developed in accordance with their usual medical care.
223812720|NCT03916432|DEVICE|HELIOS biodegradable polymer sirolimus-eluting stents|HELIOS biodegradable polymer sirolimus-eluting stents
223812721|NCT04008706|DRUG|Acalabrutinib|Acalabrutinib will be administered as one 100 mg capsule taken orally, twice daily with 8 ounces (approximately 240 mL) of water.
223812722|NCT05787561|DRUG|Avutometinib (VS-6766)|3.2 mg PO, twice weekly
223812723|NCT05787561|DRUG|Defactinib|200 mg PO BID for 3 weeks, followed by a 1 week rest period, in each 4-week (28 day) cycle.
223812724|NCT07081074|DRUG|Amino acid-derived lipids|Amino acid-derived lipids are applied to the treatment area, once daily during radiotherapy.
223812725|NCT07081074|BEHAVIORAL|standard of care|Standard of care
223812726|NCT03871348|DRUG|SAR441000|"Pharmaceutical form: concentrate for solution for injection~Route of administration: intratumoral"
223812727|NCT03871348|DRUG|Cemiplimab REGN2810|"Pharmaceutical form: solution for injection~Route of administration: intravenous"
223812728|NCT07087353|DEVICE|Edra PRO|Remote monitoring software
223812729|NCT04724330|BEHAVIORAL|Healthy for Two/Healthy for You|\~10 month (early pregnancy to 12 weeks postpartum), remotely-delivered, behavioral lifestyle intervention including health coach contacts (via phone, videoconference, and email/MyChart) and an interactive web-based platform.
223812730|NCT05653882|BIOLOGICAL|etakafusp alfa (AB248)|Intravenous infusion of etakafusp alfa (AB248): CD8+ T cell selective interleukin-2 investigational drug
223812731|NCT05653882|BIOLOGICAL|pembrolizumab|Intravenous infusion of pembrolizumab
223812732|NCT04919226|DRUG|177Lu-Edotreotide (Peptide Receptor Radionuclide Therapy) PRRT|Peptide Receptor Radionuclide Therapy (PRRT) using 177Lu-edotreotide with a defined number of cycles will be administered.
223812733|NCT04919226|DRUG|CAPTEM (Capecitabine and Temozolomide)|Best standard of care treatment (investigator's choice \[from the protocol comparator list\]) according to individual risk-benefit assessment, institutional protocols, the local Prescribing Information, local regulations, or the local guidelines.
223812734|NCT04919226|OTHER|Amino-Acid Solution|The Amino-Acid Solution (AAS) to be used in this study will contain a mixture of lysine and arginine diluted in an electrolyte solution.
223812735|NCT04919226|DRUG|Everolimus|Best standard of care treatment (investigator's choice \[from the protocol comparator list\]) according to individual risk-benefit assessment, institutional protocols, the local Prescribing Information, local regulations, or the local guidelines.
223812736|NCT04919226|DRUG|FOLFOX (Folinic acid + Fluorouracil + Oxaliplatin)|Best standard of care treatment (investigator's choice \[from the protocol comparator list\]) according to individual risk-benefit assessment, institutional protocols, the local Prescribing Information, local regulations, or the local guidelines.
223812737|NCT03211793|DRUG|Mesenchymal stromal cells|8 intramuscular injections at designated sites in the hand/forearm muscles of the most affected side. Blinded syringes will be used. Injections will be administered by an experienced clinician (plastic surgeon or hand surgeon).
223812738|NCT03211793|OTHER|Placebo|8 intramuscular injections at designated sites in the hand/forearm muscles of the most affected side. Blinded syringes will be used. Injections will be administered by an experienced clinician (plastic surgeon or hand surgeon).
223812739|NCT07093268|DRUG|Intrathecal Riluzole|Intrathecal infusion of riluzole for 6 weeks followed by 6 months treatment with safety committee approval.
223812740|NCT07092735|BEHAVIORAL|Neuro-Athletic Training|Participants receive a structured 8-week NAT program including oculomotor, vestibular, and proprioceptive drills, 3 sessions/week (35-45 minutes each).
223812741|NCT07092735|OTHER|Standard Training|Participants continue their standard in-season football training program without any NAT components.
223812742|NCT06848205|OTHER|OFF Parkinson's Medication(s)|Participants will be asked to withhold Parkinson's medications 12 hours prior to their testing visit (if extended-release Parkinson's medications are taken by the participant, they will be asked to withhold these for 24 hours prior to their testing visit).
223812743|NCT06848205|OTHER|OFF Deep Brain Stimulation|Participants will have their deep brain stimulation turned off at the beginning of their testing visit.
223812744|NCT04296604|DEVICE|Transcranial Direct Current Stimulation|In tDCS, electrodes are applied on the scalp to transmit direct current at low current amplitudes.
223812745|NCT06910358|DRUG|Placebo|Oral dose, once a day for 24 weeks
223812746|NCT06910358|DRUG|DISC-1459|Oral dose, once a day for 24 weeks
223812747|NCT06393465|DRUG|Tafamidis|61 milligrams under real world conditions
223812748|NCT07102901|DRUG|SHR2554 Tablets|Oral SHR2554 tablets.
223812749|NCT07102901|DRUG|SHR-A1811 Injection|SHR-A1811 for injection.
223812750|NCT07102901|DRUG|SHR-A1904 Injection|SHR-A1904 for injection.
223812751|NCT07102901|DRUG|SHR-1701 Injection|SHR-1701 injection
223812752|NCT03868670|DEVICE|responsive neurostimulation|The RNS® System is a novel, implantable therapeutic device that delivers responsive neurostimulation, an advanced technology designed to continuously monitor brain electrical activity, detect abnormal electrical activity and respond by delivering imperceptible levels of electrical stimulation to normalize that activity before an individual experiences seizures. This is an Early Feasibility Study determining the safety and efficacy of NAc-RNS in the treatment of LOC eating in treatment-refractory obesity.
223812753|NCT05680155|DRUG|Ecnoglutide|Subcutaneous Injection
223812754|NCT05680155|DRUG|Placebo|Subcutaneous Injection with matched volume
223812755|NCT07136545|DRUG|HCB101|QW
223812756|NCT07136545|DRUG|Pembrolizumab|200 mg IV on Day 1, cycled every 21 days;
223812757|NCT07142850|DRUG|HRS-9190|HRS-9190
223812758|NCT06946368|PROCEDURE|Intra-articular Posteromedial Surgeon Administered (IPSA) Block of EXPAREL|"Patients in this group will receive IPSA block and Local Infiltration Analgesia (LIA).~IPSA block is a pain numbing medication given by surgeon and injected inside the back and inner side of the knee joint. Local Infiltration Analgesia is a pain numbing medication injection given by the surgeon around the surgical knee area. The medications used in the procedure will be EXPAREL, and Bupivacaine HCL."
223812759|NCT06946368|PROCEDURE|Adductor Canal Block (ACB) and Local Local Infiltration Analgesia of EXPAREL|ACB is a pain numbing injection given by anesthesiologist near the adductor canal, a passage in the mid-thigh that contains nerves connecting the knee region. Local Infiltration Analgesia is a pain numbing medication injection given by the surgeon around the surgical knee area. The medications used in the procedure will be EXPAREL, and Bupivacaine HCL.
223812760|NCT06946368|PROCEDURE|Local Infiltration Analgesia (LIA) of EXPAREL|Local Infiltration Analgesia is a pain numbing medication injection given by the surgeon around the surgical knee area. The medications used in the procedure will be EXPAREL, and Bupivacaine HCL.
223812761|NCT07148271|DIETARY_SUPPLEMENT|Dietary Supplement Product|Participants will receive a dietary supplement product administered orally once daily for 8 weeks. The supplement is provided in capsule form and taken with water. The intervention is designed to modulate gut microbiota composition and diversity, with the potential to influence ocular surface outcomes in patients with dry eye disease. The regimen will be self-administered at home, with adherence monitored at study visits. Stool samples will be collected at baseline and week 8 for metagenomic sequencing, and ocular surface parameters will be assessed at the same time points. Safety will be evaluated by monitoring for adverse events throughout the intervention period.
223812762|NCT06520358|OTHER|Acute Intermittent Hypoxia (AIH)|Acute intermittent hypoxia refers to brief (acute), repetitive (intermittent) episodes of breathing oxygen-deprived air (hypoxia) alternating with breathing ambient room air.
223812763|NCT06520358|BEHAVIORAL|Task specific Airway Protection Training|The vLVC maneuver involves training participants to volitionally prolong closure of the laryngeal vestibule during swallowing, beginning with swallow onset and sustaining closure for at least 2 seconds.
223812764|NCT06520358|OTHER|Sham AIH|Sham AIH will be delivered using methods identical to AIH, except a normoxic gas mixture (\~21% O2) will be delivered. The gas mixture with normoxic air will effectively serve as a sham.
223812765|NCT07149948|BEHAVIORAL|THRIVE Integrated Care Program|The THRIVE Integrated Care Program is a psychoeducational behavioral intervention for adolescent mothers that combines reproductive health education and mental health support. It includes seven biweekly in-person or virtual sessions covering topics such as sexual health, parenting, mental health, substance use prevention, social support, and professional development. The intervention is delivered by trained medical students and staff using interactive learning modules and assessments.
223812766|NCT07153003|DRUG|Oxycodone|"Patients will receive oral Oxycodone only to treat post-operative pain:~Oxycodone 5mg~* Patients ≤75 years old: 5mg or 10 mg PO every 4 hr as needed~  * 5 mg for pain rated 4-6~ * 10 mg for pain rated 7-10~* Patients \>75 years old and/or sensitive to opioids or sedatives: 2.5mg or 5mg every 4hr as needed~  * 2.5mg for pain rated 4-6~ * 5mg for pain rated 7-10"
223812767|NCT07153003|DRUG|Tramadol and Oxycodone|"Patients will receive a combination of Tramadol and Oxycodone to take orally to treat post-operative pain:~Tramadol 50mg~* Patients ≤75 years old: 50 mg for pain rated 4-6; 100 mg for pain rated 7-10~* Patients \>75 years old and/or sensitive to opioids or sedatives; use 50 mg~* Dosing is every 8 hours as needed. Cumulative dose not to exceed 400mg in 24 hours~Oxycodone 5mg~* Patients ≤75 years old: 5mg or 10 mg PO every 4 hr as needed if still having pain after maximum tramadol administration~  * 5 mg for pain rated 4-6~ * 10 mg for pain rated 7-10~* Patients \>75 years old and/or sensitive to opioids or sedatives: 2.5mg or 5mg every 4 hr as needed if still having pain after maximum tramadol administration~  * 2.5 mg for pain rated 4-6~ * 5 mg for pain rated 7-10"
223812768|NCT07160400|DRUG|Placebo|Single dose placebo IBI3032 administered orally
223812769|NCT07160400|DRUG|IBI3032 tablets|Single dose of IBI3032 administered orally
223812770|NCT07155031|DEVICE|Pathogen reduced red blood cells|pathogen reduced red blood cells with biotin labeled aliquots will be transfused as part of routine care red cell exchange procedures
223812771|NCT07165600|OTHER|Yoga|Physical activity
223812772|NCT07165743|DIAGNOSTIC_TEST|40-Minute Real-Time First-Trimester Ultrasonography|A one-time midsagittal ultrasound performed between 11 +0 and 14 +0 weeks. Bladder emptying time and post-void longitudinal bladder diameter are recorded. No invasive procedures are performed.
223812773|NCT07164729|OTHER|PNF Stretching|Dynamic stretching of the quadriceps will be performed using walking lunges. This exercise dynamically stretches the quadriceps and hip flexors while also improving balance and coordination. During the exercise, participants stand upright, step one leg forward, and lower their body by bending the knee. They then step forward with the other leg to complete the movement. Ten steps will be performed for each leg.
223812774|NCT07164729|OTHER|Dynamic Stretching|"The Hold-Relax technique will be applied. Hold-Relax PNF stretching is based on the principle of isometric contraction of the muscle followed by passive stretching. This technique is effective for increasing muscle flexibility and reducing muscle tension. The medial and lateral parts of the quadriceps will be stretched by Flexion-Adduction-External Rotation and Flexion-Abduction-Internal Rotation patterns3. During the exercise, participants will lie prone with the knee flexed. They will be asked to attempt knee extension while the movement is resisted by the physiotherapist. The contraction will be maintained for 10 seconds, after which the participant will be instructed to relax. Following relaxation, the knee flexion angle will be increased. Ten repetitions will be performed for each leg."
223812775|NCT07165145|DIETARY_SUPPLEMENT|Organic Fruits and Vegetables|Dietary Intervention
223812776|NCT07165145|DIETARY_SUPPLEMENT|Conventional Fruits and Vegetables|Dietary Intervention
223812777|NCT07165561|BEHAVIORAL|Smartphone App|This intervention is a mobile app co-created with adolescents who have experienced suicidal thoughts. It is specifically designed for youth aged 12-17 and includes a Safety Plan, tools such as a HopeBox, and psychoeducational content for young people, their loved ones, and care providers. Furthermore, there is a 'Help' button, offering direct access to crisis support. Unlike existing apps for adults, this app is tailored to the developmental needs and lived experiences of adolescents. Access is restricted to study participants to ensure controlled evaluation.
223812778|NCT07165795|BEHAVIORAL|Transcendental Meditation|Standard TM instruction by certified TM teachers, including 4 days of initial training (60-90 min/day), then follow-up sessions (60-90 min) every 2-4 weeks.
223812779|NCT07166250|PROCEDURE|Quadratus Lumborum Block|Ultrasound-guided quadratus lumborum block performed preoperatively using local anesthetic injection at the thoracolumbar fascia for postoperative analgesia in lumbar disc herniation surgery.
223812780|NCT07166250|PROCEDURE|Retrolaminar Block|Ultrasound-guided retrolaminar block performed preoperatively using local anesthetic injection into the retrolaminar space for postoperative analgesia in lumbar disc herniation surgery
223812781|NCT07164352|BEHAVIORAL|Breathing Exercises|Diaphragmatic and pursed-lip breathing exercises supervised by a physiotherapist.
223812782|NCT07164352|BEHAVIORAL|Informational Brochure|A brochure providing education about breathing exercises for cancer patients.
223812783|NCT07165873|PROCEDURE|Erector Spinae Plane Block|30 mL of 0.25% bupivacaine was injected deep to the erector spinae muscle.
223812784|NCT07165873|PROCEDURE|Serratus anterior plane block (SAP)|10 mL was injected into the superficial plane and 20 mL into the deep plane, for a total of 30 mL of 0.25% bupivacaine.
223812785|NCT07165873|PROCEDURE|Serratus posterior superior intercostal plane block|30 mL of 0.25% bupivacaine was injected into the plane between the serratus posterior superior muscle and the rib.
223812786|NCT07164924|BIOLOGICAL|blood sample to analyse AMH level on the serum|Evaluation of MS/NMOSD inflammatory activity on the serum AMH level (ng/ml)
223812787|NCT07164625|BEHAVIORAL|Telerehabilitation Physiotherapy|Delivered via real-time video sessions focusing on strengthening and mobility exercises.
223812788|NCT07164625|BEHAVIORAL|In person physiotherapy|face-to-face, including hands-on treatments like tactile feedback and joint mobilization.
223812789|NCT07165730|BEHAVIORAL|Virtual Health Coaching with Artificial Intelligence (DIACOACH)|Participants in the intervention group will receive a 12-week virtual health coaching program using the DIACOACH application. The program includes adaptive digital education on diet, physical activity, and medication adherence, personalized reminders, daily self-monitoring, and feedback powered by artificial intelligence. The intervention is designed to improve self-care adherence and glycemic control (FBG, HbA1c, RBG) among adults with type 2 diabetes mellitus in primary care settings.
223812790|NCT07165730|BEHAVIORAL|Standard Diabetes Education|Participants in the control group will receive standard diabetes education usually provided in primary health care centers. This includes routine counseling sessions, printed educational materials, and general advice on diet, physical activity, and medication adherence, without the use of the DIACOACH application.
223812791|NCT05398367|DIETARY_SUPPLEMENT|Galactagogue Supplement for Treatment of Low Milk Supply|Participants will consume a commercially available dietary supplement on the market for augmentation of breast milk production in lactating women with low milk supply
223812792|NCT02044848|DRUG|Secukinumab|
223812793|NCT02044848|DRUG|Placebo|Placebo
223812794|NCT04274959|OTHER|ceramic onlay with shoulder preparation design.|ceramic onlay with shoulder preparation design which allowing the largest possible enamel for adhesion ,
223812795|NCT04274959|OTHER|,ceramic onlay with butt joint preparation design|ceramic onlay with butt joint preparation design with cusp reduction to protect teeth from occlusal loads and cuspal fracture
223812796|NCT03772899|DRUG|Fecal Microbial Transplantation|"All patients in this trial will receive FMT at least one week prior to treatment with approved immunotherapy (either pembrolizumab or nivolumab). Samples for FMT are sourced at and by the microbiology group under the supervision of Dr. Silverman at St Joseph's Hospital. Donor screening procedures are described in appendix 4. Transplant will be from one single donor for all participants unless Dr. Silverman's lab considers the need for more than one donor based on availability of donors. There will be no mixture of donor samples.~Donor samples are manufactured into capsules according to Kao et al, 2017."
223812797|NCT02571465|OTHER|Passive leg raising test and fluid challenge|
223812798|NCT00190905|DRUG|duloxetine HCl|
223812799|NCT01493960|DRUG|Cobitolimod|30 mg rectal dose at week 0 and 4
223812800|NCT01493960|DRUG|Placebo|Rectal dose at week 0 and 4
223812801|NCT00249249|DRUG|Pitavastatin|
223812802|NCT00249249|DRUG|Atorvastatin|
223812803|NCT05418777|DRUG|Trimethoprim Sulfamethoxazole|Receipt of suspension with the equivalent of one DS TMP-SMX by mouth every 12 hours for 10 days
223812804|NCT05418777|DRUG|Placebo|Receipt of suspension with placebo by mouth every 12 hours for 10 days
223812805|NCT04662502|DIETARY_SUPPLEMENT|Bifidobacterium longum 35624|Bifidobacterium longum 35624, 1 x 10\^9 CFU/capsule, 1 capsule/day over 1 month
223812806|NCT02391935|DRUG|RCS-01|Cultured, autologous hair follicle cells suspended in cryomedium
223812807|NCT02391935|DRUG|Placebo|Cryomedium
223812808|NCT02391935|DEVICE|Sham injection|skin penetration of the needle without injection of liquid
223812809|NCT02057289|DRUG|Micafungin|Micafungin (trade name Mycamine) is an echinocandin antifungal drug developed by Astellas Pharma. It inhibits the production of beta-1,3-glucan, an essential component of fungal cell walls. Micafungin is administered intravenously. It received final approval from the U.S. Food and Drug Administration on March 16, 2005, and gained approval in the European Union on April 25, 2008.
223812810|NCT05578625|OTHER|plasma circulation DNA methylation sequencing|10 mL of peripheral blood will be drawn from 60 multiple myeloma patients at diagnosis, 4 months post-induction, and at relapse, and cell-free DNA is then extracted and undergo bisulfite methylation sequencing.
223812811|NCT01651273|DRUG|BMS-852927|Capsules, Oral, 0.25 mg, Once daily, 28 days
223812812|NCT01651273|DRUG|BMS-852927|Capsules, Oral, 1.0 mg, Once daily, 28 days
223812813|NCT01651273|DRUG|BMS-852927|Capsules, Oral, 2.5 mg, Once daily, 28 days
223812814|NCT01651273|DRUG|Placebo|Capsules, Oral, 0 mg, Once daily, 28 days
223812815|NCT02783222|DRUG|Nab-paclitaxel|comparison of different dosages of drug
223812816|NCT05417984|DEVICE|Restoris MCK|During this study the Restoris MCK will be placed using robotic-assisted surgery. At the time of surgery tantalum markers will be placed in the tibia and femur. With these markers migration of the prothesis can be measured over time using RSA radiographs.
223812817|NCT00445198|DRUG|ABT-263|"Phase 1 dosing under two different schedules: 14 days on drug, 7 days off or continuous dosing.~\- 50 patients with SCLC and non-hematologic malignancies. Enrollment is closed in this arm of the study.~Phase 2a dosing under two different schedules: 14 days on drug, 7 days off or continuous dosing.~\- 40 patients with SCLC"
223812818|NCT01500564|DEVICE|anodal tDCS (device) Eldith DC-Stimulator|tDCS applied to the motor cortex every day of two consecutive weeks (10 sessions) at 1 mA during 20 minutes. Conductive rubber covered by sponges soaked in saline will be used, held in place by a band. The current will be gradually increased over 100 seconds.
223812819|NCT01500564|DEVICE|Sham tDCS|Participants will receive sham tDCS over the primary motor cortex of the ipsilesional hemisphere during 20 minutes of motor training (10 consecutive sessions Monday-Friday during two weeks).
223812820|NCT01595243|BEHAVIORAL|telephone consultations about psychoeducation program|experimental group will receive seven instances of telephone follow-up or face-to-face education (the day before discharge and during the first, second, third, fourth, sixth, and eighth weeks after discharge).
223812821|NCT02166450|DRUG|Nystatin|100 000 IU every 6 h as a suspension
223812822|NCT02760056|DRUG|Liothyronine sodium|Subjects will be divided into 4 groups of progressively escalating doses. Each group will have 6 subjects 4 will receive the active treatment and 2 will receive the placebo. The first group will receive 25 mcg twice daily for one week. The second group will receive 37.5 mcg twice daily for one week. The third group will receive 50 mcg twice daily for one week. The forth group will receive 75 mcg twice daily for one week.
223812823|NCT02760056|DRUG|Placebo|Patient will receive a matching placebo to take twice daily for one week.
223812824|NCT01160484|DRUG|DVD-R|40 mg dexamethasone will be administered IV on Days 1, 4, 8, and 11 of each cycle. 1.0 mg/m2 Bortezomib will be administered IV over 3 to 5 seconds followed by a standard saline flush, on Days 1, 4, 8, and 11 immediately following the dexamethasone infusion. 4.0 mg/m2 PLD will be given as a 90 minute infusion on Day 1 of Cycle 1 and subsequent doses may be administered over 30 to 60 minutes on Days 4, 8 and 11 of Cycle 1 and on Days 1, 4, 8, and 11 of each subsequent cycle, following the bortezomib administration. 10 mg/day lenalidomide will be administered PO on days 1-14 of a 28-day treatment cycle, followed by a 14-day rest period, following the PLD administration.
223812825|NCT03400501|DRUG|Insulin Degludec|Single daily dose of insulin degludec based on their fasting blood glucose levels and current long acting insulin dose
223812826|NCT03400501|DRUG|Insulin Glargine|Single daily dose of insulin glargine based on their fasting blood glucose levels and current long acting insulin dose
223812827|NCT02887469|DRUG|3% hypertonic saline|The same as above
223812828|NCT00803101|BIOLOGICAL|Beriplex® P/N (Kcentra)|Intravenous infusion, dosage depending on baseline INR, amount of coagulation factor IX and body-weight.
223812829|NCT00803101|BIOLOGICAL|Fresh frozen plasma|Intravenous infusion, dosage depending on baseline INR and body weight
223812830|NCT01782742|DRUG|Bexarotene|Subjects will be randomized 4:1 to receive 4 weeks of double blind treatment of either Bexarotene or Placebo
223812831|NCT01782742|DRUG|Placebo|
223812832|NCT02429687|DRUG|Paclitaxel|Patients receive paclitaxel 175mg/㎡ IV over 3 hours on day 1. Treatment repeats every 21 days for 4-6 courses in the absence of disease progression or unacceptable toxicity.
223812833|NCT02429687|DRUG|Carboplatin|and carboplatin AUC 5-6 IV over 1 hour on day 1. Treatment repeats every 21 days for 4-6 courses in the absence of disease progression or unacceptable toxicity.
223812834|NCT02429687|DRUG|Bleomycin|Bleomycin 30000IU IM per day for 3 days every 3 weeks for 3-4 cycles.
223812835|NCT02429687|DRUG|Etoposide|Etoposide 100mg/㎡ IV per day for 5 days every 3 weeks for 3-4 cycles.
223812836|NCT02429687|DRUG|Cisplatin|Cisplatin 20mg/㎡ IV per day for 5 days every 3 weeks for 3-4 cycles in the absence of disease progression or unacceptable toxicity.
223812837|NCT05040022|DRUG|Pneumoperitoneum pressure 10 mmHg|The abdomen will be inflated with carbon dioxide to maintain the intra-abdominal pressure at 10 mmHg (group 10)
223812838|NCT05040022|DRUG|Pneumoperitoneum pressure 14 mmHg|The abdomen will be inflated with carbon dioxide to maintain the intra-abdominal pressure at 14 mmHg (group 14).
223812839|NCT03091647|BEHAVIORAL|acupressure intervention|Women in the acupressure intervention group will learn how to press three chief energy acupoints on each side of the body through an 11-minute Chinese-language video and press three acupoints (1 minute per acupoint) on both sides of the body every day for a total of 6 minutes per day for an 8-week intervention period and record their practice on daily logs. Women will be asked to return the logs every week by email or self-addressed envelopes.
223812840|NCT03091647|BEHAVIORAL|usual care|Women in the usual care group will receive primary and oncology care from their doctors as usual, and complete daily logs recording their fatigue and daily functioning levels. They also need to return the logs every week by email or self-addressed envelopes.
223812841|NCT01012570|DRUG|Application of Adalimumab|Adalimumab will be applied according to manufacture's instruction and official guidelines.
223812842|NCT00012038|DRUG|irofulven|
223812843|NCT03784235|OTHER|18F NaF-PET/CT and cone beam CT scans|Cross sectional measures of 18F NaF-PET/CT and cone beam CT scans
223812844|NCT04435171|PROCEDURE|Renal transplantation|Open or robot assisted renal transplantation
223812845|NCT04705064|DIAGNOSTIC_TEST|Prediction of postoperative acute kidney injury using an artificial intelligence|The performance of an artificial intelligence model to predict postoperative acute kidney injury will be tested prospectively.
223812846|NCT01437150|DEVICE|Anatomical locking plate|This is a new fixation treat for acetabular posterior wall fracture.
223812847|NCT01437150|PROCEDURE|The Reconstructive Plate|Reconstructive plate was used very common in treatment of acetabular fracture.
223812848|NCT05502614|DEVICE|Neuromodulation|Transcutaneous stimulation of the dorsal genital nerve using the Innocon Medical UCon device to provide on demand relief of bladder spasms
223812849|NCT06029595|DRUG|Experimental: CHF6001 3200 μg|800 μg/actuation - 2 inhalations of CHF6001 800 μg twice daily (BID) total daily dose 3200 μg
223812850|NCT06029595|DRUG|Placebo Comparator: CHF6001 Placebo|2 inhalations of CHF6001 matching placebo BID
223812851|NCT00956696|DRUG|topiramate|oral, daily dose or twice daily dose, total daily dose 25-200mg per day duration: 16 weeks
223812852|NCT05583214|DRUG|Ondansetron 8mg|8mg of Ondansetron IV stat will be given to the group after induction of spinal anesthesia
223812853|NCT05583214|DRUG|Dexamethasone 8mg|8mg of Dexamethasone IV stat will be given to the group after induction of spinal anesthesia
223812854|NCT05583214|DRUG|Normal saline|Normal saline will be given IV stat to the group after induction of spinal anesthesia
223812855|NCT02098408|BEHAVIORAL|Cognitive remediation|"Neurocognition will be trained using the NEAR model (Medalia et al. 2003), whereas the training of social cognitive skills will be by use of the SCIT manual (Social Cognition and Interaction Training) developed by Roberts et al. 2014.~The intervention consists of 24 group sessions taking place once a week (two hours) and additional neurocognitive training at home. Furthermore, there will be a total of 12 individual sessions aiming at bridging the cognitive training to the everyday functioning of the patients."
223812856|NCT02098408|BEHAVIORAL|Standard treatment|Patients allocated to the control condition are free to choose whatever standard treatment they are offered by the clinicians managing their treatment. Usually standard treatment consists of regular contact to health professionals in the in- and outpatient facilities in Copenhagen, Denmark, and encompass different kinds of supportive counselling.
223812857|NCT02623816|DRUG|Optimal Dosing of Omeprazole|Omeprazole 20 mg
223812858|NCT04933201|OTHER|Music|Perioperative musical intervention
223812859|NCT04933201|OTHER|Routine perioperative treatment|Routine perioperative treatment
223812860|NCT00238381|PROCEDURE|5 cm colon-J-pouch|5 cm colon-J-pouch with/without temporary protective ileostomy
223812861|NCT00238381|PROCEDURE|side-to-end anastomosis|side-to-end anastomosis with/without temporary protective ileostomy
223812862|NCT00238381|PROCEDURE|straight coloanal anastomosis|straight coloanal anastomosis with/without temporary protective ileostomy
223812863|NCT01909570|PROCEDURE|Elective single embryo transfer|After the FIV/ICSI procedure, the embryo transfer in this arm would be of one embryo followed by the cryotransfer of one embryo in case of no conception in the fresh cycle.
223812864|NCT01909570|PROCEDURE|Double embryo transfer|After the FIV/ICSI procedure, the embryo transfer in this arm would be of two fresh embryos
223812865|NCT05384665|DRUG|Remifentanil|REMIFENTANIL, 5 µg/cc, solution for injection, 0.5 µg/kg, parenteral (intravenous) route, injection delay of 30 seconds, once only
223812866|NCT05384665|DRUG|Sufentanil|SUFENTANIL, 5 µg/cc, solution for injection, 0.2 µg/kg, parenteral (intravenous) route, bolus over 5 seconds, once
223812867|NCT05384665|DRUG|Placebo|PLACEBO contains 0.9% NaCl, parenteral (intravenous), bolus, one-time
223812868|NCT02026232|DRUG|Hydroxychloroquine|200mg twice daily
223812869|NCT02026232|OTHER|Hydroxychloroquine Placebo|200mg placebo twice daily
223812870|NCT00332332|BIOLOGICAL|etanercept|etanercept subcutaneous injection
223812871|NCT01776021|OTHER|cranberry juice|cranberry juice beverage at a dose of one 8 oz. beverage per day for six months
223812872|NCT01776021|OTHER|placebo beverage|placebo beverage at a dose of one 8 oz. beverage per day for six months
223812873|NCT04402528|BEHAVIORAL|Behavioral tools integrated within mehealth for ADHD software|Integrated functionality within the mehealth for ADHD software allows parents and teachers/childcare providers to set up and deliver behavioral interventions such as daily report card systems and home-based program such as star charts. Automated wizards lead parents and teachers through the process of selecting target behaviors and setting up reward schedules. Baseline data is gathered online and algorithms derive a set of behavioral goals for the child. Thereafter, parents or teachers record the child's performance directly into the software. Once behavioral monitoring begins, parents and teachers receive daily email or text communications from mehealth for ADHD alerting them to the daily rewards earned by their child. Finally, online algorithms exist that detect how a child is doing in meeting behavioral goals and prompt users to modify goals accordingly.
223812874|NCT00668135|DRUG|Vardenafil (Levitra, BAY38-9456)|Vardenafil 10 mg orally on demand prior to intercourse
223812875|NCT00668135|DRUG|Placebo|Matching placebo
223812876|NCT03594903|BEHAVIORAL|video intervention (therapy expectation violation)|The investigators asked experts (psychotherapist and scientists in the area of clinical psychology) about typical therapy expectation violations in therapy and searched the literature for information about typical therapy processes and outcomes. Having these information they designed a script for the experimental video. The patients in the video are played by actors aged from 28 to 58 years (two male and two female actors). Patients are representing common mental disorders (depression, anxiety disorder, alcohol addiction, depression after physical disease). The abbreviated name, age and disorder of the patients is displayed for 3 seconds in the video. The patients are giving information about the mostly positive outcome and the process of their therapy. All participants are watching a video with all patients (7 minutes). The videos (control and experimental group) have been evaluated by 12 experts (psychotherapist and scientists in the area of clinical psychology).
223812877|NCT03594903|BEHAVIORAL|video intervention (symptoms+ expectation)|Participants in the control group are watching a video with the same patients (actors) as in the experimental video. In this video patients are shown before or after the first therapy session. They are giving information about symptoms and their expectation on therapy but NOT about therapy outcome.
223812878|NCT06136715|BEHAVIORAL|blood products as a part of Massive Transfusion Protocol|This data repository will serve as a means to aggregate and analyze best practices as relative to MTP in the trauma patient, with specific interest in component best practices, whole blood protocols, and electrolyte/metabolite replacement
223812879|NCT05396092|BEHAVIORAL|Integrated mindfulness-based Tai Chi Chuan|MBTCC will integrate components from both the MBI and TCC groups. The entire intervention consists of eight weekly sessions of two-and-a-half to three hours each.
223812880|NCT05396092|BEHAVIORAL|Mindfulness-based intervention|The MBI group is mainly based on the basic theory and research of the foundational mindfulness-based stress reduction program. The intervention consists of eight weekly sessions of two to two-and-a-half hours each.
223812881|NCT05396092|BEHAVIORAL|Tai Chi Chuan|TCC is mainly based on a nine-form Yang-style form of TCC, which is a brief and modified version of 64-form Yang-style TCC. The entire intervention consists of eight weekly sessions of two to two-and-a-half hours each.
223812882|NCT05396092|BEHAVIORAL|Sleep Hygiene Education|SHE is based on principles used in stimulus control and sleep hygiene education, which has previously been used as the control group in sleep-related research. The entire intervention consists of eight weekly sessions of two to two-and-a-half hours each.
223812883|NCT04395859|PROCEDURE|Questionnaire|At inclusion : Questionnaire collecting data concerning the interruption of IVT treatment
223812884|NCT04395859|OTHER|Data collection up to 1 year|Data collection up to 1 year after resumption of follow-up: visual acuity, OCT : optical coherence tomography, IVT treatment, complications
223812885|NCT04591535|DRUG|WD-1603 CARBIDOPA/LEVODOPA EXTENDED-RELEASE TABLETS|WD-1603 CARBIDOPA/LEVODOPA EXTENDED-RELEASE TABLETS
223812886|NCT02790073|DRUG|SNF472|SNF472 for calciphylaxis
223812887|NCT01811979|DIETARY_SUPPLEMENT|Oral sucrose solution|Oral sucrose solution plus topical anesthetics
223812888|NCT01811979|DIETARY_SUPPLEMENT|Steril water|steril water plus topical anesthetics
223835505|NCT04598880|DRUG|Polyethylene glycol + ascorbate|Pleinvue® is administered orally in 2 doses (3 sachets) as per SmPC within the previous 18 hours to colonoscopy intervention. First dose is administered at 9 pm on the day before intervention (sachet 1: MACROGOL 3350 100 g + SODIUM SULFATE ANHYDROUS 9 g + SODIUM CHLORIDE 2 g + POTASSIUM CHLORIDE 1 g). Second dose is administered 5 hours before intervention and it is composed by 2 sachets (sachet A: MACROGOL 3350 40 g + SODIUM CHLORIDE 3,2 g + POTASSIUM CHLORIDE 1,2 g; sachet B: SODIUM ASCORBATE 48,11 g + ASCORBIC ACID 7,54 g).
223812889|NCT04861870|BEHAVIORAL|MenCare+/Bandebereho fathers'/couples' group education|MenCare+/Bandebereho was a 3 year project to engage men in maternal, newborn and child health (MNCH) and in sexual and reproductive health in Rwanda. A core component of the project is fathers'/couples' group education. The target participants were first-time parents or parents of young children living in 16 rural and semi-urban sectors selected by the implementing partner in collaboration with local authorities. The MenCare+/Bandebereho fathers'/couples' group education engaged men in 15 weekly sessions of group discussion, critical reflection and interactive activities led by a trained facilitator using a curriculum developed by RWAMREC and Promundo and approved by the Rwandan Ministry of Health, adapted from the Program P Manual. Men's partners participate in 6-8 sessions. The sessions focused on men's role in MNCH, family planning, sharing household responsibilities, intimate partner violence, conflict resolution, family budgeting, and gender equality.
223812890|NCT05279222|OTHER|Gait adaptability training|All patients will receive two gait training interventions, each consisting of twelve one hour training sessions. The training sessions will be focussed on improving gait capacity.
223812891|NCT04496869|OTHER|Online questionnaire|the investigators sent by email a Googleform online questionnaires to women followed in ART center of HFME (Hospital Femme-Mère-Enfant) . Questions are about demographic characteristics, ART history, feeling during the lockdown. To evaluate psychological impact, the investigators use PSS10 and HADS scales. Both scales are worldwide validated and used in recent COVID19's research. the investigators add some quantitative questions about de feeling during the look down, ART interruption, pregnancy desire.
223812892|NCT05553847|OTHER|Automated oxygen titration based on the oxygen saturation during activity|A device will be used, which automatically adjusts the oxygen flow to the dosage necessary for keeping the saturation at the recommended level (90-94%). If the saturation falls below 90%, oxygen flow will increase, and if the saturation increases above 94%, oxygen flow decreases in order to stay on target.
223812893|NCT02950857|DRUG|EPEG|(Pegylated erythropoeitin)
223812894|NCT04033172|DRUG|Pyrotinib Plus Fulvestrant|Pyrotinib: 400 mg/d, q.d., p.o. A course of treatment need 28 days. Fulvestrant: 500 mg/m2 q.d. i.m. A course of treatment need 28 day. First course needs extra dose of fulvestrant 500 mg/m2 q.d. i.m. on day 15.
223812895|NCT05936229|BIOLOGICAL|Interferon Beta-1A|Given IV
223812896|NCT05936229|PROCEDURE|X-Ray Imaging|Undergo x-ray
223812897|NCT05936229|PROCEDURE|Echocardiography|Undergo ECHO
223812898|NCT05936229|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
223812899|NCT05936229|PROCEDURE|Computed Tomography|Undergo CT
223812900|NCT05936229|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
223812901|NCT05936229|PROCEDURE|Lumbar Puncture|Undergo LP
223812902|NCT05936229|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
223812903|NCT05936229|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
223812904|NCT05936229|PROCEDURE|Biospecimen Collection|Undergo blood and CSF sample collection
223812905|NCT05936229|PROCEDURE|Biopsy|Undergo tissue biopsy
223812906|NCT00710112|GENETIC|gene variations|comparing variations in genes in infants who develop chronic lung disease and other diseases of prematurity and those who do not.
223812907|NCT03040882|OTHER|cotton sock|Application of a cotton sock in the immediate postoperative period before applied the Walker
223812908|NCT03040882|OTHER|Elastic Compression Wraps|Application of an Elastic Compression Wraps in the lower limb in the immediate postoperative period before applied the Walker (standard care)
223812909|NCT04581148|DIAGNOSTIC_TEST|Blood test antibodies against SARS-CoV-2|Residual blood of inpatients and outpatients will be analyzed anonymous with a quantitative test for the assessment of antibodies against SARS-CoV-2
223812910|NCT04896333|OTHER|Interaction and exposure with the Robot EBO|The participants will interact with the Robot EBO. The robot will be control by an operator that will conduct a dialogue. The dialogue will include questions related to the social, leisure, activities of daily living and informative areas.
223812911|NCT04372225|OTHER|analysis of hypocalcemia|analysis of postoperative calcium and PTH levels
223812912|NCT02985762|DRUG|EXPAREL|
223812913|NCT05011825|BEHAVIORAL|Pregnant Moms' Empowerment Program|The first session introduces women to the group, seeks to build an alliance and sense of group cohesion, and provides safety planning. The second session addresses intergenerational patterns of violence and how such violence contributes to psychopathology in both the prenatal and postnatal period, focusing on violence prevention. Information regarding cognitive restructuring, behavioral activation, and coping styles is provided in session three, as well as the role of healthy relationships and social supports in promoting resilience. This session begins with discussion on health in pregnancy, labor/delivery, and coordinating care across providers. This session also provides psychoeducation related to post-delivery parenting, including infant safety, care and breastfeeding. In the final session, group leaders assist mothers with identification, sensitivity, and responsiveness to infant cues.
223812914|NCT01746043|DRUG|Armodafinil|150 mg by mouth once a day for 6 weeks.
223812915|NCT01746043|OTHER|Placebo|1 capsule by mouth 2 times a day for 6 weeks.
223812916|NCT01746043|DRUG|Minocycline|100 mg by mouth 2 times a day for 6 weeks.
223812917|NCT01746043|BEHAVIORAL|Questionnaires|Completion of symptom questionnaires before chemoradiation and then 1 time a week during Weeks 1-10 of the study. Questionnaire take up to 5 minutes to complete.
223812918|NCT04761276|DEVICE|Surgical implantation of intra ocular lens|Cataract surgery may be indicated when the cataract reduces visual function to a level that interferes with everyday activities of the patient leading the patient to desire a surgical intervention to improve its vision.
223812919|NCT03590340|BIOLOGICAL|PfSPZ Vaccine|Metabolically active, non-replicating, radiation attenuated, aseptic, purified, cryopreserved NF54 P. falciparum (Pf) sporozoites (PfSPZ Vaccine)
223812920|NCT03590340|OTHER|Normal saline|Normal saline is 0.9% sodium chloride
223812921|NCT03590340|BIOLOGICAL|PfSPZ Challenge (for CHMI)|Live, infectious, aseptic, purified, vialed, cryopreserved, Plasmodium falciparum sporozoites, strain NF54
223812922|NCT01392300|DRUG|IncobotulinumtoxinA (400 Units)|Main period: One injection session of solution, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl), 400 units, total volume 8.0 mL; Mode of administration: intramuscular injection
223812923|NCT01392300|DRUG|Placebo Comparator|Main period: one injection session of solution, prepared by reconstitution of powder with 0.9% NaCl, corresponding total placebo volume 8.0 mL; Mode of administration: intramuscular injection
223812924|NCT00118781|DRUG|iseganan hydrochloride|
223812925|NCT04524078|OTHER|intensive integrated intervention care program|intensive integrated intervention care program \[ICP\] (lifestyle changes, patient education, adherence to practical guidelines) to transient ischemic attack or minor stroke patients would modify a variety of vascular risk factors and therefore should decrease the likelihood of recurrent stroke or vascular events
223812926|NCT02722343|DRUG|Tenofovir intravaginal ring|The participant will wear the intravaginal ring consecutively for 14 days and nights. Following study product use and at study visit 4, blood and genital tract samples will be taken (to include cervico-vaginal fluid and tissue)
223812927|NCT02722343|DRUG|Truvada|The participant will take the tablet for 14 days. taking one tablet each morning. Following study product use and at study visit 4, blood and genital tract samples will be taken (to include cervico-vaginal fluid and tissue)
223812928|NCT02938169|BEHAVIORAL|exercise|"* stabilization exercise: Lumbar stabilization is a multi-component program and involves education/training, strength, flexibility, and endurance. It is generally used during all phases of a back pain episode and may be prescribed after a thorough evaluation of the patient's specific condition.~* bracing exercise: patient is instructed as follows: Draw your navel up towards your head and in toward your spine without moving your pelvis. Continue to breathe normally as you do this.~* walking exercise: treadmill gait with tolerable gait speed~* flexibility exercise: stretching exercise(control)"
223812929|NCT04539457|BEHAVIORAL|Desktop helper|The 'Desktop Helper (version 10)' is a user-friendly information sheet developed by the IPCRG. This 'Desktop Helper (version 10)' has been developed in co-operation with several clinicians and experts in the field of COPD. These practical guidance and support are a tool for clinicians working in primary care. The 'Desktop Helper (version 10)' contains specific advice to prevent clashes. The specific advice of the 'Desktop Helper (version 10)' will be elaborated in decision trees. These will be integrated and implemented into the MedicomSmart system by Stichting Healthbase. Subsequently, these decision trees will provide GPs to conduct case-finding of COPD patients with 'medication-comorbidity clashes'. These are based on the 'Desktop Helper (version 10)' . Case finding will be done by the GP or the practice nurse (POH).
223812930|NCT04539457|BEHAVIORAL|E-learning|The e-learning module will be explanatory to the 'Desktop Helper (version 10)' how to perform the case-finding and in what way the case-finding can be beneficial to the patients with COPD and their (co)morbidities. This e-learning module will include several example cases and how to deal with the case-finding and the next steps in the process to reduce the (co)morbidity clashes with the medications of COPD. Together with the decision trees as inferred from the 'Desktop Helper (version 10)', the e-learning module is aimed at inducing a behavioral change in prescribing medication to a patient suffering from COPD and one or more (co)morbidities.
223812931|NCT02582489|BIOLOGICAL|Bone Marrow Aspirate Concentrate|Subjects undergoing autologous bone marrow aspirate concentrate will receive an intra-articular injection into the affected knee.
223812932|NCT02582489|PROCEDURE|Standard Meniscectomy|All subjects will undergo either a partial or complete meniscectomy to treat the torn meniscus.
223812933|NCT00981851|DRUG|Tiotropium (Spiriva) + Salbutamol (Ventolin)|1 time inhalation of 5 mcg of Tiotropium bromide by Respimat and 400 mcg of Salbutamol by Volume Spacer. cigarette smoking
223812934|NCT00981851|DRUG|placebo|1 time inhalation of placebo with the amount of puffs similar to the active comparator. cigarette smoking
223812935|NCT04174703|OTHER|Self-compassionate letter-writing intervention|Participants in this condition will be asked to engage in an online self-compassionate letter-writing task once per day (10-20 minutes each) for 2 weeks.
223812936|NCT04851262|BEHAVIORAL|Exercise|The intervention is to be taught by fitness trainer at the participants' home at the start of each phase. The exercise progression model for older adults recommended by the American College of Sports Medicine, which emphasise gradual increments in training load and systematically alter one or more programme components, will be adopted.
223812937|NCT06013046|BEHAVIORAL|Intensity-controlled physical activity training (IPAT)|The IPAT group will receive 40 (90 minute) one-on-one, intensity-controlled, exercise sessions by trained staff over 14 weeks. The initial 2-week period will include dedicated education on topics including physical activity guidelines and the benefits of achieving them, the feeling of moderate-to-vigorous physical activity intensity levels, and the appropriate exercises for achieving desired intensity levels. Tailored sessions will be created for each participant based on their physical fitness, goals, preferred exercise equipment and results from their baseline assessment. Each session can include vitals, pain assessment, warm-up, aerobic training, strength exercises and a cool-down. The participants will be monitored to ensure they are achieving at least 150 minutes of moderate-to-vigorous intensity physical activity weekly. Heart rate and actigraphy monitors will be worn during sessions to capture exercise intensity data. The overall goal is to improve cardiorespiratory fitness.
223835506|NCT04598880|DRUG|Sodium picosulfate + magnesium citrate|Citrafleet® is administered orally in 2 doses (2 sachets) as per SmPC within the previous 18 hours to colonoscopy intervention. First dose (sachet 1) is administered at 9 pm on the day before intervention. Second dose (sachet 2) is administered 5 hours before intervention. Sachets 1 and 2 have the same composition: SODIUM PICOSULFATE 10 mg + MAGNESIUM OXIDE 3,5 g + CITRIC ACID 10,97 g.
223835507|NCT03059836|DIETARY_SUPPLEMENT|n3 PUFA-enriched fish oil|3000mg of Eicosapentaenoic acid per day and 1800mg of Docosahexaenoic acid per day
223835508|NCT03059836|DIETARY_SUPPLEMENT|Placebo|Organic Sunflower Oil 5000mg per day
223812938|NCT06013046|BEHAVIORAL|Education and Access (EA)|The EA group will receive an initial 60 minute educational session, during which they will receive information on the adapted exercise equipment in the Orthwein Center, education on the physical activity guidelines and the health benefits of achieving them, and access to the Orthwein Center accessible gym. They will then complete a 14-week independent workout program with the goal of meeting physical activities guidelines. They will have access to Orthwein Center staff to help with minimal setup and guidance, but sessions will be self-directed. Heart rate and actigraphy monitors will be worn during sessions to capture exercise intensity data. Participants will be asked to complete a log for each session to report pain, details of the activities they completed during their workout, the RPE for each activity, and how long each activity lasted.
223812939|NCT05975606|DEVICE|repetitive transcranial magnetic stimulation (rTMS)|rTMS will be applied to primary motor cortex of the brain.
223812940|NCT05975606|DEVICE|functional electrical stimulation (FES) cycling|FES will be applied to muscles associated in cycling: quadriceps, hamstrings, tibialis anterior, gastrocnemius, soleus.
223812941|NCT04003779|OTHER|Room configuration|Adjust distance, handrails, degrees of turn for participant
223812942|NCT06196216|RADIATION|MSCT|Enhanced CT chest
223812943|NCT05957484|DEVICE|Investigational brainstem neuromodulation device|This study device is non-invasive meaning it stays outside of the body. It stimulates activity in the brain through a headset with metallic earpieces that fit into the participant's ear canals. The device will be loaded with certain neurostimulation pattern, and the earpieces will provide the stimulation at the prescribed pattern.
223812944|NCT03799068|OTHER|suprazygomatic maxillary nerve block|bilateral Suprazygomatic maxillary nerve block is performed before surgery in anaesthetized children, after aseptic preparation of the skin. The patient is in supine position with the head in neutral position. The puncture site is at the frontozygomatic angle, at the junction of the upper edge of the zygomatic arch and the frontal process. A 24G needle is attached to a syringe containing the local anaesthetic. It is advanced to reach the greater wing of sphenoid at approximately 20 mm depth, then withdrawn a few millimetres and redirected toward the nasolabial fold in a 20° forward and 10° downward direction. The progression in the pterygopalatine fossa is 35 to 45 mm. Loss of resistance after passing through the temporalis muscle assisted in determining the puncture depth. After a negative blood aspiration test, the calculated dose of the local anaesthetic is injected on each side.
223812945|NCT03799068|OTHER|surgical site infiltration|peri-incisional infiltration of bupivacaine around the incision site given by the surgeon on an anesthetized patient before the incision is done.
223812946|NCT04545996|OTHER|Suboccipital Inhibition Technique|Suboccipital Inhibition Technique For 2min And Conventional Treatment Hot Pack For 10 To 15 Mints And Muscle Energy Technique(Post Facilitation Stretch) 5 Reps × 1 Set Sessions: 2 TIME A WEEK FOR 4 CONSECUTIVE WEEKS
223812947|NCT04545996|OTHER|Cranio Cervical Flexion Exercises.|Cranio cervical flexion exercises10 repetitions for 10 seconds and conventional treatment hot pack for 10 to 15 mints and muscle energy technique(post facilitation stretch) 5 reps × 1 set Sessions: 2 TIME A WEEK FOR 4 CONSECUTIVE WEEKS
223812948|NCT01239667|OTHER|Individual oriented planning of the rehabilitation program for patients with heart failure|Individual oriented rehabilitation plan in collaboration with the patient followed by measuring health related quality of life and self care behavior
223812949|NCT02026180|DEVICE|Micropuncture Access|Femoral arterial access will be obtained either with a 21G micropuncture needle kit or an 18G standard access needle.
223812950|NCT03354364|DIETARY_SUPPLEMENT|Pea hull fiber|Snacks containing 15 g/day of ground pea hulls.
223812951|NCT03354364|DIETARY_SUPPLEMENT|Control|Snacks without added fiber.
223812952|NCT03725540|DEVICE|I-gel|Patients will be anesthetized using an appropriate sized I-gel mask according to the manufacturer's recommendations after lubrication with a water-soluble lubricant.
223812953|NCT03725540|DEVICE|Baska_mask|Patients will be anesthetized using BASKA mask after lubrication with a water-soluble lubricant.
223812954|NCT05056870|DEVICE|ACUVUE Oasys 1-Day with HydraLuxe Technology for Astigmatism|TEST
223812955|NCT05056870|DEVICE|ACUVUE Oasys 1-Day with HydraLuxe Technology|CONTROL
223812956|NCT00676130|DRUG|trimethoprim-sulfamethoxazole|"Weight-based dosing in capsule or suspension form according to the following scale:~15-19 kg (33-42 lbs): trimethoprim-sulfamethoxazole 40/200 mg four times daily~20-24 kg (42-53 lbs): trimethoprim-sulfamethoxazole 60/300 mg four times daily~25-29 kg (53-64 lbs): trimethoprim-sulfamethoxazole 72/360 mg four times daily~29-60 kg (64-132 lbs): trimethoprim-sulfamethoxazole 80/400 mg four times daily~60 kg (132 lbs): trimethoprim-sulfamethoxazole 80/400 mg four times daily~60-80 kg (132-176 lbs): trimethoprim-sulfamethoxazole 160/800 mg three times daily~\> 80 kg (176 lbs): trimethoprim-sulfamethoxazole 160/800 mg four times daily"
223812957|NCT00676130|DRUG|Cephalexin|"Weight-based dosing in capsule or suspension form according to the following scale:~15-19 kg (33-42 lbs): Cephalexin 300 mg four times daily~20-24 kg (42-53 lbs): Cephalexin 400 mg four times daily~25-29 kg (53-64 lbs): Cephalexin 500 mg four times daily~29-60 kg (64-132 lbs): Cephalexin 500 mg four times daily~60-80 kg (132-176 lbs): Cephalexin 1000 mg three times daily~\> 80 kg (176 lbs): Cephalexin 1000 mg four times daily"
223812958|NCT03171480|DRUG|Monoket Pill|Intra-vaginal application of Monoket as a cervical ripening agent for pregnant women undergoing induction of labor
223812959|NCT03171480|DRUG|Placebo|The pharmacy has compounded an identical appearing placebo
223812960|NCT05893264|OTHER|Data collection|"Several data will be collected such as:~Age, weight, height, gender, previous spine surgery, skoliosis (Y/N), palpable spinous process (Y/N), experience in years of anesthesiologist, spine level of epidural placement~and the following sonographic parameters at the level of epidural placement: skin-spinous process distance (cm), skin-transversous process distance (cm), erector spinae plane distance (cm), superior to inferior spinous process distance (cm)"
223812961|NCT05185778|BIOLOGICAL|stool examination, blood sample collected|"Stool examination macroscopically for consistency, color, and presence of blood and/or mucus and microscopically using the following methods:~* Saline and iodine wet mount.~* Formalin-ethyl acetate sedimentation method.~* Modified Ziehl-Nielsen staining : It was done to all cases with manifestations suggestive of protozoa.~  * Collection of peripheral blood samples for Automated CBC and blood indices evaluation.~ * Molecular detection of inflammatory cytokines level (IFNγ, TNFα) and antiinflammatory cytokines (IL4, IL10) by Real-time PCR(polymerase chain reaction)."
223812962|NCT01089322|DRUG|inhaled corticosteroid plus LABA plus oral corticosteroid|formoterol plus budesonide 12/400mcg 2times/day and 6/200 mcg as needed and prednisone 40 mcg
223812963|NCT02587026|OTHER|Blood sample collection|
223812964|NCT02587026|OTHER|Tumor tissue sample collection|
223812965|NCT06524063|DRUG|Survivin-loaded dendritic cell injection|The injections will be given on days 0, 14, and 28. The administration will involve both intradermal (ID) and intravenous (IV) routes.
223812966|NCT06339580|DEVICE|Volume-targeted non-invasive ventilation|A target tidal volume is set on the ventilation device, and the device will then automatically adjust delivered pressures to reach this target tidal volume.
223812967|NCT04755270|DEVICE|VR Glasses|techniques of hypnofertility and VR glasses
223812968|NCT00303160|DRUG|vitamin C & E supplements|
223812969|NCT01696331|BEHAVIORAL|Text Message Reminder|Sent TM reminder at beginning and end of each month that corresponded to required lab frequency. Patients were able to send autoresponses.
223812970|NCT01074606|DEVICE|AcrySof Toric Intraocular Lens|Implantation of the AcrySof Toric Intraocular Lens (IOL)
223812971|NCT02435368|DRUG|mycophenolic acid|Monocytes were co-cultured with LPS and/or MPA.After 12 hours, the supernatants were harvested and stored at -80°C for ELISA.
223812972|NCT00251095|DRUG|Taxol|
223812973|NCT00251095|DRUG|TOCOSOL Paclitaxel|100 mg/m2/week
223812974|NCT03830190|OTHER|Parkinson's disease nurse specialist care|Specialized nursing care provided by a Parkinson's disease nurse specialist
223812975|NCT03221088|DRUG|Jintrolong® low dose group|PEG-somatropin 0.1mg/kg/wk by weekly subcutaneous injection for 52 weeks.
223812976|NCT03221088|DRUG|Jintrolong® high dose group|PEG-somatropin 0.2 mg/kg/wk by weekly subcutaneous injection for 52 weeks.
223812977|NCT04558190|DRUG|Intralipid, 20% Intravenous Emulsion|Lipid infusion
223812978|NCT04558190|DIETARY_SUPPLEMENT|MitoQ|Oral administration of MitoQ capsules
223812979|NCT04558190|DRUG|Salbutamol|Beta2-agonist infusion
223812980|NCT02418247|DRUG|I131|
223812981|NCT02418247|DRUG|I123|
223812982|NCT01891448|OTHER|WebCONSORT tool|Authors are directed to the WebCONSORT tool. The tool allows authors to obtain a customized CONSORT checklist and flow diagram specific to their trial design (e.g., non-inferiority trial, pragmatic trial, cluster trial) and type of intervention (e.g., pharmacological or non pharmacological). The checklist items and flow diagram should then be reported in the manuscript and the completed checklist submitted to the journal along with the revision.
223812983|NCT01891448|OTHER|Modified WebCONSORT tool|Authors are directed to a different version of the WebCONSORT tool. This tool includes the flow diagram part of the tool but not the main checklist or elements relating to CONSORT extensions.
223812984|NCT03645902|DIAGNOSTIC_TEST|Magnetic resonance imaging|
223812985|NCT01181726|DRUG|Estradiol/Norethindrone acetate|1 mg/0.5 mg Tablets
223812986|NCT01181726|DRUG|Activella®|1 mg/0.5 mg Tablets
223812987|NCT03963154|BIOLOGICAL|Human Embryonic Stem Cell Derived Retinal Pigment Epithelium (RPE)|Implantation into one eye of hESC-derived RPE (Human Embryonic Stem Cell Derived Retinal Pigment Epithelium (RPE))
223812988|NCT01638247|DRUG|Tamoxifen|25 mg daily.
223812989|NCT01638247|DRUG|Tamoxifen and GnRH analogue|"25 mg Tamoxifen daily and GnRH analogue:~* Goserelin (10.8 mg s.c. after randomisation and after three months) or~* Leuprorelin (11.25 mg s.c. after randomisation and after three months)."
223812990|NCT01638247|DRUG|Exemestane and GnRH analogue|"25 mg Exemestane daily and GnRH analogue:~* Goserelin (10.8 mg s.c. after randomisation and after three months) or~* Leuprorelin (11.25 mg s.c. after randomisation and after three months)."
223812991|NCT06453655|BEHAVIORAL|Nursing Process|In the first step of the nursing process, nursing diagnoses NANDA-I and nursing outcomes (NOC) appropriate to the needs of the individual were selected. Immediately afterwards, the baseline measurements of NOCs were made. In the second stage, nursing interventions were determined in line with the selected diagnoses and started to be implemented. Instructions for the implementation of the selected NICs were reminded by phone 3 days before the procedure appointment and compliance with colonoscopy preparation instructions was monitored. In the third stage, after measurement of the NOCs were performed on the day of the procedure. In addition, the BBPS scores calculated by the endoscopist during the procedure were taken from the patient file and recorded in the data collection form and the stages of the nursing process were completed.
223812992|NCT03430193|OTHER|FIRM|"FIRM program consisted of total 10 days session including PT, in two times twenty-minute sessions per day and 4 times OT during admission initiated before transfer to rehabilitation ward.~PT (Weight bearing exercise, strengthening exercise, gait training, aerobic exercise and functional training) progressed gradually based on individual functional level and OT of activities of daily life (ADL) training (transfer, sit to stand, bed mobility, dressing, self-care retraining and using adaptive equipment) was provided."
223812993|NCT03430193|OTHER|Conventional rehabilitation|Conventional rehabilitation program consisted of total 10 days session of PT focused on simple standing and gait training, in one time twenty-minute sessions per day.
223812994|NCT05118633|BEHAVIORAL|Device and app system designed for participant to self-administer Habit Reversal Training and Stimulus Control|Participants will receive an awareness bracelet and an app that work together to implement key features of Habit Reversal Training and Stimulus Control. The participant will take part in psychoeducation, awareness training, and competing response training related to trichotillomania, as well as receive stimulus control reminders.
223812995|NCT05118633|BEHAVIORAL|Reminder bracelet and journaling app control condition|Participants will receive a bracelet programmed to vibrate randomly several times per hour during waking hours. They will be instructed this is a reminder not to pull. They will also be instructed to journal in an app on their phone several times per day.
223812996|NCT03606356|DRUG|Onabotulinum toxin A|Cranial Subcutaneous Injections
223812997|NCT03219385|DEVICE|Mirabilis System|The intervention is a transabdominal treatment performed with the Mirabilis System, during which high-intensity focused ultrasound (HIFU) is applied noninvasively through the skin using an applicator placed against the abdomen. One or more appropriately selected uterine fibroids will be treated with HIFU using integrated ultrasound imaging to guide the treatment. HIFU causes localized heating and mechanical effects to develop in the targeted fibroid(s) that result in therapeutic destruction of the fibroid tissue, leading to improvement in related symptoms.
223812998|NCT05548439|BIOLOGICAL|VBI-2901a|Intramuscular injection of VBI-2901a, an investigational trivalent coronavirus vaccine that contains three coronavirus spike proteins with aluminum phosphate adjuvant.
223812999|NCT04687735|OTHER|Intervention after nerve block|Brachial plexus block + Physical therapy
223813000|NCT00509418|DIETARY_SUPPLEMENT|Viusid|Viusid, a nutritional supplement. Three oral sachets Daily 24 weeks
223813001|NCT00509418|OTHER|Hypocaloric Diet with controlled exercise|Modified ADA diet in combination with controlled exercise daily 24 weeks
223813002|NCT02000830|DRUG|Stannsoporfin|Stannsoporfin administered by intramuscular (IM) injection
223813003|NCT02000830|DRUG|Placebo|Matching placebo administered by IM injection
223813004|NCT03688152|DRUG|INCB053914|"Dose Escalation: INCB053914 at the protocol-defined starting dose in combination with INCB050465, with dose modifications based on tolerability criteria.~Dose Expansion: Recommended dose from the dose-escalation study."
223813005|NCT03688152|DRUG|INCB050465|"Dose Escalation: INCB050465 at the protocol-defined starting dose in combination with INCB053914, with dose modifications based on tolerability criteria.~Dose Expansion: Recommended dose from the dose-escalation study."
223813006|NCT01611584|DRUG|ALA-induced Fluorescence|ALA Dose- 20 mg/kg
223813007|NCT01860586|DRUG|Bevacizumab|Bevacizumab (1.25mg/0.05mL) will be injected into the study eye, at the end of the surgical repair of the retinal detachment and at Month 1, 2 and 3.
223813008|NCT06288061|DEVICE|Non-invasive Neuromodulation|"This intervention group will receive neuromodulation treatment two days a week for a total of six sessions.~The patient is placed in the supine position with a cushion under the knees. The physiotherapist will be positioned behind the patient's head on the side to be treated. The technique will be applied on both anterolateral sides of the neck, where the Phrenic nerve passes in front of the anterior Scalene, between the Subclavian arteries and veins. Neuromodulation will be applied with a Pointer Excel II. It will be applied with negative polarity, at a frequency of 2 Hertz (HZ) and with a current intensity varying between 0 and 45 milliamperes (mA). The intensity shall be increased progressively until the patient's diaphragmatic contraction can be observed without pain. The technique shall be applied on each side for a total of 8 minutes, divided into intervals of 10 seconds of stimulation and 20 seconds of rest."
223813009|NCT06288061|OTHER|Cervico-dorsal Massage|"This intervention group will receive manual therapy two days a week for a total of six sessions.~The patient shall be placed prone position with a cushion under his or her feet. This group will receive manual therapy on the entire posterior cervical and dorsal region, the area between the occipital bone, the shoulders and the scapulae. The massage will be carried out with a little oil or cream for about 20 minutes."
223813010|NCT06232720|DEVICE|Q300 QART Medical|The Q300TM Imaging system includes a Quantitative Phase Microscope. Q300TM uses a low intensity coherent light source, in a uniquely configured interferometer, which measures light delay as it passes different locations across the sperm cell. The amount
223813011|NCT01356953|OTHER|Aerobic exercise|Intensity of aerobic exercise
223813012|NCT04526002|DEVICE|Theta-burst stimulation (TBS)|TBS comprises 3-pulse 50-Hz bursts, applied every 200 ms (at 5 Hz) as described previously (Huang, Edwards et al. 2005). iTBS consists of 2-second trains with an inter-train-interval of 8 seconds. We will repeat trains (30 pulses; 10 bursts) for 20 times to reach a total number of 600 pulses (3x10x20). cTBS will comprise uninterrupted bursts to reach a total number of 600 pulses, as done routinely by others. Concurrent TBS/fNIRS stimulation will be applied over the left (iTBS) and right (cTBS) DLPFC at an intensity of 70-120%\* resting motor threshold (RMT) (The ideal %RMT will be determined first in a pilot study). In part two, stimulation intensity for patients will be 120% RMT (titration to full therapeutic dose over the first three days), as approved by the FDA in the U.S. (Blumbeger et al. 2018). The stimulation site will be the same as in the concurrent TBS/fNIRS stimulation (see above).
224264556|NCT03227991|BEHAVIORAL|Safety Planning Intervention|The Safety Planning Intervention is a protocol driven, brief suicide prevention strategy that is a good fit for acute care settings. It involves a clinician working collaboratively with the patient to build a personalized safety plan that is documented using a templated paper form and includes warning sign identification, means restriction and personalized strategies to deescalate a suicide crisis.
224264557|NCT03227991|BEHAVIORAL|Risk factors and Warning signs|Printed information sheet listing suicide risk factors and crisis hotlines
224264558|NCT05633745|DRUG|NEU-723|Oral Doses
224264559|NCT05633745|DRUG|Placebo|Oral Doses
223813013|NCT05130801|DIAGNOSTIC_TEST|pHLIP® ICG NIRF imaging|"Pre-operative research MRI will be performed 1-3 weeks prior to the surgery. single pHLIP® ICG injection will be administered i.v. by a radiologist on the protocol one day prior to scheduled surgery on the occasion of presurgical localization (12-36 hours prior to the surgery).~In Phase I, we propose to investigate 4 different doses:~Dose level 1 = 0.04 mg/kg Dose level 2 = 0.075 mg/kg Dose level 3 = 0.15 mg/kg Dose level 4 = 0.30 mg/kg~In Phase IIa, the researchers propose to administer selected in Phase I dose of pHLIP® ICG. In Phase IIa, the researchers propose to administer pHLIP® ICG at DL2, DL3 or DL4 at different time points prior to surgery ranging from 12-110 hours, with targeted enrollment of 12 patients. Next, the selected optimal dose and timing will be used with targeted enrollment of 28 patients. The total number of subjects in Phase IIa study is 40."
223813014|NCT05703893|DIAGNOSTIC_TEST|Supine resting (REST) and active standing (STAND)|Analysis of baroreflex sensitivity
223813015|NCT01288274|OTHER|Community Based administration of DMPA|Injectable contraceptive administered by clinic based health extension worker or community based reproductive health agent using same protocol to test equivalence of community based distribution to facility based distribution
223813016|NCT01271348|DRUG|Etoricoxib|Etoricoxib film tablet, 90 mg, q.d.
223813017|NCT01271348|DRUG|placebo|Placebo tablet, q.d.
223813018|NCT01114204|DRUG|Ferumoxytol|IV Ferumoxytol
223813019|NCT01114204|DRUG|Iron Sucrose|IV Iron Sucrose
223813020|NCT00854282|PROCEDURE|Staging surgery or debulking surgery|Staging surgery or debulking surgery
223813021|NCT03476629|OTHER|Physical activity|Effects of different physical activity programs
223813022|NCT03848702|DEVICE|Distal radius fracture brace|The distal radius fracture brace is constructed from biocompatible materials (like polylactic acid; PLA) and the skin is protected by commercially available and approved waterproof padding (like Aquacast®). The major brace components are connected and reinforced with carbon rods and plastic bolt-nut connections. PLA is extensively used, for example in surgical implants, but also as biological alternative for plastics. Aquacast® is approved and used as waterproof padding in swim plaster. The biomechanical function of the distal radius brace has been tested successfully in an ex vivo setting (results to be published). The DRFB includes the distal forearm, wrist an base of the hand. The thumb and fingers are free and the DRFB provides more movement than classical casting.
223813023|NCT05093387|DRUG|Carboplatin|Given IV
223813024|NCT05093387|BIOLOGICAL|Pembrolizumab|Given IV
223813025|NCT05093387|GENETIC|Transferrin Receptor-Targeted Liposomal p53 cDNA|Given IV
223813026|NCT04191629|COMBINATION_PRODUCT|EO1404|
223813027|NCT04191629|PROCEDURE|Endothelial brushing or Descemet stripping|
223813028|NCT05210829|DIAGNOSTIC_TEST|stationary and trait anxiety scale|survey
223813029|NCT03479021|DIAGNOSTIC_TEST|Welch-Allyn Spot Vision Screener|photograph of the eye
223813030|NCT00745706|DEVICE|Implantable Loop Recorder (ILR)|Insertion of ILR 3 months prior to clinical ablation procedure to collect data on actual Atrial Fibrillation episodes and correlation with patient symptoms through patient diary entry. Then patient undergoes their previously indicated clinical ablation procedure and is then followed up with ILR insitu for 30 months post-ablation for the same as mentioned above.
223813031|NCT00228293|DEVICE|investigational monitor/defibrillator with CPR feedback|
223813032|NCT04411602|DRUG|SARS-CoV-2 plasma|To determine feasibility of convalescent plasma for treating patients in the ICU with COVID-19.
223813033|NCT00113932|PROCEDURE|High-Dose Density Therapy|Dexamethasone 40mg po 1-4, Thalidomide 200 mg po 1-6hrs then daily after transplant; Cisplatin\* 10 mg/m2 Continuous infusion 1-4;Adriamycin 10 mg/m2 Continuous infusion 1-4;Cyclophosphamide 400 mg/m2 Continuous infusion 1-4; Etoposide 40 mg/m2 Continuous infusion 1-4; Pegfilgrastim 6 mg subcutaneously 6 and 13; Darbepoetin 200μg subcutaneously Between -6 to-1 +12, \& every 2 weeks until HB \>12 gm/dl\*\*\*; Lovenox (or other LMWH) 40 mg subcutaneously Daily until Pltcount \<30,000/μl
223813034|NCT01253863|OTHER|exploration|exploration of wound for determining damaged tissue
223813035|NCT03161457|BIOLOGICAL|JHL1101|1000 mg containing 10 mg/mL rituximab to be diluted to a concentration of 1 to 4 mg/mL in 0.9% normal saline or 5% D-glucose for administration
223813036|NCT03161457|BIOLOGICAL|MabThera|1000 mg containing 10 mg/mL rituximab to be diluted to a concentration of 1 to 4 mg/mL in 0.9% normal saline or 5% D-glucose for administration
223813037|NCT05140291|OTHER|Dry Needling|"1/2 needles will placed into defined innervation fields of the trigeminal nerve and rotated. Total time will be 5-7 minutes."
223813038|NCT05140291|OTHER|Sham Dry Needling|Needle handles inside of guide tubes will be tapped in a way similar to an actual needle being set but the sham needles will be blunted.
223813039|NCT03978910|OTHER|measurements of the accuracy of the reaching movements|Euclidian distance between final position and target
223813040|NCT03611244|DEVICE|Portable seat device devised to maintain lumbar lordosis|"The posterior lumbar spine pads are used to maintain lumbar lordosis and fix it with the shoulder strap so that the hip does not slip forward (so that it does not become a sacral sitting posture).~The seat is equipped with a 5 cm air filled villus cushion to relieve pressure on the ischial tuberosity when sitting for a long time. The portable seat device can be moved so that the DMD can sit on the device even when sitting in a wheelchair or a chair for home, school, or outdoors, so that the lumbar lordosis can be constantly maintained."
223813041|NCT00674570|DRUG|Hydrocortisone|25 mg/oral one hour prior to extinction task
223813042|NCT00674570|DRUG|D-Cycloserine|50 mg/oral one hour prior to extinction task
223813043|NCT00674570|DRUG|Placebo|One hour prior to extinction task
223813044|NCT05982665|OTHER|Molecular hydrogen|Hydrogen gas, purity \>99.9%, flow rate 300 ml/min.
223813045|NCT05982665|OTHER|Placebo|Ambient air, flow rate 300 ml/min.
223813046|NCT01995448|BIOLOGICAL|Blood test|Residue of blood further to NFS.
223813047|NCT04264793|BEHAVIORAL|Behavioral Lifestyle Intervention|In addition to usual care in the health center, the intervention included 7 visits with the health center dietitian for individual nutrition counseling, invitation for group nutrition education (5 sessions), individual counseling for physical activity, invitation for a 6-weekly structured group physical activity, DVD on physical activity to perform physical activity at home.
223813048|NCT04264793|BEHAVIORAL|Usual Care|Patients received usual care including education as part of the diabetes management from their healthcare professionals (physicians and nurses), normally every 2-3 months. Visits with the health center dietitian were arranged as per physician referral.
223813049|NCT01837004|BEHAVIORAL|CORTEX|2-hour sessions for a period of four weeks prior to the initial exercise program start. One hour will be devoted to computerized training (stationary dual-task \& cognitive control training, self-priming, certainty training) whereas the other hour will be devoted to exergaming involving non-stationary, dual-task training.
223813050|NCT03633929|OTHER|KIOS OUD|Study Participants will evaluate software known as KIOS-OUD
223813051|NCT03833635|OTHER|osteopathic manipulative treatment|OMT will be used to treat premature infants after having performed a manual osteopathic assessment. Techniques used are indirect
223813052|NCT03833635|OTHER|Sham|the sham intervention consists in a stable skin-to-skin contact with the participant
223813053|NCT05301504|BIOLOGICAL|ChAdOx1 biEBOV|ChAdOx1 biEBOV is provided as a liquid in glass vials and administered intramuscularly into the deltoid of the non-dominant arm (preferably)
223813054|NCT04119453|DRUG|Rivoceranib|Film-coated tablets
223813055|NCT00379119|OTHER|diagnostic laboratory biomarker analysis|
223813056|NCT00379119|OTHER|flow cytometry|
223813057|NCT00379119|OTHER|physiologic testing|
223813058|NCT00379119|PROCEDURE|computed tomography|
223813059|NCT01391923|DEVICE|The Zeltiq System|Non-invasive cooling is applied to the treatment area with a defined cooling rate and duration.
223813060|NCT00698386|DIETARY_SUPPLEMENT|Zinc supplement|Zinc miconutrient supplements have been prepared by Cadila pharmaceutical Ltd., India, in the form of capsules.Each micronutrient capsule contains 50mg zinc (as zinc sulphate) in a lactose matrix.In this clinical trial one tablet of zinc as oral supplement will be given everyday during the entire course in line with the directly observed treatment, short-course (DOTS) strategy recommended by the World Health Organization.
223813061|NCT00698386|DIETARY_SUPPLEMENT|Placebo|Placebo have been prepared by Cadila pharmaceutical Ltd., India, in the form of capsules.The placebo consisted of lactose alone. Supplement and placebo capsules were indistinguishable in appearance both externally and internally.
223813062|NCT03933111|DIAGNOSTIC_TEST|local sound velocity measurement|All patients are scanned by Fuji film su-9000 ultrasonic system. After the lesions are found, local sound velocity measurement technology will be used to measure the sound velocity in the lesions.Pathology diagnosis or clinical follow-up results will be regard as diagnostic gold standard divide the patients into pancreatic cancer and pancreatic cancer group.
223813063|NCT04461795|DRUG|Fremanezumab-Vfrm 225 MG/1.5 ML Subcutaneous Solution [AJOVY]|225 MG/1.5 ML Subcutaneous Solution
223813064|NCT03634618|OTHER|Mirror Therapy|Mirror therapy is the treatment method in which mental performance of movements is performed by observing the movements of the healthy extremities. In the case of mirror treatment, the mirror box is placed on a fixed floor. The mirror is positioned so that the patient's body can be fully centered and the mirror image can be seen. While the affected limb is placed on the rear side of the mirror, the firm extremity is opposite to the mirror. The patient focuses on the mirror image of the moving healthy hand and, through artificial visual feedback, perceives the affected limb as moving. The exercises are as follows: flexor tendon gliding exercises, median motor exercises, wrist and forearm ROM exercises and function-oriented exercises.
223813065|NCT03634618|OTHER|Convantional Physiotherapy|The first two weeks involve only immobilisation with plaster. The next 4 weeks, patients do the exercises which follows: 15 minutes water bath, scar tissue massage, flexor tendon gliding exercises, median motor exercises, wrist flexion-extention, median nerve gliding exercise (in addition, one week after plaster removal), hand wrist stretching exercise (in addition, 2 weeks after plaster removal).
223813066|NCT00082732|BEHAVIORAL|behavioral dietary intervention|
223813067|NCT00082732|DIETARY_SUPPLEMENT|dietary intervention|
223813068|NCT00082732|PROCEDURE|therapeutic dietary intervention|
223813069|NCT00641914|DRUG|budesonide|
223813070|NCT00641914|DRUG|Placebo|
223813071|NCT00548132|DEVICE|Chlorhexidine-impregnated foam dressing|Patients in the treatment arm will have the Biopatch incorporated into their catheter care protocol. ICU nurses were instructed on the proper use of this novel dressing/sponge. Catheter dressing changes will only be done every 7 days unless there is visible blood, soiling underneath the dressing, or if the dressing comes off.
223813072|NCT00237939|DRUG|Aripiprazole|
223813073|NCT04774133|DIAGNOSTIC_TEST|Blood sample|Pazients will undergo to blood samples at predefined times
223813074|NCT02189902|DIETARY_SUPPLEMENT|4000 IU/d D3 over 12 weeks|
223813075|NCT02189902|DIETARY_SUPPLEMENT|7000 IU/d D3 over 12 weeks|
223813076|NCT01817374|DIAGNOSTIC_TEST|2D US grayscale plus quantitative VCEUS|This is a pilot study to evaluate quantitative VCEUS imaging for determining early breast cancer response to neoadjuvant chemotherapy, comparing results with volume change on grayscale US and planar CEUS, and correlating imaging findings with pathological response on surgical specimens.
223813077|NCT03375476|DIAGNOSTIC_TEST|collection of cardiovascular risk scores and intraoperative cardiovascular parameters|collection of preoperative cardiovascular risk scores and intraoperative cardiovascular parameters
223813078|NCT03375476|DIAGNOSTIC_TEST|cardiac troponin assay|plasmatic concentration of high sensitive cardiac troponin will be measured at baseline and on postoperative day 1, 2 and 3
223813079|NCT03375476|DIAGNOSTIC_TEST|Electrocardiogram|12 derivations ECG will be made at baseline and on postoperative day 1, 2, and 3
223813080|NCT06449716|OTHER|12-week progressive power-oriented resistance exercise program|2x/week, 35-45 min sessions, on leg press machine
223813081|NCT01487876|BIOLOGICAL|HBV DNA vaccine|HBV DNA vaccine means that each volunteer received 4 injections of 4 mg DNA vaccine scheduled by a prime and 3 boosts at intervals of 4, 8, 12 weeks.
223813082|NCT01487876|OTHER|Placebo|Placebo means the arm in which each volunteer received 4 injections of 4 mg placebo scheduled by a prime and 3 boosts at intervals of 4, 8, 12 weeks.
223813083|NCT01290211|DRUG|Maraviroc|maraviroc 300 mg BID x 5 days
223813084|NCT01290211|DRUG|Fosamprenavir/ritonavir|fosamprenavir/ritonavir 700/100 mg BID x 10 days
223813085|NCT01290211|DRUG|Maraviroc + Fosamprenavir/ritonavir|maraviroc 300 mg BID + fosamprenavir/ritonavir 700/100 mg BID x 10 days
223813086|NCT01290211|DRUG|Maraviroc|maraviroc 300 mg QD x 5 days
223813087|NCT01290211|DRUG|Fosamprenavir/ritonavir|fosamprenavir/ritonavir 1400/100 mg QD x 10 days
223813088|NCT01290211|DRUG|Maraviroc + Fosamprenavir/ritonavir|maraviroc 300 mg QD + fosamprenavir/ritonavir 1400/100 mg QD x 10 days
223813089|NCT00221143|GENETIC|Autologous peripheral blood CD34 positive cell therapy|
223813090|NCT05857111|DEVICE|Celbrea|The test with the CELBREA® device will be added to the routine screening according to the protocols of the health facility.
223813091|NCT05058209|DRUG|Triamcinolone acetonide extended-release injectable suspension|Zilretta (Triamcinolone acetonide extended-release injectable suspension) is indicated as an intra-articular injection for the management of pain due to knee OA. The most commonly reported adverse reactions (incidence ≥1%) in clinical studies included sinusitis (2%), cough (2%), contusions (2%) and joint swelling (3%). For additional details, please see Package Insert (http://www.zilrettalabel.com/PI.pdf). The website for Zilretta additionally lists: joint pain, headache, back pain, sore throat and runny nose, and bruising as common side effects of receiving a Zilretta injection.
223813092|NCT05058209|DRUG|Betamethasone sodium phosphate and betamethasone acetate Injectable Suspension|Celestone (betamethasone sodium phosphate and betamethasone acetate Injectable Suspension, USP 6 mg per mL) is indicated as an intra-articular injection for the management of chronic or long-term inflammation associated with multiple conditions including severe allergies, dermatological diseases, endocrine disorders, gastrointestinal diseases, hematologic disorders, neoplastic diseases, nervous system disorders, ophthalmologic diseases, renal diseases, respiratory diseases and rheumatic disorders, and others that may not be listed. Celestone Soluspan is available in generic form. The most commonly reported adverse reactions include acne, increased hunger, and weight gain.
223813093|NCT02798211|DRUG|Secukinumab 300 mg|150 mg x 2 s.c. injection
223813094|NCT02798211|DRUG|Secukinumab 150 mg|150 mg s.c. injection
223813095|NCT02798211|OTHER|Placebo|Placebo
223813096|NCT05292534|DEVICE|hearing aid amplification|Hearing aid will be fit to prescribed participant hearing loss.
223813097|NCT05292534|DEVICE|hearing aid amplification with an added sound|Hearing aid will be fit to prescribed participant hearing loss and an added sound will be activated.
223813098|NCT01982435|DRUG|Ranibizumab|Monthly injections of Intravitreal Ranibizumab 0.3 mg for 12 months in patients previously treated with Avastin for Diabetic Macular Edema.
223813099|NCT01982435|DRUG|Ranibizumab|Three Monthly injections of Intravitreal Ranibizumab 0.3 mg in patients previously treated with Avastin for Diabetic Macular Edema. Then follow-up visits may be extended by 2 weeks for a total of 12 months.
223813100|NCT03844243|DRUG|NGF|Intramuscular injection
223813101|NCT03844243|DRUG|Isotonic-saline|Intramuscular injection
223813102|NCT04034394|OTHER|Electromoxibustion|Electromoxibustion is a electric device that mimic the burning or moxa. Subjects in this group will receive electromoxibustion using a knee-brace-like device which produces thermal stimulation with a moxa pad inside. The treatment will be delivered 3 times per week for 4 weeks.
223813103|NCT04034394|OTHER|Knee health education|Subjects in this group will attend 2 lessons (120 minutes each) of health education related to knee OA symptom management in a small group of 5-7 subject. The course content is developed from the course materials from the websites of Elderly Health Service, Department of Health, Hong Kong SAR.
223813104|NCT06542237|DRUG|YCT-529|"In the Phase 1b portion of the study (Part 1), 4 dosing cohorts and one optional 5th cohort with 4 participants in each cohort will be evaluated (approximately 20 participants): 15, 30, 90 and 180 mg.~In the Phase 1b portion of the study (Part 2), 4 dosing cohorts with 4 participants in each cohort will be evaluated (approximately 16 participant): dose to range from 30 mg upto 180 mg.~In the Phase 2a portion of the study (Part 3), up to 3 cohorts of up to 10 participants (approximately 30 participants) will receive doses within the range of doses that was well tolerated and had biological activity in the Phase 1b portion."
223813105|NCT03086018|DEVICE|Successor hearing aid to Juna|The participants will all be experienced hearing instrument device users and will be switched from their current (control) devices to the new test device which succeeds the Juna device.
223813106|NCT04550663|DRUG|KD-025 CAR-T cells|Autologous genetically modified anti-NKG2DLs CAR transduced T cells
224264560|NCT00495222|PROCEDURE|Tissue plication|Tissue apposition and plication of a dilated GJ anastomosis with the Endoscopic Suturing System
224264561|NCT00495222|DEVICE|Endoscopic Suturing System|Tissue plication of dilated GJ stoma
224264562|NCT00495222|DEVICE|Tissue Plication|Tissue plication for GJ stoma reduction
224264563|NCT00073307|DRUG|Sorafenib (Nexavar, BAY43-9006)|Multi Kinase Inhibitor
224264564|NCT00073307|DRUG|Placebo|Placebo
224264565|NCT01375309|DIETARY_SUPPLEMENT|Bifidobacterium bifidum supplementation|Bifidobacterium bifidum supplementation wiht approximately 2.5\*10to9th bacteria per day
223813107|NCT05508386|OTHER|MATLAB-based interface, showing 50 EEG traces, classification of the EEG-pattern as Burst Suppression possible, yes, no.|A software environment (MATLAB) was developed, that allows the international experts to access the data set and score the traces pseudonymously. This MATLAB-based interface shows 50 EEG traces. A representative dataset was composed, consisting of definite Burst Suppression patterns (positive control), intraoperative EEG without Burst Suppression patterns (negative control), and patterns indicating different manifestations of a possible Burst Suppression-like pattern.
223813108|NCT01892345|DRUG|Eculizumab|Induction Phase: 900 mg IV weekly for 4 weeks, followed by 1200 mg for the fifth dose; Maintenance Phase: 1200 mg IV every 2 weeks
223813109|NCT01892345|DRUG|Placebo|Induction Phase: matching placebo (900 mg) IV weekly for 4 weeks, followed by matching placebo (1200 mg) for the fifth dose; Maintenance Phase: matching placebo (1200 mg) IV every 2 weeks
223813110|NCT05731089|PROCEDURE|Phacoemulsification with IVI of aflibercept|IVI was either before or after cataract surgery
223813111|NCT06009640|DEVICE|Intraoperative neurophysiological monitoring with Nicolet Endeavor IOM Machine|Integration of intraoperative neurophysiological monitoring (IONM) into laparoscopic decompression surgery to protect pelvic nerves by continuously monitoring when they are at risk during surgery.
223813112|NCT05970302|DRUG|Tislelizumab+Bevacizumab+Oxaliplatin+Capecitabine|Use the above medications on a regular basis.
223813113|NCT03759613|OTHER|Gait Analysis|"Gait Analysis: Gait analysis is not a routine assessment tool for upper extremity burn injuries. This analysis is an assessment method to estimate gait symmetry.~Restriction arm swing: Participants in group will be restricted for arm swing using a bandage. Thus, the reciprocal arm swing will be prevented."
223813114|NCT02748694|DRUG|TAK-041|TAK-041 tablets or oral suspension.
223813115|NCT02748694|DRUG|TAK-041 Placebo|TAK-041 placebo-matching suspension or tablet.
223813116|NCT05357937|BEHAVIORAL|standard physiotherapy program|A qualified physical therapist administered a structured physiotherapy program from day 1 to day 7 in both groups
223813117|NCT00727818|DEVICE|guided bone regeneration|
223813118|NCT01473381|DRUG|Vilazodone|Vilazodone was supplied as film-coated tablets.
223813119|NCT01473381|DRUG|Placebo to citalopram|Placebo to citalopram was supplied as a capsule.
223813120|NCT01473381|DRUG|Placebo to vilazodone|Placebo to vilazodone was supplied as film-coated tablets.
223813121|NCT01473381|DRUG|Citalopram|Citalopram was supplied as encapsulated tablets.
223813122|NCT03166371|DIETARY_SUPPLEMENT|Liposomal Glutathione (GSH)|Two teaspoons (containing 840 mg GSH, 420 mg/tsp) liposomal GSH (ReadiSorb®) will be taken orally twice daily for a total daily dose of 1680 mg GSH/day. Liposomal GSH will be refrigerated until use and mixed in ≈ 250 mL water or juice for oral intake. The study product will be consumed daily for 90 consecutive days after hospital discharge.
223813123|NCT03166371|OTHER|Placebo|Two teaspoons of placebo product will be taken orally twice daily. The placebo will be refrigerated until use and mixed in ≈ 250 mL water or juice for oral intake. The placebo will be consumed daily for 90 consecutive days after hospital discharge.
223813124|NCT00615381|DRUG|Insulin|insulin infusion (0-10 U/hr) vs. 0.3 U/kg/hr and boluses (0-8 U) adjusted every 15 minutes during the intraoperative period to maintain intraoperative euglycemia (blood glucose levels 80-120 mg/dL)
223813125|NCT00706225|DRUG|Bazedoxifene and conjugated estrogens|Bazedoxifene 20 mg tablet once daily for 7 days. Conjugated Estrogens 0.625 mg tablet, single doses one week apart.
223813126|NCT00586599|OTHER|measurement of inflammatory markers|measuring inflammatory markers and comparing to controls.
223813127|NCT01337414|BEHAVIORAL|VMS diary booklet|
223813128|NCT01337414|BEHAVIORAL|Standard of Care|
223813129|NCT04492150|DRUG|Dextrose 5%/Nacl 0.3% Inj_#3|250 mL/hour of dextrose 5% intravenous drip
223813130|NCT04492150|DRUG|Saline|250 mL/hour of normal saline intravenous drip
223813131|NCT01562535|OTHER|Pronation|"In this technique the arm is flexed 90 degrees and a gentle pronation is applied to the arm; then the arm is further flexed to 45 degrees until the clinician feels a click in the elbow meaning the re-accommodation of the radial head has been accomplished."
223813132|NCT01562535|OTHER|Supination|"The affected arm is in a 90 degrees flexion. The clinician will hold the arm by the elbow and then makes a gentle supination of the affected arm and flexion of the elbow until feeling the click and the child is able to move the arm without pain."
223813133|NCT03107819|DIAGNOSTIC_TEST|Plasma and urine metabolomics|Through the use of high-pressure liquid chromatography and mass spectrometry, quantitative measurements of targeted metabolites associated with amino acids, methylation, acetylation and the tricarboxylic acid (TCA) cycle will be analyzed on the blood and urine specimens.
223813134|NCT02487810|BEHAVIORAL|Cognitive load|Patients in the intuition arm of the study will be asked to complete a memorization task while they are answering survey questions.
223813135|NCT02487810|BEHAVIORAL|Deliberative instructions|Patients in the deliberative arm will be given instructions to take their time and deliberate on their decisions
223813136|NCT06003465|DRUG|LY3437943|Administered SC
223813137|NCT06003465|DEVICE|Test|Used to administer LY3437943 SC
223813138|NCT06003465|DEVICE|Reference|Used to administer LY3437943 SC
223813139|NCT01889186|DRUG|ABT-199 (Main Cohort)|Participants received a test dose of ABT-199 of ≤ 20 mg on Week 1 Day 1 of the Lead-In Period. For those with significant electrolyte and/or lymphocyte changes within 24 hours of the first dose, the 20 mg dose was maintained for 7 days with escalation to 50 mg on Week 2 Day 1. If none of the electrolyte and/or lymphocyte changes occurred within 24 hours from ABT-199 20 mg dose administration, the participant was dose-escalated to 50 mg on Week 1 Day 2. After the first dose of 50 mg, if no laboratory abnormalities occurred, the participant remained on the 50 mg dose through Week 1. After receiving the 50 mg dose for approximately 1 week (6 to 7 days), the following dose escalation proceeded with weekly increases in dose: → 100 mg → 200 mg → 400 mg (or additional lead-in steps to designated 400 mg dose), as tolerated.
223813140|NCT01889186|DRUG|ABT-199 (Safety Expansion Cohort)|Participants received an initial dose of ABT-199 of 20 mg on Week 1 Day 1 of the Lead-In Period. If one or more electrolyte changes (from the 0 hr measurement prior to dosing) suggestive of laboratory tumor lysis syndrome (LTLS) or clinical TLS (CTLS) occurred within 24 hours of the 20 mg dose, no additional doses were administered until resolution. Upon resolution of laboratory abnormalities, the 20 mg dose was continued through Week 1. If no significant findings suggestive of clinical or laboratory TLS occurred within 24 hours, the 20 mg dose was continued through Week 1 Day 7, and escalated to a dose of 50 mg on Week 2 Day 1. Those who had drug interruptions may have been allowed to escalate to and be maintained at 50 mg for 1 week after they had been on a 20 mg dose for at least 1 week (5 - 7 days). After a week at 50 mg, weekly dose escalations were implemented as follows: 100 mg → 200 mg → 400 mg (or additional lead-in steps to designated 400 mg dose) as tolerated.
223813141|NCT02221102|DRUG|Aspirin|non-steroidal anti-inflammatory drugs
223813142|NCT02221102|DRUG|edoxaban|orally active direct factor Xa inhibitor
223813143|NCT02221102|DRUG|placebo|
223813144|NCT03607825|DEVICE|Neurapheresis System|CSF filtration system and lumbar catheter
223813145|NCT02093455|DIETARY_SUPPLEMENT|Chardonnay Seed Flour (CSF)|CSF is made from wine grape skins and seeds.
223813146|NCT02093455|DIETARY_SUPPLEMENT|Placebo|
223813147|NCT06107595|BEHAVIORAL|Placebo|Participant take 1 dose placebo (odor or pill) on post-op day 0 (POD 0) and 3 placebo dose from POD 2 to POD 17
223813148|NCT04012515|DEVICE|Electrode Pads|Participants wear six electrode pads in total; three different types of pad, worn in the same positions on both sides of the face. The pads on the left-hand side of the face are replaced daily, and those on the right-hand side are replaced every other day. The pads do not administer a medical treatment or perform any other active function. The purpose of the intervention is to determine which combination of pad and replacement regime maximises the tolerability of wear over a 30-day period.
223813149|NCT01247428|DEVICE|MiStent SES|The MiStent SES is a device/drug combination comprised of two components; a stent and a drug product (sirolimus within an absorbable polymer coating).
223813150|NCT05797831|DRUG|Navtemadlin|Navtemadlin is an experimental MDM2 anticancer drug taken by mouth
223813151|NCT05797831|DRUG|Navtemadlin Placebo|Navtemadlin placebo is a placebo that is the same in appearance to navtemadlin drug taken by mouth
223813152|NCT02989272|DRUG|Sulfate, Magnesium|magnesium group (30 patients) who will receive pretreatment by intravenous infusion of magnesium sulfate 60 mg / kg
223813153|NCT02989272|OTHER|saline group|saline group (30 patients) who will receive pretreatment by saline solution
223813154|NCT01570530|PROCEDURE|Cardiac surgery|Atorvastatin therapy as prophylaxis against postoperative atrial fibrillation after cardiac surgery
223813155|NCT01570530|PROCEDURE|Cardiac surgery|Without atorvastatin therapy as prophylaxis against postoperative atrial fibrillation after cardiac surgery
223813156|NCT04310917|OTHER|blood lipoprotein (a) test|research specific blood sample
223813157|NCT03338621|DRUG|Pretomanid|200 mg tablets
223813158|NCT03338621|DRUG|Bedaquiline|100 mg tablets
223813159|NCT03338621|DRUG|Moxifloxacin|400 mg tablets
223813160|NCT03338621|DRUG|Pyrazinamide|500 mg tablets
223813161|NCT03338621|DRUG|HRZE|isoniazid 75 mg plus rifampicin 150 mg plus pyrazinamide 400 mg plus ethambutol 275 mg combination tablets
223813162|NCT03338621|DRUG|HR|isoniazid 75 mg plus rifampicin 150 mg combination tablets
223813163|NCT02993887|BEHAVIORAL|Resourcefulness Training|This intervention will include a one time face to face instruction on Resourcefulness Training that entails 8 self-help and help-seeking skills plus viewing short video vignettes of caregivers describing application of the resourcefulness skills. In addition, participants will use daily journaling to describe application of the resourcefulness skills in their daily caregiving with their technology-dependent child.
223813164|NCT02993887|BEHAVIORAL|Mindfulness|The mindfulness intervention will include the use of an app daily via Stop, Think, Breathe.
223813165|NCT05542290|PROCEDURE|Capsular tension ring implantation|Capsular tension ring implantation during phacoemulsification lens extraction and intraocular lens implantation combined with goniosynechialysis in included angle closure patients.
223813166|NCT05542290|PROCEDURE|No capsular tension ring implantation|No capsular tension ring implantation during phacoemulsification lens extraction and intraocular lens implantation combined with goniosynechialysis in included angle closure patients.
223813167|NCT04597710|GENETIC|utility of whole genome sequencing (WGS) to aid clinical decision making in patients referred for liver resection|All participants will attend their planned outpatient surgery appointment.The consultant will document the intended treatment plan for each participant in line with their usual care pathway.Following this, participants will be required to attend three dedicated study visits:The results of the MRI scans from Study Visit 1 will be analysed into a LiverMultiScan report.A report will be sent to the consultant who will review their original documented care plan alongside the LiverMultiScan report.The consultant may update the intended care plan as a result of the LiverMultiScan report, in line with the device CE-marking.Any changes to the care plan will be documented.The patient will then undergo their planned treatment.The tumour explant will be collected and samples will be stored, transported and processed for genetic sequencing and digital histopathology.Study Visit 2 will be performed remotely 12 months following their planned treatment,where patient reported outcomes will be collected
223813168|NCT06163053|DRUG|Immunotherapy|Immune checkpoint inhibitors in approved indications
223813169|NCT03056534|DEVICE|R3 Biolox Delta Ceramic Acetabular System|All study related procedures with the R3 delta Ceramic Acetabular System must be performed according to the recommended surgical technique described in the labeling and in the instructions for use (IFU).
224264566|NCT01375309|DIETARY_SUPPLEMENT|Placebo contains dextrin|0.5 of dextrin
223813170|NCT04805749|OTHER|Manual Therapy: osteopathy|"Osteopathic protocol applied at week 0, 1, 2 and 3:~1. Spinal mobilisation of L1, L2 and L3 vertebrae to stimulate the arterial supply of mesenteric attachments of the colon and small intestine.~2. Visceral osteopathic therapy to address adhesions/ fixations in the presacral fascia, Toldt fascia, posterior peritoneum and caudal peritoneum.~3. Circulatory techniques to stimulate the celiac plexus, the superior and inferior ganglia.~4. Cranial osteopathy techniques to address the vagus parasympathetic nerves."
223813171|NCT03332641|DIETARY_SUPPLEMENT|Citron peel extract|Citron peel extract for 12 weeks
223813172|NCT03332641|DIETARY_SUPPLEMENT|Placebo|Placebo for 12 weeks
223813173|NCT01291537|DRUG|Duodopa|
223813174|NCT01291537|DRUG|best médical treatment|
223813175|NCT02661100|DRUG|Pembrolizumab|200mg/kg by IV infusion on Day 1 of each 3 week cycle. Given until disease progression
223813176|NCT02661100|BIOLOGICAL|CDX-1401|1mg given subcutaneously on day 1 of each 3 week cycle. Given for 4 cycles
223813177|NCT02661100|BIOLOGICAL|Poly-ICLC|2mg given subcutaneously on day 1 and 2 of each 3 week cycle. Given for 4 cycles
223813178|NCT03133559|OTHER|Observational|We will use a deep phenotyping approach to collect multidimensional datasets from individuals infected with HIV compared to healthy controls to define circadian rhythm disruptions associated with HIV infection.
223813179|NCT06499623|DIAGNOSTIC_TEST|Blood test|Albumin, C-Reactive Protein, Cholesterol, Urea, Creatinine, Vitamin D
223813180|NCT06499623|DIAGNOSTIC_TEST|Bioelectrical Impedance Analysis|Total Impedance, Segmental Muscle Analysis, Segmental Fat Analysis, Absolute Muscle Mass Value, Muscle Mass Index, Total Body Fat Percentage, Total Body Water, Phase Angle Measurement
223813181|NCT06499623|OTHER|Nutritional Risk Assessment Questionnaire|Fill in the Questionnaire of the Working Group on Nutritional Care in Oncology and get nutrition risk score. The objective data includes weight loss in 6 months, current BMI and food tolerance, and oncological diagnosis including ongoing anti-cancer treatment.
223813182|NCT00703690|DRUG|MK0767|MK0767 2.5, 5, and 10 mg/day supplied as tablets
223813183|NCT00703690|DRUG|Comparator: fenofibrate|fenofibrate 200 mg supplied as capsules
223813184|NCT00703690|DRUG|Comparator: Placebo (unspecified)|matching placebo will be supplied as tablets/capsules.
223813185|NCT02184754|PROCEDURE|Magnetic endoscope imaging (MEI)|
223813186|NCT00361439|DRUG|Mometasone|2 puffs in each nostril once daily of nasal spray
223813187|NCT00361439|DRUG|Placebo|2 puffs in each nostril once daily of nasal spray
223813188|NCT00035074|DRUG|Methotrexate|
223813189|NCT06236867|OTHER|KaleidoscopeGroup|The group consists of 34 people. Pain level was measured during 3 dialysis sessions.In order for the patients in the kaleidoscope group to recognize the device and increase their compliance during the procedure, a practice was performed using the device before the AVF cannulation procedure. Kaleidoscope application was performed during cannulation.
223813190|NCT06236867|OTHER|Ice Application Group|The group consists of 34 people. Pain level was measured during 3 dialysis sessions. Before, during and after AVF cannulation, VAS pain scores will be evaluated after cannulation without any intervention.Ice application application was made with non-melting ice molds to the area where the index finger and thumb of the hand with fistula are joined (HOKU point)
223813191|NCT06236867|OTHER|Control Group|The group consists of 34 people. Pain level will be measured during 3 dialysis sessions. In the control group, the vital signs of the patients before AVF cannulation will be recorded.
223813192|NCT05205902|OTHER|Low-dose total-skin electron-beam therapy|Low-dose total skin electron beam therapy (12 Gy) will be delivered to the patient in 4 Gy/week, 1 Gy/day over 3 weeks by symmetrical electron beams of 6 MeV energy via a linac accelerator.
223813193|NCT05205902|OTHER|Phototherapy|"Phototherapy will be given 3 times a week during 2 months, then twice a week during one month, then once a week during one month, or until disease progression or unacceptable side effect, whatever comes first.~Patients with plaques will receive PUVA therapy and patients with patches only will receive narrow-band UVB therapy."
223813194|NCT04247659|DRUG|sodium aescinate|The main mechanism of sodium aescinate includes anti - inflammatory, anti - exudate anti - oxygen free radical ,anti - edema increased venous tension.The treatment course of sodium aescinate is 10 days,20mg/day, intravenous infusion.
223813195|NCT03204955|DRUG|Sodium chloride /sodium acetate (16.4%)|"Sodium Acetate is a sterile, nonpyrogenic solution of Sodium Acetate intended as an alternative to sodium chloride to provide sodium ion in parenteral (IV) fluid therapy.~Sodium Chloride is sterile, nonpyrogenic hypertonic saline (concentrated sodium-chloride) solution for parenteral (IV) fluid therapy."
223813196|NCT03204955|DRUG|Sodium chloride (23.4%)|Sodium Chloride is sterile, nonpyrogenic hypertonic saline (concentrated sodium-chloride) solution for parenteral (IV) fluid therapy.
223813197|NCT03204955|DRUG|PlasmaLyte|PlasmaLyte is an isotonic IV solution that mimics human physiological plasma electrolyte concentrations, osmolality and pH.
223813198|NCT06065566|DIETARY_SUPPLEMENT|L-alanyl-L-glutamine dipeptide|"1\. Once the candidate patients undergo surgery for cardiac surgery with and without cardiopulmonary bypass, the inclusion criteria will be verified. Once their inclusion in the study has been accepted, the patient must sign their informed consent letter and will be randomly assigned by closed envelope, to a study group or to a control group. The patient's weight and height will be taken once he accepts inclusion in the study and the data collection notebook will be filled.~A. Study group: patients undergoing cardiac surgery with and without cardiopulmonary bypass, who will receive the dipeptide L-alanyl-L-glutamine, at a dose of 0.4 g / kg of weight 6 hours before the surgical intervention."
223813199|NCT06065566|OTHER|Placebo|"1\. Once the candidate patients undergo surgery for cardiac surgery with and without cardiopulmonary bypass, the inclusion criteria will be verified. Once their inclusion in the study has been accepted, the patient must sign their informed consent letter and will be randomly assigned by closed envelope, to a study group or to a control group. The patient's weight and height will be taken once he accepts inclusion in the study and the data collection notebook will be filled.~B. Control group: patients undergoing cardiac surgery with and without cardiopulmonary bypass, who will receive the placebo in the form of saline solution in a volume similar to the control 6 hours before the surgical intervention."
223813200|NCT05059379|RADIATION|Entire supraclavicular lymph node radiotherapy|Radiation is delivered to the breast/chest wall, undissected axilla, internal mammary nodes and entire supraclavicular lymph node. Entire supraclavicular lymph node includes medial supraclavicular and posterior neck lymph node.
223813201|NCT05059379|RADIATION|Medial supraclavicular lymph node radiotherapy|Radiation is delivered to the breast/chest wall, undissected axilla, internal mammary nodes and entire supraclavicular lymph node.
223813202|NCT00462280|DRUG|lovastatin|Given PO
223813203|NCT00462280|OTHER|placebo|Given PO
223813204|NCT00462280|PROCEDURE|biopsy|Correlative studies
223813205|NCT00462280|PROCEDURE|laboratory biomarker analysis|Correlative studies
223813206|NCT04859582|BIOLOGICAL|Pembrolizumab|Administered as an IV infusion on Day 1 Q3W
223813207|NCT04859582|DRUG|Cisplatin|Administered as an IV infusion on Day 1 Q3W
223813208|NCT04859582|DRUG|5-fluorouracil|Administered as a continuous IV infusion on Days 1-5 Q3W
223813209|NCT04859582|DRUG|Oxaliplatin|Administered as an IV infusion on Day 1 Q3W
223813210|NCT04859582|DRUG|Capecitabine|Administered orally BID on Days 1 to 14 Q3W
223813211|NCT04859582|DRUG|Placebo for Pembrolizumab|Administered as an IV infusion on Day 1 Q3W
223813212|NCT01313286|DRUG|LY2608204 Reference|Administered orally
223813213|NCT01313286|DRUG|LY2608204 Test|Administered orally.
223813214|NCT01552590|DRUG|Tolvaptan|
223813215|NCT01552590|DRUG|Placebo|
223813216|NCT01209065|DRUG|GSK1349572|GSK1349572 is an integrase inhibitor being developed for the treatment of human immunodeficiency virus -1 infection by ViiV Healthcare. This drug is experimental and has not been approved by the Food and Drug Administration (FDA).
223813217|NCT01209065|DRUG|Fosamprenavir|Fosamprenavir is a drug in the protease inhibitor class that is approved by the FDA for the treatment of HIV infection.
223813218|NCT01209065|DRUG|Ritonavir|Ritonavir is a drug in the protease inhibitor class that is approved by the FDA for the treatment of HIV infection.
223813219|NCT00597948|BEHAVIORAL|Healthy Lifestyles Curriculum|Three consecutive days of six hours of training comprised of instruction and participant interaction.
223813220|NCT00654901|BIOLOGICAL|DTaP-IPV-Hep B-PRP~T vaccine (Batch 1)|0.5 mL, Intramuscular
223813221|NCT00654901|BIOLOGICAL|DTaP-IPV-Hep B-PRP~T vaccine (Batch 2)|0.5 mL, Intramuscular
223813222|NCT00654901|BIOLOGICAL|DTaP-IPV-Hep B-PRP~T vaccine (Batch 3)|0.5 mL, Intramuscular
223813223|NCT00654901|BIOLOGICAL|Infanrix Hexa™|0.5 mL, Intramuscular
223813224|NCT01258634|DRUG|Dexrazoxane|"Preoperative Chemotherapy Courses 1, 2, 3, 4: 750mg/m2; IV over 15 minutes on day 1~Postoperative Chemotherapy for Good Responders Courses 1 and 2: 750mg/m2 IV over 15 minutes on Day 1~Postoperative Chemotherapy for Poor Responders Courses 2 and 4: 750mg/m2 IV over 15 minutes on Day 1"
223813225|NCT01258634|DRUG|Doxorubicin|"Preoperative Chemotherapy Courses 1 and 3: 75mg/m2; IV push day 1 Courses 2 and 4: 75mg/m2; IV push day 1, hour 0~Postoperative Chemotherapy for Good Responders Course 1: 75mg/m2; IV push day 1 Course 2: 75mg/m2; IV push day 1, hour 0~Postoperative Chemotherapy for Poor Responders Course 2: 75mg/m2; IV push day 1 Course 4: 75mg/m2; IV push day 1, hour 0"
223813226|NCT01258634|DRUG|Cisplatin|"Preoperative Chemotherapy Courses 1 and 3: 60mg/m2 daily x 2 days, in 1000 ml D5W NS + 10g/m2 mannitol~Postoperative Chemotherapy for Good Responders Courses 1 and 2: 60mg/m2 daily x 2 days, in 1000 ml D5W NS + 10g/m2 mannitol~Postoperative Chemotherapy for Poor Responders:~Course 2: 60mg/m2 daily x 2 days, in 1000 ml D5W NS + 10g/m2 mannitol"
223813227|NCT01258634|DRUG|G-CSF|"Preoperative Chemotherapy Courses 1, 2, 3, and 4: 5mcg/Kg; IV/SQ starting 24 hours after chemotherapy until WBC \>10,000~Postoperative Chemotherapy for Good Responders Courses 1, 2, and 3: 5mcg/Kg; IV/SQ starting 24 hours after chemotherapy until WBC \>10,000~Postoperative Chemotherapy for Poor Responders Courses 2, 4, and 5: 5mcg/Kg; IV/SQ starting 24 hours after chemotherapy until WBC \>10,000"
223813228|NCT01258634|DRUG|PEG-filgrastim|"Preoperative Chemotherapy Courses 1, 2, 3, and 4: 6mg; SQ starting 24 hours after chemotherapy~Postoperative Chemotherapy for Good Responders Courses 1, 2, and 3: 6mg; SQ starting 24 hours after chemotherapy~Postoperative Chemotherapy for Poor Responders Courses 2 and 4: 6mg; SQ starting 24 hours after chemotherapy"
223813229|NCT01258634|DRUG|Etoposide|"Preoperative Chemotherapy Courses 2 and 4: 50mg/m2 on days 1, 2, 3, 4~Postoperative Chemotherapy for Good Responders Course 2: 50mg/m2 on days 1, 2, 3, 4 Course 3: 50mg/m2 on days, 1, 2, 3, 4 Hour 0-1~Postoperative Chemotherapy for Poor Responders Course 4: 50mg/m2 on days 1, 2, 3, 4 Course 5: 50mg/m2 on days 1, 2, 3, 4"
223813230|NCT01258634|DRUG|Ifosfamide|"Preoperative Chemotherapy Courses 2 and 4: 3g/m2; IV over 1 hour Days 1, 2, 3, 4~Postoperative Chemotherapy for Good Responders Course 2: 3g/m2; IV over 1 hour Days 1, 2, 3, 4 Course 3: 3g/m2; IV over 1 hour Days 1, 2, 3, 4~Postoperative Chemotherapy for Poor Responders Course 4: 3g/m2; IV over 1 hour Days 1, 2, 3, 4 Course 5: 3g/m2; IV over 1 hour Days 1, 2, 3, 4"
223813231|NCT01258634|DRUG|Mesna|"Preoperative Chemotherapy Courses 2 and 4: 600mg/m2, 1st dose in bag with ifosfamide, 2nd dose IV over 3 hours immediately post ifosfamide infusion, Subsequent doses - hour 5, 8, 11, 14 (IV push)~Postoperative Chemotherapy for Good Responders Courses 2 and 3: 600mg/m2, 1st dose in bag with ifosfamide, 2nd dose IV over 3 hours immediately post ifosfamide infusion, Subsequent doses - hour 5, 8, 11, 14 (IV push)~Postoperative Chemotherapy for Poor Responders Courses 4 and 5: 600mg/m2, 1st dose in bag with ifosfamide, 2nd dose IV over 3 hours immediately post ifosfamide infusion, Subsequent doses - hour 5, 8, 11, 14 (IV push)"
223813232|NCT01258634|DRUG|Leucovorin|Postoperative Chemotherapy for Poor Responders Courses 1 and 3: 15 mg/m2/dose IV or PO every 6 hours, beginning 24 hours after start of methotrexate infusion and continuing until methotrexate level is \<0.1 uM
223813233|NCT03773367|DRUG|Fluorouracil|Treatment with Fluorouracil, Oxaliplatin, and Irinotecan is given for 4 cycles pre- and postoperatively, in total 8 cycles.
223813234|NCT03773367|DRUG|Oxaliplatin|Treatment with Fluorouracil, Oxaliplatin, and Irinotecan is given for 4 cycles pre- and postoperatively, in total 8 cycles.
223813235|NCT03773367|DRUG|Irinotecan|Treatment with Fluorouracil, Oxaliplatin, and Irinotecan is given for 4 cycles pre- and postoperatively, in total 8 cycles.
223813236|NCT06461416|BEHAVIORAL|ActiveHeal|Participants will have 6 group activity sessions and six individualized sessions from home, all focused on optimizing persistence in performance of specific selected activities.
223813237|NCT05375539|DRUG|AGN-CognI.Q|Herbal dietary supplement products containing/based on AGN alcoholic extracts (including CognI.Q; Decursinol-50TM, GWB78®, Ache Action, Fast-Acting Joint Formula, EstroG-100/Profemin) are marketed in the US for memory enhancement, pain relief and for women's post-menopausal symptom management.
223813238|NCT06115252|BEHAVIORAL|Motivational Interviewing (MI)|Motivational interviewing with peer dyads starts with an open-ended exploration of the dyad's hazardous drinking behavior via personal stories about alcohol use. It includes a values clarification task and age-matched norms along with personalized feedback regarding the dyad's alcohol use. The goal of the session is to engage the dyad in a thoughtful conversation about drinking and the implications it may have on their lives, with an eye to bolstering and supporting inherent drive for behavior change.
223813239|NCT04508608|DIAGNOSTIC_TEST|Stress Gated blood pool SPECT|"After labeling of red blood cells in vivo, a sequential series of acquisition is carried out at rest and during increasing doses of dobutamine (5/10/15 μg / kg / min). The duration of acquisition is 300 seconds.~The acquisitions are carried out on dedicated cardiac gamma-camera with ultrafast Cadmium zinc telluride (CZT) detectors (DiscoveryNM530c, General electric Healthcare Israel, Israel)"
223813240|NCT04508608|DIAGNOSTIC_TEST|Dynamic SPECT|"The passage of a radiopharmaceutical bolus through the cavities of the heart and myocardium at rest and during infusion of adenosine at a dosage of 140 mcg / kg / min (for 4 minutes) is recorded.~At the peak of the stress test (after 2 minutes of administration of adenosine), a 5 ml bolus (dose 260-444 MBq) of 99mTc-methoxyisobutylisonitrile (MIBI) is administered at a rate of 1 ml / s. Immediately after the end of tracer administration, 30 ml of 0.9% sodium chloride (NaCl) is infused. A scintigraphic recording of the study begins 5 seconds before the administration of the radiopharmaceutical.~The next day, the study at rest is carried out. Scintigraphic images are recorded in tomographic mode with ECG synchronization for 600 s, at list mode.~The acquisitions are carried out on dedicated cardiac gamma-camera with ultrafast CZT detectors (DiscoveryNM530c, General electric Healthcare Israel, Israel)"
223813241|NCT00895700|BEHAVIORAL|web-based multifactorial intervention|12-week multi-factorial web-based behavioral intervention comprised of psycho-education, cognitive behavioral therapy (CBT) and relaxation therapy
223813242|NCT00724464|BIOLOGICAL|PegIntron (peginterferon alfa-2b, pegylated interferon alfa-2b)|Prior to enrollment in the study, PegIntron was to be administered at a dose of 1.5 μg/kg/week subcutaneously in accordance with approved labeling. Therapy duration varied from 24 to 48 weeks depending on HCV viral load and genotype followed by a 24-week post-treatment follow-up.
223813243|NCT00724464|DRUG|Rebetol (ribavirin)|Prior to enrollment in the study, Rebetol was to be administered at a dose of 800-1200 mg/day orally in accordance with approved labeling. Therapy duration varied from 24 to 48 weeks depending on HCV viral load and genotype followed by a 24-week post-treatment follow-up.
223813244|NCT04199260|DEVICE|papilocare vaginal gel|Papilocare is a gel vaginally administered by a single-dose cannula. Vaginal gel formulation is effective as a local treatment with controlled systemic absorption and rapid and efficient distribution
223813245|NCT03347916|DRUG|Strawberry juice as (placebo)|Patients received strawberry juice 5 ml volume, one hour before induction.
223813246|NCT03347916|DRUG|Gabapentin Oral Solution [Neurontin]|Patients received gabapentin (Neurontin oral solution 250 mg/ml, Pfizer, USA) 5 mg/kg mixed with strawberry juice to constitute 5 ml volume, one hour before induction.
223813247|NCT03292848|DRUG|Brexpiprazole|Tablet
223813248|NCT05565729|DRUG|LY3471851|Administered SC.
223813249|NCT05565729|DRUG|Placebo|Administered SC.
223813250|NCT05565729|DRUG|Levocetirizine|Administered orally.
223813251|NCT01146314|BEHAVIORAL|Family Focused Lifestyle Intervention|The lifestyle intervention is a 6-month intervention study lasting 6 months. The intervention is 14 sessions and conducted by a dietician and psychologist in a group setting with each intervention session lasting 90 minutes. The sessions are conducted weekly, biweekly, and monthly over the course of 6 months.
223813252|NCT05211271|DEVICE|Treatment of cervical neoplasia by thermal ablation|Women screened for cervical cancer by visual inspection with diluted acetic acid (VIA) presenting lesions eligible for ablative treatment were treated by thermal ablation. The treatment consisted in applying the probe on the lesion for 45 seconds at 100 degrees Celsius, with one to up to five applications depending on the lesion size. Following treatment, women were inquired about the pain level during the procedure, their satisfaction level of the procedure and whether they would recommend this treatment to their relatives. Women had a follow-up visit at 6 weeks to assess any complication of the procedure. Women were rescreened at 12 months, to evaluate the cure rate and any long-term adverse events.
223813253|NCT06510725|DEVICE|Mutitarget tDCS|Subjects will receive 20 minutes of active transcranial direct current stimulation at 2mA applied to DLPFC and M1 alternately for ten consecutive weekdays, with each target stimulated for 5 sessions.
223813254|NCT06510725|DEVICE|Single-target tDCS|Subjects will receive 20 minutes of active transcranial direct current stimulation at 2mA applied to M1 for ten consecutive weekdays.
223813255|NCT06510725|DEVICE|Sham tDCS|Subjects will receive 20 minutes of sham transcranial direct current stimulation. Ramps up and down will be applied for 15 seconds each at the beginning and end of the session. The current will be 0 mA during the interval between the initial and final ramps. Subjects will undergo stimulation once a day for ten consecutive weekdays.
223813256|NCT01875939|DRUG|Oral WCK2349|The subjects will be randomly assigned to receive WCK 2349 1000 mg as an oral dose in fed or fasting state (1:1) in the food effect study as per the randomization schedule. The subjects completing the food effect study (i.e., Period 1 and Period 2) will be administered WCK 771 800 mg as an intravenous infusion in fasting state in Period 3 of the study.
223813257|NCT01875939|DRUG|IV WCK771|The subjects will be randomly assigned to receive WCK 2349 1000 mg as an oral dose in fed or fasting state (1:1) in the food effect study as per the randomization schedule. The subjects completing the food effect study (i.e., Period 1 and Period 2) will be administered WCK 771 800 mg as an intravenous infusion in fasting state in Period 3 of the study.
223813258|NCT03066401|PROCEDURE|echography|The inferior vena cava and the internal jugular vein diameters were measured by echography before and after blood withdrawal during a standardized respiratory maneuver
223813259|NCT01448694|OTHER|No treatment|No treatment, only collecting observational data.
223813260|NCT05669950|DRUG|Lu AG13909|Solution for infusion
223813261|NCT05873452|DEVICE|Kaitoh Atherectomy System|The Kaitoh Atherectomy System is a handheld device which initiates mechanical rotation of the blade to debulk atherosclerotic lesions.
223813262|NCT05829083|DEVICE|Asymmetric nasal cannula - DUET|"DUET asymmetric nasal high flow interface that fits best to the patients' nostrils (size: one nostril of the patient should be fully occluded)~Patients will be crossed-over between the 2 interventions"
223813263|NCT05829083|DEVICE|Conventional nasal high flow cannula|"Well-established conventional nasal high flow cannula (size: medium)~Patients will be crossed-over between the 2 interventions"
223813264|NCT06451978|OTHER|Nature-based intervention|The nature-based intervention is a manualised, caregiver-led intervention consisting of a physical manual comprising of 8 sessions of 8 different nature-based activities. It is designed for the person living with dementia or mild cognitive impairment and their caregiver to carry out the sessions together, either in their own home or out in a local area of nature.
223813265|NCT05983965|DRUG|Tazemetostat|Treatment: On day 1 and day 15 of the first cycle, and day 1 of all following cycles, the subject will have office visit with physical exam, vital signs, and lab tests. The subject will take tazemetostat twice a day by mouth continuously as an outpatient. If continuing on the treatment for more than 6 cycles, visits change to every 3 months.
223813266|NCT04917809|DRUG|Erdafitinib|Participants will receive erdafitinib at a dose of 6 mg orally once daily for the first 14 days (±3 days). Serum phosphate levels will be assessed on day 14 (±3 days) and the dose of erdafitinib may be lowered based on the serum phosphate level. Treatment with erdafitinib at a dose of 6 mg orally once daily, or at a lower dose level for another 14 days (±3 days) until the day of their standard-of-care TURBT/biopsy. Standard-of-care TURBT/biopsy will be performed after approximately 28 days (±5 days) from the start of treatment with erdafitinib, and biologic and pathologic tumor response will be assessed. All participants will then be followed up for recurrence or progression in accordance with the standard of care.
223813267|NCT04741997|DRUG|Encorafenib Pill|Encorafenib 450 mg will be administered orally once per day in continuous 28-day cycles
223813268|NCT04741997|DRUG|Binimetinib Pill|Binimetinib 45 mg will be administered orally twice per day in continuous 28-day cycles
223813269|NCT04741997|DRUG|Nivolumab|Nivolumab will be administered at a dose of 480 mg IV infusion over 30 minutes every 4 weeks.
223813270|NCT01089231|DIETARY_SUPPLEMENT|Fish oil|Dietary Supplement: fish oil capsules (6 per day) 3024 mg n-3 fatty acids daily (1512 mg EPA and 1008 mg DHA) about 3 months
223813271|NCT01089231|DIETARY_SUPPLEMENT|Placebo (corn oil)|corn oil (6 capsules per day)
223813272|NCT03769779|DIETARY_SUPPLEMENT|FloraGLO Lutein|Lutein (FloraGLO™) in safflower oil
223813273|NCT03769779|DIETARY_SUPPLEMENT|Safflower Oil|Safflower Oil
223813274|NCT04425005|OTHER|Home-based exercise|Home-based exercise training, supervised by videoconference.
223813275|NCT04278625|DRUG|Acetaminophen|IV acetaminophen given as part of standard of care.
223813276|NCT04308564|DIAGNOSTIC_TEST|Blood test|Blood test for the identification of biomarkers
223813277|NCT04241094|BEHAVIORAL|Loved one assisted treatment|The investigators propose to bring a loved one into PE, one of the most researched and efficacious treatments for PTSD, to increase support for PE adherence. The intervention is a 13-session cognitive-behavioral, intimate partner-assisted treatment for PTSD that draws from PE, ICBT, and PE2.
223813278|NCT01610310|DEVICE|BIIB017 (peginterferon beta-1a) Pre-filled syringe (PFS)|125 mcg of peginterferon beta-1a (BIIB017) subcutaneous injection (SC) administered by PFS once on either Day 1 or Day 22
223813279|NCT01610310|DEVICE|BIIB017 (peginterferon beta-1a) Autoinjector|125 mcg of peginterferon beta-1a (BIIB017) subcutaneous injection (SC) administered by autoinjector once on either Day 1 or Day 22
223813280|NCT04423822|OTHER|stress test|endurance capacity
223813281|NCT01938651|PROCEDURE|high field strength magnetic resonance imaging|Undergo 7T MRI
223813282|NCT01938651|PROCEDURE|magnetic resonance spectroscopic imaging|Undergo 31P MRS
223813283|NCT01938651|PROCEDURE|chemical exchange saturation transfer magnetic resonance imaging|Undergo CEST-MRI
223813284|NCT01938651|PROCEDURE|diffusion-weighted magnetic resonance imaging|Undergo DW-MRI
223813285|NCT01938651|PROCEDURE|dynamic contrast-enhanced magnetic resonance imaging|Undergo DCE-MRI
223813286|NCT00681304|OTHER|ultrasound scan|The only study procedure involved in this project is for subjects to undergo an ultrasound scan during their radiation therapy simulation. The ultrasound is done at this time, so it can be co-registered to the routine breast treatment planning CT scan.
223813287|NCT01082562|DRUG|BMS-844421|"Ready-to-use stock solution for SC and IV, Subcutaneous, 37.5 mg~SAD: Once, 1 Day~MAD: IV loading followed by 4 weekly doses, 29 Days"
223813288|NCT01082562|DRUG|0.9% sodium chloride injection solution|"Injection solution, Subcutaneous, 37.5 mg~SAD: Once, 1 Day~MAD: IV loading followed by 4 weekly doses, 29 Days"
223813289|NCT05720923|DEVICE|Analysis with Ergometer|The analysis with the ergometer aims at assessing neuromuscular function
223813290|NCT01559233|DEVICE|FPlus RF device for wrinkles and rhytide reduction|Six RF weekly treatments for face wrinkles and rhytides reduction using the FPlus device.
223813291|NCT00165425|PROCEDURE|Echo/Stress Echo|Participants will under resting echocardiogram and stress echocardiogram (echo and stress echo) and the results will be interpreted by a cardiologist
223813292|NCT06975969|DEVICE|Versus™ Endovascular Pulmonary Artery Drug Delivery Catheter|The Versus Pulmonary Artery Catheter is a dual-tip, infusion catheter. Two lumens access and deliver physician-specified fluids, including thrombolytics, into the pulmonary arteries of each lung via a single access site. The Secondary Catheter tip telescopes independently to facilitate infusion into the contralateral lung. The device may allow for assessment of a patient's hemodynamic condition through direct intracardiac and pulmonary artery pressure monitoring. Pressure is measured through an interface between the catheter's fluid lumen and an externally located, FDA-cleared, pressure transducer. The device may include an additional lumen that is in communication with a distal flow-directed balloon.
223813293|NCT05208138|DEVICE|Senhance Surgical System from Asensus|Bariatric operation with the Senhance Surgical System
223813294|NCT04929769|OTHER|Total Laparoscopic or Robotic Radical Hysterectomy|Radical hysterectomy with bilateral pelvic lymph node dissection is performed as standard type C RH by Q-M classification, including cardinal ligaments divided at pelvic sidewall and uterosacral ligaments divided at near the sacral origin and the upper 1/4 to 1/3 of the vagina.
223813295|NCT04929769|OTHER|Total Abdominal Radical Hysterectomy|Radical hysterectomy with bilateral pelvic lymph node dissection is performed as standard type C RH by Q-M classification, including cardinal ligaments divided at pelvic sidewall and uterosacral ligaments divided at near the sacral origin and the upper 1/4 to 1/3 of the vagina.
223813296|NCT02332590|DRUG|Sarilumab|Pharmaceutical form: solution for injection in pre-filled syringe; Route of administration: SC
223813297|NCT02332590|DRUG|Adalimumab|Pharmaceutical form: solution for injection in pre-filled syringe; Route of administration: SC
223813298|NCT02332590|DRUG|Placebo (for sarilumab)|Pharmaceutical form: solution for injection in pre-filled syringe; Route of administration: SC
223813299|NCT02332590|DRUG|Placebo (for adalimumab)|Pharmaceutical form: solution for injection in pre-filled syringe; Route of administration: SC
223813300|NCT02591134|OTHER|Non Nutritive Sweetened Beverages|Non-nutritive sweeteners (NNS) beverages encompass a range of carbonated and still drinks with added artificial sweeteners. Participants will be provided with a list of permitted beverages and are expected to consume at least two portions (330ml) per day.
223813301|NCT02591134|OTHER|Control|Water beverages provided in 330ml portions to be consumed twice per day over the duration of the trial
223813302|NCT01995487|DEVICE|BioNIR|drug-eluting stent
223813303|NCT01995487|DEVICE|Resolute|drug-eluting stent
223813304|NCT04012684|DEVICE|Transcranial magnetic stimulation|For one-session rTMS, 50 trains of stimulation are given. Each train is consisted of 4-second 10 Hz, 100% resting motor threshold TMS pulses. The inter-train interval is 26 seconds.
223813305|NCT04012684|DEVICE|Sham|For one-session sham stimulation, 50 trains of stimulation are given. Each train is consisted of 4-second 10 Hz sham pulses. The inter-train interval is 26 seconds.
223813306|NCT04285255|DRUG|Fentanyl|opioids anaesthesia
223813307|NCT04285255|DRUG|Ketamine|ketamine induction and analgesia as opioids free anaesthesia versus opioids analgesia
223813308|NCT04285255|DRUG|Dexmedetomidine Injection [Precedex]|alpha 2 agonist with sedative, analgesic effect
223813309|NCT04285255|PROCEDURE|Oblique subcostal transversus abdominis plane block|Bupivacaine 0.25% injected under ultrasound usage in the transversus abdominis plane
223813310|NCT04285255|DRUG|Lidocaine|infusion of lidocaine 2%(1mg/kg/h)
223813311|NCT06267885|PROCEDURE|Cannulated screws vs wagner's technique|Fixation of fracture neck of femur by cannulated screws or wagner's technique
223813312|NCT06286605|PROCEDURE|A-oss and autogenous bone|Horizontal ridge augmentation in one stages approach will be performed using a mix of A-Oss and autologenous bone.
223813313|NCT06286605|PROCEDURE|A-oss an LCR-A|Horizontal ridge augmentation in one stages approach will be performed using OssMem with A-Oss and LCR-A
223813314|NCT06380699|DRUG|QHRD106 Injection|PEG-tissue kallikrein-1
223813315|NCT06380699|DRUG|Human Urinary Kallidinogenase|tissue kallikrein-1
223813316|NCT06380699|DRUG|placebo|placebo
223813317|NCT04858698|DEVICE|Ultrasound / Echocardiography|Ultrasound will be used to guide vascular access and to place a lead into the right ventricle.
223813318|NCT02259504|OTHER|PHASE 1- HyperSoft® 3D and HyperSoft® Helical Coils|Framing with HyperSoft® 3D or any FDA-approved bare platinum coil. Must fill and finish the the aneurysm with HyperSoft® 3D and/or HyperSoft® helical coils.
223813319|NCT02259504|OTHER|PHASE 2 - HydroSoft® 3D and HydroSoft® Helical Coils|Framing with HydroFrame® or HydroSoft® 3D coils. Must fill the aneurysm with HydroFrame®, HydroSoft® (3D and/or Helical), and/or HydroFill® Coils and finish with HydroSoft® (3D and/or Helical) Coils.
223813320|NCT04309916|DRUG|Tegoprazan|Tegoprazan 50mg tablet
223813321|NCT04309916|DRUG|Esomeprazole|Esomeprazole 40mg tablet
223813322|NCT02498834|BEHAVIORAL|Educational Video and Question Prompt List|Educational Video and Question Prompt List
223813323|NCT03438695|PROCEDURE|Motorized Spiral Enteroscopy|Motorized Spiral endoscope will be inserted and advanced with the assistance of motorized clockwise spiral rotation, After reaching the cecum or if no further advancement of the endoscope can be achieved depth of insertion required for patient treatment or diagnosis, the endoscope will be withdrawn using motorized counter-clockwise spiral rotation, also controlled by the foot pedal. If no total enteroscopy was achieved, a submucosal ink dye injection is performed as an endoscopically visible marker of the maximum insertion depth. A retrograde peranal enteroscopy is then performed on one of the following days.
223813324|NCT06196450|DIETARY_SUPPLEMENT|Vivomixx|Vivomixx is a commercially available probiotic mixture consisting of eight probiotic lactic acid bacteria and Bifidobacteria including Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus casei, Lactobacillus delbrueckii subspecies bulgaricus, Streptococcus salivarius subspecies thermophiles, Bifidobacterium breve, Bifidobacterium longum, and Bifidobacterium infantis.
223813325|NCT06196450|DIETARY_SUPPLEMENT|Microcrystalline maltose|Microcrystalline maltose as placebo
223813326|NCT04604080|OTHER|service of questionnaire|Respondents will be given a survey form only and after filling this will be collected back
223813327|NCT02219984|DRUG|Anticoagulants|
223813328|NCT04204200|DIETARY_SUPPLEMENT|liposomal vitamin C|The intake of liposomal vitamin C at 500 mg, in the morning and evening, one week before surgery, one during the day of surgery and lastly, during the first 21 post operation days.
223813329|NCT04204200|DIETARY_SUPPLEMENT|standard vitamin C|The intake of traditional vitamin C with a daily intake of 500 mg in the morning and evening for 28 days (starting 7 days before the operative procedure, on the day of the surgery and ending twenty-one days after surgery).
223813330|NCT04204200|DIETARY_SUPPLEMENT|placebo|The intake placebo was taken daily in the morning and the evening for 28 days (7 days before surgery, on the day of surgery and twenty-one days after the surgical procedure).
223813331|NCT02546414|OTHER|Platelet count/spleen diameter ratio|Platelet count were evaluated by complete blood count, and ultrasound was used to measure the longest diameter of the spleen.The platelet count/spleen diameter ratio was calculated
223813332|NCT05276167|DEVICE|hyperthermic intravesical perfusion|Participants in the experimental group will be treated with hyperthermic intravesical perfusion before receiving radical cystectomy
223813333|NCT00110370|DRUG|Lispro Mixture Therapy|
223813334|NCT00110370|DRUG|Glargine Basal-Bolus Therapy|
223813335|NCT01435863|DRUG|SP-02L (darinaparsin for injection)|Cohort 1: Darinaparsin 200 mg/m2 for 5 consecutive days every 28 days (5 days therapy, 23 days no therapy is one cycle). Subjects may start from Cycle 1 and continue to a maximum of 4 cycles of treatment.
223813336|NCT01435863|DRUG|SP-02L (darinaparsin for injection)|Cohort 2: Darinaparsin 300 mg/m2 for 5 consecutive days every 28 days (5 days therapy, 23 days no therapy is one cycle). Subjects may start from Cycle 1 and continue to a maximum of 4 cycles of treatment.
223813337|NCT01435863|DRUG|SP-02L (darinaparsin for injection)|Cohort 3: Darinaparsin 300 mg/m2 for 5 consecutive days every 21 days (5 days therapy, 16 days no therapy is one cycle). Subjects may start from Cycle 1 and continue to a maximum of 4 cycles of treatment.
223813338|NCT05347758|DRUG|HRS-7535|Drug: HRS-7535
223813339|NCT05347758|DRUG|Placebo|Drug: Placebo
223813340|NCT04756726|DRUG|cemsidomide|oral cemsidomide
223813341|NCT04756726|DRUG|Dexamethasone Oral|oral dexamethasone \[ ≤75 years old: 40 mg once per week (QW) on days 1, 8, 15, and 22; \>75 Years old: 20 mg QW on days 1, 8, 15, and 22\]
223813342|NCT05985694|DRUG|AD17002|The dosing days of AD17002 are: Days 1, 4, 8, 11, 15, 18, 22, 25, 29, and 32.
223813343|NCT05985694|DRUG|Placebo|Formulation buffer. Dosing days: 1, 4, 8, 11, 15, 18, 22, 25, 29, 32.
223813344|NCT06829667|DEVICE|Arthrex InternalBrace|Arthrex InternalBrace is composed of a polyethylene/polyester suture tape and knotless bone anchors to provide ligament repair bridging and reinforce ligament strength. There have been conflicting results surrounding the clinical efficacy of its use in lateral ligament reconstruction.
223813345|NCT06867107|DRUG|SAT-3247|AAK1 inhibitor
223813346|NCT07010575|DRUG|New TETA 4HCl Formulation|Individual patient doses will depend on the Standard of Care (SOC) therapy at study entry and guided by recommended dosing switch schedule outlined in the study protocol. The dose may subsequently be titrated based on clinical response per the investigator's judgement.
223813347|NCT07010575|DRUG|Standard of Care|Patients will be returned to their approved Wilson's Disease SOC therapy (dose and frequency) at study entry as prescribed by their treating Wilson's Disease physician.
223813348|NCT07014488|DRUG|HRS-5041 Tablets|HRS-5041 tablets.
223813349|NCT07014488|DRUG|Rifampicin Capsule|Rifampicin capsule.
223813350|NCT06184828|BIOLOGICAL|Whole blood transfusion|The transfusion of whole blood units
223813351|NCT06184828|BIOLOGICAL|Blood components transfusion|The transfusion of blood components units rather than whole blood
223813352|NCT00140205|DRUG|r-metHuLeptin|r-metreleptin was given in 3 different dose in fed and fasting states
223813353|NCT02938351|BEHAVIORAL|Collaborative care|Therapist will use iPad (Vidyo) once a week during dialysis for approximately one hour. The therapist will teach the patient cognitive-behavioral strategies to manage their mood and pain. The PI is a clinical psychologist and will provide supervision to the therapist providing the intervention. The sessions for depression will include (1) intake, (2) review of the rational for using CBT to treat depression and/or pain, (3) identifying thought patterns, (4) changing thought patterns, (5) relaxation techniques, (6) rest-activity pacing, and (7) coping strategies. Homework to practice these techniques will be provided after each session.
223813354|NCT05068869|OTHER|Dignio Digital Remote Care intervention group|"The intervention consists of Dignio Prevent (for healthcare professionals) and MyDignio (for patients). The system is CE marked and the system satisfies all regulatory requirements for privacy and information security. Various components can be added for an individualized follow-up of the patients.~Elements of the digital outpatient service in Dignio include patient reported outcomes and other questionnaires, tasks, objective measures, reminders and information, in addition to a chat function for asynchronous contact with healthcare personnel and video consultations for real-time consultations."
223813355|NCT05068869|OTHER|Usual Care Control group|Participants in the control group will receive follow-up at the outpatient clinic as per their needs.
223813356|NCT03920228|DRUG|PTX-022|PTX-022 QTORIN
223813357|NCT03920228|DRUG|Placebo|Placebo topical
223813358|NCT05025020|OTHER|interactive 3D tool|The study tool displays 3-dimensional step-by-step animations of autologous and implant-based breast reconstruction procedures.
223813359|NCT05025020|OTHER|BREAST-Q Reconstruction Module|The BREAST-Q Reconstruction Module1-3 has 6 domains that cover various aspects of patient satisfaction and quality of life. BREAST-Q is part of our standard of care for patients treated for breast cancer and referred for reconstruction.
223813360|NCT05025020|OTHER|DQI|The DQI has 3 domains that cover decision-specific questions about what it is like for a patient to make decisions about reconstruction after breast cancer treatment.
223813361|NCT05025020|OTHER|Ottawa Decision Regret Scale|The validated Decision Regret Scale measures distress or remorse after a health care decision by the use of 5 items to indicate the extent to which the respondent agrees or disagrees with the statements in the regret scale.
223813362|NCT07021898|DRUG|ERAS-4001|ERAS-4001 Administered orally
223813363|NCT07021898|DRUG|ERAS-4001 in combination|ERAS-4001 Administered orally and in combination with either Keytruda (pembrolizumab) via IV administration or Vectibix (panitumumab) via IV administration.
223813364|NCT00000657|DRUG|Zidovudine|
223813365|NCT00000657|DRUG|Didanosine|
223813366|NCT06137157|DRUG|ATR12-351|Topical ointment containing ATR12-351, a LEKTI-secreting strain of S. epidermidis
223813367|NCT04793035|DEVICE|Omega-Cuff|An omega-shaped nitinol device to be placed and secured on the Lower Esophageal Sphincter area
223813368|NCT04226365|DRUG|Nortriptyline|10mg capsule Nortryptyline
223813369|NCT04226365|DRUG|Placebo|10mg capsule Thick-It filler
223813370|NCT06872268|BEHAVIORAL|Therapeutic photography and expressive writing|Therapeutic photography, unlike phototherapy, consists of a set of photography-based activities that are initiated independently as part of an organised group or project, but in which no formal therapy is taking place within a psychotherapeutic setting. This approach, too, can be used as a routine practice in treatment pathways. The subject deepens his or her self-awareness to improve the sense of being: images become a way to express oneself, to communicate what one is unable to verbalize. Therapeutic photography can be done independently and individually, or in the presence of other professionals (nurses, sociologists, teachers, facilitators, psychologists) who accompany the individual to the understanding and production of the activity.
223813371|NCT06872268|BEHAVIORAL|Expressive writing|Expressive writing is a technique that helps to understand and manage one's experiences and emotional tensions, contributes to mental and physical well-being, decreased stress, improved relationships, and the strengthening of the immune system.
223813372|NCT07028177|OTHER|No interventions, it is a observational study|No interventions, this study is to compare the dosage requirement of etomidate during digestive endoscopy between insomnia group and normal sleep group.
223813373|NCT06698458|DEVICE|Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)|DaRT source will be inserted using endoscopy into the tumor. The sources release by recoil into the tumor short-lived alpha-emitting atoms
223813374|NCT03684148|OTHER|Motor imagery practice|In detail, they were advised to imagine maximal voluntary isometric contractions (MViC). MViC imagery practice was planned in a progressive manner. Thus, it was performed in two sets of 25 repetitions with 2 minutes of inter-sets rest period, for two weeks, and 10 additional repetitions were added on week three and four, respectively. Each MViC repetition was sustained for 5 seconds, followed by 5 seconds of inter-repetition rest periods. Additionally, after every fifth contraction, participants had a 20 seconds of rest. Following 5 days of MI practice, the participants were advised to take a break from MI for two consecutive days. After hospital discharge, the participants in the MIp group were supplied with an audio description of the exercises to be performed.
223813375|NCT07028190|OTHER|No interventions, it is a observational study|No interventions, this study is to compare the dosage requirement of ciprofol during digestive endoscopy between insomnia group and normal sleep group.
223813376|NCT07030933|DRUG|Travesol 10%|Travesol 10% (Baxter) will be administered to the post-intervention participants at a dose of 2g per kilogram of ideal body weight for up to 3 days or until the participant's discharge from the intensive care unit.
223813377|NCT06412146|BEHAVIORAL|Peer Support Group|Participation in an Online Peer Support Group
223813378|NCT05355454|DEVICE|STYLAGE® XXL|"Up to 2.0 mL will be injected in the zygomaticomalar region and optionally up to 2.0 mL in the anteromedial cheek at the first session, on each side of the face.~Up to 1.0 mL in the zygomaticomalar region and optionally up to 1.0 mL in the anteromedial cheek for the optional touch-up session, on each side of the face.~Up to 2.0 mL will be injected in the zygomaticomalar region and optionally up to 2.0 mL in the anteromedial cheek before study exit, on each side of the face."
223813379|NCT05355454|DEVICE|STYLAGE® XXL|"Up to 2.0 mL will be injected in the zygomaticomalar region and optionally up to 2.0 mL in the anteromedial cheek at the first session, on each side of the face.~Up to 1.0 mL in the zygomaticomalar region and optionally up to 1.0 mL in the anteromedial cheek for the optional touch-up session, on each side of the face.~Up to 2.0 mL will be injected in the zygomaticomalar region and optionally up to 2.0 mL in the anteromedial cheek before study exit, on each side of the face."
223813380|NCT07135375|OTHER|Rehabilitation protocol|The modified protocol will be implementen based on available scientific evidence and guided by the consensus remaches with the traumatologist at the physiotherapy center
223813381|NCT07121712|DEVICE|Mapsd Continuous Theta Burst Stimulation|A non-invasive brain stimulation technique using a MagStim Rapid2 stimulator with a 70mm air-cooled figure-of-eight coil. The stimulation target is the left auditory association cortex (MNI: -62, -40, 10), located using a Brainsight neuronavigation system. The cTBS protocol consists of 3-pulse 50 Hz bursts repeated at a 5 Hz frequency for a total of 600 pulses, delivered at 100% of the individual's resting motor threshold (RMT).
223813382|NCT07121712|DEVICE|Sham Navigated Continuous Theta Burst Stimulation|A placebo procedure using an inert sham coil that is identical in appearance and sound to the active coil but does not deliver a significant magnetic field to the cortex. All other aspects of the procedure, including neuronavigation, coil placement, duration, and sound, are identical to the active intervention to maintain the blind.
223813383|NCT05180708|DRUG|QTORIN 3.9% rapamycin anhydrous gel|QTORIN 3.9% rapamycin anhydrous gel
223813384|NCT05180708|DRUG|Vehicle|Matching vehicle (QTORIN anyhydrous gel)
223813385|NCT07038538|BEHAVIORAL|Evidence-based gastric placement|Establish an enteral nutrition management team and develop standardized procedures through a quality improvement project. Conduct a 3-month quality improvement initiative, during which regular training sessions will be provided to nurses on gastrointestinal tube placement and maintenance. These training sessions will include various formats such as lectures, group discussions, operational demonstrations, and scenario simulations, along with regular reviews of practical issues.
223813386|NCT06705270|BEHAVIORAL|Response-focused education|Once participants recover from sedation, they will receive education that is focused on their response to treatment.
223813387|NCT06705270|BEHAVIORAL|Diagnosis-focused education|Once participants recover from sedation, they will be provided education that is focused on their diagnosis of major depressive disorder.
223813388|NCT03387553|BIOLOGICAL|Dendritic Cell Vaccine (DC1)|"Study Vaccine:~Lead In Phase - Weekly as outlined in each treatment Arm.~Expansion Phase - At the optimal schedule determined at the end of the Lead In Phase.~Pre-surgery - Booster Vaccine at week 25 prior to receiving surgery.~Post-surgery - Participants will receive a series of 3 booster intranodal study vaccines given once every 6 months."
223813389|NCT03387553|DRUG|Neoadjuvant Chemotherapy|Upon completion of the 3 week series of vaccinations participants will then undergo neoadjuvant chemotherapy treatment with the TCH-P Taxotere (docetaxel), Carboplatin, Herceptin (trastuzumab), Perjeta (pertuzumab) standard of care neoadjuvant chemotherapy regimen given intravenously once every 3 weeks for up to 6 cycles. The treating physician will have the discretion to delay, modify, or shorten the neoadjuvant chemotherapy as per routine practice guidelines and physician discretion.
223813390|NCT03387553|PROCEDURE|Curative Surgery|Planned definitive curative surgery at 26 to 28 weeks.
223813391|NCT06726200|DRUG|Buprenorphine + naloxone (Suboxone)|Participants randomized to sublingual buprenorphine naloxone will initiate treatment based on clinical guidelines/standard of care
223813392|NCT06726200|DRUG|Buprenorphine Injection|Participants randomized to injectable buprenorphine naloxone will receive a 300mg injection after receiving/tolerating a single 4/1 mg sublingual buprenorphine/naloxone dose
223813393|NCT07043790|OTHER|Radical cystectomy with pelvic lymphadenectomy|"Gtoup A : Radical cystectomy group Radical cystectomy included surgical removal of the bladder, adjacent organs, and regional lymph nodes. In males, it included removal of urinary bladder, prostate, and seminal vesicles whereas in females, it included removal of urinary bladder and reproductive organs (ovaries, fallopian tubes, uterus, and anterior vagina).~Standard pelvic lymph node dissection was performed to all patients in this group."
223813394|NCT07043790|RADIATION|Trimodal therapy|"Group B : trimodal therapy group~the patients underwent maximal TURBT, where as much tumor as possible was completely resected using bipolar resectoscope. The goal was to remove all visible tumor including the underlying muscle layer and tumor edges.~This was followed by radio-sensitizing chemotherapy and radiotherapy..~Chemotherapy consisted of weekly administration of iv infusion of cisplatin (40mg/m2).~Radiotherapy delivered as EBRT aimed at delivering approximately 44- 46 Gy to the urinary bladder and pelvic lymphnodes.followed by additional boost to the bladder 54 GY and a final boost to the tumor 64-65 GY"
223813395|NCT06723912|OTHER|Health Action Process Approach-Based Program|Health Action Process Approach-Based Program: The program is planned for six weeks (six sessions). Sessions will be held once a week for 30-45 minutes. Within the scope of the program, care - structured nursing care plans based on the Health Action Process Approach will be made -, education and counseling will be provided. Sessions will be held in a quiet, calm environment in the hospital, and if such an environment cannot be provided, they will be held at the patient's home. The day, time and place of the sessions will be decided together with the participant after each interview or session. At the beginning of each session, the previous session will be briefly recalled and the homework (SWOT analysis, treatment adherence tracking chart or SMART goal plan) given in the previous session will be evaluated. At the end of each session, the evaluation of that day's session will be carried out briefly.
223813396|NCT06723314|PROCEDURE|Vestibular Subperiosteal Tunnel Access vista|CAF procedures were performed (Split-Full-Split flap), following the anesthetic agent, the sulcular incision was performed by a full thickness vertical incision till the muccogingival junction• Split thickness releasing incision was made at the flap base with full thickness flap reflection till the muccogingival junction.
223813397|NCT04739761|DRUG|Trastuzumab Deruxtecan|Participants will receive T-DXd administered using an IV bag containing 5% (w/v) dextrose injection infusion solution.
223813398|NCT07054320|OTHER|Observational procedures|Patients at the Hoskinson Health and Wellness Clinic qualifying for treatment with Rapamune (Sirolimus) receive a prescription from their physician during clinic visits as part of their standard health care. This study will evaluate the safety, monitor the adverse reactions and observe the preliminary effectiveness of physician-prescribed medical treatment with oral rapamycin \[Rapamune (Sirolimus)\] in a total of 15 adults, 18 years and older toward preventing and lowering the severity of infectious disease or infection-related illness.
223813399|NCT07072728|DRUG|Psilocybin therapy|Following a screening period, eligible participants will undergo one cycle of psilocybin-assisted psychotherapy (PAP). Non-responders at Week 10 who continue to meet eligibility criteria will be offered a second PAP cycle at the 25 mg PEX010 dose. A maximum of two PAP cycles may be given. Long-term follow-up will include a visit at Month 3 following the final PAP cycle.
223813400|NCT06714864|DRUG|(taurolidine and heparin) catheter lock solution|for central venous catheter instillation use
223813401|NCT06714864|DRUG|Standard of Care|Site specific standard of care
223813402|NCT06680037|DRUG|Azercabtagene zapreleucel (azer-cel)|IV infusion
223813403|NCT06243029|DEVICE|ECG Patch|Wearable ECG Patch designed to record and transmit physiological parameters to a mobile device or a data cloud. The device stores data locally in a memory cache designed for \>96 hours of continuous data. It continuously records a one-lead ECG and has a three-axis accelerometer. On-board algorithms use those data to compute heart rate, heart rate variability, RR-interval, respiratory rate, and an activity level indicator. The company also provides optional arrhythmia detection and reporting services, the results of which may be delivered to healthcare professionals.
223813404|NCT04546399|RADIATION|3-Dimensional Conformal Radiation Therapy|Undergo 3D-CRT
223813405|NCT04546399|PROCEDURE|Biospecimen Collection|Undergo blood, urine and cerebrospinal fluid collection
223813406|NCT04546399|BIOLOGICAL|Blinatumomab|Given IV
223813407|NCT04546399|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
223813408|NCT04546399|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
223813409|NCT04546399|DRUG|Calaspargase Pegol|Given IV
223813410|NCT04546399|DRUG|Cytarabine|Given IT
223813411|NCT04546399|DRUG|Dexamethasone|Given PO or IV
223813412|NCT04546399|DRUG|Hydrocortisone Sodium Succinate|Given IT
223813413|NCT04546399|PROCEDURE|Lumbar Puncture|Undergo lumbar puncture
223813414|NCT04546399|DRUG|Mercaptopurine|Given PO
223813415|NCT04546399|DRUG|Methotrexate|Given IT, PO, and IV
223813416|NCT04546399|BIOLOGICAL|Nivolumab|Given IV
223813417|NCT04546399|DRUG|Pegaspargase|Given IM or IV
223813418|NCT04546399|DRUG|Pegcrisantaspase|Given IM or IV
223813419|NCT04546399|DRUG|Vincristine Sulfate|Given IV push or via infusion
223813420|NCT04266886|OTHER|Best Practice|Receive usual care
223813421|NCT04266886|PROCEDURE|Hypnotherapy|Receive self-hypnosis guided relaxation
223813422|NCT04266886|OTHER|Quality-of-Life Assessment|Ancillary studies
223813423|NCT04266886|OTHER|Questionnaire Administration|Ancillary studies
223813424|NCT07085611|OTHER|Sample collection (blood and optional nasal swab)|Venous blood collection (2 tubes of 6 mL) and optional nasal swab at each visit. Aliquots analyzed for neutralizing activity against SARS-CoV-2 and MPXV using validated assays at Institut Pasteur
223813425|NCT05885334|OTHER|Control|Caregivers will not receive any educational solution different than what is done by routine in centers. After six months, performance in caregivers tasks will be video recorded.
223813426|NCT05885334|OTHER|Virtual Reality|Caregivers will receive a educational solution of virtual reality videos with care situations simulations for 1h. After six months, performance in caregivers tasks will be video recorded.
223813427|NCT05885334|OTHER|Augmented Reality|Caregivers will receive a educational solution of augmented reality videos with care situations simulations for 1h. After six months, performance in caregivers tasks will be video recorded.
223813428|NCT01061333|DRUG|Nedocromil|Nedocromil 4 mg, as metered dose inhaler 1 hour prior to allergen challenge
223813429|NCT01061333|DRUG|Comparator: Montelukast|Montelukast single 10 mg tablet administered 2 hours prior to allergen challenge
223813430|NCT01061333|DRUG|Comparator: Mometasone|Mometasone furoate 400 mcg by twisthaler, administered 2 hours prior to allergen challenge
223813431|NCT01061333|DRUG|Placebo|Mometasone placebo twisthaler, Nedocromil placebo metered dose inhaler, Montelukast placebo tablet
223813432|NCT06918665|DRUG|ivermectin infant formula preparation|The ivermectin infant formula preparation is produced by micronizing the standard 3mg ivermectin tablet and then blending it with Stage 1 infant formula (Blackmores brand) to produce a homogenous powder. This powder blend of ivermectin and infant formula is then filled into food grade clear capsules.
223813433|NCT06918665|DRUG|Standard ivermectin 3mg tablet|standard 3mg ivermectin tablet
223813434|NCT06933160|BEHAVIORAL|PromPT-MS|The experimental intervention is a 24-week progressive exercise intervention in which participants are supported through six physical therapy visits and are provided with educational material based on social cognitive theory. The individual sessions will provide tailored support for increasing physical activity behavior towards the recommended guidelines of 2-3 moderate aerobic activity sessions and two strength-training sessions per week. There are no drugs involved in the intervention.
223813435|NCT07164651|OTHER|Accelerated MRI scanning|"All patients underwent MRI scans of the abdominal and pelvic regions on the uMR 790 scanner at Tongji Hospital's Optical Valley Campus. The scanning protocol included multiplanar ACS T2WI sequences, TACS T2WI sequences, and conventional T2WI sequences.~ACS T2WI sequence: Used for preliminary motion artifact correction. TACS T2WI sequence: Employed for advanced motion artifact correction and provided dynamic images of organ movement.~Conventional T2WI sequence: Served as the standard reference for comparison."
223813436|NCT07166484|OTHER|Cosmetic product RV2666C LA2984|The product is applied, according to randomization, on an area located on the anterior side of the forearm, following the laser YAG act, once a day and under occlusion from Day 1 to Day 3 included. Then it is applied twice a day in an open way from Day 4 until Day 18 included.
223813437|NCT07164170|DRUG|ABSK043 in combination with Glecirasib|"Dose escalation cohort( Part A) ABSK043 150 mg BID in combination with Glecirasib 200 mg QD will be selected as the starting dose.~Based on the accumulated safety data and PK profile, the Safety Review Committee (SRC), composed of the investigator and the sponsor, may discuss and agree to allow exploration of other possible doses.~Dose confirmation cohort (Part B) and Expansion cohort Patients in dose confirmation cohort and expansion cohort will receive the recommended dose in dose escalation cohort and be evaluated for safety and preliminary anti-tumor activity.~All patients will continue to receive combination therapy every 21 days until disease progression, death, loss to follow-up, withdrawal of consent, intolerable toxicity, investigator decision to discontinue treatment, or end of the study."
223813438|NCT07165652|DRUG|NKF-INS(L)|Participants will receive a single subcutaneous dose of 0.3 IU/kg in either Treatment Period 1, Treatment Period 2, or Treatment period 3.
223813439|NCT07165652|DRUG|US-Humalog®|Participants will receive a single subcutaneous dose of 0.3 IU/kg in either Treatment Period 1, Treatment Period 2, or Treatment period 3.
223813440|NCT07165652|DRUG|EU-Humalog®|Participants will receive a single subcutaneous dose of 0.3 IU/kg in either Treatment Period 1, Treatment Period 2, or Treatment period 3.
223813441|NCT07165522|BEHAVIORAL|Transformative and Restorative Engagement Circle (TREC)|TREC will be co-developed in Phase 1, to focus on ensuring the presence of at least 3 key components: 1) a listening phase (focused on unconditionally hearing the experiences of autistic participants), 2) an acknowledgement phase (in which the experiences, including but not limited to harms and trauma, of autistic participants will be expressly addressed and acknowledged), 3) a negotiation/priority-setting phase, in which participants will collaboratively identify goals for future CER.
223813442|NCT07165522|BEHAVIORAL|Stakeholder Engagement in quEstion Development and prioritization (SEED)|The SEED Method is a PCORI-supported multilevel stakeholder engagement model, using a participatory framework to develop stakeholder priorities. The core premise of SEED is creating a level playing field for stakeholders, wherein participants learn how to collaboratively identify their own community's priorities, and then refine them together. It involves convening participatory Topic Groups of stakeholders, assembled based on their experience and knowledge of the area of focus (in this case, autism and ABA). It also involves additional consultative stakeholder participants to fill in key gaps in representation; this element may or may not be present in thi SEED iteration, based on the CAC-led adaptation. SEED participants convene over a period of time (adapted to the needs of the specific group, and will be matched to the length of TREC here) to conceptualize (i.e., learn how to build a conceptual model and conduct exercises to do so), generate questions (i.e., review the conceptual m
223813443|NCT07164872|RADIATION|preoperative radiotherapy|preoperative radiotherapy
223813444|NCT07165496|BEHAVIORAL|Text message-based intervention|Participants received weekly text messages to promote health and HIV testing and were followed and supported by trained healthcare counselors through two-way communication over a 12-week period. They were able to schedule a free HIV testing appointment at any time up to six months after enrollment.
223813445|NCT07166458|DIETARY_SUPPLEMENT|Kefir Peptide|Oral supplementation with kefir-derived bioactive peptides given daily in addition to standard care.
223813446|NCT07166458|OTHER|Standard Care (in control arm)|Standard fracture management including immobilization, pain control, and routine follow-up care.
223813447|NCT07164807|DRUG|Methylene Blue (0.3%) with Ropivacaine Hydrochloride (0.75%)|Perianal subcutaneous injection of 0.3% methylene blue solution (Formulation: 1.5 mL of 1% methylene blue with 3.5 mL ropivacaine hydrochloride injection).
223813448|NCT07164807|DRUG|Methylene Blue (0.1%) with Ropivacaine Hydrochloride (0.75%)|Perianal subcutaneous injection of 0.1% methylene blue solution (Formulation: 0.5 mL of 1% methylene blue with 4.5 mL ropivacaine hydrochloride injection).
223813449|NCT07165405|OTHER|Shower|Participants in this group will receive a shower administered by their partner on their back, abdomen, or entire body while standing or sitting, with the water temperature maintained between 32-37°C (the woman's preferred temperature will be applied) for at least 20 minutes upon admission to the labor room (when dilation is 4-5 cm). This will be performed under the observation of the researcher midwife. The application will be repeated when dilation reaches 7-8 cm.
223813450|NCT07165405|OTHER|Massage|Sacral Massage Application will be performed using 20x20 cm pouches filled with cherry pits. Like the shower application, massage will be performed upon admission to the delivery room (when dilation is 4-5 cm) and repeated when dilation reaches 7-8 cm. Unless the pregnant woman requests otherwise, massage will be performed while she is in the left lateral position.
223813451|NCT07165405|OTHER|Midwifery Care|Care provided by a midwife in the delivery room
223813452|NCT07166822|BEHAVIORAL|Experimental group using BumptUp mobile exercise app|This BumptUp app has been developed specifically for pregnancy with safety and screening feature. This intervention will be unique since the researchers will evaluate the cardiovascular health outcomes following the 8 weeks of intervention.
223813453|NCT07164482|BIOLOGICAL|HB- adMSCs (Hope Biosciences adipose derived mesenchymal stem cells)|Participants will receive allogenic HB-adMSCs through intravenous infusion only, with a treatment duration of 16 weeks, infusion rate 4-5mL/min and total volume of 250 mL Sodium chloride 0.9%. Each participant will receive a total of 6 doses of HB-adMSCs with a dosing regimen of approximately 2 weeks between infusion 1, infusion 2 and infusion 3, and 4 weeks between the remaining infusions.
223813454|NCT07165925|BEHAVIORAL|Gamified music training|Instrumental musical training will progress from basic (playing simple notes) to advanced levels (playing an entire song). Key training elements will include fundamental music knowledge and skills, music improvisation, rhythm, and pitch identification exercises. In particular, the core concepts of resilience will be incorporated into the training process through various gamified music activities.
223813455|NCT07165925|BEHAVIORAL|Active placebo intervention|Participants in the active placebo control group will participate in weekly 1-hour group-based indoor community leisure activities for 6 months. These activities will include (i) drawing, (ii) drama workshops, (iii) cartoon film screenings, (iv) handcraft workshops, (v) board games, and (vi) exercise classes. Each activity will span for four sessions, that is, totally 24 sessions and will be delivered by trained staff at the study centres of the collaborating non-governmental organisations.
223813456|NCT07166263|DRUG|NK510|NK510 will be administered through intravenous infusion, once a week for a total of six times.
223813457|NCT07166263|DRUG|NK510|NK510 will be administered through intraperitoneal perfusion on D1, D4, and D7 of the first week for a total of 3 times, with each 3-week cycle constituting a total of 2 cycles.
223813458|NCT07166328|DEVICE|BACKSCNR , measure the deviations of frontal and axial back asymmetry in AIS|BACKSCNR is a non-invasive surface topography device designed to assess spinal deformities, particularly scoliosis. It uses optical scanning technology to capture the three-dimensional shape of the back without radiation exposure.
223813459|NCT07164326|DRUG|Dexmedetomidine|Nebulization of dexmedetomidine
223813460|NCT07164326|DRUG|Saline|Nebulization of normal saline
223813461|NCT07164833|DRUG|BX-001N Experimental group 1|Each participant will receive BX-001N at a weight-based low dose via IV injection once daily for a total of three administrations.
223813462|NCT07164833|DRUG|BX-001N Experimental group 2|Each participant will receive BX-001N at a weight-based high dose via IV injection once daily at the same time during hospitalization, for a total of three administrations.
223813463|NCT07164833|DRUG|Placebo|Each participant will receive Placebo at a weight-based dose via IV injection once daily at the same time during hospitalization, for a total of three administrations.
223813464|NCT07166432|OTHER|observational diagnostic model development|observational diagnostic model development
223813465|NCT07165249|BEHAVIORAL|Positional release technique (PRT)|Group A (PRT): Patients lay prone for the application of the hot pack. PRT was then applied to the erector spinae muscles. The therapist identified tender points and passively positioned the patient into a position of comfort, typically involving lateral trunk flexion toward the symptomatic side. Each session involved three 90-second holds per tender point. PRT procedures followed standardized positioning principles as described in previous literature.
223813466|NCT07165249|BEHAVIORAL|Muscle energy technique|Group B (MET): Following the hot pack application, patients were assessed for segmental dysfunction via palpation of lumbar transverse processes in prone position. MET was applied using isometric contractions aimed at correcting lumbar rotational or side-bending dysfunctions. Each contraction was held for 7-10 seconds, followed by a passive stretch. The technique was repeated for 3-5 cycles per session.
223813467|NCT07164599|BEHAVIORAL|strength training|A 12-week strength training program designed for college dancesport athletes. Training is performed three times per week, 60 minutes per session, in addition to participants' regular dancesport training. Exercises include multi-joint resistance movements (e.g., squats, lunges, deadlifts, jumps) following NSCA guidelines with progressive overload based on 1RM. After the 12-week intervention, participants continue with an 8-week detraining phase without supplemental strength sessions and dance training.
223813468|NCT07164963|OTHER|upper cervical translatoric mobilisation|(UC-TSM) is defined as a system of manual techniques using straight-line forces delivered in a parallel or perpendicular direction to an individual vertebral joint or motion segment there is also increasing in body of evidence supporting the its clinical effectiveness and safety in the management of patients with cervical impairments.
223813469|NCT07164963|OTHER|sub occipital muscle energy technique|Muscle Energy Technique (MET) is another form of a gentle manual therapy intervention that primarily targets the soft tissues, though it also contributes significantly to joint mobilization. It has been reported that, adding MET to exercise program resulted in better improvement in CVA and FHP than exercise group only
223813470|NCT07164963|OTHER|traditional physical therapy|hot pack and kendel exercise
223813471|NCT07165847|DRUG|Iparomlimab and Tuvonralimab|q3w Iparomlimab and Tuvonralimab 5mg/kg on day 1 of each cycle
223813472|NCT07165847|DRUG|Oxaliplatin|130mg/m2 on day 1 of each cycle
223813473|NCT07165847|DRUG|Tegafur|\<1.25 m2, 40 mg; 1.25 to ≤1.5 m2, 50 mg; and ≥ 1.5 m2, 60 mg；po；d1-14 bid
223813474|NCT07165847|RADIATION|Radiotherapy|30 Gy/10 fractions
223813475|NCT07164469|DRUG|Fludarabine|Given by IV
223813476|NCT07164469|DRUG|Cyclophosphamide|Given by IV
223813477|NCT07164469|DRUG|CD70.CAR NK Cells|Given by IV Infusion
223813478|NCT07164469|DRUG|Rimiducid (AP1903)|Given by IV Infusion
223813479|NCT07166068|OTHER|Manual Therapy (Mobilization with Movement)|A continuous glide to the tibia will be a combined simultaneously by whether medial, lateral, anterior, posterior, or rotational-during active knee flexion and extension repeated movement as applied by Mulligan.
223813480|NCT07166068|OTHER|Exercise|standard care (exercise program to strengthen the musculature of the knee)
223813481|NCT07166068|OTHER|sham mobilization|The therapist will simulate MWM by performing slight external rotation of the skin only. This mimics the tactile sensation of true MWM without affecting the underlying joint mechanics.
223813482|NCT07166497|OTHER|Cosmetic product RV4660C CY0203|The product was applied once a day, in the evening, on the whole body/ off face on previously cleansed skin. The product was warmed in the hands before being applied in wide movements.
223813483|NCT07164365|BEHAVIORAL|Interdisciplinary Shared Decision-Making Consultation|One additional face-to-face consultation with a team (oncologist, palliative care, psychologist), following a six-step shared decision-making process.
223813484|NCT07165782|BEHAVIORAL|Brief Videos Delivered by Text Message|"The intervention consists of brief videos delivered by text message, designed to deliver psychoeducation, coping strategies, and social support guidance for youth with PTSD. The focus is to reduce avoidance behaviors, increase exposure, change cognitions and enhance social support.~The text messages will follow a six-module curriculum, covering key PTSD recovery topics:~1. Psychoeducation on PTSD - Understanding symptoms, trauma responses, and brain plasticity.~2. Reducing Avoidance - Encouraging gradual engagement with feared thoughts and situations.~3. Cognitive Coping Strategies - Introducing cognitive restructuring techniques.~4. Behavioral Coping Strategies - Teaching relaxation techniques (e.g., deep breathing, grounding).~5. Social Support - Highlighting the role of social support and strategies to strengthen connections.~6. Maintenance and Relapse Prevention - Preparing for setbacks and reinforcing progress."
223813485|NCT07166705|OTHER|Metaverse-Based Education Group|"As part of this intervention, participants will receive palpation skills training in a metaverse-based virtual learning environment. The training consists of three modules, each of which will cover the palpation of a different anatomical region:~* Module 1: Cervical region palpation~* Module 2: Thoracic region palpation~* Module 3: Lumbo-pelvic region palpation The training will be delivered in a three-dimensional virtual classroom environment using avatars. Participants will engage in interactive exercises based on scenarios structured on the metaverse platform and, under the guidance of an instructor, will practice palpation techniques on virtual patient models.~Sessions will be conducted in a group format, allowing students to interact with each other in real-time. Voice communication, motion tracking, and virtual feedback mechanisms will be used throughout the training."
223813486|NCT07166705|OTHER|Distance/Online Education Group|"As part of this intervention, a palpation skills course will be delivered to participants online via the Microsoft Teams application. The training consists of three modules, each of which will cover the palpation of different anatomical regions.~Module 1: Cervical region palpation Module 2: Thoracic region palpation Module 3: Lumbo-pelvic region palpation The training will utilize theoretical information, visual materials, and live/pre-recorded practice videos. Participants will attend the course as a group and participate in structured learning sessions guided by the instructor in each module."
223813487|NCT07166705|OTHER|Traditional Face-to-Face Education Group|"As part of this intervention, participants will be taught palpation skills in a face-to-face classroom setting using traditional teaching methods. The training consists of three modules:~Module 1: Palpation of the cervical region Module 2: Thoracic region palpation Module 3: Lumbo-pelvic region palpation Throughout the training, the instructor will conduct structured theoretical presentations, demonstrations, and face-to-face practice sessions. Students will observe palpation techniques through live demonstrations by the instructor and then have the opportunity to practice one-on-one."
223813488|NCT07165353|BEHAVIORAL|Virtual Walking|This virtual walking therapy uses a life-sized video avatar of the participant walking through a forest environment. A green screen setup combines a live video of the participant's upper body with pre-recorded walking legs, creating a full-body walking illusion. The participant is seated in a modified wheelchair that tilts 2° to each side to mimic pelvic movement during walking. This approach differs from the sham condition (Group 2), which displays only the moving forest without an avatar or wheelchair tilt, and from the standard care group (Group 3), which receives no virtual walking therapy.
223813489|NCT07165353|BEHAVIORAL|Sham Virtual Walking|Participants view a moving forest environment on a large projection screen for 10 sessions over 2 weeks (each up to 20 minutes). No avatar of the participant is displayed, and the wheelchair tilt function is disabled. This differs from the experimental intervention (Group 1), which includes a life-sized walking avatar and wheelchair tilt to mimic pelvic movement, and from the standard care group (Group 3), which receives no virtual walking therapy.
223813490|NCT07166692|OTHER|Prof. Valmed|Prof Valmed. decision support system.
223813491|NCT07165171|PROCEDURE|Innovative periodontal monitoring (SuP innovative)|"Different types of SMS messages will be sent alternately.~* Type 1 SMS: SMS providing targeted medical information specifically for diabetic patients.~* Type 2 SMS: Interactive SMS text messages written in the form of questions.~* Type 3 SMS: Before each scheduled periodontal follow-up visit (every 3 months), a reminder SMS will be sent with the date, time, and location of the appointment.~The SMS messages are intended for patients in the experimental group. Over these 24 months, the following are planned per patient:~* 1 Type 1 SMS/week (medical advice or information);~* 1 Type 2 SMS/month (interactive with suggested answers);~* 1 Type 3 SMS every 3 months (appointment reminder): 1 per visit. The various text messages will be scheduled from the beginning of the periodontal follow-up."
223813492|NCT07166354|DRUG|CS-002|CS-002 Topical Treatment
223813493|NCT07166354|DRUG|Placebo Topical Solution|Placebo Topical Solution
223813494|NCT07165626|DEVICE|Subtreshold micropulse laser therapy|Laser-treated group will receive additional subthreshold micropulse laser therapy (SMLT) 1 month after pars plana vitrectomy (PPV), using a 577 nm solid-state yellow diode laser applied to the macular area (thirty 5 × 5 spot sizes of 160 µm, zero-spot spacing, including the fovea; fixed power 250 mW; exposure time 200 ms; micropulse mode, 5% duty cycle). Control group (nonlaser group) will not receive additional laser treatment.
223813495|NCT07165626|PROCEDURE|Pars plana vitrectomy|Both groups will undergo pars plana vitrectomy (PPV) with epiretinal membrane (ERM) and internal limiting membrane (ILM) peeling prior to allocation to study arms.
223813496|NCT07165717|OTHER|No Intervention: Observational Cohort|Obsercational study
223813497|NCT07165678|DIAGNOSTIC_TEST|CTCA|Computed Tomography Cardiac angiography (CTCA) performed prior to invasive coronary angiogram (ICA).
223813498|NCT07165327|DEVICE|Injection Port for Insulin Administration|For two weeks, participants will use an injection port device for all prescribed insulin doses during pregnancy. The port is inserted and replaced approximately every 3 days. Insulin is delivered through the port using standard syringes or insulin pens, eliminating the need for multiple daily needle sticks.
223813499|NCT07165327|DEVICE|Single-Use Insulin Needles|For two weeks, participants will use standard single-use disposable needles for all prescribed insulin doses during pregnancy. A new sterile needle will be used for each injection, consistent with routine clinical practice.
223813500|NCT07165431|DIETARY_SUPPLEMENT|Postbiotic + nutritional recommendations|Study participants will consume daily one gummy containing a postbiotic formulation, along with adherence to healthy nutritional recommendations for 12 weeks.
223813501|NCT07165431|DIETARY_SUPPLEMENT|Placebo + nutritional recommendations|Study participants will consume daily one gummy containing a placebo formulation, along with adherence to healthy nutritional recommendations for 12 weeks.
223813502|NCT07166367|DRUG|ASLAN001|400mg of Oral ASLAN001 is administered twice daily, every day of each 21-day cycle
223813503|NCT07166367|DRUG|Capecitabine|1000mg/m\^2 of Oral Capecitabine is administered twice daily, on Days 1-14 of a 21-day cycle
223813504|NCT07165223|DRUG|GZR4|GZR4 s.c., once-weekly，treat-to-target dose
223813505|NCT07165223|DRUG|Insulin Icodec group|insulin Icodec s.c., once-weekly，treat-to-target dose
223813506|NCT07164456|OTHER|Education sessions|Remote and In person sessions
223813507|NCT07164456|OTHER|Questionnaire|Questionnaires given a 3,6,12 mouth follow ups
223813508|NCT07165392|OTHER|Neuromodulation|The application of neuromodulation therapy will be carried out with the support of ultrasound visualization on the anatomical area of the target nerve, seeking a motor and/or sensory response with its stimulation.
223813509|NCT07165392|OTHER|Physical Exercise|The therapeutic physical exercise will consist of 3 periods of isometric contraction of 30 seconds, with a rest period of 1 minute, varying the number of repetitions from 3 to 5 depending on the patient's symptoms.
223813510|NCT07165392|OTHER|Stretching|To stretch the muscles involved, 3 periods of maximum tolerable stretching without pain will be performed, lasting 20 seconds and resting for 30 seconds.
223813511|NCT07165470|DIETARY_SUPPLEMENT|pre-packaged low-residue diet for bowel preparation|Participants will be provided with 6 sachets of pre-packaged low-residue diet one day prior to colonoscopy
223813512|NCT07164547|DIETARY_SUPPLEMENT|Tribulus terrestris extract|625 mg oral capsule (40% saponins), single dose
223813513|NCT07164547|OTHER|Cellulose capsule (placebo)|Oral cellulose capsule, identical in appearance
223813514|NCT07166848|DEVICE|Electrodes with Currents|Electrodes will be placed on the cheeks and forehead, and treated with an amplitude of 300 µA for 30 mins
223813515|NCT07166848|DEVICE|Electrodes without Currents|Electrodes will be placed on the cheeks and forehead, and treated with an no amplitude for 30 mins
223813516|NCT07166653|BEHAVIORAL|HaH education|"The intervention consists of the online NorDigHE HaH education with tailored implementation tools em-bedded in the WHO Fast-IM. The education is delivered online and asynchronously, combining e-learning, simulations, reflection exercises, and practical task training.~The trial has adopted the evidence-based WHO Fast-track Implementation Model (WHO Fast-IM) as a framework to support the effectiveness and reporting of the implementation, and the tailored implementation tools embedded in the model will be provided as part of the intervention to support in-tegration into daily clinical routines. The tailored toolbox consists of workshops, introductory meetings, written guides, and access to a hotline staffed by project specialists to facilitate implementation."
223813517|NCT07166809|OTHER|Pelvic Floor Muscle Training (PFMT)|A structured pelvic floor muscle training program delivered remotely for 8 weeks, including exercises designed to strengthen and improve the endurance, coordination, and control of the pelvic floor muscles.
223813518|NCT07166809|OTHER|Pelvic Floor Muscle Training combined with Dynamic Neuromuscular Stabilization (PFMT+DNS)|Participants received the same 8-week remotely monitored pelvic floor muscle training program as the PFMT group, in addition to supervised Dynamic Neuromuscular Stabilization exercises three times per week. DNS exercises aimed to enhance core stability, postural control, and coordination to support pelvic floor muscle function.
223813519|NCT07164976|DRUG|Ribociclib 400mg|phase 1b cohort 1
223813520|NCT07164976|DRUG|Ribociclib 600mg|Phase 1b cohort 2
223813521|NCT07164976|DRUG|Ribociclib 600mg|phase 2
223813522|NCT07166445|OTHER|None intervention|this study is retrospective based on the CT images, which dose include any intervention.
223813523|NCT07166276|OTHER|coffee|The type of coffee consumed, the daily amount of coffee, and the frequency of consumption were measured.
223813524|NCT07165808|OTHER|Nicotine pouch: Low dose|Nicotine pouch: 3-4 mg
223813525|NCT07165808|OTHER|Nicotine pouch: High dose|Nicotine pouch: 6-8 mg
223813526|NCT07165808|OTHER|Low pH|Nicotine pouch with low pH level \[\<8.5\]
223813527|NCT07165808|OTHER|High pH|Nicotine pouch with high pH level \[\>8.5\]
223813528|NCT07164560|BIOLOGICAL|Anti-TRBC1 CAR-T cells|lentiviral vector-transducted peripheral blood-derived T cells to express anti-TRBC1 CAR
223813529|NCT07164196|OTHER|Angiopoietin-like protein-4 (ANGPTL4) Peritoneal Fluid Level|Measurement of peritoneal fluid levels of Angiopoietin-like protein-4 (ANGPTL4) level by ELISA method.
223813530|NCT07164196|OTHER|Cancer Antigen 125 (CA-125) Serum Level|Measurement of venous blood serum level of CA-125 level by ELISA method.
223813531|NCT07164196|OTHER|Angiopoietin-like protein-4 (ANGPTL4) Serum Level|Measurement of venous blood serum level of Angiopoietin-like protein-4 (ANGPTL4) Level level by ELISA method.
223813532|NCT07164222|DIAGNOSTIC_TEST|Glycated haemoglobin and triglycerides level|Follow up with triglycerides and glucose index and ratio on diabetic type 2
223813533|NCT07165769|DRUG|Induction Therapy|"All enrolled patients will receive the ZGR regimen (zanubrutinib, obinutuzumab, and lenalidomide) for induction therapy. Each cycle lasts 28 days, up to 6 cycles, followed by maintenance therapy. Patients experiencing disease progression during induction will discontinue the trial drugs but remain under survival follow-up.~1. Zanubrutinib: 160 mg twice daily, administered orally continuously.~2. Obinutuzumab: 1000 mg via intravenous infusion, administered on Days 1, 8, and 15 of Cycle 1 and subsequently on Day 1 of Cycles 2-6.~3. Lenalidomide: 25 mg once daily, taken orally on Days 1-21 of each 28-day cycle until disease progression. Doses should be taken at approximately the same time daily."
223813534|NCT07165769|DRUG|Maintenance Therapy|"Maintenance therapy consists of zanubrutinib plus lenalidomide:~Lenalidomide is continued for 1 year. Zanubrutinib is continued for 2 years. Treatment continues until disease progression, intolerability, or completion of 2 years. For patients who do not achieve complete remission (CR), therapy may continue until progression or intolerability.~1. Zanubrutinib: 160 mg twice daily, administered orally continuously.~2. Lenalidomide: 10 mg once daily, taken orally on Days 1-21, followed by a 7-day rest period, constituting a 28-day cycle."
223813535|NCT07164846|DEVICE|Therapy Sessions|You will complete up to 12 sessions using the Neuro20 suit under the direct supervision of study staff. Each session will be 1-2 hours in duration. Each session, you will change into the suit and then receive no more than 105 minutes of electrical stimulation, and then change out of the suit and have a skin check. The suit has 20 electrodes that will stimulate muscles in your upper arm (above the elbow), upper leg (above the knee), chest, abdominals, and back. Stimulation levels will be adjusted to your comfort. You will likely feel tingling and/or muscle contractions. The timing and intensity of each type of activity will depend on your individual needs and will be prescribed by the study doctor.
223813536|NCT07165509|DIETARY_SUPPLEMENT|T-2 Nutritional Supplement|"Nutritional supplement labeled T-2; dose 23 g twice daily, as specified in the protocol. Used only in the arm T-2 Supplement + Structured Diet."
223813537|NCT07165509|BEHAVIORAL|Structured Dietary Program|"Rigorous, structured dietary intervention applied according to the study protocol. Used in the arms T-2 Supplement + Structured Diet and Structured Diet Only."
223813538|NCT07166575|DIAGNOSTIC_TEST|B-mode ultrasonography|Thickness and cross-sectional area of upper trapezius muscle
223813539|NCT07165418|DRUG|Vorolanib Tablets+Everolimus|Subjects received oral vorinib 200 mg once daily (QD) plus everolimus 5 mg once daily (QD), administered within 30 minutes after breakfast daily. Treatment cycles lasted 28 days and continued until disease progression.
223813540|NCT07165418|DRUG|Sunitinib|Subjects received oral sunitinib 50 mg once daily (QD) in a 4-week on, 2-week off regimen or a 2-week on, 1-week off regimen until disease progression.
223813541|NCT07164638|PROCEDURE|lung ultrasound (LUS)|Serial lung ultrasound will be performed to patients enrolled in this study before the beginning of the surgery, every 15 minutes in the first 30 minutes, and then every 30 minutes for the rest of the operation.lung ultrasound will be used as a tool for monitoring of EVLW to identify early the subclinical pulmonary edema and ensure timely and correct diagnosis and appropriate management.
223813542|NCT07164638|PROCEDURE|IVC collapsibility index|Serial assessment of IVC collapsibility will be used as a monitoring of volume overload in patients enrolled in this study. Basal IVC scanning using ultrasound will be performed before the start of the operation and serial IVC scanning will be done during the procedure every 15 minutes in the first 30 minutes, and then every 30 minutes for the rest of the operation.
223813543|NCT07164898|DEVICE|Test patches|Patches (incontinence product cut outs) either dry, 50% saturated with water or 100% saturated with water applied to the forearm and worn for 2 hours
223813544|NCT07166003|PROCEDURE|Pneumonectomy|Patients will receive pneumonectomy after neoadjuvant treatment
223813545|NCT07166003|PROCEDURE|lobectomy|Patients will receive lobectomy after neoadjuvant immunotherapy.
223813546|NCT07166003|RADIATION|radiotherapy|Patients will receive radiotherapy after neoadjuvant immunotherapy.
223813547|NCT07166003|DRUG|Anti-Tumor Drugs|Patients will receive anti-tumor drugs.
223813548|NCT07164300|DRUG|Tranexamic acid at a dose of 10 mg/kg followed by 1 mg/kg/h|Group 1: administration of tranexamic acid at a dose of 10 mg/kg followed by 1 mg/kg/h
223813549|NCT07164300|DRUG|Tranexamic acid at a dose of 20 mg/kg|Group 2: administration of tranexamic acid at a dose of 20 mg/kg
223813550|NCT07164300|DRUG|Tranexamic acid at a dose of 30 mg/kg|Group 3: administration of tranexamic acid at a dose of 30 mg/kg
223813551|NCT07165899|BEHAVIORAL|EEG-Guided Binaural Beat Audio|30-minute audio session with dynamic frequency adjustments based on real-time EEG feedback
223813552|NCT07165899|BEHAVIORAL|Sham Control|30-minute audio session with identical tones presented to both ears (no binaural beat), EEG monitored but not used for frequency adjustment
223813553|NCT07166315|OTHER|observational study|This is an observational study based on existing treatments prescribed prior to inclusion. No interventions are given as part of this research.
223813554|NCT07165886|DRUG|Sirolimus for injection (albumin bound)|Sirolimus for injection (albumin bound), ivgtt., Q2W
223813555|NCT07165886|DRUG|Octreotide long-acting injection|SC, Q2W
223813556|NCT07165886|DRUG|Everolimus|Oral, once a day
223813557|NCT07165262|DRUG|Fentanyl (IV)|Fentanyl, Intravenous bolus administration at a dose of 1 microgram per kilogram of body weight administered once before spike stimulation and another time after resection of epileptic foci for spike stimulation.
223813558|NCT07165262|DRUG|Ketamine (0.5 mg/kg)|Ketamine, Intravenous bolus administration at a dose of 0.5 milligram per kilogram of body weight administered once before spike stimulation and another time after resection of epileptic foci for spike stimulation.
223813559|NCT07165119|OTHER|Interdisciplinary group|For 12 weeks, the subjects in the interdisciplinary group participated in 45 minutes of clinical Pilates three times a week, as in the clinical Pilates group, and 45 minutes of nurse coaching once a week, as in the nurse coaching group.
223813560|NCT07165119|OTHER|Clinical Pilates Group|Clinical Pilates was applied by a certified physiotherapist for 12 consecutive weeks. with 45-minute sessions 3 times a week and was delivered to small groups of participants (3-5). The Pilates program has been developed in accordance with the extant literature to cultivate strength, balance, and coordination in a range of body positions, including the supine, seated, kneeling, and standing positions. Participants were instructed to perform each movement with control and precision, focusing on proper breathing patterns (exhaling during flexion, inhaling during extension) and engaging their core muscles throughout the exercise The load level and progression were determined using the Borg CR10 scale: Borg ≤ 2 = light load; Borg \> 2 - \< 5 = moderate load; Borg ≥ 5 - \< 7 = heavy load; Borg ≥ 7 = near-maximum load. During the sessions, the effort level was generally maintained at a moderate intensity (Borg 3-4). Each time the intensity of the exercise was changed, the new loa
223813561|NCT07165119|OTHER|Nurse Coaching group|Training and follow-up was carried out with nurse coaching for 12 weeks lasting 45 minutes once a week .
223813562|NCT07164521|BEHAVIORAL|Music Listening (Relaxing Classical Music)|Participants listened to a standardized playlist of relaxing classical instrumental music (e.g., Mozart, Vivaldi, Debussy) for 15 minutes every hour, beginning at the 24th postpartum hour until the 48th hour. The intervention aimed to reduce postpartum anxiety and pain perception.
223813563|NCT07166510|OTHER|Yoga and meditation|For 12 months, with no restrictions or imposed frequency, as often as the participant feels the need. They can take individual or group video-guided 15-minute breaks to do tailored yoga exercises targeting areas affected by repetitive movements, fatigue, and stress (hands, wrists, shoulders, and back), or mindfulness meditation sessions focused on managing fatigue, transitioning at the end of a shift, and post-shock relaxation.
223813564|NCT07165314|PROCEDURE|Free positioning|Participants are not given instructions on how to position for intubation using direct laryngoscopy.
223813565|NCT07165314|PROCEDURE|"Sitting cross-legged (Lotus position)"|Participants are requested to sit cross-legged for intubation using direct laryngoscopy.
223813566|NCT07164534|DIETARY_SUPPLEMENT|Sodium-copper-chlorophyllin, a semi-synthetic derivative of chlorophyll, is made up of a mixture of sodium copper salts.|Oral adjuvant sodium-copper-chlorophyllin 750mg given once daily given on an empty stomach for 3 months, starting within 2 weeks of RT completion
223813567|NCT07164378|PROCEDURE|Lens-Exchange|The existing IOL will be removed and replaced by implanting SING IMT™ device in the sulcus
223813568|NCT07164378|PROCEDURE|Add-on|The SING IMT™ device will be placed in front of the existing IOL and implanted in the sulcus.
223813569|NCT07165379|OTHER|Neuromodulation|The application of neuromodulation therapy will be carried out with the support of ultrasound visualization on the anatomical area of the target nerve, seeking a motor and/or sensory response with its stimulation.
223813570|NCT07165379|OTHER|Physical Exercise|The therapeutic physical exercise will consist of 3 periods of isometric contraction of 30 seconds, with a rest period of 1 minute, varying the number of repetitions from 3 to 5 depending on the patient's symptoms.
223813571|NCT07165379|OTHER|Stretching|To stretch the muscles involved, perform three periods of maximum tolerable stretching without pain, lasting 20 seconds and resting for 30 seconds.
223813572|NCT07165288|OTHER|Continuous midwife support care|Primiparous pregnant women are provided with continuous and individual midwife support starting from the 36th week until the postpartum period.
223813573|NCT07165288|OTHER|Pilates ball usage|Primiparous pregnant women were provided with educational support starting from the prenatal period to the postnatal period. In addition, depending on the preferences of the pregnant woman, at least one of the above-mentioned practices was chosen with the accompaniment of a midwife at the time of birth.
223813574|NCT07165288|OTHER|warm shower|It was generally applied to the majority of our pregnant women within the scope of training.
223813575|NCT07166835|DIETARY_SUPPLEMENT|Nootropics (ginkgo biloba, nicergoline, piracetam, or others)|Nootropic drink containing Anthrocyanins, L-theanie and Enzogenol
223813576|NCT07166835|DIETARY_SUPPLEMENT|Placebo|Taste- and appearance-matched placebo beverage without active ingredients.
223813577|NCT07165587|DIAGNOSTIC_TEST|Bilateral duplex ultrasonography|Bilateral duplex ultrasound screening performed during hospitalization to detect symptomatic and asymptomatic deep vein thrombosis in patients with pelvic and acetabular fractures.
223813578|NCT07166679|PROCEDURE|root canal treatment with 2% taper|root canal treatment with 2%taper
223813579|NCT07166679|PROCEDURE|root canal treatment with 4% taper|root canal treatment with 4 %taper
223813580|NCT07166679|PROCEDURE|root canal treatment with 6 %taper|root canal treatment with 6 %taper
223813581|NCT07164391|BEHAVIORAL|Digital Intervention for Vietnamese-American Storytelling (VIDAS)|The intervention consists of 4 brief stories about HPV vaccine, created by Vietnamese mothers
223813582|NCT07164391|BEHAVIORAL|HPV Educational Video Intervention|The intervention consists of 4 brief informational videos about HPV and the vaccine
223813583|NCT07164391|BEHAVIORAL|Teen General Health|This intervention consists of 4 brief videos on general teen health topics, such as mental health, social media usage.
223813584|NCT06262165|OTHER|Patients with Anorexia Nervosa|Patients with Anorexia Nervosa hospitalized for malnutrition
223813585|NCT07166887|DRUG|Tolvaptan|One dose on the first day and one dose on days 3-9, for a total of eight doses.
223813586|NCT00079508|DRUG|Angiomax (bivalirudin)|250 mg vial administered as 1.0 mg/kg intravenous (IV) bolus and 2.5 mg/kg/h IV infusion during the procedure with the option to administer additional 0.1 to 0.5 mg/kg boluses to increase the level of anticoagulation as clinically indicated. A low-dose infusion could have been administered in the preoperative phase (up to 48 hours before the procedure) and in the postoperative phase (up to 14 days after the procedure) as clinically indicated for management of HIT/TS. A starting bolus of 0.1 mg/kg and/or an infusion of 0.2 mg/kg/h titrated to a desired activated partial thromboplastin time (aPTT), eg, 1.5-2.5 times baseline aPTT, was recommended.
223813587|NCT02450721|OTHER|Biomarkers serum level measurement|"Biomarker serum level measurement was performed with ELISA using following kits: Lp-PL-A2 ELISA- Cloud-CloneCorp. (USA); PAPP-A ELISA- IBL (Germany); Lp (a) ELISA Kit-AssayPro (USA ), ADMA ELISA Kit- ImmunDiagnostik ( Germany); hsCRP ELISA- Biomerica (Germany); according to the manufacturer's instructions . Absorbance of standards and samples was measured with a microplate reader Bio-Tek (USA) at a wavelength specified by the kit manufacturer . The calculation of the determined biomarkers concentration was performed using the software SOFTmaxPRO."
223813588|NCT01861574|DEVICE|Real TMS 45 min|Real TMS 45 minutes after surgery, first determined resting motor threshold (rMT) by starting with 40% of the machine output and 0.5 Hz stimulus frequency. The coil was positioned over the motor cortex and then adjusted until each pulse results in movement of the right thumb. The machine output was then adjusted to the lowest intensity that reliably produces thumb movement. Parameter estimation by sequential testing was used to determine the amount of machine energy necessary to visibly move the thumb 50% of the time. rMT was assessed before each rTMS treatment. The left prefrontal cortex was the cortical target for rTMS treatment. The EEG-10-20 system was used to locate the prefrontal cortex (F3).
223813589|NCT01861574|DEVICE|Sham TMS 45 min|Sham TMS 45 minutes after surgery used specifically designed rTMS coil that produces auditory signals identical to real (active) TMS coils but is shielded so that actual stimulation does not occur. The eSham system was used to mimic sensations of real rTMS. This system produces mild tingling on the scalp underneath the sham rTMS coil, making it difficult in differentiating between real and sham. The amount of electrical stimulation necessary to match real rTMS pulses was determined using an algorithm (parameter estimation by sequential testing). All subjects underwent the sham titration at the beginning of every rTMS session regardless of group assignment. The left prefrontal cortex was the cortical target for rTMS treatment, located using the EEG-10-20 system.
223813590|NCT01861574|DEVICE|Real TMS 4 Hours|Real TMS 4 hours after surgery, first determined resting motor threshold (rMT) by starting with 40% of the machine output and 0.5 Hz stimulus frequency. The coil was positioned over the motor cortex and then adjusted until each pulse results in movement of the right thumb. The machine output was then adjusted to the lowest intensity that reliably produces thumb movement. Parameter estimation by sequential testing was used to determine the amount of machine energy necessary to visibly move the thumb 50% of the time. rMT was assessed before each rTMS treatment. The left prefrontal cortex was the cortical target for rTMS treatment. The EEG-10-20 system was used to locate the prefrontal cortex (F3).
223813591|NCT01861574|DEVICE|Sham TMS 4 Hours|Sham TMS 4 hours after surgery used specifically designed rTMS coil that produces auditory signals identical to real (active) TMS coils but is shielded so that actual stimulation does not occur. The eSham system was used to mimic sensations of real rTMS. This system produces mild tingling on the scalp underneath the sham rTMS coil, making it difficult in differentiating between real and sham. The amount of electrical stimulation necessary to match real rTMS pulses was determined using an algorithm (parameter estimation by sequential testing). All subjects underwent the sham titration at the beginning of every rTMS session regardless of group assignment. The left prefrontal cortex was the cortical target for rTMS treatment, located using the EEG-10-20 system.
223813592|NCT00817999|DIETARY_SUPPLEMENT|Grapefruit juice|Participants received grapefruit juice during 1 of the 2 periods.
223813593|NCT00817999|DRUG|Clopidogrel 75 mg/day|
223813594|NCT00817999|DRUG|Clopidogrel 300 mg|
223813595|NCT02526355|BEHAVIORAL|Mobile based intervention|Learning through Play Plus Intervention delivered through mobile phone
223813596|NCT03983122|PROCEDURE|Laparoscopic sleeve gastrectomy|Each procedure will be completed with laparoscopy with five trocars. A 36F bougie will used to calibrate the volume of the remnant stomach. Linear gastrectomy will begin 2 cm proximal of the pylor and will continue until the gastroesophageal junction. According to the intraoperative decision and experience of the surgeon, endoscopic clips would be used to ensure hemostasis of the stapler line.
223813597|NCT00494533|DRUG|Remodulin (treprostinil sodium)|
223813598|NCT03818789|BEHAVIORAL|Mindfulness and acceptance training|A breathing mediation, body scan, talking about acceptance, and presence activity are used. All are low-impact and expected to cause no distress
223813599|NCT03818789|BEHAVIORAL|Study skills video|A YouTube video describing study skills and suggested habits is used as a control condition.
223813600|NCT04642963|RADIATION|Cardiac Radiosurgery|Non-invasive delivery of ablative radiotherapy dose to the arrhythmia substrate.
223813601|NCT02634840|PROCEDURE|bilateral sagittal split osteotomy|surgical technique to split the mandibular ramus through three osteotomy lines on the medial-cranial, buccal-caudal and anterior surface to facilitate a split of the posterior border of the mandible without injury of the inferior alveolar nerve
223813602|NCT03408275|OTHER|None - observational|None - observational
223813603|NCT00259064|DRUG|Gefitinib|
223813604|NCT00259064|OTHER|Placebo|
223813605|NCT04574830|OTHER|No Intervention|No Intervention
223813606|NCT00917163|DEVICE|Supralimus(R) Sirolimus-Eluting Coronary Stent System|Drug eluting stent implantation in the treatment of coronary artery disease.
223813607|NCT00917163|DEVICE|Xience V™ Everolimus Eluting Coronary Stent|Drug eluting stent implantation in the treatment of coronary artery disease
223813608|NCT01578863|OTHER|Intervention program for obese children|The program includes physical activity, nutrition intervention and behavioral treatment and lasts for 6 months. The aim of the program is to promote weight loss and physical activity and to promote future healthy lifestyle.
223813609|NCT03327584|PROCEDURE|Arthrocentesis|Athrocentesis
223813610|NCT05976425|DEVICE|ModPG3 Investigational Device|"* Connex Vital Sign Monitor with ModPG3~* Laptop~* Data Collection Software~* USB cable~* Power strip~* Welch Allyn FlexiPort Disposable Blood Pressure Cuffs"
223813611|NCT05976425|DEVICE|Invasive Reference Equipment|"* Surveyor S12/S19~* Hill-Rom ICU Medical data collection cable DIR 60119852~* Hill-Rom Edwards data collection cable DIR 60119853"
223813612|NCT06020625|GENETIC|Diagnostic Test|"In order to proceed with molecular characterization, the tumor sample already taken for histological diagnosis will undergo DNA and RNA extraction, which will be analyzed for qualitative and quantitative evaluation. Based on the quantitative data, the method to be used for profiling will be decided.~Multigenic genomic profiling will be performed for each patient on already taken tumor tissue using different panels depending on the quality and quantity of nucleic acids, in particular the following will be used: comprehensive Genome Profiling (CGP, ≥500 genes), if at least 40 ng of material is available; Profiling with identification of actionable mutations by targeted sequencing with panels of size \>50 genes, if \<40 ng material available."
223813613|NCT03304002|OTHER|Breast Cancer Surgery Decision Aid|We use a standard decision aid collaboratively developed by Health Dialog and the Informed Medical Decisions Foundation
223813614|NCT00993239|DRUG|Birinapant (TL32711)|30 minute intravenous (IV) infusion administered once weekly for three consecutive weeks followed by a one week off (Cycle) repeated every 4 weeks as tolerated
223813615|NCT04699435|OTHER|Control|"All patients are installed with a 30 ° proclive and have pre-oxygenation (FiO2 = 1) with a face mask. At the end of the 3-minute pre-oxygenation for the Control group, the values of ORI, SpO2, mean arterial pressure and heart rate are recorded."
223813616|NCT04699435|OTHER|PreOx_3min|"Patients with a BMI between 30 kg / m² and 40 kg / m² are distributed according to a random allocation in the group PreOx\_3min.~All patients are installed with a 30 ° proclive and have pre-oxygenation (FiO2 = 1) with a face mask. At the end of the 3-minute pre-oxygenation for the PreOx\_3min group, the values of ORI, SpO2, mean arterial pressure and heart rate are recorded."
223813617|NCT04699435|OTHER|PreOx_6min|"Patients with a BMI between 30 kg / m² and 40 kg / m² are distributed according to a random allocation in the group PreOx\_6min.~All patients are installed with a 30 ° proclive and have pre-oxygenation (FiO2 = 1) with a face mask. At the end of the 6-minute pre-oxygenation for the PreOx\_3min group, the values of ORI, SpO2, mean arterial pressure and heart rate are recorded."
223813618|NCT03152955|DRUG|Ketamine|Ketamine will be applied in patient-controlled analgesia.
223813619|NCT03152955|OTHER|scalp nerve block|Scalp nerve block is performed for the blockade of the greater occipital, superficial cervical and lesser occipital nerves with 0.5% ropivacaine.
223813620|NCT03152955|DRUG|ondansetron|Ondansetron(13ug/kg/h) is applied in patient-controlled analgesia.
223813621|NCT03152955|DRUG|Sufentanil|Sufentanil(0.02ug/kg/h) is applied in patient-controlled analgesia.
223813622|NCT05416255|DIAGNOSTIC_TEST|Measuring synovial fluid components|Using speialized techniques to measure S.F. components
223813623|NCT01495884|DRUG|non-pegylated liposomal doxorubicon (Myocet™)|
223813624|NCT01495884|DRUG|Lapatinib (Tyverb™)|
223813625|NCT00141739|DRUG|Etanercept|"Etanercept 0.4 mg/kg per dose \[maximum dose 25 mg\] SC for prophylaxis. To start in the 24 hour time period along with the initiation of the preparative regimen for the stem cell transplant.~Etanercept will be administered twice weekly until day +56 (8 weeks) post transplant."
223813626|NCT05976204|PROCEDURE|ToF primary repair|ToF primary repair for patients with ToF
223813627|NCT00944723|DIETARY_SUPPLEMENT|Zinc-fortified bread|Bread made with zinc-fortified wheat flour
223813628|NCT00944723|DIETARY_SUPPLEMENT|Zinc supplement|Liquid supplement with zinc
223813629|NCT00944723|DIETARY_SUPPLEMENT|Non-fortified bread|Daily consumption of non-fortified bread
223813630|NCT00944723|DIETARY_SUPPLEMENT|Placebo supplement|Daily intake of placebo supplement
223813631|NCT03331484|DRUG|Ticagrelor|Ticagrelor 90 mg twice daily
223813632|NCT03331484|DRUG|Rivaroxaban|Rivaroxaban 15 mg once daily (10mg for patients with moderate renal impairment, creatinine clearance: 30-50 mL/min by the Cockcoft Gault method)
223813633|NCT06052917|OTHER|DECIdE|DECIdE is a decision aid. Its a communication tool to help health providers as general practitioners or community pharmacists, to practice shared medical decision about optional prescription drug. DECIdE provide robust scientific data about benefit and risks associated to the drug under consideration. DECIdE was built based on the consensus of potentials users ( care providers and patients ), tested on users testing and finally validated by a expert consensus ( DELPHI method).
223813634|NCT05701514|PROCEDURE|Elective surgical resection of CPAM between 6 and 9 months of age|Surgical resection of the CPAM between 6 and 9 months of age
223813635|NCT04498325|DRUG|NT-I7|Supplied by study
223813636|NCT04498325|DRUG|Placebo|Supplied by study
223813637|NCT04498325|PROCEDURE|Blood for research purposes|Prior to injection (Day 0), Day 7, and Day 14
223813638|NCT04498325|PROCEDURE|Blood for pharmacokinetic samples|-Phase I only: 1-2 hours prior to dosing, 6 hours after dosing, 24 hours after dosing, Day 7, Day 14, and Day 21
223813639|NCT04498325|PROCEDURE|Nasopharyngeal, oropharyngeal, or saliva swab|-Prior to study treatment, Day 4(optional), Day 7, and Day 14
223813640|NCT04498325|PROCEDURE|Blood for anti-drug antibody (ADA)|Baseline, Day 7, Day 14, Day 21, Day 60, and Day 90. Participants with ADA positivity on Day 90 will be monitored every 90 days until antibody level returns to baseline
223813641|NCT01180543|DEVICE|Oplon Active Patch|Patches are placed over acne lesion overnight. Treatment is a single treatment.
223813642|NCT01180543|DEVICE|Placebo Patch|same as active patch
223813643|NCT05703984|DRUG|GC2129A(Period 1)|Linagliptin and Metformin Hydrochloride Tablet
223813644|NCT05703984|DRUG|Linaglptin 5mg and Metformin Hydrocholoride 1000mg(Period 1)|Linagliptin 5mg/tab and Metformin Hydrochloride 1000mg/tab (2 tablets)
223813645|NCT05703984|DRUG|GC2129A(Period 2)|Linagliptin and Metformin Hydrochloride Tablet
223813646|NCT05703984|DRUG|Linaglptin 5mg and Metformin Hydrochloride 1000mg(Period 2)|Linagliptin 5mg/tab and Metformin Hydrochloride 1000mg/tab (2 tablets)
223813647|NCT02465502|DRUG|Regorafenib (Stivarga, BAY73-4506)|Regorafenib 160 mg orally once a day for 3 weeks of every 4 week cycle (i.e., 3 weeks on, 1 week off).
223813648|NCT04308902|OTHER|VLBW|Participants previously enrolled in the Bovine vs. Human Milk-Based Fortifier Study
223813649|NCT04308902|OTHER|Term-born Comparison|Children born \>=37 weeks gestation and weighing more than 2500g
223813650|NCT00336141|DRUG|Suberoylanilide hydroxamic acid|400 mg QD (every day) for five days, followed by 9 days of no vorinostat
223813651|NCT00058422|BIOLOGICAL|darbepoetin alfa|
223813652|NCT00058422|BIOLOGICAL|filgrastim|
223813653|NCT00058422|BIOLOGICAL|rituximab|
223813654|NCT00058422|DRUG|cyclophosphamide|
223813655|NCT00058422|DRUG|doxorubicin hydrochloride|
223813656|NCT00058422|DRUG|prednisone|
223813657|NCT00058422|DRUG|vincristine sulfate|
223813658|NCT00058422|RADIATION|indium In 111 ibritumomab tiuxetan|
223813659|NCT00058422|RADIATION|yttrium Y 90 ibritumomab tiuxetan|
223813660|NCT00185640|DRUG|Cyclosporine|Starting day -3 at a dose of 5 mg/kg orally twice daily with a target trough level of 350 to 450 ng/mL
223813661|NCT00185640|DRUG|Anti-thymocyte globulin (ATG)|1.5 mg/kg for total dose of 7.5mg/kg, IV starting on day -11 to day -7 before HCT
223813662|NCT00185640|DRUG|Mycophenolate mofetil (MMF)|Begins on day 0 after HCT at a dose of 15 mg/kg. Transplant recipients who received related donor grafts received MMF twice daily and those who received unrelated donor grafts received MMF 3 times daily.
223813663|NCT00185640|DRUG|Filgrastim|"* Donors mobilized with 16 µg/kg/day filgrastim.~* As needed, myelosuppression in transplant recipients will be managed with subcutaneous filgrastim 5 µg/kg/day"
223813664|NCT00185640|RADIATION|Total Lymphoid Irradiation (TLI)|0.8 Gy/day from day -11 to day -7 (inclusive) from day -4 to day -2 (inclusive) with 2 additional fractions of 0.8 Gy delivered on day -1 for total dose of 8 Gy.
223813665|NCT00529321|BIOLOGICAL|MVA-HCV (Immunotherapy)|MVA-HCV
223813666|NCT02809898|PROCEDURE|surgery or biopsy|Do radical surgery or biopsy to obtain a pathological result
223813667|NCT02437825|DRUG|octreotide|Octreotide has been in clinical use for thirty years and approved for use in Israel in acromegaly and functional gastroenteropancreatic tumours. It is currently being used extensively in surgical patients to prevent pancreatic fistulae1, and in lymphorrhea (both lymphatic malformations and leaks from the thoracic duct)
223813668|NCT02437825|OTHER|placebo|placebo ( saline) act as comperator in this study.
223813669|NCT01390714|DRUG|E3710|"Arm A:~1. E3710 40 mg→RPZ 10 mg→E3710 20 mg~2. RPZ 10 mg→E3710 20 mg→E3710 40 mg~3. E3710 20 mg→E3710 40 mg→RPZ 10 mg~Crossover study of E3710 40 mg, E3710 20 mg, and PRZ 10 mg, once daily, for 5 days, oral administration."
223813670|NCT01390714|DRUG|E3710|"Arm B:~1. E3710 40 mg→E3710 80 mg→EPZ 40 mg~2. E3710 80 mg→EPZ 40 mg →E3710 40 mg~3. EPZ 40 mg→E3710 40 mg→E3710 80 mg~Crossover study of E3710 40 mg, E3710 80 mg, and EPZ 40 mg, once daily, for 5 days, oral administration."
223813671|NCT02287584|DRUG|DSP-5423P Placebo|DSP-5423P Placebo was applied to the subject's back, chest, or abdomen once daily
223813672|NCT02287584|DRUG|DSP-5423P 40mg|DSP-5423P 40mg was applied to the subject's back, chest, or abdomen once daily
223813673|NCT02287584|DRUG|DSP-5423P 80mg|DSP-5423P 80mg was applied to the subject's back, chest, or abdomen once daily
223813674|NCT02287584|DRUG|DSP-5423P Placebo-to-Flex|"DSP-5423P Placebo:~DSP-5423P Placebo was applied to the subject's back, chest, or abdomen once daily~DSP-5423P Flex:~DSP-5423P 20mg, 60mg or 80mg was applied to the subject's back, chest, or abdomen once daily"
223813675|NCT02287584|DRUG|DSP-5423P Active-to-Flex|"DSP-5423P Active:~DSP-5423P 40mg or 80mg was applied to the subject's back, chest, or abdomen once daily~DSP-5423P Flex:~DSP-5423P 20mg, 60mg or 80mg was applied to the subject's back, chest, or abdomen once daily"
223813676|NCT02269371|OTHER|Auricular Acupuncture|Standard of care weight loss intervention plus auricular acupuncture at Shen Men, Point Zero, and Appetite Control Point/Hunger Point in each ear.
223813677|NCT02269371|OTHER|Sham Acupuncture|Standard of care weight loss intervention plus sham acupuncture at three nonacupoints in each ear.
223813678|NCT00496002|DRUG|Clevudine|
223813679|NCT00496002|DRUG|Adefovir|
223813680|NCT03264885|OTHER|Incentive Care|ICS is a novel intervention that incorporates patient education, social support, and financial assistance to assist individuals.
223813681|NCT04942301|DRUG|Endostar|This product combined with other combined chemotherapeutics is used to treat patients with stage III/IV NSCLC who are newly treated or relapsed
223813682|NCT04942301|DEVICE|use the vein pump to pump drugs|During the first 14 days of the first cycle, the experimental drug was pumped daily with an intravenous pump. During cycles 2-4, subjects in group A were pumped with experimental drugs for 3 days and subjects in group B were pumped with experimental drugs for 7 days.
223813683|NCT04942301|COMBINATION_PRODUCT|combination therapy|Combination therapy with chemotherapy drugs was used
223813684|NCT03389139|DEVICE|Near infrared spectroscopy (spinal anesthesia)|effect of spinal anesthesia on regional renal and cerebral oxygen saturation in newborns
223813685|NCT03389139|DEVICE|Near infrared spectroscopy (general anesthesia)|effect of general anesthesia on regional renal and cerebral oxygen saturation in newborns
223813686|NCT03244462|DRUG|BAY1834845|Single oral dose (IR \[immediate release\] tablets)
223813687|NCT03244462|DRUG|BAY1834845|I.v. infusion of \[13C6\]-labeled BAY1834845
223813688|NCT03244462|DRUG|Methotrexate|Single dose of commercially available MTX
223813689|NCT00005816|BIOLOGICAL|therapeutic autologous dendritic cells|
223813690|NCT00005816|PROCEDURE|conventional surgery|
223813691|NCT03248609|OTHER|Milano grapes|Milano grapes to test post-prandial glycemic response
223813692|NCT03248609|OTHER|Table grapes|Table grapes to test post-prandial glycemic response
223813693|NCT03248609|OTHER|Grape juice|Grape juice to test post-prandial glycemic response
223813694|NCT03248609|OTHER|Glucose beverage|Standardized glucose beverage to test post-prandial glycemic response
223813695|NCT02766816|BIOLOGICAL|Part 1 study - BBio bOPV|A single dose of 2 drops (0.1 ml) orally of BBio bOPV to 20 children 60 to 83 months of age.
223813696|NCT02766816|BIOLOGICAL|Part 2 study - BBio bOPV Lot 1|Three doses of 2 drops (0.1 ml) orally of BBio bOPV Lot 1 to 270 infants at 6-8, 10-12 and 14-16 weeks of age.
223813697|NCT02766816|BIOLOGICAL|Part 2 study - BBio bOPV Lot 2|Three doses of 2 drops (0.1 ml) orally of BBio bOPV Lot 2 to 270 infants at 6-8, 10-12 and 14-16 weeks of age.
223813698|NCT02766816|BIOLOGICAL|Part 2 study - BBio bOPV Lot 3|Three doses of 2 drops (0.1 ml) orally of BBio bOPV Lot 3 to 270 infants at 6-8, 10-12 and 14-16 weeks of age.
223813699|NCT02766816|BIOLOGICAL|Part 2 study - Licensed bOPV|Three doses of 2 drops (0.1 ml) orally of a licensed bOPV to 270 infants at 6-8, 10-12 and 14-16 weeks of age.
223813700|NCT02766816|BIOLOGICAL|Part 1 study - Licensed bOPV|A single dose of 2 drops (0.1 ml) orally of a licensed bOPV to 20 children 60 to 83 months of age.
223813701|NCT03663764|DRUG|Thymosin a1|All patients received weekly thymosin a1(1.6mg) during and within 2 months after the end of chemoradiotherapy.
223813702|NCT03663764|RADIATION|hypofractionated radiotherapy|HRT using the IMRT technique was administered. For patients with limited pulmonary or pleural metastases (≤3 lesions), stereotactic body radiation therapy (SBRT) could be used.
223813703|NCT03663764|DRUG|concurrent chemoradiotherapy|All patients received weekly docetaxel(25mg/㎡) and nedaplatin or cisplatin (25mg/㎡), each of 1 day's duration, concurrently with hypofractionated radiotherapy .
223813704|NCT01454674|OTHER|2, 5 & 10 Vegetable doses|2,5 \& 10 serving dose/day combination of fresh lettuce mix, baby carrots, red bell peppers \& tomatoes consumed for 3 week intervals
223813705|NCT05537558|DRUG|Antidepressant|Antidepressant (AD) monotherapy or complex psychopharmacology such as two ADs or AD plus augmentation (second generation antipsychotics, mood stabilizers, lithium, FT3/FT4). Combination with diverse types of ongoing psychotherapy will be accepted, if commenced prior to baseline
223813706|NCT02884414|DEVICE|Cutaneous stimulation|A non-invasive external device that will be placed on the leg of the subject. The device consists of a sensing module to determine specific points in the gait cycle, a processor to analyze signal from the sensor, and a stimulus module to provide feedback to the subject.
223813707|NCT03430063|DRUG|SDREGN2810|Standard dose intravenous (IV) infusion
223813708|NCT03430063|DRUG|SDREGN2810/ipi|Combination therapy dose IV
223813709|NCT03430063|DRUG|HDREGN2810|High dose IV
223813710|NCT06281353|DRUG|Curcumin Oral Capsule|Curcumin oral capsule in nano-sized particle.
223813711|NCT06281353|DRUG|Trichloroacetic acid|TCA 90%
223813712|NCT06281353|PROCEDURE|Blood sample collection|HIV and CD4+ 4th generation.
223813713|NCT06281353|PROCEDURE|Cotton swab|Cotton swab for collecting sample from AGW lesions.
223813714|NCT03126864|PROCEDURE|Leukapheresis|After enrollment, steady state leukapheresis performed to collect apheresis material. The goal is to achieve a target total nucleated cell (TNC) yield of at least 5 x 10\^9 (expected range 5 x 10\^8 - 5 x 10\^10), for up to two days.
223813715|NCT03126864|DRUG|Fludarabine|25 mg/m2 administered by vein on Days -5 to -3.
223813716|NCT03126864|DRUG|Cyclophosphamide|900 mg/m2 administered by vein on Day -3.
223813717|NCT03126864|BIOLOGICAL|CD33-CAR-T Cell Infusion|CD33-CAR-T cell infusion administered by vein on Day 0. First group of participants receive the lowest dose level. Each new group will receive a higher dose than the one before it, if no intolerable side effects were seen. This will continue until the highest tolerable dose of T-cells is found. Starting dose level is \> 1.5 x 105/kg but ≤ 4.5 x 105/kg.
223813718|NCT00002093|DRUG|Daunorubicin (liposomal)|
223813719|NCT00002093|DRUG|Bleomycin sulfate|
223813720|NCT00002093|DRUG|Vincristine sulfate|
223813721|NCT00002093|DRUG|Doxorubicin hydrochloride|
223813722|NCT06066281|BEHAVIORAL|Neuropsychological assessment|All participants who will meet the inclusion criteria will be adminstered a pencil-paper neuropsychological tests battery including: the Digit Span Backward Task, the Brief Repeatable Battery of Neuropsychological Tests and the CST. After 15 days from the baseline evaluation the CST will be re-administrated to all subjects.
223813723|NCT02438943|OTHER|Audit|An assessment of medical records using a pre-specified audit instrument to assess the level of care given for clinic attendees with cardiovascular disease including dyslipidemia
223813724|NCT02438943|OTHER|Physician Intervention|Feedback Training sessions for physicians inclusive Motivational Interviewing training and the use of physician reminders on medical records before each clinic session
223813725|NCT02167217|DRUG|Prednisolone|Prednisolone (5mg per kg) will be taken on two consecutive days, Friday and Saturday mornings each week with breakfast
223813726|NCT02775422|BIOLOGICAL|Serological Test s for the Virus Chicken Pox Virus|
223813727|NCT01782872|PROCEDURE|Interscalene Block (ISB) - 0.375% Ropivacaine + additives|Ultrasound-guided single-injection ISB: ropivacaine 0.375% + (clonidine \[100 mcg\] + dexamethasone \[4 mg\] + buprenorphine \[150 mcg\]); Intravenous (IV): saline
223813728|NCT01782872|PROCEDURE|Interscalene Block (ISB) - 0.2% Ropivacaine + additives|Ultrasound-guided single-injection ISB: ropivacaine 0.2% + (clonidine \[100 mcg\] + dexamethasone \[4 mg\] + buprenorphine \[150 mcg\]); Intravenous: saline
223813729|NCT01782872|PROCEDURE|Interscalene Block (ISB) - 0.1% Ropivacaine + additives|Ultrasound-guided single-injection ISB: ropivacaine 0.1% + (clonidine \[100 mcg\] + dexamethasone \[4 mg\] + buprenorphine \[150 mcg\]); Intravenous: saline
223813730|NCT01782872|PROCEDURE|Interscalene Block (ISB) - Systemic Control|Ultrasound-guided single-injection ISB: ropivacaine 0.375%; Intravenous: clonidine (100 mcg) + dexamethasone (4 mg) + buprenorphine (150 mcg)
223813731|NCT00344604|BEHAVIORAL|Role of psychosocial and quality of life parameters prior to and following LASIK.|
223813732|NCT05684562|OTHER|Cardiopulmonary exercise test|CPET, the gold standard, will be used in the assessment of cardiorespiratory fitness. The cardiopulmonary exercise test system (Cosmed Quark CPET, Rome, Italy) is a safe method in which the patient can be monitored via ECG during the execution of the individual on a treadmill, and simultaneously lactate measurement, maximal O2 consumption, and CO2 production are evaluated. The Bruce protocol is the most commonly used method for KPET applied with a treadmill. However, since the Bruce protocol prefers high workload preferences, the Modified Bruce/half Bruce protocol with intermediate increments will be used. In addition, dyspnea, leg fatigue, and general fatigue at rest, during the test, and during the recovery phases after the test will be recorded with a sphygmomanometer using the Modified Borg Scale.
223813733|NCT05684562|OTHER|Pulmonary function test|Pulmonary function testing will be performed with a spirometer (Cosmed Quark CPET, Rome, Italy) connected to the CPET system using standard procedures. Forced vital capacity (FVC), forced expiratory volume in 1 second (FEV1), FEV1/FVC, peak expiratory volume measured at 25% and 75% of forced expiratory time (FEF 25-75%), and peak expiratory volume (PEF) parameters will be saved.
223813734|NCT05684562|OTHER|Respiratory muscle strength test|Intraoral maximum inspiratory pressure (MIP) and maximum expiratory pressure (MEP) will be used as indicators of respiratory muscle strength. A portable intraoral pressure gauge (MicroRPM, Micromedical, Kent, UK) and nose clip will be used during MIP and MEP assessments. MIP and MEP measurements will be obtained using standard procedures. 3 measurements will be made where the difference between each measurement is not more than 10% and the maximum value of MIP and MEP will be recorded.
223813735|NCT02696044|DRUG|triheptanoin|Participants will begin a 2 week dose titration period to achieve study drug treatment comprising of 1-4 grams per kilogram of body weight (g/kg) daily depending on age. The age-related target dose will be mixed with food or formula and administered orally or by gastronomy tube. The total daily dose can be divided into 4 equal doses taken 4 times daily. Participants will maintain the age dependent dose treatment at the 1-4 g/kg daily for four months.
223813736|NCT05763758|OTHER|No intervention|No intervention involved in this study
223813737|NCT03301727|OTHER|Cognitive-Behavioural Therapy for Insomnia (CBT-I)|Cognitive-Behavioural Therapy for Insomnia (CBT-I) is an evidence-based psycho-therapeutic intervention, combining cognitive and behavioural principles to provide psycho-education concerning contributing thoughts to sleep problem maintenance, and behavioural technique instruction to reduce sleep onset latency and promote effective sleep maintenance.
223813738|NCT04570995|DIETARY_SUPPLEMENT|Fish Oil|Dietary supplement containing fish oil, encapsulated in soft gel capsules, given 5 days per week
223813739|NCT04570995|DIETARY_SUPPLEMENT|Safflower Oil|Dietary supplement containing a placebo oil product (safflower oil), encapsulated in soft gel capsules, given 5 days per week
223813740|NCT02074046|BIOLOGICAL|cancer stem cell vaccine|
223813741|NCT04929093|BIOLOGICAL|Novel dose adjustment of Alutard SQ|novel dose adjustment schedule means directly reaching dose of Vial 4, 10,000 SQ
223813742|NCT04929093|BIOLOGICAL|conventional dose adjustment of Alutard SQ|conventional dose adjustment schedule means restarting from dose of Vial 1, 10 SQ
223813743|NCT04929093|BIOLOGICAL|Routine continuous cluster of Alutard SQ|Patient receiving continuous cluster SCIT for DM during the same period
223813744|NCT02475317|DRUG|Placebo|Participants will receive placebo matched to maralixibat/volixibat orally for 7 days.
223813745|NCT02475317|DRUG|Maralixibat|Participants will receive maralixibat in 10 mg, 20 mg, 50 mg or 100 mg doses.
223813746|NCT02475317|DRUG|Volixibat|Participants will receive volixibat in 10 mg and 20 mg doses.
223813747|NCT02607657|DRUG|Eplerenone 25 mg|
223813748|NCT02607657|DRUG|Eplerenone 50 mg|
223813749|NCT02607657|DRUG|Eplerenone 100 mg|
223813750|NCT02607657|DRUG|Eplerenone 50 mg twice a day|
223813751|NCT02607657|DRUG|Eplerenone 25 mg twice a day|
223813752|NCT02302131|OTHER|SAPIEN XT|Patients that have undergone percutaneous implantation of an Edwards SAPIEN XT Transcatheter Heart Valve in the pulmonic position at the time of data collection
223813753|NCT03575533|DIAGNOSTIC_TEST|Bayesian network 'Sherlock'|Primary objective is to validate the Bayesian Hemodynamics model 'Sherlock'. Criterion for validation is a match between Sherlock's estimate of the Hemodynamic status of a patient and a ground truth based on a cardiologist's judgement.
223813754|NCT00004902|DRUG|tocladesine|
223813755|NCT00214825|DRUG|eplerenone|50 mg daily for 6 weeks with placebo
223813756|NCT00214825|DRUG|Hydrochlorothiazide|HCTZ 12.5 mg with potassium (10 mEq) daily for 6 weeks
223813757|NCT00361101|DRUG|AMD11070|200 mg PO BID (by mouth two times per day) for 10 days.
223813758|NCT04397484|DRUG|0.5% Levobupivacaine|The plane where the sciatic nerve bifurcates will at first be identified by utlrasound. 22-gauge insulated nerve block needle will be inserted in the short axis (out-of-plane) of the ultrasound transducer, and advanced toward the cleavage between the common peroneal nerve and the tibial nerve, which is the easiest location for needle access into subparaneural compartment.Once the needle tip enters the subparaneural compartment 2-3 ml of normal saline will be injected (hydro-distension) to create a halo around both the common peroneal nerve and tibial nerve distally and the sciatic nerve proximally. The needle is then redirected to place its tip into the paraneural sheath of the common peroneal and tibial nerve through the same skin puncture and 15ml of study drug will be injected at each site (total 30ml).
223813759|NCT04397484|DRUG|2% Xylocaine with adrenaline 1:200,000|The plane where the sciatic nerve bifurcates will at first be identified by utlrasound. 22-gauge insulated nerve block needle will be inserted in the short axis (out-of-plane) of the ultrasound transducer, and advanced toward the cleavage between the common peroneal nerve and the tibial nerve, which is the easiest location for needle access into subparaneural compartment.Once the needle tip enters the subparaneural compartment 2-3 ml of normal saline will be injected (hydro-distension) to create a halo around both the common peroneal nerve and tibial nerve distally and the sciatic nerve proximally. The needle is then redirected to place its tip into the paraneural sheath of the common peroneal and tibial nerve through the same skin puncture and 15ml of study drug will be injected at each site (total 30ml).
223813760|NCT02442635|BEHAVIORAL|Yoga|Yoga breathing and postures; After this initial 3 arm experiment, yoga breathing and postures will be studied in combination.
223813761|NCT04343586|DEVICE|Blue light phototherapy|Phototherapy- Wavelength: 417±15 nm
223813762|NCT04268901|DEVICE|Samsung Gear VR|Participants 13 -21 years old can use the Samsung Gear VR. The VE to be used in this study is mobile based (Samsung with the Gear VR) and has active matrix LCDs with high pixel resolution, creating a bright, vibrant color and a quality image. The VR game is equipped with a head-tracking system, enabling the player to look around the virtual environment. In addition, there is the option to interact with the VR environment using a tap pad located on the side of the helmet. Therefore, the child will be receiving distraction via 3-D visual and auditory sensory, and tactile feedback, thus supplying a multi-sensory immersive experience. While wearing these glasses, the children only can see the HMD screen so that the immersion and presence will be increased. The VR glasses will be sanitized before every use so that the chance of infection will be minimized.
223813763|NCT04268901|DEVICE|Merge VR|Participants 10-21 years can use the Merge. The VE to be used in this study is mobile based (Pixel with the Merge) and has active matrix LCDs with high pixel resolution, creating a bright, vibrant color and a quality image. The VR game is equipped with a head-tracking system, enabling the player to look around the virtual environment. In addition, there is the option to interact with the VR environment using a tap pad located on the side of the helmet. Therefore, the child will be receiving distraction via 3-D visual and auditory sensory, and tactile feedback, thus supplying a multi-sensory immersive experience. While wearing these glasses, the children only can see the HMD screen so that the immersion and presence will be increased. The VR glasses will be sanitized before every use so that the chance of infection will be minimized.
223813764|NCT04268901|DEVICE|Oculus Go|Participants 7-21 years can use the Oculus Go. The visual a bright, vibrant color and a quality image. The VR game is equipped with a head-tracking system, enabling the player to look around the virtual environment. In addition, there is the option to interact with the VR environment using a handheld remote. Therefore, the child will be receiving distraction via 3-D visual and auditory sensory, and tactile feedback, thus supplying a multi-sensory immersive experience. While wearing these glasses, the children only can see the HMD screen so that the immersion and presence will be increased. The VR glasses will be sanitized before every use so that the chance of infection will be minimized.
223813765|NCT01005303|DRUG|Placebo|1 Tablet Daily
223813766|NCT01005303|DRUG|Forceval plus 50 micrograms Vitamin D3|Forceval: 1 Tablet Daily; Vitamin D3: 2 Tablets Daily
223813767|NCT04026165|DRUG|SEL|Tablet administered orally once daily
223813768|NCT04026165|DRUG|Placebo|Tablet administered orally once daily
223813769|NCT03552302|BEHAVIORAL|Yoga|"1. Yoga stretch warm-up exercise for 15 minutes.~2. Five kinds of yoga correction method for 30 minutes (abdominal breathing, throat breathing, wind box breathing, nasal alternating breathing, buzzing breathing).~3. Great rest for 15 minutes"
223813770|NCT05897801|DIAGNOSTIC_TEST|MeMed BV®|One blood sampling of 3ml will be drawn on the first day for the performance of the MeMed BV® test. Two rectal swabs will be taken for determining the MDRO gut colonization. Patient information regarding the specific respiratory tract infection and the treatment regimen being prescribed will be recorded in the eCRF made specifically for this trial.
223813771|NCT05007145|DRUG|PD-1 inhibitor|PD-1 Inhibitor 200mg D1 Q3W
223813772|NCT05007145|DRUG|Albumin-Bound Paclitaxel|125 mg/m\^2 D1/D8 Q3W
223813773|NCT05007145|DRUG|Cisplatin|75 mg/m\^2 D1 Q3W
223813774|NCT05007145|RADIATION|Radiation|40Gy/2.0Gy
223813775|NCT00236171|DRUG|Protopic, Advantan|
223813776|NCT00236171|PROCEDURE|Blood and Urine Test|
223813777|NCT00236171|PROCEDURE|coherence tomography|
223813778|NCT02849275|OTHER|Lactose Free 1% Milk|isocaloric study treatment containing lactose free 1% milk consumed once daily over 4-5 weeks as a control.
223813779|NCT02849275|OTHER|Probiotic Treatment|Probiotic treatment, consumed once daily, over 4-5 weeks.
223813780|NCT00853164|BEHAVIORAL|walking exercise|Subjects will be given an exercise prescription for walking 3 times a week for eight weeks
223813781|NCT00853164|BEHAVIORAL|weight training|participants will be given a weight training prescription to do 3 times a week for eight weeks.
223813782|NCT00853164|BEHAVIORAL|Usual Care|Subjects in this arm will continue with their usual care and not start any exercise program for eight weeks.
223813783|NCT04845724|OTHER|Standard Diet|
223813784|NCT04845724|OTHER|Modified Diet|
223813785|NCT04315532|OTHER|Non-surgical periodontal treatment|Non-surgical periodontal treatment was performed for pregnant and non-pregnant gingivitis patients. Gingival crevicular fluid (GCF) and saliva samples were taken from all patients baseline and after 8 weeks.
223813786|NCT04315532|OTHER|Saliva samples|Saliva samples were taken from patients for the evaluation of sex steroid and stress markers baseline and after 8 weeks.
223813787|NCT04315532|OTHER|GCF samples|GCF samples were taken from patients for the evaluation of stress markers baseline and after 8 weeks.
223813788|NCT02698540|OTHER|Nutritional Supplement|High calorie, high protein peptide based
223813789|NCT00441701|DRUG|Navarixin 1 mg|Navarixin 1 mg capsules
223813790|NCT00441701|DRUG|Navarixin 10 mg|Navarixin 10 mg capsules
223813791|NCT00441701|DRUG|Placebo to match navarixin|Placebo to navarixin capsules
223813792|NCT00441701|DRUG|Rescue medication|Salbutamol/albuterol - 2 puffs of salbutamol/albuterol approximately every 4 hours as needed for dyspnea relief
223813793|NCT00077064|DRUG|captopril|Captopril 12.5 mg t.i.d. for first two weeks, increased to 25 mg t.i.d. for the second two weeks of therapy. Thereafter, the dose will be increased to 50 mg t.i.d. for the remainder of the one-year of therapy (52 total weeks of drug administration).
223813794|NCT05279625|DEVICE|exercise training|using either elastic band, dumbbells, treadmill, cycling, machines for 6 months
223813795|NCT03112941|PROCEDURE|control group|Patients with traumatic incomplete spinal cord injury (SCI) in the control group are treated with pedicle screw fixation and decompressive laminectomy.
223813796|NCT03112941|OTHER|hyperbaric oxygen group|Patients with traumatic incomplete spinal cord injury (SCI) in the hyperbaric oxygen group are treated with pedicle screw fixation and decompressive laminectomy, and are given 0.2 MPa hyperbaric oxygen (HBO), once a day, 10 times as a course, with 5-7 days of resting between two courses, totally four courses.
223813797|NCT03987425|DEVICE|CPAP treatment|In this group of patients (CPAP group) will be prescribed CPAP treatment at optimal pressure. It will be performed a CPAP titration with an automatic or manual CPAP according to usual clinical practice.
223813798|NCT01555190|DRUG|myo-inositol 1500 gr|
223813799|NCT01555190|DRUG|myo-inositol 2000 gr + folic acid 200 mcg|
223813800|NCT04710927|DEVICE|Silver Diamine Fluoride|A single application of SDF 38% (Riva Star) on dry affected molar for 1 minute and immediately restored using HVGIC
223813801|NCT04710927|DEVICE|Papain-Based Gel|Papain based Gel (Papacare Duo) will be applied to the MIH affected molar for 60 seconds and repeated if required. The molar will be treated with SDF and restored using HVGIC
223813802|NCT04710927|DEVICE|High Viscosity Glass Ionomer Cement (HVGIC)|The molar will be restored with HVGIC
223813803|NCT00258999|DEVICE|Skin Cholesterol Testing|
223813804|NCT05867719|OTHER|Hypoxic breathing conditions|Participants will undergo three separate hypoxic conditions, along with a normoxic condition, simulating 8,000 foot elevation, 12,0000 foot elevation, and a ramp condition starting at 8,000 feet and then ascending to 12,000 feet.
223813805|NCT03328000|RADIATION|CTU and MR urethrography|computed tomographic and Magnetic Resonance Urethrography.
223813806|NCT00621543|DEVICE|IUD insertion [Copper T-380A or Levonorgestrel (intrauterine system) IUS]|When a subject has chosen a method of intra-uterine contraception and has agreed to participate in the study, she will have the intra-uterine device of her choice inserted according to the Food and Druga Administration (FDA) instructions.
223813807|NCT01702441|DRUG|Subcutaneous AKB-9778|
223813808|NCT03651102|DRUG|Thalidomide and Hydroxyurea|Dosage: Thalidomide 1-4mg/kg/day, Hydroxyurea 10-20mg/kg/day
223813809|NCT03359070|DRUG|Dapaconazole|Application of 1 gram on the lesion.
223813810|NCT03359070|DRUG|Miconazole Nitrate|Application of 1 gram on the lesion.
223813811|NCT03155932|DRUG|APD334|APD334 active treatment for 24 weeks.
223813812|NCT05012475|BEHAVIORAL|Modified Virtual Reality Gaming|Investigators customize each gaming session based on the motivators and interests of each participant. The intervention facilitates independent hand separations (minimizing stereotypies) and encourages independent arm/hand movement that serves to activate or control the computer-generated activities.
223813813|NCT01578148|PROCEDURE|Noxipoint Therapy|"Patients will be treated with a TENS device, following Noxipoint Therapy guidelines:~1. Find the cause of the pain via Noxipoint: For each injured muscle/tissue, it is discovered that there are always a pair of points at the skin surface locations of its nociceptors that are painful at light press (named Noxipoints).~2. Stimulate the corresponding pair of Nocipoints following a narrowly defined combination of intensity/ frequency (inducing the C-fiber response) and duration (about 1.5-3 minutes) of TENS at the two targeted Noxipoints.~3. Repeat (a) to (b) above for each identified injured muscle group until all pain areas are eliminated or when the session time is up.~4. Instruct the subject not to use the newly recovered muscle/tissue too much an estimated rest period depending on his/her age."
223813814|NCT01578148|PROCEDURE|Physical Therapy|"The 1.5-hour physical therapy in the control arm are provided both as standard of care and sham device comparison to Nocipoint Therapy, following these guidelines:~1. TENS stimulation (45 minutes):~   • Electrodes will be placed around the patient-identified general pain area on the neck /shoulder for TENS. Rotate the electrode pads around the pain area and stimulate again.~2. Other modalities of PT per the therapist's choice:~   * Infrared treatment on the pain areas (about 15 minutes)~  * Manual therapy to cervical and/or rotator cuff areas (about 15 minutes).~  * Exercise and training:~     * Neck exercises: Range of motion exercises to include foraminal opening for about 15 minutes, and/or~    * Shoulder exercise: Range of motion exercises to include walking the arm on the wall, rotation of the upper arm for about 15 minutes~  * Hot/cold pack to the pain area for about 15 minutes"
223813815|NCT00737425|DEVICE|PainShield|
223813816|NCT00737425|DEVICE|Sham PainShield|
223813817|NCT05670483|DEVICE|Use Of APRV mode of Ventilation|"Post operatively, Patients will be ventilated with APRV mode using GE Carescape R860 ventilator Initial Settings15~1. P high at the P plateau (or desired P mean + 3cm H2O). keep P high below 30-35 cm H2O~2. T high at 4-6 seconds~3. P low at 0~4. T low at 0.5 to 0.8 seconds.~5. ATC (automatic tube compensation) on.~6. FIO2: 40% Ventilator settings will be adjusted to keep Pco2 between 35-45 mmhg, PO2 \> 60 mmhg on FIO2 \< 50 % Once Patients are fully conscious and after complete recovery of reflexes with no postoperative bleeding nor hemodynamic instability, weaning of APRV will start as following, P-High will be lowered 2 or 3 cm of H2O pressure at a time, and T Low will be lengthened in 0.5-2.0 s increments, depending on patient tolerance. When the P-high reaches 10 cmH2O and the Thigh reaches 12-15 seconds, change the mode to pressure support (PS) mode PS of 7-8 cmH20 above PEEP of cmh2o then extubation."
223813818|NCT05670483|DEVICE|Use of conventional Synchronized Intermittent Mandatory Ventilation (SIMV) volume control mode|"Post-operatively, Patients will be ventilated with conventional Synchronized Intermittent Mandatory Ventilation (SIMV) volume control mode using GE Carescape R860 ventilator Initial Settings: 16~1. Tidal Volume 6-8 ml/kg predicted body weight~2. Respiratory rate (RR) 14 /min~3. Positive end expiratory pressure (PEEP)= 5 cmH2o~4. Pressure Support (PS) = 10 cmH2o~5. Inspiratory time 1.4 Sec~6. FIO2: 40% Ventilator settings will be adjusted to keep Pco2 between 35-45 mmhg, PO2 \> 60 mmhg on FIO2 \< 50 % Once Patients are fully conscious and after complete recovery of reflexes with no postoperative bleeding nor hemodynamic instability, weaning of mechanical ventilation will be done by switching the ventilation to pressure support (PS) mode PS of 7-8 cmH20 above PEEP of cmh2o then extubation."
223813819|NCT05137379|BEHAVIORAL|A joint functional score based on the affected joint|A joint function score according to the affected joint in patients with Ehlers-Danlos syndrome treated by surgery,: Shoulder (SSV; QuickDash), Knee (Lysholm tenger), Ankle (EFAS), Elbow and wrist (QuickDash) )
223813820|NCT00730379|DRUG|Comparator: ridaforolimus + dalotuzumab|Starting dose of oral ridaforolimus is 10 mg/day, QD, for five days. Dose rising up to 40 mg/day, QD for five days. Dose range for intravenous dalotuzumab is 7.5 mg/kg/week, 10 mg/kg/week or 7.5 mg/kg/every 14 days. Dalotuzumab will be given as an IV infusion over 1 or 2 hour(s).
223813821|NCT00519701|DRUG|hydroxyurea|
223813822|NCT04285632|OTHER|Plyometrics exercises|"Counter Movement Jump exercise. The subject will be placed in an upright standing position, with his hands on his hip. It will perform a rapid downward movement in which it will flex the hips and knees and, immediately, a rapid extension of the legs that will result in the maximum vertical jump. During the flight phase the subject will keep the legs straight. The landing will be done with both feet at the same time. The intervention will be carried out for 300 seconds, in 2 series of 30 jumps each and with 3 minutes of rest between series.~Drop Jump exercise. The players will be placed on a step, standing and with their feet shoulder-width apart. They will drop forward, landing with both feet at the same time. Upon touching the ground they will perform a maximum vertical jump. The intervention will be carried out for 600 seconds, in 2 series of 25 jumps each, and with 3 minutes of rest between series."
223813823|NCT04135157|PROCEDURE|Pectoralis nerve block II|PECS II block will be performed 30 min. before general anesthesia.
223813824|NCT04135157|PROCEDURE|Erector spine plane block|ESP block will be performed 30 minutes before general anesthesia.
223813825|NCT04135157|OTHER|Control|Only general anesthesia will be performed.
223813826|NCT02007434|DRUG|Deoxycholic Acid Injection|Formulated as an injectable solution containing deoxycholic acid at a concentration of 10 mg/mL.
223813827|NCT02007434|DRUG|Placebo|Phosphate buffered saline placebo for injection
223813828|NCT02007434|OTHER|Cold Compress|A cold compress was applied to the injection area for 10 minutes before dosing and for 15 minutes after dosing.
223813829|NCT02007434|DRUG|Lidocaine / Epinephrine|Lidocaine 4% topical cream applied 45 minutes prior to dosing across the area to be treated, followed by 0.4 mL SC injections of lidocaine HCl 1% / epinephrine 1:100,000 around the perimeter of the treatment area and across the treatment area in a regular pattern 25 minutes before dosing.
223813830|NCT02007434|DRUG|Loratadine|Loratadine 10 mg orally from Day -7 until Day 7
223813831|NCT02007434|DRUG|Ibuprofen|Ibuprofen 600 mg at least 1 hour prior to dosing and 600 mg 3 times a day for at least 3 days after dosing.
223813832|NCT02007434|OTHER|Compression Chin Strap|A compression chin strap was applied 15 minutes after dosing for at least 24 hours.
223813833|NCT05943769|PROCEDURE|Apical microsurgery|inoculation of the periapical or the periradicular lesion with the sectioning of the apical 3mm of the root followed by root-end cavity preparation and retro-filling with the MTA or TotalFill with or without composite bone grafting according to patient allocation.
223813834|NCT03649620|DIETARY_SUPPLEMENT|unripe Bokbunja Extract|tablet(1 tablet/d, 600 mg/d) for 12 weeks
223813835|NCT03649620|DIETARY_SUPPLEMENT|Placebo|Placebo for 12 weeks
223813836|NCT01287611|PROCEDURE|Purse string closure technique|Uterine Kerr incision will be closed with purse string suture
223813837|NCT01287611|PROCEDURE|Continuously locked closure technique|Uterine Kerr incision will be closed with continuously locked suturing
223813838|NCT06274684|DEVICE|Use of Virtual Reality Assistance during prostate biopsies|Patient will be equipped with VR headset providing a immersive experience during prostate biopsies
223813839|NCT03076476|DEVICE|Bioresorbable Vascular Scaffolds (BVS)|Bioresorbable Vascular Scaffold. Introduced after the interim analysis (phase 2) for comparison with DES-slow.
223813840|NCT03076476|DEVICE|Drug-Eluting Stent (DES) - slow|"Slow device inflation (mandated in the BVS IFU). To be compared with the DES-std group at interim analysis at the end of phase 1 stage.~After the interim analysis DES-slow to be compared with BVS."
223813841|NCT03076476|DEVICE|Drug-Eluting Stent (DES) - standard(std)|Metallic DES implanted in standard fashion. To be compared with the DES-slow group at interim analysis at the end of phase 1 stage.
223813842|NCT05492526|DEVICE|Ki Monitor without feedback|Physical activity Monitor - No feedback
223813843|NCT05492526|DEVICE|Ki monitor with contextualised data feedback|Physical activity monitor and feedback
223813844|NCT00732186|BIOLOGICAL|Ipilimumab|IV Solution, IV, 10 mg/kg, (if dose reduction necessary at 3 mg/kg), Every three weeks for the first 10 weeks, with a booster at week 22, Up to 38 weeks depending on response
223813845|NCT01321541|DRUG|Pixantrone + Rituximab|Pixantrone + Rituximab: Rituximab 375 mg/m2 IV on day 1 and pixantrone 50 mg/m2 (equivalent to 85mg/m2 pixantrone dimaleate)IV on days 1, 8, and 15. Regimen is given in 28-day cycles. Up to 6 cycles may be administered.
223813846|NCT01321541|DRUG|Gemcitabine + Rituximab|Gemcitabine + Rituximab: Rituximab 375 mg/m2 IV on day 1 and gemcitabine 1000 mg/m2 IV on days 1, 8, and 15. Regimen is given in 28-day cycles. Up to 6 cycles may be administered.
223813847|NCT02192970|DRUG|Bevacizumab|
223813848|NCT04074590|DRUG|LYS006|capsule for oral use
223813849|NCT04074590|DRUG|Placebo|capsule for oral use
223813850|NCT01417052|DRUG|50 mg LX3305 QD|50 mg LX3305 once daily in capsule form
223813851|NCT01417052|DRUG|100 mg LX3305 QD|100 mg LX3305 once daily in capsule form
223813852|NCT01417052|DRUG|150 mg LX3305 QD|150 mg LX3305 once daily in capsule form
223813853|NCT01417052|DRUG|200 mg LX3305 QD|200 mg LX3305 once daily in capsule form
223813854|NCT01417052|DRUG|250 mg LX3305 QD|250 mg LX3305 once daily in capsule form
223813855|NCT01417052|DRUG|300 mg LX3305 QD|300 mg LX3305 once daily in capsule form
223813856|NCT01417052|DRUG|400 mg LX3305 QD|400 mg LX3305 once daily in capsule form
223813857|NCT01417052|DRUG|250 mg LX3305 BID|250 mg LX3305 twice daily in capsule form
223813858|NCT01417052|DRUG|500 mg LX3305 QD|500 mg LX3305 once daily in capsule form
223813859|NCT01417052|DRUG|Placebo|Matching placebo dosing in capsule form
223813860|NCT03975699|OTHER|Assessment of psychological repercussions of SCD|Quantitative relevant data culled from medical files and qualitative analysis based on data gathered from child and parent interviews, were collected in the three hospitals.
223813861|NCT05578950|DRUG|itraconazole|100 mg two capsules of itraconazole were givev twice daily to 50 patients in group A for one week per month . baseline LFTs were also monitered
223813862|NCT05578950|DRUG|terbinafine|one 250 mg tablet of terbinafine were given once daily to 50 patients in group B for 12 weeks continously
223813863|NCT02541032|PROCEDURE|Intensive dental treatment|Up to five sessions of full-mouth removal of subgingival dental plaque by the use of scaling and root planning under local anesthesia. Any hopeless teeth will be extracted during this treatment period, which will be as short as possible, but will extend to no more than 4 weeks. In addition to standard scaling and root planning, the investigators seek to better suppress the oral biofilm by administering Arestin locally into the periodontal pockets ≥6 mm.
223813864|NCT02541032|PROCEDURE|Standard dental treatment|Supragingival mechanical scaling and polishing.
223813865|NCT02541032|DRUG|Arestin|To better suppress the oral biofilm by administering Arestin locally into the periodontal pockets ≥6 mm.
223813866|NCT02504125|DRUG|Tranexamic Acid|1 g of tranexamic acid in 100 mL of normal saline intravenously approximately 15 minutes before incision
223813867|NCT02504125|DRUG|Normal saline|100 mL of normal saline intravenously approximately 15 minutes before incision
223813868|NCT00213655|BIOLOGICAL|bladder tumor recurrence|bladder tumor recurrence assessed by clinical and biological exams
223813869|NCT04939545|DRUG|Ropivacain|"Intercostal continuous loco-regional ropivacaine (2 mg/ml) administration over an elastomeric pump through a surgically placed intercostal catheter (ICC) for a maximum of 72h.~As concomitant treatments a standardized anesthesia protocol including intravenous continuous application of propofol and remifentanil is used. Additionally, i.v. metamizol at a dose of 1 g will be administered at the end of surgery as a standard, if not contraindicated.~In a standardized postoperative pain protocol the use of basic oral medication is documented as part of the postoperative follow-up and consists of:~ibuprofen 3 x 400 mg p. o. for 3 days, metamizol 4 x 1 g p. o. for 3 days; if ibuprofen and/or metamizol contraindicated then paracetamol p. o. 3 x 1g for 3 days will be administered; morphine 10 mg p. o. 6 times daily will be given on a patient demand basis."
223813870|NCT04939545|DRUG|NaCl 0.9%|"Intercostal continuous loco-regional placebo solution (NaCl 0,9%) administration over an elastomeric pump through a surgically placed intercostal catheter (ICC) for a maximum of 72h. As concomitant treatments a standardized anesthesia protocol including intravenous continuous application of propofol and remifentanil is used. Additionally, i.v. metamizol at a dose of 1 g will be administered at the end of surgery as a standard, if not contraindicated.~In a standardized postoperative pain protocol the use of basic oral medication is documented as part of the postoperative follow-up and consists of:~ibuprofen 3 x 400 mg p. o. for 3 days, metamizol 4 x 1 g p. o. for 3 days; if ibuprofen and/or metamizol contraindicated then paracetamol p. o. 3 x 1g for 3 days will be administered; morphine 10 mg p. o. 6 times daily will be given on a patient demand basis."
223813871|NCT04923555|BEHAVIORAL|Vegetable proteins (VP) rich in leucine, cystein, arginine|33 volunteers will consume 400 ml of yogurt with vegetable proteins (VP) rich in leucine, cystein and arginine only once during the visit. At the beginning and the end of the intervention, exploration will be conducted at fasted state and at post-prandial state after the administration of vegetable proteins.
223813872|NCT04923555|BEHAVIORAL|Animal proteins (AP)|33 volunteers will consume 400 ml of yogurt with animal proteins (AP) rich in leucine, cystein and arginine only once during the visit. At the beginning and the end of the intervention, exploration will be conducted at fasted state and at post-prandial state after the administration of animal proteins.
223813873|NCT04923555|BEHAVIORAL|No protein (T)|33 volunteers will consume 400 ml of yogurt without any protein (T) rich in leucine, cystein and arginine only once during the visit. At the beginning and the end of the intervention, exploration will be conducted at fasted state and at post-prandial state after the administration of animal proteins.
223813874|NCT03389360|DIAGNOSTIC_TEST|procalcitonin|assessing the frequency of rising procalcitonin associated with infectious complications in immunosuppressed LDLTRx.
223813875|NCT01770210|DRUG|Patients on atorvastatin treatment|Statins Therapy
223813876|NCT02723058|BEHAVIORAL|ICMHM|ICMHM participants receive a collaborative care model adapted to include an engagement interview, attention to co-morbid conditions, and attention to basic needs.
223813877|NCT00681616|DEVICE|Compartment Monitoring System (CMS)|The CMS consists of an Introducer, Pressure Measurement \& Fluid Collection (PMFC) catheter, a Fluid Collection (FC) catheter and Compartment Pressure Monitor. The PMFC catheter removes fluid and monitors pressure via a solid-state fiber optic transducer at the tip of the catheter. The FC catheter only removes fluid and does not have a pressure transducer at the tip. The CMS Monitor senses, displays and records compartment pressure as measured by up to two PMFC catheters. In addition, the CMS Monitor measures subject blood pressure using a provided cuff for calculating the perfusion pressure of the muscle compartment.
223813878|NCT00681616|DEVICE|Compartment Monitoring System with Active Fluid Removal|Compartment Monitoring System with Active Fluid Removal
223813879|NCT00681616|DEVICE|Compartment Monitoring System without fluid removal|Compartment Monitoring System without fluid removal
223813880|NCT00035035|DRUG|GEMZAR|
223813881|NCT00035035|DRUG|ALIMTA|
223813882|NCT04449848|OTHER|Sitting after intra tympanic injection|Sitting after intra tympanic injection
223813883|NCT02656576|PROCEDURE|Tonsil Biopsy|Biopsies were obtained during endoscopy of Aero-Digestive Tract Superior under general anesthesia.
223813884|NCT02656576|PROCEDURE|Smear|The smears are made in consultation a fortnight before performing endoscopic examination. They are carried out after a local anesthetic spray in order to optimize the number of cells collected.
223813885|NCT06097676|DRUG|Placebo|Placebo
223813886|NCT06097676|DRUG|Alprazolam 2 mg|Oral dose of alprazolam 2 mg
223813887|NCT06097676|DRUG|Gabapentin Enacarbil Immediate Release (GE-IR) 200 mg|Oral dose of GE-IR 200 mg
223813888|NCT06097676|DRUG|Gabapentin Enacarbil Immediate Release (GE-IR) 450 mg|Oral dose of GE-IR 450 mg
223813889|NCT06097676|DRUG|Gabapentin Enacarbil Immediate Release (GE-IR) 700 mg|Oral dose of GE-IR 700 mg
223813890|NCT02525003|DIETARY_SUPPLEMENT|Vitamin D2|Experimental group 2: daily vitamin D2 supplement 25ug/d for 8 weeks
223813891|NCT02525003|DIETARY_SUPPLEMENT|Vitamin D3|Experimental group 3: daily vitamin D3 supplement 25ug/d for 8 weeks
223813892|NCT02525003|OTHER|Vitamin D2 fortified bread|Experimental group 4: vitamin D2 fortified bread containing 25 µg of vitamin D2/d (bread dose 87g/d) and placebo pill for 8 weeks
223813893|NCT03223532|DEVICE|PrePex Day 7 FRP|Standard PrePex procedure, foreskin and device are removed 1 week after device application.
223813894|NCT03223532|DEVICE|PrePex Day 0 FRP|Removal of the foreskin shortly after device application, the device is removed 1 week later
223813895|NCT03708640|OTHER|Digital Activity Tracker|Group wears physical activity tracker and receives physical activity feedback information informed by the tracker
223813896|NCT03708640|OTHER|Smart Text Messaging|"Group receives personalized, health coaching via smart text messages"
223813897|NCT03708640|OTHER|Physical Activity Counseling|Group receives baseline counseling on physical activity
223813898|NCT06151990|OTHER|lipid profile|Measurements for CHOL,TG,LDL-C and HDL-C obtained following an overnight fasting
223813899|NCT06350929|OTHER|Cardiac output monitoring by the Starling™ SV Sebac®|"During the surgery, the channels and monitoring equipment will be set up according to the usual procedure in the vascular surgery department. As part of the research, the Starling™ SV Sebac® electrodes will be installed (to measure cardiac flow, cardiac index (CI), stroke volume (VES), variations in stroke volume (VVES), and peripheral resistors (TPRI)).~Once the equipment is in place, anesthetic induction will be carried out according to the usual protocol with curarization and mechanical ventilation.~If the appearance of arterial hypotension is noted after anesthetic induction and mechanical ventilation, the patient will be definitively included in the study. As recommended, he will receive norepinephrine to treat hypotension.~The measurements from the monitoring will be collected at 3, 5, and 10 min after the administration of norepinephrine.~10 days after admission to the operating room, hospitalization data will be collected."
223813900|NCT04013100|DIAGNOSTIC_TEST|3D-VNE (virtual neck exploration)|The 3D-VNE model is obtained with VP Planning software (Visible Patient, Strasbourg, France), using DICOM (Digital Imaging and Communications in Medicine) images of contrasted Computed Tomography scan of the neck in operative positioning.
223813901|NCT02480595|DEVICE|Stent Graft|Endovascular repair of abdominal aortic aneurysm (EVAR)
223813902|NCT03745222|DRUG|Tislelizumab|PD-1 inhibitor (monoclonal antibody against PD-1)
223813903|NCT03745222|DRUG|Concurrent chemoradiotherapy (cCRT)|Chemotherapy options include carboplatin/paclitaxel and cisplatin/etoposide per standard of care. Radiotherapy will also be given concurrently with chemotherapy.
223813904|NCT03745222|OTHER|Placebo|Placebo
223813905|NCT06259643|OTHER|Power wheelchair soccer|Participants will practice power wheelchair soccer during the course of the power wheelchair soccer season (starting in November 2023 and ending in June 2024). Sessions are given once a week, by a coach with experience in this adaptive sport.
223813906|NCT03299686|DRUG|CJM112|300 mg CJM112 (Study treatment) s.c. injection received per week for the first 4 weeks, followed by once every two weeks up to Week 12 (Day 85) + standard of care treatment.
223813907|NCT03299686|OTHER|Placebo to CJM112|Placebo to match CJM112 + standard of care treatment
223813908|NCT02573025|DRUG|PEG-IFN alfa-2a BA-free formulation (Test)|Participants will receive single injection of 180 micrograms (mcg) of PEG-IFN alfa-2a BA-free formulation, subcutaneously via prefilled syringe in either period 1 and 2 (each period having 35 days).
223813909|NCT02573025|DRUG|PEG-IFN alfa-2a market formulation (Reference)|Participants will receive single injection of 180 mcg of PEG-IFN alfa-2a market formulation, subcutaneously via prefilled syringe in either period 1 and 2 (each period having 35 days).
223813910|NCT02709005|DRUG|5% Monolaurin Vaginal Gel|Monolaurin Vaginal Gel is a clear and colorless, non-sterile glycol-based gel for vaginal administration , and commonly referred to as glycerol monolaurate (GML). Each subject will receive intravaginal gel twice daily for three successive days for a total of 6 doses. There will be 3 clinic visits over 30 days.
223813911|NCT02709005|OTHER|Placebo|The placebo gel is a clear to opaque, colorless to light gray, non-sterile glycol-based gel for vaginal administration. The placebo gel contains the same excipients as the Monolaurin vaginal gel. Each subject will receive intravaginal gel twice daily for three successive days for a total of 6 doses. There will be 3 clinic visits over 30 days.
223813912|NCT04797091|OTHER|Retrospective data collection|Retrospective data collection to overcome the lack of knowledge on epidemiology, clinical course including diagnostic and therapeutic approaches and prognostic factors for SARS-CoV-2-infections and their complications among nephrology and elderly patients, as well as to serve as a platform for future studies and outbreak situations.
223813913|NCT06346314|OTHER|Scapular retraction exercise|Participant lies prone with hands superior to the head on a treatment plinth and lifts their elbows 10 repetitions for three sets with 30 seconds of rest between each set.
223813914|NCT03291886|DRUG|Entinostat|Given PO
223813915|NCT03291886|DRUG|Entinostat(Placebo)|Given PO
223813916|NCT03291886|DRUG|Exemestane|Given PO
223813917|NCT05240430|DRUG|Mesenchymal Stem Cell Antigen-1, Human|Human umbilical cord-derived MSCs were used in the study. MSCs were prepared/obtained/produced/provided by Atigen-Cell Technology Center, Trabzon, Turkey. MSC for patients was calculated as a single dose, 1x106 cells per kilogram. MSC was infused in 100 ml of normal saline at 2 ml/min over 40 min, as described in previous studies
223813918|NCT05834114|OTHER|Mckenzie protocol|"In this group 20 participants will receive McKenzie protocol with conventional physical therapy. Participants will be asked to sit to treat extension deficit. The participant will be in a comfortable sitting position with a proper back support. Head is kept in forward facing without any up and done movement (10 to 15 times). Then, he restored the neutral sitting posture, and at the end of the range of motion (ROM), he' tuck in chin by pushing the chin with his fingers (10 to 15 times). Subsequently, the participant will be requested to return to the original position while the therapist one hand's forefinger placed alongside the participant's mandible (to stabilize the head at full retraction position), and the heel of the other hand placed on the first or second dorsal vertebra (to provide posterior-anterior force). The exercises then repeated five or six times in a Session. the session will be of 45 mins, 3 session per week."
223813919|NCT05834114|OTHER|Rhythmic Stabilization technique|In this group participants will receive Rhythmic stabilization, with Conventional physiotherapy treatment the flexion , extension exercises performed. During flexion pattern the experimenter stood at the right side of patient and used his tip of fingers at chin. The experimenter then put his left hand at anterior side of head to apply resistance. then extension pattern is resisted and asked patient to match my resistance. The experimenter provided resistance against right rotation and lateral flexion provided during the exercise in order to induce strong muscle contractions. 3 sessions of 45 minutes a week, over a period of 10 weeks.
223813920|NCT01291147|DRUG|Levobupivicaine|levobupivicaine 0.5% continous infusion for 48 hours
223813921|NCT01291147|DRUG|0.9% Saline|0.9% saline continous infusion for 48 hours
223813922|NCT05549765|PROCEDURE|Pharmacopuncture|Pharmacopuncture is a treatment that combines 2 of the most frequented Korean medicine treatment methods - traditional acupuncture and herbal medicine - by injecting herbal medicine extract at acupoints.
223813923|NCT05549765|PROCEDURE|Korean medical treatment|acupuncture treatment, chuna, pharmacoacupuncture, Korean herbal medicine
223813924|NCT03748511|OTHER|fibroscan and stool sample|patients undergo ultrasaound (fibroscan) in order to stage the liver disease.
223813925|NCT00259922|DRUG|Placebo|Placebo
223813926|NCT00259922|DRUG|Alvimopan|0.5 mg QD
223813927|NCT00259922|DRUG|Alviompan|0.5 mg BID
223813928|NCT04879459|OTHER|Practical sessions to learn CUS exclusively on volunteers presenting a healthy gallbladder|The study days are 1 day apart for CG and IG but follow the exact same organization. Studytake place on day 0-10-30 (+/-2days). Practical sessions to learn CUS are organized either on volunteers presenting a healthy gallbladder or a pathological gallbladder (sludge, gallstones) (CG), either exclusively on volunteers presenting a healthy gallbladder (IG).
223813929|NCT04975022|DRUG|N11005|oral insulin N11005, 300IU, p.o.
223813930|NCT04975022|DRUG|Novolin R|reference preparation Novolin R, 0.1 IU/Kg, i.h.
223813931|NCT04193501|DRUG|Melatonin 3 mg|Melatonin dose: 3mg/OD Melatonin is a hormone made by the pineal gland; its biosynthesis is initiated by the uptake of the essential amino acid tryptophan and is an important inducer of sleep. Abnormality in melatonin has been shown in several studies on patients of IBS and functional constipation.
223813932|NCT04193501|OTHER|Placebo|Similar looking placebo
223813933|NCT05319106|OTHER|stem cell preparation combined with silver ion dressing|The dosage range of each cm2 ulcer wound is (1～5)×10\^6. The dosage of human umbilical cord mesenchymal stem cells for the second treatment is determined according to the severity of the ulcer. Each patient is treated for 2 consecutive times, and the interval between each treatment is 3 days.
223813934|NCT05319106|PROCEDURE|silver ion dressing|fter wound debridement, a silver ion dressing suitable for the size of the wound was cut and covered on the wound bed. Sterile gauze was covered on the silver ion dressing and fixed with adhesive tape.
223813935|NCT04293263|COMBINATION_PRODUCT|2gether app used by trained personal|"each of the elderly in the study group will listen to personalized music twice a week for an hour each time together with a musical partner. Joint listening is performed with 2 pairs of headphones that connect via a splitter to the partner's cell phone. A listening session will take place in a period of 30 minutes and not more than 60 minutes.~Musical partner - A person trained in the program's work plan, which includes contact with empathic listening and the use of a dedicated application developed for it. A musical partner will meet with the same elderly person throughout the study period.~Empathetic listening - a situation in which a person listens to music with another person, while the music enables contact and deepening the connection between people."
223813936|NCT02986607|DRUG|parathyroid hormon 1-84|Hypoparathyroidism patients will receive Natpara in continous subcutaneous infusion delivered by a pump for 4-7 days.
223813937|NCT03260530|OTHER|Locomotor evaluation|collection of parameters associated with walking and balance in patients with their usual prosthesis and then equipped with the new prosthesis
223813938|NCT03260530|OTHER|Questionnaires|Houghton's scale, PPA-LCI, ABC, QEP, SF-12, SAT-PRO, ESAT
223813939|NCT05160324|PROCEDURE|Removal of axillary lymph nodes.|Axillary dissection in patients with positive sentinel lymph node
223813940|NCT05160324|PROCEDURE|Preservation of axillary lymph nodes|Preservation of axillary lymph nodes in patients with positive sentinel lymph node
223813941|NCT02209012|DRUG|Aminolevulinic Acid (ALA)|Levulan PDT given in CP0108
223813942|NCT02209012|DRUG|Topical Solution Vehicle|Vehicle PDT given in CP0108
223813943|NCT02209012|DEVICE|BLU-U Blue Light Photodynamic Therapy Illuminator|PDT given in CP0108
223813944|NCT00785317|DRUG|Angemin vs Activelle|1 mg of oral oestradiol (E2) in continuous combination with 2 mg of DRSP or 1 mg of oral E2 in continuous combination with 0.5 mg of NETA during six months.
223813945|NCT05313386|DRUG|BXCL501|BXCL501 is given in a film form
223813946|NCT05313386|DRUG|Placebo film|Placebo is given in a film form
223813947|NCT01865305|DRUG|insulin degludec/insulin aspart 30|Single dose administrated subcutaneously (s.c., under the skin).
223813948|NCT01865305|DRUG|insulin degludec/insulin aspart 40|Single dose administrated subcutaneously (s.c., under the skin).
223813949|NCT01865305|DRUG|insulin degludec/insulin aspart 50|Single dose administrated subcutaneously (s.c., under the skin).
223813950|NCT01865305|DRUG|insulin degludec|Single dose administrated subcutaneously (s.c., under the skin).
223813951|NCT01865305|DRUG|insulin aspart|Single dose administrated subcutaneously (s.c., under the skin).
223813952|NCT01865305|DRUG|biphasic insulin aspart 30|Single dose administrated subcutaneously (s.c., under the skin) as comparator.
223813953|NCT01865305|DRUG|insulin degludec/insulin aspart 40|Single dose administrated subcutaneously (s.c., under the skin).
223813954|NCT01865305|DRUG|insulin degludec/insulin aspart 50|Single dose administrated subcutaneously (s.c., under the skin).
223813955|NCT01865305|DRUG|biphasic insulin aspart 30|Single dose administrated subcutaneously (s.c., under the skin).
223813956|NCT02150200|OTHER|shorter hospitalization stay|
223813957|NCT02150200|OTHER|questionnaires|
223813958|NCT00691132|DRUG|phenethyl isothiocyanate|Given orally
223813959|NCT00691132|OTHER|placebo|Given orally
223813960|NCT05255432|OTHER|nil intervention|Users observation using medical device on manakin, different scenarios per group
223813961|NCT02028559|DEVICE|Propulse 1|Move kidney stones with Propulse 1 device.
223813962|NCT01974037|DIETARY_SUPPLEMENT|Capsaicin|Capsaicin in the concentration of 0.5 µmol/L was mixed in the test solutions in Capsaicin\_effect subgroups
223813963|NCT01974037|DIETARY_SUPPLEMENT|NaCl|NaCl in various concentrations was desorved in the test solutions in Salt\_effect subgroups
223813964|NCT01064908|DEVICE|OxyMask|Novel vortex oxygen delivery mask
223813965|NCT01959347|PROCEDURE|Miduretheral Sling|MUS can include the TVT™ (mechanical cut mesh only, Gynecare, ETHICON Women's Health \& Urology, Somerville, NJ), TVT-O™ (mechanical cut mesh only, Gynecare), or Monarc™ (American Medical Systems, Minnetonka, MN).
223813966|NCT01959347|OTHER|Miduretheral Sling with behavioral/pelvic floor therapy|MUS is combined with components of behavioral therapy (designed to change behaviors to encourage continence), and pelvic floor muscle therapy (designed to strengthen the pelvic floor muscles, enhance the physiological closure of the bladder neck, and improve coordination). This is done prior to MUS (1 visit) and after MUS for 5 visits at 2, 4, 6, 8 weeks and 6 months.
223813967|NCT02813356|DRUG|naloxegol|non-interventional study where naloxegol is prescribed during normal clinical practice
223813968|NCT02813356|DRUG|non-PAMORA|non-interventional study where patients are exposed to non-peripherally acting mu-opioid antagonists during the normal course of clinical practice
223813969|NCT01121302|DRUG|AZD5213|0.1 mg, 0.3 mg, 1 mg, 2 mg, 4 mg, 8 mg, 16 mg, 32 mg oral solution, single ascending doses
223813970|NCT01121302|DRUG|Placebo|
223813971|NCT03321825|DEVICE|Belotero® Volume Lidocaine|Mode of application: subdermal injection
223813972|NCT05428514|OTHER|Maternity Housing|Receives a bed in the maternity home, wrap-around services, etc.
223813973|NCT03954743|BIOLOGICAL|PCV-free liquid formulation of GSK's oral live attenuated HRV vaccine|2 doses administered orally at Day 1 and at Month 1 or Month 2, according to the immunization schedule for RV vaccine administration in participating countries.
223813974|NCT03954743|BIOLOGICAL|Lyophilized formulation of GSK's oral live attenuated HRV vaccine|2 doses administered orally at Day 1 and at Month 1 or Month 2, according to the immunization schedule for RV vaccine administration in participating countries.
223813975|NCT00886067|DRUG|AZD1446|Solution, oral, single dose
223813976|NCT00886067|RADIATION|2-[18F]-F-A85380|iv, single dose
223813977|NCT01923805|DEVICE|Vitagel|Vitagel
223813978|NCT05982301|DRUG|Sintilimab, paclitaxel-albumin, oxaliplatin, 5-FU|The study has only one arm. Sintilimab 200mg d1 ivgtt+paclitaxel-albumin 125mg/m2 d1 ivgtt+oxaliplatin 85mg/m2 d1 ivgtt+5-FU 2.4g/m2 civ46h, q2w.
223813979|NCT01373632|DEVICE|Firebird 2 sirolimus-eluting stent|the Firebird 2 sirolimus-eluting stent is a SES with durable polymer based on Co-Cr stent platform
223813980|NCT01373632|DEVICE|Excel sirolimus-eluting stent|the Excel sirolimus-eluting stent is a stent with biodegradable polymer (PLA) based on stainless steel (316L) stent platform
223813981|NCT01455025|DRUG|Plerixafor granulocyte-colony stimulating factor|"Induction phase Plerixafor IV from D1 to D3 and from D8 to D10, granulocyte-colony stimulating factor IV 5 μg/kg/day from D1 to D10, Intravenous daunorubicin 60 mg/m2/day from D1 to D3 Cytarabine 500 mg/m2/day continuous infusion over 24h from D1 to D3 followed by cytarabine 2-hour bolus of 1000 mg/m2/12h from D8 to D10.~Consolidation phase Plerixafor at D1, D3 and D5, granulocyte-colony stimulating factor IV 5 μg/kg/day from D1 to D5, Cytarabine continuous infusion of 3-h bolus of 3000 mg/m2/12h D1, D3 and D5"
223813982|NCT01282801|DRUG|Venlafaxine Hydrochloride|150 mg Extended-Release Capsule
223813983|NCT01282801|DRUG|Effexor® XR|150 mg Extended-Release Capsule
223813984|NCT04714801|DRUG|adipose derived mesenchymal stromal cells|Intravenous infusion of cells
223813985|NCT04714801|DRUG|Saline|Intravenous infusion of saline
223813986|NCT00329121|DRUG|PEP005|
223813987|NCT00939601|BEHAVIORAL|Motivational Enhancement Therapy|
223813988|NCT00939601|BEHAVIORAL|Educational Counseling|
223813989|NCT03346811|DRUG|Icotinib|Patients with plasma EGFR mutation-positive are arranged to receive icotinib with a dose of 125 mg three times per day, till progressive disease or unaccepted toxicity
223813990|NCT05636462|OTHER|Global postural re-education program|"Different postures of global re-education programs are used and stretch is applied in these postures.~3 sessions per week are given and each session time is 40 minutes. Treatment is given for 4 weeks."
223813991|NCT05636462|OTHER|Conventional Physical Therapy|Isometrics and stretching is used as conventional treatment. 3 sessions per week are given and each session time is 40 minutes. Treatment is given for 4 weeks.
223813992|NCT01988948|OTHER|Various biological sampling|
223813993|NCT00927056|PROCEDURE|Microdiscectomy|Minimally invasive microdiscectomy versus conventional open microdiscectomy
223813994|NCT00829686|DRUG|Septra|(800/125) PO BID X 7 days
223813995|NCT01379027|BEHAVIORAL|Pure self-help Internet CBT for depression|Internet, CBT, Depression
223813996|NCT01379027|BEHAVIORAL|Guided self-help Internet CBT|CBT, Depression, Website intervention, coaching
223813997|NCT01379027|BEHAVIORAL|Stepped-Care Internet CBT condition|Depression CBT, Internet intervention
223813998|NCT02387996|DRUG|Nivolumab|
223813999|NCT02307591|DRUG|Best Supportive Care|Dehydration Ringer's lactate solution or normal saline intravenously Electrolytes should be monitored at regular intervals and corrected as long as vomiting and/or diarrhoea persist Fever intravenous Paracetamol Antimicrobial treatment Prophylactic 5-days course with Ampicillin should be used Pain Paracetamol,Tramadol or Pentazocine Central nervous system disturbances If a patient is restless or confused, prescribe a light sedation utilizing Midazolam, Propofol or Ketamine, preferably in association with Diazepam or Midazolam Seizures Diazepam Vomiting antiemetic medications may provide some relief and facilitate the rehydration Dyspepsia in adults, Omeprazole Diarrhoea in adults, Loperamide Acute bleeding leading to signs of haemorrhagic shock should be treated with whole blood transfusion and supportive care. Patients haemodynamically stable should not be transfused if the Hb level is \>7 mg% Septic shock intensive support care Malaria in case of positive initial test, Artesunate
223814000|NCT02307591|DRUG|Best Supportive Care + Amiodarone|"This treatment will be provided to patients in the experimental arm only in addition to best supportive care scheme .~During the first 3 days of treatment, the drug must be administered in Glucose 5% solution. Deliver through the largest possible vein inserting a long catheter (if possible a CVP line).~Day 1. Dose: 20 mg/kg/die i.v. deliver a loading dose of 5mg/kg in the 1st hour, followed by continuous infusion during the remaining 23 hours.~Example: 20 mg /kg of Amiodarone in 500 cc of Glucose 5%. Deliver 125 ml during the 1st hour followed by 16 ml/hour for the remaining 23 hours.~Day 2 - Day 3. Dose: 20 mg/kg/die i.v. Continuous infusion over 24 hrs. Example: Glucose 5% 500 ml containing 20 mg/kg of Amiodarone (infusion speed = 21 ml/hour).~Day 4 to Day 10. If no significant diarrhea and/or vomiting, shift to oral intake of Amiodarone as follows:~* Adults: 200 mg tablets, 3 times a day, according to the body weight (30mg/Kg)~* Children \< 29 kg: 5 mg/kg 3 times a day"
223814001|NCT01060553|OTHER|Acupuncture treatment|This project was initially designed as a randomized trial with one group receiving treatment and the other wait list control, with delayed treatment. Due to extremely high dropout and cancellations and failure to return for post assessment, a midpoint assessment was added. Analysis was done on pre and post measures of all subjects who completed at least the midpoint assessment. Due to the very small number of subjects in the wait list control, the ones who completed 6 or 12 weeks of acupuncture after the wait list were combined with the few who completed the initial acupuncture for a pre-post single group analysis. for those who completed both the 6 and 12 week measures, the latest one was selected for analysis
223814002|NCT02304276|RADIATION|18F-Fluoride PET-CT|Injection of 18F-Fluoride with target activity 125MBq giving an anticipated radiation exposure of 3mSv CT scanning protocol giving an anticipated radiation exposure of 13mSv
223814003|NCT02304276|RADIATION|CT calcium score of aortic valve|CT associated with an anticipated radiation exposure of 3mSv (Cohorts 2 and 3 only)
223814004|NCT03670225|DEVICE|Invia Motion Endure|NPWT Invia Motion Endure
223814005|NCT03640546|BEHAVIORAL|Within My Reach/ Within Our Reach|Relationship education workshops
223814006|NCT03263221|PROCEDURE|reduction and fixation|Surgical procedures, as plating, Proximal Femoral Nail , Dynemic Hip screw and others procedures according to needed for each types
223814007|NCT01546259|OTHER|Water colonoscopy|Colonoscopy will be performed without medications and aided by water infusion in-lieu of air insufflation during insertion of the colonoscope. The water infusion involves putting warm sterile water into the colon to open up the colon for advancement of the colonoscope until the end of the colon (cecum) is reached. The water is delivered through scope irrigation channel by an infusion pump equipped with a foot switch which will be controlled by the endoscopist. Infused water used to cleanse residual fecal matter will be suctioned as needed to clear the colonic lumen.
223814008|NCT02385019|BIOLOGICAL|Donor regulatory T cell adoptive immunotherapy in chronic graft versus host disease|"Regulatory T cells selected by a sequential 2 step procedure:~1. \- Negative selection of CD8 and CD19 cells~2. \- Positive selection of CD25 cells"
223814009|NCT04665011|DEVICE|Indicor|A simple, non-invasive tool to report pulse response to a Valsalva maneuver
223814010|NCT04665011|DEVICE|Caretaker|non-invasive blood pressure monitor
223814011|NCT01368445|DRUG|azelastine hydrochloride 0.15% Nasal Spray|1644 mcg, 2 sprays per nostril twice daily AM \& PM)
223814012|NCT01368445|DRUG|azelastine hydrochloride 0.15% and Placebo|822 mcg azelastine hydrochloride 0.15%, 2 sprays per nostril once daily (AM) and 0mg placebo spray 2 sprays per nostril once daily (PM)
223814013|NCT01368445|DRUG|Azelastine 0.1%, Nasal Spray|1096 mcg, Azelastine 0.1%,2 sprays per nostril twice daily (AM \& PM)
223814014|NCT03160287|BEHAVIORAL|Motivaltional interviews and infrequent motivational text messages|A self-management intervention will integrate use of mobile technology to prompt older adults to be physically active, provides ongoing monitoring of the amount of their physical activity and includes self-efficacy enhancements is a novel non-pharmacological intervention both for prevention and treatment of sleep deficiency in persons with OA
223814015|NCT00632281|RADIATION|Stereotactic Body Radiation Therapy|Prescription dose: 48 Gy or 60 Gy RT
223814016|NCT00345163|DRUG|bevacizumab|Intravenous repeating dose
223814017|NCT00345163|DRUG|irinotecan|Intravenous repeating dose
223814018|NCT01949103|DRUG|TD-1607|
223814019|NCT01949103|DRUG|Placebo|
223814020|NCT01378910|DRUG|Unique|Change of PI, NNRTI or integrase inhibitor to CCR5 antagonist (maraviroc)
223814021|NCT06089122|BIOLOGICAL|IVIG|Patients with primary immunodeficiency will switch to Shu Yang IVIG and optimize the posology to IgG 300 to 600 mg every 21 or 28 days in a run-in period of 2 to 6 administrations, aiming at keeping the IgG trough levels above 5 g/L. At Visit 4, at least 20 patients will perform the PK assessment, collecting additional blood samples.
223814022|NCT04262765|DRUG|Ramipril, Amlodipine and Atorvastatin|compare the pharmacokinetic of ramipril (and ramiprilat), atorvastatin as atorvastatin calcium trihydrate, amlodipine as amlodipine besilate from reference products given as a multiple dose
223814023|NCT04763811|OTHER|Focus groups|discussion between participants about representations of health, dependance, fragility, and new technologies
223814024|NCT04763811|OTHER|Individual interviews|Discussion between the searcher and the participant about representations of captors, discretion of captors, wish about feed-backs of captors
223814025|NCT02098018|BEHAVIORAL|Program 2|A well-established behavioral method for reducing stress. To maintain blinding, details will be given to participants after randomization.
223814026|NCT02098018|BEHAVIORAL|Program 1|A well-established behavioral method for reducing stress. To maintain blinding, details will be given to participants after randomization.
223814027|NCT04707196|DRUG|Abemaciclib|Administered orally
223814028|NCT04707196|DRUG|Nonsteroidal Aromatase Inhibitor (NSAI)|Letrozole or anastrozole administered orally (physician choice)
223814029|NCT04707196|DRUG|Fulvestrant|Administered intramuscularly
223814030|NCT02848716|PROCEDURE|Surgery followed with chemoradiation|"Patients with negative paraaortic lymph nodes will be managed with external beam radiotherapy to the pelvis (as defined by the surgical clips applied at the lower limit of the paraaortic node dissection) at a usual dose of 45 Gy. Limited boosts will be indicated individually on clinically involved parametria or pelvic nodes. The external beam radiation therapy will be followed by intracavitary brachytherapy (High Dose Rate (DR), Low DR or Pulse DR) with intent to cure.~Patients with metastatic disease to paraaortic lymph nodes will receive extended-field external beam radiotherapy followed by intracavitary brachytherapy with intent to cure. Patients who complete both external beam radiation and intracavitary radiotherapy will receive a total dose of 80-90 Gy low-dose equivalent to Point A.~Concurrent platinum-based chemotherapy (in the 2 sub groups above) will be given with definitive radiation therapy."
223814031|NCT02848716|RADIATION|Standard chemoradiation|"patients with negative paraaortic lymph nodes on PET imaging will be managed with external beam radiotherapy to the pelvis at a usual dose of 45 Gy. Limited boosts will be indicated individually on clinically involved parametria or pelvic nodes. The external beam radiation therapy will be followed by intracavitary brachytherapy with intent to cure (HDR, LDR or PDR). Patients who complete both external beam radiation and intracavitary radiotherapy will receive a total dose of 80-90 Gy low-dose equivalent to Point A.~Concurrent platinum-based chemotherapy will be given with definitive radiation therapy."
223814032|NCT02848716|RADIATION|chemoradiation|
223814033|NCT01862796|BEHAVIORAL|Underfeeding diet|Heart healthy diet with 35% reduced calories
223814034|NCT01862796|BEHAVIORAL|Weight maintaining diet|Heart healthy weight-maintaining diet
223814035|NCT05527067|OTHER|Data collection|Neuropsychological assessment, brain MRI, electroencephalogram and biomarker datas will be collected
223814036|NCT05527067|OTHER|Data collection|Neuropsychological assessment, brain MRI, electroencephalogram and biomarker datas will be collected
223814037|NCT00146601|DRUG|Fulvestrant|
223814038|NCT04572178|BEHAVIORAL|Cash payment and brief behavioral counseling|"The intervention consists of: (i) in person brief behavioral counseling, (ii) the evaluation of the smoking status using breath carbon monoxide, and (iii) cash payment of 25 Euro if the reading does not exceed a carbon monoxide value 3 ppm ( ppm = parts per million) on two consecutive measurements per week. The intervention starts at the earliest in pregnancy week 15 and lasts until the delivery. If they relapse, the reward is not paid. However, in the following week they have the opportunity to quit smoking and being rewarded again."
223814039|NCT04956328|DRUG|Obeticholic Acid Tablets|Obeticholic Acid：Once a day (QD) by mouth (PO).
223814040|NCT04956328|DRUG|UDCA|UDCA：continue prestudy dose
223814041|NCT04956328|DRUG|Placebo|Placebo
223814042|NCT05835557|OTHER|BFR-ST|Undergo 9 sessions of high intensity short interval training involving 3 sets of 8-10 repetitions of 30 secs interval cycling and 30 secs recovery at 100-110% of maximal aerobic power. In between sets there will be 3 mins of passive rest. Blood flow restriction will be applied for 2 mins during the passive rest at 80% of limb occlusion pressure.
223814043|NCT05835557|OTHER|ST|Undergo 9 sessions of high intensity short interval training involving 3 sets of 8-10 repetitions of 30 secs interval cycling and 30 secs recovery at 100-110% of maximal aerobic power. In between sets there will be 3 mins of passive rest. Cycling will be conducted in an environmental chamber and participants informed that the altitude is set to 2500m - actual altitude will be sea level.
223814044|NCT00228696|OTHER|none, screening only|Screening protocol with no intervention
223814045|NCT03604757|DRUG|68Ga-PSMA-617 PET/CT|PET/CT Imaging with 68Ga-PSMA-617 injection
223814046|NCT03604757|DRUG|68Ga-RM2 PET/CT|PET/CT Imaging with 68Ga-RM2 injection
223814047|NCT03352934|DRUG|Avelumab|Avelumab will be administered as intravenous infusion at 10 mg/kg once every two weeks until documented disease progression (PD), unacceptable toxicity, or any criterion for treatment withdrawal are met.
223814048|NCT04230655|DIETARY_SUPPLEMENT|Low energy diet using meal replacements|The LED phase (from baseline to 24 weeks) consists of 12 weeks with 4 portions/day of liquid meal replacements, for a total of 800-880 kcal/day, followed by a 12-week slow phasing out to a regular diet. Thereafter, an energy-reduced diet (1400-1600 kcal/day) is recommended.
223814049|NCT04230655|BEHAVIORAL|CBT-based group treatment|All participants (control and intervention) receive 2.5-hour sessions of CBT-based group treatment every 4 weeks for 1 year. Participants are randomly assigned to groups of 8-16 participants.
223814050|NCT04230655|DEVICE|Intragastric balloon|An IGB (Orbera IGB, Apollo Endosurgery Inc., Austin, Texas, (CE certified)) is set in place endoscopically by a gastroenterologist at Örebro University Hospital, Region Örebro county, and is left in the stomach for 6 months. A proton-pump inhibitor is prescribed to counteract an increased risk to develop a gastric ulcer. During the first 2 weeks, dietary adjustments are necessary to adapt to the IGB. Thereafter, an energy-reduced diet (1400-1600 kcal/day) is recommended identical to the control group. The IGB is removed endoscopically after 6 months IGB treatment.
223814051|NCT02459223|DIETARY_SUPPLEMENT|Nutritional biscuits and khichadi|Nutritional biscuits and Khichadi.
223814052|NCT02459223|DIETARY_SUPPLEMENT|Khichadi|Khichadi.
223814053|NCT02382718|BIOLOGICAL|FAST fish mCyp c 1|Subcutaneous immunotherapy
223814054|NCT02382718|BIOLOGICAL|Placebo|Subcutaneous immunotherapy
223814055|NCT06112730|OTHER|Standard pulmonnary rehabilitation|Undergo routine pulmonary rehabilitation without dietary intervention
223814056|NCT06112730|OTHER|Nutritional supplementation intervention|Receive personalized dietary guidelines based on indirect calorimetry assessment
223814057|NCT06563674|OTHER|Acceptance-based healthy lifestyles program (intervention group)|The acceptance-based healthy lifestyles program consists of 4 biweekly 60-min face-to-face interactive workshops to cover the knowledge of pneumoconiosis, exercise to maintain lung function, health diet, and home safety.
223814058|NCT06563674|OTHER|Acceptance-based healthy lifestyles program (control group)|The acceptance-based healthy lifestyles program consists of 4 biweekly 60-min face-to-face interactive workshops to cover the knowledge of pneumoconiosis, exercise to maintain lung function, health diet, and home safety.
223814059|NCT03998683|DRUG|Guselkumab 100 mg|Guselkumab 100 mg will be administered as SC injection.
223814060|NCT03998683|DRUG|Placebo|Placebo will be administered as SC injection.
223814061|NCT00302432|BEHAVIORAL|Behavior therapy, cigarette holders, Flowers Menthol|
223814062|NCT00002537|DRUG|topotecan hydrochloride|
223814063|NCT00002537|RADIATION|radiation therapy|
223814064|NCT05030259|PROCEDURE|fasciotomy|To perform fasciotomy
223814065|NCT00989586|BIOLOGICAL|milatuzumab|Patient will receive milatuzumab weekly for 4 total doses during induction therapy. Induction therapy will be defined as the first 4 weeks of study therapy. During week 1 of induction therapy, patients will receive milatuzumab on day 2. Starting in week 2, milatuzumab will be given on day 4. Provided the patient does not experience excessive toxicity or disease progression during induction therapy, the patient may continue treatment with extended induction therapy, consisting of veltuzumab day 1 and milatuzumab day 4 of weeks 12, 20, 28, and 36.
223814066|NCT00989586|BIOLOGICAL|veltuzumab|Patient will receive veltuzumab weekly for 4 total doses during induction therapy. Induction therapy will be defined as the first 4 weeks of study therapy. Provided the patient does not experience excessive toxicity or disease progression during induction therapy, the patient may continue treatment with extended induction therapy, consisting of veltuzumab day 1 and milatuzumab day 4 of weeks 12, 20, 28, and 36.
223814067|NCT00989586|PROCEDURE|Correlative/Special Studies|To correlate Fcγ receptor polymorphisms with response to treatment with the combination of veltuzumab and milatuzumab. Whole blood will be collected pre-treatment on day 1.
223814068|NCT00989586|PROCEDURE|Quantitative T-, B-, and NK cell subsets|Quantitative T-, B-, and NK- cell subsets will be assessed using flow cytometry to quantify the percentage and absolute number of cells expressing CD4, CD8, CD56, CD16, CD19, and CD20 pre-treatment on day 1, after induction (week 5, day 1), and prior to the start of therapy on day 1 week 12, day 1 week 36, and then every 4 months for one year.
223814069|NCT00989586|PROCEDURE|Pharmacokinetics|To assess the pharmacokinetics of veltuzumab in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma. Pharmacokinetics will be assessed with blood samples collected at the following time points: immediately pre- and post-infusion on day 1 of weeks 1, 2, 4, 12 and 36. One additional sample will be collected each of weeks 5 through 10 (sample may be collected any day during each of these weeks).
223814070|NCT00989586|PROCEDURE|Pharmacokinetics|To assess the pharmacokinetics of milatuzumab in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma. Pharmacokinetics will be assessed with blood samples collected at the following time points: immediately pre- and post-infusion on day 2 of week 1 and day 1 of weeks 2, 4, 12 and 36. Additional samples will be collected days 3 through 6 of week 1.
223814071|NCT00989586|PROCEDURE|Human Anti-Human Antibodies|To monitor for the development of human anti-veltuzumab antibodies and human anti-milatuzumab antibodies (HAHA) in patients receiving treatment with veltuzumab and milatuzumab. Patients will be monitored for the development of HAHA at the following timepoints: pre-treatment on day 1 of week 1, pre-treatment on day 1 of week 4, pre-treatment on day 1 of week 12, and pre-treatment on day 1 of week 36.
223814072|NCT00989586|BIOLOGICAL|veltuzumab and milatuzumab|Patient will receive veltuzumab and milatuzumab weekly for 4 total doses during induction therapy. Induction therapy will be defined as the first 4 weeks of study therapy. During week 1 of induction therapy, patients will receive veltuzumab on day 1 and milatuzumab on day 2. Starting in week 2, veltuxumab will be given on day 1 and milatuzumab will be given on day 4. Provided the patient does not experience excessive toxicity or disease progression during induction therapy, the patient may continue treatment with extended induction therapy, consisting of veltuzumab day 1 and milatuzumab day 4 of weeks 12, 20, 28, and 36.
223814073|NCT02920203|GENETIC|Heart and spleen tissue|genetic sequencing
223814074|NCT03582891|DEVICE|Summit RC+S for Motor|Using the RC+S pulse generator, investigators will measure cortical biomarkers of hyper and hypokinesia in Parkinson's and dystonia patients to develop an adaptive algorithm which adjusts the level of deep brain stimulation needed based upon the patient's physiology.
223814075|NCT03582891|DIAGNOSTIC_TEST|8-week pilot trial of Closed-loop vs. Open-loop Stimulation|These patients will participate in an 8 week clinical trial of open loop versus adaptive mode (4 weeks for each mode (interleaved), with the order counterbalanced across subjects ).
223814076|NCT03582891|DEVICE|Summit RC+S for Sleep|Using the RC+S pulse generator, investigators will measure cortical biomarkers of sleep stages in Parkinson's patients to develop an adaptive algorithm which adjusts the level of deep brain stimulation needed based upon the patient's physiology.
223814077|NCT05529758|BEHAVIORAL|Internalized Weight Bias Intervention|ACT-based programs and self-compassion have shown promise throughout research for lowering IWB (Berman et al., 2016; Levin et al., 2018; Lillis et al., 2009; Palmeira, Cunha, \& Pinto-Gouveia, 2017; Palmeira, Pinto-Gouveia, \& Cunha, 2017; Forbes et al., 2020). Therefore, using techniques from prior ACT- and self-compassion based programs, a weight bias reduction intervention will be administered. Session topics will include psychoeducation and coping for weight bias and internal weight bias, and these topics will be viewed through a self-compassionate and ACT-based lens (for example, participants may defuse from internal critical thoughts rather than challenge them). Sessions will also cover acceptance, cognitive defusion, mindfulness, committed action, and the dialectical behavioral therapy (DBT) DEARMAN skill.
223814078|NCT01954368|DRUG|Placebo|"As soon as possible from ED admission, using a study drug volume schedule, triage nurse will administer to the patient a planned weight-based volume of intranasal placebo (normal saline solution).~Half of the dose will be administrated in each nostril. The patient will then rapidly be brought to emergency room and after his pain being reassessed, appropriate treatment (following current recommendations) will be given by the ED nurse."
223814079|NCT01954368|DRUG|Sufentanil|"As soon as possible from ED admission, using a study drug volume schedule, triage nurse will administer to the patient a weight-based volume (corresponding to 0,4 mcg/kg) of intranasal sufentanil.~Half of the dose will be administrated in each nostril. The patient will then rapidly be brought to emergency room and after his pain being reassessed, appropriate treatment (following current recommendations) will be given by the ED nurse."
223814080|NCT06339060|COMBINATION_PRODUCT|Experimental: Arm 1 Organ preservation|"Arm 1 patients will undergo clinical response evaluations (CREs) after neoadjuvant therapy(A+B+C）, If cancer is detected, surgery will be performed. Patients with clinical complete response （cCR） are eligible for active surveillance where regular CREs are performed to detect regrowth of cancer.Postoperative adjuvant therapy will follow the NCCN guideline.~A: Camrelizumab 200mg IV on days 1 and 22 B: Carboplatin (AUC=2) IV and Paclitaxel-albumin (50mg/m²) IV on day 1,8,15,22,29.~C: Radiotherapy will start on day 1 of chemotherapy. A total of 41.4 Gy, 23 fractions of 1.8 Gy, 5 fractions a week.~A+B+C=Neoadjuvant therapy"
223814081|NCT06339060|COMBINATION_PRODUCT|Active Comparator: Arm 2 Surgery|"Arm 2 patients will undergo surgery after neoadjuvant therapy(B+C）.Postoperative adjuvant therapy will follow the NCCN guideline.~B: Carboplatin (AUC=2) IV and Paclitaxel-albumin (50mg/m²) IV on day 1,8,15,22,29.~C: Radiotherapy will start on day 1 of chemotherapy. A total of 41.4 Gy, 23 fractions of 1.8 Gy, 5 fractions a week."
223814082|NCT02192775|DRUG|MV-NIS|one dose in conjunction with a 4 day course intravenously
223814083|NCT00145301|DRUG|Lumiracoxib|
223814084|NCT02037438|OTHER|CONV care for the diagnosis and treatment of sleep disorders|The Conventional (CONV) intervention utilized standard-of-care diagnostic and treatment procedures for new patients with sleep disorders at the Stanford Sleep Medicine Center
223814085|NCT02037438|OTHER|PCCM for the diagnosis and treatment of sleep disorders|The Patient-Centered Outcomes and Coordinated Care Management (PCCM) intervention implemented new methodologies for the diagnosis and treatment of sleep disorders. It also incorporates the utilization of a web-based interactive portal that provides specific and relevant information and resources for patients, health care providers, and allied health professionals. The portal was designed to facilitate informed health care decisions among patients and health care providers through improved access to medical data and enhanced communications.
223814086|NCT02255032|DRUG|4 mg CLS-TA|40 mg/mL CLS-TA, Clearside's formulation of TA (CLS-TA, triamcinolone acetonide injectable suspension)
223814087|NCT02255032|DRUG|0.8 mg CLS-TA|8 mg/mL CLS-TA, Clearside's formulation of TA (CLS-TA, triamcinolone acetonide injectable suspension)
223814088|NCT00563225|DRUG|Insulin Glargine|Insulin glargine at the discretion of the investigator Subcutaneous, once daily injection (at bedtime)
223814089|NCT05168813|BIOLOGICAL|Moderna mRNA-1273|COVID-19 vaccine (mRNA-1273) developed by Moderna, Inc. is a lipid nanoparticle (LNP) dispersion of a messenger ribonucleic acid (mRNA) encoding the prefusion stabilized S protein of SARS-CoV-2 formulated in LNPs composed of 4 lipids (1 proprietary and 3 commercially available).
223814090|NCT05168813|BIOLOGICAL|Vaccine 3 Dose|COVID-19 mRNA vaccine in 100 mcg dose given as IM injection into the deltoid muscle on Day 1, Day 29, and Day 169.
223814091|NCT05168813|BIOLOGICAL|Vaccine 2 Dose|COVID-19 mRNA vaccine is to be administered as IM injection into the deltoid muscle on Day 1 and Day 169.
223814092|NCT05568875|OTHER|e-self-management intervention (Happy Hands app)|"The 12-week intervention consists of 30 short informational videos addressing the themes prioritized by the patient research partners. These themes are further operationalized into the following categories: Information on hand OA, Hand exercises, Use of assistive devices and orthoses, Medication and surgical alternatives, and Self-management of the disease. Additionally, the intervention includes a hand exercise program consisting of 8 videos providing instructions on warm up, exercises to improve mobility, strength and coordination, and a stretching exercise. The intervention group will additionally receive treatment as usual."
223814093|NCT05568875|OTHER|Treatment as usual|Treatment as usual may vary from no treatment at all to referral to a patient education group program, or occupational therapy.
223814094|NCT06155084|DRUG|HP518 - Dose Escalation|Part 1: Dose escalation Daily oral dosage with the prescribed dose level based on Cohort
223814095|NCT06155084|DRUG|HP518 - Dose Escalation|Part 1: Dose escalation Daily oral dosage with the prescribed dose level based on Cohort
223814096|NCT06155084|DRUG|HP518 -Dose Expansion|Part 2: Dose expansion Daily oral dosage with the highest dose with acceptable toxicity (RP2D) based on data from Part 1.
223814097|NCT05746481|DRUG|Tiragolumab|Tiragolumab (an investigational novel immune checkpoint inhibitor): 600 mg IV for induction treatment administered on Day 1 of each 21-day cycle for 4 cycles. Maintenance therapy will continue with tiragolumab on Day 1 of each 21-day cycle.
223814098|NCT05746481|DRUG|Atezolizumab|Atezolizumab (monoclonal antibody): 1200 mg IV administered on Day 1 of each 21-day cycle.
223814099|NCT05746481|DRUG|Pemetrexed|Pemetrexed (antifolate antineoplastic agent chemotherapy): 500 mg/m2 administered IV on Day 1 of each 21-day cycle.
223814100|NCT05746481|DRUG|Carboplatin|Carboplatin AUC 5 (alkylating agent chemotherapy): injection administered on Day 1 of each 21-day cycle.
223814101|NCT04943211|DRUG|fluorodeoxyglucose (18F-FDG)|max 6 MGBq/kg, no more than 100
223814102|NCT05375955|DRUG|PF-07038124 ointment 0.01%|Atopic Dermatitis and Plaque Psoriasis
223814103|NCT05375955|DRUG|Vehicle ointment|Atopic Dermatitis and Plaque Psoriasis
223814104|NCT05375955|DRUG|PF-07038124 ointment 0.03%|Atopic Dermatitis and Plaque Psoriasis
223814105|NCT05375955|DRUG|PF-07038124 ointment 0.06%|PF-07038124 ointment 0.06% (Plaque Psoriasis only)
223814106|NCT03550391|DRUG|Memantine|20 mg (10 mg divided twice daily). Dose will be escalated by 5 mg per week. Memantine should start at 5 mg, and then increased in 5 mg increments at the following schedule, depending on the patient's response and tolerance:
223814107|NCT03550391|RADIATION|Hippocampal-avoidant (HA-WBRT) Radiotherapy|30Gy in 10 fractions
223814108|NCT03550391|PROCEDURE|Stereotactic Radiosurgery (SRS)|18-20 or 22 Gy in single fraction
223814109|NCT05013983|BIOLOGICAL|Recombinant COVID-19 vaccine (Sf9 cells)|This vaccine is made by using baculovirus as a vector and expressing SARS-CoV-2 S-RBD in Sf9 cells, which is purified
223814110|NCT05013983|OTHER|Placebo control|Except for the absence of study vaccine antigen, all other components (aluminum hydroxide, sodium chloride, sodium
223814111|NCT01351298|DRUG|0.05% xylometazoline hydrochloride with 1% lidocaine hydrochloride|Decongestant with local anesthetic
223814112|NCT01351298|DRUG|0.05% xylometazoline hydrochloride|Decongestant
223814113|NCT01351298|DRUG|Isotonic normal saline|Placebo
223814114|NCT03383770|PROCEDURE|Regional Anesthesia Touhy|The patients receive the planned anaesthesia procedure according to the procedure to be performed. Only nerve blockages are carried out, which are considered to be analgesic useful for the planned operations on the basis of typical nerve courses. A touhy cannula is used.
223814115|NCT03383770|PROCEDURE|Regional Anesthesia Facet|The patients receive the planned anaesthesia procedure according to the procedure to be performed. Only nerve blockages are carried out, which are considered to be analgesic useful for the planned operations on the basis of typical nerve courses. A facet cannula is used.
223814116|NCT02933801|DRUG|ODM-201|ODM-201 will be given at a dose of 600 mg BID orally on a continuous basis.
223814117|NCT02933801|OTHER|Placebo|Placebo will be given at a dose of 600 mg BID orally on a continuous basis.
223814118|NCT03060798|DRUG|Desflurane|general anesthesia using desflurane.
223814119|NCT03060798|DEVICE|Near-infrared spectroscopy monitor|tissue oxygen saturation monitoring combined with vessel occlusion test
223814120|NCT04468269|OTHER|Task oriented balance training with sensory integration group|"Sitting position:~1. Sit in a chair without backrest while keeping the feet on floor.~2. Sit on a ball while keeping the feet on the floor.~Sit to stand:~1. Sit in a chair without a backrest~2. Sit in a chair without a backrest with and perform the sit-to-stand motion repeatedly.~3. Sit on a ball and perform the sit-to-stand motion repeatedly.~Standing position:~Perform bipedal standing Control Of Weight Shifting. Perform a semi-tandem stance. One Foot Standing.~Walking:~1. Walk forward~2. Walk forward cross an obstacle, and then continue to walk.~3. Walk Lateral~4. Walk Backward~5. Tandem walk"
223814121|NCT04468269|OTHER|Task oriented balance training without sensory integration group|"Sitting position:~1. Sit in a chair without a backrest while keeping the feet on a firm surface.~2. Sit on a ball while keeping the feet on the firm surface~Sit to stand:~1. Sit in a chair without a backrest with the feet on a firm surface and perform the sit-to-stand motion repeatedly.~2. Sit on a ball with the feet on the firm surface and perform the sit-to-stand motion repeatedly.~Standing position:~1. Perform bipedal standing on a firm surface.~2. Perform a semi-tandem stance on the firm surface~Walking:~1. Walk forward on a firm surface.~2. Walk forward on the firm surface, cross an obstacle, and then continue to walk.~3. Walk sideways~4. Walk Backward~5. Tandem walk"
223814122|NCT01856530|DRUG|Oxytocin|Liquid metered-dose nasal spray, 24 IU, administered once
223814123|NCT01856530|DRUG|Placebo|Matched placebo nasal spray
223814124|NCT02727686|OTHER|Water Load (WL) Post-Operative Day 1|Patient will have normonatremic 0600 hr sodium level (Serum Sodium = 135 - 145 mmol/L), ability to safely take water by mouth, and cleared to continue by treating surgeon. WL will be calculated (20 mL/kg body weight) and supplied at the bedside. Vasopressin level will be determined. Patient will have 30 minutes to consume WL, or will be excluded. Included patients will have data collected as follows: 1 hour - serum sodium, urine output; 2 hour - serum sodium, urine output, vasopressin level; 6 hours - serum sodium, urine output.
223814125|NCT03151681|DRUG|Propranolol Pill|1mg/kg of propranolol 60 minutes prior to memory reactivation
223814126|NCT06038435|BEHAVIORAL|Cognitive Orientation Approach|Cognitive training will be given for the selected occupation
223814127|NCT06038435|BEHAVIORAL|Ayres Sensory Integration Therapy|Sensory integration therapy will be applied.
223814128|NCT01899456|DEVICE|Catheter-based renal denervation|
223814129|NCT02377037|OTHER|Metabolic cost and HR associated with distinct postural behaviors|The order of the three conditions will be randomly assigned and all will be undertaken in laboratory settings. Before engaging in the experimental conditions participants will perform anthropometric and body composition assessments and also the resting EE evaluation. All evaluations will be performed at one time only, starting at 7:00 am in the morning after an overnight fast
223814130|NCT03150498|DRUG|BTD-001|BTD-001 in fed vs fasted state
223814131|NCT00232960|PROCEDURE|Radiotherapy 50 Gy|
223814132|NCT05375123|DEVICE|Ultrasound image acquisition|"Echocardiography: left ventricular systolic function of all participants were measured by tissue motion tracking of mitral annular displacement using PHILIPS.~Time points for heart image acquisition in pregnant women: As per the Guidelines for Pre-pregnancy and Pregnancy Health Care (2018) formulated by the Obstetrics Group of the Gynecology Branch of the Chinese Medical Association, a total of six echocardiographic examinations will be performed in the first trimester (11-14 weeks of gestation), the second trimester (20-24 weeks of gestation), the third trimester (29-32 weeks of gestation), prenatal term (37-41 weeks of gestation), 6 weeks and 3-6 months after delivery.~Time points for fetal heart image acquisition: Fetal heart images will be collected in the second trimester (20 to 24 weeks of gestation)."
223814133|NCT01218529|DRUG|Lapatinib|Co-administration of lapatinib 1250mg once daily during the WBRT period (2 weeks)and then monotherapy with lapatinib 1500mg once daily for 4 weeks.
223814134|NCT01081041|DRUG|Cetuximab|Administered intravenously
223814135|NCT01081041|DRUG|Cisplatin|Administered intravenously
223814136|NCT01081041|DRUG|Carboplatin|Administered intravenously
223814137|NCT01081041|DRUG|5-Fluorouracil|Administered intravenously
223814138|NCT03918070|DEVICE|Yukon Choice PC and Yukon Chrome PC|The Yukon Choice PC \& the Yukon Chrome PC Sirolimus Eluting Bioabsorbable Polymer Coronary Stent Systems are indicated for improving coronary luminal diameter in patients with symptomatic ischemic heart disease.
223814139|NCT02601534|BEHAVIORAL|Zero-time Exercise|a knowledge and motivation enhancement session at baseline, an experience sharing session at 3 months, a family gathering session at 6 months, and a holistic health session at 12 months (not a part of cRCT, for the collection of feedback only) as well as biweekly/monthly mobile messages to improve physical activity habit.
223814140|NCT02601534|BEHAVIORAL|Healthy Eating|a knowledge and motivation enhancement session at baseline, an experience sharing session at 3 months, a family gathering session at 6 months, and a holistic health session at 12 months (not a part of cRCT, for the collection of feedback only) as well as biweekly/monthly mobile messages to improve dietary habit.
223814141|NCT03911453|DRUG|Rucaparib|Patients will be treated with single agent rucaparib for 3wks and then proceed to surgery. Core-biopsies (at the time of diagnosis) and tumor from the surgical resection will be assessed for change in expression of PD-L1 by Immunohistochemical assay (IHC).
223814142|NCT03919370|OTHER|No intervention|there will be NO intervention
223814143|NCT04829383|DRUG|Atezolizumab|1,200 mg
223814144|NCT04829383|DRUG|Bevacizumab|15 mg/kg
223814145|NCT04260477|DRUG|6EH³R³Z|"A triple dose is defined as the triple of the routine dose used for a specific WHO weight band. Hence, the mg/kg within a weigh-band varies, as is the case in routine practice.~Dosing takings into consideration the fixed dose combination (FDC) tablets (one tablet: 150 mg R + 75 mg H + 400 mg Z + 275mg E). Dosage relies on tables with dosage by weight-bands used by WHO for the Cat. 1 regimen. The dosage used for the intensive phase of the Cat. 1 regimen applies for the whole treatment duration. A double dose of H and R is added to the recommended normal dose for adults (WHO,2003)"
223814146|NCT04260477|DRUG|6EHRZ|"Recommended normal dose adults (WHO, 2003)~* H: 5 (4-6) mg/kg/day~* R: 10 (8-12) mg/kg/day~* Z: 25 (20-30)mg/kg/day~* E: 15 (15-18)mg/kg/day"
223814147|NCT04630496|BEHAVIORAL|Fitbit|Electronic activity tracker
223814148|NCT06066086|PROCEDURE|A hinge flap will be performed to reinforce the buccal advancement flap to close the oroantral fistula at the most posterior area of the maxilla|The hinge flap is raised via circular incision around the oral side of the oroantral fistula then sutured with purse suture to close the sinus membrane perforation and it is used as an additional layer that reinforce the buccal advancement flap
223814149|NCT06066086|PROCEDURE|An anteriorly based palatal flap will be performed to close the oroantral fistula at the most posterior area of the maxilla|Two paralleling incisions will be performed on the palatal side of the fistula. The distance between the two incisions will be 2 to 3 mm greater than the width of the fistula. Then the two incisions will be connected together via a circular incision at the bony end of the hard palate. The flap reflection will be performed, and the greater palatine vessels will be legated and cauterized to allow lateral repositioning of the flap over the fistula. The flap will be sutured to the buccal tissues.
223814150|NCT04422093|DEVICE|OrthoKontrol|Fixing OrthoKontrol Sensor on multibracket appliance to measure cooperation
223814151|NCT06071026|DEVICE|Net Ultra Filtration Rate|The net ultra filtration rate is modified every 6 hours accordingly to randomisation
223814152|NCT06385457|BEHAVIORAL|Mindhelper- A national youth mental health promotion website|Mindhelper is an open-access, digital self-directed mental health service that provides information, self-help tools and guidance to young people in Denmark.
223814153|NCT05852223|DRUG|Pembrolizumab|Neoadjuvant pembrolizumab 200mg Q3W will be administered via IV infusion for 2 courses from the date of randomization until to the date of thyroidectomy.
223814154|NCT06250946|DRUG|HRS-7535;Placebo|HRS-7535;Placebo
223814155|NCT06250946|DRUG|Placebo|Placebo
223814156|NCT06150781|DRUG|erenumab-aooe|Dose and treatment duration will be advised by the HCP
223814157|NCT05908357|OTHER|Exergaming|Use of the exergame XboX 360 series with kinect sensor
223814158|NCT05908357|OTHER|Booklet|Use of the booklet with instructions of exercises to be done at home with tele-health through whatsapp app.
223814159|NCT04285307|BEHAVIORAL|Sleep Hygiene tips|Students receive a packet of information on how to improve their sleep habits and hygiene.
223814160|NCT06679309|OTHER|Integrated care plan|Complex care plan facilitated by the integrated care lead with 90 day follow-up, 24/7 phone support and connection with resources and services
223814161|NCT06584175|BEHAVIORAL|Internet Delivered Cognitive Behavioural Therapy|The tinnitus ICBT program consists of 1) an overview of tinnitus, depression, and anxiety; 2) managing unhelpful thoughts and learning problem solving strategies association with pain, anxiety, depression, and disability; 3) management of common symptoms associated with tinnitus, anxiety, and depression; 4) developing strategies to maintain activities while minimizing fatigue; and 5) strategies to improve quality of life through effective goal setting. Supplementary lessons can be accessed at any time (e.g., sleep, communication, problem solving, assertiveness training). Materials are presented in a didactic (i.e., text-based and audio with visual images) and case-enhanced learning format (i.e., stories demonstrate the application of skills). Case vignettes that specifically reflect the experiences of those with tinnitus are included.
223814162|NCT04201106|BEHAVIORAL|Open Label Placebo with Rationale|In the OLP + rationale group, the participants will be prescribed to take placebos for 2 weeks with the standard 4-point accompanying rationale: (1) the placebo effect is powerful, e.g. in clinical trials placebos are roughly 80% as effective as antidepressants; (2) classical conditioning is a possible mechanism for automatic self-healing - meaning that the body can automatically respond to taking placebo pills like Pavlov's dogs who salivated when they heard a bell; (3) placebo-treated patients who are more compliant have better outcomes, therefore the placebos should be taken faithfully; and (4) positive expectations increase placebo effects, but it is OK to have doubts.
223814163|NCT04201106|BEHAVIORAL|Open Label Placebo without Rationale|In the OLP without rationale group, the adolescents will be asked to take placebos for 2 weeks but they will be told that the pills contain inert substance and do not have any pharmacological effect.
223814164|NCT03761589|BEHAVIORAL|AFL Intervention|The AFL intervention consisted of two 90-minute sessions per week for 12 months for both children and parents. The child physical activity sessions, held separately from the parent sessions, aimed to achieve 60 minutes of moderate-to-vigorous physical activity during each session through structured play activities, athletic drills, and sport exercises. Child dietary behaviors were taught through educational activities in small groups. For the parent program, behavior modification techniques were used to guide parents toward changing their own and their child's behavior. Take-home materials for self-monitoring of behaviors were used for both the child and the parent in order to reinforce concepts discussed in class.
223814165|NCT03761589|BEHAVIORAL|Wait-List Control|Families that were randomly assigned to the wait-list control group were asked not to change their normal physical activity or dietary behaviors for the duration of the 12-week waiting period. They were asked to participate in the baseline and 12-week evaluations and then they were enrolled to receive the 12-week intervention.
223814166|NCT05550415|DRUG|Simvastatin 40mg|The administration of Simvastatin 40 mg in addition to ACT regiment of neoadjuvant chemotherapy
223814167|NCT05550415|DRUG|Placebo|The administration of Placebo capsule 40 mg in addition to ACT regiment of neoadjuvant chemotherapy
223814168|NCT04954586|OTHER|Pain Informed Movement|Participants will attend a twice weekly exercise program.
223814169|NCT02063828|DEVICE|Group A - Device guided breathing low dose|Group A: 15 minutes once a day, 5 days a week for 12 weeks.
223814170|NCT02063828|DEVICE|Group B - Device guided breathing high dose|Group B - 15 minutes twice a day, 5 days a week for 12 weeks.
223814171|NCT02063828|DEVICE|Group C - Usual Breathing Control Group|Group C - 15 minutes per day, 5 days a week for 12 weeks.
223814172|NCT03334500|DEVICE|[18F]FluorThanatrace|Fluorine-18 labeled FluorThanatrace \[18F\]FTT can be synthesized with high specific activity so the quantity of mass injected with the radiopharmaceutical is \< 10 μg.
223814173|NCT03334500|DRUG|Poly(ADP Ribose) Polymerase 1|Poly(ADP-ribose) polymerase (PARP) is a family of enzymes involved in base excision repair (the repair of DNA single-strand breaks) and alternative end joining (repair of DNA double-strand breaks). The molecular basis of PARP1 inhibitor function may depend on the dual roles of PARP1 as a modulator of gene transcription in addition to DNA damage repair 3.
223814174|NCT06362512|BEHAVIORAL|Dual-task training|participants receive three 60-minute COGMOTION dual-task exercise sessions per week for six consecutive weeks.
223814175|NCT06362512|BEHAVIORAL|Single-task training|participants receive 30-minute single motor tasks with 30-minute single cognitive tasks three times per week for six consecutive weeks.The cognitive and mobility exercises will be the same as those in the dual-task group, but they will be performed separately.
223814176|NCT06362512|BEHAVIORAL|Upper limb strengthening exercise|participants receive upper limb strengthening exercise for 30 minutes and flexibility exercises for 30 minutes three times per week for six consecutive weeks. The training is performed in sitting or standing position and no cognitive load will be added.
223814177|NCT05642429|BIOLOGICAL|AV-1959D|Three doses of AV-1959D administered as a sterile suspension via intradermal injection
223814178|NCT05642429|BIOLOGICAL|Placebo|Three doses of Placebo administered as a sterile suspension via intradermal injection
223814179|NCT05637203|BEHAVIORAL|THRIVE (Toward Hope, Recovery, Interpersonal Growth, Values, and Engagement)|"THRIVE is an interpersonally focused recovery and care transition program. THRIVE (previously called RELATE in our SAMHSA grants) involves engaging a person during and following acute suicidal crisis in a sequence of interpersonally focused therapeutic tasks. The purpose of THRIVE is to help CSC guests re-build connections and contribute to the world in ways they find personally meaningful, while also transitioning safely to outpatient, community-based care. THRIVE involves a Belonging and Giving Reflections Group while at the CSC, followed by a 4-week, phone-based, recovery and care transition series of coaching calls."
223814180|NCT05637203|BEHAVIORAL|Discharge / Safety Planning|"* A written safety plan completed with the person~* Mental health appointment scheduled within seven days~* One phone follow-up call within 30 days"
223814181|NCT02329548|OTHER|Alizarin Red|An Alizarin Red mixture will be applied to all exposed skin below the angle of the mandible. Once applied the patient will be tilted to 70 degrees. Serial photos will be taken once sweat begins and until conclusion of the test.
223814182|NCT06464185|DRUG|Bispecific antibody-based combined with CAR-T cell therapy|"lymphocytes collection, and bispecific antibody-based therapy will be performed after successful Lymphocytes collection: Obinutuzumab:1000mg, cycle 1 day 1(C1D1) ,IV.~Glofitamab: 2.5 mg, C1D8; 10 mg,C1D15 ; 30 mg,C2D1 and C3D1, IV. It can be combined with other Immunization therapy during the use of bispecific antibodies according to the patient's condition.~On C4D1, the patient will be pretreated with fludarabine and cyclophosphamide (FC) regimen, and then infused with CART cells at a specific dose of 4 \* 1000000/Kg. Bispecific antibody maintenance therapy will be initiated on month 1/2/3 after CART infusion. In Phase1 bispecific maintenance therapy will be divided into three dose groups, using a 3 + 3 dose escalation design. In Phase 2, bispecific maintenance therapy will be used at the MTD dose of Phase 1."
223814183|NCT05485792|DIAGNOSTIC_TEST|18F-FAPI PET/CT and 18F-FDG PET/CT|Each subject undergo both 18F-FDG and 68Ga-FAPI PET/CT scans within 1 week
223814184|NCT06579105|DRUG|Placebo (placebo matching AZD5004 film-coated tablet)|Placebo film-coated tablet (matching AZD5004)
223814185|NCT06579105|DRUG|AZD5004|AZD5004 film-coated tablet, once daily during 26 weeks
223814186|NCT06579105|DRUG|Semaglutide|3-14 mg tablets of Semaglutide
223814187|NCT02934074|OTHER|No intervention|
223814188|NCT01062503|DRUG|Zoledronic acid|ZA at a dose of 4mg will be administered by intravenous infusion over 15 minutes in at least 100mls of saline
223814189|NCT04104451|DRUG|Corlicyte|expanded umbilical cord lining mesenchymal stem cells
223814190|NCT05651776|OTHER|Physical Therapy, Exercise|Outpatient physical therapy intervention incorporating golf related assessment of skills and prescribed exercises including postural, balance, and club swing
223814191|NCT00846872|DRUG|GHRP-3 low dose|0.1 µg/kg/hr will be infused subcutaneously in a continuous manner using the Omnipod at the rate of 28 µl/hr
223814192|NCT00846872|DRUG|GHRP-3 high dose|0.5 µg/kg/hr will be infused subcutaneously in a continuous manner using the Omnipod at the rate of 28 µl/hr
223814193|NCT00846872|DRUG|Saline|5% mannitol will be infused subcutaneously in a continuous manner using the Omnipod at the rate of 28 µl/hr
223814194|NCT04113954|DRUG|Mepivacaine Injection|Injection of 0.375% mepivacaine in nerve block
223814195|NCT04113954|DRUG|Mepivacaine Injection|Injection of 1.5% mepivacaine in nerve block
223814196|NCT02335190|PROCEDURE|Radiofrequency ablation|RF ablation will be performed using 2 Nimbus multitined electrodes in a bipolar configuration. The electrodes will be placed along the lateral crest using a leap-frogging technique from the inferomedial aspect of the PSIS to the third transverse sacral tubercle at 1.5-2 cm intervals at the skin surface. A radiofrequency current will be passed for 120 seconds per site resulting in thermal coagulation of the plexus. Prior to performing the thermal lesion, electrical stimulation at 2 Hz and 2.0 V will be administered.
223814197|NCT02335190|PROCEDURE|Sensory block|Participants will undergo a lidocaine block of the PSN at the lateral crest under ultrasound guidance. 0.5 mL of 2% lidocaine will be injected from the inferomedial border of the PSIS to the third transverse sacral tubercle at approximately 1.5 cm intervals along the skin surface.
223814198|NCT02335190|DRUG|Lidocaine|
223814199|NCT00755040|DRUG|cyclosporine ophthalmic emulsion|Given as eye drops
223814200|NCT00755040|OTHER|placebo|Given as eye drops
223814201|NCT06285513|DIAGNOSTIC_TEST|Cardiac ultrasound|Cardiac ultrasound : determination of impairment of cardiac function by echocardiographic analysis (at V1, V3 and V4), Glycocheck : automatic analysis of sublingual microcirculation, Indirect calorimetry : determining the increase in energy expenditure in patients with septic shock
223814202|NCT00733980|DRUG|GSK561679|GSK561679
223814203|NCT00733980|OTHER|Placebo|Placebo
223814204|NCT03501303|PROCEDURE|No touch technique|Veins for CABG is harvested with the no touch technique
223814205|NCT03501303|PROCEDURE|Control technique|Veins for CABG is harvested with the Control technique.
223814206|NCT03626090|BIOLOGICAL|Autologous BM MSC|A total of 100-200ml will be harvested from the subject, in either a single or multiple punctures. This will be processed for autologous MSC infusion.
223814207|NCT06293209|DEVICE|3M cold pack|3M cold pack
223814208|NCT06293209|DEVICE|Perskindol cold spray|Perskindol cold spray
223814209|NCT06293209|DEVICE|Placebo|Placebo
223814210|NCT02891057|DRUG|BAY987517|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation Code: Z44-036)
223814211|NCT01957501|OTHER|MDDScoreTM|The child will receive a single blood draw (about 10 mL).
223814212|NCT03515382|DRUG|GLPG1690|A single oral dose of GLPG1690.
223814213|NCT03515382|DRUG|Itraconazole|A single oral dose of itraconazole.
223814214|NCT03515382|DRUG|Voriconazole|A single oral dose of voriconazole.
223814215|NCT03682835|DIETARY_SUPPLEMENT|FDGard|capsule containing peppermint oil and caraway oil
223814216|NCT03682835|OTHER|Placebo|Placebo capsule containing cellulose
223814217|NCT02701010|BEHAVIORAL|Structured training and leaflet|"The patients who were given both explanatory verbal instructions of the educational leaflet on the structured behavioural therapy for iOAB by continence nurse and the educational leaflet were included in this group."
223814218|NCT02701010|BEHAVIORAL|Structured training|"The patients who were given only explanatory verbal instructions of the educational leaflet on the structured behavioural therapy by continence nurse were included in this group."
223814219|NCT02701010|BEHAVIORAL|Leaflet|"The patients who were given only educational leaflet were included in this group."
223814220|NCT02701010|BEHAVIORAL|Control Group|Patients who were given unstructured explanations about continence care by a healthcare worker were included in control group.
223814221|NCT05476835|COMBINATION_PRODUCT|respiratory exercises - incentive spirometer - walking|respiratory exercises (in form of diaphragmatic breathing, pursed lip breathing exercise and incentive spirometer), rehab exercise program and walking exercise.
223814222|NCT04392063|DRUG|Melatonin 3 mg|The children received crushed Melatonin 3-mg tablets daily, 30-minutes before bedtime for 3-months.
223814223|NCT05670925|DRUG|Camrelizumab plus Famitinib with/without nab-Palitaxel|After enrollment confirmed, the regimen of Camrelizumab Combined with Famitinib will be conducted for 2 cycles (8 weeks). Patients of CR or PR after 2 cycles (8 weeks) will enter dual-therapy maintenance phase until disease progression and will be recorded as PFS-1α. Patients of PD after 2 cycles (8 weeks) will be recorded as PFS-1β. Patients of SD with 2 cycles of dual therapy wlii receive triple therapy regimen: Camrelizumab and Famitinib with nab-Paclitaxel.
223814224|NCT04077255|DRUG|Anti-EGFR antibody in combination with weekly paclitaxel|Intravenous GC-1118 in combination with weekly paclitaxel for EGFR-amplified cancer cancers as a second-line therapy
223814225|NCT00666432|OTHER|This is an observational study model that is family based|This is an observational study model that is family based
223814226|NCT04961866|DIETARY_SUPPLEMENT|parenteral protein 1 g/kg|patients received 1 g/ kg of protein
223814227|NCT04961866|DIETARY_SUPPLEMENT|Parenteral nutrition 2 g/kg|Patients received 2 g/ kg of protein
223814228|NCT03931681|DRUG|OKI-179|OKI-179 single agent
223814229|NCT00231907|BIOLOGICAL|FluMist|Live attenuated influenza vaccine (LAIV) containing approximately 10\^7 TCID50 of each of the 3 influenza strains. 0.5 mL total dose volume administered intranasally via spray applicator (approximately 0.25 mL into each nostril). Administration of Flumist in children under 5 years of age is investigational.
223814230|NCT00231907|BIOLOGICAL|Fluzone|Trivalent inactivated vaccine (TIV), licensed Fluzone preservative free pediatric dose, 0.25 mL administered intramuscularly to the anterolateral thigh muscle or deltoid muscle.
223814231|NCT03169803|DEVICE|NeuroTronik CANS Therapy™ System|The NeuroTronik CANS Therapy™ System is a percutaneous, catheter-based, bedside electrical stimulation system. The System consists of the single-use, disposable NeuroCatheter™ and NeuroCatheter™ Placement Kit, along with the reusable, bedside NeuroModulator™ Development System, and the NeuroTronik CANS Therapy™ Cable.
223814232|NCT05801575|DRUG|Chinese Herbal Medicine (CHM) teabag|Each teabag contains five herbs: Radix et Rhizoma (三七, Sanqi), Moutan Cortex (牡丹皮, Mudanpi), Puerariae Lobatae Radix (葛根, Gegen), Rosae Rugosae Flos (玫瑰花, Meiguihua), and Citri Grandis Exocarpium (化橘紅, Huajuhong). These herbs are benefit to promoting blood circulation, dredging meridians and collaterals, strengthening spleen, regulating qi and decreasing phlegm in Chinese Medicine theories.
223814233|NCT02010632|DRUG|Generic clopidogrel product Apolets®|"* Clopidogrel 75 mg once daily for 7 days~* Blood collection at 0 (before dosing), 1, 2, 4, 6, 8, 12, 24 hours after the last dose, administered at day 7"
223814234|NCT02010632|DRUG|Original clopidogrel product Plavix®|"* Clopidogrel 75 mg once daily for 7 days~* Blood collection at 0 (before dosing), 1, 2, 4, 6, 8, 12, 24 hours after the last dose, administered at day 7"
223814235|NCT03886259|OTHER|Neuromuscular exercises (NEMEX-TJR) and pain neuroscience education|"60min. of neuromuscular exercises (NEMEX-TJR) training two times a week for 3 months (12 weeks, 24 sessions). Physiotherapists will instruct and supervise the participants during the neuromuscular exercises. The aim of the neuromuscular exercise program is to restore normal movement, improve sensorimotor control, re-establishing normal motor program strategies and muscle activation.~60min. of pain neuroscience education at the beginning of intervention period and after 6 weeks. Both sessions will take 60min. and will be conducted by physiotherapists. The aim of the pain neuroscience education is to increase the pain neuroscience knowledge of the patients leading to a better understanding of their chronic pain and thereby engaging the patients in the treatment of their chronic pain and impaired function."
223814236|NCT03886259|OTHER|Pain neuroscience education|60min. of pain neuroscience education at the beginning of intervention period and after 6 weeks. Both sessions will take 60min. and will be conducted by physiotherapists. The aim of the pain neuroscience education is to increase the pain neuroscience knowledge of the patients leading to a better understanding of their chronic pain and thereby engaging the patients in the treatment of their chronic pain and impaired function.
223814237|NCT00070135|BIOLOGICAL|filgrastim|Given SC
223814238|NCT00070135|BIOLOGICAL|Anti-Thymocyte Globulin|Given IV
223814239|NCT00070135|DRUG|busulfan|Given IV
223814240|NCT00070135|DRUG|fludarabine phosphate|Given IV
223814241|NCT00070135|DRUG|methotrexate|Given IV
223814242|NCT00070135|DRUG|tacrolimus|Given PO or IV
223814243|NCT00070135|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic PBSC transplantation
223814244|NCT02947438|DRUG|EPREX®|"Recombinant human erythropoietin falls under the pharmacological class of haematopoietic / anti anaemic agents. It has been developed for the treatment of anaemia in subjects with chronic kidney disease.~Erythropoietin, also known as EPO, is a glycoprotein hormone that controls erythropoiesis, or RBC production. It is a cytokine (protein signalling molecule) for erythrocyte precursors in the bone marrow. Human EPO has a molecular weight of 34,000."
223814245|NCT02947438|DRUG|EPIAO®|"Recombinant human erythropoietin falls under the pharmacological class of haematopoietic / anti anaemic agents. It has been developed for the treatment of anaemia in subjects with chronic kidney disease.~Erythropoietin, also known as EPO, is a glycoprotein hormone that controls erythropoiesis, or RBC production. It is a cytokine (protein signalling molecule) for erythrocyte precursors in the bone marrow. Human EPO has a molecular weight of 34,000."
223814246|NCT06804122|BEHAVIORAL|EXERCISE TRAINING WITH OR WITHOUT MEDICATION|Patients are counseled how to do endurance training and strenght training at home by a trained physiotherapist.
223814247|NCT04869553|OTHER|Management pain with distraction methods ABC|"Every patient will receive :~* The usual pain management of their ward (Treatment A),~* The usual pain management of their ward with a hypnosis session (Treatment B)~* The usual pain management of their ward with a virtual reality session (Treatment C)"
223814248|NCT04869553|OTHER|Management pain with distraction methods BCA|"Every patient will receive :~* The usual pain management of their ward with a hypnosis session (Treatment B)~* The usual pain management of their ward with a virtual reality session (Treatment C)~* The usual pain management of their ward (Treatment A)"
223814249|NCT04869553|OTHER|Management pain with distraction methods CAB|"Every patient will receive :~* The usual pain management of their ward with a virtual reality session (Treatment C)~* The usual pain management of their ward (Treatment A)~* The usual pain management of their ward with a hypnosis session (Treatment B)"
223814250|NCT06247735|DRUG|K-808 (Dose A)|Administered orally once daily
223814251|NCT06247735|DRUG|K-808 (Dose B)|Administered orally once daily
223814252|NCT06247735|DRUG|Placebo|Administered orally once daily
223814253|NCT05741385|DRUG|Caffeine|Caffeine
223814254|NCT05741385|DRUG|Warfarin sodium|Warfarin sodium
223814255|NCT05741385|DRUG|Omeprazole|Omeprazole
223814256|NCT05741385|DRUG|Metoprolol|Metoprolol
223814257|NCT05741385|DRUG|Midazolam|Midazolam
223814258|NCT06341868|DEVICE|KneeStim|Participant will be randomized to either be in control or experimental group
223814259|NCT01121042|DRUG|Ondansetron|8mg per day oral capsule
223814260|NCT01121042|DRUG|Placebo|daily oral capsule matched to active study medication. Made form 100% lactose powder
223814261|NCT01057238|OTHER|Intensive Communication System|Regular family meetings once a week, using a standard protocol
223814262|NCT02522936|DRUG|Biotene oral spray|Biotene oral spray will be provided to participants.
223814263|NCT04173455|DRUG|HZ-A-018|"In the dose-escalation part, subjects will be assigned to five cohorts with increaing dose level to determine DLT and MTD during the first 28-day cycle.~In the expansion part, subjects will be assigned to two fixed dose corhort."
223814264|NCT01764087|DRUG|KX2-391 and Paclitaxel|"A treatment cycle in phase I will consist of 28 days, according to the following schedule:~KX2-391 20 mg PO once daily, Weekly paclitaxel 80 mg/m2 given intravenously over 1 hour on day 1, 8, and 15 of a 28 day cycle.~The trial will initially test the combination of weekly paclitaxel and KX2-391 given PO, once daily , continuously. In case of 2 dose-limiting toxicities (DLT) in the first cohort, this intervention will be terminated~A treatment cycle in phase II will consist of 28 days, according to the following schedule:~KX2-391 MTD PO once daily, Weekly paclitaxel 80 mg/m2 given intravenously over 1 hour on day 1, 8, and 15 of a 28 day cycle."
223814265|NCT04174248|OTHER|BCSMS App|Breast Cancer Using a Self-Management Support mHealth Application
223814266|NCT00818961|BIOLOGICAL|alemtuzumab|43 mg subcutaneously over 3 days (3 mg on day -11, 10 mg on day -10, 30 mg on day -9)
223814267|NCT00818961|BIOLOGICAL|graft-versus-tumor induction therapy|curative potential of allogeneic transplant results from the immune anti-tumor effect of donor cells or GVT/GVL
223814268|NCT00818961|BIOLOGICAL|rituximab|in patients with Cd20+ malignancies: rituximab 375 mg/m\*2 day -13. rituximab 1000 mg/m\*2 on days, -6, +1, +8.
223814269|NCT00818961|DRUG|busulfan|For patients with AML, CML, MDS, MPS and ALL only: IV or oral busulfan may be given IV busulfan: 130 mg/m2 over 3 hours once daily on days -6, -5, -4 and -3 Oral busulfan: taken every 6 hours x 15 doses beginning on day -7 at 6pm and continuing through day -3 at 6am. 1 mg/kg test dose will be given prior to day -7 and PK samples will be drawn to calculate AUC.
223814270|NCT00818961|DRUG|cyclophosphamide|750 mg/m2 infused over 1 hour once daily on days -5, -4 and -3. Cyclophosphamide will be started approximately 4 hours after the start of Fludarabine
223814271|NCT00818961|DRUG|fludarabine phosphate|For patients with CLL, NHL \& HD: 30 mg/m2 infused over 30 minutes once daily on days -5, -4 and -3 For patients with AML, CML, MDS, MPS and ALL: 40 mg/m2 infused over 30 minutes once daily on days -6, -5, -4 and -3.
223814272|NCT00818961|DRUG|methotrexate|5 mg/m2 administered on days +1, +3 and +6
223814273|NCT00818961|DRUG|tacrolimus|0.03mg/kg/day infused over 24 hours starting on day -1 and switched to oral (twice daily divided dose) on day 14 or when able to tolerate PO
223814274|NCT00818961|PROCEDURE|allogeneic bone marrow transplantation|Recipients will receive an allogeneic transplant on day 0 after receiving high-dose chemotherapy. This trial uses matched unrelated donor stem cells.
223814275|NCT05115448|OTHER|Bevel Position|During 6 dialysis sessions, cannulation was applied to the patients with the direction of the arterial needle in the antegrade direction and the conical tip facing upwards. In the next 6 dialysis sessions, cannulation was applied to the patients in an antegrade direction and with the conical tip facing down.
223814276|NCT00000280|DRUG|Nimodipine|
223814277|NCT00424125|BEHAVIORAL|Enhanced Pharmacy Care|"Participants randomized to Enhanced Pharmacy Care will have their prescriptions electronically transmitted or faxed to one of the five participating pharmacies.~Pharmacists will then provide real-time, targeted education around the purpose and use of the new and refilled ICS medications to study participants and their families at each point of contact, including rationale for their use, device teaching, dosage review, and importance of compliance. Families randomized to enhanced care will also be contacted monthly by phone and mail with reminders to fill their controller medications prescriptions and to seek ongoing longitudinal asthma care with their primary care providers."
223814278|NCT00424125|BEHAVIORAL|Control|Usual care.
223814279|NCT01530672|DEVICE|MBIO POC combined HIV syphilis test ( SnapEsi)|Venipuncture for routine ANC screening plus additional for device validation purposes.
223814280|NCT00286793|DRUG|AT-101|Oral
223814281|NCT05397535|BEHAVIORAL|Baduanjin|"Participants in Baduanjin group will receive health education on hypertension and attend a 4-hour class to learn Baduanjin before receiving the interventions after the randomization. Baduanjin exercise protocol is based on the Fitness Qigong Baduanjin Standard enacted by the General Administration of Sports in 2003. Each Badaunjin exercise session will last at least 30 minutes and be conducted at least 5 days per week for 52 weeks. These participants will be required to practice Baduanjin regularly, and the researchers will monitor their adherence to practice and provide reminders if needed."
223814282|NCT05397535|BEHAVIORAL|Brisk walking|Participants in this group will receive health education on hypertension and practice brisk walking on their own for at least 30 minutes, at least 5 days per week for 52 weeks. These participants will be required to do brisk walking regularly, and the researcher will monitor their adherence to practice and provide reminders if needed.
223814283|NCT04658641|DEVICE|Boston Scientific: Study tool computer|Compare clinical outcome measurements of complex pulse shapes to standard clinical pulse shape
223814284|NCT06387472|DEVICE|AI algorithm to evaluate photographs of skin test patch regions|Interpretation of skin test patch regions via artificial intelligence (AI)
223814285|NCT06387472|DEVICE|Allergen Patch|Contains dime-sized disks which have different substance to which a person may be allergic. Two different patches were used due to the number of allergens being tested. Each patch can only hold 10 allergens and 14 allergens were tested in patients.
223814286|NCT03843918|DRUG|LAE001|LAE001 BID will be orally administered until the subjects develop disease progression, intolerable adverse events, or trial withdrawal decided by the investigator/subject. The LAE001 dose adopted for the phase II study will be based on the RP2D determined in the phase I study.
223814287|NCT06559956|OTHER|Daytime titration polysomnography|A titration polysomnography assesses the device settings and, if necessary, the stimulation strength will be adjusted based on observed respiratory events and/or snoring. Patients in the daytime titration PSG cohort were instructed to refrain from sleeping during the night, and in the morning, they were permitted to sleep in a soundproof room without daylight at the sleep lab.
223814288|NCT02650869|DIETARY_SUPPLEMENT|Probiotics|probiotics at a dose of 3x109 CFU/day. (Cap TS6 probiotic + contain Bifidobacterium spp., Lactobacillus at 6x109 CFU = 6 billion CFU manufactured by TENSALL BIO-TECH CO.LTD.Taiwan, distributed by Century Health Care, Bangladesh)
223814289|NCT02650869|DIETARY_SUPPLEMENT|Breast milk|Normal breast milk will be given as part of standard care
223814290|NCT05152173|BIOLOGICAL|EN3835|Participant will receive a maximum dose of up to1.8mg of EN3835 injection
223814291|NCT05152173|OTHER|Placebo|Participant will receive a maximum dose of up to1.8mg of Placebo injection
223814292|NCT02239380|DRUG|Lorazepam|"intravenous administration. Dosage for adult subjects (16 years aged and over): 4 mg Dosage for pediatric subjects (3 months to \< 16 years): 0.05 mg/kg (but not exceeding 4 mg) Frequency: Intravenous administration of lorazepam. Subjects whose seizure does not stop or recurs within 10 minutes after the initial dose may receive the same amount of lorazepam injection no earlier than 10 minutes following the initial dose.~Also, subjects whose seizure stops within 10 minutes after the initial dose, but recurs thereafter (within 12 hours) may receive the same amount of lorazepam injection; a total of 2 doses will be permitted in this study."
223814293|NCT04035057|OTHER|Behaviorally Enhanced Training|Therapists in the Behaviorally Enhanced Training will receive the same didactic instruction as those in the Standard Didactic Training arm during the first full day of training. In the second half-day training, those in the Behaviorally Enhanced Training arm will focus on behavioral strategies (i.e., exposure to exposure) that provide direct experience with the process of treatment delivery.
223814294|NCT04035057|OTHER|Standard Didactic Training|Therapists in the Standard Didactic Training arm will complete training as usual, consisting of PowerPoint and video training tasks instructing the delivery of exposure therapy for anxious youth.
223814295|NCT04509895|PROCEDURE|Lateral extensile approach in calcaneal fractures fixation|The standard extended lateral approach with L-shaped incision was made in this group, which originated vertically from 5 cm over lateral malleolus or the midpoint between the fibula and Achilles tendon and ended on the base of the fifth metatarsal . The incision is made directly to the bone at the corner to create a full-thickness flap. Attention must be paid to protect the sural nerve and peroneal tendons as well.
223814296|NCT04509895|PROCEDURE|Minimally invasive sinus tarsi approach in calcaneal fractures fixation|An incision is made from the tip of the lateral malleolus toward the base of the fourth metatarsal bone. The incision lies in a plane between the superficial peroneal nerve and the sural nerve. Care is taken to bluntly dissect after the skin incision to protect the sural nerve or branches of the superficial peroneal nerve. By mobilizing the sinus tarsi fat pad dorsally, the incision was deepened. The extensor digitorum brevis muscle is sharply elevated off of the anterior process with the lateral root of the inferior extensor retinaculum and reflected dorsally and distally. The peroneus brevis and peroneus longus tendons are split, allowing exposure to the sinus tarsi and visualization of the posterior facet of the subtalar joint.
223814297|NCT03534310|DRUG|LIRAGLUTIDE 3 Mg/0.5 mL (18 Mg/3 mL) SUB-Q PEN INJECTOR (ML)|
223814298|NCT03534310|OTHER|lifestyle modification|
223814299|NCT03534310|OTHER|sleeve gastrectomy|
223814300|NCT00194051|PROCEDURE|gastric bypass surgery|
223814301|NCT01646593|DRUG|Regorafenib (BAY73-4506)|160 mg BAY73-4506, 3 weeks on drug, 1 week off
223814302|NCT01636999|DRUG|50% Nitrous Oxide/50% Oxygen|The gas mixture is provided via the Sedara portable gas delivery system. This system is equipped with a non-rebreather mask which the patient holds over their mouth and nose. The delivery of the gas is only triggered by the patient's spontaneous breath. The gas machine will be provided to the patient to use as much as they like during the 60 minutes data collection period. The only dose which the machine allows to be administered is 50% Nitrous Oxide/50% oxygen.
223814303|NCT02904876|RADIATION|Diffusion Magnetic Resonance Imaging at 6 months|2-year follow-up MRI of patients initiating treatment with Tysabri with anti-JCV antibody positive or negative. Patients enrolled will benefit from diffusion MRI at 6 months, in addition to conventional MRI.
223814304|NCT06076720|DEVICE|New head-mounted visual aids|New head-mounted visual aids such as Beyes, HOLA, Acesight and OXSIGHT are the latest wearable electronic visual aids
223814305|NCT06492824|BEHAVIORAL|Enjoyable Activities Condition|Participants complete an introduction video about the intervention. They will then take a pre-intervention survey, after which they will choose five enjoyable activities from a large list. Daily text message reminders will be sent to BA participants in the morning to remind them to do their enjoyable activities for the day, as well as a link to a checklist where they will report how frequently they have completed any of their five activities from the previous day (example text message in documentation). At the end of the month, they will complete a follow-up survey consisting of the same measures from the pre-intervention survey.
223814306|NCT06492824|BEHAVIORAL|Healthy Activities Condition|They will take a pre-intervention survey and choose five enjoyable activities from the same list; however, active control participants will not explicitly be asked to complete these activities for the intervention. Participants in the active control condition will be promoted to complete tasks such as drinking more water, going to bed early, brushing their teeth, showering or bathing for that day, and eating well balanced meals. Daily text reminders will be sent about these healthy living activities in the morning. In that same message, they will receive a link to a checklist where they will report about their completed healthy living activities for the previous day (example text message in documentation). At the end of the month, they will also complete a follow-up survey consisting of the same measures from the pre-intervention survey.
223814307|NCT02465840|PROCEDURE|custom-made dynamic hand splint|custom-made dynamic splinting with more early active exercises intervention.
223814308|NCT02465840|PROCEDURE|custom-made protective hand splint|Immobilization splint with gentle ROM exercises
223814309|NCT02465840|OTHER|physical therapy and occupational therapy|both the immobilization and Kleinert programs including physical therapy and occupational therapy for 2-3 times per week.
223814310|NCT05716906|DIETARY_SUPPLEMENT|Melatonin|5mg gummy 30 min before bedtime for 2 consecutive nights
223814311|NCT06977100|BEHAVIORAL|Gratitude|Participants in this group will receive a gratitude journal where they will be asked to write down three things they are grateful for each day and reflect why they are grateful for these things. Journaling will take place from the comfort of their home on three days of their choice per week, for a total duration of two weeks.
223814312|NCT06977100|OTHER|General Wellness|Participants in this group will receive a general wellness journal where they will be asked to reflect on three things that happened, or they did during the day (daily activities). Journaling will take place from the comfort of their home on three days of their choice per week, for a total duration of two weeks.
223814313|NCT06512558|PROCEDURE|Additional MRI with gadolinium injection and 3D camera imaging|The study includes an additional MRI with gadolinium injection, performed in addition to standard practice. In addition, 3D camera images will be acquired at the time of surgery.
223814314|NCT01325025|OTHER|High-field MRI (3 Teslas)|"* anatomical location~* conventional anatomical sequence T1, T2, FLAIR~* diffusion tensor sequence (21 directions)~* high angular resolution diffusion (HARDI) sequence~* field map~* reflexology T1, T2~* spectroscopic imaging sequence"
223814315|NCT01325025|OTHER|High-field MRI (3 Teslas)|"* anatomical location~* conventional anatomical sequence T1, T2, FLAIR~* diffusion tensor sequence (21 directions)~* high angular resolution diffusion (HARDI) sequence~* field map~* reflexology T1, T2~* spectroscopic imaging sequence"
223814316|NCT06173531|DRUG|Carbetocin|Carbetocin nasal spray 3.2 mg three times daily (TID)
223814317|NCT06173531|DRUG|Placebo|Placebo given TID, identical in appearance respective to carbetocin treatment
223814318|NCT06807775|OTHER|Dietary Intervention (time-restricted feeding model (16:8))|Time-Restricted Feeding (16:8 model): Participants can consume food in any amount during an 8-hour window (08:00-16:00), but no food or energy-containing drinks are allowed during the remaining 16-hour fasting period.
223814319|NCT06807775|OTHER|Dietary Intervention (energy restricted dietary intervention)|Participants' daily energy needs are calculated based on their basal metabolic rate and physical activity. The energy intake is then reduced by 15-25%. The diet plan consists of 3 main meals and 2-3 snacks, with the daily intake of carbohydrates, proteins, and fats making up 50-60%, 15-20%, and 25-30% of the total daily energy, respectively.
223814320|NCT04965350|BIOLOGICAL|Recombinant Human Papillomavirus Bivalent (Types 16, 18) Vaccine (Pichia pastoris)|sterile solution for intramuscular injection
223814321|NCT03534973|OTHER|Caffeine intake|Cataract surgery in eyes with prior caffeine intake
223814322|NCT03534973|OTHER|No caffeine intake|Cataract surgery in eyes without prior caffeine intake
223814323|NCT00449280|DRUG|Sorafenib|400mg BID (200 mg twice daily)
223814324|NCT00449280|DRUG|Rapamycin|30mg once weekly
223814325|NCT00449280|DRUG|Rapamycin|3mg once daily
223835509|NCT06175663|DRUG|Antihypertensive medication withdrawal|To determine if high blood pressure is caused by an overproduction of aldosterone in the adrenal gland (i.e. primary hyperaldosteronism), the plasma aldosterone/renin ratio (ARR) can be determined. Because many common hypertensive drugs are known to interfere with this ratio, patients often have to discontinue drugs prior to screening or switch to drugs that are known not to affect ARR (i.e. doxazosin, verapamil, diltiazem, hydralazine). Drugs have to be stopped for at least four weeks (for mineralocorticoid receptor antagonists) or two weeks (for diuretics, Angiotensin Converting Enzyme (ACE) inhibitors, Angiotensin Receptor Blockers (ARBs)). This often leads to a temporary increase in blood pressure. After diagnostics are completed, medication is adjusted accordingly and blood pressure levels drop again.
223814326|NCT06825871|DEVICE|Smart Inhaler Monitoring Platform for Asthma Management|"The intervention utilizes the aflo™ digital platform, a comprehensive system designed to improve asthma management through advanced technology. It integrates the following components:~1. Electronic Inhaler Sensor: The sensor attaches to a metered-dose inhaler (MDI) and a spacer (if applicable) to automate and provide feedback on the six critical steps of proper inhaler technique, such as shaking the inhaler, breathing out, inhaling slowly, and holding the breath. The sensor also records and stores medication usage data securely.~2. Mobile Application: The app delivers real-time notifications and feedback on inhaler technique, sends reminders for daily controller medication, tracks asthma symptoms, and provides monthly Asthma Control Test (ACT) assessments. It also offers reminders for spacer cleaning and customizable alerts for caregivers.~3. Clinician Portal: Data collected from the sensor and app is accessible via a secure clinician portal, enabling healthcare providers to monitor pa"
223814327|NCT06605612|DIAGNOSTIC_TEST|FBIndex|There will be no intervention.
223814328|NCT06596265|BEHAVIORAL|Fit2Lead Group 1-2|"Each park serves anywhere from 2 to 9 feeder schools within these neighborhoods (a target population of 34 000 youth residents aged 12-17 years), and transportation from schools to parks is provided at no cost within a 3-mile radius of a program park. Fit2Lead participants can also enroll in the MDPROS youth summer camp at no charge.~Work assignments support MDPROS operations and recreation staff. Interns in Phase II rotate every 8 weeks for exposure to different job opportunities, supervisors, and mentors.~Duke is conducting a secondary data analysis on data collected as part of the Fit2Lead study."
223814329|NCT06603077|DRUG|AVTX-009 Regimen 1|AVTX-009 will be administered as a subcutaneous injection every 4 weeks.
223814330|NCT06603077|DRUG|AVTX-009 Regimen 2|AVTX-009 will be administered as a subcutaneous injection every 2 weeks.
223814331|NCT06603077|DRUG|Placebo|Matching placebo will be administered as a subcutaneous injection every 2 weeks.
223814332|NCT06051890|DRUG|Extended-Release Buprenorphine (XRB)|XRB (Sublocade) will be delivered as a pre-filled 2cc subcutaneous monthly injection, using a 300mg starting dose in most cases (100mg starting doses are available per the study team's clinical judgement). XRB consists of a depot injectable formulation in polymeric solution to the abdomen and releases buprenorphine over 28-days (4-weeks) by diffusion as the polymer biodegrades. Prior to an initial injection, the participant must be stable for several days or longer on sublingual buprenorphine (SLB) at doses of 8mg/day or higher. Participants will receive at least one XRB monthly injection prior to release, which investigators anticipate to usually be the 300mg dose. Some participants will be recruited earlier during the incarceration (or experience delayed release dates and then longer than anticipated incarcerations); XRB will be continued monthly from the time of induction to the day of release.
223814333|NCT06051890|DRUG|Sublingual Buprenorphine (SLB)|Maintenance of existing SLB prescription (treatment as usual).
223814334|NCT04854304|DIAGNOSTIC_TEST|Fast Breast Abbreviated Magnetic Renounce Imaging|Fast Breast MRI Imaging
223814335|NCT04239573|PROCEDURE|Computed Tomography|Undergo CT
223814336|NCT04239573|PROCEDURE|Endoscopic Ultrasound|Undergo EUS
223814337|NCT04239573|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223814338|NCT04239573|OTHER|Quality-of-Life Assessment|Ancillary studies
223814339|NCT04239573|OTHER|Questionnaire Administration|Ancillary studies
223814340|NCT04766944|OTHER|No intervention|No intervention
223814341|NCT03851133|OTHER|Blood Sample Collection|Participants will be asked to donate blood at baseline (+/- 30 days of diagnosis date) and at the time of follow-up (approximately 6 months and approximately 12 months after baseline).
223814342|NCT03851133|OTHER|Tumor Sample collection|At the time of tissue biopsy and surgical resection (if applicable), pancreatic tumor tissue and tissue from site of metastasis will be collected.
223814343|NCT03851133|OTHER|Data Collection|Participants will be asked to complete a 3 page screening tool at the time of their in-person clinic visit, as well as questionnaires at baseline and at 6 and 12 months.
223814344|NCT06990399|DRUG|KSI-101|Intravitreal injection
223814345|NCT06990399|OTHER|Sham Comparator|Sham injections
223814346|NCT04323189|DRUG|Sitagliptin 100mg|Sitagliptin will be administered daily for 7 days, with a study day on day 7.
223814347|NCT04323189|DRUG|Placebo Oral Tablet|Placebo will be administered daily for 7 days, with a study day on day 7.
223814348|NCT06602024|BIOLOGICAL|mRNA-1010|Intramuscular (IM) injection
223814349|NCT06602024|BIOLOGICAL|Fluarix®|IM injection
223814350|NCT06602024|BIOLOGICAL|Influsplit® Tetra|IM injection
223814351|NCT06602024|BIOLOGICAL|Fluarix Tetra|IM injection
223814352|NCT06602024|BIOLOGICAL|Alpharix® Tetra|IM injection
223814353|NCT02417532|DEVICE|Rehabilitation using REX|Exercises of wheelchair dependent subjects using REX
223814354|NCT02316379|DRUG|Hyperpolarized 129 Xenon|During the scans, subject will inhale hyperpolarized Xenon gas for up to 16 seconds per scan, for up to 4 separate MR scans
223814355|NCT02316379|DEVICE|MRI|
223814356|NCT05388500|DRUG|Paclitaxel + Trastuzumab|"Regarding neoadjuvant treatment :~\- 9 to 12 weeks of neoadjuvant treatment Trastuzumab IV (8mg/kg loading dose followed by 6 mg/kg maintenance dose) or SubCutaneous (SC) (600mg fixed dose) every 3 weeks + weekly Paclitaxel IV : 80 to 90 mg/m2~Regarding adjuvant treatment patients will receive one of the following anti-HER2 therapy following the current standard to complete 1 year of anti-HER2 therapy in total :~* in case of pCR : patient will receive trastuzumab~* in case of non pCR : patients will receive trastuzumab emtansine (T-DM1)"
223814357|NCT05388500|DRUG|Trastuzumab|"Regarding neoadjuvant treatment :~\- 9 to 12 weeks of neoadjuvant treatment Trastuzumab IV (8mg/kg loading dose followed by 6 mg/kg maintenance dose) or SC (600mg fixed dose) every 3 weeks~Regarding adjuvant treatment patients will receive one of the following anti-HER2 therapy following the current standard to complete 1 year of anti-HER2 therapy in total :~* in case of pCR : patient will receive trastuzumab~* in case of non pCR : patients will receive trastuzumab emtansine (T-DM1)"
223814358|NCT06699758|OTHER|CD45RA- memory T lymphocytes cells sourced from healthy peripheral blood mononuclear cells male donors.|CD45RA- memory T lymphocytes cells sourced from healthy peripheral blood mononuclear cells male donors. These cells will be administered intranasally.
223814359|NCT06716749|DRUG|Morphine|10 mg morphine in 10 mL normal saline
223814360|NCT06716749|DRUG|Vancomycin|500 mg Vancomycin in 100 mL of normal saline
223814361|NCT07046572|DRUG|Methoxyflurane - Penthrox|3ml of Methoxyflurane via a Penthrox inhaler
223814362|NCT07046572|OTHER|Placebo Penthrox inhaler|3ml of normal saline via an identical placebo Penthrox inhaler
223814363|NCT07044544|DRUG|G-CSF|Granulocyte colony-stimulating factor (G-CSF) is a glycoprotein that stimulates the bone marrow to produce granulocytes and stem cells and release them into the bloodstream.
223814364|NCT07044544|DRUG|Decitabine|Decitabine is a hypomethylating agent.
223814365|NCT07044544|DRUG|Venetoclax|Venetoclax is a selective inhibitor of BCL-2 protein.
223814366|NCT07047235|PROCEDURE|Pulmonary vein reisolation|The pulmonary veins will be checked electrically and further ablation will be undertaken if they are not isolated.
223814367|NCT07047235|PROCEDURE|Ganglionic plexi ablation|Sites where ganglionix plexi have been found will be ablated.
223814368|NCT07047235|PROCEDURE|Substrate ablation|Areas of rate dependent conduction velocity slowing will be targeted using cathether ablation
223814369|NCT05604716|OTHER|observational study|observational study
223814370|NCT00242281|DRUG|APC-111 MP Tablet, 775 mg|
223814371|NCT02584725|DRUG|Tranexamic Acid|Comparison of 3 different doses of the drug
223814372|NCT05751941|DRUG|Abiraterone|1000 mg of Abiraterone will be given orally daily plus prednisone 5-10 mg daily
223814373|NCT05751941|DRUG|Enzalutamide|160 mg of Enzalutamide will be given orally daily ending at week 4
223814374|NCT05751941|DRUG|Apalutamide|240 mg of Apalutamide will be given orally daily ending at week 4
223814375|NCT05751941|DRUG|Sipuleucel-T|Sipuleucel-T is considered standard of care and will be infused into the participant three times at approximately 2-week intervals starting week 0, 2 and 4.
223814376|NCT05259527|DRUG|Ergocalciferol Capsules|Vitamin D2 50,000IU by mouth once weekly for 8 weeks then once per month thereafter.
223814377|NCT05259527|DIETARY_SUPPLEMENT|Cholecalciferol Capsules|Vitamin D3 5,000IU by mouth daily
223814378|NCT06861933|OTHER|Physiotherapy and rehabilitation|It is reported in the literature that scapulohumeral rehabilitation applied in primary shoulder pathologies is effective. In neurological diseases, a study was found in which scapulohumeral rehabilitation was applied to individuals diagnosed with stroke and reported that it was effective. However, when the literature was examined, no study was found in which scapulohumeral rehabilitation was applied to individuals diagnosed with PD. Therefore, our aim is to compare the effectiveness of the scapulohumeral rehabilitation program to be applied for shoulder dysfunction, which is thought to be one of the early findings in PD and is reported to be related to other main findings in PD, with the upper extremity neurorehabilitation program.
223814379|NCT06764940|DRUG|Utidelone|Utidelone 30 mg/m2/d i.v, once a day for 5 consecutive days, every 21 days as a treatment cycle.
223814380|NCT06764940|DRUG|Utidelone in combination with capecitabine|UTD1 25 mg/m2/d i.v, once a day for 5 consecutive days, every 21 days as a treatment cycle plus capecitabine 1000 mg/m2 orally twice a day, for 1 to 14 days, 21 days as a treatment cycle.
223814381|NCT06764940|DRUG|Utidelone in combination with capecitabine|Utidelone 30 mg/m2/d i.v, once a day for 5 consecutive days, every 21 days as a treatment cycle plus capecitabine 1000 mg/m2 orally twice a day, for 1 to 14 days, 21 days as a treatment cycle.
223814382|NCT06764940|DRUG|Utidelone in combination with capecitabine|Utidelone 25 mg/m2/d or 30 mg/m2/d i.v, once a day for 5 consecutive days, every 21 days as a treatment cycle plus capecitabine 1000 mg/m2 orally twice a day, for 1 to 14 days, 21 days as a treatment cycle.
223814383|NCT04334226|OTHER|Interview|Interviews will explore the patient's and caregiver's experiences and perceptions of ostomy surgery prior to the Bootcamp and after the Bootcamp from a physical, psychological, social, and spiritual perspective
223814384|NCT06772181|BEHAVIORAL|IM@Home Program|Participate in the IM@Home program delivered via Zoom
223814385|NCT06772181|OTHER|Medical Device Usage and Evaluation|Wear a FitBit activity tracker
223814386|NCT06772181|OTHER|Questionnaire Administration|Ancillary studies
223814387|NCT06772181|OTHER|Interview|Ancillary studies
223814388|NCT07073820|DRUG|PF-07868489|Participants will receive subcutaneous doses of PF-07868489 every 4 weeks
223814389|NCT06770387|BEHAVIORAL|mhealth|mobile application for postoperative period
223814390|NCT06779123|DEVICE|Transauricular vagus nerve stimulation.|TRAVAGUS is a portable electrical vagus nerve stimulator device that non-invasively activates the auricular branch of the vagus nerve in the left ear. The system consists of two units, the electrical stimulator and the ear electrodes that are mounted in a headset. The electrical signals are delivered transcutaneously to the ear via two separate cables connected to two aluminium electrodes. There is no need for electrode gel application on the auricular skin, since the conductivity of the two metallic electrodes is fully sufficient for functional electrical contact. The device is powered by 4 x 1,5V AAA batteries. The electrical source is a CE-marked tens unit termed STIM-PRO X9+, AXION GmbH, Leonberg, Germany. The investigational headset with auricular electrodes is designed and manufactured by taVNS AB in Saltsjö-Duvnäs, Sweden. Stimulation will be performed for 5 min twice daily for 12 weeks.
223814391|NCT06779123|DEVICE|transauricular vagus nerve non-stimulation|TRAVAGUS is a portable electrical vagus nerve stimulator device that non-invasively activates the auricular branch of the vagus nerve in the left ear. The system consists of two units, the electrical stimulator and the ear electrodes that are mounted in a headset. The device is placed to the ear but no stimulation will occur. The procedure is performed for 5 min twice daily for 12 weeks.
223814392|NCT07086638|DRUG|Photo-responsive nanozyme|The nanozyme scavenges ROS at the site of dermatitis and simultaneously responds to NIR light to generate mild heat, thereby promoting the healing of radiation-induced skin injury.
223814393|NCT05401110|DRUG|Osimertinib|Osimertinib given by mouth daily at 40mg or 80mg depending on the starting dose level assigned per investigator. Therapy will continue until disease progression, patient withdrawal, or treatment intolerance.
223814394|NCT05401110|DRUG|Carotuximab|Carotuximab is administered intravenously weekly for the first 4 weeks, then every 2 weeks at 10mg/kg or 15 mg/kg depending on the starting dose level assigned per investigator. Therapy will continue until disease progression, patient withdrawal, or treatment intolerance.
223814395|NCT06859424|DRUG|Conditioning Regimen A|"Busulfan and fludarabine~Recommended schedule as below:~* Days -6 to -3: Busulfan ≥ 9 mg/kg total dose (IV or PO) with pharmacokinetic (PK) monitoring recommended as per institutional practice to achieve a daily area under the curve (AUC) target of 4800-5300 μM\*min47 or busulfan plasma exposure units (BPEU) 19.7-21.75 mg x h/L48.~* Days -6 to -2: Flu 30 mg/m2/day (adjusted for renal function) is administered over a 30-60 minute IV infusion (maximum cumulative dose, 150 mg/m2)."
223814396|NCT06859424|DRUG|Conditioning Regimen B|"Fludarabine and TBI The recommended fludarabine plus TBI regimen is the following:~* Days -7, -6 and -5: Flu (30 mg/m2/day, maximum cumulative dose, 90 mg/m2), IV~* Days -4 to -1: TBI (150 cGy administered twice daily, 1200 cGy total dose)~  * Radiation sources, dose rates, and shielding follow institutional practice.~ * Although not required, it is recommended that palifermin be used to mitigate the risk of mucosal toxicity with this regimen."
223814397|NCT06859424|DRUG|Conditioning Regimen C|"Fludarabine and busulfan (Flu/Bu)~The recommended Flu/Bu regimen is the following:~* Days -6 to -2: Flu (30 mg/m2/day, recommended total dose of 150 mg/m2, but not exceeding 180 mg/m2), IV Busulfan options~* Days -5 to -4: Busulfan without PK - Busulfan 3.2 mg/kg/day IV or oral equivalent; total dose of 6.4 mg/kg IV or oral equivalent respectively~* Days -5 to -4: Busulfan with PK - target doses to AUC of 4000 μMol/min or BPEU of 16.43 mg x h/L (total BPEU of 65.72 mg x h/L) or less is allowed."
223814398|NCT06859424|DRUG|Conditioning Regimen D|"Fludarabine and melphalan (Flu/Mel)~The recommended Flu/Mel regimen is the following:~* Days -7 to -3: Flu (30 mg/m2/day or 25 mg/m2/day, total dose of 125-150 mg/m2), IV~* Day -1: Mel (100-140 mg/m2 IV for recipients aged 18-59; dose of melphalan cannot exceed 100mg/m2 if age 60 or older or calculated glomerular filtration rate (GFR) is \<60 ml/min), IV"
223814399|NCT06859424|DRUG|Conditioning Regimen E|"Fludarabine/cyclophosphamide/total body irradiation (Flu/Cy/TBI)~The recommended Flu/Cy/TBI regimen is the following:~* Days -6 to -5: Cy (14.5 mg/kg/day IV, total dose of 29 mg/kg, or single dose 50 mg/kg on Day -6 \[Minnesota regimen\])~* Days -6 to -2: Flu (30 mg/m2/day, total dose of 150 mg/m2) IV~* Day -1: TBI 200 cGy single dose Hydration and Mesna may be administered per institutional standards. For recipients of RIC/NMA AND donors matched at \<7/8, consider the addition of TBI 200-300cGy for the Flu/Bu and Flu/Mel regimens to mitigate the risk of primary graft failure."
223814400|NCT06859424|PROCEDURE|Hematopoietic Cell Transplantation|"* On Day 0, the donor PBSC graft is infused.~* Donor PBSC will be collected per NMDP/donor registry policies with a target viable CD34+ cell dose of at least 4 × 106 /kg recipient weight (actual, ideal, or adjusted ideal per institutional practice).~* Dose of CD34+ cells/kg and CD3 cells/kg infused will be recorded.~* If the donor PBSC graft is cryopreserved prior to the start of conditioning, follow institutional practices to ensure a sufficient cell dose is available for infusion after thawing.~* The graft cannot be manipulated ex vivo to deplete T cells."
223814401|NCT06859424|DRUG|PTCy (50 mg/kg D3, D4)|"Cyclophosphamide (50mg/kg ideal body weight (IBW); \[if actual body weight (ABW) \< IBW, use ABW\]) will be given on Day +3 (between 60 and 72 hours after the start of the PBSC infusion) and on Day 4 post HCT (approximately 24 hours after Day +3 cyclophosphamide). Cyclophosphamide will be given as an intravenous (IV) infusion over 1-2 hours (depending on volume), or according to institutional standards. Hydration pre- and post- cyclophosphamide and Mesna administration will be given per institutional standards.~No systemic immunosuppressive agents are given until at least 24 hours after the completion of the PTCy. This includes corticosteroids as anti-emetics but excludes any drugs listed in section 7.9.1.~Azoles (e.g., posaconazole or voriconazole) must be delayed from beginning of conditioning through completion of Day 4 PTCy dose to avoid potential drug-drug interactions with cyclophosphamide that could lead to increased toxicity."
223814402|NCT06859424|DRUG|PTCy (25 mg/kg D3, D4)|"Cyclophosphamide (25mg/kg ideal body weight (IBW); \[if actual body weight (ABW) \< IBW, use ABW\]) will be given on Day +3 (between 60 and 72 hours after the start of the PBSC infusion) and on Day 4 post HCT (approximately 24 hours after Day +3 cyclophosphamide). Cyclophosphamide will be given as an intravenous (IV) infusion over 1-2 hours (depending on volume), or according to institutional standards. Hydration pre- and post- cyclophosphamide and Mesna administration will be given per institutional standards.~No systemic immunosuppressive agents are given until at least 24 hours after the completion of the PTCy. This includes corticosteroids as anti-emetics but excludes any drugs listed in Table 4 and Table 5 in Section 7.1.~Azoles (e.g., posaconazole or voriconazole) must be delayed from beginning of conditioning through completion of Day 4 PTCy dose to avoid potential drug-drug interactions with cyclophosphamide that could lead to increased toxicity."
223814403|NCT06859424|DRUG|Post-transplant Tacrolimus|Tacrolimus will be given per institutional practices, at a dose of 0.05 mg/kg per os (PO) or an IV dose of 0.03 mg/kg of IBW starting on Day + 5. The dose of tacrolimus may be rounded to the nearest 0.5 mg for oral formulations. Subsequent dosing will be based on blood levels per institutional guidelines with a suggested range of 5-12 ng/mL. If subjects are on medications which alter the metabolism of tacrolimus (e.g., concurrent CYP3A4 inhibitors), the initial starting dose and subsequent doses should be altered as per institutional practices. Tacrolimus taper is recommended to be initiated at 100 days post HCT if there is no evidence of active GVHD and ended by Day + 180 post HCT.
223814404|NCT06859424|DRUG|Post-transplant Mycophenolate mofetil|MMF will be given at a dose of 15 mg/kg 3 times daily (TID) (based upon actual body weight) with the maximum total daily dose not to exceed 3 grams (1g TID, IV or PO). MMF prophylaxis will start Day + 5 and continue until Day + 35 post-transplant, at which time it should be discontinued (no taper necessary). Study site investigators may modify dose/taper early if clinically indicated for the study subject. Dose rounding may be done per institutional practice.
223814405|NCT06859424|DRUG|Post-transplant Abatacept|Abatacept will be given at a dose of 10 mg/kg with a maximum of 1000 mg.
223814406|NCT06859424|DRUG|Post-transplant Ruxolitinib|Ruxolitinib will be given at a dose of 5 mg/kg twice daily starting at Day 30 post HCT, provided both the absolute neutrophil count (ANC) is \> 1000/μl and platelet count is \>30,000/μl.
223814407|NCT06859424|DRUG|Supportive Care: Growth Factors|Granulocyte colony-stimulating factor (G-CSF) to accelerate neutrophil recovery should be administered starting at Day +5 with dose, route of administration, formulation, and duration of administration following institutional guidelines. Filgrastim biosimilars are permissible, but granulocyte-macrophage colony-stimulating factors are not permissible.
223814408|NCT06859424|PROCEDURE|Supportive Care: Blood Products|Transfusion thresholds for blood product support will be consistent with standard institutional guidelines. All blood products must be irradiated.
223814409|NCT06859424|OTHER|Supportive Care: Infection Prophylaxis|"Subjects should receive infection prophylaxis according to institutional guidelines and in accordance with the Center for Disease Control (CDC) guidelines49. Infection prophylaxis will include, but is not limited to, agents or strategies (e.g., polymerase chain reaction \[PCR\] screening and preemptive therapy) to reduce the risk of bacterial, viral (e.g., adenovirus, CMV, EBV, herpes simplex), opportunistic (e.g. Pneumocystis jirovecii, Toxoplasma gondii) and fungal (yeast and mold) infections.~Infection risk should assess patient-, pathogen-, and immune-related factors that increase susceptibility to infection. Minimal parameters requiring prophylaxis include but are not limited to neutropenia (ANC≤500/μL), lymphopenia (ALC≤500/μL), and exposure to immunosuppression or GvHD. Use of intravenous immunoglobulin (IVIG) should be considered for total IgG\<400 mg/dL during exposure to immunosuppression and/or GvHD."
223814410|NCT06859424|OTHER|Supportive Care: Intravenous immune globulin (IVIG)|Intravenous immune globulin (IVIG) administration will be according to local institutional standard practice for hypogammaglobulinemia but is generally not recommended.
223814411|NCT06859424|DRUG|Supportive Care: Seizure prophylaxis|Subjects will receive busulfan seizure prophylaxis with levetiracetam, fosphenytoin, or lorazepam per institutional guidelines.
223814412|NCT06859424|OTHER|Supportive Care: Monitoring and management of CRS|The use of HLA-mismatched PBSC has been associated with greater risk of CRS relative to bone marrow. Following the infusion of MMUD PBSC on Day 0, subjects should be monitored daily through Day 14 for the development of CRS. High index of suspicion is urged, particularly in the few days following infusion. Many sites have successfully intervened with tocilizumab in order to avoid severe or prolonged CRS. Supportive care is encouraged for CRS Grades 1-2 and tocilizumab (or alternative) is recommended for CRS grade 3-4 where subject outcome may be impacted (Appendix G - CRS Guidance and Management).
223814413|NCT06859424|OTHER|Supportive Care: Prophylaxis against infections|"Consider monitoring for EBV reactivation during abatacept treatment and continue for six months following HCT.~Consider monitoring and prophylaxis for CMV infection/reactivation during abatacept treatment and for six months following HCT."
223814414|NCT06859424|DRUG|Supportive Care: Prophylaxis against infections|For participants receiving ruxolitinib, the recommended maximum dose of fluconazole daily is 200 mg.
223814415|NCT06859424|OTHER|Supportive Care: Lipid elevations|Assess lipid levels 8-12 weeks from start of therapy with ruxolitinib and treat as needed.
223814416|NCT06859424|OTHER|Study treatment compliance|The administration of study agents must be recorded in the subject's medical chart for verification of study treatment compliance.
223814417|NCT06859424|OTHER|Prohibited Concomitant Therapy|"Prophylactic anti-viral cellular therapies and/or co-enrollment on studies using therapies for the prevention of GVHD is prohibited.~Subjects reported to have received prohibited therapy while on this study will be withdrawn and will not be included in the primary and secondary analyses.~No concomitant systemic immunosuppressive agents can be administered during PTCy (Day 3 and Day 4). If needed, administer at least 24 hours after completion of Day 4 PTCy.~It is crucial that no systemic immunosuppressive agents are given until at least 24 hours after completion of the Day +4 dose of PTCy. This includes corticosteroids as anti-emetics but excludes tacrolimus and MMF. Steroid use is permitted as pre-medication prior to start of conditioning but is prohibited from Day 0 through 24 hours post Day 4 PTCy administration.~If prohibited therapies are administered, these data must be reported in the study EDC on the Concomitant Medications form."
223814418|NCT06859424|OTHER|Permitted Concomitant Therapy|"Pre-medication and/or treatment for possible AEs related to PTCy are permitted. Subjects may continue all medications in compliance with local treatment center and local institutional guidelines, except those described in Section 7.9.1. If GVHD or infection occurs, enrollment on a clinical trial to treat infection or GVHD is permissible. At time of relapse, patients are permitted to enroll on a clinical trial or receive disease targeted therapy.~The following medications/therapies must be reported on the study EDC Concomitant Medications form:~* Medications taken to treat adverse events that have been reported on the study EDC Adverse Event form.~* Antimicrobial prophylaxis (viral, bacterial, fungal, parasitic).~* Antimicrobial pharmaceutical and cellular therapies used to treat grade II-III infections per BMT CTN grading criteria (Appendix D - BMT CTN Infection Grading).~* Post HCT, primary malignant disease-directed pharmaceutical and cellular therapies.~* Planned maintenance therapy"
223814419|NCT06859424|OTHER|Prohibited Concomitant Therapy|"Treatment with any other Investigational Medicinal Product (IMP) is not allowed while on study treatment. An IMP is defined as any medication without any known FDA-approved indications.~No other investigational drugs for GVHD are allowed."
223814420|NCT06859424|OTHER|Permitted Concomitant Therapy|Premedication and/or treatment for possible adverse events (AE)s related to abatacept are permitted.
223814421|NCT06859424|OTHER|Prohibited Concomitant Therapy|"Treatment with any other Investigational Medicinal Product (IMP) is not allowed while on study treatment. An IMP is defined as any medication without any known FDA-approved indications.~Concomitant use of ruxolitinib with fluconazole doses of greater than 200 mg daily should be avoided.~No other investigational drugs for GVHD are allowed."
223814422|NCT06859424|OTHER|Permitted Concomitant Therapy|Premedication and/or treatment for possible AEs related to ruxolitinib are permitted.
223814423|NCT06849791|DRUG|ABBV-932|Oral Capsule
223814424|NCT06849791|DRUG|ABBV-932|Oral tablet
223814425|NCT07100418|DRUG|HRS-7249 Injection|HRS-7249 injection.
223814426|NCT07100418|DRUG|Sodium Chloride Injection|Sodium chloride injection.
223814427|NCT06909500|BEHAVIORAL|Smartphone app|Receive access to the ACT on Vaping app
223814428|NCT06909500|BEHAVIORAL|Smartphone app|Receive access to the ACT on Vaping app
223814429|NCT06909500|OTHER|Text Message|Receive incentivized text messages to access vaping status
223814430|NCT06909500|OTHER|Text Message|Receive intervention text messages
223814431|NCT06909500|OTHER|Survey Administration|Ancillary studies
223814432|NCT07106437|OTHER|"Basel Model: Measure of total waste after completion of the procedure"|For each included case, the total waste generated will be measured in kilograms immediately after completion of the procedure and physically recorded by category in accordance with four predefined waste types: (i) paper and cardboard, (ii) regular waste (i.e., municipal solid waste or general trash), (iii) regulated medical waste (requiring specialized incineration including sharpsafe), and (iv) recyclable plastic
223814433|NCT07106437|OTHER|"Standard Model: Measure of total waste after completion of the procedure"|Simulation of a hypothetical but common practice in many hospitals, in which all waste generated during interventional procedures is disposed of as regulated medical waste, without separation.
223814434|NCT07123727|DRUG|Anktiva|600ug of NAI administered subcutaneously
223814435|NCT07130344|PROCEDURE|TAP CT-scan|Patient in the SOC arm will be followed by TAP CT-scan every 3 months, until progression or new treatment initiation or until 2 years whichever occurs first.
223814436|NCT07130344|PROCEDURE|Bone scintigraphy|Patient in the SOC arm will be followed by bone scintigraphy every 3 months, until progression or new treatment initiation or until 2 years whichever occurs first.
223814437|NCT07130344|PROCEDURE|18F-FDG PET-CT|Patient in the experimental arm will be followed by 18F-FDG PET-CT every 3 months, until progression or new treatment initiation or until 2 years whichever occurs first.
223814438|NCT06934291|DEVICE|Full-mouth ultrasonic debridement with piezoelectric device (EMS, mini piezon)|the use of ultrasonic oscillating tips allows supragingival and subgingival biofilm and dental calculus removal
223814439|NCT06934291|DEVICE|Full-mouth ultrasonic debridement with magnetostrictive device (Cavitron Select, Dentsply)|the use of ultrasonic oscillating tips allows supragingival and subgingival biofilm and dental calculus removal
223814440|NCT06931210|OTHER|Sedentary behavior|Patients in the control group will maintain their sedentary lifestyle unchanged.
223814441|NCT06931210|BEHAVIORAL|Exercise intervention|The intervention will include a combination of aerobic and resistance exercises, performed three times per week. Each session will last 80 minutes. Aerobic and resistance training will include cycling, chest press, rowing, abdominal and back muscle exercises, as well as leg strength training.
223814442|NCT07142135|OTHER|There is no intervention, only clinical description|There is no intervention, only clinical description
223814443|NCT07146464|OTHER|Self-Assembling Peptide P11-4 Self-Assembling Peptide P11-4 is a biomimetic material applied topically to white spot lesions on the enamel. It diffuses into the lesion body and forms a three-dimension|"Intervention: Self-Assembling Peptide P11-4~Intervention Description:~Self-Assembling Peptide P11-4 (SAP P11-4) is a synthetic peptide designed to mimic natural enamel matrix proteins. It is applied to cleaned, etched enamel surfaces with white spot lesions. The peptide diffuses into the subsurface lesion and self-assembles into a 3D scaffold that promotes nucleation and growth of hydroxyapatite crystals. In this study, it is applied at baseline and re-applied after 3 months. The product used is Curodont™ Repair.~Intervention: Casein Phosphopeptide-Amorphous Calcium Phosphate (CPP-ACP)~Intervention Description:~CPP-ACP is a milk-derived peptide complex that stabilizes calcium and phosphate ions in an amorphous form. When applied to enamel surfaces, it delivers these ions to promote remineralization of white spot lesions. In this study, MI Varnish™ is used as the source of CPP-ACP. The varnish is stirred and applied as a thin, uniform layer to cleaned tooth surfaces at baseline and"
223814444|NCT06949124|DRUG|SHR7280 Tablets|SHR7280 tablets.
223814445|NCT06950905|BEHAVIORAL|Feeding your demons practice|The Feeding Your Demons (FYD) is a contemplative practice based on the Tibetan Buddhist tradition, adapted in a secular form. The intervention is online and lasts a total of 8 weeks. During this period, participants will engage in weekly home practice of the FYD method using guided audio. The intervention includes 3 expert-facilitated sessions: an initial individual session, a group session at week 4, and a final group session at week 8.
223814446|NCT06950905|BEHAVIORAL|Mindfulness practice|The control group will undergo an online mindfulness meditation intervention, lasting a total of 8 weeks. It includes 3 expert-facilitated sessions: an initial individual session, a group session at week 4, and a final group session at week 8. Participants will engage in weekly home practice of mindfulness meditation using guided audio.
223814447|NCT07148726|DIETARY_SUPPLEMENT|Pyrrole Quinoline Quinone (PQQ)|Subjects will be provided with 84 capsules of the PQQ or the placebo supplement. Both supplements were in capsule form and identical in size, shape and color. The PQQ content per capsule was 10 mg. The indication was to take two capsules every evening for 6 weeks. The duration of the supplementation protocol was assessed based on a previous study (Hwang et al., 2020), while the dose was chosen according to EFSA recommendations (Turck et al., 2017).
223814448|NCT07148726|OTHER|Placebo|Subjects were provided with 84 capsules of placebo. The indication will be to take two capsules every evening for 6 weeks.
223814449|NCT07151391|DRUG|Guarana|500 mg oral medication daily
223814450|NCT07151391|DRUG|Placebo|Oral medication daily
223814451|NCT02204228|DEVICE|TITAN™ Reverse Shoulder System (TRS)|All patients will be operated on with the TITAN™ Reverse Shoulder System (TRS).
223814452|NCT07152834|DIAGNOSTIC_TEST|Blood Sampling|"For AAT Level: Residual serum from routine blood samples drawn for standard clinical care will be aliquoted into polypropylene cryotubes.~For Genetic Testing: A separate capillary blood sample will be obtained via finger prick using a sterile lancet and collected on a designated filter paper."
223814453|NCT07154329|BEHAVIORAL|Internet-Based EMDR-Flash Program|"Self-guided, internet-based EMDR-Flash program (SKY-Flash) tailored to reduce test anxiety in university students. Delivered via a secure web platform with no live therapist involvement. The intervention comprises six \~40-minute modules completed independently during the study. Each module includes brief psychoeducation and step-by-step EMDR-Flash procedures (focus on a positive engaging image with brief flash cues), guided practice, and in-platform exercises. Gamification (progress tracking, badges) and automated prompts support adherence. Unlike CBT-based online programs or clinician-delivered EMDR, this is a fully automated, low-intensity Flash protocol adapted to exam-related distress. Safety messaging and referral resources are embedded; access is via individual login and usage is recorded for adherence."
223814454|NCT07157514|DRUG|131I-apamistamab|Iodine-131 radiolabeled anti-CD45 monoclonal antibody (apamistamab). Administered IV as a dosimetric dose followed by treatment dose.
223814455|NCT07157514|DRUG|Fludarabine|Fludarabine phosphate, 30 mg/m² IV daily on Days -6 through -2.
223814456|NCT07157514|DRUG|Cyclophosphamide|Cyclophosphamide
223814457|NCT07157514|RADIATION|Total Body Irradiation (TBI)|TBI, 200 cGy on Day -1 prior to HSCT.
223814458|NCT07157514|BIOLOGICAL|Allogeneic Hematopoietic Stem Cell Transplant (HSCT)|Unmodified, G-CSF-mobilized donor stem cells infused on Day 0.
223814459|NCT07166627|PROCEDURE|surgical excision of cesarean section scar ectopic pregnancy|surgical excision by laparotomy.
223814460|NCT07166627|PROCEDURE|ultrasound guided evacuation of cesarean section scar ectopic pregnancy|ultrasound guided evacuation of cesarean section scar ectopic pregnancy trans-cervically.
223814461|NCT07166614|DRUG|dexmedetomidin|Dexmedetomidine is a highly selective α2-adrenergic receptor agonist with sedative, anxiolytic, and analgesic properties. Unlike many other sedatives, it provides sedation without significant respiratory depression, though it may cause bradycardia and hypotension
223814462|NCT07166614|DRUG|Propofol|Propofol is a short-acting intravenous anesthetic agent widely used for induction and maintenance of anesthesia as well as procedural sedation. It provides rapid onset and recovery, but is associated with respiratory depression and hypotension
223814463|NCT07165210|OTHER|No Intervention: Observational Cohort|no intervention was applied in this cohort
223814464|NCT07164508|BEHAVIORAL|Sitting Light Volleyball Intervention|16-week intervention centered around Sitting Light Volleyball, an adaptive sport developed by the Project Coordinator specifically for adults with physical disabilities.
223814465|NCT07164508|BEHAVIORAL|Group Seated Dance Intervention|16-week intervention program for adults with physical disabilities centered around para dance in a group setting of various dance styles.
223814466|NCT07166341|DEVICE|Observational|The study objectives require placement of a jugular venous bulb catheter and radial arterial line placement with ultrasound guidance. Two INVOS™ sensors (PMSENS71-A) will be placed bilaterally on the subject's forehead and two on the calf. The INVOS™ device will be evaluated for a targeted range of 70-100% SpO2 levels. Hypoxic mixtures of gas are delivered, and data are collected at approximately (\~) 5-minute intervals during steady periods of increasing and decreasing oxygen concentration.
223814467|NCT07166874|BEHAVIORAL|Gluten Free Diet|Patients in the experimental arm will received a gluten-free diet for 8 weeks.
223814468|NCT07164417|OTHER|e-PRF membrane will be used with xenograft simultaneously with implant placement.|Peripheral blood is collected in plain tubes and centrifuged (700-2000 g, 8 min) to separate plasma from red cells. The first 2-4 mL of platelet-poor plasma (PPP) is withdrawn and heated at 75 °C for 10 minutes to form albumin gel, then cooled for 1-2 minutes. Meanwhile, the remaining blood fractions (buffy coat, liquid PRF, red cells) are kept cooled to prevent premature clotting.
223814469|NCT07164417|OTHER|PRF membrane will be used with xenograft simultaneously with implant placement|Peripheral blood is collected in 9-10 mL additive-free tubes and centrifuged horizontally at 700-2000 g for 8 minutes.
223814470|NCT07166666|DEVICE|atomizer|use atomizer to provide the medication in procedure sedation
223814471|NCT07166666|DRUG|rescue medication|will be used as rescue if the atomizer medication not fully sedated
223814472|NCT07166666|DRUG|Midazolam|Intranasal administration for procedural sedation.
223814473|NCT07166666|DRUG|fentanyl|Intranasal administration for procedural sedation.
223814474|NCT07166666|DRUG|Dexmedetomidine|Intranasal administration for procedural sedation.
223814475|NCT07166666|DRUG|Placabo|use atomizer to provide the placebo in procedure sedation
223814476|NCT07165691|BEHAVIORAL|TELESCOPE, Remote Decision Coaching with Navigation Intervention|The TELESCOPE intervention involves three complementary components: 1) decision aid and coaching for LCS, 2) referral of current smokers to evidence-based smoking cessation services, and 3) for participants interested in screening, navigation to complete LCS and diagnostic testing and oncology care as needed
223814477|NCT07165197|DEVICE|Phacoemulsification with implantation of an extended depth of focus intraocular lens|Comparison of two different Extended depth of focus intraocular lenses
223814478|NCT07166029|OTHER|russian current|russian current will be is applied in 50Hz sinusoidal bursts with a duty cycle of 50% (10ms on/10ms off). Russian Stimulation (at 2500Hz or 2.5kHz) has been shown to be effective in increasing muscle strength and torque generation through stimulation of type II muscle fiber. The stimulation will be given for duration of 10 minutes on followed by 50 sec off and again 10 sec on, three tims per week plus selsected physical therapy program.
223814479|NCT07166029|OTHER|selected physical therapy program|the patients will receive selected physical therapy program in the form of TENS for 15 min, US for 5 min and exercise for 20 min
223814480|NCT07165613|OTHER|Kinesiotape|Kinesiotape is applied
223814481|NCT07165613|OTHER|Dynamic tape|dynamic tape applied
223814482|NCT07165912|BEHAVIORAL|Health Education Program|An informative leaflet will promote a healthy lifestyle with WHO guidelines to reduce cognitive decline, recommending a balanced diet, physical activity, social engagement, cognitive games, good sleep, stress management, hydration, and avoiding smoking and excessive alcohol.
223814483|NCT07165912|BEHAVIORAL|Individual Cognitive Training Program|The cognitive training program (CT) on everyday cognition (EC) will be individualized, with each participant receiving a tailored dossier. The intervention includes four 1-month training periods (P1-P4), each featuring 20 activities, conducted at a rate of 5 activities per week over 4 months.
223814484|NCT07165912|BEHAVIORAL|Group training program|The group cognitive training program (CT) on everyday cognition (EC) will be individualized, with each participant receiving a tailored dossier. The intervention includes four 1-month training periods (P1-P4), each featuring 20 activities, conducted at a rate of 5 activities per week over 4 months.
223814485|NCT01287884|OTHER|Venous Blood Gas|patients who have been identified by the treating physician as needing an ABG will receive an VBG is they consent to take part in the study
223814486|NCT05650164|DRUG|avelumab|as provided in real world practice
223814487|NCT05650164|DRUG|axitinib|as provided in real world practice
223814488|NCT05239910|DRUG|Tenalisib|Tenalisib will be administered orally twice daily in a 21-day cycle for 26 cycles (from cycle 1 to cycle 26), CHOP will be administered for 6 cycles (from Cycle 4 to Cycle 9) on Days 1 to 5 of each cycle.
223814489|NCT03114371|DRUG|Oxytocin|The study drug is oxytocin in intra-nasal administration, Syntocinon®, reconditioned as a placebo-like spray. The dosage administered will be 8 International Unit, ie 1 spray (4 International Unit per spray) in each nostril per day for the first 12 weeks, in 3 and 6 years old patients. The dosage administered will be 16 International Unit or 2 sprays in each nostril per day for the first 12 weeks, in 3 to 6 years old patients.
223814490|NCT03114371|DRUG|Placebo|Placebo should be used as a spray, similar to that of the oxytocin. The dosage administered will be 1 spray in each nostril per day for the first 12 weeks in 3 to 6 years old patients. The dosage administered will be 2 sprays in each nostril per day for the first 12 weeks, in 7 to 12 years old patients.
223814491|NCT03114371|DRUG|Oxytocin|Each patient will receive oxytocin in open label (Syntocinon® not reconditioned) from week 13 to week 24 according to the same dosages.
223814492|NCT00278538|BIOLOGICAL|Hematopoietic stem cell transplantation|Autologous hematopoietic stem cell transplantation
223814493|NCT02661802|OTHER|Oxygen Supplementation|Oxygen delivery was continuous by mask at 40%
223814494|NCT06318442|DRUG|Semaglutide Oral Product|Oral semaglutide 3mg once uptitrated to twice daily
223814495|NCT06318442|DRUG|Metformin Oral Tablet|Metformin modified release tablets 500mg once daily uptitrated to twice daily).
223814496|NCT06318442|DRUG|Placebo|Placebo tablets
223814497|NCT04187391|DEVICE|Active tDCS|Active tDCS anode is applied over the left DLPFC with the cathode over the right supraorbital region.
223814498|NCT04187391|DEVICE|Placebo tDCS|Placebo tDCS is applied but the current is turned off 10 seconds after the beginning and turned on for the last 10 seconds of the stimulation period.
223814499|NCT04187391|BEHAVIORAL|Language training|patients receive language training
223814500|NCT04187391|BEHAVIORAL|Unstructured cognitive training|patients receive unstructured cognitive training.
223814501|NCT05358587|OTHER|Ultrasound guided PENG block with 20 mL Local Anesthetic solution|In this group, US guided PENG block will be performed with 20 ml of Bupivacaine solution (0.25 %). Block will be performed 30 minutes before spinal anesthesia.
223814502|NCT05358587|OTHER|Ultrasound guided PENG block with 30 mL Local Anesthetic solution|In this group, US guided PENG block will be performed with 20 ml of Bupivacaine solution (0.25 %). Block will be performed 30 minutes before spinal anesthesia.
223814503|NCT01679236|BEHAVIORAL|Mindfulness Training for Smokers|The provides the Mindfulness Training for Smokers intervention (7 weeks long).
223814504|NCT01679236|BEHAVIORAL|Interactive Learning for Smokers|This provides the Interactive Learning for Smokers intervention (7 weeks long).
223814505|NCT04221282|DRUG|Zebinix|ESL will be initiated by the investigator in patients as a first line monotherapy or adjunctive therapy. ESL will be prescribed according to the usual care. Posology and method of administration of ESL are defined by the summary of product characteristics. Then, data on the efficacy of ESL will be collected.
223814506|NCT01266447|BIOLOGICAL|Filgrastim|Given SC
223814507|NCT01266447|OTHER|Laboratory Biomarker Analysis|Correlative studies
223814508|NCT01266447|BIOLOGICAL|Pegfilgrastim|Given SC
223814509|NCT01266447|DRUG|Topotecan Hydrochloride|Given IV
223814510|NCT01266447|DRUG|Veliparib|Given PO
223814511|NCT04318756|BEHAVIORAL|Translation and cultural adaptation go the cancer worry scale|To develop and validate the Italian version of Cancer worry scale using high risk subjects for familiarity/genetic predisposition and patients with premalignant lesions.
223814512|NCT00975221|DRUG|Cinacalcet|Administered orally at a starting dose of 30 mg twice a day (BID). Participants will be eligible for a dose titration once every 3 weeks during the placebo-controlled dose titration phase based on corrected total serum calcium concentration and safety assessments obtained the previous week. Doses may be sequentially increased to 60 mg BID, 90 mg BID, and 90 mg 3 times a day (TID).
223814513|NCT00975221|DRUG|Placebo|Administered orally following the same tiitration regimen as the experimental arm.
223814514|NCT04932005|DRUG|DZD2269|Part A: A single oral dose at 5mg, 10mg, 20mg, 40mg, 80mg, 160mg. Part C: Twice daily dosing for 7 days at 10mg, 30mg, 80mg.
223814515|NCT04932005|DRUG|placebo|Part A: A single oral dose. Part C: Twice daily dosing for 7 days.
223814516|NCT03935217|DRUG|Secnidazole|Oral Granules containing secnidazole
223814517|NCT03935217|DRUG|Placebo|Oral Granules of placebo manufactured to mimic secnidazole
223814518|NCT00663377|DRUG|losartan|losartan 50-100mg for 16 weeks
223814519|NCT02890914|OTHER|Transvaginal Ultrasound Educational DVD|"American Institute of Ultrasound in Medicine, Gynecology: Beginners Only®"
223814520|NCT04188236|DEVICE|Hernia Blocking System|Hernia Blocking System device implanted during a lumbar discectomy procedure
223814521|NCT00615394|PROCEDURE|intramyocardial bone marrow stem cells implantation|Patients with previous diagnosis of non-ischemic dilated cardiomyopathy. were included. Bone-marrow was collected from in the antero-superior iliac crest and mononuclear stem-cells were isolated by centrifugation in the density rate Ficoll-Hypaque 1.077 media. Surgical technique - The approach was through a left mini-thoracotomy. Twenty small injections of cellular suspension were directly made through a 21F butterfly needle(total=5 ml), in the anterior, lateral, posterior and apical faces of the left ventricle(average 9.6 ± 2.6 x 107 cells). After the procedure, the patients were kept in the post-operative intensive care unit for a minimum period of 24 hours. They were released from the hospital in a period that varied from five to seven days.
223814522|NCT01127217|DRUG|amlodipine/losartan|amlodipine 5mg/losartan 50mg, amlodipine 10mg/losartan 50mg (+HCTZ 12.5mg)
223814523|NCT01127217|DRUG|amlodipine|amlodipine 5mg, amlodipine 10mg (+ HCTZ 12.5mg)
223814524|NCT02932839|DEVICE|NeuroPort micro-electrode array|Implantation of the Blackrock NeuroPort micro-electrode array for up to 29 days in patients who are undergoing evaluation with intracranial EEG electrodes
223814525|NCT03559218|DEVICE|KeraStat(R) Cream|KeraStat Cream is a cream wound dressing that contains 5% keratin.
223814526|NCT03559218|OTHER|Standard of care|Patients will be instructed to follow institutional standard of care for radiation dermatitis
223814527|NCT01025622|BIOLOGICAL|autologous highly purified CD133+ stem cells (SCs)|Intrahepatic reinfusion in cirrhotic patients
223814528|NCT02882711|DRUG|Ketamine|Ketamine will be infused (slow IV infusions of ketamine (0.5 mg/kg) over 40 minutes) twice weekly over a period of 4 weeks and weekly for the following 4 weeks of the study treatment period (8 weeks total).
223814529|NCT04610216|DEVICE|Naida CI M hearing device|speech intelligibility measurement with Naida CI M hearing device
223814530|NCT02867514|DEVICE|transcranial Direct Current Stimulation (tDCS)|After locating the stimulation areas, treatment will be delivered during 30-minute session. Treatment will be occur 1 session per day during 10 days (5 days per week during 2 successive weeks). Subjects will be monitored during tDCS for any side effects or adverse events.
223814531|NCT01988363|PROCEDURE|GON injection at C2 location|GON will be identified at the novel, proximal C2 location on the symptomatic side via ultrasound guidance. Prior to injection, an independent examiner will perform a sensory exam of the involved dermatome. A 25 gauge spinal needle will be inserted into the symptomatic side after locating the GON via ultrasound at the C2 level. Subjects will be injected with treatment medication. Thirty minutes after injection, an independent examiner will test for anesthesia over the desired dermatome. VAS will be assessed pre-injection, 30 post-injection, 2 weeks post-injection and 1 month post-injection. The 2 week and 1 month assessments will be conducted by telephone.
223814532|NCT03861858|BEHAVIORAL|DBT-A|DBT-A is a multimodal therapy which consists of weekly individual therapy, weekly multifamily skills groups, as needed phone coaching, and weekly consultation team for the therapists.
223814533|NCT00299000|DRUG|Naglazyme|Weekly infusion for minimum of 52 weeks. Naglazyme is diluted in sterile 0.9% sodium chloride solution
223814534|NCT03237858|DEVICE|HeartLogic ON|Remote management of patients with CRT-D or ICD devices and the HeartLogic diagnostic feature turned OFF
223814535|NCT03237858|DEVICE|HeartLogic OFF|Remote management of patients with CRT-D or ICD devices and the HeartLogic diagnostic feature turned ON
223814536|NCT02412501|DEVICE|Resolute Onyx Stent - 2.0 mm|Clinical Evaluation of the Medtronic Resolute Onyx Zotarolimus-Eluting 2.0 mm Stent
223814537|NCT02339896|BIOLOGICAL|rabies vaccine|rabies vaccine 0.1 ml intradermal two site for 4 times
223814538|NCT05720585|OTHER|Intervention of mobile health application|According to the contents of the Subjective Memory Complaint (SMC) application intervention program for the older adults previously formulated, the intervention time and the frequency (30min / time, once a week) of each training module and other contents were determined. The application will be implemented and lasted for a total of 1 month.
223814539|NCT03578614|OTHER|Physical Activity|"3 physical activity sessions are planned by week, 2 supervised and 1 non-supervised conducted over 6 months. On the first 2 months, the supervised sessions have 10 minutes of warm-up + 5 minutes active pause (balance, agility and coordinative exercises) + 15 minutes walking + 5 minutes active pause (resistance exercises - 1 series of 12 repetitions~\- 3 callisthenic exercises) + 15 minutes walking + 5 minutes flexibility (1 series of 10 seconds in 3 different postures). The aimed intensity in these first two months is 12/13. Between the 2nd and the 4th months, the duration of the walking period increases, as well as the intensity, RPE 13/14. Between the 4th and the 6th months, again the duration of the walking period increases, as well as the intensity, RPE 14/15. To measure the intensity level of the physical activity, the Borg Rating of Perceived Exertion (RPE) ranging from 6 (rest) to 20 (maximum effort) is used."
223814540|NCT00001866|PROCEDURE|horizontal muscles of the eye will be cut and then reattached in the same position|
223814541|NCT00184483|PROCEDURE|Lichtenstein's operation|Lichtenstein's operation to repair primary unilateral inguinal hernia
223814542|NCT00184483|PROCEDURE|Prolene Hernia System|Prolene Hernia System to repair primary unilateral inguinal hernia
223814543|NCT00344812|DRUG|LAAM. buprenorphine and methadone|
223814544|NCT05085821|DEVICE|HEART|In an augmented reality environment, the patient receives visual feedback in synchrony with their cardiac-cycle (HEART)
223814545|NCT05085821|DEVICE|Placebo|In an augmented reality environment, the patient receives visual feedback out-of-synchrony with their cardiac cycle (Placebo)
223814546|NCT00002635|BIOLOGICAL|filgrastim|
223814547|NCT00002635|DRUG|aminocamptothecin|
223814548|NCT02757924|OTHER|Infant formula supplemented with prebiotics|Sole source nutrition
223814549|NCT00133757|DRUG|Bupropion SR|
223814550|NCT02635165|DEVICE|Thoracic osteosyntheses with Stracos|
223814551|NCT01333878|BIOLOGICAL|Subcutaneous Abatacept|Subcutaneous Abatacept 125 mg once weekly for 6 months
223814552|NCT01933971|DRUG|Filgrastim test|0.3 mg/mL injectable solution in 1 mL vials Manufacturer (Drug Substance): Eurogenetec S.A., B-4102 Seraing, Belgium Manufacturer (Drug Product): Areta International S.r.l., I-21040 Gerenzano, Italy Batch release: Areta International S.r.l., I-21040 Gerenzano, Italy Route of administration: subcutaneous
223814553|NCT01933971|DRUG|Filgrastim reference|"0.3 mg/mL injectable solution in 1 mL vials Licensed owner: Dompé farmaceutici S.p.A., Milan, Italy Manufacturer (Drug Product): Hoffmann - La Roche Ltd., Basel, Switzerland and Amgen Manufacturing Limited, Puertorico.~Batch release: Amgen Europe B.V., Breda, Netherlands Route of administration: subcutaneous"
223814554|NCT02126683|DRUG|Hydroxychloroquine|
223814555|NCT04703634|PROCEDURE|erector spinae block (ESP)|Administration of local anesthetic under the erector spinae muscle just below the transverse process of the thoracic 12th vertebra
223814556|NCT04482829|DRUG|Jing-yan-kang Granule|Jing-yuan-kang granule will be administered 6 days on and 1 days off for 12weeks.
223814557|NCT04482829|DRUG|PC chemotherapy and symptomatic treatment|"Drugs used in PC chemotherapy includes Pemetrexed and Cisplatin. Pemetrexed disodium for injection 500 mg per square meter, intravenous drip on day 1 in each treatment cycle.~Cisplatin injection 75 mg per square meter, intravenous drip from day 1 to day 3 in each treatment cycle. One treatment cycle will be continued for 21 days and 4 cycles will be performed.~If necessary, symptomatic treatment will also be used."
223814558|NCT04889235|PROCEDURE|Major liver resection|All patients undergo Major hepatic resection, differences between sarcopenia and no-sarcopenia groups will be observed
223814559|NCT04490135|BEHAVIORAL|Group psychotherapy|As described above
223814560|NCT05164874|DEVICE|Mobile Mammography Unit|The main intervention will be a proposition for an appointment at the MMU in complement to the current OBCS
223814561|NCT02767583|DEVICE|Exams|Patients the eligibility criteria will be proposed at the first consultation in central obesity, participate in a clinical study to assess the prevalence of subclinical damage peripheral nerves by simple and painless rapid measurement of skin conductance on the palm of the feet with the Sudoscan® device during the consultation and a Thermotest®, as well as monitoring during the various follow-up consultation after any bariatric surgery or not. This monitoring will be done by the same neurophysiological tests.
223814562|NCT01255553|RADIATION|Partial Breast Irradiation|Partial breast irradiation will be administered using a 3D conformal external beam RT technique. Two fractions of 38.5 Gy separated by at least 6 hours will be given on 5 treatment days over a period of 5 to 10 days.
223814563|NCT06286124|PROCEDURE|Hybrid Surgery|Hybrid incisional hernia repair, as described by Van den Dop et al. (2021)
223814564|NCT01862991|OTHER|Hygroscopic cervical dilators|Dilapan-S osmotic cervical dilators inserted through the internal os.
223814565|NCT01862991|DRUG|Misoprostol|400 mcg buccal misoprostol 90 pre-op
223814566|NCT01862991|DRUG|Intra-amniotic digoxin|1mg digoxin administered intra-amniotically \~24 hours pre-op in patients that are greater than 22 weeks gestation
223814567|NCT01862991|DRUG|Mifepristone|200 mcg Mifepristone orally
223814568|NCT04858802|DEVICE|PROPEL Contour Sinus Implant|370 mcg mometasone furoate-coated sinus implant
223814569|NCT04858802|PROCEDURE|Balloon Sinus Dilation Alone|No PROPEL Contour Sinus Implant
223814570|NCT03361891|BEHAVIORAL|WalkMORE Group|Hospitalized Internal Medicine patients will walk with trained volunteer coaches twice daily until hospital discharge
223814571|NCT03720418|DRUG|OXB-102|Neurosurgical delivery of OXB-102 (gene therapy) to the putamen
223814572|NCT03720418|OTHER|Imitation Surgical Procedure (ISP)|Participants randomized to the control group in Part B will receive an ISP
223814573|NCT01108458|DRUG|Pertuzumab|iv, 840 mg, 420 mg
223814574|NCT01108458|DRUG|Erlotinib|PO, 150 mg
223814575|NCT00147901|DRUG|FCCam|After an initial subcutaneous dose escalation of alemtuzumab over 2 days, 30 mg alemtuzumab s.c., cyclophosphamide 200 mg/m2 i.v. and 25 mg/m2 fludarabine i.v. were administered on three consecutive days. Treatment was repeated after 28 days for up to six cycles
223814576|NCT02328703|OTHER|Reiki Therapy|Reiki is a biofield energy therapy that is based on the idea that there is a universal energy that supports the body's innate healing abilities. A trained Reiki Master uses their hands as a conduit of the energy that goes naturally to any area of the recipient's body where it is needed. This provides a means for life force energy to recharge and rebalance the human energy fields, creating optimal conditions needed by the body's natural healing system.
223814577|NCT02556437|DRUG|HyQvia|Human immunoglobulin 10% with recombinant hyaluronidase for subcutaneous injection
223814578|NCT02556437|DRUG|Subcuvia|Human immunoglobulin 16% for subcutaneous injection
223814579|NCT04757467|OTHER|Standard physiotherapy neuro-rehabilitation|Treatment interventions which will be used for this group Passive range of movement exercises. Therapeutic positioning of the lower limb. Strengthening exercise for the lower limb. Over-ground gait training 5 times a week for 4 weeks. First week= 30 min exercise Second week= 1hour exercise Third week= 1hour and 30 min exercise Fourth week= 2 hours exercise All the treatment protocols will be applied to the patient for 5 times a week for consecutive 4 weeks. Interventions will be performed in the clinic and through home-based exercises using patient education
223814580|NCT04757467|OTHER|Repetition-CIMT|"In this group of patients, the CIMT technique will be used for treatment. Following tasks will be performed by the patient, the unaffected limb will be constrained using a tight knee brace for about3 hr.~* Sit-to-Stand~* Forward and Backward stepping~* Stair Climbing and Descending (only the first stair will be used)~* Side-to-Side stepping with the affected limb~Each task will be performed 10 times per session in the first week and 2 sessions a day. In the second week, each task will be performed 20 times per session for 2 sessions a day. In the third week, each task will be performed 30 times per session for 2 sessions a day.In the fourth week, each task will be performed 40 times per session for 2 sessions a day. The session will be held 5 days in a week for the period of consecutive 4 weeks. Total of 1000 repetitions of the above mentions tasks will be performed in 4 weeks' study time by every participant"
223814581|NCT04757467|OTHER|Hour-CIMT|A task that performed by the participants in this group will be the same as performed by the rep-CIMT group. The unaffected limb will be in constrained for 3 hours. (15) Sessions will be held 5 days in the week for a period of consecutive 4 weeks.
223814582|NCT00315913|DRUG|Propranolol|IV Propranolol 1mg/min for a total of 2 minutes. Total dose 2mg
223814583|NCT00315913|OTHER|IV Placebo|IV Saline Solution
223814584|NCT00792558|DRUG|BMS-817378|Capsule, Oral, Dose escalation to a MTD from a starting dose of 25 mg, once daily, until disease progression/subject discontinuation
223814585|NCT00744315|PROCEDURE|Mini-thoracotomy for intramyocardial injection of VEGF165|Patients with previous diagnosis of ischemic cardiopathy were included. The patient must accept and agree to be subject of clinical observation with current optimal treatment for at least 6 months. Following to that, subject undergoes intervention, in addition to consultation and assessments. Surgical technique -Ten injections VEGF165 will be made through a 25F butterfly needle in any ischemic territory where previously identified through scintigraphy. Dosis: 2.000 mg of VEGF165 in 5ml of saline solution. After the procedure, the patients will be kept in a recovery room for about 24hs and in the hospital until full clinical recovery.
223814586|NCT02561143|DIETARY_SUPPLEMENT|Improved Atta|Improved Atta is a multi macro- micronutrient bread mix. Patients will be given 100 grams of Improved Atta (to make unleavened bread) everyday for consumption for six months.
223814587|NCT02561143|DIETARY_SUPPLEMENT|Wheat flour|Whole wheat flour 100 grams (to make unleavened bread) will be given everyday for consumption for six months to the patients.
223814588|NCT02561143|BEHAVIORAL|Physical activity counseling|Depending on the physical status of the patients, low level of physical activity (walking and/or stairs), will be encouraged daily during counseling sessions.
223814589|NCT02561143|OTHER|Nutritional counseling|Dietary counseling for 30 minutes will be imparted to all patients on every hospital visits by the nutritionist. Consumption of cereals, roots and tubers, vegetables, legumes, nuts, energy dense fruits, milk products (and eggs for non-vegetarians) will be encouraged in their daily diets.
223814590|NCT00001064|DRUG|Allogenic Dendritic Cells|
223814591|NCT06015555|BEHAVIORAL|TAMO|TAMO therapy
223814592|NCT06015555|BEHAVIORAL|Postural Control exercises|Postural Control exercises
223814593|NCT02842944|DEVICE|open loop weaning group (Beacon)|mechanical ventilation following advice from the Beacon Caresystem
223814594|NCT02842944|OTHER|Routine care|Standardized routine care
223814595|NCT02366897|DEVICE|Manus Sensor Pen|Manus Sensor Pen as made by Manus Neurodynamica Ltd
223814596|NCT06445387|OTHER|Virtual Reality Glasses|"Preparation Stage of Virtual Glasses: A 20-minute video consisting of nature scenes shot with a 360-degree camera was selected by the researchers from YouTube. Permission was obtained from the person who created the video.~For the selection of music, both the music that is good for diseases were examined in the literature and an expert opinion was taken from a faculty member (Phd, assistant professor) working at the Faculty of Music and Fine Arts of a university. The music used in the video was created with works selected from the Hüseyni maqam."
223814597|NCT06445387|OTHER|Ice Application Group|Features of the ice and ice bag used for patients in ice application; Ice cubes with dimensions of 9.5 x 26 x 3.5 cm were used. The ice bag is made of cotton and polyester coated fabric and is easily bendable. In this way, the ice bag was ensured to fit properly to the patient's femoral region. It is reusable and heat insulated. The procedure was carried out by following the cold application step protocol created by the researchers using the literature.
223814598|NCT06445387|OTHER|Control Group|They continued to receive their routine treatment and care. No changes were made in their routine treatment and care.
223814599|NCT04170686|BEHAVIORAL|Zemedy App for Irritable Bowel Syndrome|The Zemedy App for irritable bowel syndrome is designed to be an engaging, self-help app for people with irritable bowel syndrome. It is based on empirically supported cognitive-behavioral, and GI focused hypnotherapy interventions for IBS.
223814600|NCT03328143|DRUG|Lavender (Lavandula angustifolia)|Lavender (Lavandula angustifolia) is an essential oil.
223814601|NCT05235620|OTHER|PatientToc use in pharmacies|PatientToc has been adapted for use in pharmacies. Patients using specific medications will be prompted to complete questionnaires about their self-reported adherence.
223814602|NCT03393338|BEHAVIORAL|DM I-TEAM|DM I-TEAM is a home-based behavioral intervention that involve 9 treatment visits with a community health worker (CHW) over 12 months. During the treatment visits, the CHW provides culturally-relevant diabetes education, and facilitates telehealth visits with a diabetes nurse educator and participants' primary care physicians (PCPs). In addition, a clinical pharmacist reviews participants' medication regimens to identify potentially inappropriate medications (PIMS), and to simply regimens when indicated to facilitate medication adherence.
223814603|NCT05465512|OTHER|response to neoadjuvant chemotherapy|Tumor regression grade (TRG) =0 or 1 was defined as a good response to neoadjuvant chemotherapy (GRNC), and TRG=2 or 3 was defined as a poor response to neoadjuvant chemotherapy (PRNC).
223814604|NCT02542540|OTHER|Training with Nintendo Wii console|Children with OI and draining for 3 months using Nintendo Wii console
223814605|NCT02020980|BIOLOGICAL|Botulinum toxin type A|"This is an observational study designed to reflect the clinical practice in real life as closely as possible.~Botulinum Toxin Type A (BoNT-A) injection administered according to the local Summary of Product Characteristics (SmPC) and the locally agreed treatment guidelines."
223814606|NCT01789996|PROCEDURE|alternative six minute walk test|"Alternate instructions will be given Subjects will~1. walk as fast as they can in 6 minutes~2. walk as normally as they can in 6 minutes~3. walk leisurely as they can in 6 minutes. Pts will serve as their own controls."
223814607|NCT01789996|PROCEDURE|Standard six minute walk test|Subjects will walk as far as they can in 6 minutes
223814608|NCT02305381|DRUG|semaglutide|Injected subcutaneously (s.c. under the skin) once-weekly. As add-on to the pre-trial background medication.
223814609|NCT02305381|DRUG|placebo|Injected subcutaneously (s.c. under the skin) once-weekly. As add-on to the pre-trial background medication.
223814610|NCT03736343|DRUG|Alcohol|Participants will complete two drinking sessions.
223814611|NCT02357290|DRUG|Open-label Treatment with N-Acetylcysteine|
223814612|NCT00469469|DRUG|Bevacizumab|
223814613|NCT04389333|DEVICE|non-contact magnetically-controlled capsule endoscopy|The novel non-contact magnetically-controlled capsule endoscopy (MCE) system (Ankon Technologies, Wuhan, China) (Figure 1) added a remote control workstation and an audio-visual exchange system to the original well-establish MCE system, which consisted of a robotic magnetic arm, a workstation (currently bypassed) and a capsule endoscope.
223814614|NCT00811447|DRUG|5-fluorouracil|600 mg/m²/day intravenous
223814615|NCT00811447|DRUG|Cisplatin|60 mg/m² or 75 mg/m² intravenous
223814616|NCT00811447|DRUG|Docetaxel|60 mg/m² intravenous
223814617|NCT01240954|DRUG|OSIRIS|OSIRIS current practice
223814618|NCT01240954|DRUG|OSIRIS other concentration 1|OSIRIS new concentration 1
223814619|NCT01240954|DRUG|OSIRIS other concentration 2|OSIRIS new concentration 2
223814620|NCT06089252|DRUG|walnut extract|Four times a day over a 10-day period
223814621|NCT01388348|DEVICE|"Dynamic Urine Vibration Holter"|"each subject will undergo intervention for the diagnosis of bladder outlet obstruction first using the Dynamic Urine Vibration Holter and then urodynamically by pressure flow study"
223814622|NCT02320032|DRUG|Aripiprazole Lauroxil|Gluteal IM injection, given once every 4 to 8 weeks
223814623|NCT02935348|RADIATION|Whole Body MRI|Routine whole body clinical MRI will be performed according to current clinical standard of care. Axial and coronal imaging from the maxilla to proximal femurs will be performed using a combination of T1 and T2 weighted sequences, with and without gadolinium administration.
223814624|NCT01213108|BEHAVIORAL|Örebro prevention program|6 presentations on alcohol-specific parenting practices to parents of 13-16 year olds youth
223814625|NCT01213108|BEHAVIORAL|Business as usual|Regular alcohol prevention activities and curricula in Swedish schools
223814626|NCT01042743|PROCEDURE|robot-assisted surgery|da Vinci surgical system® (Intuitive Surgical, Sunnyvale, CA, USA)
223814627|NCT01042743|PROCEDURE|laparoscopic right-hemicolectomy|Conventional laparoscopic procedures
223814628|NCT06156566|DRUG|Tecovirimat Oral Capsule|600 mg, twice daily, 14 days.
223814629|NCT06156566|DRUG|Placebo|3 capsules, twice daily, 14 days.
223814630|NCT04863625|BEHAVIORAL|a peer-led educational intervention based on theory of planned behavior on substance use intentions and behaviors|The intervention will be a peer led education process on substance use (smoking, drinking and chewing) prevention based on the Theory of Planned Behavior (TPB).The intervention aims to encourage anti-substance attitudes and beliefs; foster perceptions of normative support for anti-substance behavior; increase perceptions of control/self-efficacy to resist substance use, increase knowledge and risk perceptions on substance and decrease in intention to use substance and actual substance use behaviors. Six education sessions will be delivered, with one session occurring each week. Each session will be lasted 40-55 minutes. The intervention will be conducted in 30 groups of selected students from grade 9-12, a pair of peer educators will educate a 30 sized group weekly (30 students /group)/ classrooms at pre-assigned time during class periods. The six sessions will be guided by four student training modules.
223814631|NCT06081595|DRUG|Fluzoparib|Fluzoparib 100mg bid
223814632|NCT06081595|DRUG|Apatinib|Apatinib 375mg qd
223814633|NCT05257330|DIAGNOSTIC_TEST|CSF Examination|Lumbar puncture for CSF Examination
223814634|NCT02487498|DRUG|QVA149|QVA149 capsules for inhalation, delivered via QVA149 SDDPI
223814635|NCT02487498|DRUG|Umeclidinium/vilanterol|Umeclidinium/vilanterol for inhalation, delivered via ELLIPTA® inhaler
223814636|NCT02487498|DRUG|Placebo (umeclidinium/vilanterol )|Matching Placebo to umeclidinium/vilanterol for inhalation, delivered via ELLIPTA® inhaler
223814637|NCT02487498|DRUG|Placebo (QVA149)|Matching Placebo to QVA149 capsules for inhalation, delivered via QVA149 SDDPI
223814638|NCT06371599|BEHAVIORAL|Playing game|Active Distraction Methods
223814639|NCT06371599|BEHAVIORAL|Watching cartoon|Passive Distraction Methods
223814640|NCT04744857|COMBINATION_PRODUCT|The experimental apparatus consisted of artificial aortic valve, transporter and grip-loading system.|Using the grip-loading system, the artificial aortic valve was squeezed and loaded into the sheath of the transporter through the vascular approach.The artificial aortic valve is delivered and positioned at the correct anatomical position for release. For example, the artificial main valve is displayed after partial release If the aortic valve is not in the correct anatomical position, the artificial aortic valve can be recovered and placed into the sheath tube of the transporter for re-positioning and release.
223814641|NCT04391465|OTHER|Electrophysiological Pacing|Assess the MCA CBF velocity response at different paced heart rates.
223814642|NCT05044325|DRUG|GSK3884464|GSK3884464 will be administered
223814643|NCT05044325|DRUG|Placebo|Placebo to match GSK3884464 will be administered.
223814644|NCT05994391|DIETARY_SUPPLEMENT|LasoperinTM|"Active ingredients:~Scutellaria baicalensis extract, 240 mg per capsule. Acacia catechu extract, 51 mg per capsule. With no less than 180 mg of baicalin, and no less than 30 mg of catechins from the above-mentioned extracts per capsule.~Inactive ingredients:~Maltodextrin"
223814645|NCT05994391|DIETARY_SUPPLEMENT|Placeo|"Active ingredients:~N/A~Inactive ingredients:~Microcrystalline cellulose"
223814646|NCT00755222|BIOLOGICAL|AA4500|2 single injections of study drug per each treatment series up to three treatment series total in study. Each treatment series was separated by 6 weeks.
223814647|NCT00755222|BIOLOGICAL|Placebo|2 single injections of study drug per each treatment series up to three treatment series total in study. Each treatment series is separated by 6 weeks.
223814648|NCT05445544|OTHER|Observational studies, The diagnosis was preeclampsia|Observational studies, The diagnosis was preeclampsia
223814649|NCT03712735|DRUG|Bupivacaine 0.08% - fentanyl 2mcg|In each arm, bupivacaine and fentanyl are being delivered at different intervals and rates for the maintenance of labor analgesia.
223814650|NCT02492555|OTHER|SI|A routine scheduled (SI) screening of FC and DA every 3rd month
223814651|NCT02492555|OTHER|OD|A screening of FC and DA on demand (OD)
223814652|NCT05375708|RADIATION|Stereotactic body radiation therapy (SBRT)|Patients will receive a single fraction of 15 Gy to each of the macroscopic tumor sites including the primary tumor if still in situ. All lesions are treated. The treatment will be delivered in an image-guided way, either on a conventional linear accelerator (LINAC) or a MR-LINAC, whichever has the best targeting according to the treating radiation oncologist.
223814653|NCT05375708|DRUG|Maintenance therapy (CAP-B or 5-FU/LV plus bevacizumab.)|"CAP + bevacizumab (following CAPOX-B) Bevacizumab 7.5mg/kg i.v. on day 1 and 1250 mg/m2 of capecitabine, orally twice daily on days 1-14 if age is \<70 years and 1000 mg/m2 of capecitabine, orally twice daily on days 1-14 if age is higher than 70 years. CAP + bevacizumab is repeated every three weeks.~5-FU/LV + bevacizumab (following FOLFOX-B) Bevacizumab 5.0mg/kg i.v. together with leucovorin 400 mg/m2 i.v. bolus 5FU 400 mg/m2 all on day 1. Followed by continuous infusion of 5-fluorouracil 2400 mg/m2 in 46 hours. 5-FU + bevacizumab is repeated every two weeks.~5-FU/LV + bevacizumab (following FOLFOXIRI-B) Bevacizumab 5.0mg/kg i.v. together with leucovorin 400 mg/m2 i.v. all on day 1. Followed by continuous infusion of 5-fluorouracil 3200 mg/m2 in 46 hours. 5-FU + bevacizumab is repeated every two weeks.~When S1 is used a replacement for fluoropyrimidine therapy it is administered in a dose of 30mg/m2 twice daily on days 1-14. S1 is repeated every three weeks."
223814654|NCT00936832|DRUG|FOLFIRI regimen|
223814655|NCT00936832|DRUG|fluorouracil|
223814656|NCT00936832|DRUG|irinotecan hydrochloride|
223814657|NCT00936832|DRUG|leucovorin calcium|
223814658|NCT00936832|DRUG|sunitinib malate|
223814659|NCT00936832|OTHER|laboratory biomarker analysis|
223814660|NCT00936832|OTHER|pharmacogenomic studies|
223814661|NCT00936832|OTHER|pharmacological study|
223814662|NCT02574000|OTHER|ShoulderQ which is a shoulder pain questionnaire|Questions regarding shoulder pain at rest, during movement and at night with visual analogue scales. Factors affecting shoulder pain.
223814663|NCT02574000|OTHER|Clinical shoulder examination|Shoulder-Hand-Score (measuring pain, oedema, passive range of movement), muscle strength (using Oxford scale and National Institute of Health Stroke Scale (NIHSS) upper limbe motor and shoulder joint palpation (recording subluxation and soft-tissue pain).
223814664|NCT05494827|OTHER|Regular consumption of natural mineral water Borjomi® with high bicarbonate content|"Natural mineral water Borjomi® is a transparent mineral water with specific alkaline taste and smell. The chemical composition includes sodium hydrocarbonate (HCO2-) 3995 mg/l (3500-5000 mg/l), chlorides (Cl-) 360 mg/l (250-500 mg/l), and nitrites (NO2-) \<0.005 mg/l (up to 1 mg/l). The Borjomi water was packaged into standardized unlabeled 500 ml bottles. Participants were prescribed with 2 bottles (1000 ml) of daily consumption for 14 days. In order to maintain their usual water regimen, the participants additionally consumed steal drinking water on demand. The day before testing, participants were asked to abstain from their routine training and other physical activities."
223814665|NCT05494827|OTHER|Regular consumption of processed drinking water Smart Spring®|Processed drinking water Smart Spring® has no colour and smell with delicate specific taste. The chemical composition includes sodium (Na+) 33.6 mg/l, magnesium (Mg2+) 10.03 mg/l, calcium (Ca2+) 34.57 mg/l, chlorides (Cl-) 69.79 mg/l, sulfates (SO42-) 22.00 mg/l, and hydrocarbonates (HCO2-) 96.48 mg/l. The Smart Spring® water was packaged into standardized unlabeled 500 ml bottles. Participants were prescribed with 2 bottles (1000 ml) of daily consumption for 14 days. In order to maintain their usual water regimen, the participants additionally consumed steal drinking water on demand. The day before testing, participants were asked to abstain from their routine training and other physical activities.
223814666|NCT05494827|OTHER|Regular consumption of still drinking water|Still drinking water Святой Источник®is a standard steal drinking water, that has no colour, taste, and smell. The Святой Источник® water was packaged into standardized unlabeled 500 ml bottles. Participants were prescribed with 2 bottles (1000 ml) of daily consumption for 14 days. In order to maintain their usual water regimen, the participants additionally consumed steal drinking water on demand. Participants were asked to abstain from mineral water consumption for the entire observation period.
223814667|NCT02384525|PROCEDURE|Fluid management by the value of over hydration in Bioelectrical impedance|In this study, investigator measure the fluid status of the patients by bioelectrical impedance analysis and lung ultrasound. The patients are assigned into two groups, BIA and Lung Ultrasound based versus clinical-based assessment group. Ultrafiltration of BIA and Lung Ultrasound based group is adjusted to be equal to the value of over hydration measured only by BIA, not by Lung Ultrasound, because Lung Ultrasound cannot determine exact amount of the patient's fluid excess. Total amount of ultrafiltration will be removed from the patient for three days evenly. On the other hand, Ultrafiltration amount will be decided by the physician in the clinical based group. Amount of fluid removal for a day will be adjusted not to exceed 2000ml, so that total fluid removed from the patient will not exceed 6000ml for three days.
223814668|NCT02384525|PROCEDURE|Fluid management by clinical-based ultrafiltration|In this study, investigator measure the fluid status of the patients by bioelectrical impedance analysis and lung ultrasound. The patients are assigned into two groups, BIA and Lung Ultrasound based versus clinical-based assessment group. Ultrafiltration of BIA and Lung Ultrasound based group is adjusted to be equal to the value of over hydration measured only by BIA, not by Lung Ultrasound, because Lung Ultrasound cannot determine exact amount of the patient's fluid excess. Total amount of ultrafiltration will be removed from the patient for three days evenly. On the other hand, Ultrafiltration amount will be decided by the physician in the clinical based group. Amount of fluid removal for a day will be adjusted not to exceed 2000ml, so that total fluid removed from the patient will not exceed 6000ml for three days.
223814669|NCT04139980|OTHER|Virtual Reality (VR)|Each VR session is 30 minutes long. Participants are able to pause or discontinue at any time. Each participant will receive one VR sessions five times per week over the course of a two-week period.
223814670|NCT05403164|PROCEDURE|Modified Widman flap|"1. Administration of anaesthesia~2. First incision (reversed bevel incision), scalpel is placed at 45 degree, 2mm apical to gingival margin in coronal-apical direction until touching the bone and moved continuously around the teeth without any vertical releasing incisions~3. Partial mobilization of the mucoperiosteal flap (full thickness flaps both facially and orally) within the attached gingiva to the alveolar crest~4. Second incision (sulcular incision)~5. Third incision (horizontal incision), also interdentally to remove the delineated tissue and all granulation tissue which is used later for analysis.~6. Root surface debridement~7. Flap adaptation, complete coverage interdentally and suturing."
223814671|NCT05403164|PROCEDURE|Gingivectomy|"1. Administration of anaesthesia~2. Marking the base of the sulcus with pocket marker tweezer.~3. First incision (gingivectomy incision), scalpel blade placed 1mm apical to the bleeding points and the incision should be beveled 45 degrees coronally.~4. Second incision (interdental) to free the tissue which is used for analysis later.~5. Debriding the area and applying periodontal pack."
223814672|NCT05182645|BEHAVIORAL|lifestyle-modification|The group intervention is carried out once a week for 10 weeks for a total of 60 hours with elements of mindfulness-based stress reduction (MBSR) and further process of the mind / body medicine. In this project, this program will be adapted to the specific needs of crohn's disease patients.
223814673|NCT05182645|BEHAVIORAL|waiting control group|Participants in this group receive a one-time education unit within the scope of 3 hours on the influence of lifestyle factors on the disease, also self-help materials for independent training offered. Following the follow-up measure also this group is given the opportunity to participate in the multimodal stress reduction- and lifestyle modification program.
223814674|NCT00962143|DEVICE|Achilles repair with OrthADAPT augmentation|Achilles repair with OrthADAPT augmentation
223814675|NCT00962143|PROCEDURE|Achilles repair without OrthADAPT Augmentation|Achilles repair without OrthADAPT Augmentation
223814676|NCT00145457|PROCEDURE|Blood sample|
223814677|NCT00145457|PROCEDURE|Radiography|
223814678|NCT05159323|DIAGNOSTIC_TEST|Diffusion Spectrum Imaging|A novel diffusion-based magnetic resonance imaging method
223814679|NCT02034825|OTHER|Decipher Questionnaire|Each participant will complete the pre and post-Decipher eCRQs for a minimum of 5 cases, and a maximum of 25 cases.
223814680|NCT02243202|DRUG|Canagliflozin|300 mg capsule, taken once daily, orally for 26 weeks.
223814681|NCT02243202|DRUG|Phentermine|15 mg capsule, taken once daily, orally for 26 weeks.
223814682|NCT02243202|DRUG|Matching Placebo to Canagliflozin|Placebo capsules look like canagliflozin but do not contain any active drug, taken once daily, orally for 26 weeks.
223814683|NCT02243202|DRUG|Matching Placebo to Phentermine|Placebo capsules look like phentermine but do not contain any active drug, taken once daily, orally for 26 weeks.
223814684|NCT03540355|DRUG|Cipros 20 association|oral, once a day
223814685|NCT03540355|DRUG|Crestor 20 mg|Oral, once a day
223814686|NCT02378558|DEVICE|MagneMarker|The MagneMarker system includes a magnetic clip the MagneMarker, a clip placement device the MagneJector, and a magnetic field detecting probe the MagneProbe. The MagneMarker and MagneJector are used by a radiologist during a breast localization procedure. The MagneProbe is used by a surgeon to locate the MagneMarker during breast excision.
223814687|NCT00784433|DIETARY_SUPPLEMENT|alcohol|150 cc
223814688|NCT04728178|OTHER|Crystalloid solution|Crystalloid solution is a true solution and is able to pass through a semipermeable membrane.
223814689|NCT04728178|OTHER|Colloid solution|Colloid solution is a heterogeneous mixture whose particle size is intermediate between those of a solution and a suspension.
223814690|NCT04773210|DEVICE|Mini tube system|Mini tube system (FLOW-JAC System, Bogotá, Colombia) orthodontic treatment
223814691|NCT04773210|DEVICE|Conventional ligating brackets|Conventional ligating brackets (Gemini 3M Unitek Orthodontic Products bracket, Calif, USA) with Nitinol Classic or superelastic (SE) archwires 0.014 and 0.016 orthodontic treatment
223814692|NCT03361995|DEVICE|Cooling Procedure using the ZOLL Thermogard XP3 IVTM System|Cooling Procedure with ZOLL Thermogard XP3 IVTM System before and after Percutaneous Coronary Intervention (PCI)
223814693|NCT03361995|DEVICE|PCI|Standard of Care for PCI
223814694|NCT04374396|PROCEDURE|Real ultrasound-guided single shot erector spinae plane block (ESP B)|"ESP block will be performed with the patient lying in the lateral position and the surgical side at the top. After skin disinfection, sterile draping will be placed, and ultrasound probe will be sheathed. The level of the block will be at the transverse process of L2, using a 9-12 MHz linear probe and placed in a parasagittal plane 1 cm from the posterior midline. The deep plane to the erector spinae muscle (ESM) will be identified and a 22 Gauge 50 mm insulated needle will be inserted craniocaudally in plane between the transverse process and the fascia of the ESM.~After negative aspiration, 0.3 mL/kg- of bupivacaine 0.25% will be injected confirming correct position by visualizing the solution lifting the ESM off the transverse process .Spread of LA between the L1 and L4 transverse processes will be thereafter visually tracked with the transducer. In the control group, no local anesthetics will be injected."
223814695|NCT04374396|RADIATION|Sham ultrasound-guided single shot erector spinae plane block (ESP B)|"EESP block will be performed with the patient lying in the lateral position and the surgical side at the top. After skin disinfection, sterile draping will be placed, and ultrasound probe will be sheathed. The level of the block will be at the transverse process of L2, using a 9-12 MHz linear probe and placed in a parasagittal plane 1 cm from the posterior midline. The deep plane to the erector spinae muscle (ESM) will be identified and a 22 Gauge 50 mm insulated needle will be inserted craniocaudally in plane between the transverse process and the fascia of the ESM.~No local anesthetics will be injected"
223814696|NCT02337517|OTHER|Laboratory Biomarker Analysis|Correlative studies
223814697|NCT02337517|DRUG|Vismodegib|Given PO
223814698|NCT01751230|BEHAVIORAL|WIC E-Moms|Participants enrolled in the E-Moms group will receive a personalized dietary prescription to promote weight loss and arrive at pregravid weight by 6 months postpartum. Our weight loss intervention will incorporate standard WIC nutritional advice and will encouraged 150 minutes/week of moderate intensity activity, which is about 3,000 - 4,000 steps/day above baseline, as recommended for maintenance of healthy weight. Each participant will be assigned a trained weight management counselor who will provide frequent recommendations and advice and support at least once per week.
223814699|NCT02070900|DEVICE|POC CD4|Point of Care device for CD4 count testing (to be used as a clinical monitoring tool)
223814700|NCT02070900|OTHER|Programmatic Mentoring|Programmatic Mentoring aimed at messaging around CD4 count to encourage retention on lifelong ART for PMTCT patients, administered by trained clinical mentors
223814701|NCT05986123|OTHER|Topical cream Z for PIH|The topical cream Z contain combination of niacinamide, arbutin, Scutellaria Baicalensis Root Extract, Centella Asiatica Extract and Camellia Sinensis Leaf Extract. Participants will used the topical cream twice daily for 20 weeks
223814702|NCT04457830|DRUG|F520|3mg/kg every 3 weeks
223814703|NCT06251713|OTHER|VeXUS score guided fluid management strategy|"During the first 3 postoperative days, the VeXUS score is estimated daily by ultrasound. If VeXUS score \>1, diuretic-induced fluid removal will be administred (target diuresis: 2-4mL/kg/h). The diuretic administration protocol is derived from the CARRESS HF study: bolus followed by a continuous administration of Furosemide with thiazide added based on preoperative diuretic administration status.~To prevent hypokalaemia and dysnatremia, a protocol for potassium supplementation and intravenous administration of chloride serum or hypotonic perfusion is planned.~Fluid removal will be suspended if severe metabolic disturbance (pH\>7.55 with HCO3-\>40mmol/L or serum K+ \<3 mmol/L or serum Na\>150 mmol/L) or haemodynamic instability (hypoperfusion) with fluid responsiveness occurs. Regardless of the VeXUS score, diuretics will be introduced in case of pulmonary oedema.~Haemodynamic status will be every 12 hours to detect side effects attributable to diuretic-induced fluid removal."
223814704|NCT06251713|OTHER|Usual care|Fluid management will be at the discretion of attending physician, who will be blinded to the patient's VeXUS score status.
223814705|NCT06834672|DRUG|IBI354|intravenous infusion of 12 mg/kg on Day 1 of each 3-week treatment cycle
223814706|NCT06834672|DRUG|paclitaxel/Gemcitabine/Liposomal doxorubicin|paclitaxel：- Usage and dosage: 80 mg/m2 administered as an intravenous infusion on Day 1 of each weekly treatment cycle。 Gemcitabine：Usage and dosage: intravenous infusion at 1000 mg/m2 on Days 1, 8 of each 3-week treatment cycle。 Liposomal doxorubicin：Usage and dosage: intravenous infusion of 40 mg/m2 on Day 1 of each 4-week treatment cycle
223814707|NCT02659787|DRUG|0.2mg Buprenorphine|Sublingual buprenorphine tablets (0.2mg)
223814708|NCT02659787|DRUG|Placebo|Placebo
223814709|NCT04860817|BIOLOGICAL|Target CD7 CAR-T cells|"Enrolled participants are allocated to one of three different dose levels of target CD7 CAR-T cells. The infusion dose of CAR-T cells will start at low dose and then rise to higher dose after completion of low dose group.~1. Dose level one: 0.6×10\^7 cells/kg;~2. Dose level two: 1×10\^7 cells/kg;~3. Dose level three: 1.5×10\^7 cells/kg. Before CAR-T infusion, all participants will receive a preconditioning therapy suggested as: Fludarabine 30 mg/m\^2×6d, Cyclophosphamide 300 mg/m\^2×6d or Cyclophosphamide 600 mg/m\^2×6d. After completion of preconditioning therapy, infusion of CAR-T cells needs to start within 1 week. Participants will receive one infusion of CAR-T cells which will take between 15 and 30 mins."
223814710|NCT05644223|DRUG|edaravone dexborneol|intravenous edaravone dexborneol 37.5mg twice daily
223814711|NCT00582946|DEVICE|Hearing Aid|Subjects were treated with a hearing aid which provided amplification intended to treat mild to moderate sensorineural hearing loss.
223814712|NCT02405260|DRUG|TTP399 400 mg|once daily
223814713|NCT02405260|DRUG|TTP399 800 mg|once daily
223814714|NCT02405260|DRUG|Sitagliptin 100 mg|once daily
223814715|NCT02405260|DRUG|Placebo|once daily
223814716|NCT02013388|DRUG|N91115|Given PO daily for 14 days
223814717|NCT02013388|DRUG|Placebo|Given PO daily for 14 days
223814718|NCT02013388|DRUG|N91115|Given PO only on Day 1
223814719|NCT02013388|DRUG|Placebo-Day 1 only|Given PO- only on Day 1 (single dosed to match single dose treatments)
223814720|NCT03420924|DEVICE|Thermal suit|Forced-air warming device will be connected to the trouser legs of the thermal suit.
223814721|NCT03420924|DEVICE|Conventional hospital clothes|The warming mattress and a forced-air warming blanket for the lower body will be used intraoperatively.
223814722|NCT05434845|OTHER|Blood draw|An additional 8 mL of blood will be drawn during routine lab collection
223814723|NCT01153139|DEVICE|Repetitive Transcranial Magnetic Stimulation (Theta Burst Stimulation, TBS)|intermittent TBS (iTBS) to the left DLPFC (600 stimuli, 80% resting motor threshold) continuous TBS (cTBS) to the right DLPFC (600 stimuli, 80% resting motor threshold)
223814724|NCT04000620|PROCEDURE|surgery|treatment intent surgery
223814725|NCT04000620|PROCEDURE|punture|diagnostic punture
223814726|NCT04207840|COMBINATION_PRODUCT|Epinephrine (0.125 mg/inhalation)|Participants will self-administer 2 inhalations of Epinephrine (0.125 mg/inhalation) for a total dosage of 0.25 mg.
223814727|NCT04207840|COMBINATION_PRODUCT|Epinephrine Injection Auto-Injector (0.3mg/0.3mL)|Participants will receive an intramuscular injection of Epinephrine via Auto-Injector (0.30 mg of epinephrine solution in 0.30 mL). The 0.30 mL dose will be given perpendicularly as a single deep intramuscular injection into the anterolateral aspect of the thigh.
223814728|NCT04207840|COMBINATION_PRODUCT|Albuterol Sulfate (0.09 mg/inhalation)|Participants will self-administer 2 inhalations of Albuterol Sulfate (0.09 mg/inhalation) for a total dosage of 0.18 mg.
223814729|NCT04947163|DEVICE|Inspiratory Muscle Training|Participants will perform home-based IMT twice daily \[once in the morning (between 7:00 and 12:00 am) and once in the evening (between 16:00 and 21:00 pm)\], for 8 consecutive weeks, using a mechanical pressure threshold loading device. In addition, participants in this group will try to increase the inspiratory resistance when the participants feel that 30 breaths are achievable with ease or if the participants could reach 35 consecutive breaths.
223814730|NCT04947163|DEVICE|Sham IMT|Participants will perform 60 slow breaths once daily at a load setting of 0 (corresponding to \~15% \[baseline\] MIP), using the same device as the IMT group. For the sham group, the ability to adjust the training load will be prevented using sticky tape applied to the device's load adjuster.
223814731|NCT00735501|DRUG|insulin detemir|Start dose and frequency as well as dose alterations to be determined by the physician according to normal clinical evaluation
223814732|NCT00542048|DRUG|EndoTAG®-1|EndoTAG®-1 22 mg/m² twice weekly
223814733|NCT03243422|OTHER|Successful aging health education intervention|"The Successful Aging intervention will follow the protocol and materials developed for the 10 Keys™ to Healthy Aging program by the Center for Aging and Population Health Prevention Research Center at the University of Pittsburgh. This interactive, dynamic program informs older adults about risk factors for diseases. Participants will meet individually with a health educator certified to administer the program every 2-3 weeks for a total of 4 visits over approximately 8-10 weeks, and the session content will focus on a Key. Each session will also include a 5-10 minute active upper body extremity stretching program as used in the Lifestyle Interventions and Independence for Elders (LIFE) study. Participants will return for booster sessions semi-annually beginning at 6 months post-randomization."
223814734|NCT03243422|OTHER|Hearing intervention|The hearing intervention consists of fitting with hearing aids and other hearing assistive technologies plus four 1-hour comprehensive, individualized hearing rehabilitation sessions spaced over the 2-3 months post-randomization designed to provide all of the active components of the intervention. Hearing aids are instructed to be worn on a daily basis for study duration. Audiologic outcomes (e.g., hearing aid data logging, real ear measures, speech in noise, etc.) to verify the best-practices hearing intervention are gathered during study intervention visits and semi-annually beginning at 6 months post-randomization.
223814735|NCT05897632|BEHAVIORAL|Outpatient Evaluation|Subjects will receive an outpatient evaluation within 72 of being discharged from the ED.
223814736|NCT05897632|BEHAVIORAL|Hospitalization Evaluation|Patients randomized to this arm receive evaluation for their symptoms in a hospital ward, observation unit, or emergency department boarding.
223814737|NCT00949481|OTHER|Pregnancy Test|Free pregnancy test strips will be supplied to family planning clinics
223814738|NCT00949481|OTHER|Job aid|"A new job-aid will be given to immunization providers that will guide them in assessing a mother's risk for pregnancy (based on LAM criteria), and guide them in making family planning referrals, including when a woman should start to use a family planning method if she wants to prevent pregnancy. The providers in immunization clinics will be asked to make such an assessment each time a woman has her baby vaccinated.~Additionally, in family planning clinics located in the same facilities as the immunization clinics, family planning providers will be trained to use and provided with the pregnancy checklist (see links for more information on the checklist)"
223814739|NCT04585438|DRUG|Diclofenac Potassium|The drug will be used as a transparent disc applied to the mucosa
223814740|NCT02875405|PROCEDURE|Posterior left pericardiotomy|Patient will receive a posterior left sided pericardiotomy. The incision will be made posterior to the phrenic nerve and run from the inferior left pulmonary vein to the diaphragm.
223814741|NCT02173054|OTHER|Adapalene gel with Eucerin|Eucerin: 2 fingertip unit to cover all over the face twice a day. Adapalene gel: 2 fingertip unit to cover all over the face before going to bed
223814742|NCT02173054|OTHER|Adapalene gel|Adapalene gel: 2 fingertip unit to cover all over the face before going to bed
223814743|NCT02173054|OTHER|Adapalene gel with placebo moisturizer|Placebo: 2 fingertip unit to cover all over the face twice a day. Adapalene gel: 2 fingertip unit to cover all over the face before going to bed
223814744|NCT03270917|PROCEDURE|Parenchymal preserving postero-superior liver segment resection|Parenchymal preserving liver segment resection of one or two of the postero-superior liver segments (4A, 7 or 8).
223814745|NCT04671238|DEVICE|SPECT CT|SPECT/CT scan of the spine as part of a vertebroplasty
223814746|NCT04419402|DRUG|Lu-PSMA|"Patients will be given 7.5 GBq of Lu-PSMA in 4 doses. Dose 1 and 2 on Days 15 and 57. Doses 3 and 4 (Days 113 and 169) will be given following result of 68Ga-PSMA PET/CT at Day 92.~Treatment administered every 6 weeks, x 4 cycles."
223814747|NCT04419402|DRUG|Enzalutamide|160 mg (four 40 mg capsules) daily.
223814748|NCT00192309|BIOLOGICAL|CAIV-T|Liquid CAIV-T vaccine for this study consisted of three cold-adapted, attenuated, reassortant strains representing the hemagglutinin (HA) and neuraminidase (NA) antigens of the A/New Caledonia/20/99 (H1N1), A/Panama/2007/99 (H3N2) and B/Yamanashi/166/98 influenza virus strains. The reassortant vaccine strains were grown in specific pathogen-free (SPF) eggs and the allantoic fluid, which contained virus, was harvested, concentrated and purified. Each dose of CAIV-T used in this study was formulated to contain approximately 107 FFU of each of the 6:2 influenza reassortant vaccine strains.
223814749|NCT00192309|BIOLOGICAL|TIV|TIV in this study consisted of Flushield™, manufactured by Wyeth Vaccines, Marietta, PA, USA. Each 0.5 mL dose contained no less than 15 ug of the hemagglutinin antigens from each of the A/New Caledonia/20/99 (H1N1), A/Panama/2007/99 (H3N2), and B/Yamanashi/166/98 strains, making TIV in this study antigenically matched to the influenza strains contained in CAIV-T.
223814750|NCT00192309|BIOLOGICAL|Placebo|Placebo in this study consisted of physiological saline. The total volume of 0.2 mL was administered intranasally with a spray applicator (approximately 0.1 mL into each nostril).
223814751|NCT02543255|DRUG|Abiraterone acetate with prednisone|Abiraterone acetate will be administered orally as a tablet at 1000 mg/day with prednisone (5 mg oral tablet, twice daily) for 24 weeks.
223814752|NCT02543255|DRUG|Leuprolide|Leuprolide will be administered by subcutaneous injection at 22.5 mg dose every 12 weeks for 24 weeks.
223814753|NCT02543255|DRUG|Cabazitaxel with peg-filgrastim|Cabazitaxel will be administered in 6 cycles, with 20 mg/m2 per cycle and 3 weeks between cycles.
223814754|NCT01083654|BEHAVIORAL|Standard Treatment Counseling|Standard Treatment Counseling will be based on recommendations in the 2008 U.S. Public Health Service Guideline (Treating Use and Dependence) including topics on preparing to quit, nicotine addiction, coping with stressors and challenging situations, coping with withdrawal symptoms, seeking support, and relapse prevention. Counseling will be delivered in an accessible, personalized manner by Ms. Fossum (an enrolled member of the Menominee Tribe) but no American Indian culturally-appropriate treatment elements will be incorporated into the counseling. In other words, the counseling in the Standard Treatment will be similar to the kind of evidence-based counseling offered to other smokers regardless of race or ethnicity.
223814755|NCT01083654|BEHAVIORAL|Culturally-Tailored Treatment|The Culturally-Tailored Treatment consists of the Standard Treatment Counseling plus culturally-appropriate treatment elements including: discussion of the long history of sacred/traditional use of tobacco (honoring and respecting native traditions) and how it differs from use of commercial tobacco use (harming health); custom booklet on smoking and smoking cessation tailored for Menominee and other American Indian smokers; and participants will be encouraged to make their own traditional tobacco pouch (symbol of long life)
223814756|NCT04050241|DEVICE|Glidescope intubation|Anesthetists will perform intubation in patients undergoing elective neurosurgery with the Glidescope videolaryngoscope, while completing a secondary auditory task. Response times to the secondary task will be recorded, and operators will complete the NASA Task Load Index questionnaire at the end of each procedure.
223814757|NCT04050241|DEVICE|Mcintosh intubation|Anesthetists will perform intubation in patients undergoing elective neurosurgery with the Mcintosh laryngoscope, while completing a secondary auditory task. Response times to the secondary task will be recorded, and operators will complete the NASA Task Load Index questionnaire at the end of each procedure.
223814758|NCT00615732|PROCEDURE|Qigong|18 therapy sessions, during the first 3 months once a week, month 4 to 6 once every second week
223814759|NCT00615732|PROCEDURE|exercise therapy|18 therapy sessions, during the first 3 months once a week, month 4 to 6 once every second week
223814760|NCT05786729|OTHER|Aerobic Exercise (AER)|Aerobic exercise will be performed by utilizing aerobic exercise equipment 3 times per week.
223814761|NCT05786729|OTHER|Rehabilitation|Rehabilitative program is focused on completion of activities of daily living, initiation, appropriate behavior and community integration for five days per week at the Centre for Neuro Skills.
223814762|NCT06524011|BIOLOGICAL|Stromal vascular fraction (SVF) enriched platelet rich plasma (PRP) versus each alone|Adipose derived stromal vascular fraction cells will be aspirated and isolated from patient autologous adipose tissue and used to enrich patient's autologous platelet rich plasma then will be used to treat atrophic post acne scars versus each alone.
223814763|NCT06118723|PROCEDURE|Supramaximal resection|Supramaximal resection. Tumor resection continues until either the FLAIR abnormalities have been resected based on the neuronavigation (after updating the navigation intraoperatively), or when subcortical tracts are identified with intraoperative stimulation.
223814764|NCT06118723|PROCEDURE|Maximal safe resection|Maximal safe resection. Tumor resection continues until maximal safe resection has been achieved as by the neurosurgeon's opinion.
223814765|NCT05582304|DEVICE|Test Lens|ACUVUE OASYS MAX 1-Day with TearStable Technology and OptiBlue Light Filter
223814766|NCT05582304|DEVICE|Control Lens|ACUVUE OASYS 1-Day with HydraLuxe Technology
223814767|NCT02273830|DRUG|oxygen|Oxygen administered after adjustment during a waking test or at 3L/min
223814768|NCT04228640|OTHER|NMN|Investigational Product
223814769|NCT04228640|OTHER|Placebo|Starch Powder
223814770|NCT04943224|DRUG|Trametinib|\< 6 lat 0,032mg/kg, ≥ 6 lat 0,025mg/kg,
223814771|NCT00002488|DRUG|cisplatin|
223814772|NCT00002488|DRUG|cyclophosphamide|
223814773|NCT00002488|DRUG|etoposide|
223814774|NCT03419416|OTHER|Kangaroo mother care (KMC)|Skin to skin contact of newborns with mothers and exclusive breast feeding
223814775|NCT01435811|BIOLOGICAL|Norovirus challenge pool (GII.4, CIN-1)|Norovirus challenge pool (GII.4, CIN-1)
223814776|NCT03005509|OTHER|TQIM checklist|"The intervention phase will include an intense training period covering:~1. Conduct of Trauma Quality Improvement Meeting (TQIM) (and Trauma Quality Improvement program in general). The training will be delivered using the World Health Organization (WHO) Trauma Quality Improvement Programmes short course and online resources.~2. Implementation of Trauma Quality Improvement Meeting (TQIM) Checklist."
223814777|NCT01916655|BEHAVIORAL|Self-Management Care|Provision of sleep apnea-specific self-management education and support for those who are prescribed CPAP therapy
223814778|NCT01916655|BEHAVIORAL|Self-Management Mobile Care|Provision of sleep apnea-specific self-management education and support for those who are prescribed CPAP therapy via mobile phone
223814779|NCT01916655|BEHAVIORAL|Usual Care|standard and typical CPAP educational and support protocol; is the base level education and support that is provided in the other two interventions in this study.
223814780|NCT00644202|BEHAVIORAL|Counseling Sessions|Counseling Sessions at each study visit around diet and physical activity from a registered dietician
223814781|NCT00644202|BEHAVIORAL|Specialized Website|Specialized website that allows participants to track their eating and physical activity patterns, learn new weight management skills, interact with the dietician, and receive support from other participants
223814782|NCT00644202|BEHAVIORAL|Telephone Counseling Calls|5 telephone calls with a health counselor, lasting 15-20 minutes each.
223814783|NCT00991341|BIOLOGICAL|Red blood cell units stored <= 10 days|Pre-storage leukoreduced red blood cell units stored \<=10 days at time of transfusion. Can be AS1, AS3, or AS5. Frozen, deglycerolized, washed, and volume-reduced products are protocol violations.
223814784|NCT00991341|BIOLOGICAL|Red blood cell units stored >= 21 days|Pre-storage leukoreduced red blood cell units stored \>=21 days at time of transfusion. Can be AS1, AS3, or AS5. Frozen, deglycerolized, washed, and volume-reduced products are protocol violations.
223814785|NCT05842655|PROCEDURE|The wear of screw-retained implant-supported metal-ceramic dental prostheses and natural tooth|A novel digital technique to analyze the wear of screw-retained implant-supported metal-ceramic dental prostheses and natural tooth as antagonist
223814786|NCT02862379|BEHAVIORAL|home-based program|The objective of the rehabilitation program is to reduce the risk of falls after management of the risk factors identified. This intervention is a home-based program combining exercises, home modifications and education on fall risk factors
223814787|NCT02768610|DRUG|Dexmedetomidine|
223814788|NCT02768610|DRUG|Normal Saline|
223814789|NCT02615236|DEVICE|perineal ultrasound|transvaginal probe will be used to scan the perineum immediately after vaginal delivery in primiparous women
223814790|NCT02615236|PROCEDURE|Clinical diagnosis|diagnosis of OASIS clinically
223814791|NCT02098187|DRUG|Below target dose MP-3180|MP-3180 0.5 µmol/kg (0.186 mg/kg) dose (fluorescent tracer agent) was administered by IV injection over 2 minutes, followed by a 10 mL saline flush IV over 2 minutes.
223814792|NCT02098187|DRUG|At target dose MP-3180|MP-3180 1 µmol/kg (0.186 mg/kg) dose (fluorescent tracer agent) was administered by IV injection over 2 minutes, followed by a 10 mL saline flush IV over 2 minutes.
223814793|NCT02098187|DRUG|2 times above target dose MP-3180|MP-3180 2 µmol/kg (0.744 mg/kg) dose (fluorescent tracer agent) was administered by IV injection over 2 minutes, followed by a 10 mL saline flush IV over 2 minutes.
223814794|NCT02098187|DRUG|4 times above target dose MP-3180|MP-3180 4 µmol/kg (1.488 mg/kg) dose (fluorescent tracer agent) was administered by IV injection over 2 minutes, followed by a 10 mL saline flush IV over 2 minutes.
223814795|NCT02098187|DEVICE|ORFM prototype|The Optical Renal Function Monitor (ORFM) investigational device noninvasively monitors fluorescent light emission from an exogenous tracer agent over time. Prior to administration of MP-3180 and iohexol, ORFM sensor probes were affixed to each of the participants via standard adhesive pads to four locations: forehead, sternum, upper inner arm, side trunk. The administration of the MP-3180 infusion and iohexol infusion occurred at least 15 minutes after the start of the data acquisition software.
223814796|NCT02098187|OTHER|Iohexol comparator|Iohexol (Omnipaque 300, 5 mL) (comparator agent) was administered by IV injection over 2 minutes after MP-3180 injection, followed by a 10 mL saline flush IV over 2 minutes.
223814797|NCT01646190|DIETARY_SUPPLEMENT|Preoperative Carbohydrate load|oral intake in the evening before surgery and 2-3h before intubation
223814798|NCT01646190|PROCEDURE|individualized i.v fluids therapy|by Transoesophageal aortic US-Doppler done intraoperatively
223814799|NCT01646190|BEHAVIORAL|Fasting state after midnight|No preoperative glucose load
223814800|NCT01646190|BEHAVIORAL|No Nasogastric tube postoperatively|Withdrawal after complete awakening in operating room
223814801|NCT01646190|BEHAVIORAL|urinary catheter removal|at POD 1
223814802|NCT01646190|BEHAVIORAL|Oral liquids|0.3-0.5L oral liquids at 6h postoperatively on POD 0
223814803|NCT01646190|BEHAVIORAL|Stimulation of inspirex utilization|using 6-8 times/day to prevent pulmonary atelectasis
223814804|NCT01646190|BEHAVIORAL|Mobilization|First active mobilization 6h after surgery (2h on chair or 45° sitting in bed), \>4h out of bed on POD1, \>6h on POD2, complete at POD3
223814805|NCT01646190|OTHER|Preanesthetic medication|Preanesthetic oral medication before surgery
223814806|NCT02401464|DRUG|TAK-536 Tablet|TAK-536 10 mg tablet
223814807|NCT02401464|DRUG|TAK-536 Dry Syrup Formulation|TAK-536 dry syrup formulation
223814808|NCT02401464|DRUG|TAK-536 Ganule Formulation|TAK-536 granule formulation
223814809|NCT03036384|DRUG|HB Prilocaine 2% (varying dose)|Varying dose of hyperbaric (HB) prilocaine 2% according to sensitive response of previous subjects. The dose of hyperbaric prilocaine 2% will be administrated intrathecally with 100µg of morphine and 2.5µg of sufentanyl
223814810|NCT03036384|DRUG|HB Prilocaine 2%|The dose of 45mg of hyperbaric (HB) prilocaine 2% will be administrated intrathecally with 100µg of morphine and 2.5µg of sufentanyl
223814811|NCT03036384|DRUG|Sufentanil|2.5µg sufentanyl
223814812|NCT03036384|DRUG|Morphine|100 µg Morphine
223814813|NCT03611504|DEVICE|Hemospray®|Hemospray® application
223814814|NCT00864708|DEVICE|radio frequency-controlled (RF) Microstimulator (RFM) Gait System|Fully Implanted FES system to assist patient with gait component practice
223814815|NCT03076541|DEVICE|standard 24-h ambulatory polysomnography|A standard 24-h ambulatory ad libitum polysomnography including EEG, electro-oculography (EOG), electromyography (EMG), EKG, was performed by a standard clinical.
223814816|NCT04963374|OTHER|risk evolution scale|Padua score、Caprini score、Prime score
223814817|NCT02877030|OTHER|Video game|The protocol sensorimotor exercises consist of a virtual game that attaches to the Nintendo Wii and using arrows that are thrown from above, players must perform weight-shifting movements in the Nintendo platform to the target be directed to the trajectory the arrows. The goal is to catch as many arrows.
223814818|NCT02799186|PROCEDURE|blood sample for genetic analysis|
223814819|NCT05576532|DRUG|BCL2 Inhibitor plus IM2 regimen|oral bcl-2 inhibitor plus IM2(Ifosfamide plus Mitoxantrone or Idarubicin plus methotrexate) chemotherapy
223814820|NCT02489032|BEHAVIORAL|SBIRT Training & Support Tool|Program to train EAP/behavioral health practitioners in conducting alcohol SBIRT
223814821|NCT02489032|OTHER|Waitlist Control|3-month wait-list and then provided access to the SBIRT training program
223814822|NCT01330316|DRUG|BI 201335|BI 201335 for 24 weeks
223814823|NCT01330316|DRUG|PegIFN/RBV|PegIFN/RBV for 48 weeks
223814824|NCT00915135|DRUG|Ramelteon and Placebo (25 possible combinations total)|"Randomized sequence over two consecutive nights for a total of five treatment periods to include the following:~Ramelteon 4 mg, tablets, orally over two nights~Ramelteon 8 mg, tablets, orally over two nights~Ramelteon 16 mg, tablets, orally over two nights~Ramelteon 32 mg, tablets, orally over two nights~Ramelteon placebo-matching tablets, orally over two nights"
223814825|NCT00695630|DRUG|Flumazenil|2 mL, 0.2 mg SM
223814826|NCT00695630|DRUG|Placebo|2 mL sterile saline SM
223814827|NCT05152134|BEHAVIORAL|Empowered Relief On-Demand|Tailored interactive digital health treatment for chronic pain
223814828|NCT05152134|BEHAVIORAL|Health Education|The HE digital intervention is roughly 65 minutes with content discussing pain and health topics generally; it is devoid of pain education, psychological skills, and has no active strategies, worksheets, or supportive tools.
223814829|NCT03291743|DEVICE|Capsule endoscopy|PillCam(TM) CROHN'S CAPSULE
223814830|NCT06328582|BEHAVIORAL|Routine rehabilitation training|"Balance function training: Patients were instructed to achieve weight shift between the left and right sides of the balance bar in a standing position.~Walking function training: based on hip, knee, and ankle control training, patients were instructed to take steps training.~Core muscle strength training: Patients were instructed to maintain 3 minutes of training in Bridge-style movement.~Functional training of daily living: including training on dressing and undressing, independent eating, painting, and writing."
223814831|NCT06328582|PROCEDURE|Acupuncture Technique for Restoring Consciousness combined with Scalp Acupuncture|"Acupuncture Technique for Restoring Consciousness:~Main acupoints: Neiguan (bilateral), Renzhong, Sanyinjiao (affected side) Additional acupoints: Fengchi, Wangu, Yifeng (bilateral), and posterior pharyngeal wall needling.~Scalp Acupuncture Method:~Based on the standard treatment lines for scalp acupuncture \[17\], select the anterior oblique line of vertex-temporal region, posterior oblique line of vertex-temporal region, and anterior line of temporal region (bilateral)."
223814832|NCT00215540|DRUG|Lucinactant 175 mg/kg|Administered via slow intra-tracheal instillation at a dose of 175 mg/kg (5.8 mL/kg of a 30-mg/mL suspension). Initial treatment given no later than 1 hour after randomization. Additional treatments were administered every 48 hours up to a maximum of 5 doses (up to day of life (DOL) 18).
223814833|NCT00215540|DRUG|Lucinactant 90 mg/kg|Administered via slow intra-tracheal instillation at a dose of 90 mg/kg (3.0 mL/kg of a 30-mg/mL suspension). Initial treatment given no later than 1 hour after randomization. Additional treatments were administered every 48 hours up to a maximum of 5 doses (up to DOL 18).
223814834|NCT00215540|DRUG|Placebo|Sham air was administered via slow intratracheal instillation at a dose of 3.0 mL/kg volume of air. The initial treatment was given no later than 1 hour after randomization. Additional treatment were administered every 48 hours up to a maximum of 5 doses (up to DOL 18).
223814835|NCT01848379|PROCEDURE|ADT+FD|
223814836|NCT01848379|PROCEDURE|FD|
223814837|NCT02800967|DIETARY_SUPPLEMENT|Pure Aronia juice|Pure Aronia juice with appx. polyphenols content of 1000 mg gallic acid equivalents/100ml
223814838|NCT02800967|DIETARY_SUPPLEMENT|Aronia juice-based beverage|Aronia juice-based beverage with appx. polyphenols content of 250 mg gallic acid equivalents/100ml, obtained as a blend of ¼ vol. of pure Aronia juice and ¾ vol. of placebo beverage.
223814839|NCT02800967|DIETARY_SUPPLEMENT|Placebo beverage|A polyphenol-free formulation with matched nutrient composition (sugars, vitamins, minerals) and similar sensory characteristics to active interventions
223814840|NCT03010462|DEVICE|Nexstim NBS guided active rTMS|Nexstim NBS guided active rTMS + standardized task-oriented therapy
223814841|NCT03010462|DEVICE|Nexstim NBS guided sham rTMS|Nexstim NBS guided sham rTMS + standardized task-oriented therapy
223814842|NCT03356730|DRUG|Vitamin D|"Only patients with vitamin D deficiency / deficiency will be included in the study. Randomly, they will be divided into two groups. This group will receive vitamin D supplementation.~Vitamin D3 - cholecalciferol, oral suspension in drops, will be prescribed as follows:~• 5,000 IU / day - 10 drops per day for two months."
223814843|NCT03356730|OTHER|Placebo|"Only patients with vitamin D deficiency / deficiency will be included in the study. Randomly, they will be divided into two groups. This control group will receive placebo.~Placebo (olive oil mint flavor), oral suspension in drops, will be prescribed as follows:~• 10 drops per day for two months."
223814844|NCT00777907|DEVICE|Pipeline Embolization Device (PED)|1 or more PEDs placed in the parent artery of the affected aneurysm via endovascular approach.
223814845|NCT00777907|DEVICE|Coil embolization|Placement of bare platinum coils into the target aneurysm with balloon remodeling allowed.
223814846|NCT04911309|OTHER|functional exercise training|12 weeks functional exercise training twice per week, each session lasting 60 min
223814847|NCT04911309|OTHER|standard therapy / treatment|12 weeks standard therapy / treatment
223814848|NCT03145766|BIOLOGICAL|VRVg 2|Modified formulation 1 (Low) of Purified Vero Rabies Vaccine Serum Free
223814849|NCT03145766|BIOLOGICAL|VRVg 1|Initial formulation of Purified Vero Rabies Vaccine Serum Free
223814850|NCT03145766|BIOLOGICAL|Imovax Rabies|Purified inactivated rabies vaccine prepared on human diploid cell cultures
223814851|NCT03145766|BIOLOGICAL|VRVg 2|Modified formulation 2 (Medium) of Purified Vero Rabies Vaccine Serum Free
223814852|NCT03145766|BIOLOGICAL|VRVg 2|Modified formulation 3 (High) of Purified Vero Rabies Vaccine Serum Free
223814853|NCT03145766|BIOLOGICAL|Human Rabies Immunoglobulins (HRIG)|Commercialized formulation of HRIG
223814854|NCT03766256|BEHAVIORAL|Shared decision-making with pharmacists|Pharmacist will engage patient with history of gestational diabetes mellitus using Healthwise (TM) Decision Tool to help match their personal preferences and values with treatment options, specifically lifestyle change will be referred to a CDC (Center for Disease Control and Prevention) approved diabetes prevention program, and pharmacists will coordinate with primary care providers to prescribe metformin for patients interested in this treatment.
223814855|NCT04242693|BEHAVIORAL|Mobile goal-setting intervention|This intervention applied two constructs from the goal setting theory-self-monitoring and goal setting. Briefly, all participants were asked to take photos of all their meals and upload them with descriptions to an online platform. The participants in the experimental group were taken through two additional processes that represented these two constructs. Self-monitoring was operationalized by asking those in the experimental group to count the number of times they ate red/orange vegetables using a counting checklist. Goal setting was operationalized as asking them to set a goal to eat red/orange vegetables one more time tomorrow.
223814856|NCT03850080|DRUG|Autologous Conditioned Serum|"Fifteen patients with clinical and radiological signs of OA of the knee were recruited for this study. 50mL of whole blood were taken using a special syringe containing CrSO4-coated grade glass beads in order to promote IL-1ra synthesis and aggregation.The incubation period lasted 7 hours after which, the blood-filled syringes were centrifuged and the serum supernatant was filtered and aliquoted into four 3mL portions. The aliquots were stored at -20oC until their use was necessary.~Patients received 1 intra-articular injection for 4 consecutive weeks at the site of OA."
223814857|NCT00431184|DRUG|Pentazocine|see arms description
223814858|NCT00431184|DRUG|Lorazepam|see arms description
223814859|NCT05083143|BEHAVIORAL|COVID-19 pandemic|Patients diagnosed with testicular cancer in the urology clinic during and before the COVID-19 pandemic will be retrospectively evaluated and compared.
223814860|NCT00053001|BIOLOGICAL|epoetin alfa|
223814861|NCT00053001|DRUG|thalidomide|
223814862|NCT01391325|DRUG|Allopurinol|Commercially available allopurinol 100 mg and 300 mg oral tablets will be prescribed by the Investigator according to the approved product label.
223814863|NCT00895882|DRUG|vaniprevir (MK7009)|vaniprevir 300 mg soft gel capsules twice daily.
223814864|NCT00895882|DRUG|Comparator: vaniprevir (MK7009)|vaniprevir 600 mg soft gel capsules twice daily.
223814865|NCT00895882|DRUG|Comparator: Pegylated Interferon (peg-IFN) alfa-2a|Peg-IFN 180 mcg/0.5 mL subcutaneous injection once weekly
223814866|NCT00895882|DRUG|Comparator: Ribavirin|Ribavirin, at a total daily dose of 1000 mg or 1200 mg based on patient weight, will be administered twice daily.
223814867|NCT00895882|DRUG|Comparator: Placebo to vaniprevir|Placebo to vaniprevir soft gel capsules twice daily.
223814868|NCT03122054|PROCEDURE|laparoscopic cholecystectomy|First trocar was inserted with Hasson method (Subumbilical 1 cm vertical incision was made and first 10-mm trocar (VersaportTM plus V2, Covidien, USA) inserted under direct vision) and pneumoperitoneum was created with 12 mm Hg pressure. Second 10-mm trocar was inserted from subxyphoid area. Two 5-mm trocars were inserted in the right upper quadrant area. After general intrabdominal exploration, dissection was started to ensure safe-view of Calot triangle. In case of quite tough gallbladder for griping, gallbladder was drained with a gray intravenous cannula. Cystic artery and cystic duct were separately dissected and twice ligated with Endo Clip™ II ML (Covidien, USA). Gallbladder was dissected from liver bed carefully. Gallbladder was taken out from abdomen through the subumbilical incision.
223814869|NCT00171639|DRUG|zoledronic acid|
223814870|NCT02547870|DRUG|Rilpivirine (RPV)|Participants will receive one oral tablet of rilpivirine 25 milligram (mg) once on Day 1 of session 1.
223814871|NCT02547870|DRUG|Rilpivirine Long-Acting Parenteral Formulation (RPV-LA)|Participants will receive one intramuscular (IM) injection of rilpivirine long-acting parenteral formulation 600 mg once on day 1 of session 2.
223814872|NCT02547870|DRUG|Aged RPV-LA|Participants will receive one intramuscular (IM) injection of aged rilpivirine long-acting parenteral formulation 600 mg once on day 1 of session 2.
223814873|NCT04382703|BEHAVIORAL|Self-Affirmation Exercise|"The self affirming exercise is as follow:~The beginning to a sentence appears below. Below it are 4 different ways of completing the sentence. On the lines provided, please write out the beginning of the sentence and then complete it with 1 of the 4 options we have given you.~If I feel threatened or anxious, then I will …………………………………..~Options are as follows:~think about the things I value about myself, remember things that I have succeeded in, think about what I stand for or think about things that are important to me"
223814874|NCT04382703|BEHAVIORAL|Control|Given a questionnaire minus the self affirming exercise
223814875|NCT02317055|OTHER|imaging|
223814876|NCT02799472|DRUG|GSK3196165|GSK3196165 is supplied as liquid and will be administered as SC injection.
223814877|NCT02799472|DRUG|Placebo|0.9% weight by volume (w/v) sodium chloride solution administered as SC injection.
223814878|NCT02799472|DRUG|MTX|Capsule, tablet or liquid administered orally or as SC injection.
223814879|NCT02799472|DRUG|Folic (or folinic) acid|Capsule, tablet or liquid and will be administered orally.
223814880|NCT01368848|DRUG|Bevacizumab|"3 cycles BCD (Bevacizumab 7,5 mg/kg i.v., Cisplatin 75 mg/m² i.v., Docetaxel 75 mg/m²) Q3W -\> Staging~-\> further 3 cycles BCD Q3W -\> Bevacizumab Q3W until progression"
223814881|NCT01368848|DRUG|Cisplatin|"3 cycles BCD (Bevacizumab 7,5 mg/kg i.v., Cisplatin 75 mg/m² i.v., Docetaxel 75 mg/m²) Q3W -\> Staging~-\> further 3 cycles BCD Q3W"
223814882|NCT01368848|DRUG|Docetaxel|"3 cycles BCD (Bevacizumab 7,5 mg/kg i.v., Cisplatin 75 mg/m² i.v., Docetaxel 75 mg/m²) Q3W -\> Staging~-\> further 3 cycles BCD Q3W"
223814883|NCT03852849|BEHAVIORAL|Personal involved intervention strategies|Medical institutions will provide personal involved intervention strategies for patients which guided by viral load testing monthly until viral load drop below the detection limit.
223814884|NCT03852849|DRUG|The dosage of 400mg EFV|The dosage of 400mg EFV will be used in the antiviral therapy.
223814885|NCT03381404|DRUG|[14C] MT-8554|14-C MT-8554
223814886|NCT00628797|RADIATION|UVA1|intraindividual half body irradiation
223814887|NCT00628797|OTHER|UVA1|60 J/cm2 at least 36 tx
223814888|NCT01718093|DRUG|Sitagliptin|up to 50 mg twice a day
223814889|NCT01718093|DRUG|Metformin|up to 1000 mg twice a day
223814890|NCT01718093|DRUG|Sitagliptin + Metformin|up to 50/1000 mg twice a day
223814891|NCT03333798|BEHAVIORAL|Cognitive-Behavioral Intervention|"A Cognitive-Behavioral intervention will be delivered by psychologists with LPCWs support. LPCWs who will be under the supervision and guidance of psychologists.~Volunteers will receive 11 weekly sessions of which six will be provided by psychologists and five by LPCWs.~The Cognitive-Behavioral component will be delivered through a set modules that will cover the following components:~* The Cognitive-Behavioral model~* Tackling traumatic events~* Cognitive reprocessing~* Relaxation techniques~* Prevention of revictimization~* Behavioral reactivation for the start of a new life The intervention will be given within the health system and volunteers will be seen if necessary by an interdisciplinary team including social workers, general physicians and psychiatrists."
223814892|NCT03333798|BEHAVIORAL|Standard psychosocial care|"The active control group will receive standard psychosocial care for intimate partner violence, provided by the participating health centers. Standard care is delivered by psychologists, social workers, general physicians and psychiatrists. Additionally, patients receive extramural support which includes telephone calls or domiciliary visits from a variety of health professionals (doctors, nurses, social workers and nursing assistants).~Psychology consultations typically occur every four weeks in each health center. Psychologists use a variety of approaches according to their personal preferences, including humanist, psychoanalytic, psychodynamic and cognitive-behavioral approaches. At the end of the intervention psychologists will be asked which approach or approaches they used."
223814893|NCT04366063|BIOLOGICAL|Cell therapy protocol 1|Cell therapy protocol 1(n=20). Patients will receive two doses of MSCs 100×10e6 (±10%) at Day 0 and Day 2 plus Conventional treatment.
223814894|NCT04366063|BIOLOGICAL|Cell therapy protocol 2|Patients will receive two doses of MSCs 100×10e6 (±10%)at Day 0 and Day 2, intravenously plus two doses of EVs at Day 4 and Day 6 plus conventional treatment.
223814895|NCT02801669|DRUG|Du-176b|DU-176b orally administered at a dose of 15 mg once daily.
223814896|NCT02801669|DRUG|placebo|Placebo orally administered once daily.
223814897|NCT03161366|BIOLOGICAL|rVSVΔG-ZEBOV-GP|Ring vaccination with vaccination of contacts and contacts of contacts after laboratory confirmation of one Ebola Zaire case
223814898|NCT00571961|DRUG|Kaletra (lopinavir/ritonavir)|4 tablets, once a day (800 mg/dose) on Days 2 through 14 of this study
223814899|NCT00571961|DRUG|buprenorphine|Buprenorphine will be obtained through prescription at the subject's drug treatment program.
223814900|NCT00571961|OTHER|Clinical evaluations/Blood draws|Physical examinations, vital sign measurements, 12-lead electrocardiogram (ECG), clinical laboratory evaluations (blood chemistry and blood counts), PK blood draws.
223814901|NCT03131635|BEHAVIORAL|Developmental Reciprocity Treatment Program (DRT-P)|Developmental Reciprocity Treatment is an early intervention that applies developmentally-informed teaching methods in naturalistic settings in order to target social and communication deficits.
223814902|NCT03158363|OTHER|LPS, 36 hour immobilization and fast|LPS endotoxin is administered on study day 1 and immobilization and fast continue throughout study day 1 and 2.
223814903|NCT00856674|BIOLOGICAL|OPL-CCL2-LPM|"CCL2-LPM~intravenous 0.001 mg/kg, 0.01 mg/kg, 0.05 mg/kg, 0.1 mg/kg, 0.5 mg/kg, 1 mg/kg~2 doses one week apart"
223814904|NCT05347901|DIAGNOSTIC_TEST|Echocardiography, Genomics NGS sequencing|The inner diameter of left main coronary artery, anterior descending branch, circumflex branch and right coronary artery was measured by echocardiography. Blood samples were send for genomics NGS sequencing
223814905|NCT01492686|DRUG|MCI-186|Two ampoules (60 mg) of MCI-186 injection are intravenously administered once a day, for successive 14 days, followed by 14 days observation period (first cycle). The following treatment (10 days' administration during 14 days) - observation (14 days) cycle is repeated five times (2nd-6th cycles).
223814906|NCT01492686|DRUG|Placebo|Two ampoules of placebo injection are intravenously administered once a day, for successive 14 days, followed by 14 days observation period (first cycle). The following treatment (10 days' administration during 14 days) - observation (14 days) cycle is repeated five times (2nd-6th cycles).
223814907|NCT01492686|DRUG|MCI-186 in open label phase|All patients after the double blind phase may receive MCI-186 in 7th until 12th treatment - observation cycles at the patients' will.
223814908|NCT01423214|PROCEDURE|robot-assisted surgery|da Vinci surgical system® (Intuitive Surgical, Sunnyvale, CA, USA)
223814909|NCT01423214|PROCEDURE|Laparoscopic surgery|Conventional laparoscopic procedures
223814910|NCT05561777|OTHER|Physician-targeted CDS tool for PCN allergy delabeling|This intervention will provide access to a best-practices alert (BPA) containing the patient's risk-stratification status and a link to the local standard of care protocol, oral amoxicillin challenge order set and written consent form (same resources as used in pharmacist -led electronic health record dashboard). If the provider opts to perform the oral challenge and it is successfully passed, a second BPA will prompt them to update the allergy status in the medical record.
223814911|NCT00086541|DRUG|Daily Infergen (Interferon Alfacon-1, CIFN) (9 or 15 µg) + Ribavirin (1000-1200 mg, based on body weight) PO Daily for up to 48 wks|
223814912|NCT05359783|DRUG|Superparamagnetic Iron Oxide|Superparamagnetic iron oxide (SPIO) consists of an iron oxide nanoparticle core and a hydrophilic coating to make it biocompatible and colloidal stable in a suspension.
223814913|NCT01460498|DRUG|Azacitidine (AZA)|Starting Dose 50 mg/m2 by subcutaneous or by vein for 3 days of a 28 day cycle.
223814914|NCT01460498|DRUG|Tyrosine kinase inhibitor (TKI)|Continuation of dose already receiving during previous 6 months.
223814915|NCT01460498|DRUG|Azacitidine|75 mg/m2 daily for 3 days, unless MTD defined at lower dose level in Phase I then that would become dose used for Phase II.
223814916|NCT01033214|DEVICE|Endovascular repair of TAA in the descending Thoracic Aorta|Usage of the TAArget thoracic stent graft for treatment of TAA in the Descending Thoracic Aorta.
223814917|NCT03315936|DRUG|BI 894416|powder for oral solution
223814918|NCT03315936|DRUG|Placebo|Oral solution
223814919|NCT03315936|DRUG|BI 894416|Tablet
223814920|NCT00525772|DRUG|ciclesonide|low dose- 50ug and 200ug
223814921|NCT00525772|DRUG|ciclesonide|high dose- 100ug and 400ug
223814922|NCT01153269|DRUG|Lopinavir/Ritonavir (Kaletra)|3 capsules 2xdaily or 2 tablets 2xdaily Kaletra
223814923|NCT03541044|DRUG|Nicotine Prototype Mini lozenge|A single dose of a prototype nicotine 2mg lozenge will be placed in participants mouth, occasionally moving it side to side. Allowing it to slowly dissolve and try to minimize swallowing. Participants will be instructed not to chew lozenge. The lozenge should be completely dissolved.
223814924|NCT03541044|DRUG|Nicorette Mini Lozenge|A single dose of a 2 mg nicotine polacrilex mini lozenge (Nicorette Minis) will be placed in participants mouth, occasionally moving it side to side. Allowing it to slowly dissolve and try to minimize swallowing. Participants will be instructed not to chew lozenge. The lozenge should be completely dissolved.
223814925|NCT02635724|DRUG|Peramivir|
223814926|NCT04665622|OTHER|Eye-Tracking / Neuropsychological evaluations|Use of Eye-Tracking / Neuropsychological évaluations in 4 groups
223814927|NCT02190825|DEVICE|NeuGuide device|The NeuGuideTM device is indicated for anchoring sutures to ligaments of the pelvic floor
223814928|NCT02111837|OTHER|Standard infant formula|
223814929|NCT02111837|OTHER|Standard infant formula with PL1|
223814930|NCT02111837|OTHER|Standard infant formula with PL2|
223814931|NCT05794516|DRUG|ZB004|ZB004 single doses administered subcutaneously as solution
223814932|NCT05794516|DRUG|Placebo|Placebo single doses administered subcutaneously as solution
223814933|NCT00860067|BIOLOGICAL|Q/LAIV (MEDI3250)|0.2 mL dose at Day 0
223814934|NCT00860067|BIOLOGICAL|FluMist/B/Yamagata|0.2 mL dose at Day 0
223814935|NCT00860067|BIOLOGICAL|FluMist/B/Victoria|0.2 mL dose at Day 0
223814936|NCT04596137|BEHAVIORAL|İnfant pain management|Kangaroo mother care was applied to the infants during heel prick. With kangaroo mother care, the pain of infants was reduced.
223814937|NCT01729884|BIOLOGICAL|HER-2/neu peptide vaccine|Given ID
223814938|NCT05517200|DIAGNOSTIC_TEST|Machine Learning Test for Migraine|Resting EEG, and Visual and Auditory Stimulation
223814939|NCT00560612|DRUG|Paroxetine|Paroxetine 10 mg-40 mg or placebo; flexible dosing; 12-week duration.
223814940|NCT00560612|DRUG|Placebo|Placebo: same as paroxetine (active comparator)
223814941|NCT00212901|DRUG|High dose ACE-I vs ARB|
223814942|NCT01262326|OTHER|Calorie and Carbohydrate Restriction|Carbohydrate Restriction = \<20 g/d of dietary carbohydrate intake Calorie Restriction = 1200 kcal/d for women and 1500 kcal/d for men
223814943|NCT05966935|COMBINATION_PRODUCT|Fenugreek Cumin Powder|Fenugreek and Cumin seeds will be procured from the market. They will be cleaned of debris, winnowed, and grinded to fine powder passed through a mesh size of 30 for metal cleaning. 5g of fenugreek powder and 5g of cumin powder will be packed in packets. Participants in the intervention group will be instructed to consume the powder before breakfast and dinner with a glass of water.
223814944|NCT02847299|DEVICE|"increase of cough peak flow (Astral ventilator)"|instrumental increase of cough peak flow with a ventilator by hyper-insufflation and with air stacking method
223814945|NCT01930630|DEVICE|Extraesophageal saline injection (ESI)|The patients with advanced ESCC are to undergo extraesophageal injection of 15ml saline preoperatively and subsequently detected by EUS to confirm whether saline separates esophagus from adjacent organs.
223814946|NCT01457781|COMBINATION_PRODUCT|Inhaled Nitric Oxide 0.025 mg/kg IBW/hr delivered via INOpulse DS Device|Cohort 1: 0.025 mg/kg IBW/hr for up to 24 hours/day x 16 weeks (3.0 mg/L \[2440 ppm\] NO mini-cylinder; change q 24 hours) delivered via INOpulse DS Device and INOpulse DS nasal cannula
223814947|NCT01457781|COMBINATION_PRODUCT|Placebo delivered via INOpulse DS Device|Placebo 0.075 mg/kg IBW/hr for up to 24 hours/day x 16 weeks (Nitrogen N2, 99.999%) delivered via INOpulse DS Device and INOpulse DS nasal cannula
223814948|NCT01457781|COMBINATION_PRODUCT|Inhaled nitric oxide 0.075 mg/kg IBW/hr delivered via INOpulse DS Device|Cohort 2: 0.075 mg/kg IBW/hr for up to 24 hours/day x 16 weeks (6.0 mg/L \[4880 ppm\] NO mini-cylinder; change q 24 hours) delivered via INOpulse DS Device and INOpulse DS nasal cannula
223814949|NCT05590208|PROCEDURE|sleeve gastrectomy+ cruroplasty+ omental rap|sleeve gastrectomy+ cruroplasty+ omental rap
223814950|NCT01566175|DEVICE|Neovac coronary sinus reducer|reducer
223814951|NCT04193839|OTHER|Computerized Provider Order Entry (CPOE) plus Bar Code Medication Administration (BCMA)|Computerized provider order entry (CPOE) refers to the process of providers entering and sending treatment instructions - including medication, laboratory, and radiology orders - via a computer application rather than paper, fax, or telephone. The bar Code Medication Administration (BCMA) is a system that consists of a bar code reader, a portable or desktop computer with wireless connection, a computer server, and some software. Before the administration of medications to the patients the patient unique barcode identification is scanned in order to verify the patient's identity.
223814952|NCT01337557|DRUG|Bepotastine|1.5% bid
223814953|NCT02424591|DRUG|Ketamine|Infusion at a rate of 10 mcg/kg/min
223814954|NCT02424591|OTHER|Placebo|Placebo IV
223814955|NCT01446796|DEVICE|Implantable Cardioverter-Defibrillator (subject's pre-existing ICD)|Pacing parameters set to AAI 90
223814956|NCT01446796|DEVICE|Implantable Cardioverter-Defibrillator (subject's pre-existing ICD)|Pacing parameters set to DDD 90-100
223814957|NCT01426243|BIOLOGICAL|Yellow fever vaccination (STAMARIL)|Yellow fever vaccination (STAMARIL)
223814958|NCT01426243|BIOLOGICAL|Yellow fever vaccination (STAMARIL)|Yellow fever vaccination (STAMARIL)
223814959|NCT00003315|BIOLOGICAL|sargramostim|
223814960|NCT00003315|DRUG|liposomal amphotericin B|
223814961|NCT03852966|BEHAVIORAL|CBT-i/ADHD|Cognitive Behavioral Therapy for insomnia adjusted for patients with ADHD
223814962|NCT03354650|DIAGNOSTIC_TEST|blood culture|blood culture to determine causative organisms of neonatal sepsis
223814963|NCT00538096|DRUG|MEDI-538|1 of 3 target doses of MEDI-538 (5,μg/m2/24h) as a continuous IV infusion through a central line catheter. The initial treatment period will be 4 weeks in duration (Study Days 0-27), unless the patient discontinues treatment.
223814964|NCT00538096|DRUG|MEDI-538|1 of 3 target doses of MEDI-538 (10,μg/m2/24h) as a continuous IV infusion through a central line catheter. The initial treatment period will be 4 weeks in duration (Study Days 0-27), unless the patient discontinues treatment.
223814965|NCT00538096|DRUG|MEDI-538|1 of 3 target doses of MEDI-538 (15,μg/m2/24h) as a continuous IV infusion through a central line catheter. The initial treatment period will be 4 weeks in duration (Study Days 0-27), unless the patient discontinues treatment.
223814966|NCT05927025|PROCEDURE|Hand K-files|It is used for cleaning and shaping root canals.
223814967|NCT05967780|OTHER|Group A: Patients with FHP receiving standard cardiac rehabilitation|Consenting participants in this group will receive a standard cardiac rehabilitation protocol that includes preoperative education and post-operative exercises, chest physiotherapy, functional mobility and care. Phase 1 begins after the patient has been considered clinically compensated due to the optimization of the clinical treatment and/or the use of an interventional procedure. In this phase, a combination of low-intensity physical exercise (that includes range of motion exercises for upper \& lower extremities + progressive mobilization from sitting on bedside to walking short distance and up to stair climbing), incentive spirometry exercise, percussions, breathing exercises and effective coughing exercises.
223814968|NCT05967780|OTHER|Group B: Patients with FHP receiving standard cardiac rehabilitation + therapeutic exercises|"The participants who give consent will receive standard cardiac rehabilitation protocol (as Group A) with therapeutic exercise in the intervention group.~Therapeutic exercises will be delivered to the participant by treating physiotherapist in physical, verbal and written formats as individualized sessions on the ward 4 weeks before the surgery and keep him doing exercises under supervision while staying in the ward before surgery. A log will be provided to measure performance to ensure program compliance. After discharge from the hospital, the patient will continue exercises at home as performed and guided physically by the therapist and also in the exercises manual and flyer given to the patient. Patients will be instructed to follow therapeutic exercise for 4 weeks pre-operatively and 4 weeks postoperatively after discharge from the hospital."
223814969|NCT05967780|OTHER|Group C: Patients without FHP receiving standard cardiac rehabilitation|The participants without forward head posture will be included in this group and will receive same standard cardiac rehabilitation as the participants in group A.
223814970|NCT02836158|DRUG|R-IDARAM plus intrathecal chemotherapy|R-IDARAM comprised of rituximab 375 mg/m2 (day 1), idarubicin 10 mg/m2(day 2); dexamethasone 100 mg/m2 (12 h.infusion in day 2, 3 and 4); cytarabine 1 g/m2 (1 h. infusion in day 2); methotrexate 1.5 g/m2 (6 h. infusion in day 4 with folinic acid rescue). Intrathecal Immunochemotherapy comprised of rituximab 20mg, MTX 15mg, dexamethasone 5mg and Ara-c 50mg once a week.
223814971|NCT01461330|OTHER|DASH diet plus exercise|"DASH diet adapted to the usual diet of Brazilian type 2 diabetic patients = prescription of a normocaloric diet including fruits, vegetables, grain products, low fat dairy foods, legumes, without sugar, and with limited fat~Exercises: the recommended physical activity will consist of using a pedometer during the experimental period."
223814972|NCT01461330|OTHER|ADA diet|Adoption of ADA diet.
223814973|NCT05157074|BEHAVIORAL|Group Drumming Music Therapy|"All 24 Armstrong Rhythm Cycle™ sessions is conducted in a circle to ensure maximum line of sight for each participant. A variety of diverse percussion instruments ranging from hand drums, stick drums, shakers, and rhythm sticks are available as well as adaptive measures to address limited physical functioning. Instrument choice is dependent on ease of use for the level of the physical ability, skill development needs, and personal choice. Participants are informed that they are free to use the same instrument for the duration of each session or to switch instruments at any time.~Utilizing the five components of The Armstrong Rhythm Method, this protocol guides participants through three phases to achieve rhythmic skill development and group cohesion for their therapeutic benefit."
223814974|NCT05384925|OTHER|comparison|abdominal surgery as a risk factor for diverticulosis
223814975|NCT00294099|BIOLOGICAL|Aluminum hydroxide|Aluminum hydroxide adjuvant.
223814976|NCT00294099|BIOLOGICAL|Inactivated Influenza A/H5N1 Vaccine (sanofi pasteur)|Inactivated monovalent subvirion influenza H5N1 vaccine. Supplied in 0.5 mL unit dose vials as a sterile solution for IM injection. Dosages: 45 mcg, 15 mcg, 7.5, mcg, or 3.75 mcg administered with or without aluminum hydroxide adjuvant on Days 0 and 28.
223814977|NCT01498822|DRUG|Levetiracetam|250 mg and 500 mg Levetiracetam tablet, 1000 mg-3000 mg/day, maximum 50 weeks including initial up titration of 500 mg/day for 2 weeks
223814978|NCT01498822|DRUG|Oxcarbazepine|150 mg and 300 mg Oxcarbazepine tablet, 900 mg-2400 mg/day, maximum 50 weeks including 2 weeks of up titration (300 mg/day 1week then 600 mg/day 1 week)
223814979|NCT04078360|BEHAVIORAL|AMBIT (Alcohol use disorders- mobile based Brief Intervention treatment) intervention|"The intervention will consist of participants receiving messages and/IVR calls not more than twice or thrice a week on their mobile phone for a duration of 8 weeks. Messages/IVR calls will be sent through VIAMO's technology platform. Each week messages will be focussed on specific content areas derived from the formative research of the study. Some of the components of the intervention include:~1. Self awareness messages~2. Self reflection messages~3. Motivational messages~4. Messages on safe drinking, alcohol reduction, drinking management, risk management, craving management and drinking alternatives.~5. Health education messages~6. Personalized feedback and information~7. Help-seeking resources~8. Goal setting messages"
223814980|NCT04078360|BEHAVIORAL|Face to face Brief Intervention|The intervention will consist of the participants receiving the BI based on the WHO Mental Health Gap Action Programme (mhGAP) intervention from a trained researcher. The BI will be conducted over a single session (5-10 mins).
223814981|NCT04078360|BEHAVIORAL|BI leaflet intervention|The intervention will consist of an educational BI leaflet consisting of health information on alcohol consumption, and tips to manage and reduce drinking.
223814982|NCT05497427|DEVICE|BrainCheck Assessment|A computerized neurocognitive test administered via an electronic device, such as a phone, tablet or computer, that contains several assessments that will aid in establishing an individuals cognitive performance
223814983|NCT05351619|PROCEDURE|oral care bundle implementation|oral care bundle encompasses oral assessment, tooth brushing, oral / lip moisturization, and suctioning oropharyngeal secretions above the cuff.
223814984|NCT06230614|OTHER|Colistin 1 MU in normal saline 1 ml|Colistin 1 MU diluted in normal saline 1 ml, total volume of 12 ml
223814985|NCT06230614|OTHER|Colistin 1 MU in normal saline 2 ml|Colistin 1 MU diluted in normal saline 2 ml, total volume of 12 ml
223814986|NCT05649345|DRUG|TR64|TR64 tablets will be given daily for 28 days in 28-day cycles until there appears evidence of progressive disease, intolerable toxicity, or the subject discontinues from the study treatment for other reasons.
223814987|NCT06291311|OTHER|Cold physical Plasma|The treatment is administered by either the supervising specialists or assistant doctors at the University Women's Hospital, under their supervision and authorization. It's important to note that the NIPP treatment is designed to be relatively brief, with a duration not exceeding 10-20 minutes.
223814988|NCT06291311|OTHER|Control group|A potential natural healing of the HPV infection will be anticipated
223814989|NCT04037436|OTHER|Strength and Balance Training & Nutrition Education|Exercise:A kinesiologist-led twice-weekly program. Prior to attending the program, each attendee gets a 1:1 session with the kinesiologist to decide exercise starting levels. Group exercises start with a warm-up stepping game. Participants then perform 2 sets of 8 repetitions of each exercise, gradually progressing to an intensity of 3-8 repetitions maximum. Exercises include one each of a push, pull, squat, reach/press, lunge/step-up, lift and carry movement. After, there is a 10-minute group discussion to prompt making exercise routine at home. Nutrition:Two dietitian-led interactive group seminars to promote strategies to increase protein intake and sampling of protein-rich snacks and protein supplements. Seminar topics consider the cost to prepare high protein foods, the ability of retirement home residents to alter diet, how and why to spread protein intake through the day, how much protein is in their usual choices, and easy-to-consume protein-rich snacks.
223814990|NCT04037436|OTHER|Usual Care|During periods when a site is not involved in the MoveSTroNg program, participants will continue with their usual care routine. Usual care routines should not involve strength and balance exercises.
223814991|NCT00896428|DRUG|Methoxyverapamil (gallopamil)|200 mg/day (1 tablet 100 mg morning and evening) for 12 months.
223814992|NCT00896428|DRUG|Placebo.|1 tablet morning and evening for 12 months
223814993|NCT01674621|DRUG|Abaloparatide Transdermal (50 mcg)|Abaloparatide Transdermal Microneedle Active Patch
223814994|NCT01674621|DRUG|Abaloparatide Transdermal (100 mcg)|Abaloparatide Transdermal Microneedle Active Patch
223814995|NCT01674621|DRUG|Abaloparatide Transdermal (150 mcg)|Abaloparatide Transdermal Microneedle Active Patch
223814996|NCT01674621|DRUG|Abaloparatide Injection (80 mcg)|Abaloparatide Subcutaneous Injection
223814997|NCT01674621|DRUG|Abaloparatide Placebo|Abaloparatide Transdermal Microneedle Placebo Patch
223814998|NCT04535323|OTHER|Quality-of-Life Assessment|Ancillary studies
223814999|NCT04535323|OTHER|Questionnaire Administration|Ancillary studies
223815000|NCT04535323|BIOLOGICAL|Therapeutic Autologous Platelet-rich Plasma|Given via injection
223815001|NCT06324019|OTHER|putting on an examination gown|During the gynecological examination, the patient in the experimental group will be made to wear an examination gown, while the patient in the control group will use the routine practice of the hospital. In this way, with the gynecological examination clothing to be developed, the body privacy of the patients will be protected during the examination. In addition, women will feel less anxiety during gynecological examination and important steps will be taken in maintaining women\&#39;s health by ensuring regular gynecological examination.
223815002|NCT03355430|PROCEDURE|combined corneal wavefront-guided transepithelial photorefractive keratectomy (tPRK)|After at least 1 month (average 2.7 ± 1.1 months; range 1 to 4 months), all patients were scheduled for combined corneal wavefront-guided tPRK and accelerated CXL treatment. tPRK between the corneal ring segments was performed using an excimer laser (Amaris 1050 Excimer Laser platform; Schwind eye-tech-solutions GmbH and Co KG, Kleinostheim, Germany).
223815003|NCT03355430|PROCEDURE|accelerated corneal collagen cross-linking (CXL)|After at least 1 month (average 2.7 ± 1.1 months; range 1 to 4 months), all patients were scheduled for combined corneal wavefront-guided tPRK and accelerated CXL treatment. tPRK between the corneal ring segments was performed using an excimer laser (Amaris 1050 Excimer Laser platform; Schwind eye-tech-solutions GmbH and Co KG, Kleinostheim, Germany).
223815004|NCT02420145|BEHAVIORAL|Yoga|12 weeks of yoga, twice weekly for 90 minutes plus a whole-day workshop
223815005|NCT04575363|OTHER|Blood sample|Blood sample
223815006|NCT02566798|DRUG|Extract of grape and olive|"Patients are taking capsules of OleograpeSEED 3 times a day (1mg/day) in the morning, at noon and in the evening during 7 days.~Blood samples and synovial fluid are performed on D0 and D7"
223815007|NCT02566798|DRUG|Lactose|"Patients are taking capsules of placebo 3 times a day in the morning, at noon and in the evening during 7 days.~Blood samples and synovial fluid are performed on D0 and D7"
223815008|NCT01583439|DRUG|highly active antiretroviral therapy: Lopinavir/Ritonavir, Lamivudine, Zidovudine, Efavirenz, Tenofovir Disoproxil Fumarate, Emtricitabine|Atripla: one tablet administered orally once daily at bedtime, each tablet comprised of co-formulated: Efavirenz (EFV) 600mg, Emtricitabine (FTC) 200mg, Tenofovir disoproxil fumarate (TDF) 300mg(EFV/FTC/TDF). Note: the study will generally provide the fixed-dose combination Atripla, but it will also be permissible for the same drugs to be used at the same doses as individual components (or as Truvada, coformulated TDF/FTC). Other drug substitutions may be made per the protocol.
223815009|NCT01438463|BIOLOGICAL|Placebo|Increasing volumes of placebo, will be administered by subcutaneous injection (starting with 0.05 ml) at weekly intervals till the maintenance dose (0.5 ml) is reached. Subsequently, maintenance dosages, corresponding to 0.5 ml of placebo, are given at 4-weekly intervals.
223815010|NCT01438463|BIOLOGICAL|PURETHAL Mites 6,667 AU/ml|Increasing dosages, corresponding to increasing volumes of drug solution (starting with 0.05 ml), will be administered by subcutaneous injection at weekly intervals till the maintenance dose (0.5 ml) is reached. Subsequently, maintenance dosages, corresponding to 0.5 ml of drug solution, are given at 4-weekly intervals.
223815011|NCT01438463|BIOLOGICAL|PURETHAL Mites 20,000 AU/ml|Increasing dosages, corresponding to increasing volumes of drug solution (starting with 0.05 ml), will be administered by subcutaneous injection at weekly intervals till the maintenance dose (0.5 ml) is reached. Subsequently, maintenance dosages, corresponding to 0.5 ml of drug solution, are given at 4-weekly intervals.
223815012|NCT01438463|BIOLOGICAL|PURETHAL Mites 50,000 AU/ml|Increasing dosages, corresponding to increasing volumes of drug solution (starting with 0.05 ml), will be administered by subcutaneous injection at weekly intervals till the maintenance dose (0.5 ml) is reached. Subsequently, maintenance dosages, corresponding to 0.5 ml of drug solution, are given at 4-weekly intervals.
223815013|NCT01438463|BIOLOGICAL|PURETHAL Mites 100,000 AU/ml|Increasing dosages, corresponding to increasing volumes of drug solution (starting with 0.05 ml), will be administered by subcutaneous injection at weekly intervals till the maintenance dose (0.5 ml) is reached. Subsequently, maintenance dosages, corresponding to 0.5 ml of drug solution, are given at 4-weekly intervals.
223815014|NCT05341323|DRUG|Ketamine.|Peritonsillar infiltration of ketamine
223815015|NCT05341323|DRUG|Bupivacaine|peritonsillar infiltration of Bupivacaine
223815016|NCT04699227|PROCEDURE|Cuff application with inflation|The blood pressure cuff will be placed on the arm and inflated.
223815017|NCT04699227|OTHER|Sham inflation|The blood pressure cuff will be placed on the arm and not inflated.
223815018|NCT03973866|DEVICE|Alfapump|Implantation of alfapump
223815019|NCT05414318|DEVICE|Conformable GORE® TAG® Thoracic Endoprosthesis|Thoracic Endoprosthesis
223815020|NCT04586413|OTHER|No intervention - quality of life measure|Participants will be part of the creation of a Post-COVID-19 quality of life measure if involved in Phase One. In Phase Two participants will complete this post-COVID-19 quality of life measure monthly for 12 months
223815021|NCT02166957|PROCEDURE|Recanalization|"All patients received clear and detailed information about the different steps, the benefits and the risks of the procedure they would undergo, and gave an informed consent.~The rendez-vous technique shared some common characteristics whatever the etiology and the length of esophageal disruption. First, prior to start the specific endoscopic management, all the patients needed to have undergone a surgical gastrostomy one month earlier in order to allow the retrograde access. This one-month delay was necessary to get it completely healed before using it for the procedure.~The principle of the combined anterograde retrograde approach is to get an endoscopic access to both the proximal and distal side of the obstruction in the purpose to achieve better and safer recanalization, which could be carried out with either transillumination or using a needle under x-rays guidance."
223815022|NCT01526590|DRUG|Definity Contrast|While the patient is still sedated from their EUS and before tissue sampling, the patient will receive a dose of Definity intravenously through their peripheral IV access after being agitated. The dose of Definity will be 10 microliters/kg given in one to two doses, and will not exceed 2cc.
223815023|NCT06215651|DRUG|Cadonilimab lenvatinib|±TACE/HAIC
223815024|NCT04241692|DEVICE|CarnationTM Ambulatory Monitoring Sternal ECG Patch System|A newly developed cardiac rhythm monitoring system
223815025|NCT04241692|DEVICE|Conventional 24-Hour 7 Lead Holter Monitor Recorder|Traditional recordings made using a standard 24-hour Holter monitor.
223815026|NCT02006875|DEVICE|rTMS|Interventions started on the next weekday after pretest and were performed once a day for 15 consecutive weekdays. Participants in the E and C groups received rTMS (either real or sham, 1 Hz, 15 minutes), followed by a session of physical therapy for 45 minutes.
223815027|NCT05565794|DRUG|Pemigatinib|Intake of up to 3 tablets of pemigatinib (4,5 mg each) daily per oral for 14 days in a 21-day cycle (maximum of 18 cycles in total)
223815028|NCT05824390|DRUG|rituximab group|Rituximab is a human-mouse chimeric monoclonal antibody specifically targeting B cell surface antigen CD20. CD20 may act as a calcium channel to play a certain signal role and participate in the regulation of B cell maturation and differentiation. Once combined with CD20, RTX consumed CD20 + B fines through antibody-dependent cell-mediated cytotoxicity, complement-dependent cytotoxicity and direct induction of apoptosis. Recent studies have shown that B cell depletion therapy has a certain effect on many autoantibodies-mediated kidney diseases ( such as membranous nephropathy, lupus nephritis, etc. ). Therefore, rituximab combined with CD20 antigen on the surface of B cells can exhaust B cells that produce antibodies and play a therapeutic role by reducing antibody production, so this therapy also has potential therapeutic value for IgAN patients.
223815029|NCT01148862|DEVICE|The MiniMed Paradigm® X54 System|"The MiniMed Paradigm® X54 System: A insulin pump equipped with a number of features to actively manage the user's glucose levels. One example is the Low Glucose Suspend (LGS) feature. The LGS feature is only available when the pump is used with the subcutaneous glucose sensor for continuous glucose monitoring. To use this feature, the user will be required to select a sensor low suspend limit, or threshold, at which the LGS feature will be triggered. When this feature is selected, if the sensor glucose reading reaches the level that is equal to or less than the programmed threshold, the user receives an alert and the pump suspends."
223815030|NCT01478074|DRUG|G-CSF|5 mcg/kg daily from day -7 until post-nadir ANC \> 1000
223815031|NCT01478074|DRUG|Cytarabine|2 g/m2 daily from day -6 through -2
223815032|NCT01478074|DRUG|Fludarabine|30 mg/m2 daily from day -6 through -2
223815033|NCT01478074|BIOLOGICAL|Donor Natural Killer (NK) cells|Infused once on day 0. Four cohorts of escalating doses receiving 0, 1, 10, or 20 x 10\^6 cells/Kg
223815034|NCT01478074|BIOLOGICAL|ALT-801|0.04 mg/kg IV thrice weekly for 8 doses beginning day +2
223815035|NCT05155995|DRUG|HCP2001|Take it once per period.
223815036|NCT05155995|DRUG|RLD2007|Take it once per period.
223815037|NCT05155995|DRUG|RLD2008|Take it once per period.
223815038|NCT05155995|DRUG|RLD2102|Take it once per period.
223815039|NCT06051487|OTHER|titanium dioxide nanoparticles in test group|Titanium dioxide nanoparticles added to acrylic baseplate in test group
223815040|NCT02474290|DRUG|Sorafenib|The initial dose of sorafenib is 400 mg orally twice daily and is adjusted in case of suspected toxicity or resistance (dose range, 200-800 mg daily).
223815041|NCT00869882|PROCEDURE|Circumferential arthrodesis|"Patients are carefully positioned in the proned position and submitted to a posterior surgical approach under general anaesthesia. Surgical levels are viewed laterally by mean of intraoperative radiographs which can be performed at surgeon's demand during the whole surgery time.~The preceding procedure is performed. In case of foraminal stenosis, decompression is performed at the same time as discal approach via the narrowest foramen.~In addition to this, before preparation of bed for bone grafting, nerve roots are retracted and the disc nucleus is removed entirely, then endplate decortication is performed. The disc space is distracted. The most anterior part of the disc space is packed with cancellous bone. A cage packed with bone is inserted into the anterior portion of the interspace. According to cage location, bone graft could be inserted in the posterior portion of the interspace. Cage placement is radiologically checked.~The end of the procedure is the same as for GPLI."
223815042|NCT00869882|PROCEDURE|Posterolateral fusion with instrumentation|"Patients are carefully positioned in pronation and submitted to a posterior surgical approach under general anaesthesia. Surgical levels are viewed laterally by mean of intraoperative radiographs performed at surgeon's demand during the whole surgery time.~Pedicle screw instrumentation is performed, followed by posterior neural decompression depending on the type of stenosis:~* Central stenosis: decompression is performed including medial facectomy, laminectomy;~* Foraminal stenosis: foraminotomy is performed, while preserving a graft bed as large as possible;~* Pure foraminal stenosis: spinal duct is not opened. Local bone is harvested from the lamina and the spinous process and carefully fragmented for autologous graft.~Subperiosteal dissection is performed between the transverse processes and lateral aspects of the facet joints.~Two rods are placed and locked on screws in maximum compression to optimize segmental lordosis.~Bone autograft is placed into this bed."
223815043|NCT05101135|DRUG|JT-001|Subjects take the investigational products once a day for 24 weeks.
223815044|NCT05101135|DRUG|JT-001 Placebo|Subjects take the investigational products once a day for 24 weeks.
223815045|NCT05300802|DRUG|Placebo|50 ml of Ringer acetate will be added to the priming solution and followed by a continuous 50 ml infusion of Ringer acetate running at 25 ml/hour.
223815046|NCT05300802|DRUG|Dexmedetomidine Hcl 100 Mcg/mL Inj|1 mcg/kg diluted DEX will be added to the priming solution and followed by a continuous infusion of 50 ml Ringer acetate running at 25 ml/hour.
223815047|NCT05300802|DRUG|Dexmedetomidine Hcl 100 Mcg/mL Inj|0.5 mcg/kg DEX will be added to the priming solution and followed by a continuous infusion of 0.25 mcg/kg/hour DEX diluted in 50 ml of ringer acetate running at 25 ml/hour.
223815048|NCT02939300|DRUG|Nivolumab|"* Melanoma:~  \- Combination therapy with Nivolumab 1 mg/kg for 4 doses followed by monotherapy Nivolumab 480 mg per cycle.~* Non-small Cell Lung Cancer / Head and Neck Cancer:~  \- Combination therapy with Nivolumab 3 mg/kg~* Small Cell Lung Cancer / Breast Cancer / Bladder Cancer:~  \- Combination therapy with Nivolumab 1 mg/kg for 4 doses followed by monotherapy Nivolumab 240 mg per cycle.~* Renal Cell Carcinoma / Other Solid Tumors (not listed above):~  * Combination therapy with Nivolumab 3 mg/kg for 4 doses followed by monotherapy Nivolumab 480 mg per cycle."
223815049|NCT02939300|DRUG|Ipilimumab|"* Non-small Cell Lung Cancer / Head and Neck Cancer:~  \- Combination therapy with Ipilimumab 1 mg/kg~* Small Cell Lung Cancer / Breast Cancer / Bladder Cancer:~  \- Combination therapy with Ipilimumab 3 mg/kg for 4 doses~* Renal Cell Carcinoma / Other Solid Tumors (not listed above):~  * Combination therapy with Ipilimumab 3 mg/kg for 4 doses"
223815050|NCT04042116|DRUG|Lucitanib|Oral lucitanib will be administered once daily (QD) at the starting dose of 6 mg.
223815051|NCT04042116|DRUG|Lucitanib|Oral lucitanib will be administered once daily (QD). The dose will be 6 mg.
223815052|NCT04042116|DRUG|Lucitanib|"Oral lucitanib will be administered once daily (QD) at the starting dose of 6 mg.~Subjects will be allowed to intrapatient dose escalate in increments of 2 mg up to a total dose of 10 mg QD lucitanib if they meet the study specific clinical criteria."
223815053|NCT04042116|DRUG|Nivolumab|IV nivolumab 480 mg will be administered once every 4 weeks.
223815054|NCT02826369|OTHER|3.0 Tesla in Magnetic Resonance Imaging|"Eligible patient will have a standard MRI. The images taken before 4min30 and after 6min after to the injection of gadolimium contrast medium will be carried out with the standard image acquisition.~The images taken between 4min30 and 6min after the injection of gadolimium contrast medium will be carried out with the compressed sensing image acquisition."
223815055|NCT06308094|DIAGNOSTIC_TEST|CT|Pre-ablation CT is clinically acquired in patients undergoing catheter ablation. This study entails additional acquisition of the left ventricle to assess extracellular volume (ECV)
223815056|NCT00735111|OTHER|Karnofsky Performance Status Score|Karnofsky Performance Status scores will be independently completed by both the patient and their health-care provider at each routine clinic visit.
223815057|NCT00125593|DRUG|Simvastatin 20 mg|Once daily
223815058|NCT00125593|DRUG|Ezetimibe 10mg|Once daily
223815059|NCT00125593|DRUG|Placebo|Once daily
223815060|NCT06065813|DRUG|Toripalimab|200 mg Toripalimab intravenously every 3 weeks 3 doses of Toripalimab before operation 14 doses of Toripalimab 30 days after operation
223815061|NCT06065813|RADIATION|Conventional segmental radiotherapy|the does of radiation will be 40-45Gy. The day of the first dose of Toripalimab and the first day of radiation must be the same day.
223815062|NCT06065813|OTHER|opreation|The operable patients will accept radical operated in 28-42 days after the third dose of Toripalimab
223815063|NCT01155037|BIOLOGICAL|Adjuvanted vaccine against H1N1 influenza virus (GSK)|Patients infected with HIV will receive 3.75 µg of an adjuvanted A H1N1 vaccine in two applications 21 days apart.
223815064|NCT01155037|BIOLOGICAL|Adjuvanted vaccine against H1N1 influenza virus (GSK)|Patients infected with HIV will receive 7.5 µg of an adjuvanted A H1N1 vaccine in two applications 21 days apart.
223815065|NCT01155037|BIOLOGICAL|Adjuvanted vaccine against H1N1 influenza virus (GSK)|Control group will receive 3.75 µg of an adjuvanted A H1N1 vaccine in one single application.
223815066|NCT02873819|DRUG|GL-0817|GL-0817, IV at the dose 1.5 mg will be administered 3 times at 3-week intervals followed by 7 doses at 3-month intervals beginning at the Week 18 visit
223815067|NCT02873819|DRUG|Hiltonol|Hiltonol will be administered intramuscularly at the dose of 1.4 mg as adjuvant to GL0817, 3 times at 3-week intervals followed by 7 doses at 3-month intervals beginning at the Week 18 visit
223815068|NCT02873819|DRUG|Sargramostim|Sargramostim will be administered intramuscularly at the dose of 100 μg/m2, as adjuvant to GL0817, 3 times at 3-week intervals followed by 7 doses at 3-month intervals beginning at the Week 18 visit
223815069|NCT02873819|DRUG|cyclophosphamide|cyclophosphamide will be administered IV at a dose of 200 mg/m2 (maximum dose 400 mg) one day prior to first three vaccinations of GL0817 with adjuvants
223815070|NCT02873819|DRUG|Placebo|Placebo (normal saline) will be administered as per the schedule of cyclophosphamide and GL0817/adjuvants administration
223815071|NCT01597505|DRUG|Surotomycin|250 mg Surotomycin over-encapsulated tablet administered orally, twice daily for a daily total dose of 500 mg, for 10 days
223815072|NCT01597505|DRUG|Vancomycin|125 mg Vancomycin over-encapsulated capsule administered orally, four times daily for a daily total dose of 500 mg, for 10 days
223815073|NCT01597505|DRUG|Placebo|Placebo for Surotomycin over-encapsulated tablet administered orally, twice daily for 10 days
223815074|NCT03735563|DRUG|Ketamine|Individuals will receive randomly either ketamine or fentanyl as a premedication
223815075|NCT03735563|DRUG|Fentanyl|Individuals will receive randomly either ketamine or fentanyl as a premedication
223815076|NCT00009581|DRUG|L-NMMA|
223815077|NCT00009581|DRUG|Acetylcholine|
223815078|NCT04225624|BEHAVIORAL|Emotion Regulation Therapy - Attention Regulation (AR-ERT)|Participants will receive a total of eight 60 minute sessions (over 8 weeks) of individual, manual-based AR-ERT. This intervention aims to build attention regulation skills (i.e., the ability to flexibly shift and sustain attention) by teaching participants exercises for Orienting their attention and Allowing the presence of negative emotions. Participants are taught to apply these skills to counteract reactive perseverative thinking when negative emotions arise as well as proactively engage with emotion-laden situations that trigger repetitive negative thinking.
223815079|NCT04225624|BEHAVIORAL|Supportive Psychotherapy (SPT)|Participants will receive a total of eight 60 minute sessions (over 8 weeks) of individual, manual-based SPT. This intervention addresses factors that may affect participants' repetitive negative thinking symptoms (for example, relationships, work, stress), and teaches skills for managing challenges by improving self-esteem and positive coping skills.
223815080|NCT05437276|DEVICE|PoNS®|The PoNS device used in conjunction with rehabilitative physical therapy
223815081|NCT06245057|OTHER|Maternity care home model (MCHM)|The maternity care home model is defined as office based prenatal care integrated with comprehensive social services.
223815082|NCT05960370|OTHER|Observational non intervention study|An additional control scan will be performed vaginally the day of the embryo transfer. Rest of follow up and treatment will be executed as usually.
223815083|NCT04392037|DRUG|Iberdomide plus low-dose cyclophosphamide and dexamethasone|Iberdomide, low dose Cyclophosphamide and Dexamethason will be given until progression or unacceptable toxicity
223815084|NCT05533528|PROCEDURE|periodontal surgery|A sulcular incision will be made in the affected teeth, followed by an incision from the buccal aspect in the mid-portion of the interproximal tissues The buccal and lingual flaps will be elevated. For periodontal granulation tissue preservation group, the soft tissues covering the alveolar crest will be prepared. A third incision will separate the pocket epithelium from the soft tissue (granulation tissue) attached to the bone. The pocket epithelium will be removed. The root surfaces will be carefully scaled and planed in both groups. Ethylenediaminetetraacetic acid (24%) will be applied to the root surfaces and removed after 2 minutes with abundant saline solution. In the experimental group, the preserved attached soft tissue and the space between it and the root surface will be irrigated with 10% polyvinylpyrrolidone-iodine. Finally, the flaps will be positioned and sutured.
223815085|NCT06145048|DRUG|VGT-309|Intravenous drug to be given over 15-20 minutes by syringe pump.
223815086|NCT00617695|DRUG|Zolmitriptan|5mg nasal spray
223815087|NCT00617695|DRUG|Placebo|
223815088|NCT05958563|DEVICE|continuous positive airway pressure treatment|CPAP treatment for one year
223815089|NCT05514951|DIAGNOSTIC_TEST|Blood sampling|Blood sampling
223815090|NCT04474522|GENETIC|Non-invasive Preimplantation genetic testing for aneuploidy status|In the intervention group, comprehensive chromosome screening using NGS will be performed according to the recommendations of the company in all SCM samples. Sequence of replacement shall be altered by the NiPGT result after morpholgy.
223815091|NCT05454410|DRUG|MIJ821 Subcutaneous Injection 1 mg|MIJ821 supplied in vials as a powder for solution for injection, reconstituted and administered as a single SC injection on Day 1.
223815092|NCT05454410|DRUG|MIJ821 Subcutaneous Injection 4 mg|MIJ821 supplied in vials as a powder for solution for injection, reconstituted and administered as a single SC injection on Day 1.
223815093|NCT05454410|DRUG|MIJ821 Subcutaneous Injection 10 mg|MIJ821 supplied in vials as a powder for solution for injection, reconstituted and administered as a single SC injection on Day 1.
223815094|NCT05454410|DRUG|Placebo Subcutaneous Injection|0.9% sodium chloride solution administered as a single SC injection on Day 1.
223815095|NCT06070350|BIOLOGICAL|Low Titer Group O Whole Blood (LTOWB)|LTOWB is whole blood from group O donors with low titer (\<200) anti-A and anti-B antibodies. Up to 8 units of LTOWB will be allowed unless local clinical practice allows for a higher maximum dose.
223815096|NCT06070350|DRUG|Placebo|Placebo will be provided to the research pharmacy at each of the clinical sites
223815097|NCT06070350|DRUG|Tranexamic Acid (TXA)|TXA is a synthetic lysine analog that competitively inhibit activation of plasminogen, thereby decreasing the conversion of plasminogen to plasmin, preventing degradation of fibrin's matrix structure. Dose is 25mg/kg IV or IO (maximum 2 grams).
223815098|NCT06070350|BIOLOGICAL|Component Therapy (CT)|Component Therapy (CT) will be RBCs, plasma and platelet units in a 1:1:1 unit ratio. This will be given with Placebo
223815099|NCT02294617|OTHER|Electronic Cigarette|Subject will use electronic cigarette for 3 days.
223815100|NCT02294617|OTHER|Nicotrol Inhaler|Subjects will use the Nicotrol Inhaler for 3 days.
223815101|NCT06593431|RADIATION|Consolidative Radiation|Participants will receive treatment through radiation therapy
223815102|NCT01220869|DRUG|Degarelix|Degarelix was given as subcutaneous (s.c.) injections with a 240 mg starting dose followed one month later by a 80 mg maintenance dose. The maintenance dosing was repeated for an additional 5 months (total treatment period was 168 days).
223815103|NCT05261191|BIOLOGICAL|MGD020|MGD020 is a bispecific DART molecule that binds CD3 and gp41 subunit of HIV-1 envelope.
223815104|NCT05261191|BIOLOGICAL|MGD014|MGD014 is a bispecific DART molecule that binds CD3 and gp120 subunit of HIV-1 envelope.
223815105|NCT03804606|OTHER|Referral to MTM Pharmacist|Patients will be referred for an encounter with a medication therapy management pharmacist.
223815106|NCT05004688|BIOLOGICAL|Biological/Vaccine: Bacillus Calmette-Guerin (BCG)|Two Bacillus Calmette-Guérin (Japan BCG) vaccine injections spaced four week apart. Each injection will have 0.36-3.9 x 10\^6 colony forming units (CFU) reconstituted in 0.1 mL saline.
223815107|NCT05551702|BEHAVIORAL|CBT-txt|Cognitive Behavioral Therapy delivered via automated text messaging.
223815108|NCT04074200|PROCEDURE|Open Inguinal Hernia Repair|With the patient under anesthesia, a single incision is made in the groin area. The hernia defect may be closed, as per the operating surgeon's standard of care (SOC). Mesh may be used to repair the hernia, as per SOC. The specific open approach may vary due to surgeon preference and patient characteristics. After the repair, the patient will be prescribed a 5 day supply of pain medication, as per SOC.
223815109|NCT04074200|PROCEDURE|Laparoscopic Inguinal Hernia Repair|With the patient under general anesthesia, several small incisions are made in the groin area. Ports are placed, the abdomen is insufflated, and laparoscopic instruments as well as a laparoscope (a lighted scope used to visualize the hernia) are inserted to complete the repair. The hernia defect may be closed, as per the operating surgeon's standard of care (SOC). Mesh may be used to repair the hernia, as per SOC. The specific laparoscopic approach may vary due to surgeon preference and patient characteristics. After the repair, the patient will be prescribed a 5 day supply of pain medication, as per SOC.
223815110|NCT04074200|DEVICE|Robotic-Assisted Inguinal Hernia Repair|With the patient under general anesthesia, several small incisions are made in the groin area. Ports are placed, the abdomen is insufflated, and the da Vinci Robotic Surgical System (Intuitive) is docked to the patient and used to complete the procedure. The hernia defect may be closed, as per the operating surgeon's standard of care (SOC). Mesh may be used to repair the hernia, as per SOC. The specific robotic-assisted approach may vary due to surgeon preference and patient characteristics. After the repair, the patient will be prescribed a 5 day supply of pain medication, as per SOC.
223815111|NCT06770556|DEVICE|Sham iTBS|Participants will receive sham iTBS
223815112|NCT06770556|DEVICE|Active iTBS|Participants will receive active iTBS
223815113|NCT06770556|DEVICE|10 Hz TMS|Participant will receive 10 Hz TMS
223815114|NCT06770556|DEVICE|1 Hz TMS|Participant will receive 1 Hz TMS
223815115|NCT06578715|BEHAVIORAL|Emotional Freedom Technique|EFT basically involves serial tapping on acupuncture points, no needles are used, there is no invasive procedure, there are affirmation suggestions, it is an easy, painless, simple but effective method that can be done in minutes. It is realized by applying kinetic energy to certain meridians on the head and chest with the fingertips. The points where the tapping is done are the end points of the meridians in the body. They are located symmetrically on both sides of the body. Since these points are close to the skin surface, they are points that are more easily reached than the deeper buried parts of the meridians. While applying pressure with the fingertips, the individual needs to focus on the problem that bothers him/her. Another thing that needs to be done at the same time is for the person to make positive suggestions to himself/herself vocally.
223815116|NCT06576921|DRUG|Serplulimab Combined With Chemotherapy|Serplulimab (Dosage form: Lyophilized powder; Unit dose strength: 4.5 mg; Route of administration: IV infusion; Storage requirements: 2-8℃. Protect from light and freezing.) Nap-paclitaxel (Dosage form: Lyophilized powder; Unit dose strength: 100 mg; Route of administration: IV infusion; Storage requirements: \<25℃. Protect from light.) S-1 (Dosage form: Capsule; Unit dose strength: 20 mg; Route of administration: Oral; Storage requirements: 20-30℃. Protect from light.) Oxaliplatin (Dosage form: Lyophilized powder; Unit dose strength: 50 mg; Route of administration: IV infusion; Storage requirements: \<25℃. Protect from light.) Surgery: All surgical procedures are performed according to the guidelines of the Japanese Research Society for the Study of Gastric Cancer.
223815117|NCT06576921|DRUG|Placebo combined with Chemotherapy|Placebo (Dosage form: Lyophilized powder; Unit dose strength: 4.5 mg; Route of administration: IV infusion; Storage requirements: 2-8℃. Protect from light and freezing.) Nap-paclitaxel (Dosage form: Lyophilized powder; Unit dose strength: 100 mg; Route of administration: IV infusion; Storage requirements: \<25℃. Protect from light.) S-1 (Dosage form: Capsule; Unit dose strength: 20 mg; Route of administration: Oral; Storage requirements: 20-30℃. Protect from light.) Oxaliplatin (Dosage form: Lyophilized powder; Unit dose strength: 50 mg; Route of administration: IV infusion; Storage requirements: \<25℃. Protect from light.) Surgery: All surgical procedures are performed according to the guidelines of the Japanese Research Society for the Study of Gastric Cancer.
223815118|NCT03485677|DRUG|Eliglustat GZ385660|"Pharmaceutical form: Capsule, Liquid~Route of administration: Oral"
223815119|NCT03485677|DRUG|Imiglucerase GZ437843|"Pharmaceutical form: Powder for solution for infusion~Route of administration: Intravenous"
223815120|NCT00895622|RADIATION|54 Gy radiotherapy|External beam radiation therapy (EBRT) to a total dose of 54 Gy (RBE) in 30 fractions. 1.8 Gy (RBE) daily, 5 fractions per week, excluding weekends. 3D-CRT or IMRT or Proton allowed.
223815121|NCT00895622|RADIATION|60 Gy radiotherapy|External beam radiation therapy using intensity-modulated radiation therapy (IMRT) to a total dose of 60 Gy in 30 fractions. 2.0 Gy daily, 5 fractions per week, excluding weekends.
223815122|NCT05306093|DIETARY_SUPPLEMENT|Nutraceutical|Food supplements are consumed during 8 weeks by healthy volunteers
223815123|NCT05306093|DIETARY_SUPPLEMENT|Maltodextrin|Food supplements are consumed during 8 weeks by healthy volunteers
223815124|NCT04842162|DRUG|indocyanine green|indocyanine green (INFRACYANINE© 25mg/10mL).
223815125|NCT05256771|DEVICE|EMS|Abdominal muscle stimulation using EMS
223815126|NCT05256771|DEVICE|1064 nm diode laser|Adipose tissue heating using 1064 nm diode laser
223815127|NCT05256771|DEVICE|RF/PEMF|Collagen re-modelling and reduction in subcutaneous fat using RF/PEMF
223815128|NCT04084977|DIAGNOSTIC_TEST|Antibody detection|detecting anti bodies against D1, D2 receptor, tubolin Lysoganglioside
223815129|NCT02206022|DRUG|Remifentanil|Pain's evaluation for Remifentanil Group
223815130|NCT02206022|DRUG|Placebo|CVC pain's evaluation after local anesthesia + placebo infusion
223815131|NCT06363825|DRUG|camrelizumab|"TAE: 3-15ml iodized oil;~HAIC: Indurating arterial catheter, oxaliplatin 85mg/m\^2 D1, arterial infusion, lasting 1-2 hours (d1), LV 400mg/m\^2, arterial infusion, lasting 2-3 hours (d1), 5-Fu 400mg/m\^2, arterial infusion, lasting 3 hours (d1), and fluorouracil 2400 mg/m\^2 for 24-48h;~camrelizumab: 200mg, ivgtt, 30 min (not less than 20 min, not more than 60 min) every 3 weeks (21 days);~apatinib mesylate: 250mg, once a day, taken orally (the time of daily administration should be as much as possible), with warm water.Stop for 3 days before next cycle intervention.~Camrelizumab was given intravenously 1 day before TAE+HAIC treatment for each cycle, TAE+HAIC treatment was given on the second day, and oral apatinib was started after discharge."
223815132|NCT04130139|OTHER|oocyte pick up simulator|oocyte pick up simulation
223815133|NCT02138669|DEVICE|Intacs|INTACS® prescription inserts are an ophthalmic medical device designed for the reduction or elimination of myopia and astigmatism in patients with keratoconus so that their functional vision may be restored and the need for a corneal transplant procedure can potentially be deferred.
223815134|NCT06434792|DRUG|Bronpass Tab.|Twice daily for 12 weeks
223815135|NCT06434792|OTHER|Placebo|Twice daily for 12 weeks
223815136|NCT04309084|BIOLOGICAL|CYNK-001|CYNK-001 is an allogeneic off the shelf cell therapy enriched for CD56+/CD3- NK cells expanded from human placental CD34+ cells.
223815137|NCT03790761|BEHAVIORAL|PREP 8.0 Curriculum|The PREP 8.0 curriculum is an experiential curriculum designed to be implemented in a workshop or educational setting. Using techniques of cognitive-behavioral marital therapy and communication-oriented marital enhancement, PREP aims to help couples achieve high levels of relationship functioning and prevent marital problems. The PREP approach is based on research in the field of relational and marital health and success conducted at the University of Denver.
223815138|NCT05732792|OTHER|CIPS Survey|"The survey is endorsed by the European Society of Anaesthesiology and Intensive Care (ESAIC) and will be distributed from February 2023 onwards to its members for a period of 3 months.~Each anesthesiologist's participation to the survey will be voluntary and anonymous individual consent will be implied by the person's willingness to complete the survey.~The survey will also mention this.~All surveys will be administered via SurveyMonkey. Surveymonkey allows to build Health Insurance Portability and Accountability Act (HIPAA) compliant surveys that follow strict rules around the protection of health information.~Of note, Surveymonkey is also GDPR (General Data Protection Regulation) compliant.~Data gathered from the questionnaires will be safely stored on the surveymonkey database. The access to the result database is held by a password that only the authors can use to analyze the data yielded at the end of the survey period."
223815139|NCT00683709|BEHAVIORAL|Counselling as Usual|5 - 20 minutes, about the effects of clozapine on body weight, appetite, blood sugar and fats such as cholesterol and triglycerides in the blood, and how these might affect your health in the future.
223815140|NCT00683709|BEHAVIORAL|CBT|45 - 60 minutes individual treatment sessions focused on nutrition, exercise and weight control and will occur weekly for 4 weeks. After this, 10 group sessions focused on weight reduction will be held every 2 weeks. This will be followed by 6 group sessions focused on weight maintenance held every 2 weeks.
223815141|NCT00947661|DRUG|SPARC0912|Eye drops, once daily, 12 weeks
223815142|NCT00947661|DRUG|Reference0912|Eye drops, once daily, 12 weeks
223815143|NCT05699421|OTHER|screening programme|CMV screening during the first trimester of pregnancy and neonatal
223815144|NCT00779779|BIOLOGICAL|Rotarix™|Two oral doses, with at least 4 weeks interval in-between
223815145|NCT05957926|PROCEDURE|hyaluronic acid added to hydroxyapetite|"1. The procedure will be performed under complete aseptic condition, and the surgical field will be swabbed with povidone iodine solution before the operation .~2. Surgical procedure will be performed under local anesthesia (Articaine 4% with 1:100,000 adrenaline ) .~3. A full thickness mucoperiosteal flap will be reflected exposing the area of interest containing the lesion .~4. The pathological lesion will be exposed using rose head bur on low-speed handpiece under copious irrigation by normal saline .~5. The whole pathological tissues will be enucleated and sent for histopathological examination.~6. The cavity will be curetted again to remove any remaining tissues and irrigated with 0.9% normal saline .~7. hydroxyapetite with hyaluronic acid will be inserted in the bony cavity to initiate healing .~8. The flap will be repositioned and sutured with interrupted 3-0 Vicryl suture ."
223815146|NCT05957926|PROCEDURE|Hydroxyapatite alone|"1. The procedure will be performed under complete aseptic condition, and the surgical field will be swabbed with povidone iodine solution before the operation .~2. Surgical procedure will be performed under local anesthesia (Articaine 4% with 1:100,000 adrenaline ) .~3. A full thickness mucoperiosteal flap will be reflected exposing the area of interest containing the lesion .~4. The pathological lesion will be exposed using rose head bur on low-speed handpiece under copious irrigation by normal saline .~5. The whole pathological tissues will be enucleated and sent for histopathological examination.~6. The cavity will be curetted again to remove any remaining tissues and irrigated with 0.9% normal saline .~7. hydroxyapetite will be inserted in the bony cavity to initiate healing .~8. The flap will be repositioned and sutured with interrupted 3-0 Vicryl suture ."
223815147|NCT04419844|PROCEDURE|Tar with Botox|Evaluation of TAR technique in the treatment of huge abdominal wall hernia and large abdominal wall defect with Botox injection .
223815148|NCT05272332|DIAGNOSTIC_TEST|Gastric ultrasound|Gastric ultrasound upon fasting, after 4 hours, and after nasogastric aspiration, to estimate gastric volume
223815149|NCT01886001|DRUG|Povidone-Iodine|Umbilical stump care. Povidone-Iodine, USP, Swabstick Singles, applied once a day to cord stump while umbilical line(s) are in place
223815150|NCT01886001|DRUG|Chlorhexidine|Umbilical stump care. Chlorhexidine Gluconate 2% w/v; 70% Isopropyl Alcohol v/v Swabstick Single, applied once a day to cord stump while umbilical line(s) are in place
223815151|NCT01886001|DRUG|Pluronic|Umbilical stump care. Pluronic gel - (F68, Polymyxin, Nystatin, Nitrofurantoin)applied once a day to cord stump while umbilical line(s) are in place
223815152|NCT01886001|OTHER|Control|No product is applied to cord stump while umbilical line(s) are in place. This is the current standard of care at UVA.
223815153|NCT04309825|PROCEDURE|transgastrostomal endoscopy|Placement the endoscope through the g-tube port and not through the mouth of a patient undergoing an upper gi endoscopy
223815154|NCT00524199|DRUG|Mesna|12 mg/kg IV infusion over five minutes at the beginning of dialysis thrice weekly.
223815155|NCT00524199|OTHER|Saline|Saline IV infusion over five minutes at the beginning of dialysis thrice weekly.
223815156|NCT00865943|DRUG|Citalopram HBr eq. 10 mg tablets, single dose|A: Experimental Subjects received Purepac formulated products under fasting conditions
223815157|NCT00865943|DRUG|CELEXATM 10 mg tablets, single dose|B: Active comparator Subjects received Forest Pharmaceuticals, Inc. marketed products under fasting conditions
223815158|NCT04949958|OTHER|Exercise Based Manual (Supervised)|Exercise Based Manual for Pre Diabetic subjects will consist of two components; Exercise, Exercise and Education. The exercise will be supervised while other component will be home based.
223815159|NCT04949958|OTHER|Exercise Based Manual (Home Based)|Exercise Based Manual for Pre Diabetic subjects will consist of two components; Exercise and Education. All two components will be home based.
223815160|NCT04949958|OTHER|Control|General advice to be active
223815161|NCT03034018|DRUG|suvorexant|10-20 mg taken at bedtime for four weeks
223815162|NCT03034018|DRUG|placebo|placebo taken at bedtime for four weeks
223815163|NCT02552238|DRUG|Lumason|Lumason (sulfur hexafluoride-type A microspheres) an ultrasound contrast agent was administered as 2 single 2-mL IV injections during rest and stress echocardiography
223815164|NCT03285048|BEHAVIORAL|Cognitive Remediation Therapy|Brain HQ is a computer based cognitive training that uses hierarchical adaptive technology to provide challenging and demanding training that is not too frustrating or discouraging. Training includes auditory and visual sensory training, memory and executive function exercises. The Bridging group is based on similar training programs that focus on self-regulation training, problem focused cognitive behavior therapy and compensatory cognitive strategies.
223815165|NCT03538483|DRUG|Bupivacaine Hcl 0.25% Inj|30 ml %0,25 bupivacaine
223815166|NCT03538483|DRUG|Bupivacaine HCl Inj 0.25%|20 ml %0,25 bupivacaine
223815167|NCT00586170|DEVICE|EBI Bone Healing System|10 hours of treatment per day for up to 24 weeks
223815168|NCT00586170|DEVICE|Placebo Device|10 hours of treatment per day for up to 24 weeks
223815169|NCT00586170|PROCEDURE|Surgery|Open Reduction and Internal Fixation of the nonunion site
223815170|NCT05158296|DRUG|Ultevursen|RNA antisense oligonucleotide for intravitreal injection
223815171|NCT05158296|OTHER|Sham-procedure|Sham-procedure (no experimental drug administered)
223815172|NCT02725125|BIOLOGICAL|EPCAM-targeted CAR-T cells|This study have only one arm that is CAR-T experimental arm. Firstly all participators will be attended the screening, who passed the screening for the treatment of CAR-T cells, the CAR-EPCAM-modified T cells can recognize and kill tumor cells in the body，follow-up 35 months.
223815173|NCT02542644|DEVICE|Ultrahigh resolution Spectral Domain OCT|"The area of graft detachment will be measured by a customized ultra high-resolution OCT for the cornea.~A spectrometer based ultrahigh resolution Spectral Domain OCT (SDOCT) system operating at 800 nm for the anterior chamber will be employed in the present study. The spectrum of the Ti:Sapphire laser light source is centered at 800 nm. With a full width at half maximum bandwidth of 170 nm, the axial resolution is 1.3 μm in the cornea. The transverse resolution of the employed OCT system is 21 μm at the front surface of the cornea. For measurement, patients will place their head in a modified slit lamp head rest. During the measurement period, patients will be asked to look straight forward onto an internal fixation target and to avoid blinking. Different scattering patterns, e.g. raster, circular and spiral scans will be employed."
223815174|NCT01581723|DEVICE|Monopolar diathermy|monopolar diathermy
223815175|NCT01581723|DEVICE|Bipolar diathermy|bipolar diathermy
223815176|NCT00898040|GENETIC|polymorphism analysis|
223815177|NCT02766621|BIOLOGICAL|PF-06823859|Comparison of different dosages of PF-06823859 to placebo
223815178|NCT02766621|DRUG|Placebo injection SC/IV|Comparison of Placebo to different doses of PF-06823859
223815179|NCT04285658|PROCEDURE|Ureteroscopy|An outpatient endoscopic surgery that accesses the ureters and kidneys per the urethra to fragment and remove the stones. Many patients who undergo ureteroscopy (URS), Shockwave lithotripsy (SWL), or percutaneous nephrolithotomy (PCNL) also have temporary tubes placed after the surgery to facilitate drainage, either internally (a stent) or externally (a nephrostomy tube).
223815180|NCT04285658|PROCEDURE|Percutaneous Nephrolithotomy|A minimally invasive surgery in which a \~1cm flank incision is made, and a scope is passed through a tubular sheath into the kidney to fragment and remove the stone. There is typically a 1- to 2-day hospital stay. Many patients who undergo URS, SWL, or PCNL also have temporary tubes placed after the surgery to facilitate drainage, either internally (a stent) or externally (a nephrostomy tube).
223815181|NCT04285658|PROCEDURE|Shock Wave Lithotripsy|A non-invasive outpatient procedure that targets stones in the kidney or ureter with x-ray or ultrasound and uses shockwaves generated outside the body to fragment them; the fragments pass down the ureter and the patient expels them in the urine. Many patients who undergo URS, SWL, or PCNL also have temporary tubes placed after the surgery to facilitate drainage, either internally (a stent) or externally (a nephrostomy tube).
223815182|NCT03350100|DIETARY_SUPPLEMENT|Acute effect of two Saudi cultivars of date fruit on mood and cognitive performance|Acute effect of two Saudi cultivars of date fruit on mood and cognitive performance at baseline, 45 post-dose, 90 min post-dose and 135 min post-dose
223815183|NCT03091686|BEHAVIORAL|HAPA SB Intervention Slideshow|In the experimental condition, participants will receive sedentary behaviour and diabetes information in the form of a slide show that will be viewed online. The intervention aims to address all components of the Health Action Process Approach. For the experimental group, the intervention material will target risk perceptions (RP) related to sitting by presenting evidence supported by research on sedentary behaviour and diabetes risk; outcome expectancies (OE) by presenting research on the effectiveness of breaking up sedentary time for improving blood sugar and insulin levels; and self-efficacy (SE) by providing strategies on how to reduce and break up sitting time.
223815184|NCT03091686|BEHAVIORAL|HAPA MVPA Attention-Control Slideshow|In the attention-control, participants will receive information in the form of a slide show that will be viewed online. The intervention aims to address all components of the Health Action Process Approach. The attention-control slide show will take the same approach as the Experimental group slideshow but the slides will be geared towards meeting moderate-vigorous physical activity guidelines.
223815185|NCT02036645|BIOLOGICAL|MEDI1814 for IV injection|Monoclonal antibody for IV Injection
223815186|NCT02036645|BIOLOGICAL|MEDI1814 for Subcutaneous Injection|Monoclonal antibody for subcutaneous injection
223815187|NCT02036645|BIOLOGICAL|IV Placebo|Placebo for IV injection
223815188|NCT02036645|BIOLOGICAL|Placebo for Subcutaneous Injection|Subcutaneous Placebo Injection
223815189|NCT03472222|BEHAVIORAL|Arsha Vidya program|Integrated intervention program includes counselling and supportive care with the support of Arsha Vidya program
223815190|NCT01986101|DRUG|Placebo|Placebo comparator
223815191|NCT01986101|DRUG|SM-13496|SM-13496 20mg for Days 1-7 and beginning Day 8 flexibly dosed 20-60 mg/day for Weeks 2-6
223815192|NCT01986101|DRUG|SM-13496|SM-13496 20 mg/day for Days 1-2, 40 mg/day for Days 3-4, 60 mg/day for Days 5-6, 80 mg/day on Day 7 and beginning Day 8 flexibly dosed 80-120 mg/day for Weeks 2-6
223815193|NCT02817035|DEVICE|noninvasive mechanical ventilation|To examined the physiological signals of patients and healthy subjects during spontaneous breathing and noninvasive mechanical ventilation.
223815194|NCT03781921|OTHER|No intervention|There is no intervention. Each group will conduct the same tasks and questionnaires and we will compare performances between groups.
223815195|NCT05541302|DEVICE|TMS|Transcranial Magnetic Stimulation
223815196|NCT02571790|BEHAVIORAL|Relaxation optimized virtual reality|
223815197|NCT02571790|BEHAVIORAL|Classical relaxation (without Virtual Reality)|
223815198|NCT03842839|DRUG|Tiotropium Inhalation Powder [Spiriva] 0.018mg|Tiotropium bromide (Spiriva) capsule 18μg once daily inhaled.
223815199|NCT03842839|DRUG|Salbutamol sulphate aerosol (Ventolin) 0.01mg|As needed use of salbutamol sulphate aerosol (Ventolin) when exacerbation happens
223815200|NCT00252434|BEHAVIORAL|Cognitive Behavioral Therapy Development for Methamphetamine Abuse|
223815201|NCT02583438|DRUG|Saxagliptin (Bristol-Myers Squibb Company)|6-month treatment of Saxagliptin 5mg Qd
223815202|NCT06520943|OTHER|blood gas analysis|"1. Airway pressure (P plateau, Ppeak) values are taken from the anesthesia device data,~2. BIS (from routine BIS monitoring)~3. Temperature (routinely from pharyngeal temperature probe),~4. Oxygen saturation (routinely from the patient monitor)~5. End-tidal CO₂,~6. inspiratory O₂ concentration,~7. Inspiratory CO2 concentration,~8. inspiratory and expiratory desflurane concentrations,~9. tidal volume,~10. MAC is routinely obtained from anesthesia device data.~11. Blood Gas Analysis (COHgb, Ph, PO2, PCO2, SaO2, HCO3, Base deficit, glucose, lactate)"
223815203|NCT06023875|DRUG|Cadonilimab|Cadonilimab 10mg/kg. The drug was administered every 3 weeks (Q3W), and 21 days (Q3W) was a treatment cycle. The treatment regimen is recommended for three cycles until the researchers determine that the subjects cannot continue to benefit, until the disease progression (PD), the toxicity cannot be tolerated, the treatment is delayed by more than 14 days, or the patient withdraws the informed consent form or dies.
223815204|NCT06023875|DRUG|Docetaxel|Docetaxel 75mg/m2. Intravenous infusion was given every 3 weeks (Q3W), and 21 days (Q3W) was a treatment cycle. Treatment regimen is recommended for 3 cycles.
223815205|NCT06023875|DRUG|Cisplatin|Cisplatin 60mg/m2. Intravenous infusion was given every 3 weeks (Q3W), and 21 days (Q3W) was a treatment cycle. Treatment regimen is recommended for 3 cycles.
223815206|NCT03295513|OTHER|Veneered zirconia|he use of veneered zirconia is well documented in the literatures as successful restoration modality. A two Clinical performance of two different CAD/CAM-fabricated ceramic crowns revealed no chipping for veneered zirconia
223815207|NCT03295513|OTHER|Monolithic zirconia|Monolithic zirconia product presented a new generation of polycrystalline material by which full anatomical crowns and bridges can be produced
223815208|NCT01455935|DRUG|Anti-platelets and statin|
223815209|NCT01455935|DRUG|alteplase|"Full dose Intravenous thrombolysis~* 0.9 mg/kg~* Maximum dose is 90 mg~* 10% of the dose will be given over one minute~* 90% of the dose will be infused over 1 hour~* Admission to Neuro Intensive Care Unit(NICU) for 24 hours if no complications~* Neuro checks every 5 minutes during the infusion~* Neuro checks every hour after the infusion for 24 hours"
223815210|NCT01455935|PROCEDURE|intra arterial intervention|"1. Intra arterial Activase (Maximum dose of 22 mg)~2. MERCI device (Maximum of 3 tries per device, no standard time frame for how long the procedure takes)~3. PENUMBRA device (no standard time frame for how long the procedure takes)"
223815211|NCT03221725|PROCEDURE|sacrospinous ligament fixation|sacrospinous ligament fixation will be applied to prevent vaginal vault prolapse
223815212|NCT05373797|BEHAVIORAL|Procedures performed on the experimental and control groups|Intervention Group:26 Control Group (n=26):
223815213|NCT02404389|DRUG|Investigational Treatment|Topical application for two treatment cycles with twice daily applications, separated by a 4 week treatment pause and followed by 8 week treatment free follow-up.
223815214|NCT02404389|DRUG|Active comparator|Topical treatment with Aldara 3 times per week. The group will be open-label, but however blinded to the efficacy assessor, and followed by 8 week treatment free follow-up.
223815215|NCT02104492|OTHER|a 12-week Respiratory Muscles Training Program (RMTP)|Every session will be lasted 50 minutes and performed under supervision of a physiotherapist. It will be comprised of 30 minutes of progressive aerobic training program followed by peripheric resistive muscle training program which will be supplemented by a 12-week Respiratory Muscles Training Program (RMTP) with ORYGEN Dual® device for 20 minutes. Patients will be instructed to maintain adequate inspiration and expiration while using the Origen-Dual® valve at a rate of 15-20 breaths/minute. Participants will be performed five sets of 10 repetitions followed by 1-2 minutes of unloaded recovery breathing off the device, once a day, 2 days per week, for 12 weeks. The respiratory muscles training will be begun at 30% of MIP achieved at baseline and increased by 5% each week to reach 60% of the baseline assessment MIP.
223815216|NCT02104492|OTHER|Active Comparator|Every session will be comprised of 30 minutes of progressive aerobic training program followed by peripheric resistive muscle training program and Health Education Program.
223815217|NCT03265106|BIOLOGICAL|BinD19|Autologous T cells purified from the peripheral blood mononuclear cells of subjects, transduced with TCR- ζ/4-1BB lentiviral vector, expanded in vitro and then frozen for future administration.
223815218|NCT04990869|DIETARY_SUPPLEMENT|Nicotinamide Riboside|The patients will receive 1 g of Nicotinamide Riboside or placebo orally every morning and evening for 6 weeks.
223815219|NCT04990869|DIETARY_SUPPLEMENT|Placebo|Placebo
223815220|NCT03324880|BIOLOGICAL|rhPTH (1-84)|rhPTH (1-84) SC injection.
223815221|NCT03324880|BIOLOGICAL|Placebo|Placebo QD SC injection.
223815222|NCT00652938|BIOLOGICAL|HPV Vaccine (GSK580299) Cervarix TM|IM administration
223815223|NCT00652938|BIOLOGICAL|Engerix B|IM administration
223815224|NCT05239325|BEHAVIORAL|World Cancer Day Walk|Health literacy education (cancer prevention and healthy lifestyle) and free breast, prostate, cervical cancer screening
223815225|NCT05509725|DRUG|Probiotic formulation|Participants will be asked to take 2 doses daily
223815226|NCT05509725|DRUG|Placebo|Participants will be asked to take 2 doses daily
223815227|NCT01412801|BIOLOGICAL|Group B streptococcus vaccine|Subjects receive one dose of 5 μg of each of the 3 glycoconjugates present in the Group B streptococcus vaccine.
223815228|NCT02013492|DRUG|propranolol hydrochloride|Given PO
223815229|NCT02013492|OTHER|Correlative Studies|"Correlative studies will be conducted using the following materials:~* Plasma derived from peripheral blood.~* Peripheral blood mononuclear cells (PBMC) derived from patient blood~* Tumor tissue obtained at the time of core needle biopsy at the 2 month time point.~* Paraffin-embedded tumor tissue obtained pre-therapy to make the diagnosis of metastatic disease."
223815230|NCT02573922|DRUG|oxycodone-naloxone|
223815231|NCT02573922|DRUG|Oxycodone|
223815232|NCT04837859|DRUG|Tislelizumab|age 18-60: Tislelizumab alone or in combination with AVD (depending on the PET result after 2x Tislelizumab) followed by IS-RT if PET positive resudues after the end of Tis or Tis-AVD age 60+: Tislelizumab alone or in combination with AVD (depending on the PET result after 2x Tislelizumab) followed by IS-RT for all patients
223815233|NCT00116272|DRUG|Etanercept|Pregnant women previously exposed to etanercept during the first trimester. Etanercept was not administered in this non-interventional study.
223815234|NCT04376554|DRUG|TBPM-PI-HBr|TBPM-PI-HBr (2 x 300mg tablets) PO q8h \[±1 hour\] for 10 days
223815235|NCT04376554|DRUG|amoxicillin-clavulanate|amoxicillin-clavulanate (1 × 500mg/125mg tablet) PO q8h \[±1 hour\] for 10 days
223815236|NCT05647525|DIAGNOSTIC_TEST|Perform autoimmune encephalitis titer tests|We only follow up without intervention.
223815237|NCT04859660|DRUG|Tamsulosin|Participants will be given Tamsulosin or placebo in the pre-op bay prior to surgery. Post-operatively, time to void and time to discharge from the post-anesthesia care unit will be recorded.
223815238|NCT04859660|DRUG|Placebo|Participants will be given Tamsulosin or placebo in the pre-op bay prior to surgery. Post-operatively, time to void and time to discharge from the post-anesthesia care unit will be recorded.
223815239|NCT06225102|BEHAVIORAL|Kegel Exercise|"* Before teaching Kegel exercises, it was recommended that the person empty his bladder and wear comfortable clothing.~* It was said that the person should extend his legs straight while exercising and not to contract his leg, hip and abdominal muscles and not to hold his breath while the pelvic floor muscles contract.~* The relevant muscles were told to contract for 10 seconds and then relax for 10 seconds. The person was also asked to do the exercises during daily activities.~* Exercise was implemented regularly 3 times a day (minimum 30-45 exercises) in the morning, noon and evening."
223815240|NCT04795310|DEVICE|Pulsed dye laser|"PDL (Vbeam perfecta, 595 nm, Candela Corporation, Wayland, MA) was used with energy dosages of 9-11J/cm2, pulse durations of 10ms/20ms, and 7 or 10 mm handpieces with dynamic cooling device (DCD).~IPL device (M22, Lumenis Limited, Yokneam, Israel) with integration of sapphire ChillTip system for epidermal cooling were used in the study. Three wavelength bands were configured: 560-1200 nm, 590-1200 nm, and vascular wavelength bands of 530-650nm and 900-1200nm. All the treatment handpieces had a spot size of 15mm×35mm, fluence of 9-17J/cm², pulse duration of 4.0-6.0ms and pulse delay of 20-40ms, underwent the M22 advanced optimal pulse technology (AOPT) treatment."
223815241|NCT03711630|BEHAVIORAL|Meditation|Meditation practice will be through the InsightTimer smart device application. Participants will choose what types of meditation practices they will engage in and report their time spent meditating via REDCap.
223815242|NCT00824980|DRUG|IP10.C8|IP10.C8 Gel 1%
223815243|NCT00829335|PROCEDURE|IOUS-GUIDED INTRAHEPATIC VESSEL COMPRESSION|Using the IOUS, the tumor and the level targeted for compression are identified. Than, under the IOUS guidance, the surgeon compresses bilaterally the liver at the targeted position resulting in the compression of the portal pedicle feeding the tumor previously identified. This maneuver is constantly monitored in real-time just using the same microconvex probe, and it is maintained until the surface of the targeted liver area begins to discolor, at that time the first assistant marks the discolored area with the electrocautery, and the compression is released. Once the area is demarcated, liver dissection is started under intermittent Pringle's maneuver.
223815244|NCT00871650|OTHER|Sleep data recording|After completing the screening procedures, eligible participants will sleep in the laboratory for three consecutive nights of EEG sleep studies, one waking \[18F\]-FDG PET scan, and one REM sleep PET scan according to published methods.
223815245|NCT00871650|OTHER|PET scan - waking|After completing the screening procedures, eligible participants will sleep in the laboratory for three consecutive nights of EEG sleep studies, one waking \[18F\]-FDG PET scan, and one REM sleep PET scan according to published methods.
223815246|NCT00871650|OTHER|PET scan - REM Sleep|After completing the screening procedures, eligible participants will sleep in the laboratory for three consecutive nights of EEG sleep studies, one waking \[18F\]-FDG PET scan, and one REM sleep PET scan according to published methods.
223815247|NCT00081302|BIOLOGICAL|cetuximab|
223815248|NCT00081302|DRUG|carboplatin|
223815249|NCT00081302|DRUG|paclitaxel|
223815250|NCT00081302|RADIATION|radiation therapy|
223815251|NCT01547299|DRUG|Enzalutamide|
223815252|NCT01547299|DRUG|Leuprolide|
223815253|NCT01547299|DRUG|Dutasteride|
223815254|NCT03217435|PROCEDURE|Corneal epithelial allograft|A living-related donor's epithelial flap, equal in area to the recipient's diseased cornea bed, will be created using femtosecond laser technology. This corneal epithelial allograft is then ready for transplantation on the recipient's disease eye, following removal of the recipient's scarred and diseased epithelium.
223815255|NCT03217435|PROCEDURE|Limbal conjunctival allograft|A 3- to 5- clock hour limbal-conjunctival allograft will be obtained from the living-related eye. This is then ready for transplantation on the recipient's disease eye following removal of the recipient's scarred and diseased epithelium.
223815256|NCT03217435|DEVICE|Femtosecond laser|A commercial femtosecond laser to create a particular shaped graft for transplantation
223815257|NCT03217435|DEVICE|Diamond knife|A diamond knife to create a particular shaped limbal graft for transplantation
223815258|NCT04588935|DRUG|Bisoprolol; Perindopril;|based on the results of the patient study, different drug therapy regimens for cardiovascular complications during chemotherapy will be proposed
223815259|NCT03253484|RADIATION|NAFL-treatment|non ablative fractional laser 15 40 nm promoting wound healing and reduction of scar formation
223815260|NCT04490564|DIAGNOSTIC_TEST|PD-L1 Kit|Clinical performance of PD-L1 kit in CTCs of peripheral blood and tumor tissue samples
223815261|NCT06260735|DEVICE|Trans-spinal electrical stimulation|Trans-spinal electrical stimulation (ts-ES) at T11-L1 vertebral levels with short pulses at a set frequency (30Hz).
223815262|NCT06260735|DEVICE|Electrical muscle activation|Peripheral nerve (PN) or muscle (NMES) stimulation strategy was developed for each participant to optimize stance/walk capacity based on personal needs/preferences.
223815263|NCT06260735|OTHER|Treadmill walking|Stepping on a treadmill with individually preferred speed.
223815264|NCT01339286|DRUG|atomoxetine|Atomoxetine will be titrated to optimal dose, beginning with 0.5mg/kg.d, then increasing to 1.2mg/kg.d in two weeks and maintaining for 4 weeks. If the optimal dose does not achieved, the dose can be increased further to 1.4mg/kg.d and maintained for 4 weeks.
223815265|NCT01092481|DRUG|oxaliplatin|to confirm that first 3 months of oxaliplatin in 12 cycles of modified FOLFOX-6 or 8 cycles of CAPOX treatment is not inferior to 6 months of oxaliplatin in modified FOLFOX-6 or CAPOX treatment in terms of disease free survival in patients with stage II/III colon cancer.
223815266|NCT04021186|OTHER|Prevention of hyperglycemia|Bigger focus on postoperative blood-glucose levels in order to reduce incidents of hyperglycemia and other surgical complications.
223815267|NCT02468102|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|"Treatment of deep vein thrombosis (DVT) or pulmonary embolism (PE), and prevention of recurrent DVT and PE (15 mg rivaroxaban twice daily \[bid\] for 3 weeks, then 15 mg or 20 mg once daily \[od\], tablets).~Prevention of stroke and systemic embolism with non-valvular atrial fibrillation (stroke prevention in atrial fibrillation \[SPAF\]) with one or more risk factors, prior stroke or transient ischaemic attack (20 mg rivaroxaban \[od\], tablets).~Prevention of venous thromboembolism (VTE) in patients undergoing elective hip or knee replacement surgery (recommended dose: 10 mg rivaroxaban \[od\] tablets for 35 days following hip replacement surgery and 14 days following knee replacement surgery).~Co-administered with acetylsalicylic acid (ASA) alone or with ASA plus clopidogrel or ticlopidine, for the prevention of atherothrombotic events in patients after an acute coronary syndrome (ACS) with elevated cardiac biomarkers (recommended dose 2.5 mg rivaroxaban tablets \[bid\])."
223815268|NCT02468102|DRUG|Standard of care drugs|For DVT/PE treatment and SPAF, standard of care is treatment with the most widely used vitamin K antagonist, phenprocoumon, and for the secondary prevention of ACS, standard of care is antiplatelet drug(s) such as low-dose acetylsalicylic acid, clopidogrel, dipyridamole, prasugrel, ticlopidine and ticagrelor.
223815269|NCT01576718|DRUG|Fp MDPI|"Fp MDPI is an inhalation-driven multidose dry powder inhaler (MDPI) containing fluticasone propionate (Fp) dispersed in a lactose monohydrate excipient and contained within a reservoir. A metered dose of drug is delivered to a dose cup via an air pulse activated when the cap is opened.~During the treatment period, participants were randomized to 50, 100, 200 or 400 mcg of Fp one inhalation twice a day for a total daily dose of 100, 200, 400 or 800 mcg. Study drug was administered in the morning and in the evening."
223815270|NCT01576718|OTHER|Placebo MDPI|Placebo multidose dry powder inhaler (MDPI) in the morning and evening. Placebo MDPI was provided in devices identical in appearance to Fp MDPI.
223815271|NCT01576718|DRUG|Flovent Diskus|Flovent Diskus contains the active ingredient fluticasone propionate (Fp). Flovent Diskus 250 mcg was used twice a day, once in the morning and evening, for a total daily dose of 500 mcg of Fp. This therapy was not blinded as the inhaler device was different than the MDPI used in the other treatment arms.
223815272|NCT01576718|DRUG|albuterol/salbutamol|A short-acting β2-adrenergic agonists (SABA), albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI), was provided to be used as needed for the relief of asthma symptoms during both the run-in and treatment periods (to replace the subject's current rescue medication).
223815273|NCT02521402|BIOLOGICAL|Biovance|decellularized, dehydrated human amniotic membrane
223815274|NCT01742364|DEVICE|Bioject ID Pen|Participants in this arm will receive a standard dose of BCG via the Bioject ID needle-free jet injector device (investigational administration technique).
223815275|NCT01742364|DEVICE|Needle and syringe|Participants in this arm will receive a standard dose of BCG via syringe and needle by the Mantoux technique (standard of care administration technique).
223815276|NCT02836223|DEVICE|Interdental cleaning device|Water Flosser
223815277|NCT02836223|DEVICE|Manual Tooth brush|Control
223815278|NCT04302623|BEHAVIORAL|Yoga|Upa Yoga program consisting of physical postures, breathing techniques, chanting, and meditation.
223815279|NCT00045708|DRUG|ixabepilone|Given IV
223815280|NCT00045708|OTHER|pharmacological study|Correlative studies
223815281|NCT00045708|DRUG|Anticonvulsant|Drugs that induce hepatic Metabolic enzymes
223815282|NCT05736601|DEVICE|focus motion knee brace|knee brace that captures knee motion
223815283|NCT00765297|DEVICE|fall related movement (stumble) detector|movement pattern (gait,balance) of young subjects recovery of a stumble in young subjects
223815284|NCT00765297|DEVICE|fall related movement characteristic (stumble) detector|age related gait changes influencing movement pattern different pattern to recover from a trip
223815285|NCT01899066|DRUG|Lucentis, chemotherapy|"Lucentis:0.50mg/0.05ml, intravitreal injection,monthly for the first six months.~chemotherapy:vincristine,1.5mg/m2;carboplatin,560mg/ m2;etoposide,150 mg/ m2."
223815286|NCT01899066|DRUG|chemotherapy|chemotherapy:vincristine,1.5mg/m2;carboplatin,560mg/ m2;etoposide,150 mg/ m2.
223815287|NCT00284141|DRUG|Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)|"Aflibercept 4.0 mg/kg administered intravenously (IV) over a period of at least 1 hour once every 2 weeks.~Aflibercept could be reduced by 1 dose level (to 3.0 mg/kg) or 2 dose levels (to 2.0 mg/kg) in case of uncontrolled hypertension or urinary protein \>3.5 g/24 hours. Intrapatient dose escalation was not to be permitted. Participants requiring more than 2 dose level reductions would be withdrawn from study treatment."
223815288|NCT06317519|PROCEDURE|Physical Rehabilitation|5 sessions of physical rehabilitation per week. Each session lasting 45 minutes. Overall 20 sessions = 4 weeks.
223815289|NCT06317519|DEVICE|Gait Real-time Analysis Interactive Lab|5 sessions of GRAIL assisted rehabilitation per week. Each session lasting 45 minutes. Overall 20 sessions = 4 weeks.
223815290|NCT00874653|DRUG|Levonorgestrel (Mirena, BAY86-5028)|Women using Mirena for intrauterine treatment of menorrhagia
223815291|NCT01516203|DRUG|AZD5847|Eligible subjects will be randomly assigned to receive monotherapy with one of four doses of oral AZD5847 for 14 days: 500 mg orally once daily, 500 mg orally twice daily, 1200 mg orally once daily, or 800 mg orally twice daily.
223815292|NCT01516203|DRUG|Ethambutol, isoniazid, pyrazinamide, rifampin|Eligible subjects will be randomly assigned to receive treatment with standard 4 drug anti-tuberculosis regimen: Rifafour e-275 mg tablets (75 mg isoniazid/150 mg Rifampin/275 mg Ethambutol/400 mg Pyrazinamide) orally, dosed by body weight for 14 days.
223815293|NCT01882595|OTHER|Nebulization through the tracheostomy|Each subject received two nebulization sessions under spontaneous breathing in a sitting position. The first session was performed prior to tracheostomy removal. During the first nebulization, subjects inhaled the aerosol through the tracheostomy, cuff inflated and inner cannula removed.
223815294|NCT01882595|OTHER|Nebulization through the mouth|Each subject received two nebulization sessions under spontaneous breathing in a sitting position. The second nebulization was performed when the tracheostome was totally scarred. During the second nebulization, subjects inhaled the aerosol a mouth piece and wore a nose clip.
223815295|NCT00201864|DRUG|Exemestane|25 mg orally per day
223815296|NCT00201864|DRUG|Fulvestrant|250 mg IM starting on Day 8 and then every 28 days.
223815297|NCT04203927|DRUG|Empagliflozin 25 MG|SGLT-2 inhibitor
223815298|NCT05971901|DIAGNOSTIC_TEST|BV|The use of the BV test, ordered at the discretion of the treating physician
223815299|NCT01486615|DRUG|meloset (melatonin)|3 mg melatonin tablet 1-2 hour prior surgery
223815300|NCT01486615|DRUG|stresnil ( melatonin and alprazolam)|3 mg melatonin and 0.5 mg alprazolam 1-2 hr before anesthesia
223815301|NCT01486615|DRUG|(alprax) alprazolam|0.5 mg alprazolam
223815302|NCT01486615|DRUG|placebo|similar looking placebo tablet
223815303|NCT04182230|OTHER|No intervention. This study was an evalution with no intervention.|Not an interventional study
223815304|NCT03298620|OTHER|Electric toothbrush|
223815305|NCT03298620|OTHER|Control|Manual toothbrush
223815306|NCT01616875|DRUG|Cabazitaxel + Cisplatin chemotherapy|Cabazitaxel 15mg/m2 followed by cisplatin 70mg/m2 given intravenously on day 1 of each 3 weekly cycle for 4 cycles prior to radical cystectomy.
223815307|NCT02674932|BEHAVIORAL|Identifying and Using Signature Strengths|The purpose of the intervention is to identify and focus on one's morally valued strengths and utilize them (i.e. incorporate them into coping skills) to overcome challenges. The study team member and patient will discuss each top strength and ways to use them as coping skills. The patient will identify 2-4 coping mechanisms per strength, and will write his/her strengths and self-identified coping skills on index cards.
223815308|NCT02674932|BEHAVIORAL|Identifying and Writing Down Coping Skills|The study team member and patient will discuss the importance of having coping skills to deal with stressful and difficult situations. The patient will then identify at least six coping skills and write them down on index cards.
223815309|NCT02674932|BEHAVIORAL|Treatment as Usual|The study team member and patient will discuss the importance of having coping skills to deal with stressful and difficult situations. The patient will then identify coping skills that could be helpful (but will not write them down).
223815310|NCT00002443|DRUG|Indinavir sulfate|
223815311|NCT00002443|DRUG|Zidovudine|
223815312|NCT02057601|DRUG|Levobupivacaine infiltration group|The patients in the intervention group will receive peri-surgical site infiltration before wound closure with a solution of levobupivacaine 0.5% 2mg/kg body weight with epinephrine made up to a volume of 1.5ml/kg with saline.
223815313|NCT06286553|BEHAVIORAL|Trunk exercise|Trunk stabilization exercises including the following components: (a) progressive deep abdominal muscle retraining (transversus abdominis), (b) progressive pelvic floor muscle retraining, (c) abdominal muscle strengthening exercises (rectus abdominis and obliques), (d) combination of abdominal muscle control and distal extremity movements, and (e) progressive functional exercises.
223815314|NCT06286553|BEHAVIORAL|Inspiratory Muscle Training (IMT)|Inspiratory muscle strengthening exercises using inspiratory resistance (IMT devices)
223815315|NCT06286553|BEHAVIORAL|Control Group|Participants in the Control Group will receive general management information for DRA, written instructions and a single educational exercise session for contracting the deeper abdominals and pelvic floor muscles.
223815316|NCT05514119|DRUG|Fenofibrate|160mg once daily orally for 12 weeks
223815317|NCT06066710|DRUG|Propranolol|Propranolol will be given on a titration schedule in which participants will begin with small doses of the drug and increase to a larger dosage over the course of three weeks. Propranolol will be taken for a total of 9 weeks.
223815318|NCT06066710|DEVICE|Magnetic Resonance Imaging (MRI)|Magnetic Resonance Imaging (MRI) will be performed at 3 Tesla and 7 Tesla, for both propranolol and placebo arms.
223815319|NCT06066710|DRUG|Placebo|Placebo will be given on the same schedule as the propranolol regime.
223815320|NCT00019032|BIOLOGICAL|monoclonal antibody Mik-beta-1|
223815321|NCT04382924|DRUG|NP-120 (Ifenprodil)|Ifenprodil, 20 mg TID Ifenprodil, 40 mg TID
223815322|NCT01559454|DRUG|Methadone|10-60 mg/day divided by 2-4 times a day for 6 months
223815323|NCT01559454|DRUG|Buprenorphine/naloxone|4-16 mg/day divided by 2-4 times a day for 6 months
223815324|NCT04713267|DEVICE|ISABel Bed 1|During the intervention nights (2 out of 3 experiment nights), positional therapy by means of the automated bed will be applied in order to induce a change in the sleeping position.
223815325|NCT01494155|DRUG|Capecitabine|825 mg/m2 BID orally for a total of 10 days (M-F of weeks 2 and 3)
223815326|NCT01494155|DRUG|Hydroxychloroquine|400 mg BID from study day 1 until surgery. Dosing resumed upon discharge from hospital
223815327|NCT01494155|RADIATION|Proton or Photon Radiation Therapy|Daily, beginning Week 2 for 5 consecutive days
223815328|NCT03516643|OTHER|Extracorporeal Shockwave Myocardial Revascularization|extracorporeal shockwave in ischemic area evaluated by SPECT
223815329|NCT02207725|BIOLOGICAL|Andexanet|
223815330|NCT02207725|OTHER|Placebo|
223815331|NCT01966003|DRUG|Carboplatin|Administered at an area under the concentration-time curve (AUC) 6 by IV infusion Q3W
223815332|NCT01966003|DRUG|Paclitaxel|Administered 200 mg/m² IV Q3W
223815333|NCT01966003|DRUG|ABP 215|Administered 15 mg/kg Q3W by IV infusion
223815334|NCT01966003|DRUG|Bevacizumab|Administered 15 mg/kg Q3W by IV infusion
223815335|NCT02094014|BEHAVIORAL|Normal Auditory Feedback|Participants will produce sentences under normal speaking conditions, able to hear their own speech.
223815336|NCT02094014|BEHAVIORAL|Masked Auditory Feedback|Participants will produce sentences while listening to speech-shaped noise at 85 decibels (sound pressure level) to mask ability to hear their own speech.
223815337|NCT02094014|BEHAVIORAL|Altered Auditory Feedback|Participants will produce sentences while listening to their speech shifted up one octave and delayed.
223815338|NCT05147948|BEHAVIORAL|iACT for PTSD and Chronic Pain|The participants will go through internet-based Acceptance and Commitment Therapy which mainly involves: 1) Exercises focused on developing acceptance, defusion, and mindfulness skills; 2) Identification of personal values as well as valued steps and feared situations to approach during the program 3) Written exposure exercises focusing on the traumatic memory adapted from Written exposure therapy (WET) using an ACT-based framework. The treatment is delivered on a safe internet platform. Participants have planned telephone contact with their assigned psychologist 3 times during the program and can also contact their psychologist via a message system in the platform and expect answer within 48 hours.
223815339|NCT02609321|PROCEDURE|Thoracic Paravertebral Block|Thoracic paravertebral block at T3 level with bupivacaine 0.5%, dosis 1.5mg/Kg
223815340|NCT02609321|PROCEDURE|Surgical Wound Infiltration|Surgical wound infiltration on the skin and subcutaneous tissue in surgical area with bipivacaine 0.5%, dosis 1.5mg/kg
223815341|NCT05974995|PROCEDURE|Robot-assisted surgery|Total hysterectomy with bilateral salpingo-oophorectomy and lymphnodes staging using DaVinci Xi
223815342|NCT05974995|PROCEDURE|Laparoscopic surgery|Total hysterectomy with bilateral salpingo-oophorectomy and lymph nodes staging using standard laparoscopic approach
223815343|NCT00137943|BEHAVIORAL|Full Parent communication intervention|
223815344|NCT00137943|BEHAVIORAL|Brief Parent Communication Intervention|
223815345|NCT00137943|BEHAVIORAL|Control Parent Intervention|
223815346|NCT03857568|DRUG|SHR0410|drug will be dosed repeatedly
223815347|NCT03857568|DRUG|Placebo|Placebo will be dosed repeatedly
223815348|NCT03645967|DEVICE|ReadyCleanse Cloths|ReadyCleanse cloths and the standardized cleansing procedure will be the standard-of-care for catheter care and maintenance; patients will undergo routine perineal care for a minimum of twice per day and after each incontinent episode.
223815349|NCT05719948|PROCEDURE|Flouroscopic guidance cervical medial branch radiofrequency ablation|Electromagnetic wave deposition near nerve tissue for pain management
223815350|NCT00286208|DRUG|Mifepristone, misoprostol|
223815351|NCT05673629|DRUG|Utidelone Injection in combination with AC|"The treatment group will be treated with Utidelone Injection at 30 mg/m2/d administered intravenously once daily on days 1-5 of each cycle, and Doxorubicin Injection at 50mg/m2 and Cyclophosphamide Injection at 500 mg/m2, administered intravenously respectively once daily on day 1 of each cycle. One treatment cycle has 21 days, and there are 6 cycles in total.~After the neoadjuvant therapy, all patients suitable for surgery will have the operation, and they will be evaluated pre-operatively for clinical remission according to RECIST 1.1. For patients unsuitable for surgery, they will receive other treatments according to the clinical practice at each site.~Safety evaluation will be performed 28 days after the last dose, and patients will be followed up for at least 3 years for disease recurrence."
223815352|NCT05673629|DRUG|Docetaxel Injection in combination with AC|"The control group will be treated with Docetaxel Injection at 75 mg/m2, Doxorubicin Injection at 50 mg/m2, and Cyclophosphamide Injection at 500mg/m2, administered intravenously once on day 1 of each cycle. One cycle has 21 days, and there are 6 cycles in total.~After the neoadjuvant therapy, all patients suitable for surgery will have the operation, and they will be evaluated pre-operatively for clinical remission according to RECIST 1.1. For patients unsuitable for surgery, they will receive other treatments according to the clinical practice at each site.~Safety evaluation will be performed 28 days after the last dose, and patients will be followed up for at least 3 years for disease recurrence."
223815353|NCT06262061|DRUG|Propranolol|20mg oral propranolol BID x 14 days
223815354|NCT06262061|DRUG|Placebo|Placebo pill orally BID x 14 days
223815355|NCT03484455|DEVICE|Hypothermic machine perfusion|Organ Recovery Systems LifePort® Liver Transporter (LLT) System and Vasosol® Machine Perfusion Solution
223815356|NCT03484455|DEVICE|Static cold storage|Static cold storage (standard of care)
223815357|NCT01491139|DRUG|olaparib|Given twice daily. Exposure will escalate by daily dose and duration.
223815358|NCT01491139|DRUG|cisplatin|Dose will be 35mg/m2 i.v. once weekly.
223815359|NCT01491139|RADIATION|Intensity Modulated Radiotherapy|Total dose will be 70Gy in 35 fractions over 7 weeks.
223815360|NCT00170833|DRUG|Everolimus|
223815361|NCT00632957|DIETARY_SUPPLEMENT|Omega-3 Fatty acid (with SRP or OHI)|1000mg capsules three times daily, duration 28 weeks.
223815362|NCT00632957|DIETARY_SUPPLEMENT|Placebo|corn/soybean oil capsules 1g/three times daily
223815363|NCT01105702|DRUG|Temozolomide|
223815364|NCT01105702|DRUG|Bevacizumab|
223815365|NCT01105702|DRUG|Lithium Carbonate|
223815366|NCT01105702|RADIATION|Radiation|
223815367|NCT03166475|PROCEDURE|Surgical procedures|All the extractions were performed under local anaesthesia, minimally traumatic as possible. After the extraction, each patient was treated according to the group of their allocations.
223815368|NCT00615264|DRUG|DiaPep277|1.0mg dose, administered as subcutaneous injection, on 0, 1, 3, 6, 9, 12, 15, 18 and 21 months
223815369|NCT00615264|DRUG|Placebo|Mannitol (excipient) 40 mg, administered as subcutaneous injection on 1, 3, 6, 9, 12, 15, 18 and 21 months.
223815370|NCT04256356|DIETARY_SUPPLEMENT|Feeding infants with formula milk with fermented matrix at dosage of 4.6 g per 100g of powder|Infants enrolled were fed either with formula milk with fermented matrix at double dosage or with formula milk with fermented matrix at triple dosage or with standard formula during the first 3 months of life. Breastfed infants were the reference group.
223815371|NCT04256356|DIETARY_SUPPLEMENT|Feeding infants with formula milk with fermented matrix at dosage of 6.9 g per 100g of powder|Infants enrolled were fed either with formula milk with fermented matrix at double dosage or with formula milk with fermented matrix at triple dosage or with standard formula during the first 3 months of life. Breastfed infants were the reference group.
223815372|NCT04256356|OTHER|Feeding infants with standard formula milk|Infants enrolled were fed either with formula milk with fermented matrix at double dosage or with formula milk with fermented matrix at triple dosage or with standard formula during the first 3 months of life. Breastfed infants were the reference group.
223815373|NCT04256356|OTHER|Breastfeeding infants|reference group
223815374|NCT04835714|DRUG|BI 1701963|BI 1701963
223815375|NCT04835714|DRUG|BI 3011441|BI 3011441
223815376|NCT01134601|PROCEDURE|Radiation Therapy|
223815377|NCT01134601|DRUG|Capecitabine|
223815378|NCT01134601|DRUG|AZD6244|
223815379|NCT03725839|DEVICE|F&P Interface|F\&P Interface to be used for OSA therapy
223815380|NCT00577018|DRUG|Prucalopride|4 mg o.d.
223815381|NCT00577018|DRUG|Prucalopride|1 mg o.d. for 2 days, 2 mg o.d. for 2 days and 4 mg o.d. thereafter
223815382|NCT00577018|OTHER|Placebo|o.d.
223815383|NCT03767270|BIOLOGICAL|MRT5201|Codon-optimized human ornithine transcarbamylase messenger ribonucleic acid with lipid-based nanoparticles
223815384|NCT03767270|OTHER|Placebo|5% dextrose in water
223815385|NCT00005625|DRUG|trabectedin|
223815386|NCT04396041|DEVICE|Microvascular Plug (MVP)|Patient's Pulmonary AVM(s) treated via transcatheter embolization with Microvascular Plugs.
223815387|NCT04396041|DEVICE|Amplatzer Vascular Plug (AVP)|Patient's Pulmonary AVM(s) treated via transcatheter embolization with Amplatzer Vascular Plugs.
223815388|NCT04396041|DEVICE|Detachable coils|Patient's Pulmonary AVM(s) treated via transcatheter embolization with detachable coils.
223815389|NCT04492358|DRUG|Colchicine|Colchicine: ideal dose of 0.3 mg/kg/day (or the dose that approximates that adjusted for age, weight and kidney function, and 0.5 mg and 1 mg tablets)
223815390|NCT04492358|DRUG|Prednisone tablet|Prednisone 60 mg/day, in a single dose, during 3 days
223815391|NCT04492358|DRUG|standard of care|The standard treatment used in each site will be administered to the patients assigned to the control group.
223815392|NCT01489644|DRUG|repaglinide|Subjects will receive 850 mg metformin alone on a fasting state, 2 mg repaglinide alone on a fasting state, 2 mg repaglinide/850 mg metformin (NN4440 2/850) in the fasting state or 2 mg repaglinide/850 mg metformin (NN4440 2/850) immediately prior to a standardised high fat meal on 4 separate dosing visits in varying order
223815393|NCT01489644|DRUG|metformin|Subjects will receive 850 mg metformin alone on a fasting state, 2 mg repaglinide alone on a fasting state, 2 mg repaglinide/850 mg metformin (NN4440 2/850) in the fasting state or 2 mg repaglinide/850 mg metformin (NN4440 2/850) immediately prior to a standardised high fat meal on 4 separate dosing visits in varying order
223815394|NCT01489644|DRUG|repaglinide and metformin combination tablet|Subjects will receive 850 mg metformin alone on a fasting state, 2 mg repaglinide alone on a fasting state, 2 mg repaglinide/850 mg metformin (NN4440 2/850) in the fasting state or 2 mg repaglinide/850 mg metformin (NN4440 2/850) immediately prior to a standardised high fat meal on 4 separate dosing visits in varying order
223815395|NCT03841955|DEVICE|PICC with high pressure tolerance|Subjects signed informed consent, meet the inclusion criteria and did not meet the exclusion criteria, and were randomly admitted to the experimental group and given the intervention.
223815396|NCT03841955|DEVICE|rontine central venous catheter|Subjects signed informed consent, meet the inclusion criteria and did not meet the exclusion criteria, and were randomly admitted to the control group and given the intervention.
223815397|NCT05087914|DRUG|Carbidopa-Levodopa (100mg/25mg):|Participants will take 2 capsules (one containing naproxen, and the other containing either placebo or carbidopa/levodopa) 3 times per day (TID) for 5 days, the first dose is given right after the surgical procedure.
223815398|NCT05087914|DRUG|Naproxen|Participants will take 2 capsules (one containing naproxen, and the other containing either placebo or carbidopa/levodopa) 3 times per day (TID) for 5 days, the first dose is given right after the surgical procedure.
223815399|NCT03569696|BIOLOGICAL|nivolumab|The treatment phase will begin 10 ± 2 weeks from completion of R- anthracycline based therapy. Cycle 1 day 1 will occur within 72 hours from enrolment. Study treatment will be continued until nivolumab discontinuation due to disease progression, unacceptable toxicity or completion of 2 years or 30 doses of therapy. Study drug nivolumab will be administered intravenously every 2 weeks as described in the investigator brochure (IB) in a dose of 240mg over 30 minutes 46 for 8 cycles and then 480mg every 4 weeks for two years (cycle 9-30)to a maximum of 30 doses whichever comes first.
223815400|NCT02986490|BIOLOGICAL|Blood sample|Blood sample
223815401|NCT02105805|BEHAVIORAL|Dietetic group sessions|Group sessions to improve dietary adherence
223815402|NCT03015506|OTHER|Bread|
223815403|NCT02612480|DRUG|ticagrelor|7 day treatment of ticagrelor 2dd90mg after a loading dose of 180mg
223815404|NCT02612480|DRUG|Clopidogrel|7 day treatment of clopidogrel 1d75mg after a loading dose of 300mg
223815405|NCT02612480|DRUG|Acetylsalicylic acid lysinate|7 day treatment of acetylsalicyclic acid 1d80mg after a loading dose of 160mg
223815406|NCT02612480|DRUG|Placebo|7 day treatment with placebo
223815407|NCT04775238|OTHER|Silver nanoparticles|AgNPs (19±5 nm)
223815408|NCT04775238|OTHER|Copper nanoparticles|CuNPs (150-350 nm)
223815409|NCT04219098|PROCEDURE|Butterfly IQ|10ml of solution with .5cc (or one drop) sterile methylene blue will be injected intra-articularly under ultrasound guidance after a sterile prep. The remaining 20ml will be injected into the periarticular tissues after prosthesis implantation before closure.
223815410|NCT04219098|OTHER|Standard of Care|The entire volume will be injected into the periarticular tissues after prosthesis implantation before closure.
223815411|NCT03154281|DRUG|niraparib|Niraparib 100 mg will be administered orally once daily continuously. Niraparib will be administered as a flat-fixed dose (100mg, 200 mg, or 300 mg daily) depending on the cohort the patient is enrolled to, and not by body weight or body surface area. Each dose should be swallowed whole without chewing. The consumption of water is permissible. Patients should take doses at approximately the same times each day, and record this information in the patient diary. Patients will be provided with a diary in which to record their intake of study drug. However, the actual number of doses taken by the patient must be calculated from the number of tablets dispensed and returned.
223815412|NCT03154281|DRUG|everolimus|Everolimus 5 mg tablets will be used. Everolimus will be self-administered orally on a daily basis and doses will either be 5 mg (1 tablet) thrice weekly or 5 mg daily depending on the cohort the patient is enrolled to. Each cycle will be 28 days; everolimus will be taken continuously with no rest between cycles.
223815413|NCT00032045|BIOLOGICAL|gp100 antigen|
223815414|NCT00032045|BIOLOGICAL|incomplete Freund's adjuvant|
223815415|NCT00032045|BIOLOGICAL|ipilimumab|
223815416|NCT04415151|DRUG|Tofacitinib 10 mg|Tofacitinib will be administered in a dose of 10 mg twice daily by mouth (PO BID) until return to their clinical baseline (as defined by supplementary oxygen requirement), and then will continue to be administered at 5 mg PO BID for a total treatment duration of 14 days.
223815417|NCT04415151|DRUG|Placebo|Matching placebo tablets will be administered.
223815418|NCT03600896|DRUG|CYT107|"Phase I: Patients will be treated with CYT107 post CBT (from 60 to 180 days), in with 1 of 3 doses below:~* 5 mcg/kg/dose for 3 doses~* 10 mcg/kg/dose for 3 doses~* 20 mcg/kg/dose for 3 doses~The optimal recommended dose determined in Phase I will be used to treat all patient enrolled in Phase II."
223815419|NCT02732626|PROCEDURE|radiofrequency ablation|
223815420|NCT05414097|OTHER|Semi-structured focus group discussions - Women|Semi-structured focus group discussions to explore women's experiences with cervical cancer screening and treatment.
223815421|NCT05414097|OTHER|semi-structured focus groups discussions - Men|Semi-structured focus group discussions to explore partner dynamics related to women's ability to access cancer screening.
223815422|NCT05414097|OTHER|In-depth key stakeholders interviews|In-depth interviews to contextualise findings from women and men focus group discussions.
223815423|NCT05414097|OTHER|Discrete Choice Experiment - Women|Discrete Choice Experiment to determine preferences to different cancer screening models.
223815424|NCT05414097|OTHER|Development and User Pre-testing Workshops|Development and User Pre-testing Workshops to explore acceptability and feasibility of proposed interventions designed using findings from Phases 1 \&2.
223815425|NCT03237520|OTHER|Virtual Reality Therapy|VRT software and device is developed in collaboration with IIT Delhi using Kinect system. Kinect- motion sensor and computer set up is required. VRT (CIMT in a virtual environment)will be provided for 2 hours at every visit(twice weekly for first 4 weeks, once a week for next 4 weeks). VRT will be provided only during scheduled visits with the same principle as mCIMT. Functional activities like repetition of the tasks and shaping will be performed with the affected hand using VRT and CIMT while the unaffected arm is restrained
223815426|NCT03237520|OTHER|mCIMT|Modified constraint induced movement therapy will be provided to all children according to predefined protocol.
223815427|NCT03046511|DRUG|Cefazolin|A post- procedure administration of Cefazolin will be compared with a pre-operative intravenous dose
223815428|NCT01310309|DEVICE|Coronary artery placement of a drug-eluting stent|Coronary artery placement of a drug-eluting stent (XIENCE V® EECSS)
223815429|NCT01581697|DIETARY_SUPPLEMENT|Oat bran|
223815430|NCT03360877|OTHER|Health-care associated infection (HCAI)|Cleaning of the child with soap and water administered by the child's accompanying person in a structure or - a cleaning of the child with chlorhexidine gluconate administered by the child's accompanying person in the other structure
223815431|NCT02150837|OTHER|5 & 2 & 2 Plan|Medifast has developed the 5 \& 2 \& 2 Plan as a higher calorie and higher carbohydrate alternative. This plan may be selected for very obese (BMI ≥ 40kg/m2) or older (\>65 years) individuals, or for medical (e.g., diabetes) or behavioral reasons (individuals engages in high levels of physical activity). The 5 \& 2 \& 2 Plan consists of 5 Medifast meal replacements, 2 Lean \& Green meals, and 2 healthy snacks and provides 1,200-1,400 kcal, \>72g protein, \>100g of carbohydrate, and \<30% of calories from fat. The Lean \& Green meal is consumer selected and consists of 5-7 ounces of a lean protein, 1 ½ - 3 cups of non-starchy vegetables, and up to 2 healthy fat servings. The healthy snack(s) included in this plans consists of a consumer selected serving of grain/starch, dairy, or fruit.
223815432|NCT02150837|OTHER|4 & 2 & 1 Plan|Medifast has developed the 4 \& 2 \& 1 Plan as a higher calorie and higher carbohydrate alternative. This plan may be selected for very obese (BMI ≥ 40kg/m2) or older (\>65 years) individuals, or for medical (e.g., diabetes) or behavioral reasons (individuals engages in high levels of physical activity). The 4 \& 2 \& 1 Plan consists of 4 Medifast meal replacements, 2 Lean \& Green meals, and 1 healthy snack, providing 1,000-1,200 kcal, \>72g protein, \>100g carbohydrate, and \<30% of calories from fat. The Lean \& Green meal is consumer selected and consists of 5-7 ounces of a lean protein, 1 ½ - 3 cups of non-starchy vegetables, and up to 2 healthy fat servings. The healthy snack included in this plans consist of a consumer selected serving of grain/starch, dairy, or fruit.
223815433|NCT00460720|OTHER|Observational treatment compliance survey|Observational treatment compliance survey
223815434|NCT02922790|BEHAVIORAL|standard health information|Subjects will review standard health information
223815435|NCT02922790|BEHAVIORAL|standard health information plus info. on DNA damage|Subjects will review standard health information and information on DNA damage
223815436|NCT02922790|BEHAVIORAL|Subjects will review standard health information and information on DNA damage, plus pictures of their DNA damage|Subjects will review standard health information and information on DNA damage, as well as review pictures of their cells' DNA damage
223815437|NCT02478021|OTHER|Hydrocortisone|Effects of hydrocortisone compared to placebo on cognition
223815438|NCT06399367|DIAGNOSTIC_TEST|MSOT|The MSOT system used consists of a laser in the visible near-infrared and far-infrared wavelength range (660nm-1300nm) and an ultrasonic sensor connected to a computer. Using optical components, the area to be measured is illuminated with ultra-short light pulses of selectable wavelength. The light is absorbed to varying degrees inside the object - depending on the properties of the tissue. The absorption of light leads to local microscopic volume fluctuations and thereby emits pressure waves in the ultrasonic range (photoacoustic effect). MSOT enables non-invasive, non-ionizing 2D imaging with high spatial resolution (80 μm), which enables specific visualization of endogenous tissue pigments such as collagen fibers, fat, melanin, oxyhemoglobin and deoxyhemoglobin.
223815439|NCT03365986|DIAGNOSTIC_TEST|genetic screening|Patients receive genetic test to see whether they have germline cancer susceptibility gene mutations
223815440|NCT02459249|OTHER|Healthy Lifestyle|A physician and a nutritionist will be give recommendations for diet and exercise emphasizing the importance of a healthy lifestyle (suggesting moderate-intensity activity at least 150 minutes/week and to eat less sodium, fat, sugar, portions and calories). Verbal and written individualized recommendations from trained professionals (nutritionists, and physician) will be provided. Monthly sessions of at least 30 minutes covering diet, exercise, and behavior modifications were held. The first was a one-to-one meeting and was followed by group sessions based on behavioral counseling
223815441|NCT02459249|OTHER|Placebo Comparator (Treatment of Mexican Health Minister)|General and unspecific recommendations of diet and physical activity for the metabolic syndrome treatment, given for a physician
223815442|NCT00335686|DRUG|Lopinavir-rtv (Kaletra): 3 capsules (600 mg)/12 h|Lopinavir-rtv (Kaletra): 3 capsules (600 mg)/12 h
223815443|NCT00335686|DRUG|Nevirapine (Viramune): 1 comp (200mg)/12h|Nevirapine (Viramune): 1 comp (200mg)/12h
223815444|NCT02080195|DRUG|Cyclophosphamide|14.5 mg/kg/day on Days -6 and -5. 50 mg/kg/day on Days 3 and 4.
223815445|NCT02080195|DRUG|Fludarabine|30 mg/m\^2/day on Days -6 through -2.
223815446|NCT02080195|DRUG|Tacrolimus|Starting on Day 5. Dose will be adjusted according to blood levels.
223815447|NCT02080195|DRUG|Mycophenolate Mofetil|15 mg/kg three times per day from Day 5 to Day 35.
223815448|NCT02080195|DRUG|Rabbit antithymocyte globulin|0.5 mg/kg on Day -9. 2 mg/kg/day on Days -8 and -7.
223815449|NCT02080195|RADIATION|Total body irradiation|200 centigray on Day -1.
223815450|NCT02080195|BIOLOGICAL|Allogeneic bone marrow transplant|Infusion on Day 0.
223815451|NCT02601898|DEVICE|Lipoic acid|Vaginal capsules (medical device) containing 10 mg of lipoic acid (1 per day)
223815452|NCT02601898|DRUG|Progesterone|Vaginal capsules (drug) containing 200 mg of progesterone (2 per day)
223815453|NCT02211534|DEVICE|Pulsed Electromagnetic Field Device (Provant)|The PEMF device delivers non-thermal, non-ionizing pulsed electromagnetic energy to the target tissue, using 27.12 megahertz pulses lasting 42 microseconds and delivered 1000 times per second. The system generates an electromagnetic field that is continuously monitored and regulated to ensure consistent dosing. The therapeutic electromagnetic field is delivered by means of an applicator pad that is placed against the treatment site. The active and sham devices will be identical in appearance and all other physical characteristics in order to maintain the masking of the treatment.
223815454|NCT02211534|DEVICE|Sham Pulsed Electromagnetic Field Device|The Sham device will be identical in appearance, physical characteristics and operation to the Active device.
223815455|NCT00638235|DEVICE|AMS Apogee™ with IntePro|Mesh implant for posterior wall pelvic organ prolapse
223815456|NCT00638235|DEVICE|AMS Apogee™ with Intexen LP|Graft implant for posterior wall pelvic organ prolapse
223815457|NCT00638235|DEVICE|AMS Perigee™ with IntePro|Mesh implant for anterior wall pelvic organ prolapse
223815458|NCT00638235|DEVICE|AMS Perigee™ with IntePro Lite|Mesh implant for anterior wall pelvic organ prolapse
223815459|NCT00638235|DEVICE|AMS Apogee™ with IntePro Lite|Mesh implant for posterior wall pelvic organ prolapse
223815460|NCT00638235|DEVICE|AMS Elevate™ Apical & Posteiror with IntePro Lite|Mesh implant for apical and posterior wall pelvic organ prolapse
223815461|NCT00638235|DEVICE|AMS Elevate™ Apical & Posteiror with IntXen LP|Graft implant for apical and posterior wall pelvic organ prolapse
223815462|NCT00638235|DEVICE|AMS Elevate™ Anterior & Apical with IntePro Lite (Gen 1, For Study Use Only)|Mesh implant for anteiror and apical wall pelvic organ prolapse
223815463|NCT00638235|DEVICE|AMS Elevate™ Anterior & Apical with IntePro Lite (Gen 2)|Mesh implant for anteiror and apical wall pelvic organ prolapse
223815464|NCT02560935|DRUG|Hydroxyurea (Moderate Dose)|The study intervention will include moderate dose hydroxyurea therapy at 20 mg/kg/day (range 17.5 - 26 mg/kg/day) for 36 months.
223815465|NCT02560935|DRUG|Hydroxyurea (Low Dose)|The study intervention will include random allocation to low dose hydroxyurea therapy at 10 mg/kg/day (range 7 - 15 mg/kg/day) for 36 months.
223815466|NCT02608905|DRUG|Dapagliflozin|Patients with Type 2 diabetes will be randomized to receive dapagliflozin 5 mg daily for 2 weeks followed by10 mg daily for 10 weeks by mouth or matching placebo for 12 weeks. All subjects will receive measurements of fasting plasma glucose, Free Fatty Acids, inflammatory markers and adipocytokines, monocyte inflammation, as well as ultrasound assessment of flow-mediated dilatation (FMD) of the brachial artery at baseline and after 12 weeks of drug treatment with either dapagliflozin or placebo.
223815467|NCT02608905|DRUG|Placebo|Patients with Type 2 diabetes will be randomized to receive dapagliflozin 5 mg daily for 2 weeks followed by10 mg daily for 10 weeks by mouth or matching placebo for 12 weeks. All subjects will receive measurements of fasting plasma glucose, Free Fatty Acids, inflammatory markers and adipocytokines, monocyte inflammation, as well as ultrasound assessment of flow-mediated dilatation (FMD) of the brachial artery at baseline and after 12 weeks of drug treatment with either dapagliflozin or placebo.
223815468|NCT00328640|DRUG|Optimal treatment|
223815469|NCT03505476|DEVICE|Entac Medical device application|Subjects will wear a 3-inch by 3-inch stethoscope device that adheres to the skin of the abdomen via FDA approved adhesive material. It will be applied either in the operating room at the completion of surgery or in the recovery room. The device will remain on the abdomen until discharge or for 10 days, whichever comes first.
223815470|NCT03505476|OTHER|Patient Daily Assessment|The research team will ask questions of the subject regarding nausea, vomiting, passage of flatus, return of bowel function, and satisfaction with the device every day that the subject is hospitalized.
223815471|NCT03505476|OTHER|Patient Discharge Assessment|The research team will ask questions of the subject regarding satisfaction or dissatisfaction with having the device placed and attached to their abdomen.
223815472|NCT01427192|DRUG|acetazolamide|250 mg bid
223815473|NCT01427192|OTHER|Supplemental oxygen|Oxygen deliverded by nasal cannula
223815474|NCT01427192|PROCEDURE|Non-invasive ventilation|Bi-level non-invasive ventilation via nasal mask
223815475|NCT01427192|OTHER|Room air|Room air applied via sham oxygen concentrator
223815476|NCT01427192|DRUG|Placebo tablet|Placebo tablet (Mannitol) similar to acetazolamide
223815477|NCT02714101|OTHER|Equine assisted occupational therapy|Intervention was one 40 to 60 minute session per week. Half of the session was spent riding a horse and half was spent doing horse related activities. Children had 9 to 12 sessions
223815478|NCT01295567|DRUG|Dipyridamole|prior to CABG surgery 3 day treatment with dipyridamole 200mg SR twice daily
223815479|NCT01295567|DRUG|placebo|prior to CABG surgery 3 day treatment with placebo capsules twice daily
223815480|NCT03533634|PROCEDURE|Open Reduction Internal Fixation superior plate|3.5mm superior reconstruction plate
223815481|NCT03533634|PROCEDURE|Open Reduction Internal Fixation anteroinferior plate|3.5mm anteroinferior reconstruction plate
223815482|NCT05019274|OTHER|Culinary Medicine Intervention|Participants randomized to the Culinary Medicine intervention will complete a series of 6 virtual culinary medicine cooking classes (1 class per month for 6 months). Virtual sessions will be delivered via Zoom using a combination of large group instruction and small group break-out sessions in which participants prepare a recipe in their home kitchen with the virtual assistance from trained group facilitators. After preparing the dish, participants will enjoy the dish they prepared and report-back to the large group about their dish and experience. Classes will be conducted in English and Spanish with language-concordant instructors and facilitators.
223815483|NCT05019274|OTHER|Standard of Care Nutrition Visits|Participants randomized to standard of care nutrition visits will complete a series of 6 nutrition visits (1 session per month for 6 months) led by bilingual (English/Spanish) dieticians. Sessions will consist of a mix of individual and small group sessions per standard of care in the clinic.
223815484|NCT02329301|DRUG|MDA with DHAp (Eurartesim)|Eurartesim is the brand name.
223815485|NCT02329301|DRUG|Focal MDA with DHAp (Eurartesim)|Eurartesim is the brand name.
223815486|NCT05817578|DEVICE|Quantitative Sensory Testing / Dynamometry / Goniometry|Testing procedures that follow previously used protocols of the literature for all the Quantitative Sensory Testing, Dynamometry \& Goniometry
223815487|NCT04261660|OTHER|NO intervention|NO INTERVENTION
223815488|NCT00596596|DRUG|prucalopride|0,5 mg once daily
223815489|NCT00596596|DRUG|prucalopride|1 mg once daily
223815490|NCT00596596|DRUG|2 mg prucalopride|2 mg once daily
223815491|NCT00596596|DRUG|4 mg prucalopride|4 mg once daily
223815492|NCT00596596|OTHER|Placebo|placebo once daily
223815493|NCT04446715|DRUG|sufentanil|Patients will receive sufentanil in spinal anesthesia
223815494|NCT04446715|DRUG|meperidine|Patients will receive meperidine in spinal anesthesia
223815495|NCT04446715|DRUG|Bupivacaine|Patients will receive 0.5% heavy bupivacaine in spinal anesthesia
223815496|NCT00099593|BIOLOGICAL|Autologous Dendritic Cell Vaccine|
223815497|NCT03155230|OTHER|no intervention|no intervention
223815498|NCT03717662|DRUG|nicotine gum or nicotine patch|The project will provide intensive counseling at the Centre for Health Promotion (CHP) of HKU Department of Nursing Studies, female smokers who require more intensive counseling or advice on nicotine replacement therapy, upon referral from the women's organizations and trained women counselors. The smokers will receive face-to-face (or telephone) counseling and a 1 week supply of Nicotine replacement therapy (NRT) (4 mg nicotine gum or 10 mg/ 15 mg nicotine patch) from the nurse counselor, and follow up calls at 1 week, 1-, 3-, 6-, 36- and 72-month post-intervention.
223815499|NCT04731415|DEVICE|Optical coherence tomography and optical coherence tomography angiography (Optovue®)|"Optical coherence tomography and optical coherence tomography angiography (Optovue®) were performed in each trimesters and at 6 weeks after childbirth.~1. st trimester : gestational age 8-12 weeks~2. nd trimester : gestational age 24-28 weeks~3. rd trimester : gestational age 34-38 weeks"
223815500|NCT05688735|OTHER|Isosorbide Diester Moisturizer|Isosorbide Diesters (with 0.1% colloidal oatmeal) + Topical Hydrocortisone 2.5% ointment
223815501|NCT05688735|OTHER|Control Moisturizer|Topical vehicle (with 0.1% colloidal oatmeal) + Topical Hydrocortisone 2.5 % ointment
223815502|NCT01336881|GENETIC|RNA analysis|
223815503|NCT01336881|GENETIC|gene expression analysis|
223815504|NCT01336881|GENETIC|microarray analysis|
223815505|NCT01336881|GENETIC|nucleic acid sequencing|
223815506|NCT01336881|OTHER|diagnostic laboratory biomarker analysis|
223815507|NCT03784092|OTHER|feedback|feedback by electronic pedometers regarding patient mobility while undergoing labor induction
223815508|NCT03353259|COMBINATION_PRODUCT|Tranexamic acid and Tocilizumab|The first intervention is Tranexamic acid, The second intervention is Tocilizumab
223815509|NCT02815787|DRUG|SP2086|In the A sequence Glyburide was taken at 5mg qd dose on Days1,4,5,6,7 and 8; SP2086 will be administered orally (by mouth) as 200mg on Days 8.In the B sequence was that SP2086 was taken at 200mg qd dose on Days1,4,5,6,7 and 8;Glyburide will be administered orally (by mouth) as 200mg on Days 8.
223815510|NCT02815787|DRUG|Glyburide|In the A sequence Glyburide was taken at 5mg qd dose on Days1,4,5,6,7 and 8; SP2086 will be administered orally (by mouth) as 200mg on Days 8.In the B sequence was that SP2086 was taken at 200mg qd dose on Days1,4,5,6,7 and 8;Glyburide will be administered orally (by mouth) as 200mg on Days 8.
223815511|NCT01488708|DRUG|LY2127399|120 mg LY2127399 administered via subcutaneous (SC) injection for 216 weeks Participants randomized to active treatment in the core studies will remain on the same active dose. In order to ensure that the original randomization arm from the preceding core studies is not unblinded, the first dose in BCDX will be blinded, with all participants receiving 2 injections of blinded study drug.
223815512|NCT01488708|DRUG|Placebo|Placebo administered via SC injection at first dose to maintain blinding of previous study treatment.
223815513|NCT03146832|BEHAVIORAL|Exposure therapy (according to habituation approach)|Exposure instruction focuses on fear reduction during exposure sessions
223815514|NCT03146832|BEHAVIORAL|Exposure therapy (according to inhibitory learning approach)|Exposure instruction focuses on expectation violation during exposure sessions
223815515|NCT04501289|DRUG|Low dose magnesium sulphate|Participants in this arm will receive 4g of 20% intravenous (I.V.) MgSO4 (Magphate®) given over 10 minutes, followed by 3g of 50% intramuscular (I.M.) MgSO4 in each buttock statim. Then, maintenance doses will be given as 2.5g of 50% MgSO4 administered intramuscularly 4 hourly for 24 hours, for participants with severe preeclampsia and for 24 hours post delivery or post last seizure episode, whichever occurs last, for cohorts with eclampsia.
223815516|NCT04501289|DRUG|Pritchard regimen|Participants in this arm will receive loading dose as 4g of 20% MgSO4 I.V. over 10 minutes, followed by 5g of 50% MgSO4 I.M. in each buttock. Maintenance doses will be given as 5g of 50% MgSO4 I.M. 4 hourly in alternate buttock until 24 hours for patients with eclampsia and for 24 hours after delivery or after last fit, whichever occurs later, for cohorts with eclampsia.
223815517|NCT00175968|PROCEDURE|bed rest, hypocaloric nutrition|
223815518|NCT00389181|PROCEDURE|Interventional therapy|All interventional procedures are standard of care for the treatment of AVMs. They are not experimental. A patient randomized to interventional therapy is expected to begin interventional therapy within 3 months following randomization. Interventional therapy consists of endovascular attempts at occlusion of the nidus and feeding vessels, coiling or microsurgery for feeding artery aneurysms, microsurgery for BAVM itself, and radiosurgery, these alone or in various combinations and timings.
223815519|NCT00389181|OTHER|Medical management|Patients participating in the trial will receive the best medical management possible for the disorder being tested in the trial and for any general medical illnesses they are demonstrated to have. One important consideration in the medical management of patients in this trial is stroke risk factor reduction.
223815520|NCT04219618|DEVICE|Off-Pump|After a standard median sternotomy, pericardium will be divided to expose the heart and major vessels, and the aortic cannulation sutures will be placed. Pyramid positioner will be applied to the apex of the heart, and the heart will be manually elevated upward. The inflow cannula placement location and placement of the sewing ring will be done with pledged sutures. The LV diaphragmatic site coring will be completed, and immediate LV digital exploration will be accomplished. The LVAD inflow cannula will be inserted through the sewing ring into the LV cavity. Upon completing proper LVAD inflow cannula placement into the LV and securing it in position, the heart will be dropped into the pericardial cavity with the outflow graft elevated for LVAD and outflow graft de-airing and to prevent potential later air embolization. A partial occlusion clamp will be placed on the ascending aorta and appropriately trimmed outflow graft will be sewn to the aorta.
223815521|NCT04219618|DEVICE|On-Pump|A standard median sternotomy incision will be performed and pericardium divided to expose the heart and major vessels. Cannulation will be done through the aorta and the right atrium and the patient will be put on cardiopulmonary bypass (CPB). The patient's heart will be freed from the surrounding tissues. With a cylindrical blade, the surgeon will excise a core of myocardium from the apex. The LVAD sewing ring will then be sutured to the margins of the apical hole. The LVAD will be inserted into the LV cavity through the sewing ring. The outflow graft will be measured for the anastomosis into the aortic root. Partial occlusion clamp will be placed on the aortic root and the anastomosis will be performed. De-airing will be performed and the LVAD will be started. The patient will then be weaned from CPB and decannulated.
223815522|NCT04671043|DIETARY_SUPPLEMENT|Caffeine and glucose|Caffeine and glucose powder dissolved in water
223815523|NCT04671043|DIETARY_SUPPLEMENT|Glucose alone|Glucose powder dissolved in water
223815524|NCT04671043|DIETARY_SUPPLEMENT|Placebo|Artificial sweetener dissolved in water
223815525|NCT06013501|BEHAVIORAL|puppet show|puppet show to the child before and during subcutaneous application
223815526|NCT00873665|OTHER|aerobic exercise|To determine the effects of supervised aerobic exercise training versus usual care on incidence of ED among men undergoing radical prostatectomy for clinically localized prostate cancer.
223815527|NCT00873665|OTHER|wait-list control|To determine the effects of aerobic exercise training versus wait-list control on changes in patient symptoms (i.e., erectile function score, sexual functioning, urinary incontinence, and QOL) and the number of men receiving phosphodiesterases type-5 (PDE-5) inhibitor therapy as well as therapy dose.
223815528|NCT04609124|DIAGNOSTIC_TEST|Abdominal ultrasound evaluation of antral area|ultrasound assessment of antral cross sectional area
223815529|NCT02228395|DRUG|PF-04958242|Administered as specified in treatment arm
223815530|NCT02228395|DRUG|Placebo|Administered as specified in treatment arm
223815531|NCT00659984|DRUG|UltratraceTM Iobenguane I 131 Imaging|0.1 mCi/kg \[3.7 MBq/kg\] (minimum dose 1mCi \[37MBq\] but not to exceed 5 mCi \[185 MBq\]) of UltratraceTM Iobenguane I 131 given 7 -28 days before therapeutic dose administration on day 0. Thyroid protection will be administered per institutional protocol for I-131-MIBG however, thyroid blocking must be started prior to the Ultratrace imaging dose. Anterior and posterior whole body images will be taken to assess organ distribution, tumor uptake and dosimetry calculations.
223815532|NCT00659984|DRUG|UltratraceTM Iobenguane I 131 Therapy|Therapeutic dose will be given on Day 0 if dosimetry scans showed that the prescribed or adjusted dose will not exceed \> 23 Gy to the kidneys, \> 30 Gy to the liver, or \> 15 Gy to the lungs. and tumor uptake confirmed with UltratraceTM imaging dose. Only one treatment course of therapeutic UltratraceTM will be given in this study.
223815533|NCT00570024|PROCEDURE|Traditional Acupuncture|In Traditional acupuncture (TA), in which eight acupuncture points are selected, subjects will undergo three 30-minute sessions weekly for 12 weeks. Disposable acupuncture needles (1-1.5 inch sterilized stainless steel)will be inserted up to one inch deep through a plastic needle tube that is secured with adhesive tape to the skin.
223815534|NCT00570024|PROCEDURE|AA|In Traditional acupuncture (TA), in which eight acupuncture points are selected, subjects will undergo three 30-minute sessions weekly for 12 weeks. Disposable acupuncture needles (1-1.5 inch sterilized stainless steel)will be inserted up to one inch deep through a plastic needle tube that is secured with adhesive tape to the skin.
223815535|NCT06001502|DEVICE|Virtual Reality distraction therapy|The VR device simulates a 3-dimensional virtual enviroment, seeking to immerse the user in virtual surroundings
223815536|NCT03767725|BIOLOGICAL|Treatment|Phase 1 Clinical Study of The patients undergo leukapheresis. The patients then receive fludarabine and cyclophosphamide on days-5 to-3. Subjects will receive (0.6-60)x10E8 transduced CART cells as a split dose over three days as follows: Day 0, 10% fraction: (0.06-6)x10E8 CART19 cells, Day 1, 30% fraction: (0.18-18)x10E8 CART19 cells, Day 2, 60% fraction: (0.36-36)x10E8 CART cells.
223815537|NCT06019689|BEHAVIORAL|CAMI|Culturally Adapted manual-assisted problem solving training based Mobile Intervention (CAMI) for Suicidal Ideation. CMAP is a manual-assisted intervention which has been adapted from a self-help guide called Life After Self-Harm based on the principles of Cognitive behavioral therapy (CBT). This intervention is an evaluation of suicidal ideation, crisis skills, problem-solving and CBT techniques to manage emotions, negative thinking, interpersonal relationships and relapse prevention strategies.
223815538|NCT01313611|DRUG|Rituximab + bendamustine|Induction phase: rituximab and bendamustine on Day 1, Bendamustine on Day 2, Rituximab on Day 8, Rituximab on Day 15, Rituximab on Day 22, bendamustine on Day 29, Bendamustine on Day 30
223815539|NCT05157659|DIAGNOSTIC_TEST|[18F]F-AraG PET-scan|\[18F\]F-AraG PET scans are performed to assess the accumulation of activated T-cells in the tumour and healthy tissue.
223815540|NCT06025630|DRUG|TUDCA|Endoplasmic reticulum stress will be inhibited by chronic (8 weeks) oral ingestion of the dietary supplement tauroursodeoxycholic acid (TUDCA; 1,750 mg/day)
223815541|NCT06025630|DRUG|Placebo|Placebo pills containing microcrystalline cellulose will be ingested over the course of the 8 week intervention.
223815542|NCT05298176|DRUG|Afatinib, Osimertinib, Carboplatin and Pemetrexed|This study consists of 2 parts. Part 1 is defined as a first line treatment with afatinib orally (30 mg once a day) for the first 6 weeks, followed by concurrent use of afatinib (20mg once a day, part 1B) plus 2 cycles of carboplatin and pemetrexed (21 days per cycle); followed by afatinib monotherapy (30mg once a day). Part 2 comprises a 2nd line treatment with osimertinib (80 mg once daily) after failure of part 1, only in T790M positive patients for the first 6 weeks, followed by concurrent use of osimertinib (80mg once a day) plus 2 cycles of carboplatin and pemetrexed (21 days per cycle); followed by osimertinib monotherapy (80mg once a day).
223815543|NCT01945567|DEVICE|Up to 3 mA, 60 us, 130 Hz deep brain stimulation|
223815544|NCT01945567|DEVICE|Empirical unblinded deep brain stimulation programming|
223815545|NCT02426723|DRUG|Phase 1a: CWP232291|CWP232291 administered alone twice weekly every 4 weeks.
223815546|NCT02426723|DRUG|Phase 1b: CWP232291, Lenalidomide, Dexamethasone|CWP232291 administered twice weekly every 4 weeks. Lenalidomide and Dexamethasone administered per standard therapy.
223815547|NCT01300325|OTHER|3% hypertonic saline solution|Patients receive every 6 hours the nebulized 0.9% saline (Placebo comparator) (group I) or the 3% hypertonic saline solution group II) in addition to aerosolized epinephrine (1.5 mg) and to the conventional treatment (oxygen, fluids).
223815548|NCT04384822|BEHAVIORAL|Tai Chi Group|Mind-body exercise intervention
223815549|NCT04384822|BEHAVIORAL|CBT-I Group|First-line clinically recommended non-pharmacological treatment of insomnia
223815550|NCT06497400|OTHER|Brazilian Jiu Jitsu|Instruction of two classes each week for ten weeks of Brazilian Jiu Jitsu
223815551|NCT06497400|OTHER|Hatha Yoga|Instruction of two classes each week for ten weeks of Hatha Yoga
223815552|NCT06497400|OTHER|Waitlist|Participant will waitlist for 5 weeks and then be allowed to decide which intervention they want to do Group A/ Jiu Jitsu or Group B/Yoga for ten weeks..
223815553|NCT05661721|OTHER|Sweet licorice|Ecologic, vegan and gluten free, low-sodium sweet licorice pastilles made from Glycyrrhiza glabra, with a manufacturer specified content of 4% sugars, 2% glycyrrhizin and 0.03% salt, will be used as intervention. The exact glycyrrhizin content will be determined before the study begins, and participants will be instructed to consume a daily licorice dose that is equivalent to 100 mg of glycyrrhizin.
223815554|NCT05661721|OTHER|Salty licorice|A vegan and gluten free salty licorice without glycyrrhizin, flavored with ammonium chloride, with a manufacturer specified content of 0% sugars and 0.05% salt, will be used as control. The amount of salty licorice will be the same as for sweet licorice, and thus determined after the glycyrrhizin content analysis of the sweet licorice.
223815555|NCT01872637|BEHAVIORAL|Progressive Multi-Component Intervention|
223815556|NCT01872637|BEHAVIORAL|Usual Care|
223815557|NCT00069602|DEVICE|Continuous Glucose Monitoring System (CGMS)|
223815558|NCT00069602|DEVICE|GlucoWatch G2TM Biographer (GW2B)|
223815559|NCT03894150|DRUG|F0002-ADC|Every 21 days for 1 cycle, continue treatment until a maximum 16 cycles. Dose Escalating: 0.3 - 4.8 mg/kg
223815560|NCT03680664|DEVICE|Active tDCS|Excitatory bilateral stimulation to the frontal lobes, in particular the left and right DLPFC, will be applied. The anode will be placed at Fz and the cathode at Iz to achieve this bilateral frontal excitatory stimulation. Rubber electrodes will be inserted in 35-cm2 saline-soaked sponges and fixed with a headband. The direct current will be of 2 mA (current density = 0.57 A/m2) for 30 min per day.
223815561|NCT03680664|OTHER|sham tDCS|The same tDCS parameters as as the active condition will be used; however, the device will be turned off after 1 minute of active stimulation.
223815562|NCT03680664|BEHAVIORAL|MBSR|After a brief orientation session, the MBSR sessions will be conducted in 8 weekly 2.5 hour classes plus a half-day retreat. Content includes instruction and guidance to mindfulness meditation practices, gentle mindful movement, and various exercises to enhance mindfulness in everyday life. Participants will get daily at-home assignments with CDs of meditative practice.
223815563|NCT03953963|DEVICE|HydraSolve T2D™|The HydraSolve T2D™ System will be used to perform the combined minimally invasive laparoscopic and mini-laparotomy procedure to selectively extract excess intra-abdominal fat from the mesentery. All patients will receive standard nutritional counseling and their medications will be adjusted to achieve target levels of blood glucose control.
223815564|NCT03237273|OTHER|HEAD-US scoring system|HEAD-US scoring system - Ultrasound scan performed by a non-imaging specialist to assess for joint bleed or damage
223815565|NCT01971164|DRUG|JTZ-951|Subjects will receive JTZ-951 or Placebo
223815566|NCT01971164|DRUG|Placebo|
223815567|NCT00314067|PROCEDURE|Online Comprehensive Quality Management System (CQM) of alcohol-related disorders in primary care|
223815568|NCT00314067|PROCEDURE|Physician training|
223815569|NCT00314067|PROCEDURE|Practice team training|
223815570|NCT05485610|DIETARY_SUPPLEMENT|NMN intervention|NMN capsules (total of 600mg/day) for 3 months
223815571|NCT05485610|OTHER|Placebo|NMN-free placebo capsules for 3 months
223815572|NCT01694602|BIOLOGICAL|(non-radioactive) Oral deuterated 3-methylhistidine (D-3MH)|Oral dose of 9.0 mg (50 μmol) TAU-METHYL-L-HISTIDINE (METHYL-D3), Cambridge Isotope Laboratory, Cambridge, Massachusetts.
223815573|NCT05379257|COMBINATION_PRODUCT|Random dosage and time of furosemide|Random dosage and time of furosemide, using a designated app
223815574|NCT00003305|DRUG|aminopterin|
223815575|NCT00003305|DRUG|leucovorin calcium|
223815576|NCT03802864|DRUG|Liposomal Bupivacaine|After surgical sperm retrieval, the wound will be injected with liposomal bupivacaine (266 mg) mixed with standard bupivacaine (bupivacaine hydrochloride 50mg) for post-operative pain relief.
223815577|NCT03802864|DRUG|Standard Bupivacaine|After surgical sperm retrieval, the wound will be injected only with standard bupivacaine (bupivacaine hydrochloride 100mg) for post-operative pain relief.
223815578|NCT00817557|DRUG|Loteprednol|Anti-inflammatory
223815579|NCT00817557|OTHER|Rewetter|
223815580|NCT02569437|DRUG|Doxycycline|Doxycycline (200 mg PO X 1 dose on Day 1, then 100 mg PO daily) for Day 2-20
223815581|NCT02569437|DRUG|methylprednisolone|oral methylprednisolone: 32 mg x 5 days, 16 mg x 5 days, 8 mg x 10 days
223815582|NCT02569437|DRUG|nasal saline spray|nasal saline sprays: 2 sprays each nostril three times a day
223815583|NCT02569437|DRUG|Flonase|daily nasal steroid sprays (Flonase, 2 sprays each nostril daily).
223815584|NCT02569437|DRUG|sugar pill|placebo pill to match doxycycline
223815585|NCT05067569|BEHAVIORAL|SleepFix mobile application|The SleepFix app is a novel, innovative way to deliver digital brief behavioural therapy for insomnia for adults.
223815586|NCT05067569|BEHAVIORAL|Sleep Health Education|These internet-based modules provide an active control intervention consisting of 3 modules provided bi-weekly. The participant will receive a link to this information as each module is made available. Control participants will have full access to these modules for the duration of the study. They reflect basic educational information regarding sleep health for poor sleepers that is otherwise easily accessible on the internet.
223815587|NCT00325221|DEVICE|HM on|Home Monitoring activated after implantation
223815588|NCT00325221|DEVICE|HM Off|Home Monitoring activated 9 months after implantation
223815589|NCT00955786|DRUG|CX-3543|Escalating doses of CX-3543 administered intravenously daily for 5 consecutive days every 21 days.
223815590|NCT06460558|OTHER|Type 1 diabetes with insulin infusion system|No intervention
223815591|NCT02539043|DEVICE|LIPOFOCUS|In cavitation focused ultrasound procedure for reduction of localized abdominal fat, the parameters will be used: maximum power of 8 Watts at a frequency of 1 Megahertz (MHz), and the transducer is used in a timely manner by performing a sweep of the area by 03 times, at random.
223815592|NCT02539043|DEVICE|LIPOFOCUS|In cavitation focused ultrasound procedure for reduction of localized abdominal fat, the parameters will be used: maximum power of 8 Watts at a frequency of 1 MHz, and the transducer is used in a timely manner by performing a sweep of the area by 03 times, at random . The procedure is followed by stereodynamic drainage, where it will be used a printhead comprising three ERAs (effective radiation area) of 15 Watt each time this procedure is calculated through the area (size of the area to be treated) divided by ERA (cm² head size).
223815593|NCT02626832|OTHER|Procedural|All subjects receive intravenous hypertonic saline and serial blood samples are drawn for AVP concentrations
223815594|NCT05028426|PROCEDURE|Enhanced recovery program|Enhanced recovery programs are a multimodal approach to optimize patients' physiological and psychological states in the preoperative, intraoperative and postoperative care domains.
223815595|NCT04392778|BIOLOGICAL|MSC Treatment|"Protocol length: 1 week~Doses:~1. Application: 3 million cells/kg IV-------------------------------------------------0 day~2. Application: 3 million cells/kg IV ------------------------------------------------3rd day~3. Application: 3 million cells/kg IV -------------------------------------------------6th day~will be given to patients positively, clinically and radiologically diagnosed with COVID-19, followed with 3 months observation."
223815596|NCT04392778|BIOLOGICAL|Saline Control|Saline will be given to patients positively, clinically and radiologically diagnosed with COVID-19, followed with 3 months observation.
223815597|NCT02070068|DEVICE|PINPOINT System|
223815598|NCT00509834|DRUG|hLF1-11|"The study treatment consists of IV administration of:~(A) hLF1-11 (0.5mg IV bolus daily for 14 days) + fluconazole (up to 1g IV four times daily; 14 days): Group #1, n=10; OR (B) Fluconazole (up to 1g IV four times daily; 14 days) + matching placebo for hLF1-11: Group #2, n=10"
223815599|NCT00509834|DRUG|hLF1-11|0.5mg hLF1-11 iv per day for 14 consecutive days
223815600|NCT00509834|DRUG|Placebo|Placebo
223815601|NCT04227574|OTHER|Zero Time Exercise training + WhatsApp anti-inertia reminders|"Zero Time Exercise encourage people to increase physical exercise by simple movements that can be done any time at any places. We offer a 2-session training course to train the subjects to do zero-time exercise.~In addition, WhatsApp anti-inertia reminders will be sent daily by the research assistant to remind and encourage the participants to practice the Zero Time Exercise."
223815602|NCT04227574|OTHER|Zero Time Exercise training alone|Zero Time Exercise encourage people to increase physical exercise by simple movements that can be done any time at any places. We offer a 2-session training course to train the subjects to do zero-time exercise.
223815603|NCT00985985|DRUG|Nicotine|2 mg or 4 mg nicotine lozenge
223815604|NCT00985985|DRUG|Placebo|placebo lozenge
223815605|NCT01347385|PROCEDURE|Laparoscopic myomectomy with unidirectional barbed suture|Patients will be randomized to repair of the uterine defect during laparoscopic myomectomy using unidirectional barbed suture material (V-Loc 180TM, CovidienTM). For patients randomized to the barbed suture arm of the trial, any secondary fibroid that is greater than 5cm intra-operatively (as measured by a laparoscopic measurement instrument) will also be closed with barbed suture material. The cut-off of 5cm will be used, since it is generally above this size when uterine defects need to be closed in multiple layers, making the barbed suture potentially useful. Any other secondary fibroids less than 5cm will be closed with traditional extracorporeal suturing in both arms of the trial, since these can usually be closed in one layer.
223815606|NCT01347385|PROCEDURE|Traditional suture material|Patients will be randomized to repair of the uterine defect during laparoscopic myomectomy using traditional extracorporeal suturing using absorbable monofilament suture material.
223815607|NCT01993459|DRUG|Midazolam|We will administer Midazolam 3mg intravenously once pre-operatively to patients just before they undergo surgery
223815608|NCT01993459|DRUG|NaCl (sodium chloride) 0,9%|We will administer NaCl (sodium chloride) 0,9% 3ml intravenously once pre-operatively to patients just before they undergo surgery
223815609|NCT04492319|DRUG|Control Test|spermatic cord block by 19 ml Levobupivacaine 0.5% plus 1 ml 0.9 normal saline in each side
223815610|NCT04492319|DRUG|Neostigmine|spermatic cord block by 19 ml Levobupivacaine 0.5% plus 1 ml neostigmine 500 μg in each side .
223815611|NCT03266848|DIAGNOSTIC_TEST|Quantitative Magnetic Resonance Imaging|Radiological diagnosis
223815612|NCT05936606|DRUG|Clopidogrel monotherapy|Patients will receive clopidogrel monotherapy (75 mg qd) for 24 months after randomization, irrespective of PRU value or bleeding risk.
223815613|NCT05936606|DRUG|Tailored anti-platelet therapy|In the tailored therapy arm, non-HPR (PRU\<208) patients will continue clopidogrel monotherapy until the end of the study at 24 months from randomization, while HPR (PRU≥208) patients will receive dual anti-platelet therapy according to the clinical diagnosis at the time of drug-eluting stent placement: High-risk patients with prior myocardial infarction will receive ticagrelor 60 mg twice daily wiht aspirin 100 mg daily, while the remainder will receive clopidogrel 75 mg daily with aspirin 100 mg daily. For HBR patietns, early cessation of dual antiplatelet therapy or aspirin monotherapy could be considered at the investigator's discretion.
223815614|NCT05675852|OTHER|68-electrode electroencephalography with steady state visual evoked potentials|"Electroencephalography is registered through a 68-electrode electroencephalography while stimuli will be presented at the centre of the screen at a distance of 150cm.~The pattern of visual stimulation is based on the technique of steady state visual evoked potentials. These potentials consist of the presentation of a visual stimulus at a (relatively fast) periodic rate to produce an EEG signal over the occipital cortex exactly at the frequency of stimulation. By varying the value of a parameter of the stimulation (e.g. the contrast of the stimulus) varies. This variation makes it possible to determine the threshold value where an EEG response is perceived, and thus to evaluate visual parameters such as visual acuity, contrast sensitivity or recognition of more complex shapes."
223815615|NCT00675155|RADIATION|Far Infrared Radiation|Radiation: Far Infrared Radiation (5μm to 20μm wavelength) Far Infrared radiation for 30 to 40 minutes per treatment session.
223815616|NCT03262857|DRUG|use of magnesium sulfate with lidocaine in inferior alveolar nerve block|
223815617|NCT05596513|OTHER|motor learning and occupational therapy|"1. Constraint-induced movement therapy (CIMT)~2. Hand-arm bimanual intensive training (HABIT)"
223815618|NCT05596513|OTHER|Motor Learning Approaches From Working on a Vertical Surface|"1. Ball on wall, kneel to stand~2. Kneel walk cross over~3. Vertical playground puzzles and games~4. Color on big boxes~5. Fridge magnets~6. Erasing a whiteboard or chalkboard~7. Tactile feedback from textured walls"
223815619|NCT02024035|RADIATION|Radiotherapy|
223815620|NCT05631184|BEHAVIORAL|Self-administered acupressure group|Self-administered acupressure treatment group was developed on the basis of previous systematic reviews and clinical studies of acupuncture and acupressure for depression. It has robust theoretical basis of TCM. The acupoints selected are commonly used for depression according to a recent systematic review and recommended by other clinical practice guidelines.
223815621|NCT05631184|BEHAVIORAL|Mental health education group|Mental health education training group was developed based on the materials regarding depression and mental health from the Centre of Health Protection, Department of Health, the Government of Hong Kong SAR and reviewed by a clinical psychologist.
223815622|NCT04065100|DIAGNOSTIC_TEST|Sebum test|Measuring sebum in newborn
223815623|NCT00429689|PROCEDURE|Saliva sample|
223815624|NCT01078480|PROCEDURE|Operation using a precontoured titanium plate and screws|Operation using a precontoured titanium plate and screws
223815625|NCT01078480|PROCEDURE|Displaced midshaft fracture of the collar bone|Displaced midshaft fracture of the collar bone treated with an arm sling
223815626|NCT05925374|BEHAVIORAL|Substance use stigma training|The intervention is an interactive professional educational training that is designed to manipulate behavioral and normative beliefs in order to address bias and alter professional practices towards patients who use drugs.
223815627|NCT01448564|OTHER|Laser therapy|The therapeutic effects of low intensity lasers are: (i) analgesic and anti-inflammatory, (ii) regeneration, (iii) tissue healing and (vi) recovery from muscle fatigue.
223815628|NCT01448564|OTHER|Placebo laser therapy|The application of laser therapy will be a low intensity laser.
223815629|NCT01013610|DRUG|LNK-754|Escalating dose
223815630|NCT01013610|DRUG|Placebo|Escalating dose
223815631|NCT01856712|DRUG|Naltrexone|Naltexone was chosen for this study because naltrexone is the only medication available in both oral daily and injectable monthly formulations, which will allow the study to examine issues around medication adherence.
223815632|NCT02255357|DRUG|Placebo|Solution containing only the excipients of the original solution without Oxytocin.
223815633|NCT02255357|DRUG|Intranasal Oxytocin|solution containing Oxytocin 6 IU/0.1cc or per puff is used in this arm
223815634|NCT03607357|DEVICE|High Flow Nasal Oxygen|The initial flow speed is set at 30L/min and increases at 5L/min in titrated type until the patient feels uncomfortable. The temperature is set at 37℃. The fraction of inspiration O2 is set in accordance with specific condition of patient to insure oxygen saturation more than 95%.
223815635|NCT03607357|DEVICE|Non-invasive Ventilation|The values of initial pressure are set at a lower level (inspiratory pressure: 6-8cmH2O, expiratory pressure: 4cmH2O) and adjusted to a suitable level in 10-20min. The fraction of inspiration O2 is set in accordance with specific condition of patient to insure oxygen saturation more than 95%.
223815636|NCT00804401|DRUG|Naproxen Tablets, 500 mg|
223815637|NCT05782049|OTHER|Ultrasound of the salivary glands|"Salivary gland ultrasound is, a non-invasive, non-irradiating and easily accessible examination, offers promising results for the diagnosis of primary SS. It allows the identification of changes in the homogeneity of the echostructure of the main salivary glands in the parotid and submandibular region.The patient lies on the examination table with the head slightly turned to the side opposite the gland being examined. The examination will be done on the parotid and submandibular glands on both sides.The parotid glands will be measured in length and width.The surface of the gland will be calculated: (length x width)/2.The sub-maxillary glands will be measured in length and surface.~The exam will be performed in 10 minutes."
223815638|NCT05782049|OTHER|Measurement of salivary flow|Saliva flow measurement, which consists of measuring the quantity of saliva that the patient can emit in 15 minutes
223815639|NCT05782049|OTHER|A Schirmer test|A strip of blotting paper graduated from five to five millimeters is placed in the eye for 5 minutes, avoiding any corneal contact.
223815640|NCT03788538|DRUG|dexmedetomidine|10 minutes before anesthesia induction, all patients were administrated with dexmedetomidine 1 μg/kg/min.At the beginning of induction, dexmedetomidine was changed to corresponding maintenance dose in each group.
223815641|NCT03719794|DIETARY_SUPPLEMENT|Probiotic supplement|Probiotic supplement once daily (xyz) for 12 weeks
223815642|NCT03719794|DIETARY_SUPPLEMENT|Placebo supplement|Placebo supplement once daily for 12 weeks
223815643|NCT00509236|DRUG|Sitagliptin|25 mg (one 25-mg tablet) once daily
223815644|NCT00509236|DRUG|Glipizide|2.5 mg (1/2 of a 5-mg tablet) once daily, up to 10 mg twice daily (four 5-mg tablets), for a maximum of 20 mg
223815645|NCT01546792|BEHAVIORAL|Combined lifestyle intervention|Exercise training, dietary advice, behaviour change counselling
223815646|NCT00099099|BEHAVIORAL|Caloric Restriction (CR)|
223815647|NCT00897130|DRUG|Azacytidine|Azacitidine will be given at a dose of 75mg/sqm subcutaneous daily for 5 consecutive days every 28 days (every month) for a total of 8 courses. 5-Aza dosages will be adjusted
223815648|NCT04437095|OTHER|Psychological Support Based on Positive Suggestion delivered via pre-recorded MP3 message|Daily administration of audiorecording
223815649|NCT02785874|DRUG|Statin|Divide HCC patients into two groups under randomization, one is with Statin and the other is without Statin to verify whether Statin could prolong disease-free survival
223815650|NCT00927355|DRUG|Pioglitazone|6 month treatment with pioglitazone 15mg for four weeks with dose increased to 30mg if no adverse effects (swelling of lower extremities, liver enzyme elevation) noted at the four week mark.
223815651|NCT00927355|DRUG|Placebo|"The placebo pills also start out with one (15mg) pill qday and are increased to 2 tablets (30mg) qday after 4 weeks if no adverse effects are noted by study physician."
223815652|NCT05619874|BEHAVIORAL|HIFCT-S|"A functional circuit training of 30 sessions will be carried out as follows:~* Sessions 1 to 6: General circuit (two series) composed of four blocks of three exercises.~* Sessions 7 to 14: Concentrated circuit (two sets) composed of four blocks of three exercises of greater complexity than the exercises of the general circuit.~* Sessions 15 to 22: Circuit by blocks (two sets) composed of four blocks of two exercises of greater complexity than the exercises from sessions 7 to 14.~* Sessions 23 to 30: Circuit by blocks (two sets) composed of four blocks of two exercises of greater complexity than the exercises from sessions 15 to 22."
223815653|NCT05619874|BEHAVIORAL|HIFCT-P|"A functional circuit training of 30 sessions will be carried out as follows:~* Sessions 1 to 6: General circuit (two series) composed of two blocks of 6 exercises.~* Sessions 7 to 14: Concentrated circuit (two sets) composed of two blocks of 6 exercises of greater complexity than the exercises of the general circuit.~* Sessions 15 to 22: Circuit by blocks (single set) composed of five blocks of two exercises of greater complexity than the exercises from sessions 7 to 14.~* Sessions 23 to 30: Circuit by blocks (single set) composed of five blocks of two exercises of greater complexity than the exercises from sessions 15 to 22."
223815654|NCT04496999|DRUG|HDM201|Dose level 0: HDM201 40 mg QD d1,2 (midday)/ Dose level 1: HDM201 40 mg QD d1,2,3 (midday) = Starting dose/ Dose level 2: HDM201 40 mg QD d1,2,3,4,5 (midday)/ Dose level 3: HDM201 60 mg QD d1,2,3,4,5 (midday)/ Dose level 4: HDM201 80 mg QD d1,2,3,4,5 (midday)
223815655|NCT04496999|DRUG|Midostaurin|Midostaurin 50mg bid d1-28 (morning, evening)
223815656|NCT04012060|PROCEDURE|Limited access aortic valve replacement.|Limited access aortic valve replacement through partial upper hemisternotomy
223815657|NCT04012060|PROCEDURE|Conventional aortic valve replacement|Aortic valve replacement through full median sternotomy
223815658|NCT05900856|OTHER|low caloric diet regimen|lipids approximately (20: 35%) of total caloric intake, protein approximately (10: 35%) of total caloric intake and high complexed carbohydrate intake approximately (45: 65%) of total caloric intake (with increased fiber-rich whole grain breads, cereals, fruits and vegetables), for eight weeks.
223815659|NCT05900856|DEVICE|ultrasound cavitation|patients will assume standing position, the abdominal area will be divided vertically into 2 equal sections, right and left segment, extending bilaterally from the line stretching between the mid axilla above and the iliac crest below, and upward from center of diaphragm to the midpoint extending between two iliac crest below, then from supine lying position the cavitation head will be applied on each abdominal segment for 15 minutes with total treatment time 30 minutes twice per week for eight weeks
223815660|NCT03357263|BIOLOGICAL|GC3114|High-dose Quadrivalent influenza vaccine
223815661|NCT03357263|BIOLOGICAL|GCFLU Quadrivalent|Quadrivalent influenza vaccine
223815662|NCT05817266|DEVICE|Field-cycling imaging (FCI)|FCI scan
223815663|NCT04240184|OTHER|Physical workload|Cohort study - The specific study aims are to investigate 1) exposure-response associations between quantity of occupational lifting and short-term (day-to-day) changes in LBP, 2) the influence of accumulated workdays and rest days during a working week on LBP, 3) long-term association between occupational lifting exposure and LBP when assessed over 1 year, and 4) the role of psychological and social factors on the above associations.
223815664|NCT04131530|DIAGNOSTIC_TEST|The diagnosis of Artificial Intelligence and endoscopist|When the colon mucosa is observed using pCLE, endoscopist and AI will make a diagnosis independently. In addition, the endoscopist can not see the diagnosis of AI.
223815665|NCT06192147|DIETARY_SUPPLEMENT|protein restricted diet combined with vitamin D intervention|On the basis of conventional treatment, a protein restricted diet combined with vitamin D intervention plan is given
223815666|NCT02932059|BEHAVIORAL|Metamemory|Metamemory evaluation using a sentence construction strategy
223815667|NCT05254548|DRUG|ACT-539313|100 mg ACT-539313 (hard capsules) will be administered twice per day in period 2 (morning and evening of Day 8), period 3 (morning and evening of Day 9 to 14) and period 4 (morning and evening of Day 15).
223815668|NCT05254548|DRUG|Flurbiprofen|One daily dose of flurbiprofen 50 mg will be administered in period 1 (morning of Day 1), period 2 (morning of Day 8), and period 4 (morning of Day 15).
223815669|NCT05254548|DRUG|Omeprazole|A single dose of omeprazole 20 mg will be administered in period 1 (morning of Day 1), period 2 (morning of Day 8), and period 4 (morning of Day 15).
223815670|NCT05254548|DRUG|Midazolam|A single dose of midazolam 2 mg will be administered in period 1 (morning of Day 1), period 2 (morning of Day 8), and period 4 (morning of Day 15).
223815671|NCT05276232|DRUG|Cannabis(THC) inhaled|Cannabis vapor is produced from 500mg, approximately 5-10% High dose bulk cannabis plant material, 30-37.5 mg THC
223815672|NCT02769234|PROCEDURE|ERP/EEG test|The testing protocol consists of an auditory oddball ERP paradigm, followed by the collection of 3min of resting EEG. During the ERP paradigm a variety of auditory stimuli are played through the system's earphones while voltage potentials are recorded from the subject's scalp. At the end of the ERP session, 3 minutes of EEG data will be recorded while the subject is resting. The entire procedure, including set up, instructions to the subject and actual test is expected to take 45-60 minutes.
223815673|NCT02769234|PROCEDURE|Psychometric testing|Subjects that complete ERP/qEEG testing successfully will move on to clinical and neuropsychological evaluation. Demographic information with also be collected.
223815674|NCT00792103|DRUG|NP101|NP101 study patch 4 hour application
223815675|NCT03738839|DEVICE|Quantitative Light-Induced Fluorescence|White spot lesion on the tooth surfaces detected with Quantitative Light-Induced Fluorescence Orthodontic Bonding.
223815676|NCT03738839|PROCEDURE|Direct bonding|The patients in the direct bonding group received a bonding procedure with a conventional composite adhesive.
223815677|NCT03738839|PROCEDURE|Indirect bonding|For the patients in the indirect bonding group, bonding was performed with a flowable composite adhesive.
223815678|NCT02498353|RADIATION|preoperative short-course radiotherapy with local boost|Except the clinical target volume(CTV),a gross tumour volume（GTV）is delineated，and give a dose of PTV-GTV:30Gy/5F
223815679|NCT02498353|RADIATION|preoperative short-course radiotherapy without local boost|Preoperative short-course radiotherapy without local boost,the dose of radiotherapy is PTV-CTV 25Gy/5F
223815680|NCT02498353|PROCEDURE|TME surgery|both study group and control group received surgery under TME principle after radiotherapy
223815681|NCT02348684|RADIATION|Radiation therapy groups|Radiation Therapy treatment between 2000 and 2007.
223815682|NCT03435575|DEVICE|Boosth|Boosth activity tracker which measures steps
223815683|NCT03837808|DRUG|Nimotuzumab|nimotuzumab 200mg/week in concurrent with IMRT, d1,d8,d15,d22,d29,d36 of RT
223815684|NCT03837808|DRUG|Cisplatin|cisplatin 40mg/m2/week in concurrent with IMRT, d1,d8,d15,d22,d29,d36 of RT
223815685|NCT05610891|DRUG|CLR 131|CLR 131 will be administered IV (intravenously) at a dose based on patients' BSA
223815686|NCT03074214|PROCEDURE|percutaneous coronary intervention|"All STEMI patients enrolled will at first receive Device(such as: stent or balloon) treatment for their coronary artery."
223815687|NCT04802343|DRUG|BAY1817080|Oral, tablet.
223815688|NCT04802343|DRUG|Placebo|Oral, tablet.
223815689|NCT04338854|PROCEDURE|Restorative Treatment|9 groups were formed as 6 restorative and 3 protective applications. The restorative treatment groups included procedures with- and without-local anesthesia (LA). Procedures with LA included the groups as root canal treatment, pulpotomy, two-surface restoration and one-surface restoration. Procedures without LA included the groups as two-surface restoration and one-surface restoration. The protective application groups included the groups as fluoride application (by disposable arch tray or by cotton roll) and fissure sealant.
223815690|NCT00156858|DRUG|intravenous busulfan|
223815691|NCT01572389|BEHAVIORAL|Healthy Outcomes through Patient Empowerment (HOPE)|HOPE participants will receive 6 behavioral coaching telephone sessions and 3 booster sessions over a six month period followed by usual primary care during the subsequent 6 months maintenance period.
223815692|NCT01572389|BEHAVIORAL|Enhanced Usual Care|All participants receive usual VA primary care plus a dedicated screening for diabetes control and clinically significant depressive symptoms. Patients and primary care providers are notified of these results and given recommendations for usual care.
223815693|NCT02307201|DRUG|Magnesium Sulfate|The patient will receive magnesium sulfate for 24 hours postpartum
223815694|NCT00977756|DRUG|Raltegravir (RAL)|400 mg twice daily (BID)
223815695|NCT00977756|DRUG|Atazanavir (ATV)|300 mg daily
223815696|NCT00977756|DRUG|Ritonavir (RTV)|100 mg daily, dosing by weight in Group I
223815697|NCT00977756|DRUG|Tenofovir (TDF)|300 mg daily
223815698|NCT00977756|DRUG|Etravirine (ETV)|200 mg BID
223815699|NCT00977756|DRUG|Darunavir (DRV)|Dosing by weight
223815700|NCT00977756|DRUG|Maraviroc (MVC)|150 mg BID in groups J and K; 600 mg BID in group L
223815701|NCT00977756|DRUG|Lopinavir/ritonavir (LPV/r)|Coformulation of 400 mg lopinavir and 100 mg ritonavir, taken twice daily
223815702|NCT02459821|OTHER|GE-O SYSTEM|The first group will be subjected to RAGT for 9 weeks (2 sessions/ week) with a total of 18 sessions by mean of GE-O System (9). During each session, the patients will practice 15 to 20 min of simulated floor walking followed by 5 to 10 min of repetitive simulated stair climbing up and down. Breaks will be optional, but uninterrupted training intervals of at least 5 min for simulated floor walking and 3 min of simulated stair climbing will be required. When the patient reaches the maximum amount of time, speed of gait will then be progressively increased. Each session will last up to 50 minutes, the first 30 minutes will be dedicated to gait training and the last 20 minutes to stretch the lower limb's muscles.
223815703|NCT02459821|OTHER|Conventional training|The conventional walking group will be subjected to a conventional gait training for 9 weeks (2 sessions/week) with a total of 18 sessions. Each session will last altogether 50 minutes, the first 30 minutes will be dedicated to gait and stair climbing up and down training while the last 20 minutes to stretch the lower limb's muscles.
223815704|NCT02673710|OTHER|No intervention|Besides participant reported outcomes and a muscle strength test no interventions are administered, all treatment decisions are at the discretion of the physician and will be in line with local clinical practice and labeling
223815705|NCT02500329|DRUG|Gemigliptin|Gemigliptin for 4 weeks
223815706|NCT02500329|DRUG|Acarbose|Acarbose for 4 weeks
223815707|NCT03535064|OTHER|Hand Hygiene Workshop|Workshops included video-clip and interactive lecture about common infections in schools, methods of transmission, and hand washing procedure and time. Puzzle games related to hand hygiene were distributed among schoolgirls. Posters with cartoon princess picture promote for hand hygiene were also distributed among the schools.
223815708|NCT04185714|OTHER|Kinesiotaping|Kinesiotaping (KT) is an approach that supports injured muscles and joints and helps relieve pain.
223815709|NCT04185714|OTHER|Placebo taping|sham taping
223815710|NCT02294188|DEVICE|Spatial Repellent product with active ingredient (SHIELD)|Spatial Repellent Product
223815711|NCT02294188|DEVICE|Active ingredient|Transfluthrin (Active ingredient)
223815712|NCT02294188|DEVICE|Spatial Repellent product without active ingredient (SHIELD)|Spatial Repellent Product - Passive Emanator. The name of the product is SHIELD from SCJohnson
223815713|NCT03298282|OTHER|OCT (Optical Coherence Tomography)|Coronary images by OCT and selective CTA and FFR values will be registered.
223815714|NCT03298282|OTHER|Coronary CTA|Coronary images by OCT and Coronary CTA and FFR values will be registered.
223815715|NCT03298282|OTHER|FFR|Coronary images by OCT and selective CTA and FFR values will be registered.
223815716|NCT05996666|DEVICE|Liver-cancer early detection test|Blood collection and liver-cancer early detection test
223815717|NCT01145807|DRUG|TDT067|Study treatment (TDT 067, Transfersome® vehicle, or non Transfersome® placebo) will be applied twice a day for 48 weeks to the great toenail and the other nails and areas surrounding the nails on the foot. Each application will consist of 5 sprays: 1 spray each to the dorsal, medial, anterior, and frontal part of the great toe and a final spray applied evenly to the nail area of the remaining 4 toes. Patients will be instructed not to wash the treated foot or bathe for at least 4 hours after product application.
223815718|NCT01145807|DRUG|Placebo|Study treatment (TDT 067, Transfersome® vehicle, or non Transfersome® placebo) will be applied twice a day for 48 weeks to the great toenail and the other nails and areas surrounding the nails on the foot. Each application will consist of 5 sprays: 1 spray each to the dorsal, medial, anterior, and frontal part of the great toe and a final spray applied evenly to the nail area of the remaining 4 toes. Patients will be instructed not to wash the treated foot or bathe for at least 4 hours after product application.
223815719|NCT01145807|DRUG|Transfersome|Study treatment (TDT 067, Transfersome® vehicle, or non Transfersome® placebo) will be applied twice a day for 48 weeks to the great toenail and the other nails and areas surrounding the nails on the foot. Each application will consist of 5 sprays: 1 spray each to the dorsal, medial, anterior, and frontal part of the great toe and a final spray applied evenly to the nail area of the remaining 4 toes. Patients will be instructed not to wash the treated foot or bathe for at least 4 hours after product application.
223815720|NCT04617184|OTHER|NO INTERVENTION|THERE IS NO INTERVENTION TO THIS TRIAL. THIS IS A REGISTRY
223815721|NCT02648984|OTHER|The intervention is performing an exercise test|Patients and controls will undergo a bicycle stress echocardiography and a cardiopulmonary exercise test
223815722|NCT01287520|DRUG|LY2090314|Administered intravenously
223815723|NCT01287520|DRUG|pemetrexed|Administered intravenously
223815724|NCT01287520|DRUG|Carboplatin|Administered intravenously
223815725|NCT01287520|OTHER|ranitidine|Per I2H-MC-JWYA Protocol Amendment (d) approved 11 March 2010, 50 mg ranitidine given as pretreatment to LY2090314 for stomach pain.
223815726|NCT02796430|OTHER|Time needed to start indirect calorimetry measurement|Comparison of the time needed to start EE measurements by the new calorimeter and the currently used calorimeter, including the time needed for calibration, patient data input, connection to the ventilator circuit.
223815727|NCT02796430|OTHER|Indirect calorimetry measurement|Comparison of EE measurements by the new calorimeter and the currently used calorimeter when using different mechanical ventilators, different ventilation modes, different patient conditions and severity
223815728|NCT03319784|DRUG|Ketorolac|Patients assigned to Toradol group will receive a single dose of 60mg of Ketorolac (Toradol) mixed with 8mL of 1% lidocaine with epinephrine 1:100,000.
223815729|NCT03319784|DRUG|Triamcinolone Acetonide|Patients assigned to Steroid group will receive 80mg of Triamcinolone Acetonide (Kenalog) mixed with 8mL of 1% lidocaine with epinephrine 1:100,000.
223815730|NCT03587142|DRUG|Buspirone|Buspirone tablet
223815731|NCT03587142|DRUG|Placebo|"Sugar pill manufactured to mimic buspirone 10 mg tablet"
223815732|NCT01677702|DIETARY_SUPPLEMENT|Yili Lactoferrin ShuHua Milk (Lactoferrin 5mg/100ml)|Total 250mL milk (with lactoferrin 5mg/100ml) will be taken once per day at 10am daily during the 84 days intervention.
223815733|NCT01677702|DIETARY_SUPPLEMENT|Yili Lactoferrin ShuHua Milk (Lactoferrin 10mg/100ml)|Total 250mL milk (with lactoferrin 10mg/100ml) will be taken once per day at 10am daily during the 84 days intervention.
223815734|NCT01677702|DIETARY_SUPPLEMENT|Recombined low protein milk|Total 250ml of placebo milk will be taken once a day at 10am daily during the 84 day intervention.
223815735|NCT03842410|DEVICE|Single-Incision Sling|Solyx Single-Incision Sling for correction of stress urinary incontinence done in the office.
223815736|NCT02470858|DRUG|LDV/SOF+ASV|Ledipasvir/sofosbuvir (LDV/SOF) 90 mg/400 mg fixed-dose combination (FDC) tablet; administered orally once daily; Asunaprevir (ASV) 200mg, administered orally twice daily.
223815737|NCT02470858|DRUG|SOF+DCV+SMV|Sofosbuvir (SOF) 400 mg tablet administered orally once daily; Daclatasvir (DCV) 60 mg tablet administered orally once daily; Simeprevir (SMV) 150 mg tablet orally once daily.
223815738|NCT02470858|DRUG|SOF+DCV+ASV|Sofosbuvir (SOF) 400 mg tablet administered orally once daily; Daclatasvir (DCV) 60 mg tablet administered orally once daily; Asunaprevir (ASV) 200mg, administered orally twice daily.
223815739|NCT05149092|DIETARY_SUPPLEMENT|Chicken protein hydrolysate supplement|Daily oral self-administration of 18 g of supplement dissolved in water/mineral water, spread over 2-3 occasions
223815740|NCT05149092|DIETARY_SUPPLEMENT|Placebo|Daily oral self-administration of 18 g of supplement dissolved in water/mineral water, spread over 2-3 occasions
223815741|NCT02768662|DRUG|OTO-104|Single intratympanic injection of 12 mg OTO-104
223815742|NCT03673462|BIOLOGICAL|Meningococcal polysaccharide (serogroups A,C,Y and W) tetanus toxoid Conjugate vaccine (MenACYW Conjugate vaccine)|Pharmaceutical form: Liquid solution. Route of administration: Intramuscular
223815743|NCT03673462|BIOLOGICAL|Meningococcal (Groups A, C, Y and W 135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine (MENVEO®)|Pharmaceutical form: Lyophilized powder combined with liquid components Route of administration: Intramuscular
223815744|NCT03673462|BIOLOGICAL|Diphtheria, Tetanus, Acellular Pertussis, Poliovirus and Haemophilus b Vaccine|Pharmaceutical form: Liquid DTaP-IPV to reconstitute lyophilized ActHIB Route of administration: Intramuscular
223815745|NCT03673462|BIOLOGICAL|Pneumococcal 13-valent Conjugate Vaccine|Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
223815746|NCT03673462|BIOLOGICAL|Rotavirus Vaccine|Pharmaceutical form: Oral solution Route of administration: Oral
223815747|NCT03673462|BIOLOGICAL|Hepatitis B Vaccine|Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
223815748|NCT03673462|BIOLOGICAL|Measles, Mumps, and Rubella Virus Vaccine|Pharmaceutical form: Lyophilized live virus vaccine Route of administration: Subcutaneous
223815749|NCT03673462|BIOLOGICAL|Varicella Virus Vaccine|Pharmaceutical form: Suspension for injection Route of administration: Subcutaneous
223815750|NCT03874065|OTHER|Medical Chart Review|Collection of data from participant's medical chart
223815751|NCT00677443|DRUG|S-1 & Oxaliplatin|S-1 and Oxaliplatin : S-1 80 mg/m2/day, D1-14 Oxaliplatin, 130 mg/m2/day, D1 Repeated every 3 weeks
223815752|NCT00677443|DRUG|Capecitabine & Oxaliplatin|COX : Capecitabine 1000 mg/m2/day, D1-14 Oxaliplatin, 130 mg/m2/day, D1 Repeated every 3 weeks
223815753|NCT03324659|BEHAVIORAL|Exercise and Meditation|The Exercise and Meditation group will listen to recorded meditations (15 minutes) that are based on mindfulness. They will then walk on a treadmill for 30 minutes at a moderate intensity. The intervention is completed five days per week for four weeks.
223815754|NCT03324659|BEHAVIORAL|Control|The Control group will listen to a recorded audio book for 15 minutes, They will then sit quietly for 30 minutes. The intervention is completed five days per week for four weeks.
223815755|NCT01432496|DRUG|Ropivacaine 150 mg|Nebulization of Ropivacaine 150 mg in the peritoneal cavity
223815756|NCT01432496|DRUG|saline 15 ml|Nebulization of saline 15 ml in the peritoneal cavity
223815757|NCT04885270|DRUG|cisplatin i.p.|paclitaxel 135 mg/m2 i.v. and cisplatin 75 mg/m2 i.p. on day 1
223815758|NCT06103084|DIETARY_SUPPLEMENT|Bahgina|Bahgina, a locally produced cereal based food, will be provided at 200g/day/child for a duration of six months on top of the routine nutrition services provided by the local government and nutrition partners.
223815759|NCT06103084|DIETARY_SUPPLEMENT|SQLNS|Small quantity lipid based nutrient supplement (SQ-LNS) will be provided at 20g/day/child for a duration of six months on top of the routine nutrition services provided by the local government and nutrition partners.
223815760|NCT04389502|DEVICE|CaPtyVa app|The apps stores all the current local Clinical practice guidelines information related to CRC screening and surveillance and through its decision algorithms assist physicians in the screening process. In the screening function, CaPtyVa helps the physicians to classify patient´s according to their individual CRC risk and to determine how and when to start with screening tests. In the surveillance, function the app assist the physician in determining when to repeat the next colonoscopy according to guideline recommendation
223815761|NCT04389502|OTHER|Control group|current physician knowledge on local current CRC screening and surveillance guidelines
223815762|NCT03749122|PROCEDURE|Waiting time for hip fracture surgery|Time from hospital admission to start of hip fracture surgery
223815763|NCT04060602|BEHAVIORAL|Personalized Feedback|A report comparing the participant's cannabis use to peer usage, and summarizing problems experienced and risk associated with future use.
223815764|NCT04060602|BEHAVIORAL|Education|Canada's Lower-Risk Cannabis Use Guidelines prepared by the Centre for Addiction and Mental Health which outlines methods to help reduce health risks associated with cannabis use.
223815765|NCT03503825|DRUG|[Tc-99m]-RPI-T-087 Injection|A single intravenous injection of \[Tc-99m\]-RPI-T-087 followed by SPECT/CT imaging of the knee (all subjects) and whole body planar imaging (Healthy volunteers only)
223815766|NCT01770301|DRUG|Paclitaxel|
223815767|NCT01770301|DRUG|Bevacizumab|
223815768|NCT04028310|OTHER|Phonological|"* Phase 1: intervention without targeted daily training (30 minutes/ week, for 8 weeks)~* Phase 2: intervention with targeted daily training~  * Phonological training (15 minutes/ day, 5 days/week, for 8 weeks)~ * Visuo-attentional training (15 minutes/ day, 5 days/week, for 8 weeks)~ * Cross-modal training (15 minutes/ day, 5 days/week, for 8 weeks)~* Phase 3: stopping training sessions for 8 weeks"
223815769|NCT04028310|OTHER|Visual-attention|"* Phase 1: intervention without targeted daily training (30 minutes/ week, for 8 weeks)~* Phase 2: intervention with targeted daily training~  * Visuo-attentional training (15 minutes/ day, 5 days/week, for 8 weeks)~ * Phonological training (15 minutes/ day, 5 days/week, for 8 weeks)~ * Cross-modal training (15 minutes/ day, 5 days/week, for 8 weeks)~* Phase 3: stopping training sessions for 8 weeks"
223815770|NCT00871884|BEHAVIORAL|Psychoeducation|Education about the common prognostic considerations, normal symptoms experienced and etiology of symptoms following mild head injury. Includes some basic suggestions surrounding methods to diminish the impact of symptoms on one's life.
223815771|NCT00871884|BEHAVIORAL|Relaxation Training|Includes Progressive Muscle Relaxation, Guided Visualization, and various other relaxation techniques to induce deep relaxation.
223815772|NCT00871884|BEHAVIORAL|Interoceptive Exposure|Includes a variety of exercises used to elicit somatic sensations which may be feared by the participant, in an attempt to extinguish or lessen the fear reaction to these sensations.
223815773|NCT05102123|DRUG|Cytisine|Listed as a natural health product in Canada, cytisine is utilized to aid in smoking cessation
223815774|NCT05102123|BEHAVIORAL|Video Messaging|Supportive messaging utilizing a video messaging platform to encourage patients to abstain from smoking throughout the treatment period.
223815775|NCT01800201|BEHAVIORAL|Electronic Pill Bottle, Incentives, Social Influence|The intervention group (1) will use GlowCaps, a remote monitoring and reminder pill bottle; (2) assigned an engagement advisor from the study team; (3) asked to provide study team with names and contact information of up to 3 family members or friends as support partners for med adherence. The study team will contact these people in order listed until 1 agrees to this role; (4) will select a 2-digit lucky number to be used as part of the sweepstakes-based engagement incentives in which eligibility to win will be conditional on med adherence; and (5) will determine preferences for Way to Health platform communication methods.The group receiving the program intervention will also have their claims data analyzed for the 12 months post-enrollment.
223815776|NCT04105530|DEVICE|Anodal tDCS treatment|The Anodal intervention excites neuronal activity. For condition one, the anode will be attached to the left frontal region (Fp1) and the cathode will be attached to the right neck. The intervention involves a direct current of 1 mA applied for 20 minutes.
223815777|NCT04105530|DEVICE|Cathodal tDCS treatment|The Cathodal intervention inhibits or reduces neuronal activity. We propose that the use of the cathodal tDCS to the superior temporal gyrus in survivors of childhood ALL may facilitate the inhibition of over connected motor-sensory and auditory neural networks. For condition two, the cathode will be attached to the left temporal region (T3) and the anode will be attached to the right neck. The intervention involves a direct current of 1 mA applied for 20 minutes.
223815778|NCT04105530|DEVICE|Sham treatment|The sham procedure provides the same small current during ramp up to imitate the intervention, but the current is discontinued after ramping up and no intervention is provided. Sham will be applied for 20 minutes. Stimulation will start 5 minutes before testing and continue throughout completing the NIH Toolbox Cognitive Battery at each trial.
223815779|NCT04105530|OTHER|NIH Toolbox List Sorting Working Memory Test|List Sorting is using information processing and storage. Performance tends to peak in early adulthood and then decline across the life span. This task assesses working memory and requires the participant to sequence different visually- and orally-presented stimuli. The list scoring task takes approximately 7 minutes to administer. List Sorting is scored by summing the total number of items correctly recalled and sequenced on Lists-1 and -2, which can range from 0-26.
223815780|NCT04105530|OTHER|NIH Toolbox Flanker Inhibitory Control and Attention Test|The Flanker tests inhibitory control and attention and the capacity for new learning and information processing novel situations. This performance also reaches a peak in early adulthood and tends to decline across the life span. A total of 40 trials require 4 minutes. Scoring is based on both accuracy and reaction time, which will we evaluate individually as well as in combination. The raw scores are converted to a scale score with a mean of 100 and SD of 15. Higher scores indicate higher executive function.
223815781|NCT04105530|OTHER|Grooved Peg Board Test|The Grooved Peg Board test measures visual-motor coordination and motor speed. Additionally, it is cognitively challenging and has been associated with attention, perceptual speed and non-verbal reasoning. Performance is better in the dominant/preferred hand and tends to improve in childhood and decline with advancing age. The test consists of placing metal pegs with ridges along onside in matching slots as quickly as possible. The score is the time in seconds required to compete the array with each hand. Longer times reflect worse performance. Times are compared to normative data that is organized by ethnicity, age, gender and education. The test takes approximately 5 minutes to complete.
223815782|NCT04105530|OTHER|Buschke Selective Reminding Test|This selective reminding task purports to distinguish verbal memory into short-term and long-term components. Scores are organized by short- and long-term storage and retrieval with normative scores organized by age and gender. The task requires participants to remember a list of orally-presented words and recall them with selective reminders of the words that they didn't recall. The test will last 5-10 minutes and is available in four different versions, thus reducing rehearsal effects.
223815783|NCT03542097|OTHER|MGMT methylation evaluation|The MGMT methylation will be evaluated by extracting DNA from fresh and Formalin Fixed paraffin Embedded (FFPE) tumor samples
223815784|NCT02524301|DRUG|Positron Emission Tomography using [11C]diprenorphine|PET using \[11C\]diprenorphine
223815785|NCT04144803|DIAGNOSTIC_TEST|Cerebral near-infrared spectroscopy|Nonin H500 one-channel near-infrared spectroscopy monitor on forehead of the patient from before induction of anesthesia to arrival to hospital
223815786|NCT00708435|BIOLOGICAL|Beriplex® P/N (Kcentra)|Intravenous infusion, dosage depending on baseline INR, amount of coagulation factor IX and body weight
223815787|NCT00708435|BIOLOGICAL|Fresh frozen plasma|Intravenous Infusion, dosage depending on baseline INR and body weight
223815788|NCT02352363|DRUG|CVT-301|
223815789|NCT02352363|OTHER|Observational cohort|
223815790|NCT00118261|BIOLOGICAL|bevacizumab|Beginning in course 3, patients also receive bevacizumab IV over 30 minutes. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
223815791|NCT00118261|DRUG|erlotinib hydrochloride|Courses 1-3: oral erlotinib once daily on days 1-14. Patients who do not develop grade 2 toxicity after the first 3 courses (6 weeks) will have their erlotinib dose escalated. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
223815792|NCT00118261|DRUG|fluorouracil|Starting with course 2: fluorouracil IV continuously over 46 hours on days 1 and 2. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
223815793|NCT00118261|DRUG|leucovorin calcium|Starting with course 2: Leucovorin calcium IV over 2 hours on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
223815794|NCT00118261|DRUG|oxaliplatin|Starting with course 2: oxaliplatin IV over 2 hours on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
223815795|NCT01683162|DRUG|ClinOleic|the lipid of all-in-one, 0.5-3.5g/kg.d
223815796|NCT01683162|DRUG|Lipofundin|the lipid of all-in-one, 0.5-3.5g/kg.d
223815797|NCT01683162|DRUG|Intralipid|the lipid of all-in-one, 0.5-3.5g/kg.d
223815798|NCT03704532|PROCEDURE|Operative treatment|Open surgical repair of tendon rupture
223815799|NCT03704532|PROCEDURE|Nonoperative treatment|Nonoperative treatment with lower leg orthosis and functional rehabilitation
223815800|NCT05301062|DRUG|Radium-223 dichloride (Xofigo, BAY88-8223)|Treatment with Radium-223 should follow the approved local product information according to National Medical Products Administration (NMPA) approved label
223815801|NCT03193671|DIAGNOSTIC_TEST|Diagnosis|Improving diagnosis
223815802|NCT01896284|DRUG|0.5mg aflibercept|0.5mg aflibercept intravitreal injection will be performed every 4 weeks from baseline to week 8 (3 doses) and every 8 weeks until week 32.
223815803|NCT05916976|DIAGNOSTIC_TEST|cardiac MRI|Multiparametric MRI of the heart
223815804|NCT04995237|BEHAVIORAL|PPP|Participants will be provided with a weekly bag of produce, information about how to cook the produce, assistance in setting quality of life goals, and individualized teaching to support meeting participant's set goals.
223815805|NCT05025501|BEHAVIORAL|Family based Executive Function Training|Training the executive funtions of shcoolage ADHD children through tasks and games repeatly but with fun. Giving the parental training and support for the parenting role parents strategies to help the shcoolage ADHD childred coping the symptoms and develop EF in the reallife and improve parent-child relationship.
223815806|NCT05553639|BIOLOGICAL|HB-302/HB-301 Alternating 2-Vector Therapy|Alternating Therapy of HB-302 and HB-301. The first 5 doses will be administered every 3 weeks. The 6th dose will be administered 6 weeks after the 5th dose. Subsequent doses will be administered every 6 weeks.
223815807|NCT04167995|DRUG|Probiotic Formula lacteal forte|Active Comparator: Patient with attention deficit hyperactive disorder patients (n=40) will receive probiotic preparation twice daily (Lacteol Forte; Rameda, Egypt) as sachets containing 10 billion colony forming units (CFU) of Lactobacillus fermentum and Lactobacillus delbruekii for 12 weeks .
223815808|NCT01737684|DRUG|Vibegron|50 mg tablet, oral
223815809|NCT03990584|PROCEDURE|three irrigation activation methods|passive ultrasonic irrigation, sonic irrigation, manual dynamic irrigation
223815810|NCT03990584|PROCEDURE|conventional needle irrigation|conventional needle irrigation
223815811|NCT00472771|DRUG|INNO-206|
223815812|NCT05747339|BIOLOGICAL|tumor treatment vaccine injection|Patients will receive tumor treatment vaccine(TTV), which would be given deep subcutaneously in the arm or near the tumor.The initial dose is 1ml / week, if the reaction isn't obvious, the dose can be appropriately increased to 2.5-4.0ml / week.The interval between injections can be shortened or extended depending on the patient's condition and response.The duration of treatment should be extended as long as possible, at least 6-12 months.
223815813|NCT01167283|DEVICE|Electrostimulation|Electrostimulation: 35 Hz, 0.4 ms, 1 h; 5 times/week
223815814|NCT01167283|DEVICE|Sham stimulation|Sham stimulation: 1 h; 5 times/week
223815815|NCT01386996|DRUG|Budesonide/formoterol Easyhaler 320/9 microg|2 inhalations as a single dose
223815816|NCT01386996|DRUG|Symbicort Turbuhaler forte|2 inhalations as a single dose
223815817|NCT00877981|PROCEDURE|Minimal invasive Parathyroid surgery|
223815818|NCT01822938|OTHER|incentive program for physical activity|
223815819|NCT04703296|BEHAVIORAL|MBAT course|"The MBAT will involve:~(i) 4 weekly 1.5-hour course sessions. The sessions will provide guided exercises, didactic information, and discussions to promote greater mindfulness.~(ii) Daily mindfulness practice that will be facilitated by the Measuring Mindfulness App (MMA) and/or instructor-delivered mindfulness practices. The daily mindfulness practice will require about 15 minutes to complete."
223815820|NCT00978965|GENETIC|MPA SNP|Functional relevant MPA SNP will be sought in patients DNA isolated from leucocytes
223815821|NCT02990416|BIOLOGICAL|A-dmDT390-bisFv(UCHT1)|anti-T cell immunotoxin (antibody targeting CD3 on T-cells tagged with diphtheria toxin without binding domain)
223815822|NCT02990416|BIOLOGICAL|Pembrolizumab|A humanized monoclonal immunoglobulin (Ig) G4 antibody directed against human cell surface receptor PD-1 (programmed death-1 or programmed cell death-1) with potential immune checkpoint inhibitory and antineoplastic activities.
223815823|NCT02990416|RADIATION|Ionizing Radiation|Electromagnetic or corpuscular radiation capable of producing ions, directly or indirectly, in its passage through matter.
223815824|NCT02462850|DRUG|CL-108|
223815825|NCT03819725|DEVICE|Glucose monitoring|FreeStyle® Libre Pro Interstitial Glucose Meter will be applied after skin preparation with anesthetic cream (Emla®) . Interstitial glucose measurements will be recorded during 2-5 days and during meals.
223815826|NCT02266602|RADIATION|Intraoperative Radiation Therapy|Intraoperative radiation therapy at the time of partial mastectomy in early stage breast cancer
223815827|NCT03782090|DEVICE|Endobronchial intubation|"1. In control group, endobronchial intubation is performed using conventional technique with left-sided double-lumen endobronchial tube(Shiley®). The tube is introduced into the glottis via direct laryngoscopy. After the tube tip passes the vocal cord, the tube is rotated 90º toward the left. The tube is advanced according to the depth(cm) of the tube calculated by the height of patient(12.5+0.1\*height). Afterwards, the depth of the tube is adjusted by the compliance of both lung.~2. In experimental group, patients are intubated with novel double-lumen endobronchial tube(Ankor®). The tube is introduced into the glottis via direct laryngoscopy. After the tube tip passes the vocal cord, the tube is rotated 90º toward the left. Once the carinal cuff of the tube is passed through the vocal cord of patients, the carinal cuff is inflated with 5-8ml of air. The tube is advanced until the tube stops itself at some point along the tracheobronchial tree. And then the carinal cuff is deflated."
223815828|NCT05526586|OTHER|Colgate Cavity Protection Toothpaste|Participants will use Colgate Cavity Protection Toothpaste for brushing teeth twice daily.
223815829|NCT05526586|OTHER|Zero Alcohol Gum Prototype|Participants will use 20 mL of Zero Alcohol Gum Prototype Mouth Rinse for 30 seconds after brushing twice daily.
223815830|NCT05526586|OTHER|Alcohol Gum Prototype|Participants will use 20 mL of Alcohol Gum Prototype Mouth Rinse for 30 seconds after brushing twice daily.
223815831|NCT05526586|OTHER|Listerine Cool Mint Antiseptic Mouthwash|Participants will use 20 mL of Listerine Cool Mint Mouth Rinse for 30 seconds after brushing twice daily.
223815832|NCT05526586|OTHER|5% Hydroalcohol|Participants will use 20 mL of 5% Hydroalcohol Mouth Rinse for 30 seconds after brushing twice daily.
223815833|NCT02224963|BEHAVIORAL|Preventive Problem-Solving Training|Preventive Problem-solving Training is an adaptation of Problem-Solving Therapy that builds problem-solving skills and then focuses these skills on potential future problems. It aims to reduce avoidance of contemplation of future needs and enhance gathering information, decision-making, and concrete planning about future needs.
223815834|NCT02224963|BEHAVIORAL|Life and Health Review|Life and Health Review is an Enhanced Attention Control that provides classes and resource information modules, just as in intervention. It differs from the intervention in that we conduct an 8-session life and health review with subjects, in which they recount life experiences from childhood to the present.
223815835|NCT01433523|DRUG|ALK HDM AIT Placebo|Oral lyophilisate, Placebo, to be administered sublingually once daily
223815836|NCT01433523|DRUG|ALK HDM AIT 6 DU|Oral lyophilisate, 6 DU, to be administered sublingually once daily for 14-18 months.
223815837|NCT01433523|DRUG|ALK HDM AIT 12 DU|Oral lyophilisate, 12 DU, to be administered sublingually once daily for 14-18 months.
223815838|NCT01106053|DRUG|Pramipexole|Pramipexole tablet titrated up to a maximum dosage of 0.5 mg three times daily (1.5 mg/day).
223815839|NCT01276561|PROCEDURE|Single Incision Splenectomy|Patients will undergo laparoscopic splenectomy through a single incision
223815840|NCT01276561|PROCEDURE|Laparoscopic Splenectomy|Patients will undergo laparoscopic splenectomy with 4 ports, placement is surgeon dependent
223815841|NCT05713201|PROCEDURE|Percutaneous Coronary Intervention|Treatment of coronary stenoses with a drug-eluting stent or balloon
223815842|NCT01117701|PROCEDURE|Ureteroscopy with and without safety guidewire|In study arm A - with SGW, the force measurements are made with a safety guidewire in place. In study arm B - without SGW, the force measurements are made without SGW.
223815843|NCT02572947|DRUG|Dolutegravir|
223815844|NCT00518934|OTHER|Study for safety and efficiency of therapeutic angiogenesis for patients with limb ischemia by transplantation of human cord blood mononuclear cell|
223815845|NCT05550363|DRUG|Dexycu|103.4 mcg/mcl dexamethasone: equivalent dexamethasone dose: 517 mcg
223815846|NCT05550363|OTHER|Placebo/Vehicle|Placebo/vehicle, 0 mcg/mcl dexamethasone: equivalent dexamethasone dose: 0 mcg
223815847|NCT03645135|OTHER|Goal elicitation|Patients will be asked to list 2 goals for their visit
223815848|NCT05061537|BIOLOGICAL|PF-07263689|Genetically engineered oncolytic vaccinia virus
223815849|NCT05061537|BIOLOGICAL|Sasanlimab|A monoclonal antibody that blocks the interaction between PD-1 and PD-L1/ PD-L2
223815850|NCT03502616|DRUG|Tofacitinib|Oral administration twice per day
223815851|NCT06056921|BIOLOGICAL|CD19 targeted CAR-T cells|A single infusion of CD19 CAR-T cells will be administered intravenously
223815852|NCT02008591|PROCEDURE|Epidural Technique versus Dural Puncture Epidural Technique versus Combined Spinal Epidural Technique|Three different techniques, using the same medications (bupivacaine and fentanyl)
223815853|NCT02924324|DEVICE|propofol|
223815854|NCT02924324|DRUG|ropivacaine|
223815855|NCT02924324|BEHAVIORAL|Wong-Baker FACES® Pain Rating Scale|Nurses will record patient-reported pain scores.
223815856|NCT02924324|BEHAVIORAL|Post-procedural quality of life (QOL)|
223815857|NCT05800704|DIETARY_SUPPLEMENT|Nagasin|Lactobacillus, Lactococcus and Bifidobacteria strains with antimicrobial effect against C. difficile
223815858|NCT05800704|DIETARY_SUPPLEMENT|maltodextrin|maltodextrin (placebo comparator)
223815859|NCT05028153|DRUG|Azithromycin Oral Liquid Product|10 mg/kg for 3 consecutive days
223815860|NCT05028153|OTHER|Placebo mixture|Placebo mixture containing no active substance
223815861|NCT03331133|OTHER|No intervention|
223815862|NCT04892784|DEVICE|Press tack needle acupuncture|Pyonex press tack needle sized 0.20x1.2mm
223815863|NCT00076960|DRUG|Stanate (TM) [stannsoporfin, tin-mesoporphyrin]|Treatment with 4.5 mg/kg
223815864|NCT01433484|BEHAVIORAL|Maintenance of Weight Loss--Control|As the maintenance of weight loss randomized trial does not begin until a year after the start of this study, the intervention and control conditions are not yet specified. This will occur before randomization and this section will be updated before the first participant is randomized.
223815865|NCT01433484|BEHAVIORAL|Maintenance of Weight Loss--Experimental|
223815866|NCT03297931|DIETARY_SUPPLEMENT|Corn Chips + Onion Dip|Non-pulse chip + non-pulse dip
223815867|NCT03297931|DIETARY_SUPPLEMENT|Yellow pea chip + hummus|Novel pulse chip + pulse spread
223815868|NCT03297931|DIETARY_SUPPLEMENT|Pinto bean chip + hummus|Commercial pulse chip + pulse spread
223815869|NCT03297931|DIETARY_SUPPLEMENT|Pinto bean chip + onion dip|Commercial pulse chip + non-pulse spread
223815870|NCT03297931|DIETARY_SUPPLEMENT|Yellow pea chip + onion dip|Novel pulse chip + non-pulse spread
223815871|NCT03297931|DIETARY_SUPPLEMENT|Corn chips + hummus|Non-pulse chip + pulse spread
223815872|NCT03156634|OTHER|PALS|PALS is a web based patient education system that uses text and audiovisual formats to deliver patient education materials.
223815873|NCT03156634|OTHER|WebMD|WebMD is an internet based health information source.
223815874|NCT03609346|DEVICE|PCI|The placement of 1 or more stents in the diseased coronary artery lesion(s).
223815875|NCT05525936|DIAGNOSTIC_TEST|Echocardiography and central venous pressure|To perform an echocardiography, transthoracic or transesophageal and to measure central venous pressure through a central venous line.
223815876|NCT06437197|PROCEDURE|Pulpotomy|Removal of the coronal pulp chamber in an adult teeth
223815877|NCT03724396|BEHAVIORAL|Behavioral Weight Loss - BWL|All participants will be instructed on how to consume a balanced deficit diet of conventional foods; individual goals for energy intake will be based on initial body weight. Participants will be instructed in measuring portion sizes, counting calories (with a calorie counter provided or on their phone), and self-monitoring food intake. The physical activity program will focus on increasing both lifestyle activity and structured exercise programs. Behavior change recommendations include stimulus control, self-monitoring, goal setting, managing high-risk situations, meal planning, slowing eating, problem solving, social support, cognitive restructuring, lapse and relapse prevention skills, and maintaining weight loss.
223815878|NCT03724396|BEHAVIORAL|Novel Executive Function Training - NEXT|Modifies programs like CogSMART and cognitive remediation training to help participants improve executive functioning to adhere to recommendations from BWL.
223815879|NCT06792968|DRUG|Empagliflozin + Metformin hydrochloride 5 mg/1000 mg combination film-coated tablets|1 tablet of Empagliflozin + Metformin hydrochloride 5 mg/1000 mg combination film-coated table
223815880|NCT06792968|DRUG|Synjardy 5 mg/1000 mg film-coated tablets|1 tablet of Empagliflozin+Metformin 5 mg/1000 mg filmcoated tablets
223815881|NCT05706545|DIAGNOSTIC_TEST|Acquisition of cardiovascular signals and microcirculation sidestream darkfield images|ECG, arterial pressure and peripheral flow velocity via a percutaneous laser doppler will be acquired together with images of the sublingual microcirculation detected with sidestream darkfield images microscope
223815882|NCT05465902|BIOLOGICAL|Recombinant COVID-19 variant Vaccine (Sf9 Cell)|1dose, Intramuscular Injection
223815883|NCT05465902|BIOLOGICAL|COVID-19 Vaccine (Vero Cell), Inactivated|1dose, Intramuscular Injection
223815884|NCT05465902|BIOLOGICAL|mRNA COVID-19 vaccine (Moderna)|1dose, Intramuscular Injection
223815885|NCT05465902|BIOLOGICAL|Viral Vector COVID-19 vaccine (AstraZeneca)|1dose, Intramuscular Injection
223815886|NCT00387582|DRUG|Ranibizumab (Lucentis)|Lucentis 0.5 mg monthly for the first three months and then per protocol for the duration of the trial.
223815887|NCT00387582|PROCEDURE|Argon Laser|Argon laser at entry to trial and then per protocol for the duration of the study.
223815888|NCT02770781|OTHER|Exercise regimen|Subjects will receive a personal exercise regimen based on their health history and individual capability.
223815889|NCT02386657|OTHER|Satisfaction|Satisfaction questionnaire to be filled in
223815890|NCT02386657|OTHER|Biological parameters|Measure of standard routine biological parameters (Hb, GB, Plaq, LDH, CRP, TCA, INR, D Dimers) and dosage of nitrous albumin (PNA).
223815891|NCT02386657|OTHER|Pain management|Validated pain scale questionnaire to be filled in
223815892|NCT03045848|DEVICE|Biofreedom drug-coated stent|BioFreedom (Biosensors International Technologies, Singapore) is the only polymer- and carrier-free drug coated stent with Biolimus A9 in a selectively micro-structured abluminal surface. It is a stainless steel bare metal surface with 120 micron thick corrugated ring strut.
223815893|NCT03879408|DRUG|440 mg naproxen sodium with 1000 mg acetaminophen|440 mg naproxen sodium with 1000 mg acetaminophen administered as a single dose of two naproxen sodium 220 mg tablets and two acetaminophen 500 mg tablets
223815894|NCT03879408|DRUG|220 mg naproxen sodium with 650 mg acetaminophen|220 mg naproxen sodium with 650 mg acetaminophen administered as a single dose of one naproxen sodium 220 mg tablet and two acetaminophen 325 mg tablets and one placebo tablet
223815895|NCT03879408|DRUG|10 mg hydrocodone + 650 mg acetaminophen|10 mg hydrocodone with 650 mg acetaminophen administered as a single dose of two hydrocodone 5 mg + acetaminophen 325 mg tablets and two placebo tablets
223815896|NCT03879408|DRUG|440 mg naproxen sodium|440 mg naproxen sodium administered as a single dose of two naproxen sodium 220 mg tablets and two placebo tablets
223815897|NCT03879408|DRUG|Placebo tablet|Single dose of four placebo tablets
223815898|NCT02721576|DRUG|Sodium Glycididazole|Sodium Glycididazole 800mg/m2.Three times a week (once every other one day),before radiation therapy, total 5-6 weeks.
223815899|NCT01490125|DRUG|QVA149|QVA149 110/50 μg hard non-gelatin capsule, inhalation/blister once a day via SDDPI
223815900|NCT01490125|DRUG|Tiotropium|Tiotropium 18 ug hard gelatin capsule, inhalation/ blister once a day via HandiHaler® device
223815901|NCT01490125|DRUG|Placebo to QVA149|Placebo 0 mg hard non-gelatin capsule, inhalation/ blister once a day via SDDPI
223815902|NCT01490125|DRUG|Placebo to tiotropium|Placebo 0 mg hard gelatin capsule, inhalation/ blister once a day via HandiHaler® device
223815903|NCT01490125|DRUG|Salbutamol/albuterol|salbutamol/albuterol (containing CFC-free propellant -HFA 134a) inhaler used as rescue medication when needed.
223815904|NCT01160874|OTHER|Polysomnography|Sleep study monitoring
223815905|NCT01160874|OTHER|Maintenance Wakefulness Test|Sleep latency testing at 10 am, 12 am, 2 pm and 4 pm.
223815906|NCT01160874|BEHAVIORAL|Neuropsychological evaluation|Neuropsychological evaluation for cognitive functions study
223815907|NCT01160874|OTHER|Driving test on a simulator|Driving simulator test during wich a camera register different parameters as the position of the vehicle.
223815908|NCT06064864|DRUG|Infliximab-Dyyb|Continued infliximab SC 120 mg every other week, if response to SC infliximab at week 30
223815909|NCT04616014|DRUG|ORMD-0801 QD|16 mg, QD, two capsules, 8 mg each.
223815910|NCT02889666|DRUG|Cisplatin|Procedure: Preoperative chemotherapy using Cisplatin (60mg) as single agent was performed 30 days before surgery through intravenous (IV) administration. IV administration once every 7 days, totally 4 cycles. There is a 2-day interval between the last dose and surgery.
223815911|NCT02889666|DRUG|Carboplatin|Procedure: Preoperative chemotherapy using Carboplatin (400mg) as single agent was performed 30 days before surgery through intravenous (IV) administration. IV administration once every 7 days, totally 4 cycles. There is a 2-day interval between the last dose and surgery.
223815912|NCT02889666|DRUG|Docetaxel|Procedure: Preoperative chemotherapy using Docetaxel (120mg) as single agent was performed 30 days before surgery through intravenous (IV) administration. IV administration once every 7 days, totally 4 cycles. There is a 2-day interval between the last dose and surgery.
223815913|NCT02889666|DRUG|Gemcitabine/Carboplatin|Procedure: Preoperative chemotherapy using Gemcitabine (200mg) and Carboplatin (400mg) as combinational therapy agent was performed 30 days before surgery through intravenous (IV) administration. IV administration once every 7 days, totally 4 cycles. There is a 2-day interval between the last dose and surgery.
223815914|NCT02889666|DRUG|Gemcitabine/Cisplatin|Procedure: Preoperative chemotherapy using Gemcitabine (200mg) and Cisplatin (60mg) as combinational therapy agent was performed 30 days before surgery through intravenous (IV) administration. IV administration once every 7 days, totally 4 cycles. There is a 2-day interval between the last dose and surgery.
223815915|NCT02889666|DRUG|Docetaxel/Oxaliplatin|Procedure: Preoperative chemotherapy using Docetaxel (120mg) and Oxaliplatin (200mg) as combinational therapy agent was performed 30 days before surgery through intravenous (IV) administration. IV administration once every 7 days, totally 4 cycles. There is a 2-day interval between the last dose and surgery.
223815916|NCT02889666|DRUG|Docetaxel/Carboplatin|Procedure: Preoperative chemotherapy using Docetaxel (120mg) and Carboplatin (400mg) as combinational therapy agent was performed 30 days before surgery through intravenous (IV) administration. IV administration once every 7 days, totally 4 cycles. There is a 2-day interval between the last dose and surgery.
223815917|NCT02889666|DRUG|Placebo|Regular placebo in replacement of agent-specific chemotherapy was supplied to these patients.
223815918|NCT03517423|DRUG|Brivaracetam|An antiepileptic drug whose putative mechanism of action is as a result of direct inhibition of SV2A receptors, responsible for the successful release of excitatory neurotransmitters from the the neuronal presynaptic membrane.
223815919|NCT02507778|DEVICE|CellCollectorTM (Gilupi, Germany) needle|needle will be inserted before and after biopsy and will measure circulating tumor cells.
223815920|NCT01320930|BEHAVIORAL|Pulmonary rehabilitation|
223815921|NCT01320930|BEHAVIORAL|conventional care|
223815922|NCT02237508|DRUG|Z7200 without oral activated charcoal|160 ug budesonide and 4.5 ug formoterol fumarate dihydrate, administered as two inhalations (2 x Z7200 capsules) of budesonide 80 ug/inhalation and formoterol 2.25 ug/inhalation, using an RS01 inhaler (Treatment A).
223815923|NCT02237508|DRUG|Symbicort Turbohaler without oral activated charcoal|320 ug budesonide and 9 ug formoterol fumarate dihydrate, administered as two inhalations of budesonide 160 ug/inhalation and formoterol 4.5 ug/inhalation (Treatments B1 and B2).
223815924|NCT02237508|DRUG|Z7200 with oral activated charcoal|160 ug budesonide and 4.5 ug formoterol fumarate dihydrate, administered as two inhalations (2 x Z7200 capsules) of budesonide 80 ug/inhalation and formoterol 2.25 ug/inhalation, using an RS01 inhaler with a charcoal blockade (Treatment C).
223815925|NCT02237508|DRUG|Symbicort Turbohaler with oral activated charcoal|320 ug budesonide and 9 ug formoterol fumarate dihydrate, administered as two inhalations of budesonide 160 ug/inhalation and formoterol 4.5 ug/inhalation from a Symbicort Turbohaler, with charcoal blockade (Treatment D).
223815926|NCT02816086|OTHER|Interdisciplinary collaboration structure|A pharmacist is integrated in the team surrounding the patient, working by the Integrated Medicines Management (IMM) model. The IMM-model consist of medication reconciliation, medication review, standardized medication reports and counseling patients about their medication at discharge. In addition a phone meeting between the primary care physician and the study pharmacist is added after discharge.
223815927|NCT01446484|BIOLOGICAL|CD4+CD25+CD127lowFoxP3+ T regulatory cells injection|Blood samples from patients in the experimental group will be collected twice with weekly interval in the amount of 70 ml/1,73 m2. T cells CD4+ will be separated from blood samples and frozen in liquid nitrogen. At day 30 after transplantation patients will undergo subcutaneous injection of approximately 2x 10\^8 autologous T regs, expanded from previously frozen CD4+ T cells. Levels of T reg cells in patient's blood will be estimated by flow cytometry in a week after injection. That cell injection procedure will be repeated at 6 months after transplantation
223815928|NCT01446484|DRUG|Alemtuzumab|Immunosuppressant; 2 doses of drug by intravenous infusion on Days 14 - 21 before Tx and on Day 0 after Tx
223815929|NCT01446484|DRUG|Mycophenolate mofetil|Immunosuppressant; oral daily dose starting Day 2-3 until withdrawal or end of the study
223815930|NCT01446484|DRUG|Sirolimus|Immunosuppressant; oral daily dose starting no earlier then after Month 1 post-transplant until withdrawal or end of the study
223815931|NCT01446484|DRUG|Tacrolimus|Immunosuppressant; daily dose starting Day 0 until withdrawal or end of the study
223815932|NCT01446484|DRUG|Cyclosporine|Immunosuppressant; daily dose starting Day 0 until withdrawal or end of the study
223815933|NCT01446484|DRUG|Everolimus|Immunosuppressant; oral daily dose starting no earlier then after Month 1 post-transplant until withdrawal or end of the study
223815934|NCT01446484|PROCEDURE|Kidney transplantation|Living related kidney transplantation
223815935|NCT04967963|PROCEDURE|HAM|Transplantation of HAM
223815936|NCT05590884|DRUG|Gadopiclenol|Patients will receive a single dose of gadopiclenol calculated according to their BW on the day of MRI examination. Gadopiclenol will be administered at a dose of 0.05 mmol/kg BW (0.1 mL/kg BW).
223815937|NCT05840081|OTHER|Milk or yogurt beverage|Commercially available milk or yogurt (depending on experimental arm) will be incorporated into flavored drinks/smoothies to minimize perceived differences among these items, preserving the double-blind nature of the study design.
223815938|NCT04997317|DRUG|177Lu-DOTA-JR11 (Phase 0); Cycle 1 and Cycle 2 (cross-over)|177Lu-DOTA-JR11 has three main components, namely the somatostatin analogue JR11, the chemical chelator group DOTA and the beta emitter 177Lutetium (177Lu). In the Phase 0 part of the study 177Lu-DOTA-JR11 will be administered once intravenously. The activity of the first 2 cycles will be capped at 4.5 GBq (range: 4.2-4.6 GBq).
223815939|NCT04997317|DRUG|177Lu-DOTATOC (Phase 0); Cycle 1 and Cycle 2 (cross-over), Cycle 3 and 4|177Lu-DOTATOC is a therapeutic medicinal product and has 3 main components (a) 177Lutetium (177Lu), a beta-emitting radionuclide with a half-life of 6.64 days; (b) DOTA, a chemical chelator group; and (c) TOC (= \[Tyr\]3-octreotide) an agonistic somatostatin analogue which binds to sstr2 and sstr5 receptors. In the Phase 0 part of the study 177Lu-DOTATOC will be administered once intravenously. The activity of the first 2 cycles will be capped at 4.5 GBq (range: 4.2-4.6 GBq). The remaining 2 cycles will be performed with an activity of 7.4 GBq 177Lu-DOTATOC (total number of cycles = 4).
223815940|NCT04997317|DRUG|177Lu-DOTA-JR11 (Phase I/II)|In the phase I/II part of the study: 3 cycles of 177Lu-DOTA-JR11 will be administered with an activity of 4.5-7.4 GBq. Two additional 177Lu-DOTA-JR11 treatment cycles can be performed if clinically indicated
223815941|NCT04000594|DRUG|RO7234292 (RG6042)|RO7234292 (RG6042) will be administered in two IT doses of the same dose level at an interval of 28 days during the treatment period (Day 1 and Day 29). Each dose of RO7234292 (RG6042) will be administered as a single IT bolus injection.
223815942|NCT06133842|DIAGNOSTIC_TEST|Intra-op EEG and CO data collection|Intra-op EEG and CO data will be collected non-invasively. This will not guide or affect patient care of procedure in any way.
223815943|NCT03513003|DEVICE|Functional Pacifier|Children swap from their habitual pacifier to the functional pacifier and stop baby bottle
223815944|NCT03513003|BEHAVIORAL|Stop habit|Children stop the use of their pacifier and/or baby bottle
223815945|NCT05899179|BIOLOGICAL|Recombinant Mycobacterium Tuberculosis Fusion Protein|"Dosage form:injection. Main ingredients and contents: Recombinant Mycobacterium tuberculosis fusion protein, 0.3ml, 0.5ml, 1.0ml per bottle.~1\. This product is used alone: 0.1ml (5U) of this product is inhaled and injected into the palmar skin of the forearm by the Mondu's method. 2. This product combined with TB-PPD: 0.1ml(5U) of this product and 0.1ml(5U) of TB-PPD were inhaled respectively, and the product was injected intradermally into the volar side of the left forearm by the Mondu's method. After observing no abnormality for 5 minutes, TB-PPD was injected intradermally into the volar side of the right forearm."
223815946|NCT05899179|BIOLOGICAL|Purified Protein Derivative of Tuberculin|"Dosage form:injection. Main ingredients and contents:Pure protein derivatives of tuberculin,0.1ml per bottle.~Usage:0.1ml (5IU) of this product is inhaled and injected into the palmar skin of the forearm by the Mondu's method."
223815947|NCT06120803|DRUG|Esomeprazole 40 mg|Enrolled patients will receive 40 mg of esomeprazole (two pills of 20 mg strength of esomeprazole) once daily before breakfast for the entire duration of TRT (including the weekends and any interim gap period) and for two weeks after completion of thoracic radiation therapy.
223815948|NCT03855787|PROCEDURE|Ureteroscopy|Ureteroscopy for 1.5cm or less renal stones.
223815949|NCT04754139|OTHER|WeChat mobile mini-application|Sexual health education and the role of PrEP
223815950|NCT03301012|OTHER|Recovery support as usual|same as arm
223815951|NCT03301012|OTHER|Smartphone assisted relapse prevention|same as arm
223815952|NCT06064877|BIOLOGICAL|Ficlatuzumab|Ficlatuzumab (AV-299) is a humanized hepatocyte growth factor (HGF) inhibitory immunoglobulin G1 (IgG1) monoclonal antibody (mAb).
223815953|NCT06064877|BIOLOGICAL|Cetuximab|Cetuximab is an epidermal growth factor receptor (EGFR) antagonist.
223815954|NCT06064877|OTHER|Placebo|Placebo for this study will be normal saline
223815955|NCT04522180|DRUG|GHR-LRX|GHR-LRX was administered by SC injection.
223815956|NCT02890953|DRUG|Pneumostem|direct intracerebroventricular injection of mesenchymal stem cells via ventricular tap
223815957|NCT02890953|DRUG|Normal saline|direct intracerebroventricular injection of normal saline via ventricular tap
223815958|NCT05807919|OTHER|Diet low in all FODMAP groups|Randomized participants will eat this diet for 4 weeks (all meals and snacks will be provided). Participants will only eat the study food for this intervention. Participants will be asked to complete surveys, food diaries, and have blood and stools samples pre and post treatment.
223815959|NCT05807919|OTHER|Diet - Mediterranean|Randomized participants will eat this diet for 4 weeks (all meals and snacks will be provided). Participants will only eat the study food for this intervention. Participants will be asked to complete surveys, food diaries, and have blood and stools samples pre and post treatment.
223815960|NCT04705467|DEVICE|Gynecological brachytherapy|Management of gynecological malignancies is done through brachytherapy treatment, which involves the delivery of radiation via radioactive sources that are placed into or in close proximity to the tumour.
223815961|NCT01905046|DRUG|metformin hydrochloride|given PO
223815962|NCT01905046|OTHER|placebo|given PO
223815963|NCT03689075|DRUG|Envarsus Oral Product|Patients will be randomised to receive either envarsus or to continue on an immediate release tacrolimus formulation
223815964|NCT05218993|DIAGNOSTIC_TEST|A new dual-task measurement method with images|Football players will perform Illinois t test with and without cognitive demand with images. These images will represent scenarios from football with some of the players in the scene are from his team and others from opposing team. The player will be asked to look at the image and say the number on the player in following scenarios; The player to whom he can pass the ball, The player who is most likely to intervene the ball, The player who can score the goal. In order to reduce the other possibilities, opposing team players will be positioned in a specific way to block all team-mates but one.
223815965|NCT05218993|DIAGNOSTIC_TEST|A new dual-task measurement method with cards|Football players will perform Illinois t test with and without cognitive demand with cards and balls. On the path of Illinois t test, there will be 3 football balls, 3-meters apart from each other, and there will be cards behind each, which can only be seen when the player about to hit the ball. This cards will vary in color (blue or red), which mean right or left. If the player sees red card, he will shoot the ball to the left side goal and if the player sees blue card, he will shoot the ball to the right side.
223815966|NCT06547892|DRUG|Vasopressin|"To dilute vasopressin, an ampoule containing 20 IU/ml (1 ml) of vasopressin will be used, which will be mixed with 100 ml of 0.9% physiological solution, resulting in a solution with a concentration of 0.2 IU/ ml. In this study, both central and peripheral vein infusion will be permitted.~The vasopressin administration protocol will consist of an initial dose of 0.02 IU/min (equivalent to 6 ml/h), which can be increased to 0.03 IU/min (9 ml/h) if the mean arterial pressure (MAP) is less than or equal to 65 mmHg. On the other hand, if MAP exceeds 90 mmHg, the dose can be reduced to 0.01 IU/min (3 ml/h). The minimum period for adjusting the drug dosage should be one hour."
223815967|NCT06547892|OTHER|0,9% saline solution|Similar to the intervention protocol, but using a placebo composed of 0.9% saline solution.
223815968|NCT06334042|DIAGNOSTIC_TEST|Serum Chromium Level|Measuring serum chromium levels from patients who admitted in intensive care unit.
223815969|NCT05885282|DEVICE|paraspinal vibration|In addition to lumbar spinal stabilization exercises, LV will be applied to the cervical and lumbar paraspinal muscles. Spinal stabilization exercises will be as in the control group. The duration of a session will be 50 minutes, with spinal stabilization exercises 40 minutes and LV 10 minutes.LV will be applied before the exercises. LV will be applied to the cervical paraspinal muscles for a total of 5 minutes (2.5 minutes on the right side, 2.5 minutes on the left side) while the patients are in a sitting position. LV will be applied to the lumbar paraspinal muscles for a total of 5 minutes (2.5 minutes on the right side, 2.5 minutes on the left side) while the patients are lying in the prone position. LV application will be made with Vibrasens © device and vibration frequency 80 Hz amplitude 1 mm will be selected.
223815970|NCT05885282|DEVICE|gastrosoleus muscle complex vibration|In addition to lumbar spinal stabilization exercises, LV will be applied to the gastrosoleus muscle complex. LV application will be applied sequentially, bilaterally, to the gastrosoleus complex. LV will be applied before the exercises. LV will be applied for a total of 10 minutes (5 minutes each on the right and left) while the patients are lying in the prone position. LV application will be made with Vibrasens © device and vibration frequency 80 Hz amplitude 1 mm will be selected.
223815971|NCT05885282|OTHER|Control Exercise|Lumbar spinal stabilization exerciseswill be given. Lumbar spinal stabilization exercises; Diaphragmatic breathing, and contraction of the transversus abdominis and multifidus muscles will be taught in the supine position. Activation of these muscles will be studied in different positions (prone, crawling, sitting, and sitting on different surfaces). The focus will be on increasing kinesthetic awareness. It will be desirable to ensure and maintain the activation of these muscles during subsequent exercises. Exercises will be continued according to the patient's functional status and individual needs. Advancement of exercises; extremity movements on dynamic surfaces, narrowing of support surfaces, reciprocal movements, increasing the number of resistance and repetitions. The duration of a session will be 40 minutes.
223815972|NCT03489057|BEHAVIORAL|Prostate Cancer Education and Resources for Couples (PERC)|PERC uses mHealth technologies to dramatically increase couples' accessibility to posttreatment supportive care whenever and wherever they feel comfortable accessing it. PERC aims to improve QOL for both patients and partners by enhancing positive appraisals of illness and boosting self-efficacy, social support from multiple sources, and healthy behaviors for symptom self-management at home.
223815973|NCT03489057|BEHAVIORAL|usual care plus NCI website|The usual care plus NCI website provides generic information about prostate cancer treatment options, research, causes, and statistics; coping resources that are not prostate cancer-specific; support from non-providers via a toll free phone and LiveHelp Online Chat about cancer-related questions, clinical trials, and quitting smoking.
223815974|NCT03267680|DRUG|Cyclophosphamide|Given IV
223815975|NCT03267680|DRUG|Indomethacin|Given PO
223815976|NCT03267680|BIOLOGICAL|IRX-2|Given via submucosal injection or SC
223815977|NCT03267680|OTHER|Laboratory Biomarker Analysis|Correlative studies
223815978|NCT03267680|DIETARY_SUPPLEMENT|Multivitamin|Given zinc-containing multivitamin PO
223815979|NCT03267680|DRUG|Omeprazole|Given PO
223815980|NCT03267680|OTHER|Placebo|Given via submucosal injections or SC
223815981|NCT03267680|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgical resection
223815982|NCT06632704|DEVICE|Colgate Toothbrush assist|toothbrush handle assignment to all subjects; subjects will have a choice between two brush heads
223815983|NCT04734548|DRUG|ApTOLL|ApTOLL is a Toll-like receptor 4 (TLR4) antagonist, a receptor that is involved in innate immune responses but also responds to tissue damage, and therefore it is directly involved in a large number of diseases where the inflammatory response is involved. ApTOLL has demonstrated specific binding to human TLR4 as well as a TLR4 antagonistic effect, reducing inflammation and improving outcome after different disease models.
223815984|NCT04734548|OTHER|Placebo|White freeze-dried powder which is indistinguishable to ApTOLL for taste, color, texture and size.
223815985|NCT03394521|OTHER|Routine clinical practice|This is an observational study
223815986|NCT05649644|PROCEDURE|Selective Trunk Block (SeTB)|Patient will lie supine on the examination couch with the ipsilateral arm in the neutral position (adducted), neck slightly extended and the head turned slightly to the contralateral side. After local anesthetic (LA) infiltration (1-2 ml lidocaine 1%), the nerve block needle will be inserted and placed within the interscalene groove. Then, a 7 ml of a 1:1 mixture of lidocaine 2% with 1:200,000 epinephrine and levobupivacaine 0.5% will be slowly injected in aliquots. After that, the tip will be redirected lateral to the middle trunk. A further 8 ml of the LA mixture will be injected after which the nerve block needle will be completely withdrawn. The transducer will then be manipulated to a sub-omohyoid position. After LA infiltration, the nerve block needle is inserted in-plane until the needle tip is positioned close to and lateral to (9-12 o'clock position) the inferior trunk. A 10 ml of the LA mixture is injected in small aliquots and the needle will be removed after the injection.
223815987|NCT05649644|PROCEDURE|Supraclavicular Brachial Plexus Block (SC BPB)|Patient will lie supine on the examination couch with the ipsilateral arm in the neutral position (adducted), neck slightly extended and the head turned slightly to the contralateral side. Patient will receive a subcutaneous infiltration with 1-2 ml of 0.9% normal saline (NS) at the superior and middle trunk level after which the needle will be completely withdrawn. Then, a local anesthetic (LA) infiltration (1-2 ml lidocaine 1%) will then be performed at the supraclavicular fossa and the nerve block will be inserted in-plane to place the needle tip at the corner pocket. After that, 15-ml of a 1:1 mixture of lidocaine 2% with 1:200,000 epinephrine and levobupivacaine 0.5% will be slowly injected in aliquots. Once completed, the needle tip is gently withdrawn and redirected into the cluster formed by the divisions of brachial plexus. Then, the remaining 10-ml of the same LA mixture will be injected in small aliquots and the needle will be removed after the injection.
223815988|NCT02030782|OTHER|Quality Improvement (QI) for depression|Major intervention components included a) expert leader teams who planned and implemented the intervention at each clinic, b) care managers who supported primary care clinicians with depression evaluation and management, c) access to cognitive-behavior therapy for depression within each primary care clinic, and d) patient and provider choice regarding treatment modality.
223815989|NCT02030782|OTHER|Usual Care|Usual care enhanced by provider education regarding depression evaluation and management
223815990|NCT03551275|BIOLOGICAL|BCD-132|Dose Escalation Study
223815991|NCT00559299|DRUG|GSK163090|
223815992|NCT00324584|DEVICE|Telemonitoring of glucose values using GlucoNet device|
223815993|NCT01368900|DEVICE|Ulthera® System treatment|Focused ultrasound energy delivered below the surface of the skin.
223815994|NCT05171751|DRUG|Octreotide Injection|Octreotide subcutaneous injection for congenital hyperinsulinemia with ineffective diazine
223815995|NCT01786902|DRUG|DA-3002|
223815996|NCT00000881|DRUG|Cidofovir|
223815997|NCT00000881|DRUG|Probenecid|
223815998|NCT05478980|DIETARY_SUPPLEMENT|Night Time Tea|Night-time Tea
223815999|NCT05478980|DIETARY_SUPPLEMENT|Control Tea|Feel New Tea
223816000|NCT02201914|DRUG|Clomiphene citrate|patients receive clomiphene citrate 100 mg daily starting on day 2 for 5 days and 450 IU recombinant FSH and 225 IU recombinant LH daily starting on day 5; Cetrorelix 0,25 mg was administered daily when one or more follicle reached 13-14 mm in diameter until the hCG injection
223816001|NCT02201914|DRUG|Daily FSH and LH plus Cetrorelix|Women receive an initial daily dose of 450 IU recombinant FSH and 225 IU recombinant LH starting on day 3; Cetrorelix 0,25 mg was administered daily when one or more follicle reached 13-14 mm in diameter until the hCG injection.
223816002|NCT02201914|DRUG|Triptorelin plus daily FSH anh LH|women receive short-acting Triptorelin 0,05 mg daily starting on day 1 until the hCG injection and 450 IU recombinant FSH and 225 IU recombinant LH daily starting on day 2.
223816003|NCT05753787|OTHER|preservative-free solution of standard post-cataract eye drops|Usage of preservative-free eye drops in comparison to the standard preserved drops with dexamethasone 0.01%.
223816004|NCT04027348|DRUG|Dexamethasone|Given IV
223816005|NCT04027348|DRUG|Metoclopramide|Given IV
223816006|NCT04027348|DRUG|Octreotide|Given IV
223816007|NCT02622204|PROCEDURE|Corrective osteotomy|corrective osteotomy for varus alignment
223816008|NCT03943966|DIAGNOSTIC_TEST|18F-GP1 PET CT|PET CT scan using platelet radiotracer 18F-GP1
223816009|NCT02701127|DRUG|Oral niacinamide, 1 gram daily|
223816010|NCT02701127|DRUG|Oral niacinamide, 3 gram daily|
223816011|NCT02701127|DRUG|Placebo|
223816012|NCT02932046|DIETARY_SUPPLEMENT|Standardized noon meal|"The meal is treatment as usual in the specialized somatic stabilization ward for patients with severe anorexia nervosa."
223816013|NCT04859634|DEVICE|Taking an ultra-widefield fundus image|The participant only needs to take an ultra-widefield fundus image as usual.
223816014|NCT00283920|DRUG|[(11)C] PBR28|
223816015|NCT02076984|PROCEDURE|Laparoscopic incisional or ventral hernia repair|
223816016|NCT02487472|OTHER|Data collection|Data sheet, ZBPI questionnaire and EQ-5D 5L Health state questionnaire
223816017|NCT04505501|DRUG|N-803|N-803 is a novel IL-15 superagonist complex that enhances NK cell and CD8+ T-cell proliferation and activation.
223816018|NCT03785067|DRUG|telmisartan 20mg + amlodipine 2.5mg +indapamide 1.25mg|1 capsule taken orally once daily for 36 months
223816019|NCT03785067|DRUG|Placebo oral capsule|1 capsule taken orally once daily for 36 months
223816020|NCT05598242|BIOLOGICAL|Amniotic membrane extract eye drops (AMEED)|Following a 2-week wash out period, patients were allocated randomly to receive AMEED, administered as 1 drop in each eye 6 times daily, respectively, for 30 days.
223816021|NCT01622010|BEHAVIORAL|Allied Health Education Class Option|An Allied Health Education Class is provided as part of standard care on an optional basis. It involves a one time attendance at a 90 minute class which provides basic education from a multidisciplinary team.
223816022|NCT01622010|OTHER|Physiotherapy treatment intervention on referral|The option exists for referral to physiotherapy, according to standard protocol, for assessment and individual exercise prescription.
223816023|NCT01622010|DEVICE|Keeping the Beat with Physiotherapy: Heart Failure edition|Educational DVD covering the basics of physiotherapy education for the patient with heart failure.
223816024|NCT01226901|DRUG|MK-4827|MK-4287, 150 mg or 300 mg capsule, orally, once daily in 21 day cycles.
223816025|NCT02034708|DRUG|Dotarem®|Dotarem® 0.1 mmoL/kg (0.2 mL/kg), intravenous (I.V.) bolus.
223816026|NCT02034708|DRUG|Gadovist®/Gadavist®|Gadovist®/Gadavist®, 0.1mmol/kg (0.1mL/kg), intravenous (I.V.) bolus.
223816027|NCT00220974|BEHAVIORAL|Internet-based tailored advice on cardiovascular risk|
223816028|NCT03817138|OTHER|Exposures: Markers of disease progression|From early phases of the study, it is expected that six main domains will be assessed which will include over N=100 potential markers reflecting different markers of dementia disease progression identifiable from patients' primary care EHR.
223816029|NCT02716337|DIETARY_SUPPLEMENT|Addition of human milk fortifiers according to human milk analysis|
223816030|NCT00973661|BEHAVIORAL|Electronic tool set for counseling overweight patients|"Physicians randomized to the electronic tools arm will receive access to a tool set to aid with counseling of overweight patients. This tool set includes the following components: automatic calculation of BMI, alert for overweight status, counseling template for weight loss goal-setting, linkage to referral options, and access to relevant patient handouts. Physicians randomized to the usual care arm will not receive access to these tools, and will continue to provide their usual care for overweight patients."
223816031|NCT04983563|DEVICE|Actigraphy, eTact|Actigraphy will be realized twice a day during 30 minutes and Lipsitz scoring system will be realized at the same moment to analyze the correlation between Lipsitz scoring system and actigraphy.
223816032|NCT02897908|PROCEDURE|vibration controlled transient elastography (VCTE)|Once on the examination table, the subject will be instructed to place the right arm under their head and to cross their right ankle over the left ankle. The subject will then be asked to slightly bend to the left side to open the intercostal space. Subsequently, a handheld probe is placed in the intercostal space overlaying the right hepatic lobe. The velocity of returning shear waves, measured at a depth of 25-65 mm, is converted into a liver stiffness measurement (LSM). The LSM obtained from a given VCTE exam is the median value of at least 10 successful measurements. This information, along with clinical data associated with the patient will be placed in a database for use in identifying potential subjects for future trials.
223816033|NCT01382329|BIOLOGICAL|H5N1 (pre-)pandemic influenza vaccine (whole virion, Vero Cell derived, inactivated)|Intramuscular injection into the musculus deltoideus or subcutaneous injection in the upper arm
223816034|NCT02592538|DEVICE|radiofrequency ablation|All patients underwent biliary sphincterotomy. Cholangiogram was performed to confirm stricture location, length and diameter. The Habib Endo HPB (Hepatobiliary) probe (EMcision, HitchinHerts, UK) was then advanced over a wire at the level of the biliary stricture and ablation using ERBE generator set at 7-10 watts for a time period of 90-120 s was conducted. A 1- to 2-min resting period after energy delivery was allowed before moving the catheter along the length of the stricture to ablate the rest of the stricture.
223816035|NCT02592538|DRUG|S-1|In the RFA plus S-1 group, treatment with S-1 began within 1 month after RFA. Based on the patient's body surface area, S-1 was administered as follows: when the level of total bilirubin was less than 2 mg/dl. Based on the body surface area, S-1 was administered if \<1.25 m2, 80 mg/day; if 1.25-1.5 m2, 100 mg/day; if≥1.5 m2, 120 mg/day. S-1 was administered orally twice daily for 14 days, followed by 7 days without treatment.
223816036|NCT02592538|DEVICE|Stent|Plastic stent(s) were placed after RFA depending on the location of the malignant obstruction
223816037|NCT05782257|DIETARY_SUPPLEMENT|Zinc Supplementation|Take one 25mg Zn gluconate tablet daily
223816038|NCT05782257|OTHER|Zn-Optimized Diet|Consume 11 mg/day of zinc-rich foods for females and 14 mg/day in males.
223816039|NCT00153959|BEHAVIORAL|acute psychiatric day care|
223816040|NCT03455322|DRUG|norepinephrine versus midodrine & octreotide|either intravenous infusion (IVi) norepinephrine in a dose of 0.05-0.3ug/Kg/min. to keep mean arterial pressure ≥ 80-100mmHg \& continued either until HRS reversal or for maximum 10 days or oral midodrine 5mg three times/day \& can be increased every 24h up to 12.5mg three times daily plus octreotide 100ug/ 6h subcutaneous \& if needed increased to 200ug/6h.
223816041|NCT01552954|BEHAVIORAL|Intensive education of low salt diet|For 8 weeks, dietitian will call patients to take the information according to pre-defined questionnaire, to check the daily diet habit and daily food taken, and to guide how to lessen sodium intake for 30 min at each call. The call will be done once a week for 8 weeks.
223816042|NCT04843930|DEVICE|AKL-T01|AKL-T01 will be administered as a 6-week intervention. It is an algorithmically delivered iPad-based video game designed to improve cognitive health by targeting attention and attentional control processes.
223816043|NCT01265901|DRUG|Sunitinib|As per label.
223816044|NCT01265901|BIOLOGICAL|GM-CSF|Intradermal injection of GM-CSF as adjuvant.
223816045|NCT01265901|DRUG|Cyclophosphamide|One single low-dose i.v. infusion prior to the first vaccination
223816046|NCT01265901|DRUG|IMA901|Intradermal vaccinations with IMA901 vaccine.
223816047|NCT00516464|DRUG|Lucentis (ranibizumab)|
223816048|NCT01970605|PROCEDURE|Surgical reconstruction|"In contrast to silver acetate impregnated vascular graft, Silver Graft can be immersed in an antibiotic containing solution prior to implantation. This practice should always be followed according to each participant's hospital guidelines and experience. The long term efficacy of the metallic silver coating will not be reduced.~Common practice antibiotic co-medication before, during and after surgery needs to be documented but is at the discretion of each participating institution.~Due to the registry character of this assessment, i.e. routine use of the investigational product, local antibiotics, e.g. dipping of the vascular graft into a rifampin solution is permissible."
223816049|NCT03119727|DEVICE|FreeO2|All include patients will have automatic administration of oxygen by FreeO2 up to 3 day or until weaning of oxygen adminisatrion
223816050|NCT03042598|DEVICE|Biphasic Cuirass Ventilation|The RTX Respirator will be applied to the patient's chest to provide non-invasive ventilatory support using a Biphasic Cuirass Ventilation technology to increase the safe apnic period during intubation.
223816051|NCT01599923|BIOLOGICAL|Antivenin Centruroides (scorpion) equine immune F(ab')2|3 vials of Alacramyn reconstituted in 50 ml of normal saline as an IV infusion over 10 minutes.
223816052|NCT04391946|BEHAVIORAL|Data registry|Collection of clinical data, treatment regimens and survival data
223816053|NCT03655925|DIAGNOSTIC_TEST|plasmatic HLA-G|plasmatic HLA-G by blood sample
223816054|NCT00223626|DRUG|Topiramate|the maximum topiramate test dose is 200 mg/d.
223816055|NCT01355601|OTHER|Nutritional Beverage|Nutritional Beverage with varying types and levels of carbohydrates
223816056|NCT01355601|OTHER|Nutritional Beverage|Nutritional beverage with varying types and levels of carbohydrates
223816057|NCT02708225|BEHAVIORAL|medical clown|a medical clown will assist the child during the performance of pulmonary function test
223816058|NCT00545961|DRUG|placebo|mixture, 0.28125 ml/kg twice a day for 7 days
223816059|NCT00545961|DRUG|amoxicillin clavulanate acid|mixture 0.28125 ml / kg twice a day for 7 days
223816060|NCT01931735|PROCEDURE|Randomized Meniscectomy|Arthroscopic meniscectomy
223816061|NCT01931735|PROCEDURE|Randomized Lavage|Arthroscopic Lavage
223816062|NCT01931735|PROCEDURE|Standard of Care Meniscectomy Pre-Amend|Arthroscopic meniscectomy
223816063|NCT01931735|PROCEDURE|Standard of Care Meniscectomy Post-Amend|Arthroscopic meniscectomy
223816064|NCT04786379|PROCEDURE|Arthroscopic Irrigation and Debridement|Patients with confirmed septic arthritis treated with multiple small incisions to perform irrigation and debridement with partial synovectomy.
223816065|NCT04786379|PROCEDURE|Open Arthrotomy with irrigation and debridement|Patients with confirmed septic arthritis treated with a single large incision, open arthrotomy to perform irrigation and debridement with partial synovectomy.
223816066|NCT02144922|DRUG|Pitavastatin|statin
223816067|NCT02144922|OTHER|Control|Life style modification alone
223816068|NCT00774384|BIOLOGICAL|NZ MenB OMV vaccine (NZ98/254)|3 doses by intramuscular injection
223816069|NCT05771701|DEVICE|Pain pressure threshold measurement|"Pain pressure threshold (PPT) is used to measure deep muscular tissue sensitivity. The test determines the amount of pressure over a given area in which a steadily increasing nonpainful pressure stimulus turns into a painful pressure sensation. A varying pressure is applied from 0.5 to 1 kg/sec in a perpendicular direction relative to the muscle. PPT has no standard protocol on administration and placement. Equipment used varies with many handheld electric algometers.~PPT has been used on a wide variety of patients and conditions, including musculoskeletal and neuromuscular disorders (eg, Parkinson disease, tension headaches, pelvic pain, low back pain, myofascial trigger points, sacroiliac joint pain, knee osteoarthritis, skin humidity, shoulder pain, lateral epicondylitis)."
223816070|NCT02719990|DRUG|somavaratan|Long-acting recombinant human growth hormone therapy administered subcutaneously twice-monthly
223816071|NCT02595216|DEVICE|Profound System|The Profound system is indicated for use in dermatologic and general surgical procedures for electrocoagulation and hemostasis, and the percutaneous treatment of submental laxity
223816072|NCT05290844|OTHER|cricoid pressure|cricoid force in pediatric patients
223816073|NCT00992667|DRUG|Apocynin nebulization|6 ml of apocynin of total dose 3 mg (0.5 mg/ml dissolved in sterile 0.9% NaCl as the study drug) has been nebulized for 15-20 min through the mouthpiece with using of a nose clip. A nebulizer Pulmo Aide AP-50 (DeVilbiss; Richmond, VA) was used (mass median aerosol diameter 3.1 mm, output 0.3 ml/min.)
223816074|NCT05365477|BEHAVIORAL|Empiric Therapy: Diet|Diet: High water intake - at least 2.5 liters daily Reduce sugar-sweetened cola intake to ≤3 cans per week. Reduce salt intake to \<2000mg sodium daily Reduce red meat intake to two 4-ounce portions per week Normal calcium intake: 3 servings of dairy products (or their equivalents) per day Increase vegetable and fruit intake to ≥5 servings per day Reduce oxalate intake to \<100 mg/day
223816075|NCT05365477|DRUG|Empiric Therapy: Drug|Drug(s): indapamide 1.25mg and potassium citrate 15mEq daily.
223816076|NCT05365477|BEHAVIORAL|Selective Therapy: Diet|"Diet:~Volume \<2.5L Increase fluid intake to ≥ 2.5L/d, based on specific urine volume~Calcium \>250mg male, \>200mg female Reduce red meat intake to two 4-oz portions/wk; reduce sodium intake to\<2000mg/d, avoid vitamin D + calcium supplements~Oxalate \>40mg Reduce dietary oxalate intake to \<100 mg/d; increase fiber intake to 25-35 g/d~Citrate \<450mg male, \<550mg female Reduce red meat intake to two 4-oz portions/wk; increase fruit and vegetable intake to ≥5 svgs/d~pH\<5.8 Reduce red meat intake to two 4-oz portions/wk; increase fruit and vegetable intake to ≥5 svgs/d~Uric acid \>800mg male, \>750mg female Reduce red meat intake to two 4- oz portions/wk; increase fruit and vegetable intake to ≥5 svgs/d~Sodium \>150mmol Reduce sodium intake to \<2000mg/d~Sulfate \> 80mEq or urine urea nitrogen \>14g Reduce red meat intake to three 3-4 oz portions/wk; increase fruit and vegetable intake to ≥5 svgs/d"
223816077|NCT05365477|DRUG|Selective Therapy: Drug|"Drug(s):~For calcium \>250mg male, \>200mg female: indapamide 1.25mg and potassium chloride 20mEq. At 1 month if persistent, then increase to indapamide 2.5mg and potassium chloride 20mEq. For citrate \<450mg male, \<550mg female: potassium citrate 15mEq BID. At 1 month if persistent, then increase to potassium citrate 30mEq BID. For pH\<5.8: potassium citrate 15mEq BID. At month if persistent, then increase to potassium citrate 30mEq BID. For uric acid \>800mg male, \>750mg female: allopurinol 300mg.~If both elevated calcium and low pH: indapamide 1.25mg and potassium citrate 15mEq BID If both elevated calcium and low citrate: indapamide 1.25mg and potassium citrate 15mEq BID"
223816078|NCT03275974|BIOLOGICAL|Carbon C 11 Glutamine|Given by IV
223816079|NCT03275974|BIOLOGICAL|Fluorine F 18 L-glutamate Derivative BAY94-9392|Given by IV
223816080|NCT03275974|PROCEDURE|Positron Emission Tomography|Undergo PET scan
223816081|NCT03275974|PROCEDURE|Blood Draw|Undergo venous blood draws
223816082|NCT05098093|DIETARY_SUPPLEMENT|SBE|Hard-shell capsule
223816083|NCT05098093|DIETARY_SUPPLEMENT|DBE|Hard-shell capsule
223816084|NCT05098093|DIETARY_SUPPLEMENT|BP|Hard-shell capsule
223816085|NCT03464487|DIETARY_SUPPLEMENT|Low Glycemic Index Therapy Diet|Low Glycemic Index Therapy Diet allows only carbohydrates with Glycemic Index less than 50 and also restricts daily carbohydrate intake to less than 40-60 gram per day.
223816086|NCT01016301|OTHER|Pharmacist service|Medication Review, medication report
223816087|NCT03547401|DEVICE|Ankle Non-invasive Blood pressure measurement|Non-invasive blood pressure measured simultaneously at the arm (model IntelliVue M8105a MP5 Phillips, calibrated).
223816088|NCT03547401|DEVICE|Arm Non-invasive Blood pressure measurement|Non-invasive blood pressure measured simultaneously at the ankle (model IntelliVue M8105a MP5 Phillips, calibrated).
223816089|NCT02030730|BEHAVIORAL|Triple P Seminar Series|The intervention was delivered by the researcher and an accredited TripleP practitioner. The seminars took place in a conference room located within a bookshop. The seminars were re-offered for parents who could not attend the scheduled day.
223816090|NCT04151225|DRUG|GSK2330811|GSK2330811 will be available as SC injection with a unit dose strength of 150 mg/mL. GSK2330811 will be available in single-use pre-filled syringe.
223816091|NCT04151225|DRUG|Placebo|Placebo will be available as SC injection of 0.9 percent saline solution. It will be available as single-use pre-filled syringe.
223816092|NCT05861128|DRUG|Jaktinib|Participants will receive 100 mg Jaktinib orally twice daily for 32 weeks
223816093|NCT00893399|DRUG|Gemtuzumab Ozogamicin (Mylotarg)|"Induction Cycle 1, 2: GO 3mg/m² by intravenous infusion (IVI) on day 1 (total dose 3 mg/m2). Start after etoposide IVI. No dose reduction is foreseen in elderly (\> 60 yrs) patients.~Consolidation 1: GO 3mg/m² by intravenous infusion (IVI) on day 1 (total dose 3 mg/m2). Start after first dose of high-dose cytarabine. No dose reduction is foreseen in elderly (\> 60 yrs) patients.~For all patients experiencing prolonged thrombocytopenia CTC-Grade 3/4 during the first or second induction therapy, which occurs for more than day 35 after start of the cycle, the further cycles of therapy will be administered without Gemtuzumab ozogamicin.~Consolidation 2, 3: no GO"
223816094|NCT00893399|DRUG|standard chemotherapy|Idarubicin, Etoposide, Cytarabine, ATRA, Pegfilgrastim
223816095|NCT03619590|OTHER|Data Collection|When the pregnancy is reported prospectively, the Registry will collect registration data from the reporter through telephone interview or a short registration form. In the month of the estimated date of delivery, follow-up will be sought by telephone contact or a form mailed to the health professional. Information about maternal events throughout the pregnancy, pregnancy outcome, and neonatal health is requested. Additional follow-up is not sought from subsequent health care providers.
223816096|NCT05601401|DRUG|RC48-ADC|RC48-ADC 2.0 mg/kg IV every 14 days
223816097|NCT02439749|DEVICE|Symplicity Spyral™ multi-electrode renal denervation system|After a renal angiography according to standard procedures, subjects remain blinded and are immediately treated with the renal denervation procedure after randomization.
223816098|NCT02439749|PROCEDURE|Sham Procedure|After a renal angiography according to standard procedures, subjects remain blinded and remain on the catheterization lab table for at least 20 minutes prior to introducer sheath removal.
223816099|NCT02616887|RADIATION|Single dose SBRT and VMAT technique|One fraction of 18 Gy delivered in one day with VMAT and Flattening filter-free (FFF) beams.
223816100|NCT06332079|PROCEDURE|166Holmium TARE|166Ho-TARE treatment comprises of two hospital visits: one for a work-up procedure and another for the therapy procedure, with usually a 1-2 weeks interval.
223816101|NCT06332079|DRUG|Cetuximab|Target agent
223816102|NCT06332079|DRUG|Panitumumab|Target agent
223816103|NCT06332079|DRUG|5-Fluorouracil|Chemotherapy
223816104|NCT06332079|DRUG|Bevacizumab|Target agent
223816105|NCT06332079|DRUG|Capecitabine|Chemotherapy
223816106|NCT02244255|DRUG|FLOMAX® capsules|
223816107|NCT02244255|DRUG|Ascending doses of HYTRIN® capsules|
223816108|NCT01833143|DRUG|Bortezomib|
223816109|NCT01833143|DRUG|Acyclovir|
223816110|NCT01217008|BIOLOGICAL|GRNOPC1|One injection of 2 million GRNOPC1 cells.
223816111|NCT03917784|DRUG|Curcumin|Oral supplementation with curcumin 500 mg oral dosing for 3 months
223816112|NCT03917784|DRUG|Starch|Oral supplementation with starch 500 mg oral dosing for 3 months
223816113|NCT03995784|BIOLOGICAL|Coagulation Factor IX variant|Single intravenous injection of CB2679d/Dalcinonacog alfa
223816114|NCT03995784|BIOLOGICAL|Coagulation Factor IX variant|Daily subcutaneous injections of CB2679d/Dalcinonacog alfa for 28 days
223816115|NCT01737099|DIETARY_SUPPLEMENT|DHA-O|
223816116|NCT01737099|DIETARY_SUPPLEMENT|Fish oil|
223816117|NCT01737099|DIETARY_SUPPLEMENT|Placebo|
223816118|NCT05956704|DEVICE|Orthokeratology with aspheric wide inversion zone design in the optical zone|An orthokeratology lens with an altered optical zone design is designed for an aspherical wide inversion arc in the optical zone
223816119|NCT05956704|DEVICE|Orthokeratology with traditional spherical design in the optical zone|Subjects wore the orthokeratology with traditional spherical design in the optical zone
223816120|NCT01677143|DRUG|Bupivacaine 5mg/ml|5 ml in trocar area
223816121|NCT01870362|DRUG|Probiotic (Inersan)|
223816122|NCT01870362|DRUG|Placebo|
223816123|NCT04000659|DEVICE|Episealer Knee System|The Episealer Knee System is comprised of individualized endoprosthetic resurfacing implants and implantation tools (Episealer Toolkit). The implants are designed to replace the articulating surface which has been damaged due to femoral knee chondral and osteochondral defects.
223816124|NCT04000659|PROCEDURE|Microfracture|Microfracture is a minimally invasive surgical technique developed to repair defects in articular cartilage and reduce pain in the knee joint. Microfracture techniques are described in the orthopedic literature and are performed arthroscopically.
223816125|NCT04716413|DRUG|Dsuvia|Subject will receive up to 2 doses of Dsuvia. The first dose will be intra-op and the second dose will be post-op (if needed)
223816126|NCT03895437|BIOLOGICAL|TOL-3021|TOL-3021 1 mg is a bacterial plasmid expression vector containing the coding sequences for the human proinsulin (hINS) gene.
223816127|NCT03895437|OTHER|TOL-3021 Placebo|TOL-3021 Placebo
223816128|NCT05474729|DRUG|minocycline|minocycline capsule 100mg per day orally
223816129|NCT02202434|DEVICE|Lotus Valve System|Procedure: Transcatheter aortic valve replacement (TAVR)
223816130|NCT02202434|DEVICE|CoreValve/Evolut R Transcatheter Aortic Valve Replacement System|Procedure: Transcatheter aortic valve replacement (TAVR)
223816131|NCT02202434|DEVICE|LOTUS Edge Valve System|Procedure: Transcatheter aortic valve replacement (TAVR)
223816132|NCT06244121|DRUG|Pyridoxine|pyridoxine (Vitamin B6) will be given as an anti oxidant.
223816133|NCT06244121|DRUG|Placebo|Placebo will be given in control group
223816134|NCT04013958|DRUG|IV Ketamine|IV Ketamine 0.1 mg/kg with IV morphine -0.1 mg/kg with IM Sailne 0.9%
223816135|NCT04013958|DRUG|IM Ketamine|IM Ketamine 0.3 mg/kg with IV morphine -0.1 mg/kg
223816136|NCT02323347|OTHER|Progesterone|Progesterone level
223816137|NCT04186676|OTHER|MINOCA registry|Prevalence, demographics, clinical profile, anginal status, presence of cardiovascular risk factors, management and outcomes
223816138|NCT04186676|DIAGNOSTIC_TEST|CCTA Phenotypes|"1. Complete normal coronary arteries~2. Diffuse non-obstructive coronary artery disease~3. Non-obstructive high-risk plaques~4. Myocardial bridges"
223816139|NCT01105806|BEHAVIORAL|(CPR) video and questionnaires|Baseline Assessments (10 mins),Intervention:CPR video or script (5 mins) Post intervention assessments (10 mins), Longitudinal chart review follow-up (6 months)
223816140|NCT01105806|BEHAVIORAL|cardiopulmonary resuscitation (CPR) narrative script and questionnaires|Baseline Assessments (10 mins),Intervention:CPR video or script (5 mins) Post intervention assessments (10 mins), Longitudinal chart review follow-up (6 months)
223816141|NCT01886963|DEVICE|SPY - Unblinded use of SPY Elite|Surgeon plans tissue advancement flaps with the aid of Spy Elite System imaging
223816142|NCT01886963|DEVICE|Control - Blinded use of SPY Elite|Surgeon is blinded to Spy Elite imaging and plans tissue advancement flaps according to clinical judgment alone
223816143|NCT03610737|DEVICE|MILD Procedure|"The percutaneous procedure is performed under fluoroscopic guidance to effect a lumbar decompression with minimal surrounding tissue and bone disruption. The mild® Device Kit is utilized to access, capture and remove bone and tissue.~Other Name: MILD lumbar decompression"
223816144|NCT03610737|OTHER|Conventional Medical Management (CMM)|CMM can include physical therapy, home exercise, pain medication, epidural steroid injections, nerve blocks, and other lumbar steroid injections.
223816145|NCT03659253|DIAGNOSTIC_TEST|Oral Fluid Based Self Testing|The intervention will introduce provider supervised and unsupervised self-testing as an option for early HIV diagnosis among MSM community in Denpasar Bali Indonesia.
223816146|NCT03659253|PROCEDURE|Simplified ART Initiation|In this intervention, there will be a change in the clinical practice of ART initiation. In the current practice, clients are asked to perform full pre-ART laboratory examination (complete blood count, liver and renal function tests) before decision of ART initiation. In this intervention, the study participants who are already confirmed as HIV positive and meet specific clinical criteria (see below) will initiate ART (antiretroviral therapy) immediately (after clients' approval) without having to perform full pre-ART laboratory examination. Here, laboratory criteria for initiating ART will be simplified and specific laboratory examination, I.e. creatinine test will be delayed in two weeks after ART initiation.
223816147|NCT03659253|PROCEDURE|CBO AND BROTHEL-BASED ART SERVICE|The CBOs involved in this intervention are Kebaya and Vesta. Kebaya is an CBO working for Transgender (TG) community. It serves as community gathering place for TG and others, as HIV testing site on regular bases, and also as shelter for homeless HIV patients. The proposed intervention Is that HATI Project will provide HIV testing and treatment in the community, CBO and brothel in collaboration with nearby Puskesmas.
223816148|NCT03659253|BEHAVIORAL|SMS REMINDER|HATI SMS reminder: short message services as reminders to inform ART patients when to take medication, visit the clinics (1 week before the next visit) and remind if they miss clinic appointment.
223816149|NCT03659253|PROCEDURE|MOTIVATIONAL INTERVIEWING|"The approach used in this intervention is an individual counselling with a MI approach, as it is considered a brief form of therapy have been known to be effective in improving HIV treatment adherence.~The sessions will be held from 3 to up to 10 MI counselling over 6-month period of intervention. The goal of this intervention is to help PWID gain an understanding of their medication-taking behaviors and the actions necessary to successfully maintain a high level of adherence"
223816150|NCT05220007|DIAGNOSTIC_TEST|Humphrey visual field testing|Perimetry was performed with the Humphrey Field Analyzer (Carl Zeiss Meditec Inc). Participants performed a 30-2 or a 24-2 Swedish Interactive Threshold Algorithm (SITA) standard test with stimulus size III, and standard Humphrey background luminance of 31.5 apostilbs. The participants were selected by simple random sampling to perform the HVF test with presbyopic collection lenses followed by without presbyopic collection lenses, or without presbyopic collection lenses followed by with presbyopic collection lenses. The power of presbyopic correction lens at the testing distance of 33 cm (the bowl radius) was auto-calculated according to the recommendation by the Humphrey Field Analyzer's manufacturer, depending on the current refractive error and the patient's age.
223816151|NCT01686165|DRUG|belinostat|Given IV
223816152|NCT01686165|BIOLOGICAL|rituximab|Given IV
223816153|NCT01686165|RADIATION|yttrium Y 90 ibritumomab tiuxetan|Given IV
223816154|NCT03303677|DRUG|Saline Nasal|topical nasal saline rinses
223816155|NCT03303677|DRUG|Budesonide Nasal|saline + budesonide nasal saline irrigation
223816156|NCT03303677|DRUG|Topical Antibacterial (Product)|The antibiotic would be chosen based on intra operative culture sensitives as is our standard practice. The antibiotic would be selected from Levaquin, Vancomycin, Gentamicin, Ciprofloxacin, Mupirocin, and Trimethoprim/Sulfamethoxazole
223816157|NCT00575497|PROCEDURE|More frequent hemodialysis|Six Day per week short daily hemodialysis
223816158|NCT00575497|PROCEDURE|More frequent hemodialysis|Six nights per week nocturnal hemodialysis
223816159|NCT00575497|PROCEDURE|More frequent hemodialysis|Every other day short daily hemodialysis
223816160|NCT00575497|PROCEDURE|More frequent hemodialysis|Every other night hemodialysis
223816161|NCT00575497|PROCEDURE|More frequent hemodialysis|5 days per week short daily hemodialysis
223816162|NCT00575497|PROCEDURE|More frequent hemodialysis|5 nights per week hemodialysis
223816163|NCT00575497|PROCEDURE|Conventional Hemodialysis|3 days per week short daily hemodialysis
223816164|NCT02825134|DEVICE|Transcatheter aortic valve replacement|Retrograde transfemoral transcatheter aortic valve replacement with any CE mark approved aortic bioprosthesis with or without concomitant percutaneous coronary intervention.
223816165|NCT02825134|DEVICE|Surgical aortic valve replacement|Conventional surgical aortic valve replacement with a bioprosthesis using normothermic cardiopulmonary bypass and cold blood cardioplegia cardiac arrest with or without concomitant coronary artery bypass graft surgery.
223816166|NCT01788345|OTHER|non- invasive ventilation|non-invasive bi-level ventilation with IPAP and EPAP.
223816167|NCT03221010|BEHAVIORAL|Motivational Interviewing|Motivational Interview (MI) is a person-centered, communicative method whose purpose is to work and increase the user's motivation for behavior change.
223816168|NCT03221010|BEHAVIORAL|Traditional cognitive-behavioral approach|This approach aims to combine cognitive interventions in the training of behavioral skills in patients, developing strategies to cope with the problem and detecting situations of risk, mobilizing the subject for his own process of change. Helps correct cognitive dysfunctions and behavioral changes in specific situations.
223816169|NCT00095914|DRUG|paclitaxel|
223816170|NCT00095914|DRUG|paclitaxel albumin-stabilized nanoparticle formulation|
223816171|NCT05168917|DIAGNOSTIC_TEST|LIAISON Calprotectin|Immunoassay for fecal calprotectin measurement
223816172|NCT00764374|DRUG|YM443|oral
223816173|NCT05182073|DRUG|FT576 (Allogenic CAR NK cells with BCMA expression)|Experimental Interventional Therapy: FT576 comprises allogeneic natural killer (NK) cells, derived from a clonal, CD38-knockout, human-induced pluripotent stem cell line (iPSC) that expresses anti-B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR), high-affinity, non-cleavable CD16 (hnCD16), and IL-15/IL-15 receptor fusion protein (IL-15RF).
223816174|NCT05182073|DRUG|Cyclophosphamide|Conditioning Agent
223816175|NCT05182073|DRUG|Fludarabine|Conditioning Agent
223816176|NCT05182073|DRUG|Daratumumab|Anti-CD38 Monoclonal Antibody
223816177|NCT05182073|DRUG|Bendamustine|Conditioning Agent
223816178|NCT04319601|DRUG|Rituximab|a new chemotherapy regimen
223816179|NCT05398380|OTHER|Liver transplantation|Liver transplantation
223816180|NCT00649363|DRUG|Ondansetron Orally Disintegrating Tablets 8 mg|8mg, single dose fasting
223816181|NCT00649363|DRUG|Zofran ODT® Tablets 8 mg|8mg, single dose fasting
223816182|NCT01313546|OTHER|Stimulation of quariceps muscle|stimulation of quadriceps muscle through the stimulating catheter
223816183|NCT03615521|OTHER|Hotpack|Hotpack applied 20 minutes for knee 3 session for 6 weeks
223816184|NCT03615521|OTHER|Ultrasound|Ultrasound applied 10 minutes for knee 3 session for 6 weeks
223816185|NCT03615521|OTHER|Combine Exercise|Proprioceptive Neuromusculer Facilitation Technique İnclude eccentric and concentric contractions 3 session for 6 week
223816186|NCT03615521|OTHER|Repeated Contraction Exercise|Proprioceptive Neuromusculer Facilitation Technique include concentric contractions 3 session for 6 week
223816187|NCT03615521|OTHER|Standart Exercise Therapy|"Quadriceps, hamstring and hip muscle strength exercise. Hamstring stretch exercise.~3 session for 6 week"
223816188|NCT04297787|DEVICE|Thrombolysis in combination with endhole aspiration|The treatment protocol the study team will be following is as follows. First, a pulse spray tPA infusion with 20 cc of 8 mg tPA and saline will be administered to the thrombus with a 20-minute dwell time. Afterwards, an 8F curved sheath (Indigo 8 Torq Tip, ranges 85 to 115 cm) with CAT8 penumbra device will be used to aspirate the thrombus. If the operating physician deems necessary, they will have the option at that point to balloon plasty, stent, or use catheter-directed thrombolysis at this point. Clinical parameters such as areas of clinically-significant stenosis, extent of thrombus, (more parameters) will be tracked at the time of the procedure. The device is being used is FDA approved and being used according to FDA indications.
223816189|NCT03841123|OTHER|Dietary Counseling|"The intervention will consist of an individualized, face-to-face, 20 to 30 minute counseling session to mothers by trained health workers who will address healthy eating practices during the first two years of life. A printed, colorful and illustrated material will be used to assist mothers in appropriate food choices, mainly to avoid the introduction of sugar and ultra-processed foods. In addition, they will receive a booklet which addresses the Ten Steps of Healthy Feeding for children from Birth to Two years of life. The research team will focus on Step2: Do not give added sugar or foods with added sugar, and Step8:Do not offer ultra-processed foods as candies and soft drinks. To reinforce the intervention, mothers will receive telephone calls up to the infant reach six months."
223816190|NCT00823420|PROCEDURE|prematuration culture|"The aneuploidy rate and the developmental potential of embryos obtained from PDE3 inhibitor-treated oocytes (a prolonged IVM (PMC)) in comparison to conventional IVM will be analysed. It is intended to assess the nuclear and cytogenetic constitution of the obtained embryos."
223816191|NCT05885113|BEHAVIORAL|NIDCAP Developmental Care|The intervention of Individualized Developmental Care (IDC) is designed to minimize the mismatch between the fragile infant brain's expectations and the experiences of stress and pain inherent in the hospital environment. An ICU that provides individualized, developmentally-supportive care includes a soothing environment, supports parents as their child's primary caregiver, providing continual adjustment of caregiving in support of the child's wellbeing by reading the infant's cues and providing interventions to calmness throughout caregiving, capitalizing on the infant's strengths, and providing supports toward healing, growth and learning. NIDCAP is the experimental intervention to be tested in the current study. NIDCAP is the only evidence-based, comprehensive, internationally recognized program of IDC.
223816192|NCT02176044|DRUG|Sodium Nitroprusside infusion|
223816193|NCT02176044|OTHER|Placebo|
223816194|NCT05404230|DIETARY_SUPPLEMENT|Fish oil|Fish oil containing poly unsaturated fatty acids.
223816195|NCT05404230|DIETARY_SUPPLEMENT|Corn oil|Corn oil
223816196|NCT02931890|DRUG|Docetaxel|3 weekly course of docetaxel i.v in arm 1 and 2
223816197|NCT02931890|DRUG|Oxaliplatin|3 weekly course oxaliplatin as a 2 hr i.v. in arm 1 and 2
223816198|NCT02931890|DRUG|Capecitabine|oral capecitabine in arm 1 and 2
223816199|NCT02931890|PROCEDURE|gastrectomy|resection of gastric cancer after pre-operative chemotherapy for all arms
223816200|NCT02931890|RADIATION|radiotherapy of gastric cancer|5 weeks of radiation, 5 times a week with a total of 45 Gy (in arm 2 and 3)
223816201|NCT02931890|DRUG|Paclitaxel|5 weeks of paclitaxel i.v once a week (in arm 2 and 3)
223816202|NCT02931890|DRUG|Carboplatin|5 weeks of carboplatin i.v once a week (in arm 2 and 3)
223816203|NCT05538182|DEVICE|Spectacles|Based on the refraction results, study participants diagnosed with refractive error will be dispensed two free pairs of distance spectacles.
223816204|NCT02679521|DEVICE|ESWT|"Radial extracorporeal shock wave therapy (rESWT) was performed by the principal investigator with a Swiss DolorClast device (EMS Electro Medical Systems Corporation; Dallas, Texas, USA).~The Swiss DolorClast device obtained Pre-Market Approval (PMA) by FDA as Class III orthopedic lithotripsy device to treat heel pain associated with chronic proximal plantar fasciitis on May 8, 2007 (PMA # P050004), and was re-classified as Class III Generator, Shock Wave, For Pain Relief (Product Code NBN) in the Spring 2009. The present study started on October 3, 2007.~Each patient received two sessions of rESWT one week apart, with 2,000 impulses per session (air pressure of the device set at 3.5 bar; impulses applied with the 15 mm applicator at frequency of 8 Hz)."
223816205|NCT02679521|DEVICE|Placebo|Placebo treatment was performed identically as rESWT but with a clasp on the heel that prevented transmission of the impulses from the applicator to the skin at the treatment site.
223816206|NCT00128011|BIOLOGICAL|killed oral cholera vaccine|
223816207|NCT00369681|DRUG|Bleomycin|
223816208|NCT00369681|BIOLOGICAL|Rituximab|
223816209|NCT00369681|DRUG|Dacarbazine|
223816210|NCT00369681|DRUG|Doxorubicin|
223816211|NCT00369681|DRUG|Vinblastine|
223816212|NCT02317224|PROCEDURE|"3-Hole subxiphorid and subcostal approach"|"3-Hole subxiphorid and subcostal approach anterior mediastinum tumor resection"
223816213|NCT02317224|PROCEDURE|Trans sternal approach|Trans sternal approach anterior mediastinum tumor resection
223816214|NCT02317224|PROCEDURE|VATS approach|Video-assisted thoracoscope anterior mediastinum tumor resection
223816215|NCT00204269|DRUG|Testosterone Gel Wolff|
223816216|NCT06020664|DRUG|NOX-1416+SOC|NOX1416+SOC as provided in Arm/group description
223816217|NCT06020664|OTHER|Placebo+SOC|Placebo+SOC as provided in Arm/group description
223816218|NCT04717973|DIAGNOSTIC_TEST|laboratory testing of CBC, serum ferritin, and vitamin B 12|"laboratory testing of CBC, serum ferritin, and vitamin B 12, vitamin D and ionized serum calcium after the 1st month, 3rd month, 6th month, and then after one year postoperative.~The pre-operative and post-operative measures will be compared in patients who will be subjected to Laparoscopic Sleeve Gastrectomy versus Laparoscopic Gastric Bypass."
223816219|NCT01022086|PROCEDURE|Cardiac MRI|Cardiac magnetic resonance (CMR) imaging, otherwise called a cardiac (heart) MRI is a safe and standard clinical test that creates detailed images of your heart. It uses a computer to create images of your heart as it is beating, producing both still and moving pictures of your heart and major blood vessels. This test will allow the health professionals to obtain images of your beating heart and to look at the structure and function. Cardiac MRIs can help diagnose and evaluate a number of diseases conditions (such as heart failure, and heart valve disease) and will help doctors decide how to treat or manage patients who have heart problems.
223816220|NCT01022086|BIOLOGICAL|Biomarker Testing|"In addition to undergoing CMR imaging, patients will also have blood tests for two proteins, which serve as markers of heart injury and heart failure. These are called BNP and Troponin. These blood tests are currently used in clinical practice, but their precise role in monitoring heart function in cancer patients has not been well studied. Since the precise cause of Trastuzumab-induced heart damage is currently unknown, it is hoped that these two blood markers will provide valuable insights into how this happens.~Peripheral venous blood samples will also be drawn at each CMR time-point. TGF β1, amino terminal propeptide of procollagen type I (PINP) and type III (PIIINP) and the carboxy-terminal telopeptide of collagen type 1 (CITP) will be measured by radioimmunoassay."
223816221|NCT03815084|DRUG|pd-1 and DC-NK cells|total dose of 10ml KEYTRUDA® (pembrolizumab) will be administered at day0, 60million DC cells and 3 billion NK at day1, 3 billion NK cells at day2, 3 billion NK cells at day3 .
223816222|NCT00487734|RADIATION|Testosterone gel|testosterone gel, applied daily. Dosed to achieve testosterone level \<500 ng/dL. Possible doses include 2.5g, 5g, 7.5g or 10g gel packets.
223816223|NCT00487734|DRUG|Placebo for testosterone gel|Placebo gel, 2.5g for each gel packet
223816224|NCT03436134|OTHER|Sessions of conventional apheresis|"Patient receiving sessions of Plasma exchange as treatment of chronic antibody mediated rejection.~The plasma exchange uses a single filter to remove whole plasma and the volume is replaced with a matched volume of blood products +/- saline.) 8 sessions plasma exchange.Patients will have one session per day, 4 consecutive days and then three days without, then one session per day for 4 consecutive days. That's 11 days of treatment at all. The fourth and eighth sessions will be followed by an infusion of Rituximab 375 mg / m2.~At the beginning and at the end of each session, the patients will have a blood test to measure the parameters of the routine care and the analyzes, collection of biological samples planned for the study."
223816225|NCT03436134|OTHER|Sessions of news apheresis with double filtration|"Patient receiving DFPP as treatment of chronic antibody mediated rejection. 8 sessions~A Double filtration plasmapheresis (DFPP) is a variation of plasma exchange. The circuit contains two plasma filters : the first is a standard plasma filter and the second is a high molecular weight filter that primarily removes immunoglobulins. The depleted plasma is returned to the blood circuit and then to the patient."
223816226|NCT05772234|DRUG|Lactated ringers solution|Intravenous 20 mL/kg Ringer's lactate solution within 60 min from the start of ESWL, directly followed by 3 mL/kg per h for 8 h.
223816227|NCT05772234|DRUG|normal saline|Intravenous fluid infusion with normal saline (maximum of 1.5mL/kg per h or 3L per 24h).
223816228|NCT00694382|DRUG|Semuloparin sodium|"0.4 mL solution in ready-to-use 0.5 ml pre-filled syringe~Subcutaneous injection"
223816229|NCT00694382|DRUG|Placebo (for semuloparin)|"0.4 mL solution in ready-to-use 0.5 ml prefilled syringe strictly identical in appearance but without active component~Subcutaneous injection"
223816230|NCT05158478|DIAGNOSTIC_TEST|blood glucose measurement, blood glucose monitor for personal use|measurement of the blood glucose concentration using the blood glucose monitor for personal use (TJ100)
223816231|NCT05158478|DIAGNOSTIC_TEST|blood glucose measurement, laboratory reference device|measurement of the blood glucose concentration using a laboratory reference device (YSI 2300 Stat Plus)
223816232|NCT01420432|BIOLOGICAL|Human umbilical cord-derived MSCs|1.0E+6 MSC/kg, IV drop and repeat repeated after three months
223816233|NCT05957302|DRUG|Ketamine|100 mg of ketamine diluted in 10 mL saline (10 mg /mL) and patient will receive 0.1 mL/kg
223816234|NCT05957302|DRUG|Fentanyl|100 mcg of fentanyl diluted in 10 mL saline (10 mcg /mL) and patient will receive 0.1 mL/kg
223816235|NCT05174923|BEHAVIORAL|Short Performance Physical Battery (SPPB Test)|The SPPB includes balance stands, a 4-meter walk and 5 timed chair stands.
223816236|NCT05174923|BEHAVIORAL|30 Second Chair Stand Test (30CST)|The 30CST measures the number of times a person can rise from a seated to standing position within 30 seconds.
223816237|NCT05174923|BEHAVIORAL|Hand grip dynamometry|Grip strength is used as a marker of overall muscle strength.
223816238|NCT06215001|PROCEDURE|Mechanical ventilation setting (Positive end-expiratory pressure) according to Expiratory Flow Limitation|Positive End expiratory pressure will be set according to the positive end-expiratory pressure able to revert the expiratory flow limitation.
223816239|NCT06215001|PROCEDURE|Mechanical ventilation setting (Positive end-expiratory pressure) not according to Expiratory Flow Limitation|Positive End expiratory pressure will be set not according to the positive end-expiratory pressure able to revert the expiratory flow limitation but to a standard level of 4 cmH2O.
223816240|NCT00351637|DRUG|Sublingual Methadone|
223816241|NCT04328402|DIAGNOSTIC_TEST|Polysomnography|Polysomnography, referred to as type I, allows assessing several sleep physiologic parameters (eg, EEG, electrooculogram, electromyogram, electrocardiogram, airflow, respiratory effort, oxygen saturation), whereas audio-video recording enables to document tooth-grinding sounds and distinguishing between rhythmic masticatory muscle activity (RMMA) and orofacial and other muscular activity during sleep. The apnea and hypopnea index (AHI) is defined as the number of obstructive apneas and hypopneas per hour of sleep. Obstructive Sleep Apnea is defined in PSG when AHI≥1 and is divided into the following categories, according to severity: mild OSA (AHI 1-4.9), moderate OSA (AHI 5-9.9) and severe OSA (IAH≥10). Based on the RMMA index (number of episodes per hour of sleep), sleep bruxism is diagnosed when episodes are greater than or equal to 2 (low-frequency SB, mild bruxism) or episodes are greater than or equal to 4 (high frequency SB, severe bruxism).
223816242|NCT01921881|OTHER|St John's wort|
223816243|NCT01396577|DRUG|perampanel|3 x 2 mg perampanel once per day
223816244|NCT01396577|DRUG|perampanel|6 mg perampanel once per day
223816245|NCT03134014|DIETARY_SUPPLEMENT|Breakfast|If randomized to a breakfast consuming group, participants will be given breakfasts to consume between 6:00-8:00 am.
223816246|NCT00276107|BIOLOGICAL|Prevenar|
223816247|NCT01619332|DRUG|Placebo|Placebo will be given orally once daily for 28 days to patients assigned to placebo in a randomized and blinded manner
223816248|NCT01619332|DRUG|Sitagliptin|Sitaglitpin will be given orally once daily for 28 days to patients assigned to this treatment in a randomized and blinded manner
223816249|NCT01619332|DRUG|LEZ763|LEZ763 will be given orally once daily for 28 days in a randomized and blinded manner
223816250|NCT03083535|PROCEDURE|Tooth Brushing|Tooth Brushing with Dentifrice Tooth Brushing with Dentifrice (Standard Tooth Brushing technique will be demonstrated by using same type of tooth brush and toothpaste).
223816251|NCT03083535|PROCEDURE|aloe vera Massaging|Tooth Brushing with Dentifrice (with same type of tooth brush and toothpaste) and massaging with aloe vera gel
223816252|NCT03083535|PROCEDURE|SRP with aloe vera massaging|on one side of the arch only Scaling and Root Planing(SRP) to be done, while on the other side, after the Scaling and Root Planing massaging with aloe vera ge; shall be carried out by the patients/subjects
223816253|NCT04380129|OTHER|Music therapy-conversation sessions|"The intervention will be performed four times per patient at a frequency once weekly. An effort shall be made to ensure that each treatment is exactly seven days from the previous one within ± one day. The musical hearing will include Helen Bonny's program Caring, which is proposed by the author of this Music therapy model as the most suitable for patients with chronic and severe pain. The program is as follows:~* Haydn - Cello Konzert in C, Adagio~* Dvorak - Serenade in E-Dur, Larghetto~* Warlock - Capriol Suite, Pieds en I'air"
223816254|NCT04380129|OTHER|Music Listening|Music Listening to Helen Bonny's programme.
223816255|NCT00409695|DRUG|Low Dose Thymoglobulin (ATG)|2.5 mg /kg by vein every other day for 3 doses (total dose = 7.5 mg/ kg).
223816256|NCT00409695|DRUG|High Dose Thymoglobulin (ATG)|1.25mg/kg by vein every other day for 3 doses (total dose = 3.75mg/kg)
223816257|NCT02596763|DRUG|Baclofen|Patient receiving an off-label baclofen treatment for alcohol use disorder for less than 1 month.
223816258|NCT04438902|DRUG|osimertinib mesylate tablets and anlotinib hydrochloride capsules|osimertinib mesylate tablets 80mg qd and anlotinib hydrochloride capsules 10mg qd day 1-14 of a 21-day cycle
223816259|NCT02710786|PROCEDURE|Gastric bypass|Gastric bypass surgery, i.e., small gastric pouch and excluded main stomach
223816260|NCT00998907|DEVICE|PDS plus|triclosan-coated polydiaxanon 910 suture materials with antiseptic activity (PDS plus®, Ethicon GmbH, Norderstedt, Germany)
223816261|NCT00998907|DEVICE|PDS II|polyglactin 910 suture material for abdominal wall closure
223816262|NCT00084214|DRUG|STA-4783|
223816263|NCT00084214|DRUG|Paclitaxel|
223816264|NCT01833312|DEVICE|Hypothermia|In patients randomised to therapeutic hypothermia, induction of cooling will be started by infusion of 4°C isotone saline or Ringer's lactate administered over a period of 30 to 60 minutes. A body temperature between 34.0 and 35.0°C will be targeted. Body temperature will be monitored through bladder or rectal thermal probes, and cooling procedures will be adapted to keep body temperature as close as possible to the target. Maintenance of body temperature in the target range will be performed with a surface or endovascular cooling device. After a cooling period of 24h, controlled rewarming to 36°C with a rate of 0.2°C/h will be started. After 36°C have been reached, the device will be disconnected.
223816265|NCT01833312|DRUG|Buspirone|anti-shivering treatment
223816266|NCT01833312|DRUG|Pethidine|anti-shivering treatment
223816267|NCT03634501|BIOLOGICAL|Activated NK|Cell suspension
223816268|NCT02183935|DEVICE|Duodena-jejunal liner|
223816269|NCT01047644|OTHER|Reduced port-flush schedule|3-month port-flushing
223816270|NCT02347514|BEHAVIORAL|Diabetes group visit|
223816271|NCT00357045|DRUG|Paroxetine|
223816272|NCT05514262|OTHER|The stress ball|Covid-19 vaccination procedure with individuals in the stress ball group: With this group, a yellow stress ball will be used which is 6cm in diameter, of medium hardness and made of high quality silicone, and which returns to its original shape after being squeezed. The researcher will explain to the individuals in the group how they should use the stress ball five minutes before beginning the vaccination and during the procedure. The individuals will be taught to take the stress ball in their right hand, the side on which the vaccination will not be given, and, counting from one to three, to squeeze and release the ball, continuing until the procedure is finished. It will be explained that during the procedure, they should give their attention to the stress ball and focus on squeezing it.
223816273|NCT05514262|DEVICE|The Buzzy® device|Covid-19 vaccination procedure with individuals in the Buzzy® group: Individuals in this group will use the Buzzy® device. Before the vaccination procedure, the researcher will place the Buzzy® device, which will be at room temperature, on the vaccination site, and it will vibrate in a non-discomforting way for one minute. After this, the Buzzy® device will be removed from the site, and the nurse will perform the vaccination. Because Buzzy® is a device which can be re-used, it will be disinfected after each vaccination procedure, and re-used with other individuals. The Buzzy® device also has ice wings which will not be used in this study, and only the body of the device will be used to provide vibration.
223816274|NCT05867641|BEHAVIORAL|Immersive VR Therapy in Head-Mounted Display (HMD) (Solo)|"Caregivers will be trained to administer VR\&R therapy to their loved ones with dementia, in their private home/residence. Participants with dementia will view immersive VR experiences using a commercially-available VR head-mounted device for up to 30 minutes a time, approximately every other day (or as desired), for two weeks. The caregiver will use the custom application on a tablet to select and monitor what their loved one sees in VR.~Staying nearby to monitor for safety and assistance, the caregiver may choose to use the time when their loved one is engaged to take some respite time for themselves (e.g., make a cup of coffee, have an uninterrupted phone call)."
223816275|NCT05867641|BEHAVIORAL|Immersive VR Therapy in a Head-Mounted Display (HMD) (Social)|"Participants with dementia will view immersive VR experiences using a commercially-available VR head-mounted device for up to 30 minutes a time, 2 to 3 times per week, for 2 weeks. A research assistant who is trained in dementia care will use the custom application on a tablet to select and monitor what their loved one sees in VR.~Staying nearby to monitor for safety and assistance, the caregiver may choose to use the time when their loved one is engaged to take some respite time for themselves (e.g., make a cup of coffee, have an uninterrupted phone call)."
223816276|NCT06000319|BIOLOGICAL|Natural Matrix Protein (NMP) Fibers|human bone allograft
223816277|NCT06000319|PROCEDURE|Lumbar interbody fusion|Procedure that involves removing the intervertebral disk from the disk space between between 2 or more vertebrae between L1 and S1. When the disk space has been cleared out, the surgeon fills the void between the vertebrae with a bone void filler.
223816278|NCT06000319|PROCEDURE|Cervical interbody fusion|Procedure that involves removing the intervertebral disk from the disk space between between 2 or more vertebrae between C2 and T1. When the disk space has been cleared out, the surgeon fills the void between the vertebrae with a bone void filler.
223816279|NCT01802684|BIOLOGICAL|aflibercept|Aflibercept (VEGF Trap) Recombinant human protein, at 25 mg/ml Dose : 4 mg/Kg -Day 1, q2w Route of administration: Intravenous (60 min infusion)
223816280|NCT02710305|DRUG|oral hyoscine butyl bromide tablets plus lidocaine cream|patients will take oral hyoscine butyl bromide 30 minutes before the procedure plus lidocaine anesthetic cream placed into their cervix immediately before the procedure
223816281|NCT02710305|DRUG|oral placebo tablets plus placebo cream|patients will take oral placebo 30 minutes before the procedure plus placebo cream placed into their cervix immediately before the procedure
223816282|NCT02991482|DRUG|Pembrolizumab|Pembrolizumab (MK-3475) is a potent and highly selective humanised monoclonal antibody (mAb) of the IgG4/kappa isotype designed to directly block the interaction between PD-1 and its ligands, PD-L1 and PD-L2. This blockade enhances functional activity of the target lymphocytes to facilitate tumour regression and ultimately immune rejection.
223816283|NCT02991482|DRUG|Gemcitabine|"Gemcitabine replaces one of the building blocks of nucleic acids, in this case cytidine, during DNA replication. The process arrests tumour growth, as new nucleosides cannot be attached to the faulty nucleoside, resulting in apoptosis (cellular suicide)."
223816284|NCT02991482|DRUG|Vinorelbine|Vinorelbine is a vinca alkaloid cytotoxic chemotherapy that is available in intravenous and oral preparations with EMA licenses in lung cancer and breast cancer. Vinorelbine blocks mitosis in phase G2-M, causing cell death in interphase or at the following mitosis.
223816285|NCT03450655|OTHER|10-week aerobic exercise program|An aerobic exercise program consisting of 45-60 minute sessions 3 times a week for 10 weeks.
223816286|NCT02692690|DEVICE|Stimulette r4x|
223816287|NCT00327184|BIOLOGICAL|Haemophilus influenzae type b- and meningococcal serogroup C (vaccine)|Two primary vaccination doses at 3 and 5 months of age and a booster dose at 11 months of age.
223816288|NCT00327184|BIOLOGICAL|Infanrix Penta|Two primary vaccination doses at 3 and 5 months of age and a booster dose at 11 months of age.
223816289|NCT00327184|BIOLOGICAL|Infanrix hexa|Two primary vaccination doses at 3 and 5 months of age and a booster dose at 11 months of age
223816290|NCT00327184|BIOLOGICAL|Neis-Vac-C|Two primary vaccination doses at 3 and 5 months of age and a booster dose at 11 months of age
223816291|NCT05391932|BEHAVIORAL|MINDGAPS|Utilize wearable sensor technology to provide simple, precise measures of gaze and postural stability, as well as remote monitoring of patient adherence to vestibular exercises during a 6-week training period. Additionally, NIH Toolbox data will be used to display patient status compared to normative values and to indicate progress over time relative to measurement error.
223816292|NCT00401635|DRUG|liposomal doxorubicin|
223816293|NCT00401635|DRUG|carboplatin|
223816294|NCT05873725|DRUG|Follitropin delta|Evaluation of the IVF cycle using the prescribed medication
223816295|NCT06191263|DRUG|RVU120|RVU120 is a potent, selective inhibitor of CDK8 and its paralog CDK19
223816296|NCT06191263|DRUG|Venetoclax|Venetoclax specifically binds to BCL-2, displacing proapoptotic proteins and triggering events that lead to apoptosis
223816297|NCT06847126|DRUG|Intravenous beta-lactam antimicrobial for 2 weeks Plus Intravenous Metronidazole (750 mg q 8 hourly) for 2 weeks|Intravenous beta-lactam antimicrobial for 2 weeks Plus Intravenous Metronidazole (750 mg q 8 hourly) for 2 weeks and standard care
223816298|NCT06847126|DRUG|Tablet Cefixime (200 mg q 12 hourly) for 2 weeks Plus Tablet Metronidazole (800 mg q 8 hourly) for 2 weeks|Tablet Cefixime (200 mg q 12 hourly) for 2 weeks Plus Tablet Metronidazole (800 mg q 8 hourly) for 2 weeks
223816299|NCT06847126|OTHER|Standard medical care|Percutaneous drainage or aspiration of the abscess along resuscitative and symptomatic medications
223816300|NCT03396484|DRUG|Methyldopa|Tablet for oral dosing
223816301|NCT03396484|DRUG|Placebo|Tablet for oral dosing
223816302|NCT02320422|BEHAVIORAL|Behavioral Telehealth|The telemetric intervention (administered via telephone, or interactive video chat applications such as FaceTime ® or Skype ®) will enable the intervention team (IT) to address non-adherence from a remote location, using a structured, tailored approach
223816303|NCT01421095|DRUG|recombinant FSH|Each participant will recieve recombinant FSH (150 IU) intravenously
223816304|NCT01724645|DIETARY_SUPPLEMENT|Korean traditional diets|"The consumption of Korean traditional diets reflecting the characteristics of Korean traditional diets without the limitation of calories has an effect on control of cardiovascular risk factor, so this study instructed all subjects of the intervention group to consume about 2,100kcal of served meals freely.~The Korean Traditional diets, which encourages the intake of cooked rice, vegetables,soup,Kimchi and soy fermented foods."
223816305|NCT01724645|DIETARY_SUPPLEMENT|Control group|"Told to  eat as usal diets."
223816306|NCT05426564|DIAGNOSTIC_TEST|Quantra System|Diagnostic device to monitor coagulation properties of a whole blood sample at the point-of-care.
223816307|NCT03182140|DRUG|Kyleena|Kyleena - intrauterine delivery system containing 19.5 mg LNG
223816308|NCT00108238|DRUG|Estradiol followed by progesterone|
223816309|NCT00108238|DRUG|Raloxifene|
223816310|NCT03215901|BEHAVIORAL|A Beautiful Future Video|Video delivering information on the longevity gains due to HIV treatment in the area.
223816311|NCT03215901|BEHAVIORAL|Active Control Video|Video on another topic.
223816312|NCT01705535|BEHAVIORAL|Individual supervised pelvic floor muscle exercises|Six individual treatments of 45 minutes by a physiotherapist specialized in pelvic floor disorders. Preparation of an individual adapted training program for the pelvic floor muscles. Encouragement to perform the pelvic floor muscle training program on a daily basis
223816313|NCT01705535|OTHER|Massage of the neck and back|six individual treatments of 30 minutes by a physiotherapist. The participants will get no instructions of pelvic floor muscle exercises.
223816314|NCT01705535|BEHAVIORAL|Standard information and guidance|Advice about diet and fiber supplements. Information about optimizing bowel emptying including use of medicine. Advice about use of antidiarrheal medication if appropriate.
223816315|NCT02118480|OTHER|cognitive remediation program: REHACOP|Specifically, REHACOP group remediation with PD patients consisted of: Attention unit (4 weeks) training sustained, selective, alternant and divided attention; Memory unit (3 weeks) focusing on visual and verbal learning, recall and recognizing memory; Language unit (3 weeks) including grammar, syntax, vocabulary, verbal fluency, verbal comprehension, abstract language; Executive functions unit (2 weeks) training cognitive planning, proverbs, analogies; and Social cognition unit (1 week) exercising theory of mind, social reasoning and moral dilemmas.
223816316|NCT02118480|OTHER|Occupational Therapy|The activities included drawing, reading the daily news and constructing using different materials (such as paper or wood). These activities were accomplished in a group format and with the same frequency as the implementation of REHACOP in the experimental group.
223816317|NCT04293588|DIAGNOSTIC_TEST|spirometry, FOT, Induced sputum, bloods, nasal brushes, nasal lavage, skin prick, throat swab|At the point of baseline visit, exacerbation and annual visit, the above tests will be performed to allow comparison of a participants profile before and during an exacerbation
223816318|NCT04693676|BIOLOGICAL|Prizloncabtagene Autoleucel|Autologous 2nd generation CD19/CD20-directed CAR-T cells, single infusion intravenously
223816319|NCT04398446|DRUG|Hemp-based CBD|3x Daily dosing for 12 weeks
223816320|NCT04398446|OTHER|Placebo oral tablet|3x Daily dosing for 12 weeks
223816321|NCT05900622|OTHER|Reduced postoperative braking and bed rest time.Lower extremity on the puncture side with a 2-hour brake+Get out of bed after 4 hours|Braking time is defined as the time from the start of postoperative lying down until the patient sits up in bed and can move the lower limbs Bed rest is the time from when the patient is lying down to when they are on the floor after the procedure, but it has been identified as the most difficult part of post-vascular puncture intervention care
223816322|NCT05900622|OTHER|Significantly reduce postoperative braking and bed rest time.No braking of the lower limb on the side of the puncture+Get out of bed after 2 hours|Braking time is defined as the time from the start of postoperative lying down until the patient sits up in bed and can move the lower limbs Bed rest is the time from when the patient is lying down to when they are on the floor after the procedure, but it has been identified as the most difficult part of post-vascular puncture intervention care
223816323|NCT02105441|DEVICE|Cochlear implant|Implantable hearing device
223816324|NCT05624840|DRUG|Nirmatrelvir/ritonavir|Nirmatrelvir-ritonavir (Paxlovid)
223816325|NCT00518128|PROCEDURE|Surgical OSA treatment|uvulopalatopharyngoplasty +/-tonsillectomy, genioglossus advancement, and hyoid suspension
223816326|NCT00518128|PROCEDURE|Positive Airway Pressure Therapy|Continuous positive airway pressure for treatment of obstructive sleep apnea
223816327|NCT00756522|OTHER|There is no intervention. Study is observational.|There is no intervention. Study is observational.
223816328|NCT02751918|DRUG|Anetumab ravtansine (BAY94-9343)|Anetumab ravtansine will be administered on Day 1 of every 21-day treatment cycle.
223816329|NCT02751918|DRUG|Pegylated Liposomal Doxorubicin|Pegylated liposomal doxoribicin will be administered on Day 1 of every 21-day treatment cycle.
223816330|NCT03035305|DIETARY_SUPPLEMENT|Lipid-based Nutrient Supplement (LNS)|"For each round of SMC distribution (total of 4 rounds):~* For children aged 6-11 months: 15 sachets/month or 50g every two days for 4 weeks~* For children aged 12-59 months: 21 sachets/month or 50g per day for 3 weeks"
223816331|NCT03035305|DRUG|Seasonal malaria chemoprevention|"For each round of SMC distribution (total of 4 rounds):~* For children aged 6-11 months: sulfadoxine 250mg/pyrimethamine 12.5mg and amodiaquine 75mg~* For children aged 12-59 months: sulfadoxine 500mg/pyrimethamine 25mg and amodiaquine 150mg~D1 : 1 tablet sulfadoxine-pyrimethamine + 1 tablet amodiaquine D2 : 1 tablet amodiaquine D3 : 1 tablet amodiaquine"
223816332|NCT04484714|BEHAVIORAL|Exercise|Participants will participate in a 12-week virtually supported home-based aerobic and resistance exercise program, twice weekly using the Heal-Me application. Sessions will be completed as virtual live classes or supported follow-along independent home workouts. Sessions will progress in duration and difficulty over the course of the program, aiming to have participants meet the 2019 Exercise Guidelines for Cancer Survivors by the end of the program. Each session will include aerobic exercise (i.e. walking, cycling, or cardio circuit), and a full-body resistance training routine using free weights, body weight exercises, and/or bands, followed by balance and stretching exercises.
223816333|NCT05721508|OTHER|Combined physical and cognitive program|All participants will complete 12-week training sessions combining physical and cognitive activities, with two 1-hour sessions per week.
223816334|NCT03863522|PROCEDURE|Fine needle aspiration|Fine needle aspiration is a type of biopsy procedure to diagnose suspicious lesions. After giving numbing medicine, a thin needle is inserted into the breast to obtain a sample. This procedure is followed by the standard of care and will last about 10 minutes. The sample will be analyzed by a diagnostic cartridge and by the cytopathologist.
223816335|NCT03863522|DEVICE|Cancer Detection cartridge|The Cancer Detection cartridge has the ability to measure methylated gene changes in breast cells. The device will not be in contact with the patients. The FNA samples will be smeared on a slide which will be placed into the cartridge for analysis.
223816336|NCT04515121|DEVICE|HD-tCES|The high definition transcranial electrical stimulation was applied using a 1\*4 ring electrode configuration. The anodal electrode was placed on the ipsilesional C1/C2, and the remaining 4 cathodal electrodes were placed in a radius of approximately 7.5 cm from anode (Cz, F3, T7, and P3 on the left hemisphere or Cz, F4, T8, and P4 on the right hemisphere). HD-tCES will be applied for 20 minutes at an intensity of 1.0 mA direct current stimulation and a specific-added waveform each time, 3 times a week, lasting for 4 weeks.
223816337|NCT04515121|DEVICE|Sham HD-tCES|The high definition transcranial electrical stimulation was applied using a 1\*4 ring electrode configuration. The anodal electrode was placed on the ipsilesional C1/C2, and the remaining 4 cathodal electrodes were placed in a radius of approximately 7.5 cm from anode (Cz, F3, T7, and P3 on the left hemisphere or Cz, F4, T8, and P4 on the right hemisphere). Sham HD-tCES will consist of a 5-second ramp up to 1.0 mA direct current stimulation and a specific-added waveform followed immediately by a 5-second ramp down, no current in the middle 19 minutes 40 seconds, and a ramp-up and ramp-down period during the last 10 seconds.
223816338|NCT04515121|OTHER|Lower limb rehabilitation|Lower limb rehabilitation programs will be selected and graded in accordance with each patient's lower limb function and specific aims of activities of daily living. Lower limb rehabilitation will be provided for 30 minutes each time, 3 times a week, lasting for 4 weeks.
223816339|NCT00532324|OTHER|CA-MRSA Decolonization|In later stages of this study, women found to be nasally and/or vaginally colonized with CA-MRSA will be randomized to receive postpartum, either: 1) attempted decolonization with intranasal mupirocin twice a day for one to two weeks with or without diluted chlorhexidine or Clorox baths two to three times a week for one to two weeks or, 2) no intervention. The primary study is observational only.
223816340|NCT04121481|DIETARY_SUPPLEMENT|Clinical Investigation on Enhanced Sports Nutrition and Performance Activities by Prodovite VMP35 Supplement|Assess the Sports Nutrition efficacy of Prodovite VMP35 against the Placebo sample
223816341|NCT04121481|DIETARY_SUPPLEMENT|Broad Spectrum Safety|Benefits in Sports Nutrition
223816342|NCT05899660|DIETARY_SUPPLEMENT|Active Comparator: Omega-3|It is a dietary supplement made of fish oil rich in n-3 PUFA.
223816343|NCT05899660|DIETARY_SUPPLEMENT|Placebo Comparator: olive oil|Refined olive oil is the usual placebo used in studies with n-3 PUFA.
223816344|NCT00400543|DEVICE|Continuous positive airway pressure (CPAP)|
223816345|NCT02396537|DRUG|Lidocaine|Administered intranasally prior to Midazolam administration.
223816346|NCT02396537|DRUG|Midazolam|Administered to all patients immediately after study drug (Lidocaine or Placebo) administered.
223816347|NCT02396537|DRUG|0.9% Saline|Administered intranasally prior to Midazolam administration.
223816348|NCT03774602|BEHAVIORAL|Health promotion and provision of RMNCH services|Implementation of quality, high-impact interventions at institutional and community levels to increase access to and utilization of RMNCH services
223816349|NCT05447624|PROCEDURE|Radiofrequency ablation of genicular nerves|The RF cannula will be placed near the nerve with an in-plane technique from proximal to distal. Sensory stimulation will be performed at 50 Hz to ensure localization. The sensory threshold should be less than 0.6 V. To prevent ablation of the motor nerves, when the nerve is stimulated with 2.0 V at 2 Hz, it will be seen that there is no fasciculation in the relevant region of the lower extremity. Before starting the ablation procedure, 2 mL of 1% lidocaine solution will be injected around the nerve, after vascularity control, in order to reduce the pain and the risk of neuritis during the procedure. Then the temperature will be adjusted to 80° degrees and applied for 90 seconds and the process will be terminated.
223816350|NCT00871403|DRUG|pazopanib and pemetrexed|oral pazopanib 600 mg once daily and pemetrexed intravenous (IV) 500mg/m\^2 once every 3 weeks, then pazopanib 800 mg once daily
223816351|NCT00871403|DRUG|pemetrexed and cisplatin|pemetrexed IV 500 mg/m\^2 and cisplatin IV 75 mg/m\^2 once every 3 weeks
223816352|NCT02599103|OTHER|Fat-free milkshake|participants drinks a fat-free milk shakes
223816353|NCT02599103|OTHER|Olive oil|participants drinks the milk shakes prepared from 60g of olive oil
223816354|NCT02599103|OTHER|Soybean oil|participants drinks the milk shakes prepared from 60g of soybean oil
223816355|NCT02599103|OTHER|Fried soybean oil|participants drinks the milk shakes prepared from 60g of fried soybean oil
223816356|NCT02599103|OTHER|Palm oil|participants drinks the milk shakes prepared from 60g of palm oil
223816357|NCT02599103|OTHER|Fried palm oil|participants drinks the milk shakes prepared from 60g of fried palm oil
223816358|NCT02599103|OTHER|Camellia oil|participants drinks the milk shakes prepared from 60g of camellia oil
223816359|NCT02599103|OTHER|Fried camellia oil|participants drinks the milk shakes prepared from 60g of fried camellia oil
223816360|NCT02599103|OTHER|Tallow|participants drinks the milk shakes prepared from 60g of tallow
223816361|NCT02599103|OTHER|Fried tallow|participants drinks the milk shakes prepared from 60g of fried tallow
223816362|NCT01057615|DIETARY_SUPPLEMENT|Fish Oil|10 fish oil (3.2g EPA + 2.0g DHA) capsules per day for 3 weeks
223816363|NCT01057615|DIETARY_SUPPLEMENT|Ascorbic Acid|2 pharmaceutical grade ascorbic acid (1500mg) capsules per day for 3 weeks
223816364|NCT01057615|DIETARY_SUPPLEMENT|Fish Oil Placebo|10 placebo fish oil (soy bean oil) capsules per day for 3 weeks
223816365|NCT01057615|DIETARY_SUPPLEMENT|Ascorbic Acid Placebo|2 placebo ascorbic acid (sucrose) capsules per day for 3 weeks
223816366|NCT01562912|DEVICE|Radiofrequency Ablation Procedure|Application of radiofrequency energy will be delivered during PV antral isolation procedure and should be performed with a standard, open irrigated ablation catheter and a mapping system as the investigator would perform the procedure normally.
223816367|NCT01562912|DEVICE|PVAC Ablation Procedure|Application of radiofrequency energy with the Pulmonary Vein Ablation Catheter(PVAC)to eliminate potentials arising from the pulmonary veins.
223816368|NCT05989373|DIAGNOSTIC_TEST|Scratch collapse test|Scratch test performed by the surgeon but with a dynamometer
223816369|NCT05420441|DEVICE|Phonophoresis with chitosan|Patients in this group will receive chitosan through phonophoresis plus conventional treatment. For the phonophoresis parameters: pulsed ultrasonic waves (25%) of 1 MHz frequency and 1 W/cm2 intensity applied with a 5 cm diameter transducer. The total time of ultrasound application was eight minutes.Patients will also receive conventional Physical therapy program
223816370|NCT05420441|DEVICE|Phonophoresis with glucoasmine|Patients in this group will receive glucosamine through phonophoresis plus conventional treatment. For the phonophoresis parameters: pulsed ultrasonic waves (25%) of 1 MHz frequency and 1 W/cm2 intensity applied with a 5 cm diameter transducer. The total time of ultrasound application was eight minutes.Patients will also receive conventional Physical therapy program.
223816371|NCT05420441|PROCEDURE|Conventional Physical Therapy|Patients in the control group will receive the conventional treatment for knee osteoarthritis only, which will include the application of TENS, pulsed ultrasound, infrared light and exercise.
223816372|NCT04887948|BIOLOGICAL|20-valent pneumococcal conjugate vaccine (20vPnC)|20-valent pneumococcal conjugate vaccine (20vPnC)
223816373|NCT04887948|BIOLOGICAL|BNT162b2|RNA-based SARS-CoV-2 vaccine (BNT162b2)
223816374|NCT04887948|OTHER|Saline|Normal saline for injection
223816375|NCT00748124|DEVICE|PleuraSeal Sealant System|Lung Sealant Device + standard tissue closing techniques (sutures/staples)
223816376|NCT00748124|PROCEDURE|Standard Tissue Closure Techniques|Standard tissue closure techniques (sutures/ staples) alone
223816377|NCT00304512|DRUG|migalastat HCl|
223816378|NCT03405272|BIOLOGICAL|Recombinant Anti-EGFR Monoclonal Antibody（SCT200）|Experimental: recombinant anti-EGFR monoclonal antibody（SCT200） Recombinant Anti-EGFR Monoclonal Antibody（SCT200）. Initially, SCT200 6.0mg/kg will be administered at day 1 every week for a maximum of 6 cycles. After 6 cycles SCT200 8.0mg/kg will be administered at day 2 every weeks until disease progression.
223816379|NCT00787319|OTHER|no intervention|Outpatients with age-related macular degeneration (AMD)
223816380|NCT01729117|OTHER|Meal Replacement|5 Meal Replacements/day will be given for 3 months and then 1/day for 9 months.
223816381|NCT01729117|OTHER|Standard Care|Standard Care only
223816382|NCT02342665|DRUG|Copanlisib (BAY80-6946)|Dosing is weekly for the first 3 weeks (on Days 1, 8, and 15) of a 28-day cycle, followed by a 1-week break (i.e., no infusion on Day 22).
223816383|NCT02312856|DEVICE|PulseRider|Adjunctive device for endovascular embolization of intracranial aneurysms
223816384|NCT00371527|DRUG|ipratropium|
223816385|NCT05461014|BEHAVIORAL|dCBI|"The dCBI, RxWell, is a trans-CBT mobile app product addressing depression and anxiety that was developed based on standard CBT techniques. RxWell provides users users with 40 brief (5-10 minute) skill building techniques for anxiety and depression. Users will have access to a goal-setting tab and in the moment relief section which contains over 17 techniques,14 of which are brief audios to help users engage relaxation responses. The user will be provided with the depression path, which has 40 unique techniques, and if the user expresses significant anxiety, the coach will have the ability to personalize the program by pulling in any of the 53 techniques from the anxiety path, so that the individual can utilize the proper CBT techniques that fit with their presentation. The coaches are trained to provide assistance with adult care transition readiness."
223816386|NCT01637701|PROCEDURE|PkEP|Plasmakinetic enucleation of the prostate
223816387|NCT01637701|PROCEDURE|B-TURP|Bipolar transurethral resection of the prostate
223816388|NCT01170195|DIETARY_SUPPLEMENT|Calmera-Licorice Root Extract (Licogen)|100 mg per day
223816389|NCT00602680|DRUG|SSR180711C|duration of treatment: 4 weeks
223816390|NCT00602680|DRUG|donepezil|duration of treatment: 4 weeks
223816391|NCT00602680|DRUG|placebo|duration of treatment: 4 weeks
223816392|NCT03861520|DEVICE|Midtrimester anomaly scan|A detailed anomaly scan to detect soft markers at 16 to 24 weeks pregnancy
223816393|NCT03861520|GENETIC|Fetal Karyotyping|Fetal karyotyping after birth to confirm chromosomal anomaly diagnosed clinically
223816394|NCT00063102|DRUG|ABT-751|
223816395|NCT01778946|DRUG|Low Dose Nicotine (7mg)|
223816396|NCT01778946|DRUG|Moderate Dose Nicotine (14mg)|
223816397|NCT03075904|DRUG|ALXN1830|Administered via IV infusion.
223816398|NCT05107479|BEHAVIORAL|COVID-19 Vaccine IVR Training|The intervention consists of 5 interactive voice response (IVR) modules conveying information about COVID-19 vaccines and vaccine administration best practices. Module topics include the following: 1) the importance of COVID-19 vaccines and recipient eligibility, 2) overview of and differences between approved COVID-19 vaccines , 3) surveillance of adverse vaccine events, 4) organizing a vaccination site, and safe storage and handling COVID-19 vaccines, and 5) micro planning and communication strategies for COVID-19 vaccination efforts. The training will be offered in five local languages: French, Lingala, Swahili, Kikongo, and Tshiluba.
223816399|NCT05107479|BEHAVIORAL|Control Condition|The control arm will receive the COVID-19 Vaccine IVR Training after an estimated month-long delay. The control arm will be told upon completion of the baseline survey that the training will commence at a later estimated date and will not receive any additional information until the treatment group completes training.
223816400|NCT01933451|OTHER|Intraoperative fluid therapy|Intraoperative fluid therapy is directed by pulse pressure variation to a setting value, above 18% or below 13%.
223816401|NCT01598402|DRUG|amoxicillin/clavulanic acid suspension|625 mg tid, start day 29 after the start of CRT until 14 days after the end of CRT
223816402|NCT02579798|DEVICE|PEEP (positive end-expiratory pressure)|
223816403|NCT00591201|DRUG|infliximab|Infliximab 5mg/kg diluted in 250 ml of isotonic solution of sodium chloride will be administered by the intravenous route on weeks 0, 2, 6, 12, 18, 24, 30, 36, 42, and 48.
223816404|NCT00591201|DRUG|Placebo|Placebo -powder diluted in 250 ml of isotonic solution of sodium chloride- will be administered on weeks 0, 2 and 6.
223816405|NCT01691521|DRUG|Mepolizumab IV|Mepolizumab 75 mg IV will be administered every 4 weeks with the last dose at Week 28
223816406|NCT01691521|DRUG|Mepolizumab SC|Mepolizumab 100 mg SC will be administered every 4 weeks with the last dose at Week 28
223816407|NCT01691521|DRUG|IV Placebo|Normal saline (placebo) will be administered IV every 4 weeks with the last dose at Week 28
223816408|NCT01691521|DRUG|SC Placebo|Normal saline (placebo) will be administered SC every 4 weeks with the last dose at Week 28
223816409|NCT01581840|DRUG|radiochemotherapy|Radiotherapy : PTV1 45 Gy 5 weeks PTV2 20 Gy 2 weeks Chemotherapy : 5Fu (400 to 1000 mg/m²) mitomycin : 10 mg/m²
223816410|NCT01581840|DRUG|Panitumumab|3 or 6 mg/kg (according to dose level)
223816411|NCT00727324|DRUG|bovine intestinal alkaline phosphatase (BIAP)|30,000U/24h for 7 consecutive days via a duodenal catheter
223816412|NCT05811039|DEVICE|Remo-Wax® Oil|Remo-Wax® Oil (abbreviated RWO; GMDN (Global Medical Device Nomenclature) code 46259, Earwax softening oil), is a CE-marked, non-sterile fluid mixture, used for prevention of impacted earwax. Remo-Wax® Oil also moisturizes the skin in the ear canal and reduces itching and irritation caused by the ear canal dryness
223816413|NCT01802814|DRUG|SR-A + Epratuzumab|
223816414|NCT01802814|DRUG|SR-B + Epratuzumab|
223816415|NCT01864863|DRUG|HGP1206|One Bosentan 125 mg tablet
223816416|NCT01864863|DRUG|Traclear|Two Bosentan 62.5 mg tablets
223816417|NCT06400966|OTHER|Training method|Jigsaw Technique
223816418|NCT02062866|PROCEDURE|Purse-String|"The wound will be closed using one, long, continuous suture which will enter and exit run through the skin along the inner edge of the wound. The start and stopping point will be adjacent to one another. The suture will then be pulled on either side to essentially cinch down the wound, decreasing the size of the wound."
223816419|NCT02062866|PROCEDURE|Second Intent|The wound will not be sutured, and allowed to heal on its own.
223816420|NCT00628901|PROCEDURE|Uterine Fibroid Embolization (UFE)|Uterine Fibroid Embolization is used in treating Uterine Fibroids. The procedure involves injecting embolization particles into the fibroid via the uterine artery which causes the fibroid to shrink or subside. Patients are usually released from the hospital the day after the procedure.
223816421|NCT00628901|DEVICE|Contour SE™ Microspheres|Polyvinyl alcohol Microsphere embolization devices intended to provide targeted vascular occlusion or reduction of blood flow upon selective placement and are currently marketed for use in hypervascular tumors, including leiomyoma uteri and arteriovenous malformations
223816422|NCT00628901|DEVICE|Embosphere® Microspheres|Biocompatible, hydrophilic, nonresorbable, microspheres used in the embolization of arteriovenous malformations, hypervascular tumors, and symptomatic uterine fibroids.
223816423|NCT02558270|DRUG|Dapagliflozin|
223816424|NCT02558270|DRUG|Placebo|
223816425|NCT03582605|DRUG|Amoxicillin|see previous descriptions
223816426|NCT03582605|DRUG|Placebo oral capsule|see previous descriptions
223816427|NCT02252614|DRUG|naproxen sodium codein|Pain intensity, contramal consumption
223816428|NCT02252614|DRUG|paracetamol codein|Pain intensity, contramal consumption
223816429|NCT02252614|DRUG|Placebo|Pain intensity, contramal consumption
223816430|NCT00770432|DRUG|Polyethylene glycol 3350|Polyethylene glycol 3350 powder for solution. Single dose (17 grams in 4 to 8 ounces of beverage) for 7 days.
223816431|NCT00770432|OTHER|Placebo, maltodextrin 500 powder for solution|Maltodextrin 500 powder for solution, One single dose (one capful) in any 4 - 8 ounces beverage for 7 days.
223816432|NCT00312702|BIOLOGICAL|Falciparum Malaria Protein 11 with AS02A adjuvant|vaccine
223816433|NCT00818363|DRUG|SABER-Bupivacaine|Injectable Extended Release Solution; 5.0 mL SABER-Bupivacaine/Once
223816434|NCT00818363|DRUG|SABER-Placebo|Injectable Solution; 5.0 mL SABER-Placebo/Once
223816435|NCT04944355|OTHER|ultrasound|diagnosis of morbid adherent placenta and incidence of urinary tract injuries during surgery
223816436|NCT00988221|DRUG|Tocilizumab|Tocilizumab was supplied as a sterile solution in vials.
223816437|NCT00988221|DRUG|Placebo|Placebo to tocilizumab was supplied as a sterile solution in vials.
223816438|NCT02038686|DEVICE|PFN-A|
223816439|NCT04073264|PROCEDURE|monofilament|In the intervention group,monofilament absorbable suture,will be used.
223816440|NCT00977496|PROCEDURE|Nasal Swab|Swabs will be moistened in sterile 0.9% sodium chloride solution and rotated in the anterior vestibule of both nares and processed for S aureus cultures and for bacterial DNA extraction.
223816441|NCT00483834|DRUG|Bevacizumab|7.5mg/kg, IV, day 1 of each cycle
223816442|NCT00483834|DRUG|Irinotecan|200mg/m\^2, IV, day 1 each cycle
223816443|NCT00483834|DRUG|Capecitabine|1000mg/m\^2 or 750mg/m\^2 for patients over 65yrs old PO BID, day 1-14 each cycle
223816444|NCT00633919|BIOLOGICAL|SLITone(TM) Dermatophagoides mix|Sublingual immunotherapy with SLITone Dermatophagoides mix (200 STU) once daily for 2 years
223816445|NCT00633919|BIOLOGICAL|Placebo|Sublingual immunotherapy once daily for 2 years
223816446|NCT00633919|DRUG|Salbutamol inhaler|200 µg per puff; a short acting beta2-agonist (please refer to the 'detailed description' for details on the use)
223816447|NCT00633919|DRUG|Budesonide/formoterol inhaler|80/4.5 µg per inhalation; a combination of inhaled corticosteroids and long acting beta2-agonist (please refer to the 'detailed description' for details on the use)
223816448|NCT00633919|DRUG|Prednisone tablet|5 mg per tablet; oral corticosteroids (please refer to the 'detailed description' for details on the use)
223816449|NCT00633919|DRUG|Desloratadine tablet|5 mg per tablet: anti-histamine (please refer to the 'detailed description' for details on the use)
223816450|NCT00633919|DRUG|Budesonide nasal spray|64 µg per puff; inhaled corticosteroid (please refer to the 'detailed description' for details on the use)
223816451|NCT00602914|DEVICE|MicronJet|The micronJet is a microneedle injection device designed for intradermal delivery of drugs (i.e. delivery into the skin). In this study the MicronJet will be used to inject insulin vs. a convention needle injection.
223816452|NCT00602914|DEVICE|MicronJet|MicronJet, Intradermal Injection
223816453|NCT04154215|DIAGNOSTIC_TEST|PET-CT FDG brain scan|"Scans will be performed in Discovery MI PET/CT scanner (by GE). Dynamic FDG PET scan start immediately after a bolus injection of 18F-FDG (0.1 mCi/kg) 5. Dynamic PET scan protocol of 30 min will be follow by a static scan protocol with a duration of 8 min combined with a low dose CT scan.~The radiation exposure of the patients is equal to the radiation exposure during the routine PET-CT FDG brain scan. The only discomfort to the patient is a longer scan duration.~After the scan is concluded the patient will be released with no restrictions. Each of the acquired PET images will undergo visual assessment. In addition, quantification of the image data using Standardized Uptake Values (SUV) and kinetic model. The correlation between the clinical information, visual assessment and quantitative parameters will be tested. Sensitivity and accuracy of the quantification methods will be calculated."
223816454|NCT05135546|DRUG|Recombinant nonimmunogenic staphylokinase|15 mg of drug reconstituted in 6 ml of 0.9% solution of NaCl for inhalation Other Name: Fortelyzin®
223816455|NCT05135546|DRUG|Placebo|6 ml of 0.9% solution of NaCl for inhalation
223816456|NCT03912623|OTHER|SPA Treatment with therapeutic education and physical activity|3 weeks SPA Treatment plus therapeutic education plus physical activity
223816457|NCT03912623|OTHER|Week end|access to the station for a week end after maintenance of usual treatment during 6 months
223816458|NCT01552122|DRUG|Odanacatib|Odanacatib 50 mg compressed tablet will be administered orally, once-a-week, for 24 months
223816459|NCT01552122|DRUG|Alendronate|Alendronate 70 mg compressed tablets will be administered orally, once-a-week, for 24 months; and a reduced dose of 35 mg will be administered in the same fashion to a subset of women, Japanese participants only, for the same 24-month duration.
223816460|NCT01552122|OTHER|Placebo (odanacatib)|One compressed tablet administered orally, once-a-week, for 24 months.
223816461|NCT01552122|DIETARY_SUPPLEMENT|Cholecalciferol (Vitamin D3)|Two (2) 2800 IU compressed tablets administered orally, once-a-week, for 24 months.
223816462|NCT01552122|DIETARY_SUPPLEMENT|Calcium carbonate|Dietary and supplemental sources, taken as needed, to ensure a total daily calcium intake of approximately 1200 mg.
223816463|NCT01552122|OTHER|Placebo (alendronate)|One compressed tablet administered orally, once-a-week, for 24 months.
223816464|NCT02672501|DRUG|anti-CD19-CAR-T cells|a 2nd CAR, CD19 as target protein, 4-1BB as co- stimulator, and optimized the spatial conformation by a suitable hinge \& transmembrane domain sequences
223816465|NCT03509532|DEVICE|PCI|PCI
223816466|NCT02756832|DRUG|Alogliptin Benzoate|Alogliptin benzoate tablets
223816467|NCT01040390|DRUG|Lappa Arctium|To start with subjects will be prescribed Lappa Arctium in 6 potency to be taken in form of pills 4 times a day for seven days. Dosage and frequency will be changed, if required, based on the condition of subject and their response according to homoeopathic principles.
223816468|NCT00906048|DRUG|Levofloxacin (HR355) and Rifampicin Therapy|"Film-coated scored tablet measured at 500 mg of levofloxacin and capsule at 300 mg of rifampicin per os once a day~Weight \< 70 kg: 1 tablet of levofloxacin and 2 capsules of rifampicin Weight \> 70 kg: 1 tablet of levofloxacin and 3 capsules of rifampicin"
223816469|NCT03615781|PROCEDURE|Two week's arm - surgery|The investigators perform a surgical drainage of the infection along with the complete removal of the infected orthopedic implant.
223816470|NCT03615781|PROCEDURE|Four week's arm - surgery|The investigators perform a surgical drainage of the infection along with the complete removal of the infected orthopedic implant.
223816471|NCT03615781|DRUG|Two week's arm - drugs|After the surgical implant removal, the investigators prescribe a total of 2 weeks of systemic targeted antibiotic therapy against the causative pathogen(s), of which one week is recommended to be intravenously.
223816472|NCT03615781|DRUG|Four week's arm - drugs|After the surgical implant removal, the investigators prescribe a total of 4 weeks of systemic targeted antibiotic therapy against the causative pathogen(s), of which one week is recommended to be intravenously.
223816473|NCT03763916|PROCEDURE|Ureteric dissection|clamping and cutting the round ligament, clamping and cutting the ovarian ligament with ovarian preservation, careful dissection and clamping of the broad ligament varicosities, careful dissection of the post leaflet of the broad ligament until ureter is reached, careful dissection and exposure of both ureter and proper identification of the iliac vessels
223816474|NCT03763916|PROCEDURE|Preoperative ureteric stenting|preoperative insertion of ureteric catheters is performed by the urologist in our team just before the start of cesarean hysterectomy. Patient is positioned in lithotomy, cystoscopy \[Karl storz\] is done to identify the ureteric orifices. ureteric catheters \[Roche\] are inserted followed by the insertion of Foley's urethral catheter
223816475|NCT03763916|PROCEDURE|Cesarean hysterectomy|lateral dissection of the uterus is completed from the pelvic side wall, followed by very CAREFUL BLADDER DISSECTION. Finally clamping of the uterine vessels is done below the level of the placenta with or without complete removal of the cervix. Closure of the uterine stump is performed followed by CAREFUL HEMOSTASIS then closure of the abdomen is performed after leaving two wide bore drains
223816476|NCT03221101|DEVICE|Home ventilator|
223816477|NCT01364597|DRUG|Brivaracetam (BRV)|The max BRV dose will be 5.0 mg/kg/day, not to exceed a dose of 200 mg/day for subjects with body weight \>40kg. Subjects may receive oral solution or oral tablets. The LTFU subjects will start dosing in N01266 on the individualized BRV dose they were receiving at the completion of the core study. Subjects must be able to tolerate the min BRV dose specified in the core study to be eligible for entry into the Evaluation Period of N01266. Dose can be adjusted as considered necessary by the Investigator and required by the subject's medical condition. All subjects who prematurely discontinue the study should complete an EDV and have their BRV dose down titrated by a maximum of half the dose every week for a maximum of 4 weeks until a dose of 1 mg/kg/day (50 mg/day for subjects with body weights \>50kg) is reached.
223816478|NCT00002396|DRUG|Tenofovir disoproxil fumarate|
223816479|NCT03629860|PROCEDURE|Atrophic maxillary alveolar ridge augmentation|Autogenous bone blocks from chin and ascending ramus are obtained and used for reconstruction of atrophic maxillary ridges
223816480|NCT02013596|OTHER|TEAS pretreatment|Electric stimulation was given through electrode attached to specific acupoints for 30mins before anesthesia induction
223816481|NCT02013596|OTHER|TEAS treatment|Transcutaneous Electrical Acupoint Stimulation was given to the patient at the same time of the start of anesthesia induction for 30mins
223816482|NCT04005027|OTHER|Intermittent graded exercise test|Participants will run on a treadmill until volitional exhaustion. The speed of the treadmill belt will increase incrementally every 3 minutes. Within each 3 minute stage the speed will vary between the target speed and a complete pause (e.g target speed = 8 km/hr)
223816483|NCT03262558|OTHER|No intervention|Patients will undergo standard clinical routine practice in this indication
223816484|NCT03028090|DEVICE|SHERLOCK 3CG™ Tip Confirmation System with MODUS Software|The SHERLOCK 3CG™ Tip Confirmation System (TCS) is a fully-integrated magnetic tracking and ECG-based PICC tip confirmation technology. It was cleared by the FDA on March 19, 2012 and is indicated for use as an alternative to chest x-ray and fluoroscopy for PICC tip placement confirmation in adult patients. In order to further develop the SHERLOCK 3CG™ platform and simplify the PICC placement for the clinician, Bard Access Systems, Inc. is developing MODUS, a software package.
223816485|NCT03495804|DRUG|polyethylene glycol|Experimental group was given polyethylene glycol as oral contrast agent.
223816486|NCT03495804|DRUG|mannitol|Active comparator group was given mannitol as oral contrast agent.
223816487|NCT01991821|DRUG|APD421|
223816488|NCT01991821|DRUG|Placebo|
223816489|NCT05068739|PROCEDURE|PA-EMR|Standard oval-shaped, braided wire polypectomy snare with 10 mm or 20 mm loop diameter will be used. With the duodenoscope in a semi-long position, the tip of the snare will be anchored just below the transverse fold of the ampulla and opened above-downwards fashion until the orifice will be seen. The orifice will be strictly preserved to avoid the risk of PEP and approximately the upper two-thirds of the ampullary mound will be grabbed by the snare. The direction and the depth will be controlled by combined movements of the elevator and wheels of the duodenoscope. After removal of the mucosa, the wall of choledochus will be seen clearly and standard wire-guided cannulation (WGC) will be performed. If cannulation can not be achieved with WGC, an additional incision will be performed to the wall of the choledochus with a needle knife.
223816490|NCT05068739|PROCEDURE|NKF|The needle knife will be placed at the junction of the upper one-third and lower two-thirds of the papillary roof (bulging portion). Minimal, superficial incisions will be made in the 11-12 o'clock direction. The length of the fistulotomy will be at the endoscopist's discretion, depending on the shape of the papilla. The cut will be extended until bile juice, the pinkish bile duct mucosa, and/or the bulging of the white sphincter of the Oddi's muscle is visible.
223816491|NCT02889601|OTHER|Psycho-behavioural assessment|DAPHNE Scale
223816492|NCT00480896|DRUG|tacrolimus ointment|Topical application
223816493|NCT00480896|DRUG|Placebo ointment|Topical application
223816494|NCT00545350|OTHER|Fall prevention exercise program|"Weekly physical exercise sessions in small groups, led by a qualified and specially trained instructor, and supplemented by simple exercises to do at home.~The exercise program will focus on progressive balance retraining but will also include strength/resistance, coordination and flexibility training exercises."
223816495|NCT04597502|DIETARY_SUPPLEMENT|Terminalia Chebula fruit extract|Oral TC fruit extract supplement taken by mouth twice per day
223816496|NCT04597502|DIETARY_SUPPLEMENT|Placebo|Oral placebo taken by mouth twice per day
223816497|NCT04597502|OTHER|Topical Terminalia Chebula|Applied to both forearms and dorsal hands
223816498|NCT04597502|OTHER|Topical Placebo|Applied to both forearms and dorsal hands
223816499|NCT01405755|BEHAVIORAL|Appropriate complementary feeding messages|Messages delivered through National Vaccine Program and radio
223816500|NCT00390195|DRUG|RAD001 (everolimus)|Arm 1: 2.5, 5, 7.5 or 10 mg of RAD001 daily
223816501|NCT00390195|DRUG|RAD001 (everolimus)|Arm 2: 20, 30, 50 or 70 mg of RAD001 daily
223816502|NCT01537679|BEHAVIORAL|Kirtan Kriya meditation|Meditation will be taught to 20 caregivers and supervised by Helen Lavretsky, M.D during their first visit. Meditation Kirtan Kriya will be performed for 12 minutes every day at the same time of the day for 8 weeks. Compliance will be monitored during visits and by daily diaries that will be reviewed at each visit.
223816503|NCT01537679|BEHAVIORAL|Relaxation|Participants in the relaxation group will be asked to relax in a quiet place with eyes closed while listening to the music on the relaxation CD for 12 minutes every day at the same time for 8 weeks.
223816504|NCT00187915|DRUG|Mycophenolate mofetil + Tacrolimus|Target MPA exposure to 30-60 mg/L/h during first month post-transplant
223816505|NCT00187915|DRUG|Mycophenolate mofetil + Cyclosporin|Target MPA exposure to 30-60 mg/L/h during first month post-transplant
223816506|NCT03884504|DEVICE|Ventricular Assist Device System|Ventricular Assist Device System
223816507|NCT04203537|DRUG|CA-008|Local administration during surgery
223816508|NCT04203537|DRUG|Placebo|Local administration during surgery
223816509|NCT04678921|DRUG|TJ210001|human anti-C5aR monoclonal antibody
223816510|NCT05507658|DRUG|Tislelizumab combined with Oxaliplatin and Capecitabine|"Drugs:~1. Tistelizumab 200mg, iv.gtt, D1, Q3W;~2. Chemotherapy (XELOX) : oxaliplatin (130 mg/m2), iv.gtt, D1, Q3W; Capecitabine (1000mg/m2), P.O.B.I.D., D1-D14, Q3W.~Neoadjuvant therapy:~1. Tislelizumab combined with XELOX, Q3W, for 2\~3 cycles;~2. D2 radical gastrectomy after neoadjuvant therapy.~Adjuvant therapy:~1. From 4 to 8 weeks after surgery, the treatment dose was the same as above;~2. Patients who achieved MPR and non-MPR on pathological evaluation were treated with tirelizumab +XELOX 3\~8 cycles;~3. Tumor evaluation performed every 3 cycles;~4. The maximum duration of adjuvant therapy was not more than 8 cycles."
223816511|NCT02569359|DIETARY_SUPPLEMENT|shea nut oil extract|
223816512|NCT02569359|OTHER|Placebo|
223816513|NCT04164654|BEHAVIORAL|Loneliness Intervention|28 days of engagement with the Nod app, which consists of interactive exercises drawn from cognitive behavioral therapy (e.g behavioral activation and cognitive reframing exercises), positive psychology (e.g. acts of kindness), and mindful self-compassion programs (e.g. loving-kindness meditations)
223816514|NCT06304662|OTHER|Yoga intervention|Over 12 weeks, students will attend 50-minute yoga sessions twice a week. Sessions start with 10 minutes of mindful breathing and gentle warm-up movements, followed by 30 minutes of tailored yoga postures for relaxation and stretching. Students progress from basic to advanced postures, with adaptations for individual needs. Each session ends with a guided meditation for inner calm. A 10-minute cool-down encourages deep relaxation. Emphasis is on stress reduction, flexibility, and mindfulness, tailored to university life challenges. Continuous assessment ensures sessions meet students' evolving needs and optimize yoga's benefits in the university setting.
223816515|NCT04581200|BEHAVIORAL|Lift|The intervention is a mobile app-based mindfulness training program designed to be used over a 1-month period.
223816516|NCT01566630|DRUG|Placebo|Placebo to RLX030 as intravenous infusion for 72 hours
223816517|NCT01566630|DRUG|RLX030|RLX030 1 mg/mL vials
223816518|NCT01543412|DRUG|FOLFIRI|Irinotecan 180 mg/m2 iv on day 1, Leucovorin(l-form) 200 mg/m2 iv on day 1,2 5-FU 400 mg/m2 iv bolus on day 1,2 5-FU 600 mg/m2 iv by ci for 22 hrs on day 1,2 repeated every 2 wks
223816519|NCT03579290|BEHAVIORAL|CBT4CBT program|"The 'CBT for CBT' program is modeled closely on our NIDA-published CBT manual. Seven core skill modules will cover the following topics, which correspond to the major session topics in the manual:~* Understanding and changing patterns of drug use,~* Coping with craving,~* Substance refusal skills,~* Seemingly irrelevant decisions,~* Planning for emergencies, and~* Problem-solving skills.~* Staying Safe"
223816520|NCT03511417|DEVICE|over-the-counter hearing device|Individuals will use commercially-available over-the-counter hearing devices for specified periods of time.
223816521|NCT04173767|DEVICE|high flow nasal cannula ventilation|High-flow nasal cannula (HFNC) ventilation therapy: supply heated \& humidified air up to 60 L/min of flow; effects: positive end expiratory pressure effect, humidification.
223816522|NCT06133114|DRUG|Clonazepam|0.5 mg twice a day (1 mg a day)
223816523|NCT06133114|DRUG|Olanzapine|2.5 mg once a day of Olanzapine
223816524|NCT06133114|DRUG|Buprenorphine|2 mg once a day of Buprenorphine
223816525|NCT01423786|DIETARY_SUPPLEMENT|Early Oral Nutrition|Once enrolled in the study, patients will be allowed a oral diet that is low in fat.
223816526|NCT01908322|DRUG|Sorafenib (Nexavar, BAY43-9006)|Patients will be followed-up from start of Nexavar therapy until death or drop out due to any reason or end of study
223816527|NCT03584503|OTHER|Suction Above Cuff Endotracheal Tube|Suction Above Cuff Endotracheal Tube (SACETT) has a dorsal port above the cuff designed to allow continuous or intermittent suctioning of secretions from the subglottic space
223816528|NCT01351532|BEHAVIORAL|smoking cessation program|cross-theoretical model integrating smoking cessation counseling, smoking cessation drug utilization, physician interview and telephone counseling persuasion,
223816529|NCT01351532|BEHAVIORAL|Lifestyle counseling|ross-theoretical model integrating smoking cessation counseling,physician interview and telephone counseling persuasion
223816530|NCT03131960|DEVICE|Paired Vagus Nerve Stimulation|Stimulation of the vagus nerve that is paired with upper limb rehabilitation movements.
223816531|NCT03131960|OTHER|Rehabilitation|Rehabilitation movements to improve upper limb function after stroke
223816532|NCT01781390|OTHER|Placebo|Matching placebo solution for infusion.
223816533|NCT01781390|BIOLOGICAL|Mesenchymal Precursor Cells (MPC) 12.5 M|MPC 12.5 M solution for infusion.
223816534|NCT01781390|BIOLOGICAL|Mesenchymal Precursor Cells (MPC) 25 M|MPC 25 M solution for infusion.
223816535|NCT05486442|BEHAVIORAL|ACT for weight-related experiential avoidance|Participants in the experimental group received weight concern-related ACT training in a group setting. Each session focused on different dimensions of ACT and included relevant exercises and homeworks. Dimensions studied included creative hopelessness, control strategies, mindfulness exercises, values and barries to values and commitment to action.
223816536|NCT02768415|DRUG|Apatinib|
223816537|NCT02768415|DRUG|Oral Vinorelbine|
223816538|NCT01361373|DRUG|L- DOPA|Sinemet up to 10 mg/kg/ day increasing gradually for 2 weeks
223816539|NCT01361373|DRUG|placebo|placebo for 2 weeks
223816540|NCT03579914|DRUG|intravenous Placebo|Patients receive intravenous Placebo (saline) injection
223816541|NCT03579914|DRUG|Metoprolol Injectable Product|Patients receive intravenous Metoprolol injection
223816542|NCT03579914|DEVICE|Romote Ischemic Conditioning (RIC)|Patients receive RIC treatment
223816543|NCT03579914|COMBINATION_PRODUCT|Metoprolol & RIC|Patients receive Metoprolol \& RIC treatment
223816544|NCT05829291|DEVICE|Diffusing Alpha Radiation Emitters Therapy (DaRT)|"Alpha DaRT Applicators (the Alpha Needle Applicator, the Alpha Flex Applicator, and the Alpha Plant Applicator) and radioactive sources named Alpha DaRT Seeds - Ra-224 coated onto stainless steel tubes inserted into the tumor. Collectively, the Alpha DaRT Applicators and Seeds are referred to as the Alpha DaRT Device."
223816545|NCT06459895|DIAGNOSTIC_TEST|Long non-coding MALAT1 gene expression assay:|RNA extraction (isolation from whole blood) II-Synthesis of CDNA from RNA by reverse transcription III-Gene expression assay by RT-PCR reaction
223816546|NCT04806646|DRUG|Sonidegib|TS1: assumption 14 days on and 14 days off. TS2: assumption 7 days on and 21 days off.
223816547|NCT04559282|DEVICE|New Sound Processor|The new Sound Processor is intended to be used as part of the Cochlear Baha System which uses bone conduction to transmit sounds to the cochlea. The New Sound Processor is indicated for patients with up to 55 dB sensorineural hearing loss.
223816548|NCT04754672|BEHAVIORAL|Continuous aerobic and resistance exercise intervention|Continuous aerobic and resistance exercises intervention
223816549|NCT04754672|BEHAVIORAL|Continuous aerobic and aerobic interval exercise intervention|Continuous aerobic and aerobic interval exercise intervention
223816550|NCT01609816|DRUG|Dasatinib|Patients receive dasatinib PO every day (QD) for 6 months.
223816551|NCT00622713|DRUG|Rivastigmine transdermal patch|The study treatment was delivered as a patch sizes 5 and 10 cm\^2 containing respectively 9 and 18 mg of rivastigmine. During the first 4 weeks of the study, patients applied a new rivastigmine 5 cm\^2 patch once daily. At the end of the 4 weeks, if tolerability was satisfactory, the dosage was increased and patients applied rivastigmine 10 cm\^2 patch once daily for an additional 4 weeks. Thereafter, and until the end of the study, patients remained at the maximum tolerated dose, either 5 or 10 cm\^2.
223816552|NCT03139396|PROCEDURE|tub shaped inlay bridge design|inlay retained bridge with tub shaped retainer on both abutments
223816553|NCT00347997|DEVICE|217z Laser|LASIK correction of myopia and myopic astigmatism
223816554|NCT02653573|BEHAVIORAL|Coaching|Self-management education
223816555|NCT01625923|DRUG|Olanzapine|Subjects will initially start on olanzapine 2.5 mg per mouth daily. Subjects will return on days 7 and 14 to determine response to medication and medication dose can be increased to 5 mg and 10 mg, respectively, based on incomplete symptom response (mean change GCSI-DD \< 0.5). The total dose of olanzapine will not exceed 10 mg daily during this study and subjects will continue on treatment for a total of 8 weeks.
223816556|NCT02918500|DRUG|Nicoderm Patch|Nicotine replacement therapy patch
223816557|NCT02929550|OTHER|Well-controlled|Both groups got treatment but well-controlled reached target of LDL-C\<1.8 mmol/l
223816558|NCT00594191|DRUG|Simvastatin|20 mg/day p.o., increased to 40 mg/day at day 15 if no safety end-point was met
223816559|NCT00594191|DRUG|Placebo|Placebo with the same characteristics of the drug and at the same dose
223816560|NCT02390427|DRUG|Taselisib|
223816561|NCT02390427|DRUG|Trastuzumab emtansine|
223816562|NCT02390427|DRUG|Pertuzumab|
223816563|NCT02390427|DRUG|Trastuzumab|
223816564|NCT02390427|DRUG|Paclitaxel|
223816565|NCT00159705|DRUG|pregabalin|
223816566|NCT01457105|DEVICE|Endoscopic retrograde cholangiography (ERC) (ComVi biliary stent)|Metal stents placement in the main biliary duct during ERC
223816567|NCT02575898|OTHER|First Session|Creative Practice and Positive Re-enforcement
223816568|NCT02575898|OTHER|Second Session|Disease Related
223816569|NCT02575898|BEHAVIORAL|Third through Sixth Sessions|Life Review and Legacy
223816570|NCT00021034|DRUG|chemotherapy|
223816571|NCT00021034|DRUG|taurolidine|
223816572|NCT03243643|DRUG|HS-10241|HS-10241 is provided as white, film-coated,immediate release tablets containing HS-10241 at dosage strengths of 20mg/50mg/100 mg. Multiple tablets of HS-10241 will be administered daily to achieve targeted doses of HS-10241: 200 mg-1200 mg. Tablets will be orally administered with 240 ml water, once daily, 1 hour before/after a meal.
223816573|NCT03243643|DRUG|Apatinib|Apatinib is provided as white, film-coated,immediate release tablets containing aptinib at dosage strengths of 250mg. Apatinib will be administered daily to achieve targeted doses of 500 mg. Tablets will be orally administered with 240 ml water, once daily, 1 hour before/after a meal.
223816574|NCT06344234|DIAGNOSTIC_TEST|End-inspiratory Maneuvers|Airway pressure, flow, and esophageal pressure will be continuously recorded in all patients using a dedicated pneumotachograph and pressure transducer: all signals will be acquired and stored. Once a stable ventilation pattern is observed NIV will be administered by setting ventilator in invasive-pressure support ventilation. PEEP and PS-level will by kept constant while expiratory trigger will be adjusted to optimize patient-ventilatory synchrony. Immediately after, sudden end-inspiratory and end-expiratory occlusion maneuvers will be performed to measure plateau pressure and end-expiratory airway occlusion pressure (ΔPocc), respectively. Invasive PSV will be used only to perform the occlusion maneuvers, subsequently, PSV will be delivered in non-invasive PSV mode. Patient's blood-gas parameters and vital signs will be collected, including discomfort assessment. During the occlusion maneuvers, diaphragm ultrasound will be performed, and images will be recorded.
223816575|NCT02232841|DEVICE|Mechanical Ventilation|Subjects will receive mechanical ventilation as part of their standard of care, as specified in the enrollment criteria
223816576|NCT02232841|DEVICE|CT Scan|Subjects will receive a CT scan as part of their standard of care, as specified in the enrollment criteria
223816577|NCT01105013|DRUG|Clotrimazole|Apply the product in sufficient quantity to cover the affected area 2 times daily (every 12 hours) for 60 days.
223816578|NCT00974701|DEVICE|PillCam ESO2|The capsule to be tested in this proposed study, PillCam ESO 2 capsule Endoscopy, is an improved version with exactly the same dimensions as the current PillCam ESO capsule, both in length and diameter.
223816579|NCT04404478|BEHAVIORAL|B-SWELL: Midlife Black Women's Stress Reduction Wellness Program|Stress reduction and culturally tailored information on healthy lifestyle behaviors will be used to increase healthy lifestyle behaviors according to the AHA's Life's Simple 7. Focus of intervention on per support, goal setting, stress reduction, and culturally relevant information.
223816580|NCT04404478|BEHAVIORAL|WE: Wellness program for Midlife Black Women|Culturally tailored information will be provided about healthy lifestyle behaviors will be used to increase healthy lifestyle behaviors according to the AHA's Life's Simple 7. Focus of intervention on peer support and culturally relevant content.
223816581|NCT04114747|OTHER|Starting at high or low blood pressure|Using norepinephrine, patients will receive high or low blood pressure to start with and after measurements cross to receive the other blood pressure target
223816582|NCT00640237|DIETARY_SUPPLEMENT|Alpha-D3|We will use the vitamin alpha-D3 drops of CTS pharmaceutical firm , that contains 5000 IU in ml. Every patient in the interventional group will receive two dose of 100000 IU (20 ml)vitamin alpha-D3 within a month period.
223816583|NCT00839345|DRUG|clopidogrel|The intervention will involve the change of dosage or change of drug. The traditional maintenance dose of clopidogrel is 75 mg per day. We will test in non-responders to this classical dose higher doses up to 225mg per day. In patients,who will not respond to this 3times higher dose,clopidogrel will be replaced by ticlopidine.
223816584|NCT03485911|DRUG|BCX7353 capsules|BCX7353 oral capsules administered once daily
223816585|NCT03485911|DRUG|Placebo oral capsule|Matching oral capsules administered once daily
223816586|NCT04175353|DIETARY_SUPPLEMENT|Dairy snack|The effects of dairy snack are compared with orange juice.
223816587|NCT04175353|DIETARY_SUPPLEMENT|Berry snack|The effects of two berry snacks are compared with berry soup.
223816588|NCT00002757|BIOLOGICAL|filgrastim|
223816589|NCT00002757|DRUG|cyclophosphamide|
223816590|NCT00002757|DRUG|cytarabine|
223816591|NCT00002757|DRUG|doxorubicin hydrochloride|
223816592|NCT00002757|DRUG|etoposide|
223816593|NCT00002757|DRUG|methotrexate|
223816594|NCT00002757|DRUG|prednisolone|
223816595|NCT00002757|DRUG|prednisone|
223816596|NCT00002757|DRUG|therapeutic hydrocortisone|
223816597|NCT00002757|DRUG|vincristine sulfate|
223816598|NCT02568943|DRUG|Panobinostat|Panobinostat (PAN \[LBH589\]) is an orally administered pan-deacetylase inhibitor (DACi) belonging to a structurally novel class of compounds deregulating cell proliferation and survival mechanisms of cancer cells.
223816599|NCT04097405|DRUG|D-0120|Randomized, Double-Blind, Placebo-Controlled, Multiple Dose and Dose Escalation of D-0120 or Placebo
223816600|NCT04097405|DRUG|Placebo oral tablet|Randomized, Double-Blind, Placebo-Controlled, Multiple Dose and Dose Escalation of D-0120 or Placebo
223816601|NCT05591248|DEVICE|VRR|Eligible patients meeting the inclusion criteria and signed a consent, will have 3x/week the guided rehabilitation session with the VR-tool (with a maximum of 9 VRR-sessions).
223816602|NCT05506865|DRUG|Indacaterol|Indacaterol, one inhales capsule, 150 mcgr, by dry powder dispositive
223816603|NCT05506865|DRUG|Tiotropium|Tiotropium 18 mcgr, one inhaled capsule, by dry powder inhaler handihaler
223816604|NCT04990206|BEHAVIORAL|TranS-C|"TranS-C will be provided in eight weekly, one-on-one 50-minute sessions delivered remotely by two-way video conferencing. Each week will include goal setting and homework assignments which will be reviewed in the following session.~The sessions will include information on sleep and circadian rhythms, behavioral change and motivation, and goal setting. The topics covered in the sessions include establishing regular sleep-wake times, learning a wind-down route, learning a wake-up routine, improving daytime functioning, correcting unhelpful sleep-related beliefs, and maintenance of behavior change."
223816605|NCT02481375|DIETARY_SUPPLEMENT|Multiple micronutrients|12-wk supplementation of vitamin A, B1, B2, B6 ,B12, D, E, niacin, folic acid, zinc, copper, selenium, iodine
223816606|NCT02481375|DIETARY_SUPPLEMENT|Iron|12-wk supplementation of iron
223816607|NCT02481375|DIETARY_SUPPLEMENT|Placebo|12-wk supplementation of placebo
223816608|NCT02410993|PROCEDURE|CABG surgery|
223816609|NCT05647863|OTHER|Functional Cognitive and Sensory Treatment (F-CaST)|F-CaST, a client-centered care, is a functional cognitive sensory intervention focusing on improving Executive Function (EF) and sensory modulation impairments using a modification of the Functional and Cognitive Occupational Therapy Treatment.
223816610|NCT02131038|OTHER|Medica device, drug-like|Ectoin (R) Allergy Nasal Spray
223816611|NCT02374632|OTHER|Meal tests after saline injection|Fixed breakfast meal and ad libitum lunch meal
223816612|NCT02374632|OTHER|Meal tests after octreotide injection|Fixed breakfast meal and ad libitum lunch meal
223816613|NCT02374632|OTHER|Sham feeding|
223816614|NCT05458167|DEVICE|Hedia Diabetes Assistant bolus calculator with a physical activity module|Hedia Diabetes Assistant bolus calculator with a physical activity module is a software device that calculates an insulin bolus based on blood glucose, carbohydrates and physical activity.
223816615|NCT03528174|DEVICE|Artificial Pancreas Control system (APC)|This intervention is a single hormone closed loop system including a Nexus 5 smart phone, two tslim insulin pumps, a Dexcom G5 CGM and two PDT glucose sensing cannulas that together make up a new experimental, investigational device system. The algorithm included in the APC is an automated version of the Fading Memory Proportional Derivative (FMPD) insulin and glucagon control algorithm.
223816616|NCT03528174|DEVICE|Pacific Diabetes Technologies CGM Insulin Infusion system|An integrated combination CGM/insulin infusion system
223816617|NCT05878119|DRUG|Investigational Product - MIB 626|The MIB-626 will be a GMP-grade microcrystalline solid NMN mixed with inert excipients (including microcrystalline cellulose) and compressed into tablets at a dose strength of 500 mg per tablet, enabling administration of the 1,000 mg twice daily using two tablets taken twice daily.
223816618|NCT05878119|DRUG|Placebo|Placebo - Participants randomized to placebo will receive Matching placebo tablets will be provided by Metro International Biotech, LLC
223816619|NCT05878119|OTHER|Standardized, progressive, high intensity, multidimensional exercise|Participants will be asked to perform high intensity, standardized, progressive, multidimensional exercise.
223816620|NCT05878119|OTHER|Usual Physical Activity|Participants will be asked to perform usual physical activity per listed in the protocol
223816621|NCT03002038|DRUG|Azathioprine|Patients are started with Azathioprine 50 mg tablets, taken orally twice a day. The medication dose is increased gradually with the aim of lymphocytes count bellow 1500 and to the maximum dose of 3 g Azathioprine per day. Cell blood count is checked once a week in the first month of treatment, once every two weeks in the second month of treatment, and monthly in the third month of treatment to make decision about medication dose.
223816622|NCT03002038|DRUG|Rituximab|Patients will receive 1 g of Rituximab (two vials of RediTux 500 mg/50 ml) in 500 cc normal saline serum through intravenous infusion and this will be repeated two weeks later. This cycle will be repeated every 6 months.
223816623|NCT06363058|OTHER|ES Cycling Training|Implementing Electrical Stimulation (ES) Cycling combined with priming strategies to enhance motor learning tasks
223816624|NCT01356316|BIOLOGICAL|AdimFlu-S Vaccine 2010-2011|Per ml contains following strains 30μg, A/California/7/2009 (H1N1), A/Perth/16/2009 (H3N2) and B/Brisbane/60/2008
223816625|NCT02263001|OTHER|Auricular acupuncture|Auricular therapy for treatment of musculoskeletal pain
223816626|NCT02263001|OTHER|Usual Care|Usual care therapy consists of over-the-counter and prescribed pharmacotherapy
223816627|NCT03690830|OTHER|metabolomics analysis|collect blood samples and endometrial cells
223816628|NCT04976114|PROCEDURE|Story book with information about surgery techniques|Presurgery use of Story book. The parents with the child read a book with information about surgery techniques the days before surgery.
223816629|NCT04976114|PROCEDURE|Video with information about surgery techniques|Presurgery use of video. The parents with the child watch a video with information about surgery techniques the days before surgery.
223816630|NCT04976114|PROCEDURE|Story book and Video with information about surgery techniques|Presurgery use of video and story book. The parents with the child watch a video and read a book (both) with information about surgery techniques the days before surgery.
223816631|NCT03982043|BEHAVIORAL|Text2Connect|Text2Connect is a personalized text messaging intervention for patients and parents that targets self-identified barriers to engaging in treatment to increase the likelihood that a depressed or suicidal patient will initiate recommended services.
223816632|NCT00380016|PROCEDURE|Percutaneous Transluminal Angioplasty|
223816633|NCT05436912|DRUG|Selpercatinib|Administered orally.
223816634|NCT00003086|BIOLOGICAL|filgrastim|
223816635|NCT00003086|DRUG|CAF regimen|
223816636|NCT00003086|DRUG|carboplatin|
223816637|NCT00003086|DRUG|cisplatin|
223816638|NCT00003086|DRUG|cyclophosphamide|
223816639|NCT00003086|DRUG|doxorubicin hydrochloride|
223816640|NCT00003086|DRUG|fluorouracil|
223816641|NCT00003086|DRUG|ifosfamide|
223816642|NCT00003086|DRUG|melphalan|
223816643|NCT00003086|DRUG|paclitaxel|
223816644|NCT00003086|DRUG|thiotepa|
223816645|NCT00003086|PROCEDURE|peripheral blood stem cell transplantation|
223816646|NCT00003086|RADIATION|samarium Sm 153 lexidronam pentasodium|
223816647|NCT01959191|DRUG|Dual antiplatelet therapy including aspirin and clopidogrel after off-pump coronary bypass surgery|aspirin 100mg/day and clopidogrel 75mg/day, PO, from the day of surgery for 1 year
223816648|NCT01295723|RADIATION|Hypofractionated Whole Breast Radiation Therapy|"Hypofractionated Whole Breast Radiation Therapy must start within 14-56 days postoperatively (week 2-8 post-op)~* Single reference dose per fraction: 2.7 Gy (ICRU)~* Number of fractions: 15~* Number of fractions per week: 5~* Regular Radiation Therapy breaks: Weekend/ Holidays (not exceeding 7 days break)~* Total dose: 50.5 Gy (40.5 WBRT + 10 Gy boost) Radiation: Intraoperative Electron Radiation Therapy"
223816649|NCT01295723|RADIATION|Intraoperative Electron Radiation Therapy|Intraoperative Electron Radiation Therapy (IOERT) is delivered after completion of the lumpectomy and sentinel node procedure. IOERT is performed on mobile or fixed linac with variable electron energies in the range of 4-12 MeV
223816650|NCT01616576|DEVICE|Control first, then Experimental|Control condition is currently marketed sound processing strategy.
223816651|NCT01616576|DEVICE|Experimental first, then Control|Experimental condition is newly modified sound processing strategy.
223816652|NCT00006002|DRUG|dexamethasone|
223816653|NCT00006002|DRUG|semaxanib|
223816654|NCT00353613|BEHAVIORAL|Package of targeted interventions to reduce error|Interventions will include changes in administration of antibiotics and the improved monitoring of blood glucose and body temperature peri-operatively.
223816655|NCT00997737|DEVICE|DB, VI and FI|Two modalities of respiratory exercises based on deep and slow inspirations will be used: DB and IS. During DB, the researcher will place one hand slightly below the lower ribs in the abdominal region of the subject and the subject will be instructed to perform inspirations up to the maximum level of volume avoiding rib cage displacement; this recommendation will also be valid for exercises using incentive spirometers. IS will be executed using two different devices: Triflo II and Voldyne.
223816656|NCT01605760|DRUG|immunotherapy Staloral|Staloral (R) 300 is a sublingual solution of allergen extracts for allergen immunotherapy. During a 16 day incrementally increasing dose period, patients took daily increasing doses period, patients took 1-8 drops of the 100 IR/ml extract during the first 8 days. Then, on days 9-16, patients took 1-8 drops of the 300 IR/ml extract. Next, patients received maintenance treatment consisting of five applications of eight drops (equivalent to 0.5 mL) of 300 IR/mL extract five times a week. The mean duration of the treatment was 28.2 months (range: 3-36 months).
223816657|NCT01379976|DRUG|Acetylcarnitine|"ALC or placebo will be administered concurrently with CHT at 1000 mg sachet three times every day (before meals).~Treatment should be administered for a maximum of 6 cycles for both arms unless progression or unacceptable toxicity, or treatment refusal."
223816658|NCT01379976|DRUG|Placebo|"ALC or placebo will be administered concurrently with CHT at 1000 mg sachet three times every day (before meals).~Treatment should be administered for a maximum of 6 cycles for both arms unless progression or unacceptable toxicity, or treatment refusal."
223816659|NCT04813601|DEVICE|ATLAS 2030|The participant will attend the laboratory every week, two days a week. The therapy will consist of the use of the exoskeleton for rehabilitative purposes. At the end of each three-month period, each patient's data will be monitored.
223816660|NCT04278378|DIETARY_SUPPLEMENT|Riboflavin|1.6 mg riboflavin / day for 24 weeks
223816661|NCT04278378|DIETARY_SUPPLEMENT|Folic acid|0.4 mg folic acid / day for 24 weeks
223816662|NCT04278378|DIETARY_SUPPLEMENT|Placebo|
223816663|NCT00979602|BIOLOGICAL|GSK2340274A|One intramuscular injection
223816664|NCT00979602|BIOLOGICAL|GSK2340273A|One intramuscular injection
223816665|NCT02904902|DRUG|adalimumab|Subcutaneous Injection
223816666|NCT02904616|DEVICE|mobile spectrofluorimeter|
223816667|NCT04396080|PROCEDURE|Partial restoration in posterior teeth|Teeth in need of onlays that will be treated with this type of treatment, choosing the most suitable material for each patient and following the manufacturer's instructions for their cementing and adhesion.
223816668|NCT04313569|PROCEDURE|Arthroscopic menisctomy|Arthroscopic medial menisctomy
223816669|NCT04453514|BEHAVIORAL|Trauma-informed yoga video recording|Pre-recorded video of a 45-minute trauma-informed yoga practice. The yoga practice can be done standing or sitting in a chair. The yoga practice is comprised of slow, gentle movements combined with paying attention to the body and the breath. The practice uses invitational language and encourages participants to make choices and customize the movements according to their individual needs.
223816670|NCT04658823|DRUG|HOV-12020 (Palm tocotrienols complex)|Oral Softgel capsule containing mixed tocotrienols and tocopherol with enhanced absorption delivery system; 1 capsule twice daily
223816671|NCT04658823|DRUG|Placebo|Oral Softgel capsule containing soybean oil; 1 capsule twice daily
223816672|NCT03040921|PROCEDURE|Uterine transposition.|Surgical transposition of the uterus to the upper abdomen. After the end of radiotherapy, rectosigmoidectomy is performed and the uterus is repositioned into the pelvis.
223816673|NCT04803617|OTHER|Assessment of pulmonary function and pectoralis muscle strength|In both groups, forced vital capacity (FVC), forced expiratory volume in one second (FEV1) and FEV1 / FVC ratio were measured with portable spirometer according to the guidelines of the American Thoracic Society (ATS) and the European Respiratory Society (ERS). Maximal inspiratory (MIP) and expiratory pressure (MEP) were evaluated with mouth pressure device as per ATS/ERS guidelines. Sensation of dyspnea was assessed with Modified medical council research scale. Pectoralis muscle strength were measured isometrically using with digital hand held dynamometer.
223816674|NCT05531032|OTHER|Phone Interview|Phone interview questionnaire
223816675|NCT05864300|BEHAVIORAL|Neurocheck frequency|Randomized to hourly or every-other-hour examinations
223816676|NCT06636838|BEHAVIORAL|Spanish-Speaking Provider|Spanish speaking patients will be seen by our Spanish-speaking provider
223816677|NCT04921384|DRUG|Placebo|0.9% normal saline, intravenously
223816678|NCT04921384|DRUG|Eptinezumab|Solution for infusion, intravenously
223816679|NCT04780698|DIAGNOSTIC_TEST|SARS-CoV-2 RT-PCR Assay for Detection of COVID-19 Infection|COVID-19 infection and antibody testing
223816680|NCT04754256|BEHAVIORAL|Council of Nutrition Appetite Questionnaire - test for applicability in Danish COPD patients|Council of Nutrition Appetite Questionnaire - test for applicability in Danish COPD patients and for correlation of scores with lung function, CAT-score and other
223816681|NCT03911427|OTHER|Active oat beverage|Powder packaged in sachets, mixed with water and consumed 3 times per day for 1 month
223816682|NCT03911427|OTHER|Control rice beverage|Powder packaged in sachets, mixed with water and consumed 3 times per day for 1 month
223816683|NCT02872298|DEVICE|Targeted Lung Denervation (TLD)|The Nuvaira Lung Denervation System, manufactured by Nuvaira, Inc., is intended to deliver TLD Therapy using predetermined radiofrequency (RF) energy over a predetermined period of time to ablate airway nerve trunks which are located on the outside of the main bronchi.
223816684|NCT06315803|DEVICE|Real-time 3D Xplane ultrasound|After the puncture needle is in the skin, the longitudinal section of the Xplane mode can be adjusted to keep the needle in the proposed plane.
223816685|NCT02712398|DEVICE|Phasix™ ST|Phasix™ ST is a fully resorbable mesh with a hydrogel coating that is also resorbable.
223816686|NCT02926235|DRUG|Amino Acid|Treatment arm
223816687|NCT02926235|OTHER|Placebo|
223816688|NCT06431438|DRUG|TQA3810|TQA3810 is a small-molecule Toll-like receptor (TLR8) agonist
223816689|NCT01719237|DRUG|Ropivacine and Chloroprocaine mixture|Chloroprocaine is added to Ropivacaine
223816690|NCT01719237|DRUG|Ropivacaine only|Ropivacaine diluted with normal saline instead of chloroprocaine
223816691|NCT05174884|DRUG|22.2 mg Etonogestrel (ENG)|Subdermal insertion of a single Casea S pellet (22.2 mg ENG) in healthy female participants
223816692|NCT05174884|DRUG|44.4 mg Etonogestrel (ENG)|Subdermal insertion of a two Casea S pellet (44.4 mg ENG) in healthy female participants
223816693|NCT00699140|BIOLOGICAL|IGIV3I Grifols|Immune Globulin Intravenous (Human)
223816694|NCT04047511|DEVICE|VRTierOne|"As a virtual reality source, VRTierOne device (Stolgraf®) were used. Thanks to using head mounted display and the phenomenon of total immersion VRTierOne Stolgraf® provides an intense visual, auditory and kinesthetic stimulation. It can have a calming and mood-improving effect or help the patients recognize their psychological resources and motivate to the rehabilitation process. In the virtual therapeutic garden there are a rich set of symbols and metaphors based on Ericksonian Psychotherapy approach. The most important is the Garden of Revival which symbolizes the patient's health. It used to be full of life and energy, now it is neglected, requires work to be revived. In the therapeutic process day by day, the lector (therapist) tells the patient a symbolic story about his/her situation. By performing tasks in the virtual garden, the patient influences the course of this story, becomes an active participant of the therapeutic process and sees the effects his work."
223816695|NCT04047511|BEHAVIORAL|Group general fitness training|A single session of general fitness training will be composed of low-intensity, general-fitness exercises. Most of the exercises will be carried out in a sitting position and standing positon. The session will contain aerobic (general warm-up), musculo-articular (strengthening muscles and joints range of motion) and stabilizing exercises (improve spatio-visual coordination). Perception of effort will be monitored using the Borg 6-20 rating the perceived exertion. Conducted by a physiotherapist in group form.
223816696|NCT04047511|BEHAVIORAL|Group Psychoeducation|A single sesstion will contain mini-lectures about mental well-being and psychohygiene, conduced by a psychotherapist in group form.
223816697|NCT04402164|DEVICE|Herbst appliance|telescopic appliance for mandibular advancement
223816698|NCT01516411|BEHAVIORAL|Mobile Intervention for Lifestyle Eating/Exercise @ Stanford|Participants are randomized to one of 4 groups, each of which uses a different Smartphone app to promote health behavior change
223816699|NCT03266822|OTHER|No intervention|Observational study
223816700|NCT02523521|BEHAVIORAL|Physical activity program|physical activity program for a bronchopulmonary dysplasia children.
223816701|NCT02238717|DRUG|PF-06372865 (65mg)|single oral dose (65 mg)
223816702|NCT02238717|DRUG|PF-06372865 (15mg)|single oral dose (15mg)
223816703|NCT02238717|DRUG|Pregabalin|single oral dose (300mg)
223816704|NCT02238717|DRUG|Placebo|matching oral placebo
223816705|NCT04309929|DRUG|Analgesics|All patients will undergo the anesthesiological and surgical treatment provided for the patient's clinical conditions and in no case will the patients undergo a change in the normal diagnostic-therapeutic path due to participation in this study.
223816706|NCT02335151|DRUG|Desflurane|Apply desflurane as anesthetic
223816707|NCT02283359|DRUG|Selinexor|Selinexor is a potent slowly reversible covalent Selective Inhibitor of Nuclear Export (SINE) that specifically blocks the karyopherin protein Exportin 1 or XPO1.
223816708|NCT02283359|DRUG|Irinotecan|Irinotecan is a topoisomerase inhibitor and is approved by FDA to treat colorectal cancer. It is administered intravenously.
223816709|NCT02576158|PROCEDURE|TCT，HPV，colposcopic inspection|
223816710|NCT05423327|PROCEDURE|No Intervention|Single blood draw
223816711|NCT05302505|OTHER|simulation-based training|Based-simulation training for nurses in a simulation center : puncture of arteriovenous fistula and utilization of echograph and conversational hypnosis
223816712|NCT03312608|DIAGNOSTIC_TEST|Navigated transcranial magnetic stimulation|
223816713|NCT06107764|DEVICE|intermittant theta burst stimulation (iTBS)|iTBS consists of 2 s trains of 3 pulses at 50 Hz, repeated at 5 Hz, every 10s for a total of 600 pulses.
223816714|NCT06107764|DEVICE|continuous theta burst stimulation (cTBS)|cTBS consists of 3 pulses at 50 Hz repeated at 5 Hz (every 200ms) continuously for a total of 600 pulses
223816715|NCT06107764|DEVICE|sham rTMS|sham rTMS does not deliver a significant change in magnetic field strength
223816716|NCT03154372|OTHER|Expert supervised practice with validated metrics|
223816717|NCT03154372|OTHER|self guided practice with validated metrics|
223816718|NCT00634816|RADIATION|DXA Scan|The patients will undergo total body, spine, proximal femoral, and forearm DEXA testing in a standardized fashion. Patients who have undergone limb surgery or irradiation to an extremity for local disease control will also undergo selected site DEXA or pQCT scanning, depending upon the site, of the affected extremity and the identical site on the contra-lateral extremity.
223816719|NCT03018002|OTHER|iSTAR|"Each component of the iSTAR intervention targets a specific point along the HIV continuum: confidential, onsite integrated laboratory tests during baby showers targets HIV diagnosis (b) church-based Health Advisors (CHAs) trained in motivational interviewing and quality improvement skills as promotoras target linkage, engagement and adherence by providing counseling and other support to HIV-infected women and children (c) integrated network of community and clinic case management targets reduction in loss to follow-up.~CHAs will support participants during the study period by being available to accompany them to clinic visits, review laboratory results and medications after clinic visits. They will be available to speak with them at intervals to see how they are doing either by phone or through home visits as they prefer. At each follow-up study visit, the trained CHA will review and collect data on participants' clinic visits, treatment, and laboratory results."
223816720|NCT04750655|DRUG|Moxifloxacin (Topical)|We are using moxifloxacin as indicated and as intended for use as an antibiotic during surgery. Frequency of postoperative antibiotics dependent on group randomization.
223816721|NCT04479280|DEVICE|Sonclot Coagulation and platelet function Analyzer SCP1, Sienco, USA|studying coagulation disorders in COVID19 critically ill patients
223816722|NCT03517618|DRUG|S-1+leucovorin|"Eligible patients will receive TS-1 orally 40-60 mg (depending on patient's body surface area (BSA)) in combination with calcium folinate 30 mg twice a day for 7 days in a 2-week cycle.~The treatment will be administered until disease progression, intolerable toxicity, or consent withdrawal during any time of the study."
223816723|NCT02012062|DRUG|TPF neoadjuvant chemotherapy|
223816724|NCT02012062|DRUG|Concurrent chemotherapy with cisplatin during radiotherapy|
223816725|NCT02012062|DRUG|Concurrent nimotuzumab during radiotherapy|
223816726|NCT02012062|RADIATION|Radical radiotherapy|
223816727|NCT00421434|DRUG|Nitazoxanide|One oral nitazoxanide 500 mg tablet with food twice daily for 48 weeks.
223816728|NCT00421434|BIOLOGICAL|Peginterferon alfa-2a|Weekly injections of 180µg peginterferon alfa-2a for 36 weeks.
223816729|NCT00421434|BIOLOGICAL|Peginterferon alfa-2a|Weekly injections of 180 µg peginterferon alfa-2a for 48 weeks.
223816730|NCT00421434|DRUG|Ribavirin|Oral ribavirin 1000 mg (body weight \<75 kg) or 1200 mg (body weight ≥75 kg) daily in two divided doses for 36 weeks.
223816731|NCT00421434|DRUG|Ribavirin|Oral ribavirin 1000 mg (body weight \<75 kg) or 1200 mg (body weight ≥75 kg) daily in two divided doses for 48 weeks.
223816732|NCT02931201|DEVICE|18F-FDG PET/CT|18F-FDG PET/CT will be conducted before, during and after chemotherapy. Patients were instructed to fast for at least 6 h before PET. The blood glucose level was measured to ensure that it was \<200 mg/dL. 18F-FDG was intravenously administered at a dose of 3.7 MBq/kg. Approximately 60 ± 10 min post-injection, a whole-body acquisition commenced in 6-8 bed positions (1 min/bed) using a hybrid system (PHILIPS Gemini TF) and covered from the base of the skull to the upper thigh, which was followed by CT in a non-contrast phase (modulated 100 mAs; 120 kV; slice thickness, 3 mm) for attenuation correction and anatomical localization purposes. The head acquisition was performed in one bed position (8-10 min/bed).
223816733|NCT01023243|OTHER|Brochure: Care of the Feet for Those at Risk|Patient education materials and key messages for care of the feet for those patients at risk
223816734|NCT01023243|OTHER|Quality Survey: foot exam, tobacco and aspirin use|NCQA Patient Survey
223816735|NCT02936050|PROCEDURE|Diagnostic ultrasound|All participants will be examined by diagnostic ultrasound by nurses for the assessment of the Cardiac size and function, and for volumic state. Transmission of the ultrasound recordings by telemedicine and interpretation by specialist in echocardiography and heart failure. All participants will then be examined by reference imaging in specific ultrasound laboratories.
223816736|NCT00800280|DRUG|PD 0332334|Single 300 mg dose of PD 0332334 immediate release capsules administered orally
223816737|NCT00800280|DRUG|PD 0332334|Single 300 mg dose of PD 0332334 immediate release capsules administered orally on Day 2.
223816738|NCT00800280|DRUG|cimetidine|600 mg q 6 hours cimetidine immediate release formulation administered orally on Days 1 through 5.
223816739|NCT05490264|BIOLOGICAL|[68Ga]Ga-NOTA-SNA002|\[68Ga\]Ga-NOTA-SNA002（PD-L1 PET Tracer）for Positron Emission Tomography
223816740|NCT03551314|OTHER|Nasal Intermittent Positive Pressure|"\- NIPPV The following parameters: inspiratory pressure = 15 cmH2O / final expiratory positive pressure = 6 cmH2O / inspiratory time = 0.40 / flow = 6-8 L.min-1 / respiratory rate = 24.~Respiratory inductive plethysmography is used to evaluate breathing pattern (tidal volume, respiratory rate, minute ventilation, mean inspiratory flow) and chest wall motion (labor breathing index - LBI, phase relation in inspiratory breathing - PhRIB, phase relation in expiratory breathing - PhREB, total phase relation - PhRTB and phase angle)."
223816741|NCT03551314|OTHER|Continuous Positive Airway Pressure|"\- CPAP The following parameters: pressure of 6 cmH2O, with flow of 6-8L/min.~Respiratory inductive plethysmography is used to evaluate breathing pattern (tidal volume, respiratory rate, minute ventilation, mean inspiratory flow) and chest wall motion (labor breathing index - LBI, phase relation in inspiratory breathing - PhRIB, phase relation in expiratory breathing - PhREB, total phase relation - PhRTB and phase angle)."
223816742|NCT00782496|DEVICE|Education + new meter|Diabetes education and a new meter with basic features
223816743|NCT00782496|DEVICE|Education + new meter + feature activation|Diabetes education and a new meter with advanced features
223816744|NCT00070811|PROCEDURE|Lip revision surgery|Full or partial muscle thickness lip revision surgery.
223816745|NCT00853502|DRUG|testosterone cypionate|dose dependent on pubertal stage, intramuscular injection once every 3 weeks for 12 months
223816746|NCT04706533|DIAGNOSTIC_TEST|Biomarkers of inflammation|Biomarkers were measured on blood samples collected within 48 hours of admission
223816747|NCT01481545|RADIATION|Radiation therapy|Radiation therapy will be administered at the total dose of 45 Gy, given with five weekly fractions over a period of 5 weeks. The daily fraction dose will be 1.8 Gy
223816748|NCT01481545|DRUG|Oxaliplatin|100 mg/m2 on day 1 every 2 weeks for 3 cycles (for patients with resectable organ metastases (M1), an additional 2 cycles of chemotherapy will be given after radiation therapy)
223816749|NCT01481545|DRUG|Raltitrexed|2.5 mg/m2 on day 1 every 2 weeks for 3 cycles (for patients with resectable organ metastases (M1) , an additional 2 cycles of chemotherapy will be given after radiation therapy)
223816750|NCT01481545|DRUG|levofolinic acid|250 mg/m2 on day 2 every 2 weeks for 3 cycles (for patients with resectable organ metastases (M1), an additional 2 cycles of chemotherapy will be given after radiation therapy)
223816751|NCT01481545|DRUG|5-fluorouracil|800 mg/m2 on day 2 every 2 weeks for 3 cycles (for patients with resectable organ metastases (M1), an additional 2 cycles of chemotherapy will be given after radiation therapy)
223816752|NCT01481545|DRUG|Bevacizumab|will be given by intravenous infusion at the dose of 5 mg/kg concurrent with chemotherapy and radiotherapy every 2 weeks for 4 cycles from -14 days to start chemo-radiotherapy (classical schedule) or 4 days before the concurrent administration of chemotherapy and radiation therapy for 2 cycles if the number of TRG1 was not reached in the first stage (statistical design) with the classical schedule (for patients with resectable organ metastases (M1), one additional administration of bevacizumab will be given after radiation therapy)
223816753|NCT00844909|DRUG|CNTO 136|
223816754|NCT02503683|DRUG|ALN-AAT|Single or multiple doses of ALN-AAT by subcutaneous (sc) injection
223816755|NCT02503683|DRUG|Sterile Normal Saline (0.9% NaCl)|calculated volume to match active comparator
223816756|NCT03831321|DRUG|Diclofenac Sodium|50 mg of diclofenac sodium will be administered to intervention group one hour before cystoscopy and lubricant gel with lidocaine will be administered to all patients just before cystoscopy.
223816757|NCT03831321|DEVICE|Cystoscopy|Diagnostic cystoscopy
223816758|NCT03831321|DRUG|Lubricant Gel|To prevent patients from side effects of cystoscopy ( like urethral strictures and discomfort)
223816759|NCT01208740|DRUG|Metformin|500 mg three times daily
223816760|NCT01208740|DRUG|Placebo|1 pill three times daily
223816761|NCT01038115|PROCEDURE|Atrial fibrillation ablation|Comparison of three different techniques for pulmonary vein isolation
223816762|NCT03642860|DRUG|Triheptanoin|Daily treatment with Triheptanoin oil for 14 days (7 days titration period in addition to 7 days full dose period with 1g/kg/day).
223816763|NCT03642860|DRUG|Placebo Oil|Daily treatment with Safflower oil for 14 days (7 days titration period in addition to 7 days full dose period with 1g/kg/day).
223816764|NCT03562065|BIOLOGICAL|mesenchymal stem cells|"Allogeneic Umbilical Cord derived-MSCs injected by slow intravenous infusion according to the weight of the recipient and patient groups in the study, at doses of:~* 1.10\^6 CSM / kg~* 2.10\^6 CSM / kg~* 4.10\^6 CSM / kg 1 injection during 30min to 1h by Intravenous infusion"
223816765|NCT03392207|BIOLOGICAL|Seasonal Influenza Vaccine|Trivalent, Fragmented, Inactivated Seasonal Influenza Vaccine (2018 Southern Hemisphere Season) produced at Butantan Institute
223816766|NCT03371641|BEHAVIORAL|ASQ parental questionnaire|ASQ parental questionnaire
223816767|NCT03371641|BEHAVIORAL|Development scales|WPPSI - IV and NEPSY development scales
223816768|NCT03371641|BEHAVIORAL|Scale of Conners|Scale of Conners
223816769|NCT03371641|BEHAVIORAL|SCQ Questionnaire|SCQ questionnaire
223816770|NCT03371641|PROCEDURE|Blood sample (mother)|Blood sample (mother) before delivery
223816771|NCT03371641|PROCEDURE|Cord blood sample|Cord blood sample after delivery
223816772|NCT03371641|PROCEDURE|Placenta sample|Placenta sample
223816773|NCT00990340|DEVICE|T-jet® containing TevTropin®|Needle-free delivery method for 14 days before cross-over to other arm
223816774|NCT00990340|PROCEDURE|TevTropin® needle-syringe injection method|comparison of delivery methods for 14 days before cross-over to other arm
223816775|NCT00584402|DRUG|perflutren lipid microspheres|perflutren lipid microspheres IV in 0.1 cc doses, as needed, to enhance lesion conspicuity
223816776|NCT02283489|DRUG|recombinant human endostatin adenovirus|"Specification: 1mL/division, 1.0×1012 virus particle (VP). ESD01 preparation: Thaw at room temperature, dilute with normal saline to required volume (no more than 2 mL).~Method of administration: Intratumor injection, once a week for 2 weeks, every 3 weeks for one cycle. Select only one target lesion even when lesions are present. The target lesion is the largest and easiest to inject. This will be fixed during the study."
223816777|NCT02283489|DRUG|Cisplatin injection|Specification: 2ml: 10mg. Usage: 25mg/m2, days 1 to 3, according to instruction.
223816778|NCT02283489|DRUG|Paclitaxel injection|Specification: 5ml: 30mg. Usage: 160mg/m2 intravenously on day 1, according to instruction.
223816779|NCT00462137|PROCEDURE|Sleep Studies|
223816780|NCT01987817|BIOLOGICAL|AR101 powder provided in capsules|Study product formulated to contain peanut protein at different dosage strengths for use as defined in the protocol
223816781|NCT01987817|BIOLOGICAL|Placebo powder provided in capsules|Study product formulated to contain only inactive ingredients for use as defined in the protocol
223816782|NCT02821624|DRUG|G1T38 (CDK 4/6 Inhibitor)|CDK 4/6 Inhibitor
223816783|NCT02821624|DRUG|Placebo|Placebo
223816784|NCT02094521|DRUG|NNC0113-0987|For oral administration. All subjects will be treated for 10 consecutive days with five days on 5 mg NNC0113-0987 followed by five days on 10 mg NNC0113-0987. Dose escalation is chosen to increase gastrointestinal tolerability.
223816785|NCT06291662|DEVICE|3D printer applications|Patients will undergo TC/MRI as per routinary care. Custom 3D-devices will be printed on the basis of these images. The device will be used to establish pre-operative surgical options in terms of tissue/bones demolition/reconstruction.
223816786|NCT04438863|DIAGNOSTIC_TEST|home spirometry|portable hand-held spirometer to collect and store daily spirometric data (including FVC, FEV1, forced expiratory flow after 25 to 75% of vital capacity has been expelled, and peak flow).
223816787|NCT04244851|OTHER|Malnourished patients|"Data of included patients will be recorded during hospitalization using medical charts.~Every patient will be contacted by phone 3 months after hospital discharge. A sample of patients and their caregivers will be interviewed to better understand their perception of malnutrition and what they need to better take care of malnutrition."
223816788|NCT00210327|DRUG|Bortezomib (drug)|
223816789|NCT03285841|DEVICE|OCT-AFI|Both groups will be imaged with the OCT-AFI device. Imaging will not influence standard of care biospies, treatment and procedures.
223816790|NCT02459158|DRUG|ME1100 inhalation solution|Low dose of ME1100 inhalation solution twice daily for up to 14 days to be administered via eFlow nebulizer system
223816791|NCT02459158|DRUG|ME1100 inhalation solution|High dose of ME1100 inhalation solution twice daily for up to 14 days to be administered via eFlow nebulizer system
223816792|NCT03590756|OTHER|16 weeks mango intake|Participants will be provided fresh frozen Ataulfo mangoes.
223816793|NCT02070484|BIOLOGICAL|NuCel|
223816794|NCT02070484|BIOLOGICAL|Demineralized Bone Matrix|
223816795|NCT01100554|DEVICE|Sleep endoscopy|Conscious sedation will be done under intravenous propofol infusion. The sedative level would be monitored and adjusted accord to the Bispectral Index monitor. After the adequate sedative level is achieved, a bronchoscopy (Olympus, BF) was inserted from the right nostril. The velopharynx, oropharynx, larynx, and hypopharynx obstructions were evaluated.
223816796|NCT04059757|BIOLOGICAL|Fecal Microbiota Transplantation (FMT)|1 dose = 30 capsules on day 1 of Fecal Microbiota Transplantation
223816797|NCT00682643|DRUG|fluticasone furoate nasal spray|fluticasone furoate nasal spray
223816798|NCT00682643|DRUG|vehicle placebo nasal spray|placebo
223816799|NCT01054261|DRUG|avanafil|200 mg avanafil tablet QD
223816800|NCT02243241|DRUG|HYD|Hydrocodone bitartrate 80 mg (day 9), 120 mg (day 12), 160 mg \[(1) 40 mg tablet + (1) 120 mg tablet\] (day 15) extended-release tablets administered orally every 24 hours.
223816801|NCT02243241|DRUG|Moxifloxacin|Moxifloxacin 400 mg tablets administered orally on the morning of day 9, day 12, and day 15 only.
223816802|NCT02243241|DRUG|Placebo for HYD|Placebo to match HYD tablets administered orally every 24 hours.
223816803|NCT02243241|DRUG|Placebo for moxifloxacin|Placebo to match moxifloxacin tablets administered orally on the mornings of day 9, day 12, and day 15 only.
223816804|NCT02293772|OTHER|Hypoxic ambulatory|21 days confinement in normobaric hypoxic (FiO2 = 14%) environment
223816805|NCT02293772|OTHER|Hypoxic Bedrest|21 days supine bedrest in normobaric hypoxic (FiO2 = 14%) environment
223816806|NCT02293772|OTHER|Normoxic Bedrest|21 days supine bedrest in normobaric normoxic (FiO2 = 21%) environment
223816807|NCT00190502|DRUG|Polyclonal anti-T-cell antibodies|
223816808|NCT02529150|BEHAVIORAL|Exercise|This is an exercise intervention study. All 10 participants will complete 26 weeks high dose exercise (60% of peak aerobic capacity 45 min/session, 5 sessions per week).
223816809|NCT05848479|OTHER|Abdominal bracing|they will perform 3 times/week of static abdominal contraction for six weeks.
223816810|NCT05848479|OTHER|clamshell exercise|Each women will be positioned in side lying on the floor, with the pelvis and the spine in neutral position, the hips will bent at 45° and the knees flexed to 90°. She will abduct the top knee as far as possible, while keeping the heels together, then return to the starting position , the position will be maintained for 5 seconds in an abduction state, and repeated 10 times, with rest for 1 minute to minimize muscle fatigue,they will perform 3 times/week fo 6 weeks
223816811|NCT04681118|BIOLOGICAL|NurOwn (MSC-NTF cells)|Intrathecal administration
223816812|NCT04045730|DRUG|Gemcitabine|All patients will receive treatment with gemcitabine, nab-paclitaxel, PVHA, and pembrolizumab.
223816813|NCT03118284|OTHER|urine collection|
223816814|NCT03118284|OTHER|Blood collection|
223816815|NCT03118284|BEHAVIORAL|NRS|
223816816|NCT06349148|DIETARY_SUPPLEMENT|enteral immunonutrition|Patients in this group receives 2 bottles of immunonutrients per day (Impact, Nestlé, approximately 700 kcal).
223816817|NCT06349148|DIETARY_SUPPLEMENT|standard oral enteral nutrition|Patients in the control group receives isoenergetic standard oral enteral nutrition ( emulsion or Nutrison).
223816818|NCT01949688|BIOLOGICAL|HLA-A*2402 or A*0201 restricted peptides|"Open Label, Non-Randomized, Safety/Efficacy study:~1. HLA-A\*2402-positive patients will be vaccinated subcutaneously once a week with HLA-A\*2402 restricted peptides for VEGF-R1 and VEGF-R2 with adjuvant.~2. HLA-A\*0201-positive patients will be vaccinated subcutaneously once a week with HLA-A\*0201 restricted peptides for VEGF-R1 and VEGF-R2 with adjuvant."
223816819|NCT00566176|DEVICE|Surgical Ablation using the AtriCure Bipolar System|Surgical Ablation using the AtriCure Bipolar System
223816820|NCT05780294|DRUG|5-fu|5-fu: 200mg/m2/d, continuous intravenous infusion on the 1st to 30th day of each cycle.
223816821|NCT05780294|DRUG|Lobaplatin|30mg/m2, used on the 1st and 28th day of each cycle.
223816822|NCT05780294|DRUG|Placebo|2 tablets/dose 3 times for peri-chemotherapy prophylaxis and inter-chemotherapy period, 3 tablets/dose 3 times daily during chemotherapy, and continued to be given orally 2 tablets/dose 3 times daily for 4 weeks after the end of chemotherapy.
223816823|NCT05780294|DRUG|leucogen|40 mg/dose was used 3 times for peri-chemotherapy prophylaxis and inter-chemotherapy period, and 60 mg/dose was used 3 times daily during chemotherapy, and 40 mg/dose was continued orally 3 times daily for 4 weeks after the end of chemotherapy.
223816824|NCT04211922|DRUG|Alkotinib Capsules|Alkotinib 400mg QD
223816825|NCT03187990|DRUG|[68Ga]PSMA-11|PET/MRI with \[68Ga\]PSMA will be compared to mpMRI for biopsy guidance.
223816826|NCT03187990|DRUG|[18F]PSMA-1007|18F-PSMA-1007 PET/CT for biopsy guidance and intraoperative target verification.
223816827|NCT05180292|DRUG|Carvedilol 12.5 MG|Carvedilol 12.5 mg
223816828|NCT05529160|DEVICE|FERTI LILY Conception Cup|The FERTI-LILY Conception Cup is indicated for over-the-counter (OTC) home use by couples trying to conceive. The FERTI·LILY device OTC contains a cervical cap attached to a stem. The FERTI-LILY Conception Cup is intended to push semen towards the cervix as an aid in conception. It is designed to be inserted vaginally after intercourse and left in place for 20-60 minutes. The device is recommended to be used during the ovulatory phase of the menstrual cycle. It is not to be left in place for longer than six hours. The device may be re-used up to 18 times or over 6 cycles.
223816829|NCT03549884|PROCEDURE|Delayed cord clamping|Cord clamping will be performed after 60 seconds of life in infants delivered by cesarean section
223816830|NCT03549884|PROCEDURE|Early cord clamping|Cord clamping will be performed within 10 seconds of life in infants delivered by cesarean section
223816831|NCT03390868|BEHAVIORAL|Web-based training for staff|This web-based training program is focusing on strengthening the carers' communication skills. Video lectures on the definitions, characteristics and causes of challenging behavior will be given. Video lectures will also be given on the importance of the carers' views on their values, emotions, abilities and attitude towards people with intellectual disabilities and on the impact that workplace culture and environmental factors have on the quality of interactions. The program also includes written cases that gives the participants opportunities to reflect upon approaches supporting a successful interaction. It also covers factors to consider when mental illness and challenging behavior occur. The time to complete the web-based training program is estimated at approximately ten hours.
223816832|NCT01177423|PROCEDURE|Dental anesthesia|Pulpal and periapical molar and premolar sedation is randomly managed among studied population and Pulp-tester measures anesthesia minute by minute.
223816833|NCT04065503|BIOLOGICAL|Probiotic Strains|A commercial product containing L. helveticus R0052, L. casei HA-108, B. breve HA-129, and B. longum R0175 and S. thermophilus HA-110 be given to healthy adults across a 10-week open label pilot study.
223816834|NCT01870388|DRUG|Baricitinib|Administered orally
223816835|NCT01852058|BIOLOGICAL|OnabotulinumtoxinA|OnabotulinumtoxinA injected into the detrusor wall. Treatments were administered as needed with a minimum of a 12-week interval between doses.
223816836|NCT02930473|BEHAVIORAL|NIC Psychotherapeutic Intervention(s) for Anxiety|Patients will be treated by NIC psychotherapeutic intervention(s) for anxiety (e.g. anxiety reduction) plus psychopharmaceuticals prescribed by their psychiatrist.
223816837|NCT02930473|DRUG|Psychopharmaceuticals (any drugs prescribed by the psychiatrist)|Patients will be treated only by psychopharmaceuticals prescribed by their psychiatrist.
223816838|NCT00957606|PROCEDURE|blood sampling, DXA-scan, bone scintigraphy|Blood sampling 5 times DXA-scan 5 times Bone scintigraphy 3 times
223816839|NCT05316584|BEHAVIORAL|Remote monitoring|See prior description of the intervention.
223816840|NCT04770363|DEVICE|Transcranial Direct Current Stimulation (tDCS)|Transcranial direct current stimulation (tDCS) is an emerging non-invasive brain stimulation technique which has been utilized in examining cortical function in healthy subjects and also showed significant outcome in neurological rehabilitation. A safe, portable, noninvasive painless, reversible, selective and focal brain stimulation technique, applied by sponge electrodes over the scalp. tDCS is capable of modulating the excitability of targeted brain zones through delivering a sustained direct current (DC), showed altering neuronal membrane potentials based on the polarity of the current. Researchers demonstrated modulating effects of anodal (increases cortical excitability) and cathodal (decreases cortical excitability) tDCS on brain tissue. The expected effects of tDCS brain stimulation exceeds the duration. Animal studies showed neuronal depolarization and increasing neuronal excitability of the anodal stimulation, and opposite results with cathodal stimulation.
223816841|NCT00622180|DEVICE|NBUVB|NBUVB hand foot box
223816842|NCT00622180|DEVICE|Monochromacitc Excimer light|Treatment with Monochromacitc Excimer light
223816843|NCT06300255|BEHAVIORAL|H.O.O.V.E.S. Healing Intensives|"H.O.O.V.E.S. is a private, donor-supported charity dedicated to providing fully-funded, \[4\]-day, non-clinical healing intensives for veterans, their families and caregivers, and first responders across the nation who are seeking recovery from service-connected stress. 1~References~1\. Home. HOOVES for Vets. Accessed January 24, 2024. https://www.hooves.us/."
223816844|NCT02280239|DRUG|Acetaminophen|one-time dose of acetaminophen 650mg given via the enteral route (via the gut)
223816845|NCT02280239|DRUG|Placebo|one-time dose of placebo (identical capsule) given via the enteral route (via the gut)
223816846|NCT06292351|DRUG|DMB-I (Dimebon)|20 mg 3 times a day, or 10 mg + 10 mg 3 times a day (for DMB-I + Placebo arm)
223816847|NCT06292351|OTHER|Placebo|20 mg 3 times a day, or 10 mg + 10 mg 3 times a day (for DMB-I + Placebo arm)
223816848|NCT05505877|DRUG|BR790+Tislelizumab|"BR790 will be administered orally, variable dose.~Tislelizumab will be administered as an intravenous infusion,fixed dose."
223816849|NCT00217646|DRUG|Sorafenib Tosylate|Given orally
223816850|NCT04978155|DIAGNOSTIC_TEST|Duplex ultrasound performed by the surgeon after locoregional anesthesia|Just after locoregional anesthesia, the surgeon perform a duplex ultrasound to determinate if the target vessel chosen to create the arterio-venous fistulae match with the pre-operative duplex performed during the consultation. So the plan can be changed such as more distal, more proximal creation, changing vein or artery target.
223816851|NCT01818674|BEHAVIORAL|Microclinic Behavioral Health Full Program (education curriculum in classroom setting, plus full social interaction program)|A 6-month intervention program (sessions and educational materials) aims to increase knowledge and skills in diabetes self-management and peer support and monitoring. The curriculum include causes of diabetes, prevention of complications, symptoms, self-management strategies, diet, exercise, peer monitoring and support by trained Project nurses from MoH health centers, local physicians, and university professors. Each class will provide 2-3 hours of discussion to foster active class participation and engagement.
223816852|NCT01818674|BEHAVIORAL|Microclinic Behavioral Health Basic Program (education-only in classroom setting; no structured social interactions)|This basic program (6 month) aims to increase participants knowledge about diabetes self-management, but without structured social interaction programming. While group classroom setting is still used for delivery of the educational curriculum, the education program in group B have no group-based or team-building activities, group goal setting, and classroom program is lecture style with more limited class participation and interaction.
223816853|NCT06447350|BEHAVIORAL|Induced hypocrisy|Induced hypocrisy task
223816854|NCT06447350|BEHAVIORAL|social identity mapping|Social identity mapping task
223816855|NCT06447350|BEHAVIORAL|Motivational modeling|Motivational modeling task
223816856|NCT06447350|BEHAVIORAL|motivational interviewing|motivational interviewing
223816857|NCT02385994|DEVICE|enLighten Laser|enLighten Laser treatment with dual-pulse width and dual-wavelength
223816858|NCT05203120|RADIATION|Proton therapy|All patients will receive proton therapy 67.5Gy/15fx
223816859|NCT01353222|BIOLOGICAL|DN24-02|DN24-02 is an autologous cellular immunotherapy product designed to stimulate an immune response against HER2/neu. It consists of autologous peripheral blood mononuclear cells (PBMCs), including antigen presenting cells (APCs), which are activated ex vivo with a recombinant fusion protein, BA7072.
223816860|NCT01353222|OTHER|Standard of Care|Observation only until documentation of disease recurrence.
223816861|NCT06320301|DRUG|Adebrelimab + GEMOX + TKI|"Adebrelimab 20 mg/kg, once every 3 weeks (Q3W), maintained for 1 year. The interval between two doses should not be less than 12 days.~Tyrosine kinase inhibitor (TKI) Lenvatinib: 12 mg (3 capsules 4 mg) or 8 mg (2 capsules 4 mg) once daily (QD) at fixed times daily, on an empty stomach or with food; Apatinib: 250mg orally, QD, 5 days of medication, 2 days off (5 on 2 off) or once every other day (QOD), half an hour after meals; Sorafenib: 0.4g (2 × 0.2g) twice or once daily on an empty stomach or with a low-fat or medium-fat diet Anlotinib: 12 mg orally before breakfast, QD. The drug was taken continuously for 2 weeks and stopped for 1 week.~GEMOX: gemcitabine 800mg/m2 and oxaliplatin 85mg/m2, intravenous infusion, D2, D15, D29, until 6 cycles of treatment were completed, or the patients who did not reach 6 cycles had intolerable adverse reactions, then the combination chemotherapy was terminated."
223816862|NCT05597657|OTHER|Fluid administration (Fresenius Kabi Sodium Chloride 0.9%)|All participants in substudy 2 will be administered 2 liters of isotonic saline infusion (Fresenius Kabi Sodium Chloride 0.9%) intravenously. CMR and echocardiography will be performed before and after infusion.
223816863|NCT02636270|DRUG|Increlex|Treat PAPP-A2 deficient patients with Increlex
223816864|NCT04762693|DEVICE|Hyfe cough tracker|A mobile app that runs in the background of smartphones and detects putative cough sounds.
223816865|NCT01119898|DRUG|PENNSAID Gel|2 mL applied to the front, back and sides of the knee twice a day (morning and night) for 4 weeks
223816866|NCT01119898|DRUG|Vehicle|2 mL applied to the front, back and sides of the knee twice a day (morning and night) for 4 weeks
223816867|NCT02432469|BEHAVIORAL|APP intervention|The APP contains education materials about secondary intervention of coronary artery disease, patients can surf and read them very easily. The APP also collects information on medication prescription by doctors, reminds patients at every time of taking medications, and asks for feedback from patients at 8 pm every day. The APP also pushes a patient-specific questionnaire with 10-15 questions weekly, to collect information about patients' medication adherence and self-management on blood pressure, blood lipid, blood glucose, physical activity, diet and body weight. APP pushes series of recommendations right after patients' finishing the questionnaire to help them improve their secondary prevention.
223816868|NCT03407690|OTHER|nasal swab|collection of nasal swab to allow carriage of pneumococci to be assessed
223816869|NCT02572557|DEVICE|TruFreeze Spray CryoTherapy|TruFreeze Spray CryoTherapy using liquid nitrogen
223816870|NCT02572557|DRUG|Liquid nitrogen|TruFreeze Spray CryoTherapy using liquid nitrogen
223816871|NCT01574768|PROCEDURE|Lateral Pharyngoplasty|Tonsilectomy, microdissection of the superior pharyngeal constrictor muscle within the tonsillar fossa and sectioning of this muscle
223816872|NCT01806584|BIOLOGICAL|SRM003|One time implant (3 SRM003 pieces) on surgery day.
223816873|NCT01806584|OTHER|Participating Site's standard practice|Subjects will receive sites' standard practice treatment during the surgical procedure
223816874|NCT03207139|DRUG|Ga-68 PSMA ligand|"For PET/CT PSMA ligand scan, the subject will have catheter(s) placed for intravenous administration of \[68Ga\]PSMA ligand . Subjects will receive a single intravenous bolus of 2-5 mCi \[68Ga\]PSMA ligand and received PET/CT scan 60 minutes later. The data acquisition begin with non-contrast CT at 120kVp, automated mAs, and a pitch of 1.5, followed by PET acquisition from the mid-thigh to skull-base, 3 minutes each bed. After image acquisition, the subject will be observed for half an hour, and will be discharged if no adverse event happens.~The estimated organ doses show that the kidneys and the urinary bladder wall were the organs with the highest dose. As presented, the effective doses for patients were 0.023 mSv/MBq ± 15% (maximum deviation), leading to an effective dose of 3.4 mSv for an injected activity of 150 MBq."
223816875|NCT01455207|BEHAVIORAL|Neuropsychological testing|assessment of memory, executive functions and ataxia
223816876|NCT01455207|BIOLOGICAL|blood draw|hepatic markers, red blood markers and vitamin markers
223816877|NCT01455207|GENETIC|genetic testing|genes coding for thiamine enzymes (α-ketoglutarate dehydrogenase complex, transketolase et pyruvate dehydrogenase)
223816878|NCT01455207|OTHER|Brain imaging examination|MRI, DTI and PET examinations
223816879|NCT03945864|DEVICE|antimicrobial synthetic bone graft|It will be determined whether the silver ion-doped antimicrobial synthetic bone graft that has the capacity to fill the bone voids also has the capacity to treat the infection in the bone in 12 patients with chronic osteomyelitis
223816880|NCT03945864|DEVICE|parentaral antimicrobials and pure bone grafts|Historical data of the department will be used for comparison of the results
223816881|NCT05716984|DRUG|recombinant human brain natriuretic peptide|rhBNP 500μg + 0.9% sodium chloride 50ml, the concentration is 10 μg/ml, loading dose 1.5 μg/kg iv, followed by 0.0075 μg/kg·min with micro-pump injection for 72 hours.
223816882|NCT05716984|DRUG|Placebo|placebo 500μg + 0.9% sodium chloride 50ml, the concentration is 10 μg/ml, loading dose 1.5 μg/kg iv, followed by 0.0075 μg/kg·min with micro-pump injection for 72 hours.
223816883|NCT06185010|OTHER|One Resistance Training Set (Single Session)|The participants will perform a resistance training session with one set per exercise. The training sequence will be the following: i) 10 minutes of warm-up walking on the treadmill at 50% of maximal walking velocity, ii) 1 set of 10 repetitions at 60% of one-repetition maximum (1RM) in the leg press, iii) 1 set of 10 repetitions at 55% 1RM in the chest press, iv) 1 set of 10 repetitions in the sit-to-stand exercise, v) 1 set of 10 repetitions in the 1-kg medicine ball throw exercise, and vi) 5 minutes walking on the treadmill at 60% of maximal walking velocity.
223816884|NCT06185010|OTHER|Three Resistance Training Sets (Single Session)|The participants will perform a resistance training session with three sets per exercise. The training sequence will be the following: i) 10 minutes of warm-up walking on the treadmill at 50% of maximal walking velocity, ii) 3 sets of 10 repetitions at 60% of one-repetition maximum (1RM) in the leg press, iii) 3 sets of 10 repetitions at 55% 1RM in the chest press, iv) 3 sets of 10 repetitions in the sit-to-stand exercise, v) 3 sets of 10 repetitions in the 1-kg medicine ball throw exercise, and vi) 5 minutes walking on the treadmill at 60% of maximal walking velocity.
223816885|NCT06185010|OTHER|One Resistance Training Set (8 Weeks)|The participants will perform eight weeks of resistance training with one set per exercise. The training sequence will be the following: i) 10 minutes of warm-up walking on the treadmill at 50% of maximal walking velocity, ii) 1 set of 10 repetitions between 50-70% of one-repetition maximum (1RM) in the leg press, iii) 1 set of 10 repetitions between 40-60% 1RM in the chest press, iv) 1 set of 6-12 repetitions in the sit-to-stand exercise, v) 1 set of 6-12 repetitions in the 1-kg medicine ball throw exercise, and vi) 5 minutes walking on the treadmill at 60% of maximal walking velocity.
223816886|NCT06185010|OTHER|Three Resistance Training Sets (8 Weeks)|The participants will perform eight weeks of resistance training with three sets per exercise. The training sequence will be the following: i) 10 minutes of warm-up walking on the treadmill at 50% of maximal walking velocity, ii) 3 sets of 10 repetitions between 50-70% of one-repetition maximum (1RM) in the leg press, iii) 3 sets of 10 repetitions between 40-60% 1RM in the chest press, iv) 3 sets of 6-12 repetitions in the sit-to-stand exercise, v) 3 sets of 6-12 repetitions in the 1-kg medicine ball throw exercise, and vi) 5 minutes walking on the treadmill at 60% of maximal walking velocity.
223816887|NCT06185010|OTHER|Control (8 Weeks)|The participants in the control group will maintain their regular daily activities without performing any form of physical exercise.
223816888|NCT01665703|PROCEDURE|FDG PET/MR|Patients will be asked to undergo a voluntary gadolinium enhanced MRI with simultaneous acquisition of FDG-PET uptake within 4 weeks prior to surgery.
223816889|NCT05378243|DEVICE|Robotic Gait Training|Use of a walker adapted with robotic components to promote proper walking gait
223816890|NCT05378243|BEHAVIORAL|Functional Clinical Therapy|Personalized program of physical therapy targeted to improving walking gait
223816891|NCT01593202|BEHAVIORAL|Dialectical behavior therapy|"16 weeks of Dialectical behavior therapy with one weekly session of individual therapy, one weekly session of multifamily skills training group, telephone coaching and ancillary family therapy and/or pharmacological treatment as needed.~The treatment has been developed by Marsha Linehan (Linehan, 1993a; 1993b)and adapted for adolescents by Alec Miller (Miller, Rathus \& Linehan, 2007). Individual DBT therapists have been trained by drs Alec L Miller and Sarah K Reynolds and have a minimum of one year clinical practise as DBT therapists. The therapists are organised in two consultation teams supervised on a bimonthly basis throughout the entire study by drs Miller and Reynolds respectively."
223816892|NCT01593202|BEHAVIORAL|Enhanced usual care|16 weeks of outpatient treatment in child and adolescent psychiatric clinics in Oslo, on average one weekly session of individual therapy and ancillary supportive. family and/or pharmacological treatment as needed.
223816893|NCT05063214|DIAGNOSTIC_TEST|Muscle ultrasound evaluation|Muscle ultrasound evaluation will be performed in patients admitted with COVID-19 requiring invasive mechanical ventilation. The measurements of thickness and thickening fraction will occur for diaphragm, abdominal - rectus abdominis, internal oblique, external oblique and transverse abdomen - and parasternal intercostal muscles. Serial measurements of the thickness and echogenicity of the quadriceps femoris muscle will also be performed.
223816894|NCT02907814|DEVICE|Optical Coherence Tomography (OCT)|The OCT scan is a brief, non-contact scan of the back of the eye using infrared light. Subjects will see a light and be asked to look forwards while the scan is completed.
223816895|NCT02907814|OTHER|Eye Exam|This is a brief, non-contact ocular exam.
223816896|NCT05788835|PROCEDURE|DEB-TACE and HAIC|Drug-eluting bead transarterial chemoembolization sequential Hepatic Artery Chemotherapy Infusion
223816897|NCT05788835|PROCEDURE|DEB-TACE|Drug-eluting bead transarterial chemoembolization
223816898|NCT00834808|DRUG|Tramadol HCl|One single oral administration of Tramadol HCl 100 mg, 200 mg or 300 mg as per randomization schedule.
223816899|NCT02716389|OTHER|Zebris CMS 70|
223816900|NCT02716389|OTHER|3-D Bulls Eye Spirit Meter|
223816901|NCT03716284|PROCEDURE|Electromagnetic navigation bronchoscopy (ENB)|ENB is carried out by a ENB system（LungCare, China) with/without other guided bronchoscopy techniques and/or ROSE, which can offer real-time navigation for bronchoscopy reaching peripheral pulmonary nodules.
223816902|NCT00583622|DRUG|Bevacizumab|5 mg/kg by vein daily over 90 minutes for 2 Days
223816903|NCT00583622|DRUG|Carboplatin|333 mg/m\^2 by vein over 2 hours for 3 Days
223816904|NCT00583622|DRUG|Docetaxel|300 mg/m\^2 by vein over 2 hours for 1 Day
223816905|NCT00583622|DRUG|Gemcitabine|1,800 mg/m2 by vein over 3 hours for 4 Days
223816906|NCT00583622|DRUG|Melphalan|50 mg/m\^2 by vein over 15 minutes for 3 Days
223816907|NCT00583622|PROCEDURE|Stem Cell Transplant|"* Stem Cell Removal via apheresis through a central venous catheter (CVC), usually in chest~* Stem Cell Replacement through CVC over about 30-60 minutes, Day 7 of treatment, following study drug regimen"
223816908|NCT04023071|DRUG|FT516|Experimental Interventional Therapy
223816909|NCT04023071|DRUG|Rituximab|Monoclonal Antibody
223816910|NCT04023071|DRUG|Obinutuzumab|Monoclonal Antibody
223816911|NCT04023071|DRUG|Cyclophosphamide|Conditioning agent
223816912|NCT04023071|DRUG|Fludarabine|Conditioning agent
223816913|NCT04023071|DRUG|IL-2|Biologic response modifier
223816914|NCT04023071|DRUG|Bendamustine|Conditioning agent
223816915|NCT05403190|DEVICE|da Vinci SP system|using da Vinci SP system to perform extraperitoneal approach radical prostatectomy
223816916|NCT03266614|BEHAVIORAL|Recovery 4 Us|R4US is a social media program aimed at the enhancement of community participation and overall recovery of individuals with psychiatric disabilities.
223816917|NCT00163995|DRUG|urotensin II|
223816918|NCT04398537|DEVICE|5mm retraction of clip deployment apparatus.|Advancing the clip to the biopsy site and retracting 5 mm and then deploying. This is one method of standard of care and involves depositing the clip after retraction of the deployment apparatus 5 mm.
223816919|NCT04398537|DEVICE|No retraction of clip deployment apparatus.|This is one method of standard of care and the clip will be deployed at the biopsy site.
223816920|NCT03994783|DRUG|Rituximab|2 intravenous infusions of rituximab or approved biosimilar given 14 days +/- 2 days apart.
223816921|NCT03994783|DRUG|Methylprednisolone|Intravenous infusion of methylprednisolone
223816922|NCT03994783|DRUG|Intravenous Immunoglobulin|High dose (2 g/kg total) or Low dose (100 mg/kg, n=7)
223816923|NCT03994783|PROCEDURE|Plasma Exchange|Blood is removed from the patient and filtered to remove the plasma. Red and white blood cells and platelets are returned to the patient with replacement fluid.
223816924|NCT03333850|DEVICE|Visual feedback of physical activity|A monitor (tablet) will display the level of physical activity during hospitalisation. The monitor will be placed at the bedside (table).
223816925|NCT03333850|DEVICE|No feedback of physical activity|There will be no visual feedback of the physical activity (no monitor placed at the bedside (table)).
223816926|NCT03333850|DEVICE|Measurement of physical activity|A pair of accelerometers placed on the chest and on the thigh will measure the physical activity level during hospitalisation. The measurement is made continuously and stored on a secure web-server.
223816927|NCT02717169|DEVICE|Biometrical tracker|35 participants are wearing a activity, sleep and heart rate tracker day and night time over a period of 5 month. The wrist watch is equipped with accelerometer, heart rate monitor using oximetry sensor, 3 led lights and vibrating alarm. The tracker is connected over Bluetooth with a smartphone App displaying the measured values and permitting to show different statistics related to amount of steps, sleep duration and heart rate over days, weeks and months.
223816928|NCT05919693|DRUG|EYE103|EYE103 is a humanized antibody formulated for IVT administration
223816929|NCT01759069|PROCEDURE|Surgical treatment with microscope|
223816930|NCT05313750|DRUG|anti-infective therapy sitafloxacin|anti-infective therapy
223816931|NCT05313750|DRUG|anti-infective therapy levofloxacin|anti-infective therapy
223816932|NCT03975764|DIAGNOSTIC_TEST|Collection of fecal sample|Analysis of fecal microbiome
223816933|NCT02640443|DRUG|Sulfamethoxazole|60 mg sulfamethoxazole per kg bodyweight (maximal of 3g) divided in 2 doses per day during 3 weeks
223816934|NCT01664520|DRUG|Dexmedetomidine infusion|"Both static and dynamic autoregulation are assessed first during propofol infusion, before commencement of dexmedetomidine infusion. Dexmedetomidine infusion is commenced with a dose of 0.7 μg/kg/h and propofol infusion is stopped concomitantly. After 2 hours dexmedetomidine infusion, the static and dynamic autoregulation are assessed. If there are no signs of worsening of autoregulation, then the dexmedetomidine infusion is increased to 1 μg/kg/h and after 2 hours the static and dynamic autoregulation are assessed again. However, if autoregulation worsens during dexmedetomidine infusion, it will be stopped and further testing with dexmedetomidine will not be carried out. If autoregulation does not worsen with the 1 μg/kg/h dose then the dose will be increased to 1.4 μg/kg/h. After 2 hours infusion the dynamic and static autoregulation are assessed again.~Blood samples for determining dexmedetomidine plasma concentration are collected alongside with the autoregulation assessments"
223816935|NCT02675790|DRUG|Moderate Dose Hydroxyurea|Hydroxyurea therapy at 20 mg/kg/day for primary stroke prevention.
223816936|NCT02675790|DRUG|Low Dose Hydroxyurea|Hydroxyurea therapy at 10 mg/kg/day (range 7 - 15 mg/kg/day) for primary stroke prevention.
223816937|NCT02452086|DEVICE|Low Level Laser(Ga-As)|Low level laser therapy(904 nm Wavelength), 90 milliwatt, 2 Joule/centimeter2
223816938|NCT02452086|PROCEDURE|Placebo|LLLT with zero intensity
223816939|NCT06120673|DRUG|Obinutuzumab|"Participants will receive an intravenous infusion of 1,000mg Obinutuzumab at Weeks 0, 2, 24 and 26.~Prior to the administration of obinutuzumab, the participant will receive pre-medications consisting of all three:~* IV methylprednisolone 80 mg,~* Paracetamol 1,000 mg orally,~* Either cetirizine 10 mg orally or diphenhydramine 50 mg orally. These pre-medications must be completed between 30 to 60 minutes prior to the obinutuzumab infusion."
223816940|NCT06120673|DRUG|Oral prednisolone and cyclophosphamide|"Participants will receive a combination of oral prednisolone and cyclophosphamide with 2 options (Option A and B).~Option A: Cyclical prednisolone and cyclophosphamide with IV methylprednisolone~* IV methylprednisolone 500-1000 mg will be given on days 1, 2 and 3 at the start of months 1, 3, and 5.~* Oral prednisolone will be given at 0.5 mg/kg/day (max 50 mg/day) in months 1, 3, and 5.~* Oral cyclophosphamide will be given in months 2, 4 and 6, adjusted by age and weight~Option B: Concurrent prednisolone and cyclophosphamide without IV methylprednisolone~* Oral prednisolone will be given to meet a cumulative dose equivalent to 0.5 mg/kg/day for 90 days (max 50 mg/day).~* Oral cyclophosphamide will be given for 90 days, adjusted by age and weight"
223816941|NCT05741099|BIOLOGICAL|Umbilical cord mesenchymal stem cells implantation|Patient in Mscs group will receive MSCs implantation by intravenous injection.
223816942|NCT05741099|OTHER|Comparator|Patients in comparator group will receive placebo treatment
223816943|NCT05389111|OTHER|Internal discourses|This intervention will take place following the randomization performed at the V1 visit. It will be held in videoconference, will be led by a professional of the training field, specialist of the trail activity and trained in the use of mental strategies
223816944|NCT05389111|OTHER|Non internal discourses|This intervention will take place following the randomization performed at the V1 visit. It will be held in videoconference, and will be conducted by a professional of the training field, specialist of the trail activity and coach of mountain guide
223816945|NCT03921190|PROCEDURE|Local anesthesia|Patients scheduled for a dental procedure that requires local anesthesia will be given the injection using two 2 techniques; an open-mouth and closed-mouth techniques
223816946|NCT04503096|DEVICE|High-dose accelerated rTMS|A MagVenture MagPro Transcranial Magnetic Stimulation (TMS) System will be utilized. All participants will receive open-label treatment for approximately eight, 3-minute sessions of intermittent theta burst rTMS on each of three days within an eight-day span. A single session = 600 pulses at 120% resting motor threshold (rMT), intermittent Theta Burst Stimulation (iTBS) triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 s to left dorsolateral prefrontal cortex. Total pulses = 14,400. To enable adherence and retention, the days do not need to be contiguous. Same day sessions will be separated by 10-15 minutes, but more accounting for participant comfort.
223816947|NCT01480596|BIOLOGICAL|Belimumab|10mg/kg IV infusion
223816948|NCT01480596|OTHER|Placebo|placebo IV infusion
223816949|NCT00825097|PROCEDURE|Selective tibial neurotomy|Selective tibial neurotomy is a neurosurgical intervention consisting in partially and selectively cutting the motor nerve branches destinated to the spastic muscles.
223816950|NCT00825097|DRUG|Botulinum toxin injection|Botulinum toxin type A
223816951|NCT03072225|DRUG|Herbal Medicine C-117|Herbal Medicine C-117 formula including 2 herbals and 2 insects
223816952|NCT03072225|DRUG|The Placebo of Herbal Medicine C-117|The Placebo of Herbal Medicine C-117 formula including 4 herbals
223816953|NCT02544828|DRUG|Iron Sucrose 200mg|Iron Sucrose 200mg is administered after anesthesia induction.
223816954|NCT02544828|DRUG|placebo|placebo (normal saline) is administered after anesthesia induction
223816955|NCT02281760|DRUG|Dabrafenib Mesylate|Description: Dabrafenib mesylate (GSK2118436B) is a potent and selective BRAF kinase inhibitor. This inhibition suppresses downstream activity of pERK, a biomarker, and has antiproliferative activity against BRAF mutant tumors.The mode of action is consistent with ATP competitive inhibition.
223816956|NCT02281760|DRUG|Trametinib Dimethyl Sulfoxide|Trametinib dimethyl sulfoxide is a reversible, highly selective, allosteric inhibitor of mitogen-activated extracellular signal regulated kinase 1 (MEK1) and MEK2. Tumor cells commonly have hyperactivated extracellular signal-related kinase (ERK) pathways in which MEK is a critical component. Trametinib dimethyl sulfoxide inhibits activation of MEK by RAF kinases and MEK kinases.
223816957|NCT05733962|DEVICE|Use of the device DBL-4pen|"During the treatment period, the patient will use~* the DBL-4pen device (consisting of a software hosting the Diabeloop algorithm installed on a smartphone)~* the associated device #1: Dexcom G6, Continuous Glucose Monitoring (CGM)~* the associated device #2: Two Mallya caps for their rapid- and long-acting insulin pens.~The regulation algorithm hosted by DBL-4pen software recommends insulin doses to be administrated by the patient."
223816958|NCT01021774|PROCEDURE|Anal fistula treatment|A comparison of collagen plug vs advancement flap surgery
223816959|NCT02378532|DRUG|Chloroquine|Three cohorts of 3 patients will receive chloroquine in escalating doses (3 dose levels: 200 mg up to 600 mg daily) during standard treatment (radiotherapy and temozolomide) for newly diagnosed GBM. Extra patients can be added to a cohort in case of dose limiting toxicity, resulting in a maximum of 6 patients per dose level. Based on the results of the DSMB an additional leven of 300mg was added.
223816960|NCT02378532|RADIATION|Radiotherapy|Patients will receive megavoltage radiotherapy in a conventionally fractionated regimen of 59.4 Gy in 33 fractions in 6.5 weeks, using modern computer-based treatment planning and delivery techniques. Treatment should start within 6 weeks of surgery.
223816961|NCT02378532|DRUG|Temozolomide|Patients will take TMZ 75 mg/m² po qd during the course of radiotherapy six adjuvant cycles of TMZ. After a 4 week break, patients will receive up to six cycles of adjuvant oral TMZ 150 - 200 mg/m² po qd for 5 days every 28 days. The starting dose is 150 mg/m² po qd. At the start of cycle 2 the dose will be escalated to 200mg/m2, if the CTC non-hematologic toxicity for cycle 1 is grade ≤2 (except for alopecia, nausea, and vomiting), absolute neutrophil count is ≥1.5 x 109/L and the platelet count ≥ 100 x 109/L.
223816962|NCT04785664|OTHER|Community-based pro-Active Monitoring Program|The Intervention provides phone monitoring addressed to all the clients and home visits tailored to the individual needs. Moreover, it activates other formal or informal care resources based on the needs of the patients reported in the Individualized Care Plan (ICP) which derives from the assessment of multidimensional frailty. The main peculiarity of the program is that the operators identify the main problem of the client and try to track down the best solution in agreement with the client. It can be a health or social intervention or a different kind. Interventions may include assistance to make clients' houses safer thereby reducing risk factors for falls or reviewing the therapeutic scheme to improve patient adherence to the treatment in collaboration with the GP.
223816963|NCT02446795|DRUG|Sunitinib|Sunitinib: 50mg once daily orally for 4 weeks followed by 2 weeks off treatment (either at 8 a.m. or at 8 p.m.)
223816964|NCT02446795|DRUG|Isoquercetin|Isoquercetin: 225mg twice a day(at 08 a.m. and at 4 p.m)/Isoquercetin: 450 mg twice a day(at 08 a.m. and at 4 p.m).
223816965|NCT02446795|DRUG|Placebo|Placebo: 225mg twice a day(at 08 a.m. and at 4 p.m)/Placebo: 450 mg twice a day(at 08 a.m. and at 4 p.m).
223816966|NCT02948881|DRUG|ibandronate|
223816967|NCT01453348|BIOLOGICAL|MenACWY-CRM|Novartis meningococcal ACWY conjugate vaccine will be administered intramuscularly (IM) on day 1.
223816968|NCT01453348|BIOLOGICAL|Combined inactivated hepatitis A & recombinant hepatitis B|Combined inactivated hepatitis A and recombinant hepatitis B vaccine will be administered by IM on days 1, 8 \& 29 for subjects unprimed with hepatitis A and B; and a single booster injection on day 1 for primed subjects.
223816969|NCT01453348|BIOLOGICAL|Recombinant hepatitis B vaccine|Recombinant hepatitis B vaccine will be administered intramuscularly on days 8 and 29
223816970|NCT01453348|BIOLOGICAL|Inactivated hepatitis A vaccine|Inactivated hepatitis A will be administered intramuscularly on days 8 and 29.
223816971|NCT04146246|DIAGNOSTIC_TEST|G6PD assay|A test for G6PD deficiency.
223816972|NCT00595270|BIOLOGICAL|IC51|
223816973|NCT01673893|DEVICE|ClearWay™ Rx catheter|
223816974|NCT04919902|PROCEDURE|Electric cardioversion|Electric cardioversion in short sedation according to established clinical practice and indications
223816975|NCT01115985|DRUG|ASP1585|oral
223816976|NCT01115985|DRUG|atorvastatin|oral
223816977|NCT05915962|PROCEDURE|collecting a Nanofat-type microfat autograft|"Collecting and preparing a Nanofat autograft.~The protocol provides for the fat sample to be taken in a doctor's office during a consultation. The preparation will then be carried out at the MEARY center for cell and gene therapy of the AP-HP, at the Saint Louis hospital in Paris."
223816978|NCT01412190|DEVICE|Restylane Vital Light|Treatment of up to 4 ml for one side of the face, one hand and one side of the décolletage dispensed by 10ul doses 0.5-1 cm apart. 3 treatment sessions 4 weeks apart.
223816979|NCT01412190|OTHER|No treatment|One side of face, one hand and one side of the décolletage is left untreated as a control.
223816980|NCT05680961|DEVICE|Monitoring Device|Monitoring Device
223816981|NCT04122391|OTHER|sound level volume|Noise level during cardiac arrest
223816982|NCT00002763|BIOLOGICAL|recombinant interferon alfa|
223816983|NCT05330416|DEVICE|Group Reference Strategy|Patients undergoing surgery for anoperineal suppuration in the context of Crohn's disease with detailed examination of the suppuration and drainage with a seton.
223816984|NCT05330416|OTHER|Group Test Strategy|Patients undergoing surgery for anoperineal suppuration in the context of Crohn's disease with detailed examination of the suppuration without drainage via a seton.
223816985|NCT01445223|DRUG|Lopinavir ritonavir|400mg BD 100mg BD
223816986|NCT01445223|DRUG|Atazanavir ritonavir|300mg QD 100mg QD
223816987|NCT01445223|DRUG|Efavirenz|600mg QD
223816988|NCT00363610|DRUG|Oncaspar & Gemzar; advanced and/or solid tumors and lymphoma|
223816989|NCT00890175|DRUG|Inhaled loxapine @ 0 & 10 h|10 mg, 2 doses, 10 hours apart
223816990|NCT00890175|DRUG|Inhaled placebo @ 2 & 10 hours|placebo, 2 doses, 10 hours apart
223816991|NCT00954733|OTHER|Arterial blood draw|One arterial blood draw
223816992|NCT04996290|PROCEDURE|PENG + LFCN block|Regional anesthesia technique
223816993|NCT04996290|DRUG|Ropivacaine injection|Local anesthetic used for peripheral nerve block.
223816994|NCT01852331|DRUG|PGD granules|The preparation of Peony-Glycyrrhiza Decoction (PGD) granules is in compliance with Pharmacopoeia of the People's Republic of China and Good Manufacturing Practice (GMP). Briefly, sliced, broiled Paeoniae Alba Radix and Glycyrrhizae Radix in a ratio of 1:1 in weight will be immersed and boiled in an 8-fold volume of distilled water for 2.5 hours. This process will be repeated twice. The extract solution will be pooled and concentrated into granule form. Weight of the resulting granules contained in two 9g-sachet packs (to be taken in one day) is equivalent to 45 g raw herbal materials which are supplied for one day.
223816995|NCT01852331|DRUG|Placebo|The placebo granules are prepared to be identical to PGD granules in smell, taste and color.
223816996|NCT01108757|DRUG|Bactrim|Bactrim DS BID for 3 days
223816997|NCT01108757|OTHER|Placebo|Corn starch capsules
223816998|NCT03051022|DRUG|Dexamethasone 8 mg|Dexamethasone 8 mg was given via epidural catheter as an adjuvant to 12.5 mg of 0.125% bupivacaine in 10 cc syringe and added with 0.9% sodium chloride until the volume was 10 cc.
223816999|NCT03051022|DRUG|Morphine 2 mg|Morphine 2 mg was given via epidural catheter as an adjuvant to 12.5 mg of 0.125% bupivacaine in 10 cc syringe and added with 0.9% sodium chloride until the volume was 10 cc.
223817000|NCT01373996|DEVICE|Wireless invasive blood pressure monitoring (Hybymed® Wireless IBPM System)|"The readings of invasive arterial pressure were obtained from 2 identical pressure transducers, connected to a common arterial line via a Y connector. Data was collected from one transducer via a direct cable connection and from the second transducer via wireless transmission of the signal to the patient's bedside monitor using the HMW 10 Wireless System.~A comparison of data received by patient's bedside monitor from the two transducers was done (standard connection vs. wireless connection), as well as a comparison of data collected by the transmitter and data received by the receiver of the HMW 10 Wireless System."
223817001|NCT01255943|BEHAVIORAL|healthcare staff processes for infection prevention|Toyota lean and positive deviance discovery and action dialogues to facilitate process improvement
223817002|NCT01110343|BEHAVIORAL|mindfulness intervention|a 6 -week behavioral intervention lasting 1.5 hours per week with a trained parent mentor, 3 monthly booster sessions and follow-up
223817003|NCT01110343|BEHAVIORAL|Conventional parent Support Group|a 6 week behavioral program, consisting of 1.5 hour weekly sessions run by a trained parent mentor with a structured curriculum based on the strengths of support groups like emotional support, advocacy and training. There are 3 monthly booster sessions and follow-up.
223817004|NCT06342427|DIAGNOSTIC_TEST|DESTINEX|A panel of microRNA, whose expression level is tested in serum samples.
223817005|NCT02394041|DEVICE|Acupuncture|Method of acupuncture: check the condition of skin, disinfect if needed, insert sterile needles with special handling for each point, remove the needles after 15 minutes.
223817006|NCT02394041|DEVICE|Sham acupuncture|Sham acupuncture with sham needles
223817007|NCT05345379|OTHER|Single intervention|Single intervention at the day of fixed orthodontic appliance bonding
223817008|NCT05434117|BEHAVIORAL|High-intensity interval Nordic walking|Participants will complete supervised exercise sessions twice weekly for 10 weeks. Exercise specialists will educate participants in proper use of walking poles and basic Nordic walking techniques and supervise the exercise training sessions. HIIT-NoW will be 45 min in duration using Nordic poles and consists of (i) a 10-min warm-up at 30-59% heart rate reserve (HRR, light-to-moderate intensity); (ii) 4 × 4 min of high-intensity work periods at 60-89% HRR (vigorous intensity) interspersed with 3 min of low-intensity work periods at 30-59% HRR (light-to-moderate intensity); and, (iii) a 10-min cooldown at 30-39% HRR (light intensity). To allow participants to acclimatize to the HIIT-NoW protocol, the training intensity will target 60-69% HRR for the first week, 70-79% HRR in the second week, and 80-89% HRR from the third week onward. If participants do not tolerate 89% HRR well, they will exercise as close to 89% HRR as possible.
223817009|NCT05434117|BEHAVIORAL|Standard cardiovascular rehabilitation|Individuals assigned to standard CR will attend onsite exercise-based CR comprised of one onsite exercise session per week for 8-10 weeks. The onsite CR offers exercise sessions tailored to the fitness of patients and strengthening exercise.
223817010|NCT00006232|DRUG|dexamethasone|
223817011|NCT00006232|DRUG|doxorubicin hydrochloride|
223817012|NCT00006232|DRUG|idarubicin|
223817013|NCT00006232|DRUG|vincristine sulfate|
223817014|NCT03551808|DRUG|using of Ketorolac Tromethamine Eye Drop|using of Ketorolac Tromethamine Eye Drop one day before the surgery in each 8 hours and continue it for 4 weeks after the surgery
223817015|NCT00710372|BIOLOGICAL|CYT006-AngQb|s.c. injection
223817016|NCT00438620|BEHAVIORAL|Home-based physical activity program|the role of physical activity as a Quality of Life intervention
223817017|NCT04627519|DIETARY_SUPPLEMENT|Rhea Health Tone®|Rhea Health Tone® 2 ml twice daily after the meal (every 12 hours)
223817018|NCT05388058|DRUG|Cannabidiol|Applied topically
223817019|NCT05388058|DRUG|Placebo Administration|Applied topically
223817020|NCT05388058|OTHER|Quality-of-Life Assessment|Ancillary studies
223817021|NCT05388058|OTHER|Questionnaire Administration|Ancillary studies
223817022|NCT01216163|DRUG|Novel Ibuprofen|Single-dose of novel ibuprofen (equal to 400 mg ibuprofen)
223817023|NCT01216163|DRUG|Acetaminophen|Single-dose of acetaminophen (1000mg)
223817024|NCT01216163|DRUG|Placebo|Single-dose of placebo
223817025|NCT02812472|OTHER|Treadmill training with functional electrical stimulation|
223817026|NCT02812472|OTHER|Treadmill training without functional electrical stimulation|
223817027|NCT02914314|DRUG|perampanel|oral suspension.
223817028|NCT05720013|DIETARY_SUPPLEMENT|Beetroot Juice supplement|The experimental arm includes orally ingesting 140 mL Beet-It Sport Nitrate 400.
223817029|NCT05720013|DIETARY_SUPPLEMENT|Placebo supplement|he placebo arm involves orally ingesting a 140 mL placebo solution with the dietary nitrate removed.
223817030|NCT03564782|BIOLOGICAL|PVSRIPO|The live, attenuated, oral (Sabin), serotype 1 poliovirus vaccine booster will be administered 1 week before PVSRIPO injection. The study drug, PVSRIPO, is the live attenuated, oral (Sabin) serotype 1 poliovirus vaccine containing a heterologous internal ribosomal entry site (IRES) derived from the human rhinovirus type 2 (HRV2). It will be given at a dose of 1x10\^8 TCID50 (tissue culture infectious dose) directly into the breast tumor.
223817031|NCT05680974|OTHER|If a targetable cytokine is increased in the lesional skin of a patient, this patient is treated with the respective antibody therapy (off-label use of approved drug).|If a targetable cytokine is increased in the lesional skin of a patient, this patient is treated with the respective antibody therapy (off-label use of approved drug).
223817032|NCT00102479|DRUG|Aripiprazole|
223817033|NCT02484001|DRUG|ESL 800 mg|one (1) tablet of 800 mg (QD).
223817034|NCT02484001|DRUG|ESL 1200 mg|one (1) and a half tablets of 800 mg (QD). ESL tablets are scored and can be divided in two equal halves (each one containing 400 mg ESL)
223817035|NCT02484001|DRUG|ESL 1600 mg|two (2) tablets of 800 mg (QD).
223817036|NCT02484001|DRUG|ESL 400 mg|half tablet of 800 mg (QD). ESL tablets are scored and can be divided in two equal halves (each one containing 400 mg ESL)
223817037|NCT02786264|DRUG|Dexmedetomidine with propofol|A dexmedetomidine- dominant anesthetic will be defined as an anesthetic that included a continuous infusion of dexmedetomidine within 15 minutes of anesthesia start. This group was subsequently modified in light of retrospective data collection to specify a group receiving dexmedetomidine in combination with propofol.
223817038|NCT02786264|DRUG|Propofol|A propofol-dominant anesthetic will be defined as an anesthetic that included a continuous infusion of propofol within 15 minutes of anesthesia start. This definition was subsequently modified to include patients who received propofol infusion but not dexmedetomidine.
223817039|NCT04111523|DRUG|SY-007|A single dose of SY-007 or placebo injection(1mg-45mg)
223817040|NCT02080104|DRUG|intarvenous and intramusculer 10 IU oxytocin|intarvenous and intramusculer 10 IU oxytocin
223817041|NCT00210262|BEHAVIORAL|Feedback and Education|
223817042|NCT01583023|DRUG|Bupropion|150mg daily for first week, 300mg daily thereafter for a total of 8 weeks
223817043|NCT01583023|DEVICE|Active Repetitive Transcranial Magnetic Stimulation|Daily left DLPFC, at 110% motor threshold, with a frequency of 10 Hz. Stimulation will be applied in 5-second trains with a 10-second inter-train interval, for 30 trains per session. This treatment will be provided for the first 4 weeks of the study.
223817044|NCT01583023|OTHER|Placebo|150mg daily first week, 300mg daily thereafter for a total of 8 weeks.
223817045|NCT01583023|DEVICE|Sham repetitive transcranial magnetic stimulation|Sham rTMS will also begin their treatment 5 times a week for 4 weeks in junction with pharmacotherapy (Wellbutrin). Sham rTMS will be delivered at a frequency of 10 Hz and stimulation will be applied in 5-second trains with a 20-second inter-train interval, for 30 trains per session.
223817046|NCT00227864|BEHAVIORAL|Behavior Therapy|
223817047|NCT00227864|OTHER|Treatment as Usual|
223817048|NCT02139657|BIOLOGICAL|RIG-C|
223817049|NCT04618263|DRUG|GATE-101|GATE-101 is a metabotropic glutamate receptor type 2/3 antagonist
223817050|NCT01859793|DRUG|sitagliptin|100 mg pill, administered once/day orally
223817051|NCT01859793|DRUG|Placebo|Matching placebo in appearance given once/day orally
223817052|NCT04257708|DIAGNOSTIC_TEST|ultrasound|Transvaginal us to assess the cavity
223817053|NCT01947660|DRUG|Systemic analgesia + Continuous regional anesthesia|Systemic analgesia + Continuous regional anesthesia, peri neural for the 2 to 4 first days post-operative
223817054|NCT01947660|DRUG|Systemic analgesia|Systemic analgesia as usual
223817055|NCT01047722|DRUG|Aspirin ingestion followed by doing a Bleeding Volume Test|Patient drinks a glass of Gatorade containing 325 mg of aspirin, then one hour later a bleeding volume test is performed.
223817056|NCT01047722|PROCEDURE|Gatorade Placebo followed by Bleeding Volume Test.|Patient drinks a glass of Gatorade, then one hour later a bleeding volume test is performed.
223817057|NCT00351897|DEVICE|pulsed dye (585nm) laser therapy|
223817058|NCT04286126|DEVICE|Active bilateral DMPFC|Participants in this arm will receive rTMS to bilateral DMPFC. The DMPFC will be targeted utilizing either Nexstim's eField neuronavigation system or Localite's neuronavigation system. Stimulation intensity will be standardized at 100% of resting motor threshold (RMT).
223817059|NCT04286126|DEVICE|Active right-sided OFC|Participants in this arm will receive rTMS to the right OFC. The right OFC will be targeted utilizing either Nexstim's eField neuronavigation system or Localite's neuronavigation system. Stimulation intensity will be standardized at 110% of resting motor threshold (RMT).
223817060|NCT02413463|PROCEDURE|augmented recession|medial rectus muscle recession using augmented formula ( average of the distance angle with correction and the near angle without correction)
223817061|NCT02413463|PROCEDURE|Faden|medial rectus muscle recession (using the distance angle with correction) with posterior scleral fixation( Faden)
223817062|NCT03798600|DRUG|Caspofungin|In accordance with routine clinical practice, Caspofungin will be given at the loading dose of 70 mg followed by 50 mg daily (for people \< 80 kg body weight). No dose reduction will be performed in Child-Pugh score A or B. Duration of therapy will be performed in accordance with ESCMID guidelines and clinical conditions.
223817063|NCT01735396|DRUG|Abiraterone Acetate|Abiraterone acetate 1000 mg orally daily (supplied as four 250 mg tablets) and prednisone 5 mg orally twice daily
223817064|NCT04372160|OTHER|Dietary assessment|24-hr dietary recall
223817065|NCT02002182|BIOLOGICAL|ADXS11-001 (ADXS-HPV)|ADXS11-001 (ADXS-HPV) is a live attenuated Listeria monocytogenes (Lm)-LLO immunotherapy developed for the treatment of HPV-associated dysplasia and malignancy.
223817066|NCT06123598|BEHAVIORAL|Therapeutic exercise program plus action observation training|Participants make an observation of actions related to the training they are going to perform before each session. Subsequently, they perform the therapeutic exercise program of 6 sessions in a period of 2 weeks.
223817067|NCT06123598|BEHAVIORAL|Therapeutic exercise program plus sham action observation training|Participants make a sham observation before each session. Subsequently, they perform the therapeutic exercise program of 6 sessions in a period of 2 weeks.
223817068|NCT03394443|BEHAVIORAL|Semi-structured interviews|"Semi-structured interviews of the parents of preterm infants. 3 weeks after their child has left hospital. They will be made either at the University Hospital of Besançon. They will take place in a dedicated hospital ward to ensure the confidentiality of the statements made between the investigator and the parent.~They will follow a predefined questionnaire. They will be fully recorded on a dictaphone with note taking during the interview by the investigator and will be transcribed in writing anonymously and confidentially on Word.~The content of the interviews will be analyzed:~* As a first step, it will be a vertical analysis of the thematization of each interview~* Then, in a second step, a transversal analysis between the contents of the different interviews."
223817069|NCT02635074|DRUG|Cytarabine|Given IV
223817070|NCT02635074|DRUG|Ibrutinib|Given PO
223817071|NCT02635074|DRUG|Idarubicin|Given IV
223817072|NCT00217880|PROCEDURE|Bronchoscopy|A bronchoscopy test will occur to view the participant's airways.
223817073|NCT04190147|OTHER|Structural, functional and metabolic eye examinations|Structural, functional and metabolic eye examinations
223817074|NCT03988582|BIOLOGICAL|EBV-specific T-cells|During each cycle, patients will receive intravenous (IV) EBV-CTLs at a dose of 1×106 CD3+ cells/kg on Days 1, 8, and 15, followed by a 2-week observation period.
223817075|NCT05707611|OTHER|Running|The participant perform running on treadmill at moderate intensity exercise 30 minutes/time. Physiological variables, lung function variables, allergic rhinitis symptoms variables, and cytokines level in nasal secretion variables were analyzed during pre-and post-exercise.
223817076|NCT05707611|OTHER|Cycling|The participant perform cycling on cycle ergometer at moderate intensity exercise 30 minutes/time. Physiological variables, lung function variables, allergic rhinitis symptoms variables, and cytokines level in nasal secretion variables were analyzed during pre-and post-exercise.
223817077|NCT05707611|OTHER|Swimming|The participant perform swimming at moderate intensity exercise 30 minutes/time. Physiological variables, lung function variables, allergic rhinitis symptoms variables, and cytokines level in nasal secretion variables were analyzed during pre-and post-exercise.
223817078|NCT03472703|OTHER|Break-Lunch time|The time for the break and lunch will be contrary, depending on their visit/session
223817079|NCT03108729|DRUG|Eslicarbazepine acetate|Eslicarbazepine acetate tablets, taken once daily for 1 year. The daily maintenance dose will be within the range of 300 mg to 1600 mg ESL, and is determined by body weight, clinical response and tolerability.
223817080|NCT01535742|DEVICE|Ambu Aura-i size 1.5|Device will be placed and fiberoptic tracheal intubation will be performed and timed. Laryngeal grade of view will also be assessed
223817081|NCT01535742|DEVICE|air-Q ILA size 1.5|Device will be placed and fiberoptic tracheal intubation will be performed and timed. Laryngeal grade of view will also be assessed
223817082|NCT01535742|DEVICE|Ambu Aura-i size 2|Device will be placed and fiberoptic tracheal intubation will be performed and timed. Laryngeal grade of view will also be assessed
223817083|NCT01535742|DEVICE|air-Q ILA size 2|Device will be placed and fiberoptic tracheal intubation will be performed and timed. Laryngeal grade of view will also be assessed
223817084|NCT02702700|DRUG|Cisplatin, liposomal|Lipoplatin IV 200 mg/m2
223817085|NCT02702700|DRUG|Verteporfin|Visudyne® IV 3 mg/m2
223817086|NCT02702700|DEVICE|Device for Intrapleural Visudyne-mediated Low-Dose Photodynamic Therapy with integrated in situ light dosimetry|Intrapleural photo-induction will be realized in the chest cavity with low-dose PDT using Visudyne® 3mg/m2 as photosensitizer, activated by 689 nm laser light with a fluence of 10J/cm2 and a fluence rate of \<10mWcm2.
223817087|NCT04146896|DRUG|NYX-2925 50 mg|NYX-2925 administered orally
223817088|NCT04146896|DRUG|Placebo|Placebo administered orally
223817089|NCT03628963|DEVICE|Concerto+|a user-centered, multifunctional and personalized eHealth platform
223817090|NCT00720174|BIOLOGICAL|Cixutumumab|Given IV
223817091|NCT00720174|DRUG|Doxorubicin Hydrochloride|Given IV
223817092|NCT00720174|OTHER|Laboratory Biomarker Analysis|Correlative studies
223817093|NCT02053025|DIETARY_SUPPLEMENT|mycoprotein|
223817094|NCT02053025|DIETARY_SUPPLEMENT|control protein|
223817095|NCT05091866|OTHER|Quality-of-Life Assessment|Ancillary studies
223817096|NCT05091866|OTHER|Questionnaire Administration|Ancillary studies
223817097|NCT05091866|BIOLOGICAL|Therapeutic Progesterone|Given SC
223817098|NCT03215940|DRUG|Delta-9-Tetrahydrocannabinol|An oral dose of Delta-9-Tetrahydrocannabinol (THC) will be given once a day for five day with pain ratings taken before and after each dose every day.
223817099|NCT03215940|DRUG|Cannabidiol|An oral dose of Cannabidiol (CBD) will be given once a day for five day with pain ratings taken before and after each dose every day.
223817100|NCT03215940|DRUG|Placebos|An oral placebo will be given once a day for five day with pain ratings taken before and after each dose every day.
223817101|NCT02555462|DEVICE|Real-Ear Measurement system integrated in hearing aid fitting software|The subjects individual response of the ear canal gets measured with the help of a probe tube and a following hearing aid fitting.
223817102|NCT04296890|DRUG|Mirvetuximab Soravtansine|Mirvetuximab Soravtansine is an antibody drug conjugate designed to target folate receptor α (FRα). It consists of the humanized anti-FRα mAb M9346A attached via a cleavable disulfide linker to the cytotoxic maytansinoid, DM4.
223817103|NCT05883631|DEVICE|Electrographic Flow (EGF) mapping and ablation of EGF-identified sources of Atrial Fibrillation|"In addition to standard touch-up of pulmonary vein isolation, subjects receive targeted source ablation guided by Electrographic Flow™ (EGF) mapping. EGF mapping enables the full spatiotemporal reconstruction of organized atrial electrical wavefront propagation to identify active sources or origins of excitation that may trigger atrial fibrillation (AF).~EGF-identified sources with activity above the threshold (≥ 25%) are considered significant and targeted with radiofrequency ablation. The procedure concludes when all EGF-identified sources are eliminated, defined as reducing source activity below the threshold."
223817104|NCT05883631|DEVICE|Electrographic Flow (EGF) mapping (no ablation)|"In addition to standard pulmonary vein isolation (PVI), subjects receive Electrographic Flow™ (EGF) mapping. PVI may be performed using any commercially available platform/catheter.~EGF mapping enables the full spatiotemporal reconstruction of organized atrial electrical wavefront propagation to identify active sources or origins of excitation that may trigger atrial fibrillation (AF). EGF-identified sources with activity above the threshold (≥ 25%) are marked as relevant; however, no EGF-guided ablations are performed during this index procedure. If subjects have AF recurrence after the 90-day blanking period, they may undergo a recurrence procedure and EGF-guided ablation."
223817105|NCT05400746|BIOLOGICAL|Pfs48/45 in Matrix-M|Three doses of Pfs48/45 in Matrix-M at different doses
223817106|NCT01650493|DEVICE|Clinpro 5000|Dentrifice containing 950ppm fluoride
223817107|NCT01650493|DEVICE|MI Paste Plus|Dentrifice containing 950ppm fluoride
223817108|NCT01650493|DEVICE|Tom's of Maine|Dentrifice that is fluoride free
223817109|NCT03184896|PROCEDURE|Hip Fracture Surgery|Hip Fracture Surgery
223817110|NCT02227316|DRUG|IV Ibuprofen|Uterine fibroid embolization
223817111|NCT02227316|DRUG|IV Acetaminophen|Uterine fibroid embolization
223817112|NCT02227316|DRUG|Intravenous placebo/Intravenous placebo|Uterine fibroid embolization
223817113|NCT05971914|PROCEDURE|Autogenous tooth derived particulate graft and a novel split thickness papilla curtain flap|Extracted deciduous teeth were prepared immediately after removal according to the manufacturer's instructions with the Bonmaker® device. Ready to use autogenous tooth bone graft (ATB) was mixed with fibrin glue in 3D planned and printed plastic cuvettes to obtain a sticky graft closely matching the shape and extent of the bony defect. The preshaped sticky ATB graft was inserted and compacted in the cleft defect. Subsequently, the tension-free split thickness flap was repositioned by shifting all buccal surgical papillae mesially to the adjacent or the second adjacent interproximal space, depending on the horizontal extent of the cleft.
223817114|NCT04491812|OTHER|Kinesio Tape|Elastic Kinesiology Tape
223817115|NCT04491812|OTHER|Physical therapy program|designed physical therapy program
223817116|NCT04787510|DRUG|low molecular weight Heparin as standard of care treatment|STANDARD OF CARE
223817117|NCT04737902|PROCEDURE|Erector spinae plane block|Unilateral ESP block was performed between T3 and T7 levels depending on the thoracic surgical incision. The patient is placed in lateral decubitus position, under sterile conditions, a high frequency (6-15 MHz) linear-array transducer (Sonosite® Edge II, Bothell, USA) was placed in a longitudinal parasagittal orientation 2 cm from the posterior midline to visualise the tips of the transverse processes deep to the erector spinae muscle (ESM). A 21 G, 50 mm or 100 mm needle (Pajunk UniPlex NanoLine; Germany) was advanced in-plane with the ultrasound beam. The needle tip was directed to the plane between the transverse process and the posterior fascia of the ESM. Correct needle tip location was confirmed by ultrasound visualisation of linear fluid spread in the fascial plane. The injection of 0.5 to 1 ml of bupivacaine was 0.5% with epinephrine 5 µg/ml; then, a total of 20-30 ml of the same local anaesthetic was administered.
223817118|NCT03209141|DIAGNOSTIC_TEST|Diastolic function evaluation|Diastolic function assessed by impedance cardiography (test to be validated) is compared with the assessment by echocardiography (clinical standard)
223817119|NCT01686880|DEVICE|Sirsphere trans-arterial radioembolization|Patients will receive Sirsphere trans-arterial radioembolization before surgery
223817120|NCT04747730|OTHER|Transcendental Meditation training|The programme targets inmates in HMP Warren Hill who are eligible to learn the meditation technique, who are staying in prison for at least six months since the beginning of the programme and who provide the signed informed consent. The sample of eligible inmates is approximately 190 inmates out of 250 currently in the prison. Inmates will be contacted by the research team in prison during introductory sessions of the research intervention.
223817121|NCT03075059|BEHAVIORAL|Child Life|For patients randomized to the intervention group, the Child Life specialist will reach out via telephone to offer support and expertise in helping prepare their child and themselves for outpatient surgery to help decrease anxiety and increase coping. Concepts covered will include: developmentally appropriate language for explaining surgery and related procedures, potential coping skills to ease separation for caregivers and pediatric patients. Additionally, written materials (attached) covering the same information will be sent via mail or email covering the same information discussed in the phone conversation to serve as a refresher and resource before the day of surgery. On the day of surgery, the patient will receive standard of care (SOC) Child Life Services available to all patients.
223817122|NCT05962710|DEVICE|FreeStyle Libre 3|FreeStyle Libre 3 Continuous Glucose Monitoring System
223817123|NCT01093144|DEVICE|pelvic measurements using the LaborPro Device|pelvic measurements using the LaborPro Device,ultrasound non invasive measurements
223817124|NCT02277743|DRUG|Dupilumab|Subcutaneous injection alternated among the different quadrants of the abdomen, upper thighs and upper arms
223817125|NCT02277743|DRUG|Placebo (for Dupilumab)|Subcutaneous injection alternated among the different quadrants of the abdomen, upper thighs and upper arms
223817126|NCT01224158|DEVICE|Experimental Power Toothbrush|Following a placebo mouthwash phase, Subjects will be asked to brush their teeth (twice per day with the experimental toothbrush and toothpaste provided) moving to the next quadrant of the mouth at 30-second intervals.
223817127|NCT01224158|DEVICE|Flat trimmed Manual Toothbrush|Following a placebo mouthwash phase, Subjects will be asked to brush their teeth (twice per day using the toothbrush and toothpaste provided) in their usual manner.
223817128|NCT04654988|DRUG|Prednisone|Prednisone: 1 mg/kg daily for 4 weeks followed by gradually tapered dose for 5 months
223817129|NCT04654988|DRUG|Azathioprine|Azathioprine: 2 mg/kg daily for 12 months
223817130|NCT04654988|DRUG|Placebo Prednisone|Placebo Prednisone
223817131|NCT04654988|DRUG|Placebo Azathioprine|Placebo Azathioprine
223817132|NCT01674374|OTHER|placebo|Given PO
223817133|NCT01674374|PROCEDURE|quality-of-life assessment|Ancillary studies
223817134|NCT01674374|OTHER|questionnaire administration|Ancillary studies
223817135|NCT01674374|DRUG|Vaccinium myrtillus/Macleaya cordata/Echinacea angustifolia extract granules|Given PO
223817136|NCT02055157|DRUG|BMN 111|BMN 111 will be administered daily for 24 months in an open-label sequential dose adjustment fashion.
223817137|NCT03976466|DEVICE|Antibiotic local prophylaxis with medicated calcium sulfate beads|Antibiotic prophylaxis in patients with non-modifiable risk factors for periprosthetic joint infection
223817138|NCT03976466|PROCEDURE|Classical parenteral antibiotic prophylaxis|Antibiotic prophylaxis in patients with non-modifiable risk factors for periprosthetic joint infection
223817139|NCT01557322|BIOLOGICAL|etanercept|This is a Non-interventional study. The data is being analyzed retrospectively. The data consists of 2 cohorts; biologic and non-biologic
223817140|NCT01557322|DRUG|methotrexate (MTX)|This is a Non-interventional study. The data is being analyzed retrospectively. The data consists of 2 cohorts; biologic and non-biologic
223817141|NCT02247336|BEHAVIORAL|Family health history platform (MeTree)|Participants will enter their family health history information into a family health history platform, patients and providers will receive a decision support document and pedigree
223817142|NCT00733499|DEVICE|LCS Complete Duofix|Orthopaedic implant for total knee replacement with Duofix biological fixation surfaces
223817143|NCT00733499|DEVICE|LCS Complete Porocoat|Orthopaedic implant for total knee replacement with Porocoat biological fixation surfaces
223817144|NCT06405399|OTHER|Educational intervention. observation guide|An observation checklist based on the Lasater Clinical Judgment Rubric (LCJR) was created and adapted to the simulated clinical experience in order to address the learning outcomes to be achieved by nursing students. This resulted in a list of forty items divided into four main groups: patient safety (8 items), communication and relationship with the patient (7 items), teamwork (7 items) and technical skills (18 items).
223817145|NCT03177122|DRUG|Myo-inositol|Patients belonging to this group will receive 1 gram of Myo-Inositol, in combination with alpha- lipoic acid and cysteine, (Celine Tablets; Surveal Pharmaceuticals; Belgium) starting 6 weeks prior to stimulation and extending until final oocyte maturation, combined with 400 µg of folic acid supplemented daily.
223817146|NCT03809364|BEHAVIORAL|START Together|Behavioral intervention using a cognitive behavioral couple therapy (CBCT) framework designed to improve the couple's communication and problem-solving behavior.
223817147|NCT02739347|DEVICE|Active Trans-cranial direct-current stimulation|Active stimulation group will receive 20 min of 2 mA direct current stimulation.
223817148|NCT02739347|DEVICE|Sham Trans-cranial direct current stimulation|This will be an active sham involving brief (15 msec) low current (0.11 mA) pulses every 550 ms.
223817149|NCT05995626|DRUG|Hyaluronidase|Hyaluronidase injection is used during fluid administration under the skin to help achieve hydration, to increase the dispersion and absorption of other injected drugs, or during some types of urography (imaging of the urinary tract) to help improve resorption of drugs used during the procedure.
223817150|NCT05995626|DEVICE|CO2 laser|CO2 lasers use an aiming beam to see where the treatment beam will impact the focus tissue, which will then be cleanly incised. The CO2 lasers have greater precision for laser surgery and have more flexibility in tip sizes and protocols.
223817151|NCT06501898|DIETARY_SUPPLEMENT|CoreBiome|300 mg, once daily of tributyrin for 4 weeks
223817152|NCT06501898|DIETARY_SUPPLEMENT|Placebo|300 mg, once daily of placebo for 4 weeks
223817153|NCT00967382|DRUG|dalteparin sodium|"Subject's randomize to treatment arm will receive dalteparin sodium 5,000 IU s.c. daily starting on randomization day until 20 weeks gestational age then;~dalteparin sodium 5,000 IU s.c. bid from 20 weeks to onset of labour or 37 weeks gestation (discontinued at the discretion of the investigator/obstetrician)~Within 24 hours of delivery, all subject's, regardless of randomization allocation will receive dalteparin sodium 5,000 IU s.c. daily for 6 weeks post-partum"
223817154|NCT00177203|BEHAVIORAL|Brief Behavioral Treatment of Insomnia or Information|"The behavioral treatment involves education about sleep and its disorders; habits that help and hurt sleep; and recommendations about sleep hours and time in bed. It involves two meetings with a nurse who is part of the research team.~In the information condition, participants are given similar information in printed brochures that are published by the American Academy of Sleep Medicine. They are instructed to read the information."
223817155|NCT02218879|DRUG|Tecfidera|Oral Tecfidera 240 mg bid
223817156|NCT03929562|BEHAVIORAL|Brief advice|One 10-minute brief advice session
223817157|NCT03929562|BEHAVIORAL|Health coaching|Two 45-minute health coaching sessions will use a non-confrontation motivational interviewing (MI) style. Intervention delivery will include expressing concern about unhealthy drinking, providing feedback linking alcohol use and health (related to surgery and general health), advising the patient regarding abstinence or alcohol use reduction, and working with the patient to set a drinking goal if he/she is ready to change. We will also include a personalized feedback component to address the links between pre-operative alcohol use and postoperative morbidity/mortality.
223817158|NCT01190046|BEHAVIORAL|Resistance exercise training|Lower extremity resistance exercise training 3x/wk
223817159|NCT00378443|DRUG|prednisone + Inhibace/Cozaar|
223817160|NCT00378443|DRUG|Inhibace/Cozaar|
223817161|NCT02461810|DEVICE|Vertebral fracture surgery SpineJack®|Vertebral augmentation for one osteoporotic vertebral compression fracture
223817162|NCT02461810|PROCEDURE|Balloon Kyphoplasty|
223817163|NCT00465933|DRUG|AIDA|
223817164|NCT05648162|DEVICE|Electrical acupuncture|Electrical acupuncture (2Hz, 150 μs) once daily (five times a week), for 20 minutes each session, totaling 20 sessions.
223817165|NCT05648162|DEVICE|Acupuncture|Electrical acupuncture (no electricity) once daily (five times a week), for 20 minutes each session, totaling 20 sessions.
223817166|NCT05648162|DEVICE|tDCS|tDCS (1mA) once daily (five times a week), for 20 minutes each session, totaling 20 sessions.
223817167|NCT05648162|DEVICE|sham tDCS|tDCS (no electricity) once daily (five times a week), for 20 minutes each session, totaling 20 sessions.
223817168|NCT05648162|OTHER|NDT-Bobath Rehabilitation|NDT-Bobath Rehabilitation once daily (five times a week), for 30 minutes each session, totaling 20 sessions.
223817169|NCT00103961|BEHAVIORAL|Questionnaire|A behavioral questionnaire will occur at Week 8
223817170|NCT00779974|OTHER|Evaluation|For this research study each enrolled subject will have a clinical exam, including range of motion (ROM), and strength testing. The lift off and belly compression tests will be performed. An ultrasound of the shoulder will be done to determine the integrity of the subscapularis tendon. An EMG will be done to determine functionality of the subscapularis.
223817171|NCT05225688|BEHAVIORAL|Bike exertion test|maximal exercise test
223817172|NCT00953537|DRUG|capecitabine|
223817173|NCT00953537|OTHER|laboratory biomarker analysis|
223817174|NCT00953537|OTHER|pharmacological study|
223817175|NCT06253949|PROCEDURE|ligation of inferior mesenteric artery in colorectal cancer|This study will include two groups of patients: group (A) and (B). In group (A), the inferior mesenteric artery will be ligated at its origin (high-tie), While in group (B), it will be ligated after the origin of the left colic artery (low-tie).
223817176|NCT00285493|DRUG|Antibiotics|
223817177|NCT00742638|DRUG|Quetiapine fumarate|Investigational product: quetiapine fumarate tablet 25 mg and 200 mg
223817178|NCT00742638|DRUG|Sodium valproate|Sodium valproate tablet 200 mg
223817179|NCT01727063|PROCEDURE|Cell Therapy|Intramyocardial injection of autologous bone marrow-derived cells
223817180|NCT01778556|BIOLOGICAL|Metreleptin|Recombinant analog of the human hormone, leptin
223817181|NCT05114525|BEHAVIORAL|Survey questionnaire|The survey questionnaire will include semi-structured questions about patient demographics and patient understanding of the risks and benefits of radiation, different treatment options, the treatment process, utility of visual aid presentation and information gathering preference using a semi-structured questionnaire
223817182|NCT04520802|DIAGNOSTIC_TEST|18F-DPA-714 PET/CT neuroimaging|"* Pre- and postoperative neuroimaging using 18F-DPA-714 PET/CT and brain MRI.~* Longitudinal neuropsychological examinations (up to 6 months postoperatively)~* Blood samples are drawn to assess the severity of the systemic inflammatory response"
223817183|NCT00061763|DRUG|Deferasirox|
223817184|NCT00166725|DRUG|Octreotide LAR|
223817185|NCT03020225|DIETARY_SUPPLEMENT|White cheese|animal protein food source: White cheese (contains 30g protein), intact, plus 250ml mineral water
223817186|NCT03020225|DIETARY_SUPPLEMENT|Green peas|Green peas (contains 30g protein), intact, cooked, plus 250ml mineral water
223817187|NCT03020225|DIETARY_SUPPLEMENT|Mankai|Wolffia globosa (Mankai, contains 30g protein), intact, cooked, plus 250ml mineral water
223817188|NCT05540314|PROCEDURE|robotic bariatric surgery|robotic bariatric surgery
223817189|NCT03299790|OTHER|high-intensity interval exercise training (HIIT)|This program includes 24 weeks of exercise training and is divided in different phases (phase 1: week 1-2, equal to the MIT group, phase 2: week 3-6, 6 bouts of high-intensity exercise, phase 3: week 7-12, 7 bouts of high-intensity exercise, phase 4: week 13-24, 8 bouts of high-intensity exercise). The exercise training program consists of 3 exercise sessions per week (for 6 months).
223817190|NCT03299790|OTHER|moderate-intensity exercise training (MIT)|This program includes 24 weeks of exercise training and is not devided in phases. The exercise training program consists of 3 endurance exercise sessions per week (for 6 months). The total exercise volume equals the exercise volume of the HIIT group.
223817191|NCT00593125|DRUG|levetiracetam|The participants will start receiving Levetiracetam 500mg in the mornings of the first day on week 2. The dose will be titrated every third day, until the target dose of 3000mg/day is achieved by week 4. The study medication must be titrated to 3000 mg/day or to the subject's maximum tolerated dose (MTD). The physician overseeing this titration as well as all study staff will not be blind to the subject's medication administration. The medication will be discontinued over a two-week period
223817192|NCT03527355|BIOLOGICAL|Vi-DT|Manufacturer: SK Bioscience Co., Ltd. Ingredient: Purified Vi-polysaccharide conjugated to diphtheria toxoid Dose: 0.5 mL/Vial
223817193|NCT03527355|BIOLOGICAL|FluQuadri™|"Manufacturer: Sanofi Pasteur Dose: 0.25 ml~\*Participants who have not been vaccinated for flu before, will receive a second dose of flu-vaccine after unblinding."
223817194|NCT03527355|OTHER|0.9% sodium chloride isotonic solution|Manufacture: Euro-Med Inc. Dose: 0.5 mL
223817195|NCT03154502|DIAGNOSTIC_TEST|Urinary sodium excretion|Urinary sodium and potassium were measured using the Ion-Selective Electrode (ISE) indirect Na-K-Cl for Gen.2 (Roche Diagnostic, Switzerland).
223817196|NCT01235403|DRUG|Lacosamide|"Lacosamide : 50 mg tablets bid. Titration phase: (12 weeks) 100 mg/day: duration 1 to 3 weeks. Then uptitration to optimal therapeutic dose of 200 mg/day to 400 mg/day, in steps of 100 mg/day and a time period per step of 1 to 3 weeks.~Maintenance phase (12 weeks): Optimal therapeutic dose 200 mg/day to 400 mg/day.~Taper phase if needed: 3 to 4 weeks"
223817197|NCT00538928|OTHER|lung protective ventilation|tidal volume 6 ml/kg ideal body weight
223817198|NCT06184243|BEHAVIORAL|Parent Training|Parent training will cover the topic of creating social skills, goal setting, creating a video model, how to implement the video model intervention, and the parent-child interaction procedures during play. Parents will learn the steps in the fidelity checklist and demonstrate the steps at 90% proficiency by the end of the training. Parent coaching will continue before and after child intervention sessions.
223817199|NCT06184243|BEHAVIORAL|Video Modeling|The child will be recorded for a video model engaging in play at their home. The videos will be created with the parent and researcher in the home. A video using the same materials in the same location will be created depicting the child in a play scenario. The video will be two-to-three minutes in length. Each child will receive at least three sessions of intervention and no more than five sessions of intervention per week.
223817200|NCT02296190|DRUG|Etripamil|intranasal administration via 4 prefilled Aptar Pharma Unit-Dose Spray devices
223817201|NCT02296190|DRUG|Placebo|intranasal administration via 4 prefilled Aptar Pharma Unit-Dose Spray devices
223817202|NCT04860947|DIAGNOSTIC_TEST|Brain MRI|"* Axial DWI with ADC card~* Axial 2D TSE T2/DP or 3DT2~* Gadolinium injection (0.1 mmol/kg)~* 3D Fluid-attenuated inversion recovery~* 3D T1 with Gadolinium injection."
223817203|NCT04860947|DIAGNOSTIC_TEST|Spinal Cord MRI|Sagittal T2 Sagittal T1 with Gadolinium injection
223817204|NCT04860947|DIAGNOSTIC_TEST|Retinal imaging|spectral-domain high definition optical coherence tomography
223817205|NCT00795457|BIOLOGICAL|GAA/TT-peptide vaccine and poly-ICLC|Participants will be treated with subcutaneous injections of GAA/TT-vaccines on Weeks 0, 3, 6, 9, 12, 15, 18 and 21. I.m. poly-ICLC will be administered (20 mg/kg i.m.) on the day of, and on day 4 after each vaccine (e.g. if the vaccine is administered on Thursday, poly-ICLC will be administered on the day of vaccine and the following Monday). Each vaccine will be administered within 2 hours before or after the i.m. poly-ICLC administration.
223817206|NCT00795457|BIOLOGICAL|GAA/TT-peptide vaccine and poly-ICLC|Participants will be treated with subcutaneous injections of GAA/TT-vaccines on Weeks 0, 3, 6, 9, 12, 15, 18 and 21. I.m. poly-ICLC will be administered (20 mg/kg i.m.) on the day of, and on day 4 after each vaccine (e.g. if the vaccine is administered on Thursday, poly-ICLC will be administered on the day of vaccine and the following Monday). Each vaccine will be administered within 2 hours before or after the i.m. poly-ICLC administration.
223817207|NCT03278535|DIAGNOSTIC_TEST|CAREN-based gait analysis|subjects only walk at CAREN at different speed
223817208|NCT04305002|DRUG|Exenatide|Injections, 2 mg once weekly for 18 months
223817209|NCT04305002|DRUG|Placebo|Injections, once weekly for 18 months
223817210|NCT02564783|OTHER|No intervention|No intervention
223817211|NCT01996358|DRUG|Succinylcholine|Anaesthesia is induced and maintained with propofol (1-2 mg/kg) and remifentanil (0,5 µg/kg). The study arm is immobilized and after cleaning the skin a dual electrode for peripheral nerve stimulation is placed over the ulnar nerve near the wrist. Neuromuscular monitoring is performed with accelerometry. After induction of anaesthesia the patient receives muscle relaxant according to the study group.
223817212|NCT01996358|DRUG|Rocuronium 0,3|General anaesthesia is induced and maintained with propofol (1-2mg/kg) and remifentanil (0,5µg/kg). The study arm is immobilized and after cleaning the skin a dual electrode for peripheral nerve stimulation is placed over the ulnar nerve near the wrist. Neuromuscular monitoring is performed with accelerometry. The Patient receives the muscle relaxant according to the study group.
223817213|NCT01996358|DRUG|Rocuronium 0,6|General anaesthesia is induced and maintained with propofol (1-2mg/kg) and remifentanil (0,5µg/kg). The study arm is immobilized and after cleaning the skin a dual electrode for peripheral nerve stimulation is placed over the ulnar nerve near the wrist. Neuromuscular monitoring is performed with accelerometry. The Patient receives the muscle relaxant according to the study group.
223817214|NCT00717314|DRUG|Mycophenolate mofetil|1.5 to 2.0 g daily PO BID
223817215|NCT00717314|DRUG|CNI (50%)|50% reduction from BL
223817216|NCT00717314|DRUG|CNI (≥75%)|≥75% reduction from BL
223817217|NCT00584935|DRUG|Rituximab|The Rituximab dose is 1000mg (1gm) given as an IV infusion every two weeks for 2 doses (days 1 and 15).
223817218|NCT06249763|DIETARY_SUPPLEMENT|High gluten diet|Trial period A: gluten free diet added daily granola bars with 10 g gluten/day (intervention).
223817219|NCT06249763|DIETARY_SUPPLEMENT|Gluten free diet|Trial period B: gluten free diet added daily granola bars with \<1 g gluten/day (placebo).
223817220|NCT03682705|DRUG|Elsubrutinib|Elsubrutinib capsule will be administered orally.
223817221|NCT03682705|DRUG|Upadacitinib|Upadacitinib tablet will be administered orally.
223817222|NCT03682705|DRUG|Placebo for elsubrutinib|Placebo capsule for elsubrutinib will be administered orally.
223817223|NCT03682705|DRUG|Placebo for upadacitinib|Placebo tablet for upadacitinib will be administered orally.
223817224|NCT04410289|PROCEDURE|Airway positioning per specified protocol followed by Direct Laryngoscopy and Endotracheal Intubation|Positioning of the patient's head and neck for the purpose of direct laryngoscopy and endotracheal intubation
223817225|NCT04410289|PROCEDURE|Airway positioning per provider preference followed by Direct Laryngoscopy and Endotracheal Intubation|Positioning of the patient's head and neck for the purpose of direct laryngoscopy and endotracheal intubation
223817226|NCT04409067|DIAGNOSTIC_TEST|electromyography|Surface electromyography (sEMG) was used as an additional non-invasive tool for assessing patients with TMD.The electromyographical (EMG) potentials of the temporalis and masseter muscles were measured with a DAB-Bluetooth Instrument (Zebris Medical GmbH, Germany) at rest and during maximum voluntary clenching (MVC).
223817227|NCT02768454|DRUG|medical review of controlled broad-spectrum antibiotics|medical review of outcome of antibiotics stewardship by pharmacists and infectious disease physicians
223817228|NCT00117156|DRUG|Fludarabine|
223817229|NCT00117156|DRUG|Rituximab|
223817230|NCT04002804|BIOLOGICAL|Dendritic Cells Vaccine|"Right after the surgical resection of the recurrent tumor, leukapheresis will be performed.~At least 5x109 PBMC must be collected by leukapheresis, so as to make the whole immunotherapy schedule workable.~Starting at week 3, immunotherapy will include 4 bi-weeekly vaccinations first (injections I, II, III, IV), two further monthly vaccinations (injections V, VI) and a final vaccination (injection VII) two months after the sixth one. Injections I, V, VI and VII will contain 10 million tumor lysate-loaded DC, while the others will be of 5 million cells only.~Vaccine doses will be injected in the forearm of the patient."
223817231|NCT01919970|OTHER|Cognitive Behavioral Therapy|This condition involves 12 weekly CBT sessions.
223817232|NCT01919970|OTHER|Treatment as usual|This condition allows participants to seek out various services. Considering the number of possible treatment options, there is no way to identify or list them.
223817233|NCT04043962|BEHAVIORAL|Web-based CBT (Web-MAP)|see arm description
223817234|NCT02162303|DRUG|Colchicine|0.6 mg a day of active treatment or placebo for 24 weeks
223817235|NCT02162303|DRUG|Placebo|Sugar,given once daily, over 6 months.To mimic active treatment
223817236|NCT01667367|DRUG|RG1662|Single oral dose
223817237|NCT01667367|DRUG|placebo|Single oral dose
223817238|NCT02541825|DEVICE|the stent of diameter of 7mm|108 patients use the stent of diameter of 7mm in TIPS
223817239|NCT02541825|DEVICE|the stent of diameter of 8mm|108 patients use the stent of diameter of 8mm in TIPS
223817240|NCT04615182|DEVICE|Transplant|To enable continued clinical access to DCD heart transplantation in the U.S. and to continue to collect additional data on the performance of the OCS Heart System to resuscitate, preserve and assess hearts donated after circulatory death for transplantation to increase the pool of donor hearts available for transplantation.
223817241|NCT05248321|DRUG|Tranexamic Acid Powder|2g tranexamic acid powder will be given via the endoscopy directly to the peptic ulcer
223817242|NCT03575338|PROCEDURE|Open Scarf Osteotomy|Open Scarf Osteotomy
223817243|NCT03575338|PROCEDURE|Minimally invasive scarf Osteotomy|Minimally invasive scarf Osteotomy
223817244|NCT02629211|DEVICE|NaviAid™ AB|NaviAid™ AB Procedure
223817245|NCT05233943|DEVICE|Spinal Mouse and Digital Inclinometer|"The spinal mouse device is non-invasive and does not have any danger. The posture is evaluated by moving from top to bottom on the spine of the person. Data on the device is transferred to the computer via Bluetooth. The person's posture is evaluated in the sagittal plane by making maximum flexion, neutral stance and maximum extension positions, and in the frontal plane by lateral flexion to the right and left.~Digital Inclinometer; It is a non-invasive measurement tool that investigators measure the position sense of the body, which has two parts, one fixed and one movable. The immobile part of the digital inclinometer is placed at the sacrum and the movable part is placed at the T4 spine level. The person is made 30 degrees of trunk flexion. Then, he is expected to perform 5 repetitions of 30 degrees of trunk flexion with his eyes closed. Deviation angles are recorded."
223817246|NCT00206193|DRUG|mifepristone|
223817247|NCT00206193|DRUG|misoprostol|
223817248|NCT00206193|DRUG|sulprostone|
223817249|NCT04952584|BIOLOGICAL|CD30.CAR-EBVST cells|"The dose is based on the number of CD30.CAR-expressing cells. In our previous study the highest dose was 2 × 10\^8 cells/m2 and we did not reach a MTD.~There will be a gap of 4 weeks between the first and second patient on each dose level.~On Day 0 of study, patients will receive their planned single dose of investigational T cell product by IV infusion over approximately 1 to 10 minutes in an expected volume of 1 to 50 mL."
223817250|NCT02084537|PROCEDURE|Endoscopic treatment|Treated by single or multiple transmural cystogastrostomy tracts, 15mm balloon dilation, two 7fr double pigtail plastic stents or lumen-apposing metal stents and nasocystic drainage catheter, with or without endoscopic necrosectomy as needed.
223817251|NCT02084537|PROCEDURE|Minimally invasive surgical necrosectomy|Video-assisted retroperitoneal debridement (VARD) or laparoscopic cystogastrostomy with internal debridement.
223817252|NCT00188955|DRUG|sirolimus|
223817253|NCT01335516|OTHER|Glypressin (terlipressin)|Study drug (without placebo)
223817254|NCT05338918|OTHER|Mental Imagery with Virtual Reality Training|Mental Imagery TASK Practice with Virtual Reality Training: 30-40 minutes treatment sessions will be performed three times a week for six weeks, Part 1: 2-3 minutes of relaxation Part 2: Visual Imagery (external motor imagery training) for 5-8 minutes Part 3: Actual Task Practice for 10 minutes Part 4: Virtual Reality based training (including games for lower limb functions) for 10 minutes Part 5:Task Oriented training for 10 minutes Tasks for both (mental imagery + actual task practice) will be: Sit-stand task, Static stance (30 seconds), Indoor walk on a leveled surface, Walk indoor towards target, Forward / Side Stepping, Walking outdoors
223817255|NCT05338918|OTHER|Virtual Reality Training|Virtual Reality Training: 30-40 minutes treatment sessions will be performed three times a week for six weeks. Games will include River rush, 20000 water leaks, reflex ridge along with task oriented training. Tasks will be: Sit-stand task, Static stance (30 seconds), Indoor walk on a leveled surface, Walk indoor towards target, Forward / Side Stepping, Walking outdoors
223817256|NCT06181032|DRUG|Adebrelimab|Adebrelimab: 1200mg or 20mg/kg, iv, D1, Q3W;
223817257|NCT06181032|DRUG|Apatinib|Apatinib: 250 mg, po, QD, Q3W;
223817258|NCT06181032|DRUG|Gemcitabine|Gemcitabine: 1000 mg/m2, iv, 30min, D1, D8, Q3W;
223817259|NCT06181032|DRUG|Cisplatin|Cisplatin: 25 mg/m2, iv, 30min, D1, D8, Q3W; Injection sequence: adebelizumab → gemcitabine → cisplatin (sequential interval of at least 30 min), 3 cycles of neoadjuvant therapy.
223817260|NCT04247997|PROCEDURE|disconnect pulmonary vague nerve branches|When the operation is in the right side, the Azygous vein bow is used as the marker, and in the left side, the aortic arch is used as the marker to identify the vagus nerve trunk.Then the surgeons dissect the vagus nerve trunk. This is used as a clue to find the vagus nerve pulmonary branch leading to the hilum. The position of the detachment is after the anterior and posterior pulmonary branches of the vagus nerve separating from the trunk and before the formation of the lung plexus.
223817261|NCT02995850|DRUG|CRS+HIPEC|"1. Ib~   * Dose-escalation of intraperitoneal paclitaxel will follow a modified 3 + 3 dose escalation procedure.~2. II~   ① CRS If PCI \<12, CRS will be performed by gastrectomy with D2-lymphadenectomy and resection of any involved adjacent structures.~   If PCI≥12, instead of CRS, 3 times of IP paclitaxel +cisplatin and oral S-1 chemotherapy every 3 weeks, and then PCI \<12, CRS will be done.~   ② Extensiveintraperitoneal lavage Peritoneal lavage after CRS will be done with 10 L before HIPEC.~   ③ HIPEC Following surgery HIPEC will be performed using CDDP (60 mg/m2) and PTX (P2RD mg/m2). IP chemotherapy will be performed.~   ④ Post-operative intraperitoneal chemotherapy Postoperative chemotherapy will be done 8 cycles of IP paclitaxel+ cisplatin and oral S-1 after 4 weeks."
223817262|NCT02729935|DRUG|Parecoxib|40 mg of intravenous parecoxib 30 min before surgery
223817263|NCT02729935|DRUG|Placebo|An equal volume of saline
223817264|NCT02384655|DRUG|Fenugreek seed meal|3x3 capsules of fenugreek seeds per day for 14 days
223817265|NCT03054038|DRUG|Afatinib|Given by mouth
223817266|NCT03054038|BIOLOGICAL|Necitumumab|Given IV
223817267|NCT03054038|OTHER|Laboratory Biomarker Analysis|Correlative studies
223817268|NCT03803891|PROCEDURE|Endoscopic full-thickness resection|Endoscopic full-thickness resection (EFTR) with Over-The-Scope-Clip in colorectal lesions
223817269|NCT04886427|OTHER|No intervention|Measure the experiences of the current care
223817270|NCT06333210|BIOLOGICAL|anti-TRBV9 monoclonal antibody infusions|infusions
223817271|NCT06333210|OTHER|Placebo infusions|infusions
223817272|NCT06333210|DRUG|Adalimumab subcutaneous injection|subcutaneous injection
223817273|NCT06333210|OTHER|Placebo subcutaneous injection|subcutaneous injection
223817274|NCT05408143|OTHER|CC|To promote prompt effective care for medically complex children at all hours, we developed an outpatient comprehensive care (CC) program at the University of Texas Health Science Center at Houston (UTH) that now includes a hospital consultation service by the outpatient CC providers (the hospital component) and a conventional telemedicine (CTM) audio-visual program (the home component).
223817275|NCT05408143|DEVICE|enhanced telemedicine (ETM)|"An enhanced telemedicine program (using HIPAA-compliant, mobile TytoCareTM devices) will be added to CC to allow providers to remotely visualize the skin, throat, \& ears, auscultate the heart \& lungs, and measure illnesses during clinic hours and chronic illnesses during the detailed patient evaluation to be conducted at least every 6 months by virtual patient rounds in the home. These visits will involve the parent(s), the PCP, and if needed any of 10 specialists, particularly pulmonology, gastroenterology, neurology, and physical medicine and rehabilitation. A social worker, nutritionist, or psychologist will be involved as needed. Each PCP will perform 2-3 virtual patient rounds per week to proactively identify medical problems, suboptimal adherence to treatment, dosing errors, or other problems and intervene before CMC develop a serious illness or require avoidable clinic visits, Emergency Department visits, or hospitalizations."
223817276|NCT03516864|DEVICE|MIMOSA Imager|The MultIspectral MObile tiSsue Assessment (MIMOSA) Imager acquires digital images to calculate anatomical details of chronic wounds (e.g. diameter, surface area, and perimeter). The device can be worn from a lanyard, and clips onto a smartphone, using natural ambient lighting to capture images of a wound. The MIMOSA also uses up to 6 near-infrared LEDs to illuminate tissue with different wavelengths of light to assess tissue oxygenation.
223817277|NCT03516864|DEVICE|Kent Camera|The Food and Drug Administration (FDA) has previously approved a near-infrared device called the Kent camera for the assessment of tissue oxygenation.
223817278|NCT00637819|DRUG|Leflunomide|A loading dose of LEF 100mg daily for 3 days, followed by LEF 20mg daily for the remainder of the study or matching placebo
223817279|NCT03129048|BEHAVIORAL|MedDiet|"Research subjects will be randomly assigned to one of three intervention groups.~The MedDiet-A group will learn about and how to adhere to the Mediterranean Diet. Over the course of 8 months, they will receive twenty-two classes 60-minute in length.~The MedDiet-WL group will learn about the Mediterranean Diet, how to adhere to is and engage in lifestyle choices like exercising and eating fewer calories so that they will loose weight. Over the course of 8 months they will receive 22 classes, each 90 minutes in length.~The Typical Diet Control group will be asked to maintain current eating and activity patterns over the course of the 14 month study."
223817280|NCT02140710|PROCEDURE|Osteopathic treatment|visceral osteopathic treatment algorithm: Global listening and local listening on the abdomen Release lower ribs and thoracic diaphragm Pylorusrelaxation Release of the Duodenum and the C-Loop Small intestine diagnosis- Lifting the gut and bringing it to a stillpoint Root of mesentery diagnosis (and manipulation) Mobilisation of the ileocoecalic valve Mobilisation of colon ascendens, transversum, descendens Root of sigmoid diagnosis and manipulation
223817281|NCT05214313|BEHAVIORAL|Music Therapy|"The standardised music therapy protocol of 45 minutes will include at each session :~* 10 min of musical listening in a soothing environment (relaxation chair and reduced and coloured lighting) in sensory isolation (with headphones) and aimed at relaxation as a preamble to the active phase of the protocol~* Active phase: (25 min)~* 5 min of receptive music therapy linked to a given emotion, different at each session (joy, sadness, anger and fear) aimed at emotional management (feeling and distancing),~* 20 minutes of active music therapy with instrumental and vocal improvisation that solicits the body physiologically,~* 10 minutes of musical listening in sensory isolation for a state of rest.~The entire protocol is carried out with the permanent perception of heartbeats set to a physiological frequency of 50 to 100 BPM."
223817282|NCT03281824|BIOLOGICAL|ALT-P7 (HM2-MMAE)|Antibody-Drug Conjugate
223817283|NCT00477477|OTHER|Diet|Low glycemic load diet prepared/delivered for 8 weeks, and counseled for 4 more months. Daily multivitamin.
223817284|NCT00477477|OTHER|Diet|Low saturated fat diet prepared/delivered for 8 weeks, and counseled for 4 more months. Daily multivitamin.
223817285|NCT03204058|DRUG|Placebos|Oral prophylaxis followed by placement of placebo gel
223817286|NCT03204058|DRUG|Rosuvastatin|Oral prophylaxis followed by placement of rosuvastatin gel
223817287|NCT03204058|DRUG|Metformin|Oral prophylaxis followed by placement of metformin gel
223817288|NCT05674591|BEHAVIORAL|Cognitive Processing Therapy (CPT)|The CPT therapist will teach the patient about PTSD, depression, and anxiety, and outline the treatment regimen and rationale for its effectiveness. In the initial sessions, women will be asked to express their impact statements on the intimate partner violence to which they had been subjected. Women will be taught how to differentiate between events, thoughts, and emotions, as well as their interrelationships. Thoughts of self-blame and other misconceptions of the situation will be addressed using Socratic questioning. Women will be instructed on how to detect and counteract negative thoughts, as well as how to communicate more effectively. Women will be encouraged to evaluate negative thinking relating to five themes: safety, trust, power/control, self-esteem, and intimacy. During the final sessions, their impact statements on the violence to which they had been subjected will be altered to include emotional and cognitive insights obtained during the CPT.
223817289|NCT02826525|DRUG|AZD4076|Investigational product
223817290|NCT02826525|DRUG|Placebo|Control
223817291|NCT01336621|DRUG|Retigabine IR|Flexible dose between 300 mg/day (minimum) and 1200 mg/day (maximum)
223817292|NCT05128643|BIOLOGICAL|Recombinant novel coronavirus vaccine (CHO cell)|Intramuscular injection of deltoid muscle of upper arm of 25μg/0.5ml/person dose Recombinant novel coronavirus vaccine (CHO cells).
223817293|NCT03571737|DRUG|Ibuprofen|Ibuprofen tablet
223817294|NCT03571737|DRUG|Lidocaine Patch 4%|Lidocaine patch
223817295|NCT03715712|OTHER|standardized blood pressure management|Standardized blood pressure management of a mean blood pressure \> 65mmHg and a systolic blood pressure of \< 160mmHg using norepinephrine continuous infusion
223817296|NCT03715712|OTHER|Individualized blood pressure management|Individualized blood pressure management of 20% within the preoperative ward blood pressure using norepinephrine continuous infusion
223817297|NCT05453747|OTHER|Exercise|After evaluating the age groups and physical characteristics of the athletes under the titles of Warm-Up, Core/Balance/Reactive, Speed/Agility/Quickness, Resistance and Cool-Down, the exercise programs that differ for the athlete under these exercise types are listed with the NASM program and shared with the athletes. During the 8-week period between the 2 evaluations, it was applied 2 days a week on the team's fitness days.
223817298|NCT05453747|OTHER|Exercise 2|After evaluating the age groups and physical characteristics of the athletes under the titles of Warm-Up, Core/Balance/Reactive, Speed/Agility/Quickness, Resistance and Cool-Down, the exercise programs that differ for the athlete under these exercise types are listed with the NASM program and shared with the athletes. During the 8-week period between the 2 evaluations, it was applied 2 days a week on the team's fitness days.
223817299|NCT00056225|DRUG|Folate|
223817300|NCT00056225|DRUG|Vitamin B6|
223817301|NCT00056225|DRUG|Vitamin B12|
223817302|NCT04727073|DRUG|Experimental: Spironolactone|Spironolactone (an aldosterone antagonist) in tablet form taken daily. The initial study drug dose is 25 mg/day (one tablet) and may be titrated up to 50 mg/day (two tablets) within 4 weeks if kidney function at VR was \> 30 mL/min/m2 and potassium \< 4.5 mmol/L.
223817303|NCT04727073|DRUG|Placebo Comparator|Placebo of Spironolactone in tablet form taken daily with dosage escalation rules in accordance with dosage of the study drug Spironolactone.
223817304|NCT01771822|DRUG|Ibuprofen 5% topical gel|0.2 ml applied daily for 21 days over 3 weeks under occlusive conditions
223817305|NCT01771822|DRUG|Topical gel vehicle|0.2 ml applied daily for 21 days over 3 weeks under occlusive conditions
223817306|NCT01771822|DRUG|Sodium lauryl sulfate 0.2%|0.2 ml applied daily for 21 days over 3 weeks under occlusive conditions
223817307|NCT01771822|DRUG|Sodium chloride solution 0.9% (saline)|0.2 ml applied daily for 21 days over 3 weeks under occlusive conditions
223817308|NCT01186614|DEVICE|Automated CPR|Automated CPR utilised by paramedics to facilitate CPR during transport to hospital
223817309|NCT01186614|DEVICE|ECMO|Insertion of peripheral VA ECMO
223817310|NCT01186614|PROCEDURE|Coronary angiography|Coronary angiography and intervention where necessary will be performed following ECMO insertion
223817311|NCT01186614|PROCEDURE|Therapeutic Hypothermia|Paramedic initiated hypothermia with intravenous ice cold fluid and then continued for 24 hours (33 degrees)
223817312|NCT00001565|DRUG|phenylbutyrate|
223817313|NCT02294539|DRUG|Losartan 50mg/amlodipine 5mg|once daily, 1T, PO medication
223817314|NCT02294539|DRUG|Losartan 100mg/amlodipine 5mg|once daily, 1T, PO medication
223817315|NCT02294539|DRUG|Losartan 50mg/Hydrochlorothiazide 12.5mg|once daily, 1T, PO medication
223817316|NCT02294539|DRUG|Losartan 100mg/Hydrochlorothiazide 25mg|once daily, 1T, PO medication
223817317|NCT01126060|DRUG|Usage of Fibrin sealant|Usage of 1 vial of fibrin sealant after hemostasis in total thyroidectomy with anterior compartment neck dissection
223817318|NCT01126060|PROCEDURE|Thyroidectomy|surgical removal of bilateral thyroid glands
223817319|NCT00002928|DRUG|paclitaxel|
223817320|NCT00628836|DEVICE|BION stimulation|"The study will have two phases, each with a six week duration. During phase 1, the BION group will be implanted with BIONs in the middle deltoid and supraspinatus muscles. The muscles will be stimulated electrically by way of the BION and an external controller for one to two hours per day at 5pps in an on-off duty cycle train. The SE group will begin surface stimulation similar to that of BE group.~Subjects in either group whose initial therapy in phase 1 successfully reduces the amount of shoulder subluxation to 5mm or less will go off stimulation for six weeks, and be reassessed whether subluxation is redeveloping.~If a subject in either group does not respond sufficiently to phase 1 therapy, the participant will move to phase 2 where the shoulder will be stimulated at up to 25 pps either with surface stimulation (SE group) or BION stimulation (BE group) for another six weeks. At the end of phase 2, participants will go off stimulation for six weeks and then be reevaluated."
223817321|NCT01874145|DRUG|GA 20 mg/mL|Glatiramer acetate (GA) 20 mg/mL subcutaneous (SC) injection, the commercial product, is a single-use pre-filled syringe (PFS) containing 1.0 ml of a clear, colorless to slightly yellow, sterile, non-pyrogenic solution.
223817322|NCT01874145|DRUG|GA 40 mg/mL|Glatiramer acetate (GA) 40 mg/mL subcutaneous (SC) injection, is a single-use pre-filled syringe (PFS) containing 1.0 ml of a clear, colorless to slightly yellow, sterile, non-pyrogenic solution.
223817323|NCT03299764|DEVICE|Pursed lip breathing ventilation|A non-invasive ventilation device mimicking the pursed lip breathing in COPD patients will be used.
223817324|NCT03299764|DEVICE|Standard non-invasive ventilation|Standard non-invasive ventilation
223817325|NCT01659398|DEVICE|External Counterpulsation (EECP)|A noninvasive neuroimaging technique. Administration of 35 hours EECP therapy over a 7 week period. EECP to be administered for 1 hour, 5 times a week.
223817326|NCT04453215|DEVICE|GaAlAs semiconductor diode laser device|low-level laser therapy
223817327|NCT05772429|DRUG|Epidiolex|Administered as an oral solution
223817328|NCT04929808|OTHER|Hydrating emollient for acute radiodermatitis|"The emollient has a calming effect, and hydrating and anti-oxidative properties.~An absorbable wound dressing will be applied on painful and moist wounds. In case of severe itch, a systemic antihistaminic agent can be prescribed by the radiotherapist."
223817329|NCT04929808|OTHER|Standard institutional skin care|The control patients will receive the institutional standard skin care, which includes the application of Flamigel® (Flen Pharma, Kontich, BELGIUM). In addition, Mepilex® (Mölnlycke Health Care, Berchem, Belgium), an absorbable wound dressing will be applied on painful and moist wounds. In case of severe itch, a systemic antihistaminic agent can be prescribed by the radiotherapist.
223817330|NCT01273428|DRUG|HP011-101|
223817331|NCT01273428|DEVICE|HP-828-101|
223817332|NCT01273428|OTHER|Standard Care|
223817333|NCT05715359|PROCEDURE|Reconstruction|Standardized template for reconstruction of continious defects of the jaws.
223817334|NCT01861834|DRUG|Omegaven 10%|"Patients with a sustained TPN requirement due to short bowel syndrome and TPN-associated liver disease that threatens progression to liver failure and death, for which the only available means of prevention at present is timely liver and/or intestinal transplant.~Omegaven 10%, 1 gram/kg, IV, every 12 hours until transplantation, or stopping TPN"
223817335|NCT02139358|DRUG|Gemcitabine|The Phase I trial will start at the recommended phase II dose (RP2D) for gemcitabine but will have a de-escalation dose levels in the event that an unacceptable toxicity requires dose reduction. Dose level 0 = gemcitabine (1200 mg/m2) IV D1,8 q21 days; Dose level -1 = gemcitabine (1000 mg/m\^2) IV D1,8 q21 days; Dose level -2 = gemcitabine (850 mg/m\^2) IV D1,8 q21 days. The RP2D will be the dose level where 0-1 dose limiting toxicities (DLTs) in six patients occur.
223817336|NCT02139358|DRUG|Trastuzumab|Trastuzumab will be given using an 8 mg/kg loading dose on cycle one, day one (C1D1), followed by 6 mg/kg IV on subsequent cycles every (q) 21 days.
223817337|NCT02139358|DRUG|Pertuzumab|Pertuzumab will be given using an 840 mg IV loading dose on C1D1, followed by 420 mg IV on subsequent cycles q 21 days.
223817338|NCT00595972|DRUG|ECF-endostar|Epirubicin 50mg/M2 D1, Cisplatin 60mg/M2 D1, FU 500mg/M2 D1-5, endostar 7.5mg/M2 D1-14, treatment cycle repeat every 3 weeks. Treatment should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
223817339|NCT06419244|DIAGNOSTIC_TEST|Myosteatosis|Determination of myosteatosis by imaging
223817340|NCT04575727|DRUG|[11C]MPC6827|Subjects will receive a microdose ( 10 µg) of \[11C\]MPC6827 (dose of 20 mCi)
223817341|NCT00730314|PROCEDURE|Hematopoietic stem cell transplantation|hematopoietic stem cell transplantation conditioning regimen depending on graft source
223817342|NCT01635075|BEHAVIORAL|Exercise|1-mile treadmill walk
223817343|NCT01635075|BEHAVIORAL|passive control|20 min inactivity
223817344|NCT04898712|DRUG|Tranexamic Acid 500 MG|Tranexamic Acid 500mg oral tablets
223817345|NCT04898712|DRUG|Placebo|The placebo will consist of an identical capsule to over-encapsulated tranexamic acid oral tablet entirely filled with microcrystalline cellulose, and sealed.
223817346|NCT00416260|OTHER|High Frequency Oscillation and Tracheal Gas Insufflation|Intermittent combined use of High Frequency Oscillation and Tracheal Gas Insufflation until the PaO2/inspired oxygen fraction ratio remains above than 150 mm Hg for more than 24 hours.
223817347|NCT04485130|DRUG|Disulfiram|This study will provide disulfiram. Participants in Cohort 1 receiving disulfiram will take 2 capsules of disulfiram (each capsule contains 500 mg DSF plus 27.75 mg microcrystalline cellulose powder) per day for a total of 5 consecutive days. Participants in Cohort 2 receiving placebo will take 4 capsules of disulfiram (each capsule contains 500 mg DSF plus 27.75 mg microcrystalline cellulose powder) per day for a total of 5 consecutive days.
223817348|NCT04485130|DRUG|Placebo|This study will provide placebo. Participants in Cohort 1 receiving placebo will take 2 capsules of placebo (each capsule contains only microcrystalline cellulose powder) per day for a total of 5 consecutive days. Participants in Cohort 2 receiving placebo will take 4 capsules of placebo (each capsule contains only microcrystalline cellulose powder) per day for a total of 5 consecutive days
223817349|NCT05238064|DRUG|Parsaclisib|"Phase Ib: Parsaclisib is taken orally every day continuously, at approximately the same time every day, without food restriction, once a day. This stage follows the traditional 3+3 model. Parsaclisib is set at 10 mg/day, 15 mg/day, 20 mg/day 3 dose groups, starting from 10 mg/day, each group included 3 subjects. The final dose determined at this stage will be used in the Phase II study.~Phase II:~Induced treatment: Received the initial dose of Parsaclisib determined in Phase Ib.~Maintain treatment: 2.5mg orally every day continuously, once a day until disease progression, death or unacceptable toxicity developments. The maximum treatment time of Parsaclisib is no more than 2 years."
223817350|NCT05238064|DRUG|CHOP|Cyclophosphamide: 750mg/m2, IV, d1 Doxorubicin: 50mg/m2, IV, d1 Vincristine: 1.4mg/m2, IV, d1 (maximum 2mg) Prednison: 100mg, po, d1-5 21 days per cycle
223817351|NCT00402337|DRUG|linaclotide acetate|oral, once daily.
223817352|NCT00402337|DRUG|Matching placebo|oral, once daily
223817353|NCT05909839|OTHER|7T MRI network analysis for deep brain stimulation in essential tremor|We hypothesize that the implementation of 7T MRI network analysis can enhance the effectiveness of DBS by improving motor symptoms and quality of life in ET patients.
223817354|NCT05784805|DEVICE|PLIFU|Participants will be treated with up to 2 sessions of PLIFU (on the same day), while monitored with surface EEG and will be observed for the remainder of the hospital stay as deemed by the primary care team. The system non-invasively delivers ultrasound sonications intracranially that selectively target specific areas of the brain.
223817355|NCT02178566|DRUG|Inhaled Treprostinil|A dose of inhaled treprostinil or placebo will be administered to all study participants prior to each of their Pulmonary Rehab sessions. Three puffs of inhaled treprostinil dose will be administered each time to all patients .
223817356|NCT04634461|DEVICE|Cardiac Monitor|RHYTHMSTAR Mobile Cardiac Monitoring System
223817357|NCT03731754|PROCEDURE|Traditional Closure|Primary closure discontinuously the perineal wound of APR
223817358|NCT03731754|PROCEDURE|"Cross closure"|Two triangles of skin in the horizontal direction are excised to enlarge the skin incision, and the tumor resected. Then circumferential subcuticular suture of wound, and with tightening of the circumferential suture, the wound resembles a cross.
223817359|NCT02934620|DEVICE|CSD500 Condom|CSD500 is a commercial condom that complies fully with the requirements of ISO 4074, the international standard for male latex condoms. The product is designed to increase sexual pleasure.
223817360|NCT02934620|DEVICE|Standard Condom|The standard condom is a standard condom in Vietnam at the time of the study. It is provided for pregnancy and disease prevention.
223817361|NCT02934620|BEHAVIORAL|Condom Counseling|The intervention arm will receive counseling that briefly addresses condom's dual protection against pregnancy and HIV/STI but that otherwise emphasizes the potential for increased sexual pleasure with CSD500 use. Counseling to this arm also will include CSD500-specific instructions, such as the need to briefly massage the gel inside the condom teat onto the penis head after donning the condom and to not use multiple condoms within a 24-hour period. The control arm will receive standard counseling to use condoms for pregnancy and disease prevention without receiving any messages about the use of condoms for sexual pleasure.
223817362|NCT06111144|BEHAVIORAL|Polarized training intensity distribution (TID) and mental training using mindfulness|Polarized TID model group with mindfulness program (POL+)
223817363|NCT06111144|BEHAVIORAL|Pyramidal training intensity distribution (TID) and mental training using mindfulness|Pyramidal TID model group with mindfulness program (PYR+)
223817364|NCT06111144|BEHAVIORAL|Polarized training intensity distribution (TID) without mindfulness|Polarized TID model group without mindfulness program (POL-)
223817365|NCT06111144|BEHAVIORAL|Pyramidal training intensity distribution (TID) without mindfulness|Pyramidal TID model group without mindfulness program (PYR-).
223817366|NCT01237795|OTHER|Dentifrice|Dentifrices (4 formulations) used as auxiliary agents for brushing complete dentures.
223817367|NCT03705819|DRUG|[11C]-NOP46|Subjects will receive a microdose (≤10 µg) of \[11C\]-NOP46.
223817368|NCT03705819|RADIATION|PET/CT scan|After subjects receive a microdose of \[11C\]-NOP46, whole body PET/CT scan(s) will be performed to determine dosimetry and perform an initial safety evaluation of the radiotracer in Stage 1 and region of interests in Stage 2.
223817369|NCT04631705|BIOLOGICAL|DZIF-10c|Inhaled administration of the human monoclonal antibody DZIF-10c
223817370|NCT04631705|BIOLOGICAL|DZIF-10c|Intravenous administration of the human monoclonal antibody DZIF-10c
223817371|NCT04631705|DRUG|Placebo|Inhalation of DZIF-10c diluent as placebo
223817372|NCT04631705|DRUG|Placebo|Intravenous infusion of sterile normal saline (NaCl 0.9%) as placebo
223817373|NCT04341961|OTHER|Pomegranate Juice|Drinking 8 oz of pomegranate juice daily for 2 weeks.
223817374|NCT02992587|OTHER|CAF, Comprehensive assessment of frailty|CAF, Comprehensive assessment of frailty. A scoring system of the patients physical status. By smaller physical test of balance, strength and walking speed.
223817375|NCT01474213|DRUG|dexmedetomidine group|1-1.5cmg/kg dexmedetomidine infusion within 10 minutes, while followed by maintainly infusing 0.7cmg/kg/min dexmedetomidine
223817376|NCT01474213|DRUG|remifentanil group|target controlled 3.5-4ng/ml remifentanil infused(blood plasma concentration)
223817377|NCT02658630|DEVICE|Robot + TTT exercise|The intervention will be completed 36 visits approximately 3x/week for 12-18 weeks. The training progression will be sequential with 12 visits completed on the wrist robot, followed by 12 visits on the shoulder-elbow robot and completing with 12 visits alternating sessions on the wrist and shoulder-elbow robot. Participants will perform robot training for 45 minutes with each robot followed by 15 minutes of TTT practice to complete their 60 minute intervention session.
223817378|NCT02124343|OTHER|Interval Exercise|
223817379|NCT03013088|DEVICE|CTO Crossing|With confirmation that the target vessel is completely occluded by the target CTO lesion, the operator shall initially attempt crossing the proximal end of the target CTO lesion by advancing ShockWireTM device ≥ 1cm. The SoundBite Crossing device can be activated as needed to perform the procedure and may be used for the entire length of the lesion(s).
223817380|NCT02130284|DEVICE|Predictive Low Glucose Management Feature in Insulin pump|All subjects will undergo hypoglycemic induction at Visit 2 with target set to 65 mg/dL using the rate of change basal increase algorithm. Low Limit setting when PLGM ON is 65 mg/dL.
223817381|NCT04846023|DEVICE|aEEG via vEEGix|Amplitude-Integrated EEG can be achieved with a limited number of frontal electrodes. There is a new aEEG technology available: VEEGix, developed by NeuroServo Inc. It is a miniaturized aEEG, non-intrusive, portable and resistant to patient's movements. Its main advantage is its simplicity of use as a single adhesive strip including all electrodes is fixed to the patient's forehead and is connected to the VEEGix device
223817382|NCT00066430|PROCEDURE|infrared photocoagulation therapy|
223817383|NCT00066430|DEVICE|Infrared Coagulator|IRC treatment of up to 3 HGAIN lesions at baseline (study initiation). A second IRC treatment may be administered for recurrent lesions at the 3 month visit.
223817384|NCT02125448|DEVICE|MRI and PET-CT|
223817385|NCT00187330|DRUG|Intravenous N-acetylcysteine|
223817386|NCT00377780|DRUG|Non pegylated liposomal doxorubicin, trastuzumab, docetaxel|max. 6 courses
223817387|NCT00511979|DRUG|Technosphere Insulin|
223817388|NCT00511979|DRUG|Technosphere insulin|
223817389|NCT00511979|DRUG|Technosphere insulin|
223817390|NCT00511979|DRUG|Regular human insulin|
223817391|NCT05767775|OTHER|Assessment of synovial- and adipose tissue-derived inflammatory biomarkers|"Parafﬁn-embedded synovial tissue (ST) specimens will be stained for H\&E and other sections will be stained for CD68, CD21, CD20, CD3, CD31 and Masson Trichrome Goldner with light green to assess the microanatomical organization of resident synovial inflammatory cells. Some synovial samples will be used for tissue resident macrophages subpopulations analysis using FACS gated on their expression of the CD64+/CD11b+/MHC-ClassII+/CD206+/-/Lineage-.~Each RA patient reaching a stable clinical (DAS\<1.6 for at least two different evaluations 6 months apart) and imaging (PDUS negative signal) remission under Tofacitinib treatment will undergo synovial biopsy and each synovial tissue sample will be processed as above.~Plasma levels of adipokines will be tested through ELISA method at baseline, 3, 6 and 12 months of follow-up in all patients."
223817392|NCT02206490|DRUG|naltrexone|Randomized controlled trial of naltrexone for Gulf War Illness.
223817393|NCT02206490|DRUG|Dextromethorphan|Randomized controlled trial of dextromethorphan for Gulf War Illness
223817394|NCT01737346|DRUG|lomustine and procarbazine|1 cycle (4 weeks) includes CCNU 75mg/m2 (D1) and procarbazine 60mg/m2 (D11-D24)by mouth for up to 6 cycles
223817395|NCT03482505|DEVICE|INVSENSOR00004|The INVSENSOR00004 will be placed on the subject's neck or chest to provide acoustic respiration rate.
223817396|NCT04462315|DRUG|Everolimus Eluting Coronary Stent System|Everolimus Eluting Coronary Stent System (Everolimus Arm) implantation
223817397|NCT04462315|DEVICE|Cobalt chromium balloon expandable stent (non-drug-eluting stent Arm)|Cobalt chromium balloon-expandable stent (non-drug-eluting stent Arm) implantation
223817398|NCT01521884|OTHER|SC anti-TNF|SC anti-TNF
223817399|NCT00793156|DRUG|Nalfurafine HCl 2.5 µg|Daily dose of 2.5 µg
223817400|NCT00793156|DRUG|Nalfurafine HCl 5.0 µg|Daily dose of 5.0 µg
223817401|NCT00793156|OTHER|Placebo|Placebo daily dose
223817402|NCT02048748|DEVICE|Weight and blood pressure device|Weight and blood pressure device integrated in a home telemonitoring kit. The weight scale is Withings The Smart Bodyscale. The blood pressure device is MEDISANA iHealth BP3.
223817403|NCT02048748|DEVICE|Home telemonitoring device|An iPad 2 WiFi 16GB (Model A1395) tablet integrating the telemonitoring kit.
223817404|NCT06203184|OTHER|video based exercises|Respiratory muscle training and other factors will be examined through 12 weeks of video-based game exercises.
223817405|NCT04601441|DRUG|Apalutamide|Apalutamide 240 mg administered orally once a day as four 60 mg tablets
223817406|NCT02540395|DRUG|Tacrolimus (for Group B)|Tacrolimus (for Group B) will be administered orally twice a day (bid). Tacrolimus (for Group B) will be initially given at the 0,1mg/kg bid to achieve a stable 12-hour trough level of 8-10 ng/mL during the first month after transplantation to progressively tapper to 6-8ng/ml thereafter.
223817407|NCT02540395|DRUG|MMF (mycophenolate mofetil) (for Group B)|"MMF (mycophenolate mofetil) will be administered orally to patients in group B at conventional doses (1gr/12h) before transplant procedure and during the first 7 days after transplant. For subjects who develop nausea, diarrhea, or other MMF(mycophenolate mofetil) -related gastrointestinal adverse effects (eg, symptoms fully assessed and deemed not to have an etiology other than intolerability to MMF), the MMF(mycophenolate mofetil) dose may be decreased to the maximally tolerated dose.~Subjects unable to tolerate the reduced dose may be converted to mycophenolate sodium (Myfortic™) or to Myfenax.~From day 8 on, patients will not receive MMF."
223817408|NCT02540395|DRUG|6-methyl prednisolone (Steroids) (for Group B)|"At the time of surgery, all patients will receive 500mg of 6-methyl prednisolone (Steroids, Urbason, Methypred).~Patients in group B will receive 250mg of 6-methyl prednisolone (or equivalent) on day 2, 125 mg on day 3, 60 mg on day 4 and 30 mg on day 5. From day 6 on, patients will receive 0.25 mg/kg/d of 6-methyl-prednisolone (Steroids, Urbason, Methypred) until month 1, then tapering until discontinuation on month 2 will be performed."
223817409|NCT02540395|DRUG|Tacrolimus (for Group A)|"The study group A will receive Tacrolimus (for Group A) (Prograf) to achieve 4-8 ng/ml trough levels during all the duration of the study.~Tacrolimus (for Group A) (Tacrolimus) capsules should generally be administered on an empty stomach or at least 1 hour before or 2 to 3 hours after a meal, to achieve maximal absorption."
223817410|NCT02540395|DRUG|Mycofenolate mofetil (MMF) (for Group A)|"Mycophenolate mofetil (MMF) (Cellcept, Myfortic, Myfenax) (for Group A) will be administered orally to patients in group A at conventional doses (1gr/12h). For subjects who develop nausea, diarrhea, or other Mycophenolate mofetil (MMF) (for Group A) -related gastrointestinal adverse effects (eg, symptoms fully assessed and deemed not to have an etiology other than intolerability to Mycophenolate mofetil (MMF) (for Group A), the Mycophenolate mofetil (MMF) (for Group A) dose may be decreased to the maximally tolerated dose.~Subjects unable to tolerate the reduced dose may be converted to mycophenolate sodium (Myfortic™).~The first dose of Mycophenolate mofetil (MMF) (for Group A) should be administered before transplantation."
223817411|NCT02540395|DRUG|6-methyl prednisolone (Steroids) (for Group A)|"At the time of surgery, all patients will receive 500 mg of 6-methyl prednisolone (steroids for Group A).~Patients in arm A will receive 20 mg/day of 6-methyl prednisolone (steroids for Group A) (or the equivalent) during the first 2 weeks after transplantation, then tapering to 15 mg from week 3 to week 4 to finally be maintained at 5mg/day."
223817412|NCT02821819|OTHER|Random start ovarian stimulation|Egg-donors will start ovarian stimulation randomly at different moments throughout the menstrual cycle.
223817413|NCT02821819|DRUG|Gonadotrophins|Urinary FSH 150-225 IU/d
223817414|NCT02821819|DRUG|GnRH antagonist|Cetrorelix acetate 0,25 mg/d starting five days after ovarian stimulation
223817415|NCT02821819|DRUG|GnRH agonist|GnRH agonist triggering with triptorelin 0,2 mg for final follicular maturation.
223817416|NCT04183907|BEHAVIORAL|Transform|"The Partner, Blue Mesa Health, has developed a lifestyle intervention program for pre-diabetics that aims to prevent or delay the onset of type 2 diabetes through incremental changes to health behaviours. Transform is based on the CDC's National Diabetes Prevention Program (DPP). Blue Mesa Health adapted the National DPP into a digital experience by combining the use of technology- an app, wearable activity trackers (Fitbit) and digital scales- with the professional guidance of remote health coaches.~It is a 6-month intervention that helps individuals establish healthier lifestyle habits. Each participant strives to achieve 2 primary goals:~Attaining 5 to 7 percent weight loss from their starting bodyweight Engaging in at least 150 minutes of weekly physical activity"
223817417|NCT03565068|DRUG|MK-8189|MK-8189 4 mg tablet(s) will be administered orally QD for a total daily dose of 4 mg, 8 mg, 12 mg, 16 mg, 20 mg, 24 mg, 36 mg or 48 mg.
223817418|NCT03565068|DRUG|Placebo|MK-8189 dose-matching placebo tablets will be administered orally QD.
223817419|NCT03565068|DRUG|Background AAP Therapy|Participants with schizophrenia in Panel C will be on background therapy with an AAP medication (e.g., olanzapine, quetiapine, paliperidone, asenapine, iloperidone, aripirprazole, lurasidone, risperidone \[not to exceed daily dose of 6 mg\], or ziprasidone) throughout the study. Participants should be on a stable and well tolerated treatment regimen for at least 2 months prior to screening. NOTE: clozapine is not allowed.
223817420|NCT05368181|DRUG|Methylprednisolone|Methylprednisolone starts with the dose of 2 mg/kg for 5 days. If no signs of aGvHD, the dose of methylprednisolone is gradually taper with the following 16 days.
223817421|NCT06205797|DRUG|HU-045|"HU-045 is a medicine that is injected into muscles and used to improve the look of moderate to severe frown lines between the eyebrows (glabellar lines) in adults for a short period of time (temporary). It should be reconstituted with sterile, preservative-free 0.9% saline before use.~White powder~Other Names:~IncobotulinumtoxinA"
223817422|NCT06205797|DRUG|Xeomin®|"Xeomin® is a prescription medicine that is injected into muscles and used to improve the look of moderate to severe frown lines between the eyebrows (glabellar lines) in adults for a short period of time (temporary). It should be reconstituted with sterile, preservative-free 0.9% saline before use.~Other Names:~IncobotulinumtoxinA"
223817423|NCT02911350|DRUG|Hormone Suppressors|
223817424|NCT02911350|DRUG|Paclitaxel|
223817425|NCT02911350|RADIATION|Radiation Therapy|
223817426|NCT01978080|DEVICE|Kinesia HomeView|
223817427|NCT03280771|COMBINATION_PRODUCT|Hope Soap|HOPE SOAP© is a colourful, translucent bar of soap with a toy embedded in its centre.
223817428|NCT03280771|COMBINATION_PRODUCT|Control group soap|A colourful, translucent bar or soap with the toy alongside it
223817429|NCT00085202|BIOLOGICAL|filgrastim|Given subcutaneously
223817430|NCT00085202|DRUG|cisplatin|Given IV
223817431|NCT00085202|DRUG|cyclophosphamide|Given IV
223817432|NCT00085202|DRUG|vincristine|Given IV
223817433|NCT00085202|PROCEDURE|autologous hematopoietic stem cell transplantation|Patients undergo autologous stem cell transplantation
223817434|NCT00085202|RADIATION|radiation therapy|Patients undergo craniospinal radiotherapy once daily 5 days a week for 6 weeks.
223817435|NCT01199159|DRUG|Misoprostol|400mcg misoprostol given sublingually 30 minutes before total abdominal hysterectomy
223817436|NCT01199159|DRUG|Vitamin B 6|20mg vitamin B6 given sublingually 30 minutes before total abdominal hysterectomy
223817437|NCT02654210|OTHER|No Intervention|No Intervention
223817438|NCT05978505|DRUG|Reboxetine 4 MG Oral Tablet|7 nightly doses (4mg) to commence after surgery.
223817439|NCT05978505|DRUG|Placebo|7 nightly doses to commence after surgery.
223817440|NCT05558514|OTHER|Place-based cochlear implant mapping|Pre-operative, 3D CT scans of the temporal bone will be uploaded into a deep learning-based tool which automatically resamples, crops, segments, analyzes, and measures the patient's specific cochlear anatomy. These measurements will be input into an individualized pitch mapping function to determine a patient-specific tonotopic distribution of frequencies (place-based map). At device activation (approximately 1 month post-surgery) CIs will be programmed according to the place-based map.
223817441|NCT05558514|OTHER|Default cochlear implant mapping|At device activation (approximately 1 month post-surgery) CIs will be programmed according to the clinical default program.
223817442|NCT05423691|DRUG|CK0804|CK0804 is a cryopreserved, allogeneic T-regulatory cell product that is manipulated to traffic to the bone marrow.
223817445|NCT04016948|DEVICE|Probe-based confocal laser endomicroscopy optical biopsy|In the pCLE group, after intravenous injection of fluorescein, the optical biopsy will be performed, using a confocal miniprobe, to exam the rectal mucosa when the rectum transection is ready. The raters will analyse the CLE images to determine whether the distal margin is positive. In the IFS group, intra-operative frozen section will be performed at the site of distal margin after the rectum transection.
223817446|NCT04016948|DEVICE|Intra-operative frozen section|In the pCLE group, after intravenous injection of fluorescein, the optical biopsy will be performed, using a confocal miniprobe, to exam the rectal mucosa when the rectum transection is ready. The raters will analyse the CLE images to determine whether the distal margin is positive. In the IFS group, intra-operative frozen section will be performed at the site of distal margin after the rectum transection.
223817447|NCT06682078|OTHER|Not applicable . Non-interventional retrospective study, only on datas.|Not applicable . Non-interventional retrospective study, only on datas.
223817448|NCT05851937|BEHAVIORAL|Written language intervention|Young adults with Intellectual and Developmental Disabilities (IDD) are taught reading comprehension strategies in three phases (before, during, after) using a graphic organizer as visual support. At the beginning of each phase, the interventionist: (a) defines the strategies, (b) describes and models how to use the strategies, and (c) answers questions about the strategies. Then the participant practices the strategies during 45-min sessions, two times per week, over 3 months. Each session follows the teach-model-coach-review format, the interventionist: (a) reviews the strategies (5 min), (b) models the strategies using a think-aloud (10 min), (c) prompts the participant to practice the strategies with support (15 min), (d) prompts the participant to use a think-aloud to practice the strategies independently using a functional literacy text (10 min), and (e) reviews and summarizes the session (review; 5 min).
223817449|NCT06077773|DRUG|Oral EP262|Once daily
223817450|NCT06077773|DRUG|Placebo|Once daily
223817451|NCT06134856|PROCEDURE|Ankle mobilization|Ankle joint mobilization as described in treatment arm description
223817452|NCT06134856|PROCEDURE|Sham treatment|Light passive movement of the foot and ankle, avoiding the end-ranges which may actually elicit a mechanical change
223817453|NCT02803268|DRUG|MT-8554 low dose|
223817454|NCT02803268|DRUG|MT-8554 middle dose|
223817455|NCT02803268|DRUG|MT-8554 high dose|
223817456|NCT02803268|DRUG|Placebo|
223817457|NCT06327464|DIETARY_SUPPLEMENT|Exogenous ketones|Consumption of a single exogenous ketone supplement with breakfast
223817458|NCT05256095|BEHAVIORAL|Thinking in Speech|Thinking in Speech is a therapy to help children with autism learn to cope with daily stressors and improve their communication.
223817459|NCT02081950|BIOLOGICAL|Enoxaparin sodium|comparison of 2 different administration of drug
223817460|NCT04844580|DRUG|Inhaled Aviptadil|Aviptadil is the synthetic analogue of the Vasoactive Intestinal Peptide (VIP), a biologically active 28 amino acid natural peptide that is endogenously synthesized in humans. It is one of the signaling molecules of the neuroendocrine immune network and has vasodilator, anti-proliferative, anti-inflammatory and immunomodulatory properties.
223817461|NCT04844580|DRUG|Placebo|Aviptadil Placebo will be used for this arm.
223817462|NCT06578936|OTHER|abdominal massage andwarm application|Abdominal massage and hot application will be applied to the patients at least 30 minutes after the morning and evening meals (08:30 am, 20:30 pm) for 15 minutes each, similar to the literature. The hot application will be applied to the abdominal area with a hot water thermophore for 15 minutes before the abdominal massage. After the hot application, abdominal massage will be started. In the abdominal massage, which will be applied clockwise to stimulate bowel movements, four basic movements will be used: superficial exertion, deep exertion, petrisage and vibration.
223817463|NCT03011723|BEHAVIORAL|Resource oriented music therapy|"10 weeks of tailored individual music therapy for PWD and a caregiver. Pre and post assessment in addition.~The music therapy consists of one or more of the following activities:~1. Singing~2. Listening to live music~3. Listening to recorded music~4. Dancing~5. Conversations about memories/reminiscence~6. Exercising to music~7. Breathing exercises and relaxing exercises~The treatment is following the principles of resource oriented music therapy as described by Rolvsjord et al (2005)"
223817464|NCT03620630|DEVICE|myCOPD|myCOPD is a multi faceted web based application designed to support people with COPD in the Long term management of their COPD.
223817465|NCT01286441|DRUG|10% EISO|During the Treatment Period, subjects will apply study medication (10% EISO) to all warts in the treatment area for 12 weeks and will then be followed for an additional 12 weeks. Subjects achieving complete resolution will continue to apply the study medication for the entire 12-week treatment period. During the Follow-up Period, subjects will be followed by telephone every 4 weeks for 12 weeks.
223817466|NCT01286441|DRUG|Placebo|During the Treatment Period, subjects will apply placebo to all warts in the treatment area for 12 weeks and will then be followed for an additional 12 weeks. Subjects achieving complete resolution will continue to apply the study medication for the entire 12-week treatment period. During the Follow-up Period, subjects will be followed by telephone every 4 weeks for 12 weeks.
223817467|NCT01286441|DRUG|20% EISO|During the Treatment Period, subjects will apply study medication (20% EISO) to all warts in the treatment area for 12 weeks and will then be followed for an additional 12 weeks. Subjects achieving complete resolution will continue to apply the study medication for the entire 12-week treatment period. During the Follow-up Period, subjects will be followed by telephone every 4 weeks for 12 weeks.
223817468|NCT01286441|DRUG|30% EISO|During the Treatment Period, subjects will apply study medication (30% EISO) to all warts in the treatment area for 12 weeks and will then be followed for an additional 12 weeks. Subjects achieving complete resolution will continue to apply the study medication for the entire 12-week treatment period. During the Follow-up Period, subjects will be followed by telephone every 4 weeks for 12 weeks.
223817469|NCT02020239|OTHER|Exercise|
223817470|NCT01203670|DIETARY_SUPPLEMENT|Phytalgic|Volunteers have to take three soft capsules per day, one in the morning and two in the evening.
223817471|NCT02101086|OTHER|Blood transfusion|Whenever the infant indicated to receive transfusion, a blood product request was sent to the blood bank. This infant was randomly assigned to the autologous or the allogeneic product labeled for each patient at birth in the blood bank
223817472|NCT03017326|DRUG|Cisplatin|Arms A and B - cisplatin is used alone Arms C, D, E and F - cisplatin us used in combination
223817473|NCT03017326|DRUG|Doxorubicin|Arms C, D and E used in combination
223817474|NCT03017326|DRUG|Carboplatin|Arms C and D used in combination
223817475|NCT03017326|DRUG|5Fluorouracil|Arm C used alone
223817476|NCT03017326|DRUG|Vincristine|Arms C and D used in combination
223817477|NCT03017326|DRUG|Etoposide|Arm D used in combination
223817478|NCT03017326|DRUG|Irinotecan|Arm D used in combination
223817479|NCT03017326|DRUG|Gemcitabine|Arm F used in combination
223817480|NCT03017326|DRUG|Oxaliplatin|Arm F used in combination
223817481|NCT03017326|DRUG|Sorafenib|Arm used in combination
223817482|NCT03852043|BEHAVIORAL|High-intensity interval training|The intervals of high intensity are conducted between 90 and 95 % of heart rate maximum (HRmax) and resting between 50 and 60 % of the HRmax 15 loads of 30 seconds at high intensity, with 60 seconds of recovery at loads of moderate intensity.
223817483|NCT03852043|BEHAVIORAL|Moderate-intensity continuous training|The continuous training will be carried out at an intensity between 65 and 75% of the HRmax.
223817484|NCT05968014|PROCEDURE|PENG vs FICB|pericapsular nerve group block versus fascia iliaca compartment block
223817485|NCT01436201|DRUG|Digoxin|Administered orally
223817486|NCT01436201|BIOLOGICAL|Dulaglutide|Administered as subcutaneous injection
223817487|NCT01435655|DRUG|tafamidis|tafamidis meglumine 20 mg QD
223817488|NCT04987632|DRUG|Letrozole|Letrozole, an aromatase inhibitor, is considered to be the first-line drug for ovulation induction in PCOS.
223817489|NCT04987632|DEVICE|acupuncture|Domestic and foreign studies suggest that acupuncture and electroacupuncture can improve the menstrual cycle of PCOS and reduce the level of total testosterone; Acupuncture can regulate glucose homeostasis by stimulating the autonomic nervous system of PCOS patients. Our previous studies and a large number of literatures have proved that acupuncture can improve insulin resistance in PCOS, and acupuncture can improve the pregnancy rate in PCOS.
223817490|NCT04987632|OTHER|Governor vessel moxibustion|It can warm the kidney, promote digestion and absorption, remove dampness and promote blood circulation
223817491|NCT06022835|OTHER|Chlorhexidine Gluconate-gel (CHG) Dressing|Participants used Tegaderm™ CHG dressing for 4 months. The dressing was changed every seven days or soiled.
223817492|NCT00110890|DRUG|cinacalcet|Treatment with cinacalcet will be initiated at a dose of 30 mg/day. Possible daily doses of cinacalcet are 30, 60, 90, 120, and 180 mg.
223817493|NCT00110890|OTHER|Standard of care|Subjects randomised to the standard care arm are to receive appropriate therapy in accordance with the investigator's practice in an attempt to achieve the K/DOQI PTH, serum calcium, phosphorus, and Ca x P treatment targets.
223817494|NCT03319082|COMBINATION_PRODUCT|Corneal Collagen Cross-linking|Photrexa Viscous (riboflavin 5'-phosphate in 20% dextran ophthalmic solution), Photrexa (riboflavin 5'-phosphate ophthalmic solution), and the KXL System (UV Irradiation).
223817495|NCT00887276|DRUG|Moxifloxacin|"intravenous infusion: at least 3 days until to the drug switch (oral use),3 times daily (all 8 hours)~1. 20 ml physiologic saline solution (placebo)(over 30 min) + Moxifloxacin infusion solution(400 mg/250ml) over 60 minutes~2. 20 ml physiologic saline solution (placebo) (over 30 min)~3. 20 ml physiologic saline solution (placebo) (over 30 min)~following oral therapy(possible at the earliest day 4): 3 times daily (all 8 hours):~1. 1 capsule Moxifloxacin (400 mg) + 1 capsule Placebo~2. 2 capsules Placebo~3. 2 capsules Placebo~Total time of the therapy:at least 7 days, but at most 10 days"
223817496|NCT00887276|DRUG|Ampicillin;Amoxicillin|"intravenous infusion:at least 3 days until to the drug switch (oral use), 3 times daily (all 8 hours)~1. 2 g Ampicillin dissolved in 20 ml aqua (i.v. over 30 min) + 250 ml physiologic saline solution (placebo) (over 60 min)~2. 2 g Ampicillin dissolved in 20 ml aqua (i.v. over 30 min)~3. 2 g Ampicillin dissolved in 20 ml aqua (i.v. over 30 min)~following oral therapy(possible at the earliest day 4): 3 times daily (all 8 hours):~1. 2 capsules Amoxicillin (0,5 g)~2. 2 capsules Amoxicillin (0,5 g)~3. 2 capsules Amoxicillin (0,5 g)~Total time of the therapy: at least 7 days, but at most 10 days"
223817497|NCT06040996|BEHAVIORAL|Improving Parenting Skills adult ADHD (IPSA)|Parent training program for parents with ADHD. The program combines structured group-based skills training with individualized support, including occupational therapist support to help parents improve their own prerequisites for bringing about change and facilitate use of the introduced parenting skills.
223817498|NCT06040996|OTHER|Continued Routine Services|Continued Routine Services while waiting for IPSA (offered approximately 6 months later)
223817499|NCT05325255|OTHER|Myofascial release of subscapularis|It is the application of manual pressure over myofascial trigger point that induces ischemia and causes release of trigger points
223817500|NCT05325255|OTHER|Maitland mobilization|It is the type of mobilization technique that uses passive accessory mobilization to reduce pain and stiffness and increasing range of motion
223817501|NCT05325255|OTHER|Stretching exercises|It is the technique use to increase flexibility and range of motion of short and hypomobile structures
223817502|NCT05325255|OTHER|Cold pack|It is the application of cold to provide analgesic effects
223817503|NCT02287116|DEVICE|Easy Flow system and INCA® nasal cannulae set|
223817504|NCT01975220|DRUG|Empagliflozin/Metformin XR, FDC|Experimental: high dose empagliflozin/metformin XR, FDC tablet
223817505|NCT01975220|DRUG|Empagliflozin/Metformin XR FDC|Experimental: low dose empagliflozin/metformin XR, FDC tablet
223817506|NCT01975220|DRUG|25 mg Empagliflozin/1000 mg Metformin XR, FDC|Experimental, high dose Empagliflozin/Metformin XR,FDC Tablet
223817507|NCT01975220|DRUG|1 tablet Empagliflozin/2 tablets Metformin XR|Active Comparator: 1x empagliflozin/2x metformin XR tablets
223817508|NCT01975220|DRUG|1 tablet Empagliflozin/3 tablets Metformin XR|Active Comparator: 1x empagliflozin/3x metformin XR tablets
223817509|NCT01975220|DRUG|1 tablet Empagliflozin/2 tablets Metformin XR|Active Comparator: 1x empagliflozin/2x metformin XR tablets
223817510|NCT02378740|DRUG|Saline|"The study drug (either ketamine or saline) will be administered from the beginning of anesthesia through the commencement of wound closure to provide the following dose of ketamine:~0.5 mg/kg loading dose 8.3 mcg/kg/min (0.5 mg/kg/hr) infusion"
223817511|NCT02378740|DRUG|Ketamine|"The study drug (either ketamine or saline) will be administered from the beginning of anesthesia through the commencement of wound closure to provide the following dose of ketamine:~0.5 mg/kg loading dose 8.3 mcg/kg/min (0.5 mg/kg/hr) infusion"
223817512|NCT00003884|DRUG|zoledronic acid|
223817513|NCT00003884|PROCEDURE|quality-of-life assessment|
223817514|NCT02839343|RADIATION|radiation therapy|
223817515|NCT02839343|PROCEDURE|surgery|
223817516|NCT02839343|DRUG|mFOLFIRINOX|oxaliplatin IV, irinotecan IV, leucovorin IV and 5-FU IV
223817517|NCT02839343|DRUG|FOLFOX|oxaliplatin IV, leucovorin IV and 5-FU IV
223817518|NCT01774864|DRUG|DA-8159 (Udenafil)|
223817519|NCT01774864|DRUG|Placebo|
223817520|NCT01915576|DRUG|BAY1125976|Oral administration once daily. Starting dose is 10 mg and will be escalated depending on any dose-limiting toxicities
223817521|NCT01915576|DRUG|BAY1125976|Oral administration twice daily. Starting dose is 40mg twice daily and will be escalated depending on any dose-limiting toxicities
223817522|NCT01915576|DRUG|BAY1125976|Oral administration of the defined MTD which shows optimal safety, PK profile, PD target inhibition and preliminary efficacy (once daily or twice daily) in different patient groups
223817523|NCT05813067|DIETARY_SUPPLEMENT|JDS-HF 3.0|Take 2 capsules once daily in the mornings with food
223817524|NCT05813067|DIETARY_SUPPLEMENT|Placebo|Take 2 capsules once daily in the mornings with food
223817525|NCT02009202|DRUG|polyethylene glycol|
223817526|NCT02009202|DRUG|picosulphate|
223817527|NCT02434289|DIETARY_SUPPLEMENT|Dietary protein products|Increased protein intake via dairy products, guided by a dietician.
223817528|NCT02434289|OTHER|Resistance exercise training|Resistance exercise training in small groups for twelve weeks, two times a week, guided by physiotherapists.
223817529|NCT05234359|DIAGNOSTIC_TEST|Serology Testing|A simple home sampling kit containing volumetric absorption microsampling devices (Mitra(R) cartidge device, Neoteryx LLC) will be used by the participants to collect a finger stick blood sample (10 ul; a few drops). Kits will be delivered to participants' homes and returned by mail. An instructional video will be provided.
223817530|NCT05234359|DIAGNOSTIC_TEST|Stool sample|Stool samples collected for genetic, microbial and viral analysis.
223817531|NCT04729894|OTHER|Medication Lockbox|Participants will receive a medication lockbox to store medications in their home.
223817532|NCT04729894|BEHAVIORAL|Education|Participants will receive information on safe medication storage practices.
223817533|NCT01576822|OTHER|This protocol will utilize a sauna as the primary method of detoxification.|"This study is a randomized, 2-arm, dose-finding safety and feasibility trial. After screening, informed consent and randomization, participants will complete a medically-monitored sauna-based detoxification program.~High Dose Participants randomized to this group will undergo a protocol consisting of 2 hours of sauna therapy per day, for a minimum of 5 days per week, completed in 3 weeks or less (21 days). (15 total sessions, 30 hours of sauna).~Low Dose Participants randomized to this group will undergo a protocol consisting of 1 hour of sauna therapy per day, for a minimum of 3 days per week, completed in 3 weeks or less (21 days). (9 total sessions, 9 hours of sauna)."
223817534|NCT04104750|OTHER|assessment scales (BFI, QLQ, TESS)|the patient's Fatigue will be measured during the treatment period with antiblastic drugs and part of the followup period. To this end the BFI scale validated in Italian will be used (Mendoza et al 1999; Catania et al, 2013) which includes 9 items with a score for each of 0 to 10 and a consequent total score from 0 to 90. The measurement will take place in 4 times: the day of enrollment, 6 months, 12 months and 24 months after enrollment.the quality of life of patients measured by the EORTC QLQ C-30 scale (Aaronson et al, 1993) and the level of autonomy measured by the TESS scale (Davis et al, 1996) in 4 steps: the enrollment day , at 6 months, at 12 months and at 24 months from enrollment.
223817535|NCT02000414|DRUG|intraperitoneal daptomycin|intraperitoneal daptomycin administartion and study of daptomycin kinetics
223817536|NCT00180128|DRUG|all-trans retinoid acid|
223817537|NCT00180128|DRUG|idarubicin|
223817538|NCT00180128|DRUG|mitoxantrone|
223817539|NCT00180128|DRUG|daunorubicin|
223817540|NCT00180128|DRUG|cytarabine|
223817541|NCT01602081|DEVICE|reinforce soft tissue|reinforce soft tissue
223817542|NCT00263328|DRUG|Tacrolimus|Standard of care
223817543|NCT00263328|DRUG|CP-690,550|CP-690,550 5 mg BID
223817544|NCT00263328|DRUG|CP-690,550|CP-690,550 10 mg BID
223817545|NCT01814059|DRUG|sirolimus|
223817546|NCT02296632|BEHAVIORAL|Motion sensors and daily online assessments|Patients will be asked to wear motion sensors during their waking hours and complete daily Patient Reported Outcomes online assessments.
223817547|NCT04465825|BEHAVIORAL|HITT: intermittent high intensity exercise|Intermittent bouts of 30-60 seconds of exercise at 90% of peak intensity (HITT).
223817548|NCT06194409|DIAGNOSTIC_TEST|Echocardiography, Urine analysis , blood culture|All patients will be investigated by ECG, Urine analysis, blood culture , Echocardiography
223817549|NCT03056625|OTHER|Vitamin A fortified rice|Lactating women will receive fortified rice one meal per day on weekdays for a period of 14 weeks.
223817550|NCT03056625|OTHER|Normal rice|Lactating women will receive normal rice one meal per day on weekdays for a period of 14 weeks.
223817551|NCT01003925|BEHAVIORAL|Standard of care for osteoarthritis treatment|Standard of care educational materials to inform patients about choices for knee pain.
223817552|NCT01003925|BEHAVIORAL|Conjoint Analysis for Osteoarthritis|Conjoint Analysis computer software to inform patients about choices for knee pain.
223817553|NCT02092558|DRUG|Second-generation cephalosporin, nitrofurantoin, 1% aminoglycoside solution|
223817554|NCT02092558|DRUG|cephalosporin with chemotherapeutics|Second-generation cephalosporin was prescribed for 10 days, and then treatment crossover with chemotherapeutics in therapeutic dose (change in every week) during 3 months
223817555|NCT01909414|BIOLOGICAL|GEO-D03 DNA Vaccine|DNA GEO-D03 vaccine will be administered as a 3 mg dose IM.
223817556|NCT01909414|BIOLOGICAL|MVA/HIV62B Vaccine|MVA/HIV62B vaccine will be administered as a 1 x 10\^8 TCID50 dose IM.
223817557|NCT01909414|BIOLOGICAL|Placebo for DNA GEO-D03|Placebo for DNA GEO-D03 (administered as 0.9 percent Sodium Chloride for Injection) will be administered IM.
223817558|NCT01909414|BIOLOGICAL|Placebo for MVA/HIV62B Vaccine|Placebo for MVA/HIV62B 1 x 10\^8 TCID50 (administered as 0.9 percent Sodium Chloride for Injection) will be administered IM.
223817559|NCT01199926|DIETARY_SUPPLEMENT|Vitamin D|4000 IU of vitamin D per day for 12 weeks.
223817560|NCT01199926|DRUG|Placebo|Placebo (microcrystalline cellulose) ingestion each day for 12 weeks.
223817561|NCT00717821|DRUG|Methoxy Polyethylene Glycol-epoetin Beta|Participants who are receiving SC or IV epoetin beta or darbepoetin alfa will receive monthly injections of methoxy polyethylene glycol-epoetin beta, with the starting dose of 120 or 200 micrograms calculated from the last weekly dose of epoetin beta or darbepoetin alfa previously administered, using the same route of administration (SC or IV). Thereafter, when the hemoglobin concentration will increase or decrease in a clinically significant amount, a dose adjustment will be performed according to specific provided guidance. Total duration of treatment will be up to 48 weeks.
223817562|NCT00717821|DRUG|Epoetin Beta|Participants who are receiving SC or IV epoetin beta will continue to receive the treatment at the same dose, same administration intervals, and the same route of administration. When necessary, dose adjustments will be performed according to SmPC. Total duration of treatment will be up to 48 weeks.
223817563|NCT00717821|DRUG|Darbepoetin Alfa|Participants who are receiving SC or IV darbepoetin alfa will continue to receive the treatment at the same dose, same administration intervals, and the same route of administration. When necessary, dose adjustments will be performed according to SmPC. Total duration of treatment will be up to 48 weeks.
223817564|NCT01960530|DRUG|Hydrocortisone granules|Multi-particulate granules
223817565|NCT01960530|DRUG|Hydrocortisone Tablet|Standard hydrocortisone tablets
223817566|NCT01960530|DRUG|i.v. Hydrocortisone Injection|Standard hydrocortisone solution for intravenous injection
223817567|NCT01960530|OTHER|Dexamethasone|Challenge agent
223817568|NCT03899168|OTHER|Social Tag Popularity|The relative size of treatment tags in a tag cloud was either larger for antidepressant treatments or psychotherapy treatments.
223817569|NCT03899168|OTHER|Confidence in Prior Attitudes|Participants thought back of situations in which they were either confident or doubtful about their own knowledge. This should elicit a mindset where participants are more or less confident about their own prior attitudes.
223817570|NCT03899168|OTHER|Source Credibility|The source credibility of the community that allegedly collected and labelled the blog posts was either high or low in terms of expertise. Either experts (high credibility) or first semester students (low credibility) did allegedly collect blog posts. This was indicated by banners on top of the navigation platform in the internet browser.
223817571|NCT05461261|DRUG|Docetaxel|Docetaxel will be given intravenously 75 mg/m2 every 3 weeks for 6 cycles.
223817572|NCT05461261|DRUG|Prednisolone Acetate|5mg Prednisolone Acetate will be given orally twice a day during treatment.
223817573|NCT05461261|DRUG|Platinum-based drugs|Platinum-based drugs will be given intravenously 70 mg/m2 every 3 weeks for 6 cycles. Cisplatin or carboplatin will be carefully chosen according to each patient's Creatinine Clearance.
223817574|NCT02676596|DRUG|K-312 10 mg QD|
223817575|NCT02676596|DRUG|K-312 25 mg QD|
223817576|NCT02676596|DRUG|K-312 50 mg QD|
223817577|NCT02676596|DRUG|K-312 100 mg QD|
223817578|NCT02676596|DRUG|K-312 200 mg QD|
223817579|NCT02676596|DRUG|K-312 400 mg QD|
223817580|NCT02676596|OTHER|Placebo|
223817581|NCT01301274|DRUG|hypotonic|0.45% NaCl/5% dextrose IV maintenance fluids
223817582|NCT01301274|DRUG|isotonic|0.9% NaCl/5% dextrose IV maintenance fluids
223817583|NCT02890537|DRUG|Core decompression/PREOB® implantation|All subjects received a core decompression under general anesthesia combined with the implantation of PREOB® into the necrotic lesion (single administration).
223817584|NCT02890537|DRUG|Core decompression/BMC implantation|All subjects received a core decompression under general anesthesia combined with the implantation of BMC into the necrotic lesion (single administration).
223817585|NCT00661661|DRUG|CP-690,550|5 mg BID up to 10 mg BID until launch
223817586|NCT01925027|DEVICE|Nano+ DES|All patients will be treated with the NanoTM Polymer-free Sirolimus Coronary Stent System. All patients will undergo angiographic (QCA) investigation at baseline (pre- and post-procedure) and at 3 months follow-up. All patients will undergo OCT investigation at 3 months follow-up. All patients will be evaluated clinically at 3, 4, 5 months (for patients with 6 months OCT follow-up evaluation will be at 8 months) and at 1 and 2 years.
223817587|NCT04365517|DRUG|Sitagliptin|We propose a randomized controlled open label intervention study. Patients with type 2 diabetes admitted to COVID-19 and randomized to the study group will be treated with sitagliptin at an adjusted dosage for estimated glomerular filtrate: 100 mg once daily (estimated glomerular filtration rate less than or equal to 45 mL / min / 1.73 m2 ) or 50 mg (estimated glomerular filtration rate 30-45 mL / min / 1.73 m2) in combination or not with insulin. Patients with stage IV and V renal failure (estimated glomerular filtration rate less than or equal to 30 mL / min / 1.73 m2) will be excluded
223817588|NCT04836117|OTHER|SomaSignal Test Results|SomaLogic, Inc. translates patterns from 5000 protein measurements made in thousands of participants in clinical trials into validated models (SomaSignal Tests) that predict important health outcomes or correlate with established health measures. SomaLogic, Inc. has developed these protein-based tests for the detection, subtyping and prognosis of heart disease and related medical, physiological and behavioral conditions. These tests are demonstrated in large retrospective studies to provide information superior to best available alternatives.
223817589|NCT03489096|DEVICE|Cryoballoon Ablation: PVI + substrate modification|Standard pulmonary vein isolation using cryoballoon ablation, followed by left atrial fibrosis substrate modification using cryoballoon ablation
223817590|NCT03916601|DRUG|SAR341402|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
223817591|NCT03916601|DRUG|Insulin Aspart|"Pharmaceutical form: suspension for injection~Route of administration: subcutaneous"
223817592|NCT03916601|DRUG|Insulin Aspart|"Pharmaceutical form: suspension for injection~Route of administration: subcutaneous"
223817593|NCT03916601|DRUG|SAR341402|"Pharmaceutical form: suspension for injection~Route of administration: subcutaneous"
223817594|NCT00656318|OTHER|oral contraceptive pill (OCP; OCPs)|Daily administration of oral contraceptive pill for up to 3 months (2 months of daily administration required for the study).
223817595|NCT03288090|OTHER|FSS: Fatigue Severity Scale|Fatigue scale with 9 items rated from 1 to 7, assessing physical fatigue, fatigue in the psychosocial environment and fatigue in general (3 items in each category).
223817596|NCT03288090|OTHER|Neuropsychological evaluation battery|A standardized French neuropsychological battery for the cognitive evaluation of stroke patients.
223817597|NCT03288090|OTHER|Other functional scores|Rankin Score, Instrumental Activities of Daily Living (IADL) Score, Rivermead Mobility Index (RMI) scale, Hospital Anxiety Depression scale (HAD) scale for depression / anxiety, Stroke Specific Quality of Life scale for quality of life, Quality Index of Pittsburgh Sleep (PSQI), Vertical Analog Visual Scale for Pain and Vertical Digital Visual Scale
223817598|NCT04064242|DRUG|CMK389|single i.v. dose every 4 weeks
223817599|NCT04064242|DRUG|Placebo|single i.v. dose every 4 weeks
223817600|NCT05765279|DRUG|HH-120 nasal spray 1|HH-120 nasal spray 5 times daily for 3 consecutive days
223817601|NCT05765279|DRUG|HH-120 nasal spray 2|HH-120 nasal spray 8 times daily for 3 consecutive days
223817602|NCT05765279|DRUG|Placebo Comparator 1|Placebo nasal spray 5 times daily for 3 consecutive days
223817603|NCT05765279|DRUG|Placebo Comparator 2|Placebo nasal spray 8 times daily for 3 consecutive days
223817604|NCT02970253|PROCEDURE|Capsular resection|Capsular resection
223817605|NCT02970253|PROCEDURE|Capsular retention|Capsular retention
223817606|NCT03324399|DIETARY_SUPPLEMENT|probiotic|a proprietary probiotic formulation
223817607|NCT04154865|OTHER|Hypercapnia|Eligible subjects will undergo transcranial Doppler assessment before and after hypercapnia exposure.
223817608|NCT04154865|DEVICE|Transcranial Doppler|A transcranial Doppler ultrasound probe will be used to assess middle cerebral artery velocity to quantify cerebral blood flow at various time points throughout the study visit.
223817609|NCT04154865|DEVICE|Cycle ergometer|A cycle ergometer will be used to acutely increase cerebral blood flow.
223817610|NCT04154865|OTHER|Cognitive Tests|A battery of cognitive tests will be completed by the subject.
223817611|NCT03020875|DRUG|Ofirmev|Intravenously administered acetaminophen.
223817612|NCT03020875|DRUG|Per Os Acetaminophen|Orally administered acetaminophen.
223817613|NCT06203886|DEVICE|LumbaCure|LumbaCure® is a device developed to induce specific mobilization of the lower back in patients requiring physical rehabilitation for orthopaedic disorders, particularly chronic low back pain.
223817614|NCT06410495|BEHAVIORAL|NiteCAPP SINCC|Standard CBT-I techniques along with modules targeting noncompliance in children with ODD and their parents.
223817615|NCT06581809|OTHER|Algosteril|hemostatic dressing
223817616|NCT06581809|OTHER|Other Dressings: interface, hydrocellular, hydrofiber|Non-haemostatic dressing
223817617|NCT05726058|DEVICE|XyCAM with oxygen|After the standard imaging protocols, participants will be asked to inhale 100% oxygen through a mask and will be re-imaged using the XyCAM RI or XyCAM FC.
223817618|NCT04332042|DRUG|Tofacitinib|Tofacitinib 10mg twice a day will be administered within 24h from hospital admission for 14 days
223817619|NCT02635269|OTHER|Sugar|10 minutes before exercising, the subjects are given a bolus of glucose solution 0.2 g/kg in a cubital vein catheter and a constant infusion of 10% glucose solution is started (100ml/h). The infusion continues throughout the exercise period.
223817620|NCT00609427|BEHAVIORAL|MEMO programme (Inst Universitaire de Geriatrie, Montreal)|8 weekly group training sessions in mnemonic strategies, administered by clinical psychologist.
223817621|NCT00609427|BEHAVIORAL|External memory aids training|8 weekly group sessions of training in the use of external memory aids, administered by clinical psychologist
223817622|NCT04512066|DRUG|RO6889450|Participants will receive oral RO6889450 QD.
223817623|NCT04512066|DRUG|Placebo|Participants will receive oral placebo QD.
223817624|NCT04512066|DRUG|Risperidone|Participants will receive oral risperidone QD.
223817625|NCT00871052|DRUG|Calcipotriol-containing cream|Topical treatment twice a day for 7 days
223817626|NCT04989127|DIAGNOSTIC_TEST|Diagnosis|All of the patients withstand a radiological examination, including panoramic radiography, and all were handled by the same surgeon and assistant.
223817627|NCT04989127|PROCEDURE|traditional osteotomies|In all groups the flap incision was triangular in shape which avoids muscle involvement (Archer flap).
223817628|NCT04989127|BIOLOGICAL|Platelet Rich Fibrin|Platelet rich fibrin (PRF), is an example and popular procedure for accelerate healing of soft and hard tissue because of the presence of various growth factors.a blood sample was taken without anticoagulant in 10 mL glass-coated plastic tubes that were immediately centrifuged (Elektro-mag M415P) at 3,000 rpm for 10 min (approximately 400 g) (13). The platelet-poor plasma that accumulated at the top of the tubes was discarded.PRF was dissected approximately 2 mm below its contact point with the red corpuscles situated beneath, to include any remaining platelets that may have localized below the junction between the PRF and red corpuscles.
223817629|NCT04989127|DRUG|Antibiotics, Penicillin|Antibiotics are prescribed for the patients.
223817630|NCT04989127|DRUG|Analgesic|Analgesics are prescribed for the patients.
223817631|NCT04989127|DRUG|Antibiotic|Patients with penicillin allergy
223817632|NCT03520400|BEHAVIORAL|Exercise Therapy|Patients will adhere to one year of exercise therapy for the investigators' study. At minimum, subjects will aim to participate in approximately 30-60 minutes of aerobic exercise 5-7 days per week and 15-30 minutes of resistance/anaerobic exercise 2-3 times per week.
223817633|NCT00445679|DRUG|DVS SR|Arm 1: 50mg DVS SR tablet, QD, 8 weeks treatment with 2 week taper Arm 2: 100mg DVS SR tablet, QD, 8 weeks treatment with 2 week taper Arm 3: 200mg DVS SR tablet, QD, 8 weeks treatment with 2 week taper
223817634|NCT00445679|DRUG|Paroxetine|20 mg Paroxetine capsule, QD, 8 weeks treatment with 2 week taper
223817635|NCT00859651|DRUG|Cholecalciferol|"Cholecalciferol is a vitamin D3. Vitamin D is important for the absorption of calcium from the stomach and for the functioning of calcium in the body. Cholecalciferol is used to treat or prevent many conditions caused by a lack of vitamin D.~Cholecalciferol will be available in gel capsule form at 10,000 IU (0.25 mg cholecalciferol) each."
223817636|NCT00859651|DRUG|Placebo capsule|Matching placebo capsules
223817637|NCT06509451|DRUG|Giomer pit and fissure sealant without etching|S-PRG filler containig pit and fissure sealant without etching step
223817638|NCT06509451|DRUG|Giomer pit and fissure sealant with etching|S-PRG filler containig pit and fissure sealant with etching step
223817639|NCT05199623|DRUG|tailored Guizhi decoction|Tailored guizhi decoction powder is a compound Chinese herbal medicine which contains 7.0g of guizhi, 1.5g of chuanxiong, 1.5g of zhimu, 1.5g of xinyi, 0.3g of mahuang, 1.0g of baizh, 2.0g of jili, 1.5g of fuling, and 1.0g of danshen.
223817640|NCT05199623|BEHAVIORAL|Olfactory training (OT)|Four odorant bottles of PEA, lemon, eucalyptus, and clove oils were given. Patients were instructed to sniff the liquid in each bottle for 10 seconds, twice a day.
223817641|NCT02837354|OTHER|No intervention|
223817642|NCT04366726|COMBINATION_PRODUCT|abaloparatide-sMTS|Abaloparatide-sMTS is a drug-device combination product consisting of the drug abaloparatide coated onto an sMTS array for transdermal administration of abaloparatide.
223817643|NCT03857230|DRUG|Follitropin alfa (Primapur)|"During the crossover pharmacokinetic phase, after 42 days of combined oral contraceptive (ethinylestradiol and drospirenone) administration subjects with endogenous level of follicle stimulating hormone (FSH) less than 5 IU/l were randomly assigned to receive one of the following treatment sequences:~Sequence A: Single subcutaneous injection of 300 IU Primapur on study day 1, after 10 days of wash out a single subcutaneous injection of 300 IU Gonal-F.~Sequence B: Single subcutaneous injection of 300 IU US Gonal-F on study day 1, after 10 days of wash out a single subcutaneous injection of 300 IU Primapur."
223817644|NCT03857230|DRUG|Follitropin alfa (Gonal-F)|"During the crossover pharmacokinetic phase, after 42 days of combined oral contraceptive (ethinylestradiol and drospirenone) administration subjects with endogenous level of follicle stimulating hormone (FSH) less than 5 IU/l were randomly assigned to receive one of the following treatment sequences:~Sequence A: Single subcutaneous injection of 300 IU Primapur on study day 1, after 10 days of wash out a single subcutaneous injection of 300 IU Gonal-F.~Sequence B: Single subcutaneous injection of 300 IU US Gonal-F on study day 1, after 10 days of wash out a single subcutaneous injection of 300 IU Primapur."
223817645|NCT01654601|DRUG|DWCZP|Multiple dose
223817646|NCT01654601|DRUG|Clozaril|multiple-dose
223817647|NCT03988075|OTHER|Acetaminophen and hydrocodone based pain control|Patients receive acetaminophen 650mg every 4 for pain level 1-3, hydrocodone/acetaminophen 5/325mg every 4 for pain level 4-6, or hydrocodone/acetaminophen 10/650mg every 4 for pain level 7-10 on as needed basis.
223817648|NCT03988075|OTHER|Acetaminophen and ibuprofen based pain control|Patients receive standing dose of acetaminophen 650mg every 8 hours and ibuprofen 800mg every 8 hours with alternating ibuprofen and acetaminophen every 4 hours.
223817649|NCT01988272|DEVICE|SPECT/CT imaging|Patients will undergo scanning on the above system.
223817650|NCT06139068|OTHER|Narrative Group Counseling|Two of the principles that explain how narrative therapy works are: to always maintain a stance of curiosity on the part of the practitioner and to ask questions to which the practitioner does not actually know the answers and to which the answer is known to the participants. To guide therapeutic conversations that include these questions, Michael White and David Epston have designed a series of conversation maps in the application of narrative therapy. Taking these maps into consideration, the sessions were planned with the guidance of relevant literature and structured with expert opinions. Group counseling was applied to the intervention group once a week in 8 sessions. The intervention was completed face to face, in a calm, quiet and bright environment, with a round seating plan. One session lasted 90 minutes. Each session was completed in two parts with a 10-minute break.
223817651|NCT06139068|OTHER|stress coping interviews|In addition to the students' routine practices, four sessions of stress coping interviews will be held for the control group, with an interval of two weeks, after the information meeting.
223817652|NCT03007654|DEVICE|Mediclore|apply medical device fully around intrauterine surgery area
223817653|NCT03007654|DEVICE|Adept|apply medical device fully around intrauterine surgery area
223817654|NCT04834817|DEVICE|Celluma POD|A blue and near infrared handheld LED device
223817655|NCT04451408|DRUG|LY3372993|Administered IV or SC.
223817656|NCT04451408|DRUG|Placebo|Administered IV or SC.
223817657|NCT04248647|BEHAVIORAL|Multimodal prehabilitation|"This arm will receive a 4-week prehabilitation program consisting of:~Exercise: Participants will receive a 3x/week aerobic and strength training exercise program. They will perform 2 workouts per week at home and attend an in-hospital supervised exercise session once per week.~Nutritional counselling: Participants will meet with a registered dietician who will provide personalized nutritional recommendations and a whey protein supplement, tailored according to participants' self-reported dietary intake and anthropometric measurements.~Psychological support: Participants will receive a 90-minute session at baseline, and weekly in-hospital follow-ups throughout the preoperative period. The sessions will aim to reduce preoperative distress and improve adherence to the exercise program and nutritional recommendations. Psychological support will be delivered by a trained master's student, under the direct supervision of a registered Clinical Psychologist."
223817658|NCT01888211|DIETARY_SUPPLEMENT|Omega 3 fatty acid supplementation|2 grams Omacor daily
223817659|NCT01888211|DIETARY_SUPPLEMENT|Olive Oil|2 grams olive oil daily
223817660|NCT04180644|OTHER|Skin tape strips|Skin tape strips will be collected from lesional and non-lesional skin. Adhesive skin sampling discs will be firmly pressed against the skin in a hairless location (not the face) followed by lifting it free of the skin. These discs will then be used to evaluate proteins and lipids in the upper layers of skin.
223817661|NCT00212498|PROCEDURE|Develop a bank of blood samples from patients infected with TB for future molecular genetics studies and serological studies|Blood sample
223817662|NCT06104280|OTHER|Post-Illumination Pupillary Response (PIPR)|The PIPR is measured in six, 80-s test periods in which the stimulus, either Blue (470 nm) or Red (623 nm), is presented to the dilated eye while the pupil response of the un-dilated eye is measured (consensual pupil response
223817663|NCT06104280|OTHER|Polysomnography|Measure electroencephalography (EEG), electrooculography (EOG), electromyography (EMG), electrocardiography (ECG), respiratory channels (effort and nasal pressure), and oxygen saturation.
223817664|NCT06104280|OTHER|Multiple Sleep Latency Test|Assist in the diagnosis of disorders of hypersomnolence,63 it is also used in research to quantify daytime sleepiness and serves as a more objective measure of daytime sleepiness than self-report questionnaires
223817665|NCT06104280|BEHAVIORAL|Ecological Momentary Assessments|Morning after overnight Visit 2, participants will complete ecological momentary assessments (EMAs) over a 10-day assessment period. Using EMA through the InsightTM mHealth platform to capture momentary craving, withdrawal and mood states across 10 days among persons who smoke and nonsmokers prior to an overnight procedures. Participants will complete morning and evening sleep diaries via the EMA InsightTM mHealth platform self-reported sleep and wake information, fatigue, naps, opioid craving and withdrawal.
223817666|NCT06104280|DEVICE|Actigraphy|7-day actigraphy period will be used to determine the habitual sleep start and wake times. The CamNTech MotionWatch8 (Cambridge, UK) is a solid-state piezo-electric accelerometer that collects data on activity (i.e., arm motion) and ambient light.Actigraphy data are downloaded from the MotionWatch8 into the software (MotionWare) for analysis, management, and exportation. Bed and wake times will be entered by the subjects via a REDCap link and this information coupled with the sleep diary reports will be entered to determine sleep intervals. Algorithms in the Motion Watch 8 software will determine sleep start, sleep end, total sleep time (duration), sleep quality, sleep efficiency, wake after sleep onset, and sleep fragmentation
223817667|NCT06104280|OTHER|DLMO|Participants will be given an evening meal and then be accompanied to the UAB Highlands Hospital Sleep Unit by 5:30pm. The sleep unit allows for strict control of light exposure (\< 5 lux at eye level), room temperature and oral intake factors that could alter melatonin levels.Participants will be allowed to sleep in darkness until 8:00am, at which time they will be provided transportation.We will also bank frozen samples taken prior to the light exposure for later calculation of the Dim Light Melatonin Onset (DLMO), a circadian phase estimate.
223817668|NCT06104280|OTHER|Melatonin Suppression Test|The sleep unit allows for strict control of light exposure (\< 5 lux at eye level), room temperature and oral intake factors that could alter melatonin levels. Participants will be asked to refrain from caffeine consumption 12 hours before reporting to the sleep unit and will provide 2-3 ml of saliva every 30 minutes starting at 6:00pm and ending after the light exposure. For melatonin suppression, 2-hours light exposure will begin 2 hours before the calculated mid-sleep time. Collection saliva samples 1-h, 30-min, and immediately before the light exposure and every 30 min throughout exposure. Samples will be centrifuged and frozen/stored at -20ºC until assay and remaining samples stored at -80ºC. Melatonin levels will be assayed via the Buhlmann Direct Saliva Melatonin. Melatonin suppression will be calculated as the percent decrease from the sample taken immediately prior to the light exposure
223817669|NCT03790670|DRUG|sargramostim|Recombinant human GM-CSF produced by recombinant DNA technology using a yeast (S. cerevisiae) expression system
223817670|NCT06859879|DIETARY_SUPPLEMENT|Dietary Supplement: low-dose Rosemary and Daylily extract|Supplement containing Rosemary and Daylily extract
223817671|NCT06859879|DIETARY_SUPPLEMENT|Dietary Supplement: medium-dose Rosemary and Daylily extract|Supplement containing Rosemary and Daylily extract
223817672|NCT06859879|DIETARY_SUPPLEMENT|Dietary Supplement: control|Supplement containing placebo
223817673|NCT06384339|DIAGNOSTIC_TEST|CSIV, Social motive|The CSIV is a self-report measure and assesses interpersonal values using eight octant scales, which are aggregated into overall communion and agency scores, ranging from -4 to +4 .
223817674|NCT06384339|DIAGNOSTIC_TEST|Interpersonal messages and behavior|"The Impact Message Inventory - Circumplex (IMI-C) Brief Version is a self-report transactional inventory designed to measure a target person's interpersonal behavior on four octant scales dominance, hostility, submissiveness, and friendliness by assessing the covert responses or impact messages of another person. Each subscale consists of 7 items, with each item scored on a 4-point Likert scale from 1 (not at all) to 4 (very much so). The minimum score per scale is 7 and the maximum score is 28."
223817675|NCT06384339|DIAGNOSTIC_TEST|CCS, Social motive|The CCS is a elf-report inventory, that measures tendencies towards competitiveness versus caring in social interactions. The minimum score for the two subscales competitiveness and caring are 9 and the maximum score is 90.
223817676|NCT06130176|PROCEDURE|Single-step Functional Sinus Endoscopy and Transoral Surgery|In each patient, the operation will be carried out by an otorhinolaryngologist and a maxillofacial surgeon. The procedures of the functional sinus endoscopy (FSE) will performed as follow: Under general anesthesia, the origin of the turbinate, and the lateral nasal wall will be conducted. The following stage will be infundibulotomy, which ensures that the uncinate process will be completely removed. The ostium will be dilated with a Stammberger dilatator starting with a 0-degree endoscope then shift to a 30- or 45-degree endoscope to clean the sinus. The cavity will be irrigated after removal of the odontogenic diseases and the purulent discharge will suctioned.In addition to FSE, the maxillofacial surgeon will conduct the necessary oral surgery procedures.The needed transoral procedures will be tooth extraction, oro-antral fistula closure or cystectomy.
223817677|NCT06130176|PROCEDURE|Functional sinus endoscopy|All patients in this group will only be treated with FSE, which will be conducted by an otolaryngologist. The FSE procedures will be carried out in the same way as the group of Single-step Functional Sinus Endoscopy and Transoral Surgery.
223817678|NCT06130176|PROCEDURE|Trans oral Surgery|Every patient in this group will only be treated with transoral surgical procedures to remove dental pathology. Oral and maxillofacial surgeons will undertake these treatments. The procedure will be either tooth extraction, oro-antral fistula closure, or cystectomy. If extraction is not needed, endodontic treatment will be performed to remove necrotic pulp. The oro-antral fistula will be closed in two layers using a buccal advanced flap and a palatal rotational flap. In the case of odontogenic cysts, the lesion will be removed by raising a trapezoidal flap.
223817679|NCT06361472|OTHER|Standard Care|Standard Care includes exercises, mobilization, manual therapy, education, and Neck Wellness Home Care Guide (NWHCG). The rehabilitation program is based on current clinical practice guidelines aimed at reducing neck pain, improving range of motion, enhancing functionality, and promoting physical activity motivation. Each patient will receive active exercises and manual therapy techniques. Educational components will cover pain science, physical activity benefits, and return to normal activities , supplemented by a NWHCG. Treatment sessions will be conducted, featuring a one-to-one interaction between the participant and the physiotherapist. It will last 4 weeks, with two sessions per week, 45 minutes/session (8 treatment sessions).
223817680|NCT06361472|BEHAVIORAL|Contextual Factors|Bundle of contextual factors divided into three categories: professional, treatment, and healthcare setting features. Regarding the professional contextual factors, they include reputation, appearance, and positive attitudes. The treatment contextual factors encompass positive attitudes, verbal communication, non-verbal communication, empathetic therapeutic alliance, therapeutic touch, and the use of a mirror to show the patient what is being performed. Finally, the healthcare setting contextual factors feature a comfortable setting, adequate environmental conditions, and appropriate design.
223817681|NCT03535337|BEHAVIORAL|CPS|Assessment of participant's medication adherence and barrier problem solving via phone conversation
223817682|NCT03535337|BEHAVIORAL|SMS|Participants will receive a text message, which will be an electronic reminder regarding medication adherence. Participants will then text back a confirmatory response.
223817683|NCT01511822|DRUG|Drospirenone Ethinyl estradiol|Drospirenone 3mg/die Ethinyl estradiol 30 mg/die (21 days/month for 6 months)
223817684|NCT01511822|DRUG|Drospirenone Ethinyl estradiol Myo-inositol|Drospirenone 3mg/die Ethinyl estradiol 30 mg/die (21 days/months for 6 months) + Myo-inositol 6g /die for 6 months
223817685|NCT01511822|DRUG|placebo|
223817686|NCT02427711|DEVICE|Bipolar sealer|Prospective trial with Aquamantys for surgical skin and capsula incision w a retrospective control group using a conventional scalpel skin and capsula incision.
223817687|NCT06614049|BEHAVIORAL|Human Coach-supported Digital/AI Personal Health Assistant to Improve Adherence to Lipid-Lowering Medications|Receive personalised feedback and educational content curated by local clinicians and pharmacists through the CADENCE D-PHA app coupled with six sessions of human coaching on top of usual clinical care for lipid management over 6 months
223817688|NCT05153395|OTHER|Carbon dioxide breathing|Hypercapnic (5% carbon dioxide) air will be administered before and after intra-nasal insulin exposure.
223817689|NCT05153395|OTHER|Neurovascular Coupling|Participants will be asked to repeatedly open and close their eyes. With eyes open, participants will focus on a visual image. This will be done before and after intra-nasal insulin exposure.
223817690|NCT05153395|DRUG|Human insulin|Participants will be administered human insulin (160 IU) as a bolus using an intra-nasal device.
223817691|NCT04754607|OTHER|Low Level Laser Therapy|Eight target points (superior, mediolateral, inferior border of the right and left thyroid lobes, right and left sides of the isthmus) will be marked with a surgical pen by determining the thyroid borders on the skin by thyroid ultrasonography by the specialist physician. Low-level laser (28.57 J / cm2) fixed applications will be made on the thyroid gland, approximately 1 cm from each other. In practice, the patient's neck will be maintained in the extension position. Each application will last 20 seconds and the radiant energy will be 2 J, the tip of the laser will be kept in contact with the skin and upright. Duration of treatment is 6 sessions 2 days a week. The cumulative dose will be 96 J.
223817692|NCT04754607|OTHER|Sham|Probes were placed in the sham laser group in a similar way as in the treatment group. The screen of the laser device was active; however, the energy was set as 0 J and the power as 0 mW , respectively,and the same operations were also performed.
223817693|NCT05968976|PROCEDURE|Awake DBS|55 patients receive awake DBS (current standard procedure)
223817694|NCT05968976|PROCEDURE|Asleep DBS|55 patients receive asleep DBS
223817695|NCT06626373|OTHER|Elderberry Juice|Participants will consume elderberry juice 1-week.
223817696|NCT06626373|OTHER|Placebo Beverage|Participants will consume placebo beverage twice/day for 1-week.
223817697|NCT06624774|OTHER|Prehabilitation|The structured exercise sessions will be conducted in a homebased setting, consisting of 8 resistance exercises (RE). The 8 RE's will include 4 upper body and 4 lower body exercises (Sit to stand, chest press, heel raises, bicep curls, leg abduction, tricep kickbacks, lunges, mid row). This is adapted from an existing home-based trial in cardiac patients. In addition, the structured exercise programme will include a walking programme. Participants will receive a Fitbit charge 5 activity monitor. Additionally, participants will conduct daily IMT via a Powerbreathe medic plus device. Participants will conduct 6 sets of 6 breaths at 50% of peak inspiratory pressure that has been measured at baseline. Education will be delivered via pre-recorded videos or in person
223817698|NCT06625424|OTHER|Short Sprint Interval Training with passive recovery|"Participants will perform short sprint interval training on a flat running track in field. Each lane will be materialized by placing cones 5 m from each other for a total of 30 m on which Subject will perform Short Sprint Interval Training.~The instructions will be to travel the greatest distance possible in 10 seconds, making trips of 5, 10, 15 m, etc. Participants will opt for 1 minute of active recovery i.e. they will perform brisk walk between 6 bouts of 10 sec sprint.~The duration of the training will be of 2 weeks."
223817699|NCT06625424|OTHER|Short Sprint Interval Training with Active Recovery|"Participants will perform short sprint interval training on a flat running track in field. Each lane will be materialized by placing cones 5 m from each other for a total of 30 m on which the Subjects will perform Short Sprint Interval Training.~The instructions will be to travel the greatest distance possible in 10 seconds, making trips of 5, 10, 15 m, etc.~Participants will opt for 1 minute of active recovery i.e. they will perform brisk walk between 6 bouts of 10 sec sprint.~The duration of the training will be of 2 weeks."
223817700|NCT06624891|OTHER|perioperative fluid responsiveness with the Pleth variability index|Perioperative fluid challenge and responsiveness will be based on monitoring the pleth variability index. In fact, volemia will be estimated with the PVI.
223817701|NCT06624891|OTHER|perioperative fluid responsiveness with delta PP|fluid challenge and responsiveness during intervention will be based on monitoring delta PP.
223817702|NCT06624761|DEVICE|ShotBlocker|A randomized study investigating ShotBlocker in painkillers containing different active ingredients could not be found.
223817703|NCT02272725|DRUG|Ibuprofen|Ibuprofen
223817704|NCT02272725|DRUG|Placebo|Tasteless and inert visually identical (to ibuprofen) pills
223817705|NCT05352802|BEHAVIORAL|Multimodal prehabilitation program|Multimodal prehabilitation programs have adopted planned, structural, repetitive and purposeful approach that includes elements of exercise, nutritional and psychological.
223817706|NCT05352802|BEHAVIORAL|ERAS protocol|The core content is to adopt a series of optimized measures performed during the perioperative period on the basis of evidence-based medical findings to reduce the physiological and psychological stress of patients and to accelerate their recovery.
223817707|NCT01817192|DRUG|Adjuvant Chemotherapy|Patients who have undergone complete resection of NSCLC that has been documented histologically to be non-squamous and that is pathological Stage I or IIA, will undergo testing with the 14-Gene Prognostic Assay. Patients determined to be intermediate or high risk and who meet all eligibility criteria will be randomized either to observation or to four cycles of adjuvant therapy with a standard NSCLC platinum-based doublet.
223817708|NCT01817192|OTHER|Radiographic surveillance|Serial radiographic surveillance is a current standard of care for Stage I or Stage IIA lung cancer. All intermediate or high risk patients randomized to observation or chemotherapy will have routine CT Scans at 6 month intervals until 5 years after enrollment and at yearly intervals thereafter until the end of the study period.
223817709|NCT01817192|OTHER|14-Gene Prognostic Assay|This CLIA-approved assay is a standard tool that is now available to all clinicians to improve the prognostic evaluation of patients after resection of Stage I or Stage IIA non-squamous NSCLC. It will be performed on tumor specimens for patients who are potentially eligible for this study. Patients identified through the assay as intermediate or high-risk will be randomized to either adjuvant chemotherapy or observation.
223817710|NCT06913127|OTHER|High intensity exercise post stroke|The patients are all admitted with an acute/ subacute stroke in an inpatient rehabilitation ward. They are randomized into a high intensity exercise or a low intensity exercise group that will last for 20 consecutive sessions. At the end of the experimental period, outcomes including functional outcomes, questionnaires, physical activity and fNIRS (functional near infrared spectroscopy) measurements will be compared between the two groups.
223817711|NCT06918379|DEVICE|Cogmed Working Memory Training (CWMT)|"This is an intensive, eye-tracking working memory (WM) training in school-aged children and young adults with severe cerebral palsy. The Cogmed Working Memory Training (CWMT) software was used as intervention software. The CWMT is adaptive, meaning, it becomes either progressively more difficult or less difficult depending on participants' performance. When a participant completes a trial correctly, the level will increase for the next trial. When a participant makes an error, the next trial will either remain on the same level or decrease in level depending on the type of error made. The CWMT program thus adapts on an individualized basis to participant's performance, allowing for training to occur at or close to an individual's highest capacity.~Participants with severe cerebral palsy, users of eye-tracking technology, trained for \~30 minutes, 5 days a week for 5 weeks, i.e. 25 training sessions in total."
223817712|NCT06925594|OTHER|Human TH-SC01 cell injection|Human TH-SC01 cell injection is a cell suspension in aseptic buffered solution containing human expanded umbilical cord-derived stem cells of allogeneic origin in disposable vials with no preservative agents. The cells will be given at a dose of 120 million cells (5 million cells / mL) for intralesional injection.
223817713|NCT06925594|OTHER|Saline solution|Placebo (saline solution) will be given also for intralesional injection at the same quantity (volume, 24 mL) and following the same schedule.
223817714|NCT06925035|DEVICE|1927nm fractional thulium fiber laser(TFL)|Prior to each session, Compound Lidocaine Cream (Beijing Ziguang Medication Manufacture Corporation Ltd.) was administered topically to the participants' faces for a duration of 30-40 minutes. Following sterilization with alcohol, the entire facial area was treated with a 1927 nm fractional thulium fiber laser (TFL) (WONTECH, Lavieen, South Korea). TFL parameters included a pulse energy of 8-10 mJ, an output power of 10 W, and a pulse spacing of 0.8 mm, ensuring comprehensive coverage of photodamaged regions.
223817715|NCT06925035|DRUG|supramolecular salicylic acid(SSA)|30% SSA (SSA and placebo are provided by Broda ,Shanghai Rui Zhi Medicine Technology, Shanghai, China.) or placebo(the base material of 30% SSA) were randomly assigned to be applied on one side of the face immediately after completion of the 1927nm TFL treatment. The 30% SSA was maintained on facial skin until reaching the clinical endpoint, manifested as mild erythema and/or a characteristic frost-like epidermal whitening. Additionally, the combination therapy side of the subjects was treated with one session of 30% SSA biweekly and 2% SSA daily over a period of 16 weeks.
223817716|NCT06925971|DEVICE|Experimental Device A, a self-expanding rapamycin target-eluting stent (MicroPort NeuroTech, Shanghai, China)|Experimental Device A, a self-expanding rapamycin target-eluting stent (MicroPort NeuroTech, Shanghai, China)
223817717|NCT06925971|DEVICE|Experimental Device B, a balloon-expandable rapamycin target-eluting stent (MicroPort NeuroTech, Shanghai, China)|Experimental Device B, a balloon-expandable rapamycin target-eluting stent (MicroPort NeuroTech, Shanghai, China)
223817718|NCT06925971|DEVICE|Apollo® Intracranial Artery Stent System, a balloon-expandable bare-metal stent (MicroPort NeuroTech, Shanghai, China),|Apollo® Intracranial Artery Stent System, a balloon-expandable bare-metal stent (MicroPort NeuroTech, Shanghai, China)
223817719|NCT03569839|DRUG|Propofol|Patients undergoing surgery, TIVA (total intravenous anaesthesia)
223817720|NCT00211978|DRUG|calcium acetate|667 mg gelcaps, 1-3 t.i.d. (titrated to serum phosphorus level)
223817721|NCT00211978|DRUG|placebo|gelcap, 1-3 t.i.d. (titrated to serum phosphorus level)
223817722|NCT05059912|BIOLOGICAL|Humanized CD7 CAR-T cells|Patients will receive infusion of CAR T-cells targeting CD7 to confirm the safety and efficacy of CD7 CAR T-Cells in CD7+ relapsed or refractory T cell lymphoma
223817723|NCT06351111|DEVICE|Active VNS|Subjects will receive active VNS paired with either of the three rehabilitation trainings
223817724|NCT02136433|DEVICE|Tablet - self exercise|
223817725|NCT02136433|OTHER|GRASP self exercise|
223817726|NCT01194284|DRUG|Mifamurtide|Mifamurtide will be prescribed to patients with high-grade osteosarcoma as part of their treatment regimen within the context of prevailing standard oncology practice. The recommended dose of mifamurtide is 2 mg/m2. Mifamurtide will be administered for 36 weeks as adjuvant therapy following surgical resection.
223817727|NCT06106815|OTHER|Rehabilitation exercises|The Graded Repetitive Arm Supplementary Program (GRASP) is designed to improve upper extremity function in individuals with stroke. The GRASP program includes exercises for stretching, coordination, arm and hand strengthening, and fine motor skills.
223817728|NCT06106815|OTHER|Usual Care|Usual Care
223817729|NCT02843802|DEVICE|Cryosurgery|Argon-helium cryosurgical system (percutaneous ablation under CT or ultrasound guidance)
223817730|NCT02843802|BIOLOGICAL|NK Immunotherapy|Natural killer cell (each treatment: about 10 billion cells transfusion in 3 times, i.v.)
223817731|NCT03950180|OTHER|Prostate Cancer Comorbidity Index (PCCI) score|Life expectancy information
223817732|NCT00818103|DRUG|atorvastatin|Atorvastatin 40mg p.o. qn for 2 years
223817733|NCT00818103|DRUG|β-interferon|β-interferon 50ug i.m. qod for 2 years
223817734|NCT00818103|DRUG|EPO|EPO 10000U i.h. bid for 5 days
223817735|NCT03279055|BEHAVIORAL|SHUTi|Sleep Healthy Using the Internet (SHUTi) is a publicly available insomnia intervention program. It focuses on 5 treatment components that form the core of CBT-I: sleep restriction, stimulus control, cognitive restructuring, sleep behaviors, and relapse prevention.
223817736|NCT04290065|OTHER|Manual therapy|The patient will be lying supine, relaxed. The physiotherapist, located at the patient's head, will cover the occipital bone with one hand while the palm of the hand will rest on the lambdoid suture, and the fingers will be introduced into the suboccipital space. The other hand, with a glove, will be inserted into the patient's oral cavity, resting respectively the index and middle fingers, each in an upper dental hemiarchy, on the chewing face of the tooth. An axial traction will be carried out until the three tension barriers of equal size between them are overcome, in an estimated time between 1.50 and 3 minutes. All manual therapy sessions will be performed by the same physiotherapist, following the same protocol and under the same conditions.
223817737|NCT00345319|BIOLOGICAL|rabies vaccine|Administration of PCECV according to ESSEN regimen
223817738|NCT03942679|OTHER|PRP|Patients in this group will receive three ultrasound guided PRP injections in the supraspinatus tendon with one week interval (Ilhanli et al., 2015). After the injection, patients will be instructed to limit the use of shoulder for at least 24 hours and to use cold therapy for pain. After the third injection, ROM, and stretching exercises will be allowed and one month after the end of injections, patients will be recommended to begin the strengthening program as tolerated. Exercise is performed with 10 repeats five sessions per week.
223817739|NCT03942679|OTHER|physiotherapy|Patients in this group will be treated with hot pack for 15 minutes, ultrasound in continuous mode (1.5 watt/cm2 for five minutes), trans-cutaneous electrical nerve stimulation in brief-intense mode for 15 minutes, range of motion (ROM), followed by stretching and strengthening exercises with 10 repeats 15 sessions (five sessions per week for three weeks). After the physical therapy, the exercise program will be continued as homework during the follow-up period.
223817740|NCT02392611|DRUG|Alobresib|Tablet administered orally once daily on Study Day 1 through Cycle 1 Day 28 of 28 days cycle
223817741|NCT02392611|DRUG|Exemestane|Tablets administered orally once daily on Cycle 1 Day 1 of 28 days cycle
223817742|NCT02392611|DRUG|Fulvestrant|Administered intramuscularly on Cycle 1 Day 1 of 28 days cycle and every 28 days
223817743|NCT01468779|DIETARY_SUPPLEMENT|Probiotics|The probiotics pills are given orally in the amount of two pills twice a day as early as two days before surgery until ten days after surgery.
223817744|NCT01468779|DIETARY_SUPPLEMENT|Sugar pill|
223817745|NCT03325205|OTHER|Anodal tDCS|Anodal Transcranial direct current stimulation (tDCS) is a non- invasive brain stimulation technique. Low intensity current (1-2 mA) is induced to increase excitability, stimulate plasticity and enhance cognitive functions.
223817746|NCT03325205|OTHER|Sham tDCS|The electrodes are placed over the same areas as in the anodal tDCS condition. Participants will receive sham tDCS instead of anodal tDCS
223817747|NCT05434143|BEHAVIORAL|Chorus Sleep|"During the 6-week intervention, participants will receive daily reminders to complete their daily sleep log and a link to a chorus sleep class for them to listen to that night.~The daily sleep class involve listening to 15 minute audio sessions, which include guided mediation and breathing exercises."
223817748|NCT06331429|BEHAVIORAL|EmoTiCare|"The EMOTICARE technological platform intervenes in users through a serious game, i.e. a video game whose main purpose is to teach or provide the player with certain skills that serve to achieve a higher purpose than the game itself.~The game works in 6 areas, each of which refers to one of the variables that are analysed or considered important in the adaptation to the disease: Area 1. Psychoeducation of DM1; 2. Emotional awareness and expression; 3. Emotional regulation; 4. Problem solving; 5. Self-esteem and identity;6. Social skills and communication"
223817749|NCT04243460|PROCEDURE|Xenogeneic collagen matrix (XCM) graft augmentation|"12 months after gingival augmentation Measurement of marginal bone level and soft tissue thickness were done. STT (soft tissue thickness) was measured using ultrasonography with a Pirop® dental, ultrasound device (Echoson Company, Poland). The patients underwent a clinical and ultrasound examination before, 3 and 12 months after gingival augmentation (GA) respectively to evaluate TKT at two points using ultrasound equipment (Pirop®, Echoson).~Intraoral radiographs were taken using a paralleling technique with a Rinn-type film holder in high resolution mode (Visualixe HD®, Gendex®, USA). Two images of each region were selected to calculate the marginal bone changes:"
223817750|NCT04243460|PROCEDURE|Connective tissue graft augmentation (CTG)|12 months after gingival augmentation Measurement of marginal bone level and soft tissue thickness were done. STT (soft tissue thickness) was measured using ultrasonography with a Pirop® dental, ultrasound device (Echoson Company, Poland). The patients underwent a clinical and ultrasound examination before, 3 and 12 months after gingival augmentation (GA) respectively to evaluate STT (soft tissue thickness) at two points using ultrasound equipment (Pirop®, Echoson).
223817751|NCT01129531|DRUG|AGN-214868|AGN-214868 injected into areas of postherpetic neuralgia pain for total dose per treatment.
223817752|NCT01129531|DRUG|Placebo to AGN-214868|Placebo to AGN-214868 injected into areas of postherpetic neuralgia pain per treatment.
223817753|NCT02030912|DRUG|3 doses of amoxicillin daily for 7 days|
223817754|NCT02030912|DRUG|2 doses of minocycline daily for five days|
223817755|NCT02030912|OTHER|2 doses of placebo daily for five days|
223817756|NCT01713699|PROCEDURE|lumbar puncture|
223817757|NCT03045029|DRUG|Oral treprostinil|Sustained-release oral tablets for TID administration
223817758|NCT05449886|PROCEDURE|TVC|Tidal volume challenge from 6ml/kg to 10ml/kg for 1 min.
223817759|NCT01547520|DRUG|Meperidine|intramuscular, 25 mg, 5 to 10 minutes before EGD
223817760|NCT01547520|DRUG|normal saline|25 ml of normal saline, intramuscular, 5 to 10 minutes before EGD
223817761|NCT00172120|DRUG|ALX1-11|
223817762|NCT00965003|PROCEDURE|MRI scan|Standard of Care
223817763|NCT00939731|DRUG|PF-02341066|A 250-mg single dose of PF-02341066 administered as 1 x 50-mg Powder-in-Capsule and 2 x 100-mg Powder-in-Capsules
223817764|NCT00939731|DRUG|PF-02341066|A 250-mg single dose of PF-02341066 administered as 1 x 50-mg Immediate Release Tablet and 2 x 100-mg Immediate Release Tablets
223817765|NCT00888758|DEVICE|biolimus A9|200 patients with STEMI will be treated using Biomatrix stent.
223817766|NCT00888758|DEVICE|everolimus|200 patients with STEMI will be treated with PROMUS DES.
223817767|NCT04740203|DRUG|CAR-T cells targeting CD19 and CD22|Each subject receives sequential CD19 and CD22 CAR-T cells by intravenous infusion
223817768|NCT00997724|PROCEDURE|a-VATS|In brief, general anesthesia with selective lung ventilation was performed with the use of a double-lumen endotracheal tube. When postoperative mechanical ventilation was necessary, a standard endotracheal tube was substituted for the double-lumen tube. Patients were placed in the lateral decubitus position. Two thoracoports were placed in the sixth or seventh intercostal space (ICS) on the anterior axillary line and in the seventh or eighth ICS on the posterior axillary line; an anterolateral minithoracotomy (7 cm) was made in the fourth ICS for an upper lobectomy or in the fifth ICS for a middle or lower lobectomy.
223817769|NCT05289284|OTHER|No intervention|No intervention
223817770|NCT02185885|PROCEDURE|Increased bloodpressure during CPB.|
223817771|NCT04409548|OTHER|All of the spatial and Temporal Gait parameters|
223817772|NCT02760758|DRUG|CDI-31244|NNI
223817773|NCT02760758|DRUG|Placebo|no active ingredients
223817774|NCT05813626|DRUG|Toripalimab|Toripalimab (240 mg Q3W for 3 cycles) combine with chemotherapy
223817775|NCT02670252|DRUG|Busulfan (BU)|Busulfan was administered at 3.2 mg/kg/day on days -7 to -4.
223817776|NCT02670252|DRUG|Cyclophosphamide (CY)|Cyclophosphamide was administered at 60 mg/kg/day on days -3 to -2.
223817777|NCT02670252|RADIATION|Total Body Irradiation (TBI)|Total Body Irradiation was given 4.5 Gy TBI/day on days -5 and -4.
223817778|NCT05995080|OTHER|clorhexidine gluconate bathing|daily skin cleansing with chlorhexidine gluconate
223817779|NCT02336919|BEHAVIORAL|Txt2Prevent|A 60-day text messaging program called Txt2Prevent (see description in the arm description).
223817780|NCT01407588|PROCEDURE|Magnetic navigation|Ablation with use of the magnetic navigation system
223817781|NCT01407588|PROCEDURE|Ablation performed with manual navigation|Atrial fibrillation ablation performed with manual navigation
223817782|NCT03913208|PROCEDURE|Priority to freeze|Priority for cryopreservation and later on embryo transfer in artificial cycle with endometrium preparation by the exogenous administration of estrogen-progesterone.
223817783|NCT03913208|PROCEDURE|Fresh embryo transfer|usual strategy of giving the priority for fresh embryo transfer
223817784|NCT04094337|BEHAVIORAL|Internet-assisted treatment|Internet-assisted treatment
223817785|NCT02489266|BIOLOGICAL|AKTi-treated TIL|On day 0, cells will be infused intravenously (IV) over 20-30 minutes (between 1 and 4 days after the last dose of fludarabine).
223817786|NCT02489266|DRUG|Cyclophosphamide|Patients will receive Cyclophosphamide 60 mg/kg/day x 2 days.
223817787|NCT02489266|DRUG|Fludarabine|Patients will receive Fludarabine 25 mg/m2/day for 5 days.
223817788|NCT02489266|DRUG|Aldesleukin|Aldesleukin 720,000 IU/kg IV (based on total body weight) over 15 minutes approximately every 8 hours beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses).
223817789|NCT04988425|DRUG|TNFα Monoclonal Antibody|Subcutaneous injection of 50mg of TNFα monoclonal antibody immediately after admission before surgery.
223817790|NCT04988425|DRUG|Methylprednisolone|Injection of 500mg of methylprednisolone immediately after admission before surgery.
223817791|NCT04988425|DRUG|Saline|Injection of the same volume of saline immediately after admission before surgery
223817792|NCT02540785|PROCEDURE|lenticule extraction|Four femtosecond incisions were created in succession: the posterior surface of the refractive lenticule (spiral in), the lenticule border, the anterior surface of the refractive lenticule (spiral out), and the corneal flap in the superior region. After the suction was released, the flap was opened using a thin, blunt spatula and the free refractive lenticule was subsequently grasped with a forceps and extracted, after which the flap was repositioned carefully
223817793|NCT02540785|PROCEDURE|small-incision lenticule extraction|Four femtosecond incisions were created in succession: the posterior surface of the refractive lenticule (spiral in), the lenticule border, the anterior surface of the refractive lenticule (spiral out), make a small incision
223817794|NCT03880084|OTHER|Observation|To systematically assess the onset of delirium, quantify the level of agitation/sedation, estimate the grade of pain and survey the level of dyspnea in patients undergoing non invasive mechanical ventilation
223817795|NCT03690934|PROCEDURE|Fistula-tract laser closure (FiLAC™)|The procedure was performed with a diode laser platform emitting laser energy of 15 W at a wavelength of 1470 nm by means of a radial ﬁber. For obliteration, the ﬁstula track is treated with a continuous slow retraction of the laser ﬁbre withdrawn at a rate of approximately 1 cm per 2-3s.
223817796|NCT03690934|PROCEDURE|Monopolar coagulation of fistulous tract|The procedure was performed with a monopolar coagulator platform emitting monopolar coagulation. For obliteration, the ﬁstula track is treated with a continuous slow retraction of the monopolar energy with suturing the internal fistulas opening.
223817797|NCT04372823|BEHAVIORAL|Policy/program|Policy/program to improve nutrition and increase physical activity
223817798|NCT05094193|PROCEDURE|Trocar-site infiltration|20 mL of ropivacaine 0.375% (6 mL in 10 mm trocar site and 4 mL in 6 mm trocar site)
223817799|NCT05094193|PROCEDURE|TAP block|bilateral ultrasound-guided TAP block with 20 mL of ropivacaine 0.375% in each side
223817800|NCT05094193|PROCEDURE|Trocar site infiltration placebo|20 mL of normal saline
223817801|NCT05094193|PROCEDURE|TAP block placebo|bilateral ultrasound-guided TAP block with 20 mL of normal saline in each side
223817802|NCT04108481|DRUG|Durvalumab|Immunotherapy
223817803|NCT04108481|RADIATION|Yttrium-90 RadioEmbolization|Microscopic radioactive particles (TheraSphere®) will be used for radioembolization to deliver the Y90 drug to the liver
223817804|NCT04636801|DRUG|Experimental: CHF6001 1600µg|CHF6001 400µg, 2 inhalations bid (total daily dose of 1600µg).
223817805|NCT04636801|DRUG|Experimental: CHF6001 3200µg|CHF6001 800µg, 2 inhalations bid (total daily dose of 3200µg).
223817806|NCT04636801|DRUG|Placebo|CHF6001 matching placebo, 2 inhalations bid.
223817807|NCT01285193|BEHAVIORAL|Breath control|A music CD with sound cues is used to guide the subject to breathe in a regular and slower rate. This is practiced for at least 15 minutes a day over 2 months.
223817808|NCT02691689|OTHER|Genetic testing|Genetic testing by DNA sequencing on blood samples after DNA extraction
223817809|NCT04404621|BEHAVIORAL|Physical exercise (PE) training and computer-based brain (CBB)|18 weeks of PE and CBB.
223817810|NCT04923477|OTHER|Therapeutic Exercise for Rotator Cuff Tendinopathy / Subacromial Pain Syndrome|Therapeutic exercise of resistance and mobility via a combination of HEP and in-person/virtual visits 5 days/ wk. Exercise program instruction in person, then 2-3 visits /wk x 8 wks (in-person or virtual) with a trained professional for the progression of exercises. Adherence to exercise will be measured daily via text and recorded in a mobile app. Patients will start with Phase 1 exercises of shoulder external \& internal rotation, scapular stabilization, and active shoulder elevation; resistance levels of elastic bands will be assigned and progressed based on patient-reported shoulder pain and perceived difficulty. Patients will be advanced to Phase 2 when they complete Phase 1. The exercise protocol will be delivered with the methods previously published by Tate, 2010 and Mintken 2016.
223817811|NCT05770830|DEVICE|Esophageal temperature|Temperature data measured by esophageal temperature probe (disposable probe, Ace-medical, Seoul, Korea)
223817812|NCT05770830|DEVICE|Skin core temperature|Temperature data measured by skin core temperature device measured by 3M™ Bair Hugger™
223817813|NCT06329193|OTHER|Mid-Season Camp Period Loading|The daily gym included warm-up protocol (dynamic stretching of the major muscle groups of the upper and lower extremities and jogging), crunches, sit-ups, reverse sit-ups, prone bridge, side bridge, bench press, mini squat (with body weight and/or ancillary equipment), lunge (with body weight and/or ancillary equipment), leg extension, leg curl, leg press, calf raises (with body weight and/or ancillary equipment), and cool-down protocol (dynamic stretching of the major muscle groups of the upper and lower extremities). The field-based exercises included warm-up protocol (dynamic stretching of the major muscle groups of the upper and lower extremities and jogging), dynamic balance (with different balance trainer such as Both Sides Utilized \[BOSU\], trampoline), tactical training, passing, dribbling, and shooting practice, agility and speed practice, and cool-down protocol (dynamic stretching of the major muscle groups of the upper and lower extremities)
223817814|NCT01494870|PROCEDURE|PCI|urgent PCI on admission
223817815|NCT00433615|DRUG|R744|100μg(s.c./i.v.)/4 week for 8 weeks, then 25\~400μg(s.c./i.v.)/4 week for 40 weeks
223817816|NCT00433615|DRUG|R744|150μg(s.c./i.v.)/4 week for 8 weeks, then 25\~400μg(s.c./i.v.)/4 week for 40 weeks
223817817|NCT02354716|DEVICE|EndoFLIP|The Endolumenal Functional Lumenal Imaging Probe Imaging System is a technology developed to measure the dimensions \& function of a variety of hollow organs throughout the body. Since receiving FDA clearance for sale in the United States EndoFLIP has been used in a variety of clinical applications. We intend to investigate the potential clinical applications of EndoFLIP in the upper GI tract in patients with esophageal stenoses who require endoscopic therapy for benign esophageal strictures. The use of EndoFLIP to characterize a stricture pre- \& post- dilation may offer insight in to the clinical and endoscopic predictors of successful stricture dilation, \& what characteristics determine \& predict refractory \& recurrent strictures.
223817818|NCT00242801|DRUG|Gefitinib|
223817819|NCT00056940|BEHAVIORAL|Stages of Change|
223817820|NCT00056940|BEHAVIORAL|Safety Check approach|
223817821|NCT04092179|DRUG|Enasidenib|Enasidenib is a drug that blocks a protein called isocitrate dehydrogenase (IDH) 2 from working. The family of IDH proteins have been indicated in the development of leukemia. By blocking IDH2, enasidenib may help stop cancer cells from growing. It is believed that the drug may be more useful in patients with a change (mutation) in their IDH 2 protein. The IDH2 gene (substances in the body that contain instructions for the proper development and function of cells) makes IDH2 proteins. As such, only patients with IDH 2 mutated gene are eligible for this study. Enasidenib is currently approved for the treatment of IDH2 mutated AML.
223817822|NCT04092179|DRUG|Venetoclax|Venetoclax is a drug that blocks a protein called B-cell lymphoma (BCL2) protein from working. BCL2 is a protein that helps control whether a cell lives or dies and is thought to help cancer cells to live. Blocking BCL2 is believed to help kill cancer cells. Venetoclax is currently approved for the treatment of type of blood cancer called chronic lymphocytic leukemia (CLL) who have received prior treatment.
223817823|NCT06047236|OTHER|Sampling|Evaluation of immune characteristics by using patient's stool, saliva and blood samples.
223817824|NCT04588818|DRUG|Adalimumab plus Methotrexate|"Adalimumab 40 mg (≥30kg weight) or 20mg (\<30kg weight) subcutaneously every other week without loading dose.~Methotrexate(10 to 20 mg per square meter of body-surface area; maximum dose, 20 mg) ."
223817825|NCT04034459|DRUG|Bevacizumab|Bevacizumab 5 mg/kg BW iv over 30 to 90\* min day 1
223817826|NCT04034459|DRUG|Irinotecan|Irinotecan 150 mg/m² iv, 30 - 90 min. day 1
223817827|NCT04034459|DRUG|Folinic acid|Folinic acid (racemic) 400 mg/m² iv, 120 min. day 1
223817828|NCT04034459|DRUG|Oxaliplatin|Oxaliplatin 85mg/m² day 1
223817829|NCT04034459|DRUG|5-FU|5-FU 3000 mg/m² iv over 48 h days 1-2
223817830|NCT04034459|DRUG|Cetuximab|Cetuximab initially 400 mg/m² with infusion rate of ≤5 mg/min., subsequently 250 mg/m² iv with infusion rate of ≤10 mg/min. days 1+8
223817831|NCT00482638|DRUG|MK0493|
223817832|NCT00294216|DRUG|Omega-3-acid ethyl ester 90 (n-3 PUFA)|
223817833|NCT00380120|DRUG|sodium warfarin|dosage: as much as it is required to prolong the international normalized ratio, checked every 2-3 weeks, between 2.0 and 3.0
223817834|NCT00380120|DRUG|Sodium warfarin|As much drug as it is necessary to prolong the international normalized ratio between 2.0 and 3.0
223817835|NCT04930107|DRUG|Fluconazole 150 mg|Treatment will be offered to participants if clinical exam and clinical samples are consistent with vulvovaginal candidiasis (VVC). Females presenting with a suspected first-time yeast infection will be treated with fluconazole 150 mg orally.
223817836|NCT04930107|DRUG|Boric Acid Supp,Vag|Treatment will be offered to participants if clinical exam and clinical samples are consistent with vulvovaginal candidiasis (VVC). Women that have had a prior documented VVC infection that has recurred on fluconazole will be treated with boric acid, 600 mg intravaginally at bedtime for 7 days.
223817837|NCT01213043|BIOLOGICAL|Prolastin-C, 60 mg/kg|60 mg/kg weekly infusion of Prolastin-C for 8 weeks
223817838|NCT01213043|BIOLOGICAL|Prolastin-C, 120 mg/kg|120 mg/kg weekly infusion of Prolastin-C for 8 weeks
223817839|NCT02831179|DRUG|Capecitabine|Given PO
223817840|NCT02831179|DRUG|Temozolomide|Given PI
223817841|NCT02831179|DRUG|Veliparib|given PO
223817842|NCT02831179|OTHER|Pharmacological Study|Correlative studies
223817843|NCT02831179|OTHER|Laboratory Biomarker Analysis|Correlative studies
223817844|NCT05484583|DRUG|Durvalumab + carboplatin/cisplatin + etoposide|Induction period (3 weeks as a cycle, 4 cycles of administration): Durvalumab + carboplatin/cisplatin + etoposide, intravenous drip
223817845|NCT05484583|RADIATION|Consolidation radiotherapy|Consolidation radiotherapy period: radiotherapy for primary chest lesions + oligometastatic lesions.
223817846|NCT05484583|DRUG|Durvalumab|Maintenance phase (administered every 4 weeks): Durvalumab intravenous infusion
223817847|NCT00791115|PROCEDURE|whole-mount sectioning of the prostate|A standard open retropubic radical prostatectomy will be performed. Whole fresh prostate is be embedded in gel and oriented in the anatomic position in a plastic cylinder using wood skewers. Standard pathology reports are generated from this tissue
223817848|NCT03514862|BEHAVIORAL|Mindfulness Booster Training|Four additional mindfulness booster sessions after the 4-week MBI program.
223817849|NCT03514862|BEHAVIORAL|Mindfulness-Based Intervention (MBI)|MBI program is delivered once a week for 4 weeks, 90 minutes each preceded by a 90-minute orientation session. The training sessions will include discussion, and introduction and practice of mindfulness practices.
223817850|NCT03514862|BEHAVIORAL|Self-Practice|4 weeks of self-practice after the MBI training.
223817851|NCT00406471|DRUG|Ranibizumab (Lucentis)|500 microgram intravitreal injection for 8 months or 300 microgram intravitreal injection for 8 months
223817852|NCT06696040|DEVICE|Passive mobilization using a device|"The protocol consists of three moments: initial assessment, use of the device, and final assessment.~In the initial assessment, participants will be positioned supine on a stretcher, where the muscle tone of the lower limb(s) will be tested using the Modified Ashworth Scale. After the physical test with the Modified Ashworth Scale, the TUG test will be carried out, and, finally, gait assessment with the BAIOBIT Inertial Meter with Accelerometer and Gyroscope.~At the end of the initial assessment, the Autofisio500 device will be used. To do this, the participant will be positioned again and comfortably supine on the stretcher, and the previously tested lower limb will be attached to the device for movement, between the knee and ankle joints, for 30 minutes, at maximum speed (11 RPM).~For the final assessment, the Modified Ashowrth Scale, TUG and gait assessment with the Inertial Meter with Accelerometer and BAIOBIT Gyroscope will be applied again."
223817853|NCT02085538|DRUG|palbociclib|palbociclib 125 mg oral capsule with food once
223817854|NCT02085538|DRUG|palbociclib|palbociclib 125 mg oral capsule with food once
223817855|NCT02085538|DRUG|palbociclib|palbociclib 125 mg oral capsule with food once
223817856|NCT02085538|DRUG|palbociclib|palbociclib 125 mg oral capsule with food once
223817857|NCT03839485|DRUG|Endodontic treatment using Guedes-Pinto Paste|Dental procedure in which the entire pulp chamber is removed from the crown and roots of a tooth and the root filling material Guedes-Pinto paste is applied
223817858|NCT03839485|DRUG|Endodontic using Guedes-Pinto Paste without antibiotic|Dental procedure in which the entire pulp chamber is removed from the crown and roots of a tooth and the root filling material Guedes-Pinto paste without antibiotic is applied
223817859|NCT02536001|DEVICE|One mesh Endofast reliant system|One mesh (anterior One mesh Endofast reliant system) will be used to correct both anterior and apical prolapse
223817860|NCT02536001|DEVICE|two meshes Endofast reliant system|Two meshes (anterior and posterior Endofast reliant system) will be used to correct separately the anterior compartment and the apical compartment
223817861|NCT02998814|OTHER|acid-etch|acid-etch
223817862|NCT02998814|OTHER|self-etch adhesive|Self etch (7th generation ) bonding agent
223817863|NCT02998814|OTHER|etch-and-rinse adhesive|Total etch bonding agent (5th generation)
223817864|NCT02998814|OTHER|self-etch adhesive after acid-etch|acid etch + self-etch adhesive Self etch (7th generation ) bonding agent
223817865|NCT05621083|DIETARY_SUPPLEMENT|Omega- 3|In the fish oil supplement period, the participants will receive concentrated fish oil which is equal to in total 2.3 g EPA+DHA per day during 6 weeks.
223817866|NCT05621083|DIETARY_SUPPLEMENT|HOSO|In the HOSO period, the participants will receive similar amount of HOSO per day during 6 weeks.
223817867|NCT04143334|DIAGNOSTIC_TEST|Conventional survey|
223817868|NCT01435434|DEVICE|the Sepax is a tool to standardize adult stem cell. Ignite ®ICS injectable scaffold manufactured by Wright Medical Technology.|
223817869|NCT01610154|DRUG|Sitagliptin|Sitagliptin 100 mg QD for 12 weeks
223817870|NCT02415777|DRUG|Ursodeoxycholic acid, thiamine, riboflavin|
223817871|NCT05332977|DEVICE|CAD-CAM fabricated provisional prosthesis|Insertion of CAD-CAM fabricated provisional prosthesis (CAD-CAM) on axially placed or titled implants for rehabilitation of atrophic maxilla
223817872|NCT05332977|DEVICE|DC (denture conversion) provisional prosthesis|Insertion of denture conversion (DC) provisional prosthesis on axially placed or titled implants for rehabilitation of atrophic maxilla
223817873|NCT00426322|DEVICE|bovine bone mineral particles (Bio-Oss®)|bovine bone mineral particles used for sinus augmentation prior to dental implant placement
223817874|NCT03609125|OTHER|CBS eyedrop|The product is dispensed as sterile frozen vials containing 0.8 ml of product for the daily administration. The product is thawed and administered at a dose of 1 drop / 8 times each eye during the waking period.
223817875|NCT04953338|OTHER|Exposure of mental health condtion of interest|Common mental health conditions consist of depressive episodes, recurrent depressive disorder and anxiety disorder.
223817876|NCT01678443|BIOLOGICAL|indium In 111 anti-CD45 monoclonal antibody BC8|Given IV
223817877|NCT01678443|RADIATION|yttrium Y 90 anti-CD45 monoclonal antibody BC8|Given IV
223817878|NCT01678443|PROCEDURE|peripheral blood stem cell transplantation|Undergo autologous peripheral blood stem cell transplant
223817879|NCT03322826|PROCEDURE|systematic sampling of the lymph-node|Systematic Sampling of lymph nodes
223817880|NCT03322826|PROCEDURE|lymphadenectomy|Routine lymph nodes dissection in lung cancer
223817881|NCT03623932|DRUG|immunosuppressor/TNFalpha|Standard Treatment : immunosuppressor/TNFalpha as in standard practice
223817882|NCT03623932|BEHAVIORAL|Hypnosis|8 hypnosis group sessions during 2 months
223817883|NCT03413254|OTHER|Routine follow-up|Patients visit the outpatient clinic twice a year during the first two to three years and annually thereafter, until five years postoperative. CEA-levels are determined at 3, 6, 9, 12, 15, 18, 21, 24, 30, 36, 48 and 60 months after primary resection. Detection of liver metastases with ultrasound or CT is performed at 12, 24, 36, 48 and 60 months postoperative. At 6 and 18 months postoperative, a CT-scan is part of the study protocol, but ultrasound of the liver is allowed for other time intervals during follow-up. Colonoscopy is performed at 12 and 48 months postoperative.
223817884|NCT03413254|PROCEDURE|Second look DLS|Second look DLS is performed within one month from negative CT at 6-9 months (depending last date of adjuvant chemotherapy) and normal CEA. Laparoscopic access to the abdominal cavity is obtained under general anaesthesia, followed by adhesiolysis if necessary. Complete staging is performed, with biopsy of any lesion suspicious of PM, and determining the peritoneal cancer index (PCI) in case of PM. Conversion to laparotomy not allowed for better exposure, but only for intra-operative complications.
223817885|NCT03413254|PROCEDURE|Third look DLS|Third look DLS is performed within one month from negative CT at 18 months and normal CEA. Laparoscopic access to the abdominal cavity is obtained under general anaesthesia, followed by adhesiolysis if necessary. Complete staging is performed, with biopsy of any lesion suspicious of PM, and determining the peritoneal cancer index (PCI) in case of PM. Conversion to laparotomy not allowed for better exposure, but only for intra-operative complications.
223817886|NCT03780127|DRUG|Fenfluramine Hydrochloride|ZX008 drug product is an oral aqueous solution of fenfluramine hydrochloride. The product is sugar free and is intended to be compatible with KD.
223817887|NCT01860443|OTHER|Telepsychiatry collaborative program|"The intervention includes:~* Online training for the health staff~* Medical and psychological treatment, as described in the AUGE Clinical Guidelines for Depression~* Online supervision in a web platform by specialists~* Telephone monitoring"
223817888|NCT01860443|OTHER|Usual care|"* Online training for the health staff~* Medical and psychological treatment, as described in the AUGE Clinical Guidelines for Depression"
223817889|NCT05043701|DRUG|Personalized drug combination|A personalized drug combination will be prescribed to each patient based on the functional drug screen
223817890|NCT01380886|OTHER|experimental infant formula with alternate protein source|experimental infant formula to be fed ad libitum
223817891|NCT01380886|OTHER|Infant formula powder|powdered infant formula to be fed ad libitum
223817892|NCT02221856|PROCEDURE|Motion View|Motion View, a software we are using to place brackets virtually on a 3D rendition of a patients teeth, will be used to indirectly bond brackets onto patient's teeth with a 3D printed plastic transfer JIG in which the brackets will be precisely placed on the patients teeth according to the computer-guided software.
223817893|NCT02221856|PROCEDURE|Conventional Orthodontic Treatment|orthodontic treatment using non-customized brackets and stock wires
223817894|NCT05138159|DRUG|Donafenib|Donafenib: 200mg po bid.
223817895|NCT05138159|DRUG|S1|S-1 capsule: According to the body surface area \<1.25m2 40mg/d, 1.25 \~ 1.5 m2 50 mg/d, \> 1.5m2 60mg/d po bid, taking 14 days, stopping for 7 days, 21 days for 1 cycle.
223817896|NCT02949921|DEVICE|Radiesse injectable implant and 2% lidocaine HCL|Radiesse injectable implant injected in small boluses (0.2-0.5cc/bolus). No more than 0.5cc per bolus. No more than 3 cc (2 syringes) will be injected per hand.
223817897|NCT01024790|BEHAVIORAL|Exercise group|24 week group exercise class supplemented with behavioral activation strategies
223817898|NCT02715817|OTHER|Virtual Rehabilitation|It is the use of the NW games for rehabilitation of balance and gaite in post-stroke patients.
223817899|NCT02715817|OTHER|Conventional therapeutic exercises|It is the use of the conventional therapeutic exercises for rehabilitation of balance and gait in post-stroke patients.
223817900|NCT02715817|OTHER|Virtual Rehabilitation and Conventional Therapeutic Exercise|It is the use of the conventional exercises and of the NW for rehabilitation of balance and gait in post-stroke patients.
223817901|NCT02435771|DRUG|Ergocalciferols|Treatment 1- 400,000 IU
223817902|NCT02435771|DRUG|Ergocalciferols|Treatment 2- 800,000 IU
223817903|NCT02304250|DRUG|Dexamethasone|dexamethasone 1ml (5mg)
223817904|NCT02304250|DRUG|saline|saline 1ml
223817905|NCT00073879|BIOLOGICAL|alemtuzumab|
223817906|NCT00073879|BIOLOGICAL|graft-versus-tumor induction therapy|
223817907|NCT00073879|DRUG|cyclophosphamide|
223817908|NCT00073879|DRUG|fludarabine phosphate|
223817909|NCT00073879|PROCEDURE|allogeneic bone marrow transplantation|
223817910|NCT00073879|PROCEDURE|peripheral blood stem cell transplantation|
223817911|NCT02117232|DEVICE|Visualization balloon|"The Visualization Balloon is a disposable medical device that is used during the advancement of the colonoscope inside the colon. The intended use of the Visualization Balloon is to help insertion of the colonoscope into the colon without the aid of gas (air or CO2) insufflation as with standard colonoscopy. The Visualization Balloon is inserted through the biopsy channel of the colonoscope prior to the colonoscope introduction into the rectum. The Visualization Balloon is an inflatable balloon that opens up the lumen of the gastrointestinal tract, thereby allowing the endoscopist to advance the endoscope inside and to view the gastrointestinal tract through the clear balloon."
223817912|NCT02117232|DEVICE|Traditional CO2 insufflation colonoscopy|"Traditional colonoscopy performed with CO2 insufflation without Visualization balloon"
223817913|NCT01091623|OTHER|training|
223817914|NCT01091623|OTHER|training|
223817915|NCT01091623|OTHER|training|
223817916|NCT06158763|BEHAVIORAL|Web-based CBT guided self-help Interventions|An existing CBT-based transdiagnostic self-help manual (Naeem et al., 2014) that has been used successfully in RCTs (Amin et al., 2020; Naeem et al., 2014) and has been used as an online intervention (http://khushiorkhatoon.com/) will be further adapted. The intervention consists of seven modules, including cognitive restructuring, problem-solving and behavioural activation.
223817917|NCT04508179|DRUG|7HP349 Single Ascending Dose|Part A: 7HP349 Capsules, Single Ascending Dose (SAD)
223817918|NCT04508179|DRUG|7HP349 Multiple Ascending Dose|Part B: 7HP349 Capsules, Multiple Ascending Dose (MAD)
223817919|NCT04508179|DRUG|Placebo Single Ascending Dose|Part A: Placebo Capsules, Single Ascending Dose (SAD)
223817920|NCT04508179|DRUG|Placebo Multiple Ascending Dose|Part B: Placebo Capsules, Multiple Ascending Dose (MAD)
223817921|NCT04508179|DRUG|7HP349 Food Effect|Part C: 7HP349 Capsules, Food Effect
223817922|NCT04100122|PROCEDURE|Blood drawing|Blood drawn will be done once using 15 mL of blood volume (Serum or plasma samples will be collected during the routine follow up of level of sIgE to wheat or during the oral food challenge test which intravenous insertion routinely prepared in case of the emergency reaction occurred). The specimen will be transferred to the Icahn School of Medicine at Mount Sinai, New York, USA for Laboratory processing (Luminex-based peptide assay)
223817923|NCT06468072|OTHER|Expressivity protocol for children with autism|The activities proposed by this protocol stimulate different expressive skills, which are often lacking in people with autism. For this reason, the protocol is based on the strengthening of the following skills: perception of the body in movement in the space (4 sessions), the expressiveness of the body in its entirety (4 sessions), breathing and the use of the voice to express emotions in relation to the environment (4 sessions), rhythm and movement, to develop motor coordination and the expressiveness of movements (4 sessions). The protocol consists of 16 sessions: a weekly group session lasting one hour.
223817924|NCT06468072|OTHER|Expressivity protocol for non-autistic children|The activities proposed by this protocol stimulate different expressive skills. The protocol is based on the strengthening of the following skills: perception of the body in movement in space (4 sessions), the expressiveness of the body in its entirety (4 sessions), breathing and the use of the voice to express emotions in relation to the environment (4 sessions), rhythm and movement, to develop motor coordination and the expressiveness of movements (4 sessions). The protocol consists of 16 sessions: a weekly group session lasting one hour.
223817925|NCT05147168|OTHER|Questionnaire|Psychometric Validation of Chinese Version of the EORTC QLQ-PAN26 and EORTC QLQ-C30 in Taiwan
223817926|NCT05923580|BEHAVIORAL|Group- based cardiac telerehabilitation|Group-based cardiac telerehabilitation promotes information, skills, and support for the management of coronary artery disease in coronary patients. The rehabilitation model includes independent familiarization with information content, assignments, and group meetings, as well as the opportunity for a chat and peer support. The intervention is a health professional- lead, and registered rehabilitation model with a start and end.
223817927|NCT02941393|DEVICE|Intrauterine pressure catheter|
223817928|NCT02941393|DEVICE|External tocodynamometry|
223817929|NCT05936632|OTHER|Discrete Choice Experiment (DCE)|DCE survey experiment
223817930|NCT01835600|OTHER|PEEP|PEEP means that when mechanical ventilation is suspended, the value of expiratory valve in the anesthesia machine is set at 10 cmH2O with 1 L/min 100% oxygen.
223817931|NCT00560664|PROCEDURE|Autologous chondrocytes transplantation|Cartilage was harvested, then transferred for cell isolation and culture. Cells are suspended in agarose and transferred to cylindrical molds and surgically implanted 4 weeks later.
223817932|NCT00560664|PROCEDURE|Mosaicoplasty|Osteochondral patch are sampled and then implanted during the same surgical procedure
223817933|NCT00103337|DRUG|cilengitide|Given IV
223817934|NCT00103337|OTHER|laboratory biomarker analysis|Correlative studies
223817935|NCT03038984|BEHAVIORAL|At Home Screening procedure On demand|Home monitoring is a supportive treatment. Patients are randomized to screen themselves on demand
223817936|NCT03038984|BEHAVIORAL|At Home Screening procedure every 3 months|Home monitoring is a supportive treatment. Patients are randomized to screen themselves every 3 months
223817937|NCT05910086|OTHER|collection of data from the medical record|"collection of data from the medical record:~1. During epidural space puncture = cerebrospinal fluid (CSF) reflux, presence of glucose / strip, saline injection, intrathecal catheter insertion, intrathecal levobupivacaine and sufentanil injection, catheter insertion time, number of punctures, function of the person performing the procedure.~2. Analgesia and hemodynamics during labor, blood pressure, pulse rate, amount of local anesthetic used, whether emergency cesarean section was performed~3. Demographic data (age, weight, height, body mass index (BMI))~4. Post-partum monitoring of decubitus or orthostatic headaches, intensity, any other associated clinical signs~5. Analgesics used and their efficacy~6. The use of one or more blood patches, with the volume injected and their efficacy~7. Identification of the breach during epidural analgesia or after delivery~8. Call the patient at 1 week to reassess the episode and its consequences."
223817938|NCT02309177|DRUG|nab-Paclitaxel|
223817939|NCT02309177|DRUG|Nivolumab|
223817940|NCT02309177|DRUG|Gemcitabine|
223817941|NCT02309177|DRUG|Carboplatin|
223817942|NCT03644355|BEHAVIORAL|Lifestyle counseling|Inter-disciplinary, interactive, family based behavioral intervention for overweight children
223817943|NCT03459703|BEHAVIORAL|Early Time-Restricted Feeding|Eat all meals between 7 am - 3 pm for an average of ≥6 days per week.
223817944|NCT03459703|BEHAVIORAL|Control Schedule|Eat all meals over a 12-hour or longer period for an average of ≥6 days per week.
223817945|NCT03459703|BEHAVIORAL|Structured Weight Loss Program|A structured weight loss program with physical activity recommendations and dietary counseling.
223817946|NCT01698086|OTHER|Vestibular rehabilitation: balance and eye movement exercises|The Experimental group will perform 1-hour supervised intervention sessions 2x/wk for 6-wks, then 1x/wk for 8-weeks, for a total of 20 supervised sessions. The intervention is a progressive vestibular rehabilitation program comprised of balance and eye movement exercises as detailed in our preliminary study report. The balance training includes standing and walking tasks on varied types of compliant surfaces, base of support, head movements, visual input and eye-hand tasks. The tasks will progress from simple to more complex. Eye movement exercises will include voluntary saccadic eye movements and smooth pursuit movements. Vestibulo-ocular eye training will be performed while visually fixating on a stationary object, while moving the head up and down and side to side at various speeds, progressing from sitting to standing on firm and compliant surface. Participants in the Experimental group will be given items of the exercise program to perform as a home exercise program.
223817947|NCT01098149|OTHER|BD and BVC, AFB|Some patients are randomized into the AFB, the others into the BD and BVC
223817948|NCT00157274|DRUG|alemtuzumab|
223817949|NCT04180839|BEHAVIORAL|gaming-related retrieval-extinction|"During one training session,participants will first view a 5-min retrieval video containing gaming content and then, 10 minutes later, receive 1-hour of extinction training in which they will be administered four sequences of video, picture and in vivo gaming cues.~The whole training includes 2 training sessions. Participants will receive one training session once a day for two consectutive days."
223817950|NCT04180839|BEHAVIORAL|nongaming-related retrieval-extinction|"During one session,participants will first view a 5-min neutral video and then, 10 minutes later, receive 1-hour of extinction training in which they will be administered four sequences of video, picture and in vivo gaming cues.~The whole procedure includes 2 sessions. Participants will receive one session once a day for two consectutive days."
223817951|NCT00597714|DRUG|Non-myeloablative Stem Cell Transplantation|The preparative regimen is 4 days of daily fludarabine at 40 mg/m2/d infused over 30 minutes; melphalan 140 mg/m2/d for 1 day administered over 15 minutes; 4 days of Alemtuzumab at 20 mg/d in 250 ml of normal saline infused over 3 hours. Group B's prep regimen will begin on day -5 or day -4 and busulfan 130mg/m2/d for 2 days over 3 hours. The peripheral blood stem cells (PBSCs) will be infused over 2-4 days. Patient evaluations will occur 2 times per week by physical exam for toxicity through day 45.
223817952|NCT01350141|OTHER|Placebo|An infusion lasting approximately 60 minutes
223817953|NCT01350141|DRUG|PF-04950615 (RN316)|An infusion lasting approximately 60 minutes
223817954|NCT01350141|DRUG|PF-04950615 (RN316)|An infusion lasting approximately 60 minutes
223817955|NCT05198193|BEHAVIORAL|No Message Given|Participants in this arm are not given any intervention.
223817956|NCT05198193|BEHAVIORAL|Positive Message Given - Older Adults|Participants in this arm are given a positively framed message from an older adult's point of view.
223817957|NCT05198193|BEHAVIORAL|Negative Message Given - Older Adults|Participants in this arm are given a negatively framed message from an older adult's point of view.
223817958|NCT05198193|BEHAVIORAL|Positive Message Given - Younger Adults|Participants in this arm are given a positively framed message from an adult child's point of view.
223817959|NCT05198193|BEHAVIORAL|Negative Message Given - Younger Adults|Participants in this arm are given a negatively framed message from an adult child's point of view.
223817960|NCT00802555|DRUG|ARQ 197|360 mg administered twice daily until disease progression, unacceptable toxicity, or other discontinuation criterion is met
223817961|NCT06121960|DIAGNOSTIC_TEST|spirometry|"Inclusion visit:~Performing spirometry.~Visit 2 (in the month following the inclusion visit):~Induction of a self-induced cognitive trance by the participant; performance of spirometry before, during the trance then 8 minutes after the end of the trance Actimetry during trance"
223817962|NCT04736017|DEVICE|TSB Axo|The TSB Axo is a wearable biosignal recording device combined with an auditory stimulation. The device consists of pre-gelled biosignal electrodes, headphones integrated in a headband, and a biosignal processing module.
223817963|NCT02461875|DRUG|Cabergoline|Patients receive cabergoline 0.5 mg p.o at bed time for 8 days starting on the day of HCG administration.
223817964|NCT02461875|DRUG|GnRH antagonist rescue & cabergoline|when the leading follicle reaches 16 mm, HP-uFSH is continued at daily dose of 75 IU/day till the day of HCG administration. Moreover, Gn RH agonist (triptorelin) is discontinued and GnRH antagonist (Cetrorelix acetate)0.25 mg S.C is administered daily till the day of HCG administration. Serum estradiol is measured daily and HCG (5,000 IU/I.M) is administered when serum estradiol level drops below 3500 pg/ml . Moreover, cabergoline 0.5 mg p.o is administered at bed time for 8 days starting on the day of HCG administration.
223817965|NCT00519896|DRUG|sunitinib malate|Given PO
223817966|NCT03192540|OTHER|Exercise|Participants will undergo an exercise protocol once a week, for eight weeks. Exercise will be continuous for one hour.
223817967|NCT01588990|DRUG|Oxaliplatin|Participants will receive oxaliplatin 85 milligrams per square meter (mg/m\^2) IV infusion on Day 1 of every 2 weeks cycle during alternative Phase A treatment or 130 mg/m\^2 on Day 1 of every 3 weeks cycle during Phase A treatment.
223817968|NCT01588990|DRUG|Capecitabine|Participants will receive capecitabine 1000 mg/m\^2 per oral (PO) twice daily on Days 1-14 of 3 weeks cycle during Phase A treatment.
223817969|NCT01588990|DRUG|Bevacizumab|Participants will receive 7.5 mg/kg IV infusion on Day 1 every 3 weeks (Phase A treatment) or 5 mg/kg IV on Day 1 every 2 weeks (Alternative Phase A treatment and Phase B).
223817970|NCT01588990|DRUG|Leucovorin|Participants will receive leucovorin 400 mg/m\^2 IV on Day 1 every 2 weeks (Alternative Phase A treatment and Phase B). Investigators may elect to chose low dose of leucovorin (either 20 mg/m\^2 or 50 mg total dose).
223817971|NCT01588990|DRUG|5-Fluouracil|Participants will receive 5-fluouracil loading dose of 400 mg/m\^2 IV on Day 1 followed by 2400 mg/m\^2 continuous IV infusion over 46 hours Day 1 (Alternative Phase A treatment and Phase B).
223817972|NCT01588990|DRUG|Irinotecan|Participants will receive irinotecan 180 mg/m\^2 IV on Day 1 every 2 weeks during Phase B treatment.
223817973|NCT01286220|OTHER|Dilute bleach baths|Patients in the intervention group will be instructed to bathe in a dilute bleach bath twice weekly for 10 minutes.
223817974|NCT01286220|OTHER|Water|Patients in the placebo group will be instructed to bathe in plain water twice weekly for 10 minutes.
223817975|NCT05635318|DEVICE|FDA approved medications for ADHD plus Quantitative EEG Neurofeedback|A mathematical approach to analyzing EEG data, called quantitative electroencephalography (qEEG), can be used to develop a visual map of the type and location of brain waves or rhythms. Other more specific wave patterns, such as event-related potentials, can also be seen in the EEG.NF converts signals such as EEG into visual or auditory information, and then subjects selectively enhance or inhibit certain components through training. There are three common NF protocols for ADHD: theta/beta training, sensorimotor rhythm (SMR) training, and slow cortical potentials (SCP) training.
223817976|NCT05635318|DRUG|FDA approved medications for ADHD|Ritalin (methylphenidate HCl); Ritalin LA, Ritalin SR Strattera (atomoxetine HCl)
223817977|NCT02784470|DEVICE|gastroduodenal stent placement|
223817978|NCT02784470|PROCEDURE|gastrojejunostomy|
223817979|NCT02900612|OTHER|Water aerobics training.|The WA group will be trained adopting the interval method, performing six blocks of five minutes each one, alternating four minutes at intensities corresponding to 90 to 100% of the heart rate corresponding to the second ventilatory threshold (HRVT2) and one minute at intensities between 80 and 90% HRVT2.
223817980|NCT02900612|OTHER|Water resistance training.|The WR group will perform four to eight sets of 20 to 10 seconds along the macrocycle, always at maximal speed execution of the exercises.
223817981|NCT02900612|OTHER|Control Group|The control group will perform relaxation classes, including meditation, balance exercises, coordination exercises.
223817982|NCT02367716|DEVICE|CRT|The study will include the Quartet™ family of left heart leads or any newer St. Jude Medical quadripolar CRT systems, including CRT-P systems, that China Food and Drug Administration (CFDA) might approve in the future
223817983|NCT00494260|BEHAVIORAL|Social Learning and Cognitive Behavioral Therapy (SLCBT)|The SLCBT condition consists of 3 main components: 1.) relaxation training, 2.) working with parent and child to modify family responses to illness and wellness behaviors, and 3.) cognitive restructuring to address and alter dysfunctional cognitions regarding symptoms and their implications for functioning through cognitive therapy techniques
223817984|NCT00494260|BEHAVIORAL|Education Support (ES)|The ES condition focuses on education about GI system anatomy and function, information about the United States Department of Agriculture nutrition guidelines, and additional food-related information such as how to read food product labels. The ES condition was developed to provide a credible alternative condition that would control for therapist and patient time and attention.
223817985|NCT00750282|DRUG|Florbetaben (BAY94-9172)|Healthy volunteers and patients with probable Alzheimer's disease receiving single injection of investigational medicinal product BAY 94-9172 followed by subsequent PET imaging sessions
223817986|NCT03837392|DIAGNOSTIC_TEST|Baseline Assessment (18-26 weeks pregnant)|At baseline, participants will complete several interviews and questionnaires online and via phone to determine psychological history, current functioning, history of trauma, coping styles, and demographic variables.
223817987|NCT03837392|BEHAVIORAL|Online Intervention and Phone Coaching Interventions|ACT is a cognitive-behavioral therapy that seeks to promote psychological flexibility. The active comparator is the Supportive Control. Two phone coaching sessions will occur 2- and 4-weeks post-intervention in both conditions.
223817988|NCT03837392|DIAGNOSTIC_TEST|Follow Up Assessments: 34-36 weeks pregnant and 4-week postpartum|The follow-up assessments at 34-36 weeks pregnancy and 4-weeks postpartum will be completed via REDCap, an online secure survey platform in order to reduce participant burden.
223817989|NCT03837392|DIAGNOSTIC_TEST|Follow Up Assessments: 8 weeks postpartum|The follow-up assessment at 8-weeks postpartum will be completed via phone.
223817990|NCT00625235|DIETARY_SUPPLEMENT|VLED followed by a high protein or high carbohydrate diet|
223817991|NCT04215185|DEVICE|Arterial LIne|Continuous non-invasive recording of CS6BP will be taken parallel to the recording of an invasive arterial line. ECG data recorded in the ICU will also be collected.
223817992|NCT03427554|DRUG|Tretinoin cream 0.1%|Tretinoin cream 0.1% (Taro Pharmaceuticals Inc.)
223817993|NCT03427554|DRUG|RETIN-A® Cream|RETIN-A® (Tretinoin) Cream (Valeant)
223817994|NCT03427554|DRUG|Vehicle of the test product|Vehicle for Tretinoin cream 0.1% (Taro Pharmaceuticals Inc.)
223817995|NCT00539643|DEVICE|Bead Block microspheres|Bead Block (Beads) microsphere, 100-300 micron with additional larger size beads as necessary to achieve stasis
223817996|NCT00539643|OTHER|Bead + Dox Arm|Bead + Dox Arm: Hepatic arterial embolization with 100-300 micron drug eluting microspheres (LC Bead) loaded with 150 mg Doxorubicin, followed by embolization with Bead Block microspheres (100-300 micron and larger size beads as necessary) until stasis is evident.
223817997|NCT03697525|DEVICE|Vibration|Low-amplitude rMV (frequency 100 Hz; amplitude range 0.2-0.5 mm) is applied over the flexor carpi radialis and the biceps brachii for the upper limb treatment, and/or over the quadriceps femoris for the lower limb treatment, by means of a specific commercial device (Cro®System, NEMOCOsrl).
223817998|NCT06510530|DIETARY_SUPPLEMENT|Astragalus|Patients in the intervention group will receive capsules of the Astragalus plant (scientific name: Astragalus membranaceus, common name: Huang Qi) at an initial dose of 2 grams (4 capsules) per day with the option of increasing the dose to 4 grams (8 capsules) per day according to researchers' assessment and patient tolerance. The dose was determined by a focus group of 5 herbalists and according to data from the literature on oncology patients. The duration of the treatment will be up to a month from the end of the chemotherapy treatment which usually lasts up to six months.
223817999|NCT06510530|DIETARY_SUPPLEMENT|Placebo|Placebo capsules that look similar to Astragalus capsules will be given to patients from the control group, between 4 and 8 capsules per day according to the researcher's assessment and tolerability. The duration of the treatment will be up to a month from the end of the chemotherapy treatment which usually lasts up to six months.
223818000|NCT02648971|PROCEDURE|Single Portal Knee Arthroscopy|Patients in Group 1 will undergo knee arthroscopy using a single portal.
223818001|NCT02648971|PROCEDURE|Two Portal Knee Arthroscopy|Patients in Group 2 will undergo knee arthroscopy using two portals.
223818002|NCT03620838|DRUG|oral contraceptive pill, oral progesterone|ovarian endometrioma cyst excision
223818003|NCT04935814|DRUG|Vasopressin, Arginine|Once vasopressin infusion started, patients positions will be randomized: Trendelenburg (-30°), anti Trendelenburg (+30°) and supine position (0°).
223818004|NCT02530814|OTHER|Blood Collection|Onetime blood collection.
223818005|NCT02220296|DRUG|Insulin 338|Healthy subjects will receive a single dose of insulin 338 in ascending doses. Injected subcutaneously (under the skin).
223818006|NCT02220296|DRUG|placebo|Healthy subjects will receive a single dose of placebo. Injected subcutaneously (under the skin).
223818007|NCT02220296|DRUG|Insulin 338|Subjects with type 1 DM will receive a single dose of insulin 338 in ascending doses. Injected subcutaneously (under the skin).
223818008|NCT02220296|DRUG|insulin glargine|Subjects with type 1 DM will receive 0.4 U/kg insulin glargine once daily for 4 days. Injected subcutaneously (under the skin).
223818009|NCT05438186|DRUG|Liraglutide|Participants with obesity who received initial prescription of Saxenda® (liragltuide 3.0 milligrams (mg) once daily)) and maintained treatment with Saxenda® for at least 16 weeks, without treatment break, following the initial prescription for weight management.
223818010|NCT06371131|PROCEDURE|Right -stellate ganglion block|The experimental group was given right stellate ganglion block 30 minutes before anesthesia induction
223818011|NCT04725656|PROCEDURE|Smoking cessation counseling|Smoking cessation counseling at baseline, week 1, and week 4.
223818012|NCT04725656|OTHER|Open system vape device and nicotine salt e-liquids|Ad libitum use of nicotine salt e-liquids during three months.
223818013|NCT03862287|DRUG|Lidocaine|See arm description.
223818014|NCT03862287|DRUG|Bupivacaine Hcl 0.5% Inj_#2|See arm description.
223818015|NCT01208298|DEVICE|Cold Sore Patch|All eligible subjects received CSP-Night at Screening Visit 1. Subjects were instructed to initiate therapy within approximately 1 hour of onset of their first sign or symptom. Treatment was continued until the lesion healed, or for a maximum of 10 days. All subjects were expected to return to the study center for clinical assessments within 24 hours and 48 hours after initiating treatment, and every other day thereafter, with a final visit at Day 10 or at the time of completion/ discontinuation if before Day 10.
223818016|NCT05072925|OTHER|Tobacco products|Products will be used under defined (10 puffs, 30 seconds apart) and ad libitum puffing conditions
223818017|NCT05639790|COMBINATION_PRODUCT|Electronic cigarettes + Health Counselling|Ad libitum use of electronic cigarettes for 1 month
223818018|NCT05639790|OTHER|Health Counselling|Health Counselling from a licensed mental health counselor
223818019|NCT03654339|PROCEDURE|root coverage|"Group A: After administration of local anaesthesia using ophthalmic microsurgical knives a V-shaped incision was made in the gingival recession area. the gingiva was removed .the adjacent partial thickness pedicle flap was reflected from the donor area .the pedicle flap was then covered over the recipient site. then secured with 6-0 absorbable sling suture without tension. the surgical procedure was done with seilar microscope 40X magnification.~Group B: After administration of local anaesthesia using 15 no blade a V-shaped incision was made in the gingival recession area . gingiva was removed .the adjacent partial thickness pedicle flap was reflected from the donor area .the pedicle flap was then covered over the recipient site. then carefully secured with 4-0 absorbable sling suture"
223818020|NCT00030420|DRUG|Celecoxib|400mg by mouth, twice a day, each dose given with meals, to start -7 days prior to first cycle of treatment.
223818021|NCT00030420|DRUG|Docetaxel|On day 1, 75mg/m2 IV over 60 minutes, repeated every 21 days
223818022|NCT02895022|DRUG|Lidocaine 2% adrénalinée|
223818023|NCT02895022|DEVICE|Epidural catheter|
223818024|NCT02895022|PROCEDURE|Caesarean section|
223818025|NCT00174603|DRUG|quetiapine|
223818026|NCT05801458|PROCEDURE|Modeling Resin Insertion Technique|One drop of modeling resin will be dispensed into a clean mixing well. Following the placement of the resin composite into the prepared site, a composite instrument (round-ended plugger with a diameter of 2 mm) will be dipped into the modeling resin. With modeling resin on the instrument, the resin composite is sculpted and manipulated to the desired shape. This will be repeated with each increment. Each increment will be polymerized for 20 sec with a LED light-curing unit.
223818027|NCT05801458|PROCEDURE|Conventional resin composite Incremental Placement Technique|A three-step etch-and-rinse adhesive system will be used according to the manufacturer's instructions. 37.5% phosphoric acid (Kerr Co, Orange, CA, USA) will be applied to the enamel and dentin for a period of 30 s and 15 s, respectively. Subsequently the cavities will then be rinsed with an air/water spray for 15 s. A layer of primer will be applied to the dentin for 30 sec, afterward gentle air-drying for 5 sec. Then, the bond (AdheSE adhesive) will be applied on the enamel and dentin and light cured with a LED curing unit for about 30 sec. Tetric N-Ceram will then be applied using an incremental filling technique, each increment will not exceed 2mm in thickness. Each increment will be polymerized for 20 sec with a LED light-curing unit.
223818028|NCT05716620|DIAGNOSTIC_TEST|MRI|USG and MRI will be performed on the same day. US will be performed prior to MRI. There will be two rounds of screening 6 months apart using paired US and non-enhanced AMRI.
223818029|NCT05529784|DRUG|Dupilumab 300 MG/2 ML Subcutaneous Solution [DUPIXENT]|Dupilumab 300mg in pre-filled injector Q2W
223818030|NCT03733561|DRUG|LY03003|LY03003 (rotigotine extended release microspheres for intramuscular \[IM\] injection)
223818031|NCT03733561|DRUG|Neupro 4Mg/24Hr Transdermal Patch|neupro patch
223818032|NCT02343003|DEVICE|Cooled Radiofrequency|Delivery of energy to ablate sensory nerves via cooled radiofrequency probe
223818033|NCT02343003|DRUG|Corticosteroid injection|Delivery of corticosteroid into knee by injection with needle to reduce knee pain
223818034|NCT00058201|DRUG|fluorouracil|Given IV
223818035|NCT00058201|DRUG|gemcitabine hydrochloride|Given IV
223818036|NCT00058201|DRUG|leucovorin calcium|Given IV
223818037|NCT00058201|OTHER|clinical observation|No intervention
223818038|NCT05797064|PROCEDURE|Natural Orifice Specimen Extraction Surgery|Natural Orifice Specimen Extraction Surgery (NOSES) is a minimally invasive surgical technique that aims to reduce the size and number of incisions required during certain surgeries. In NOSES, the surgical specimen (such as a diseased organ or tumor) is removed from the body through a natural orifice (such as the mouth, anus, or vagina), rather than through an incision in the abdominal wall. In this trial, we will extract surgical specimens from the rectum to reduce trauma to the abdominal wall.
223818039|NCT01299090|DEVICE|Pelleve Wrinkle Treatment System - includes the Pelleve Handpiece and S5 generator|two treatments spaced 30 days apart
223818040|NCT03183583|PROCEDURE|Tissue adhesive in primary Total Hip and Total Knee arthroplasty|Use of tissue adhesive in primary Total Hip and Total Knee arthroplasty
223818041|NCT04334421|DEVICE|Composite mesh|Pelvic floor is reconstructed by synthetic composite mesh (Symbotex, Medtronic) to improve healing and prevent perineal herniation.
223818042|NCT04048863|DEVICE|B. Braun Peripheral Advantage (PA) Program|B. Braun PA includes: Christie VeinViewer® Vision2 , Introcan Safety® IV Catheters, STEADYCare™ Smallbore Extension Set, and the PA Education
223818043|NCT04048863|DEVICE|Hospital Standard of Care|Standard of Care for PIVC access per hospital protocol
223818044|NCT02430701|PROCEDURE|Irreversible electroporation (IRE)|Irreversible Electroportion For Unresectable Esophageal Neoplasms guide with ultrasound or/and CT.
223818045|NCT02430701|DEVICE|NanoKnife|
223818046|NCT01576367|BIOLOGICAL|ACZ885|
223818047|NCT04564950|OTHER|Observation of serum and salivary Galectin-3 levels|Observation of serum and salivary Galectin-3 levels and correlation with periodontal indices
223818048|NCT02428244|BEHAVIORAL|Motivational Interviewing|Motivational Interviewing coupled with education will be provided to help participants understand the risks associated with smoking and their fracture care. They will be referred to the quitline.
223818049|NCT02428244|BEHAVIORAL|Motivational Interviewing + Follow-up|"Motivational Interviewing coupled with education will be provided to help participants understand the risks associated with smoking and their fracture care. They will be referred to the quitline.~In this intervention, the participants will receive additional motivational interviewing sessions at 2 weeks, 6 weeks, 3 months and 6 months."
223818050|NCT03059875|BEHAVIORAL|Medical consultation for a Standardized Geriatric Evaluation|
223818051|NCT04458116|DIETARY_SUPPLEMENT|Curcumin|Participants will receive 1.5 grams of turmeric 95% curcumin for 1 month (3 capsules / day containing 500mg each for 4 weeks).
223818052|NCT06163352|DRUG|Norepinephrine|The sample consisted of all medical and surgical patients over 18 who do not have pressure injury upon admission and received one or more vasopressor agent infusions (norepinephrine, epinephrine, dopamine) for at least 48 hours during their stay in the ICU and pressure injury development was assessed. The effect of combined use of more than one vasopressor agent on the development of pressure injury was investigated, considering the type and quantity of vasopressors (norepinephrine and dopamine), vasopressor combinations, total duration of infusion, and doses of vasopressors used.
223818053|NCT02085681|OTHER|Tele-medicine|Patients at the diabetes clinics will be subjected to non-mydriatic retinal imaging and the images will be transferred to the eye hospital via internet using a specified software - Aravind Diabetic Retinopathy Evaluation Software (ADRES) that enables a retinal specialist to read and grad the image and send the feedback immediately to the diabetes clinic. Based on the presence or absence of DR the patients will be referred to the eye hospital for detailed retinal examination.
223818054|NCT02085681|OTHER|Conventional referral|All eligible patients in the conventional arm will be counselled on the importance of eye screening and will be referred to the eye hospital
223818055|NCT04821128|OTHER|Radiologic and pathological review.|"We will analyse the pre operative scannographic and MRI (if available) images, and the post operative pathological analyses.~The scanners will be reviewed by 2 well trained clinicians (one head and neck radiologist and one head and neck surgeon).~Then we will analyse the correlation between the radiological and the pathological analysis."
223818056|NCT02999425|OTHER|Education|Educational intervention
223818057|NCT03432884|DRUG|BGB-3111|Subjects will receive BGB-3111
223818058|NCT03432884|DRUG|Placebo|Subjects will receive Placebo
223818059|NCT03432884|DRUG|Moxifloxacin|Subjects will receive Moxifloxicin
223818060|NCT01059032|OTHER|Using a 3 dimentional post processing filter|Using a 3 dimentional post processing filter
223818061|NCT05118230|OTHER|Inclisiran|Prospective observational study. There is no treatment allocation. Chinese Patients who receive inclisiran in authorized health institutions are eligible to enroll into this study.
223818062|NCT04359771|DEVICE|Yellow micro-pulse laser|applying 577-nm yellow laser in a micro-pulse mode over the macular area including the fovea
223818063|NCT04359771|DEVICE|Diode micro-pulse laser|applying 810-nm infra-red diode laser in a micro-pulse mode over the macular area including the fovea
223818064|NCT00003137|DRUG|irinotecan hydrochloride|
223818065|NCT00257959|DRUG|amiodarone beta blocker sotalol|
223818066|NCT01511796|OTHER|upper limb rehabiliation|3 months upper rehabilation (twice a week) and then 3 more months upper limb rehabitation ( twice a week)
223818067|NCT05296291|DEVICE|High-translucent monolithic zirconia Bridge|Each patient will be treated according to standard of care with implants from Nobel Biocare, the Branmark system and then randomly assigned to receive a bridge made of either 1) metal ceramic (Nobel Procera, titanium skeleton), 2) zirconia ceramics (Nobel Procera zirconia skeleton) or 3) high-translucent monolithic zirconia (Nobel Procera).
223818068|NCT05296291|DEVICE|Zirconium oxide ceramics Framework|Each patient will be treated according to standard of care with implants from Nobel Biocare, the Branmark system and then randomly assigned to receive a bridge made of either 1) metal ceramic (Nobel Procera, titanium skeleton), 2) zirconia ceramics (Nobel Procera zirconia skeleton) or 3) high-translucent monolithic zirconia (Nobel Procera).
223818069|NCT05296291|DEVICE|Metal-ceramic Framework|Each patient will be treated according to standard of care with implants from Nobel Biocare, the Branmark system and then randomly assigned to receive a bridge made of either 1) metal ceramic (Nobel Procera, titanium skeleton), 2) zirconia ceramics (Nobel Procera zirconia skeleton) or 3) high-translucent monolithic zirconia (Nobel Procera).
223818070|NCT01398423|DRUG|Active Control|Losartan potassium (50 mg) plus placebo to match alpha lipoic acid (600 mg)
223818071|NCT01398423|DRUG|INV-144|INV-144 is a combination drug product consisting of losartan potassium (50mg) and alpha lipoic acid (600 mg)
223818072|NCT03427190|OTHER|APSOM vs Control|In complement to actions described in the control arm, the patient's general practitioner (GP) and the patient him/herself will be contacted within 21 days of hospital discharge in order to organize an appointment between them two; this consultation is expected to take place between day 22 and day 45 after hospital discharge. If the patient does not have a GP, a health-care professional (HCP) will be provided. .GP (or HCP) will also be contacted at 6 and 13 months.
223818073|NCT00326638|RADIATION|Arm B: Helical Tomotherapy Intensity Modulated Radiotherapy|"IMRT using Helical Tomotherapy\* 7800 cGY/39 Fractions once daily Monday to Friday for 8 weeks~* Initial IMRT to Nodes/Prostate + Seminal Vesicles 4,600 cGy/23~* Boost IMRT to Prostate 3,200 cGy/16"
223818074|NCT00326638|OTHER|Arm A: 3D-Conformal Radiation|"3DCRT 7800 cGY/39 Fractions/ STD Technique\* once daily Monday to Friday for 8 weeks~* Initial 4F 3DCRT to Nodes/ Prostate + Seminal Vesicles 4,600 cGy/23~* Boost 6 F 3DCRT to Prostate 3,200 cGy/16"
223818075|NCT05172895|OTHER|Presence, prevalence, severity, and morphological characteristics of anemia|Evaluation of the presence, prevalence, severity, and morphological characteristics of anemia, trying to define, when possible, the underlying pathogenetic mechanisms, paying particular attention to the characteristics of menstrual cycles, the iron, folate and vitamin B12 metabolism, any chronic inflammatory state, and thyroid hormones.
223818076|NCT05172895|OTHER|Effect of gluten-free diet on anemia|Evaluation of the therapeutic responses (i.e., improvement/regression) of anemia after at least one year of GFD.
223818077|NCT03372837|DRUG|Rituximab|The administration of rituximab at 375 mg/m\^2/day by intravenous infusion on Day 1 of each 21-day cycle with up to 6 cycles. Dose modifications are not permitted.
223818078|NCT03592277|DRUG|Vitamin C|Patients will receive 1.5g of vitamin C in 100mL of 0.9% sodium chloride (normal saline) every six hours for four days or until discharge from the ICU, whichever happens first (seventeen dose maximum).
223818079|NCT03592277|DRUG|Vitamin B1|Patients will also receive 200 mg of IV vitamin B1 every 12 hours in 50 mL of normal saline for four days or until ICU discharge (whichever happens first, nine dose maximum).
223818080|NCT04325087|DEVICE|iTBS|Administration of an iTBS protocol over the dlPFC
223818081|NCT04325087|DEVICE|Placebo iTBS|Administration of a placebo TMS protocol over the dlPFC
223818082|NCT02112760|OTHER|specific stabilization exercise|The specific stabilization exercise refers to an exercise that targets the deep trunk muscle, including the multifidus and transversus abdominis with ultrasound feedback.
223818083|NCT04866121|PROCEDURE|Acupuncture|A standardized acupuncture protocol will be administered
223818084|NCT01462162|DRUG|Tocilizumab|
223818085|NCT01503840|DRUG|sugammadex|sugammadex 10 mg/ml diluted solution dosage: 1mg/kg i.v. (0,1 ml/kg)
223818086|NCT01503840|DRUG|Sodium chloride solution|Sodium chloride solution 0,9% dosage: 0,1 ml/kg i.v.
223818087|NCT03853460|PROCEDURE|epidural catheter|ultrasound low frequency probe will be used to determine the depth of the posterior complex to assists placement of midline thoracic epidural
223818088|NCT03853460|PROCEDURE|nerve block catheter|ultrasound guided placement of bilateral quadratus lumborum catheters
223818089|NCT00282724|DRUG|Liarozole|
223818090|NCT04912674|DEVICE|Symphony OCT System|Surgical intervention will be patient specified by treating surgeon.
223818091|NCT04757818|OTHER|0.07% cetylpyridinium chloride (CPC) in mouthwash|A mouthwash and gargles with 15 ml of 0.07% cetylpyridinium chloride (CPC) in mouthwash for 1 minute.
223818092|NCT04757818|OTHER|Distilled water with the same colorant as the experimental product|A mouthwash and gargles with 15 ml of distilled water for 1 minute
223818093|NCT05383664|OTHER|Ultra Violet Light Exposure|Subjects will stand at the determined distance from the UV lamps facing towards them to achieve full body UV exposure. They will stand for the time indicated to achieve the appropriate dose. Each exposure will range from about 1 minute to 4.5 minutes to deliver a dose ranging from 0.22J/cm2 to 0.88J/cm2. Subjects will then rotate to irradiate their back side for the same time to achieve the same dose. On the second visit clinical examination will be conducted for erythema. If no erythema is apparent, the dosage on subsequent visits may increase to the max of 0.88 J/cm2.
223818094|NCT03775226|DEVICE|ChampioNIR® SFA Stent|The ChampioNIR® SFA Stent is composed of a Nitinol alloy structure with an elastomeric micro-fiber mesh and is designed specifically to be used in the peripheral vasculature. The stent is characterized by high flexibility, strong radial support and high resistance to fractures, as well as high deliverability and precise positioning.
223818095|NCT00000157|DRUG|Aspirin|
223818096|NCT01346514|BEHAVIORAL|Intensive Addiction/Housing Case Management|AHCM provided: 1) support in obtaining/maintaining housing through education about resources, coordination with VA and community housing program providers, assistance in establishing housing program eligibility, and problem-solving around threats to housing stability; 2) support for SUD and related issues that affect housing status through treatment engagement/re-engagement, referrals for needed services (e.g. psychiatric, medical, vocational), and addressing substance use issues proactively; 3) promotion of residential stability through Life Skills Training, which was designed to improve key skills (room and self-care, money management, and community participation).
223818097|NCT01346514|BEHAVIORAL|Housing Support Group|The HSG focused on gaining support from fellow study participants and learning from those who successfully obtained housing. Group facilitators provided education about housing resources and assistance with housing-related issues.
223818098|NCT00909480|DRUG|insulin detemir|"Treat-to-target (individually adjusted dose) titration according to titration algorithm.~S.c. (under the skin) injection once daily as an add-on to subjects' stable pre-trial metformin dose (at least 1500 mg/day). Any other use of OAD will be discontinued"
223818099|NCT00909480|DRUG|insulin glargine|"Treat-to-target (individually adjusted dose) titration according to titration algorithm.~S.c. (under the skin) injection once daily as an add-on to subjects' stable pre-trial metformin dose (at least 1500 mg/day). Any other use of OAD will be discontinued"
223818100|NCT00861601|DRUG|eltrombopag 12.5 milligrams (mg) tablet|eltrombopag 12.5 mg tablet once a day
223818101|NCT00861601|DRUG|eltrombopag 25 mg tablet|eltrombopag 25 mg tablet once a day
223818102|NCT01215357|DRUG|Ecopipam|50mg tablets
223818103|NCT02561169|DRUG|Oseltamivir|Those randomized to the intervention will receive oseltamivir 75 mg orally twice daily for 5 days within 72 hours of symptom onset. For patients with a known creatinine clearance \< 10 ml/min, the recommended dose of 75mg orally daily for 5 days of either intervention or placebo will be administered.
223818104|NCT02561169|OTHER|Placebo|Those randomized to the control arm will receive 75mg placebo calcium carbonate pills taken twice daily for five days within 72 hours of symptom onset and will be identical in appearance to oseltamivir. For patients with a known creatinine clearance \< 10 ml/min, the recommended dose of 75mg orally daily for 5 days of either intervention or placebo will be administered.
223818105|NCT04454086|OTHER|Aerobic Exercise|Undergo aerobic exercise
223818106|NCT04454086|OTHER|Exercise Counseling|Receive behavioral activity counseling
223818107|NCT04454086|OTHER|Nutritional Assessment|Receive nutritional counseling
223818108|NCT04454086|OTHER|Quality-of-Life Assessment|Ancillary studies
223818109|NCT04454086|OTHER|Questionnaire Administration|Ancillary studies
223818110|NCT04454086|OTHER|Resistance Training|Undergo resistance exercises
223818111|NCT00355017|PROCEDURE|BNP-guided care in addition to multidisciplinary management|
223818112|NCT04978259|DRUG|Remdesivir|Intravenous remdesivir during hospital stay up to 10 days in addition to standard care.
223818113|NCT05782205|PROCEDURE|Severe complications following radical gastrectomy|The respondents are limited to surgeons who had previously experienced severe complications following radical gastrectomy as chief surgeons.
223818114|NCT00977405|DEVICE|Collatamp Gentamicin Implant|Collatamp Gentamicin placed into subcutaneous layer of dirty abdominal wounds
223818115|NCT00098163|BIOLOGICAL|ALVAC-HIV vCP1521|One 1-ml dose of HIV-1 vaccine administered after birth on or before Day 3 and at weeks 4, 8, and 12.
223818116|NCT00098163|BIOLOGICAL|ALVAC HIV-1 vCP1521|One 1-ml dose of HIV-1 vaccine placebo administered after birth on or before Day 3 and at Weeks 4, 8, and 12.
223818117|NCT04599738|OTHER|Wheat muffin|Participants consumed a control muffin made of wheat flour.
223818118|NCT04599738|OTHER|Finger millet grain muffin|Participants consumed a test muffin made of finger millet grain and wheat flour.
223818119|NCT00002159|DRUG|Itraconazole|
223818120|NCT00002159|DRUG|Amphotericin B|
223818121|NCT03571984|BEHAVIORAL|Moving on ABC Plus|The intervention has two components. CBT Moving on After Breast Cancer
223818122|NCT02881008|DRUG|Entecavir|
223818123|NCT02881008|DRUG|Myrcludex B|
223818124|NCT01492491|DEVICE|SUPRA-HFR|usual dialytic prescription for duration, frequency, acid buffer and anticoagulation regimen.
223818125|NCT04783064|PROCEDURE|Interscalene brachial plexus block|Interscalene brachial plexus block is performed at ipsilateral side of the affected shoulder.
223818126|NCT04191109|OTHER|Observational study|This is an observational study in which the amount of therapy performed during the rehabilitation program will be registered.Data regarding feasibility and safety of the program will be also recorded. Indeed, functional, cognitive and quality of life outcomes will be assessed.
223818127|NCT03282279|PROCEDURE|TVOR|Ultrasound guided transvaginal oocyte retrieval (TVOR) in deep sedation for IVF.
223818128|NCT03614338|BEHAVIORAL|Small changes weight loss program|"This intervention uses a small-changes approach to calorie reduction (operationalized as 6 100-calories changes per day) along with increasing leisure-time physical activity and self-regulation strategies to produce weight loss. The intervention will be delivered via 12 face-to-face group sessions."
223818129|NCT00993824|DRUG|colesevelam HCl|3.75 grams of colesevelam HCl (6 tablets)
223818130|NCT00993824|DRUG|placebo|
223818131|NCT01222429|OTHER|vegan diet|Intervention group participants will follow a low-fat vegan diet and will receive instruction on this diet through the course of the study
223818132|NCT01222429|OTHER|diet following ADA guidelines|participants will be given instruction on the ADA guidelines for diabetes, and will follow an individualized plan based on these guidelines
223818133|NCT01949597|PROCEDURE|laparoscopic surgery for deep endometriosis|
223818134|NCT05834036|DRUG|Amoxicillin Oral Capsule|Amoxicillin 875mg every 12 hours for 7 days.
223818135|NCT01749072|DRUG|Gefitinib group|Gefitinib 250mg once per day until the progression disease or intolerant side effects
223818136|NCT01749072|DRUG|Vinorelbine, Ifosfamide, Mesna|Vinorelbine 25mg/m2 d1,d8; Ifosfamide 1.25g/m1 d1-d3 (Usually 2g d1-d3); Mesna 400mg 0,4,8 hours after Ifosfamide administration for uroprotection d1-d3;
223818137|NCT02013336|DRUG|MM-398 (Irinotecan Sucrosofate Liposome Injection) plus cyclophosphamide|chemotherapy
223818138|NCT03148236|DRUG|Vitamin C|200mg/kg/day split into 4 doses infused every six hours over 30 minutes in 50ml D5W
223818139|NCT03148236|OTHER|Placebo|50mL infused over 30 minutes
223818140|NCT02207517|PROCEDURE|Office-based vergence/accommodative therapy|The OBVAT program has been divided into 4 phases. Within each phase there are a number of categories such as gross convergence, vergence, and accommodation. The therapy procedures in each category have been arranged sequentially from easiest to most difficult
223818141|NCT01720823|DEVICE|home polysomnography (GETEMED)|
223818142|NCT01720823|DEVICE|standard polysomnography (BRAINNET II)|
223818143|NCT02243774|BEHAVIORAL|Core letter signed by Surgeon General|The core letter provides information about influenza and the risks associated with it, incorporating a number of behavioral insights. All four letters evaluated in this study will contain the same tops and bodies that are included in the core letter, but the signature and P.S. tag region will differ among the various intervention groups. In this intervention, the core letter is signed by and includes a picture of the Surgeon General. The letter ends after the signature line and the space beneath the signature line is left blank where a P.S. tag region could be appended.
223818144|NCT02243774|BEHAVIORAL|Core letter signed by the Director of the National Vaccine Program|The core letter is signed by and includes a picture of the Director of the National Vaccine Program. The letter ends after the signature line and the space beneath the signature line is left blank where a P.S. tag region could be appended.
223818145|NCT02243774|BEHAVIORAL|Core letter signed by Surgeon General + implementation prompt|The core letter is signed by and includes a picture of the Surgeon General. Below the signature line of the core letter, an implementation intention prompt is provided in the P.S. tag region that invites the recipient to write in the day of week, month, day, and time at which he or she plans to get vaccinated.
223818146|NCT02243774|BEHAVIORAL|Core letter signed by SG + enhanced implementation prompt|"The core letter is signed by and includes a picture of the Surgeon General (SG). Below the signature line of the core letter, an enhanced implementation intention prompt is provided in the P.S. tag region that prompts recipients to decide now - by checking one of two boxes - indicating they will or will not get vaccinated. The options use language that highlights the losses incumbent in refusing to vaccinate. In addition, an implementation intention prompt is embedded into the checkbox for indicating a choice to be vaccinated."
223818147|NCT05453175|OTHER|Interrupting sitting with Physical activity|Participants will engage in three minutes of walking, five sit to stands and five calf raises every thirty minutes
223818148|NCT06494969|DEVICE|Intraocular pressure measurement|Intraocular pressures were measured and recorded at 8 predefined time points using a tonometer; before anesthesia induction (T1), 10 min after induction (T2), immediately before the beginning of CPB (T3), 3 minute after the beginning of CPB (T4), 3 minute after cross-clamping (T5), 3min after cross-clamp removal (T6), immediately before the weaning of CPB (T7), and end of the surgery (immediately after skin closure) (T8).
223818149|NCT01998490|OTHER|Animal-assisted activity|
223818150|NCT01998490|OTHER|Robot-assisted activity|
223818151|NCT06495541|DRUG|Pyrotinib|Administration method: Pyrrolitinib standard dose: 400 mg once a day, oral administration within 30 minutes after breakfast, continuous administration for 21 days per cycle. The dosage can be determined by the doctor according to the actual situation Make adjustments. Other medications: The doctor selects the medication plan based on the actual situation.
223818152|NCT01617317|DRUG|Hyperimmune intravenous immunoglobulin|Single intravenous infusion of 0.4g/kg of H1N1 2009 H-IVIG
223818153|NCT01617317|DRUG|Intravenous immunoglobulin|Single intravenous infusion of 0.4g/kg of simple IVIG
223818154|NCT02230436|OTHER|Early drain removal|Removing drain(s) on postoperative day 3
223818155|NCT02230436|OTHER|Late drain removal|Removing drain(s) on postoperative day 4 or later
223818156|NCT05799664|DEVICE|TLD|Patients allocated to experimental group will receive TLD therapy during which radiofrequency energy will be delivered to vagus nerve surrounding airway under bronchoscopy.
223818157|NCT05799664|OTHER|Sham TLD procedure|Patients allocated to control group will receive sham TLD procedure during which catheter will be placed in all treatment locations with no radiofrequency energy delivered.
223818158|NCT05799664|OTHER|Standard of care|Patients will also receive standard of care that meet the recommendations of GOLD guideline.
223818159|NCT04266288|DRUG|Ketamine|Active drug
223818160|NCT04266288|DRUG|Sodium Chloride 0.9%|Placebo
223818161|NCT05250401|DIAGNOSTIC_TEST|liver functions and thyroid functions|laboratory tests
223818162|NCT05108064|DIAGNOSTIC_TEST|Artificial intelligence model|Results of artificial intelligence model will be compared with the gold standard
223818163|NCT01426282|OTHER|no intervention|no intervention
223818164|NCT01426282|OTHER|health education|"15 minutes health education given by nurse according to  The Chinese Resident Meals Guide  , National Revision Committee of the Guidelines of Hypertension Prevention and Control in 2005 ,  Guidelines on Prevention and Treatment of Blood Lipid Abnormality in Chinese Adults  ,  Guideline for diagnosis and treatment of patients with chronic stable angina , Guideline for prevention and treatment overweight and obesity in chinese adults "
223818165|NCT03788460|OTHER|no intervention|no intervention
223818166|NCT00557609|DRUG|ARQ 197|360 mg administered twice daily until disease progression or other discontinuation criterion is met
223818167|NCT01302561|DIETARY_SUPPLEMENT|Sucrose|5 g of sucrose twice daily for 24 weeks
223818168|NCT01302561|DIETARY_SUPPLEMENT|Galactooligosaccharide|2.5 g galactooligosaccharide plus 2.5 g sucrose twice daily for 24 weeks
223818169|NCT00363194|DRUG|Pazopanib (GW786034)|Pazopanib (GW786034)
223818170|NCT01973036|DEVICE|Foley Catheter|The balloon will be inflated with 30 cc of sterile saline. The catheter will be taped to the patient's leg so that traction is maintained. The catheter will be assessed hourly for expulsion by a health care provider by applying gentle traction on the catheter or a vaginal examination if it is unclear by traction. Once the Foley catheter is expelled or 12 hours reached, the induction will be continued with oxytocin per this protocol.
223818171|NCT01973036|DRUG|Oxytocin|Each arm will receive oxytocin at a rate of 2 milliunits/milliliter. If the fetal status is reassuring, this can be increased by 2 milliunits/milliliter every 30 minutes to achieve an adequate contraction pattern as per the institution's definition to a maximum of 30 milliunits/milliliter. This infusion may be continued until delivery.
223818172|NCT00653549|DRUG|Torsemide|Tablets, 20 mg, single-dose
223818173|NCT00653549|DRUG|Demadex|tablets, 20 mg, single-dose
223818174|NCT01455792|PROCEDURE|Biopsies using image fusion|MRI and soft image fusion guided biopsy
223818175|NCT01455792|PROCEDURE|Gold standard biopsy|Gold standard TRUS biopsy
223818176|NCT01821417|DEVICE|Microtextured dental implant treatment|Microtextured dental implant treatment will include a surgically inserted device implanted into edentulous areas of the jaw where natural teeth have been lost and adequate bone exists.
223818177|NCT01821417|DEVICE|Dental implant treatment|Treatment with dental implants; implants with a machined collar will be surgically implanted into edentulous areas of the jaw where natural teeth have been lost and adequate bone exists.
223818178|NCT05988164|OTHER|Eye Mask|Patients in the intervention group will be given eye masks and asked to sleep with them at 22:00 or earlier.
223818179|NCT03561337|DIETARY_SUPPLEMENT|PROTEIN-CARBOHYDRATE|PRO before and PRO-CHO after training
223818180|NCT03561337|DIETARY_SUPPLEMENT|CARBOHDYRATE|CHO before and after training
223818181|NCT04772053|PROCEDURE|Tumor biopsy|Archived or fresh tumor biopsy samples will be collected.
223818182|NCT04599101|DEVICE|Nose Frida nasal suction device|Caregivers will be given a Nose Frida device to remove the child's nasal secretions.
223818183|NCT04599101|DEVICE|Bulb syringe nasal suction device|Caregivers will be given a bulb syringe device to remove the child's nasal secretions.
223818184|NCT06323811|DIAGNOSTIC_TEST|CMR|Advanced CMR imaging including a novel quantitative free-breathing 3D perfusion sequence, 3D LGE imaging and a cine Dixon sequence
223818185|NCT00000230|DRUG|Buprenorphine|
223818186|NCT05125393|PROCEDURE|Laparoscopic linear stapler|The ileocecal or ascending colon tumors were resected using a combined cephalic caudal approach. When the accessory right colonic vein is separated from the head and then turned to the caudal side for upward dissociation. After no metastasis of 203 groups of lymph nodes is confirmed according to ICG development during the operation, the Henle stem and its root tissue were resected with a linear stapler.
223818187|NCT04804774|BEHAVIORAL|WW program modified for people with Type 2 diabetes|This 6-month intervention includes the use of WW's mobile app, weekly virtual workshops, and private online community. The program involves: self-monitoring of weight, dietary intake, and physical activity; dietary changes; increasing physical activity; shift in mindset; and behavioral strategies to manage goals. Participants will set goals and weigh-in with a coach via virtual workshop weekly and be encouraged to use the app and private online community daily. The virtual workshop features a behavior change technique and enables the participant to practice it to support their goals. Participants are given a personalized food plan based on expert healthy eating guidelines, an activity plan to promote regular physical activity and techniques to help shift mindset for lasting change. The coach will help with goal setting, overcoming setbacks, and follow-up on progress toward goals weekly. Participants will be encouraged to participate in a private Facebook group for motivational support.
223818188|NCT05288023|DRUG|Azithromycin for Oral Suspension|"Azithromycin will be administered as a single dose in oral suspension form for children (up to the maximum adult dose of 1g).~Dosage will be calculated by age for children aged 1-5 months. For children 6-59 months of age, height-based dosing will be used via height-stick approximation as currently performed by Niger's trachoma program."
223818189|NCT04459559|DEVICE|Tactile Cueing Device|Each participant receives an individual training on how to use the Tactile Cueing Device and the set-up of the TCD will be done according to the results of a 10MWT and the participant's preferences. Gait assessments with an activated or deactivated TCD are executed using the Timed Up and Go test, the 2-Minute Waling test and a treadmill (C-Mill). Also a long-term test run of the TCD during one day is planned.
223818190|NCT01916941|DRUG|Prazosin|
223818191|NCT01916941|DRUG|Placebo|
223818192|NCT00098254|DRUG|BAY 43-9006 (Sorafenib)|Self administered oral doses at 400 mg twice a day with 250 ml (8 oz.) of water each morning and evening (i.e., 12-hourly) continuously in a 28 day cycle. Tablets may be taken with or without food.
223818193|NCT03017131|BIOLOGICAL|Aldesleukin|Given SC
223818194|NCT03017131|DRUG|Cyclophosphamide|Given IV
223818195|NCT03017131|DRUG|Decitabine|Given IV
223818196|NCT03017131|BIOLOGICAL|Genetically Engineered NY-ESO-1-specific T Lymphocytes|Given IV and IP
223818197|NCT03017131|OTHER|Laboratory Biomarker Analysis|Correlative studies
223818198|NCT00006115|DRUG|FOLFIRI regimen|
223818199|NCT00006115|DRUG|FOLFOX regimen|
223818200|NCT00006115|DRUG|fluorouracil|
223818201|NCT00006115|DRUG|irinotecan hydrochloride|
223818202|NCT00006115|DRUG|leucovorin calcium|
223818203|NCT00006115|DRUG|oxaliplatin|
223818204|NCT00004924|DRUG|irinotecan hydrochloride|
223818205|NCT00004924|DRUG|paclitaxel|
223818206|NCT02118337|BIOLOGICAL|MEDI0680|Participants will receive IV infusion of MEDI0680 0.1 or 0.5 or 2.5 or 10 or 20 mg/kg Q2W in dose-escalation phase and 20 mg/kg Q2W in dose-expansion phase.
223818207|NCT02118337|BIOLOGICAL|Durvalumab|Participants will receive IV infusion of durvalumab 3 and 10 mg Q2W in dose-escalation phase and 750 mg Q2W in dose-expansion phase.
223818208|NCT02118337|BIOLOGICAL|Nivolumab|Participants will receive IV infusion of nivolumab 240 mg Q2W in dose-expansion phase.
223818209|NCT02835846|DRUG|Estrogen Cream|Participants are provided a vaginal estrogen cream (i.e., Premarin Cream® 0.625 mg conjugated estrogen/gram) and instructed to use 0.5 grams with an applicator twice weekly for 12 weeks.
223818210|NCT02707419|DEVICE|Experimental group|Video of the exercises
223818211|NCT02707419|DEVICE|Control group|video of nature scenes
223818212|NCT02707419|DEVICE|Conventional physiotherapy|Mobilization, exercises and transfer practice.
223818213|NCT00073437|DRUG|Infliximab|
223818214|NCT02115997|DRUG|Methylprednisolone|Methyprednisolone will be administered 1 to 3 pulses at a dose of 1000 milligram (mg) IV at the discretion of the investigator.
223818215|NCT02115997|DRUG|Prednisone|Prednisone will be administered orally at tapered dose (start at 1 milligrams per kilogram per day \[mg/kg/day\]) at the discretion of investigator given daily until participants are off the drug.
223818216|NCT02115997|DRUG|Rituximab|Rituximab will be administered at 375 milligrams per meter square (mg/m\^2) of body surface area given by IV infusion once weekly from Week 1 to 4.
223818217|NCT01261143|DRUG|BK-C-0701|tablet, 8 weeks
223818218|NCT06018909|BEHAVIORAL|Cognitive-Behavioral Interventions Package|CBIP was developed by researchers in line with the relevant literature according to the developmental characteristics of children. Opinions were obtained from experts in the field of pediatrics or psychiatric nursing regarding CBIP. CBIP consisted of cognitive and behavioral practices to prevent/reduce procedural pain and anxiety.
223818219|NCT04404608|DIAGNOSTIC_TEST|Complete blood picture, bone marrow aspiration cytology|none except the regular routine investigations in such cases
223818220|NCT00798226|DIETARY_SUPPLEMENT|n-3 fatty acid|Oral intake of 4 capsules daily from week 24 of gestation to 1 week after delivery
223818221|NCT00798226|DIETARY_SUPPLEMENT|olive oil|Oral intake of 4 capsules (1 g) daily from 24 weeks of gestation to 1 week after delivery
223818222|NCT04506190|PROCEDURE|Revisional bariatric surgery|Subjects who undergo revisional bariatric surgery
223818223|NCT02962570|DEVICE|On Demand Oxygen Delivery|Supplemental oxygen flow is controlled such that it is on only during inhalation.
223818224|NCT02962570|DEVICE|Traditional, Always-On, Oxygen Delivery|Supplemental oxygen flow is constantly on, irrespective of whether the patient is inhaling or exhaling.
223818225|NCT02962570|DEVICE|Oxygen Flow Stopped|Supplemental oxygen flow is stopped completely for a brief period to allow undisturbed end-tidal oxygen and CO2 measurements
223818226|NCT04855305|DRUG|Hyperpolarized 129Xe|Hyperpolarized 129Xe will be administered in multiple doses in volumes that are tailored to the participant's total lung capacity (TLC) followed by a breath hold of up to 15 seconds.
223818227|NCT02974881|DEVICE|Transcatheter Mitral Valve Replacement|Minimally invasive transcatheter mitral valve implantation using the HighLife™ TMVR system
223818228|NCT02628392|DRUG|DS-8500a|DS-8500a tablets 25mg, 50mg, 75mg
223818229|NCT02628392|DRUG|Sitagliptin|capsules
223818230|NCT02628392|DRUG|placebo|matching DS-8500a tablets and sitagliptin capsules
223818231|NCT02555839|DRUG|Pomalidomide|4mg capsule on d1 through 21 of a 28 day cycle
223818232|NCT02555839|DRUG|Dexamethasone|40 mg (≤75 years) or 20mg (\>75 years) oral on d1, 8, 15, 22 of a 28 day cycle
223818233|NCT02555839|DRUG|Pomalidomide|4mg capsule on d1 through 14 of a 21 day cycle
223818234|NCT02555839|DRUG|Dexamethasone|cycle 1-8: 20mg PO (≤75 years) or 10mg (\>75years) on Days 1, 2, 4, 5, 8, 9, 11, 12 of a 21 day cycle; from cycle 9 onwards: Dexamethasone 20mg PO (≤75 years) or 10mg (\>75years) on Days 1, 2, 8, 9 of a 21 day cycle
223818235|NCT02555839|DRUG|Bortezomib|cycle 1-8: Bortezomib (1,3mg/m2) s.c. on day 1, 4, 8, 11 of a 21 day cycle; from cycle 9 onwards: Bortezomib (1,3mg/m2) s.c. on day 1 and 8 of a 21 day cycle,
223818236|NCT04046003|BEHAVIORAL|Tai chi exercise|24-form Yang style Tai Chi (60 min/session, 3 sessions/week) for 8 weeks
223818237|NCT04893590|BEHAVIORAL|Fatigue self-management SMS intervention|Participants will set up an initial goal for the SMS intervention related to fatigue management, and prior to beginning the intervention they will be trained to use the SMS system. Participants will receive text messages each day, providing tips and techniques to help self-manage fatigue. Weekly the participants will be asked to provide feedback regarding their fatigue levels and their patient activation will be re-assessed at the halfway point of intervention.
223818238|NCT04910984|BEHAVIORAL|Chatbot messages|Automated personalized messages containing HIV testing-related information, motivation and skills
223818239|NCT04910984|BEHAVIORAL|Attention-matched educational materials|Attention-matched educational materials manually sent by our research assistant. These educational materials will be retrieved from CDC and WHO websites and curated into short articles (\<200 words) and pictures. All educational materials will be screened by HIV experts from University of Malaya to ensure accuracy before being sent to participants.
223818240|NCT02401074|BIOLOGICAL|Segmental Bronchoprovocation with Allergen (SBP-Ag)|Premedication will consist of intramuscular glycopyrolate (0.2 mg), and midazolam (0.5-2.0 mg). Subjects will also be given a short-acting beta agonist, albuterol (2 puffs, 180 mcg) prior to bronchoscopy. Following nasopharyngeal anesthesia (topical lidocaine), the fiberoptic bronchoscope will then be passed into a pulmonary segment or subsegment. During the SBP-Ag challenge, approximately 15% of the Ag-PD20 allergenic extract will be instilled into the segment (5)
223818241|NCT02475603|PROCEDURE|Total knee arthroplasty|Total knee arthroplasty
223818242|NCT00674466|DRUG|1.5 mg or 2.0 mg CJC-1134-PC|twice-a-week
223818243|NCT00674466|DRUG|Placebo|twice-a-week
223818244|NCT05078060|BIOLOGICAL|Quadrivalent Influenza Vaccine|Intramuscular or subcutaneous administration
223818245|NCT05078060|BIOLOGICAL|High-Dose Quadrivalent Influenza Vaccine|Intramuscular administration
223818246|NCT03167684|DEVICE|Oral appliance therapy|Fitted oral appliance
223818247|NCT05847179|DRUG|Progerinin|"This is a Phase 2, open-label study to evaluate the safety and Tolerability of Progerinin for the treatment of BMD Bone Mineral Density (BMD) Loss in Subjects with Typical Werner Syndrome.~. There will be up to 5 subjects that will receive treatment with Progerinin twice daily for approximately 1 year. This study will have three phases: Screening Phase, Treatment Phase, and Follow-Up Phase."
223818248|NCT04822844|OTHER|Lavender Essential Oil|Within 5 minutes of arrival at the PACU, the PACU nurse will proactively offer the patient a 2x2 gauze with two drops of essential oil (patient's choice of ginger or lavender essential oil) for all patients who have opted to participate, regardless of their nausea and vomiting status. Participating patients will continue to use the essential oil during their stay in the PACU, which is typically 45-60 minutes.
223818249|NCT04822844|OTHER|Ginger Essential Oil|Within 5 minutes of arrival at the PACU, the PACU nurse will proactively offer the patient a 2x2 gauze with two drops of essential oil (patient's choice of ginger or lavender essential oil) for all patients who have opted to participate, regardless of their nausea and vomiting status. Participating patients will continue to use the essential oil during their stay in the PACU, which is typically 45-60 minutes.
223818250|NCT04957862|PROCEDURE|Robotic Assisted Evacuation|On the day of surgery, the patient is placed in the prone position. After the Mayfield skull clamp is positioned to reduce interference, the videometric tracker of robot will automatically scan the preliminary markers to complete patient-to-image registration. Following the registration, the robotic arm will move on command according to the planned puncture trajectory and stop at a defined distance to the marked target point. The entry point is marked on the scalp along the puncture trajectory, then a scalp incision and burr-hole drilling will be performed. After penetrating the dura with unipolar electrocautery, a drainage tube will be gently inserted to the defined depth under the indication of the disinfected robotic arm. The liquefied hematoma will be withdrawn slowly by a 10 mL syringe.
223818251|NCT06374940|PROCEDURE|Manipulator-assisted Abdominal Hysterectomy|Manipulator-assisted Abdominal Hysterectomy
223818252|NCT00943306|DRUG|lomitapide|5-60 mg po every day
223818253|NCT04531163|DRUG|N Acetylcysteine|(NAC) is a drug used in the experiment and participant are treated with it by 1200mg/day dose for two months.
223818254|NCT01359267|DRUG|99mTc-EC-DG|99mTc-EC-DG will be used before the SPECT/CT scans throughout the study to determine the its effectiveness. 20 mCi of 99mtc-EC-DG will be administered through a vein through a catheter. This will be done before the SPECT/CT scan at 4 weeks and 10 weeks.
223818255|NCT05460923|OTHER|Proprioceptive Neuromuscular Facilitation|including trunk twists, supine to sit, knee to chest, crawling, and bridges. Every session will be 45 minutes. Patients will be given 5 sessions per week and the study will last for 12 months
223818256|NCT05460923|OTHER|Swiss Ball Exercises|trunk twists, supine to sit, knee to chest, crawling, and bridges. Every session will be 45 minutes. Patients will be given 5 sessions per week and the study will last for 12 months
223818257|NCT06560957|BEHAVIORAL|Time restricted eating|Time restricted eating involves restricting the window in which calories are consumed to 8-10 hours, without altering diet quality or caloric intake. In this study, time restricted eating will be a consistent 10-h eating window between 06:00 and 19:00, considered an early TRE pattern, for all days of the week, as chosen by the participant. They will need to consume all food and beverages (except water) during this window for the duration of the 8-week intervention.
223818258|NCT06560957|BEHAVIORAL|Eating ad libitum with nutritional counselling|Nutritional counselling will include customized advice delivered by a registered dietician about dietary choices while allowing individuals to eat at any time of day.
223818259|NCT05765864|DIAGNOSTIC_TEST|Enrollment questionnaire, General questionnaire1, General questionnaire2, General questionnaire3|The questionnaires will cover general and demographic data, information on previous treatments, medication received, mental disorder at discharge (ICD), psychosocial situations (ICD), physical illnesses (ICD), COVID status (vaccinated, recovered, tested), use of psychoactive substances, history of self-harm, suicide attempts, school performance, experience with peers, sexual orientation and identity, residence, family composition, family history of mental disorders, self-harm and suicide attempts.
223818260|NCT05765864|DIAGNOSTIC_TEST|Columbia Suicide Severity Rating Scale (CSSRS)|"The questionnaire is scientifically supported, has the most evidence of utility and efficacy, and is internationally accepted. It has been translated into more than 100 different languages, including Slovene. It is easy to use, suitable for all age groups and adapted for successful use outside the hospital setting, for example in schools, colleges, police, military and elsewhere. It contains 2 screening questions on suicidality and 4 more specific questions, 6 items in total.~Posner K, Brown GK, Stanley B, et al. Am J Psychiatry 2011;168:1266-77."
223818261|NCT05765864|DIAGNOSTIC_TEST|The Brief Non-Suicidal Self-Injury Assessment Tool (B-NSSI-AT)|"used for research purposes to assess the core characteristics of NSSI (form, frequency, function) as well as the secondary characteristics of NSSI (habituation, context of NSSI, perceived impact on life and treatment).~Whitlock J, Exner-Cortens D, Purington A. Psychol Assess 2014;26:935-46."
223818262|NCT05765864|DIAGNOSTIC_TEST|Experiences in Close Relationships-Relationship Structures (ECR-RS)|"Assesses the pattern of attachment to attachment figures (friend, romantic partner, mother, father) in adults and adolescents. The questionnaire has been officially translated into Slovene and used with several samples of Slovene adults and adolescents.~Fraley RC, Waller NG, Brennan KA. J Pers Soc Psychol 2000;78:350-65."
223818263|NCT05765864|DIAGNOSTIC_TEST|Trauma Symptom Checklist for Children (TSCC)|"The questionnaire helps to assess children's/adolescents' experiences of various traumatic experiences, such as physical or sexual violence, peer violence, loss, witnessing violent acts, natural disasters, etc. The questionnaire consists of 6 clinical scales (Anxiety, Depression, Anger, Post-traumatic Stress Symptom, Dissociativeness (two subscales), Sexual Concerns) and 2 validity scales. 6 clinical scales (Anxiety, Depressiveness, Anger, Post-traumatic Stress Symptom, Dissociativeness (two subscales), and 2 validity scales) are included.~https://www.center-pds.si/Katalogtestov/Kliničnitesti/Vprašalnikotravmatiziranostiotrokinmladostnik. aspx"
223818264|NCT05765864|DIAGNOSTIC_TEST|Personality Assessment Inventory-Adolescent (PAI-A)|"An objective-type self-assessment questionnaire for assessing personality in adolescents. It has 264 items to be answered on a 4-point scale. 22 independent scales are obtained (Inconsistency, Rarity, Negative impression, Positive impression, Physical complaints, Anxiety, Anxiety-related disorders, Depressiveness, Mania, Paranoid, Schizophrenia, Borderline traits, Antisocial traits, Alcohol problems, Drug problems, Aggressiveness, Suicidal ideation, Stress, Lack of support, Refusal to deal, Dominance, Warmth).~https://www.center-pds.si/Katalogtestov/Kliničnitesti/Vprašalnikzaocenoosebnosti-oblikazamladostnike-PAI-A.aspx"
223818265|NCT05765864|DIAGNOSTIC_TEST|Inventory Of Statements About Self-Injury; ISAS|"A self-assessment questionnaire used for research purposes to assess the basic characteristics of NSSI (form, frequency, function, time to event). It also assesses the desire to stop. The questionnaire has been previously translated into Slovene and used in a population of adolescents with self-injurious behaviour.~Glenn CR, Klonsky ED. One-year test-retest reliability of the Inventory of Statements about Self-Injury (ISAS). Assessment. 2011 Sep;18(3):375-8. doi: 10.1177/1073191111411669."
223818266|NCT05765864|DIAGNOSTIC_TEST|The Level of Personality Functioning Scale-Brief Form 2.0; LPFSBF 2.0|"A short, user-friendly instrument that gives a quick impression of the expression of personality pathology. It consists of 12 items grouped into two higher-order domains: self-functioning and interpersonal functioning. Participants are asked to rate the 12 items on a four-point Likert scale ranging from 1 (completely false) to 4 (completely true). A total score (sum of all items), a self-functioning score (sum of items 1-6) and an interpersonal functioning score (sum of items 7-12) can be calculated. Satisfactory internal consistency and promising construct validity have been demonstrated. Sensitivity to change after three months of treatment was high.~Weekers LC, Hutsebaut J, Kamphuis JH. The Level of Personality Functioning Scale-Brief Form 2.0: Update of a brief instrument for assessing level of personality functioning. Personal Ment Health 2019;13:3-14."
223818267|NCT05765864|DIAGNOSTIC_TEST|Borderline Personality Features Scale, BPFSC-11|"The BPFS-C-11 includes BPD indicators such as affective instability, identity problems and negative attitudes. Responses to the items are on a 5-point Likert scale ranging from 'not at all true' to 'always true'. Studies have shown construct validity of interpretations of BPFS-C-11 scores through positive associations with other measures of BPD and positive associations with measures of BPD correlates, including emotional dysregulation. In a recent sample, the Cronbach's α over 4 years of follow-up was 0.86, 0.85, 0.86 and 0.90, respectively. The scale has been officially translated into Slovenian and will be used with the permission of the authors. It is intended for use by children and adolescents aged 9-11 years and consists of 11 items.~Sharp, C., Steinberg, L., Temple, J., Newlin, E. An 11-Item Measure to Assess Borderline Traits in Adolescents: Refinement of the BPFSC Using IRT . Personality Disorders: Theory, Research, and Treatment 2014;5(1):70-78."
223818268|NCT05765864|OTHER|Dynamic Appraisal of Situational Aggression-Youth Version (DASA-YV)|"It's a professional assessment tool which provides a daily assessment of the risk of heteroaggression. The evaluation is efficient and takes less than five minutes. The nurse in charge of each patient completes the DASA-YV once a day.~Dutch SG, Patil N. Validating a Measurement Tool to Predict Aggressive Behavior in Hospitalized Youth. J Am Psychiatr Nurses Assoc 2019;25:396-404."
223818269|NCT05765864|OTHER|Adolescent Self-Harm Risk Scale; ASHRS|It's a professional assessment tool which provides a daily assessment of the risk of heteroaggression. This is the scale we developed for the present study. It will be used to assess and predict the short-term risk of self-harm behaviour during hospitalisation (assessment at admission) and the long-term risk after discharge (assessment at discharge).
223818270|NCT05765864|DIAGNOSTIC_TEST|Lifetime Incidence of Traumatic Events questionnaire (LITE)|"Is a short checklist for screening and assessing the exposure to trauma in children and adolescents. It covers a broad range of potentially upsetting situations that can cause trauma to children and adolescents, such as a car accident, fire, death of a family member, exposure to threats, sexual assault, or witnessing violence. The questionnaire had been validated on a Slovene population of children and adolesscents.~Greenwald R, Rubin A. Assessment of posttraumatic symptoms in children:~development and preliminary validation of parent and child scales. Res Soc Work Pract. (1999) 9:61-75. doi: 10.1177/104973159900900105 Uršicˇ K, Bucik V, Klemencˇ icˇ S, Bratina N, Battelino T, Dovcˇ K and Drobnicˇ Radobuljac M (2021) Validation of the Lifetime Incidence of Traumatic Events (LITE-S/P) Questionnaires in Children and Adolescents in Slovenia. Front. Psychiatry 12:665315. doi: 10.3389/fpsyt.2021.665315"
223818271|NCT05765864|GENETIC|Genetic methods|DNA isolation, Sequencing, Libraries preparation, Analisys; Bioinformatics (Base Calling, Variant Calling, Quantification and evaluation of short tandem repetitions, Methylation sites detection).
223818272|NCT01615354|DRUG|Aleglitazar|Multiple oral doses
223818273|NCT01615354|DRUG|Microgynon®|Multiple oral doses
223818274|NCT01615354|DRUG|Placebo|Multiple oral doses
223818275|NCT02774603|OTHER|Aquatic Locomotor Training|
223818276|NCT02774603|OTHER|Land Locomotor Training|
223818277|NCT01447849|DRUG|lubiprostone|24mcg twice a day (BID) 1 week
223818278|NCT01447849|DRUG|placebo|Placebo pills twice a day for one week.
223818279|NCT04987190|PROCEDURE|alveolar bone graft|alveolar bone graft with Scarpa fascia done when patients were at 9 year of age
223818280|NCT03123289|DRUG|68-Gallium citrate PET/CT scan|After establishment of an intravenous access, approximately 5 mCi of 68Ga-citrate (Zevacor Molecular, Somerset, NJ, USA) will be administered intravenously. Whole body PET/CT scan will be performed after 60 minutes of uptake phase.
223818281|NCT03123289|DRUG|18F FDG PET/CT scan|Subjects will undergo FDG PET/CT scan using the same imaging parameters either on the same day or within the next 24-48 hours. The subjects will be requested to fast for a minimum of 4 h prior to PET acquisition. After confirmation of a blood glucose level ≤200 mg/dl, technologists will establish the intravenous access and the subject will receive approximately 10 mCi of 18F-FDG (Zevacor Molecular, Somerset, NJ, USA) intravenously. The subject will be placed in uptake room for 60 minutes to allow for optimal localization of the compound. The subjects will be requested to void prior to administration of 18FDG and again prior to image acquisition.
223818282|NCT00372801|DRUG|Ibuprofen|
223818283|NCT05448898|DRUG|Traditional Chinese Medicine CU Xiu Tang|Oral Traditional Chinese Medicine CU Xiu Tang once a day and repeat and deliberate sniffing of a set of odorants for 20 seconds each at least twice a day for at least 3 months
223818284|NCT05448898|OTHER|Olfactory Training|repeat and deliberate sniffing of a set of odorants for 20 seconds each at least twice a day for at least 3 months
223818285|NCT04732208|DIAGNOSTIC_TEST|Colour fundus photography|Fundus images will be captured before and after administration of mydriatic agent
223818286|NCT02201056|DRUG|TAK-935|TAK-935 oral solution
223818287|NCT02201056|DRUG|Placebo|TAK-935 placebo-matching oral solution
223818288|NCT01847170|BIOLOGICAL|Fecal Microbial Transplantation|
223818289|NCT01970787|DEVICE|Radiofrequency Ablation (RFA) using the HALO Ablation System|
223818290|NCT01395823|DIETARY_SUPPLEMENT|ergocalciferol supplementation|50,000 IU given either weekly; weekly for 3 months then monthly for 3 months; monthly
223818291|NCT01395823|OTHER|placebo|placebo pill given weekly, weekly for 3 months then monthly for 3 months; monthly
223818292|NCT00898014|GENETIC|fluorescence in situ hybridization|
223818293|NCT00898014|OTHER|immunologic technique|
223818294|NCT00898014|OTHER|laboratory biomarker analysis|
223818295|NCT02323087|DEVICE|FLEXICULT™ SSI-Urinary Kit|Urine culture and sensitivity testing will be performed on the intervention group by means of a POCT, the FLEXICULT™ SSI-Urinary Kit. The kit is designed as an ordinary Petri dish but with higher sides. The Petri dish is divided into 6 compartments: 1 large one for quantitative analysis and 5 smaller ones for susceptibility testing (Fig. 1). The agar in each of the smaller compartments contains 1 of 5 antimicrobials: trimethoprim, sulfamethoxazole, ampicillin, nitrofurantoin and mecillinam. The agar plate is flooded with the urine specimen for a couple of seconds and then incubated at 35°C over night. The following day the plate is read. When reading the compartment for quantitative analysis the lower limit is:103 colony-forming units (cfu) per milliliter.
223818296|NCT02323087|DEVICE|ID FlexicultTM|Point of care culture will be performed using ID FlexicultTM,which is a chromogenic agar plate for identification and quantitation of urinary tract pathogens. The agar plate is for cultivation of urine, which makes it possible to identify the bacteria and quantitate the amount of bacteria. Based on bacterial colony color and size can be determined which bacteria are involved. For example, an E. coli bacteria will grow with big red colonies, and Enterobacter sp. will grow with large dark blue / purple colonies. The sample is seeded with a 10 uL inoculation needle, the lid is applied and the agar plate incubated with the lid down at 35 0C overnight. The plate is read the next day
223818297|NCT02168543|DRUG|Alendronate|
223818298|NCT02168543|DRUG|Placebo|
223818299|NCT04617132|BEHAVIORAL|MBCT/MBSR|This intervention teaches the practice of mindfulness - being aware of the present moment without judgement - to help reduce the emotional reactivity to thoughts and bodily sensations, which prevents downward spirals into depression, anxiety, or fear.
223818300|NCT01648621|BEHAVIORAL|40 minute standardized education session|40 minute standardized education session based on the Living Well with COPD Patient's Education Tool on study enrolment to assess and improve understanding of disease and ability to monitor symptoms and recognize exacerbation
223818301|NCT01648621|BEHAVIORAL|Individualized action plan|Individualized action plan using the Living Well with COPD template with patient individualized modification to address management strategies for exacerbation of comorbidity developed during the initial 40 minute session with case manager.
223818302|NCT01648621|BEHAVIORAL|Individualized care plan|Individualized care plan for management of COPD and comorbidities developed by the case manager in consultation with family physician and specialists.
223818303|NCT01648621|BEHAVIORAL|Standardized reinforcement/motivational interviewing and action plan teach-back sessions|Standardized reinforcement/motivational interviewing and action plan teach-back sessions based on Living Well with COPD modules as well as assessment of symptoms, progress and problems, and problem solving by phone weekly for 12 weeks, then monthly for 9 months (21 sessions) (telephone script; NOTE: case managers will make up to 3 attempts to contact participants during each week of the 12 weeks of weekly phone calls before determining inability to contact the participant for that week.
223818304|NCT01648621|BEHAVIORAL|Tele-home monitoring|"Tele-home monitoring of SpO2, weight, dyspnea, sputum quantity and characteristics, and general well-being for maximum of 6 months.~Inclusion criteria for tele-home monitoring:~a. compatible phone line b. patient consent c. patient or caregiver demonstrated ability to use monitoring equipment d. patient unable to attend outpatient/community appointments for assessment and monitoring because of environmental barriers to access (e.g. physician's office only accessible by stairs) e. severe dyspnea on activities of daily living (Medical Research Council Questionnaire for Assessing Severity of Breathlessness \[MRC\] Class 4 \& 5 or modified MRC \[mMRC\] 3 \& 4) f. frequent ED visits (\> 2) in last 12 months~5\. 12 weeks of clinical stability with no ED visits."
223818305|NCT01648621|BEHAVIORAL|Coordinated and improved communication|Coordinated and improved communication between the patient, family caregivers, family physicians, specialists, and Community Care Access Centres (CCACs) facilitated by the case manager. This will include phone contact by case manager to family physicians and CCAC case manager if applicable after initial enrollment, education session and development of action plan, then monthly to report general status as well as after subsequent ED presentations/hospital admissions
223818306|NCT01648621|BEHAVIORAL|Priority access|Priority access to ambulatory clinics (Respirology and other specialties as required including Psychiatry) facilitated through the case manager.
223818307|NCT01648621|BEHAVIORAL|Dictated patient summary|Dictated patient summary sent by specialists (e.g. respirologists) to family physicians following each respiratory centre visit (every 12 weeks)
223818308|NCT01648621|BEHAVIORAL|in-hospital rehabilitation/self-management program|"Referral to an 8 week in-hospital rehabilitation and self-management education program for patients that are:~1. have had a recent exacerbation, but are now clinically stable;~2. symptomatic COPD including reduced activity levels and increased dyspnea despite pharmacological treatment;~3. have stabilized comorbidity (no evidence of active ischemic, musculoskeletal, psychiatric or other systemic disease); and~4. have sufficient motivation to participate."
223818309|NCT01648621|BEHAVIORAL|Smoking cessation|Referral to a smoking cessation program (as applicable)
223818310|NCT01648621|BEHAVIORAL|Action plan Respirologist|Individualized action plan developed with treating respirologist at the discretion of the attending respirologist.
223818311|NCT01648621|BEHAVIORAL|Web based self management materials|Referral to educational materials and resources (Living Well with COPD module printouts provided during COPD rehabilitation classes at a cost to the individual)
223818312|NCT02081222|PROCEDURE|surgery for congenital heart disease with cardiopulmonary bypass|surgery for congenital heart disease with cardiopulmonary bypass
223818313|NCT01633125|OTHER|Group music therapy|The academically trained music therapist with previous relevant clinical experience will apply receptive and active music therapy techniques. The receptive methods will include music imagery,The active techniques will include musical improvisation and song writing.
223818314|NCT01759654|BIOLOGICAL|AdimFlu-V|
223818315|NCT01789697|OTHER|cellular device/computers|A random group of patients will receive text messages to their cellular device from the surgeon, as well as emails to their email addresses.
223818316|NCT03919812|DIETARY_SUPPLEMENT|Cholecalciferol supplementation|supplementation received by subject according to their vitamin D status: insufficiency or deficiency.
223818317|NCT01741116|DRUG|TKI258|Investigational treatment refers to TKI258 in this study Until Progression, unacceptable toxicity, withdrawal
223818318|NCT02780830|DRUG|AZD2014|AZD2014 will be supplied as oral tablets. AZD2014 will be taken orally twice per day on an intermittent dosing schedule, 2 days on and 5 days off of each week.
223818319|NCT02780830|DRUG|Ibrutinib|Ibrutinib will be provided in hard gelatin capsules in opaque high-density polyethylene bottles. On days of AZD2014 dosing, ibrutinib will be taken with the morning dose of AZD2014.
223818320|NCT04251871|DRUG|Conventional medicines (Oxygen therapy, alfa interferon via aerosol inhalation, and lopinavir/ritonavir) and Traditional Chinese Medicines (TCMs) granules|"Conventional medicines: oxygen therapy, antiviral therapy (alfa interferon via aerosol inhalation, and lopinavir/ritonavir, 400mg/100mg, p.o, bid) for 14 days.~Traditional Chinese Medicines (TCMs) granules: 20g, p.o, bid, for 14 days."
223818321|NCT04251871|DRUG|Conventional medicines (Oxygen therapy, alfa interferon via aerosol inhalation, and lopinavir/ritonavir)|Conventional medicines: oxygen therapy, antiviral therapy (alfa interferon via aerosol inhalation, and lopinavir/ritonavir, 400mg/100mg, p.o, bid) for 14 days.
223818322|NCT00925821|PROCEDURE|allogeneic stem cell transplant versus second autologous transplantation|Transplantation of stem cells from a MRD or MUD, respectively after dose-reduced conditioning versus autologous stem cell graft after preparation with melphalan 200 mg/m²
223818323|NCT00925821|DRUG|RAD|After enrollment, patients are to receive four cycles of RAD induction treatment: a combination of lenalidomide (Revlimid), adriamycin, and dexamethasone.
223818324|NCT03114917|OTHER|Cognitive AppRoaches to coMbatting Suicidality (CARMS)|The investigators' psychological therapy is a recovery-focused, structured, time-limited, socio-cognitive intervention. It is based upon the investigators' recently developed treatment manual (Tarrier et al., 2013) and pilot RCTs in the community (Tarrier et al., 2014) and in prison (Tarrier et al., accepted). The intervention modifies negative appraisals of emotional regulation, social support, and interpersonal problem-solving. As a consequence, perceptions of defeat, entrapment, and hopelessness will be improved indirectly. In addition, perceptions of defeat, entrapment, and hopelessness will be worked on directly during the therapy.
223818325|NCT06245122|DRUG|CS23546|Tablets administered orally.
223818326|NCT01257711|PROCEDURE|Roux-en-Y or Billroth II|Roux-en-Y had fewer problems related to reflux of bile but a higher incidence of stasis in the Roux limb resulting in longer hospital stay. Some surgeon avoids doing Roux-en-Y is a triad of post operative symptoms including abdominal pain, vomiting and nausea called Roux-en-Y loop syndrome. Billroth II reconstruction is a simpler operation with only one anastomosis and faster operating time. This has implications while managing gastric cancer patients who may be malnourished and a simpler procedure may have lesser risk of complications and yield better outcomes. Billroth II has increased reflux associated problem like esophagitis and gastritis, risk of afferent loop and dumping syndrome. Long term nutritional outcomes are similar for both procedures.
223818327|NCT06391684|BEHAVIORAL|Social/non social; predictable vs unpredictable|Task 1: social predictable vs social unpredictable ; Task2 a. social \& b. non social, predictable/unpredictable (for both)
223818328|NCT01036022|DRUG|GSK1399686|Each dose level of GSK1399686 will be subsequently tested in a cohort of approximately 20 patients, who will be randomized in a 3:1:1 ratio to receive GSK1399686 (once daily over 4 weeks, followed by 2 weeks dosing with placebo), placebo, or ASACOL (t.i.d. for 6 weeks), respectively.
223818329|NCT00432081|DRUG|indomethacin|
223818330|NCT03300570|DRUG|Dolcanatide|Given PO
223818331|NCT03300570|OTHER|Laboratory Biomarker Analysis|Correlative studies
223818332|NCT03300570|OTHER|Placebo Administration|Given PO
223818333|NCT03300570|OTHER|Questionnaire Administration|Ancillary studies
223818334|NCT05845775|PROCEDURE|Percutaneous dilatational tracheostomy|The percutaneous dilatational tracheostomy procedure will be performed via fiberoptic bronchoscopy
223818335|NCT05845775|DEVICE|Bronchoscopy|Fiberoptic bronchoscopy
223818336|NCT05845775|DEVICE|ultrasonography|ultrasonography
223818337|NCT05845775|DIAGNOSTIC_TEST|Bronchoscopy application|Fiberoptic bronchoscopy application
223818338|NCT05845775|DIAGNOSTIC_TEST|Ultrasound examination|Ultrasound examination
223818339|NCT05305014|DIAGNOSTIC_TEST|blood inflammatory markers (TNF-α, IL1ra, RsIL-2, IL-6, IL-10, IL-18, IFNγ, MCP-1/CCL2 GFAP)|Bioassays of blood inflammatory markers (TNF-α, IL1ra, RsIL-2, IL-6, IL-10, IL-18, IFNγ, MCP-1/CCL2 GFAP) from sera babcocked in the HYCORE mother study.
223818340|NCT04318158|DRUG|Bupivacaine|single shot US guided TAP block using 20 ml bupivacaine 0.25%.
223818341|NCT04318158|DRUG|Dexmedetomidine|Single shot US guided TAP block using 20 ml bupivacaine 0.25% + 50 µg dexmedetomedine on each side.
223818342|NCT04318158|DRUG|Fentanyl|Single shot US guided TAP block using 20 ml bupivacaine 0.25% + 50 µg fentanyl on each side.
223818343|NCT04485715|OTHER|AI system|The real-time assistance of AI system
223818344|NCT04904822|PROCEDURE|Vaginal bisection|Uterine bisection vaginally by scalpel 24
223818345|NCT04904822|PROCEDURE|Abdominal bisection|Uterine bisection by endokinfe
223818346|NCT00160420|DRUG|Asoprisnil|5mg Tablet, oral Daily for 12 months
223818347|NCT01417611|PROCEDURE|i-scan CE, SE, TE mode|I-scan technology is the newly developed image enhanced endoscopy technology, classified as a digital contrast method among endoscopic imaging techniques. I-scan has three modes of image enhancement, i.e. surface enhancement (SE); contrast enhancement (CE); and tone enhancement (TE). The three modes (SE, CE and TE) are arranged in series, therefore, it is possible to apply two or more of these three modes at one time. Switching the levels or modes of enhancements can be done on a real-time basis, without any time lag by pushing a relevant button, thus enabling efficient endoscopic observation.
223818348|NCT04686162|OTHER|bae application|"Patients will be assisted by a research team member to install and configure the application bae on their smartphone; then, they will be trained to use it.~Bae proposes 4 types of assessments :~1. 5 times a day during 3 days, every month (5 minutes) : patients can assess their emotions, their thoughts, their behavior and their occurrence context.~2. Weekly (7 minutes) : consists of a summary of the week, about their emotions, thoughts, behavior, their relationships (family, work, friends), and their quality of life.~3. Monthly (5 minutes): assessment of the usefulness and satisfaction about the application.~4. Assessment available at any time An action plan is designed to support the participants, to help them facing difficult emotions and feelings, and to encourage them to ask for help.~They can contact a relative or call the psychiatric emergency service directly by clicking on a button.~Patients can try to identify their own warning signs, to prevent suicidal behavior."
223818349|NCT03070717|PROCEDURE|Observation & Diagnosis|SD-OCT, fundus autofluorescence, fundus photography, optional microperimetry, ophthalmic exams (BCVA, optical biometry), blood sampling.
223818350|NCT04362163|DEVICE|Snorkel-based improvised personal protective equipment|An improvised PPE design based on a full face snorkel mask mated to a heat-and-moisture exchange filter via a 3D printed adaptor.
223818351|NCT04238312|DEVICE|RESPeRATE™|Fifty-five anxious pediatric dental patients received a breathing session of 10 minutes, using the RESPeRATE™ device.
223818352|NCT04238312|BEHAVIORAL|Tell, Show and Do technique|Fifty-five anxious pediatric dental patients received a traditional behavior management technique (Tell-Show-Do).
223818353|NCT02447835|DRUG|Olanzapine|Olanzapine is approved for the treatment of schizophrenia and mania associated with bipolar disorder. Olanzapine is a psychotropic agent that belongs to the thienobenzodiazepine class. The chemical designation is 2-methyl-4-4methyl-1 piperazinyl-10H-thienol (2,3-b)\[1,5\]benzodiazepine. The molecular formula is C17H20N4S which corresponds to a molecular weight of 312.44.Olanzpine is a yellow crystalline solid which is practically insoluble in water. Olanzapine is a selective monoaminergic antagonist with high affinity binding to the following receptors:5HT2A2C, 5HT6, dopamine 2-4, histamine H1, and adrenergic α-1. In addition olanzapine is an antagonist with moderate affinity for muscarinic M1-5 and 5HT3. The mechanism of action of olanzapine is unknown although it may be mediated through a combination of dopamine and serotonergic type 2 receptors.
223818354|NCT04045444|OTHER|walking|Every participants will performed a set of tasks of 2 min. Each task will be separated by a 2 min resting period. The tasks will be walking at 3 km/h, walking while doing the cognitive task, walking at the preferred speed, walking at the preferred speed while doing the cognitive task.
223818355|NCT04045444|OTHER|cognitive task|Every participants will performed a set of tasks of 2 min. Each task will be separated by a 2 min resting period. The tasks will be a cognitive task, a control cognitive task.
223818356|NCT01491074|DRUG|Tocilizumab 280 mg|Intravenous administration of 280 mg Tocilizumab (14 ml), mixed with 86 ml 0.9% NaCl
223818357|NCT01491074|DRUG|NaCl 0.9% 100 ml|Placebo
223818358|NCT00576732|DRUG|Placebo|Oral solution qd or bid for 6 weeks
223818359|NCT00576732|DRUG|Risperidone high dose|Risperidone oral solution 1.25 mg (if \<45 kg) or 1.75 mg (if \>=45 kg) qd or bid for 6 weeks
223818360|NCT00576732|DRUG|Risperidone low dose|Risperidone oral solution 0.125 mg (if \<45 kg) or 0.175 mg (if \>=45 kg) qd or bid for 6 weeks
223818361|NCT00920023|DRUG|Superparamagnetic Iron Oxide Magnetic Resonance Imaging|Two MRIs will be performed over a two day period. The second scan will be done 48 hours after intravenous infusion of ferumoxytol
223818362|NCT03188120|DRUG|Spiriva Respimat|Drug
223818363|NCT02628132|DRUG|Paclitaxel|Paclitaxel will be given weekly for 6 cycles
223818364|NCT02628132|DRUG|Durvalumab|Durvalumab will be given q2 wks concurrently with paclitaxel.
223818365|NCT01769170|DRUG|Brincidofovir|
223818366|NCT01769170|OTHER|Placebo|
223818367|NCT03591367|DIAGNOSTIC_TEST|MicroRNAs-155|Quantitative analysis of cell-free miR-155 using RT-qPCR.
223818368|NCT03591367|DIAGNOSTIC_TEST|Human telomerase reverse transcriptase|Analysis TERT by TERT messenger RNA (mRNA)expression by reverse transcription-quantitative polymerase chain reaction.
223818369|NCT02807428|DRUG|AYX1 Injection 660 mg/6 mL|6 mL solution for intrathecal injection with 660 mg of AYX1 (Brivoligide)
223818370|NCT02807428|DRUG|Placebo Injection 6 mL|6 mL solution for intrathecal injection; vehicle formulation designed to mimic AYX1 Injection (with no active drug)
223818371|NCT02978443|DRUG|Nivolumab|nivolumab administered IV over 60 minutes at 1 mg/kg every 3 weeks for 4 treatment cycles (Induction) then continue with nivolumab administered IV over 60 minutes at 3 mg/kg every 2 weeks
223818372|NCT02978443|DRUG|Ipilimumab|ipilimumab administered IV over 90 minutes at 3 mg/kg every 3 weeks for 4 treatment cycles (Induction)
223818373|NCT02536638|OTHER|Exposure to pyelonephritis|Pyelonephritis group are patients with exposure to pyelonephritis Without pyelonephritis group are patients without pyelonephritis
223818374|NCT01472874|DRUG|Once a day Trientine|Trientine at a dosage of \~15 mg/kg rounded upwards to the nearest 250 or 300 mg in a single daily dosage. The entire daily dosage will be taken at once in the AM an hour before any meal. Duration of the study is 1 year.
223818375|NCT04961008|OTHER|Bottle-PEP|A device that gives positive pressure from a bottle with the help of a non deflating tube
223818376|NCT04961008|OTHER|Routine physiotherapy|Routine pulmonary physiotherapy
223818377|NCT04902222|DRUG|Morphine|Administration of 0.1 mg/kg (IBW) intravenous morphine
223818378|NCT03219008|DRUG|Fluoxetine|Fluoxetine is one kind of selective serotonin reuptake inhibitor(SSRIs), whose effect is much better than other non-underload subtypes compared with underload subtypes.So patients would be treated with fluoxetine only.
223818379|NCT03219008|COMBINATION_PRODUCT|fluoxetine + cognitive-behavioral treatment（CBT）|the investigators would recommend fluoxetine to help to cure depressive disorder.And CBT is a very effective way for patients to alleviate or relieve clinical symptoms during episode stage.
223818380|NCT03219008|DRUG|fluoxetine + Amfebutamone|Amfebutamone is one kind of SNRIs, and it shows much better therapy effect on patients with exhaustion /dizziness.So the investigators recommend these two drugs to help to cure patients with depressive disorder.
223818381|NCT03219008|COMBINATION_PRODUCT|physical treatment+fluoxetine+amfebutamone|the investigators recommend drug(fluoxetine and amfebutamone) and physical treatment as intervention.
223818382|NCT03219008|DRUG|Fluvoxamine|Fluvoxamine could inhibit CYP1A2 and CYP2C19 and affect the metabolism of melatonin, and help to release symptoms of depressive disorder with sleep problems.
223818383|NCT03219008|DRUG|Lithium+fluvoxamine|the investigators recommend lithium as a mood stabilizer and use fluvoxamine to affect the level of melatonin.
223818384|NCT03219008|COMBINATION_PRODUCT|fluvoxamine + lithium + physical therapy|the investigators recommend depressants and mood stabilizers as well as physical therapy to help to cure depressive disorder.
223818385|NCT03219008|COMBINATION_PRODUCT|Cognitive behavior treatment +fluvoxamine|the investigators recommend behavioral therapy as well as drugs.
223818386|NCT03219008|DRUG|Mirtazapine/SNRIs|Mirtazapine is one kind of antagonist of a2 adrenergic receptors and could block 5-hydroxytryptamine2 and 5-hydroxytryptamine3,help to release symptoms like anxiety or somatization.Besides, SNRIs could also make similar effect on patients.Therefore, the investigators recommend mirtazapine/SNRIs to treat patients with depressive disorder.
223818387|NCT03219008|COMBINATION_PRODUCT|mirtazapine+ Cognitive behavior treatment|the investigators recommend CBT and mirtazapine as interventions.The dosage and frequency would depend on patients' severity of symptoms .
223818388|NCT03219008|DRUG|mirtazapine + SNRIs|the investigator recommend mirtazapine and SNRIs to treat patients with major depressive disorder.
223818389|NCT03219008|COMBINATION_PRODUCT|mirtazapine + SNRIs + physical therapy|the investigators would manage to use drugs and physical treatment to help to release the symptoms of depressive disorder.
223818390|NCT03219008|OTHER|TAU(treat as usual)|patients in this group would receive therapy strategies according to their symptoms and preference.
223818391|NCT04797182|DRUG|avatrombopag|avatrombopag,60 mg/d,po
223818392|NCT02607371|OTHER|VKAs|VKA have been prescribed in the customary manner in accordance with the terms of the marketing authorization; decision to prescribe these agents has been made at least 3 months prior to study inclusion; assignment of a patient to a particular therapeutic strategy is only made retrospectively (treatment decision falls within current practice and the prescription of the medicines is separated from the decision to include the patient in the study)
223818393|NCT02607371|OTHER|NOACs including Rivaroxaban (Xarelto, BAY59-7939)|NOAC have been prescribed in the customary manner in accordance with the terms of the marketing authorization; decision to prescribe these agents has been made at least 3 months prior to study inclusion; assignment of a patient to a particular therapeutic strategy is only made retrospectively (treatment decision falls within current practice and the prescription of the medicines is separated from the decision to include the patient in the study)
223818394|NCT02607371|OTHER|Edoxaban|NOAC have been prescribed in the customary manner in accordance with the terms of the marketing authorization; decision to prescribe these agents has been made at least 3 months prior to study inclusion; assignment of a patient to a particular therapeutic strategy is only made retrospectively (treatment decision falls within current practice and the prescription of the medicines is separated from the decision to include the patient in the study)
223818395|NCT02607371|OTHER|Apixaban|NOAC have been prescribed in the customary manner in accordance with the terms of the marketing authorization; decision to prescribe these agents has been made at least 3 months prior to study inclusion; assignment of a patient to a particular therapeutic strategy is only made retrospectively (treatment decision falls within current practice and the prescription of the medicines is separated from the decision to include the patient in the study)
223818396|NCT02607371|OTHER|Dabigatran-etexilate|NOAC have been prescribed in the customary manner in accordance with the terms of the marketing authorization; decision to prescribe these agents has been made at least 3 months prior to study inclusion; assignment of a patient to a particular therapeutic strategy is only made retrospectively (treatment decision falls within current practice and the prescription of the medicines is separated from the decision to include the patient in the study)
223818397|NCT03381222|DIAGNOSTIC_TEST|epiaoryic scan|Epiaortic scan will be performed by use L15-7i Phillips®. Ultrasound probe cover with sterile cover. Five standard epiaortic views will be collected
223818398|NCT03146039|RADIATION|Radiation Therapy|"Whole pelvis radiation therapy will be delivered according to institutional standard of care.~SBRT is delivered with 5 fractions of 5.5-8 Gy prescribed to the high-risk CTV, with dose constraints identical to those for high dose rate, volume-directed brachytherapy. The patient will undergo arc therapy with a minimum of two arcs. On-line kV CBCT will be used to verify the isocenter prior to each arc delivery. Patients will be resimulated for SBRT boost planning."
223818399|NCT04603976|DRUG|Erenumab|Erenumab 70 mg or 140 mg packed in a SureClick® Autoinjector Pen (AI)
223818400|NCT00781066|PROCEDURE|Controlled cord traction|"1. Clamp the cord close to the perineum (once pulsation stops, or after three minutes in a healthy newborn), hold it in one hand.~2. Place the other hand just above the woman's pubic bone and stabilize the uterus by applying counter-pressure during controlled cord traction.~3. Keep slight tension on the cord and await a strong uterine contraction (2-3 minutes).~4. With the strong uterine contraction, encourage the mother to push and very gently pull downward on the cord to deliver the placenta. Continue to apply counter-pressure to the uterus.~5. If the placenta does not descend during 30-40 seconds of CCT, do not continue to pull on the cord:~   * Gently hold the cord and wait until the uterus is well contracted again;~  * With the next contraction, repeat CCT with counter-pressure."
223818401|NCT00781066|PROCEDURE|No controlled cord traction|"1. Clamp the cord close to the perineum (once pulsation stops, or after three minutes in a healthy newborn).~2. No CCT will be used and no fundal pressure. The placenta will be delivered physiologically, and signs for placental separation will be awaited (gush of blood from the vagina, descent of the umbilical cord, and increase in the height of the uterus in the abdomen as the lower segment was distended).~3. After separation, delivery of the placenta will be aided only by maternal expulsive efforts and/or gravity."
223818402|NCT05529745|OTHER|Neurorehabilitation cerebellar cognitive disorder|Influence of neurorehabilitation treatment lines of physiotherapy and exercise therapy including scheduled occupational therapy to adapt and improve cognitive-affective disorders in cerebellar lesions.
223818403|NCT04430413|BIOLOGICAL|Platelet Rich Plasma|Autologous PRP obtained via double centrifugation process of the participant's blood sample. PRP was prepared by the double Spain strategy.
223818404|NCT05013866|PROCEDURE|Repair resin composite proximal|Repair proximal composite resin restoration, removing the defective material and then restoring it with another composite resin
223818405|NCT00347581|PROCEDURE|Base-in prism glasses for reading|
223818406|NCT00347581|PROCEDURE|Placebo reading glasses|
223818407|NCT03402516|DEVICE|18.5 resector|hysteroscopic myomectomy with a 18.5 Fr resector after cervical dilatation until Hegar bougie number 7
223818408|NCT03402516|DEVICE|26Fr resector|hysteroscopic myomectomy with a 26Fr resector after cervical dilatation until Hegar bougie number 10
223818409|NCT01450202|OTHER|bowel insufflation gas|air insufflation, during colonoscopy and esophagogastroduodenoscopy
223818410|NCT01450202|OTHER|bowel insufflation gas|CO2 insufflation, during colonoscopy and esophagogastroduodenoscopy
223818411|NCT02915094|DRUG|Anakinra|
223818412|NCT03249506|DRUG|Canagliflozin|Participants who received canagliflozin as a part of routine clinical practice and met new user criteria, will be included in SGLT2i new user group.
223818413|NCT03249506|DRUG|Empagliflozin|Participants who received empagliflozin as a part of routine clinical practice and met new user criteria, will be included in SGLT2i new user group.
223818414|NCT03249506|DRUG|Dapagliflozin|Participants who received dapagliflozin as a part of routine clinical practice and met new user criteria, will be included in SGLT2i new user group.
223818415|NCT03249506|DRUG|Dipeptidyl Peptidase-4 Inhibitor (DPP-4)|Participants who received a DPP-4 as a part of routine clinical practice and met new user criteria, will be included in non-SGLT2i new users group.
223818416|NCT03249506|DRUG|Glucagon-Like Peptide-1 Agonist (GLP-1)|Participants who received a GLP-1 as a part of routine clinical practice and met new user criteria, will be included in non-SGLT2i new users group.
223818417|NCT03249506|DRUG|Thiazolidinedione (TZD)|Participants who received a TZD as a part of routine clinical practice and met new user criteria, will be included in non-SGLT2i new users group.
223818418|NCT03249506|DRUG|Sulfonylureas|Participants who received a sulfonylureas as a part of routine clinical practice and met new user criteria, will be included in non-SGLT2i new users group.
223818419|NCT03249506|DRUG|Insulin|Participants who received a insulin as a part of routine clinical practice and met new user criteria, will be included in non-SGLT2i new users group.
223818420|NCT01802255|DRUG|Sevoflurane|Sedation with inhaled anesthetic via AnaConDa.
223818421|NCT01802255|DRUG|Midazolam|Intravenous sedation.
223818422|NCT05124093|PROCEDURE|Apnoeic oxygenation|"After 2mins 45 seconds of pre-oxygenation with high-flow nasal oxygen at Fio2 1.0 at 50L/min, anaesthesia is induced with 1-1.5mcg/kg remifentanil plus 2-3mg/kg propofol. Propofol (10mg/kg/hr) and remifentanil (0.15mcg/kg/min) infusions administered until study conclusion.~At the onset of apnoea, 1mg/kg rocuronium administered. Jaw thrust performed. High-flow nasal oxygen adjusted to the randomised flow rate. Videolaryngoscopy after 1 minute of apnoea. Airway patency maintained. Tracheal intubation after 4 minutes of apnoea.~Positive pressure ventilation commenced at Spo2 92%. Failure to obtain view of glottis with videolaryngoscope results in withdrawal from the study.~Blood samples obtained from an arterial catheter immediately prior to commencing pre-oxygenation, after 90 and 180 seconds of pre-oxygenation, after each minute of apnoea until six minutes of apnoea, and every two minutes of apnoea thereafter, until Spo2 92%."
223818423|NCT06459830|OTHER|Mime Therapy with Neural Mobilization|"Experimental group will receive mime therapy and neural mobilization session with small resting intervals.~Self- facial massages for 10 minutes. Breathing and relaxation exercises for 5 mins. Exercises to enhance coordination between both sides of the face and to reduce synkinesis.~Exercises to assist with eye and lip closure for 5 mins. Articulation Exercises for 5 mins. Facial expression exercises for 10 mins.~Facial Neural Mobilization:~Facial mobilization technique will apply when the patient in supine position with head on the table in neural rotation.~The circular movement and horizontal traction will be applied 25 times in three sets with a 5-second rest period in between a single manipulation and a 30- second rest period in between the sets.~All the participates in the experimental group will receive 15 treatment sessions. Each session will held for 60 minutes per day, 5 days per week, for total duration of 3 weeks."
223818424|NCT06459830|OTHER|Mime Therapy with Placebo Mobilization|"Control group will receive mime therapy and placebo nerve mobilization session with small resting intervals.~Self- facial massages for 10 minutes. Breathing and relaxation exercises for 5 mins. Exercises to enhance coordination between both sides of the face and to reduce synkinesis.~Exercises to assist with eye and lip closure for 5 mins. Articulation Exercises for 5 mins. Facial expression exercises for 10 mins.~Placebo Nerve Mobilization Technique:~The placebo nerve mobilization followed all the procedures of real nerve mobilization without applying horizontal and circular auricular traction. The purpose of this placebo nerve mobilization is not to deprived the control group from therapy and equalize the time duration of treatment protocol.~All the participates in the control group will receive 15 treatment sessions. Each session will held for 60 minutes per day, 5 days per week, for total duration of 3 weeks."
223818425|NCT00910455|DRUG|SRX246|single oral dose of SRX246 capsule
223818426|NCT00910455|DRUG|Placebo|Single oral dose of placebo capsule
223818427|NCT05635292|BEHAVIORAL|Tele-CBT|8 weekly 1-hr telemedicine visits with a licensed Ph.D. psychologist from the University of Pennsylvania (permissible to practice across state lines under PSYPACT), plus usual care and referral to an IBD Help Center (email, phone, online chat with IBD information specialist)
223818428|NCT01985828|RADIATION|CyberKnife|
223818429|NCT01985828|OTHER|Androgen Deprivation Therapy (ADT)|
223818430|NCT01985828|RADIATION|Intensity Modulated radiation therapy (IMRT)|Per current standard of care
223818431|NCT04013217|COMBINATION_PRODUCT|Eribulin ORA|Oral eribulin mesylate will be supplied as an aqueous solution and HM30181A-UK
223818432|NCT00658138|DEVICE|3M ESPE Adper Scotchbond SE|To be used per manufacturer's instructions.
223818433|NCT00658138|DEVICE|3M ESPE Adper Scotchbond 1XT|To be used per manufacturer's instructions.
223818434|NCT00006018|DRUG|BMS-214662|This is a dose-escalation study of BMS-214662. BMS-214662 IV over 1 hour on day 3 of course 1. For all subsequent courses, patients receive BMS-214662 IV over 1 hour on day 1 (30 minutes after paclitaxel). Treatment repeats every 3 weeks for at least 2 courses in the absence of disease progression or unacceptable toxicity.
223818435|NCT00006018|DRUG|paclitaxel|Patients receive paclitaxel IV over 3 hours on day 1 of course 1. For all subsequent courses, patients receive paclitaxel IV over 3 hours on day 1. Treatment repeats every 3 weeks for at least 2 courses in the absence of disease progression or unacceptable toxicity.
223818436|NCT03238300|DRUG|N-Acetylcysteine|N-Acetylcysteine; 600mg capsules by mouth, two pills twice daily (total 2400 mg/day). Participants will undergo MRI (including magnetic resonance imaging and functional MRI during an alcohol cue reactivity task) at baseline, after 10 days of N-Acetylcysteine and after 10 days of placebo.
223818437|NCT03238300|DRUG|Placebo Oral Capsule|N-acetylcysteine-matched placebo tablet two pills twice daily. Participants will undergo MRI (including magnetic resonance imaging and functional MRI during an alcohol cue reactivity task) at baseline, after 10 days of N-Acetylcysteine and after 10 days of placebo.
223818438|NCT03651050|BEHAVIORAL|Faith Based Outreach (FBO)|Faith base outreach groups will be trained in P-MHDT
223818439|NCT03651050|BEHAVIORAL|community-health-workers (CHW)|COmmon health workers will be trained in P-MHDT
223818440|NCT01394874|BEHAVIORAL|TLC|Computer-based telephone linked communication will be used to counsel subjects to adhere to their exercise program over time.
223818441|NCT05840848|DIETARY_SUPPLEMENT|Control beta-carotene supplement plus Placebo|15 mg beta-carotene supplement from BIOVEA consumed before breakfast together with an empty capsule.
223818442|NCT05840848|DIETARY_SUPPLEMENT|Control beta-carotene supplement plus iron Supplement|15 mg Beta-carotene supplement from BIOVEA consumed before breakfast together with 25 mg iron (FeSO4; Woerwag Pharma GmbH \& Co. KG, Boeblingen, Germany)
223818443|NCT05840848|DIETARY_SUPPLEMENT|Control beta-carotene supplement plus zinc Supplement|15 mg Beta-carotene supplement from BIOVEA consumed before breakfast together with 30 mg zinc (ZnSO4; Woerwag Pharma GmbH \& Co. KG, Boeblingen, Germany)
223818444|NCT04073810|DIAGNOSTIC_TEST|PET imaging|Coronary 68Ga-DOTATATE PET-MRI or PET-CT at baseline and 3 months
223818445|NCT04073810|DIAGNOSTIC_TEST|Coronary CT angiography|CTCA at baseline and 2 years
223818446|NCT04073810|DIAGNOSTIC_TEST|Cardiac MRI|Cardiac MRI at 1 year
223818447|NCT01741519|DRUG|LDLL600|Comparison of 3 different doses LDLL600 in long-term infusion. 54 PK samples, BP and ECG measurement time points, several local tolerability measurement time points.
223818448|NCT01741519|DRUG|Brevibloc|Comparison of 3 different doses Esmolol in long-term infusion. 54 PK samples, BP and ECG measurement time points, several local tolerability measurement time points.
223818449|NCT05558865|BEHAVIORAL|somnovia|Participants receive access to the digital health application somnovia
223818450|NCT00524225|DRUG|Neumega (Oprelvekin, Interleukin 11, IL-11)|25 micrograms/kg by subcutaneous injection once daily for four days, followed by once daily on days 1-3 before and after elective surgery or dental procedure
223818451|NCT05446610|OTHER|Fermented product of Pleurotus eryngii mushroom|I Stimulation of human colonic biopsies with the fermented product of Pleurotus eryngii mushroom
223818452|NCT03926793|DRUG|GB002|GB002 low dose or high dose for inhalation
223818453|NCT03926793|DRUG|Placebo|Placebo for inhalation
223818454|NCT03926793|DEVICE|Generic Dry Powder Inhaler|Generic dry powder inhaler for GB002 or Placebo delivery
223818455|NCT05020262|OTHER|CT Image reconstruction|Retrospectively collects CT Images and reconstruct using PI/PC and Idose4/Cardiac Images to assessment the performance of the two new software functions of Incisive CT. No direct intervention to patients. And ICF is exempted by EC.
223818456|NCT00710632|OTHER|laboratory biomarker analysis|
223818457|NCT00710632|OTHER|physiologic testing|
223818458|NCT00710632|OTHER|questionnaire administration|
223818459|NCT00710632|PROCEDURE|management of therapy complications|
223818460|NCT02980926|DRUG|Mepivacaine|This is a shorter acting spinal anesthetic as compared to the current standard of care at this institution.
223818461|NCT02980926|DRUG|Bupivacaine|This is the current standard of care at this institution and many centers. This is a longer acting spinal anesthetic compared to the study drug.
223818462|NCT05878392|OTHER|bone filling materials|the buccal jumping gap was packed using PRF in group 1 the buccal jumping gap was packed using xenograft in group 2 the buccal jumping gap was packed using Alloplastic β-tricalcium phosphate in group 3
223818463|NCT04182711|DEVICE|Device|Phase 1: Time taken for each patient is 25 mins Phase 2: Time taken for each patient is 30 mins
223818464|NCT04885933|DIAGNOSTIC_TEST|sarcopenia measurement|BIA for fat free muscle mass hand grasp strength
223818465|NCT00114361|DRUG|Ribavirin|1200 mg a day, 48 weeks
223818466|NCT00114361|DRUG|Peginterferon alpha 2a|180 µg per week, 48 weeks
223818467|NCT02249455|DEVICE|Acapella|Treatment time for 20 min twice daily
223818468|NCT02249455|OTHER|ELTGOL|ELTGOL technique 20 min twice daily
223818469|NCT02249455|OTHER|conventional physiotherapy|Conventional physiotherapy was given twice daily for 20 min
223818470|NCT03778034|OTHER|female with Forward head posture|measuring tmj proprioception with open eyes and closed eyes for mouth opening,right deviation,left deviation and protrusion,cranio vertebral angle and shoulder angle
223818471|NCT03778034|OTHER|healthy female without (FHP)|measuring tmj proprioception with open eyes and closed eyes for mouth opening,right deviation,left deviation and protrusion,cranio vertebral angle and shoulder angle
223818472|NCT03490214|DEVICE|Multispectral Optoacoustic Tomography|Non-invasive transcutaneous imaging of subcellular muscle components
223818473|NCT00755014|OTHER|red wine|One group (n=20) that consumed red wine (100 ml) daily for 3 weeks Another group (n=20) that consumed beer (250 ml) daily for 3 weeks
223818474|NCT01099514|DRUG|Nilotinib|D1\~ Nilotinib 400 mg (2 capsules) PO BID q 28 days
223818475|NCT02261584|DEVICE|Microwave Thermal Coagulation|Microwave thermal coagulation of splenic parenchyma.
223818476|NCT02261584|DEVICE|Partial Splenic Embolization|Femoral artery approach will be used for splenic artery catheterization with the tip of the catheter always well advanced selectively into the splenic artery. Embolizing agent will be injected in small increments. Arteriography in between divided doses will be done to document the extent of devascularization.
223818477|NCT03241602|DRUG|Intraperitoneal lidocaine|the investigator prepares syringes 1.75 ml/kg of 0.2% lidocaine (3.5 mg/kg) or the same volume of normal saline, for intraperitoneal administration. The solution to be instillated will be splashed under the right diaphragmatic area by the surgeon and complete the procedure.
223818478|NCT03241602|PROCEDURE|Pulmonary Recruitment|pulmonary recruitment maneuver will be done and consist of five manual pulmonary inflations with a maximum pressure of 40 cm H2O. The anestheiologist hold the fifth positive pressure inflation for approximately 5 seconds
223818479|NCT03241602|COMBINATION_PRODUCT|Combined intraperitoneal lidocaine and pulmonary recruitment maneuver|the investigator prepares syringes 1.75 ml/kg of 0.2% lidocaine (3.5 mg/kg) or the same volume of normal saline, for intraperitoneal administration. The solution to be instillated will be splashed under the right diaphragmatic area by the surgeon and complete the procedure before the recovery of the patient pulmonary recruitment maneuver will be done and consist of five manual pulmonary inflations with a maximum pressure of 40 cm H2O. The anestheiologist hold the fifth positive pressure inflation for approximately 5 seconds
223818480|NCT06451822|DEVICE|mIntense L+AS|The investigated dermal filler mIntense L+AS is intended to be used as a temporary filler, administered by intradermal or subcutaneous injections, to correct small skin defects, such as wrinkles or scars.
223818481|NCT01121198|DRUG|ASP1941|oral
223818482|NCT01121198|DRUG|placebo|oral
223818483|NCT01893827|DRUG|XR-NTX (Extended-Release Naltrexone)|380mg (4cc) XR-NTX administered by IM injection 1x/month for 6 months.
223818484|NCT01893827|DRUG|Oral Naltrexone (O-NTX)|50mg pill form of naltrexone taken 1x/day for 6 months.
223818485|NCT01897701|BIOLOGICAL|Monovalent Avian Influenza VLP (H7N9)|
223818486|NCT01897701|BIOLOGICAL|Adjuvant 1|
223818487|NCT01897701|BIOLOGICAL|Placebo|
223818488|NCT02740855|DEVICE|Alcomed 3011®|Endtidal ethanol measurement
223818489|NCT06341621|DRUG|3-year abemaciclib without chemo|aromatase inhibitors (± ovarian suppression) plus 3-year abemaciclib (100mg bid) without chemotherapy.
223818490|NCT06341621|DRUG|treatment of physician's choice|treatment of physician's choice including whether to receive chemotherapy, chemotherapy regimen and endocrine therapy regimen.
223818491|NCT01060202|DRUG|No intervention|This is an observational study. Patients receiving bortezomib injection intravenously (into a vein) 1.3 mg/m2 twice a week for 21 days will be observed.
223818492|NCT06858566|OTHER|Kaligo + score|The Kaligo + Score will be taken twice a week during baseline and intervention and once a week during follow-up.
223818493|NCT05335382|BEHAVIORAL|Brief Interventions (BI)|'Brief Interventions' (BI) is a multitude of interventions used in patient visits within PCBH. BI start immediately at the initial consultation, which ends with a personally tailored and evidence-informed plan adjusted to the patient's context. The interventions within BI often have their foundation in CBT, ACT or Motivational Interviewing (MI), however interventions from other schools of therapy can also be used. The common theme is that they are principle-based rather than manual-based and focus on behavioural change in relation to a problem, rather than focusing on a specific diagnosis. Follow-up appointments are scheduled flexibly depending on the patient's perceived need. A BI treatment usually consists of 1-4 appointments with several weeks apart and has an open ending, where the patient easily can schedule a new appointment. Clinicians delivering brief interventions will have had 3 days of training as well as regular supervision.
223818494|NCT05335382|BEHAVIORAL|Care As Usual (CAU)|Care As Usual includes the PCC's current routine care for patients with mental and behavioral problems. This can include a multitude of procedures and treatment, such as pharmacological treatment, supportive care, cognitive behavioural therapy (CBT) and psychodynamic therapy of varying lengths. Interviews with patients as well as medical journals will be used to categorise what type of care each individual patient has received.
223818495|NCT00278070|DRUG|vinorelbine oral formulation|Patients will take three times a week \[Monday, Wednesday and Friday\] by mouth, a standard dose of soft capsules of vinorelbine given at dose ascribed by randomization procedure
223818496|NCT02089230|DRUG|MEK 162|"Phase I Starting Dose of MEK 162: 15 mg by mouth twice a day in a 28 day cycle.~Phase II Starting Dose of MEK 162: Maximum tolerated dose from Phase I."
223818497|NCT01921816|DEVICE|Prismocitrate 18/0, Prism0cal|Subjects on continuous hemodiafiltration will ordinarily receive heparin as the anticoagulation. In our study, regional citrate anticoagulation with Prismacitrate is used to replace heparin. Citrate has been shown in study to be safer than heparin with reduced bleeding risk
223818498|NCT00686140|DRUG|celecoxib|400mg/day, twice a day, 12 weeks
223818499|NCT00686140|DRUG|Placebo|twice a day, 12 weeks
223818500|NCT05465161|DEVICE|Sting Mark Fiducial Marker|Device insertion will occur with the designated needles and through the appropriate organ-specific route and imaging guidance. Multiple STING-MARK fiducials will be inserted. Plain film x-rays in 3 planes of the organs with the marker inserted will be taken and recorded.
223818501|NCT02561286|BEHAVIORAL|BRO HIV Risk Reduction Intervention|BRO HIV Risk Reduction Intervention was designed to strengthen outcome expectancies supporting condom use and other sexual risk reduction strategies and skill and self-efficacy to use condoms and reduce sexual risk behaviors. It consisted of three 90-min one-on-one individual sessions implemented during 3 consecutive weeks by specially trained facilitators using standardized intervention manuals. Sessions 1 and 2 included take-home assignments that the participants reviewed at the subsequent session. The delivery of the intervention was tailored to the information that the participants provided during the sessions, including the context in which behaviors occurred and participants' motivation for the behaviors.
223818502|NCT02561286|BEHAVIORAL|Health Promotion Intervention|"Health Promotion Intervention was designed to provide a control for Hawthorne effects, reducing the likelihood that the HIV/STI risk-reduction intervention's effects could be attributed to non-specific features, including special attention. It focused on increasing physical activity and fruit-and-vegetable consumption and decreasing fat consumption to reduce the risk of chronic diseases, including heart disease, hypertension, stroke, diabetes, and certain cancers-leading causes of morbidity and mortality among African Americans It also consisted of three 90-min one-on-one individual sessions implemented during 3 consecutive weeks by specially trained facilitators using standardized intervention manuals."
223818503|NCT05047874|BEHAVIORAL|systemic methylprednisolone|short-term (3 days) high-dose (1000 mg) systemic methylprednisolone and low-dose long-term (2x 40 mg) systemic methylprednisolone
223818504|NCT01949233|DRUG|Irbesartan 150-300mg capsules daily for 6 months|
223818505|NCT01949233|DRUG|Doxycycline 100-200mg capsules daily for 6 months|
223818506|NCT01949233|DRUG|Doxycycline placebo capsules daily for 6 months|
223818507|NCT01949233|DRUG|Irbesartan placebo capsules daily for 6 months|
223818508|NCT00186498|DRUG|memantine|Patients received a memantine containing capsule starting the day before ECT begins and while receiving ECT
223818509|NCT00186498|DRUG|Placebo Oral Capsule|Patients received a placebo capsule starting the day before ECT begins and while receiving ECT
223818510|NCT06898983|DRUG|Romiplostim N01|Romiplostim N01 will be administered via subcutaneous injection once weekly when patients develop Grade 3 thrombocytopenia (platelet count \< 50×10⁹/L) following leukemia treatment. The recommended initial dose is 5 µg/kg, with a maximum single dose not exceeding 250 µg. Treatment may continue for up to 8 doses.
223818511|NCT06901128|BEHAVIORAL|cognitive therapy|The CT-SAD-A manual developed by Clark and Leigh
223818512|NCT01147289|DRUG|Dextralgen|Dexalgen® will be administered at a dose equivalent to dexamethasone 1.5 mg, dipyrone 500 mg, and hydroxocobalamin 5 mg (one ampoule for each type) a day at a single intramuscular dose. Both drugs will be administered for 3 days, at least.
223818513|NCT01147289|DRUG|Meloxicam|Meloxicam (Movatec®, Boehringer Ingelheim) will be administered as 15 mg (one ampoule) a day at a single intramuscular dose. Both drugs will be administered for 3 days, at least.
223818514|NCT06462716|DRUG|BY101298 Capsules|An oral DNA-PK Inhibitor
223818515|NCT06846554|DRUG|APL-9796|3 Cohorts are planned in Part A.
223818516|NCT06846554|DRUG|APL-9796|The decision to initiate optional Part B in WHO Group 3 PH-ILD participants will be made by the Safety Review Committee (SRC).
223818517|NCT05145413|DRUG|Xanomeline and Trospium Chloride Capsules|KarXT 50 mg/20 mg BID KarXT 75mg/20 mg BID KarXT 100mg/20 mg BID KarXT 125mg/30 mg BID
223818518|NCT05145413|DRUG|Placebo|Placebo Capsules
223818519|NCT06924983|PROCEDURE|Simple neuroendoscopic hematoma evacuation|For patients with spontaneous intracerebral hemorrhage within 24 hours after the onset of the disease, only simple neuroendoscopic evacuation of hematoma will be performed
223818520|NCT06924983|COMBINATION_PRODUCT|Neuroendoscopic hematoma evacuation combined with sodium methylprednisolone succinate|For patients with spontaneous intracerebral hemorrhage within 24 hours after the onset of the disease, they will be treated with the combination of neuroendoscopic hematoma evacuation and sodium methylprednisolone succinate. Administer sodium methylprednisolone succinate for injection by intravenous injection 6 hours after the onset of the disease. Specific administration: Intravenous injection at a dosage of 2 mg/kg, once daily, for three consecutive days.
223818521|NCT02790021|PROCEDURE|Lymphaticovenous anastomosis (LVA)|LVA is a minimally invasive procedure that can be performed under local anesthesia. Indocyanine green (ICG) lymphography is used to visualize the (obstructed) lymphatic vessels. When using the images as a guide, the lymphatic pathways and the sites for incisions for lymphaticovenous anastomoses are marked with a pen. The patient's limb is then prepared for surgery. Under a surgical microscope the lymphatic vessels are identified and viable lymphatic vessels are anastomosed to similarly sized adjacent recipient venules in the subdermal plane.
223818522|NCT01009879|DRUG|Etanercept|Etanercept 50 mg SQ qweek
223818523|NCT06916689|DRUG|1L PEG-Asc|PEG 3350 plus sodium sulfate plus sodium chloride plus potassium chloride plus ascorbic acid plus sodium ascorbate
223818524|NCT06921304|BEHAVIORAL|Intensive Lifestyle Intervention|ILI combines a low-calorie dietary approach with improved lifestyle and physical activity, in addition to usual medical care. Behavioral support for lifestyle intervention will also be provided.
223818525|NCT06926270|DEVICE|TMS|Magstim ,Rapid 2
223818526|NCT03469284|OTHER|Best Practice|Given standard of care therapy
223818527|NCT03469284|DRUG|Methylene Blue|Given lower dose PO
223818528|NCT03469284|DRUG|Methylene Blue|Given medium dose PO
223818529|NCT03469284|DRUG|Methylene Blue|Given higher dose PO
223818530|NCT05208554|BEHAVIORAL|Integrated health counseling and step prescription|8 weekly dyad-based sessions with a health counselor to train couples in the use of communal coping strategies to support one another in achieving physical activity goals plus individualized step prescription based on remotely-monitored Fitbit-derived step counts the week prior
223818531|NCT01007890|OTHER|ChemoFX Assay|Test of an algorithm to predict pathologic response in patients treated with neoadjuvant chemotherapy for breast cancer.
223818532|NCT03075241|DRUG|Zolpidem|Zolpidem tablets, 10mg, 10pm (before bedtime) for 14 nights
223818533|NCT03075241|DRUG|Zoplicone|Zoplicone tablets, 7.5mg, 10pm (before bedtime) for 14 nights
223818534|NCT03075241|DRUG|Placebo|Inactive or inert pill which will be used as a comparator
223818535|NCT06267443|PROCEDURE|Comparison of erector spina plane block, parasternal block plus local infiltration to the tube sides for postoperative analgesia|"Group 1: erector spina plane block: With USG guidance at the thoracal level of 4-5, with 20ml 2.5% bupivacaine ESPB will be performed. after surgery in the ICU pain score and atelectasia will be evaluated.~Group 2: With USG guidance parasternal block will be performed after intubation bilaterally with 10 ml 0.25% bupivacaine each side. at the end of the surgery infiltration of chest tube sides will be performed with 10 ml 2.5% bupivacain."
223818536|NCT00720408|DRUG|Prograf-XL|oral
223818537|NCT00720408|DRUG|Prograf|oral
223818538|NCT00720408|DRUG|MMF|oral
223818539|NCT01175148|DRUG|Atorvastatin calcium (Lipitor)|40 mg PO daily
223818540|NCT05236621|DRUG|Pomalidomide|4 mg pomalidomide capsules administered orally
223818541|NCT05236621|DRUG|Dexamethasone|40 mg dexamethasone tablets administered orally
223818542|NCT01010477|DRUG|Nicotine Nasal Spray|minimum 8 doses of nasal spray per day; maximum of 5 doses per hour, no more than 40 doses per day
223818543|NCT01010477|BEHAVIORAL|Behavioral counseling|Both groups will receive behavioral intervention designed for schizophrenia delivered as 15 individual counseling sessions over 26 weeks.
223818544|NCT02757482|OTHER|training|
223818545|NCT04108546|DEVICE|Electroacupuncture device|The technical characteristics of the device will be: power supply with alkaline batteries (4 pieces), 6V voltage, 6 independently regulated channels, symmetrical biphasic rectangular pulse, excitation from pen type electrode 0.48mA, with high 0.32mA + / -25% \& low 0.16mA +/- 25%. Three preset programs to avoid tolerance effect: program 1) 1-6Hz, program 2) 30-100Hz, program 3) 2-100Hz. Low frequencies (2Hz) cause release of endorphins in the brain and enkephalins in the spinal cord, high frequencies (30-100Hz) cause release of dynorphins in the spinal cord, while medium frequencies (15Hz) cause simultaneous release of endorphin and dynorphin. At low frequencies slow diffuse analgesia is achieved with a long duration of analgesic effect, while at high frequencies rapid local analgesic effect of short duration is achieved.
223818546|NCT04108546|DRUG|Epidural analgesia|Epidural analgesia with lidocaine 2%, 1.5 ml, and Dexamethasone 8 mg
223818547|NCT03570983|DRUG|Allopurinol|Dosage: Allopurinol 200 mg/m2/day starts on the day prior to BCNU, day -8 and stops on day -1.
223818548|NCT03570983|DRUG|Carmustine|Dosage: Carmustine 300 mg/m2 IV x 1 will be infused over 3 hours on autografting day -7. Carmustine should not be infused with solutions or tubing containing or previously containing bicarbonate solution.
223818549|NCT03570983|DRUG|Etoposide|Dosage: Etoposide 100 mg/m2 IV BID will be administered in 500-1000 cc normal saline over 2 hours on autografting days -6, -5, -4, and -3 for a total dose of 800 mg/m2. Etoposide may not be infused with sodium bicarbonate solutions.
223818550|NCT03570983|DRUG|Cytarabine|Dosage: Cytarabine 100 mg/m2 IV BID will be infused over 3 hours on autografting days -6, -5, -4 and -3. Availability and administration: Cytarabine is available in a reconstituted form in solutions containing 20, 50 and 100 mg of cytarabine per mL.
223818551|NCT03570983|DRUG|Melphalan|Melphalan will be administered at a dose of 200 mg/m2 IV x 1 infused over 30 minutes on autografting day -2.
223818552|NCT03585296|DRUG|ATI-502|Topical Solution
223818553|NCT03841656|PROCEDURE|PARORISKIMPLANT|Patients attending periodontal and implant treatment at the Department of Periodontology of the Dental Faculty at Strasbourg, France, between 2000-2015.
223818554|NCT05613101|PROCEDURE|Erector Spinae Plane Block|After the necessary asepsis and antisepsis procedures, the linear ultrasound probe was placed parasagittally 2-3 cm lateral to the spinous process at the L3 or L4 level and the transverse process was visualized. The peripheral block needle (85 mm B Braun Stimuplex A) was advanced in plane up to the transverse process and 10 ml 0.5% bupivacaine hydrochloride 10 ml 0.9% isotonic NaCl mixture was applied on the erector spina muscle.
223818555|NCT05613101|PROCEDURE|Adductor Canal Block|After the necessary asepsis and antisepsis procedures, the linear ultrasound probe was placed in the middle between the medial condyle and the SIAS, and the superficial femoral artery (FSA) was visualized under the sartorius muscle. By following the FSA distally, the point where the sartorius muscle crosses the adductor magnus muscle, which is the beginning of the adductor canal, was found and the saphenous nerve was visualized hyperechoic in the anterolateral aspect of the FSA. 20 cc 0.5% bupivacaine hydrochloride was applied
223818556|NCT05124106|DIAGNOSTIC_TEST|Raman Spectrometry|Bladder tumor is examined with Raman spectrometry during endoscopy
223818557|NCT05046522|DRUG|Palmitoylethanolamide sold as Levagen +|Investigational product to be taken as a 700mg (2 x 350mg) dosage at onset of migraine. If unresolved at 2 hours post onset of migraine, a second dose of 700mg (2 x 350mg) is to be taken.
223818558|NCT05046522|DRUG|Placebo comparator - maltodextrin and microcrystalline cellulose mix|Placebo product to be taken as a 700mg (2 x 350mg) dosage at onset of migraine. If unresolved at 2 hours post onset of migraine, a second dose of 700mg (2 x 350mg) is to be taken.
223818559|NCT01633801|DEVICE|Use of high flows versus oxygen therapy|Once extubation has taken place the child will be placed either on traditional oxygen therapy or high flow nasal cannulae according to randomization.
223818560|NCT01633801|DEVICE|oxygen therapy|Once extubation has taken place the child will be placed either on traditional oxygen therapy or high flow nasal cannulae according to randomization.
223818561|NCT04436458|DRUG|Niclosamide Oral Tablet|Continued SOC therapy together with niclosamide TID for 14 days
223818562|NCT04436458|DRUG|Placebo|Continued SOC therapy together with placebo tablets matching niclosamide for 14 days
223818563|NCT05742243|DRUG|Abatacept (CTLA4-Ig) and nasal insulin (Humulin R®)|Abatacept injected subcutaneously once per week and nasal insulin inhaled for 10 consecutive days initially and twice per week thereafter
223818564|NCT05742243|DRUG|Abatacept (CTLA4-Ig) and nasal placebo (0.9% sodium chloride)|Abatacept injected subcutaneously once per week and nasal placebo inhaled for 10 consecutive days initially and twice per week thereafter
223818565|NCT00462670|DRUG|OPC-41061(Tolvaptan)|0, 15mg of OPC-41061 per day for 7days p.o. administration
223818566|NCT00026858|BEHAVIORAL|collaboration|
223818567|NCT04421742|DRUG|Beclomethasone Dipropionate/Formoterol Fumarate|BDP/FF NEXThaler® 100/6 μg b.i.d.
223818568|NCT02205216|DEVICE|Active tDCS|anode over the motor and premotor cortex with cathodes placed over both mastoids. TDCS will be applied for 20 minutes at 2 mA.
223818569|NCT02205216|DEVICE|Sham tDCS|"anode and cathode placed 1 cm apart over the forehead and DC (1mA) applied for 1-2 min, short-circuited through the skin creating the same temporary tingling sensation without effects on the brain."
223818570|NCT02205216|BEHAVIORAL|Rehabilitation Therapy|"All patients will undergo a rehabilitation therapy intervention (2x a week for 4 weeks = 8 intervention sessions) with simultaneous sham or active tDCS. The trained physiotherapist will follow a standardized program with checklist. Each of the 8 training session will last approximately 45min. The rehabilitative interventions include:~1. cognitive training: attentional strategies (mental counting, mental obstacle)~2. transfer training: everyday activities~3. motor training (walking) with sensory cueing (visual, acoustic, cane, ball) The rehabilitation therapy is divided into two sessions both including a 5 minutes warm-up and the learning of cueing and movement strategies based on different modalities (cognitive, visual, tactile and auditory)."
223818571|NCT02245763|DEVICE|Leaflet Clip|
223818572|NCT06546098|DRUG|Molgramostim nebulizer solution|Solution for inhalation
223818573|NCT02144948|DRUG|e.-coli-nissle|1 ml qd for 24 weeks
223818574|NCT02110732|DIETARY_SUPPLEMENT|Lactobacillus rhamnosus GG|
223818575|NCT02160171|DEVICE|Algorithm for Neonatal Seizure Recognition|Software system for neonatal seizure detection recognition
223818576|NCT03606122|DRUG|PD P 506 A|PD P 506 A is a dermal patch of 4 cm² in size loaded with 2 mg 5-ALA (as 5-ALA HCl) per cm²
223818577|NCT02425748|BIOLOGICAL|DC-CIK|DC-CIK cells will be used against tumor cells.
223818578|NCT02425748|BIOLOGICAL|γδ T Cell|γδ T cells will be used against non small lung tumor.
223818579|NCT02425748|BIOLOGICAL|γδ T/DC-CIK cells|γδ T/DC-CIK cells will be used against lung tumor.
223818580|NCT04940013|DRUG|Misoprostol|Study participants are given misoprostol alone for menstrual regulation.
223818581|NCT00039325|BIOLOGICAL|dendritic cell-MART-1 peptide vaccine|Subjects will receive MART-1 adenovirus-transduced dendritic cells (DC)at dose of 10\^6 (for arm A) or 10\^7 (for arms B-E). Subjects will receive a total of three biweekly vaccinations given intradermally. If significant clinical or immunological response (to be defined later) is noted, subjects will be eligible for up to 6 additional monthly vaccine administrations.
223818582|NCT03082716|DRUG|Custodiol Solution|After cross clamping patient will receive single dose of HTK custodiol cardioplegia. at temperature of 4-8°C and will be perfused for 6-8 minutes. Dose will start from 400 up to 1000 ml according to the child's body weight. Perfusion pressure will be kept at 70 - 80 mmHg until the heart is arrested.
223818583|NCT03082716|DRUG|Blood cardioplegia|After cross clamping patient will receive blood cardioplegia, delivered by microplegia delivery system by adding potassium to the blood (K= 35 ml eq/L) . The initial dose will be 35ml/ kg, and subsequent doses 20-15 ml/kg given every 20 minutes at a Temperature of 10 - 15 °C, while maintaining a perfusion pressure of 100-125 mmHg.
223818584|NCT00799695|BEHAVIORAL|phone call contact|A sample of subjects who had not completed their annual diabetic screening exams were contacted by phone and offered appointments for eye exams
223818585|NCT04981691|BIOLOGICAL|anti-MESO CAR T cells|Autologous genetically modified anti-MESO CAR T cells
223818586|NCT03798002|OTHER|Neuro-muscular exercise training Group|"Training takes place 3 days a week for 8 weeks follow up, under the supervision of physical therapist A training session lasts for 40 minutes, and consists of three parts.~PART 1:Warming up:~warm-up period consists of ergometer cycling for 10 minutes~PART 2: Circuit program:~comprises four exercises, core stability/postural function; postural orientation; lower extremity muscle strength; and functional exercises. Each exercise is performed 2-3 sets 10-15 repetitions.~PART 3:Cooling down:~The cooling down part consists of walking exercises forward and backwards, about 10 meters in each direction, in front of mirror (mobility exercises for the lower extremity muscles for a total of about 10 minutes. Changes in patient's symptom assessed by structural questionnaire"
223818587|NCT03798002|OTHER|quadriceps training program|"Apply Tens (10min+ hot pack 7-10min) Before excercise ROM,Quadriceps and hamstring stretching exercise's and strengthening exercises.~4th-6th week (in addition): Straight leg raise, Quads over a roll, Hamstring curls. 7th and 8th week (in addition): Elastic band exercise, Hamstring curls, Quads chair, isometric strengthening All exercises are performed in set of 10 repetitions. 1 set of all exercises was twice a day for first 3 week, and 2 sets twice a day until 6th week and then 3 sets twice a day until 8th week"
223818588|NCT00840008|OTHER|Educational intervention|As per detailed protocol.
223818589|NCT03497507|DEVICE|Sham bracelet|Patients will wear bracelets on both hands
223818590|NCT03497507|DEVICE|Acupressure bracelet|Patients will wear bracelets on both hands.
223818591|NCT03313102|BIOLOGICAL|blood samples|sample of 16 blood tubes
223818592|NCT00633932|DRUG|Esomeprazole|20mg once daily
223818593|NCT00633932|DRUG|Esomeprazole|40 mg once daily
223818594|NCT00633932|DRUG|Omeprazole|20mg once daily
223818595|NCT01662531|BIOLOGICAL|rIX-FP|Recombinant Fusion Protein Linking Coagulation Factor IX with Albumin (rIX-FP)
223818596|NCT01469455|DRUG|DT01|"DT01 starting dose will be 16 mg and it is planned to be increased to 32, 48 mg and 64 mg, or higher.~DT01 will be administered 3 times a week (e.g., Mondays, Wednesdays and Fridays) over 2 weeks (6 administrations of DT01 in total) at least 3 hours prior to the radiotherapy sessions."
223818597|NCT04719663|BEHAVIORAL|Biological illness and treatment rationale|Depression is described as a brain disorder and the role of monoamine, brain structures, and brain functions are reported as central mechanisms of relevance for its etiology and treatment. Biological processes are illustrated using typical charts and visualizations. Psychological influences are mentioned, but only as a byproduct of the disorder.
223818598|NCT04719663|BEHAVIORAL|Psychological illness and treatment rationale|Depression is described as a psychological disorder resulting from emotion regulation deficits. The suppression of emotions receives a special role in explaining depression. The psychological processes are illustrated using charts and visualizations. Biological aspects are mentioned, but only as a byproduct of the disorder.
223818599|NCT04719663|DRUG|Active pharmacological placebo|"The active placebo pill does not have direct effects on the brain. Buscopan (butylscopolamine, 10 mg daily, 1 pill in the morning) does not cross the blood-brain barrier, yet induces some smaller side effects that resemble those of antidepressants (e.g., mouth dryness, fatigue, nausea). Treatment duration is 4 weeks. The rationale is briefly explained to participants as stimulating the biological balance in humans with depression, using a well-tolerated drug similar to Buscopan, which is well-known from pain treatments."
223818600|NCT04719663|BEHAVIORAL|Active psychological placebo|"Emotional writing consists of writing about emotional experiences (4 sessions, one per week, 30 minutes each). The study instructor will be present displaying standard psychotherapeutic attitudes but will not read the participant's notes. The rationale for this treatment is briefly explained as improving the dealing with emotions to achieve a psychological balance in humans with depression."
223818601|NCT01207323|DRUG|MEHD7945A|MEHD7945A will be administered as specified in the individual arms.
223818602|NCT03221062|DEVICE|Laser en Bloc Resection|Procedure: Laser en Bloc Resection of bladder tumor Procedure: Hydroknife transurethral resection of bladder tumor Procedure: conventional transurethral resection
223818603|NCT02529475|DRUG|Gadoteric acid|Comparison with patients with Meniere's disease
223818604|NCT00482274|DRUG|docetaxel|Docetaxel 75 mg/m2 intravenously (IV) over 60 minutes will be given on day 1 of each 21 day cycle.
223818605|NCT03794258|DRUG|SOF+DCV+CDI-31244|Sofosbuvir (SOF) 400 mg administered orally once daily; Daclatasvir (DCV) 60 mg administered orally once daily; CDI-31244 400 mg administered orally once daily.
223818606|NCT03794258|DRUG|SOF+DCV+CDI-31244+ASV|Sofosbuvir (SOF) 400 mg administered orally once daily; Daclatasvir (DCV) 60 mg administered orally once daily; CDI-31244 400 mg orally once daily; Asunaprevir (ASV) 200mg administered orally twice daily.
223818607|NCT06463821|OTHER|observational questionnaires|Patient data were collected from questionnaires.
223818608|NCT04836858|BIOLOGICAL|CMK389|Active
223818609|NCT04836858|BIOLOGICAL|Placebo|Placebo Comparator
223818610|NCT01262443|PROCEDURE|Radiofrequency Ablation|Radiofrequency ablation by a standard 4mm irrigated flexible tip catheter
223818611|NCT05781139|DIAGNOSTIC_TEST|levels of Neurofilaments (NfL) in serum|the levels Neurofilaments (NfL) (Abcam, USA), C-X-C motif chemokine 13 (CXCL13) and Chitinase 3-like Protein 1 (Sigma-aldrich, Germany) will be determined in the serum and CSF (if available) in the different participant groups.
223818612|NCT04184323|DRUG|EX-527 (Selisistat)|EX-527 is a specific inhibitor of the histone deacetylase Sirtuin-1 (SirT1). It is being given to reverse the effects of endometriosis, namely progesterone resistance, that is thought to interfere with the establishment of pregnancy in women with endometriosis
223818613|NCT04184323|DRUG|Placebo|We will use the same vehicle for producing the active drug such as maltose without any hormones or active components
223818614|NCT02695602|PROCEDURE|Microdebrider-Assisted Inferior Turbinoplasty (MAIT)|
223818615|NCT02695602|PROCEDURE|Submucous Resection with non powered instrument|
223818616|NCT04394507|DIAGNOSTIC_TEST|Near-Infrared Fluorescence imaging|.Near-infrared imaging was used to evaluate the function of the superficial lymphatic vessels in the right lower leg and foot as previously described.doi: 10.1161/CIRCIMAGING.118.008074.
223818617|NCT04394507|DIAGNOSTIC_TEST|Strain Gauge Plethysmography|Strain Gauge Plethysmography to asses capillary filtration rate og the lower limb
223818618|NCT00004011|DRUG|carboplatin|
223818619|NCT00004011|DRUG|paclitaxel|
223818620|NCT00004011|PROCEDURE|conventional surgery|
223818621|NCT00001015|DRUG|Ribavirin|
223818622|NCT00621907|DRUG|chirocaine (Levobupivacaine)|levobupivacaine 0,5 % 30 ml infiltration (150 mg)
223818623|NCT00621907|DRUG|sodium chloride|sodium chloride : 0,9% 30 ml
223818624|NCT00642798|DRUG|sitagliptin phosphate|Sitagliptin 100mg once daily on Day 1 for single dose, and once daily on Day4-9 for multiple dose.
223818625|NCT03361787|BEHAVIORAL|"Parentship- a multi dimensional intervention program to improve parental resilience"|"Parentship is a multi dimensional intervention program to improve parental resilience and adolescent participation using the OPC model."
223818626|NCT03060564|PROCEDURE|tendon graft|JRF Orthopedics Tendon Graft
223818627|NCT03060564|OTHER|No intervention|No intervention
223818628|NCT04599686|DRUG|ADT|On the day of enrollment, luteinizing hormone-releasing hormone agonist (LHRHa) was given for ADT.
223818629|NCT04599686|RADIATION|SBRT|Evaluating men with oligometastatic prostate cancer lesions randomized to stereotactic body radiation therapy (SBRT) (3-5 fractions).
223818630|NCT03056664|PROCEDURE|Routine drainage surgery|
223818631|NCT03056664|BIOLOGICAL|MSC injection 01|Local MSC injection in peri-anal with a dose of 3×10E6/kg
223818632|NCT03056664|BIOLOGICAL|MSC injection 02|Local MSC injection in peri-anal with a dose of 6×10E6/kg
223818633|NCT03056664|OTHER|placebo|NS injection instead of MSC
223818634|NCT05735457|OTHER|A short, animated storytelling video on dietary sodium|Participants in the Intervention Arm will view a short, animated storytelling video on dietary sodium and the risks of cardiovascular disease due to increased intake of sodium.
223818635|NCT05735457|OTHER|A short, animated storytelling attention placebo video|The Attention Placebo Control Arm will view an attention placebo control video, unrelated to the outcomes measured in this trial.
223818636|NCT06001983|OTHER|imaginary resisted exercises|"1. Imagination of squeezing a Sponge ball 15 reps~2. Imagination of Finger Exerciser 15 reps~3. Imagination of Theraband 15 reps~4. Imagination of pressing Rubber ball 15 reps~5. Imagination of pressing Hard object 15 reps"
223818637|NCT06001983|OTHER|physical resisted exercises|"1. Resisted exercise of Squeezing a Sponge ball 15 reps~2. Resisted exercise of Finger Exerciser 15 reps~3. Resisted exercise of pulling theraband 15 reps~4. Resisted exercise of pressing Rubber ball 15 reps~5. Resisted exercise of pressing Hard object 15 reps"
223818638|NCT02948959|DRUG|Dupilumab|"Pharmaceutical form: Solution~Route of administration: Subcutaneous"
223818639|NCT02948959|DRUG|Placebo|"Pharmaceutical form: Solution~Route of administration: Subcutaneous"
223818640|NCT02948959|DRUG|Asthma Controller Therapies|"Pharmaceutical form: Aerosol, capsules, tablets, oral solution~Route of administration: Inhaled, oral"
223818641|NCT02948959|DRUG|Asthma Reliever Therapies|"Pharmaceutical form: Nebulized, aerosol~Route of administration: Inhaled"
223818642|NCT05258123|DRUG|Ginkgo Biloba Extract|Ginkgo biloba extract with 360mg was administered
223818643|NCT05258123|DRUG|Placebo oral tablet|Placebo with nine tables was administered
223818644|NCT02199821|DIETARY_SUPPLEMENT|Formula with soybean oil, medium-chain triglycerides|
223818645|NCT02199821|DIETARY_SUPPLEMENT|Soybean oil formula commonly used in the hospital|
223818646|NCT06159374|OTHER|exercise and environmental conditions|Participants will perform interval training for 4 weeks in a variety of environmental conditions. There will be a measurement of aerobic and anaerobic capacity before and after the training. Before and after the first and last workout, blood will be drawn for biochemical analysis.
223818647|NCT03062059|DRUG|Intravesical 2000mg/52.6ml gemcitabine instillation|Intravesical 2000mg/52.6ml gemcitabine instillation during operation to prevent intravesical recurrence after radical nephroureterectomy in upper urinary tract urothelial carcinoma
223818648|NCT03062059|OTHER|Normal saline|Intravesical 52.6ml normal saline instillation after radical nephroureterectomy in upper urinary tract urothelial carcinoma
223818649|NCT06091462|OTHER|Virtual Reality Based Interactive Therapeutic Dementia Patient Education Program|"Virtual reality is an interactive three-dimensional environment where computer simulation-based fictions and the real and virtual worlds are combined.~Within the scope of this training, in the content of the module on the subject of Dementia; dementia definition, risk factors, signs and symptoms, complications, treatment and nursing care and patient and/or caregiver education. exists. After applying the dementia module, students complete the program by switching to a virtual reality-based simulation program for dementia."
223818650|NCT02596022|DRUG|CI-581a|a 50 minute infusion 24 hours prior to cocaine self-administration session
223818651|NCT02596022|DRUG|CI-581b|a 50 minute infusion 24 hours prior to cocaine self-administration session
223818652|NCT00793221|DEVICE|Implantation of sirolimus-eluting coronary stent|Implantation of sirolimus-eluting coronary stent after dilatation of the coronary occlusion
223818653|NCT00793221|DEVICE|Implantation of everolimus-eluting coronary stent|Implantation of everolimus-eluting coronary stent after dilatation of the coronary occlusion
223818654|NCT00810082|DEVICE|ActiveStep|ActiveStep™ is a training simulator. The system uses a computer-controlled treadmill to recreate life-like dynamic balance challenges such as slipping and tripping in a safe, controlled environment.
223818655|NCT00810082|OTHER|Standard Physical Therapy for Fall Prevention|Standard physical therapy for fall prevention
223818656|NCT02892487|OTHER|Swallowing therapy|Patients will undergo active swallowing therapy with a speech and language therapist (twice a week) combined to a detailed program of swallowing auto-exercises (twice a day) from start of radiotherapy to one month after the end.
223818657|NCT05151497|OTHER|Experimental group:Halliwick + Método Watsu|Carrying out the Ten Points Program through the Halliwick Concept, together with the Watsu Method through a series of relaxation maneuvers and mobilization of the body in float, and an immersion time of 15 minutes without doing physical activity in a pool at a temperature of 30ºC , to decrease spasticity of various muscles.
223818658|NCT05151497|OTHER|Control group:Halliwick|Exclusive use of treatment through the Halliwick Concept Ten Point Program, along with immersion in hot water to reduce spasticity in various muscles.
223818659|NCT00500240|DRUG|Insulin Glargine|Use of human insulin glargine for slow decrease of blood sugar level over 24 hours.
223818660|NCT00500240|DRUG|Insulin Aspart|Use of human insulin aspart for rapid lowering of the blood glucose level over 24 hours.
223818661|NCT02508532|DRUG|Avapritinib|avapritinib tablets
223818662|NCT02334566|BEHAVIORAL|NET TX|Intervention procedures are a behavioral intervention (NET \& KIDNET) with 8-12 sessions administered on a weekly basis.
223818663|NCT01756521|DRUG|Moxifloxacin|
223818664|NCT03097861|DRUG|Lubiprostone|24 mcg administered orally BID
223818665|NCT03097861|DRUG|Placebo|24 mcg administered orally BID
223818666|NCT03577158|DEVICE|Closed-loop controller with exercise mitigation module|"Each subject will undergo three exercise tests, each one at 1-2 week intervals, thus completing the 3 experiments in about 6 weeks. The day of the experiment, the participant will do 3 sets of 15 minutes of cycloergometer at 70% of VO2max with 5 minutes of rest between them. On the first arm, participants will receive Sliding Mode Reference Conditioning (SMRC) Closed-loop insulin administration with a mitigation mode, based on subcutaneous continuous glucose monitoring (First arm, Closed-loop study with mitigation module).~Commercial insulin infusion systems and continuous glucose monitoring devices will be used."
223818667|NCT03577158|DEVICE|Closed-loop controller without exercise mitigation module|"On the second arm, participants will receive Sliding Mode Reference Conditioning (SMRC) Closed-loop insulin administration without a mitigation mode, based on subcutaneous continuous glucose monitoring (Second arm, Closed-loop study without mitigation module).~Commercial insulin infusion systems and continuous glucose monitoring devices will be used."
223818668|NCT03577158|DEVICE|Open-loop insulin infusion system|Standard subcutaneous insulin infusion based on the individual insulin sensibility. Commercial insulin infusion systems and continuous subcutaneous glucose monitoring devices will be used.
223818669|NCT05712161|DEVICE|DurAVRTM THV System|The DurAVR™ Transcatheter Heart Valve (THV) is a balloon expandable transcatheter aortic valve
223818670|NCT04232046|OTHER|Massage|Massage the trigger points in 8 different points for 1 min in circle direction and 3 times a day.
223818671|NCT00507741|DRUG|Vintafolide|Part A: Induction Phase: vintafolide 1.0 mg intravenous injection, Monday through Friday, for the first 3 weeks of each 4 week cycle. Maintenance Phase: vintafolide 2.5 mg intravenous injection, Monday, Wednesday and Friday, weeks 1 and 3 of each 4 week cycle. At the investigator's discretion, participants may receive vintafolide via an ambulatory pump after the first week of therapy has been administered in the clinic setting. Part B: vintafolide 2.5 mg intravenous injection, Monday, Wednesday and Friday, weeks 1 and 3 of each 4 week cycle. At the investigator's discretion, participants may receive vintafolide via an ambulatory pump after the first week of therapy has been administered in the clinic setting.
223818672|NCT00507741|DRUG|Ertafolide|
223818673|NCT04001179|OTHER|Pulmonary embolism diagnosis by nuclear medicine imaging|nuclear medicine imaging
223818674|NCT01287637|PROCEDURE|Early reversal of temporary ileostomy|Temporary ileostomy is reversed 8-13 days after the primary surgery
223818675|NCT01287637|PROCEDURE|Standard reversal of temporary ileostomy|Patients in the control group will have the ileostomy reversed according to standard treatment, which is 12-26 weeks after primary operation
223818676|NCT02952664|BEHAVIORAL|PUMP Monitoring|A video camera will be placed in each subject room for recording the repositioning events to correlate the monitor signals with the actual subject repositioning captured by the video.
223818677|NCT00885573|DEVICE|Measurement of pharyngeal sensitivity (SENSITEST)|Measurement of pharyngeal sensitivity using the SENSITEST the morning following the nocturnal polysomnographic recording to diagnose sleep disordered breathing.
223818678|NCT00034840|DRUG|telmisartan, valsartan|
223818679|NCT04481828|PROCEDURE|gastrectomy|gastric resection with lymph node dissection(D1+,D2) for stomach cancer.
223818680|NCT03187015|DRUG|Entinostat|HDAC (histone deacetylase inhibitor)
223818681|NCT03187015|DRUG|Midazolam|benzodiazepine central nervous system (CNS) depressant
223818682|NCT05275491|DIAGNOSTIC_TEST|Calcium|Free calcium serum levels
223818683|NCT05275491|DIAGNOSTIC_TEST|Fibroblast growth factor 23|Serum level
223818684|NCT05275491|DIAGNOSTIC_TEST|Sclerostin|Serum level
223818685|NCT05275491|DIAGNOSTIC_TEST|parathyroid hormone|serum level
223818686|NCT02299258|DEVICE|Standard stents MTN-CG-s-20/100|The ends of the stents were semi-spherical with diameters of 28 mm and length of 20 mm. The length of the stents was 100 mm
223818687|NCT02299258|DEVICE|Tailored stents MTN-WE-20/100-A|cup-shaped or funnel-shaped, according to the shapes of the proximal GOOs.
223818688|NCT02841293|PROCEDURE|Biological mesh|The intervention consists of suturing a biological mesh in the pelvic floor defect. The mesh will be sutured at each side of the coccyx or distal sacrum and directly to the residual pelvic floor muscle and fascia by using interrupted or continuous hand-sewn sutures with an appropriate amount of tension. The mesh that will be used is the Cellis prosthesis from Meccellis Biotech, reference C1015E which size is 10x15cm.
223818689|NCT02841293|PROCEDURE|Primary perineal wound closure|The intervention consists of stitching the ischioanal and subcutaneous fat using interrupted Vicryl sutures in one or two layers similar to primary perineal closure
223818690|NCT05737433|DRUG|[14C]-rencofilstat 225mg|radio-labelled 225mg oral dose of rencofilstat
223818691|NCT04180241|PROCEDURE|POEM|Peroral endoscopic myotomy
223818692|NCT04002583|DIAGNOSTIC_TEST|Computer assisted ambulatory electroencephalogram|A portable 16 channel CAA-EEG is used to detect epileptiform abnormalities in a 48 hour ambulatory electroencephalogram (EEG)
223818693|NCT04359030|DIAGNOSTIC_TEST|Multislice CT scanning for aortic wall calcification|Multislice CT scanning for aortic wall calcification
223818694|NCT04359030|DIAGNOSTIC_TEST|Transthoracic stress echocardiography|Transthoracic stress echocardiography
223818695|NCT03078153|BEHAVIORAL|Financial Incentive|Participants will receive a $50 gift card at 3- and 6- month follow-up visits.
223818696|NCT03078153|BEHAVIORAL|Social Media Group|Participants will be invited to a study Facebook group which will have links to PrEP information and provide a forum for participants to ask questions and communicate their experience with PrEP
223818697|NCT06339554|DRUG|Alectinib 150 MG [Alecensa]|First line treatment for cohorts A and B
223818698|NCT00274001|DRUG|Nevirapine|
223818699|NCT01544959|DRUG|fentanyl|Use of esmolol and metoprolol compared to use of fentanyl for hemodynamic control during general anesthesia. At induction, fentanyl (2 mcg/kg) is replaced by esmolol (1 mg/kg). During the case, with a standardised anesthesia, response to surgical stimulation will be medicated either by fentanyl (50 mcg aliquot) or metropolol (2.5 mg), for a maximum of 6 doses. After this, fentanyl will be given unblindly.
223818700|NCT01544959|DRUG|beta-blocker (esmolol, metropolol)|esmolol is used at induction and lopressor during surgery instead of fentanyl in response to surgical stimulation.
223818701|NCT04080310|DRUG|Efficacy and safety of combination therapy of moderate-intensity statin and ezetimibe compared to high-intensity statin|"This study is a multicenter, randomized, open-label, parallel, phase IV trial. The study is planned to include 272 patients with clinical ASCVD requiring optimal statin therapy.~After enrollment, subjects are randomized into two groups in a 1:1 manner. patients in combination therapy group(rosuvastation 10mg and ezetimibe 10mg daily) will be provided a fixed-dose single pill comibation and patients in the intensive statin group will receive rosuvastatin 20mg daily."
223818702|NCT02375282|PROCEDURE|Ambulation orderly|The responsibility of the ambulation orderly is to walk patients after having a cardiac surgery, such as a coronary artery bypass surgery or a valve surgery. Baystate Medical Center hired an ambulation orderly May 8, 2013. The ambulation orderly is generally a high school graduate with some training in safe lifting and exercise, but extensive training is not required. In general, the goal is to have 1 ambulation orderly present 7 days a week for 8 hr per day. When available, ambulation orderlies are responsible for walking the patients who have been cleared by the clinical exercise physiologist or nurse up to 4 times per day. The walking of the patients occurs through the halls of the 6th floor of the Mass Mutual wing of Baystate Medical Center.
223818703|NCT04303312|OTHER|Benzydamine Hydrochloride|Patients will rinse by mouth three times daily for 20 days
223818704|NCT04303312|COMBINATION_PRODUCT|Solcoseryl and pumpkin seed oil|Patients will receive by mouth three times daily for 20 days
223818705|NCT00868699|DRUG|lurasidone|lurasidone 20 mg/day for Days 1-2, 40 mg/day for Days 3-4, 60 mg/day for Days 5-6 and 80 mg/day on Day 7 and 80-120 mg/day
223818706|NCT00868699|DRUG|lurasidone|lurasidone 20 mg/day for Days 1-7
223818707|NCT00868699|DRUG|Placebo|Placebo Comparator
223818708|NCT01834222|BIOLOGICAL|Non-intervention|Non-intervention
223818709|NCT04172805|DRUG|anlotinib and toripalimab|Anlotinib 12mg orally per day, two weeks on , one week off; 240 mg of toripalimab (fixed dose) every three weeks. Repeat every three weeks. Patients with disease control (CR + PR + SD) and tolerable adverse reactions continued to take medication until the researchers concluded that patients were not suitable to continue medication or the efficacy evaluation was disease progression (PD). No other antineoplastic treatment can be given during the treatment.
223818710|NCT01208155|DRUG|Fostamatinib|Oral tablets, 50 mg x 2, single dose
223818711|NCT01208155|DRUG|Fostamatinib|Oral tablets, 100 mg Batch 1, single dose
223818712|NCT01208155|DRUG|Fostamatinib|Oral tablets, 100 mg Batch 2, single dose
223818713|NCT01208155|DRUG|Fostamatinib|Oral tablets, 100 mg Batch 3, single dose
223818714|NCT02398968|DIETARY_SUPPLEMENT|iron fumerate|iron fumerate supplementation (6mg/kg/d) for arm 1 iron fumerate supplementation (1mg/kg/d) for arm 2
223818715|NCT04251065|DRUG|Daratumumab|"Daratumumab in combination with Gemcitabine, Dexamethasone and Cisplatin (D-GDP).~Induction phase:~4-6 courses (according to response after cycle 4 and to patient compliance) of D-GDP every 21 days pursuant to the following schedule: Daratumumab cycle 1: 8 mg/kg i.v. on day 2 and on day 9; cycle 2-6: 16 mg/kg i.v. on day 2 and day 9) Gemcitabine 1000 mg/sm i.v. day 1 and day 8 (gemcitabine on day 8 to be skipped in case of grade 3-4 toxicity) Cisplatin 75 mg/sm i.v. day 1 Dexamethasone 40 mg i.v. or po days 1-2-3-4-9 G-CSF from day 3 to 6, and from day 10 to 13 (to be prolonged if necessary)~Maintenance:~starting 28 days after the beginning of cycle 4 or 6 (or, in case of toxicity grade \> 1, after toxicity is resolved) and up to 24 cycles from start of D-GDP according to the following schedule: Daratumumab 16 mg/kg single administration every 28 days."
223818716|NCT03892629|BEHAVIORAL|Baduanjin exercise|Participants received Baduanjin exercise. Each Baduanjin exercise session lasts 30 minutes and continues twice a day, 5 times per week for 12 weeks
223818717|NCT03892629|DEVICE|Instrument rehabilitation|Participants received pulmanory rehabilitation by using tri-ball respiratory trainer. Each instrument exercise session lasts 30 minutes and continues twice a day, 5 times per week for 12 weeks
223818718|NCT01054573|DRUG|Telaprevir|750 mg orally every 8 hours (q8h) for 12 weeks
223818719|NCT01054573|DRUG|pegylated interferon (Peg-IFN) alfa-2a|180 microgram (mcg) by subcutaneous injection once weekly for 48 weeks.
223818720|NCT01054573|DRUG|ribavirin (RBV)|1,000 or 1,200 mg/day (weight based) orally twice daily for 48 weeks.
223818721|NCT03213990|OTHER|Continuous infusion|Clinician prescribed beta-lactam antibiotic will be administered via continuous infusion for as long as prescribed whilst in the ICU
223818722|NCT03213990|OTHER|Intermittent infusion|Clinician prescribed beta-lactam antibiotic will be administered via intermittent infusion for as long as prescribed whilst in the ICU
223818723|NCT01069575|BIOLOGICAL|HLA-A*2402restricted URLC10, CDCA1, and KIF20A peptides|Escalating doses of every peptide will be administered by subcutaneous injection on days 1, 8, 15 and 22 of each treatment cycle. Planned doses of peptides are 1.0mg, 2.0mg and 3.0mg.
223818724|NCT00235924|DRUG|soy isoflavone|
223818725|NCT04244435|PROCEDURE|CABG|coronary artery bypass grafting with and without cardiopulmonary bypass
223818726|NCT04244435|DRUG|thoracic epidural analgesia|thoracic epidural analgesia at the level of 1-10 thoracic vertebrae (ropivacainum 0,2-0,5% 5-10 ml/h)
223818727|NCT04244435|DRUG|analgesia of opioids|Opioids will be used for perioperative analgesia
223818728|NCT03885011|DRUG|CSF-1|This treatment arm consists of 2 different concentrations of CSF-1. Subjects randomized to the CSF-1 treatment arm will receive their first dose of CSF-1 in-office at Visit 2. All subjects will dose twice a day in both eyes with a single drop for approximately 1 week. At Visit 3, subjects randomized to the CSF-1 arm will now receive a different concentration of CSF-1. Subjects will continue dosing twice a day in both eyes for approximately 1 week.
223818729|NCT03885011|DRUG|CSF-1 Component #1|"This treatment arm consists of 2 different concentrations of CSF-1 Component #1.~Subjects randomized to the CSF-1 Component #1 treatment arm will receive their first dose of CSF-1 Component #1 in-office at Visit 2. All subjects will dose twice a day in both eyes with a single drop for approximately 1 week. At Visit 3, subjects randomized to the CSF-1 Component #1 arm will now receive a different concentration of CSF-1 Component #1. Subjects will continue dosing twice a day in both eyes for approximately 1 week."
223818730|NCT03885011|DRUG|CSF-1 Component #2|This treatment arm consists of a single concentration of CSF-1 Component #2. Subjects randomized to the CSF-1 Component #2 treatment arm will receive their first dose of CSF-1 Component #2 in-office at Visit 2. All subjects will dose twice a day in both eyes with a single drop for approximately 1 week. At Visit 3, subjects randomized to the CSF-1 Component #2 arm will continue dosing with the same concentration of CSF-1 Component #2. Subjects will continue dosing twice a day in both eyes for approximately 1 week.
223818731|NCT05075187|DIAGNOSTIC_TEST|Genetic Screening|Blood samples will be collected from clinically diagnosed or suspected FTD patients and will be analysed for a broad range of pathogenic variants in genes associated with FTD.
223818732|NCT01141023|DRUG|DaTscan|
223818733|NCT05863286|DRUG|Botulinum toxin type A|"Botulinum toxin is produced by the gram-positive, anaerobic, spore-forming bacterium Clostridium botulinum, and is one of the most lethal biological toxins known to man.~Botulinum toxin has seven antigenically different serotypes and exerts a paralytic action by rapidly and strongly binding to presynaptic cholinergic nerve terminals. It is then internalized and ultimately inhibits the exocytosis of acetylcholine by decreasing the frequency of acetylcholine release. Without its nerve supply, the muscle fiber will deteriorate; however, the muscle will regain its strength as the nerves regenerate."
223818734|NCT00517985|DRUG|Duloxetine|During the current study, for a short period of time participants will receive a placebo (a pill that looks like the study drug but which does not contain any medication), although during the majority of the study, participants will be receiving the actual study medication (Duloxetine). The initial dose of Duloxetine to be given will be a 30 mg dose with the dosage increased over time to 60 mg per day. This study will be blinded, meaning that participants will not know whether they are taking placebo or the study drug. However, all subjects will receive duloxetine for the majority of the time they are enrolled in the trial. Investigators will know when subjects are receiving the placebo but in order to maintain the blinding of this study, the study staff will not be able to tell participants when they are taking placebo and when they are taking Duloxetine.
223818735|NCT04342624|DIETARY_SUPPLEMENT|Cinnamon|Cinnamon supplement
223818736|NCT04342624|OTHER|Placebo|Placebo
223818737|NCT01725386|DRUG|Capecitabine|Oral tablet(s) administered according to prescribing information
223818738|NCT01140334|BEHAVIORAL|Voucher Reinforcement|Patients in this condition will be able to earn a voucher for each week that they have attended all scheduled psychiatric sessions. These sessions may include individual therapy appointments, group therapy appointments, or psychiatrist appointments. Each voucher will be worth $25, and can be exchanged for goods and services that will be purchased by a research assistant. The maximum amount of voucher earnings over the study is $300.
223818739|NCT01140334|BEHAVIORAL|Standard Control|Patients assigned to this condition will be treated at ATS for psychological problems. They will be scheduled to participate in individual therapy sessions with a psychiatrist and with their substance abuse counselor. They will also be referred to attend group therapy one time per week. No voucher incentive will be offered in this condition.
223818740|NCT04670237|DEVICE|Liberty677MTY Multifocal Toric IOL|multifocal, toric intraocular lens (IOL)
223818741|NCT02822560|DEVICE|pEVAR|percutaneous femoral access using a suture-mediated closure device
223818742|NCT02822560|PROCEDURE|open femoral access|cutdown to femoral artery and surgical closure
223818743|NCT03812536|OTHER|No Void|Currently the protocol at The Ohio State University Hospital requires voiding spontaneously prior to discharge from the PACU. Our intervention group will be discharged home without having to void spontaneously as a discharge criteria.
223818744|NCT00152009|DRUG|SPD503 (Guanfacine hydrochloride) (2 mg)|
223818745|NCT00152009|DRUG|SPD503 (3 mg)|
223818746|NCT00152009|DRUG|SPD503 (4 mg)|
223818747|NCT00152009|DRUG|Placebo|
223818748|NCT05773014|PROCEDURE|Speculum Exams|Same as arm
223818749|NCT05773014|PROCEDURE|Digital Exams|Same as arm
223818750|NCT03597035|DRUG|Spironolactone|The study participants will receive concomitant treatment with Veltassa 8.4 grams per day and Spironolactone 25 mg per day or maximum tolerated dose. If dictated by the potassium level, Veltassa can be increased to 16.8 grams per day.
223818751|NCT04598906|BEHAVIORAL|Virtual environment rehabilitation|The participants attended 10-15 computer sessions during 6-12 weeks. Each session lasted 30 minutes and consisted of the set of virtual environment tasks (Shooting Range,Virtual Supermarket Shopping Task and Objects). Shooting range demands differentiation of targets from non-targets and focuses on training of selective attention, psychomotor speed and inhibition control. Virtual Supermarket Shopping requires memorizing the shopping list and searching for products in the supermarket area. Objects requires memorizing of the spatial and temporal context while searching for objects.
223818752|NCT04598906|BEHAVIORAL|Paper-pencil rehabilitation|The participants in the paper-pencil rehabilitation attended 10-15 paper pencil sessions for 6-12 weeks. Each session lasted 45 minutes. Each paper-pencil session starts with a warm-up game. The session continues with a set of paper-pencil tasks focused on attention, fine motor skills, recall, short-term and long-term memory, verbal fluency, visual search, cognitive flexibility, abstraction and executive functions, numerical abilities. The tasks are adapted according to the participant´s abilities.
223818753|NCT02650232|DEVICE|SOMNOtouch device (Somnomedics)|In each arm, we will evaluate the capacity of SOMNOtouch to measure the baroreflex sensitivity compared to Finapre Nova (reference)
223818754|NCT02650232|PROCEDURE|Orthostatic test|"For each arm we will proceed to an orthostatic test day one and day two with :~* 10 minutes in supine position~* 10 minutes in sitting position~* 5 minutes in standing position~* 5 minutes in supine position"
223818755|NCT02650232|DEVICE|Finapres Nova device (FMS system)|
223818756|NCT01031875|DRUG|pazopanib hydrochloride|
223818757|NCT01031875|RADIATION|fludeoxyglucose F 18|
223818758|NCT00440089|BEHAVIORAL|Hands-on-Healing|
223818759|NCT03813628|OTHER|polished celtra press full coverage crown|a full coverage crown in esthetic area made from celtra press ceramic( zirconia reinforced lithium silicate) and finished by just polishing
223818760|NCT03813628|OTHER|glazed celtra press full coverage crowns|a full coverage crown in esthetic area made from celtra press ceramic( zirconia reinforced lithium silicate) and finished by glazing
223818761|NCT03813628|OTHER|contralateral natural teeth|the polished and glazed all ceramic crowns will be compared by the contralateral natural teeth
223818762|NCT05859633|DIAGNOSTIC_TEST|Neutrophil/Lymphocyte Ratio in acute pancreatitis|role of Neutrophil/Lymphocyte Ratio in acute pancreatitis
223818763|NCT06320665|OTHER|Radiographic measurement|Measurements taken on 3D radiographs, to assess third molar inclusion and skeletal typology (vertical and sagittal)
223818764|NCT04804371|DRUG|F18-FDG|Evaluate FDG uptake
223818765|NCT05250011|DRUG|Dapagliflozin|Dapagliflozin, prescribed as per approved indication and current medical practice. Participants will not receive any experimental disease management intervention or experimental treatment as a consequence of their participation in the study.
223818766|NCT05672680|DRUG|0.25% Bupivacaine|received during TAP block
223818767|NCT05672680|DRUG|Placebo|placebo equivalent
223818768|NCT05672680|PROCEDURE|TAP block|The intervention is a transabdominal plane (TAP) block given in the abdomen to block pain receptors on nerves -during surgery can presumably decrease postoperative pain. Currently, TAP blocks are approved for use and performed based on surgeon preference (e.g. some surgeons perform them on every case, others variably, etc.).
223818769|NCT00524914|DRUG|apomorphine|Acute apomorphine subcutaneous 3 mg
223818770|NCT00524914|DRUG|placebo|placebo subcutaneous
223818771|NCT00693576|DRUG|simvastatin|20 mg simvastatin daily
223818772|NCT00671008|DRUG|biphasic insulin aspart 30|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
223818773|NCT00671008|DRUG|insulin detemir|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
223818774|NCT01592162|DRUG|Propofol (Astra-Zeneca), NaCl 0.9%|propofol administered by a closed-loop system and saline
223818775|NCT01592162|DRUG|propofol 1% (Astra-Zeneca) and remifentanil|propofol administered by a closed-loop system and remifentanil (2 ng/ml, target controled infusion)
223818776|NCT01592162|DRUG|propofol 1% (Astra-Zeneca) and remifentanil|propofol administered by a closed-loop system and remifentanil (4 ng/ml, target controled infusion)
223818777|NCT01592162|DRUG|Propofol (Astra-Zeneca), NaCl 0.9%|propofol administered by a closed-loop system and saline
223818778|NCT01592162|DRUG|Propofol (Astra-Zeneca) and remifentanil|propofol administered by a closed-loop system and remifentanil (2 ng/ml, target controled infusion)
223818779|NCT01592162|DRUG|Propofol (Astra-Zeneca) and remifentanil|propofol administered by a closed-loop system and remifentanil (4 ng/ml, target controled infusion)
223818780|NCT01592162|DRUG|Propofol (B-Braun) and NaCl 0.9%|propofol administered by a closed-loop system and saline
223818781|NCT01592162|DRUG|Propofol (B-Braun) and remifentanil|propofol administered by a closed-loop system and remifentanil (2 ng/ml, target controled infusion)
223818782|NCT01592162|DRUG|Propofol (B-Braun) and remifentanil|propofol administered by a closed-loop system and remifentanil (4 ng/ml, target controled infusion)
223818783|NCT05375435|DRUG|triple therapy|high-dose glucocorticoids + cyclophosphamide + calcineurin inhibitor
223818784|NCT05375435|DRUG|dual-therapy|high-dose glucocorticoids + cyclophosphamide/calcineurin inhibitor
223818785|NCT03145571|PROCEDURE|Continuity of midwifery care|Pre-natal care in rural villages performed by the midwives from the local hospital
223818786|NCT02810093|OTHER|retrospective medical records analyze|Ten thousand medical records (between years 2000 and 2016) will be analyzed
223818787|NCT03771196|OTHER|Bioactive Restorative Material|enhanced RMGIs with an ionic resin matrix, a shock-absorbing resin component, and bioactive fillers that mimic the physical and chemical properties of natural teeth
223818788|NCT03771196|OTHER|Resin-modified glass ionomer|Enhanced glass ionomer with acceptable mechanical properties and esthtic properties
223818789|NCT01765595|OTHER|DDI+|
223818790|NCT05076149|DRUG|VX-121/TEZ/D-IVA|Fixed-dose combination tablets for oral administration.
223818791|NCT05076149|DRUG|ELX/TEZ/IVA|Fixed-dose combination tablets for oral administration.
223818792|NCT05076149|DRUG|IVA|Tablet for oral administration.
223818793|NCT05076149|DRUG|Placebo (matched to VX-121/TEZ/D-IVA)|Placebo matched to VX-121/TEZ/D-IVA for oral administration.
223818794|NCT05076149|DRUG|Placebo (matched to ELX/TEZ/IVA)|Placebo matched to ELX/TEZ/IVA for oral administration.
223818795|NCT05076149|DRUG|Placebo (matched to IVA)|Placebo matched to IVA for oral administration.
223818796|NCT02465996|DEVICE|pCLE examination|All FD patients received pCLE examination.
223818797|NCT02465996|DRUG|Puyuanhewei|FD patients willing to receive Puyuanhewei were given 4 pills three times a day regardless of PDS or EPS for 4 weeks after pCLE examination.
223818798|NCT02914925|DEVICE|ArmeoSpring/CIT|Participating group will receive therapy with the Armeo®Spring Pediatric and CIT for 6 hours per day, 5 days per week for three weeks, totaling 90 hours
223818799|NCT05096208|BIOLOGICAL|RSVpreF (Group 1)|RSV vaccine (RSVpreF)
223818800|NCT05096208|BIOLOGICAL|RSVpreF (Group 2)|RSV vaccine (RSVpreF)
223818801|NCT05096208|BIOLOGICAL|RSVpreF (Group 3)|RSV vaccine (RSVpreF)
223818802|NCT05096208|BIOLOGICAL|Placebo|Placebo
223818803|NCT05219266|DRUG|midostaurin|Patients receive midostaurin
223818804|NCT05916092|DEVICE|TransLoc 3D|TransLoc 3D SI Joint Fusion System
223818805|NCT00844116|DEVICE|spirometry|Conventional and telematic spirometry
223818806|NCT02087501|DEVICE|Horizon™ Abdominal Aortic Aneurysm Stent Graft System|All patient eligible to undergo stent implantation will receive the Horizon™ Abdominal Aortic Aneurysm Stent Graft System and its designated Delivery System.
223818807|NCT03907163|DRUG|Dronabinol|Capsules containing 5 mg Dronabinol
223818808|NCT03907163|OTHER|Placebo|capsules identical in appearance to dronabinol
223818809|NCT05842785|DRUG|Phase I dose escalation|The eligible subjects will receive TSN222 via intratumoral (i.t.) injection on Days 1, 8 and 15 of every 28-day cycle until disease progression or unacceptable toxicity.
223818810|NCT05842785|DRUG|Phase II-HNSCC|The eligible subjects will receive RP2D of TSN222 via intratumoral (i.t.) injection on Days 1, 8 and 15 of every 28-day cycle until disease progression or unacceptable toxicity.
223818811|NCT05842785|DRUG|Phase II-Advanced melanoma|The eligible subjects will receive RP2D of TSN222 via intratumoral (i.t.) injection on Days 1, 8 and 15 of every 28-day cycle until disease progression or unacceptable toxicity.
223818812|NCT05842785|DRUG|Phase II-solid tumors or lymphomas|The eligible subjects will receive RP2D of TSN222 via intratumoral (i.t.) injection on Days 1, 8 and 15 of every 28-day cycle until disease progression or unacceptable toxicity.
223818813|NCT00094328|DRUG|Bicalutamide|oral
223818814|NCT00094328|DRUG|Anastrozole|oral
223818815|NCT04498195|BEHAVIORAL|increased exercise and physical activity|Participants were encouraged to increase physical activity for 12-week study duration and wear an activity tracker for a minimum of 12 hours a day.
223818816|NCT01483937|DEVICE|Usual care physical therapy plus SEMD|Patients will receive usual care physical therapy while wearing SEMD. SEMD protocols will also be provided to device subjects.
223818817|NCT01483937|OTHER|Usual care physical therapy only|Subjects will receive usual care physical therapy from vestibular and balance specialists.
223818818|NCT03877965|DRUG|Digoxin|Drug administered per standard of care, with a dosing regimen within the labeled dose range of 7.5-20 mcg/kg/day divided in 2 or 3 equal doses
223818819|NCT03458767|BEHAVIORAL|Eight weekly 90-minute group educational sessions|Eight weekly 90-minute group educational sessions, originally developed for the MAPSS-MS intervention, adapted for remote web-based delivery.
223818820|NCT02978001|OTHER|Stabile Isotope tracers|Non-radioactive tracers used in hyperinsulinaemic euglycaemic clamp
223818821|NCT06010901|DRUG|TQB2618 injection|TQB2618 is a monoclonal antibody targeting T cell immunoglobulin and mucin domain-3 (TIM-3) receptor.
223818822|NCT06010901|DRUG|Penpulimab injection|Penpulimab is a humanized Immunoglobulin G-1 (IgG1) monoclonal antibody that binds to human programmed cell death 1 (PD-1), a cell membrane protein that is primarily expressed on activated T cells and inhibits T cell activation.
223818823|NCT06010901|DRUG|Anlotinib hydrochloride capsules|Anlotinib hydrochloride is a muti-target tyrosine kinase inhibitor.
223818824|NCT02920775|OTHER|Non-interventional study - retrospective database review|
223818825|NCT04158180|DIAGNOSTIC_TEST|Questionnaire|A battery of questionnaires will be propose to the participants
223818826|NCT03207906|DRUG|VBP-926|Topical VBP-926 solution
223818827|NCT02541214|DEVICE|Trial Nasal Mask|
223818828|NCT00960674|PROCEDURE|Tactile massage|Gentle massage given for one hour by specially educated massage therapists, usually registered nurses.
223818829|NCT00960674|BEHAVIORAL|Relaxation|Relaxation by a CD with relaxation exercises, at least one hour per week for ten weeks
223818830|NCT03889613|OTHER|prospective follow-up with videocapsule|prospective follow-up with videocapsule
223818831|NCT04626973|DRUG|Ezetimibe/Statin Combination therarpy (ezetimibe plus rosuvastatin)|"For statin naive patients, patients would initially receive Ezetimibe 10mg plus Rosuvastatin 10 or 20 mg.~For non-statin naive patients, regimens are to be changed to the equivalent dose of ezetimibe+rosuvastatin combination in case of already achieved LDL-cholesterol target (\<55 mg/dL) and to be dosed up than the equivalent dose of study drugs in case of not yet achieved LDL-cholesterol target."
223818832|NCT04626973|DRUG|Statin monotherapy (rosuvastatin or atorvastatin)|"For statin naive patients, patients would initially receive Rosuvastatin 20mg or Atorvastatin 40 or 80 mg.~For non-statin native patients, regimens are to be change to equivalent dose of atorvastatin or rosuvastatin in case of already achieved LDL-cholesterol target (\<55 mg/dL) and to be dosed up than the equivalent dose of study drugs in case of not yet achieved LDL-cholesterol target."
223818833|NCT04626973|DRUG|Ezetimibe/Statin Combination therarpy (ezetimibe plus rosuvastatin)|"For statin naive patients, patients would initially receive Ezetimibe 10mg plus Rosuvastatin 5 or 10mg.~For non-statin naive patients, regimens are to be changed to the equivalent dose of ezetimibe+rosuvastatin combination in case of already achieved LDL-cholesterol target (\<70 mg/dL) and to be dosed up than the equivalent dose of study drugs in case of not yet achieved LDL-cholesterol target."
223818834|NCT04626973|DRUG|Statin monotherapy (rosuvastatin or atorvastatin)|For statin naive patients, patients would initially receive Rosuvastatin 10 or 20mg or Atorvastatin 20 or 40mg. For non-statin native patients, regimens are to be change to equivalent dose of atorvastatin or rosuvastatin in case of already achieved LDL-cholesterol target (\<70 mg/dL) and to be dosed up than the equivalent dose of study drugs in case of not yet achieved LDL-cholesterol target.
223818835|NCT04557826|DEVICE|RD19|Experimental device that uses safe electromagnetic energy to stimulate the proximal repository of respiratory tract infectious disease pathogens
223818836|NCT05998200|OTHER|Serum with low concentration AHA (1% Glycolic acid and Lactic acid) and PGA|Participants will used the serum twice daily for 8 weeks
223818837|NCT04551092|DEVICE|NEVR|a non-invasive, non-pharmacological alternative to treat pain by combining an innovative electroencephalography (EEG)-based Neurofeedback solution in an immersive virtual reality (VR) environment.
223818838|NCT01875185|DRUG|Aspirin 81 mg|Aspirin 81 mg orally daily for 7 days
223818839|NCT04838613|DRUG|[18F]CTT1057|Single intravenous dose of approximately 370 Mega-Becquerel (MBq) and subsequent PET/CT scan
223818840|NCT04838613|DRUG|[68Ga]Ga-PSMA-11|Single intravenous dose of approximately 150 MBq and subsequent PET/CT scan
223818841|NCT00600379|DEVICE|Virtual reality system (CAREN™ Integrated Reality System; MOTEK BV, Netherlands).|Training 2/w for 9 weeks (total 18 sessions).
223818842|NCT01686581|DRUG|botulinum toxin Type A|Botulinum toxin Type A (BOTOX®) administered according to physician prescription.
223818843|NCT00008021|BIOLOGICAL|filgrastim|
223818844|NCT00008021|BIOLOGICAL|monoclonal antibody Lym-1|
223818845|NCT00008021|DRUG|cyclosporine|
223818846|NCT00008021|DRUG|paclitaxel|
223818847|NCT00008021|PROCEDURE|peripheral blood stem cell transplantation|
223818848|NCT00008021|RADIATION|indium In 111 monoclonal antibody Lym-1|
223818849|NCT00008021|RADIATION|yttrium Y 90 monoclonal antibody Lym-1|
223818850|NCT04802096|OTHER|inspiratory muscle training|Intensity of inspiratory muscle training will be set at 30% of maximal inspiratory pressure. Subjects in intervention experimental group will perform 15 breaths per set, 6 sets per day on daily basis. The intervention will be last for 8 weeks.
223818851|NCT04802096|OTHER|pulmonary rehabilitation|Pulmonary rehabilitation consists of aerobic exercise training, strength training, and education related to airway clearance and drug utilization. All of subjects will receive 8-week pulmonary rehabilitation.
223818852|NCT01618084|DEVICE|Tritanium acetabular component|Total hip arthroplasty using a tritanium uncemented acetabular component
223818853|NCT02597465|DRUG|SPARC1507|The administered dose is calculated based on the BSA calculated for the subject on Day 1 of the Cycle
223818854|NCT02597465|DRUG|Reference1507|Investigators choice including chemotherapy or supportive therapy
223818855|NCT00913185|DRUG|Acne Free, Proactiv|
223818856|NCT00632008|DRUG|Soluble beta-glucan (SBG)|Topical application of SBG to the wound, at least twice a week until complete healing or for 8 maximum weeks
223818857|NCT00632008|DRUG|Placebo comparator|Topical application of placebo to wound, at least twice a week until compleate healing or for maximum 8 weeks.
223818858|NCT00399763|DRUG|Atomoxetine|Half of participants are randomized to atomoxetine plus individual cognitive behavioral therapy targeting substance use disorder
223818859|NCT00399763|DRUG|Placebo|Half of participants are randomized to placebo plus individual cognitive behavioral therapy targeting substance use disorder
223818860|NCT04211415|DRUG|DS-2741a|Single, subcutaneous injection (upper arm, upper part of the thigh, or abdominal wall in principle) administered weekly for 4 weeks
223818861|NCT04211415|DRUG|Placebo|Single, subcutaneous injection administered weekly for 4 weeks
223818862|NCT02005315|DRUG|Vantictumab|Administered intravenous (IV) infusion.
223818863|NCT02005315|DRUG|Nab-Paclitaxel|Nab-Paclitaxel will be administered by intravenous (IV) infusion.
223818864|NCT02005315|DRUG|Gemcitabine|Gemcitabine will be administered by intravenous (IV) infusion.
223818865|NCT04182880|DRUG|CPL-01|CPL-01 will be administered
223818866|NCT04182880|DRUG|Placebo|Placebo will be administered
223818867|NCT03389477|DRUG|Palbociclib|Palbociclib is an oral drug available as capsules (or as liquid suspension). The capsules should be taken with food
223818868|NCT03389477|DRUG|Cetuximab|-Cetuximab must not be administered as an IV push or bolus
223818869|NCT03389477|DRUG|Cisplatin|-Patients will receive cisplatin via intravenous (IV) infusion over 60 minutes.
223818870|NCT03389477|RADIATION|Intensity-Modulated Radiation Therapy|-Once daily fractions Monday through Friday, with one additional fraction of RT administered on (preferably) Fridays
223818871|NCT03389477|PROCEDURE|Tumor biopsy|"* Tumor tissue will be collected at baseline and then after two cycles of neoadjuvant palbociclib monotherapy~* If the patient has been previously enrolled in Washington University's TAP protocol (head and neck bank, HRPO #201102323), tissue that has been banked may be accessed in lieu of fresh biopsy at baseline."
223818872|NCT03389477|PROCEDURE|Peripheral blood draw|Baseline and post-treatment
223818873|NCT03475121|COMBINATION_PRODUCT|Combination Chemotherapy plus Intrathecal Topotecan|Adjuvant chemotherapy with a reduced dose (compared to GALOP I protocol) of carboplatin
223818874|NCT03475121|COMBINATION_PRODUCT|Higher Dose Combination Chemotherapy plus Intrathecal Topotecan|GALOP I-based systemic adjuvant therapy plus intrathecal topotecan
223818875|NCT03475121|COMBINATION_PRODUCT|Higher Dose Combination Chemotherapy plus Intrathecal Topotecan and Orbital Radiotherapy|GALOP I-based systemic adjuvant therapy plus intrathecal topotecan and orbital radiotherapy (45 Gy) up to chiasm
223818876|NCT03475121|OTHER|No Adjuvant Therapy|Patients will not receive any adjuvant therapy after enucleation of the affected eye.
223818877|NCT03746184|OTHER|Treatment course|Pursued treatment for knee OA, including type of health care provider, time period of treatment course, and types of treatments received, will be recorded via the patient-reported questionnaire.
223818878|NCT06406062|DEVICE|ANDOANGEL|"Polyps were identified by endoscopists assisted by an AI system: rectangular box marks; Monitoring of ileocecal position: whether blindness was reached was displayed in the lower left corner of the interface.~Mirror entry and exit time monitoring: the operation time is displayed in the upper left corner of the interface.~Colonoscopy withdrawal speed monitoring: the relative withdrawal speed was displayed on the left side of the interface."
223818879|NCT05133882|DRUG|Clifutinib Besylate|The queue 1 is divided into Induction therapy and Consolidation therapy and Maintenance treatment The queue 2 will receive oral Clifutinib Besylate once daily until disease progression or unacceptable toxicity occurs
223818880|NCT06100510|DRUG|Aspirin 325mg|Cohort B will receive one (1) 325 mg aspirin 24 hours prior to their second blood draw.
223818881|NCT06806020|OTHER|SEAS approach|"The SEAS approach provides a thorough evaluation of the patient before the treatment starts. In addition to the usual measurements for the specific assessment of the scoliosis (Cobb degrees, Bunnel, trunk decompensation, sagittal postural structure and aesthetic parameters), the patient performs a series of tests. The objectives are: assessment of physical conditions (strength and elasticity of certain muscle areas that are more likely 6 influence the structure of the pelvis and the spine), assessment of neuromotor ability related to the alignment of the spine and the pelvis (balance, management of body movements with closed eyes, optical/manual skills) (Romano et al, 2015).~The main aim of SEAS is to reverse the Stokes vicious cycle, so, the abnormal loading created by the scoliosis with an asymmetric growth leading to worsening of curves that will lead to further asymmetric growth due to increased asymmetrical loading (ettany et al 2014).~The goal of SEAS exercises is to develop an a"
223818882|NCT06806020|OTHER|BSPTS school|"Barcelona scoliosis physical therapy school (BSPTS): Based on the theory that scoliosis posture promotes curve progression, according to the vicious cycle model, Barcelona Scoliosis Physical Therapy School (BSPTS) is a physiotherapeutic method that can be defined as a therapy plan of cognitive, sensory-motor, and kinesthetic training to teach the patient to improve their scoliosis 3D posture and shape. The BSTPS method aims to: 1) improve aesthetics and correct scoliotic posture; 2) stabilize the spine and stop the progression of the curve; 3) inform patients and their families about the condition and available treatments; 4) enhance breathing; 5) increase activity, including daily living activities and functional mobility; 6) enhance general self-image and self-esteem; and 7) reduce pain. The initial ideas serve as the foundation for BSPTS correctional Principles (Berdishevsky et al 2016)."
223818883|NCT03536546|BEHAVIORAL|Alcohol Peer Mentor Intervention|A Veteran Peer research assistant will have contact with a study participant once in person in the emergency department at enrollment, and up to 6 times after enrollment over the course of 2 months. Participants will receive brief advice from a peer. Brief advice content will be based on strengths-based discussions with participants regarding their drinking and personal goals and preferences. Participants will also receive a resource pamphlet on alcohol and other health issues. Follow-up contact will be made by phone. The content of the follow-up peer intervention will be based on the manual developed by the study team to address strengths-based intervention topics.
223818884|NCT03536546|BEHAVIORAL|Brief Advice|Participants will receive brief substance use advice from a non-peer research staff member in the emergency department. Brief advice content will mirror standard care practices currently provided in VHA when a patient endorses hazardous drinking behaviors. Participants will also receive a resource pamphlet on alcohol and other health issues.
223818885|NCT04044729|DRUG|Cannabidiol|500mg dose, suspended in medical grade olive oil and then mixed into chocolate pudding
223818886|NCT04044729|DRUG|Placebo|Placebo
223818887|NCT00142727|DRUG|Methadone|
223818888|NCT00142727|DRUG|Full opioid agonist|
223818889|NCT00142727|DRUG|Partial opioid agonist|
223818890|NCT00142727|DRUG|Opioid antagonist|
223818891|NCT04143841|DEVICE|Viveye OMNS treatment|The Viveye OMNS treatment ( \~30 min) will be applied once, during the treatment visit only
223818892|NCT04143841|DEVICE|Viveye OMNS sham treatment|The Viveye OMNS sham treatment ( \~30 min) will be applied once, during the treatment visit only
223818893|NCT03202381|DRUG|Degarelix|"Degarelix (Firmagon®) will be administered as a subcutaneous injection in the abdominal region every 28 days, in according to the following schedule:~* Starting dose: 240 mg administered as two consecutive subcutaneous injections of 120 mg each (2 x 3 mL injections).~* Maintenance dose: 80 mg administered as one subcutaneous injection of 80 mg (1 x 4 mL injection).~Treatment will be continued till clinically indicated or till disease progression."
223818894|NCT03403426|DEVICE|Wingman Crossing Catheter|Endovascular CTO crossing
223818895|NCT00626366|RADIATION|Sinus CT Scan|Subjects will undergo a Xoran miniCAT scan of their sinuses
223818896|NCT00626366|DRUG|Omnipaque 240 Contrast Solution|Subjects will spray 2-4 drops of half-strength Omnipaque 240 mgI/mL into each nare. Each spray is approximately 0.1 ml.
223818897|NCT00626366|DRUG|Omnipaque 240 mg I/mL|Subjects will place two drops of half-strength Omnipaque 240 mg I/mL intranasally to each nose. Each drop is approximately 1 ml.
223818898|NCT04834310|DRUG|Cefazolin|All patients will receive an intraoperative dose of IV Cefazolin 2 g (re-dose after 4 hours) or IV Clindamycin 600mg (re-dose after 6 hours) for penicillin allergic patients.
223818899|NCT04834310|DRUG|Cephalexin|The experimental group will receive a postoperative 5-day course of Cephalexin 500 mg QID or Clindamycin 300 mg QID for penicillin allergic patients. All capsules will be encapsulated with size 00 dark-colored capsules compounded by the UCLA Investigational Pharmacy.
223818900|NCT04834310|OTHER|Placebo|The placebo group will receive a postoperative 5-day course of placebos (sugar capsules). All capsules will be encapsulated with size 00 dark-colored capsules compounded by the UCLA Investigational Pharmacy.
223818901|NCT05217238|DRUG|Remifentanil|Advanced intravenous injection of remifentanil before the rocuronium injection
223818902|NCT01657266|DRUG|PRO-155|Pre-medication (before surgery) and maintenance treatment.
223818903|NCT01657266|DRUG|Nevanac|Pre-medication (before surgery) and maintenance treatment.
223818904|NCT05042089|OTHER|No intervention will be applied.|The preoperative imaging of the participants, who were grouped according to the postoperative pathology results, will be examined.
223818905|NCT01473498|OTHER|Haemodynamic management|"Patients will be treated with fluid and norepinephrine to achieve and maintain a mean arterial pressure of 65 mm Hg. Then they will be randomized in two groups.~In the first group (study group, n=30), mean arterial pressure will be increased to 85 mm Hg for 72 hours by increasing the dose of norepinephrine in patients."
223818906|NCT01473498|OTHER|Haemodynamic management|"Patients will be treated with fluid and norepinephrine to achieve and maintain a mean arterial pressure of 65 mm Hg. Then they will be randomized in two groups.~In this group (control group, n=30), mean arterial pressure will be maintained at 65 mm Hg."
223818907|NCT02976142|PROCEDURE|neoadjuvant chemoimmunotherapy|
223818908|NCT02486679|DRUG|Prostin (PGE2) tablets|
223818909|NCT02486679|DEVICE|Foley catheter|
223818910|NCT04482543|DRUG|Methotrexate|Intra-silicone oil injection of 250 µg methotrexate is done at the end of surgery and is repeated at weeks 3 and 6 postoperatively.
223818911|NCT03076944|DRUG|UltraEZ|Prophylaxis, apply uniformly on the teeth, wait 15 minutes, remove the gel from the teeth with cotton and abundant water.
223818912|NCT03076944|DRUG|Enamelast|Prophylaxis; dry the teeth; apply uniformly on the teeth with a thin layer.
223818913|NCT00909428|DRUG|Solifenacin Succinate|Participants take 10mg daily solifenacin succinate for 30 days
223818914|NCT03021668|DEVICE|Prevena Peel & Place Dressing|Prevena Peel \& Place Dressing is a device that can be used for closure of the surgical site. It provides negative pressure to the surgical wound
223818915|NCT03021668|OTHER|Standard Closure of the Surgical Incision|This would involve standard closure of the incision site
223818916|NCT03791580|BEHAVIORAL|Commitment nudge|"The commitment nudge will ask clinicians to commit to discussing high-risk polypharmacy at the next office visit with patients who have high-risk polypharmacy. Clinicians who commit will receive a reminder just before the next office visit begins. The patient will also receive notification of the commitment via EHR patient portal.~This nudge will be operationalized via two sequential clinician-facing EHR best practice alerts (BPAs): the first at time of opening any encounter (including encounters other than a face-to-face office visit, e.g., medication refills), and the second (contingent on making a commitment to discuss high-risk polypharmacy) at time of opening the subsequent encounter for a face-to-face office visit. Each of these BPAs will describe the specific high-risk polypharmacy criterion (or criteria) the patient meets, the specific harms associated with the medication(s) triggering the criterion/criteria, and lower-risk alternative treatment strategies."
223818917|NCT03791580|BEHAVIORAL|Justification nudge|The justification nudge will ask clinicians who prescribe or renew a drug that meets high-risk polypharmacy criteria (in the context of the patient's other medications) to write a brief justification for prescribing this high-risk medication. This written justification will be recorded in the patient's medical record. The best practice alert requesting the justification will also describe the specific high-risk polypharmacy criterion (or criteria) the patient meets, the specific harms associated with the medication(s) triggering the criterion/criteria, and lower-risk alternative treatment strategies.
223818918|NCT01920048|PROCEDURE|Percutaneous Coronary Intervention|
223818919|NCT01920048|DRUG|Drug Therapy for Heart Failure|The optimal combination of drugs and doses for each patient will be individualized and will be determined by his/her physician, in accordance with local and international clinical practice guidelines
223818920|NCT01920048|DEVICE|Device Therapy for Heart Failure|The optimal device therapy for each patient will be individualized and will be determined by his/her physician, in accordance with local and international clinical practice guidelines. In most cases the device will be an Implantable Cardioverter Defibrillator and/or Cardiac Resynchronization Therapy.
223818921|NCT03904030|OTHER|Rehabilitation with or without Anti-Gravity Treadmill|The study will include patients with grade III-IV primary knee osteoarthritis. The investigators will take 27 patients to the both groups. The investigators will look after more specifically the anti-gravity treadmill rehabilitation and traditional rehabilitation after arthroplasty. Follow-up is one year. Functional tests will be made and questionnaires will be given to the patients before operation and after operation. After 6 to 8 weeks, 4 months and 12 months of operation questionnaires will be fil up again. After six month the investigators will send a questionnaire and there will be asked possible rehabilitation sessions, use of drugs and possible complications after knee arthroplasty.
223818922|NCT06318325|DIAGNOSTIC_TEST|examination|examination of tendon, muscle joints and injuries
223818923|NCT01086865|DRUG|Apetiviton BC|"Administer the recommended dosage preferably one hour before the main meal:~Children (2 to 6 years): 2.5 mL 3 x daily. Adults (18 to 50 years): 5 mL 3 x daily. Elderly (60 to 80 years): 5 ml 3 x daily."
223818924|NCT01122381|DRUG|ethosuximide|ethosuximide (ESX)
223818925|NCT01122381|OTHER|placebo comparator|placebo
223818926|NCT02621957|DRUG|GDC-0810|During Period 2 subjects will be administered an oral 600 mg dose GDC-0810 daily beginning on Day 5 for 4 consecutive days (from Days 5 to 8, inclusive).
223818927|NCT02621957|DRUG|Pravastatin|Subjects will receive a single oral dose of 10 mg pravastatin on Day 1 in Period 1 and Day 7 in Period 2.
223818928|NCT01563848|PROCEDURE|Cryoballoon ablation|After double transseptal puncture, selective PV angiography was performed to identify the PV ostia in 2 projections (right anterior oblique 30º, left anterior oblique 40 º). Baseline potentials of all PVs were recorded with a Lasso catheter (Biosense Webster, Inc., Diamond Bar, California). To assess the exact position of the inflated balloon in relation to the left atrial (LA)-PV junction, contrast medium was injected from the distal lumen of the cryoballon catheter . CBA was performed for a target time of 300 seconds. The right phrenic nerve was constantly paced from the superior caval vein during freezing at the septal PVs. After each freeze, PV conduction was revaluated by the Lasso catheter.
223818929|NCT01563848|PROCEDURE|Implantation of loop recorder|"The RevealXT was implanted in the parasternal area of the chest. The requirement for defining the exact final position was an R-wave amplitude ≥0.4 mV assessed through the Vector Check.~Patients were provided with the Patient Assistant, a toolthat allows each patient to store the ECG through the implanted device during symptoms: datawere collected in order to analyze heart rhythm during symptomatic events"
223818930|NCT01563848|PROCEDURE|Radiofrequency ablation|Externally-irrigated tip (5-mm tip, Celsius Thermo-Cool, Biosense Webster, Diamond Bar, CA, USA). Temperature-controlled RF delivery was performed with a maximum power output of 50 W and temperature limit of 50 C. The catheter was irrigated using 0.9% saline infusion at a ﬂow rate of 20-40 mL/min during RF delivery and 2 mL/min between applications using a commercially available pump (Cool Flow, Biosense Webster).
223818931|NCT02447289|DRUG|Intranasal ketamine|Ketamine injectable solution in a concentration of 50.0 mg/mL administered into the nose with an atomizer; dose of 4.0 mg/kg, maximum 100.0 mg
223818932|NCT02447289|DRUG|Oral ketamine|Ketamine injectable solution in a concentration of 50.0 mg/mL via oral route; dose of 4.0 mg/kg maximum 100.0 mg
223818933|NCT02447289|DRUG|Intranasal midazolam|Midazolam injectable solution in a concentration of 5.0 mg/mL administered into the nose with an atomizer; dose of 0.2 mg/kg, maximum 5.0 mg
223818934|NCT02447289|DRUG|Oral midazolam|Midazolam oral solution in a concentration of 2.0 mg/mL via oral route; dose of 0.5 mg/kg, maximum 5.0 mg when associated with ketamine; dose of 1.0 mg/kg, maximum 20.0 mg when give as a solely agent
223818935|NCT00651053|DEVICE|EUS|Sensitivity and specificity of EUS will be compared with PFT as reference standard.
223818936|NCT01507636|OTHER|Occupational Therapy|Occupational therapy using a special arm function training.
223818937|NCT01507636|OTHER|Physical therapy|Physical therapy for arm force training.
223818938|NCT02522858|DRUG|Atropine|"To evaluate the effectiveness of atropine on prevention bradycardia,atropine 0.01\~0.03mg/kg up to 0.5mg would be injected intravenously just before starting loading dose of dexmedetomidine in group A.~During operation, heart rate decreasing 30% from initial heart rate or under 40/min would be regarded as bradycardia needing treatment, and atropine 0.5mg will be injected intravenously. This intervention would be applied to both group."
223818939|NCT02522858|DRUG|Dexmedetomidine|Dexmedetomidine is a highly selective a2 adrenergic receptor antagonist used as sedative agent. After confirming the fixation level of spinal anesthesia, the loading dose(0.6ug/kg) of dexmedetomidine which is diluted with normal saline as 4ug/mL would be started for 10 minutes.Maintenance dose(0.25ug/kg/hr) would be continued after loading dose.
223818940|NCT02522858|DRUG|Ephedrine|Systolic blood pressure decreasing 30% from basal blood pressure or under 90 mm Hg would be regarded as hypotension needing treatment, and ephedrine 5mg will be injected intravenously.
223818941|NCT02461095|OTHER|Impairment based approach|This intervention will consist of exercise, mechanics training, education, manual therapy and modalities. The treatment will address the impairments found during the evaluation. This approach is a typical individualized physical therapy treatment approach.
223818942|NCT02461095|OTHER|PFPS Algorithm approach|Physical Therapy treatment for Patellofemoral Pain Syndrome based upon a treatment algorithm that addresses patients: fear avoidance beliefs, flexibility, body mechanics, and strength. The exercises and treatments are individualized to each patient with the goals of low fear avoidance beliefs, flexibility, body mechanics, and strength and are performed in a sequential manner
223818943|NCT00667472|DRUG|Ranibizumab|Combined Pulsed Dye Laser and Topical Ranibizumab for Treatment of Port Wine Stain Birthmarks
223818944|NCT00667472|DEVICE|Pulsed Dye Laser|Combined Pulsed Dye Laser and Topical Ranibizumab for Treatment of Port Wine Stain Birthmarks
223818945|NCT00480792|BIOLOGICAL|GenHevac B Pasteur|Intra-muscular injection 20 microgramme Intramuscular use at M0, M1, M6
223818946|NCT00480792|BIOLOGICAL|GenHevac B Pasteur|Intra-muscular injection 40 microgramme intramuscular use at M0, M1,M2, M6
223818947|NCT00480792|BIOLOGICAL|GenHevac B Pasteur|GenHevac-B 4 microgramme Intradermal use at M0, M1, M2, M6
223818948|NCT02329184|DRUG|MYK-461|
223818949|NCT02217280|DRUG|Injection with Gadolinium|Gadavist (gadobutrol) injection is a gadolinium-based contrast agent indicated for intravenous use in diagnostic magnetic resonance imaging (MRI) in adults and children (2 years of age and older) to detect and visualize areas with disrupted blood brain barrier (BBB) and/or abnormal vascularity of the central nervous system
223818950|NCT03078088|DRUG|Tham|alkalinizer
223818951|NCT03078088|DRUG|Saline|Placebo
223818952|NCT00554008|PROCEDURE|laparoscopic appendectomy|appendix removal via scope
223818953|NCT00554008|PROCEDURE|open appendectomy|open operation for removal of appendix
223818954|NCT01015976|PROCEDURE|bariatric surgery|Roux en Y bariatric surgery
223818955|NCT01015976|OTHER|control|No surgery
223818956|NCT00116844|DRUG|Valaciclovir|Valtrex 1g once daily
223818957|NCT00116844|DRUG|Placebo|placebo
223818958|NCT04760522|GENETIC|WGS Diagnostic: Blood take for genetic diagnostic|Blood sampling, short clinical characterization, WGS based sequencing, NGS analysis and other omics analysis (transcriptomics, proteomics, metabolomics).
223818959|NCT02131870|DIETARY_SUPPLEMENT|L plantarum DSM 9843 or placebo|
223818960|NCT02515565|DRUG|cephalosporin with or without erythromycin|Second- or third-generation cephalosporin (cefuroxime, cefotaxime, or ceftriaxone) with or without erythromycin, given parenterally; parenteral therapy should continue until the patient has been afebrile for more than 24 hours and oxygen saturation exceeds 95 percent.
223818961|NCT02515565|OTHER|Physiotherapy program|The physiotherapy treatment will be performed during the hospitalization, every day during 45-60 minutes added to the standard medical treatment. I will include breathing exercises, electrostimulation in quadriceps with voluntary contraction and exercises with theraband.
223818962|NCT02640248|DEVICE|Cuff ETT|
223818963|NCT02174887|DRUG|Nab-paclitaxel + Gemcitabine|"Gemcitabine 1 g/m² IV infusion over 30 minutes at D1-D8-D15 every 28 days in combination with Nab-paclitaxel 125 mg/m² IV infusion over 30 minutes at D1-D8-D15 every 28 days~The patients will receive 2 cycles of treatment every 28 days:"
223818964|NCT01933880|DRUG|Osmotic Release Oral System Methylphenidate Hydrochloride (OROS-MPH)|Osmotic release oral system methylphenidate hydrochloride (OROS-MPH) starting at initial dosage of 18 milligram per day (mg/d) which can be increased to 36mg/d up to a maximum dosage of 54mg/d according to the therapeutic effect and tolerance or maintained at 36 mg or re-adjusted to 18mg due to intolerance.
223818965|NCT01933880|OTHER|No intervention|Participants did not receive any study drug in this group. Participants were assessed for changes in the cognitive functions and the efficacy was compared with ADHD children.
223818966|NCT04418635|DIETARY_SUPPLEMENT|Prosta-OK® Neo or Prosta-OK® Neo-matched placebo|the patient planed to receive Tamsulosin 0.2mg once daily is randomized to the experiment group or placebo group. After randomization, the patient received Tamsulosin therapy with Prosta-OK® Neo or Prosta-OK® Neo-matched placebo 707mg 2 tablets twice daily for 85 days.
223818967|NCT00709462|BIOLOGICAL|CDX1307|
223818968|NCT01899313|BEHAVIORAL|CBT- based SMS text messaging intervention|
223818969|NCT01899313|BEHAVIORAL|CBT group therapy|
223818970|NCT02513108|PROCEDURE|same day discharge|same day discharge after PCI for stable CAD
223818971|NCT04781361|DRUG|Intravenous isotonic fluid - NaCl 131-154 mmol/L in 5% dextrose|Isotonic group will be given fluids containing 131-154 mmol/L Sodium Chloride
223818972|NCT04781361|DRUG|Intravenous Hypotonic fluid- Sodium Chloride < 130 mmol/L|"Hypotonic group will be given fluids containing lower than 130 mmol/L :~Dextrose 5% in 0.2% Sodium Chloride, or Dextrose 5% in 0.33 % Sodium Chloride,or Dextrose 5% in %0.45 Sodium Chloride, or Intravenous fluid containing Sodium Chloride \< 130 mmol/L"
223818973|NCT03135665|DEVICE|Ultrasound|"Scolioscan, the ultrasound system reported to be reliable and valid for spinal deformity assessment, will be used. The system composes of an ultrasound scanner with a linear probe of 100 mm in width and frequency range of 4-10MHz, a frame structure and a spatial sensor which is attached to the ultrasound probe for spatial data capture. Daily calibration will be performed using a phantom to assure accuracy of spine image formation and subsequent angle measurement.~Subjects will stand on the Scolioscan platform with a standardized posture kept stable with pegs throughout the scanning process.. After adjusting the ultrasound scanner setting, the probe will be steered from L5 to T1 spinous process for scanning.~SPA will be used to determine the ultrasound-based Referral Status through predicting whether the Cobb angle is beyond the referral threshold of ≥20° or not. There are two values for the Referral Status: either for specialist referral or not for specialist referral."
223818974|NCT04810117|DIAGNOSTIC_TEST|Serodiagnosis of IgG and IgM|IgG and IgM antibodies will be detected in COVID-19 patients
223818975|NCT02582138|OTHER|Multicomponent intervention (MCI)|"The multicomponent intervention will include physical activity (PA), nutrition and information and communications technology (ICT). The PA will be of moderate intensity and will include aerobic, strength, flexibility, and balance training. Walking will be the primary mode of PA .~The nutritional intervention will combine individual nutritional assessment and personalised dietary recommendations to achieve:~* a daily total energy intake of 25-30 kcal/kg body weight;~* an average protein daily intake between 1.0 and 1.2 g/Kg/body weight.~The ICT component will involve the use of an ad hoc technological device to record actimetry data to support the elaboration of a personalised training programme."
223818976|NCT02582138|OTHER|Healthy Aging Lifestyle Education (HALE)|The healthy aging lifestyle education programme will be based on a workshop series. Participants will receive information on a variety of topics of relevance to older adults (e.g., recommended preventive services and screenings at different ages). The programme will also include a short instructor-led programme (5-10 minutes) of upper extremity stretching exercises or some relaxation techniques that will be performed at the end of each workshop.
223818977|NCT04751422|OTHER|Electronic Health Record Review|Medical data is collected
223818978|NCT05396989|OTHER|No intervention|No intervention
223818979|NCT05278689|OTHER|No intervention|No intervention
223818980|NCT02244164|DRUG|Incretinomimetics|
223818981|NCT02244164|DRUG|DPP-4 inhibitors|
223818982|NCT02645084|OTHER|Offering an online risk assessment questionnaire|Offering an online risk assessment questionnaire to CRC patients, to facilitate the detection of colorectal cancer patients with hereditary or familial colorectal cancer
223818983|NCT02380222|OTHER|Interview|Single interview lasting approximately one hour
223818984|NCT05535543|PROCEDURE|Prone Positioning|Patients will be turned to prone position and they will be left in prone position for a duration of at least 16 hours to a maximum of 24 hours. This duration is recommended by the ARDS guidelines.
223818985|NCT01385358|PROCEDURE|Thoracoscopically Assisted Surgical Ablation|Surgical AF ablation including pulmonary vein isolation, gananglionated plexi ablation +/- LAA excision/exclusion.
223818986|NCT01385358|PROCEDURE|Catheter Ablation|In this arm, study subjects will undergo conventional catheter ablation as their index procedure. This will include pulmonary vein isolation, linear and electrogram based ablation.
223818987|NCT04453423|DRUG|Anlotinib + Pemetrexed+Carboplatin|"Anlotinib: 12mg, QD, PO, d1-14, 21 days per cycle~Carboplatin: AUC 5 on day 1 of 21 days per cycle~Pemetrexed: 500mg/m2 iv on day 1 of 21 days per cycle"
223818988|NCT04453423|DRUG|Pemetrexed|500mg/m2 iv on day 1 of 21 days per cycle(maintenance phase)
223818989|NCT04453423|DRUG|Anlotinib + Pemetrexed|"Anlotinib:12mg, QD, PO, d1-14, 21 days per cycle(maintenance phase)~Pemetrexed:500mg/m2 iv on day 1 of 21 days per cycle(maintenance phase)"
223818990|NCT04453423|DRUG|Anlotinib|12mg, QD, PO, d1-14, 21 days per cycle(maintenance phase)
223818991|NCT04618601|DRUG|Spironolactone|Patients randomized to the high-dose spironolactone group will receive oral spironolactone (≥100 mg) on top of standard of care treatment for acute heart failure immediately after randomization and in the afternoon of each subsequent day unless the serum potassium level is \>5 mmol/L. The exact dose will be determined based on a pre-specified algorithm provided.
223818992|NCT03784040|DRUG|OTSGC-A24|OTSGC-A24 is administered as a subcutaneous (under the skin) injection. Nivolumab and ipilimumab are administered by intravenous (IV) infusion, meaning the drug is given through a catheter in a vein. A pump will be used to ensure the correct amount of medicine is given through the catheter. The nivolumab and ipilimumab infusions each take about 30 minutes. There will be a break of about 30 minutes in between the nivolumab and ipilimumab infusions (if given on the same day). OTSGC-A24 and nivolumab are administered every 2 weeks, while ipilimumab is administered every 6 weeks.
223818993|NCT03784040|DRUG|Nivolumab|OTSGC-A24 is administered as a subcutaneous (under the skin) injection. Nivolumab and ipilimumab are administered by intravenous (IV) infusion, meaning the drug is given through a catheter in a vein. A pump will be used to ensure the correct amount of medicine is given through the catheter. The nivolumab and ipilimumab infusions each take about 30 minutes. There will be a break of about 30 minutes in between the nivolumab and ipilimumab infusions (if given on the same day). OTSGC-A24 and nivolumab are administered every 2 weeks, while ipilimumab is administered every 6 weeks.
223818994|NCT03784040|DRUG|Ipilimumab|OTSGC-A24 is administered as a subcutaneous (under the skin) injection. Nivolumab and ipilimumab are administered by intravenous (IV) infusion, meaning the drug is given through a catheter in a vein. A pump will be used to ensure the correct amount of medicine is given through the catheter. The nivolumab and ipilimumab infusions each take about 30 minutes. There will be a break of about 30 minutes in between the nivolumab and ipilimumab infusions (if given on the same day). OTSGC-A24 and nivolumab are administered every 2 weeks, while ipilimumab is administered every 6 weeks.
223818995|NCT04916964|OTHER|Test and exercise home-based program|"Eight home-based physiotherapy sessions will occur in two months, once a week, to activate the preserved implicit memory (PIM). The recommendations are to train three weeks with the same exercise program, three times a week (one time coached by the attributed physiotherapist and two times coached by a natural or family caregiver). After three weeks, the participants can choose if they want to keep the same exercises or change all or some of these, in testing other tasks. Every training session will be planned to last 45 minutes. During each training session, the participant will note on his/her own Training booklet each task performed. The Training booklet will be used to plane, organize, and remember details for the next training session."
223818996|NCT02395133|DRUG|Dupilumab|Subcutaneous injection of Dupilumab 300 mg alternatively with placebo (matched to Dupilumab) was administered.
223818997|NCT02395133|DRUG|Placebo|Subcutaneous injection of Placebo (for Dupilumab) was administered once weekly (QW).
223818998|NCT02789475|DRUG|Amlodipine|Amlodipine administration
223818999|NCT02789475|DRUG|Rosuvastatin|Rosuvastatin administration
223819000|NCT04798443|PROCEDURE|subureteral endoscopic Injection of Dextranomer/Hyaluronic acid (Dexell)|The subureteral endoscopic injection was done under general anesthesia. the investigators used the subureteral injection technique (STING), as described by O'Donnell and Puri. The volume of Dexell was injected until ureteral orifice collapse in all patients. The needle was held for 30 s.
223819001|NCT04798443|PROCEDURE|open ureteral reimplantation (Lich-Gregoir)|The juxtavesical ureter is dissected by open surgery and a submucosal groove is created extending laterally from the ureteral hiatus along the course of the ureter. The ureter is placed in the groove and the detrusor is closed over the ureter with ureteric stent fixation for 21 days. the surgical wound is closed in layers. Urethral catheter for bladder drainage for 3-5 days.
223819002|NCT03537079|OTHER|hypoxia air|Normobaric hypoxia is generated by adding azote in normal air to decrease the oxygen availability.
223819003|NCT04567511|DRUG|Emicizumab|bispecific monoclonal antibody binding to activated Factor IX and Factor X
223819004|NCT02609646|DRUG|Linezolid|Drug choice is performed according to standard clinical practice, that will not be modified by the participation in the study. As a consequence, assignment of patients to groups is not protocol based, but it is defined by standard clinical choices.
223819005|NCT02609646|DRUG|Meropenem|Drug choice is performed according to standard clinical practice, that will not be modified by the participation in the study. As a consequence, assignment of patients to groups is not protocol based, but it is defined by standard clinical choices.
223819006|NCT02609646|DRUG|Piperacillin-tazobactam combination product|Drug choice is performed according to standard clinical practice, that will not be modified by the participation in the study. As a consequence, assignment of patients to groups is not protocol based, but it is defined by standard clinical choices.
223819007|NCT02609646|DRUG|Vancomycin|Drug choice is performed according to standard clinical practice, that will not be modified by the participation in the study. As a consequence, assignment of patients to groups is not protocol based, but it is defined by standard clinical choices.
223819008|NCT02079064|DRUG|Desflurane|Inhalational anesthetic
223819009|NCT02079064|DRUG|Propofol|Intravenous anesthetic that can be given by continuous infusion
223819010|NCT02824302|OTHER|Survey|Patients coming for induction of labor will be handed a survey regarding their expectation of their coming labor pain. And then will be followed up after 24 hours of their delivery.
223819011|NCT03829163|DEVICE|Hydraulic Adjustable Walker|The HAW is a based on a conventional walker but has innovative telescoping legs with a leg adjustment assembly that includes at least one valve and at least one tube that delivers hydraulic fluid into the legs and allows a user to control the length of each leg. The legs of the walker are hydraulically adjustable, so that the front legs may be shortened and the back legs extended, or two side legs shortened and the two opposing side legs extended, so as to allow the walker to be securely placed on two different steps. This allows the user to be able to stand on a stair without worrying about sharing the same stair with the device. It also ensures that the height of the walker continues to be the right height for the user to minimize loss of balance.
223819012|NCT03829163|DEVICE|Conventional Walker|A walker consists primarily of a metal frame with four legs which are stabilized by crossbars. These walker frames come in a variety of shapes and sizes; many consist primarily of two inverted U-shaped leg modules connected by crossbars. Regardless of the shape or form of the leg modules, each walker frame forms a 3-sided box with an opening in which the user may stand.
223819013|NCT01057784|PROCEDURE|Bariatric surgery.|Bariatric Surgery
223819014|NCT01768208|DRUG|Saxagliptin|
223819015|NCT01705743|DRUG|Sevoflurane+Nitrous oxide|60% nitrous oxide +40% oxygen+ Sevoflurane
223819016|NCT01705743|DRUG|Sevoflurane|100% oxygen+ Sevoflurane
223819017|NCT03968757|DEVICE|easyEndoTM Universal Linear Cutting Stapler and reloads (Ezisurg Medical)|Device for creation of anastomoses during laparoscopic RYGB surgery manufactured by Ezisurg Medical.
223819018|NCT02491190|BEHAVIORAL|EMPOWER Educational Module|Evidence-based video module delivering content of the Right Question intervention from Deen et al. (2011)
223819019|NCT03737084|BEHAVIORAL|CBCT Intervention|The training consists of six weekly sessions. The participant will receive six guided meditation audio, relative to each session, to practice during the week.
223819020|NCT06341725|OTHER|malignant lymph nodes|observational study
223819021|NCT03444233|OTHER|Diet|7 days fruit-rich diet, 7 days HFCS-rich diet
223819022|NCT03245385|DRUG|Treatment with Halobetasol propionate 0.05% topical spray|Patients will be treated with topical halobetasol 0.05% spray applied twice daily for 14 days. Patients will be instructed not to rub over the affected area after application of spray. Each patient is expected to receive 28 doses. The maximum amount of test product applied per week will not exceed 50 g
223819023|NCT02833688|DRUG|dexmedetomidine|dexmedetomidine 2mg is diluted in 0.9% sodium chloride with the concentration of 4 ug ml-1 is administered with an loading dose of 0.5ug kg-1 of 10 min, and maintained with infusion rate of 0.5 ug kg-1 h-1. The infusion is ceased after the resection of the hepatic issues.
223819024|NCT02833688|DRUG|0.9% sodium chloride|0.9% sodium chloride is administered with an loading dose of 0.5ug kg-1 of 10 min, and maintained with infusion rate of 0.5 ug kg-1 h-1. The infusion is ceased after the resection of the hepatic issues.
223819025|NCT05514080|OTHER|Insulin closed-loop|41-hour intervention period in which the participants are treated with rapid insulin in the closed-loop system.
223819026|NCT01905644|PROCEDURE|Perineal ultrasound|Perineal ultrasound will be used after delivery to help detect anal sphincter ruptures.
223819027|NCT04896632|DRUG|INE 963|Part A: Single ascending dose with 7 planned cohorts\> Part B: multiple dose with 2 planned cohort q24x3 days
223819028|NCT04896632|OTHER|Placebo|Part A: single ascending dose with 7 planned cohorts. Part B: multiple dose with 2 planned q24x3 days.
223819029|NCT00722501|DRUG|ERB-257|
223819030|NCT00722501|OTHER|placebo|
223819031|NCT05360030|DRUG|Naloxone|The volunteer received an intravenous bolus followed by a continuous infusion of naloxone, which was continued throughout the pcTBS session
223819032|NCT05360030|DRUG|Saline|The volunteer received an intravenous bolus followed by a continuous infusion of placebo (saline), which was continued throughout the pcTBS session
223819033|NCT05360030|DRUG|Ketamine Hydrochloride|The volunteer received an intravenous bolus followed by a continuous infusion of ketamine, which was continued throughout the pcTBS session
223819034|NCT05360030|DEVICE|pcTBS of M1|Prolonged continuous theta-burst stimulation (pcTBS) was administered to the left M1 at 80% RMT, consisting of a burst of 3 pulses given at 50 Hz repeated every 5 Hz. A total of 1,200 pulses were delivered with the TMS coil positioned in a posterior-anterior (PA) direction parallel to the midline
223819035|NCT05360030|DEVICE|pcTBS of DLPFC|Prolonged continuous theta-burst stimulation (pcTBS) was administered to the left DLPFC at 80% RMT, consisting of a burst of 3 pulses given at 50 Hz repeated every 5 Hz. A total of 1,200 pulses were delivered with the TMS coil positioned in a posterior-anterior (PA) direction parallel to the midline
223819036|NCT05360030|DEVICE|SHAM stimulation|The Sham stimulation was delivered using the same pcTBS protocol, with the coil being flipped 90◦to the scalp so that the magnetic field would be delivered away from the scalp
223819037|NCT03062202|BEHAVIORAL|SilverCloud|SilverCloud Health is a leading provider of online therapeutic solutions to support and promote positive behavior change and mental wellness. SilverCloud delivers interventions for all of the anxiety disorders (panic disorder, social anxiety, phobias, GAD, health anxiety, OCD), depression and also comorbid depression and anxiety. The programs for the treatment of depression and anxiety employ several innovative engagement strategies for improving the user experience. These are divided into several categories: personal, interactive, supportive, and social. Research on the SilverCloud interventions has yielded significant clinical outcomes (Richards et al., 2015).
223819038|NCT00962247|DEVICE|Television reduction device|A TV allowance helps turn off the television when the time limits have been met.
223819039|NCT03156322|DRUG|5 mL epidural initiation volume (bupivacaine + fentanyl)|5 mL 0.625% bupivacaine + 2 μg/mL fentanyl solution is administered from epidural catheter
223819040|NCT03156322|DRUG|10 mL epidural initiation volume (bupivacaine + fentanyl)|10 mL 0.625% bupivacaine + 2 μg/mL fentanyl solution is administered from epidural catheter
223819041|NCT03156322|DRUG|20 mL epidural initiation volume (bupivacaine + fentanyl)|20 mL 0.625% bupivacaine + + 2 μg/mL fentanyl solution is administered from epidural catheter
223819042|NCT05841238|DRUG|LY3502970|Administered orally.
223819043|NCT02233933|OTHER|Hemospray|hemospray is used after argon coagulation to stop bleeding
223819044|NCT01487044|DRUG|Macugen (Pegaptanib Sodium)|"Pegaptanib sodium drug substance is a pegylated (40 kDa branched PEG molecule consisting of two 20 kDa PEG arms) anti-VEGF aptamer. It is formulated in phosphate buffered saline at pH 6-7. Sodium hydroxide or hydrochloric acid may be added for pH adjustment.~Pegaptanib sodium is formulated at 0.3mg/90µl and presented in USP Type I glass barrel syringes sealed with a bromobutyl rubber plunger stopper. The syringe has a needle attachment at allows for a 30-guage need to be fixed to the syringe prior to injection. The stoppered syringe is packaged in a foil pouch. The drug product is preservative-free and intended for single use by intravitreous injection only."
223819045|NCT06383780|DRUG|GP combined with Tislelizumab|Gemcitabine combined with cisplatin regimen combined with Tislelizumab
223819046|NCT06383780|DRUG|TPC combined with Tislelizumab|cisplatin, nab-paclitaxel and capecitabine regimen combined with Tislelizumab
223819047|NCT02462954|DEVICE|ContraGel|
223819048|NCT02462954|DEVICE|HEC Universal Placebo gel|
223819049|NCT00346801|DRUG|Celecoxib|100 mg by mouth (PO) twice daily for 5 days before beginning radiation therapy; continued 7 days per week throughout radiation treatment (about 7 weeks).
223819050|NCT00346801|DRUG|Cisplatin|25 mg/m\^2 IV over 60 minutes on Day 1, Weeks 2-8
223819051|NCT00346801|DRUG|CPT-11|30 mg/m\^2 IV over 90 minutes on Day 1, Weeks 2-8, followed by cisplatin which will be infused for 60 minutes.
223819052|NCT00346801|RADIATION|Concurrent Thoracic Radiation Therapy|63 Gy at 1.8 Gy/Fx in 35 Fractions over 7 weeks starting 2nd week of celebrex.
223819053|NCT02653638|OTHER|Control|"1. Transcranial Doppler~2. Blood Pressure~3. Heart Rate~4. Oxygen Saturation"
223819054|NCT02653638|DRUG|Indomethacin|"1. Transcranial Doppler~2. Blood Pressure~3. Heart Rate~4. Oxygen Saturation"
223819055|NCT04040257|BEHAVIORAL|Team-based approach|Team-based participation in the The Perinatal Quality Foundation Fetal Monitoring Credentialing (PQF/FMC) exam.
223819056|NCT00509548|DRUG|TG100801|Eye drop, twice a day, 30 days.
223819057|NCT00740558|PROCEDURE|Activator methods technique|Chiropractic adjustment by a manually assisted mechanical force
223819058|NCT00740558|PROCEDURE|Traditional chiropractic adjustment|Lumbar roll according to the Diversified technique of chiropractic adjusting
223819059|NCT03661502|DEVICE|VVV|ventilation mode with variable tidal volume is chosen. the average tidal volume is 6 ml/kg and respiratory rate adapted to reach end tidal con between 30 and 50 mmHg
223819060|NCT03661502|DEVICE|PCV|ventilation mode with constant tidal volume is chosen. the tidal volume is 6 ml/kg and respiratory rate adapted to reach end tidal con between 30 and 50 mmHg
223819061|NCT01161368|DRUG|Lapatinib, Vinorelbine|"Lapatinib 1250mg orally once daily continuously~plus~Vinorelbine 20 mg/m2 intravenously (IV) once weekly \[Days 1 and 8\] for 2 weeks, followed by a rest week in a 3-week cycle."
223819062|NCT01771393|DEVICE|CBCT prior to MDCT|Cone-beam scanner is performed immediately after arthrography, then multidetector scanner is performed.
223819063|NCT01771393|DEVICE|MDCT prior to CBCT|Multidetector scanner is performed immediately after arthrography, then Cone-beam scanner is performed.
223819064|NCT04061226|DEVICE|Overnight polysomnography|Overnight polysomnography will be performed in a sleep laboratory (EEG, EOG, EMG, ECG, respiratory movements of the chest and abdomen, oro-nasal airflow, and O2 saturation will be examined
223819065|NCT02467517|DRUG|Ketamine|
223819066|NCT02467517|DRUG|Magnesium Sulfate|
223819067|NCT02467517|DRUG|placebo : sodium chloride|
223819068|NCT04612946|BEHAVIORAL|Referral to Telemedicine LCS Counseling Visit|Patients in the intervention arm will be invited to complete a telemedicine LCS counseling visit, and asked for permission to be referred directly to the LCS navigator to help schedule an appointment. They will also be given the option to directly contact the LCS navigator. Telemedicine counseling visits will be conducted using established clinical procedures for virtual or telephone visits at Penn Medicine. In accordance with reimbursement policies for lung cancer screening, these visits will be conducted by a physician or nurse practitioner within the Lung Cancer Screening Program at Penn Medicine. Counseling visits are covered without co-pay as standalone visits according to USPSTF guidelines and costs will not be covered by the study. LCS is an evidence-based practice and considered standard of care for those who are eligible and desire to be screened. Clinicians retain full control on how to conduct LCS counseling or LDCT in this trial.
223819069|NCT04612946|BEHAVIORAL|Usual Care|Patients in the usual care arm will be provided with contact information for the Penn LCS Program and encouraged to discuss LCS with their providers.
223819070|NCT01373762|BEHAVIORAL|Exercise Videogame Bikes|The intervention group will receive an exercise videogame bike that will be linked into their Sony Playstation 2® (Sony Computer Entertainment America Inc, Foster City, California). The Active Cycle® system reads the participant's cycling cadence which, in combination with a handlebar-mounted game controller, allows each participant to play a variety of Sony Playstation 2 and 3® videogames while exercising. The control-distraction group will receive a traditional stationary bike (i.e., same bike as the Active Cycle, but without the videogame controllers), which will be placed in front of their television. The recommended exercise training regime for both conditions will be activity of moderate intensity exercise (i.e., 60 to 75% of heart rate reserve), 3 days/week for 30 minutes/day.
223819071|NCT05613114|DRUG|Dalfampridine 10 MG|The participants in the experimental group received dalfampridine administered as 10 mg extended-release tablets every twelve hours for 8 weeks.
223819072|NCT05613114|DRUG|Placebo|Control group received a placebo drug with the same administration method (2 times per week for the total duration of 8 weeks).
223819073|NCT05613114|BEHAVIORAL|Physiotherapy|Conventional physiotherapy program including stretching and flexibility, strengthening, walking and balance exercises which were mainly focused on the lower limbs and improving walking. The program was applied 2 times per week for the total duration of 8 weeks.
223819074|NCT01580839|DRUG|Tissue Plasminogen Activator (Alteplase)|0.9 mg/kg up to a maximum of 90mg, intravenous, 10% as bolus and the remainder over 1 hour
223819075|NCT01580839|DRUG|Placebo|placebo provided as 50mg lyophilised powder to be reconstituted with sterile water in glass vials indistinguishable from active drug
223819076|NCT03732625|DRUG|Raltegravir|DTG will be replaced by Raltegravir (RAL) 1200 QD, maintaining the other two drugs that constituted the triple therapy established before the inclusion of the patient in the study.
223819077|NCT01125722|DEVICE|Non-invasive neurostimulation device|Active electrode patches are worn for 4 weeks, one per week, during the treatment phase of the study. The patch is placed by the investigator.
223819078|NCT01125722|DEVICE|Non-invasive neurostimulation device|Active electrode patches are worn for 4 weeks, one per week, during the treatment phase of the study. The patch is placed by the subject.
223819079|NCT03474549|DEVICE|Tigertriever revascularization device|Mechanical Thrombectomy
223819080|NCT02223039|BIOLOGICAL|AbGn-168H|AbGn-168H monoclonal antibody
223819081|NCT02223039|BIOLOGICAL|Placebo|Placebo of AbGn-168H
223819082|NCT04871984|DEVICE|Ureteroscopy for upper tract stone treatment with Holmium laser|Rigid or flexible ureteroscopy for ureteral or renal stone. Lithotripsy with Holmium laser
223819083|NCT04871984|DEVICE|Ureteroscopy for upper tract stone treatment with Thulium laser|Rigid or flexible ureteroscopy for ureteral or renal stone. Lithotripsy with Thulium laser
223819084|NCT04209413|PROCEDURE|Patients referred for a knee ligamentoplasty|knee ligamentoplasty
223819085|NCT01106443|PROCEDURE|Total Thyroidectomy + CLND|Total thyroidectomy includes removing all possible thyroid tissue. Central lymph node dissection is a neck level 6 dissection. This includes removal of all central lymphatics from carotid artery to carotid artery and hyoid to sternum/clavicle.
223819086|NCT01106443|PROCEDURE|Total thyroidectomy - CLND|Removal of all possible thyroid tissue without dissection of neck level 6.
223819087|NCT01106443|PROCEDURE|Hemi-thyroidectomy + CLND|Removal of one thyroid lobe and ipsilateral central lymph nodes
223819088|NCT01106443|PROCEDURE|Hemi-thyroidectomy - CLND|Removal of one thyroid lobe only. No lymphatic dissection.
223819089|NCT02262546|DRUG|Pramipexole extended-release (ER) tablets|
223819090|NCT02262546|DRUG|Pramipexole immediate-release (IR) tablets|
223819091|NCT02262546|DRUG|Moxifloxacin|
223819092|NCT02262546|DRUG|Pramipexole Placebo|
223819093|NCT02262546|DRUG|Moxifloxacin Placebo|
223819094|NCT00910403|PROCEDURE|LASIK|Excimer Laser Ablation using LASIK
223819095|NCT04741516|DRUG|Foquest|The drug being evaluated in this study is controlled release methylphenidate HCl control (Foquest®). Foquest® is a novel formulation of MPH developed by Purdue Pharma (Canada) and is approved in Canada for the treatment of ADHD in patients six years of age and older. Foquest® is the first methylphenidate product approved in Canada with an onset of action within one hour and a duration of action up to and including 16 hours (Wigal et al.2016). Foquest® is an ADHD treatment option for patients who require a rapid onset of action and extended duration of action
223819096|NCT00493077|DRUG|low immunogenic interferon-beta-1a|dosage and frequency as per Biogen Idec protocol
223819097|NCT00045435|PROCEDURE|nonmyeloablative allogeneic hematopoietic stem cell transplantation|Undergo nonmyeloablative allogeneic PBSC transplant
223819098|NCT00045435|DRUG|fludarabine phosphate|Given IV
223819099|NCT00045435|RADIATION|total-body irradiation|Undergo TBI
223819100|NCT00045435|DRUG|cyclosporine|Given PO
223819101|NCT00045435|DRUG|mycophenolate mofetil|Given PO
223819102|NCT00045435|PROCEDURE|peripheral blood stem cell transplantation|Undergo nonmyeloablative allogeneic PBSC transplant
223819103|NCT00921063|DRUG|PD 0332334|250 mg capsule, BID for 4 weeks
223819104|NCT00921063|DRUG|PD 0332334|100 mg capsule, BID for 4 weeks
223819105|NCT00921063|DRUG|placebo|0 mg capsule, BID for 4 weeks
223819106|NCT00921063|DRUG|Alprazolam extended release|1 mg capsule, BID for 4 weeks
223819107|NCT00674622|DRUG|Prolotherapy|Injection of 15% dextrose with lidocaine at the lateral epicondyle
223819108|NCT00674622|PROCEDURE|Placebo|Saline/lidocaine
223819109|NCT00738101|DRUG|Omegaven|Therapy with Omegaven will be provided at a dose of 1 gm/kg/day (by continuous infusion). Omegaven will be infused intravenously through either a central or peripheral catheter in conjunction with parenteral nutrition. Treatment will be given for as long as the child needs any TPN AND has a conjugated bilirubin greater than 2 mg/dL for a maximum of 5 years. If the infant no longer is requiring any TPN, then the Omegaven will be stopped regardless of bilirubin. If the bilirubin is less than 2 mg/dL but the child still requires TPN, then the Omegaven will be continued until the infant no longer requires TPN.
223819110|NCT03621202|DEVICE|Saranas Early Bird Bleed Monitoring System (EBBMS)|Participants will undergo their planned endovascular procedure with monitoring for internal bleeding using the Saranas EBBMS.
223819111|NCT02442843|DEVICE|Active tDCS|Participants will be randomized into active or sham stimulation in the first tDCS session. Participants will then have the option to complete 9 additional session of tDCS which will be active tDCS or a combination of active and sham tDCS in a non-randomized manner over two consecutive weeks. Each session will last 1 - 2 hours.
223819112|NCT02442843|DEVICE|Sham tDCS|Participants will be randomized into active or sham stimulation in the first tDCS session. Participants will then have the option to complete 9 additional session of tDCS which will be active tDCS or a combination of active and sham tDCS in a non-randomized manner over two consecutive weeks. Each session will last 1 - 2 hours.
223819113|NCT03680625|DEVICE|Passive Distraction|Patients in this group will be offered an iPad® showing a video while they will undergo their pins' removal and/or removal of sutures. There will be videos appropriate for each age group. The child can choose from the videos presented on the iPad® and start watching 5 minutes before the beginning of the procedure to assure similar preparation for both groups.
223819114|NCT03680625|DEVICE|Virtual Reality Distraction|Patients in this group will be offered virtual reality distraction through the use of Oculus Quest® while they undergo their pins' removal and/or removal of sutures. VR produces a high level of immersion, with high photorealism while maintaining the low latency necessary to induce presence and prevent cybersickness symptoms such as nausea, vomiting, headache. The videogame was developed by our team with three levels of difficulty, and approved by pediatric healthcare professionals. The game, oculus head-mounted device and computer will be available in the procedure room and ready for immediate use. The head-mounted device will be adjusted to the head of the child before any procedure and a period of 5 minutes will be allotted prior to pin and/or suture removal in order for the child to get acquainted with the game and immersed in the virtual environment.
223819115|NCT02484170|DRUG|Mannitol cream|Apply to area of postherpetic neuralgia pain as needed for pain control. Usual frequency is 2 to 3 times per day.For crossover study, will be applied for 7 days. For observational study, will be applied up to 3 months
223819116|NCT02484170|DRUG|Placebo|Apply to area of postherpetic neuralgia pain as needed for pain control.Usual frequency is unknown. For crossover study, will be applied for 7 days. Will not be used after crossover study
223819117|NCT00402194|DRUG|Losartan|Tablet, 100mg, once per day for 3 months
223819118|NCT01948635|DEVICE|tapered PVC-cuffed tracheal tubes|Patients will be intubated with tapered-shape tracheal tubes
223819119|NCT01948635|DEVICE|Standard PVC-cuffed tracheal tube|Patients will be intubated with standard PVC cuffed tracheal tubes
223819120|NCT03288896|BEHAVIORAL|Alerta Alcohol|The intervention consists of preventive messages about the benefits of not consuming alcohol, reducing the positive attitudes and encouraging the negative attitudes towards alcohol drinking and binge drinking, as well as social influence and self-efficacy, by personalized feedback. Skills and action plans are encouraged to help the student to reject binge drinking. This information is presented through different tailored messages. Moreover, four avatars (two males and two females), which can be chosen as part of the story development. This story consists of a short story about the alcohol consumption by adolescents.The stories take place in three different scenarios (at home, at celebrations and in public places).
223819121|NCT04997707|DRUG|Propofol Abbott|in a rate of 75-100 μg/kg/min in P group, and 25μg/kg/min in BA group
223819122|NCT04997707|DRUG|Sevoflurane Inhalation Solution|in BA group will be calculated by age-adjusted end - tidal MAC as follows: for age of 18-25 years, 26-40 years and ≥40 years MAC will be 2.6%, 2.2% and 1.8% respectively then final concentration to be delivered will be 0.2% lower than calculated half MAC.
223819123|NCT04997707|DIAGNOSTIC_TEST|transcranial motor evoked potential(Tcm|using NIM-SPINE™ SYSTEM (2005 Medtronic Sofamor Danek USA, Inc.). The stimulation used is a train-of-five square wave stimulation, 2ms inter-stimulus interval, 500 μs width and 40-220 mA intensity which can be increased with 10 mA steps till muscle answer potential is recorded.
223819124|NCT04895514|PROCEDURE|Gamma-irradiated corneal tissue inlay|A mid-stomal pocket will be made into the cornea with a femtosecond laser (Intralase). A small disc of gamma-irradiated preserved corneal tissue will then be placed into the pocket
223819125|NCT02519101|DEVICE|continuous noninvasive blood pressure monitoring ClearSight-Device|Noninvasive continuous blood pressure monitoring using the volume clamp method (ClearSight-Device)
223819126|NCT05839223|OTHER|Education|"educational process (recommendations) about isotretinoin by a clinical pharmacist.~The information included: the degree of the importance of adherence to the drug and the recommendations, the correct method of taking it, the importance of doing periodic laboratory tests (lipid profile, liver enzyme test, and pregnancy test), common side effects, how to properly avoid and deal with side effects, precaution warnings they should pay attention to, and what are the cases in which the drug should be stopped."
223819127|NCT04369001|BEHAVIORAL|Community-Based Exercise|Participants will complete 150 minutes of exercise per week for 12 weeks. Exercise per week will be documented using exercise logs. The exercise protocol will be a culturally-tailored community-based exercise intervention based on the aerobic exercise goals used in the Program ACTIVE study and psychoeducational materials adapted from Program ACTIVE based on feedback from Black men with T2D. Exercise in Program ACTIVE will be obtained through individualized community-based activities that participants in the focus groups indicate as feasible rather than the highly controlled laboratory environment. Exercise goals will be adapted to accommodate the physical and medical restrictions of an older-adult diabetes population.
223819128|NCT04369001|BEHAVIORAL|Cognitive Behavioral Therapy|Participants will receive 10 sessions of CBT using a manualized approach based on Beck's model of cognitive therapy. Sessions are to be completed once weekly in conjunction with weekly exercise. The Program ACTIVE CBT intervention includes: presentation of CBT model; thought records, cognitive distortions, counterarguments, cognitive reframing, automatic thoughts, core beliefs, and relapse prevention. Session goals will be tailored to the needs of men so that the order of topics may vary. Each session will begin with the designation of session goals, review of previously assigned homework, and introduction of new concepts and skills. Individually-tailored homework assignments designed to provide practice with the concepts/skills of the session will be assigned.
223819129|NCT01406522|DRUG|Oral tacrine|Tacrine, 160 mg per day, four times daily
223819130|NCT01406522|DRUG|Oral placebo|Microcrystalline cellulose
223819131|NCT01958840|BEHAVIORAL|Behavioral Activation for Depression Treatment|
223819132|NCT01958840|BEHAVIORAL|Supportive Counseling|
223819133|NCT04416698|BEHAVIORAL|Individual qualitative interview|Individual interviews will be conducted to understanding the needs and concerns of youth smokers of e-cigarette or other new tobacco products, including their risk perceptions, and the behaviour, attitudes, and experiences related to these tobacco products.
223819134|NCT04416698|BEHAVIORAL|cross-sectional survey study|structured questionnaire will be constructed for a cross-sectional survey to further explore the behaviour, attitudes, and experiences related to electronic cigarettes or other new tobacco products among youth.
223819135|NCT03520465|DEVICE|DynaMesh®-CICAT longitudinal measure 10x35 cm|
223819136|NCT04953364|BEHAVIORAL|SMART|SMART includes mental and physical wellness, residual/prosthetic limb managements, use of a prosthesis and weekly peer-support calls or video call over Zoom, hosted by University of British Columbia, depends on participant's preference, promoting motivation and establishing goal setting and action planning. The tablet will also allow asynchronous contact with trainers through a secure website.
223819137|NCT04953364|BEHAVIORAL|Control|The control group will receive a care booklet and weekly contacts for 6 weeks.
223819138|NCT01397994|DRUG|Nicorandil|Patients would be advised 10mg bd nicorandil for the first seven days. Drug will be titrated to 20 mg bd after one week, atenolol 50 mg will be given along with nicorandil from day 1
223819139|NCT01397994|DRUG|Atenolol|Patients in the control arm would be advised atenolol 50 mg od
223819140|NCT03448159|DRUG|Fluoxetine Hydrochloride|Half of the participants will take fluoxetine for a period of 15-17 weeks (depending on ramp-up period).
223819141|NCT03448159|OTHER|Placebo|Half of the participants will take the a placebo for a period of 15-17 weeks (depending on ramp-up period).
223819142|NCT03448159|BEHAVIORAL|Exercise Program|All participants will take part in a 12-week exercise program. The program will run 3 times/week, 1 hour/class.
223819143|NCT05119075|OTHER|Dopaminergic OFF-drug state|Dopaminergic OFF-drug state: Overnight withdrawal of dopaminergic antiparkinsonian drugs during visit 3 or 4. The sequence of drug conditions (dopaminergic OFF-drug/ON-drug state or ON-drug/OFF-drug state) will be randomized.
223819144|NCT05119075|OTHER|Dopaminergic ON-drug state|Dopaminergic ON-drug state: Patient will be evaluated in his/her regular treatment in dopaminergic ON-drug state at visit 3 or 4. The sequence of drug conditions (dopaminergic OFF-drug/ON-drug state or ON-drug/OFF-drug state) will be randomized.
223819145|NCT03311932|DRUG|Infacort®|Immediate release multiparticulate formulation (granules) of hydrocortisone
223819146|NCT03311932|DRUG|Cortef®|Immediate release hydrocortisone tablets
223819147|NCT00203060|DRUG|Rasagiline Mesylate|tablet, 1 or 2 mg, daily, 58 weeks
223819148|NCT00203060|DRUG|placebo|tablet, once daily, 58 weeks
223819149|NCT01928134|DIETARY_SUPPLEMENT|Vit K2+ Vit D3+ calcium carbonate (CaCO3)|
223819150|NCT01928134|DIETARY_SUPPLEMENT|Vit K2+CaCO3|
223819151|NCT02168764|DEVICE|ATI Neurostimulation System|All subjects will be implanted with the ATI Neurostimulator which, along with the ATI Remote Controller, provides electrical stimulation.
223819152|NCT00051168|DRUG|Travatan|Travoprost (0.004%) 1 drop each eye once daily
223819153|NCT04236258|DRUG|NIFEdipine ER|Postpartum women with high blood pressure will be randomized to receive nifedipine extended release 30mg daily as their starting antihypertensive.
223819154|NCT04236258|DRUG|Enalapril|Postpartum women with high blood pressure will be randomized to receive enalapril 10 mg daily as their starting antihypertensive.
223819155|NCT00709059|BIOLOGICAL|PegIntron (peginterferon alfa-2b; SCH 54031)|PegIntron 1.5 ug/kg body weight per week subcutaneously for 48 weeks
223819156|NCT00709059|DRUG|Rebetol (ribavirin; SCH 18908)|Rebetol administered based on body weight 800-1200 mg/day (\<65 kg: 800 mg; 65 - 85 kg: 1000 mg; \>85 kg: 1200 mg) orally for 48 weeks
223819157|NCT06053034|DEVICE|Solio alpha cure plus|The SOLIO Alfa Cure Plus is the only home-use device with FDA clearance that uses the proprietary synergy of three energy sources (IR, RF, and LLLT), and this study aims to assess the SOLIO Alfa Cure Plus's efficiency in providing pain relief. This technology is the first noninvasive and patented home RF device. SOLIO Alfa Cure Plus uses continuous RF, the internal controller reduces the RF power while reaching the treatment temperature of 39- 42 Celsius.The SOLIO Alfa Cure Plus Device is a round device equipped with a strap for hand holding, it is to be used while connected to a socket. The device is used by an assistant (usually a family member) on the participant's back for 20 minutes while moving it around in circles on the lower back.
223819158|NCT00003640|BIOLOGICAL|filgrastim|
223819159|NCT00003640|DRUG|cisplatin|
223819160|NCT00003640|DRUG|doxorubicin hydrochloride|
223819161|NCT00003640|DRUG|methotrexate|
223819162|NCT00003640|DRUG|vinblastine sulfate|
223819163|NCT00003640|PROCEDURE|surgical procedure|
223819164|NCT00003640|RADIATION|radiation therapy|
223819165|NCT05048849|BIOLOGICAL|MVC-COV1901(S protein with adjuvant)|Approximately 500 participants will receive 2 doses of MVC-COV1901(S-2P protein with adjuvant) at Day 1 and Day 29 via intramuscular (IM) injection in the deltoid region
223819166|NCT05823246|DRUG|QLF31907|Intravenous infusion once every two weeks. The dose administered in part 2 will depend on the outcome of part 1.
223819167|NCT04531566|DIETARY_SUPPLEMENT|Oral Feed|Infant will be seen by occupational therapist (OT) twice a week and assessed for oral cues. If infant shows oral cues then the occupational therapist will proceed with feeding strategies. Oral feeding strategies include pacifier dips, open nipple trials with syringe controlled bolus size (1-4mls) and po trials up to 10mls.
223819168|NCT04531566|DIETARY_SUPPLEMENT|Usual care|Infants will not start oral feeds until on HFNC 2 Litres or less. Oral feeds will be started on the discretion of the physician.
223819169|NCT02355613|RADIATION|Radiosurgery with Gamma Knife Perfexion|Gamma Knife Radiosurgery is a very precise form of therapeutic radiology. Even though it is called surgery, a Gamma Knife procedure does not involve actual surgery but it uses 192 isocentric beams of highly-focused gamma rays (60-Co) to treat small to medium size lesions. Minimum beam size is 4 mm. This procedure is frame based.
223819170|NCT02355613|RADIATION|Linac-based Radiosurgery with EDGE|EDGE linear accelerator from Varian (Varian, Palo Alto, USA) is a C-arm machine specifically developed for radiosurgery frameless treatment. The characteristics of this linac are a high level of precision and the possibility to include multiple positioning systems for stereotactical treatments, among which Cone Beam CT (CBCT), the Optical Surface Monitoring System (OSMS), and Calypso.
223819171|NCT05556317|BEHAVIORAL|Resistive exercise|advices and resistive exercise
223819172|NCT01710163|DRUG|Lithium|Starting at 300 mg daily, weekly dose will be adjusted according to blood serum level (between 0.5 -0.8mEq/l) according to efficacy and tolerability.
223819173|NCT01710163|DRUG|Aripiprazole|Starting at 10 mg daily, dose will be adjusted up to 15 mg daily according to efficacy and tolerability.
223819174|NCT00846443|OTHER|Concurrent Pemetrexed, Cisplatin and Radiotherapy|pemetrexed:400 mg/m2, IV, day 1 and day 22; cisplatin: 25 mg/m2, IV, days 1-3 and 22-24; radiotherapy:66 Gy in 33 fractions
223819175|NCT00846443|OTHER|Concurrent Pemetrexed, Cisplatin and Radiotherapy|pemetrexed:500 mg/m2, IV, day 1 and day 22; cisplatin: 25 mg/m2, IV, days 1-3 and 22-24; radiotherapy:66 Gy in 33 fractions
223819176|NCT00846443|OTHER|Concurrent Pemetrexed, Cisplatin and Radiotherapy|pemetrexed:500 mg/m2, IV, day 1 and day 22; cisplatin: 25 mg/m2, IV, days 1-3 and 22-24; radiotherapy:70 Gy in 35 fractions
223819177|NCT00846443|OTHER|Concurrent Pemetrexed, Cisplatin and Radiotherapy|pemetrexed:500 mg/m2, IV, day 1 and day 22; cisplatin: 25 mg/m2, IV, days 1-3 and 22-24; radiotherapy:74 Gy in 37 fractions
223819178|NCT06053554|PROCEDURE|Phakoemulsification|Femtolaser is used to perform a standard 5.0mm CCC centred on the pupil or limbus and to fragment the lens nucleus toguarantee reproducible results in every eye.After the CCC and nucleus fragmentation the anterior segment is filled with viscoelastics, the rhexis lenticule is removed and hydrodisection of the nucleus is performed. Subsequently phacoemulsification for nucleus and irrigation/aspiration of the lens cortex is performed. The capsular bag and AC is then filled with a cohesive viscoelastic and the IOL is implanted with the haptics in the back or with the haptics in the sulcus. At the end of surgery, the viscoelastic is removed using the irrigation aspiration probe, intracameral antibiotic is instilled, the CCI and paracenteses are hydrated and sealed.
223819179|NCT06053554|DEVICE|Ziemer Z8 Femtolaser|The femto second laser used for certain steps (capsulorhexis, nucleus fragmentation) of the cataract surgery.
223819180|NCT06053554|DEVICE|Kowa Avansee Preset|The used 3 piece intra ocular lens
223819181|NCT01786330|DEVICE|Procare abdominal binder|
223819182|NCT01786330|OTHER|Standard of Care|
223819183|NCT01154569|DRUG|Azithromycin|500 mg single dose
223819184|NCT05664932|BIOLOGICAL|Recombinant SARS-CoV-2 Vaccine (CHO Cell) LYB001|Intramuscular injection of Recombinant SARS-CoV-2 Vaccine (CHO Cell) LYB001 in the deltoid muscle of the upper arm at day 0. The inoculation dose is 0.5 mL.
223819185|NCT05664932|BIOLOGICAL|ZF2001|Intramuscular injection of ZF2001 in the deltoid muscle of the upper arm at day 0. The inoculation dose is 0.5 mL.
223819186|NCT04553263|DRUG|Contrave 8Mg-90Mg Extended-Release Tablet|Naltrexone HCl/Bupropion HCl is an FDA-approved weight-loss medication with efficacy via the mesolimbic dopamine system to reduce hunger and help control cravings.
223819187|NCT04553263|DRUG|Bupropion|Bupropion is FDA-approved and marketed both as an antidepressant agent (Wellbutrin®) and treatment for smoking cessation (Zyban®) and has shown efficacy in reducing symptoms of depression and drug craving in stimulant users. it is also a promising candidate to improve cognition function.
223819188|NCT00270361|DRUG|nesiritide|
223819189|NCT00270361|DRUG|usual long term cardiac medications|
223819190|NCT00270361|DRUG|nesiritide|
223819191|NCT00020553|PROCEDURE|psychosocial assessment and care|
223819192|NCT00855010|DRUG|pioglitazone|pioglitazone 45 mg daily
223819193|NCT00855010|DRUG|placebo|one daily
223819194|NCT01933022|DRUG|Eligard|Subcutaneous Injection
223819195|NCT00671203|PROCEDURE|Reestablish colon blood flow|If ischemia is detected, and the detection in consistent with the physician's clinical view, blood flow to the colon is established using any of the known techniques that would be used had the diagnosis been made in the absence of T-Stat, which include changes in the deployment of stents and/or coils, reanastomosis, reimplantation, or stenting, of obstructed vessels, or other established techniques.
223819196|NCT05382754|DIAGNOSTIC_TEST|Home sleep apnea test|Level II home sleep apnea testing evaluates for obstructive sleep apnea in the home environment with parental supervision.
223819197|NCT05382754|DIAGNOSTIC_TEST|In-lab polysomnography|Overnight sleep study in the sleep laboratory with continuous monitoring by clinical staff.
223819198|NCT06487598|DRUG|inj insulin to one group|One group- only inj insulin for 3 months.
223819199|NCT06487598|DRUG|Inj Insulin with Tab Nisha-Amalaki 500 mg twice a day|second group- Inj Insulin with Tab Nisha-Dhatri 500 mg twice a day
223819200|NCT03584620|OTHER|Inspiratory muscle training|Inspiratory Muscle Training was performed with an exercise tool (Powerbreath®) with a resistance range of 0-90. The training intensity was started with 30% of the Maximum Inspiratory Pressure (MIP) value obtained as a result of the mouth pressure measurement, training was progressively increased from 30% to 60% considering that they were terminal-stage pulmonary disease patients. Patients were asked to perform IMT for 15 minutes, twice a day, 7 days a week, for 3 months.
223819201|NCT03584620|OTHER|Pulmonary rehabilitation|"Aerobic training:The aerobic exercise program consists of treadmill walking, cycle ergometer and arm ergometer training. Group exercises were performed in sets of 15 minutes each with three exercise modalities.~Strength training:It is recommended that resistance targets are set at loads equivalent to 20 to 40% of a 1-repetition maximum (1RM) maneuver and performed between 8 to 12 repetitions for 1 to 2 sets per session.~Home exercise programme:The program included breathing exercises (local expansion exercises, diaphragmatic breathing and pursed lip breathing), free walking, upper and lower extremity strengthening exercises with Thera-Band"
223819202|NCT06113848|DRUG|Intra-Arterial TNK and Albumin|The study population was divided into four groups, one of which had intra-arterial TNK and albumin.
223819203|NCT06113848|DRUG|Intra-Arterial TNK|The study population was divided into four groups, one of which had intra-arterial TNK .
223819204|NCT06113848|DRUG|Intra-Arterial Albumin|The study population was divided into four groups, one of which had intra-arterial albumin.
223819205|NCT06113848|OTHER|sham|The study population was divided into four groups, one of which had no intra-arterial TNK and albumin.
223819206|NCT06016530|BEHAVIORAL|Sleep Deprivation|During a sleep deprivation period lasting over 36 hours, individual fluctuations of various metabolites will be measured throughout the day (12 hours) for each participant while adhering to a standardized diet. To achieve this, blood samples will be collected and processed into plasma or peripheral blood mononuclear cells (PBMCs).
223819207|NCT06016530|DRUG|Dexamethasone Supplementation|"Dexamethasone belongs to the drug class of corticosteroids. It is a synthetic glucocorticoid that activates glucocorticoid receptor (GR) and the hypothalamic-pituitary-adrenal (HPA) axis selectively.~Following the administration of 1 mg of dexamethasone as a pharmacological stressor, individual fluctuations of various metabolites will be measured throughout the day (12 hours) for each participant under a standardized diet. To facilitate this, blood samples will be collected and processed into plasma or peripheral blood mononuclear cells (PBMCs)."
223819208|NCT02007005|DRUG|abnobaVISCUM Fraxini|intravesical instillation 6 times, once weekly, in increasing dosages until dose-limiting-toxicity occurs
223819209|NCT00356954|DRUG|N-acetylcystein|
223819210|NCT00356954|DRUG|ascorbic acid|
223819211|NCT00411593|DRUG|Bevacizumab|15 g/kg by vein every 3 weeks on day 1 of each cycle.
223819212|NCT00411593|DRUG|Bortezomib|"Phase I Starting dose: 1.6 mg/m2 by vein on days 1, 8 of each 3 week cycle.~Phase II: MTD from Phase I."
223819213|NCT01620567|OTHER|avocado|1 avocado/day for 6 months
223819214|NCT01620567|OTHER|potato or chickpea|1 cup potatoes or chickpeas/day for 6 months
223819215|NCT00256503|BEHAVIORAL|Cognitive-Behavioral Therapy for Insomnia|Insomnia Subjects receive CBT-I
223819216|NCT02969525|OTHER|Placebo|
223819217|NCT02969525|DRUG|Bimekizumab|Bimekizumab in different dosage regimens.
223819218|NCT05924399|BEHAVIORAL|Affect Labeling Training|(1) Participants will view combat-relevant images and then label the image or how they feel while viewing the image. (2) Participants will view facial expressions and then label the image. (3) Participants will view negative combat- irrelevant images (such as snakes or spiders) and then label the image or how they feel while viewing the image. (4) Participants will complete Go-NoGo trials similar to the fMRI Go-NoGo task described above. Participants will receive all four types of inhibitory training.
223819219|NCT03977558|BEHAVIORAL|Intervention group|Isocaloric diet including \~50g canola oil
223819220|NCT03977558|BEHAVIORAL|Control group|ESC/EAS Guidelines for the management of dyslipidemias
223819221|NCT00241527|DRUG|Esomeprazole|
223819222|NCT03340948|BEHAVIORAL|Mindfulness Based Stress Reduction (MBSR)|An 8-week course in mindfulness meditation, yoga training and weekly group support in the form of weekly 2,5 hour meetings at the hospital.
223819223|NCT01568346|OTHER|MRI|Breast MRI
223819224|NCT03445065|DEVICE|Eversense XL CGM System|The Eversense XL Continuous Glucose Monitoring (CGM) System consists of an implantable sensor inserted under the skin, an external transmitter, and a Mobile Medical Application (MMA) for display of glucose information that runs on a Handheld Device (HHD).
223819225|NCT03445065|DEVICE|Usual SMBG or FGM device used by participants|Commercially available products in France for self-monitoring of blood glucose (SMBG) or flash glucose monitoring (FGM) were considered as comparators for this study.
223819226|NCT05962983|BEHAVIORAL|Small Steps for Big Changes Program|Participants will be asked to attend six one on one sessions providing diet and exercise counselling each lasting 20-30 minutes over the course of six weeks. The nutrition counselling will introduce participants to a healthy dietary changes for reducing added sugar intake and refined/processed carbohydrate intake as well as increasing vegetable consumption. After counselling sessions, participants will complete their chosen form of aerobic exercise: 1) traditional continuous exercise that involves exercising at a constant pace for 20-30 minutes (moderate-intensity continuous training, MICT); or 2) interval exercise that involves alternating between 30 seconds and 1-minute of brisk exercise and 1-minute of easy exercise for \~15 min (high-intensity interval training, HIIT). Both exercise forms could be completed on treadmill, elliptical or stationary bike. In total, each session will last approximately one hour.
223819227|NCT02172625|DIETARY_SUPPLEMENT|Protandim Dietary Supplement|This was a randomized, block design, controlling for 5-km performance and sex. Subjects were given 675 mg per day (1 pill per day) of Protandim for 90 days. Subjects ran a 5-km time trial before and after the supplementation period. Blood samples were taken pre and post supplementation.
223819228|NCT02172625|OTHER|Placebo Group|This was a randomized, block design, controlling for 5-km performance and sex. Subjects were given 675 mg per day (1 pill per day) of corn starch for 90 days. Subjects ran a 5-km time trial before and after the supplementation period. Blood samples were taken pre and post supplementation.
223819229|NCT00524030|DRUG|pregabalin 600 mg/day|pregabalin 600 mg/day (300mg BID), duration is 20 weeks.
223819230|NCT00524030|DRUG|pregabalin 150 mg/day|pregabalin 150 mg/day (75mg BID), duration is 20 weeks.
223819231|NCT03079310|DEVICE|Spinal cord stimulation|Range of pulse widths (200-500 microseconds) and frequencies (30-130 Hz) will be assessed for each patient
223819232|NCT01218945|PROCEDURE|Cell Culture|Aim of this study is to isolate and cultivate fat-derived progenitor cells and differentiation into osteoblasts. Therefore, our research idea is to pre-engineer large synthetic bone grafts and study the vascularization process in vivo.
223819233|NCT03315130|DRUG|zilucoplan (RA101495)|Daily subcutaneous (SC) injection
223819234|NCT03315130|DRUG|Placebo|Daily subcutaneous (SC) injection
223819235|NCT02707692|BIOLOGICAL|Fluarix|Intramuscular injection with Fluarix® .
223819236|NCT02707692|BIOLOGICAL|Pneumovax|Intramuscular injection with Pneumovax.
223819237|NCT02707692|OTHER|Placebo|Intramuscular injection with sterile saline (placebo).
223819238|NCT00295438|DEVICE|Robot-Based Tele-Echography (TER)|Robot-Based Tele-Echography, ultrasound performed by the radiologist
223819239|NCT00295438|DEVICE|ultrasound method FAST|FAST,ultrasound performed by the emergency doctor
223819240|NCT02914132|DEVICE|Seraph 100 Filter|Treatment of renal replacement therapy patients with bacteremia.
223819241|NCT00849004|OTHER|silicone gel|silicone gel
223819242|NCT00849004|OTHER|silicone sheet|silicone sheet
223819243|NCT00849004|OTHER|paper tape|paper tape
223819244|NCT01583244|DRUG|No Intervention (subjects were previously treated with Orencia®)|No Intervention
223819245|NCT06565104|BEHAVIORAL|Multidimensional Sleep Health Sessions|The two sleep health educational sessions will include didactic content on defining sleep health, reviewing sleep recommendations, outlining the role of sleep in preserving cardiometabolic health, and correcting unhelpful sleep-related beliefs and debunking myths. Participants will learn to maximize the benefits of self-monitoring using a Fitbit and will receive a sleep mask, ear plugs, a blue light blocker, and an indoor air purifier to improve their sleep environment.
223819246|NCT06565104|BEHAVIORAL|Healthy Diet Sessions|The two diet sessions include an overview of nutrition basics, examples of healthy dietary patterns and cooking methods to increase consumption of plant-based foods such as fruits, vegetables, and whole grains, promote choosing more lean proteins such as fish, and reduce intakes of red and processed meats, sugary foods, and sugar-sweetened beverages.
223819247|NCT06565104|BEHAVIORAL|Physical Activity Sessions|The two physical activity sessions provide an overview of the physical activity guidelines and include 30-60 minutes of exercise and a healthy living community resource mapping exercise. These sessions also address achieving and maintaining a healthy body weight.
223819248|NCT04839198|BEHAVIORAL|Android Wear smartwatch|All participants will wear an Android Wear smartwatch, and will complete ecological momentary assessments (EMA).
223819249|NCT04839198|BEHAVIORAL|Adaptive Treatment|"Participants will have access to a Dashboard button in the InsightTM app that displays personalized statistics based on their progress and patterns in the study.The dashboard will update as more data is collected about the participant's smoking habits, starting in the pre-quit period and continuing through the post-quit period. Second, in the post-quit period, participants will receive treatment messages when the machine learning algorithm determines that they are at high risk for lapse.At the follow-up visit, participants will complete a survey to evaluate what they liked and disliked about the intervention, how accurate they thought the app was in predicting their risk, and how useful they found the dashboard."
223819250|NCT04839198|DRUG|Nicotine Patch|At Visit 2, participants will be asked to begin their attempt to quit smoking and will receive a 12-week supply of nicotine replacement therapy (i.e., nicotine patches and gum)
223819251|NCT04839198|BEHAVIORAL|interviewing-based counseling|At Visit 2, participants will be asked to begin their attempt to quit smoking and meet with a Tobacco Treatment Specialist, who will provide motivational interviewing-based counseling, help the participants develop a quit plan, and discuss relapse prevention. During the 6-weeks of the study, participants will have the option of attending up to 6 counseling sessions with the Tobacco Treatment Specialist, either in-person or via phone or web.
223819252|NCT05128149|OTHER|no intervention|no intervention
223819253|NCT05055856|DIAGNOSTIC_TEST|urine sample|Each participant will give a urine sample for diagnose of asymptomatic bacteriuria
223819254|NCT05055856|DIAGNOSTIC_TEST|Blood and urine sample|Each participant will give a urine and blood sample for diagnose of SIADH
223819255|NCT05806749|COMBINATION_PRODUCT|Donor CD34+, CD3+. and belumosudil|"Immediately after living donor kidney transplantation, subjects will begin a conditioning regimen of rATG and total lymphoid irradiation. An infusion of at least 8 X106 donor CD34 cells/kg recipient weight and of at least 10 X106 donor CD3 cells/kg recipient weight will then be given. A triple immunosuppressive regimen of tacrolimus, corticosteroids, and mycophenolate will be utilized.~Corticosteroids will be given on a tapering schedule from day 0 through the first four months. Tacrolimus will be given on a tapering schedule from day 1 through month 18. Mycophenolate will be given at a fixed dose from day 11 through month 12.~Subjects will receive belumosudil 200 mg by mouth daily from day 28 following the kidney transplant through month 24."
223819256|NCT00036998|PROCEDURE|conventional surgery|
223819257|NCT00036998|PROCEDURE|neoadjuvant therapy|
223819258|NCT00036998|PROCEDURE|thermal ablation therapy|
223819259|NCT06979414|BEHAVIORAL|Nurse-led Transfer Programme with Family Involvement|This behavioral intervention was structured in three phases: (1) Pre-transfer preparation, where the patient's primary caregiver visited the ICU for emotional support following verbal instruction and infection control measures; (2) Accompanied transfer to the general ward, led by an ICU nurse, with the caregiver present to provide emotional reassurance; (3) Post-transfer monitoring, where the patient's vital signs and anxiety levels were reassessed within 30-60 minutes of arrival. The goal of the intervention was to reduce ICU transfer-related anxiety through nurse-led, family-involved emotional support.
223819260|NCT05323461|BIOLOGICAL|SCTV01C|intramuscular injection
223819261|NCT05323461|BIOLOGICAL|SCTV01E|intramuscular injection
223819262|NCT05323461|BIOLOGICAL|Sinopharm inactivated COVID-19 vaccine|intramuscular injection
223819263|NCT05323461|BIOLOGICAL|Comirnaty|intramuscular injection
223819264|NCT05448300|DEVICE|Colonoscopy with water exchange or air insufflation methods|Using computer-aided polyp detection algorithm on colonoscopy with water exchange or air insufflation methods. This computer-aided algorithm does not intervene directly the colonoscopy procedure.
223819265|NCT00649558|DRUG|Pioglitazone HCl Tablets 45 mg|45mg, single dose fasting
223819266|NCT00649558|DRUG|Actos® Tablets 45 mg|45mg, single dose fasting
223819267|NCT04868760|DRUG|Ipilimumab|Drug: Ipilimumab 0.1 mg/kg and 0.3 mg/kg in preparatory experiments and 0.3 mg/kg in formal experiment.
223819268|NCT04868760|DRUG|IBI310|Drug: IBI310 0.1 mg/kg and 0.3 mg/kg in preparatory experiments and 0.3 mg/kg in formal experiment.
223819269|NCT04394364|DEVICE|Bispectral index|The BIS monitor will be attached to patients' forehead before anesthetized and kept until the end of the surgery
223819270|NCT05129267|OTHER|Group B|Scaling and Root debridement + iPRF
223819271|NCT05129267|OTHER|Group C|Scaling and Root debridement + iPRF together with vitamin C
223819272|NCT04537468|OTHER|Skin squame collection|Subjects underwent skin squame collection by scraping. The investigator gently scraped the surface of a lesional skin area for patients with psoriasis, and of a non-lesional skin area for healthy volunteers to collect superficial cells. These samples were analyzed by gene expression analyses.
223819273|NCT04537468|OTHER|Tape strip collection|The first subjects had up to 35 tape strips from a maximum of 4 areas (4 X 35 strippings) on the trunk or limbs (excluding the genital area). Patients with atopic dermatitis or psoriasis had tape stripping performed on lesional skin areas and the control subjects had tape stripping performed on nonlesional skin areas. The next subjects were used to determine the optimal number of tape strips required to obtain a good signal by gene expression analyses.
223819274|NCT04537468|OTHER|Tape strip and skin biopsy collection|Subjects had tape stripping on up to 3 different skin areas (2 areas on lesional skin and one area of nonlesional skin for patients with atopic dermatitis or psoriasis, and 2 areas of healthy skin for control subjects) using the optimal number of tape strips, as determined in the previous part. One 4-mm skin biopsy on a tape stripped area plus one 4-mm biopsy on non-tape-stripped skin (2 biopsies per subject) were also collected.
223819275|NCT05944055|BIOLOGICAL|Is 25 OH vitamin D overdose a risk factor of bronchopulmonary dysplasia or death ?|Vitamin D overdose is frequent among preterm infants receiving the current supplementation (Mauras 2022, Kołodziejczyk-Nowotarska 2021). In our NICU, the protocol was to daily administrate 55 UI vitamin D during parenteral nutrition then 1000 UI during enteral nutrition for babies weighing more than 1000 g and 1200UI during enteral nutrition for babies weighing less than 1000 g. The dosage was adapted each month after a plasmatic measure of 25OH-D in order to maintain 25OH-D between 50 nmol/L and 120 nmol/L.
223819276|NCT00385892|DEVICE|Abdominal binder|
223819277|NCT03540914|DRUG|ACETAZOLAMIDE oral capsule|Administration of 1x125mg acetazolamide in the morning, 2x125mg in the evening, starting 24 hours before departure to 3'100m
223819278|NCT03540914|DRUG|Placebo oral capsule|Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3'100m
223819279|NCT00118898|DRUG|Abacavir/Lamivudine|600 mg abacavir/300 mg lamivudine tablet taken orally daily
223819280|NCT00118898|DRUG|Atazanavir|300 mg tablet taken orally daily
223819281|NCT00118898|DRUG|Efavirenz|600 mg tablet taken orally daily
223819282|NCT00118898|DRUG|Emtricitabine/Tenofovir disoproxil fumarate|200 mg emtricitabine/300 mg tenofovir disoproxil fumarate tablet taken orally daily
223819283|NCT00118898|DRUG|Ritonavir|100 mg tablet taken orally daily
223819284|NCT00118898|DRUG|Abacavir/Lamivudine placebo|Placebo tablet taken orally daily
223819285|NCT00118898|DRUG|Emtricitabine/Tenofovir disoproxil fumarate placebo|Placebo tablet taken orally daily
223819286|NCT03387202|PROCEDURE|Laparoscopic lateral suspension with mesh|V-shaped ccm wide and 25cm length mesh strip is prepared from a 30x30cm Prolene mesh (Ethicon J\&J).Deep dissection of the uterovesical space is performed.Cutaneous incisions are bilaterally made 3cmsuperoposterior to the anteriosuperior iliac spine.A grasper is introduced retroperitoneally through the subperitoneum holding the beginning part of mesh until reaching the vesicovaginal space in an oblique route rather than transverse.Broad ligament is lifted upward and tunnel is practiced in its lower third.Assistant grasper catches the distal mesh and pulls out through the opposite subperitoneal tunnel.Corner of mesh is fixed to the pubocervical fascia,uterine cervix and isthmus with Absorba Tack™(Covidien, Mansfield,USA).Tension-free lateral mesh suspension is achieved at the desired level
223819287|NCT03387202|DIAGNOSTIC_TEST|Transperineal ultrasound|Vaginal length, bladder neck mobility and pelvic floor biometry with anterioposterior hiatal diameter and pelvic organ descent measurements are measured by transperineal ultrasonography to assess anatomic success in the preoperative and at postoperative first third and sixth months if available.
223819288|NCT04131569|DIAGNOSTIC_TEST|ESBL-E fecal carriage screening according to routine care|ESBL-E fecal carriage screening according to routine care
223819289|NCT03664505|DEVICE|Compression garment (manual)|Garment based on manual measurement
223819290|NCT03664505|DEVICE|Compression garment (scan)|Garment based on scan measurement
223819291|NCT06711744|DIAGNOSTIC_TEST|Implant stability quotient|Screw a smart peg into the implant and record the values from a dedicated device
223819292|NCT06613529|OTHER|online mindfulness training|"Use publicly available online mindfulness training resources. The training content was to guide patients to practice mindfulness techniques, including where the body is, the mind is and relaxation learning."
223819293|NCT06619691|OTHER|Fine motor skills|Only intervention
223819294|NCT06626113|DRUG|ascorbic acid|ascorbic acid
223819295|NCT06624748|BEHAVIORAL|emotional and physical support to the pregnant woman provided by attendant|The companion will provide emotional and physical support to the pregnant woman (such as massage, supporting the pregnant woman while moving, taking a warm shower, etc.), and all interventions made by the companion and their duration will be recorded by the researcher in the 'Birth Process Support Form'. When the cervical dilatation is 8 cm, the Birth Comfort Scale will be applied to the pregnant woman, and two hours after the birth, the Birth Satisfaction Scale and the Postpartum Comfort Scale will be applied. Information about the birth process will be recorded in the Birth Information Form. In addition, semi-structured questions in the 'Companion Interview Form' will be asked to the companions selected for qualitative interviews and voice recording will be recorded.
223819296|NCT06624553|DEVICE|FreeStyle Libre 2, flash glucose monitoring|"Currently, at the Hospital de la Santa Creu i Sant Pau, when starting monitoring in people with DM2, capillary glycemia monitoring is used, following the therapeutic education protocols in basal insulinization in the debut of DM2 and in optimization of treatment, protocols that are also applied to similar cases.~The intervention group (FreeStyle Libre 2) will be provided with the necessary material to carry out the monitoring via a glucose sensor. Satisfaction with treatment will be assessed at the final study visit."
223819297|NCT05871710|OTHER|Turkish version of the Tele-Pulmonary Rehabilitation Acceptance Scale|The Tele-Pulmonary Rehabilitation Acceptance Scale is a measuring tool that assesses the level of acceptance towards telerehabilitation programs among healthcare providers and patients in the field of pulmonary rehabilitation. It is used to evaluate the attitudes, beliefs, and perceptions of potential users towards telerehabilitation, which is a form of healthcare delivery that utilizes telecommunication technology to provide remote rehabilitation services to patients. The scale is intended to provide a standardized data collection tool that can be used to measure the level of acceptance of telerehabilitation programs among different groups of potential users. This scale will be translated into Turkish by a researcher who has an advanced level of knowledge in English and whose native language is Turkish.
223819298|NCT05871710|OTHER|Scale Evaluation Form|The healthcare providers and the patients will be asked about their opinions on the scale's construction, usefulness, and scope using a 100 mm visual analog scale.
223819299|NCT05304598|DRUG|Dexmedetomidine|a single intravenous (i.v.) dose of dexmedetomidine, 0.2 mcg/kg over 10 minutes
223819300|NCT05304598|OTHER|Usual Care|routine awake intubation as per current unit standard of care,
223819301|NCT06626152|DRUG|Apo-levocarb|As above.
223819302|NCT00091247|DRUG|tetracycline hydrochloride|
223819303|NCT00091247|OTHER|placebo|
223819304|NCT06687265|DRUG|Metformin|one pill of 500 mg per os twice a day for 28 days.
223819305|NCT06687265|DRUG|Placebo|one pill per os twice a day for 28 days.
223819306|NCT04959890|GENETIC|Strimvelis|This non-interventional, retrospective, methodology study will use peripheral blood and bone marrow samples previously taken from subjects treated with gRV-GT. The study does not require subjects to undergo any further treatment, intervention or blood withdrawal. Eligible samples will be shipped to a central laboratory and will undergo DNA extraction prior to S-EPTS/LM-PCR analysis. Each analysis run will include a control DNA sample and up to four subject samples. Each sample will be analysed in triplicate.
223819307|NCT05273255|BIOLOGICAL|Fecal Microbiota Transplantation (FMT)|Single-dose of fecal microbiota from FMT-Donor transplanted endoscopically to FMT-Recipient in between two cycles of CI.
223819308|NCT06634069|DRUG|Sodium Lactate|0.5M HSL (containing 504mM of sodium and lactate)
223819309|NCT06634069|DRUG|3% NaCl|active compartor 3% NaCl
223819310|NCT04454398|BIOLOGICAL|COVI-GUARD|COVI-GUARD (STI-1499) is a monoclonal antibody which targets the COVID-19 spike protein
223819311|NCT04454398|OTHER|Standard of Care|Standard of Care as determined by the Investigator
223819312|NCT04454398|DRUG|Placebo|Diluent
223819313|NCT00459238|OTHER|counseling intervention|subjects will receive telephone based counseling
223819314|NCT00459238|OTHER|educational intervention|subjects will received telephone based education
223819315|NCT06900868|OTHER|Assigned Interventions|SDR Smart dentine replacement material nonbioactive
223819316|NCT06899893|DEVICE|iTBS|Sixty patients experiencing post-stroke negative emotions were recruited and categorized into groups based on their conditions. The group with post-stroke balance dysfunction underwent intermittent theta burst stimulation (iTBS) of the cerebellum, while the group with post-stroke cognitive dysfunction received iTBS stimulation of the left dorsolateral prefrontal cortex (DLPFC), and the group with post-stroke motor dysfunction underwent iTBS stimulation of the primary motor cortex (M1).The TMS stimulation protocol consisted of 20-minute sessions, five times a week, for a total of ten sessions, utilizing a figure-of-eight coil (model B9076, coil diameter 92 mm, manufactured by Yiruide Company in Wuhan, China, transcranial magnetic therapy device model NS5000). The stimulation intensity was set at 80% of the active motor threshold, with the coil positioned tangentially to the scalp and the handle oriented upwards.
223819317|NCT06899477|DRUG|mFOLFOXIRI|Up to 6 cycles, every 2 weeks, mFOLFOXIRI: Oxaliplatin 85 mg/m2 2 h day 1, Irinotecan 150 mg/m2 60-90 min day 1, Folinic acid 400 mg/m2 \~1 h day 1, followed by 5-FU 2400 mg/m2 46 h
223819318|NCT06899477|DRUG|mFOLFOX-6|Up to 6 cycles, every 2 weeks, mFOLFOX-6: Oxaliplatin 85 mg/m2 2 h day 1, Folinic acid 400 mg/m2 \~1 h day 1, (optional: 5-FU 400 mg/m2 bolus), followed by 5-FU 2400 mg/m2 46 h.
223819319|NCT06899477|DRUG|CAPOX|Up to 4 cycles, every 3 weeks, CAPOX: Oxaliplatin 130 mg/m2 3 h day 1, Capecitabine 1000 mg/m2 ORALLY taken twice daily d1-d14
223819320|NCT05984680|OTHER|Observational Phase 1|Noninterventional study
223819321|NCT05984680|OTHER|Observational Phase 2, Group I|Noninterventional study
223819322|NCT05984680|OTHER|Observational Phase 2, Group II|Noninterventional study
223819323|NCT05984680|OTHER|Observational Phase 3|Noninterventional study
223819324|NCT06900673|BEHAVIORAL|Collaborative Life Skills|Student, parents, and teachers in the intervention condition will receive the digitally adapted Collaborative Life Skills program.
223819325|NCT06900101|OTHER|Study the evolution and correlation between cerebral autoregulation index|"Objective n°1: Study the correlation between autoregulation index:~The investigators will look for a correlation between several auroregulation index such as the PRx, ORx and Cox.~Objective n°2: Evaluation and detection of EEG prognostic patterns: The investigators will look for quantitaive EEG changes during the early phase of acute brain injuries."
223819326|NCT06899685|OTHER|tradional physical therapy treatment|Instructions, hot backs, Deep transverse friction massage, passive \&self stretch, Neck isometric and Scapular retraction exercises
223819327|NCT06899685|OTHER|KT|Kinesiotaping
223819328|NCT06899685|DEVICE|IASTM|Instrument Assisted Soft Tissue Mobolization
223819329|NCT06901102|DRUG|Bee Venom Injection|This intervention involves the administration of purified bee venom from Apis mellifera species (Abevac) via subcutaneous injections. The dosage starts at 0.05 mL three times a week and gradually escalates to 0.5 mL three times a week by week 5. The total duration of the treatment is 6 months. Bee venom is being evaluated for its potential immunomodulatory effects, including enhancing regulatory T cell function and improving mineral bone disorder (MBD) in patients undergoing hemodialysis.
223819330|NCT06901102|DRUG|Standard Care for CKD-MBD|This intervention represents the standard care for patients with chronic kidney disease-mineral bone disorder (CKD-MBD) undergoing hemodialysis. The treatment typically includes phosphate binders to control phosphorus levels, vitamin D receptor activators to regulate calcium and phosphorus metabolism, and calcimimetics to control parathyroid hormone (PTH) levels. The specific regimen may vary according to individual patient needs, but the control group will not receive bee venom injections as part of their therapy.
223819331|NCT06900387|DIETARY_SUPPLEMENT|Tablet Calcinum-Calcium Carbonate (500mg) daily and Vitamin D3 (Cholecalciferol) tablet (60,000 IU) once a month.|Oral Calcium Carbonate supplement 500 mg from La Renon Healthcare Pvt Ltd to be administered daily for the period of 6 months. Oral Vitamin D3 (Cholecalciferol) supplement 60,000 IU from Eris Lifesciences Ltd to be administered once a month for the period of 6 months.
223819332|NCT06900387|DIETARY_SUPPLEMENT|Tablet Tayo- Vitamin D3 (Cholecalciferol) (60,000 IU) once a month.|Oral Vitamin D3 (Cholecalciferol) supplement 60,000 IU from Eris Lifesciences Ltd to be administered once a month for the period of 6 months.
223819333|NCT06900387|OTHER|Control Group|No additional intervention was given to control group.
223819334|NCT05159401|PROCEDURE|prevention of respiratory failure|Positive dynamics during CT or X-ray examinations in the form of reduction of hypoventilation zones, straightening of lung tissue
223819335|NCT00421213|DRUG|Darinaparsin|300mg/m2 of Darinaparsin given daily for five consecutive days to be repeated every 28 days for up to six months.
223819336|NCT06925191|DIAGNOSTIC_TEST|Group A (Experimental): 29 affected ankles of both genders diagnosed with Chronic ankle instability (CAI) who met the inclusion criteria. Group B (Control): 29 matched non-affected with CAI|"1-90-90Active knee extension test 2.Core muscles endurance tests(a. The static endurance tests b. The dynamic endurance tests)~Time Frame: 1 session"
223819337|NCT06926556|DEVICE|Defocus microlenses|Different microlenses array (H.M.E.C，High Precision Micro Encircle and H.A.L.T, highly aspheric lenslet technology) for controlling myopia progression in children and adolescents.
223819338|NCT06925009|DIAGNOSTIC_TEST|Ultrasound mesurements|Compare various clinical test with ultrasound parameters to predict difficult videolaryngoscopy intubation.
223819339|NCT00193713|DRUG|bifeprunox|
223819340|NCT02640378|OTHER|NO intervention|This study was a cross-sectional study. It had no intervention.
223819341|NCT05880589|DIETARY_SUPPLEMENT|Milk secretory supplement group|Take 2 tablet 2 times per day for 14 days
223819342|NCT05880589|DIETARY_SUPPLEMENT|Placebo group|Take 2 tablet 2 times per day for 14 days
223819343|NCT01457040|DRUG|TBI+CY+VP-16|CR Cohort will receive conditioning regimen of TBI+CY+VP-16: TBI: 4.5Gy/d, -5d, -4d; CY: 60mg/kg/d, -3d, -2d; VP-16: 15mg/kg/d, -3d, -2d
223819344|NCT01457040|DRUG|FA+TBI+CY+VP-16|NR Cohort will receive conditioning regimen of FA+TBI+CY+VP-16: Flu: 35mg/m2/d: -10\~-6d; AraC: 1g/m2/d, -10d\~-6d; TBI: 4.5Gy/d, -5d,-4d; CY:60mg/kg/d, -3d, -2d; VP-16: 15mg/kg, -3d, -2d
223819345|NCT03972774|DIAGNOSTIC_TEST|PET Stress Test|Cardiac positron emission tomography (PET)/computed tomography (CT) and test-result dependent management
223819346|NCT03972774|OTHER|Non-PET Medical Management|Appropriate medical management without cardiac PET stress-imaging
223819347|NCT03909802|BEHAVIORAL|Self-and family management of diabetic foot ulcers programs|The intervention combines self-management and family management focusing on behavioral changes in patients with diabetic foot ulcers. Self-management focuses on intensive health education of physical activities, diet, medication, foot care, and blood glucose control. Family management focuses on problem-solving, establishing roles, and effective involvement in providing care amid individuals suffering DFU.
223819348|NCT03909802|OTHER|Usual care|Usual care
223819349|NCT03651063|OTHER|social robot|Reach To Grasp games with a social robot
223819350|NCT03651063|OTHER|computer group|reach to grasp games with a computer screen
223819351|NCT04768933|DIETARY_SUPPLEMENT|Toddler Milk|At least three 130 mL servings daily of study formula are recommended for a total daily intake of 390 mL. Study participants will continue this feeding regimen Days 4 to 28 (approximately 4 weeks).
223819352|NCT01170975|DRUG|Tesetaxel 10 mg with and then without food|Treatment Period 1: Tesetaxel 10 mg in the fed state; Treatment Period 2: Tesetaxel 10 mg in the fasted state
223819353|NCT01170975|DRUG|Tesetaxel 10 mg without and then with food|Treatment Period 1: Tesetaxel 10 mg in the fasted state; Treatment Period 2: Tesetaxel 10 mg in the fed state
223819354|NCT02241720|DRUG|regorafenib|
223819355|NCT02327624|DRUG|Clopidogrel|Compare Clopidogrel to two doses of Ticagrelor 60 and 90
223819356|NCT02327624|DRUG|Ticagrelor 60|Compare Clopidogrel to two doses of Ticagrelor 60 and 90
223819357|NCT02327624|DRUG|Ticagrelor 90|Compare Clopidogrel to two doses of Ticagrelor 60 and 90
223819358|NCT01342185|DEVICE|medical ozone therapy with tianyi|Medical ozone therapy with instrument made in China Patients in this arm will receive autohemotherapy. First month: ozone concentration: 20µg \~40µg /ml;The second month: 30µg/ml × 100ml oxygen- ozone gas × 100 ml blood;The third month: 20µg/ml × 100ml oxygen- ozone gas× 100 ml blood.
223819359|NCT01342185|DEVICE|medical ozone therapy with humares|Medical ozone therapy with instrument made in Germany Patients in this group will receive autohemotherapy treatment, regime as ArmⅠ.
223819360|NCT01342185|DRUG|Diammonium glycyrrhizinate Capsules|Drug: Diammonium glycyrrhizinate Capsules Patients in this group will receive oral Diammonium glycyrrhizinate Capsules 150mg, three times a day for 12 weeks.
223819361|NCT02215330|DRUG|Eplerenone|
223819362|NCT02215330|DRUG|Maltodextrin|
223819363|NCT03125590|OTHER|Testing the PEQ (Personalized Exercise Questionnaire)|Administer the questionnaire to 114 participants to classify their facilitators, barriers and preferences to exercise
223819364|NCT03423875|DIAGNOSTIC_TEST|PrEDICT game score|PrEDICT game score will be shared with the emergency physicians and health care professionals
223819365|NCT00429494|DRUG|Leuprolide Acetate|22.5 mg IM injection 2 months before transplant and 3 months post-transplant.
223819366|NCT00429494|BEHAVIORAL|Questionnaire|Questionnaires taking about 15 minutes to complete.
223819367|NCT00429494|PROCEDURE|Hematopoietic Stem Cell Transplantation|Stem cell infusion on Day 0.
223819368|NCT00675324|DRUG|Laxabon|Laxabon 4 litres, starting the day (e.m.) before the colonoscopy
223819369|NCT00675324|DIETARY_SUPPLEMENT|Fresubin Energy drink|30 kcal/kg\*day five days before colonoscopy
223819370|NCT00345813|DIETARY_SUPPLEMENT|soy isoflavones|Given orally
223819371|NCT00345813|DIETARY_SUPPLEMENT|soy protein isolate|Given orally
223819372|NCT00345813|OTHER|placebo|Given orally
223819373|NCT01163903|DRUG|pantoprazole sodium for injection|Single 3-weekly doses of pantoprazole using the following dose escalation scheme for successive groups of patients: 80, 160, 240 and 320mg i.v. of pantoprazole to be given every 3 weeks, 30-60 (±5) minutes prior to doxorubicin. Treatment will be repeated on Day 1 of a 21-day cycle until radiographic or symptomatic progression or unacceptable toxicity or a maximum of 4 cycles (for patients who have received prior anthracyclines), and up to 8 cycles (for those with no prior exposure to anthracyclines).
223819374|NCT01163903|DRUG|doxorubicin hydrochloride injection|60 mg/m2, IV, scheduled on day 1 of every 3-week interval, 30-60 (±5) minutes after pantoprazole administration.
223819375|NCT05595421|DEVICE|Transcranial direct current stimulation (tDCS)|See detail in arm/group descriptions regarding the intervention.
223819376|NCT05267314|DEVICE|pharyngeal exerciser + standard therapy|Use of Pharyngeal exerciser
223819377|NCT00976703|OTHER|weighted bag|For the weighted bag, a 500cc saline bag will be taped to an empty Foley bag which will be attached to the cervical Foley catheter. This bag will then be placed to gravity over the end of the bed. The bed will be raised so that the bag does not touch the floor. The foley and the bag will be re-assessed every 30min by the nursing staff.
223819378|NCT00976703|OTHER|leg taping|For the leg taping, the cervical foley catheter will be pulled to gentle traction and attached to the patient's inner thigh using a reclosable foley catheter fastener. The foley catheter and the traction will be assessed every 30min by the nursing staff. The tension will be renewed and the Foley re-adjusted if necessary at each check.
223819379|NCT02041247|BIOLOGICAL|VAC-3S|VAC-3S is administered via intra-muscular route in the arm.
223819380|NCT00347100|DRUG|Insulin Glargine|Throughout study period
223819381|NCT00347100|DRUG|Glyburide|Combination throughout the study period. Titrate to FPG ≤ 100 mg/dl.
223819382|NCT00347100|DRUG|Glyclazide|Combination throughout the study period. Titrate to FPG ≤ 100 mg/dl.
223819383|NCT00347100|DRUG|Glimiperide|Combination throughout the study period. Titrate to FPG ≤ 100 mg/dl.
223819384|NCT00347100|DRUG|Glipizide|Combination throughout the study period. Titrate to FPG ≤ 100 mg/dl.
223819385|NCT00347100|DRUG|Metformin|Combination throughout the study period. Titrate to FPG ≤ 100 mg/dl.
223819386|NCT03289481|DIETARY_SUPPLEMENT|Active lozenge|nitric oxide generating lozenge
223819387|NCT03289481|DRUG|Placebo|placebo tablet
223819388|NCT03717675|DEVICE|NovaCross™ Chronic Total Occlusion micro-catheter|The NovaCross™ micro catheter is a guidewire positioning and support micro catheter for improving chronic total occlusion (CTO) crossability. The NovaCross™ gains its supportive characteristics through the use of a unique operator-controlled Nitinol scaffold and an extendable segment. Investigators will use the NovaCross Micro catheter during a standard of care catheterization of patients diagnosed with coronary total occlusion.
223819389|NCT02689856|DRUG|Hydrocortisone acetate and lidocaine hydrochloride|Hydrocortisone and lidocaine in combination
223819390|NCT02689856|DRUG|Placebo control|Vehicle cream alone
223819391|NCT02689856|DRUG|Hydrocortisone acetate|hydrocortisone alone
223819392|NCT02689856|DRUG|Lidocaine hydrochloride|lidocaine alone
223819393|NCT01556074|BEHAVIORAL|Yoga treatment|Biweekly 90-minute group yoga classes for 8 weeks and on non-class days participants will be asked to devote 15 minutes per day to a prescribed home yoga practice.
223819394|NCT05655104|OTHER|Couplet Care|In the Couplet Care model, the parents are provided access to the infant stabilisation room and encouragement for early skin-to-skin contact, mothers receive their postpartum care in the same NICU room with the infant, and fathers/partners also have a bed in the same NICU room.
223819395|NCT06421909|BEHAVIORAL|mindfulness-based educational intervention|Mindfulness-based educational intervention is a structured program that incorporates principles of mindfulness to help individuals develop greater awareness and acceptance of their thoughts, feelings, and bodily sensations. The intervention typically includes mindfulness meditation practices, cognitive-behavioral techniques, and educational components about stress management and emotional regulation. By fostering a non-judgmental and present-focused attitude, participants learn to manage their symptoms more effectively and improve their overall quality of life.
223819396|NCT01705275|DRUG|ONO-8539|ONO-8539
223819397|NCT01705275|OTHER|Placebo|Identical to ONO-8539 tablet but without active ingedient
223819398|NCT05627401|PROCEDURE|Modified multiple orbital wall decompression|Thyroid dysfunction of all patients is stabilized by ATDs until treatment of TAO is completed. All patients with sight-threatening GO were admitted for emergency steroid pulse therapy. And additional drugs for protecting gastrointestinal mucous membrane, potassium and calcium supplements, and sedatives were used. All emergency cases, whose signs of visual impairment clinically attributable to GO existed despite first-line steroid treatment, were referred and discussed at the surgical board of our interdisciplinary center for prompt surgical orbital decompression. Urgent orbital decompression was performed when response is absent or poor within 1-2 weeks.
223819399|NCT04166929|BIOLOGICAL|Haplo SCT with NK cells|Patients in this arm receive haplo-SCT followed by one boost of NK cells one/two weeks after the transplant. Lymphocyte are collected by apheresis from the donor one-two weeks after BM harvest. CD3 negative/CD56 positive cells are selected by immunomagnetic columns (other lymphocytes are stored to be used as DLI)
223819400|NCT04166929|BIOLOGICAL|Haplo SCT|Patients in this arm receive a standard haplo-SCT. All administerd therapies are the same as in other arm, except for the NK cell boost..
223819401|NCT00485576|DRUG|eculizumab|eculizumab 600 mg or matching placebo iv infusion.
223819402|NCT01364402|DRUG|Epoetin beta|50,000U intravenously
223819403|NCT01364402|DRUG|Saline 0.9%|normal saline intravenously
223819404|NCT01315275|DRUG|Ranibizumab|
223819405|NCT03657381|DRUG|Recombinant Humanized Anti-PD-1 Monoclonal Antibody Injection|Biological: F520 single-dose:0.2mg/kg, 1.0mg/kg, 3.0mg/kg, 200mg/times, 10mg/kg; multiple dosing: 1mg/kg, 3mg/kg, 200mg/times, 10mg/kg, treat every 2 weeks; multiple dosing: 3mg/kg, 200mg/times, treat every 3 weeks.
223819406|NCT01934699|DEVICE|Cardiac ultrasound|Patient will get echocardiographic examination during coronary angiography. 2D-Strain Analysis will be performed based on data of these echocardiographic examination. Only when vitality in the contraction impaired segments will be established based on 2D-Strain Analysis, PCI will be performed.
223819407|NCT01934699|DEVICE|MRI scanner|Coronary angiography on patient will be canceled. Patients will get viability assessment using MRI within the next 7 days. When vitality will be established with MRI, patient will get PCI.
223819408|NCT01858480|DRUG|D-ribose|D-ribose powder for oral solution and D-ribose for injection.
223819409|NCT01858480|OTHER|Placebo|Placebo dosage form designed to mock active.
223819410|NCT03128437|BEHAVIORAL|Aerobic Exercise|At each of the six exposure sessions, participants will be invited to engage in 2-minute warm-up on the treadmill. Following this warm-up period, participants will be asked to briskly walk or jog on the treadmill at a speed that maintains their heart rate at 60-80% of maximum age-predicted heart rate for 20 minutes using the formula: (220-age) x (0.60 \[lower bound\] or 0.80 \[upper bound\]). Participants will be fitted with a heart rate monitor, which will be checked by a research assistant at 5-minute intervals in order to ensure adherence to this prescription; participants will be asked to adjust treadmill speed in order to remain in this range. Following each 20-minute exposure, participants will complete 5 minutes of cool down walking on the treadmill. Assessments will take place at baseline, week 2 (post-intervention), week 4, and week 8.
223819411|NCT00638196|DRUG|Linoleic Acid/Oleic Acid|Dietary Supplement: Linoleic acid emulsion 30g bid/Oleic acid emulsion 30g bid
223819412|NCT02424409|BEHAVIORAL|2: Intervention|"1. The corticoid treatment (Prednisolone or Prednisone) given from the ED for the first day if the patient is discharged at nighttime or during the weekend.~   A detailed prescription including 1) A written prescription of the corticosteroid treatment given orally for a total treatment length of 7 days 2) A written prescription describing the adaptation of the inhaled treatment 3) Peak expiratory flowmeter~2. A written action plan with formalized recommendations for the patient~3. A formal letter and recommendations to the general practitioner including information about the ED visit, and the necessity to program a follow up with regular consultations as well as to program spirometry evaluation for his patient.~   The ED doctor at discharge will explain all these documents orally~4. Recommendations for an early contact with the general practitioner;~5. Telephone call of the emergency department to the patient at day 7 +/-1 in order to ensure the link with the general practitioner."
223819413|NCT02424409|BEHAVIORAL|1: Control|patients without discharge protocol
223819414|NCT02479516|BEHAVIORAL|Community Health Assessment Program Philippines (CHAP-P)|
223819415|NCT03264768|DEVICE|endobronchial valves|A ambulatory diagnostic bronchoscopy under general anesthesia will evaluate the presence or absence of collateral ventilation . The targeted lobar airway is temporarily occluded by means of a balloon catheter, which blocks inspiratory flow but allows expiratory flow, in order to assess whether the air flow gradually declines to zero, meaning absence of collateral ventilation. Only in case collateral ventilation is excluded, a therapeutic bronchoscopy will be scheduled to insert the one-directional endobronchial valves in the targeted lobar airways. We will only perform a unilateral intervention during which we will treat one or maximal two lobes at one side.
223819416|NCT03264768|BEHAVIORAL|physical activity tele coaching|3 month physical activity tele coaching intervention consisting of a project tailored smartphone application in combination with a step counter providing direct feedback.
223819417|NCT03264768|PROCEDURE|Lung volume reduction surgery (LVRS)|Patients not eligible for endoscopic lung volume reduction (or non responders of this intervention) can be referred for surgical lung volume reduction. With this procedure, the most emphysematous parts of the lungs will be surgically removed.
223819418|NCT03804515|DRUG|14C-labeled poziotinib|a single capsule containing 12 mg of 14C-labeled poziotinib (approximately 90 to 110 μCi) will be administered orally
223819419|NCT00517465|DRUG|Placebo|po bid
223819420|NCT00517465|DRUG|RG1511|Starting multiple doses of 100mg po bid escalated in subsequent groups of patients to potential maximum multiple dose of 1200mg po bid.
223819421|NCT02047565|DRUG|60mg edoxaban|
223819422|NCT02047565|DRUG|180mg edoxaban|
223819423|NCT02047565|DRUG|50 IU/kg Beriplex P/N|
223819424|NCT02047565|DRUG|25 IU/kg Beriplex P/N|
223819425|NCT02047565|DRUG|10 IU/kg Beriplex P/N|
223819426|NCT02128165|DEVICE|BMI more than 45 BMI|Air filled gastric balloon (Heliosphere) those BMI above 45
223819427|NCT02128165|DEVICE|BMI less than 45 BMI|Air filled gastric balloon (Heliosphere) those BMI below 45
223819428|NCT01568632|DRUG|Imetelstat|
223819429|NCT02942680|DRUG|acetylsalicylic acid started for 24 hours before surgery|
223819430|NCT02942680|DRUG|acetylsalicylic acid stayed for 5 days before surgery|
223819431|NCT02382237|DEVICE|PET/TDM|Evaluation of nutrition absorption by TEP/TDM
223819432|NCT02839122|DRUG|Tadalafil|
223819433|NCT02839122|DRUG|Dutasteride|
223819434|NCT05606315|DRUG|Remimazolam Besylate|NS 50ML + Remimazolam besylate(50mg , 2mg:2ml), IV-Pump,maintenance dose 0.5-3mg/kg/h.
223819435|NCT05606315|DRUG|Propofol|Propofol (50ml, 0.5g), IV-Pump, maintenance dose 0.3-4.0mg/kg/h.
223819436|NCT05606315|DRUG|Midazolam|Midazolam (10mg,2ml), IV-Pump, maintenance dose 0.02-0.1mg/kg/h.
223819437|NCT02129816|DRUG|Bryophyllum|
223819438|NCT01114750|DRUG|Insulin in dextran matrix capsule (and placebo)|Single dose capsule (and placebo)
223819439|NCT03075501|BEHAVIORAL|Paired|Drug conditioning is assessed by pairing drug administration with a given context.
223819440|NCT03075501|DRUG|Stimulant or sedative|CS+ for paired, CS0 for unpaired
223819441|NCT03075501|DRUG|Placebo|CS- for paired, CS0 for unpaired
223819442|NCT02261090|DRUG|Formulation B: Pramipexole Slow release (SR) tablet|
223819443|NCT02261090|DRUG|Formulation C: Pramipexole Slow release tablet|
223819444|NCT02261090|DRUG|Formulation D: Pramipexole Slow release tablet|
223819445|NCT02261090|DRUG|Formulation E: Pramipexole Slow release tablet|
223819446|NCT02261090|DRUG|Formulation F: Pramipexole Slow release tablet|
223819447|NCT02261090|DRUG|Formulation G: Pramipexole Slow release tablet|
223819448|NCT02261090|DRUG|Formulation H: Pramipexole Slow release tablet|
223819449|NCT02261090|DRUG|Pramipexole immediate release (IR) tablets|
223819450|NCT04691713|DRUG|Targeting CD276 autologous chimeric antigen receptor T cells|Chimeric antigen receptor T cells (car-t) is one of the most effective therapies for malignant tumors (especially hematological tumors). Like other immunotherapies, the basic principle is to use the patient's own immune cells to clear cancer cells. Chimeric antigen receptor (car) is the core component of car-t, which endows T cells with the ability to recognize tumor antigens in an independent manner, which enables car modified T cells to recognize a wider range of targets than natural T cell surface receptors (TCR). The basic design of car includes a tumor associated antigen binding region (usually derived from scFv segment of monoclonal antibody antigen binding region), transmembrane region and intracellular signal region. The selection of target antigen is a key determinant for the specificity and effectiveness of car and the safety of genetically modified T cells.
223819451|NCT00753883|DRUG|simvastatin|simvastatin 20 mg/QD for 6 Weeks.
223819452|NCT00753883|DRUG|Ezetimibe|Ezetimibe 10 mg/QD for 8 weeks.
223819453|NCT05142670|PROCEDURE|experimental group: task-oriented training individualized by the gravity perception|All participants received 50 minutes of physical therapy per session for 5 days per week for 8 weeks. Subjects in the experimental group underwent 20 minutes of task-oriented training individualized by the gravity perception following 30 minutes of regular physical therapy. All outcome measurements were evaluated on the day before intervention (pretraining), 4 weeks and 8 weeks after training by the same physical therapist (who was blinded to the group of the subjects). These regular protocols including preparatory techniques, mat activity, sitting, standing, and walking training.
223819454|NCT05142670|PROCEDURE|control group: visual feedback treatment|Subjects in the control group underwent 20 minutes of visual feedback (VF) treatment. The regular physical therapy protocols for the control group were the same as those used for the experimental group. These regular protocols including preparatory techniques, mat activity, sitting, standing, and walking training.
223819455|NCT04910815|DEVICE|Atmo Gas Capsule|The Atmo gas capsule is an ingestible electronic device. This capsule consists of gas and temperature sensors, electronic circuits, radio transmitter and silver oxide batteries. It can measure the concentrations and types of intestinal gases in individuals and give an indication of gut transit time. This data is used for research purposes to gain an understanding of the microbiota's localised functionality. The data from the sensors is transmitted out of the body over the radio frequency to a handheld receiver. The capsule passes out of the human body at the end of the measurement and is disposable.
223819456|NCT04910815|DIAGNOSTIC_TEST|Glucose Breath Test|Glucose is a sugar that will be broken down by bacteria if present in the small bowel with hydrogen gas as a by-product. The hydrogen produced through fermentation is measured in the patients exhaled breath
223819457|NCT04910815|DIAGNOSTIC_TEST|Fructoolifosaccharides (FOS) Breath Test|FOS is a long chain carbohydrate that can only be broken down by bacteria with hydrogen gas as a by-product. The hydrogen produced through fermentation is measured in the patients exhaled breath
223819458|NCT04910815|PROCEDURE|Jejunal Aspiration and culture|Endoscopic procedure to determine microbial load of the Small bowel. This is the gold standard to determine the Active SIBO cases
223819459|NCT04910815|DRUG|Rifaximin|Rifaximin (550g) 1 capsule twice a day for 14 days.
223819460|NCT04910815|DRUG|Placebo|randomised administration of either placebo or Rifaximin (550g) 1 capsule twice a day for 14 days. The placebo will be encapsulated maize starch and pregelatinised maize starch
223819461|NCT01950442|DEVICE|Balloon dilation|
223819462|NCT03375125|DIETARY_SUPPLEMENT|Probiotic|L. reuteri DSM 17938 \& L. reuteri ATCC PTA 5289 ) will be given at a dose of 2x10\^8 Colony Forming Units (CFU). One lozenges is to be taken twice per day (one in the morning and one in the afternoon) giving a total daily dose of at least 4x108 CFU/day.
223819463|NCT03375125|OTHER|Placebo|Placebo will have identical appearance, taste, and flavor, except for lacking the bacteria. One lozenges will be taken twice per day (one in the morning and one in the afternoon)
223819464|NCT02970032|DRUG|Real time heparin dose adjustment|Patients will have steady state anti-Xa levels drawn at least 6 hours after initiation of heparin infusion. Patients with out of range anti-Xa levels will receive real time heparin dose adjustment followed by repeat anti-Xa levels.
223819465|NCT02970032|DRUG|Standard heparin dose|Patients will be placed on heparin infusions per their surgeon's discretion.
223819466|NCT02471885|PROCEDURE|Remote Ischaemic Conditioning|each cycle of Remote Ischaemic Conditioning (RIC) consists of inflating a blood pressure cuff on the upper limb (arm) upto 200mm Hg (systolic BP + 20 mm Hg for low platelets, e.g. 50-150 x 10\^9/L; skip RIC if platelets \< 50 x 10\^9/L) for 5 minutes, then deflated to 0 mm Hg for 5 minutes.
223819467|NCT02471885|OTHER|Placebo|Sham control blood pressure cuff placement at 10 mm Hg for 5 minutes, then deflated to 0 mm Hg for 5 minutes.
223819468|NCT06155578|DRUG|Topical 25% sodium metabisulfite (SM) in pediatric cold cream|Topical 25% sodium metabisulfite (SM) in pediatric cold cream will be applied twice daily on hand calcinosis.
223819469|NCT06155578|DRUG|Placebo|Pediatric cold cream will be applied twice daily on hand calcinosis.
223819470|NCT01938105|OTHER|Nimotuzumab+chemoradiotherapy|"Nimotuzumab 200mg per week will be administered concurrent with platinum-based chemotherapy and intensity-modulated radiation therapy. After the preoperative treatment, patients will be assessed for tumor response and operability. For those who are considered to be candidates for operation, radical surgery will be performed.~\--------------------------------------------------------------------------------"
223819471|NCT00561444|BEHAVIORAL|Questionnaire|Questionnaires taking 20 minutes to complete.
223819472|NCT03966079|DRUG|recombinant tissue plasminogen activator|Patients receive 20 mg of single-dose recombinant tissue plasminogen activator delivered through the catheter
223819473|NCT05551481|PROCEDURE|To evaluate the clinical performance of indirect resin composite restorations, which were luted with two different resin cement, in posterior teeth for up to 2 years.|resin cement (Variolink II, Ivoclar Vivadent)-self-adhesive resin cement (Relyx U200, 3M ESPE)
223819474|NCT04655079|DEVICE|Anodal transcranial direct current stimulation (a-tDCS)|tDCS is delivered by a battery-driven constant current stimulator thought a pair of saline soaked surface sponge electrodes. The active electrode (anode) is placed on the scalp over the left dlPFC (F3) according to the 10 to 20 international electroencephalogram coordinates) and the cathode is placed over the right deltoid muscle. During real stimulation a constant current of 2mA (milli Ampere) is applied for 20 minutes.
223819475|NCT04655079|DEVICE|Sham Condition|For the sham condition the electrode placement is the same of active tDCS but the electric current is ramped down 5 seconds after the beginning of the stimulation.
223819476|NCT00004585|DRUG|Abacavir sulfate, Lamivudine and Zidovudine|
223819477|NCT00004585|DRUG|Lamivudine/Zidovudine|
223819478|NCT00004585|DRUG|Abacavir sulfate|
223819479|NCT00004585|DRUG|Efavirenz|
223819480|NCT00957931|PROCEDURE|Bone marrow transplantation|Bone marrow transplantation using matched unrelated donors, reduced intensity conditioning regimen, and co-transplanting mesenchymal stromal cells derived from parental bone marrow.
223819481|NCT00957931|BIOLOGICAL|Mesenchymal Stromal Cells|
223819482|NCT02682212|OTHER|Physiotherapy intervention|Compare the effect of early physiotherapy intervention (pelvic floor muscle training, PFMT) with standard care on pelvic floor dysfunction symptoms, quality of life (QoL) and (pelvic floor muscle (PFM) strength, for women who answered the questionnaire positively for 1) urinary incontinence, 2) other dysfunction of the pelvic floor.
223819483|NCT04178538|PROCEDURE|ACL reconstruction with bone marrow, demineralized bone marix, and internal brace augmentation|ACL reconstruction with bone marrow, demineralized bone marix, and internal brace augmentation with all inside technique
223819484|NCT04178538|PROCEDURE|Standard ACL reconstruction with all inside technique|Standard ACL reconstruction with all inside technique
223819485|NCT05488938|OTHER|Rehabilitative Intervention|Each program will require the daily performance of different postures and therapeutic activities at the girls' educational facilities and homes, based on the availability of families, for 10 months. Specific strategies that will be implemented will include maintaining asymmetrical postures that oppose the scoliosis curve during activities and exercises in sitting, standing, and walking positions (according to each participant's functional abilities). These strategies refer to a hypercorrective postural positioning of scoliosis. In addition, activities involving weight bearing on the lower limbs, such as walking and standing for at least two hours a day, will be encouraged, and passive stretching and spinal mobilization exercises will be conducted.
223819486|NCT02409550|OTHER|CARATKids Questionnaire|
223819487|NCT00857805|PROCEDURE|Transarterial Chemoembolization|Application of carboplatin, doxorubicin in ethiodol into the artery for one or more sessions.
223819488|NCT00857805|RADIATION|Proton Beam Radiotherapy|Fifteen consecutive sessions
223819489|NCT02372123|OTHER|lifestyle advice|Investigators will give lifestyle advice to patients such as exercising regularly, limiting caffeine, sugar and alcohol intake, reduction or cessation of smoking
223819490|NCT02372123|OTHER|connective tissue manipulation|Investigators will apply connective tissue manipulation on lumbosacral, lower thoracic, and anterior pelvic regions starting from the estimated time of ovulation until the next period begins
223819491|NCT01712555|PROCEDURE|autologous fat grafting with PRP to anophthalmic orbits|
223819492|NCT02349568|PROCEDURE|High risk group|Patients with high risk underwent EUS examination under conscious sedation. EUS was examined from second part of duodenum up to duodenal bulb. All patients even if negative EUS examination of CBD stone were underwent ERCP in the same session. The ERCPs were performed in standard manner. All patients were contacted by phone on day 1, 3 and 30 after the procedure.
223819493|NCT02349568|PROCEDURE|Intermediate risk group|Patients with intermediate risk underwent EUS examination under conscious sedation. EUS was examined from second part of duodenum up to duodenal bulb. ERCPs were done at the discretion of the attending physicians. The ERCPs were performed in standard manner. The patients without ERCP done were contacted at 3 months interval to assess symptoms and LFT for 12 months.
223819494|NCT04867785|DRUG|LY3437943|Administered SC
223819495|NCT04867785|DRUG|Dulaglutide|Administered SC
223819496|NCT04867785|DRUG|Placebo|Administered SC
223819497|NCT00208585|DRUG|sertraline|
223819498|NCT01289041|DRUG|BKM120|
223819499|NCT04162990|BEHAVIORAL|Lifestyle remodeling Intervention|Participants will be received 2 phases of intervention of lifestyle remodeling, 3 months for each phase, which contained cognitive stimulating activities and physical activities.
223819500|NCT04162990|BEHAVIORAL|Does Comparator: regular treatment|Participants in this group would be treated as usual, which contained the healthy education.
223819501|NCT01751815|PROCEDURE|Acu-TENS|Patients randomized to the experimental group will receive Acu-TENS on acupoints relevant to the treatment of abdominal pain and distension, including Zusanli (stomach meridian ST-36), Hegu (large intestine meridian LI-4), Neiguan (pericardium meridian PC-6), Tianshu (stomach meridian ST-25), and Dachangshu (bladder meridian BL-25).
223819502|NCT01751815|PROCEDURE|Placebo-TENS|Patients randomized to the control group will receive placebo-TENS at the same acupoints.
223819503|NCT02184663|OTHER|without APA program|Control Arm : chemotherapy alone
223819504|NCT02184663|OTHER|APA program|Experimental Arm : chemotherapy + APA program during 16 weeks (aerobic and muscular strength exercises)
223819505|NCT02813967|RADIATION|Radiotherapy 54 Gy|Radiotherapy was administered in 1.8 Gy fractions 5 times weekly to a total dose of 54 Gy.
223819506|NCT02813967|RADIATION|Radiotherapy 60 Gy|Radiotherapy was administered in 2 Gy fractions 5 times weekly to a total dose of 60Gy.
223819507|NCT02813967|DRUG|S-1|S-1 70mg/m2 was administered on days 1-14 and 29-42.
223819508|NCT05520385|DIAGNOSTIC_TEST|blood group and Rh|check of blood group , Rh for patient and control
223819509|NCT02994602|DRUG|Nestorone + Testosterone Combination Gel|The combined gel is a transdermal treatment that will be applied as three single applications to a male subject's arms and shoulders on three different treatment days. The formulation will be a hydro alcoholic gel containing about 1.43% T (14.3 mg T/g gel). About 9 to 14% of the steroid (T or NES) in the gel applied is available to the body. The amount of gel to be applied each application will be approximately 5 mL in volume. The gel application volume will contain 62.5 mg of T that will deliver approximately 6 mg T to the body per day (Swerdloff et al., 2000; Wang et al., 2000). This gel volume will also contain 8.3 mg of NES that will deliver about 0.8 mg of NES to the body per day (NES 8 mg/d + T 60 mg/d (NES8/T60) gel).
223819510|NCT02177539|DRUG|Cyclopentolate|Traditional scheme. Cyclopentolate, repeat dosage 5 minutes and then wait 40 minutes to retinoscopy. Total wait 45 minutes.
223819511|NCT02177539|DRUG|Cyclopentolate+tropicamide+phenylephrine|New scheme. All drugs together and wait 30 minutes for retinoscopy
223819512|NCT05918562|DIETARY_SUPPLEMENT|Low fiber diet|Low fiber diet including cereal, white bread, eggs, meat, dairy
223819513|NCT05918562|DIETARY_SUPPLEMENT|Standard clear liquid diet|Standard clear liquid diet including broth, jello, water, juice
223819514|NCT01062763|DRUG|spironolactone|25 to 50 mg once daily
223819515|NCT01062763|DRUG|placebo|addition of placebo 1 to 2 tablets daily
223819516|NCT06190262|BEHAVIORAL|The intervention is community based group psychoeducation|The intervention is community based group psychoeducation
223819517|NCT01110083|DRUG|EMD 1204831|Subjects will receive EMD 1204831 twice a day for 21 days during each treatment cycle
223819518|NCT05510726|DEVICE|shearwave elastography|shearwave elastography on upper or lower limb
223819519|NCT01403441|DEVICE|Radiosurgical Neuromodulation using the Cyberknife|our team has selected 60 Gray (Gy) as the dose to the target margin to be used for radiosurgical neuromodulation in patients with intractable bipolar disorder; the target being the anterior cingulate (Cg) that correlates with Brodmann area 25 (Cg25).
223819520|NCT02494921|DRUG|Docetaxel-PNP|Given IV
223819521|NCT02494921|DRUG|Ribociclib|Given Orally
223819522|NCT02494921|DRUG|Prednisone|Given Orally
223819523|NCT02494921|DRUG|Filgrastim|Given IV
223819524|NCT01913158|DRUG|Anucort-HC, 25 Mg Rectal Suppository|Hydrocortisone acetate suppositories
223819525|NCT01913158|DRUG|Placebo suppository|Hydrogenated palm kernel oil suppositories
223819526|NCT03534765|DIAGNOSTIC_TEST|CT abdomen +/- pelvis|Diagnostic CT scan (only if requested by responsible clinicians)
223819527|NCT03534765|DIAGNOSTIC_TEST|Edmunton Frailty Score|Patient completed previously valided questionnaire quantifying frailty.
223819528|NCT03534765|PROCEDURE|Emergency laparotomy for general surgical pathology|Emergency general surgical laparotomy (defined by the UK NELA body)
223819529|NCT02152228|DRUG|EnteraBio's Oral Parathyroid Hormone (1-34)|Oral administration
223819530|NCT01247714|DIETARY_SUPPLEMENT|T-Diet plus Standard|T-Diet plus Standard is a complete balanced protein and energy oral nutrition supplement, indicated for the dietary management of patients with related malnutrition.
223819531|NCT01247714|DIETARY_SUPPLEMENT|T-Diet plus Diabet NP|T-Diet plus Diabet NP is a complete balanced oral nutrition supplement, indicated for the dietary management of diabetic patients or hyperglycemia related malnutrition.
223819532|NCT01247714|DIETARY_SUPPLEMENT|Glucerna|GLUCERNA 1.0 CAL is a reduced-carbohydrate, modified-fat, fiber-containing formula clinically shown to blunt blood-glucose response in patients with abnormal glucose tolerance.
223819533|NCT01247714|DIETARY_SUPPLEMENT|Novasource|Complete high protein diet for diabetic patients and hyperglycemic
223819534|NCT04618822|BEHAVIORAL|Teaching involving whole-body movements|The intervention consist of three 30 minutes sessions per week for eight weeks. Activities are conducted in small groups of six children and focus on the acquisition of letterforms, letter-sound correspondences and reading and spelling of short words. Activities involve whole-body movements and have been developed with the embodied learning theory in mind, linking movement closely to the learning content.
223819535|NCT04618822|BEHAVIORAL|Teaching involving hand movements|The intervention consist of three 30 minutes sessions per week for eight weeks. Activities are conducted in small groups of six children and focus on the acquisition of letterforms, letter-sound correspondences and reading and spelling of short words. Activities involve movements using hands and arms and have been developed with the embodied learning theory in mind, linking movement closely to the learning content.
223819536|NCT04618822|BEHAVIORAL|Teaching involving minimal motor movements (control)|The control condition consist of three 30 minutes sessions per week for eight weeks. Activities are conducted in groups of app. twelve children and focus on the acquisition of letterforms, letter-sound correspondences and reading and spelling of short words. Activities are completed seated on a chair using paper and pencil.
223819537|NCT00660335|DRUG|RG1068 (synthetic human secretin)|Single-dose, IV infusion
223819538|NCT03926065|OTHER|Plain Vegetables Served in 100% Portion Size|Lunch includes (a) vegetables without added flavoring (b) the baseline portion size of vegetables
223819539|NCT03926065|OTHER|Plain Vegetables Served in 200% Portion Size|Lunch includes (a) vegetables without added flavoring (b) 200% of the baseline portion size of vegetables
223819540|NCT03926065|OTHER|Enhanced Vegetables Served in 100% Portion Size|Lunch includes (a) vegetables with added flavoring (b) the baseline portion size of vegetables
223819541|NCT03926065|OTHER|Enhanced Vegetables Served in 200% Portion Size|Lunch includes (a) vegetables with added flavoring (b) 200% of the baseline portion size of vegetables
223819542|NCT05762614|OTHER|Dyspnea assessment|Dyspnea assessment, respiratory variability, Spirometry, Electromyography
223819543|NCT00847795|DRUG|Avotermin|Intradermal administration
223819544|NCT00847795|DRUG|Placebo|Placebo
223819545|NCT02795208|PROCEDURE|Lung recruitment maneuver|The lung recruitment maneuver consists in a brief and controlled increment in airways pressure (20 cmH2O of PEEP + 20 cmH2O of driving pressure) for 10 breaths.
223819546|NCT01556698|DRUG|NVN1000|
223819547|NCT01556698|DRUG|Vehicle|Placebo
223819548|NCT04661475|DRUG|Dexmedetomidine Injection [Precedex]|ECT and anaesthetic treatment protocols will be determined by the local ECT services. ECT being given twice a week. The anesthetic induction agent of choice will usually be propofol, with thiopental permissible as an alternative. For safety reasons, any drug contraindicated to be given with DEX will be avoided. Especially the once known to decrease arterial pressure and heart rate excessively. Oral psychotropic medication to be continued by the patient's treating clinical team will remain unchanged where possible for at least the first 4 ECT treatments, and ideally until end of ECT. Eligible subjects will be allocated randomly to receive either 0.5µg/kg dexmedetomidine add on (diluted to 10 ml with 0.9% saline) at a steady rate of 1 ml/min, for 10 min.Participants in the two groups will receive DEX or Saline adjunct thrice weekly for 3 weeks.
223819549|NCT04661475|DRUG|Normal saline|while patients in the Control group will be infused with 10 ml of 0.9% saline at the same rate, over 10 minutes before anesthesia induction for ECT procedure.
223819550|NCT03833128|DRUG|Low Dose REN001|Oral
223819551|NCT03833128|DRUG|High Dose REN001|Oral
223819552|NCT01914809|OTHER|samples blood|
223819553|NCT01914809|OTHER|biopsy placentaire|
223819554|NCT02254083|DRUG|BIBT 986 BS - low|
223819555|NCT02254083|DRUG|BIBT 986 BS - high|
223819556|NCT02254083|DRUG|Placebo|
223819557|NCT04845464|OTHER|Cognitive Assessment (not diagnostic)|Sleep quality and cognition will be assessed in young adults
223819558|NCT03833180|DRUG|Zilovertamab vedotin|Zilovertamab vedotin administered via IV infusion per Schedule 1, 2, or 3 according to participant allocation.
223819559|NCT02300337|DEVICE|Reduce Cuff pressure|We reduce the Cuff Pressure from the LTS-D (Laryngeal Tube suction) from 60 to 50 to 40 to 30cmH2O and measure the Delta from Inspiration to Expiration Tidalvolume (Delta Vt). The Delta Vt shows the actual leakage.
223819560|NCT03260127|BEHAVIORAL|Computerized executive function training plus CPT (CEFT-CPT)|Participants randomized to the CEFT-CPT arm will receive 6 weeks of computerized executive function training and then 6 weeks of standard Cognitive Processing Therapy for PTSD (total of 12 sessions)
223819561|NCT03260127|BEHAVIORAL|Word game training plus CPT (WT-CPT)|Participants randomized to the WT-CPT arm will receive 6 weeks of computerized word game training and then 6 weeks of standard Cognitive Processing Therapy for PTSD (total of 12 sessions)
223819562|NCT05624866|DRUG|Dexmedetomidine|injection of 1 microgram/kg dexmeditomidine + 10 cc saline injection nearby median nerve as hydro-dissection
223819563|NCT05624866|DRUG|Triamcinolone|injection of 40 mg triamcinolone + 10 cc saline injection nearby median nerve as hydro-dissection
223819564|NCT04822740|DEVICE|Control Glucose Monitoring System|"With a sensor, transmitter and display device (receiver and/or compatible smart device).~The CGMS sends glucose readings to a compatible smart device every 5 minutes. In this study the CGMS for all patients with use of the results of the device in real time by the health care team for the Experimental arm and without the use of the results by the health care team for Active Comparator (Conventional strategy ."
223819565|NCT02393521|DEVICE|Shindo® vibration mattress|vibration therapy was self-administered while the subject was laying in supine in a polyurethane mattress
223819566|NCT03394456|OTHER|diabetes program|Comprehensive diabetes program (weekly to bimonthly CHW mHealth contact (phone, text) for 12-months and monthly diabetes group visits for 6-months)
223819567|NCT03394456|OTHER|telehealth training and support for Community Health Workers|weekly 1-hour diabetes training and patient support for CHWs via telehealth i.e., ZOOM technology for the study duration
223819568|NCT05430048|DRUG|nasal Desmopressin|compare the effect of nasal desmopressin versus oral bisoprolol for controlling bleeding and improving surgical field clarity during functional endoscopic sinus surgery.
223819569|NCT02714868|BEHAVIORAL|Project TEAM|Project TEAM is a manualized, group-based intervention designed to be co-facilitated by an experienced leader with a disability (disability advocate) and a licensed service provider (such as an occupational therapist, social worker, or educator). Project TEAM includes eight group sessions and two experiential learning field trips for each participant. Weekly phone calls with peer mentors with disabilities support achievement of each participant's personal activity goal.
223819570|NCT02714868|BEHAVIORAL|Matched Comparison|Participants set goal to try a new activity in the community
223819571|NCT00981474|DRUG|blood pressure maintenance based on cerebral blood flow autoregulation measurement|Blood pressure lowered or raised
223819572|NCT00981474|DEVICE|Control group|Institutional standard of care.
223819573|NCT04639778|OTHER|Control Group|Clinical visits conducted by a multidisciplinary team every year
223819574|NCT04639778|OTHER|Intervention Group|Clinical visits are triggered by weight evolution measured by connected balance
223819575|NCT05439239|OTHER|Repeated sprint training|"Participants will perform 7 weeks of cycling repeated sprint training (2x/week). Inspired oxygen fraction (FiO2) will be set to 14.6% and 20.9% for the hypoxic and normoxic group to simulate an altitude of 3000 m and 300 m, respectively.~The training sessions will consist of a 10-min warm up followed by 3 sets of 5 x 10-s all-out repeated sprints on the cycle ergometer. The number of sets will decrease to two during week 7. Participants will be instructed to try to reach and maintain maximal power output during each sprint. An active recovery at 30% of VO2max will be allowed for 20 s between sprints and for 5 min between sets. The training will end with a 10-min cool down at 30% VO2max. An individual fixed torque of 0.7 will be used during the sprints and it will be reduced to 0.5 Nm/kg at week 7."
223819576|NCT02678767|DRUG|Ferumoxytol|All subjects will receive neurocognitive testing. Subjects will have a brain MRI prior to drug infusion. A one-time ferumoxytol IV infusion will be given at a dose of 4mg Fe/kg up to a maximum of 510mg of elemental iron delivered at a rate of 1ml/sec. A second brain MRI will be completed post-infusion
223819577|NCT03800979|DRUG|Tofacitinib|Tofacitinib is an oral medicine in Janus kinase inhibitor 3 group which has been approved by FDA in treating Rheumatoid Arthritis. It has ability to inhibit nerve signal Interferon-ɣ and Interleukin-15 between white blood cell(WBC) and the nucleus of hair follicle cell causing the production of WBC type CD8+NKG2D+ T cell to slow down which this type of WBC is one of the cause of hair loss.
223819578|NCT00082537|DRUG|caspofungin acetate|Duration of Treatment: 28-90 days
223819579|NCT00082537|DRUG|Comparator: AmBisome|Duration of Treatment: 28-90 days
223819580|NCT04463121|DEVICE|Moderato IPG's CNT pacing signals|Assesment of cardiac function and sympatheric activity will be obtained simultaneously
223819581|NCT04463121|DEVICE|CD Leycom Pressure/Volume Combination Catheters|Simultaneous recording of the Pressure, Volume measurements and ECG signals will be done for constant monitoring of intra-ventricular pressure and volume.
223819582|NCT00255346|DRUG|Dasatinib (BMS-354825)|70 mg orally twice daily
223819583|NCT05855902|BEHAVIORAL|group art therapy|Art therapy will be offered in a weekly 1.5 hour group. Clients are provided a prompt and then asked to express their feelings using art, such as drawing/painting/etc.
223819584|NCT00674323|DRUG|Verteporfin Photodynamic Therapy|After a 10-minute intravenous infusion of verteporfin at a dose of 6 mg/m\^2 body surface area, light application of 50 J/cm\^2 to the study eye was begun 15 minutes after the start of infusion.
223819585|NCT00674323|DRUG|Ranibizumab|Ranibizumab at dose of 0.5 mg administered as an intravitreal injection.
223819586|NCT03595501|DEVICE|Hematology Analyzer - OLO|Complete blood counts from OLO will be determined from analysis of whole blood samples
223819587|NCT03595501|DEVICE|Hematology Analyzer - Predicate|Complete blood counts from Predicate will be determined from analysis of whole blood samples
223819588|NCT05765084|BIOLOGICAL|Dendritic cell vaccination|WT1/DC vaccines (8-10 x 10\^6 cells in 500 μL saline solution with 5% human albumin) will be administered through intradermal injection at 5 sites (100 μL/site) in the ventromedial region of the upper arm (5-10 cm from the axillary lymph nodes). Injection sites will alternate between left and right arms. WT1/DC vaccines are administered on day 14 of each 3-weekly platinum/pemetrexed-based chemotherapy cycle. Additional WT1/DC vaccinations after the study treatment schedule can be administered (optional) at 4-weekly intervals (± 1 week).
223819589|NCT05765084|DRUG|Atezolizumab|Atezolizumab (1200 mg) will be administered on day 0 of each 3-weekly platinum/pemetrexed-based chemotherapy cycle. Atezolizumab should be administered before chemotherapy administration as an IV infusion over 60 (±15) minutes. If the first infusion is tolerated, all subsequent infusions may bedelivered over 30 (±10) minutes. Additional atezolizumab treatment (1680 mg) after the study treatment schedule can be administered (optional) at 4-weekly intervals (± 1 week) as an IV infusion over 30-60 minutes.
223819590|NCT05765084|DRUG|Platinum/pemetrexed based chemotherapy|On the first day of each cycle (day 0), pemetrexed 500 mg/m2 should be administered as intravenous (IV) infusion over 10 minutes, followed by cisplatin 75 mg/m2 as IV over approximately 2 hours. The actual doses of the drugs to be administered to patients will be determined by calculating the patient's body surface area at the beginning of each cycle. For ease of dose administration, the protocol allows ± 5% variance in the calculated total dose per infusion. If deemed necessary, the treating physician can decide to replace cisplatin by carboplatin. In that case, carboplatin will be delivered to an area under the concentration-time curve (AUC) of 5 as an IV infusion over 1 hour.
223819591|NCT04806230|DRUG|sertraline, mirtazapine, venlafaxine, citalopram, escitalopram|Naturalistic treatment
223819592|NCT00171132|DRUG|valsartan|
223819593|NCT00171132|DRUG|atenolol|
223819594|NCT00171132|DRUG|hydrochlorothiazide|
223819595|NCT00894634|DRUG|Brompheniramine maleate|
223819596|NCT00675194|DRUG|Cisplatin, Irinotecan, Capecitabine|
223819597|NCT06428461|PROCEDURE|Supraclavicular brachial plexus block|A supraclavicular brachial plexus block will be performed under ultrasound guidance. The patient will be taken to the preoperative block room, positioned supine with the bed elevated at a 30° angle, and the head turned away from the arm being blocked. To avoid intraneural injection, the block will use both ultrasound and a nerve stimulator (Plexygon, Vygon-Italy) with a 22G 50 mm 20° stimulating needle (Echoplex, Braun-France). A low-frequency ultrasound probe will be placed above the clavicle to visualize the subclavian artery and vein. Using an in-plane approach, the needle will be inserted laterally to medially from the mid-clavicular point through the skin and subcutaneous tissue. Under ultrasound guidance, the needle will be advanced towards the anatomical corner where the brachial plexus and subclavian artery are adjacent (corner pocket), and a local anesthetic agent will be injected to perform the block.
223819598|NCT06428461|DEVICE|Measurement of Optic Nerve Sheath Diameter (ONSD) Using B-Mode Ultrasound|Before the block, both eyes will be measured for optic nerve sheath diameter (ONSD) using B-mode ultrasound (USG) with a GE LOGIQ E device. The patient will be supine with the bed elevated at a 30° angle, eyes closed, and a protective barrier applied. Both globes will be filled with water-soluble ultrasound gel, and imaging will be done with a 7.5 MHz linear probe at a 7 cm depth. For transverse ONSD measurement, the probe will be placed transversely in the coronal plane, with the marker notch pointing right. When the optic nerve entry into the globe is clear, transverse ONSD will be measured 3 mm below. For sagittal measurement, the probe will be placed sagittally in the coronal plane, with the marker notch pointing towards the body. Sagittal ONSD will be measured 3 mm below the entry point. Both internal and external diameters of the optic nerve sheath will be measured in transverse and sagittal planes, and the transverse diameter of the globe will also be measured.
223819599|NCT06428461|DEVICE|Assessment of Peripheral Nerve Block Success Using Perfusion Index Measurement|Investigator plan to measure the Perfusion Index (PI) as an objective method for determining the success of peripheral nerve blocks, different from traditional tests. PI is an indicator of peripheral perfusion that can be continuously measured non-invasively with a pulse oximeter. PI represents the ratio of pulsatile blood flow to non-pulsatile blood flow in peripheral tissue. The Mindray uMEC 12 device will be used for this measurement.
223819600|NCT06428461|DEVICE|End-Tidal Carbon Dioxide (EtCO2) Measurement|End-tidal carbon dioxide (EtCO2) measurement: The Medtronic Capnostream 35 device will be used for EtCO2 measurements. All patients will receive oxygen support at a rate of 1-2 L/min. If peripheral oxygen saturation falls below 95%, oxygen support will be increased to 3-6 L/min via nasal cannula.
223819601|NCT01989286|OTHER|Assessment|The posture, motor development and balance are going to be assessed.
223819602|NCT02437474|BEHAVIORAL|Omnivorous diet|Adopting or continuing the selected diet for 6 months (omnivorous)
223819603|NCT02437474|BEHAVIORAL|Lacto-ovo-vegetarian diet|Adopting or continuing the selected diet for 6 months (lacto-ovo-vegetarian)
223819604|NCT02437474|BEHAVIORAL|Vegan diet|Adopting or continuing the selected diet for 6 months (vegan)
223819605|NCT01408758|OTHER|Virtual Clinician Research Tool (VCRT)|The Virtual Clinician Research Tool (VCRT) will use Self-Determination Theory (SDT) to guide the process or style of how two national guidelines (one for hyperlipidemia, 1 for tobacco dependence)will be operationalized into a virtual format that patients can access online using any internet connected personal computer to develop their plan for change (in this project regarding tobacco or nutrition).
223819606|NCT01408758|OTHER|No VCRT, only physician counseling at visits|No intervention
223819607|NCT00708526|OTHER|standard of care for phase one anesthesia care|Patients received intravenous fentanyl at the discretion of the attending anesthesiologist. Anesthesia was induced with a remifentanil infusion, lidocaine, propofol, and rocuronium or succinylcholine at the anesthesiologist's discretion. Maintenance anesthesia was 6% end tidal desflurane with oxygen flows of 2 L/min (though clinicians could deviate from this at their discretion). Clinicians were directed to maintain blood pressure at ±20% of baseline. A baseline remifentanil infusion was used throughout each case, and both remifentanil and fentanyl were titrated at the anesthesiologist's discretion. Ventilation was adjusted to maintain an end tidal carbon dioxide concentration (EtCO2) of 35 mmHg. Ondansetron 4 mg was given prophylactically before the end of surgery.
223819608|NCT00708526|DEVICE|Quick Emergence Device|The Quick Emergence Device is placed between the endotracheal tube and the anesthesia breathing circuit to enable hypercapnia when ventilation is increased. The end-tidal gas sampling line is connected between the device and the endotracheal tube connector. Minute ventilation is doubled and the EtCO2 is elevated to approximately 48 mmHg from the previous maintenance level of 35 mmHg.
223819609|NCT01828190|OTHER|Hyperbaric oxygen|HBOT will be given for 40 sessions of 2 atmospheres for 90 minutes each session, 5 times a week (2 months). TNF alpha blocker therapy will remain the treatment received before recruitment.
223819610|NCT01381627|DRUG|Remifentanil|Remifentanil IV bolus 0.5 mcg/kg bolus in 10 minutes. Initial bolus followed by infusion 0.05-0.25 mcg/kg/min for OAA/S 2-3. Remifentanil IV bolus 0.3 mcg/kg PRN for time-limited painful stimuli.
223819611|NCT01381627|DRUG|Dexmedetomidine|Dexmedetomidine 0.4 mcg/kg IV bolus in 10 minutes. Dexmedetomidine 0.5-1.0 mcgg/kg/h for OAA/S 2-3. Midazolam 0.015 mg/kg bolus IV PRN.
223819612|NCT01061437|DRUG|PACx14|Standard 14 day, 3 drug regimen: lansoprazole, amoxicillin, clarithromycin (PACx14)
223819613|NCT01061437|DRUG|PACMx5|Concomitant therapy - 5 day, 4 drug regimen: lansoprazole, amoxicillin, clarithromycin, metronidazole (PACMx5)
223819614|NCT01061437|DRUG|PAx5/PCMx5|Sequential Therapy - 10 day, 4-drug regimen: lansoprazole, amoxicillin for 5 days, followed by lansoprazole, clarithromycin and metronidazole for 5 days (PAx5/PCMx5)
223819615|NCT00750100|DRUG|human chorionic gonadotropin|hCG 200IU in the late follicular phase
223819616|NCT00750100|DRUG|recombinant gonadotropins|200 IU per day during controlled ovarian stimulation
223819617|NCT05683106|DEVICE|Custom silicone digital orthosis (CSDO)|Custom silicone digital orthosis (CSDO) will be made under mold to provide realignment of toes, protection or replacement of a segment that was amputated.They will be indicated for corrections of rigid/fixed or flexible toes deformities.CSDO will be constructed using different types of silicone and different hardness considering whether the deformities are rigid or flexible and,when necessary,these components of the orthoses will be merged.Intervention participants will be asked to clean the CSDO and interdigital spaces with soap and water;adequate drying of the fingers and interdigital region;always wear the CSDO with appropriate footwear and socks;keep monitoring the integrity of the CSDO and always communicate any identification of changes in the feet or CSDO.Adverse effects will be evaluated, such as:possible skin irritation; discomfort or pain;contractures;trauma due to friction.Adherence will be verified every 3 months and via telephone contact,monthly.
223819618|NCT01042899|BEHAVIORAL|Teen Online Problem Solving (TOPS)|The TOPS program has 10 sessions that provide training in stress management, problem solving, communication, and social skills to all enrolled families, while the remaining 6 sessions address content related to the stressors and burdens of individual families. Each self-guided online session includes real adolescents talking about how TBI affected them, content regarding the skill, video clips showing adolescents and/or families modeling the skill, and exercises giving the family an opportunity to practice the skill. After the completion of the self-guided web pages, the family will meet with the therapist via videoconference; the therapist will review the exercises and help the family implement the problem-solving process with a problem or goal identified by the family.
223819619|NCT01042899|BEHAVIORAL|Teen Online Problem Solving--Teen Only (TOPS-TO)|TOPS-TO targets the same skills as TOPS and includes largely the same website and intervention content. However, it differs with respect to the extent of family involvement in the sessions. In TOPS-TO, sessions will be conducted with the child or adolescent alone, rather than with the family as whole. Parents will be given access to the TOPS-TO website content via their own password protected site so they will understand the skills that their child is learning. However, only the adolescent, and not the parents, will participate in the synchronous videoconferences with the therapist.
223819620|NCT01042899|BEHAVIORAL|Internet Resources Comparison (IRC)|Families in the IRC group will also receive a computer, printer, and high-speed internet access if they do not currently have these. Additionally, IRC families receive access to a home page of brain injury resources and links (identical to those given on the TOPS and TOPS-TO homepage) but will not be able to access specific session content. This will enable us to equate the groups with respect to access to the information and resources available on the Web.
223819621|NCT00714532|BEHAVIORAL|Expert System Only|Expert system which includes a stage-matched manual, and a series of 3 individualized tailored feedback reports at baseline, 1, and 3 months
223819622|NCT00714532|BEHAVIORAL|Enhanced Expert System|"The intervention consists of 3 components:~* Expert system which includes a stage-matched manual, and a series of 3 individualized tailored feedback reports at baseline, 1, and 3 months~* scheduled smoking intervention, which includes a tailored-made 3-week smoking reduction schedule and a stage-matched tip guide to explain why and how to use the smoking reduction intervention~* telephone check-in calls to provide brief counseling and technical support to motivate participants to use the intervention materials~* a 2-week supply of nicotine gum or lozenge per participants' choice to use during smoking reduction"
223819623|NCT00367913|DRUG|Addition of clarithromycin to rifampicin and ethambutol|
223819624|NCT00367913|DRUG|Addition of Ciprofloxacin to rifampicin and ethambutol|
223819625|NCT00367913|BIOLOGICAL|Vaccination with M.vaccae|
223819626|NCT00805493|DRUG|Riluzole|
223819627|NCT03446105|BEHAVIORAL|App-based behavioral intervention|Achieving Wellness After Kancer in Early life (AWAKE) is a behavioral intervention that includes a smartphone app and coaching. AWAKE contains eight modules, and participants will complete the one module every week. App functioning will facilitate weekly homework assignments and include health education messaging, the ability to track progress toward goals over time via self-monitoring and graphical depictions of progress, audio-recordings of guided imagery exercises and relaxation exercises (e.g., progressive muscle relaxation), videos of topic-related inspirational material, and a portal for interacting with the coach. The coach will call each intervention participant weekly. Each coaching session will last roughly 30 minutes and involve four segments that will correspond to the module for the week. The coach will send daily text messages to participants encouraging their goal pursuits and providing other sources of support related to that week's homework.
223819628|NCT03446105|BEHAVIORAL|Attention control group|The attention control group will receive the same components as the intervention group, but the educational modules will contain different content than those receiving the AWAKE intervention.
223819629|NCT01676532|OTHER|Students attending SBHC|School based health clinic. This is a cohort study as such there is only one group of children who used the SBHC
223819630|NCT02208570|OTHER|PPV>14%|Patients whose preoperative pulse pressure variation during spontaneous ventilation exceed 14
223819631|NCT02208570|DRUG|Volume loading|Hydroxyethyl starch solution 6ml/kg iv injection
223819632|NCT02208570|OTHER|PPV<14%|Patients whose preoperative pulse pressure variation during spontaneous ventilation does not exceed 14
223819633|NCT05065385|DIAGNOSTIC_TEST|INTER-NDA|Neurodevelopmental Screening Test at age 2 years.
223819634|NCT04470219|OTHER|Cognitive support by RemindMe|
223819635|NCT01917305|DEVICE|platform-shifted implant|
223819636|NCT01520389|DRUG|MM-151|MM-151
223819637|NCT01520389|DRUG|MM-151 + irinotecan|MM-151 + irinotecan
223819638|NCT02045433|RADIATION|SABR Boost Therapy|"1. Initial Pelvic (+/- Para-aortic) fractionated external beam Radiation with 45 Gy to combined PTV with a boost to 55Gy for PET positive/CT enlarged nodes;~2. Image Guided Hypofractionated Radiation Treatment boost to Cervix High risk CTV/PTV 28GY/4 fx.~Patients will receive 4 fractions of 7 Gy each via stereotactic body radiation as boost therapy to a volume that encompasses the cervical tumor. A minimum of 40 hours should separate each treatment."
223819639|NCT05340257|DRUG|Augmentin ES|Amoxicillin and clavulanic acid in fixed dose combination will be administered
223819640|NCT05639907|DEVICE|K21 Cavity cleanser|K21 Cavity cleanser is rinsed over the TAD and allowed to dry. The TAD is placed where needed for orthodontic therapy following the Department of Orthodontics protocols.
223819641|NCT05639907|DEVICE|Ethanol control|Ethanol is rinsed over the TAD and allowed to dry. The TAD is placed where needed for orthodontic therapy following the Department of Orthodontics protocols.
223819642|NCT05130255|DRUG|GD2-SADA:177Lu-DOTA Complex|The IMP is a two-step radioimmunotherapy, delivered as two separate products GD2-SADA and 177Lu-DOTA, both will be administered as an IV infusion
223819643|NCT02636972|DRUG|OCPs|"Participants in the contraceptive pill groups can use any one of the following contraceptive pills:~Oestradiol valerate and dienogest, drospirenone and ethinyl estradiol , ethinyloestradiol and levonorgestrel, cyproterone and ethinyl estradiol, ethinylestradiol and norethisterone, Nomegestrol Acetate and Oestradiol and Ethinyl Estra"
223819644|NCT05516225|DRUG|PBCLN-003|Human Milk Oligosaccharide Concentrate
223819645|NCT03542526|DEVICE|electrogradiogram|12 lead ecg ambulatory blood prussre
223819646|NCT03542526|DEVICE|ambulatory blood prussre|ambulatory blood pressure to measure blood pressure
223819647|NCT03654781|DRUG|Triple therapy|triple therapy:a 10-day course of a Lansoprazole (proton pump inhibitor )combined with amoxicillin (2 × 1 g daily) and clarithromycin (2 × 500 mg daily).(trio)
223819648|NCT03654781|PROCEDURE|professional periodontal treatment|periodontal treatment consisting of mechanical periodontal treatment (scaling and root planing) Oral hygiene insruction Periodontal treatment started concurrently with triple therapy
223819649|NCT03270514|DRUG|Exparel Injectable Product|Liposomal bupivacaine 20 cc (226 mg) + Bupivacaine Hydrochloride 0.25% 40 cc (100 mg) + made up to calculated volume with normal saline solution based on the length of the incision and number of chest tubes (20 cc per tube + 20cc per inch of incision)
223819650|NCT03270514|DRUG|Bupivacaine Hydrochloride|Bupivacaine 0.25% 2 mg/kg not to exceed 150 mg - made up to made up to calculated volume with normal saline solution based on the length of the incision and number of chest tubes (20 cc per tube + 20cc per inch of incision)
223819651|NCT03395808|DRUG|Tramadol|IV; 50 mg given at Hours 0, 2, 4, 8 and every 4 hours thereafter, for a total of up to 43 doses
223819652|NCT03781830|OTHER|mHealth Intervention|The video DOT app will allow transplant recipients to see their medication regimen, record themselves taking every dose, report side effects or symptoms, visualize their treatment progress, access educational content, and track appointments. This information is encrypted and transmitted to a HIPAA-secure web portal for providers to review.
223819653|NCT02799303|DEVICE|Multi-parametric MRI|Non contrast magnetic resonance imaging using T1/T2 weighting, DWI and ADC will be performed. MRI images will be reviewed by a single uro-radiologist and assessed using the PiRADs standards.
223819654|NCT02799303|OTHER|PSA testing|Serum prostate specific antigen (PSA) testing will be performed using a standardized laboratory assay.
223819655|NCT05304715|DRUG|Bezlotoxumab|Single intravenous infusion of bezlotoxumab
223819656|NCT05304715|DRUG|Normal saline 0.9% or 5% dextrose water|Single intravenous infusion - Placebo arm
223819657|NCT01942902|DEVICE|Continuous Glucose Monitoring System|
223819658|NCT00813696|DRUG|gemcitabine|1000 mg/m2 IV weekly for 7 weeks. Starting at week 9, gemcitabine 1000 mg/m2 on days 1, 8, and 15 every 4 weeks
223819659|NCT00813696|DRUG|cisplatin|25 mg/m2 IV on days 1, 8, and 15 every 4 weeks
223819660|NCT01614639|PROCEDURE|Acupuncture|A licensed acupuncturist will perform acupuncture for two 30 minute sessions.
223819661|NCT01654991|BEHAVIORAL|Home Screening|Home-based STD screening using self-obtained urine samples and study paid postal return of samples.
223819662|NCT01654991|BEHAVIORAL|Clinic Screening|Clinic-based STD screening using self-obtained urine samples in a local university clinical setting.
223819663|NCT03434002|OTHER|Training by Virtual Reality Simulation|Those Randomized 15 residents will be receive Local Anesthetic Systemic Toxicity simulation training by Virtual Reality simulation and after two weeks, they will be evaluated by investigators by using the same performance evaluation tool.
223819664|NCT03434002|OTHER|Training by Mannequin Based Simulation|Randomized other 15 residents will be receive Local Anesthetic Systemic Toxicity simulation training by mannequin based simulation and after two weeks, they will be evaluated by investigators by using the same performance evaluation tool.
223819665|NCT05099913|DRUG|Deanxit|Central neuromodulators was applied in refractory FD patients for different time
223819666|NCT02372760|DEVICE|BA by spray catheter (Olympus PW-205V)|This group will be having the bronchoscopic anesthesia (lidocaine) injected through the spray catheter (Olympus PW-205V)
223819667|NCT02372760|OTHER|BA classic anesthesia|This group will have the bronchoscopic anesthesia (lidocaine) injected through the bronchoscope's working channel.
223819668|NCT02372760|DRUG|Anesthesia|Both groups will receive lidocaine as the anesthesia for bronchoscopy
223819669|NCT03697382|BEHAVIORAL|Very Low Steps|Subjects will have a 2-day control period during which step count and diet will be controlled for and recreated for the other trials. Following this 2-day period, they will undergo the Very Low Stepping trial with the acute bout of exercise on day 2. Day 3 will consist of the lipid tolerance test to determine the ability of the body to clear triglycerides.
223819670|NCT03697382|BEHAVIORAL|Low Steps|Subjects will have a 2-day control period during which step count and diet will be controlled for and recreated for the other trials. Following this 2-day period, they will undergo the Low Stepping trial with the acute bout of exercise on day 2. Day 3 will consist of the lipid tolerance test to determine the ability of the body to clear triglycerides.
223819671|NCT03697382|BEHAVIORAL|Moderate Steps|Subjects will have a 2-day control period during which step count and diet will be controlled for and recreated for the other trials. Following this 2-day period, they will undergo the Moderate Stepping trial with the acute bout of exercise on day 2. Day 3 will consist of the lipid tolerance test to determine the ability of the body to clear triglycerides.
223819672|NCT00409786|BEHAVIORAL|Virtual Lifestyle Management (VLM)|16 weekly lessons followed by monthly maintenance lessons
223819673|NCT01884714|OTHER|High fat/high calorie meal|All subjects are provided a high calorie (\~1300kcal) and high fat (\~60g fat) breakfast meal.
223819674|NCT05672303|BEHAVIORAL|Palmar grasp reflex|The reflex can be stimulated by moving an object distally across the palm. In the study, at the beginning of the vaccine administration, the right hand of the infant will be moved distally along the palm with the researcher's index finger, thus providing reflex stimulation.
223819675|NCT06437730|OTHER|Integrated Neuromuscular Inhibition Technique:|MTrPs points will be released with ischemic compression, position of ease will be acquired, and in the last METs will be performed. Ischemic compression applied through thumb on trigger point present in any muscle around the knee joint. Compression will be increased gradually until first resistance will feel and maintained until it resolves, further increases then until no tissue resistance will be felt under thumb. This process is maintained for 30sec and repeated 3-5 times per session. Positional release technique: after applying pressure on trigger point, patient will acquire position of ease that is maintained for 20 sec whether its extension or flexion of knee. This process is repeated 3-5 times per session. Muscle Energy Technique will be applied on the muscle in which isometric contraction is maintained for 7-10sec against 20-25% strength. After completion of muscular contraction, the limb is moved away for muscular stretch and then position is maintained for 30 seconds
223819676|NCT06437730|OTHER|Dry needling:|"Dry needle will be targeting trigger points (TrPs) using in-and-out techniques such as 'pistoning' or 'sparrow pecking'. 0.25x25mm needle is inserted.~For vastus laterals patient is supine line with knee extended performing an isometric quadriceps contraction, maintaining a clean technique by using gloves and performing an alcohol wipe down bracket the tissue to be treated and inserting needle with direct approach towards the femur, performing pistoning. For vastus medialis patient is supine line with 30 degrees of knee flexion. A headless 0.25x25mm needle fixed between the fingers of non-dominant hand and inserted perpendicularly to the MTrPs with metacarpophalangeal flexion extension of 1st and 2nd fingers of dominant hand. For Gastrocnemius patient is prone lying and bolstered supported slight knee bend, for the upper part anterior medial approach is used and center of muscle belly slight medial anterior approach is used."
223819677|NCT05268575|OTHER|performing endoscopy|Hemorrhoids will be treated by endoscopic sclerotherapy or endoscopic rubber band ligation or endoscopic sclerotherapy combined with rubber band ligation
223819678|NCT05594849|DRUG|Budesonide Orodispersible Tablets (Jorveza)|Patients that swith to Budesonide Orodispersible Tablets (Jorveza)
223819679|NCT05165953|OTHER|no intervention|there was no intervention in the study
223819680|NCT05344261|PROCEDURE|Targeted Muscle Re-innervation|Targeted Muscle Re-innervation involves re-routing transected nerve ends to functional motor nerves proximal to the site of amputation.
223819681|NCT05344261|PROCEDURE|Regenerative Peripheral Nerve Interface|Regenerative Peripheral Nerve Interface involves placing transected nerve ends in harvested muscle grafts.
223819682|NCT05344261|PROCEDURE|Standard Post-Amputation Surgical Care|Standard post-amputation surgical care involves placing transected nerve ends into muscle/soft tissue proximal to the site of amputation.
223819683|NCT05603988|DEVICE|Intracanal Diode laser irradiation|After endodontic retreatment, root canals will be irradiated with a 980 nm diode laser coupled with optical fibre 200 μm (Litemedics, Italy) with setting 1.2-watt power, in pulsed mode. The irradiation protocol will be of 5-sec irradiation followed by a 10-sec pause, which constituted one lasing cycle. The lasing cycle will be performed four times for each tooth. The tip will be positioned 1 mm short of the apex. Followed by activation during which it will be slowly dragged at a speed of approximately 2 mm/ sec in a way that the root canals will be irradiated from the apical to the coronal portion, in a helicoidal movement touching the canal walls.
223819684|NCT05603988|OTHER|Placebo|"After endodontic retreatment, mock laser application (Placebo group) will be applied:~The fiberoptic tip will be inserted inside the root canal, mimicking the laser irradiation group, but not activated"
223819685|NCT03584893|PROCEDURE|Blood sampling for Cholestanol Analysis|Cholestanol analysis will be performed to see the Rate of juvenile cataract patients whose cholestanol test result is above threshold (3.75 mg/mL) and suspected CTX cases
223819686|NCT01349413|DRUG|Esomeprazole 20mg|Oral Esomeprazole 20mg daily for 8 weeks
223819687|NCT01349413|OTHER|Placebo|Identical looking placebo
223819688|NCT06139874|BEHAVIORAL|THRIVE|Early intervention for depression that directly targets developing affective systems and builds on the empirical literature on emotion development and prevention.
223819689|NCT06139874|BEHAVIORAL|Parenting Wisely|Online asynchronous parenting program.
223819690|NCT04508556|DEVICE|Breath Biopsy face masks with removable filters and fitted PVA strip|Device developed for collection of breath samples
223819691|NCT04508556|DIAGNOSTIC_TEST|Nasopharyngeal swab|Is a method for collecting a clinical test sample of nasal secretions from the back of the nose and throat.
223819692|NCT04508556|DIAGNOSTIC_TEST|oropharyngeal swabs|Is a method for collecting a clinical test sample from the back of the throat.
223819693|NCT00219440|OTHER|Actos plus standard diet|Actos plus standard diet
223819694|NCT00219440|OTHER|Actos plus structured diet|Actos plus structured diet
223819695|NCT00219440|OTHER|Metformin plus standard diet|Metformin plus standard diet
223819696|NCT02761655|BEHAVIORAL|Memory Strategies|Memory strategies on encoding retention, retrieval, execution and monitoring
223819697|NCT03719053|DRUG|Tenofovir|pre- and post-dosing measurements of TFV and TFV-DP in plasma and PBMCs.
223819698|NCT03207217|OTHER|Web-based training Product|A series of 4 modules to train providers to more effectively manage patients who screen positive for risk of suicide. The modules are: Risk Assessment, Safety Planning, Access to Lethal Means, and Willingness to accept referral.
223819699|NCT01960647|DEVICE|Percutaneous transluminal angioplasty with uncoated balloon|
223819700|NCT01960647|DEVICE|Percutaneous transluminal angioplasty with Paclitaxel balloon|
223819701|NCT00498563|PROCEDURE|altitude exposure in hypobaric chamber|
223819702|NCT01898702|BEHAVIORAL|Diabetes expert patients programme|Nine-weekly informative and educational sessions by a teaching patient who has experience on diabetes
223819703|NCT06450717|DEVICE|Khymeia VRRS|VRRS is an electronic device for remote rehabilitation of cognitive (e.g., memory, attention, spatial perception, logical-mathematical skills, language, executive functions...) and motor (gross and fine motor skills) functions. It can be used in on-line and off-line mode at home, and the exercises are chosen by the therapist according to the patient's specific difficulties and needs from a cognitive and motor library.
223819704|NCT04340128|DRUG|Meglumine antimoniate|Intra-lesional injection once a week, 0.1/cm2
223819705|NCT04340128|DRUG|Meglumine antimoniate|Intra-lesional injection twice a week, 0.1/cm2
223819706|NCT03138174|DEVICE|OneTouch Verio Flex Blood Glucose Monitoring System|Blood Glucose Monitoring System
223819707|NCT01896635|BIOLOGICAL|FMT infusions|Active FMT derived from healthy anonymous pre-screened donors
223819708|NCT01896635|OTHER|Placebo infusion|Placebo infusion not containing any donor microbial material
223819709|NCT04477421|PROCEDURE|FS-SMILE|Femtosecond small incision lenticule extraction
223819710|NCT04477421|PROCEDURE|S-LASIK|Femtosecond laser Insitu keratomileusis
223819711|NCT00154310|DRUG|Everolimus|Everolimus tablets orally twice a day to maintain a level of 6- 10 ng/mL.
223819712|NCT00154310|DRUG|Cyclosporine|Tablets orally twice a day to maintain protocol specific target blood levels
223819713|NCT00154310|DRUG|Enteric-coated mycophenolate sodium|Enteric-coated mycophenolate sodium orally twice a day to achieve a target dose of 1440 mg/day.
223819714|NCT00154310|DRUG|Corticosteroids|Corticosteroids were added to the immunosuppressive regimen with a minimum dose of 5mg prednisolone or equivalent and had to be continued throughout the first year.
223819715|NCT04125524|DIAGNOSTIC_TEST|Terahertz metamaterials|A diagnostic test used to identify specific tumour markers will be carried out on serum samples using terahertz metamaterials.
223819716|NCT04399356|DRUG|Niclosamide|Participants in the treatment arm will receive Niclosamide 2 grams orally once daily for 7 days in addition to current standard of care treatment. Oropharyngeal swab samples will be collected for viral shedding as measured by PCR on days 3, 7, 10, 14. Fecal samples will be collected for viral shedding as measured by PCR on days 3, 7, 10, 14, 21. A baseline fecal and oropharyngeal sample will be obtained on Day 1 prior to starting dosing of Niclosamide/ placebo.
223819717|NCT04399356|DRUG|Placebo|The collection of oropharyngeal samples will be observed by a Study Team member via the telehealth platform.
223819718|NCT04399356|OTHER|Telehealth monitoring|In addition to Niclosamide or placebo treatments, all enrolled patients will be provided a home thermometer as well as a fingertip probe pulse oximeter, with the specific instructions to monitor both temperature at oxygen saturation at the time of daily oral administration of drug. The collection of oropharyngeal samples will be directly observed by a Study Team member via the telehealth platform.
223819719|NCT00790153|DRUG|Insulin|Insulin infusion given during 3 hours at one occasion.
223819720|NCT00790153|DRUG|AZD1656|Single dose oral suspension given at one occasion.
223819721|NCT05730790|OTHER|Cognitive-motor dual task training (DTT)|"For session 1 to 3, the training comprises of 4 cycles of the following: 2 min dual tasking, 2 min rest, 2 min dual tasking, 2 min rest. For session 4 to 6, the training comprises of 4 cycles of the following: 2.5 min dual tasking, 1.5 min rest, 2.5 min dual tasking, 1.5 min rest. For session 7 to 14, the training comprises of 4 cycles of the following: 3 min dual tasking, 1 min rest, 3 min dual tasking, 1 min rest. The treadmill speed is maintained at 40%, 50% and 60% of participant's original gait speed at session 1 to 3, 4 to 6, and 7 to 14 respectively.~There are 10 levels in the VR game. Participant will start at level 1 of VR game at session 1 and can progress to the next level at the subsequent session if game percentage \> 80%."
223819722|NCT05730790|OTHER|Cognitive single task training (CSTT)|"For session 1 to 3, the training comprises of 4 cycles of the following: 2 min VR gaming, 2 min rest, 2 min VR gaming and 2 min rest. For session 4 to 6, the training comprises of 4 cycles of the following: 2.5 min VR gaming, 1.5 min rest, 2.5 min VR gaming and 1.5 min rest. For session 7 to 14, the training comprises of 4 cycles of the following: 3 min VR gaming, 1 min rest, 3 min VR gaming and 1 min rest.~There are 10 levels in the VR game. Participant will start at level 1 of VR game at session 1 and can progress to the next level at the subsequent session if game percentage \> 80%."
223819723|NCT05730790|OTHER|Motor single task training (MSTT)|For session 1 to 3, the training comprises of 4 cycles of the following: 8 min treadmill walking at 40% of participant's original gait speed followed by 2 min rest. For session 4 to 6, the training comprises of 4 cycles of the following: 8 min treadmill walking at 50% of participant's original gait speed followed by 2 min rest. For session 7 to 14, the training comprises of 4 cycles of the following: 8 min treadmill walking at 60% of the participant's original gait speed followed by 2 min rest.
223819724|NCT00961025|DRUG|DA-1229|"single dose study : DA-1229 1.25,2.5,5,10,20,40,60mg~multiple dose study : DA-1229 5,10,20,40mg"
223819725|NCT00961025|DRUG|Placebo|placebo
223819726|NCT04458623|DIAGNOSTIC_TEST|Air Test|.The Air-Test may represent an accurate, simple, inexpensive and non-invasive method for diagnosing postoperative atelectasis.
223819727|NCT02875275|OTHER|Glucose with grass jelly solution|50 g glucose and 3.12 g grass jelly dissolve in water (top up to 200g)
223819728|NCT02875275|OTHER|Glucose with grass jelly (solid)|50 g glucose and 3.12 g grass jelly and 3.12g starch dissolve in hot water (top up to 200g)
223819729|NCT02875275|OTHER|Porridge and juice with coconut oil|Add instant porridge with hot water with oil. Consume with commercially available orange juice
223819730|NCT02875275|OTHER|Porridge and juice with coconut oil gel|Add instant porridge with hot water with oleogel. Consume with commercially available orange juice
223819731|NCT02833441|BEHAVIORAL|Peer Support|
223819732|NCT02478346|DRUG|Fluorescein Sodium|Conventional microsurgical and biopsy procedures and techniques including histopathology and intraoperative imaging will be performed through the completion of the surgery. The surgeon will resect and remove what he believes is the tumor based on previously known criteria (standards of care) regardless of what the Fluorescein angiography demonstrates. For vascular lesions, fluorescein sodium 10% (100mg/1mL) will be injected and used to assess its application after the conventional methods have confirmed the exclusion of the aneurysm. No patient's care will be affected by the results of the Fluorescein angiography.
223819733|NCT01250964|PROCEDURE|Lens insertion during cataract surgery|After cataract removal during cataract surgery, a lens needs to be injected into the eye. Both arms are routinely used but different methods for injecting the lens.
223819734|NCT06160622|DRUG|Leritrelvir|Oral
223819735|NCT05872529|BEHAVIORAL|Education|The education which consists processed EEG monitoring and SBI approach
223819736|NCT02321280|DRUG|Denosumab|Single dose subcutaneous administration
223819737|NCT03247374|DEVICE|"ProComp5 Infiniti Biofeedback"|"Each participant will attend 5 sessions per week for a total duration of 5 weeks. At the beginning of the bio-feedback session, a surface electrode will be applied to the mylohyoid muscle. The computer will produce visual feedback of the muscular activity on the screen. The patient will be required to swallow at a given time, with food bolus if possible, and perform maneuvers that favour swallowing strength and efficacy: they are requested to do classical maneuvers that favour swallowing efficacy that is effortful swallow, supraglottic swallow, and Masako maneuver. The experimental group will perform this training for 45 minutes."
223819738|NCT03247374|OTHER|Standard Speech and Language Therapy|"Each participant will attend 5 sessions per week for a total duration of 5 weeks. The patient will be required to swallow at a given time, with food bolus if possible, and perform maneuvers that favour swallowing strength and efficacy receiving verbal feedback from the speech and language therapist. They are requested to do classical maneuvers that favour swallowing efficacy that is effortful swallow, supraglottic swallow, and Masako maneuver. The control group will perform this training for 45 minutes."
223819739|NCT02689934|DIETARY_SUPPLEMENT|Lactoflorene colesterolo|1.8 g + 1.8 g once a day per os
223819740|NCT02689934|DIETARY_SUPPLEMENT|Placebo lactoflorene colesterolo|1.8 g + 1.8 g once a day per os
223819741|NCT05363657|PROCEDURE|Partial Nephrectomy (PN)|Conservative removal of kidney tumor. The procedure can be performed either with an open or laparoscopic or robotic approach.
223819742|NCT05363657|PROCEDURE|Radical Nephrectomy (RN)|Surgical removal of the affected kidney. Adrenal removal can be performed according to surgeon choice and clinical characteristics of the renal tumor. The procedure can be performed either with an open or laparoscopic or robotic approach.
223819743|NCT05363657|PROCEDURE|Ablation therapy (AT)|The procedure of tumor ablation performed with radiofrequency or cryoablation. The procedure can be performed either with a laparoscopic approach or percutaneous access.
223819744|NCT05363657|DIAGNOSTIC_TEST|Active Surveillance (AS)|Active surveillance is defined as the initial management including the monitoring of renal tumor size by serial imaging with delayed treatment in case of progression.
223819745|NCT03735160|DEVICE|pressure sensor|Pressure sensor at the angle of intratracheal tube and nasal alar
223819746|NCT02235363|PROCEDURE|thread lift|In facial rejuvenating surgery, the current trend calls for fewer and less noticeable scars with desired results. Especially to improve the jowls and nasolabial folds, the thread lift is a simple and inexpensive technique for patients who do not wish to undergo the typical facelift surgery, but the weak points of it are less effective and shorter duration than the conventional facelift.The investigators propose the new method of the thread lifting the subdermal and subcutaneous layer by use of the retaining ligaments with two fixation points on both temporal fascia and retaining ligaments.
223819747|NCT00612157|DRUG|Eszopiclone|Eszopiclone 3mg orally at bedtime for 14 nights
223819748|NCT00612157|DRUG|Placebo control|Matching placebo
223819749|NCT00305500|DRUG|escitalopram|
223819750|NCT02853461|OTHER|Sonication|Ultrasound bath (40 kHz, 1 W/cm2, 1 min) of bearing components of the prosthesis in sterile conditions.
223819751|NCT02853461|OTHER|Microbiological analysis|Plating the sonicates on agar plates.
223819752|NCT04508296|DIAGNOSTIC_TEST|Goal directed de-escalation therapy|Patients received de-escalation fluid management using either diuretics or ultrafiltration during continuous RRT in the case of GEDVI \> 650 mL/m2 or EVLWI \> 10 mL/kg depending on the randomization group. The primary goal of de-escalation was to obtain a cumulative fluid balance after 48 hrs from the study baseline of 0 to -3000 mL. In the case of GEDVI \< 650 mL/m2 or EVLWI \< 10 mL/kg, the target fluid balance was in the range of 0 to +3000 mL
223819753|NCT04566302|DEVICE|SECM Skin Imaging|Consented Participants will be asked to allow their forearm to be imaged by the dermatoscope on the same skin/lesions as a control comparison. We will be trying to image pigmented skin/lesions present on the forearm. This will be followed by imaging using the SECM Skin imaging device
223819754|NCT00965796|DRUG|Lidocaine|Lidocaine 2 mg/kg/h- during surgical procedure Saline
223819755|NCT02111226|OTHER|SMS text messaging|short message service
223819756|NCT05822336|OTHER|Duration of Intramuscular Injections|This study was a single-group crossover clinical trial, where each participant acted as their own control. Two intramuscular injections into the right and left Dorsal Gluteal Region (DRG) were recorded for each participant. One was administered by a nurse, according to the unit's routine, and took 5 seconds to complete. A day after, the same nurse gave the other injection in the opposite DGR, taking 40 seconds to administer. The five-second injections were considered the control group, while the 40 seconds injections were the intervention group. The order of interventions was randomized. The pain level was determined and recorded immediately after each injection.
223819757|NCT05885919|DRUG|Edaravone Dexborneol Concentrated Solution for injection|Edaravone and Dexborneol Concentrated Solution for Injection, 15 ml (37.5 mg, containing edaravone 30 mg and dexborneol 7.5 mg) in 3 ampoule bottles, twice a day for 10 to 14 days.
223819758|NCT05885919|DRUG|Edaravone Dexborneol placebo|Edaravone and Dexborneol placebo, 15 ml in 3 ampoule bottles, twice a day for 10 to 14 days.
223819759|NCT06383325|COMBINATION_PRODUCT|Chemotherapy|Detection of hepatotoxicity in acute leukemia patients during chemotherapy
223819760|NCT06444022|BIOLOGICAL|Human amniotic epithelial stem cells（hAESCs）|Human Amniotic Epithelial Cells Prevent Acute Graft-versus-host Disease After Hematopoietic Stem Cell Transplantation (hAECs-GVHD)
223819761|NCT06444022|BIOLOGICAL|placebo (cell preservation solution)|Same dose placebo (cell preservation solution) injections as control group
223819762|NCT01028261|DRUG|ZGN-433|Subjects will receive placebo or ZGN-433 twice weekly over 6 weeks treatment period for a total of 12 doses. A range of doses will be evaluated.
223819763|NCT01850368|RADIATION|Stereotactic ablative radiotherapy|"The HCC patients with major portal vein tumor thrombosis (tumor thrombosis in the main portal vein or 1st branch of portal vein) will be included in this study. Total stereotactic ablative radiotherapy (SABR) doses will be 40 Gy in 4 fractionations. Patients receive 4 fractionations separated by \>48 hours.~At least 700 ml of normal liver (entire liver minus cumulative GTV) should not receive a total dose of \> 19.2 Gy in three fractions. If volume of normal liver does not exceed 700 ml, at least 70% of normal liver should not receive a total dose of \> 19.2 Gy. Dose of spinal cord do not exceed 26 Gy. Dose of esophagus, stomach and intestine do not exceed 35 Gy."
223819764|NCT05437354|OTHER|survey|Oncology medical staff should respond to a survey
223819765|NCT05016544|DRUG|inetetamab|All dose levels will receive 8 mg/kg loading dose for cycle 1, followed by 6 mg/kg in subsequent cycles, every 3 weeks.
223819766|NCT05016544|DRUG|Pytotinib|"Starting pytotinib Dose of 240mg:~Cohort 1: pyrotinib 240mg p.o. d1 to d21, q3w; Cohort 2: pyrotinib 320mg p.o. d1 to d21, q3w; Cohort 3: pyrotinib 400mg p.o. d1 to d21, q3w."
223819767|NCT01678820|DRUG|Sitagliptin/Simvastatin FDC|Sitagliptin 100 mg/Simvastatin 40 mg fixed-dose combination tablet
223819768|NCT01678820|DRUG|Sitagliptin|Sitagliptin 100 mg tablet
223819769|NCT01678820|DRUG|Simvastatin|Simvastatin 40 mg tablet
223819770|NCT01678820|DRUG|Placebo to sitagliptin|Matching placebo to sitagliptin 100 mg tablet
223819771|NCT01678820|DRUG|Placebo to simvastatin|Matching placebo to simvastatin 40 mg tablet
223819772|NCT01678820|DRUG|Placebo to Sitagliptin/Simvastatin FDC|Matching placebo to sitagliptin 100 mg/simvastatin 40 mg FDC tablet
223819773|NCT01678820|DRUG|Metformin|Participants will continue on their stable, pre-screening metformin daily dose of \>= 1500 mg for at least 12 weeks prior to randomization and during the study
223819774|NCT01678820|DRUG|Glimepiride|Following randomization, participants requiring glycemic rescue may receive open-label glimepiride initiated at a dose of 1 mg/day or 2 mg/day which may be up-titrated to 6 mg/day taken once daily with breakfast or the first main meal of the day.
223819775|NCT05815732|OTHER|Physical exercise|Personalized exercise program, with defined modalities, intensity, duration, frequency and progression of the exercise.
223819776|NCT01335503|DIETARY_SUPPLEMENT|AN-PEP|Endoprotease enzyme (AN-PEP)
223819777|NCT06249490|BEHAVIORAL|routine rehabilitation treatment|All participants were given routine rehabilitation treatment by professional rehabilitation therapists, including exercise therapy, guided education, psychological therapy, acupuncture and massage therapy
223819778|NCT06249490|DEVICE|Stellate ganglion block|The patients were provided with Stellate ganglion block , using 0.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate ganglion block . The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
223819779|NCT06249490|DRUG|Lidocaine Hydrochloride Injection|The patients were provided with Stellate ganglion block , using 0.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate ganglion block . The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
223819780|NCT02749851|DEVICE|MRI|Recently-developed placenta-specific magnetic resonance imaging (MRI) tools will be used to quantify maternal perfusion and oxygen transfer throughout pregnancy in 3 groups of human subjects: 1) non-smokers, 2) smokers, 3) individuals at high risk for adverse outcome. The objective of this work is to develop a new non-invasive clinical tool for early identification of placental dysfunction.
223819781|NCT02749851|DEVICE|MRI - IUGR|Recently-developed placenta-specific magnetic resonance imaging (MRI) tools will be used to quantify maternal perfusion and oxygen transfer throughout pregnancy. The objective of this ancillary arm is to further test the sensitivity of placental magnetic resonance imaging to detect abnormal perfusion and oxygenation in confirmed cases of IUGR between gestational ages 28 to 36 weeks.
223819782|NCT00247819|PROCEDURE|Blood draw|
223819783|NCT01536041|DRUG|ONO-6950|200 mg QD, single dose
223819784|NCT01536041|DRUG|ONO-6950|20 mg QD, single dose
223819785|NCT01536041|DRUG|Montelukast|10 mg Montelukast, QD single dose
223819786|NCT01536041|DRUG|Placebo|Placebo to match ONO-6950 tablets or leukotriene receptor antagonist (LTRA) tablets dosed in a similar manner
223819787|NCT00133939|PROCEDURE|Mechanical ventilation|
223819788|NCT02019134|BEHAVIORAL|relaxation exercise|relaxation exercise
223819789|NCT02019134|OTHER|ususal care|
223819790|NCT03395249|DRUG|SPR994|"SAD: Double-blind dosing will occur in all SAD Cohorts except for Cohort 12. In each cohort, six subjects will receive one of five different timed release formulations of SPR994 and 2 subjects will receive placebo. Subjects in SAD Cohorts 2, 3, 6, 16 and 17 will receive a single dose following a 10-h fast. Subjects in SAD Cohorts 1, 8-15 will receive one dose of SPR994 or placebo following a 10-h fast on Day 1 and a second dose following consumption of a standardized meal on Day 7. The dose escalation steps may be altered following review of the safety data of each cohort.~MAD: Double-blind dosing will occur in all MAD Cohorts. Subjects will receive multiple doses of an optimal timed release formulation of SPR994 in MAD Cohort 4 (300 mg) and Cohort 5 (600 mg) or placebo for 14 consecutive days at either BID or TID dosing beginning on Day 1."
223819791|NCT03395249|DRUG|Placebo Oral Tablet|Mannitol 200SD SAD: Two subjects in each cohort will receive matching placebo. MAD: Two participants in each cohort will receive matching placebo.
223819792|NCT03395249|DRUG|Orapenem®|Tebipenem pivoxil granules
223819793|NCT03278301|DEVICE|Robotic-assisted PCI|The CorPath GRX is intended for use in the remote delivery and manipulation of guidewires and rapid exchange balloon/stent catheters, and remote manipulation of guide catheters during percutaneous coronary intervention (PCI) procedures.
223819794|NCT04476420|DIETARY_SUPPLEMENT|Nigella sativa oil|Using N.sativa oil as an alternative to conventional management will help us to find a treatment option which is non-invasive, cost effective, inexpensive, easy available and belongs to a natural source with almost no side effects.
223819795|NCT04476420|DRUG|Betamethasone Valerate|it is a conventionally used drug for treating OSMF
223819796|NCT04524728|DRUG|Palbociclib|tablets
223819797|NCT04524728|DRUG|Letrozole 2.5mg|tablets
223819798|NCT04524728|DRUG|Fulvestrant|intramuscolar injections
223819799|NCT04530539|DIETARY_SUPPLEMENT|Vitamin C|1000mg Vitamin C, at bedtime
223819800|NCT04530539|DIETARY_SUPPLEMENT|melatonin|10mg melatonin, at bedtime
223819801|NCT04530539|DIETARY_SUPPLEMENT|Placebo|Placebo at bedtime
223819802|NCT04530539|OTHER|Symptom Survey|Daily symptom survey to be completed by patient electronically
223819803|NCT04071119|DRUG|Oxytocin nasal spray|Participants administer the oxytocin (40 IU) twice a day for 5 - 7 days
223819804|NCT04071119|DRUG|Placebo|Participants administer the placebo (40 IU) twice a day for 5 - 7 days
223819805|NCT03900377|DRUG|SyB L-0501RI|The specified dose of SyB L-0501RI and rituximab will be administered by intravenous rapid infusion over 10 minutes on specified days.
223819806|NCT00175461|PROCEDURE|hip surgery|Comparison of the clinical effectiveness and cost-effectiveness of the MIS anterolateral approach (MIS Watson Jones, G3) versus anterolateral mini or posterolateral mini approaches in primary total hip arthroplasty
223819807|NCT01247519|OTHER|Post-hospitalization care|Post-hospitalization care included telephone call contact for caring after discharge, for opening for question, and for health education.
223819808|NCT00829205|BIOLOGICAL|filgrastim|
223819809|NCT00829205|BIOLOGICAL|rituximab|
223819810|NCT00829205|DIETARY_SUPPLEMENT|Se-methyl-seleno-L-cysteine|
223819811|NCT00829205|DRUG|carboplatin|
223819812|NCT00829205|DRUG|etoposide|
223819813|NCT00829205|DRUG|ifosfamide|
223819814|NCT00829205|OTHER|laboratory biomarker analysis|
223819815|NCT00829205|OTHER|pharmacological study|
223819816|NCT06062940|BEHAVIORAL|SHARE Approach|The SHARE Approach training was given at each of these centers, teaching skills to clinicians about shared decision making.
223819817|NCT00668499|DRUG|VEGF-Antisense Oligonucleotide , Pemetrexed, Cisplatin|VEGF-AS either 100 or 200mg/m2 IV days 1-5, Pemetrexed 500mg/m2 and Cisplatin 75mg/m2 IV on day 1. Cycle repeated every 3 weeks until 6 cycles completed, unless PD or toxicities
223819818|NCT04219722|DEVICE|Injection of DESIRIAL®|"DESIRIAL® is a hyaluronic acid injectable gel intended to treat symptoms associated with vulvovaginal atrophy in postmenopausal women by vaginal mucosa rehydration in this study.~1 mL of DESIRIAL® will be injected in the vestibule and on the posterior and lateral walls of the vagina, 2 to 3 cm after the introitus."
223819819|NCT04219722|OTHER|Injection of placebo|"Placebo is an isotonic saline solution (0.9% NaCl).~1 mL of placebo will be injected in the vestibule and on the posterior and lateral walls of the vagina, 2 to 3 cm after the introitus."
223819820|NCT03447730|DRUG|SYNB1020|SYNB1020 was supplied at a concentration of approximately 1 × 10\^11 CFU/mL in a buffered solution in 5 mL cryovials with a nominal 5 mL fill volume, administered with 100 mL of masking buffer solution.
223819821|NCT03447730|OTHER|Placebo|Subjects received placebo orally in a chilled buffered solution (100 mL).
223819822|NCT01187329|OTHER|hyperinsulinemic normoglycemic clamp (HNC)|Prior to anesthetic induction, a baseline blood glucose value will be obtained, followed by an insulin infusion of 5 mU.Kg-1.min-1. When blood glucose is \<110 mg/dL, a variable continuous infusion of glucose (dextrose 20%) supplemented with potassium (40 mEq/L) and phosphate (30 mmol/L) is administered to preserve normoglycemia (80-110 mg/dL). The glucose infusion is titrated to target glucose levels by checking blood glucose every 5 - 15 min with Accu-Check (Roche Diagnostics, Switzerland) glucose monitor. At sternal closure, insulin infusion is decreased to 1 mU/Kg/min. On admission to the ICU, insulin treatment follows the ICU protocol. The dextrose infusion is slowly weaned off over 2 - 4 hrs maintaining blood glucose \> 80 mg/dL. Arterial blood glucose is measured every 30 - 60 min for 2 hrs, then, as stated in ICU protocol.
223819823|NCT01187329|OTHER|control group|Baseline arterial blood glucose will be obtained before anesthetic induction. Repeat measurements are performed every 30-90 min. Glucose \>150 on CPB will receive insulin according to intraoperative protocol. After surgery, insulin is given according to ICU protocol. Target glucose \< 180 mg/dL.
223819824|NCT03115749|OTHER|Intestinal biopsies during colonoscopy|Intestinal biopsies during colonoscopy
223819825|NCT03115749|OTHER|Biopsies taken on surgical specimen|biopsies taken on surgical specimen after intestinal resection
223819826|NCT02419729|DEVICE|CO2 laser|SMARTXIDE2 V2LR (DEKA-Pulse) was used in each application using minimal parameters suggested by the laser's software ( Power of 30 W, 1000us emission time, 1000um spacing and a level of SmartStack 2)
223819827|NCT02419729|DRUG|Estrogen|Topical estrogen cream treatment: Estriol 1mg daily.
223819828|NCT02419729|DRUG|Placebo of Estrogen|Placebo of topical estrogen cream.
223819829|NCT02419729|DEVICE|Placebo of CO2 laser|SMARTXIDE2 V2LR (DEKA-Pulse) was used in each applications using minimal parameters suggested by the laser's software but power of 0.5 W was stipulated for the placebo intervention and other parameters remained unchanged.
223819830|NCT02501213|DRUG|Spironolactone (+/- Furosemide)|Administration of spironolactone alone 100 mg/day each morning, increased in increments of 100 mg / week to a maximum of 400 mg / day in the absence of efficiency. In case of ineffectiveness or hyperkalemia: addition of Furosemide 40 mg / day increased in increments of 40 mg / week to a maximum of 160 mg / day in the absence of efficiency.
223819831|NCT01994356|BEHAVIORAL|Physician self-disclosure of personal IUC use|Physicians self-disclosed personal intrauterine contraceptive use to subjects in intervention arm of study during contraceptive counseling
223819832|NCT01994356|BEHAVIORAL|Usual contraceptive counseling|all subjects recieved usual contraceptive counseling
223819833|NCT03869515|OTHER|No intervention|It's an observational study, so no intervention will be carried out.
223819834|NCT02611544|BEHAVIORAL|Acceptance and Commitment Therapy|6-week ACT intervention group (n=33)
223819835|NCT02611544|BEHAVIORAL|Survivorship Education|6-week survivorship education group (SE; n=32)
223819836|NCT02611544|BEHAVIORAL|Enhanced Usual Care|enhanced usual care (EUC; n=26)
223819837|NCT01350505|BEHAVIORAL|White light exposure|\~200 lux of broad spectrum white light
223819838|NCT01350505|BEHAVIORAL|Dim white light exposure|\~28 lux of broad spectrum white light
223819839|NCT01350505|BEHAVIORAL|Very dim white light exposure|\<0.5 lux of broad spectrum white light
223819840|NCT01350505|BEHAVIORAL|Dim orange light exposure|\~28 lux of orange light
223819841|NCT02694003|BEHAVIORAL|BNBD-NDD Intervention|The intervention comprises 5 sessions, consisting of educational materials followed by interactive activities, designed to facilitate the successful application of the behavioural strategies. Clinicians and caregivers share tips and recommendations about implementing the strategies, providing modelling and emotional/social support, through supplemental videos. Caregivers complete daily internet sleep diaries that track sleep-related variables and patterns, associations between changes in caregivers' behaviour and children's sleep, and associations between changes in children's sleep and their daytime functioning. At the end of each session, caregivers receive a personalized plan for the week, linking relevant session strategies to caregivers' goals for their children's sleep.
223819842|NCT05299021|PROCEDURE|Double-point SAPB|A high-frequency linear probe (6-13 MHz) of the ultrasound machine was used to identify the fifth rib in the midaxillary line. The anatomic landmarks of the block were identified: latissimus dorsi, serratus anterior, and the intercostal muscles in the fourth and fifth intercostal levels. After sterilization and draping, an 20-gauge needle was introduced craniocaudally using an in-plane technique. The needle tip was advanced, targeting the plane between the serratus anterior muscle and the fifth rib. Needle position was confirmed by injection of 1-to-2 mL of saline after negative aspiration. And use the same method targeting the plane between the serratus anterior muscle and the third rib.Under real-time visualization, total 30 mL of 0.375% ropivacaine and 0.5 μ g/kg dexmedetomidine mixture will be injected into the two points with 15 ml separately.
223819843|NCT05299021|PROCEDURE|Single-point SAPB|A high-frequency linear probe (6-13 MHz) of the ultrasound machine was used to identify the fifth rib in the midaxillary line. The anatomic landmarks of the block were identified: latissimus dorsi, serratus anterior, and the intercostal muscles in the fourth and fifth intercostal levels. After sterilization and draping, an 20-gauge needle was introduced craniocaudally using an in-plane technique. The needle tip was advanced, targeting the plane between the serratus anterior muscle and the fifth rib. Needle position was confirmed by injection of 1-to-2 mL of saline after negative aspiration.Under real-time visualization, total 30 mL of 0.375% ropivacaine and 0.5μ g/kg dexmedetomidine mixture will be injected.
223819844|NCT04441723|DEVICE|Osteosynthesis with Gamma 3 nail , using a dynamic lag screw as a proximal fixation.|Closed reduction and surgical stabilization of intertrochanteric hip fractures using Gamma 3 nail , with dynamic lag screw as proximal fixation
223819845|NCT04441723|DEVICE|Osteosynthesis with Gamma 3 nail , using a static lag screw as a proximal fixation.|Closed reduction and surgical stabilization of intertrochanteric hip fractures using Gamma 3 nail , with static lag screw as proximal fixation
223819846|NCT05266963|DRUG|CREON|The study will enroll 6-10 adult subjects with T1D who will receive both pancreatic enzyme replacement (CREON) or placebo each for 7 days in a random order. The effect of the intervention will be monitored by continuous glucose monitoring, diet recording, capsule counts, a mixed-meal tolerance test, and a survey to assess symptoms of PEI. This study design will allow for estimation of the effect of pancreatic enzyme replacement on the measured parameters.
223819847|NCT05266963|DRUG|Placebo|Placebo
223819848|NCT02826590|OTHER|Neck passive mobilizations|Passive mobilizations performed to the neck of the participant by a Physiotherapist
223819849|NCT02826590|OTHER|Manual contact|Manual contact applied to the neck of the participant by a Physiotherapist
223819850|NCT03813212|DEVICE|MRI|Magnetic resonance imaging. Trans-abdominal sonography (TAS) and transvaginal sonography (TVS) will be performed using a 3.5 or 5 MHz transabdominal convex transducer and a 7 MHz trans-vaginal transducer.
223819851|NCT01304121|DEVICE|Bioactive glass (SP53P4)|Commercial resorbable bone graft substitute (Vioxid Ltd)
223819852|NCT02704897|OTHER|Wound Assessment Tool|A set of questions relating to the symptoms of wound infection
223819853|NCT01441817|PROCEDURE|Internal fixation|Internal fixation of the medial malleolus following open reduction and internal fixation of the lateral and, if required, posterior malleolus.
223819854|NCT01235572|PROCEDURE|standard follow-up care|Undergo early discharge and standard outpatient care
223819855|NCT01235572|OTHER|medical chart review|Undergo early discharge and standard outpatient care
223819856|NCT01235572|PROCEDURE|quality-of-life assessment|Ancillary studies
223819857|NCT01596218|DRUG|Brentuximab Vedotin|Starting dose is 0.6 mg/kg weekly x 3
223819858|NCT02204137|OTHER|Falls Risk Questionnaire|
223819859|NCT02204137|OTHER|Cancer and Aging Research Group Geriatric Assessment|
223819860|NCT02204137|OTHER|Falls Efficacy Scale-International (FES-1)|
223819861|NCT02204137|OTHER|Health Related Quality of Life using the Functional Assessment of Cancer Therapy - Gynecologic Oncology Group Neurotoxicity Scale (FACT GOG/NTX)|
223819862|NCT03690219|OTHER|no intervention|no intervention
223819863|NCT05289258|BEHAVIORAL|Neuropsychological treatment|combination of the programs tested by (Von Ah et al. 2012). These programs are, on the one hand, a cognitive training adapted from the Advanced Cognitive Training for Independent and Vital Elderly (ACTIVE) (Jobe et al., 2001) and, on the other, a processing speed training using the Insight program (from Posit Science) (Mahncke et al., 2006). The first consists of teaching patients memorization techniques, and the second consists of a series of exercises on information processing of varying difficulty. These exercises automatically adjust your difficulty to maintain an 85% rate of return. Treatment is carried out in groups of 10 cancer survivors. It consists of 10 weekly sessions of 2 hours each (the first hour for memory training and the second for processing speed exercises). In order to improve the adherence to treatment of the participants, emails and telephone text messages will be sent with reminders of appointments and tasks to be performed.
223819864|NCT05289258|BEHAVIORAL|Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders (PU).|This intervention focuses on a deficit in emotional regulation common in all emotional disorders (ED). Therefore, it focuses on the adaptive value of emotions and promotes tolerance to intense emotions as well as the identification and modification of dysfunctional emotional regulation strategies. Patients receive 10 group therapy sessions (3-5 cancer survivors per group) with all PU modules (Barlow et al., 2011). The Spanish version of the therapist's guide and the patient's workbook are used (Barlow et al., 2015). All patients receive the workbook to help them read the contents of each session, do the recommended exercises between sessions, and to help them once the treatment is finished. The treatment lasts 10 weeks (one session a week). As in the previous intervention group, emails and telephone text messages will be used with reminders of appointments and tasks to be carried out.
223819865|NCT05289258|BEHAVIORAL|Waitlist group|The control group will receive the Adapted Mnesic Cognitive Training (ACTIVE) (Jobe, et al., 2001), as well as the Insight (Posit Science) program (Mahncke et al., 2006) once the interventions in groups 1 and 2 have been completed.
223819866|NCT04702568|DRUG|BCX9930|BCX9930 for oral administration
223819867|NCT04702568|DRUG|Eculizumab|Administered at stable dose at the time of study entry
223819868|NCT04702568|DRUG|Ravulizumab|Administered at stable dose at the time of study entry
223819869|NCT00363337|DRUG|aripiprazole|open label treatment with aripiprazole
223819870|NCT00393523|BIOLOGICAL|Comparator: Modified Process Hepatitis B Vaccine|Single dose 5 µg/0.5ml modified process hepatitis B vaccine
223819871|NCT00393523|BIOLOGICAL|Comparator: Comparator: ENGERIX-B|Single dose 10 µg/0.5ml ENGERIX-B
223819872|NCT01696318|BEHAVIORAL|Support for the Family Health Team|Participation in physical educator, dietitian and pharmacist in primary health care
223819873|NCT00245401|DEVICE|CYPHERTM Sirolimus-Eluting Coronary Stent|
223819874|NCT04521517|BEHAVIORAL|pamphlet describing the timing of family planning during postpartum with methods advantages and disadvantages of family planning|a pamphlet describing the timing of family planning during postpartum with methods advantages and disadvantages of family planning
223819875|NCT00726349|OTHER|No intervention|Observational study.
223819876|NCT04091360|DRUG|Part A: RPL554|Single dose RPL554 via metered dose inhaler.
223819877|NCT04091360|DRUG|Placebos|Part A: Single dose placebo via metered dose inhaler. Part B: Repeat doses of placebo via metered dose inhaler in crossover fashion. One dose administered twice daily over 7 days.
223819878|NCT04091360|DRUG|Part B: RPL554|Part B: Repeat doses via metered dose inhaler in crossover fashion. One dose administered twice daily over 7 days.
223819879|NCT00572338|OTHER|No drugs are involved|No treatment or drugs are involved in this research. Participating in this study requires that blood and bone marrow samples be obtained as a part of the diagnostic work-up or follow-up of participant's multiple myeloma. Bone marrow/peripheral blood samples will be collected at the same time for research purposes. Data will be collected including demographic information gathered from your medical record, including gender, date of birth, ethnicity, date of diagnosis, laboratory and pathology results, treatment protocols, dates of relapses, subsequent treatment protocols, and current treatments and medications.
223819880|NCT04339517|PROCEDURE|Aspiration of seroma fluid|Fluid will be collected from the lumpectomy site of patients between one to six weeks post-surgery and tested for the presence of persistent tumor cells (PTCs).
223819881|NCT02544802|DRUG|Adipose-Derived Mesenchymal Stem Cells|
223819882|NCT06100055|DEVICE|Rectal Irrigation|"Rectal irrigation is the introduction of warm tap water through the anal canal into the rectum to initiate defaecation.~Two alternative irrigation systems based on volume delivered exist: low-volume irrigation system depending on the manufacturer delivers approximately between 110ml to 300ml per irrigation and high-volume irrigation system delivers between 300ml to 1500ml per irrigation."
223819883|NCT05021003|OTHER|pressure biofeedback|: Core stabilization training with pressure biofeedback unit
223819884|NCT05021003|OTHER|core stabilization exercises|: Core stabilization training without pressure biofeedback unit
223819885|NCT06189404|DRUG|Tigulixostat|300 mg oral dose
223819886|NCT06189404|DRUG|Theophylline|400 mg oral dose
223819887|NCT00423852|BIOLOGICAL|filgrastim|
223819888|NCT00423852|DRUG|carboplatin|
223819889|NCT00423852|DRUG|ifosfamide|
223819890|NCT00423852|DRUG|paclitaxel|
223819891|NCT00423852|PROCEDURE|autologous hematopoietic stem cell transplantation|
223819892|NCT00423852|PROCEDURE|peripheral blood stem cell transplantation|
223819893|NCT01774318|OTHER|aEEG and conventional EEG measurement|aEEG and conventional EEG measurement including video-polysomnography
223819894|NCT03934632|OTHER|Postabsorptive|Saline will be infused to mimic postabsorptive circulating amino acid concentrations
223819895|NCT03934632|OTHER|Postprandial|An amino acid infusate will be administered to mimic postprandial circulating amino acid concentrations
223819896|NCT03934632|PROCEDURE|Immobilisation|One leg will undergo 2 days immobilisation prior to the test day
223819897|NCT00572624|BEHAVIORAL|Diet|Participants attended 20 group behavioral modification sessions led by a behaviorist, a registered dietician, and a physical therapist. The meal plans ranged from 1200 to 1500 kilocalories per day, depending on subject sex and BMI, and were designed to achieve ≤1% body weight loss/week. Participants completed daily food records, and were taught a variety of weight management skills. The exercise component included strength, flexibility, balance, and endurance instruction, gradually increasing to 30 minutes of exercise 5 days/week.
223819898|NCT00572624|PROCEDURE|Gastric bypass surgery|The same surgeon performed all bypass procedures using standard techniques. A small (\~20 ml) proximal gastric pouch was created by stapling the stomach, and a 75-cm Roux-en-Y limb was constructed by transecting the jejunum distal to the ligament of Treitz, and creating a jejunojejunostomy 75 cm distal to the transection.
223819899|NCT00419653|DRUG|Amisulpride|
223819900|NCT00419653|DRUG|Olanzapine|
223819901|NCT00419653|DRUG|Haloperidol|
223819902|NCT02951559|DEVICE|Nasal Brushing|"Nasal brushing will be performed in non-sedated patients as follows. After administration of a local vasoconstrictor (1% epinephrine) with the use of a nasal tampon, inserted into the nasal cavity of the patient to locate the olfactory mucosa lining the nasal vault. A sterile, disposable brush (Copanflock, Copan, Brescia, Italy) will be inserted gently rolled on the mucosal surface, withdrawn,and immersed in 0.9% saline solution, UTM (Universal Transporter Medium) or 4% formaldehyde. Two swabs will be collected for each nostril."
223819903|NCT06547372|OTHER|Dietary Intervention on Atopy|The primary aim of this dietary intervention study is to assess the effectiveness of a dietary pattern characterized by lower saturated fats, higher wholegrains, fruit, and vegetables in reducing the severity of AD in young Singapore adults, as measured by changes in Scoring Atopic Dermatitis (SCORAD) scores, over a 2-month intervention period.
223819904|NCT00803621|OTHER|Toxoplasma PCR assay|Toxoplasma PCR assay
223819905|NCT04235634|DRUG|Prostavasin|Minimal invasive Cannulation of the Superior Mesenteric Artery (SMA) and subsequent intra-arterial application of prostaglandin E1 (Initial Bolus 20ug, followed by continuous Infusion of 60-80ug/24hr for 24-72hrs)
223819906|NCT00273559|DRUG|prednisone|group 2 will remain on 5 mg of prednisone for at least 90 days post transplant.
223819907|NCT02273297|OTHER|Maternal factors|
223819908|NCT01589952|DRUG|Pegalyted interferon, Entecavir|Pegalyted interferon: 90 micro gms subcutaneously once weekly for 24 weeks Entecavir: 0.5 mg orally once daily for 24 weeks
223819909|NCT03350243|OTHER|CCENT Intervention|"1. Acceptance and Commitment Therapy approach: engaging families through structured individual or group sessions within the NICU and continue this support once discharged.~2. Care coordination: supporting providers in clear communication when liaising across various levels of care as well as supporting families in system and resource navigation.~3. Anticipatory guidance: proactive education targeting normal challenges in caring for a child who required intensive care support."
223819910|NCT05345288|DEVICE|BrainHQ cognitive training|"Posit Science's BrainHQ exercises are based on the science of neuroplasticity, also called brain plasticity. Brain plasticity is your brain's natural ability to remodel itself throughout life. The brain is always changing, sometimes for better, and sometimes for worse. What BrainHQ's exercises do is harness that change and direct it in ways that can enhance your overall performance and improve the quality of your life. BrainHQ exercises are grouped into six categories: Attention, Memory, Brain Speed, Intelligence, People Skills, and Navigation."
223819911|NCT05345288|DEVICE|BrainHQ control games|BrainHQ also offers control games for research studies. The control activities will be games similar to candy crush, connect four, gem swap and battleship.
223819912|NCT05433155|DEVICE|Nasotracheal intubation|Nontracheal intubation using clinical standard videolaryngoscopy or direct laryngoscopy
223819913|NCT00640796|PROCEDURE|Haploidentical donor derived natural killer cell infusion|Therapeutic cell infusion
223819914|NCT00640796|DRUG|Chemotherapy|Cyclophosphamide, Fludarabine, Interleukin-2, Mesna
223819915|NCT00640796|DEVICE|CliniMACS|Cell selection system based on magnetic-activated cell sorting
223819916|NCT05230979|OTHER|Common bean baked snack|Participants with normal weight (n=18) and with overweight (n=18) will attend the institute after 10-14 h fasting. Initially, they are going to complete a physical activity questionnaire, and the first visual analog scale (VAS) of subjective satiety questionnaire followed by a finger-prick blood sample. Immediately, they will be instructed to consume 40 g of the preload (common bean baked snack, cooked beans or white bread) along with 100 mL of water within 10 min. The VAS and blood glucose will be measured every 15 min after starting to eat the test food. Another VAS will be used to assess the palatability of the preload products. After 45 min, an ad libitum meal consisting of freshly prepared sandwiches and 250 mL of water will be served in a single portion. Finally, the VAS of subjective satiety is going to be assessed again.
223819917|NCT05230979|OTHER|Cooked beans|Participants with normal weight (n=18) and with overweight (n=18) will attend the institute after 10-14 h fasting. Initially, they are going to complete a physical activity questionnaire, and the first visual analog scale (VAS) of subjective satiety questionnaire followed by a finger-prick blood sample. Immediately, they will be instructed to consume 40 g of the preload (common bean baked snack, cooked beans or white bread) along with 100 mL of water within 10 min. The VAS and blood glucose will be measured every 15 min after starting to eat the test food. Another VAS will be used to assess the palatability of the preload products. After 45 min, an ad libitum meal consisting of freshly prepared sandwiches and 250 mL of water will be served in a single portion. Finally, the VAS of subjective satiety is going to be assessed again.
223819918|NCT05230979|OTHER|White bread|Participants with normal weight (n=18) and with overweight (n=18) will attend the institute after 10-14 h fasting. Initially, they are going to complete a physical activity questionnaire, and the first visual analog scale (VAS) of subjective satiety questionnaire followed by a finger-prick blood sample. Immediately, they will be instructed to consume 40 g of the preload (common bean baked snack, cooked beans or white bread) along with 100 mL of water within 10 min. The VAS and blood glucose will be measured every 15 min after starting to eat the test food. Another VAS will be used to assess the palatability of the preload products. After 45 min, an ad libitum meal consisting of freshly prepared sandwiches and 250 mL of water will be served in a single portion. Finally, the VAS of subjective satiety is going to be assessed again.
223819919|NCT05230979|OTHER|Anhydrous glucose (first session) (for glycemic index determination)|Participants with normal weight or overweight (n=10) will attend the institute after 10-14 h fasting. At first, two baseline finger-prick blood samples will be collected with 5 min between the samples. Then, they are going to consume a reference glucose solution containing 25 g of anhydrous glucose per 250 mL of water within 12-15 min. Later, finger-prick blood samples will be taken at 15, 30, 45, 60, 90 and 120 min after starting to drink the reference glucose solution. Areas under the glucose response curves (iAUC) will be calculated using the trapezoidal rule, ignoring the areas below the fasting value.
223819920|NCT05230979|OTHER|Anhydrous glucose (second session) (for glycemic index determination)|Participants with normal weight or overweight (n=10) will attend the institute after 10-14 h fasting. At first, two baseline finger-prick blood samples will be collected with 5 min between the samples. Then, they are going to consume 54 g of common bean baked snack with 250 mL of water within 12-15 min. Later, finger-prick blood samples will be taken at 15, 30, 45, 60, 90 and 120 min after starting to eat the test food. Areas under the glucose response curves (iAUC) will be calculated using the trapezoidal rule, ignoring the areas below the fasting value.
223819921|NCT05230979|OTHER|Common bean baked snack (for glycemic index determination)|Participants with normal weight or overweight (n=10) will attend the institute after 10-14 h fasting. At first, two baseline finger-prick blood samples will be collected with 5 min between the samples. Then, they are going to consume 54 g of common bean baked snack with 250 mL of water within 12-15 min. Later, finger-prick blood samples will be taken at 15, 30, 45, 60, 90 and 120 min after starting to eat the test food. Areas under the glucose response curves (iAUC) will be calculated using the trapezoidal rule, ignoring the areas below the fasting value.
223819922|NCT00003379|DRUG|cisplatin|
223819923|NCT00003379|DRUG|paclitaxel|
223819924|NCT00003379|RADIATION|brachytherapy|
223819925|NCT00003379|RADIATION|radiation therapy|
223819926|NCT00544960|DRUG|AT-101 and docetaxel|AT-101 30 mg bid on days 1, 2, and 3 of each 21 day cycle, docetaxel, 75 mg/m2 on day 1 of each 21 day cycle; until progression or unacceptable toxicity develops
223819927|NCT00544960|DRUG|placebo and docetaxel|placebo 3 tabs bid on days 1, 2, and 3 of each 21 day cycle, docetaxel, 75 mg/m2 on day 1 of each 21 day cycle; until progression or unacceptable toxicity develops
223819928|NCT06354335|OTHER|Employees exposed to a major hospital reorganisation|Occupational exposure
223819929|NCT05320016|DRUG|Remimazolam|Effects of remimazolam on quality of recovery scores after ambulatory hysteroscopic surgery
223819930|NCT04294394|OTHER|rhomboid block|Rhombid block, on the other hand, is a method which make up analgesia by providing lokal anestethetic enjection between intercostal muscles and rhomboid muscles and blocks between t3- t9 levels
223819931|NCT04294394|OTHER|erector spinae block|The Erector spinae plan block is a recently developed regional block method .Adminestering of lokal anesthetic between the transver proces and erector spinae muscles provides the dorsal and ventral branch blokades of regional spinal nerve and make up the analgesia.İt have a wide range usage such as surgery of thoracal and abdominal area
223819932|NCT04294394|OTHER|control|For postoperative analgesia, all patients (including Rhomboid block and Erector spinae block) will be administered 100 mg tramadol and 1 gr paracetamol. No additional intervention other than this medical approach will be applied in the control group.
223819933|NCT00812513|DRUG|R-Pdf/Gbb 0.01% gel|rhPDGF 0.01% gel is applied to the wound, then covered with dressing once daily for 3 months
223819934|NCT05122572|BIOLOGICAL|Oncolytic Virus Injection (RT-01）|Intravenous injection of RT-01 with or without Nivolumab
223819935|NCT00754975|DEVICE|JACTAX LD DES|Drug Eluting Stent
223819936|NCT00754975|DEVICE|TAXUS™ Libertè™ DES|Drug Eluting Stent
223819937|NCT02055937|PROCEDURE|immediate implant breast reconstruction|Eligible patients will undergo radical mastectomy with axillary lymph nodes sampling followed by immediate and single-stage breast reconstruction using the acellular dermal matrix Strattice™
223819938|NCT00057187|BEHAVIORAL|Contracting, Prompting and Reinforcing|
223819939|NCT02777996|DEVICE|Low Dose Computed Tomography|Assessment protocol were adopted from the ELCAP study (modified) for Non Calcific Nodule with a diameter of less- equal than 5 mm at baseline and 3mm at repeated.
223819940|NCT03622203|DEVICE|Biofreedom|Use of Biofreedom in real life patients
223819941|NCT02936713|OTHER|Fermented milk product with probiotics (FMPP)|2 pots of 125g FMPP / day
223819942|NCT00548067|DRUG|Valsartan/hydrochlorothiazide (HCTZ)|
223819943|NCT00548067|DRUG|Valsartan/amlodipine|
223819944|NCT00548067|DRUG|Amlodipine/hydrochlorothiazide(HCTZ)|
223819945|NCT00548067|DRUG|Valsartan/amlodipine/hydrochlorothiazide(HCTZ)|
223819946|NCT01053754|BIOLOGICAL|"long synacthen stimulation test"|IM injection of 1 mg of delate synacthen which can be realized in ambulatory conditions
223819947|NCT00181090|BEHAVIORAL|Modified Atkins diet|
223819948|NCT05006677|DRUG|non-vitamin K antagonist oral anticoagulants (NOACs)|Collecting information of patients with VT who received NOACs
223819949|NCT05006677|DRUG|vitamin K antagonists (VKAs)|Collecting information of patients with VT who received VKAs
223819950|NCT05006677|DRUG|antiplatelet agents|Collecting information of patients with VT who received antiplatelet agents
223819951|NCT05006677|OTHER|non-antithrombotic therapy|Collecting information of patients with VT without any antithrombotic therapy
223819952|NCT01083940|OTHER|Computerized reminders on hypertension intensification|Reminder generated to prompt providers to intensify therapy when patient's blood pressure remains uncontrolled
223819953|NCT00744263|BIOLOGICAL|VACCINE: placebo|0.5 mL, single intra-muscular injection
223819954|NCT00744263|BIOLOGICAL|VACCINE: 13-valent pneumococcal conjugate vaccine|0.5 mL, single intra-muscular injection
223819955|NCT06383702|DRUG|pregabalin sustained-release tablets|Subjects will take pregabalin sustained-release tablets for the duration of 14 weeks. The dosage will include 165 mg daily (for the titration and the withdraw period) and 330 mg daily for the fixed-dose period.
223819956|NCT06383702|DRUG|Placebo|Subjects will take placebo tablets for the duration of 14 weeks. The dosage will include 165 mg daily (for the titration and the withdraw period) and 330 mg daily for the fixed-dose period.
223819957|NCT03084497|PROCEDURE|Infant Massage|"The first day, investigators will make the initial assessment of the baby through Psychomotor Development Scale of Early Childhood Brunet- Lézine. Participants will keep the sessions early attention and will participate in the course of Infant Massage, which develop for 5 weeks.~Infant Massage course will take place with families and is based on the methodology and program of the International Association of Infant Massage ( IAIM ), created by Vimala McClure. The course will consist of 5 sessions (one per week) approximately 90 minutes. Parents will practice everyday the movements learned during the time of the study.~When the course of Infant Massage finished, Investigators will conduct the final evaluation of the baby, the same way as in the initial evaluation."
223819958|NCT03491423|OTHER|Short and fast step test without measurement of pulmonary gas exchange|For one minute, the patient should climb up and down a 17.5 cm high step as quickly as possible while holding onto a bar in front of the step.
223819959|NCT03491423|BIOLOGICAL|glucose meter|glucose meter to measure lactatemia
223819960|NCT03491423|OTHER|ECG / heart rate|ECG and heart rate (HR) collection by telemetry
223819961|NCT03491423|OTHER|questionnaires|VAS pain assessment and evaluation of effort perception according to Borg's scale
223819962|NCT03491423|OTHER|Short and fast step test with measurement of pulmonary gas exchange|For one minute, the patient should climb up and down a 17.5 cm high step as quickly as possible while holding onto a bar in front of the step.
223819963|NCT04361032|DRUG|Tocilizumab Injection|Tocilizumab (LOC) (8mg/ kg per day) (1 injection per infusion). Only on the 1st day (D0)
223819964|NCT04361032|DRUG|Deferoxamine|Deferoxamine (Desferal 500 mg, powder, and solvent for IV solution for injection)
223819965|NCT04261179|DRUG|Lymphoseek|50 μg microgram(s), timepoint: 30-60 minutes
223819966|NCT04261179|DRUG|Nanocoll|500 μg microgram(s), timepoint: 30-60 minutes
223819967|NCT01351428|DRUG|Nifedipine|30-60 mg, twice daily
223819968|NCT03748017|DIETARY_SUPPLEMENT|Placebo-Control Supplement|A once-daily oral dose of the placebo-control supplement will be consumed by adults for 14 consecutive days.
223819969|NCT03748017|DIETARY_SUPPLEMENT|Streptococcus-Containing Probiotic Supplement|A once-daily oral dose of the streptococcus-containing probiotic supplement will be consumed by adults for 14 consecutive days.
223819970|NCT06382285|DRUG|Continues peripheral block|ropivacaine (Naropin) 0.2% according to a protocol 8-10 cc per hour up to 24 hours after surgery
223819971|NCT02771730|BIOLOGICAL|Ad4-mgag|A live replication-competent Adenovirus type-4 vector encoding a mosaic HIV Gag antigen, delivered orally by enteric-coated capsules.
223819972|NCT02771730|BIOLOGICAL|Ad4-EnvC150|A live replication-competent Adenovirus type-4 vector encoding an HIV clade C Env protein (gp150 1086.C), delivered orally by enteric-coated capsules.
223819973|NCT02771730|OTHER|Placebo Comparator|Oral sucrose capsules
223819974|NCT02771730|BIOLOGICAL|AIDSVAX B/E|300 mcg of subtype B (MN) HIV gp120 glycoprotein and 300 mcg of subtype E (A244) HIV gp120 glycoprotein adsorbed onto 600 mcg of aluminum hydroxide gel adjuvant, administered intramuscularly (IM).
223819975|NCT00910520|BIOLOGICAL|onabotulinumtoxinA|OnabotulinumtoxinA (botulinum toxin Type A) 100 U injected into the detrusor at Day 1, followed by a repeat injection of onabotulinumtoxinA 100 U after a minimum of 12 weeks (if applicable). Or, if placebo is administered at Day 1, onabotulinumtoxinA 100 U injected after a minimum of 12 weeks (if applicable).
223819976|NCT00910520|DRUG|normal saline|Normal saline (placebo) injected into the detrusor at Day 1.
223819977|NCT05240274|DRUG|Metformin|metformin 500mg OD for 3 months to start within 10 days post-renal transplant
223819978|NCT05240274|DRUG|Placebo|placebo 500mg OD for 3 months to start within 10 days post-renal transplant
223819979|NCT03467438|DRUG|Zinc-l-carnosine|Patients will be asked to take the investigational product as already mentioned (blindly).
223819980|NCT03467438|OTHER|Placebo|Patients will be asked to take placebo as already mentioned (blindly).
223819981|NCT06464471|OTHER|Self-reported online geriatric assessment (CHAMP)|The CHAMP tool is a self reported online tool that has been developed to increase patients' accessibility to geriatric assessment and improve treatment decision making. The tool includes questions about function, mobility, cognition, nutrition, social support, depression substance use disorders, and miscellaneous items. Based on usability testing in the previous phase of this study, the tool can be completed in approximately 10-15 minutes. The tool generates a summary report with recommendations for patients and clinicians.
223819982|NCT04636606|PROCEDURE|Home Exercise|Educational training program about oral dysphagia in patients with temporomandibular disorders.
223819983|NCT04636606|PROCEDURE|Manual Therapy Combined with Home Exercise|Manual therapy program combined with educational training program about oral dysphagia in patients with temporomandibular disorders.
223819984|NCT04636606|PROCEDURE|Orofacial Myofunctional Therapy combined with Manual Therapy and Home Exercise|Orofacial Myofunctional Therapy program with combination of Manual therapy and educational training program about oral dysphagia in patients with temporomandibular disorders.
223819985|NCT00279656|BEHAVIORAL|Pharmaceutical care|
223819986|NCT02914379|DRUG|[¹⁴C]-LY3337641|Administered orally
223819987|NCT01515189|BIOLOGICAL|Ipilimumab|
223819988|NCT02746042|DRUG|Sinupret extract coated tablets|1 coated tablet 3 times a day for 16-weeks (1-1-1)
223819989|NCT02746042|DRUG|Placebo coated tablets|1 coated tablet 3 times a day for 16-weeks (1-1-1)
223819990|NCT04191681|DRUG|Sacubitril-Valsartan|Sacubitril-valsartan at low or equivalent dose to be initiated or added to patients randomized to this arm, and titrated up every 2-4 weeks, per standard practice guidelines and label recommendations per physician's discretion.
223819991|NCT04191681|DRUG|Usual care (standard-of-care) arm|Other oral vasodilator therapy to be continued or initiated to patients randomized to this arm, and titrated up every 2-4 weeks, per standard practice guidelines and label recommendations per physician's discretion.
223819992|NCT04669223|DEVICE|Seldinger chest drain insertion|Different sizes of chest drain will be inserted with seldinger technique
223819993|NCT06250439|OTHER|ECMO-Flow variations|"The protocol unfolds in 5 steps as follows, each step lasting between 10 and 15 minutes to allow for the patient's hemodynamic adaptation. At each step, invasive and non-invasive hemodynamic evaluation is performed.~1. The 1st step is called 100% flow: it involves recording the patient's hemodynamic measurements at the baseline, i.e., at 100% of their ECMO-VA flow, previously set by the clinician entirely independently of the study.~2. The 2nd step is called 125% flow: the patient's ECMO-VA flow is increased to 125% of the initial flow.~3. The 3rd step is called 150% flow: the patient's ECMO-VA flow is increased to 150% of the initial flow.~4. The 4th step is called 175% flow: the patient's ECMO-VA flow is increased to 175% of the initial flow.~5. The 5th and final step is called 200% flow: the patient's ECMO-VA flow is increased to 200% of the initial flow."
223819994|NCT05590546|OTHER|No intervention|No intervention, only performing cross-sectional analysis of pooled data collected in previous studies
223819995|NCT03787680|DRUG|Olaparib|300 mg by mouth twice a day for days 1-28 of a 28-day cycle.
223819996|NCT03787680|DRUG|AZD6738|160 mg by mouth daily for days 1-7 of a 28-day cycle.
223819997|NCT06058923|PROCEDURE|M-MIST|This is characterized by a vestibular mucoperiosteal envelope flap without relaxing incisions. Sulcular incisions will be made on the vestibular surface of the teeth included in the surgical area, adjacent to the infraosseous defect. The mesiodistal extension of the flap will be kept to a minimum necessary to access the defect. In the papillary area over the infraosseous defect, an oblique or horizontal incision will be made at the level of the interdental papilla, following the contour of the bone crest. The vestibular flap will be elevated, leaving the lingual/palatal portion adhered, only to allow access to the bone defect. The defect will be instrumented with mini-curettes and specific ultrasonic tips, and the defect will be filled only with a blood clot after this procedure. Primary closure will be achieved with internal vertical and/or horizontal mattress sutures, which may be complemented with simple sutures, all using specific suture threads.
223819998|NCT06058923|PROCEDURE|MIST|A vestibular envelope flap, without vertical relaxing incisions, will be raised on the vestibular and lingual/palatal sides. Primary intrasulcular incisions will be made to the alveolar crest, encompassing the teeth included in the surgical area. In the interproximal area, incisions will follow the principle of preserving the papilla (Modified Papilla Preservation Technique = MPPT or Simplified Papilla Preservation Flap = SPPF), depending on the available interproximal space (Cortellini et al., 1995, 1999). The mesiodistal extension of the flap will be minimized to provide adequate access to the defect. The defect will be instrumented using mini-curettes and specific ultrasonic tips, and the defect will be filled only with a blood clot after these procedures. Flap closure will be achieved with internal horizontal and/or vertical mattress sutures, which may be modified or complemented with simple sutures, all using specific suture threads.
223819999|NCT05503966|BEHAVIORAL|Attentional Bias Modification|The ABM task is based on a computerized visual Dot-probe task. In the dot-probe task paired stimuli of negative (angry and fearful), positive (happy) or neutral faces are presented, followed by one or two probes (dots) appearing in the spatial location of one of the stimuli. Participants are then required to press one of two buttons as quickly as possible to indicate the number of dots in the probe. In the ABM condition, probes are in the same locus as the more positive/less negative stimuli in 87% of the trials, as opposed to 13% with probes in the same locus as more negative/less positive stimuli. Thus, when completing the ABM, participants should learn to deploy their attention toward the relatively more positive stimuli, and in this way develop a more positive AB.
223820000|NCT06411769|BEHAVIORAL|50K4LIfe|This intervention will consist of the Walking Challenge only.
223820001|NCT06411769|BEHAVIORAL|SMS Text Messaging|In this intervention, participants will received notifications onto the Pathverse app
223820002|NCT06411769|BEHAVIORAL|Individual|In this Phase 2 individual-level intervention, participants will receive remote education modules and one-to-one monthly phone-based coaching.
223820003|NCT06411769|BEHAVIORAL|School|In this Phase 2 school-level intervention, participants will receive group educational sessions, school environmental modifications (floor distance markings, signage in corridors and breakrooms, promotional items), and participate in work time/weekend group walks/hikes.
223820004|NCT02583763|OTHER|Echocardiography|During the ultrasound examinations standardized, moving sequences of the heart will be saved. Analyzes are performed off-line and analyzed by vector velocity imaging software.
223820005|NCT02583763|PROCEDURE|Blood sample|The investigators will take a blood sample from the umbilical cord at birth and again at 9 years of age.
223820006|NCT06599619|DRUG|Single agent, adjuvant anti-PD1 therapy|"One of the following Single-agent, adjuvant anti-PD1 therapies:~Nivolumab is a type of targeted therapy drug called an immune checkpoint inhibitor (a type of immunotherapy). It is a monoclonal antibody that binds to the protein PD-1 on the surface of immune cells called T cells. It works by keeping cancer cells from suppressing the immune system.~Dose = 240 mg IV every 2 weeks/480 mg every 4 weeks or, Pembrolizumab is a monoclonal antibody and a type of immune checkpoint inhibitor that's used in cancer immunotherapy. It works by attaching to the PD-1 protein on the surface of T cells, which are immune cells. This prevents cancer cells from suppressing the immune system, allowing the immune system to attack and kill the cancer cells.~Dose = 200 mg IV every 3 weeks/ 400 mg every 6 weeks"
223820007|NCT05815316|DRUG|18F-PSMA-1007|(3S, 10S, 14S)-1-\[4-\[\[(2S)-4-carboxy-3-\[(2S)-4-carboxy-2-(6-\[18F\]fluoropyridin-3- amido)butanamido\]butanamido\]methyl\]phenyl\]-3- \[(naphtalen-2-yl)methyl\]-1,4,12-trioxo-2,5,11,13-tetraazahexadecane- 10,14,16-tricarboxilyc acid
223820008|NCT03390777|PROCEDURE|surgery|surgery without the use of prgf
223820009|NCT03390777|DEVICE|PRGF after surgery|surgery and application of PRGF
223820010|NCT00885989|DRUG|SLV338|5 - 1000 mg IV
223820011|NCT00885989|DRUG|Placebo|Placebo
223820012|NCT06160752|DRUG|Phase 1 Part A - dose escalation TYRA-200 taken once daily by mouth in 28-day cycles|TYRA-200 is an oral, novel potent FGFR 1/2/3 tyrosine kinase inhibitor that targets tumors that contain activating gene alterations of FGFR2.
223820013|NCT06160752|DRUG|Phase 1 Part B - dose expansion TYRA-200 taken once daily by mouth in 28-day cycles|TYRA-200 is an oral, novel potent FGFR 1/2/3 tyrosine kinase inhibitor that targets tumors that contain activating gene alterations of FGFR2.
223820014|NCT01108393|DRUG|Agomelatine A|"Agomelatine 25 mg film-coated tablet~Agomelatine 2x25mg film-coated tablet"
223820015|NCT01108393|DRUG|Placebo|Placebo
223820016|NCT02753348|OTHER|Echocardiography|
223820017|NCT02753348|OTHER|Blood analysis from umbilical cord blood|
223820018|NCT02753348|OTHER|ECG|
223820019|NCT02753348|OTHER|Measurement of oxygen saturation|
223835510|NCT06363955|DEVICE|Carbamide Peroxide Mouthwash|The experinmental mouthwah is a solution containing 4.3% w/v hydrogen carbamide, which breaks down to 1.51% w/v hydrogen peroxide, serving as the active ingredient. Participants rinse (swish and spit) with the mouthwash three times a day for one minute each time, using a 10ml quantity (as indicated by a marking line inside the bottle cap) for a total of 14 days, starting from day 0, i.e. the day of the biopsy (see procedure in the detailed description). Consumption of liquid or solid foods should be avoided for at least thirty minutes following each rinse. Participants are asked to maintain their usual oral hygiene routine. It is a Class IIa, CE-marked medical device made and distributed by Intermed S.A. and Ioulia And Irene Tseti Pharmaceutical Laboratories S.A.
223820020|NCT00702416|PROCEDURE|Ultrasound-guided continuous interscalene brachial plexus block|"With patients in the supine position, a high-frequency (10-12 MHz) ultrasound transducer in a sterile sheath will be applied to explore the interscalene region and locate the brachial plexus. The transducer will be positioned so as to image the C5 and C6 roots in a single view. Visualization of the C7 root in the same scan will be sought, but will not be required.~A 50-mm, 20 G needle will be advanced in-plane from the postero-lateral side of the transducer. Injection of the local anesthetic will be performed in small aliquots while repositioning of the needle in order to optimize spread of the injectate around the nerve roots.~At the end of the injection, a catheter will be threaded through the needle. The catheter will be positioned to lie deep and close to the imaged nerve roots."
223820021|NCT00702416|PROCEDURE|Continuous interscalene brachial plexus block using electrical nerve stimulation|"With patients in the supine position, the head will be rotated to the contralateral side. The interscalene groove will be palpated.~A 35-mm, 20 G needle will be inserted at the estimated C6 level (cricoid cartilage) with a 30-45° angle to the skin. The needle will be advanced along a line joining the insertion site to the axilla.~An electrical nerve stimulator will be used at an initial intensity of 1.0 mA (frequency: 2 Hz, pulse width: 0.2 ms). A musculocutaneous or axillary-nerve mediated twitch will be sought~Injection of the local anesthetic will start with a visible motor response at a current \<0.5 mA. The catheter will be positioned to as to elicit a motor response at ≤0.4 mA."
223820022|NCT00702416|DRUG|Ropivacaine|"Block induction \[1% (wt/vol) solution\]:~20 ml (200 mg)~Postoperative analgesia \[0.2% (wt/vol) solution\]:~* Background infusion: 4 ml/h (8 mg/h)~* Incremental on-demand dose: 2 ml (4 mg)~* Lockout time: 15 min"
223820023|NCT00702416|DRUG|Paracetamol|1 g iv q8h
223820024|NCT00702416|DRUG|Morphine|5 mg im prn q1h (in the postoperative period)
223820025|NCT00702416|DRUG|Fentanyl|50 µg iv prn (in the intraoperative period)
223820026|NCT00702416|PROCEDURE|General anesthesia|"Will be given in case of block failure and/or patient discomfort intractable with fentanyl during the procedure.~The technique will be left at the discretion of the attending anesthesiologist. Monitored anesthesia care will also be acceptable; the block will be considered as failed in that case as well."
223820027|NCT06082414|OTHER|no interventions|no interventions because of an observational study
223820028|NCT04378660|DIAGNOSTIC_TEST|Artificial intelligence for polyp detection|Colonoscopy enriched with artificial intelligence tool developed for polyp detection, implemented as a second observer
223820029|NCT04804098|PROCEDURE|Compression Profile/Schedule: 15 minute Non-Linear compression from start of the daily treatment until treatment pressure is reached (45 fsw)|Patients will be compressed according to the 15 minute non-linear compression schedule on a rotating daily basis. A total of 2 randomized hyperbaric treatment compression profiles (accepted standards of care) will be alternated over the patients course of treatment on a daily basis daily to the prescribed treatment depth. There are multiple patients exposed during the compression profile randomized for that day. The patients are exposed over the course of 4-12 weeks using one of the two compression protocols to be studied on alternating days.
223820030|NCT04804098|PROCEDURE|Compression Profile/Schedule: 15 minute Linear compression from start of the daily treatment until treatment pressure is reached (45 fsw)|Patients will be compressed according to the 15 minute linear compression schedule on a rotating daily basis with compression. A total of 2 randomized hyperbaric treatment compression profiles (accepted standards of care) will be alternated over the patients course of treatment on a daily basis daily to the prescribed treatment depth. There are multiple patients exposed during the compression profile randomized for that day. The patients are exposed over the course of 4-12 weeks using one of the two compression protocols to be studied on alternating days.
223820031|NCT02995902|DEVICE|FLT-PET|
223820032|NCT02995902|DEVICE|MRI|
223820033|NCT01988896|DRUG|Atezolizumab|Atezolizumab will be administered at a fixed dose as specified via IV infusion.
223820034|NCT01988896|DRUG|Cobimetinib|Cobimetinib will be administered orally at an escalating dose during Stage 1 and at RP2D during Stage 2.
223820035|NCT05341778|OTHER|Shoulder bridge|The shoulder bridge is great for, strengthening your gluteal muscles, quadriceps, hamstrings, pelvic floor, abdominals and back muscles; most notably the tiny ones which control movement of each individual vertebrae and can weaken after episodes of back pain.
223820036|NCT05341778|OTHER|Clam shell|Scissors is an abdominal exercise that strengthens the transverse abdominals, helping flatten your belly and strengthen your entire core. Scissors is not only a core strength move, but it is also a great stretch for your hamstrings and your lower back.
223820037|NCT05341778|OTHER|Scissors|Scissors is an abdominal exercise that strengthens the transverse abdominals, helping flatten your belly and strengthen your entire core. Scissors is not only a core strength move, but it is also a great stretch for your hamstrings and your lower back.
223820038|NCT05341778|OTHER|Adductor squeeze|Adductor Squeeze exercise The SQ exercise is an isometric hip adduction exercise with the player holding a ball between their knees.
223820039|NCT05341778|OTHER|Pelvic clock supine|The pelvic clock is a brilliant exercise to help achieve flexibility and strength in the lower back, pelvic floor, and core-in order to prevent pain and injury.
223820040|NCT05341778|OTHER|urine hold and tummy tuck in|During tummy tuck patients are able to strategically tighten and reinforce the muscles around the pelvic floor, urethra, and other structures. This increased strength and support greatly reduces stress urinary incontinence
223820041|NCT05341778|OTHER|Bridging|A bridge exercise isolates and strengthens your gluteus (butt) muscles - the gluteus maximus, medius and minimus - and hamstrings, which are the main muscles that make up the posterior chain. It is done by lying on your back with your knees bent, feet flat on the ground and at a comfortable distance from your butt.
223820042|NCT05341778|OTHER|Split table top|To strengthen your abs, shoulders, arms and legs. The most important part of this move is to contract your abs fully before you start to lower your hips
223820043|NCT05341778|DEVICE|Electrical muscle stimulation|Electric stimulation works by mimicking the natural way by which the body exercises its muscles. The electrodes attached to the skin deliver impulses that make the muscles contract. It is beneficial in increasing the patient's range of motion and improves the circulation of the body.
223820044|NCT06437665|BEHAVIORAL|The intervention name in this study is ADAS-integrated driver simulation training.|The intervention involves providing older drivers (≥65 years of age) with training sessions utilizing a high-fidelity driving simulator. This training focuses on the integration and use of Lane Departure Warning (LDW), Cruise Control (CC), and Forward Proximity Warning (FPW) technologies, collectively referred to as ADAS. The training is designed to familiarize participants with these advanced driver assistance systems, enabling them to effectively utilize these features while driving.
223820045|NCT04848194|PROCEDURE|skin biopsy and blood sampling|"* 4 skin biopsies outside the face under local anesthesia: 2 in damaged zone, 2 in non-damage zone.~* A blood sample"
223820046|NCT03881176|DEVICE|PoNS Treatment|"The study site will deploy either PoNS Treatment Schedule A or PoNS Treatment Schedule B. Both PoNS Treatment Schedules will consist of three stages: an in-clinic training program, a home training program, and an extended home training program.~During all stages of the study, subjects will complete three training sessions per day, morning, afternoon and evening, 6 days per week. Daily evening sessions and training sessions on weekends will always be performed independently, at-home by the subject"
223820047|NCT05458024|DRUG|Vitamin D 2|300,000 international units (IUs) of Ergocalciferol in 6 50,000 IU capsules.
223820048|NCT05458024|DRUG|Vitamin D2 Placebo|Inert substance will be administered in 6 capsules indistinguishable from the 50,000 IU
223820049|NCT05120648|BEHAVIORAL|Biofeedback|We propose to study whether patients who complete a clinical six-session biofeedback protocol will demonstrate improvements in mental and physical health.
223820050|NCT05851248|PROCEDURE|Buccal muco-gingival tissue graft|"Recipient Site Preparation. In the GR, a sulcular incision limited to the vestibular face will be made, which will continue until reaching the tip of the buccal papillae on each side of the GR. Two vertical incisions from the base of the two papillae to the bottom of the vestibule and one horizontal incision will connect the ends of both vertical incisions to remove the pedicle tissue. The exposed root surface will be cleaned and smoothed with mini-curettes.~Donor site preparation. The incisions will be made in the same way as in the recipient area, including both papillae. The vertical incision will measure the distance from the cementoenamel junction (CEJ) to the bony dehiscence in the GR tooth, plus at least 2 mm. The tissue between the incisions will be elevated fjull or partial thickness close to the bone in the keratinized portion and superficially in the mucosal portion. A soft tissue substitute will be adapted and sutured to protect the donor site."
223820051|NCT05851248|PROCEDURE|Palatal connective tissue graft|"Recipient Site Preparation. In the GR, a sulcular incision limited to the vestibular face will be made, which will continue until reaching the tip of the buccal papillae on each side of the GR. Two vertical incisions from the base of the two papillae to the bottom of the vestibule and one horizontal incision will connect the ends of both vertical incisions to remove the pedicle tissue. The exposed root surface will be cleaned and smoothed with mini-curettes.~Donor site preparation A connective tissue graft will be taken from the palatal area, at the level of the premolars, which will include the two papillae. The size of the graft will be the same as that of the recipient area. A soft tissue substitute will be adapted and sutured to protect the donor site, especially if there is exposed bone."
223820052|NCT05701176|DIAGNOSTIC_TEST|[18F]F-AraG PET scan|\[18F\]F-AraG PET scans are performed to assess the accumulation of activated T-cells in the tumour and healthy tissue.
223820053|NCT06453096|OTHER|prevalence of personality disorders|the prevalence of personality disorders will be investigated with a retrospective study
223820054|NCT04706130|DRUG|Primaquine|After treatment of the blood stage infection, enrolled participants will receive either no primaquine, a low dose of primaquine or a high dose of primaquine against liver parasites
223820055|NCT04706130|DRUG|Artesunate|All enrolled participants will receive a 7-day treatment of artesunate ((2 mg/kg/day) to clear blood-stage parasites
223820056|NCT03653832|DRUG|Dexmedetomidine|"Patients will commence intravenous infusion of open-label study drug according to a weight-based dose regimen as early as possible post-randomisation, and within a maximum of two hours.~Bedside clinical staff will transition patients to achieve sedation with the allocated α2-agonist agent as quickly as clinically feasible and safe, to replicate the way these drugs would be used in routine practice. Additional opiate will be used for analgesia using clinical judgement. Once established, additional propofol will only be used when the maximum α2-agonist dose is reached or because cardiovascular or other side-effects limit dose escalation."
223820057|NCT03653832|DRUG|Clonidine|"Patients will commence intravenous infusion of open-label study drug according to a weight-based dose regimen as early as possible post-randomisation, and within a maximum of two hours.~Bedside clinical staff will transition patients to achieve sedation with the allocated α2-agonist agent as quickly as clinically feasible and safe, to replicate the way these drugs would be used in routine practice. Additional opiate will be used for analgesia using clinical judgement. Once established, additional propofol will only be used when the maximum α2-agonist dose is reached or because cardiovascular or other side-effects limit dose escalation."
223820058|NCT03653832|DRUG|Propofol|Patients will continue to receive intravenous propofol according to current usual care.
223820059|NCT05257057|DIAGNOSTIC_TEST|Immunohistochemical staining|Immunohistochemistry will be performed on the endometrial tissue specimens
223820060|NCT05654168|DIAGNOSTIC_TEST|Imaging|The thickness of the musculature to be studied will be measured with ultrasonography
223820061|NCT05777174|DRUG|MB-102|18.6 mg/mL in a 7.0 mL volume administered by intravenous injection over 30 - 60 seconds, followed by a 10 mL normal saline flush administered intravenously over 30 - 60 seconds
223820062|NCT05777174|DEVICE|MediBeacon Transdermal Glomerular Filtration Rate Measurement System (TGFR)|On treatment day, participants had the TGFR reusable sensor with disposable adhesive ring placed on their chest, and the MediBeacon® Transdermal GFR Measurement System was initiated to collect background fluorescence. When this was completed, participants received a single dose of MB-102. Fluorescent measurements were collected for 12-24 hours. For those with significant renal compromise, fluorescent measurements were continued until the sensor no longer detected MB-102 in the body.
223820063|NCT05229653|DRUG|Ketamine|Participants in this arm will receive intravenously (IV) ketamine (0.6 mg/kg) while recovering in the post anesthesia care unit (PACU) on the day of the surgery after subject has been deemed to be stable (hemodynamically stable, awake). The study physician will administer the study intervention via an intravenous pump to deliver 0.6 mg/kg ketamine over at least 30 minutes.
223820064|NCT05229653|DRUG|Placebo|Participants in this arm will receive intravenously (IV) matching equal dose of placebo while recovering in the post anesthesia care unit (PACU) on the day of the surgery after subject has been deemed to be stable (hemodynamically stable, awake). The study physician will administer the study intervention via an intravenous pump to deliver equal volume saline over at least 30 minutes.
223820065|NCT01345084|RADIATION|Radiation Therapy|66- 70 Gy External, Fractions of 2.0 Gy per day, 5 days a week
223820066|NCT01345084|DRUG|Nimotuzumab|200 mg, IV, weekly doses during the radiation therapy until completing 6 months (Diluted into 250 mL of sodium chloride sterile solution 0.9% in intravenous infusion for 30 minutes).
223820067|NCT01345084|DRUG|Cisplatin|75 mg/m2, IV, doses every 3 weeks (a total of three doses)
223820068|NCT06023901|DIAGNOSTIC_TEST|Apical periodontitis|Radiography of the patients were taken. Blood samples were collected from those patient
223820069|NCT05310279|OTHER|GAIMplank|The GAIMplank video game controller will be used to play active video games.
223820070|NCT02667886|DRUG|X4P-001|Continuous, oral dosing
223820071|NCT02667886|DRUG|axitinib|Continuous, oral dosing
223820072|NCT06028958|OTHER|Neck Isometrics Exercises|Isometric exercises are tightening (contractions) of a specific muscle or group of muscles. During isometric exercises, the muscle doesn't noticeably change length. The affected joint also doesn't move. Isometric exercises help maintain strength.
223820073|NCT06028958|OTHER|Global Posture Re-Education|Global postural rehabilitation (GPR) is an approach that considers the body in its overall aspect. This technique aims to relax the envelope of the muscles (fascia) while relaxing the muscle chains to reduce the strain on the joints. The end result is a more suitable posture and less pain.
223820074|NCT05997290|BIOLOGICAL|BNT162b2 (Omi XBB.1.5)|BNT162b2 monovalent (Omicron XBB.1.5)
223820075|NCT05997290|BIOLOGICAL|BNT162b2 (Omi JN.1)|BNT162b2 monovalent (Omicron JN.1)
223820076|NCT05997290|BIOLOGICAL|BNT162b2 (Omi KP.2)|BNT162b2 monovalent (Omicron KP.2)
223820077|NCT05487794|DRUG|Testosterone Cypionate 100 MG/ML|Testosterone is also responsible for increasing hematocrit by stimulating erythropoiesis (Velho et al., 2017). In cisgender men, who are hypogonadal and do not adequately produce testosterone, treatment with the use of testosterone is associated with stimulation of erythropoiesis, which can potentially increase blood viscosity, resulting in secondary erythrocytosis (Hajjar et al., 1997).
223820078|NCT00594217|DRUG|oral micronized progesterone suspension|oral micronized progesterone suspension, single 100 mg oral dose
223820079|NCT00594217|OTHER|Placebo|Placebo contains only inert ingredients and is not expected to exert any direct physiological effects
223820080|NCT03997578|PROCEDURE|NIPSA (Non-incised papilla surgical approach)|To access the defect, a single horizontal or oblique apical incision will be made in the mucosa located on the bony cortex, far from the marginal tissues and apically to the edge of the bony crest delimiting the defect. The incision will be extended mesiodistally as necessary to allow access to the defect and correct debridement of the granulation tissue. The tissue coronal to the incision will be raised full thickness, trying to maintain the preoperative papillae architecture intact. The granulation tissue and epithelium of the pocket will be eliminated. The affected root will be scaled and planed, and calculus eliminated. Once the defect will be debrided, the regenerative biomaterials will be applied. Then the incision line will be sutured by a double suture line to facilitate closing without tension: The first with internal horizontal mattress sutures to approximate the connective tissue of both edges of the mucosal incision, and the second with single interrupted sutures.
223820081|NCT03997578|PROCEDURE|NIPSA plus connective tissue graft|In these patients, the following methodology will be added to the technique described for the NIPSA group: once the biomaterials are applied, a connective tissue graft, taken at the level of the first upper molar, will be sutured to the base of the soft supra-alveolar tissue and to the palatal tissue, which has not been disinserted, using simple sutures.
223820082|NCT03442673|DRUG|Vinorelbine|Stimulation with vinorelbine together with G-CSF for mobilization of autologous stem cells
223820083|NCT03442673|DRUG|Gemcitabine|Stimulation with gemcitabine together with G-CSF for mobilization of autologous stem cells
223820084|NCT03442673|DRUG|G-CSF|Cytokine stimulation with G-CSF for mobilization of autologous stem cells
223820085|NCT00856947|DIETARY_SUPPLEMENT|Cholecalciferol D3|2 tablets of 1200 IU daily from week 24 of gestation to 1 week after delivery
223820086|NCT00856947|OTHER|Placebo tablet|2 tablets containing no active substance
223820087|NCT05809531|DRUG|Pegcetacoplan|Complement (C3) Inhibitor
223820088|NCT05581615|OTHER|Inulin|Each intervention provided 10 g/d inulin split into two dosages of 5 g.
223820089|NCT00617721|OTHER|Blood withdrawal|Observational study. Limited blood withdrawal. Any other intervention will be determined by the patient's clinical status.
223820090|NCT04949711|BEHAVIORAL|ridesharing voucher|Ridesharing vouchers will be given for completing each of the online surveys, for a possible total of $80 if you complete all three surveys. You will be paid with electronic vouchers that will be sent to your cell phone.
223820091|NCT04949711|BEHAVIORAL|online shopping voucher|Online shopping vouchers will be given for completing each of the online surveys, for a possible total of $80 if you complete all three surveys. You will be paid with electronic vouchers that will be sent to your cell phone.
223820092|NCT03764098|DRUG|Guanfacine ER|Guanfacine Extended Release (6mg/day ER)
223820093|NCT03764098|OTHER|Placebo|Placebo
223820094|NCT06413784|OTHER|Morning chronotype|Sleep quality, gestational diabetes and pregnancy symptoms of morning chronotype individuals were examined.
223820095|NCT06413784|OTHER|Intermediate chronotype|Sleep quality, gestational diabetes and pregnancy symptoms of intermediate chronotype individuals were examined.
223820096|NCT06413784|OTHER|Evening chronotype|Sleep quality, gestational diabetes and pregnancy symptoms of evening chronotype individuals were examined.
223820097|NCT02650843|OTHER|DAT SPECT imaging|
223820098|NCT06278246|RADIATION|PET Scan|PET scan using the novel \[11C\]MK-6884 tracer to measure M4R during the antipsychotic-free state
223820099|NCT06823843|DRUG|Glycerin trinitrate (GTN)|2 sublingual puffs for a total dose of 800 µg
223820100|NCT06823843|DRUG|Saline (NaCl 0,9 %) (placebo)|2 puffs of sublingual saline
223820101|NCT04959929|DEVICE|Focal vibration therapy|Myovolt is a wearable rehabilitative device that delivers vibration to the region of the body where the motors are worn. Participants are asked to apply the vibration to specific leg locations twice a day, for about 30 minutes at a time, and to record their response using a provided log. They may be asked to try applying the device at different location or using different vibration parameters (pulse frequency or intensity).
223820102|NCT03614962|DEVICE|Warmth + TENS|"A hat device will offer the electrical stimulation (pulse width of 120 milliseconds at about 100 Hz with constant current 0.02mA-0.7 mA, intensity setting at sensory threshold) over 4 acupuncture points over the scalp, including Baihui (GV20), Sishencong (EX-HN1), Fengchi (GB20) and Shenting (GV24). Selection of acupuncture points has been based on the recommendation of traditional Chinese medicine.~A custom-built warmth pad surrounding the TENS electrodes could produce the controlled comfortable warmth sensation, with default setting at 37degrees to 40 degrees Celsius."
223820103|NCT03614962|DEVICE|Warmth + placebo-TENS|A custom-built warmth pad surrounding the TENS electrodes could produce the controlled comfortable warmth sensation, with default setting at 37degrees to 40 degrees Celsius. The TENS electrodes are presented in the cap but no output will be delivered via these electrodes.
223820104|NCT03614962|DEVICE|TENS|A hat device will offer the electrical stimulation (pulse width of 120 milliseconds at about 100 Hz with constant current 0.02mA-0.7 mA, intensity setting at sensory threshold) over 4 acupuncture points over the scalp, including Baihui (GV20), Sishencong (EX-HN1), Fengchi (GB20) and Shenting (GV24). Selection of acupuncture points has been based on the recommendation of traditional Chinese medicine.
223820105|NCT03614962|DEVICE|Warmth only|A custom-built warmth pad surrounding the TENS electrodes could produce the controlled comfortable warmth sensation, with default setting at 37degrees to 40 degrees Celsius. No built-in TENS electrodes in the cap.
223820106|NCT03614962|DEVICE|control|No warmth pad and TENS electrodes presented in the cap.
223820107|NCT00747123|BIOLOGICAL|ACE-011|ACE-011 given by the subcutaneous route of administration monthly for 4 doses.
223820108|NCT00747123|BIOLOGICAL|Placebo|Placebo given by the subcutaneous route of administration monthly for 4 doses.
223820109|NCT04974398|DRUG|Penpulimab|Arm A: Penpulimab (200 mg, administered on Day 1 of each cycle, Q3W) +cisplatin (80 mg/m2) or carboplatin (AUC 5) (administered on Day 1 of each cycle, Q3W, up to 6 cycles) + gemcitabine (1000 mg/ m2, administered on Days 1 and 8 of each cycle, Q3W, up to 6 cycles), 3 weeks (21 days) per cycle; followed by penpulimab (200 mg, administered on Day 1 of each cycle, Q3W) as maintenance treatment.
223820110|NCT04974398|DRUG|placebo|Arm B: Placebo (200 mg, administered on Day 1 of each cycle, Q3W) + cisplatin (80 mg/m2) or carboplatin (AUC 5) (administered on Day 1 of each cycle, Q3W, up to 6 cycles) + gemcitabine (1000 mg/m2, administered on Days 1 and 8 of each cycle, Q3W, up to 6 cycles), every 3 weeks (21 days) per cycle; followed by placebo(200 mg, administered on Day 1 of each cycle, Q3W) as maintenance treatment. Subjects in Arm B will have the opportunity to crossover to openlabel treatment with penpulimab monotherapy after radiographic disease progression.
223820111|NCT06562842|OTHER|Regular exercise|Participants will perform regular exercise training for 12 weeks, followed by 4 weeks of detraining.
223820112|NCT06562842|OTHER|Control comparator|Participants will remain sedentary throughout the 16-weeks intervention period.
223820113|NCT06452511|DRUG|Metformin|In the Metformin arm of this study, 50 overweight women with polycystic ovary syndrome (PCOS) and infertility will receive a combination treatment of Letrozole and Metformin. Letrozole, aimed at inducing ovulation, will be administered according to a specified dosage regimen, alongside Metformin, an insulin-sensitizing agent used to manage PCOS, prescribed at a specified dosage regimen. Participants will undergo regular monitoring to assess ovulation and pregnancy outcomes, involving baseline assessments of health status and fertility parameters, ongoing monitoring visits to track ovulation through ultrasound and hormone levels, and final evaluation of ovulation rates and pregnancy outcomes at the study's end. This arm seeks to determine the efficacy of Metformin as an adjunct to Letrozole in improving ovulation induction and pregnancy rates among overweight women with PCOS.
223820114|NCT06452511|DRUG|pep2dia|In the Pep2dia arm of this study, 50 overweight women diagnosed with polycystic ovary syndrome (PCOS) and experiencing infertility will receive a combination treatment of Letrozole and Pep2dia. Letrozole, utilized to induce ovulation, will be administered according to a specified dosage regimen, along with Pep2dia, a peptide-based therapy tailored to manage PCOS, prescribed at a specified dosage regimen. Participants will undergo regular monitoring to assess ovulation and pregnancy outcomes, involving baseline assessments of health status and fertility parameters, ongoing monitoring visits to track ovulation through ultrasound and hormone levels, and a final evaluation of ovulation rates and pregnancy outcomes at the conclusion of the study period. This arm seeks to ascertain the effectiveness of Pep2dia as an adjunct to Letrozole in enhancing ovulation induction and pregnancy rates among overweight women with PCOS.
223820115|NCT06188065|DIAGNOSTIC_TEST|Blood eosinophil count|To determine the time it takes for blood eosinophil count to recover to baseline stable state following severe exacerbation of COPD associated with admission eosinopenia and to explore independent factors associated with admission eosinopenia.
223820116|NCT03635489|DRUG|Paclitaxel|175 mg/m\^2 IV infusion on Day 1 of each 21-day cycle.
223820117|NCT03635489|DRUG|Bevacizumab|15 mg/kg IV infusion on Day 1 of each 21-day cycle.
223820118|NCT03635489|DRUG|Carboplatin|Area Under the Curve (AUC) of 6 mg/ml/min on Day 1 of each 21-day cycle.
223820119|NCT03635489|DRUG|Placebo|Placebo matched to bevacizumab IV infusion on Day 1 of each 21-day cycle.
223820120|NCT01454453|DRUG|Patients- dose titration|dose titration (patients) - 4-10 weeks
223820121|NCT03461848|OTHER|CYPHP Evelina London Model of care|Universal services offer, Paediatric hotlines, Education and training for health professionals, Online decision support tools and guidelines, Young people-friendly access to primary care, and Resilience training in schools, Targeted services offered dependent on need. Children with any of the tracer conditions will be offered pathway based care including early intervention for physical and related mental health needs, paediatric nursing support, care plans shared with schools, medication reviews, and peer-led parenting support. Self-management support, social support signposting, and safety-netting are offered to all.
223820122|NCT03461848|OTHER|Enhanced Usual Care|Universal services offer, Paediatric hotlines, Education and training for health professionals, Online decision support tools and guidelines, Young people-friendly access to primary care, and Resilience training in schools, Self-management support, social support signposting, and safety-netting are offered to all.
223820123|NCT00973570|BEHAVIORAL|TABADO program|The intervention takes place in 3 stages: (i) a general information session on tobacco consumption is delivered to all teenagers, both smokers and nonsmokers. (ii) For smokers wishing to join the program, this session is followed by individualized consultations with a team of tobacco addiction physicians. (iii) The volunteers then benefit from a small group approach, consisting of discussion sessions to share experiences, strengthen motivation, and prevent relapse. There will be 4 sessions in total, comprising individual counseling and work in groups spread over 3 months (taking into account the availability of the trainees because of their alternate-week training schedule).
223820124|NCT06143696|DRUG|Qingxin Zishen decoction|Oral administration, 1 dose daily, twice a day
223820125|NCT06143696|DRUG|Femoston|Oral administration, 1 pill each time, once a day
223820126|NCT05094167|OTHER|V9|one times a day during the whole treatment
223820127|NCT05094167|OTHER|placebo|placebo
223820128|NCT06342180|DIAGNOSTIC_TEST|Serum uric acid level|An amount of 2-3 ml of blood sample will be collected from the patients after 8-12 hours of fasting and will be kept frozen at -70 degrees to calculate the serum UA level.
223820129|NCT02702310|OTHER|Quality-of-Life Assessment|At initial visit (day 1) - for determination of a baseline quality of life, patients will be given a self-reported questionnaire called the Skindex-29. Following standard of care radiation treatments, at weeks 6 \& 12, and every 3 months thereafter, patients will complete the Skindex-29 questionnaire.
223820130|NCT02702310|OTHER|Objective Grading of Skin Findings|At initial visit (day 1) , using mSWAT the radiation oncologist can follow the patient's treatment response by accurately grading the severity of the patient's skin findings. Following standard of care radiation treatments, at weeks 6 \& 12, and every 3 months thereafter, mSWAT will again be determined by physician. Follow-up visits will continue until patient has a change in disease.
223820131|NCT00426426|BEHAVIORAL|Cognitive-Behavioural Therapy|12 sessions with Cognitive-Behavioural Therapy (CBT), and waiting list will be over 12 weeks, and then allocated into Meta-Cognitive Therapy.
223820132|NCT00426426|BEHAVIORAL|Meta-Cognitive Therapy|12 sessions with Meta-Cognitive Therapy (MCT), and waiting list will be over 12 weeks, and then allocated into Cognitive-Behavioural Therapy .
223820133|NCT00426426|BEHAVIORAL|Waiting list|
223820134|NCT04338425|BEHAVIORAL|Voice call|Attending surgeons will contact with their patients on the day of surgery after discharge via voice call.
223820135|NCT04338425|BEHAVIORAL|Video call|Attending surgeons will contact with their patients on the day of surgery after discharge via video call (video conferencing application such as FaceTime or Skype)
223820136|NCT01905254|DEVICE|Transient elastography (TE)|TE and minilaparoscopic guided liver biopsy were performed by physicians blinded to the results the other within a period of less than 3 months.
223820137|NCT01905254|OTHER|Liver biopsy|Minilaparoscopic guided liver biopsy was performed within a period of 3 months of Transient Elastography
223820138|NCT01876641|DRUG|Vemurafenib + Cobimetinib, Decitabine|
223820139|NCT06287996|OTHER|footbath and actigraphy|Receive warm water foot bath for 4 weeks, 1 hour before going to bed every night (7-9PM), temperature 42℃ for 20 minutes, water depth 10cm above the ankle joint and wearing an actigraphy for 4 weeks
223820140|NCT06287996|DEVICE|actigraphy|Wearing an actigraphy for 4 weeks
223820141|NCT04534634|COMBINATION_PRODUCT|IFN-α combined with CAR-T cell therapy|"Adults: 14 daily intramuscular injections 300 million IU of Interferon-α for a 28-day cycle.~Children: 14 daily intramuscular injections 200mg/m\^2 of Interferon-α for a 28-day cycle.~CAR T cell: (1-2)×10\^7/kg, intravenously infusion."
223820142|NCT02213328|DRUG|Truvada|Fixed-dose combination tablet containing 200 mg of FTC plus 300 mg of TDF, taken once daily by mouth.
223820143|NCT01268202|DRUG|Pravastatin|Pravastatin 40mg/day during 12 months
223820144|NCT02138266|DEVICE|Topcon Specular Microscope SP-1P|
223820145|NCT02138266|DEVICE|Konan Specular Microscope CELLCHEK XL|
223820146|NCT02402296|DRUG|β-1,3/1,6-D-glucan|15 patients (in group II) suffering from localized aggressive periodontitis followed a strict plaque control program (within two weeks); followed by a systemic course of β-1,3/1,6-D-glucan oral supplementation for 40 days.
223820147|NCT02402296|OTHER|Placebo|15 patients (in group I) suffering from localized aggressive periodontitis followed a strict plaque control program (within two weeks); followed by a systemic course of placebo capsules oral supplementation for 40 days.
223820148|NCT06534073|DEVICE|Socks|Plantar orthotic elements will be designed, according to the participants' previous baropodometric pattern, to alleviate pathological plantar pressure. These elements will be integrated into commonly worn items by patients, such as stockings or socks.
223820149|NCT06534073|DEVICE|Standard device|Removable device of digital alignment to stabilize and unload the affected metatarsophalangeal joint. They do not require frequent replacement as they are washable and reusable elements.
223820150|NCT06534073|DEVICE|Foot orthoses|Custom-made foot orthoses.
223820151|NCT03706118|OTHER|Magnetic resonance imaging|At month 0, 12, 24 and 36 participants will be examined by quantitative magnetic resonance imaging of brain, cervical and part of thoracic spine.
223820152|NCT00001599|DRUG|Thalidomide|
223820153|NCT00775814|DRUG|Candesartan and Hydrochlorothiazide|Candesartan 8 mg, tablets, orally, once daily and hydrochlorothiazide 12.5 mg, tablets, orally, once daily for 2 weeks; increased to Candesartan 16 mg, tablets, orally, once daily and hydrochlorothiazide 12.5 mg, tablets, orally, once daily for up to 24 weeks.
223820154|NCT00775814|DRUG|Hydrochlorothiazide (HCT)|Candesartan placebo-matching tablets and hydrochlorothiazide 12.5 mg, tablets, orally, once daily for up to 24 weeks.
223820155|NCT01807650|DRUG|Oleogel-S10, non-adhesive wound dressing|1 cm or 100 mg Oleogel-S10 per cm2 wound area (corresponds to thickness of approximately 1 mm or 0.04 inch) every 3 to 4 days until 95% epithelialization of the wound or end of treatment at Day 28
223820156|NCT01807650|DEVICE|Non-adhesive wound dressing only|Soft silicone faced polyurethane foam dressing such as Mepilex® only every 3 to 4 days until 95% epithelialization of the wound or end of treatment at Day 28
223820157|NCT05435755|BIOLOGICAL|hAESCs treatment|Precise Transplantation of hAESCs Into the Ventricle for Parkinson's Disease.
223820158|NCT05435755|BIOLOGICAL|placebo (saline)|2 times placebo (normal saline) injections as control group
223820159|NCT00736489|DRUG|AZD3199|Dry powder for inhalation, single dose
223820160|NCT00736489|DRUG|Formoterol|Dry powder for inhalation, single dose
223820161|NCT00736489|DRUG|Placebo|Dry powder for inhalation, single dose
223820162|NCT00016692|DRUG|Z-100|
223820163|NCT00762632|DRUG|NILOTINIB|400 mg Nilotinib bid (total daily dose 800 mg) should be continued 25 weeks
223820164|NCT00762632|DRUG|EVEROLIMUS|Everolimus at 2,5 mg/day should be continued 25 weeks.
223820165|NCT05084417|OTHER|N/A This is an observational study|As this is an observational study, there are no interventions assigned to either cohort.
223820166|NCT06340074|BEHAVIORAL|HELM|HELM is a 9-month, data-driven organizational and leadership implementation strategy that entails eight core components: 1) Assessment and Feedback. 2) Initial Training. 3) Leadership Development Plan. 4) Individual Coaching. 5) Group Coaching. 6) Organizational Strategy Development. 7) Professional Learning Collaboratives. 8) Graduation.
223820167|NCT06340074|BEHAVIORAL|Implementation Attention Control (IAC)|Schools assigned to the IAC condition received an online, self-paced, independent studies program broadly focused on leadership and management. The program did not specifically discuss implementation leadership or climate. The program included four content modules hosted on a web-based learning portal: 1) Motivating and Engaging Employees, 2) Authentic Leadership, 3) Managing Diverse Teams, and 4) Fostering an Idea Culture. Each module consisted of one content-specific 60-minute webinar.
223820168|NCT04015115|BEHAVIORAL|Youth Opioid Recovery Support service model|see arm 1 description
223820169|NCT00203151|DRUG|edratide|0.5 mg, 1.0 mg, 2.5 mg injection once weekly
223820170|NCT01858467|DEVICE|Endotracheal intubation|Portex endotracheal tube 6.5mm or 7.0mm internal diameter
223820171|NCT01858467|DEVICE|Supreme Laryngeal Mask Airway|Supreme Laryngeal Mask Airway Size 3 or Size 4 with gastric tube insertion.
223820172|NCT00414739|DRUG|Benzalkonium chloride|
223820173|NCT06491199|OTHER|Home blood pressure telemonitoring program and clinician monitoring|"Home Blood Pressure Telemonitoring (HBPT) includes used of an app to collect and transmit blood pressure readings.~Clinician monitoring includes OBIM physicians reviewing transmitted BP data and contacting patients to adjust antihypertensive medication regimens."
223820174|NCT05302557|OTHER|Ileostomy stimulation|Daily stimulation of the efferent loop will be performed during the two weeks prior to the surgery.
223820175|NCT03874845|BEHAVIORAL|Mindfulness-Based Cognitive Therapy|Participants will attend 8 weekly group therapy sessions. Prior to and after therapy participants will have assessments related to their PTSD, fill out surveys, and have an fMRI.
223820176|NCT03874845|BEHAVIORAL|Muscle Relaxation Therapy|Participants will attend 8 weekly group therapy sessions. Prior to and after therapy participants will have assessments related to their PTSD, fill out surveys, and have an fMRI.
223820177|NCT05312437|OTHER|Interruptive Alert, CDS|"Experimental: CDS Intervention Adult patients in the highest predicted risk tier (\>=2% predicted risk) at the time visit registration (aka check-in).~The Intervention would then be described as:~Physicians review a Best Practice Advisory describing the patient's risk and choose from the following options:~1. Document face-to-face suicide risk screening with the Columbia Suicide Severity Rating Scale (CDS complete once the CSSRS is complete)~2. Agree to screen using an alternative method chosen at the clinician's discretion (CDS complete)~3. Disagree with alert and provide a rationale for disagreement (CDS complete)~4. Indicate suicide risk face-to-face screening has already occurred (CDS complete)~5. Dismiss the alert. The alert will be available in Epic Storyboard persistently until acted on further. The Storyboard functionality after dismissal is identical to the Passive Prompt, CDS intervention (below)"
223820178|NCT05312437|OTHER|Passive Prompt, CDS|"Adult patients in the highest predicted risk tier (\>=2% predicted risk, based on our research study, DOI: 10.1001/jamanetworkopen.2021.1428) at the time of visit registration (aka check-in) will be randomized to either the Interruptive Alert or Passive Prompt CDS intervention arms.~In the Passive Prompt arm, the physician who next opens the patients' charts after check-in (e.g., Chart Review) will see a Storyboard icon for Elevated Suicide Risk on the left side of the screen. Hovering over this icon will bring up a window with the BPA information in a view identical to the Interruptive Alert arm. Clicking on the window will bring up the BPA with full functionality as in the Interruptive Alert arm."
223820179|NCT01165073|DIETARY_SUPPLEMENT|Osmolite and B.C.A.A.|Feeding inserted into enteral tubes
223820180|NCT01165073|DIETARY_SUPPLEMENT|Normal oral intake & supplementation if necessary|Enteral nutrition
223820181|NCT04410679|BIOLOGICAL|injectable PRF|blood sample and centrifuged to obtain i-PRF
223820182|NCT01816763|BEHAVIORAL|NRS pain one week|Eligible patients will be randomly assigned to complete a patient-reported 'NRS one week' on a tablet prior to making contact with a nursing staff vital signs screener.
223820183|NCT01816763|BEHAVIORAL|PEG|Eligible patients will be assigned to complete a patient-reported enhanced pain screening with the PEG on a tablet prior to making contact with a nursing staff vital signs screener.
223820184|NCT01816763|BEHAVIORAL|DVPRS|Eligible patients will be randomly assigned to complete a patient-reported 'DVPRS' on a tablet prior to making contact with a nursing staff vital signs screener.
223820185|NCT02271750|PROCEDURE|lumbar puncture|for spinal fluid
223820186|NCT04934137|BEHAVIORAL|Sensoria|The Sensoria system uses a force-sensing mat installed under the wheelchair cushion that connects via Bluetooth to a mobile app. The mobile app displays information about weight shifts, goal-setting functions, and feedback on performance/outcomes.
223820187|NCT04934137|BEHAVIORAL|AW-Shift|The AW-Shift system uses a pressure-sensing mat installed on top of the wheelchair cushion that connects via Bluetooth to a mobile app. The mobile app displays visual representation of the seating surface and can set reminders for weight shifts.
223820188|NCT00663117|DRUG|Naltrexone-HCl|naltrexone 4.5 mg
223820189|NCT00663117|DRUG|Placebo|Placebo
223820190|NCT00311155|DRUG|olmesartan medoxomil + hydrochlorothiazide, if necessary + amlodipine, if necessary|Olmesartan medoxomil oral tablets 20 mg for 4 weeks followed by, if necessary: Olmesartan medoxomil oral tablets 20 mg + hydrochlorothiazide oral tablets 12.5 mg for 4 weeks, followed by, if necessary: Olmesartan medoxomil oral tablets 20 mg + hydrochlorothiazide oral tablets 25 mg for 4 weeks, followed by, if necessary: Olmesartan medoxomil oral tablets 20 mg + hydrochlorothiazide oral tablets 25 mg + amlodipine oral tablets 5 mg for 4 weeks, followed by, if necessary: Olmesartan medoxomil oral tablets 20 mg + hydrochlorothiazide oral tablets 25 mg + amlodipine oral tablets 10 mg for 4 weeks. All study medications are to be taken once daily. The subject's participation completes when blood pressure goals are achieved.
223820191|NCT01633086|DRUG|nitric oxide gel|"1. st gel: sodium nitrites,BID local use X 28 days~2. nd gel: maleic/ascorbic acids ,BID local use X 28 days"
223820192|NCT01633086|DRUG|placebo gel|placebo gel,BID local use X 28 days
223820193|NCT04684641|DRUG|Standard Dose YPT-01|Participants will be randomized to receive the standard dose of phage therapy YPT-01.
223820194|NCT04684641|OTHER|Placebo|Participants will be randomized to receive the placebo.
223820195|NCT05176782|DRUG|HTK cardioplegia|will receive HTK cardioplegia in volume 30 ml/Kg given by antegrade route through an aortic route cannula.
223820196|NCT05176782|DRUG|Cold Cadioplegia|as the will receive group cold Blood Cardioplegia in volume 20mL/kg given by antegrade route through an aortic route cannula and repeated 10mL/kg/dose every 25minutes at 8-12°C for maintenance. This technique considered the standard management in this age.
223820197|NCT02243631|DRUG|Probenecid|Treatment
223820198|NCT03117517|DRUG|Metformin|Metformin (1000 mg)
223820199|NCT03117517|DRUG|Metformin, Pioglitazone|Metformin (1000 mg) Pioglitazone (30 mg)
223820200|NCT04878419|OTHER|Virtual Educational Program|Multiple virtual interactive sessions to provide education/knowledge about Type 1 Diabetes Mellitus care
223820201|NCT02765555|DRUG|RBP-7000|Single dose
223820202|NCT06386081|DIETARY_SUPPLEMENT|Citrus pectin with low DE|Dietary intervention with citrus pectin with low DE. Participants will orally take the supplement twice a day, after dissolving it in 100ml of water, for 2 months.
223820203|NCT06386081|DIETARY_SUPPLEMENT|Apple pectin with high DE|Dietary intervention with apple pectin with high DE. Participants will orally take the supplement twice a day, after dissolving it in 100ml of water, for 2 months.
223820204|NCT06386081|DIETARY_SUPPLEMENT|Placebo|Participants will orally take the placebo (maltodextrin) twice a day, after dissolving it in 100ml of water, for 2 months. Maltodextrin is highly digestible and in small amounts will have limited impact on gut microbiome.
223820205|NCT05834582|DRUG|Fluzoparib+Paclitaxel|Fluzoparib+Paclitaxel for 4 cycles if tumor response is SD after 2 cycles of EC induced chemotherapy
223820206|NCT05834582|DRUG|Epirubicin+Cyclophosphamide|Epirubicin+Cyclophosphamide
223820207|NCT04198740|DIAGNOSTIC_TEST|Tear sample collection via Schirmer strip and subsequent analysis by mass spectrometry|During regular consultations at the ophthalmology department of the CHUM, eligible patients will undergo a standard 5 minute Schirmer tear test. The Schirmer strips will serve as tear samples and will be sent to UQAM's Department of chemistry for mass spectrometry analysis.
223820208|NCT04670926|DIAGNOSTIC_TEST|TruGraf|"TruGraf results will be available in real-time and used by the physician in conjunction with other standard of care labs to guide management of immunosuppression as follows:~Patients with a stable serum creatinine and eGFR of \> 45 mL/min who also have a TruGraf TX result at month 3 will have their Mycophenolate Mofetil or Mycophenolate Sodium decreased from a standard dose of 1000 mg twice daily to 500 mg twice daily or 720 mg twice daily to 360 mg twice daily respectively.~Patients with a stable serum creatinine and estimated eGFR of \> 45 mL/min who also have a TruGraf TX result at months 4, 5, and 6 will have their Tacrolimus target trough level decreased to a target between 3 and 6.~Patients with TruGraf not-TX will have no further immunosuppression reduction and continued to be monitored."
223820209|NCT04670926|OTHER|Standard of Care|Patient's immunosuppression will be managed per the current CPMC standard of care that includes continuation of Mycophenolate Mofetil or Mycopheonolate Sodium at 1000 mg bid or 720 mg bid respectively. The dose may be decreased at the discretion of the physician for drug adverse effects such as diarrhea or other gastrointestinal side-effects or neutropenia as is the standard of care. Patients will be maintained on Tacrolimus at target levels that are considered standard of care by the managing physician.
223820210|NCT02948348|DRUG|Nivolumab|Capecitabine:Dose of 1650mg/m2,14days, Radiation:45Gy/25 fractions, Nivolumab :240mg on day1 of each cycle, Surgical therapy:The resection (LAR), intersphincteric resection (ISR), or abdominoperineal resection (APR).
223820211|NCT02948348|DRUG|Ipilimumab|For only Cohort D,1 mg/kg at six-week intervals
223820212|NCT00896129|OTHER|HRQOL Survey Packet|Questionnaires
223820213|NCT00991159|BIOLOGICAL|RN316|Single, escalating doses of RN316 administered IV. Doses planned for testing = 0.3, 1.0, 3.0, 6.0, 12.0, and 18.0 mg/kg.
223820214|NCT01785628|DIETARY_SUPPLEMENT|Sarcosine Capsule|Sarcosine is a glycine transporter-1 (GlyT-1) inhibitor. By blocking glycine uptake, sarcosine increases synaptic glycine concentration to enhance NMDA receptor function.
223820215|NCT01785628|DIETARY_SUPPLEMENT|Placebo Capsule|Placebo is dextrin composition.
223820216|NCT00840996|DRUG|Lidocaine|perioperative intravenous lidocaine (2 mg/kg/h) with maximum of 200 mg/h starting at induction of anesthesia and continuing until discharge from the PACU or a maximum of 8 hours
223820217|NCT00840996|DRUG|placebo|perioperative placebo IV saline infusion of 2 mg/kg/h with maximum of 200 mg/h starting at induction of anesthesia and continuing until discharge from the PACU or a maximum of 8 hours
223820218|NCT00321334|PROCEDURE|Chemotherapy+Surgery|Docetaxel:75mg/m2 on D1 cycle,3 cycles Carboplatin:AUC=5 on D1 cycle,3 cycles
223820219|NCT05601713|OTHER|No cooling (control)|Participants are exposed to 38°C, 35% relative humidity for 6 hours without cooling interventions (control condition). Drinking water is available ad libitum.
223820220|NCT05601713|OTHER|Lower limb immersion|Participants are exposed to 38°C, 35% relative humidity for 6 hours. For the last 40 min of each hour, participants lower limbs are immersed in cool water (\~20°C) up to the level of mid calf. Drinking water is available ad libitum.
223820221|NCT05601713|OTHER|Lower limb immersion + neck cooling|Participants are exposed to 38°C, 35% relative humidity for 6 hours. For the last 40 min of each hour, participants lower limbs are immersed in cool water (\~20°C) up to the level of mid calf. During limb immersion, a towel soaked in cool water (\~20°C) is placed around the participants neck. The towel is re-wet half way through the 40-min limb immersion. Drinking water is available ad libitum.
223820222|NCT06039228|BEHAVIORAL|Acceptance and commitment therapy|Four sessions of group acceptance and commitment therapy, with each session lasting for 1.5 hours.
223820223|NCT05601921|DEVICE|Repetitive transcranial magnetic stimulation|Repetitive transcranial magnetic stimulation (rTMS) is a noninvasive intervention that uses magnetic fields to stimulate nerve cells to improve the symptoms of a variety of disorders. In recent years, TMS studies have been conducted in many painful conditions, which are thought to have complex pain mechanisms in the pathogenesis, and its effectiveness has been reported.
223820224|NCT05601921|DEVICE|Sham Repetitive transcranial magnetic stimulation|Sham Repetitive transcranial magnetic stimulation
223820225|NCT01265641|DRUG|AZD1981, 2000mg|Single oral dose, tablets
223820226|NCT01265641|DRUG|AZD1981, 200mg|Single oral dose, tablets
223820227|NCT01265641|DRUG|Moxifloxacin, 400mg|Single oral dose, capsule
223820228|NCT01265641|DRUG|Placebo|Single oral dose, tablets
223820229|NCT05027737|PROCEDURE|Early Ileostomy Closure|Following a negative leak test (CT scan with rectally-administered water-soluble contrast on post-operative day 7, 8 or 9), patients will undergo standardized reversal of their diverting loop ileostomy (stapled side-side functional end-to end anastomosis, purse-string closure of the ileostomy wound, and no use of epidural analgesia) between post-operative days 10-14.
223820230|NCT05114694|PROCEDURE|early APM|Early APM group were patients have knee syndrome within 3 to 6 months
223820231|NCT05114694|PROCEDURE|delayed APM|delayed APM group recruit participants who received delayed APM surgery within 6 to 12 months
223820232|NCT04278677|DIETARY_SUPPLEMENT|melatonin|Melatonin capsules to be taken for 6 weeks
223820233|NCT03285295|DEVICE|Alinity s HBsAg and Alinity s HBsAg Confirmatory Assay|For all donor specimens with investigational Alinity s HBsAg and Alinity s HBsAg Confirmatory results that are discordant with final status after supplemental testing, an attempt will be made to obtain a follow-up whole blood specimen approximately 4 to 6 weeks after initial donation for further analysis.
223820234|NCT03285295|DEVICE|Alinity s HTLV I/II Assay|For all donor specimens with investigational Alinity s HTLV I/II results that are discordant with final status after supplemental testing, an attempt will be made to obtain a follow-up whole blood specimen approximately 4 to 6 weeks after initial donation for further analysis.
223820235|NCT03285295|DEVICE|Alinity s Anti-HCV Assay|For all donor specimens with investigational Alinity s Anti-HCV results that are discordant with final status after supplemental testing, an attempt will be made to obtain a follow-up whole blood specimen approximately 4 to 6 weeks after initial donation for further analysis.
223820236|NCT03285295|DEVICE|Alinity s HIV Ag/Ab Combo Assay|For all donor specimens with investigational Alinity s HIV Ag/Ab Combo results that are discordant with final status after supplemental testing, an attempt will be made to obtain a follow-up whole blood specimen approximately 4 to 6 weeks after initial donation for further analysis.
223820237|NCT03285295|DEVICE|Alinity s Anti-HBc Assay|For all donor specimens with investigational Alinity s Anti-HBc results that are discordant with final status after supplemental testing, an attempt will be made to obtain a follow-up whole blood specimen approximately 4 to 6 weeks after initial donation for further analysis.
223820238|NCT03285295|DEVICE|Alinity s Chagas Assay|For all donor specimens with investigational Alinity s Chagas results that are discordant with final status after supplemental testing, an attempt will be made to obtain a follow-up whole blood specimen approximately 4 to 6 weeks after initial donation for further analysis.
223820239|NCT02200939|DEVICE|Bioinductive implant|
223820240|NCT02200939|DEVICE|Surgical repair|Surgical repair with commercially-available sutures/suture anchors.
223820241|NCT02746575|DRUG|metoprolol|
223820242|NCT02365974|DEVICE|Transcutaneous Electrical Stimulation|TENS will be applied in the cervicothoracic ganglion region located between the C7 and T4 vertebral processes for 40 minutes three times weekly for a total of four weeks. The intensity in milliamps will be adjusted depending on the sensitivity of each individual patient.
223820243|NCT02365974|DEVICE|No Transcutaneous Electrical Stimulation|The sham group will be submitted to the procedure to fit the stimulation equipment. without be submitted to stimulation.
223820244|NCT03221504|OTHER|Longer therapy duration|Patients will receive cefuroxime axetil orally. Treatment will involve the supply of cefuroxime axetil 30 mg/kg/d in two divided doses (in blinded bottles).
223820245|NCT03221504|OTHER|Shorter therapy duration|Patients will receive placebo orally (in blinded bottles). The volume of the placebo will be like cefuroxime syrup.
223820246|NCT00674635|DRUG|GSK3152314A|Part A single IV dose; Part B 3 repeat IV dose at Day 1, Day 28 and Day 56; Part C single SC dose
223820247|NCT00674635|DRUG|Placebo|matching placebo
223820248|NCT06217887|DRUG|loxenatide Group|Loxenatide will be initiated and maintained at 0.2mg once weekly until the completion of the study. All patients will also continue on their existing dose and regimen of metformin throughout the study.
223820249|NCT06217887|DRUG|Gliclazide Group|Gliclazide will be initiated and maintained at 30mg/day every morning. If necessary, the dose can be increased to 120mg once daily. All patients will also continue on their existing dose and regimen of metformin throughout the study.
223820250|NCT00659594|DRUG|Ciclesonide|200µg Ciclesonide versus Placebo
223820251|NCT00659594|DRUG|Placebo|placebo
223820252|NCT06319768|DRUG|Pentoxifylline|Patients will be treated with intralesional PTX (Trentoximal Ampoule 100 mg/5 ml) in a dose of 1mg per lesion at a distance 1cm between two atrophic lesions with a maximum 20 mg per session (with insulin syringe 30Gx8mm). Lesion blanching is the endpoint of injection
223820253|NCT06319768|DRUG|platelet rich plasma|Patients will be treated with intralesional PRP. PRP will be obtained by the double-spin method, followed by the collection of 10 mL of autologous whole blood into tubes containing trisodium citrate as an anticoagulant. The collected blood will first be centrifuged at 1000 RPM for 10 minutes at room temperature to separate the red blood cells at the bottom of the tube, the buffy coat (containing the white blood cells) in the middle, and the plasma above (soft spin). Then, the upper plasma will be pipetted above the buffy coat to undergo another centrifugation at 1500 RPM for another10 minutes (hard spin) to obtain a platelet pellet in the bottom of the tube (with a platelet count 4-4.5 times higher than that of baseline) and a platelet-poor plasma(PPP) in the upper part. The PPP will be partly removed and partly used to re-suspend the platelets to finally produce 2 mL of PRP
223820254|NCT06319768|DRUG|combined pentoxifylline and platelet rich plasma|Patients will be treated with a combination of both intralesional 1mg of PTX per lesion (with a maximum 20mg per session) then 0.1ml of intralesional PRP at the same lesion after 5 minutes
223820255|NCT02753205|DRUG|Dexmedetomidine|infusion of dexmedetomidine 0.5ug/kg/h for 10 min and after that, infusion of dexmedetomidine 0.4ug/kg/h until the end of surgery
223820256|NCT02753205|DRUG|normal saline|infusion of normal saline
223820257|NCT01752595|BEHAVIORAL|Preference Based Rhythmic Auditory Stimulation Music|"Patients that have been randomized into arms 2 and 3 will be blinded to the intervention they are receiving (i.e. preference-based playlist vs. preference-based playlist that has been edited to include Rhythmic Auditory Stimulation (RAS). RAS drives synchronous neural oscillation (entrainment) and functions in two ways: (1) facilitates pace and heart-rate synchrony and (2) facilitates brain state dominance (getting into the zone). RAS will be accomplished through: (1) sequencing of subject self-selected music based on tempo, (2) accentuation of the rhythmic driving pulse with added percussive-type sounds, (3) addition of binaurally detuned pitches to follow bass lines at brain-state target frequencies (e.g., 8 Hz alpha, or 16 Hz beta), and (4) the addition of binaurally detuned background sounds (e.g., low frequency hum) at target Hz frequencies. RAS is implemented as inherent and natural to the music and may remain imperceptible to most."
223820258|NCT01752595|OTHER|Preference Based Music Intervention|
223820259|NCT01293019|PROCEDURE|Osteopathic treatment|Real treatment of osteopathy
223820260|NCT01293019|PROCEDURE|Sham Placebo|Sham treatment of osteopathy
223820261|NCT01293019|PROCEDURE|Usual care|Classical treatment of pain in cystic fibrosis patients
223820262|NCT03239873|BIOLOGICAL|VARIVAX® PE34 Process|Varicella virus vaccine live manufactured with a new passage extension process (PE34)
223820263|NCT03239873|BIOLOGICAL|VARIVAX® 2016 Commercial Process|Varicella virus vaccine live manufactured with the 2016 commercial process
223820264|NCT03239873|BIOLOGICAL|M-M-R II®|Measles, Mumps, and Rubella virus vaccine live
223820265|NCT02446925|DEVICE|Surefire® Infusion System|Utilization of Surefire® Infusion System for Y-90 glass microsphere embolization
223820266|NCT02446925|DEVICE|Standard End-hole catheter|Utilization of Standard End-hole catheter for Y-90 glass microsphere embolization
223820267|NCT03996408|DRUG|Anlotinib|a multi-target receptor tyrosine kinase inhibitor
223820268|NCT03996408|DRUG|TQB2450|TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.
223820269|NCT02040987|DRUG|AZD3293|AZD3293 oral solution - one single dose (low dose).
223820270|NCT02040987|DRUG|AZD3293|AZD3293 oral solution - one single dose (high dose).
223820271|NCT02040987|DRUG|Placebo|Placebo oral solution - one single dose
223820272|NCT02040987|DRUG|Moxifloxacin|Moxifloxacin tablet - one single dose
223820273|NCT06297499|DRUG|Ondansetron 8mg|administration of an IV solution of 8mg ondansetron (4ml)
223820274|NCT02169895|DRUG|BIA 9-1067|
223820275|NCT02169895|DRUG|Placebo|
223820276|NCT02169895|DRUG|Prolopa®|levodopa/benserazide 100/25 mg
223820277|NCT00605319|DRUG|Toviaz (Fesoterodine)|4mg to 8mg by mouth once daily
223820278|NCT02505139|OTHER|the number of circulating tumor cells|
223820279|NCT05491668|DIAGNOSTIC_TEST|Non-hyperemic pressure ratio assessment pre and post PCI|Pre and post PCI invasive physiologic assessment
223820280|NCT00239018|DRUG|Enteric-Coated Mycophenolate Sodium (EC-MPS)|
223820281|NCT01239693|DIETARY_SUPPLEMENT|IFA|Women during pregnancy: 1 tablet of iron+ folate daily until delivery (60 mg iron + 400 ug folic acid) Women during lactation (from delivery to 6 months post-partum): 1 daily tablet of calcium (200 mg), akin to placebo Children from 6 to 18 months of age: None
223820282|NCT01239693|DIETARY_SUPPLEMENT|MMN|Women during pregnancy: 1 tablet of multiple micronutrients daily until delivery Women during lactation (from delivery to 6 months post-partum): 1 daily tablet of multiple micronutrients Children from 6 to 18 months of age: None
223820283|NCT01239693|DIETARY_SUPPLEMENT|LNS|Women during pregnancy: 1 sachet of LNS-P\&L (20 g of LNS) daily until delivery Women during lactation (from delivery to 6 months post-partum): 1 daily sachet of LNS-P\&L (20 g of LNS) Children from 6 to 18 months of age: 2 daily sachet of LNS-20gM (20 g of LNS)
223820284|NCT01926522|DEVICE|Technological Rehabilitation|"The length of stride of reference used during the exercise is personalized and depends on the height of patients. Each patient carries out the feedback for 20 minutes with the aim of generating the most symmetric and regular gait.~Patients, with the dynamometer, work on strengthening of flexor and extensor muscles with ankle speeds at 90°/sec and 120°/sec. The strengthening technique was performed twice for 10 minutes each time with a 1 minute rest between sets.~The session ends with a 20-minute feedback on dynamic balance platform by carrying out exercises in which they need to reach randomly appearing targets. Subjects begin with 12 minutes the first 4 sessions, progress to 16 minutes the next 2 sessions, then 18' (2 sessions), and finally 20', if able, during the last 4 sessions."
223820285|NCT01926522|OTHER|Control Rehabilitation|When needed, more than on e therapist are employed in the intervention for safety reasons.
223820286|NCT01886638|DRUG|Abacavir|
223820287|NCT01250119|DRUG|erlotinib [Tarceva]|150 mg daily, orally
223820288|NCT05340218|OTHER|Speech analysis|Speech analysis to detect and monitor mild cognitive impairment
223820289|NCT02819856|DRUG|Placebo|0 mg SPI-1005 bid po x 21d
223820290|NCT02819856|DRUG|SPI-1005 Ebselen 200mg Capsule x1|200 mg SPI-1005 bid po x21d
223820291|NCT02819856|DRUG|SPI-1005 Ebselen 200mg Capsule x2|400 mg SPI-1005 bid po x 21d
223820292|NCT02819856|DRUG|SPI-1005 Ebselen 200mg Capsule x3|600 mg SPI-1005 bid po x 21d
223820293|NCT00002163|DRUG|Abacavir sulfate|
223820294|NCT02670538|DRUG|Cariprazine|Cariprazine capsule one per day orally.
223820295|NCT02670538|DRUG|Placebo|Matching placebo capsule one per day orally.
223820296|NCT03508999|DRUG|Metronidazole gel|The application of metronidazole gel is effective in the management of gingivitis in patients undergoing orthodontic therapy. Additionally, the constant reminder therapy at weekly interval would also lead to improvement in the oral hygiene.16 According to pertinent literature survey, none of the study has been conducted to compare the effectiveness of SMS reminders and use of anaerobic gel to reduce gingival inflammation.
223820297|NCT03508999|OTHER|SMS text reminder|Subjects will be provided biweekly reminder via 'SMS text reminder' in the form of text message reinforcing oral hygiene. Additionally, patients will be given standard oral hygiene instructions on the visit with a placebo gel topically instructed to apply on the marginal gingiva for the next 4 weeks, twice a day for 30 minutes, after morning and evening tooth brushing.
223820298|NCT03508999|OTHER|Placebo gel|Group C will be subjects will be given standard oral hygiene instructions on the visit with a placebo gel topically instructed to apply on the marginal gingiva for the next 4 weeks, twice a day for 30 minutes, after morning and evening tooth brushing.
223820299|NCT02887989|DEVICE|Virtual Reality|A menu of VR experiences, lasting from 3-30 minutes each. For example, patients may watch a soothing virtual campfire, or fly over a scenic landscape, or play an interactive game.
223820300|NCT02887989|DEVICE|Health and Wellness Channel|Relaxing content broadcast passively on the patient in-room television channel.
223820301|NCT01383057|PROCEDURE|Femtosecond Laser|Using the Femtosecond Laser to make a clear corneal incision.
223820302|NCT01486602|DRUG|carboplatin|IV
223820303|NCT01486602|DRUG|paclitaxel|IV
223820304|NCT01486602|RADIATION|radiation therapy|Defined per the protocol
223820305|NCT03820531|DIAGNOSTIC_TEST|Next Generation Sequencing|DNA Mutational Analysis in pancreas cyst fluid concerning KRAS/GNAS-mutations and mutations in tumor supressor genes
223820306|NCT03820531|DIAGNOSTIC_TEST|CEA and lipase|"Measuring CEA and lipase level in pancreas cyst fluid:~CEA \> 192 ng/ml and lipase \> 200 U/l = mucinous cyst"
223820307|NCT03820531|DIAGNOSTIC_TEST|Cytology|"Cytology in pancreas cyst fluid:~mucinous versus non-mucinous cyst; LGD versus HGD/Carcinoma"
223820308|NCT03820531|DIAGNOSTIC_TEST|Histology of resected pancreas cyst|Histology of resected pancreas cyst concerning mucinous versus non-mucinous cyst, IPMN versus non-IPMN and LGD versus HGD/Carcinoma
223820309|NCT00436579|DRUG|sorafenib tosylate|Given orally
223820310|NCT00436579|OTHER|pharmacological study|
223820311|NCT00436579|PROCEDURE|assessment of therapy complications|Ancillary studies
223820312|NCT00436579|OTHER|laboratory biomarker analysis|Correlative studies
223820313|NCT01132638|DRUG|Magnesium Pantoprazole|1 capsule daily, 40 mg, orally, 30 minutes before breakfast
223820314|NCT01132638|DRUG|Magnesium Esomeprazole|1 capsule daily, 40 mg, orally, 30 minutes before breakfast
223820315|NCT06359600|DRUG|HS-10501 tablet|Administered orally
223820316|NCT06359600|DRUG|Placebo|Administered orally
223820317|NCT00076791|DRUG|Emtricitabine/Tenofovir disoproxil fumarate|900 mg of TDF combined with 600 mg emtricitabine
223820318|NCT00076791|DRUG|Tenofovir disoproxil fumarate|600 mg oral dose of TDF
223820319|NCT04762225|BIOLOGICAL|RPTR-168|Escalating doses of RPTR-168 as a monotherapy
223820320|NCT01342822|DEVICE|Angioplasty (PROMUS Element™, and Xience™ Prime stent)|Patients with symptomatic ischemic heart disease due to stenotic lesions amenable to percutaneous treatment with a drug eluting stent in a consecutive unselected patient population, provided that the proposed research use of the product is consistent with the approved (labeled) uses of such product and with the reimbursed indications (in countries where reimbursement procedure applies, eg France) and does not violate any other applicable law, regulation or ethical directive/code.
223820321|NCT05648357|BIOLOGICAL|Fluarix Tetra Vaccine|A single dose of Fluarix Tetra vaccine administered intramuscularly (IM) on day 1.
223820322|NCT03813550|DIAGNOSTIC_TEST|Fecal and blood samples|Fecal samples for intestinal microbiota analysis; Blood and fecal samples for assessment of various forms of vitamin K
223820323|NCT03620721|BEHAVIORAL|mindfulness|8-week mindfulness based group intervention
223820324|NCT05309538|OTHER|Modified eply & Semont maneuver|repositioning maneauvers
223820325|NCT05309538|OTHER|betahistine & Modified eply & Semont maneuver|antihistamine plus repositioning maneuvers
223820326|NCT03644069|BIOLOGICAL|Nexvax2|Nexvax2 subcutaenous (SQ) injections: 32 in total, at twice weekly intervals
223820327|NCT03644069|BIOLOGICAL|Placebo|Placebo SQ injections: 32 in total, at twice weekly intervals
223820328|NCT00248300|OTHER|Chlorhexidine|Chlorhexidine, 5 ml swab to the oral cavity within 12 hours of endotracheal tube intubation
223820329|NCT02176421|DEVICE|VOLBELLA® with lidocaine|VOLBELLA® with lidocaine administered to correct skin depression during initial treatment and optional top-up treatment 14 days later.
223820330|NCT05913375|RADIATION|Stereotactic Body Radiotherapy|Non-invasive delivery of ablative radiotherapy dose to the arrhythmia substrate defined with electroanatomical mapping (EAM)
223820331|NCT01496534|DRUG|Cisplatin|Gemcitabine 1000 mg/m2 IV on days 1 + 8 Cisplatin 70 mg/m2 IV day 1 Dovitinib given orally on days 1-5, 8-12 and 15-19. Treatment will be recycled every 21-days. The dose of dovitinib will be escalated in successive cohorts
223820332|NCT01496534|DRUG|Carboplatin|Gemcitabine 1000 mg/m2 IV on days 1 + 8 Carboplatin AUC 5 IV day 1 Dovitinib given orally on days 1-5, 8-12 and 15-19. Treatment will be recycled every 21-days. The dose of dovitinib will be escalated in successive cohorts
223820333|NCT04676126|DIETARY_SUPPLEMENT|Lumega-Z|Medical food which contains lutein, zeaxanthin, and meso-zeaxanthin
223820334|NCT04676126|DRUG|Dorzolamide Hcl 2% Oph Soln|Topical carbonic anhydrase inhibitor
223820335|NCT04676126|OTHER|Placebo|Specially formulated non macular pigment-containing formulation which tastes similar to the commercial medical food being evaluated in this study
223820336|NCT06139991|DRUG|Treatment A (BDA MDI HFO)|Randomized participants will receive Treatment A (BDA MDI HFO) on Day 1 under fasted condition.
223820337|NCT06139991|DRUG|Treatment B (BDA MDI HFA)|Randomized participants will receive Treatment B (BDA MDI HFA) on Day 1 under fasted condition.
223820338|NCT01749501|DRUG|Rocuronium|0.6 mg/Kg once
223820339|NCT01749501|OTHER|Placebo|Normal saline same amt as 0.6mg/kg of study drug
223820340|NCT05642546|DRUG|NM8074|Novel, recombinant, humanized monoclonal antibody that selectively binds to human Factor Bb with high affinity and blocks the formation of Alternative Pathway (AP) driven C3 and C5 convertases
223820341|NCT05642546|DRUG|Placebo|Saline Placebo
223820342|NCT01657630|DEVICE|Accu-Chek Combo System|12 weeks using the Accu Chek Combo System, which is an insulin pump system that offers a remote control integrating a bolus calculator, a blood glucose meter, data storage and analysis function.
223820343|NCT03988010|DRUG|Amantadine Sulfate|200mg/500ml i.v. solution for infusion
223820344|NCT03988010|DRUG|Placebo (for amantadine sulphate)|500 cc 0.9% sodium chloride
223820345|NCT02341456|DRUG|AZD1775|AZD1775 is a highly selective, adenosine-triphosphate (ATP) competitive, small-molecule inhibitor of the WEE1 kinase that sensitizes tumour cells to cytotoxic agents and is being developed for the treatment of advanced solid tumours and p53 pathway deficient malignancies. Gemcitabine is a nucleoside analog used as chemotherapy.
223820346|NCT02341456|DRUG|Paclitaxel|Paclitaxel is a mitotic inhibitor used in cancer chemotherapy ; it and docetaxel represent the taxane family of drugs.
223820347|NCT02341456|DRUG|carboplatin|Carboplatin is a chemotherapy drug used against some forms of cancer (mainly ovarian carcinoma, lung, head and neck cancers as well as endometrial, esophageal, bladder, breast and cervical; central nervous system or germ cell tumors; osteogenic sarcoma, and as preparation for a stem cell or bone marrow transplant.).
223820348|NCT01740102|PROCEDURE|RIPC|The remote ischemic preconditioning will consist of three sequential sphygmomanometer cuff inflations. The cuff will be inflated up to 200 mmHg for 5 minutes and then deflated for 5 minutes. This cycle will be performed three times in total. The entire preconditioning will therefore last for 25 minutes.
223820349|NCT06241261|DRUG|Silver diamine fluoride gel|Application of 38% SDF gel every 6 months
223820350|NCT06241261|DRUG|Silver diamine fluoride solution|Application of 38% SDF solution every 6 months
223820351|NCT03975426|PROCEDURE|open reduction and internal fixation with fixation by absorbable screws|Group A received conservative therapy involving bed rest with the affected lower extremity positioned with the hip and knee in flexion to ensure minimal tension of the muscles attached to the ASIS avulsion fracture. Group B received open reduction and internal fixation with fixation by absorbable screws.
223820352|NCT01971606|DRUG|Rosuvastatin|"Patients will be randomized in a ratio of 1:1 to A) High-dose rosuvastatin vs. B) Placebo.~A) Rosuvastatin group : Administration of 40mg of rosuvastatin PO 12 hours before surgery and 20mg of rosuvastatin PO 2hours before surgery and 10mg of rosuvastatin PO daily at postoperative period.~B) Placebo group : Administration of placebo at 12 hours and 2 hours before surgery and 10mg of rosuvastatin PO daily at postoperative period."
223820353|NCT02691104|DEVICE|SMART COPD app to promote physical activity in COPD. Used in conjunction with a Fitbit Charge|An app which allows users to set physical activity goals, monitors progress towards those goals, and provides feedback to users. Several options for types of physical activity (daily walk, daily step count, and aerobic / strengthening exercises) which can be tailored to the individual user. Designed to be used in consultation with a physiotherapist initially, and then used independently by the individual with COPD. The app will first be used alongside pulmonary rehabilitation (PR), with physiotherapist advice on exercises and setting goals. After PR the individual with COPD will receive weekly contact from a physiotherapist for the first 4 weeks, and then no contact for the second 4 weeks
223820354|NCT02691104|DEVICE|Control|Participants will follow the (usual care) PR programme. They will be asked to wear a blinided (cannot see step count) Fitbit Charge during the time they are on PR and then for 8 weeks afterwards
223820355|NCT06179264|BEHAVIORAL|ACT Guide for Chronic Health Conditions|Acceptance and commitment therapy (ACT) combines the skills of acceptance, cognitive defusion, being present, self as context, values, and committed action to help individuals engage with a meaningful life. The current project is an online, self-guided, 6-session intervention based on ACT. The program is intended to help individuals with chronic health conditions improve their quality of life and mental health. Each session is expected to take about 30 minutes each, and the entire program will take 6 weeks to complete, as users will be encouraged to work on one session per week. Within each session, participants will read about concepts and ACT metaphors, apply ACT concepts to general and chronic health condition specific vignettes, and apply ACT concepts to their own lives and situations related to their chronic health condition. Interactive experiences are included in each session and ends with a printable summary with practice skills before proceeding.
223820356|NCT03619941|DIETARY_SUPPLEMENT|Montmorency Tart Cherry Juice|"100% natural, tart Montmorency cherry concentrate (30mL) diluted with 100mL water.~Concentrate contains no sweeteners, preservatives, flavourings or added sugar."
223820357|NCT03619941|DIETARY_SUPPLEMENT|Placebo|Placebo drink attempted to match for total energy content, macronutrient content, appearance and taste of Montmorency tart cherry juice.
223820358|NCT03149016|PROCEDURE|Corticotomy-assisted Retraction|Using a tunneling technique, the researcher will perform the intervention in the alveolar bone surrounding the upper incisors before retraction.
223820359|NCT04903457|DEVICE|Transcranial Direct Current Stimulation|Transcranial direct current stimulation is a form of noninvasive neuromodulation that uses constant and low direct current delivered via electrodes on the scalp.
223820360|NCT04903457|BEHAVIORAL|Motor learning|Sequential finger tapping task training is applied to stroke patients.
223820361|NCT06340165|DRUG|Anlotinib|Anrotinib is available in 12 mg, 10 mg, and 8 mg doses. The recommended dose of Anrotinib is 12 mg taken by mouth once daily, continuously, for 2 weeks on and 1 week off, in a 21-day cycle.
223820362|NCT02585596|DRUG|YH23537 1000mg/day|YH23537 500mg 2 tab
223820363|NCT02585596|DRUG|YH23537 2000mg/day|YH23537 500mg 4 tab
223820364|NCT02585596|DRUG|YH23537 3000mg/day|YH23537 500mg 6 tab
223820365|NCT02585596|DRUG|placebo|YH23537 500mg tab placebo
223820366|NCT00301080|DRUG|D-cycloserine|
223820367|NCT00301080|OTHER|Placebo|
223820368|NCT00358137|BEHAVIORAL|Aerobic Conditioning Program|
223820369|NCT00358137|BEHAVIORAL|Strength Training Program|
223820370|NCT01595412|PROCEDURE|Laparoscopic Resection Rectopexy|laparoscopic sigmoidectomy with suture rectopexy
223820371|NCT01595412|PROCEDURE|Laparoscopic Ventral Rectopexy|laparoscopic ventral rectopexy with mesh
223820372|NCT06164925|DIAGNOSTIC_TEST|Nutrition screening and assessment|"The patient is interviewed for changes in body weight in the last six months and food intake in the last two weeks.~The investigator evaluates the patient's diet, symptoms related to their nutritional status, and functional capacity according to the Subjective Global Assessment (SGA). The SGA tool itself is completed by the researcher.~Height and weight of the patient are measured, if not yet recorded, and BMI is calculated.~The patient's muscle mass is measured using mid-upper arm circumference (MUAC), calf circumference (CC) and bioelectrical impedance (BIA), and their muscle function assessed using hand grip strength."
223820373|NCT05914402|PROCEDURE|axillary surgery de-escalation after NAT|the process of axillary surgical evaluation will be spared after NAT using the prediction model if the probability is more than 90%.
223820374|NCT01641926|BIOLOGICAL|PEG-Intron™|PEG-Intron subcutaneously (SC) once weekly for a total of 48 weeks
223820375|NCT01641926|BIOLOGICAL|PEGASYS™|PEGASYS subcutaneously (SC) once weekly for a total of 48 weeks
223820376|NCT03485014|DRUG|Exparel|EXPAREL 4 mg/kg
223820377|NCT02899364|DRUG|Sodium thiosulfate|see description under experimental arm
223820378|NCT02899364|DRUG|Sodium chloride 0.9%|see description under placebo comparator arm
223820379|NCT02899364|PROCEDURE|primary percutaneous coronary intervention|Primary treatment of the ischemia-related coronary artery is left to discretion of the operator and might consist of thrombus aspiration, balloon inflation and stent implantation. Additional balloon angioplasty or stenting of the culprit or other lesions will be performed when necessary.
223820380|NCT02899364|OTHER|cardiac magnetic resonance imaging|CMR-imaging will be used for assessment of infarct size, left ventricular function, quantification of myocardial scar and diffuse myocardial fibrosis. CMR-imaging examinations will be performed on a 3 Tesla scanner using a phased array cardiac receiver coil at 4 months after randomization according to standard protocols. The full study protocol lasts approximately 45 minutes and includes anatomy and function, LGE and T1-mapping.
223820381|NCT06158425|RADIATION|long-leg radiograph|A flat-panel digital radiography(DR) equipment (Siemens DR AXIOM Aristos AX/VX) was used to capture full-length bipedal lower extremities in a standing position. The technician moved the detector from top to bottom, capturing four parts: the bilateral hip joints, femur, tibia and fibula and ankle joint. The exposure parameters for each part were as follows: 1st exposure - 85kV, 75mAs; 2nd exposure - 80kV, 50mAs; 3rd exposure - 75kV, 40mAs; 4th exposure - 68kV, 20mAs. The distance from the source (kv-kg) was 300cm, and the field of view was 43.18cm x 43.18cm. All 4 X-rays were stitched using the Siemens DR Station.
223820382|NCT00885963|DRUG|sapacitabine|twice daily by mouth for 7 days or once daily by mouth for 5 days/week x 2 weeks every 21 days
223820383|NCT03062774|BIOLOGICAL|PB-119 injection|
223820384|NCT00084643|BIOLOGICAL|GTI-2040|Given IV
223820385|NCT00084643|DRUG|oxaliplatin|Given IV
223820386|NCT00084643|DRUG|capecitabine|Given orally
223820387|NCT00084643|OTHER|pharmacological study|Correlative studies
223820388|NCT00084643|OTHER|laboratory biomarker analysis|Correlative studies
223820389|NCT02916797|OTHER|Stepping training with feedback|Stepping training with the use of external feedback. The subjects will be instructed to shift/take their body-weight onto the affected leg until the green zone of the displayed section is lighting and a beep sound to alarm the subjects to step the non-affected leg forward and backward as much as they can.
223820390|NCT00288301|BEHAVIORAL|Weight loss intervention|weight loss intervention
223820391|NCT00415792|DRUG|Arvekap, Pregnyl|
223820392|NCT02294630|DRUG|Surfactant|Two doses of surfactant to be administered as aerosol will be tested - 100 mg phospholipid/kg and 200 mg phospholipid/kg. Each dose will be tested at two dilutions and with two nebulizers. Each enrolled infant may receive a maximum of two aerosol treatments of a single dilution with a single nebulizer.
223835511|NCT06363955|DEVICE|Placebo mouthwash|Placebo mouthwash is a similar (look-and-taste-alike) solution to the experinmental mouthwash made by the same manufacturer, without active ingredients. Participants rinse (swish and spit) with the mouthwash three times a day for one minute each time, using a 10ml quantity (as indicated by a marking line inside the bottle cap) for a total of 14 days, starting from day 0, i.e. the day of the biopsy (see procedure in the detailed description). Consumption of liquid or solid foods should be avoided for at least thirty minutes following each rinse. Participants are asked to maintain their usual oral hygiene routine.
223820393|NCT04040881|BEHAVIORAL|Remote monitoring using smartphone accelerometer|"Patients will be instructed to carry the smartphone around their hips during waking hours, regardless of whether they are at home or outside (a nylon hip holster will be provided) and to keep it turned on at all times.~Daily steps will be recorded for at least seven days before the start of chemotherapy, and the median baseline number of daily steps will be calculated for each patient.~On the first day of chemotherapy, patients will receive side effect education as per standard of care. Patients will be instructed to continue carrying the smartphone daily as indicated for the entire duration of the first three chemotherapy cycles.~At the end of the follow-up period (or sooner in cases of early interruption of chemotherapy due to toxicity or disease progression; a change in chemotherapy regimen; or hospitalizations lasting ≥3 days), patients will rate their satisfaction with the intervention using a Likert-scale questionnaire and open-ended questions."
223820394|NCT00749125|DRUG|Lexapro|10 mg by mouth once per day for first 2 weeks, with psychiatric re-evaluation every 2 weeks to determine if any change in dosage is required, with a maximum of 20 mg per day
223820395|NCT02567825|DEVICE|Tympanostomy tube placement|As per routine care, tympanostomy tubes will be inserted under general anesthesia, using a small radial incision in the anteroinferior portion of the tympanic membrane; a Teflon® Armstrong-type tympanostomy tube will be used.
223820396|NCT02567825|DRUG|Amoxicillin-Clavulanate and/or Ceftriaxone|Children randomized to nonsurgical management will receive stepwise therapy with amoxicillin-clavulanate (90/6.4 mg/kg in two divided doses for 10 days), and in the event of inadequate response, ceftriaxone (75 mg/kg intramuscularly, repeated in 48 hours), as recommended in the American Academy of Pediatrics guidelines.
223820397|NCT02567825|DRUG|Ofloxacin Otic|Participants randomized to receive tympanostomy tubes will also be followed overtime for recurrences of AOM and treated with topical ofloxacin (Floxin® 0.3%, 5 mL) 5 drops into the affected ear twice daily for 10 days. Persistence of otorrhea after 7 days of treatment will be considered inadequate response, and children so affected will be prescribed empiric amoxicillin-clavulanate (90/6.4 mg/kg/day in two divided doses) followed by culture-directed therapy 48 hours later.
223820398|NCT05512429|OTHER|measured of body composition with computed tomography|Multislice and single-slice computed tomography images were used for assessment of body composition including visceral adipose tissue (VAT), subcutaneous adipose tissue (SAT), skeletal muscle mass volume (SMMV)
223820399|NCT03202095|DRUG|Creatine Monohydrate|5 grams daily of oral creatine monohydrate powder.
223820400|NCT03749577|DIETARY_SUPPLEMENT|L-citrulline|L-citrulline 9g per day (capsule, per os) during 14 days;
223820401|NCT03749577|DIETARY_SUPPLEMENT|Beetroot juice|Concentrated 70 ml beetroot juice bottles containing 6.45 mmol of nitrates
223820402|NCT03749577|DIETARY_SUPPLEMENT|L-citrulline placebo|L-citrulline placebo (maltodextrin) 9g per day (capsule, per os) during 14 days
223820403|NCT03749577|DIETARY_SUPPLEMENT|Denitrated beetroot juice|Concentrated 70 ml nitrate-depleted beetroot juice
223820404|NCT01626222|DRUG|Exemestane|Exemestane is supplied by Novartis until Everolimus is commercially available for the study setting. Afterwards the investigator will prescribe Exemestane according to the individual label. Commercially available Exemestane will be supplied as tablets of 25 mg strength for oral administration. Complete guidelines for management and administration of Exemestane can be found in the package insert. Exemestane will be dosed starting on treatment Day 1. Patients will be instructed to take 1 tablet of 25 mg Exemestane orally. Package insert instructions should be followed. On the first day of each cycle, patients will receive an adequate drug supply (before commercial availability) or a prescription (after commercial availability) for self-administration at home. The investigator must emphasize compliance and will instruct the patient to take Exemestane exactly as prescribed.
223820405|NCT01626222|DRUG|Everolimus (RAD001)|Everolimus (RAD001) is supplied by Novartis until Everolimus is commercially available for the study setting. Afterwards the investigator will prescribe Everolimus according to the individual label. Everolimus is formulated as tablets of 10 and 5 mg strength for oral administration. All study medication will be packaged into blister packs. The blisters should be opened only at the time of administration, as the drugs are both hygroscopic and light sensitive. Everolimus will be dosed starting on treatment Day 1. Patients will be instructed to take 1 tablet × 10 mg Everolimus orally with a large glass of water once daily at the same time each day with or without food. On the first day of each cycle, patients will receive an adequate drug supply (before commercial availability) or a prescription (after commercial availability) for self-administration at home. The investigator must emphasize compliance and will instruct the patient to take Everolimus exactly as prescribed.
223820406|NCT05626764|OTHER|QoL & irAEs determinants|Assesment of the QoL \& irAEs determinants in patients diagnosed with solid tumor and treated in France, Netherlands, Portugal, Spain, with immunotherapy by immune checkpoint inhibitors.
223820407|NCT05626764|OTHER|QoL & irAEs determinants|Assesment of the QoL \& irAEs determinants in patients diagnosed with hematologic cancer and treated in France, Netherlands, Portugal, Spain, by CAR-T cells.
223820408|NCT01548937|DRUG|I-123 ADAM|"This study will recruit a total of 40 evaluable subjects (20 cognitively depressive, and 20 AD depressive), Each evaluable subject involved in this study must fulfill all the inclusion and exclusion criteria according the subject grouping.~Safety measurement will be evaluated by medical history, vital signs, physical examinations, laboratory examinations and collecting of adverse events."
223820409|NCT03195465|DIETARY_SUPPLEMENT|Dark Chocolate|Dark Chocolate bars with 70% cacao and 30% organic cane sugar where 4 squares of the dark chocolate will be administered twice daily between the hours of 6 a.m. and 6 p.m. daily for four weeks.
223820410|NCT04863989|PROCEDURE|tube thoracostomy|insertion of intercostal tube for drainage of traumatic hemothorax or pneumothorax
223820411|NCT02943889|BIOLOGICAL|Mesenchymal stem cell transplantation|Bone marrow aspiration by clinical pathologist. Isolation, propagation and differentiation of stem cells will be done in stem cell center. After confirmation of the trans-differentiation into hepatocytes at the laboratory level, it will be infused into the portal vein under ultrasound guidance.
223820412|NCT05250622|OTHER|Japanese-translated evidence summaries (Advanced Clinical Evidence report from OrthoEvidence)|Participants will receive emails with the link to Japanese-translated version of evidence summaries.
223820413|NCT05250622|OTHER|English evidence summaries (Advanced Clinical Evidence report from OrthoEvidence)|Participants will receive emails with the link to English version of evidence summaries.
223820414|NCT02913976|DEVICE|Kinesio Taping|Four Kinesio Taping strips will be placed with tension on skin forming an asterisk. The point of intersection of the four strips will be just above the myofascial trigger point. The subject will remain three days with the strips on his skin
223820415|NCT02913976|DEVICE|Sham Kinesio Taping|Four Kinesio Taping strips will be placed without tension on skin forming an asterisk. The point of intersection of the four strips will be just above the myofascial trigger point. The subject will remain three days with the strips on his skin
223820416|NCT00167895|PROCEDURE|Adding platelet concentrate to the wound|
223820417|NCT04865211|DRUG|Liposomal bupivacaine|Use of liposomal bupivicaine as intraoperative local anesthesia
223820418|NCT04865211|DRUG|Bupivacaine Injection|Use of bupivicaine as intraoperative local anesthesia
223820419|NCT04865211|DRUG|Placebo|Use of saline as placebo for local anesthesia
223820420|NCT00458614|DRUG|Lansoprazole|
223820421|NCT05489939|DRUG|The compound methyl salicylate liniment|The compound methyl salicylate liniment (Ammeltz) has been developed by Japan Sendai Kobayashi Pharmaceutical Co. and has been listed in Japan for many years. It is composed of various components, such as methyl salicylate, menthol, camphor, chlorpheniramine maleate, and thymol.
223820422|NCT02991443|BEHAVIORAL|Mindfulness based stress reduction|Mindfulness based stress reduction consisted of 8 group sessions for parents of children with IBD
223820423|NCT04266639|DEVICE|Remote Ischemic Conditioning|RIC is commonly achieved by inflation of a blood pressure cuff to induce 5-minute cycles of limb ischemia alternating with 5 minutes of reperfusion
223820424|NCT04266639|DEVICE|Sham Remote Ischemic Conditioning|Sham Comparator (Sham-RIC)
223820425|NCT02319070|OTHER|Survey|Recombinant antihemophilic factor VIII (FVIII) on Secondary Prophylaxis treatment scheduled according to daily routine
223820426|NCT02319070|OTHER|Survey|Recombinant antihemophilic factor VIII (FVIII) On Demand treatment scheduled according to daily routine
223820427|NCT01101360|DEVICE|Matrix RF|Section of port wine stain to be treated 5 times every 5 weeks (+/- 1 week)
223820428|NCT01101360|DEVICE|Matrix RF followed by Pulse Dye Laser|Section of port wine stain to be treated 5 times every 5 weeks (+/- 1 week)
223820429|NCT01101360|DEVICE|Pulse Dye Laser followed by Matrix RF|Section of port wine stain to be treated 5 times every 5 weeks (+/- 1 week)
223820430|NCT00904891|BEHAVIORAL|Cognitive-behavioral group|Six sessions of cognitive-behavioral depression prevention group intervention
223820431|NCT00904891|BEHAVIORAL|Cognitive-behavioral bibliotherapy|"Cognitive-behavioral bibliotherapy, delivered from the book Feeling Good"
223820432|NCT01540565|OTHER|Laboratory Biomarker Analysis|Correlative studies
223820433|NCT01540565|DRUG|Veliparib|Given PO
223820434|NCT00302783|BEHAVIORAL|Multi-Source Feedback: including self-assessment & coaching|
223820435|NCT01222468|DRUG|nabilone 0.5 mg|nabilone 0.5 mg tablets od titrated to a maximum daily dose of 3mg po over an 11-week phase
223820436|NCT01222468|DRUG|placebo|placebo 0.5 mg po daily, dose titrated to a maximum daily dose of 3.0mg po over an 11-week phase
223820437|NCT04194996|PROCEDURE|Surgical intervention|Surgical interventions will be patient specified by treating surgeon.
223820438|NCT00242203|DRUG|Zometa|
223820439|NCT00242203|DRUG|Epirubicin|
223820440|NCT00242203|DRUG|Docetaxel|
223820441|NCT00242203|DRUG|Trastuzumab|ONLY for patients that are Her-2 overexpressing by 3+ by ICH for FSH
223820442|NCT00242203|RADIATION|External beam radiation|
223820443|NCT00242203|PROCEDURE|Modified radical mastectomy or breast conserving surgery with axillary lymph node dissection|
223820444|NCT00975052|DRUG|sitagliptin phosphate|100 mg sitagliptin daily for two days in one out of four treatment periods
223820445|NCT00975052|DRUG|Comparator: metformin|500 mg twice daily on Day 1 and 1000 mg once daily on Day 2 in one of four treatment periods.
223820446|NCT00975052|DRUG|Comparator: sitagliptin and metformin|100 mg sitagliptin once daily and 500 mg metformin twice daily on Day 1 and 100 mg sitagliptin once daily and 1000 mg metformin once daily on Day 2 in one of four treatment periods.
223820447|NCT00975052|DRUG|Comparator: placebo|Placebo only on Days 1 and 2 in one of four treatment periods.
223820448|NCT02590692|BIOLOGICAL|CPCB-RPE1|Patients will receive one CPCB-RPE1 implant of approximately 100,000 differentiated RPE cells attached to a small parylene membrane. The density of cells on the membrane represents the approximate density of RPE cells in the human eye. The membrane size was chosen to cover a substantial portion of the macular region of the retina.
223820449|NCT02306265|DEVICE|FFDM|2D imaging of the breast using Full-Field Digital Mammography (FFDM) device
223820450|NCT02306265|DEVICE|DBT|3D imaging of the breast using Digital Breast Tomosynthesis (DBT) device
223820451|NCT03191357|OTHER|n/a observational|Observational study
223820452|NCT04488003|DRUG|Ulixertinib|Oral, 600 mg, twice daily, for 28-days in each treatment cycle
223820453|NCT04488003|DRUG|Physician's Choice|Physician's choice will be restricted to two approved (not off-label) treatments for each tumor histology (agents targeting BRAF or MEK kinases and experimental agents are not permitted as physician choice)).
223820454|NCT03349268|DEVICE|Pulsed xenon ultraviolet (PX-UV) Device|"Two Detroit Medical Center (DMC) acute-care hospitals are being proposed for this project, Sinai-Grace Hospital (SGH) and Detroit Receiving Hospital (DRH). SGH is a 383-bed hospital, and DRH is a 248-bed hospital. The study will be conducted in eight hospital units in SGH and eight hospital units in DRH, including two medical intensive care units (ICUs), two surgical ICUs and 12 non-ICU medical-surgical wards. The 16 study units include a total of 379 beds.~Devices will be deployed on these study units with the sham and intervention devices split evenly between SGH and DRH. Within each study site, the types of devices (PX-UV vs sham) will be assigned randomly to the units in Phase 1 and then switched in Phase 2."
223820455|NCT03349268|DEVICE|Sham Device|"Two Detroit Medical Center (DMC) acute-care hospitals are being proposed for this project, Sinai-Grace Hospital (SGH) and Detroit Receiving Hospital (DRH). SGH is a 383-bed hospital, and DRH is a 248-bed hospital. The study will be conducted in eight hospital units in SGH and eight hospital units in DRH, including two medical intensive care units (ICUs), two surgical ICUs and 12 non-ICU medical-surgical wards. The 16 study units include a total of 379 beds.~Devices will be deployed on these study units with the sham and intervention devices split evenly between SGH and DRH. Within each study site, the types of devices (PX-UV vs sham) will be assigned randomly to the units in Phase 1 and then switched in Phase 2."
223820456|NCT01706419|DIETARY_SUPPLEMENT|Fortified rice cold extruded kernel|
223820457|NCT01706419|DIETARY_SUPPLEMENT|fortified rice warm extruded kernel|
223820458|NCT01706419|DIETARY_SUPPLEMENT|fortiified rice hot extruded kernel|
223820459|NCT03436966|DEVICE|MULTI SLICE CT|Positive enteric contrast, can, however, obscure IV contrast enhancement of the bowel wall. In addition, positive oral contrast agents opacify but do not always well distend the bowel. IV contrast is administered and images are acquired in the portal venous phase, which is optimized for visceral organ evaluation.
223820460|NCT05808530|BEHAVIORAL|Cognitive Stimulation Therapy|"CST involves the use of standard tasks that focus on cognitive functions, designed to meet varying levels of difficulty in accordance with the individual's ability and rehabilitation. A detailed guide for CST is available for a range of health and care professionals, including care workers, occupational therapists, psychologists, and nurses (https://www.ucl.ac.uk/international-cognitive-stimulation-therapy/) publications/cst-manuals). The CST application consists of 14 sessions of 45-50 minutes, 2 days a week.~Intervention Group Week 1=Getting acquainted and applying pre-tests Week 2=Physical games and Sounds Week 3=Childhood and Food Week 4=Current events and Faces / Scenes Week 5=Word association and Creativity Week 6=Categorizing Objects and Orientation Week 7= Money usage and Games Week 8=Word Games and Team Competition Week 9=Closing and post-test application"
223820461|NCT02168790|DEVICE|Amniotic membrane ring|The amniotic membrane ring system (AmnioClip) is device for sutureless application of amniotic membrane to oculare surfaces. Amniotic membrane is mounted between the two rings with a specially designed, accessory mounting device.
223820462|NCT06111690|PROCEDURE|Blood Flow Restriction Training (BFRT)|Participants will be performing low-resistance exercise with (BFRT). Intervention will start at least seven days after initial evaluation, so it does not influence measures of real-time physical activity. We will use a log to register exercise completion and to record bilateral knee pain before, during and after each intervention session
223820463|NCT01406002|DRUG|darexaban|oral
223820464|NCT01406002|DRUG|Rifampicin|oral
223820465|NCT02733705|OTHER|Control|normal saline IV
223820466|NCT02733705|DRUG|Fentanyl|fentanyl 0.5 mcg/kg ideal BW
223820467|NCT02733705|DRUG|propofol|propofol infusion
223820468|NCT00779558|DRUG|Heparin sulfate infusion at 10 units/kg/hour|Infusion of heparin to prevent central line thrombosis in infants after cardiac surgery
223820469|NCT00779558|DRUG|Placebo infusion|Infusion of normal saline
223820470|NCT01992705|OTHER|Chemotherapy(FOLFIRINOX) + SBRT prior to surgery if applicable|Patients will receive chemotherapy (21d/cycle for a total of 4 cycles) plus SBRT before screening for surgical resection of the pancreas.
223820471|NCT01992705|DRUG|-Oxaliplatin 85 mg/m2 IV on Day 1|Oxaliplatin 85 mg/m2 IV on Day 1 of each cycle (21d/cycle for a total of 4 cycles).
223820472|NCT01992705|DRUG|-Irinotecan 180 mg/m2 IV on Day 1|Irinotecan 180 mg/m2 IV on Day 1 of each cycle (21d/cycle for a total of 4 cycles).
223820473|NCT01992705|DRUG|-5-FU (Fluorouracil) 2,400 mg/m2 IV over 46-48 hours|5-FU (Fluorouracil) 2,400 mg/m2 IV over 46-48 hours of each cycle (21d/cycle for a total of 4 cycles.
223820474|NCT04145037|DRUG|AVR-RD-02|AVR-RD-02 Drug product: active substance is autologous CD34+ enriched hematopoietic stem cells (HSCs) that have been genetically modified ex vivo with a lentiviral vector (LV) to contain a ribonucleic acid (RNA) transcript that, after reverse transcription, results in codon-optimized, complementary deoxyribonucleic acid (cDNA) that, upon its integration into human genome, encodes for functional human glucocerebrosidase (GCase).
223820475|NCT04602897|OTHER|forced coughing|The cough group patients were asked to cough a forced cough during different steps of IUD insertion
223820476|NCT03324711|DIAGNOSTIC_TEST|"Antillanisée Mini Mental State Examination (MMSEa)"|"Antillanisée version of the Mini Mental State Examination (MMSEa), is a version adaptated to the French West Indies creole culture."
223820477|NCT01756560|DRUG|dexamethsone|
223820478|NCT01756560|DRUG|Bupivacaine|
223820479|NCT01907139|BEHAVIORAL|Robot-assisted therapy|Instrumentation of the ArmeoSpring with position sensors at each joint enables it to be used as a 3D input device for computer game play with the hemiparetic arm. Games were designed to simulate functional arm movements to provide training in a simple virtual reality environment. Vu Therapy games were developed with the goal of enabling repetitive task-specific practice including grocery shopping, cleaning a stovetop, and playing basketball. In this way, stroke patients who are unable to use their severely weakened arms in a functional way are able to practice task-specific movements in a simulated, gravity-reduced environment. Auditory and visual feedback is provided throughout game play to maintain the patient's attention and motivation. In addition, users are provided objective feedback of task performance at the end of each game to enhance motivation and awareness of progress.
223820480|NCT01907139|BEHAVIORAL|Distributed constraint-induced therapy|The dCIT group will focus on restriction on movement of the unaffected hand by placement of the hand in a mitt for 6 hours/day and intensive training of the affected UL in functional tasks for 1.5 hours/weekday over the 4 weeks. Participants in this group will focus on the intensive training of the affected arm in functional activities with behavioral shaping. The shaping techniques will involve individualized task selection, graded task difficulty (e.g., practicing deficient parts of the selected activity and then performing the entire activity), verbal feedback, prompting, physical assistance with movements, and modeling. The level of challenge will be adapted based on patient ability and improvement. Participants will be also required to place their unaffected hand and wrist in a mitt for 6 hours a day during the 4-week period and document mitt compliance in daily logs.
223820481|NCT01907139|BEHAVIORAL|Dose-matched control therapy|The DMCT group mediated by the therapists will be designed to control for the duration of therapy in amount of therapy hours. This group will received a structured protocol using conventional occupational therapy techniques such as neuro-developmental techniques with emphasis on functional tasks and muscle strengthening. The treatment protocol will include (1) passive range of motion exercises, stretching of the affected limb, or facilitatory and inhibitory techniques for 15 to 20 minutes, (2) tasks for training fine motor or dexterous function for 20 minutes, (3) arm exercises or gross motor training for 20 minutes, (4) muscle strengthening of the affected UL for 15 to 20 minutes, and (5) activities of daily living or functional tasks practice for 15 to 20 minutes. The activities will be adapted based on the level of motor impairment and individual needs of the patients.
223820482|NCT03179943|DRUG|Atezolizumab|Patients will be administered atezolizumab intravenously on day 1 and day 22 of a 6 week cycle for the period of 8 cycles.
223820483|NCT03179943|DRUG|Guadecitabine|Guadecitabine will be administered subcutaneously on days 1 through 5 of the 6 week cycle for the period of 4 cycles
223820484|NCT02307513|DRUG|Apremilast|Tablets for oral administration
223820485|NCT02307513|DRUG|Placebo|Tablets for oral administration
223820486|NCT05242016|OTHER|structured individual reminiscence|reminiscence therapy
223820487|NCT05242016|OTHER|unstructured social interview|placebo
223820488|NCT01837290|DRUG|dexmedetomidine infusion for premedication|Group Dexmedetomidine (Group D): Midazolam 0.02 mg/kg + 0.5 μg/kg/10 min dexmedetomidine infusion for premedication; Spinal block (Hyperbaric bupivacaine 0.5% 12.5 mg) (n=30)
223820489|NCT01837290|DRUG|Midazolam|intravenous Midazolam 0.02 mg/kg for premedication
223820490|NCT01837290|DRUG|saline infusion|Saline infusion to facilitate blinding
223820491|NCT01837290|DRUG|Spinal block with hyperbaric bupivacaine 0.5% 12.5 mg|Hyperbaric bupivacaine injection for spinal block
223820492|NCT03868241|DEVICE|Coated devices|Gold-silver-palladium coated devices (endotracheal tube, central venous catheter and urinary catheter) will be used whenever necessary. All three devices are required to be inserted as soon as possible after randomization and need for all three devices are the main inclusion criteria
223820493|NCT03868241|DEVICE|Control|Devices without coating available at each participating intensive care unit
223820494|NCT00709748|DEVICE|Empi Select TENS Device|The Empi Select TENS device delivers therapeutic electrical currents at various frequencies (intensities) and periods of time for the treatment of pain.
223820495|NCT00709748|DEVICE|Placebo|Subjects in this study arm will receive control (not fully active) Empi Select TENS devices.
223820496|NCT06539975|DRUG|Evening Primrose Oil 1000 MG|Evening primrose oil 1000mg vaginally plus misoprostal for induction of labor
223820497|NCT02872727|OTHER|Respiratoy health, biological investigations|Once the subjects have agreed to participate, self-surveys on their lifestyle habits will be filled and EACand urine samplings will be taken during one same consultation, in addition to exhaled CO and No measurements. This consultation will also include a spirometry test. The employees' workstation data (and their evolution since the first study) will be collected. Therefore, the volunteers' participation is limited to one single visit including non-invasive examinations and self-surveys.
223820498|NCT03769805|DRUG|Anlotinib|Anlotinib hydrochloride capsule 12 mg, orally, once a day, oral before breakfast, according to the research program for 2 weeks, discontinued for 1 week.
223820499|NCT02977884|BEHAVIORAL|The Complete Health Improvement Program|CHIP focuses on food, diet, activity, exercise, stress management, by viewing videos, cooking demonstrations, discussion, and exercise. Intervention nurtures intelligent self-care through enhanced understanding of the epidemiology, etiology, and risk factors associated with chronic lifestyle related diseases. The primary focus is the consumption of plant-based whole foods, such as fresh fruits, vegetables, whole grains, legumes, and nuts. The goal was to keep dietary fat below 20% of total calories, daily intake of added sugar below 10 tsps, sodium below 2,000 mg, and cholesterol below 50 mg. High fiber food intake (\>35 g/day) is encouraged, and flexibility exercises, a daily walk of 30 minutes or 10,000 steps and daily use of stress management techniques.
223835512|NCT05123716|DRUG|MDMA|Participants will be given 100 mg of MDMA
223820500|NCT05232513|OTHER|Hand massage|Hand massage is an initiative that improves the communication between the massager and the individual, reduces anxiety, and provides comfort and relaxation.
223820501|NCT03214289|BIOLOGICAL|Fecal Microbiota Transplantation|Thirty fecal microbiota capsules produced from a single healthy donor, unrelated to the participant.
223820502|NCT06012864|PROCEDURE|PNL|percutaneous extraction of the stones in the kidney
223820503|NCT00130793|BIOLOGICAL|Comparator: zoster vaccine live (Oka/Merck) refrigerated formulation|1 dose of 0.65-mL/dose subcutaneous injection of zoster vaccine live (Oka/Merck) refrigerated formulation at Day 1
223820504|NCT00130793|BIOLOGICAL|Comparator: zoster vaccine live (Oka/Merck) frozen formulation|1 dose of 0.65-mL/dose subcutaneous injection of zoster vaccine live (Oka/Meck) frozen formulation at Day 1
223820505|NCT02351323|DRUG|Glutamine (Pharmacological doses)|30 grams/day of glutamine for 12-14 months
223820506|NCT02351323|BEHAVIORAL|Lifestyle change|Lifestyle change as recommended by Registered Dietitian
223820507|NCT00624715|DRUG|THC|"* High dose: 0.036 mg/kg (2.5 mg in a 70 kg individual)IV (in the vein) dissolved in ethanol. Equivalent to smoking a full joint~* Low dose: 0.018 mg/kg (1.25 mg in a 70kg individual) IV (in the vein) dissolved in ethanol.Equivalent to smoking ½ of a joint~* Very low dose: 0.0036 mg/kg (0.25 mg in a 70 kg individual)IV (in the vein) dissolved in ethanol. Equivalent to smoking 1/10 of a joint"
223820508|NCT00624715|DRUG|Placebo|Placebo: Small amount of ethanol IV (in the vein), (quarter teaspoon).
223820509|NCT04175418|OTHER|Supervised Exercise Program|The exercise program in this group includes aerobic (walking) training and exercises to strengthen the upper and lower extremities and trunk muscles.
223820510|NCT04175418|OTHER|Online Education Program|The exercise program in this group includes aerobic (walking) training and home exercises to strengthen the upper and lower extremities and trunk muscles.
223820511|NCT05016011|BIOLOGICAL|Human umbilical cord-derived mesenchymal stem cells (hUC-MSCs)|Human umbilical cord-derived mesenchymal stem cells
223820512|NCT05016011|PROCEDURE|Marrow cellution|Patients will undergo marrow cellution surgical procedure.
223820513|NCT06053060|OTHER|Randomisation Standard Dynacup or Dynacup One C|Randomisation
223820514|NCT06134323|DEVICE|medication-combined transcutaneous vagus nerve stimulation|Two electrodes will be applied 2 cm below the left carotid sinus for active stimulation
223820515|NCT06134323|DEVICE|medication-combined sham stimulation|Two electrodes will be applied 2 cm below the left carotid sinus for sham stimulation
223820516|NCT05389891|OTHER|Hemoglobinopathy Nursing Program|"Hemoglobinopathy Nursing Program is more informative for Groupe 1 than Group 2"
223820517|NCT00453102|DRUG|Rituximab|IV Infusion of 250mg/m² of Rituximab Within 4 hours on Days 1, 7, 8, 9 0.4 millicuries (mCi)/kilogram (kg) (14.8 megabecquerels (MBq)/kilogram (kg)) for patients with normal platelet count 0.3 mCi/kg (11.1 MBq/kg) for patients with platelet count of 100,000-149,000 cells/mm³
223820518|NCT00453102|DRUG|Ibritumomab Tiuxetan|"IV injection of Y-90 Zevalin® over 10 minutes on Days 1, 7, 8, 9:~0.4 mCi/kg (14.8 MBq/kg) for patients with normal platelet count 0.3 mCi/kg (11.1 MBq/kg) for patients with platelet count of 100,000-149,000 cells/mm³"
223820519|NCT03733743|OTHER|Standardized living protocol|Subjects stay at the research facility for 44 hours and adhere to a standard sleeping, eating and activity protocol. During this protocol, multiple measurements will be performed including skeletal muscle biopsies (m. vastus lateralis), blood draws, indirect calorimetry and MRS measurements.
223820520|NCT00159978|PROCEDURE|18F-FLT and 18F-MISO-PET|18F-FLT-PET-images will be acquired one hour after injection of 250 MBq FLT. 18F-MISO-PET: 400 MBq FMISO will be injected intravenously. Marker administration: The day before surgery (≤ 24h) pimonidazole (500 mg/m2) will be administered intravenously in 100 ml saline over 20 min. IdUrd (200 mg) will be administered as bolus injection 20 min before surgery.
223820521|NCT05491369|OTHER|Epilepsy application|Nanacara is an epilepsy application which helps people with epilepsy to self-manage their conditions.
223820522|NCT03154944|DEVICE|Ostomy device 1|This device consists of a known adhesive and a new top film
223820523|NCT03154944|DEVICE|Ostomy device 2|This device consists of a new adhesive and a known top film
223820524|NCT03154944|DEVICE|Ostomy device 3|This device consists of a known adhesive and a new top film
223820525|NCT01782963|DRUG|Lenalidomide|
223820526|NCT01782963|DRUG|Bortezomib|
223820527|NCT01782963|DRUG|Dexamethasone|
223820528|NCT06215690|DIAGNOSTIC_TEST|Ultrasound measurements|"Evaluation will be performed by ultrasonography. The following measurements will be taken with the ultrasonographic examination.~* BPD (Biparietal Diameter)~* HC (Head Circumference)~* AC (Abdominal Circumference)~* FL (Femur Length)~* EFW (Estimated Fetal Weight)~* Umbilical Artery Doppler Sistole/Diastole (S/D) ,Pulsatility İndex (PI), Resistance İndex (RI)~* Middle Cerebral Artery S/D,PI,RI~* Uterine Artery Doppler PI~* Anterior Cerebral Artery S/D,PI,RI~* CPUR (Cerebral - Placental - Uterin PI Ratio)~* CPR (Cerebral - Placental PI Ratio)~* The deepest free single vertical pocket in the amnion mai~* Cavum Septum Pellucidum: Width - Length Diameters~* OFD (Occipitofrontal length)~* FAPD (Frontal Anterior Posterior Diameter)~* FAPD/OFD ratio~* Cerebellar diameter~* Lateral ventricle depth~* Insular depth~* Sylvian fissure depth"
223820529|NCT02980003|DRUG|isotonic saline|patients will start hydration with isotonic saline 6 hours before angiography and continue for 12 hours after the procedure.
223820530|NCT02980003|DRUG|i.v. sodium bicarbonate|patients will start hydration with isotonic saline 6 hours before angiography and continue for 12 hours after the procedure. The patient receives solution of 1.4% sodium bicarbonate (167 mEq/L; 334 mOsm/L) one hours and six hours after procedure.
223820531|NCT02980003|DRUG|oral sodium bicarbonate|patients will start hydration with isotonic saline 6 hours before angiography and continue for 12 hours after the procedure. One hour before the angiography and 3 hours after patients will receive oral sodium bicarbonate at the dose of 4 g (47.6 mEq) dissolved in 60 mL of water
223820532|NCT03705455|BEHAVIORAL|ISAP SMS|ISAP SMS is a text message for caregivers use that provides immunization schedule and vaccine availability at the nearest immunization clinic.
223820533|NCT05509543|DRUG|IY-NT-T|Ilaprazole 20mg
223820534|NCT05509543|DRUG|IY-NT-R|Ilaprazole 10mg
223820535|NCT05236413|BEHAVIORAL|High Intensity Interval Exercise|"Patients will be required to report for three sessions of supervised stationary cycling exercise per week over a period of 4-weeks. Training heart rates will be determined based on the pre-testing VO2peak and peak heart rate (PHR). All sessions will be supervised by trained personnel.~Patients will start with eight intervals of 2-min duration at 80-85% of PHR, separated by 2 min of recovery at 50% of PHR, progressing to four, 4-min intervals at 90-95% PHR, separated by 3 min at 50% PHR by the end of week 2.~Each training session will begin with a 10-min warm-up at 50% of PHR and end with a 5-min cool down at 50% PHR. Subjects will be weighed prior to every exercise session and weight tracked to ensure that their volume status hasn't changed significantly. Subjects will be instructed to maintain usual levels of physical activity and usual diet during the study and not to make any modifications to the same."
223820536|NCT05236413|BEHAVIORAL|Dietary Approaches to Stop Hypertension (DASH) Diet|Patients will be interviewed with regard to their food/religious preferences and food allergies and a 7-day rotating meal plan will be designed per their preferences along with a registered dietitian. This will ensure that patients receive food that is acceptable to them. Participants will then be provided pre-packaged meals for 4-weeks with macronutrient compositions as follows - (Carbohydrates -55-60%, Protein -15-20%, Fat -15-25%, Fiber -35-45g/day). All foods will be labeled, sealed, and packed for weekly delivery and will be designed such that they can be refrigerated or frozen and stored without significant alterations to nutritional content. All food will be prepared by the UVA Hospital Nutrition Services department in conjunction with a registered dietician. Deviations (if any) from the study meal plan will be recorded by the participants in a food record provided at the start of each diet intervention period.
223820537|NCT05236413|BEHAVIORAL|Exercise + DASH Diet|Patients will undergo both the exercise training intervention and DASH diet as explained above.
223820538|NCT04249219|OTHER|Viewing e-cigarette ads|All participants will see the same e-cigarette ads presented in a random order.
223820539|NCT02479997|DRUG|Indocyanine green|"ICG is cyanine dye used in medical diagnostics. It is used for determining cardiac output, hepatic function, and liver blood flow, and for ophthalmic angiography.~In this study, Investigator uses ICG as a fluorescent dye which is used in medicine as an indicator substance . And it will allow detection of SLN more convenientlty."
223820540|NCT02479997|DRUG|Radioisotope|Nuclear medicine uses radiation to provide diagnostic information about the functioning of a person's specific organs, or to treat them. Diagnostic procedures using radioisotopes are now routine.
223820541|NCT05758545|DEVICE|COMS One device|The COMS One device incorporates technologies for optical and magnetic stimulation. The optical stimulation component is designed to emit light by two types of light emitting diodes (LEDs) in the wavelength of 660 nm (red) and 830 nm (near infrared) range of the electromagnetic spectra. The magnetic stimulation component is generated by a coil emitting pulse modulated magnetic fields in the extremely low frequency (ELF) range of the electromagnetic spectra. The COMS One is a lightweight, portable device. The device is locally applied via a single use disposable component (COMStouch) that provides a base and sterile barrier for the unit. The device is attached via a single use strap (COMSfix). The device has been slightly adapted in order to make sure blinding is achieved/maintained. The specific feature that has been modified for the purpose of blinding is sensor detecting whether the device is lying on the skin.
223820542|NCT05758545|DEVICE|Sham device|The Sham device is a lightweight, portable device. The device is applied via a single use disposable component (COMStouch) that provides a base and sterile barrier for the unit. The device is attached via a single use strap (COMSfix). The device has been slightly adapted in order to make sure blinding is achieved/maintained. The specific features that have been modified for the purposes of blinding include the following: 1) therapeutic output, and 2) sensor detecting whether the device is lying on the skin.
223820543|NCT05790239|DRUG|3,4-methylenedioxymethamphetamine|Initial doses per Experimental Session include 68 mg or 100 mg MDMA (equivalent to 80 mg or 120 mg MDMA HCl), followed 1.5 to 2 hours later by a supplemental dose of 34 mg or 50 mg MDMA (equivalent to 40 mg or 60 mg MDMA HCl).
223820544|NCT05790239|DRUG|d-amphetamine|Initial dose per experimental session will be 5 mg or 10 mg d-amphetamine, followed 1.5 to 2 hours later by supplemental dose of 2.5 mg or 5 mg d-amphetamine.
223820545|NCT05790239|BEHAVIORAL|Therapy|Participants assigned to MDMA and d-amphetamine will undergo a therapeutic approach, which is detailed in the MDMA-Assisted Therapy Treatment Manual and administered by MAPS-trained therapists. In brief, this therapy is guided by the subject's own recollections of traumatic events. The subject and two therapists provide a comfortable and supportive environment and allow the subject to guide the discussion. Subjects are encouraged to experience and express fear, anger, and grief with less likelihood of feeling overwhelmed by these emotions. MDMA seems to engender internal awareness that even painful feelings that arise are an important part of the therapeutic process. In addition, feelings of empathy, love, and deep appreciation often emerge, along with a clearer perspective of the trauma as a past event, a more accurate perspective about its significance, and a heightened awareness of the support and safety that exists in the present.
223820546|NCT05126823|BEHAVIORAL|Acceptance and commitment therapy + app|In the group ACT+app, experiential exercises are carried out, metaphors, discussions and assignments are used to promote awareness and flexibility about the thoughts and emotions associated with cancer and interleaved non-contact activities, which will serve as support for each of the modules. The non-contact activities will consist of assigning tasks, practices (mindfulness, breathing), reminder systems, recording, reinforcement and monitoring. Resources such as short texts, videos, audio files and recording systems will be used
223820547|NCT05126823|BEHAVIORAL|Acceptance and commitment therapy|In the group ACT, experiential exercises are carried out, metaphors, discussions and assignments are used to promote awareness and flexibility about the thoughts and emotions associated with cancer
223820548|NCT06077110|OTHER|Precision Care Clinic services|The Service Intervention is the Precision Care Clinic being delivered at the Prince of Wales Hospital. This clinic provides a streamlined, multidisciplinary model to seamlessly integrate research-led precision medicine into the routine oncology setting.
223835513|NCT05123716|DRUG|placebo oral tablet|Participants will be given a placebo capsule that will only contain lactose.
223820549|NCT05706532|DIAGNOSTIC_TEST|active standing|Data are acquired with patients resting in supine position for 10 minutes and for 10 minutes during active standing
223820550|NCT01533571|PROCEDURE|Immediate implant placement with simultaneous bone grafting|"* Flapless surgery is used for surgical implant installation.~* Implant is placed in the cingulum position of adjacent teeth incisal edge.~* After placement of optimal implant the remaining gap between the implant and the surrounding bony walls should be at least 2 mm or should be need for GBR of buccal plate outside the socket.~* Two types of bone graft materials will be applied for two groups of patients: Group I - natural bovine bone grafting material + resorbable natural soft tissue membrane; Group II - processed human allograft + resorbable natural soft tissue membrane .~Crown can be fixed on abutment if there is initial stability under 35 Ncm insertion torque. If insertion torque will be less, crown should be bond to neighboring teeth using composite material."
223820551|NCT03780374|DEVICE|Phonak Audéo L2M with Sound Processing Principle 1|Compensation of a hearing loss with Sound Processing Principle 1.
223820552|NCT03780374|DEVICE|Phonak Audéo L2M with Sound Processing Principle 2|Compensation of a hearing loss with Sound Processing Principle 2.
223820553|NCT03780374|DEVICE|Phonak Audéo L2M with Sound Processing Principle 3|Compensation of a hearing loss with Sound Processing Principle 3.
223820554|NCT03500640|BEHAVIORAL|DPP Intensive: 30-minute calls|Ongoing DPP intervention and behavioral progress review to prevent relapse and improve cardiometabolic and functional health targets as keys to healthy aging.
223820555|NCT03500640|BEHAVIORAL|DPP Support: 15-minute calls|No further behavioral intervention materials provided; phone-contacts for mutual social support and accountability
223820556|NCT06139718|BEHAVIORAL|ACT Guide Lite|ACT Guide Lite is a single session online mental health program that is designed to take 30-45 minutes to complete. The single session self-guided intervention includes a series of sections that teach key ACT skills.
223820557|NCT01650519|DRUG|IV ibuprofen|800 mg intravenous ibuprofen administered intravenously over 10 minutes.
223820558|NCT01650519|DRUG|IV ketorolac|30 mg ketorolac for patients \< 65 years of age (15 mg ketorolac for patients \> 65 years of age) administered intravenously over no less than 15 seconds
223820559|NCT01737281|BEHAVIORAL|Proactive outreach|Proactive contact (mail and phone) offering smoking cessation medications and telephone counseling.
223820560|NCT01737281|BEHAVIORAL|Usual care|Usual smoking cessation care from VA clinical staff.
223820561|NCT06084533|DRUG|[11C]-CS1P1|Participants will receive a single intravenous bolus injection of 10.0 - 20.0 milliCurie (mCi) of the investigational radiotracer \[11C\]-CS1P1. Participants will then undergo a \[11C\]-CS1P1 PET scan.
223820562|NCT05819073|OTHER|Plain water|Subjects will use plain water as an oral rinse twice a day for 3 days.
223820563|NCT05819073|OTHER|CPE|Subjects will use a cranberry-derived oral rinse twice a day for 11 days.
223820564|NCT03694132|DEVICE|functional MRI|conditioning brain activity with peripheral stimulations
223820565|NCT03694132|DEVICE|structural MRI|diffusion MRI and tractography for evaluating the brain structures
223820566|NCT03694132|DEVICE|EEG/MEG|conditioning brain activity with peripheral stimulations
223820567|NCT04913129|OTHER|Exercise Training|8 week home-based exercise therapy 4-5 times/week
223820568|NCT06851104|DRUG|Cadonilimab (AK104)|Patients with hepatocellular carcinoma after curative hepatectomy would receive cadonilimab 10 mg/kg intravenous infusion (dissolved in 0.9% NaCl 250 mL, within 60 minutes) Q3W, until disease progression, death, intolerance to toxicity, withdrawal of informed consent, initiation of new anti-tumor treatment, or termination of treatment for other reasons specified in the protocol. The maximum treatment duration for cadonilimab is 6 months.
223820569|NCT04918225|RADIATION|Magnetic Resonance Imaging|"Encephalic (about 30 minutes\*)~* lesion location assessment: 3D FLAIR, 3DT1, 3DT2 (standard OFSEP protocol)~* lesion severity assessment: Axial magnetization transfer imaging (mt0, mt1)~* tract location assessment: 30 directions diffusion imaging (standard OFSEP protocol)~* B0 and B1 mapping to correct for B0 and B1 inhomogeneities~  ● Spinal cord (about 50 minutes\*)~* lesion location assessment: cervical and thoracic sagittal T2 TSE (0.7x0.7x2.5mm3), axial cervical MEDIC T2\* (0.7x0.7x3mm3), axial thoracic T2 (0.5x0.5x3mm3)~* lesion severity assessment: Axial magnetization transfer imaging (mt0, mt1, 0.7x0.7x3mm3) on the cervical cord and on the thoracic cord~* tract location assessment: performed from registration on atlas~* B0 and B1 mapping to correct for B0 and B1 inhomogeneities"
223820570|NCT04918225|DIAGNOSTIC_TEST|Neurological examination|Global disability will be scored using the Expanded Disability Status Scale score
223820571|NCT04918225|DIAGNOSTIC_TEST|Multiple Sclerosis Functional Composite|"* Walking disability will be scored using the 25-foot timed-walked test~* Arm disability will be scored using the nine-hole peg test"
223820572|NCT04918225|DIAGNOSTIC_TEST|Physiotherapist examination|"* American Society Injury. Association motor subscore for each limb~* The muscle strength using a dynamometer. Two muscle groups will be tested for the upper (elbow flexors and extensors) and lower limbs (hip flexors and ankle dorsiflexion).~* The Ashworth Scale and the Tardieu Scale to assess spasticity.~* 6 minutes walking test~* Fatigue Severity Scale~* MFIS : Modified Fatigue Impact Scale"
223820573|NCT04967391|PROCEDURE|Tumescence During STSG Harvest|Tumescence injections performed prior to STSG harvest
223820574|NCT05617001|DEVICE|Kardia 12L|The purpose of this study is to collect clinical validation data to support an FDA submission for a 510(k) for the Kardia 12L hardware which enables the simultaneous diagnostic quality recording of all 6 limb leads and any chest lead. We will be recording both Leads V1 and V2 in a sequential fashion along with the V4 and Limb leads and a simultaneous 12-lead ECG to validate the hardware and a Deep Neural Network model which expands the 5 leads into a complete 12-lead ECG. The 12-lead ECG used for validation of the recordings and the 12-lead synthesis model is the GE Cardiosoft System which is FDA cleared.
223820575|NCT02457416|OTHER|Peanut|Treatment with peanut in increasing doses until a maintenance dose
223820576|NCT00501878|DRUG|2.5% or 10% phenylephrine|
223820577|NCT04459286|DRUG|Nitazoxanide and atazanavir/ritonavir|1000 mg nitazoxanide tablets twice daily and 300/100 mg atazanavir/ritonavir tablets once daily with meal
223820578|NCT04459286|OTHER|Standard of Care|SOC will be as determined by the clinical team at the treatment centres in line with the current National Interim Guidelines for Clinical Management of COVID-19
223820579|NCT03861806|BEHAVIORAL|PAS true|Participants will receive paired associative stimulation (transcranial magnetic stimulation and peripheral nerve stimulation) with an inter-stimulus interval length known to modulate corticospinal excitability.
223820580|NCT03861806|BEHAVIORAL|PAS sham|Participants will receive paired associative stimulation (transcranial magnetic stimulation and peripheral nerve stimulation) with an inter-stimulus interval length known to not modulate corticospinal excitability.
223820581|NCT00226512|DRUG|Campath-1H /ATG|
223820582|NCT00722579|DEVICE|PRESILLION cobalt chromium stent|PTCA with bare-metal stent
223820583|NCT00737880|OTHER|Organ perfusion during pancreas procurement|Usage of UW or HTK perfusion solution during in situ abdominal organ perfusion in multi-organ procurement
223820584|NCT02993939|PROCEDURE|Interscalene block|Ultrasound guided single shot block above the clavicle
223820585|NCT02993939|PROCEDURE|Infraclavicular-suprascapular block|Combined block of nerves far away from phrenic nerve
223820586|NCT01025934|DRUG|Bevacizumab|
223820587|NCT01025934|OTHER|sham|
223820588|NCT05726682|DRUG|SAR445419|Pharmaceutical form: cell suspension Route of administration: Intravenous (IV) injection
223820589|NCT01508013|BEHAVIORAL|Appearance-Focused Website Intervention|The intervention is a teen-friendly website with information concerning the health and appearance effects of indoor tanning.
223820590|NCT01508013|BEHAVIORAL|Control Website|The control website contains information about alcohol and drug abuse which is oriented for a teen audience.
223820591|NCT03718962|DEVICE|Surrounding needling+ phototherapy|Surrounding needling+ phototherapy
223820592|NCT03718962|DEVICE|phototherapy|phototherapy
223820593|NCT00001060|BIOLOGICAL|HIV-1 C4-V3 Polyvalent Peptide Vaccine|
223820594|NCT00280826|DRUG|Efalizumab|Participants who qualified for the study received weekly subcutaneous treatments of efalizumab, with the first dose being a test dose of 0.7 mg/kg and subsequent doses of 1 mg/kg (not to exceed 200 mg per dose), for a total treatment duration of 16 weeks.
223820595|NCT01202487|DRUG|LET - Lidocaine Epinephrine Tetracaine|One time application of 3 cc of Lidocaine Epinephrine Tetracaine Solution at least 45 minutes prior to laceration repair
223820596|NCT03612427|DIETARY_SUPPLEMENT|S. Cholesterol S. Triglyceride|S. Cholesterol S. Triglycerides
223820597|NCT04902820|OTHER|PrEPTECH website|The intervention is a web site delivering access to PrEP telehealth. The platform provides access to laboratory testing for PrEP eligibility delivered to a participant's home, telehealth care and PrEP prescriptions for those eligible delivered asynchronously through an online form for all adult participants and through telephone appointments for adolescent participants, and a mail-order pharmacy for PrEP. Additionally, free PrEP medication will be provided through the intervention. Transgender female and adolescent cisgender male participants will receive free PrEP medication (emtricitabine \[200 mg\]/tenofovir disoproxil fumarate \[300 mg\]) for the duration of their participation in the study, while adult cisgender male participants will receive a free 30-day supply of PrEP and subsequently have to pay for PrEP medication through insurance, patient assistance programs, or out of pocket.
223820598|NCT04902820|OTHER|Online PrEP resource list|Participants will receive access to an online list of web-based resources about PrEP and how to locate and pay for PrEP care and contact information for a professional PrEP navigator at a local community-based organization partnering with the study.
223820599|NCT04931394|OTHER|Adjuvant chemotherapy guided by organoid drug sensitivity test|Adjuvant chemotherapy guided by organoid will be given to pancreatic cancer patients.
223820600|NCT05072184|PROCEDURE|ESP block|ESP block group who will receive preoperative US-guided bilateral ESP block with 20 ml of bupivacaine 0.25% on each side
223820601|NCT02487095|DRUG|Topotecan|Topotecan (in combination with VX-970 (M6620) administered by intravenous (IV) Days 1-5 in a 21 day cycle, until disease progression or development of intolerable side effects.
223820602|NCT02487095|DRUG|VX-970 (M6620)|VX-970 (M6620 (in combination with Topotecan) administered by intravenous (IV) Day 5 or Days 2 and 5 in a 21 day cycle, until disease progression or development of intolerable side effects.
223820603|NCT00347243|PROCEDURE|phacoemulsification (cataract surgery)|
223820604|NCT03555357|OTHER|Platelet Rich Fibrin|Platelet Rich Fibrin (PRF) is the next generation of PRP and contains very high concentrations white blood cells, fibrin and a small amount of mesenchymal stem cells found circulating in our bloodstreams. Due to a lack of anticoagulant in the tube, PRF becomes a gel after 15-20 minutes of being isolated. These properties make PRF useful in reconstructive and aesthetic medicine but may also be beneficial for scar therapy in the same way PRP is currently used.
223820605|NCT03555357|OTHER|Platelet Rich Plasma|Platelet Rich Plasma (PRP) has been used in surgical settings to stimulate healing and promote tissue regeneration. In the field of cosmetic medicine, PRP has been used topically or as an injection to stimulate collagen production and enhance the efficacy of cosmetic procedures such as fat transfer, hair loss therapies, laser treatments, and microneedling. Harvested PRP has platelets, fibrin, and white blood cells, which contribute to wound healing, neocollagenesis, and elastogenesis
223820606|NCT04566588|PROCEDURE|EAR HoLEP|early apical release holmium enucleation of the prostate (EAR HoLEP), as a surgical treatment for benign prostatic hyperplasia
223820607|NCT04566588|PROCEDURE|Classic HoLEP|classic holmium enucleation of the prostate as a surgical treatment for benign prostatic hyperplasia
223820608|NCT05809661|BEHAVIORAL|implementation of the nurse navigation program|Adult patients with intestinal stoma were contacted continuously for 6 months.
223820609|NCT02041689|BEHAVIORAL|Interview|Each participant will complete two interview sessions with the primary investigator. Each interview will be conducted in a private, quiet room. Parents may choose to remain with the child during the interview if they would like, but only the responses of the child will be analyzed. Each interview session will last no more than one hour; if the child is not able to respond to each of the primary interview questions during this time, a second follow-up session will be scheduled so that the remainder of the questions can be answered. All interviews will be audio-recorded and transcribed.
223820610|NCT02041689|BEHAVIORAL|Observations|Observations help to give insights about interpersonal interactions, actions, non-verbal cues, and the activities and function of areas within the hospital. Three kinds of observation will be used: participant observation, non-participant observation, and guided activities. These observations will be conducted to learn more about the hospital environment as it intersects with the learning experiences of the participants.
223835514|NCT00000926|DRUG|Nonoxynol-9|
223835515|NCT03246672|BEHAVIORAL|maintenance intervention|Participants will receive calls at weeks 1, 2, 3, 4, 6, 8, 10, 12, and 14 that focus on satisfaction with outcomes of behavior change, self-monitoring, relapse planning, and social support.
223820611|NCT02041689|BEHAVIORAL|Guided Activities|"This study will use three different types of arts and play-based activities to give participants a variety of ways to express their thoughts and perceptions of what it is like to learn about their cancer diagnosis and treatment.~The first activity will be a guided medical play opportunity that prompts the child to use actual medical equipment while taking care of a doll.~For the second activity, the child will be given a digital camera to use and a prompt that asks them to photograph things and individuals in the hospital that have helped them to learn about their diagnosis and treatment.~The third activity will be an open-ended art prompt in which the child will create an artistic representation of what it means to have cancer and get treatment."
223820612|NCT04092465|PROCEDURE|Pulmonary parenchyma resection, lobectomy, pneumonectomy, sleeve lobectomy, extended lobectomy/pneumonectomy|Resection of the downstaged locally advanced NSCLC through formal thoracotomy
223820613|NCT01965379|OTHER|Restriction on food containing phosphorus additives|The substitution of foods containing phosphorus additives for others with the same nutritional value for each individual of the study.
223820614|NCT01965379|OTHER|Standard care|The control group mantained the usual renal diet oriented prior to the study with a booklet.
223820615|NCT00015821|DRUG|thalidomide|Given PO
223820616|NCT00015821|OTHER|laboratory biomarker analysis|Correlative studies
223820617|NCT05398146|BEHAVIORAL|mathematical operations|Prepared by the researchers, the form involved mathematical operations such as addition, subtraction, multiplication, and division. The difficulty level of the mathematical operations in the form was determined by age groups of children. Accordingly, mathematical operations were divided into 3 groups primary school, secondary school and high school levels.
223820618|NCT05398146|BEHAVIORAL|ball squeezing|For the children in the BS group, a softball that could fit in the palm and be easily squeezed by the child was used.
223820619|NCT05398146|BEHAVIORAL|listening to music|Children were allowed to listen to music with headphones during dressing changes.
223820620|NCT05398146|OTHER|kontrol grubu|No application was made during dressing change in children. Routine dressing change of the clinic was applied.
223820621|NCT02705781|DEVICE|smARTrack Feeding Tube System|
223820622|NCT02117934|BIOLOGICAL|HEPLISAV|Intramuscular injections at Week 0 and Week 4, plus a placebo injection at Week 24
223820623|NCT02117934|BIOLOGICAL|Engerix-B|Intramuscular injections at Week 0, Week 4, and Week 24
223820624|NCT01639105|PROCEDURE|Laser treatment|10 600 NM ABLATIEVE FRACTIONATED LASER
223820625|NCT05041816|DEVICE|Focal vibration therapy|Myovolt delivers vibration with a frequency between 60-300 Hz, and acceleration force between 1.8g to 19.1g peak to peak. Myovolt intensity will be set to \~up to 2X the participant's initial Myovolt perception threshold (however, the maximum intensity will be limited to 19.1g which is the maximum intensity the device can deliver). If the stimulation does not feel strong, the participant will be asked to manually increase the intensity until it feels strong but comfortable.
223820626|NCT04888247|DEVICE|CLARITY|Trans-septal mitral valve replacement
223820627|NCT03860168|OTHER|PICU Up!|The PICU Up! intervention is a multifaceted mobility program incorporating the ABCDEF bundle components into routine PICU care through multidisciplinary staff education and a structured pathway to determine a patient's daily mobility goal. PICU Up! was developed by a collaborative multidisciplinary team approach, and the central components include the consultation and involvement of physical therapy/occupational therapy (PT/OT) by PICU Day 3, sleep hygiene promotion and routine delirium screening for all PICU patients utilizing a validated tool.
223820628|NCT05889923|DEVICE|With EDU|using the EDU to perform the procedure
223820629|NCT06163664|BEHAVIORAL|Use of chatGPT for 1 week|Use of chatGPT for 1 week
223820630|NCT05778526|BEHAVIORAL|Virtual reality|There are a total of 12 training sessions for 3 weeks (4 sessions per week). Each session of the Social VR intervention lasts for a maximum of 20 minutes. The intervention contains three real-life virtual scenarios, including (1) a classroom and playground, (2) an MTR station and compartment, and (3) a supermarket and restaurant.
223820631|NCT05778526|BEHAVIORAL|Traditional social skills training|There are a total of 12 training sessions for 3 weeks (4 sessions per week). Each session lasts for a maximum of 20 minutes. Four modules will be covered in the 3-week training: (1) how to introduce yourself and basic social skills; (2) how to listen to others; (3) how to share with others; (4) learn to know how people feel and how to empathise.
223835516|NCT02062411|BEHAVIORAL|CBT only|Participants will learn 12 sessions including educational information about ADHD and skills in organization and plan, reducing distractibility, and adaptive thinking.
223820632|NCT05965843|OTHER|underling disease|"Nowadays Covid-19 virus has become milder than before however severe outcomes still happen in people with underlying diseases after infection.~For example, previous research indicated cirrhosis was an independent predictor for COVID-19 mortality.~More efforts shoud be make to explore the association between underlying diseases and severe COVID-19."
223820633|NCT00732602|OTHER|GIP-infusion|
223820634|NCT00732602|OTHER|Sodium-chloride|
223820635|NCT00732602|OTHER|GLP-2 infusion|
223820636|NCT05433324|OTHER|MRI and PET Scans|All groups will undergo cognitive tests and brain imaging scans (MRI \& PET)
223820637|NCT06547034|DEVICE|Ultrasound|Breast Ultrasound
223820638|NCT05336409|BIOLOGICAL|CNTY-101|CNTY-101 cells for intravenous (IV) infusion
223820639|NCT05336409|BIOLOGICAL|IL-2|IL-2 subcutaneous (SQ) injection
223820640|NCT05336409|DRUG|Lymphodepleting Chemotherapy|LDC as prespecified in the protocol.
223820641|NCT04856501|BEHAVIORAL|PALS intervention condition|The Play and Learning Strategies (PALS) intervention provides parents with behaviors that, collectively, are known as a responsive parenting style. Four constructs make up this responsive parenting style: 1) contingent responsiveness, (responses are conditionally linked to the child's signals) 2) warm sensitivity (high levels of affection and understanding of child states), 3) maintaining vs. redirecting attention, and 4) verbal scaffolding (providing child appropriate language supports). Parents assigned to this intervention will be paired with a coach who will guide them through the program over the course of 9 weekly sessions. The intervention (ePALS) will be implemented via an internet adaptation through the Children's Learning Institute's ENGAGE platform. However, ePALS could easily be adapted for other platforms and accessed with any web-enabled device.
223820642|NCT04856501|BEHAVIORAL|Control condition|Families assigned to the control condition will be provided with a website with information corresponding to milestones of toddler development. Control families will be asked to review that week's materials before the each of the 9 weekly coach calls. The active control condition serves three important purposes: 1) Maintains an active line of communication and accurate contact records for Post-test 1 and Post-test 2 session scheduling; 2) Masks participant's awareness of intervention vs. control assignment; and 3) Approximates communication with intervention staff such that results showing ePALS effects are attributable to intervention rather than regular communication with an interventionist.
223820643|NCT05425251|DIAGNOSTIC_TEST|GFAP and UCH-L1|2x5mL blood samples will be used to determine the performance of the automated VIDAS TBI platform in assessing serum concentrations of GFAP and UCH-L1 to rule out the need for a CT-scan after mTBI.
223820644|NCT06411327|DEVICE|Augmented reality|Augmented Reality Devices - data collected from the Guiding-Pad app will be fed to two AR devices (i.e. team leader and medication nurse), which will provide role-specific decision support for these two providers.
223820645|NCT06411327|DEVICE|LCD Screen|LCD Screen - data collected from the Guiding-Pad app will be fed to the LCD screen, which will be mounted on a wall, in clear view for the entire resuscitation team to see.
223820646|NCT06818201|DEVICE|NIBS|A total of 16 sessions will be scheduled, distributed over 8 weeks (2 sessions/week). The continuous current intensity will be set at 2 mA, for 20 minutes. Two electrodes, anode (red) and cathode (black), will be used along with two sponge pads with conductive gel, all combined into a helmet for each patient. The electrodes will be placed according to the international 10-20 system in tDCS. The stimulated area will be the primary motor cortex (M1), so the anode will be placed at the C3 or C4 points and the cathode will be placed at the contralateral supraorbital area Fp1 or Fp2.
223820647|NCT06818201|PROCEDURE|Rehabilitation|This protocol will consist of 72 sessions, distributed as 3 sessions per week over a period of 24 weeks. Strength will be the prioritized method of work and will be present in all phases. Additionally, periodic measurements will be included to ensure that the patient is making adequate progress and meets the necessary progression criteria to advance to the next phase
223820648|NCT06818201|BEHAVIORAL|Sham Comparator|The device will be configured to produce an ascending ramp lasting 30 seconds, identical to the one used in the experimental group, followed by a descending ramp of another 30 seconds. Thus, the control group will experience a sensation of tingling on the scalp, similar to that felt by the experimental group. This stimulation will have a total duration of 1 minute, which will not be sufficient to induce changes in cortical excitability
223820649|NCT03108157|PROCEDURE|Endometrial scratch|Patients included in the study group will be performed an endometrial scratch with Pipelle Cournier 3 to 4 weeks before embryo transfer.
223820650|NCT03557086|BEHAVIORAL|Advance Care Planning Video Decision Support Tool|Advance care planning video intervention as previously described
223820651|NCT03557086|OTHER|Verbal Narrative|Verbal description of end of life care options
223820652|NCT00555022|DRUG|GSK1160724|GSK1160724 will be available with dosing strengths of 10, 50 and 125 micrograms/blister for inhalation using the DISKUS inhaler.
223820653|NCT00555022|DRUG|Tiotropium bromide|Tiotropium bromide capsules will be supplied with a dose of 18 micrograms administered via a HandiHaler device.
223820654|NCT00555022|DRUG|Placebo|Subjects will receive placebo.
223820655|NCT06362902|PROCEDURE|Laparoscopic right hemicolectomy with transrectal specimen extraction|Laparoscopic right hemicolectomy with transrectal specimen extraction
223820656|NCT05740410|DEVICE|ClotTriever Catheter|Treatment of iliofemoral deep vein thrombosis with the ClotTriever catheter
223820657|NCT05520840|DIAGNOSTIC_TEST|blood sampling for screening of biomarkers|Patient aged 50 years or older referred for screening colonoscopy after a positive fecal immunochemical test or for endoscopic resection of a previously identified suspicious colorectal lesion will have a blood sampling for biomarkers detection
223820658|NCT00156806|PROCEDURE|Aloe barbadensis topical application in a moisturizing cream vehicle.|
223820659|NCT04504643|OTHER|Technology-assisted circuit training|Circuit training assisted by Fitlight™ 3 times a week for one hour during 8 weeks
223820660|NCT04504643|OTHER|Conventional circuit training|Conventional circuit training including single and dual task 3 times a week for one hour during 8 weeks
223820661|NCT04504643|OTHER|Nordic walking|Classic nordic walking 3 times a week for one hour during 8 weeks
223820662|NCT00025584|DRUG|bortezomib|Given IV
223820663|NCT00025584|OTHER|laboratory biomarker analysis|Correlative studies
223820664|NCT01454635|DRUG|Sertraline|dosage,frequency and duration
223820665|NCT02390934|RADIATION|Radium 223|
223820666|NCT06259383|DRUG|Ivermectin|3-day 1 daily dose of 400 μg/kg oral ivermectin
223820667|NCT01129635|PROCEDURE|Cardiac Resynchronization Therapy (CRT) implantation|"The impedance measurement is performed during device implantation following CMR. After the RV and LV leads are inserted, secured and tested, they will be connected to the impedance monitor. Impedance recording of at least ten beats will be acquired and stored for future analysis. Each recording will be tagged with the anatomical location of the LV lead. Subsequently, the LV lead will be moved to a different location and the same procedure will be repeated until accessible coronary sinus sites are exhausted. The ultimate LV lead location is determined by the implanting electrophysiologist and is not constrained by the study protocol. Finally, the LV lead will be tested again and the rest of the implantation procedure will proceed as routine.~Arm: CRT Candidate"
223820668|NCT00925535|DRUG|Lersivirine|1000 mg once daily for 10 days
223820669|NCT00925535|DRUG|Rifabutin|300 mg once daily for 10 days
223820670|NCT00925535|DRUG|Lersivirine|1000 mg once daily for 10 days
223820671|NCT00925535|DRUG|Rifabutin|300 mg once daily for 10 days
223820672|NCT05706090|DRUG|fentanyl will be added|If adequate anagesia is not provided with the block, 1 microgram/kg of fentanyl will be added
223820673|NCT05706090|PROCEDURE|general anesthesia|If adequate anagesia is not provided with the block, general anesthesia will be administered.
223820674|NCT00978484|BEHAVIORAL|Virtual Reality Exposure Therapy - Dynamic|10 weeks of Virtual Reality Exposure using full, immersive VR
223820675|NCT00978484|BEHAVIORAL|Augmented Exposure Therapy|Exposure Therapy augmented with a still computer image
223820676|NCT03204084|DEVICE|Low-temperature Plasma Surgery System|In pterygium surgery with fibrin glue(FG) and conjunctival autograft we use Low-temperature Plasma Surgery System(LTP)do the ablation of tissue and hemostasis.
223820677|NCT01758484|OTHER|palliative care|Undergo supportive care intervention
223820678|NCT01758484|OTHER|questionnaire administration|Ancillary studies
223820679|NCT01758484|PROCEDURE|quality-of-life assessment|Ancillary studies
223820680|NCT01279343|DEVICE|Foley bulb|This is a randomized trial comparing foley bulb with the use of misoprostol versus use of misoprostol alone for cervical ripening and labor induction.
223820681|NCT03040284|DEVICE|Echodia® hand-held equipment (ELIOS)|
223820682|NCT05288725|BIOLOGICAL|Bone Marrow Derived MSCs|Autologous bone marrow aspirate (BMA) is an orthobiologic injection used in knee osteoarthritis therapy. Bone marrow aspirate is harvested from the posterior superior iliac crest (PSIS) of the spine using the Marrow Cellutions kit. BMA will be injected into the knee using ultrasound guidance.
223820683|NCT05288725|DRUG|Corticosteroid|The corticosteroid is prepared in a 10 ml syringe by combining 1-2 mL Kenalog \[40 mg/dL\], 6-8 mL sterile normal saline, 3-4 mL Ropivicaine 1%.
223820684|NCT05288725|DEVICE|Bone Marrow Aspirate|The Marrow Cellutions kit is an FDA approved device for harvesting bone marrow aspirate.
223820685|NCT04534114|DRUG|Fesomersen sodium (BAY2976217)|Study intervention will be injected subcutaneously.
223820686|NCT04534114|DRUG|Placebo|Matching placebo to BAY2976217 will be injected subcutaneously.
223820687|NCT03287414|DRUG|VAY736|300 mg VAY736 administered subcutaneously every 4 weeks for 48 weeks
223820688|NCT03287414|DRUG|Placebo|Placebo administered subcutaneously every 4 weeks for 48 weeks
223820689|NCT03287414|DRUG|Standard of Care (SoC)|Background standard-of-care treatment for IPF: nintedanib, pirfenidone, or no background therapy
223820690|NCT00367965|DRUG|Eszopiclone|eszopiclone 3 mg
223820691|NCT00367965|DRUG|placebo|placebo tablet
223820692|NCT03340584|OTHER|the Nine Castle Net Format Taping|The intervention group received traditional rehabilitation and Taping throughout all rehabilitation period.The taping including a Nine Castle Net Format of taping in both side of surgery knee.We will exchange the new taping for every two days， for a week.Traditional rehabilitation included occupational therapy and physical therapy, patients took part in the traditional rehabilitation training for 30 minutes each day, for a week.
223820693|NCT03340584|OTHER|traditional rehabilitation|traditional rehabilitation included occupational therapy and physical therapy, patients took part in the traditional rehabilitation training for 30 minutes each day, for a week.
223835517|NCT02062411|BEHAVIORAL|CBT with booster sessions|Participants are provided with the same CBT programme and additional 3 booster sessions which summarize and extend the 3 main topics of the CBT programme in order to improve the skills practice ability.
223835518|NCT04635787|DEVICE|ANNE One|Wireless vital sign monitoring device
223835519|NCT01913964|DRUG|Acetylcarnitine|
223820694|NCT01529281|DIETARY_SUPPLEMENT|Branch Chain Amino Acid (BCAA)|Supplementation lasted for a total of 12 days; this was based on previous research showing a positive with BCAA supplementation on markers of muscle damage. Participants ingested 10 g, twice per day (morning and evening) of BCAA . The BCAA supplement contained a ratio of 2:1:1 (leucine, isoleucine and valine, respectively). The BCAA was in powder form where each serving was mixed with \~300 ml of water.
223820695|NCT01529281|DIETARY_SUPPLEMENT|Placebo - asparmate|Supplementation lasted for a total of 12 days. Participants ingested an equivalent looking volume to 10 g of BCAA, twice per day (morning and evening) of placebo (aspartame based artificial sweetener). The BCAA supplement contained a ratio of 2:1:1 (leucine, isoleucine and valine, respectively). The artificial sweetener was in powder form where each serving was mixed with \~300 ml of water.
223820696|NCT02759185|DRUG|High THC cannabis|Three weeks of smoking cannabis containing more THC than CBD with amount smoked limited to no more than 1.8 g per day.
223820697|NCT02759185|DRUG|High CBD cannabis|Three weeks of smoking cannabis containing more CBD than THC with amount smoked limited to no more than 1.8 g per day.
223820698|NCT02759185|DRUG|THC/CBD cannabis|Three weeks of smoking cannabis containing equal amounts of THC and CBD with smoking limited to no more than 1.8 g per day.
223820699|NCT02759185|DRUG|Placebo cannabis|Three weeks of smoking cannabis with low levels of THC and CBD with smoking limited to no more than 1.8 per day.
223820700|NCT04444284|BIOLOGICAL|Investigational RSV vaccine MV-012-968 (Dosage 1)|Single dose administered intranasally on Day 1
223820701|NCT04444284|BIOLOGICAL|Investigational RSV vaccine MV-012-968 (Dosage 2)|Single dose administered intranasally on Day 1
223820702|NCT04444284|OTHER|Placebo|Single dose administered intranasally on Day 1
223820703|NCT04444284|BIOLOGICAL|Investigational RSV vaccine MV-012-968 (Dosage 3)|Single dose administered intranasally on Day 1
223820704|NCT00836602|DRUG|BMS-779788|Oral Solution, Oral, 1 mg, Once daily, 7 days
223820705|NCT00836602|DRUG|BMS-779788|Oral Solution, Oral, 2 mg, Once daily, 7 days
223820706|NCT00836602|DRUG|BMS-779788|Oral Solution, Oral, \<= 4 mg, Once daily, 7 days
223820707|NCT00836602|DRUG|Placebo|Oral Solution, Oral, 0 mg, Once daily, 7 days
223820708|NCT06540001|DEVICE|Automated visual acuity|The automated visual acuity device is developed in collaboration with Tan Tock Seng Hospital, Singapore Institute of Technology and Nanyang Technological University. It uses artificial intelligence for pose estimation and speech recognition to infer if the participant is reading the correct letters displayed on the screen.
223820709|NCT02110745|DRUG|Sevofluorane|Comparison of different induction drugs and techniques
223820710|NCT02110745|DRUG|Propofol|Comparison of different induction drugs and techniques
223820711|NCT00161070|DRUG|anticoagulation|
223820712|NCT00161070|DRUG|aspirin and dipyridamole|
223820713|NCT00161070|DRUG|aspirin alone|
223820714|NCT01226914|DRUG|EVICEL|EVICEL
223820715|NCT03163576|DRUG|Niacin|tablets
223820716|NCT03163576|DRUG|Phosphate Binder|tablets
223820717|NCT03454464|PROCEDURE|Conventional|Conventional operation ,Thyroidectomy was performed first, and central compartment dissection was performed. This is a routine procedure
223820718|NCT03454464|PROCEDURE|central neck dissection first|central neck dissection first ,after FNA confirmed of thyroid carcinoma, the central compartment neck dissection was carried out before thyroidectomy , finally complement of central compartment neck dissection.
223820719|NCT03245255|DRUG|Sonazoid|Whenever a patient undergoes cardiac catheterization, which routinely includes intracardiac pressure monitoring using a pressure catheter, as part of their standard clinical care and agrees to participate in the study, we will acquire research data. With Sonazoid infusion, SHAPE algorithm will be initiated to determine optimum acoustic pressure. Then, at the optimum acoustic pressure, SHAPE specific data will be acquired from the cardiac chambers and aorta synchronously with the pressures recorded by the catheter (as a part of the patient's standard of care). After acquiring the ultrasound imaging data, the remainder of the heart catheterization will be completed by the attending cardiologist according to the patients' standard of care.
223820720|NCT01800695|DRUG|ABT-414|ABT-414 will be administered by intravenous infusion
223820721|NCT01800695|DRUG|Temozolomide|Temozolomide will be administered per label and local prescribing regulations.
223820722|NCT01800695|RADIATION|Whole Brain Radiation|Whole Brain radiation will be administered in 30 fractions.
223820723|NCT02623114|DRUG|methylphenidate|The patients received a fixed dose of medication for 2 weeks. The dose was increased according to the clinician's judgment. The patients came to the hospital at week 2,4,6,8,16,24wks, 9, 12,15,18,21,24 months
223820724|NCT02623114|DRUG|atomoxetine|The patients received a fixed dose of medication for 2 weeks. The dose was increased according to the clinician's judgment. The patients came to the hospital at week 2,4,6,8,16,24wks, 9, 12,15,18,21,24 months
223820725|NCT01196208|DRUG|brentuximab vedotin|Every 21 days by intravenous infusion (1.8 mg/kg)
223820726|NCT05640622|OTHER|Gait Outcomes Assessment List (GOAL)|Gait Outcomes Assessment List (GOAL) is a scale developed to contribute to the determination of treatment goals. This questionnaire includes the priorities, expectations, and goals of children with CP who can walk and reveals their walking characteristics.
223820727|NCT01919359|DIETARY_SUPPLEMENT|Multizyme Cellular Vitality Cyruta Plus SHEP|
223835520|NCT01913964|DRUG|Placebo|(sugar pill)
223835521|NCT02548195|DRUG|oxaliplatin and gemcitabine|oxaliplatin and gemcitabine (GEMOX regimen): day 1: oxaliplatin 85 mg/m2, gemcitabine 1000 mg/m2; day 8: gemcitabine 1000 mg/m2 every three weeks for 6-8 cycles in total.
223835522|NCT02548195|DRUG|capecitabine|capecitabine 1250 mg/m2, twice daily for two weeks plus one week rest for 8 cycles in total.
223820728|NCT00968435|OTHER|bevacizumab, cisplatin, cetuximab, radiation therapy|Patients will receive intensity-modulated radiation therapy (IMRT) in once-daily fractions. A total dose of 70Gy is planned for the primary tumor site over approximately 33 treatment days. Day 1 will refer to the first day of radiation therapy. Concurrent with radiation therapy, patients will receive cisplatin (50 mg/m2 IV on Days 1, 2 and 22, 23) and bevacizumab (15 mg/kg IV on Days 1 and 22). Cetuximab will be administered according to the Bonner regimen (4),with a loading dose approximately 7 days prior to the start of radiation therapy (400 mg/m2 IV once, on approximately Day minus 7), followed by weekly cetuximab infusions (250 mg/m2 IV weekly X 7 infusions) until the completion of radiation therapy.
223820729|NCT04765735|DEVICE|Open-loop testing, Closed-loop testing - External Spinal Cord Stimulator (SCS)|SCS therapy with an external neurostimulator using either open-loop or closed loop algorithm
223820730|NCT02613221|DRUG|Panitumumab + TAS-102|panitumumab + TAS-102 combination therapy
223820731|NCT02458001|BEHAVIORAL|SAFFRON stepped care|"Behavioral: SAFFRON stepped care Stepped care (Improving Access to Psychological Therapies, 2012; Richards et al., 2012) adapted for the gynaecological cancer setting to produce a 3-step model including a clinical assessment and treatment algorithm.~Assessment Algorithm FSFI Interventions~Level 1:~Best available self-help literature on psychosexual difficulties after cancer as judged by the project team and two patient advocates.~Level 2:~A 3-5 session manualised psycho-educational intervention delivered fortnightly by study trained CNSs with taping and supervision for adherence to protocol and manual.~Level 3:~16 weekly session manualised brief psychotherapy adaptation of InterPersonal Therapy, IPT (Interpersonal Psychotherapy for Sexual Adjustment post Gynaecological Cancer, IPT-APGyC)"
223820732|NCT03839732|DIAGNOSTIC_TEST|Score of abdominal aorta calcifications|Radiographs showing VC will be used to assess whether the computer assisted VC scoring (primary objective) and Quantitative Vertebral Morphometry (QVM, limited to lumbar spine, secondary objective n.1) through the Calcify2D software are less variable with respect to the traditional visual scoring of VC and QVM.
223820733|NCT01465607|BEHAVIORAL|Mujer Segura|Brief (35-minute) counseling intervention using techniques from Motivational Interviewing and principles of social cognitive theory (SCT) and theory of reasoned action (TRA).
223820734|NCT01465607|BEHAVIORAL|CENSIDA counseling program|Didactic HIV and STI counseling involving some personal risk assessment and presenting appropriate information on methods of transmission and for avoiding or reducing the risk of infection. Based on a counseling manual disseminated by CENSIDA, Mexico's federal HIV-AIDS prevention agency.
223820735|NCT01970852|OTHER|Standard tablet computer|No special enhancements or links to personal health information.
223820736|NCT01970852|OTHER|Enhanced tablet computer|Tablet computer with personalized access to data from the patient's electronic health record.
223820737|NCT01087996|BIOLOGICAL|Auto-hMSCs|Biological: Autologous human mesenchymal stem cells (Auto-hMSCs) Participants will receive 40 million cells/mL delivered in either a dose of 0.5 mL per injection x 1 injection for a total of 0.2 x 10\^8 (20 million) Auto-hMSCs, a dose of 0.5 mL per injection x 5 injections for a total of 1 x 10\^8 (100 million) Auto-hMSCs, or a dose of 0.5 mL per injection x 10 injections for a total of 2 x 10\^8 (200 million) Auto-hMSCs. The injections will be administered transendocardially during cardiac catheterization using the Biocardia Helical Infusion Catheter.
223820738|NCT01087996|BIOLOGICAL|Allo-hMSCs|Biological: Allogeneic human mesenchymal stem cells (Allo-hMSCs) Participants will receive 40 million cells/mL delivered in either a dose of 0.5 mL per injection x 1 injection for a total of 0.2 x 10\^8 (20 million) Allo-hMSCs, a dose of 0.5 mL per injection x 5 injections for a total of 1 x 10\^8 (100 million) Allo-hMSCs, or a dose of 0.5 mL per injection x 10 injections for a total of 2 x 10\^8 (200 million) Allo-hMSCs. The injections will be administered transendocardially during cardiac catheterization using the Biocardia Helical Infusion Catheter.
223820739|NCT01984801|DRUG|0.3% GSK1940029 gel|200 mg of the gel will be applied to individual patches by using a spatula
223820740|NCT01984801|DRUG|1% GSK1940029 gel|200 mg of the gel will be applied to individual patches by using a spatula
223820741|NCT01984801|DRUG|0.3%/1% vehicle gel only|200 mg of the gel will be applied to individual patches by using a spatula
223820742|NCT01984801|OTHER|Sterile distilled water|200 µL of the solution will be applied to individual patches by using a pipette or syringe
223820743|NCT01984801|OTHER|0.5% SLS in sterile distilled water|200 µL of the solution will be applied to individual patches by using a pipette or syringe
223820744|NCT01984801|OTHER|0.1% SLS in sterile distilled water|200 µL of the solution will be applied to individual patches by using a pipette or syringe
223820745|NCT01984801|OTHER|Patch only|Only patch will be applied
223820746|NCT02411838|OTHER|Calorie restriction|"Calorie restriction will be achieved by alternate day fasting. During the day of fasting the subject will be allowed to eat two salads with light dressing, not to go over approximately 500 calories. The CR group subjects will fast on day 2 (second day of steroids) and then continue to fast on alternate days until day 15. This is the end of the Acute CR phase of the Study, and patients may discontinue the study at this point.~Chronic CR phase At the end of the Acute CR phase, both groups will be offered to enroll in the alternate day fasting regimen for 6 months (Chronic CR phase). During this phase, patients with a BMI \<28 will follow a regimen of fasting for two days per week while patients with BMI\>28 will follow a regimen of fasting for three days per week."
223820747|NCT04307459|OTHER|standard operating procedures|standard operating procedures represented by continuous positive airway pressure (CPAP) therapy or non invasive ventilation, pharmacological treatment as antiviral and antibiotic drugs, bronchodilators, xanthines, enteral nutrition, hydration.
223820748|NCT03626532|BEHAVIORAL|Mindfulness-Based Stress Reduction (MBSR)|"The MBSR program is a mind-body approach developed by Kabat-Zinn to reduce pain and stress through mindfulness meditation. MBSR is a form of mental training characterized by the self-regulation of attention and focal orientation to present moment experiences. Mindfulness practice is thought to effectively promote emotional and cognitive control. Mindfulness includes directing awareness away from thoughts, emotions and sensations towards some specific anchor to the present, such as the breath. Participants will engage in various practices including breath awareness, body scans, mindful listening, etc."
223820749|NCT03626532|BEHAVIORAL|Lifestyle Education (LifeEd)|This group will engage in light stretching exercises at each session. They will also be provided with information drawn from the scientific literature on topics related to healthy aging, including physical activity, sedentary behavior, nutrition, hydration, stress, sleep, and cognitively stimulating activities. Group discussion will be incorporated throughout.
223820750|NCT03758014|DRUG|Chlorogenic acid for Injection|Chlorogenic acid (CHA) is a class 1 innovative small molecular natural drug, developed by Sichuan Jiuzhang Biological Science and Technology Co., Ltd. The mechanism of broad-spectrum antitumor activity is immunoregulation.
223820751|NCT03758014|DRUG|Lomustine|Lomustine (INN), abbreviated as CCNU (original brand name (formerly available) is CeeNU, now marketed as Gleostine), is an alkylating nitrosourea compound used in chemotherapy. It is closely related to semustine and is in the same family as streptozotocin. It is a highly lipid-soluble drug, thus it crosses the blood-brain barrier. This property makes it ideal for treating brain tumors, which is its primary use.
223820752|NCT01008475|DRUG|EMD 525797 250 mg|EMD 525797 will be administered at a target dose of 250 mg as a 1-hour intravenous infusion for every 2 week until radio-graphically documented PD (as assessed by the investigator), unacceptable toxicity or eligibility for curative resection (investigator's assessment), or withdrawal of consent .
223820753|NCT01008475|DRUG|EMD 525797 500 mg|"Safety part: EMD 525797 will be administered at a target dose of 500 mg as a 1-hour intravenous infusion for every 2 weeks until radio-graphically documented PD (as assessed by the investigator), unacceptable toxicity or eligibility for curative resection (investigator's assessment), or withdrawal of consent .~Randomized part: EMD 525797 will be administered at a target dose of 500 mg as a 1-hour intravenous infusion for every 2 weeks until radio-graphically documented PD (as assessed by the investigator), unacceptable toxicity or eligibility for curative resection (investigator's assessment), or withdrawal of consent."
223820754|NCT01008475|DRUG|EMD 525797 750 mg|EMD 525797 will be administered at a target dose of 750 mg as a 1-hour intravenous infusion for every 2 weeks until radio-graphically documented PD (as assessed by the investigator), unacceptable toxicity or eligibility for curative resection (investigator's assessment), or withdrawal of consent .
223820755|NCT01008475|DRUG|EMD 525797 1000 mg|"Safety part: EMD 525797 will be administered at a target dose of 1000 mg as a 1-hour intravenous infusion for every 2 weeks until radio-graphically documented PD (as assessed by the investigator), unacceptable toxicity or eligibility for curative resection (investigator's assessment), or withdrawal of consent .~Randomized part: EMD 525797 will be administered at a target dose of 1000 mg as a 1-hour intravenous infusion for every 2 weeks until radio-graphically documented PD (as assessed by the investigator), unacceptable toxicity or eligibility for curative resection (investigator's assessment), or withdrawal of consent."
223820756|NCT01008475|DRUG|Cetuximab|"Safety part: Cetuximab will be administered at a dose of 400 milligram per square meter (mg/m\^2) on Day 1 Cycle 1 (Week 1) as IV infusion for 2 hours, and then at a dose of 250 mg/m\^2 on Day 8 (Week 2) once weekly until DLT.~Randomized part: Cetuximab will be administered at a dose of 400 milligram per square meter (mg/m\^2) on Day 1 Cycle 1 (Week 1) as IV infusion for 2 hours, and then at a dose of 250 mg/m\^2 on Day 8 (Week 2) once weekly until radio-graphically documented PD (as assessed by the investigator), unacceptable toxicity or eligibility for curative resection (investigator's assessment), or withdrawal of consent."
223820757|NCT01008475|DRUG|Irinotecan|"Safety part: Irinotecan will be administered at a dose of 180 mg/m\^2 as IV infusion for 30-90 minutes for every 2 weeks until radio-graphically documented PD (as assessed by the investigator), unacceptable toxicity or eligibility for curative resection (investigator's assessment), or withdrawal of consent .~Randomized part: Irinotecan will be administered at a dose of 180 mg/m\^2 as IV infusion for 30-90 minutes for every 2 weeks until radio-graphically documented PD (as assessed by the investigator), unacceptable toxicity or eligibility for curative resection (investigator's assessment), or withdrawal of consent."
223820758|NCT04236921|DRUG|DopaSnap®|immediate release CD/LD 25/100mg; Riverside Pharmaceuticals Corporation, USA
223820759|NCT04236921|DRUG|RDL of CD-LD|(immediate release CD/LD 25/100mg; Merck Sharp \& Dohme Corp., USA),
223820760|NCT01704911|PROCEDURE|Transradial Coronary Intervention|
223820761|NCT01704911|PROCEDURE|Transfemoral Coronary Intervention|
223820762|NCT01704911|DEVICE|Coronary Stent System|Any kind of coronary stent system
223820763|NCT01322789|BIOLOGICAL|Intravenous Mesenchymal stem cell infusion|Four consecutive intravenous infusions 1 week apart followed by 4 consecutive infusions 1 month apart
223820764|NCT02500459|DRUG|topotecan|intraparenchymally-administered topotecan will use the Cleveland Multiport Catheter to directly infuse topotecan into the tumor site of patients with suspected recurrent/progressive high grade glioma (HGG). This drug is already FDA approved to be administered intravenously.
223820765|NCT02500459|DEVICE|Cleveland Multiport Catheter|The Cleveland Multiport Catheter will directly infuse topotecan into the tumor site of patients with suspected recurrent/progressive high grade glioma (HGG). Standard treatment is to adminsiter the drug intravenously.
223820766|NCT05030896|OTHER|Invasive treatment and exercise therapy|The subjects of experimental group will perform therapeutic exercise program and they will be receive Percutaneous Electrolysis therapy and the subjects of experimental group will perform the same exercise program and they will be receive only needling puncture
223835523|NCT05167526|DRUG|ASP8731|Oral
223835524|NCT05167526|DRUG|ASP8731 Matching Placebo|Oral
223835525|NCT06261944|DEVICE|Near-infrared (NIR)|Near-infrared assessment of glycated keratin in middle fingernail
223835526|NCT02420275|OTHER|placebo|THIS GROUP WILL RECEIVE NO BRIGHT LIGHT
223820767|NCT01913106|DRUG|HSV-tk +Valacyclovir in Combination with Brachytherapy|"The investigators insert a gene from a herpes simplex virus (HSV), which is a small piece of the basic structure of the virus, into the prostate gland tumor cells. The gene is called the thymidine kinase (tk) gene, which the cell uses to make a protein that can change valacyclovir, The way the tk gene will be transported into the tumor cells is by using a vector or vehicle to carry the tk gene into the cells. In this case the vector is a virus - an adenovirus. Scientists at the Department of Cell and Gene Therapy at The Methodist Hospital removed a portion of the adenovirus' genetic material that allows it to replicate so that it cannot cause infections. In place of the removed genetic material the scientists inserted the tk gene. Now the vector can carry the tk gene into tumor cells. When the vector/gene combination gets into tumor cells, it inserts itself into the cells' command center (nucleus) and tells the tumor cells to begin making thymidine kinase protein."
223820768|NCT01838408|OTHER|Ez2go Complete|EZ2Go Complete
223820769|NCT01838408|OTHER|LoSo Prep|LoSo Prep ™ Magnesium Citrate plus Bisacodyl Kit Study Arm
223820770|NCT02668016|DRUG|Atorvastatin|Atorvastatin 20mg tablets taken orally once daily for one month.
223820771|NCT02668016|OTHER|Placebo|Placebo tablets taken orally once daily for one month
223820772|NCT04472377|DEVICE|Self sampling kit for collecting discharge from vaginal fornix|A device to collect exfoliative cells from vaginal fornix that can self-operated with ease and comfort.
223820773|NCT06255015|DEVICE|Breastfeeding toolkit card|The card is delivered at 24 weeks and is also referred to in the 32 and 36 week antenatal meetings. It will also be referred to in the first 24 hours post-partum and in home visits.
223820774|NCT00019539|DRUG|bevacizumab|
223820775|NCT00019539|DRUG|thalidomide|
223820776|NCT02848482|DEVICE|Photodynamic therapy|Photodynamic therapy (HELBO Photodynaimc Systems GmbH, Wels, Austria)
223820777|NCT02848482|PROCEDURE|Mechanical debridement|Plastic scalers (Have implantrecallset, Kerr, Italy) will be used to curette the contaminated sites.
223820778|NCT02848482|DRUG|Irrigation|0.2% chlorhexidine digluconate solution (Bioworld, Madision, US) will be irrigated at contaminated sites for 1 minute.
223820779|NCT02978053|BEHAVIORAL|Bright light|Bright light for 30 minutes during night shifts (between 2 AM and 3 AM the first night, between 3 AM and 4 AM the second night, between 4 AM and 5 AM the third night).
223820780|NCT02978053|BEHAVIORAL|Red light|Red light for 30 minutes during night shifts (between 2 AM and 3 AM the first night, between 3 AM and 4 AM the second night, between 4 AM and 5 AM the third night).
223820781|NCT02917941|DRUG|Ixazomib|Ixazomib capsules
223820782|NCT02917941|DRUG|Lenalidomide|Lenalidomide capsules
223820783|NCT02917941|DRUG|Dexamethasone|Dexamethasone Tablets
223820784|NCT00248196|DEVICE|Reprieve Endovascular Temperature Therapy System|
223820785|NCT00449098|DEVICE|OculusGen Biodegradable Collagen Matrix Implant|Trabeculectomy with OculusGen Biodegradable Collagen Matrix Implant
223820786|NCT00449098|DRUG|Trabeculectomy with MMC|Trabeculectomy with MMC
223820787|NCT00594971|OTHER|Organisational intervention|A shared care approach in which extra effort is put into improving the communication between the hospital and the primary sector.
223820788|NCT00594971|OTHER|Referral to a specialist palliative care team.|Discharge with referral to a specialist palliative care team. This is a patient-centred shared care model in which the palliative team helps to organise the patient's treatment and care.
223820789|NCT00812188|OTHER|Medium Dose UVA-1|UVA-1 phototherapy treatment (60 J/cm2) three times per week for 12 weeks.
223820790|NCT00812188|OTHER|High Dose UVA-1|High dose (120 J/cm2)UVA-1 phototherapy three times per week for 12 weeks.
223820791|NCT01298921|DRUG|Oxygen|A demand valve delivers oxygen to the user as soon as they try to inhale from an attached mask or mouth tube. As the user starts to inhale, the slight drop in pressure within the mouth piece or mask lifts a valve and starts the oxygen flow. If the user inhales more deeply, more oxygen will flow in response to the increased demand, hence the name demand valve. Unlike a constant flow O2 regulator, a demand valve has no flow meter or flow rate controls, but it is capable of delivering O2 from 0 to 160 liters per minute (LPM). When using a demand valve, O2 dosage is controlled by respiration rate
223820792|NCT01298921|DRUG|Oxygen|100 percent continuous oxygen given via a non-rebreather facemask at 7 to 15 liters per minute for 20 minutes
223820793|NCT04846764|OTHER|Neuropsychological tests|"Scales and tests to evaluate:~* laterality~* anxiety~* depression~* professional level~* education level~* pre-morbid level~* memory disorders~Experimental procedure"
223820794|NCT04636346|BEHAVIORAL|Acceptance and Commitment Therapy|Seven group sessions
223820795|NCT04636346|OTHER|Questionnaires|Outcomes measured include anxiety, depression, fear of recurrence, psychological flexibility, mindfulness; values based living, and quality of life. Participants completed surveys at 4 time points, pre and post, and two follow-up time points.
223820796|NCT05958160|OTHER|Modified Atkins diet|The modified Atkins diet is a less restrictive version of the ketogenic diet
223820797|NCT05958160|DRUG|Topiramate|Topiramate is an anti-seizure medication
223820798|NCT06201221|PROCEDURE|single-port laparoscopy surgery|The two groups underwent different surgical procedures.
223820799|NCT06201221|PROCEDURE|multiport laparoscopy surgery|The two groups underwent different surgical procedures.
223820800|NCT04065217|PROCEDURE|Diode laser 980-nm|Before starting the laser session, cosmetics or makeup were removed and the skin was cleaned. The area was anesthetized by the application of as EMLA lotion (lidocaine 2.5% + prilocaine 2.5%) \[ONLY MEDICAL; CAT No. R331/72394/P001\] 20 minutes before the session. During the procedure, the laser probe was held perpendicular to the lesion and a guide beam was used to direct the application. The patient wore protective eye goggles \[CE; DIR 8001100L4\]. After the session, cool air was applied to the whole region. Each patient received a maximum of six sessions, delivered at two-week intervals. Patients reported itchiness and erythema during the session.
223820801|NCT02681705|DRUG|Temozolomide|Temozolomide is applied to these patients as a chemotherapy drug with a dosage of 75mg/m2, daily. The chemotherapy and radiation are combined as temozolomide is taken 1 hour prior to every fraction of radiotherapy. In 4 weeks after the completion of radiotherapy, temozolomide is given for 8 cycles (dosage: the 1st cycle, 150mg/m2, daily × 5 days, 4 weeks a cycle; the 2-8th cycle, 200mg/m2, daily × 5 days, 4 weeks a cycle and repeated again).
223820802|NCT02681705|RADIATION|Craniospinal Radiation|Craniospinal radiation will begin within 28 days of surgery. Craniospinal Radiation therapy will last for 6 weeks, five days per week. Once a week during radiation, subjects will also be treated with chemotherapy (Temozolomide).
223820803|NCT00615134|DRUG|enfuvirtide [Fuzeon]|90mg sc bid
223820804|NCT00615134|DRUG|Optimized background ARV therapy|As prescribed
223820805|NCT02172703|DEVICE|Non-invasive ICP measurement device|"The non-invasive ICP measurement device used in this study has been developed in the Telematic Science Laboratory at the Kaunas University of Technology, Lithuania.~The non-invasive method is based on two-depth TCD technique for simultaneously measuring flow velocities in the intracranial and extracranial segments of the ophthalmic artery (OA)."
223820806|NCT03879603|BIOLOGICAL|VRC-WEVVLP073-00-VP|VRC-WEVVLP073-00-VP is composed of 1:1:1 ratio of WEE, EEE, and VEE virus-like particles (VLP)
223820807|NCT03879603|OTHER|VRC-GENMIX083-AL-VP|VRC-GENMIX083-AL-VP is an adjuvant
223820808|NCT02237339|DRUG|Allopurinol|Uric acid lowering medication.
223820809|NCT02237339|DRUG|Placebo|
223820810|NCT04553692|DRUG|Aplitabart (IGM-8444)|DR5 Agonist Investigational Drug
223820811|NCT04553692|DRUG|FOLFIRI|Chemotherapy Regimen
223820812|NCT04553692|DRUG|Bevacizumab (and approved biosimilars)|Targeted Therapy
223820813|NCT04553692|DRUG|Birinapant|SMAC-mimetic Investigational Drug
223820814|NCT04553692|DRUG|Venetoclax|Targeted Therapy
223820815|NCT04553692|DRUG|Gemcitabine|Chemotherapy
223820816|NCT04553692|DRUG|Docetaxel|Chemotherapy
223820817|NCT04553692|DRUG|Azacitidine|Chemotherapy
223820818|NCT05067933|DRUG|VXA-CoV2-1.1-S|COVID-19 (SARS-CoV-2) E1-/E3-Deleted Replication Defective Recombinant Adenovirus 5 with dsRNA Adjuvant Oral Tablet Vaccine
223820819|NCT05067933|OTHER|Placebo Tablets|Placebo tablets matching the active vaccine tablets
223820820|NCT03522077|DEVICE|RadAR EasyCLik plus ®-STF hemostatic pad|Chitosan-based, non-woven pad with a unique, proprietary fiber structure that when hydrated with tissue fluids forms a gel-like synthetic clot in conjunction with the RadAR EasyCLik compression device
223820821|NCT03522077|DEVICE|TR BAND® Compression device plus ®-STF hemostatic pad|Chitosan-based, non-woven pad with a unique, proprietary fiber structure that when hydrated with tissue fluids forms a gel-like synthetic clot in conjunction with the TR BAND® compression device
223820822|NCT03522077|DEVICE|SoftSeal®-STF hemostatic pad|Chitosan-based, non-woven pad with a unique, proprietary fiber structure that when hydrated with tissue fluids forms a gel-like synthetic clot
223820823|NCT03522077|DEVICE|VascBand™ Hemostat|The VascBand™ Hemostat is an FDA-approved compression device designed to assist hemostasis of arterial, venous and hemodialysis percutaneous access sites.
223820824|NCT04570774|PROCEDURE|Repetitive transcranial magnetic stimulation|rTMS over cerebral motor cortex and cerebellar hemisphere
223820825|NCT06118996|DEVICE|3D Ultrasound Image Acquisition|A custom device will be used with a clinical ultrasound machine to acquire ultrasound images of the breast.
223820826|NCT03652753|DRUG|N-acetylcysteine|4 mL of a 20% solution of NAC will be injected into the ankle of patients with pilon fractures at the time of their external fixator surgery
223820827|NCT03652753|DRUG|Saline|4 mL of a 20% solution of saline will be injected into the ankle of patients with pilon fractures at the time of their external fixator surgery
223820828|NCT03002064|DRUG|Docetaxel|60mg per square metre on day 1, repeated every 3 weeks till progression or at most 6 cycles.
223820829|NCT03002064|DRUG|Fluorouracil|5-fluorouracil 3750mg per square metre, civ 120 hours every 3 weeks till progression or at most 6 cycles
223820830|NCT03002064|DRUG|Cisplatin|Cisplatin: 60mg per square metre on day 1, repeated every 3 weeks till progression or at most 6 cycles
223820831|NCT04444648|COMBINATION_PRODUCT|No intervention|No intervention
223820832|NCT04463368|PROCEDURE|Isolated hepatic perfusion|The procedure is performed under general anaesthesia. The caval vein is isolated infrahepatically above the renal veins and suprahepatically between the diaphragm and the pericardium. A catheter is placed in the retrohepatic portion of the caval vein for perfusion outflow. The portal vein is clamped and the proper hepatic artery is cannulated via the gastroduodenal artery. The liver perfusion is performed at a rate of 8- 9 ml/kg/min with a target liver temperature of 40 degrees Celsius. The leakage from the system was continuously recorded using Technetium labelled albumin (Vasculosis) injected into the perfusion circuit. Melphalan (1 mg/kg bodyweight divided into two doses, given 30 minutes apart) is added to the perfusion system. The perfusion is then continued for 60 minutes, after which the perfusion was discontinued.
223820833|NCT04463368|DRUG|Ipilimumab|4 courses of ipilimumab 3mg/kg every third week
223820834|NCT04463368|DRUG|Nivolumab|4 courses of nivolumab 1mg/kg every third week
223820835|NCT02844699|DRUG|Mobilan (M-VM3)|Mobilan (M-VM3), innovative experimental drug based on non-replicate adenoviral delivery system consisting genomic vector coding TLR5-receptor and its ligand 502s.
223820836|NCT02844699|DRUG|Placebo|5% infusion solution of dextrose (glucose)
223835527|NCT02420275|DEVICE|"Luminette,Lucimed Belgium"|THIS GROUP WILL RECEIVE BLEU LIGHT ENRICHIDED IN WITHE BRIGHT LIGHT
223835528|NCT02617420|DEVICE|Propeller Health Monitoring Device|
223835529|NCT03666065|DRUG|Aspart insulin|Standard insulin
223835530|NCT04840953|DEVICE|Vçac|VAC THERAPY vs SURGICAL DREINAGE
223835531|NCT03667235|OTHER|Treatment of human pericardium with glutaraldehyde in OZAKI procedure|10 versus 20 minutes treatment of human pericardium with 0.6% glutaraldehyde in OZAKI procedure
223835532|NCT03667235|OTHER|Treatment of human aortic valve tissue with glutaraldehyde|10 versus 20 minutes treatment of human aortic valve tissue with 0.6%glutaraldehyde
223820837|NCT02636257|PROCEDURE|Recessive Spherical Headed Silicone Intubation|Local anesthesia,regular disinfection, spread sterile towels, exposure operative side.2%lidocaine infiltration anesthesia to inferior orbital nerves, lacrimal punctum and lacrimal sac. Nasal cavity was packed with gauze soaked in 2%ephedrine with 1%tetracaine 15 minutes before procedure.A routine silicone tube of spherical intubation was performed. Dilatated lacrimal point to the end, then inserted the probe with line from lacrimal punctum to inferior meatus through nasolacrimal duct.Cut the line and flush the lacrimal duct physiological saline in 5 mL, flowing the line into the inferior meatus, then suctioned out the line with nasal endoscopy and extracted the probe and dilatated the lacrimal duct again. Insert the spherical silicone tube from lacrimal point to the lacrimal sac, reversing to vertical direction to ensure the tube is inserted into the nasolacrimal duct, then catch the above line but cut short the follow one and fix.Unobstructed lacrimal irrigation.
223820838|NCT02636257|PROCEDURE|Dacryocystorhinostomy|Surgery was performed under local anesthesia.Incision was taken over anterior lacrimal crest.Medial palpebral ligament was identified.Orbicularis was separated.Reflection of periosteum and dissection of lacrimal sac from lacrimal fossa was done.Sac was excised to make'H'shaped anterior and posterior flaps. Bony osteum of sufficient size was made with bone punch.Nasal mucosa was cut to make anterior and posterior flaps.Subsequently anterior to anterior and posterior to posterior flaps were sutured.
223820839|NCT00000605|DRUG|hormone replacement therapy|
223820840|NCT00000605|DRUG|estrogens|
223820841|NCT00000605|DRUG|medroxyprogesterone|
223820842|NCT05850468|DRUG|fentanyl infusion after general anesthesia and erector spinea block|intraoperative opioid infusion in active comparative group
223820843|NCT05850468|DRUG|lidocaine 2% and dextometometidine infusion after general anesthesia and erector spinea block|intraoperative non opioid infusion in experimental group
223820844|NCT01191203|DRUG|Copper IUD|Copper IUD (CuT360)
223820845|NCT01191203|DRUG|Depo Medroxyprogesterone acetate|DMPA 150 mg IM q 3 months
223820846|NCT02623010|DRUG|Imbruvica|Bruton's Tyrosine Kinase Inhibitor Ibrutinib as maintenance treatment in elderly patients with primary CNS lymphoma following first line chemotherapy treatment
223820847|NCT01316770|DRUG|Dexamethasone Parotid Irrigation|Irrigation of the parotid gland from one side of the mouth with dexamethasone.
223820848|NCT01316770|DRUG|Placebo Parotid Irrigation|Irrigation of the parotid gland on the opposite side of the mouth with placebo saline.
223820849|NCT02719379|BIOLOGICAL|Pneumonococcal Polysaccharide Vaccine 23-valent (PPSV-23)|
223820850|NCT04138836|DRUG|BBT-877|BBT-877 oral capsule.
223820851|NCT04138836|DRUG|Midazolam|Midazolam oral syrup.
223820852|NCT04138836|DRUG|Itraconazole|Itraconazole oral capsule.
223820853|NCT04138836|DRUG|Esomeprazole|Esomeprazole oral capsule.
223820854|NCT02106585|DRUG|JTT-251 or Placebo|Subjects will receive JTT-251 or Placebo
223820855|NCT03595930|DRUG|Arnuity|ARNUITY consist of Fluticasone Furoate, is an Inhaled corticosteroids (ICS) medicine taken as one inhalation, once daily, for the control and prevention of asthma in adults and children aged 12 years and older.
223820856|NCT01618474|DRUG|DX|Docetaxel 60mg/m2, intravenous infusion, day 1; Capecitabine 1000mg/m2, oral administration, twice a day, day1-14; 3 weeks a cycle for 8 consecutive cycles.
223820857|NCT01618474|DRUG|XELOX|oxaliplatin 130mg/m2, intravenous infusion, day 1; Capecitabine 1000mg/m2, oral administration, twice a day, day 1-14, 3 weeks a cycle for 8 consecutive cycles
223820858|NCT06068231|DEVICE|Temporary Crown|Implants were loaded with temporary restorations 6 to 8 weeks after implantation and had occlusal contact with opposing dentition.
223820859|NCT06068231|DEVICE|Permanent Crown|Implants were loaded with permanent restorations at least 3 months after implantation and had occlusal contact with opposing dentition.
223820860|NCT04958330|PROCEDURE|lateral prostate capsule sparing|When resect the bladder and prostate, the lateral prostate capsule will be preserved.
223820861|NCT02102880|GENETIC|the polymerase chain reaction (PCR)|
223820862|NCT05837208|OTHER|RV4369A cosmetic product|"The product is applied 1 or 2 times during the 2 study visits. The product is recovered by the technician after application of the product by the volunteer.~Application modalities:~Inclusion Assessment: The study product is given to the volunteer who applies it to his face (forehead) according to his usual habits.~After a waiting time and Multispectral camera measurements, the study product is again applied by the volunteer to his face according to his usual habits.~Final assessment: The study product is applied by the Clinical Research Technician on the subject's forearm on 4 delimited areas at specific quantities.~After a waiting period and Multispectral camera measurements on the forearm areas, the study product is given to the volunteer who applies it on his face according to the recommendations of use provided by the Technician."
223820863|NCT03294889|RADIATION|Stereotactic body radition (SBRT)|"Ultra-hypofractionated single-fraction SBRT with urethra-sparing with image-guidance and intra-fractional control motion with the Calypso® system.~* 19 Gy in a single fraction to the whole prostate gland ± proximal seminal vesicles~* 17 Gy in a single fraction to the urethra planning-risk volume (PRV)"
223820864|NCT04227743|DEVICE|cryobiopsy|. The cryobiopsy samples will be obtained by advancement of the cryoprobe into the working channel of the bronchoscope to touch the tip of the endobronchial tumor. The freezing time will be approximately 4 seconds. Then, flexible bronchoscope together with tissue sample attached to the tip of the frozen probe will be extracted outside the bronchial tree. The tissue sample will be released from the probe's tip by plunging it into saline at room temperature. FB will be reintroduced after cryobiopsy to evaluate and control the bleeding.
223820865|NCT04882774|DRUG|Treprostinil Diolamine|Oral treprostinil 0.125 mg TID titrated as clinically indicated and tolerated to a maximum of 6 mg TID
223820866|NCT05145725|BEHAVIORAL|Quality of life questionnaires|Different questionnaires to fill : SRS-22r, SF-36 score, TAPS, KIDSCREEN10
223820867|NCT03269240|BEHAVIORAL|Acquisition of Knowledge and clinical skills|LDHF is a novel training approach that is being compared to the traditional training approach
223820868|NCT03269240|OTHER|Onsite training|Participants are training at their health facilities
223820869|NCT03269240|OTHER|Off-site training|Participants from different health facilities are gathered together in a central location for training, away from their workplaces
223820870|NCT03684122|BIOLOGICAL|Injection of Umbilical cord derived MSCs|Allogenic umbilical cord derived MSCs which are to be injected intrathecally and intravenously as a treatment option for consenting PD patients
223820871|NCT01622244|OTHER|Co-ordinated Access to Care from Hospital Emergency Departments|brief, intensive case management for frequent users of hospital Emergency Departments who have mental health and/or addictions problems
223820872|NCT01622244|OTHER|Coordinated Access to Care from Hospital Emergency Departments|Participants will receive brief, intensive case management to connect them to health and social services and supports in the community
223820873|NCT01622244|BEHAVIORAL|Counseling and Resource Education|Participants will receive usual care as well as an educational session and resource guide outlining community-based services
223820874|NCT04999644|DRUG|Full Nicotine Cigarettes|A full nicotine tobacco cigarette that will be smoked by participants
223820875|NCT04999644|DRUG|Reduced Nicotine Cigarettes|A reduced nicotine tobacco cigarette that will be smoked by participants
223820876|NCT04999644|BEHAVIORAL|Average Nicotine Expectancy|"Participant instructed the cigarette is the same level of nicotine as your usual brand."
223820877|NCT04999644|BEHAVIORAL|Very Low Nicotine Expectancy|"Participant instructed the cigarette is a very low level of nicotine compared to your usual brand."
223820878|NCT02260401|OTHER|Individualized report|Each patient will receive an individualized report that contains their own outcome data for the first years of the LESS trial (including pain and function following treatment with epidural injections)
223820879|NCT05272670|BEHAVIORAL|A digital foot self-management program|A 4-week digital foot self-management program based on Bandura's Self-Efficacy model. The proposed functions include checking conditions of foot, cleaning, cutting or removing corns and calluses, trimming, clipping nails, foot exercise, dietary related to foot care, foot care logs, etc. Which was developed for older adults with diabetic foot self-management by the study team. Week 1 one-hour face-to-face training session after participant recruitment and allocation. The outline session is 30 min to introduce key topics and function in the app platform, 15 min to install the app and to demonstrate the use of the app, 15min to discuss and practice. Week 2 to week 4 following phone call once per week at the end of week and LINE messages 3 times per week.by research nurse, who will encourage and monitor participant's compliance with the program at home by using the digital platform. Participants are informed that technical phone support is available during the trial.
223820880|NCT06243185|DRUG|Dalpiciclib plus letrozole|Dalpiciclib 150mg qd, d1-21, repeated once every 4 weeks. Letrozole 2.5mg qd, repeated once every 4 weeks.
223820881|NCT01674348|DRUG|P2202|Novel oral drug with potent and selective 11 beta-hydroxysteroid dehydrogenase type 1 (11b-HSD1) inhibitory properties, being developed for the management of type 2 diabetes mellitus
223820882|NCT01674348|DRUG|Placebo|Placebo
223820883|NCT05222464|OTHER|Standard of care treatments|Interventions will consist of 4 classes of standard of care treatments, namely, lifestyle modifications, complementary and alternative medicine (CAM) therapies, prescription medications, or adjustment of anti-cancer therapy.
223820884|NCT00771225|PROCEDURE|fascial repair|surgery to treat genital prolapse with fascia repair
223820885|NCT00771225|PROCEDURE|mesh repair|surgery to genital prolapse with mesh
223820886|NCT00114608|DEVICE|The Focus™ Neuromuscular Stimulation System|"Electrical foot stimulation was produced by surface electrodes placed on the sole of the foot over the plantar muscle group. Electrical stimulation was delivered by The Focus™ Neuromuscular Stimulation System, Empi, Inc. (St. Paul, MN.) The crucial stimulus parameters were: biphasic symmetrical square wave at 50 pulses per second, phase duration of 300 microseconds, a starting ramp up time of 2 seconds and a finishing ramp down time of 2 seconds per stimulation cycle, and a stimulation cycle of 12 seconds on and 48 seconds off per minute. Stimulation was increased to an intensity just sufficient to create a slight visible muscle twitch. This level of intensity caused no evident discomfort in any of the subjects in our first study. Subjects were continually monitored throughout this study for any indication of discomfort.The Focus™ Neuromuscular Stimulation System created electrical stimulation of the plantar foot muscles."
223820887|NCT03547492|BEHAVIORAL|Teaching Talking|Written packet including 8 lessons: What's My Corrected Age, Watch Me Learn (language milestones in the 1st year of life), Reading Aloud, Sing-a-long: Sleepy Songs, Sing-a-long: Alert Songs, Copying First Sounds, Playing Games, Talk to Your Baby.
223820888|NCT03547492|BEHAVIORAL|LENA recordings-language|LENA a special recording device. It records for 16 hours inside a specially designed infant vest. The recording is analyzed by a computer that generates an output of total number of adult words, infant vocalizations and conversational turns during the recording period. 4 LENA recordings are obtained: baseline, after reviewing Teaching Talking and linguistic feedback of first recording, 4 and 12 months of age. Participants are mailed feedback of their 2nd, 4 and 12 month recordings.
223820889|NCT03547492|BEHAVIORAL|LENA recordings-motor|LENA a special recording device. It records for 16 hours inside a specially designed infant vest. The recording is analyzed by a computer that generates an output of total number of adult words, infant vocalizations and conversational turns during the recording period. 4 LENA recordings are obtained: baseline, 2nd, 4 and 12 months of age. Participants are mailed feedback on recordings after completing study.
223820890|NCT03547492|BEHAVIORAL|Mastering Movement|A written curriculum containing 5 lessons adopted from Beautiful Beginnings: What's My Corrected Age, Watch Me Move! (review of motor milestones in 1st year), Gentle Stretching and Exercise, Tummy Time, Help Me Learn to...
223820891|NCT03547492|BEHAVIORAL|Language text messages|12 weekly text messages. Each is 1-2 sentences to review concepts of Teaching Talking
223820892|NCT03547492|BEHAVIORAL|Motor text messages|4 text messages sent every 4 weeks. Each is 1-2 sentences reviewing concepts of Mastering Movement
223820893|NCT01691625|OTHER|concurrent chemoradiotherapy plus DC-CIK immunotherapy|"Radiotherapy:Patients will be conducted CT simulation, and three-dimensional conformal radiation therapy (3DCRT) or Intensity-modulated radiation therapy(IMRT)was performed. 1.8-2.0 Gy/fraction, 5 fractions a week, with a total dose of 60-66Gy will be delivered for all patients by 6-MV-X-ray of linear accelerator.~Chemotherapy: Patients will be concurrently administered with irradiation every 4 weeks with PT regimen (cis-platinum of 20 mg/m2/d, d2-5; PTX(paclitaxel)of 80mg/m2/d, d1,d8) for 4 cycles.The chemotherapy will be concurrently given with irradiation.~DC-CIK Immunotherapy:Mononuclear cells were collected aseptically with blood cell separator composition apheresis 3 days before concurrent chemoradiation, and cultured DC-CIK cells for 10 days. Cells were infused back to the patients in 3 times between the Chemoradiation intermittent period."
223820894|NCT01691625|OTHER|Concurrent chemoradiation only|"Radiotherapy:Patients will be conducted CT simulation, and three-dimensional conformal radiation therapy (3DCRT) or Intensity-modulated radiation therapy(IMRT)was performed. 1.8-2.0 Gy/fraction, 5 fractions a week, with a total dose of 60-66Gy will be delivered for all patients by 6-MV-X-ray of linear accelerator.~Chemotherapy: Patients will be concurrently administered with irradiation every 4 weeks with PT regimen (cis-platinum of 20 mg/m2/d, d2-5; PTX(paclitaxel)of 80mg/m2/d, d1,d8) for 4 cycles.The chemotherapy will be concurrently given with irradiation."
223820895|NCT01583101|OTHER|Receiving Highlighted Prompts|Prompts received by physicians were highlighted.
223820896|NCT01583101|OTHER|Receiving Non-highlighted Prompts|Prompts received by physicians were not highlighted.
223820897|NCT03468959|BEHAVIORAL|Maternal Supplemental PUFA Intake|Maternal Supplemental PUFA Intake included sources from the questionnaires and plasma
223820898|NCT04444635|PROCEDURE|Serratus Anterior Plan Block+ Fentanyl infusion|"After induction of anesthesia, the patients will be put on the lateral position with the diseased side up. A linear ultrasound transducer will be placed in a sagittal plane over the mid-clavicular region of the thoracic cage.~Then counting down ribs till the fifth rib will be identified in the mid-axillary line. The following muscles will be identified overlying the fifth rib: the latissimus dorsi (superficial and posterior),teres major (superior) and serratus muscles (deep and inferior). Under complete sterile conditions, the needle (25 G needle) will be introduced in-plane with respect to the ultrasound probe targeting the plane superficial to the serratus anterior muscle. Then, 2 mg/kg of 0.25% bupivacaine will be injected with continuous ultrasound guidance. In addition to continuous fentanyl infusion"
223820899|NCT04444635|DRUG|Fentanyl|Continuous fentanyl infusion throughout the surgical procedure.
223820900|NCT02633930|DRUG|Berberine|: given for 14 days at a dose of berberine 100 mg 3 tablets TID, lansoprazole 30 mg BID, amoxicillin 500 mg 2 capsules BID, and colloidal bismuth tartrate capsule55 mg 4 capsules BID
223820901|NCT02633930|DRUG|clarithromycin|Clarithromycin-containing quadruple therapy group 500 mg 1 tablet BID plus amoxicillin 500 mg 2 capsules BID, lansoprazole 30mg 1tablet BID, and colloidal bismuth tartrate capsule55 mg 4 capsules BID.
223820902|NCT02633930|DRUG|Bismuth|Bismuth:given for 14 days at a dose of colloidal bismuth tartrate capsule 55 mg 4 capsules BID, lansoprazole30 mg BID, amoxicillin 500 mg 2 capsules BID, and clarithromycin 500 mg 1 tablet BID or given for 14 days at a dose of colloidal bismuth tartrate capsule 55 mg 4 capsules BID, lansoprazole30 mg BID, amoxicillin 500 mg 2 capsules BID, and berberine 100 mg 3 tablet TID
223820903|NCT02633930|DRUG|Lansoprazole|Lansoprazole 30mg 1tablet BID plus amoxicillin 500 mg 2 capsules BID, clarithromycin 500 mg 1 tablet BID, and colloidal bismuth tartrate capsule 55 mg 4 capsules BID or berberine 100 mg 3 tablets TID given to berberine-containing quadruple therapy group or clarithromycin-containing quadruple therapy group
223820904|NCT02633930|DRUG|amoxicillin|Amoxicillin 500 mg 2 capsules BID plus lansoprazole 30mg 1tablet BID, clarithromycin 500 mg 1 tablet BID, and colloidal bismuth tartrate capsule 55 mg 4 capsules BID or berberine 100 mg 3 tablets TID as a dose given for clarithromycin-containing quadruple therapy or berberine-containing quadruple therapy.
223820905|NCT01021592|DRUG|bortezomib|Injection into a vein 1.3 mg/m2 twice a week for 21 days
223820906|NCT04450186|OTHER|EEG/fMRI neurofeedback|EEG/fMRI neurofeedback
223820907|NCT06197906|DEVICE|Device implant|subcutaneous device implanting
223820908|NCT01422525|PROCEDURE|spectral domain optical coherence tomography|RNFL thickness measurement using spectral domain optical coherence tomography at baseline, 1, 3 and 6 months postoperatively.
223820909|NCT02345525|BEHAVIORAL|mCIMT|"This intervention is based on 3 main aspects:~1. intensive training of functional tasks with the affected arm (massed practice)~2. constraint of the un-affected hand through a mitt~3. shaping techniques designed to transfer gains to the real world activities~The 2 hours massed practice will be performed in a outpatient clinic with a supervision of PT."
223820910|NCT02345525|BEHAVIORAL|hCIMT|"This intervention is based on 3 main aspects:~1. intensive training of functional tasks with the affected arm (massed practice)~2. constraint of the un-affected hand through a mitt~3. shaping techniques designed to transfer gains to the real world activities~In this group, a comprehensive set of the material necessary to perform the training at home and a booklet containing an explanation of the exercises that can be done will be provided to subjects.~In addition, 2 hospital visits will be scheduled to instruct subjects and caregivers on the training and to update activities (1 visit at the beginning + 1 visit after 1 week)."
223820911|NCT04511416|DRUG|Metformin XR, 500-2000mg nocte|Metformin XR, 500-2000mg nocte
223820912|NCT04151784|OTHER|Pulmonary Group|Data collection will be obtained on the day an individual has an appointment at the pulmonary clinic. After patients meet with their pulmonary physicians, the physicians will inform them about the study and explain that participation is voluntary. If a patient agrees, the researcher will provide copies of the questionnaires and again clarify that participation is voluntary. The workflow of the clinic will not be interrupted while the researcher conducts the study, and he will only ask participants to fill out the questionnaires if they have enough time to participate.
223820913|NCT04151784|OTHER|Healthy Control|The second group will be recruited as a control group consisting of healthy adult participants through purposive convenience sampling at other collaborating UAB sites. The principal investigator will collect self-report responses through a questionnaire packet given to anyone willing to participate in the study
223820914|NCT04235790|DEVICE|Eye Tracking Device|Eye tracking glasses
223820915|NCT05282290|DRUG|Antihypertensive drugs (no restriction on the type of drugs)|"The division of care unit doctors and nurses is clear, the former is responsible for giving medical advice, the latter is responsible for carrying it out.~The experimental group and the control group were given intravenous antihypertensive drugs (no restriction on the type of drugs), and their blood pressure reached the standard within 2 hours after vascular opening."
223820916|NCT02165332|DRUG|Part 1: SAD RO7033877|Single dose
223820917|NCT02165332|DRUG|Part 1: SAD placebo|Single dose
223820918|NCT02165332|DRUG|Part 2: Treatment A, RO7033877|Single dose RO7033877 and moxifloxacin placebo
223820919|NCT02165332|DRUG|Part 2: Treatment B, RO7033877|Single dose RO7033877 and moxifloxacin placebo
223820920|NCT02165332|DRUG|Part 2: Treatment C, moxifloxacin|Single dose moxifloxacin and RO7033877 placebo
223820921|NCT02165332|DRUG|Part 2: Treatment D, RO7033877 and moxifloxacin placebo|Single dose moxifloxacin placebo and RO7033877 placebo
223820922|NCT05420922|DRUG|Lenvatinib Oral Product|Lenvatinib or Sorafenib
223820923|NCT05420922|DRUG|PD-1 inhibitor|Programmed cell death protein-1 (PD-1) or Programmed cell death ligand 1 (PDL-1
223820924|NCT05420922|PROCEDURE|Local treatment|Local treatment include: TACE, HAIC, RF Ablation, Microwave Ablation, Radiotherapy, etc.
223820925|NCT03080116|DRUG|ARN-509|240mg/day (4x60mg tablets, Oral administration: OS)
223820926|NCT03080116|DRUG|Degarelix|1st injection: 120mg Subcutaneous administration (SC) x2, 2nd-3rd SC injection 80mg monthly
223820927|NCT03080116|OTHER|Placebo|4 tablets, per OS
223820928|NCT05882201|PROCEDURE|Fascia Iliaca compartment block group|"Group FICB Fascia: with the patient supine, the skin was prepped and draped with alcohol solution 70%,~. A 22-G needle will be visualized entering the fascia Lata and the FI. bupivacaine, up to 2.5mg/kg of lean body weight with a volume of injectate of .5 ml/kg up to 40 ml will be injected after aspiration beneath the fascia Lata."
223820929|NCT05882201|PROCEDURE|Femoral nerve block group|✓ Group FNB; With the patient supine, the skin will be prepped and draped with alcohol solution 70% The nerve in the crosssection is a triangular white structure lateral to the femoral artery. Ultrasoundallows direct visualization of the needle and nerve as well as real-time monitoring of the injection of local anesthetic. An in-plane approach will be used to direct needle placement to the femoral nerve and inject after aspiration with bupivacaine, up to 2.5mg/kg of lean body weight with a volume of injectate of .5 ml/kg up to 40ml.
223820930|NCT05882201|PROCEDURE|General care|using ordinary technique
223820931|NCT04595721|BEHAVIORAL|Hidden object|Participant will be instructed to look at the hidden object image on the overhead light to look for a number of objects and observe the image.
223820932|NCT04595721|BEHAVIORAL|Stress ball|Participants will be handed a single-use, squeezable stress ball and instructed to squeeze the stress ball.
223820933|NCT02310022|DRUG|Drug Omega 3|4 g (4 capsules) once a day, administered with food
223820934|NCT02310022|DRUG|Drug Omega-3 Comparator|4 g (4 capsules) once a day, administered with food
223820935|NCT01437163|DEVICE|TopHat 655 rejuvenation system|TopHat 655 system is to be applied every other day for 16 weeks for a pre-programmed time period
223820936|NCT01437163|DEVICE|Laser and/or Light Hair Rejuvenation System|A red incandescent light source replaces all lasers and light emitting diodes.
223820937|NCT01665339|OTHER|preload diet|All participants were prescribed a calorie-restricted diet (-200 to -500 kcal/d). Calorie requirements of each subject were estimated based on resting energy expenditure (REE) by using Harris- Benedict equation and also considering the physical activity levels. The diets were constructed to provide similar proportions of carbohydrates (55% energy), protein (15% energy) and total fat (30% energy).
223820938|NCT01665339|OTHER|control diet|All participants were prescribed a calorie-restricted diet (-200 to -500 kcal/d). Calorie requirements of each subject were estimated based on resting energy expenditure (REE) by using Harris- Benedict equation and also considering the physical activity levels. The diets were constructed to provide similar proportions of carbohydrates (55% energy), protein (15% energy) and total fat (30% energy).
223820939|NCT04076410|DEVICE|Z1 lens|CE marked device
223820940|NCT04076410|DEVICE|Experimental Lens 1|CE marked device
223820941|NCT04076410|DEVICE|Experimental Lens 2|CE marked device
223820942|NCT04076410|DEVICE|Experimental Lens 3|CE marked device
223820943|NCT04076410|DEVICE|Experimental Lens 4|CE marked device
223820944|NCT01217424|OTHER|questionnaire administration|
223820945|NCT01217424|PROCEDURE|aromatherapy and essential oils|
223820946|NCT01217424|PROCEDURE|management of therapy complications|
223820947|NCT01217424|PROCEDURE|massage therapy|
223820948|NCT01217424|PROCEDURE|psychosocial assessment and care|
223820949|NCT01217424|PROCEDURE|reflexology procedure|
223820950|NCT04099043|DEVICE|Cascade Continuous Glucose Monitoring System|Continuous Glucose Monitoring for 15 days
223820951|NCT02981901|OTHER|Patient with ovarian epithelial cancer|
223820952|NCT03009682|DRUG|Olaparib|"Dosage and Schedule : Olaparib 300 mg BID per os every 12 hours administered daily. One cycle is consisted of 21 days.~Two x 150 mg olaparib tablets should be taken at the same times each morning and evening of each day, approximately 12 hours apart with approximately 240 mL of water. The olaparib tablets should be swallowed whole and not chewed, crushed, dissolved or divided. Olaparib can be taken with a light meal/snack."
223820953|NCT04106232|OTHER|No change in procedure except for specimen collection throughout procedure|Stool specimens will be taken before and during the HyGIeaCare procedure. Microbiome comparisons will be made across all specimens
223820954|NCT01793025|BIOLOGICAL|ATAC Therapy|Unselected peripheral blood mononuclear cells given 24-48 hours after induction or consolidation chemotherapy
223820955|NCT02228954|PROCEDURE|Molecular imaging|
223820956|NCT02946918|DRUG|Levothyroxine|Patients post-thyroidectomy will receive either levothyroxine in tablet form or in gelcaps. Initial dose 1.5-1.8 mcg per kg, orally and daily
223820957|NCT04606537|DRUG|Itraconazole|200 mg itraconazole, given orally as 20 mL × 10-mg/mL solution BID on Day 15, followed by QD dosing on Days 16 through 23, inclusive.
223820958|NCT04606537|DRUG|Rifampin|600 mg rifampin, given orally as 2 × 300-mg capsules QD on Days 15 through 25, inclusive.
223820959|NCT04606537|DRUG|KBP-5074|0.5 mg KBP-5074, given orally as 1 × 0.5-mg tablet on Days 1 and 19 or Days 1 and 21
223820960|NCT05884463|DRUG|18F-FAPI|Intravenous injection of one dosage of 18F-FAPI.
223820961|NCT05884463|DRUG|18F-FDG|Intravenous injection of one dosage of 18F-FDG.
223820962|NCT02473458|DRUG|Licorice whole extract|"Patients randomly received one of below capsules labeled with codes during the first 24 hours after stroke attack:~1. Starch-filled capsules (as placebo)~2. 450 mg whole licorice extract capsules~3. 900 mg whole licorice extract capsules"
223820963|NCT02473458|DRUG|Placebo|
223820964|NCT02843256|DEVICE|Isomark Canary|The Isomark Canary will analyze the exhaled air and generate a breath delta value.
223820965|NCT00069784|DRUG|insulin glargine (HOE901)|Cartridges for use in a pen device, each containing 3 mL of insulin glargine 100 U/mL solution for injection
223820966|NCT00069784|DRUG|omega-3 polyunsaturated fatty acids (PUFA)|Gelatin capsules (containing icosapent ethyl esters 465 mg and doconexent ethyl esters 375 mg) for oral administration
223820967|NCT00069784|DRUG|placebo|Matching placebo gelatin capsules (containing olive oil) for oral administration
223820968|NCT00069784|DEVICE|reusable pen device for insulin injection|
223820969|NCT00106132|DRUG|Triamcinolone Acetonide|
223820970|NCT03339284|DRUG|Dexamethasone sodium phosphate|Dexamethasone injection
223820971|NCT03339284|DRUG|Ropivacaine Hydrocloride|Ropivacaine injection
223820972|NCT03339284|DRUG|Sodium Chloride 9mg/mL|Sodium Chloride injection
223820973|NCT03757143|DRUG|Povidone-Iodine-Alcohol|Povidone-Iodine-Alcohol will be used to disinfect the skin
223820974|NCT03757143|DRUG|Chlorhexidine-Alcohol|Chlorhexidine-Alcohol will be used to disinfect the skin
223820975|NCT03757143|DEVICE|Insyte Autoguard BC Winged|Pose of Insyte Autoguard BC Winged
223820976|NCT03757143|DEVICE|Nexiva single port catheter, MaxZero needless connector, PureHub Deinfecting Caps and Posiflush prefilled saline syringes|Pose of Nexiva single port catheter
223820977|NCT02654990|DRUG|Panobinostat Capsules|20 mg, 10 mg or 15 mg (for dose reductions only)
223820978|NCT02654990|DRUG|Bortezomib Injection|1.3 mg/square meter subcutaneous administration. Cycle 1-4: 2 weeks on/1 week off, BIW for participants ≤ 75 years at time of screening; once a week for participants \> 75 years. Cycle 5+: once a week for all participants.
223820979|NCT02654990|DRUG|Dexamethasone tablets|Pre and 24 hours after bortezomib administration. Participants ≤ 75 years at time of screening: 20 mg/dose participants; \> 75 years: 10 mg/dose.
223820980|NCT01147484|DRUG|Foretinib|foretinib, at a continuous oral daily dose of 60 mg
223820981|NCT05722470|BEHAVIORAL|eating disorders|Assessment of eating disorders among adolescents
223820982|NCT03465020|OTHER|Observation|Safety and efficacy outcomes of patients on different treatments
223820983|NCT03267823|DIAGNOSTIC_TEST|International Normal Ratio (INR)|Blood test for INR using laboratory and point of care methods
223820984|NCT04036461|DRUG|CC-99712|CC-99712
223820985|NCT04036461|DRUG|BMS-986405|BMS-986405
223820986|NCT04255342|DEVICE|Implant Placement and Temporary Crown using AstraTech Implant System EV, Final Crown Delivery|At least 3 months after tooth removal and bone grafting, a dental implant will be placed using Azento, a commercially-available product that uses computer technology to plan the dental implant placement using the AstraTech Implant System EV and an immediate implant temporary crown using Azento. After 3 months with the temporary crown, a definitive all-ceramic crown, made using a digital workflow will be placed.
223820987|NCT01672853|BIOLOGICAL|Simtuzumab|Subcutaneous injections weekly for a total of 96 injections
223820988|NCT01672853|BIOLOGICAL|Placebo|Subcutaneous injections weekly for a total of 96 injections
223820989|NCT05878275|BEHAVIORAL|Parent Informational Session|Parents will receive a brochure on the importance of tummy time and limiting baby gear and watch a video on the importance of tummy time and limiting baby gear and receive support for implementing tummy time if requested.
223820990|NCT06899386|OTHER|Group CI and CII - BeautiBond Xtreme (total-etch technique) + Beautifil LS|the enamel was etched for 30 seconds and the dentin for 15 seconds using 35% phosphoric acid gel (Ultradent). The acid was then rinsed off, and excess moisture was removed with an air spray. To protect the dentin during air blasting, an absorbent paper was held over it using clinical tweezers, ensuring a whitish appearance for the enamel and slightly moist dentin. Excess water on the cotton roll was dried as well. The BeautiBond Xtreme adhesive system was applied without any waiting time, followed by a gentle air spray for 3 seconds and then a strong air blast to ensure solvent evaporation. Finally, the adhesive was light-cured for 5 seconds using a LED photopolymerizer (Gran Valo LED Curing Light, Ultradent).
223820991|NCT06899386|OTHER|Group TI and TII - BeautiBond Xtreme (self-etch technique) + Beautifil LS:|no acid etching was performed on either the enamel or dentin. The BeautiBond Xtreme adhesive system was applied immediately, without any waiting time, followed by a gentle air spray for 3 seconds and then a strong air blast to ensure solvent evaporation. The adhesive was then light-cured for 5 seconds using a LED photopolymerizer (Gran Valo LED Curing Light, Ultradent).
223820992|NCT06899386|OTHER|Group TIII and TIV - BeautiBond Xtreme (selective acid-etch technique) + Beautifil LS|the enamel was etched for 15 seconds using 35% phosphoric acid gel (Ultradent). The acid was then rinsed off, and excess moisture was removed with an air spray, leaving the enamel with a whitish appearance. Excess water on the cotton roll was also dried. Next, the BeautiBond Xtreme adhesive system was applied immediately, without any waiting time, followed by a gentle air spray for 3 seconds and then a strong air blast to ensure solvent evaporation. The adhesive was then light-cured for 5 seconds using a LED photopolymerizer (Gran Valo LED Curing Light, Ultradent).
223820993|NCT06900790|PROCEDURE|ERCP|There are two intervention methods for pediatric pancreatic duct stones. One is to remove the pancreatic duct stones through Endoscopic Retrograde Cholangiopancreatography(ERCP), while simultaneously dilating the pancreatic duct and placing a stent to assist in the normal drainage of pancreatic juice. The other is local resection of the pancreatic head combined with longitudinal pancreaticojejunostomy (Frey surgery).
223820994|NCT06899906|OTHER|Determine patient demographic and clinical characteristics at baseline|Description of demographic data (sex, age), comorbidities (Charlson scores), septic history, and medical management (antibiotic therapy)
223820995|NCT06899958|DEVICE|Fractional Laser|Three fractional laser treatments to the abdomen and thighs at 4 week intervals.
223820996|NCT06899698|OTHER|Inspiratory muscle training|Only participants in the Study group 'Thirty chronic hemiplegic patients with mild cognitive impairment, and suffering from orthostatic hypotension' will receive inspiratory muscle training using Respiratory muscle strength: Threshold Inspiratory muscle trainer (TIMT): Philips Respironics model (Tayland- B00J417PHM), for 30 minutes per day for at least 3 days a week for 8 weeks.
223820997|NCT06899698|OTHER|Traditional Training|Both the study and control group 'Sixty chronic hemiplegic patients with mild cognitive impairment, and suffering from orthostatic hypotension' will receive a. bobath technique 'passive mobilization associated with tactile and proprioceptive stimuli aims to inhibits spasticity'; b. Proprioceptive neuromuscular facilitation 'based on spiral and diagonal patterns of movements in line to achieve normal movements' c. Rood technique 'focuses on the developmental sequence of recovery (from basic to complex) and the use of sensory stimulation to facilitate movement and postural responses' d. Johnstone method 'includes positioning and splinting to inhibit abnormal patterns and controlling tone to restore central control' e. Functional electrical stimulation; f. Balance training, j. Pelvic, and gait training, h. Activities of daily living, and finally, g. Sensrimotor training 'Active and active-assistive range-of motion exercises, Graded activities Start with easy activities'.
223820998|NCT06907550|DIAGNOSTIC_TEST|The Mitomic Endometriosis Test (MET) blood test for early detection of endometriosis|Patients will complete a questionnaire about their endometriosis symptoms and a sample of blood will be taken prior to their laparoscopy and sent to the laboratory for testing.
223820999|NCT06922903|DRUG|INR101|INR101
223821000|NCT05569824|DIAGNOSTIC_TEST|Lateral-flow Device|An additional amount of 0.1-0.2 ml (2-4 drops) of bronco-alveolar lavage (BAL) fluid will be collected during the bronchoscopy which is carried out as part of the standard of care. The LFD test will be carried out on the BAL fluid collected.
223821001|NCT00395915|DRUG|aripiprazole|
223821002|NCT00268619|DRUG|Ramipril|
223821003|NCT05544058|OTHER|Retrospective study|Retrospective study
223821004|NCT00933842|DRUG|LACTIC ACID(ND)|Treatment duration: 5 weeks
223821005|NCT04722861|OTHER|GVFQ-40|GVFQ-40 is a 40-item questionnaire developed to evaluate the visual ability of glaucoma patients in detail. It consists of 40 items and measures the impact of glaucoma on restriction of participation in daily activities in five domains of functioning. Each item is rated on a five-level scale from ''no difficulty'' to ''can't do because of vision''. Another possible response is that the activity is not performed for nonvisual reasons.
223821006|NCT01484795|DEVICE|BILEVEL (Respironics)|Bilevel was delivered by a Bipap® ventilator (Respironics Inc, Murrysville, PA), applied via facial mask, with inspiratory positive pressure (IPAP) of 20 cmH2O and expiratory positive airway pressure (EPAP) of 10 cmH2O.
223821007|NCT01484795|DEVICE|Continuos positive airway pressure (Respironics)|CPAP was delivered by a ventilator (Respironics Inc, Murrysville, PA), applied via a facial mask, with expiratory positive airway pressure of 10 cmH2O.
223821008|NCT04142814|PROCEDURE|T-PEP|"First of all, a corrugated tube for ventilation is assembled: in one end with an antibacterial filter for ventilation and then an inflation system (like Auxiliary Manual Breathing Unit - AMBU); in the other end with a connector and then a one-way PEP Valve. The latter holds a junction for the tracheal cannula and a pressure gauge. A Venturi Resistor is placed in the expiratory part of the PEP Valve.~After connection to the tracheal cannula, the disostructive maneuver is manually executed by a respiratory physiotherapist."
223821009|NCT04142814|PROCEDURE|IPV|IPV is delivered via a commercial device that can be set by frequency, duration of inspiratory time, inspiratory-expiratory ratio and positive end-expiratory pressure, based on patients characteristics and clinical needs. It is connected to the patient's tracheal cannula via a Mount catheter. The air supplied is sterile, due to the presence of an antibacterial filter present in the device.
223821010|NCT05056064|OTHER|Oral exercise|exercise remain tongue
223821011|NCT01178437|DEVICE|T-VNS® Stimulator cM02 (Transcutaneous Stimulation of the Vagus Nerve)|daily, transcutaneous, electrical stimulation of the vagus nerve by the t-VNS device for a period of 9 months
223821012|NCT04472780|DEVICE|Hyperbaric oxygen Therapy HBOT|HBOT therapy protocol: in an eight-seat hyperbaric chamber 40 sessions of HBOT duration: 1 hour rhythm: 5 sessions / week pressure: 1.7 ATA (7 meters) O2 concentration: 100%
223821013|NCT02818660|DRUG|Synachten|To stimulate the adrenals to increase the cortisol Production as much as possible
223821014|NCT01265030|DRUG|Sirolimus|"* Loading dose of 12 milligrams/meter2; Per Os (PO), by mouth day 1 (Max dose 12 milligrams)~* Starting 24 hours after the initial loading dose, patients will receive a dose of 4 milligrams/meter2 daily; Per Os (PO), by mouth days 2 through 28 (Max dose 4 milligram/day)"
223821015|NCT05176704|DEVICE|Eye-Tracking|Eye-tracking technology and algorithms used to successfully capture and track eye movements using an electronic tablet and the embedded camera of the device.
223821016|NCT05611697|PROCEDURE|Single anastomosis sleeve ileal bypass|The abdominal cavity is entered directly (visual trocar) with or without the use of Verres needle. A 6-port set up and a liver retractor is utilized. A sleeve gastrectomy is performed as described below, but division of the stomach starts 6 cm proximal to the pylorus. The small bowel is measured 300cm from the ileocecal valve, with the small bowel stretched and markers placed on the graspers, and connected to the antrum of the stomach with a 45mm stapler. The anastomosis is positioned slightly ventral on the antrum. A 12 mm port positioned left to the midline is used for introduction of the stapler, which is directed distally from the patient's left to right side. 3.0 cm of 45 mm stapler is used the anastomosis; completed with a 2-0 PDS running suture. The biliopancreatic limb is anchored to the sleeve 4 cm proximal to the anastomosis (non-resorbable V-loc 3-0). Fascia defect is closed for the port where the specimen is extracted. The mesenteric defect is not closed.
223821017|NCT05611697|PROCEDURE|Sleeve gastrectomy|In the laparoscopic sleeve gastrectomy, the abdominal cavity is entered directly with a visual trocar with or without the use of Verres needle. The set up includes a total of 5 ports. The Natanson liver retractor is utilized. The greater omentum is separated from the major side of the stomach from the pylorus to the angle of His. The left crus is visualized and the hiatus is inspected for the presence of hernia. A 36 French bougie is introduced and the stomach is divided along this from 4-5cm proximal to the pylorus to 1cm lateral to the angle of His using two purple cartridges (Medtronic Tri-Staple™ technology) followed by beige 60mm cartridges to the angle of His, 1 cm lateral to the esophagus. The sleeve is tested for leaks with instillation of 50ml methylene blue in the tube. The fascia defect is closed with suture for the port site where the specimen is extracted.
223821018|NCT01959945|BIOLOGICAL|Flublok® Quadrivalent Influenza Virus Vaccine|Intramuscular (Relevant year formulation)
223821019|NCT01959945|BIOLOGICAL|Fluarix Quadrivalent® Influenza Virus Vaccine|Intramuscular (Relevant year formulation)
223821020|NCT02110446|DRUG|SS-1|"The patients will be divided into two groups (A and B) at random and all of them keep the routine treatment in the rheumatology OPD. Group A patients will receive 12 weeks SS-1 treatment first, and then stop the SS-1 for 4 weeks for wash-out phase, and then receive 12weeks placebo treatment. Group B patients receive 12 weeks placebo first, and then stop the placebo treatment for 4 weeks for wash-out phase, and then receive 12weeks SS-1 treatment.~SS-1 is composed of 3 traditional Chinese herbal formula: Gan-Lu-Yin, Sang-Ju-Yin and Xuefu-Zhuyu-Decoction with the ratio of 2:1:1. The placebo is composed with corn starch, pigment and minimal dose of 1% SS-1. Patients in both groups take 6 gram of SS-1/Placebo three times per day."
223821021|NCT02110446|DRUG|Placebo|The placebo is composed of corn starch, pigment and minimal dose of 1% SS-1. Patients take 6 gram of experiment medicine three times per day.
223821022|NCT05696418|PROCEDURE|Total knee arthroplasty with a Mobile Bearing system.|The prostheses will be cruciate scarifying cemented DePuy Synthes PFC Sigma with a Mobile Bearing system without resurfacing the patella.
223821023|NCT05696418|PROCEDURE|Total knee arthroplasty with a Fixed Bearing system.|The prostheses will be cruciate scarifying cemented DePuy Synthes PFC Sigma with a Fixed Bearing system without resurfacing the patella.
223821024|NCT06285942|DRUG|Edoxaban|To use of Edoxaban via PEG in patients with an indication to anticoagulation therapy according to current guidelines
223821025|NCT06285942|DRUG|No Edoxaban|Other DOACs through PEG or subcutaneous heparin or LMWH
223821026|NCT00288197|DRUG|voriconazole|
223821027|NCT01992549|BIOLOGICAL|Human-cl rhFVIII|
223821028|NCT03396731|DEVICE|geko™ medical device|The geko™ device, manufactured by Firstkind Ltd (High Wycombe, United Kingdom), is a small disposable, battery powered CE marked medical device.
223821029|NCT04855110|DRUG|Warfarin Sodium started on Day 2 after caesarean section (in a dose that achieves a therapeutic level as indicated by the cardiology consultant)|Warfarin started on day 2 after caesarean section in patients with mechanical heart valve prosthesis
223821030|NCT04855110|DRUG|Warfarin Sodium started on day 5 after caesarean section (in a dose that achieves a therapeutic level as indicated by the cardiology consultant)|Warfarin started on day 5 after caesarean section in patients with mechanical heart valve prosthesis
223821031|NCT01590771|DRUG|Sitagliptin|Sitagliptin 100 mg oral tablet once daily for 24 weeks
223821032|NCT01590771|DRUG|Placebo|Matching placebo to sitagliptin oral tablet once daily for 24 weeks
223821033|NCT01590771|DRUG|Gliclazide|Participants will continue ongoing open-label therapy with gliclazide (dosed according to the China drug label) throughout the study.
223821034|NCT01590771|DRUG|Glimepiride|Participants will continue ongoing open-label therapy with glimepiride (dosed according to the China drug label) throughout the study.
223821035|NCT01590771|DRUG|Metformin|Participants will continue ongoing open-label therapy with metformin (at least 1500 mg daily) throughout the study.
223821036|NCT02729636|DEVICE|multi-pad functional electrical stimulation (FES)|"Treatment includes two automated phases: optimization of stimulation parameters and application during the walk.~Optimization of stimulation parameters: The stimulator generates short bursts of electrical impulses and sends them to each of the 16 pads of the multi-pad electrode. Each pad is the same size. Pads are sorted in two rows by 8 pads. Common anode is placed under the knee. Based on FES-induced foot movements, automated algorithm suggests parameters which are evaluated by medical doctor/therapist.~Assisted walking: During assisted walking, pattern for plantar flexion is activated in push off phase and pattern for dorsiflexion in swing phase of the gait."
223821037|NCT02729636|OTHER|Conventional therapy|2\. All study subjects received the conventional stroke rehabilitation program of physiotherapy based on the neurodevelopmental facilitation approach and occupational therapy focused on activities of daily living during the treatment for 60 min a day, 5 days a week, for 4-weeks. Conventional therapy was given by trained therapists and consisted of the following strategies: strategies to joint mobilization and range of motion exercises; exercises to improve strength; strategies to manage spasticity; exercises for increase range of motion, compensatory strategy; strategies to improve balance, and mobility.
223821038|NCT04489589|DRUG|Midodrine|10mg PO/NG q8h
223821039|NCT04489589|DRUG|Placebo|10mg PO/NG q8h
223821040|NCT00000990|DRUG|Zidovudine|
223821041|NCT01495221|DRUG|Alfilbercept|All patients will receive 2.0 mg intravitreal aflibercept injection.
223821042|NCT02253524|DRUG|Dimenhydrinate|50 mg Dramamine with 5 cc syringe in 150 ml normal saline given as a slow intravenous infusion over 15 minutes
223821043|NCT02253524|DRUG|Metoclopramide|10 mg Metoclopramide with 5 cc syringe in 150 ml normal saline given as a slow intravenous infusion over 15 minutes
223821044|NCT03289390|DRUG|Acetaminophen|Acetaminophen given at discretion of medical team for PDA treatment. Research team to evaluate pre and post laboratory values and echocardiograms.
223821045|NCT02019563|PROCEDURE|RCT Group|After complete removal of all caries, if a pulp exposure is detected the pulp chamber will be opened and the pulp tissue removed. The canal will be irrigated with water and then filled with non-reinforced ZOE.
223821046|NCT02019563|PROCEDURE|MTA/FS pulpotomy Group|After complete removal of all caries, if a pulp exposure is detected the pulp chamber will be opened and vital coronal pulp to a depth of 2mm below free gingival margin will be removed. A solution of ferric sulfate will be applied to the amputated pulp surface and then flushed with water. MTA paste is then used to cover over the exposed amputated pulp surface.
223821047|NCT06529549|OTHER|Organoid-Based Drug Sensitivity Screening|Residual tissue of bone metastatic sites from biopsies for genetic testing will be collected to culture organoid and perform drug sensitivity screening
223821048|NCT02323035|DEVICE|Headgear|Investigative Headgear with CPAP Mask.
223821049|NCT01916499|OTHER|3 tesla magnetic resonance imaging findings; coronary artery status|
223821050|NCT01916499|OTHER|3 tesla magnetic resonance imaging findings; ventricular function and morphology|
223821051|NCT04866511|OTHER|Narrative Exposure Therapy|"NET is a trauma-focused psychological treatment for people who experienced multiple traumas (Schaeur et al., 2011).~An adaptation named KIDNET was developed for use with children and young people (Neuner et al., 2008; Schauer et al., 2011, 2017).~Participants will be offered 6-10 weekly sessions of NET lasting approximately 90 minutes each. The sessions will be delivered by a Trainee Clinical Psychologist via videoconferencing, in line with the UK's Government guidelines around reducing face-to-face contacts during the Covid-19 pandemic."
223821052|NCT03765463|BEHAVIORAL|Habit Reversal Training|4 sessions of habit reversal training
223821053|NCT05468775|BEHAVIORAL|Naked eye 3D vision training|20 minutes of naked eye 3D vision training every day
223821054|NCT02585037|OTHER|Kinesio Taping® bandage|"The Kinesio Taping® bandage will be applied in an I format in the wrist flexor muscles of a dominant and non-dominant limb in G1 and G2 groups."
223821055|NCT02585037|OTHER|Dynamometer Jamar® pressure|The Jamar® dynamometer will be adjusted to the second position for measurement of maximal voluntary strength of handgrip. A muscle contraction period of three seconds will be performed in order to record handgrip strength.
223821056|NCT02585037|OTHER|Placebo|For the control group (G3) the Kinesio Taping® bandage will be placed from the lateral extremity to the medial axis.
223821057|NCT04853901|DRUG|Remdesivir|Remdesivir loading dose of 200 mg intravenously followed by 100 mg/day intravenously for 5 to 10days
223821058|NCT04853901|DRUG|Standard of care_1|Hydroxycoloroquine 400mg twice on day 1 then 200mg tab twice 2-10 days
223821059|NCT04853901|DRUG|Standard of care_2|Methylprednisolone 1-2mg/kg for 5-7 days
223821060|NCT00162643|DRUG|zidovudine+lamivudine+lopinavir/ritonavir|
223821061|NCT00162643|DRUG|zidovudine + lamivudine + efavirenz|
223821062|NCT03880318|PROCEDURE|Joint Preserving Surgery in spasmodic flat foot|extensor digitorum longus, peroneus brevis and tertius lengthening together with calcaneal osteotomies
223821063|NCT01997320|OTHER|Heavy resistance exercise and nutrition|Heavy resistance exercise of the lower extremities three times weekly for 12 weeks.
223821064|NCT01997320|OTHER|Nutrition supplement|Two daily administrations of nutrient supplementation, each containing 20g of milk protein.
223821065|NCT02209636|DRUG|Lanthanum carbonate|Non-calcium containing phosphorus binder
223821066|NCT02209636|DRUG|placebo|Table identical to lanthanum carbonate but with no active ingredient
223821067|NCT02209636|DRUG|Ascorbic Acid|Intravenous administration during measurement of flow mediated dilation.
223821068|NCT02209636|DRUG|Nitroglycerin|Drug that is administered under the tongue that relaxes blood vessels. To be administered during measurement of flow mediated dilation.
223821069|NCT02209636|PROCEDURE|Flow-mediated dilation measurement|Measurement of the blood flow in the brachial artery, an artery in the upper arm, using ultrasound.
223821070|NCT02209636|PROCEDURE|Aortic pulse-wave velocity|Measurement of the stiffness of the arteries using a transcutaneous tonometer, a small device placed over the skin over the carotid, brachial, radial and femoral arteries.
223821071|NCT02209636|PROCEDURE|Endothelial cell collection|Collection of endothelial cells from vein in arm. A flexible wire is inserted through an IV into a forearm vein to collect endothelial cells for further study. This is performed at the baseline visit and and the final study visit.
223821072|NCT00767104|OTHER|Silk like Pillowcase|sleep on silk-like pillowcase each night
223821073|NCT00767104|OTHER|Cotton Pillowcase|Sleep on placebo cotton pillowcase each night
223821074|NCT02705040|OTHER|Normal|bone mineral density T\>=-1.0
223821075|NCT02705040|OTHER|Osteopenia|bone mineral density -1.0\>T\>=-2.5
223821076|NCT02705040|OTHER|Osteoporosis|bone mineral density T\<-2.5
223821077|NCT04048499|DEVICE|the Colour Assessment and Diagnosis (CAD) test|The CAD test (City Occupational Ltd, London, UK) measures the severity of red-green and yellow-blue colour vision loss according to red-green and yellow-blue thresholds which are expressed in CAD units and diagnoses accurately the subject's class of colour vision
223821078|NCT05860725|BEHAVIORAL|PSA Development|Health sciences students from a regional community college in Appalachian Virginia will be asked to to develop and submit a public service announcement (PSA) and to watch virtual training webinars that support the development of the PSAs. They will also be asked to complete surveys at three time points: before the PSA contest starts, after the PSA contest ends, and upon submitting a PSA.
223821079|NCT05860725|BEHAVIORAL|HPV vaccination focused social marketing campaign|Community members who use a regional health services focused non-profits rideshare buses and/or view their social media pages will be exposed to a 12-week social marketing campaign that uses PSAs developed in Phase 1. Community members will also complete surveys at three time points: before the start of the social marketing campaign, during the social marketing campaign, and after the social marketing campaign.
223821080|NCT00003320|PROCEDURE|surgical procedure|
223821081|NCT00003320|RADIATION|radiation therapy|
223821082|NCT00003320|RADIATION|stereotactic radiosurgery|
223821083|NCT02783820|DRUG|MMV390048 40 mg|
223821084|NCT02783820|DRUG|Placebo to match MMV390048 40 mg|
223821085|NCT02783820|DRUG|MMV390048 80 mg|
223821086|NCT02783820|DRUG|Placebo to match MMV390048 80 mg|
223821087|NCT02783820|DRUG|MMV390048 120 mg|
223821088|NCT02783820|DRUG|Placebo to match MMV390048 120 mg|
223821089|NCT04151693|BEHAVIORAL|Health Psychological Group Rehabilitation for Patients With Chronic Fatigue Syndrome (ME/CFS)|Adaptation (support own agency), rehabilitation and improvement of functional capacity.
223821090|NCT00856934|BIOLOGICAL|Autologous Platelet Rich Plasma|Platelet Rich Plasma isolated from patient blood sprayed onto wound bed along with 10% Calcium Chloride solution in a 10 to 1 proportion.
223821091|NCT00856934|BIOLOGICAL|Keratinocyte suspension|Autologous keratinocytes isolated from skin biopsy suspended in platelet rich plasma before spraying.
223821092|NCT00856934|OTHER|Standard dressings|Three layers of paraffin gauze, topped with standard dry bandages and an elastic bandage.
223821093|NCT02668406|OTHER|Venous blood sampling (2 timepoints) (Phase A and B)|8.5ml at Day 1 + 8.5ml at Day 5
223821094|NCT02668406|OTHER|Venous blood sampling (1 timepoint) (Phase A and B)|8.5ml at Day 1
223821095|NCT02668406|OTHER|Voided urine sampling (first sample) (Phase A)|At least 20ml upon confirmation of being part of one of the 3 study groups
223821096|NCT02668406|OTHER|Voided urine sampling (second sample) (Phase A)|At least 20ml during routine hospital stay or routine follow-up visit
223821097|NCT06230302|DIETARY_SUPPLEMENT|Whey postbiotics derived from kefir lactic acid bacteria|Kefir (alcoholic fermented dairy product made by fermenting cow, goat, or sheep milk) whey derived from lactic acid bacteria postbiotics
223821098|NCT06230302|DIETARY_SUPPLEMENT|Placebo powder|A powder product including Flavor, Calcium carbonate, Lactose, Maltodextrin, Sugar, Carboxy methyl cellulose. This cannot be distinguished from the postbiotics by inspection.
223821099|NCT01900054|DRUG|Bepotastine besilate|Two TAU-284 5mg tablets will be taken orally twice a day
223821100|NCT05936203|OTHER|Insulin therapy adjustment|Strategies used to manage glucose control during a prolonged aerobic exercise
223821101|NCT05936203|OTHER|Nutritional adjustment|Strategies used to manage glucose control during a prolonged aerobic exercise
223821102|NCT05936203|OTHER|Combination of strategies|Strategies used to manage glucose control during a prolonged aerobic exercise
223821103|NCT01186328|DRUG|EZN-3042|Dose will be assigned at study entry. To be given as a 2 hour intravenous infusion on days -5, -2, 8, 15, 22 and 29. Dose levels: L0 (level zero): 1.5 mg/kg, L1: 2.5 mg/kg, L2: 5 mg/kg, L3: 6.5 mg/kg
223821104|NCT01186328|DRUG|Cytarabine|"Given intrathecally on day -6. Patients who may have received intrathecal chemotherapy within 7 days of day 0 as part of their prior maintenance chemotherapy (e.g. before the diagnosis of relapse) or as part of the diagnostic workup will not receive this dose of IT cytarabine. If given, dose is defined by age:~1-1.99 years: 30 mg 2-2.99 years: 50 mg~Greater than or equal to 3 years: 70 mg.~Cytarabine is also part of the triple intrathecal therapy given to CNS 3 patients on Days 8, 15, 22 and 29. Dose is defined by age:~1. \- 1.99 years: 16 mg~2. \- 2.99 years: 20 mg~3. \- 8.99 years: 24 mg~Greater than or equal to 9 years: 30 mg"
223821105|NCT01186328|DRUG|Doxorubicin|60 mg/m2/day given intravenous infusion (IV) over 15 minutes on day 1.
223821106|NCT01186328|DRUG|Prednisone|40 mg/m2/day divided BID or TID given orally on days 1 through 29. For patients who are unable to tolerate prednisone orally, substitute IV methylprednisolone at 80% of the oral prednisone dose.
223821107|NCT01186328|DRUG|Vincristine|1.5 mg/m2/day (maximum dose 2 mg) given intravenous push over 1 minute or infusion via mini-bag as per institutional policy on days 1, 8, 15 and 22.
223821108|NCT01186328|DRUG|PEG-asparaginase|2500 IU/m2 intramuscular injection on days 2, 9, 16, 23. If available, Erwinia L-asparaginase may be substituted for pegaspargase in patients with clinically significant prior allergies to pegaspargase.
223821109|NCT01186328|DRUG|Methotrexate|"Given intrathecally to patients with CNS1 or CNS2 disease at the dose defined by age below on days 15 and 36:~1-1.99 years: 8 mg 2-2.99 years: 10 mg 3-8.99 years: 12 mg~Greater than or equal to 9 years: 15 mg~Given as part of the Triple intrathecal therapy to patients with CNS 3 disease at the doses defined by age below on days 8, 15, 22 and 29:~1. \- 1.99 years: 8 mg~2. \- 2.99 years: 10 mg~3. \- 8.99 years: 12 mg~Greater than or equal to 9 years: 15 mg"
223821110|NCT01186328|DRUG|Hydrocortisone|"Given as part of the Triple intrathecal therapy to patients with CNS 3 disease at the doses defined by age below on days 8, 15, 22 and 29:~1. \- 1.99 years: 8 mg~2. \- 2.99 years: 10 mg~3. \- 8.99 years: 12 mg~Greater than or equal to 9 years: 15 mg"
223821111|NCT03047174|OTHER|Mepitel® Film|Mepitel® Film is a gentle, sterile, transparent, breathable film dressing consisting of polyurethane film coated with a special contact layer. The film dressing is supported with a paper frame for ease of application. Mepitel® Film is an ultra thin, transparent, breathable soft silicone film dressing.
223821112|NCT03047174|OTHER|Standard Care|"Cream: Fatty cream with 2-5% urea is applied to the irradiated skin 3-4 times daily.~Mometasone furoate cream: In addition to the fatty cream with 2-5% urea, mometasone furoate cream (solution 0.1%) is applied to the irradiated skin once daily."
223821113|NCT06007079|DEVICE|CPM Device|Wearable monitor
223821114|NCT03648125|DEVICE|with artificial occlusal disturbance|"A silicon artificial occlusal disturbance is made from a mould of the rowers mouth and placed in the mouth during the training session.~With artificial occlusal disturbance : Maximal Intercuspal Occlusion (MIO) with silicone splint increases the vertical dimension of occlusion of 1, 2 and 4 mm."
223821115|NCT03648125|DEVICE|without artificial occlusal disturbance|The training session is performed without occlusal disturbance
223821116|NCT01108835|OTHER|Comprehensive care programme|"Intervention group:~* Patients will be interviewed by a respiratory nurse and given education in 1-2 sessions~* Physiotherapist assessment and training (individualized physical training programme to perform at home or a short course out-patient pulmonary rehabilitation)~* Respiratory physician assessment and optimization of treatment~* Patients will also be taught about a personalized action plan by the physician and respiratory nurse.~* Subsequent intervention: Patients will receive monthly telephone calls by a respiratory nurse for a period of 1 year to assess their conditions and also answer their queries."
223821117|NCT02890238|DRUG|Clomiphene citrate|50mg (clomid,) orally 2 times/day from 2nd- 7th day of the cycle
223821118|NCT02890238|DRUG|sildenafil citrate|20mg tab from 7th-11th day of the same cycle orally 3times/day
223821119|NCT02890238|DRUG|Placebo|tab from 7th-11th day of the same cycle orally 3times/day
223821120|NCT02473861|OTHER|Exercise|Moderate intensity aerobic and resistance training. Five minutes each of warm-up, cool-down, balance and flexibility will also be performed.
223821121|NCT04172493|PROCEDURE|Hyperspectral Endoscopy (HySE)|Undergo hyperspectral endoscopy
223821122|NCT04172493|DEVICE|White Light Endoscopy (WLE)|Undergo white light endoscopy
223821123|NCT00665990|DRUG|Bevacizumab|Bevacizumab starting dose of 5 mg/kg every 3 weeks increasing in combination with Sorafenib and Cyclophosphamide until maximum tolerated dose
223821124|NCT00665990|DRUG|Sorafenib|Sorafenib 90 mg/m2 PO every 12 hours increasing in combination with Bevacizumab and Cyclophosphamide until maximum tolerated dose
223821125|NCT00665990|DRUG|Cyclophosphamide|Cyclophosphamide 50 mg/m2 PO once daily increasing in combination with Bevacizumab and Sorafenib until maximum tolerated dose
223821126|NCT03015116|OTHER|Stretching|Daily foot and ankle stretching protocol
223821127|NCT03015116|OTHER|Cryotherapy|Daily cryotherapy in conjunction with stretching
223821128|NCT03015116|DEVICE|Photobiomodulation Low Power|Photobiomodulation treatment with 10W power output
223821129|NCT03015116|DEVICE|Photobiomodulation High Power|Photobiomodulation treatment with 25W power output
223821130|NCT01015807|DRUG|Bupivacaine Placebo|2 x 20mL 0.9% NaCl
223821131|NCT01015807|DRUG|Clonidine Placebo|2 x 1mL 0.9% NaCl
223821132|NCT01015807|DRUG|Bupivacaine|2 x 20mL 0.375% Bupivacaine = 150 mg Bupivacaine
223821133|NCT01015807|DRUG|Clonidine|2 x 1ml Clonidine = 150 µg Clonidine
223821134|NCT02732093|PROCEDURE|stellate block|
223821135|NCT02732093|DRUG|Na.Cl 0.9% (placebo)|
223821136|NCT02732093|DRUG|lidocaine 2%|
223821137|NCT02075021|DRUG|Lenalidomide|
223821138|NCT02075021|DRUG|nab-paclitaxel|
223821139|NCT02778191|DRUG|cisplatin|100 mg/m2 day 1, 22 and 43
223821140|NCT02778191|DRUG|carboplatin|carboplatin 300-350 mg/m2 day 1, 22 and 43
223821141|NCT02778191|DRUG|5-FU|5-FU 600 mg/m2 days 1-4, 22-25 and 43-46
223821142|NCT00783471|DRUG|Erlotinib, Docetaxel|Drug: Erlotinib 150 mg po daily, days 1-12 Drug: Docetaxel 75 mg/m2 IV over 30 min on day 15 Treatment will be repeated every 21 days
223821143|NCT00783471|DRUG|Docetaxel, Erlotinib|Drug: Docetaxel 75 mg/m2 IV over 30 min on day 1 Drug: Erlotinib 150 mg po daily, days 4-15 Treatment will be repeated every 21 days
223821144|NCT04748419|RADIATION|consolidative hypofractionated radiation therapy (hfRT)|Consolidative hfRT will start from 6.5Gy x 2 fractions and dose escalate to 10Gy x 2 fractions in a 3+3 design
223821145|NCT04748419|DRUG|Durvalumab 50 MG/ML|Durvalumab 10 mg/kg via a 60-minute iv infusion every two weeks ± 3 days for up to 12 months
223821146|NCT00361361|DEVICE|Excimer Laser Therapy|excimer laser is a UV 308nm laser. repeated sessions (10 sessions) needed. once per week.
223821147|NCT03053921|PROCEDURE|recession coverage|recession coverage done using Zuchellis technique
223821148|NCT03053921|PROCEDURE|recession coverage and membrane|recession coverage done using Zuchellis technique with placental membrane
223821149|NCT02629068|BEHAVIORAL|PURPOSE|"The first week of the intervention will focus on welcoming everyone to the facebook group and laying down the ground rules for participation. Each additional week of the intervention will focus on a specific topic to promote discussion and learning of each particular skill; however, questions and discussions on other relevant topics are always welcome and encouraged.~Week 1: Welcome Week Week 2: SUD Basics Week 3: Problem of Stigma Week 4: Communication Skills Week 5: Parental Monitoring Week 6: Stress Management Week 7: Family and Valued Directions Week 8: Putting It All Together"
223821150|NCT05721443|DRUG|Dalpiciclib+cetuximab|"The dosing regimen for cetuximab combined with dalpiciclib is: the starting dose of cetuximab is 400 mg/m2, titrated over 120 minutes, and the titration rate should be limited to 5 ml/min. A maintenance dose of 250 mg/m2, titrated over not less than 60 minutes, with pretreatment with H1 receptor blocker desensitization prior to dosing, administered once weekly.~The recommended dose of dalpiciclib is 150 mg once daily for 21 days, followed by 7 days of discontinuation (3/1 dosing regimen) for a 28-day treatment cycle. Take the drug at approximately the same time each day. If the patient vomits or misses a dose, the dose should not be made up that day. The next dose should be taken as usual.~Subjects will continue treatment with cetuximab in combination with dalpiciclib until termination criteria are met."
223821151|NCT03924713|BEHAVIORAL|Supportive services|Assessment of behavioral, medical, and social needs, development of individual goals and action plan, follow-up to assist and work to ensure identified needs/goals are met. CHWs use their professional judgement to assess how long follow-up is required.
223821152|NCT02951910|DEVICE|Ophylosa tear supplement|Tear film dynamics is assessed by non-invasive tear film breakup time (NI-BUT) in parallel with continuous recordings of ocular sensations during forced blinking. Corneal sensitivity thresholds to selective stimulation of corneal mechanonociceptors, thermal receptors and chemical nociceptors are assessed using the Belmonte gas esthesiometer. All baseline measurements are repeated after one month of tear supplementation with zinc-hyaluronate (Ophylosa eye drop) 4x/day
223821153|NCT01352143|DRUG|Recombinant activated factor VII|Plasma will be spiked in vitro with recombinant activated factor VII to assess increases in thrombin generation with and without the drug
223821154|NCT01352143|DRUG|Prothrombin Complex Concentrate|Plasma will be spiked in vitro with prothrombin complex concentrate to determine increases in thrombin generation with and without the drug
223821155|NCT02762981|DRUG|Relacorilant with nab-paclitaxel|Relacorilant is supplied as capsules for oral dosing. Nab-paclitaxel administered as an IV infusion.
223821156|NCT05480332|DEVICE|EndoPAT|"We will use the standard non-invasive EndoPAT finger probes to conduct the studies. A single finger on each hand will be placed into a probe equipped with pressure sensors. A baseline recording period will be obtained. After five minutes, an occlusion phase will start where a blood pressure cuff on the patient's non-dominant arm will be inflated to 60mmHg above the patient's systolic pressure, or 200mmHg, whichever is higher. This phase will be conducted in concert with the standard instructions provided with the EndoPAT system. The occlusion phase will last for five minutes, after which time the cuff will be deflated. There will then be a five minute post-occlusion recording period. The test will then be completed.~The baseline period, occlusion period, and post-occlusion period will then be analyzed. A reactive hyperemia index score will be the desired output from the EndoPAT computer software, and will become the primary data point."
223821157|NCT03847038|PROCEDURE|Preventive strategies advice and dementia risk estimate disclosure|The BBRC-DemPrev-2018 study is a multimodal lifestyle-interventional, longitudinal, and prospective study of participants with a subjective perception of cognitive decline (SCD) or with mild cognitive impairment (MCI). Participants are disclosed their 5-year dementia risk estimate
223821158|NCT03712540|DRUG|BMS-986278|Oral administration 30 mg
223821159|NCT03712540|DRUG|Rifampin|Oral administration 600 mg
223821160|NCT01516775|OTHER|clear fluid ingestion|drinking of clear fluid in preoperative period
223821161|NCT02790216|PROCEDURE|Brachytherapy|Biopsies will be obtained after intraoperative plan to rule out significant cancer outside a high risk planning target volume
223821162|NCT00005788|BIOLOGICAL|aldesleukin|
223821163|NCT04777929|OTHER|test Phthalates, estrogen and progesterone|test mothers Phthalates in their urine, and test estrogen and progesterone receptor in placental tissue
223821164|NCT05017324|DEVICE|WGS DST strategy|WGS DST strategy for diagnosing the TB drug resistance profile and an algorithm-determined individualised RR-TB treatment recommendation
223821165|NCT02610218|OTHER|CTC and cfDNA analysis|The enumeration of CTCs as well as the detection of HER2 expression will be achieved via the integrated subtraction enrichment (SET) and immunostaining-fluorescence in situ hybridization (iFISH) platform. Further, for the geneomic analysis, the enriched single CTC will be isolated for single-cell targeted sequencing. While for cfDNA analysis, extracted DNA from plasma will be directly subjected to targeted sequencing. Tumor response evaluation will be performed after two cycles of chemotherapy by CT/MRI based on RECIST. Clinical data, including tumor stage, metastastic organ, chemotherapy regimen, objective response, progression free survival, overall survival, etc, will be collected according to study protocol.
223821166|NCT05468515|DIAGNOSTIC_TEST|pulse oxygen saturation|preductal oxygen saturation
223821167|NCT02880007|RADIATION|External Beam Radiation Therapy|45 Gy pelvis / 25 fr
223821168|NCT02880007|RADIATION|PDR Brachytherapy|1 puls/hour ; 12 Gy / day
223821169|NCT02880007|DRUG|Cisplatin|increase in dose to the target volume at high risk (85 to 90 Gy over 90% of its volume) and the intermediate target volume (60 Gy to 90 % of its volume) in 3D Pulsed Dose Rate Brachytherapy
223821170|NCT00891306|GENETIC|Alipogene Tiparvovec (AMT-011), Human LPL [S447X]|intra muscular, 1 x E12 gc per kg body weight, injected in a single series of intramuscular injections
223821171|NCT00891306|DRUG|mycophenolate mofetil|oral, 2 g/day, day -3 till week 12
223821172|NCT00891306|DRUG|cyclosporine|oral, 3 mg/kg/day, day -3 till week 12
223821173|NCT00891306|DRUG|methylprednisolone|single intravenous bolus of methylprednisolone (1 mg/kg bodyweight)
223821174|NCT03279848|OTHER||Stroke rehabilitation
223821175|NCT00976469|BIOLOGICAL|H1N1 pandemic influenza vaccine (whole virion, Vero cell-derived, inactivated)|2-dose priming at a 21-day interval, intramuscular injection in either the upper arm or thigh, depending on the subject´s age
223821176|NCT00976469|BIOLOGICAL|Seasonal trivalent influenza vaccine (licensed) for the season 2010/2011|Booster vaccination at Day 360 after first vaccination (only in subjects who received the 7.5 µg dose of the H1N1 pandemic influenza vaccine)
223821177|NCT01357590|DEVICE|Thoracic Endovascular Stent Graft System (ThoraflexTM)|Thoracic Endovascular Stent Graft System
223821178|NCT06476626|OTHER|Maternal Reflective Function Workshop|4 session group online intervention focused on psycho-educational knowledge regarding emotional regulation and specifically MRF. group size- up to 15 participants. 2 sessions will be during pregnancy and 2 sessions will taken place 1 and 3 months after birth.
223821179|NCT02398058|DRUG|trabectedin|trabectedin will be administered in a 24-h continuous i.v. infusion every 3 weeks
223821180|NCT02398058|DRUG|olaparib|olaparib will be administered in a continuous daily dose every 12 hours
223821181|NCT06297681|DRUG|Daratumumab + Bortezomib + Dexamethasone + Dapagliflozin|The treatment medication for enrolled patients must comply with the treatment regimen of Daratumumab + Bortezomib + Dexamethasone: subcutaneous injection of 1800mg of Daratumumab, d1, 8,15,22 (28 day cycle); (After 2 cycles of improvement in cardiac indicators, it can be adjusted to intravenous injection of daratumumab); Bortezomib 1.3 mg/m2 d1, 8, 15, 22; D1, 8, 15, 22; Dexamethasone 20 mg d1, 2, 8, 9, 15, 16, 22, 23. When NTProBNP is greater than 5400ng/ml, bortezomib 1.0mg/m2; When NTProBNP is greater than 8500ng/ml, bortezomib is 0.7mg/m2. When NTProBNP is greater than 10000ng/ml, bortezomib is temporarily not allowed; NTProBNP greater than 4500ng/ml dexamethasone starts at 10 mg/dose. All patients were given Dapagliflozin 10mg/day at the beginning of treatment (creatinine clearance rate greater than 20ml/min).
223821182|NCT03388112|DIETARY_SUPPLEMENT|Probiotics|the patients in this arm will receive probiotics blend of Bifidobacterium longum, Lactobacillus acidophilus, Enterococcus faecalis with does of 1.5\*10\^7CFU for 2 weeks
223821183|NCT03136796|DRUG|Meropenem|Patients will receive intravenous antibiotics eighter empirically or based on a culture.
223821184|NCT03580213|OTHER|Hand therapy MCPJ affected|Prevention of oedema, treatment of scar, splinting to maintain or improve extension, exercises, activity of daily living as exercise. Instructions, demonstration and advices.
223821185|NCT03580213|OTHER|Hand therapy PIPJ affected|Prevention of oedema, treatment of scar, splinting to maintain or improve extension, exercises, activity of daily living as exercise. Instructions, demonstration and advices. Possible additional splint and exercises specifically for the PIPJ extension.
223821186|NCT06205732|OTHER|Immunotherapy, targeted therapy.|Immunotherapy (sintilimab, camrelizumab, tislelizumab, atezolizumab, durvalumab, cardenilumab, and pembrolizumab); targeted therapy (apatinib, lenvatinib, sorafenib, and regorafenib).
223821187|NCT05164731|BIOLOGICAL|SARS-CoV-2 Vaccine, Inactivated (Vero Cell)|the third does was given 3, 4, 5 or 6 months after two doses
223821188|NCT01678014|PROCEDURE|Deep Brain Stimulation(DBS)|Deep Brain Stimulation(DBS)is a neurosurgical procedure which include the implantation of deep brain electrodes and the connect to an implantable pulse generator (IPG) that is implanted below the collarbone.
223821189|NCT01678014|PROCEDURE|Capsulotomy|
223821190|NCT05027399|BEHAVIORAL|Nursing teleconsultation for lifestyle changes|Guidance on better medication adherence, monitoring of signs and symptoms of exacerbation of heart failure, guidance on the need for fluid restriction.
223821191|NCT00018005|BEHAVIORAL|Self-Management|18 in-person group sessions providing self-management training.
223821192|NCT00018005|OTHER|attention control|18 educational mailings follow by a a telephone call.
223821193|NCT04953013|DRUG|sodium bicarbonate|Drug exposure
223821194|NCT02999711|DRUG|REGN3500|REGN3500 dose
223821195|NCT02999711|DRUG|Placebo|Matching placebo
223821196|NCT00816387|PROCEDURE|Fallopian tube sperm perfusion|Patients are treated with fallopian tube sperm perfusion
223821197|NCT00816387|PROCEDURE|Intrauterine insemination using standard catheter|Patients are treated with standard intrauterine insemination
223821198|NCT00144872|DRUG|Lamotrigine|Lamotrigine will be given as chewable dispersible tablets with dosing strengths of 2, 5, 25, and 100 milligrams.
223821199|NCT02999620|DIETARY_SUPPLEMENT|Alpha-cyclodextrin|Alpha-cyclodextrin (α-CD) is a soluble dietary fiber that has a history of use in foods and as a pharmaceutical excipient. Recently the ability of the fiber to bind to dietary fat has led to further investigation of the possible health benefits of dietary supplementation with this fiber.
223821200|NCT02999620|DIETARY_SUPPLEMENT|Placebo|Identical looking placebo tablet to active (Alpha-cyclodextrin)
223821201|NCT04439006|OTHER|Best Practice|Receive usual care
223821202|NCT04439006|DRUG|Ibrutinib|Given PO
223821203|NCT05902130|OTHER|symptoms of a myocardial infarction|Analysis of the differences in symptoms of a myocardial infarction between a man and a woman
223821204|NCT01625195|DIETARY_SUPPLEMENT|omega-3 fatty acid supplementation|This study will use a randomized placebo-controlled double-blind design and the intervention period will be 6 months. Participants will be instructed to consume 4 x 1285 mg fish oil capsules/d, two capsules with each of the main daily meals. The placebo will be composed of corn/soybean oil as used in other randomized placebo-controlled trials. The daily treatment will provide 1.2 g/d of DHA and 2.4 g/d of EPA (Ocean Nutrition Canada, Dartmouth, NS). All capsules will contain citrus flavor to mask the fishy taste and odor of the LC-omega-3 oil and will be provided to the participants monthly.
223821205|NCT01625195|DIETARY_SUPPLEMENT|corn/soybean oil placebo|This study will use a randomized placebo-controlled double-blind design and the intervention period will be 6 months. Participants will be instructed to consume 4x 1285 mg capsules/d, two capsulesat breackfast and two capsules at dinner. The placebo will be composed of corn/soybean oil as used in other randomized placebo-controlled trials.
223821206|NCT01738022|OTHER|Administration of gas mixtures|
223821207|NCT05002374|OTHER|Vestibular rehabilitation with optokinetic stimulation|Vestibular rehabilitation incorporated with optokinetic stimulation in virtual reality environment for five consecutive days
223821208|NCT05002374|OTHER|Vestibular rehabilitation|Customized vestibular rehabilitation for five consecutive days
223821209|NCT00584805|BIOLOGICAL|Inactivated, Dried, TSI-GSD 104, EEE|Subjects will receive 0.5ml SQ, as a two-dose primary series (days 0 and 28) and 0.1ml, as a mandatory booster dose at 6 months. A booster dose may be administered before 6 months if PRNT80 is \< 1:40 after day 28. Up to four booster doses may be given in any 1-year period.
223821210|NCT00613288|DRUG|Testosterone (Testogel), GnRH analog (Leuprorelide) and Placebo|"The trial is a double blinded, randomised cross-over study of 4 x 2 days with an interval of 1 month in between. 12 healthy young male participants will receive the GnRH-agonist leuprorelide 7,5 mg s.c. 3 weeks before examination on 3 occasions, and a fourth day without intervention.~The four days will include treatment on the examination day, Day 1 with:~1. Placebo (hypogonadism after leuprorelide injection)~2. Testosterone gel 50 mg applicated in the morning at 06.00 am (physiologic substitution - after leuprorelide injection).~3. Testosterone gel 150 mg applicated in the morning at 06.00 am (supra-physiologic substitution - after leuprorelide injection).~4. No treatment."
223821211|NCT03229616|DRUG|Busulfan (BU)|Busulfan was administered at 3.2 mg/kg/day on days -7 to -4.
223821212|NCT03229616|DRUG|Cyclophosphamide (CY)|Cyclophosphamide was administered at 60 mg/kg/day on days -3 to -2.
223821213|NCT03229616|DRUG|Etoposide (VP-16)|Etoposide was administered at 15 mg/kg/day on days -3 to -2.
223821214|NCT01760746|OTHER|Injection of Avastin / Lucentis, sampling aqueous humour|"Study participants will be divided into two arms. Subjects will receive Avastin or Lucentis a few days before vitrectomy surgery. The assignment will be double-masked.The first sample of aqueous humor will be obtained immediately prior to the intravitreal injection.~On the same of the intravitreal injection, a blood sample will be taken for hemoglobin A1C measurement. Approximately 1 week later when patients are having their scheduled vitrectomy surgery, an additional sample of aqueous humour will be obtained .~Intraocular cytokines levels will be measured in aqueous humor samples using multiplex cytokine assays."
223821215|NCT01839357|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Rivaroxaban 20 mg orally once daily for 6 weeks; subjects with severe to moderate renal impairment (ie, CrCl of 15 to 49 mL/min, inclusive) will receive the adjusted dose of 15 mg orally once daily for 6 weeks in the study.
223821216|NCT04048759|BEHAVIORAL|Remote Low|Participants will attend 40 min remotely delivered group MVPA sessions once a week, receive a step counter, access to resources for increasing MVPA, and one 20-min remotely delivered individual support/education session/wk.
223821217|NCT04048759|BEHAVIORAL|Remote High|Participants will attend 40 min remotely delivered group MVPA sessions 3x a week, receive a step counter, access to resources for increasing MVPA, and one 20-min remotely delivered individual support/education session/wk.
223821218|NCT04048759|BEHAVIORAL|Personal Coach|Participants will receive a step counter, access to resources for increasing MVPA, and monthly remote individual support/education.
223821219|NCT00213564|DRUG|response to infliximab associated with methotrexate|
223821220|NCT03915080|DRUG|Oktokog alpha|adjusting dose and dose interval according to MyPKFIT
223821221|NCT04017429|PROCEDURE|Open flap debridement with osteoplasty|Treatment of furcation grade III defect with open flap debridement followed by osteoplasty treatment. Osteoplasty includes altering the bone buccal to the furcation opening to \>90 degrees relative to the apico-coronal axis of the tooth.
223821222|NCT04017429|PROCEDURE|Open flap debridement without osteoplasty|Treatment of furcation grade III defect with open flap debridement only.
223821223|NCT00739895|PROCEDURE|Cardiac magnetic Resonance study|follow-up studies
223821224|NCT00739895|PROCEDURE|Blood testing|Blood sample tested for myocardial biomarkers
223821225|NCT05819905|DIAGNOSTIC_TEST|PET/CT|Pre treatment staging 18F-FDG PET/CT
223821226|NCT03668730|RADIATION|Intensity-modulated radiation therapy|Patients undergo low-dose OR standard dose IMRT based on their radiographic response to induction chemotherapy
223821227|NCT03668730|DRUG|Paclitaxel liposome|Patients receive Paclitaxel liposome by 135mg/m2 with a total of two cycles.
223821228|NCT03668730|DRUG|Cisplatin|Patients receive Cisplatin by 25mg/m2 on day1-day3 with a total of two cycles as induction chemotherapy ; patients receive cisplatin by 100mg/m2 with a total of three cycles as concurrent chemotherapy.
223821229|NCT03668730|DRUG|5-Fluorouracil|Patients receive 5-Fluorouracil by 3750mg/m2 civ120h with a total of three cycles.
223821230|NCT03043222|DEVICE|UroLift as artifical device for prostatic urethral lift.|UroLift as artifical device for prostatic urethral lift. The PUL treatment is a minimally invasive approach to treating an enlarged prostate, or BPH, that lifts or holds the enlarged prostate tissue using clips so that it is out of the way so it no longer blocks the urethra. There is no cutting, heating or removal of prostate tissue.
223821231|NCT03043222|DEVICE|Embospheres Microspheres as embolic agents for prostate artery embolization|Embospheres Microspheres as embolic agents for prostate artery embolization Arterial access will be obtained.Under live X-ray monitoring and using contrast, a catheter will be advanced into the artery to the prostate gland.Small micro spherical particles (Embopheres Microspheres) will be injected though the catheter to occlude the artery and cut off blood supply to the enlarged prostate. The prostate is then expected to shrink , thus relieving urinary symptoms related to prostate enlargement.There is no cutting or removal of prostate tissue.Once the procedure is complete, in case of wrist access compression will be achieved with a band; in case of groin access a closure device will be used to plug the site of entry.
223821232|NCT01077362|DRUG|placebo|SC injections
223821233|NCT01077362|DRUG|ustekinumab 45 mg|SC injections
223821234|NCT01077362|DRUG|ustekinumab 90 mg|SC injections
223821235|NCT00888901|DRUG|eltrombopag|eltrombopag tablets daily, in increasing dosage, for three months
223821236|NCT00888901|DRUG|corticosteroids (Aprednislon)|corticosteroids in decreasing dosage
223821237|NCT01503138|BEHAVIORAL|Purpose-built intervention|A purpose-built intervention consists of: (i) Empowerment; (ii) Parenting workshops; and (iii) Telephone social support and Peer support.
223821238|NCT00125099|BIOLOGICAL|VRC-HIVDNA009-00-VP|
223821239|NCT02100150|DRUG|NNZ-2566|Glycyl-L-2-Methylpropyl-L-Glutamic Acid (NNZ-2566) supplied as a lyophilized powder (3g in 30 milliliter vials) for reconstitution with strawberry flavored solution 0.5% v/v in Water for Injection.
223821240|NCT02100150|DRUG|Placebo|Strawberry flavored solution 0.5% v/v in Water for Injection
223821241|NCT03179800|DEVICE|MobiusHD|The MobiusHD device is a self-expanding nitinol implant that is delivered intravascularly to the internal carotid sinus via the delivery catheter.
223821242|NCT03179800|OTHER|Sham Implantation|Sham Implantation
223821243|NCT00460317|DRUG|AMG 706|125 mg QD orally every day
223821244|NCT00460317|DRUG|placebo|125 mg QD orally every day
223821245|NCT00460317|DRUG|paclitaxel|200mg/m2 on day 1 of each 3 week cycle +/- 3 days for a max of 6 cycles
223821246|NCT00460317|DRUG|carboplatin|AUC of 600mg/mL x min by Calvert formula on day 1 of each 3 week cycle +/- 3 days for a max of 6 cycles
223821247|NCT03068013|BEHAVIORAL|CALM|CALM intervention covers four domains, namely: 1) Symptom management and communication with health care providers; 2) Changes in self and relations with close others, 3) Spiritual well-being, sense of meaning and purpose, 4) Preparing for the future, sustaining hope and facing mortality
223821248|NCT03068013|BEHAVIORAL|SPI|Active Comparator: Supportive psycho-oncology intervention Supportive psycho-oncology intervention (SPI) includes counseling, psychoeducation and crisis intervention, which is the usual care intervention provided in our centres.
223821249|NCT05772975|BIOLOGICAL|H-PRF (Horizontal-platelet rich fibrin)|Platelet-rich fibrin is an autologous biomaterial originating from human blood following centrifugation without additives that contains supraphysiological doses of growth factors. it serves as a biological healing matrix by supporting cell migration and cytokine release. H-PRF is obtained by horizontal centrifugation using (Bio-PRF) centrifuge on 700 g force for 8 minutes. This way the cells separate much more efficiently throughout the entire membrane/clot.
223821250|NCT05772975|BIOLOGICAL|E-PRF|Platelet-rich fibrin is an autologous biomaterial originating from human blood following centrifugation without additives that contains supraphysiological doses of growth factors. In order to extend its resorption period heating method is used. After centrifugation of blood using (Bio-PRF) centrifuge on 700 g force for 8 minutes top layer is heated for 10 minutes at 75°C in BIO-Heat device. When cooled it is mixed with cell rich buffy coat. This way PRF with extended life is obtained.
223821251|NCT04069260|DRUG|ELX-02|ELX-02 is a small molecule, new chemical entity being developed for the treatment of genetic diseases caused by nonsense mutations. ELX-02 is a eukaryotic ribosomal selective glycoside (ERSG).
223821252|NCT04041440|BEHAVIORAL|clEAR auditory training|Children play auditory brain training computer games
223821253|NCT01624649|DRUG|Methylphenidate hydrochloride|Form = tablet, route = oral, administered as a flexible dosage
223821254|NCT01624649|DRUG|Atomoxetine|Form = tablet, route = oral;
223821255|NCT05852028|DRUG|Selinexor|this is a real-world. Patients who use selinexor-based regimens in lymphoma will be followed up without interfering with the choice of treatment options for patients
223821256|NCT00003048|DRUG|Amifostine Trihydrate|Escalating dose IV for two weeks, followed by 2 weeks of rest. Each treatment cycle is 4 weeks.
223821257|NCT03257423|DRUG|Ertapenem followed by levofloxacin and metronidazole|Ertapenem 1 g i.v. daily for either 2 days (MAPPAC + APPAC II patients) or 3 days (MAPPAC + APPAC III) followed by p.o. levofloxacin 500 mg x 1 + metronidazole 500 mg x 3 for either 5 days (APPAC II + MAPPAC) or 4 days (APPAC III + MAPPAC)
223821258|NCT03257423|DRUG|Moxifloxacin|Moxifloxacin 400 mg once a day for seven days (APPAC II + MAPPAC)
223821259|NCT03257423|PROCEDURE|Appendectomy|Primarily laparoscopic appendectomy for either complicated acute appendicitis or uncomplicated acute appendicitis (refusing to participate in APPAC II or III trials or recurrent acute appendicitis).
223821260|NCT03257423|OTHER|Placebo|Placebo i.v. once a day for three days (APPAC III + MAPPAC) followed by placebo capsules three times a day for four days.
223821261|NCT01113619|DRUG|RP-G28 or placebo|Qualified subjects randomized to daily dosing with RP-G28 or placebo
223821262|NCT01113619|DRUG|RP-G28 or placebo|Daily dosing
223821263|NCT01731587|OTHER|Biological: MUC1 peptide specific immunotherapy|Eight consecutive weekly subcutaneous administration with reconstituted L-BLP25 (containing 806 microgram of BLP25 lipopeptide) followed by administrations at 6-week intervals, commencing at Week 14, until disease progression is documented.
223821264|NCT01731587|DRUG|Cyclophosphamide (CPA)|A single intravenous infusion of 300 milligram per square meter (to a maximum of 600 milligram) of CPA will be given three days before the first L-BLP25 administration.
223821265|NCT04142060|DRUG|Enzalutamide|Patients will be dispensed with oral enzalutamide 160 mg (four 40 mg capsules) as a self-administered single oral daily dose, continuously.
223821266|NCT00517075|DEVICE|Transcranial Magnetic Stimulation (TMS)|For rTMS, the coil is held flat on the scalp. 40 trains of 10 Hz rTMS will be delivered in trains lasting 4 seconds, with an intertrain interval of 26 seconds, for a total of 20 minutes (1600 pulses per day) at 100% motor threshold. Subjects will receive rTMS once a day, 5 days a week, for 4 weeks. During the first week of rTMS sessions only, in the event that the patient cannot tolerate these stimulation parameters, intensity relative to motor threshold may be titrated downward, in a masked fashion, to 80%, with all other dose parameters remaining the same.
223821267|NCT00517075|DEVICE|Transcranial Magnetic Stimulation (TMS)|For rTMS, the coil is held flat on the scalp. 40 trains of 10 Hz rTMS will be delivered in trains lasting 4 seconds, with an intertrain interval of 26 seconds, for a total of 20 minutes (1600 pulses per day) at 100% motor threshold. Subjects will receive rTMS once a day, 5 days a week, for 4 weeks. During the first week of rTMS sessions only, in the event that the patient cannot tolerate these stimulation parameters, intensity relative to motor threshold may be titrated downward, in a masked fashion, to 80%, with all other dose parameters remaining the same.
223821268|NCT00517075|DEVICE|Transcranial Magnetic Stimulation (TMS)|For rTMS, the coil is held flat on the scalp. 40 trains of 10 Hz rTMS will be delivered in trains lasting 4 seconds, with an intertrain interval of 26 seconds, for a total of 20 minutes (1600 pulses per day) at 100% motor threshold. Subjects will receive rTMS once a day, 5 days a week, for 4 weeks. During the first week of rTMS sessions only, in the event that the patient cannot tolerate these stimulation parameters, intensity relative to motor threshold may be titrated downward, in a masked fashion, to 80%, with all other dose parameters remaining the same.
223821269|NCT00517075|DEVICE|repetitive transcranial magnetic stimulation|For rTMS, the coil is held flat on the scalp. 40 trains of 10 Hz rTMS will be delivered in trains lasting 4 seconds, with an intertrain interval of 26 seconds, for a total of 20 minutes (1600 pulses per day) at 100% motor threshold. Subjects will receive rTMS once a day, 5 days a week, for 4 weeks. During the first week of rTMS sessions only, in the event that the patient cannot tolerate these stimulation parameters, intensity relative to motor threshold may be titrated downward, in a masked fashion, to 80%, with all other dose parameters remaining the same.
223821270|NCT02247804|DRUG|Bimatoprost SR|Bimatoprost SR administered in the study eye on Day 1, Week 16, and Week 32.
223821271|NCT02247804|DRUG|Active Comparator: Timolol 0.5%|Timolol 0.5% administered once in the morning and once in the evening for up to 20 months.
223821272|NCT02247804|OTHER|Sham: Applicator Without Needle|Sham administered on Day 1, Week 16, and Week 32.
223821273|NCT02247804|DRUG|Timolol Vehicle (placebo)|Timolol vehicle administered once in the morning and once in the evening for up to 20 months.
223821274|NCT01646684|DRUG|SOM230|
223821275|NCT05716789|PROCEDURE|CPR|CPR in cardiac arrest patients
223821276|NCT03456167|OTHER|RecoverWell mobile app for follow-up care|The mobile app follow-up care is an application that can be loaded onto a smartphone. It allows the patient to submit photos of their surgical site, QoR15 scores, and EORTC selected adverse events scores. The information collected is transmitted to members of the surgical team (i.e. the primary surgeon) and used to monitor recovery over the first 6 weeks following surgery.
223821277|NCT02917265|DEVICE|TENS for vagus stimulation|TENS electrodes are applied on an area of the external ear innervated by the auricular branch of the vagus nerve.
223821278|NCT02917265|DEVICE|TENS for sham stimulation|TENS electrodes are applied on an area of the external ear devoid of vagus innervation.
223821279|NCT05377970|OTHER|Thinkific Prehabilitation Exercise Program|Prehabilitation exercise program through the Thinkific platform
223821280|NCT00128622|BIOLOGICAL|denileukin diftitox|
223821281|NCT00128622|BIOLOGICAL|recombinant fowlpox-CEA(6D)/TRICOM vaccine|
223821282|NCT00128622|BIOLOGICAL|therapeutic autologous dendritic cells|
223821283|NCT00722995|PROCEDURE|Sleeve gastrectomy|Laparoscopic sleeve gastrectomy is a restrictive procedure for the treatment for morbid obesity
223821284|NCT00722995|PROCEDURE|Gastric Bypass|Laparoscopic gastric bypass is a restrictive and difficult absorption procedure for the treatment of morbid obesity
223821285|NCT02326350|DRUG|Aspirin 75mg|Active treatment
223821286|NCT02326350|DRUG|Lactose powder|Placebo
223821287|NCT04213313|DRUG|Treatment of bacterial keratitis|0.3% Levofloxacin Eye Drops or 0.3% Tobramycin Eye Drops QID
223821288|NCT04213313|DRUG|Treatment of fungal keratitis|1% Fluconazole Eye Drops or 0.25% Amphotericin B Eye Drops QID
223821289|NCT04213313|DRUG|Treatment of viral keratitis|0.1% Acyclovir eye drops QID ，Ganciclovir gel QN，Famiclovir tablets 0.25g TID
223821290|NCT04213313|DIAGNOSTIC_TEST|corneal scraping|culture and sensitivity of corneal ulcerated infiltrating edge tissue
223821291|NCT04213313|OTHER|Sequencing|polymerase chain reaction with sequence specific primers(PCR-SSP) and Sanger sequencing
223821292|NCT05177575|PROCEDURE|Thoracotomy application|The chronic pain findings of the patients who underwent thoracotomy will be questioned at the postoperative 3rd and 6th months.
223821293|NCT04406350|PROCEDURE|Intraoperative tight control of respiratory end-tidal gases|Control of ET CO2 and ET O2 during conduct of anesthesia.
223821294|NCT03621293|DRUG|Modulation of Inspired Fraction of Oxygen (FiO2)|"In the two groups, if patient is not in the range of arterial oxygen pressure (PaO2), Inspired Fraction of Oxygen (FiO2) will be modified from 5 percent if difference between target is less than 5 mmHg and from 10 percent if difference from target is higher. A new arterial blood gases (ABG) will be performed 30 minutes later to check for the oxygen target range. When ABG are performed, pulsed oxymetry is compared with arterial saturation (SaO2) to adapt survey. Between each ABG, FiO2 is modified from 5 percent to 5 percent each five minutes until reaching good pulsed oxygen saturation (SpO2) target (that can be modified in function of the comparison of arterial oxygen saturation (SaO2 and SpO2 with ABG).~This management of FiO2 will be done until extubation of the patient."
223821295|NCT02218840|OTHER|Smoking topography|Evaluation of cigar smoking topography
223821296|NCT00714623|DEVICE|Sirolimus-Eluting Bx Velocity Coronary Stent (CypherTM Sirolimus-Eluting Stent)|Indications for use: The CYPHER™ Sirolimus-eluting Coronary Stent is indicated for improving coronary luminal diameter in patients with symptomatic ischemic disease due to discrete de novo lesions of length less than or equal to 30 mm in native coronary arteries with a reference vessel diameter between 2.5 and 3.5 mm. Long-term outcome (beyond 12 months) for this permanent implant is unknown at present.
223821297|NCT03942380|DIAGNOSTIC_TEST|Liquid biopsy|The intervention is a liquid biopsy as a blood sample taken in a peripheral vein. The blood samples are analyzed for cell free DNA, RNA and HPV-DNA
223821298|NCT01015313|OTHER|intensive sodium management|"1. dietary sodium restriction~2. avoiding positive sodium balance during dialysis by: aligning dialysate sodium with plasma sodium, avoiding sodium profiling, and avoiding saline solutions to treat intradialytic symptoms"
223821299|NCT00980005|BIOLOGICAL|GSK investigational vaccine GSK1557482A|One intramuscular injection for primed subjects, two intramuscular injections for unprimed subjects
223821300|NCT00980005|BIOLOGICAL|Fluzone®|One intramuscular injection for primed subjects, two intramuscular injections for unprimed subjects
223821301|NCT01285284|OTHER|Music|A previously defined list of songs will be administered by headphones to these patients.
223821302|NCT01285284|OTHER|No music|No music will be administered by the headphones connected to the MP3 device.
223821303|NCT02378519|BEHAVIORAL|Web-prog, followed by CBT + PT|This arm of the single system experimental design starts with a baseline phase of 8 weeks where the subjects are introduced into to the interactive web-based self-help program. The baseline-period is followed by the intervention period which consists of a continued use of the interactive web-based self-help program, now with with cognitive behavioral therapy coaching in combination with individually tailored physiotherapy according to the person's needs for 16 weeks.
223821304|NCT02378519|BEHAVIORAL|Base, followed by Web + CBT + PT|The intervention consists of a interactive web-based selfadministrated program with cognitive behavioral therapy coaching in combination with tailored physiotherapy according to the person's needs for 16 weeks.
223821305|NCT01026714|DRUG|flurbiprofen|assessment of flurbiprofen plasmatic and capillary rates
223821306|NCT01026714|DRUG|flurbiprofen, rifampicin|assessment of flurbiprofen plasmatic and capillary rates
223821307|NCT01026714|DRUG|flurbiprofen + fluconazole|assessment of flurbiprofen plasmatic and capillary rates
223821308|NCT03811106|DEVICE|NeuromuscularElectricalStimulation+ConventionalPhysiotherapy|Sırt ekstansör kaslarına nöromusküler elektrik stimülasyonu uygulanacaktır
223821309|NCT03811106|OTHER|Conventional physiotherapy and rehabilitation|Konvansiyonel fizyoterapi ve rehabilitasyon uygulamaları yapılacaktır.
223821310|NCT00204308|DRUG|Combination tenofovir-emtricitabine|Tenofovir disoproxil 300 mg / emtricitabine 200 mg taken as a single dose during labor
223821311|NCT04106843|DRUG|Lutetium Lu 177 Dotatate|Given IV
223821312|NCT04426084|OTHER|Hypertension|Exposure : Any registered diagnosis of I10 within 15 years or a registered pick-up of a prescription of antihypertensive treatment (ATC C02CA, C02DB02, C03, C07, C08, C09) within one year before index date in the Swedish prescribed drug register (exluding those with a registered diagnosis of other indications for betablocker (heart failure, atrial fibrillation) or ACE-inhibitor, ARB(heart failure) ) Exposures will be compared between cases and controls and between cases with different outcomes and controls
223821313|NCT04426084|OTHER|Diabetes type 2|"Exposure: Any registered diagnosis of E11 within 15 years or a registered pick-up of a prescription with any antidiabetic treatment (ATC A10) within one year before index date in the Swedish prescribed drug register.~Exposures will be compared between cases and controls and between cases with different outcomes and controls"
223821314|NCT04426084|OTHER|Obesity|Exposure: Diagnosis ICD E66 within 15 years before index date Exposures will be compared between cases and controls and between cases with different outcomes and controls
223821315|NCT04426084|DRUG|Antihypertensive Agents|"Pick up of a prescription of C02CA, C02DB02, C03, C07, C08, C09 registered in the Swedish prescribed drug register within 6 month before index date.~Exposures will be studied separately for each antihypertensive class and compared between cases and controls and between cases with different outcomes and controls"
223821316|NCT04426084|DRUG|Statins (Cardiovascular Agents)|Pick up of a prescription of C10AA registered in the Swedish prescribed drug register within 6 month before index date.
223821317|NCT04426084|OTHER|Chronic kidney disease|Exposure: Diagnosis ICD N18 within 15 years before index date Exposures will be compared between cases and controls and between cases with different outcomes (mechanical ventilation, continuous renal replacement therapy mortality) and controls. Exposures will thereafter be compared in subgroups by BMI at ICU-admission and in subgroups matched by history of type 2 diabetes.
223821318|NCT02893683|OTHER|Paris Visual Learning Test|
223821319|NCT00692406|BEHAVIORAL|Smoking Abstinence|Smokers were scanned after having quitting smoking for 24 hours, and scanned after smoking as usual.
223821320|NCT01474460|DIETARY_SUPPLEMENT|phytonadione|Phytonadione 200mcg PO daily for 6 months + normal dose of warfarin and standard of care treatment
223821321|NCT00825032|PROCEDURE|comprehensive PR|Inpatient comprehensive PR program that lasted lasted 3 weeks and included a minimum of 15 daily sessions of specific training for lower extremities, education, nutritional intervention, psychosocial intervention. It complied with the recommendation of the ATS/ERS.
223821322|NCT00825032|PROCEDURE|UEET|Experimental program consisting of 15 additional daily sessions of unsupported UEET.
223821323|NCT02082626|DRUG|Eribulin mesylate|
223821324|NCT01627080|OTHER|Cardiac Biomarker Blood Draws|Blood (about 1 teaspoon) drawn to measure cardiac biomarkers at the following time points: within 12-24 hours of the start of radiation, one (1) time during the third week of radiation, within 48 hours after completion of radiation, and about 1 to 2 months after completion of radiation therapy.
223821325|NCT05424445|DRUG|Misoprostol|Women presenting at the study site with an indication for IOL will receive written and oral information about the study. They will have the opportunity to ask questions. If the woman agrees to participate and is deemed eligible, she will sign informed consent. The Swedish national guidelines regarding the method of IOL will be followed. Women will have an abdominal palpation to exclude malpresentation, a CTG, and a digital cervical exam to establish bishop score (BS) prior to inclusion (as per clinical practice). Randomization will be performed by the attending physician, midwife or study coordinator. Randomization will be by opening numbered opaque sealed envelopes in sequential order containing the randomization code. There are no restrictions for use of other medications. All concomitant medication will be recorded in the CRF.
223821326|NCT05971134|BEHAVIORAL|Acupreesure applied|Acupressure was applied to the LI4 acupuncture point for 3 minutes by the researcher for the intervention group
223821327|NCT05666414|PROCEDURE|sandwich interpositional bone grafting computer guided|performing the 2 vertical and the 1 horizontal osteotomies using a cutting patient specific guide and fixation of the vertically elevated bony segment after gap calculation using patient specific fixation guides
223821328|NCT05666414|PROCEDURE|conventional interpositional bone grafting|performing the conventional interpositional sandwich osteotomies free-hand and fixation of the mobilized bone segment free-hand
223821329|NCT05461690|DRUG|Niraparib|200mg once a day for patients with body weight \<77kg or baseline platelet count \<150,000/µL, and 300mg once a day for patients with body weight ≥ 77kg and baseline platelet count ≥ 150,000/µL until disease progression or intolerable toxicity whichever occurs first.
223821330|NCT03102658|DRUG|Micafungin|Administration of study drug
223821331|NCT04116944|BEHAVIORAL|Resistance exercise training|The ecologically-valid resistance exercise training was designed according to World Health Organization and American College of Sports Medicine guidelines. The eight-week, twice-weekly intervention was designed to be performed at a moderate intensity. The resistance of each exercise was such that when participants could successfully complete 2 sets of 12 repetitions at a certain load, the resistance was increased incrementally up to 5% for the following session. Exercise sessions were scheduled with at least one day of rest between sessions. The eight exercises included the barbell squat, barbell bench press, hexagon bar deadlift, dumbbell shoulder lateral raise, barbell bent over rows, dumbbell lunges, dumbbell curls, and abdominal crunches.
223821332|NCT04116944|OTHER|Wait-list|Participants randomized to the delayed-start wait-list condition completed questionnaires once-weekly. The investigator sent a weekly email to the participant providing links to the questionnaires. Participants that completed the eight-week wait-list condition were offered the eight weeks of RET either immediately upon completion, or later at a time of their convenience while the trial was ongoing. Each participant randomized to the eight-week wait-list also completed two 30-minute bouts of seated quiet rest in an empty room at weeks one and eight.
223821333|NCT05977920|OTHER|Caffeine|s. description
223835533|NCT03613779|COMBINATION_PRODUCT|LUS-guided therapy|Lung ultrasound guided therapy; if pulmonary congestion (more or equal than 3 B-lines), high dose (80-120mg PO/day furosemide) will be prescribed until next follow up re-assessment. If no congestion (less than 3 B-lines), low dose (0-40mg PO/day furosemide) will be prescribed until next follow up re-assessment
223835534|NCT03613779|OTHER|Standard of Care|Standard of care will be provided.
223835535|NCT00002087|DRUG|Alvircept sudotox|
223821334|NCT02476214|BEHAVIORAL|group prenatal care|"Intervention group Groups of 8-12 women who are in similar week of pregnancy / due date. The first group session will begin at 12-14 week (depends on gestational age at first OBGYN visit). The group meetings will be held once a month until 28 weeks of pregnancy. From 28 weeks and until the end of pregnancy or 40 weeks, it will be held once every two weeks (according to the Ministry of Health guidelines). The last session will be held approximately 6 weeks after birth.~There will be about 10 group sessions. Each session will be around 90 minutes. At the beginning of every group meeting, the nurse will preform a short anamnesis and measures in private, followed by discussion and guidance. At the end of the session, if needed, women can have private time with the nurse."
223821335|NCT05284292|DEVICE|GUARDIAN platform|The enrolled elderly subjects and their caregivers will use at home the GUARDIAN platform consists of the Senior App, the Caregiver App and the Misty II robot.
223821336|NCT01617005|DRUG|Tocilizumab|Participants will receive tocilizumab treatment according to effective official SPC. The study protocol does not enforce treatment initiation and also does not specify any treatment regimen.
223821337|NCT02869919|OTHER|AKI|Vitamin D levels
223821338|NCT00547690|OTHER|Acupuncture and Strengthening|Acupuncture and strengthening
223821339|NCT00547690|OTHER|Strengthening Alone|Strengthening training program
223821340|NCT02720289|OTHER|Video-based social learning class|Brief child passenger safety lecture by a child passenger safety technician and viewing of a car seat video.
223821341|NCT02720289|OTHER|Traditional didactic class|Child passenger safety lecture by a child passenger safety technician.
223821342|NCT04151875|DEVICE|Extraction orthodontic treatment|orthodontic treatment with teeth extraction
223821343|NCT04151875|DEVICE|Non-extraction orthodontic treatment|Non-extraction orthodontic treatment
223821344|NCT04232189|OTHER|no intervention|no intervention, just specimen collection
223821345|NCT04323982|PROCEDURE|new surgical procedure|（ACCC + I / A + PCCC + TA+ A-vit) or （ACCC + I / A + PCCC + IOL + TA + A-vit）
223821346|NCT04323982|PROCEDURE|traditional surgical procedure|（ACCC + I / A + PCCC + A-vit) or （ACCC + I / A + PCCC + IOL + A-vit）
223821347|NCT01698658|OTHER|ultrasound tomography|Undergo ultrasound tomography using SoftVue
223821348|NCT01698658|PROCEDURE|magnetic resonance imaging|Undergo MRI of the breast
223821349|NCT01159223|DRUG|ATV/r|All participants will be randomized to take ATV/r 200 mg/100 mg OD or ATV/r 300/100 mg OD. NRTIs background regimens will remain unchanged if possible. NRTIs background may include zidovudine/lamivudine, zidovudine plus ddI, ddI plus lamivudine, tenofovir plus lamivudine, tenofovir/emtricitabine, zidovudine plus tenofovir. NRTI backbone could be switched or modified due to toxicity or intolerance
223821350|NCT01762423|DEVICE|Active Device (IVIVI SofPulse)|
223821351|NCT01762423|DEVICE|Sham Device|
223821352|NCT05713682|PROCEDURE|alveolar ridge preservation|bone grafting at extracted sites
223821353|NCT06031597|RADIATION|radiotherapy|"Radiotherapy techniques: Volumetric-modulated arc therapy (VMAT) and image guided radiotherapy (IGRT).~Radiotherapy dose: Radical prescription dose of 60 gray (Gy) ± 10%, 2 Gy per session, once a day, 5 days a week."
223821354|NCT06031597|DRUG|Platinum-Based Drug|Cisplatin 25 mg/m2 once per week for a total of 5-6 cycles. For participants who have not completed 4 cycles of conversion chemotherapy in combination with immunotherapy, the original chemotherapy regimen may also be used, with the total number of chemotherapy cycles not exceeding 6 cycles.
223821355|NCT06031597|DRUG|Immunotherapy|Concurrent programmed cell death 1 (PD-1) or programmed cell death L1 (PD-L1) inhibitors every 3 weeks during radiotherapy and no more than 3 doses during the course of radiotherapy.
223821356|NCT06031597|DRUG|Immunotherapeutic Agent|All participants will be evaluated within 1-42 days after receiving radiation (chemotherapy). If disease progression does not occur, adjuvant therapy with a PD-1 or PD-L1 inhibitor is continued until disease progression up to 1 year.
223821357|NCT00288028|DRUG|bortezomib|Dose of Bortezomib\* Level 1: 1.3 mg/m2 on Day 1, 4, 8, 11 - Every 21 days; Level 2: 1.3 mg/m2 on Day 1, 4, 8, 11 - Every 28 days; Level 3: 1.0 mg/m2 on Day 1, 8, 15 - Every 28 days; Level 4: 1.0 mg/m2 on Day 1, 8, 15 - Every 35 days
223821358|NCT03758118|DIETARY_SUPPLEMENT|Citicoline|Citicoline administered in oral solution
223821359|NCT05825664|PROCEDURE|Endoscopic resection|Group 1: Polyps are resected by UEMR Group 2: Polyps are resected by CEMR
223821360|NCT04973111|DRUG|CT-868 as SC Injection|CT-868
223821361|NCT04973111|DRUG|Placebo as SC Injection|Placebo
223821362|NCT04973111|DRUG|Active Comparator as SC Injection|Active Comparator
223821363|NCT00185510|DRUG|Methylprednisolone Aceponate (Advantan, BAY86-4862)|In maintenance phase, Methylprednisolone Aceponate cream is applied topically twice a week.
223821364|NCT00185510|DRUG|Placebo|2 days a week Vehicle (Advabase)
223821365|NCT02300285|DEVICE|Continuous Glucose Monitoring|Continuous glucose monitors (CGM) will be used to monitor blood sugar levels in enrolled subjects. CGMs measure blood sugar in the tissue just under the skin every few seconds and report average blood sugar every 5 minutes. In our study, the CGMs will function as monitoring systems. In the CGM protocol group the CGM will let the medical team know if there is a concerning blood sugar level, so that the medical team can then check a blood sugar level by the standard way (usually in a small drop of blood) and then decide if they need to give any medical treatment. In the Standard of Care group the CGM data will not be visible to the medical team but the medical team will be informed by the researchers if there are multiple unrecognized episodes of severe hypoglycemia.
223821366|NCT00827593|BEHAVIORAL|Standard behavioral weight loss treatment|Participants will receive 12 months of university-based behavioral weight loss treatment
223821367|NCT00827593|BEHAVIORAL|Weight Watchers|Participants will receive 12 months of Weight Watchers
223821368|NCT00827593|BEHAVIORAL|Combined Treatment|Participants will receive university-based behavioral weight loss treatment followed by Weight Watchers
223821369|NCT06335108|PROCEDURE|General Anaesthesia|Breast surgery is carried out under general anesthesia.
223821370|NCT06335108|PROCEDURE|Local tumescent anaesthesia|Breast surgery is carried out under local tumescent anesthesia.
223821371|NCT03946800|BIOLOGICAL|MEDI1191|Subjects will receive MEDI1191 (at least twice)
223821372|NCT03946800|BIOLOGICAL|Durvalumab|Subject will receive durvalumab every 4 weeks
223821373|NCT04658186|DRUG|UCB0599|Drug: UCB0599 Pharmaceutical form: Granules in capsules Route of administration: Oral use Participants will receive UCB0599 in a pre-specified sequence during the Treatment Period.
223821374|NCT04658186|DRUG|Placebo|Drug: Placebo Pharmaceutical form: Capsules Route of administration: Oral use Participants will receive Placebo in a pre-specified sequence during the Treatment Period.
223821375|NCT05652036|BIOLOGICAL|Intradetrusor Botox Injections|100 units of OnabotuliumtoxinA is injected into the detrusor muscle in 1 mL aliquots using a cystoscope.
223821376|NCT05675332|BEHAVIORAL|Task-based behavioral intervention|Brief behavioral intervention is absent of stressors.
223821377|NCT05675332|BEHAVIORAL|Task-based behavioral intervention|Brief behavioral intervention involves interacting with common everyday types of stress.
223821378|NCT05335109|DRUG|Xenon|"Xenon is injected into the body by inhalation in the form of xenon-oxygen mixtures, in which the concentration of xenon is 30%, and oxygen is 30%.~Xenon inhalation is carried out for 30 min daily for 3 days."
223821379|NCT05335109|DRUG|Oxygen 30 %|"Oxygen-air mixture is injected into the body by inhalation. The oxygen concentration is 30%.~Inhalation of oxygen-air mixture is carried out for 30 min daily for 3 days"
223821380|NCT05437822|DRUG|Tranexamic acid|2 g of tranexamic acid in 50 mL of saline
223821381|NCT03754205|DEVICE|Microablative Fractional CO2 laser|3 therapies intravaginally administered will be applied at monthly intervals
223821382|NCT06465277|DIAGNOSTIC_TEST|Dobutamine stress CMR|"Dobutamine stress testing will be undertaken in keeping with local departmental clinical guidelines with a graded increase in dobutamine infusion up to a maximum of 10microgram/kg/min. The patients' medications will be managed in keeping with the usual clinical practice and departmental guidelines.~At rest and on each graded level of dobutamine infusion we will collect cine loops of the cardiac cycle including a short-axis stack of the ventricles, a four-chamber view and flow imaging perpendicular to the main, left and right pulmonary arteries.~Post-processing will be dual reported by blinded observers using the Argus analysis software (Siemens) according to a standardised protocol. A safety report of each CMR scan will be generated by a consultant cardiologist, any abnormalities identified will be referred to the appropriate medical speciality and highlighted to the patient's clinical team."
223821383|NCT06465277|DIAGNOSTIC_TEST|Cardiac biomarker sample|blood samples will be collected pre-operatively, in recovery, on post-operative days 1 and 2, and at 4-8 weeks post-operatively
223821384|NCT04250753|OTHER|Walking task|30 meters walking task (15 meters round trip) following by a rest period of 2 minutes. Participants are invited to perform the 30 meters walking task twice. Inertial sensors are put on each participant foot.
223821385|NCT03546348|OTHER|no intervention|only measurement of the carrying angle
223821386|NCT03264963|OTHER|Smart phone game play|Voice controlled smart phone game play 15 minutes daily and recording sounds of sleep environment 2 night per week for 12 weeks
223821387|NCT03264963|OTHER|Control|Recording of sleep environment 2 nights per week for 12 weeks
223821388|NCT04808375|OTHER||
223821389|NCT02320747|OTHER|Tai Chi|
223821390|NCT02286167|OTHER|Diet modification|All patients will be participate in the intermittent, modified Atkins diet
223821391|NCT04859894|DIAGNOSTIC_TEST|Physiological testing|Cardiopulmonary exercise testing, Lung Function Testing and in some cases echocardiography. 20 subjects will perform DNA-methylation testing.
223821392|NCT03589742|DEVICE|AblaView® Ablation Catheter|The AblaView® Ablation Catheter is a regular RF ablation catheter with the same physical characteristics and the same biocompatible materials, with an 8 French (2.66 mm) sheath and 180º deflection angle. The tip of the catheter has 15 holes distributed around it where the irrigation will be delivered into the patient's blood. The front irrigation hole will deliver at the same time the infrared light for the OCR system.
223821393|NCT02760329|PROCEDURE|Blood draw|Biomarkers analyses
223821394|NCT02760329|PROCEDURE|Urine|Biomarker analyses
223821395|NCT02760329|PROCEDURE|Lung function measurements|FEV1, FVC, PEF, FEF25-75%, IC, calculated FEV1/FVC ratio and calculated FEV1 % predicted
223821396|NCT02760329|PROCEDURE|Fractional Exhaled Nitric Oxide (FENO)|Measures level of exhaled nitric oxide.
223821397|NCT02954458|DRUG|TED|0.05 mg/kg SC injection once daily.
223821398|NCT02954458|OTHER|SOC|Standard safety assessments and adjustments in nutritional support.
223821399|NCT02954458|DEVICE|Syringe|Teduglutide will be administered using syringe.
223821400|NCT02954458|DEVICE|Needle|Teduglutide will be administered using needle.
223821401|NCT02690077|PROCEDURE|Family-Centered Cesarean|Procedure involves lowering part of the surgical drape exposing a transparent window through which the mother can watch the birth of her baby; the baby will be placed on her chest immediately after the delivery. Cleaning and evaluation of the baby will be done by a nurse who is standing at the head of the bed.
223821402|NCT02690077|PROCEDURE|Traditional Cesarean|Procedure involves keeping the surgical drape up throughout the entire surgery so that the birthing process will not be visible to the mother, and the baby will be taken to the warmer to be evaluated and cleaned after birth but is available to be laid on the mother's chest at any point upon request.
223821403|NCT05472584|OTHER|Electrophysiology assessment - corticospinal tract|Kinematics and cortical spinal motor excitability
223821404|NCT05472584|OTHER|Electrophysiology assessment - reticulospinal tract|Kinematics and reticular spinal motor excitability
223821405|NCT05472584|OTHER|Electrophysiology assessment - spinal motoneuron|Kinematics and spinal motoneuron excitability
223821406|NCT05472584|OTHER|Activity-based training|Motor task
223821407|NCT05472584|OTHER|Transcutaneous spinal cord stimulation|Non-invasive spinal cord stimulation
223821408|NCT01845974|DEVICE|ThermoCool® SF NAV Catheter|The experimental group will receive the low flow catheter (ThermoCool® SF NAV Catheter) All data will be collected pre and post procedure therefore patients will act as their own control within each therapeutic group.
223821409|NCT01845974|DEVICE|ThermoCool® catheter|The control group will receive the higher flow catheter (ThermoCool® catheter). All data will be collected pre and post procedure therefore patients will act as their own control within each therapeutic group.
223821410|NCT04399460|OTHER|Dairy-based commercially available food products|Full-fat milk (3.25% milk, 250 mL), assortment of yogurts, and cheeses
223821411|NCT04399460|OTHER|Restrictive Eating|Dietitian will assist with 500 kcal/day reduction through limiting of macronutrients 45-65% energy from carbohydrates 20-35% energy from fat 10-35% energy from protein
223821412|NCT03486587|DRUG|Bacillus Cereus tablets|Bacillus Cereus tablets was taken two tablets three times a day.
223821413|NCT05408468|BEHAVIORAL|FAMCOPE-ICU|(1) FAMCOPE-ICU is a digital eHealth emotion regulation and coping intervention. FAMCOPE-ICU contains three digital modules representing the three interventional doses. Corresponding with Gross's Extended Process Model of Emotion Regulation, the three respective doses entail assessments, adaptive feedback, and interactive activities pertaining to understanding their affective experiences, learning strategies to regulate emotions and stress, and practicing these skills in a virtual decision-making task. Each dose of the intervention is expected to last 10-15 minutes
223821414|NCT04186403|DRUG|Brexpiprazole|Administered as tablets.
223821415|NCT06844539|DEVICE|Fully automated insulin delivery with CamAPS HX|Fully automated insulin delivery with CamAPS HX app, Libre 3 glucose sensor and Ypsopump insulin pump.
223821416|NCT06844539|DEVICE|Standard diabetes therapy with a glucose sensor|Standard diabetes therapy with a Freestyle Libre 3 glucose sensor
223821417|NCT05889884|DEVICE|Extended maxillary fixed retainer|Bonding extended maxillary fixed retainer from right first maxillary premolar to left maxillary first premolar for 6 months then assessment of relapse using 3D superimposition , little index , lateral cephalometric assessment along with PDL assessment with quality of life ,function and speech assessment
223821418|NCT04879199|DIAGNOSTIC_TEST|Static stability measurement|"The child stands barefoot on dual force platforms in two (CP: three) different conditions: barefoot and with shoes (CP: and with orthosis). Each condition is recorded three times each lasting for 30s, and 30s rest between them. Both conditions are recorded with and without wearing a headset. The order of conditions (within each Virtual Reality (VR)-condition) is randomized. For each condition, the child rests in a comfortable position for 20s with the heels on the same level and arms hanging at their sides. Between both VR-conditions, the child rests for 120 s."
223821419|NCT04879199|DIAGNOSTIC_TEST|Dynamic stability measurement|"The child walks at their normal walking speed on a 10-m walkway in two (CP: three) different conditions: barefoot and with shoes (CP: and with orthosis). For each condition, at least six error-free trials are recorded. Errors in data may occur due to hidden or lost markers during walking or software interruptions. Both conditions are recorded with and without wearing a headset. The order of conditions (within each VR-condition) is randomized."
223821420|NCT02820363|DEVICE|"CERAMENT|G"|"Surgical repair of tibia fracture, CERAMENT™\|G applied to bony voids."
223821421|NCT02820363|PROCEDURE|SOC treatment|surgical repair of tibial fracture
223821422|NCT00930943|DRUG|Oxymorphone ER|40 mg qd twice
223835536|NCT02430636|PROCEDURE|Irreversible electroporation (IRE)|Irreversible Electroportion For Unresectable Stomach Neoplasms guide with ultrasound or/and CT.
223835537|NCT02430636|DEVICE|NanoKnife|
223835538|NCT05401682|OTHER|Cox chiropractic care|Manual distraction of spine in a prone position using specially assisted table
223821423|NCT01618890|PROCEDURE|Hepatic venous pressure gradient measurement|"Perform baseline HVPG measurement, then start propranolol 20 mg orally twice daily (BID), increase the dose stepwise to maximum tolerated dose. After 4 weeks a second HVPG is performed.~In hemodynamic nonresponders from the study arm, repeated endoscopic band ligation is performed in daycare setting with intervals of 2-4 weeks.~In hemodynamic responders (HVPG second measurement\< 12 mmHg or \>20% reduction in HVPG compared to baseline) beta-blockers are continued until end of follow-up."
223821424|NCT06439940|DIAGNOSTIC_TEST|Blood sample extraction|We do not alter the patient\&#39;s regular gynecological check-up in any way. The patient will undergo a mammogram and a blood draw. We will then separate a small aliquot of blood for the purposes of the research protocol.
223821425|NCT05762848|DEVICE|Mobile Phone Head Circumference App|Measurement of Head circumference of Babies/Infants with a mobile phone application.
223821426|NCT05189054|RADIATION|stereotacitic body radiation therapy|The patients were treated with high-dose and low fractionated radiotherapy, using modern precision radiotherapy technology.
223821427|NCT00578721|DRUG|Aspirin|325 mg taken daily with an arginine-restricted diet
223821428|NCT02440347|DEVICE|Computer controlled anesthetic delivery by Anaeject|Single dose of 0.6ml 4% articaine with epinephrine (1:100.000) delivered by computer controlled local anesthetic delivery system (Anaeject).
223821429|NCT02440347|DEVICE|Conventional anesthetic delivery by carpule syringe|Single dose of 0.6ml 4% articaine with epinephrine (1:100.000) delivered by conventional syringe (carpule syringe).
223821430|NCT00405639|DRUG|Nesiritide|Subjects randomized to this arm will receive 5 microgram/Kg subcutaneous (SQ) injection of nesiritide on Day 1. If after the first SQ injection the subject's systolic blood pressure is \>90 mmHG and no symptoms of hypotension, then the second dose can be increased to 10 microgram/Kg. Subjects will self-administer the second dose 12 hours after the first dose, then self-administer the third dose 12 hours after the second dose. Subjects will be dismissed with instructions and supplies for 6 weeks of SQ administration twice a day. After 6 weeks, the subjects will return to the lab for assessments, and will be dismissed with supplies for 6 more weeks of SQ administration twice a day.
223821431|NCT00405639|DRUG|Placebo|Normal saline will be used for placebo.
223821432|NCT03992534|COMBINATION_PRODUCT|LACTIN-V|Vaginal supplementation with L. crispatus CTV-05.
223821433|NCT00612534|DRUG|Sufentanil NanoTab|5 mcg Sufentanil NanoTab taken sublingually q 20 minutes as needed for pain for 12 hours
223821434|NCT00612534|DRUG|Placebo NanoTab|Placebo NanoTab taken sublingually q 20 minutes as needed for pain for 12 hours
223821435|NCT00612534|DRUG|Sufentanil NanoTab|10 mcg Sufentanil NanoTab taken sublingually q 20 minutes as needed for pain for 12 hours
223821436|NCT00612534|DRUG|Sufentanil NanoTab|15 mcg Sufentanil NanoTab taken sublingually q 20 minutes as needed for pain for 12 hours
223821437|NCT00265330|DRUG|Ziprasidone oral capsules|Study medications will include oral ziprasidone capsules of 20 mg, 40 mg, 60 mg, and 80 mg strength. Subjects will be dosed daily for 26 weeks using a flexible dose design with a minimal dose range of 20mg bid to a maximum dose range of 80 mg bid .
223821438|NCT00142922|BEHAVIORAL|Breaking Down Barriers|completed
223821439|NCT02039661|DRUG|Lidocaine Spray|These patients received 2 puff lidocaine spray
223821440|NCT02039661|DRUG|Placebo|
223821441|NCT00853281|OTHER|Hammocks with LLIN|Locally-made hammocks covered with long lasting insecticidal nel (LLIN)
223821442|NCT00853281|OTHER|Standard vector control measures|Insectice-treated net
223821443|NCT02688465|DRUG|Apomorphine|
223821444|NCT03482856|BEHAVIORAL|MNA plus CBT-I|MNA plus CBT-I includes 3 sessions (1 group, 1 online and 1 individual session) of therapeutic pain neuroscience education, 6 individual sessions of CBT-I and 9 individual sessions of time-contingent dynamic and functional cognition-targeted exercise therapy, combined with home exercises. CBT-I is the standard evidence-based care for treating chronic primary insomnia and typically includes changing negative thoughts about sleep, sleep hygiene, sleep restriction therapy, and teaching relaxation skills. The 18 sessions will be spread over a period of 14 weeks.
223821445|NCT03482856|BEHAVIORAL|MNA alone|MNA alone includes 3 sessions (1 group, 1 online and 1 individual session) of therapeutic pain neuroscience education, and 15 individual sessions of time-contingent dynamic and functional cognition-targeted exercise therapy, combined with home exercises. The 18 sessions will be spread over a period of 14 weeks.
223821446|NCT00722384|DRUG|bevasiranib|
223821447|NCT00722384|DRUG|bevasiranib|The first three patients enrolled will receive 0.1 mg Cand5 in the study eye, the next three patients enrolled will receive 0.33 mg Cand5 in the study eye, the following three patients enrolled will receive 1.0 mg Cand5 in the study eye, the following three patients enrolled will receive 1.5 mg Cand5 in the study eye, and the remaining three patients enrolled will receive 3.0 mg Cand5 in the study eye. The third patient enrolled at each dose level will complete their two-week visit before the next dose level group may be treated.
223821448|NCT06345001|DRUG|BAY3630942|IV, Single administration
223821449|NCT06345001|DRUG|BAY3547922|IV, Single infusion
223821450|NCT06028035|DIETARY_SUPPLEMENT|BB01|20 grams minimally processed form of Hemp hulls in the form of a bar/wafer.
223821451|NCT02553811|DIAGNOSTIC_TEST|accuracy diagnostic|effectiveness of the ultrasonography and electromiography for best performance and diagnostic accuracy in carpal tunnel syndrome
223821452|NCT05922839|DRUG|Zanubrutinib|Zanubrutinib 160mg, orally, twice daily, for a minimum of 3 months, and for effective patients, continue to use for 2 years after achieving optimal therapeutic effect.
223821453|NCT01431040|OTHER|No bowel prep|Participants in this group will have a regular diet and no bowel prep the day prior surgery up until midnight.
223821454|NCT01431040|OTHER|Clear liquid diet and 2 Fleet's enemas|Participants in this group will receive a clear liquid diet and 2 Fleets enemas in the late afternoon prior to surgery.
223821455|NCT01194895|OTHER|protective ventilation|set tidal volume of 5ml/kg during one-lung ventilation
223821456|NCT01194895|OTHER|conventional ventilation|keep tidal volume at 8ml/kg during one-lung ventilation
223821457|NCT02480816|DIETARY_SUPPLEMENT|Mineral water|Intake of 1 L per day of the mineral water (BW or CW) with main meals, crossover design
223821458|NCT02558361|DRUG|Treatment with Apremilast|Standard dosing with apremilast (Otezla) will be used. \[30mg po BID after initial titration\]
223821459|NCT06560411|DEVICE|Non-Invasive Ventilation|Provide continuous or intermittent ventilatory support for the care of individuals who require mechanical ventilation
223821460|NCT01463280|DRUG|tumescent lidocaine infiltration|Tumescent local anesthesia containing dilute lidocaine is infiltrated into subcutaneous tissue prior to liposuction
223821461|NCT00737412|OTHER|Probiotic: Bio-K+ CL1285|The probiotic Bio-K+ CL1285 RX®, a mixture of Lactobacillus acidophilus and Lactobacillus casei, contains over 50 billion living bacteria per administered dose.
223821462|NCT00737412|OTHER|Placebo|Matching capsules devoid of microorganisms
223821463|NCT04075617|DEVICE|electronic habit reminder|Habit reminder in the form of wrist watch with music that display as reminder is one of recent innovations for cessation of the habit in short time and the child accepts it and it's comfortable
223821464|NCT04075617|OTHER|palatal crib|Fixed palatal crib is commonly used and recommended for treating thumb/finger sucking habit.
223821465|NCT05601934|OTHER|Neurophysiological Facilitation Techniques|Increased enlargement of the ribs during inspiration and increased movement in the epigastric region and tone of the abdominal muscles also decreased respiratory rate are some of the changes that occur after these stimuli. In addition to these, involuntary increase in cough, sputum production also decrease in pathological sounds felt on auscultation, decrease in aspiration requirement, rapid return in chest wall stabilization and improvement in respiratory pattern can be observed after application with this application, positive and long-term effective results can be seen in a short time.
223821466|NCT03566303|DRUG|Rivaroxaban 15 mg|Rivaroxaban 15 mg BID
223821467|NCT03566303|DRUG|Warfarin|Warfarin
223821468|NCT05093049|DEVICE|Renuvion APR System|The Renuvion APR Handpiece (K191542) is a sterile, single use electrosurgical (monopolar) device intended to be used in conjunction with compatible generators for the percutaneous delivery of radiofrequency energy and/or helium plasma for cutting, coagulation and ablation of soft tissue. The Renuvion APR Handpiece is compatible with the Electrosurgical Generators BVX-200H/P (K170188), and APYX-JS3/RS3 (K192867) owned by Apyx Medical that are indicated for delivery of radiofrequency energy and/or helium gas plasma to cut, coagulate, and ablate soft tissue during open and laparoscopic surgical procedures.
223821469|NCT05093049|PROCEDURE|Gynecomastia Correction Surgery|Gynecomastia correction surgery as per the investigators standard treatment of care utilizing liposuction.
223821470|NCT01053377|DRUG|Tamiflu (verum)|
223821471|NCT01053377|DRUG|Tamiflu placebo|
223821472|NCT02805426|DRUG|Tranexamic Acid|
223821473|NCT02805426|DRUG|Placebo|
223821474|NCT02805426|DRUG|Misoprostol|
223821475|NCT04768842|DRUG|LY3209590|Administered SC.
223821476|NCT00246987|DRUG|Muraglitazar|
223821477|NCT03322098|DRUG|Atropine|Atropine injection (0.01 mg/kg, max 0.5 mg) within 3 minutes before spinal anesthesia
223821478|NCT03322098|DRUG|Glycopyrrolate|Glycopyrrolate (0.00 4mg/kg, max 0.2 mg) within 3 minutes before spinal anesthesia
223821479|NCT02571374|DIETARY_SUPPLEMENT|symbiotic group|this group received sachets of symbiotic
223821480|NCT02571374|DIETARY_SUPPLEMENT|placebo group|this group received placebo
223821481|NCT06148220|RADIATION|[18F]RCCB6 and [68Ga]Ga-NOTA-RCCB6 PET/CT imaging|Intravenous injection of 3.7 MBq \[0.1 mCi\]/kg of \[18F\]RCCB6 or \[68Ga\]Ga-NOTA-RCCB6 in a single dose
223821482|NCT03186482|DRUG|Descovy® (TAF/FTC)|25/200 mg once daily for 28 days (DAYS 1-28).
223821483|NCT03186482|DRUG|Viread® (TDF)|245 mg once daily for 28 days (DAYS 57-84).
223821484|NCT03186482|DRUG|Rifadin® (Rifampicin)|600 mg once daily for 28 days (DAYS 29-56).
223821485|NCT04146649|PROCEDURE|Arthrocentesis|Patients will receive a joint arthrocentesis to remove fluid from the joint.
223821486|NCT01680393|DEVICE|Sequential compression device|a sequential compression device will be applied to the legs
223821487|NCT01680393|OTHER|TED stockings|TED stockings will be applied to the patients legs during surgery
223821488|NCT03425448|DRUG|Heparin|Heparin hemodialysis catheter lock solution
223821489|NCT03425448|DEVICE|Neutrolin|Neutrolin hemodialysis catheter lock
223821490|NCT03252080|BEHAVIORAL|short-term intensive education|The patients of both groups are given the education classes once a week in the first month (total 4 times), 5 hours per class. The education classes are taught by a dedicated team of diabetes specialist doctors and nurses, with the contents including a basic understanding of diabetes, diabetic diet, exercise, drug treatments and blood glucose monitoring.
223821491|NCT03252080|BEHAVIORAL|Holistic management|The specialist nurses talk individually with the patients for 10-15 min per week. The nurses ask the patients about their results of self-blood glucose monitoring, help them find the reasons of poor blood glucose control as well as answer the patient's questions.
223821492|NCT02205801|PROCEDURE|Superficial Cervical Plexus Block|0.25% Marcaine is injected lateral to the sternocleidomastoid bilaterally (10mL on each side) after induction of anesthesia and prior to incision and scheduled thyroidectomy or parathyroidectomy.
223821493|NCT02205801|PROCEDURE|Local Wound Infiltration|0.50% Marcaine is injected at the site of incision (10mL) after induction of anesthesia and prior to incision and scheduled thyroidectomy or parathyroidectomy.
223821494|NCT02205801|DRUG|0.9% saline|
223821495|NCT02205801|DRUG|Marcaine|
223821496|NCT01677364|DRUG|Oxytocin|Arm - Induction of labour
223821497|NCT02730182|OTHER|altitude exposure|altitude exposure
223821498|NCT06356194|DRUG|Cohort 1: Days 1-7 Bemnifosbuvir (BEM)/Ruzasvir (RZR) co-administered. Days 8-17 Bemnifosbuvir (BEM)/Ruzasvir (RZR) co-administered + Biktarvy (BIK). Days 18-24 BIK|A co-administered dose of Bemnifosbuvir (BEM)/Ruzasvir (RZR) as separate formulations and Biktarvy (BIK)
223821499|NCT06356194|DRUG|Cohort 2: Days 1-10 Biktarvy (BIK). Days 11-17 Bemnifosbuvir (BEM)/Ruzasvir (RZR) co-administered + Biktarvy (BIK). Days 18-24 Bemnifosbuvir (BEM)/Ruzasvir (RZR) co-administered.|A co-administered dose of Bemnifosbuvir (BEM)/Ruzasvir (RZR) as separate formulations and Biktarvy (BIK)
223821500|NCT05401643|OTHER|Xemio mobile application|"The study consists in a mHealth intervention provided through the Xemio mobile application for breast cancer survivors. This application is installed in the personal smartphones of the participants after they are randomized in the mHealth intervention group. The Xemio app components are symptom tracking, up-to-date calendar of events organized by patient's organizations, virtual talks with experts, articles regarding new information of the disease, physical activity tracking, and evidence-based information regarding symptoms, non-pharmacological treatments for side effects, and information about common drugs to treat breast cancer. The participants can freely use the Xemio mobile application for a total of 12 months.~The control group does not have access to the Xemio application for the duration of the study but they are offered access to it at the completion of the intervention. The participants of both arms continued to receive the usual care from their oncology teams."
223821501|NCT05356390|OTHER|Stabilization exercises|"Stabilization training is an active form of physical therapy designed to strengthen muscles to support the spine and help prevent lower back pain.~Group A performed stabilization exercises for 4 weeks. In stabilization exercises, floor bridging, heel prop and alternate arm and leg exercises were administered in iliopsoas, gluteal and hamstring groups.~On eligible participants baseline assessment was done,3 sessions were given 3days per week, post intervention assessment was taken at 4th week."
223821502|NCT05356390|OTHER|Muscle energy techniques|"Muscle Energy Technique (MET) is a is a form of manual therapy, widely used in Osteopathy, that uses a muscle's own energy in the form of gentle isometric contractions to relax the muscles via autogenic or reciprocal inhibition and lengthen the muscle.~Muscle energy techniques were given to group B. These techniques are active form of manual therapy in which patient uses its own energy on request to aid in treatment.~On eligible participants baseline assessment was done,3 sessions were given 3days per week, post intervention assessment was taken at 4th week."
223821503|NCT03945318|DRUG|BION-1301 Single Dose|A solution for IV infusion administered as a single dose.
223821504|NCT03945318|DRUG|Placebo Single Dose|A solution by IV infusion administered as a single dose.
223821505|NCT03945318|DRUG|BION-1301 Multiple Doses|A solution for IV infusion or SC injections (Part 3 only) administered as multiple doses.
223821506|NCT03945318|DRUG|Placebo Multiple Doses|A solution by IV infusion administered as multiple doses.
223821507|NCT03945318|DRUG|BION-1301 Single Dose|SC injection administration as a single dose using vials or pre-filled syringes (PFS) (Part 4 only).
223821508|NCT06214858|DRUG|SHEN211 tablets|SHEN211 tablets, tablets, specification: 0.11g, 10 tablets/box, storage: sealed, not more than 25℃ storage.
223821509|NCT06214858|DRUG|SHEN211 placebo tablets|placebo tablets, tablets, specification: 0g, 10 tablets/box, storage: sealed, not more than 25℃ storage.
223821510|NCT04242433|DRUG|Direct Acting Antivirals|"All subjects with viremic chronic hepatitis C will be given DAAs based on the MMPHCRF Treatment algorithm. Patients will be assessed for cirrhosis, prior treatment exposure, high risk groups like dialysis patients, HIV-HCV coinfection, etc. Accordingly treatment will be provided at any of the 25 peripheral centres or at the apex nodal treatment centre (PGIMER) of the MMPHCRF.~Baseline and post treatment RAS samples will be collected with consent."
223821511|NCT04059692|OTHER|Cervical manipulation intervention|Cervical manipulative technique
223821512|NCT04059692|OTHER|Placebo intervention|Sham intervention
223821513|NCT01547988|OTHER|Balance Training Intervention|The intervention group participated in a total of 24 one-hour training sessions over a period of 12 weeks. The training program utilized different size balls as a general tool in a series of progressively more difficult exercises targeting sitting, standing, and gait-related balance control. The program included exercises at five different levels of progressively more challenging balance exercises. Levels 1-4 focused on voluntarily controlled balance exercises, whereas level 5 also included perturbation exercises to trigger automatic compensatory stepping responses. All levels included attention-demanding dual task exercises that required subjects to simultaneously perform motor and cognitive activities.
223821514|NCT02093325|DRUG|Eltrombopag|This will be a Phase III, randomized, double-blind, placebo-controlled clinical trial. Qualified subjects will be randomly assigned to receive either the test treatment or the placebo at 2:1 ratio. Once subjects are randomized, they will be treated with Arm A: Eltrombopag 50 mg/day (n=55) or Arm B: placebo (n=28) once a day for 7 days.
223821515|NCT02093325|DRUG|Placebo|This will be a Phase III, randomized, double-blind, placebo-controlled clinical trial. Qualified subjects will be randomly assigned to receive either the test treatment or the placebo at 2:1 ratio. Once subjects are randomized, they will be treated with Arm A: Eltrombopag 50 mg/day (n=55) or Arm B: placebo (n=28) once a day for 7 days.
223821516|NCT01443221|DRUG|mitiglinide and metformin|Free combination of Mitiglinide 10mg and Metformin 500mg
223821517|NCT01443221|DRUG|mitiglinide and metformin|Fixed-dose combination of Mitiglinide 10mg and Metformin 500mg
223821518|NCT00002947|RADIATION|indium In 111 pentetreotide|
223821519|NCT03944044|OTHER|Paracetamol route in palliative-care patients: intravenous versus subcutaneous route Pharmacokinetics study protocol|Compare the pharmacokinetic (PK) of SC and intravenous (IV) routes in the same patient in a palliative care situation, to determine if there is a PK equivalence between these two modes of administration of Paracetamol.
223821520|NCT02073825|BEHAVIORAL|Web Brief Intervention (WBI)|4-session WBI
223821521|NCT05541562|DIAGNOSTIC_TEST|clinical laboratory tests, and imaging characteristics|Data included the demographic status, etiology of the liver disease, clinical laboratory tests, and imaging characteristics. Clinical laboratory tests included D-dimer, activated partial thromboplastin time (APTT), prothrombin time (PT), antithrombin III, international normalized ratio (INR), thrombin time (TT), albumin (Alb), serum creatinine, hemoglobin, platelet count, white blood cell count, neutrophil count, lymphocyte count, monocyte count, model for end-stage liver disease (MELD) score, and Child-Pugh score. Imaging characteristics included splenic vein diameter, splenic vein velocity, portal vein diameter, and portal vein velocity.
223821522|NCT01536184|BEHAVIORAL|Circle of Security (COS)|COS is a community based, visually supported, individualized attachment protocol appropriate for use with preschoolers and children and their parents/caregivers. It is based on attachment theory of John Bowlby and Mary Ainsworth and integrates neuroscientific principles of emotional regulation and attachment. The protocol contains both educational and therapeutic components. The goals of the intervention include increasing caregiver sensitivity and appropriate responsiveness to their child through increasing their capacity to recognize and understand their child's cues, and increasing caregiver self-reflection on their own caregiving behaviour.
223821523|NCT05421338|DRUG|BI 456906 (C-14)|BI 456906 (C-14)
223821524|NCT01974700|DRUG|Levetiracetam|500 mg intravenous dose during the operative case then 500 mg orally twice a day for a total of seven days
223821525|NCT03192644|PROCEDURE|TAI|transarterial chemoinfusion with mFOLFOX6 (oxaliplatin, calcium folinate, and 5-FU)
223821526|NCT03192644|PROCEDURE|TACE|transarterial chemoembolization with epidoxorubicin and cisplatin and lipiodol
223821527|NCT03192644|DRUG|epidoxorubicin and cisplatin and lipiodol|epidoxorubicin and cisplatin and lipiodol
223821528|NCT03192644|DRUG|mFOLFOX6 (oxaliplatin, calcium folinate, and 5-FU)|oxaliplatin, calcium folinate, and 5-FU
223821529|NCT02234063|OTHER|Immediate Genetic Testing|Participants will receive the APOL1 genetic test. Trained research staff will meet with participants to communicate results and lifetime ESRD risk attributable to variations in the APOL1 gene. Primary care providers will receive APOL1 genetic risk information via a best practice alert in the participant's EMR upon commencement of a patient encounter and through results filed in the participant's genetics results section of their EMR.
223821530|NCT02813746|DIETARY_SUPPLEMENT|Fitness program|
223821531|NCT02813746|BEHAVIORAL|Stop smoking|
223821532|NCT02813746|PROCEDURE|Endometrial fluid collection|
223821533|NCT04142502|DRUG|Propofol|Propofol as a sedation drug
223821534|NCT04142502|DRUG|Dexmedetomidin|Dexmedetomidine as a sedation drug
223821535|NCT05164302|PROCEDURE|Auricular acupuncture|Auricular acupuncture is a method for diagnosing and treating physical and psychosomatic dysfunctions by stimulating a specific point in the ear. To conducting this intervention, we use press tack needles to perform auricular acupuncture.
223821536|NCT02034253|DRUG|Risperidone|Patients with psychosis will be provided a 16 week regimen of the antipsychotic drug Risperidone in accordance with standard care.
223821537|NCT02503267|OTHER|none intervention|
223821538|NCT00087542|DRUG|ACP-103|
223821539|NCT00830622|OTHER|Cell Phone Intervention|Participant receives weekly SMS text messages from the health care provider.
223821540|NCT04842214|BEHAVIORAL|Oncological Rehabilitation|Multidimensional rehabilitation
223821541|NCT00496405|DRUG|bevacizumab|
223821542|NCT04665024|PROCEDURE|preoperative chest physiotherapy|"The patients were approached to partake in the investigation after they got full clarifications about the point of study. They were allocated into two groups and reassurance was achieved about the absence of any side effects.Furthermore, the examination was approved by the ethical committee.~Effects of preoperative chest physiotherapy were compared between two groups, by measuring the lung functions, oxygen saturation, pulmonary complications and length of hospital staying. Lung functions were completed by utilizing spirometry parameters, oxygen saturation was measured by pulse oximeter and pulmonary complications were diagnosed by specialist doctors."
223821543|NCT04665024|PROCEDURE|postoperative chest physiotherapy|"Postoperative chest physiotherapy made in both two groups was similar to the preoperative chest physiotherapy but this was achieved by physiotherapists and made once a day for 10-25 minutes depending on the lectures of postoperative days."
223821544|NCT04645784|OTHER|Supporting Student-Athletes Mental Wellness|The module addresses: 1) managing your own mental wellness; 2) signs and symptoms of mental health problems; 3) role of student-athletes in creating a positive team environment that is supportive of mental health care seeking; 4) the role of a student-athlete in helping teammates; 5) how to identify emergency and non-emergency mental health situations.
223821545|NCT01416233|PROCEDURE|autologous fat grafting to the orbit|subjects will undergo fat harvesting followed by autologous fat grafting into the orbit into their anophthalmic orbit
223821546|NCT04182854|DRUG|Furosemid hydrochlorothiazide|furosemide 100mg for one month;furosemide 200mg for one month;furosemide 100mg and hydrochlorothiazide 25mg for one month;
223821547|NCT01575743|BEHAVIORAL|aerobic exercising|All participants take part in an aerobic exercise training program with a total weekly energy expenditure of 17.5 kcal/kg/week over the entire 12-week intervention period. The dose of exercise is determined using exercise prescription guidelines established by the American College of Sports Medicine (ACSM, American College of Sports Medicine, 2000). All trainings take place at a local public gym under supervision of previously trained exercise coaches from the Institute of Exercise and Health Sciences of the University Basel. Participants can choose between different training devices for cardiovascular training. Energy expenditure is assessed using the values of burned calories provided by the training devices based on age, weight and training performance. Heart rate is monitored during all training sessions with chest belt heart rate monitors (Polar®) to ensure training below the anaerobic threshold with heart rates between 60 - 75 % of the maximum heart rate.
223821548|NCT05826015|DRUG|Paclitaxel|IV over 3 hours
223821549|NCT05826015|DRUG|Batiraxcept|IV over 60 minutes
223821550|NCT01715610|DRUG|Clavulin|Patients will be randomized to the antibiotic or placebo arm via a random number generator.
223821551|NCT01715610|DRUG|Randomization to Placebo|Patient's post-drainage of antibiotics will receive placebo and not receive antibiotics
223821552|NCT01715610|DRUG|Clindamycin|Patients will be randomized to the antibiotic or placebo arm via a random number generator
223821553|NCT01395654|DRUG|isoniazid, rifampin, pyrazinamide|rechallenge of isoniazid (INH), rifampin (RIF), and pyrazinamide (PZA) aftr recovery from hepatitis
223821554|NCT01407211|DIETARY_SUPPLEMENT|vitamin A|"25000 IU/day vitamin A 6 months~1 Cap/Day~1 cap placebo/day for 6 month"
223821555|NCT04909580|BEHAVIORAL|Decision coaching with a patient decision aid|Decision coaching guided by the Ottawa Decision Support Framework
223821556|NCT04192084|PROCEDURE|microvascular partial toe transfer|we will perform microvascular partial toe transfer for patients with traumatic amputation of one or more digits
223821557|NCT05254639|DRUG|DONEPEZIL|5 mg daily for 4 weeks + 10 mg daily for 12 weeks according to tolerance or efficacy
223821558|NCT05254639|DRUG|PLACEBO|5 mg daily for 4 weeks + 10 mg daily for 12 weeks according to tolerance or efficacy
223821559|NCT02630095|DRUG|Nadroparin Calcium and Warfarin|Patients will take warfarin started at a dose of 2.5mg/d and with titration of dose to maintain a target INR of 2-3, and during the of perioperative period of Endoscopic treatment changing to use Nadroparin Calcium 4100IU／d，subcutaneous.
223821560|NCT02630095|DEVICE|Doppler ultrasound and CT|all patient will take Doppler ultrasound examination every 3 months ；Abdominal CT will be done every 6 months。
223821561|NCT03760263|DRUG|Tacrolimus|Immunosuppressive drug that can prevent organ rejection after transplant in its oral form.
223821562|NCT01222143|DRUG|NOVE-HiDAC|"NOVE-HiDAC consists of mitoxantrone, etoposide, and modified high-dose cytarabine. During induction patients will receive mitoxantrone by IV on Days 6-10, etoposide by IV on Days 6-10 and cytarabine by IV on Days 11-12.~During consolidation patients will be receiving mitoxantrone by IV on Days 1-10 and cytarabine by IV on Days 6, 8 and 10."
223821563|NCT01222143|DRUG|Nilotinib|"The dose of nilotinib will be determined according to a dose escalation design. There will be three dose levels used in the study.~During induction, nilotinib will be given orally on Days 1-12.~During consolidation, nilotinib will be given orally on Days 1-10."
223821564|NCT03800732|OTHER|With Meal during night work|Two nights of work with a meal during the shift and after will go to the laboratory the morning for eating a test meal ad libitum, which will consist of foods of various compositions and food groups. Preprandial metabolic assessments will be conducted (ghrelin, GLP-1 - glucagon-like peptide 1, PYY-peptide YY). The following postprandial evaluations will be carried out and in the 24 hours following the experiment: food choices (record of all foods) and food perceptions (hunger, appetite, satiety and eating).
223821565|NCT03800732|OTHER|Without Meal during night work|Two nights of work without a meal during the shift and after will go to the laboratory the morning for eating a test meal ad libitum, which will consist of foods of various compositions and food groups. Preprandial metabolic assessments will be conducted (ghrelin, GLP-1 - glucagon-like peptide 1, PYY-peptide YY). The following postprandial evaluations will be carried out and in the 24 hours following the experiment: food choices (record of all foods) and food perceptions (hunger, appetite, satiety and eating).
223821566|NCT03800732|OTHER|Sleep night|Two sleep nights and after will go to the laboratory the morning for eating a test meal ad libitum, which will consist of foods of various compositions and food groups. Preprandial metabolic assessments will be conducted (ghrelin, GLP-1 - glucagon-like peptide 1, PYY-peptide YY). The following postprandial evaluations will be carried out and in the 24 hours following the experiment: food choices (record of all foods) and food perceptions (hunger, appetite, satiety and eating).
223821567|NCT05586464|DRUG|Ban xia xie xin Decoction and bismuth quadruplicate group|Ban xia xie xin Decoction:10g of banxia, 10g of huangqin, 6g of coptis chinensis, 6g of dried ginger, 6g of ginseng, 6g of roasted licorice, 6g of Chinese jujube Bismuth quadruplicate: Esomeprazole (nexium, Tablets 20mg/tablet, 20mg bid), amoxicillin ( Tablets 25mg/tablet,100mg bid), furazolidone (Tablets100mg/tablet,100mg bid) and pectin bismuth gel (Gel 150mg/bag, 150mg qid).
223821568|NCT05586464|DRUG|Bismuth quadruplicate group|Bismuth quadruplicate: Esomeprazole (nexium, Tablets 20mg/tablet, 20mg bid), amoxicillin ( Tablets 25mg/tablet,100mg bid), furazolidone (Tablets100mg/tablet,100mg bid) and pectin bismuth gel (Gel 150mg/bag, 150mg qid).
223821569|NCT06480214|PROCEDURE|endoscopic spine surgery|we would administer the endoscopic spine surgery to patients with Lumbar spinal stenosis and Lumbar disc herniation.
223821570|NCT04816019|BIOLOGICAL|ChAdOx1 nCov-19|A single dose of ChAdOx1 nCov-19 delivered intranasally (IN)
223821571|NCT01551004|DRUG|CRS3123|CRS3123, a methionyl-tRNA synthetase inhibitor, will be supplied in 100 and 200 milligram capsules. Subjects randomized to active drug in Cohorts A through E will receive 100 mg, 200 mg, 400 mg, 800 mg and 1200 mg respectively, as a single oral dose.
223821572|NCT01551004|OTHER|Placebo|Matching placebo capsules will be given to 2 subjects of each cohort.
223821573|NCT05683717|DRUG|TT-01488 Tablets|TT-01488 tablet will be administered orally once daily per protocol defined schedule.
223821574|NCT01525134|DEVICE|"Alere Determine lateral-flow urine lipoarabinomannan assay"|"lateral-flow (point-of-care) urine test to detect the lipoarabinomannan (LAM) component of the M. tuberculosis antigen in the urine of TB suspects, in vitro.~Manufacturer: Alere"
223821575|NCT01525134|DEVICE|"Alere Clearview ELISA urine LAM assay"|"ELISA-based urine test to detect the lipoarabinomannan component of the M. tuberculosis antigen in the urine of TB suspects, in vitro.~Manufacturer: Alere."
223821576|NCT04963361|OTHER|patients were exposed to fear of movement|Patients completed the questionnaires independently
223821577|NCT04963361|OTHER|patients were not exposed to fear of movement|Patients completed the questionnaires independently
223821578|NCT01706302|OTHER|Data collection|The previous study has used four primary data sources: the General Practice Research Data (GPRD \[recently re-named Clinical Practice Research Datalink (CPRD)\], for mild outcomes), the Hospital Episode Statistics database (HES, for hospitalizations), the Office of National Statistics mortality database (ONS, for mortality), and weekly virology data from the Health Protection Agency (HPA). The extracted data are referred to as the EPI-FLU-018 BOD UK DB database. Weekly time series will be generated to estimate the RSV burden and characterize it in terms of incidence of GP consultations, hospitalizations and deaths for each of the respiratory and non-respiratory outcomes (including GP antibiotic prescriptions), stratified by age and risk group.
223821579|NCT05796180|BEHAVIORAL|Behavioral: sexual health counseling based on the BETTER model|"The content of the research will be discussed by face-to-face interviews with women who gave birth vaginally and applied to the hospital for birth control 8-10 weeks after delivery. Pre-evaluation forms will be applied to women who have agreed to participate in the study to evaluate the inclusion criteria. Women who meet the inclusion criteria will be divided into experimental-control groups using the block randomization method.~An appointment will be made for interviews with the women in the experimental group. It is planned that these meetings will be held in the form of online video calls and will last an average of 45 minutes. The final tests will be held 8 weeks after the online meetings are over."
223821580|NCT04466215|DRUG|Miricorilant|900 mg (6 x 150 mg) tablets taken orally once daily for two weeks
223821581|NCT04466215|DRUG|Placebo oral tablet|Six placebo tablets taken orally once daily for two weeks
223821582|NCT04655885|BEHAVIORAL|Optimization of cardiac flow by base water-electrolyte supply|optimization of cardiac flow by base water-electrolyte supply of 1 ml / kg / h by Ringer Lactate® and faced with any decrease of more than 10% of the VES compared to the reference VES, achievement of an optimization of the preload by administration of 250 ml of Ringer Lactate® with renewal until correction of the VES.
223821583|NCT04655885|BEHAVIORAL|Control arm|increase basic hydro-electrolyte supply of 6 ml / kg / h by Ringer Lactate® and 1: 1 blood loss compensation by crystalloids of the same nature.
223821584|NCT05154123|DRUG|Drug: AT-527 + rosuvastatin|"* Day 1: A single dose of rosuvastatin will be administered.~* Day 8: A single dose of AT-527 and rosuvastatin will be co-administered."
223821585|NCT05154123|DRUG|AT-527 + rosuvastatin|"* Day 1: A single dose of rosuvastatin will be administered.~* Day 8: A single staggered dose of AT-527 and rosuvastatin will be administered (2 hours later)"
223821586|NCT02669095|DEVICE|Investigational Contact Lenses (Test)|
223821587|NCT02669095|DEVICE|Marketed Contact Lenses (Control)|
223821588|NCT00832195|DEVICE|Motion Controlling Running Shoe|Running shoe with thermoplastic mid-foot shank stiffener, denser durometer foam on medial aspect of mid-sole, reinforced heel counter, wider sole-plate, and lateral foam crash-pad.
223821589|NCT00832195|DEVICE|Neutral Running Shoe|Standard running shoe with single density mid-sole foam.
223821590|NCT04212364|BEHAVIORAL|Peer Education|In this intervention, people who use opiates will be trained to be peer educators.
223821591|NCT04212364|DRUG|Narcan Nasal Product|All study participants will be trained in how to use nasal Narcan and they will receive a nasal Narcan kit.
223821592|NCT04263103|OTHER|SJ-RS-WL2015 visual training program software|It is a software with perceptual learning methods for binocular functions
223821593|NCT03399162|BEHAVIORAL|PREHAB Workshop|PREHAB workshop/education session in the Prevention and Rehabilitation Centre regarding nursing, nutrition, physiotherapy, psychology, and diabetes.
223821594|NCT03399162|BEHAVIORAL|PREHAB Exercise Program|An 8-week program that consists of: (1) 2x/week 60-minute supervised exercise sessions; and (2) 3x/week 30-minute home-based exercise sessions.
223821595|NCT04804995|OTHER|There is no intervention.|No intervention.
223821596|NCT02871830|BEHAVIORAL|Physical Activity|15 mins physical activity per day within the school setting.
223821597|NCT06437093|OTHER|TEACHING RELACTATION TECHNIQUES|"In our midwifery intervention, the mother was firstly educated about breastfeeding and relactation, using educational brochures prepared by the researchers. Afterwards, the mother was taught nipple stimulation, skin-to-skin contact and finger feeding method, and the first feeding of the baby was performed together with the mother. After this first intervention in the FHC, all interventions were performed at home. The follow-ups continued for 15 days with one day of telephone support and one day of home visit. Since the majority of mothers did not accept video calls (privacy, etc.), telephone support was provided only verbally."
223821598|NCT02778126|DRUG|[¹⁴C]Prexasertib|Administered IV Infusion
223821599|NCT02778126|DRUG|Prexasertib|Administered IV Infusion
223821600|NCT00352898|BIOLOGICAL|MeMuRu-OKA (study vac)|
223821601|NCT00352898|BIOLOGICAL|MMR, Varicella vacc (control)|
223821602|NCT01655602|PROCEDURE|Trichophytic closure upper edge trimming|'Trichophytic closure technique' can be done by trimming upper or lower wound edge for about 1 millimeter (as Fig.1) before wound closure. Then the linear scar will be less visible after hair growth. Anyway, there is no exactly wound edge (upper, lower or both) that recommended for the excellent cosmetic results without any severe side effects. Therefore, this study was designed to determine which is the best trichophytic closure technique.
223821603|NCT01655602|PROCEDURE|Trichophytic closure lower edge trimming|'Trichophytic closure technique' can be done by trimming upper or lower wound edge for about 1 millimeter (as Fig.1) before wound closure. Then the linear scar will be less visible after hair growth. Anyway, there is no exactly wound edge (upper, lower or both) that recommended for the excellent cosmetic results without any severe side effects. Therefore, this study was designed to determine which is the best trichophytic closure technique.
223821604|NCT01655602|PROCEDURE|Trichophytic closure both edge trimming|'Trichophytic closure technique' can be done by trimming upper and lower wound edge for about 0.5 millimeter (as Fig.1) before wound closure. Then the linear scar will be less visible after hair growth. Anyway, there is no exactly wound edge (upper, lower or both) that recommended for the excellent cosmetic results without any severe side effects. Therefore, this study was designed to determine which is the best trichophytic closure technique.
223821605|NCT05787158|OTHER|Muscle energy techniques|Group A: 20 patients were included in this group. This studygroup was assigned with basic treatment protocol with 15 minutes of TENS and thermal therapy for 10 minutes followed by muscle energy technique (Post facilitation stretching exercises). The intervention was given three days per weekfor six weeks. Each total session lasted for 45minutes. METs were applied for the weakened muscles. (21). Group B: 20 Patients of this group were given core stability exercises by the female physical therapist in three different levels. Each level continued for a duration of two weeks in which the patients were trained for the exercises. The patients were provided sessions thrice per week with 2 sets of 10 repetitions and a hold of 10 second after TENS for 15 minutes and thermal therapy for 10 minutes
223821606|NCT01204268|PROCEDURE|Sev-I group|Sevoflurane will be given before the cerebral artery clip as a preconditioning procedure for the coming ischemia-reperfusion injury.
223821607|NCT01204268|PROCEDURE|Sevo continuous inhalation|Patients will receive the anesthesia with continuous inhalation of sevoflurane.
223821608|NCT00926003|BEHAVIORAL|Full Computerized cognitive training|8 weeks of 3 times weekly intervention for 60 min per session with the full titrating version of Captain's Log program (3 games for attention, 3 games for visual spatial working memory, 3 games for reasoning/planning
223835539|NCT00615082|BEHAVIORAL|Mindfulness-Based Stress Reduction|An 8-week course led by an experienced instructor in a group format of up to 15 people. Participants in the MBSR course learn mindfulness meditation techniques and simple yoga exercises such as stretching.
223821609|NCT00926003|BEHAVIORAL|Limited computerized cognitive training|Locked Captain's Log CCRT that rotates randomly among simplest level of computer cognitive games training. 8 weeks of 3 times weekly intervention for 60 min per session with the non-titrating version of Captain's Log program (3 games for attention, 3 games for visual spatial working memory, 3 games for reasoning/planning).
223821610|NCT02109198|DEVICE|Active CN-NINM PoNS|Delivery of active stimulation of the tongue during in-person therapy sessions (1 hour) and during two home sessions (40 minutes) daily on 6 of 7 days per week (120 total sessions). Stimulation sessions will be separated by at least 4 hours.
223821611|NCT02109198|DEVICE|Sham CN-NINM PoNS|Delivery of sham stimulation of the tongue during in-person therapy sessions (1 hour) and during two home sessions (40 minutes) daily on 6 of 7 days per week (120 total sessions). Stimulation sessions will be separated by at least 4 hours.
223821612|NCT02801188|DRUG|Bupivacaine|Paravertebral blockade will be performed using combined mixture of bupivacaine 0.5% and water soluble radio-opaque dye.
223821613|NCT02801188|DRUG|Mixture of bupivacaine and dexmedetomidine|Paravertebral blockade will be performed using combined mixture of bupivacaine 0.5%, water soluble radio-opaque dye, and1 ug/kg of dexmedetomidine
223821614|NCT06017830|DEVICE|Physical treatment agents|Physical treatment agents such as TENS (transcutaneous electric nerve stimulation), hot pack and ultrasound will be applied to patients with low back pain. Sexual function will be assessed before, just after and 3 months later physical therapy.
223821615|NCT06014138|DRUG|Propofol|Standard care, propofol sedation - 2 hour periods of observation before and after inhaled volatile sedation
223821616|NCT06014138|DRUG|Isoflurane|Inhaled volatile sedation for 6 hours - 2 hours wash in / wash out, followed by 4 hours of observations
223821617|NCT00202774|DRUG|(capecitabine, oxaliplatin, 5-fluorouracil)|
223821618|NCT02408237|DEVICE|Active tDCS Ambulatory|Procedure begins with the placement of an anode electrode placed on the primary motor cortex (cortex contralateral to the dominant) and the cathode is placed on the contralateral supraorbital region. It is used 1mA direct current transcranial stimulation applied for 20 minutes. Will be held a single session of stimulation. The total time, with initial assessment, tDCS session and final evaluation will be approximately 4 hours.
223821619|NCT02408237|DEVICE|Sham tDCS Ambulatory|In sham group, we follow the same procedure and time as the active tDCS ambulatory protocol, but the device will be in the mode sham (inactive). The current is only applied for 30 seconds, so subjects feel a sense of the initial stimulation, but not the remainder receive current. In this group one session will also be held. The total time, with initial assessment, tDCS session and final evaluation will be approximately 4 hours.
223821620|NCT02408237|DEVICE|Active tDCS Home use|The procedure and stimulation time is exactly the same that Active tDCS - ambulatory use, but will use the apparatus for domestic use. Will be explained to the participant as placement of the cap and the device management. This group will be made 11 sessions of tDCS, the first held in the Hospital, with supervision of the researcher. The remaining 10 will be held in the participant's home. The total time of the first meeting, with initial assessment, tDCS session and final evaluation will be around 4 hours. The time of last evaluation is approximately 1 hour.
223821621|NCT02408237|DEVICE|Sham tDCS Home use|The procedure and stimulation time is exactly the same that Active tDCS - ambulatory use, but will use the apparatus for domestic use. In sham group, we follow the same procedure and time as the active tDCS protocol, but the device will be in the sham mode (inactive). The total time of the first meeting, with initial assessment, tDCS session and final evaluation will be around 4 hours. The time of last evaluation is approximately 1 hour.
223821622|NCT05720234|DRUG|avatrombopag|Patients with body weight ≥50kg were given 60mg/day and patients with body weight \< 50kg were given 40mg/day for 12 weeks.
223821623|NCT06129201|OTHER|Tongue image|Using intelligent imaging devices to collect subject tongue images
223821624|NCT04576364|DRUG|Magnesium sulfate for 12 hour|drug used to prevent convulsions in patients having preeclampsia with severe features
223821625|NCT04576364|DRUG|Magnesium sulfate for 24 hour|drug used to prevent convulsions in patients having preeclampsia with severe features
223821626|NCT00406224|DRUG|breathing 100% oxygen|
223821627|NCT02477280|DRUG|Methylphenidate|Cross-over
223821628|NCT02477280|DRUG|Placebo|Medikinet
223821629|NCT06250647|OTHER|vitamin K diet|500mcg of Vitamin K intake provided by the selection of vitamin k rich foods in the menu.
223821630|NCT03253016|DIAGNOSTIC_TEST|vaginal swab -microbiome test and blood test for cytokines|vaginal microbiome test and blood test for cytokines repeated during pregnancy in the 3 arms
223821631|NCT01396317|DRUG|Tocilizumab|Tocilizumab is a humanized anti-interleukin-6 receptor antibody that has been FDA approved for the treatment of rheumatoid arthritis (RA). This molecule binds to the IL-6 binding site of human IL-6 receptor, and competitively inhibits IL-6 signaling.
223821632|NCT00097643|BEHAVIORAL|exercise|
223821633|NCT00097643|BEHAVIORAL|health promotion|
223821634|NCT02255396|OTHER|ESTRADIOL|
223821635|NCT05958498|COMBINATION_PRODUCT|injectable platelet rich fibrin and microosteoperforation|i-PRF which second product of blood versus mops which is surgical procedure
223821636|NCT02294474|DRUG|SAR342434|SAR342434 100 U/mL (dose range of 1 Unit to 80 Units) self-administered by subcutaneous (SC) injection, immediately (within 5 -10 minutes) before meals intake. Dose adjusted to achieve 2 hour post prandial glucose (PPG) in range of 6.7 to 8.9 mmol/L (120 to 160 mg/dL) while avoiding hypoglycemia.
223821637|NCT02294474|DRUG|Humalog|Humalog 100 U/ml (dose range of 1 unit to 60 units) self-administered by SC injection, immediately (within 5-10 minutes) before meals intake. Dose adjusted to achieve a 2 hour PPG in range of 6.7 to 8.9 mmol/L (120 to 160 mg/dL) while avoiding hypoglycemia.
223821638|NCT02294474|DRUG|insulin glargine HOE901|Insulin glargine 100 U/mL injected QD subcutaneously consistent with the local label. Doses adjusted to achieve glycemic target for fasting, preprandial plasma glucose (SMPG) between 4.4 to 7.2 mmol/L (80 to 130 mg/dL) without hypoglycemia.
223821639|NCT00267696|DRUG|Bevacizumab|Bevacizumab(Avastin)=10mg/kg on day 1, day 15 of a 28 day cycle.
223821640|NCT00267696|DRUG|Gemcitabine|A regimen consisting of gemcitabine 1000 mg/m2 will be administered on day 1 and day 15 of a 28 day cycle
223821641|NCT00267696|DRUG|Carboplatin|
223821642|NCT01456234|DRUG|Oseltamivir|Oseltamivir 75 mg BID
223821643|NCT03178955|DRUG|Etanercept|Circadian activity rhythm parameters will be evaluated for 7 days prior to Enbrel treatment through 7 days after initiation of Enbrel treatment and again 28-35 days after the second Enbrel treatment.
223821644|NCT04296474|DRUG|ALK Alutard 5-grasses and birch|Intralymphatic injections
223821645|NCT04296474|DRUG|ALK Diluent|intralymphatic injections
223821646|NCT01001949|DIETARY_SUPPLEMENT|Wheat Bran Extract|soft drink comprising WBE and natural flavor and coloring agent, ingestion after breakfast and after dinner
223821647|NCT01001949|DIETARY_SUPPLEMENT|placebo|soft drink with natural flavor and coloring agent, without WBE, ingestion after breakfast and dinner
223821648|NCT02333760|GENETIC|Autologous CD34+ cells transduced with WASP lentiviral vector|Follow up of ex vivo gene therapy transplantation of patient's autologous CD34+ cells transduced with lentiviral vector containing human WASP gene
223821649|NCT04815317|OTHER|Auditive stimulation|"The auditory stimulation will consist of listening to relaxing pieces of music from MP3 files from the International Center for Music Therapy (Noisy le Grand, France).~Listening will be done through noise-cancelling headphones (PLANTRONICS, Gamecom 780, Santa Cruz, California, USA) for 10 minutes."
223821650|NCT04815317|OTHER|Sensitive stimulation|Sensitive stimulation will consist of administering fresh air to the patient's face by means of a fan without blades (DYSON AM01, Malmesbury, UK) for 10 minutes.
223821651|NCT04815317|OTHER|Auditory control|"The auditory control condition will consist of listening to a pink noise. The pink noise, like the white noise, is a normalized noise. The sound produced on a TV set that is out of adjustment during the snow effect is a representative example of such noise. Pink noise is a random signal whose power spectral density decreases by 3dB per octave. This signal is closer to the sensitivity of the ear than white noise."
223821652|NCT04815317|OTHER|Sensitive control|The sensitive control condition will be achieved by administering fresh air on the calf.
223821653|NCT05200936|DRUG|MM-120|MM-120 is a psychedelic drug that can cause intensified thoughts, emotions, and sensory perception. At sufficiently high dosages MM-120 manifests primarily visual, as well as auditory, hallucinations.
223821654|NCT05200936|OTHER|Placebo|A treatment which is designed to have no therapeutic value.
223821655|NCT04604067|DRUG|Acalabrutinib|"Cohort A: 6 cycles of acalabrutinib-R-CHOP~Cohort B: 2 cycles of R-CHOP and 2 cycles of acalabrutinb-R-CHOP followed by 2 cycles of acalabrutinib single agent~Cohort C: 4 cycles of R-CHOP followed by 2 cycles of rituximab single agent~Cohort D: 6 cycles of R-CHOP~Rituximab 375 mg/m2 IV Day 1, cyclophosphamide 750 mg/m2 IV Day 1, doxorubicin 50 mg/m2 IV Day 1, vincristine 1.4 mg/m2 (maximum 2 mg) IV Day 1; prednisone 100 mg PO d1-5; Acalabrutinib 100 mg BID Day 1-21, cycles repeated every 21 days"
223821656|NCT03115554|PROCEDURE|PVI Plus Catheter Ablation|Patients with sustained AF following PVI will receive additional linear or focal intracardiac catheter ablation for AF.
223821657|NCT03115554|PROCEDURE|PVI Alone|Patients with sustained AF following PVI will not receive additional linear or focal intracardiac catheter ablation for AF.
223821658|NCT03443713|DEVICE|Dexcom G6 CGM|Subjects will wear a Dexcom G6 CGM for the 28 days they are on study.
223821659|NCT04686279|DRUG|Tenofovir Douche|660 mg TFV in 125 mL hypo-osmolar solution
223821660|NCT01756261|DRUG|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|Patients treated with EYLEA under practical manner for AMD.
223821661|NCT05277675|DRUG|Tislelizumab/Sintilimab+Lenvatinib/Bevacizumab|Immune checkpoint inhibitor (tislelizumab/sintilimab) combined with anti-angiogenic drugs (lenvatinib/bevacizumab) used as neoadjuvant therapy
223821662|NCT05277675|PROCEDURE|RFA|RFA will be performed in a percutaneous way guided contrast enhanced ultrasound.
223821663|NCT05098106|DIAGNOSTIC_TEST|Bronchoscopy, blood sampling; testing.|BAL and blood samples are measured by hematology analyzer, flow cytometry, western blot, RNAseq analysis and multiplex.
223821664|NCT06480110|DRUG|Docetaxel + Ebastine|Ebastine is administered once daily.
223821665|NCT06480110|DRUG|Docetaxel|docetaxel every three weeks
223821666|NCT04765319|BEHAVIORAL|CPT for PTSD|Evidence based psychotherapy for PTSD
223821667|NCT04875364|DRUG|Eszopiclone|2mg of Eszopiclone just before going to sleep.
223821668|NCT04875364|OTHER|Supplemental Oxygen|Constant oxygen flow at 4 Liters per minutes for the duration of time in bed via nasal cannula.
223821669|NCT04875364|DEVICE|Continuous Positive Airway Pressure (CPAP)|A standard CPAP device will be provided using the settings as prescribed by the treating physician.
223821670|NCT01620905|PROCEDURE|Manipulation|Single level cervical spine joint manipulation
223821671|NCT04893655|DRUG|Dobutamine Hydrochloride|dobutamine infusion will be started at 2mcg/kg/min after min 10 minutes dobutamine infusion will be raised to 5mcg/kg/min
223821672|NCT01690884|DRUG|Adenosine|Adenosine will be infused into the brachial artery at 0.125 mg/min for 15 minutes and then at 0.5 mg/min for an additional 15 minutes,
223821673|NCT01126138|DRUG|Vinorelbine plus Capecitabine for 6 cycles, followed by Capecitabine|Capecitabine: 1,000 mg/m2 PO twice daily (day 1-14) Vinorelbine: 25 mg/m2 IV over 3 hours on day 1 and 8, every 3 weeks 21 days as one cycle and 6 cycles are required
223821674|NCT01126138|DRUG|Docetaxel plus Capecitabine for 6 cycles, followed by Capecitabine|"Capecitabine: 1,000 mg/m2 PO twice daily (day 1-14), Docetaxel: 75 mg/m2 IV over 3 hours on day 1, every 3 weeks, 21 days as one cycle and 6 cycles are required.~Followed by Capecitabine: 1,000 mg/m2 PO twice daily (day 1-14) 21 days as one cycle until progression or unacceptable toxicity"
223821675|NCT01897831|DRUG|xin te mie|durg:Piperacillin Sodium and Sulbactam Sodium for Injection(2:1) 1.5-3.0g,iv,bid for 7-14 days Serious infections:6.0-12.0g,iv,tid for 7-14 days
223821676|NCT02649062|BIOLOGICAL|NGM282|
223821677|NCT02649062|OTHER|Placebo|
223821678|NCT04131790|BEHAVIORAL|Tele-Behavioral Activation|Five 1-hour sessions of BA delivered by a trained interventionist via video-conferencing
223821679|NCT04131790|BEHAVIORAL|Tele-Friendly Visiting|Five 1-hour FV sessions delivered by a trained interventionist via video-conferencing
223821680|NCT05035368|DRUG|Ladarixin|Ladarixin will be administered orally at the dose of 400 mg twice a day at about 12-hour interval (morning and evening).
223821681|NCT05035368|OTHER|Placebo|Placebo is administered with the same schedule of Ladarixin.
223821682|NCT03185559|DEVICE|Relievion Device- Treatment Stimulation|1 Hour self-administered treatment specific occipital and supraorbital transcutaneous nerve stimulation
223821683|NCT03185559|DEVICE|Relievion Device- Sham stimulation|1 Hour self-administered sham occipital and supraorbital transcutaneous nerve stimulation
223821684|NCT02944656|DRUG|Gabapentin|Participants in this group will receive 600 mg of gabapentin given 1-2 hours pre-operatively in conjunction with perioperative paracervical block for surgical abortion. Gabapentin is an FDA approved medication that is used to prevent seizures and to treat various forms of chronic and acute pain.
223821685|NCT02944656|DRUG|Placebo|Participants in this group will receive 600 mg of gelatin capsules that are identical in appearance to gabapentin capsules. The placebo will be given 1-2 hours pre-operatively in conjunction with perioperative paracervical block for surgical abortion.
223821686|NCT00017056|DRUG|ixabepilone|
223821687|NCT04916418|DRUG|Placebo|TTP block with initial dose of placebo (NaCl0.9%) 20 ml per catheter (total volume 40ml), followed by 20 ml per catheter every 8 hours until 72 hours from the first dose has passed.
223821688|NCT04916418|DRUG|Ropivacaine|TTP block with initial dose of ropivacaine 0.5% (5 mg / ml) 20 ml per catheter (total volume 40ml), followed by doses of ropivacaine 0.2% (2 mg / ml) 20 ml per catheter every 8 hours until 72 hours from the first dose has passed.
223821689|NCT05694182|OTHER|Other: Oral superfruits supplement|The supplement contain superfruits that are beneficial for human health
223821690|NCT05091853|DEVICE|Adhesix mesh|2 meshes are used; the self-gripping Progrip mesh and the self-adhesive Adhesix mesh
223821691|NCT02232308|DRUG|Nizatidine|Nizatidine (150 mg) will be administered once daily for the first 3 days, then twice daily for days 4-9, and once on day 10.
223821692|NCT02232308|DRUG|Lisinopril|Lisinopril (10 mg) will be administered once daily for the first 3 days, then twice daily for days 4-9, and once on day 10.
223821693|NCT02232308|DRUG|Placebo|Placebo capsules to match active drug will be administered once daily for the first 3 days, then twice daily for days 4-9, and once on day 10.
223821694|NCT01330602|BEHAVIORAL|IMPRESS intervention|"The key elements of the IMPRESS intervention include:~* Promoting a healthy lifestyle~* Supporting lifestyle and risk modification~* Encouraging active self-management of risk and chronic disease~* Improving coordination of care~* Pharmacological therapy"
223821695|NCT05034848|PROCEDURE|Assessment of BMD by DXA and HRpQCT|"* DXA : BMD assessment at the left hip, rachis and both legs~* HRpQCT : Volumic Bone mineral density, cortical and trabecular parameters, at the non dominant radius and legs~* Biological samples"
223821696|NCT05721001|DEVICE|Surgical Repair|In Frozen Elephant Trunk procedure, the proximal aortic arch is replaced with a dacron graft, and a thoracic stent graft, sutured to the distal end of the dacron prosthesis, is deployed antegradely into the descending aorta. This mostly one-stage alternative approach eliminates the interval mortality rate related to the conventional elephant trunk procedure. Moreover, it constitutes a solution in fragile patients who cannot safely complete a second major operation after surviving the first.
223821697|NCT06606366|PROCEDURE|Blood sample taken for the liquid biopsy|36 mL will be taken for the study.
223821698|NCT05473000|BEHAVIORAL|Exercise|Submaximal and maximal exercise
223821699|NCT05473000|OTHER|Ozone|Delivery of ozone air pollution at 170ppb
223821700|NCT05473000|OTHER|Room air|Delivery of room air
223821701|NCT06667505|BEHAVIORAL|Choice-ICD|The eHealth intervention theoretically driven, interactive and provides personalised information to patients and family members when and where they wish to access it. Five short (2-3 minutes) videos, involving patients, caregivers and professionals, are uploaded onto the APP, alongside animation clips and useful links to online resources. A discussion forum will be accessible for participants using the APP, which will be closely moderated by the researcher, who will ensure any concerning posts or dialogue are promptly removed, and the necessary action is taken. The diary function will allow patients to record and be reminded of future appointments. Patients and family members will engage with the intervention for 3 months.
223821702|NCT05879198|BEHAVIORAL|Computer-based Intervention|The current project proposes to pilot a computer-based working memory training program to improve delay discounting and prevent substance use among at-risk adolescents in a traditionally underserved area.
223821703|NCT06163560|DEVICE|"Smartphone app Happy Baby HK"|"Happy Baby HK will provide developmental stage, developmental aspects, parenting videos and cartoon images created for new mothers."
223821704|NCT06163560|DEVICE|Family Health Service parenting booklet|The parenting booklet is publicly available and provides brief caretaking tips for mothers with children under 3 years of age.
223821705|NCT04567394|BEHAVIORAL|Peer Network Counseling-txt|4-week text counseling program
223821706|NCT06625008|OTHER|3D-printed model|The Department of Radiology at Vanderbilt University Medical Center will create a 3D-printed human torso model that includes the colon, rectum, and a stoma on the abdominal wall. This model will be used to provide pre-operative counseling during the surgical consent for patients.
223821707|NCT06624319|DRUG|Dexmedetomidine as adjuvent to bupvacaine in tap block|The analgesic effect of Two different doses of dexmedetomidine as adjuvent to bupivacaine in tap block
223821708|NCT06926101|DEVICE|dental implants|dental implant placement by full or partial thickness flap
223821709|NCT06925763|DRUG|Nitroglycerin|cardiac disease treatment drug
223821710|NCT06926127|GENETIC|Whole Exome Sequencing (WES)|Blood samples, buccal swabs, and pathological tissue samples (skin/muscle) will be collected, and subsequently, DNA extracted from those tissues will be used for genomic analysis using Whole Exome Sequencing. The sample will follow the diagnostic pipeline already established inside the hospital. Moreover, the remaning aliquots of DNA extracted from the tissue (peripheral blood or tissue specimen) will be sent by the Genomics core facility to the Biobank for storage upon analysis completion.
223821711|NCT06926504|BEHAVIORAL|The care process S-TeamBirth|The intervention consists of the entire care team conducting huddles together with the birthing woman and her partner to plan the care, using the S-TeamBirth whiteboard to communicate and visualize decisions
223821712|NCT06926504|BEHAVIORAL|S-TeamBirth|Involving the entire care team including the woman and her partner in planning the care using team huddles and the S-TeamBirth whiteboard
223835540|NCT00615082|BEHAVIORAL|Caregiver Education & Social Support|An 8-week course led by experienced instructors in a group format of up to 15 people. Participants in the CESS course learn about a variety of important issues related to elder care and receive social and emotional support in a group discussion format.
223821713|NCT06925841|OTHER|Experimental|Two pre-selected mother-baby themed images to be used in the study will be printed separately on A4-sized papers (21.0 cm × 29.7 cm). Each participant will receive a new image every day.At the beginning of the study, each participant will be provided with a set of 12 colored pencils (orange, red, pink, purple, light blue, dark blue, light green, dark green, light brown, dark brown, black, and white). Colored pencils have been preferred over soft-tipped pencils due to their requirement for greater physical effort and their ability to facilitate a clearer expression of emotions. Participants in the intervention group will receive routine care and will engage in a 30-minute daily coloring activity.
223821714|NCT06925841|OTHER|routine care|The control group will receive routine care provided by the nurse.
223821715|NCT06926517|OTHER|life and death courses|Life and death issues in the post-epidemic era - Curriculum planning that integrates life and death care, reflective learning and teaching practice on the new coronavirus pneumonia issue, introducing 18-week theme courses, each course is 100 minutes
223821716|NCT02073097|DRUG|Carfilzomib|"Given IV, according to dose level. Cohorts begin with dose level (DL)1, escalated in standard 3+3 design to identify a recommended phase 2 dose DL (-2) 11 mg/m2 on day 1 and 2 every 21 days, cycles 1-6~DL (-1) 15 mg/m2 on days 1 and 2 every 21 days, cycles 1-6~DL (1) 20 mg/m2 days 1,2 every 21 days, cycles 1-6~DL (2) 20 mg/m2 days 1,2 of cycle 1 followed by 27 mg/m2 days 1,2 every 21 days for cycles 2-6.~DL (3) 20 mg/m2 days 1,2 of cycle 1 followed by 36 mg/m2 days 1,2 every 21 days for cycles 2-6.~DL(4) 20 mg/m2 days 1,2 of cycle 1 followed by 45 mg/m2 days 1,2 every 21 days for cycles 2-6~DL (5) 20 mg/m2 days 1,2 of cycle 1 followed by 56 mg/m2 days 1,2 every 21 days for cycles 2-6"
223821717|NCT02073097|BIOLOGICAL|Rituximab|Given IV (375mg/m\^2)
223821718|NCT02073097|DRUG|Cyclophosphamide|Given IV (750mg/m\^2)
223821719|NCT02073097|DRUG|Doxorubicin hydrochloride|Given IV (50mg/m\^2)
223821720|NCT02073097|DRUG|Vincristine sulfate|Given IV (1.4mg/m\^2)
223821721|NCT02073097|DRUG|Prednisone|Given PO (100mg)
223821722|NCT02073097|DRUG|Pegfilgrastim|6 mg SC day 4 (every 21 days). Filgrastim 300 or 480 mcg IV/SC daily days 1-10 may be substituted if pegfilgrastim is not available. ONPROTM is also an acceptable method of administration.
223821723|NCT02073097|DRUG|Acyclovir|PO (400mg)
223821724|NCT05172206|OTHER|symptom-focused rehabilitation|Patients in this arm will be referred to a 3-week inpatient comprehensive rehabilitation program. Initially, patients will be classified into one out of three clusters namely: Cluster A (Fatigue), Cluster B (cognition), or Cluster C (physical). The content of the rehabilitation program will be individually adapted according to the patient's most relevant symptom cluster.
223821725|NCT05172206|OTHER|usual care|Patients in this arm do not receive any intervention beyond usual care during the study phase. However, all patients in this group will get the opportunity to also receive a rehabilitation program after the study phase.
223821726|NCT06899672|OTHER|Alginate mixed with distilled water|Alginate will be mixed with distilled water only, without any disinfectant additive, to serve as the control for comparison
223821727|NCT06899672|OTHER|0.2% Chlorhexidine + Alginate|Alginate will be mixed with 0.2% Chlorhexidine solution to evaluate its effect on the linear dimensional stability of alginate impressions
223821728|NCT06899672|OTHER|1% Chitosan + Alginate|Alginate will be mixed with 1% Chitosan solution to assess its influence on the linear dimensional stability of alginate impressions
223821729|NCT06899672|OTHER|0.2% Silver Nitrate + Alginate|Alginate will be mixed with 0.2% Silver Nitrate solution to determine its effect on the dimensional stability of alginate impressions
223821730|NCT06899672|OTHER|Green-synthesized Silver Nanoparticles + Alginate|Alginate will be mixed with a solution of green-synthesized Silver Nanoparticles to investigate its effect on the dimensional stability of alginate impressions
223821731|NCT06899672|OTHER|15% Povidone-Iodine + Alginate|Alginate will be mixed with 15% Povidone-Iodine solution to analyze its influence on the dimensional stability of alginate impressions
223821732|NCT06900517|DIETARY_SUPPLEMENT|Salvia officinalis Gel|From each participant, two sites of periodontal pockets ( ≥ 5 mm ) were selected and randomly allocated to either the test site (treated with scaling and RSD with S. officinalis gel) or the control site (treated with scaling and RSD alone).
223821733|NCT06899581|DIETARY_SUPPLEMENT|Enteral nutrition Food Derived Ingredient|"For this case-control analysis, children with AML will be matched to cancer-free controls for age, sex and race. No antibiotics for 6 months. In collaboration with Professor Konstantinos Gerasimidis Professor of Clinical Nutrition School of Medicine. University of Glasgow. Healthy children have been recruited from the community via poster and social media advertisement. The whole bowel movement was collected in a disposable stool collection kit and stored in a benchtop freezer provided to study participants. Researcher defrosted the sample, homogenised it with mechanical kneading and aliquots were stored in -80.~Cases: children with AML: Stool specimens will be obtained at three predefined time points for microbiome analysis: baseline start of AML treatment (within 2 weeks of admission); after induction chemotherapy initiation (6-8weeks); recovery phase 6-8 months."
223821734|NCT06899659|DEVICE|JuggerStitch™ Meniscal Repair Device|Participants assigned to investigational group undergoing arthroscopy meniscal repair with JuggerStitch™ Meniscal Repair Device.
223821735|NCT06899659|DEVICE|Fast-Fix 360 Meniscal Repair System|Participants assigned to control group undergoing arthroscopy meniscal repair with the Fast-Fix 360 Meniscal Repair System.
223821736|NCT06900829|BEHAVIORAL|HIV team implementation|"A local hiv team will be implemented in a certain hospital. This will result in different activities, with a focus on:~* audit and feedback (reminding health care professionals to test for hiv)~* stigma reduction (raising awareness on existing hiv stigma towards hiv)~* education (increasing knowledge on hiv among health care professionals)~* linkage to prevention and care (improving pathways for hiv care and prevention)"
223821737|NCT06875947|DIETARY_SUPPLEMENT|Moringa Oleifera Leaf Micronized Powders in Capsule|"Moringa Oleifera Leaf Micronized Powders (MOLMP)~Source: Derived from finely ground Moringa Oleifera leaves using micronization technology to enhance bioavailability.~Dosage: 650 mg per capsule, taken three times daily (1,950 mg/day). Administration Duration: 60 days. Monitoring: Self-administration under weekly compliance checks."
223821738|NCT06875947|DIETARY_SUPPLEMENT|Standard Iron Tablets (Fe + Folic Acid)|Dosage: One tablet containing 60 mg iron and 400 mcg folic acid per day. Administration Duration: 60 days.
223821739|NCT06829901|PROCEDURE|Fetoscopic Laser Photocoagulation|Patients who choose to undergo fetoscopic selective laser photocoagulation for complicated monochorionic-diamniotic twin pregnancies with twin-to-twin transfusion syndrome will be offered participation in the study. All participants will undergo selective laser photocoagulation and entry into the uterus will be achieved using one of two accepted methods, either direct entry or the Seldinger technique.
223821740|NCT06763107|PROCEDURE|Athletic Shoulder (ASH) and Inverse Athletic Shoulder (IASH) Tests|Participants perform the Athletic Shoulder (ASH) test and Inverse Athletic Shoulder (IASH) test to measure maximal isometric shoulder strength in three positions (180º, 135º, 90º) during two separate sessions. Data is used to assess test reliability and validity for high-performance swimmers.
223821741|NCT06370689|OTHER|Preoxygenation|Preoxygenation of volunteers over 3 minutes
223821742|NCT06900400|DIAGNOSTIC_TEST|"Sustained-Paced Finger Tapping (Petilli et al., 2018)"|"Sustained-Paced Finger Tapping (Petilli et al., 2018) a computerized test that lasts approximately 10 minutes. It involves maintaining and reproducing the rhythm of a sound (auditory version)."
223821743|NCT06925828|OTHER|No intervention|No intervention
223821744|NCT06925256|DIAGNOSTIC_TEST|nerve conduction study|median ulnar and radial motor- sensory nerve conduction studies will be performed.
223821745|NCT06901076|DIETARY_SUPPLEMENT|Nisatol|Nisatol® (developed by PharmExtracta) containing Nigella sativa seeds oil and Vitamin E, 1 capsule soft gel after breakfast and 1 capsule soft gel after dinner for 6 months
223821746|NCT06901076|OTHER|Placebo|Placebo
223821747|NCT01438788|OTHER|Low protein diet|Patients will receive a diet with 0.6-0.8 grams of protein/kilogram body weight/day for one year. Bread, biscuits and pasta will be in part substituted with aproteic food.
223821748|NCT06736977|BEHAVIORAL|The Onsite Nurse-Led Education Programme on IPC|"The programme was designed to enhance CCWs' IPC knowledge and attitudes through lectures, interactive discussions, information sharing, and Q\&A sessions. It also aims to improve their IPC practices and self-efficacy through demonstrations, role-playing exercises, and a work assignment focused on IPC self-monitoring.~The programme includes five educational sessions totalling 12 hours, along with one session for work assignment on daily self-monitoring of IPC practices over five days. The educational sessions cover the following topics:~1. General concepts of infectious diseases~2. Vaccination~3. Standard precautions: The use of personal protective equipment, environmental cleaning and disinfection, handling food and feeding, and waste management~4. Standard precautions: Hand hygiene~5. Common infectious diseases in DCCs and management."
223821749|NCT06736977|BEHAVIORAL|The Online Nurse-Led Education Programme on IPC|The online version of the nurse-led education programme was conducted using an online meeting platform. It includes the same content, learning activities, and materials as the onsite delivery programme, except for the practice stations, which cannot be provided to participants in the online delivery. Additionally, all documents will be available for download via the online platform.
223821750|NCT06901375|DRUG|Vonoprazan|20 mg tablet twice daily
223821751|NCT06901375|DRUG|Amoxicillin|1 g tablet three times daily
223821752|NCT06901375|DRUG|Zuojin Wan|3 g tablet twice daily
223821753|NCT05963386|DRUG|177Lu-DOTA-EB-FAPI radionuclide therapy|radionuclide therapy using 177Lu-DOTA-EB-FAPI 90 mCi (3.3 GBq) will be performed 6-weekly. A maximum of 4 cycles will be administered.
223821754|NCT06384456|DRUG|Topical TRanexamic Acid|10mL of 100mg/mL TXA will be administered into the surgical wound prior closure.
223821755|NCT06384456|DRUG|Placebo|10mL of 100mg/mL normal saline will be administered into the surgical wound prior closure.
223821756|NCT06925867|OTHER|Frequency Filtered Music|The frequency filtered music intervention is 2.5 hours of classical music that has been filtered by applying an algorithm to alternate narrowing and expanding the range of acoustic frequencies over time, with the alternations intensifying in frequency range over the course of administration. The filtering is optimized for the frequency response of adult human hearing and intended to mimic the expression of the human voice around a central set of frequencies of 800-1200 Hz, the approximate resonant frequency of the human ear. The filtering method is similar to adjusting the treble and bass settings on a stereo system while music is playing; the melody and instruments can still be heard, but the highest and lowest pitches are modulated over time.
223821757|NCT06925867|OTHER|Unfiltered Music|The unfiltered music intervention is 2.5 hours of classical music with. The playlist of pieces is identical to the filtered music condition.
223821758|NCT06925867|BEHAVIORAL|Cognitive Processing Therapy for PTSD|Cognitive processing therapy (CPT) is a cognitive therapy that focuses on why patients believe the traumatic event occurred, how that event affected their beliefs about self and others, and how to evaluate their beliefs. Patients then learn to label events, thoughts, and subsequent emotions while the therapist helps them examine the facts and context of the trauma through Socratic questioning. Using progressive worksheets, patients are taught to examine their own thoughts and emotions and develop new, more balanced thinking about traumatic events.
223821759|NCT06924905|DIAGNOSTIC_TEST|the pelvic floor disability index|20 questions divided into three sections: Pelvic Organ prolapse Distress Inventory 6 (POPDI-6), Colorectal-Anal distress Inventory 8 (CRAD-8) and Urinary distress Inventory 6 (UDI-6).
223821760|NCT06925698|DRUG|Placebo plus immunosuppression|"Participants in this arm will receive placebo plus standard immunosuppressive therapy consisting of:~Azathioprine (2.5 mg/kg/day, maximum 200 mg/day, oral) Methylprednisolone (0.5 mg/kg/day, oral, tapered over 12 weeks according to protocol) This intervention represents the standard treatment for venous thrombosis associated with Behçet's Disease and serves as the control arm of the study."
223821761|NCT06925698|DRUG|Rivaroxaban plus immunosupression|"Participants in this arm will receive standard immunosuppressive therapy as described above, plus Rivaroxaban (20 mg/day, oral, for 12 months).~This intervention aims to evaluate whether the addition of oral anticoagulation (Rivaroxaban) to immunosuppressive therapy reduces the risk of thrombotic relapse and post-thrombotic syndrome compared to immunosuppressive therapy alone."
223821762|NCT06916780|OTHER|Laser and ultrasound|Laser and ultrasound will be applied in group A as traditional method. On the other hand they will applied axillary in experimental groups
223821763|NCT05118815|OTHER|Slim abutment|Use a narrower abutment to see if they present a better biological seal.
223821764|NCT05118815|OTHER|Standard abutment|Use a standard abutment
223821765|NCT03073460|OTHER|Ultrasound examination|This exam is performed at 40 weeks gestation
223821766|NCT01628211|PROCEDURE|Laparoscopy|second look laparoscopy to evaluate for peritoneal carcinosis
223821767|NCT01628211|PROCEDURE|peritonectomy|for patients with PCI \< 20
223821768|NCT01628211|DRUG|Folinic Acid|20 mg/m2 IV given just before HIPEC for patients with PCI \< 20
223821769|NCT01628211|DRUG|5-Fluorouracil|400 mg/m2 IV given just before HIPEC in patients with PCI \< 20
223821770|NCT01628211|DRUG|Oxaliplatin|460 mg/m2 intraperitoneal hyperthermic perfusion for patients with PCI \< 20
223821771|NCT01628211|DRUG|systemic chemotherapy|according to national Italian (AIOM) guidelines and may include biotherapies for patients with PCI \> 20
223821772|NCT02981784|DRUG|Ponatinib (Iclusig®)|Novel tyrosine kinase inhibitor active in patients with an ABL T315I mutation compared to conventional or reduced intensity allogeneic stem cell transplantation.
223821773|NCT02981784|PROCEDURE|allogeneic stem cell transplantation|
223821774|NCT03770013|DRUG|bupivacaine|bupivacaine 0.25% a total volume of 40 ml (20 ml each side
223821775|NCT03770013|DRUG|Dexmedetomidine|Dexmedetomidine 0.5 mcg/kg
223821776|NCT03770013|DRUG|clonidine|1ug/kg clonidine
223821777|NCT03770013|DRUG|placebo|add placebo 9normal saline)
223821778|NCT02947464|PROCEDURE|Standard clinical practice|Control weight will be started in obese children to decrease upper airway resistance and airway collapsibility. Close follow-up in order to detect comorbidities.
223821779|NCT02947464|DEVICE|Standard clinical practice + Rapid Maxillary Expansion|Mid-palatal suture osteogenic distraction delivered through a self-activated acrylic intraoral device custom-fit into the children´s palate and maxillary posterior teeth providing a transverse expansion of the dentofacial skeleton.
223821780|NCT02769065|DRUG|TAK-071|TAK-071 capsules
223821781|NCT02769065|DRUG|Donepezil|Donepezil over-encapsulated tablet
223821782|NCT02769065|DRUG|TAK-071 Placebo|TAK-071 placebo-matching capsules
223821783|NCT02769065|DRUG|Donepezil Placebo|Donepezil placebo-matching over-encapsulated tablet
223821784|NCT06228664|OTHER|foam rolling|Foam Rolling Technique on trapezius and suboccipital muscles.conventional therapy (15 min Hot pack, neck isometric exercises and cervical ROM exercises within pain free range). Patients will be treated 3 times per week for 6 consecutive weeks
223821785|NCT06228664|OTHER|bowen therapy|Bowen Therapy. conventional therapy (15 min Hot pack, neck isometric exercises and cervical ROM exercises within pain free range) will be given to both groups. Patients will be treated 3 times per week for 6 consecutive weeks
223821786|NCT04285437|BEHAVIORAL|infant massage|Mother will be trained how to massage their babies by International Association of Infant Massage (IAIM) Certified Infant Massage Instructor, and then their babies will be massaged by themselves during the first 2 months after birth.
223821787|NCT00519246|DRUG|Saline|Saline 5 ml administrated intravenously
223821788|NCT00519246|DRUG|Opioid|Butorphanol tartrate 1 mg i.v.
223821789|NCT00519246|DRUG|Opioid|Butorphanol Tartrate 2 mg i.v.
223821790|NCT00519246|DRUG|NSAID|Flurbiprofen Axetil 50 mg i.v.
223821791|NCT00519246|DRUG|NSAID|Flurbiprofen Axetil 100 mg i.v.
223821792|NCT00519246|DRUG|Opioid|Tramadol Hydrochloride 10 mg i.v.
223821793|NCT00519246|DRUG|Opioid|Tramadol Hydrochloride 20 mg i.v.
223821794|NCT02831829|OTHER|water-based exercise training|Water-based training will be performed in upright position, in waist to xyphoid process deep thermo-neutral water at temperature of 32,8 C. The immersed exercise will include two session of aerobic and calisthenic exercise per day, six days of a week, both lasting 30 minutes
223821795|NCT02831829|OTHER|land-based exercise training|Land-based training will include two aerobic and calisthenic exercise session per day, six days of a week, both lasting 30 minutes
223821796|NCT00552786|DRUG|N-acetylcysteine (NAC)|600mg twice daily for 2 weeks
223821797|NCT00552786|DRUG|glucose|1 gm glucose capsule
223821798|NCT00003241|DRUG|phenylacetate|
223821799|NCT02764775|DEVICE|Headpod|Adaptive equipment to assist with active head movements
223821800|NCT02910518|DRUG|Insulin glulisine (U300)|"Pharmaceutical form: solution~Route of administration: subcutaneous"
223821801|NCT02910518|DRUG|Insulin glulisine|"Pharmaceutical form: solution~Route of administration: subcutaneous"
223821802|NCT02910518|DRUG|Insulin aspart|"Pharmaceutical form: solution~Route of administration: intravenous/subcutaneous"
223821803|NCT02910518|DRUG|NPH insulin|"Pharmaceutical form: solution~Route of administration: subcutaneous"
223821804|NCT02910518|DRUG|Glucagon|"Pharmaceutical form: Powder and solvent for solution for injection~Route of administration: subcutaneous"
223821805|NCT02910518|DRUG|Glucose|"Pharmaceutical form: solution~Route of administration: intravenous"
223821806|NCT02910518|DRUG|Heparin|"Pharmaceutical form: solution~Route of administration: intravenous"
223821807|NCT03549234|DRUG|Erector Spinae (single injection)|Ropivacaine 0.5% (with epinephrine 1:200,000-400,000) will be administered via the needle into the target plane.
223821808|NCT03549234|DRUG|Paravertebral (single injection)|Ropivacaine 0.5% (with epinephrine 1:200,000-400,000) will be administered via the needle into the target plane.
223821809|NCT04708301|DIAGNOSTIC_TEST|T1 mapping|T1 mapping is a specialised heart scan that measures the magnetic properties of heart tissue and displays them as an image or map
223821810|NCT02055703|DRUG|E2609|
223821811|NCT02055703|DRUG|itraconazole|
223821812|NCT02055703|DRUG|rifampin|
223821813|NCT02055703|DRUG|digoxin|
223821814|NCT02055703|DRUG|donepezil|
223821815|NCT05878223|DEVICE|Extracorporeal shock waves|Both group received extracorporeal shock waves therapy
223821816|NCT00814515|DRUG|NOVA22007 (Ciclosporin 0.1%)|Ciclosporin 0.1% Ophthalmic Emulsions
223821817|NCT00814515|DRUG|NOVA22007|Vehicle
223821818|NCT01490203|DRUG|Gd-EOB-DTPA|"1. Gd-EOB-DTPA enhanced MRI will be obtained within 1 week before, and within 3 to 5 days after surgical resection of the liver.~2. Gd-EOB-DTPA will be administered intravenously with an amount of 0.1mL/kg, 1mL/sec injection rate, followed by saline infusion."
223821819|NCT01490203|DRUG|Gd-EOB-DTPA|"1. Gd-EOB-DTPA enhanced MRI will be performed within 3 days of obtaining ICG R15 test.~2. Gd-EOB-DTPA will be administered intravenously with an amount of 0.1mL/kg, 1mL/sec injection rate, followed by saline infusion."
223821820|NCT01490203|PROCEDURE|MRI|"1. Gd-EOB-DTPA enhanced MRI will be obtained within 1 week before, and within 3 to 5 days after surgical resection of the liver.~2. Multiphasic MRI including dynamic hepatocyte specific phase will be performed for evaluation of hepatic extraction fraction, with 25 phase dynamic MRI obtained until 30 minutes after contrast injection."
223821821|NCT01490203|PROCEDURE|MRI|"1. Gd-EOB-DTPA enhanced MRI will be performed within 3 days of obtaining ICG R15 test.~2. Multiphasic MRI including dynamic hepatocyte specific phase will be performed for evaluation of hepatic extraction fraction, with 25 phase dynamic MRI obtained until 30 minutes after contrast injection."
223821822|NCT00726336|DRUG|GSK1349572 and tenofovir|
223821823|NCT04358341|DRUG|Irinotecan|150 mg/m2 ivdrip every 14 days
223821824|NCT04358341|DRUG|DOXOrubicin Liposome Injection|25 mg/m2 ivdrip every 14 days
223821825|NCT04358341|DRUG|5fluorouracil|400mg/m2 iv bolus and 2400 mg/m2 civ 46h every 14 days
223821826|NCT03220945|OTHER|Yoga|Receive yoga instruction
223821827|NCT06285760|DRUG|Standarized diuretic therapy|Patients hospitalized with decompensated heart failure and fluid overload who require diuretic treatment for relieve of congestion. Standarized diuretic protocol according to guidelines will be applied. It consists of intravenous furosemide, SGLT2 inhibitors and acetazolamide if congestion persist.
223821828|NCT04255082|OTHER|assess the impact of mindfulness-based interventions on inpatients' and outpatients' stress, patient-provider communication, and other measures of SDM at MDMC.|"Effectiveness of the mindfulness-based intervention which will be assessed by:~Baseline and post-intervention perception of stress and anxiety Impact of stress on communication Emotional/Brain state Level of SDM during a pivotal visit with provider e.g. treatment planning visit (for outpatients only) The Emotional Distress-Anxiety (PROMIS, 2016), Communication Short Form (Cella, PROMIS, 2013), Emotional/Brain State Question (Mellin, 2017) and The Shared Decision Making dyadic OPTION scale (Melbourne, 2016) will be used to evaluate these outcomes.~Feasibility of such a study in the patient population and setting. This will be measured by the barriers encountered and the ability to successfully carry out the study."
223821829|NCT04022889|DEVICE|INTERCEPT Treated Platelets|Apheresis platelet components in 100% plasma collected using the Trima separator, prepared with the INTERCEPT Blood System for Platelets (Test Platelets) and stored for 7days at 20-24°C with continuous agitation. Samples from the Test component will be processed with either the BEST or the Variant 1 procedure prior to radiolabeling. The radiolabeled autologous Test and Control platelets (approximately 10-30 mL) will be simultaneously administered intravenously into the subject.
223821830|NCT04674774|DRUG|Tegoprazan|oral administration of tegoprazan-based bismuth quadruple therapy(tegoprazan 50 mg b.i.d, bismuth 300 mg q.i.d, metronidazole 500 mg t.i.d, tetracycline 500 mg q.i.d) for 14 days
223821831|NCT04674774|DRUG|Lansoprazole|oral administration of PPI-based bismuth quadruple therapy(lansoprazole 30 mg b.i.d, bismuth 300 mg q.i.d, metronidazole 500 mg t.i.d, tetracycline 500 mg q.i.d) for 14 day
223821832|NCT02859467|OTHER|Kinesio Taping and Inhibitory Treatment Techniques|"Kinesio Taping on trapezius, infraspinatus, and paravertebral muscles~Inhibitory Treatment Techniques:~* Release Technique of the trapezius muscle.~* Release Technique for scalene muscles.~* Technique suboccipital inhibition.~* Technique hands crossed for induction dorsal superficial fascia."
223821833|NCT02859467|OTHER|Exercise and Electrical Stimulation Therapy|Session for general physical activities (joint mobility, muscle strength and elasticity), and electrical stimulation therapy on para vertebral muscles.
223821834|NCT04130334|PROCEDURE|After mechanical trephination, horizontal meridian of donor's cornea sutured to horizontal meridian of recipient cornea|After mechanical trephination, horizontal meridian of donor's cornea sutured to horizontal meridian of recipient cornea
223821835|NCT04130334|PROCEDURE|: After mechanical trephination, horizontal meridian of donor's cornea sutured to vertical meridian of recipient cornea|: After mechanical trephination, horizontal meridian of donor's cornea sutured to vertical meridian of recipient cornea
223821836|NCT01334944|DRUG|Intravenous ibuprofen|400 mg or 800 mg intravenous ibuprofen administered intravenously over 5-10 minutes
223821837|NCT02254408|DRUG|Presatovir|Presatovir 200 mg (4 × 50 mg tablets) administered orally or via nasogastric (NG) tube
223821838|NCT02254408|DRUG|Placebo|Tablets administered orally or via nasogastric tube
223821839|NCT05697549|BEHAVIORAL|cognitive behavior language therapy|Cognitive behavior language therapy is an extensive form of Cognitive behavior therapy. and it is used in the management of speech-language related problems. It helps the individuals to change their unhelpful thoughts and beliefs that cause difficulty for them to communicate properly and effectively. and it also helps the individuals to use their remaining language abilities, to restore their language abilities and to learn the other ways of communication i.e. pointing, gesturing and Augmentative alternative communication.
223821840|NCT06019013|DRUG|QLF3108|QLF3108 will be administered independent of body weight.
223821841|NCT01057030|DRUG|BMS-708163|Capsules, Oral, 125 mg, once daily, 14 days
223821842|NCT01057030|DRUG|Placebo|Capsules, Oral, 0 mg, once daily, 14 days
223821843|NCT05417334|DEVICE|Resistive Capicitive Monopolar Radiofrequency|5 Radiofrequency sessions including the abdominal region, the vulva and pelvic floor tissue and Thiele massage done daily by the patient at home
223821844|NCT01526811|DEVICE|Endurant Stent graft|Endurant Stent graft implantation
223821845|NCT05126979|BIOLOGICAL|Inactivated Split Influenza Vaccine|
223821846|NCT05126979|BIOLOGICAL|Placebo|
223821847|NCT06255821|BEHAVIORAL|Exposure|One-session of graded in-vivo exposure with a spider. Each task is first modeled by the experimenter. Prior to the exposure, participants receive psychoeducation on anxiety and phobias.
223821848|NCT04199533|BEHAVIORAL|RUBI|Parent-mediated behavioral program targeting disruptive behavior utilizing principle of applied behavior analysis
223821849|NCT04199533|BEHAVIORAL|RUBIES|School-staff mediated behavioral program targeting disruptive behavior utilizing principle of applied behavior analysis
223821850|NCT05072288|OTHER|Remote activity program|Participant will have to do exercise at home everyday (15min/day)
223821851|NCT04707404|PROCEDURE|Cranioplasty|The surgery implanted artificial material to repair the skull defect.
223821852|NCT03295903|DIETARY_SUPPLEMENT|Cannabidiol supplement|Subjects will be administered in a double-blinded, randomized and cross-over design
223821853|NCT05600725|OTHER|novel atrial pacing approach|See US Patent #10987516. An atrial pacing method that preserves atrioventricular and interventricular synchrony to reproduce an exercise-typical envelope of heart rate.
223821854|NCT05600725|OTHER|sham pacing approach|A pacemaker/ICD interrogator/programmer will be used to simulate changes in pacing rate over the same time period as the intervention group but the programming changes will not actually be implemented and not change in paced heart rate will occur.
223821855|NCT01406704|DRUG|Rosiglitazone|Rosiglitazone (8 mg/day)
223821856|NCT01406704|DRUG|alpha-lipoic acid|alpha-lipoic acid (1800 mg/day)
223821857|NCT01406704|DRUG|Rosiglitazone/alpha-lipoic acid|combination of Rosiglitazone (8 mg/day) and Thioctic acid (1800 mg/day)
223821858|NCT02986061|DEVICE|Urinary catheter|
223821859|NCT01656837|BEHAVIORAL|Comprehensive Community Treatment|
223821860|NCT01656837|BEHAVIORAL|MST-BSF|
223821861|NCT02406885|DRUG|Apixaban|New Oral Anticoagulants (NOACs) are currently available for prophylaxis against venous thromboembolism in patients undergoing total hip or knee replacement surgery.
223821862|NCT01995019|DRUG|Methylprednisolone|1 ml single dose Intra-articular Depo-Medrol 40 mg/ml
223821863|NCT01995019|DRUG|Physiologic saline|1 ml intra-articular placebo
223821864|NCT04239729|BEHAVIORAL|ACT Website and Coaching|The ACT website includes sixteen sessions and is designed to teach a series of skills from ACT applied to hoarding. The intervention also includes brief supportive coaching (an initial phone call and weekly support over email).
223821865|NCT02291432|BIOLOGICAL|autologous muscle-derived cells (AMDC)|Cell treatment
223821866|NCT00150995|DRUG|Tetrathiomolybdate|
223821867|NCT03389841|OTHER|Education|Education of the caregiver about early symptoms and signs of heart failure
223821868|NCT02275247|DRUG|Stellate Ganglion Block|stellate ganglion block will be administered using either 6-8mL saline (Group 1) or 0.25% ropivacaine 6-8mL (Group 2)
223821869|NCT02492113|PROCEDURE|Positive end-expiratory pressure (PEEP)|"Titrated-PEEP. After recruitment maneuver and decremental PEEP trial, the Titrated-PEEP is identified. Patients will have two spontaneous breathing trials (SBTs). In this arm, patients will have SBT at Titrated-PEEP, with the PSV=0 and FiO2 unchanged."
223821870|NCT02492113|PROCEDURE|ZEEP|"After recruitment maneuver and decremental PEEP trial, the Titrated-PEEP is identified. Patients will have two spontaneous breathing trials (SBTs). In this arm, patients will have SBT at PEEP = 0-5 cmH2O, with the PSV=0 and FiO2 unchanged."
223821871|NCT04563390|BEHAVIORAL|Projection-based augmented reality exposure therapy (P-ARET).|"The intervention will be based on exposure therapy to cockroaches using P-ARET. The treatment will follow the guidelines of the one-session treatment (OST). Main components: Psychoeducation, Exposure to the feared object (cockroach), modeling (the therapist will interact with the phobic stimulus first and if possible, the patient will follow the same steps), cognitive challenge, and reinforcement and relapse prevention."
223821872|NCT04563390|BEHAVIORAL|In vivo exposure therapy|"The intervention will be based on traditional in vivo exposure therapy to real cockroaches. The treatment will follow the guidelines of the one-session treatment (OST). Main components: Psychoeducation, Exposure to the feared object (cockroach), modeling (the therapist will interact with the phobic stimulus first and if possible, the patient will follow the same steps), cognitive challenge, and reinforcement and relapse prevention."
223821873|NCT00642629|DRUG|STA 5326 mesylate|STA 5326 mesylate 100mg taken orally twice a day for 8 weeks with the option to continue at the same dose and frequency for an additional 4 weeks.
223821874|NCT00642629|DRUG|Placebo|Placebo taken orally twice a day for 8 weeks with the option to continue at the same dose and frequency for an additional 4 weeks.
223821875|NCT04734535|DEVICE|HEMOBLAST™ Bellows|Intraoperative bleeding during epidural spine surgery will be treated with HEMOBLAST™ Bellows
223821876|NCT04734535|DEVICE|absorbable gelatin sponge with thrombin|Intraoperative bleeding during epidural spine surgery will be treated with absorbable gelatin sponge with thrombin
223821877|NCT01486134|PROCEDURE|Multipolar Radiofrequency ablation|Percutaneous multipolar radiofrequency ablation.
223821878|NCT04885114|GENETIC|Intraparenchymal rAAV1 - (mi)RNA HTT|Single dose MRI guided intraparenchymal infusion of rAAV1 - (mi)RNA HTT.
223821879|NCT02070120|DRUG|Mitomycin C|Patients assigned to the chemoresection group will receive 4 once weekly intravesical instillations of 40mg MMC as outpatients.
223821880|NCT02070120|PROCEDURE|Surgical Management|Patients in this group should be treated according to local practice. Surgical interventions may include transurethral resection (TUR) or ablation.
223821881|NCT04937426|DIAGNOSTIC_TEST|Fluorescent-labeled Urease Inhibitor Marker to Detect Helicobacter Pylori|Diagnostic laboratory test for detection of helicobacter pylori
223821882|NCT02145078|DRUG|docetaxel|Given IV
223821883|NCT02145078|DRUG|pemetrexed disodium|Given IV
223821884|NCT02145078|DRUG|gemcitabine hydrochloride|Given IV
223821885|NCT02145078|OTHER|laboratory biomarker analysis|Correlative studies
223821886|NCT00477906|BIOLOGICAL|M-Vax- autologous, hapten-modified melanoma vaccine|Autologous, DNP-modified melanoma cells in suspension Dose: 12+-8 million cells Route: intradermal Frequency: weekly X7 + 6 month booster
223821887|NCT06342895|DEVICE|Nutritional support prescription and delivery monitoring feedback|Real-time availability in an integrated computer interface (Nutrow) of all clinical and biological information related to nutritional support including recommended, prescribed, and delivered calories and proteins and enteral feed delivery transmitted by the Feedim medical device
223821888|NCT06342895|DEVICE|Usual care|Usual use of standard clinical and biological information related to nutritional support as available through the ICU electronic health record (i.e. without any calculated information on recommended, prescribed, or received calories and protein, only information on prescribed products and volumes as collected by and presented in the ICU EHR) In this arm, participants, investigators, and healthcare professionals will be blinded to real-time enteral feed volumes that will be collected by the Feedim medical device and transmitted to the electronic study case report form.
223821889|NCT00237484|DRUG|Induction dose of (a) infliximab followed by combination of (b) pegylated interferon alfa-2b and (c) ribavirin|"1. Powder for intravenous infusion (100 mg strength), intravenous, single dose of 5 mg/kg, at Day -7, prior to initiation of the following combination therapy:~2. powder for injection in vials or Redipen (80, 100, 120, and 150 microgram strengths), subcutaneous, dose of 1.5 micrograms/kg, weekly for up to 48 weeks~3. 200 mg capsules, oral, dose of 800-1400 mg (weight based dosing as per PEGETRON Product Monograph), daily for up to 48 weeks"
223821890|NCT00237484|DRUG|Combination of (a) pegylated interferon alfa-2b and (b) ribavirin|"1. Powder for injection in vials or Redipen (80, 100, 120, and 150 microgram strengths), subcutaneous, dose of 1.5 micrograms/kg, weekly for up to 48 weeks~2. 200 mg capsules, oral, dose of 800-1400 mg (weight based dosing as per PEGETRON Product Monograph), daily for up to 48 weeks"
223821891|NCT04759742|DRUG|ropivacaine|According to previous clinical experience, 0.5% ropivacaine was given in the subarachnoid cavity, and the initial dose was set at 2.5 mL (12.5mg). Dixon's up-and down method was adopted to adjust or down-adjust the dose of ropivacaine in the next patient according to the experimental results of the previous patient, and the adjusted dose was 0.1 mL (0.5mg).
223821892|NCT03298503|OTHER|task-priority strategies|"posture-focus strategy: when performing postural-suprapostural task (dual-task), the patient mainly focus on postural task (standing/walking).~supraposture-focus strategy: when performing postural-suprapostural task (dual-task), the patient mainly focus on suprapostural task (stabilize the tray)."
223821893|NCT03375580|DIETARY_SUPPLEMENT|TLC|transform life custom (TLC)
223821894|NCT03375580|DRUG|metformin|0.5g metformin group，PO tid
223821895|NCT03375580|DRUG|Compound Zhenzhu Tiaozhi capsule|Compound Zhenzhu Tiaozhi capsules consist of eight Chinese herbal medications, such as Ligustrum lucidum, Atractylodes macrocephala, Radix Salviae Miltiorrhizae, pseudo-ginseng, Astragalus membranaceus.
223821896|NCT03375580|DRUG|Simvastatin|20mg simvastatin, PO qn
223821897|NCT06475469|BIOLOGICAL|Blood sampling & Chest CT without injection|Anlaysis of the repartition of non-tumorous lymphocytic subpopulation in patients with untreated Chronic Lymphocytic Leukemia (CLL)
223821898|NCT00170404|DRUG|Folic Acid|
223821899|NCT00170404|DRUG|Micronutrients: Vitamins B1, B2, B6, Niacin, B12, C, E.|
223821900|NCT00170404|DRUG|Selenium|
223821901|NCT00170404|DRUG|Vitamin A|
223821902|NCT01758861|DRUG|EPO group|
223821903|NCT01758861|DRUG|Placebo|
223821904|NCT05362682|OTHER|Sinopharm Vaccine|Sinopharm Vaccine will be administered by the Govt as part of COVID-19vaccination campaign
223821905|NCT01974505|DEVICE|intubation using optiscope|Optiscope (Clarus Medical, Minneapolis, MN, USA) is a semi-rigid fiberscope designed for endotracheal intubation. Anesthetic providers who are novice on optiscope will perform intubation using optiscope.
223821906|NCT02139475|PROCEDURE|Colonoscopy|
223821907|NCT05269784|PROCEDURE|Minimally Invasive Lung Surgery Under ERAS With Completely Tubeless Protocol|Minimally Invasive Lung Surgery Under ERAS With Completely Tubeless Protocol
223821908|NCT05269784|PROCEDURE|Minimally Invasive Lung Surgery Under ERAS With partially Tubeless Protocol|Minimally Invasive Lung Surgery Under ERAS With partially Tubeless Protocol
223821909|NCT00158210|DRUG|Rivastigmine|
223821910|NCT03327402|DRUG|SHP465|SHP465 capsule will be administered at a dose of 6.25 mg, orally once daily for 4 weeks. SHP465 is comprised of sulfate salts of dextroamphetamine and amphetamine, with dextroamphetamine saccharate and amphetamine aspartate monohydrate, which provide a composite enantiomer ratio of 3:1 d-amphetamine to l-amphetamine.
223821911|NCT01231841|DRUG|cyclosporine|Given orally
223821912|NCT01231841|BIOLOGICAL|anti-thymocyte globulin|Given IV
223821913|NCT03165162|BEHAVIORAL|Food Order|randomly assigned orders of 7 bowls of granola, each with a different food label.
223821914|NCT02674490|DEVICE|A-tDCS (1 mA)|1 mA of A-tDCS stimulation is induced between two 5 cm x 5 cm saline soaked sponges where one sponge (anode: A-tDCS) is placed on the scalp over the targeted cortical region. Ramping up of the current to 1 mA occurs over 10-15 seconds to allow participants to habituate to the tingling sensation. A-tDCS stimulation will be active only in the first 20 minutes of the 45-minute treatment session.
223821915|NCT02674490|BEHAVIORAL|SALT|Computer-delivered naming treatment requires matching word (heard and seen being produced by the speaker) with pictures depicting common objects. It is run on a laptop computer with headphones and 2 large response buttons. During treatment, a picture appears on the laptop screen for 2 seconds. Then, a video of the speaker's face below the nose is presented on the screen saying a word that either matches or does not match the picture. The participant is instructed to press a green response button if the word matches the picture and press the red response button if the word does not match the picture.
223821916|NCT02674490|DEVICE|Sham|1 mA of A-tDCS stimulation is induced between two 5 cm x 5 cm saline soaked sponges where one sponge (anode: A-tDCS) is placed on the scalp over the targeted cortical region. Ramping up of the current to 1 mA occurs over 10-15 seconds to allow participants to habituate to the tingling sensation. Then, the current will be ramped back down to 0 mA in the sham condition. Termination of the stimulation after the ramping up process is generally undetectable, and the brief duration of stimulation yields no functional effects.
223821917|NCT02440594|BEHAVIORAL|Enhanced BHL Program Services|Patients or their caregivers will work with a BHP to provided additional support and education beyond the services received in the Standard BHL Program.
223821918|NCT02440594|BEHAVIORAL|Standard BHL Program Services|Patients or their caregivers receive a baseline clinical assessment as well as monitoring of symptoms and referral to community resources.
223821919|NCT04170868|OTHER|ADHD Psycheducation|The videos will disseminate evidence-based strategies for the management of Attention Deficit Hyperactivity Disorder (ADHD). Each video, roughly two minutes, will both introduce the viewer to a single ADHD management strategy and explain how said strategy can effectively be integrated into their life.
223821920|NCT01673074|DRUG|(PDT) Photodynamic therapy|photosensitizer
223821921|NCT03836508|DEVICE|Medium cut-off|"All the dialysis sessions in this arm will be performed with the medium cut-off membrane (MCO) manufactured by Baxter International Corp. membrane for three months. This membrane will exclusively be used in hemodialysis. After third month, all patients will be switched to high-flux membrane manufactured by Fresenius.~Modalities of hemodialysis : Blood flow: 300-400 mL/min; Dialysate flow: 500-800 mL/min"
223821922|NCT03836508|DEVICE|High-Flux|"All the dialysis sessions in this arm will be performed with the high-flux membrane manufactured by Fresenius for three months. This membrane will exclusively be used in hemodialysis. After third month, all patients will be switched to MCO manufactured by Baxter International Corp.~Modalities of hemodialysis : Blood flow: 300-400 mL/min; Dialysate flow: 500-800 mL/min"
223821923|NCT04563806|DEVICE|Magnetic Resonance Imaging|Undergo MRI-guided surgery
223821924|NCT04563806|PROCEDURE|Therapeutic Conventional Surgery|Undergo spinal surgery
223821925|NCT00226564|DRUG|Alfentanil|
223821926|NCT00910637|DRUG|Gestodene/EE Patch (BAY86-5016)|55 mg ethinyl estradiol \& 2.1 mg gestodene, 21 days for 13 cycles
223821927|NCT06257719|OTHER|Compare the epidemiological characteristics, clinical presentations, surgical treatments and risk factors for preoperative complications of ALMs between paediatric and adult participants.|Compare the epidemiological characteristics, clinical presentations, surgical treatments and risk factors for preoperative complications of ALMs between paediatric and adult participants.
223821928|NCT04940182|DRUG|XC221|Participants will receive XC221 100 mg 2 times a day during 14 full days
223821929|NCT04940182|DRUG|Placebo|Participants will receive Placebo 2 times a day during 14 full days
223821930|NCT03775408|DEVICE|FAST|Orthopaedic surgeons will use the FAST device to facilitate entry point selection and alignment of a guidewire for intramedullary nailing of femoral shaft fractures.
223821931|NCT03810313|DRUG|Brolucizumab 6 mg|Solution for injection (intravitreal use)
223821932|NCT03810313|DRUG|Aflibercept 2 mg|Solution for injection (Intravitreal use)
223821933|NCT03810313|OTHER|Sham injection|Empty sterile syringe without a needle administered as a sham injection for masking. From Week 24 to Week 72 inclusive, a sham treatment was performed to maintain subject masking in case treatment with brolucizumab or aflibercept was not deemed necessary by the investigator.
223821934|NCT01377415|DRUG|bupivacaine|bupivacaine 5 mg/ml infusion 2 ml/h 48 h
223821935|NCT01898143|OTHER|Whole body vibration|
223821936|NCT00595829|DRUG|XL019|XL019 capsules administered orally
223821937|NCT00512551|PROCEDURE|Tumor Biopsies|Biopsies of the cervical tumor performed first before any treatment is given, and the second about 48 hours after radiation treatment has began.
223821938|NCT02738671|BEHAVIORAL|Cognitive assessment|
223821939|NCT02738671|OTHER|functional magnetic resonance imaging|
223821940|NCT02738671|OTHER|olfactory function measurement|
223821941|NCT02738671|PROCEDURE|bariatric surgery|Only a subgroup of the subjects will have the bariatric surgery.
223821942|NCT01079689|OTHER|needle stimulation|stimulation with acupuncture needles
223821943|NCT03133663|OTHER|Electrocardiogram group|Experimental
223821944|NCT03133663|OTHER|Pulse oximeter and auscultation group|Control
223821945|NCT03232320|DRUG|Meditoxin|Meditoxin (Botulinum toxin type A)
223821946|NCT03232320|DRUG|Placebo|Placebo (Normal saline)
223821947|NCT05203575|BEHAVIORAL|Fast-forwarding in Cycle 1|"The fast-forwarding intervention will consist of a projection of future risk of co-morbidities. A visual projection model will be built using archival data available through the Singapore Diabetes Registry. The projection model will use the current profile of the participant to calculate a risk profile for the participant's potential complications and co-morbidities, which will be presented as a pie chart. The tool will also present alternative scenarios to the participant and visualize how the likelihood of complications or co-morbidities would decrease or increases if his/her habits changed. This will provide the motivational aspect of the intervention.~This intervention takes place during Cycle 1 (first 14 weeks)."
223821948|NCT05203575|BEHAVIORAL|Goal-Setting plus Weekly Nudge in Cycle 1|"The procedure for goal-setting will start with the participant receiving a list of possible goals. The moderator will go through the list with the participant to identify which goals the participant is comfortable with and could reasonably achieve, and to tick off those goals that the participant has already achieved. The participants will choose their own goals. In each subsequent week, the moderator will check-in with the participant and tick off the goal(s) that have been achieved.~Chat groups of 10-15 people will be formed to administer the weekly nudge. The participants will be encouraged to introduce themselves and to interact with each other during each the chat session. Every week for the following 14 weeks, the moderator will post diabetes-related content on the WhatsApp chat group and introduce topics of interest according to a planned schedule.~This intervention takes place during Cycle 1 (first 14 weeks)."
223821949|NCT05203575|BEHAVIORAL|Fast-forwarding in Cycle 2|"The fast-forwarding intervention will consist of a projection of future risk of co-morbidities. A visual projection model will be built using archival data available through the Singapore Diabetes Registry. The projection model will use the current profile of the participant to calculate a risk profile for the participant's potential complications and co-morbidities, which will be presented as a pie chart. The tool will also present alternative scenarios to the participant and visualize how the likelihood of complications or co-morbidities would decrease or increases if his/her habits changed. This will provide the motivational aspect of the intervention.~This intervention takes place during Cycle 2 (second 14 weeks)."
223821950|NCT05203575|BEHAVIORAL|Goal-Setting plus Weekly Nudge in Cycle 2|"The procedure for goal-setting will start with the participant receiving a list of possible goals. The moderator will go through the list with the participant to identify which goals the participant is comfortable with and could reasonably achieve, and to tick off those goals that the participant has already achieved. The participants will choose their own goals. In each subsequent week, the moderator will check-in with the participant and tick off the goal(s) that have been achieved.~Chat groups of 10-15 people will be formed to administer the weekly nudge. The participants will be encouraged to introduce themselves and to interact with each other during each the chat session. Every week for the following 14 weeks, the moderator will post diabetes-related content on the WhatsApp chat group and introduce topics of interest according to a planned schedule.~This intervention takes place during Cycle 2 (second 14 weeks)."
223821951|NCT01829893|DRUG|In combination of 0.2mg finasteride and 5mg tamsulosin|oral medication with 240 mL water
223821952|NCT01829893|DRUG|GL2701 capsule|oral medication with 240 mL water
223821953|NCT01217489|PROCEDURE|Breast scan - Electrical Impedance Mammography|Scanning of the breast on a non-invasive device, using harmless minute electrical currents
223821954|NCT04672512|DRUG|CORT125329 lipid capsule formulation|CORT125329 lipid capsule formulation 1 or 2 for oral administration
223821955|NCT04672512|DRUG|Placebo|Placebo matching CORT125329 lipid capsule formulation 1 or 2 for oral administration
223821956|NCT04672512|DRUG|Prednisone|Prednisone tablet for oral administration
223821957|NCT03923361|DRUG|Diprivan|Similar to the high-intensity propofol treatments in Phase 1, the anesthesiologist will administer an induction dose of propofol followed by a continuous infusion, insert an airway, and begin mechanical ventilation. Propofol dosing will be adjusted with the goal of achieving a burst-suppression state with a SR of 40-60 for 12-15 minutes.
223821958|NCT05334121|DIETARY_SUPPLEMENT|Beta-alanine|The product will be consumed every day for 4 weeks. Four intakes of 3g each, separated by three hours each, will be carried out.
223821959|NCT05334121|OTHER|Control product consumption|Product with identical characteristics to the experimental product. The product will be consumed every day for 4 weeks. Four intakes of 3g each, separated by three hours each, will be carried out.
223821960|NCT01812382|DRUG|Retapamulin Microdialysis|After a 30 minutes equilibration period of the microdialysis procedure/infusion with normal saline solution, 50nanogram (ng)/mL Retapamulin injectable solution will be infused at a flow rate of 1.5 microliter/minute over a period of 90 minutes. The total dose perfused for each of the 3 microdialysis tubes will be 6.75ng.
223821961|NCT00509002|DRUG|Gefitinib|250 mg by mouth once a day, every day, at about same time in morning.
223821962|NCT05749601|OTHER|Influence of the metabolic syndrome (MetS) parameters on knee osteoarthritis (KOA) severity, the assesment of the reactive oxygen species and reactive nitrogen species in knee synovial fluid|Highlighting the influence of environment of origin on KOA incidence and corelated impact of high-density lipoprotein (HDL), low-density lipoprotein (LDL), total cholesterol, triglycerides and body mass index (BMI). The analytes from synovial fluid were determined by fluorometric method.
223821963|NCT05749601|OTHER|The influence of patellofemoral morphology in the radiological severity of knee osteoarthritis|Highlighting the influence of distal femoral torsion angle, patellofemoral congruence angle and sulcus angle, in KOA severity under the influence of sex and age.
223821964|NCT05749601|OTHER|The influence of ROS from the synovial fluid on the severity of KOA|Highlighting the influence of ROS from the synovial fluid in KOA severity under the influence of some biochemicals blood constants.
223821965|NCT02379559|BEHAVIORAL|Exercise|For the first 12-weeks, participants will come to our community based research office for up to 50 min/session, 3-days/week of supervised exercise. Exercise duration will increase from 75 min/wk at week 1 to 150 min/wk by week 4. Thereafter, men will maintain 150 min/wk of moderate-intensity physical activity.
223821966|NCT02379559|BEHAVIORAL|Attention Control|We will provide weekly healthy lifestyle tips via text messages, and will include tips such as managing stressors in life and getting better sleep.
223821967|NCT01532817|DEVICE|AlphaCore|A single 90 second stimulation to the vagus nerve on the right side of the neck
223821968|NCT03029780|BIOLOGICAL|Opdivo|Specified dose on specified days
223821969|NCT03029780|BIOLOGICAL|Yervoy|Specified dose on specified days
223821970|NCT04323228|DIETARY_SUPPLEMENT|Oral supplement enriched in antioxidants|the intervention group will receive a commercially available antioxidant supplement, which will be given to patients with COVID-19 in the morning after breakfast.
223821971|NCT04323228|DIETARY_SUPPLEMENT|cellulose-containing placebo capsules|The placebo group will receive an oral supplement at the same time in the same shape/size/color.
223821972|NCT00618696|BIOLOGICAL|anti-CD45 monoclonal antibody AHN-12|150 mg/m\^2 cold antibody at Day 0
223821973|NCT00618696|RADIATION|yttrium Y 90 anti-CD45 monoclonal antibody AHN-12|Dose per scheduled level; 2.5-12.5 mCi/m\^2
223821974|NCT03066622|DRUG|Standard of Care as per attending physician|Patients are randomized to standard of care medication (as determined by attending physician)
223821975|NCT03066622|DRUG|5mg rapidly dissolving olanzapine|5mg rapidly dissolving olanzapine
223821976|NCT03311425|DRUG|Methylprednisolone|Application of 40mg Depomedrol (methylprednisolone acetate) suspension into the retropharyngeal space prior to incision closure
223821977|NCT03311425|DRUG|Dexamethasone|Administration of 10mg Dexamethasone IV intraoperatively
223821978|NCT03380793|DRUG|morinidazole|morinidazole and sodium chloride injection (500 mg intravenous, twice daily for 5-7 days) with aztreonam and (or) etimicin.
223821979|NCT01111838|DRUG|STA-9090|Patients will be enrolled and receive 200mg/m2 of STA-9090. Patients will receive single agent STA-9090 intravenous (I.V.) infusion (an indwelling catheter may not be used) over 60 minutes weekly (three weeks on and one week off). Follow-up imaging will be performed every 8 weeks to evaluate response.
223821980|NCT00002901|DRUG|docetaxel|
223821981|NCT03347175|PROCEDURE|Volume controlled ventilation|Volume controlled ventilation mode
223821982|NCT03347175|PROCEDURE|Pressure controlled ventilation|Pressure controlled ventilation
223821983|NCT03347175|PROCEDURE|CPAP mode|CPAP mode only
223821984|NCT02707458|DRUG|Probucol|"Probucol was used with good effect for more than a decade in Canada and the US to reduce plasma cholesterol. Although withdrawn from the Canadian and US markets by its manufacturer for commercial reasons, it is still widely used for this purpose in Japan and Korea. Over the past decade, long-term follow-up studies in Asian populations at high risk of cardiovascular events have shown that the drug reduces the incidence of these events in a manner not unlike statin drugs used widely in Canada and the US."
223821985|NCT00641719|DRUG|Duloxetine hydrochloride|Duloxetine 40 mg QD, PO, 1 year
223821986|NCT00641719|DRUG|Duloxetine hydrochloride|Duloxetine 60 mg QD, PO, 1 year
223821987|NCT03303469|DRUG|FMISO|FMISO PET/CT imaging at baseline
223821988|NCT03303469|DRUG|FMISO|FMISO PET/CT post TACE
223821989|NCT03303469|DRUG|FMISO|FMISO PET/CT post SBRT
223821990|NCT01920425|DEVICE|Kinesia HomeView|Motion sensor based telemedicine system for assessment of movement disorder motor symptoms in the home. Includes automated motor assessment using motion sensor and electronic dyskinesia diary.
223821991|NCT01920425|OTHER|Hand-written diary|Hand-written paper diary indicating state (Off, On without dyskinesias, on with non-troublesome dyskinesias, on with troublesome dyskinesias) at 30 minute intervals.
223821992|NCT02487550|BIOLOGICAL|DC-CIK|Patients with renal cell carcinoma will receive autologous dendritic cells loaded with autologous tumor lysate (dendritic cell vaccine) by venous infusion of CIK cells.
223821993|NCT02487550|BIOLOGICAL|IL-2/IFN-α|Patients with renal cell carcinoma will receive IL-2/IFN-α by venous infusion.
223821994|NCT03170245|DIAGNOSTIC_TEST|Interleukin-6|serum samples used for doing the test by ELISA
223821995|NCT03170245|DIAGNOSTIC_TEST|HsC-RP|serum samples used for doing the test by ELISA
223821996|NCT03170245|DIAGNOSTIC_TEST|Adiponectin level|serum samples used for doing the test by ELISA
223821997|NCT03170245|DIAGNOSTIC_TEST|Carotid intima media thickness|Done by carotid doppler
223821998|NCT02444663|RADIATION|Clinician Valgus|Clinician performed valgus stress X-ray under fluoroscopy
223821999|NCT02444663|RADIATION|Clinician Varus|Clinician performed varus stress X-ray under fluoroscopy
223822000|NCT02444663|RADIATION|Device Valgus - 0 Newton|Device (Oxford Stress System for Knee Arthroplasty Radiographs (OSSKAR)) performed valgus stress X-ray under fluoroscopy.
223822001|NCT02444663|RADIATION|Device Valgus - 10 Newton|Device (Oxford Stress System for Knee Arthroplasty Radiographs (OSSKAR)) performed varus stress X-ray under fluoroscopy.
223822002|NCT02444663|RADIATION|Device Valgus - 20 Newton|Device (Oxford Stress System for Knee Arthroplasty Radiographs (OSSKAR)) performed valgus stress X-ray under fluoroscopy.
223822003|NCT02444663|RADIATION|Device Valgus - 30 Newton|Device (Oxford Stress System for Knee Arthroplasty Radiographs (OSSKAR)) performed valgus stress X-ray under fluoroscopy.
223822004|NCT02444663|RADIATION|Device Varus - 0 Newton|Device (Oxford Stress System for Knee Arthroplasty Radiographs (OSSKAR)) performed valgus stress X-ray under fluoroscopy.
223822005|NCT02444663|RADIATION|Device Varus - 10 Newton|Device (Oxford Stress System for Knee Arthroplasty Radiographs (OSSKAR)) performed valgus stress X-ray under fluoroscopy.
223822006|NCT02444663|RADIATION|Device Varus - 20 Newton|Device (Oxford Stress System for Knee Arthroplasty Radiographs (OSSKAR)) performed valgus stress X-ray under fluoroscopy.
223822007|NCT02444663|RADIATION|Device Varus - 30 Newton|Device (Oxford Stress System for Knee Arthroplasty Radiographs (OSSKAR)) performed valgus stress X-ray under fluoroscopy.
223822008|NCT00766454|GENETIC|DNA analysis|
223822009|NCT00766454|GENETIC|mutation analysis|
223822010|NCT00766454|GENETIC|polymorphism analysis|
223822011|NCT00766454|OTHER|laboratory biomarker analysis|
223822012|NCT00766454|OTHER|medical chart review|
223822013|NCT00766454|OTHER|questionnaire administration|
223822014|NCT00766454|PROCEDURE|evaluation of cancer risk factors|
223822015|NCT00958022|DRUG|LBH589 and carboplatin with etoposide|"LBH589 will be given in oral formulation starting at a dose of 10 mg (Dose Level 1) 3x/week (2 days apart, e.g. Mon, Wed, Fri), during 2 weeks out of 3-weekly dosing schedule. After establishing the MTD at a 2 out 3 weeks dosing schedule, a 3 out of 3 weeks dosing schedule will be tested at that dose. This schedule will be adopted in the absence of limiting toxicities. Will be continued weekly after completion of 6 cycles of combo chemotherapy until progression or intolerable toxicities.~Etoposide: Cycles 1-6: 100 mg/m² IV over 60 mins, Days 1-3 every 21 days for 6 cycles Carboplatin: commercially available as a sterile lyophilized powder available in single dose vials containing 50mg, 150mg, or 450mg of carboplatin. Each vial contains equal parts by weight of carboplatin \& mannitol. Commercial supplies will be used for this study. It will be administered as an i.v. infusion over 30 minutes. The dose will be calculated based on patient's body weight at each treatment visit."
223822016|NCT02923102|DIETARY_SUPPLEMENT|Aloysia citriodora extract|2 capsules with 200mg - daily dosage 400mg
223822017|NCT02923102|DIETARY_SUPPLEMENT|Maltodextrin|2 capsules with 200mg - daily dosage 400mg
223822018|NCT04741802|BEHAVIORAL|TOPS|weight loss program (Take Off Pounds Sensibly, TOPS) for overweight and obese African American breast cancer survivors in the local chapter of a national African American breast cancer support group (Sisters Network Triangle North Carolina, SNTNC).
223822019|NCT06355635|OTHER|Choice and Monitoring|current practive of vasoactive and inotrope drugs
223822020|NCT01212536|DEVICE|Airtraq laryngoscopy|laryngoscopy and intubation
223822021|NCT06310902|DIAGNOSTIC_TEST|Single-cell Sequencing Analysis|Identification of rare cell populations, the characterization of cell types and subtypes, and the discovery of novel cell states.
223822022|NCT00553098|BIOLOGICAL|Alemtuzumab|Given IV
223822023|NCT00553098|PROCEDURE|Allogeneic Bone Marrow Transplantation|Undergo HCT
223822024|NCT00553098|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo HCT
223822025|NCT00553098|DRUG|Cyclosporine|Given PO or IV
223822026|NCT00553098|DRUG|Fludarabine Phosphate|Given IV
223822027|NCT00553098|OTHER|Laboratory Biomarker Analysis|Correlative study
223822028|NCT00553098|DRUG|Mycophenolate Mofetil|Given PO or IV
223822029|NCT00553098|RADIATION|Total-Body Irradiation|Undergo low dose TBI
223822030|NCT01785563|DEVICE|Nasal NIV-NAVA|Infants will be placed on nasal NIV-NAVA. Patients initial NAVA level will be set to generate a peak inspiratory pressure that is 8 cm of water greater than their current peak end expiratory pressure. If the infants are on nasal NIV-NAVA at the time of study entry their NAVA level will be increased by 50% rounded up to the nearest 0.1 cm of water per microvolt.
223822031|NCT02766179|DEVICE|CPAP|CPAP is used for 6 weeks
223822032|NCT02766179|DEVICE|Somnoguard|Somnoguard is used for 6 weeks
223822033|NCT01872910|DRUG|Placebo|Administered orally
223822034|NCT01872910|DRUG|LY3023703|Administered orally
223822035|NCT01872910|DRUG|Celecoxib|Administered orally
223822036|NCT00100932|DRUG|E7389 28 Day Cycle|E7389 1.4 mg/m\^2 IV bolus on Days 1, 8, and 15 of a 28 day cycle.
223822037|NCT00100932|DRUG|E7389 21 Day Cycle|E7389 1.4 mg/m\^2 IV bolus on Days 1 and 8 of a 21 day cycle.
223822038|NCT01616771|DEVICE|Macintosh laryngoscope|Glottis view assessment by direct visualization using Macintosh laryngoscope
223822039|NCT01616771|DEVICE|GVL selected by weight|Glottis view assessment by GVL selected by weight which is usually selected first
223822040|NCT01616771|DEVICE|smaller sized GVL|Glottis view assessment by GVL which is smaller in one size than GVL selected by age
223822041|NCT00744328|DRUG|Transdermal Estradiol|Estradiol patch ranging in dose from 50 to 200 mcg/day
223822042|NCT00744328|DRUG|Sertraline|Sertraline dose will range from 50 - 200 mg/day
223822043|NCT00744328|OTHER|Placebo|Placebo patches and pills that are identical to transdermal estradiol and oral sertraline, respectively, will be used.
223822044|NCT00000508|BEHAVIORAL|smoking cessation|
223822045|NCT00000508|BEHAVIORAL|diet, reducing|
223822046|NCT00000508|BEHAVIORAL|exercise|
223822047|NCT00000508|BEHAVIORAL|diet, fat-restricted|
223822048|NCT02093676|BEHAVIORAL|"experimental protocol treatment The New Authority"|
223822049|NCT02720822|DRUG|Placebo|Treatment with placebo is given as one double-blind capsule in the morning.
223822050|NCT02720822|DRUG|Morphine Sulfate|Treatment with sustained-release morphine sulfate is given as one double-blind capsule in the morning.
223822051|NCT02720822|DRUG|Plus laxative (Docusate with senna)|If patients are taking morphine, a laxative will be offered. This applies whatever the dose of morphine being taken (8mg, 16mg, 24mg or 32 mg).
223822052|NCT02720822|DRUG|Plus placebo laxative|If the patients are taking placebo, a placebo laxative will be offered.
223822053|NCT02720822|DEVICE|FitBit charge HR (Accelerometer)|A Fitbit will be worn by patients during week 1 and week 3.
223822054|NCT04066140|OTHER|No intervention|No Intervention. Observational Study.
223822055|NCT00815035|DRUG|Peanut OIT|Peanut flour that is orally ingested in a graded fashion.
223822056|NCT00815035|DRUG|Placebo|Oat flour used as a placebo that is orally ingested a graded fashion
223822057|NCT01784692|DIETARY_SUPPLEMENT|Immulina|
223822058|NCT01767935|PROCEDURE|cryosurgery|Undergo cryosurgery
223822059|NCT01767935|RADIATION|radiation therapy|Undergo radiation therapy
223822060|NCT01767935|PROCEDURE|quality-of-life assessment|Ancillary studies
223822061|NCT05224635|PROCEDURE|Vascular Injury|The Society of Vascular Surgery has established a robust vascular disease registry but this organization's focus is on vascular disease and lacks capture of the data points necessary to discern trauma-specific outcomes. Recent military experience from the United States and United Kingdom, including the Balad Vascular Registry and the Global War on Terror (GWOT) Vascular Registry have provided a contemporary assessment of wartime vascular injury, but again these studies have been retrospective case series and registry reviews. Furthermore, applications of lessons learned in wartime vascular injury do not completely translate to management in trauma centers in the United States.
223822062|NCT02387216|DRUG|MM-121|Investigational, fully human antibody targeting and inhibiting ErbB3
223822063|NCT02387216|DRUG|Docetaxel|approved chemotherapy treatment for NSCLC
223822064|NCT01238224|DRUG|Tadalafil|This is an acute study. Tadalafil 20 mg administered prior to a meal
223822065|NCT04381936|DRUG|Lopinavir-Ritonavir|Lopinavir 400mg-Ritonavir 100mg by mouth (or nasogastric tube) every 12 hours for 10 days.
223822066|NCT04381936|DRUG|Corticosteroid|Corticosteroid in the form of dexamethasone administered as an oral (liquid or tablets) or intravenous preparation 6 mg once daily for 10 days. In pregnancy or breastfeeding women, prednisolone 40 mg administered by mouth (or intravenous hydrocortisone 80 mg twice daily) should be used instead of dexamethasone. Corticosteroid (in children ≤44 weeks gestational age, or \>44 weeks gestational age with PIMS-TS only) in the form of Hydrocortisone or Methylprednisolone sodium succinate (see Protocol for timing and dosage)
223822067|NCT04381936|DRUG|Hydroxychloroquine|Hydroxychloroquine by mouth for a total of 10 days (see Protocol for timing and dosage).
223822068|NCT04381936|DRUG|Azithromycin|Azithromycin 500mg by mouth (or nasogastric tube) or intravenously once daily for 10 days.
223822069|NCT04381936|BIOLOGICAL|Convalescent plasma|Single unit of ABO compatible convalescent plasma (275mls +/- 75 mls) intravenous per day on study days 1 (as soon as possible after randomisation) and 2 (with a minimum of 12 hour interval between 1st and 2nd units).
223822070|NCT04381936|DRUG|Tocilizumab|Tocilizumab by intravenous infusion with the dose determined by body weight (see Protocol for dosage)
223822071|NCT04381936|BIOLOGICAL|Immunoglobulin|Intravenous immunoglobulin (IVIg) for children \>44 weeks gestational age and \<18 years with PIMS-TS only (see Protocol for dosage)
223822072|NCT04381936|DRUG|Synthetic neutralising antibodies|Patients ≥12 years only with COVID-19 pneumonia: A single dose of REGN10933 + REGN10987 8 g (4 g of each monoclonal antibody) in 250ml 0.9% saline infused intravenously over 60 minutes +/- 15 minutes as soon as possible after randomisation
223822073|NCT04381936|DRUG|Aspirin|150 mg by mouth (or nasogastric tube) or per rectum once daily until discharge, for adults ≥18 years old.
223822074|NCT04381936|DRUG|Colchicine|1 mg after randomisation followed by 500mcg 12 hours later and then 500 mcg twice daily by mouth or nasogastric tube for 10 days in total, for men ≥18 years old and women ≥55 years old only
223822075|NCT04381936|DRUG|Baricitinib|UK \[age ≥2 years with COVID pneumonia\] and India \[age ≥18 years with COVID-19 pneumonia\]: 4 mg once daily by mouth or nasogastric tube for 10 days in total.
223822076|NCT04381936|DRUG|Anakinra|For children ≥1 \<18 years old only: subcutaneously or intravenously once daily for 7 days or discharge (if sooner). NB Anakinra will be excluded from the randomisation of children \<10 kg in weight.
223822077|NCT04381936|DRUG|Dimethyl fumarate|Early phase assessment. UK adults ≥18 years old only (excluding those on ECMO). 120 mg every 12 hours for 4 doses followed by 240 mg every 12 hours by mouth for 8 days (10 days in total).
223822078|NCT04381936|DRUG|High Dose Corticosteroid|Adults ≥18 years old with hypoxia only. Dexamethasone 20 mg (base) once daily by mouth, nasogastric tube or intravenous infusion for 5 days follow by dexamethasone 10 mg (base) once daily by mouth, nasogastric tube or intravenous infusion for 5 days.
223822079|NCT04381936|DRUG|Empagliflozin|Adults ≥18 years old only. 10 mg once daily by mouth for 28 days (or until discharge, if earlier).
223822080|NCT04381936|DRUG|Sotrovimab|UK patients ≥12 years old. 1000 mg in 100 mL 0.9% sodium chloride or 5% dextrose by intravenous infusion over 1 hour as soon as possible after randomisation.
223822081|NCT04381936|DRUG|Molnupiravir|Patients ≥18 years old. 800 mg twice daily for 5 days by mouth.
223822082|NCT04381936|DRUG|Paxlovid|UK patients ≥18 years old. 300/100 mg twice daily for 5 days by mouth.
223822083|NCT04381936|DRUG|Baloxavir Marboxil|"Patients ≥12 years old in the UK (or ≥18 years old in other countries), with or without SARS-CoV-2 co-infection.~40mg (or 80mg if weight ≥80kg) once daily by mouth or nasogastic tube to be given on day 1 and day 4."
223822084|NCT04381936|DRUG|Oseltamivir|"Any age in the UK (or ≥18 years old in other countries), with or without SARS-CoV-2 co-infection.~75mg twice daily by mouth or nasogastric tube for five days. (See Protocol for detailed dosage information)"
223822085|NCT04381936|DRUG|Low-dose corticosteroids: Dexamethasone|Any age in the UK (or ≥18 years old in other countries), without suspected or confirmed SARS-CoV-2 infection, and with clinical evidence of hypoxia (i.e. receiving oxygen or with oxygen saturations \<92% on room air) 6mg once daily given orally or intravenously for ten days or until discharge (whichever happens earliest)
223822086|NCT04381936|DRUG|Low-dose corticosteroids: Dexamethasone|≥18 years old) with a diagnosis of community-acquired pneumonia (with planned antibiotic use and without suspected or confirmed SARS-CoV-2, influenza, active pulmonary tuberculosis, or Pneumocystis jirovecii infection) 6mg once daily given orally or intravenously for ten days or until discharge (whichever happens earliest)
223822087|NCT02724722|BEHAVIORAL|Assigned intervention|a simple flyer plus face-to-face health education and give one bag containing stainless steel-made tableware for eating out use
223822088|NCT02724722|BEHAVIORAL|No intervention|a simple flyer only with no face-to-face health education and give one bag not containing stainless steel-made tableware for eating out use
223822089|NCT03017157|OTHER|Echo-cardiogram|Patients will undergo echo-cardiogram to determine improvement in their heart function and this will be compared to thyroid function
223822090|NCT03017157|OTHER|Blood test|Blood test to determine thyroid function
223822091|NCT02861144|OTHER|Ma ka hana ka ̒ike|Ma ka hana ka ̒ike is a self-management program for diabetic patients which includes 5 interactive group sessions lasting 1-1/2 hours in length delivered by community peer educators once a month for 6 months.
223822092|NCT02861144|OTHER|Hanapū Provider Toolbox|Hanapū Provider Toolbox is an educational tools that will aid the health care providers in guiding their patients to optimal glycemic control.
223822093|NCT00310323|DRUG|Dextromethorphan|0.5 mg/kg (maximum 30 mg)
223822094|NCT00310323|DRUG|Caffeine|Administered as 4 ounces of Coca-Cola
223822095|NCT01393080|DRUG|Nimotuzumab and TP regimen|"1. TP Regims：Paclitaxel Liposome,135mg/m2,d1;Carbopatin（AUC=5） d2, 3 weeks/cycle, for 4 cycles.~2. Nimotuzumab: 200mg/w, weekly, for 6 weeks; Consolidation treatment， 200mg every 2 weeks, until the end of 4 cycles of chemotherapy or the disease progression."
223822096|NCT01393080|DRUG|TP regimen|TP Regimen：Paclitaxel Liposome,135mg/m2,d1;Carbopatin（AUC=5） d2, 3 weeks/cycle,for 4 cycles.
223822097|NCT04919174|DRUG|Remimazolam|Sedation with remimazolam
223822098|NCT04919174|DRUG|Dexmedetomidine|Sedation with dexmedetomidine
223822099|NCT00166686|DRUG|Clonidine|
223822100|NCT06481254|OTHER|Hawthorn Vinegar Group|To routine oral mucositis treatment, patients with DM in the hawthorn vinegar group gargled with 1 tablespoon (10 cc) of diluted hawthorn vinegar (mixed with 40 cc water) for 1 minute 15-20 minutes before meals 3 times a day for 14 days.
223822101|NCT06481254|OTHER|Black Mulberry Syrup Group|To routine oral mucositis treatment, patients with DM in the black mulberry syrup group pure black mulberry syrup for 1 minute 15-20 minutes before meals 3 times a day for 14 days.
223822102|NCT06481254|OTHER|Green Tea Group|To routine oral mucositis treatment, patients with DM in the green tea group gargled with 50 cc green tea for 1 minute 15-20 minutes before meals 3 times a day for 14 days.
223822103|NCT06321978|DEVICE|Mepilex Border Flex|Usage of Mepilex Border Flex according to intended use and standard of care.
223822104|NCT06288711|BEHAVIORAL|Prolonged exposure therapy|Twelve weekly 60-minute telemedicine-delivered prolonged exposure therapy sessions provided by therapists trained in prolonged exposure therapy.
223822105|NCT06288711|BEHAVIORAL|Financial incentives|Financial incentives contingent upon completion of prolonged exposure therapy sessions
223822106|NCT06288711|BEHAVIORAL|Treatment as usual|Continued standard buprenorphine or methadone maintenance treatment from current treatment provider.
223822107|NCT02418975|OTHER|Very low-calorie protein-based diet|Patients will receive a homemade very low-calorie (\~5 kcal/kg of ideal body weight /day) protein-based formula (milk proteins; 1.2 g per kilogram of ideal body weight) for 4 weeks by a polyurethane nasogastric feeding tube.
223822108|NCT02418975|OTHER|Hypocaloric diet|Patients will receive a commercial balanced enteral formula (\~20 kcal/kg of ideal body weight /day; protein content, 1.0 g per kilogram of ideal body weight) for 4 weeks by a polyurethane nasogastric feeding tube.
223822109|NCT04363385|BIOLOGICAL|Biological test|Blood sample
223822110|NCT00433953|DRUG|Mycophenolate Mofetil (CellCept)|
223822111|NCT00433953|BEHAVIORAL|Dietary Monitoring|
223822112|NCT00433953|BEHAVIORAL|Drug Diary|
223822113|NCT00433953|PROCEDURE|Blood Sampling|
223822114|NCT00179699|DRUG|CC-5013|
223822115|NCT00179699|DRUG|pemetrexed|
223822116|NCT02534532|OTHER|AF screening|Screening of AF in an opportunistic screening program using a smartphone device/application confirmed by ECG
223822117|NCT01560260|OTHER|Laboratory Biomarker Analysis|Correlative studies
223822118|NCT01560260|DRUG|Linsitinib|Given PO
223822119|NCT01560260|OTHER|Pharmacological Study|Correlative studies
223822120|NCT05952297|DEVICE|Sleep Wellness Device (BeCurie)|This device emits micro electromagnetic stimulation
223822121|NCT04654247|BEHAVIORAL|Quality audit and feedback|Endoscopists received quality report generated by Endo.Adm.
223822122|NCT04654247|BEHAVIORAL|Control|None feedback.
223822123|NCT04060225|OTHER|Coffee|Starbuck's brand blonde roast coffee, 20 ounces
223822124|NCT02223117|BIOLOGICAL|Thrombosomes|Freeze-dried platelets
223822125|NCT02223117|BIOLOGICAL|Placebo|
223822126|NCT03375632|DRUG|FYU-981|Oral daily dosing for 14 weeks
223822127|NCT00282997|DRUG|pregabalin|
223822128|NCT06044363|OTHER|Satir group|Participants in the intervention group will receive a 10-session, 3-hour/session intervention that spans over a period of five days (2 sessions/day). The intervention program will be conducted on specific weekends, with a gap of 1 to 2 weeks. The total duration of the intervention will be 30 hours.
223822129|NCT02235701|DRUG|170 mg/m2 aldoxorubicin|administered at 170 mg/m2 plus 1 gm/m2/day ifosfamide by continuous intravenous infusion for up to 14 days on Day 1 every 28 days
223822130|NCT02235701|DRUG|250 mg/m2 aldoxorubicin|administered at 250 mg/m2 plus 1 gm/m2/day ifosfamide by continuous intravenous infusion for up to 14 days on Day 1 every 28 days
223822131|NCT05285254|OTHER|Certified Child Life Specialist Support|Provides psychosocial care to children and families confronting stressful and painful situations
223822132|NCT05059054|OTHER|Strengthening exercise|"Strengthening exercise program Participants performed this protocol at home for 3 times per day. The participants progress their exercise based on the achievement of the previous level of each exercise protocol. The physical therapist recorded the level of each exercise for each participant during eight times of treatment. Total time for this section is approximately 30 minutes. Detail of the strengthening exercise is in the following.~1. Toe curl exercise (toe flexors strengthening)~2. Ankle evertor exercise (peroneal strengthening)~3. Ankle invertor exercise (tibialis posterior strengthening)~4. Heel raise exercise (high-load strength training)"
223822133|NCT05059054|OTHER|Insole (CFO) group|"The CFO insole group The participants will receive the foot assessment before making the CFO for each participant. The 3-quarter-length CFO will be made from thermoplastic material (rigid foot orthoses) which consists of four layers i.e. two layers of 0.5-mm polyvinyl chloride (PVC) and one layer of 1.5-mm thick fiber to increase strength of foot orthoses in the bottom layers as well as one layer of 1.2-mm genuine leather in the upper layer to increase comfort.~The participants will be asked to use the CFO in daily life during weight-bearing activities."
223822134|NCT00525265|DRUG|OPC-41061(Tolvaptan)|Subjects will be orally administered OPC-41061 7.5 mg or 15 mg once daily after breakfast for seven days.
223822135|NCT00525265|DRUG|Placebo|Subjects will be orally administered placebo once daily after breakfast for seven days.
223822136|NCT02104635|BEHAVIORAL|Delivery of a Post-Partum Package|
223822137|NCT00073827|DRUG|levalbuterol tartrate MDI|levalbuterol 90 mcg QID
223822138|NCT00073827|DRUG|racemic albuterol MDI|racemic albuterol 180 mcg QID
223822139|NCT00073827|DRUG|Placebo|Placebo MDI QID
223822140|NCT05415033|OTHER|BREAST-Q|arabic version of breast questionnaire
223822141|NCT01915433|OTHER|Wahls Paleo Plus|The study diet is based upon a Paleolithic Diet, also known as a Hunter Gatherer Diet, which exceeds the recommended daily allowance of water soluble vitamins and minerals 1.5 to 8 fold and improves lipids, inflammatory biomarkers and blood pressure. The study diet is further structured to be a low in carbohydrate and high in fat but still ensure consumption of the specific micronutrients important to optimal brain function. This diet is designed to induce a low level nutritional ketosis.
223822142|NCT01915433|OTHER|Wahls Diet|The study diet is based upon a Paleolithic Diet, also known as a Hunter Gatherer Diet, which exceeds the recommended daily allowance of water soluble vitamins and minerals 1.5 to 8 fold and improves lipids, inflammatory biomarkers and blood pressure. The study diet is further structured to be a low glycemic diet and also ensure consumption of the specific micronutrients important to optimal brain function.
223822143|NCT06061432|PROCEDURE|Endoscopic restoration of gastrointestinal continuity after Hartmann procedure|EndoHARP is a new technique proposed to restore gastrointestinal continuity after the Hartmann's procedure. For EndoHARP, a fixed loop of the large intestine will be identified on endosonography after an echoendoscope is inserted into the rectal stump under endoscopic guidance. Then, using the set for inserting self-expandable metal transmural endoprosthesis (20 mm in diameter and 10 mm in length) with electrocautery (as in endoscopic gastroenterostomy), EUS-guided anastomosis of the rectal stump to the large intestine loop will be performed, allowing the natural passage of intestinal contents through the endoscopic anastomosis, restoring gastrointestinal continuity. The aim of leaving the self-expandable transmural endoprosthesis in the anastomosis is not only to maintain the patency of the intestinal anastomosis of at least 20 mm in diameter, but also to diminish the risk of endoscopic intestinal anastomotic leak by completely covering the prosthesis with a polymer layer.
223822144|NCT05436964|OTHER|saline|Patients in the experimental group were given a loading dose of 0.6 μg/kg of saline intravenously after 10 minutes of intubation, followed by a continuous infusion at a rate of 0.4 μg/kg/h until 30 min before the end of the surgery.continuous infusion at a rate of 0.4 μg/kg/h until 30 min before the end of the surgery.
223822145|NCT05436964|DRUG|Dexmedetomidine|Patients in the experimental group were given a loading dose of 0.6 μg/kg of dexmedetomidine intravenously after 10 minutes of intubation, followed by a continuous infusion at a rate of 0.4 μg/kg/h until 30 min before the end of the surgery.
223822146|NCT01729234|DIETARY_SUPPLEMENT|Nitrate|Dietary Supplement
223822147|NCT01729234|DIETARY_SUPPLEMENT|Placebo|Dietary Supplement
223822148|NCT05353959|OTHER|No intervention|No intervention
223822149|NCT03107377|DRUG|EVO100|5 g dose applied up to 1 hour prior to coitus
223822150|NCT03107377|DRUG|Placebo|5 g dose applied up to 1 hour prior to coitus
223822151|NCT02218528|DIETARY_SUPPLEMENT|Plant-based ingredient|
223822152|NCT02218528|DIETARY_SUPPLEMENT|No Plant-based ingredient|
223822153|NCT03826511|OTHER|Tiszasüly hot mud-pack therapy|Patients received Tiszasüly hot mud-packs (42 Celsius degree) for 30 minutes on 10 occasions for 2 weeks (10 working days) on the painful knee.
223822154|NCT03826511|OTHER|Kolop mud-pack|Patients received Kolop hot mud-packs (42 Celsius degree) for 30 minutes on 10 occasions for 2 weeks (10 working days) on the painful knee.
223822155|NCT05145946|BEHAVIORAL|Video Game Training Group 1|Closed-loop audiomotor game. Home-based training sessions for 3.5 hours per week over an 8-week.
223822156|NCT05145946|BEHAVIORAL|Video Game Training Group 2|Auditory memory game. Home-based training sessions for 3.5 hours per week over an 8-week.
223822157|NCT05439577|DRUG|Mucopolysaccharide Polysulfate Cream|Patients using Hirudoid® alone
223822158|NCT05439577|DRUG|Mucopolysaccharide Polysulfate Cream and glucocorticoids|Patients using Hirudoid® and glucocorticoids (Combination therapy, but not always)
223822159|NCT00373932|BEHAVIORAL|Coached exercise persistence intervention|Collaborative symptom and exercise monitoring and weekly reinforcement for exercise persistence from nurse coach via a mobile device and telephone.
223822160|NCT00373932|BEHAVIORAL|Self-Monitored exercise persistence intervention|Self-monitoring of symptoms and exercise using a mobile device
223822161|NCT03577574|PROCEDURE|retrobulbar anesthesia|2% lidocaine 4ml injected into retrobulbar space
223822162|NCT03577574|PROCEDURE|peribulbar anesthesia|2% lidocaine 4 to 8ml injected into peribulbar space
223822163|NCT03577574|PROCEDURE|two step anesthesia|conjunctival cul-de-sac anesthetized with 0.5% proparacaine hydrochloride drops three times + 2% lidocaine 0.6 to 0.8ml subconjunctival injection
223822164|NCT03648203|BEHAVIORAL|Technology Enabled Asthma Management System|See description of arm
223822165|NCT03596437|DEVICE|Ultra High Frequency ultrasound system|Agreement for carotid intima-media thickness in vascular Ehlers Danlos Syndrome and for triple signal identification in fibromuscular dysplasia will be assessed.
223822166|NCT01448954|DRUG|ADC3680B oral|Once daily for 28 days
223822167|NCT01448954|DRUG|Placebo oral|Once daily for 28 days
223822168|NCT02482636|BIOLOGICAL|DTaP/IPV/Hib vaccine|Given at 2, 3 and 4 months to Group 1 and 2
223822169|NCT02482636|BIOLOGICAL|13 valent Pneumococcal Conjugate Vaccine|Given at 2,4 and 12 months in group 1, given at 3 and 12 months in group 2
223822170|NCT02482636|BIOLOGICAL|Rotavirus vaccine|Given at 2 and 3 months to Group 1 and 2
223822171|NCT02482636|BIOLOGICAL|4-component Meningococcal B vaccine|Given at 2, 4 and 12 months to Group 1 and 2
223822172|NCT02482636|BIOLOGICAL|Meningococcal C/Hib vaccine (MenC/Hib vaccine)|Given at 12 months to Group1 and 2
223822173|NCT02482636|BIOLOGICAL|Measles/Mumps/Rubella Vaccine (MMR vaccine)|Given at 13 months to Groups 1 and 2
223822174|NCT02415374|OTHER|Avenanthramides|AVAs are a group of diphenolic acids that are found only in oats (Avena sativa). In this study, each dietary group of subjects will receive three cookies made with oat flour containing high-AVA (H-AVA, 229.56 mg/kg) and low-AVA (L-AVA, 32.69 mg/kg).
223822175|NCT04336423|DIAGNOSTIC_TEST|Obtain samples from sputum and feces|Samples are obtained from participants. No further intervention is required. Obtained samples will be further analyzed.
223822176|NCT00211237|DEVICE|Balloon Kyphoplasty|Ballon Kyphoplasty is a minimally invasive technique aimed at reduction of VCFs using KyphX® Inflatable Bone Tamps followed by fracture fixation with KyphX® HV-R™ Bone Cement.
223822177|NCT00211237|OTHER|Non Surgical Management|Non-surgical treatment includes, but is not limited to, the following: back brace, pain medication, physical therapy, walking aids, bed rest, and radiation treatment.
223822178|NCT02390063|BIOLOGICAL|ChAdOx1.5T4|A recombinant simian adenovirus encoding human tumour-associated antigen 5T4
223822179|NCT02390063|BIOLOGICAL|MVA.5T4|A recombinant replication deficient Modified Vaccinia Ankara virus encoding human tumour-associated antigen 5T4
223822180|NCT02390063|DRUG|Cyclophosphamide|Metronomic cyclophosphamide (50mg bd)
223822181|NCT00227500|DRUG|Pravastatin|
223822182|NCT00741715|DRUG|AVE5530|oral administration once daily in the evening with dinner
223822183|NCT00741715|DRUG|atorvastatin|oral administration once daily in the evening with dinner
223822184|NCT00741715|DRUG|placebo|oral administration once daily in the evening with dinner
223822185|NCT00875732|DEVICE|Bi Ventricular Pacing|
223822186|NCT00875732|DEVICE|Right Ventricular Pacing|
223822187|NCT01946581|PROCEDURE|Cataract Surgery|
223822188|NCT05242575|BEHAVIORAL|The information provided in the iVFT and control book parallel one another.|"An immersive virtual fled trip (iVFT) is a form of virtual reality (VR). The term immersive refers to an experience where the senses become heightened through multisensory input (e.g., visual, auditory, proprioceptive). When adding peripherals such as a head-mounted device (HMD) (e.g., goggles with 3D-lenses), a mobile phone becomes a pseudo-theater providing a 360-degree view that mimics the real world. For example, one can experience a simulated rollercoaster or visit the moon that may otherwise be inaccessible in day-to-day life. Also, a VFT provides for context and aids in background knowledge that is a crucial aspect of learning.~Participants will receive three interventions sessions each last 15-minutes."
223822189|NCT04443387|DRUG|Vitamin D|A double-blinded, randomized, placebo-controlled study of VitD supplementation on 45 asthmatics with VitD deficiency was performed. Moderate to severe asthmatics between 18 and 65 years of age who had clinician-diagnosed asthma with 25-hydroxyvitamin D3 (25 D3) level less than 20ng/mL at the screening visit were recruited at the Rashid Hospital, Dubai, U.A.E., and the Zayed Military Hospital, Abu Dhabi, U.A.E. Subjects were excluded if they had used any previous VitD supplementation, had any other respiratory diseases or co-morbid conditions or were smokers. According to the American Academy of Family Physicians guidelines, participants received 50, 000 IU of VitD orally or placebo weekly over 8 weeks. Subjects were blinded to treatment and allocated to receive a VitD dose or placebo by the randomization schedule.
223822190|NCT04443387|OTHER|Placebo|A double-blinded, randomized, placebo-controlled study of VitD supplementation on 45 asthmatics with VitD deficiency was performed. Moderate to severe asthmatics between 18 and 65 years of age who had clinician-diagnosed asthma with 25-hydroxyvitamin D3 (25 D3) level less than 20ng/mL at the screening visit were recruited at the Rashid Hospital, Dubai, U.A.E., and the Zayed Military Hospital, Abu Dhabi, U.A.E. Subjects were excluded if they had used any previous VitD supplementation, had any other respiratory diseases or co-morbid conditions or were smokers. According to the American Academy of Family Physicians guidelines, participants received 50, 000 IU of VitD orally or placebo weekly over 8 weeks. Subjects were blinded to treatment and allocated to receive a VitD dose or placebo by the randomization schedule.
223822191|NCT04548271|DRUG|Camrelizumab|Anti-PD-1 targeted immunotherapy
223822192|NCT04548271|DRUG|Apatinib|A small-molecule vascular endothelial growth factors receptor (VEGFR) tyrosine kinase inhibitor
223822193|NCT03757806|OTHER|Experimental group|"LiFE4D is an individualised programme, adapted to the participant's needs/preferences.~People with Dementia will receive assistance to increase their physical activity multiple times/day in their everyday tasks with the support/supervision of their caregivers.~The programme last for 12 weeks, with a lower face tracking over time with the health professional but replaced by caregivers. The intervention includes face-to-face sessions and phone calls. Face-to-face sessions aim to adapt physical activity to everyday tasks, increase tasks frequency and intensity, monitor progress, clarify doubts, motivate and manage expectations. Phone calls aim to monitor motivation/evolution and clarify doubts."
223822194|NCT04078035|BEHAVIORAL|Socio-evaluative speech task|5-minute speech task designed to induce physiological arousal in a laboratory setting.
223822195|NCT04078035|BEHAVIORAL|Control, Quiet Rest|5-minute quiet rest period.
223822196|NCT05250258|OTHER|Telephone peer support by telephone|"Peer support by telephone from experienced father to new father with depressive symtoms.~4 times or more if requested during 4 months"
223822197|NCT01013792|DEVICE|Wound Dressing|Acetate mesh carrier with ointment (water, PEGs)
223822198|NCT01013792|DEVICE|Wound Dressing|Acetate mesh carrier with ointment (water, PEGs, cations, citric acid)
223822199|NCT00001495|DRUG|irinotecan (CPT-11)|
223822200|NCT05921071|DRUG|Tranexamic acid|One gram of tranexamic acid (Hexakapron) is administered intravenously before surgery
223822201|NCT05921071|DRUG|Placebo|patients will receive 10 ml of normal saline 0.9% intravenously.
223822202|NCT02100722|PROCEDURE|FFR guided PCI|
223822203|NCT02100722|PROCEDURE|CABG|Coronary Artery Bypass Graft Surgery (CABG)
223822204|NCT02100722|DEVICE|Resolute Integrity Stent|Durable polymer zotarolimus-eluting stent
223822205|NCT02100722|DEVICE|Resolute Onyx Stent|Durable polymer zotarolimus-eluting stent
223822206|NCT01261715|PROCEDURE|Dermabond- liquid skin adhesive|Dermabond- liquid skin adhesive
223822207|NCT06473701|DRUG|Dronabinol 2.5mg Capsule|Dronabinol 2.5 mg pr capsule. Titration up till 20 mg daily dose.
223822208|NCT06473701|DRUG|Placebo|Dronabinol-matched placebo capsule containing no active substance.
223822209|NCT03961009|BIOLOGICAL|Kedrion IVIG 10%|Kedrion intravenous immunoglobulin (IVIg) 10%
223822210|NCT01349894|DEVICE|SNaP® Wound Care System|Wound dressing applications using customized system. Dressing applications changes per manufacturer recommendation.
223822211|NCT04394585|BEHAVIORAL|smart phone app based human coaching program|"1. experimental arm~   * 1:1 coaching using smart phone app~  * Patients are provided several articles about postoperative care (symptom management, diet, and exercise) in the app.~  * Patients are encouraged to report their diet diaries and exercise everyday by the coach.~  * Patients can ask to the coach using the app and the coach answer when they check them.~2. Comparator arm - Patient have consulting with clinical nutritionist at 1 month and 3 months postoperatively."
223822212|NCT06285565|COMBINATION_PRODUCT|Nurse-led telephone coaching intervention with home telemonitoring of vital signs|In addition to standard care, the intervention group will receive a nurse-led supportive programme that involves a pre-discharge educational meeting and 6-month telephone coaching sessions. Patient's caregivers will also be invited to participate. After discharge, patients will be asked to measure their vital signs, daily. In case of alteration, the nurse will ascertain the presence of congestion symptoms and decide to reinforce the recommendations for self-management, request a specialist medical consultant, or refer to the emergency services
223822213|NCT03351218|BEHAVIORAL|Behavioral testing - computerized tasks|Cognitive behavioral testing and cerebral MRI
223822214|NCT03875079|DRUG|RO6874281|"Part I Safety Run in:~Cohort 1.1: RO6874281 will be administered by intravenous (IV) infusion; 10 mg (Q3W) every 3 weeks and will be observed over 2 administration cycles (i.e. 6 weeks) in order to confirm the safety of the proposed dose and schedule that will be used in Part II of this study.~Cohort 1.2: RO6874281 will be administered by IV infusion via an induction and maintenance phase; 10 mg (QW) every week for 3 weeks followed by 10 mg (Q3W) every 3 weeks and will be observed over 2 administration cycles (6 weeks) to confirm safety of the proposed dose and schedule to be used in Part III of this study.~Part II Expansion: RO6874281 will be administered by IV infusion; 10 mg (Q3W) every 3 weeks (or lower dose level depending on Part I Cohort 1.1 outcome).~Part III Expansion: RO6874281 will be administered by IV infusion; 10 mg (QW) every week or 10mg (Q3W) every 3 weeks (or lower dose level depending on Part I Cohorts 1.1 and 1.2 outcomes) in either a Q3W or QW/Q3W schedule."
223822215|NCT03875079|DRUG|Pembrolizumab|"Part I Safety Run in (Cohorts 1.1 and 1.2): Pembrolizumab will be administered by IV; 200 mg Q3W and will be observed over 2 administration cycles (i.e. 6 weeks).~Part II Expansion: Pembrolizumab will be administered by IV; 200 mg Q3W (or lower dose level depending on Part I Cohort 1.1 outcome)~Part III Expansion: Pembrolizumab will be administered by IV; 200 mg Q3W (or lower dose level depending on Part I Cohorts 1.1 and 1.2 outcomes)"
223822216|NCT02541383|DRUG|Bortezomib (VELCADE), Thalidomide, and Dexamethasone (VTD)|Part 1: 4 Cycles of Bortezomib,Thalidomide and Dexamethasone induction therapy, followed by Autologous Stem Cell Transplantation, followed by 2 cycles of Bortezomib, Thalidomide and Dexamethasone consolidation
223822217|NCT02541383|DRUG|Bortezomib, Thalidomide, Dexamethasone (VTD) + daratumumab|Part 1: 4 Cycles of Bortezomib, Thalidomide and Dexamethasone plus daratumumab 16mg/kg induction therapy, followed by Autologous Stem Cell Transplantation, followed by 2 cycles of Bortezomib, Thalidomide and Dexamethasone plus daratumumab 16 mg/kg consolidation
223822218|NCT02541383|DRUG|Daratumumab|Daratumumab 16mg/kg every 8 weeks for 2 years
223822219|NCT05425303|DIAGNOSTIC_TEST|Exposure to risk for injury|Athletes will be examined in the preseason stage and will be monitored during the competitive season.
223822220|NCT05786274|DIAGNOSTIC_TEST|Cerebral autoregulation monitoring|Perioperative characterization of cerebral autoregulation and autonomic function; characterization of adverse events after surgery
223822221|NCT00785525|DRUG|Filgrastim|PBSC donors will receive 10 µg/kg of filgrastim subcutaneously each day of a five day mobilization schedule.
223822222|NCT04978545|OTHER|calciumhydroxide, intracanal medicament|In the CH group, calcium hydroxide powder (Calxyl; OCO Products, Dirnstein, Germany) was mixed with saline in a ratio 1:1 and the paste was inserted into the canal by using lentulo spirals (Malleifer-Dentsply).
223822223|NCT04978545|OTHER|chlorhexidine, intracanal medicament|, chlorhexidine gel 2% (Gluco-Chex 2% gel, Cerkamed, Stalowa Wola, Polland) was placed into the root canals of this group with an Ultradent Capillary Tip (Ultradent products).
223822224|NCT05500703|DRUG|Dexmedetomidine Injectable Solution|continuous pump of 1.5ug / kg / h Dexmedetomidine 15min before anesthesia induction, continuous infusion for 30min after anesthesia induction, and then nuclear magnetic scanning was started.
223822225|NCT05500703|DRUG|Sodium Chloride 0.9% Inj|the equivalent Sodium Chloride 0.9% Inj was continuously pumped before anesthesia induction, induced by opioids for 15min, and intraoperative fMRI scanning was started after continuous infusion for 30min.
223822226|NCT03705845|DRUG|placebo softgel|Each placebo softgel of 430 mg olive oil will contain no TT or tocopherols at detectable levels.
223822227|NCT03705845|DRUG|DeltaGold® Tocotrienol 70%|DeltaGold® Tocotrienol 70% contains 430 mg tocotrienol (90% δ-tocotrienol + 10% γ-tocotrienol) with a 70% purity, representing 300 mg tocotrienol.
223822228|NCT05796518|OTHER|PREVENT Cardiovascular Health Assessment Tool|Participants will access a heart health information visualization tool online using a personal device or a study tablet computer using their e-mail address to log-in. Investigators will review participant lab results specifically related to their cardiovascular health (e.g. blood pressure, cholesterol) in order to personalize the heart health tool for participants. A brief survey before and after use of the tool will also be completed by participants.
223822229|NCT05796518|OTHER|Survey|A brief survey before and after use of the tool will also be completed by participants.
223822230|NCT05796518|OTHER|Interview Regarding Heart Health|Participants will be asked questions related to their heart health.
223835541|NCT01347645|DRUG|FOLFIRI|Comparator dose and mode of administration The FOLFIRI regimen consists of irinotecan at 180 mg/m2 (IV infusion) on Day 1 of each 14-day cycle, leucovorin at 200 mg/m2 (400 mg/m2 if using d,l-racemic mixture of leucovorin) by IV infusion on Day 1 of each cycle, and 5-FU at 400 mg/m2 as an IV bolus injection followed by a total of 2400 mg/m2 by continuous IV infusion over 46 hours over Days 1 and 2 via an ambulatory programmable pump (the use of an ambulatory pump is optional).
223822231|NCT05324345|BEHAVIORAL|Prehabilitation group|All patients will be guided to use the network learning platform which including details in text, pictures and videos of their individualized prehabilitation strategy after a complete assessment. Multimodal prehabilitation strategy includes conventional guidance (including preoperative anesthesia assessment, drug treatment recommendations for chronic disease, quit smoking and abstinence), physical exercise (moderate aerobic exercise combined with resistance exercise and respiratory training), nutritional suggestion and optimization (whey protein supplement), and psychological therapy. All movements can be practiced with the reference to the standard videos in the network learning platform. Patients will check the prehabilitation content daily and form their own training tasks in the network learning platform. Standardized short message interviews will be sent to patients twice a week to optimize adherence and promote timely feedback.
223822232|NCT06412328|OTHER|Psychoeducation|The psychoeducation program based on psychosocial support is a total of 8 sessions. Families participating in the study received the psychoeducation program over 4 weeks, with two sessions per week, each session lasting 60 minutes. Parents were included in group work during the psychoeducation program.
223822233|NCT00259415|BEHAVIORAL|Caregiver support via telephone|
223822234|NCT04031521|DIAGNOSTIC_TEST|Near infrared spectroscopy|NIRS is an emerging technology for measuring tissue oxygenation and endothelial function. NIRS light can penetrate through biological tissues, including skin, bone, and muscle. Similar to other optical methods, light is applied to the region of interest and undergoes scattering and absorption before being detected by a photosensor. This technique is commonly used to assess oxygen availability and consumption in living tissues. Using different wavelengths, NIRS can differentiate between oxygenated and deoxygenated hemoglobin in blood and can measure changes in total hemoglobin concentration, using the sum of oxygenated and deoxygenated hemoglobin.
223822235|NCT05791890|DRUG|Gilteritinib|observational study to evaluate the incidence of infections during therapy with Gilteritinb
223822236|NCT05764291|BEHAVIORAL|FIT-TEENS|FIT-TEENS is a digital behaviour change intervention which provides information on physical activity and behaviour change support towards physical activity, presented in multimedia format through an online learning platform (EdApp). The contents is developed in Malay language and consist of 10 self-paced modules and activities. The objectives of FIT-TEENS are for the participants to be able to 1) review the definitions and health benefits of physical activity 2) provide an overview of physical activity guidelines 3) write a SMART goal about physical activity 4) be aware of barriers to physical activity and how to overcome them.
223822237|NCT00058227|DRUG|alvocidib|Given IV
223822238|NCT00058227|DRUG|fludarabine phosphate|Given IV
223822239|NCT00058227|BIOLOGICAL|rituximab|Given IV
223822240|NCT00058227|OTHER|pharmacological study|Correlative studies
223822241|NCT06059534|DIETARY_SUPPLEMENT|Dietary supplementation with placebo.|Volunteers will be provided with the placebo capsules. For each volunteer, different age-associated skin parameters will be measured with specialized equipment before the treatment and 4, 8 and 12 weeks after the first oral intake of the product.
223822242|NCT06059534|DIETARY_SUPPLEMENT|Dietary supplementation with DracoBelleTM Nu.|Volunteers will be provided with the DracoBelleTM Nu capsules. For each volunteer, different age-associated skin parameters will be measured with specialized equipment before the treatment and 4, 8 and 12 weeks after the first oral intake of the product.
223822243|NCT04197011|DEVICE|prosthetic device|Individuals with TFA will use a combination of prosthetic devices.
223822244|NCT04379037|DEVICE|Transcutaneous Auricular Vagus Nerve Stimulation|Transcutaneous vagus nerve stimulation involves stimulating the auricular branch of the vagus nerve with a imperceptible electrical current within the concha of the ear.
223822245|NCT03908073|DEVICE|Transcutaneous vagal nerve stimulation|The use of a transcutaneous vagal nerve stimulator by the participant
223822246|NCT02066896|DEVICE|Lasertherapy|Laser 808 wave length infrared Ga AlAs(gallium-aluminum-arsenide). The laser beam applied bilaterally in non contact mode to each salivary gland area, extra orally to the parotid and submandibular glands and intramurally to the sublingual gland/ 4 Joules/cm2 each point (active group)
223822247|NCT02066896|DEVICE|Sham Lasertherapy|Laser 808 wave length infrared Ga AlAs(gallium-aluminum-arsenide).The device will be applied with the laser pen closed by aluminium foil (placebo group).
223822248|NCT04923308|OTHER|Triage results disclosed|Following the chiropractor triage assessment, the working diagnosis and risk stratification or referral need will be communicated to the specialist using a standardized clinical note, prior to the patient's consultation and without further discussion.
223822249|NCT04923308|OTHER|Triage results undisclosed|Following the chiropractor triage assessment, the working diagnosis and risk stratification or referral need will not be communicated to the specialist.
223822250|NCT00513786|DRUG|Carboplatin|AUC (area under curve) 5 Intervenous (IV) over 30 minutes given every 21 days for a maximum of 6 cycles.
223822251|NCT00513786|DRUG|Paclitaxel|175 mg/m2 over 3 hours given every 21 days for a maximum of 6 cycles.
223822252|NCT00513786|DRUG|bevacizumab|15 mg/kg intervenous (IV) given every 21 days for a maximum of 6 cycles.
223822253|NCT03764540|DRUG|Cabazitaxel plus prednisone|"Cabazitaxel 25 mg/m² intravenously on day 1 of each cycle, plus prednisone 10 mg orally given daily.~A cycle is defined as a 3-weeks period for a maximum of 10 cycles."
223822254|NCT03764540|DRUG|Docetaxel plus prednisone|"Docetaxel 75 mg/m² intravenously on day 1 of each cycle, plus prednisone 10 mg orally given daily.~A cycle is defined as a 3-weeks period for a maximum of 10 cycles."
223822255|NCT03794375|OTHER|Telehealth|After 45 days after the estimated date of the consultation (6 months after discharge), the Telehealth staff will contact the patient to check if the consultation was actually performed. When individuals report difficulty accessing the unit, contact will be made to the primary care teams and the Telehealth staff will schedule the appointment. A new contact will be made in 12 months to verify if the consultation was actually performed.
223822256|NCT03794375|OTHER|Usual care|The patients will remain in care at the HCPA thyroid disease outpatient clinic during the study period. This follow-up will be done by endocrinologists, and the patients will undergo clinical, biochemical (TSH, thyroglobulin, and antithyroglobulin) and radiological (cervical ultrasound) tests to seek disease recurrence. The patient's consultation will be done one or twice a year.
223822257|NCT06489223|DEVICE|Orofacial Myofunctional Rehabilitation Pacifier|The pacifier will be offered to the child
223822258|NCT04677400|OTHER|More than Body Appearance (MBA) Intervention|"The MBA is an online psychological intervention designed to improve body image. The intervention lasts 15 days, and it comprises two types of activity (1st and 2nd week).~During the first week of the MBA intervention, participants sill read three blocks of psychoeducational material including information about: 1) body image; 2) positive body image and healthy lifestyles; and 3) body functionality.~During the second week participants produce 3 structured writing assessment pertaining to body functionality and why it is important. Each assignment focused on two areas of body functionality: 1) body's senses and physical capacities; 2) health and creative skills; 3) self-care/daily routine and communication with others. For each writing assignment, participants were asked to reflect, describe, and specify why these aspects of body functionality were personally important and meaningful to them."
223822259|NCT05205317|DRUG|Metformin Hydrochloride Sustained-release Tablets|drug
223822260|NCT05205317|PROCEDURE|Vaginal repair|The procedure of vaginal repair of CSD was shown as following. The bladder was dissected away carefully from the uterus toward the abdominal cavity until the peritoneum was reached. The CSD tissue was cut to the normal healthy muscle after the abdominal cavity had been entered, and the lower uterine segments had been completely exposed. A double layer of 1-0 absorbable interrupted sutures was used to close the incisions.
223822261|NCT06133764|PROCEDURE|Enucleation+ Peripheral Ostectomy+Carnoy's solution chemical cauterization (E+CS + PO)|The enucleation procedures, which were meticulously carried out in order to remove the odontogenic keratocyst in one piece without breaking its lining or leaving any epithelial remnants.The peripheral ostectomy treatment will be carried out with a large spherical bur and plenty of irrigation.After filling the bone cavity with more sterile gauze, the Carnoy's solution was slowly injected into it with a plastic syringe. The gauze was continuously injected with CS until it was fully saturated without leaking too much into the surrounding tissues. The CS was held in place for 3 minutes.
223822262|NCT06133764|PROCEDURE|Decompression/ marsupialization (D/M)|A surgical window will be created in the cyst wall to drain the contents while retaining continuity between the cyst and the oral cavity
223822263|NCT06133764|PROCEDURE|Enucleation (E)|The enucleation will be accomplished in the same manner that it will be performed in the group of Enucleation+ Peripheral Ostectomy+Carnoy's solution chemical cauterization (E+ PO+ CS).
223822264|NCT06133764|PROCEDURE|Enucleation+Carnoy's solution (E+CS)|Both enucleation and Carnoy's solution will be carried out as planned in the group Enucleation+ Peripheral Ostectomy+Carnoy's solution chemical cauterization (E+ PO+ CS).
223822265|NCT06133764|PROCEDURE|Enucleation+ Peripheral Ostectomy (E+ PO)|Both enucleation and peripheral ostectomy will be carried out as planned in the group Enucleation+ Peripheral Ostectomy+ Carnoy's solution chemical cauterization (E+ PO+ CS).
223822266|NCT04127552|PROCEDURE|Adrenalectomy|Adrenalectomy according to 2016 ESE guidelines
223822267|NCT06285968|BEHAVIORAL|Multidimensional Sleep Health Promotion Intervention|Multi-component multidimensional sleep health promotion intervention that includes sleep health and sleep hygiene education, behavioral coaching, personalized feedback, goal setting and establishment of a sleep health plan, self-monitoring, supportive accountability, and addressing light and noise in the sleep environment.
223822268|NCT01065350|DRUG|Propofol|As part of the induction, subjects will be given 2 milligrams per kilogram of body weight (mg/kg) of propofol. The clinician will receive a 20 milliliter (mL) syringe of propofol. If the dose, 2 mg/kg, does not add up to a total of 20 mL, normal saline will be added to make up for the 20 mL. The clinician and observer will be blinded to the medication and doses being administered during induction given that both syringes, syringes in the propofol and ketofol groups, will look identical (will both appear to be propofol only). The propofol group will also be given an additional 10 mL syringe of propofol due to any patient responding to stimulus after induction. The 10 mL syringe represents 1 mg/kg of propofol. If patient receives both the 20 and 10ml syringe, he or she will receive a total of 3mg/kg of propofol.
223822269|NCT01065350|DRUG|Ketamine|As part of the induction, patients will be given 20ml syringe of ketofol which is weight based such that ketamine will represent 0.75mg/kg of the dose and propofol, 1.5mg/kg. The clinician and observer will be blinded to the medication and doses being administered during induction given that both 20ml syringes (propofol group and ketofol group) will look identical (will both appear to be propofol only). Additional 10ml syringe will be given due to any patient responding to stimulus after induction. The 10ml syringe will represent 0.25mg/kg of ketamine and 0.5mg/kg of propofol. If the patient receives both the 20 and 10ml rescue syringe, he or she will receive a total of 1mg/kg of ketamine and 2mg/kg of propofol.
223822270|NCT00246233|DRUG|methylphenidate|
223822271|NCT03629652|OTHER|head-down position treatment|In the head-down position, the body is in the supine position with the head lowered to 30 degrees
223822272|NCT03629652|OTHER|Conventional Rehabilitation|The body is in the supine position without lowered head
223822273|NCT01468441|DRUG|Triptorelin|Triptorelin (0.1 mg, Gonapeptyl® Daily; Ferring, Kiel, Germany) in alternate-days from Day 1 of the menstrual cycle until the day of hCG administration.
223822274|NCT01468441|DRUG|Cetrorelix|When patients presented at least two follicles ≥ 14mm upon scan on days 7- 9, GnRH antagonist (cetrorelix, 0.25 mg/day, Cetrotide®; EMD Serono, Inc, Rockland, MA, USA) administration is started and continued until hCG administration.
223822275|NCT02210793|PROCEDURE|transepithelial PRK|
223822276|NCT02210793|PROCEDURE|LASIK|
223822277|NCT00674089|DIETARY_SUPPLEMENT|Vitamin A|Vitamin A 50,000 IU
223822278|NCT00674089|DIETARY_SUPPLEMENT|Placebo|Vitamin A Placebo
223822279|NCT00840255|BEHAVIORAL|BBTI-MV|Twenty participants will be randomized to BBTI-MV. As previously described, the intervention will be delivered over 4 consecutive weeks, which include individual face-to-face visits on Weeks 1 and 3, and telephone appointments on Weeks 2 and 4. Interventions will be delivered at Western Psychiatric Institutes and Clinic. If possible, (according to space availability), the face-to-face sessions may also be conducted at the VAPHS clinics or at Reserve and Veterans Centers locally and regionally to strengthen our relations with local care and services providers and centers, and to facilitate future collaborative efforts. The duration of the first treatment visit is 45-minutes, and the follow-up visit on Week 3 will last no more than 30 minutes. Brief (\<20 minutes) telephone sessions will be conducted on Weeks 2 and 4.
223822280|NCT00840255|OTHER|Information Control|Participants will receive two brochures from the American Academy on Sleep Medicine of Sleep Hygiene and on Insomnia. The therapists will read the content of the 2 brochures with participants, and discuss how the information provide relates to individual participants' sleep experiences. No recommendations for altering sleep schedules will be made by the assigned therapist. Participants will be instructed to read these two brochures over the course of the following week, and to consider how the information provided in the brochures related to their own sleep patterns
223822281|NCT00189592|DEVICE|ArthroCare TOPAZ™ MicroDebrider™ using Coblation|Percutaneous treatment of plantar fascia using the Topaz device. No incision performed.
223822282|NCT00189592|PROCEDURE|Surgical Fasciotomy|Standard surgical fasciotomy using an incision to treat the plantar fascia.
223822283|NCT01373450|DRUG|Oxyntomodulin|3.0 pmol/kg/min as an intravenous (IV) infusion in the morning of the day of graded glucose infusion (GGI) (Day 1)
223822284|NCT01373450|DRUG|Liraglutide 0.6 mg|Single subcutaneous dose in the evening of the day before the GGI (Day-1)
223822285|NCT01373450|DRUG|Liraglutide 1.2 mg|Single subcutaneous dose in the evening of the day before the GGI (Day-1)
223822286|NCT01373450|DRUG|Placebo for Oxyntomodulin|IV infusion in the morning of the day of GGI (Day 1)
223822287|NCT01373450|DRUG|Placebo for Liraglutide|Single subcutaneous dose in the evening of the day before the GGI (Day-1)
223822288|NCT00627900|DEVICE|bare metal stent|implantation of a bare metal stent
223822289|NCT00627900|DEVICE|Cypher-Stent (Implantation of a sirolimus-eluting stent)|Implantation of a sirolimus-eluting stent
223822290|NCT03893201|OTHER|Questionnaires|Questionnaires to assess quality of life
223822291|NCT02985983|DRUG|Brodalumab|Administered Brodalumab by subcutaneous (SC) injection until week 66.
223822292|NCT02985983|DRUG|Placebo|Administered Placebo by subcutaneous (SC) injection until week 16. Administered Brodalumab by SC injection from week 17 until week 66.
223822293|NCT02865070|DEVICE|Skin Sensor|Wireless vitals monitor
223822294|NCT00158340|BEHAVIORAL|Guided self-help cognitive behavioral therapy (CBT)|Participants receive eight sessions of guided self-help CBT.
223822295|NCT00158340|BEHAVIORAL|Usual clinical care|Control group participants receive treatment as usual.
223822296|NCT06483425|GENETIC|Sequencing of DNA, RNA, and Proteins|Sequencing of DNA, RNA, and Proteins for Tumor, Blood, Ascite, and other samples before and after treatment.
223822297|NCT04659395|OTHER|Emergency nurses|Emergency nurses who are trained for one-day in ultrasound-guided femoral nerve block
223822298|NCT05794802|DIETARY_SUPPLEMENT|BHB supplement|Oral consumption of 0.5 g/kg of a BHB supplement (KE4; Ketoneaid®, Falls Church, Virginia, USA)
223822299|NCT05794802|OTHER|Placebo solution|80 to 120 ml of a placebo solution, depending on the participant's body weight, with the addition of stevia and bitter agent solution (Bitrex, Scotland, UK) as well as the same flavouring as the ketone supplement drink (provided by Ketoneaid)
223822300|NCT01906671|DRUG|Xaluprine|Comparison of plasma kinetics after administration of 6-mercaptopurine in the form of a tablet (Puri-Nethol) and in the form of an oral liquid formulation (Xaluprine). Each patient will be included in both arms of the study, because of the cross-over design.
223822301|NCT01906671|DRUG|Puri-Nethol|Comparison of plasma kinetics after administration of 6-mercaptopurine in the form of a tablet (Puri-Nethol) and in the form of an oral liquid formulation (Xaluprine). Each patient will be included in both arms of the study, because of the cross-over design.
223822302|NCT01928316|DRUG|Mizolastine domestic (made in China)|Healthy male volunteers will receive 10 mg domestic (made in China) mizolastine tablets on Day 1 and Day 8
223822303|NCT01928316|DRUG|Mizolastine (imported)|Healthy male volunteers will receive 10 mg imported mizolastine tablets on Day 1 and Day 8
223822304|NCT04623320|DIAGNOSTIC_TEST|euglycaemic clamp test|clamp test (golden standard) to determine insulin resistance
223822305|NCT04623320|DIAGNOSTIC_TEST|13C glucose breath test|13C glucose breath test to compare with the golden standard
223822306|NCT06382714|OTHER|For the intervention group, a museum visit with virtual reality glasses will be applied.|Patients will visit a museum while undergoing hemodialysis with virtual reality glasses for a total of five sessions for intervention group
223822307|NCT04653441|BEHAVIORAL|Child-Caregiver-Advocacy-Resilience [ChildCARE] intervention|"The proposed multimodal Child Caregiver-Advocacy-Resilience intervention (ChildCARE) will include three integrated components: the individual child (peer-group activities), family (caregiver parenting skill training), and the local community (community advocacy)."
223822308|NCT00235599|PROCEDURE|IGFBP-3 Stimulation Test|
223822309|NCT02516722|DEVICE|Therapeutic Intra-Vascular UltraSound (TIVUS™) System|"The TIVUS™ System generates high intensity, non-focused ultrasonic energy that is delivered through the wall of the pulmonary artery to achieve local nerve deactivation.~Denervation in the pulmonary arteries (PDN) would be performed during right heart catheterization. The PDN procedure would be attempted in the main, right and left pulmonary arteries, close to the main bifurcation."
223822310|NCT00510458|DEVICE|LFIT™ Femoral Heads With X3® Insert|LFIT™ Anatomic CoCr Femoral Heads With X3® Polyethylene Insert in total hip replacement
223822311|NCT05555992|DEVICE|Electrical Activation Mapping Guided Cardiac resynchronization therapy|To study the feasibility to optimize configuration of CRT delivery for acute correction of electrical dyssynchrony using a noninvasive mapping of global electrical activation
223822312|NCT05573503|OTHER|Bring it up - Assessment and support of patients' sexuality in cancer nursing|"Participants will attend a five week online university course, Bring it up - Assessment and support of patients' sexuality in cancer nursing. The course addresses theories and models about sexuality in relation to cancer illness, conversation techniques, models for addressing sensitive topics, methods for assessing the impact of cancer on sexuality, methods for preventing and treating sexual problems in relation to cancer, relevant nursing interventions for person-centred counselling about sexuality, and ethical aspects.~The teaching consists of literature, online lectures, seminars, clinical practice, and written exams. A university certificate will be issued to participants who pass all exams."
223822313|NCT02569710|DRUG|AL-335|AL-335 tablets will be administered in a dose range of 400 to 1200 mg once daily (QD).
223822314|NCT02569710|DRUG|Odalasvir (ODV)|ODV capsules will be administered in a dose range of 25 to 50 mg.
223822315|NCT02569710|DRUG|Simeprevir (SMV)|SMV tablets will be administered in a dose range of 75 to 150 mg QD or every other day (QOD).
223822316|NCT01175889|DEVICE|E-Z Clean ACE Blade|The prospective assessment of the E-Z Clean ACE electrosurgical electrodes using the ACE Blade in the ACE Mode for targeted procedures such as abdominoplasty, bilateral breast reduction, bilateral breast lifts, bilateral brachioplasty, bilateral lateral thigh and buttocks lifts, or any combination thereof.
223822317|NCT05296499|DIAGNOSTIC_TEST|Cardiopulmonary exercise test (CPET)|Cardiopulmonary exercise testing using cycle ergonomenter
223822318|NCT05296499|DIAGNOSTIC_TEST|Exercise cardiac MRI|Exercise cardiac MRI using supine cycle, participants exercised to peak workload as determined by CPET
223822319|NCT05296499|OTHER|6 minute walk test|6MWT
223822320|NCT05296499|DIAGNOSTIC_TEST|Blood tests|FBC, U\&E, LFTS
223822321|NCT05296499|OTHER|Quality of life questionnaires|SF36, EQ5D, VEINES-QoL/Sym
223822322|NCT05296499|OTHER|Repeat baseline assessments|repeat baseline
223822323|NCT05296499|DIAGNOSTIC_TEST|MR venogram|MRI scan of venous system
223822324|NCT02929225|DRUG|Bifid Triple Viable Capsules|BIFICO is prescribed as a dose of 4 capsules twice daily in half hours after meals.
223822325|NCT02929225|OTHER|placebo|placebo is also prescribed as a dose of 4 capsules twice daily
223822326|NCT02043028|DEVICE|Chest compression with a step stool|Participants compress the chest of a manikin with a standing posture using a step stool during 5 minutes
223822327|NCT02043028|DEVICE|Chest compression with a kneeling stool|Participants compress the chest of a manikin with kneeling posture using a kneeling stool during 5 minutes
223822328|NCT04433962|OTHER|Exercise training|
223822329|NCT03120689|OTHER|Live Surgery using VITOM|The vaginal operative field will be filmed with a VITOM® camera and the image from the VITOM® camera will be projected live within the operating room, so that the operating team can reference the image during the surgery.
223822330|NCT03120689|OTHER|Live Surgery without VITOM|The vaginal operation will not be filmed and learner observation will take place in the traditional way, with them looking at the physical surgical field.
223822331|NCT03120689|OTHER|Video viewing with VITOM|They will view the 10-minute standardized video filmed with the VITOM® camera.
223822332|NCT03120689|OTHER|Video viewing with standard handheld high-definition camera|They will view the 10-minute standardized video filmed with the standard, handheld high-definition camera.
223822333|NCT03352843|DRUG|Primaquine|All patients will be administered with a single low-dose of primaquine in addition to standard artemether-lumefantrine regimen, and then followed-up for 28 days for clinical and laboratory assessment to assess safety and efficacy.
223822334|NCT05585138|OTHER|segmental breathing exercise|Group-A (interventional group) will receive segmental breathing exercises and deep breathing. segmental breathing exercise will be performed by taking a deep and long breath from nose patient inhale air in to lungs and in exhalation therapist will apply pressure on intercostal spaces at apical, lateral and posterior for one month 5 days a week and 2 sessions per day for 15 minutes for each patient. conventional treatment will be for one month 5 days a week 10 to 15 repetitions of deep breathing exercise 2 times a day.
223822335|NCT05585138|OTHER|deep breathing|conventional treatment will be for one month 5 days a week 10 to 15 repetitions of deep breathing exercise 2 times a day. . deep breathing exercise will be performed by taking a deep and long breath from nose patient inhale air in to lungs and will exhale through mouth.
223822336|NCT00116402|DRUG|fluticasone and salmeterol|"1. will start with fluticasone 220 mcg BID first and then crossover to combination therapy with salmeterol 50 mcg BID~2. will start with salmeterol 50 mcg BID first and then crossover to combination therapy with fluticasone 220 mcg BID."
223822337|NCT02269514|OTHER|Own Brand Cigarette|combustible cigarette brand style smoked most frequently by subject
223822338|NCT02269514|OTHER|Electronic Cigarette #1|VUSE® Digital Vapor Cigarette (original flavor, 14mg nicotine)
223822339|NCT02269514|OTHER|Electronic Cigarette #2|VUSE® Digital Vapor Cigarette (original flavor, 29mg nicotine)
223822340|NCT02269514|OTHER|Electronic Cigarette #3|VUSE® Digital Vapor Cigarette (original flavor, 36mg nicotine)
223822341|NCT02269514|OTHER|Leading U.S. Nicotine Gum|4 mg nicotine polacrilex gum
223822342|NCT02149784|PROCEDURE|Surgical resection of primary tumor|Surgical resection of primary tumor of mCRC patients who were respond to first line chemotherapy'
223822343|NCT03373864|PROCEDURE|Unilateral spinal anesthesia|Unilateral spinal anesthesia with hypobaric local anesthesia allowing a lateralized anesthesia of the fractured limb.
223822344|NCT03373864|PROCEDURE|General anesthesia|General anesthesia following the latest recommendations for elderly patients (SFAR 2017)
223822345|NCT02603822|DIETARY_SUPPLEMENT|12C mannitol|12C mannitol 100 mg
223822346|NCT02603822|DRUG|Indomethacin|Subjects will receive six 25 mg capsules of Indomethacin (immediate release). The subjects will take 3 capsules 8 hours before the timing of visit 5 (before fasting), and 3 additional capsules 30 minutes before visit 5.
223822347|NCT02603822|DIETARY_SUPPLEMENT|13C mannitol|13C mannitol 100 mg
223822348|NCT02603822|DIETARY_SUPPLEMENT|Lactulose|lactulose 1 g
223822349|NCT00425425|BIOLOGICAL|cetuximab|
223822350|NCT00425425|DRUG|fluorouracil|
223822351|NCT00425425|DRUG|oxaliplatin|
223822352|NCT00425425|PROCEDURE|conventional surgery|
223822353|NCT00425425|PROCEDURE|neoadjuvant therapy|
223822354|NCT00425425|RADIATION|radiation therapy|
223822355|NCT05341102|DRUG|LY3556050|Administered orally.
223822356|NCT05341102|DRUG|Placebo|Administered orally.
223822357|NCT02716038|DRUG|MPDL3280A|MPDL3280A is a human, Fc optimized, monoclonal antibody directed against the protein ligand programmed cell death-1 ligand 1 (PD-L1), with potential immune checkpoint inhibitory and antineoplastic activities. Atezolizumab binds to PD-L1, blocking its binding to and activation of its receptor programmed death 1 (PD-1) expressed on activated T-cells, which may enhance the T-cell-mediated immune response to neoplasms and reverse T-cell inactivation. MPDL3280A 1200 mg will be administered as a 60 minute IV infusion on first administration, then over 30 minutes subsequently if tolerated.
223822358|NCT02716038|DRUG|Carboplatin|Carboplatin is a second-generation platinum compound with a broad spectrum of antineoplastic properties. Carboplatin contains a platinum atom complexed with two ammonia groups and a cyclobutane-dicarboxyl residue. This agent is activated intracellularly to form reactive platinum complexes that bind to nucleophilic groups, thereby inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links. These carboplatin-induced DNA and protein effects result in apoptosis and cell growth inhibition. Carboplatin area under the curve (AUC)=6 will be administered as a 30 minute IV infusion immediately after nab-paclitaxel.
223822359|NCT02716038|DRUG|Nab-paclitaxel|Nab-paclitaxel is an albumin-stabilized nanoparticle formulation of the natural taxane paclitaxel with antineoplastic activity. Nab-paclitaxel binds to and stabilizes microtubules, preventing their depolymerization and so inhibiting cellular motility, mitosis, and replication. Nab-paclitaxel 100 mg/m2 will be administered as a 30 minute IV infusion.
223822360|NCT04596033|BIOLOGICAL|GEN-011|Personalized neoantigen adoptive cell therapy (ACT)
223822361|NCT04596033|DRUG|IL-2|Cytokine
223822362|NCT04596033|DRUG|Fludarabine|Lymphodepletion drug
223822363|NCT04596033|DRUG|Cyclophosphamide|Lymphodepletion drug
223822364|NCT03573908|DRUG|Linaclotide|Oral capsule
223822365|NCT03573908|DRUG|Placebo|Matching placebo oral capsule
223822366|NCT04006925|DRUG|Sodium Oxybate|"Sodium Oxybate will be titrated up weekly by 1.5g nightly dose increments from an initial 4.5g total nightly dose (which could be given in two unequal doses if needed, or one single dose no greater than 4.5g) to an optimal individual dose based on clinical response on RBD symptoms and tolerance, to a maximum nightly dose of 9g (flexible dose period lasting up to 8 weeks). The optimal dose will then be continued for at least 4 weeks (stable dose)."
223822367|NCT04006925|OTHER|Placebo|Placebo will be similar in appearance, smell and flavor to the subjects, so that the investigators and participants will be unable to distinguish it from sodium oxybate.
223822368|NCT06076356|OTHER|Foam Rolling|Foam Roller for 90 seconds over anterior (quadriceps) and posterior (hamstrings) aspect of thigh.
223822369|NCT06076356|OTHER|Kinesio Taping|Kinesio taping over anterior (quadriceps) and posterior (hamstrings) aspect of thigh.
223822370|NCT01874314|DRUG|SQ109|300mg or 450mg of SQ109 administered orally, once daily for 7 days.
223822371|NCT01874314|OTHER|SQ109 Placebo|Placebo is a round, coated, yellow, unscored tablet. SQ109 Placebo administered orally, once daily for 7 days.
223822372|NCT01874314|DRUG|Moxifloxacin|400mg of moxifloxacin (positive control) administered orally, once daily for 7 days.
223822373|NCT04549311|DRUG|Antibiotic 1 arm (amoxicillin + clavulanic acid)|Prescription of antibiotics (amoxicillin + clavulanic acid) after incision and drainage of perianal abscess.
223822374|NCT04549311|DRUG|Antibiotic 2 arm (ciprofloxacin + metronidazole)|Prescription of antibiotics (ciprofloxacin + metronidazole) after incision and drainage of perianal abscess.
223822375|NCT05249062|DEVICE|SHAPES app|Participants will be asked to use the app and connected devices daily for 3 months.
223822376|NCT01755143|OTHER|Magnetic Resonance Imaging scan sequences of the head, neck, and chest|
223822377|NCT01755143|DEVICE|Pacemaker System|
223822378|NCT00134602|BEHAVIORAL|Needs assessment followed by tailored intervention|
223822379|NCT04994496|BEHAVIORAL|Two-week web-based self-help intervention based on principles of positive psychology|"The web-based self-help intervention consists of 14 exercises based on the following positive psychology domains: personal strengths, pleasure, gratitude, engagement (flow, mindfulness) and positive relationships.~The (partly interactive) exercises are created to be implemented by the participants themselves without support of a therapist.~Before starting the intervention, the participants are told that they will receive a daily email with an instruction for a short exercise over the period of two weeks. The participants are instructed to complete the exercises every day and are told that they will be asked to evaluate these exercises at the next appointment (post-test, week 2)"
223822380|NCT04994496|BEHAVIORAL|Two-week web-based text messages containing fun facts|"The web-based sham intervention consists of 14 text messages containing random interesting facts (fun facts).~Before starting the sham intervention, the participants are told that they will receive a daily email with a text message to read every over the period of two weeks. The participants are instructed to read these text messages every day and are told that they will be asked to evaluate these exercises at the next appointment (post-test, week 2)"
223822381|NCT02949401|BEHAVIORAL|Use of Virtual Reality App|The VR app will consist of relaxation techniques as well as a virtual tour of the hospital (pre-op area, IV placement, cath lab, and post-op area).
223822382|NCT02640391|OTHER|colonoscopy|
223822383|NCT05186337|BEHAVIORAL|FROA-BD programme|The experimental group (n=42) will receive a 4-month intervention consisting of 32 sessions of treatment.
223822384|NCT01292070|BIOLOGICAL|Intradermal Human Fcγ1-Fel d1 fusion protein|"Part A: 7 sequential 10-fold dose increments from 0.001 BAU/mL to 1,000 BAU/mL; An 8th dose of 10,000 BAU/mL might be given only if the 10 BAU/mL of CAT is the dose that elicits a bump or hive of \>= to 10mm.~Part B: 5 sequential 10-fold dose increments from 0.1 BAU/mL to 1,000 BAU/mL; An 6th dose of 10,000 BAU/mL might be given only if the 10 BAU/mL of CAT is the dose that elicits a bump or hive of \>= to 10mm."
223822385|NCT01292070|BIOLOGICAL|Positive Control - standardized cat hair allergenic extract (CAT)|4 sequential 10-fold injections starting from 0.01 BAU/mL to 10 BAU/mL
223822386|NCT01292070|BIOLOGICAL|Positive Control - Histamine Prick|1.0 mg/mL
223822387|NCT01292070|BIOLOGICAL|Negative Control - Intradermal Diluent|Saline, Albumin with Phenol (HSA) sterile diluent
223822388|NCT01623648|OTHER|Arm 1 Whey Breakfast|The patients will be assigned to eat 42 g protein namely from Whey protein in the breakfast (660 kcal), lunch (560 kcal) and dinner (280 kcal)
223822389|NCT01623648|OTHER|Arm 2 No Whey Breakfast|The patients will be assigned to eat 42 g protein from other sources in the breakfast (660 kcal), lunch (560 kcal) and dinner (280 kcal)
223822390|NCT01623648|OTHER|Arm 3 Low Protein Breakfast|The patients will be assigned to eat 22 g protein from other sources in the breakfast (660 kcal), lunch (560 kcal) and dinner (280 kcal)
223822391|NCT02456701|BIOLOGICAL|KTN3379|IV every 2 weeks
223822392|NCT02456701|DRUG|vemurafenib|960 mg po bid
223822393|NCT04345458|DRUG|prefilled liquid etanercept(Yisaipu)|
223822394|NCT04345458|DRUG|lyophilized etanercept powder(Yisaipu)|
223822395|NCT03430141|OTHER|Nutritarian Diet-style|Nutritarian Diet-style: Daily consumption of greens, beans/legumes, a variety of other vegetables, fresh or frozen fruits, nuts, seeds and whole grains. Participants are encouraged to minimize consumption of refined grains, vegetable oils, processed foods, and to limit animal products.
223822396|NCT01555164|DRUG|Ranolazine|Ranolazine tablet(s) administered orally
223822397|NCT01555164|DRUG|Placebo to match ranolazine|Placebo to match ranolazine for the duration of the study
223822398|NCT01555164|DRUG|Metformin|Metformin tablet(s) administered orally once daily
223822399|NCT01555164|DRUG|Placebo to match metformin|Placebo to match metformin for the duration of the study
223822400|NCT01555164|BEHAVIORAL|Diet|Participants are instructed to continue the diet regimen prescribed by their physician.
223822401|NCT01555164|BEHAVIORAL|Exercise|Participants are instructed to continue the exercise regimen prescribed by their physician.
223822402|NCT03290612|DIETARY_SUPPLEMENT|Vitamin C|1.5g Ascorbic Acid
223822403|NCT03290612|OTHER|Placebo|Inactive placebo to mimic 1.5g ascorbic acid.
223822404|NCT04547270|OTHER|Ultrasound scan|Volunteers will have an ultrasound scanning of both sides of their neck lying in supine position. Sequentially the scanning will start from the base of the neck (supraclavicular fossa) to the upper part of the interscalene groove and then in the reverse direction to the supraclavicular fossa. Images will be recorded as video loops.
223822405|NCT01424475|GENETIC|Healthy|Healthy Volunteers
223822406|NCT01424475|GENETIC|PKD Patients|PKS Patients
223822407|NCT01589562|DRUG|Megace 800mg/20ml|Megestrol acetate 800mg/20ml, Suspension, Single dose
223822408|NCT01589562|DRUG|DW-ES(B) 625mg/5ml|Megestrol acetate 625mg/5ml, Nano suspension, Single dose
223822409|NCT00002760|DRUG|ketoconazole|400 mg PO tid for as long as treatment is effective
223822410|NCT00002760|DRUG|therapeutic hydrocortisone|hydrocortisone 30 mg PO q am and 10 mg PO qhs for as long as treatment is effective
223822411|NCT00002760|OTHER|Withdrawal of antiandrogen therapy|no drugs given
223822412|NCT01986361|DRUG|flurbiprofen|A single flurbiprofen 8.75 mg lozenge which also contains 1 mg of menthol in its vehicle base for flavour and taste purposes (blinding). Lozenge is sucked until dissolved, and not chewed, bit or swallowed.
223822413|NCT01986361|DRUG|placebo|A single placebo lozenge which also contains 1 mg of menthol in its vehicle base for flavour and taste purposes (blinding). Lozenge is sucked until dissolved, and not chewed, bit or swallowed.
223822414|NCT04555902|BEHAVIORAL|Postcard|The postcard includes appeals to get annual mammograms and provides information for ordering a mammogram.
223822415|NCT04555902|BEHAVIORAL|Small Gift|Pink socks are included in the mailer. The gift increases salience of the mailer and it potentially promotes reciprocation from the recipient in the form of ordering a mammogram.
223822416|NCT04555902|BEHAVIORAL|Loss Frame and Fear Appeals|The postcard is enhanced with language that frames the situation in terms of losses. It also uses fear appeals by stating the risks of breast cancer, while also stating that a mammogram screening is an accessible way to address those risks.
223822417|NCT03791502|OTHER|Pilates Method Exercises|Pilates Method exercises performed on the apparatus, on the ground and with accessories. They will always be performed by a physiotherapist with teaching certification in the Pilates methodology and will be supervised by two properly trained physiotherapy trainees. Participants will start the exercise program in small groups of up to 8 people, twice a week for 60 minutes, for 12 weeks, totaling 24 sessions. The first day of intervention for both groups will be devoted to explaining the six principles described by Joseph Pilates: centralization, concentration, control, precision, fluidity and breathing, and some fundamentals such as the neutral position of the spine. And in all sessions, these principles will be remembered by the physiotherapist.
223822418|NCT02260076|DRUG|PEG 400|
223822419|NCT02260076|DRUG|Placebo|
223822420|NCT02430363|DRUG|MK - 3475|Administered Intravenously
223822421|NCT02430363|BIOLOGICAL|Suppressor of the PI3K/Akt pathways|Capsules orally with food
223822422|NCT03340558|BIOLOGICAL|Atezolizumab|Atezolizumab is a fully humanized, engineered monoclonal antibody of IgG1 isotype against the protein programmed cell death-ligand 1.
223822423|NCT03340558|DRUG|Cobimetinib|MEK inhibitor
223822424|NCT05166525|OTHER|Medically tailored meals|Compare medically tailored meals vs. medically tailored meals with enhanced nutritional counseling vs. usual care
223822425|NCT00374660|DRUG|Oxaliplatin|Oxaliplatin will be administered in a 2-hour infusion on Days 1 and 15 of a 28-day cycle. The dose levels ranged from 40 to 80 mg/m\^2 by dose escalations in 10 mg/m2 increments if no dose-limiting toxicity.
223822426|NCT00374660|DRUG|Irofulven|Thirty minutes after completion of oxaliplatin infusion, irofulven will be administered as a 30-minute infusion on Days 1 and 15 of a 28-day cycle. The dose levels ranged from 0.30 to 0.40 mg/kg if no dose-limiting toxicity.
223822427|NCT04840277|DEVICE|Remote hearing aid adjustment|The intervention group is offered remote hearing aid adjustment whilst the control group is offered traditional hearing aid adjustment the requires physical appointments at the clinic. Remote hearing aid adjustment is applicable through mobile applications that hearing aid users download to their mobile phones.
223822428|NCT06183814|BIOLOGICAL|EXG102-031|EXG102-031 is a recombinant adeno-associated virus (rAAV) expressing an angiopoietin domain and VEGF receptor (ABD-VEGFR) fusion protein. EXG102-031 will be administered by subretinal injection.
223822429|NCT01709305|DRUG|Metformin|Metformin, 500 mg or 850 mg oral tablets, twice or three times a day (BID or TID) for a total dose of at least 1500 mg daily; administered with food.
223822430|NCT01709305|DRUG|Sitagliptin|Sitagliptin, 100 mg oral tablet, once daily (QD); administered with or without food
223822431|NCT01709305|DRUG|Acarbose|Acarbose, 50 mg oral tablets, TID (150 mg total daily dose); administered with the first bite of each main meal.
223822432|NCT01709305|DRUG|Repaglinide|Repaglinide, 0.5 mg and/or 1 mg oral tablets, TID (up to 16 mg daily); administered within 30 minutes of each meal.
223822433|NCT01709305|DRUG|Glimepiride|Glimepiride, 1 mg and/or 2 mg oral tablets, QD (up to 6 mg daily); administered before the first main meal of the day
223822434|NCT01709305|DRUG|Gliclazide|Gliclazide, 30 mg oral tablets, QD or BID (30 mg to 120 mg total daily dose); administered with meal.
223822435|NCT02281526|DRUG|BIA 2-093|
223822436|NCT01736501|OTHER|Genetics education at baseline|
223822437|NCT01736501|OTHER|Hypothetical genomic scenarios at follow-up|
223822438|NCT05171413|OTHER|Prediction model|We develop and validate clinical models to predict treatment responses and survival outcomes in patients with biopsy-proven with soft tissue sarcoma.
223822439|NCT00813137|DRUG|Folfox4 plus recombinant human endostatin (Endostar)|Endostar 15mg iv drip D1\~7, D15\~21, Oxaliplatin 85mg/m2 iv drip D1,15, CF 200mg/m2 iv drip D1,2,15,16, 5-Fu 400mg/m2 iv D1,2,15,16, 5-Fu 600mg/m2 civ D1,2,15,16
223822440|NCT03909178|PROCEDURE|Hip Arthroscopy Surgery with Acetabular Labral Repair (SPT group)|Patients randomized to the SPT group provided consent for arthroscopic acetabular labral repair with femoroacetabular osteoplasty. As previously described in various technique publications from our group, the senior surgeon's (S.D.M.) hip arthroscopy technique includes intra-articular fluid distension for initial portal placement, puncture capsulotomy, autograft capsular augmentation if insufficient or degenerative labral tissue is encountered, intermittent traction, sparing use of electrocautery, and preservation of the chrondrolabral junction. All SPT patients underwent a standardized postoperative physical therapy protocol developed jointly by the senior author (a sports medicine fellowship-trained orthopaedic surgeon) and the physical therapists. Patients were kept weightbearing as tolerated on crutches for 6 weeks to maintain a level pelvis without lurching when walking and were instructed to avoid impact loading exercises for 6 months.
223822441|NCT03909178|PROCEDURE|Physical Therapy Focused on the Hip and Hemi-pelvis (PT group)|PTA patients were assigned a standardized, 24-week course of supervised, core-based PT. This course was designed in concert with physical therapists within our institution to help address symptoms of labral tear in patients older than 40 who had mild to moderate OA. Weeks 1 and 2 focused on normalizing gait, and weeks 3 through 24 focused on optimizing range of motion (ROM) while slowly integrating strength training. Unlike the prerandomization PT protocol, the PTA protocol was predominantly physical therapist-supervised (at least 1 in-person visit per week).
223822442|NCT05904223|DIAGNOSTIC_TEST|Respiratory Panel PCR Sputum|Multiplex PCR Respiratory Panel from Biomerieux used on Patients Sputum
223822443|NCT02294136|BEHAVIORAL|Prep-C|PREP-C is a web-based structured clinical interview that healthcare providers of diverse disciplines can be trained to administer. It provides an assessment of a client's psychosocial readiness to begin HCV treatment and identifies domains of functioning which require tailored intervention to improve treatment readiness.
223822444|NCT02294136|BEHAVIORAL|Educational Control|Attention Control
223822445|NCT00077311|BIOLOGICAL|darbepoetin alfa|200 mcg sub Q on day 1 of each cycle if HgB \< or = 11 g/dL
223822446|NCT00077311|BIOLOGICAL|pegfilgrastim|6 mg sub Q day 2 of each cycle
223822447|NCT00077311|DRUG|cisplatin|75 mg/sq m IV over 1 hr Day 1 of each cycle
223822448|NCT00077311|DRUG|docetaxel|75 mg/sq m IV over 1 hr Day 1 of each cycle
223822449|NCT00077311|DRUG|BNP7787|40 g IV over 30 min Day 1 of each cycle
223822450|NCT01362556|DRUG|Sodium bicarbonate|"Administration of a calculated amount of sodium bicarbonate 8% \[SB\] after arterial blood gas measurement according to Base Excess \[BE\] and Body weight \[kg\].~Formula: SB \[ml\] = -BE \* kg \* 0.1"
223822451|NCT01362556|DRUG|Sodium Chloride|"Administration of a calculated amount of sodium chloride 0.9% \[SC\] after arterial blood gas measurement according to Base Excess \[BE\] and Body weight \[kg\].~Formula: SC \[ml\] = -BE \* kg \* 0.1"
223822452|NCT00305383|DRUG|Viramidine|
223822453|NCT00305383|DRUG|Peginterferon alfa-2b|
223822454|NCT06014736|DRUG|XJ101 for Injection|XJ101 is a recombinant humanized single domain antibody-Fc (human immunoglobulin G1 type) fusion protein.
223822455|NCT06014736|DRUG|Placebo|Placebo contains only excipients.
223822456|NCT00171873|DRUG|Octreotide LAR (Long-acting release)|30 mg intramuscularly every 28 days
223822457|NCT00171873|DRUG|Placebo|Sodium chloride intramuscularly every 28 days
223822458|NCT03697980|DEVICE|HeartWare Ventricular Assist Device|The HVAD is an implantable centrifugal rotary blood pump that is implanted in the pericardial space and is designed to provide up to 10 L/min of blood flow from the left ventricular to the aorta. The HVAD System is comprised of three major components: the HVAD (pump) with inflow and outflow conduits, a Controller (microprocessor unit that controls the operation of the HVAD), and power sources (AC and DC power adapters that provide power to the Controller and implanted HVAD).
223822459|NCT02891343|OTHER|2-hour period of hypoxia|During this period, the FiO2 will be set on 21% (normoxia condition). A filter will be put between the mask and the tubes connecting it to the machine generating hypoxia (equipment reference = Altitrainer NP190). On that filter a gas analyser will monitor the FiO2 and a capnography monitor (Capnostream 20, ORIDION) will also be installed.
223822460|NCT02440984|PROCEDURE|Colonic biopsies during endoscopy|eligible patients will have physical examination, colonic biopsies during endoscopy and anal manometry with barostat. these investigations are part of the usual healthcare. Colonic biopsies will be used to study intestinal permeability, colonic inflammation and enteric nervous system.
223822461|NCT04496141|DIAGNOSTIC_TEST|SARS-CoV-2 antibody immunoassays|Different commercial SARS-CoV-2 antibody immunoassays
223822462|NCT06351644|DRUG|ON 123300|"dosed starting at 200 mg of ON 123300 (NARAZACICLIB) daily for four weeks. Dose levels will be 160 mg, 200 mg, 240 mg, 280 mg, 320 mg. Treatment cycles will be four weeks long.~ON 123300 (NARAZACICLIB) is available as an oral formulation ON 123300 (NARAZACICLIB) monolactate capsules (containing 40 mg free base) and is provided in 120 cc high-density polyethylene (HDPE) bottles with child-resistant closures containing 30 hard gelatin capsules. ON 123300 (NARAZACICLIB) is also available in tablet form. The tablets are 40 mm (oblong) and 120 mg (round). Either form, capsules or tablets, may be used in this study."
223822463|NCT06351644|DRUG|Dexamethasone|Weekly oral dexamethasone 20mg
223822464|NCT05104502|BEHAVIORAL|Dietary Fasting|"The study will consist of two days of eating a controlled habitual diet and one 36-hour period of water-only fasting with glucose monitoring as a measure of compliance. Water intake will be limited to 2 liters/day to prevent electrolyte abnormalities. Subjects will undergo 4 separate blood-draws consisting of an overnight fasted sample (Baseline), a 2-hour postprandial sample (Fed), a 36-hour fasted sample (Fasted), and final 2-hour postprandial sample after the fasting period (Refed)."
223822465|NCT05821413|BEHAVIORAL|Data to care|Participants meet with a case manager who asks about health, basic needs such as housing and finances, and relationships and support systems. A score is assigned that reflects how much support is needed. A care plan is developed to address areas of need. The case manager meets regularly with participants to determine if needs are being met and identify strategies for meeting those needs. Participants with higher scores will receive more intensive contact with case managers, typically every month, until their level of need goes down. All participants will have their level and types of needs reassessed to determine if they need additional support or are moving toward self-management. Participants work with case managers for 6 months.
223822466|NCT05821413|BEHAVIORAL|Standard of Care|Participants can use standard case management and other services offered by the clinic.
223822467|NCT00946335|DRUG|veliparib|Given PO
223822468|NCT00946335|DRUG|temozolomide|Given PO
223822469|NCT00946335|OTHER|pharmacological study|Correlative studies
223822470|NCT00946335|OTHER|laboratory biomarker analysis|Correlative studies
223822471|NCT03696030|BIOLOGICAL|Chimeric Antigen Receptor T-Cell Therapy|Given HER2-CAR T cells via intraventricular administration
223822472|NCT04352478|DIAGNOSTIC_TEST|Histopathological result|Incidental gallbladder cancer and other pathology
223822473|NCT06423378|DEVICE|OSSIOfiber® Trimmable Fixation Nails|"Subjects will be treated with cannulated nails before or after arthroscopic management of their concomitant pathology at the discretion of the investigator. Technique described below. Following nail placement, tissue layers will be closed in standard fashion.~1. Preop MRI views used to estimate the proper depth \& location of nail placement on the femur and/or tibia~2. Exposure is gained to medial tibia~3. 1.4 mm K-Wire is placed through medial tibia parallel to the articular joint surface \~ 1 cm distal to the articular joint line~4. A depth gauge is placed over K-Wire to determine required length of cannulated nail~5. A 4.0 mm cannulated drill bit used over K-Wire to prepare the pilot hole~6. Tamp is used to insert pre-trimmed 4.0 mm cannulated nail into the pilot hole and K-Wire is subsequently removed~7. Intraop fluoroscopy can confirm adequate nail placement prior to removing K-wire~8. Repeat steps for additional nails"
223822474|NCT00539279|BEHAVIORAL|Prolonged Exposure Therapy (PE)|PE is a therapy that aims to reduce PTSD symptoms via a systematic exposure to feared memories (by imaginal exposure - repeated narration about the traumatic memory) and situations (by in vivo exposure - engaging in feared but safe activities or facing feared situations).
223822475|NCT00539279|BEHAVIORAL|Relaxation Training (RT)|RT aims to teach relaxation methods in an effort to reduce anxiety. RT includes Progressive Muscle Relaxation, Imagery Rehearsal, and breathing training.
223822476|NCT05485415|BEHAVIORAL|Multimodal intervention|Participants in the intervention group will receive personalised advice on sleep, light exposure, meal times and physical activity.
223822477|NCT05485415|BEHAVIORAL|Control|General sleep advice
223822478|NCT01381419|DRUG|GSK1144814|Single dose.
223822479|NCT01381419|DRUG|GSK1144814|Single dose which may be split in up to three divided doses given 2 to 3 hours apart.
223822480|NCT01381419|DRUG|GSK1144814|Single dose that may be split in up to three divided doses given 2 to 3 hours apart.
223822481|NCT02178644|DRUG|Chemo with concomitant Capecitabine and KD018|Patients will receive a course of chemo-radiation with concomitant Capecitabine and KD018, and to compare this to the toxicity seen in patients treated with Capecitabine and radiation therapy alone, in patients with T3-T4 and N0-N2, M0 rectal cancer.
223822482|NCT03408743|BEHAVIORAL|Knowledge Alone|Increase knowledge relate d STIs, STI risk, alcohol impairment, condom use skills, alcohol use behavior tracking skills, testing \& treatment services.
223822483|NCT03408743|BEHAVIORAL|Self-efficacy alone|Increase self-efficacy to us e protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
223822484|NCT03408743|BEHAVIORAL|Perceived benefits alone|Increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol.
223822485|NCT03408743|BEHAVIORAL|Benefits and self-efficacy|Increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
223822486|NCT03408743|BEHAVIORAL|Injunctive norms alone|Correct misperceptions regarding approval of alcohol misuse \& sexual risk taking.
223822487|NCT03408743|BEHAVIORAL|Injunctive norms and self-efficacy|Correct misperceptions regarding approval of alcohol misuse \& sexual risk taking and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
223822488|NCT03408743|BEHAVIORAL|Injunctive norms and benefits|Correct misperceptions regarding approval of alcohol misuse \& sexual risk taking and increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
223822489|NCT03408743|BEHAVIORAL|Injunctive norms, benefits, self-efficacy|Correct misperceptions regarding approval of alcohol misuse \& sexual risk taking; increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex; and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
223822490|NCT03408743|BEHAVIORAL|Descriptive norms alone|Correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors.
223822491|NCT03408743|BEHAVIORAL|Descriptive norms and self-efficacy|Correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
223822492|NCT03408743|BEHAVIORAL|Descriptive norms and perceived benefits|Correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors and increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol.
223822493|NCT03408743|BEHAVIORAL|Descriptive norms, benefits, self-efficacy|Correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol; and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
223822494|NCT03408743|BEHAVIORAL|Descriptive norms and injunctive norms|Correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors and correct misperceptions regarding approval of alcohol misuse \& sexual risk taking.
223822495|NCT03408743|BEHAVIORAL|Descriptive and injunctive norms, self-efficacy|orrect misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; correct misperceptions regarding approval of alcohol misuse \& sexual risk taking; and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
223822496|NCT03408743|BEHAVIORAL|Descriptive and injunctive norms, and benefits|Correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; correct misperceptions regarding approval of alcohol misuse \& sexual risk taking; and increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol.
223822497|NCT03408743|BEHAVIORAL|Descriptive & injunctive norms, benefits, efficacy|Correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; correct misperceptions regarding approval of alcohol misuse \& sexual risk taking; increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol; and Increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
223822498|NCT03408743|BEHAVIORAL|Expectancies alone|Decrease the expectation that alcohol is needed to have good sexual encounter.
223822499|NCT03408743|BEHAVIORAL|Expectancies and self-efficacy|Decrease the expectation that alcohol is needed to have good sexual encounter and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
223822500|NCT03408743|BEHAVIORAL|Expectancies and perceived benefits|Decrease the expectation that alcohol is needed to have good sexual encounter and increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol.
223822501|NCT03408743|BEHAVIORAL|Expectancies, benefits, self-efficacy|Decrease the expectation that alcohol is needed to have good sexual encounter; increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol; and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
223822502|NCT03408743|BEHAVIORAL|Expectancies and injunctive norms|Decrease the expectation that alcohol is needed to have good sexual encounter and correct misperceptions regarding approval of alcohol misuse \& sexual risk taking.
223822503|NCT03408743|BEHAVIORAL|Expectancies, injunctive norms, self-efficacy|Decrease the expectation that alcohol is needed to have good sexual encounter; correct misperceptions regarding approval of alcohol misuse \& sexual risk taking; and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
223822504|NCT03408743|BEHAVIORAL|Expectancies, injunctive norms, and benefits|Decrease the expectation that alcohol is needed to have good sexual encounter; correct misperceptions regarding approval of alcohol misuse \& sexual risk taking; and increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol.
223822505|NCT03408743|BEHAVIORAL|Expectancies, injunctive norms, benefits, efficacy|Decrease the expectation that alcohol is needed to have good sexual encounter; correct misperceptions regarding approval of alcohol misuse \& sexual risk taking; increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol; and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
223822506|NCT03408743|BEHAVIORAL|Expectancies and descriptive norms|Decrease the expectation that alcohol is needed to have good sexual encounter and correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors.
223822507|NCT03408743|BEHAVIORAL|Expectancies, descriptive norms, & self-efficacy|Decrease the expectation that alcohol is needed to have good sexual encounter; correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
223822508|NCT03408743|BEHAVIORAL|Expectancies, descriptive norms, benefits|Decrease the expectation that alcohol is needed to have good sexual encounter; correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; and increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol.
223822509|NCT03408743|BEHAVIORAL|Expectancies, descriptive norms, benefits, efficacy|Decrease the expectation that alcohol is needed to have good sexual encounter; correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol; and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
223822510|NCT03408743|BEHAVIORAL|Expectancies, descriptive and injunctive norms|Decrease the expectation that alcohol is needed to have good sexual encounter; correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; and correct misperceptions regarding approval of alcohol misuse \& sexual risk taking.
223822511|NCT03408743|BEHAVIORAL|Expectancies, descriptive & injunctive norms, efficacy|Decrease the expectation that alcohol is needed to have good sexual encounter; correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; correct misperceptions regarding approval of alcohol misuse \& sexual risk taking; and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
223822512|NCT03408743|BEHAVIORAL|Expectancies, descriptive & injunctive norms, benefits|Decrease the expectation that alcohol is needed to have good sexual encounter; correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; correct misperceptions regarding approval of alcohol misuse \& sexual risk taking; and increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol.
223822513|NCT03408743|BEHAVIORAL|Expectancies, descriptive & injunctive, benefits, efficacy|Decrease the expectation that alcohol is needed to have good sexual encounter; correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; correct misperceptions regarding approval of alcohol misuse \& sexual risk taking; increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol; and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
223822514|NCT02490891|DEVICE|RGD K5 PET scan|PET scan with a tracer specific for angiogenesis (RGD K5) will be performed before and after 2 cycles of chemotherapy
223822515|NCT00234156|PROCEDURE|oral fructose and high fat diet|"High fat diet: The composition will be: 35% of energy as fat, 50% carbohydrate, 15% protein (\~1.3 g/kg), sat:mono:poly 1:3:1, cholesterol 200 mg/d, 30% starch,15% sugar, 3% fructose, and 25 gm fiber/d. This relatively high fat diet, which falls within the recommendations by the National Kidney Foundation for hemodialysis patients, will suppress fatty acid synthesis in normal volunteers.~Fructose in 360 ml water will be orally administered as 1.4 g/kg (\~100 g or 400 kcal for a 70 kg person), divided into 30 mL (1 ounce) doses given every 1/2h for 6 hours."
223822516|NCT06810622|OTHER|Navigate-Kidney CHW|A CHW will provide support during visits every 2 weeks for 3 months (i.e., 6 visits during first 3 months) followed by monthly visits until end of study or until 3 months following KRT start. As well as receiving educational materials that describe prevention of CKD progression, KRT options, and conservative management in English or Spanish
223822517|NCT06810622|OTHER|Standard Care|Participants will receive standard medical care as well as educational materials developed that describe prevention of CKD progression, KRT options, and conservative management in English or Spanish
223822518|NCT03221660|DEVICE|F-Composite 2 system|Procedures will be done using local anesthesia (if the patients wants that). The cavity is prepared according to the principles of the adhesive technique. First the adhesive will be applied and polymerized, afterwards the flowable resin-based restorative material will be applied and polymerized and then the sculptable resin-based restorative material will be applied and polymerized; all materials will be light-cured within short time with an experimental curing light.
223822519|NCT04699916|OTHER|EEG based protocol for deep sedation|Protocol established to guide sedation drug dosification to maintain the patient with a Suppression Rate (SR) less than 1% and a Spectral Edge Frequency 95 over 10 Hz
223822520|NCT03104647|OTHER|VRP-Clinic|Subjects will perform a series of neck movements guided by graphic instructions appearing in the virtual reality environment
223822521|NCT06527547|DEVICE|Transcutaneous Auricular Vagus Nerve Stimulation|Treatment using the Huatuo electronic acupuncture device (model SDZ-IIB) with electrodes placed on the auricular points related to the heart and kidney. Pulsed wave type is sparse-dense wave, with a frequency of 20Hz and intensity set to the highest level tolerable without pain. Patients will perform self-treatment at home for 30 minutes, twice daily, for 5 days a week over 4 weeks.
223822522|NCT06527547|DEVICE|Sham Stimulation|Treatment using the same Huatuo electronic acupuncture device with electrodes placed on different ear points (over the ear helix). The device settings (pulse type, frequency, intensity) are the same as the experimental group but do not correspond to traditional acupuncture points. Patients will also perform self-treatment at home as per the same schedule as the experimental group.
223822523|NCT05371509|DEVICE|Myofunctional therapy (MT) nozzle|Water bottle nozzle designed to allow the user to repeatedly perform the tongue suction, tongue press, and swallow exercise movements while also providing targeted resistance to train and improve tongue, soft palate, and pharyngeal muscle strength and endurance.
223822524|NCT05371509|OTHER|Placebo nozzle|The placebo bottle nozzle will look similar to the MT nozzle; but is not expected to function the same as the MT nozzle.
223822525|NCT05840861|DRUG|Vortioxetine|All MDD patients will receive 5mg of Vortioxetine per day at the start of this study, which will be gradually increased to 10mg per day within one week.
223822526|NCT05840861|DRUG|Quetiapine|All patients with bipolar disorder will receive 50mg of Quetiapine at day 1, 100mg of Quetiapine at day 2, 200mg of Quetiapine at day 3, and 400mg of Quetiapine per day since day 4.
223822527|NCT06243289|OTHER|Tolerance induction|Exposure of peripheral blood mononuclear cells extracted from donated patient blood to a combination of vitamin D3 and interleukin 10 to test whether tolerogenic dendritic cells can be generated and have the same functional capacity between donors with and without kidney disease (exposure of PBMC to the uremic environment)
223822528|NCT06660212|DEVICE|Photobiomodulation|The laser therapy will be delivered in progressively higher doses, based on individual participants. Each stage will follow this sequence of applications: (1) perineum application (DUO-240 red and infrared array in the surface of the perineum) and (2) LDR-100 probe on the vestibula more generally. Doses will increase from 40%-100% power over the course of the intervention
223822529|NCT06660212|DEVICE|Sham photobiomodulation|The laser therapy will be delivered in progressively higher doses, based on individual participants tolerance. Each stage will follow this sequence of applications: (1) perineum application (DUO-240 red and infrared array in the surface of the perineum) and (2) LDR-100 probe on the vestibula more generally. . Doses will always be set to 1% power over the course of the intervention
223822530|NCT06660212|PROCEDURE|Multimodal physiotherapy|A total of 10 sessions of multimodal physiotherapy interventions will be provided to each of the participants in the multimodal physiotherapy (mPT) and multimodal physiotherapy combined with photobiomodulation treatment (mPT+PBM) groups. In general, each session will take place in the following order:1) Subjective assessment of the condition and screening for adverse effects or deterioration of the condition, 2)Education, 3) Relaxation Techniques, 4) Pelvic Floor Muscle Exercises, 5) Manual techniques, 6) exercises with accommodators, 7) Global exercises, 8) Assessment of the post-treatment condition and 9) adjustment of the weekly exercise program to be done at home. Each of these 9 treatments will be adjusted and tailored to each participant and progressed based on individual preference and response to treatment under the discretion of the study physiotherapist.
223822531|NCT06670781|DEVICE|Experimental: Intervention arm: Goal-Directed Valsalva maneuver|For the Goal directed Valsalva maneuver, the same method patients are instructed to blow into a plastic pipe connected to the manometer device, in order to reach a pressure of 40 mmHg for at least 5 seconds. Then patients are instructed to exhale quickly.
223822532|NCT06670781|DEVICE|Control - standard of care: Self-Directed Valsalva maneuver|The Valsalva maneuver is performed by the patient taking a normal (or deep) inspiration, followed by forceful expiration against a closed airway for up to 15 to 20 sec and then release of the expiratory effort on entry of saline into the right atrium.
223822533|NCT01091402|PROCEDURE|autologous serum skin test, serum IL-18|
223822534|NCT01338012|BIOLOGICAL|sipuleucel-T|Sipuleucel-T is an autologous cellular product consisting of antigen presenting cells (APCs) activated with PA2024, a recombinant fusion protein composed of prostatic acid phosphatase (PAP), linked to granulocyte-macrophage colony-stimulating factor (GM-CSF).
223822535|NCT06611683|PROCEDURE|Inspiratory muscle training|A threshold inspiratory muscule device used a starting resistance set at 30% maximum inspiratory pressure, connecting to subject artificial airway. The subjects were then instructed to perform fast and forceful inspirations against added inspiratory resistance. The inspiratory muscle training was conducted twice daily over five consecutive days, followed by a two-day rest period. This regimen continued for three consecutive weeks or until the subject no longer required ventilator support.
223822536|NCT06611683|PROCEDURE|Routine care|Subjects received routine care without intervention.
223822537|NCT02714205|DRUG|transdermal nitroglycerin|Study participants will be randomized to transdermal nitroglycerin patch or placebo patch. Participants will wear a study medication patch daily, for 12 weeks.
223822538|NCT02714205|DRUG|Placebo|Study participants will be randomized to transdermal nitroglycerin patch or placebo patch. Participants will wear a study medication patch daily, for 12 weeks.
223822539|NCT06181721|DEVICE|Omnipod 5 Automated Glucose Control System|The Omnipod 5 Automated Glucose Control System will provide automated insulin delivery
223822540|NCT01905709|BIOLOGICAL|Human fecal matter|
223822541|NCT04396821|DRUG|TST001|TST001 is a humanized IgG1 monoclonal antibody.
223822542|NCT04396821|DRUG|Nivolumab Injection [Opdivo]|Nivolumab is one of the PD-1 checkpoint inhibitors, and has proved clinical benefit for multiple late-stage malignancies
223822543|NCT04396821|DRUG|mFOLFOX6|mFOLFOX6 is a combination chemotherapy regimen including the drugs leucovorin calcium (folinic acid), fluorouracil, and oxaliplatin.
223822544|NCT04396821|DRUG|Gemcitabine|Chemotherapy medication
223822545|NCT04396821|DRUG|Albumin-Bound Paclitaxel|Chemotherapy medication
223822546|NCT06565169|BEHAVIORAL|Primary Care Team Advance Care Planning With People with Alzheimer's Disease or a Related Dementia Training|Included in arm/group descriptions
223822547|NCT06565169|BEHAVIORAL|Care as Usual|Included in arm/group descriptions
223822548|NCT06624579|PROCEDURE|confocal endomicroscopy|The study incorporates confocal endomicroscopy as an additional diagnostic modality for assessing barrier dysfunction and treatment response in UC patients. Confocal endomicroscopy enables real-time visualization of mucosal changes at a cellular level during endoscopy, potentially enhancing the detection of treatment response and mucosal healing.
223822549|NCT06624605|OTHER|Large Language Model-generated Plain Language Summary of Ophthalmology notes|Prospective, randomized Quality Improvement study with real-world implementation of Large Language Model-generated Plain Language Summaries of Ophthalmology notes.
223835542|NCT01347645|DRUG|E7820|"Test product: dose and mode of administration:~E7820 is administered orally in tablet form once daily, every day of each 14-day treatment cycle. For the Phase Ib portion, the doses will be 40 mg/day, 70 mg/day, and 100 mg/day, and for the Pase II portion, the dose will be the MTD in combination with Irinotecan, as determined during the Phase ib portion of the study.~The irinotecan regimen consists of an irinotecan dose of 180 mg/m2 by IV infusion once every 2 weeks (Day 1 of each 14-day cycle)."
223822550|NCT06689618|DEVICE|Exercise|The WB-EMS Device is a fitness device that delivers whole-body electrical muscle stimulation in conjunction with exercise programs. After donning a base layer consisting of fitted shorts and shirt, a vest, shorts, and arm straps with integrated electrodes mapped to major muscle groups (biceps, triceps, pectorals, abdominals, periscapular musculature, paraspinal musculature, gluteus musculature, quadriceps, and hamstrings) are donned. The suit connects to an impulse pack that communicates with the Katalyst iPad App to deliver the programmed stimulation to the participant. Within the Katalyst App, there are leveled exercise programs where low levels (i.e. Level 1 and 2) are simple movements and higher levels (i.e. Levels 3, 4, and 5) have more complex and dynamic movements. There is complete user control of the stimulation level of each individual muscle group to tailor to participant responses and tolerance.
223822551|NCT06701994|BEHAVIORAL|Innovative Kinesiotaping Bandage Group|This group will receive an innovative kinesiotaping bandage developed specifically for this study. The kinesiotape will be applied directly to the skin on the ankle, combining water resistance with restrictive properties to stabilise the joint while maintaining flexibility. Unlike traditional tape, the kinesiotape is designed to perform well in aquatic conditions, making it suitable for triathlon demands. It provides joint support while allowing a greater range of motion, aiming to enhance performance across all phases of the sport. To maintain blinding, the bandage will also be covered with an opaque stocking.
223822552|NCT06701994|BEHAVIORAL|Traditional Tape Bandage Group|Participants in this group will receive a traditional ankle bandage using functional tape. The bandage is applied directly to the skin and is designed to restrict ankle inversion and plantar flexion, providing stability to prevent recurrent injuries. Traditional tape bandages are widely used in sports due to their effective joint stabilisation. However, they have significant limitations in aquatic environments as they lack water resistance, which makes them less effective during the swimming phase of triathlons. The bandage will be covered with an opaque stocking to ensure blinding, preventing participants or evaluators from identifying the type of intervention.
223822553|NCT06701994|BEHAVIORAL|Placebo Bandage Group|Participants in this group will receive a placebo bandage consisting of a simple gauze wrap applied directly to the ankle. The gauze lacks stabilising or therapeutic properties and is used as a control to account for potential placebo effects. Although it mimics the application process of the other bandages, it does not provide functional or structural support to the ankle joint. An opaque stocking will cover the gauze to ensure that neither participants nor evaluators can distinguish the placebo bandage from the others, maintaining the integrity of the blinding process.
223822554|NCT06110962|DEVICE|Sleeptracker-AI|The Sleeptracker-AI Monitor (Fullpower Technologies, California, USA) is a commercially available, unobtrusive, and non-wearable home sleep monitoring device. It is either pre-installed in a mattress or can be purchased separately by consumers where it is placed under the mattress. The device uses piezo-electric sensors that register the forces exerted through the mattress by features such as the subject's motion, respiration, heartbeats, and snoring vibrations.
223822555|NCT05252819|DIAGNOSTIC_TEST|Magnetic Resonance Imaging and an optional blood test|One whole-Body MRI that takes approximately 35minutes One blood test, which it is an optional component at this stage
223822556|NCT06707818|OTHER|Preoperative Interventions|During the initial surgical consultation, participants will provide informed consent. Demographic data and several validated assessment scales will be collected, including the Perceived Socioeconomic Status Scale (8), Ten-Item Personality Inventory (9), Pain Catastrophizing Scale (10), Hospital Anxiety and Depression Scale (11), Rosenberg Self-Esteem Scale (12), Quality of Recovery-15 (QoR-15) questionnaire (13), and the Visual Analog Scale (VAS) for pain (14).
223822557|NCT06707818|OTHER|Intraoperative Interventions|All surgical procedures will follow the standard general anesthesia protocol of the hospital. General anesthesia induction will involve propofol (1-2 mg/kg), fentanyl (1 mcg/kg), and rocuronium (0.6 mg/kg) for endotracheal intubation. Anesthesia maintenance will be performed with desflurane (4-6%) and remifentanil (0.1 mcg/kg/min), with adjustments as needed based on blood pressure and heart rate. Post-induction, dexamethasone (4 mg) will be administered for anti-inflammatory effects. To support postoperative pain management, tramadol (1 mg/kg), ibuprofen (400 mg), and paracetamol (1 g) will be administered before the end of the procedure. Ondansetron (4 mg) will be used for nausea prophylaxis. All intraoperative medications and dosages will be recorded without intervention.
223822558|NCT06707818|OTHER|Postoperative Interventions|"In the recovery room, analgesic interventions will follow the hospital's standard protocol: patients with VAS scores between 3 and 7 will receive 25 mcg of fentanyl, while those with scores above 7 will receive 50 mcg.~All patients will receive standard multimodal analgesia during the ward stay, including paracetamol (1 g, three times daily) and ibuprofen (400 mg, twice daily). Patient-controlled analgesia (PCA) devices will administer tramadol (10 mg IV per patient request, without continuous infusion)."
223822559|NCT06926582|DRUG|HS-10374 6mg tablets|Administered orally QD for 12 weeks
223822560|NCT06926582|DRUG|HS-10374-matched placebo tablets|Administered orally QD for 12 weeks
223822561|NCT06925880|DIETARY_SUPPLEMENT|Creatine Monohydrate|The intervention will consist of daily supplementation with micronized creatine monohydrate (FullGas Sport Creatine 200 mesh) for 12 weeks. The intervention will start at the time of hospital discharge with a loading dose of 20g/day for 1 week, divided into 4 intakes of 5g to favor digestive tolerance (breakfast, lunch, snack and dinner). Subsequently, a maintenance dose of 5g/day will be continued for 11 weeks (breakfast). Creatine should be consumed with food to improve its absorption.
223822562|NCT06925880|OTHER|Placebo|The control group will follow the same rehabilitation regimen as the intervention group and will receive a placebo with FullGas Sport microcrystalline cellulose. Its physical and organoleptic characteristics are the same as micronized creatine monohydrate. The dosage will be the same as that indicated for the study intervention: it will start at the time of hospital discharge with a loading dose of 20g/day for 1 week, divided into 4 intakes of 5g to favor digestive tolerance (breakfast, lunch, snack and dinner). Subsequently, a maintenance dose of 5g/day will be continued for 11 weeks (breakfast).
223822563|NCT06924931|BEHAVIORAL|LCME training programme|A LCME training program was conducted from March 2017 to October 2017 in the CDR, inspired by the National English Laparoscopic Colorectal Surgery Course. All certified colorectal surgeons from three public hospitals in the CDR were invited. The training programme was conducted over 2-3 days, occurring twice within an 8-month period.
223822564|NCT06926465|OTHER|Conventional treatment|conventional treatment including (hot pack, Stretching of the pectoralis minor, Resisted shoulder external rotation , Prone Extension ,Prone Horizontal Abduction with External Rotation ,Side-lying Forward Flexion ,Posterior capsule stretch (sleeper stretch)
223822565|NCT06926465|OTHER|Trunk integrated kinetic chain exercises|"This group will receive conventional treatment plus four trunk integrated kinetic chain exercises:~1. Quadruped shoulder flexion~2. Shoulder flexion with trunk rotation~3. Shoulder external rotation from shoulder at 45° internal rotation and the elbow at 90° flexion with trunk rotation~4. Shoulder external rotation from shoulder at 90° abduction and the elbow at 90° flexion while with trunk rotation"
223822566|NCT06925919|DRUG|IDB-011 dose level 1|IDB-774 + IDB-898
223822567|NCT06925919|DRUG|IDB-011 dose level 2|IDB-774 + IDB-898
223822568|NCT06925919|DRUG|IDB-011 dose level 3|IDB-774 + IDB-898
223822569|NCT06925919|DRUG|IDB-011 dose level 4|IDB-774 + IDB-898
223822570|NCT06925919|DRUG|IDB-011 dose level 5|IDB-774 + IDB-898
223822571|NCT06925919|OTHER|Placebo|Normal saline
223822572|NCT06926218|DRUG|HSK47388|cohort 1 to cohort 5
223822573|NCT06926218|DRUG|Placebo|cohort 1 to cohort 5
223822574|NCT06926543|DRUG|Chemoradiation|This intervention will consist of getting chemotherapy followed by radiotherapy, i.e, in a sequential manner
223822575|NCT06926543|DRUG|Chemoradiation|This intervention will consist of getting chemotherapy and radiotherapy at the same time, i.e, in a concurrent manner.
223822576|NCT06925568|OTHER|No Intervention: Observational Cohort|"This is an observational study, so there is no direct intervention. However, the study involves documenting and analyzing the existing management strategies, including~* use of diagnostic tools ECG, troponin tests, etc~* Administration of medications such as antiplates and anticoagulants.~* Reperfusion therapies -thrombolysis, PCI"
223822577|NCT06924996|PROCEDURE|Endovascular Thrombectomy (EVT)|A maximum of six attempts to retrieve the thrombus in a single vessel can be made with any Solitaire AB/FR device or aspiration. In case an atherosclerotic lesion is found underlying the occlusive lesion, angioplasty and subsequent stenting through detachment of the Solitaire device will be allowed
223822578|NCT06925412|PROCEDURE|MMC sponge application|Three micro swabs soaked in 0.03% MMC were subconjunctivally applied, followed by the creation of a fornix-based conjunctival flap. Subsequently, the standard trabeculectomy procedure was initiated without additional irrigation of the MMC application site
223822579|NCT06925412|PROCEDURE|Sub-tenon MMC injection|MMC was administered via a sub-tenon injection. A 30-gauge needle was inserted into the conjunctiva and carefully advanced laterally along Tenon's capsule. A cannula was employed to minimize the excessive spread of MMC over the anticipated conjunctival incision site. After MMC delivery, a fornix-based conjunctival peritomy was performed, and both groups proceeded to undergo standard trabeculectomy
223822580|NCT06926413|DRUG|Aumolertinib；midazolam|"Midazolam :~The enrolled subjects will receive a single oral dose of Midazolam 2 mg (2 mg/mL, 1 mL) on D1 of the run-in period and on C2D1.~Aumolertinib :~Starting from C1D1, the enrolled subjects will receive oral dose of aumolertinib 110 mg (55 mg/tablet, 2 tablets) once daily until the criteria for terminating treatment are met."
223822581|NCT06891937|BEHAVIORAL|Positive psychology|5-week positive psychology intervention
223822582|NCT06895317|BEHAVIORAL|Remote rehabilitation|To develop and validate a quantitative assessment system based on wearable sensors
223822583|NCT06895317|BEHAVIORAL|Rehabilitation face to face|Compare the validity of face-to-face physiotherapy with remote physiotherapy
223822584|NCT02332343|OTHER|No intervention - Natural history study|
223822585|NCT06365411|DIAGNOSTIC_TEST|Biomarker discovery and validation - with focus on genomic biomarkers|Biomarker discovery and validation - with focus on genomic biomarkers
223822586|NCT05174793|OTHER|dehydration and rehydration|dehydration and rehydration
223822587|NCT03681418|PROCEDURE|Ultrasound-guided axillary lymph nodes FNAC and\or CNB.|Ultrasound-guided axillary lymph node fine needle aspiration and\\or core needle biopsy of the most suspicious lymph node. If all the lymph nodes appeared similar or normal, the lymph node that is lowest in the axilla will be selected because it is considered to most likely be the sentinel node.
223822588|NCT06810518|DEVICE|ALPCO Calprotectin CLIA|Measurement of calprotectin in feces
223822589|NCT06897670|OTHER|Observational assessment using functional near-infrared spectroscopy (fNIRS), a noninvasive, portable brain imaging tool that measures changes in brain blood flow and oxygen levels.|"Functional near-infrared spectroscopy (fNIRS) transcutaneously measures changes in oxyhemoglobin in the prefrontal cortex using light detection. It is designed to measure variations in cerebral hemodynamics on a real-time basis by radiating a near light beam, at two wavelengths of 780nm and 850nm of laser, into the cerebral cortex.~Participants will undergo a one-time functional near-infrared spectroscopy (fNIRS) procedure to measure cerebral hemodynamic patterns.~* Resting-State Measurement: 5-10 min resting-state scans.~* Task-Based Measurement: Participants will be shown an instruction video. Participants will complete a Verbal Fluency Task (VFT) during the fNIRS scan (15-20 min).~* During the fNIRS scan, optional basic vital signs will be measured using respiratory belts, photoplethysmography (PPG), and electrocardiogram (ECG).~* Each participant will complete 3 sets of resting-state and task-based measurements.~Total estimated time for fNIRS assessment: 45-60 min."
223822590|NCT06574854|OTHER|DSW|Descending Stair Walking
223822591|NCT06574854|OTHER|ASW|Ascending Stair Walking
223822592|NCT06899568|PROCEDURE|z mini plate with lingual extension|parasympheseal fracture model fixed with z mini plate with lingual extension
223822593|NCT06899568|PROCEDURE|two mini plates|parasympheseal fracture model fixed with conventional 2 mini plates
223822594|NCT06780566|DIAGNOSTIC_TEST|Point-of-care PCR testing for respiratory viruses|A nasal swab will be collected by trained research staff in full personal protective equipment (PPE) and placed into 3 mL of viral transport medium. The sample will be immediately processed and analysed in the ED using the Xpert® Xpress SARS-CoV-2/Flu/RSV test according to the manufacturer's instructions. The results of the test will be documented in the patient's paper or electronic case notes, and the clinical team will be directly informed of all results. The participant or legal guardian who signs the consent form will also be informed of the results when appropriate.
223822595|NCT06780566|DIAGNOSTIC_TEST|Laboratory PCR testing for respiratory viruses|The ordering of test for respiratory pathogens will be decided by the treating clinical team. All tests will be performed using the standard methods of the hospital laboratory.
223822596|NCT06899841|DRUG|Dexmedetomidine|different doses of dexmedetomidine added to bupivacaine in erector spinae plane block
223822597|NCT06900582|PROCEDURE|Sentinel Lymph Node Mapping|The SLN mapping protocol will follow the EU guidelines and the consensus in competency assessment tool. Prior to SLN mapping, a full inspection of the pelvic areas with white light is performed to exclude the presence of extrauterine disease. The next surgical steps will be 1- identification of external iliac vessels, 2- identification of internal iliac artery, 3- dissection of the ureter, 4- development of paravesical space and 5- identification of obliterated umbilical ligament. The dissection technique must avoid disrupting lymphatic channels and isolate nodal tissue from the local anatomy. Indocyanine green (1.25mg/mL) will be injected in the cervix at the 3 and 9 o'clock positions, with 1mL superficial and 1mL deep, for a total of 4mL. All mapped SLNs must be completely excised, and any visually suspicious nodes should also be removed, regardless of the mapping results. If the SLN mapping appears to be unfeasible, a side-specific pelvic lymphadenectomy will be performed.
223822598|NCT06900582|PROCEDURE|Comprehensive pelvic and para-aortic lymphadenectomy|"The resection of at least one lymph node in each of the 12 retroperitoneal regions is necessary:~A: upper para-aortic region B: lower para-aortic region C: interaorto-caval region D: paracaval region E: right and left iliaca communis region F: right and left iliaca externa region G: right and left fossa obturatoria region: defined by external and internal arteria iliaca, pelvic sidewall H: right and left iliaca interna region: lymph nodes adjacent to or medial of the internal iliacal artery"
223822599|NCT06899867|OTHER|Measure of cardiac index with thermodilution and transesophageal echocardiography|At 4 times of surgery, end-expiratory occlusion (EEO) test and measure of cardiac index before and after test with ETO and thermodilution
223822600|NCT06899867|OTHER|Surgical anastomosis echography|Visualisation of surgical anastomosis through transesophageal echocardiography : stenosis, doppler velocity, collar diameter
223822601|NCT06900010|BIOLOGICAL|CM336 Injection|subcutaneous CM336 administration
223822602|NCT06899724|DRUG|Anesthetics, Inhalation|Inhaled analgesia
223822603|NCT06899724|DRUG|Intravenous Sedatives with or Without Analgesia|IV Fentanyl and midazolam
223822604|NCT06900179|OTHER|MFWs with AR|MFWs with AR This study utilized MyWeb AR as the primary development platform to create an AR-enhanced teaching curriculum for malignant fungating wound (MFW) care. Based on the 2022 Clinical Care Guidelines for Malignant Fungating Wounds and expert input from oncology specialists, the content covers key aspects of MFW care, including wound assessment, symptom identification, and care principles such as odor control, exudate management, and infection prevention. The program uses 3D object elements and animations to create interactive AR scenarios, allowing participants to engage in simulated clinical decision-making and care management, thereby enhancing their skills in a safe and controlled environment.
223822605|NCT06900179|OTHER|Classroom Teaching|Classroom Teaching and Case Sharing Introduction to Updated MFWs Care Guidelines and Clinical Applications MFWs Wound Care Management of Common MFWs-Related Complications Case Sharing on MFWs Complication Management: Researchers
223822606|NCT06899464|DRUG|14-day Cerebrolysin treatment|14-day cerebrolysin treatment initiated within 6 hours of onset of stroke
223822607|NCT06899464|OTHER|Standard of Care (SOC)|Standard of care treatment
223822608|NCT06899997|OTHER|Time-restrictred feeding|Time-restricted feeding pattern consisting of an 8 h eating window (from 6-8 am to 14-16 pm) followed by a 16 h fasting period
223822609|NCT06899997|OTHER|Non-time restricted feeding|14h eating window (from 6-8 am to 8-10 pm), followed by a 10 h fasting period
223822610|NCT06900166|DRUG|PegIFN alfa-2b|180 μg/ 0.5 ml ,hypodermic injection once a week
223822611|NCT06900166|DRUG|PegIFN alfa-2b and NUC|180 μg/ 0.5 ml ,hypodermic injection once a week, NUC drugs should be used according to the instructions of each drug
223822612|NCT06735261|PROCEDURE|Sphenopalatine Ganglion Block using 2% lidocaine|A hollow-stem swab soaked in viscous Xylocaine is inserted into the patient's nasal cavity (one swab per nostril) until it stops. 1.5ml Lidocaine 20% (20mg/ml) is injected into each swab using a 5ml syringe and a pink trocar. Both swabs are left in place for 10 min.
223822613|NCT05859165|DIETARY_SUPPLEMENT|Nutren Diabetes|Product replace phase: 1-5 days, tube feeding, 25kcal/kg/day Formal intervention phase:7 days, tube feeding, 25kcal/kg/day
223822614|NCT05859165|DIETARY_SUPPLEMENT|Fresubin Diabetes|Product replace phase: 1-5 days, tube feeding, 25kcal/kg/day Formal intervention phase:7 days, tube feeding, 25kcal/kg/day
223835543|NCT00388362|DRUG|Sirolimus|Patients will receive sirolimus at 2 mg/day orally with monitoring of trough drug levels weekly for 2 weeks to achieve trough drug levels 7-12 ng/ml. Along with prednisone therapy.
223822615|NCT06900959|COMBINATION_PRODUCT|transcranial static field stimulation (tSMS) and transcranial (tDCS)|"* tSMS is a non-invasive brain stimulation (NIBS) technique that involves the application of a neodymium magnet to the scalp. Since the initial study introducing this method, numerous subsequent studies have confirmed that tSMS can lead to a reduction in corticospinal excitability.~* Transcranial direct current stimulation (tDCS) is a non-invasive brain stimulation (NIBS) technique that applies low-voltage electrical currents through surface electrodes on the scalp. Depending on the stimulation type (anodal or cathodal) tDCS can induce long-lasting increases or decreases in neuronal excitability and vascular-neuronal activity coupling. Cathodal stimulation leads to hyperpolarization and a reduction in excitability, whereas anodal stimulation induces depolarization and enhances excitability."
223822616|NCT06899412|OTHER|self adhesive flowable composite|FIT SA is a self-adhesive, light-cured, flowable restorative with two discrete viscosities, F03 (low flow) and F10 (high flow) UDMA,HEMA,Phosphonic acid monomer, S-PRG filler based on fluoroboroaluminosilicate glass, Polymerizationinitiator,Pigments and others, Shofu's exclusive GIOMER technology gives FIT SA the ability to release and recharge fluoride and other beneficial ions for the life of the restoration.
223822617|NCT06899412|OTHER|Conventional flowable composite|Conventional flowable composite (bulk fil)
223822618|NCT06926088|DRUG|Impact of BMI on CDK4/6 Inhibitors Efficacy and Safety|Patients aged ≥18 years with advanced HR-positive breast cancer who received CDK4/6 inhibitors at six hospitals in China were included in this study.
223822619|NCT06925997|DRUG|Colesevelam|Colesevelam is an approved drug with well known adverse events. Gastrointestinal side effects (Obstipation, flatulence, abdominal pain, diarrhea, nausea, meteorism, vomiting, chanced faeces) are very common (\>10%) or common (1-10%), but are mild and tolerable in most cases. All participants will be monitored closely, and colesevelam will be discontinued if the subject experience unreserved adverse events. All effects of colesevelam are transient (17-19) as the compound is not absorbed to the systemic circulation, i.e. treatment effects cease when the drug is excreted from the intestine. Specifically, no permanent metabolic effects of colesevelam has been observed in crossover experiments (27). Therefore, 8 weeks of colesevelam treatment as planned in the current study will have no long lasting positive or negative effects on the participants.
223822620|NCT06926478|DRUG|Adalimumab Injection|10% (4.0mg/0.04ml) dissolved in sterile saline to be injected once during the time of the Boston Keratoprosthesis (Kpro) Surgery.
223822621|NCT06925711|DEVICE|Near-Infrared Spectroscopy (NIRS)|Controlled hypotensive anesthesia during orthognathic surgery with cerebral oxygen saturation monitoring using Near-Infrared Spectroscopy (NIRS). NIRS was used to continuously monitor regional cerebral oxygen saturation (rSO2) throughout the procedure to observe the effects of controlled hypotension on cerebral perfusion
223822622|NCT06925126|OTHER|Not applicable- observational study|This is an observational cohort study with no planned interventions. Participants will be followed over multiple time points to evaluate treatment outcomes based on the standard care process.
223822623|NCT06926439|DRUG|Long chain lipid emulsion|For patients presenting with fat soluble drug overdose, administer a weight-based infusion of long-chain lipid emulsion at 0.05 ml/kg/min for 1 hour, not to exceed a total of 250 mL.
223822624|NCT06926166|OTHER|No intervention|No intervention
223822625|NCT06925425|OTHER|Task specific electrical stimulation ( TASES )|"Each child in group B receive the designed program plus the task specific electrical stimulation (TASES) for 20 minutes during the weight bearing exercises as push up , prone on hands on wedge and quadruped with weight shifting.~The electrical stimulation is applied with the following parameters. Pulse frequency 25-50 HZ, pulse duration 300 micro second, intensity to display a visible muscle contraction, for 20 minutes.~First channel, one electrode will be placed at the middle of triceps muscle, the second electrode will be placed more distal towards the elbow joint itself (about 3 cm above the olecranon process).~Second channel, one electrode will be placed over finger and wrist extensors motor point to allow activation of fingers and wrist extensors. The other electrode will be placed over the tendonous portion of the forearm between motor points of extensor carpi radialis and extensor carpi ulnaris muscles."
223822626|NCT06925425|OTHER|Designed Physical therapy program|The program used a combination of open-and closed-chain exercises. Exercises for facilitating transitions as supine to sit with hand weight bearing , side lying to side sit , side sitting to quadruped, weight bearing exercises as prone on hands on wedge , quadruped with weight shifting and push up exercise for one hour.
223835544|NCT00388362|DRUG|Prednisone|Prednisone therapy will remain at the dose the patient received at the time sirolimus was begun. Withdrawal of prednisone will began after first evidence of improvement of chronic GVHD.
223835545|NCT00178243|PROCEDURE|3D Conformal Radiation Therapy and Radiosurgery|
223835546|NCT01141660|DEVICE|Endotracheal Tube|Patients randomized to either Laryngeal Mask Airway or Endotracheal tube prior to undergoing adenotonsillectomy.
223835547|NCT01141660|DEVICE|Laryngeal mask airway|Randomized to either Laryngeal mask airway or endotracheal tube
223822627|NCT06900465|BEHAVIORAL|Caregiver Psychoeducation Group for Children and Adolescents with Emotional and Behavioral Disorders (CPG-CA)|The CPG-CA intervention is a group psychoeducational internvention for family caregivers of children and adolescents with E/BDs in China. It will consist of 10 to 15 family caregivers of children and adolescents with E/BDs, meeting once a week for 1.5 to 2 hours per session, for a total of 12 sessions over a 3-month period. The sessions will cover the following themes: (1) knowledge about child and adolescent emotional and behavioral disorders; (2) coping skills for common emotional and behavioral problems in children and adolescents; (3) problem-solving skills; (4) communication skills with children and adolescents; (5) positive parenting techniques; and (6) self-care techniques. A variety of facilitation techniques will be used in the intervention, including didactic teaching, group discussion, role-playing, and homework assignment.
223822628|NCT06900192|BIOLOGICAL|Orca-Q|Allogeneic (donor) stem cell graft
223822629|NCT06900192|DRUG|myeloablative regimen|Myeloablative regimen of busulfan, fludarabine, and thiotepa.
223822630|NCT06901180|PROCEDURE|short scar periareolar inferior pedicle reduction mammoplasty|reduction mammoplasty that minimizes scar with better cosmetic outcomes
223822631|NCT06900686|DRUG|PD1 Inhibitor|PD1 Inhibitor
223822632|NCT06900036|PROCEDURE|Platelet-Rich Fibrin (PRF) Application for Alveolar Preservation|This intervention involves the application of platelet-rich fibrin (PRF) in the extraction socket following premolar extraction to assess its effectiveness in alveolar bone preservation. PRF is a biological autologous material derived from the patient's own blood, promoting bone regeneration, wound healing, and tissue repair.
223822633|NCT06900322|OTHER|Experimental Group (stimuli and handling; physical therapy [PediaSuit])|"Participants underwent a one-hour daily protocol (5 times a week) of stimuli and handling based on the neuroevolutionary concept, and motor physical therapy with therapeutic garments (PediaSuit).~During therapy based in PediaSuit protocol therapy suits were used to stimulate proprioception, muscle contraction, and postural stability.Traction bands were placed on the trunk to stimulate muscle control by stabilizing this area and the antigravity muscles.The ability exercise unit was also used to stimulate postural stability and muscle resistance, according to the functional ability of each child.~Neuroevolutionary concept is a problem-solving approach focused on the treatment of functional impairments, postural alignment and movement.~Therefore, Neuroevolutionary concept is an individualised approach aimed at improving functionality and, consequently, the quality of life of individuals with neurological deficits."
223822634|NCT06900322|OTHER|control group (conventional physical therapy)|Participants kept the therapeutic routine (conventional physical therapy).
223822635|NCT06212908|OTHER|Basic Periodontal Therapy|All patients received oral hygiene instructions (interproximal cleaning with floss and interdental brushes, brushing instructions on the Bass technique). The patients were also encouraged to brush the back of the tongue once a day. Subsequently, all patients underwent supragingival scaling, prophylaxis, and polishing. Supragingival scaling was performed using manual instruments (Gracey curettes) and an ultrasonic device.
223822636|NCT06900738|DEVICE|Inflammometer|Patients wear an inflammometer for Photoplethysmography measurements.
223822637|NCT06887621|DRUG|Encapsulated amisulpride 50 mg (matched for color, weight, smell and size)|Amisulpride will be delivered orally 1 hour before anesthesia induction.
223822638|NCT06887621|DRUG|Encapsulated placebo (matched for color, weight, smell and size)|Placebo will be delivered orally 1 hour before anesthesia induction.
223822639|NCT06900478|DRUG|Icariin Soft Capsules+TACE|"TACE: perform preoperative infusion chemotherapy, then selectively inject 2 to 5 mL of iodized oil and embolize.~Icariin Soft Capsules：take 6 tablets each time, orally, twice a day."
223822640|NCT06926400|DEVICE|Coronary artery sawtooth cutting balloon dilation catheter|Ninety-one subjects who met the inclusion criteria were enrolled and randomly assigned to the treatment group using a coronary artery sawtooth cutting balloon dilation catheter.
223822641|NCT06926400|DEVICE|Cutting balloon catheter|Ninety-one subjects who met the inclusion criteria were enrolled and randomly assigned to the treatment group using a cutting balloon catheter.
223822642|NCT05379712|OTHER|Resource® Support Plus|Nestlé Resource Support Plus® is a high energy- and protein-density Medical Food enriched with omega 3 polyunsaturated fatty acids. This is a nutritionally complete formula, in an easy to swallow, palatable, concentrated low volume, available in 2 flavours optimized for cancer patients undergoing chemotherapy and/or radiation in taste tests. It provides in a 125 mL serving: 250 kcal, 11.5 g protein and 0.95g of omega-3 fatty acid (eicosapentaenoic acid, EPA).
223822643|NCT03616067|DRUG|Botox® injection|Botox® injection in salivary glands will be performed one month after inclusion. It will be performed with one injection point per gland (parotids and submandibulars)
223822644|NCT03616067|DRUG|Scopoderm® patches arm|Scopoderm® patches will be initiated one month after inclusion. The patches will be renewed every 3 days, alternating behind each ear.
223822645|NCT06907095|DIAGNOSTIC_TEST|biological samples|biological samples (blood, urine, saliva, stools in option)
223822646|NCT06925516|DRUG|Apatinib and Adebrelimab in Combination With chemotherapy|Patients would receive Adebrelimab (IV 1200mg q3w) and apatinib (PO 250mg qd) plus GEMOX (up to 6 cycles) in 21day cycles. Apatinib and Adebrelimab would be maintained until the disease progressed or intolerable toxicity and adverse reactions or the medication was used for two years.
223822647|NCT06919445|OTHER|'Text Connect' text messages|The Text Connect message includes 1) a link to a FindHelp (an online social resource database available in over 100 languages) search tailored to the recipient's home ZIP code 2) information regarding applying for the Supplemental Nutrition Assistance Program (SNAP), and information regarding applying for the Special Supplemental Program for Women, Infants, and Children (WIC). All text message content was initially developed in consultation with caregivers of children with FI identified during an admission through a Community Engagement studio and was approved by the institution's Effective Health Communication Core. The investigators have adapted the content based on feedback from participants in the pilot study.
223822648|NCT03491098|DRUG|Mometasone Furoate spray|"Mometasone Furoate spray one puff in each nostril daily for 8 weeks~hypertonic sea water solution spray one puff in each nostril daily for (8) weeks."
223822649|NCT03491098|DRUG|prednisolone sodium phosphate 15mg|three times per day for 1 week then gradual withdrawal over 2 weeks
223822650|NCT03491098|DRUG|hypertonic sea water solution spray|one puff in each nostril daily for 8 weeks
223822651|NCT04066985|BEHAVIORAL|Growth Mindset Online Single-Session Program|30minute self-administered program for youths
223822652|NCT04066985|BEHAVIORAL|Self-Kindness Online Single-Session Program|30minute self-administered program for youths
223822653|NCT04066985|BEHAVIORAL|Supportive Therapy Online Single-Session Program (Control)|30minute self-administered active comparator program for youths
223822654|NCT00634985|DRUG|eletriptan|40 mg oral tablet for migraine attack; additional 40 mg oral tablet \>2 hours from first dose if migraine reoccurred within 24 hours of achieving response
223822655|NCT02384967|DRUG|Darunavir|to assess efficacy of a reduced dose strategy of darunavir to 400 mg/d in HIV-1 infected patients virologically suppressed under a once daily regimen including darunavir 800 mg/d and two nucleoside reverse transcriptase inhibitors (NRTI), to maintain the viral load lower than 50 copies / mL at 48 weeks of treatment.
223822656|NCT01382940|DRUG|rituximab|1000 mg in 250 mL intravenous infusion
223822657|NCT01382940|DRUG|methotrexate|10 to 25 mg/week (oral or parenteral)
223822658|NCT01382940|DRUG|methylprednisolone|100 mg methylprednisolone administered by slow intravenous infusion at least 30 minutes prior to the start of each study drug infusion
223822659|NCT01382940|DRUG|acetaminophen|1 gram acetaminophen administered orally 30 to 60 minutes prior to the start of each study drug infusion
223822660|NCT01382940|DRUG|antihistamine|50 mg diphenhydramine hydrochloride or equivalent dose of alternate antihistamine administered orally 30 to 60 minutes prior to the start of each study drug infusion
223822661|NCT02134210|DRUG|Etanercept|Head-to-head comparison
223822662|NCT02134210|DRUG|CHS-0214|
223822663|NCT02350920|BEHAVIORAL|Acceptance and Committment Therapy (ACT)|This intervention will run with 12-15 participants in each group for a duration of 8 weeks. Each group session will last 1-1.5 hours.
223822664|NCT04944030|PROCEDURE|Metastasis biopsy|Metastasis biopsy will be performed for multi-omic analysis Biological/Vaccine: Biomarkers blood, urine and microbiota samples Biomarkers blood, urine and microbiota samples for multi-omic analysis Behavioral: Patient Reported Outcome (PRO) Patient Reported Outcome (PRO) will be collected throughout the study duration to assess quality of life, anxiety, depression distress, physical activity and food habits.
223822665|NCT01982877|BEHAVIORAL|Four Supports Intervention|The Four Supports Intervention is a multi-faceted intervention involving the addition of a trained nurse/social worker interventionist to the patient's care team who delivers four kinds of support: emotional support, communication support, decision support, and anticipatory grief support.
223822666|NCT01982877|BEHAVIORAL|Educational Control Intervention|In addition to usual care, enrolled surrogates will receive two 15-minute education sessions about critical illness and mechanical ventilation on days 2 and 5, delivered by a research staff coordinator with education in critical care nursing.
223822667|NCT01296490|OTHER|Stress test|Stress test while running on a treadmill until exhaustion for 8-12 minutes. Blood will be drawn before, 5 minutes after and an hour after the test.
223822668|NCT04242420|DIAGNOSTIC_TEST|Genotyping|Genotyping for single nucleotide polymorphisms for Connexin 37\&43, Mannose binding lectin (MBL) and transforming growth factor beta (TGF beta) genotypes
223822669|NCT04242420|DIAGNOSTIC_TEST|Lung function|Spirometry,
223822670|NCT04242420|DIAGNOSTIC_TEST|Microbiology|Bacterial culture from Sputum or swab
223822671|NCT04242420|DIAGNOSTIC_TEST|Blood sample|Interleukin-8 assay (via chemiluminescence) blood cell count
223822672|NCT04242420|DIAGNOSTIC_TEST|Induced Sputum|Interleukin-8 assay (via chemiluminescence) blood cell count
223822673|NCT00808301|OTHER|Gluten-free products|Gluten-free bakery products containing oatmeal.
223822674|NCT01492179|DRUG|Normal saline|Normal saline would be administered intravenously and intra-abdominally.
223822675|NCT01492179|DRUG|Intravenous Lidocaine|Standardized infusion of lidocaine during 24 h. 100 mg bolus and 50 mg/h during 24 h would be administered.
223822676|NCT01492179|DRUG|Intra-abdominal Lidocaine|Lidocaine 5 mg/ml; 100 mg would be administered intraoperatively intra-abdominally and subsequently 50 mg/h as intermittent injection intra-abdominally during 24 h
223822677|NCT03804996|DRUG|TG-1801|Intravenous infusion over 1 hour every 4 weeks
223822678|NCT03804996|BIOLOGICAL|Ublituximab|"recombinant chimeric anti-CD20 monoclonal antibody, available in 25 mg/mL administered as an IV infusion once every 4 weeks"
223822679|NCT04360122|DRUG|Levamisole|Levamisole (150 mg/day for two days per week for 2 months
223822680|NCT04360122|DRUG|Isoprinosine|Isoprinosine (1 g 3 times per day daily) for two months
223822681|NCT04360122|DRUG|Levamisole and Isoprinosine|Levamisole (150 mg/day for two days per week for 2 months and Isoprinosine (1 g 3 times per day daily) for two months
223822682|NCT03622385|OTHER|DNA Methylation|No intervention will be performed. Blood and tissue samples will be analyzed for biomarkers that may be used to develop a diagnostic panel for early detection and diagnosis of high grade serous epithelial ovarian cancer.
223822683|NCT03383796|PROCEDURE|Three dimensional laparoscopic resection for pCCA|Three dimensional laparoscopic resection for pCCA
223822684|NCT03383796|PROCEDURE|Open resection for pCCA|Open resection for pCCA
223822685|NCT00221949|DEVICE|Ultrasound|
223822686|NCT01596283|PROCEDURE|Standard fluid management|The patient will receive standard fluid management
223822687|NCT01596283|DEVICE|Goal directed fluid therapy with the Edwards EV1000 system|This arm will have fluid therapy guided by the Edwards EV1000 system.
223822688|NCT04978610|BEHAVIORAL|Virtual Acceptance Commitment Therapy|"For a period of 6 continuous weeks, participants will meet weekly in a virtual group ACT session with a licensed psychologist hosted on a secure, HIPAA compliant, Zoom account. Each session is 1.5 hours will focus on one ACT concept including Acceptance, Values, Mindfulness, Cognitive Defusion, Experiential Avoidance, and Willingness and Committed Action. Subjects will be given the opportunity to share their thoughts as well as their responses to the exercises at various points throughout the sessions.~At the beginning of each session, each participant will be required to fill out a short survey on their stress and pain the preceding week. Participants in the control group will not complete weekly measures. All measures will be completed online via a REDCap survey web link. Follow up measures will mirror initial baseline measures in order to measure the within group and between group changes in study outcomes."
223822689|NCT02308332|DRUG|Eviplera|switch from Atripla to emtricitabine/rilpivirine/tenofovir (Eviplera)
223822690|NCT05535140|OTHER|G8 Screening Tool|Determine the feasibility of implementing an online patient self-reported G8 assessment, on new patients \>65y/o who are scheduled with the medical oncology department.
223822691|NCT00720902|PROCEDURE|Blood draws|Subjects will have serum cardiovascular markers assessed
223822692|NCT00720902|DRUG|growth hormone releasing hormone (GHRH) & arginine|Subjects will receive GHRH and arginine intravenously and then have blood drawn at frequent intervals over a 90 minutes to assess growth hormone secretion.
223822693|NCT00720902|PROCEDURE|Carotid ultrasound|Subjects will have an ultrasound of their neck to assess their carotid arteries to look for intima-medial thickness.
223822694|NCT00720902|PROCEDURE|MRI|Subjects will have MRI and MR spectroscopy of the abdomen and lower extremities to assess for fat in internal organs and muscle.
223822695|NCT00720902|PROCEDURE|Endothelial cell biopsy|Subjects will undergo endothelial cell biopsies to harvest endothelial cells to study. It will occur once and takes approximately 20 minutes. Patients will have an iv placed and then a sterile wire is passed back and forth in the iv a couple of times. Three wires are passed.
223822696|NCT00782977|OTHER|Nasal oxygen therapy|Arm 1: Nasal cannulae with no oxygen flow. Arm 2: Nasal cannulae with oxygen flow at 5 L/min Arm 3: Nasal cannulae with oxygen flow at 10 L/min
223822697|NCT01486758|DRUG|Azithromycin|Oral azithromycin 10 mg/kg once daily for 7 days followed by 5mg/kg once daily for additional 7 days.
223822698|NCT01486758|DRUG|Placebo|
223822699|NCT02906085|DRUG|Endothelin-1|
223822700|NCT02906085|DRUG|Placebo|Isotonic saline
223822701|NCT04968262|OTHER|Sepsis therapy|Patients receiving sepsis therapy followed the international guidelines of the 2016 Surviving Sepsis Campaign regarding fluid resuscitation, feeding, vasopressor, respiratory, anticoagulation and hydrocortisone therapy, along with ulcer prophylaxis and sedation. Blood and urine samples were collected at the intensive care unit from this patient group at three time points (T1-3): T1: within 24 hours after admission; T2: second day morning; T3: third day morning of follow-up. 24 patients were documented without sepsis and acute kidney injury as a control group.
223822702|NCT04968262|OTHER|Sepsis-related acute kidney injury therapy|Patient management of sepsis and sepsis-related acute kidney injury followed the international guidelines of the 2016 Surviving Sepsis Campaign regarding fluid resuscitation, feeding, vasopressor, respiratory, anticoagulation and hydrocortisone therapy, along with ulcer prophylaxis, sedation and renal replacement therapy (if needed). In this patient group, blood and urine sampling was performed at three time points (T1-3): T1: within 24 hours after admission; T2: second day morning; T3: third day morning of follow-up.
223822703|NCT04835896|DRUG|M7824+paclitaxel|M7824 will be administered intravenously at a dose of 1200 mg every 3 weeks in combination with paclitaxel 80 (or 70) mg/m2 once a week for 3 weeks (each cycle is 4 weeks)
223822704|NCT02655471|DRUG|"Raltegravir and Zidovudine"|Through measure of pro-viral load and clinical score, we evaluate about safety and efficacy of combination of Raltegravir 400 mg BID and zidovudine 300 mg BID in patients with recent onset of Tropical Spastic paraparesis due HTLV-1 during 48 weeks
223822705|NCT00871819|DEVICE|Precision Spinal Cord Stimulation (SCS)|Various SCS device programming parameters
223822706|NCT05260372|DIAGNOSTIC_TEST|Quantification of donor-derived cell-free DNA|Quantification of ddcfDNA on serial plasma samples during follow-up after lung transplantation
223822707|NCT02608489|DRUG|Diquafosol (Diquas)|Diquafosol group used diquafosol 6 times a day during study period.
223822708|NCT02608489|DRUG|Sodium Hyaluronate (Hyalein)|Hyaluronate group used sodium hyaluronate 6 times a day during study period.
223822709|NCT03758820|BEHAVIORAL|Behavorial Cognitive Therapy (BCT)|"Check-in : review of the homewok Talk : Presentation of the aim of the session Group Activity : Relaxation and Execises Refreshment break Homework : exercises to practice at home and explanation about the forms to fill in.~Passout : session handbook and supports for exercises."
223822710|NCT03605160|PROCEDURE|traditional polish|After phacoemulsification and I/A, switch to polish mode and use I/A instrument to remove the RLFs visible on the posterior capsule before injection of viscoelastic agent. IOP: 55mmHg; Aspiration: 0-10; Vacuum: 0-20. The standard for stopping polish is that the RLFs can no longer be absorbed by the side holes on the I/A instrument in this mode, or there are no discernible RLFs on the posterior capsule. If RLFs on the posterior capsular are found after IOL implantation, polish to remove them after the removal of viscoelastic agents.
223822711|NCT03605160|PROCEDURE|fluid-jet|After phacoemulsification and I/A, inject viscoelastic agent and implant IOL without polish. Use I/A instrument to remove viscoelastic agent. A 27G irrigating syringe was used, and the RLFs on the posterior capsule were gently aligned to make a fluid-jet basically parallel to the iris. The liquid pressure of 50-120 mmHg is produced. The standard for stopping in this mode is that the RLFs can no longer be washed down from the capsule, or there are no discernible RLFs on the posterior capsule.
223822712|NCT01411501|OTHER|acupuncture|"Thrust and lift the needle to achieve De Qi. After being needled, the points will be punctured again using auxiliary needles 2 mm lateral to the first needle, and to a depth of 2 mm without manual stimulation. Put the electric stimulator on the pair of needles with a continuous wave, 20Hz. The current intensity is increased to the patients' maximum tolerance and then slightly reduced to a bearable level (0.1-1.0 mA).~Huatuo Brand needle (φ0.30×25mm,φ0.30×40mm,φ0.30×50mm, produced by Suzhou Medical Appliance Factory) and G6805-1A electro-acupuncture apparatus(produced by Shanghai Huayi Medical Instrument Co. Ltd.) will be used.~Five sessions/week in the first 2 weeks, three sessions/week for in the last 2 weeks."
223822713|NCT01411501|DRUG|mosapride citrate|4-week oral use of mosapride citrate, 5mg, three times daily 0.5 hour before meal
223822714|NCT05250713|DEVICE|Transcranial stimulation|Patients will receive either direct current stimulation or alternate stimulation.
223822715|NCT00289237|BEHAVIORAL|Lifestyle intervention|
223822716|NCT05134714|DEVICE|CAD/CAM zircon band and loop space maintainer|Solid monolithic zirconia material which utilizes CAD/CAM technology for its designing and milling of the restoration will be used for fabrication of the space maintainer.
223822717|NCT05134714|DEVICE|Conventional metal band and loop space maintainer|Stainless steel appropriate band will be selected according to the size of the abutment teeth and then design of the loop will be obtained, then will be send to the laboratory for soldering.
223822718|NCT03505450|OTHER|Population Sample|full sample of recruited participants
223822719|NCT03505450|OTHER|Purposive sample|purposive sample of recruited participants
223822720|NCT01712243|OTHER|Light|
223822721|NCT05817435|BIOLOGICAL|efgartigimod PH20 SC as a prefilled syringe presentation|efgartigimod PH20 SC as a prefilled syringe presentation
223822722|NCT05817435|BIOLOGICAL|efgartigimod PH20 SC as a vial + syringe presentation|efgartigimod PH20 SC as a vial + syringe presentation
223822723|NCT04316728|DEVICE|VivaDiag™ COVID-19 lgM/IgG Rapid Test|VivaDiag™ COVID-19 lgM/IgG Rapid Test is an in vitro diagnostic for the qualitative determination of COVID-19 IgM and IgG antibodies in human whole blood (from vein or fingertip), serum or plasma
223822724|NCT00003759|BIOLOGICAL|BCG vaccine|
223822725|NCT00003759|DRUG|valrubicin|
223822726|NCT00003759|PROCEDURE|conventional surgery|
223822727|NCT01496716|PROCEDURE|Hip arthroplasty|The purpose of hip arthroplasties is to reduce pain and increase mobility.
223822728|NCT03550430|BEHAVIORAL|alpha/delta neurofeedback|neurofeedback training protocol seeking to decrease the alpha/delta ratio, by simultaneous rewarding alpha and inhibiting delta activity.
223822729|NCT03550430|BEHAVIORAL|beta/theta neurofeedback|neurofeedback training protocol seeking to decrease the beta/theta ratio, by simultaneous rewarding beta and inhibiting theta activity.
223822730|NCT03550430|OTHER|Diary completion|completion of diary relating to participants' experience of tinnitus intensity, interference, coping, harm and disability. Rated three times daily on numerical scale (0 - 10) for two weeks.
223822731|NCT03607201|OTHER|No intervention|Routine care
223822732|NCT02519647|DEVICE|Tracheal intubation with Gliderite|Tracheal intubation with Gliderite
223822733|NCT02519647|DEVICE|Tracheal intubation with S-guide|Tracheal intubation with S-guide
223822734|NCT01365533|DRUG|Roflumilast|Roflumilast 500 μg, one tablet once daily, orally
223822735|NCT01365533|DRUG|Placebo|Placebo, one tablet once daily, orally
223822736|NCT02482272|DRUG|Lamivudine|Lamivudine 100mg/day orally
223822737|NCT02482272|DRUG|Adefovir|Adefovir 10mg/day orally
223822738|NCT02482272|DRUG|Entecavir|Entecavir 1mg/day orally
223822739|NCT02313818|BEHAVIORAL|Cognitive Processing Therapy-Cognitive Only|Cognitive Processing Therapy-Cognitive Only (CPT-C) is an evidence-based form of Cognitive Behavioral Therapy (CBT) used to treat PTSD. CPT is a manualized program that focuses on challenging beliefs and assumptions related to the trauma, oneself, and the world. Individual sessions will be conducted twice weekly for 4-24 sessions; each session is 60 minutes.
223822740|NCT00298142|PROCEDURE|Usual Care provided by a medical doctor (GP or Neurologist)|
223822741|NCT00298142|PROCEDURE|Usual care plus Physio-/ Manual Therapy|
223822742|NCT01671839|DEVICE|Subcutaneous tissue release with the Cabochon System|Device: Subcutaneous tissue release
223822743|NCT01918696|BEHAVIORAL|Anger Reduction Treatment|Eight 15-minute sessions of interpretation modification to reduce angry interpretation biases.
223822744|NCT01918696|BEHAVIORAL|Progressive Muscle Relaxation|Eight 15-minute sessions of progressive muscle relaxation (PMR) including formulation of a plan to use PMR when angry.
223822745|NCT01918696|BEHAVIORAL|Control Condition|Eight 15-minute sessions of informative videos on healthy living.
223822746|NCT01077479|DRUG|Metformin|Metformin 1500mg nocte for 6 months
223822747|NCT04534413|DEVICE|composite optical fiberscope (COF)|Fiber Technology
223822748|NCT02163655|DRUG|FUROSEMIDE|Furosemide, 20mg pills, will be administered every 24 houras, for a maximum of five days
223822749|NCT02163655|DRUG|Placebo|Placebo pills, identical to the intervention (furosemide pills), will be administered every 24 hour for a maximum of five days
223822750|NCT00905502|DRUG|Lactated Ringer's solution|Patients in the RG received 4 ml/kg•hr of Lactated Ringer's solution (RL) throughout the intra-operative period
223822751|NCT00905502|DRUG|Lactated Ringer's solution|patients in the LG received 10 ml/kg•hr of RL solution intraoperatively
223822752|NCT03297008|OTHER|No internvetion|No intervention, this is an observational study
223822753|NCT02914184|BIOLOGICAL|HRV PCV-free liquid vaccine|Subjects will receive two doses of PCV-free HRV vaccine at 6 and 12 weeks of age. The vaccine will be administered orally
223822754|NCT02914184|BIOLOGICAL|Rotarix|Subjects will receive two doses of currently licensed lyophilised HRV vaccine at 6 and 12 weeks of age. The vaccine will be administered orally
223822755|NCT03873194|OTHER|Meditation|Participants will be instructed to find a comfortable position, with a straight back, feeling the general state of their bodies (tensions, pains, heat, cold, etc.), to relax and pay attention to their own breathing, being aware of the air that gets into and out of the lungs. The women will be told that whenever their attention disperses (to another focus such as a thought, a sound, a body sensation, a judgment, etc.) they should go back to the original focus (breathing) with no feeling/judgment about the loss of focus. The practice involves focus and attention exercises and the gradual insertion of other anchors (focus points) as participants improve their skills in this practice.
223822756|NCT03873194|OTHER|conventional treatment|"Early prenatal care, when possible, is recommended as the first measure. Prenatal appointments usually take place fortnightly or weekly for hypertensive pregnant women. Extensive lab testing including specific tests for the first trimester, as well as tests for the diagnosis of superimposed pre-eclampsia and for the evaluation of lesions in target organs.~Drug treatment is only used when non-drug measures against hypertension are inefficient to decrease blood pressure levels and diastolic pressure is 90 mmHg or higher (in the first half of pregnancy) and over 100 mmHg (after 20 weeks)."
223822757|NCT03841825|BEHAVIORAL|Oral hygiene instructions|Oral hygiene instructions and motivation
223822758|NCT04861662|PROCEDURE|Free gingival graft procedure|Free gingival graft procedure applied to implants with KM\<2 mm to increase the width of keratinized mucosa surrounding them
223822759|NCT00798174|DEVICE|Standard configuration vs. azygos coil|Addition of an azygos vein defibrillation coil instead of a standard SVC coil.
223822760|NCT03410290|OTHER|Online Questionnaire|The online questionnaire includes questions about factors that impacted a patients diagnosis of vasculitis.
223822761|NCT00011024|PROCEDURE|Self Hypnosis|
223822762|NCT00011024|PROCEDURE|Acupuncture|
223822763|NCT00011024|PROCEDURE|Osteopathic Manipulation|
223822764|NCT03755635|COMBINATION_PRODUCT|The WHO multimodal hand hygiene strategy|Comprises five essential elements; system change-availability of alcohol-based hand rub at the point of care and/ or access to safe continuous water supply and soap and towels; training and education of healthcare professionals; monitoring of hand hygiene practices and performance feedback; reminders in the workplace; and the creation of a hand hygiene safety culture with the participation of both individual healthcare workers and senior hospital managers.
223822765|NCT00602186|DRUG|tamsolusin|0.4 mg /day
223822766|NCT00602186|DRUG|prazosin|1 mg/day
223822767|NCT05635136|OTHER|Dynamic full-field optical coherence tomography analysis of kidney transplant biopsy|Dynamic full-field optical coherence tomography analysis of kidney transplant biopsy before conventional histopathological analysis
223822768|NCT02020499|DRUG|Somatuline Autogel® (lanreotide) 60, 90, 120 mg.|Patients receiving treatment as prescribed by the investigator and according to current treatment recommendations and routine clinical practice, and in line with local regulations.
223822769|NCT01567943|BEHAVIORAL|Contingency Management|Behavioral reinforcement for alcohol abstinence
223822770|NCT06241690|OTHER|the cold applications in post-suture pain reduces the child's pain|The experimental groups was applied cold applications immediately after 20 minutes the suture. Later, The experimental groups was applied cold applications again for 20 minutes 1 hour, 2 hours and 6 hours after the suture.
223822771|NCT04275180|DRUG|Argatroban|Argatroban plus standard medical treatment
223822772|NCT01481155|PROCEDURE|ablative CO2 laser therapy|CO2 laser therapy
223822773|NCT01481155|PROCEDURE|photodynamic therapy|Treatment with 5-ALA cream, application time at least 4 h, red light radiation with 76 J/cm²
223822774|NCT06210451|OTHER|Sterile water-based gel|Insertion of the speculum during ET will be performed using 5 gr of water-based, sterile gel
223822775|NCT02436083|DRUG|antibiotic (use of penicilline, unacid, cefuroxime)|prophylactic antibiotics
223822776|NCT03316417|OTHER|Renal Tolerance to Immunotherapy|The main objective is to describe the renal tolerance of these innovative therapies within a population homogeneous of patients.
223822777|NCT01083147|DEVICE|FORESEE HOME|Home Monitoring
223822778|NCT03418870|BEHAVIORAL|Family Integrated Care|Parents of infants assigned to mFI-Care will be trained and treated as primary caregivers for their infants and participate in daily medical rounds, with mFI-Care-trained nurses serving as teachers and coaches.
223822779|NCT01478113|DRUG|Amphetamine/dextroamphetamine|The amphetamine/dextroamphetamine will be in a pill formulation. The dosage of the amphetamine/dextroamphetamine will be flexibly adjusted up or down by a study clinician based on the participant's response. Dose ranges will be 1-3 pills (placebo or 5 mg amphetamine) in the morning and 1-3 pills (placebo or 5 mg amphetamine) at noon.
223822780|NCT01478113|DRUG|Placebo|The placebo will match the dextroamphetamine in form, dosage, frequency, and duration.
223822781|NCT01478113|BEHAVIORAL|Well-being therapy|Therapy sessions will last between 30-50 minutes. The sessions will take place at every visit after the screening visit.
223822782|NCT06243107|BEHAVIORAL|Tai-chi|Participants will each receive a Tai Chi manual and have access to an instructional audio-visual material via a QR code. The instructional material is tailored specifically for cancer patients. Participants will receive individualized guidance and instructions from the researcher (YH) until they have completed all the executions on the checklist to the required standards.
223822783|NCT02415920|DRUG|Oxytocin|Participants will be randomly assigned to intra-nasally administer either oxytocin or a placebo on their first visit and then they will receive the other spray during their second visit.
223822784|NCT02415920|DRUG|Placebo|Participants will be randomly assigned to intra-nasally administer either oxytocin or a placebo on their first visit and then they will receive the other spray during their second visit.
223822785|NCT02991235|DIETARY_SUPPLEMENT|PRJ212|6 capsules of study product will be taken daily and orally.
223822786|NCT02991235|DIETARY_SUPPLEMENT|Placebo|6 capsules of study product will be taken daily and orally.
223822787|NCT05327335|DEVICE|Intelligent robotics for elderly assistance - sarcopenia|Participants will use the robotics system and integrated environment to perform daily self-care to uncover problems in functionality, usability, and acceptance of the robotic device prototype. The system, connected to mobile apps and the Internet, will serve as a platform to measure and record data on how the participants engage in pre-specified activities. The experiment will last six months, and the outcome will be assessed pre- and post-implementation for comparison and validation. The major testing criteria include the design specifications for functionalities and reliability, user experiences, system security and privacy.
223822788|NCT01842737|PROCEDURE|Spinal treatment|This treatment will be applied to the low back region only. During a HVLA treatment, the study doctor will ask the participant to lie on their side on a treatment table. After carefully helping the participant into the proper position, the doctor will make a quick and controlled push with their hand to slightly move joints in the low back. During this procedure, the participant may feel and/or hear a popping sound. After treatment, the doctor may ask the participant to rest on the table for a few moments. During palpation procedure, the doctor will touch several areas in the low back while asking questions about pain, tenderness and other sensations felt during this procedure. The participant will watch the doctor perform the palpation procedure in real time with a tablet computer.
223822789|NCT01842737|PROCEDURE|Massage|The study doctor will perform a massage of each foot while the participant lies face up in a relaxed position on a treatment table. The procedure will last approximately 10-20 minutes including massage to the toes, heel, sole, and top of each foot.
223822790|NCT00674115|DRUG|Omeprazole/sodium bicarbonate|Omeprazole/sodium bicarbonate. Single dose per day for either 1 or 7 days.
223822791|NCT00674115|DRUG|omeprazole magnesium|Omeprazole 20 mg tablet. Single dose per day for either 1 or 7 days.
223822792|NCT00674115|DRUG|sodium bicarbonate|Sodium bicarbonate. Single dose.
223822793|NCT01703702|DRUG|florbetapir (18F)|Single i.v. bolus injection of 370MBq (10 mCi) followed by saline flush, 50 minutes prior to imaging, 10 minute image duration
223822794|NCT00721656|DRUG|Placebo|
223822795|NCT00721656|DRUG|KLS-0611|
223822796|NCT05099016|OTHER|Joint Effort|The Joint Effort intervention is available in the form of an iPhone mobile application (running on iOS 13 and 14) in French language. It aims to support young adults in school who have used cannabis in the past month into taking action on their cannabis use.
223822797|NCT05099016|OTHER|Brief normative feedback and standard information|The brief normative feedback is based on the frequency of cannabis use use. Participants will also be offered basic reliable non personalized information on lower-risk cannabis use in the form of official public websites.
223822798|NCT06305689|PROCEDURE|Surgery|Surgical procedure to the gastrocnemius and/or plantar fascia
223822799|NCT06305689|PROCEDURE|Serial Casting|Repeated casts weekly until desired dorsiflexion range achieved
223822800|NCT03181126|DRUG|Navitoclax|tablet
223822801|NCT03181126|DRUG|Chemotherapy|peg-asparaginase (or other form of asparaginase, per local standard of care (intravenous) + vincristine (intravenous) + dexamethasone (oral) + tyrosine kinase inhibitor (TKI) (if applicable, oral)
223822802|NCT03181126|DRUG|Venetoclax|tablet
223822803|NCT03837613|PROCEDURE|tumor resection and neck dissection|Surgical removal of the tumor with adequate safety margins. In addition to neck dissection to dissect the cervical lymph nodes.
223822804|NCT03355755|DEVICE|EksoGT with SmartAssist software|Intervention will consist of exercise using the EksoGT exoskeleton for supported walking. The EksoGT is a powered motorized orthosis intended to enable individuals who are experiencing muscular or neurological conditions affecting their lower extremities to perform ambulatory functions such as gait training.
223822805|NCT03971838|BEHAVIORAL|Positive Outcomes for Women|"Women and their children 10+ can consent to participate in the diabetes prevention programming offered through the research center. We will collect data at three time points, baseline, 4-6 months, and 12 months.~2\. Instead of participating in Encourage, women may participate in other diabetes prevention programming/weight management programming offered by other entities. Researchers will consent these women into the study to complete 3 data collection points, baseline, 4-6 months, and 12 months. Additionally, researchers will consent women to obtain data from their chosen program. For instance, if a woman chooses to do a Diabetes Prevention Program through the YMCA, researchers will ask women to self report their weekly attendance and weight."
223822806|NCT04315025|BIOLOGICAL|Umbilical Cord Mesenchymal Stem Cell (UC-MSC)|Umbilical Cord Mesenchymal Stem Cell (UC-MSC) injected by peribulbar
223822807|NCT04315025|BIOLOGICAL|Conditioned Medium (CM)|Conditioned Medium (CM) injected by peribulbar
223822808|NCT04712201|PROCEDURE|En bloc transurethral resection of bladder tumor (TURBT)|En bloc transurethral resection of bladder tumor using thulium:yttrium aluminium garnet, monopolar and bipolar energy
223822809|NCT04712201|PROCEDURE|Conventional TURBT|Conventional transurethral resection of bladder tumor using monopolar and bipolar energy
223822810|NCT05217043|OTHER|intracranial brain recording|Any patient benefiting from a long-term intracranial brain recording.
223822811|NCT01400230|PROCEDURE|diagnostic procedures CCTA, CAG, IVUS and FFR|Diagnostic procedures including computed tomography, coronary angiography, intravascular ultrasound, fractional flow reserve were performed in the patients suspected ischemic heart disease.
223822812|NCT03093428|DRUG|Radium-223|Radium-223 is a calcium mimetic that hones in on bone metastases. It binds to new bone stroma and emits alpha particles, which induce double-stranded DNA breaks that result in tumor cell death.
223822813|NCT03093428|DRUG|Pembrolizumab|Pembrolizumab is a PD-1 inhibitor. Pembrolizumab binds to human PD-1 and blocks the interaction between PD1 and its ligands.
223822814|NCT04570553|PROCEDURE|surgical staging|Patients will undergo standard surgical staging for endometrial cancer utilizing either a V-care uterine manipulator or sponge stick
223822815|NCT06152016|OTHER|BE-FAST|This intervention includes those randomized to the education with the BE-FAST mnemonic.
223822816|NCT06152016|OTHER|FAST|This intervention includes those randomized to the education with the FAST mnemonic.
223822817|NCT05907460|DEVICE|transesophageal echocardiography examination during cardiopulmonary resuscitation|Perform transesophageal echocardiography in patients with out-of-hospital cardiac arrest during cardiopulmonary resuscitation and adjust the chest compression site to compress the left ventricle and avoid left ventricular outflow tract.
223822818|NCT04506008|RADIATION|Ultra-Hypo-fractionation Radiotherapy|Five fractions of pre-operative radiation
223822819|NCT04506008|PROCEDURE|Resection|Surgery
223822820|NCT04506008|OTHER|Questionnaire Administration|Ancillary studies
223822821|NCT04506008|RADIATION|Moderately-Hypo-fractionation Radiotherapy|15 fractions of pre-operative radiation
223822822|NCT05084222|DRUG|Buventol® Easyhaler® 200 µg/inhalation dmDPI|Two doses will be administered
223822823|NCT05084222|DRUG|Bufomix® Easyhaler® 160/4.5 µg/inhalation dmDPI|Two doses will be administered
223822824|NCT05084222|DRUG|Ventoline® Evohaler® 100 µg/inhalation pMDI|Four doses will be administered via Volumatic spacer
223822825|NCT06305039|DIAGNOSTIC_TEST|Diagnostic tests of cochlear implant or acoustic hearing function|Because the cochlear implant participants in the study will use cochlear implant devices that they have already received as part of their standard-of-care treatment, the medical device itself is not an intervention for the purposes of this study. The intervention here will be to carry out diagnostic tests of cochlear implant or acoustic hearing function. This will include perceptual tests of sound localization, speech understanding in noise, binaural fusion, and loudness comparisons.
223822826|NCT06305039|BEHAVIORAL|Targeted aural rehabilitation of the poorer performing ear|Subjects will undergo listening practice on a tablet computer over headphones at home. For the test group, the aural rehabilitation will be targeted at the poorer ear. For the comparison control group, a sham aural rehabilitation will present speech to both ears.
223822827|NCT00978354|DRUG|Furosemide|Continuous intravenous infusion of furosemide titrated to urine output
223822828|NCT00978354|DRUG|Normal Saline|Continuous intravenous infusion 0.9% normal saline placebo control
223822829|NCT02629055|OTHER|Respiratory EMG|Titration of non-invasive ventilation on surface respiratory muscle activity
223822830|NCT00041756|DRUG|PG-530742|One 25 mg PG-530742 tablet, twice daily for for one year
223822831|NCT00041756|DRUG|Placebo|One placebo tablet, twice daily for for one year
223822832|NCT00041756|DRUG|50 mg PG-530742|One 50 mg PG-530742 tablet, twice daily for for one year
223822833|NCT00041756|DRUG|100 mg PG-530742|100 mg PG-530742 tablet, twice a day for one year
223822834|NCT00041756|DRUG|200 mg PG-530742|200 mg PG-530742 tablet, twice a day for one year
223822835|NCT03020563|DRUG|Liposomal Bupivacaine|Liposomal Bupivacaine
223822836|NCT03020563|DRUG|Bupivacaine|Bupivacaine
223822837|NCT04334239|OTHER|Oncological certification|Oncological certification encompasses a variety of criteria such as treatment according to the clinical guidelines, staffing, technical infrastructure, minimum caseloads, and multidisciplinary care.
223822838|NCT01179360|OTHER|Integrated FDG PET/CT|Optimized PET/CT imaging with dedicated head-and-neck protocol
223822839|NCT03980184|DRUG|Guanfacine|Guanfacine 3mg/day Versus Placebo
223822840|NCT03980184|OTHER|Behavioral Counseling|placebo
223822841|NCT00603265|DRUG|ADL5859|
223822842|NCT00603265|DRUG|Duloxetine|
223822843|NCT00603265|DRUG|Placebo|
223822844|NCT05798039|BEHAVIORAL|ENRICH|Participants will receive additional heart health-focused materials and guidance in sessions with their nurse home visitor. The nurse will help them choose and work towards behavior goals to support their health. This will include goals for activity, diet, weight, blood pressure, diabetes, smoking, social relationships, sleep, parenting, and getting health care.
223822845|NCT02002884|DRUG|IncobotulinumtoxinA (8 Units per kg body weight)|Active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl); Mode of administration: intramuscular injection into spastic muscles.
223822846|NCT02002884|DRUG|IncobotulinumtoxinA (6 Units per kg body weight)|Active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl); Mode of administration: intramuscular injection into spastic muscles.
223822847|NCT02002884|DRUG|IncobotulinumtoxinA (2 Units per kg body weight)|Active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl); Mode of administration: intramuscular injection into spastic muscles.
223822848|NCT05975502|OTHER|Epidemiological study|Study of epidemiological characteristics of women with syphilis during pregnancy and of children born from mothers with syphilis during pregnancy.
223822849|NCT02966002|DRUG|Aspirin|
223822850|NCT06261047|RADIATION|radiotherapy|radiotherapy
223822851|NCT03498222|DRUG|Atezolizumab|Administered at a fixed dose of 1200 mg (equivalent to an average body weight-based dose of 15mg/kg) by intravenous (IV) infusion every 3 weeks (21 days).
223822852|NCT03498222|DRUG|Pemetrexed|Administered at a fixed dose of 500mg/m2 by IV infusion every 3 weeks.
223822853|NCT03498222|DRUG|Carboplatin|Administered at a fixed dose of AUC5 by IV infusion every 3 weeks.
223822854|NCT03498222|DRUG|ADI PEG20|Administered by intramuscular (IM) injection to patients once weekly.
223822855|NCT01642602|DRUG|Dexlansoprazole|Dexlansoprazole delayed-release capsules.
223822856|NCT02768948|DRUG|telmisartan during 6 months|telmisartan during 6 months
223822857|NCT02768948|DRUG|Losartan during 6 months|Losartan during 6 months
223822858|NCT02768948|PROCEDURE|blood sample|blood sample
223822859|NCT02852018|GENETIC|Identification of genetic polymorphisms|
223822860|NCT04107623|DIAGNOSTIC_TEST|Indocyanine Green|Using Q-ICG perfusion of the remaining Gastric Conduit will be compared
223822861|NCT04315103|COMBINATION_PRODUCT|a single intraarticular injection of HYAJOINT Plus (3 ml) followed by 3 ml PRP|All the injections were done by the same experienced physician using aseptic procedures.
223822862|NCT05985603|OTHER|CIMT Group|In this group of patients CIMT technique will be used for treatment
223822863|NCT05985603|OTHER|Mirror Therapy group|patient will perform movements in semi-reclined and sitting positions with the mirror placed between the two lower extremities.
223822864|NCT04684082|DEVICE|Colonic irrigation with the Colon Hydromat|"A designated health professional will administer to the patient the colonic irrigation procedure - using the Colon Hydromat device, a CE certified device for colonic irrigation and cleansing before endoscopic procedures."
223822865|NCT03377790|COMBINATION_PRODUCT|VP-102 - Cantharidin, Topical Film Forming Solution|VP-102, a single-use drug device combination product containing (cantharidin) topical solution, 0.7% (w/v). Up to 4 applications of VP-102 will be administered to Molluscum lesions at 21-day intervals.
223822866|NCT03377790|COMBINATION_PRODUCT|Placebo -Topical Film Forming Solution without VP-102|Placebo a single-use drug device combination product containing only the vehicle. Up to 4 applications of Placebo will be administered to Molluscum lesions at 21-day intervals.
223822867|NCT00439166|DRUG|doxycycline|capsule, 100 mg, b.i.d., daily for 1 year
223822868|NCT00439166|DRUG|rifampicin|capsule, 300mg, o.d., daily for 11 months (administration starts in 2nd month of trial)
223822869|NCT00439166|DRUG|Placebo matched to doxycycline|Doxycycline-matched - blue capsule, b.i.d.,daily for 12 months
223822870|NCT00439166|DRUG|Placebo matched to Rifampin|Rifampin-matched - red capsule, o.d., daily for 11 months starting at month 2.
223822871|NCT05125523|DRUG|Sirolimus for Injection (Albumin Bound)|Sirolimus for Injection (Albumin Bound), intravenously, once a week, 28 days per cycle (three weeks-on and one week-off)
223822872|NCT03072381|BIOLOGICAL|Platelet Rich Plasma - Group 1|Subjects in Group 1 (PRP) will receive a single ultrasound-guided intratendinous (common extensor tendon origin) injection of up to 3 mL autologous PEAK platelet-rich plasma at week 0 (baseline).
223822873|NCT03072381|DRUG|Corticosteroid Control - Group 2|Subjects in Group 2 (corticosteroid control) will receive a single ultrasound-guided intratendinous injection approximately (may be limited by tendon/soft tissue limitations of the subject) of 2 mL 1% lidocaine + 1mL of him 40mg Kenalog (triamcinolone hexacetonide, 40mg/mL) at week 0.
223822874|NCT01047475|DRUG|MB-6|6# TID with meal
223822875|NCT01047475|DRUG|Placebo|6# TID with meal
223822876|NCT01503541|GENETIC|DNA analysis|
223822877|NCT01503541|GENETIC|RNA analysis|
223822878|NCT01503541|GENETIC|gene expression analysis|
223822879|NCT01503541|GENETIC|mutation analysis|
223822880|NCT01503541|GENETIC|polymerase chain reaction|
223822881|NCT01503541|OTHER|laboratory biomarker analysis|
223822882|NCT05835193|OTHER|Diagnostic Test: Distance Visual Acuity Examination|Best spectacle-corrected distance visual acuity and reading capacity of pre-school students in Alexandroupolis, Greece will be examined via a web-based digital visual acuity chart
223822883|NCT00504465|DRUG|dinoprostone|
223822884|NCT06170957|OTHER|Modified pacifier|"In this project, a pacifier produced from a modified pacifier shield made of polypropylene (PP), a biocompatible polymer, which is made suitable for intubation tube in newborns connected to mechanical ventilator, will be used in the light of literature information. No study on the modification of the pacifier shield has been found in the literature, and a utility model application (file number 2020/03477 dated 06 March 2020) was made for this pacifier shield, which is planned to be modified, and the utility model application was accepted on 04.02.2022.~In the application of heel blood collection to newborns, a) before the procedure (20 minutes before), b) immediately before the procedure (20. minutes), c) during the procedure (between the 20th and 40th minutes), and d) 20 minutes after the procedure (40 minutes) will be evaluated once for each application, a total of four times."
223822885|NCT04746547|DRUG|Dolutegravir 50 MG|Twice daily dolutegravir with rifampicin containing TB treatment
223822886|NCT04746547|DRUG|Dolutegravir 10 MG|Twice daily dolutegravir with rifampicin containing TB treatment
223822887|NCT02546154|DRUG|10% Iron Isomaltoside 1000|Standard clinical practice and following the Monofer® label (SPC)
223822888|NCT02802683|DRUG|Bupivacaine|spinal anesthesia with hyperbaric bupivacaine
223822889|NCT02802683|DRUG|Levobupivacaine|spinal anesthesia with isobaric levobupivacaine
223822890|NCT02802683|DRUG|Phenylephrine|continous infusion of phenylephrine
223822891|NCT02802683|DRUG|normal saline|continous infusion of normal saline
223822892|NCT06275425|DRUG|Total intravenous anesthesia with Byfavo|General anesthesia is maintained with intravenous continuous administration of Byfavo.
223822893|NCT06275425|DRUG|Inhalation anesthesia with Sevoflurane|General anesthesia is maintained with Sevoflurane.
223822894|NCT00547287|DRUG|tadalafil|20 mg tadalafil as needed by mouth no more than once a day for a 4 week initiation period and a 4 weeks treatment period.
223822895|NCT00547287|DRUG|sildenafil|Current dosage of sildenafil is continued for 4 weeks (no more than once a day) of treatment assessment then the wash-out period will begin.
223822896|NCT00284869|DRUG|LPS|
223822897|NCT03539367|DRUG|ACETAZOLAMIDE oral capsule|Administration of 1x125mg acetazolamide in the morning, 2x125mg in the evening, starting 24 hours before departure to 3'100m
223822898|NCT03539367|DRUG|Placebo oral capsule|Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3'100m
223822899|NCT05806502|DIAGNOSTIC_TEST|Nω-hydroxy-nor-arginine|Arginase inhibitor
223822900|NCT00810758|DRUG|PF-04878691 3mg|Oral solution, 3mg, twice weekly, 2 weeks
223822901|NCT00810758|DRUG|PF-04878691 6mg|Oral solution, 6mg, twice weekly, 2 weeks
223822902|NCT00810758|DRUG|PF-04878691 9mg|Oral solution, 9mg, twice weekly, 2 weeks
223822903|NCT03748602|PROCEDURE|Thoracic outlet decompression|TOD consists out of first rib resection with partial scalenectomy and neurolysis. If there are also complaints below the pectoral minor tendon insertion, a pectoral minor tenotomy is performed.
223822904|NCT04229030|DRUG|RZL-012|small synthetic molecule for the treatment of Dercum's Disease lipomas
223822905|NCT04229030|DRUG|Vehicle|Vehicle of RZL-012 drug product
223822906|NCT00001202|DRUG|Spironolactone|
223822907|NCT00001202|DRUG|Testolactone|
223822908|NCT00001202|DRUG|Deslorelin|
223822909|NCT04202744|OTHER|Shoulder and core evaluations|Five main parameters of the shoulder were assessed: the flexibility of pectoralis minor muscle, tightness of the posterior shoulder capsule, glenohumeral range of motion of internal and external rotation (sum of internal and external rotation: total range of motion), the strength of rotator cuff muscles and scapula position. As core parameters, trunk muscle endurance (flexor, extensor, and laterals) and core stability were evaluated.
223822910|NCT03548116|DEVICE|Ultrasound|A specially designed ultrasound will be placed against the abdomen of an individual in order to administer low levels of insonification to the spleen.
223822911|NCT03548116|DEVICE|Sham Ultrasound|A specially designed ultrasound will be placed against the abdomen of an individual in order to administer sham insonification to the spleen.
223822912|NCT04891796|OTHER|No intervention|No intervention
223822913|NCT01474616|OTHER|Sit-to-Stand Activity|Health care aides will be expected to prompt residents to repeatedly stand up and sit down on four occasions throughout the day (twice on each of the day and evening shifts). The number of repetitions on each occasion will vary according to residents' ability and fatigue. The sit-to-stand activity is to be integrated into usual care routines such as when entering the dining room at mealtimes, while toileting, and on other occasions of regular activity. The timing and location will be at the discretion of the health care aide.
223822914|NCT06624943|DRUG|biosimilar insulin glargine|Once daily injection of biosimilar insulin glargine via reusable pen
223822915|NCT06626100|BEHAVIORAL|Exercise-themed game|The intervention includes three parts: quiz questions on knowledge on and benefits of exercise; monitored step count using smartphone tracker; whatsapp reminders on the benefits of exercise.
223822916|NCT06626100|BEHAVIORAL|Diet-themed game|The intervention includes two parts: quiz questions on knowledge on and benefits of healthy diet; whatsapp reminders on the benefits of healthy diet.
223822917|NCT01321398|OTHER|Esophageal Pressure Monitoring|An esophageal pressure monitor will be placed through the mouth into the esophagus by a study physician. Placement will be confirmed by a bedside chest X-ray. Once placement has been confirmed all air will be evacuated from the balloon by syringe. One ml of air will then be injected to partially inflate the esophageal balloon. Pleural pressure measurements will be recorded after 1 minute without spontaneous breathing or patient care related movement. This measurement will be repeated at 30 minutes and at 60 minutes after the first measurement. Trans-pulmonary pressure is calculated as the difference between esophageal pressure and mouth pressure. Once the measurements have been recorded, the catheter will be removed.
223822918|NCT06160739|DRUG|Sirolimus 1Mg Oral Tablet|patients with Microcystic , Mixed Lymphatic and Vascular Malformations will be given sirolimus 1 mg oral tab for 3-6 months with follow up of lesion size by clinical exam \& ultrasound \& MRI to compare lesion size before \& after use of the drug with observation of potential side effects \& after exclusion of it before use of the drug
223822919|NCT03389607|DIAGNOSTIC_TEST|spinal anesthesia|before spinal anesthesia, before 5 min opening of tourniquet and 2 hr after operation SCUBE-1, MDA and TAC will measured from plasma
223822920|NCT03101241|DRUG|CX-8998|T-type calcium channel blocker
223822921|NCT03101241|DRUG|Placebo|Placebo comparator
223822922|NCT02746913|DEVICE|Urodynamics|Urodynamics is performed with the Aquarius XT Laborie system and a fluoroscopic images are obtained with a GE OCE 9800 c-arm fluoroscopy unit. Urodynamic testing will be performed in a seated position with a pessary from the ambulatory pessary trial in place. Post residual void will be measured at the start of the urodynamics.
223822923|NCT02746913|DEVICE|Pessary|A pessary is a silicone disc that is used in to support the uterus and vagina of women with vaginal prolapse. During this study, the pessary that will be used is a ring with support. This is a disc shape with a membrane stretched across the center. It is a device used in standard practice and is safe to keep in place for up to 3 months at a time. The subjects will be fit with a pessary asked to wear the pessary for 3 days.
223822924|NCT01998594|PROCEDURE|Arthroplasty|A longitudinal dorsoradial incision is made from the base of the first metacarpal to the radial styloid for access to the thumb CMC joint. Trapeziectomy is performed piecemeal using sharp and blunt dissection. The base of the first metacarpal is then decorticated with a sagittal saw. A 4x7 cm sheet of thin FlexHD (HADM) is fashioned by a 4-0 monocryl suture imbrication into the size and shape of the subject's trapezium, keeping the dermal side exposed as much as possible. The allograft is secured with multiple interrupted 3-0 Ticron sutures and the bundle is placed into the post-trapeziectomy space. Additional suture fixation is performed between the FlexHD and the volar capsule of the trapezium, and base of the thumb metacarpal using 4-0 Mersilene sutures. The control treatment group will have the same trapeziectomy but without the placement of the FlexHD acellular dermal matrix.
223822925|NCT01904214|DRUG|BAF312|Treatment with a single oral dose of 0.25 mg BAF312
223822926|NCT04498247|BIOLOGICAL|V591|1 or 2 ascending doses of V591 will be administered via intramuscular (IM) injection.
223822927|NCT04498247|OTHER|Placebo|Placebo (0.9% sodium chloride) administered via IM injection.
223822928|NCT00713674|OTHER|Theraworx|Theraworx swab intranasal BID for 5 days
223822929|NCT00713674|DRUG|mupirocin antibiotic ointment|mupirocin antibiotic ointment swab intranasal BID for 5 days
223822930|NCT00975988|DRUG|TYKERB® tablets|Patients administrated TYKERB® tablets according to the prescribing information
223822931|NCT00852826|PROCEDURE|Standard axillary lymphadenectomy|Standard axillary lymphadenectomy
223822932|NCT00852826|PROCEDURE|Collagen sponge coated with human coagulation factors|Three patches of collagen sponge coated with human coagulation factors (TachoSil®, Nycomed Pharma, AS) were perpendicularly placed at the end of lymphadenectomy on the axillary neurovascular bundle, thoracodorsal pedicle, and costal wall, covering the axillary walls
223822933|NCT02925260|OTHER|MRI with ileal pouch contrast and enema.|Pre enema 20mg IV or IM Hyoscine Butylbromide (Buscopan) Pre enema Small Field of View (SFOV) T2 sagittal series Pre enema SFOV T2 axial series Pre enema SFOV T1 sagittal series (fat suppressed) Pre enema SFOV T1 axial series (fat suppressed) Enema infiltration started During enema filling Dynamic T1 sagittal single image, fat suppressed, aligned on pouch-anal anastomosis During enema filling T1 sagittal series (fat suppressed) During enema filling T1 axial series (fat suppressed) Jelly infiltrated and held Evacuating series Oblique sagittal T2 evacuating series of the mid and distal pouch, aligned to the pouch-anal anastomosis
223822934|NCT00191360|DRUG|Somatropin|
223822935|NCT04049903|DRUG|MP0310|MP0310 will be examined for safety, tolerability, PK, and PD activity in subjects with advanced solid tumors
223822936|NCT03469349|DRUG|Actovegin|Actovegin intravenous infusion and tablets.
223822937|NCT03469349|DRUG|Placebo|Actovegin placebo-matching intravenous infusion and tablets.
223822938|NCT01090908|DRUG|Antibiotic|
223822939|NCT01083420|DRUG|Minocycline|Minocycline 0.2% mouthwash
223822940|NCT01083420|DRUG|Dexamethasone|Dexamethasone 0.01% mouthwash
223822941|NCT06319235|DRUG|IMP|DUOFAG® is a phage cocktail (cutaneous liquid) manufactured by MB PHARMA s.r.o. and it contains bacteriophages active against Staphylococcus aureus and Pseudomonas aeruginosa.
223822942|NCT06319235|DRUG|Placebo|0.9% Sodium Chloride Injection solution was manufactured by B. Braun Melsungen AG. Marketing authorization number assigned from the State Institute for drug control (Czech Republic): 76/847/92-B/C
223822943|NCT06489574|PROCEDURE|thoracic epidural with dexmedetomidine in patients undergoing thoracotomy surgery|"A thoracic epidural catheter will be inserted at the T6- T7 intervertebral space, with the patient in the sitting position with standard aseptic precautions using an 18-G Touhy needle via a midline or paramedian approach with a loss of resistance method. A test dose of 3 ml of 2% lignocaine with adrenaline 5 µ/ml will be administered.~For thoracic surgery the sensory dermatome blockade needs to cover the incision and intercostal drains and may extend from T4 to T8.~The epidural drug will be administered according to the group allocation over a period of 10 minutes as follows:~Group A:~Patients will receive 50 μg dexmedetomidine with 10 ml of 0.125% bupivacaine followed by a continuous infusion of (10 ml bupivacaine + 25 μg dexmedetomidine + 39 ml saline with rate of 5 ml per hour)."
223822944|NCT06489574|PROCEDURE|thoracic epidural with fentanyl in patients undergoing thoracotomy surgery|"A thoracic epidural catheter will be inserted at the T6- T7 intervertebral space, with the patient in the sitting position with standard aseptic precautions using an 18-G Touhy needle via a midline or paramedian approach with a loss of resistance method. A test dose of 3 ml of 2% lignocaine with adrenaline 5 µ/ml will be administered.~For thoracic surgery the sensory dermatome blockade needs to cover the incision and intercostal drains and may extend from T4 to T8.~The epidural drug will be administered according to the group allocation over a period of 10 minutes as follows:~Group B:~Patients will receive 50 μg fentanyl in addition to 10 ml 0.125% bupivacaine followed by a continuous infusion (10 ml bupivacaine + 100 μg fentanyl + 38 ml saline with rate of 5 ml per hour)."
223822945|NCT01422369|DRUG|Pitavastatin (NK-104)|Pitavastatin (NK-104) 4mg once daily (QD)
223822946|NCT01422369|DRUG|Darunavir/Ritonavir (Prezista)|Darunavir/Ritonavir (Prezista) 800 mg/100 mg
223822947|NCT04299334|PROCEDURE|adjustable neochordae Technique|"Classic ring annuloplasty will be done using Carpentier or physio ring, then neochordal placement will be done using the looping technique. The length of the chordae is adjusted to achieve the optimal length.~In this study, Surgeons use relatively short loops because of the augmentation of the length with extra loops suspended with Gortex. Placement of at least 8-12 chordae of the corresponding heads of the papillary muscle tip to achieve proper management of the prolapse and longevity of the repair."
223822948|NCT05082896|PROCEDURE|Type of anesthesia choice|Use of conscious sedation vs. general anesthesia
223822949|NCT01797341|DRUG|Tacrolimus|
223822950|NCT01797341|DRUG|Tacrolimus|
223822951|NCT06186557|OTHER|No intervention|No intervention
223822952|NCT05829980|PROCEDURE|Laser assisted in-situ keratomileusis|Laser-Assisted In Situ Keratomileusis is a procedure that permanently changes the shape of the cornea using an excimer laser and the mechanical microkeratome (a blade device) used to cut a flap in the cornea.
223822953|NCT05829980|PROCEDURE|Photorefractive keratectomy|Photorefractive keratectomy is a laser refractive procedure used to ablate the corneal stroma to correct refractive errors without cutting flap
223822954|NCT01077726|DRUG|capecitabine [Xeloda]|1000mg/m2 po bid on days 1-14 of each 3 week cycle
223822955|NCT03984032|DEVICE|LMA Protector Cuff Pilot|Assessing the clinical performance of LMA Protector Cuff Pilot
223822956|NCT03984032|DEVICE|LMA Supreme|Assessing the clinical performance of LMA Supreme
223822957|NCT05642273|DEVICE|oXiris membrane|oXiris membrane for 24h
223822958|NCT05642273|DIAGNOSTIC_TEST|Blood tests|Blood tests just after randomization (0 h) and at 24 h, 48 h and 7 days
223822959|NCT05244811|DRUG|Combined Oral Contraceptive|effect of cocs in treatment of ovarian cysts
223822960|NCT05244811|DRUG|Progestin|effect of progestin in treatment of ovarian cystn
223822961|NCT00079911|DRUG|valacyclovir hydrochloride|valacyclovir hydrochloride
223822962|NCT04572529|PROCEDURE|Cardiac Valve replacement|Open heart surgery to replace the valvular infective endocarditis
223822963|NCT06108089|DIAGNOSTIC_TEST|[18F]MISO-PET/CT|18F\]MISO-PET/CT will be acquired in each patient as the standard of references of tumor hypoxia.
223822964|NCT05256693|DRUG|Vancomycin|Oral vancomycin (powder) 125mg twice a day
223822965|NCT05256693|DRUG|Placebo|Vancomycine placebo (powder) twice a day
223822966|NCT01572246|OTHER|Optimal placement of return pad|The ESU return pad will be placed in an optimal position in order to direct ME current away from the ICD pulse generators.
223822967|NCT01961596|OTHER|Cooling Ice Spray|"A bursts of the Cooling Ice Spray over a period of 10 seconds (15 cm distance) will be applied at the dominant foot in before each test."
223822968|NCT01961596|OTHER|water|A bursts of the water spray (room temperature over a period of 10 seconds (15 cm distance) will be applied at the dominant foot in before each test.
223822969|NCT02676323|DRUG|Panobinostat|Panobinostat will be given orally (PO) on days 1, 3, 5, 8, 10, and 12.
223822970|NCT02676323|DRUG|Fludarabine|Fludarabine will be given intravenously (IV), 30 mg/m\^2/dose over 30 minutes, daily for 5 days (days 8-12).
223822971|NCT02676323|DRUG|Cytarabine|Cytarabine will be given IV, 2 gram/m\^2/dose over 4 hours, daily for 5 days (days 8-12).
223822972|NCT02676323|DRUG|Intrathecal Triples|Given intrathecally (IT).
223822973|NCT02676323|DRUG|Leucovorin|Leucovorin (5 mg/m\^2/dose, max 5 mg) may be given PO or IV at 24 and 30 hours after each ITMHA.
223822974|NCT03492736|DIETARY_SUPPLEMENT|Melatonin|30 days 10mg Melatonin taken nightly 1 hour before bed
223822975|NCT03492736|OTHER|Placebo|30 days placebo taken nightly 1 hour before bed
223822976|NCT02773680|DEVICE|"electrical impedance tomography"|One continous electrical impedance tomography (EIT) measurement per subject of approximately 5 minutes duration (2 min prior to MDCT scanning, during end-inspiratory MDCT acquisition and 2 min after MDCT scanning)
223822977|NCT02784223|DEVICE|Radiation : PET-CT with F18-choline examination|PET-CT with F18-choline examination will be performed before surgery
223822978|NCT00008463|DRUG|Ribavirin|
223822979|NCT00008463|DRUG|Interferon alfa-2a|
223822980|NCT00008463|DRUG|Peginterferon alfa-2a|
223822981|NCT01381874|DRUG|Exemestane|Abiraterone acetate, type=equal, unit=mg, number=250, form=tablet, route=oral use, 4 tablets
223822982|NCT01381874|DRUG|Abiraterone acetate + Prednisone/ Prednisolone + Exemestane|Prednisone or Prednisolone, type=equal, unit=mg, number=5, form=tablet, route=oral use. All drugs are taken once daily.
223822983|NCT01381874|DRUG|Abiraterone acetate + Prednisone or Prednisolone|Abiraterone acetate, type=equal, unit=mg, number=250, form=tablet, route=oral use, 4 tablets
223822984|NCT06265883|PROCEDURE|Len+DEB-TACE+HAIC|Patients received TACE with drug-eluting beads and FOLFOX-HAIC. DEB-TACE and/or HAIC was repeated for viable tumors demonstrated by follow-up imaging in patients without worsening liver function or contraindications. Lenvatinib was orally administered at a dose of 12 mg/day (bodyweight 60 kg) or 8mg/day (bodyweight \<60 kg). It was initiated within 7 days after the first DEB-TACE or DEB-TACE+HAIC and continued until unacceptable toxicity or disease progression occurred.
223822985|NCT06265883|PROCEDURE|Len+DEB-TACE|Patients received TACE with drug-eluting beads. DEB-TACE was repeated for viable tumors demonstrated by follow-up imaging in patients without worsening liver function or contraindications. Lenvatinib was orally administered at a dose of 12 mg/day (bodyweight 60 kg) or 8mg/day (bodyweight \<60 kg). It was initiated within 7 days after the first DEB-TACE or DEB-TACE+HAIC and continued until unacceptable toxicity or disease progression occurred.
223822986|NCT00664820|DIETARY_SUPPLEMENT|Probiotic capsules containing Lactobacillus rhamnosus GR-1 and L. reuteri RC-14|2 capsules daily for 3 months.
223822987|NCT05512728|DEVICE|VR|"The IVR environment was provided by Shinecon VR (Shinecon, china). Shinecon VR features, have a large field of view and high-quality display; with aspheric lens , lens diameter 40MM, view angle 108 , sharpness 99%, visibility 100%, color .38MM and pupillary distance adjustment 65 MM.~The shinecon VR setup was powered by a HUAWEI Y7 prime phone running the freely available IVR software.~Shinecon VR provides videos for nature, forest, wind, desert and animals. That included noise-cancelling headphones playing background sound from the IVR simulation."
223822988|NCT05512728|DRUG|Midazolam|• (titration of 0.05 mg/kg per dose) according to Modified Wilson sedation scale Score to achieve grade 1 (Oriented, eyes may be closed but can respond to 'Can you tell me your name?' 'Can you tell me where you are right now?'
223822989|NCT02979626|PROCEDURE|Respiratory nasal swab|Nasal swabs will be obtained for testing by the study nurses. If a respiratory sample has already been collected as part of routine clinical care, this will replace the study collection, and no additional testing will be required.
223822990|NCT00509158|BIOLOGICAL|arm I: PfLSA-3-rec with aluminium hydroxide as adjuvant|
223822991|NCT00509158|BIOLOGICAL|arm 2: PfLSA-3-rec with Montanide Isa 720 as adjuvant|
223822992|NCT02970513|OTHER|Psychiatric evaluation|The purpose of this study is to determine whether the presence of pathogenic Escherichia coli in colon is associated with psychiatric disorders.
223822993|NCT03885804|DRUG|Quadratus lamborum dexmedetomidine intravenous|Patients will receive quadratus lamborum block on the same surgical side then a bolus of 0.5 ml/Kg bupivacaine 0.25% in addition to 2ml normal saline will be injected then dexmedetomidine (precedex 200 micrograms per 2ml, Abbott laboratories, Abbott park, IL, USA) which will be prepared in concentration 1μg/ml. 1ml/kg loading dose will be given over 10 min followed by 0.5 ml/kg/h infusion maintenance dose till the end of surgery
223822994|NCT03885804|DRUG|Quadratus lamborum dexmedetomidine perineural group(|Patients will receive quadratus lamborum block on the same surgical side then1μ g/kg diluted to 2 mL with 0.9% saline added to 0.5 ml/kg of 0.25% bupivacaine in addition to saline infusion 1ml/kg IV loading dose followed by by 0.5 ml/kg/h infusion maintenance dose till the end of surgery.
223822995|NCT03771157|DRUG|Shingrix vaccine|On day one, patients will receive the first of two doses of the Shingrix vaccine administered as an injection into the muscle in their upper arm. The second dose of vaccine will be administered as an injection to their upper arm approximately 2 months after the first dose.
223822996|NCT00452179|DRUG|APD125|
223822997|NCT02796781|BIOLOGICAL|Lung stem cells|Patients will receive clinical grade lung stem cells (LSCs)injected into lung via fiberoptic bronchoscopy.
223822998|NCT01419860|PROCEDURE|Elective colon resection|In our scientific experiment, we evaluate microcirculation in colon wall and anastomosis with laser induced fluorescence videoangiography of ICG. By implementing this technique we can measure average pixel intensity of fluorescence signal in area of interest on bowel, which represents tissue perfusion in this respective part of intestinal wall.
223822999|NCT01737996|DRUG|BI 207127 + faldaprevir|fixed dose combination
223823000|NCT02934360|DEVICE|TR(ACE) Assay Testing|Serial plasma testing with TR(ACE) Assay
223823001|NCT01927692|OTHER|Skin biopsy|An optional skin biopsy will be performed in up to 5 subjects at baseline and 2 weeks after therapeutic plasma exchange is completed.
223823002|NCT01927692|OTHER|Single Fiber Electromyography|An optional SFEMG study will be performed at baseline and 2 weeks after therapeutic plasma exchange is completed.
223823003|NCT00398775|PROCEDURE|antibiotic discontinuation|
223823004|NCT04346550|OTHER|Suction drain|Post operatively, in both arms including drain group and no drain group, parameters of pain was assessed by visual analog scale (VAS) from 0 (no pain) to 10 (worst pain), assessed at 1st postoperative day by the duty doctor or the nurse. VAS \> 3 was considered as post surgical pain. The total number of hospital stay was noted from the day of operation till the day of discharge and discharge criteria was taken as a patient having pain as per VAS\<3, no fever and tolerating oral intake
223823005|NCT04678622|DEVICE|Bioferula3D|Custom splint with 3D technology classified as a custom medical device
223823006|NCT02467322|DRUG|Albumin|MVP of less than 5 liters with iv albumin at a dose 8 gms/L of ascitic fluid.
223823007|NCT02467322|DRUG|ascitic fluid|
223823008|NCT04752891|OTHER|AOM diagnosis with app|the diagnosis made by a senior physician using a traditional otoscope. the diagnosis made by the junior physician using an otoendoscope fixed on a connected smartphone
223823009|NCT04752891|OTHER|AOM diagnosis without app|the diagnosis made by a senior physician and by the junior physician, using a traditional otoscope
223823010|NCT05268484|DEVICE|Perturbation-based Training with visual cues using Neurocom|Participants will participate in 16 anticipatory postural adjustments (APA) and compensatory postural adjustments (CPA) training sessions using the Neurocom Balance Platform. Each session will last for 1 hour. During the APA portion, a visual cue on the front screen in the form of a countdown timer showing the remaining seconds to the onset of the upcoming perturbation. This information will allow an opportunity for the participant to adjust their posture to handle the upcoming perturbation in the best possible way and also train them to anticipate upcoming disturbances and execute corrective motor outputs. This will ensure the generation of APA in a consistent and repetitive manner. In CPA, after a 5 second pause, the platform will oscillate at 1 Hz, with a constant amplitude, in the anterior-posterior direction for 50 seconds, followed by an additional 5 second quiet period. The participant will wear a safety harness at all times and a spotter will be present at all times.
223823011|NCT02746822|OTHER||
223823012|NCT00452413|DRUG|enzastaurin|Administered orally
223823013|NCT00452413|DRUG|erlotinib|Administered orally
223823014|NCT06123572|OTHER|Placebo|Placebo Comparator
223823015|NCT06123572|OTHER|Anti-Ageing and Skin Brightening Gel|Anti-Ageing and Skin Brightening Gel.
223823016|NCT03438240|DRUG|Bupivacaine|patients will receive combined general anesthesia / epidural analgesia with 15 ml bupivacaine 0.20%
223823017|NCT03438240|DRUG|Fentanyl|Plus 50 µg fentanyl
223823018|NCT03438240|DRUG|Dexmedetomidine|Plus 50 µg dexmedetomidine
223823019|NCT04586777|DEVICE|transvertebral direct current stimulation (tvDCS)|tvDCS is a painless, non-invasive form of spinal stimulation which delivers safe, low levels of electrical current to the spinal cord through the back. It is believed to be able to influence the excitability of the brain and spinal cord.
223823020|NCT01027364|DRUG|Factor IX (rFIXFc)|
223823021|NCT01027364|DRUG|rFIX|
223823022|NCT01248962|DRUG|carboplatin|Carboplatin Standard 30-minute infusion. All patients will receive identical chemotherapy premedications including dexamethasone 20mg the night before and morning of infusion, montelukast 10mg once daily for three days prior to carboplatin infusion, and ranitidine 50mg (or famotidine 20mg IV)IV and diphenhydramine 50mg IV before carboplatin infusion.
223823023|NCT01248962|DRUG|carboplatin|Extended 3-hour infusion carboplatin. All patients will receive identical chemotherapy premedications including dexamethasone 20mg the night before and morning of infusion, montelukast 10mg once daily for three days prior to carboplatin infusion, and ranitidine 50mg IV (or famotidine 20mg IV) and diphenhydramine 50mg IV before carboplatin infusion.
223823024|NCT02487940|DRUG|Intralipid 20%|Women with RIF received intralipid 20% (at a dose of 9mg/mL of the total blood volume, corresponding to 2 mL intralipid diluted at 20% in 250 mL normal saline) given over 1-2 hours on the day of oocyte retrieval. Dose is repeated on/the following day of a positive pregnancy test, followed by a final dose 2-3 weeks later when attending for pregnancy scan.
223823025|NCT02487940|DRUG|Normal saline|Women with RIF received intravenous infusion of 250 mL physiological saline solution over 1-2 hours on the day of oocyte retrieval. Dose is repeated on/the following day of a positive pregnancy test, followed by a final dose 2-3 weeks later when attending for pregnancy scan.
223823026|NCT05083260|DRUG|NE3107|NE3107 is an investigational orally bioavailable, blood-brain barrier permeable anti-inflammatory agent with a new mechanism of action targeting multiple mechanisms of pathology in Parkinson's disease
223823027|NCT05083260|DRUG|placebo|Hard gelatin capsule containing only common excipients for oral formulations
223823028|NCT00303563|DRUG|P38 Inhibitor (4)|50mg po qd
223823029|NCT00303563|DRUG|P38 Inhibitor (4)|150mg po qd
223823030|NCT00303563|DRUG|P38 Inhibitor (4)|300mg po qd
223823031|NCT00303563|DRUG|Placebo|po qd
223823032|NCT00985543|DRUG|lopinavir/ritonavir|Each participant received three sequential doses of lopinavir/ritonavir: 400/100 mg twice daily (2 heat-stable 200/50 mg tablets BID), 200/150 mg twice daily (1 heat-stable 200/50 mg tablet BID plus 1 ritonavir 100 mg capsule BID), and 200/50 mg twice daily (1 heat-stable 200/50 mg tablet BID). Each dosing phase lasted for 7 days and each phase was separated by a 7-day wash-out period.
223823033|NCT03119610|DRUG|Oxytocin nasal spray|Self administered Oxytocin nasal spray q.i.d. for 8 weeks versus placebo (normal saline nasal spray)
223823034|NCT03119610|DRUG|Placebo nasal spray|Self administered Placebo nasal spray q.i.d. for 8 weeks (normal saline nasal spray)
223823035|NCT02854358|DRUG|mixed powder of A. digitata and M. sylvestris|
223823036|NCT02854358|DRUG|Hypozalix spray (artificial saliva)|Hypozalix spray (artificial saliva)
223823037|NCT01711957|PROCEDURE|Liver transplantation|Standardized technique of liver transplantation Organ procurement follow the rules of the Swiss transplant society
223823038|NCT04960553|DEVICE|Exufiber® and Mepilex® Border Flex|Post Market Clinical Follow-up Investigation applying Exufiber® and Mepilex® Border Flex to 102 subjects who meet the study criteria for up to 12 weeks
223823039|NCT00114634|DIETARY_SUPPLEMENT|Egg yolk preparation with cholesterol|Egg yolk preparation with cholesterol
223823040|NCT00114634|DIETARY_SUPPLEMENT|Egg substitute, without cholesterol|Placebo control. Egg substitute, without cholesterol
223823041|NCT02476955|DRUG|ARQ 092 + carboplatin + paclitaxel (Closed)|Subjects will receive ARQ 092 orally at dose levels specified for their respective dose cohorts plus carboplatin (AUC6, intravenously, Day 1) plus paclitaxel (175 mg/m2, intravenously, Day 1) on a 21-day schedule.
223823042|NCT02476955|DRUG|ARQ 092 + paclitaxel (Closed)|ARQ 092 will be administered orally at 200 mg twice a day (BID) weekly (Cohort 1P) of a 28-day cycle in combination with an intravenous (IV) infusion of paclitaxel (80 mg/m2). ARQ 092 will be administered once a week on Day 1, Day 8, Day 15, and Day 22 of each 28-day cycle; paclitaxel will be administered once a week on Day 1, Day 8, and Day 15 for three consecutive weeks followed by one week off of each 28-day cycle.
223823043|NCT02476955|DRUG|ARQ 092 + anastrozole|ARQ 092 will be administered orally at 150 mg QD, 5 days on/9 days of a 28 day cycle in combination with anastrozole which will be administered orally at 1 mg QD continuously.
223823044|NCT00692640|DRUG|XL147 (SAR245408)|Gelatin capsules supplied in 25-mg and 100-mg strengths; daily dosing for 21 days/7 days off
223823045|NCT00692640|DRUG|Erlotinib|Tablets supplied in 25-mg, 100-mg, and 150-mg strengths; daily dosing
223823046|NCT03283696|DRUG|Olaratumab|Administered IV
223823047|NCT03283696|DRUG|Doxorubicin|Administered IV
223823048|NCT03283696|DRUG|Ifosfamide|Administered IV
223823049|NCT03283696|DRUG|Mesna|Administered per standard of care
223823050|NCT05763082|DRUG|roflumilast cream 0.3%|test product
223823051|NCT05763082|DRUG|Zoryve|Reference Listed Drug product
223823052|NCT05763082|DRUG|Placebo|placebo
223823053|NCT00611117|OTHER|Physical Activity Level|High vs. low physical activity during a high fat diet consumption.
223823054|NCT05606263|DRUG|Caldonirimab and Nimotuzumab|Subjects will receive caldonirimab (6mg/Kg, q2w) until disease progression or for a maximum of 12 months, and Nimotuzumab (400mg/time, q2w) for a total of 8 cycles
223823055|NCT02104830|BIOLOGICAL|Empegfilrastim 6 mg|Empegfilgrastim is supplied as solution for injection 3 mg/ml. Empegfilgrastim is to be administered 24 h after the chemotherapy at dose of 6 mg.
223823056|NCT02104830|BIOLOGICAL|Filgrastim|Filgrastim should be administered no earlier than 24 hours after the administration of cytotoxic chemotherapy. Filgrastim should be administered daily for up to 2 weeks until the ANC has reached 10 000/mm3 following the expected chemotherapy-induced neutrophil nadir.
223823057|NCT02104830|BIOLOGICAL|Placebo №1|Placebo №1 is supplied as solution for injection 1.0 ml. Placebo №1 is to be administered 24 h after the chemotherapy at dose of 1.0.
223823058|NCT02104830|BIOLOGICAL|Placebo №2|Placebo №2 should be administered no earlier than 24 hours after the administration of cytotoxic chemotherapy. Placebo №2 is supplied as solution for injection 0.0083 ml/kg.
223823059|NCT02104830|BIOLOGICAL|Empegfilrastim 7.5 mg|Empegfilgrastim is supplied as solution for injection 3 mg/ml. Empegfilgrastim is to be administered 24 h after the chemotherapy at dose of 6 mg.
223823060|NCT04530357|BIOLOGICAL|QazCovid-in® - COVID-19 inactivated vaccine|QazCovid-in® (inactivated) Vaccine manufactured by Research Institute for Biological Safety Problems Republic of Kazakhstan
223823061|NCT04530357|OTHER|Placebo|Placebo (sodium chloride bufus, solvent for the preparation of dosage forms for injection 0.9%) The use of placebo: intramuscularly, twice, spaced 21 days apart, at a dose of 0.5 ml (22 volunteers)
223823062|NCT03895736|BIOLOGICAL|blood sampling|Sampling of 15 ml of blood during a blood test at Day 0, Day 1 and Day 3
223823063|NCT01605734|PROCEDURE|TACE|After obtaining arterial access,a diagnostic visceral arteriogram will be performed to demonstrate arterial supply to the tumor and the presence of variant arterial anatomy.After having positioned the catheter within the artery feeding tumor,the chemoembolization mixture will be infused into th e artery until stagnant flow is observed.
223823064|NCT01605734|DRUG|sorafenib combined with TACE|All patients will receive Sorafenib (800 mg/day) p.o. beginning four weeks after the first TACE and every day thereafter until patient death or premature withdrawal from study
223823065|NCT05790226|DEVICE|Sentry System|any labelling or contrast agents. The Sentry System uses the Sentry Probe, a flexible cable that terminates in a stylus that delivers a small beam of light to the surface of the excised tissue specimen and collects the Raman spectrum of the light coming back from the same area of the specimen.
223823066|NCT00863889|DRUG|Depomedrol injection|1 cc of Depomedrol 80
223823067|NCT00863889|DRUG|Lidocaine, Marcaine|4 cc of each local anesthetic
223823068|NCT03524456|OTHER|Home blood pressure monitoring|Participants would use a blood pressure device at home, that sends the readings automatically to the health center via SMS. The physicians would use this tool for medication management or rescheduling visits.
223823069|NCT04924764|OTHER|Conventional physical therapy.|Conventionally used intervention for subacute and chronic neck pain.
223823070|NCT01381835|DRUG|TMC435|150 mg capsule once daily for 7 days
223823071|NCT00822003|DRUG|Oral GLP-1|GLP-1 tablet (2mg)
223823072|NCT00822003|DRUG|Placebo|Control tablet
223823073|NCT04402658|DRUG|Inhaled salbutamol|Participants will inhale 800 μg salbutamol (or placebo) using a standard metered dose inhaler used for asthma treatment, and a standard spacer device will be used to allow optimal delivery of the drug to the lung. The inhaler delivers 100 μg of salbutamol with each actuation (i.e., 8 puffs/actuations gives 800 μg) with inhalation time being approximately \~2 min (10 breaths) and the manufacturer's user instructions will be followed. Although complete uptake of salbutamol cannot be concluded as any salbutamol left in the spacer, mouth or remaining in the lung will be not measured. This dose of Salbutamol is chosen because it is the highest dose permitted by the World Anti Doping Agency (WADA).
223823074|NCT04538924|OTHER|extended clinical, laboratory and instrumental examination; treatment options comparison|Multimodality investigation and different treatment comparison
223823075|NCT04654546|OTHER|Ultrasound abdominal scan|"A complete ultrasound scan of the abdominal organs using a clinical ultrasound device in the Imaging Institute at Haemek medical center. The ultrasound images will be visually coupled to previous CT images of the same patient at the time of the examination, using a Fusion system located in the ultrasound device mentioned above.~The coupled CT and ultrasound images will be encoded and be sent to the SAMPL laboratory in Weizmann institute, there it will serve as a learning platform for the artificial intelligence system."
223823076|NCT01149213|DEVICE|transcranial direct current stimulation|tDCS will be applied at 2mA/30 minutes, every other week during the first three months than once a month during the next three months.
223823077|NCT00240838|DRUG|acetaminophen extended release caplets|
223823078|NCT05924282|PROCEDURE|Curative intent surgery|Curative intent surgery means that surgeons intend to perform R0 resection.
223823079|NCT01001780|DRUG|Pentostatin; Cyclophosphamide; Rituximab|Pentostatin 2mg/m2 IV day+1 (up to 6 cycles) Cyclophosphamide 600mg/m2 IV day+1 (up to 6 cycles) Rituximab 375mg/m2 IV day+1 (up to 6 cycles)
223823080|NCT05677737|OTHER|Education|"Educational program; It will be applied to the individuals in the experimental group for an average of 40 minutes in a time period they are suitable through the online platform prepared for the individuals in the experimental group in a three-month period. The literature will be scanned and appropriate educational materials will be created, and videos will be used to support education.~Educational program During the first interview, the individuals in the experimental group will be introduced to the online platform, their entrance will be provided, they will be informed about how to follow the trainings, and sample applications will be made.~Six main topics will be covered in the training program and will be completed every two weeks in three months."
223823081|NCT03290573|DEVICE|short peripheral venous catheter|short peripheral venous catheter for infusion therapy in adult patients
223823082|NCT02583568|DRUG|Bevacizumab-800CW|three days prior to surgery bevacizumab-800CW will be administered
223823083|NCT01054690|DEVICE|Bactiguard Infection Protection (BIP) Cathter.|
223823084|NCT01054690|DEVICE|Silicone Urinary Catheter|
223823085|NCT03376503|DRUG|Pegfilgrastim|PK,PD and safety assessment
223823086|NCT03601104|OTHER|High intensity eccentric training|High intensity eccentric training group with 80% of isometric peak torque.
223823087|NCT03601104|OTHER|High intensity eccentric training with BFR|Eccentric high intensity training group with 80% of isometric peak torque associated with blood flow restriction (40% of absolute occlusion pressure).
223823088|NCT03601104|OTHER|Low intensity eccentric training with BFR|Low intensity eccentric training group with 40% of isometric peak torque associated with blood flow restriction (40% of absolute occlusion pressure).
223823089|NCT03601104|OTHER|Low intensity eccentric training|Low intensity eccentric training group with 40% of isometric peak torque
223823090|NCT06281262|DIAGNOSTIC_TEST|Peripheral blood collection|"The phenotypic characteristics of leukocytes will be compared between the groups to identify immunological markers of women at risk of preterm delivery.~Samples from the controls will be taken to define a baseline for the measured leukocyte populations."
223823091|NCT06281262|DIAGNOSTIC_TEST|Swab sample collection|Oral, vaginal and rectal swabs will be collected and stored for analysis of microbiota at the time of inclusion. At birth, oral, vaginal and rectal swabs and part of the placenta (placental tissue) will be collected for further analysis.
223823092|NCT00557622|DRUG|paroxetine|BRL29060A (paroxetine hydrochloride hydrate, hereafter paroxetine) administered orally over the dose range of 20 mg to 50 mg once daily after supper for 12 weeks in Japanese patients with posttraumatic stress disorder (PTSD)
223823093|NCT00557622|OTHER|placebo|placebo
223823094|NCT01539863|OTHER|maintenance care|Participants will receive treatment at regular intervals during the study, a maximum of 12 and a minimum of 4 treatments as decided by the treating chiropractor
223823095|NCT01539863|OTHER|Treatment as needed|Participants may never receive treatment, there is no upper limit
223823096|NCT05434221|OTHER|COPE|"The experimental group receives the COPE during their internships. The COPE consists of two part: (1) communication skills teaching and simulation practice; (2) clinical communication teaching: record the clinical treatment process of the interns and turn them into verbatim drafts. Experts then complied the strengths and weaknesses of the interns' communication skills based on the verbatim manuscripts and gave feedback on the interns' communication skills.~The interns in the experimental group will participate 1 time of the communication skills teaching and simulation practice, and 3 times of the clinical communication teaching in three months."
223823097|NCT01097486|BIOLOGICAL|NeoFuse|Single Dose NeoFuse Surgical Implantation
223823098|NCT01097486|PROCEDURE|Allograft|Single Dose Allograft Surgical Implantation
223823099|NCT04962438|DRUG|Anti-VEGF|Anti-tumor drugs targeting the vascular endothelial growth factor (VEGF) signaling pathway
223823100|NCT01962025|PROCEDURE|Buttonhole needling technique|the intervention is the type of needling used for home hemodialysis patients. They will be randomized to either buttonhole cannulation or stepladder cannulation
223823101|NCT00407784|DRUG|eplerenone|
223823102|NCT03450681|PROCEDURE|Pulsed radiofrequency of the saphenous nerve before knee replacement surgery|A trained anesthesiologist and pain clinician performs ultrasound guided pulsed radiofrequency on the saphenous nerve of a patient undergoing knee replacement surgery, prior to the beginning of the surgical act.
223823103|NCT03450681|PROCEDURE|Mock incision|A trained anesthesiologist and pain clinician performs a mock incision on the pulsed radiofrequency needle insertion site
223823104|NCT04780724|OTHER|Hypoxic gas mixture|Gas mixture of 12% O2 and 88% N2 for five minutes.
223823105|NCT04780724|OTHER|Hypercapnic and hypoxic gas mixture|Gas mixture of 12% O2, 5% CO2, and 88% N2 for five minutes.
223823106|NCT04780724|OTHER|SpO2 measurement|Two SpO2 measuring devices are active simultaneously during measurement.
223823107|NCT02765490|DRUG|AL-335|AL-335 800 mg (2\*400) tablet will be administered once daily.
223823108|NCT02765490|DRUG|Odalasvir|Odalasvir 25 mg tablet will be administered once daily.
223823109|NCT02765490|DRUG|Simeprevir|Simeprevir 75 mg capsule will be administered once daily.
223823110|NCT04412590|OTHER|Vermont Family Based Approach|Comprehensive and individualized program to promote emotional health and wellbeing in families using evidence-based health promotion, prevention and intervention.
223823111|NCT04412590|OTHER|Treatment as Usual|Pediatric care as usual.
223823112|NCT01468922|DRUG|Pazopanib|Vascular endothelial growth factor (VEGFR) inhibitor
223823113|NCT01468922|DRUG|ARQ 197|Hepatocyte growth factor receptor (mesenchymal-epithelial transition factor \[c-MET\]) inhibitor
223823114|NCT02381002|OTHER|Weight reduction program|Overweight and obese children (6-12 years old) from patient group accepting enrollment were assigned to weight reduction program for 6 months with monthly follow up. The program comprise: 1) Diet regimen: Healthy balanced diet was prescribed. The amount of calories was determined according to 24-hour recall then 250-500 calories were subtracted from total intake which decrease weight by 0.25-0.5 kg/week. 2) Exercise:were instructed to practice walking for at least 30 minutes 3-4 times per week.
223823115|NCT02551744|DRUG|histamine-2 receptor antagonist group|famotidine tab 40 mg qd for 6 months.
223823116|NCT02551744|DRUG|proton pump inhibitor group|pantoprazole tab 40 mg qd for 6 months.
223823117|NCT04315714|OTHER|Yoga Program|Six-week, twice weekly, 60-minute private yoga program (delivered online/virtually via Zoom).
223823118|NCT01425164|DRUG|Ivabradine|ivabradine tablets, 5 to 7.5 mg bis-in-die.
223823119|NCT01425164|DRUG|Carvedilol|carvedilol tablets, 12.5 to 25 mg bis-in-die.
223823120|NCT04079283|DIAGNOSTIC_TEST|Clinical|Clinical: A diagnostic model incorporating clinical variables (Age, Pathological diagnosis, level of serum tumor biomarkers etc.)
223823121|NCT04079283|DIAGNOSTIC_TEST|Semantic|Semantic: A diagnostic model incorporating semantic radiological features (shape, location, border, density etc.)
223823122|NCT04079283|DIAGNOSTIC_TEST|Radiomic|Radiomic: A diagnostic model incorporating quantitative radiomic features (histogram, texture, morphology etc.)
223823123|NCT03147066|DRUG|Dezocine|Dezocine (0.1 mg/kg）will be infused during surgery
223823124|NCT03147066|DRUG|Flurbiprofen Axetil|Flurbiprofen Axetil (1 mg/kg）will be infused during surgery
223823125|NCT05096676|DRUG|Oxytocin: Including placebo|Individual received age-dependent dosing of oxytocin and placebo. Participants aged 13-18 years received a dose of 24 IU (3 puffs to each nostril), and younger participants (aged 12 years) received 16 IU.
223823126|NCT02991144|GENETIC|scAAV8OTC|non-replicating, recombinant scAAV8 encoding human ornithine transcarbamylase (OTC)
223823127|NCT02991144|DRUG|Reactive Corticosteroid Taper Regimen|"Oral prednisone \[or oral prednisolone\] 60 mg/day week 1, 40 mg/day Week 2, 30 mg/day Weeks 3 and 4, tapered by 5 mg/week Week 5 and beyond until liver enzymes return to baseline levels.~Corticosteroid treatment will be considered when a participant's alanine aminotransferase (ALT) level exceeded the upper limit of normal (ULN) and the ALT increase was considered by the Investigator to be related to DTX301."
223823128|NCT02991144|DRUG|Prophylactic Corticosteroid Taper Regimen|"Oral prednisone \[or oral prednisolone\] 60 mg/day at least 5 days prior to DTX301 administration, tapered over 9 weeks.~A prophylactic corticosteroid taper regimen will be administered to prevent or minimize transient vector-induced hepatic effects."
223823129|NCT03662997|DEVICE|Bordered Five-Layer Foam Dressing|Bordered, five-layer, flexible foam dressing with soft silicone adhesive technology
223823130|NCT03662997|DEVICE|Hydropolymer Foam Dressing|Hydropolymer, adhesive foam island dressing
223823131|NCT03662997|DEVICE|Hydrocellular Multi-Layer Foam Dressing|Multi-layered, hydrocellular foam dressing with silicone adhesive
223823132|NCT00007475|PROCEDURE|Plasma exchange|A course of plasma exchange of 5 treatments over 10 days, then administration of cyclophosphamide.
223823133|NCT00007475|DRUG|Cyclophosphamide|For GFR \> 50 ml/min/1.73 m2 received oral cyclophosphamide at a dose of 2 mg/kg/ day for 3 months. For GFR \< 50 ml/min/1.73 m2 but \> 10 ml/min/1.73 m2 will receive oral cyclophosphamide at a 25% reduced dose or 1.5 mg/kg/d for 3 months.
223823134|NCT06320873|OTHER|archery respiratory parameters|Evaluation of respiratory functions, respiratory muscle strength and shooting performance in archers
223823135|NCT01719224|PROCEDURE|elevated body position|45 degrees elevated upper body position
223823136|NCT01719224|PROCEDURE|supine body position|non-elevated upper body position
223823137|NCT01777594|DRUG|G-202|G-202 administered by intravenous infusion (IV, in the vein) on Days 1, 2 and 3 of each 28-day cycle until progression or development of unacceptable toxicity
223823138|NCT00247364|DRUG|Levetiracetam (Keppra)|
223823139|NCT03591757|DRUG|Tolcapone|Tolcapone will be administered at 300 mg/day (100mg TID) orally to participants for 14 days and then 600 mg/day (200 mg TID) orally to participants for 14 days (approximately 5 hours apart). Participants will initiate 200mg TID after blood collection on Day 14.
223823140|NCT05399095|BEHAVIORAL|Supine positioning: 5 days|Supine positioning for 5 days after DMEK
223823141|NCT05399095|BEHAVIORAL|Supine positioning: 1 days|Supine positioning for 1 days after DMEK
223823142|NCT03000673|DRUG|Enoxaparin|Specified dose of Enoxaparin on specified days
223823143|NCT03000673|DRUG|unfractionated heparin (UFH)|Specified dose of UFH on specified days
223823144|NCT03000673|DRUG|BMS-986177|Specified dose of BMS-986177 on specified day
223823145|NCT00260819|DRUG|Bosentan|Single dose administration of 250 mg bosentan (2 pills Tracleer 125 mg) or placebo
223823146|NCT00260819|DRUG|Bosentam TRACLEER|Single dose administration of 250 mg bosentan (2 pills Tracleer 125 mg) or placebo
223823147|NCT02172300|DRUG|Tiotropium inhalation capsules|
223823148|NCT02172300|DRUG|Placebo inhalation capsules|
223823149|NCT01121484|DRUG|desvenlafaxine succinate sustained-release|50-mg DVS SR tablets taken orally once daily.
223823150|NCT01121484|DRUG|placebo|Placebo tablets taken orally once daily.
223823151|NCT01472562|DRUG|lenalidomide|"Induction phase: 20 mg/day for days 1-21 of a 28-day cycle for 12 cycles. If no excess toxicity is observed the dose will be increased to 25 mg/day.~Maintenance phase: Lenalidomide will be given at 15 mg/day for days 1-21 of a 28-day cycle."
223823152|NCT01472562|BIOLOGICAL|rituximab|"Induction phase: Rituximab will be administered at 375 mg/m2 per dose for a total of 9 doses. The first 4 doses will be administered weekly starting on day 1 of lenalidomide (e.g. days 1, 8, 15 and 22). Subsequent rituximab doses will be administered for one dose each at weeks 12, 20, 28, 36 and 44.~Maintenance phase: Rituximab at 375 mg/m2 per dose will be administered for one dose every 8 weeks, starting at week 52."
223823153|NCT01557621|BEHAVIORAL|Collaborative Pop-Based R/R: Phone/Mail Group|Within each county, half of patients will be randomized to a phone/mail group (2 auto-dialer calls and 2 postcards) and the other half of patients will be put in a mail-only group (4 mailings). The following collaborative approaches will be utilized: patient addresses and phone numbers will be updated prior to recall for electronic Flat File Format practices; all notices to parents (auto-dialer calls and mailings) will appear to come both from the local public health department and providers who choose to have their name listed; all bad addresses and phone numbers will be updated by calling the last provider of care. Up to 4 notices will be sent to parents of children who are still not up to date for recommended immunizations.
223823154|NCT01557621|BEHAVIORAL|Collaborative Pop-Based R/R: Mail-Only Group|Parents will receive up to four mailings if their child appears in need of immunizations according to CIIS. The Collaborative method is the same as in the auto-dialer/mail group; however patients in this group will not receive telephone calls.
223823155|NCT01557621|BEHAVIORAL|Practice-based Recall|All practices will receive training on how to conduct practice-based recall using CIIS and educational materials to use within their practices to promote compliance with the infant vaccination schedule. Individual practices will make their own decisions about the extent to which they follow the recommendations and implement recall within their practice. Although the study team will not provide them with any additional interventions, we will track any other interventions they independently do (websites, newsletters, telephone) in order to assess the effect of these additional interventions.
223823156|NCT03788902|DRUG|Ritalin|Single dose of Ritalin IR 0.3-0.5 mg/kg OR placebo
223823157|NCT01512745|DRUG|apatinib|apatinib 850 mg qd p.o. until disease progression or intolerable toxicity or patients withdrawal of consent
223823158|NCT01512745|DRUG|placebo|placebo qd p.o. until disease progression or intolerable toxicity or patients withdrawal of consent
223823159|NCT03311022|DRUG|Nefopam Hydrochloride 30mg Tablets|
223823160|NCT03311022|DRUG|Acupan® 30mg Tablets|
223823161|NCT06116201|OTHER|Estradiol|Estradiol
223823162|NCT06116201|OTHER|Estradiol and Anti-Androgen|Estradiol and Anti-Androgen
223823163|NCT06116201|OTHER|No intervention|No intervention
223823164|NCT00642135|DRUG|Mydriasert®|Premature newborns and neonates treated using ophthalmologic insert Mydriasert®
223823165|NCT00642135|DRUG|phenylephrine and tropicamide eyedrops|Premature newborns and neonates treated using reference treatment (association of Phenylephrine and tropicamide eyedrops)
223823166|NCT00243828|DEVICE|Total Face Mask|
223823167|NCT04860414|BIOLOGICAL|Blood sampling|Fasting blood glucose, dosage of acylated and non-acylated ghrelin, leptin, insulin and serotonin.
223823168|NCT04860414|OTHER|Cognitive Assessment|QPC Cognitive complaint questionnaire, CDR functional autonomy scales and IADL 4 items, MMSE cognitive scores, Dubois 5-word test, clock test, BREF, Isaacs test, BARD naming battery and MADRS depression scale
223823169|NCT04860414|OTHER|Subjective taste tests|Scales of taste perceptive intensity, taste pleasure, hunger sensation (visual analogue scales from 0 to 10 cm) and food preferences on the one hand, and on the other hand, subjective tests of taste threshold determination by triangular tests of increasing sugar solution concentrations.
223823170|NCT04860414|OTHER|Objective taste tests|Recording of gustatory evoked potentials
223823171|NCT01274065|GENETIC|Genetic analysis|The research team will review data following DNA sample analysis and identify variants in genes that result in impaired drug metabolism
223823172|NCT02665702|DRUG|NVB|25mg/m2 ，D1，8
223823173|NCT02665702|DRUG|DDP|75mg/m2 ，D1 or 25mg/m2 D1-3
223823174|NCT02665702|DRUG|Endostar|15mg/d，d1-d7 civ
223823175|NCT03062098|DEVICE|ultrasound imaging|Ultrasound imaging during embryo transfer using a small vaginal probe.
223823176|NCT03866642|DEVICE|Cadence Total Ankle Replacment|Cadence Total Ankle prosthesis
223823177|NCT00813410|PROCEDURE|Glucose measurement at the sc. insulin delivery site|Overnight fasting and oral glucose tolerance test (OGTT) combined with simultaneous subcutaneous insulin delivery and glucose sampling using a single microdialysis or microperfusion probe.
223823178|NCT02548858|PROCEDURE|Perineorrhaphy|Those patients who are randomized to undergo a perineorrhaphy as part of their vaginal or abdominal reconstructive procedure for pelvic organ prolapse.
223823179|NCT02548858|PROCEDURE|No Perineorrhaphy|Those patients who are randomized not to undergo a perineorrhaphy as part of their vaginal or abdominal reconstructive procedure for pelvic organ prolapse.
223823180|NCT04775121|OTHER|Deuterium Glucose|Oral administration of 20 g Deuterium Glucose on a 3-hour
223823181|NCT04935723|OTHER|Reiki|The study was conducted as a three-group interventional randomized controlled trial to examine the effect of Reiki touch therapy on surgical fear, pain, anxiety and vital signs in patients undergoing open abdominal surgery. Reiki was applied to the first group and sham reiki to the second group. Group 3 formed the control group.
223823182|NCT02357810|DRUG|Pazopanib Hydrochloride|Given PO
223823183|NCT02357810|DRUG|Oral Topotecan Hydrochloride|Given PO
223823184|NCT02357810|OTHER|Laboratory Biomarker Analysis|Correlative studies
223823185|NCT01416701|DIETARY_SUPPLEMENT|Vitamin D (D3, cholecalciferol)|Week 0-4: 152 mcg/daily (4 tablets) Week 5-52: 76 mcg/daily (2 tablets)
223823186|NCT01416701|DIETARY_SUPPLEMENT|Placebo (cellulose)|Week 0-4: 4 tablets daily Week 4-52: 2 tablets daily
223823187|NCT03354130|OTHER|Processed meat dietary intervention|Randomized cross-over dietary intervention with 5 different diets
223823188|NCT02734680|RADIATION|Concurrent chemoradiotherapy(CCRT)|Radiation and take gemcitabine(GEM)
223823189|NCT02734680|RADIATION|Stereotactic Radiotherapy(SBRT)|Stereotactic Radiotherapy(SBRT) (total dose: 45 Gy; single dose: 3 Gy; Frequency:15)
223823190|NCT02734680|DRUG|S-1|Taking S-1 orally after radiation
223823191|NCT02761460|DRUG|PEG-rhG-CSF|PEG-rhG-CSF 6mg is given for patients Greater than or equal to 45 kg, 3mg is given for those less than 45kg 24-48 hours after chemotherapy
223823192|NCT03541772|DIETARY_SUPPLEMENT|Oncoxin-Viusid®|Radiotherapy for 6-8 weeks, chemotherapy for 1-22-43 days during Radiotherapy and Oncoxin-Viusid® (75 ml/day) before/during/after both treatments
223823193|NCT03541772|DIETARY_SUPPLEMENT|Placebo|Radiotherapy for 6-8 weeks, chemotherapy for 1-22-43 days during Radiotherapy and placebo (75ml/day) before/during/after both treatments
223823194|NCT02007408|DRUG|Paracervical block|
223823195|NCT02007408|DRUG|Lidocaine spray|
223823196|NCT02007408|DRUG|Paracervical block + lidocaine spray|
223823197|NCT05296096|OTHER|Protein dosage and rehabilitation team delivered exercise prescription|"The dietitian and rehabilitation team will be consulted on enrollment and will assess the patient for nutritional and functional status using the institutional criteria and physical exam. The study dietitian will prescribe the protein goal based on the randomization assignment and age group. For the high protein arm, protein goals will be 3g/kg/day for ages 1-1yrs, and 2.4g/kg/day for ages greater than 12 years.~The rehabilitation team will determine the appropriate highest level of mobility (HLM) for the day in collaboration with the medical team on morning rounds. The rehabilitation team will prescribe passive or active participation in two 30-minute HLM sessions, individualized to their baseline function and clinical status and/or restrictions."
223823198|NCT01466296|DEVICE|Chaotic Perturbation|"Each subject will undergo 36 intervention sessions, 3 times per week over 12 weeks. Each session will last up to 45 minuets, depending on the subject's endurance. During each session the subject will perform basic stretching and muscle strengthening, then wear the random shoes and perform a set of exercises following specific verbal tasks, e.g., Walk 5 strides forward, or, Walk to the right side until I ask you to stop. During this stage of walking the device will impose perturbations in the range tolerated by the subject. The therapist will make a written report of each session."
223823199|NCT01466296|DEVICE|Dummy not active shoes|"Each subject will undergo 36 intervention sessions, 3 times per week over 12 weeks. Each session will last up to 45 minuets, depending on the subject's endurance. During each session the subject will perform basic stretching and muscle strengthening, then wear the dummy shoes and perform a set of exercises following specific verbal tasks, e.g., Walk 5 strides forward, or, Walk to the right side until I ask you to stop. During this stage of walking the device will not impose perturbations. The therapist will make a written report of each session."
223823200|NCT01466296|DEVICE|Treadmill training|Each subject will undergo 36 intervention sessions, 3 times per week over 12 weeks. Each session will last up to 45 minuets, depending on the subject's endurance. During each session the subject will exercise basic stretching and muscle strengthening, then walk on the treadmill. A physiotherapist according the subject's rate of improvement will determine the increase in treadmill velocity and slope. The therapist will make a written report after each session.
223823201|NCT00668824|DRUG|Vasovist|
223823202|NCT04651400|DRUG|Antithrombin III|Antithrombin III
223823203|NCT03767634|OTHER|Parenteral nutrition|Parenteral nutrition is the administration of an intravenous solution containing amino acids (with or without lipids) to provide nutritional support.
223823204|NCT01458184|BEHAVIORAL|PhoneCare system|"The aim of this study is to assess the effectiveness of Telephone-Linked Care for Complex Patients (TLC-C) in the care of patients with complex health care needs. TLC-C uses conversational computer telephony to monitor patients' multiple diseases between their ambulatory care visits. The system monitors patients through virtual visits and detects and notifies clinicians about important clinical problems to attend to. It also promotes patient self-care (e.g., medication adherence and appointment preparation)."
223823205|NCT02762838|BIOLOGICAL|BCD-055|BCD-055 is infliximab biosimilar
223823206|NCT02762838|BIOLOGICAL|Remicade®|
223823207|NCT02762838|DRUG|Methotrexate|All patients will receive methotrexate in a dose from 10 to 25 mg per week.
223823208|NCT02762838|DRUG|Folic acid|All patients will receive folic acid in a dose of 5 mg per week.
223823209|NCT00675506|DRUG|Growth hormone releasing hormone (GHRH) 1-44|2-mg sub-cutaneous injections once daily for 12 months
223823210|NCT00675506|DRUG|Placebo|2-mg sub-cutaneous injections once daily for 12 months
223823211|NCT00936221|DRUG|AZD6244|oral capsules, 75mg twice daily
223823212|NCT00936221|DRUG|Dacarbazine|1000 mg/m2 iv infusion over at least 60 min. on day 1 of each 21 cycle
223823213|NCT00936221|DRUG|Placebo|Placebo
223823214|NCT03820323|DIAGNOSTIC_TEST|POC VL and targeted DRM testing.|Point-of-care Viral Load Testing will be done to ensure that providers and caregivers receive the results with in 24 hours study. Targeted DRM testing will be performed during the initiation of ART and when viremia (VL\>1000 copies/mL) is detected.
223823215|NCT03820323|DIAGNOSTIC_TEST|SOC VL testing|SOC VL testing is done at 6 months after ART initiation then every 3 months if unsuppressed, otherwise every 12 months. DRM testing is conducted only if failing 2nd line ART.
223823216|NCT01376960|PROCEDURE|elective forefoot surgery|Includes both soft-tissue and osseous procedures.
223823217|NCT03151395|OTHER|Sputum and blood sampling|Evaluation of the occurrence of potential bacterial and viral pathogens in the sputum of stable COPD patients and at the time of AECOPD.
223823218|NCT03093857|DIAGNOSTIC_TEST|Determination of biomarker|Liquor, blood, and urine samples will be drawn and measured at different time points.
223823219|NCT05247827|OTHER|Targeted phantom limb motor execution (exercise)|The targeted phantom motor execution is a specific training program for people with TTA that has been designed to improve the muscles' strength, coordination, and flexibility at the amputated and contralateral intact sides. Such training consists of repeated short-term, short rest interval, and moderate-intensity exercises (Schoenfeld 2010, Krutki, Mrowczynski et al. 2017). Targeted phantom motor execution can improve the body image considering its induced muscular impacts. People with TTA will be trained to follow specific movements of their foot-ankle complexes simultaneously, in order to increase PLA, as well as induce muscular morphologic and brain neuroplastic changes (Moseley and Brugger 2009).
223823220|NCT00796432|DRUG|OROS paliperidone|
223823221|NCT01100060|DRUG|azithromycin (AZ) microsphere|AZ microsphere (2000 mg) single dose on Day 1.
223823222|NCT01100060|DRUG|test chloroquine (CQ) formulation|Test CQ formulation, 620 mg CQ base, single dose on Day 1.
223823223|NCT01100060|DRUG|azithromycin (AZ)|AZ IR 4 x 500 mg tablets, single dose on Day 1.
223823224|NCT01100060|DRUG|chloroquine (CQ)|CQ 2 x 500 mg (600 mg CQ base) tablets, single dose on Day 1
223823225|NCT05981963|DRUG|[14C]-BMS-986196|Specified dose on specified days
223823226|NCT01312987|DIETARY_SUPPLEMENT|Lipid-based nutritional supplement|"After gradual introduction of the lipid-based nutritional supplement, daily dose per child is as follows:~3 teaspoons 3 x day for children younger than 12 months 4.5 teaspoons 3 x day for children older than 12 months"
223823227|NCT03954457|BEHAVIORAL|A-CWS|The A-CWS intervention is a 15-session culturally-grounded, cognitive-behavioral group intervention designed to develop and enhance African American youths' skills for coping with stress. The intervention structure allows implementation within traditional school and other community settings. The A-CWS uses standard cognitive-behavioral strategies (e.g., relaxation training, cognitive restructuring) to help African American youth identify and cope with individual and contextual stressors, using culturally consistent coping strategies. The intervention emphasizes the identification and management of stressors associated with suicide risk (e.g., racism-related stress, community violence exposure) and the unique experiences of low-resourced, urban African American adolescents (e.g., community violence exposure). The structured, manualized A-CWS curriculum is designed to be sustainable and user-friendly, to ensure that the A-CWS is delivered effectively and with a high degree of fidelity.
223823228|NCT03954457|BEHAVIORAL|Standard Care Control|The standard care control condition consisted of standard case management services delivered by the SBHC. Participants randomly assigned to the standard care control condition were referred to the SBHC social worker for case management. Standard care ranged from brief intervention by the SBHC social worker, to more intensive intervention by the SBHC social worker, to outside referral to local community service providers. SBHC social workers determined type and duration of services based on individual participant needs.
223823229|NCT01878123|BIOLOGICAL|AMP-110|Dose levels 1 through 7: Single intravenous infusion on Day 0
223823230|NCT01878123|OTHER|Placebo|Dose levels 4 through 7: Single intravenous infusion on Day 0
223823231|NCT00728117|OTHER|feeding|Study infants will receive trophic enteral nutrition (15 ml/kg/day) during the study drug period.The study drug period is defined as the interval between administration of the first dose of ibuprofen or indomethacin and 24 hours after the last dose of ibuprofen or indomethacin.
223823232|NCT00728117|OTHER|fasting|Study infants will be fasted during the study drug period.The study drug period is defined as the interval between administration of the first dose of ibuprofen or indomethacin and 24 hours after the last dose of ibuprofen or indomethacin.
223823233|NCT01141270|DRUG|AFOLIA|single sc injection, 225 IU
223823234|NCT01141270|DRUG|Gonal-f|single sc injection, 225IU
223823235|NCT00879996|DRUG|Methadone|Oral, 10-60 mg per day, 2-4 times per day, 6 months
223823236|NCT00879996|DRUG|Buprenorphine/naloxone|Sub-lingual, 4-16 mg per day, divided 2-4 times/day, 6 months
223823237|NCT02078505|BEHAVIORAL|diet|Carbohydrate poor diet
223823238|NCT01229982|DRUG|Latanoprost-PPDS|Punctal Plug
223823239|NCT05538260|PROCEDURE|Repair of ocular trauma in children below 16 years old|Diagnosis and repair of pediatric ocular trauma
223823240|NCT01566929|DIETARY_SUPPLEMENT|Low calorie diet treatment|Reduction of calorie intake to only 800 kcal/day by using LCD during 12 weeks
223823241|NCT05156463|COMBINATION_PRODUCT|PAI Tool and Exercise Coaching|Use of PAI tool and self-monitoring tools to increase physical activity and reduce sedentary behaviors. Participants will receive a personalized physical assessment and counseling from healthcare provider, exercise logs and a Garmin activity tracker to use between visits and 9 exercise coaching calls between clinical visits.
223823242|NCT05429437|BIOLOGICAL|Injectable platelet rich fibrin .|i-PRF with maxillary canine retraction that will be performed two times on intervention sides according to a standardized protocol.
223823243|NCT05429437|BIOLOGICAL|Injectable platelet rich fibrin .|i-PRF that will be performed four times on intervention sides according to a standardized protocol.
223823244|NCT04797325|DRUG|Vedolizumab|Repeatedly vedolizumab infusion at week 0, 2, 6, 14, 22
223823245|NCT04797325|DRUG|Prednisolone|tablet prednisolone plus infliximab in severe cases.
223823246|NCT02207439|DRUG|Nelfinavir (Viracept®) 1250 mg|Period 1: Nelfinavir Lead-In (1250 mg bid, 7-14 days).
223823247|NCT02207439|OTHER|Chemoradiation|Period 2: Concurrent Chemoradiation (70 Gy over 7 weeks) with Nelfinavir (1250 mg bid)
223823248|NCT06381011|OTHER|Local Vibration|The patients in the study group will receive local vibration application including different frequency values on the neck and back regions for five consecutive days.
223823249|NCT04825444|DEVICE|Photoacoustic inspection|Use photoacoustic imaging system to image breast blood vessels
223823250|NCT04785326|DRUG|DMB-3115|45mg or 90mg dose subcutaneous administration
223823251|NCT04785326|DRUG|Stelara|45mg or 90mg dose subcutaneous administration
223823252|NCT00482222|BIOLOGICAL|cetuximab|
223823253|NCT00482222|DRUG|capecitabine|
223823254|NCT00482222|DRUG|fluorouracil|
223823255|NCT00482222|DRUG|leucovorin calcium|
223823256|NCT00482222|DRUG|oxaliplatin|
223823257|NCT00482222|OTHER|study of socioeconomic and demographic variables|
223823258|NCT00482222|PROCEDURE|adjuvant therapy|
223823259|NCT00482222|PROCEDURE|neoadjuvant therapy|
223823260|NCT00482222|PROCEDURE|quality-of-life assessment|
223823261|NCT04878016|BIOLOGICAL|ZKAB001|Patients will receive ZKAB001 5mg/kg administered by IV infusion every 21days，
223823262|NCT04878016|DRUG|Placebo|Patients will receive placebo administered by IV infusion every 21days.
223823263|NCT04878016|DRUG|Carboplatin|Carboplatin should be administered after completion of placebo/ZKAB001 by IV infusion over 30-60 minutes to achieve an initial target AUC of 5 mg/mL/min. Carboplatin and etoposide will be used for a total of 4 cycles， followed by placebo/ZKAB001 maintenance therapy.
223823264|NCT04878016|DRUG|Etoposide|"Etoposide (100 mg/m\^2) should be administered intravenously over 60 minutes following carboplatin administration. On Days 2 and 3 of each cycle, etoposide 100 mg/m2) should be administered intravenously over 60 minutes.~Carboplatin and etoposide will be used for a total of 4 cycles， followed by placebo/ZKAB001 maintenance therapy."
223823265|NCT02912468|DRUG|Dupilumab SAR231893 (REGN668)|"Pharmaceutical form: Solution~Route of administration: Subcutaneous"
223823266|NCT02912468|DRUG|Placebo|"Pharmaceutical form: Solution~Route of administration: Subcutaneous"
223823267|NCT02912468|DRUG|Mometasone furoate 50 micrograms|"Pharmaceutical form: Suspension (Nasal spray)~Route of administration: Intranasal"
223823268|NCT03928145|DRUG|Chlorthalidone 25 mg|Chlorthalidone 25 mg taken orally in the morning for 12 weeks.
223823269|NCT03928145|DRUG|Hydrochlorothiazide 50 mg|Hydrochlorothiazide 50 mg taken orally in the morning for 12 weeks.
223823270|NCT03928145|DRUG|Amiloride 20 mg|Amiloride 20 mg taken orally in the morning for 12 weeks.
223823271|NCT03928145|DRUG|Amiloride 10 mg|Amiloride 10 mg taken orally in the morning for 12 weeks.
223823272|NCT05800782|BEHAVIORAL|Face Memory Training|Computer-based training using faces targeting face memory
223823273|NCT05800782|BEHAVIORAL|Face Perception Training|Computer-based training using faces targeting improving face perception
223823274|NCT05800782|BEHAVIORAL|Placebo control training|Computer-based training using faces not targeting improving face perception or memory
223823275|NCT04723043|DEVICE|mechanical ventilation modes|ventilation with pressure controlled mode in laparoscopic abdominal surgery ventilation with volume controlled mode in laparoscopic abdominal surgery
223823276|NCT00967213|DRUG|ranibizumab|Lucentis® (ranibizumab) 0.3mg (0.05ml volume) intravitreal injection. Eligible patients will be initially received three session of monthly injection of Lucentis® (week 0, 4, 8). After 4 weeks from third injection, a session of verteporfin PDT (week 12) and fourth injection of Lucentis® (week 16) will be added at intervals of 4 weeks. Two more combined treatment with verteporfin PDT and Lucentis® injection 4 weeks apart can be added at the treating physician's discretion in 3-month intervals (week 28, week 40).
223823277|NCT00476619|DRUG|erythropoeitin|Subjects will receive a one-time dose of either placebo, or EPO 40,000 U intravenously 30 to 240 minutes prior to intravenous contrast administration.
223823278|NCT03462134|OTHER|Survey|Survey amongst orthopaedic surgeons
223823279|NCT06205641|DRUG|Xuanfei Baidu Granule Placebo|Take Xuanfei Baidu Granule Placebo 1 bag in the morning and evening with boiling water for 5 days.
223823280|NCT06205641|DRUG|Xuanfei Baidu Granule|Take Xuanfei Baidu Granule 1 bag in the morning and evening with boiling water for 5 days.
223823281|NCT06205641|DRUG|Baloxavir Marboxil Tablet|Take Baloxavir Marboxil Tablet 2 tablets orally, once a day, for 1 day.
223823282|NCT01339598|DEVICE|Transcranial direct current stimulation (Eldith DC Stimulator)|Eldith DC Stimulator (NeuroConn GmbH, Germany)
223823283|NCT03485274|DRUG|Vortioxetine|oral medication taken once daily
223823284|NCT03485274|OTHER|Treatment as Usual|Any pharmacological or non-pharmacotherapy modalities other than use of vortioxetine
223823285|NCT01413230|DRUG|cholecalciferol|100 000 UI of cholecalciferol per week during 4 then 100 000 UI of cholecalciferol per month for 6 months
223823286|NCT02340702|OTHER|COPD|COPD as diagnosed clinically or based on pulmonary function test showing post-bronchodilator forced expiratory volume in one second to forced vital capacity ratio of \<0.7.
223823287|NCT04062435|DRUG|Drop application in the inferior fornix|See Arms
223823288|NCT04062435|DRUG|Drop application on the cornea|See Arms
223823289|NCT02641249|DEVICE|Vibration|A device providing vibrations is placed on the subject and vibration is turned on and off in a 6 hour on/off sequence. Heart rate, respiratory pauses and oxygen saturation are compared during vibration (intervention) and without vibration (no intervention) in the same subject.
223823290|NCT05157516|PROCEDURE|erector spinea block|the patients will receive a single injection erector spinea block after induction of general anesthesia
223823291|NCT05157516|PROCEDURE|Caudal epidural block|the patients will receive caudal epidural block after induction of general anesthesia
223823292|NCT00811421|DRUG|Sulphadoxine-pyrimethamine|SP oral administration (500mg sulphadoxine and 25mg pyrimethamine) as IPTp at the 1st and 2nd Antenatal Clinic visit
223823293|NCT00811421|DRUG|Mefloquine (full dose)|MQ oral administration (15 mg/Kg) on 1 day at the 1st and 2nd Antenatal Clinic visit as IPTp
223823294|NCT00811421|DRUG|Mefloquine (split dose)|MQ oral administration (15 mg/kg) split dose over 2 days at the 1st and 2nd ANC visit as IPTp
223823295|NCT00811421|DRUG|placebo|MQ-placebo oral administration at the 1st, 2nd and 3rd Antenatal Clinic visit as IPTp
223823296|NCT00811421|DRUG|mefloquine|MQ oral administration (15 mg/Kg) at the 1st and 2nd Antenatal Clinic visit as IPTp
223823297|NCT00278590|BIOLOGICAL|Allogeneic Stem Cell Transplantation|Allogeneic stem cell transplantation will be performed.
223823298|NCT02826980|OTHER|questionnaire|Patients consultant in gynecology in the service of Doctor Sauvanet, for whom a diagnosis of endometriosis has been established (clinical history and imaging tests confirming the diagnosis) will be offered to fill a self-administered questionnaire during their consultation
223823299|NCT05739032|OTHER|Aerobic exercise and strength training|"Aerobic Exercise Training: The individuals in the study group were given aerobic exercise training at 70-80% of the 6MWT average speed. Patients performed exercise three days per week (twice under the supervision of a physiotherapist and once at home) for 30 minutes a day.~Strength Training: Lower and upper extremity strengthening training was performed three days a week, 3x10-12 repetitions per day, with the help of a resistance band suitable for muscle strength. Hip flexion, hip abduction, knee flexion, and knee extension exercises for the lower extremity, and shoulder flexion, shoulder extension, shoulder abduction, shoulder elevation, external rotation, horizontal shoulder abduction, and scapular adduction exercises for the upper extremity were performed."
223823300|NCT02108145|PROCEDURE|bilateral metal stent insertion|
223823301|NCT02108145|PROCEDURE|unilateral metal stent insertion|
223823302|NCT02811094|OTHER|polymerase chain reaction (PCR) technique of blood transcriptome analysis|this study (LUMIER2 study) is to test the hypothesis that a test score or prognostic transcriptomic allows to discriminate clinically quiescent or patients who will not present a push of Systemic Lupus Erythematosus
223823303|NCT00900081|OTHER|immunohistochemistry staining method|
223823304|NCT00900081|OTHER|laboratory biomarker analysis|
223823305|NCT00900081|OTHER|medical chart review|
223823306|NCT00242749|DRUG|Gefitinib, Cisplatin and Radiotherapy|
223823307|NCT02597933|DRUG|Nintedanib|
223823308|NCT02597933|DRUG|Placebo|
223823309|NCT04205929|DRUG|Placebo|Placebo (oral) once daily for 30 days. Treatment to be started after 3 consecutive days of bleeding
223823310|NCT04205929|DRUG|Curcumin|Curcumin 600 mg (oral) once daily for 30 days. Treatment to be started after 3 consecutive days of bleeding
223823311|NCT01806519|BEHAVIORAL|Motor control intervention of head posture|"The tailored motor control intervention used for motor learning-procedure described by Fitts and Posner, further developed and adapted to rehabilitation of the spine by O´Sullivan.~The stages involved in the process was the Cognitive stage, Associative stage and the Autonomous stage"
223823312|NCT04489420|BIOLOGICAL|CYNK001-IV|Planned Starting dose dor IV 1.2x10\^9 cells/dose
223823313|NCT04489420|BIOLOGICAL|CYNK001-IT|Planned starting dose for IT 200 x10\^6 +/- 50 x10\^6 cells dose
223823314|NCT03331029|DEVICE|transesophageal investigation|Comparison of 3D ultrasound with transesophageal echocardiography
223823315|NCT05561348|DEVICE|Transcutaneous auricular vagus nerve stimulation|Transcutaneous auricular vagus nerve stimulation was conducted by transcutaneous electrical stimulation therapy instrument to the cymba conchae of left ear in the vicinity of the auricular branch vagus nerve. Stimulation parameters: frequency = 20 Hz; pulse width = 500 μs, twice a day, 30 minutes each time. In the sham stimulation group, the electrodes were fixed at the same position without releasing current.
223823316|NCT01333085|DRUG|carboplatin|
223823317|NCT01333085|DRUG|RAD001|
223823318|NCT01333085|DRUG|paclitaxel|
223823319|NCT01377558|OTHER|Aerobic endurance training intervention|"The aerobic endurance training group will use cardiovascular training devices~week 1-4: 15 minutes warm up (group) 15 minutes intervention at 80-100% vAT two times per week~week 5-13: 15 minutes warm up (group) 30 minutes intervention at 95-110% vAT two times per week~week 14-26: 15 minutes warm up (group) 45 minutes intervention at 95-110% vAT two times per week"
223823320|NCT01377558|OTHER|Strength endurance training intervention|"The strength endurance training intervention group will perform eight exercises on weight machines (Milon circuit training- 60 seconds activity, 30 seconds break)~week 1-4: 15 minutes warm up (group) 1 session resistance training intensity 3 (Buskies) two times per week~week 5-13: 15 minutes warm up (group) 2 sessions resistance training intensity 5 (Buskies) two times per week~week 14-26: 15 minutes warm up (group) 3 sessions resistance training intensity 5 (Buskies) two times per week"
223823321|NCT01377558|OTHER|Combined aerobic endurance and strength endurance training|"week 1-4: 15 minutes warm up (group) 15 minutes intervention at 80-100% vAT once per week and 15 minutes warm up (group) 1 session resistance training intensity 3 (Buskies) once per week~week 5-13: 15 minutes warm up (group) 15 minutes intervention at 95-110% vAT and 1 session resistance training intensity 5 (Buskies) two times per week~week 14-26: 15 minutes warm up (group) 30 minutes intervention at 95-110% vAT and 1 session resistance training intensity 5 (Buskies) once a week and 15 minutes warm up (group) 15 minutes intervention at 95-110% vAT and 2 sessions resistance training intensity 5 (Buskies) once a week"
223823322|NCT03603392|OTHER|Physical activity program|
223823323|NCT03290560|DRUG|Recombinant human tissue kallikrein|Recombinant human tissue kallikrein
223823324|NCT03290560|OTHER|Placebo|Placebo Comparator: Phosphate buffered saline
223823325|NCT01191060|DRUG|Lenalidomide, Bortezomib|"Lenalidomide/Bortézomib/Dexamethasone cycles:~Number of cycles: 8 cycles for arm A~Cycle length~Dosage:~* Lenalidomide: 25 mg/day on days 1-14 of each cycle~* Bortézomib: 1.3 mg/m2 on days 1, 4, 8, and 11 for 1 cycle of each cycle~Maintenance phase (12 months):~Cycle length: 28 days Dosage: Lenalidomide: 10 mg/day continuously for 28 days during 3 months and if the participant tolerates 10 mg/day without complication, a dose increase to 15 mg/day will be allowed"
223823326|NCT01191060|DRUG|Lenalidomide, Bortezomib|"Lenalidomide Bortezomib Dexamethasone cycles:~Number of cycles: 5 cycles for arm B~Cycle length~Dosage:~* Lenalidomide: 25 mg/day on days 1-14 of each cycle~* Bortézomib: 1.3 mg/m2 on days 1, 4, 8, and 11 for 1 cycle of each cycle~Maintenance phase (12 months):~Cycle length: 28 days Dosage: Lenalidomide: 10 mg/day continuously for 28 days during 3 months and if the participant tolerates 10 mg/day without complication, a dose increase to 15 mg/day will be allowed"
223823327|NCT06081335|DEVICE|EdgeEndo x7 continuous rotation files|endodontic files operating in continuous rotation
223823328|NCT06081335|DEVICE|EdgeOne Fire reciprocating files|endodontic files operating in reciprocating motion
223823329|NCT01920503|DRUG|Doxorubicin|Doxorubicina is loaded at the concentration of 50-75 mg/mq onto 2 ml of 70-150 µm M1 microspheres and is infused by TACE method
223823330|NCT03555630|DIAGNOSTIC_TEST|Thromboelastogram|Blood sample processing for thromboelastogram
223823331|NCT02081235|PROCEDURE|surgery for congenital heart disease|surgery for congenital heart disease
223823332|NCT04975828|DIAGNOSTIC_TEST|albumin creatinine ratio -EGFR-fundus examination- coronary angiography.|albumin creatinine ratio and EGFR to assess. diabetic nephropathy. fundus examination to assess. diabetic retinopathy. assess of coronary artery disease by coronary angiography. assess diabetic nephropathy by neurologic examination.
223823333|NCT02224482|BEHAVIORAL|PROGRESS|PROGRESS is a multimedia website designed to help prostate cancer survivors.
223823334|NCT05431634|DRUG|Experimental drug: ESK-001|Multiple doses of ESK-001
223823335|NCT05431634|OTHER|Placebo|Placebo
223823336|NCT05394233|DRUG|Tislelizumab Combined With Bevacizumab and Platinum Plus Pemetrexed|Bevacizumab: 7.5 mg/kg administered as an intravenous infusion on Day 1 of each 3-week cycle Cisplatin 75 mg/m2 will be administered as an intravenous infusion over 2 hours, every 3 weeks, Pemetrexed, 500 mg/m2, intravenously every 3 weeks, Tislelizumab, 200 mg IV every 3 weeks
223823337|NCT05564741|DRUG|Norepinephrine 1 MG/ML|As proxy for hypotension we record amount of Norepinephrine given during the study time of 30 minutes
223823338|NCT01880372|DIETARY_SUPPLEMENT|Alpha Lipoic Acid|Same as Arm description
223823339|NCT01913639|DRUG|Regorafenib|
223823340|NCT01913639|DRUG|5-Fluorouracil|
223823341|NCT01913639|DRUG|Leucovorin|
223823342|NCT01913639|DRUG|Oxaliplatin|
223823343|NCT00880321|DRUG|GSK2118436|Dose escalation with GSK2118436 may proceed until either a maximum tolerated dose is established, or the toxicokinetic safety limit is reached.
223823344|NCT00880321|DRUG|GSK2118436|Part 2 will use the recommended Part 2 dose of GSK2118436 identified during Part 1 of the study. Biologically active doses will be identified by measurement of pharmacodynamic markers in tumor tissue and blood across a range of doses and these doses may be explored in Part 2.
223823345|NCT00880321|DRUG|Midazolam|Midazolam will be administered alone and with GSK2118436 in a sub-set of subjects in Part 2 to study the effect of GSK2118436 on CYP3A using midazolam as a probe.
223823346|NCT01391351|OTHER|blood samples|"blood samples in patients receiving Taxol and carboplatin chemotherapy :~* On Day 1 of the first course of chemotherapy~* On Day 1 of the second course of chemotherapy~* Before the surgery, if programmed via J1 or the fourth cycle of chemotherapy~* At the end of chemotherapy"
223823347|NCT01391351|OTHER|blood samples|"blood samples in patients receiving Taxol and carboplatin chemotherapy with avastin:~* On Day 1 of the first course of chemotherapy~* On Day 1 of the second course of chemotherapy~* Before the surgery, if programmed via J1 or the fourth cycle of chemotherapy~* At the end of chemotherapy"
223823348|NCT01805882|DRUG|Sofosbuvir|
223823349|NCT01805882|DRUG|Ledipasvir|
223823350|NCT01805882|DRUG|GS-9669|
223823351|NCT01805882|DRUG|GS-9451|
223823352|NCT00002658|BIOLOGICAL|filgrastim|
223823353|NCT00002658|DRUG|amsacrine|
223823354|NCT00002658|DRUG|cyclophosphamide|
223823355|NCT00002658|DRUG|cytarabine|
223823356|NCT00002658|DRUG|daunorubicin hydrochloride|
223823357|NCT00002658|DRUG|etoposide|
223823358|NCT00002658|DRUG|idarubicin|
223823359|NCT00002658|DRUG|mitoxantrone hydrochloride|
223823360|NCT00002658|DRUG|thioguanine|
223823361|NCT00002658|DRUG|tretinoin|
223823362|NCT00002658|PROCEDURE|allogeneic bone marrow transplantation|
223823363|NCT00002658|PROCEDURE|autologous bone marrow transplantation|
223823364|NCT00002658|PROCEDURE|peripheral blood stem cell transplantation|
223823365|NCT00002658|RADIATION|radiation therapy|
223823366|NCT01225822|DRUG|Enoxaparin|Enoxaparin 40 mg s.c once a day for 5-10 days of treatment period
223823367|NCT01225822|DRUG|BIBR 1048|50 mg b.i.d BIBR 1048 capsule twice a day for 5-10 days of treatment period
223823368|NCT01225822|DRUG|BIBR 1048|150 mg b.i.d BIBR 1048 capsule twice a day for 5-10 treatment period
223823369|NCT01225822|DRUG|BIBR 1048|225 mg b.i.d BIBR 1048 capsule twice a day for 5-10 treatment period
223823370|NCT01225822|DRUG|BIBR 1048|300 mg q.d BIBR 1048 capsule for 5-10 treatment period
223823371|NCT03987256|OTHER|Initial rehabilitation protocol|During 12 weeks, under kinesitherapist guidance, patients will perform daily eccentric stretching and strengthening of the ECRB and periscapular musculature, manual therapies, and kinesiotaping. They will also use orthotics after 6 weeks if kinesiotaping is not effective. At weeks 1-5, patients will undergo weekly ultrasound-guided focused shockwave therapy under the following protocol: 0,15- 0,30mJ/mm2 (the highest energy flux the patient can well tolerate), 1500 shocks at 5Hz at the origin of common extensor or flexor tendon.
223823372|NCT03987256|PROCEDURE|Needling with PRP|"In case of failure of proper rehabilitation and shockwave therapy, patients will have a block of the radialis nerve just above the arcade of Frohse with 1 ml of procaine 2%. Then, a single needling of the ECRB enthesis (peppering technique) will be performed as follow: , ultrasound-guided, 25 repetitions with a 20 gauge needle. At the end of the procedure, the lesion will be fulfilled with PRP.~Details of PRP preparation (ACP Arthrex): 15 ml of blood, no activators or anticoagulants, poor in white blood cells (the last mm of buffy coat above the red blood cells pellet is not collected).~Excentric stretching and strengthening, as well as orthotics or kinesiotaping will be continued as long as symptoms persists during the 6 first months after the needling procedure."
223823373|NCT03987256|PROCEDURE|Needling with saline solution|"In case of failure of proper rehabilitation and shockwave therapy, patients will have a block of the radialis nerve just above the arcade of Frohse with 1 ml of procaine 2%. Then, a single needling of the ECRB enthesis (peppering technique) will be performed as follow: , ultrasound-guided, 25 repetitions with a 20 gauge needle. At the end of the procedure, the lesion will be fulfilled with saline solution.~Excentric stretching and strengthening, as well as orthotics or kinesiotaping will be continued as long as symptoms persists during the 6 first months after the needling procedure."
223823374|NCT01360567|DIETARY_SUPPLEMENT|Green tea extract|500 mg . one capsule of green tea extract, 3 times per day
223823375|NCT01360567|DIETARY_SUPPLEMENT|Placebo|500 mg . one capsule of placebo, 3 times per day
223823376|NCT05269537|RADIATION|Transthoracic Echocardiography|Measurement of cardiac output in supine position with left lateral tilt at baseline, at 10 minutes after intrathecal injection, immediately after delivery, and at 1 hour after intrathecal injection
223823377|NCT05269537|PROCEDURE|Spinal Anesthesia|Performed at the L3-L4 or L4-L5 interspace using 25-gauge spinal needle
223823378|NCT05269537|DRUG|Intrathecal Bupivacaine|Bupivacaine 12.5 mg (2.5 mL 0.5%) will be administered in the subarachnoid space
223823379|NCT05269537|DRUG|Intrathecal Fentanyl|Fentanyl 15 μg will be administered in the subarachnoid space
223823380|NCT05269537|DRUG|Crystalloid Coload 1000 mL|Ringer acetate 1000 mL will be administered over 10 minutes starting immediately after intrathecal injection
223823381|NCT05269537|PROCEDURE|Cesarean Delivery|Lower segment cesarean section using the Pfannenstiel incision and uterine exteriorization
223823382|NCT05269537|DRUG|Intravenous Ephedrine|Intravenous ephedrine 3, 5, and 10 mg will be administered when Systolic blood pressure decreases below 90%, 80%, and 70% of baseline, respectively.
223823383|NCT05269537|DRUG|Oxytocin|Intravenous oxytocin 10 U in 500 mL Ringer acetate will be administered over 30 minutes starting immediately after delivery of the fetus
223823384|NCT00818064|DRUG|anti-IL-20|Single s.c. injection (per dose cohort)
223823385|NCT00818064|DRUG|placebo|Single s.c. injection (per dose cohort)
223823386|NCT02221245|PROCEDURE|Tumor Biopsy via Ultrasound Endoscopy|The staging ultrasound endoscopy is performed on patients previously diagnosed with esophageal cancer via diagnostic biopsy. The staging ultrasound identifies affected lymph nodes and depth of tumor to the esophageal wall. The tumor sampling is via a biopsy forcep (one pass to obtain 100 cells).
223823387|NCT02225977|DRUG|Gilenya|
223823388|NCT05769751|OTHER|Electronic medical record and hospital information system or other available resources|This is a non-interventional study. No study medication will be provided to the participants.
223823389|NCT06489691|OTHER|6-minute walk test (6MWT)|6-minute walk test (6MWT) will be performed according to clinical standards
223823390|NCT01290822|DEVICE|BiVP|Biventricular pacing
223823391|NCT01290822|DEVICE|AAI Pacing|Atrial pacing
223823392|NCT03501693|DEVICE|DBT plus S-View|DBT plus S-View images
223823393|NCT03501693|DEVICE|FFDM Alone|FFDM alone images
223823394|NCT06568744|OTHER|Intervention resuscitation|"In fluid responsive patients, fluid intolerance will be checked.~Lung Ultrasound (LUS): Anterior LUS with 4-point assessment at each hemithorax. Min:0 and a max:24. Low risk: \< 10; intermediate risk: 10-14 or delta of 2 points. High risk: \>14, or an increase \>4 from baseline.~VExUS: Low risk: Grade 0-1. Intermediate risk: 2. High risk: 3 E/e' ratio: Low risk: \<8. Intermediate risk: 8-13. High risk \>14. Central venous pressure (CVP): Low risk \<12 mmHg. Intermediate risk: 12-15 mmHg or a delta of 3 mmHg. High risk \> 15 mmHg or \>5 mmHg increase after a fluid challenge.~In low-risk, a fluid challenge of 500 ml of balanced crystalloid will be performed in 30 minutes. If intermediate risk, a fluid challenge of 250 ml of balanced crystalloid in 30 minutes. If high-risk signals, alternative strategies (vasopressor and inodilator tests) will be deployed. After each challenge, peripheral perfusion, fluid responsiveness and intolerance will be re-assessed."
223823395|NCT06568744|OTHER|Standard of Care resuscitation|In fluid responsive patients, fluid challenges of 500 ml of balanced crystalloid will be performed in 30 minutes. After a fluid challenge, peripheral perfusion status and fluid responsiveness will be re-measured. If the patient persists with hypoperfusion, successive fluid challenges will be performed until hypoperfusion resolves or the patient becomes fluid unresponsive. If hypoperfusion signals persists and the patient becomes fluid unresponsive, alternative resuscitation interventions will be deployed, which include: 1) vasopressor titration to higher mean arterial pressure (MAP) targets in a MAP-test, and 2) addition of an inotrope to increase cardiac output in an inodilator test. If hypoperfusion fails to resolve, rescue therapies such as high-volume hemofiltration will be initiated.
223823396|NCT02735837|DRUG|Doxycycline Group|Doxycycline 3% topical gel was put into the periodontal pocket using an insulin syringe
223823397|NCT02735837|DRUG|placebo topical gel|placebo topical gel was put into the periodontal pocket using an insulin syringe
223823398|NCT01529671|DRUG|PF-05089771|PF-05089771 will be dosed as a suspension twice daily (BID)
223823399|NCT01529671|DRUG|PF-05089771|PF-05089771 will be dosed as a suspension twice daily (BID)
223823400|NCT01529671|DRUG|PF-05089771|PF-05089771 will be dosed as a suspension twice daily (BID)
223823401|NCT01529671|DRUG|PF-05089771|PF-05089771 will be dosed as a suspension twice daily (BID)
223823402|NCT01529671|DRUG|PF-05089771|PF-05089771 will be dosed as a suspension BID
223823403|NCT03767985|OTHER|Dichoptic video game therapy|Dichoptic video gaming for 1 hour per week, viewed through the Oculus Rift.
223823404|NCT03767985|OTHER|Occlusion therapy|Occlusion therapy for 2 hours per day, 7 days a week
223823405|NCT04642586|DIAGNOSTIC_TEST|multimodal magnetic resonance imaging|Brain MRI exam (without contrast injection)
223823406|NCT04642586|DIAGNOSTIC_TEST|blood test|Blood test to evaluate cardiovascular risk factors (cholesterol, triglycerides, LDL and HDL-CT, serum creatinine, fasting glucose, serum potassium), .
223823407|NCT04642586|DIAGNOSTIC_TEST|neuropsychological assessment|neuropsychological assessment
223823408|NCT05867264|OTHER|Early drinking water|"After passing the evaluation by the anesthesiologist team in PACU, the EOF1 group drank 200ml of water.~The evaluation criteria for the anesthesiologist team are:~1. Steward's awakening score is ≥ 6 points.~2. Level of sobriety ≥ 3.~3. There is no need to wait for intestinal peristalsis, based on the patient's wishes, and the feeding should be completed within 2 hours after the surgery."
223823409|NCT05867264|COMBINATION_PRODUCT|Early consumption of carbohydrates|"After passing the evaluation by the anesthesiologist team in PACU, the EOF2 group had a drinking capacity of 200ml of 12.5% carbohydrates (100ml containing 12.5g of maltodextrin, fructose, and glucose).~The evaluation criteria for the anesthesiologist team are:~1. Steward's awakening score is 6 points.~2. Level of sobriety ≥ 3.~3. There is no need to wait for intestinal peristalsis, based on the patient's wishes, and the feeding should be completed within 2 hours after the surgery."
223823410|NCT05867264|OTHER|Late feeding group|After observing the vital signs for 30 minutes after surgery, patients in Group C were sent back to the ward to continue fasting and drinking for at least 6 hours. After the anus exhausts, they began to gradually drink and eat
223823411|NCT02164097|DRUG|ODSH|
223823412|NCT00927043|OTHER|Epidemiological study according to clinical practice|Epidemiological study according to clinical practice.
223823413|NCT04394845|DIAGNOSTIC_TEST|[18F]GTP1|\[18F\]GTP1 IV bolus injection of up to 370 megabecquerel (MBq) (10 millicurie \[mCi\]), with a maximum drug mass dose of 10 microgram (μg).
223823414|NCT04683523|OTHER|Exercise|Resistance training using dumbbells and therabands
223823415|NCT05647551|DRUG|BOTOX®/VISTABEL®|Facial Injection
223823416|NCT05647551|DEVICE|Juvéderm® VOLBELLA® with Lidocaine|Facial Injection
223823417|NCT05647551|DEVICE|Juvéderm® VOLIFT® with Lidocaine|Facial Injection
223823418|NCT05647551|DEVICE|Juvéderm® VOLUMA® with Lidocaine|Facial Injection
223823419|NCT05915390|DIETARY_SUPPLEMENT|walnuts|walnuts will provide 15% of the total energy
223823420|NCT05915390|DIETARY_SUPPLEMENT|Habitual diet|continue with habitual diet and abstain from walnuts
223823421|NCT02223754|DEVICE|lotrafilcon B|Soft contact lens to be worn as daily wear, monthly replacement modality.
223823422|NCT02223754|DEVICE|etafilcon A|Soft contact lens to be worn as daily wear, daily disposable modality.
223823423|NCT00004062|DRUG|azacitidine|
223823424|NCT00004062|DRUG|liothyronine sodium|
223823425|NCT00004062|RADIATION|iodine I 131|
223823426|NCT04395183|DRUG|5-Hydroxytryptophan 100 MG|5-HTP 100mg PO BID
223823427|NCT04395183|DRUG|Creatine monohydrate|Creatine monohydrate 5g PO qday
223823428|NCT04395183|DRUG|placebo matched to 5-HTP|placebo matched to 5-HTP
223823429|NCT04395183|DRUG|Placebo|Dextrose either as loose powder (matched to creatine) or encapsulated (matched to 5-HTP)
223823430|NCT06050902|DEVICE|Subclavian venipuncture for catheter placement using the needle-steering device|"1. Navigation software is implemented in an ultrasound machine.~2. A linear ultrasound probe (similar in appearance to a standard ultrasound probe) is used~3. Magnetization of the puncture needle after short introduction of the needle in a dedicated device.~4. Real time needle guidance on the ultrasound screen during the puncture."
223823431|NCT00664638|DEVICE|Symplicty(TM) Catheter System|Renal denervation using the Symplicity Catheter System
223823432|NCT00315588|DRUG|Islet Transplantation|Islet Transplantation in subjects with a previous kidney transplant.
223823433|NCT02491021|OTHER|Rehabilitation Class|A 6 week programme of exercise and education in an out patient setting
223823434|NCT04195880|OTHER|Interventions to Reduce Acute Care Transfers|Experimental CLCs were trained in INTERACT QI Intervention, containing tools, strategies and educational resources designed to catch and manage acute changes in conditions early that a Veteran may be experiencing, leading to a potential reduction in preventable hospital transfers from CLCs.
223823435|NCT01252121|OTHER|Systane Ultra Lubricant Eye Drops|One drop in study eye, one time, during office visit.
223823436|NCT01252121|OTHER|Hialid 0.1 Artificial Tears Eye Drops|One drop in study eye, one time, during office visit.
223823437|NCT01252121|OTHER|Unisol 4 Saline Solution|One drop in study eye, one time, during office visit.
223823438|NCT05188755|OTHER|Indirect calorimetric test during submaximal exercise|"* metabolic evaluation by indirect calorimetry at rest and during exercise~* evaluation of cardiac output~* peripheral quantitative computed tomography (pQCT) of the muscle cross section~* evaluation of body composition~* assessment of physical capacity (chair test and 3 min step-test)~* blood test~* assess the level of physical activity"
223823439|NCT04942808|RADIATION|Periapical radiographs|Periapical radiographs on reevaluation
223823440|NCT05684913|PROCEDURE|Zn granulate stent after FGG surgery|Immediately after FGG harvesting from the palatal tissue, homeostasis was achieved by sterile wet gauzes and the ZnG was prepared according to the manufacturer guidelines. Briefly, approximately 10 grams of granulate was poured into hot water and then manually shaped to cover the surgical area. The retention was achieved from the palatal, occlusal and buccal surfaces of the teeth. The patient was asked to wear the ZnG for 7 days except for eating.(
223823441|NCT05684913|PROCEDURE|Hemostatic agent suturing|Immediately after FGG harvesting from the palatal tissue, homeostasis was achieved by sterile wet gauzes. Then hemostatic agent containing cellulose were sutured on the palatal wound area with 4.0 vicryl sutures in this group. Sutures were removed after 7 days.
223823442|NCT00816933|PROCEDURE|appendectomy|appendectomy according to the number of trocar
223823443|NCT02733783|DEVICE|Cold dry air machine|Cold Dry Air (CDA)- nasal provocation: Compressed dry air is delivered through a transparent anaesthesia mask placed over the nose and mouth of the patients. Subjects are instructed to breath through the nose only. Exposure to CDA lasts for 15 minutes. The flow, measured by a gas flow analyzer of Dräger was set at 12,5 l/min. The temperature of the air reaching the nose is at -10° C with a relative humidity of 10%-15%.
223823444|NCT03915184|BIOLOGICAL|zevor-cel|A single autologous chimeric antigen receptor-B-cell maturation antigen (CAR-BCMA T cell) infusion
223823445|NCT06127576|DEVICE|paraboloid geometry double and triple dental abutment-implant|"The implants were inserted with the margin between machined and micro-rough surface at bone level. The abutment and crowns were assembled and screw retained onto the implant with a torque of 35 Ncm.~The implants were cylindrical with internal hexagon and without surface treatment, presenting 4.0 mm in diameter and length varying between 10 and 13 mm.~Acording to the manual work model measurements, DA or TA acrylic individualized design and paraboloid surfaces of the DA (elliptical) and TA (hyperbolic) had been made."
223823446|NCT06210906|OTHER|Assessment of gastric volume|Gastric volume is assessed using ultrasound.
223823447|NCT01139463|DRUG|Haloperidol or olanzapine|Haloperidol tablet - 5 mg twice daily (morning and evening) by mouth Olanzapine tablet - 5 mg twice daily (morning and evening) by mouth
223823448|NCT02206308|BIOLOGICAL|Chimeric anti-CD20 monoclonal antibody|
223823449|NCT06900075|DRUG|Efsubaglutide Alfa 3mg Q2W and 1mg QW|Efsubaglutide Alfa 3 mg administered once every two weeks for 8 weeks, followed by a switch to Efsubaglutide Alfa 1 mg administered once weekly for an additional 8 weeks of treatment.
223823450|NCT06900075|DRUG|Efsubaglutide Alfa 1mg QW and 3mg Q2W|Efsubaglutide Alfa 1 mg administered once weekly for 8 weeks, followed by a switch to Efsubaglutide Alfa 3 mg administered once every two weeks for an additional 8 weeks of treatment.
223835548|NCT06845683|OTHER|Group A|Progressive wall squat exercises will commence with a knee flexion angle of 135°, instructed to hold this position for 20 seconds, exercise progresses, the knee joint angle will be decreased by 10° until reaching the 95° stage or until participants can no longer maintain the knee joint angle within 5° of the target value due to volitional fatigue. Cognitive tasks during the intervention, including the recall of words and counting forward (1, 4, 7, 10...) and backward (...10, 7, 4, 1) by adding 3 to the digits. Sustained stretching (with a hold time of 10 seconds per stretch, totaling 10 repetitions per session) and active range of motion exercises (10 repetitions per session) targeting both the upper and lower extremities in routine rehabilitation.
223823451|NCT05474534|DEVICE|Neurofeedback (MUSE 2)|During each at-home treatment session, mothers will place the MUSE 2 on their heads and connect it to the app on their personal device. Their brain activity is monitored by the MUSE 2 and is represented on the app through audio-based feedback (e.g., birds chirping, sounds of waves lapping on the beach) that mothers will listen to with earbuds as they direct their focus on maintaining a calm state of mind during the session; when a calm state is maintained, they are rewarded with calming sounds. The goal is to gain increased conscious control over their own brain activity. The audio feedback, primarily composed of nature-based sounds, is meant to guide their brain activity into a calm state. The session will begin, and the MUSE 2 will provide audio feedback in real time to guide their brainwave activity into an optimal frequency bandwidth range (e.g., as their brain activity reaches the target state, sounds of wind would subside to peaceful waves or other rewarding audio feedback).
223823452|NCT01693692|DRUG|TD-9855 Group 1|
223823453|NCT01693692|DRUG|TD-9855 Group 2|
223823454|NCT01693692|DRUG|Placebo|
223823455|NCT06912061|PROCEDURE|Needle tendon lengthening technique|"Percutaneous Achilles tendon lengthening with the needle technique is performed by applying a series of microtenotomies to the tendon using needle pricks while the tendon is stretched. A withdrawal needle with a diameter of 1.1-1.2 mm is used. The needle pricks gradually weaken the tendon and stretch it to the desired length without opening the skin or tendon sheath. As a rule, it is desirable to achieve approximately 10-15 degrees of dorsiflexion before concluding the lengthening.~Local infiltration anesthesia is applied, followed by a simple bandage. The surgical procedure typically takes 3-4 minutes. Finally, a boot cast in soft plaster with the foot and ankle in neutral position is applied, and it can be fully weight-bearing immediately.~The cast is removed at the clinic after 4 weeks. After cast removal, the child/adolescent should be allowed gentle activity - not sports - for another 4 weeks, thereafter unrestricted activity.~Physical therapy may be utilized as needed, locally."
223823456|NCT06917235|PROCEDURE|Wrist and carpal arthrodesis|All patients that fit the inclusion criteria and accept the arthrodesis surgery will be followed up over the course of 1 year. The wrist and carpal arthrodesis procedures will include radioscapholunate, scaphoid-trapezium-trapezoid (STT), and four-corner arthrodeses.
223823457|NCT06920667|DIETARY_SUPPLEMENT|Protein-Creatine-Omega-3-Vitamin D Supplement|Participants will receive a daily powdered supplement containing 30 g of whey protein isolate, 5 g of creatine monohydrate, 1 g of omega-3 fatty acids (EPA/DHA), and 1,000 IU of vitamin D3. The supplement will be taken once daily for 12 weeks, dissolved in water. It is designed to reduce glycemic variability and improve metabolic parameters in individuals with recently diagnosed type 2 diabetes.
223823458|NCT06920667|DIETARY_SUPPLEMENT|Placebo (Maltodextrin)|Participants will receive a daily powdered placebo formulated with maltodextrin, without any active ingredients (no whey protein, creatine, omega-3, or vitamin D). It is identical in appearance, taste, and packaging to the active supplement. It will be taken once daily for 12 weeks and administered in the same conditions as the intervention group.
223823459|NCT06473012|BEHAVIORAL|Cognitive Behavioral Therapy for Caregivers of Older Adults|Cognitive Behavioral Therapy Intervention for Caregivers of Older Adults is designed to be implemented in a group setting with 12 to 15 caregivers in a group. It consists of 6 weekly sessions, and each session lasts for 90 minutes to 120 minutes. The content of the intervention is based on lifestyle intervention, CBT and effective communication skills. Home practices will be assigned to the participants in between each weekly session.
223823460|NCT06473012|BEHAVIORAL|Control intervention for Caregivers of Older Adults|The control group receives 6 weekly education sessions on useful healthcare information (mental health, physical health, health ageing and dementia). Each session lasts for 90 minutes to 120 minutes.
223823461|NCT00297193|PROCEDURE|Autologous haematopoietic stem cell transplant|All patients will be mobilised prior to randomisation. Those receiving early transplantation will be compared over the first year with those whose transplant has been delayed.
223823462|NCT06926452|PROCEDURE|Pontic site augmentation with sub-epithelial connective tissue graft.|Pontic site augmentation with sub-epithelial connective tissue graft.
223823463|NCT06926452|PROCEDURE|Pontic site augmenation using multi-layered platelet rich fibrin|Pontic site augmenation using multi-layered platelet rich fibrin
223823464|NCT06925958|DIAGNOSTIC_TEST|Flow cytometry|CD38 Flow cytometry testing
223823465|NCT06925152|DRUG|Bupivicaine intervention arm|TAP blocks in intervention group will include 0.5% bupivacaine in 30mL solution of 15mL normal saline and 15mL bupivacaine
223823466|NCT06925152|DRUG|Placebo arm|Placebo group TAP block syringe will include 30mL normal saline
223823467|NCT06925334|DRUG|Degludec insulin|The pre-mixed human insulin or insulin analogues were stopped, and the treatment was switched to Delgol insulin liraglutide injection. The initial dose was subcutaneous injection of 80% (not more than 16 units) of the full daily dose of medium-acting insulin in the original insulin, once a day, and the dose of Delgol insulin liraglutide injection was adjusted according to the fasting blood glucose level. Example 1: If the patient is currently using Novorin 30 20iu bid, the conversion calculation is 40\*70%\*80%=22.4 units, which should be 16 units; In example 2, the patient applied eubrine 50 20 IU bid, and the conversion calculation was 40\*50%\*80%=16 units.
223835549|NCT06845683|OTHER|Group B|Progressive wall squat exercises will commence with a knee flexion angle of 135°, instructed to hold this position for 20 seconds, exercise progresses, the knee joint angle will be decreased by 10° until reaching the 95° stage or until participants can no longer maintain the knee joint angle within 5° of the target value due to volitional fatigue. Sustained stretching (with a hold time of 10 seconds per stretch, totaling 10 repetitions per session) and active range of motion exercises (10 repetitions per session) targeting both the upper and lower extremities in routine rehabilitation.
223835550|NCT00305201|DRUG|pravastatin|
223823468|NCT06925139|DEVICE|Non-ablative monopolar radiofrequency treatment|"Protocol for the experimental group:~Tissue preparation phase: 5 minutes with the circular resistive monopolar electrode, applying slow circular or semicircular movements in the perineal area. The temperature will be gradually increased based on the patient's temperature perception, ensuring it remains comfortable (approximately 5 out of 10).~Main phase: 10 minutes using the intracavitary capacitive electrode connected to the PLUMA handle, lightly resting it on the tissues and continuously moving the electrode. The temperature should reach 40-42°C in the tissue and be maintained for at least 10 minutes.~Final phase: 5 minutes with the circular resistive monopolar electrode, applying it similarly to the preparatory phase, with a subthermal effect, reaching a self-reported thermal sensation of 3 to 4 out of 10.~Protocol for the sham group: this group will receive the same treatment protocol that treatment group, but without the application of heat."
223823469|NCT02805595|DRUG|23.4% Hypertonic saline|Saline Injections
223823470|NCT05899582|PROCEDURE|Extracranial-Intracranial Bypass Surgery|Extracranial-intracranial bypass surgery plus medical treatment
223823471|NCT05899582|OTHER|Medical treatment alone|Best medical treatment alone according to current clinical guidelines, including antiplatelet drugs (e.g. aspirin) and risk factor controls.
223823472|NCT05672212|DEVICE|ANI (Analgesia/Nociception Index) monitoring|Intraoperative analgesia was provided by injection of sufentanil, which was performed according to ANI monitor.
223823473|NCT05672212|DEVICE|standard monitoring|Intraoperative analgesia was provided by injection of sufentanil, which was performed according to the clinician's assessment.
223823474|NCT05672212|DRUG|Sufentanil|Sufentanil
223823475|NCT01829984|OTHER|Verbal and Written Instruction|"Pre-teaching Evaluation: Patient~* Pre-teaching Evaluation: Caregiver~  o To be completed immediately before the teaching. Administered by the nurse who will provide the teaching. The form utilized will depend on if the patient or caregiver will be administering the injection.~* Post-teaching Evaluation: Patient Post-teaching Evaluation: Caregiver To be completed immediately after the teaching. Administered by the nurse who provided the teaching. The form utilized will depend on if the patient or caregiver will be administering the injection."
223823476|NCT01829984|OTHER|Verbal and Written Plus Simulation|"Post-injection Evaluation: Patient~* Post-injection Evaluation: Caregiver~  o To be completed after the injection is administered (outside of MSKCC) by the patient or caregiver. The form utilized will depend on if the patient or caregiver has administered the injection. They will return this evaluation at the patient's next visit (2 weeks later).~* Nurse Evaluation: Control~* Nurse Evaluation: Model o To be completed immediately following the completion of the teaching by the nurse. The form utilized will depend on if the teaching was part of the control or intervention phase of the study."
223823477|NCT06230991|DIETARY_SUPPLEMENT|SIM05|SIM05 contains a blend of food-grade Bifidobacterium and Lactobacillus strains plus prebiotics
223823478|NCT03657927|DEVICE|C-MAC videolaryngoscope|An intubating device that is used for endotracheal intubation. Endotracheal intubation was applied by anesthesiologist with C-MAC videolaryngoscope.
223823479|NCT03657927|DEVICE|McGrath MAC videolaryngoscope|An intubating device that is used for endotracheal intubation. Endotracheal intubation was applied by anesthesiologist with McGrath MAC videolaryngoscope.
223823480|NCT04532242|BEHAVIORAL|Cognitive reappraisal|Participants will be trained to follow instructions to look/respond naturally or use cognitive reappraisal to reframe or reconsider a negative picture to decrease negative emotion.
223823481|NCT03672513|DIETARY_SUPPLEMENT|Placebo Comparator|Oral administration of 1 daily capsule containing lactose
223823482|NCT03672513|DIETARY_SUPPLEMENT|Zinc Supplement|Oral administration of 1 daily capsule containing 50 mg/day of Zn
223823483|NCT03672513|DIETARY_SUPPLEMENT|Magnesium supplement|Oral administration of 1 daily capsule containing 500 mg/day of Magnesium
223823484|NCT04567693|OTHER|Early spaced-out appointments|Newly-diagnosed PLWH currently attend health centers monthly for ART pick-up and quarterly for clinical visits. In the intervention arms, participants will attend health centers quarterly for ART pick-up and semi-annually for clinical visits.
223823485|NCT00749385|DRUG|PN 400|A single tablet containing delayed-release naproxen (500mg) plus immediate-release esomeprazole (20mg)
223823486|NCT00749385|DRUG|EC naproxen plus EC esomeprazole|Enteric-coated naproxen tablet (500mg) plus enteric-coated esomeprazole capsule (20mg)
223823487|NCT00749385|DRUG|EC naproxen|Enteric-coated naproxen tablet (500mg)
223823488|NCT00749385|DRUG|EC esomeprazole|Enteric-coated esomeprazole capsule (20mg)
223823489|NCT00937170|DEVICE|Zimmer LPS flex Gender Specific Implant (Total knee replacement)|Outcomes comparison between a gender specific total knee implant, a standard total knee implant by the same company, and a standard total knee implant from another company
223823490|NCT00937170|DEVICE|Zimmer High Flex LPS Implant (Total knee replacement)|Outcomes comparison between a gender specific total knee implant, a standard total knee implant by the same company, and a standard total knee implant from another company
223823491|NCT00937170|DEVICE|Stryker Triathlon Implant (Total knee replacement)|Outcomes comparison between a gender specific total knee implant, a standard total knee implant by the same company, and a standard total knee implant from another company
223823492|NCT01230606|OTHER|discharge vs. overnight stay|At six hours post-PCI,patients will be randomized to be discharged immediately or to stay overnight in the hospital for observation and discharged the following day. Randomization will occur in a 1:1 ratio. Additionally, randomization will be performed stratified by study site.
223823493|NCT02608762|RADIATION|standard adjuvant local radiation therapy or cranial radiation therapy|
223823494|NCT03722264|DEVICE|OpalSeal|OpalSeal is a fluoride releasing orthodontic primer that is FDA approved for use during bonding of orthodontic brackets
223823495|NCT03722264|DEVICE|TransbondXT|Transbond is a primer used to bond orthodontic brackets that does not contain fluoride
223823496|NCT05193084|DEVICE|Heartfelt Device|"The Heartfelt Device is a CE marked device that measures the volume of the foot/lower leg. By positioning the Heartfelt device in the bedroom, automatic measurements can be made whenever the subject gets in and out of bed. Feet identification software, complemented by manual checks, ensures that photographs are only taken of the specified subject. Data is censored so that the part of the body which is 50cm above the floor is not stored. Encrypted, anonymised data is transmitted over the internet to the company's secure servers. For this study, no personal identifiable data will be stored on the device or on the servers used by the device.~The volume readings collected can be presented to the clinical team on a web interface. This is not presented against identifiable data, but only participant ID. However, in the current pilot, volume readings will not be reviewed by the clinical team until the point of data analysis, after the study period."
223823497|NCT05193084|DEVICE|Connected weighing scales|"The connected weighing scales are Xiaomi Smart Scales (CE marked, manufactured by Anhui Huami Informeyshn Technologies).~The participant will be instructed to use those scales for the period of the study, as often as directed by their healthcare professional(s) (the fact that a participant has not used scales regularly in the past is not an exclusion criteria). The weighing scales display weight so that the participants can record the weight in their own heart failure records (paper weight diary).~The study team will check the patient's paper weight diary in case they choose to use another set of scales.~The participant will be able to see the weight readings on the weighing scales during the study.~The scales will record patient weight as well as the date and time of the measurements."
223823498|NCT04178512|DRUG|Drug:dexamethasone in group Dexamethasone,fentanyl in group Fentanyl,normal saline 0.9%in group Control|prevention of shivering after spinal anesthesia in patients undergoing trans urethral prostatectomy through injection of spinal additives
223823499|NCT06414564|DEVICE|Medtronic 780G insulin pump|Subjects on insulin infusion by 780G AHCL system
223823500|NCT03855163|BEHAVIORAL|Inspection visits|Normative intervention aimed at enforcing compliance with legal occupational health and safety requirements
223823501|NCT03855163|BEHAVIORAL|Guidance workshops|Pedagogical intervention aimed to motivate managers and employee representatives to comply with legal occupational health and safety requirements
223823502|NCT03855163|BEHAVIORAL|Online risk assessment tool|Pedagogical intervention aimed to motivate managers and employee representatives to comply with legal occupational health and safety requirements
223823503|NCT02959671|DEVICE|Lower Anterior EXD-952 Self-ligating Brackets|Placement of EXD-952 Self-ligating Brackets on mandibular incisors
223823504|NCT00054964|DRUG|Albuterol HFA-BOI|Albuterol HFA breath operated inhaler, 90 mcg/sprau
223823505|NCT00054964|DRUG|Albuterol HFA-MDI|Albuterol HFA multi-dose inhaler
223835551|NCT01219621|PROCEDURE|Symphony Dual Chamber Rate Responsive Device|Echocardiography ANP/BNP measurements
223835552|NCT01448837|DRUG|Bimatoprost/Timolol, 24-hour intraocular pressure monitoring|Administered once in the evening
223823506|NCT03366220|DRUG|Plasma|Initial resuscitation with plasma will be 10 mL/kg (700 mL in a typical 70 kg adult). Traditional doses of plasma, when used to correct coagulopathy range from 10-15 mL/kg.23 The plasma will be administered at a rate of 2-3 mL/kg/hr (140-210 mL/hr in a typical 70 kg adult). A research physician will be at bedside to follow patient resuscitation. Plasma administration may be terminated before the entire dose is administered if patients show clinical improvement. After the initial dose of plasma has been given, subsequent resuscitation will follow usual care using balanced crystalloids.
223823507|NCT03366220|DRUG|Balanced crystalloids|Usual care using balanced crystalloids (Iso-Lyte or Plasma-Lyte) only will follow Surviving Sepsis Campaign guidelines. Controls will receive 30 mL/kg (2100 mL in a typical 70 kg adult) of crystalloids within the first 3 hours. Subsequent resuscitation with balanced crystalloids will be titrated to the endpoints of resuscitation.
223823508|NCT03020329|DRUG|Paclitaxel liposome|"Patients receive paclitaxel liposome(135mg/m2 on day 1),cisplatin (75mg/m2 Separate injection on day 1 to 3) and 5-fluorouracil (3750mg/m2 CIV 120h ) every three weeks for three cycl es before the radiotherapy.~Patients receive radical radiotherapy and cisplatin (100mg/m2) every three weeks for three cycles during radiotherapy.~Radical radiotherapy:Intensive modulate radiotherapy (IMRT),total dose for nasopharynx and nodule of neck:60Gy/30F,2.0Gy/daily."
223823509|NCT03020329|DRUG|Cisplatin|Cisplatin (75mg/m2 Separate injection on day 1 to 3) with Paclitaxel liposome and 5-fu every three weeks for three cycles before the radiotherapy.Cisplatin(100mg/m2) every three weeks for three cycles during radiotherapy.
223823510|NCT03020329|DRUG|5-fu|Fluorouracil (3750mg/m2 CIV 120h)with Paclitaxel liposomeand cisplatin every three weeks for three cycles before the radiotherapy.
223823511|NCT03020329|RADIATION|Radical radiotherapy|Intensive modulate radiotherapy (IMRT) will be implement,total dose for nasopharynx and nodule of neck:60Gy(Gray)/30F(Fraction),2.0Gy/daily,5 days/week.
223823512|NCT06131996|OTHER|Volar supported splint|participants used volar supported splint during sleep for 4 weeks. Exercise was performed at home for a total of 12 sessions, three sessions per week.
223823513|NCT06131996|OTHER|elastic splint|participants used velastic splint during sleep for 4 weeks. Exercise was performed at home for a total of 12 sessions, three sessions per week
223823514|NCT03462706|PROCEDURE|Cold Snare|Subjects randomized to Cold Snare Intervention will have any polyps sized 6mm to 15mm removed using cold snare techniques (no electrocautery, no submucosal injection.)
223823515|NCT03462706|PROCEDURE|Hot Snare|Subjects randomized to Hot Snare Intervention will have any polyps sized 6mm to 15mm removed using hot snare techniques (with electrocautery, no submucosal injection.)
223823516|NCT03462706|PROCEDURE|Cold EMR|Subjects randomized to Cold EMR will have any polyps sized 6mm to 15mm removed using cold EMR techniques (no electrocautery, with submucosal injection.)
223823517|NCT03462706|PROCEDURE|Hot EMR|Subjects randomized to Hot EMR will have any polyps sized 6mm to 15mm removed using hot EMR techniques (with electrocautery, with submucosal injection.)
223823518|NCT04805463|OTHER|Control group|The group that did not undergo any procedure after gingivectomy and gingivoplasty operation. Periodontal pack (Coe-Pak, GC America Inc, IL, USA) was applied to the wound area.
223823519|NCT04805463|OTHER|PRF group|The group in which PRF is applied to the wound area after gingivectomy and gingivoplasty operation. Periodontal pack (Coe-Pak, GC America Inc, IL, USA)was applied over the PRF.
223823520|NCT04805463|OTHER|CGF group|The group in which CGF is applied to the wound area after gingivectomy and gingivoplasty operation. Periodontal pack (Coe-Pak, GC America Inc, IL, USA) was applied over the CGF.
223823521|NCT04805463|OTHER|AFG group|The group in which AFG is applied to the wound area after gingivectomy and gingivoplasty operation. Periodontal pack (Coe-Pak, GC America Inc, IL, USA) was applied over the AFG.
223823522|NCT05568836|DIETARY_SUPPLEMENT|vitamin D supplementation|Intervention group will receive a single IM injection of 300000 IU vitamin D
223823523|NCT05568836|OTHER|control|control group will receive nothing
223823524|NCT02617264|PROCEDURE|SPOT|Injecting the ink (SPOT) to the axillary lymph node prior the surgery. During the surgery the lymph nodes will be tasted to diagnose the marked node.
223823525|NCT00749216|DRUG|Solanezumab|
223823526|NCT02468609|RADIATION|Ultralow-Dose-CT|Patients undergoing thoracic normal dose-CT with undergo an additional Ultralow-Dose-CT
223823527|NCT05808335|DRUG|Standard of care|"The following medications listed are allowed to be administered during the course of the clinical study.~1. Tenofovir (including salt-free or salt-modifying drugs)~2. Entecavir (including salt-free or salt-modifying drugs)"
223823528|NCT03729102|BIOLOGICAL|Blood drawn after rabies vaccine booster vaccination|All participants would be given one dose of rabies vaccine and monitor the immunological cells i.e., regulatory T cell, regulatory B cell, T follicular helper cells, cytokines i.e., IL-10, TGF-Beta, and Rabies neutralizing antibody titers, before and after the booster injection
223823529|NCT03499015|PROCEDURE|Balloon Eustachian Tuboplasty (BET)|A balloon catheter is used to dilate the cartilage part of the eustachian tube and is inserted through the nose to reach the opening of the tube, located in the nasopharynx.
223823530|NCT05904743|BIOLOGICAL|Afrezza|Pharmaceutical form: powder Route of administration: inhalation
223823531|NCT05904743|BIOLOGICAL|insulin degludec|Pharmaceutical form: solution for injection Route of administration: subcutaneous
223823532|NCT05904743|BIOLOGICAL|Rapid-acting Insulin Analog|Pharmaceutical form: clear and colorless solution for injection Route of administration: subcutaneous
223823533|NCT05904743|BIOLOGICAL|Basal Insulin|Pharmaceutical form: clear and colorless solution for injection Route of administration: subcutaneous
223823534|NCT05121623|OTHER|Questionnaire|Online auto-administered Questionnaire
223823535|NCT02231229|OTHER|PCR-based strategy|Treatment based on the results of detection of resistance to isoniazid and rifampicin using PCR (GenoType ® Mycobacterium Tuberculosis Drug Resistance (MTBDR)plus 2.0) in a smear positive patient with pulmonary tuberculosis: initiation of a 3 drug combination (isoniazid (H / INH); rifampicin (R /RIF); pyrazinamide (Z / PZA)) if no resistance is detected and treatment based on suspected resistance in case of INH and/or RIF resistant strain.
223835553|NCT01448837|DRUG|Latanoprost, 24-hour intraocular pressure monitoring|assessment of 24-hour efficacy for the two drugs after 3 months of chronic dosing
223823536|NCT02231229|DRUG|conventional therapy|Initiation of a standard 4 drug combination (isoniazid (H / INH); rifampicin (R /RIF); pyrazinamide (Z / PZA); ethambutol (EMB or E)) until the results of DST are available.
223823537|NCT05081505|BEHAVIORAL|Structural exercise course|12-week structured exercise class, team competition, social support, and incentive strategy
223823538|NCT05081505|BEHAVIORAL|Autonomous group class|12-week autonomous group class, team competition, social support, and incentive strategy
223823539|NCT05520502|OTHER|PILATES EXERCISE|12 WEEKS, 3 SESSIONS A WEEK 36 SESSIONS IN A TOTAL OF PLANNED MAT 1 PILATES EXERCISES
223823540|NCT03816241|OTHER|Frame|Vignette is framed in a way that nudges participant to leave a legacy
223823541|NCT03816241|OTHER|Norms|Vignette informs the participant that most people choose an option to try to nudge participant into choosing that option as well
223823542|NCT03842462|OTHER|nCPAP|infants receive primary non-invasive respiratory support by mean of nCPAP
223823543|NCT03842462|OTHER|NIPPV|infants receive primary non-invasive respiratory support by mean of NIPPV
223823544|NCT03842462|OTHER|NHFOV|infants receive primary non-invasive respiratory support by mean of NHFOV
223823545|NCT00708721|DRUG|Clofarabine|Clofarabine is a rationally designed, second generation purine nucleoside analogue. Clofarabine was designed as a hybrid molecule to overcome the limitations and incorporate the best qualities of both fludarabine (F-ara-A) and cladribine (2-CdA, CdA) both of which are currently approved by various regulatory authorities for treatment of hematologic malignancies.
223823546|NCT05730738|DRUG|Dalfampridine ER, 10 Mg Oral Tablet, Extended Release|The only approved treatment for impaired ambulation in MS is Dalfampridine (also known as fampridine, 4-aminopyridine, 4-AP). Fampridine penetrates the blood-brain barrier and improves impaired axonal conduction by selectively blocking potassium channels
223823547|NCT05730738|DRUG|Placebo|placebo similar to Dalfampridine capsule
223823548|NCT01033292|DRUG|BSI-201|IV infusion, 5.6 mg/kg
223823549|NCT02896816|OTHER|Surface EMG, MRI and PET Scan|It will consist of two assessment sessions; one where muscle activity of the arms as well as movement characteristics will be assessed during a reaching task; and another where muscle activity of the legs and movement characteristics will be assessed while walking on a treadmill. Clinical evaluations will also be performed. In addition, individuals with Parkinson's disease will undergo brain scans at Massachusetts General Hospital to examine whether there are any relationships between muscle activity and brain function.
223823550|NCT02896816|OTHER|Surface EMG|It will consist of two assessment sessions; one where muscle activity of the arms as well as movement characteristics will be assessed during a reaching task; and another where muscle activity of the legs and movement characteristics will be assessed while walking on a treadmill. Clinical evaluations will also be performed.
223823551|NCT01464008|DRUG|Pegylated interferon alfa-2a and ribavirin|all patients were given peginterferon alfa-2a (40KD) (Pegasys®; Roche, Basel, Switzerland) 135 or 180 µg by subcutaneous injection once weekly, and received twice daily oral ribavirin at a target total daily dose of 13 mg/kg/day. .
223835554|NCT01438229|DEVICE|St. Jude Medical renal artery ablation system: RF ablation generator (IBI 1500T11.5) and Renal artery ablation catheter (DS3D001, DS3D002)|Catheter-based RF ablation in renal artery
223835555|NCT00209027|OTHER|fMRI|fMRI scanning during behavioral reward task
223823552|NCT03729921|PROCEDURE|gastric variceal ligation|The highest point of the variceal vein was used as the primary ligation site. If the input vein was not obvious, the edge of the variceal vein was ligated. The variceal veins were ligated with a 6-ring ligation device, and more than 18 rings rubber bands could be applied in one session. GVL was performed regularly until varices were obliterated or reduced to residual small varices, which could not be ligated. The residual small varices was treated by cyanoacrylate injection.
223823553|NCT03729921|PROCEDURE|gastric variceal obturation|Gastric varices were uniformly treated via the sandwich technique, which starts with an injection of lauromacrogol, followed by N-butyl cyanoacrylate, then finished with flush of lauromacrogol. The number of injection sites and volume of lauromacrogol and cyanoacrylate used, directly correlated with the size of the varix. Multiple injection sites were chosen in attempt to obliterate the varix or varices in one session. Volume of lauromacrogol used ranged from 2-10ml, while that of cyanoacrylate ranged from 0.5-2ml, per injection site.
223823554|NCT01392222|BEHAVIORAL|Focus groups|"The focus groups will cover the following issues~* Perceptions of thyroid cancer and disease status~* Sources of information used in papillary microcarcinoma treatment decision-making~* Treatment decision-making processes and influential factors~* Perceived barriers to active surveillance to treat papillary microcarcinoma (for the immediate surgery sub-sample)~* Perceived facilitators to active surveillance to treat papillary microcarcinoma (for the non-immediate surgery sub-sample)~* Views about how to improve acceptability of active surveillance as a disease management option"
223823555|NCT01392222|BEHAVIORAL|Focus groups|"The focus groups will cover the following issues:~* Perceptions of thyroid cancer and disease status~* Sources of information used in papillary microcarcinoma treatment decision-making~* Treatment decision-making processes and influential factors~* Perceived barriers to active surveillance to treat papillary microcarcinoma (for the immediate surgery sub-sample)~* Perceived facilitators to active surveillance to treat papillary microcarcinoma (for the non-immediate surgery sub-sample)~* Views about how to improve acceptability of active surveillance as a disease management option"
223823556|NCT06183086|DEVICE|Linovera®|Apply Linovera® at least twice a day (recommended every 12 h) on the pressure ulcer/injury until Category-1 pressure ulcer/injury is healed or until discharge.
223823557|NCT00847821|DRUG|Bazedoxifene 10 mg/CE 0.625 mg|No dose taken during this study; however, this intervention was taken while study 3115A1-303 was ongoing. In the 3115A1-303 study, test article was supplied as bazedoxifene/CE tablets in capsules. The dosage was one capsule orally, once daily, at approximately the same time each day on a continuous regiment for 2 years, or until early discontinuation from the study.
223823558|NCT00847821|DRUG|Bazedoxifene 20 mg/CE 0.625 mg|No dose taken during this study; however, this intervention was taken while study 3115A1-303 was ongoing. In the 3115A1-303 study, test article was supplied as bazedoxifene/CE tablets in capsules. The dosage was one capsule orally, once daily, at approximately the same time each day on a continuous regiment for 2 years, or until early discontinuation from the study.
223823559|NCT00847821|DRUG|Bazedoxifene 40 mg/CE 0.625 mg|No dose taken during this study; however, this intervention was taken while study 3115A1-303 was ongoing. In the 3115A1-303 study, test article was supplied as bazedoxifene/CE tablets in capsules. The dosage was one capsule orally, once daily, at approximately the same time each day on a continuous regiment for 2 years, or until early discontinuation from the study.
223823560|NCT00847821|DRUG|Bazedoxifene 10 mg/CE 0.45 mg|No dose taken during this study; however, this intervention was taken while study 3115A1-303 was ongoing. In the 3115A1-303 study, test article was supplied as bazedoxifene/CE tablets in capsules. The dosage was one capsule orally, once daily, at approximately the same time each day on a continuous regiment for 2 years, or until early discontinuation from the study.
223823561|NCT00847821|DRUG|Bazedoxifene 20 mg/CE 0.45 mg|No dose taken during this study; however, this intervention was taken while study 3115A1-303 was ongoing. In the 3115A1-303 study, test article was supplied as bazedoxifene/CE tablets in capsules. The dosage was one capsule orally, once daily, at approximately the same time each day on a continuous regiment for 2 years, or until early discontinuation from the study.
223823562|NCT00847821|DRUG|Bazedoxifene 40 mg/CE 0.45 mg|No dose taken during this study; however, this intervention was taken while study 3115A1-303 was ongoing. In the 3115A1-303 study, test article was supplied as bazedoxifene/CE tablets in capsules. The dosage was one capsule orally, once daily, at approximately the same time each day on a continuous regiment for 2 years, or until early discontinuation from the study.
223835556|NCT00209027|DRUG|Aripiprazole|30 mg by mouth once daily
223835557|NCT01643395|OTHER|vertebroplasty|Vertebroplasty consists in the injection of cement (PMMA) in the damaged vertebral body to prevent further collapse
223823563|NCT00847821|DRUG|Raloxifene 60 mg|No dose taken during this study; however, this intervention was taken while study 3115A1-303 was ongoing. In the 3115A1-303 study, test article was supplied as raloxifene tablets in capsules. The dosage was one capsule orally, once daily, at approximately the same time each day on a continuous regiment for 2 years, or until early discontinuation from the study.
223823564|NCT00847821|DRUG|Placebo|No dose taken during this study; however, this intervention was taken while study 3115A1-303 was ongoing. In the 3115A1-303 study, test article was supplied as placebo capsules. The dosage was one capsule orally, once daily, at approximately the same time each day on a continuous regiment for 2 years, or until early discontinuation from the study.
223823565|NCT04354766|OTHER|Blood sample|This study will require a blood sample (4 ACD tubes, 20 ml) at one time.
223823566|NCT04068363|OTHER|non interventional|non interventional study
223823567|NCT04105972|DRUG|ELX/TEZ/IVA|FDC tablet for oral administration.
223823568|NCT04105972|DRUG|TEZ/IVA|Fixed-dose combination (FDC) tablet for oral administration.
223823569|NCT04105972|DRUG|IVA|Mono tablet for oral administration.
223823570|NCT02803060|DRUG|Coppertone (BAY987516)|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.(Formaulation number- SR15-62 -Z15-038).
223823571|NCT04380298|DRUG|Ketorolac|30ml of local infiltration solution containing 60mg ropivacaine
223823572|NCT04380298|DRUG|Ropivacaine|30ml of local infiltration solution containing 6mg ketorolac
223823573|NCT04380298|DRUG|Epinephrine|30ml of local infiltration solution containing 0.1mg epinephrine
223823574|NCT02341287|DEVICE|Warming hydrogel glove|Subjects wore the warming hydrogel glove in either the first or second two-week period.
223823575|NCT02341287|DEVICE|Non-thermal glove|Subjects wore the non-thermal glove in either the first or second two-week period.
223823576|NCT02687412|PROCEDURE|pre-operative assessment, counseling and education|pre-operative assessment, counseling and FT management education
223823577|NCT02687412|PROCEDURE|Preoperative nutritional drink up to 4 h prior to surgery|Preoperative nutritional drink up to 4 h prior to surgery mechanical bowl preparation should not be used
223823578|NCT02687412|PROCEDURE|bowel preparation|patients are not received mechanical bowel preparation, only oral intestinal cleaner 12 h pre-operation can be accepted, but no need of liquid stool
223823579|NCT02687412|PROCEDURE|preoperative treatment with carbohydrates|preoperative treatment with carbohydrates (patients without diabetes).
223823580|NCT02687412|PROCEDURE|fast solid|fast solid food before 6 h and liquid food Intake of clear fluids 2 h before anaesthesia;
223823581|NCT02687412|PROCEDURE|avoiding hypothermia|avoiding hypothermia, keeping the intra-operative lowtemperature at 36 ±0.5 degree centigrade; antiemetics at end of anaesthesia.
223823582|NCT02687412|PROCEDURE|Postoperative glycaemic control|Postoperative glycaemic control;
223823583|NCT02687412|PROCEDURE|postoperative nausea and vomiting (PONV) control;|
223823584|NCT02687412|PROCEDURE|early postoperative diet|early postoperative diet(3-6 h after surgery, patients resumed a liquid diet, 12 h after surgery patients began to take solid diet).
223823585|NCT02687412|PROCEDURE|pre-operative fasting at least 8h|
223823586|NCT02687412|PROCEDURE|bowel preparation for traditional surgery|Oral bowel preparations or mechanical bowl until liquid stool
223823587|NCT02687412|PROCEDURE|began to take solid diet after anal exhaust|6 h after surgery, patients resumed a liquid diet, patients began to take solid diet after anal exhaust
223823588|NCT03711864|BIOLOGICAL|IM21 CAR-T cells|fludarabine and cyclophosphamide Two days before cell infusion,all patients will be treated with fludarabine and cyclophosphamide for 3 days
223823589|NCT00553202|BIOLOGICAL|anti-thymocyte globulin|Given IV
223823590|NCT00553202|DRUG|busulfan|Given IV
223823591|NCT00553202|DRUG|cyclophosphamide|Given IV
223823592|NCT00553202|DRUG|cyclosporine|Given IV or orally
223823593|NCT00553202|DRUG|methotrexate|Given IV
223823594|NCT00553202|DRUG|methylprednisolone|Given IV
223823595|NCT00553202|DRUG|tacrolimus|Given IV
223823596|NCT00553202|OTHER|laboratory biomarker analysis|Correlative studies
223823597|NCT00553202|OTHER|pharmacological study|Correlative studies
223823598|NCT00553202|PROCEDURE|allogeneic bone marrow transplantation|allogeneic bone marrow transplantation
223823599|NCT00553202|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Undergo allogeneic hematopoietic SCT
223823600|NCT01097395|DRUG|ribavirin|Randomization to standard weight based ribavirin dosing (1000 or 1200 mg daily) or concentration-guided dosing based on first dose AUC0-12
223823601|NCT03963323|DIETARY_SUPPLEMENT|Glucosamine Sulfate/Chondroitin Sulfate Tablet|Given PO
223823602|NCT03963323|OTHER|Placebo|Given PO
223823603|NCT02040272|PROCEDURE|(Extended) pleurectomy decortication|
223823604|NCT05284305|OTHER|Pregnancy|DT with a history of concomitant or subsequent pregnancy.
223823605|NCT01643941|BIOLOGICAL|SA4Ag vaccine low dose|Subjects receive 1 intramuscular injection (0.5 mL) of the low dose level of the SA4Ag vaccine.
223823606|NCT01643941|PROCEDURE|Blood draw|Blood for HIV, HBV and HCV screening will be collected prior to enrollment for Phase 1 subjects. Blood for hematology, coagulation and blood chemistry will be collected at a minimum of 3 timepoints from Phase 1 subjects. Blood for immunogenicity will be collected from all subjects at various timepoints.
223823607|NCT01643941|PROCEDURE|Colonization swab sample|Colonization swabs will be collected from all subjects at various timepoints.
223823608|NCT01643941|BIOLOGICAL|SA4Ag vaccine mid dose|Subjects receive 1 intramuscular injection (0.5 mL) of the mid dose level of the SA4Ag vaccine.
223823609|NCT01643941|PROCEDURE|Blood draw|Blood for HIV, HBV and HCV screening will be collected prior to enrollment for Phase 1 subjects. Blood for hematology, coagulation and blood chemistry will be collected at a minimum of 3 timepoints from Phase 1 subjects. Blood for immunogenicity will be collected from all subjects at various timepoints.
223823610|NCT01643941|PROCEDURE|Colonization swab sample|Colonization swabs will be collected from all subjects at various timepoints.
223823611|NCT01643941|BIOLOGICAL|SA4Ag vaccine high dose|Subjects receive 1 intramuscular injection (0.5 mL) of the high dose level of the SA4Ag vaccine.
223823612|NCT01643941|PROCEDURE|Blood draw|Blood for HIV, HBV and HCV screening will be collected prior to enrollment for Phase 1 subjects. Blood for hematology, coagulation and blood chemistry will be collected at a minimum of 3 timepoints from Phase 1 subjects. Blood for immunogenicity will be collected from all subjects at various timepoints.
223823613|NCT01643941|PROCEDURE|Colonization swab sample|Colonization swabs will be collected from all subjects at various timepoints.
223823614|NCT01643941|BIOLOGICAL|SA3Ag vaccine|Phase 2 only: Subjects receive 1 intramuscular injection (0.5 mL) of the mid dose level of the SA3Ag vaccine.
223823615|NCT01643941|PROCEDURE|Blood sample|Blood for immunogenicity will be collected from all subjects at various timepoints.
223823616|NCT01643941|PROCEDURE|Colonization swab sample|Colonization swabs will be collected from all subjects at various timepoints.
223823617|NCT01643941|BIOLOGICAL|Placebo|Subjects receive one intramuscular injection (0.5 mL) of placebo which contains excipients of the vaccine formulation minus the active ingredients.
223823618|NCT01643941|PROCEDURE|Blood draw|Blood for HIV, HBV and HCV screening will be collected prior to enrollment for Phase 1 subjects. Blood for hematology, coagulation and blood chemistry will be collected at a minimum of 3 timepoints from Phase 1 subjects. Blood for immunogenicity will be collected from all subjects at various timepoints.
223823619|NCT01643941|PROCEDURE|Colonization swab samples|Colonization swabs will be collected from all subjects at various timepoints.
223823620|NCT03906305|OTHER|Dry needling in a myofascial trigger points area plus physical therapy based on Bobath concept|"Other: Dry Needling Participants will receive dry needling application over a myofascial trigger point by an experienced physical therapist with clinical experience in neurological patients, that will be inserted into taut bands of the following shoulder spastic muscles (when a trigger point was present): upper trapezius, supraspinatus, infraspinatus and deltoid anterior.~Other: Physical Therapy~Participants will receive physical therapy treatment based on the modulating Bobath technique. This technique will be applied using the general parameters, carrying out similar action protocols with every patient, based on the aim of normalizing upper limb muscle tone.~Device: stainless steel needles (0.3mm x 50mm)"
223823621|NCT03906305|OTHER|Dry needling in a non myofascial trigger points area plus physical therapy based on Bobath concept|"Other: Dry Needling Participants will receive dry needling application carried out over a non trigger point area by an experienced physical therapist with clinical experience in neurological patients, that will be inserted into a non trigger point spastic muscle of the shoulder area: upper trapezius, supraspinatus, infraspinatus and deltoid anterior.~Other: Physical Therapy Participants will receive physical therapy treatment based on the modulating Bobath technique. This technique will be applied using the general parameters, carrying out similar action protocols with every patient, based on the aim of normalizing upper limb muscle tone.~Device: stainless steel needles (0.3mm x 50mm)"
223823622|NCT01401413|DRUG|ramelteon|8 mg nightly for 30 nights
223823623|NCT01401413|DRUG|placebo|placebo control i pill nightly for 30 nights
223823624|NCT04905108|DRUG|Riboflavin|Administration of riboflavin one drop every 2 minutes during UVA exposure
223823625|NCT04905108|DRUG|Riboflavin|Administration of riboflavin one drop every 10 minutes during UVA exposure
223823626|NCT03785457|OTHER|Repetitive Trunk Extension|Subjects will be asked to perform standing repetitive trunk extension at a rate of 10 per 45 seconds (Figure 2), repeated five times with 15-second rest breaks.
223823627|NCT03785457|OTHER|Sustained Trunk Extension|Subjects will be asked to perform standing sustained trunk extension for 5 x 45 seconds with 15-second rest breaks.
223823628|NCT01176604|RADIATION|Yttrium Y 90 Glass Microspheres|Given via catheter
223823629|NCT05208853|BIOLOGICAL|Anti CD30 CAR-T Cell Injection|"After enrollment, subjects complete the apheresis, then complete the lymphodepletion, and then receive the dose escalation test: 1.5×10\^7 cells，1.5×10\^8 cells，5× 10\^8 cells.~Drug: Fludarabine~Fludarabine is used for lymphodepletion.~Drug: Cyclophosphamide~Cyclophosphamide is used for lymphodepletion"
223823630|NCT05486429|COMBINATION_PRODUCT|Abdominal ultrasound and lipid profile|"All patients will be subjected to: -~* Complete history taking with stress on:~  * Age, sex, comorbid conditions (diabetes, hypertension, ischemic heart disease)~ * History of intake of lipid lowering drugs.~* Thorough clinical examination:~General examination, vital sign, height, weight, body mass index. Abdominal examination (hepatomegaly, splenomegaly, ascites)~* Laboratory Investigation:~  1.Lipid profile (total cholesterol, triglyceride, HDL, LDL, VLDL (~  .2Liver function tests (ALT, AST, Albumin, Bilirubin, PT, PC, INR) 3.Complete blood picture. 4.Serology for HBV, HCV. 5.Serum creatinine. 6.Fasting and postprandial blood sugar.~* Radiological Investigation:~  1.Abdominal ultrasound.~* FIB - 4 it combines platelets count, ALI, AST and age.~* AST/Platelets ratio index is calculated as (AST/upper limit of normal range) /Platelets count (10\^9/L) ×100."
223823631|NCT00764192|PROCEDURE|blood sample|blood sample before and after a single HD
223823632|NCT00764192|PROCEDURE|Flow-mediated dilation (FMD) before and after a single HD|measuring of the flow-mediated dilation using high-resolution ultrasound
223823633|NCT04981132|BEHAVIORAL|Pain Neuroscience education + Progressive therapeutic exercise training|The education group will have a comprehensive patient education which includes; description, transmission, representation of pain, central sensitization, neuroplasticity, its relation to body systems, psychosocial and emotional factors affecting pain, pain behavior, and lifestyle changes to cope with pain, etc. Plus, the group will have supervised progressive therapeutic exercises via the telerehabilitation method.
223823634|NCT04981132|BEHAVIORAL|Progressive therapeutic exercise training|The exercise group will have supervised progressive therapeutic exercises via the telerehabilitation method.
223823635|NCT03678259|DRUG|124I-p5+14 Injection|124I-p5+14 Injection which is a formulation of a synthetic, all natural, 45 amino acid peptide (MW = 4766.4) with a net +12 positive charge
223823636|NCT02593305|DIETARY_SUPPLEMENT|Super Beets|Nitrate rich beetroot powder (10g/day) for 4 weeks
223823637|NCT02593305|DIETARY_SUPPLEMENT|Super Beets Placebo|Nitrate deficient beetroot powder (10g/day) for 4 weeks
223823638|NCT01190215|BIOLOGICAL|FluarixTM|One Intramuscular injection
223823639|NCT01190215|BIOLOGICAL|HavrixTM Junior (in subjects of 15 years old or below) or HavrixTM (in subjects above 15 years old)|Two Intramuscular injections
223823640|NCT05883917|PROCEDURE|robot assisted gait training|Gait training using SUBAR® (Cretem, Korea) proceeded by adjusting parameters (gait speed, step length, and degree of knee flexion) according to the patient's leg length and gait function. The parameters were set to the maximum levels tolerated by the patient. The patients underwent 30 min of robot-assisted training using SUBAR® with 30 min of conventional physiotherapy, 5 days a week for 12 weeks.
223823641|NCT01556815|PROCEDURE|Transarterial Chemoembolization (TACE)|Procedure:TACE TACE will be carried out with an emulsion of 50mg doxorubicin with lipiodol in a total volume of 10-20 mL; additional embolisation will be carried out with gelatin sponge particles. TACE will be repeated every 4 weeks for 2 cycles; additional cycles will be offered if clinically indicated .
223823642|NCT01556815|OTHER|Sorafenib in combination with TACE|"Drug: Sorafenib All patients will receive Sorafenib (800 mg/day) p.o. beginning one week after the first TACE and every day thereafter until patient death or premature withdrawal from study.~Procedure: TACE~TACE will be carried out with an emulsion of 50mg doxorubicin with lipiodol in a total volume of 10-20 mL; additional embolisation will be carried out with gelatin sponge particles. TACE will be repeated every 4 weeks for 2 cycles; additional cycles will be offered if clinically indicated ."
223823643|NCT04561882|DEVICE|Transcatheter exclusion of atrial septal aneurysm|"Through transseptal perforation, transcatheter reconstruction of atrial septum was achieved with PFO occluder to cover the whole ASA.~Device: Cardi-O-Fix™ patent foramen ovale occluder (Starway Medical Technology, Inc. Beijing, CN)"
223823644|NCT02621736|OTHER|blood sampling|At 4 visits capillary blood sampling for copeptin measurement will be performed with each child.
223823645|NCT05402540|OTHER|STRAIN COUNTER STRAIN GROUP|"Strain Counterstrain Technique in combination with conventional physiotherapy (Hot pack, Codmans exercises, active assisted exercises, Pendulum exercises, Finger Ladder Exercise, Maitland mobilization of shoulder joint.~Therapist palpate surrounding and opposing tissues to locate trigger point by using one or two finger pads to monitor fasciculation and MTrP.~Hold the POC (position of comfort) until fasciculation decreases significantly or ceases. Average positions hold time while pressure is 90 s to 3 min.~Release tissue or joint slowly and reassess. Each patient will receive total 6 sessions (3sessions/week) over a period of 2 weeks.~Assessment would be done on baseline and after every three sessions."
223823646|NCT05402540|OTHER|ACTIVE RELESAE TECHNIQUE GROUP|"Active Release Technique in combination with conventional physiotherapy (Hot pack, Codmans exercises, active assisted exercises, Pendulum exercises, Finger Ladder Exercise, Maitland mobilization of shoulder joint.~The targeted muscle will be palpated while the therapist will looks for localized tenderness or trigger points with referred pain elicitation.~With the thumb therapist will relieve the trigger point. In ART the particular muscle is taken from shortened to lengthened position or from lengthened to shortened position.~Duration of treatment will be 8-15 minutes. Each patient will receive total 6 sessions (3sessions/week) over a period of 2 weeks.~Assessment would be done on baseline and after every three sessions."
223823647|NCT00584701|DRUG|Risperidone|Dose will start at 0.5 mg and may be increased throughout the course of the study if no adverse events occur
223823648|NCT00365560|DRUG|tiotropium|
223823649|NCT00365560|DRUG|placebo|
223823650|NCT01161472|DRUG|4mg fesoterodine|4mg tablet once daily for 6 days
223823651|NCT01161472|DRUG|8mg fesoterodine|4mg tablet once daily for 3 days followed by 8mg tablet once daily for 3 days
223823652|NCT01161472|DRUG|alprazolam 1mg|1mg tablet once on last day of treatment period at clinic
223823653|NCT01161472|DRUG|Placebo|Placebo tablet for fesoterodine once daily for 6 days and placebo tablet for alprazolam once on last day of treatment period at clinic
223823654|NCT03659643|DIAGNOSTIC_TEST|EEG with SPR analysis|qEEG with SPR analysis was performed in group 1 during 2011-2013 and in group 2, the same procedure is performed.
223823655|NCT05039762|PROCEDURE|Extracorporeal anastomosis|Laparoscopic right hemicolectomy will be carried out. The dissection is performed laparoscopically. When the right hemicolon is sufficiently mobilized and the vessels (ileocolic pedicle, right colic pedicle and the right branch of the middle colic pedicle) are ligated, a horizontal incision in the upper right quadrant is made. Through this incision the right hemicolon is extracted, the small bowel and the transverse colon are divided using staplers. The side-to-side ileocolic anastomosis is then handsewn.
223823656|NCT05039762|PROCEDURE|Intracorporeal anastomosis|Laparoscopic right hemicolectomy will be carried out. The dissection is performed laparoscopically. The right hemicolon is mobilized and the vessels (ileocolic pedicle, right colic pedicle and the right branch of the middle colic pedicle) are ligated. The small bowel and the transverse colon are then divided using laparoscopic staplers. The side-to-side ileocolic anastomosis is formed by creating a small opening in the small bowel and the transverse colon, through which the laparoscopic stapler is used to join the bowel ends. The remaining opening is sutured laparoscopically. The specimen is retrieved through a Pfannenstiel incision.
223823657|NCT01449240|OTHER|No treatment|
223823658|NCT01996072|DRUG|EC17|
223823659|NCT01715337|OTHER|pulmonary rehabilitation|3-week rehabilitation including exercise training, breathing therapy, psychosocial support, medical treatment etc.
223823660|NCT00612222|BIOLOGICAL|autologous anti-MART-1 F5 T-cell receptor gene-engineered peripheral blood lymphocytes|ALVAC vaccine-approximately two hours prior to cell infusion, patients will receive 0.5 mL containing a target dose of 10\^7 CCID50 (with a range of approximately 10\^6,4 to 10\^7,9/mL) of the MART-1 ALVAC virus subcutaneously in each extremity (total of 4 x 10\^7 CCID50/2 mL). This will be repeated on day 14.
223823661|NCT00612222|BIOLOGICAL|ALVAC MART-1 Vaccine|ALVAC vaccine-approximately two hours prior to cell infusion, patients will receive 0.5 mL containing a target dose of 10\^7 CCID50 (with a range of approximately 10\^6,4 to 10\^7,9/mL) of the MART-1 ALVAC virus subcutaneously in each extremity (total of 4 x 10\^7 CCID50/2 mL). This will be repeated on day 14.
223823662|NCT00612222|BIOLOGICAL|aldesleukin|Aldesleukin - 720,000 IU/kg intravenous over 15 minutes every 8 hours beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum 15 doses)
223823663|NCT00612222|DRUG|cyclophosphamide|60 mg/kg day x 2 days intravenous in 250 ml dextrose 5% in water (D5W) with Mesna 15 mg/kg day x 2 days over 1 hour
223823664|NCT00612222|DRUG|fludarabine phosphate|25 mg/m\^2 day intravenous piggy back over 30 minutes for 5 days
223823665|NCT02726776|OTHER|Suspension in a harness|
223823666|NCT02726776|OTHER|Climbing|
223823667|NCT00554983|BIOLOGICAL|recombinant birch pollen allergen|subcutaneous injections (s.c.). Dosage escalation phase from 0.75 to 80 microgram maintenance dose s.c. injections of 80 microgram
223823668|NCT00554983|BIOLOGICAL|placebo|subcutaneous injections (s.c.). Dosage escalation phase from 0.75 to 80 microgram maintenance dose s.c. injections of 80 microgram
223823669|NCT03117465|OTHER|the experimental group|Stroke hemiplegia patients are randomly assigned to the experimental group (scalp acupuncture + low frequency repetitive transcranial magnetic stimulation + routine rehabilitation treatment). All patients in the day of inpatient and the fourteenth day received DTI magnetic resonance examination twice to study the change in white matter fiber microstructure.
223823670|NCT03117465|OTHER|the control group|Stroke hemiplegia patients are randomly assigned to the control group (scalp acupuncture + routine rehabilitation treatment). All patients in the day of inpatient and the fourteenth day received DTI magnetic resonance examination twice to study the change in white matter fiber microstructure.
223823671|NCT03326089|PROCEDURE|Pulmonary rehabilitation|Endurance training for 30 minutes, 3 times/week for 2 months followed by resistance training
223823672|NCT02342314|DRUG|LY3143753 (Part A)|Administered via SC injection
223823673|NCT02342314|DRUG|LY3185643 (Part B)|Administered via SC injection
223823674|NCT02342314|DRUG|Placebo (Part A and Part B)|Administered via SC injection
223823675|NCT02342314|DRUG|rGlucagon (Part B)|Administered via SC injection
223823676|NCT05640739|BEHAVIORAL|Demonstration method for the use of the Metered Dose Inhaler|The effectiveness of the training given by the demonstration method for the use of the Metered Dose Inhaler (MDI)
223823677|NCT05640739|BEHAVIORAL|Video watching method for the use of the Metered Dose Inhaler|The effectiveness of the training given by video watching method for the use of the Metered Dose Inhaler (MDI)
223823678|NCT03756454|BIOLOGICAL|Bezlotoxumab|Patients receiving Bezlotoxumab post-operatively.
223823679|NCT03756454|OTHER|Normal Saline|Placebo
223823680|NCT05920525|DEVICE|Electrical stimulation|A specific device will be used to stimulate the remodeling procedures in the alveolar bone.
223823681|NCT05920525|PROCEDURE|Traditional retraction of the front upper teeth|The retraction will be performed using coil springs which will help in moving the anterior teeth backward without the need to employ any additional procedure or device to accelerate this movement.
223823682|NCT04829435|DRUG|ALLN-346|ALLN-346 (Engineered Urate Oxidase) is an orally administered, novel urate oxidase; provided as capsules for oral administration; It is a proprietary enzyme designed to degrade urate in the intestinal tract
223823683|NCT04829435|DRUG|Placebo|Matched placebo capsules are similar in weight and appearance to the ALLN-346 capsules
223823684|NCT04291235|PROCEDURE|Airway Management Pathway|Patients in this group will receive several components that comprise airway management pathway: (1) daily spontaneous breathing trials (SBTs); (2) prompt extubation following successful extubation readiness criteria; (3) high-flow nasal oxygen for at least 24 hours following extubation.
223823685|NCT04291235|PROCEDURE|Usual Care|Patients in this group will be treated according to usual care, which may include extubation or tracheostomy timed according to treating physicians' discretion.
223823686|NCT00768430|DRUG|Ketamine|Single dose .5 mg/kg IV (in the vein) infused over 40 minutes
223823687|NCT00768430|DRUG|Midazolam|single dose 0.045 mg/kg IV infused over 40 minutes
223823688|NCT03054688|DEVICE|Somnotouch NIBP|Somnotouch NIBP in addition to standard blood pressure measurement
223823689|NCT02459184|OTHER|Income Security Health Promotion|"The ISHP will work to improve the income security of participants within this study. To that end, her activities include:~* Providing one-to-one case management support and ongoing follow-up to diverse low-income patients and families regarding their income security.~* Developing and implementing targeted information self-help sessions, such as; banking basics, income tax submissions, and social service forms, for the target population~* Developing and maintaining up-to-date detailed knowledge of financial issues and financial services affecting low-income people, and applying this knowledge in his/her work.~* Assisting individual low-income patients with income security-focused interventions, including access to tax benefits, applications for income security programs such as social assistance and seniors and child benefits, and navigation of disability support programs."
223823690|NCT03118375|DEVICE|super-power BAHA processor|The super-power BAHA processor will be provided for use at the study visit only to run different types of hearing tests, speech understanding tests in quiet, and speech understanding tests in noise. The same tests will be performed with the use of the subject's current BAHA processor for comparison.
223823691|NCT05428904|OTHER|Virtual Reality Simulation|Virtual reality applications are a type of three-dimensional computer-based simulation that gives a sense of being anywhere and provides various data to the sense organs for this. However, virtual reality applications are a simulation model that creates a sense of reality for the participants and allows mutual communication with a computer-based dynamic environment.
223823692|NCT05751538|OTHER|No intervention|No intervention
223823693|NCT01983137|DRUG|Targinact® (oxycodone/naloxone)|
223823694|NCT02734108|DEVICE|Transcranial direct current stimulation|Anodal transcranial direct current stimulation over the dorsolateral prefrontal cortex
223823695|NCT04042285|DEVICE|Extracorporeal shockwave therapy in addition to standard care|Extracorporeal shockwave therapy will be given at 120 pulses/cm2, penetration 5mm at a dose of 0.1mJ/mm2 at 5 pulses/second. Participants will receive 3 sessions of shockwave therapy in a 7-day period. Standard care as per the NICE and IWGDF guidelines.
223823696|NCT00954954|DEVICE|Standard PS RP-MB (P.F.C Sigma Rotating Platform knee)|Comparison of different types of knee prosthesis
223823697|NCT00954954|DEVICE|High-flexion PS RP-MB (P.F.C Sigma Rotating Platform Flex)|Comparison of different types of knee prosthesis
223823698|NCT01653808|DEVICE|Elisio-210H|comparison of efficacy and biocompatibility of Elisio-210H dialyzer between conventional hemodialysis and on line hemodiafiltration
223823699|NCT01653808|PROCEDURE|conventional hemodialysis|comparison of conventional hemodialysis with on line hemodiafiltration using Elisio-210H dialyzer
223823700|NCT01653808|PROCEDURE|on line hemodiafiltration|comparison of on line hemodiafiltration with conventional hemodialysis using Elisio-210H dialyzer
223823701|NCT01030978|BEHAVIORAL|Bright Bodies Healthy Lifestyle Program|Subjects attend program with a caregiver or parent twice per week for 6 mos. Exercise is 2x/wk, behavior mod/nutrition 1 x/wk, and parent class 1 x/wk. Smart Moves curriculum is utilized for nutrition and behavior mod.
223823702|NCT01030978|BEHAVIORAL|Control|Subjects will be given basic instruction by clinical provider and goals will be followed up every 3 months.
223823703|NCT02128256|DEVICE|Cerament G|
223823704|NCT00525135|DRUG|Valproic Acid|"OUTLINE: This is a pilot study.~Patients receive valproic acid daily for 16 weeks. Dose increases on Days 4 and 8; dose remains the same for weeks 2-10. All patients will undergo a Thyrogen® (thyrotropin alfa for injection) RAI scan at entry to the study and after completion of 10 weeks of valproic acid treatment.~Quality of life is assessed at the end of every week through a study diary.~Patients are followed at 1, 2, 4, 6, 8, 10, 12, 14, 16, and 17 (Schedule 1) weeks. Patients return for follow-up at 3, 6, and 12 months."
223823705|NCT05192850|DRUG|Metformin use|As an observational study, this is past exposure to metformin that occurred during the study period
223823706|NCT01052402|BIOLOGICAL|H5N1 Influenza Vaccine (Whole Virion, Vero Cell-Derived, Inactivated), non-adjuvanted formulation|Two vaccinations, 21 days apart, followed by a heterologous booster vaccination on Day 360
223823707|NCT01001481|OTHER|Risk status for medication adherence|Examination of risk status for medication adherence in a cohort of Australian patients diagnosed with schizophrenia
223823708|NCT04095143|DIAGNOSTIC_TEST|Portal vein flow|Doppler assessment performed on day 0, 3 and 7.
223823709|NCT04095143|DIAGNOSTIC_TEST|Intra-renal flow|Doppler assessment performed on day 0, 3 and 7.
223823710|NCT04095143|DIAGNOSTIC_TEST|Hepatic vein flow|Doppler assessment performed on day 0, 3 and 7.
223823711|NCT04095143|DIAGNOSTIC_TEST|Pulmonary B-lines|Ultrasound assessment of performed on day 0, 3 and 7.
223823712|NCT04095143|DIAGNOSTIC_TEST|Dimensions of the inferior vena cava|Ultrasound assessment of performed on day 0, 3 and 7.
223823713|NCT04095143|DIAGNOSTIC_TEST|Left ventricular function|Ultrasound assessment of performed on day 0, 3 and 7.
223823714|NCT04095143|DIAGNOSTIC_TEST|Right ventricular function|Ultrasound assessment of performed on day 0, 3 and 7.
223823715|NCT00544063|DRUG|irinotecan hydrochloride|
223823716|NCT00544063|DRUG|oxaliplatin|
223823717|NCT01226563|DEVICE|IK-5001|4 mL (+/- 0.2 mL) administered through intracoronary slow bolus injection over 15 to 30 seconds at least 2 days after PCI but within 5 days of onset of symptoms.
223823718|NCT01226563|DEVICE|Saline Solution|4 mL (+/- 0.2 mL) slow bolus, intracoronary injection of saline solution will be administered over 15 to 30 seconds at least 2 days after percutaneous coronary intervention (PCI) but within 5 days of onset of symptoms.
223823719|NCT00010439|DRUG|Alendronate|Pill, 35mg or 70mg weekly, depending upon the body weight for 12 months.
223823720|NCT01819025|BEHAVIORAL|4 face-to-face therapy session and a smartphone-app|An 8 week blended therapy with both face-to-face therapy sessions and support through a smartphone application.
223823721|NCT01819025|BEHAVIORAL|CBT, treatment as usual|10 sessions of face-to-face therapy, full behavioral activation
223823722|NCT01073800|DRUG|atorvastatin 80 mg per os daily|atorvastatin 80 mg per os daily
223823723|NCT01073800|DRUG|placebo|placebo
223823724|NCT00742820|DRUG|Calcium Acetate Oral Solution 667 mg per 5 mL|Drug: Calcium acetate oral solution 667 mg calcium acetate, USP per 5 mL (169 mg of elemental calcium per 5 mL); Dosage: 30 mL of calcium acetate oral solution; Dosage frequency: three times per day with meals; Duration: 3 days and the morning of day 4, in total ten doses
223823725|NCT00742820|DRUG|Calcium Acetate 667 mg GelCaps|Drug: PhosLo GelCaps (calcium acetate) 667 mg (169 mg of elemental calcium per gelcap); Dosage: 6 gelcaps; Dosage frequency: three times per day with meals; Duration: 3 days and the morning of day 4, in total ten doses.
223823726|NCT00742820|DIETARY_SUPPLEMENT|Calcium Citrate 950 mg Caplets|Drug: Calcium Citrate 950 mg Caplets (200 mg of elemental calcium per caplet); Dosage: 5 caplets; Dosage frequency: three times per day with meals; Duration: 3 days and the morning of day 4, in total ten doses
223823727|NCT02811016|DRUG|Budesonide 200|200 µg inhaled at 7:00 a.m. and 7 p.m.
223823728|NCT02811016|DRUG|Budesonide 800|800 µg inhaled at 7:00 a.m. and 7 p.m.
223823729|NCT02811016|DRUG|Placebo|Placebo Inhalation at 7:00 a.m. and 7 p.m.
223823730|NCT02825901|DIETARY_SUPPLEMENT|Placebo|Ingest placebo drink 100ml/day for 8 weeks
223823731|NCT02825901|DIETARY_SUPPLEMENT|Djulis-Buckwheat|Ingest Djulis-Buckwheat drink 100ml/day for 8 weeks
223823732|NCT02825901|DIETARY_SUPPLEMENT|Buckwheat|Ingest Buckwheat drink 100ml/day for 8 weeks
223823733|NCT04369638|DEVICE|3D NAM|"After consent and birth of the child, a face MRI will be taken of the newborn before discharge from the hospital utilizing the feed and swaddle technique. The MRI will be sent to the dental team to convert into a format compatible with 3D software. With the image, a NAM appliance will be digitally fabricated and 3D printed. The 3D printed model will be tested for fit on stone model made from traditional impression. Both traditional NAM and 3D printed NAM will be inserted at delivery appointment. Fit will be assessed of both appliances by applying a try-in paste to the intaglio surface and counting the number of spots needing adjustment."
223823734|NCT04369638|DEVICE|Traditional NAM|The patient will be seen for visit at the clinic for traditional intraoral impression and a dental stone model will be poured. An acrylic NAM will be fabricated on the stone model. The 3D printed model will be tested for fit on stone model made from traditional impression. Both traditional NAM and 3D printed NAM will be inserted at delivery appointment. Fit will be assessed of both appliances by applying a try-in paste to the intaglio surface and counting the number of spots needing adjustment.
223823735|NCT00951262|BEHAVIORAL|a life review program|The life review program includes reviewing a life and formalating a life booklet. Reviewing a life consists of three weekly sessions separately addressing illness experience, adulthood life and childhood and adolescence life. Each session lasts about 30 to 60mintues.A booklet with photos documented significant life events will be produced as a gift for the subjects. The edition, photos and contents fo the booklet are determined by the subjects.
223823736|NCT02504437|BIOLOGICAL|BMMSCs|
223823737|NCT03491345|DRUG|Avelumab|avelumab 10mg/kg, IV, q 2 weeks
223823738|NCT03804190|OTHER|questionaire|dutch musculoskeletal questionaire
223823739|NCT00421525|BIOLOGICAL|milatuzumab|twice weekly dosing for 4 weeks, total of 8 doses
223823740|NCT02304965|BEHAVIORAL|Daily physical activity|A combination of walking (\> 10.000 steps per day) and cycling on a stationary bicycle at home at an individual intensity. For the activity walking patients need to walk at a certain speed (e.g. 3 km/h) in order to be in the range of pulsatility as obtained from their pre-training treadmill test. For cycling a defined power in watt and duration will be given to each patient as defined from the pre-training cycling test.
223823741|NCT05905991|OTHER|Enhanced Stress Resilience Training|"The ESRT intervention will consist of 1) five weekly one-hour sessions (in-person or virtual) led by a certified instructor; 2) smartphone-based exercises that bring informal practice into daily life; 3) videos on principles and concepts taught each week; and 4) meditation recordings of various lengths and styles supporting the prescribed daily practice of up to 20 min/day. Weekly didactic and experiential activities will cover mindfulness-based intervention concepts and skills, such as cultivating resilience, awareness of the body, managing thoughts, responding versus reacting, transforming circumstances, and advocacy through mindful communication. The ESRT smartphone app (Mindful Brian) houses all course materials (pre-class materials and post-class materials) and sends class reminders and messages. Considering nurses' shifts, ESRT will be offered in two separate sessions each week."
223823742|NCT00002456|DRUG|cyclosporine|
223823743|NCT00002456|DRUG|methotrexate|
223823744|NCT00002456|PROCEDURE|allogeneic bone marrow transplantation|
223823745|NCT05304923|PROCEDURE|Supraglottic jet oxygenation and ventilation|Supraglottic jet oxygenation and ventilation is conducted using a Wei nasal jet tube (WNJ, Well Lead Medical Co. Ltd, Guangzhou, China) which is connected to a manual jet ventilator (Well Lead Medical Co. Ltd, Guangzhou, China) via its jet port. The initial settings of SJOV are: driving pressure (DP) 15psi, respiratory rate (RR) 20 bpm, inspiratory-to-expiratory (I/E) ratio 1:2, and gas supply 100% oxygen.
223823746|NCT05304923|PROCEDURE|Nasal cannula oxygen supply|Oxygen supplementation at 2 liters min-1 is delivered via a nasal cannula
223823747|NCT01392716|DRUG|rituximab [MabThera/Rituxan]|375 mg/m2 intravenously once a week for 4 weeks
223823748|NCT02282410|DRUG|ADVATE|The baseline ABR will be assessed from bleeding log and clinic records from preceding year. Subjects will initially be treated standard prophylaxis(20 - 40 IU/Kg body weight 2-3 times one week with ADVATE for 1 year.
223823749|NCT01112514|DRUG|indocyanine green|Administered intravenously during endoscopic near-infrared (NIR) imaging
223823750|NCT05859802|DRUG|Dalfampridine Pill|Subjects were blinded and randomized into 2 groups; Group 1 received physical therapy 2 x a week for 12 weeks while taking dalfampridine 10 mg two times day
223823751|NCT05859802|DRUG|Placebo|Subjects were blinded and randomized into 2 groups; Group 1 received physical therapy 2 x a week for 12 weeks while taking a placebo pill two times day
223823752|NCT05201911|DRUG|124I-AT03|IV injection of the radiolabeled compound on day 1 followed by Positron Emission Tomography/Computed Tomography (PET/CT) scanning on Days 2, 4 and 8 to. The first 3 subjects enrolled will have two additional scans on Day 1.
223823753|NCT02611050|BEHAVIORAL|The Multi-vessel Coronary Artery Disease Option Grid|The Multi-vessel Coronary Artery Disease Option Grid is a patient decision aid used during the clinical visit. It is one page and contains a table a patient's frequently asked questions and the respective information for each treatment strategy. The Multi-vessel Coronary Artery Disease Option Grid was developed using patient and provider feedback and has been field-tested in clinic by cardiologists and surgeons.
223823754|NCT02611050|BEHAVIORAL|Usual Care|In usual care clinicians will discuss the patient diagnosis and treatment options typical to routine care for that clinician.
223823755|NCT04157998|DRUG|normal saline|intrvenous administration of 10ml normal saline preoperative
223823756|NCT04157998|DRUG|Metoclopramide 10mg|intrvenous administration of 10mg metoclopramide diluted in 10ml normal saline preoperative
223823757|NCT01118455|DEVICE|Vagus Nerve Stimulation (VNS) Therapy|Vagus Nerve Stimulation (VNS) Therapy is delivered by an implantable device similar to a pacemaker that sends mild stimulation to the left vagus nerve to help improve seizure control.
223823758|NCT01118455|DRUG|Anti-Epileptic Drug (AED)|Subject has tried at least 2 appropriate AEDs tested to tolerance or to blood levels at upper end of the target range of which at least 2 had been tolerated at normal doses.
223823759|NCT04235101|DRUG|SYD985 + Niraparib|SYD985 powder for concentrate for solution for infusion Niraparib 100 mg per hard capsule
223823760|NCT03848364|BEHAVIORAL|Hip Hop Stroke 2.0|HHS2.0 is an innovative, multimedia program, a brief 3-hour (1hr/day for 3 days), school-based intervention designed to educate at-risk populations concerning stroke symptoms and calling 911 immediately in the event they occur (stroke literacy). HHS2.0 is accessed and delivered via a web link online as self-administered, interactive modules that target 4th and 5th grade children in the school system (ages 9-11) using narrative cartoons and multimedia games.
223823761|NCT01538108|DEVICE|PTA Balloon catheter with paclitaxel|patients treated by the NMB's PTA Balloon catheter with paclitaxel
223823762|NCT01538108|PROCEDURE|Plain Balloon angioplasty (PBA)|PBA
223823763|NCT04939636|DIETARY_SUPPLEMENT|Vitamin D3 capsules 4000IU/100µg.|Vitamin D3 supplementation
223823764|NCT04939636|DIETARY_SUPPLEMENT|Vitamin D3 capsules 600IU/15µg.|Vitamin D3 supplementation
223823765|NCT00543400|DRUG|M118|intravenous (IV) infusion
223823766|NCT00543400|DRUG|Unfractionated Heparin|IV infusion
223823767|NCT01432535|DRUG|PegIFN-2b (Sylatron®)|Single 4.5 μg/kg dose
223823768|NCT06028581|OTHER|breastfeeding support system|Using the breastfeeding support system
223823769|NCT01584492|DRUG|beclomethasone+formoterol 50/6 (1 inhalation)|CHF 1535 50/6 (fixed combination of extrafine beclomethasone dipropionate 50 µg + formoterol fumarate 6 µg/metered dose) administered via a pMDI with spacer
223823770|NCT01584492|DRUG|CHF 1535 50/6 (2 inhalations)|CHF 1535 50/6 (fixed combination of extrafine beclomethasone dipropionate 50 µg + formoterol fumarate 6 µg/metered dose) administered via a pMDI with spacer
223823771|NCT01584492|DRUG|CHF 1535 50/6 (4 inhalations)|CHF 1535 50/6 (fixed combination of extrafine beclomethasone dipropionate 50 µg + formoterol fumarate 6 µg/metered dose) administered via a pMDI with spacer
223823772|NCT01584492|DRUG|Formoterol + Beclomethasone dipropionate|"* Formoterol HFA pMDI 6 µg / actuation~* Extrafine BDP HFA pMDI 50 µg/actuation"
223823773|NCT01584492|DRUG|Placebo (6 inhalations)|Matched placebo via pMDI
223823774|NCT04464616|PROCEDURE|spinal anaesthesia|spinal anaesthesia will be performed with the patient in sitting position at the L3-L4 or L4-L5 interspaces with a 25 or 27 G spinal tip needle with the study drug in the total volume of 3 ml.
223823775|NCT06010290|DRUG|18F-SMBT-1|Each participant receives intravenous injection of 18F-SMBT-1, and undergo PET/CT imaging within the special time. 18F-FP-CIT and 18F-FDG PET/CT are used to assess the change of cerebral dopamine transporters and glucose metabolism for auxiliary diagnosis.
223823776|NCT04977518|OTHER|no intervention|no intervention
223823777|NCT00790920|DRUG|Desmoteplase|90 μg/kg bodyweight, IV, single bolus over 1 - 2 minutes on 1st day
223823778|NCT00790920|DRUG|Placebo|IV, single bolus over 1 - 2 minutes on 1st day
223823779|NCT02618720|DRUG|ornidazole|
223823780|NCT02618720|DRUG|Placebo|
223823781|NCT06167629|DIAGNOSTIC_TEST|PET 18F-PSMA|Subjects will be subjected to a PET examination according to international guidelines and where requested by the specialist. In particular, patients will be administered the radiopharmaceutical 18 F PSMA. Approximately two hours after administration, the patient is positioned on the PET/CT equipment table and image acquisition begins.
223823782|NCT04619953|OTHER|Dynamic Postural Stability Training|The dynamic postural stability training, will consist of marching on unstable surface and on treadmill both with open and with closed eyes.
223823783|NCT04619953|OTHER|Cognitive-Motor Training|The cognitive-motor training consisted of a dual task paradigm: each patient was asked to walk without stopping and was explained that, during the task, they might hear a sound, and in that case, they should have look at the stimulus 'side and recognize a visual target. This dual task was performed both marching on an unstable surface and marching on treadmill.
223823784|NCT04619953|OTHER|Conventional Therapy|The conventional neuromotor rehabilitation will consist in muscles stretching, active-assisted mobilizations, neuromuscular facilitations, gait training and balance exercises using swinging platforms
223835558|NCT01643395|OTHER|conservative therapy|The study is a prospective, randomized trial comparing conservative treatment (brace) and vertebroplasty in acute (less than 15 days after trauma) traumatic vertebral compression fracture (VCF) type A according Magerl classification.
223823785|NCT04693936|COMBINATION_PRODUCT|Nutraceutical Combination Plan|"Multivitamin (My Total Health) 1 tablet per day Vitamin C (My Immuno) 1 scoop per day Calcium-Magnesium combination (My Calmag) 1 scoop per day Omega 3-6-9 My Omega Krill. 1 capsule per day Glutamine (L-Glutamin \&Chios Mastiha) 1 tablet per day Probiotics 40 billion 1 capsule per day~Nutraceuticals will be received daily along with the patient's customary psoriasis/Hashimoto's disease treatment."
223823786|NCT03009890|PROCEDURE|Surgery (Open Reduction Internal Fixation)|Either volar of dorsal plating or both
223823787|NCT03009890|PROCEDURE|Cast treatment|Hospitals may use their preferred protocol
223823788|NCT06099951|DRUG|Serplulimab + FOLFOXIRI|Starting from day 0, the patient will receive 8 cycles of FOLFOXIRI regimen at specific intervals. The FOLFOXIRI regimen includes irinotecan 165mg/m2, oxaliplatin 85mg/m2, calcium folinate 200mg/m2 on day 1, followed by continuous intravenous infusion of 5-FU 2400mg/m2/day for 46 hours. This regimen is repeated every 14 days.During radiotherapy (Monday to Friday), the patient will receive capecitabine 1650mg/m2/day orally twice daily. Serplulimab immunotherapy will be administered every 2 weeks during the FOLFOXIRI neoadjuvant chemotherapy period. Serplulimab will be given on the first day and the 14th day of radiotherapy, dissolved in 100ml normal saline and administered intravenously over 30-60 minutes at a dose of 200mg.
223823789|NCT06099951|RADIATION|Radiation therapy|Radiation therapy
223823790|NCT05565274|DRUG|Pentazocine plus placebo|30mg of pentazocine and 2milliLitre of injection water
223823791|NCT01200030|BEHAVIORAL|electrical stimulation with exercises|electrical stimulation with exercises
223823792|NCT01200030|BEHAVIORAL|placebo stimulation with exercises|placebo stimulation with exercises
223823793|NCT02770508|DRUG|darunavir/ritonavir|
223823794|NCT02770508|DRUG|Lamivudine|
223823795|NCT02770508|DRUG|emtricitabine-tenofovir(FTC/TDF)|
223823796|NCT00385853|DRUG|PTK787/ZK 222584|Twice daily for each 28-day cycle
223823797|NCT00385853|DRUG|Temozolomide|Daily for each 28-day cycle
223823798|NCT00385853|PROCEDURE|Radiation Therapy|For 7 weeks beginning on day 5 of the first treatment cycle
223823799|NCT01216891|BEHAVIORAL|Multi-element, team-oriented treatment|Participants will receive treatment and services based on their needs coordinated by a small team that is led by a clinical coordinator. Services that are available to the participants include social skills training, medication treatment to address symptoms, education and employment advising, and substance use treatment.
223823800|NCT02127827|DEVICE|Automated Ambulatory Glycemic Controller (AAGC)|
223823801|NCT04879758|GENETIC|Genetic Risk Estimate|The genetic risk information includes individual remaining-lifetime and 10-year genetic risk estimates for T2D as well as a dichotomized genetic risk category: 'increased genetic risk' (if their genetic risk is higher than the average population risk) or 'no increased genetic risk' (if their genetic risk is not higher than the average population risk).
223823802|NCT04879758|OTHER|Genetic Risk Estimate + Fitbit Functions|"The genetic risk information includes individual remaining-lifetime and 10-year genetic risk estimates for T2D as well as a dichotomized genetic risk category: 'increased genetic risk' (if their genetic risk is higher than the average population risk) or 'no increased genetic risk' (if their genetic risk is not higher than the average population risk).~The two unique Fitbit functions are step goal setting and prompts. Individualized daily step goals will be set to be 10% higher than participants' own baseline Fitbit step counts. The 'Reminder To Move' function of Fitbit will be used as a prompt to remind participants to reduce sedentary time and walk at least 250 steps/hour within a specified timeframe (i.e., from 9am to 10pm in the proposed research). If the user has not accumulated at least 250 steps/hour, a reminder (for example, 150 steps to go) will appear on the Fitbit screen at 10 minutes before the hour (for example, at 10:50 a.m.) and cause the device to vibrate."
223823803|NCT03200301|PROCEDURE|Intact Umbilical Cord Milking|Immediately after delivery, the infant will be placed at or ∼20 cm below the level of the placenta and about 20 cm of the intact umbilical cord will be milked towards the umbilicus three times. The technique consists of pinching the cord close to the placenta and milking about 20 cm segment of the cord proximal to the umbilicus, towards the infant over a 2-second duration. The cord will then be released and allowed to refill with blood for a brief 2-second pause between each milking motion. After completion of milking three times, the cord will be clamped close to the umbilicus and the neonate handed over to the neonatal team. The procedure of cord milking will be completed within 20 seconds.
223823804|NCT02632786|DRUG|NEOD001|NEOD001 is a monoclonal antibody directed at soluble and insoluble light chain aggregates
223823805|NCT02632786|DRUG|Placebo|Saline Bag
223823806|NCT01928225|BIOLOGICAL|Human Papillomavirus vaccine|The participants receive the qHPV vaccine at entry, week 4 and week 26
223835559|NCT03377075|DEVICE|AL measurement|IOL Master 500 (Carl Zeiss AG, Germany)
223823807|NCT06381817|BIOLOGICAL|Haplo-cord HCT|Haploidentical hematopoietic cell transplantation will be performed with coinfusion of an unrelated cord blood unit
223823808|NCT06381817|BIOLOGICAL|Haplo-HCT|Hematopoietic cell transplantation will be performed with a haploidentical donor
223823809|NCT01768754|BEHAVIORAL|Usual and Fast Walking Speeds|Stable patients with chronic obstructive pulmonary disease will demonstrate their usual and fast walking speeds over a 30 m course, with speed calculated over the middle 10 m using optical sensors. The test will be repeated after a 5 minute rest; this procedure will then be repeated on two subsequent days, at the same time of day, within one week.
223823810|NCT05539196|DEVICE|Exablate Pallidotomy, Unilateral|Unilateral pallidotomy using focused ultrasound for the treatment of Parkinson's Disease with medication-refractory moderate to severe motor complications.
223823811|NCT02096614|DRUG|TBI-1201|TBI-1201(5\*10\^8 or 5\*10\^9) is administered.
223823812|NCT02096614|DRUG|Cyclophosphamide|Cyclophosphamide (750mg/m2/day x 2 days Intravenous (IV)) is administered as pre-treatment medication of TBI-1201
223823813|NCT02096614|DRUG|Fludarabine|Fludarabine (20mg/m2 x 5 days Intravenous(IV)) is administered as pre-treatment medication of TBI-1201 in combination with cyclophosphamide.
223823814|NCT05276843|COMBINATION_PRODUCT|Qigong exercise program|Qigong is a low-impact, weight-bearing exercise characterized by gentle movements designed to dissipate force throughout the body while the subject changes poses, with well-coordinated sequences of both isometric and isotonic segmental movements in the trunk and 4 extremities.
223823815|NCT03197103|DRUG|N-Acetylcysteine (NAC)|For more information read Experimental Arm description
223823816|NCT03457285|OTHER|Physiotherapy|"Participants, with a confirmed diagnosis of AS, will be invited to participate. Once participants have provided informed consent, they will be required to complete the outcome measures provided. Participants will be set up to use the online exercise application and educated on its use.~Participants will then have access to videos of suitable exercises or exercise classes to follow and education material on their condition to read. Participants will be able to complete AS specific outcome measures and record their progress. Participants will also have a monthly video call with the senior rheumatology physiotherapist to discuss their exercise programme, symptoms and management. The participants will also record their compliance with their exercise programmes.~After the 6 month pilot period, participants will be required to complete the same outcome measures completed at the start of the study."
223823817|NCT02302950|DRUG|raltegravir|HIV therapy component
223823818|NCT01451736|DRUG|paliperidone palmitate|long-acting injectable
223823819|NCT01451736|DRUG|risperidone|oral
223823820|NCT05279430|BEHAVIORAL|Inspiratory muscle training|Patients allocated to the IMT arm will be instructed to train at home twice daily, for 20 minutes each session, using a Threshold inspiratory muscle trainer (Respironics Inc., Parsippany, NJ). They will be instructed by a physiotherapist responsible for training intervention and educated to maintain diaphragmatic breathing during the training period. The subjects will start breathing at a resistance equal to 25% to 30% of their maximal inspiratory mouth pressure (MIP) for 1 week. The respiratory therapist will examine the patients at weekly intervals by checking the diary card and measuring the MIP each time. The resistance will be modified each session according to the 25% to 30% of their MIP measured.
223823821|NCT02265224|DRUG|N-acetylcysteine|The product was administered according to the randomisation list and cross-over design, with 150 mL of still mineral water under fasting conditions on study day 1 of periods 1 or 2 at 8:00±1 h.
223823822|NCT04767360|DEVICE|Bioness-300|Therapeutic treatment of foot drop with the electrical stimulation device Bioness L300.
223823823|NCT04799860|BEHAVIORAL|health promotive work-way|"Clinical intervention: The patient is asked to fill in a screening form with life-style related questions. The caregiver takes adequate measures according to the recommendations of the national guideline and the filled in screeing form. The caregiver documents the measures taken.~Implementation intervention as described previously: using tailored strategies to support implementation of the gudieline-based recommendations"
223823824|NCT05389020|OTHER|Newly developed real-size infant's arm and leg manikin|The control group used conventional manikins made by Nasco; meanwhile, two newly designed real-size manikins were prepared for the intervention group: the right arm and right leg. Real-size manikins were developed based on the mean of anthropometric measurement of 50 Indonesian infants' arms and legs of healthy term neonates born in Dr Cipto Mangunkusumo Hospital. The manikins were made of Thermoplastic Polyurethane (TPU) filament using three-dimensional (3D) printing technology. The manufacturing process was carried out by the Medical Physics Department, Universitas Indonesia.
223823825|NCT05950854|DIAGNOSTIC_TEST|Weight-bearing MRI|Four MRI scans with 0.25T scanner: weight-bearing and non-weight-bearing with flexed and extended knee
223823826|NCT01754454|BIOLOGICAL|Human Umbilical Cord Derived MSC|1×10\^6 UC-MSCs per kg intravenous injection the number of infusions: once a week, for four weeks in a row Time interval: estimate the condition of follow-up visit afer 28 days
223823827|NCT03681795|DIAGNOSTIC_TEST|Experimental MRI exam and PET scan exam with radiotracer|MRI exam and PET scan exam with radiotracer
223823828|NCT04572919|PROCEDURE|lateral advancement flap|Patients were randomly assigned to undergo either lateral advancement flap or classic Limberg flap for treatment of non-complicated pilonidal sinus
223823829|NCT04572919|PROCEDURE|classic Limberg flap|Patients were randomly assigned to undergo either lateral advancement flap or classic Limberg flap for treatment of non-complicated pilonidal sinus
223823830|NCT02724813|BEHAVIORAL|Cognitive Orientation to Occupational Preformance (COOP)|
223823831|NCT04922996|DRUG|Calcium Dobesilate|Dosage of calcium dobesilate in different tissues
223823832|NCT01760018|DRUG|desflurane group|anesthesia is maintained with desflurane and remifentanil (Desflurane group)
223823833|NCT01760018|DRUG|TIVA group|anesthesia is maintained with fresofol and remifentanil (TIVA group).
223823834|NCT01232309|DIETARY_SUPPLEMENT|Chitin-Glucan|3 x 500 mg capsules (tid) = 4.5 mg daily dose
223823835|NCT01232309|DIETARY_SUPPLEMENT|Low Dose Chitin-Glucan|3 x 167 mg capsules (tid) = 1.5 g daily dose
223823836|NCT01232309|DIETARY_SUPPLEMENT|Low Dose Chitin-Glucan + Olive Extract|3 x 167 mg capsules (tid) = 1.5 g daily dose (C-G) + 135 mg olive extract
223823837|NCT01232309|DIETARY_SUPPLEMENT|Placebo|3 x 500 mg capsules (tid)
223823838|NCT02134119|DIETARY_SUPPLEMENT|Echinacea-based dietary supplement|Echinacea-based dietary supplement given at 8,000mg/day or 16,000 mg/day by mouth
223823839|NCT02134119|DRUG|Placebo|Sugar pill manufactured to mimic dietary supplement
223823840|NCT01127906|DRUG|PF-04531083 100mg|Oral PF-04531083 100mg suspension single dose
223823841|NCT01127906|DRUG|PF-04531083 2000mg|Oral PF-04531083 2000mg suspension single dose
223823842|NCT01127906|DRUG|Placebo suspension|Oral Placebo suspension (matched to PF-04531083 suspension)
223823843|NCT01127906|DRUG|Placebo tablet|Oral Placebo tablet (matched to Oxycodone)
223823844|NCT01127906|DRUG|Oxycodone 20mg|Oral Oxycodone 20mg (Oxycontin) controlled release formulation
223823845|NCT03942913|OTHER|an observational study|this study is to describe the initial anti-thrombotic treatment strategy prescribed to the AF patient population undergoing PCI by using drug class description.
223823846|NCT06450574|DRUG|Capecitabine (Xeloda)|Capecitabine 825 mg/m2 every 12 hours orally on days of radiotherapy
223823847|NCT06450574|RADIATION|50.4 Gy|Radiotherapy was administered in daily fractions of 1.8 Gy 5 days a week according to standard schema. The total dose is 45 Gy plus a boost of 5.4 Gy to the tumor area
223823848|NCT06450574|PROCEDURE|Transanal Endoscopic Microsurgery (TEM)|10 weeks after Chemoradiotherapy
223823849|NCT06450574|PROCEDURE|Transanal Endoscopic Microsurgery|Standard surgical treatment of T1, N0, M0 rectal cancer. Early after diagnosis
223823850|NCT03709290|RADIATION|mri|mri brain \& spinal cord
223823851|NCT01454830|BEHAVIORAL|Tailored|Individualized on critical indicator (Self-efficacy measure in Sleep Apnea) measured at each intervention delivery period (pre-diagnosis, immediately post-diagnosis, post-CPAP titration, and during week 1 of home CPAP treatment. Intervention components include patient education, preparatory skills training, modification of inaccurate/unrealistic cognitive perceptions of risk, outcome expectations, and treatment self-efficacy
223823852|NCT01454830|OTHER|Usual care|Usual care comparison group will proceed from initial clinical evaluation for OSA, diagnosis by polysomnography, CPAP titration polysomnography, and home CPAP treatment initiation as per current standard of care
223823853|NCT03051126|OTHER|Tissue Samples|Fresh residual tissue samples will be obtained during parathyroid and/or pancreas tumor intervention (for pancreas tumor intervention in MEN1 patients with hyperparathyroidism and pancreatic lesions).
223823854|NCT00982150|DRUG|Talampanel|50mg capsules tid
223823855|NCT02013973|OTHER|AMH-analysis|At the first visit to the IVF-clinic a blood sample for serum-AMH is taken and frozen for later analysis in the AMH-group. The AMH assay used is the Beckman Coulter AMH Gene II assay. The analysis result will be added to the algorthm deciding what starting gonadotropin dose the patient is having.
223823856|NCT06345222|PROCEDURE|Prolotherapy|"The Modified Prolotherapy technique was applied in the study and 0.5cc 5% Dextrose injection was applied per injection to the tendon entesis and/or tendon of the patient's non-rheumatic chronic, myoskeletal knee-induced, pain-inducing sensation. The follow-up period was determined as 1 month after the last injection. The ligaments to be injected within the scope of the research (context knee pain) were determined as Lateral Collateral Ligament (LCL), AnteroLateral Collateral Ligament (ALL), Medial Collateral Ligament (MCL), Pes Anserius and Patellar Ligament."
223823857|NCT02524132|BEHAVIORAL|Physical Activity|
223823858|NCT02663414|DEVICE|Atlas Knee System|The Atlas Knee System is an approved device (CE Marked) and is an extra-capsular knee implant specifically designed to treat patients with uni-compartmental, medial knee osteoarthritis (OA).
223823859|NCT00152763|BEHAVIORAL|Cognitive Behaviour Therapy (CBT)|Cognitive behavior therapy tailored to psychological adaptation to an ICD, included 8 telephone counselling sessions, plus psycho-educational booklet and a therapist manual.
223823860|NCT00152763|OTHER|Usual Cardiac Care (UCC)|Usual cardiac care (UCC) was defined as whatever the respective ICD treatment sites routinely offer their patients. All patients received standard educational materials explaining their heart disease and the ICD device. Follow-up appointments include device interrogation (i.e., to extract arrhythmia events and ICD therapies) and trouble-shooting at 6-months intervals, cardiac care as necessary, and nonsystematic supportive reassurance delivered informally in the clinic. Each centre also had access to a cardiac rehabilitation program and psychiatric consultation as needed.
223823861|NCT00136812|BEHAVIORAL|stage-tailored intervention|This intervention consists of nicotine patch therapy during hospitalization; a stage-based self-help manual; an individualized, expert-system, feedback report at intake, 3 months and 6 months post-hospitalization with carbon copies sent to participants' outpatient clinicians; and an individual 30-min smoking cessation counseling sessions during hospitalization. Additionally, up to 10 weeks of nicotine patch is provided to intervention participants intending to stay quit following hospital discharge.
223823862|NCT03929419|DRUG|intranasal insulin|application of 160 units human insulin
223823863|NCT03929419|DRUG|Placebo spray|nasal spray containing placebo solution
223823864|NCT04283344|OTHER|KY Ticket to Healthy Food Benefits|Households in the treatment group received an extra monthly SNAP benefit amount through two new intervention-related deductions to the SNAP benefit formula
223823865|NCT00902889|PROCEDURE|Stimulation|6 weeks stimulation with GPI (lower caudal two contacts), 4 weeks wash-out, 6 weeks stimulation GPE (upper cranial two contacts)
223823866|NCT00902889|PROCEDURE|Stimulation|6 weeks stimulation with GPE (upper cranial two contacts), 4 weeks wash-out, 6 weeks stimulation with GPI (lower caudal two contacts)
223823867|NCT05693493|DEVICE|Proprioceptive knee brace|For the intervention group that randomly consisted of 15 subjects will be using a design of knee brace (Reaction Web®; DonJoy, Vista, CA). The elastomeric web design helps to reduce pain by dispersing load across the knee. The web acts like a spring to absorb shock and shifts the peak loads away from the painful area of the knee. Elastomeric web acts to dynamically stabilise the patella on all sides, bringing the patella into proper tracking position to reduce pain for patients with general patellofemoral instabilities. Reaction Web® has dual-axis hinges that are flexible, creating synergy with the elastomeric web for optimal fit and support, and providing energy dispersion to the knee.
223823868|NCT05799300|PROCEDURE|Intrathecal anaesthesia|Low dose 0.5% hyperbaric bupivacaine (1.3mls, 0.65mg) intrathecal anaesthesia.
223823869|NCT05843474|BEHAVIORAL|Take it Personal!|Take it Personal! is a six-week indicated prevention program for youth with a mild intellectual disability or borderline intellectual functioning. The program aims to teach youngsters skills to reduce their substance use (alcohol, cannabis, and other drugs). The prevention program differentiates four personality profiles associated with a higher risk for problematic substance use: sensation seeking, impulsivity, anxiety sensitivity and negative thinking. For each of the four personality profiles, different program outlines were developed that are similar in structure but have their own personality-specific materials, games and (psychomotor) exercises. There are weekly individual- and group sessions with three to four participants, led by a clinical psychologist and a psychomotor therapist. Motivational interviewing and cognitive behavioral therapeutic principles are applied, both of which have proven effectiveness in decreasing substance use the target group.
223823870|NCT04932382|DRUG|Misoprostol|will be used 3 h before IUD insertion
223823871|NCT04932382|DEVICE|IUD|a copper T380A IUD
223823872|NCT01824563|OTHER|Observational study|
223823873|NCT02294110|OTHER|spinal anesthesia|non diabetes mellitus
223823874|NCT03930914|DEVICE|Parasym (TM) Transcutaneous Electrical Nerve Stimulation (TENS) Device|Daily use of Parasym (TM) device on tragus or ear lobe, as assigned treatment arm
223823875|NCT04683289|PROCEDURE|trabeculotomy|performing partial unroofing of the SC and viscoelastic injection into the 2 ostia of the canal. This was followed by connecting the scalemm canal to the anterior chamber
223823876|NCT04343781|OTHER|observation|observation of clinical symptoms related to COVID-19 disease
223823877|NCT00569803|DRUG|belatacept|single dose, 116 days
223823878|NCT00569803|DRUG|Placebo|Subcutaneous injection of placebo solution (product ID: 224818-N000- 029)
223823879|NCT03019120|DRUG|Vitamin D|"1. Subjects will undergo a cognitive evaluation using the Montreal Cognitive Assessment (MoCA) screening test and the Neurotrax computerized cognitive assessment battery.~2. Subjects will receive a supplemental monthly oral dose of 60000 units Vitamin D administered by a nurse for a period of 3 months.~3. Levels of serum calcium will be repeated monthly (end of month 1, 2, 3).~4. Subjects will undergo a repeat blood test to examine the level of vitamin D at the end of 3 months of follow-up.~5. At 3-month follow-up subjects will be asked to complete the Neurotrax computerized cognitive assessment battery."
223823880|NCT01324479|DRUG|INC280|
223823881|NCT01993823|DRUG|G238|Five drops into the ear canal twice daily for 14 days
223823882|NCT01993823|DRUG|Clotrimazole|Five drops into the ear canal twice daily for 14 days
223823883|NCT00994474|PROCEDURE|Fractional carbon dioxide laser treatment|With the CO2 laser (Fraxel Re:pair, Solta Medical Inc., Hayward, CA), patients received two passes at 15 mJ (1st pass) and 20 mJ (2nd pass), respectively, with a total density of 20 %. We employed 'pin-point bleeding' and serosanguinous exudate as a clinical end point. The pulse duration was 10 msec.
223823884|NCT00994474|PROCEDURE|Fractional Er:YAG laser treatment|The Er:YAG laser (MCL 30 Dermablate, Asclepion Laser Technologies GmbH, Jena, Germany) was used in 4 passes with a total fluence of 60 J/cm² and pulse stacking (6 stacked pulses); the pulse duration was 400 μsec.
223823885|NCT00695682|DRUG|intravitreal injection of infliximab|All subjects will receive 0.5 mg/ 0.05 mL of infliximab by intravitreal injection at their first treatment visit or the 6 weeks visit if eligible for a repeat injection.
223823886|NCT01235975|BIOLOGICAL|Meningococcal vaccine GSK 134612|Intramuscular injection
223823887|NCT01235975|BIOLOGICAL|MencevaxACWY TM|Subcutaneous injection
223823888|NCT05643417|DRUG|HAIC、Bevacizumab、Camrelizumab|HAIC: refer to genetic test results，D1 Bevacizumab：7.5mg/Kg, D2, Q3W Camrelizumab：200mg, D2, Q3W
223823889|NCT03304860|OTHER|Survey|Survey with 4-7 questions about each parents' demographics and CRC screening history. Depending on answers, provided a CRC screening document and asked to discuss screening with parents, followed by a brief survey in 4 months
223823890|NCT03338205|DRUG|Ketamine|1 mg/kg ketamine bolus IV
223823891|NCT02006420|DEVICE|ARFI-SVI Ultrasound|Ultrasound imaging of arm and leg lasting approximately 5-10 minutes. Participants will also undergo durometer scoring on the forearm and thigh as part of the study. This lasts approximately 5-10 minutes.
223823892|NCT02580773|DRUG|Prophylactic anticoagulation ( INNOHEP®)|subcutaneous anticoagulation with low molecular weight heparin (tinzaparin) at a prophylactic dose (4500 UI/day)
223823893|NCT02580773|DRUG|Curative anticoagulation ( INNOHEP®)|subcutaneous anticoagulation with low molecular weight heparin (tinzaparin) at a curative dose (175 UI/kg/day for 7 days)
223823894|NCT01907074|DRUG|Cholates|Cholates is given intravenously (IV push) and by mouth, once per study visit
223823895|NCT01282671|OTHER|Breathing exercises|On the fourth postoperative day the patients are randomly assigned to a Treatment group continuing to perform deep breathing exercises for 2 months postoperatively and to a Control group who will perform no breathing exercises after the third postoperative day. Patient management is otherwise similar in the groups. The patients in the Deep breathing group will be instructed to perform breathing exercises (3 x 10 deep breaths) 5 times a day (document compliance) during the two postoperative months. A Positive expiratory pressure (PEP) device PEP ventil, System 22 (Rium Medical, Täby, Sweden) is used to create an expiratory resistance of +10 cm H2O.
223823896|NCT04989985|DRUG|Oxaliplatin+S-1|"Drug: Oxaliplatin Oxaliplatin: 130mg/m2，iv drip for 2h，d1, q3w~Drug: S-1 S-1: 40\~60mg Bid，d1\~14, q3w"
223823897|NCT04989985|DRUG|Sinitilimab+oxaliplatin+S-1|"Drug: Sintilimab Sintilimab, recombinant humanized anti-PD-1 monoclonal antibody for injection; 200mg ivdrip, d1, q3w.~Other Name: PD-1 antibody~Drug: Oxaliplatin Oxaliplatin: 130mg/m2，iv drip for 2h，d1, q3w~Drug: S-1 S-1: 40\~60mg Bid，d1\~14, q3w"
223823898|NCT01933503|DRUG|OCA 5 mg|
223823899|NCT01933503|DRUG|OCA 10 mg|
223823900|NCT01933503|DRUG|OCA 25 mg|
223823901|NCT05261932|PROCEDURE|AI-assisted guided biopsy|The surface of the adenoma was classified and identified by the AI system, and different areas of the adenoma were marked by distribution to guide the endoscopist for biopsy to obtain the poorly differentiated portion of the lesion.
223823902|NCT00791921|DRUG|CDP870|400mg CDP870 given at Week0, 2, 4 and thereafter 200mg CDP870 given every 2weeks until Week22 subcutaneously(SC)
223823903|NCT00791921|DRUG|Placebo of CDP870|Placebo given every 2 weeks until Week22 (SC)
223823904|NCT04736589|DRUG|Inetetamab|Initial dose of 8mg/kg, completed in 90 minutes IV infusion, and then 6 mg/kg over 30-90 minutes IV infusion every 3 weeks.
223823905|NCT04736589|DRUG|Rapamycin|Oral 2mg, once a day.
223823906|NCT04736589|DRUG|Pyrotinib|Oral 400mg, once a day.
223823907|NCT04736589|DRUG|Chemotherapy|Chemotherapy drugs are not limited in this trial, please refer to their instructions for specific usage.
223823908|NCT00389974|DRUG|sunitinib malate|Given PO
223823909|NCT05496621|OTHER|Questionnaire|1st Stage Keele Start MSk tool translated into Turkish and its cultural adaptation, 2nd Stage Statistical analysis of reliability and validity of Turkish Keele start msk tool
223823910|NCT01197079|OTHER|Survey|Self administered anonymous survey
223823911|NCT01175538|DRUG|Lactulose|In the Gp-L group, patients will receive 30-60 ml of lactulose in 2 or 3 divided doses so that patient passes 2-3 semisoft stools per day
223823912|NCT01175538|DRUG|Lactulose|lactulose will be used in 30-60ml/day
223823913|NCT03188900|BIOLOGICAL|A collection of maternal plasma and serum|A collection of maternal plasma and serum from patients with preeclampsia (PE) and normal pregnancy (NP)
223823914|NCT03266471|DIAGNOSTIC_TEST|Baseline blood sample|Blood sample for cytokine measurements and genetics.
223823915|NCT03266471|DIAGNOSTIC_TEST|Baseline intestinal biopsies|Up to 20 additional biopsies will be obtained at the time of standard of care colonoscopy. It is not felt that additional biopsies substantially increases the risk of a colonoscopy. Cytokine measurements will be performed on the tissue collected.
223823916|NCT03266471|OTHER|Crohn's disease activity index (CDAI)|To determine response, a Crohn's Disease Activity Index (CDAI) score will be obtained at time point 1 and time point 2 in all enrolled CD patients. The CDAI is a well validated symptom index for CD which assesses 8 factors including stool frequency, abdominal pain, general well being, CD complications, HCT, and deviation from ideal body weight.
223823917|NCT03266471|DIAGNOSTIC_TEST|Post treatment blood sample|Blood sample for cytokine measurements after patients have been on therapy for at least 6 weeks but no more than 52 weeks.
223823918|NCT03266471|DIAGNOSTIC_TEST|Post treatment intestinal biopsies|Up to 20 additional biopsies will be obtained at the time of standard of care colonoscopy at least 6 weeks but no more than 52 weeks after initiation of therapy. It is not felt that additional biopsies substantially increases the risk of a colonoscopy. Cytokine measurements will be performed on the tissue collected.
223823919|NCT03266471|DIAGNOSTIC_TEST|Baseline stool sample|Stool sample for inflammatory markers or microbiome analysis.
223823920|NCT03266471|DIAGNOSTIC_TEST|Post treatment stool sample|Stool sample for inflammatory markers or microbiome analysis.
223823921|NCT05297721|OTHER|Knowledge|Measuring the level of knowledge about skin tears
223823922|NCT00474175|DRUG|Placebo gel|single dose (less than 1g) of a matching placebo gel
223823923|NCT00474175|DRUG|benzocaine|single dose (less than 1g) of 10% benzocaine gel formulation
223823924|NCT00474175|DRUG|benzocaine|single dose (less than 1g) of 20% benzocaine gel formulation
223823925|NCT01305746|DRUG|A-623|High dose given subcutaneously once a week until A623 is approved for clinical use in SLE or the Sponsor discontinues the study
223823926|NCT01305746|DRUG|A-623|Low dose given subcutaneously once a week until A623 is approved for clinical use in SLE or the Sponsor discontinues the study
223823927|NCT01305746|DRUG|A-623|High dose given subcutaneously once every 4 weeks until A623 is approved for clinical use in SLE or the Sponsor discontinues the study
223823928|NCT04695340|DIETARY_SUPPLEMENT|Psyllium|Psyllium is given to patients
223823929|NCT01620359|DEVICE|ExAblate MRgFUS|100% ablation of an up-to-2-cm breast cancer visible on an contrast-enhanced MRI with 5-10 mm margins around the primary tumor
223823930|NCT04542226|DRUG|Polyoxidonium|Polyoxidonium (azoximer bromide) is administered in the dose of 12 mg (contents of 2 vials) once daily intravenously (IV) for 3 days, then every other day intramuscularly (IM) on days 5-17 (the total treatment course is 10 injections)
223823931|NCT05601635|DIETARY_SUPPLEMENT|ButyraGen™|ButyraGen™ contains tributyrin as the primary active as well as Sunfiber®, a partially hydrolyzed guar fiber, and acacia fiber.
223823932|NCT03874780|DEVICE|Vibe Delivery system|delivery of Botox (TM) to the bladder wall using an ultrasound technology with the Vibe delivery system
223823933|NCT03848091|OTHER|Antibiotic pretreatment|a strategy with antibiotic pretreatment before one-step exchange arthroplasty in patients who bacteria responsible for the infection has been indentified (puncture, blood cultures,...)
223823934|NCT02456974|PROCEDURE|blood sampling in patients receiving amoxicillin-clavulanate as part of routine clinical care|
223823935|NCT02456974|PROCEDURE|blood sampling in patients receiving piperacilline-tazobactam as part of routine clinical care.|
223823936|NCT02456974|PROCEDURE|blood sampling in patients receiving vancomycin as part of routine clinical care.|
223823937|NCT02456974|PROCEDURE|blood sampling in patients receiving teicoplanin as part of routine clinical care.|
223823938|NCT02456974|PROCEDURE|blood sampling in patients receiving meropenem as part of routine clinical care.|
223823939|NCT02456974|PROCEDURE|blood sampling and urine smapling in patients receiving ciprofloxacin as part of routine clinical care.|
223823940|NCT02456974|PROCEDURE|blood sampling in patients receiving amikacin as part of routine clinical care.|
223823941|NCT04463784|DRUG|Efavirenz 400Mg Oral Tablet|The experimental arm will receive 400mg efavirenz per randomization with other two antiretroviral medication (tenofovir and lamivudine).
223823942|NCT04463784|DRUG|Efavirenz 600Mg Oral Tablet|The active comparator arm will receive 600mg efavirenz per randomization with other two antiretroviral medication (tenofovir and lamivudine).
223823943|NCT02792985|BEHAVIORAL|Multisensory stimulation protocol|"Participation in occupation-based multisensory stimulation (e.g. personal care with aromatic soaps, varying water temperatures and textured sponges, drink preparation of different flavoured beverages) with a variety of different sensory stimuli (e.g. strong smells, different shapes and weights). The participant will receive two individual 30-minute therapy sessions with an Occupational Therapist.~An enriched environment will be set up in the participant´s bedroom. It will include items that provide a range of meaningful sensory stimuli (e.g. familiar personal objects, projection of photos and known places, familiar music). The participant is encouraged to follow a timetable including regular rest breaks through out the day in their room."
223823944|NCT02792985|BEHAVIORAL|Control protocol|"Retraining of basic activities of daily living or participation in table top tasks and games in an individual 30 minute session or a one hour small group session with an Occupational Therapist.~Minimal changes are made to the participant´s room (e.g. orientation board, photos of family and friends)."
223823945|NCT00635765|DRUG|C2L-OCT-01 PR 30 mg|Administered by deep IM (gluteus) on Day 1. Beginning on Day 42, drug injection frequency (6, 5 or 4 weeks) and dose modification/adjustment will be allowed for every 3 drug injections based on the mean serum GH and clinical symptoms obtained at the last visit of study C2L-OCT-01 PR-301 and during the course of this study.
223823946|NCT02810314|BEHAVIORAL|neuropsychological battery|neuropsychological battery including cognitive and behavioural tests
223823947|NCT02810314|OTHER|resting state functional magnetic resonance image (rs-fMRI)|rs-fMRI
223823948|NCT01460160|DRUG|Dasatinib|Tablets, Oral, 60 mg/m2, Once daily, 2 years or until unacceptable toxicity
223823949|NCT02357043|DEVICE|Dario Blood Glucose Monitoring System|Finger-stick obtained with BGMS
223823950|NCT02357043|DEVICE|YSI|Finger-stick sample obtained by nurse/technician to be tested with YSI
223823951|NCT01291238|BEHAVIORAL|Healthier, Smarter, Happier|Increased physical activity and decreased sugar and fat intake during school hours
223823952|NCT02091739|DRUG|IncobotulinumtoxinA (100 Units)|Active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).
223823953|NCT02091739|DRUG|IncobotulinumtoxinA (75 Units)|Active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).
223823954|NCT02091739|DRUG|Placebo|Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).
223823955|NCT01948180|BIOLOGICAL|baltaleucel-T|Autologous EBV-specific T-cells
223823956|NCT05666544|OTHER|Web-based patient decision aid|After the clinic, use web-based patient decision aid of renal replacement therapy to conduct education.
223823957|NCT05666544|OTHER|Written health education leaflets|After the clinic, use a written health education leaflet on renal replacement therapy to conduct education.
223823958|NCT00192023|DRUG|atomoxetine 0.5 mg/kg/day|atomoxetine 0.5 milligrams per kilogram per day (mg/kg/day) daily (QD), by mouth (PO)
223823959|NCT00192023|DRUG|placebo|
223823960|NCT00192023|DRUG|atomoxetine 1.2 mg/kg/day|atomoxetine 1.2 mg/kg/day QD, PO
223823961|NCT00192023|DRUG|atomoxetine 1.2-1.4 mg/kg/day|atomoxetine 1.2 - 1.4 mg/kg/day QD, PO
223823962|NCT00022217|DRUG|carboplatin|
223823963|NCT00022217|DRUG|cisplatin-e therapeutic implant|
223823964|NCT00022217|DRUG|paclitaxel|
223823965|NCT03213496|BEHAVIORAL|Walk prescription|30-40 minutes daily, for five days at the week, all weeks up to surgery.
223823966|NCT03213496|OTHER|Conventional care|Patient do not walk before surgery
223823967|NCT01336959|DRUG|BCT197 Part A|open label single dose administration of 10mg BCT197, 2 hours prior to surgery
223823968|NCT01336959|DRUG|Placebo|Single dose matching placebo administered 2 prior to surgery
223823969|NCT01336959|DRUG|BCT197 Part B|BCT197 50mg single dose administered 2 hours prior to surgery
223823970|NCT02086162|BEHAVIORAL|Web-based motivational decision support system|
223823971|NCT02086162|BEHAVIORAL|NCI Education|
223823972|NCT04337060|PROCEDURE|Single-injection ultrasound-guided bilateral erector spinae plane (ESP) block-Sham|"With the patient in the sitting position, 20 ml normal saline will be administered between the T11 spinous process and the erector spinae muscles with the guidance of an ultrasound probe placed on a parasagittal plane.~Intraoperative analgesia: after anesthesia induction, paracetamol 1 gr intravenous (IV)+ tenoxicam 20 mg IV + morphine 0.05 mg/kg IV (max 4 mg).~Postoperative analgesia: IV morphine patient-controlled analgesia (PCA) of 0.5 mg/ml morphine (demand dose 1 mg; lockout interval 8 m; 6 mg/h limit)."
223823973|NCT04337060|PROCEDURE|Single-injection ultrasound-guided bilateral erector spinae plane block-Lidocaine/Bupivacaine|"With the patient in the sitting position, 10 ml 1% lidocaine + 10 ml 0.5% bupivacaine will be administered between the T11 spinous process and the erector spinae muscles with the guidance of an ultrasound probe placed on a parasagittal plane.~Intraoperative analgesia: After anesthesia induction, paracetamol 1 gr IV + tenoxicam 20 mg IV + morphine 0.05 mg/kg IV (max 4 mg).~Postoperative analgesia: IV PCA of 0.5 mg/ml morphine (demand dose 1 mg; lockout interval 8 m; 6 mg/h limit)."
223823974|NCT04337060|OTHER|Pain follow-up and monitorization|Numeric Rating Scale (NRS) pain score will be recorded from 15th minute in recovery room followed by 1.-3.-6.-12.-18.-24.hours with two different conditions which are at rest and while couching.If NRS score becomes ≥4 Dexketoprofen 50 mg will be administered (max 4 times).
223823975|NCT03326947|DRUG|docetaxel, cisplatin and 5-fluorouracil|"Drug: TPF induction chemotherapy TPF induction chemotherapy: 2 cycles; docetaxel(75mg/m\^2), cisplatin(75 mg/m\^2), 5-Fu(750 mg/m\^2/day) for 5 days; 16 days later, the 2nd cycle. 2 weeks later, surgery.~Surgery: radical resection and full neck dissection with reconstruction. Radiotherapy: 4-6 weeks after surgery, 1.8-2Gy/day, 5 days/week for 6 weeks, and totally 54-60Gy, for high risk factors, concurrent chemotherapy with cisplatin of 80mg/m2.~Other Names:~TPF protocol group Procedure/Surgery: surgery In the TPF group,surgery was performed at least 2 weeks after completion of induction chemotherapy.Surgery group includes radical resection of the primary lesion and full neck dissection(functional or radical) with proper reconstruction(pedicle or free flap) were performed.~Radiation: radiotherapy"
223823976|NCT04929366|PROCEDURE|Hypothermic dialysis followed with routine dialysis|Hypothermic dialysis (35.5 degrees Celsius dialysate) followed with routine dialysis (36.5 degrees Celsius dialysate)
223823977|NCT04929366|PROCEDURE|Routine dialysis followed with hypothermic dialysis|Routine dialysis (36.5 degrees Celsius dialysate) followed with hypothermic dialysis (35.5 degrees Celsius dialysate)
223823978|NCT03620682|BEHAVIORAL|Coaching sessions|Participants receive three 30-minute phone sessions with a doctorate-level therapist over the course of one month. These sessions are skills-based and focus on improving participants' problem solving through cognitive-behavioral techniques. Participants are allowed to text the therapist between sessions for information and support.
223823979|NCT03620682|BEHAVIORAL|Mobile applications|Participants will have access to 3 mobile apps for the duration of the study, and after it ends. One app will push participants a daily, self-reflective survey to complete, and a daily motivational or instructional tip to rate. Other apps will provide education and exercises on various aspects of mental health and wellness, such as sleep and relaxation.
223823980|NCT00687336|OTHER|Empirical Hp eradication|Empirical Helicobacter pylori treatment initiated immediately after oral intake is resumed
223823981|NCT00687336|OTHER|Eradication treatment guided by a positive test|Eradication treatment given if there is at least one positive diagnostic test (URT, histological test, breath test or serology) for Helicobacter pylori.
223823982|NCT04848181|DRUG|cyproterone acetate|two weeks Cyproterone acetate administration before TURP
223823983|NCT04848181|DRUG|finasteride|two weeks finasteride administration before TURP
223823984|NCT04848181|DRUG|no treatment received|no treatment received before TURP
223823985|NCT04230460|DRUG|Cannabis (THC) (Inhaled) Placebo|Cannabis vapor is produced from 500 mg of dried plant material (placebo) (0% THC). Participants will inhale ad libitum over 10 minutes.
223823986|NCT04230460|DRUG|Cannabis (High% THC) (Inhaled)|Cannabis vapor is produced from 500 mg of dried plant material (7.5% THC). Participants will inhale ad libitum over 10 minutes.
223823987|NCT04230460|DRUG|Cannabis (Very High% THC) (Inhaled)|Cannabis vapor is produced from 500 mg of dried plant material (12.5% THC). Participants will inhale ad libitum over 10 minutes.
223823988|NCT04230460|DRUG|Alcohol (oral)|Subjects will be dosed to achieve a 0.05% Blood Alcohol Concentration (BAC), so the amount of alcohol consumed will be calculated to produce a peak BAC of 0.065%. Subjects will be served three equal-sized drinks, 10-minutes apart, and be instructed to pace each drink evenly over the 10-minute period.
223823989|NCT01876563|DIETARY_SUPPLEMENT|vitamin D|one tab 4000 IU/day vitamin D
223823990|NCT01876563|DIETARY_SUPPLEMENT|placebo|one tab per day placebo
223823991|NCT00344006|DRUG|chlorproguanil-dapsone-artesunate|
223823992|NCT00344006|DRUG|artemether-lumefantrine|
223823993|NCT04035655|BEHAVIORAL|Coma Recovery Scale - revised|"Assessment of the level of consciousness by the dedicated Coma Recovery Scale - Revised, current gold-standard in consciousness level assessment.~Assessment before and after the tDCS session (immediately before and after the electrophysiological assessment, see below)."
223823994|NCT04035655|DIAGNOSTIC_TEST|Electrophysiological recordings|"The electrophysiological assessment consisted of:~* a 5 minutes resting state high-density EEG recording~* a approximately 6 minutes auditory oddball paradigm These two procedures were administered immediately before and after the tDCS session"
223823995|NCT00543660|PROCEDURE|Descemet Stripping Automated Endothelial Keratoplasty (DSAEK)|
223823996|NCT03357367|DEVICE|TiVi system|"Device: TiVi system A galvanic current (0.1 mA) will be applied between 2 patches on the forearm of patient and protocol was repeated at 4 minutes.~Microvascular response to current application (CIV) will be recorded by TiVi system 10 minutes later.~Measurement of the value of skin blood flow (by TiVi system) at the stimulated area as compare to a non stimulated adjacent skin value taken as a reference Usual treatment will be recorded"
223823997|NCT00695747|PROCEDURE|2 Site procedure- Phacoemulsification/IOL and Trabeculectomy|2 Site Combined Procedure: in which a temporal clear cornea approach would be used for the cataract/IOL part of the procedure, and immediately thereafter the superior limbus would be employed for a limbus-based trabeculectomy
223823998|NCT02276391|DRUG|Telmisartan/HCTZ combination|
223823999|NCT02276391|DRUG|Telmisartan|
223824000|NCT03747770|BIOLOGICAL|Bivalent HPV vaccine CERVARIX®|Bivalent HPV vaccine(Glaxo Smith Kline, GSK, Rixensart, Belgium) presented as a suspension for intramuscular injection containing purified viral L1 protein for HPV types 16 and 18. Each 0.5 mL dose of the bivalent vaccine contains 20μg of HPV-16 L1 protein and 20 μg of HPV-18 L1 protein adsorbed onto a proprietary adjuvant system containing 500 μg of aluminum hydroxide and 50 μg of 3-O-desacyl-4-monophosphoryl lipid A (AS04)
223824001|NCT01803230|DIETARY_SUPPLEMENT|creatine supplementation|creatine supplementation
223824002|NCT01803230|DIETARY_SUPPLEMENT|Placebo|
223824003|NCT04760730|BIOLOGICAL|AZD1222|"Active substance: ChAdOx1 nCoV-19, a replicant-deficient simian adenoviral vector in the amount of 5 х 10\^10 particles (nominal) per dose (unit dose strength \> 0.7 × 10\^11 vp/mL).~Solution for intramuscular injection, supplied in vials in a carton box"
223824004|NCT04760730|BIOLOGICAL|rAd26-S|"Component I (Dose 1) - (0.5 ml per dose) contains:~Active substance: recombinant adenovirus serotype 26 particles containing the SARS-CoV-2 protein S gene, in the amount of (1.0±0.5) х 10\^11 particles per dose (unit dose strength 1 × 10\^11 vp/0.5 mL) .~Solution for intramuscular injection, supplied in vials in containers"
223824005|NCT05386251|BEHAVIORAL|BPT/OST|See Arm description.
223824006|NCT05386251|BEHAVIORAL|Peer Support|See Arm description
223824007|NCT02142582|DIETARY_SUPPLEMENT|WHO ORS|Participants will be randomized into one of the two groups. They will be provided with one of the two ORS solutions. Then, they will be followed for 6 months.
223824008|NCT02142582|DIETARY_SUPPLEMENT|Commercial ORS|Participants will be instructed to dilute contents of the provided ORS to a 1 liter bottle and sip all day.
223824009|NCT03070509|DRUG|Lisdexamfetamine|lisdexamfetamine 50 mg single dose
223824010|NCT02712697|DRUG|WM (Shentong Granules)|Shentong Granules with Prednisone
223824011|NCT02712697|DRUG|Hormone (prednisone)|Oral prednisone
223824012|NCT05342103|PROCEDURE|high flow oxygenation|All patients will have FiO2 started at 0.4 and titrated to maintain oxygen saturation (SpO2) ≥ 95%.
223824013|NCT01458990|DRUG|Omeprazole|20mg PO BID for 20 days
223824014|NCT01442272|DRUG|Hidroferol®|Hidroferol® drinkable ampoule in oral solution, 266 mcg (1 drinkable ampoule) each 15 days during 12 months
223824015|NCT01442272|DRUG|Paricalcitol: Zemplar®|Paricalcitol (Zemplar®) oral capsule , 1 mcg (1 capsule)each 24 hours during 12 months
223824016|NCT01442272|DRUG|Habitual medication|Habitual medication
223824017|NCT00986115|DRUG|Memantine|After a two-month prospective baseline during which seizure frequency and neurocognitive parameters are documented, patients will be randomized to either memantine or placebo and evaluated after twelve months on study drug. The treatment period will consist of a one month dose escalation phase, followed by an eleven month maintenance phase. The dose escalation is 5 mg in PM for days 1-7, 5 mg twice daily for days 8-14, 5 mg in AM and 10 mg in PM for days 15-21 and 10 mg twice daily from day 22 and continue.
223824018|NCT00986115|DRUG|Placebo|After a two-month prospective baseline during which seizure frequency and neurocognitive parameters are documented, patients will be randomized to either memantine or placebo and evaluated after twelve months on study drug. The treatment period will consist of a one month dose escalation phase, followed by an eleven month maintenance phase. The dose escalation is 5 mg in PM for days 1-7, 5 mg twice daily for days 8-14, 5 mg in AM and 10 mg in PM for days 15-21 and 10 mg twice daily from day 22 and continue.
223824019|NCT06488391|BEHAVIORAL|Using a Portable Visualized Device for Self-Directed Breathing Training|Using a Portable Visualized Device for Self-Directed Breathing Training
223824020|NCT01937637|BEHAVIORAL|Cognitive Behavioral Intervention for Breathlessness|Cognitive behavioral intervention for breathlessness, delivered by nurse practitioners during outpatient oncology appointments, in up to 8 patients with advanced lung cancer.
223824021|NCT04227496|DEVICE|Auditory disturbances|A sound will be played from a portable device (smartphone) during movement
223824022|NCT02690636|RADIATION|radiotherapy|daily fractions, five fractions per week.
223824023|NCT00308737|DRUG|Technosphere® Insulin Inhalation Powder|Inhalation, 15U/30U
223824024|NCT00308737|DRUG|Usual Care|Subjects will receive antidiabetes treatment at the discretion of their physicians
223824025|NCT02109796|DEVICE|transcranial Direct current stimulation|
223824026|NCT00493337|BEHAVIORAL|advanced adherence counseling+reminder|
223824027|NCT00493337|DEVICE|Compliance Card|
223824028|NCT00101309|BIOLOGICAL|aldesleukin|
223824029|NCT00101309|BIOLOGICAL|autologous EBV-transformed B lymphoblastoid-tumor fusion cell vaccine|
223824030|NCT00101309|BIOLOGICAL|therapeutic autologous lymphocytes|
223824031|NCT00089895|DRUG|Eptifibatide (Integrilin)|intravenous; 180 mcg/kg bolus followed by infusion of 2 mcg/kg/min for 12 to 96 hours (or longer if necessary to complete the 18- to 24-hour post-PCI infusion period, or up to 120 hours in patients who proceed to CABG \[coronary artery bypass graft\]); second bolus of 180 mcg/kg administered 10 minutes after first bolus.
223824032|NCT00089895|DRUG|Placebo|intravenous; delivery to match eptifibatide to maintain blind
223824033|NCT00000942|DRUG|Nevirapine|
223824034|NCT00829361|OTHER|Telemedicine|Two way site independent audio/video telemedicine system with DICOM.
223824035|NCT00023790|DRUG|silicon phthalocyanine 4|Patients receive silicon phthalocyanine 4 (Pc 4) IV over 2 hours on day 1 followed by light therapy over 30-60 minutes on day 2. Treatment repeats in 6 weeks for a total of 2 courses in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of Pc 4.
223824036|NCT06495437|BIOLOGICAL|Intravenous infusion of extracellular vesicle preparation derived from Wharton's jelly mesenchymal stem cells.|The trial protocol includes a 3-week screening period and a 12-week study period after enrollment. The specific trial protocol is detailed in the figure above. Cell-derived extracellular vesicle formulation will be administered at week 0, with central visits conducted during the administration period. Central visits will also be conducted at weeks 1, 4, and 12 post-administration, with a phone visit at week 8. The entire study will last for 12 weeks. Following the final follow-up visit, further observation of the intervention's effects and safety will continue for an additional 3 months. During this 3-month period, there will be no artificial intervention or restriction on the medication and biological methods for the participants in each group.
223824037|NCT04192474|DEVICE|Flexible cystoscopy|Treatment with the investigational device: Ambu® aScope™ 4 Cysto
223824038|NCT00099723|DRUG|VSL#3|
223824039|NCT05482737|OTHER|no intervention|This is an observational retrospective study (meta-analysis)
223824040|NCT05644353|DRUG|Mirikizumab|Administered SC.
223824041|NCT05657444|DRUG|Tenecteplase|intra-arterial tenecteplase during endovascular treatment
223824042|NCT03622879|BEHAVIORAL|MT|A customised angle-adjustable frame with a mirror board (60 × 90 cm) will be used. All subjects are instructed to perform hip flexion/abduction, knee flexion/extension and ankle dorsiflexion/plantarflexion on the intact-limb during a 15 minutes period.
223824043|NCT03622879|DEVICE|TENS|TENS will be delivered to the common peroneal nerve of the paretic leg. The stimulation frequency will be 100Hz and with an intensity just below the motor threshold.
223824044|NCT03622879|BEHAVIORAL|Lower-limb task-oriented training|The lower-limb task-oriented training comprises 6 exercises, namely stepping up and down, heel lift a dorsiflexed position, partial squatting, kicking a ball with alternate legs, gait re-education and transition training. Each exercise last for 10 minutes
223824045|NCT04937036|DIAGNOSTIC_TEST|Polysomnography|Each of the patients will undergo polysomnography
223824046|NCT04637165|OTHER|This is a non-interventional study|This is a non-interventional study
223824047|NCT04783298|OTHER|App|An application to deliver a series of behavioral questionnaires and decision-making game
223824048|NCT05330741|OTHER|Designed Physical Therapy Program|The designed physical therapy program include gentle stretching exercises, static muscle contraction, facilitation of trunk control from different positions, balance training from different positions on tilting board, facilitation of righting, protective and equilibrium reactions from different positions, facilitation of standing from different positions, gait training and, climbing stairs up and down.
223835560|NCT03377075|DEVICE|OCT|Choroidal and retinal thickness measurement (DRI OCT-1 Model Triton (plus), Topcon, Tokyo, Japan)
223824049|NCT05330741|OTHER|Whole-Body Vibration|"The designed physical therapy program (mentioned before)~\+ Whole-body vibration (WBV) training, child will be asked to stand with slightly flexed knees (30 degrees of knee flexion), and both feet will be placed at an equal distance from the center of the platform to achieve an equal distribution of body weight over both feet. The device will set to produce a peak-to-peak sinusoidal vibration with an amplitude of 2 mm and a vibration frequency ranged from 25 to 30 Hz. WBV will applied for (30 sec. of WBV, 1 min rest, 10 repetitions), (45 sec. of WBV, 1 min rest, 10 repetitions), (60 sec. of WBV, 1 min rest, 10 repetitions) in the 1st, 2nd. and 3rd. months respectively."
223824050|NCT05330741|OTHER|Gravity Force Stimulation|"The designed physical therapy program (mentioned before)~\+ Gravity force stimulation child will be asked to maintain his balance on GFS during each of the following positions as a progression (standing and walking on the surface of two beams connecting the two boxes - standing and walking crossly on the surface of one beam connecting the two boxes - standing and walking sideward on the surface of one beam connecting the two boxes - standing and walking on the edge of the two beams - standing and walking on the edge of one beam: most difficult)"
223824051|NCT06159413|DEVICE|VIRTUAL REALITY|LUMBAR MULTIFIDUS MUSCLES FUNCTION AMONG PATIENTS WITH LOW BACK PAIN: VIRTUAL REALITY VERSUS STABILIZATION EXERCISES.
223824052|NCT01181505|DRUG|Tolterodine|
223824053|NCT02888067|DRUG|Rocuronium bromide 0.5 mg/kg|Moderate neuromuscular blockade with rocuronium bromide
223824054|NCT02888067|DRUG|Rocuronium bromide 1.0 mg/kg|Deep neuromuscular blockade with rocuronium bromide
223824055|NCT02888067|DRUG|Sugammadex sodium 2 mg/kg|Reversal with sugammadex sodium
223824056|NCT02888067|DRUG|Sugammadex sodium 4 mg/kg|Reversal with sugammadex sodium
223824057|NCT03361696|OTHER|Help to use the Interface System of Communication and Control of the Environment|the occupational therapist and the ergonomics engineers at the rate of 4 sessions per patient for periods of 2 to 3 hours help patient to use use the Interface System of Communication and Control of the Environment
223824058|NCT03065114|OTHER|PGS|chromosome abnormality test from PGS and relationship between embryo development
223824059|NCT04778514|DRUG|Dual Prevention Pill|a single over-encapsulated DPP containing a PrEP tablet and a COC
223824060|NCT04778514|DRUG|PrEP and combined oral contraceptive (COC) as two separate tablets|PrEP tablet and a COC as two separate tablets
223824061|NCT00960921|DRUG|Iron sucrose|An intravenous infusion of 100 mg of iron is administered on days 0, 4, 8, 12, 16 and 20 of the study, giving a total of six iron infusions for each participant in the iron group over the course of the 28-day study period.
223824062|NCT00960921|DRUG|Normal saline|An intravenous infusion of 100 ml of normal (0.9 %) saline is administered on days 0, 4, 8, 12, 16 and 20 of the study, giving a total of six saline (placebo) infusions for each participant in the saline group over the course of the 28-day study period.
223824063|NCT03116490|PROCEDURE|Anesthesia type|RA group uses regional anesthesia(epidural, spinal, combined spinal and epidural anesthesia or nerve block) ,and GA group uses general anesthesia(general anesthesia combined with peripheral nerve blockade, general anesthesia combined with spinal/epidural anesthesia or single general anesthesia) .
223824064|NCT00049998|DRUG|topotecan|
223824065|NCT05943314|BIOLOGICAL|CLL1/+CD33 CAR-T|CLL1/+CD33 CAR T is a type of CAR T cell therapy for patients with treating/relapsed acute myeloid leukemia.
223824066|NCT01535274|OTHER|Inspired oxygen fraction / end tidal carbon dioxide|"Following induction of anesthesia, FIO2 and minute ventilation will be sequentially adjusted to achieve:~1. FIO2 30% (70% nitrogen), PETCO2 30mmHg - supine position.~2. FIO2 30% (70% nitrogen), PETCO2 30mmHg - beach chair position.~3. FIO2 100%, PETCO2 30mmHg - beach chair position.~4. FIO2 100%, PETCO2 45mmHg - beach chair position.~5. FIO2 30% (70% nitrogen), PETCO2 30mmHg - beach chair position."
223824067|NCT03679767|DRUG|Retifanlimab|Retifanlimab administered intravenously at 500 mg every 4 weeks
223824068|NCT02310698|DEVICE|contrast enhanced digital mammography (CEDM)|
223824069|NCT02310698|DEVICE|whole breast screening ultrasound (WBUS)|
223824070|NCT03173092|DRUG|Ixazomib|Ixazomib capsules.
223824071|NCT03173092|DRUG|Lenalidomide|Lenalidomide capsules.
223824072|NCT03173092|DRUG|Dexamethasone|Dexamethasone.
223824073|NCT03548805|PROCEDURE|ologen® Collagen Matrix|Ologen is a collagen matrix used to modulate wound healing in the postoperative period to promote diffuse blebs
223824074|NCT03548805|PROCEDURE|Trabeculectomy with low dose mitomycin C|Trabeculectomy with low dose MMC
223824075|NCT05210556|OTHER|Diagnosed with Surgical Site Infection|As an observational study, this notates patients who were diagnosed with a deep organ/space surgical site infection within 30 days of surgery
223824076|NCT04161040|BEHAVIORAL|Performance-based incentives|Participants will earn $1 per minute of engagement in physical activity.
223824077|NCT04730843|DRUG|ES102|ES102 is administered via intravenous injection once every 21 days, every 21 days as a treatment cycle.
223824078|NCT02130453|DRUG|Regadenoson|0.4 mg by vein given during nuclear stress testing with echocardiography strain measurements.
223824079|NCT05998837|DRUG|Dapagliflozin 10mg Tab|"Dapagliflozin will be add on RAAS-i titrated with the aim to reach optimal blood pressure control as defined by European Society of Hypertension (i.e., 120-130/70-80 mmHg) in all subject.~Prior to randomization all the patient with Type 2 Diabetes must have undergone at least 4 weeks of therapy with metformin and/or repaglinide"
223835561|NCT02181205|DRUG|bupivacaine|
223835562|NCT02181205|DRUG|placebo|
223835563|NCT02459340|OTHER|therapeutic treatment (inpatient and outpatient setting)|
223824080|NCT05998837|DRUG|Placebo|"Placebo will be add on RAAS-i titrated with the aim to reach optimal blood pressure control as defined by European Society of Hypertension (i.e., 120-130/70-80 mmHg) in all subject.~Prior to randomization all the patient with Type 2 Diabetes must have undergone at least 4 weeks of therapy with metformin and/or repaglinide"
223824081|NCT06850831|DRUG|Antipac|The first group is the NAC group, which will get intracoronary NAC 480 mg immediately after the lesion is opened during primary PCI. And the second group will have placebo immediately after the lesion is opened during primary PCI.
223824082|NCT04772885|DRUG|KT-474/Placebo|KT-474 or matching placebo oral tablet(s)
223824083|NCT04772885|DRUG|KT-474|KT-474 oral tablet(s)
223824084|NCT05763784|DEVICE|Tightrope|Tightrope use special fiber and a set of metal buttons to fix diastasis of a joint.
223824085|NCT05487430|BEHAVIORAL|Positive Self-Affirmation|Each participant of the intervention group was given a set of earphones and an MP3 player which included an audio recording with a background sound of birds crowing and river-like flowing water together with the positive affirmation sentences. The self-affirmation sentences were created by the first author by paying special attention to not using negative predicates and words with negative meanings such as pain, nausea, and discomfort. In the audio recording, the affirmative sentences were verbalized by the first author with a soothing voice. Between each sentence, a pause is given so that the patient can repeat each sentence verbally or internally. The audio recording lasted 5 minutes 40 seconds and the patients were asked to listen to it at least once a day, however, they were encouraged to listen to it as much as they wanted.
223824086|NCT05851599|OTHER|SKF7® Labisia pumila standardized extract|Botanical extract of Labisia pumila (Kacip Fatimah)
223824087|NCT01407354|DEVICE|Lokomat treadmill training|Lokomat treadmill training: 12 wks, 3x/wk, 45 mins@session
223824088|NCT01407354|OTHER|Aquatic exercise therapy|Aquatic exercise training: 12 wks, 3x/wk, 45 mins@session
223824089|NCT03033459|BEHAVIORAL|Motivational Interviewing|"Motivational Interviewing (MI) is a psychosocial intervention designed to help individuals increase readiness for behavior change by increasing intrinsic motivation and resolving ambivalence. MI founders MI conversations help clients change behavior through identifying and resolving discrepancies between goal behaviors and actual behaviors. Behavior change is promoted through the elicitation of change talk, or client-verbalized arguments for change. In MI, change talk is elicited through two major components: the therapeutic relationship, or the embodiment of the spirit of MI, and technical skill."
223824090|NCT03033459|BEHAVIORAL|Psychoeducation Control|Psychoeducation on infant development, age 0-15 months, brief education on breastfeeding.
223824091|NCT02118662|OTHER|Energy Expenditure during seated in an office chair|You will first rest motionless in a chair for 20 minutes. You will complete the working conditions for 15 minutes each at your own self-selected level of effort. A rest period of 5 minutes will be given between each condition. During the working conditions, you will be asked to retype a displayed standard set of text.
223824092|NCT02118662|OTHER|Energy Expenditure during seated and typing|You will complete this working conditions for 15 minutes. A rest period of 5 minutes will be given between each condition. During the working conditions, you will be asked to retype a displayed standard set of text.
223824093|NCT02118662|OTHER|Energy Expenditure during Treadmill walking work condition|You will complete the working conditions for 15 minutes each at your own self-selected level of effort. A rest period of 5 minutes will be given between each condition. During the working conditions, you will be asked to retype a displayed standard set of text.
223824094|NCT02118662|OTHER|Energy Expenditure during cycling work condition|You will complete the working conditions for 15 minutes each at your own self-selected level of effort. A rest period of 5 minutes will be given between each condition. During the working conditions, you will be asked to retype a displayed standard set of text.
223824095|NCT04849221|OTHER|Tympanometry measurement in both ears|Measurement once or twice a day and at every change of more than 10 mmHg in ICP, over the entire period of time that ICP is measured by a probe or DVE
223824096|NCT04849221|OTHER|Collection of clinical and paraclinical data|"Patient: gender, weight/height, age, etiology of ICP entry, reason for ICP monitoring, presence of external (otoscopy), middle (otoscopy + CT) or internal (CT) ear abnormality, presence of inclusion and non-inclusion criteria, measurement of patient tilt.~healthy subjects: gender, weight/height, age, presence of abnormality of the external (otoscopy), middle (otoscopy) or internal ear (questioning), presence of inclusion and non-inclusion criteria..."
223824097|NCT04849221|OTHER|Intracranial pressure reading (ICP)|a single measure
223824098|NCT02556151|PROCEDURE|Repetitive lumbosacral magnetic stimulation (rTLSMS)|Patients randomized to Six sessions of weekly therapy with either 1 HZ or 5 Hz or 15 Hz magnetic stimulations of the lumbar and sacral regions.
223824099|NCT00762840|DEVICE|the Apexum Protocol|using the apexum kit for minimally invasive removal of periapical lesion tissue.
223824100|NCT00762840|PROCEDURE|Conventional endodontic procedure|Standard root canal treatment
223824101|NCT02204579|DRUG|NPSP795|
223824102|NCT00723437|DRUG|acitretin|Acitretin at the dosage of 0.2 to 0.3 mg/Kg/day for 6 months.
223824103|NCT03999268|BEHAVIORAL|I-START|Designed as a supplementary educational tool for patients on insulin therapy, I-START includes an injection plan to reinforce the knowledge and behaviors that users have been taught by their health care provider. This is done through eight modules created for the benefit of new and experienced insulin users, and those using pens or vial/syringes. The modules address a variety of topics pertinent to insulin therapy, including overcoming psychosocial barriers, injection techniques and best practices, managing hypo- and hyperglycemic events, monitoring blood glucose and troubleshooting and problem solving. At the end of each module, users can self-evaluate their confidence in mastering the information presented. This gives them the ability to move forward into the next module, repeat material already presented and/or save features of the modules that they would like to revisit at another time.
223824104|NCT03999268|BEHAVIORAL|Standard Insulin Administration Education|Standard best practices for training patients to administer insulin therapy include 1) a thorough patient assessment prior to therapy initiation to address barriers, including evaluation for diminished cognitive capacity or other problem that may impair safe insulin self-administration, and assessment of health literacy and numeracy skills; 2) observation of a patient's injection practice, with re-education provided as needed; 3) use of appropriate language is necessary when teaching injection technique; 4) dose preparation, which includes inspecting the insulin dose for accuracy (following manufacturer instructions); and 5) review of signs, symptoms and treatment of hypoglycemia must be included as a critical component of the training.
223824105|NCT01621204|DRUG|Eltrombopag|Participants are started on 50mg daily oral pill (or 25mg daily for patients of East Asian descent) 21 days before surgery. Dose may be adjusted based on subsequent platelet counts (minimum 25mg; maximum 75mg).
223824106|NCT01621204|DRUG|IVIG infusion|IVIG infusion (1-2 g/kg) given 7 (+/-2) days prior to surgery; with an additional infusion allowed within one week of achievement of surgical hemostasis, if needed
223824107|NCT02778399|DRUG|Placebo|Placebo tablets for oral administration once daily
223824108|NCT02778399|DRUG|OBE2109|OBE2109 tablets for oral administration once daily
223824109|NCT03347747|OTHER|Study Photography + Personal & Medical History Collection|3D facial images taken and complete a detailed study questionnaire
223824110|NCT03501043|DRUG|Dysport|Dysport 1000 to 1500 units to be distributed on the basis of clinical indication to ankle plantar flexors (gastrocnemius and soleus), knee extensors and flexors, tibialis posterior and long toe flexors.
223824111|NCT04189263|OTHER|Carbohydrate restricted dietary intervention|Carbohydrate restricted dietary intervention (\<20 g carbohydrates/day)
223824112|NCT04189263|DRUG|standard of care aromatase inhibitors|standard of care aromatase inhibitors
223824113|NCT02475525|DIETARY_SUPPLEMENT|Arginine enriched oral nutritional supplement|oral nutritional supplement containing arginine
223824114|NCT04268992|OTHER|Long-term exercise|All patients randomised to long-term exercise will perform exercise training at least three times a week for three months. The exercise is supervised and individualised.
223824115|NCT02081456|OTHER|Soft Tissue Mobilization|Patients in the STM group received treatment in supine, with their head resting on one pillow and the involved UE positioned in abduction and external rotation to preload the neural structures of the upper limb. Manual pressure was applied to the soft tissues of the upper quadrant in a deep, stroking manner with the intention to improve the mobility of the soft tissues surrounding the pathway of the neural structures of the upper limb as well as any tender or tight tissues. The therapist spent approximately 7 minutes on the neck and scapular region, 4 minutes on the upper arm, and 4 minutes on the forearm and hand. The therapist was allowed to vary the time spent on each region according to his/her assessment of the patient's condition. The procedure lasted a total of 15 minutes.
223824116|NCT02081456|DEVICE|Therapeutic Ultrasound|Patients received therapeutic US applied for a period of 5 minutes to the most painful region of the neck, then a second 5-minute dose at the most painful region of the upper extremity. The US dose was 0.5 w/cm2, with sonation time 50% and frequency 1 MHz.40,52 The patient lay supine with the hand of the involved upper extremity placed on the abdomen and the elbow supported on a pillow. The two US doses and interaction time with the patient lasted a total of 15 minutes in an attempt to have equal patient/therapist contact between the two groups.
223824117|NCT03027063|BEHAVIORAL|10,000 steps|Participants will be asked to achieve 10,000 steps daily and to participate in 30 minutes of continuous exercise of their choosing. They will also receive text messages during the week and weekly motivational call
223824118|NCT03027063|BEHAVIORAL|Usual Care|Participants will receive the ACC/AHA exercise guidelines
223824119|NCT05528718|DRUG|Nitrous oxide gas for inhalation|This sub-study does not have an intervention and based on the main study the participants who have received N2O will be compared with the midazolam placebo group.
223824120|NCT05528718|DRUG|Midazolam injection|This sub-study does not have an intervention and based on the main study the participants who have received N2O will be compared with the midazolam placebo group.
223824121|NCT04542408|DRUG|Anticoagulation Agents (Edoxaban and/or high dose LMWH)|In-hospital (ICU \& normal ward): weight-adapted LMWH, high dose/ therapeutic dose (according to respective SmPC) After discharge and in ambulatory patients: Edoxaban according to SmPC until
223824122|NCT04542408|DRUG|Low dose Low molecular weight heparin or Placebo|In-hospital (ICU \& normal ward): LMWH, prophylactic dose as part of SOC After discharge and in ambulatory patients: Administration of oral pla-cebo according to the dosing rules for Edoxaban
223824123|NCT05650944|DIAGNOSTIC_TEST|Hemogram|Sysmex XN-1000 hematological analyzer
223824124|NCT00621816|DRUG|nitroprusside|nitroprusside continuous infusion, dose to be titrated to clinical effect
223824125|NCT00621816|DRUG|placebo infusion|blinded placebo infusion, to be infused at same rate as open-label nitroprusside infusion
223824126|NCT03428126|DRUG|Durvalumab|Dose Escalation and Dose Expansion Dose: 1500 mg by vein every 4 weeks in a 28 day cycle.
223824127|NCT03428126|DRUG|Trametinib|"Dose Escalation Starting Dose: 2mg by mouth daily in a 28 day cycle.~Dose Expansion Dose: MTD from Dose Escalation."
223824128|NCT04483934|BIOLOGICAL|Dermal fibroblasts|"Cultured autologous dermal fibroblasts.~For PR: The name dermal fibroblasts is exactly the name of the cell product registered by our ministry of health. There is no trade or international name."
223824129|NCT04483934|DEVICE|LED phototherapy|LED phototherapy
223824130|NCT00773058|DRUG|hydrocortisone|hydrocortisone 100mg q8h
223824131|NCT00773058|DRUG|placebo|normal saline 100ml q8h
223824132|NCT05903716|DIAGNOSTIC_TEST|Hormone|At baseline 17-OH Progesterone, DHEA, DHEAS, Androstenedione, Aldosterone, Testosterone, Dihydrotestosterone, Estradiol, 17-OH Pregnenolone, Androsterone, Cortisol, Corticosterone, 11-Degesterone, 21, -Deoxycortisol, Pregnenolone, 11-Deoxycorticostreone hormones will be evaluated.In addition, the FSH, LH, Prolactin, Estrogen, Testosterone, free testosterone, DHEA-s, SHBG, TSH, T4 hormone levels of the patients will be evaluated from all patients
223824133|NCT05903716|DRUG|Isotretinoin|İn the 3rd month of isotretinoin treatment, 17-OH Progesterone, DHEA, DHEAS, Androstenedione, Aldosterone, Testosterone, Dihydrotestosterone, Estradiol, 17-OH Pregnenolone, Androsterone, Cortisol, Corticosterone, 11-Degesterone, 21, -Deoxycortisol, Pregnenolone, 11-Deoxycorticostreone hormones will be evaluated.In addition, the FSH, LH, Prolactin, Estrogen, Testosterone, free testosterone, DHEA-s, SHBG, TSH, T4 hormone levels of the patients will be evaluated by ELISA method
223824134|NCT00049400|DRUG|BMS-247550|BMS-247550 as a 3-hour infusion on Day 1 of a three-week cycle
223824135|NCT02572843|DRUG|MEDI4736 (anti-PD-L1)|fixed dosing 750 mg
223824136|NCT03671733|DRUG|Liraglutide|The treatment of Liraglutide lasted three months,During the first week: 0.6mg per day, subcutaneous injection;During the second week: 1.2mg per day, subcutaneous injection; From third week onwards, 1.8mg per day, subcutaneous injection.
223824137|NCT03671733|DRUG|Exenatide|10mcg once a day for 4 weeks increased to 10mcg twice a day for 8 weeks.
223824138|NCT03671733|DRUG|Exenatide Microspheres for Injection|Exenatide 2 mg injection once weekly for 12 weeks.
223824139|NCT02703207|DEVICE|Positive airway pressure|CPAP will be applied as standard of care for diagnosis of moderate to severe OSA
223824140|NCT02703207|DEVICE|NIPPV and /or oxygen|supplemental oxygen will be applied to PAP/non-invasive positive pressure therapy
223824141|NCT02952911|DEVICE|Smartphone and Smartwatch|Multiple sclerosis participants and healthy controls are required to wear the smartwatch; and to carry smartphone preferably in a median position in a belt bag, or alternatively in their pocket as they go about their daily routine.
223824142|NCT06350292|BEHAVIORAL|SLEEP: COPE|Standard CBT-I techniques along with modules targeting noncompliance in children with ODD and their parents.
223824143|NCT04407351|DEVICE|Green LED light|Investigators arrange 12 weeks green LED light phototherapy.
223824144|NCT04407351|DEVICE|Red LED light (placebo)|Investigators arrange 12 weeks red LED light phototherapy (placebo).
223824145|NCT00003216|DRUG|fluorouracil|
223824146|NCT00003216|DRUG|gemcitabine hydrochloride|
223824147|NCT00003216|RADIATION|radiation therapy|
223824148|NCT03207646|OTHER|BrightHeart®|BrightHeart® has two components: smartphone mobile based application and a human coach. It is a combined approach of medication adherence, exercise, diet, sleep and stress reduction.
223824149|NCT00914290|DRUG|IPX056|IPX056 ER capsule containing 10 mg baclofen
223824150|NCT00914290|DRUG|Baclofen IR|Encapsulated baclofen tablet 5 mg per capsule
223824151|NCT00914290|DRUG|Placebo IPX056|Placebo capsule for IPX056
223824152|NCT00914290|DRUG|Placebo IR|Placebo encapsulated baclofen placebo tablet
223824153|NCT00447954|COMBINATION_PRODUCT|High Dose NT-501 implant|High Dose NT-501
223824154|NCT00447954|COMBINATION_PRODUCT|Low Dose NT-501 implant|Low Dose NT-501
223824155|NCT00447954|OTHER|Sham|Sham Procedure
223824156|NCT00884754|DEVICE|GlideScope rigid stylet|Patients will be intubated either with a rigid stylet meant to be used with the GlideScope, or with a standard malleable stylet used with other modalities of intubation.
223824157|NCT00477061|DRUG|Morphine|
223824158|NCT01231139|DRUG|Paracetamol|Intravenous paracetamol, 1 gram (100mls), administered over 30 minutes (every 4 hours for 3 days).
223824159|NCT01231139|DRUG|0.9% Sodium Chloride Schedule:|Identical placebo: 100mls saline given intravenous over 30 minutes (every 4 hours for 3 days)
223824160|NCT04930237|DRUG|Relistor Injectable Product|12-mg RELISTOR to be administered as once-daily subcutaneous injections for 4 to 7 days
223824161|NCT04930237|DRUG|Docusate Calcium|Standard of care
223824162|NCT04930237|DRUG|Bisacodyl|Standard of Care
223824163|NCT04930237|DRUG|Milk of magnesia|Standard of Care
223824164|NCT04930237|DRUG|Magnesium citrate|Standard of Care
223824165|NCT04930237|DRUG|Senna|Standard of Care
223824166|NCT04930237|DRUG|Enema|Standard of Care
223824167|NCT05651360|DIAGNOSTIC_TEST|low-dose CT|Low-dose CT scan will be performed, not exceeding 30% radiation dose of the standard CT. Low-dose CT images will be reconstructed with TrueFidelity high. The low-dose CT will be performed directly after the standard CT to avoid bias from differences in the timing of the contrast phase.
223824168|NCT03556358|BIOLOGICAL|TX05 (trastuzumab)|8 mg/kg, 90 min IV infusion (Cycle 5), followed by 6 mg/kg, 60 min IV infusion (Cycles 6 - 8)
223824169|NCT03556358|BIOLOGICAL|Herceptin®|8 mg/kg, 90 min IV infusion (Cycle 5), followed by 6 mg/kg, 60 min IV infusion (Cycles 6 - 8)
223824170|NCT03556358|DRUG|Paclitaxel|175 mg/m\^2, 60 min IV infusion, every 3 weeks (Cycles 5-8)
223824171|NCT03556358|DRUG|Epirubicin|75 mg/m\^2, IV bolus infusion, every 3 weeks (Cycles 1-4)
223824172|NCT03556358|DRUG|Cyclophosphamide|600 mg/m\^2, 30 min IV infusion, every 3 weeks (Cycles 1-4)
223824173|NCT01550172|BEHAVIORAL|Sleep Behavioral Therapy A and NHMS|"The night home monitoring system provides caregivers with reliable alerts and information regarding the whereabouts of the person with dementia during the night.~Sleep behavioral therapy A uses a combination of cognitive exercises and behavior adjustments."
223824174|NCT01550172|BEHAVIORAL|Sleep Behavioral Therapy B and NHMS|"The night home monitoring system (NHMS) provides caregivers with reliable alerts and information regarding the whereabouts of the person with dementia during the night.~Sleep behavioral therapy B uses primarily behavioral adjustments."
223824175|NCT04121039|DRUG|Apatinib|Apatinib (500 mg qd p.o.) until disease progression or intolerable toxicity or refused by the patients.
223824176|NCT04121039|DRUG|POF|The POF regimen consisted of a 3-hour infusion of paclitaxel (135 mg/m2) followed by oxaliplatin (85 mg/m2) and Calcium Levofolinate (200 mg/m2).Subsequently, a 46-hour infusion of fluorouracil (2400 mg/m2) was administered using an ambulatory pump, repeating the cycle every 14 days.
223824177|NCT02381990|PROCEDURE|FUSE IMAGE MRI GUIDED PROSTATE CRYOTHERAPY|"Biopsy proven Prostate Cancer is delimited and defined by MP-MRI. The MRI study is fused with transrectal ultrasound in realtime. The cryogenic cryoprobes/devices are employed to freeze and all circuled or noted cancer lesions. Two freeze 8 min/ thaw 10 min clycles are performed. Thermocouples are used to monitor treatment areas and safety margins"
223824178|NCT01351025|DRUG|atorvastatin|10 mg daily for 4 weeks, if no symptoms or lab findings suggestive of atorvastatin toxicity, dose increase to 20 mg daily from week 4- week 20
223824179|NCT01351025|DRUG|atorvastatin|Starting at week 24, 10 mg daily for 4 weeks. If no symptoms or lab findings suggestive of atorvastatin toxicity were found, 20 mg daily from week 28- week 44.
223824180|NCT01351025|DRUG|placebo for atorvastin|One tablet once daily for 4 weeks. If no symptoms or lab findings suggestive of toxicity were found, then increase the dose to two tablets once daily.
223824181|NCT00515437|BIOLOGICAL|Botulinum Toxin Type B (Myobloc)|
223824182|NCT00515437|BIOLOGICAL|Matched placebo to Myobloc|
223824183|NCT04363099|OTHER|observational|observational management of outpatients COVID 19
223824184|NCT06445790|BEHAVIORAL|Cognitive Behavior Therapy for Chronic Pelvic Pain-CBT-cp|CBT-cp will be administered weekly sessions for 12 weeks.
223824185|NCT03393702|DRUG|Gabapentin|"1. Patients in this arm of the study receive identical capsules, containing 15 mg/kg of oral gabapentin.~2. Patients after surgery receive identical capsules, containing 7,5 mg/kg of oral gabapentin 2 times per day."
223824186|NCT03393702|DRUG|Placebo|"1. Patients in this arm of the study receive identical placebo capsules 1 hour before surgery.~2. Patients after surgery receive identical placebo capsules 2 times per day."
223824187|NCT06248840|DEVICE|Intermittent Oral-esophageal Tube Feeding|During the 15-day treatment, both groups of patients are hospitalized, while conventional care and enteral nutrition support are provided to the two groups. Specifically, conventional care includes health education, dietary adjustments, nasopharyngeal hygiene, management of risk factors (blood pressure and lipid control, etc.), exercise rehabilitation, and psychological support. The frequency and content of these interventions are arranged based on the health condition.The observation group receives Intermittent Oral-esophageal Tube Feeding for enteral nutrition support (developed by the Dysphagia Institute of Zhengzhou University, CN201821314797.2), which is made of silicone material, 40 cm long, with an inner diameter of 0.54 cm.
223824188|NCT06248840|DEVICE|nasogastric tube feeding|During the 15-day treatment, both groups of patients are hospitalized, while conventional care and enteral nutrition support are provided to the two groups. Specifically, conventional care includes health education, dietary adjustments, nasopharyngeal hygiene, management of risk factors (blood pressure and lipid control, etc.), exercise rehabilitation, and psychological support. The frequency and content of these interventions are arranged based on the health condition.The control group is provided with nutritional support as nasogastric tube feeding, performed 6-10 times per day according to relevant guidelines, with an interval of more than 2 hours between every two feedings, and a feeding volume not exceeding 200 ml per time.
223824189|NCT04761614|BIOLOGICAL|Bevacizumab|Given IVPB
223824190|NCT04761614|DRUG|Fluorouracil|Given IV
223824191|NCT04761614|DRUG|Leucovorin Calcium|Given IVPB
223824192|NCT04761614|DRUG|Oxaliplatin|Given IVPB
223824193|NCT04761614|DRUG|Riluzole|Given PO
223824194|NCT03260582|OTHER|LifePod®|The software is a web-based application designed to support persons adhering to lifestyle advice and medication. The patient can log information about lifestyle (i.e. diet, exercise, and smoking), measurements (i.e. weight, pulse and blood pressure), symptoms and medication and can review data in graphs displaying registered values in relation to recommended targets. The software provides positive feedback on healthy choices and gives general recommendations on exercise training, physical activity and healthy diet. Reminders are generated in the case of decreasing registrations. Finally, short text messages (SMS) will be sent out 2-3 times a week with tips on healthy lifestyle.
223824195|NCT03607188|DRUG|Alkotinib|Alkotinib 200mg QD、 Alkotinib 300mg QD、 Alkotinib 400mg QD、 Alkotinib 500mg QD、 Alkotinib 600mg QD
223824196|NCT05102422|DRUG|Propofol 1 % Injectable Suspension|Induction and maintenance of general anesthesia using the intravenous anesthetic
223824197|NCT05102422|DRUG|Sevoflurane inhalant product|Induction and maintenance of general anesthesia using the inhaled anesthetic sevoflurane
223824198|NCT01861522|DRUG|Bepotastine besilate|Two TAU-284 5mg tablets will be taken orally twice a day
223824199|NCT01861522|DRUG|Placebo|Two Placebo tablets will be taken orally twice a day
223824200|NCT03952221|DEVICE|Continuous ultrasound therapy|continuous US therapy once a day, 9 minutes/session for two weeks (10 occasions) with BTL-4825S Premium device, 5 cm2 probe, 3 MHz frequency, 1,5 W/cm2 SATA intensity
223824201|NCT03952221|DEVICE|pulsed ultrasound therapy|pulsed US therapy once a day, 9 minutes/session, for two weeks (10 occasions) with BTL-4825S Premium device, 5 cm2 probe, 3 MHz frequency, 1,5 W/cm2 SATA intensity, 50% duty cycle
223824202|NCT03952221|DEVICE|US and electrotherapy (sonotens)|US and electrotherapy (transcutaneous electrical nerve stimulation) once a day, 10 minutes /session, for two weeks (10 occasions) with BTL-4825S Premium device, 5 cm2 probe, US: 3 MHz frequency, 0,5 W/cm2 SATA intensity, TENS: application in conventional mode at 100 Hz frequency and 100 μs wavelength
223824203|NCT03952221|DEVICE|Sham ultrasound therapy|sham US therapy once a day for two weeks (10 occasions) with BTL-4825S Premium device, 5 cm2 probe, 0 MHz frequency, 0 W/cm2 SATA intensity
223824204|NCT00550550|DRUG|Placebo|Placebo sublingual tablet, once daily
223824205|NCT00550550|BIOLOGICAL|SCH 697243|Grass sublingual tablet, once daily
223824206|NCT00550550|DRUG|Loratadine Syrup 1 mg/mL Rescue Treatment|Loratadine Syrup 1 mg/mL was dosed orally once daily at a dose of 5 mg for children aged 5 to \<6 years of age and at a dose of 10 mg for children aged 6 to \<18 years of age as rescue medication for symptoms of rhinoconjunctivitis among participants with a total symptom score ≥4.
223824207|NCT00550550|DRUG|Loratadine 10 mg Rescue Treatment|Loratadine 10 mg RediTabs tablets were dosed orally once daily at a dose of 10 mg for children aged 6 to \<18 years of age as rescue medication for symptoms of rhinoconjunctivitis among participants with a total symptom score ≥4.
223824208|NCT00550550|DRUG|Olopatadine 0.1% Rescue Treatment|Olopatadine hydrochloride 0.1% ophthalmic solution was dosed intraocularly at a dose of 1 drop in each affected eye twice daily, in addition to loratadine, as rescue medication for participants with persistent eye symptoms due to rhinoconjunctivitis.
223824209|NCT00550550|DRUG|Mometasone furoate 50 mcg Rescue Treatment|Mometasone furoate monohydrate nasal spray 50 mcg was dosed intranasally at a dose of one spray in each nostril once daily for participants aged 5 to \<12 years and a dose of 2 sprays in each nostril once daily for participants aged 12 to \<18 years as rescue medication for nasal symptoms of rhinoconjunctivitis among participants with a total symptom score of ≥4 despite loratadine and mometasone furoate nasal spray.
223824210|NCT00550550|DRUG|Albuterol 108 mcg Rescue Treatment|Albuterol sulfate inhalation aerosol 108 mcg/inhalation was administered via inhalation at a dose of 2 inhalations every 4 to 6 hours as rescue medication among participants aged 5 to \<18 years with asthma symptoms .
223824211|NCT00550550|DRUG|Fluticasone 44 mcg Rescue Treatment|Fluticasone propionate inhalation aerosol 44 mcg/inhalation was administered via inhalation at a dose of 2 inhalations twice daily among participants aged 12 to \<18 years up to a maximum dose of 10 inhalations twice daily, in combination with albuterol, among participants with ≥4 albuterol sulfate inhalations/day for 2 days as rescue medication for nocturnal asthma or shortness of breath.
223824212|NCT00550550|DRUG|Prednisone 5 mg Rescue Treatment|Prednisone tablet 5 mg was administered orally at a dose of 1 mg/kg/day once daily up to a maximum of 50 mg/day on Day 1, and at a dose of 0.5 mg/kg/day once daily up to a maximum of 25 mg/day on Days 2, 3, 5, and 7 as rescue medication for asthma exacerbation at the discretion of the investigator.
223824213|NCT00893347|BEHAVIORAL|Treatment as usual|Single session with early intervention coordinator for assessment, education about mild traumatic brain injury, and recommendations for symptom management.
223824214|NCT00893347|BEHAVIORAL|Cognitive-behavioural therapy|6-session manualized cognitive-behavioural therapy protocol designed to prevent persistent post-concussion syndrome
223824215|NCT03158389|DRUG|APG101|weekly i.v.
223824216|NCT03158389|DRUG|Alectinib|twice daily (oral)
223824217|NCT03158389|DRUG|Idasanutlin|orally on 5 days of a 28 days cycle
223824218|NCT03158389|DRUG|Atezolizumab|i.v. every 3 weeks
223824219|NCT03158389|DRUG|Vismodegib|daily orally
223824220|NCT03158389|DRUG|Temsirolimus|weekly i.v.
223824221|NCT03158389|DRUG|Palbociclib|orally on 21 days of a 28 days cycle
223824222|NCT05806944|DEVICE|TMS followed by Sham TMS|double blinded crossover schedule in which participants will undergo TMS and assessment in one visit, followed by sham-TMS and assessment the next visit.
223824223|NCT05806944|DEVICE|Sham TMS followed by TMS|double blinded crossover schedule in which participants will undergo sham TMS and assessment in one visit, followed by TMS and assessment the next visit.
223824224|NCT05156502|DEVICE|Fractionated Laser (Pixel CO2-Alma)|The Laser will be administered at baseline (visit 2, day 0), at visit 3 (day 28) and at visit 4 (day 56) into vagina and vestibule, following the IFU of the device.
223824225|NCT05156502|DEVICE|Fractionated Laser (Pixel CO.2-Alma)|Device: Fractionated Laser (Pixel CO2-Alma) The Laser will be administered at baseline (visit 2, day 0), at visit 3 (day 28) and at visit 4 (day 56) into vagina only, following the IFU of the device.
223824226|NCT04740619|PROCEDURE|Natural Orifice Specimen Extraction|Natural Orifice Specimen Extraction via transanal
223824227|NCT01612325|DEVICE|Holmium-166 polylactic microspheres|Radioembolisation with 600 mg of Holmium-166 microspheres with a patient liver size adjusted activity. The desired whole liver dose is 60 Gy.
223824228|NCT06335732|DIAGNOSTIC_TEST|Cross section study; single group related measurement design.|Two hundred pediatric physiotherapists from both genders were participated in the current study. They were selected randomly from the Outpatient Clinic of pediatric physiotherapists of Hospitals of Ministry of Health in Cairo-Egypt, the duration of this study was six months started from December 2022 to June 2023
223824229|NCT00987064|DEVICE|Temperature controlled Laminar Airflow (Protexo)|The intervention is designed to reduce the allergen load in the patients breathing zone by vertically displacing the allergens, originating from the bed and the ambient room environment, with a temperature controlled laminar airflow (TLA) during night sleep. The airflow is filtered through a high efficiency particulate air filter(HEPA), slightly cooled and ''showered'' over the subject. Due to the higher density, the cooled air descends slowly, and displaces the allergens from the breathing zone.
223824230|NCT00987064|DEVICE|Placebo TLA|TLA treatment with disabled filtration function
223824231|NCT02826967|PROCEDURE|Colonic Irrigation|
223824232|NCT00377286|DIETARY_SUPPLEMENT|Glucosamine (a dietary supplement)|1500 mg in 16 oz lite lemonade, once per day for 6 months
223824233|NCT00377286|OTHER|16 oz lite lemonade|16 oz lite lemonade 1 time daily for 6 months
223824234|NCT04089098|DIAGNOSTIC_TEST|passive leg raising versus mini volume challenge|Blood samples will be collected and ultrasound evaluation of renal perfusion conducted in study participants immediately before conducting passive leg raising (PLR). PLR will then be carried out on study participants, followed by MVC. PLR- and/or MVC-responsive patients will receive a further 700 ml fluid immediately after the MVC. Renal perfusion will be further assessed 1 and 24 hours after the MVC.
223824235|NCT04446897|BIOLOGICAL|mesenchymal stem cells|autologous mesenchymal stem cells
223824236|NCT04446897|OTHER|standard treatment|standard treatment according to clinical protocols
223824237|NCT05474521|DEVICE|CODTimer test|The Illinois test times of the participants will be measured with different phone applications that measure the change of direction performance, and each individual will perform the test twice.
223824238|NCT05674630|DEVICE|Magic Touch drug eluting balloon based strategy|Adult patients with chronic coronary syndrome deemed suitable for percutaneous intervention and significant long de-novo coronary lesion randomized in the experimental arm will receive treatment with drug eluting balloon (Magic Touch®) followed by invasive follow up (FFR and IVUS) at 6 ot 12 months in a randomized fashion.
223824239|NCT05674630|DEVICE|Drug-eluting stent-based strategy|Adult patients with chronic coronary syndrome deemed suitable for percutaneous intervention and significant long de-novo coronary lesion randomized in the control arm will receive treatment with drug-eluting stent followed by invasive follow up (FFR and IVUS) at 6 ot 12 months in a randomized fashion.
223824240|NCT04129814|PROCEDURE|Non surgical periodontal therapy|single session full-mouth scaling and root planing
223824241|NCT02456805|OTHER|Infant Formula 1|Feed ab libitum
223824242|NCT02456805|OTHER|Infant Formula 2|Feed ab libitum
223824243|NCT02565121|DRUG|corticosteroids|
223824244|NCT02565121|BEHAVIORAL|olfactory stimulation|stimulation with odorants by sniffing 4 different odorants for a total of 5 minutes twice a day during 3 months
223824245|NCT03626441|DIETARY_SUPPLEMENT|Ginger|Capsules containing 0.5g ginger powder, flavoured with non-active essence of ginger
223824246|NCT03626441|DIETARY_SUPPLEMENT|Placebo|Two coloured capsules containing 0.5 mg of cornstarch and flavoured with non-active essence of ginger.
223824247|NCT03573661|DEVICE|Breast Cancer Locator (BCL)|This locator will be constructed pre-operatively, sterilized and provided to the surgeon at the time of procedure. The outline of the breast cancer on the breast surface at the point where the cancer is closest to the skin is built into the locator, so that the surgeon can simply apply the locator to the patient's breast and trace the tumor outline on the skin.
223824248|NCT04269915|BIOLOGICAL|female Schistosoma mansoni cercariae|Viable female Schistosoma mansoni cercariae of the Puerto Rican strain
223824249|NCT03583645|BEHAVIORAL|Incremental theory of personality|"The experimental intervention (originally developed by David S. Yeager and colleagues) teaches that individuals have the potential to change. It has three main parts. First, participants are asked to read scientific studies that provide evidence that behaviors are controlled by thoughts and feelings in brains, and that pathways in the brain have the potential to be changed under the right circumstances. Second, participants read several testimonials purportedly written by upperclassmen to bring credibility to the ITP. Finally, participants are asked to write their own version of such a narrative. This self-persuasive writing exercise has been shown to facilitate the internalization of the intervention message, building on a long line of research on cognitive dissonance."
223824250|NCT03583645|OTHER|Educational Intervention|The educational intervention involved scientific information about the human brain. It was designed to be parallel to the experimental intervention and, hence, it has also three main parts. First, participants are asked to read scientific information about the different areas of the brain and their specialties. Second, participants read several testimonials written by upperclassmen about their transition to high school and how their brains help them to adapt to the new space and all the physical differences of the building and the classes. Finally, participants are asked to write a letter to another student explaining the main things he or she has learned about the brain and thinks are important for adapting to the new physical environment in high school.
223824251|NCT00697190|DEVICE|senofilcon A toric|silicone hydrogel contact lens for patients with astigmatism
223824252|NCT00697190|DEVICE|galyfilcon A toric|silicone hydrogel contact lens for patients with astigmatism
223824253|NCT01654081|DRUG|Irinotecan|Irinotecan 125 mg/m2 on days 1, 8, 15 and 22 of every 6- week cycle
223824254|NCT05603832|DRUG|F14|625 mg intra-articular sustained-release celecoxib
223824255|NCT05603832|DRUG|0.25 % Bupivacaine HCl|Local anesthetic
223824256|NCT05603832|DRUG|Acetaminophen|Analgesic
223824257|NCT05603832|DRUG|Methocarbamol|Muscle relaxant
223824258|NCT05917301|RADIATION|hypofractionation|This study is being done to see if hypofractionation in treating sarcoma, will also provide patients with a faster and safer treatment outcome.
223824259|NCT00911313|DRUG|Letrozole tablets (Femara; Novartis Pharma, Switzerland)|2.5 mg letrozole daily from day 3 of the menses for 5 days
223824260|NCT00911313|DRUG|metformin HCl (Cidophage®; CID,Cairo, Egypt)|metformin HCl 1500 daily for 6-8 weeks
223824261|NCT00911313|DRUG|CC (Clomid®; Global Napi Pharmaceuticals, Cairo, Egypt)|150 mg CC for 5 days starting from day 3 of menstruation
223824262|NCT05232474|DEVICE|KomPas+|KomPas+ is a guideline-based clinical decision support system. With KomPas+, the aim is to integrate KomPas with the guideline recommendations for the conservative treatment process of patients with intermittent claudication. KomPas+ is a web-based tool, aimed to facilitate person-centered and participatory healthcare. Therapists have access to a tool that will help, for example, to improve consistency between patient-specific goals and the treatment plan. Using KomPas+, therapists are encouraged to discuss choices in the treatment plan with the patient. It is expected that the included topics in KomPas+ will not be burdensome for both patients and therapists. Topics to discuss are, for example, Frequency, Intensity, Time and Type (FITT) for drawing up a training schedule. KomPas+ is meant to facilitate therapists and patients in the SDM process. It does not force patients to take part in the SDM process against their will.
223824263|NCT05232474|DEVICE|KomPas|KomPas is an online tool showing personalized outcome forecasts. These forecasts have been developed using real-world data of patients with intermittent claudication for physiotherapists in daily practice. The forecasts visualize the estimated outcome of supervised exercise therapy (walking distance and quality of life), for an individual patient with intermittent claudication. The information provided is based on patients similar to the individual patient from a large database. The actual outcome data of these similar patients are used to create an individual forecast. KomPas plots the estimated therapy outcome in time, thereby making personalized outcome forecasts. The forecasts are not used to direct the choices of treatment, but to motivate the patient, monitor the treatment process and to set realistic goals.
223824264|NCT04486391|DRUG|Tislelizumab|200 mg administered via intravenous (IV) infusion once every 3 weeks
223824265|NCT04486391|DRUG|Salvage Chemotherapy|Salvage chemotherapy administered as assessed as appropriate by the investigator in accordance with the local guideline, including but not limited to DHAP (dexamethasone, cisplatin, high-dose cytarabine), ESHAP (etoposide, methylprednisolone, high-dose cytarabine and cisplatin), DICE (dexamethasone, ifosfamide, carboplatin, etoposide), ICE (ifosfamide, carboplatin, etoposide), IGEV (ifosfamide, gemcitabine, vinorelbine, prednisone), GVD (gemcitabine, vinorelbine, liposomal doxorubicin), and MINE (etoposide, ifosfamide, mesna, mitoxantrone)
223824266|NCT06166394|DRUG|Spinal hypobaric Mepivacaine Local Anesthetic Injection|• Administration of a hypobaric spinal mixture for Day-Surgery patients: 3.4ml of 1.5% mepivacaine created by 3ml 2% mepivacaine with 1ml sterile water, and then discarding 0.6ml
223824267|NCT06166394|DRUG|Spinal hypobaric Bupivacaine Local Anesthetic Injection|"Administration of a hypobaric spinal mixture for In-patients:~3ml of 0.33% bupivacaine created by 2ml 0.5% bupivacaine with 1ml sterile water"
223824268|NCT00381641|OTHER|Laboratory Biomarker Analysis|Optional correlative studies
223824269|NCT00381641|OTHER|Pharmacogenomic Study|Optional correlative studies
223824270|NCT00381641|DRUG|Sunitinib|Given PO
223824271|NCT00381641|DRUG|Sunitinib Malate|Given PO
223824272|NCT05357560|BIOLOGICAL|Matrix-M with RH5.2 VLP and/or R21|3 doses of 50 µg of Matrix-M in combination with RH5.2 VLP and/or R21 at different doses and at different timepoints
223824273|NCT00249743|DEVICE|FallSaver (formerly called NOCwatch)|
223824274|NCT05496322|DEVICE|Continuous Non Invasive Blood Pressure Monitoring|Continuous non-invasive arterial pressure monitoring
223824275|NCT05496322|DEVICE|Intermittent Non Invasive Blood Pressure Monitoring|Intermittent non-invasive arterial pressure monitoring
223824276|NCT06624384|DRUG|Group 1 drug|Group 1: In this group, the aim is to compare 2 drugs, cyclosporine 0.05% and Lifitgrast . In one eye, cyclosporine 0.05% eye drops are randomly poured and in the opposite eye, Lifitgrast eye drops are poured.
223824277|NCT06624384|DRUG|Group 2: Drug and placebo|Group 2: In this group, the aim is to compare 2 drugs, cyclosporine 0.05% and Artelac artificial tear as a placebo. In one eye, cyclosporine 0.05% eye drops are randomly poured, and in the opposite eye, Artelac artificial tear are poured.
223824278|NCT06624384|DRUG|Group 3: Drug and palcebo|Group 3: In this group, the aim is to compare 2 drugs, Lifitgrast and Artelac artificial tear as a placebo. In one eye, Lifitgrast eye drops are randomly poured, and in the opposite eye, Artelac artificial tear are poured.
223824279|NCT01598298|DRUG|duloxetine hydrochloride|Given PO
223824280|NCT01598298|OTHER|placebo|Given PO
223824281|NCT06710990|DRUG|SHR-A1811|SHR-A1811
223824282|NCT06710990|DRUG|Ritonavir|Ritonavir
223824283|NCT06710990|DRUG|Itraconazole|Itraconazole
223824284|NCT06716359|OTHER|Observational study without intervention|Observational study without intervention
223824285|NCT06926257|OTHER|Experimental group (B) - breathing training using VR|"The Flowborne VR - Biofeedback Breathing Meditation game is an interactive training environment that guides the participant through a series of breathing exercises. The app adjusts the difficulty level and pace of the workout in real time based on the participant's physiological parameters, such as breathing rhythm.~Types of exercises in the game:~1. diaphragmatic breathing - the participant takes slow, controlled breaths, inhaling into the diaphragm and exhaling at a set pace. The game visualizes breathing through animations of water waves and background color changes.~2. rhythmic breathing - the participant sts his breathing rhythm to the changing visual and audio stimuli, allowing for synchronous breathing control.~3. Controlled exhalation lengthening - the participant learns the technique of slow exhalation of air to improve relaxation and reduce tension."
223824286|NCT06926257|OTHER|Experimental group (C) - breathing training using relaxation music|"* Diaphragmatic breathing - the conscious engagement of the diaphragm in the inhalation process.~* Controlled exhalation lengthening - a technique to lengthen the exhalation phase.~* Rhythmic breathing - synchronizing breathing with a set pace to improve breath control.~Structure of each session:~1. introductory phase (3 minutes)~   * Participants assume a comfortable sitting or lying position.~  * Brief instruction on proper breathing.~2. training phase (15 minutes).~   * Participants listen to relaxation music while focusing on the breathing techniques they learned before the session.~  * Breathing techniques used include those learned during the training: diaphragmatic breathing, controlled expiration lengthening, rhythmic breathing.~     3 Relaxation phase (2 minutes)~  * Gradual exit from the training session, focusing attention on the sensations of the body and mind."
223824287|NCT06924944|PROCEDURE|cataract surgery|cataract surgery treated with bilateral Clareon Vivity toric and non-toric IOL
223824288|NCT06925048|DRUG|PD-1 inhbitor+SHR0302|PD-1 inhbitor+SHR0302 in the maintenance treatment
223824289|NCT06925048|DRUG|PD-L1 inhibitor+SHR0302|PD-L1 inhibitor+SHR0302 in second line
223824290|NCT06925230|PROCEDURE|arthroscopic assisted volar scapholunate capsulodesis|arthroscopic assisted volar scapholunate capsulodesis using PDS 2.00 sutures
223824291|NCT06925230|PROCEDURE|arthroscopic assisted dorsal scapholunate capsulodesis|arthroscopic assisted dorsal scapholunate capsulodesis using PDS 2.00 sutures
223824292|NCT06925230|PROCEDURE|arthroscopic assisted combined volar and dorsal scapholunate capsulodesis|arthroscopic assisted combined volar and dorsal scapholunate capsulodesis using PDS 2.00 sutures
223824293|NCT05691361|DRUG|ADX-324|siRNA duplex oligonucleotide
223824294|NCT05691361|DRUG|Placebo|saline
223824295|NCT06025877|OTHER|PrecivityAD2(TM) blood test|The PrecivityAD2 blood test measures plasma amyloid beta (Aβ) peptides 42 and 40 (Aβ42/40) Ratio and phosphorylated tau (p-tau) compared to non-phosphorylated tau (np-tau) at amino acid 217 of the tau peptide (p-tau217/np-tau217) ratio to determine whether a patient with signs or symptoms of cognitive impairment is likely to have brain amyloid plaques, a pathological hallmark of AD.
223824296|NCT06899529|PROCEDURE|Bevacizumab|Bevacizumab will be given immediately after surgery in the Treatment Group
223824297|NCT06925087|OTHER|Myofascial Release Technique|During the application of Myofascial Release Technique (MRT), the fingers or hand will be first placed on the treatment area. Pressure will be applied to the soft tissue until the restricted layer was felt, and then the fascia was moved along the surface of the underlying layers while maintaining contact with the deeper layers. Tension will be applied for approximately 60-90 seconds, and if a release will not felt, the duration will extended until the release occurred. MRT will be performed with dry hands, without the use of any intermediary substances, and will be applied in both supine and prone positions. In the treatment program, anterolateral release techniques (targeting fascia superficialis, fascia transversalis, and fascia extraperitonealis) will be applied in the supine position, while posterior release techniques (targeting fascia thoracolumbalis and erector spinae) will be applied in the prone position.
223824298|NCT06925087|OTHER|Kinesio Taping Technique|"Two different techniques will be used in the Kinesio Taping application. First, four I-shaped Kinesio tapes (Kinesio Tex® Gold), each 5 cm wide and 0.5 mm thick, will be applied in a star-shaped pattern using the space correction technique with 25-50% tension at the S2-S4 level (sacral region) while the participant will in a seated position. Additionally, to direct the uterus into retroversion during menstruation, a 15 cm long I-shaped tape will be applied to the suprapubic region using the ligament correction technique with 100% tension."
223824299|NCT04000737|DRUG|Sorafenib+YIV-906|Patients will be given sorafenib (400 mg BID) daily for a 28-day course with YIV-906 (3 capsules, BID) 4 days on and 3 days off weekly in each course.
223824300|NCT04000737|DRUG|Sorafenib+placebo|Patients will be given sorafenib (400 mg BID) daily for a 28-day course with placebo (3 capsules, BID) 4 days on and 3 days off weekly in each course.
223824301|NCT03813147|DRUG|Azacitidine|Given IV
223824302|NCT03813147|DRUG|Cytarabine|Given intrathecally and IV
223824303|NCT03813147|DRUG|Fludarabine Phosphate|Given IV
223824304|NCT03813147|DRUG|Methotrexate|Given intrathecally
223824305|NCT03813147|DRUG|Pevonedistat|Given IV
223824306|NCT03813147|DRUG|Therapeutic Hydrocortisone|Given intrathecally
223824307|NCT04326413|PROCEDURE|Oral hygiene instruction and simple scaling|Monitor the changes of gum condition
223824308|NCT06767293|BEHAVIORAL|I-InTERACT Parenting Intervention (I2P) and coaching sessions|Online learning sessions for parents of preterm children
223824309|NCT06767293|BEHAVIORAL|I-InTERACT Parenting Microlearning Intervention (I2P Micro) and coaching sessions|Online microlearning sessions for parents of preterm children
223824310|NCT06767293|OTHER|Internet Resources|control condition
223824311|NCT06918223|BEHAVIORAL|Thyroid Informed Surgical Consent Augmenting Video (TISCAV)|Participants randomized to the intervention group will receive a surgeon-created Thyroid Informed Surgical Consent Augmenting Video (TISCAV). This 8-minute video includes animated visuals and a surgeon voiceover explaining thyroid anatomy, surgical options (lobectomy vs. total thyroidectomy), risks, benefits, and expectations. The TISCAV was designed and reviewed by an endocrine surgery team to improve patient comprehension, confidence, satisfaction, and reduce decision regret compared to standard verbal consent alone.
223824312|NCT06918223|BEHAVIORAL|Standard Consent|Participants receiving the Standard Consent intervention will undergo the routine informed consent process for thyroid surgery provided by their surgeon. This process includes a verbal discussion covering thyroidectomy procedure details, potential risks and complications, benefits, alternatives such as active surveillance, and an opportunity to ask questions.
223824313|NCT06921616|PROCEDURE|Simple neuroendoscopic hematoma evacuation|For patients with spontaneous intracerebral hemorrhage within 24 hours after the onset of the disease, only simple neuroendoscopic evacuation of hematoma will be performed
223824314|NCT06921616|COMBINATION_PRODUCT|Neuroendoscopic hematoma evacuation combined with sodium methylprednisolone succinate|"For patients with spontaneous intracerebral hemorrhage within 24 hours after the onset of the disease, they will be treated with the combination of neuroendoscopic hematoma evacuation and sodium methylprednisolone succinate.~Administer sodium methylprednisolone succinate for injection by intravenous injection 6 hours after the onset of the disease. Specific administration: Intravenous injection at a dosage of 2 mg/kg, once daily, for three consecutive days."
223824315|NCT04542096|DEVICE|Lung electrical impedance tomography monitoring|A belt for recording changes in electrical impedance in the skin will be fastened for the purpose of this study with no other additional procedures
223824316|NCT06508138|BIOLOGICAL|pNGVL4a-Sig/E7(detox)/HSP70 plasmid DNA; TA-HPV vaccinia virus|"About 1 month before donating blood, donors are required to come to outpatient clinic once a week to receive the following vaccine series:~Week 1: PVX1 (1 of 3): intramuscular injection (IM) of 3mg DNA prime with pNGVL4a-Sig/E7(detox)/HSP70 vaccine Week 2: PVX1 (2 of 3): IM 3mg DNA prime with pNGVL4a-Sig/E7(detox)/HSP70 vaccine Week 3: PVX1 (3 of 3): IM TA-HPV vaccinia boost Pause for 2 weeks Peripheral blood collection and possible bone marrow harvest depending on randomization"
223824317|NCT04009187|BEHAVIORAL|In-person wheelchair propulsion training program|The wheelchair propulsion (WP) intervention is based on our previous pilot work and the best available evidence on WP training. The CPGs recommend minimizing the force and frequency of pushes while using long strokes during propulsion. Each training session will include massed practice with repetitions overground. Each session is organized to limit the number of variables (i.e., long push strokes and dropping the hands down below axle) presented to the participant at one time. Propulsion Set A will focus on using longer push strokes. Propulsion Set B will focus on dropping the hand down toward the axle. Propulsion Set C will focus on both A and B.
223824318|NCT04009187|BEHAVIORAL|30-minute education session|Both groups will receive a 30-minute education session regarding the CPGs. This education session will follow the instructions provided in Rice and colleagues. (L. A. Rice et al., 2014). It consists of the importance of practicing biomechanical efficient propulsion. The material lists out the consequences and the impact of upper limb pain and injury. It provides a detailed step by step on how to propel properly. They will view the video that shows the biomechanics of efficient and inefficient propulsion.
223824319|NCT01768546|BEHAVIORAL|Virtual Diabetes Prevention Program|Participants will view 16 Video On Demand reality based TV episodes that follow 6 adults with pre-diabetes actively participating in a DPP lifestyle intervention.
223824320|NCT01768546|BEHAVIORAL|Interactive tracking and problem solving web portal|
223824321|NCT01532180|DEVICE|aura6000 System|The aura6000 device is an implanted hypoglossal nerve stimulator designed to maintain wakeful muscle tone of the tongue during sleep. It is implanted through a short surgical procedure. The implant is programmed to provide the optimal stimulation parameters for the patient. The therapy is controlled by a hand-held remote control allowing the patient to start, stop, and pause the therapy during times of sleep.
223824322|NCT03739294|DRUG|Fluticasone Furoate/ Vilanterol Trifenatate|Asthma inhalation medication
223824323|NCT02936037|DRUG|MD1003 100mg capsule|
223824324|NCT02936037|DRUG|PLACEBO|an inactive substance
223824325|NCT00944281|DIETARY_SUPPLEMENT|LNS-Zn5|Daily consumption of 20 g LNS containing 5 mg of zinc and daily placebo supplement
223824326|NCT00944281|DIETARY_SUPPLEMENT|LNS-Zn10|Daily consumption of 20 g LNS containing 10 mg of zinc and daily placebo supplement
223824327|NCT00944281|DIETARY_SUPPLEMENT|LNS-Zn0|20 g of LNS containing 0 mg of zinc and a daily placebo supplement
223824328|NCT00944281|DIETARY_SUPPLEMENT|Suppl-Zn5|Daily 5 mg zinc supplement ant consumption of 20 g LNS containing 0 mg of zinc
223824329|NCT04057911|DEVICE|Active NIBS|Cathodal noninvasive brain stimulation will be given for 20 mins.
223824330|NCT04057911|DEVICE|Sham NIBS|The electrode placement will be same, but the electric current will be ramped down 5 seconds after the beginning of the stimulation
223824331|NCT02405117|BEHAVIORAL|LiveWell System|For 16 weeks, participants will be asked to carry a mobile phone and wear a wrist-worn device for measuring activity. Participants in this arm will receive the psychosocial intervention via a smartphone and context-dependent feedback based on self-report and behavioral data. Providers whose patients are randomized to this arm will also be asked to enroll in order to receive information and notifications about patient status for the duration of the study
223824332|NCT03518528|DRUG|Estradiol 2 MG|Vaginal estradiol (Provames, Sanofi) 4mg per day from day 3 to first pregnancy test. If pregnancy test is positive, treatment is to continue until 8 weeks
223824333|NCT03518528|DRUG|Estradiol 100 µg|transdermal estradiol (Vivelledot, Novartis) 100 µg on day 3, then 200 µg day 7 and every 4 days, until first pregnancy test. If pregnancy test is positive, treatment is to continue until 8 weeks.
223824334|NCT04867876|BEHAVIORAL|Physical Therapy|Management of urinary incontinence by a physical therapist will include but is not limited to biofeedback, dietary management, alleviation of constipation, and neuromuscular re-education.
223824335|NCT04986735|DRUG|Empagliflozin|All subjects will have a baseline assessment and be prospectively followed up for 52 weeks to examine their outcome after receiving empagliflozin for neutropenia and neutrophil dysfunction.
223824336|NCT06102031|DEVICE|ReDS-Guided|"ReDS™ measurements will be shared with the treating clinicians to guide diuretic treatment when discharge, home visit and outpatient follow-up, but blinded to the subjects.~At discharge:① If the ReDS™ reading \<36%, discharge as planned; ②ReDS™ reading ≥36%, increase the oral diuretic dose, discharge as planned.~When home visit and outpatient follow-up: ① If the ReDS™ reading \<20%, hold diuretics; ② If the ReDS™ reading was between 21-35%, maintain current diuretic dose and optimize GDMT. If the ReDS™ change ≥ 6% from the previous one, increase diuretic dose and optimize the GDMT; ③ If the ReDS™ reading was between 36-45%, increase diuretics and optimize the GDMT, then repeat ReDS™ test after 1 week(home visit); ④ If the ReDS™ reading was above 46%, consider intravenous diuretic therapy, and repeat ReDS™ test after 1 week(home visit) or hospitalization."
223824337|NCT06102031|OTHER|Usual care|ReDS measurements will not be shared with the treating clinicians and the subjects, diuretic treatment will only be guided using standard clinical care.
223824338|NCT00241137|DRUG|valsartan|
223824339|NCT03045393|DRUG|Mirvetuximab Soravtansine (IMGN853)|Mirvetuximab Soravtansine is a targeted drug for tumors that express high levels of folate receptor alpha.
223824340|NCT01562847|DRUG|Nilotinib|Patients will be treated with 800 mg nilotinib daily.
223824341|NCT05371119|OTHER|Exercise Intervention|Training with light load with blood flow restriction (BFR)
223824342|NCT04666922|DRUG|BI 765080|BI 765080
223824343|NCT04666922|DRUG|Placebo|Placebo; 0.9% saline for injection
223824344|NCT05241561|DRUG|Cabozantinib|"Cabozantinib will be prescribed following its Marketing Authorization with an initiation at a reduced dose of 40 mg per day. The dose will be adjusted according to safety.~At the end of the first cycle, patients may be eligible for an increase in the dose of cabozantinib (up to 60 mg per day) if the following criteria are met: no adverse effects of grade 3 or 4 cabozantinib-related, no dose reduction or interruption for safety reasons, no long-lasting grade 2 cabozantinib-related adverse effects requiring maximum supportive care. Continuation to 40 mg per day or reduction to 20 mg per day are the other alternatives depending on the safety profile."
223824345|NCT05241561|BIOLOGICAL|Blood sample|biomonitoring and pharmacokinetics
223824346|NCT05241561|OTHER|Questionnaires of quality of life|FKSI-19 and FKSI-DRS and EUROQOL EQ-5D-5L
223824347|NCT06429358|DIETARY_SUPPLEMENT|Lactobacillus rhamnosus|The probiotic supplement was delivered in the form of easy-to-swallow capsules.
223824348|NCT06429358|OTHER|Control Group|Participants in the control group were given a placebo that looked, tasted, and felt just like the probiotic pill.
223824349|NCT01228344|OTHER|Artemether-lumefantrine|
223824350|NCT01821430|DRUG|Pregabalin|Titration of intervention will begin with 50mg PO BID x 2 days, then 100mg PO BID x 2 days, then 150mg PO BID X 2 days, then on day 7 full dose of Pregabalin 400mg PO QD for six weeks
223824351|NCT01821430|DRUG|Placebo|Placebo group will follow the same titration as the pregabalin group
223824352|NCT00794001|BEHAVIORAL|Data analysis and Feedback|Data analysis feedback: quarterly meetings with all stakeholders to present data and discuss potential areas of improvement.
223824353|NCT05878782|OTHER|MCRO+Occupational therapy|Experimental group A will combine the assessment of occupational problems (MCRO) and an occupational therapy intervention.
223824354|NCT05878782|OTHER|MCRO without intervention|Experimental group B will have only the MCRO assessment because the occupational problems assessment alone (without intervention) could improve quality of life and occupational performance outcomes, according to the Nielsen, 2019 study
223824355|NCT00000343|BEHAVIORAL|counseling|
223824356|NCT03465449|BEHAVIORAL|CKD-EDU|Palliative Care based coaching intervention for support with dialysis-related decision making.
223824357|NCT03465449|OTHER|usual care|Nephrologist based usual care
223824358|NCT00244374|BIOLOGICAL|Hepatitis A & B vaccine|Each subject will receive a total of 4 immunizations over 6 months on a 0-1-2-6 month schedule. At the initial visit, subjects\>18 years of age will receive the Twinrix vaccine and subjects\<18 years of age will receive the Engerix-B vaccine. Cohort subjects\>18 years found to have HAV antibody at screening will receive Engerix-B for their remaining 3 immunizations. All subjects will receive: an immunization record with the first vaccine dose entered and the dates the next doses are due; helpful hints for remembering vaccine appointments; and written instructions on where and how to get immunized outside of SF.
223824359|NCT00244374|BEHAVIORAL|Outreach|Outreach worker vaccine adherence support: Half of cohort subjects will be assigned to outreach worker vaccine adherence support and will meet with their outreach workers from Haight Ashbury Youth Outreach Team (HAYOT) and Glide Health Services on the day of vaccine cohort study enrollment. Intensive vaccination tracking and in-person outreach support will begin one week before the second and third vaccine doses are due, and again two weeks before the fourth dose is due.
223824360|NCT00244374|BEHAVIORAL|AIC|The Adult Immunization Clinic (AIC) is a public low-cost vaccine clinic located centrally at 101 Grove Street in the lobby of the San Francisco Department of Public Health (SFDPH). The clinic is open from Monday-Friday 9 a.m. to 4 p.m. Nurses at the AIC will be available 40 hours/week to administer free immunizations to study subjects.
223824361|NCT00244374|BEHAVIORAL|SEP|Subjects randomized to a set of syringe exchange programs for administration of viral hepatitis immunizations at Month 1, 2, 6. Research nurses will provide 16 hours/week of vaccine administration services at SEPs well attended by young IDU. The San Francisco Needle Exchange (SFNE) serves primarily youth and young adults on Mondays, Wednesdays, and Fridays from 5-7 p.m. in an indoor location in the Haight-Ashbury district. A study nurse will be at SFNE for a total of 6 hours per week. HIV Prevention Project (HPP) sites also operate for 2 hrs each (Tues, Thu, Fri, Sat). Medical services are provided either in a clinic setting at indoor sites (6th Street) or at outdoor sites (Hemlock Alley, Duboce). A study nurse will attend each of these 5 weekly sites for a total of 10 hours/week.
223824362|NCT00000342|DRUG|Risperidone|
223824363|NCT04343443|PROCEDURE|Clinical examination centered on congestion|Clinical examination centered on congestion (ASCEND, NYHA and Ambrosy Score) will be performed before discharge from hospital
223824364|NCT04343443|PROCEDURE|Cardio-pulmonary, peritoneal, jugular and renal Doppler ultrasounds and liver elastography|Cardio-pulmonary, peritoneal, jugular and renal Doppler ultrasounds and liver elastography will be performed before discharge from hospital
223824365|NCT04343443|PROCEDURE|Biological: Blood sample retrieved for biological assessment and biobanking|Blood sample collection will be performed before discharge from hospital
223824366|NCT04343443|PROCEDURE|Telephone interview|Telephone interview will be performed at 3, 12 months and 24 months after discharge from hospital
223824367|NCT04343443|BEHAVIORAL|Kansas City Cardiomyopathy Questionnaire (KCCQ)|Questionnaire centered on patient's quality of life at discharge and 3, 12 and 24 months after discharge
223824368|NCT03463915|DRUG|Bladder instillation WITH triamcinolone acetonide|Bladder instillation mixture of heparin (10,000 units), 2% viscous lidocaine (10 mL), 8.4% sodium bicarbonate (15 mL of 1 mEq/mL), 0.5% bupivacaine (10 mL of 5 mg/mL) plus triamcinolone acetonide (1 vial, 40 milligrams (mg)/1 milliliters (mL).
223824369|NCT03463915|DRUG|Bladder instillation WITHOUT triamcinolone acetonide|Bladder instillation mixture of heparin (10,000 units), 2% viscous lidocaine (10 mL), 8.4% sodium bicarbonate (15 mL of 1 mEq/mL), and 0.5% bupivacaine (10 mL of 5 mg/mL).
223824370|NCT01123460|OTHER|enzyme-linked immunosorbent assay|
223824371|NCT01123460|OTHER|laboratory biomarker analysis|
223824372|NCT01732146|DRUG|erythropoietin Beta|erythropoietin intravenous injection (5000 U/ 0.3 ml)1000 to 1500 U/kg/dose X 3 given every 24 hours with the first dose within 12 hours of delivery
223824373|NCT01732146|DRUG|Placebo|
223824374|NCT03218332|DIAGNOSTIC_TEST|Biomarkers for detecting possible CTE invivo|Detection biomarkers for possible CTE: Imaging/blood/CSF/PET-tau/MRI/europsychological assessment
223824375|NCT03792321|DRUG|Testosterone Undecanoate|1000 mg i.m. every 10 weeks
223824376|NCT03792321|DRUG|Placebo|
223824377|NCT06120517|COMBINATION_PRODUCT|emg- biofeedback|EMG activity shows the electrical activity measured during striated muscle contraction. The electrical activity of the muscle is in microvolts (1 volt = 1,000,000μV). Biofeedback units usually produce audio or visual feedback depending on the amount of electrical activity. Recording the bio-electrical activity of the muscle is a practical indicator of its contractility.
223824378|NCT04651114|BEHAVIORAL|Decision-making tool|"Women will be directed to a secure website to download a copy of the decision making tool and worksheets (they can download as many copies as they wish to). The women will use the tool and worksheets at their own pace for the pilot study period.~The decision making tool is a 23-page tool and set of 9 downloadable worksheets. The tool covers topics relevant to women with disabilities in considering or planning a pregnancy: 1) Overview of Pregnancy: 2) Knowing what is important; 3) Partners, family and important relationships; 4) Physical function and independence; 5) Health and wellbeing; 6) Caring for an infant; 7) Financial resources \& insurance; 8) How to find reliable information and resources; 9) Connecting with other women with physical disabilities; 10) Dealing with reactions of others, stigma and bias, pressure; and 11) Reaching a decision."
223824379|NCT01923896|BEHAVIORAL|Behavioral Intervention|Behavioral intervention targeting severe feeding disorders involves the combination of escape extinction and antecedent manipulation of food presentation to lessen the aversive quality of the meal. This allows treatment to address the consequences maintaining food refusal in the least restrictive environment while ameliorating possible side effects associated with extinction procedures.
223824380|NCT01923896|DRUG|d-cycloserine (DCS)|
223824381|NCT01923896|DRUG|Placebo|lactose powder
223824382|NCT00647634|DRUG|Alprazolam Extended-Release Tablets 3 mg|3mg, single dose fasting
223824383|NCT00647634|DRUG|Xanax XR® Tablets (3 mg|3mg, single dose fasting
223824384|NCT03707444|DEVICE|Scrambler Therapy Device|Superficial neuromodulation using EKG type electrodes \[Scrambler (MC5-A Calmare) Therapy\]
223824385|NCT02410967|BEHAVIORAL|Attention Bias Modification|At each of eight sessions, participants complete 160 computer administered trials wherein a pair of threatening stimuli and neutral stimuli is presented simultaneously and then followed immediately by a probe. The probe always replaces the neutral stimulus and never replaces the threatening stimulus. The intervention is based on the idea that attention can be shaped via repetitive computer based training methods, and training attention toward neutral stimuli will lead to a reduction in anxiety and its disorders.
223824386|NCT02410967|BEHAVIORAL|Placebo Attention Task|At each of eight sessions, participants complete 160 computer administered trials wherein a pair of threatening stimuli and neutral stimuli is presented simultaneously and then followed immediately by a probe. The probe replaces the neutral stimulus and the threatening stimulus with equal probability.
223824387|NCT04394520|OTHER|Modified Introduction|A variation in the introductory content to motivate participants to complete the survey. Participants will be presented with modified introductory language based on the findings from local focus groups and key informant interviews.
223824388|NCT04394520|OTHER|Active Opt-in|A variation in the consent mode to motivate participants to complete the survey. Participants will be given the choice to actively opt-in to the survey, if they do not respond, the survey will terminate.
223824389|NCT04394520|OTHER|Active Opt-out|A variation in the consent mode to motivate participants to complete the survey. Participants will be given the choice to actively opt-out to the survey, if they do not respond, the survey will continue.
223824390|NCT04394520|OTHER|Passive Opt-in|A variation in the consent mode to motivate participants to complete the survey. Participants will be given the choice to passively opt-in to the survey, if they do not hang-up, the survey will continue.
223824391|NCT05145842|PROCEDURE|floroscopy|After proper antiseptic dressing and draping, sacral hiatus was identified. the position of the needle was confirmed by lateral and anteroposterior fluoroscopic images. The needle was introduced up to S3 level for proper spread of the drug.
223824392|NCT05145842|PROCEDURE|ultrasound+fluoroscopy|After proper antiseptic dressing and draping, the caudal region will be shown in the longitudinal section using sterile probe cover and gel. Under ultrasonographic imaging, the sacrococcygeal ligament will be crossed and the needle will not be advanced any further once the sacral canal is entered. The fluoroscopy phase of the combined imaging will be started and the needle position will be checked by taking an anteroposterior view. The needle tip will be positioned at the sacral 3 level. The needle will be repositioned until the proper position is achieved. The research will be terminated at this point and the time to this stage and the radiation exposure dose will be obtained.
223824393|NCT00474929|DRUG|RAD001|Phase I: Dose level 0: RAD001 5mg every other day; Dose level 1: RAD001 5mg every day; Dose level 2: RAD001 5mg every day; Dose level 3: RAD001 10mg every day; Phase II: RAD001 5mg every day;
223824394|NCT00474929|DRUG|Sorafenib|Phase I: Dose level 0: Sorafenib 200 mg twice daily; Dose level 1: Sorafenib 200 mg twice daily; Dose level 2: Sorafenib 400 mg twice daily; Dose level 3: Sorafenib 400 mg twice daily; Phase II: Sorafenib 200 mg twice daily;
223824395|NCT00819403|DRUG|simvastatin|Subjects will receive 6 weeks of simvastatin 40 mg, after which atherothrombotic biomarker assessment will be studied.
223824396|NCT00819403|DRUG|ezetimibe/simvastatin|Subjects will receive 6 weeks of ezetimibe/simvastatin 10/40 mg, after which atherothrombotic biomarker assessment will be studied.
223824397|NCT03661996|DRUG|CNTX-4975-05|Osteoarthritis (OA) intra-articular injection of CNTX-4975-05
223824398|NCT03661996|DRUG|Lidocaine without epinephrine|15 mL lidocaine intra-articular injection
223824399|NCT03661996|DEVICE|ElastoGel|Cooling Device
223824400|NCT03661996|DEVICE|Breg Ice Water Pump|Cooling Device
223824401|NCT00421226|DRUG|ACZ885|
223824402|NCT04906109|DRUG|Vemlidy Tab|1T
223824403|NCT04906109|DRUG|DA-2803 Tab|1T
223824404|NCT04914052|OTHER|Filming facial expressions|Study participants' facial expressions will be videoed by a camera placed in front of the patient's bed during their stay in the post anesthesia care unit.
223824405|NCT01735357|DIETARY_SUPPLEMENT|EPA-rich triacylglycerol oil|
223824406|NCT01735357|DIETARY_SUPPLEMENT|Placebo - olive oil (BP specification)|
223824407|NCT01735357|DIETARY_SUPPLEMENT|DHA-rich triacylglycerol oil|
223824408|NCT02807740|OTHER|Virtual reality|Each session will consist of multiple exercises. These ones are already described, each exercise will be performed by the patient for 4 minutes followed by a 1 minute of rest.
223824409|NCT02807740|OTHER|Conventional rehabilitation program|In each C rehabilitation session, patients underwent 3 phases: 1) Warm-up phase: passive mobilization of main joints and muscular strengthen of lower limbs; 2) Active phase (both standing than seated): exercises of motor coordination with upper and lower limbs, balance training, start and stop exercises, deambulation training; 3) cool-down phase (with seated patient): manipulation exercises, mobilization exercises, respiratory exercises.
223824410|NCT06124742|DEVICE|clear aligners|taste perception will be evaluated before and after using clear aligners.
223824411|NCT00068380|DRUG|imatinib mesylate|Given orally
223824412|NCT00068380|OTHER|laboratory biomarker analysis|Correlative studies
223824413|NCT05800808|PROCEDURE|High Intensity Intervals|8x4 min cycling bouts at 85% of VO2peak
223824414|NCT05800808|PROCEDURE|Moderate Exercise|81 minutes of cycling at 50% VO2peak
223824415|NCT03963947|BIOLOGICAL|Beltavac® Polymerized with house dust mites|Adminstration of Beltavac® Polymerized with house dust mites according to the routine clinical practice
223824416|NCT06004284|OTHER|control|"Ergonomics training will be given to each of the control group participants individually. The content of this training will include what is ergonomics, the purpose of ergonomics, musculoskeletal diseases in employees, work-related musculoskeletal risk fa"
223824417|NCT06004284|OTHER|exercise group|The exercise training program will be applied for 8 weeks, 3 days a week and for an average of 20-30 minutes. After the maneuver is taught, stretching exercises lasting 5 minutes for warm-up purposes and posture and core exercises lasting 25 minutes will be taught. Among the stretching exercises, quadratus lumborum stretching, hamstring stretching, erector spina stretching, hip extensor stretching exercises will be applied. Posterior pelvic tilt exercise will be performed as a control and smoothing exercise for the vertebrae of the lumbar and pelvic region. Among the core stabilization exercises, bridging, plank, plank in side lying, abdominal strengthening, cross arm leg lifting exercises in crawling position will be performed. Each exercise position will be required to be maintained for 8 seconds and to do 10-15 repetitions.
223824418|NCT00645216|DRUG|CP-945,598|Subjects take CP-945,598 alone for 21 days
223824419|NCT00645216|DRUG|CP-945,598|Subjects take CP-945,598 from Days 1 to 7, then take CP-945,598 and Grapefruit Juice from Days 8 to 21
223824420|NCT04033679|OTHER|Active TDCS|Participants will receive active TDCS stimulation.
223824421|NCT04033679|OTHER|Sham TDCS|Participants will receive sham TDCS stimulation.
223824422|NCT02696122|PROCEDURE|Local Group|General anesthesia willl be induced with propofol 2 mg mg. kg-1 and alfentanyl 30 mcg.kg-1. Once an appropriate depth of anesthesia had been obtained, a laryngeal mask airway (LMA) will be positioned. The anesthesia will be maintained by propofol 4 to 5 mg. kg-1.h-1. Ventilation will controlled by adjusting the flow volume and respiratory rate to keep the end-tidal CO2 level (PETCO2) between 30 and 40 mmHg. For local anesthesia, approximately 50 ml of 0.5% ropivacaive will infiltrated along the line of incision in the subcutaneous plane, followed by peripheral nerve block technique (e.g., ilioinguinal-hypogastric nerve block) and local wound infiltration at the fascial level.
223824423|NCT02696122|PROCEDURE|Spinal anesthesia|Spinal puncture will be performed with the patient in the sitting position, using 27G disposable Quincke needles (B. Braun, Meisungen, AG). After obtaining CSF, 15 mg of 0.5% hyperbaric bupivacaine will be injected.
223824424|NCT04859439|DRUG|DBPR108 tablets|Drug: DBPR108, tablet, oral
223824425|NCT06261684|DRUG|Intralesional Acyclovir|Intralesional Acyclovir in plantar warts
223824426|NCT06261684|DEVICE|Cryotherapy|Cryotherapy of plantar warts
223824427|NCT04502056|BEHAVIORAL|Acknowledgement Racial Injustice AMA|Investigators will examine whether acknowledgements of racial inequality are helpful towards improving knowledge retention and behaviors associated with the intervention among participants. In this arm, participants will receive a AMA statement on racial injustice.
223824428|NCT04502056|BEHAVIORAL|African American Sender Acknowledgement|Investigators will also vary the messenger of the acknowledgement sender. In this arm participants receive a African American sender in acknowledgment of AMA
223824429|NCT04502056|BEHAVIORAL|African American Sender in Informational Videos.|Investigators will vary the sender of the informational covid-19 videos. In this arm, participants receive a African American sender in informational videos.
223824430|NCT04502056|BEHAVIORAL|Racial Inequality Highlighted|Investigators will include information on race-specific covid-19 cases and deaths in one variation in the messaging. In this arm, participants receive disproportionate race-specific Covid-19 facts
223824431|NCT04502056|BEHAVIORAL|AMA Acknowledgement Drug Pricing|Investigators will examine whether acknowledgements of racial inequality are helpful towards improving knowledge retention and behaviors associated with the intervention among participants. In this arm, participants receive AMA information on drug pricing
223824432|NCT04502056|BEHAVIORAL|White Sender in Acknowledgement|Investigators will also vary the messenger of the acknowledgement sender. In this arm, participants receive a white sender in the acknowledgement
223824433|NCT04502056|BEHAVIORAL|White Sender in Informational Videos|Investigators will vary the messenger of the informational covid-19 videos. In this arm, participants receive white sender in the informational video
223824434|NCT04502056|BEHAVIORAL|No Racial Inequality Highlighting|In this arm, the disproportionate burden of Covid-19 on communities of color will not be highlighted
223824435|NCT04502056|BEHAVIORAL|Placebo videos|Videos not related to covid-19 will be shown
223824436|NCT03311763|BEHAVIORAL|EIM Fitness Practitioners|Exercise is Medicine Practitioners will facilitate peer groups that attend twice-weekly exercise classes for 8 weeks, with clinical monitoring and advise regarding increasing physical activity.
223824437|NCT03311763|BEHAVIORAL|Counseling and wearable device|Brief exercise counseling session and provision of a wearable fitness tracking device to promote physical activity.
223824438|NCT03880695|DRUG|Anlotinib+ Liposomal Doxorubicin|Anlotinib : 12 mg, qd, po day 8-21 every 3 weeks Liposomal Doxorubicin: 50 mg/m2, day 1 every 3 weeks
223824439|NCT01342692|DRUG|Azacitidine|6 cycles of Azacitidine 75 mg/m2 subcutaneously daily for 7 days, every 4 weeks The first course will be started on day 1 regardless of the blood count. Subsequent courses will be scheduled every 4 weeks
223824440|NCT01342692|DRUG|Azacitidine associated with Valproic acid|"6 cycles of Azacitidine 75 mg/m2 subcutaneously daily for 7 days, every 4 weeks Valproic Acid (Depakine-Chrono®) (VPA) will be administered concomitantly for a minimum of 6 cycles.~\- In patients aged 60 years or less: VPA (25 mg/kg twice a day i.e. 50 mg/kg/d) administered orally, daily for 7 days (days 1-7)~\- In patients older than 60 years: VPA (17.5 mg/kg twice a day i.e. 35 mg/Kg/d) administered orally daily for 7 days (days 1-7)"
223824441|NCT01342692|DRUG|Azacitidine associated with Lenalidomide|"6 cycles of Azacitidine 75 mg/m2 subcutaneously daily for 7 days, every 4 weeks Lenalidomide (Revlimid®) will be administered once daily orally as continuous schedule started on day 1 of Azacitidine.~Patients will receive Lenalidomide 10 mg/d, during 14 days (D1 to D14)"
223824442|NCT01342692|DRUG|Azacitidine associated with Idarubicine|Azacitidine (Vidaza®) will be administered similarly to group 1 exposed above. Idarubicin (Zavedos®) as the reconstituted solution, will be administered slowly by the intravenous route over 60 minutes at 10 mg/m²of body-surface area on day 8 of Azacitidine or day 10 if azacitidine was administered according to (5-2-2 regimen)
223824443|NCT02122341|DEVICE|BackStop|BackStop™ is a FDA approved device. It is intended for use during ureteroscopic lithotripsy to prevent retrograde migration of stones and stone fragments. It is comprised of a solution of a thermosensitive polymer, a purified version of poloxamer 407 having been fractionated in saline. BackStop™, which is injected above the stone, is provided in sterile, pre-filled 2.5ml and 5ml syringes along with and a corresponding injector and a catheter (3F or 5F).
223824444|NCT00975572|BIOLOGICAL|split-virion, non-adjuvanted H1N1 vaccine of 30 μg|440 participants (110 elders, 110 adults, 110 adolescents and 110 children) to receive split-virion, non-adjuvanted H1N1 vaccine of 30 μg on day 0 and 21.
223824445|NCT00975572|BIOLOGICAL|Experimental: split-virion, adjuvanted H1N1 vaccine of 7.5 μg|440 participants (110 elders,110 adults, 110 adolescents and 110 children) to receive split-virion, adjuvanted H1N1 vaccine of 7.5 μg on day 0 and 21.
223824446|NCT00975572|BIOLOGICAL|Experimental: split-virion, adjuvanted H1N1 vaccine of 15 μg|440 participants (110 elders, 110 adults, 110 adolescents and 110 children) to receive split-virion, adjuvanted H1N1 vaccine of 15 μg on day 0 and 21.
223824447|NCT00975572|BIOLOGICAL|Experimental: split-virion, adjuvanted H1N1 vaccine of 30 μg|330 participants (110 elders, 110 adults, and 110 adolescents) to receive split-virion, adjuvanted H1N1 vaccine of 30 μg on day 0 and 21.
223824448|NCT00975572|BIOLOGICAL|Experimental: split-virion, non-adjuvanted H1N1 vaccine of 15 μg|440 participants (110 elders, 110 adults, 110 adolescents and 110 children) to receive split-virion, non-adjuvanted H1N1 vaccine of 15 μg on day 0 and 21.
223824449|NCT00975572|BIOLOGICAL|Placebo Comparator: Placebo control|110 adults to receive placebo control (Phosphate Buffer Saline) on day 0 and 21.
223824450|NCT00067990|DRUG|Losartan 100mg|To be started within three months of transplant and continued for five years.
223824451|NCT00067990|DRUG|Placebo|No treatment with continued follow-up for five years.
223824452|NCT04935138|GENETIC|cfDNA analysis|sequencing data from cfDNA analysis
223824453|NCT00724139|DEVICE|: APOS biomechanical gait system, Apos - Sports and Medical Technologies Ltd. Hertzlia, Israel|training program utilizing a novel biomechanical system comprising four modular elements attached onto foot-worn platforms which conveys perturbation throughout the gait cycle
223824454|NCT00004650|DRUG|conjugated estrogens|
223824455|NCT00004650|DRUG|Medroxyprogesterone|
223824456|NCT03558958|DRUG|P-188 NF|Poloxamer administered daily via sc injection at 5 mg/Kg
223824457|NCT03971708|DRUG|Lidocaine|Local anesthetic
223824458|NCT03971708|DRUG|Ropivacaine|Local anesthetic
223824459|NCT01973491|DRUG|ATX-MS-1467|Subjects will receive ATX-MS-1467 50 microgram (mcg), 200 mcg and 800 mcg on Day 1, Day 15 and Day 29 respectively during the titration period followed by biweekly dose of ATX-MS-1467 800 mcg for 16 weeks during the treatment period.
223824460|NCT04595539|BEHAVIORAL|Behavioral Activation treatment with Attention Training Technique|"The BATD includes the development of a shared formulation, psychoeducation, self-monitoring of daily activities, identifying depressed behaviours, developing alternative goal orientated behaviours, scheduling of valued activities, and problem solving around difficulties implementing scheduled activities.~Wells's Attention Training is a task designed to train selective attention to specific information by training individuals to attend to multiple auditory external sources. In addition to auditory exercices, the ATT sessions included psychoeducation, discussion around rumination (e.g. controllability, usefulness), self-report evaluation of self-focused before and after the auditory exercices, and transfer to everyday life."
223824461|NCT00981396|BEHAVIORAL|EFT (Emotional Freedom Techniques)|EFT is a brief but efficacious stress-reduction intervention. It combines exposure, cognitive structuring, and somatic stimulation.
223824462|NCT00981396|BEHAVIORAL|CBT (Cognitive Behavioral Therapy)|CBT is a behavioral intervention that seeks to challenge and change negative client cognitions about events and life circumstances.
223824463|NCT00529919|DIETARY_SUPPLEMENT|Weight loss|Weight loss study including consumption of either 22-25 g of medium chain triglyceride oil or olive oil
223824464|NCT02576782|DRUG|Perineural Dexamethasone and bupivacaine|
223824465|NCT02576782|DRUG|Systemic Dexamethasone plus perineural bupivacaine|
223824466|NCT02576782|DRUG|intravenous saline plus perineural bupivacaine|
223824467|NCT06341426|DRUG|Single Psychedelic Dose Psilocybin|One psychedelic dose (1mg of psilocybin + 25mg of psilocybin) taken in conjunction with psilocybin-assisted psychotherapy
223824468|NCT06341426|DRUG|Two Psychedelic Doses Psilocybin|Two psychedelic doses (25 mg of psilocybin + 25mg of psilocybin) taken in conjunction with psilocybin-assisted psychotherapy
223824469|NCT00780936|PROCEDURE|femoral nerve block|
223824470|NCT03941314|DEVICE|Supera® Peripheral Stent System|The index procedure is placing a selfexpandable stent at a femoro-popliteal location. The way the stenosis or occlusion is traversed is not part of the study. It is mandatory to prepare then the vessel with PTA (at least the size of the stent) and thereafter insert the stent. Post-PTA can be performed with same balloon, but post-PTA is not mandatory to be performed.
223824471|NCT03941314|DEVICE|EverFlex™ Self-Expanding Peripheral Stent System|The index procedure is placing a selfexpandable stent at a femoro-popliteal location. The way the stenosis or occlusion is traversed is not part of the study. It is mandatory to prepare then the vessel with PTA (at least the size of the stent) and thereafter insert the stent. Post-PTA can be performed with same balloon, but post-PTA is not mandatory to be performed.
223824472|NCT00393744|DRUG|pristinamycin|50 mg/kg/d in 2 doses for children, and 1g twice daily in adults for 4 days
223824473|NCT00393744|DRUG|amoxicillin|50 mg/kg/d in 2 doses in children and 1 g twice daily in adults for 6 days
223824474|NCT05969938|DIAGNOSTIC_TEST|MRD detection|Peripheral blood samples were collected for MRD detection before neoadjuvant chemoradiotherapy, during neoadjuvant chemoradiotherapy, and 3-4 weeks after radical surgery. For patients who achieved cCR after neoadjuvant therapy and adopted the W \& W strategy, the sampling time point was 3 months after the start of watching and waiting.
223824475|NCT05294874|OTHER|gait training|walking forward, sideway and backward walking on balance board
223824476|NCT00003220|DRUG|bryostatin 1|
223824477|NCT00499850|DRUG|ZD6474 (vandetanib)|once daily oral dose
223824478|NCT00499850|DRUG|5-Fluorouracil|intravenous infusion
223824479|NCT00499850|DRUG|Leucovorin|intravenous infusion
223824480|NCT00499850|DRUG|Oxaliplatin|intravenous infusion
223824481|NCT01914367|BIOLOGICAL|cervarix|3 doses will be given, one on Day 0, one on Day 30 and one on Day 180 ± 7 days, intramuscular in the deltoid muscle of the non-dominant arm
223824482|NCT01914367|BIOLOGICAL|Gardasil|3 doses will be given, one on Day 0, one on Day 60 ± 2 days and one on Day 180 ± 7 days, intramuscular in the deltoid muscle of the non-dominant arm
223824483|NCT04825821|PROCEDURE|Clinical and ultrasonographic assessment|Routinely assessment by objective examination and transvaginal ultrasonographic scan 6, 12, and 24 months after the surgical procedures
223824484|NCT00422799|DRUG|Bortezomib|Once weekly for 3 weeks
223824485|NCT00422799|DRUG|Rituximab|Intravenously once a week for the first and fourth weeks of a cycle
223824486|NCT00102050|DRUG|NM-702 (phosphodiesterase inhibitor)|
223824487|NCT04733911|OTHER|75 eccentric contractions|An acute bout of eccentric exercise will be performed on an isokinetic dynamometer, including 5 sets of 15 repetitions, with 30 sec rest intervals,at 60 degrees/sec.
223824488|NCT04733911|OTHER|150 eccentric contractions|An acute bout of eccentric exercise will be performed on an isokinetic dynamometer, including 10 sets of 15 repetitions, with 30 sec rest intervals,at 60 degrees/sec.
223824489|NCT04733911|OTHER|300 eccentric contractions|An acute bout of eccentric exercise will be performed on an isokinetic dynamometer, including 20 sets of 15 repetitions, with 30 sec rest intervals,at 60 degrees/sec.
223824490|NCT06110845|DEVICE|QPlasia OncoReader Breast (QPORB)|Automated diagnostic algorithm
223824491|NCT01134133|OTHER|Anti-gurgling intervention|1\. head of bed 30 degrees or higher, 2. swallowing evaluation-based feeding, 3. sedatives titrated to minimal effective dose.
223824492|NCT01965158|DRUG|Naldemedine|Naldemedine 0.2 mg tablet taken orally once a day
223824493|NCT01965158|DRUG|Placebo|Placebo tablet taken orally once a day
223824494|NCT02025920|OTHER|Salmon Group|
223824495|NCT02025920|OTHER|Cod Group|
223824496|NCT02025920|OTHER|Meat Group|
223824497|NCT00988546|OTHER|Computer based template for exam documentation|exam documentation performed using computer based template
223824498|NCT00988546|OTHER|Dictation for exam documentation|exam documentation performed using dictation, the standard practice
223824499|NCT05255484|DRUG|LM-108|Administered intravenously
223824500|NCT05255484|DRUG|An Anti-PD-1 Antibody|Administered intravenously
223824501|NCT04204213|BEHAVIORAL|Tai Chi Exercise|8 Section Brocade (Baduanjin) sitting Tai Chi classes + Healthcare Education seminars
223824502|NCT01818934|PROCEDURE|hip ultrasound|Standardized single-examiner Hip ultrasound was offered to all babies in the universal group, babies at increased risk in the selective group, and to no babies in the clinical exam only group
223824503|NCT01152541|DRUG|Riboflavin/Dextran|Administration of riboflavin/dextran every 2 minutes for the duration of UV exposure
223824504|NCT01152541|DRUG|Hypotonic Riboflavin|Administration of hypotonic riboflavin every 2 minutes for the duration of UV exposure.
223824505|NCT02728921|DRUG|5% Albumin infusion 30 min|Intravenous infusion of 5% Albumin at a dose of 10 ml/kg during 30 minutes. Dose is based on ideal weight.
223824506|NCT02728921|DRUG|5% Albumin infusion 3 hours|Intravenous infusion of 5% Albumin at a dose of 10 ml/kg during 3 hours. Dose is based on ideal weight.
223824507|NCT06381440|DEVICE|Lokomat device (Hocoma AG, Volketswil, Switzerland).|Robot Assisted Gait Training device
223824508|NCT06381440|OTHER|Conventional walking training|Self-paced supervised walking training
223824509|NCT01430312|DRUG|azelaic acid pre-foam formulation|
223824510|NCT01430312|DRUG|Vehicle pre-foam formulation|
223824511|NCT01430312|DRUG|Water|
223824512|NCT01430312|DRUG|Sodium lauryl sulfate|
223824513|NCT01950117|PROCEDURE|Endoscopic mucosal resection|Nonpedunculated neoplastic colorectal polyps from 10 mm to 25 mm in diameter were resected after submucosal injection of saline solution before removal.
223824514|NCT01950117|PROCEDURE|Conventional polypectomy|Nonpedunculated neoplastic colorectal polyps from 10 mm to 25 mm in diameter were resected using conventional polypectomy. Submucosal injection of saline solution before removal was not performed.
223824515|NCT01365520|DRUG|turoctocog alfa|A single dose will be administered i.v. (into the vein). Subjects will be randomised to one of two lots of NNC 0155-0000-0004.
223824516|NCT04571762|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|SBRT (a fraction dose adapted to the OAR geometry-of-the-day, 5 fractions) performed on the MR-Linac
223824517|NCT04037384|BEHAVIORAL|Eye yoga|Eye yoga exercises at home given by a trained instructor
223824518|NCT04037384|BEHAVIORAL|Passive Reading|Passive reading at home
223824519|NCT00157742|PROCEDURE|Spinal Cord Stimulation (SCS)|
223824520|NCT00157742|PROCEDURE|Percutaneous Myocardial Laser Revascularisation (PMR)|
223824521|NCT03169179|BEHAVIORAL|Fitbit and Bupa Boost app|Fitbit Charge 2™ wearable physical activity monitor and Bupa Boost health and wellbeing smartphone app. 12 weeks initial use (individual goal-setting in weeks 1-6 then social features of the app in weeks 7-12) followed by a further five months of optional use (as desired by the participant).
223824522|NCT03022838|DRUG|Caffeine|From the point of enrollment, patients will substitute their daily dietary caffeine with either placebo- or capsulated caffeine tablets (Recip®, 100mg).
223824523|NCT02196493|DRUG|Azithromycin|250mg azithromycin three times per week for 12 weeks
223824524|NCT06530901|DIAGNOSTIC_TEST|Multidimensional ultrasound of the inferior vena cava|Cross-sectional parameters of the inferior vena cava include two-dimensional longitudinal diameter, cross-sectional length and short diameter, circumference, and cross-sectional area, as well as cross-sectional length and short diameter, circumference, and cross-sectional area in three-dimensional imaging
223824525|NCT00684086|BEHAVIORAL|Diabetes Self Management Program|
223824526|NCT04316767|BEHAVIORAL|App Intervention|Participants will receive access to a self-care app for use on their smartphone. The app provides a suite of tools based on cognitive behavioral therapy and mindfulness. The app guides users through a variety of short lessons (3-5 minutes) that teach users to self-manage stress, mood, anxiety, and depression. Participants will be encouraged to use the app on a daily basis and will be able to use the app at their discretion.
223824527|NCT00247624|DRUG|Eszopiclone|Eszopiclone 3 mg every night for 8 weeks
223824528|NCT00247624|DRUG|Fluoxetine|Fluoxetine 20 mg every morning for 9 weeks
223824529|NCT00247624|DRUG|Placebo|Placebo every night for 8 weeks
223824530|NCT02183870|DRUG|Crizotinib|250mg crizotinib bid until end of treatment
223824531|NCT03074812|DEVICE|Transcranial Direct Current Stimulation|Transcranial direct current stimulation (tDCS) is a commonly used non-invasive form of brain stimulation for studying motor functions in health and disease \[36\]. It involves the attachment of surface electrodes to the scalp through which very small electric currents (1 or 2mA) are applied via a current regulated device. The currents do not produce any sensation. The applied current affects excitability of underlying neural tissue.
223824532|NCT00000811|DRUG|Azithromycin|
223824533|NCT00000811|DRUG|Atovaquone|
223824534|NCT00000811|DRUG|Sulfamethoxazole-Trimethoprim|
223824535|NCT03321006|DEVICE|Phonak Audeo B-R 90 hearing aid device (Active)|Hearing aids will be the latest Audeo B-R 90 devices manufactured by Phonak. Full amplification hearing aids will have their gain determined by audiometric profile as per standard clinical practice
223824536|NCT03321006|DRUG|Duloxetine or escitalopram|We opted to allow two potential medication choices so that study participation could be offered to individuals who had previously taken one medication and either not responded or not tolerated it. After 4 weeks if subjects do not meet remission criteria (HRSD≤10), the dose of study medication will be increased to escitalopram 20mg or duloxetine 60mg for the remaining 8 weeks of the study.
223824537|NCT03321006|DEVICE|Audeo B-R 90 hearing aid device (Sham)|Hearing aids will be the latest Audeo B-R 90 devices manufactured by Phonak. Low amplification hearing aids will be programmed to a hearing threshold of 10dB across all frequencies
223824538|NCT05297643|DEVICE|Ekstracorporeal Shock Wave Therapy (ESWT)|Extracorporeal Shock Wave Therapy (ESWT); It is a treatment method in which high-intensity pressure waves are applied to the desired point in the body. It has been used in the treatment of kidney stones in previous years, and changes in bone tissue have been observed (12). Today, it is used in musculoskeletal system diseases such as plantar fasciitis, epicondylitis, achiltendinitis, osteoarthritis
223824539|NCT05297643|OTHER|complex decongestive therapy|Complex decongestive therapy consists of manual lymphatic degeneration, compression therapy, skin care and remedal exercise.
223824540|NCT00831363|PROCEDURE|minimally invasive total hip arthroplasty|minimally invasive total hip arthroplasty
223824541|NCT00831363|PROCEDURE|standard approach total hip arthroplasty|standard Hardinge approach/traditional transgluteal approach
223824542|NCT00616564|DRUG|GM-CSF|Concomitant Priming with GM-CSF
223824543|NCT03096171|BEHAVIORAL|Flourishing App Program|This intervention is based on relaxation, well-being promotion, meditation practices and positive psychology principles. The program is being evaluated in a classroom format into another project and was adapted for this project in the application format for mobile devices. It will last for 16 weeks, with trainings of 20 minutes, four times a week.
223824544|NCT05016414|OTHER|Lower body negative pressure|lower body negative pressure at -20mmHg delivered via a custom designed sleeping sack
223824545|NCT04131478|GENETIC|Pharmacogenetic testing|Pharmacogenetic testing for TNF alfa
223824546|NCT02095795|DEVICE|Technological Rehabilitation|The Lokomat (Hocoma, Zurich, Switzerland) is robotic device conformed as an exoskeleton on the lower limbs of the patient. Through active and passive actuators, it realize a proper trajectory with an associated motion profile of the involved limbs. The results are physically guide repetitive, rhythmic, bilateral lower extremity movements in order to simulate a physiological gait cycle.The system uses a dynamic body weight-support system to support the participant above a motorized treadmill synchronized with the Lokomat. Participants were provided verbal encouragement to actively step in conjunction with the movement presented by the Lokomat.
223824547|NCT02095795|OTHER|Control Rehabilitation|When needed, more than one therapist are employed in the intervention for safety reasons.
223824548|NCT03719365|DEVICE|NAVAPSV|During the first trial, PSV will be set in order to obtain a Vt between 6 and 8 ml/kg; this support level will be defined as PSV100. Subsequently, the corresponding NAVA level (NAVA 100) will be determined using a dedicated ventilator function (NAVA Preview) which is able to estimate NAVA level in order to deliver an equivalent inspiratory peak pressure (Paw peak) compared to that obtained during PSV mode. Afterwards, PSV100 and NAVA100 will be first increased (PSV150 and NAVA150) during the second trial and then decreased during the third trial (PSV50 and NAVA150) by 50% from basal value. During the study period, PEEP and FiO2 will be kept equal to the values in use before patient enrollment.
223824549|NCT00310895|DRUG|Imetelstat Sodium (GRN163L)|Dose increase by 25% if tolerated infused over 2 hours
223824550|NCT03008525|BIOLOGICAL|subcutaneous and visceral adipose tissue biopsies|Subcutaneous and visceral adipose tissue biopsies during operation
223824551|NCT03008525|BIOLOGICAL|blood samples analysis|"Blood sampling is required to measure plasma cholecalciferol, calcidiol and calcitriol concentrations, as well as biological parameters of interest.~Another plasma/serum tube is used to measure pro- and anti-inflammatory cytokines and adiponectin."
223824552|NCT03484338|BEHAVIORAL|Accelerated Resolution Therapy|ART is an evidence-based therapy for the treatment of depressive symptoms and trauma and stress-related disorders that includes the core components of trauma-focused therapy including imaging rescripting, voluntary image replacement, guided visualization with use of eye movements, desensitization and processing of distressing memories, and in-vitro exposure to future feared triggers
223824553|NCT01382485|OTHER|RIA harvesting group|Subjects allocated to the RIA group will have the graft harvested in a standardized fashion using the technique described by Quintero et al. Briefly, the RIA device is a single-pass reamer that is connected to an aspirator and irrigator, allowing simultaneous reaming, irrigation, and aspiration of the contents of the femoral canal. RIA head size and tube length will be chosen based on preoperative templating of anteroposterior and lateral radiographs of the donor femur (a head size of 2mm larger than the inner cortical diameter at the isthmus of the femur will be selected). Fluoroscopic imaging will be used to confirm guidewire positioning and avoid eccentric reaming. Bone graft will be harvested from the central femoral canal and from each femoral condyle in 3 separate passes.
223824554|NCT01382485|OTHER|AICBG harvesting group|Iliac crest bone graft will be harvested from the anterior iliac crest through an incision beginning 2cm posterior to the anterior superior iliac spine and carried posteriorly. A window will be made in the iliac crest and a curette will subsequently be used to harvest the cancellous bone. The incision will be closed in 3 layers. The infiltration of local anaesthetic will be at the discretion of the surgeon.
223824555|NCT02304016|BEHAVIORAL|Pelvic floor physical therapy|Patients in this arm will be receiving pelvic floor physical therapy
223824556|NCT04985006|BEHAVIORAL|running at moderate intensity|intensity was determined by calculating the subject's heart rate reserve using the formula: ((resting heart rate maximal - resting heart rate) x % of target intensity) + resting heart rate. At moderate intensity, the subject will be asked to run at 50-59% Heart rate reserve (HRR) for 30 minutes from the time the target intensity is reached.
223824557|NCT04985006|BEHAVIORAL|running at high intensity|intensity was determined by calculating the subject's heart rate reserve using the formula: ((resting heart rate maximal - resting heart rate) x % of target intensity) + resting heart rate. At moderate intensity, the subject will be asked to run at 70-75% HRR for 30 minutes from the time the target intensity is reached.
223824558|NCT01190332|PROCEDURE|endoscopic sphincterotomy by conventional method|
223824559|NCT01190332|PROCEDURE|endoscopic sphincterotomy by rendezvous method|
223824560|NCT03560258|BIOLOGICAL|p24CE1/2 pDNA vaccine|4 mg administered by one injection/electroporation
223824561|NCT03560258|BIOLOGICAL|p24CE1/2 pDNA vaccine admixed with full-length p55^gag pDNA vaccine|2 mg p24CE1/2 pDNA admixed with 2 mg full-length p55\^gag pDNA administered by one injection/electroporation
223824562|NCT03560258|BIOLOGICAL|Full-length p55^gag pDNA vaccine|4 mg full-length p55\^gag pDNA vaccine administered by one injection/electroporation
223824563|NCT03560258|BIOLOGICAL|Placebo|1 mL placebo administered by one injection/electroporation
223824564|NCT00717678|DRUG|Prograf-XL|oral
223824565|NCT00717678|DRUG|Prograf|oral
223824566|NCT00717678|DRUG|MMF|oral
223824567|NCT05942352|DRUG|Ligustrazine by intravenously administration|Ligustrazine hydrochloride was administered intravenously by dissolving 40mg in 250ml saline per day for 15 days
223824568|NCT05942352|DRUG|Ligustrazine by mouth|50 mg Ligustrazine tablet by mouth would be maintained for 1 year
223824569|NCT05942352|DRUG|Placebo by intravenously administration|Intravenous administration of 250ml saline per day for 15 days
223824570|NCT05942352|DRUG|Placebo by mouth|50 mg placebo tablet by mouth would be maintained for 1 year
223824571|NCT00010686|DRUG|Dietary Phytoestrogens|
223824572|NCT02006121|DRUG|Apomorphine hydrochloride|Apomorphine hydrochloride 5 mg/ml solution for infusion in pre-filled syringe
223824573|NCT02006121|DRUG|Placebo|Sodium chloride 9 mg/ml
223824574|NCT03337191|DRUG|Levobupivacaine|% 0,125 levobupivacaine
223824575|NCT03337191|DRUG|Morphine Sulfate|10 mq/kg morphine sulfate
223824576|NCT03337191|DEVICE|Ultrasound|Ultrasound guided caudal block
223824577|NCT02420756|DEVICE|PET Scan|
223824578|NCT00946179|BIOLOGICAL|Influenza virus (split virion, inactivated) vaccine|0.5 mL, Intramuscular
223824579|NCT03354325|BEHAVIORAL|Scheduled PCP follow-up|Parents of children randomized to scheduled follow up will be instructed to follow up with their primary care physician within 4 days of discharge regardless of improvement and/or symptom resolution. Research coordinators will verify that the child has a scheduled follow up appointment prior to discharge.
223824580|NCT03354325|BEHAVIORAL|As needed PCP follow-up|At the time of hospital discharge, parents will be instructed that the child does not need to automatically follow up with his/her primary care physician. Rather, the child should follow up on an as needed basis: if the child does not improve or if new concerns arise.
223824581|NCT01798186|DRUG|Cannabis|Participants will be exposed to cannabis smoke present in ambient air
223824582|NCT05208385|PROCEDURE|video-assisted umbilical closure|video-assisted umbilical closure
223824583|NCT00101660|DRUG|Dasatinib|Tablets; oral; 70 mg BID, depending on response
223824584|NCT01899274|DEVICE|bant iPhone application|
223824585|NCT06089174|OTHER|Ultra-trail|Questionnaires sent to runners at various pre-race and post-race times (Day3, Day6, Day10, Day14 and Day21)
223824586|NCT01113658|DEVICE|SNaP Wound Care System|"The intervention is negative pressure wound therapy (NPWT) with the Spiracur SNaP Wound Care system for the treatment of a variety of acute and chronic wounds including pressure ulcers, trauma wounds, diabetic foot ulcers, venous stasis ulcers, and skin grafts.~The Spiracur SNaP Wound Care system weighs less than 4 ounces, does not utilize an electric pump (device has no electrically powered parts), is fully disposable after use, and is designed for particularly small chronic wounds that require advanced wound care management. It delivers NPWT at a constant pressure level over several days without any required adjustments by the patient or clinician."
223824587|NCT00068874|BEHAVIORAL|Coping skills and cognitive restructuring techniques|This is a cognitive psychoeducational program designed to enhance coping and adaptation to SLE. Participants will attend five study visits over 5 months. The first three visits are biweekly, 45-minute sessions during which the adolescent will be taught coping skills and cognitive restructuring techniques. The coping skills training will include training in relaxation, distraction, and problem-solving skills. The cognitive restructuring techniques will assist adolescents in using more accurate and adaptive cognitive responses.
223824588|NCT00068874|BEHAVIORAL|Educational training|Participants will attend five study visits that will include disease-appropriate education materials.
223824589|NCT06153823|OTHER|virtual reality glasses|child behavior management will be done by using VR glasses distraction
223824590|NCT06153823|OTHER|Tell Show and Do|child behavior management will be done by using tell show and do technique
223824591|NCT06184490|PROCEDURE|Prone position with thoraco-abdominal cushion|Prone position with cushions positioned laterally on the chest, abdomen, and pelvis
223824592|NCT04769713|PROCEDURE|Hepatic Hilar Nerve Block Needle placement|Placement of a needle within 2cm of the portal vein bifurcation along its anterior surface for injection of nerve block agent (for nerve block) or saline (placebo) under US or CT guidance.
223824593|NCT04769713|DRUG|Injection of Ropivacaine in the hepatic hilum for the hepatic hilar nerve block|Injection of 15 ml 0.5% Ropivacaine at the hepatic hilum along the anterior surface of the portal vein within 2cm of the bifurcation.
223824594|NCT04769713|DRUG|Injection of normal saline in the hepatic hilum for the sham procedure|15 ml sterile normal saline is injected at the hepatic hilum along the anterior surface of the portal vein within 2cm of the bifurcation.
223824595|NCT04696718|DIETARY_SUPPLEMENT|daily supplementation|the patients will consume 1 pill of probiotic each day for 28 days per treatments each treatment is separated by a wash out period of 21 days
223824596|NCT02254837|DEVICE|Zilver PTX Drug-Eluting Stent|
223824597|NCT02223065|DRUG|Saxagliptin|
223824598|NCT02223065|DRUG|Dapagliflozin|
223824599|NCT06174935|DRUG|0.01% atropine ophthalmic drop|0.01% atropine ophthalmic drop will be applied daily to the affected eye
223824600|NCT02783118|OTHER|Self administered online CBT|"The app being tested has two main components: courses and exercises. Courses represent the psycho-educational and therapeutic background of the program, comprising the following topics: information on depression, psychological vulnerability, what is CBT, healthy and unhealthy negative emotions, rational and irrational thoughts, how behaviors contribute to depression, sleep hygiene, social support, and relaxation techniques. Exercises use the information presented in the courses and follow the structure of a regular therapy session and/or therapeutic homework.~The following exercises are included in the app:~1. The Emotional Pulse exercise~2. The Sticky Notes exercise~3. The Find Irrational Thoughts~4. The Change Irrational Thoughts"
223824601|NCT06442813|BEHAVIORAL|EFT GROUP|One times one pregnancy
223824602|NCT05706792|DEVICE|Nordic Sensi Chair|The Nordic Sensi Chair is an electrically operated rocking chair with built-in MusiCure music composed by Niels Eje. It is equipped with an integrated audio system with music recording based on more than 15 years of research on the calming and mentally stimulating effect of sound. The Nordic Sensi Chair has three different programs: Relax for deep relaxation, Refresh for recovery and Comfort for gentle relaxation. A 5 kg fiber blanket increases the feeling of security and relaxation, while helping users to perceive their own body. In addition to musical programming, the Nordic Sensi Chair provides predefined tactile stimulation and rocking motion, for a relaxing multi-sensory experience. All settings can be easily customized at the touch of a button. For the purposes of this study, the NSC deep relaxation program (Relax Program) was used.
223824603|NCT05091944|DEVICE|web-based birth decision aid|Women in the intervention group receive both usual care and decision support (an interactive web-based birth decision aid). The innovative interactive web-based birth decision aid comprised five components: Component 1-a communication aid video involves 2 expert's talk about how to participate in SDM and prepare self with choice talk, option talk and decision talk(10 minutes )and practice communication skills with clinician(10 minutes); Component 2-overall of the function and features of birth decision aid. Component 3-introduce the benefits and risk of vaginal birth after cesarean; Component 4- the benefits and risk of elective repeat cesarean section; Component 5 -a quit to confirm women's knowledge regarding the two choices and confirm women's values.
223824604|NCT01614847|DRUG|Artificial tears|At random, subjects will receive isotonic artificial tear or a control (normal saline).
223824605|NCT02190760|DRUG|Dexamethasone|
223824606|NCT02190760|DRUG|Bupivacaine|
223824607|NCT00332605|DRUG|Naltrexone plus N-Acetyl Cysteine|daily
223824608|NCT00332605|DRUG|Placebo|daily
223824609|NCT00485056|DRUG|Pioglitazone|45mgs daily
223824610|NCT03266185|OTHER|Shorter PICT|Shorter post-infusion cooling time
223824611|NCT00245856|DRUG|Dalteparin sodium injection|200units/kg subcutaneous daily for one month, followed by 150units/kg subcutaneous daily for two additional months or 200 units/kg subcutaneously daily for 5 days followed by warfarin.
223824612|NCT00245856|DRUG|Warfarin|Titrated to INR 2-3 through study month 3
223824613|NCT04361513|DRUG|Bupivacaine hydrochloride 0.5% (Marcaine, Pfizer)|3 point genicular nerve block
223824614|NCT04361513|DRUG|triamcinolone 40 milligrams (Kenacort, Bristol Myers Squip)|intra-articular injection of triamcinilone
223824615|NCT04229680|OTHER|High Salt|Consumption of pills containing table salt for 10 days.
223824616|NCT04229680|OTHER|Recommended Salt|Consumption of pills containing dextrose for 10 days.
223824617|NCT01003184|DRUG|exenatide once weekly|subcutaneous injection, 2mg, once a week
223824618|NCT01003184|DRUG|insulin detemir|subcutaneous injection, with dosage titrated according to the determir label and published titration schedule, once or twice a day
223824619|NCT04393740|DIAGNOSTIC_TEST|scheimpflug imaging using pentacam|corneal tomography imaging using pentacam device (based on Scheimpflug principle )
223824620|NCT01280240|DRUG|Monofer(R)|Intravenous bolus injection given over app. 2 minutes only once
223824621|NCT01165840|DRUG|Dapsone|100 mg PO x 1 dose
223824622|NCT02693834|DEVICE|Posterior Leaf spring AFO|Posterior Leaf Spring AFO is an over the shelf polypropylene ankle foot orthosis to assist foot drop.
223824623|NCT02693834|DEVICE|Double adjustable AFO|Double adjustable AFO is a custom AFO with double action metal upright joints
223824624|NCT04707131|DRUG|LEM-S401|siRNA encapsulated in DegradaBALL®
223824625|NCT04707131|DRUG|Placebo|Placebo
223824626|NCT04848662|DRUG|BDA MDI (PT027) 160/180 μg|Combination Product: Budesonide/albuterol sulfate metered-dose inhaler 80/90 μg per puff. Two puffs to administer 160/180 μg dose.
223824627|NCT04848662|DRUG|Pulmicort Respules 0.5 MG/ML Inhalation Suspension|Budesonide 0.5 mg/ml. Each 2 ml Respule contains 1 mg budesonide.
223824628|NCT04114240|DRUG|Xybilun|Erectil dysfunction, Viagra generic (sildénafil)
223824629|NCT04535336|OTHER|Vitality acupunch (VA) exercise program|The VA had 3 phases and took 40 minutes to complete.
223824630|NCT04535336|OTHER|Control|Participants maintained their daily activities.
223824631|NCT01754883|DRUG|Lithium Carbonate|Oral Lithium carbonate to target serum levle of 0.6-0.8.
223824632|NCT03072082|DRUG|Danlou Tablet|Conventional western medicine \& Danlou Tablet
223824633|NCT03072082|DRUG|DanLou Tablet placebo|Conventional western medicine \& placebo (for Danlou Tablet)
223824634|NCT03072082|DRUG|Aspirin Enteric-coated Tablets|100 mg tablet, one tablet daily.
223824635|NCT03072082|DRUG|Clopidogrel Hydrogen Sulfate 75 MG Oral Tablet|One tablet daily. (for patients who can't use aspirin)
223824636|NCT03072082|DRUG|Atorvastatin calcium|10 mg tablet, two tablets each night.
223824637|NCT03072082|DRUG|Isosorbide Mononitrate Tab 20 MG|One tablet two times daily.
223824638|NCT03072082|DRUG|Metoprolol Tartrate Tab 25 MG|12.5 mg or 25 mg two times daily.
223824639|NCT03072082|DRUG|Trimetazidine Dihydrochloride Tablets|20 mg tablet, one tablet three times daily.
223824640|NCT02781896|DEVICE|pacing catheter|Rapid pacing during TAVI is required to ensure transient cardiac standstill while predilatation is performed and the valve is being positioned and deployed. In the right ventricular pacing arm, rapid pacing is provided by a standard right ventricular pacing catheter.
223824641|NCT02781896|DEVICE|valve delivery guidewire|Rapid pacing during TAVI is required to ensure transient cardiac standstill while predilatation is performed and the valve is being positioned and deployed. In the Left ventricular pacing arm, rapid pacing is provided via the valve-delivery guidewire inserted into the left ventricle. The cathode of an external pacemaker is placed on the external end of the guidewire using an alligator clamp. The TAVI catheter provides the necessary insulation. The anode is attached directly to the subcutaneous tissue at the femoral entry site (also using an alligator clamp).
223824642|NCT02183116|DRUG|Meloxicam|
223824643|NCT01440127|DRUG|Metformin|Pills will be taken for one week prior to the scheduled surgery or biopsy procedure.
223824644|NCT02779023|BEHAVIORAL|Cognitive-Behavior Therapy for Insomnia (CBT-I)|
223824645|NCT05146960|OTHER|Temporal summation|Temporal summation will be evoked in each predetermined area
223824646|NCT05146960|OTHER|Placebo|PPTs will be assessed once in each predetermined area
223824647|NCT03452176|DEVICE|Scrambler|Scrambler is a non-invasive pain modifying technique that utilizes transcutaneous electrical stimulation of nociceptive fibers with the intent of re-organizing maladaptive signaling pathways which has been investigated for treatment of peripheral neuropathy.
223824648|NCT03452176|DEVICE|Scrambler Sham Control|Sham control should be indistinguishable to the participants from experimental Scrambler therapy.
223824649|NCT04868643|DEVICE|The DIMI Renal Replacement Therapy (RRT) System|To demonstrate that the safety and efficacy of the DIMI RRT remains consistent when used In-Center by trained dialysis nurses versus in an In-Home environment by trained Care Partners and Subjects.
223824650|NCT05666687|DRUG|MIJ821|MIJ821 will be administered as an i.v. infusion
223824651|NCT01874106|OTHER|Diet Therapy|The patients in this arm were educated to follow a especial type of diet (anti-inflammatory diet)in addition to nutrition counseling for 10 weeks.
223824652|NCT01874106|OTHER|Control Group|The patients in this arm received nutrition counseling and education in general based on their needs as a control group for 10 weeks.
223824653|NCT06469411|BIOLOGICAL|Secretome (set of substances released from the cell to its surroundings) of mesenchymal stem cells retrieved from the placenta (containing 400 microgram protein/ milliliter)|Patients in the intervention arm received 6 doses of secretome of mesenchymal stem cells retrieved from the placenta (containing 400 microgram protein/ milliliter) 4 cc dissolved in albumin 20% every week for 6 weeks
223824654|NCT06469411|OTHER|4 cc distilled water dissolved in albumin 20%|Patients in the control arm received 6 doses of 4 cc distilled water dissolved in albumin 20% every week for 6 weeks
223824655|NCT00001626|DRUG|antithymocyte globulin|antithymocyte globulin
223824656|NCT00001626|DRUG|cyclophosphamide|cyclophosphamide
223824657|NCT00001626|DRUG|cyclosporine|cyclosporine
223824658|NCT00817804|DEVICE|Use of the V60 Mask Ventilator|The V60 Mask Ventilator used to provide noninvasive ventilation. It is compared to the patient's conventional ventilator in a cross-over study. The ventilator settings can range from CPAP to Pressure Support ventilation with values of IPAP and EPAP to match the conventional ventilation on which the patient had been placed.
223824659|NCT04842864|BEHAVIORAL|Fasting|23 hours fasting
223824660|NCT03459313|OTHER|Active group|For this study, the Frisk.Friidrott (Healthy.Athletics/Track\&Field) website has been developed. The purpose of the website is to provide an easy-to-use tool that can assist coaches and parents involved in youth athletics with information how to structure training and recovery planning, provide guidance on possible injuries, and provide other information on health for youth athletes.
223824661|NCT02289989|DRUG|Oregano extract cream|An experimental cream will be applied to one of the arms of the patient which will be an oregano extract and will be compared to the standard treatment which will be hydrocortisone 1% ointment
223824662|NCT02289989|DRUG|Hydrocortisone|An experimental cream will be applied to one of the arms of the patient which will be an oregano extract and will be compared to the standard treatment which will be hydrocortisone 1% ointment
223824663|NCT02772575|PROCEDURE|Hepatic trans-arterial embolization (TAE)|
223824664|NCT02772575|DEVICE|MRI/CT scan|
223824665|NCT02772575|PROCEDURE|biopsy|
223824666|NCT02772575|OTHER|blood draw|
223824667|NCT04353193|DRUG|Terlipressin|Terlipressin 1mg IV bolus
223824668|NCT04353193|DRUG|Terlipressin|Terlipressin by IV continuous infusion at a rate of 2mg/day (max 4mg/day) during 2 hours
223824669|NCT04353193|DRUG|Octreotide|Octreotide 50mcg IV bolus plus continuous infusion at a rate of 50mcg/h during 2 hours
223824670|NCT04885387|DEVICE|chest CT|chest CT pectus deformities diagnostic
223824671|NCT04885387|DEVICE|Magnetic Resonance Imaging and a low-cost portable three-dimensional scanning device|Magnetic Resonance Imaging and a low-cost portable three-dimensional scanning device pectus deformities diagnostic
223824672|NCT01743690|BIOLOGICAL|Probiotic lactobacilli reuteri|
223824673|NCT01743690|DRUG|Nystatin|
223824674|NCT01743690|DRUG|fluocinolone|
223824675|NCT00873301|PROCEDURE|vestibulectomy|Evaluation of the outcome of vestibulectomy which is the treatment of vulvar vestibulitis
223824676|NCT01953770|DRUG|PEG-L-asparaginase ind|1,000 U/m2 on day 3 of induction therapy, intravenously, in 200 ml of saline, during 1 hour
223824677|NCT01953770|DRUG|PEG-L-asparaginase cons|1,000 U/m2 intravenously, in 200 ml of saline, during 1 hour, 24 hours after methotrexate on weeks 7, 9, and 11 - days 44, 58, and 72 (phase S1), weeks 15, 17, and 19 - days 100, 114, 128 (phase S2), weeks 23, 25, and 27 - days 156, 170, 184 (phase S3).
223824678|NCT01953770|DRUG|E.coli L-asparaginase|E.coli L-asparaginase (asparaginase medac) 5,000 U/m2 intramuscularly weekly, 24 hours after methotrexate dose, from week 7 to week 12 - days 44, 51, 58. 65, 72, 79 (phase S1), from week 15 to week 20 - days 100, 107, 114, 121, 128, 135 (phase S2), from week 23 to week 28 - days 156, 163, 170, 177, 184, 191 (phase S3).
223824679|NCT01953770|DRUG|High-dose Methotrexate|2,000 mg/m2 per 24 hours is given at days 43, 57, and 71 (weeks 7, 9, and 11). 1/5 of the total dose is given as slow intravenous bolus over 3-5 minutes. 4/5 of the total dose of methotrexate is injected as continuous 24 hours infusion.
223824680|NCT01953770|DRUG|Low-dose Methotrexate|30 mg/м2 is given intramuscularly 1 time weekly - days 43, 50, 57, 64, 71, and 78 (weeks 7, 8, 9, 10, 11, and 12).
223824681|NCT01953770|DRUG|Triple intrathecal therapy|Intrathecal injection of 3 drugs is additionally given three times during phase S-2 (weeks 15, 17, and 19 - days 99, 113, and 127), and three times during phase S-3 (weeks 23, 25, and 27 - days 155, 169, and 183).
223824682|NCT01953770|RADIATION|Cranial irradiation|12 Gy cranial irradiation is conducted at weeks 31-32 of the Protocol in patients \>3 years of age
223824683|NCT01953770|DRUG|Daunorubicin|Daunorubicin at a dose of 45 mg/m2 i.v. for 6 hours on day 8 of induction therapy
223824684|NCT04362657|DIAGNOSTIC_TEST|Computer Aided Diagnosis|Computer Aided diagnosis is an environment-enhancing technology developed to aid humans to improve their accuracy, speed and confidence by providing live feedback during the procedure, on request, or after the procedure has been completed.
223824685|NCT04746651|OTHER|Guided Self Help|Guided self help appointments with prison staff - 4x 30 minute appointments.
223824686|NCT01863927|OTHER|Research intervention|After heat acclimation the participant will be randomly exposed to 4 conditions during four separate consecutive days: 1) walking on a treadmill for two hours in hot-wet conditions (30OC, 70% RH) while wearing military uniforms and a vest (control group); 2) walking on a treadmill for two hours in hot-dry conditions (40OC, 30% RH) while wearing military uniforms and a vest (control group); 3) walking on a treadmill for two hours in hot-wet conditions (30OC, 70% RH) while wearing military uniforms and a vest with a ventilator (experimental group); 4) walking on a treadmill for two hours in hot-dry conditions (40OC, 30% RH) while wearing military uniforms and a vest with a ventilator (experimental group)
223824687|NCT00642837|DRUG|Tramadol/acetaminophen|Osteoarthritis, flexible dose depending on patients' pain relief
223824688|NCT00642837|DRUG|Tramadol/acetaminophen|Post surgical neurophatic pain, flexible dose depending on patients' pain relief
223824689|NCT00642837|DRUG|Tramadol/acetaminophen|Post traumatic neuropathic pain, flexible dose depending on patient pain relief
223824690|NCT00642837|DRUG|Tramadol/acetaminophen|Spinal Cord Injury, flexible dose depending on patients' pain relief
223824691|NCT00642837|DRUG|Tramadol/acetaminophen|Failed Back Surgery Syndrome,flexible dose depending on patients' pain relief
223824692|NCT00642837|DRUG|Tramadol/acetaminophen|Diabetic Neuropathy, flexible dose depending on patients' pain relief
223824693|NCT00642837|DRUG|Tramadol/acetaminophen|Post stroke pain, flexible dose depending on patients' pain relief
223824694|NCT00642837|DRUG|Tramadol/acetaminophen|Low back pain, flexible dose depending on patients' pain relief
223824695|NCT00642837|DRUG|Tramadol/acetaminophen|Post Herpetic Neuralgia, flexible dose depending on patients' pain relief
223824696|NCT00642837|DRUG|Tramadol/acetaminophen|Complex Regional Pain Syndrome, flexible dose depending on patients' pain relief
223824697|NCT00221286|DRUG|pegylated interferon alfa-2a|
223824698|NCT00221286|DRUG|tenofovir DF / emtricitabine combination therapy|
223824699|NCT00221286|DRUG|pegIFN / TDF / FTC combination therapy|
223824700|NCT01107743|DRUG|Amlodipine/Atorvastatin|"Amlodipine and Atorvastatin combination Tablet is indicated in following subjects for whom treatment with both amlodipine and atorvastatin is appropriate.~Subjects with concurrent hypertension or angina pectoris and hypercholesterolemia or familial hypercholesterolemia Indications for amlodipine and atorvastatin.~For oral use, amlodipine and atorvastatin combination tablet is given once daily. Dosage must be individualized based on dosage and administration for each individual component.~Amlodipine~* Hypertension Usual adult dosage is 2.5-5 mg of amlodipine given orally as a single daily dose.~* Angina pectoris For oral use, the usual adult dosage is 5 mg of amlodipine once daily. Atorvastatin~* Hypercholesterolemia For oral use, the usual adult dosage is 10-20 mg of atorvastatin once daily.~* Familial hypercholesterolemia For oral use, the usual adult dosage is 10-40 mg of atorvastatin once daily."
223824701|NCT03246243|DEVICE|nfant feeding solution|The study will record the sucking activity of the hospitalized infants over time, from their first oral sucking session including non-nutritive and nutritive sucking, until discharge, using an FDA-approved device that equips a typical bottle and nipple commonly used in the NICU with a non-invasive sensor to measure sucking activity. Each infant's nutritive and non-nutritive sucking patterns will be measured, and will comprise the 'sucking session' conducted with the bottle sensor.
223824702|NCT05179941|PROCEDURE|Perfusion with Indocyanine green|Infusion of Indocyanine green to determine perfusion of the subscapularis tendon change after tenotomy vs peel technique and subsequent intra-operative repair.
223824703|NCT03706911|DRUG|VM-1500A-LAI|VM-1500A (parent drug of elsulfavirine) IM injection dosage form
223824704|NCT04985734|DIAGNOSTIC_TEST|Specific diagnostic work-up for ATTR-CM patients|Technetium-scintigraphy
223824705|NCT01903343|DEVICE|shear wave elastography|ultrasound
223824706|NCT03862196|BEHAVIORAL|Tailored text messages to improve retention in HIV care|Trained counselors will deliver the text messages. After a block randomization, the trained counselor (a nurse) will send the first welcoming message to participants in the intervention arm. The nurse will send 2 tailored text messages per week. In addition 2 to 4 days before an appointment, the nurse will send a message reminder. In addition, the nurse will have bilateral communication with participants using text messages according to their needs. The participants of the intervention arm will interact with the nurse during 3 months with a semi-structured strategy, that is, with template text messages (predesigned) and open messages (for which the nurse will be trained). Three and six months after started the intervention the variables of interest will be assessed.
223824707|NCT06387589|PROCEDURE|Core stability exercises|"Core stability Exercises will include:~PLANK SIDE PLANK BIRD DOG MS GILL CURLUP PLANK + LEG RAISES SIDE PLANK + LEG RAISES PLANK + WALKS SIDE TO SIDE SIDE PLANK + TWIST BIRD DOG"
223824708|NCT06387589|PROCEDURE|Static Stretching of Iliopsoas|Static Stretching of Iliopsoas (Hold for 7-8s x 10 reps) Week 1 Lifting the leg while lying in a prone position with the knee bent Week 2 Lifting the leg in a prone position with a straight knee Week 3 Stretch in the modified Thomas test position Week 4 Modified launch stretch
223824709|NCT06387589|PROCEDURE|Post Facilitation Stretch of Iliopsoas|"Post Facilitation Stretch of Iliopsoas (5-10s x 10 reps) Patient's position supine at the edge of the table, non-effected hip and knee in flexion, experimental thigh and leg hang on the edge of table. Extend the hip of the opposite thigh up to the barrier. After that, the patient flexes the hip against maximal resistance (isometric) and breathes in for 5-10 seconds. Tell the patient Relax, whereas the therapist applies a rapid stretch to a new barrier and is held for 10 seconds."
223824710|NCT00321204|PROCEDURE|TZD reducing the incidence of atrial arrhythmias|
223824711|NCT01534455|DRUG|Lapatinib + 1,23 mg Eribulin|Lapatinib 1000 mg/day + Eribulin 1,23 mg/m2 i.v. on day 1 and 8, q21
223824712|NCT01534455|DRUG|Lapatinib + 1,76 mg Eribulin|Lapatinib 1000 mg/day + Eribulin 1,23 mg/m2 i.v. on day 1 and 8, q21
223824713|NCT00516750|DRUG|cisplatin|
223824714|NCT00516750|DRUG|doxorubicin hydrochloride|
223824715|NCT00516750|DRUG|methotrexate|
223824716|NCT00516750|DRUG|vinblastine|
223824717|NCT00516750|GENETIC|gene expression profiling|
223824718|NCT00516750|PROCEDURE|neoadjuvant therapy|
223824719|NCT04475848|DRUG|RO6953958|"Part 1: RO6953958 will be administered in an adaptive manner. The starting dose is planned to be 5 milligrams (mg).~Part 2: The starting dose is planned to be 45 mg.~Part 3: RO6953958 will be administered QD following a standardized breakfast on Day 3 to Day 14 at the maximum dose QD that was tested in the ongoing Part 2 (MAD)."
223824720|NCT04475848|DRUG|Placebo|"Part 1: A placebo will be administered in an adaptive manner. The starting dose is planned to be 5 mg.~Part 2: The starting dose is planned to be 45 mg."
223824721|NCT04475848|DRUG|Midazolam|Midazolam will be administered as single intervenous (IV) bolus injection of 100 micrograms (ug) on Day 1 and Day 13, and as single oral dose of 300 ug on Day 2 and Day 14.
223824722|NCT06441058|OTHER|No patient treatment is associated with the study|No patient treatment is associated with the study.
223824723|NCT04996199|DRUG|Oxcarbazepine|oxcarbazepine 150mg BD initial dose , followup will be done at 15days, 6weeks, 10 weeks interval
223824724|NCT04996199|DRUG|Carbamazepine|carbamazepine 100mg BD initial dose, follow up will be done 2weeks, 6 weeks \& 10weeks
223824725|NCT00508339|BEHAVIORAL|Questionnaire|Toronto Extremity Salvage Score (TESS) questionnaire.
223824726|NCT06115902|DRUG|TQB2102 for injection|TQB2102 for injection is a HER2 dual-antibody-drug Conjugate (ADC)
223824727|NCT02562963|BIOLOGICAL|natural killer T cell|The eligible patients are infused with two doses of (4±0.5)x10\^9 NKT cells in one course of treatment.
223824728|NCT02496403|BEHAVIORAL|Standard Medical Management (SMM)|SMM is designed to provide basic advice about opioid dependence and encouragement to adhere to treatment recommendations. Sessions provide support and monitoring of medication compliance, dose, withdrawal, adverse effects, and discussion of medical complications of opioid and other drug use. Early in treatment, the focus will be on helping patients adjust to the medications (e.g., monitoring withdrawal or other adverse symptoms, tolerating discomfort, curtailing illicit drug use, and referral to self-help). As treatment progresses, the practitioner may focus more on educating the patient about the social and behavioral factors perpetuating addiction and encourage behavioral and lifestyle change to support recovery.
223824729|NCT00189111|PROCEDURE|Cardiac Imaging + Treatment|
223824730|NCT02494206|DRUG|QBX258|Once patients are registered for the trial, they will be treated with QBX258 (VAK694 3mg/kg and QAX576 6mg/kg) delivered via peripheral intravenous injection once every 4 weeks (+ 1 week) for 4 treatments.
223824731|NCT01644396|BIOLOGICAL|Adalimumab|
223824732|NCT04440644|BEHAVIORAL|BBI|administration of psychometric test
223824733|NCT06241196|DEVICE|implant|Implant will be placed through the surgical guide in the extraction socket
223824734|NCT06241196|PROCEDURE|Vestibular Socket Therapy|tunnel incision will be made in labial vestibule
223824735|NCT06241196|DRUG|Alloderm|allogenic soft tissue substitute
223824736|NCT06241196|DRUG|Xenogenic bone membrane shield|xenogenic bone membrane
223824737|NCT06241196|PROCEDURE|Connective tissue graft|soft tissue harvesting from palate
223824738|NCT06475287|DRUG|HAIC（Mitoxantrone+Raltitrexed）、anlotinib、TQB2450|The combination therapy of HAIC with TQB2450 and Anlotinib was administered to enrolled patients in no particular order. Patients received routine hepatic artery catheterization via femoral artery puncture, followed by routine hepatic artery catheterization and infusion chemotherapy with 5% sodium bicarbonate 150ml + liposomal mitoxantrone (10mg) for 2-4 hours + Raltitrexed (2mg/m2) for 2-4 hours, every three weeks for at least two cycles. Systemic treatment was given every 21 days, with a fixed dose of 1200mg of TQB2450 injection on the first day of each systemic treatment cycle (1-7 days after HAIC treatment), administered intravenously over 60 minutes initially, followed by 30 minutes if tolerated. Anlotinib was administered orally once daily at a dose of 10mg, with a two-week break every three weeks. Treatment continued until unacceptable toxicity or loss of clinical benefit (as assessed by the investigator based on imaging, biochemical indicators, and patient clinical status).
223824739|NCT06153940|DEVICE|Treatment|"The Everglade™ Stem, is a second generation cementless blade style hip stem Forged in Titanium and proximally Antero-Posterior (AP) flared with Titanium Plasma Spray + Hydroxyapatite (TPS + HA) coated for bone on-growth.~The stem has distal geometry and a polished anodized surface finish to minimize the stem hanging in Dorr A femurs.~The World Acetabular Cup is a porous coated and mated with the Cross-linked polyethylene World Liner"
223824740|NCT05453981|BEHAVIORAL|Transdiagnostic Sleep and Circadian Intervention|Transdiagnostic Sleep and Circadian Intervention (TranS-C) integrates elements of evidence-based interventions, namely cognitive-behavioural therapy for insomnia, delayed sleep phase type, and interpersonal and social rhythm therapy. It targets common sleep disturbances in disorders and has improved disorder-focused symptoms and sleep and circadian functioning in patients with Severe mental illness (SMI).
223824741|NCT05696314|DIAGNOSTIC_TEST|Transoral Ultrasound|The oropharynx is scanned using high-frequency, small-footprint ultrasound transducers placed onto the suspected oropharynx sub-locations (e.g. tonsils or tongue base). Lidocaine spray or gel will be applied prior to scanning to reduce the gag reflex.
223824742|NCT05696314|DIAGNOSTIC_TEST|Transcervical Ultrasound|Curved low-frequency ultrasound transducers will be placed on the submental region on the skin of the neck, and the tongue base will be visualized in the midline in transverse and sagittal planes. The tonsils will be visualized adjacent to the tongue base on either side in oblique transverse and oblique sagittal planes, deep to the submandibular glands.
223824743|NCT06007482|DRUG|ES009|ES009 is administered via intravenous infusion, once every 21 days.
223824744|NCT03535831|DIAGNOSTIC_TEST|18F-DCFPyL|The purpose of this study is to determine if use of 18F-DCFPyL would increase the detection of lesions and to better inform your oncologist on the best method of treatment for your disease.
223824745|NCT03312686|DIAGNOSTIC_TEST|endoflip|Resolution of esophageal eosinophilia by a 2-month course of high dose PPI in patients will lead to improvement in esophageal distensibility, and thus should produce improvement in dysphagia symptoms.
223824746|NCT00740103|DRUG|Semapimod|60 mg IV x 3 days q 6 - 8 weeks
223824747|NCT04986982|DRUG|Opicapone 50 mg|Opicapone (BIA 9-1067) 50 mg hard capsules. Oral administration, once daily, at least 1 hour before or after the last daily dose of L-dopa/DDCI
223824748|NCT04986982|OTHER|Placebo|Matching placebo hard capsules. Oral administration, once daily, at least 1 hour before or after the last daily dose of L-dopa/DDCI
223824749|NCT05298098|DRUG|Hypertonic Saline Solution|Patients receive intravenous infusion of HSS (50ml of 10% NaCl) + Furosemide ( 250mg of furosemide) administered over one hour twice a day.
223824750|NCT05298098|DRUG|Placebo|Patients receive intravenous infusion of 5% Dextrose Solution (50ml of Dextrose 5%) + Furosemide (250mg of furosemide) administered over one hour twice a day.
223824751|NCT01155661|DRUG|LY2216684 (edivoxetine)|12 to 18 milligrams (mg), administered orally, once daily for 54 weeks, adjunctive to a selective serotonin reuptake inhibitor (SSRI)
223824752|NCT01155661|DRUG|SSRI|Participants should have been on their SSRI for at least 6 weeks prior and were to continue on their stable dose throughout the study.
223824753|NCT01860014|DRUG|Poractant alfa|Curosurf: 100 mg/kg-intratracheal, just after pulmonary hemorrhage
223824754|NCT01860014|DRUG|Beractant|Survanta: 100 mg/kg-intratracheal, just after pulmonary hemorrhage
223824755|NCT06227962|DIAGNOSTIC_TEST|Neuropsychological assesment|Estimated intelligence (subtasks of Wechsler Intelligence Scale for Children - Fifth edition -Dutch version \[WISC-V-NL\] or Wechsler Adult Intelligence Scale - Forth edition - Dutch version \[WAIS-IV-NL\]); Vienna reaction time; Rey auditory verbal learning test; Word fluency; Beery-Buktenica Developmental Test of Visual-Motor Integration, 6th Edition; Test of Everyday Attention for Children (TEA-Ch), subtask Score!/ or Test of Everyday Attention (TEA), subtask Elevator task; Trail making test; Word-color interference test
223824756|NCT06227962|DIAGNOSTIC_TEST|Psychosocial functioning and quality of life (questionnaires)|Anxiety (PROMIS); Depression (PROMIS); Peer-interaction (PROMIS); Perceived neurocognitive functioning (PROMIS); Participation and activity (PAY-CY); Trauma (KJTS/PCL-5); Health related quality of life (PEDSQL)
223824757|NCT06227962|DIAGNOSTIC_TEST|Parental psychosocial functioning (questionnaires)|Anxiety (PROMIS); Depression (PROMIS); Distress Thermometer-Parents (DT-P); Trauma (PCL-5)
223824758|NCT00583232|DRUG|Stable isotope infusions|Stable isotope infusion will be given via an intravenous catheter. Subjects will receive a priming dose and a continuous dose.
223824759|NCT00526383|DRUG|Tricyclic antidepressants|antidepressant version medical dispositive
223824760|NCT01291316|DRUG|Clonazepam|clonazepam, 1 mg, single oral dose
223824761|NCT01291316|DRUG|Tolterodine|Tolterodine 1,37mg, single oral dose
223824762|NCT01291316|DRUG|clobazam|clobazam 20 mg, single oral dose
223824763|NCT04488367|DRUG|Tranexamic acid|10 mg/kg IV TXA in the ED, repeat doses before skin incision and in PACU
223824764|NCT04488367|DRUG|Normal Saline|100 mL 0.9% normal saline in the ED, 10 mg/kg IV TXA before skin incision and in PACU
223824765|NCT03047772|DRUG|Atorvastatin|Routine dose of Atorvastatin therapy
223824766|NCT03047772|DRUG|Intensive Atorvastatin|Intensive dose of Atorvastatin therapy
223824767|NCT03047772|DRUG|Low dose BMMSC|Low dose autologous Bone Marrow Mesenchymal Stem Cells transplantation
223824768|NCT03047772|DRUG|Middle dose BMMSC|Middle dose autologous Bone Marrow Mesenchymal Stem Cells transplantation
223824769|NCT03047772|DRUG|High dose BMMSC|High dose autologous Bone Marrow Mesenchymal Stem Cells transplantation
223824770|NCT03047772|DRUG|Transplantation|Optimal dose autologous Bone Marrow Mesenchymal Stem Cells transplantation
223824771|NCT04911062|DRUG|Bupivacaine HCI without epinephrine|100 mg administered via injection into the surgical site.
223824772|NCT04911062|DRUG|HTX-011|HTX-011 (bupivacaine/meloxicam) dose up to 200 mg/6 mg administered via application into the surgical site.
223824773|NCT04911062|DEVICE|Luer Lock Applicator|Applicator for instillation.
223824774|NCT04023149|DRUG|recombinant human interleukin-2 (rhIL-2)|Drug: rhIL-2; Pharmaceutical form: solution; Route of administration: oral gargle.
223824775|NCT04023149|DRUG|placebo|Drug: placebo; Pharmaceutical form: solution; Route of administration: oral gargle.
223824776|NCT05014321|DEVICE|EC16 medical device (CE marked)|Application on brown spots located on the face (1 treatment during the study).
223824777|NCT05014321|DEVICE|device prototype (810A-v1)|Application on brown spots located on the face (4 treatments during the study).
223824778|NCT05014321|DEVICE|device prototype (810B-v1)|Application on brown spots located on the face (4 treatments during the study).
223824779|NCT05014321|DEVICE|device prototype (810C-v1)|Application on brown spots located on the face (4 treatments during the study).
223824780|NCT03646903|BEHAVIORAL|Cognitive Bias Modification|Cognitive bias modification (CBM) interventions typically involve the completion of brief, web-based tasks in which individuals are presented with a series of stimuli (e.g., words, sentences) and trained to respond in a manner that is positive or neutral, rather than negative and unhelpful. CBM interventions rely on the premise that repeated reinforcement of adaptive cognitions and a reshaping of negative cognitions enhance functioning and reduce distress.
223824781|NCT03646903|BEHAVIORAL|Psychoeducation|Psychoeducation-based interventions rely on the premise that enhancing knowledge about psychiatric symptoms and treatment will facilitate treatment engagement.
223824782|NCT05571384|BEHAVIORAL|high intensity body-weight circuit|"Bodyweight and suspension training equipment (TRX® Fit System) with modified movements. Modified Squats: participants will be instructed to hold the handles of the band with arms extended, participants will then lean back in a standing position and perform a squat within a comfortable range of motion while weight is being distributed to the band. Modified Rows: participants will grab the bands with arms and legs extended. They will find a comfortable angle by which to perform a row (pulling the handles to the rib cage) with arms at a 45-degree angle. Modified Push-Ups: perform push-ups on their knees with a flat back and hands underneath their shoulders. They will be instructed to lower their chest towards the ground in a controlled manner and as far as comfort will allow them. Modified Crunches: participants will lay on their back with feet approximately 8-10 inches from their buttocks, and asked to lift their shoulders slightly off the ground."
223824783|NCT01960075|DRUG|Fosphenytoin|
223824784|NCT01960075|DRUG|Levetiracetam|
223824785|NCT01960075|DRUG|Valproic acid|
223824786|NCT00449241|DEVICE|Acupuncture|
223824787|NCT03501329|COMBINATION_PRODUCT|Biological,Psychological and Social support|
223824788|NCT05779306|DEVICE|IOL Master 700|Biometry using the IOL Master 700
223824789|NCT05779306|DEVICE|Casia-2|Anterior segment-OCT to evaluate lens tilt
223824790|NCT05779306|DEVICE|MS-39|Corneal Topography using the MS-39
223824791|NCT05779306|DEVICE|OSIRIS|Abberometry using the OSIRIS-Abberometer
223824792|NCT05779306|DEVICE|Autorefractor|Evaluation of Refraction using an Autorefractor
223824793|NCT05779306|DIAGNOSTIC_TEST|Subjective Refraction|Refraction performed by experienced staff
223824794|NCT00161395|BEHAVIORAL|Instruction in the Creighton Model Fertility Care System|Instruction in the Creighton Model Fertility Care System.
223824795|NCT00161395|BEHAVIORAL|Preconception advice|Preconception advice for diet and frequency of intercourse.
223824796|NCT04113681|PROCEDURE|Geniculate Artery Embolization|"1. Conscious sedation : midazolam and fentanyl~2. Local anesthesia : Lidocaine 2% subcutaneous~3. Retrograde or anterograde common femoral artery access - 4Fr introducer~4. Sub-therapeutic anticoagulation (heparin 2000 IU IA)~5. Lower extremity arteriography~6. Selective and supra-selective catheterization of geniculate arteries supplying painful region of the knee~7. If abnormal arterial blushes are demonstrated selective and supra-selective embolization will be performed with Embozene microspheres (100 microns to 200 microns) - cold saline or ice-packs sac to be applied to overlying skin if significant cutaneous arteries are demonstrated at angiography.~8. Angiographic end-points: embolization of abnormal blush while preserving the parent vessel~9. Arteriotomy closure (manual compression or closure device)"
223824797|NCT00061516|DRUG|BETAXON (levobetaxolol HCl)|levobetaxolol suspension, 0.5%
223824798|NCT00061516|DRUG|AZOPT (brinzolamide)|brinzolamide suspension, 1%
223824799|NCT01396395|DRUG|Nicorandil|The subjects will receive Nicorandil 5 mg tablet orally three times daily for a period of 12 weeks along with the standard treatment.
223824800|NCT01396395|DRUG|Standard Treatment|The subjects will receive one of the standard anti-anginal therapies which included but not limited to aspirin, ACEI, lipid lowering statins and beta blockers according to the recommendation of guidelines. If the subject's condition permitted, they should take all these medicines. However, the dose, route, frequency and duration were determined by investigators according to subject's specific condition.
223824801|NCT05779553|DIAGNOSTIC_TEST|Tumor Endothelial Marker 1 ( TEM1 ) by ELISA kits|measurement of serum TEM1 in CRC patients, its relation to staging and comparing the diagnostic performance of serum TEM1 with serum CEA and CA19-9 for diagnosis of CRC. and Early detection of CRC patient
223824802|NCT00852670|DRUG|ACT-128800|ACT-128800 administered orally once daily
223824803|NCT00852670|DRUG|Placebo|Matching placebo capsules administered orally once daily
223824804|NCT02400437|DRUG|Ixazomib|Doses given on Days 1, 8, and 15 in induction and maintenance cycles.
223824805|NCT02400437|DRUG|Dexamethasone|Doses given on Days 1, 8, and 15 in induction and maintenance cycles.
223824806|NCT02400437|DRUG|Rituximab|Doses given on Day 1 of induction and maintenance cycles.
223824807|NCT02538770|OTHER|Rapid diagnostics using Anyplex TMII RV16 Detection|Rapid diagnostics using Anyplex TMII RV16 Detection, i.e. physician receives results of respiratory virus PCR as soon as they are available
223824808|NCT02538770|OTHER|Delayed diagnostics Anyplex TMII RV16 Detection|Delayed diagnostics Anyplex TMII RV16 Detection, i.e. physician receives results of respiratory virus PCR after one week delay unless specifically solicited
223824809|NCT02088632|BIOLOGICAL|Incobotulinumtoxina|Incobotulinumtoxina (Xeomin) is botulinum toxin type A and is administered via intramuscular injection.
223824810|NCT02088632|OTHER|Placebo Comparator|Normal saline is sterile sodium chloride without and preservatives.
223824811|NCT06199661|BEHAVIORAL|APEX|Three phases: warm-up, high-intensity interval training (HIIT) phase, cool-down. A 10-minute warm-up included deep breathing meditation and dynamic joint mobility exercises. Then, a 40-minute strength and balance workout in HIIT format with five different high-intensity (HI) exercises interspersed with five different postural stability recovery exercises. The HI intervals focused on enhancing cardiovascular fitness, muscle strength, and motor performance. The recovery intervals incorporated balance and mobility exercises. The HI exercises lasted 30 seconds for the first three weeks and then increased to 45 seconds in the fourth week while the recovery exercises lasted 60 seconds throughout the entire intervention. The HIIT phase was repeated three times in the 40 minute block. Lastly, a 10-minute cooldown consisting of standing and seated exercises similar to the warm-up.
223824812|NCT05646199|DRUG|Metformin|Participants will receive metformin
223824813|NCT05646199|DRUG|Semaglutide Injectable Product|Participants in this group will receive injectable Semaglutide
223824814|NCT01280734|DRUG|Circadin (R) 2 mg|One 2 mg tablet at 23:00
223824815|NCT01280734|DRUG|Stilnox (R) 10 mg|One 10 mg encapsulated tablet at 23:00
223824816|NCT01280734|DRUG|Placebo|One tablet or encapsulated tablet at 23:00
223824817|NCT00004202|DRUG|carboplatin|
223824818|NCT00004202|DRUG|chemotherapy|
223824819|NCT00004202|DRUG|efaproxiral|
223824820|NCT00004202|DRUG|paclitaxel|
223824821|NCT00004202|RADIATION|radiation therapy|
223824822|NCT03179813|PROCEDURE|Hydrocortisone|During the third molar extraction the hydrocortisone solution will be used in the test group
223824823|NCT03179813|PROCEDURE|Control|During the third molar extraction the saline solution will be used in the control group
223824824|NCT02101918|RADIATION|Computed Tomography Perfusion Imaging|Undergo computed tomography perfusion imaging
223824825|NCT02101918|OTHER|Laboratory Biomarker Analysis|Correlative studies
223824826|NCT02101918|BIOLOGICAL|Ziv-Aflibercept|Given IV
223824827|NCT00882921|BIOLOGICAL|Idursulfase|Patients received idursulfase as prescribed by their physician following locally approved prescribing information. Patients will not be provided idursulfase by Shire Human Genetic Therapies, Inc. or the HOS.
223824828|NCT04845035|DRUG|Dasatinib|By mouth
223824829|NCT04845035|DRUG|Ponatinib|By mouth
223824830|NCT04845035|DRUG|Berlin-Frankfurt-Münster Chemotherapy|with varied cycles, including Daunorubicin, Vincristine, Prednisone, Pegaspargase, Rituximab, Cytarabine, Mercaptopurine, Cyclophosphamide, Methotrexate, Doxorubicin, Thioguanine, and Dexamethasone
223824831|NCT04845035|DRUG|Methotrexate and Cytarabine|Intrathecal
223824832|NCT00817375|DRUG|SSRI treated group|Antidepressant administration of SSRI class for 6 weeks under therapeutic dose
223824833|NCT00817375|DRUG|non-SSRI treated group|Antidepressant administration of non-SSRI class for 6 weeks under therapeutic dose
223824834|NCT01370005|DRUG|Placebo|Placebo matching BI 10773 low dose
223824835|NCT01370005|DRUG|BI 10773|BI 10773 high dose once daily
223824836|NCT01370005|DRUG|Placebo|Placebo matching BI 10773 low dose
223824837|NCT01370005|DRUG|BI 10773|BI 10773 low dose once daily
223824838|NCT01370005|DRUG|Placebo|Placebo matching BI 10773 high dose
223824839|NCT01370005|DRUG|Placebo|Placebo matching BI 10773 high dose
223824840|NCT03581123|BEHAVIORAL|Supported-Self Management (SSM)|Provides low back pain sufferers opportunities to develop the capacity and motivation to self-manage their pain in an adaptive manner. This includes psychological/behavioral strategies, mind-body approaches, lifestyle advice, pain education and pain coping.
223824841|NCT03581123|OTHER|Spinal Manipulation Therapy (SMT)|SMT will address the biological and physical aspects of low back pain (e.g. spinal dysfunction) with the intention of restoring maximum movement and functional ability of the spine.
223824842|NCT03581123|COMBINATION_PRODUCT|SMT + SSM|Combination Treatment
223824843|NCT03581123|DRUG|Standard Medical Care (SMC)|Guideline based medical care informed by the American College of Physicians' guidelines on noninvasive treatment for low back pain.
223824844|NCT02009696|DEVICE|Patients with a ProMRI Pacemaker System|Bradycardia Slow Heart Beat
223824845|NCT02009696|OTHER|Magnetic Resonance Imaging (MRI) scan|MRI scan of heart/chest or thoracic spine.
223824846|NCT06172608|OTHER|psychoeducational intervention|". Intervention group (I) will receive psychosocial education which will be consist of two parts. 1) Face to Face 2) Community based intervention.~1. Face to face: This face to face session will be consisting of 30-minute session soon after inclusion into the study. A leaflet consisting of all information will be provided to all the patents taking part in the study.~2. Community Based Intervention: In community based interventions prerecorded videos about all the topics covered in face to face session will be made available to parents via a secure online platform. Parents can easily browse it easily when they need it. These videos will be recorded in local language (Urdu), which is easy to understand for almost all the people."
223824847|NCT05907577|OTHER|Observational|No interventions.
223824848|NCT01154894|OTHER|Aravita including arachidonic acid and docosaheaenoic acid|Nine of 13 Participants were treated with 6 capsules of Aravita per day for 16-week trial, remaining 4 participants aged under 12 years received 3 capsules per day.
223824849|NCT01364974|DRUG|ASP015K|oral
223824850|NCT01364974|DRUG|Placebo|oral
223824851|NCT00641758|DRUG|Pycnogenol|Pycnogenol 100mg twice daily
223824852|NCT00641758|DRUG|Placebo|Placebo 100mg twice daily
223824853|NCT01790360|BEHAVIORAL|Patient Navigation (PN) Intervention|Patient Navigation is defined as an individual relationship between a navigator and participant to promote retention in the continuum of HIV care . For this study, three experienced navigators will be hired. Their primary role will be to ensure that participants are linked to an HIV primary care provider, that they attend at least one scheduled visit within three months of receiving a confirmed HIV diagnosis, and that they are retained in care (as defined by attending three HIV visits within nine months of diagnosis). To promote linkage to HIV care, navigators will help participants identify material and other barriers to accessing care and will work with participants to overcome those barriers.
223824854|NCT01790360|BEHAVIORAL|Financial Incentives (FI) Intervention|After confirmation that they have completed their first HIV primary care visit, Financial Incentive participants will receive a gift card. Additionally, the coordinator will flip a coin and give participants a bonus gift card if the coin flip comes up heads. Participants who attend the second HIV primary care visit will receive a gift card. Patients who attend a third HIV primary care visit will receive a gift card. Study staff will be responsible for confirming participants' attendance at appointments.
223824855|NCT01317290|DIETARY_SUPPLEMENT|n-3 PUFA free olive oil|negative control
223824856|NCT01317290|DIETARY_SUPPLEMENT|linseed oil|
223824857|NCT02568332|BIOLOGICAL|AdCh3NSmut1|Genetic vaccine against Hepatitis C virus infection
223824858|NCT02568332|BIOLOGICAL|MVA-NSmut|Genetic vaccine against Hepatitis C virus infection
223824859|NCT04301440|DEVICE|The emission of electromagnetic with the probes|The patient will be in the lying position, a probe will be positioned in the middle of the chest and the second probe below the xyphoid. The probes will be fixed by a band to keep them in place. The emission of electromagnetic waves is painless.
223824860|NCT04301440|DEVICE|The emission of electromagnetic without the probes|The patient will be in the lying position, a probe will be positioned in the middle of the chest and the second probe below the xyphoid. The probes will be fixed by a band to keep them in place. The emission of electromagnetic waves is painless.
223824861|NCT05527730|DEVICE|Comparison of PRO-FIT or SELF-FIT fitting|add
223824862|NCT04248842|DEVICE|Continuous monitoring system|Patients recruited will be continuously monitored with Isansys Lifetouch patch, Isansys wireless blood pressure monitor (Meditech Blue BP-05), Nonin WristOx 3150 as well as departments standard monitors
223824863|NCT03910348|DEVICE|Whole-body vibration exercise|The WBV training consisted of a high frequency (30-40 Hz) vibration stimulus at a low setting on a Power Plate pro5 vibration platform (Performance Health Systems, LLC, Northbrook, IL, USA).
223824864|NCT03910348|OTHER|High-impact exercise|In the high-impact exercise program, the patients were asked to jump using a jump-rope at the beginning of each session
223824865|NCT05570682|PROCEDURE|TCI|General anesthesia will be induced with a TCI pump
223824866|NCT05570682|PROCEDURE|Manual induction|General anestehsia will be induced and maintained using a pro kilo regimen.
223824867|NCT05545241|BEHAVIORAL|Neurofeedback + BART/EEG|"10 sessions of emotional neurofeedback (max of 2 sessions per week and max of 10 weeks).~Before (Baseline, Day 0) and at the study completion (after 10 neurofeedback sessions, Week 5), a EEG record is realized during the BART, assessing risk-taking behavior."
223824868|NCT05545241|BEHAVIORAL|BART/EEG only|only the twice EEG record are realized during the BART, assessing risk-taking behavior (every corresponding to the pre and post-neurofeedback evaluations in arm I)
223824869|NCT06055192|OTHER|Survey|Survey
223824870|NCT05490329|BEHAVIORAL|Tough Talks COVID|Intervention participants will download the TT-C app from the iOS or Google Play store and complete the intervention within one month.
223824871|NCT05523440|DRUG|Bevacizumab|Bevacizumab infusion.
223824872|NCT05523440|DRUG|Niraparib|Niraparib oral capsule.
223824873|NCT06084559|OTHER|Supplemental oxygen therapy|Mobile oxygen via pressurized bottle or mobile oxygen concentrator will be applied
223824874|NCT06084559|OTHER|Sham Oxygen therapy|Patients will reveice pressurized air via a nasal cannula
223824875|NCT06476184|DRUG|Carboplatin|"Patients will be randomized 1:1:~* Experimental arm: Densification of the chemotherapy administration dose and dosing schedule of carboplatin-paclitaxel (carboplatin AUC 5 every 3 weeks on day 1 and paclitaxel 80 mg/m2 every week, on day 1, day 8, and day 15, with 3 week-cycles) for 3 cycles~* Standard arm: Continuation of the same 3-weekly carboplatin-paclitaxel, as administered during the neo-adjuvant chemotherapy"
223824876|NCT06476184|DRUG|Paclitaxel|"Patients will be randomized 1:1:~* Experimental arm: Densification of the chemotherapy administration dose and dosing schedule of carboplatin-paclitaxel (carboplatin AUC 5 every 3 weeks on day 1 and paclitaxel 80 mg/m2 every week, on day 1, day 8, and day 15, with 3 week-cycles) for 3 cycles~* Standard arm: Continuation of the same 3-weekly carboplatin-paclitaxel, as administered during the neo-adjuvant chemotherapy"
223824877|NCT05536102|DRUG|PLD|20mg/m2, day 1, q3w
223824878|NCT05536102|DRUG|Oxaliplatin|130 mg/m2, day 1, q3w
223824879|NCT05536102|DRUG|Capecitabine|1000 mg/m2, days 1-14, q3w
223824880|NCT05536102|DRUG|Tislelizumab|200 mg, day 1, q3w
223824881|NCT04140253|BEHAVIORAL|Pelvic floor muscle training (PFMT) with lumbopelvic stabilization|"Pelvic floor muscle training (PFMT) with lumbopelvic stabilization.~1. Educating of probands about anatomy, physiology, and pelvic floor muscles functions~2. Training of pelvic floor muscles in different position~3. Training of pelvic floor muscles with lumbopelvic stabilization~Exercise 5 times a week for 20-30 minutes a day, after initial training with a physiotherapist."
223824882|NCT05363969|DEVICE|Fractionated laser resurfacing|Patients will receive 3-4 treatments with fractionated laser resurfacing
223824883|NCT01834443|DEVICE|Direct current galvanic vestibular stimulation|
223824884|NCT00856661|DRUG|Desmoteplase|90 μg/kg bodyweight, IV, single bolus over 1 to 2 minutes on 1st day
223824885|NCT00856661|DRUG|Placebo|IV, single bolus over 1 to 2 minutes on 1st day
223824886|NCT04417387|OTHER|Observational|
223824887|NCT06112223|DRUG|Gabapentin|Patients will receive oral gabapentin 600 mg 1 hour before the surgery.
223824888|NCT06112223|DRUG|Tramadol|Patients will receive oral tramadol 100 mg 1 hour before the surgery.
223824889|NCT04131595|BIOLOGICAL|MVA-BN-WEV Dose 1|1 x 10\^7 Inf.U MVA-BN-WEV vaccine
223824890|NCT04131595|BIOLOGICAL|MVA-BN-WEV Dose 2|1 x 10\^8 Inf.U MVA-BN-WEV vaccine
223824891|NCT04131595|BIOLOGICAL|MVA-BN-WEV Dose 3|2 x 10\^8 Inf.U MVA-BN-WEV vaccine.
223824892|NCT01336985|DRUG|Irinotecan|
223824893|NCT01336985|PROCEDURE|Chemoembolization|
223824894|NCT01336985|DEVICE|Drug-Eluting Beads|
223824895|NCT01336985|PROCEDURE|Biopsy|
223824896|NCT02420743|PROCEDURE|serum ferritin|serum ferritin will be measured serially at 26, 30 and 34 weeks gestation.
223824897|NCT02420743|PROCEDURE|MCA Doppler|MCA peak systolic value will be assessed at 26, 30 and 34 weeks gestation.
223824898|NCT04013412|DIETARY_SUPPLEMENT|Protein-Calorie Restriction|Four day dietary intervention immediately before surgery of ScandiShake \[any of 4 flavors\] mixed with almond milk, calculated individually for a total daily volume to achieve 30% caloric restriction and 70% protein restriction, based on body weight and activity level.
223824899|NCT00953303|DRUG|glucocorticoid|One dose of Dexamethasone (20mg/day) followed by prednisone 1mg/kg/day with a maximum dose of 60mg/day.
223824900|NCT00953303|DRUG|standard care|The patients will be given standard care such as diuretics, inotropic and/or vasodilator in acute decompensated congestive heart failure management.
223824901|NCT01980615|DRUG|Inhaled BGF (PT010) Dose 1|
223824902|NCT01980615|DRUG|Inhaled BGF (PT010) Dose 2|
223824903|NCT01980615|DRUG|Inhaled BGF (PT010) Dose 3|
223824904|NCT01980615|DRUG|Inhaled GFF (PT003)|
223824905|NCT01980615|DRUG|Inhaled Symbicort Dose 1|
223824906|NCT01980615|DRUG|Inhaled Symbicort Dose 2|
223824907|NCT02120664|DRUG|Florbetapir (18F)|
223824908|NCT02120664|DRUG|11C-PiB|
223824909|NCT05480670|DIETARY_SUPPLEMENT|Berberine|550 mg Berberine supplement BDS for 3-months + changes in diet/life style.
223824910|NCT04662463|BEHAVIORAL|Cognitive Bias Modification for Interpretation (CBM-I)|Patients will receive CBM-I training by reading and imaging themselves in a series of emotionally ambiguous scenarios. Each scenario ends with an incomplete final word. Patients need to complete the final word to resolve the scenario in a positive direction.
223824911|NCT04662463|BEHAVIORAL|Placebo|Patients will receive placebo task which uses neutral rather than emotional material.
223824912|NCT04966143|BIOLOGICAL|LY011|Targeting CLDN 18.2 Car-T injection
223824913|NCT02460263|DEVICE|Tablo Hemodialysis System|
223824914|NCT01170416|OTHER|12-lead body surface mapping|An average of 20 distinct left ventricular sites will be mapped using 12-lead body surface mapping electrodes and recorded for 15 seconds, then sent to a computer for further analysis.
223824915|NCT03916744|DRUG|Giredestrant|Giredestrant will be administered orally once daily (QD) starting on Day 1 up to and including the day of surgery (if allowed per local process) on Day 15 (+/-2 days).
223824916|NCT03916744|PROCEDURE|Surgery|Breast cancer surgery will take place on Day 15 (+/-2 days).
223824917|NCT06062459|OTHER|Motor Control Exercise|Motor control exercises focusing on the activation and control of deep spinal muscles
223824918|NCT06062459|OTHER|Balance Training|Balance training exercises on to enhance proprioception and stability
223824919|NCT06062459|OTHER|Control Group|Participants received hot pack and stretching exercise
223824920|NCT03176238|DRUG|everolimus|one 10 mg tablet or two 5 mg tablets of everolimus were administered orally once daily on a continuous dosing schedule starting on Day 1
223824921|NCT03176238|DRUG|exemestane|25 mg tablet was administered orally once daily on a continuous dosing schedule starting on Day 1
223824922|NCT05043402|DRUG|navicixizumab|navicixizumab IV
223824923|NCT05043402|DEVICE|Xerna™ TME Panel|RNA-seq-based biomarker platform that classifies any given patient tumor sample into phenotypes based on the dominant biology of the tumor microenvironment (TME).
223824924|NCT04524598|DEVICE|Limbix Spark|The Limbix Spark program is divided into 5 levels. Each level provides educational information about cognitive behavioral therapy and interactive activities.
223824925|NCT04524598|OTHER|Psychoeducation|The Psychoeducation program is divided into 5 lessons. Each lesson covers a different topic about depression.
223824926|NCT00017940|GENETIC|Human Nerve Growth Factor|
223824927|NCT00497640|PROCEDURE|Artificial Neural Network|Use of a predicted optimal CPAP
223824928|NCT04771338|BEHAVIORAL|VR-JIT/KF-STRIDE|Treatment group will receive 12 sessions of job interview training protocol.
223824929|NCT01233583|DRUG|Dovobet, neotigason, etanercept, adalimumab. infliximab|Dovobet ointment 15g/day for 6 weeks Neotigason capsule 50mg per day (oral) for 6 weeks Enbrel 50mg twice weekly subcutaneous injection for 6 weeks Humira 80mg week 0, 40 mg week 1 then every other week therafter subcutaneous injection for 6 weeks Remicade 3 separate doses of 5mg/kg intavenous injection for 6 weeks
223824930|NCT02301156|DRUG|Ublituximab|Administered as an IV infusion
223824931|NCT02301156|DRUG|Ibrutinib|Administered orally
223824932|NCT00486135|DRUG|XL147 (SAR245408)|Gelatin capsules supplied in 25-mg and 100-mg dosage strengths
223824933|NCT00486135|DRUG|XL147 (SAR245408)|Tablets supplied as 100-mg, 150-mg, and 200-mg dosage strengths
223824934|NCT02630524|BEHAVIORAL|eHealth Behavioral Lifestyle Intervention Device: Telecoach|Participants will receive weekly/biweekly coaching sessions with a telecoach and use eHealth platform to log food and exercise, review daily goals, and find strategies for reaching goals.
223824935|NCT01473472|DRUG|Truvada|2 tablets of truvada within 24 hours before first sexual relations, then 1 tablet of Truvada during the period of sexual activity including the last sexual intercourse, finally, a last dose of 1 tablet of Truvada approximately 24 hours later
223824936|NCT01473472|DRUG|Placebo|2 tablets of placebo within 24 hours before first sexual relations, then 1 tablet of placebo every 24 hours during the period of sexual activity including the last sexual intercourse, finally, a last dose of 1 tablet of placebo approximatively 24 hours later
223824937|NCT00274690|DRUG|GW679769|
223824938|NCT00903734|DRUG|Erlotinib Hydrochloride (Tarceva)|Dose of 150 mg daily by mouth.
223824939|NCT02811757|PROCEDURE|tenotomy|
223824940|NCT02811757|PROCEDURE|tenodesis|
223824941|NCT02974530|OTHER|Neurological evaluation|
223824942|NCT02974530|OTHER|Laryngological evaluation|
223824943|NCT02974530|OTHER|MRI evaluation|
223824944|NCT02974530|OTHER|Breathing investigation|
223824945|NCT02974530|OTHER|MRI and articulatory investigation|
223824946|NCT02974530|OTHER|Postural investigation|
223824947|NCT02974530|OTHER|Voice and soundscape investigation|
223824948|NCT04380532|BIOLOGICAL|V-SARS|Therapeutic vaccine formulated as a pill derived from heat-inactivated plasma from COVID-19 patients administered once-per-day to at least 20 healthy volunters for at least one month
223824949|NCT05334927|BEHAVIORAL|Medicine Overuse Headache/New Daily Persistent Headache|At the end of the 24th month visit, the patient is free to choose whether to conduct a face-to-face visit once a year until death.
223824950|NCT05334927|BEHAVIORAL|Chronic Migraine|long-term follow-up
223824951|NCT05334927|BEHAVIORAL|Patients with other types of primary headache|No collection Brain imaging、Cognitive function test、Biological sample
223824952|NCT03324503|DRUG|Glucocorticoid (prednisone or prednisolone)|≥ 30 mg/day prednisone or prednisolone taken orally as per local clinical practice of sarcoidosis initial induction therapy
223824953|NCT03211715|OTHER|questionnaire|Rectal cancer patients who received sphincter saving surgery will be asked to fill up questionnaire related to bowel dysfunction
223824954|NCT03236922|PROCEDURE|Pubococcygeus sling|The pubococcygeus muscles is dissected from the vaginal side walls and approximated at the midline just below the urethra.
223824955|NCT03236922|PROCEDURE|Rectus fascia sling|Rectus fascia is dissected out cephalad to the pubic symphysis and tunneled beneath the urethra.
223824956|NCT02676908|OTHER|Compression socks for 2 weeks|Patients in the intervention group will be asked to wear compression stockings for two weeks post-operatively
223824957|NCT03368079|DEVICE|Negative Pressure Suction Catheter|The negative pressure suction device to be used in the study will be a Foley catheter. The catheter will be placed through the gastrostomy tube site, directed retrograde through the esophagus, and terminating in the PES.
223824958|NCT02592200|DIETARY_SUPPLEMENT|Lactobacillus gasseri DSM 27123|109 CFU (divided in two doses) per day for 28 days
223824959|NCT02592200|DIETARY_SUPPLEMENT|Placebo|Two doses per day for 28 days
223824960|NCT00061113|DRUG|Fluoxetine + outpatient cognitive behavioral therapy|single fixed morning dose 20 mg X 15 weeks
223824961|NCT00061113|DRUG|fluoxetine|20mg, QD x 16 weeks
223824962|NCT00061113|DRUG|placebo + CBT|single fixed morning dose X 16 weeks
223824963|NCT01326273|PROCEDURE|Lymphopheresis|Lymphopheresis
223824964|NCT01326273|PROCEDURE|CMV specific lymphocyte infusion|CMV specific lymphocyte infusion
223824965|NCT01326273|PROCEDURE|Peripheral blood for CMV DNA PCR|Peripheral blood for CMV DNA PCR
223824966|NCT01326273|PROCEDURE|Haematology/Blood chemistry|Haematology/Blood chemistry analysis, Collection of blood for ancillary laboratory tests.
223824967|NCT00001266|DRUG|Suramin|
223824968|NCT00194480|DRUG|Pegylated Interferon|Weekly injections of pegIntereferon
223824969|NCT05480020|OTHER|Streptococcus salivarius M18 toothpaste|"Probiotics Streptococcus salivarius M18 toothpaste 1 million cfu/g~In this study, a toothpaste formulation containing S. salivarius M18 will be evaluated for its potential for delivering the probiotic to the oral cavity."
223824970|NCT05480020|OTHER|Streptococcus salivarius M18 toothpaste|"Probiotics Streptococcus salivarius M18 toothpaste 10 million cfu/g~In this study, a toothpaste formulation containing S. salivarius M18 will be evaluated for its potential for delivering the probiotic to the oral cavity."
223824971|NCT05480020|OTHER|Streptococcus salivarius M18 toothpaste|"Probiotics Streptococcus salivarius M18 toothpaste 100 million cfu/g~In this study, a toothpaste formulation containing S. salivarius M18 will be evaluated for its potential for delivering the probiotic to the oral cavity."
223824972|NCT04848883|BEHAVIORAL|Advanced AMS program|"1. \- Telephone acces to infectious disease experts to discuss patients' therpies during working days.~2. \- Biweeckly meetings with infectious diseases experts and antimicrobial stewardship group."
223824973|NCT04848883|BEHAVIORAL|Standard AMS program|"1. \- Educational materials.~2. \- Updated local antibiotic guidelines.~3. \- Promotion of delayed antibiotic prescription.~4. \- Promotion of Streptococcus pyogenes antigen test (Streptotest) if bacterial tonsillitis is suspected.~5. \- Daily report to GP of multiresistant bacteria isolates in urinary samples.~6. \- Quarterly reports to prescribers of AMS outcomes at the centre-level."
223824974|NCT05730530|BEHAVIORAL|Nutrition education curriculum|This intervention consists of a 6-week-long nutrition education curriculum aimed at improving fruit and vegetable acceptance and consumption. Sessions will occur within the classroom 3 times per week for 6 weeks. Each week, the sessions will consist of 2 days of teaching activities and 1 day of taste-test activities designed for children to guess various common fruits and vegetables, assemble recipes including 2-4 different fruits and vegetables, and then taste the foods. These activities will be conducted in a full-classroom group setting.
223824975|NCT05373134|DRUG|Pentoxifylline|400mg OD x 1 week, 400mg BD x 1 week then increased to 400mg TDS and continued
223824976|NCT05373134|OTHER|Placebo|Placebo
223824977|NCT01394484|OTHER|Intervention I|Four servings of dairy foods (milk and yogurt) per day for 42 days.
223824978|NCT01394484|DIETARY_SUPPLEMENT|Intervention II|1200 mg of supplemental calcium and 400 IU of vitamin D3 for 42 days
223824979|NCT03515057|DIAGNOSTIC_TEST|Single lead handheld electrocardiogram|Screening for atrial fibrillation during outpatient primary care office visits among patients 65 years and older
223824980|NCT00525603|DRUG|Cyclophosphamide|200 mg/m\^2/day 3-5 IV 5-30 minutes
223824981|NCT00525603|DRUG|Fludarabine|20 mg/m\^2/day 3-5 IV 5-30 minutes
223824982|NCT00525603|DRUG|Alemtuzumab|30 mg Days 1, 3, 5 IV 2-4 hours
223824983|NCT00525603|DRUG|Rituximab|375 mg/m\^2/day 2 IV 4-6 hours
223824984|NCT00854516|PROCEDURE|A new treatment approach is to have an effective working pressure combined with a low resting pressure.|"Procedure Schedule: The total duration for study participation will be 14 days (8 visits).~Subject eligibility will be determined at the initiation visit. All eligible subjects will receive the compression device on the study leg and will return to the clinical center at day 1, 2, 3, 4, 7, 10 and 14 to assess safety. At each clinical visit (except visit day 14) the compression device will be reapplied. The study participation ends after 14 days."
223824985|NCT02260505|DRUG|Imatinib maintenance|Either 300 or 400 mg/day in accordance with the last dose routinely taken by the patient in the 3-year period before randomization. The treatment will be orally taken at time of meal with a large glass of water
223824986|NCT02638623|DRUG|Lactated Ringer|2L Lactated Ringer administered prior to primary knee or hip arthroplasty
223824987|NCT02638623|DRUG|Placebo|No additional fluids will be administered
223824988|NCT02918929|DRUG|EDP 305|
223824989|NCT02918929|DRUG|Placebo|placebo to match EDP 305
223824990|NCT04011579|OTHER|MSFIT|MSFIT, by using the Microsoft Kinect Motion Controller Xbox to deliver adapted physical activity, offers the possibility to transform the Pilates exercises into a virtual reality game. Each exercise is implemented with different levels of difficulty in order to allow the adaptation to the capacities of the user.
223824991|NCT02932592|DEVICE|Continuous Glucose Monitoring System (i Pro 2 - Medtronic)|This device can register blood glucose values and excursions. This device consists of a needle (applied in subcutaneous way) and of a recording device.
223824992|NCT00280657|DRUG|Valette|1 tablet 0.030 mg ethinylestradiol / 2 mg dienogest + 1 placebo tablet daily for 21 days followed by a 7-day tablet-free interval, oral administration for 6 cycles
223824993|NCT00280657|DRUG|Diane|1 tablet 0.035 mg ethinylestradiol / 2 mg cyproterone acetate + 1 placebo tablet daily for 21 days followed by a 7-day tablet-free interval, oral administration for 6 cycles
223824994|NCT00280657|DRUG|Placebo|2 placebo tablets daily for 21 days followed by a 7-day tablet-free interval, oral administration for 6 cycles
223824995|NCT02454829|OTHER|questionnaire|A questionnaire will be send concerning the patient's ovarian function since the cryopreservation procedure i.e: progression of puberty, menstrual cycle, hormonal treatment, desire for pregnancy, occurence of pregnancy, details of pregnancy, need for ART (Artificial Reproductive Techniques), and about the patient's satisfaction concerning the cryopreservation procedure. Data collected will be correlated with treatments received.
223824996|NCT03493763|DIAGNOSTIC_TEST|5hmC profile in plasma cell-free DNA after liver resection|Peripheral blood is drawn every 3 months after liver resection for 5hmC test (Time frame: 2 years or until tumor recurrence).
223824997|NCT02975635|OTHER|Questionnaire|Patients are given a questionnaire with items related to personality and behaviour.
223824998|NCT04280822|DRUG|Neoadjuvant immunochemotherapy|"Neo-adjuvant chemotherapy(cisplatin and paclitaxel):~Paclitaxel, 175mg/m2, d1, Cisplatin, 75mg/m2, d1, 3 week, 2 cycles. JS001, 240mg ivgtt, d3, \>30min, 3week, 2 cycles~Surgery:~2-3weeks after Neo-adjuvant chemotherapy Surgeons: the operation shall be performed by senior thoracic surgeons. Try to achieve the consistency of operation quality.~Operation: the thoracic esophagectomy must be through right thoracic cavity. (open and minimally invasive McKeown or Ivor Lewis). Total two-field lymphadenectomy (right and left recurrent laryngeal nerve lymph nodes must be included).~After surgery/ maintain period:~JS001, 240mg ivgtt, d3, \>30min, 3week (8 cycles at most)"
223824999|NCT02010801|PROCEDURE|irreversible electroporation|
223825000|NCT02010801|DEVICE|nanoknife AngioDynamics US Ltd|
223825001|NCT03545347|DRUG|Nandrolone Decanoate|Injections every 3 weeks, last injection at week 12. Women 50 mg, men with total testosterone ≥ 11 nmol/l will receive 100 mg, and men with total testosterone \< 11 nmol/l will receive a dose of 200 mg.
223825002|NCT03545347|DIETARY_SUPPLEMENT|Protein-rich nutritional supplement|The protein-rich nutritional supplement is a liquid containing 18 g milk-based protein pr bottle. Patients will receive a minimum of 1.35 g/kg bodyweight/day); which means that most patients will receive 2 bottles per day for 12 weeks.
223825003|NCT03545347|OTHER|Physical therapy|The physical therapy intervention will include progressive strength training initiated daily on weekdays during hospitalization and continued twice per week in the outpatient rehabilitation program in the municipality (treatment as usual but with strength training as an obligatory component) for a total intervention period of 12 weeks from time of inclusion.
223825004|NCT03545347|DRUG|Sodium Chloride 9mg/ml Injection|Placebo injection of 1 ml Sodium Chloride
223825005|NCT02520648|OTHER|Neuro-lymphatic treatment|The physical therapist applied direct firm rotary pressure, via thumb or tip finger, for 1 minute, from the transverse processes of T1 to the transverse processes of T12. To finish the intervention, hands were placed on the skull and sacrum during 2 minutes without movement.
223825006|NCT02520648|OTHER|Articulatory spinal manual therapy|Then the therapist performs pressures in the transverse apophysis from D1 to D12 (level of the paravertebral muscles, at a distance of 2 fingers of the spinous apophysis), applying sustained pressure during expiratory time until the articulatory barrier is reached.
223825007|NCT02520648|OTHER|Articulatory costal Manual therapy|The therapist performs costal-vertebral articulatory movement, from 1st to 12th rib (level of the outside paravertebral muscles, at a distance of 4 fingers from the spinous apophysis on the back of the costal body) applying a sustained pressure during expiratory time and promoting its biomechanics, up to the articulatory barrier.
223825008|NCT04535622|BEHAVIORAL|A structured exercise|Exercise training will be conducted by a physical therapist which will take about 10 to 15 minutes. Patient education will include how to keep face down in various postures, and how to actively exercise the related muscles and joints while maintaining face-down posture through video clip and brochure. Patients will go through three times of self-exercise sessions everyday according to the training provided to the patients. Active exercise for the FDP patients will include exercise in a hands and knees position, limb exercise in an FDP, and exercise in a standing position. The exercises were performed within the range of individual muscle strength and fitness.
223825009|NCT03848598|DIAGNOSTIC_TEST|Evaluation of local tendon deformation|Ultrasound-based speckle tracking to evaluate the local tendon tissue displacement during isometric exercise.
223825010|NCT03810222|OTHER|N/A (Observational Study)|This is an observational study and does not include interventions. Exposure is TBI.
223825011|NCT02743923|DRUG|carboplatin|AUC 6
223825012|NCT02743923|DRUG|paclitaxel|200mg/m2
223825013|NCT02743923|DRUG|Bevacizumab|15 mg/kg
223825014|NCT02743923|DRUG|Pemetrexed|500 mg/m2
223825015|NCT02743923|DRUG|cisplatin|75 mg/m2
223825016|NCT04402437|PROCEDURE|LP Block|Subjects randomized to the lumbar plexus block group will receive a subcutaneous lidocaine skin wheal 3-4 cm lateral to midline on the operative side along the intercristal line. A nerve stimulator will be sent to 1-1.5mA and a stimulating needle inserted perpendicular to the skin. The needle will be advanced slowly until the quadriceps muscle is stimulated and maintained at less than 0.6mAs. Ropivacaine (20ml, 0.5%) will be injected slowly with frequent aspiration to rule out inadvertent intravascular needle placement.
223825017|NCT04402437|PROCEDURE|QL Block|Subjects randomized to the quadratus plexus block group will receive a subcutaneous lidocaine skin wheal that will be placed after ultrasound identification of external oblique, internal oblique, transverse abdominus and quadratus lumborum muscles. A needle will then be advanced under ultrasound guidance below the internal oblique aponeurosis and lateral to the quadratus lumborum muscle. Ropivacaine (20ml, 0.5%) will be injected slowly with frequent aspiration to rule out inadvertent intravascular needle placement. Local anesthetic injection will also be observed with real time ultrasound guidance.
223825018|NCT03323580|OTHER|GDFT|Target parameter will be titrated with fluid bolus, and thus individual amount varied depending on the parameter value at that time. Maintenance of oxygenation, hemoglobin, blood glucose, core temperature and hemodynamics, such as mean arterial pressure and heart rate, will be applied according to the same standard for each patient.
223825019|NCT03323580|OTHER|traditional fluid therapy|Fluid therapy will be done without goal directed. Maintenance of oxygenation, hemoglobin, blood glucose, core temperature and hemodynamics, such as mean arterial pressure and heart rate, will be applied according to the same standard for each patient.
223825020|NCT02402088|BEHAVIORAL|Stress Imagery|"The stress imagery script will be based on subjects' description of a recent personal stressful event that they had experienced as most stressful. Most stressful is determined by having the subjects rate the perceived stress experienced by them on a 10-point Likert scale where 1=not at all stressful and 10=the most stress they felt recently in their life. Only situations rated as 8 or above on this scale are accepted as appropriate for script development. Examples of acceptable stressful situations include breakup with significant other, a verbal argument with a significant other or family member or unemployment-related stress, such as being fired or laid off from work."
223825021|NCT02402088|BEHAVIORAL|Food Cue Imagery|A food cue script will be developed from the subjects' experience of eating their most favorite foods. Examples include ordering pizza, cooking a favorite meal, or going out to a restaurant.
223825022|NCT02402088|BEHAVIORAL|Neutral-Relaxing|A neutral-relaxing script will be developed from the subjects' commonly experienced neutral-relaxing situations, such as a trip to the beach or park.
223825023|NCT04152343|DEVICE|RFA Physics Library -- a Planning and Guidance Platform (PGP)|Research software used to support liver RFA of HCC lesions \>2cm
223825024|NCT05134402|DIAGNOSTIC_TEST|Sleepiz One Connect|Sleepiz One Connect measurements over 10 nights
223825025|NCT02514421|DEVICE|Electroporation|Irreversible electroporation (IRE) will be performed under computed tomography (CT) guidance, during which 2 to 6 needles are advanced into the pancreatic tumor where a specified field strength will be applied.
223825026|NCT02514421|DRUG|gemcitabine|The chemotherapy schedule will include administration of gemcitabine 1000mg/m2 IV infusion over approximately 30 minutes on days 1, 8, and 15 of each 28 day cycle.
223825027|NCT02514421|DRUG|nab-paclitaxel|The chemotherapy schedule will include administration of nab-paclitaxel 125mg/m2 intravenous (IV) over approximately 30 to 45 minutes on Days 1, 8, and 15.
223825028|NCT03322371|DEVICE|2-lead limited electroencephalography recording|The EEG recording device will be placed in conjunction with the standard formal polysomnography (PSG). The EEG device will remain in place as long as PSG leads are connected to the subject and PSG machine.
223825029|NCT03519243|BIOLOGICAL|BCD-131|subcutaneously monthly
223825030|NCT03519243|BIOLOGICAL|Mircera|subcutaneously monthly
223825031|NCT03646630|PROCEDURE|Quadratus Lumborum Block|Posterior or QL block type 2 , a bolus of 0.5 ml/Kg bupivacaine 0.25%
223825032|NCT03646630|PROCEDURE|Caudal Block|caudal block with 1 ml/kg of bupivacaine 0.25%.
223825033|NCT01370681|DRUG|Period I : HKB0701 and SLM0807, Period II : CJ30001|
223825034|NCT01370681|DRUG|Period I : CJ30001, Period II : HKB0701 and SLM0807|
223825035|NCT01279733|GENETIC|Microarray analysis|"Microarray performed on prenatal specimen:~Fluorescence in-situ hybridization (FISH) or other standardized tests such as qPCR or MLPA will be performed on the fetal sample to confirm abnormal MA findings of known and unknown clinical significance which are discordant with CC findings, including anomalies normally detected by karyotyping.~Microarray analysis of DNA from parental blood samples will be used to determine whether CNVs detected in a fetal sample are also present in a healthy parent, in which case no further evaluation will take place, moreover any finding in a fetus which is duplicated in a parental microarray is considered to be confirmed."
223825036|NCT01965938|DEVICE|RIFL (Rigid and Flexing Laryngoscope)|Patients in the RIFL group will undergo bronchoscopy using the Rigid and Flexing Laryngoscope. Once the carina is visualized with the bronchoscope, the endotracheal tube will be advanced, and the bronchoscope removed.
223825037|NCT01965938|DEVICE|Fiberoptic Bronchoscope|Patients in the control group will undergo bronchoscopy using the flexible fiberoptic bronchoscope. Once the carina is visualized with the bronchoscope, the endotracheal tube will be advanced, and the bronchoscope removed.
223825038|NCT03585101|DRUG|Elbasvir/grazoprevir|Daily fixed-dose combination (FDC) elbasvir (EBR) (50 mg)/grazoprevir (GZR) (100 mg) for 12 weeks
223825039|NCT04946929|DRUG|Ticagrelor Oral Tablet [Brilinta]|Ticagrelor, 2-3mg/kg, 12h, p.o.
223825040|NCT04946929|DRUG|Low molecular weight heparin|half amount low molecular weight heparin
223825041|NCT02090634|BEHAVIORAL|Psychoeducation|Participants will also receive daily text messages to evaluate mood, but these messages will not remind participants about medication adherence.
223825042|NCT02090634|BEHAVIORAL|individualized Texting for Adherence Building (iTAB)|Intervention is designed to send automated text messages to HIV+ persons who have bipolar disorder (BD+). Text messages are personalized, automated, real-time text messages. The iTAB intervention is designed to improve adherence to ART and psychotropic medications among HIV+/BD+ persons above and beyond an active comparator group.
223825043|NCT01164228|DRUG|Gemcitabine|Given IV
223825044|NCT01164228|DRUG|Sunitinib|Given PO
223825045|NCT01465828|DRUG|Clopidogrel|Patient will be randomized to this intervention will receive in the first time the high clopidogrel dose and after 14 days we will change their therapy with standard dose of prasugrel (crossover).
223825046|NCT01465828|DRUG|prasugrel|Patient will be randomized to this intervention will receive in the first time the standard dose of prasugrel and after 14 days we will change their therapy with high dose of clopidogrel (crossover).
223825047|NCT05995301|DRUG|Ropivacaine in Transversus abdominis plane|This group received 20ml of Ropivacaine 0.2% Injectable Solution in bilateral transversus abdominis plane at the end of surgery
223825048|NCT05995301|DRUG|Ropivacaine in Local infiltration at port site|This group received local infiltration of 20ml of Ropivacaine 0.2% Injectable Solutionat port sites at the end of surgery
223825049|NCT03036059|DRUG|400 μg/kg Ivermectin + 400 mg Albendazole|400ug/Kg, tablet, given orally once or twice a year.
223825050|NCT01534884|BIOLOGICAL|rituximab|1000 mg by intravenous (IV) infusion. Each patient may receive 2 courses of treatment.
223825051|NCT05354063|BIOLOGICAL|20 μg dose of SYS6006|20 μg dose of SYS6006 vaccine IM on day 0 and day 21.
223825052|NCT05354063|BIOLOGICAL|30 μg dose of SYS6006|30 μg dose of SYS6006 vaccine IM on day 0 and day 21.
223825053|NCT05354063|DRUG|Placebo|Placebo IM on day 0 and day 21.
223825054|NCT01164462|BIOLOGICAL|blood test: rapid finger-stick blood specimen test|
223825055|NCT01164462|BIOLOGICAL|blood test: conventional test|
223825056|NCT02955121|OTHER|Prescriber Access to Genetic Information|
223825057|NCT02390739|DRUG|Aldesleukin|Aldeskeukin 720,000 IU/kg IV over 15 minutes approximately every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 3 days (maximum of 9 doses).
223825058|NCT02390739|DRUG|Fludarabine|Day -7 to -3:Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days.
223825059|NCT02390739|DRUG|Cyclophosphamide|Days -7 and -6:Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W over 1 hour.
223825060|NCT02390739|BIOLOGICAL|Anti-Thyroglobulin mTCR PBL|On day 0, one to four days after last dose of fludarabine, cells will be infused intravenously (IV) over 20 to 30 minutes.
223825061|NCT00005837|DRUG|oxaliplatin|
223825062|NCT05643820|DRUG|Permethrin 5% topical lotion|patients in group A prescribed with 5% topical permethrin lotion two overnight applications seven days apart
223825063|NCT05643820|DRUG|Ivermectin|patients in group B and weighing more than 15 kgs were given oral ivermectin 200 microgram/kg two doses seven days apart
223825064|NCT06056622|OTHER|Combined Exercises|"The treatment involving multisensory stimulation through active movement was structured into two distinct segments. The initial segment encompassed exercises executed on a wobble board, comprising tasks such as squats, passing a ball between hands and to another individual, maintaining a single-leg stance, and gently destabilizing each other's balance. The subsequent segment involved exercises performed on a soft mat, including activities such as jumping from a small box and landing with both knees flexed, passing the ball to a team member during a two-leg jump, executing a two-leg jump while rotating the trunk by 90 degrees, and leaping from a small box onto a soft mat while balancing on one leg. Each of these exercises was repeated ten times within each session.~Balance-related exercises were conducted with participants assuming a shoulder-width stance on both firm and soft surfaces."
223825065|NCT06056622|OTHER|Placebo Exercise|Participants allocated to the control group will receive placebo treatment sessions, which entailed a 10-minute exposure to a visual evoked potential (VEP) measurement screen while holding a mouse. During this time, participants were given instructions to click the mouse whenever the screen exhibited a change in color. These activities were carried out while seated in a chair equipped with arm support
223825066|NCT03804775|DIAGNOSTIC_TEST|Serum lipid profile|Blood samples drawn from the patients and controls will be analyzed for serum cholesterol, serum triglycerides, serum LDLs and serum HDL levels. All the results will be recorded on a performa
223825067|NCT00650143|DRUG|Lenograstim (GRANOCYTE)=GCSF|10 µg/kg/d s.c. for 5 days divided in two dosages per day
223825068|NCT00650143|DRUG|Sitagliptin (Januvia)|100 mg p.o. per day for 28 days
223825069|NCT00650143|DRUG|Sodium Chloride (NaCl) 0.9 %|applied s.c. twice a day for 5 days
223825070|NCT00650143|DRUG|Gelatin|One capsule p.o. per day for 28 days
223825071|NCT01606696|BEHAVIORAL|HIIT|Higher intensity interval training.
223825072|NCT01606696|BEHAVIORAL|Standard intensity non-interval training|Standard intensity non-interval training.
223825073|NCT00167830|BEHAVIORAL|Motivational Interviewing|Biweekly meetings with a behavior specialist to review subject's progress with the protocol and explore challenges subject is facing in adopting healthy lifestyle behaviors.
223825074|NCT00167830|BEHAVIORAL|Strength and Cardiovascular Conditioning|Subjects take part in an exercise program to include 30 minutes of cardiorespiratory exercise at 70% maximum heart rate, and 30 minutes of strength training on Nautilus machines.
223825075|NCT00167830|BEHAVIORAL|Food selection and portion control|Subjects meet on a biweekly basis with a registered dietitian who presents educational information about healthy food selection and portion control.
223825076|NCT05893199|DEVICE|Clinical monitoring using the Ti.Care app (https://ti.care/es)|Clinical monitoring using the Ti.Care app (https://ti.care/es)
223825077|NCT05893199|OTHER|Usual care|usual follow-up in primary care both arms
223825078|NCT02440802|GENETIC|Saliva sample collection for genetic analyses|Patients with Prostate cancer receiving androgen deprivation treatment with a GnRH antagonist will be followed-up for 6 months for quality of life. At Baseline, 3 months and 6 months of treatment QoL data will be collected, as well as body parameters. At Baseline, once, a saliva sample will be collected for genetic analyses.
223825079|NCT01457235|OTHER|Cognitive Remediation|All subjects will complete an MR brain scan, blood test, saliva test, and a neuropsychological battery of manual and computerised tests at baseline, at week 12 (end of active treatment) and week 26 (follow-up). Subjects randomly allocated to an active group will participate in a 12-week group-based cognitive remediation programme once a week for two hours. The waiting list group continues treatment as usual.
223825080|NCT05710705|DEVICE|portable prototype of bioimpedance measurement|"The device will be installed during the patient's operation. It will be attached to the healthy skin of the flap (without wound or scar) by sterile glue. It will then be covered with a self-adhesive tegaderm type dressing. The wound will be isolated from the device with a hermetic silicone dressing of the Mepilex type, for example. There will therefore be no communication between the measuring device and the surgical wound."
223825081|NCT00838799|DRUG|RGH-896|45 mg TID, capsules, 14 weeks.
223825082|NCT00838799|DRUG|RGH-896|30 mg TID, capsules, 14 weeks.
223825083|NCT00838799|DRUG|RGH-896|15 mg TID, capsules, 14 weeks.
223825084|NCT00838799|DRUG|pregabalin|100 mg, TID, capsules, 14 weeks.
223825085|NCT00838799|DRUG|placebo|TID, capsules, 14 weeks.
223825086|NCT00347516|PROCEDURE|IOL calculation formula|
223825087|NCT01257659|PROCEDURE|STARR rectocele repair|The STARR transanal stapling system is used to repair a rectocele.
223825088|NCT01257659|PROCEDURE|Elevate mesh rectocele repair|A posterior Elevate mesh is placed transvaginally to repair a rectocele.
223825089|NCT05023135|DEVICE|DeepView SnapShot Portable (DV-SSP)|DV-SSP assistive imaging to collect observational data
223825090|NCT02390856|DEVICE|Conventus DRS|The Conventus DRS (TM) is an intramedullary device intended to treat distal radius fractures. The device remains flexible during placement, but is made rigid at the completion of the surgical implant procedure. The implant is made from titanium alloy (Ti-6A1-4V) and Nitinol.
223825091|NCT02390856|DEVICE|Volar Plate|A volar plate is a metallic plate fastened directly to the fractured bone with screws, to hold the fracture fragments in proper position. Volar plate fixation is the traditional surgical method for distal radius fractures.
223825092|NCT03846414|DRUG|PEG-rhG-CSF|PEG-rhG-CSF was administered 24 hours after the end of chemotherapy for each chemotherapy cycle.
223825093|NCT00370721|DRUG|bevacizumab|
223825094|NCT04803578|OTHER|Conventional physiotherapy|The subjects will receive rehabilitation according to the guidelines on the management of subjects after knee or hip arthroplasty, recovery of joint Range of Motion, recovery of lower limb strength, education to the crutches management, and stairs climbing and descending
223825095|NCT02468635|OTHER|upper limb exercises|HEATING PHASE: diagonals for upper and lower limbs (5-10 minutes). AEROBIC PHASE: aerobic exercise on a treadmill or bicycle between 5 - 30 minutes and rest 1-2 minutes according to the Borg scale and patient tolerance (Borg scores for dyspnea 4-5); RESISTANCE STAGE: upper limb exercises with weight training equipment or dumbbells (the patient's adaptation) with 50% of maximum load reached the maximum repetition test. Series 2 minutes and rest interval between sets 1-2 minutes. RESPIRATORY TRAINING : Strengthening of the respiratory muscles 5-15 minutes with Threshold with load of 50% of the affected MIP (measure maximal inspiratory pressure) evaluation. RELAXATION: Stretching and muscle massage therapy group involved in the 5-10 minute workout.
223825096|NCT02468635|OTHER|without training for upper limb|HEATING PHASE: diagonals for upper and lower limbs (5-10 minutes). AEROBIC PHASE: aerobic exercise on a treadmill or bicycle between 5 - 30 minutes and rest 1-2 minutes according to the Borg scale and patient tolerance (Borg scores for dyspnea 4-5); RESPIRATORY TRAINING: Strengthening respiratory muscles 5-15 minutes with Threshold with load of 50% of MIP hit in the evaluation. RELAXATION: Stretching and muscle massage therapy group involved in the 5-10 minute workout.
223825097|NCT04152265|PROCEDURE|colonoscopy|colonoscopy
223825098|NCT04152265|OTHER|questionnaires|complete the two questionnaires (Food Frequency Questionnaire (FFQ) and the questionnaire of The World Health Organization Quality of Life (WHOQOL-BREF)
223825099|NCT04152265|OTHER|demographic data collections|completing the demographic questionnaire
223825100|NCT04152265|OTHER|anthropometric data collections|For the determination of anthropometric data will be used a professional body mass composition analyser (Seca,Hamburg, Germany)
223825101|NCT04152265|PROCEDURE|Collecte the biological samples|blood and faeces collections
223825102|NCT05886322|DIAGNOSTIC_TEST|patient reported outcome measures|MIAH, mHI, Manotiba IBD Index, p-HBI/SCCAI, IBD-control
223825103|NCT05886322|DIAGNOSTIC_TEST|fecal calprotectin|fecal calprotectin point-of-care test and laboratory test
223825104|NCT05886322|DIAGNOSTIC_TEST|colonoscopy|endoscopic activity scores (SES-CD, UCEIS, MES)
223825105|NCT03757234|DRUG|Omadacycline|po tablets
223825106|NCT03757234|DRUG|Levofloxacin|iv solution/po tablets
223825107|NCT03757234|DRUG|Omadacycline|iv solution
223825108|NCT05053243|DEVICE|Kardia 12L|The purpose of this study is to collect clinical validation data to support an FDA submission for a 510(k) for the Kardia 12L hardware which enables the simultaneous diagnostic quality recording of all 6 limb leads and any chest lead. We will be recording both Leads V2 and V4 in a sequential fashion along with the Limb leads and a simultaneous 12-lead ECG to validate the hardware and a Deep Neural Network model which expands the 7 leads into a complete 12-lead ECG. The 12-lead ECG used for validation of the recordings and the 12-lead synthesis model is the GE Cardiosoft System which is FDA cleared.
223825109|NCT03604822|PROCEDURE|Music therapy|ALS-specific, individualized MT protocol was delivered to study participants in their homes twice weekly for the duration of six weeks by the researcher. Facilitating music structures were composed by the researcher to support cueing, timing and intensity of breathing and vocalization exercises. These structures were regularly modified to suit the unique capabilities, current individual demands and progress of each participant. One familiar song, selected by the participant, was used for each participant in therapeutic singing exercise closing each session. Individualized exercises sets for independent practice were provided at session 3 to each participants. ALS-specific voice health guidelines were provided for participants prior to start of the treatment.
223825110|NCT02568579|PROCEDURE|blood sample/ stool sample|blood sample to be done when possible with standard of care lab draw. Stool sample to be collected monthly at home.
223825111|NCT00671905|PROCEDURE|GP ablation|HF stimulation-guided and anatomic ablation of the main right and left atrial GP
223825112|NCT00671905|PROCEDURE|PV isolation|Circumferential PV isolation
223825113|NCT03331185|BIOLOGICAL|Freeze Dried Bone Allograft|Human derived bone particles used in oral and periodontal grafting procedures
223825114|NCT03331185|BIOLOGICAL|L-PRF clot|L-PRF is a second-generation platelet rich plasma obtained from autologous blood and contains several different growth factors, platelets and leucocytes in a complex fibrin matrix to accelerate the healing of soft and hard tissues.
223825115|NCT05412810|OTHER|oxygen|oxygen exposure of more than 50% for 1.5 hours
223825116|NCT01320423|PROCEDURE|Surgical Trial|Surgical Trial in Lobar Intracerebral Haemorrhage
223825117|NCT05494229|OTHER|Pars-plana vitrectomy|Pars-plana vitrectomy
223825118|NCT00308932|DRUG|HFA FP MDI|
223825119|NCT04890795|DRUG|AL8326 tablets|10mg/tablet;Oral administration, once daily.
223825120|NCT01632943|DEVICE|Symplicity renal denervation system|"Previous research has shown that disrupting the nerves of the kidney may successfully decrease blood pressure.~A less invasive approach to disrupting these nerves is to apply a brief high temperature near the nerves (renal denervation). This can now be done with an experimental medical device called the Symplicity renal denervation system. The System includes a catheter that is inserted into your blood vessels and an RF-generator."
223825121|NCT00886639|OTHER|6MWT with oxygen|2 liter per minute as continuous-flow
223825122|NCT00886639|OTHER|6MWT with medical air|2 liters as continuous-flow
223825123|NCT05694403|OTHER|Survey|Questionnaire
223825124|NCT01871558|DRUG|Vildagliptin|50 mg b.i.d
223825125|NCT01871558|DRUG|Metformin|metformin is to be kept unchanged
223825126|NCT01871558|DRUG|sulfonylurea (SU)|
223825127|NCT01871558|DRUG|Basal Insulin|
223825128|NCT02837562|OTHER|Slit lamp eye examination|All participants in the trial will undergo a slit lamp eye examination
223825129|NCT02974816|DEVICE|Glooko's mobile application|Standard of care and Remote monitoring
223825130|NCT01338922|DEVICE|Continuous subcutaneous insulin infusion therapy|Insulin is given continuously using an insulin pump. Devices are allowed having marketing approval. Insulins are permitted with marketing approval.
223825131|NCT01338922|DEVICE|Multiple daily injection therapy|Multiple daily injection therapy with different devices and insulin types. Devices and insulin types have to have marketing approval.
223825132|NCT03203694|BEHAVIORAL|Walking: Intervention arm in diabetics|The walking program will consist of 45 minutes of walking (at a moderate pace) 5 days per week for 8 weeks.
223825133|NCT03203694|OTHER|Walking: No intervention in diabetics|Subjects will be instructed to continue their usual lifestyle for 8 weeks.
223825134|NCT03203694|OTHER|Walking: Healthy cohort as reference controls|Subjects will be studied at one time only.
223825135|NCT03203694|BEHAVIORAL|Lower body heating: Intervention arm in healthy subjects|This intervention consists of 60 minutes of lower body heating (40-42 degree C).
223825136|NCT03203694|BEHAVIORAL|Lower body heating: Intervention arm in diabetics|This intervention consists of 60 minutes of lower body heating (40-42 degree C) 7 days per week for 7 days.
223825137|NCT03203694|OTHER|Lower body heating: Healthy cohort as reference controls|Subjects will be studied at one time only.
223825138|NCT06040034|DRUG|Lidocaine IV|Lidocaine given as bolus or continuous infusion.
223825139|NCT05999708|DRUG|GSK4381406|GSK4381406 will be administered.
223825140|NCT05999708|DRUG|Placebo|Placebo will be administered.
223825141|NCT05999708|DRUG|Indomethacin|Indomethacin will be administered.
223825142|NCT02040558|DRUG|MNK-010|
223825143|NCT00984360|DRUG|Naltrexone|380mg extended-release, given once by intramuscular gluteal injection
223825144|NCT05854030|DIAGNOSTIC_TEST|collect plasma samples and clinical features|8ml of peripheral blood need to be collected from pre- and post-treatment advanced pulmonary squamous carcinoma separately
223825145|NCT04195529|GENETIC|presence of genetic variants|identification of the presence of genetic variants
223825146|NCT02139423|OTHER|CMV PCR|
223825147|NCT05932056|BEHAVIORAL|Miles de Manos (Thousands of Hands)|Miles de Manos (Thousands of Hands) is a school-based group intervention that incorporates elements of evidence-based behavior management interventions in parent, teacher, and parent-teacher joint sessions.
223825148|NCT00977769|DRUG|carbetocin 100 µg|Hemodynamic effect of
223825149|NCT00977769|DRUG|oxytocin 5 u|Hemodynamic effect of
223825150|NCT00977769|DRUG|placebo (NaCl)|Hemodynamic effect of
223825151|NCT02578914|DRUG|NS2 Ophthalmic Drops (0.5%)|
223825152|NCT02578914|DRUG|NS2 Ophthalmic Drops Vehicle (0.0%)|
223825153|NCT03454425|DEVICE|Exablate Subthalamotomy|ExAblate Subthalomotomy for the Treatment of Parkinson's Disease Motor Features
223825154|NCT03454425|DEVICE|Sham Exablate Subthalamotomy|Sham ExAblate Subthalomotomy for the Treatment of Parkinson's Disease Motor Features
223825155|NCT01103960|DRUG|Telmisartan80mg+Amlodipine5mg|combination therapy
223825156|NCT01103960|DRUG|amlodipine 5mg|monotherapy
223825157|NCT01103960|DRUG|Telmisartan80mg+Amlodipine 5mg|combination therapy
223825158|NCT01215214|DRUG|midazolam|midazolam: 3mg iv
223825159|NCT02377960|BEHAVIORAL|IMB model-based initiation of antihypertensive medication|1.An IMB model-based initiation of medication i.e. a nine-point check list to be fulfilled by physician and patient together when ordering the antihypertensive medication for the first time
223825160|NCT02377960|BEHAVIORAL|Tailored SMS-text message support|2.Tailored SMS-text message support for the first 12 months of medication. At the beginning (2 weeks), text messages are send on daily basis and focused on medications-reminders and coping with potential side-effects of medication. After that, text messages will be sent less often and the focus will change to keeping up with medication and reminding of importance of performing adequate home BP self-monitoring, achieving the BP target and attending clinical appointments.
223825161|NCT02377960|BEHAVIORAL|Usual care|Usual care
223825162|NCT03396432|DEVICE|Video Laryngoscopy for ET placement|Tracheal intubation performed with the Storz C-Mac Video Laryngoscope
223825163|NCT03396432|DEVICE|Direct Laryngoscopy for ET Placement|Tracheal Intubation performed with the Miller Blade
223825164|NCT03034499|PROCEDURE|Single-port sacrocolpopexy|Single-port sacrocolpopexy surgery for the repair of vaginal apex prolapse.
223825165|NCT03034499|PROCEDURE|Multi-port sacrocolpopexy|Multi-port sacrocolpopexy surgery for the repair of vaginal apex prolapse.
223825166|NCT03716674|DEVICE|Metronome|Patients completed 4 walking sessions of at least 10 minutes each. During each session, no auditory rhythm was given, or the rhythm of a Rhythmic Auditory Stimulation (RAS) adapted to the pace of comfort of each patient using a metronome was broadcasted via headphones. In all, 4 conditions were tested: walk with no RAS or an isochronous RAS or a random RAS or a RAS with an autocorrelated metronome rhythm.
223825167|NCT04570241|BEHAVIORAL|Malaria toolkit|Knowledge, attitude, and practice on malaria
223825168|NCT06550349|OTHER|N/A - non-interventional study|N/A - non-interventional study. Data collection only.
223825169|NCT02617225|BEHAVIORAL|DHaAL Intervention|"This group handwashing program is for rural elementary schools to institutionalize the practice of handwashing before mid-day meal consumption and after use of toilets by harnessing the theory of social peer pressure.~DHaAL intervention consists of: (1) capacity building of school teachers to implement group handwashing; (2) installing group handwashing station; (3) generating demand among students to wash hands in group; and (4) establishing systems to sustain handwashing infrastructure and behaviors."
223825170|NCT02617225|BEHAVIORAL|DHaAL + CFSS Intervention|In addition to support under DHaAL, several intervention schools receive a more holistic and participatory support that focuses on health, safety, nutrition status, and psychological wellbeing of the children, and thus can also influence handwashing practices (and other WASH facilities). CFSS provides capacity building support and establishes systems to improve school environment, learning outcome, teachers capacity, and physical education for children.
223825171|NCT02961114|PROCEDURE|Microcannula Harvest Adipose|Use of closed syringe microcannula harvest of autologous AD-tSVF from subdermal adipose deposits to create a AD-cSVF
223825172|NCT02961114|DEVICE|Centricyte 1000|Use of Centricyte 1000 closed system digestion, incubation/agitation, and centrifugation to acquire a concentrated pellet of AD-cSVF
223825173|NCT02961114|BIOLOGICAL|IV Sterile Normal Saline|Sterile Normal Saline deployment of AD-cSVF in suspension of 500cc in IV pathway
223825174|NCT01661556|DRUG|Miconazole|Miconazole 2% cream will be applied twice a day for 9 weeks. The affected surface will be washed and dried before application with a thin layer of the emulsion as indicated on the affected areas of the face.
223825175|NCT01661556|DRUG|Hydroquinone|Hydroquinone 4% cream (Topical use), will be applied twice a day for 9 weeks. The affected surface will be washed and dried before application with a thin layer of the emulsion on affected areas of the face.
223825176|NCT02708433|DRUG|Lidocaine|Lidocaine
223825177|NCT00799643|DRUG|Salsalate|Salsalate 3.5 g/d orally, divided dosing
223825178|NCT00799643|DRUG|Salsalate Placebo|
223825179|NCT01747590|DRUG|Zolpidem|
223825180|NCT01747590|DRUG|Alprazolam|
223825181|NCT01747590|DRUG|Caffeine|
223825182|NCT01747590|OTHER|Placebo|
223825183|NCT04287868|BIOLOGICAL|PDS0101|PDS0101 will be administered on Day (D)1, D15, D29 followed by booster vaccines every 4 weeks for up to a year. Subcutaneous 1.0mL (2.4mg of total peptide and 3 mg of R-DOTAP) injection.
223825184|NCT04287868|BIOLOGICAL|M7824|M7824 will be administered at a flat dose of 1,200 mg intravenous (IV) (over 1 hour) once every 2 weeks.
223825185|NCT04287868|BIOLOGICAL|NHS-IL12|NHS-IL12 will be administered at as dose of potentially de-escalating doses by subcutaneous (SC) injection every 4 weeks.
223825186|NCT06713460|BEHAVIORAL|BEAM|Multicomponent intervention
223825187|NCT06882447|DRUG|Trial drug: QL1706, HPV 9-valent vaccine|QL1706: Dose: 5 mg/kg ; intravenous infusion (ivgtt), administered on day 1 of each cycle and once every 3 weeks (21 days).
223825188|NCT01315730|DEVICE|Tactile Stimulation|See Arms
223825189|NCT06796699|DRUG|GH56 Capsule|GH56 capsule for oral administration at specified doses on scheduled days.
223825190|NCT06899373|DEVICE|Continuous glucometer|The continuous glucometer is a wearable device that measures interstitial glucose levels 24 hours per day and transmits readings every one minute.
223825191|NCT06899880|OTHER|Describe the perfusion parameters during a deresuscitation strategy and their association with the outcome.|Arterial lactate, pCO2 gap, SvO2, capillary refill time and mottling score anomalies will be described during the first 5 days of the deresuscitation strategy.
223825192|NCT06900309|OTHER|Specific exercise program|An 8-weeks specific exercise program based on lower limb plyomteric exercises
223825193|NCT06900309|OTHER|General exercise program|An 8-weeks of general exercise program focused on whole-body exercises
223825194|NCT01828307|BEHAVIORAL|Motivational enhancement therapy (MET)|MET is a client-centered, directive method of enhancing intrinsic motivation for change by exploring and resolving ambivalence. In this intervention MET will focus on exercise.
223825195|NCT01828307|BEHAVIORAL|Contingency management|Contingency management is a behavioral treatment that utilizes extrinsic motivation by offering individuals tangible rewards such as prizes for completion of specific target behaviors. The target behavior in this study is exercise.
223825196|NCT01828307|BEHAVIORAL|Standard Aftercare Treatment|Aftercare includes the following topics: substance use, high-risk situations, coping and life skills training, focus groups for depression and anxiety, and AIDS education.
223825197|NCT03649269|DIETARY_SUPPLEMENT|PC-300 tea.|Patients had to drink one cup of the tea half an hour before breakfast, main meal and dinner.
223825198|NCT03649269|DRUG|Bezafibrate|Patients were prescribed 200 mg/day at night.
223825199|NCT02370290|OTHER|Medical Chart Review|Clinical and imaging information collected
223825200|NCT02370290|OTHER|Informational Intervention|Clinical and imaging data collected
223825201|NCT00747383|DRUG|Glimepiride|3mg oral tablet.
223825202|NCT00747383|DRUG|Sitagliptin|100mg oral tablet.
223825203|NCT00743990|OTHER|Ointment containing camphor, eucalyptus oil, and menthol|One time use
223825204|NCT00743990|OTHER|Petroleum jelly|One time use
223825205|NCT02709642|BEHAVIORAL|Deposit Contract|"A deposit contract (DC) is an agreement in which study participants puts their own money at risk, with the goal of earning it back by achieving a goal, in this case maintaining prior weight loss. If DC participants successfully maintain their weight, they get their money back. If they are not successful, they lose their money. For each 10 week period for one year, DC participants will make a deposit of at least $100 but will be allowed to increase their contribution if they would prefer."
223825206|NCT04361474|DRUG|Budesonide Nasal|Nasal irrigation with budesonide and physiological saline morning and evening, for 30 days, in addition to olfactory rehabilitation twice a day.
223825207|NCT04361474|OTHER|Physiological serum|Nasal irrigation with physiological saline morning and evening, for 30 days, in addition to olfactory re-education twice a day.
223825208|NCT04910087|DIAGNOSTIC_TEST|Sonographic optic nerve sheath diameter measurement|With the linear ultrasound probe operating at 11 MHz in B mode, it will be measured in 2 planes, 3.0 mm behind the optic disc, the transverse plane where the probe is placed horizontally and the sagittal plane where the probe is placed vertically. Then, the average of these measurements will be recorded for both eyes every 10 minutes.
223825209|NCT00451841|DEVICE|RTube Exhaled Breath Condensate Collection System|Subjects breath through the device to collect exhaled breath condensate
223825210|NCT06494319|BEHAVIORAL|Stress NAVIGATOR (Mobile Health Application)|Participants will be prompted to complete their assessments each week (or upon completion of each session) via the Stress NAVIGATOR mobile health app
223825211|NCT06494319|BEHAVIORAL|SIT NAVIGATOR|Participants will complete 11 self-paced virtual SIT sessions in the SIT-NAVIGATOR classroom. Participants will be asked to complete at least one session per week, in a minimum of 12 weeks and a maximum of 14 weeks.
223825212|NCT01167179|BEHAVIORAL|nurse-led consultation|Content of the intervention The intervention consists of structured and standardised nursing follow up consultations comprising a thorough needs assessment, supportive counseling, adequate referral to other care providers if necessary and improvement of the continuity of follow-up care. The goals of nursing follow-up care are summarised as helping patients (and often their partners too) to cope with the physical and psychosocial consequences of treatment and help them to gradually adjust to 'the life after', and into survivorship.
223825213|NCT04161599|DRUG|Cefuroxime (750mg) I.V|Extra dosage
223825214|NCT04161599|PROCEDURE|Colonic Surgery|Colonic Surgery
223825215|NCT04161599|DRUG|Cefuroxime 750mg oral|Oral prophylaxis
223825216|NCT04161599|DRUG|Metronidazole 250 MG Oral Tablet [Flagyl]|Oral prophylaxis
223825217|NCT04161599|DRUG|Metronidazole 1 g Intravenous|IV prophylaxis
223825218|NCT04161599|DRUG|Cefuroxime 1,5 g Intravenous|IV prophylaxis
223825219|NCT04161599|DRUG|Sodium picosulfate, light magnesium oxide, anhydrous citric acid 10 mg/3.5 g/10.97 g Oral|Laxative for bowel cleansing
223825220|NCT05456815|OTHER|Standardized diet|During 9 weeks all food products will be standardized and provided by the Research Unit. The standardized diet is based on the average food composition in the Netherlands.
223825221|NCT01352234|DRUG|Acetylsalicylic Acid 160 mg|Capsule containing Acetylsalicylic Acid 160mg pill with lactose
223825222|NCT01352234|DRUG|Acetylsalicylic Acid 80 mg|Capsule containing Acetylsalicylic Acid 80mg pill with lactose
223825223|NCT01976611|BIOLOGICAL|botulinum toxin Type A|Botulinum toxin Type A treatment for chronic migraine as per local standard of care in clinical practice.
223825224|NCT02781506|DRUG|Nivolumab|Nivolumab IV, administered per standard of care according to institutional guidelines at the discretion of the treating medical oncologist
223825225|NCT02781506|RADIATION|SAbR|SAbR (1-3 lesions)
223825226|NCT01158378|DEVICE|Adherus Dural Sealant|In situ polymerizing sealant
223825227|NCT06275932|OTHER|Interventional group|Newborns will be covered with a thermal blanket during skin-to-skin contact in delivery room.
223825228|NCT06275932|OTHER|Standard of care group|Newborns will be covered with a bed wetting mat and cotton sheet during skin-to-skin contact in delivery room.
223825229|NCT02597205|BEHAVIORAL|physician-facing app and patient-facing messages|A physician-facing app was designed to help physicians with recruiting and managing patients and with evidence-based medications prescription. Messages were also developed to send to patients to improve their medical adherence and modify lifestyle.
223825230|NCT03017235|DRUG|Sodium Picosulfate, Magnesium Oxide and Anhydrous Citric Acid Oral Solution|Supplied as two 160 mL ready-to-drink bottles, per subject, without further reconstitution, before administration.
223825231|NCT03017235|DRUG|Sodium Picosulfate, Magnesium Oxide and Anhydrous Citric Powder|Supplied as two sachets per subject. Subjects will be instructed to reconstitute the medication by combining the contents of one packet with approximately five (5) ounces of cold water and stirring for two to three minutes.
223825232|NCT02043730|DRUG|Nab-paclitaxel and Gemcitabine|Chemotherapy will consist of nab-paclitaxel 125 mg/mq over 30 min and gemcitabine 1000 mg/mq weekly on days 1, 8 and 15 of a 28-day cycle
223825233|NCT02043730|DRUG|Gemcitabine|gemcitabine 1000 mg/mq over 30 minutes on days 1, 8 and 15 of a 28-day cycle.
223825234|NCT02885519|BEHAVIORAL|IBBIS mental health care and standard vocational rehabilitation|"Standard vocational rehabilitation.~Stepped mental health care provided by the IBBIS mental health care team (e.g. nurses, psychologists and medical doctors) with the treatment modalities:~Psychoeducation Bibliotherapy Stress-coaching Mindfulness-based stress reduction Monitoring and re-assessment"
223825235|NCT02885519|BEHAVIORAL|Integrated mental health care and vocational rehabilitation|"Integrated mental health care and vocational rehabilitation provided by the IBBIS team. The IBBIS team is composed by employment specialists from the municipal job centers and health care professionals from the mental health services (e.g. nurses, psychologists, and medical doctors).~Mental health care is provided according to a stepped care model with the following treatment modalities:~Psychoeducation Bibliotherapy Stress-coaching Mindfulness-based stress reduction Monitoring and re-assessment~Vocational rehabilitation is inspired by Individual Placement and Support and is a workplace-oriented intervention with problem-solving conversations as a core element"
223825236|NCT03990077|DRUG|HL-085|HL-085 ( Capsule) is one MEK inhibitor.
223825237|NCT03990077|DRUG|Docetaxel|Docetaxel is an antineoplastic drug by inhibiting microtubule depolymerization, and attenuating of the effects of bcl-2 and bcl-xL gene expression.
223825238|NCT05189509|DRUG|TNK-Tissue Plasminogen Activator|0.25 mg TNK thrombolysis
223825239|NCT03335930|BEHAVIORAL|a 12-week moderate-intensity exercise training|a 12-week, aerobic, moderate-intensity exercise training
223825240|NCT02892942|DRUG|Gonal-F®|225 to 450 IU/d; from day 2 of menstrual cycle onward
223825241|NCT02892942|DRUG|Cetrotide®|0.25 mg/day, starting on day 6 of Gonal-F®.
223825242|NCT02892942|DRUG|Cetrotide®|1.5 mg/day (6 ampoules of 0.25 mg), starting on day 1 (S1) of Gonal-F® treatment until dhCG
223825243|NCT05683236|OTHER|Health education|Doctors carried out health education for patients to avoid patients giving up their lives, encouraged them to actively cooperate with medical staff, and instructed patients on how to face the disease with a brave and strong attitude and actively fight the disease. Nurses conducted daily psychological counselling for patients, learnt their inner thoughts through communication with patients, and provided timely comfort and encouragement. An attention-shifting method can be used to alleviate the patient's attention to the disease, effectively improving internal depression and avoiding depression. For patients with anxiety and loneliness, family members were instructed to accompany and care.
223825244|NCT05683236|OTHER|Comfort care|Reasonable control of indoor temperature and humidity is necessary to ensure that warm, light conditions permit properly dressed patients to feel warm. Nurses need to ensure that patients are kept clean and tidy in personal hygiene. They would regularly assist patients in turning over while giving patients sufficient respect.
223825245|NCT05683236|OTHER|Pain care|Clinicians should regularly evaluate the patient's physical pain and give reasonable analgesic drugs to patients. Nurses should closely observe the medication response of patients. At the same time, it is necessary to observe and record patients' physical pain daily and take effective pain control measures.
223825246|NCT05683236|OTHER|Dietary care|The clinical nutritionist formulated appropriate nutritional diets according to the nutritional status and personal preferences of patients, provided nutritional support for patients, and followed up with patients once a week after discharge to improve their nutritional status.
223825247|NCT05683236|OTHER|Psychological and social support care|"Two nurses with psychological counselling qualifications in the team used the anxiety and depression scale to evaluate the psychological and emotional status of patients and referred to The Questionnaire Survey on Awareness of Palliative Care by the Department of Elderly Section of the union medical college hospital. The content mainly included the patient's medical history and general situation, the needs and awareness of patients and their families for palliative care, the choice of patients and their families for the final treatment plan, and the needs of families for grief counselling. Timely professional counselling and intervention were undertaken to alleviate the patient's adverse emotions."
223825248|NCT05683236|OTHER|routine nursing intervention|The control group was given routine nursing intervention, strictly in accordance with a routine treatment process, monitoring the vital signs of patients, giving basic nursing, health education, diet guidance and so on.
223825249|NCT04602494|DRUG|Varenicline|varenicline: 0.5 mg once daily on days 1-3, 0.5 mg twice daily on days 4-7 and starting on day 8, 1 mg twice daily for a total of 12 weeks
223825250|NCT04602494|DRUG|Placebo|Identical placebo: 0.5 mg once daily on days 1-3, 0.5 mg twice daily on days 4-7 and starting on day 8, 1 mg twice daily for a total of 12 weeks
223825251|NCT03731130|OTHER|EORTC QLQ C30|standardized questionaire
223825252|NCT03731130|OTHER|EORTC QLQ CR29|standardized questionaire
223825253|NCT00062621|PROCEDURE|Combined bone marrow and kidney transplant|
223825254|NCT00338767|BEHAVIORAL|Directly Observed Therapy (DOT)|DOT includes storefront directly observed therapy of prescribed anti-depressants. Participants will meet with a study psychiatrist, who will prescribe an appropriate antidepressant medication. Subsequent meetings with the psychiatrist will occur weekly for the first 3 weeks, and then monthly for the duration of the study. Additionally, participants will have DOT visits every weekday morning for 1 month to take their antidepressant medications. After the first month, DOT visits will occur weekly or biweekly, depending on the medication regimen.
223825255|NCT00338767|DRUG|Fluoxetine|Medication treatment includes flouxetine for treatment of depression.
223825256|NCT03084419|DRUG|Abatacept|"The IV dose varies according to weight:~\<60kg=500mg~≥60 but≤100kg=750mg \>100kg=1g~This equates to approximately 10mg/kg."
223825257|NCT04675112|BEHAVIORAL|Cognitive Behavioral Treatment (CBT) and Tinnitus Retraining Therapy (TRT)|"CBT is a psychologically informed treatment. Depending on individual patient needs, relevant areas of tinnitus education and management/self-management strategies, such as managing the emotional consequences of tinnitus, rapid relaxation, managing fear and avoidance behaviors and changing unhelpful thoughts and beliefs, are applied in accordance to a published manual \[10\].~TRT is based on the neurophysiological model focusing more on education and sound therapy than on analytical cognitive and behavioral interventions. A TRT program is usually included in a management scheme with hearing aids."
223825258|NCT01919463|BEHAVIORAL|Abdominal Compression|Abdominal Compression is conducted by GI assistants during intubation process to facilitate the process. It can be conducted at different ares of the abdomen with different force.
223825259|NCT01919463|DEVICE|Guidance of Magnetic Endoscopic Imaging (MEI) System|Live image of MEI can show the form of the colonoscope inside the body. Live image is show to colonoscopist for facilitating the intubation process.
223825260|NCT03177889|COMBINATION_PRODUCT|Traditional Chinese Medicine (TCM)|"Traditional Chinese Medicine plus oral mucolytics \[ambroxol 30mg tid, or N-acetylcysteine 0.2g tid, serrapeptase 10mg tid, or carbocisteine 500mg tid\];~Agastache rugosus 5g, Scutellaria baicalensis 10g, Radix Puerariae 10g, Acorus tatarinowii schott 10g, Fructus Liquidambaris 5g, gypsum 15 g, Rheum officinale 5 g, Folium sennae 5 g, Codonopsis pilosula 10g, Radix Salviae Miltiorrhizae 10g, Lignum millettiae 10 g, Liquiritia glycyrrhiza 10 g~Optional formulae: bile arisaema 15g, polygala tenuifolia 15g, Mangnolia officinalis 10g, Fructus aurantii immaturus 10g; Magnetite 15-30g and reddle15-30g"
223825261|NCT00892190|DRUG|dasatinib (SPRYCEL)|DL0 - 50 mg every 24 hours DL1 (START)- 70 mg every 24 hours DL2 - 100 mg every 24 hours DL3 - 140 mg every 24 hours
223825262|NCT00892190|DRUG|all trans retinoic acid (VESANOID)|22.5mg/m2 every 12 hours
223825263|NCT03935464|BEHAVIORAL|PUMA|Collect urine on intervention participants and screen for presence of TFV. Feedback will be provided to the participant based on the results on their adherence with provision of standard adherence counseling.
223825264|NCT00650390|BIOLOGICAL|adalimumab|40 mg adalimumab every other week
223825265|NCT05046535|BEHAVIORAL|Sleep quality and physical activity|"Self-reported assessments will be used to measure the following: overall sleep quality, insomnia symptoms, Obstructive sleep apnea.~Physical activity will be measured objectively using the 6MWT, 9HPT, and cardiorespiratory fitness using the VO2 submaximal test on the recumbent stepper."
223825266|NCT05046535|GENETIC|Nicotine dependence|DNA sequencing for 20-25 subjects out of the whole sample will be performed. Sanger sequencing to all subjects will also be performed to identify related genes
223825267|NCT05046535|DIAGNOSTIC_TEST|Nicotine and cotinine serum levels|Cotinine serum level which is a major metabolite of nicotine and the preferred biomarker for measuring tobacco use will be measured together with nicotine levels using Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS).
223825268|NCT05046535|BEHAVIORAL|Smoking|Surveys that measure nicotine dependence and smoking behavior
223825269|NCT00563589|DRUG|mycophenolate mofetil, methotrexate, cyclosporin|
223825270|NCT00563589|DRUG|Methotrexate and cyclosporin|
223825271|NCT04373915|BEHAVIORAL|Remote Bedside Rounding|Parents of infants on the medical team utilizing remote rounding will have the opportunity to participate in rounds by video conferencing at the infant's bedside. Participation will be tracked and surveys regarding stress, satisfaction, and attachment will be completed by parents in both groups.
223825272|NCT01301768|OTHER|Group Education|Group educational workshops about dietary habits in the first trimester because it is when organogenesis occurs and therefore when the iodine deficiency in the mother is an important risk in the development of the fetal central nervous system.
223825273|NCT01040767|OTHER|Didactic training in basic ultrasound and the EFAST|Physicians in the classroom group (class) listened to traditional lectures, while the web group (web) watched narrated lectures online. All participants completed a pre- and post-test, and a second post-test eight weeks later. Both groups underwent hands-on training after the first post-test.
223825274|NCT01517243|DRUG|Sunitinib|Sunitinib 50mg by mouth daily for 4 weeks followed by a two week rest
223825275|NCT01517243|DRUG|Temsirolimus|Temsirolimus 25mg IV weekly for 4 weeks followed by a two week rest
223825276|NCT00983489|BEHAVIORAL|video demonstration|video will be shown to mothers
223825277|NCT00983489|BEHAVIORAL|counselling|breast feeding counselling
223825278|NCT03083392|PROCEDURE|treatment of chronic maxillary sinusitis using DIVA system|chronic maxillary sinusitis treatment utilizing DIVA system for antral lavage
223825279|NCT03083392|DEVICE|"dynamic implant valve approach - DIVA system"|The DIVA system will be used to apply saline lavage to the maxillary sinus
223825280|NCT01493661|OTHER|Chronic Sleep Restriction|All volunteers will undergo 25% of sleep restriction of their total sleep time at the beginning sleep for five consecutive days. The nights will be monitored by polysomnography.
223825281|NCT01728038|BEHAVIORAL|Cessation Counseling|Parental Smokers will be given brief cessation counseling, nicotine replacement therapy and Quitline connection.
223825282|NCT02105636|DRUG|Nivolumab|
223825283|NCT02105636|DRUG|Cetuximab|
223825284|NCT02105636|DRUG|Methotrexate|
223825285|NCT02105636|DRUG|Docetaxel|
223825286|NCT03413410|DRUG|Metoprolol|Patients with acute coronary syndrome take metoprolol during hospital and after discharge in the optimal dosing pathway.
223825287|NCT05764226|DRUG|HA35(L20200708MP07707, Ministry of Health, Mongolia)was freshly manufactured by mixing hyaluronidase PH20 injectable solution (H31022111) and high-molecular-weight HA injectable solution (H20174089)|One hundred milligrams of the freshly made 35 kDa low molecular weight HA fragment HA35 was injected into the tissue under the heath skin immediately surrounding the chronic wounds once a day for 10 days.
223825288|NCT05793710|BEHAVIORAL|The principle of laughter plus Qigong|"The intervention program include muscle stretching, breathing exercises, and closing exercises. The laughing practice method begins with a warm-up consisting of laughing to stretch the body, yawning, and exerting the voice, and ends with expelling all the qi in order to return to natural movements and return to taking care of your body and mind (He et al., 2021).~The LQP program meets once a week for 90 minutes and runs for 12 weeks. The program content: the laughter skills were 50-60 minutes, the feedback was 30 minutes, and relaxation was 10 minutes."
223825289|NCT02281175|BEHAVIORAL|Psychosocial intervention|Based on a cognitive-behavioral approach, the psychosocial intervention (PASSE-65+) is specifically designed to help older BZD users to better manage their withdrawal symptoms, to stop their medication, and to improve their general psychological well-being
223825290|NCT02281175|BEHAVIORAL|a weekly physician intervention|Informative document + 12 meetings (once a week; 30 minutes) with a physician who will supervise the gradual withdrawal
223825291|NCT03481790|DRUG|Lactoferrin|(Pravotin sachets, Hygint, Egypt): 100 mg in 1/4 glass of water before meals twice a day for 4 weeks.
223825292|NCT03481790|DRUG|ferrous sulphate + folic acid (vitamin B9)|(Ferrofol capsules, Eipico, Egypt): Dried ferrous sulphate 150 mg + Folic acid (Vitamin B9) 150 mg at least 1 hour before or 2 hours after meals three times a day for 4 weeks.
223825293|NCT05197257|DRUG|Ga-PSMA-11|The PSMA Sterile Cold Kit, is a kit comprising all needed materials (lyophilized PSMA for PSMA reconstitution, elution vial for Ga and ancillary materials for transfer between vials) to perform a room-temperature radiolabelling of PSMA-11 with Ga. Ga is not part of the kit and should be provided in the form gallium chloride solution following the requirements of the relevant local regulations. PSMA-11 radiolabelled with Ga is administered in patients with prostate cancer recurrence after radical treatment.
223825294|NCT03743896|DRUG|Transdermal Glucosamine Cream|
223825295|NCT02712671|RADIATION|Chest radiograph|A chest radiograph involves the participant standing in front of a film and a low dose of radiation passes through the chest. This will be used to look for evidence of tuberculosis infection.
223825296|NCT02712671|PROCEDURE|Blood interferon gamma release assay|Test of T-lymphocytes' response to exposure with tuberculosis antigens. This test is used for the diagnosis of latent tuberculosis infection and involves a blood sample in lithium heparin tube. It will be performed in an off site laboratory (Oxford Immunotec, Abingdon, Oxfordshire, United Kingdom).
223825297|NCT02712671|PROCEDURE|Tuberculin skin testing (TST)|An intradermal test for latent tuberculosis infection that involves a small injection of purified protein derivative (PPD) from inactivated Mycobacterium tuberculosis. The reaction is interpreted at 48-72 hours by measuring the induration produced.
223825298|NCT02712671|PROCEDURE|Sputum induction for mycobacterial microscopy and culture|Participants will breathe in a nebuliser salt solution (3.5% normal saline) for 15 minutes and asked to cough up a sputum sample. This is undertaken in a negative pressure tent. The sample will be tested for mycobacteria under the microscope and then cultured for 42 days in liquid culture bottles the microbiology laboratory.
223825299|NCT02712671|OTHER|Mycobacterium tuberculosis polymerase chain reaction testing|Sputum from sputum induction will be tested using the GeneXpert system using polymerase chain reaction to identify genes present in Mycobacterium tuberculosis. This test is performed in a microbiology laboratory and tests for the presence of Mycobacterium tuberculosis in sputum, plus genes associated with drug resistance.
223825300|NCT02712671|PROCEDURE|Spirometry|Participants will be asked to blow into a spirometer to measure how much air they can expel in one second and in a whole breath. This will be repeated six times (three times before inhaling 3.5% saline solution and three times five minutes after breathing 3.5% saline solution). The results will be used to identify those whose airways are sensitive to the solution and to look for the presence of airways disease (asthma or chronic obstructive pulmonary disease).
223825301|NCT00375141|DEVICE|Pulsed dye laser, Intense pulsed light|
223825302|NCT03164941|PROCEDURE|Selective Laser Trabeculoplasty|Laser treatment for glaucoma.
223825303|NCT02381743|BEHAVIORAL|Group 2 intervention daily SMS bullet point|Group 2 subjects receive a daily SMS bullet point, summarizing a key clinical point pertinent to the CBPA's daily work.
223825304|NCT02381743|BEHAVIORAL|Group 3 intervention daily SMS bullet point|Group 3 subjects receive a c phrased as a multiple choice question. The content mirrors that of group 2, but is presented as a question to render it interactive
223825305|NCT04071977|DRUG|Combined antioxidant therapy|It consists of a tablet with lutein (10 mg), astaxanthin (4 mg), Zeaxanthin (1 mg), vitamin C (L-ascorbic acid 180 mg), vitamin E (DL-alpha tocopherol 30 mg), zinc (zinc oxide 20 mg), copper (copper sulfate 1 mg), taken once a day for 12 months
223825306|NCT04071977|OTHER|Placebo|It consists in a capsule with 100 mg of magnesium oxide
223825307|NCT00505726|PROCEDURE|Reflectance Confocal Imaging|Microscopic images taken during routine colposcopy where disinfected probe inserted into vagina and placed against cervix, 1-3 regions imaged (2 abnormal and one normal), and each taking about 1-2 minutes.
223825308|NCT00235443|DRUG|lacosamide|Open-label treatment (two times per day) with film-coated tablets include 100mg/day, 200mg/day, 300mg/day, 400mg/day, 500mg/day, and 600mg/day throughout individual study period.
223825309|NCT05217836|DIAGNOSTIC_TEST|ferritin; iron; transferrin; transferrin saturation; hemoglobin in reticulocyte; hepcidin|All patients will have the following laboratory parameters determined: ferritin, iron, transferrin, transferrin saturation, hemoglobin in reticulocyte, hepcidin. Patients with hemoglobin in reticulocyte below reference range will receive parenteral iron.
223825310|NCT00376051|DRUG|Citalopram|Titrates from 10mg/day to 40mg/day, increases 10mg per week.
223825311|NCT00296842|BEHAVIORAL|Early psychological intervention|Psychoeducation, trauma narrative, provision of coping skills
223825312|NCT04719403|OTHER|HealthPAL|Participants who are randomly assigned to the HealthPAL arm will have immediate post- visit access to audio/video-recordings of their clinical visit through a HIPAA-compliant web-based program called HealthPAL.
223825313|NCT03431051|OTHER|Healthy Beverage Initiative|A Healthy Beverage Initiative will be instituted at two hospital campuses.
223825314|NCT03746743|DIAGNOSTIC_TEST|score for neonatal sepsis|score for neonatal sepsis to predict morbidity
223825315|NCT00023842|BIOLOGICAL|BCG vaccine|
223825316|NCT00023842|DRUG|mitomycin C|
223825317|NCT00023842|PROCEDURE|adjuvant therapy|
223825318|NCT00023842|PROCEDURE|conventional surgery|
223825319|NCT03488290|BEHAVIORAL|LTP Plus TF-CBT|Experimental: LTP Plus TF-CBT LTP Plus TF-CBT group participants will receive group intervention by masters' level trained facilitators weekly during the first two months and then fortnightly. It comprises of two components i.e. LTP and TF CBT. LTP aims at enabling parents to improve their child's psychosocial development by educating about child development and the importance of mother-child play. TF CBT aim is to modify excessively negative appraisals of the trauma and its sequelae by careful questioning
223825320|NCT03488290|OTHER|Treatment as Usual|The Treatment as Usual group will receive routine care
223825321|NCT02814474|OTHER|Na-3-hydroxybutyrate|Infusion of Na-3-hydroxybutyrate (0.18 g/kg/hour) for 390 minutes
223825322|NCT02814474|OTHER|Saline|Infusion of 0.9 % saline
223825323|NCT03313219|DRUG|Gentuximab Injection|Gentuximab Injection (Recombinant anti-VEGFR2 human-mouse chimeric monoclonal antibody injection)
223825324|NCT03029247|DRUG|Daprodustat|Daprodustat will be available as oral tablets at unit dose strength of 1, 2, 4, 6, 8 and 10 mg.
223825325|NCT03029247|DRUG|Epoetin alfa|Epoetin alfa will be administered according to local labelling and clinical practice guidelines to keep Hgb in the target range (10.0-11.0 g/dL)
223825326|NCT00206154|DRUG|Budesonide/formoterol pMDI|
223825327|NCT00206154|DRUG|Budesonide pMDI|
223825328|NCT00206154|DRUG|Formoterol Turbuhaler|
223825329|NCT01045122|DRUG|Propofol|For propofol, the current study will employ the Marsh parameters, with an initial effect site target concentration of 1.0 mcg/ml, a level likely to produce only mild sedation. Though our patient population is expected to be predominantly obese, a previous pharmacokinetic study has validated that constant infusions utilizing the dosing scheme of mcg-1•kg-1•min will yield similar effect site concentrations.25 The effect site target will be increased in increments approximately every five minutes until the pharmacodynamic targets defined in the study are attained.
223825330|NCT01045122|DRUG|Dexmedetomidine|For dexmedetomidine, an intravenous loading dose of 0.5 mcg/kg will be infused over 10 minutes and followed by an infusion starting at 0.5 mcg/kg/hr. This infusion will be titrated up to a maximum of 1.2 mcg/kg/hr.
223825331|NCT00807521|DRUG|Dexamethasone|Single high dose bolus of dexamethasone before surgery
223825332|NCT00807521|DRUG|Placebo|Placebo for dexamethasone
223825333|NCT01048645|DRUG|ATRA|Patients were assigned to receive ATRA 20 mg/m2/day (RA/PC) 1 week prior to treatment until completing two courses of chemotherapy based on paclitaxel and cisplatin
223825334|NCT01048645|OTHER|PLACEBO|Patients were randomized to receive or placebo (P/PC) 1 week prior to treatment until completing two courses of chemotherapy based on paclitaxel and cisplatin
223825335|NCT02606955|DEVICE|BIA DW|All patients undergo a Clinical DW assessment. Then, they undergo a HD session in which BIA DW (injection of 800 microAmpere at 50 kilohertz alternating sinusoidal current with a standard tetrapolar technique) is determined. BIA DW is determined by performing the REsistance Stabilization Test (REST).
223825336|NCT01976364|DRUG|Tofacitinib|Tofacitinib 5 mg tablet twice daily
223825337|NCT01976364|DRUG|Tofacitinib|Tofactinib 10 mg tablet twice daily
223825338|NCT01976364|DRUG|Methotrexate|Methotrexate 7.5-20 mg weekly
223825339|NCT01976364|DRUG|Placebo Methotrexate|Placebo to match active methotrexate orally once a week
223825340|NCT02250521|DEVICE|McGrath MAC enhanced direct laryngoscope|"The McGRATH® MAC enhanced direct laryngoscope (EDL) combines the familiarity of direct laryngoscopy with an inline video camera for an enhanced view.~All 100 patients will be intubated using the McGRATH® MAC video laryngoscope, either through direct or indirect vision laryngoscopy. The LCD monitor of the McGRATH™ MAC was initially covered; if the anesthesiologist visualized a modified C-L grade 1-3 view, the patient was intubated utilizing this direct view. If the anesthesiologist observed a modified C-L grade 4 view during their initial direct view, the patient was intubated using the indirect method. If intubation via direct laryngoscopy was unsuccessful on the first attempt, the patient was intubated using the indirect view. If both methods of laryngoscopy were unsuccessful, the rescue intubation technique was performed at the discretion of the anesthesiologist."
223825341|NCT05051332|DRUG|Autologous Chondrocyte Implantation (CartiLife®)|CartiLife consists of small beads (1 mm in diameter) in suspension, developed from pellet culture of autologous costal chondrocytes after multiplication. The beads are implanted in an injective manner with fibrin glue through minimal arthrotomy. The dose depends on the size (volume) of the defect, recommended dose is 480 pellets/cm\^3 defect
223825342|NCT05051332|PROCEDURE|Microfracture Surgery|Microfracture surgery, performed by arthroscopy after the joint is cleaned of calcified cartilage, will be conducted using an awl or drill to create tiny fractures in the subchondral bone plate
223825343|NCT01200537|DRUG|Estradiol|This group of patients will receive estradiol patches prior to the IVF cycle.
223825344|NCT01200537|DRUG|Oral Contraceptive Pills (OCP)|This group of patients will receive OCP's prior to the IVF cycle.
223825345|NCT01073839|DRUG|Cisplatin and Gemcitabine|Cisplatin 25 mg/m2 days 1 and 8; next cycle starting day 22. Gemcitabine 1000 mg/m2 days 1 and 8; next cycle starting day 22. Total of 8 cycles.
223825346|NCT02360839|DEVICE|EUS-guided fine needle biopsy sampling (EUS-FNB)|Dual sampling with EUS-FNA and EUS-FNB in a randomized order.
223825347|NCT04161417|OTHER|Patients with suspected or confirmed pancreatic cancer will be be asked to provide biopsy material for molecular profiling|Patients with suspected or confirmed pancreatic cancer will be be asked to provide biopsy material for molecular profiling. This will enable patient enrolment into a currently available PRIMUS study
223825348|NCT04134858|OTHER|The nurse-led health coaching program|The intervention was based on the customized nurse-led health-coaching program. The program consisted of an individual health-coaching nurse, health-coaching sessions and a written action plan according to each participant´s individual needs.
223825349|NCT01668433|DRUG|Regimens (Primaquine, Methylene blue)|Primaquine 45 mg single dose Or Methylene Blue 600 mg single dose followed by Methylene Blue 600 mg single dose or Primaquine 45 mg single dose.
223825350|NCT02318719|DRUG|Placebo|Placebo
223825351|NCT02318719|DRUG|DS-5565|
223825352|NCT01868035|DRUG|tositumomab and iodine I-131 tositumomab|"Subjects received the following treatments of TST/I-131 TST by intravenous (IV) infusion:~Dosimetric Dose: 450 mg of TST infused over 1 hour immediately followed by 35 mg of TST labeled with 5 milliCuries (mCi) of I 131 infused over 30 minutes.~Therapeutic Dose: 7 to 14 days after the dosimetric dose, 450 mg of TST infused over 60 minutes, immediately followed by 35 mg of TST labeled with the subject-specific mCi activity of I 131 needed to deliver a total body dose of 75 centiGrays (cGy), infused over 30 minutes for subjects with a platelet count of 150,000/mm3. Subjects with platelet counts of 100,000 to 149,999/mm3 received 65 cGy, and obese subjects were dosed based upon 137% of their calculated lean body mass."
223825353|NCT02492646|PROCEDURE|Saline group|After anesthetic induction, patients will be intubated with endotracheal tube which was immersed in normal saline before intubation.
223825354|NCT02492646|PROCEDURE|Dry group|After anesthetic induction, patients will be intubated with endotracheal tube which was not immersed in normal saline.
223825355|NCT02767635|DRUG|Botox-Epic|injected 20 units of Botox into lateral epicondyle in Botox-Epic group
223825356|NCT02767635|DRUG|Botox-Tend|injected 20 units of Botox into tender point of muscles in Botox-Tend group
223825357|NCT02767635|DRUG|triamcinolone acetonide (Steroid)|injected 40mg of triamcinolone acetonide into lateral epicondyle in Steroid group
223825358|NCT03656484|DRUG|Tetracycline-Metronidazole (TM) group|Following mechanical debridement (scaling and root planning) the above-mentioned paste will be topically administrated in the periodontal pocket of affected teeth once a day, for 30 consecutive days.
223825359|NCT03656484|DRUG|TM-Melatonin-Hyaluronic acid (TM-MHa) group|Following mechanical debridement (scaling and root planning) the above-mentioned paste will be topically administrated in the periodontal pocket of affected teeth once a day, for 30 consecutive days.
223825360|NCT00432835|DEVICE|Gastric Electrical Stimulator, Enterra, Medtronics, Inc.|All patients received a GES electrode, endoscopically placed and connected to an external device at baseline. The device was turned ON to provide 72 continuous hours of active stimulation and OFF to deactivate stimulation
223825361|NCT05707650|PROCEDURE|reverse breech extraction technique or push technique|using reverse breech extraction technique or push technique for disimpaction of fetal head during cs of a fully dilated cervix
223825362|NCT06037174|PROCEDURE|minimally invasive procedure|different minimally invasive approach to complete thyroidectomy, including endoscopy-assisted subclavian approach, robot-assisted transaxillary or transoral approach (not leaving scar on the neck)
223825363|NCT06037174|PROCEDURE|Conventional Open Surgery|Conventional Open Surgery
223825364|NCT04853862|OTHER|questionnaire|Questionnaire for health-related quality of life evaluation
223825365|NCT03959774|DEVICE|IPC NET|a digital pack with connected bracelet and connected balance will be given to the patient. IPC NET and Nokia Health applications will be downloaded. Pairing between connected objects and the smartphone will be done during the inclusion visit
223825366|NCT01704885|BEHAVIORAL|Play Intervention|
223825367|NCT01704885|OTHER|Questionnaires|
223825368|NCT04130711|OTHER|Visual virtual Conditions|"The objective is to evaluate if certain virtual visual conditions can increase the illusion of movement induced by the tendon vibration of the upper limb.~Thirty healthy volunteers and 20 post-stroke subjects will test 3 different situations of vibration applications, with no EEG Neurofeedback session. It will be applied to the subject (healthy and post-stroke) according to a randomized order a vibrator for a few minutes on his non-dominant (or deficit) hand hidden from view, with a screen representing a static virtual hand, then a vibrator on his hand hidden with a screen representing an animated virtual hand, then a vibrator on his hand hidden with a screen representing an empty background."
223825369|NCT04130711|OTHER|Standard EEG|Twenty healthy volunteers test 3 separate electroencephalographic recording conditions without Neurofeedback. It will be applied to the subject an EEG headset recording brain activity during the application of vibration stimulation producing the illusion of movement on the non-dominant hand or during a task Mental imagery of the upper limb, or during the joint application of vibratory stimulation and a mental imaging task on the affected upper limb in a randomized order.
223825370|NCT04130711|OTHER|Neurofeedback Training Stroke Patients|The post-stroke subject is evaluated on clinical tests (FMA, ARAT, MAL, NHPT, Finger Tapping test) during the first visit. Then, he performs 12 sessions of NFB (on his deficit member) lasting 45 minutes, spread over 6 weeks, depending on the feedback modality that has been drawn randomly (visual or visuo-vibratory). A second visit after the first NFB session and a third visit after the last NFB session evaluates the motor skills of the trained upper limb (FMA, ARAT, MAL, NHPT, Finger Tapping test) and a satisfaction questionnaire is given to the subject for evaluate tolerance and satisfaction with the feedback modality assigned. Evaluation of changes of EEG sensorimotor rhythms at the end of the program.
223825371|NCT02916082|PROCEDURE|Cervical length measurement|Vaginal ultrasound to measure cervical length previous to use of prostaglandins.
223825372|NCT00423293|DRUG|fluorouracil|1000 mg/m\^2/day 96-hour continous infusion (M-F) starting on day 1 and again on day 29 of radiation therapy.
223825373|NCT00423293|DRUG|mitomycin C|10 mg/m\^2 intravenous therapy on day 1 and day 29 of radiation therapy.
223825374|NCT00423293|RADIATION|Intensity-modulated radiation therapy|"Prescription dose depends on tumor staging.~T2N0: The primary tumor PTV (planning target volume) (PTVA) receives 50.4 Gy in 28 fractions (fx) at 1.8 Gy/fx. The nodal PTVs receive 42 Gy in 28 fx at 1.5 Gy/fx. PTVA receive 50.4 Gy in 28 fractions at 1.8 Gy/fx. PTV42 receive 42 Gy in 28 fx at 1.5 Gy/fx and will include all nodal regions.~T3N0 or T4N0: The primary tumor PTV (PTVA) will receive 54 Gy in 30 fx at 1.8 Gy/fx. The nodal PTVs will receive 45 Gy in 30 fx at 1.5 Gy/fx. PTVA will receive 54 Gy in 30 fx at 1.80 Gy/fx. PTV45 will receive 45 Gy in 30 fx electively at 1.5 Gy/fx and will include all nodal regions.~For N+ disease: The primary tumor PTV (PTVA) will receive 54 Gy in 30 fx at 1.8 Gy/fx. For involved nodes ≤ 3 cm in maximum dimension, the involved nodal PTV will receive 50.4 Gy in 30 fx at 1.68 Gy/fx. For involved nodes \> 3 cm in maximum dimension, the involved nodal PTV will receive 54 Gy in 30 fx at 1.80 Gy/fx."
223825375|NCT02486549|PROCEDURE|Supraclavicular Block|Under ultrasound guidance an insulated needle is advanced with in- plane technique into the brachial plexus sheath and 20ml 0.25% bupivacaine will be administered
223825376|NCT02486549|PROCEDURE|Interscalene Block|Under ultrasound guidance an insulated needle will be placed through the middle scalene muscle,into the interscalene groove with in-plane technique and 20ml 0.25%bupivacaine will be administered into the brachial plexus
223825377|NCT02486549|DRUG|Bupivacaine|20ml 0.25% bupivacaine will be injected for brachial plexus block
223825378|NCT02486549|DEVICE|Ultrasound|The Ultrasound will be used for brachial plexus visualization
223825379|NCT01862458|BIOLOGICAL|tPA alone|
223825380|NCT01862458|BIOLOGICAL|tPA plus dornase|
223825381|NCT01912222|DRUG|IXAZOMIB|
223825382|NCT02342925|OTHER|Omnipaque 300|647 mg/mL of iohexol, equivalent to 300 mg/mL of iodine, used for assessment of glomerular function and other measure of renal function
223825383|NCT02342925|DRUG|RG1662|Oral administration twice daily
223825384|NCT02342925|DRUG|metformin|Single 850 mg dose of metformin
223825385|NCT03902938|BIOLOGICAL|Biodesign Otologic graft|Patient's mastoid cavity will be covered with porcine small intestine submucosa, Biodesign.
223825386|NCT03902938|OTHER|Autograft temporalis fascia|Patient's mastoid cavity will be covered with covered with autograft.
223825387|NCT01727492|DRUG|Antioxidantia|
223825388|NCT03051490|DRUG|Liprotamase|oral, soluble, non-enterically coated, non-porcine, pancreatic enzyme replacement
223825389|NCT03051490|DRUG|porcine PERT|oral, enterically-coated, pig-derived, pancreatic enzyme replacement
223825390|NCT02328092|DEVICE|rSMS in treatment of Nocturnal Enuresis|Real rSMS (15 Hz at 50% of maximum stimulator output (10 seconds on and 30 seconds off) with a total of 1500 pulses and the hand of the coil upword. The stimulation was repeated for 10 sessions, 5 sessions per week and 2 days off. Sham rSMS received stimulation using the same coil, the same session frequency, in the same setting, but the coil was tilted 90.
223825391|NCT02421900|OTHER|radio-frequency catheter ablation of atrial fibrillation|radio-frequency catheter ablation of atrial fibrillation
223825392|NCT00701337|DRUG|oestradiol|oestradiol 2 mg oral route 30 days
223825393|NCT00701337|DRUG|oestradiol|oestradio transdermal patch 60ug by 24 hours 30 days
223825394|NCT01014221|OTHER|Acupuncture|acupuncture administered in 8 sessions over 4 weeks
223825395|NCT01014221|DRUG|Prednisolone|2 weeks of prednisolone 20 mg daily followed by 2 weeks of prednisolone 10 mg daily
223825396|NCT04923295|DRUG|Dapagliflozin 10Mg Tab|Effect of Dapagliflozin on ultrafiltration and PET results among peritoneal dialysis patients
223825397|NCT03693716|PROCEDURE|Dynamic Anterior Stabilization|All-arthroscopic trans subscapular Long Head of the Biceps tenodesis in the anterior-inferior glenoid with all-suture anchors
223825398|NCT03154359|DRUG|Atomoxetine Hydrochloride|Atomoxetine dose adjusted to achieve pre-defined concentration
223825399|NCT04208360|DEVICE|StethoMe stethoscope|Assessing whether use of the StethoMe AI lung sounds analysis software provides clinical benefit by improving the identification of abnormal lung sounds.
223825400|NCT03006627|DRUG|postoperative morphine|Postoperatively, A loading dose of morphine will be given in incremental doses of 1 mg 5 min apart, till the VAS score reached ≤3. The dose of morphine required to reduce the VAS score to ≤3 will be recorded. Subsequently, PCA pump will be configured to deliver a bolus of 1 mg with a lock-out period lasting for 20 min.
223825401|NCT02874664|DRUG|Rovalpituzumab Tesirine|Rovalpituzumab tesirine is a DLL3 targeted antibody drug conjugate (ADC)
223825402|NCT00885352|DRUG|Sitagliptin|Sitagliptin 100 mg tablet orally once daily for 26 weeks.
223825403|NCT00885352|DRUG|Comparator: Placebo|Placebo to sitagliptin 100 mg tablet orally once daily for 26 weeks.
223825404|NCT00885352|DRUG|Pioglitazone|Participants taking 30 mg or more pioglitazone oral tablet(s) daily at screening in combination with metformin will enter a 4-week dose-stable period followed by a 2-week single-blind run-in and a 26-week treatment period. Participants taking 4 mg or more rosiglitazone oral tablet(s) daily at screening in combination with metformin were to be switched to a corresponding dose of pioglitazone prior to starting a 4-week dose-stable period. Participants who are taking less than 30 mg/day or no pioglitazone at screening will be titrated to a stable dose of at least 30 mg pioglitazone once daily over a maximum of 4 weeks followed by a dose-stable period of 10 weeks, a 2-week single-blind placebo run-in, and a 26-week treatment period. Total treatment with pioglitazone will be up to 42 weeks.
223835564|NCT03487003|DRUG|rocuronium|After standard anesthetic monitoring (non-invasive blood pressure monitor, pulse oximetry, 3-lead echocardiography), patients are inhaled with sevoflurane. When the patients asleep, 0.3 mg/kg rocuronium is administered. After 2 min, flexible laryngeal mask airway (fLMA) is inserted using standard method. The fLMA is inflated with air to 40 cmH2O using manometry. The oropharyngeal leak pressure (OLP) was determined by the method described by Lopez-Gil and colleagues.
223825405|NCT00885352|DRUG|Metformin|Participants taking 1500 mg or more metformin oral tablet(s) and at least 30 mg pioglitazone or 4 mg rosiglitazone daily at screening will enter a 4-week dose-stable period followed by a 2-week single-blind placebo run-in, and a 26-week treatment period. Participants who are taking less than 1500 mg/day metformin at screening will be titrated to a stable dose of at least 1500 mg metformin once daily over a maximum of 4 weeks followed by a dose-stable period of 10 weeks, a 2-week single-blind placebo run-in, and a 26-week treatment period. Total treatment with metformin will be up to 42 weeks.
223825406|NCT00885352|DRUG|Glipizide|Participants not meeting specific glycemic controls during the 26-week treatment period will use glipizide oral tablets as rescue therapy. In countries where glipizide is not available, participants will receive a sulfonylurea marketed in that country.
223825407|NCT03337932|DRUG|Doxycycline 100 milligram Oral Tablet bid, 7 days|Patients will receive doxycycline for 7 days.
223825408|NCT03337932|DRUG|Doxycycline 100 milligram Oral Tablet bid, 14 days|Patients will receive doxycycline for 14 days.
223825409|NCT03337932|DRUG|Controls without a history of lyme disease.|No intervention.
223825410|NCT01502995|DEVICE|Laser light (U-Step Walking Stabilizer with laser light)|Use of a laser light on a rolling walker during episodes of freezing of gait.
223825411|NCT00365378|BIOLOGICAL|Comparator: HPV 16 L1 Vaccine|A 0.5 intramuscular injection given at Day 1, Month 2, and Month 6
223825412|NCT00365378|BIOLOGICAL|Comparator: Placebo|A 0.5 intramuscular placebo injection given at Day 1, Month 2, and Month 6
223825413|NCT03296709|DEVICE|PPC z|Installation of a preformed pediatric zircona crown
223825414|NCT03296709|DEVICE|PPC m|Installation of a preformed pediatric metal crown
223825415|NCT04499716|PROCEDURE|IPACK|25 milliliters of ropivacaine 0.3% will be injected between popliteal artery and femur.
223825416|NCT04499716|PROCEDURE|Femoral triangle block|25 milliliters of ropivacaine 0.3% will be injected on the lateral side of the femoral artery at the distal part of the femoral triangle.
223825417|NCT04499716|PROCEDURE|Obturator nerve block|20 milliliters of ropivacaine 0.3% will be injected between the adductor magnus and adductor brevis muscles and between the adductor brevis muscle the pectineus.
223825418|NCT04499716|PROCEDURE|Femoral nerve block|20 milliliters of ropivacaine 0.3% will be injected in supine position under the fascia iliaca lateral to the femoral artery.
223825419|NCT04499716|PROCEDURE|Sciatic nerve block|25 milliliters of ropivacaine 0.3% will be injected in prone position in the subgluteal space by lateral approach.
223825420|NCT04499716|PROCEDURE|Lateral femoral cutaneous nerve block|5 milliliters of ropivacaine 0.3% will be injected laterally to the sartorius muscle.
223825421|NCT00992537|DRUG|insulin degludec|Insulin degludec single-dose of 0.5 U/kg body weight injected subcutaneously (under the skin).
223825422|NCT00992537|DRUG|insulin degludec/insulin aspart|Insulin degludec/insulin aspart single-dose of 0.5 U/kg body weight injected subcutaneously (under the skin).
223825423|NCT00992537|DRUG|insulin aspart|Insulin aspart single-dose of 0.5 U/kg body weight injected subcutaneously (under the skin).
223825424|NCT06456099|DRUG|Ultrasound-guided corticosteroid injection|Participants will receive one ultrasound-guided injection with 1 ml Kenalog 40mg/ml and 1 ml Lidocaine 10mg/ml superficial to the insertion of the gluteus medius and minimus tendons on the greater trochanter of the hip at baseline, Prior to the beginning of exercises.
223825425|NCT06456099|BEHAVIORAL|Home exercise program|"Our exercise protocol is based on previous literature and expert opinions that has been synthesized in a Delphi study conducted by our research group. The exercise program consists of three body weighted strength exercises, that are to be performed every second day for a period of eight weeks (see appendix 6, Træningsvejledning). Exercise instructions will be available as a handout and online with video instructions. The corticosteroid injection usually causes a flare-up in pain with a duration of up to 48 hours. Participants will be instructed to begin the exercises as soon as possible after this flare-up has settled. Compliance to exercises are measured using a training diary that the participants must fill out during the study period (see appendix 7, Træningsdagbog)."
223825426|NCT06456099|BEHAVIORAL|Patient information leaflet|"In order to support self-management and modification of tendon load, participants will receive a handout at baseline that contains information about GTPS and advice on load management (see appendix 8, Folder - Smerter på ydersiden af hoften). The participants will be encouraged to read the leaflet regularly and follow the advice."
223825427|NCT02093039|DEVICE|decision aid group|The paper-based leaflet DECIDEO is a 12-page pocket leaflet providing scientific information about the advantages and disadvantages of participating in the national breast screening program, understandable by all, constructed to conform with the International Patient Decision Aid Standards
223825428|NCT02508922|DIETARY_SUPPLEMENT|Vitamin D3|2,000iu vitamin D drops will be taken daily for 20 weeks
223825429|NCT02508922|DIETARY_SUPPLEMENT|Placebo|Matching placebo drops will be taken daily for 20 weeks
223825430|NCT04452448|DEVICE|LASIK|All cases were operated upon using Wavelight Allegretto EX-500 excimer laser (Alcon Laboratories, Inc., Fort Worth, TX) with wave front optimized ablation profile WFO. The Moria II microkeratome (Moria, Anthony, France) was used in all cases.
223825431|NCT02733302|BEHAVIORAL|Hope theory|Adapted Physical Activity
223825432|NCT03278886|DRUG|Low dose naltrexone|4.5 mg of low dose naltrexone taken once daily for 8 weeks
223825433|NCT03278886|DRUG|Nalmefene|18 mg of nalmefene taken once daily for 8 weeks
223825434|NCT05960383|DIAGNOSTIC_TEST|BioFire Pneumonia Panel Plus|Assessment of sensbility and specificity of BioFire Pneumonia Panel Plus in lung transplantation
223825435|NCT05839353|OTHER|SBAR training by serious game|SBAR training by serious game
223825436|NCT04082091|BEHAVIORAL|SELECT mHealth Program|"Individuals will be screened via the telephone, using a mobile-based algorithm that prompts questions about hypertension, risk of Diabetes Mellitus, use of smokeless tobacco and smoking, level of physical activity, and main nutritional choices. These questions are based on tools that have been validated in studies undertaken in this population and will be directly administered by trained research staff of Aga Khan University. Screening will prompt triage into three categories: high - referred to the conveniently located integrated medical center for a medical teleconsultation and fasting glucose test; medium - receive fasting glucose test and BP measurement; and low risk. All subjects in each category will be enrolled in an e\_Prescription intervention for lifestyle change tailored to their individual risk profile."
223825437|NCT04607824|BEHAVIORAL|Duchenne Muscular Dystrophy group|Assessment of heart rate variability at rest and during computational task in people with Duchenne muscular dystrophy
223825438|NCT04607824|BEHAVIORAL|Typical Development group|Assessment of heart rate variability at rest and during computational task in people with typical Development
223825439|NCT01316341|DRUG|BI10773|patient to receive a tablet containing high dose BI10773 p.o. plus one placebo
223825440|NCT01316341|DRUG|Placebo|patient to receive two placebos
223825441|NCT01316341|DRUG|Placebo|patient to receive two placebos
223825442|NCT01316341|DRUG|Placebo|patient to receive two placebos
223825443|NCT01316341|DRUG|BI10773|patient to receive a tablet containing low dose BI10773 p.o. plus one placebo
223825444|NCT04161807|DEVICE|Nerivio|The device delivers transcutaneous electrical stimulation to the upper arm to induce conditioned pain modulation (CPM) that activates a descending endogenous analgesic mechanism. The treatment is self-administered and controlled by a smartphone application.
223825445|NCT02390843|DRUG|Simvastatin|The starting dose of simvastatin will be 140 mg/m\^2/dose BID for 21 days for the first group. Dose escalation for subsequent groups will be 180 mg/m\^2/dose BID, 225 mg/m\^2/dose BID, and 290 mg/m\^2/dose BID. If the maximum tolerated dose (MTD) has been exceeded at the first dose level, then the subsequent cohort of subjects will be treated at a dose of 100 mg/m2/dose BID (dose level 0). Simvastatin will be administered orally twice daily, approximately 12 hours apart. Feeding tube (nasogastric tube or gastrostomy tube, NOT a jejunum localized tube) administration is allowed. If a subject vomits a dose of simvastatin, it will not be repeated.
223825446|NCT02390843|DRUG|Cyclophosphamide|The dose of cyclophosphamide will be fixed at 250 mg/m\^2/dose. Cyclophosphamide will be administered intravenously over 30 minutes once daily for 5 days every 21 days.
223825447|NCT02390843|DRUG|Topotecan|The dose of topotecan will be fixed at 0.75 mg/m\^2/dose. Topotecan will be administered, after cyclophosphamide, intravenously over 30 minutes once daily for 5 days every 21 days.
223825448|NCT02390843|DRUG|Myeloid growth factor|Myeloid growth factor (G-CSF or pegylated G-CSF) will be initiated 24-48 hours after the completion of topotecan and cyclophosphamide for all subjects, which would be day 6 or 7. Myeloid growth factor should continue until the absolute neutrophil count is greater than 2,000/mm\^3
223825449|NCT02875301|BEHAVIORAL|150 Minutes Week|This group will complete aerobic based exercise 150 minutes per week. Participants will obtain minutes through supervised on site exercise and home based exercise. An exercise duration of 30 minutes will be achieved by the forth week of the program and be maintained for the duration of the intervention. Heart rate will be monitored to ensure proper intensity levels. Participants will also be instructed to exercise at home for 30 minutes for two other days of the week at a similar intensity. The prescribed intensity will be 50-60% of the maximum heart rate reserve for weeks one to six and 60-75% for the remainder of the program. Participants in the walking conditions will wear heart rate monitors and be encouraged to walk within their target heart rate zone. During the Covid-19 pandemic shutdown, all intervention exercise was been shifted to home based.
223825450|NCT02875301|BEHAVIORAL|225 Minutes Week|This group will complete aerobic based exercise 225 minutes per week. Participants will obtain minutes through supervised on site exercise and home base exercise. A walking duration of 45 minutes will be achieved by the seventh week of the program. This will be maintained for the duration of the intervention and heart rate will be monitored to ensure proper intensity levels. Participants will be instructed to exercise at home for 45 minutes for two other days of the week at a similar intensity. The prescribed intensity will be 50-60% of the maximum heart rate reserve for weeks one to six and 60-75% for the remainder of the program. Participants in the walking conditions will wear heart rate monitors and be encouraged to walk within their target heart rate zone. During the Covid-19 pandemic shutdown, all intervention exercise has been shifted to home based.
223835565|NCT03487003|DRUG|saline|After standard anesthetic monitoring (non-invasive blood pressure monitor, pulse oximetry, 3-lead echocardiography), patients are inhaled with sevoflurane. When the patients asleep, 0.3 mg/kg saline is administered. After 2 min, flexible laryngeal mask airway (fLMA) is inserted using standard method. The fLMA is inflated with air to 40 cmH2O using manometry. The oropharyngeal leak pressure (OLP) was determined by the method described by Lopez-Gil and colleagues
223825451|NCT02875301|BEHAVIORAL|Stretch and Tone|The control condition will focus on improving balance, flexibility, and strength. This group will obtain 150 minutes per week via in person sessions, zoom sessions and home based stretching. Resistance bands, balance disks, yoga blocks, and exercise mats will be used to engage in non-cardiorespiratory activities. These are progressive in nature and include modifications to accommodate injuries, physical difficulties, etc. A new set of similar, yet slightly more challenging activities will be introduced every four weeks. During the first two weeks, participants are introduced to the new activities, and, during the second two weeks, they are encouraged to increase intensity by using more weight or more repetitions. During the current Covid-19 pandemic, all intervention exercise has been shifted to home based.
223825452|NCT02312180|BIOLOGICAL|Plasminogen (Human) Intravenous|Plasma-derived purified plasminogen formulated for intravenous administration
223825453|NCT04649827|OTHER|Clinical Observation|This is an observational study, so there are no interventions. Investigators will collect data about demographics, comorbidities, medications, and other risk factors such as the severity of disease at admission, need for advanced life support, need for invasive mechanical ventilation and main outcomes during hospitalization.
223825454|NCT00864526|DRUG|Oxycodone HCl 5 mg / Ibuprofen 400 mg tablets, single dose|A: Experimental SSubjects received Actavis formulated products under fasting conditions
223825455|NCT00864526|DRUG|COMBONOX® tablets, single dose|B: Active comparator Subjects received Forest Pharmaceuticals, Inc formulated products under fasting conditions
223825456|NCT03383562|PROCEDURE|operation in different stages of the day|operation was arranged in the morning ,afternoon or at night
223825457|NCT04822480|BEHAVIORAL|Diabetes Prevention Program (DPP)|Individuals with prediabetes can mitigate the risks and costs of diabetes by taking preventative action, such as participation in a National Diabetes Prevention Program (DPP). The DPP began as a multisite randomized controlled trial demonstrating the effectiveness and cost-benefit of a 12-month intensive lifestyle intervention over pharmaceutical treatment for preventing or delaying diabetes among prediabetic participants. In 2010, Congress authorized the Centers for Disease Control and Prevention to lead the dissemination of the DPP as a targeted approach (high risk populations) and population-based strategy to reduce the incidence of diabetes and diabetes-related healthcare costs. The goal is to achieve modest weight loss (7%) by developing and implementing behavior change skills resulting in lifestyle modifications such as physical activity (150 minutes per week) and dietary and nutritional practices.
223825458|NCT04745494|OTHER|OT administration|OT nasal administration
223825459|NCT04745494|OTHER|Placebo administration|Placebo nasal administration
223825460|NCT04318730|DRUG|Camrelizumab|Camrelizumab was administered 200mg iv every 3 weeks, Apatinib was administered 250 mg p.o. qd.
223825461|NCT04738721|BEHAVIORAL|Evaluation|"Within the scope of the course, the demographic information of the students (such as height, weight, body mass index) is recorded and the physical activity status is recorded with International Physical Activity Questionnaire Short Form (UFAA). Cardiovascular endurance with 6-Minute Walking Test, flexibility and circumference of waist, hip and neck with the Sit and Lie Test and body composition and Body Fat Ratio will be evaluated. After a full year of quarantine, the same students who were previously evaluated and accepted to participate in the current study will be evaluated with online remote video viewing methods (Teams, Zoom, etc.) and, with the same tests and measurements under supervision by the researchers."
223825462|NCT04307498|BEHAVIORAL|Intensive Outpatient Program - Prolonged Exposure|Prolonged Exposure for Posttraumatic Stress Disorder (PE for PTSD; Foa, Hembree, \& Rothbaum, 2007) is an empirically supported behavioral therapy that utilizes exposure-based interventions to target the psychological mechanisms (i.e., avoidance; maladaptive cognitive changes) thought to maintain trauma-related symptoms. IOP-PE includes 15 days of PE treatment delivered over three consecutive weeks. The standard outpatient PE protocol has modified with seven treatment augmentations to meet the unique needs of post-9/11 veterans.
223825463|NCT03290157|DEVICE|ColoprAPP|Additional downloaded SPA for reminding the crucial steps of colonoscopy preparation
223825464|NCT04699357|DRUG|Atropine|different concentrations (0.01%/0.04%/0.1%) of atropine were administered to high myopic children
223825465|NCT00439829|DRUG|Gonal F|"* 450 IU Gonal-f (Serono Canada) subcutaneously daily (225 IU BID; injections to be given after bloodwork).~* Dosing to begin on day 1 or day 4 (day 1=first day of menses), continuing until administration of human Chorionic Gonadotropin (hCG; see below).~* Gonal-f dose may be further reduced, at the discretion of the study physician, to minimize the risk of OHSS."
223825466|NCT00439829|DRUG|Luveris|"* 0.250 mg Cetrotide (Serono Canada) and 75 IU Luveris (Serono Canada) subcutaneously daily when one or more of the following conditions are met:~  * leading follicle is \> 13 mm in diameter~ * if 6 or more follicles develop to \> 10 mm and E2 \> 1000 pmol/L~* Dosing to continue until administration of hCG (see below)."
223825467|NCT00439829|DRUG|Cetrotide|"* 0.250 mg Cetrotide (Serono Canada) and 75 IU Luveris (Serono Canada) subcutaneously daily when one or more of the following conditions are met:~  * leading follicle is \> 13 mm in diameter~ * if 6 or more follicles develop to \> 10 mm and E2 \> 1000 pmol/L~* Dosing to continue until administration of hCG (see below)."
223825468|NCT00439829|DRUG|hCG|"\- 10,000 IU hCG (Pharmaceutical Partners of Canada Inc.) subcutaneously when:~o \> 3 follicles are \> 17 mm in diameter"
223825469|NCT01705808|DRUG|Protein C concentrate|
223835566|NCT05359159|OTHER|Data collection|Data collection
223825470|NCT04386226|DIETARY_SUPPLEMENT|Ambrotose LIFE|Ambrotose LIFE contains aloe vera extract inner leaf gel, arabinogalactin, ghatti gum, glucosamine hydrogen chloride, gum tragacanth, vitamin A, beta carotene, wakame algae extract, rice starch, RiFiber (rice bran), and Modified Citrus Pectin with Sodium Alginate.
223825471|NCT04386226|DIETARY_SUPPLEMENT|Advanced Ambrotose|Advanced Ambrotose contains aloe vera extract inner leaf gel, arabinogalactan, ghatti gum, glucosamine hydrogen chloride, gum tragacanth, vitamin A, beta carotene, wakame algae extract, and rice starch
223825472|NCT04386226|OTHER|Placebo|Maltodextrin
223825473|NCT04997044|OTHER|Concomitant physical rehabilitation|Children of this group will receive a regular exercise rehabilitation program including starching exercises, functional strength training and static and dynamic balance exercises.The program will be conducted by six licensed pediatric physical therapists for one hour/session, 3 times/week, and six successive months.
223825474|NCT04997044|OTHER|Standard Orthotic Management|A custom-made articulating ankle foot orthosis was prescribed with a hinge at the level of the medial malleolus extends distally to the tip of the toes and proximally on the posterior surface of the leg to about 5 cm below the knee and secured straps. It is fabricated to permit free ankle dorsiflexion and lock the plantar flexion at 0 dorsiflexion. The splinting schedule started gradually for 2 h/day in the first month, 4 h/day in the second month to the entire wake-up time of the day.
223825475|NCT04997044|OTHER|selective dorsal rhizotomy|The surgical procedures were tailored to each child according to preoperative assessment plan. All SDRs were performed by a single neurosurgeon through an osteoplastic laminotomy from L2 to L5 that left the facet joints intact.
223825476|NCT02848261|BEHAVIORAL|Developmental Demands|Education and training related to use of CGM in this age group
223825477|NCT02848261|BEHAVIORAL|Distress Reduction|Education and training on reducing distress
223825478|NCT02848261|BEHAVIORAL|Remote Monitoring|Education and training on the use of remote monitoring
223825479|NCT02848261|BEHAVIORAL|Fear of Hypoglycemia|Education and training on reducing fear of hypoglycemia
223825480|NCT02848261|BEHAVIORAL|No intervention|No intervention - serves as the control group
223825481|NCT03740880|OTHER|Dual trigger|dual trigger: 10.000 IU hCG i.m. and 0.3 mg Deca
223825482|NCT04931459|DRUG|ACU193|Intravenous ACU193
223825483|NCT04931459|DRUG|Placebo|Intravenous Placebo
223825484|NCT03254160|DRUG|DNS-3379|DNS-3379
223825485|NCT03254160|DRUG|Placebo|Placebo
223825486|NCT05992714|DEVICE|Virtual Reality Glasses group|Except for the preparation of the patient for the procedure, since the arthroscopy procedure takes approximately 60 minutes, 60-minute 360-degree VR video scenes will be watched using VR head device
223825487|NCT05992714|DEVICE|white noise group|Except for the preparation of the patient for the procedure, since the arthroscopy procedure takes approximately 60 minutes, 60-minute 360-degree VR video scenes will be watched using phone
223825488|NCT04139148|DEVICE|Ture Transcranial Direct Current Stimulation (tDCS)|Ture 1-2 mA current of tDCS intervention in patients' binary brain DLPFC areas(20 mm).
223825489|NCT04139148|DEVICE|Sham Transcranial Direct Current Stimulation (tDCS)|Sham tDCS intervention in patients' binary brain DLPFC areas(20 mm).
223825490|NCT02252458|DRUG|Fentanyl|
223825491|NCT03562546|OTHER|Strength From Within|A 12 week at home structured resistance exercise programme using resistance bands. Participants will also receive a walking programme, a warm up and cool down, and ankle range of motion exercises.
223825492|NCT03491748|DRUG|ETX0282|Oral Gelatin capsules
223825493|NCT03491748|DRUG|Cefpodoxime proxetil|Oral tablets
223825494|NCT03491748|DRUG|Placebo|Oral Gelatin capsules
223825495|NCT05445856|DRUG|Methadone|Methadone is administered as a single intravenous dose after induction of anesthesia and prior to initiation of surgery
223825496|NCT05445856|DRUG|Fentanyl|Fentanyl is administered as a single intravenous dose after induction of anesthesia and prior to initiation of surgery
223825497|NCT04316390|DIETARY_SUPPLEMENT|Control|study drink (two weeks)
223825498|NCT04316390|DIETARY_SUPPLEMENT|Hesperidin|study drink + Hesperidin 600 mg (two weeks)
223825499|NCT04316390|DIETARY_SUPPLEMENT|Vitamin C|study drink + Vitamin C 250 mg (two weeks)
223825500|NCT04316390|DIETARY_SUPPLEMENT|Hesperidin + Vitamin C|study drink + Hesperidin 600 mg + Vitamin C 250 mg (two weeks)
223825501|NCT03523182|DIETARY_SUPPLEMENT|Spirulina|"Arthrospira platensis, also known as spirulina, is a blue-green micro-algae indigenous to Africa.~Spirulina group (n=251) receive a soya-maize-based porridge with the addition of spirulina.~We used 10 g per day of spirulina powder with a mealie meal and soya flour porridge blend."
223825502|NCT03523182|DIETARY_SUPPLEMENT|Control|Children receive a soya-maize-based porridge for 12 months. We use a mealie meal and soya flour porridge blend.
223825503|NCT00151918|DRUG|Lanthanum carbonate|
223825504|NCT00624325|DRUG|interferon alfa-2b|12 MU daily continuously subcutaneous
223825505|NCT00624325|DRUG|interferon alfa-2b|9 MU daily continuously subcutaneous
223825506|NCT00624325|DRUG|interferon alfa-2b|6 MU daily continuously subcutaneous
223825507|NCT00282815|DEVICE|continuous positive airway pressure or CPAP|RemStar Pro (Respironics, Inc.) The CPAP is applied through a nasal mask during the hours of sleep. Positive air pressure holds the naso-oro-pharyngeal airway open during sleep.
223825508|NCT00282815|DEVICE|sham CPAP|sham CPAP
223825509|NCT02490618|OTHER|Probiotic tablet- Biogaia|
223825510|NCT02490618|OTHER|Placebo tablet|
223825511|NCT00082602|DRUG|galantamine ER|
223825512|NCT04015791|OTHER|NOCISCAN-LS Disc MR Spectroscopy|The investigational Nociscan Suite is a software suite that works with existing high field MR systems and MRS pulse sequence via and optimized protocol to conduct MRS exam of lumbar discs. The software suite post-processes the NOCISCAN-LS disc MRS exam data to calculate ratios of spectroscopic signals at regions along the MRS frequency spectrum associated with certain chemicals that change with degeneration and pain
223825513|NCT01129505|BEHAVIORAL|Nutrition & Exercise Lifestyle Intervention Program (NELIP)|"Nutrition- individualize total energy intake with a minimum of 2000 kcal/day with a restriction of not more than 33% total energy intake, total carbohydrate of 40-50% total energy intake, total fat intake of 30% of total energy intake (substituting monounsaturated fatty acids for saturated and trans-fatty acids), and approximately 30% dedicated to protein intake.~Exercise-25 minutes of walking per session, 3-4 times per week, each subsequent week increasing by 2 mins to a maximum of 40 mins/session.~Family-based Behavioural Treatment (FBBT) Coupled with the individualized NELIP for each woman, FBBT will be presented in 3 group sessions (including family members), focussing on strategies to make healthy lifestyle choices with behavioural strategies."
223825514|NCT04955704|DEVICE|InferRead CT Pneumonia.AI|InferRead CT Pneumonia.AI reads chest CT DICOM images from medical imaging storage devices and triages cases by detecting pneumonia lesions and then flagging suspected cases in the study list. InferRead CT Pneumonia.AI is a tool to assist clinicians and it does not replace the interpretation and diagnosis by clinicians.
223825515|NCT01471158|DRUG|Brinzolamide/Timolol Maleate Fixed Combination (AZARGA)|Brinzolamide/timolol maleate fixed combination, one drop instilled in one eye at baseline, followed by one drop instilled in each eye once in either first intervention period or second intervention period.
223825516|NCT01471158|DRUG|Dorzolamide/timolol Maleate Fixed Combination (COSOPT)|Dorzolamide/timolol maleate fixed combination, one drop instilled in one eye at baseline, followed by one drop instilled in each eye once in either first intervention period or second intervention period.
223825517|NCT03312179|DEVICE|PCI and DES stenting|Percutaneous coronary intervention (PCI) and direct stenting (DES) of culprit lesion vessel.
223825518|NCT03312179|DRUG|Incretins|Patients treated before study enrollment by incretin drugs (6 months drugs exposure)
223825519|NCT00669903|DRUG|AZD0328|
223825520|NCT00669903|DRUG|Placebo|
223825521|NCT06031909|DIAGNOSTIC_TEST|Multimodal frailty assessment|"Different domains are assessed during hospital stay, these include:~* Clinical scores: Clinical Frailty scale (CFS), Groningen Frailty index (GFI)~* Brain frailty: assessing white matter hyperintensieties, atrophy and lacunar strokes in initial brain imaging~* Laboratory values: laboratory Frailty index (FI-Lab), inflammatory markers~* Nutrition: Controlling nutritional status score (CONUT-score), body mass index, dysphagia assessment (FOIS)~* Mobility/strengths: de Morton Mobility Index (DEMMI), grip strenghts of non-paralytic arm via dynamometer, muscle mass estimated by sonographic measurement of the biceps brachii muscle and the rectus femoris muscle."
223825522|NCT00504296|DRUG|HDAC inhibitor SB939|SB939 will be administered initially for 3 consecutive days every other week at the first dose level and then for 5 consecutive days every other week at escalating doses.
223825523|NCT00504296|OTHER|immunoenzyme technique|
223825524|NCT00504296|OTHER|immunohistochemistry staining method|
223825525|NCT00504296|OTHER|immunologic technique|
223825526|NCT00504296|OTHER|laboratory biomarker analysis|
223825527|NCT00504296|OTHER|liquid chromatography|
223825528|NCT00504296|OTHER|mass spectrometry|
223825529|NCT00504296|OTHER|pharmacological study|
223825530|NCT01205321|DRUG|Bombesin (68Ga) labeled (BAY86-7548)|Cancer patients, single intravenous bolus injection of 140 MBq BAY86-7548 on day one of the treatment period, PET/CT
223825531|NCT01205321|DRUG|Bombesin (68Ga) labeled (BAY86-7548)|Healthy volunteers, single intravenous bolus injection of 140 MBq BAY86-7548 on day one of the treatment period, whole body PET/CT for determination of effective dose, kinetics of BAY86-7548 in blood
223835567|NCT04943900|DRUG|BMS-986416|Specified dose on specified days
223825532|NCT01915199|OTHER|Intensive Care|Comprehensive intervention on hypertension through optimization of drug therapy, introduction of home blood pressure monitoring, and lifestyle guidance
223825533|NCT03203668|RADIATION|18F-choline PET/CT|18F-choline PET/CT imaging (neck, mediastinum)
223825534|NCT01082172|DEVICE|Implant Thoracic Stent Graft|Endovascular implant of Thoracic Aortic Aneurysm Stent Graft
223825535|NCT06082622|COMBINATION_PRODUCT|laxatives|triple therapy of drugs, behaviour and mental axis
223825536|NCT06321250|DRUG|JMKX003948|Subjects will receive JMKX003948 tablets until disease progression
223825537|NCT02419430|BEHAVIORAL|MBRT ClassRoom and Phone Application|2 hours/week for 6 week, in classroom intervention involving mindfulness based resilience training.focused on mindfulness and self-compassion training, including body awareness, breath awareness, mindful movement, awareness of thoughts, and awareness of emotion. Core concepts included: normalizing experience of stress and changing one's relationship with an experience; learning to be a compassionate observer of self in order to appreciate the moment; recognizing undue efforts to control something that has already happened; shifting attention to felt body sense and away from the narrative; and redirecting attention to a value as a way of evoking positive states that enhance the present moment experience. Participants also use the smartphone to track their sleep and subjective well-being.
223825538|NCT02419430|BEHAVIORAL|Phone application only|"Participants will track their sleep and subjective well-being and also choose one of the following weekly challenges, which is completed via smartphone interactions:~* Joys of Life~* Count your blessings~* Think differenc, feel better~* Exercising --\> Happier~  \+ Exercising --\> Sleep~* Pre-Sleep routine~* Eat that frog~* Mindful Meditation"
223825539|NCT02419430|BEHAVIORAL|Questionnaires|At baseline, immediately after the last MBRT session (6 weeks) and again at 3 and 6 months, all participants will complete questionnaires, including: 1) WHO-5 Well-Being Index; 2) DASS-21; 3) VAS-Fatigue; 4) MBI-Human Services version; 5) Self-Compassion Scale; 6) Connor-Davidson 2-item resilience scale; 7) Compassion to others scale.
223825540|NCT05597800|DRUG|Nivolumab and Ipilimumab|"Nivolumab will be administered with ipilimumab, plus 2 cycles of histology-based platinum doublet chemotherapy:~* Squamous histology: carboplatin AUC 6 + paclitaxel 200 mg/m2~* Non-squamous histology: carboplatin AUC 5 or 6 + pemetrexed 500 mg/m2 or cisplatin 75 mg/m2 + pemetrexed 500 mg/m Dosing: nivolumab 360 mg every 3 weeks + ipilimumab 1 mg/kg every 6 weeks (up to maximum 2 years) + histology-based, platinum doublet chemotherapy (every 3 weeks for two cycles)."
223825541|NCT05402800|OTHER|FSFI questionnaire|The FSFI is a reliable test for the assessment of sexual function in women. The Arabic version of this test, was used. The FSFI is comprised of six domains (desire, arousal, lubrication, orgasm, satisfaction, and pain) with score ranges of 0 (or 1) to 5. The total FSFI score ranges from 2.0 to 36. The translated version of the FSFI test was used in this study. All questions in the FSFI questionnaire were explained by the physician one by one, and they were filled in a suitable and silent environment where patients could comfortably share such intimate information
223825542|NCT01356641|DRUG|Antibiotic treatment alone|Amoxicillin/clavulanic acid 100/10 mg/kg 6-hourly Gentamicin 7 mg/kg once daily At least 48 hours intravenous administration, in total seven days of antibiotics Oral amoxicillin/clavulanic acid 50/12.5mg/kg
223825543|NCT01356641|PROCEDURE|Appendectomy|Appendectomy either open or laparoscopic depending on the surgeon's preference
223825544|NCT00837525|PROCEDURE|nasal valve implant|Injectable implantation of a biodegradable material for support of the Nasal valve.
223825545|NCT03316612|DIETARY_SUPPLEMENT|Vaccinium Myrtillus L. extract|Twice a day, 2 tablets each time. Do not take any other medicine, traditional Chinese medicine, or dietary supplements.
223825546|NCT03316612|DIETARY_SUPPLEMENT|Placebo|Twice a day, 2 tablets each time. Do not take any other medicine, traditional Chinese medicine, or dietary supplements.
223825547|NCT04789577|BIOLOGICAL|FLU-Q-PAN H7N9 Formulation 1|Participants received two doses of the FLU-Q-PAN H7N9 Formulation 1 vaccine by intramuscular injection in the non-dominant arm.
223825548|NCT04789577|BIOLOGICAL|FLU-Q-PAN H7N9 Formulation 2|Participants received two doses of the FLU-Q-PAN H7N9 Formulation 2 vaccine by intramuscular injection in the non-dominant arm.
223825549|NCT04789577|BIOLOGICAL|FLU-Q-PAN H7N9 Formulation 3|Participants received two doses of the FLU-Q-PAN H7N9 Formulation 3 vaccine by intramuscular injection in the non-dominant arm.
223825550|NCT04789577|BIOLOGICAL|AS03B|Participants received two doses of the AS03B adjuvant by intramuscular injection in the non-dominant arm.
223825551|NCT04789577|BIOLOGICAL|AS03A|Participants received two doses of the AS03A adjuvant by intramuscular injection in the non-dominant arm.
223825552|NCT04789577|DRUG|Placebo|Participants received two doses of Placebo by intramuscular injection in the non-dominant arm.
223825553|NCT00058019|DRUG|ixabepilone|Given IV
223825554|NCT00773955|DRUG|R-(-)-gossypol acetic acid|Given orally
223825555|NCT00773955|OTHER|pharmacological study|Correlative studies
223825556|NCT00773955|OTHER|laboratory biomarker analysis|Correlative studies
223825557|NCT03961113|OTHER|Assessment by questionnaire|"At diagnosis a gerontological evaluation will be carried out including the following tests: ADL, iADL, MNA, SF 36, SPPB, FRIED criteria and GDS. The set of scales and scores of the procedure is commonly used in geriatrics to assess the fragility of the patient.~A monthly telephone reassessment conducted by an ARC will collect ADL and iADL from the first month to the eleventh month. The end-of-study consultation will be conducted by a geriatrician at the 12th month and will include the following tests: ADL, iADL, MNA, SF 36, the SPPB, the criteria of FRIED and the GDS"
223825558|NCT04102436|DRUG|Fludarabine|Days -7 to -3: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days.
223825559|NCT04102436|DRUG|Cyclophosphamide|Days -7 and -6: Cyclophosphamide 60 mg/kg/day x 2 days IV in 250 mL D5W infused simultaneously with mesna 15 mg/kg/day over 1 hour x 2 days.
223825560|NCT04102436|DRUG|Aldesleukin|Aldesleukin 720,000 IU/kg or 72,000 IU/kg (based on total body weight) IV over 15 minutes approximately every 8 hours beginning within 24 hours of cell infusion and continuing for up to 4 days (maximum 10 doses).
223825561|NCT04102436|BIOLOGICAL|Sleeping Beauty Transposed PBL|Day 0: Cells are to be infused at a dose not to exceed 1.5e11 in 400 mL intravenously on the Patient Care Unit over 20-30 minutes or as clinically determined by an investigator for patient safety (between 2-4 days after the last dose of fludarabine).
223825562|NCT02267720|PROCEDURE|Occlusal-proximal ART restorations - Ketac Molar|Occlusal-proximal ART restorations - Ketac Molar
223835568|NCT04943900|DRUG|Nivolumab|Specified dose on specified days
223825563|NCT02267720|PROCEDURE|Occlusal-proximal ART restorations - Vitro Molar|Occlusal-proximal ART restorations - Vitro Molar
223825564|NCT02443662|OTHER|Catheterization|Routine catheterization during follow up.
223825565|NCT06098495|GENETIC|search for epigenetic profile of infertility|examine the epigenetic profile of DNA extracted from MGCs and blood sample
223825566|NCT01827254|OTHER|sunitinib: observational study|Observational study evaluating patients who were treated with sunitinib in 1st line and in 3rd line
223825567|NCT03967990|OTHER|Refined cornmeal flour|48 g/d of refined cornmeal flour served to participants as two daily 24 g servings via pita breads and/or muffins
223825568|NCT03967990|OTHER|50/50 refined cornmeal-bran mix|48 g/d of a mix of 50% refined cornmeal flour and 50% corn bran flour served to participants as two daily 24 g servings via pita breads and/or muffins
223825569|NCT03967990|OTHER|Whole grain cornmeal flour|48 g/d of whole grain cornmeal flour served to participants as two daily 24 g servings via pita breads and/or muffins
223825570|NCT04905732|DEVICE|NHFOV|After documenting parental consent, the ventilated infants with BPD were randomly assigned to NHFOV
223825571|NCT04905732|DEVICE|NCPAP|After documenting parental consent, the ventilated infants with BPD were randomly assigned to NCPAP
223825572|NCT02096133|DRUG|Cholecalciferol|Vitamin D3 solution
223825573|NCT02096133|OTHER|Placebo comparator|Placebo comparator
223825574|NCT01561092|DRUG|Escitalopram|5 or 10 mg escitalopram tablets administered orally once daily
223825575|NCT01561092|DRUG|Placebo|Tablets
223825576|NCT06392672|BEHAVIORAL|Intervention Group: Group to which the clinical pharmacist makes recommendations|The drugs administered to patients during scheduled hospital visits will be recorded. A detailed medication review will be conducted by the clinical pharmacist. As a result of a comprehensive evaluation, recommendations were made to doctors regarding drug-related problems and were recorded.
223825577|NCT04724356|OTHER|Virtual Reality|Intervention was led once per day, five days a week, over 8 weeks.
223825578|NCT04724356|OTHER|Resistance Exercise|Intervention was led once per day, five days a week, over 8 weeks.
223825579|NCT01764373|OTHER|Aerobic Exercise|Aerobic exercises in the program include cycle ergometers, treadmills, recumbent steppers and elliptical trainers.
223825580|NCT04479722|DEVICE|Left atrial appendage closure procedure|Implant LAAC system in LAA through percutaneous intervention
223825581|NCT01780129|DRUG|Polydatin Injectable|Dilute two 100mg/5mL vials of HW6 into 500mL 0.9% NaCl injection and administer as i.v. infusion over 2 hours. The drug should be given as early as possible right after the IC Form is signed on Day 1, and once every 24 hours for additional 4 doses.
223825582|NCT04299477|PROCEDURE|non-surgical periodontal treatment|supra- and subgingival scaling, and root planning
223825583|NCT00562978|BIOLOGICAL|filgrastim|
223825584|NCT00562978|DRUG|cyclophosphamide|
223825585|NCT00562978|DRUG|etoposide|
223825586|NCT00562978|PROCEDURE|AHSCT|
223825587|NCT00562978|RADIATION|yttrium Y 90 ibritumomab tiuxetan|
223825588|NCT03949660|DEVICE|Stimulation for blood pressure without stand|Consists of 80 daily training sessions using epidural stimulation optimized for blood pressure for up to 6 hours of stimulation a day.
223825589|NCT03949660|DEVICE|Stimulation for blood pressure with stand|Consists of 80 daily sessions similar to the 1st intervention (without stand) plus 2 hours of epidural stimulation optimized for stand training.
223825590|NCT03949660|DEVICE|Stimulation for trunk and core without stand|Consists of 80 daily training sessions using epidural stimulation optimized for trunk/core/voluntary function for up to 6 hours of stimulation a day.
223825591|NCT03949660|DEVICE|Stimulation for trunk or core with stand|Consists of 80 daily sessions similar to the 1st intervention (without stand) plus 2 hours of epidural stimulation optimized for stand training.
223825592|NCT06272305|PROCEDURE|This research does not require any specific investigation and does not imply any modification of treatment.|Collection of data from the medical record for patients with a non specific carotid endarterectomy
223825593|NCT04002219|DIETARY_SUPPLEMENT|beverage containing mushroom-extracts|Subjects recruited from both arms will receive treatment and be followed up clinically for 8 weeks.
223825594|NCT00258180|BIOLOGICAL|filgrastim|Administered IV or subcutaneously once daily beginning on day 10 and continuing for 3 days or until blood counts recover
223825595|NCT00258180|DRUG|cyclophosphamide|Administered IV over 1 hour on days 1-4
223825596|NCT05602207|DRUG|Abrocitinib|100 mg Abrocitinib once daily (QD) for 12 weeks
223825597|NCT00152971|DRUG|Dabigatran Dose 1 - day 2 to completion|low dose regimen taken once daily
223825598|NCT00152971|DRUG|Dabigatran Dose 1 - day 1|low dose regimen taken once daily
223825599|NCT00152971|DRUG|Dabigatran Dose 2 - day 2 to completion|high dose regimen taken once daily
223825600|NCT00152971|DRUG|Dabigatran Dose 2 - day 1|high dose regimen taken once daily
223825601|NCT00152971|DRUG|Enoxaparin|30 mg subcutaneously twice daily
223825602|NCT05425849|OTHER|rose oil aromatherapy|Aromatherapy refers to the medicinal or therapeutic use of essential oils absorbed through the skin or the olfactory system. The positive effects of social support, such as hand-holding, on anxiety and pain have been described
223825603|NCT00028860|BIOLOGICAL|filgrastim|
223825604|NCT00028860|DRUG|carboplatin|
223825605|NCT00028860|DRUG|gemcitabine hydrochloride|
223825606|NCT00028860|DRUG|ifosfamide|
223825607|NCT00028860|DRUG|paclitaxel|
223825608|NCT00028860|PROCEDURE|adjuvant therapy|
223835569|NCT05158257|DEVICE|balloon and Stent|balloon dilatation combined stent angioplasty
223825609|NCT02921373|BIOLOGICAL|19F Cell Sense-labeled PBMC|"Peripheral blood mononuclear cells (PBMC) will be isolated from patient whole blood samples and labeled in a GMP facility with GMP grade 19F Cell Sense imaging agent.~These cells will be re-administered to the patient prior to imaging."
223825610|NCT02921373|DEVICE|MRI|Participants will undergo Magnetic Resonance Imaging (MRI) at 1 hour and 24 hours following PBMC administration
223825611|NCT00252213|DRUG|Human BNP|
223825612|NCT03655990|DEVICE|Treatment with the JUVORA™ Dental Disc|treatment with the JUVORA™ Dental Disc
223825613|NCT01099930|OTHER|immuno-ablation and autologous CD34 selected hematopoietic stem cell transplantation (HSCT),|"Stem Cell Mobilization with Cyclophosphamide 4.5 gm/m2 and rhGCSF 10 ug/kg/d x 10 day.~Stem Cell Collection with Cobe Spectra Stem Cell Purification with Miltenyi CliniMACS Stem Cell Transplant Conditioning with Busulphan 9.6 mg/kg iv, Cyclophosphamide 200 mg/kg iv, rabbit ATG 5 mg/kg iv followed by CD34 selected autologous hematopoietic stem cell transplant"
223825614|NCT01099930|OTHER|Standard Therapy|Patient will receive standard therapy as decided upon by their treating neurologist.
223825615|NCT02707523|DRUG|Azithromycin 10 mg|
223825616|NCT02707523|DRUG|Azithromycin 20mg|
223825617|NCT02707523|DRUG|Placebo|
223825618|NCT03452605|DIETARY_SUPPLEMENT|cocoa flavanol supplementation|cocoa flavanols (containing 196 mg epicatechin)
223825619|NCT03976895|PROCEDURE|Supine position (SP)|"Infants under high flow nasal cannula (HFNC) will be positioned in the supine position.~Patients may be positioned temporarily in lateral position between periods of supine position to limit ventilatory disorders, as it is usually done in critical care units during bronchiolitis."
223825620|NCT03976895|PROCEDURE|Prone position (PP)|"Infants under high flow nasal cannula (HFNC) will be placed in the prone position during at least 24 hours over the first 48 hours. The positioning will be standardized (chest on the bed plan and abdomen cleared) and children should be placed in the prone position immediately after randomization.~Patients may be positioned temporarily in lateral position between periods of prone position to limit ventilatory disorders, as it is usually done in critical care units during bronchiolitis."
223825621|NCT00955734|OTHER|Early motion|One set of patients will begin wrist motion at 1 week after surgery.
223825622|NCT00955734|OTHER|Immobilization|This set of patients will be casted for 6 weeks after surgery.
223825623|NCT01570595|BEHAVIORAL|Web-Based Tailored Smoking Cessation Intervention|"The Experimental group will be given an ID number to log in to the quit smoking program, and complete their first log-in with a research assistant. The online program is made up of 8 separate, weekly online sessions that take approximately 15-30 minutes to complete. The entire program is meant to be completed in 7 weeks. Participants are asked to provide an email address and/or cell phone number so reminders can be sent to complete the sessions. If participants are late completing a session, they will receive a call from clinic staff as a reminder. The standard care group will receive advice to quit, a quit-smoking brochure, and an offer of three months of nicotine replacement therapy (nicotine patches)."
223825624|NCT01570595|BEHAVIORAL|Standard of Care|advice to quit, a quit-smoking brochure, and an offer of three months of nicotine replacement therapy (nicotine patches).
223825625|NCT02674360|BEHAVIORAL|SDM Training|
223825626|NCT01361620|DRUG|aspirin|aspirin 81mg, 7-10 days
223825627|NCT02920151|OTHER|balance exercises circuit|Thirteen workstations were organized in a circuit format on involved multidirectional gait in different bases of support, unstable surfaces, functional reach, exercise with balls, and single-leg stance
223825628|NCT00706784|DRUG|Ethylvinyl Acetate (EVA) Vaginal Ring Delivery System|Ethylvinyl Acetate (EVA) Vaginal Ring Delivery System
223825629|NCT03222258|BEHAVIORAL|Early palliative care|Palliative Care Team provide a self-learning booklet, medical treatment and consultation about Advance Care Planning with chemotherapy by oncologist.
223825630|NCT03222258|BEHAVIORAL|Routine hospice care|Palliative Care Team provide a routine hospice care the same as other patients who doesn't participate this study after the chemotherapy is totally terminated
223825631|NCT04896125|DRUG|Lumigan PF; Xalatan|Lumigan PF: 0.03% bimatoprost (preservative-free) Xalatan: 0.005% latanoprost (containing 0.02% BAK as a preservative) All patients were instructed to use only the given study medication during the study period.
223825632|NCT01615575|PROCEDURE|Transanal haemorrhoidal dearterialisation|Closure of the arterial blood flow to the haemorrhoidal plexus, using a dedicated proctoscope with a Doppler probe, and a rectal mucopexy
223825633|NCT01615575|PROCEDURE|Stapler haemorrhoidopexy|Haemorrhoidopexy with a single dedicated circular stapling device (PPH 03, Ethicon Endo-Surgery, Ohio, USA).
223825634|NCT03125941|DRUG|Dexamethasone|pre-operative intravenous administration
223825635|NCT03176446|DEVICE|Local anesthesia with traditional technique|Puncture with short needle in the region of the apical third of the tooth to be anesthetized Injection of local anesthetic, with speed 1ml / min
223825636|NCT03176446|DEVICE|Local anesthesia with computerized technique|Puncture with short needle in the region of the apical third of the tooth to be anesthetized according to the recommendations of the manufacturer Injection of local anesthetic with computerized anesthesia equipment, with speed 0.5 ml / min
223825637|NCT03176446|DEVICE|Local anesthesia with DentalVibe technique|Use of DentalVibe in the apical region of the tooth to be anesthetized according to the manufacturer's guidelines Puncture with short needle enters the tips of the DentalVibe Injection of local anesthetic with traditional carpule, with speed 1 ml / min
223825638|NCT03176446|DRUG|Topic anesthesia|Application of topical anesthetic for 60 seconds with benzocaine
223825639|NCT03176446|DRUG|Local anesthetic|2% lidocaine with epinephrine 1: 100000 1.8 mL
223825640|NCT01619046|BIOLOGICAL|GreenGene™ F and an approved recombinant Factor VIII product|one 50 IU/kg, intra-venous infusion over 5 minutes, Infusion rate \< 10 mL/min
223825641|NCT01619046|BIOLOGICAL|GreenGene™ F|intra-venous infusion, 30 ± 5 IU/kg infusions 3 times per week with dose escalation to 45 ± 5 IU/kg if appropriate, for 50 exposure days
223825642|NCT01619046|BIOLOGICAL|GreenGene™ F|"intra-venous infusion,~On-demand safety and efficacy substudy:~minor bleed = 10-20 IU/kg moderate bleed = 15-30 IU/kg major bleed = 30-50 IU/kg"
223825643|NCT01619046|BIOLOGICAL|GreenGene™ F|"intra venous infusion,~Surgical substudy:~Minor surgery including tooth extraction = Post in fusion FVIII level of 60-100% of normal. A single bolus infusion (30-50 IU/kg) beginning within one hour of the operation. Optional additional dosing every 12 to 24 hours as needed to control bleeding.~Major surgery = Pre- and post infusion FVIII level 80-120% of normal. Preoperative bolus infusion: 40-60 IU/kg. Verified 100% activity prior to surgery. Maintenance bolus infusion (40-60 IU/kg) repeat infusions every 8 to 24 hours, depending on the desired level."
223825644|NCT01989559|BIOLOGICAL|gp100:209-217(210M) Peptide Vaccine|Given SC
223825645|NCT01989559|BIOLOGICAL|HPV 16 E7:12-20 Peptide Vaccine|Given SC
223825646|NCT01989559|OTHER|Laboratory Biomarker Analysis|Correlative studies
223825647|NCT03853317|BIOLOGICAL|Avelumab|For the treatment of adults and pediatric patients 12 years and older with Metastatic Merkel Cell Carcinoma (MCC).
223825648|NCT03853317|BIOLOGICAL|N-803|Recombinant human super agonist interleukin-15 (IL-15) complex
223825649|NCT03853317|BIOLOGICAL|haNK™|haNK™ for Infusion is a human, allogeneic, NK cell line that has been engineered to produce endogenous, intracellularly retained IL-2 and to express CD16, the high-affinity (158V) Fc gamma receptor (FcγRIIIa/CD16a).
223825650|NCT00131859|PROCEDURE|Diffusion-tensor imaging|Obtain a Diffusion tensor MRI of brain.
223825651|NCT01122004|DRUG|Pregabalin|
223825652|NCT01122004|DRUG|Pregabalin|
223825653|NCT05185518|DEVICE|Use of novel insulin injection port|use subcutaneous port into which glucose monitor is embedded
223825654|NCT02918240|PROCEDURE|Appointment intervals|
223825655|NCT02918240|DEVICE|fixed orthodontic braces|
223825656|NCT01710917|DRUG|Targinact® (oxycodon/naloxon)|
223825657|NCT05904860|OTHER|Backward Gait Training|Backward gait training will be provided within parallel bars, a mirror, and on a firm surface. The harness belt will be around the patient's torso to avoid sudden falls.
223825658|NCT05904860|OTHER|Forward Gait Training|Forward gait training will be provided within parallel bars, a mirror, and on a firm surface. The harness belt will be around the patient's torso to avoid sudden falls.
223825659|NCT04583683|BEHAVIORAL|Very low calorie diet with Fortimel (Nutricia) supplementation|Patients will undergo a very low calorie diet
223825660|NCT04583683|PROCEDURE|Metabolic Surgery|Patients will undergo metabolic surgery
223825661|NCT00195390|BIOLOGICAL|Prevenar|Prevenar 0.5ml/ Vial and PFS
223825662|NCT00111124|DRUG|Enbrel®|
223825663|NCT00779584|DRUG|MK-8776|IV infusion
223825664|NCT00779584|DRUG|Gemcitabine|IV infusion
223825665|NCT00084734|DRUG|capecitabine|Oral
223825666|NCT00084734|DRUG|cisplatin|IV
223825667|NCT00084734|DRUG|docetaxel|IV
223825668|NCT05032118|DRUG|Ketamine Hydrochloride|Titratable ketamine infusion + low fixed-dose propofol.
223825669|NCT05032118|DRUG|Propofol|Standard of care titratable propofol infusion.
223825670|NCT05425030|DIETARY_SUPPLEMENT|Low-Sodium Salt Substitute|Tata SuperLite low-sodium salt substitute has 30% of the weight of the product replaced with potassium chloride (KCl) which is itself a non-prescription dietary supplement. Each household randomized to the intervention arm will receive one bag (1.5kg) per month to utilize instead of their usual table/cooking salt.
223825671|NCT05425030|BEHAVIORAL|Information/Education|Community health workers will provide basic information on high blood pressure, the health consequences of excessive salt consumption, and feedback to the participant on the likely quantity of salt s/he consumes (estimated using a questionnaire)
223825672|NCT01896115|DEVICE|Vercise DBS settings|Deep brain stimulation set at short pulse width and monopolar stimulation using current steering
223825673|NCT04833101|BIOLOGICAL|recombinant Ad5 vectored COVID-19 vaccine|This vaccine contains 5×10\^10 virus particles of recombinant replication defective human type-5 adenovirus expressing SARS-CoV-2 S protein, which is produced by CanSino Biologics Inc. It is a liquid dosage form, 0.5 ml / bottle.
223825674|NCT04833101|BIOLOGICAL|RBD-based protein subunit vaccine (ZF2001) against COVID-19|This is a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19, made by using CHO cell, 25μg/dose, produced by Anhui Zhifei Longcom Biopharmaceutical Co.,Ltd.
223825675|NCT04833101|BIOLOGICAL|trivalent split influenza vaccine|This vaccine contains 15 μ g H1NI, 15 μ g H3N2 and 15 μ g B-series hemagglutinin, produced by Dalian Aleph Biomedical Co., Ltd.It is a liquid dosage form, 0.5 ml / bottle.
223825676|NCT02796287|PROCEDURE|achieving a neuropsychological examination in the acute amnesic phase|achieving a neuropsychological examination in the acute phase in addition to the normal protocole
223825677|NCT02796287|PROCEDURE|Neurological consultation with neuropsychological evaluation|Neurological consultation with neuropsychological evaluation one year after the acute amnesic phase
223825678|NCT02796287|RADIATION|MRI|Brain MRI with the same protocol or an acquisition time of 15 minutes without gadolinium, one year after the acute amesic phase
223825679|NCT01253122|DRUG|TRx0037|
223825680|NCT01086566|BIOLOGICAL|Influenza Virus Vaccine, Monovalent A/H5N1 A/Indonesia/05/2005|Inactivated monovalent subvirion H5N1 vaccine (HA of A/Indonesia/05/05) provided in unit-dose vials containing 0.5 mL of either 30 mcg/mL A/H5N1 HA or 180 mcg/mL A/H5N1 HA. Subjects will receive 1 of 2 dose levels of vaccine, 15 or 90 mcg.
223825681|NCT00406419|DRUG|Methotrexate|Methotrexate tablet was administered orally at a dose 7.5-25 mg
223825682|NCT00406419|DRUG|ocrelizumab|Ocrelizumab was administered via IV infusion at a dose specified in arm description
223825683|NCT00406419|DRUG|Placebo|Matching placebo to ocrelizumab was administered via IV infusion
223825684|NCT02467413|DRUG|BAC|(vapor fraction from seeds of Glycine max (L.) Merr. and composition thereof)
223825685|NCT02467413|OTHER|BAC Matched Vehicle|BAC Matched Vehicle
223825686|NCT03603015|DIAGNOSTIC_TEST|Penile cuff test|Comparison of invasive vs non-invasive urodynamics
223825687|NCT01280318|PROCEDURE|head and neck surgery|Blood Sample of biomakers at 3 days, 5 weeks and 3 months after surgery.
223825688|NCT00536068|DRUG|Acetylsalicylic acid, acetaminophen, diclofenac, naproxen, placebo|"1. Acetylsalicylic acid 100mg/po and acetaminophen 3x1g/po for 4 days~2. Acetylsalicylic acid 100mg/po and diclofenac 3x50mg/po for 4 days~3. Acetylsalicylic acid 100mg/po and naproxen 3x250mg/po for 4 days~4. Acetylsalicylic acid 100mg/po and placebo 3x1/po for 4 days"
223825689|NCT03122262|DRUG|Dolutegravir|DTG 50mg Oral Tablet once daily
223825690|NCT03122262|DRUG|Tenofovir Alafenamide|TAF/FTC 25/200mg Oral Tablet once daily
223825691|NCT03122262|DRUG|Truvada|
223825692|NCT03122262|DRUG|Atripla|
223825693|NCT04619342|DEVICE|GSMs-TACE|TACE using epirubicin (30-40mg/m2) and gelatin sponge microspheres (150-350μm or 350-560μm)
223825694|NCT04619342|PROCEDURE|Surgical Resection|Surgical Resection of PVTT
223825695|NCT02878213|DEVICE|D700 System|Atrial Fibrillation Ablation Procedure
223825696|NCT04887181|OTHER|Teethmate Desensitizer|Powder and liquid contained in the material were mixed. It was applied to the buccal surface of the sensitive tooth. then it was washed away from the tooth surface. 1-4 sessions were applied until the sensitivity disappeared.
223825697|NCT04887181|OTHER|Gluma Desensitizer|The material was applied to the buccal surface of the tooth with sensitivity. It was washed with water and removed from the tooth surface. 1-4 sessions were applied until the sensitivity disappeared.
223825698|NCT04887181|OTHER|Hybrid Bond|It was applied to the buccal surface of the sensitive tooth with an applicator. It was cured with a LED light device. Dentin sensitivity was checked with evaporative air application. The process was repeated until the sensitivity disappeared.
223825699|NCT04786522|DIAGNOSTIC_TEST|Bioimpedenziometry, Handgrip strenght evaluation|The measurement of body composition was performed using Bioimpedance (BIA 101, Akern srl, Pontassieve (FI), Italy). The handgrip dynamometer (Jamar, Sammons Preston, Bolingbrook, IL, USA) was used to determine the isometric force of the forearm.
223825700|NCT04786522|DIAGNOSTIC_TEST|Evaluation on blood specimens|Serum samples were assayed for calcium, phosphorus, magnesium, iron, lactate dehydrogenase (Ldh), creatine phosphokinase (Cpk), creatine kinase myocardial band (Ckmmb), myoglobin, thyroid stimulating hormone (TSH), 25(OH)-Vitamin D, osteocalcin, bone alkaline phosphatase (b-ALP), C-terminal telopeptide of type I collagen (CTX-I), haptoglobin, sclerostin, myostatin, and Irisin. Irisin serum concentrations were detected using a competitive ELISA kit (AdipoGen, Liestal, Switzerland)
223825701|NCT00264472|DRUG|ADH300004|5 mg
223825702|NCT05542732|DEVICE|CardioWatch 287-2|CardioWatch 287-2 (CW2 Test Device or CW2). This medical device is based on the precursor CardioWatch 287-1 approved by EU-MDR under number 20M00011CRT01, CW2 has two red, two infrared and two green LEDs, and two photosensors compared to its precursor.
223825703|NCT05083624|BEHAVIORAL|rehabilation therapy|After comprehensive assessment by doctors, nurses and rehabilitation therapists, patients gradually begin rehabilitation treatment.IMS 0: no mobilisation or passively exercised by staff. IMS 1: sitting in bed and actively exercising .IMS 2: passively moved to chair without standing.IMS 3: sitting over edge of bed.IMS 4: standing in front of bed.IMS 5: transferring bed to chair.IMS 6: marching on spot.IMS 7: walking with assistance of more than one person.IMS 8: walking with assistance of one person.IMS 9: walking independently with a gait aid.IMS 10: walking independently without a gait aid.
223825704|NCT00974519|DRUG|Fuzheng 3|"Immunity 3 (Fuzheng 3), 8.75g / twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days.~Immunity 1 (Fuzheng 1) simulation agent, 8.75g / twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days."
223825705|NCT00974519|DRUG|Fuzheng 1|"Immunity 1 (Fuzheng 1), 8.75g / twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days.~Immunity 3 (Fuzheng 3) simulation agent, 8.75g / twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days."
223825706|NCT00974519|DRUG|Placebo|"Immunity 1 (Fuzheng 1) simulation agent, 8.75g / twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days.~Immunity 3 (Fuzheng 3) simulation agent, 8.75g / twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days."
223825707|NCT00886262|DRUG|Vasopressin|Patients randomly assigned to the experimental arm of the study will receive vasopressin 0.5U/hr IV (20 U vasopressin in 250mL of 0.9% NaCL to infuse at a rate of 6.25mL/hr) via internal jugular catheter. Vasopressin infusion is started at the time of incision and is stopped at the time abdominal closure is completed
223825708|NCT00886262|DRUG|Normal saline placebo|Patients randomly assigned to the placebo arm of the study will receive placebo (0.9% NaCl to infuse at a rate of 6.25 mL/hr) via internal jugular catheter
223825709|NCT03713372|DRUG|Anti-EGFR monoclonal antibody|Initially, 6.0mg/kg of SCT200 will be administered once a week for a maximum of 6 cycles. After 6 cycles, 8.0mg/kg of SCT200 will be administered every two weeks until disease progression.
223825710|NCT05477706|OTHER|Personalized Support for Progress (PSP)|Personalized Support for Progress (PSP) is a Peer Specialist delivered intervention in which a peer supports Veterans in prioritizing their needs and attaining access to the Veterans' preferred services.
223825711|NCT05477706|OTHER|Tailored Referral (TR)|TR consists of detailed resource information and referral, consistent with standard practice.
223825712|NCT01610232|DEVICE|Photon stimulation by light-emitting diodes (LEDs)|Treadmill training with the application of the phototherapy was performed twice a week for 6 months, each session lasting 45 min at intensities between 85% and 90% maximal heart rate. The average power and power density on the skin were 100 mW and 39 mW/cm2, respectively. The treatment time was 45 min bilaterally in both thighs. These parameters led to an approximate fluence of 108 J/cm2.
223825713|NCT01610232|OTHER|Treadmill training|Treadmill training without the application of the phototherapy was performed twice a week for 6 months, each session lasting 45 min at intensities between 85% and 90% maximal heart rate
223825714|NCT06475716|BEHAVIORAL|Internet-based guided programme Spring|Spring is an online guided self-help programme based on the principles of trauma-focused cognitive behavioral therapy and consists of 8 steps designed for delivery over 8 weeks. The steps cover psychoeducation, grounding techniques, management of anxiety, behavioral activation, imaginal exposure, cognitive restructuring, in vivo exposure, and prevention of relapse. The user of the programme also receives up to 3 hours of therapist guidance.
223825715|NCT05164497|OTHER|Deliberate practice training|"The experimental condition consists of five weeks of deliberate practice training of non-specific psychotherapy skills organized as (1) classroom training and (2) homework. The classroom training consists of 15 hours (5 days x 3 hours) of deliberate practice training. Each day will be organized around a theme: (a) Empathy, (b) establishing the therapeutic alliance, (c) working with alliance ruptures, (d) formulation of an interpersonal focus, and (e) clinical expertise - a synthesis. The training will include theoretical introductions, students defining individual training goals, model responses of good psychotherapeutic skills, and student role-play. Regarding homework, after each of the five classes, the students will use Theravue to watch and respond to three therapy videos related to the theme of the previous class. The students have to deliver at least two new responses to each video informed by feedback from teachers and peers and a checklist describing a good response."
223825716|NCT05164497|OTHER|Theoretical teaching|The control condition will consist of five weeks of theoretical teaching of non-specific psychotherapy skills performed as (1) classroom teaching and (2) homework. Regarding classroom teaching, the 15 hours (5 days x 3 hours) of teaching will be organized around the same five themes as the experimental condition (see points a-d above). The class will consist of the teacher's presentation of theory and research findings, videos with master therapists defining core concepts, and group discussions of literature. Regarding homework, the participants will read literature and use a restricted version of Theravue to complete home assignments where they record their answers to three theoretical questions related to the theme of the preceding classroom teaching.
223825717|NCT03343405|BEHAVIORAL|Online Mind/Body Program for Fertility|The Mind/Body intervention involves (1) reducing physical symptoms of stress, (2) enhancing lifestyle behaviors related to fertility, (4) self-nurturing and coping skills, and (5) relaxation methods.
223825718|NCT03716622|DRUG|Furazolidone|bismuth-furazolidone-containing quadruple regimens
223825719|NCT03716622|DRUG|Clarithromycin|bismuth-clarithromycin-containing quadruple regimens
223825720|NCT04070053|OTHER|TheraPPP Pathway|"TheraPPP Steps:~Step 1. All mechanically ventilated patients will have a height measured and documented. Step 2. Screening for HRF. Step 3. Initiate Lung Protective Ventilation (LPV). Step 4. Paralysis. Step 5. Prone Positioning."
223825721|NCT05771584|DRUG|AST-301|100 μg
223825722|NCT05771584|DRUG|rhuGM-CSF|100 μg
223825723|NCT06023355|PROCEDURE|HYBRID|It involves the combination of a sternal sparing left internal mammary artery (LIMA) bypass and percutaneous coronary intervention (PCI) with drug-eluting stents (DES) for non-left anterior descending (LAD) lesions. Through minimally invasive surgical techniques, HCR carries the potential for faster recovery postoperatively, fewer in-hospital complications, and lower utilization of healthcare resources, while providing the key benefits of LIMA-LAD grafting.
223825724|NCT04263090|DRUG|Rigosertib|Rigosertib will be dosed twice a day for 21 consecutive days, followed by 7 days off treatment (each cycle duration: 28 days). Rigosertib escalation will occur with three dose levels (dose D1: 280mg twice daily; dose D2: 560mg qAM, 280mg qPM; dose D3: 560mg twice daily).
223825725|NCT04263090|DRUG|Nivolumab|Nivolumab will be dosed once ever 2 weeks (twice per 28-day cycle; standard fixed dose of 240mg).
223825726|NCT01790321|DEVICE|LSF-filtering device|LifeStraw Family is a water purification device that by means of hollow fibres removes solid particles (\<0.5 NTU turbidity reduction), bacteria (\>Log 6 reduction), viruses (\>Log 4 reduction) and cysts (\>Log 3 reduction). Zinc fortification is provided by a chamber housing a zinc releasing glass-plate that is placed annexed to the hollow fibre column. It is estimated that the LSF can provide about 5 mg of zinc/l of filtered water. By consuming daily a portion of 0.6 litres of enriched water, \>100% of the age-specific estimated physiologic requirement would be covered, assuming a fractional absorption of 40%.
223825727|NCT02498730|BEHAVIORAL|Interval Training|High Intensity Interval Training at 100% VO2Max
223825728|NCT02498730|BEHAVIORAL|Continuous Training|Continuous Stimulous at 60% VO2Max
223825729|NCT02498730|BEHAVIORAL|Control|Only Dependent Variables Measures
223825730|NCT02660762|DRUG|Vincristine|induction therapy I：1.4 mg/m2 IV d1, 8, 15, 22； consolidation therapy(Cycle 1)：1.4 mg/m2 IV d1, 8, 15, 22； Maintenance therapy: 1.4 mg/m2 intravenously every 3 months for a total of 2.5 years
223825731|NCT02660762|DRUG|Daunorubicin|induction therapy I：60 mg/m2 IV d1, 8, 15, 22； consolidation therapy(Cycle 3)：25 mg/m2 IV d1, 8, 15, 22；
223825732|NCT02660762|DRUG|Pegaspargase|induction therapy I: 2500U/m2,im,d8,22 Intensification therapy:2500U/m2 im, d2,23 consolidation therapy(Cycle 2，4)：2500U/m2 im, d1
223825733|NCT02660762|DRUG|Prednisone|induction therapy I：60 mg/m2 PO d1-28; Maintenance therapy:prednisone 60 mg/m2 orally for 5 days every 3 months for a total of 2.5 years
223825734|NCT02660762|DRUG|Intrathecal Methotrexate|induction therapy I：12.5 mg IT d15 induction therapy II：12.5 mg IT d1, 8, 15, 22
223825735|NCT02660762|DRUG|Cyclophosphamide|induction therapy II:650 mg/m2 IV d1, 15, 29 consolidation therapy(Cycle 3)：650 mg/m2 IV，d29
223825736|NCT02660762|DRUG|Cytarabine|induction therapy II:75 mg/m2 IV d1-4, 8-11, 15-18, 22-25 consolidation therapy(Cycle 1，2，4)：75 mg/m2 intravenously on days 1 to 5 consolidation therapy(Cycle 3):75 mg/m2 intravenously on days 31 to 34 and 38 to 41
223825737|NCT02660762|DRUG|6-Mercaptopurine|induction therapy II:60 mg/m2 PO d1-28 Maintenance therapy:75 mg/m2 orally each day for a total of 2.5 years
223825738|NCT02660762|DRUG|Methotrexate|Intensification therapy:3 g/m2 intravenously given on days 1, 8, and 22 Maintenance therapy:20 mg/m2 orally or intravenously once a week for a total of 2.5 years.
223825739|NCT02660762|DRUG|Etoposide|consolidation therapy(Cycle 1，2，4)：100 mg/m2 intravenously on days 1 to 5
223825740|NCT02660762|DRUG|dexamethasone|consolidation therapy(Cycle 1)：10mg/m2 orally on days 1 to 28
223825741|NCT02660762|DRUG|thioguanine|consolidation therapy(Cycle 3): 60 mg/m2 orally on days 29 to 42
223825742|NCT02660762|DRUG|intrathecal cytarabine|50 mg intrathecal cytarabine was given on 4 occasions 3 months apart during maintenance therapy.
223825743|NCT01245868|DRUG|Lidocaine|
223825744|NCT01245868|DRUG|bupivacaine|
223825745|NCT02926508|DIETARY_SUPPLEMENT|Bimuno (BGOS)|"The active supplement of the food supplement (Bimuno) used in this study is called galacto-oliogosaccharides (Bimuno®, BGOS). BGOS is a compound metabolised by specific bifidobacteria, which are beneficial bacteria, in our colon. Bimuno (2.3 calories) is composed by the following ingredients per gram of Bimuno: 0.96g dry matter; \<01g Fat; \<0.06g Protein; 0.821g GOS; 0.119g Lactose; 0.0331g Glucose and 0.0029g Galactose. Bimuno is tasteless.~Bimuno will be supplied in coded sachets (3.5g) for dispensing by parents. Each participant will be required to consume 1 sachet daily during breakfast, by mixing it with food or in a drink."
223825746|NCT02926508|OTHER|Maltodextrin|"Maltodextrin is a polysaccharide in powder form, which grows most bacteria in the gut, and not specifically the beneficial bifidobacteria.~The placebo will also be provided in daily coded sachets (3.5g) for dispensing by parents. Each participant will be required to consume 1 sachet daily during breakfast, by mixing it with food or in a drink.~This placebo has been used in previous studies, in which Bimuno was used as the active intervention. The placebo will be similar in taste and colour to the active intervention."
223825747|NCT03143335|PROCEDURE|Retropectoral immediate breast reconstruction|Immediate reconstruction with the implant placed in a standard fashion, i.e. retropectoral in combination with an acellular dermal matrix.
223825748|NCT03143335|PROCEDURE|Prepectoral immediate breast reconstruction|Immediate breast reconstruction with the implant placed prepectoral supported by acellular dermal matrix alone.
223825749|NCT03411889|DIAGNOSTIC_TEST|MRI scanning|MRI scanning during tear drainage
223825750|NCT02626702|OTHER|Observational|Excess blood from subjects will be analyzed to explore the relationship between Immune Modulators and IVF outcomes.
223825751|NCT02302066|BIOLOGICAL|Takeda's Tetravalent Dengue Vaccine Candidate (TDV)|TDV subcutaneous injection
223825752|NCT02302066|BIOLOGICAL|TDV Placebo|Placebo-matching vaccine
223825753|NCT06480799|DIETARY_SUPPLEMENT|Fibre intervention|Inulin fibre (5g) and Pectin fibre (15g) was randomly allocated to eligible participants in order to test specific effects on gut microbiome composition and metabolic markers.
223825754|NCT06480799|DIETARY_SUPPLEMENT|Placebo intervention|Maltodextrin (10g) served as a control/ placebo to compare the effects observed with inulin and pectin.
223825755|NCT04844437|DIAGNOSTIC_TEST|Transperineal ultrasound|The fetal head station is evaluated by transperineal ultrasonography in valsalva.
223825756|NCT05115409|DRUG|Anti-PD-1 Antibody Plus Chidamide and Rituximab|Anti-PD-1 Antibody 200mg, ivd, D1, every 3 weeks Chidamide 30mg, po,D-1, 4, 8, 11, 15, 18, every 3 weeks Rituximab 375mg/m2, ivd, D1, every 3 weeks
223825757|NCT01569035|DRUG|warfarin|3 mg warfarin oral tablet for 2 to 3 weeks
223825758|NCT03492892|DEVICE|Acupuncture|Stimulate acupoint with filiform needles to restore the healthy condition of patients
223825759|NCT03492892|DEVICE|Sham Acupuncture|Stimulate non-acupoint with filiform needles to treat the condition of patients
223825760|NCT04707339|PROCEDURE|Appendicectomy|Laparoscopic or Open Appendicectomy
223825761|NCT03510624|DRUG|Rebaudioside A|Rebaudioside A 3g
223825762|NCT03510624|DRUG|Placebo|Empty capsules
223825763|NCT05982704|DRUG|tixagevimab/cilgavimab 150+150 mg|Administration of tixagevimab/cilgavimab at a dose of 150+150 mg in patients with moderate/severe coronavirus infection.
223825764|NCT05982704|DRUG|tixagevimab/cilgavimab 300+300 mg|Administration of tixagevimab/cilgavimab at a dose of 300+300 mg in patients with moderate/severe coronavirus infection.
223825765|NCT05982704|DRUG|regdanvimab|Administration of regdanvimab at a dose of 40 mg/kg body weight in patients with moderate/severe coronavirus infection.
223825766|NCT05024422|DRUG|Cabergoline|Administration of Cabergoline (one dose of 1mg, up to 24 hours postpartum, or 0.25 mg twice a day for two days)
223825767|NCT05024422|DRUG|Pyridoxine|Administration of Pyridoxine (200 mg X 3 per day for a week)
223825768|NCT02122653|OTHER|Weight training|Participants will perform 4 weeks of Weight training for lower extremities.
223825769|NCT02122653|DEVICE|Electronic muscle stimulator|Participants will perform 4 weeks of electrical stimulation for Quadriceps muscle belly.
223825770|NCT00628914|DRUG|escitalopram and eszopiclone|escitalopram 10mg tabs QD and eszopiclone 3 mg tabs QD for 8 weeks
223825771|NCT00628914|DRUG|Escitalopram, eszopiclone, and placebo|Escitalopram 10mg tabs QD for 8 weeks; Eszopiclone 3mg tabs QD for initial 4 weeks then placebo tabs QD for final 4 weeks
223825772|NCT00628914|DRUG|Escitalopram|Escitalopram 10mg tabs QD and placebo tabs QD for 8 weeks
223825773|NCT02698449|PROCEDURE|transcranial direct current stimulation|intensity provided will be 2 milliampere during 20 minutes using 2 electrodes (7x5cm). Anode electrode will be located on the right prefrontal dorsolateral area; cathode electrode will be located on the left supraorbital area.
223825774|NCT02698449|PROCEDURE|Specific cognitive rehabilitation|Specific cognitive rehabilitation will be personalized regarding the cognitive complaint and will include a training part and an ecological part.
223825775|NCT02698449|PROCEDURE|Nonspecific cognitive rehabilitation|Nonspecific cognitive rehabilitation will be focused on representation of body in space.
223825776|NCT02698449|PROCEDURE|transcranial direct current stimulation sham|the same operation that transcranial direct current stimulating but it is a sham surgery
223825777|NCT02698449|RADIATION|functional Magnetic Resonance Imaging n-back task|the n-back cognitive task was developed : 3 runs will be provided (0-back, 1-back and 2-back), each will be composed of 8 activation blocks and 8 resting blocks alternatively presented.
223825778|NCT04612816|OTHER|Prehospital ultrasound|Feasibility of real time PEU transmission in a university affiliated preclinical emergency system.
223825779|NCT04732429|DRUG|HST5040|Liquid solution
223825780|NCT04732429|DRUG|Placebo|Liquid solution
223825781|NCT02875834|DRUG|Sodium Zirconium Cyclosilicate (ZS) 10g|Suspension administered 10g orally three times per day, in the first 48-hour of the study for all patients (48-hour open label initial phase)
223825782|NCT02875834|DRUG|Sodium Zirconium Cyclosilicate (ZS) 5g|Suspension administered 5g orally once daily for 28 days after the first 48-hour open label initial phase.
223825783|NCT02875834|DRUG|Sodium Zirconium Cyclosilicate (ZS) 10g|Suspension administered 10g orally once daily for 28 days after the first 48-hour open label initial phase.
223825784|NCT02875834|DRUG|Placebo|Suspension administered orally placebo once daily for 28 days after the first 48-hour open label initial phase.
223825785|NCT05893680|OTHER|Group to play online games|Playing games in children is one of the non-pharmacological pain relief methods. In this study, the effect of playing an online game on pain level in children who underwent orthopedic surgery for pain management after the surgery was measured.
223825786|NCT05893680|OTHER|Group that received cold application|Previous studies have demonstrated that cold application has anti-inflammatory, muscle spasm reducing, and pain relieving properties. In this study, the effect of cold application on pain level in children who underwent orthopedic surgery was investigated.
223825787|NCT05893680|DRUG|Group that received placebo (PHYSIOLOGICAL SALINE ISOTONIC 9 mg/ml AMPULE)|The placebo effect has been demonstrated in various studies today. Some of these studies describe placebo analgesia. In this study, the placebo analgesic effect was investigated, and the child and parent were told that an analgesic was applied, but instead 2 cc of PF 0.9% ISOTONIC SODIUM CHLORIDE solution was intravenously administered.
223825788|NCT05893680|OTHER|Group that played an online game and received cold application at the same time|To investigate the combined effect of online gaming and cold application as two separate non-pharmacological interventions, both interventions were applied together in this group
223825789|NCT01032044|DEVICE|Standard endoscopic evaluation|Treatment modalities can include endoscopic mucosal resection, radio-frequency ablation or photodynamic therapy
223835570|NCT05158257|DEVICE|endovascular debulking and DCB|endovascular debulking combined drug-coated balloon
223825790|NCT01032044|DEVICE|pCLE guided evaluation|Treatment modalities include endoscopic mucosal resection, radio-frequency ablation, or photodynamic therapy. probe-based Confocal Laser Endomicroscopy is used to decide on re-treatment or not, and to guide and evaluate the treatment during the same endoscopic procedure.
223825791|NCT03317028|DRUG|CS02 tablet and placebo tablet|Subjects receive CS02 tablet or placebo tablet BID daily with a stable dose of metformin monotherapy of ≥ 1500 mg/day for 12 weeks treatment.
223825792|NCT03311230|BEHAVIORAL|Supportive social incentive|A family member or friend will be used as a support person in this study, to receive updates and support the participant in their progress.
223825793|NCT03311230|BEHAVIORAL|Competitive social incentive|Participants in this intervention will be competing against each other in the game.
223825794|NCT03311230|BEHAVIORAL|Collaborative social incentive|Participants in this intervention will be working with each other in the game.
223825795|NCT02973555|OTHER|PRP injection|autologous intrauterine infusion of PRP
223825796|NCT03342053|DRUG|RO7234292 (RG6042)|Intrathecal injection
223825797|NCT01695733|BIOLOGICAL|trivalent influenza vaccine|
223825798|NCT01302938|DRUG|Tolterodine ER|One 4 mg capsule will be taken with water every day with or without food. It should be swallowed whole without chewing.
223825799|NCT01302938|DRUG|Placebo|A placebo of Tolterodine ER 4 mg will be taken with water every day with or without food. It should be swallowed whole without chewing.
223825800|NCT00957164|BEHAVIORAL|Brief Prolonged Exposure Protocol|The PTSD treatment used in this study is an adaptation of a brief Prolonged Exposure treatment protocol for PTSD as illustrated in a 2005 paper published by Cigrang, Peterson, and Schobitz 54 in which a 4-session prolonged exposure treatment was used to address PTSD symptoms in three injured soldiers recently exposed to trauma. The authors found a 50+% decrease in PTSD symptoms after these four sessions. The present study will rely upon a similar brief PTSD intervention for treating chronic PTSD among trauma-exposed injured active duty service members. The PTSD intervention will be expanded into five sessions over 5 weeks to include an initial session for assessment and education on the co-morbidity of pain and PTSD. All PTSD treatment will be provided under the direct care or supervision of a Master Trained therapist in Prolonged Exposure.
223825801|NCT00957164|BEHAVIORAL|Chronic Pain Management Treatment|Pain treatment will involve five-sessions over 5 weeks of individual treatment protocol based on the existing chronic pain management program through the Clinical Health Psychology Service at Wilford Hall Medical Center. This treatment will involve covering the difference between chronic and acute pain, the role of cognitive, behavioral, and emotional variables in pain progression, and ways to manage these variables to prevent the development of chronic pain.
223825802|NCT00957164|BEHAVIORAL|Self-Care|participants randomized to either the Pain-only or PTSD-only groups will receive five sessions of pain- or PTSD-specific treatment followed by five sessions of self-care placebo over 5 weeks. The self-care module will be manualized for reliability and fidelity between providers and will involve 60-minute sessions covering various topics.
223825803|NCT02057003|DRUG|DAA against HCV|
223825804|NCT03696719|DEVICE|BIS bispectral index monitoring device|In addition to the standard monitoring prescribed by the American society of Anesthesiologists, all study participants will be monitored with the BIS, a noninvasive monitoring device which measures the depth of anesthesia. The monitoring is performed using noninvasive electrodes placed on the forehead.
223825805|NCT03696719|BIOLOGICAL|NSE cerebral biomarker testing|Venous blood will be collected from each participant in the surgery room prior to anesthesia induction, throughout anesthesia and one hour following surgery in the PACU in order to assess NSE cerebral biomarker according to the ELISA method requirements. At each one of the assessment points 9 cc of venous of blood will be taken from each of the study participants, while routine blood tests are taken.
223825806|NCT05884229|OTHER|Intra-operative analgesia guided by SPI|In the SPI-guided group, when SPI is higher than 50 for the first time and for more than 3 minutes, we will administer 1,0 μg/kg of fentanyl LBW. When SPI is again higher than 50 and for more than 5 minutes, we will re-administer 1,0 μg/kg of fentanyl LBW. We will repeat until SPI is between 20-50.
223825807|NCT01233609|DRUG|Valproic Acid|One to four 250mg softgels by mouth daily (dose determined by body weight)
223825808|NCT01233609|DRUG|Placebo|Dosage per subject weight- same schedule as the active comparator
223825809|NCT04904081|DRUG|Indocyanine green|The ICG group will involve the patient receiving standard care for either HD or ARM, in addition to 1.25mg (maximum dose less than 2mg/kg body weight) of ICG intraoperatively, administered intravenously. ICG will be administered by a member of the anesthesia team when directed by the surgeon (research team member).
223825810|NCT01115543|DRUG|alfacalcidol and calcitriol|The initial dose of alfacalcidol was twice that of calcitriol.Both were adjusted to control intact PTH within the ranges of 150-300 pg/ml.
223825811|NCT05505253|DRUG|Alfacalcidol 0.0005 MG|Alfacalcidol 0.5 mcg is given orally for 3 months, then vitamin D3 and vitamin D receptor levels are measured
223825812|NCT05505253|DRUG|Placebo|Placebo drug is given orally for 3 months, then vitamin D3 and vitamin D receptor levels are measured
223825813|NCT02319733|DEVICE|Bioresorbable vascular scaffold|Implantation of Bioresorbable vascular scaffold in vulnerable plaques
223825814|NCT05031676|OTHER|opioid free anesthesia|Maintenance of anesthesia was done with halothane. The incision was allowed at 1.2 MAC of halothane. This halogen was administered according to the hemodynamic parameters and the habits of the anesthesia team. Before waking up, all the patients benefited from preventive analgesia with 1 g paracetamol combined with 20 mg nefopam by slow intravenous injection over approximately 15 minutes.
223825815|NCT04398615|DEVICE|Wearable watch device|Every study participant will be given a wearable watch device at the beginning of the study and will be instructed on how to use the device and to wear it continuously throughout the duration of the study (6 months total follow-up). The device will register biometric data and automatically archived. During the follow-up period both healthcare personnel and investigators will not be aware of data (including fall events) registered by the experimental device.
223825816|NCT01067027|DIETARY_SUPPLEMENT|Lactobacillus reuteri|5 drops of study product 30 minutes before feeding.
223825817|NCT03881930|OTHER|Balance rehabilitation with modified visual input|Patients will perform the exercises alternatively: while keeping their eyes closed or their vision will be obstructed by a opaque mask or disturbed by moving luminous dots projected on the environment in a dark room without any visual reference cues.
223825818|NCT03881930|OTHER|Balance rehabilitation with no modified visual input|Patients will perform the exercises while keeping their eyes openned
223825819|NCT00230139|DEVICE|SPECT/CT|
223825820|NCT03545373|DRUG|Azithromycin|Azithromycin tablet taken orally
223825821|NCT03545373|DRUG|Amoxicillin|Amoxicillin tablets taken orally
223825822|NCT04453241|BIOLOGICAL|NBP615|Intramuscular injection, 0.5ml
223825823|NCT04453241|BIOLOGICAL|Gardasil|Intramuscular injection, 0.5ml
223825824|NCT00204126|DEVICE|Treadmill with partial body weight support|
223825825|NCT00204126|DEVICE|Surface Functional Electrical Stimulation|
223825826|NCT02069574|PROCEDURE|non-surgical periodontal therapy|
223825827|NCT03265990|PROCEDURE|ligasure haemroidectomy|In ligasure group,After the haemorrhoids are prolapsed out from the anal canal with an artery forceps,Ligasure haemorrhoidectomy will be performed by applying the ligasure forceps close to the edge of each pile.Repeated applications of the device will be performed and excision will be continued into the anal canal,lifting the pile from the internal anal sphincter,to the level of the vascular pedicle,which will be finally divided.
223825828|NCT03265990|PROCEDURE|Conventional haemorrhoidectomy|"According to the Ferguson technique~* Manual anal sphincter stretching up to 4 fingers~* Delivery of hemorrhoidal masses with artery forceps,one being applied at the base of haemorrhoid,the other at the apex.~* skin incision at the base of haemorrhoids and submucosal dissection to lift the haemorrhoid mass off the internal sphincter.~After this the haemorrhoid pedicle will be transfixed and the mucosal edges of the defect will be opposed."
223825829|NCT02961374|DRUG|Erlotinib|Given PO
223825830|NCT02961374|DRUG|Erlotinib Hydrochloride|Given PO
223825831|NCT03178513|OTHER|Home visit|"The visit will be entirely patient tailored, last approximately one hour, and at a minimum will entail:~* Medical assessment~* Psychosocial assessment~* Medication reconciliation~* Follow-up of inpatient primary team's specific recommendations~* Follow-up, as needed, with primary care team or inpatient team"
223825832|NCT03835936|OTHER|High frequency compression of the chest wall group|The protocol in the high frequency compression of the chest wall group device consists of the Smart Vest® application, with a fixed frequency of 13 Hz and a time of 15 minutes. The selected mode will be the normal (fixed parameters) and the pressure of 4 units (12 cm H2O). The patient remains seated on his parents, and with a cotton garment between the vest and the skin of the patient to prevent skin lesions.
223835571|NCT01163149|DRUG|asfotase alfa|Cohort 1: Daily SC injections of 0.3 mg/kg asfotase alfa (total of 2.1 mg/kg/week)
223835572|NCT01163149|DRUG|asfotase alfa|Cohort 2: Daily SC injections of 0.5 mg/kg Asfotase Alfa (3.5 mg/kg/week total)
223825833|NCT03835936|OTHER|Manual maneuvers physiotherapy group|20 minutes of manual maneuvers physiotherapy based on prolonged slow expiration: passive technique of expiratory help applied to the baby through a slow thoracic-abdominal pressure that begins at the end of spontaneous expiration and continues to the residual volume. The physiotherapist through the cough provoked or stimulation of the trachea gets expectoration of sputum, to be able to assess its weight.
223825834|NCT03386955|DRUG|BPI-7711 Capsule|Phase I: BPI-7711 capsule(30mg, 60mg, 120mg, 180mg, 240mg...) Phase IIa: BPI-7711 capsule(with recommend phase II dose)
223825835|NCT02291484|DEVICE|Cardiac CT scan|CT-guided management
223825836|NCT04670003|OTHER|users|Data of users of the web-application
223825837|NCT05727943|DRUG|Clioquinol|add on clioquinol to concomitant ASM
223825838|NCT00735644|BIOLOGICAL|Japanese encephalitis vaccine|0.5 mL, Subcutaneous
223825839|NCT00735644|BIOLOGICAL|Japanese encephalitis vaccine|0.5 mL, Subcutaneous
223825840|NCT00735644|BIOLOGICAL|Japanese encephalitis vaccine|0.5 mL, Subcutaneous
223825841|NCT00735644|BIOLOGICAL|Japanese encephalitis vaccine (Acambis)|0.5 mL, Subcutaneous
223825842|NCT00735644|BIOLOGICAL|Hepatitis A vaccine|0.5 mL, Intramuscular
223825843|NCT03664219|OTHER|isolation of IAN from implant with collagen membrane|comparing between the neurosensory disturbances with and without isolation of the inferior alveolar nerve from implant
223825844|NCT00003344|DRUG|irinotecan hydrochloride|
223825845|NCT00003344|RADIATION|radiation therapy|
223825846|NCT05815901|DRUG|Epaminurad 6 mg|Epaminurad 6 mg tablet
223825847|NCT05815901|DRUG|Epaminurad 9 mg|Epaminurad 9 mg tablet
223825848|NCT05815901|DRUG|Febuxostat 40 mg|Febuxostat 40 mg tablet
223825849|NCT05815901|DRUG|Febuxostat 80 mg|Febuxostat 80 mg tablet
223825850|NCT05815901|DRUG|Epaminurad 6 mg placebo|Placebo tablet
223825851|NCT05815901|DRUG|Epaminurad 9 mg placebo|Placebo tablet
223825852|NCT05815901|DRUG|Febuxostat 40 mg placebo|Placebo tablet
223825853|NCT05815901|DRUG|Febuxostat 80 mg placebo|Placebo tablet
223825854|NCT00002536|DRUG|cisplatin|
223825855|NCT00002536|DRUG|vincristine sulfate|
223825856|NCT00002536|PROCEDURE|surgical procedure|
223825857|NCT00002536|RADIATION|radiation therapy|
223825858|NCT04032379|OTHER|Standard treatment|No intervention, some patients have additional neuro-psychological testing.
223825859|NCT03966612|OTHER|Questionnaires|"Questionnaires about:~* Socio-professional situation~* Lifestyle~* Health~* NME 1~* specific breast cancer survey~* Imaging"
223825860|NCT01586312|OTHER|Allogenic mesenchymal stromal cells injection|Mesenchymal stem cells prepared from bone marrow of healthy donors and expanded for 3-4 weeks according to our procedure described in PEI Num. 10-134, authorized by the Spanish Medicine Agency
223825861|NCT01586312|DRUG|Hyaluronic Acid|Intra-articular injection of 60 mg of hyaluronic acid (Durolane) in a single injection (3 ml)
223825862|NCT01639794|DRUG|Vesitirim™ (Solifenacin)|Oral
223825863|NCT00119990|DRUG|Icodextrin (dialysate)|2 liter of extraneal are given with one fill for 4 hours.
223825864|NCT00119990|DRUG|Physioneal (dialysate) 1.36% and 2.27%|2 liter of Physioneal of 1.36% or 3.86% are given with one fill for 4 hours one two different days.
223825865|NCT01325649|PROCEDURE|total mesorectal excision / long course radiochemotherapy|long course 5-FU based radiochemotherapy before total mesorectal excision
223825866|NCT01325649|RADIATION|long course 5-FU bases radiochemotherapy|
223825867|NCT02587559|PROCEDURE|physical therapy|application of manual therapy techniques to upper extremity along with therapeutic exercise procedures to the axioscapular and rotator cuff musculature
223825868|NCT00296387|DRUG|Rosuvastatin|
223825869|NCT00296387|DRUG|Atorvastatin|
223825870|NCT05126043|DIAGNOSTIC_TEST|Triglycerides/high density lipoprotein ratio|Lipid profile
223825871|NCT05096468|DRUG|S-ketamine and pregabalin|"* Drug: Pregabalin~* 150mg (2hrs) pre operatively and 75mg twice daily post operatively for 7 days(POD1-7), followed by dose reduction to 75mg once daily for 7 days(POD8-14)~* Drug: S-ketamine infusion~* 0.5 mg/kg bolus after induction of anesthesia +0.12 mg/kg/h continuous intravenous infusion for 48 h"
223825872|NCT05096468|DRUG|Normal saline and placebo capsule|"* Drug: Placebo capsules~* Two placebo capsules (2hrs) preoperatively and twice daily post operatively for 7days, followed by dose reduction to single capsule once daily for 7days~* Drug: Normal saline~* 0.9% saline bolus after induction of anesthesia + intravenous infusion for 48 hours"
223825873|NCT01068301|DRUG|Plerixafor|Plerixafor in combination with fludarabine, thiotepa and melphalan as a conditioning regimen for patients undergoing a second allogeneic transplant procedure (bone marrow or peripheral blood). A traditional 3+3 phase I design will be employed during this study, where dose escalations are planned in groups of 3 participants. No intra-participant escalation will be allowed and dose escalation will not be considered until toxicity information is available from at least 3 evaluable participants at the current dose level.Plerixafor will be given intravenously (IV) rather than subcutaneously (SQ) to minimize discomfort associated with repeated daily injections (up to 3) to the pediatric population of this study.
223825874|NCT03661034|DEVICE|GammaSense Stimulation System (non-invasive, non-significant risk)|Non-invasive, non-significant risk audio-visual sensory stimulation device
223825875|NCT03798704|DIAGNOSTIC_TEST|IFA, LIAISON|Comparison of two diagnostic serological tests - IFA and LIAISON.
223825876|NCT03029260|OTHER|Neural mobilization - tension.|"Neural mobilization in tension consists of using combinations of joint movement known to maximize the tension and lengthening of peripheral nervous structures.~The intervention will be delivered in one session only."
223825877|NCT03029260|OTHER|Neural mobilization - gliding|"Gliding neural mobilization consists of using combinations of joint movement known to maximize the movement of the peripheral nerves in relation to adjacent structures.~The intervention will be delivered in one session only."
223825878|NCT01327118|DRUG|Prostaglandin F2alpha|intravenous injection
223825879|NCT01327118|DRUG|Isoton sodium chloride|intravenous injection
223825880|NCT02041923|BEHAVIORAL|H-HOPE|Infant remediation using a developmentally appropriate multisensory intervention addresses the specific behavioral organization needs of premature infants. Maternal redefinition and re-education by a nurse-community advocate team uses participatory guidance to address the needs of mothers of premature infants.
223825881|NCT02041923|OTHER|Attention Control|Mothers received equal amount of attention from the team. Attention consisted of additional teaching regarding premature infant care.
223825882|NCT02529878|DRUG|S1/Paclitaxel chemotherapy plus Apatinib|S1:60mg twice daily(after the breakfast and supper) for two weeks, and then suspend for one week Paclitaxel:150mg/m2,iv, 3h, at day1 Apatinib:500mg once daily
223825883|NCT02687490|DRUG|Abraxane|125 mg/m2, D1, D8, D15
223825884|NCT02693301|OTHER|Exercise program|
223825885|NCT00371852|DRUG|lactoserum|
223825886|NCT03274219|BIOLOGICAL|bb21217|autologous T cells transduced ex-vivo with anti-BCMA CAR lentiviral vector encoding the chimeric antigen receptor (CAR) targeted to human BCMA, suspended in cryopreservative solution
223825887|NCT05914025|BEHAVIORAL|Behavioral Activation|Individuals will be provided with information about maladaptive patterns of behavior and how to correct these cycles with activity scheduling to elicit more positive emotional experiences. Participants will be provided with categories/lists of activities and a downloadable calendar after receiving the psychoeducation.
223825888|NCT00654134|BIOLOGICAL|Clinical Center Reference Endotoxin|20,000 EU inhaled
223825889|NCT02780622|DRUG|Oseltamivir|Oseltamivir 75 mg orally, twice daily for 4 days and once on Day 5.
223825890|NCT02780622|DRUG|Warfarin|Warfarin once daily, at a dose determined through titration by participants' usual hematologist.
223825891|NCT01173640|DRUG|Midazolam|2 mg oral dose
223825892|NCT01173640|DIETARY_SUPPLEMENT|resveratrol (single dose)|1 g oral dose
223825893|NCT01173640|DIETARY_SUPPLEMENT|resveratrol (multiple dose)|1 g oral dose for 8 days
223825894|NCT02956434|BEHAVIORAL|Brief Family Intervention|Two 50-minute sessions aimed at helping family members be most supportive to their loved one's treatment goals.
223825895|NCT01100047|DRUG|AZD5069|Oral suspension
223825896|NCT01100047|DRUG|Placebo|Oral suspension
223825897|NCT05147727|DRUG|Fluconazole、Famitinib|Fluconazole, once daily on Days 12 to 24; Famitinib, once daily on Days 1 and 15
223825898|NCT02021539|PROCEDURE|Cervical ultrasound +elastography 1|Included patients will have a cervical ultrasound upon arrival in the maternity ward. This latter exam will include elastographic measurements, and will be followed by a vaginal fibronectin measurement. Patients will then be treated via a tocolytic (anti-contraction treatment), and two hours later a second cervial ultrasound including elastographic measures will be performed.
223825899|NCT02021539|BIOLOGICAL|Vaginal fibronectin measurement|Included patients will have a cervical ultrasound upon arrival in the maternity ward. This latter exam will include elastographic measurements, and will be followed by a vaginal fibronectin measurement. Patients will then be treated via a tocolytic (anti-contraction treatment), and two hours later a second cervial ultrasound including elastographic measures will be performed.
223825900|NCT02021539|DRUG|Tocolytic treatment for 2 hours|Included patients will have a cervical ultrasound upon arrival in the maternity ward. This latter exam will include elastographic measurements, and will be followed by a vaginal fibronectin measurement. Patients will then be treated via a tocolytic (anti-contraction treatment), and two hours later a second cervial ultrasound including elastographic measures will be performed.
223825901|NCT02021539|PROCEDURE|Cervical ultrasound +elastography 2|Included patients will have a cervical ultrasound upon arrival in the maternity ward. This latter exam will include elastographic measurements, and will be followed by a vaginal fibronectin measurement. Patients will then be treated via a tocolytic (anti-contraction treatment), and two hours later a second cervial ultrasound including elastographic measures will be performed.
223825902|NCT03970993|BIOLOGICAL|R21 Matrix-M vaccination|Three dose vaccination of 2μg, 10μg or 50μg of R21 and 50ug Matrix-M delivered intramuscularly
223825903|NCT03970993|BIOLOGICAL|R21 Matrix-M vaccination and CHMI|Three dose vaccination of 2μg, 10μg or 50μg of R21 and 50ug Matrix-M delivered intramuscularly. Volunteers then have the option to be challenged with malaria by mosquito bite
223825904|NCT03970993|BIOLOGICAL|R21 Matrix-M vaccination booster|Optional R21 Matrix-M vaccination booster following a three dose vaccination schedule
223825905|NCT03346213|DRUG|MonoFer|Anaemic patients undergoing major surgery who would routinely be receiving intravenous iron 'MonoFer' will get this as part of routine care. They will then have a CPET repeated at least 10 days afterwards.
223825906|NCT03039439|PROCEDURE|Biospecimen Collection|Previously collected tumor tissue and blood samples
223825907|NCT03039439|OTHER|Laboratory Biomarker Analysis|Correlative studies
223825908|NCT04826328|DRUG|FX301|FX301 is an extended-release formulation of funapide being developed as a single injection peripheral nerve block for the management of acute postsurgical pain
223825909|NCT04826328|DRUG|Normal Saline|Single peripheral nerve injection
223825910|NCT06000982|DRUG|PTCY|PTCY as 40mg/kg or 50mg/kg at day +3 and +4 for GVHD prophylaxis
223825911|NCT02415998|PROCEDURE|TEE|Epidural catheter will be placed under guidance of transesophageal echography in specific thoracic spinal segment.
223825912|NCT04902417|OTHER|Dairy Foods (Yoghurt, Cheese, Milk)|Participants will be provided with a combination of dairy products (Yoghurt, Cheese, Milk) to be consumed daily, for a total of 3 servings per day
223825913|NCT00874432|DRUG|angiotensin converting enzyme inhibitor|Active comparator in chronic kidney disease and age matched control will take 1x40mg per day Placebo comparator in chronic kidney disease and age matched control will take 1 placebo pill per day
223825914|NCT00874432|DRUG|lisinopril|1 x 40 mg per day
223825915|NCT06411990|DEVICE|Fenestrated Endovascular Aneurysm Repair using the LIFE Device System|Fenestrated Endovascular Aneurysm Repair
223825916|NCT04007445|BEHAVIORAL|Formally Directed Group (Exercise Group)|This group will receive a 12-week exercise intervention that will educate and support the person's ability to exercise. Working with a trainer, the participant will attend a 12-week (3 x week) exercise program that has been personalized to their goals. Each session will include warm-up, stretching, cardiovascular exercises, strength exercises, and cool-down. Each session will be 1-2 hours in duration. The participants may wear accelerometers and heart rate monitors to help determine the level of intensity of the exercises, as they should be performing at least 150 minutes of moderate to vigorous exercise each week. By the end of the 12-week program, the goal is for participants to guide their own exercise regimens.
223825917|NCT04007445|OTHER|Self-Directed Group (Control Group)|This group will receive a 1-hour education session during which they will learn about the National Council on Health, Physical Activity and Disability (NCHPAD) website, an information and resource center on health promotion for people with disabilities. During the session participants will be given an overview of the website and asked to find three resources they find of interest. Their strength and fitness will also be assessed by completing a 1-rep max test. The participants will then be asked to maintain their regular physical activity for the next 12 weeks and complete a weekly physical activity log to track their exercise participation. A staff member will phone each person every week for the 12-week period and have the participant report his or her physical activity during the week.
223825918|NCT06291935|DRUG|VG901|"Administered as specified in the treatment arm. Study Cohort 1 - Low dose; Study Cohort 2 - High dose~Other Names:~Gene Therapy (AAV2.NN-CNGA1)"
223825919|NCT03280134|PROCEDURE|axillary lymph node dissection (ALND)|If the patients had predictive nSLN+, need further axillary lymph node dissection.
223825920|NCT03884114|OTHER|High-fidelity simulation|The first evaluation modality studied is high fidelity (HF) simulation. In our study, this modality is considered to be the gold-standard assessment method of clinical assessment, because HF simulation corresponds to the modality which reflects the best clinical competence in hospital settings. The HF pediatric manikin used (SimBaby), is able to reproduce all the signs of an asthma exacerbation (coughing, wheezing, tachypnea, chest indrawing, seesaw respiration, cyanosis). In the simulation room, participants can use the same items that those present in the simulation game (a glass of water, paracetamol, short acting beta-agonist, controller treatment (Fluticasone), an asthma spacer with a facial mask, saline nose drops to perform nasal irrigation, oral steroids in tablets (prednisone), and a phone).
223835573|NCT02758678|BIOLOGICAL|A single 2 ml heparinised peripheral blood sample|A single 2 ml heparinised peripheral blood sample was centrifuges to get serum specimens. Serum separation and Raman spectroscopy analysis:
223825921|NCT03884114|OTHER|Simulation game|"EfficAsthme is a simulation game used on a tablet computer. This simulation game was developed to train parents on the management of asthma exacerbations of their children. For the purpose of the study, EfficAsthme is diverted from its original use to assess students' clinical skills. The training scenario A polluted atmosphere is used in this study. Participants need to observe the signs presented by the child, and to determine the severity of the asthma exacerbation. From a menu on the right of the screen, the participant can choose several actions, especially to provide the short acting beta-agonist."
223825922|NCT03884114|OTHER|Multiple choice questionnaire|The third evaluation modality corresponds to a multiple choice questionnaire (MCQ) including 15 questions. As for HF-simulation and the simulation game, the MCQ starts with the same briefing and continues with 15 questions regarding the management of a moderate asthma exacerbation.
223825923|NCT01809041|DRUG|Sevoflurane|
223825924|NCT01809041|DRUG|propofol|
223825925|NCT01809041|DRUG|remifentanil|
223825926|NCT05014581|DRUG|Noradrenaline|Pre-emptive continuous infusion of noradrenaline during the peri-intubation period
223825927|NCT05694897|PROCEDURE|Erector spinae block using bupivacaine 0.25% and magnesium sulfate|"After induction of general anesthesia the patients will be flipped to the prone position and ESP block was performed using, a high frequency linear ultrasound probe placed longitudinally 2 to 3 cm lateral to the 10th thoracic vertebrae, and the trapezius and erector Spinae muscles identified.~An 18-G Tuohy needle passed along the plane of the transducer until its tip hit the transverse process of T10; the needle was then withdrawn slightly.~Total volume of 25 ml was injected including 20 mL 0.25% bupivacaine plus 3.75 ml NS and 125 mg MgSO4 (1.25ml)."
223825928|NCT05694897|PROCEDURE|Erector spinae block using bupivacaine and dememdetomidine|"After induction of general anesthesia the patients will be flipped to the prone position and ESP block was performed using, a high frequency linear ultrasound probe placed longitudinally 2 to 3 cm lateral to the 10th thoracic vertebrae, and the trapezius and erector Spinae muscles identified.~An 18-G Tuohy needle passed along the plane of the transducer until its tip hit the transverse process of T10; the needle was then withdrawn slightly.~Total volume of 25 ml was injected including 20 mL 0.25% bupivacaine plus dexmedetomidine 1ug/kg."
223825929|NCT04196218|OTHER|Driving simulator|Computer simulated driving assessment
223825930|NCT01518946|DRUG|Midodrine HCl|dose at the subject's current dose level
223825931|NCT01518946|DRUG|Placebo|single dose of matching placebo
223825932|NCT01147692|BIOLOGICAL|simvastatin plus albiglutide|A single dose of 80mg simvastatin on Day 1 followed by 5 weekly doses of subcutaneous albiglutide followed by a single dose of 80mg simvastatin on Day 38.
223825933|NCT06384612|BEHAVIORAL|use of pocket cards|Use of pocket cards of 22 cm x 11 cm size prepared by students every week in classes
223825934|NCT04821739|DEVICE|AGN1 LOEP SV Kit|The AGN1 LOEP SV Kit is intended for fixation of pathological fractures of the vertebral body using vertebral augmentation.
223825935|NCT06645054|BEHAVIORAL|Standard rehabilitation|The patients will receive standard rehabilitation that comprises assessment performed by a multidisciplinary team (physical-and-rehabilitation-medicine specialist physician, physiotherapist, occupational therapist, psychologist, social worker, prosthetics-and-orthotics engineer).
223825936|NCT06645054|DEVICE|Lower-limb prosthesis|The patients from the LLL group will be fitted with an appropriate lower-limb prosthesis.
223825937|NCT06645054|DEVICE|Lower-limb orthosis|The patients from the LLO group will be fitted with an appropriate lower-limb orthosis.
223825938|NCT00384059|BIOLOGICAL|13-valent Pneumococcal Conjugate Vaccine|Single 0.5 mL dose given at 2, 3, 4, and 12 months of age
223825939|NCT00384059|BIOLOGICAL|7vPnC|Single 0.5 mL dose given at 2, 3, 4 and 12 months of age
223825940|NCT00384059|BIOLOGICAL|Pediacel|concommitant vaccine, both at arm 1 and at arm 2, at 2 months, 3 months and 4 months of age
223825941|NCT00384059|BIOLOGICAL|NeisVac-C|concomittant vaccine, both at arm 1 and at arm 2, at 2 months and 4 months of age
223825942|NCT00384059|BIOLOGICAL|Menitorix|concomitant vaccine, both at arm 1 and at arm 2, at 12 months of age
223825943|NCT04235582|BEHAVIORAL|App + Inputs Contingency Management|The app has programmed contingencies whereby incentives can be earned for behaviors that are inputs to abstaining from drug use (e.g., attending psychotherapy or taking SUD psychopharmacology).
223825944|NCT04235582|BEHAVIORAL|App + Outcomes Contingency Management|The app has programmed contingencies whereby incentives can be earned for outcomes of abstaining from drug use (e.g., drug-negative saliva samples on saliva opioid tests).
223825945|NCT05917223|DIETARY_SUPPLEMENT|Milk protein ingestion|It's just an acute intervention, so the participant assigned to the Milk protein ingestion group will consume 20 g of milk protein during infusion protocol.
223825946|NCT05917223|DIETARY_SUPPLEMENT|Cron protein ingestion|It's just an acute intervention, so the participant assigned to the Corn protein ingestion group will consume 20 g of corn protein isolation during infusion protocol.
223825947|NCT05917223|DIETARY_SUPPLEMENT|Corn+Pea protein ingestion|It's just an acute intervention, so the participant assigned to the Corn+Pea protein ingestion group will consume 20 g of Corn+Pea protein isolation during infusion protocol.
223825948|NCT05917223|DIETARY_SUPPLEMENT|Non-protein, low energy|It's just an acute intervention, so the participant assigned to the Non-protein, low energy group will consume 20 g of carbohydrate during infusion protocol.
223825949|NCT00914277|DRUG|SAR407899|Oral administration
223825950|NCT00914277|DRUG|Placebo|Oral administration
223825951|NCT00914277|DRUG|Sildenafil|Oral administration
223825952|NCT04601363|DEVICE|Patient Specific Rod|Posterior spinal fusion rod
223825953|NCT01774071|DRUG|89Zr- DFO-MSTP2109A|"If you are enrolled onto Group 1:~Once you are given the diagnostic agent, the following procedures will be done:~PET scans at the approximate times:~* 1-4 hours after the injection~* 24 hours after the injection (the next day, Day 2)~* 48-120 hours after the injection (on either Day 3, 4, or 5)~* 144-168 hours after the injection (on either Day 6, 7, or 8) You will also have research bloods drawn on the following times and days,~* Day 1: before the injection, approximately 5 minutes after, 30 minutes after, 1 hour after and 2-4 hours after the injection.~* At each time of your scheduled PET scan."
223825954|NCT01774071|DRUG|89Zr DFO-MSTP2109A|"If you are enrolled onto Group 2:~Once you are given the study drug, the following procedures will be done:~You will have one PET scan done. The timing of the PET scan will be determined at the time of your enrollment (\~ 3-7 days after injection).~No research blood work will be drawn in Group 2"
223825955|NCT04852588|PROCEDURE|Endobronchial ultrasound-guided transbronchial fine needle aspiration (EBUS-TFNA)|Chest lymph node sampling procedure by EBUS
223825956|NCT04852588|PROCEDURE|Transesophageal ultrasound-guided fine needle aspiration (EUS-FNA)|Chest lymph node sampling procedure by EUS
223825957|NCT06519825|OTHER|Exercise|Inspiratory muscle strength training program will be applied to the FHP-C group for 7 days/6 weeks.
223825958|NCT02493049|DRUG|Domperidone|Addition of Domperidone to current Disease Modifying Therapy.
223825959|NCT04632628|BEHAVIORAL|Web-based Cognitive Behavior Therapy for Insomnia (CBT-I)|Participants will complete 4 web-based CBT- I sessions. Lesson 1: Sleep Hygiene and Stimulus Control Lesson 2: Sleep Restriction and Relaxation Strategies Lesson 3: Identifying and Restructuring Dysfunction Thoughts Lesson 4: Practical Recommendations, Review, and Maintenance of Change
223825960|NCT06919172|DEVICE|transcranial magnetic stimulation|Transcranial magnetic stimulation delivered to the scalp targeting specific brain structures via stereotactic guidance.
223825961|NCT02763683|RADIATION|PiB and VAT|There is no intervention for this study. The PiB and VAT are used during the PET procedures to help to identify any excessive abnormal proteins in the brain.
223825962|NCT06619730|DEVICE|Sedline Brain Function Monitor|The anesthesia provider will use the Sedline Brain Function Monitor information to affect their anesthetic dosing.
223825963|NCT06619782|OTHER|Practice Facilitation|Practice facilitation (PF) is a supplemental support to increase competence and and adoption of the National Institute of Mental Health (NIMH) youth suicide prevention. pathway in primary care. Practices will receive 6 months of PF which involves clinic- and provider- level data review and adoption data for the 5 components of the prevention pathway, clinical coaching around implementing the different components , logistical coaching in identifying multilevel contextual barriers to implementation and strategies to overcome them
223825964|NCT06619782|OTHER|Training in National Institute of Mental Health Youth Suicide Prevention Pathway|Training in the National Institute of Mental Health (NIMH) Youth Suicide Prevention Pathway involves a 2-hour in-person presentation created in consultation with NIMH, Zero Suicide and Substance Abuse and Mental Health Services Administration. It is delivered by a licensed professional counselor with content expertise to all primary care practice personnel involved in the prevention pathway. The first hour focuses on conducting Ask Suicide Screening Questions (ASQ) screening, identifying risk/protective factors, identifying warning signs and conducting a brief suicide safety assessment. The second hour covers safety planning, lethal means safety, behavioral health referrals and arranging follow-up. Didactic and interactive methods are used, including group discussion, activities, videos and case vignettes
223825965|NCT06621966|OTHER|Olive Oil Topical Oil|The IVG will receive standard PI prevention care along with a topical application of olive oil for 7 consecutive days. PI point prevalence and baseline risk assessments will be performed prior to the intervention. Post-intervention assessments will be conducted from days 3 to 8. Descriptive statistics and paired sample t-tests will be utilized for data analysis.
223825966|NCT03768765|PROCEDURE|Holmium Laser Prostate Surgery|Patients will undergo standard of care holmium laser prostate surgery
223825967|NCT06623968|PROCEDURE|Dental implants|Long-term follow-up study on singel-tooth implants
223825968|NCT06624397|OTHER|CAREFREE Carer's Programme|This programme was developed to provide carers with an opportunity to develop an understanding of Anorexia from a Biopsychosocial framework, taking into account the complex array of biological, psychological and social/environmental factors associated with the development and maintenance of this disorder. CAREFREE programme is unique in its focus on providing a framework for understanding AN from a Schema - Compassion Focused framework, incorporating psychoeducation in regard to both Anorexia Nervosa and Carer Burnout. The programme has a relational focus, with an emphasis on improving emotional fluency, family communication skills and self-other compassion.
223825969|NCT06875687|OTHER|Prostaglandin Analog-Based Eyelash Serum|This intervention consists of a prostaglandin analog-based eyelash serum applied once daily to the upper eyelid margin for six weeks. The serum contains dechloro dihydroxy difluoro ethylcloprostenolamide (DDDE), a prostaglandin analog known to promote eyelash growth. The formulation also includes panax ginseng root extract, urtica dioica extract, panthenol, niacinamide, and biotinoyl tripeptide-1, which contribute to hair follicle nourishment. The study evaluates its effects on ocular surface integrity, tear film stability, and eyelash growth.
223825970|NCT06691893|DEVICE|RELiZORB|RELiZORB (immobilized lipase) is a therapeutic device designed to enhance fat absorption in patients receiving enteral tube feedings. It works by hydrolyzing fats found in enteral formulas. RELiZORB is a single-use cartridge that connects in-line with enteral feeding sets. It contains lipase covalently bound to small polymer beads, forming a complex called iLipase, which remains within the cartridge. As the enteral formula passes through the cartridge, its fat content is hydrolyzed upon contact with iLipase. This process is especially beneficial for the absorption of long-chain polyunsaturated fatty acids, which require hydrolysis by pancreatic lipase for proper intestinal absorption. RELiZORB is compatible with a wide variety of commercially available enteral formulas.
223825971|NCT04540302|DEVICE|Merit WRAPSODY Endovascular Stent Graft|Target lesion treated with stent graft placement
223825972|NCT04540302|DEVICE|PTA|Target lesion treated with standard percutaneous transluminal angioplasty (PTA)
223825973|NCT05786781|DEVICE|Transarterial CT angiography|Transarterial catheter-directed CT angiography during interventional treatment of hemoptysis
223825974|NCT06925360|DRUG|intravenous immunoglobulin|1 g/kg/day for the first 2 days, 0.5 g/kg/day for next 3 days (total does 3.5 g/kg), repeatable 1\~2 times if necessary (5 days after the last infusion).
223825975|NCT03150927|DIETARY_SUPPLEMENT|Probiotic Microbial Composite|125mg (or 250 mg) of BiOWiSH Probiotic Microbial Composite™ is to be dosed once daily. Product will be supplied in capsule form to be administered orally. Each subject will be given a 15-day supply (30 capsules) to take with them after their initial visit. Capsules will be administered every 15 days by primary investigators at follow up visits.
223825976|NCT03150927|DIETARY_SUPPLEMENT|Placebo|125mg (or 250 mg) of Placebo is to be dosed once daily. Product will be supplied in capsule form to be administered orally. Each subject will be given a 15-day supply (30 capsules) to take with them after their initial visit. Capsules will be administered every 15 days by primary investigators at follow up visits.
223825977|NCT04259671|DEVICE|My Autism Passport (MAP) Application|Families will be given the application to upload to their mobile device and will be provided information on how to use the App by the research team. MAP is a mobile alternative to the paper version, and offers additional benefits such as the ability to set reminders, see regional developmental service agencies and other resources on a map, and directs the caregiver to information so that they may further their understanding about how to support their child.
223825978|NCT06899399|PROCEDURE|Endovascular treatment|"Participants will receive carotid artery stenting as the primary intervention. The procedure will be performed via femoral artery access (radial access allowed for anatomically challenging cases) with mandatory use of an embolic protection device (EPD). Stent selection and EPD type will be determined by the operator based on lesion characteristics.~Pre-procedural dual antiplatelet therapy (DAPT: aspirin 100 mg/day + clopidogrel 75 mg/day) will be administered for ≥3-5 days. Post-procedural DAPT will continue for 3 months, transitioning to aspirin monotherapy (100 mg/day) thereafter. Statins and risk factor management (blood pressure、LDL-C, glycemic control) will align with standardized protocols."
223825979|NCT06899399|DRUG|Best medical treatment|Participants will receive intensive medical management, including aspirin (75-325 mg/day) or alternative antiplatelet agents (clopidogrel/dipyridamole) for intolerance. Statin therapy and risk factor control targets (blood pressure, lipids, glucose, lifestyle) will mirror the experimental group. Both groups will undergo regular follow-up for adherence monitoring.
223825980|NCT06926309|OTHER|Peer mentoring|The peer mentor selected by the researchers will be given postpartum perineal care education and peer mentoring education. The peer mentor will prepare perineal care education materials under the supervision of the researchers. Then, the experimental group will be divided into small groups and given 4 hours of perineal care education to their peers.
223825981|NCT01830088|BEHAVIORAL|Attachment Based Family Therapy|Attachment-Based Family Therapy (ABFT) is is primarily a process oriented, emotion focused treatment guided by a semi-structured treatment protocol. ABFT aims to improve the family's capacity for problem solving, affect regulation, and organization. This strengthens family cohesion which can buffer against depression, suicidal thinking, and risk behaviors
223825982|NCT01830088|BEHAVIORAL|Enhanced Usual Care|No attempt is made to control any aspect of the enhanced usual care except for pre-scheduled assessment plan
223825983|NCT06901206|PROCEDURE|Neonatologist performed lung ultrasound|Neonatologist performed lung ultrasound is performed at T0 (reported persistent increased FiO2 demand) and T1 (one hour after T0). NPLUS may be able to detect loss of aeration and lead to more targeted interventions to improve lung aeration. A comprehensive lung ultrasound examination will take 5 minutes or less to perform and involves minimal handling for the patient.
223825984|NCT06900504|OTHER|Sleep hygiene education|A structured training booklet will be prepared to ensure sleep hygiene for individuals. In addition, sleep hygiene training will be provided to individuals.
223825985|NCT06831149|PROCEDURE|Removal of pharyngeal mucosa with decreased perfusion will be performed|Surgical removal of underperfused tissue versus nonremoval of tissue
223825986|NCT06831149|DEVICE|SPY-PHI|SPY Portable Handheld Imaging (SPY-PHI)
223825987|NCT06831149|DRUG|ICG (Indocyanine Green)|ICG will be used in conjunction with the SPY-PHI system for tissue imaging.
223825988|NCT06899425|OTHER|Hot pack|The participants will be treated by hot packs on neck for 15 minutes, 3 times per weeks for 12 weeks.
223825989|NCT06899425|OTHER|Kinesio tape|The participants will be treated by hot packs and kinesio tape. The tape will be placed for several days (3-5 days of application) then it will be removed and repeated for 12 weeks.
223825990|NCT04591977|DEVICE|HPV Self-Sampling Kit (Evalyn Brush)|The Evalyn Brush is a self-sampling kit that can be used to collect a sample to screen for HPV/Cervical cancer at home.
223825991|NCT05164432|DIAGNOSTIC_TEST|MRI scan|Women will have an MRI scan during pregnancy to evaluate the fetus and placenta
223825992|NCT06828549|BEHAVIORAL|MOSAIC|All MOSAIC PWD participants receive monthly phone coaching following a semi-structured protocol plus daily automated text message support. MOSAIC uses the mobile phone-delivered structure and functionality developed for FAMS (NCT04347291). Tailoring rules novel to MOSAIC determine phone coaching protocol content, text message content, and the involvement of a SP. Semi-structured protocols used in prior studies (and in the case of NCT04334109 adapted for mobile phone-delivery) are employed. Per tailoring rules, enrolled SPs may be invited to participate in monthly coaching calls with the PWD and/or receive text messages about supporting the PWD. The study will not assess outcomes or effects among SPs.
223825993|NCT06828549|BEHAVIORAL|Print Materials|Quality print materials about diabetes management provided upon enrollment and in quarterly study newsletters
223825994|NCT03271034|DIETARY_SUPPLEMENT|Weight loss|Participants will lose weight by utilizing a low caloric diet and meeting with a study dietitian and/or behaviorist weekly for \~4 months.
223825995|NCT03148977|PROCEDURE|Graft|Autogenous skin grafting is the only definitive treatment for the full thickness burn injuries, and thus represents the centerpiece of modern burn care.
223825996|NCT00405353|DRUG|Androgel 10 grams of gel containing 100 mg of testosterone|testosterone gel
223825997|NCT02556905|DRUG|REVLIMID®|The recommended starting dose of REVLIMID® is 25mg/day with water orally administered as a single 25mg capsule on Days 1-21 of repeated 28-day cycles. Dose can be adjusted upon the clinical laboratory result.
223825998|NCT02556905|DRUG|Dexamethasone|The recommended dose of dexamethasone is 40mg/day on Days 1-4, 9-12, and 17-20 of each 28-day cycle for the 4 cycle of therapy and then 40mg/day orally on Days 1-4 every 28 days.
223825999|NCT06925607|DRUG|Mesenchymal Stem Cells (MSCs)|single dose injection (120 million cells)
223826000|NCT06927180|DRUG|SHR-A1811|an anti-HER2 antibody-drug conjugate (ADC)
223826001|NCT06927180|DRUG|Pertuzumab|Pertuzumab
223826002|NCT06927180|DRUG|Albumin-Paclitaxel|Nab paclitaxel
223826003|NCT06927180|DRUG|Docetaxel|Docetaxel
223826004|NCT06927180|DRUG|Carboplatin|Carboplatin
223826005|NCT06927180|DRUG|Trastuzumab|Trastuzumab
223826006|NCT04683809|OTHER|Telerehabilitation|Patients will attend rehabilitation sessions through online programmes for rehabilitation
223826007|NCT03606941|DEVICE|electroacupuncture treatment|"Participants in the electroacupuncture group received acupuncture (0.30mm×70mm) at bilaterally Shenmen (HT7) acupoints (0.3-0.5 inch), Neiguan (PC6) acupoints (0.5-1 inch), Baihui (DU20) acupoint (0.5-0.8 inch) and Yintang (EX-HN3) acupoint (0.3-0.5 inch) 30 minutes before anesthesia induction. After Deqi, electroacupuncture stimulation apparatus (HANS G6805-2, Huayi Co, Shanghai, China) is connected with the density wave (2/100 Hz), width 0.25 ms, intensity of 1 \~ 30 mA (gradually increase to the patient's maximum tolerance) and maintained the end of operation."
223826008|NCT03606941|DEVICE|sham electroacupuncture treatment|"Participants in the sham electroacupuncture group received shallow needling (0.30mm×25mm) at bilateral sham HT7, PC6, DU20 and EX-HN3 (nonacupoints located 1 inch beside acupoints, about 20mm). Specifically, the depth of needle insertion into nonacupoints is 3-5mm and avoided manual stimulation and no Deqi without actual current output, and retained the needle until the end of surgery."
223826009|NCT00141882|DRUG|memantine|
223826010|NCT04961320|BEHAVIORAL|Occupational Therapy|Participate in OT session
223826011|NCT04961320|OTHER|Questionnaire Administration|Complete questionnaires
223826012|NCT00877903|DRUG|Prochymal®|Intravenous infusion of ex vivo cultured adult human mesenchymal stem cells
223826013|NCT00877903|DRUG|Placebo|Intravenous infusion of excipients of Prochymal®
223826014|NCT03598218|RADIATION|Hypofraction radiation|"Hypofractionated dose IMRT: GTVnx 60Gy, GTVnd 60Gy, PTV1 50Gy and PTV2 45Gy in 25 fractions, 5 days/week.~Induced chemotherapy: Paclitaxel 135mg/m2 D1+Cisplatin 80mg/m2 D1(or D1-3), 3-week chemotherapy for 3 cycles. After radiation, patients receive adjuvant chemotherapy Paclitaxel 135mg/m2 D1+Cisplatin 80mg/m2 D1(or D1-3), 3-week chemotherapy for 3 cycles."
223826015|NCT03598218|RADIATION|Standard dose IMRT|"Standard dose IMRT: GTVnx 69.69Gy, GTVnd 60-68Gy, PTV1 54.9Gy and PTV2 54Gy in 33 fractions, 5 days/week.~Induced chemotherapy: Paclitaxel 135mg/m2 D1+Cisplatin 80mg/m2 D1(or D1-3), 3-week chemotherapy for 3 cycles. After radiation, patients receive adjuvant chemotherapy Paclitaxel 135mg/m2 D1+Cisplatin 80mg/m2 D1(or D1-3), 3-week chemotherapy for 3 cycles."
223826016|NCT04474015|DEVICE|transcranial electric stimulation|NeuroConn® DC Plus stimulator: the NeuroConn® stimulator can be programmed with specific frequencies of stimulation ranging from 0.5 to 500 Hz. This device is therefore appropriate for the present study to stimulate only at 0.75 or 3.0 Hz. Also, the NeuroConn only allows low current intensities to be chosen. The maximum current intensity that can be delivered with this stimulator is 5 milliamps.
223826017|NCT00794625|DRUG|Valproate|Standard therapeutic doses of valproate, set according to valproic acid blood level, for 8 weeks
223826018|NCT00794625|DRUG|Risperidone|Standard therapeutic doses of risperidone for 8 weeks
223826019|NCT00794625|DRUG|Placebo|An inactive substance at identical dosing to active treatments for 8 weeks
223826020|NCT00794625|DRUG|Stimulant medication|Stimulant medication standard in the care of ADHD, such as methylphenidate or dextroamphetamine
223826021|NCT00794625|BEHAVIORAL|Behavioral family counseling|Weekly behavioral counseling with a therapist
223826022|NCT02593539|DRUG|Nemiralisib|Participants will be administered nemiralisib
223826023|NCT06208722|BEHAVIORAL|Testing a Mobile App to Improve Toothbrushing Skills and Habits in Teens With Autism|Information provided in arm descriptions.
223826024|NCT04091906|DEVICE|Peripheral blood mononuclear cell apheresis|Peripheral blood mononuclear cell donation for tumor immunotherapy study of UCAR-T cells
223826025|NCT00259376|DRUG|Dronedarone (SR33589)|oral administration
223826026|NCT00259376|DRUG|placebo|oral administration
223826027|NCT02701322|BEHAVIORAL|Medical clown|
223826028|NCT00766896|DRUG|Aspirin (platelet sensitive versus platelet hyperreactivity)|"The dose of aspirin to be prescribed in this study will be 300 mg orally or by nasogastric tube once a day (assisted therapy), with first dose tomography soon after admission if the patient has no indication of thrombolytic therapy. After the acute phase, patients will receive aspirin at a dose of 200 mg/day. Aspirin will be administered in a simple preparation (no buffer, no extended release)."
223826029|NCT06043596|BEHAVIORAL|SafeSpace Sexual Health|The overall goal of the program is to prevent adolescent pregnancy and STIs by increasing sexual agency, increasing the use of condoms and contraception, and promoting healthy relationships and healthy life skills among adolescents.
223826030|NCT06043596|BEHAVIORAL|SafeSpace General Health|This arm represents the comparison group. SafeSpace General Health will act as the active comparator, while providing youth with lessons, facts, and resources about general health topics.
223826031|NCT01971320|DEVICE|Urostim I stimulation|Urostim I stimulation will be done during meals for 6 weeks
223826032|NCT02671721|OTHER|Maximal Compliance|PEEP will be set at the maximum static respiratory system compliance during a descending PEEP titration curve.
223826033|NCT02671721|OTHER|Transpulmonary Pressure|We will use transpulmonary pressure values obtained using an naso/orogastric tube during the operative procedure to titrate PEEP intraoperatively.
223826034|NCT00226473|DRUG|Cisplatin, Vindesine, Dacarbazine (drugs)|
223826035|NCT00000611|DRUG|hormone replacement therapy|
223826036|NCT00000611|DRUG|estrogens|
223826037|NCT00000611|DRUG|progestins|
223826038|NCT00000611|DRUG|estrogen replacement therapy|
223826039|NCT00000611|BEHAVIORAL|diet, fat-restricted|
223826040|NCT00000611|DRUG|calcium|
223826041|NCT00000611|DRUG|vitamin D|
223826042|NCT00000611|BEHAVIORAL|dietary supplements|
223826043|NCT00649389|DRUG|Olmesartan medoxomil|40mg olmesartan medoxomil
223826044|NCT00649389|DRUG|Amlodipine|Amlodipine 10mg
223826045|NCT00649389|DRUG|Hydrochlorothiazide|Hydrochlorothiazide 25mg
223826046|NCT02762344|DRUG|heparin|routinary heparin administration during coronary angiography/PCI
223826047|NCT03350113|DEVICE|Blood sampling for analysis|Blood Sampling for Analysis
223826048|NCT05664139|DRUG|Recombinant Human Adenovirus Type 5 Injection,Camrelizumab,Nab-paclitaxel|"Recombinant Human Adenovirus Type 5 Injection:①the longest diameter of the lesion≥10mm and≤40mm, inject 1ml into the tumor each time;②the longest diameter of the lesion≥40mm and≤80mm, inject 2ml into the tumor each time. planned injections at D1. Every 3 weeks is a period, a total of 4 cycles; if there are visceral and superficial lesions at the same time, the injection lesions will be selected by the investigator based on possible benefits.~Camrelizumab:200mg/time.Intravenous within 48 hours after injection of recombinant human adenovirus type 5 injection. Every 3 weeks is a period, and the treatment is continued until the subject has disease progression or unacceptable toxicity or death.~Nab-paclitaxel:260mg/m2, D1, every 3 weeks as a period, a total of 4-6 cycles (determined by the investigator), or continue treatment until the subject has disease progression or Intolerable toxicity or death."
223826049|NCT05386186|DRUG|Glimepiride|Initiate glimepiride 1-4mg once daily as an add-on therapy to metformin and adjust the glimepiride dosage to 1-6 mg once daily in the first 12 weeks according to the diabetes management guideline recommended by the Chinese Diabetes Society.
223826050|NCT05386186|DRUG|Sitagliptin|Add sitagliptin 100mg once daily in all patients randomized to this arm.
223826051|NCT01806740|DRUG|Gadoterate meglumine|Gadoterate meglumine was administered at a dose of 0.1 mmol/kg (0.2 mL/kg) using a power injector, in an intravenous bolus at a rate of 3 mL/sec.
223826052|NCT05115019|BIOLOGICAL|RUTI® vaccine|Each dose of the RUTI® vaccine contains 25 µg of fragmented, purified and liposomed heat-inactivated Mycobacterium tuberculosis bacilli (FCMtb) in a total volum of 0.3mL.
223826053|NCT05115019|BIOLOGICAL|Placebo|Physiological serum, 0.9% NaCl, will be used as a placebo
223826054|NCT04059393|OTHER|Internet-Based Intervention|Complete web-based legacy intervention
223826055|NCT04059393|OTHER|Best Practice|Receive standard of care
223826056|NCT04059393|OTHER|Quality-of-Life Assessment|Ancillary studies
223826057|NCT04059393|OTHER|Questionnaire Administration|Ancillary studies
223826058|NCT03176095|DIETARY_SUPPLEMENT|Probiotic|
223826059|NCT03176095|DIETARY_SUPPLEMENT|Placebo|
223826060|NCT02049060|DRUG|Tivantinib|"•- 1 level: Tivantinib 120 mg p.o. BID + Carboplatin AUC 5 i.v. day 1 every 3 weeks + Pemetrexed 500 mg/mq i.v. day 1 every 3 weeks~•0 level: Tivantinib 240 mg p.o. BID + Carboplatin AUC 5 i.v. day 1 every 3 weeks + Pemetrexed 500 mg/mq i.v. day 1 every 3 weeks~•+ 1 level: Tivantinib 360 mg p.o. BID + Carboplatin AUC 5 i.v. day 1 every 3 weeks + Pemetrexed 500 mg/mq i.v. day 1 every 3 weeks"
223826061|NCT03941613|PROCEDURE|SEEG guided RF-TC|SEEG implantation after evaluation, record the interictal and ictal EEG, and perform RF-TC after the localization confirmation.
223826062|NCT03941613|PROCEDURE|Anterior temporal lobectomy|classical surgical treatment for mesial temporal lobe epilepsy, including the resection of neocortex for 5.5cm in non dominant hemisphere or 4.5cm in dominant hemisphere
223826063|NCT04152785|BEHAVIORAL|Information regarding GHG and/or nutrition|Participants will have to select a meal from a menu.
223826064|NCT02571205|DRUG|Sustanon (testosterone)|Standard incremental regimen of Sustanon
223826065|NCT02391870|BEHAVIORAL|MBCT-PD|Using an iterative process, the investigators modified MBCT to include a focus on perinatal depression (MBCT-PD). The modifications took into account developmental processes associated with the perinatal period, characteristics and correlates of perinatal depression, and the physical aspects of pregnancy.
223826066|NCT00153946|DRUG|Edaravone|30mg/20mL vial, twice per day, not longer than two weeks
223826067|NCT02444988|OTHER|0.9% Saline|0.9% Saline will be used whenever an isotonic crystalloid is ordered
223826068|NCT02444988|OTHER|Physiologically-balanced isotonic crystalloid|Lactated Ringers or Plasma-Lyte© A will be used whenever an isotonic crystalloid is ordered
223826069|NCT02448836|DEVICE|dTMS H-coil system:magstim stimulator rapid2,BrainswayH1coil|Patients will undergo 8 sessions of dTMS treatment for two weeks (4 sessions every week).
223826070|NCT02448836|DEVICE|Sham: dTMS H-coil system:magstim stimulator rapid2,BrainswayH1coil|Patients will undergo 8 sessions of Sham dTMS treatment for two weeks (4 sessions every week).
223826071|NCT05140811|DRUG|IMM01|IMM01 is intravenously once a week, every 28 days for a treatment cycle;
223826072|NCT05140811|DRUG|Azacitidine|Azacitidine 75 mg/m/ day is administered subcutaneously for 7 consecutive days, with each 28-day treatment cycle planned for 6 treatment cycles
223826073|NCT02801474|PROCEDURE|direct fracture reduction and fixation|In the DR group, the posterior malleolar fracture was reduced and fixed in a direct way via a posterolateral approach with the patients in prone position.
223826074|NCT02801474|PROCEDURE|indirect fracture reduction and fixation|In the IR group, the posterior malleolus was reduced through ligamentotaxis following open reduction and internal fixation of lateral and medial malleolar fractures. Percutaneous cannulated screws were used to fix the posterior malleolar in anterior-to-posterior direction.
223826075|NCT04126096|DIAGNOSTIC_TEST|Skin Testing beta-lactams|Percutaneous skin prick followed by Intradermal Injections of NMBAs at increasing concentrations compared with an established positive and negative control.
223826076|NCT06081374|DEVICE|simulation implication|Breastfeeding education is planned by dressing pregnant women with simulation models.
223826077|NCT03693274|BEHAVIORAL|BreathAware for Pain Management|Patients will be given access to a BreathAware, a 16- week web-based mindfulness course, which will be initiated at their enrollment. BreathAware is a self-paced course comprised of 2-3 minute lessons delivered via video, audio and technology-based guided instruction, and is available on a phone or tablet.
223826078|NCT03240536|OTHER|Choosing Wisely form|"The investigators will fax a Choosing Wisely form to ordering physicians that will include information from the Canadian Rheumatology Association Canada Choosing Wisely Guidelines. Three points will be included with some additional explanation of why these are important.~The three guidelines included will be:~1. Don't order an ANA as a screening test in patients without specific signs or symptoms of systemic lupus erythematous (SLE) or another connective tissue disorder (CTD).~2. Don't routinely image patients with low back pain regardless of the duration of symptoms unless that are clinical reasons to suspect serious underlying pathology~3. Don' routinely order a shoulder ultrasound as it is likely to indicate a tear in many people over the age of 50 years and will not change the initial management."
223826079|NCT01175772|DRUG|Cytophosphan, Celecoxib, Methotrexate|"Metronomic Chemotherapy as maintenance treatment for patients with Ovarian Cancer~* Cytophosphan tab 50 mg -1x1 per day, continuous~* Celecoxib tab 200 mg - 1x2 per day, continuous~* Methotrexate tab 2.5 mg - 1x2 per day, 2 days weekly"
223835574|NCT06029361|DEVICE|Selfit Device group|During 21 days, intervention group will receive physical therapy of 45 minutes which 15 minutes out of the 45 minutes will be with the SELFIT system
223835575|NCT06029361|OTHER|Control Group|Conventional physical therapy of 45 minute
223835576|NCT01932996|DRUG|nicotine patch plus nicotine gum/lozenge|12-week treatment with nicotine patch plus nicotine gum/lozenge
223826080|NCT05689086|OTHER|Virtual Heart Failure Optimization Program|"Participants referred to the Virtual Heart Failure Optimization Program will be seen for initial consultation by a HF program nurse and cardiologist within 1 week. Patients will be offered the opportunity to participate in virtual cardiac rehabilitation.~Following this, patients will be assessed virtually every two weeks by a HF program nurse for addition and up-titration of medical therapy. All medication changes will be performed algorithmically and reviewed with the overseeing cardiologist. Following all medication changes, appropriate monitoring will be performed algorithmically as well.~All participants will be asked if they would like to participate in cardiac rehabilitation and an automatic referral will be sent by the overseeing cardiologist. Virtual cardiac rehabilitation will be conducted weekly with phone follow-up appointments with a program kinesiologist and virtual education programming."
223826081|NCT00771693|DRUG|Insulin aspart (Novorapid®)|a cross-over study with subcutaneous injection of insulin aspart 0.1U/kg, 0.2u/kg or placebo, before the meal, on 3 different occasions.
223826082|NCT00836173|DRUG|RICE|RICE treatment: Rituximab by intravenous infusion over 6-8 hours on day 1, Eptoposide by intravenous infusion over 2 hours on day 3-5, a 1-hour infusion of Carboplatin on day 4 and a 24-hour infusion of Ifosfamide on day 4, each cycle is 14 days (2 weeks). Patients will receive 3 cycles of RICE treatment.
223826083|NCT00836173|DRUG|GaRD Treatment|After RICE treatment, patients will have gallium nitrate IV through a vein continuously over a 7 day period. Patients will also receive rituximab by intravenous infusion over a 3-6 hour period on day 1 of each cycle. Dexamethasone will be given as pills to be taken for 4 days in a row on the first 4 days of each cycle. The length of each cycle is 21 days (3 weeks). All patients will have 2 cycles of GaRD.
223826084|NCT01984424|DRUG|Atorvastatin|Atorvastatin was supplied as over-encapsulated 20 mg tablets
223826085|NCT01984424|DRUG|Placebo to Atorvastatin|Placebo matching to atorvastatin supplied as over-encapsulated tablets
223826086|NCT01984424|OTHER|Placebo to Ezetimibe|Placebo matching to Ezetimibe supplied as over-encapsulated tablets.
223826087|NCT01984424|DRUG|Ezetimibe|Ezetimibe was supplied as 10 mg tablets, over-encapsulated for blinding.
223826088|NCT01984424|OTHER|Placebo to Evolocumab|Placebo matching to evolocumab supplied as single-use prefilled autoinjector/pen(s)
223826089|NCT01984424|DRUG|Evolocumab|Evolocumab supplied as single-use prefilled autoinjector/pen(s)
223826090|NCT01551316|DRUG|MN-221|This drug is intravenously infused and delivers 1200 mcg to the patient in 1 hour duration. This dose is repeated over 4 days (Day 1 1200 mcg once; Day 2 1200 mcg twice; Day 3 1200 mcg twice; Day 4 1200 mcg once).
223826091|NCT01551316|DRUG|Placebo|This intervention consists of a placebo intravenous infusion, one that contains no active medication. During the double-blind procedure, patients will be infused with placebo intravenously one time on Day 1, twice on Days 2 and 3, and one time on Day 4.
223826092|NCT05516368|BEHAVIORAL|TF-CBT|Modular TF-CBT therapy programme of 16 weekly individual sessions, each lasting 60-90 minutes.
223826093|NCT02643719|BEHAVIORAL|Relaxation Therapy|Between 30-60 minutes after the standard of care medication administration (metoclopramide, magnesium, prochlorperazine, ketorolac, or steroids at discretion of treating physician), patient receives training in relaxation therapy.
223826094|NCT02643719|DRUG|Topiramate|"Preventive medication prescriptions given to the patient along with written instructions and information about side effects:~Topiramate 25mg tabs (with a plan to increase to 100mg)"
223826095|NCT02643719|DRUG|Standard of Care|Standard discharge instruction sheet plus standard of care medication as prescribed by treating physician. The clinical team will be instructed to address post-discharge care as appropriate
223826096|NCT02643719|DRUG|Abortive Medication (Naproxen and Sumatriptan)|All participants will receive abortive medication for acute treatment of their migraine. Preferred medications are Naproxen (500mg) and Sumatriptan (100mg)
223826097|NCT02802319|DEVICE|Porcine Xenograft (Zcore)|Ridge preservation bone grafting after tooth extraction
223826098|NCT02802319|DEVICE|Bovine Xenograft (Bio-Oss)|Ridge preservation bone grafting after tooth extraction
223826099|NCT02532959|DEVICE|Diagnostic Breath Analysis|Conduct exhaled breath samples
223826100|NCT03780595|DRUG|Passiflora incarnata|Passiflora pills administration up to 6 pills per day
223826101|NCT03780595|DRUG|Control|Control pills administration up to 6 pills per day
223826102|NCT00077636|DRUG|Copegus|400mg po bid for 16 weeks
223826103|NCT00077636|DRUG|Copegus|400mg po bid for 24 weeks
223826104|NCT00077636|DRUG|peginterferon alfa-2a [Pegasys]|180 micrograms sc weekly for 16 weeks
223826105|NCT00077636|DRUG|peginterferon alfa-2a [Pegasys]|180 micrograms sc weekly for 24 weeks
223826106|NCT00592319|DRUG|Celebrex|oral taking of Celebrex (100 mg, BID) for 9 months
223826107|NCT00592319|DEVICE|PDL|once time radiation on laryngeal papilloma with PDL , at 6.0-8.0 J
223826108|NCT00592319|PROCEDURE|CO2 laser or microsurgery|once-time surgery to remove laryngeal papilloma
223826109|NCT00027521|BIOLOGICAL|bleomycin sulfate|
223826110|NCT00027521|DRUG|electroporation therapy|
223826111|NCT04944394|OTHER|online questionnaire|"Administration of an online questionnaire (Limesurvey platform) at M0~\- This questionnaire includes a characterization of the professional (center, profession, usual department and department during the health crisis, family situation). Generic stress factors, the traumatic impact of the crisis and collective and individual coping strategies are also collected."
223826112|NCT04944394|OTHER|questionnaire survey|A questionnaire survey of the chief physician of the intensive care unit of each hospital will make it possible to characterize the support provided by the institution and how it changed over time
223835577|NCT01932996|BEHAVIORAL|Intensive Alcohol Intervention|Intensive alcohol abstinence counseling using CBT will include weekly individual sessions for 3 months followed by monthly booster group sessions for 3 months
223835578|NCT04457622|OTHER|Auditory perception tasks in healthy participants|"The participants complete auditory perception tasks while EEG, and MEG record brain signals (primary outcome measure). The tasks acquire behavioral responses with button presses (secondary outcome measure).~All analyses are intra-subject (no analyses are between-subject)."
223826113|NCT01422681|DEVICE|minimally invasive extracorporeal carbon dioxide removal|"The application of the extracorporeal carbon dioxide removal will be initiated by using a modified continuous veno-venous hemofiltration system equipped with a membrane lung with a total membrane surface of 1,35 m2 (Decap® Smart).~Femoral vein is accessed via a double lumen catheter (14 F) inserted with the Seldinger technique and connected with the extracorporeal circuit. Blood flow is driven through the circuit by a roller nonocclusive low-flow pump (0- 450 ml/min) through a membrane lung (Euroset) that is connected to a fresh gas flow source delivering 100% oxygen at a constant rate of 8 l/min. Exiting the membrane lung, blood is driven to a hemofilter (Medica D250). The resulting plasmatic water is recirculated through the membrane lung by a peristaltic pump (0-155 ml/min)."
223826114|NCT02483013|OTHER|whitening dentifrices|Two groups: participants received the instructions to use only the blinded supplied whitening dentifrice (Colgate Luminous White® or Close up White Now®) and toothbrush to make the habitual oral hygiene, three times per day during four weeks
223826115|NCT02483013|OTHER|Placebo|One group: participants received the instructions to use only the blinded supplied non-whitening dentifrice (Sorriso®) and toothbrush to make the habitual oral hygiene, three times per day during four weeks
223826116|NCT02133482|DRUG|Placebo|placebo solution
223826117|NCT02133482|DRUG|BI 639667|oral solution BI 639667, single rising doses
223826118|NCT02032173|DRUG|Ranibizumab 0.5mg|Intravitreal injection with standard dose of 0.5 mg/0.05mL Pro re nata (PRN)
223826119|NCT05082142|DRUG|Tranexamic acid|Patients in the intervention arm will receive 1g of intraoperative IV TXA during the HoLEP procedure.
223826120|NCT02010697|BEHAVIORAL|Messages targeting nonsmokers|
223826121|NCT02010697|BEHAVIORAL|Messages targeting smokers|
223826122|NCT05149781|PROCEDURE|Standardized diagnosis and treatment|Patients with endocrine hypertension undergo surgery or medication depending on the cause after completion of standard diagnostic procedures. Patients with primary hypertension receive medication.
223826123|NCT01163110|DIETARY_SUPPLEMENT|Realbuild|Patient with chemotherapy induced thrombocytopenia takes RNA fragments orally to accelerate time to platelet recovery
223826124|NCT00061230|BEHAVIORAL|biofeedback-monitored relaxation training|
223826125|NCT03321513|DRUG|intravitreous aflibercept|"Intravitreous aflibercept injection is made by Regeneron Pharmaceuticals, Inc. and is approved by the FDA for the treatment of neovascular age-related macular degeneration, macular edema due to central retinal vein occlusion, macular edema due to branch retinal vein occlusion, diabetic macular edema, and diabetic retinopathy in eyes with diabetic macular edema.~Study eyes assigned to receive aflibercept will receive a dose of 2.0 mg in 0.05 cc. Aflibercept will be obtained commercially by the clinical site. The physical, chemical, and pharmaceutical properties and formulation of aflibercept are provided in the Package Insert.~Intravitreous Injection Technique The injection is preceded by a povidone iodine prep of the conjunctiva. In general, topical antibiotics in the pre-, peri-, or post-injection period should not be used.~The injection will be performed using sterile technique"
223826126|NCT03321513|DRUG|Bevacizumab + Deferred Aflibercept Group|"Bevacizumab is made by Genentech, Inc. and is approved by the FDA for the treatment of metastatic colorectal cancer as well as the treatment of non-squamous non-small cell lung cancer, glioblastoma, and metastatic renal cell carcinoma.~Study eyes assigned to receive bevacizumab will receive a dose of 1.25 mg provided by a single compounding pharmacy identified by the Network and distributed by the Network. The volume of the injections will be 0.05 cc.~Intravitreous injection technique: The injection is preceded by a povidone iodine prep of the conjunctiva. In general, topical antibiotics in the pre-, peri-, or post-injection period should not be used.~The injection will be performed using a sterile technique."
223826127|NCT03938064|DRUG|Prontogest 400 mg vaginal pessaries|natural progesterone in the form of vaginal suppositories 400 mg
223826128|NCT03669653|PROCEDURE|Remote ischemic conditioning|Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflations of a blood pressure cuff to 200 mm Hg. RIC will be conducted twice daily for 7 days.
223826129|NCT03669653|PROCEDURE|Sham remote ischemic conditioning|Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflations of a blood pressure cuff to 60 mm Hg. RIC will be conducted twice daily for 7 days.
223826130|NCT04639921|DIAGNOSTIC_TEST|positive test followed by gluten-free diet|DBPCFC with gluten
223826131|NCT04639921|DIETARY_SUPPLEMENT|Placebo|Placebo
223826132|NCT05414838|DIETARY_SUPPLEMENT|Curcumin, Omega-3 and Vitamin-D (COD)|"Acumin™ Turmeric Complex (Dr. D's Ultra BioTurmeric) 500 mg daily (NPN 80087842)~Omega-3 supplements (combination of DHA and EPA) 900 mg daily (NPN 80019234)~Vitamin D3 supplements 2500 IU daily (NPN 80108995)"
223826133|NCT01694810|DRUG|2% NVN1000 Topical Gel|2% NVN1000 Topical Gel once daily for 4 weeks
223826134|NCT01694810|DRUG|4% NVN1000 Topical Gel|4% NVN1000 4% Topical Gel applied once daily 4 weeks
223826135|NCT01694810|DRUG|8% NVN1000 Topical Gel|8% NVN1000 Topical Gel applied once daily for 4 weeks
223826136|NCT01694810|DRUG|Vehicle Topical Gel|Vehicle Topical Gel applied once daily
223835579|NCT05616949|BEHAVIORAL|Treatment as Usual (TAU) (Arm 1)|Treatment as Usual (TAU): The treatment and/or other services received as part of usual care while living in a recovery residence. This arm serves as the active comparator group for the study.
223826137|NCT06307119|BEHAVIORAL|Occupational Therapy and Relaxation Group|"MOHO Based Intervention~The client-centered occupational therapy comprises five distinct stages:~1. Client-Centered Goal Setting:It involves collaboratively establishing goals the client's needs and aspirations.~2. Creating the Therapy Plan:Comprehensive therapy plan is devised from the findings from OSA and MOHOST results.~3. Implementing the Interventions:These interventions aimed addressing various personal challenges,financial management,stress management.~4. Evaluating the Results:It involves adjusting the therapy plan as needed based on the participant's responses and outcomes.~5. Receiving Feedback~Jacobson's Progressive Muscle Relaxation~Starting with the lower extremities,participants sequentially tensed and relaxed muscle groups,moving from distal to proximal regions,encompassing toes,ankles,thighs,buttocks,abdomen,fingers,triceps,shoulders,and face.During all these stages,it was ensured to maintain contraction for 5 seconds and to relax and rest for 10 seconds."
223826138|NCT06307119|BEHAVIORAL|Relaxation Group|Jacobson's Progressive Muscle Relaxation (JPMR) Participants underwent training in relaxation techniques involving mental visualization and Jacobson's progressive muscle relaxation method with the aid of music. Starting with the lower extremities, participants sequentially tensed and relaxed muscle groups, moving from distal to proximal regions, encompassing toes, ankles, thighs, buttocks, abdomen, fingers, triceps, shoulders, cervical muscles, and face. During all these stages, it was ensured to maintain contraction for 5 seconds and to relax and rest for 10 seconds.
223826139|NCT01993017|OTHER|Cognitive Behavioral Therapy (CBT)|"The main intervention is the impact of screening on quality of life and health care costs. CBT is provided only if depressive symptoms are detected and participant prefers this type of treatment.~CBT will be centrally telephone-administered by a trained CBT treatment specialist. The treatment specialist will work with local team members throughout a participant's involvement in the study, and will closely follow each participant until he or she has reached a requisite level of improvement ."
223826140|NCT01993017|DRUG|Antidepressant Medication|"The main intervention is the impact of screening on quality of life and health care costs. Antidepressant Medication is provided only if depressive symptoms are detected and patient prefers this type of treatment.~Antidepressants should be started at the lowest dose, but should be adjusted upward to be within the therapeutic range within 1 week, with further adjustment higher in the therapeutic range possible at 3-4 weeks. Dosage of the first medication selected will be in the therapeutic range by 3 weeks of the initial step, as tolerated."
223826141|NCT01993017|OTHER|Standard Care|Participants will receive standard care from either their primary care provider (PCP), or PCP-referred mental health provider in one of the arms, IF depressive symptoms are detected.
223826142|NCT01993017|OTHER|Depressive symptom screener|8-item Patient Health Questionnaire, PHQ-8
223826143|NCT01993017|OTHER|No intervention|
223826144|NCT02280057|DRUG|Metformin|Metformin 1500 mg (=2 pills) per day in six months
223826145|NCT02280057|DRUG|Placebo|2 pills per day in six months; pills look like metformin pills
223826146|NCT05412459|DRUG|99mTc-DARPinG3|Diagnostic test (99mTc-DARPinG3-based SPECT) is used for the assessment of the effect of anticancer therapy.
223826147|NCT02757521|DRUG|Nitrous Oxide|50% nitrous oxide/ 50% oxygen, 3 one hour inhalation treatments per Stage, every other day (M,W,F)
223826148|NCT02757521|DRUG|Placebo|50% nitrogen {inert}/ 50% oxygen, 3 one hour inhalation treatments per Stage, every other day (M,W,F)
223826149|NCT02851966|PROCEDURE|mTESE|mTESE time may be postponed or advanced.
223826150|NCT00586079|PROCEDURE|Deep brain stimulation surgery.|Deep brain stimulation surgery.
223826151|NCT06030453|COMBINATION_PRODUCT|SMART HOME strategy|Sleep hygiene: quiet and dim environment for 6 hours to facilitate sleep (Score: 0-100%).Multidisciplinary collaboration: pharmacists, respiratory therapists, rehabilitation therapists, and physical therapists (Score: ≥20%).Assessment : Evaluating and assessing the levels of pain, anxiety, and agitation (Score: 0-100%).Release of tracheal tubes and restraints: relieving pressure from tracheal tubes and restraints (Score: 0-100%).Time and schedule: Orienting the patient to time and a schedule (Score: 0-100%).Home-like environment and Hearing: A comfortable environment similar to home and music (Score: 0-100%).Orientation support: assisting with a sense of person, time, and place (Score: 0-100%).Medication review : Reviewing and adjusting medications (Score: ≥20%).Early mobilization and nutrition(Score: 0-100%).
223826152|NCT06030453|COMBINATION_PRODUCT|PADIS nursing intervention|pharmacological treatments for pain, agitation, delirium, immobility, and sleep disruption as well as nursing interventions
223826153|NCT03369184|DRUG|Oxygen gas|The intervention is administered as previously described. The duration of intervention is 10 minutes.
223826154|NCT03369184|OTHER|Ambient air|Administered similarly to treatment arm, via an open face mask and during 10 minutes
223826155|NCT01279330|OTHER|Co-signed Letter|Patients receive a personalized stimulus letter co-signed by their general practitioner and the medical coordinator of ADECA.
223826156|NCT01279330|OTHER|Control|No intervention (Patients receive by mail the materials needed for stool samples).
223826157|NCT05264610|OTHER|Data collection (Laboratory tests, Radiologic diagnostics, Patient data taken from existing medical charts)|Data collection: Bone turnover laboratory parameters: alkaline phosphatase (AP), calcium (corrected for albumin), PTH, Calcidiol (25-OH-D3), N-terminales Kollagen Typ 1 -. Propeptid (P1NP), glomerular filtration rate (GFR), calcium/creatinine (in urine); Radiologic diagnostics: Bone densitometry (DEXA), X-rays, computer tomograms, MRI for analysis of time of the bone healing (or a non-union); Patient data taken from existing medical charts: side effects, tolerability of PTH, patient compliance, presence of previous illnesses as risk factors for the formation of pseudoarthrosis, indication for therapy, time at which therapy started and length of therapy with PTH, precise characterization of the operation (type and whether it is a revision or first operation).
223826158|NCT04811963|DEVICE|Non-Invasive Controlled Hypoxia|Following arterial cannulation, hypoxia is induced by reducing the percent of inspired oxygen the subject breathes while simultaneous measurements are recorded from the test pulse oximeters and arterial blood samples are collected at targeted levels of saturation.
223826159|NCT00003511|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Multiple Myeloma will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
223826160|NCT00462722|DRUG|Ibuprofen|400 mg with each exercise session (up to 5 days per week) for 9 months
223826161|NCT00462722|DRUG|Placebo|with each exercise session (up to 5 days per week) for 9 months
223826162|NCT00462722|BEHAVIORAL|musculoskeletal-loading exercise|Exercise training program designed to increase bone and muscle mass, including weight lifting and weight-bearing exercises such as jumping in place and treadmill walking up to 5 days per week for 9 months
223826163|NCT03472287|DRUG|Diacerein 1% Ointment|Diacerein 1% Ointment administered topically
223826164|NCT01306721|DRUG|fexofenadine HCL (M016455)|Pharmaceutical form:tablet Route of administration: oral
223826165|NCT01306721|DRUG|pseudoephedrine|"Pharmaceutical form:tablet~Route of administration: oral"
223826166|NCT01306721|DRUG|fexofenadine HCL matching placebo|"Pharmaceutical form:tablet~Route of administration: oral"
223826167|NCT01306721|DRUG|pseudoephedrine matching placebo|"Pharmaceutical form:tablet~Route of administration: oral"
223826168|NCT01395043|PROCEDURE|Placing bilateral TAP-catheters preoperatively|Place bilateral TAP-catheters preoperatively and give repeated boluses of local analgetics in order to treat postoperative pain after colon-surgery.
223826169|NCT01395043|DRUG|Bupivacain 2.5 mg/ml with epinephrine bolus in TAP-catheters|Intermittent boluses of Bupivacain 2.5 mg/ml with epinephrine, 20 ml in each catheter every 12 hours for the first 2 postoperative days.
223826170|NCT02800824|DRUG|Budesonide|
223826171|NCT02800824|DRUG|Uceris|
223826172|NCT01508299|PROCEDURE|skin test|skin test with the Suspected raw food
223826173|NCT05760729|DIAGNOSTIC_TEST|Cognitive testing|Cognitive tests will be carried: MOCA, trail making test, digit symbol substitution, forward and backward digit testing.
223826174|NCT03945110|DEVICE|iAluRil® intravesical instillations|50ml of a sterile solution of sodium hyaluronate (1.6% 800mg/50ml) and sodium chondroitin sulphate (2% - 1 g/50ml) is administered intravesically (directly into the bladder) via a pre-filled syringe connected to a catheter and held in the bladder for at least 30 minutes.
223826175|NCT01683994|DRUG|Cabozantinib|Assigned dose given daily during each 21 day cycle. Treatment may continue until disease progression or intolerable toxicity.
223826176|NCT01683994|DRUG|Docetaxel|75mg/m\^2 intravenous (IV) over approximately 60 minutes on cycle 1 day 1 and repeated every 21 days until disease progression or intolerable toxicity.
223826177|NCT01683994|DRUG|Prednisone|5 mg by mouth (PO) twice a day during each 21 day cycle until disease progression or intolerable toxicity.
223826178|NCT05990920|BIOLOGICAL|SNK02|SNK02 is ex vivo expanded allogeneic NK cells for IV injection, is a light-yellow cryopreserved cell suspension consisting of NK cells isolated from healthy donor's peripheral blood mononuclear cells.
223826179|NCT01026376|DRUG|decitabine|Cycles of 15mg/m2 infusion during 3h, 3 times a day, per 3 days
223826180|NCT01026376|DRUG|decitabine|Cycles of 20mg/m2 infusion during 1h, once a day, per 5 days
223826181|NCT02949674|DRUG|Ropivacaine|It will be used as a analgesic dose in surgical site before surgery.
223826182|NCT02949674|DRUG|Bupivacaine|It will be used as a analgesic dose in surgical site before surgery.
223826183|NCT02723279|BEHAVIORAL|EPNS|Electrical pudendal nerve stimulation Four sacral points are selected. The two upper points are located about 1 cm bilateral to the sacrococcygeal joint. On the upper points, a needle of 0.40 Х 100 mm is inserted perpendicularly to a depth of 80 to 90 mm to produce a sensation referred to the urethra or the anus. The locations of the two lower points are about 1 cm bilateral to the tip of the coccyx. On the lower points, a needle of 0.40 Х 100 or 125 mm is inserted obliquely towards the ischiorectal fossa to a depth of 90 to 110 mm to produce a sensation referred to the urethra. After the sensation referred to the above regions is produced, each of two pairs of electrodes from a G6805-2 Multi-Purpose Health Device is connected with the two ipsilaterally inserted needles.
223826184|NCT02723279|DRUG|TT|Tolterodine tartrate (GSK， UK) 4mg per day is taken orally for six weeks
223826185|NCT03979261|DIAGNOSTIC_TEST|evolution of sex ratio according to age|Histological study of the collected valves to study the differences according to the sex of the inflammatory reaction and the cellular type found.
223826186|NCT04868474|BEHAVIORAL|Training program and decision aid|1\) a one-time, in-person, 2.5-hour training program encouraging participating GPs to present quitting smoking with a quit aid as the default choice to their eligible patients, and 2) access to an electronic decision aid that presents available quit aids. The 2.5-hour training program consists of: 1.5 hours of didactic teaching, with information about pharmacologic quit aids, electronic cigarettes, presenting quitting as a default choice, the decision aid, and a video of a model consultation. This is followed by 1 hour of role plays to practice presenting quitting as a default choice using the decision aid.
223826187|NCT04868474|BEHAVIORAL|Refresher course|A 45-minute refresher training about smoking cessation that does not aim to change GP behaviour. It will include the same information about pharmacologic quit aids and electronic cigarettes.
223826188|NCT01084928|BEHAVIORAL|Lifestyle Intervention Classes|The intervention will be based on the Diabetes Prevention Program but tailored to the needs of the community based on feedback gathered in focus groups. Classes will be group-based and will use a variety of teaching techniques and group-based work to teach participants about behavior change, diet, and physical activity. Participant will be required to attend one group exercise class per week based on traditional Indian dances and other culturally appropriate activities. In order to reach their weekly exercise goal of 150 minutes or more per week, participants will also be able to attend an additional group exercise class, an organized group walk, do a culturally-tailored work out video created by the study staff, and/or exercise on their own.
223826189|NCT05707832|DRUG|Amphotericin B cholesteryl Sulfate Complex for Injection|Intravenous injection (IV), once a day after reaching the recommended dose of 3.0-4.0 mg/kg for treatment. Subjects will receive ABCD intravenous therapy for at least 2 weeks, and the longest course of treatment will not exceed 6 weeks.
223826190|NCT06548685|PROCEDURE|Bone Grafting|Bone grafting in some sites and Vegetable Ivory Grafting in Parallel sites
223826191|NCT06548685|OTHER|Vegetable Derived|Tooth extraction followed by socket preservation with vegetable ivory
223826192|NCT02621567|DEVICE|Bright Light Therapy Lamp|TRAVelite Desk Lamp manufactured by Northern Light Technologies, located in Montreal, Quebec. The light is emitted from a lamp. The florescent tubes in the box are covered with a diffusing screen to ensure even distribution of light and protection from ultraviolet light. These lamps also have a stand which enables users to place the box horizontally or vertically on most surfaces. These lamps emit light of intensity 10,000 lux.
223826193|NCT02621567|DEVICE|Modified Dim Lamp|TRAVelite Desk Lamp manufactured by Northern Light Technologies, located in Montreal, Quebec. The light is emitted from a lamp. The florescent tubes in the box are covered with a diffusing screen to ensure even distribution of light and protection from ultraviolet light. These lamps also have a stand which enables users to place the box horizontally or vertically on most surfaces. These lamps have been modified to emit light of intensity 500 lux.
223826194|NCT02333929|DEVICE|STA- Rivaroxaban Calibrator&Control|One sample blood collected per patient the day of the treatment (drawn soon after the the drug intake)
223835580|NCT05616949|BEHAVIORAL|Peer Recovery Support Services (PRSS) + TAU (experimental- Arm 2)|Peer Recovery Support Services (PRSS) Intervention: The experimental group for this study that involves the implementation of the PRSS intervention. This study will test the preliminary efficacy of the PRSS intervention on Medications for Opioid Use Disorder (MOUD) retention by evenly randomizing N=50 individuals on MOUD living in recovery residences (RRs) to either a 24-week course of the experimental PRSS intervention layered on top of treatment as usual services
223835581|NCT01968161|DRUG|Asenapine|
223826195|NCT05591625|BEHAVIORAL|Eye Movement Desensitisation and Reprocessing|"EMDR is a trauma-focussed, psychological talking therapy whereby the participant verbally relates a narrative of an emotionally disturbing memory, in brief sequential doses, while simultaneously focusing on an external stimulus, most commonly side-to-side finger movements of the psychological therapist. EMDR aims to enable an individual to process memories of the event in order to reduce psychological morbidity. EMDR is widely practiced, so is scalable. It is also protocolised, so can be taught and tested, and allows for fidelity assessment in controlled studies.~The number of sessions will depend on ongoing presence of disturbing memories. This will be determined by the psychological therapist and participant."
223826196|NCT04853147|DRUG|palonosetron, dexamethasone, and fosaprepitant dissolved in 0.9% NaCl|palonosetron 0.075 mg, iv, dexamethasone 5mg, iv, fosaprepitant 150mg dissolved in 0.9% NaCl 150ml, iv.drip,
223826197|NCT04853147|DRUG|palonosetron, dexamethasone, and 0.9% NaCl|palonosetron 0.075 mg, iv, dexamethasone 5mg, iv, 0.9% NaCl 150ml, iv.drip,
223826198|NCT03355963|OTHER|saline injection|The control group: received an IC 1 ml saline injection one day after the penile Doppler/trimix test.
223826199|NCT03355963|BIOLOGICAL|Botulinum toxin type A 50 units|The treatment group B: received a single IC injection of BTX-A 50 units one day after the penile Doppler/trimix test.
223826200|NCT03355963|BIOLOGICAL|Botulinum toxin type A 100 units|The treatment group C: received a single IC injection of BTX-A 100 units one day after the penile Doppler/trimix test.
223826201|NCT00027638|DRUG|thalidomide|
223826202|NCT02835456|DEVICE|Sharklet Catheter insertion|
223826203|NCT02835456|DEVICE|Silicone Foley Catheter insertion|
223826204|NCT02569450|BEHAVIORAL|Surgical outcomes monitoring using Shewhart control chart|"* Assistance by a local surgeon responsible for the implementation of intervention within his/her department~* Quarterly team meeting to interpret variations in observed outcomes on the control charts~* Restitution of surgical outcomes based on wall posters in operating room~* Training sessions provided to local surgeon for appropriate control chart utilization"
223826205|NCT06457100|DRUG|Esmolol Injection|Before induction of anesthesia, 0.5 mg/kg of esmolol was pumped intravenously and infused within 1 minute, followed by a pumping rate of 3 mg/kg/h until the end of the procedure.
223826206|NCT06457100|DRUG|Lidocaine IV|Before induction of anesthesia, 2 mg/kg of lidocaine was pumped intravenously and infused within 10 minute, followed by a pumping rate of 2 mg/kg/h until the end of the procedure.
223826207|NCT01708889|BIOLOGICAL|BMS-914143 (Peginterferon Lambda-1a)|
223826208|NCT06017687|DEVICE|OptiBP Study app|Each participant will use OptiBP Study app to measure their blood pressure optically by applying their fingertip to their smartphone camera, and subsequently enter the blood pressure values obtained by measuring it with their own blood pressure cuff.
223826209|NCT00404534|DRUG|Amoxicillin, Clarythromycin, Omeprazole for ten days|Amoxicillin 1000 mg BID, clarythromycin 500 mg BID for ten days in the experimental group and placebo of Amoxicillin 1000 mg BID and placebo of clarythromycin 500 mg BID in the placebo comparator. Both groups receive omeprazole 20 mg bid for 10 days.
223826210|NCT00917267|DRUG|exenatide once weekly|2.0mg subcutaneous injection, once a week
223826211|NCT00917267|DRUG|exenatide twice daily|5mcg subcutaneous injection twice a day (4 weeks), 10mcg subcutaneous injection twice a day (22 weeks)
223826212|NCT06529900|BEHAVIORAL|oral mastication training|Through specific exercises and techniques aimed at enhancing masticatory function and overall oral health.
223826213|NCT06529900|BEHAVIORAL|texture and diet education|Teach the knowledge and techniques of softening food textures.
223826214|NCT03507543|DRUG|IMP4297|The dose levels will be escalated following a modified 3+3 dose escalation scheme.
223826215|NCT00823550|DRUG|Entecavir|entecavir 0.5 mg QD
223826216|NCT00823550|DRUG|Lamivudine|lamivudine 100 mg QD
223826217|NCT03376841|DRUG|Cenicriviroc|1 tablet; single-dose oral administration
223826218|NCT02858765|OTHER|Application of white polychromatic light for 2h30 at different times of day|
223826219|NCT05980429|OTHER|Music Therapy, prescribed|"All music pieces selected for the prescribed intervention contain compositional elements of relaxation analyzed, prepared, and recorded by professional concert artists and a Grammy-nominated composer. The compositional elements included Accentuation, Articulation, Dynamic Range, Familiarity, Interpretive Expertise, Melodic Shape, Meter, Recording Quality, Repetition, Register, Rubato, Tempo, Texture, Timbre, Transition, and Tonality. These 15 repertoire-selecting parameters were used to choose the prescribed music play list for this study. Music used for the study was downloaded from a password-protected Google Drive accessible to the study participants assigned to the prescribed music intervention group."
223826220|NCT05980429|OTHER|Music Therapy, self-selected|All music pieces were self-selected by the participant
223826221|NCT06171906|BIOLOGICAL|mesenchymal stromal cells|On the basis of conventional PGF treatment for poor implantation, the enrolled patients were injected with 1×10\^6/kg mesenchymal stem cells of cord blood weekly for 4 consecutive weeks
223826222|NCT00268931|BEHAVIORAL|Movement Training|This group of infants underwent specific movement training activities two times per day with their parents.
223826223|NCT00268931|BEHAVIORAL|Social Training|This group underwent special social interactions with their parents two times each day.
223826224|NCT02213419|DRUG|Endoscopic ultrasonography-guided double ethanol lavage|"A radial echoendoscope and a 22 gauge needle were then used for cyst fluid aspiration and ethanol lavage.~The 80 percent volume of cyst fluid was aspirated, and the pure ethanol was injected into the collapsed cyst until the original shape was restored. After 3-5 minutes, the reaspiration of the injected ethanol was then performed. The pure ethanol was reinjected into the collapsed cyst, followed by reaspiration of maximal possible volume for 3-5 minutes."
223826225|NCT03859375|OTHER|microbial skin counts in the disinfection area after paints of skin disinfectants|microbial skin counts in the disinfection area after 2 and 3 paints of skin disinfectants (chlorhexidine in alcohol \[CHX\] and povidone iodine in alcohol \[PI\])
223826226|NCT03157024|DEVICE|Ring Sham (RS)|
223826227|NCT03157024|DEVICE|Real Needle (RN)|
223826228|NCT03157024|DEVICE|Kim Sham (KS)|
223826229|NCT03063970|DEVICE|Dynamic Lycra Orthosis|Dynamic lycra orthoses: made to measure fabric lycra compression gauntlets individually tailored to correct upper limb movement and positioning. Worn for eight hours per day but may be removed for therapy and washing.
223826230|NCT03063970|OTHER|Usual Rehabilitation|Physiotherapy or Occupational Therapy delivered as routine part of rehabilitation
223826231|NCT00243555|PROCEDURE|allergy skin testing|
223826232|NCT00243555|PROCEDURE|venepuncture|
223826233|NCT00719602|DRUG|Lamivudine|Taken orally twice daily
223826234|NCT00719602|DRUG|Lopinavir/Ritonavir|Taken orally twice daily
223826235|NCT00719602|DRUG|Nevirapine|Taken orally twice daily
223826236|NCT00719602|DRUG|Zidovudine|Taken orally twice daily
223826237|NCT01863602|DRUG|Lamotrigine tablets|Administered for long-term according to the prescribing information in the locally approved label by the authorities.
223826238|NCT04402593|BEHAVIORAL|Modified Heidelberg Model of Neuro-Music Therapy|6 sessions, 2 sessions a week including the following interventions: resonance training, music relaxation, Intonation Training and session review/homework.
223826239|NCT00061620|DRUG|Tezacitabine (FMdC)|7.5 mg/m2 bolus infusion daily x 5
223826240|NCT03728153|DRUG|Fluoxetine 20 MG Oral Tablet|Once-daily dosing for 90 days
223826241|NCT04037111|DEVICE|Transcutaneous electrical vagus nerve stimulation|The patient received active VNS and escitalopram oxalate tablets for 2 months.When the VNS was stimulated, the two electrodes were vertically attached to the left carotid sinus at 2cm, or the auricular clip electrode was applied to the tragus.
223826242|NCT04037111|DEVICE|Sham vagus nerve stimulation|The patient received sham VNS.When the VNS was stimulated, the two electrodes were vertically attached to the left carotid sinus at 2cm, or the auricular clip electrode was applied to the tragus.
223826243|NCT04037111|DRUG|drug treatment|Escitalopram oxalate tablets should be taken orally once every morning for 2 months, each time 10-20mg
223826244|NCT02606669|DIETARY_SUPPLEMENT|Meal Replacement|Using a Meal Replacement product, supplemented by protein powder and multivitamin
223826245|NCT02960763|DRUG|Aripiprazole Augmentation|Augment current antidepressant treatment with aripiprazole (tablets). Start at 2 mg daily; increase every two weeks (i.e., to 5, 7, 10 mg) to a maximum of 15 mg daily based on symptom severity and side effects.
223826246|NCT02960763|DRUG|Bupropion Augmentation|Augment current antidepressant treatment with bupropion once-daily extended release, starting at 150 mg daily; titrated after four weeks to 300 mg daily based on symptom severity and side effects.
223826247|NCT02960763|DRUG|Switch to bupropion|Taper from current antidepressant therapy. Start bupropion once-daily extended release at 150 mg daily; titrated after four weeks to 300 mg daily based on symptom severity and side effects.
223826248|NCT02960763|DRUG|Lithium Augmentation|Augment current antidepressant treatment with lithium carbonate tablets starting at 300 mg daily, titrated per blood level to 0.4-0.6 meQ/L.
223826249|NCT02960763|DRUG|Switch to nortriptyline|Taper from current antidepressant therapy. Start on nortriptyline tablets starting at 1 mg per kg of body weight daily, titrated per blood level to 80-120 ng/ml
223826250|NCT02348398|DRUG|Pazopanib|600 mg by mouth daily in a 28 day cycle.
223826251|NCT02348398|DRUG|Topotecan|0.25 mg by mouth daily for 21 days of a 28 day cycle.
223826252|NCT02348398|BEHAVIORAL|Phone Call|During follow up if disease gets worse, participant called by study staff every 3 months. Each call should last about 5 minutes.
223826253|NCT05985057|OTHER|Artificial intelligence|Prediction of carbapenem resistance via deep machine learning model
223826254|NCT00335725|DRUG|Follicle Stimulating Hormone|subcutaneous injection of FSH. Starting dose: 225 IU.
223826255|NCT00335725|DRUG|Follicle Stimulating Hormone|subcutaneous injection of FSH. Starting dose: 225 IU.
223826256|NCT01935921|BIOLOGICAL|Cetuximab|Given IV
223826257|NCT01935921|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
223826258|NCT01935921|BIOLOGICAL|Ipilimumab|Given IV
223826259|NCT01935921|OTHER|Laboratory Biomarker Analysis|Correlative studies
223826260|NCT00656461|DRUG|MKC-1|30 mg and 100 mg capsules, dosed BID daily on a continuous schedule
223826261|NCT00312858|BIOLOGICAL|Comparator: VAQTA™ (Hepatitis A vaccine)|VAQTA™ 0.5 mL injection
223826262|NCT00312858|BIOLOGICAL|Comparator: ProQuad™ (Measles, Mumps, Rubella and Varicella vaccine)|ProQuad™ 0.5 mL injection
223826263|NCT00312858|BIOLOGICAL|Comparator: Prevnar™ (Pneumococcal 7-Valent Conjugate vaccine)|Prevnar™ 0.5 mL injection
223826264|NCT00204659|DRUG|Rituximab + CHOP chemotherapy|standard Rituximab + CHOP chemo-immunotherapy
223826265|NCT02604836|DRUG|Ibandronate|Film-coated oral ibandronate tablet (150 mg) once-monthly
223826266|NCT04343482|DEVICE|wearable vital signs sensor|vital signs monitoring during maternal non-stress testing
223826267|NCT02774408|DEVICE|Saturation sensitive backup ventilation|
223826268|NCT05620030|OTHER|Univentricular Heart|Prevention of complications when discovered
223826269|NCT00548041|OTHER|HIV test by oral swab|Eligible subjects underwent rapid HIV testing by oral swab.
223826270|NCT03638635|DRUG|Bupivacaine|Abdominal injection of bupivacaine into fascial layer.
223826271|NCT03638635|DRUG|Bupivacaine liposome|Abdominal injection of bupivacaine liposome into fascial layer.
223826272|NCT03406793|DIETARY_SUPPLEMENT|Standard MNP|Standard MNP, 15 micronutrients (Vitamin A 400 µg, vitamin D 5 µg, vitamin E 5 mg, vitamin C 30 mg, thiamine 0.5 mg, riboflavin 0.5 mg, niacin 6 mg, pyridoxine 0.5 mg, vitamin B12 0.9 mg, folate 150 µg, iron 10 mg, zinc 4.1 mg, copper 0.56 mg, selenium 17.0 µg and iodine 90 µg). Daily supplementation for 24 weeks.
223826273|NCT03406793|DIETARY_SUPPLEMENT|High zinc, low iron MNP|Same as group 1, except with 10 mg zinc instead of 4.1 mg and 6 mg iron instead of 10 mg. Daily supplementation for 24 weeks.
223826274|NCT03406793|DIETARY_SUPPLEMENT|High zinc, low/no iron on alternating days|Same as study group 1, except with 10 mg zinc instead of 4.1 mg, and 6 mg iron and no iron on alternating days instead of 10 mg. Daily supplementation for 24 weeks.
223826275|NCT03406793|DIETARY_SUPPLEMENT|Dispersible zinc supplement|10 mg zinc in a dispersible tablet. Daily supplementation for 24 weeks.
223826276|NCT03406793|DIETARY_SUPPLEMENT|Intermittent zinc supplement|10 mg zinc in a dispersible tablet. Daily supplementation for 14 days at baseline and 3 months, placebo tablet on all other days.
223826277|NCT03406793|DIETARY_SUPPLEMENT|Placebo powder|Daily provision of a placebo powder for 24 weeks.
223826278|NCT01603420|DRUG|Luteinizing hormone-releasing hormone (LHRH)|Androgen suppression therapy using luteinizing hormone-releasing hormone (LHRH) agonists such as leuprolide, goserelin, buserelin, triptorelin.
223826279|NCT01603420|DRUG|Docetaxel|Docetaxel 20mg/m2 IV every 7 days x 8 weeks.
223826280|NCT01603420|OTHER|Conformal Radiation Therapy (RT)|1.8 Gy(RBE) (or Gy for IMRT) per fraction,five fractions per week for a total dose of 79.2 Gy (RBE) (or Gy).
223826281|NCT00252590|BEHAVIORAL|Health Motivational Feedback|Personalized feedback on health status
223826282|NCT00252590|BEHAVIORAL|Health Education|Generalized health education related to alcohol use
223826283|NCT00252590|BEHAVIORAL|Control - treatment as usual|Control group with no additional intervention
223826284|NCT02100540|DRUG|I placebo capsule|I placebo capsule
223826285|NCT02100540|DRUG|II RDC 0.3mg capsule|II RDC 0.3mg capsule
223826286|NCT02100540|DRUG|III RDC 0.6mg capsule|III RDC 0.6mg capsule
223826287|NCT03103022|DRUG|Acetaminophen|Oral acetaminophen \[160 mg/5ml concentration\] will be administered every 6 hours with dose of 15 mg/kg/dose for a total of twelve doses
223826288|NCT03103022|DRUG|ibuprofen|Oral ibuprofen \[100 mg/5 ml\] at 10 mg/kg/dose on first day followed by 5 mg/kg/dose at 24 and 48 hours for a total of three doses
223826289|NCT00802659|RADIATION|Stereotactic radiotherapy|This study has 4 treatment groups: This will be determined based on what radiation treatment doses have been previously given to the patient on this study, how effective the dose has been with treatment patient's pain, and how many side effects participants before you have experienced.
223826290|NCT03188614|DRUG|Fluid resuscitation|The placebo group is resuscitated with normal saline, the experimental group is resuscitated with balanced fluid.
223826291|NCT00289770|BIOLOGICAL|Twinrix™|Intramuscular injection, 3 doses
223826292|NCT00164853|PROCEDURE|endoscopic balloon dilatation|Refer to description under arms
223826293|NCT00164853|PROCEDURE|Standard sphincterotomy|Refer to under arms
223826294|NCT03393299|PROCEDURE|STOPP/START criteria|software which helps to do the drug reconciliation
223826295|NCT03685032|DRUG|Dexamethasone|The 4 mg of dexamethasone in 1 ml intravenous was administrated after patient received general anesthesia
223826296|NCT03685032|DRUG|Ondansetron|The 4 mg of ondansetron in 2 ml intravenous was administrated at the end of the operation.
223826297|NCT03685032|DRUG|0.9% Sodium Chloride Injection|The 0.9% sodium chloride in 1 ml intravenous was administrated after patient received general anesthesia. At the end of operation, the 0.9% sodium chloride in 2 ml intravenous was administrated.
223826298|NCT05140187|BIOLOGICAL|CMV-TCR-T cells|The patients with CMV infection after HSCT will receive one to three doses of donor-derived CMV-TCR-T cells, with the escalated doses including 1×10\^3/kg, 1×10\^5/kg, and 5×10\^5/kg CMV-TCR-T cells per dose.
223826299|NCT01905579|PROCEDURE|Paracentesis of the anterior chamber|Aqueous humor parenthesis for quantitative protein analysis in patients with and without uveitis.
223826300|NCT02916992|RADIATION|CT scan of the thorax|A low dose CT scan of the thorax (2mSv) wil be performed once.
223826301|NCT02916992|GENETIC|blood sample for FLCN mutation analyses|A venous punction in order to withdraw 16ml blood is undertaken once.
223826302|NCT01617083|DRUG|Azithromycin|Antibiotic used to treat infections
223826303|NCT01617083|DRUG|Placebo|Thickening compound with sugar and flavoring
223826304|NCT00498836|DRUG|CP-4055|CP-4055 5mg/mL for infusion, dose: 200 mg/m2/day, schedule d1-5 q4w, 30 minutes IV infusion
223826305|NCT00498836|DRUG|Sorafenib (Nexavar)|Sorafenib 200 mg tablets, dose: 400 mg/day, daily dosing
223826306|NCT05491343|DRUG|MedroxyPROGESTERone Injection [Depo-Provera]|The drug-induced endometrial changes would likely to prevent the shedding of endometrium, in turn preventing the exposure of AVM.
223826307|NCT05491343|DEVICE|Other|Follow up using US
223826308|NCT02430818|DRUG|ketamine|
223826309|NCT02430818|DRUG|morphine|
223826310|NCT02676752|PROCEDURE|Medical Examination|Evaluation of secondary lymphedema and fibrosis (LEF) status
223826311|NCT02676752|OTHER|Questionnaire Administration|Completion of questionnaires
223826312|NCT02676752|PROCEDURE|Shear Wave Elastography|Undergo ultrasound shear wave elastrography
223826313|NCT00157651|DRUG|warfarin|Daily oral warfarin with INR monitored weekly, adjusted to keep INR between 1.5 and 1.9
223826314|NCT00157651|DRUG|placebo|matching placebo for warfarin, adjusted according to sham INR generated by unblinded warfarin monitor
223826315|NCT00839774|OTHER|Whole yellow pea flour|Whole pea flour was administered at 50 g/day.
223826316|NCT00839774|OTHER|Fractionated pea flour|Fractionated pea flour was administered according to the level of fiber in whole pea flour treatment. 12 g/day
223826317|NCT00839774|OTHER|White wheat flour|White wheat flour will be administered at 50 g/day
223826318|NCT03904537|BIOLOGICAL|anti-PD-1 antibody-activated TILs|Participants would received one dose anti-PD-1 antibody-activated TILs at the final cycle of XELOX regimen chemotherapy
223826319|NCT05112341|RADIATION|radiation therapy|the patient first is simulated then delineation is done
223826320|NCT05293288|DEVICE|EEG-guided general anesthesia|pEEG monitoring will start with the beginning of induction of general anesthesia and will end with the end of surgery (surgical suture). In the EEG-guided group, depth of anesthesia will be adjusted to target PSI values between 25 and 50 and spectral edge frequency between 10 and 15. In case of contradictory values, the raw EEG waveforms, ARTF, EMG, as well as the overall clinical situation will be evaluated for decision making.
223826321|NCT04821999|DEVICE|a 940-nm diode laser|a 940-nm diode laser (EPIC™, BIOLASE, www.biolase.com) with an adjustable pain therapy handpiece capable of creating diffuse laser energy patterns ranging from 15 mm to 30 mm in size.
223826322|NCT03529448|DRUG|TN-TC11G|"TN-TC11G dose will be gradually increased as follows:~Week 1: TN-TC11G: 0-0-5 mg (THC 5 mg + CBD 5 mg; in the mornings, 90 minutes after breakfast; in the afternoons, 90 minutes after lunch; in the evenings, 90 minutes after dinner).~Week 2: TN-TC11G: 5-0-5 mg Week 3: TN-TC11G: 5-5-5 mg Week 4: TN-TC11G: 5-5-10 mg Week 5: TN-TC11G: 5-5-15 mg Week 6: TN-TC11G: 10-10-15 mg Week 7: TN-TC11G: 10-10-20 mg. Week 8: TN-TC11G: 15-15-30 mg Week 9: TN-TC11G: 20-20-40 mg TN-TC11G will be administered daily at the relevant dose level according to the individual titration performed in the first 9 weeks of treatment. If there is any dose reduction, the reduced dose must be administered."
223835582|NCT00338715|DEVICE|PVI with Medtronic's Cardioblate BP2 radiofrequency catheter|Ablation of the right and left pulmonary veins
223835583|NCT01517022|DRUG|nicotine replacement therapy|nicotine replacement therapy 2mg for patients cessation arm for period of 6 weeks
223835584|NCT04685473|DRUG|T-1101 (Tosylate)|T-1101 (Tosylate) Capsule
223826323|NCT03529448|DRUG|Temozolomide Oral Product|"During RT, patients will receive Temozolomide (TMZ). All patients will be given TMZ at 75 mg/m2/d concurrently with RT for a maximum of 42 days.~At 4 weeks after RT completion, patients will start taking TMZ at 150 mg/m2/d for the first 5 days of a 28-day cycle. If first cycle is well tolerated, patients will receive TMZ at 200 mg/m2/d for the first 5 days of every subsequent 28-day cycle for another 5 cycles."
223826324|NCT03529448|RADIATION|Radiotherapy|All the patients will receive the Stupp regimen. The radiotherapy (RT) treatment will be administered in fractions of 1.8-2.0 Gy/day delivered 5 days/week to a total dose of 58-60 Gy. Radiotherapy will be delivered to the gross tumor volume with a 2-3 cm margin for the clinical target volume.
223826325|NCT06781281|DRUG|Serplulimab|Serplulimab
223826326|NCT06781281|DRUG|NabPE|Epirubicin 75mg/m2 ivgtt +Albumin Paclitaxel 260mg/m2
223826327|NCT06523738|DIAGNOSTIC_TEST|1. electrical/pharmacological cardioversion. 2.pulmonary vein isolation|1\. electrical/pharmacological cardioversion. 2. pulmonary vein isolation for persistent atrial fibrillation
223826328|NCT01138930|DRUG|Berberine|1.5g daily for 3 month
223826329|NCT01138930|DRUG|Placebo|placebo daily
223826330|NCT03535402|DRUG|Sarilumab|SC administration of 200 mg twice a week
223826331|NCT06365307|COMBINATION_PRODUCT|"Osteoplastic material based on octacalcium phosphate and biologically active nucleic acids for bone tissue regeneration Nucleostim-VEGF (Histograft)"|Due to the localization of the pathological process, all patients are divided into two groups: 1 - cervical spine, 2 - lumbar spine. Within these groups, patients are treated with either gene-activated osteoplastic material Histograft or synthetic osteoplastic material based on β-TCP (β-tricalcium phosphate) for spinal fusion of the cervical spine, or with bone autograft for spinal fusion of the lumbar spine.
223826332|NCT06365307|OTHER|Synthetic osteoplastic material based on β-TCP or bone autograft|Due to the localization of the pathological process, all patients are divided into two groups: 1 - cervical spine, 2 - lumbar spine. Within these groups, patients are treated with either gene-activated osteoplastic material Histograft or synthetic osteoplastic material based on β-TCP (β-tricalcium phosphate) for spinal fusion of the cervical spine, or with bone autograft for spinal fusion of the lumbar spine.
223826333|NCT05815927|DRUG|Pembrolizumab|Pembrolizumab: 400mg Q6W up to 2 years (i.e 17 cycles).
223826334|NCT05815927|RADIATION|stereotattic ablation radiotherapy (SABR)|Total dose and number of fractions will depend on the site of the disease. Three-fraction regimens will deliver a fraction every second day, and five-fraction regimens are delivered daily. All treatments have to be completed within 10 working days.
223826335|NCT05340751|DIAGNOSTIC_TEST|Blood drawn|Hemoglobin and Hematocrit Levels
223826336|NCT00118625|BIOLOGICAL|Tree MATA MPL|
223826337|NCT01677780|DRUG|RO5045337|Participants will receive RO5045337 orally in doses ranging from 20 milligram per square meter (mg/m\^2) to 1800 mg/m\^2 daily, and up to 1500 mg dose twice daily on a variety of schedules including daily for up to 20 days and weekly dosing for 3 weeks in 28 day cycles until disease progression or unacceptable toxicity with maximum treatment duration of 24 months.
223826338|NCT04399551|DRUG|CAB OLI|CAB will be available as 30 milligrams (mg) tablet. It will be administered as one tablet once daily with food from Day 1 to Month 1.
223826339|NCT04399551|DRUG|CAB LA|CAB LA 600 mg will be administered as intramuscular (IM) injection.
223826340|NCT04399551|DRUG|RPV OLI|RPV will be available as 25 mg tablet. It will be administered as one tablet once daily with food from Day 1 to Month 1.
223826341|NCT04399551|DRUG|RPV LA|RPV LA 900 mg will be administered as IM injection.
223826342|NCT04399551|OTHER|Continuous Quality Improvement (CQI) calls|CQI will be attended by the enhanced arm (Arm-E). The CQI calls will be conducted to identify problems/challenges, generate plans to address the challenges, and identify how to measure the change that results from the plan.
223826343|NCT05469542|DEVICE|Everbeat Ring|The primary objective of this study is to assess the concordance of specific ECG parameters obtained in the everbeat nine-lead ECG waveform with those obtained in the comparable leads from a standard 12-lead ECG recorder.
223826344|NCT01014975|BIOLOGICAL|Plasmin (Human)|Plasmin (Human), 20 mg, delivered through a catheter into a thrombus
223826345|NCT01014975|BIOLOGICAL|Plasmin (Human)|Plasmin (Human), 40 mg, delivered through a catheter into a thrombus
223826346|NCT01014975|BIOLOGICAL|Plasmin (Human)|Plasmin (Human), 80 mg, delivered through a catheter into a thrombus
223826347|NCT00172081|DRUG|placebo|Daily subcutaneous injection with placebo
223826348|NCT00172081|DRUG|ALX1-11|PTH (1-84) 100 mcg injected subcutaneously into the thigh or abdomen
223826349|NCT00420134|PROCEDURE|injection of progenitor of hepatocyte drived from Mesenchymal stem cell|
223826350|NCT05012449|PROCEDURE|Arthrography-assisted joystick technology.|Arthrography-assisted joystick technology.
223826351|NCT01336634|DRUG|Dabrafenib|Dabrafenib study treatment was provided as 50 mg and 75 mg hydroxypropyl methylcellulose (HPMC) capsules. Each capsule contains 50 mg or 75 mg of free base (present as the mesylate salt)
223826352|NCT01336634|DRUG|Trametinib|Trametinib study treatment was provided as 0.5 mg and 2 mg tablets. Each tablet contained 0.5 mg or 2 mg of trametinib parent (present as the dimethyl sulfoxide solvate)
223826353|NCT02961881|DRUG|blinatumomab|Blinatumomab used as both continuous IV infusion and subcutaneous injection
223826354|NCT02803567|BEHAVIORAL|Brief psycho-educational intervention|Participants in the intervention arm will receive a computerized brief intervention composed of tailored feedback and psycho-education specific to their chronic condition.
223826355|NCT06428149|PROCEDURE|Midline interproximal soft-tissue incision|Firstly, the marginal tissue will be elevated around the periodontal defect, through the tunneling of the tissues, entering through the gingival sulcus and the periodontal pocket of the teeth involved in the defect periodontal. Once the marginal tissues have been disinserted to full thickness, the soft supra-alveolar component of the defect to be reconstructed will be stretched, in a buccal direction, with a blunt instrument, applying pressure on the lingual aspect. Visualizing the midpoint of the interproximal tissue, the papilla will be dissected at its midpoint, entering through the mesial aspect, with the scalpel blade perpendicular to the central axis of the teeth.
223826356|NCT06428149|PROCEDURE|Marginal approach by palatal incision|First, an incision will be made in the palatal aspect of the interproximal papilla, at the base of the papilla, parallel to the axis of the tooth until touching the palatine alveolar crest, in order to detach and move the papilla from its base, attached to the vestibular flap. From the palatal incision the interproximal tissue will be elevated towards the buccal until the buccal bone crest is exposed.
223826357|NCT06428149|PROCEDURE|Minimally invasive surgical technique|The defect will be accessed through an incision at the base of the papilla on the vestibular aspect. Depending on the anatomy of the interproximal space, two types of incisions will be made: simplified papilla preservation flap (SPPF) when the width of the interproximal space is equal to or less than 2 mm, or modified papilla preservation technique (MPPT) when the width is greater than 2 millimeters. The interproximal incision will extend intrasulcular on the lingual and buccal aspect of the teeth adjacent to the defect, and mesio-distally it will extend as necessary to allow access to the defect and its debridement. The papilla will move from its base towards the palatine.
223826358|NCT01446263|PROCEDURE|Radial access versus femoral access for coronary angiography and intervention|Radial access or femoral access for coronary angiography and intervention in patients with prior coronary artery bypass grafts
223826359|NCT05518292|OTHER|rhomboid intercostal block|Ultrasound guided RIB will apply with 10-12 MHz linear ultrasound transducer, in plane technique. Patients will placed in the sitting position. 22G spinal needle needle will be inserted to plane between the rhomboid muscle and intercostal muscles over the T5-6 ribs 2 cm to 3 cm medially from the medial border of the scapula. 20 ml of bupivacaine 0.25% will inject into the fascial plane.
223826360|NCT05518292|OTHER|serratus anterior plane block|Patients will placed in the lateral position with the diseased side up. A 10-12 MHz linear ultrasound transducer is placed over the mid-clavicular region of the thoracic cage in a sagittal plane. The fifth rib is identified in the mid-axillary line. The following muscles are identified easily overlying the fifth rib: the latissimus dorsi (superficial and posterior), teres major (superior) and serratus muscle (deep and inferior). As an extra-reference point, the thoracodorsal artery is used to aid the identification of the plane superficial to the serratus muscle. The needle (22G spinal needle) will be introduced in-plane with respect to the ultrasound probe targeting the plane superficial to the serratus muscle. Under continuous ultrasound guidance, 20 ml of bupivacaine 0.25% will inject.
223826361|NCT05429658|DEVICE|Thrombectomy|The Route 92 Medical Reperfusion System is indicated for use in the revascularization of patients with acute ischemic stroke secondary to intracranial large vessel occlusive disease within the internal carotid, middle cerebral, basilar and vertebral arteries.
223826362|NCT00947037|DRUG|AP-CD/LD|
223826363|NCT00861926|DRUG|Ventolin|Ventolin : salbutamol sulfate 100µg
223826364|NCT00861926|DRUG|beclometasone /formoterol|BDP 100µg/FF 6µg, 1 inhalation bid
223826365|NCT04289701|OTHER|Health Services for Systematic Hypertension Management|"The systematic hypertension management health services from the Hypertension prevention and control initiative in China project. Main services are as follows:~1. Healthcare provider training and patient education.~2. Standardized guideline-based hypertension diagnosis, treatment and management recommendation.~3. Patient-centered, pan-cycle continuous hypertension management via the organizing framework of NMAH and sharing digital platform.~4. Periodical Patient follow-up via blood pressure monitor-sharing system and in collaboration with other basic local public health programs.~5. Outcome and performance evaluation quarterly.~6. Incentives for healthcare organizations and primary healthcare providers, and subsidies to patients.~7. Certification for Honorary Hypertension Centers at county levels and establishment for hypertension clinics at primary care centers."
223826366|NCT02268617|OTHER|Treadmill Walking|Following instructions and familiarization with the treadmill, participants will walk on the treadmill for 20 minutes total with rest periods as needed. Treadmill speed will be set at each participant's overground comfortable walking speed for the first 5 minutes, provided that they can walk safely. If necessary the speed will be lowered until a safe gait is achieved. After 5 minutes the speed will be incrementally increased by10% each 5 minutes (3 times) as long as a safe gait (i.e., no abnormal vital signs, excessive effort, or loss of balance occurrences) can be maintained. If the gait pattern becomes unsafe or more abnormal the speed will revert to the previous safe speed and be maintained at this level until the end of training session.
223826367|NCT03379064|BEHAVIORAL|Culturally adapted Cognitive Behavior Therapy for IBS|Culturally adapted Cognitive Behavior Therapy for IBS
223826368|NCT05625581|DRUG|tofacitinib|All subjects were treated immediately after non randomized enrollment. The treatment scheme of the experimental group: glucocorticoid+tropitib; the treatment scheme of the control group: glucocorticoid+cyclophosphamide.
223826369|NCT04532021|DIAGNOSTIC_TEST|matrix metalloproteinase 14, neopterin, and orosomucoid 1 measurements|These three markers levels will be measured using a commercially available enzyme-linked immunosorbent assay (ELISA) kit.
223826370|NCT02721641|DRUG|Herceptin|Herceptin will be administered as either 2 milligrams per kilogram (mg/kg) once weekly (first dose as a 4-mg/kg loading dose) or 6 mg/kg every 3 weeks (first dose as an 8-mg/kg loading dose) via IV infusion over 90 minutes.
223826371|NCT03579797|BEHAVIORAL|Screening, referral, follow-up and health management|Field screening, remote diagnosis, comprehensive assessment, referral, and eye health management of diabetics were the main study processes. The community health service centers (CHSC) are responsible for the field screening. The designated medical institutions (DMI) of each district are responsible for the remote diagnosis and comprehensive assessment of diabetic eye diseases, especially diabetic retinopathy (DR), based on comprehensive evaluation through the remote reading system (RRS) and Shanghai eye health information service system (SEHISS). The staff of CHSC urged the referral objects promptly for further diagnosis and treatment in DMI. According to the diagnosis after clinically confirmed, all the study participants will be recommended appropriate eye health management.
223826372|NCT01863043|PROCEDURE|No aspiration of gastric contents|Infants will not have routine aspiration of gastric contents prior to every feeding to assess residual gastric contents.
223826373|NCT01863043|PROCEDURE|Routine aspiration of gastric contents|Infants will have routine aspiration of gastric contents prior to each feeding to monitor the amount of residual gastric contents remaining in the stomach.
223826374|NCT03350659|DRUG|Midodrine|Midodrine single 5mg/day
223826375|NCT03350659|DRUG|Atomoxetine|Atomoxetine single 18mg/day
223826376|NCT00313911|BIOLOGICAL|DTaP-IPV-HB-PRP~T|0.5 mL, Intramuscular (IM)
223826377|NCT00313911|BIOLOGICAL|Tritanrix-HepB/Hib|0.5 mL, Intramuscular
223826378|NCT04192513|DRUG|J. lividum|Investigational Product
223826379|NCT05246072|DRUG|Ivermectin + colchicine|In addition to the local standard of care for COVID 19 patients, the patient will receive Ivermectin + colchicine
223826380|NCT05246072|DRUG|Colchicine|In addition to the local standard of care for COVID 19 patients, the patient will receive colchicine
223826381|NCT02193802|DEVICE|PillCam® COLON 2 and PillCam Crohn's capsules|"Patient preparation for PillCam® COLON 2 and PillCam Crohn's capsule procedure:~Patients will drink only clear liquids beginning 12 noon the day prior to the procedure,12 hour fast prior to the procedure and 1 L of PEG on the morning two hours before the capsule ingestion.~Patients can drink clear liquids 2 hours and eat 4 hours post ingestion. Eight hours post ingestion the data recorder should be removed. Patients will confirm excretion of the capsule or as required by the investigator."
223826382|NCT03301688|BIOLOGICAL|Toripalimab|To compare the different drug batch number with different process
223826383|NCT04232098|OTHER|Heat to ankle|Heat administered via hot water to ankle level
223826384|NCT04232098|OTHER|Heat to calf|Heat administered via hot water to calf level
223826385|NCT03376802|DRUG|SAR425899|"Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous"
223826386|NCT03376802|DRUG|Placebo|"Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous"
223826387|NCT01068314|OTHER|Repetitive arm exercise|After baseline testing and randomization, subjects in this group are instructed to perform repetitive handgrip exercise with an upper arm compression band until arm fatigue occurs. After resting 1 minute this exercise is repeated 9 times daily for 6 weeks.
223826388|NCT03901560|OTHER|Music Therapy|
223826389|NCT03384953|BEHAVIORAL|Clinical Hypnosis - Group Treatment|group treatment
223826390|NCT03384953|BEHAVIORAL|Clinical Hypnosis - Individual Treatment|individual treatment
223826391|NCT03720782|DEVICE|LEGION Porous HA Tibial Baseplate and/or the LEGION Porous HA CR Femoral Component|LEGION Porous HA Tibial Baseplate (with and without holes) and/or the LEGION Porous HA CR Femoral Component
223826392|NCT06441825|OTHER|Increased multimodal observation including digital monitoring|Digital monitoring combined with repeated clinical assessments and retrospective analysis of serological markers
223826393|NCT01912781|DEVICE|FID 120947A contact lens disinfecting solution|Investigational 3% hydrogen peroxide solution intended for simultaneous cleaning, protein removal, disinfecting and storage of gas permeable contact lenses
223826394|NCT01912781|DEVICE|Boston Simplus multi-action solution|Commercially available solution indicated for cleaning, removing protein, rinsing, disinfecting, conditioning, storing and cushioning of fluoro silicone acrylate and silicone acrylate rigid gas permeable contact lenses
223826395|NCT01912781|DEVICE|Gas permeable contact lenses|Commercially available gas permeable contact lenses worn a minimum of 8 hours each day on a daily wear basis for the duration of the study (90 days).
223826396|NCT04041752|BEHAVIORAL|SOLID|condition with a classical meal served using solid food items
223826397|NCT04041752|BEHAVIORAL|LIQUID_P|condition with a liquid meal served using a powder solution
223826398|NCT04041752|BEHAVIORAL|LIQUID_L|condition with a pre-prepared meal served using a liquid solution.
223826399|NCT04396223|DRUG|Avelumab Injection|Avelumab administration at 800mg a 1 hour IV infusion once every 14 days during 4 months ½ (median)
223826400|NCT04396223|DRUG|Methotrexate 1 GM Injection|methotrexate administration at 1mg/kg/day during 4 months ½ (median)
223826401|NCT04974814|DRUG|Rosuvastatin 40mg|patients in active arms will be preloaded with a single 40 mg rosuvastatin in ER before PCI
223826402|NCT04974814|DRUG|Atorvastatin 80mg|patients in active arms will be preloaded with a single 80 mg atorvastatin in ER before PCI
223826403|NCT04974814|DRUG|Control Test|patients in control arm will not preloaded with statin in ER before PCI
223826404|NCT01982214|DEVICE|sedentary|No intervention
223826405|NCT01982214|DEVICE|Vibration|Subjects will be submitted to the WBV for 5 to 20 minutes, 2 or 3 times a week with frequencies between 35 to 50 Hz while 12 months
223826406|NCT04183634|DRUG|Rotigotine TTS (Test)|Transdermal patch containing Rotigotine 18 mg to deliver 8 mg/24.
223826407|NCT04183634|DRUG|Neupro (Reference)|Neupro®: transdermal patch containing Rotigotine 18 mg to deliver 8 mg/24 h.
223826408|NCT01515904|BEHAVIORAL|STOMP Clinic|"A new interdisciplinary clinic (STOMP) was created to provide care for children and adolescents with severe 'complex' obesity. As part of the program, a subset of adolescents undergo bariatric surgery. The core elements include an interdisciplinary team, frequent visits, individualized care plans for medically-complex adolescents) and building on other aspects, such as increased psychosocial intervention; involvement of a key worker (nurse practitioner) to support families; provision of continuity of care with other health providers in all settings, community services and schools; a more diverse patient population; and group support sessions."
223826409|NCT01971580|DRUG|Ambrisentan|
223826410|NCT01973894|PROCEDURE|Blood and urine sampling|"Blood and urine sampling will follow this schedule:~* 24h: blood (3ml)~* 48h: blood (3ml) and urine~* End of infusion: blood (3ml)~* 6h after end of infusion: blood (3ml) and urine. Blood samples will be centrifuged for 10 minutes at 3300rpm, then supernatant will be placed into test tubes and stored at -20°C; urine samples will be freeze at -20°C as well.~Then all frozen samples will be analyzed to get Midazolam concentrations."
223826411|NCT05691348|PROCEDURE|Ambulatory appendectomy|Appendectomy will be performed in outpatient surgery unit. Patient will be discharge from the hospital the same day as surgery
223826412|NCT05691348|PROCEDURE|Conventional appendectomy|Appendectomy will be performed in digestive surgery department. Patient will be discharge from the hospital the day after surgery: he will spend a night under observation
223826413|NCT00854295|DEVICE|NexGen LPS-Flex Mobile Bearing Knee|Total Knee Replacement
223826414|NCT06384378|DRUG|11C-ER176|ER176 is a PET tracer that binds to the 18 kDa translocator protein (TSPO), which is expressed by activated microglia and astrocytes and is therefore an index of brain inflammation.
223826415|NCT04808128|OTHER|Drink A + SC|Consumption of energy drink that contains 80mg caffeine and 27g carbohydrates per 250ml together with simple carbohydrates.
223826416|NCT04808128|OTHER|Drink B + SC|Consumption of soft drink, non-caffeine drink that contains 27g carbohydrates per 250ml together with simple carbohydrates.
223826417|NCT04808128|OTHER|Drink C + SC|Consumption of soda water, non-caffeine and non-carbohydrate drink together with simple carbohydrates.
223826418|NCT04808128|OTHER|Drink A + CC|Consumption of energy drink that contains 80mg caffeine and 27g carbohydrates per 250ml together with complex carbohydrates.
223826419|NCT04808128|OTHER|Drink B + CC|Consumption of soft drink, non-caffeine drink that contains 27g carbohydrates per 250ml together with complex carbohydrates.
223826420|NCT04808128|OTHER|Drink C + CC|Consumption of soda water, non-caffeine and non-carbohydrate drink together with complex carbohydrates.
223826421|NCT00953914|DRUG|Pyridostigmine|Pills containing 30 mg of Pyridostigmine will be orally administered 3 times daily for 1 day.
223826422|NCT00953914|DRUG|Placebo|If subject is randomized to placebo, placebo pills will give 30 mg orally 3 times daily for 2 days
223826423|NCT04679103|BIOLOGICAL|Eculizumab (JSC GENERIUM, Russia)|Eculizumab
223826424|NCT02710760|OTHER|Adoption Encouragement Treatment|Households in the Adoption Encouragement Treatment received child nutrition focused guidance on the nutritional and agronomic benefits of Quality Protein Maize (QPM) adoption, and the opportunity to order up to 6 kg of QPM seed to plant in their own fields.
223826425|NCT02710760|OTHER|Consumption Encouragement Treatment|Households in the Consumption Encouragement Treatment received the same guidance as households in the Adoption Encouragement Treatment, as well as additional guidance on the importance of specifically targeting foods made with QPM to young children and tools to help households keep the grain separate and remember to feed QPM-based foods to the young children.
223826426|NCT04856943|PROCEDURE|Smartconsent application|Patients asigned to smartconsent group will sign informed consent through a Tablet.
223826427|NCT04856943|OTHER|Control group|Patient asigned to control group will sing the informed consent in papel, as it is performed in clinical practice
223826428|NCT04250337|BIOLOGICAL|Lebrikizumab|Subcutaneous injection
223826429|NCT04250337|OTHER|Placebo|Subcutaneous injection
223826430|NCT04250337|OTHER|Topical Corticosteroid|Topical Corticosteroid
223826431|NCT04127084|DRUG|SGLT2 Inhibition|Dapagliflozine 5-10 mg once daily tablet treatment or Empagliflozin10 mg once daily tablet treatment or Canagliflozin 100 mg once daily tablet treatment
223826432|NCT02301637|DEVICE|Eeva™ Test|The Eeva System is indicated to provide adjunctive information on events occurring during the first two days of development that may predict further development to the blastocyst stage on Day 5 of development. This adjunctive information aids in the selection of embryo(s) for transfer on Day 3 when, following morphological assessment on Day 3, there are multiple embryos deemed suitable for transfer or freezing.
223826433|NCT04743375|OTHER|wound dressing application|Sericin dressing with collagen or Bactigras will be used as a primary dressing for treating the STSG donor site.
223826434|NCT00003284|BIOLOGICAL|filgrastim|
223826435|NCT00003284|DRUG|carboplatin|
223826436|NCT00003284|DRUG|etoposide|
223826437|NCT00003284|DRUG|ifosfamide|
223826438|NCT00003284|DRUG|paclitaxel|
223826439|NCT00003284|PROCEDURE|peripheral blood stem cell transplantation|
223826440|NCT00003284|RADIATION|radiation therapy|
223826441|NCT00026897|PROCEDURE|Gamma-camera imaging|
223826442|NCT00026897|PROCEDURE|Low-risk biopsy|
223826443|NCT06391814|BIOLOGICAL|EBV-specific T cells|Consolidative cellular immunotherapy consisting of one (or up to 4) infusion of ex vivo expanded T cells
223826444|NCT02611310|OTHER|No intervention|No intervention administered in this study.
223826445|NCT03497494|PROCEDURE|2 cm away from the pylorus edge|2 cm away from the pylorus edge
223826446|NCT03497494|PROCEDURE|4 cm away from the pylorus edge|4 cm away from the pylorus edge
223826447|NCT03497494|PROCEDURE|6 cm away from the pylorus edge|6 cm away from the pylorus edge
223826448|NCT03497494|PROCEDURE|LRYGB|laparoscopic Roux-en-Y gastric bypass
223826449|NCT01582880|DRUG|Riboflavin|Used to treat donor cornea before implantation
223826450|NCT02027363|DRUG|Capecitabine|maintenance with apecitabine，1,000 mg/m2 twice a day， days1-15，every 3 weeks，until progression, unacceptable toxicity, or patient withdrawal.
223826451|NCT02027363|OTHER|Observation|Patients with metastatic colorectal cancer who achieved objective response or stable disease after 4-6 months first-line chemotherapy would stop the chemotherapy and observation
223826452|NCT03219203|BIOLOGICAL|Hepatitis B vaccine|Hepatitis B vaccine (20 µg/ml) 1 ml intramuscular injection in single (at 0 month) or 3-dose series (at 0, 1, 6 months)
223826453|NCT01418612|DRUG|Venlafaxine Hydrochloride Extended-Release Capsules of Torrent Pharmaceuticals Limited|
223826454|NCT03984019|DIAGNOSTIC_TEST|Cardiac condition measurements|Cardiac MRI, ECG, echocardiography, cardiac blood markers
223826455|NCT03077373|BEHAVIORAL|Counseling letter|"The brief counseling letter intervention aiming to reduce physical inactivity, sedentary time in leisure time as well as smoking is based on behavior change theories (Transtheoretical model of health behavior change and Health Action Process Approach).~The computerized intervention system includes up to six interactions with participants. Recurrent assessments are initiated by the system and provide data for scheduling the proceeding intervention steps and selection of relevant content. Physical activity, sedentary time, smoking, and motivational measures to change or maintain behaviors according to the recommendations will be monitored over time and used to provide feedback in the form of letters."
223826456|NCT00969345|OTHER|Stretching Exercises|Conducted twice a week, with instructions for home exercises twice a day, and registering each session on a log sheet.
223826457|NCT00969345|OTHER|Respiratory Exercises conducted twice a day for 10 minutes|Conducted twice a week, with instructions for home exercises twice a day, and registering each session on a log sheet.
223826458|NCT02566070|OTHER|Continuous Gastric Feeding|
223826459|NCT02566070|OTHER|Bolus Gastric Feeding|
223826460|NCT00872430|OTHER|Placebo|In order to produce similar taste and color, 7 drops of caramel color and 10 drops of orange essence were mixed into 1.6 liters of boiling water. The patients received 150 ml of placebo 3 times a day for 5 days.
223826461|NCT00872430|OTHER|Klein Laxative Tea|The laxative tea was prepared using 1 gram of grinded plant into 150 ml of water, left under infusion by 5 minutes. Patients received 150 ml of tea 3 times a day for 5 days.
223826462|NCT00462436|BEHAVIORAL|Consumption of Dietary Portfolio|The study involves following an aggressive low fat diet that is high in viscous fiber, nuts and soy protein. The diet is individually tailored to meet individual participants needs.
223826463|NCT02951351|DRUG|Proparacaine|Extra proparacaine will be applied to the conjunctival surface to determine its role in patient experience.
223826464|NCT02951351|PROCEDURE|Conjunctival culture|Conjunctival cultures will be performed to ensure that the intervention does not interfere with antisepsis.
223826465|NCT04883593|DRUG|TA103|The assigned Investigational Product will be applied to the skin between, under, all over the toes, sole and sides of the entire foot. Both feet are to be treated in the same way, even if the skin looks healthy and lesions are present on one foot only.
223826466|NCT04883593|DRUG|Placebo Control|The assigned Investigational Product will be applied to the skin between, under, all over the toes, sole and sides of the entire foot. Both feet are to be treated in the same way, even if the skin looks healthy and lesions are present on one foot only.
223826467|NCT04765293|OTHER|Physical Therapy|Physical Therapy Gravity strengthening exercises vs standard physical therapy
223826468|NCT06056986|DIAGNOSTIC_TEST|multimodal ultrasound|Dynamic contrast-enhanced ultrasound and shear wave elastography are perfomed on target intestinal loop
223826469|NCT05033743|DRUG|Secnidazole 2 GM Oral Granules|Once weekly 2g oral secnidazole for 18 weeks
223826470|NCT01479686|PROCEDURE|iMRI|3.0TiMRI guided resection in adults with glioma
223826471|NCT01479686|PROCEDURE|conventional neuronavigation|conventional neuronavigation guided resection in adults with glioma
223826472|NCT04720963|DRUG|Remimazolam|intranasal remimazolam
223826473|NCT04720963|OTHER|Distilled water for injection|intranasal distilled water for injection
223826474|NCT04720963|DRUG|Dexmedetomidine|Intranasal dexmedetomidine
223826475|NCT01478815|BEHAVIORAL|contingency management|Participants will receive the opportunity to win prizes for submitting cocaine negative urine samples.
223826476|NCT01478815|OTHER|Standard Care|Standard Care
223826477|NCT04217993|DRUG|Jaktinib hydrochloride tablets|Jaktinib hydrochloride tablets 100mg twice dose group，Jaktinib hydrochloride tablets 150mg qd dose group, Jaktinib hydrochloride tablets 200mg qd dose group and Jaktinib hydrochloride tablets 100mg qd dose group
223826478|NCT00967174|DRUG|Nicotine Patch|25 mg nicotine patch applied on the lower back, according to treatment sequence, daily for 21 days.
223826479|NCT00967174|DRUG|Placebo Patch|Placebo Patch applied on the lower back, according to treatment sequence, daily for 21 days.
223826480|NCT00967174|DRUG|SLS Comparator Patch|0.1% (w/v) SLS patch applied on the lower back, according to treatment sequence, daily for 21 days.
223826481|NCT04084782|DEVICE|Fungal Nail Treatment Kit|The treatment kit consists of 5 disposable nail files to be used to remove the top layer of the infected nail at various times throughout the use of the product and a liquid formulation and brush applicator.
223826482|NCT00356486|DRUG|Peginterferon alfa-2a, Ribavirin, epoetin-β|Peginterferon alfa-2a(270 µg/week) + Ribavirin (1600 mg/day) + epoetin-β (450 UI/kg/week) for 4 weeks. Peginterferon alfa-2a (180 µg/week) + Ribavirin(1000-1200 mg/day) for 8 weeks
223826483|NCT00356486|DRUG|Peginterferon alfa-2a + Ribavirin for 12 weeks|Peginterferon alfa-2a (40 KD) (180 µg/week) subcutaneous + Ribavirin(1000-1200 mg/day) oral/day for 12 weeks
223826484|NCT04537897|DRUG|BI 474121|BI474121
223826485|NCT04537897|DRUG|Midazolam|Midazolam
223826486|NCT04537897|DRUG|Placebo|Placebo
223826487|NCT00692055|DRUG|PN400|naproxen 375 mg / esomeprazole 20 mg
223826488|NCT00692055|DRUG|Naproxen|naproxen 375 mg
223826489|NCT02936154|DRUG|PF-06650833|
223826490|NCT02936154|DRUG|placebo|
223826491|NCT04966780|PROCEDURE|acute abdominal surgery|Acute surgery for acute abdominal disease
223826492|NCT03136250|OTHER|Group A (Control Group - Static Stretching + Standard Treatment)|o Conventional Gold Standard treatment (Manual Therapy + Modalities) Conventional Static Stretching 15-30 seconds hold 3-5 repetitions (Page P, 2012) for Ant/Middle/Posterior Scaleni, Sternocleidomastoid, Levator Scapulae and Upper Trapezius Muscles.
223826493|NCT03136250|OTHER|Group B (Autogenic Inhibition - PIR + Standard treatment)|o Conventional Gold Standard treatment (Manual Therapy + Modalities) Post Isometric Relaxation MET (3-5 reps) for Ant/Middle/Posterior Scaleni, Sternocleidomastoid, Levator Scapulae and Upper Trapezius Muscles. (Chaitow L, 2006)
223826494|NCT03136250|OTHER|Group C (Reciprocal Inhibition - RI + Standard treatment)|o Conventional Gold Standard treatment (Manual Therapy + Modalities) Reciprocal Inhibition MET (3-5 reps) for Ant/Middle/Posterior Scaleni, Sternocleidomastoid,Levator Scapulae and Upper Trapezius Muscles (Chaitow L, 2006)
223826495|NCT05816148|OTHER|Questionnaire survey|On leisure physical activity, barriers to physical activity and quality of life.
223826496|NCT01580098|OTHER|Self-monitoring for patients with Diabetes mellitus type 2|Patients are submitting their vital parameters via a Web Portal or automatic devices to the hospital.
223826497|NCT01580098|OTHER|Nurse-monitoring for patients with Diabetes mellitus type 2|Nurses are submitting the vital parameters of the patient via mobile device.
223826498|NCT02572336|DRUG|THR-18|THR-18 is an 18-mer peptide derived from the sequence of human plasminogen activator inhibitor 1 (PAI-1), having the ability to bind to a site of tissue plasminogen activator (tPA) distal to its catalytic site and uncouple the beneficial clot-dissolving properties of tPA from its deleterious non-fibrinolytic effects.
223826499|NCT02572336|DRUG|Placebo|Placebo is a THR-18 lookalike, to be administered with tPA.
223826500|NCT02572336|DRUG|Tissue Plasminogen Activator (tPA)|tPA is a thrombolytic agent. tPA is not an investigational drug.
223826501|NCT00005881|OTHER|Quality of Life Forms|Completion of the instrument \[Minneapolis-Manchester Quality of Life (MM-QOL)\] that measures HRQOL in the survivors of childhood cancer in a standardized, valid way and to assess the feasibility of incorporating this endpoint in a variety of clinical trials.
223826502|NCT02591420|BIOLOGICAL|VRC01|40 mg/kg of VRC01 will be administered as an intravenous infusion over 30 to 60 minutes using a volumetric pump
223826503|NCT02591420|BIOLOGICAL|Placebo for VRC01|Administered as an intravenous infusion over 30 to 60 minutes using a volumetric pump
223826504|NCT02591420|DRUG|Antiretroviral therapy (ART) (regimen will vary within countries and by patient)|ART is provided by the study sites and consists of country guideline-recommended, available first line once-daily oral combination therapy: currently either efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg or efavirenz 600 mg/lamivudine 300 mg/tenofovir disoproxil fumarate 300 mg. This initial ART regimen may be adjusted or switched to an alternate regimen as clinically indicated for regimen intolerance or failure.
223826505|NCT05073744|DRUG|Nalbuphine|Nalbuphine hydrochloride injection or morphine hydrochloride injection is used for perioperative tumor ablation
223826506|NCT05073744|DRUG|Morphine|Morphine hydrochloride injection is used for perioperative tumor ablation
223826507|NCT03305302|PROCEDURE|Sample of cancerous epithelium from the tongue|Harvesting and culture of cancerous epithelium from the surgical piece
223826508|NCT00197028|BIOLOGICAL|RTS,S/AS02D|3-dose intramuscular injection in the thigh
223826509|NCT00197028|BIOLOGICAL|TETRActHib™|3-dose intramuscular injection in the thigh.
223826510|NCT00197028|BIOLOGICAL|Engerix-B®|3-dose intramuscular injection in the thigh.
223826511|NCT05637411|OTHER|Predictive model|We will define and validate predictive models of risk of exacerbations in asthmatic patients
223826512|NCT03308058|BEHAVIORAL|Breastfeeding computer education|Breastfeeding computer education
223826513|NCT03531255|DRUG|Pegcetacoplan|Complement (C3) Inhibitor
223826514|NCT03716544|DEVICE|Amplification with hearing aid|Use of hearing aids
223826515|NCT03716544|DEVICE|Customized music|Customized music delivered via an iPod
223826516|NCT01109823|DRUG|intravenous administration of levofloxacin|Intravenous administration of levofloxacin is used.
223826517|NCT02672384|PROCEDURE|Dental examination and a point of care P. gingivalis test (Denka Seiken Co (Japan) )|Dental examination Study exams (oral and blood sample collection)
223826518|NCT01622543|DRUG|Folfox plus Bevacizumab and reolysin|FOLFOX6/bevacizumab given every 14 days plus reolysin days 1-5 on cycles 1, 2, 4, 6, 8 and alternate cycles thereafter
223826519|NCT01622543|DRUG|Folfox plus Bevacizumab|FOLFOX6/bevacizumab given every 14 days.
223826520|NCT03036501|DRUG|[^14C]-Risdiplam|\[\^14C\]-Risdiplam 18 mg oral solution with approximately 0.75 megabecquerel MBq (20 microcuries \[μCi\]) of \[14C\]-labeled Risdiplam.
223826521|NCT03486925|DRUG|oxytocin treatment|intranasal administration of oxytocin (24IU)
223826522|NCT03486925|DRUG|placebo treatment|intranasal administration of placebo
223826523|NCT02019784|DRUG|Rifaximin-α|Rifaximin-α will be compared to placebo with the various outcome measures assessed at baseline (pre-randomisation), and then at 30 days and 90 days.
223826524|NCT02019784|DRUG|Placebo Oral Tablet|Placebo Oral Tablet
223826525|NCT04791202|DRUG|Dextrose|See arm descriptions
223826526|NCT04791202|DRUG|Methylprednisolone Acetate 40 MG/ML|See arm descriptions
223826527|NCT00458679|BIOLOGICAL|CD40 LIGAND AND IL-2-EXPRESSING TUMOR CELLS VACCINE|Patients will receive a fixed dose (2 x 10\^7) of IL-2 secreting B-cells together with (2 x 10\^7)hCD40L expressing B-cells. They will receive 18 deltoid injections over 52 weeks.
223826528|NCT05842460|BEHAVIORAL|Nutrient warning labels|Inclusion of nutrient warning labels, which are currently mandatory in Brazil, to images of food products.
223826529|NCT05842460|BEHAVIORAL|Nutrient and ultraprocessed warning labels|Inclusion of nutrient warning labels, which are currently mandatory in Brazil, and an experimental ultraprocessed warning label to images of food products.
223826530|NCT04946955|OTHER|Application and website with or without promotion|Development of an application and a website to de-stigmatise mental health and support the user in seeking help
223826531|NCT00387257|DRUG|Rilapladib (SB-659032)|
223826532|NCT00840372|PROCEDURE|Buttonhole cannulation with semi-blunt needles|Use of semi-blunt needles, compared to blunt needles, at every dialysis session
223826533|NCT05656443|DRUG|GST-HG171/Ritonavir|dose of 150 mg GST-HG171 with 100 mg ritonavir
223826534|NCT05656443|DRUG|Placebo|Placebo
223826535|NCT06286540|DEVICE|Lymphoblock|1 time per surgery with the exposition for 20 minutes.
223826536|NCT06286540|DEVICE|Placebo|1 time per surgery with the exposition for 20 minutes.
223826537|NCT03788005|PROCEDURE|Early mobilization|Early mobilization as soon as possible and within a maximum of 12 hours following burr hole craniostomy for chronic subdural hematomas.
223826538|NCT02493218|BEHAVIORAL|Mindfulness Instruction|Age-appropriate instruction on mindfulness concepts and practices, adapted from the mindfulness-based stress reduction (MBSR) program. Classes are 45-90 minutes each and held weekly for 12 weeks.
223826539|NCT02493218|BEHAVIORAL|Health Education|Age-appropriate health education concepts and topics. Classes are 45-90 minutes each and held weekly for 12 weeks.
223826540|NCT05170308|DEVICE|CO2 fractional laser|The study subjects' body will be divided into two equal halves along sagittal midline section with one side receiving treatment with fractional CO2 laser (experimental) to treat dyspigmentation in lichen planus pigmentosus
223826541|NCT00078104|PROCEDURE|Extraction of wisdom teeth|
223826542|NCT06222008|OTHER|no Intervention|Observational study, no intervention
223826543|NCT01634958|BIOLOGICAL|Depigoid Phleum|Suspension for subcutaneous injection Build-up phase (day 1): 0,1mL + 0,2mL + 0,2mL s.c.injections in intervals of 30 minutes Maintenance phase: 5x single s.c. injection of 0,5mL every 4 weeks
223826544|NCT05150587|DRUG|Rifaximin|Rifaximin tablets
223826545|NCT05150587|DRUG|Placebo|Placebo tablets
223826546|NCT02364232|BEHAVIORAL|bilateral training with and without mirror feedback|
223826547|NCT01674933|DRUG|Duraphat® Fluoride Varnish|0.25 ml per application will be painted on tooth surfaces by a Childsmile trained Extended Duties Dental Nurse, currently registered with the UK General Dental Council
223826548|NCT01674933|BEHAVIORAL|treatment as usual|includes supervised toothbrushing, distribution of toothbrushes and toothpaste and oral health advice given at nursery school.
223826549|NCT05231564|OTHER|hybrid training|The experimental group trained two to three sessions of 45 to 50 minutes a week with a recovery of 24 to 48 hours between each session to burn 500 kcal. The first three weeks held hybrid training with a metabolic program and the other three weeks held a strength training program.
223826550|NCT03900143|DEVICE|Tightra vaginal device|Vaginal device for improvement of vaginal symptoms, reduce vaginal laxity, improve sexual functioning, and treat stress urinary incontinence.
223826551|NCT05947773|OTHER|Learning to walk with a robot|The patients completed a 1-hour learning to walk program using a soft exoskeleton. The protocol includes several difficult parts of the walk. (Walking protocol)
223826552|NCT05947773|OTHER|Walking group|The walking protocol was performed without robotic assistance for 1 hour every day for 3 weeks.
223826553|NCT05947773|OTHER|Control group|The control group performed the physiotherapy treatment for 3 weeks.
223826554|NCT02810730|PROCEDURE|Pancreatic MRI|Pancreatic MRI in the 6 months following the first consultation
223826555|NCT01643746|DEVICE|Supera Stent|Angioplasty and stenting will performed according to the guidelines of the Society of Interventional Radiology and the instruction for use for each stent. Patients will be allocated to Supera stent versus LifeStent based on block randomization (block size 4 patients).
223826556|NCT01643746|DEVICE|Life Stent|Angioplasty and stenting will performed according to the guidelines of the Society of Interventional Radiology and the instruction for use for each stent. Patients will be allocated to Supera stent versus LifeStent based on block randomization (block size 4 patients).
223826557|NCT01247493|DRUG|induction chemotherapy (fludarabine, cytarabine, idarubicin)|fludarabine, cytarabine, idarubicin
223826558|NCT00249496|BEHAVIORAL|Contingency management|Participants in the Contingency Management group will be employed for one year in a Therapeutic Workplace business and will have to provide drug-free urine samples to work and earn salary.
223826559|NCT00249496|BEHAVIORAL|Employment Only|Employment Only participants will be offered employment for one year, but these participants will not have to provide drug-free urine samples to work.
223826560|NCT04561011|BEHAVIORAL|Internet-delivered Cognitive Behavioural Therapy(ICBT)|ICBT provides online structured self-help modules over several months based on the principles of CBT in combination with weekly guidance through emails and telephone calls. The course comprises 6 online lessons that provide psychoeducation about: 1) symptom identification and the cognitive behavioural model; 2) thought monitoring and challenging; 3) de-arousal strategies and pleasant activity scheduling; 4) graduated exposure/pacing; 5) memory and attention; and 6) relapse prevention. Participants will also have the opportunity to ask any questions regarding the content of the program materials and will receive a response from their Guide within 48-72 hours. Guide will spend \~15 mins. per week/per participant. All Guides have completed a university program (psychology or social work) and are registered clinicians or students working under supervision of a registered clinician.
223826561|NCT01088308|PROCEDURE|High rate atrial and vetricular stimulation|The right atria and ventricle of the subject will be electrically stimulated at high rate mimicking tachycardia episodes using electrodes placed in the right atria and ventricle.
223826562|NCT01088308|PROCEDURE|Ventricular Tachycardia induction|A programmed electrical stimulation protocol will be performed using an electrode placed in the right ventricle.
223826563|NCT04639089|DRUG|platlet rich plasma on sternal healing post median sternotomy|"Patient data will be collected preoperatively and intraoperatively and these risk factors will be studied Patients will be distributed to two equal groups. Demographic data : Age - gender - weight - BMI-DM-hist. of radiotherapy exposure -BIMA~Intraoperative :~We will apply 10cm plasma contain 1 million platlets on the sternal edge of only one group of them before sternal closure.~post-operative The patients will be followed till being discharged from hospital and after the first 3 months after surgery"
223826564|NCT02066350|PROCEDURE|Single pancreas transplantation|
223826565|NCT04874376|DEVICE|IOL implantation experimental (Isopure 1.2.3.)|Implantation of Premium Monofocal Isopure 12.3 with retrospective data collection
223826566|NCT05531019|DIETARY_SUPPLEMENT|Echinochrome A|Dietary Supplement with Echinochroma A Simple randomized design, in this arm patients will take 6ml of a 0.025% Echinochroma A solution twice a day for 90 days. 3 mg of Echinochroma A will be consumed per day.
223826567|NCT05531019|OTHER|Control|Simple randomized design, in this arm patients will take 6ml of an fructose aqueous solution twice a day for 90 days with the same flavor as the treatment
223826568|NCT01738893|DRUG|Gabapentin 300 mg|Test product
223826569|NCT01738893|DRUG|Gabapentin 300 mg|Reference product
223826570|NCT04806412|DIAGNOSTIC_TEST|meassurement of PD-L1, ALK, EGFR|"PD-L1 test will be performed on cell-blocks using PD-L1 antibodies 22C3 and staining platform Dako Omnis (Agilent, Glostrup -Denmark).~ALK test will be performed on cell-blocks using staining platform Dako Omnis (Agilent, Glostrup- Denmark) and ALK antibodies Origene clone: OT1A4. Sample quality is assessed as for PD-L1.~EGFR mutation analysis will be performed as follows: after tumor content evaluation of hematoxylin and eosin stained slides, relevant regions are macrodissected and subjected to a standard genomic DNA extraction procedure using the GeneRead DNA FFPE Kit (Qiagen). Samples will be analysed using the GeneRead QIAact Actionable Insights Tumor Panel (Qiagen)"
223826571|NCT00000143|DEVICE|Ganciclovir implant and oral ganciclovir|oral ganciclovir, 1 gm three times daily
223826572|NCT00000143|DRUG|Cidofovir intravenous|intravenous, 5 mg/kg once weekly for two doses, followed by 5 mg/kg every other week
223826573|NCT05923593|DIETARY_SUPPLEMENT|MAG oil oral nutritional supplement (ONS)|The study product is suitable for use as an oral nutritional supplement (ONS).The study product contains MAG oil.
223826574|NCT02456337|DEVICE|Mucograft|Coronally advanced flap associated to Xenogenous collagen matrix graft (mucograft) for the treatment of gingival recessions Miller Class I or II.
223826575|NCT02456337|DEVICE|Emdogain|Coronally advanced flap associated to Enamel Matrix Derivative (Emdogain) for the treatment of gingival recessions Miller Class I or II.
223826576|NCT02456337|PROCEDURE|Coronally Advanced flap|Coronally advanced flap for the treatment of gingival recessions Miller Class I or II.
223826577|NCT00044460|DRUG|rosiglitazone|
223826578|NCT02885727|DRUG|Durvalumab|Evaluate if the combination of RT and durvalumab can improve median PFS compared to chemotherapy historical control data in metastatic pancreas cancer patients who have progressed through first-line chemotherapy
223826579|NCT02885727|RADIATION|Radiation Therapy|The primary intent of RT in this study is to augment a pancreatic cancer-specific immune response when given with durvalumab.
223826580|NCT01923389|OTHER|Placebo|0.9% w/v sodium chloride injection, United States Pharmacopeia (USP), twice a week for 4 weeks.
223826581|NCT01923389|DRUG|100 mg PF-05231023|100 mg IV infusion twice a week for 4 weeks
223826582|NCT05901415|PROCEDURE|Combined anterior lumbar plexus and lateral sacral plexus block in a semi-supine position|We proposed a modified approach of combined anterior LPB and lateral SPB with the patients posed in a semi-supine position aiming to reduce the pain and discomfort induced by position changing effectively.
223826583|NCT05901415|PROCEDURE|Combined anterior lumbar plexus and lateral sacral plexus block in a classical position.|Patients posed in a classical position and received combined anterior LPB and lateral SPB.
223826584|NCT00002802|DRUG|carboplatin|
223826585|NCT00002802|DRUG|cisplatin|
223826586|NCT00002802|DRUG|cyclophosphamide|
223826587|NCT00002802|DRUG|dacarbazine|
223826588|NCT00002802|DRUG|doxorubicin hydrochloride|
223826589|NCT00002802|DRUG|etoposide|
223826590|NCT00002802|DRUG|ifosfamide|
223826591|NCT00002802|DRUG|melphalan|
223826592|NCT00002802|DRUG|mesna|
223826593|NCT00002802|DRUG|vincristine sulfate|
223826594|NCT00002802|DRUG|vindesine|
223826595|NCT00002802|PROCEDURE|autologous bone marrow transplantation|
223826596|NCT00002802|PROCEDURE|conventional surgery|
223826597|NCT00002802|RADIATION|low-LET cobalt-60 gamma ray therapy|
223826598|NCT00002802|RADIATION|low-LET electron therapy|
223826599|NCT00002802|RADIATION|low-LET photon therapy|
223826600|NCT00002802|RADIATION|radioisotope therapy|
223826601|NCT04503538|OTHER|Telemedicine visit|Participants will be provided with a Wifi-and cellular enabled electronic tablet. Additionally, participants will receive a kit that contains a thermometer, a blood pressure monitoring cuff, and a pulse oximeter (to measure oxygen saturation level). Participants will attend an educational session to learn how the telemedicine visit works. Caregivers should attend with participants and will be trained to take temperatures, blood pressures, and oxygen saturation levels. Participants will also be asked to complete a test telehealth visit.
223826602|NCT03802162|DRUG|CKD-355A (D797/Memantine HCl 20mg)|once a day
223826603|NCT03802162|DRUG|CKD-355B (D797/Memantine HCl 20mg)|once a day
223826604|NCT03802162|DRUG|D797|once a day
223826605|NCT03802162|DRUG|D324 (Memantine HCl 10mg)|twice a day
223826606|NCT01568827|DIETARY_SUPPLEMENT|Blackraspberry Slurry|Blackraspberry slurry is 45 g blackraspberry powder mixed in 8oz. water. This is equivalent to 450 g fresh black raspberries.
223826607|NCT05575674|DEVICE|Myoelectric Elbow-Wrist-Hand Orthosis|An arm orthosis that uses myoelectric signals to control the level of mechanical assistance provided to a user's elbow and hand in order to overcome upper limb weakness or paralysis and achieve functional tasks.
223826608|NCT00649740|DRUG|Topiramate Sprinkle Capsules 25 mg|25mg, single dose fasting
223826609|NCT00649740|DRUG|Topamax® Sprinkle Capsule 25 mg|25mg, single dose fasting
223826610|NCT01887314|DIETARY_SUPPLEMENT|Standardized Ginger extract|
223826611|NCT02827786|DEVICE|Electromagnetic Acoustic Imaging|Electromagnetic Acoustic imaging (EMA) is a novel experimental platform utilizing the combination of electromagnetic radio frequency (RF) and acoustic waves to enhance ultrasound images. The resultant imaging allows (based on early experimental models) tissue differentiation based on its mechanical and electrical properties. Combined with conventional US scanning, this technology potentially allows high spatial resolution imaging of a target tissue with superimposed high contrast functional information. This is a proof-of-concept pilot study in humans.
223826612|NCT00894582|PROCEDURE|Components separation hernia repair|Components separation is one method currently employed for repair of massive ventral hernias. In this study we simply measured the volume of patients' abdomen (who were already undergoing this surgery) as well as their pulmonary function both pre and postoperatively.
223826613|NCT04065282|DRUG|Sintilimab|3 cycles before radical surgery
223826614|NCT04065282|DRUG|Oxaliplatin|85mg/m2 Q3W, 3 cycles perioperation
223826615|NCT04065282|DRUG|Capecitabine|1000mg/m2 bid po D1\~14 Q3W, 3 cycles perioperation
223826616|NCT03903679|DEVICE|Laryngeal mask airway|Patients will be maintained with laryngeal mask airway during the septal surgery.
223826617|NCT03903679|DEVICE|Endotracheal tube|Patients will be maintained with endotracheal tube during the septal surgery.
223826618|NCT03758027|BEHAVIORAL|CARESS|"The goals of each component are as follows:~* Communicate alternatively - a method to bring the brain back and remove the individual from his/her limbic system;~* Release endorphins - a release for the internal stress created by the emotion; and~* Self-soothe - a method of quelling and containing."
223826619|NCT03758027|BEHAVIORAL|Isometric Exercise|5-minute protocol for cravings management and affect regulation
223826620|NCT05983926|PROCEDURE|Subtotal colectomy was performed|"Colonic subtotal resection, also known as subtotal colectomy, is a surgical procedure used to treat colonic diseases such asconstipation, colon cancer, ulcerative colitis, and others.~The purpose of this surgery is to remove a portion of the colon in the patient's body. Unlike a total colectomy, which involves removing the entire colon, a subtotal colectomy only removes a portion of the colon. The procedure typically involves removing the diseased part of the colon and reconnecting the remaining colon. This allows for the preservation of some normal colonic function, enabling the patient to have regular bowel movements."
223826621|NCT03947359|DIAGNOSTIC_TEST|Fibroscan Touch 502 M probe|Measurement of liver stiffness
223826622|NCT03947359|DIAGNOSTIC_TEST|Fibroscan Touch 502 S probe|Measurement of liver stiffness
223826623|NCT03068806|DIAGNOSTIC_TEST|Electroencephalography (EEG) and Magnetic Resonance Imaging (MRI)|The investigators will use these techniques combined with attention tests, memory tests, and clinical interviews to explore connections between these measures and activity in the brain in patients with a diagnosis of schizophrenia and healthy controls.
223826624|NCT02378402|OTHER|Proton (1H-) magnetic resonance (MR) spectroscopy|PRESS localized 1D MRS sequence was used on a 3-T MR system. The lipid resonances will be analyzed using the LC-Model algorithm, and a Cramer-Rao lower bound (CRLB) threshold of 50% was used as quality control. Resonances of fatty acid (FA, lipid resonances δ 0.9, 1.3 and 1.6 ppm) and polyunsaturated fatty acid (PUFA, lipid resonance δ 2.1 and 2.3, 2.8, 5.3 ppm) will be evaluated on MRS, with ratios normalized with total TG value.
223826625|NCT03292146|DRUG|Denosumab 60 MG [Prolia]|Denosumab 60mg injection at baseline and 6 months
223826626|NCT03292146|DRUG|Placebo Injection|Placebo Injection at baseline and 6 months
223826627|NCT03292146|DRUG|Alendronate 70Mg Tab|Alendronate 70mg PO weekly starting at Month 12 through 24 months.
223826628|NCT01058434|DRUG|TKI258|
223826629|NCT05983744|OTHER|0 Hz Control|Lower body negative pressure (LBNP) applied to -60 mmHg for 10-min
223826630|NCT05983744|OTHER|0.1 Hz PPT|Lower body negative pressure (LBNP) applied at a frequency of 0.1 Hz from -30 mmHg to -90 mmHg
223826631|NCT05983744|OTHER|0.05 Hz PPT|Lower body negative pressure (LBNP) applied at a frequency of 0.05 Hz from -30 mmHg to -90 mmHg
223826632|NCT01070823|DRUG|Tysabri® (natalizumab)|Prescribed according to the TYSABRI Outreach: United Commitment to Health (TOUCH) Prescribing Program
223826633|NCT00545363|DRUG|Ibandronate|Participants will receive ibandronate 150 mg QM orally for 6 months.
223826634|NCT05799937|PROCEDURE|Non Surgical Root Canal Treatment|After administration of LA and rubber dam isolation, access cavity will be prepared using carbide burs in high speed hand piece with copious irrigation. Working length will be determined using root ZX apex locator and will be verified radiographically. Canal preparation will be done with rotary instruments . 5ml of 5.25% NaOCl will be used as irrigant after each instrument. After instrumentation , the canals will be irrigated with 5.0 ml of 17% EDTA for 1minute followed by irrigation with 5.0 ml of 5.25% NaOCl. Canals will be dried with absorbent paper points, filled with calcium hydroxide paste and access cavity will be restored with IRM. Patients will be recalled after 1 week.At the next appointment, after paste removal, copious irrigation with 5.25% NaOCl will be done and canals will be dried with paper points. Canals will be obturated with Gutta-Percha and ZOE based sealer.
223826635|NCT00707213|DRUG|[18F]fluoro-2-deoxy-D-glucose (FDG)|FDG-PET/CT scan-The scans that will be done with a radioactive sugar (\[18F\]fluoro-2-deoxy-D-glucose) and positron emission tomography (FDG-PET/CT). These scans will help to identify areas of possible infection.
223826636|NCT01233882|DRUG|Bosutinib|Single dose of 200 mg of bosutinib in subjects with normal renal function
223826637|NCT01233882|DRUG|Bosutinib|Single dose of 200 mg of bosutinib in subjects with mild renal impairment
223826638|NCT01233882|DRUG|Bosutinib|Single dose of 200 mg of bosutinib in subjects with moderate renal impairment
223826639|NCT01233882|DRUG|Bosutinib|Single dose of 200 mg of bosutinib in subjects with severe renal impairment
223826640|NCT02231437|DRUG|Berodual®|
223826641|NCT04017390|DRUG|Theraworx Foam|Apply Theraworx Foam alone
223826642|NCT04017390|DRUG|Placebo Foam|Apply placebo foam alone
223826643|NCT04017390|OTHER|Theraworx Foam and night splint|Apply Theraworx Foam and night time splint
223826644|NCT04017390|OTHER|Placebo Foam and night time splint|Apply placebo foam and night time splint
223826645|NCT01197820|DEVICE|MRI|"Patients will have a regular hepatic or kidney MRI investigation; we will add our sequences on their initial protocol. At first, one thermometry sequence is performed before angular correction is achieved with the following parameters: FOV=300 mm, matrix=96\*96, TE/TR=18/72 ms, 67 lines/TR, Sense factor=1.4, 5 slices (4 coronal et 1 sagittal), 30° Flip angle.~In order to determine the main direction of motion, a set of 200 images are acquired during motion with two interleaved orthogonal slices (one coronal and one sagittal) centered on the region of interest, with the read out direction aligned with the head-feet direction. True-fisp images are acquired during 40 seconds with the following parameters: FOV=400 mm, matrix=128\*109, TE/TR=1.2/2.43 ms, 60° flip angle, and 6 mm slice thickness.~Then the tested software proposes an angular correction to minimize out of plane motion. For each set of orientations, MR thermometry is performed"
223826646|NCT00366301|DRUG|Insulin glargine injection|Once daily for 14 weeks
223826647|NCT00366301|DRUG|metformin|Up to 4 pils per day (2g per day) maximum
223826648|NCT00366301|DRUG|Placebo pill|Up to 4 pills per day
223826649|NCT05351645|BEHAVIORAL|Treatment|"Once per day for a 14-day trial period, participants in the Treatment group were assigned to read a first-person narrative about a past issue with suicidal thoughts or behaviors. These narratives each contained positive elements, such as providing details about how the author had overcome issues with suicide, suggesting that people with suicidal thought are not alone, or encouraging people with suicidal thoughts/behaviors to have hope."
223826650|NCT00299195|DRUG|sulindac|Sulindac 150 mg po bid x 24 weeks
223826651|NCT00299195|DRUG|Placebo|Placebo bid x 24 weeks
223826652|NCT03792217|OTHER|1.3% NaOCl|Endodontic irrigant
223826653|NCT03792217|OTHER|5.25% NaOCl|Endodontic irrigant
223826654|NCT00179712|DRUG|CC-5013|
223826655|NCT00179712|DRUG|topotecan|
223826656|NCT02354963|PROCEDURE|In vitro fragmentation of the ovarian tissue|Unilateral ovarian cortex extraction, in vitro fragmentation and reimplantation.
223826657|NCT04737317|DIAGNOSTIC_TEST|ECG, Echo, laboratory tests, CMR, PET-CT, Biopsy|ECG - 12 leads ECG Echo: transthoracic echocardiography laboratory tests: full blood count, electrolytes, creatinine, high sensitive cardiac troponin T, angiontesin converting enzyme, soluble interleukin-2 receptor, cardiac magnetic resonance imaging: 1.5 Tesla scanner, Conventional cine imaging and late gadolinium enhancement imaging PET-CT: 18F-fluorodeoxyglucose (FDG)- positron emission tomograph Biopsy: cardiac biopsy = endomyocardial biopsy, left and right ventricle, at least 5 specimens in formaldehyd and 3 specimens for testing of infectious agents Biopsy: extracardiac biopsy, as accessible according to imaging
223826658|NCT06289634|BEHAVIORAL|Man-made sounds|Participants will be asked to listen to the assigned sounds (relaxing music) for 30 minutes a day for 15 days.
223826659|NCT06289634|BEHAVIORAL|Natural sounds|Participants will be asked to listen to the assigned sounds (birds, ocean, wind) for 30 minutes a day for 15 days.
223826660|NCT05391360|DRUG|Freethiadine tablets(part I)|Subjects will receive either a single dose of Freethiadine on Day 1 only (SAD HV), twice daily dosing of Freethiadine starting on Day 1 through Day 10 (MAD HV)
223826661|NCT05391360|DRUG|Freethiadine tablets (part II)|once or twice daily for consecutive 28 days
223826662|NCT05391360|DRUG|Freethiadine placebo tablets|Subjects will receive either a single dose of Freethiadine on Day 1 only (SAD HV), twice daily dosing of Freethiadine starting on Day 1 through Day 10 (MAD HV)
223826663|NCT05391360|DRUG|entecavir tablets|once daily for consecutive 28 days
223826664|NCT01372605|OTHER|Measurement-Based Care collaborative depression management|Depression Care Manager collects metrics on depressive severity and side effects and provides decision support regarding antidepressant initiation and modification to HIV providers who prescribe medications
223826665|NCT01372605|OTHER|Enhanced Usual Care|
223826666|NCT01348776|DEVICE|Hair2Go (Mē)|Treatment with Hair2Go Device 7 times every week with maintenance treatments once a month for 3 months
223826667|NCT01305278|OTHER|Use of Nintendo Wii Balance Gaming system|Use of Nintendo Wii Balance Gaming system
223826668|NCT01463293|DIETARY_SUPPLEMENT|B. lactis HN019|Capsule containing 10 billion cfu B. lactis HN019 once a day
223826669|NCT01463293|DIETARY_SUPPLEMENT|B. lactis HN019|Capsule containing 1 billion cfu B. lactis HN019 once a day
223826670|NCT01463293|DIETARY_SUPPLEMENT|Placebo|Capsule containing no probiotic once a day
223826671|NCT03650660|OTHER|Trans-thoracic ultrasound|Trans-thoracic ultrasound performed by an expert and a non-expert
223826672|NCT05243381|BIOLOGICAL|20 ml blood test|20 ml blood test
223826673|NCT03741244|DRUG|apatinib|Apatinib is an oral small molecule antiangiogenic targeted drug developed in China. More and more studies found that antiangiogenic drugs have outstanding performance in treating glioma. From the perspective of clinical and molecular mechanism, the combination of Temozolomide and apatinib may have synergistic effect especially to TMZ insensitivity patients(MGMT gene promoter unmethylated) and poor prognosis (IDH1 wild type) population
223826674|NCT03741244|DRUG|Temozolomide|Temozolomide，alkylating agent， is the standard first-line chemotherapy of glioma.
223826675|NCT03917641|BIOLOGICAL|Khat leaves|One of the two compressions (one per each eye) the patient will use will contain the Khat leaves.
223826676|NCT04453501|DRUG|favorable outcome|Whether patient under such regimen had a favorable outcome (no transfer in intensive care unit or death)
223826677|NCT00951509|OTHER|Power Mobility Road Test (PMRT)|All subjects will underwent the Power Mobility Road Test (PMRT), and the clinicians scored the driving performance within each condition.
223826678|NCT04930328|DRUG|Oxbryta® (voxelotor) 500-mg Tablets|Patients will have received treatment with Oxbryta as prescribed by their physician at the approved dose per local prescribing information, as part of their usual care.
223826679|NCT02753725|DRUG|Fentanyl|The intervention arm will comprise Fentanyl given at a dose of one microgram per kilogramme body weight administered approximately ten minutes to the end of surgery determined by the time when the mouth gag will be removed.
223826680|NCT02753725|DRUG|Normal saline|the placebo arm will be given normal saline at a volume equivalent to Fentanyl dose per body weight,administered approximately ten minutes to the end of surgery determined by the time when the mouth gag will be removed
223826681|NCT04817917|BIOLOGICAL|Japanese Encephalitis Vaccine (Vero Cell), Inactivated;|The investigators recruit 6 years old children who have been vaccinated by 2-3 doses of JE vaccines with different immunization strategies. For participants from Group 1 and Group 2 who haven't completed the JE immunization schedules, a booster dose of JEV-I will be administered at 6 years old.
223826682|NCT04817917|OTHER|No prospective interventions|The investigators recruit 6 years old children who have been vaccinated by 2-3 doses of JE vaccines with different immunization strategies. Participants from Group 3-5 have completed the JE immunization schedules with JEV-I or/and JEV-L. No prospective intervention will be given.
223826683|NCT03698760|DIAGNOSTIC_TEST|Olfactory test|"Olfactory test:~All fragrances tested are kept in an airtight case protected from cold and heat.~The test is done on a tablet and the data will be automatically saved. The first screen is about the administrative data, sex and age of the subject. Olfactory test: six odors among the fourteen are proposed in a randomized way."
223826684|NCT02327273|DRUG|BMS-963272|
223826685|NCT02327273|DRUG|Placebo|
223826686|NCT01812538|DRUG|DIC075V|"Four single dose treatments:~* Placebo (normal saline)~* Moxifloxacin (positive control)~* DIC075V 37.5 mg~* DIC075V 75 mg~All subjects receive each of the 4 treatments."
223826687|NCT02963688|GENETIC|Ion AmpliSeq BRCA 1/2 Panel (Life Technologies, Carlsbad, CA, USA) ,Ion PGM platform|BRCA1,2 Germline /Somatic mutation test
223826688|NCT03965819|DIETARY_SUPPLEMENT|Pain Bloc-R|Herbal Supplement containing Vit D3, Vit B6, Vit B12, White Willow Bark, Angelica Root, Acetyl L-carnitine HCl, Caffeine, L-Theanine, Benfotiamine, and L-Tetrahydropalmatine
223826689|NCT03965819|OTHER|Active Comparator - Acetaminophen|DIN 02447479 Encapsulated for Blinding Purposes
223826690|NCT03965819|OTHER|Placebo|No active ingredients
223826691|NCT02958618|PROCEDURE|"30 group"|A limited sphincterotomy (EST) was performed prior to the EPBD.The length of the sphincterotomy incision was limited to a third of the size of the papilla. A CRE balloon (diameter 10, 12, 15, 18) was chosen according to the diameter of bile duct. The balloon was then gradually filled with diluted contrast medium under endoscopic and fluoroscopic guidance to observe the disappearance of the waist. Once the waist disappeared, the balloon remained inflated for 30 seconds. The stones were then retrieved by a basket or retrieval balloon. An ENBD catheter (.) was routinely placed into the CBD after stone removal.
223826692|NCT02958618|PROCEDURE|"60 group"|A limited sphincterotomy (EST) was performed prior to the EPBD.The length of the sphincterotomy incision was limited to a third of the size of the papilla. A CRE balloon (diameter 10, 12, 15, 18) was chosen according to the diameter of bile duct. The balloon was then gradually filled with diluted contrast medium under endoscopic and fluoroscopic guidance to observe the disappearance of the waist. Once the waist disappeared, the balloon remained inflated for 60 seconds. The stones were then retrieved by a basket or retrieval balloon. An ENBD catheter (.) was routinely placed into the CBD after stone removal.
223826693|NCT02958618|PROCEDURE|"180 group"|A limited sphincterotomy (EST) was performed prior to the EPBD.The length of the sphincterotomy incision was limited to a third of the size of the papilla. A CRE balloon (diameter 10, 12, 15, 18 ) was chosen according to the diameter of bile duct. The balloon was then gradually filled with diluted contrast medium under endoscopic and fluoroscopic guidance to observe the disappearance of the waist. Once the waist disappeared, the balloon remained inflated for 180 seconds. The stones were then retrieved by a basket or retrieval balloon. An ENBD catheter (.) was routinely placed into the CBD after stone removal.
223826694|NCT04797819|DIAGNOSTIC_TEST|Coronary plaque components|Coronary plaque components were detected by CCTA method
223826695|NCT01885273|PROCEDURE|Pressurized irrigation method|The pressurized irrigation device is modified from using a special Syringe, connected to Gomco's Vacuum/Pressure Pump Model 309 that generate steady irrigation stream at pressure between 4 to 15 psi that is recommended to be safe and effective pressure for wound cleansing.
223826696|NCT01885273|PROCEDURE|Swabbing wound cleansing method|All patients in control group had wounds cleansed with swabbing technique using forceps and cotton wool (in sterile dressing pack)
223826697|NCT04021992|DRUG|gemcitabine, vinorelbine and doxorubicin liposome, with or without rituximab|All patients enrolled in the study will accept gemcitabine, oral vinorelbine and doxorubicin liposome, with or without rituximab as their salvage chemotherapy.
223826698|NCT03783481|DEVICE|Mobile community|Install an application (app) on subjects' smartphone. Subject's will join the mobile community using the application through which they can check their own and other members daily steps and communicate with each other.
223826699|NCT03783481|OTHER|No Mobile community|No Mobile community
223826700|NCT01115023|OTHER|iron cooking pot|the mother was instructed to cook the family food in the iron cooking pot for the study period (60 days) as frequently in the day as possible.
223826701|NCT05914831|RADIATION|Ultra-fractionated WBI|An ultra-short course of radiotherapy with 26Gy in 5 fractions will be administered to the whole breast where the tumor was located.
223826702|NCT05914831|RADIATION|Ultra-fractionated PBI|An ultra-short course of radiotherapy with 26Gy in 5 fractions will be administered to the part of the breast where the tumor was located.
223826703|NCT02708589|DIETARY_SUPPLEMENT|probiotic|
223826704|NCT02708589|OTHER|Placebo|
223826705|NCT01830192|OTHER|Training set|We evaluate the clinical, ultrasound and laboratory features to predict endometrial cancer disease preoperative
223826706|NCT01830192|OTHER|VERIFICATION SET|We evaluate the clinical, ultrasound and laboratory features to predict endometrial cancer disease preoperative
223826707|NCT04513678|BEHAVIORAL|ImmunOncoTool Condition|Immunotherapy education + irAE monitoring + Facilitation of patient-provider communication
223826708|NCT02069769|BEHAVIORAL|communication with oncology team|Oncology team will contact patients and families via telephone at specific intervals
223826709|NCT06534970|DEVICE|Three-dimensional stereophotogrammetry|Three stereoscopic photographs
223826710|NCT06534970|OTHER|Questionnaires|"* SF-36 quality of life scale for general health inquiry~* Rosenberg Self-Esteem Scale~* Self-perception scale"
223826711|NCT03317223|DRUG|CJ-12420/Clarithromycin/Amoxicillin|CJ-12420 or Lansoprazole +Clarithromycin/Amoxicillin will be administrated twice a day, for 7 days
223826712|NCT00385554|DRUG|UC-781 carbomer gel, 0.1% and 0.25%|
223826713|NCT05029024|OTHER|30-minute mindful breathing|The four exercises included identifying the in-and out-breath, following the entire length of the breath, bringing the mind back to the body and relaxing the whole body. Each exercise lasted 7.5 minutes.
223826714|NCT05029024|OTHER|control group|standard care alone
223826715|NCT03679195|DIETARY_SUPPLEMENT|NO Ultra|6-week supplementation period with 764 mg/day of cranberry and grape seed extracts (containing polyphenols) and 2 g/day of L-citrulline Participants will have to take daily 2 NO Ultra capsules (containing 382 mg cranberry and grape seed extracts / 1 g L-citrulline) between breakfast and lunch and 2 other NO Ultra capsules between lunch and dinner.
223826716|NCT03679195|DIETARY_SUPPLEMENT|Placebo|"6-week supplementation period with placebo capsules (the active ingredients will be replaced by cellulose)~Participants will have to take 2 capsules of cellulose between breakfast and lunch and 2 capsules between lunch and dinner to match the number of capsules ingested daily by the NO Ultra group."
223826717|NCT02762734|OTHER|MEDIA|"The intervention for the group MEDIA is a keeping in touch intervention through sending of SMS (or mail or other new media). The patient will receive 6 SMS (or mail or other new media) during 6 months after the suicide attempt. The first one 7 days after the suicide attempt and the last one after 6 months. The first SMS (or mail or other new media) is sent soon after the suicide attempt because studies on adult suicide attempters underline the importance of an early start for the connectedness measures. The text message are evolving in time, and are adapted to the genre of the adolescent."
223826718|NCT03780270|DEVICE|Fluoride Varnish|Fluor Protector S (Ivoclar, 7'700 ppm F-)
223826719|NCT03780270|DEVICE|Curodont Repair|P11-4 (monomeric peptide) - for professional use
223826720|NCT03780270|DEVICE|Curodont Protect|Tooth gel (containing P11-4 assembled to a fibrillary matrix) - for home use (OTC)
223826721|NCT00381355|PROCEDURE|Written Action Plan for Acute Asthma|
223826722|NCT05510635|OTHER|interactive bibliotherapy|The researcher selected two picture books whose central issues are about the common emotional distress of adolescents with cancer, that is, negative emotion coping, and self-worth. The researcher will read the story to the participant and then use the interview guideline to discuss it with him or her one by one. The interview guideline for interactive bibliotherapy is listed according to the mechanism of bibliotherapy, including identification, catharsis, and insight, and additional questions leading a reader to think deeply.
223826723|NCT05510635|OTHER|reading bibliotherapy|The researcher selected two picture books whose central issues are about the common emotional distress of adolescents with cancer, that is, negative emotion coping, and self-worth. The participant can take 20 to 25 minutes to read the story. No one can bother the participant during the intervention.
223826724|NCT00119925|BEHAVIORAL|patient education|patient leaflets about national guideline contents
223826725|NCT00119925|BEHAVIORAL|professional audit and feedback (guideline adherence)|feedback on current practice according to quality indicators
223826726|NCT00119925|BEHAVIORAL|professional education (communication/shared decision making)|educational tools for professionals concerning communication and shared decision making
223826727|NCT00119925|OTHER|information tools|tools and checklists to improve information provision
223826728|NCT05596357|OTHER|questionnaires|The patient must answer questionnaires before and after reconstructive surgery
223826729|NCT04613882|DEVICE|Soft Toric Custom Made Contact lens|Subjects will be randomized to wear soft toric custom made lenses for 30 minutes in one eye with other eye patched.
223826730|NCT04613882|DEVICE|Soft Spherical Contact Lenses|Subjects will be randomized to wear soft spherical contact lenses for 30 minutes in one eye with other eye patched.
223826731|NCT04613882|DEVICE|Spectacle Correction|Subjects will be randomized to wear spectacle Correction for 30 minutes in one eye with other eye patched.
223826732|NCT00309608|DRUG|Linagliptin|Linagliptin medium dose tablet once daily
223826733|NCT00309608|DRUG|Linagliptin|Linagliptin high dose tablet once daily
223826734|NCT00309608|DRUG|Linagliptin|Linagliptin low dose tablet once daily
223826735|NCT00309608|DRUG|Placebo|Placebo tablets once daily
223826736|NCT00309608|DRUG|Glimepiride|Glimepiride tablets once daily
223826737|NCT04426344|DEVICE|ensoETM device|Core warming will be performed using standard technique per instructions for use for the esophageal heat transfer device. The esophageal heat transfer device will be set to 42°C temperature after initial placement, and maintained at 42°C for the duration of treatment. It is expected that patient temperature will increase from baseline by 1°C to 2°C, but due to ongoing heat loss from the patient, the expected maximum patient temperature is below 39°C. The time course of illness of COVID-19 is such that most patients no longer have fever by the time of mechanical ventilation.\[41\] If patient temperature increases above this range and reaches 39.8°C, the device will be set to an operating temperature of 40°C, thereby preventing any further increase in patient temperature (ambient heat loss precludes patient from reaching device operating temperature).
223826738|NCT00004438|DRUG|leuprolide|
223826739|NCT00621296|DRUG|MP-424 (Telaprevir)|Three tablets of MP-424 250mg tablet at a time, every 8 hours, 24 weeks administration (dose in a day: 2250 mg)
223826740|NCT06380634|BEHAVIORAL|Experimental group- Motivational Interview|Pregnant women who applied to the gynecology clinic and met the inclusion criteria were informed about the study. Those who agreed were informed about the purpose of the research. Firstly, the Informed Volunteer and Introductory Information Form was applied to the women, then the Personal Care Products Use Evaluation Form, Self-Efficacy Scale and Endocrine Disruptors Attitude Scale were applied. Then, the experimental group was informed about the motivational interviewing technique. A total of 3 interviews were held. The final test was made at the fourth meeting.
223826741|NCT06017674|PROCEDURE|Intra-articular Pulsed Radiofrequency|A 22-gauge 10 cm radiofrequency cannula with a 10-mm active tip was advanced to the mid-tibiofemoral joint under fluoroscopic guidance. After needle insertion, paresthesia-pain and motor stimulation tests were performed using sensory (50 Hz) and motor (2 Hz, 1 V) stimulation to confirm the absence of stimulation. Intra-articular Pulsed Radiofrequency (IAPRF) was applied at 45 V voltage for 20 ms pulse width for 360 s, followed by a 480 ms silent phase. The tissue temperature was adjusted to not exceed 42°C.
223826742|NCT06017674|DRUG|Steroid Injection|8 mg dexamethasone was applied into the tibio-femoral joint with a 22-gauge, 10 cm needle under fluoroscopy.
223826743|NCT02810067|PROCEDURE|Tunnel + AlloDerm|A coronally positioned tunnel (CPT) technique for root coverage will be used with acellular dermal matrix (AlloDerm).
223826744|NCT02810067|PROCEDURE|Tunnel + Novomatrix|A coronally positioned tunnel (CPT) technique for root coverage will be used with acellular dermal matrix (Novomatrix).
223826745|NCT02049710|BEHAVIORAL|Seventeen Days|Interactive video includes highlighting salience of active choices in sexual decision making, modeling different responses to sexual situations, cognitive rehearsal of preventive behaviors, and information about hormonal and non-hormonal contraception
223826746|NCT02049710|BEHAVIORAL|Driving Skills for Life|Interactive video includes guidance and practice for safe driving techniques, driver and car care tips, an eco-driving learning module, and interactive driving games.
223826747|NCT04723849|DIETARY_SUPPLEMENT|Auxilie® Immuplus, Envicon Medical, Verona, Italy|"Subjects took one tablet per day orally starting day one after the visit and continuing for the 6-month duration of the study. Height (cm) and weight (kg) were measured for each child at every visit. Endothelial function was assessed using two methodologies: a post occlusive release hyperemic test (PORH) and a heat provocation test (HPT)."
223826748|NCT03918954|DEVICE|Virtual sensory room|A pair of virtual reality glasses (Oculus Go) with installed the program Calm Place, a program designed for anxiety reduction.
223826749|NCT03918954|OTHER|Sensory room|A room with calming elements that patients can use to feel calm.
223826750|NCT01440582|DRUG|Panobinostat|"Induction Therapy (Part A, 21-day cycles): 10 mg by mouth on Days 1, 3, 5, 8, 10, and 12 for 2 weeks with 1 week of rest at the end of each cycle.~Induction Therapy (Part B, 28-day cycles): 10 mg by mouth on Days 1, 3, 5, 15, 17, and 19 of every cycle.~Maintenance dose (Part A, 28-day cycles): Maximum tolerated dose (MTD) from Induction phase on Days 1, 3, 5, 8, 10, and 12 of each cycle.~Maintenance dose (Part B, 28-day cycles): Maximum tolerated dose (MTD) from Induction phase on Days 1, 3, 5, 15, 17, 19 of each cycle."
223826751|NCT01440582|DRUG|Bortezomib|"Induction Therapy (Part A, 21-day cycles): 1.3 mg/m\^2 by vein daily on days 1, 4, 8 and 11 of Cycles 1 - 8.~Induction Therapy (Part B, 28-day cycles): 1.3 mg/m\^2 by vein daily on days 1, 8 and 15 of Cycles 1 - 8."
223826752|NCT01440582|DRUG|Lenalidomide|"Induction Therapy (Part A, 21-day cycles): 25 mg by mouth daily on days 1-14 of every cycle.~Induction Therapy (Part B, 28-day cycles): 25 mg by mouth daily on days 1-21 of every cycle.~Maintenance dose (Parts A and B, 28-day cycles): Last tolerated dose from Induction Phase on Days 1 - 21 of each cycle."
223826753|NCT01440582|DRUG|Dexamethasone|"Induction Therapy (Part A, 21-day cycles): 20 mg by mouth daily on Days 1, 2, 4, 5, 8, 9, 11 and 12 of Cycles 1 - 8.~Induction Therapy (Part B, 28-day cycles): 20 mg by mouth daily on Days 1, 2, 8, 9, 15 and 16 of Cycles 1-8.~Maintenance dose (Parts A and B, 28-day cycles): Last tolerated dose from Induction Phase on Days 1, 8, 15, 21 of each cycle."
223826754|NCT01440582|BEHAVIORAL|Symptom Questionnaire|Completed on day 1 of each cycle.
223826755|NCT03244293|OTHER|no intervention|
223826756|NCT05778721|OTHER|respond to questionnaires by telephone|Seasonal Pattern Assessment Questionnaire (SPAQ) questionnaires and Sachs bipolarity index and Idiopathic Hypersomnia (IH) severity score
223826757|NCT00721643|DIETARY_SUPPLEMENT|angel's plant (Angelica keiskei)|Healthy control, one time dose of 5g dry power of Angelica keiskei
223826758|NCT00721643|DIETARY_SUPPLEMENT|Angel's plant (Angelica keiskei)|Metaboic syndrome subjects, one time dose of 5g dry powder of angel's plant (Angelica keiskei)
223826759|NCT01759615|OTHER|Early Enteral feeding|Feeding with expressed breast milk @ 8ml/kg/day for 48 hrs after randomization at 60+/-12 hrs of life
223826760|NCT01759615|OTHER|Late enteral feeding|Nil per oral for another 48 hrs after randomization at 60+/-12 hrs of life followed by Feeding with expressed breast milk @ 8ml/kg/day for 48 hrs
223826761|NCT01076283|DRUG|Baclofen|Baclofen 10mg t.i.d.
223826762|NCT01076283|DRUG|Cyproheptadine|'active' placebo
223826763|NCT06819319|DRUG|SHR-A2102 ; Adebrelimab injection|SHR-A2102 is administered intravenously, Adebrelimab is administered intravenously
223826764|NCT02671383|DRUG|Darunavir|Darunavir/ritonavir 400/100mg (DRV/r) once daily plus nucleoside/nucleotide reverse transcriptase inhibitors.
223826765|NCT02671383|DRUG|Lopinavir|Lopinavir/ritonavir 400/100mg (LPV/r) twice daily plus nucleoside/nucleotide reverse transcriptase inhibitors.
223826766|NCT06658340|BEHAVIORAL|Positivity in Post-COVID|A training to support well-being and self-management in patients with post-COVID-19 syndrome
223826767|NCT06661057|DEVICE|Vivally system stimulation|During the first month, participants will do the stimulation at different time points: 1) supine while in bed, 2) seated in the morning, 3) sitting in the afternoon, and 4) sitting in the evening. Participants will measure the circumference of their ankle prior to each use. Participants will use the System for an additional 2 months with the preferred stimulation parameters based on the study team's recommendations from the first month of use.
223826768|NCT03692715|DRUG|Ciprofloxacin|Oral or intravenous ciprofloxacin prior to shockwave lithotripsy.
223826769|NCT03692715|DRUG|Placebo|identical oral placebo if oral cipro was used, or intravenous saline alone in a blinded fashion if IV cipro was used prior to shockwave lithotripsy.
223826770|NCT01369134|DEVICE|Adper Easy Bond Self-etch dental adhesive|Bonding composite to restore Class I or Class II cavities
223826771|NCT04991506|DRUG|ES102|The active ingredient of ES102 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4)
223826772|NCT04991506|DRUG|JS001|JS001 is administered via intravenous injection once every 21 days, every 21 days as a treatment cycle.
223826773|NCT06613126|BEHAVIORAL|Symptom Management APP group|Based on symptom management theory and the relevant literature, the researcher designed a symptom management APP. The APP includes a symptom recording system, symptom management skills, and Tourette Syndrome knowledge information to facilitate parents' and children's joint learning.
223826774|NCT06613126|OTHER|health education instructions group|To receive outpatient verbal and paper health education guidance from healthcare providers.
223826775|NCT06624683|DEVICE|Intelligent footbath basin|before night sleep, takes 30 mins, starting from the first day of the menstrual cycle (MC) and continuing for 28 days.
223826776|NCT05669573|PROCEDURE|Early feeding group|Patients in the early diet group started oral intake 6 hours after ESWL of the day of procedure with a soft diet comprised 200 mL with 170 kilocalories.
223826777|NCT05669573|PROCEDURE|Standard fasting group|Patients in the standard fasting group were fasted for 24 hours after the first ESWL operation, and close observation during this fasting period.
223826778|NCT03190681|DRUG|Ritalin 10Mg Tablet|oral ingestion of 3 tablets in a single-dose
223826779|NCT03190681|DRUG|Placebo Oral Tablet|oral ingestion of 3 tablets in a single-dose
223826780|NCT02867657|BEHAVIORAL|Mindfulness|Five days MBSR curriculum with meditation and yoga
223826781|NCT06700226|DEVICE|AblaView® Unipolar PFA System|Patients with symptomatic paroxysmal atrial fibrillation will be treated with the AblaView® Unipolar PFA System system to achieve electrical isolation of the pulmonary veins. The AblaView® Unipolar PFA Catheter is a regular PFA irrigated catheter. The tip of the catheter has 7 holes distributed around that deliver at the same time irrigation and near infrared light for the OCR system, which will be processed and interpreted by the Console.
223826782|NCT06889207|BEHAVIORAL|Physical exercise prehabilitation|Patients in the intervention group will have two supervised training sessions per week for eight weeks in group sessions supervised by a physiotherapist.
223826783|NCT06925308|BEHAVIORAL|Conversation|The design consists of two parts. In the first part, the researcher will have a conversation (with a formal and informal phase, where the subject will be given the idea that only the formal part is part of the study) with an adult with ASD during which covert recordings of the subject's eye behavior will be made, and in addition skin conductance and duration/frequency of eye contact of the subject will be recorded, without the subject knowing that this is intended for the purpose of studying eye contact. In the second part, the researcher and subject will watch the covert recording of the subject's eye behavior, during which the subject's skin conductance will be recorded and details of the subject's behavior as seen by the researcher.
223826784|NCT06925347|OTHER|medical adhesive tape|After the patients were assigned to the control and experimental groups, the tube of the patient in the control group was fixed with acrylic medical adhesive tape, and the tube of the patient in the experimental group was fixed with silicone medical adhesive tape.
223826785|NCT06925386|DRUG|Standard therapy|The standard therapy for participants included a structured skincare regimen. A face wash was used once daily before bedtime to cleanse the skin. In the morning, a non-comedogenic sunscreen and a moisturizer were applied to protect and hydrate the skin. Additionally, a night cream containing clindamycin and tretinoin was applied once daily at night, specifically on acne-affected areas, to target inflammation and promote skin renewal.
223826786|NCT06925386|DIETARY_SUPPLEMENT|HEXBIO|The oral probiotics given are Hexbio®, an oral probiotic containing multiple beneficial bacterial strains, including Lactobacillus acidophilus BCMC® 12130, Lactobacillus casei BCMC® 12313, Lactobacillus lactis BCMC® 12451, Bifidobacterium bifidum BCMC®02290, Bifidobacterium longum BCMC® 02120, and Bifidobacterium infantis BCMC®02129. This probiotic was administered in granule form and swallowed directly. Participants consumed the probiotic twice daily, after breakfast and dinner, for eight weeks to support gut microbiome balance and potential skin health benefits.
223826787|NCT06925386|BIOLOGICAL|Secretome|The topical secretome used is a hydrogel-based serum containing secretome components, including cytokines, growth factors, exosomes, microvesicles, and cell differentiation factors. The serum is formulated with a hydrogel base consisting of xanthan gum, sclerotium gum, 1% alginate, 2% glycerin, 1% caprylyl glycol, and 96% aqua. It is applied after cleansing the face with a facial cleanser, twice daily, in the morning and evening, for eight weeks
223826788|NCT06926569|DRUG|Amphotericin B|After enrollment, participants will be 1:1 randomly assigned into two groups for induction therapy after informed consent: single high-dose L-AmB group (10 mg/kg single intravenous dose of L-AMB) and control group (amphotericin B deoxycholate(AmBD) at 0.5-0.7 mg/kg/d intravenously for 14 days as the standard of care recommended by local guidelines).Thereafter, all participants in both groups will start consolidation therapy within 24 hours of the induction treatment, 200mg itraconazole(or voriconazole) q12h will be given for 10 weeks. After consolidation therapy, all participants will take oral itraconazole 200mg qd as secondary prophylaxis until their CD4+ cell counts are higher than 100cells/mm3 for at least 6 months. For the antiretroviral therapy, all participants will start B/F/TAF qd within 7 days after initiating antifungal therapy
223826789|NCT06926569|DRUG|AmBisome|After enrollment, participants will be 1:1 randomly assigned into two groups for induction therapy after informed consent: single high-dose L-AmB group (10 mg/kg single intravenous dose of L-AMB) and control group (amphotericin B deoxycholate(AmBD) at 0.5-0.7 mg/kg/d intravenously for 14 days as the standard of care recommended by local guidelines).Thereafter, all participants in both groups will start consolidation therapy within 24 hours of the induction treatment, 200mg itraconazole(or voriconazole) q12h will be given for 10 weeks. After consolidation therapy, all participants will take oral itraconazole 200mg qd as secondary prophylaxis until their CD4+ cell counts are higher than 100cells/mm3 for at least 6 months. For the antiretroviral therapy, all participants will start B/F/TAF qd within 7 days after initiating antifungal therapy.
223826790|NCT06734351|DEVICE|NOA VOLUME|Subcutaneous and/or Supraperiosteal Plane Injection
223826791|NCT06734351|DEVICE|VOLUMA XC|Subcutaneous and/or Supraperiosteal Plane Injection
223826792|NCT01919996|DRUG|Azithromycin|Azithromycin oral suspension (immediate release) 12 mg/kg/day x 5 days
223826793|NCT01413672|DEVICE|Use of CASTLE barrier|Test barrier to be used in place of normal barrier. Otherwise normal routine is followed
223826794|NCT02358798|OTHER|3 years-assessment of respiratory function|
223826795|NCT06130813|OTHER|increased perioperative communication program|Thanks to this communication program, informative content (8 times) will be shared with patients.
223826796|NCT06900972|DRUG|Gelafundin|Volunteers will undergo a comprehensive transthoracic echocardiography to measure left ventricular torsion, global longitudinal strain, left atrial strain and free wall right ventricular strain before any intervention. Initially, 500 ml of the specified but blinded solution will be administered, followed by a repeat of the echocardiographic process. Subsequently, an additional 500 ml will be given, totaling 1000 ml, and strain curves will be reacquired. After a washout period of 7 days, the same procedure will be repeated with the second solution.
223826797|NCT06900972|DRUG|Saline (NaCl 0,9 %) (placebo)|Volunteers will undergo a comprehensive transthoracic echocardiography to measure left ventricular torsion, global longitudinal strain, left atrial strain and free wall right ventricular strain before any intervention. Initially, 500 ml of the specified but blinded solution will be administered, followed by a repeat of the echocardiographic process. Subsequently, an additional 500 ml will be given, totaling 1000 ml, and strain curves will be reacquired. After a washout period of 7 days, the same procedure will be repeated with the second solution
223826798|NCT06900608|BEHAVIORAL|Acceptance and Commitment Therapy|A 6-session ACT intervention was implemented targeting Cognitive Defusion (CD) and Values-Based Activity Scheduling (VBAS). During the first 3 sessions, the therapist taught participants how to defuse from negative self-thoughts using didactic and experiential techniques and emphasized the relationship between negative thoughts and the self and learning to observe negative thoughts for what they are - thoughts, words, ideas, and evaluations. During sessions 4-6, the therapist used similar techniques to focus on behaving in meaningful ways without letting negative thoughts dictate behavior. During these VBAS sessions, the participant identified their values and worked with the therapist to decide on goals that were values-consistent, and focused on those foals without letting negative thoughts and emotions get in the way of living toward them.
223826799|NCT06900608|BEHAVIORAL|Treatment as usual|"The 6-session supportive therapy (ST) condition emphasized the exploration of feelings; helping the client to become aware of and talk about emotional experiences with no attempt to change thoughts, behaviors, or the client's experiences directly (Greenberg et al., 1998). Psychoeducation emphasized the untoward effects of not acknowledging or exploring feelings and benefits of identification and talking about feelings. The therapist used open-ended questions, reflective listening, empathy, and clarification questions. Therapists did not give advice, offer solutions, make interpretations, or disagree with/confront the client. For homework, the participants were asked to complete awareness homework, involving monitoring of presence, intensity, and duration of emotions with no prescription to change them or do anything differently."
223826800|NCT06900907|DEVICE|Diode laser|A single session was applied to three points of the tooth extraction site.
223826801|NCT06900907|COMBINATION_PRODUCT|Hyaluronic acid|1 cc of hyaluronic acid gel was placed into the extraction socket, followed by suturing.
223826802|NCT06900907|COMBINATION_PRODUCT|Ozone|Topical ozone was applied to the extraction socket, followed by suturing.
223826803|NCT06900907|DRUG|Methylprednisolone|In addition to the standard prescribed medication, 4 mg of oral methylprednisolone was prescribed postoperatively.
223826804|NCT06900907|PROCEDURE|Control|Only the standard prescribed medication was provided.
223826805|NCT06818032|OTHER|Negative control|Participants will be given a breakfast meal with 76 grams of bread and 60 grams of jam per 2000 daily calories.
223826806|NCT06818032|OTHER|Avocado|Participants will be given a bread and jam breakfast (76 grams of bread and 60 grams of jam per 2000 daily calories) supplemented with 84 grams of avocado per 2000 daily calories.
223826807|NCT06818032|OTHER|Fat and fiber addition|Participants will be given a bread and jam breakfast (76 grams of bread and 60 grams of jam per 2000 daily calories) supplemented with 13 grams of fat (mix of high-oleic safflower oil, safflower oil, palm oil, and macadamia nut oil) and 5.5 grams of fiber (mix of cellulose and pectin) per 2000 daily calories.
223826808|NCT06900660|DIETARY_SUPPLEMENT|Collagen Drinks|Dosage: 50 mL/day; duration: 8 weeks
223826809|NCT06900491|OTHER|self-questionnaires|Patients will fill in these self-questionnaires on a tablet or on paper, depending on the availability of tablets in the centres, before and after consulting the doctor. These questionnaires assess the severity of the disease and quality of life.
223826810|NCT06900491|OTHER|unique collection of saddles|Stool samples will be taken at each visit, i.e. approximately every 6 months for patients
223826811|NCT06899984|BEHAVIORAL|Patient Navigator|Patient Navigator will provide additional support to participants using their standard of care CGM device.
223826812|NCT06901219|BEHAVIORAL|Running Fatigue Protocol|The experimental group went through a fatigue protocol, in which speed and incline increase one unit each minute passing, and stopped when rate of perceived exertion level reached ≥ 18, and the plasma lactate level differed from the baseline by ≥ 4mmol/L.
223826813|NCT06901271|DRUG|EMLA Cream|EMLA cream (2.5 grams) was applied to the treatment area 60 minutes before the procedure and covered with a transparent and impermeable dressing.
223826814|NCT06901271|DEVICE|Buzzy|The buzzy device was placed on the procedure area 60 seconds before the procedure and turned on. The cold and vibration application continued during the procedure.
223826815|NCT06901271|DRUG|Cold spray|Cold spray was applied to the procedure area for 5 seconds from a distance of 15 cm immediately before the procedure.
223826816|NCT06900088|DRUG|Selinexor|maintenance therapy with Selinexor combined with Azacitidine in patients with high-risk myeloid neoplasms after transplantation
223826817|NCT04086953|DIAGNOSTIC_TEST|6-minute walk test|This test is carried out in a 30-meter long walking corridor with two cones placed at the ends of the course and representing the turning zones
223826818|NCT04086953|DIAGNOSTIC_TEST|Walk-Time Limit Tes|Endurance test where the patient must walk at the same speed during the whole test (time limit). The test is carried out in a corridor 10 meter long.
223826819|NCT04086953|DIAGNOSTIC_TEST|Incremental shuttle walk test|Incremental walking test suitable for patients with chronic respiratory diseases. To perform this test, it is necessary to have a 10-meter walking corridor. The walking speed is dictated by a sound signal previously recorded. Every minute, the time between each beep is decreased and therefore the walking speed increased. The increment is 0.17m / sec every minute. Shifting to a higher speed is indicated by a triple beep. At most, the ISWT includes 12 speed levels.
223826820|NCT04086953|DIAGNOSTIC_TEST|Endurance shuttle walk test|"Constant load endurance running test performed on the same 10 meter run as the ISWT.~The patient is walking at a constant speed imposed by the audio beeps as for the ISWT. The objective of this test is to maintain the imposed walking speed as long as possible. The speed is calculated from the ISWT."
223826821|NCT04086953|DIAGNOSTIC_TEST|Respiratory Functional Assessment|Forced vital capacity, total lung capacity, forced expiratory volume measured during the first second of forced expiration, and carbon monoxide diffusion capacity will be measured by plethysmographic examination and spirometry.
223826822|NCT06848894|DRUG|Human urinary kallidinogenase (HUK)|HUK (0.15 PNA) and sodium chloride injection (100ml), once per day
223826823|NCT06848894|DRUG|Placebo|placebo (0 PNA) and sodium chloride injection (100ml), once per day
223826824|NCT06901232|BEHAVIORAL|Mindfulness Training|"All participants will complete a single 45-minute mindfulness training at Visit 2, with a refresher prior to the second mbNF session at Visit 3. Clinically trained study staff will conduct the training with the aim of teaching mental noting, a core mindfulness technique to be practiced and employed during neurofeedback. Mental noting is a major component of Vipassana (insight mindfulness meditation); its key principles include: concentration, observing sensory experience,'' not 'efforting', and contentment.Specifically, participants will be taught to mentally label/note whatever sensation is most prominent in their sensory experience from moment to moment (e.g., seeing, hearing, feeling, thinking). Training will be personalized to identify scenarios in which mental noting can be applied in the context of each person's daily life, explaining the goal of using these strategies to manage distress in daily life."
223826825|NCT06901232|BEHAVIORAL|Active mindfulness-based neurofeedback (Active mbNF)|Before the MRI scan, participants will practice mental noting by verbalizing their mental label with the study clinician providing feedback. Participants will then complete a silent practice of mental noting while viewing simulated neurofeedback. Participants will be trained until they feel competent to use mental noting in the scanner. During active mbNF (6 runs, 2.5 minutes each), participants will use mental noting with the aim of controlling visual feedback. Specifically, they will attempt to move the position of the white dot toward the (upper) red circle and away from the (lower) blue circle.
223826826|NCT06901232|BEHAVIORAL|Sham mindfulness-based neurofeedback|Before the MRI scan, participants will practice mental noting by verbalizing their mental label with the study clinician providing feedback. Participants will then complete a silent practice of mental noting while viewing simulated neurofeedback. Participants will be trained until they feel competent to use mental noting in the scanner. During sham mbNF, participants will view a visual display (white dot, red and blue circles) extracted from a previously acquired mbNF session. The display will be independent from brain activity in the sham condition and will simply mirror the stimuli observed by those in the mbNF group. This ensures participants across groups are viewing equivalent stimuli for the same amount of overall time.
223826827|NCT06901050|OTHER|FAST HUGS WITH ICU approach|"FAST HUGS WITH ICU; It is an abbreviation of Feeding, Analgesia, Sedation, Thromboembolic prophylaxis, Head of bed elevation, Stress Ulcer prophylaxis and Glucose control Spontaneous breathing trial, Water Balance and constipation, Investigation and results, Therapy, Hypo-hyper delirium, Invasive devices, Check the daily infection parameters, Use a checlist. With this approach, patients will be followed up."
223826828|NCT05965245|BEHAVIORAL|Suubi-Mhealth|Suubi-Mhealth is a theoretically-based digital therapeutics tool that aims to provide educational content on depression while considering the unique needs of SSA youth living with HIV. This educational content will be aligned with scientific recommendations for cognitive-behavioral therapy for adherence and depression as applied to HIV medication adherence. Core instruction will include psychoeducation on the interplay between HIV and depression; minimizing cognitive distortions related to ART adherence and stigma, as well as depression; challenging negative automatic thoughts; analysis and development of behavioral skills; reducing environmental stressors. Suubi-Mhealth will also have a social networking center in which patients can contact the research team, peers who are also taking part in this intervention, and other trusted individuals such as loved ones. Other features include tools for setting and monitoring goals, and a clinical management dashboard for the research team.
223826829|NCT05905497|DRUG|Bemnifosbuvir (BEM)|BEM administered BID for 4 days and QD on Day 5 (9 consecutive doses)
223826830|NCT03161860|BEHAVIORAL|Personalised citizen assistance for social participation(APIC)|The APIC involves a non-professional attendant who, after 2 to 5 days of training, provides a two to three-hour stimulation session each week over a six to eighteen-month period targeting significant social and leisure activities that are otherwise difficult for older adults to accomplish.
223826831|NCT00386308|DRUG|Tranexamic acid tablets|3900 mg/Day
223826832|NCT00386308|DRUG|Placebo tablets|
223826833|NCT02906683|DRUG|TAS-303|Oral administration for 8 weeks, once daily.
223826834|NCT02906683|DRUG|Placebo|Oral administration for 8 weeks, once daily.
223826835|NCT04377022|OTHER|Combined Therapy (Aerobic Exercise in addition to conventional therapy)|"There are two intervention arm in the study~1. Combined therapy~2. Conventional Therapy"
223826836|NCT02546687|OTHER|Venous blood sampling|"The investigators will take 1-2 cc of venous blood from proximal part of stomach before gastric tube creation and in the same time the investigators will take same amount of venous blood from peripheral vein. This blood will be analyzed in the ABL800 FLEX blood gas analyzer as a routine blood analyses that making by anesthesiologist during the operation. This blood sampling the investigators will make again after 15-30 minutes from the same area in proximal stomach (after creation of gastric tube) and peripheral vein just before anastomosis creation. The investigators will measure components of venous blood gases (O2, pH, CO2, lactate) from the area of future anastomosis before construction of gastric tube and just before creation of anastomosis ( after 15-30 minutes), compare the results of this analysis with systemic venous blood."
223826837|NCT01340482|DRUG|KRN23|Subjects will receive escalating doses of KRN23 administered by SC injections every 28-days (up to 4 doses) based on a dosing algorithm and discretion of the investigator and sponsor.
223826838|NCT04917549|OTHER|detection of oral lesions|oral lesions in patient diagnosed with COVID-19
223826839|NCT02351440|DRUG|duloxetine|patients will be randomized to receive either duloxetine or placebo
223826840|NCT02351440|DRUG|placebo|placebo
223826841|NCT04346641|DIAGNOSTIC_TEST|Facial Measurements and Tooth Size and Pulp Volume|Radiographic images of patients who have been indicated for cone-beam computed tomography for the upper jaw for various reasons (such as impacted teeth, sinusitis, skeletal anomalies) will be reviewed retrospectively. Facial measurements (lower face height, midface height, inter-zygomatic distance, inter-pupillary distance, inter alar distance, epicanthus distance, the distance between commissures) of the patients who received cone beam computed tomography will be measured in the clinic. Mesiodistal distance, buccal palatal distance, root length, pulp volume of maxillary sixth tooth will be measured using cone beam computed tomography. The data obtained will be compared.
223826842|NCT01662622|DRUG|Sevoflurane|"The design of experiment is referred to the Dixon up-and-down method. The first subject was designed to receive end-tidal sevoflurane concentration of 1.7%. For each subject, 30 min interval time was given. The isoelectric EEG was considered as significant when the isoelectric state last for more than 1min. The maximal burst suppression rate was recorded if isoelectric EEG was not reached. Heart rate and MAP, were recorded 2 and 1min before and 3 min after skin incision. Adrenergic reflexes positive cases were counted."
223826843|NCT01396928|PROCEDURE|Colonic reservoir|Type of reservoir to be performed
223826844|NCT02074540|OTHER|Questionnaire|Questionnaire that is based on socio-demographic characteristics, Morisky's Four-Item Self-Reported Adherence Measure, Becker's Theory of Health Beliefs and Mishel's Theory of Uncertainty
223826845|NCT05741970|PROCEDURE|Scaling and root planing|Each tooth with inflammation symptoms was cleaned with scalers, curettes and ultrasonic devices routinely.
223826846|NCT06439290|PROCEDURE|Phonosurgery|Gender-affirming voice surgery (such as glottoplasty, cricothyroid approximation, thyroplasty and chondrolaryngoplasty), in addition to gender-affirming voice training and hormone therapy, plays an important role in achieving a gender-congruent voice in transgender and gender diverse people. In addition, these interventions are sometimes performed on cisgender men or women who wish to change their voice. However, the impact of these interventions on broad voice characteristics needs to be further investigated.
223826847|NCT06439290|PROCEDURE|Mastectomy/breast augmentation|Control group of PFAB and PMAB persons undergoing a mastectomy or breast augmentation surgery.
223826848|NCT05723848|DEVICE|Smartwatch (Withings Scanwatch)|All-day monitoring of patients via smartwatch
223826849|NCT02044237|BEHAVIORAL|Decoupling|
223826850|NCT02044237|BEHAVIORAL|Progressive relaxation|
223826851|NCT03629873|DRUG|Chidamide|Chidamide 30mg po d-7、-4、0、3; Carmustine 300mg/m\^2 IVD d-6; Etoposide 150mg/m\^2/d qd IVD d-5\~-2; Cytarabine 150mg/m\^2 q12h IVD d-5\~-2; Cyclophosphamide 1.0g/m\^2/d qd IVD d-5\~-2
223826852|NCT01282476|DRUG|Panobinostat with Rituximab|Panobinostat 40 mg orally 3 x weekly Rituximab 375 mg/m\^2 IV days 1,8,15,and 22 of cycle 1, and then on day 1 of subsequent cycles.
223826853|NCT04822935|PROCEDURE|Vertebral Body Tethering|VBT surgery is a surgery performed by thoracotomy in adolescent idiopathic scoliosis patients.
223826854|NCT04324463|DRUG|Colchicine|oral medication
223826855|NCT04324463|DRUG|Interferon-Beta|subcutaneous injection
223826856|NCT04324463|DRUG|Aspirin|oral medication
223826857|NCT04324463|DRUG|Rivaroxaban|oral medication
223826858|NCT02328157|DEVICE|Vitrectomy with cataract surgery and toric IOL|
223826859|NCT02328157|DEVICE|Vitrectomy with cataract surgery and common IOL|
223826860|NCT00366860|BEHAVIORAL|Soy bread|
223826861|NCT00743587|DRUG|Placebo|Oral, a double-dummy approach will be used to maintain the blind between active tablet and capsule doses
223826862|NCT00743587|DRUG|Oxycodone|Oral, 1 x 20mg controlled-release tablets
223826863|NCT00743587|DRUG|Tramadol|Oral, 2 x 50mg immediate release capsules
223826864|NCT00743587|DRUG|Naproxen|Oral, 1 x 500mg enteric-coated
223826865|NCT04118985|BEHAVIORAL|Cognitive rehabilitation and health behavior change intervention|Cognitive rehabilitation and health behavior change intervention in a group-based program intervention compared to self-implementation of techniques without these interventions
223826866|NCT04118985|BEHAVIORAL|Self-implementation|Self-implementation of cognitive rehabilitation and health behavior change recommendations
223826867|NCT03124680|COMBINATION_PRODUCT|Opioid free|Peroperative opioid free anesthesia will be obtained via a combination of dexmedetomidine, ketamine, lidocaine and magnesium sulfate
223826868|NCT03124680|COMBINATION_PRODUCT|opioid group|Opioid anesthesia will follow the current standard approach of our hospital.
223826869|NCT02377830|DEVICE|In-bed cycle ergometer (Restorative Therapies RT300 Supine)|
223826870|NCT02377830|OTHER|Routine physiotherapy|activities to assist with optimizing airway clearance and respiratory function, and, based on the patient's alertness and medical stability, activities to maintain or increase limb range of motion and strength, in- and out of bed mobility, and ambulation
223826871|NCT02320786|BEHAVIORAL|CoPILOT|Participants in both groups will receive twelve hours of training in a standard powered wheelchair however the CoPILOT groups will use remote control technology we have developed. The technology provides the trainer with remote control of wheelchair speed and direction allowing the trainer to override the participant's actions as needed to ensure safe error-free shared controlled wheelchair training. The CoPILOT approach will accommodate varied learning needs, as per adult learning principles, while decreasing trainer input until the participant can complete tasks independently.
223826872|NCT01336062|DRUG|Nanoparticle Albumin-Bound Paclitaxel|this study evaluate 3 dose level of nab-paclitaxel:100 mg /m2;125 mg /m2;80 mg /m2;
223826873|NCT03552718|BIOLOGICAL|YE-NEO-001|Personalized recombinant yeast-based vaccine engineered to express multiple neoantigen epitopes (neoepitopes) based on an individual subject's tumor molecular profile.
223826874|NCT03687268|DRUG|Naloxone HCl PR tablets|oral administration
223826875|NCT03687268|DRUG|Placebo Oral Tablet|Placebo
223826876|NCT03847779|OTHER|"Rest"|Cutaneous perfusion and vasomotion assessment at rest in supoine position
223826877|NCT03847779|OTHER|"Exercise"|Cutaneous perfusion and vasomotion assessment after the 6minute-wlaking test
223826878|NCT03847779|OTHER|"Foot lowering"|Cutaneous perfusion and vasomotion assessment after foot lowering
223826879|NCT03847779|OTHER|"Hyperthermia"|Cutaneous perfusion and vasomotion assessment during hyperthermia
223826880|NCT01542541|DRUG|Rifaximin|550mg BID for 2 days
223826881|NCT00437125|DRUG|Duloxetine hydrochloride|Duloxetine 30 milligram (mg) once daily (QD) orally (PO) for 1 week, then duloxetine 60 mg QD PO for 11 weeks
223826882|NCT00355407|DRUG|Darbepoetin alfa|
223826883|NCT02248961|DRUG|Fimasartan|"Starting dose of Kanarb (Fimasartan) is 60 mg, orally, once a day in the morning. The subjects will visit the clinical site every 4 weeks to measure Arterial blood pressure (ABP). The dose will be doubled in case if SBP ≥140 mmHg or DBP ≥90 mmHg at Visit 3 (Day 28) or at Visit 4 (Day 56).~If necessary, the dose of the study drug may be increased based on the assessment of patient's condition performed at the phone contact (Day14±3). Patient may be called for an unscheduled visit for treatment adjustment (decided individually, with possibility of dose titration as per investigator's judgment, indicated in source documents).~When possibilities are, the patient should be administrated by the study medication at the same time in the morning."
223826884|NCT02248961|DRUG|Losartan|Cozaar® (Losartan), manufactured by MERCK SHARP \& DOHME B.V., Netherlands, tablets 50/100 mg
223826885|NCT01817634|DIETARY_SUPPLEMENT|Fish powder corn-soy blend'+ Fish oil capsule.|Omega 3 food supplement: 500 mg DHA + EPA, daily for 12 months. Omega 3 capsule: 500 mg DHA + EPA, daily for 12 months.
223826886|NCT01817634|DIETARY_SUPPLEMENT|Fish powder corn-soy blend + corn oil capsule.|Omega 3 food supplement: 500 mg DHA + EPA, daily for 12 months. Control capsule: 0 mg DHA + EPA, daily for 12 months.
223826887|NCT01817634|DIETARY_SUPPLEMENT|Corn-soy blend + fish oil capsule.|control food supplement: 0 mg DHA + EPA, daily for 12 months. Omega 3 capsule: 500 mg DHA + EPA, daily for 12 months.
223826888|NCT01817634|DIETARY_SUPPLEMENT|Corn-soy blend + corn oil capsule.|control food supplement: 0 mg DHA + EPA, daily for 12 months. Control capsule: 0 mg DHA + EPA, daily for 12 months.
223826889|NCT06066489|OTHER|educational program about VAP|An educational program about VAP that includes VAP bundle from CDC as core measures , equipment related measures and general measures.
223826890|NCT03257592|DRUG|[11C]DPA-713|\[11C\]DPA-713 PET imaging
223826891|NCT05012215|PROCEDURE|Paravertebral|Ultrasound-guided paravertebral block
223826892|NCT05012215|PROCEDURE|Caudal block|Caudal block
223826893|NCT01628302|BEHAVIORAL|Lowering salt in diet|Low salt diet (50mmol)for three weeks.
223826894|NCT02468921|PROCEDURE|Thyroidectomy|Regular thyroidectomy or hemithyroidectomy through Kocher's skin incision
223826895|NCT01935960|OTHER|Laboratory Biomarker Analysis|Correlative studies
223826896|NCT01935960|OTHER|Pharmacological Study|Correlative studies
223826897|NCT01935960|OTHER|Placebo|Given PO
223826898|NCT01935960|DRUG|Retinoid 9cUAB30|Given PO
223826899|NCT06354621|DIETARY_SUPPLEMENT|Vitamin-D supplementation|Participants receiving a daily dose of vitamin D supplementation
223826900|NCT00165295|DRUG|Sildenafil citrate (Viagra)|
223826901|NCT00206960|DRUG|zuclopenthixol|Patients will be administered zuclopenthixol orally in doses between 4 -24 mg/day, depending on an effective reduction of symptoms
223826902|NCT00206960|DRUG|risperidone|Patients will be administered risperidone orally in doses between 1-6 mg/day, depending on an effective reduction of symptoms
223826903|NCT00763399|DIETARY_SUPPLEMENT|probiotics (antibiophilus(Lactobacillus casei), bio-three)|probiotics (antibiophilus(Lactobacillus casei), bio-three) 4x 10\^8CFU/day
223826904|NCT02164162|DEVICE|Lokomat (Hocoma, Zurich, Switzerland)|Patients allocated to the Experimental group performed a Robotic Assistested Gait Training by means of the Lokomat. The Lokomat is robotic device set up as an exoskeleton on the lower limbs of the patient. The system uses a dynamic body weight-support system to support he participant above a motorized treadmill synchronized with the Lokomat.
223826905|NCT02164162|OTHER|Conventional physical treatment|Patients allocated to the Control Group performed a general exercise program and a conventional gait training. The general exercise program consisted in cardiovascular warm-up exercises, muscle stretching exercises, active-assisted or active isometric and isotonic exercises for the main muscles of the trunk and limbs, relaxation exercises, coordination and dual task activities and balance exercises. The conventional gait therapy was based on the proprioceptive neuromuscular facilitation (PNF) concept (lasting 30 minutes), with rhythmic initiation, slow reversal, and agonistic reversal exercises applied to the pelvic region, each 10 minutes long. The same trained therapist treated all the patients in this group and standardized the duration of each part of the treatment.
223826906|NCT02033460|OTHER|Manual Therapy and Education|Manual therapy will consist on Traction oscillatory,craniocervical region, Mobilization of upper cervical region in flexion, Side glide roll, Mobilization upper cervical anteroposterior with Wedge, Sliding lateral techniques and High-velocity technique in dorsal region. And Education of the physiology of pain and Education about cognitive behavioral perspective will add to manual therapy treatment.
223826907|NCT02033460|OTHER|Manual Therapy|Manual therapy will consist on Traction oscillatory, Maintained traction in the craniocervical region, Mobilization of upper cervical region in flexion, Side glide roll, Mobilization upper cervical anteroposterior with Wedge, Sliding lateral C1- C2 ( 2 minutes) , C2 -C3, and C5 -C6 and High-velocity technique in dorsal region.
223826908|NCT02033460|OTHER|Manual therapy, Education and Exercise|Manual therapy will consist on Traction oscillatory,craniocervical region, Mobilization of upper cervical region in flexion, Side glide roll, Mobilization upper cervical anteroposterior with Wedge, Sliding lateral techniques and High-velocity technique in dorsal region. And Education of the physiology of pain and Education about cognitive behavioral perspective and Craniocervical exercise will add to this arm.
223826909|NCT01602952|DRUG|Radotinib|50mg, 100mg or 200mg Capsule BID
223826910|NCT05755230|OTHER|No intervention|No intervention
223826911|NCT05297916|OTHER|enteral feeding|to intake oral feeding or delay it
223826912|NCT04842994|DEVICE|IONM tube|The standardized technique of IONM-RLNs (bilaterally) will be used, including indirect vagal response evaluation at the beginning and also at the end of surgery according to the recommendations formulated by the International Intraoperative Neural Monitoring Study Group (INMSG) (Randolph GW, Dralle H. 2011).
223826913|NCT01316146|DRUG|CAR.CD30 T cells|"Three dose levels will be evaluated:~Group One, 2x10\^7 cells/m\^2~Group Two, 1x10\^8 cells/m\^2~Group Three, 2x10\^8 cells/m\^2;~Cell Administration: CAR+ ATL will be given by intravenous injection over 1-10 minutes through either a peripheral or a central line. The expected volume will be 1-50cc."
223826914|NCT06071520|DRUG|Fostamatinib|Patient treated with fostamatinib in the period described
223826915|NCT01419145|OTHER|Multimodal intervention|Nutritional supplements aimed at optimal energy balance and protein intake (2 cartons of ProSure per day), nutritional advice, home-based self-assisted exercise program and anti-inflammatory treatment (300 mg celecoxib) for 6 weeks. The aerobic exercise program is performed as self-administered daily walking sessions, aiming for a minimum of two sessions 30 minutes on a weekly basis. Other aerobic activities could be used instead of walking. The resistance exercise program should be performed 3 times weekly and lasts about 20 minutes. The program is targeting major muscle groups in the upper body and legs with use of weights. The intensity of the exercise and performance of the exercises are adapted to the individual patient's disease burden and physical performance.
223826916|NCT01419145|OTHER|Standard care|Standard cancer care
223826917|NCT00670462|BEHAVIORAL|Standard Behavioral Treatment (SBT)|SBT is state-of-the-art behavioral weight loss treatment, comprised of 6 months of weekly treatment meetings followed by 6 months of biweekly meetings and 6 months of monthly meetings. Topical coverage and behavioral assignments include typical combination of energy balance information and self-control skills training. MTT has the same number of treatment contacts, but the contacts are distributed in distinct 8-week segments, each of which have a unique topic and unique behavioral assignments. Between each segment, participants are left on their own for 4 weeks with instructions to continue regular weighing but otherwise to make their own choices about what to do for weight control.
223826918|NCT00670462|BEHAVIORAL|Maintenance-Tailored Treatment (MTT)|
223826919|NCT05155592|BIOLOGICAL|reduction or discontinuation of Adalimumab|For patients with non-infectious uveitis whose inflammation stabilizes after treated with Adalimumab, extended dosing intervals to once a month, during which inflammatory status is monitored. If there was no recurrence within 6 months, Adalimumab was discontinued, and whether inflammation recurred after withdrawal was observed.
223826920|NCT00864838|DRUG|Acetazolamide|250 mg 1 hour before intravitreal injection
223826921|NCT00864838|DRUG|Brimonidine tartarate|1 drop 1 hour before intravitreal injection
223826922|NCT00864838|PROCEDURE|Anterior chamber paracentesis|Immediately after bevacizumab injection
223826923|NCT01339988|DRUG|Busulfan/Cyclophosphamide|"Conditioning regimen:~Cyclophosphamide 50mg/kg/day for 4 days + Busulfan 0.8-1.0mg/kg/day for 4 days."
223826924|NCT04662671|DEVICE|RD-X19|Experimental device that uses safe electromagnetic energy to stimulate the proximal repository of respiratory tract infectious disease pathogens.
223826925|NCT05245604|DRUG|TJO-087|Cyclosporine ophthalmic nano-emulsion 0.08%, 1 drop once daily
223826926|NCT05245604|DRUG|Cyclosporine ophthalmic solution 0.05%|Cyclosporine ophthalmic solution 0.05%, 1 drop twice/day
223826927|NCT01549522|BEHAVIORAL|bulletin board or telephone depth interview (TDI)|experiential based research. anonymous participation.
223826928|NCT01549522|BEHAVIORAL|interview regarding experiences and opinions as to condition and treatment|not a drug trial. experential/opinion based research.
223826929|NCT01742637|DRUG|Adapalene and Benzoyl Peroxide Gel 0.1%/2.5%|Adapalene and Benzoyl Peroxide Gel 0.1%/2.5% (Taro Pharmaceuticals Inc.)applied topically once daily for 84 consecutive days.
223826930|NCT01742637|DRUG|Epiduo® Gel|Epiduo® (Adapalene and Benzoyl Peroxide Gel 0.1%/2.5%) (Galderma Laboratories, L.P.)applied topically once daily for 84 consecutive days.
223826931|NCT01742637|DRUG|Placebo|Placebo (vehicle of test product) (Taro Pharmaceuticals Inc.)applied topically once daily for 84 consecutive days.
223826932|NCT05451381|DRUG|Propofol|sedation after cardiac surgery
223826933|NCT05451381|DRUG|Dexmedetomidine|sedation after cardiac surgery
223826934|NCT05451381|DRUG|Dexmedetomidine and Propofol|sedation after cardiac surgery
223826935|NCT03378843|OTHER|Spermidine content of natural diet|The exposure consists in the long-term average dietary intake of the polyamine spermidine
223826936|NCT01784315|DRUG|Artemisinin combination therapies (ACT)will be used for Chloroquine resistant P.vivax|4 tablets of ACT on 0,8,24,36,48 and 60 hours will be given for Chloroquine resistant P.vivax infection.
223826937|NCT01784315|DRUG|Chloroquine and Primaquine|Chloroquine:10mg/kg for day1,2 and 5mg/kg for day 3 Primaquine: 0.25mg/kg daily for 14 days.
223826938|NCT02746757|OTHER|Remote conditioning|
223826939|NCT02746757|DRUG|Exendin 9-39|
223826940|NCT00453310|DRUG|sunitinib malate|
223826941|NCT01267825|DRUG|CT-guided corticosteroid+ bupivicaine|CT-guided corticosteroid+ bupivicaine Also get standard medical care
223826942|NCT01267825|DRUG|Standard medical care|Naproxen + Oxycodone/ Acetaminophen
223826943|NCT00259818|DRUG|EM-1421|
223826944|NCT03706157|DRUG|Super selective transarterial chemoembolization of CHC, with doxorubicin reconstituted in 5cc iso-osmolar ionic iodinated contrast media|Super selective transarterial chemoembolization of CHC, with doxorubicin reconstituted in 5cc iso-osmolar ionic iodinated contrast media
223826945|NCT03706157|DRUG|Super selective transarterial chemoembolization of CHC, with doxorubicin reconstituted in 5cc normal saline|Super selective transarterial chemoembolization of CHC, with doxorubicin reconstituted in 5cc normal saline
223826946|NCT02790593|DEVICE|Juxta-Cures™|Juxta-CURES™ is an adjustable compression device, which may be used as a secondary dressing for the treatment of open venous stasis ulcers. It is an inelastic wrap around device with a Built-In-Pressure System™, which allows patients to easily and accurately apply pressure to their own leg and adjust it throughout the day.
223826947|NCT02790593|DEVICE|Standard Compression|Compression bandaging
223826948|NCT02790593|DEVICE|PicoPress®|Pressure monitoring to be done at time of bandage application and removal for both arms of the study.
223826949|NCT02790593|DEVICE|Silhoutte® 3D wound imaging system|Photographic imaging system to measure wound surface area and depth. Picture to be taken at each appointment. This intervention is for both arms of the study.
223826950|NCT04551196|DRUG|Alternating Acetaminophen and Ibuprofen|Subjects will alternate their post-operative acetaminophen and ibuprofen every 3 hours.
223826951|NCT04551196|DRUG|Combined Acetaminophen and Ibuprofen|Subjects will take their post-operative acetaminophen and ibuprofen together every 6 hours.
223826952|NCT04651270|DEVICE|SurroundScope|The study will evaluate standard laparoscopic surgery using the 270Surgical system. The procedure will be performed according to the institution's standard of care, using the SurroundScope for visualization.
223826953|NCT00196989|DRUG|Pioglitazone|
223826954|NCT00196989|DRUG|GW677954|
223826955|NCT03922802|DEVICE|Acute Intermittent Hypoxia + Non Invasive Spinal Cord Stimulation + Gait Training|Subjects will receive up to 45 minutes of AIH prior to receiving transcutaneous electrical spinal cord stimulation delivered by a Transcutaneous Spinal Cord Neurostimulator while performing locomotor activities.
223826956|NCT03922802|OTHER|Sham Acute Intermittent Hypoxia + Non Invasive Spinal Cord Stimulation + Gait Training|Subjects will perform locomotor activities with transcutaneous electrical spinal cord stimulation after receiving sham acute intermittent hypoxia
223826957|NCT03922802|OTHER|Sham Acute Intermittent Hypoxia + Sham Non Invasive Spinal Cord Stimulation + Gait Training|Subjects will perform locomotor activities with sham transcutaneous electrical spinal cord stimulation after receiving sham acute intermittent hypoxia
223826958|NCT06286579|DEVICE|Immediately implant placement|After atraumatic tooth extraction immediate implant placement with SOI surface and loading will be performed with temporary restoration. After osseointegration (8 weeks), the temporary restoration will be modified according to the soft tissue management. After 3 to 4 months, a definitive digital or analog impression will be taken and later definitive restoration will be delivered
223826959|NCT06286579|DEVICE|Delayed|"After atraumatic tooth extraction, the extraction site will be left to heal for 4 months, just grafting with A-Oss and suture, according to a socket preservation procedure. Four month later, implant will be place and immediate loadind with temporary restoration will be performed.~After osseointegration (8 weeks), the temporary restoration will be modified according to the soft tissue management. After 3 to 4 months, a definitive digital or analog impression will be taken and later definitive restoration will be delivered"
223826960|NCT04453670|PROCEDURE|autopsy|autopsy
223826961|NCT03815279|DRUG|Carfilzomib|Carfilzomib will be administered intravenously three times per cycle (28 day cycles) for cycle 1-12. Thereafter twice per cycle for cycle 13-24
223826962|NCT03815279|DRUG|Lenalidomide|Lenalidomide PO once daily on days 1-21 of a 28 day cycle
223826963|NCT03815279|DRUG|Dexamethasone|Dexamethasone will be administered weekly
223826964|NCT05706987|DRUG|Lidocaine|continuous lidocaine infusion perioperatively
223826965|NCT05706987|DRUG|Normal saline|normal saline
223826966|NCT00871351|DRUG|Ezetimibe|1 tablet of 10 mg daily for 12 weeks (Weeks 5-16)
223826967|NCT00871351|DRUG|Atorvastatin|1 tablet of 10 mg daily for 12 weeks (Weeks 5-16)
223826968|NCT00871351|DRUG|Atorvastatin|2 tablets of 10 mg daily for 12 weeks (Weeks 5-16)
223826969|NCT00871351|DRUG|Rosuvastatin|1 tablet of 2.5 mg daily for 12 weeks (Weeks 5-16)
223826970|NCT00744237|DRUG|Nebivolol|"* Nebivolol 5 mg (overencapsulated 5-mg marketed tablet), oral administration~* Nebivolol 10 mg (overencapsulated 10-mg marketed tablet), oral administration~* Nebivolol 20 mg (overencapsulated 20-mg marketed tablet) oral administration~* Nebivolol 40 mg (two overencapsulated 20-mg tablets) oral administration"
223826971|NCT00744237|DRUG|Metoprolol ER|"* Metoprolol ER 50 mg (overencapsulated 50-mg tablet) oral administration~* Metoprolol ER 100 mg (two overencapsulated 50-mg tablets) oral administration~* Metoprolol ER 200 mg (overencapsulated 200-mg tablet) oral administration~* Metoprolol ER 400 mg (two overencapsulated 200-mg tablets) oral administration"
223826972|NCT00744237|DRUG|HCTZ|"* HCTZ 12.5 mg (overencapsulated 12.5 capsule), oral administration~* HCTZ 25 mg (two capsules, overencapsulated 12.5-mg capsules), oral administration"
223826973|NCT02640599|OTHER|Vestibular Rehabilitation + Aerobic Exercise|Subjects in the experimental group will undergo traditional Vestibular Rehabilitation as well as participate in an aerobic exercise training program.
223826974|NCT02640599|OTHER|Vestibular Rehabilitation|The control group will receive standard care which includes participation in vestibular physical therapy treatments 1-2 times per week.
223826975|NCT01743300|DRUG|Sunitinib|All patients receive once daily 50 mg sunitinib for 6 weeks in the registered schedule of 4 weeks on two weeks off treatment.
223826976|NCT01743300|DRUG|Midazolam|All patients receive three times midazolam 7,5 mg on PK day 1,2, and 3 e.g. between day 14-21 of treatment, on day 28 of treatment and on day 42 of treatment.
223826977|NCT01743300|OTHER|Orange juice|The orange juice will be administered 3 times per day for 1 period of 3 days in the 4th week of treatment with sunitinib, just before PK day 2 on day 28 of treatment
223826978|NCT01743300|OTHER|Grapefruit juice|The grapefruit juice will be administered 3 times per day for 1 period of 3 days in the 4th week of treatment with sunitinib, just before PK day 2 on day 28 of treatment
223826979|NCT03992885|DRUG|Icotinib|"Intervention: Drug: Icotinib Ectinib 125mg/ tablet, one tablet at a time, three times a day, take orally~Intervention: Drug: Carboplatin/ Cisplatin Pemetrexed 500mg/m2, intravenous infusion, day 1;Carboplatin AUC6/ Cisplatin 75mg/m2,intravenous infusion, day 1,21 days for a cycle"
223826980|NCT00291655|DRUG|Levetiracetam|500 mg oral tablets,1000 - 3000 mg/day, twice a day (BID), duration of the study
223826981|NCT03169192|DRUG|Zoledronic Acid|intravenous injections once every 3 months
223826982|NCT02791490|DRUG|Sitagliptin|Oral tablet, 100 mg, once daily at approximately the same time each day
223826983|NCT02791490|DRUG|Placebo|Oral tablet, once daily at approximately the same time each day
223826984|NCT02791490|DRUG|Metformin IR|All participants will take Met-IR as background medication. Initially, they will take 1 x 500 mg tablet Met-IR b.i.d. (1000 mg/day). After randomization, all participants will be titrated to 2 x 500 mg tablets of Met-IR b.i.d. (2000 mg/day).
223826985|NCT06313996|DRUG|Cyclophosphamide|Specified dose on specified days
223826986|NCT06313996|DRUG|Doxorubicin|Specified dose on specified days
223826987|NCT06313996|DRUG|Vincristine|Specified dose on specified days
223826988|NCT06313996|DRUG|Rituximab|Specified dose on specified days
223826989|NCT06313996|DRUG|Prednisone|Specified dose on specified days
223826990|NCT06313996|DRUG|Bendamustine|Specified dose on specified days
223826991|NCT06313996|DRUG|Lenalidomide|Specified dose on specified days
223826992|NCT06313996|DRUG|Fludarabine|Specified dose on specified days
223826993|NCT06313996|DRUG|Liso-cel|Specified dose on specified days
223826994|NCT02686541|DEVICE|Atherectomy followed by Drug Eluting Balloon (DEB)|"Patient will undergo an intervention under anaesthesia. After pre-arthrectomy Intravascular ultrasound (IVUS) of the affected arterial segment, patient will undergo treatment with Arthrectomy, followed by post-arthrectomy IVUS analysis.~Following arthrectomy, the affected vessel will be treated by supplementary Ranger Drug Eluting Balloon (DEB).~During post-procedure, patients will be started on dual antiplatelets for 3 month post intervention followed by Aspirin for life unless contraindicated. Clinical follow-up, duplex ultrasound (to assess for re-stenosis) and Ankle Brachial Pressure Index (ABPI) will be performed at 1-month, 6-month and 12-month. Assessment of the symptoms, pulse, and clinical patency will be performed at each visit."
223826995|NCT01656603|BIOLOGICAL|unlicensed CBU|infusion of unlicensed cord blood units
223826996|NCT02419547|DRUG|Versed|Phase 1: Standard induction of controled sedation with intravenous agent then programed stimulation to induce ventricular tachycardia
223826997|NCT02419547|DRUG|Fentanyl|Phase 1: Standard induction of controled sedation with intravenous agent then programed stimulation to induce ventricular tachycardia
223826998|NCT02419547|DRUG|Propofol|Phase 2: Standard induction of GETA with intravenous agent then programed stimulation to induce ventricular tachycardia
223826999|NCT02419547|DRUG|Sevoflurane|Phase 3: Standard induction of GETA with inhalent agent then programed stimulation to induce ventricular tachycardia
223827000|NCT01750593|PROCEDURE|Radiofrequency ablation of the thyroid nodule|Under USG control, the nodule will be ablated by radiofrequency with a needle that has an active tip of 1 cm.
223827001|NCT05313009|DRUG|Sotorasib and Tarloxotinib|Sotorasib 960 mg PO daily + tarloxotinib 150 mg/m2 IV weekly
223827002|NCT05313009|DRUG|Sotorasib and Tarloxotinib|Sotorasib 960 mg PO daily + tarloxotinib IV weekly at the combination RP2D (RP2Dc).
223827003|NCT05612776|OTHER|HIIT|HIIT training will consist of performing high intensity intervals along with passive rests. The intensity of the exercise will be progressively increased and the rest time will be decreased. All participants will perform the same training according to the maximum heart rate reached in the Bruce test.
223827004|NCT05612776|OTHER|HRV|The intervention group will perform HRV-based training, measuring HRV every day before training in order to obtain HRV normality ranges for each participant. If the HRV value is within the normal range, the participant will perform a high intensity training but if the HRV value is below the normal range, the participant will perform a continuous training at low intensity as active rest.
223827005|NCT05756452|DIAGNOSTIC_TEST|Anamnesis and clinical evaluation|All partecipants will undergo a global echocardiographic evaluation, a 24-hour ECG Holter recording to assess HRV and blood samples collection for neurotransmitter measurements, platelet activation and reactivity evaluation and inflammatory profile assessment by proteomics analysis, inflammasome activity evaluation, NLRP3, pro-IL-18 and pro-IL-1β expression level by qPCR and epigenetic analysis.
223827006|NCT00125580|BEHAVIORAL|Infant sleep instruction|
223827007|NCT00582491|DRUG|Modafinil|Modafinil 400mg orally every day for 16 days
223827008|NCT00582491|DRUG|Placebo|Placebo orally everyday for 16 days
223827009|NCT03692221|DRUG|MSC Treatment group 1 (low dose)|Autologous Bone Marrow Derived Mesenchymal Stem Cells (MSC) - A one time injection of 1-2 ml of a 4 x 106/ml concentration solution
223827010|NCT03692221|DRUG|MSC Treatment group 2 (high dose)|Autologous Bone Marrow Derived Mesenchymal Stem Cells (MSC) - A one time injection of 1-2 ml of a 4 x 106/ml concentration solution
223827011|NCT03692221|OTHER|Healthy Control (no treatment)|Comparative analysis of psychometric and morphometric based data
223827012|NCT05196048|OTHER|No Intervention|No Intervention
223827013|NCT04516421|DIETARY_SUPPLEMENT|Protein supplementation|The experimental group contained 14g protein, 0.6g fat, 7g carbohydrate, 4.4 g BCAA , 2.4g glutamate, 0.5g arginine and 0.4g taurine with 90 kcal/pack (Affix Health, Taiwan Branch).
223827014|NCT04516421|DIETARY_SUPPLEMENT|Placebo oat drink|placebo oat drink contained 1.5g protein, 0.5g fat, 0.1g carbohydrate with 8.3kcal/pack (Zhan Xuan, Co. Ltd., Taiwan).
223827015|NCT02952573|DRUG|JNJ-42756493|Once daily dosing
223827016|NCT02952573|DRUG|Dexamethasone|Cycle 1 and 2: OD dosing on days 1-4, 9-12, and 17-20;Cycle 3: OD dosing on days 1, 8, 15, 22
223827017|NCT04330014|BEHAVIORAL|vaccine|affect vaccination on children
223827018|NCT00765427|DRUG|QLT091001|7-day repeated dose
223827019|NCT00350701|DRUG|androgel|androgel 5g
223827020|NCT00350701|DRUG|androgel 10g|androgel 10g
223827021|NCT00350701|DRUG|placebo|placebo
223827022|NCT03364439|DRUG|Treatment plan|R-CHOP14 or R-CHOP21 for 6 cycles Restaging after 2, 4, 6 cycles Consolidation therapy with RT (36 Gy) if PET positive (PET after 6 R-CHOP cycles)
223827023|NCT03145467|DRUG|Paracetamol|1000 mg of paracetamol (Parol Tablet - Atabay İlaç Fabrikası A.Ş.) Oral (PO) was given 100 patients
223827024|NCT03145467|DRUG|Zolmitriptan|Zolmitirptan 2,5 mg (Zomig Tablet - Astra Zeneca) oral (PO) was given 100 patients
223827025|NCT04894461|DEVICE|Moxibustion|The moxibustion treatment sessions are three times per week for eight weeks. Indirect moxa stick will be used.
223827026|NCT05199805|BEHAVIORAL|Mindfulness-based pain management|The structured program will include mindfulness exercises, meditation, a gentle body exercise series, and body awareness exercises, as well as information about pain, mindfulness-based pain management, and pain regulation methods suitable for everyday life. During the 8 weeks, treatment as usual is allowed.
223827027|NCT05911490|BEHAVIORAL|Prolonged sitting|In the laboratory, after consuming 1st meal, participants sat on a chair for 180 min. After 180 min, the 2nd meal was provided. After finishing the 2nd meal, participants sat on a chair for another 120 min. After data collection was completed in the laboratory, participants were asked to keep wearing the same pedometer and to record any food and liquid consumption for the rest of the day (until midnight) under free-living conditions.
223827028|NCT05911490|BEHAVIORAL|Breaking prolonged sitting|In the laboratory, after consuming 1st meal, participants walked 2 min on a treadmill every 20 minutes for the following 180 min. For the remainder of the time participants sat on the chair. After 180 min, the 2nd meal was provided. After finishing the 2nd meal, participants continued 2 min of walking every 20 min for the following 120 min. After data collection was completed in the laboratory, participants were asked to keep wearing the same pedometer and to record any food and liquid consumption for the rest of the day (until midnight) under free-living conditions.
223827029|NCT03562351|OTHER|Verbal Instructions Educational Intervention|Caregivers will undergo training with verbal instructions
223827030|NCT03562351|OTHER|Video Educational Intervention|Caregivers will undergo training with an educational video
223827031|NCT03562351|OTHER|Mannequin Educational Intervention|Caregivers will undergo training with a mannequin
223827032|NCT02459080|DRUG|TD-4208|
223827033|NCT02459080|DRUG|Placebo|
223827034|NCT03664037|DRUG|Dexamethasone phosphate|each patient received 8 mg of intravenous DEX diluted in 100 ml 0.9% sodium chloride (normal saline \[NS\]) intravenous infusion (IVI) over 15 min 2 hours preoperatively
223827035|NCT03664037|DRUG|Placebo|each patient received 100 mL 0.9% NS IVI over 15 min (Placebo) 2 hours preoperatively
223827036|NCT00450320|DRUG|sirolimus|The target rapamycin trough level will be 5-10 ng/mL. The initial dose will be dependent upon the type of HAART regimen. Subjects will continue on study protocol for six cycles as long as their KS is stable or continuing to respond to study medication. Treatment will be extended for up to six additional cycles if the subject has met criteria for a response. Subjects with no more than stable disease will have treatment discontinued after six cycles. Protocol treatment will be discontinued if the subject develops tumor progression, unacceptable toxicity or develops one of the protocol-defined reasons for treatment discontinuation at any time during the study.
223827037|NCT02450864|OTHER|ESWT|Preoperatively, the ROM of the shoulder is measure with the patient in a sitting position. A goniometer is used to measure the angle to which the patient could maximally passively forward flex or abduct the shoulder. External rotation and internal rotation of the shoulders are determined with the patient's arm in a resting position. The investigators assessed shoulder ROM using the SROMD. Normal shoulder ROM without scapular stabilization is considered to be 180° of forward flexion, 180° of abduction, 90° of external rotation, and 90° of internal rotation with the arm at the side. By summation of the measured deficit of ROM, the SROMD is obtained. Patients are defined as having shoulder stiffness if SROMD \>270degrees.
223827038|NCT00517426|DRUG|acetazolamide|i.v. 500 mg of acetazolamide for the acute study and 500 mg of acetazolamide p.o. t.i.d. for two days
223827039|NCT02843958|DEVICE|HEMOPTIC|
223827040|NCT04831008|OTHER|Figure-of-eight suture|Using the figure-of-eight closure technique when closing access for structural heart therapies.
223827041|NCT04831008|OTHER|Perclose Device|Using the Perclose device when closing access for structural heart therapies.
223827042|NCT00325936|DRUG|Cilnidipine|10\~20mg, qd, po for 3 months or 12 months.
223827043|NCT06110741|OTHER|Blood and saliva sampling|Collecting blood and saliva sample
223827044|NCT06110741|OTHER|Survey|Collecting data on infectious diseases during the study period
223827045|NCT01775930|DRUG|Carfilzomib|20 mg/m2 over 30 minutes by vein infusion on Days 1 and 2 and a dose of 56 mg/m2 over 30 minutes by vein infusion on Days 8, 9, 15, and 16 of each 4 week cycle.
223827046|NCT02969980|DRUG|Cyclophosphamide|Cyclophosphamide 50 mg/kg/day i.v. daily on days 3 and 4 of hematopoietic cell transplantation
223827047|NCT02654093|DRUG|Cholecalciferol|
223827048|NCT02654093|DRUG|Raloxifene|
223827049|NCT02654093|DRUG|Cholecalciferol and Raloxifene co-administration|
223827050|NCT04420546|BEHAVIORAL|Volitional help sheet|Participants are asked to choose from a list of strategies for increasing physical activity
223827051|NCT04420546|BEHAVIORAL|Volitional help sheet|Participants are asked to choose from a list of strategies for avoiding self-harm
223827052|NCT04141072|DIAGNOSTIC_TEST|Shrunken Pore Syndrome|eGFR Cystatin C ≤ 60% of eGFR Creatinine
223827053|NCT04047381|OTHER|Measurement of Quality of Life|Quality of life will be measured using Atrial Fibrillation Impact Questionnaire, Short Form-36 and Pittsburgh Sleep Quality Index
223827054|NCT03487718|BIOLOGICAL|Leukocyte platelet rich fibrin plug + d-PTFE membrane|Following tooth extraction, an autologous leukocyte platelet rich fibrin plug will be placed in the socket and covered with a d-PTFE membrane
223827055|NCT03487718|DEVICE|d-PTFE membrane|Following tooth extraction, the socket will be covered with a d-PTFE membrane
223827056|NCT01208415|DEVICE|Endovascular repair for aortoiliac or iliac aneurysms.|Implantation of the Zenith® Branch Endovascular Graft-Iliac Bifurcation, the Zenith® Connection Endovascular Covered Stent/ConnectSX™ and the Zenith® Flex AAA Endovascular Graft.
223827057|NCT06360003|PROCEDURE|Right Ventricular Outflow Tract Posterior Septum Pacing|The Right Ventricular Outflow Tract (RVOT) posterior septum pacing is routinely performed to observe the QRS complex characteristics of the 12 lead ECG (with a focus on comparing their differences with the R-wave amplitude of spontaneous ventricular arrhythmias in the right chest (V1\~V3) leads). When the pacing-induced R-wave amplitudes are all lower than spontaneous VAs in V1\~V3, we predict the origin of Left Ventricular Outflow Tract (LVOT), mapping and ablation in LVOT; otherwise we predict the origin of RVOT, mapping and ablation in RVOT.If fails, go to the opposite site to do mapping and ablation. If still fails, go to distal great cardiac vein (DGCV) to do mapping and ablation.
223827058|NCT06360003|PROCEDURE|systemic mapping and ablation|The TC or ST ablation catheter is delivered to ventricular outflow tract (VOT) to perform systemic mapping and ablation.
223827059|NCT04645524|DRUG|AD182|Oral capsule administered before bed
223827060|NCT04645524|DRUG|AD504|Oral capsule administered before bed
223827061|NCT04645524|DRUG|Placebo|Oral capsule administered before bed
223827062|NCT04645524|DIAGNOSTIC_TEST|Polysomnography|for all arms
223827063|NCT01115491|DRUG|bevacizumab [Avastin]|Bevacizumab 10 mg/kg body weight will be administered intravenously every two weeks
223827064|NCT01115491|DRUG|temozolomide|Daily by the oral route (dose, 150 mg/m2) on days 1 to 7 and 15 to 21 of each cycle
223827065|NCT06291532|DEVICE|Rehabilitation with VRRS|"The patients underwent an experimental intervention lasting two months (9 sessions lasting about 40 minutes) integrated into the regular activity of a semi-residential center for autistic adolescents and young adults.~The proposed exercises were 2D and the patient interacted with the scenarios through the touch screen. For all participants, the tasks were the same, but difficulty and duration varied according to the needs and goals to be achieved."
223827066|NCT02930642|BEHAVIORAL|Mindful Eating|Mindful eating is a behavioral strategy in which food is eaten slowly, with deliberate and focused attention on the features of food, the process of eating, and physiological responses to eating. Objectivity is key.
223827067|NCT02930642|OTHER|Nutrition DVD|Participants watch a 50 minute video on nutrition to control for verbal aspects of food.
223827068|NCT00322608|DRUG|NPI-2358|Treatment on Days 1, 8 and 15 in a 28 day cycle
223827069|NCT01607385|DRUG|GSK2330672|BID, repeat doses
223827070|NCT01607385|DRUG|Placebo|BID, repeat doses
223827071|NCT01607385|DRUG|GSK1614235|BID, co-dosed BID with last dosing day of active/placebo repeat doses
223827072|NCT03436160|DRUG|WR826647|100 mcg Carbon-14 radio labeled WR826647 at an exposure no greater than 250 nCi per dose, administered both IV (bolus) and PO with a six half-life wash-out period between IV and PO administration. Interim analyses will be done at Day 14 following the IV dosing groups in order to assess half-lives of the three compounds to ensure the wash-out period between IV and PO dosing is at least six half-lives long.
223827073|NCT03436160|DRUG|WR909388|100 mcg Carbon-14 radio labeled WR909388 at an exposure no greater than 250 nCi per dose, administered both IV (bolus) and PO with a six half-life wash-out period between IV and PO administration. Interim analyses will be done at Day 14 following the IV dosing groups in order to assess half-lives of the three compounds to ensure the wash-out period between IV and PO dosing is at least six half-lives long.
223827074|NCT03436160|DRUG|WR909390|100 mcg Carbon-14 radio labeled WR909309 at an exposure no greater than 250 nCi per dose, administered both IV (bolus) and PO with a six half-life wash-out period between IV and PO administration. Interim analyses will be done at Day 14 following the IV dosing groups in order to assess half-lives of the three compounds to ensure the wash-out period between IV and PO dosing is at least six half-lives long.
223827075|NCT00828906|DRUG|DuoTrav|DuoTrav Eye Drops
223827076|NCT05089058|BEHAVIORAL|Brief, digitally delivered imagery-competing task intervention package, comprised of:|"Two sessions guided (remotely) by a researcher. Sessions comprised of:~(i) task procedure: a memory cue followed by playing imagery-competing computer game task with mental rotation instructions. Monitoring of intrusive memories to select hotspot cue, and which intrusion to target.~(ii) accompanying information, including rationale for the brief cognitive task.~(iii) option to use the brief cognitive task after the session (self-administered); option to engage in up to 6 guided booster sessions supported by a researcher."
223827077|NCT05089058|BEHAVIORAL|Brief, digitally delivered relaxation task intervention, comprised of:|"Brief, digitally delivered relaxation task intervention, comprised of:~Two sessions guided (remotely) by a researcher. Sessions comprised of:~(i) relaxation exercise task using instruction components from progressive muscle relaxation~(ii) accompanying information, including rationale for the brief relaxation exercise task.~(iii) option to use the brief relaxation exercise task after the session (self-administered); option to engage in up to 6 guided booster sessions supported by a researcher."
223827078|NCT01168063|DRUG|Molecular detection of antibiotic resistance|Helico DR®, triple therapy (Proton Pomp Inhibitor (PPI), amoxicillin, clarithromycin, metronidazole)
223827079|NCT01168063|DRUG|standard triple therapy (PPI, amoxicillin, clarithromycin, metronidazole)|"2 lines of treatments :~1\) PPI + Amoxicillin + Clarithromycin for 7 days~1\) PPI + Amoxicillin + Metronidazole for 14 days"
223827080|NCT04003662|DEVICE|Vital Signs Measurement|Vital signs are measured twice with standard of care equipment while recording digital video data at the same time.
223827081|NCT02424552|DRUG|Vitamin D3|Initial single dose 100000 IU, beginning from the second day 4000 IU/day for 24 weeks.
223827082|NCT02424552|DRUG|Placebo|Filling material: lactose monohydrate, cellulose, magnesium stearate
223827083|NCT04466423|BEHAVIORAL|Small group meetings (COMPASS: COlleagues Meeting to Promote And Sustain Satisfaction)|The first 15 minutes of each session will be semi-structured discussion involving i) check in and ii) dialogue about the assigned question. Group leaders will be provided 3-4 discussion questions for each session. The group (or the leader) can choose the one they are most interested in and will then spend 10-15 minutes discussing the question together. Questions will touch on key themes for discussion (see the attached topics list) and are derived from our previous intervention studies. The remainder of the time can be used for socializing and building relationships with colleagues.
223827084|NCT04297241|DRUG|Isosorbide Dinitrate|All patients will be given a 6 week titration regimen of study medication. Patients will begin at a 5mg dosage and titrate up to 30mg three times per day if each subsequent dose is tolerated.
223827085|NCT01598974|PROCEDURE|Traditional Acupuncture|
223827086|NCT01598974|PROCEDURE|Laser Acupuncture|
223827087|NCT00724425|DRUG|IPI-493|Capsules, Multiple Schedules
223827088|NCT03587792|PROCEDURE|stapedectomy|Stapedectomy as described in literature with stapes removal, Carbon Dioxide (CO2) laser platinectomy and placement of a prothesis(piston) between the incus long process and the stapes footplate
223827089|NCT02569320|DRUG|Dexamethasone|Given PO
223827090|NCT02569320|DRUG|HDAC Inhibitor AR-42|Given PO
223827091|NCT02569320|OTHER|Laboratory Biomarker Analysis|Correlative studies
223827092|NCT02569320|DRUG|Pomalidomide|Given PO
223827093|NCT02861391|DEVICE|CO2 AcuPulse Laser|Each subject will receive 3 laser treatments 4 weeks apart and 3 Follow Up visits, at 1, 3, and 6 months following the last treatment.
223827094|NCT02861391|DEVICE|Sham Laser|Each subject will receive 3 sham treatments 4 weeks apart and 3 Follow Up visits, at 1, 3, and 6 months following the last treatment.
223827095|NCT00762684|DRUG|TAK-559|TAK-559 32 mg, tablets, orally, once daily for up to 26 weeks.
223827096|NCT00762684|DRUG|Placebo|TAK-559 placebo-matching tablets, orally, once daily for up to 26 weeks.
223827097|NCT03856996|BIOLOGICAL|Stable CH505TF gp120|Administered by IM injection in the deltoid of the non-dominant arm
223827098|NCT03856996|BIOLOGICAL|Transient CH505TF gp120|Administered by IM injection in the deltoid of the non-dominant arm
223827099|NCT03856996|BIOLOGICAL|Glucopyranosyl Lipid Adjuvant-Stable Emulsion (GLA-SE)|Admixed with Stable CH505TF gp120 or Transient CH505TF gp120 for IM injection in the deltoid of the non-dominant arm
223827100|NCT05136911|BEHAVIORAL|SALT-Intervention|Participants in the intervention group will have access to all standard care as provided to the usual care group participants. In addition, participants in the intervention group will receive the SALT-intervention developed by the principal investigator in the form of a SALT-intervention consist of the Salt Intervention manual, five online modules which include a virtual cooking demonstration and five ten-minute weekly telephone calls delivered by the principal investigator.These strategies aim to increase knowledge, enhance self-management abilities and provide social support.
223827101|NCT06240858|PROCEDURE|Laparoscopic transabdominal preperitoneal hernia repair.|The TAPP group used self-gripping mesh for laparoscopic transperitoneal preperitoneal hernia repair.
223827102|NCT06240858|PROCEDURE|Lichtenstein hernia repair.|The Lichtenstein group used self-gripping mesh for Lichtenstein hernia repair.
223827103|NCT03959592|DRUG|Lutein, zeaxanthin and mesozeaxanthin|The intervention will involve supplementation with the macular carotenoids (1 pill daily with a meal containing lutein, zeaxanthin, mesozeaxanthin) for six months, to determine the effects on visual performance in glaucoma patients.
223827104|NCT03959592|OTHER|Placebo|This intervention involves an inert pill (1 pill daily with a meal) that contains only sunflower oil, for six months.
223827105|NCT02324023|DEVICE|Endoscopic ultrasound|All patients will be evaluated by EUS and CE-EUS, using radial EUS instruments. The EUS scope will be inserted under direct vision, passed by the tumour and examination should begin during withdrawal at 7.5 MHz. The tumour will be characterized describing its echogenicity, echo structure, size, extent into the bowel wall and surrounding structures, and it will be staged using the modification of the TNM classification, based on a five-layer intestinal wall model. The presence/absence of power Doppler signals will be noted. For CE-EUS parameters for objective measurement of tumour perfusion will include maximum intensity of enhancement, mean transit time, time to peak (wash-in time), wash-in slope, area under the curve, representing indirectly blood flow or blood volume in CRC patients.
223827106|NCT03411824|OTHER|no intervention|Non applicable
223827107|NCT02646306|OTHER|shoulder proprioceptive rehabilitation tool|"Using of this tool to measure which is the average error in reaching back in both healthy subjects and subjects with shoulder impingement syndrome starting from the assumption that the shoulder, through the articulation scapulothoracic, helps to determine direction and distance during the reaching of an object."
223827108|NCT04075799|OTHER|high-intensity interval training|The HIIT protocol consists of 8 weeks using stair climbing three times per week. The warm-up will consist of 2 minutes of ascending and descending the stairs at a comfortable pace. The high-intensity intermittent exercise will comprise 6-12 x 30-seconds bouts of ascending at an all-effort. A 30- seconds walking recovery will occur between the exercise bouts. Post-exercise the subject will walk during a 2-minute cool down. Every session will last between 10 to 15 minutes. The number of bouts (6-12) will be increased progressively over the weeks. The first (week 1) and final week (week 8) of the exercise program will be monitored by a trained exercise physiologist. During supervised visits, heart rate and rating of perceived exertion (OMNI scale) will be measured at the end of each bout and after active recovery. Subjects will have the option to request further monitoring if desired.
223827109|NCT04408027|BEHAVIORAL|Virtual-Care Cognitive Behavioural Therapy|The feasibility, participation barriers, and acceptability of the intervention, virtual-care cognitive behavioural therapy (VC-CBT), will be evaluated for children with anxiety. The VC-CBT protocol will involve 12 sessions (of one hour in duration) delivered by a CBT therapist using PHIPA (Personal Health Information Protection Act) compliant Zoom. An initial session will review therapy goals and psychoeducation about anxiety. Sessions 2 and 3 will focus on feeling identification and will introduce relaxation strategies. Sessions 4 and 5 will introduce cognitive distortions and restructuring strategies. Sessions 6 and 7 will introduce exposure tasks. Sessions 8 to 11 will involve practicing cognitive restructuring skills and completing exposures. The final session will review relapse prevention. Parents will participate in the first and last sessions, as well as join at the end of each session for a brief review of the skills learned during the session.
223827110|NCT02827942|DRUG|vonoprazan 20 mg bid|Vonoprazan is potent acid inhibitor. Vonoprazan 20 mg is dosed twice daily for 1 week.
223827111|NCT02827942|DRUG|Amoxicillin 500 mg tid|Amoxicillin is antibiotics. Its bactericidal effect is time-dependent. Then, 500 mg of amoxicillin is dosed three times daily for 1 week.
223827112|NCT02827942|DRUG|Amoxicillin 750 mg bid|Amoxicillin is antibiotics. Its bactericidal effect is time-dependent. However, the standard regimen in Japan, 750 mg of amoxicillin is dosed twice daily with clarithromycin or metronidazole for 1 week. Then, 750 mg of amoxicillin is dosed twice daily.
223827113|NCT02827942|DRUG|Clarithromycin 200 mg bid|Clarithromycin is antibiotics. It is involved in the standard first line regimen in Japan. Then, 200 mg of clarithromycin is dosed twice daily for 1 week.
223827114|NCT02827942|DRUG|Metronidazole 250 mg bid|Metronidazole is antimicrobial agent. It is involved in the standard second line regimen in Japan. Then, 250 mg of metronidazole is dosed twice daily for 1 week.
223827115|NCT06158308|PROCEDURE|Laproscopic Appendicectomy|A type of surgery done without a large incision. Instead, from 1 to 3 tiny cuts are made. A long, thin tube called a laparoscope is put into one of the incisions. It has a tiny video camera and surgical tools.
223827116|NCT06158308|PROCEDURE|Open Appendicectomy|A cut or incision about 2 to 4 inches long is made in the lower right-hand side of your belly or abdomen. The appendix is taken out through the incision.
223827117|NCT04694729|OTHER|videoconference-based|Exercises will be done 3 days a week for 6 weeks, with the help of a physiotherapist via video conference.
223827118|NCT04694729|OTHER|video-based|The exercise video will be sent to the patients and they will do it 3 days a week for 6 weeks. The subjects will be asked to keep an exercise diary and the status of the diaries will be followed by calling once a week.
223827119|NCT04149041|DIAGNOSTIC_TEST|ultrasound|POCUS is applied to adult patients in an emergency department.
223827120|NCT02085837|OTHER|Education|Additional education will be provided by nurses to improve communication and reduce fragmentation of care.
223827121|NCT02085837|OTHER|Daily weight measurement and monitoring|Monitor weight to avoid problems related to hypervolemia.
223827122|NCT02085837|OTHER|Universal Dietary education|To improve diet and health
223827123|NCT02085837|OTHER|Medication review|Medication will be reviewed by nurses to detect any discrepancies to reduce medication error.
223827124|NCT02085837|OTHER|Focused advanced directive program|Education will be provided to increase awareness and encourage patients to have advanced directive.
223827125|NCT02085837|OTHER|Countdown to fistula program|To reduce the number of patients starting dialysis with catheter in place, comprehensive stepwise intervention will be provided by nurses to ensure arterio-venous (AV) fistula placement in all appropriate patients, with coordinated follow up and failure recovery processes.
223827126|NCT02340520|DRUG|Theophylline|Oral
223827127|NCT02340520|DRUG|Roflumilast|Oral
223827128|NCT03259282|BIOLOGICAL|Analysis of gamma globulin|Electrophoresis of proteins
223827129|NCT05174104|PROCEDURE|Vestibular Rehabilitation|The home exercise schedule consists of a patient-tailored association of adaptation (without and with the target moving on pitch and yaw planes for 1 min each three times per day), substitution, habituation, and balance and gait exercises. All the unilateral vestibular hypofunction patients will be followed in the clinic twice a week for 4 weeks for 30-45 min and evaluated for adherence. Between supervised sessions, patients will perform a twice-daily home exercise plan for a total of 30-40 min/day
223827130|NCT01918319|BEHAVIORAL|Lifestyle intervention|Energy requirements for each participant were individually estimated according to weight and level of activity during pregnancy. Women in the active intervention group were encouraged to be moderately physically active 30-60 minutes a day.Women in this group also had free full time membership in a fitness center for six months. In the fitness centers they had closed training classes with trained physiotherapists for one hour each week.
223827131|NCT01003639|DRUG|Acetazolamide|Subjects will begin with four 250 mg tablets daily. Tablets will be divided among two doses, taken with meals. Beginning on day 7, subjects will increase the dose by 1 pill every week until 16 tablets daily is reached (4 grams acetazolamide or placebo) or side effects prohibit increasing the dosage further. Thus, subjects who are able to tolerate the study medication will reach the maximum dose by day 84.
223827132|NCT01003639|DRUG|Placebo|Subjects will begin with four tablets daily. Tablets will be divided among two doses, taken with meals. Beginning on day 7, subjects will increase the dose by 1 pill every week until 16 tablets daily is reached (4 grams acetazolamide or placebo) or side effects prohibit increasing the dosage further. Thus, subjects who are able to tolerate the study medication will reach the maximum dose by day 84.
223827133|NCT01003639|BEHAVIORAL|Formal weight loss counselling program|Teleconference, web-based from central location, using site visits and subject self-assessment tools
223827134|NCT02552433|DIETARY_SUPPLEMENT|protein intake assessment and optimisation|
223827135|NCT05276323|DRUG|Medihoney Derma Cream|applied topically, twice a day, on all affected areas in the body for two weeks.
223827136|NCT05276323|DRUG|Hydrocortisone 1% cream|applied topically, twice a day, on all affected areas in the body for two weeks.
223827137|NCT01903408|RADIATION|Intensity-modulated radiotherapy of the pelvic lymph nodes using SIB|The intervention is the use of modern radiation techniques with simultaneous integrated boost (SIB)
223827138|NCT02092038|DRUG|Temozolomide|Neoadjuvant treatment with concurrent temozolomide and radiation therapy, followed by surgery and then further temozolomide.
223827139|NCT02092038|RADIATION|partial brain irradiation|Neoadjuvant treatment with concurrent temozolomide and radiation therapy, followed by surgery and then further temozolomide.
223827140|NCT02092038|PROCEDURE|stereotactic biopsy of brain tumor|will be assessed for tumor type and tumor markers
223827141|NCT02092038|PROCEDURE|craniotomy and tumor resection|maximal safe resection
223827142|NCT01586338|DRUG|Hylan G-F 20|Intra-articular injection (pre-filled glass syringe)
223827143|NCT03803020|OTHER|fractional flow reserve and SPECT detection|fractional flow reserve and SPECT detection
223827144|NCT00284089|DRUG|Ranibizumab|Ranibizumab was administered by intravitreal injection in the study eye. Intravitreal injection was performed by the investigator following slitlamp examination.
223827145|NCT05171140|PROCEDURE|Triangular Nail Placement of Femoral Neck|Triangular Nail Placement of Femoral Neck in arm A Femoral Neck Inverted Triangle Nail Surgery in arm B
223827146|NCT06255093|BEHAVIORAL|Community-based recreation program referral|Provide referral to local Parks and Recreation for programs of interest and participation. Participants will have the option to join a program (up to 4months) and have access to additional resources via study webpage to identify support services.
223827147|NCT06255093|BEHAVIORAL|Pre-surveys only|Receive online wellness education and anxiety treatment options information
223827148|NCT02811900|PROCEDURE|Roux en Y gastric bypass|Laparoscopic RYGB is performed as following: a gastric pouch of approximately 30mL was obtained using successive firings of the Endo GIATM linear stapler, followed by the creation of an antecolic alimentary limb of 150cm and of a biliopancreatic limb of 75cm. A gastrojejunal anastomosis was fashioned with the PCEEA™ 28 circular stapler until 2012, and using the Endo GIA™ linear stapler afterwards. The mesenteric defect and Petersen's defect were closed using a non-absorbable running suture.
223827149|NCT02811900|PROCEDURE|Sleeve gastrectomy|Laparoscopic SG is performed as following: after greater curvature mobilization, the gastric tube was calibrated over a 36F bougie and transection started approximately 5-6 cm from the pylorus toward the left diaphragmatic crus, using successive firings of 3.5- or 4.8-mm-high staples, depending on gastric thickness.
223827150|NCT02811900|PROCEDURE|Gastric banding|Laparoscopic gastric banding is performed as following: a perigastric tunel is performed by blunt dissection and the banding is calibrated over the stomach.
223827151|NCT02811900|PROCEDURE|Intragastric balloon|Flexible endoscopy is used to place intragastric balloon for a maximum interval of six months.
223827152|NCT05448586|DRUG|Opioid|Use of balanced anesthesia including opioids during anesthesia for gynecologic cancer surgery
223827153|NCT04071470|BEHAVIORAL|Storytelling|Couples in the storytelling intervention will receive 3 storytelling sessions- the couple can include any family or friends who they feel could support them during their treatment. Stories will include stories of couples who are supportive, those who experience difficulties, and families who do/do not support their use of PrEP
223827154|NCT04071470|DRUG|PrEP|Patients at risk of HIV acquisition will be provided PrEP medications and counseling in ANC
223827155|NCT05937009|OTHER|Orienteering exercise program|Orienteering exercise program running for 12 weeks (30-45 minutes, 3 sessions/week). Sessions will have 4 phases: 1) Signature of attendance sheet; 2) warm-up exercises for 5 minutes; 3) Start of orienteering proofs, where the departs will occur individually, with 3 interval minutes between participants; 4) stretches session, to return to a calm state.
223827156|NCT04362137|DRUG|Ruxolitinib|Ruxolitinib 5 mg tablets
223827157|NCT04362137|DRUG|Placebo|Matching-image placebo
223827158|NCT03676920|BEHAVIORAL|Discussions of Cost App (DISCO App)|The DISCO App is an app-based and patient-focused intervention designed to improve the frequency and quality of patient-oncologist treatment cost discussions. The DISCO App allows patients to provide basic demographic information (e.g., employment status, insurance status, etc), and uses that information to provide patients with an individually-tailored list of treatment cost questions they can ask their provider.
223827159|NCT00114309|DRUG|131-I-TM-601|131I-TM601, in solution, delivered intracavitarily following surgical resection 3 weekly administrations, 0.8 mg TM601 and 40mCi 131Iodine, per dose.
223827160|NCT00114309|DRUG|131I-TM601|131I-TM601, in solution, delivered intracavitarily following surgical resection 6 weekly administrations, 0.8 mg TM601 and 40mCi 131Iodine, per dose.
223827161|NCT02383511|DRUG|SMT C1100|Period 1, SMT C1100 1250 mg BID; Period 2, Placebo BID; Period 3, SMT C1100 2500 mg BID
223827162|NCT02383511|DRUG|SMT C1100|Period 1, SMT C1100 1250 mg BID; Period 2, SMT C1100 2500 mg BID; Period 3, Placebo BID
223827163|NCT02383511|DRUG|SMT C1100|Period 1, Placebo BID; Period 2, SMT C1100 1250 mg BID; Period 3, SMT C1100 2500 mg BID
223827164|NCT00253786|OTHER|Intensive multifactorial therapy|Blood glucose control: HbA1c \< 6.2% Blood pressure control: SBP \< 125 mmHg, DBP: \< 75 mmHg Lipid profile: T-cho \< 180 mg/dl, LDL-cho \< 100 mg/dl, HDL-cho \>40 mg/dl Dietary intervention: TDEI \< 30 kcal/kg/day, sodium \< 5 g/day, protein \< 0.8 g/kg/day Pharmacological intervention: ACE-Is or ARBs, HMG-CoA reductase inhibitors, multivitamins Instruction by co-medicals: Taking medicines, smoking cessation, nutrition care
223827165|NCT00253786|OTHER|Standard therapy|Blood glucose control: HbA1c \< 6.9% Blood pressure control: SBP \< 130 mmHg, DBP: \< 80 mmHg Lipid profile: T-cho \< 200 mg/dl, LDL-cho \< 120 mg/dl, HDL-cho \>40 mg/dl, Dietary intervention: TDEI \< 25-30 kcal/kg/day, sodium \< 6 g/day, protein \< 1.0 g/kg/day Pharmacological intervention: No restrictions (continuing prior therapy) Instruction by co-medicals: No restrictions (continuing prior therapy)
223827166|NCT06100601|BEHAVIORAL|ANS regulation therapy|innovative intervention for functional dysphonia
223827167|NCT06100601|BEHAVIORAL|conventional voice therapy (CVT)|conventional voice therapy traditionally provided for functional dysphonia
223827168|NCT06100601|BEHAVIORAL|ANS regulation therapy + CVT|combination of ANS regulation therapy and CVT
223827169|NCT00771875|DRUG|Rabbit Antithymocyte Globulin (RATG)|All patients will receive Thymoglobulin dosed based on CD3 count. Patients will be redosed when the CD3 count is ≥ 25. Depending on rejection severity, Thymoglobulin will be given for a maximum of 7-14 days. CD3 levels will be monitored daily.
223827170|NCT00771875|DRUG|Rituximab|Rituximab dose of 375 mg/ m2 on day 2. Patients will be premedicated with an antihistamine and acetaminophen prior to dosing per institution standard of care.
223827171|NCT00771875|DRUG|Bortezomib|Patient will receive 1.3 mg/m2 via IV push over 3-5 seconds on days 2, 5, 9, and 12. Consolidation course of bortezomib will be dosed at 1.3 mg/m2 IVP X 4 doses administered on days 1, 4, 7 and 10.
223827172|NCT00771875|DRUG|Acetaminophen|Patients will be premedicated with acetaminophen prior to dosing per institution standard of care.
223827173|NCT00771875|DRUG|Antihistamine|Patients will be premedicated with an antihistamine prior to dosing per institution standard of care.
223827174|NCT00771875|DRUG|Methylprednisolone|Methylprednisolone 250 mg with 1st dose of Thymoglobulin. Methylprednisolone 125 mg on treatment day 2 subsequent corticosteroids per institution standard of care; following treatment, corticosteroid therapy will resume at the pre-rejection dose.
223827175|NCT00941538|DIAGNOSTIC_TEST|Experimental: Screening with EBV VCA/EBNA1-IgA testing|Participants in the screening towns will be offered screening tests. Those with high-risk scores will be referred to a diagnostic workup examination using fiberoptic endoscopy examination and nasopharyngeal biopsies if suspicious lesions is observed.
223827176|NCT02032667|BEHAVIORAL|Multi-player condition|Children in the multi-player condition will be able to play with and compete against other children in real time.
223827177|NCT04089774|BEHAVIORAL|Adapted Physical Activity (APA)|Supported by an Adapted Physical Activity (APA), at the rate of 3 sessions per week supervised by the association SCO STE MARGUERITE, spread over 12 months
223827178|NCT03306043|DRUG|Mepolizumab|Mepolizumab will be available as 100 mg vial for injection. Subjects will receive three 100 mg SC injections for every 4 Weeks for a total of 5 doses during 20 Week treatment period.
223827179|NCT05245799|BEHAVIORAL|Speech Language Therapy|Children who are deaf/hard of hearing will receive typical speech and language therapy with a speech pathologist. Reading time is prescribed 20 min, 3x/week.
223827180|NCT05245799|BEHAVIORAL|Digital Software Application|The Hear Me Read app is an IOS-based software application that enables parents and speech-language pathologists to partner together to help deaf/hard of hearing children (D/HH) achieve reading, speech and language goals through interactive digital storybook reading.
223827181|NCT02685371|BEHAVIORAL|Breathing|Subjects will have to breath 1- Spontaneously 2- to produce a negative pressure of -15 to -30 cm of water and 3- to produce a negative pressure more than -30 cm of water.
223827182|NCT03497884|DEVICE|rTMS|For the l-Hz sessions (low frequency), stimulation is delivered at 100% of the subject's resting motor threshold at 1 Hz continuously over 30 min for a total of 1,800 pluses. The 10-Hz stimulation (high frequency) is delivered at 100% of the subject's resting motor threshold via 60 trains of 3-s 10-Hz rTMS (30 pulses per train).
223827183|NCT00785538|BIOLOGICAL|IMC-A12|"Cohort 1~3 milligrams/kilogram (mg/kg), I.V. once a week, for 4 weeks, followed by a 2-week observation period."
223827184|NCT00785538|BIOLOGICAL|IMC-A12|"Cohort 2~6 mg/kg, I.V. once a week, for 4 weeks, followed by a 2-week observation period."
223827185|NCT00785538|BIOLOGICAL|IMC-A12|"Cohort 3~10 mg/kg, I.V. once a week, for 4 weeks, followed by a 2-week observation period."
223827186|NCT00785538|BIOLOGICAL|IMC-A12|"Cohort 4~15 mg/kg, I.V. once a week, for 4 weeks, followed by a 2-week observation period."
223827187|NCT00785538|BIOLOGICAL|IMC-A12|"Cohort 5~21 mg/kg, I.V. once a week, for 4 weeks, followed by a 2-week observation period."
223827188|NCT00785538|BIOLOGICAL|IMC-A12|"Cohort 6~27 mg/kg, I.V. once a week, for 4 weeks, followed by a 2-week observation period."
223827189|NCT05565235|DRUG|patients will receive intraoperative serratus block with bupivacaine|no additives
223827190|NCT05565235|DRUG|serratus block with bupivacaine /magnesium|magnesium added
223827191|NCT05565235|DRUG|serratus block with bupivacaine with nalbuphine|nalbuphine added
223827192|NCT02529397|BEHAVIORAL|Adaptive Working Memory Training|Participants will train for 30-40 minutes per day, five days per week at home for 5 weeks using an adaptive cognitive training program which becomes increasingly challenging as the participant masters each level. Behavioral classes will teach the principles of weight management and exercise.
223827193|NCT02529397|BEHAVIORAL|Non-adaptive cognitive training|Participants will train for 30-40 minutes per day, five days per week at home for 5 weeks using a non-adaptive cognitive training program. Behavioral classes will teach the principles of weight management and exercise.
223827194|NCT04276090|DEVICE|Hepatic artery infusion pump placement using the Synchromed II pump and the Codman tapered arterial catheter.|Patients will undergo surgical hepatic artery infusion pump placement using the Synchromed II pump and the Codman tapered arterial catheter.
223827195|NCT04276090|DRUG|Hepatic artery infusion pump floxuridine and dexamethasone|Patients will receive infusion of floxuridine (FUDR) and dexamethasone via hepatic artery infusion through the implanted pump
223827196|NCT04276090|DRUG|Systemic chemotherapy for colorectal liver metastases|Patients will receive disease-appropriate systemic chemotherapy for colorectal liver metastases (FOLFOX, FOLFIRI, or irinotecan/oxaliplatin, or panitumumab if KRAS/NRAS wild type)
223827197|NCT04276090|DRUG|Systemic chemotherapy for intrahepatic cholangiocarcinoma|Patients will receive disease-appropriate systemic chemotherapy for intrahepatic cholangiocarcinoma (gemcitabine/oxaliplatin or gemcitabine alone)
223827198|NCT01799720|DIETARY_SUPPLEMENT|Less oxidized oil and diet|Analyze the effect of dietary supplements Omega-3 with different levels of oxidation in the lipid profile of women who consume these supplements. For this purpose we have designed a single-blind, parallel-groups, randomized controlled trial. Finally 52 women between 25 and 75 years old randomly were distributed into three groups. Participants from group 1 took 2 capsules/day of one of the less oxidized oil (containing 300 mg EPA + DHA) and diet, . Follow-up 30 days
223827199|NCT01799720|DIETARY_SUPPLEMENT|More oxidized oil and diet|Analyze the effect of dietary supplements Omega-3 with different levels of oxidation in the lipid profile of women who consume these supplements. For this purpose we have designed a single-blind, parallel-groups, randomized controlled trial. Finally 52 women between 25 and 75 years old randomly were distributed into three groups. Participants from group 2 took 2 capsules/day of one of the more oxidized oil (containing 300 mg EPA + DHA) and diet . Follow-up 30 days
223827200|NCT01799720|DRUG|Hypercholesterolemic diet|Analyze the effect of dietary supplements Omega-3 with different levels of oxidation in the lipid profile of women who consume these supplements. For this purpose we have designed a single-blind, parallel-groups, randomized controlled trial. Finally 52 women between 25 and 75 years old randomly were distributed into three groups. Participants from group 3 only received the diet and no capsules. Follow-up 30 days
223827201|NCT04465058|OTHER|COVID19|viral infection
223827202|NCT00002499|DRUG|asparaginase|
223827203|NCT00002499|DRUG|cytarabine|
223827204|NCT00002499|DRUG|daunorubicin hydrochloride|
223827205|NCT00002499|DRUG|dexamethasone|
223827206|NCT00002499|DRUG|methotrexate|
223827207|NCT00002499|DRUG|prednisone|
223827208|NCT00002499|DRUG|vincristine sulfate|
223827209|NCT00002499|RADIATION|radiation therapy|
223827210|NCT01234649|DRUG|Metformin XR plus placebo|Metformin plus Placebo Metformin 500 mg qd 2 weeks 500 mg bid 2 weeks 500 mg am, 1000 mg pm- 2 weeks 1000 mg bid -98 weeks (end study) Placebo-start 1 injection SC QD step up to a max dose as tolerated
223827211|NCT01234649|DRUG|Metformin XR plus liraglutide|Metformin XR-500 qd for 2 weeks, 500 mg bid 2 weeks; 500 mg am, 1000 mg pm- 2 weeks - 1000 bid final dose Liraglutide- start 0.6 mg SC QD step up to 1.2 mg to a max dose of 1.8 mg SC QD as tolerated during the 4-wk non-forced dose-escalation period ( maximum allowed dose of 1.8 mg SC QD)
223827212|NCT00566943|DEVICE|PSD Veritas Collagen Matrix|Roux-en-Y gastric by-pass surgery. Surgeon creates a small pouch from the stomach and then by-passes a large portion of the small intestine. The body cannot absorb as many calories or nutrients thus resulting in weight loss.
223827213|NCT00566943|PROCEDURE|Roux-en-Y gastric by-pass surgery with no buttress|Patients who have laparoscopic Roux-en-Y gastric by-pass surgery without staple line buttress material. No buttress material will be used on staple line including stomach/pouch, anastomostic junctions, (gastrojejunostomy (GJ) gastric to intestine, or jejunojejunostomy (JJ) intestine to intestine intestine to mesentery.
223827214|NCT04454762|DRUG|Cabozantinib|oral administration (40 mg daily, reduced dose 20 mg daily)
223827215|NCT00515398|OTHER|Observation|Ex vivo administration of AT2220
223827216|NCT03948425|RADIATION|spectral CT|Head spectral CT
223827217|NCT00318149|BIOLOGICAL|Fluarix|1 dose administered intramuscularly in the deltoid region of the non-dominant arm
223827218|NCT00318149|BIOLOGICAL|Fluarix-AS25|1 dose administered intramuscularly into the deltoid region of the non-dominant arm
223827219|NCT00318149|BIOLOGICAL|Fluarix-AS50|1 dose administered intramuscularly into the deltoid region of the non-dominant arm
223827220|NCT00318149|BIOLOGICAL|Fluarix-AS01B|1 dose administered intramuscularly into the deltoid region of the non-dominant arm
223827221|NCT00318149|BIOLOGICAL|Fluarix-AS01E|1 dose administered intramuscularly into the deltoid region of the non-dominant arm
223827222|NCT02916004|DEVICE|Measurement of NFR and PDR|Feasibility testing of NFR and PDR in sedated, ventilated patients. Comparison of NFR and PDR with standard routine care of pain assessment
223827223|NCT04663568|DEVICE|Levonorgestrel-releasing intrauterine system|Levonorgestrel-releasing intrauterine system will be inserted during the menstrual cycle
223827224|NCT05713760|DRUG|Tirbanibulin Ointment 1%|Klisyri® ointment is a microtubule inhibitor for topical use and is currently on the market for the treatment of actinic keratosis of the face or scalp. The chemical name of tirbanibulin is N-benzyl-2-(5-(4-(2- morpholinoethoxy)phenyl)pyridin-2-yl) acetamide. Tirbanibulin ointment 1% contains 10 mg tirbanibulin per gram of white to off-white ointment containing mono- and di-glycerides and propylene glycol and is supplied in packets containing 250 mg of tirbanibulin ointment 1%. Each packet includes single-dose packets (2.5 mg tirbanibulin in 250 mg) to be applied to evenly cover up to 25 cm² of the treatment field once daily for 5 consecutive days using 1 single-dose packet per application.
223827225|NCT01304082|DRUG|Lidocaine|1 ml subcutaneous injection of 0.9% lidocaine, given once
223827226|NCT01304082|DRUG|normal saline|1 ml subcutaneous injection 0.9% sodium chloride, given once
223827227|NCT01304082|DRUG|alkalinized lidocaine|1 ml subcutaneous injection of 0.9% lidocaine and 0.84% sodium bicarbonate
223827228|NCT05148832|DRUG|Administration of Systemic Corticosteroid|10 mg of systemic corticosteroids were prescribed weekly to patients to observe taste and smell sensation recovery.
223827229|NCT01015222|DRUG|Dasatinib|Starting dose of 50 mg daily PO for 28 day cycle
223827230|NCT01015222|DRUG|Bevacizumab|Starting dose 5 mg/kg IV Day 1 and 15
223827231|NCT01015222|DRUG|Paclitaxel|Starting dose 40 mg/m2 IV Day 1, 8 and 15
223827232|NCT01779479|DRUG|Cabacitaxel|Cabazitaxel 25 mg/m² i.v. (Day 1) every 3 weeks (cycle) as 1-hour i.v infusion for a total of up to 4 cycles over a maximum total treatment period of 15 weeks before surgery
223827233|NCT01779479|DRUG|Paclitaxel|Paclitaxel 80 mg/m² as 1-hour i.v infusion. Patients will receive weekly (Days 1, 8, 15) paclitaxel administrations for a maximum of 12 infusions for a maximum of 4 cycles over a maximum total treatment period of 15 weeks before surgery (1 cycle = 3 weeks).
223827234|NCT06428838|BIOLOGICAL|Eptinezumab|The study treatment consists of a single infusion of eptinezumab (100mg/mL).
223827235|NCT06428838|OTHER|Standard of Care|SoC may include a combination of Toradol, Metoclopramide, and/or Benadryl. Ketamine and/or Midazolam may also be used, according to a stepwise approach, at the discretion of the treating physician. The timing and dose of all medication(s) administered in the ED will be recorded.
223827236|NCT06547398|RADIATION|Adaptive radiotherapy +/- Margin Reduction|Radiotherapy using adaptive technology to recontour and replan daily as required. Reductions in the PTV margin will also be introduced in the second phase of this study.
223827237|NCT06547398|RADIATION|Image guided radiotherapy|Standard radiation treatment used in the department of radiation oncology for prostate cancer
223827238|NCT01269008|DEVICE|Medtronic ePID 2.0|Closed loop system is an automated insulin delivery system based on body blood sugar. It consists of an Insulin pump, glucose sensor, and a device presently a laptop with all the algorithms.
223827239|NCT03267290|DIAGNOSTIC_TEST|Sonazoid- CEUS, CEMRI, CECT|Sonazoid- CEUS+CEMRI in a characterization of HCC, in comparison with CECT+CEMRI.
223827240|NCT06220383|PROCEDURE|Hall technique|Prepless crown technique
223827241|NCT06220383|PROCEDURE|Conventional technique|1 or 1,5 mm preparation on mesial, distal and occlusal of the tooth
223827242|NCT02591680|OTHER|Neuromuscular training|
223827243|NCT02591680|OTHER|Muscle strengthening|
223827244|NCT02591680|DEVICE|Sensorimotor|
223827245|NCT06312293|DEVICE|Transcutaneous Vagus Nerve Stimulation|All techniques used to stimulate the vagal nerve are called vagus nerve stimulation.
223827246|NCT04324255|PROCEDURE|LT|Liver transplantation
223827247|NCT04524572|BEHAVIORAL|Motion sensor|To explore the role of a motion sensor with accompanying web application on step counts, energy balance, and metabolic markers in nurses
223827248|NCT02901145|DRUG|Nivolumab,low dose cyclophosphamide|treatment with IV Nivolumab 3mg/kg every 2 weeks . after a month-addition of low dose cyclophosphamide at a starting dose of 50 mg/kg/day x7 days every 14 days with dose adaptation based on level of Tregulatory cells on follow up immunophenotype.
223827249|NCT00054925|BEHAVIORAL|Personal contact (PC)|This arm uses brief, individual contacts on a monthly basis which emphasize core elements of weight maintenance. Monthly contacts with an interventionist occur for 30 months after the end of Phase I. Face-to-face contacts occur approximately every four months (e.g., three annually), with telephone contacts occurring every month between FTF contacts.
223827250|NCT00054925|BEHAVIORAL|Interactive technology (IT)|The website utilizes collaborative goal setting and problem-solving strategies to identify contingent action plans for perceived obstacles to success. In order to tailor the intervention to the needs of the participant, the action plan can be updated anytime and as frequently as desired by the individual. Participants are encouraged to input data on weight, food records, physical activity, and goals on a weekly basis. Participants are not restricted to logging on to the website only once a week. Rather, participants have the option of logging on to the website to enter data, communicate with other participants, or to seek other information, as frequently as they wish.
223827251|NCT03093740|DRUG|Zepatier|Based on negative viral resistance testing of the donor treatment will be Zepatier
223827252|NCT03093740|DRUG|Zepatier plus Sofosbuvir|Based on positive viral resistance testing of the donor treatment will be Zepatier with Sofosbuvir
223827253|NCT05291221|DRUG|intratracheal saline|At the end of the operation by 15min, 5ml of 0.9% normal saline was sprayed down the intratracheal tube of patients
223827254|NCT05291221|DRUG|intratracheal Dexmedetomidine|At the end of the operation by 15min, Dexmedetomidine (0.5µg/kg, diluted in 5mL saline in a medical spray bottle) was sprayed down the intratracheal tube of patients
223827255|NCT05291221|DRUG|intratracheal Lidocaine|At the end of the operation by 15min, (5ml) 2% of lidocaine was sprayed down the intratracheal tube of patients.
223827256|NCT01805817|DRUG|YASMIN® (Drospirenone/Ethinyl Estradiol)|oral contraceptive pills
223827257|NCT01805817|DEVICE|The Copper-T is an intrauterine device (IUD)|intrauterine device for contraception
223827258|NCT01805817|DEVICE|levonorgestrel-releasing system|intrauterine device
223827259|NCT03572855|COMBINATION_PRODUCT|Scoliosis Brace|Brace will be fitted to each subject by a spine orthopedic surgeon before the testing. The subject will wear the fitted brace for 2 months.
223827260|NCT01633216|BIOLOGICAL|Bivalent OPV 2 week interval|Group A will receive 3 doses of bOPV at 6, 8 and 10 weeks of age (2-week interval between doses).
223827261|NCT01633216|BIOLOGICAL|Bivalent OPV 4 week interval|Group B will receive 3 doses of bOPV at 6, 10 and 14 weeks of age (4-week interval between doses).
223827262|NCT01633216|BIOLOGICAL|Monovalent OPV 2 week interval|Group C will receive 3 doses of mOPV1 at 6, 8 and 10 weeks of age (2-week interval between doses).
223827263|NCT01633216|BIOLOGICAL|Monovalent OPV 4 week interval|Group D will receive 3 doses of mOPV1 at 6, 10 and 14 weeks of age (4-week interval between doses).
223827264|NCT01633216|BIOLOGICAL|Trivalent OPV 4 week interval|Group E will receive 3 doses of tOPV at 6, 10 and 14 weeks of age (4-week interval between doses and similar to the current routine immunization schedule).
223827265|NCT05518422|DRUG|Hyperinsulinemic, euglycemic infusion|60 minute infusion
223827266|NCT00412035|DRUG|Botulinum toxin A injection|10 units per kilo to maximum of 400 units
223827267|NCT00412035|DRUG|saline injection|10 units per kilo to maximum of 400 units
223827268|NCT05341375|PROCEDURE|Thoracic paravertebral block|"The patient was placed in lateral supine position, and the T5 spinous process was moved 2 to 3cm laterally to the operative side as the puncture point, and the pleura and T5 transverse process were observed, and the paraspinal space was observed on the lower lateral side of the transverse process. Using in-plane technique, the needle position was adjusted under ultrasound visualization to reach the paraspinal space. 20ml 0.375% ropivacaine was injected into the suction syringe when there was no blood or gas, and the drug liquid could be seen spreading outside the pleura. Landscape sign appeared, indicating successful block"
223827269|NCT05341375|DRUG|Esketamine|Group TE received s-ketamine anesthesia induction dose of 0.3 mg/kg on the basis of TA group. Anesthesia maintenance dose of 0.2ug/kg/h was pumped to 30min before the end of the operation
223827270|NCT05341375|BEHAVIORAL|Measurement of cognitive function|Patients undergoing thoracoscopic surgery underwent general anesthesia.MMSE was assessed at one day before surgery, one day after surgery, and three months after surgery
223827271|NCT05341375|BEHAVIORAL|The assessment of cognitive function|Participants were assessed for MMSE at the same period as the group C
223827275|NCT04362592|DEVICE|In Utero Endoscopic Correction of Myelomeningocele IDE - Percutaneous Technique|The percutaneous approach uses endoscopes through a closed maternal abdomen and closed uterus to perform the spina bifida correction.
223827276|NCT04362592|DEVICE|In Utero Endoscopic Correction of Myelomeningocele IDE - Laparotomy/Uterine Exteriorization Technique|The laparotomy/uterine exteriorization technique uses endoscopes through an open abdomen and closed, exteriorized uterus to perform the spina bifida correction.
223827277|NCT01358838|DEVICE|ablative 10600 nm fractional laser therapy|"Half of the scar, or one of two comparable scars, will be treated with the ablative 10600 nm fractional laser. There wil be 3 treatments, with 8 weeks apart.~Half of the scar, or one of two comparable scars, will receive no treatment at all."
223827278|NCT02586337|DRUG|Anlotinib|Anlotinib p.o. qd
223827279|NCT02586337|DRUG|Placebo|Placebo p.o. qd
223827280|NCT01898637|OTHER|Augmented pulse oximetry using incentive spirometer.|Augmented pulse oximetry using incentive spirometer.
223827281|NCT01898637|DEVICE|Incentive spirometer.|The incentive spirometer is a simple passive device that measures the amount of air a person can inhale.
223827282|NCT05724056|DEVICE|Idroflog®|"The study intervention posology will be based on current labeling of Idroflog®. Participants will be self-administering one drop in each eye 4 times a day every day during the study period.~Administration should follow the label guidelines. Participants should detach a single vial from the strip, remove the flap at the top by rotating it and instill 1 drop into the conjunctival sac of each eye, dropping them from above."
223827283|NCT05724056|DEVICE|Sodium Hyaluronate 0.18% (Vismed®)|"The control intervention posology will be based on current labeling of Idroflog®. Participants will be self-administering one drop in each eye 4 times a day every day during the study period.~Administration should follow the label guidelines. Participants should detach a single vial from the strip, remove the flap at the top by rotating it and instill 1 drop into the conjunctival sac of each eye, dropping them from above."
223827284|NCT01266694|DRUG|Colchicines|oral form, 1 mg, once a day during 14 days
223827285|NCT01266694|DRUG|Placebo|oral form, placebo
223827286|NCT02008968|DRUG|allopurinol 300 mg./day|
223827287|NCT02008968|OTHER|No intervention|
223827288|NCT02008968|DRUG|Normouricemic|
223827289|NCT02215733|DRUG|ARB|other than telmisartan
223827290|NCT02215733|DRUG|ACEI|
223827291|NCT02215733|DRUG|Beta-blockers|
223827292|NCT02215733|DRUG|Diuretics|
223827293|NCT02215733|DRUG|Telmisartan|
223827294|NCT03581877|DRUG|Alteplase|As stated before, low dose r-tpa will be administered through a peripheral vein for PLST.
223827295|NCT03581877|DEVICE|EKOS|As stated before, the EKos device will be used for ultrasound assisted catheter directed thrombolysis or ACDT, same dose t-tpa will administered through the pulmonary catheter. It will be given at a fixed dose over 24 hours.
223827296|NCT01028079|DRUG|Acetylsalicylic Acid (Aspirin, BAYE4465)|Aspirin 1000 mg (solid dose caplet) to be given three times daily as for 2 consecutive days (48 hours), followed by Aspirin 1000 mg (solid dose caplet) to be taken as per need, but not more than three times daily for the following 3 days (72 hours). Total treatment period has not to exceed 5 days and total daily dose has not to exceed 3000 mg Aspirin.
223827297|NCT01028079|DRUG|Ibuprofen|Ibuprofen 400 mg caplet to be given three times a day as for 2 consecutive days (48 hours), followed by ibuprofen 400 mg caplet to be given as per need, but not more than three times a day for the following 3 days (72 hours). Total treatment period has not to exceed 5 days and total daily dose has not to exceed 1200 mg ibuprofen.
223827298|NCT01028079|DRUG|Placebo|Placebo (two placebos: Placebo Aspirin and Placebo Ibuprofen) to be given three times a day for a maximum of 5 consecutive days in the same regimen as for Experimental Drug and Active Comparator.
223827299|NCT00538174|DRUG|Dapagliflozin|Tablets, Oral, once daily up, to 14 days
223827300|NCT00538174|DRUG|placebo|Tablets, Oral, 0 mg, once daily, up to 14 days
223827301|NCT01177839|OTHER|Screening sheets|Reviewing screening sheets
223827302|NCT05518760|OTHER|no intervention|no intervention
223827303|NCT04321967|DRUG|Nitroglycerin Paste|1g of 2% Nitroglycerin paste topical application
223827304|NCT04321967|DRUG|Dermabond|Topical skin adhesive
223827305|NCT04527848|DRUG|small amount of undiluted C3F8|vitrectomy followed by peeling of the internal limiting membrane and, after that, intraocular gas injection
223827306|NCT05738460|DRUG|antibiotics|Reproductive tract GBS colonization group of mothers during pregnancy，Use of antibiotics
223827307|NCT05598177|DRUG|dexmedetomidine|The participant will pump dexmedetomidine at the rate of 1μg/(Kg·h) for 10 minutes at the beginning of anesthesia induction, and then maintain the pump at a rate of 0.5μg/(Kg·h) during the operation.
223827308|NCT05598177|DRUG|Placebo|The participant will pump saline without dexmedetomidine at the same speed as group D.
223827309|NCT03001232|BEHAVIORAL|Movement-oriented Dementia Care|The intervention is a new multidisciplinary approach that focuses on optimizing physical activity and independence in daily care and activities. MDC intended to incorporate all persons surrounding the patients. The nursing staff was intensively trained by an expert in MDC, and played a central role in continuously stimulating patients to function as independently as possible. Geriatric physicians and physiotherapists advised the nursing staff about participants' medical and physical limitations to ensure safe stimulation. Consequently, a plan was created for each resident to determine the daily routines they were capable of performing themselves. Caregivers and volunteers were informed about the benefits of an active lifestyle during several open meetings.
223827310|NCT00105586|DRUG|Escitalopram|Participants will either take 10 to 20 mg of escitalopram or placebo. Participants who wish to participate in the open-label extension receive an additional 12 weeks of escitalopram.
223827311|NCT01143623|DIETARY_SUPPLEMENT|Probiotic|L. acidophilus, L. paracasei, B. lactis; 2.5 billion cfu capsule once per day
223827312|NCT01143623|DIETARY_SUPPLEMENT|Probiotic|L. acidophilus, L. paracasei, B. lactis; 10 billion cfu capsule once per day
223827313|NCT01143623|OTHER|Placebo|Placebo
223827314|NCT02306122|BEHAVIORAL|Pharmacist calls patient unless physician cancels call|
223827315|NCT02306122|BEHAVIORAL|Patient nonadherence information sent to physician|
223827316|NCT02306122|BEHAVIORAL|Pharmacist calls patient if physician requests call|
223827317|NCT02306122|BEHAVIORAL|Doctor receives information and may be allowed certain actions|
223827318|NCT01805193|OTHER|Computed tomography myocardial perfusion imaging|
223827319|NCT01805193|OTHER|Oxygen 15 labelled water positron emission tomography|
223827320|NCT05097768|DRUG|Dexamethasone 0.5mg|The patients will be randomly given the medication by mouth 60 min before administering IANB.
223827321|NCT05097768|DRUG|Ketorolac 10 Mg Oral Tablet|The patients will be randomly given the medication by mouth 60 min before administering IANB.
223827322|NCT05097768|DRUG|Meloxicam 7.5 mg|The patients will be randomly given the medication by mouth 60 min before administering IANB.
223827323|NCT05097768|DRUG|Ibuprofen 600 mg|The patients will be randomly given the medication by mouth 60 min before administering IANB.
223827324|NCT05097768|DRUG|Placebo|The patients will be randomly given the medication by mouth 60 min before administering IANB.
223827325|NCT00675415|DIAGNOSTIC_TEST|Capnography|Capnography: Passive measurement of carbon dioxide via a special bite block which allows graphic assessment of the subject's respiratory activity
223827326|NCT02262260|DRUG|Labeled regime arm|Treatment will be given monthly and will be continued until maximum visual acuity is achieved (the patient's visual acuity is stable for three consecutive monthly assessments performed while on ranibizumab treatment). Thereafter patients should be monitored monthly for visual acuity. Treatment will be resumed when monitoring indicates loss of visual acuity due to DME. Monthly injections should then be administered until stable visual acuity is reached again for three consecutive monthly assessments (implying a minimum of two injections). The interval between two doses should not be shorter than 1 month.
223827327|NCT02262260|DRUG|Wait and Extend regime arm|Lucentis (ranibizumab) 0.5 mg will be injected subsequently at baseline, month 1 and 2. After the three initial loading doses, patients will be called for the control visits 1 month later. If the visual acuity has reached a stable level and there is no sign of edema on OCT, patients will not receive intravitreal injection and will be called to come back 6 weeks later. The interval is increased by 2 weeks until a maximum of 8 weeks as long as the patient presents as stable regarding visual acuity, central retinal thickness and clinical findings. If there is a negative change, the interval is shortened back to 4 weeks.
223827328|NCT00198601|DRUG|Gentamicin in Uniject Pre-filled syringe|
223827329|NCT00780182|DRUG|CMX001|CMX001 tablet fasted, CMX001 tablet fed, CMX001 solution fasted
223827330|NCT01642082|BIOLOGICAL|Dalantercept|Given SC
223827331|NCT01642082|OTHER|Laboratory Biomarker Analysis|Correlative studies
223827332|NCT01354834|DRUG|hMG|Patients with a condition
223827333|NCT01761539|OTHER|Aggressive Hydration|Receives 20cc/kg bolus and 3cc/kg/hr thereafter.
223827334|NCT01761539|OTHER|Moderate Hydration|Receives 10cc/kg bolus and 1.5cc/kg/hr thereafter.
223827335|NCT00128245|DRUG|Pimecrolimus|
223827336|NCT00128245|DRUG|Vehicle|Placebo
223827337|NCT02312674|DIETARY_SUPPLEMENT|Oral nutritional supplement|Beginning with the start of palliative therapy, depending on the nutritional status, one, two, or three cans per day are ingested during a period of three months.
223827338|NCT04022005|DRUG|Chidamide, Rituximab, Gemcitabine,Oxaliplatin|"All patients enrolled in the study will accept Chidamide + R-GemOx (Rituximab, Gemcitabine and Oxaliplatin) as their salvage chemotherapy.~Patients with CR or PR will receive chidamide maintenance therapy."
223827339|NCT01794117|DRUG|Anakinra|An initial dose of anakinra 100 mg/day will be administered daily via self-administered subcutaneous injection. If active disease persists at this dose, anakinra dose may be escalated up to 200 mg/day injected subcutaneously daily at week 4 and 300mg/day at week 8.
223827340|NCT03904511|OTHER|Souroubea-Platanus Preparation|Extracts of S. Sympetala and P. occidentalis.
223827341|NCT03904511|OTHER|Placebo|Placebo
223827342|NCT03132623|DRUG|andrographolide sulfonate|Xiyanping injection 10-20ml/d, With 0.9% Sodium Chloride Injection 100ml-250ml diluted intravenous drip (not with other drugs in the same container mixed use), control drip speed per minute of 30-40 drops.
223827343|NCT03132623|DRUG|andrographolide sulfonate simulation|Xiyanping injection simulation(0.9% normal saline) 10-20ml/d, The treatment method is the same as the experimental group.
223827344|NCT02737020|DRUG|Rhodiola|Rhodiola rosea 200mg pill up to four times a day
223827345|NCT02737020|DRUG|Placebo|up to four times a day
223827346|NCT06391216|DIETARY_SUPPLEMENT|Lactobacillus helveticus R0052 and Bifidobacterium longum R0175|8-week supplementation (56 days); 3 × 10\^9 CFU/day
223827347|NCT06391216|DIETARY_SUPPLEMENT|Placebo|8-week supplementation (56 days)
223827348|NCT03734991|DRUG|Ibrexafungerp|Ibrexafungerp 300 mg BID for 1 day
223827349|NCT03734991|DRUG|Placebo|Matching placebo
223827350|NCT04779905|DIAGNOSTIC_TEST|urinary albumbin/creatinine ratio|detection of microalbuminuria in nafld patients
223827351|NCT05825898|PROCEDURE|Surgery or Transcatheter tricuspid valve intervention|Isolated tricuspid valve surgery or Transcatheter tricuspid valve intervention
223827352|NCT03784534|OTHER|Imaging|high= density (64 sensors) EEG and anatomical MRI (T1 and tensor imaging) scan
223827353|NCT03784534|BEHAVIORAL|Clinical and behavioral testing : Motor recovery progress|NIHSS with motor subitems and Rankin and Barthel score, measure of functional independence and Hemispatial neglect, test of Ashworth
223827354|NCT03784534|BEHAVIORAL|Clinical and behavioral testing : Motor skills|the ARAT or ACTION RESEARCH ARM TEST, hand grip strength, Fugl Meyer
223827355|NCT05365113|PROCEDURE|alveolar recruitment maneuver|"When patient is under general anesthesia, an arterial catheter is placed for cardiac output and stroke volume (SV) monitoring. To avoid pre-load dependency bias, the blood volume will be optimized. A 250mL fluid-challenge of a balanced crystalloid solution is administered under cover of the SV monitoring. If SV variation is greater than 10%, a new fluid-challenge is performed to obtain a reference SV, corresponding to the patient's optimal blood volume.The patient is then pre-load independent.~Then, patients will be randomized into two groups: a first group will receive a CPAP ARM: 40 cmH2O for 50 seconds, followed by a 10-minute break corresponding to a period of return to basal state; then an extended sigh ARM (e-sigh) also lasting 50seconds (driving pressure: 10cmH2O and successive PEEP levels at 10,15,20,25 and 30cmH2O, a respiratory rate set at 30/min in controlled pressure - 5cycles at each PEEP level); a second group will receive the same two ARM modalities in reverse order."
223827356|NCT05958329|BEHAVIORAL|HRV Biofeedback|5 minute daily sessions of HRV biofeedback
223827357|NCT03343860|PROCEDURE|AT case 1.1|"In the case of AT at the time of ablation :~In the case of sinus rhythm restoration, PV will be re-isolated if necessary and lines (CTI, roof and mitral) already blocked during the first procedure will be re-blocked if necessary. Inducibility will be tested but no ablation will be carried out and a DCC post AT mapping will be performed if necessary. The procedure will end up after these steps."
223827358|NCT03343860|PROCEDURE|AT case 2.1|"In the case of AT at the time of ablation :~In the case of sinus rhythm restoration, PV will be re-isolated if necessary and lines (CTI, roof and mitral) already blocked during the first procedure will be re-blocked if necessary. Then inducibility will be tested and all inducible AT will be mapped and ablated (max 5 consecutive AT)"
223827359|NCT03343860|PROCEDURE|AT case 1.2|"In the case of AT at the time of ablation :~In the case of termination to another AT, a DCC will be performed. Thereafter, PV will be re-isolated if necessary and lines (CTI, roof and mitral) already blocked during the first procedure will be re-blocked if necessary. Inducibility will be tested but no ablation will be carried out and a DCC post AT mapping will be performed if necessary. The procedure will end up after these steps."
223827360|NCT03343860|PROCEDURE|AT case 1.3|"In the case of AT at the time of ablation :~In the case of AF deterioration, a DCC will be performed. Thereafter, PV will be re-isolated if necessary and lines (CTI, roof and mitral) already blocked during the first procedure will be re-blocked if necessary. Inducibility will be tested but no ablation will be carried out and a DCC post AT mapping will be performed if necessary. The procedure will end up after these steps"
223827361|NCT03343860|PROCEDURE|AT case 1.4|"In the case of AT at the time of ablation :~In the case of no AT termination, a DCC will be performed. Thereafter, PV will be re-isolated if necessary and lines (CTI, roof and mitral) already blocked during the first procedure will be re-blocked if necessary. Inducibility will be tested but no ablation will be carried out and a DCC post AT mapping will be performed if necessary. The procedure will end up after these steps."
223827362|NCT03343860|PROCEDURE|AT case 2.2|"In the case of AT at the time of ablation :~In the case of termination to another AT, ablation of the subsequent AT will be performed until sinus rhythm restoration. Thereafter, PV will be re-isolated if necessary and lines (CTI, roof and mitral) already blocked during the first procedure will be re-blocked if necessary. Then inducibility will be tested and all inducible AT will be mapped and ablated (max 5 consecutive AT)"
223827363|NCT03343860|PROCEDURE|AT case 2.3|"In the case of AT at the time of ablation :~In the case of AF deterioration, a DCC will be performed. Thereafter, PV will be re-isolated if necessary and lines (CTI, roof and mitral) already blocked during the first procedure will be re-blocked if necessary. Then inducibility will be tested and all inducible AT will be mapped and ablated (max 5 consecutive AT)"
223827364|NCT03343860|PROCEDURE|AT case 2.4|"In the case of AT at the time of ablation :~In the case of no AT termination, a DCC will be performed. Thereafter, PV will be re-isolated if necessary and lines (CTI, roof and mitral) already blocked during the first procedure will be re-blocked if necessary. Then inducibility will be tested and all inducible AT will be mapped and ablated (max 5 consecutive AT)"
223827365|NCT03343860|PROCEDURE|SR Case 1|"In the case of SR at the time of ablation:~PV will be re-isolated if necessary and lines (CTI, roof and mitral) already blocked during the first procedure will be re-blocked if necessary. The CTI line will be performed in all patients with a ECG showing a typical counterclockwise flutter. Inducibility will be tested but no ablation will be carried out and a DCC post AT mapping will be performed if necessary. The procedure will end up after these steps."
223827366|NCT03343860|PROCEDURE|SR Case 2|"In the case of SR at the time of ablation:~PV will be re-isolated if necessary and lines (CTI, roof and mitral) already blocked during the first procedure will be re-blocked if necessary. The CTI line will be performed in all patients with a ECG showing a typical counterclockwise flutter. Then inducibility will be tested and all inducible AT will be mapped and ablated (max 10 consecutive AT)"
223827367|NCT04103554|DRUG|Sacubitril-Valsartan|Sacubitril-Valsartan 24/26 mg BID, 49/51 mg BID, 97/103 mg BID
223827368|NCT04103554|DRUG|Standard of care|standard of care used for treating BP
223827369|NCT04124874|OTHER|There will be no intervention|There will be no intervention
223827370|NCT00735449|DRUG|Fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5%|1 drop of fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% taken approximately 12 hours apart, up to 2 times a day.
223827371|NCT00735449|DRUG|timolol maleate 0.5%|1 drop of timolol maleate 0.5% taken approximately 12 hours apart, up to 2 times a day.
223827372|NCT00735449|DRUG|latanoprost 0.005%|1 drop of latanoprost 0.005% once nightly.
223827373|NCT05711888|BEHAVIORAL|Semantic Recognition Procedure|A semantic recognition task is going to be added to administrated FCSRT procedure after immediate and delayed recall phases.
223827374|NCT06574828|DRUG|BIIB091|Administered as specified in the treatment arm.
223827375|NCT06574828|DRUG|Moxifloxacin|Administered as specified in the treatment arm.
223827376|NCT06574828|DRUG|BIIB091-matched Placebo|Administered as specified in the treatment arm.
223827377|NCT06574828|DRUG|Moxifloxacin-matched Placebo|Administered as specified in the treatment arm.
223827378|NCT04287049|DRUG|Azithromycin|Azithromycin 250 mg PO daily
223827379|NCT06206616|BEHAVIORAL|Gluten-free diet|"Pediatric patients affected by newly diagnosed Celiac Disease (CD) according to the European Society for Paediatric Gastroenterology Hepatology and Nutrition (ESPGHAN) criteria will start a gluten-free diet (GFD), as normally expected for all CD patients. The assessment of adherence to the GFD will be carried out through the monthly compilation, by the children and/or their parents, of a specifically created and validated questionnaire.~Before and after the start of GFD enrolled patients will undergo an abdominal ultrasound to establish the presence and degree of hepatic steatosis."
223827380|NCT00240292|DRUG|Rosuvastatin|
223827381|NCT05127798|OTHER|Evaluation of first line treatment with intensive treatment outcome in adult patients with AML.|Evaluation of first line treatment with intensive treatment outcome (or event free survival and overall survival and toxicity) in adult patients between 18 and 70 years old with AML.
223827382|NCT05536778|OTHER|Realization of the 3 tests|The participants will have to perform the isokinetic evaluation during one session and the two functional tests during another session. Those sessions will be separated by 14 days.
223827383|NCT01849900|OTHER|Knowing your body|"Women will receive the Knowing your body kit. The kit contains: 6 ovulation test strips, a 12 month menstrual log sheet/calendar, and a thermometer to help women determine their body temperature; and educational materials that contain information on female body parts involved in pregnancy, hormones and the menstrual cycle, how birth control works, body temperature changes, characteristics of cervical fluid, and adapting to pregnancy during the first trimester. Participants will receive a total of 10 visits. During the first visit, the nursing student/community health workers team will review the intervention kit and continue to discuss topics related to women's health during subsequent visits."
223827384|NCT01849900|BEHAVIORAL|Healthy Lifestyle|Women will receive educational materials on healthy lifestyle such as maintaining good nutrition and the importance of folic acid for women of childbearing age during the first visit. Participants will receive a total of 10 visits. The nursing student/community health workers team will continue to discuss topics related to promoting healthy lifestyle during subsequent visits.
223827385|NCT03513601|DRUG|(R)-CHOP regimen|(rituximab 375mg/m2 d0 ivgtt),cyclophosphamide 750mg/m2 d1、8 ivgtt,epirubicin 50mg/m2 d1、8 ivgtt,vincristine 2mg d1、8 ivgtt,prednisone 60mg d1-5 po.Every 21 days for one cycle and six cycles are required. Efficacy was evaluated every two cycles.
223827386|NCT03513601|DRUG|(R)-CVP regimen|The dose of the chemical was reduced by 20%，(rituximab 375mg/m2 d0 ivgtt),cyclophosphamide 750mg/m2 d1、8 ivgtt,vincristine 2mg d1、8 ivgtt,prednisone 60mg d1-5 po.Every 21 days for one cycle and one or two cycles are required. Efficacy was evaluated every two cycles. Subsequent (rituximab 375mg/m2 d0 ivgtt)， oral cyclophosphamide .
223827387|NCT06493136|DRUG|lidocaine gel|questionnaire
223827388|NCT02322814|DRUG|Cobimetinib|Cobimetinib will be administered orally at a dose of 60 milligrams (mg) per day, once a day, on Day 3 through Day 23 of each 28-day treatment cycle.
223827389|NCT02322814|DRUG|Paclitaxel|Paclitaxel will be administered at a dose of 80 milligrams per square meter (mg/m\^2) by intravenous (IV) infusion on Day 1, Day 8, and Day 15 of each 28-day cycle according to prescribing information.
223827390|NCT02322814|DRUG|Placebo|Placebo matching to cobimetinib will be administered orally, once a day, on Day 3 through Day 23 of each 28 day treatment cycle.
223827391|NCT02322814|DRUG|Atezolizumab|Atezolizumab will be administered to Cohorts II and III at a dose of 840 mg IV every 2 weeks on Days 1 and 15 of each 28-day treatment cycle.
223827392|NCT02322814|DRUG|Nab-Paclitaxel|Nab-Paclitaxel will be administered to Cohort III according to the local prescribing information at a starting dose of 100 mg/m\^2 by IV infusion on Days 1, 8, and 15 of each 28 day cycle.
223827393|NCT04875832|BEHAVIORAL|Eye Movement Desensitization and Reprocessing - EMDR|"EMDR is a comprehensive psychotherapy approach, originally developed to treat the victims of trauma. EMDR is guided by an information processing model known as the Adaptive Information Processing (AIP) model. One of the key assumptions of the AIP model is that dysfunctionally stored (disturbing) memories are the cause of several mental pathologies. EMDR is therefore used to address a range of complaints that follow distressing life experiences and it~is characterized by an eight-phase psychotherapy approach. The intervention is based on the use of bilateral stimulation (e.g., taps, tones, or eye movements), which aims to stimulate the information processing system of the brain in combination with other methods of established psychotherapies. EMDR is widely recognized as an empirically supported treatment for post-traumatic stress disorder (PTSD) and it is one of the best psychological treatment focused on the ri-processing of recent traumatic experiences"
223827394|NCT03587298|PROCEDURE|Real-Time (Supersonic)- 2D shear wave elastography (rt-SWE)|"The SWE is carried out intercostally. If possible, the patient should hold the breath for 5-10 seconds. So-called colour charts are used, which indicate the derived liver stiffness in colour-coded form. In addition to the visual assessment of these colour charts, the quantitative ROI-based measurement of the SWE in kPa is performed in the hardest appearing areas. The measurement is performed at 5 different sites of the liver parenchyma and all SWE values are recorded."
223827395|NCT02462525|DRUG|ABBV-838|Varying doses of ABBV-838
223827396|NCT02462525|DRUG|Pomalidomide|Administered orally per the label.
223827397|NCT02462525|DRUG|Dexamethasone|Administered orally per the label.
223827398|NCT05907486|DRUG|N-acetyl-cysteine|8g/d (\>=45kg); 200mg/kg.d (\<45kg), intravenously for at least 4 hours, day -9 to day +45
223827399|NCT05907486|DRUG|Busulfan|3.2mg/kg, day-7 to day -5, intravenously
223827400|NCT05907486|DRUG|Cytarabine|2g/m2, day -8, intravenously
223827401|NCT05907486|DRUG|Cyclophosphamide|1.8g/m2, day -4 to day -3, intravenously
223827402|NCT02290002|DRUG|Calcium Dobesilate|1 cap / 8 hs Calcium Dobesilate ( 500mg) will be given at day of HCG injection and for 21 days
223827403|NCT02290002|OTHER|coasting|In group B, coasting (withholding gonadotrophins while maintaining pituitary suppression) for 3 days then either giving triggering or cycle cancellation is done
223827404|NCT02310451|BIOLOGICAL|blood test|blood test to J0-M3-M6-M12
223827405|NCT03668262|DRUG|Cis-atracurium|Different concentration of cis-atracurium
223827406|NCT02874651|DRUG|Apatinib|Patients will take oral apatinib. The initial dose is 500 mg once daily. 28 days as one cycle. After 1 cycle, the dose will be escalated to 750 mg once daily in patients with good tolerance. Dose interruption or reduction is permitted in case of adverse events per protocol.
223827407|NCT02874651|DRUG|Placebo|Patients will take oral placebo. The initial dose is 500 mg once daily. 28 days as one cycle. After 1 cycle, the dose will be escalated to 750 mg once daily in patients with good tolerance. Dose interruption or reduction is permitted in case of adverse events per protocol.
223827408|NCT04137614|PROCEDURE|Drug coated balloon (DCB)|Drug coated balloon (DCB）is a new type of PTA, which could improve the re-stenosis rate significantly.
223827409|NCT04137614|PROCEDURE|Digital substraction angiography (DSA)|DSA was used to evaluated the stenosis of renal artery
223827410|NCT00238732|DRUG|Bazedoxifene/Conjugated Estrogen|
223827411|NCT04506749|DIETARY_SUPPLEMENT|Dietary supplement consumption|The consumption time was 56 days. Consumed 100 grams daily to consume during the day.
223827412|NCT00591864|DEVICE|Molecular Breast Imaging|Molecular breast Imaging is a new nuclear medicine technique for imaging the breast. It uses small filed of view semiconductor-based gamma cameras that use Cadmium Zinc Telluride detectors. These have superior spatial and energy resolution to conventional sodium iodide detectors.
223827413|NCT02459093|DEVICE|poliglecaprone 25 suture|cesarean delivery incision closure with poliglecaprone 25 suture
223827414|NCT02459093|DEVICE|polyglactin 910 suture|cesarean delivery incision closure with polyglactin 910 suture
223827415|NCT00118092|DRUG|tanespimycin|Given IV
223827416|NCT00118092|OTHER|laboratory biomarker analysis|Correlative studies
223827417|NCT05095363|BEHAVIORAL|PCplanner|A mobile app platform that will display participant survey results to clinicians to facilitate communication on specific needs as well as provide resources on advance care planning to participants.
223827418|NCT04247399|OTHER|Simulation-based learning|Pre-clinical simulation-based learning at Simbionix GI-mentor II virtual reality simulator and OGI CLA 4 phantom.
223827419|NCT04714437|BEHAVIORAL|F|The participant will be asked to chew the latex bag naturally.
223827420|NCT04714437|BEHAVIORAL|R|The participant will be asked to chew the latex bag unilaterally on the right-side.
223827421|NCT04714437|BEHAVIORAL|L|The participant will be asked to chew the latex bag unilaterally on the left-side.
223827422|NCT04714437|BEHAVIORAL|A1|The participant will be asked to chew the latex bag changing the side once.
223827423|NCT04714437|BEHAVIORAL|A3|The participant will be asked to chew the latex bag changing the side three times.
223827424|NCT04714437|BEHAVIORAL|A5|The participant will be asked to chew the latex bag changing the side five times.
223827425|NCT04337086|DEVICE|T4k Appliance|The pre-fabricated, hard, polyurethane, pink T4K™ (Myo functional research Co., Australia) was used in the study. It consisted of: facial bows, lingual bows / tongue guard, lingual tag / tongue tag, dental channels with a pre-determined bite position and a lip bumper. In the first week, the patients were instructed to gradually increase the wearing time of the appliance during the daytime. By the second week, the patients were instructed to wear the appliance achieving at least 8 hours during sleeping. The Trainer usually needs no adjustments. The patients were asked to place it themselves inside their mouths. The distal ends of the appliance were trimmed 2-3 mm with an acrylic bur on a straight hand piece if they were too long or the patient could not keep his lips together. By the end of the first 4 weeks, the patients were wearing the appliances minimum of 1 hour during the day plus the overnight wear following the manufacturer's instructions.
223827426|NCT04337086|DEVICE|Twin block appliance|The twin block was used, and instructions were given to wear the appliance nearly full-time. Selective sequential inter-occlusal trimming was done monthly after the 2nd month in the occlusal surface of the maxillary bite blocks to clear over the mandibular molars allowing their eruption in a more favourable mesial direction and to increase the vertical dimension. Trimming was done in the fitting surface over the maxillary and mandibular premolars whenever needed to allow their full eruption and to level the occlusal plane
223827427|NCT01741454|DRUG|Tamsulosin|0.4 mg by mouth once per day.
223827428|NCT01741454|DRUG|Tolterodine ER|4 mg by mouth once a day.
223827429|NCT03555825|DEVICE|Hocoma ArmeoSpring|A spring-loaded upper extremity exoskeleton with 3 joints and 6 degrees of freedom. Participants use the more affected upper extremity to control and engage in therapeutic games.
223827430|NCT05089435|DEVICE|EZYPRO® ECG Recorder|EZYPRO is an ECG monitoring patch designed to enhance the arrhythmia detection rate by applying 14 days in a home setting environment.
223827431|NCT02601716|BIOLOGICAL|PfSPZ Vaccine|Aseptic, purified, cryopreserved, radiation-attenuated, Plasmodium falciparum (Pf) sporozoites
223827432|NCT02601716|BIOLOGICAL|CHMI (7G8)|CHMI is conducted by exposure to the bites of five mosquitoes infected with heterologous (7G8) Pf parasites.
223827433|NCT02601716|BIOLOGICAL|CHMI (NF135.C10)|CHMI is conducted by exposure to the bites of three to five mosquitoes infected with heterologous (NF135.C10) Pf parasites.
223827434|NCT05315661|DRUG|ET-STEM|mesenchymal stem cells preconditioned with ethionamide
223827435|NCT03579264|BEHAVIORAL|My Viva Plan|Use of the online platform, My Viva Plan, to support health and wellness.
223827436|NCT02820584|BIOLOGICAL|GSC-loaded autologous dendritic cells|
223827437|NCT01222923|DRUG|Risperidone|1 mg orally disintegrating tablets
223827438|NCT04598893|BIOLOGICAL|Teplizumab|Received teplizumab in PROTECT Study
223827439|NCT04598893|OTHER|Placebo|Received placebo in PROTECT study
223827440|NCT03412968|PROCEDURE|Polysulfone Filter|The intervention for this group consisted using a Polysulfone filter in order to hemofiltration in the procedure involving Cardiopulmonary Bypass (CPB).The perfusionist's role is essential during the procedure, as they control both Cardiac Output (CO) and gas exchange, depending on their action, will affect blood lactate levels.
223827441|NCT03412968|PROCEDURE|Procedure/ Surgery: without Polysulfone Filter|In this group, no intervention is performed during the procedure involving Cardiopulmonary Bypass (CPB)
223827442|NCT00964457|DRUG|cetuximab|cetuximab 500mg per meter square every second week
223827443|NCT03885466|BEHAVIORAL|Nordic Walking exercise|Participants will initially train 3 times per week for 3 months. Training sessions will be led by trained peer- and/or student-instructors. Nordic walking sessions (starting at 20 and progressing to 60min/session) will include a warm-up, strengthening, and dynamic balance and stretching exercises in addition to Nordic walking, as per the Saskatoon Health Region guide (Saskatoon Health Region, 2014). Training (distance and intensity) will be progressive and individually set.
223827444|NCT05997121|DEVICE|Transforaminal lumbar interbody fusion|Transforaminal Lumbar Interbody Fusion indicates a surgical approach in the lumbar spine to fuse the discal space between two vertebrae. These are joined by removing the disc and placing a cage in its place to restore the vertebral height. Screws and rods are also added to maintain the level secure while the bones fuse together.
223827445|NCT02873026|DRUG|Triamcinolone Acetonide|Following the repair of the open globe eye trauma, the use of Triamcinolone Acetonide will be investigated
223827446|NCT02028832|PROCEDURE|PIM consult and service provision|If service is requested, treatment options include acupuncture/acupressure, massage, and reiki
223827447|NCT02028832|PROCEDURE|Usual care|Usual care consists of all conventional care options in pediatric oncology including medication and other therapies.
223827448|NCT03729024|DEVICE|Light Adjustable lens (LAL) and Light Delivery Device (LDD)|Primary and Fellow eyes will receive Light adjustable lens with Light delivery Device treatments
223827449|NCT00070993|DRUG|creatine monohydrate|
223827450|NCT01978366|DRUG|HT-100|May be administered in either fed or fasted state
223827451|NCT05984316|OTHER|Exercise|"Dual task exercises are defined as the appropriate direction of attention during two activities performed at the same time. Dual task performance is required during many activities in daily life. Multitasking is complicated to understand because it is divided into social, physical, and psychological branches.~The simultaneous occurrence of movement and cognitive processes is seen as a part of social participation. Considering that one task affects the other, dual task is defined as the simultaneous performance of two tasks that can be performed independently, can be evaluated separately, and have different purposes.~Each task must be incompatible and measurable, achievable alone or in different combinations. The increased need for information processing alone does not constitute dual-tasking."
223827452|NCT05265455|DIETARY_SUPPLEMENT|Plant sterols 2.5 g/day|Daily consumption of one stick (2.5 g of plant sterols) during lunch or dinner for 3 weeks
223827453|NCT05265455|DIETARY_SUPPLEMENT|Placebo|Daily consumption of one stick (the same matrix without plant sterols) during lunch or dinner for 3 weeks
223827454|NCT05876611|DEVICE|New type of self stabilizing atlantoaxial fusion cage|Using the above-mentioned new fusion cage for the treatment of atlantoaxial dislocation
223827455|NCT03030937|DRUG|Apatinib|Apatinib, a novel targeted inhibitor of VEGF receptor 2 (VEGFR2).
223827456|NCT03030937|DRUG|Irinotecan|Irinotecan was used as second line treatment with AGC.
223827457|NCT01676948|DRUG|ACZ885|
223827458|NCT01676948|DRUG|Canakinumab|
223827459|NCT01676948|DRUG|Canakinumab|"Patients rolling over into this study from CACZ885G2301E1 (Cohort 1) will continue on their established canakinumab dose of either 4 mg/kg SC given every 4 weeks or 2mg/kg SC given every 4 weeks, until eligible for dose reduction.~Canakinumab-naïve patients"
223827460|NCT01676948|DRUG|Canakinumab|Patients rolling over into this study from CACZ885G2301E1(Cohort 2) will receive a standard canakinumab dose of 4mg/kg SC given every 4 weeks, until eligible for dose reduction
223827461|NCT02698683|OTHER|lymphocyte count|lymphocyte count
223827462|NCT03233178|OTHER|Non-interventional|
223827463|NCT01152294|BEHAVIORAL|DVD & Booklet called: Managing Menopause|DVD and booklet that provides information about treatment choices for menopause symptoms. Complete title: Managing Menopause: Choosing treatments for menopause symptoms
223827464|NCT00610701|DEVICE|Anterior pin placement|Anteriorly-placed (front of the leg) femoral external fixator pins
223827465|NCT00610701|DEVICE|Lateral pin placement|Laterally-placed (side of the leg) femoral external fixator pind
223827466|NCT00502034|DRUG|Interferon Alfa-2a|Interferon Alfa-2a in combination with Interleukin
223827467|NCT00502034|DRUG|Interleukin-2|Interferon Alfa-2a in combination with Interleukin
223827468|NCT02067234|OTHER|Routine Care/Education|Nursing staff will spend time educating the patient and family about therapy involved in medically treating atopic dermatitis. This might include different topical therapy to use as well as how often to apply and when to apply.
223827469|NCT02067234|BEHAVIORAL|Psychoeducation/Coping Prevention|In addition to routine care, the psychologist will meet with family to review psychoeducation about the mind-body connection as well as introduce and review different strategies regarding coping with stress, sleep strategies, and behavior strategies.
223827470|NCT03329521|OTHER|Multicomponent intervention|Patients in 13 of the 26 CKD programs will receive a multicomponent intervention or usual care. The intervention has four main components: (1) support for local quality improvement teams and administrative needs; (2) tailored education and resources for staff, patients, and living kidney donor candidates; (3) support from kidney transplant recipients and living kidney donors; and (4) program-level performance reports and oversight by program leaders.
223827471|NCT02641457|DRUG|Aflibercept|12 eyes received an intraocular injection of 2.00 mg of aflibercept (IA) and IOP were measured by tonometer. The neovascularization was evaluated by biomicroscope.
223827472|NCT02641457|DRUG|Ranibizumab|12 eyes received an intraocular injection of 1.25mg ranibizumab and IOP were measured by tonometer. The neovascularization was evaluated by biomicroscope.
223827473|NCT02401308|PROCEDURE|Deep Brain Stimulation surgery|Deep Brain Stimulation surgery: awake vs. asleep
223827474|NCT01294501|OTHER|Medication administration educational module|The Research Assistant (RA) will enter the subject's language (English or Spanish), the type of medicine (tablet/capsule, liquid, or ointment) from the antibiotic prescription, and the frequency (once a day, twice a day, three times a day, four times a day) from the antibiotic prescription into the web-based educational module on medication administration so that a tailored module will be setup for the subject. The subject will then view the educational interactive module. After the subject is done with the module, the RA will administer a verbal post-test. The post-test will include questions on medication administration as well as questions on fever assessment and management.
223827475|NCT06451315|PROCEDURE|Analyze CTscans pre-operatively by Nurea System|CTscans will be analyzed pre-operatively (6 months before intervention) and post-operatively with an early control scan (up to one-month post-EVAR), compared to a 3, 6 and 12-month control scan by system develop by Nurea
223827476|NCT06451315|PROCEDURE|Analyze CTscans pre-operatively by hospital practitioner|CTscans will be analyzed pre-operatively (6 months before intervention) and post-operatively with an early control scan (up to one-month post-EVAR), compared to a 3, 6 and 12-month control scan by an hospital practitioner
223827477|NCT01720784|DIETARY_SUPPLEMENT|Alginate dietary fiber|
223827478|NCT01720784|DIETARY_SUPPLEMENT|Placebo|
223827479|NCT06461819|RADIATION|Low- and medium-risk studies performed after biodegradable substance injection prostate cancer dose increase.|this researcher used a biodegradable material injection technique. after subdivision radical received radiation therapy We plan to conduct a phase II clinical study to evaluate the safety of prostate cancer patients.
223827480|NCT01744925|DRUG|Icotinib of routine dose|Icotinib: 125mg, oral administration, three times per day.
223827481|NCT01744925|DRUG|Icotinib of high dose|Icotinib: 375mg, oral administration, three times per day.
223827482|NCT02736968|DRUG|Auranofin|Auranofin is a gold-containing chemical salt available as 3mg capsules
223827483|NCT02736968|OTHER|Placebo|Placebo
223827484|NCT04100512|DEVICE|Oscillating Positive Expiratory Pressure Device|Aerobika® Oscillating Positive Expiratory Pressure (OPEP) device is a drug-free, easy to use, hand-held device with a proprietary pressure-oscillation dynamic that provides intermittent resistance and creates positive pressure and oscillations simultaneously. The Aerobika® OPEP device opens weak or collapsed airways to mobilize and assist mucociliary clearance to the upper airways where it can be coughed out.
223827485|NCT04100512|DEVICE|Incentive spirometry|An incentive spirometer is a device that measures how deeply you can inhale (breathe in). It helps you take slow, deep breaths to expand and fill your lungs with air. The incentive spirometer is made up of a breathing tube, an air chamber, and an indicator.
223827486|NCT00147225|DRUG|AMG 531|"Beginning with Cycle 2, administered in one of two schedules, either on day after chemotherapy and 2 days later (study cycle) or on day -5 (pre dose) and on day after chemotherapy (post dose) or combination of pre/post days of 21-28 day treatment cycle. Combination if Optimal biological dose (OBD) not reached, additional treatment at 10 mcg/kg dose level, with AMG 531 administered on day -5 (pre dose) and on day after chemotherapy (post dose).~1, 3, or 10 mcg/kg given as injection under the skin (subcutaneous)"
223827487|NCT00147225|DRUG|Carboplatin|AUC=11; Cycle 1 chemotherapy alone then 3 weeks later, in Cycle 2, same dose of chemotherapy followed by AMG 531.
223827488|NCT00147225|DRUG|Adriamycin|75-90 mg/m\^2 IV
223827489|NCT00147225|DRUG|Ifosfamide|10 gm/m\^2 IV; OR, High dose ifosfamide = 14 gm/m\^2.
223827490|NCT00412633|BEHAVIORAL|Diet and physical activity interventions|Weekly web-based intervention that included goal setting, self-monitoring, weekly behavioral skills, nutrition and physical activity tips, and access to a health coach.
223827491|NCT00412633|BEHAVIORAL|Computer technology to tailor, promote and sustain health behavior change & improve health care delivery.|Weekly web-based intervention that included goal setting, self-monitoring, weekly behavioral skills, nutrition and physical activity tips, and access to a health coach.
223827492|NCT05760976|DRUG|Cisatracurium|Advanced intravenous injection of cisatracurium before the succinylcholine injection
223827493|NCT05309460|DRUG|Labetalol Oral Tablet|See Labetalol arm.
223827494|NCT05309460|DRUG|NIFEdipine ER|See Nifedipine arm.
223827495|NCT02998021|DEVICE|Vibrating Dumbbell|Supervised training sessions will occur optimally, 3 times per week for a total of 12 consecutive weeks. The sessions will involve nine exercises specifically designed to improve upper limb muscle function. The beginning training intensity for each participant will be based on their one rep max for each exercise, which is determined during baseline laboratory testing in accordance with standard procedures. Training intensity will be adjusted progressively, first by increasing the frequency of the vibration (max. 40 Hz) then by the addition of more weight, based on weekly assessments and consultation with the senior investigators.
223827496|NCT02998021|DEVICE|Standard Dumbbell|"Supervised training sessions will occur optimally, 3 times per week for a total of 12 consecutive weeks.~The sessions will involve nine exercises specifically designed to improve upper limb muscle function. The beginning training intensity for each participant will be based on their one rep max for each exercise, which is determined during baseline laboratory testing in accordance with standard procedures. Training intensity will be adjusted progressively by the addition of more weight, based on weekly assessments and consultation with the senior investigators.~To obtain as much data as possible on resistance training with vibration within study timeline, a modification was recently approved by the Institutional Review Board (IRB) to cease enrolling subjects into standard dumbbell training."
223827497|NCT06180941|DRUG|magnesium sulfate.|magnesium sulfate as adjuvant to bupivacaine in supraclavicular brachial plexus block in pediatrics.
223827498|NCT06180941|DRUG|clonidine.|clonidine as adjuvant to bupivacaine in supraclavicular brachial plexus block in pediatrics.
223827499|NCT01628627|DEVICE|Frequency Modulated Neural Stimulation (FREMS) (Aptiva)|FREMS consisted of sequences of biphasic (negative and positive), asymmetric and electrically balanced pulses, composed of: 1) an active phase of high negative voltage spike (variable, max -300 V) and extra short duration (variable, 10-100 μsec, mostly \~40 μsec); followed by: 2) a recharging phase of low voltage and long duration (0.9 - 999 msec); pulse frequency was variable, ranging 1 to 1,000 Hz, mainly in the low range 1-50 Hz. Three cycles of 10 consecutive (one a day for 5 days/week) applications to both lower limbs were delivered.
223827500|NCT01628627|DEVICE|sham treatment (Aptiva)|The sham treatment consisted of no electrical pulses delivered by the same device used to deliver the FREMS treatment and with the same treatment procedure and schedule.
223827501|NCT05639621|PROCEDURE|Accompaniment|presence of a person freely chosen by the patient, who will escort in a visual and tactile way during the endoscopic procedure
223827502|NCT02500563|OTHER|Amino acid based infant formula|
223827503|NCT02500563|OTHER|Extensively hydrolyzed casein infant formula|
223827504|NCT02500563|OTHER|Mother's own breast milk|
223827505|NCT01225913|DRUG|fluticasone/salmeterol in all asthmatics|budesonide 80ug/formoterol 4.5ug, 2 inhalations bid X 20-60 days or fluticasone 100ug/salmeterol 50ug, 1 inhalation bid X 20-60 days
223827506|NCT01225913|DRUG|budesonide/formoterol or fluticasone/salmeterol in all asthmatics|budesonide 160ug/formoterol 4.5ug, 2 inhalations bid or fluticasone 250ug/salmeterol 50ug, 1 inhalations bid
223827507|NCT05315284|PROCEDURE|the Use of Titanium Elastic Nail in The Fixation of Fresh Non-comminuted Fracture Mid-shaft Clavicle|Fixation of Fresh Non-comminuted Fracture Mid-shaft Clavicle
223827508|NCT00641173|DRUG|paroxetine|treatment with SSRI paroxetine
223827509|NCT00641173|DRUG|placebo|treatment with placebo
223827510|NCT05036928|DIAGNOSTIC_TEST|Monocyte distribution width (MDW）|All enrolled patients will receive test with MDW.
223827511|NCT01335295|DRUG|Flavocoxid|Flavocoxid capsules TTD 500 mg/die or 1000 mg/die for 1 year
223827512|NCT00655551|DRUG|lacosamide|Single loading intravenous (iv) lacosamide 200 mg dose administered over a 15 minute infusion duration followed by oral lacosamide 200 mg/day (100 mg twice daily) for 6.5 days
223827513|NCT00655551|DRUG|lacosamide|Single loading intravenous (iv) lacosamide 300 mg dose administered over a 15 minute infusion duration followed by oral lacosamide 300 mg/day (150 mg twice daily) for 6.5 days
223827514|NCT00655551|DRUG|lacosamide|Single loading intravenous (iv) lacosamide 400 mg dose administered over a 15 minute infusion duration followed by oral lacosamide 400 mg/day (200 mg twice daily) for 6.5 days
223827515|NCT02324764|DEVICE|Glidesheath Slender|testing the efficacy and safety of the new transradial sheath in comparison to the standard 6 french sheath.
223827516|NCT02324764|DEVICE|standard 6- French radial sheath|
223827517|NCT04737213|DRUG|SGM-101|Fluorescence guided surgery
223827518|NCT01861457|OTHER|Nozin® Nasal Sanitizer®|The treatment agent tested was the alcohol and natural oil preparation that comprises the commercially available over-the-counter (OTC) product, NOZIN® Nasal Sanitizer® antiseptic, by Global Life Technologies Corp, with the addition of benzalkonium chloride (0.13%), as described for the patented and safety-tested formulation.
223827519|NCT01861457|OTHER|Placebo|The placebo preparation, utilized to account for the potential mechanical effects of the application process, was phosphate buffered saline (PBS).
223827520|NCT01800708|DRUG|Triamcinolone acetonide|
223827521|NCT01800708|DRUG|Prednisolone syrup|
223827522|NCT05185596|DEVICE|Transesophageal Echocardiography|transesophageal Echocardiography during advanced life support
223827523|NCT00932334|BEHAVIORAL|TALK PLUS|Participants receive and educational video and booklet about living kidney donation and meet with a social worker
223827524|NCT00932334|BEHAVIORAL|TALK Standard|Participants receive and educational video and booklet about living kidney donation
223827525|NCT00932334|BEHAVIORAL|Usual Care|Participants receive their usual care
223827526|NCT00319059|DRUG|systemic administration of 99mTc-HYNIC-Annexin A5|
223827527|NCT00319059|BEHAVIORAL|10 minutes of ischemic handgripping|
223827528|NCT06038890|PROCEDURE|Holmium laser enucleation of the prostate using the veil-sparing technique|Holmium laser enucleation of the prostate using the veil-sparing technique
223827529|NCT00216450|DRUG|rabeprazole sodium|
223827530|NCT02372864|BEHAVIORAL|Mindfulness based stress reduction (MBSR)|Mindfulness based stress reduction (MBSR) is a standardized eight-week psychosocial intervention delivered by certified trainers. The programme consists of a weekly class of two and half hours for a period of eight weeks and a full retreat day. Furthermore participants are asked to practice exercises at home for 45 minutes, six days a week. The MBSR class will consist of ten to twelve persons, starting at different weekdays and moments of the day. If during the inclusion process it becomes apparent that a group of participants (provided a sufficient group size) comes from a region (e.g. Friesland or Overijssel) with a considerable amount of traveling time to the UMCG, efforts will be made to start a MBSR training in the region with trainers from the UMCG.
223827531|NCT01411722|DEVICE|Neurally adjust ventilatory assist (NAVA) and a nasogastric tube to measure the electrical activity of the diaphragm (EAdi catheter)|Nava is a new ventilatory mode which delivers pressure in proportion of the the Electrical activity of the diaphragm (EAdi), a reflection of the neural respiratory output. EAdi will be obtained through a nasogastric tube with a multiple array of electrodes placed at its distal end. Correct positioning of the EAdi catheter is assured by means of a specific function of the ventilator (''EAdi catheter positioning''). The EAdi signal is processed according to the American Thoracic Society (ATS) recommendations and filtered by algorithms designed to provide the highest possible signal-to-noise ratio
223827532|NCT05287516|OTHER|Breakfast meal|A meal consisting of breakfast biscuits and water.
223827533|NCT05690542|OTHER|blood tests|evaluate the possible impact of iron oxide nanoparticles (superparamagnetic iron oxide = SPIONs) (N=10) in the blood circulation;
223827534|NCT00517309|BIOLOGICAL|V501, Gardasil, Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine / Duration of Treatment : 4 Years|
223827535|NCT00517309|BIOLOGICAL|Comparator: placebo (concomitant-vaccine matched) / Duration of Treatment : 4 Years|
223827536|NCT03798834|DRUG|Fascia iliaca block (FIB)|ultrasound-guided Fascia iliaca block
223827537|NCT03798834|OTHER|Spinal anesthesia|Spinal anaesthesia using 2 ml hyperbaric bupivacaine 0.5%
223827538|NCT00460148|DRUG|Ropinirole|
223827539|NCT04275843|DIETARY_SUPPLEMENT|Traditional Diet|Consuming an traditional whole foods based diet for 4 weeks.
223827540|NCT04275843|DIETARY_SUPPLEMENT|Modern Diet|Consuming an processed formulation of the traditional diet for 4 weeks.
223827541|NCT03135704|DEVICE|"Re Spine"|A new mattress design made of special materials and built in a specially shaped structure that allows the brain to relax the body and dissipate tension accumulated on the lumbar spine.
223827542|NCT03135704|OTHER|Physiotherapy|Usual protocol for treatment of low back pain
223827543|NCT00549887|DRUG|Analog or Human Insulin|prescribed in accordance with usual clinical practice
223827544|NCT00179530|BEHAVIORAL|Relaxation Response|Relaxation training
223827545|NCT00941564|OTHER|Infant Formula milk based|Consume ad lib
223827546|NCT00941564|OTHER|Infant formula milk based|consume ad lib
223827547|NCT00847990|OTHER|Maternal blood screening test for fetal aneuploidy|One blood draw of 20 to 30 mL
223827548|NCT00265707|DEVICE|Blood pressure measurement|
223827549|NCT00599547|PROCEDURE|Allogeneic Stem Cell Transplantation|Allogeneic Stem Cell Transplantation after dose-reduced Conditioning for Myelofibrosis Patients
223827550|NCT03152045|BEHAVIORAL|Communication Intervention|In this study, Investigators are testing the feasibility, acceptability, and preliminary efficacy of a systems intervention that asks adolescents to report their risk behaviors before their encounter. Both clinicians and patients will receive a Feedback Guide that gives them tips on effective ways to communicate about these behaviors.
223827551|NCT04536571|DEVICE|Test Contact lens|Subjects will be randomized to wear test lenses for 30 minutes, and then cross-over to control lenses.
223827552|NCT04536571|DEVICE|Control Contact lens|Subjects will be randomized to wear control lenses for 30 minutes, and then cross-over to test lenses.
223827553|NCT04340908|DRUG|Dapagliflozin 10 MG|10 mg tablet, oral, once daily, 1-year treatment, postoperation
223827554|NCT04340908|DRUG|Placebos|matching placebo tablet, oral, once daily, 1-year treatment, postoperation
223827555|NCT02141958|DRUG|Fenretinide|Fenretinide oral capsules of 100mg, each selected dose being administered once daily for 21 days (treatment cycle). Up to three total daily dose levels will be assessed in the study, as follows: 100mg of Fenretinide (one capsule) for the first treatment cycle, 200mg of Fenretinide (two capsules) in the second treatment cycle, and 300mg or 400mg of Fenretinide (3 or 4 capsules) will be selected for the third treatment cycle, based on safety and PK data collected.
223827556|NCT02141958|DRUG|Placebo|A matching placebo will be used to keep the study double-blind.
223827557|NCT03150524|DIAGNOSTIC_TEST|TCD- cerebral blood flow velocities|Participants will undergo daily TCD for monitoring of cerebral blood flow.
223827558|NCT03150524|BEHAVIORAL|Headache pain score|Participants will be evaluated by nurses for headache frequency and severity every shift.
223827559|NCT03150524|OTHER|Neurological examination|Patients will be examined routinely for evidence of neurological improvement/decline and/or evidence of a complication such as stroke or hemorrhage.
223827560|NCT03150524|DIAGNOSTIC_TEST|Repeat Neuroimaging|All patients will also be seen at 90 days (+/- 30 days) and administered a headache diary, repeat neuroimaging, and neurological examination.
223827561|NCT03150524|DRUG|Nimodipine|Participants will be administered nimodipine every 4 hours.
223827562|NCT03150524|DRUG|Verapamil ER|Participants will be administered long acting verapamil every 12 hours.
223827563|NCT04922190|BEHAVIORAL|Physical Activity Coaching|Participants will receive up to 5 coaching sessions by a physical or occupational therapist. The intervention will focus on facilitating physical activity engagement and development of specific and measurable goals. The recommended program will be individualized to each participant but will primarily focus on increasing general physical activity (e.g. steps per day) as well as engagement in moderate intensity aerobic exercise a minimum of three times per week. At the follow up sessions the therapist will review progress with the current exercise plan and progress and discuss barriers and facilitators for exercise engagement. Participants will have the option to use a Fitbit or other device to monitor their heart rate and physical activity during the course of the intervention period.
223827564|NCT02765022|DEVICE|Clip closure|Complete clip closure of secondary lesions after the endoscopic mucosal resection
223827565|NCT02765022|PROCEDURE|No clip closure|Observation: no clip closure of secondary lesions after the endoscopic mucosal resection
223827566|NCT03230383|DRUG|PF-06865571|Multiple ascending dose of PF-06865571 as extemporaneously prepared suspension for 14 consecutive days with total daily dose of 90mg, 300mg, 900mg, 1800mg, 3000mg and TBD.
223827567|NCT03230383|DRUG|PF-06865571|Multiple ascending dose of PF-06865571 as extemporaneously prepared suspension for 14 consecutive days with total daily dose of 90mg, 300mg, 900mg, 1800mg, 3000mg and TBD.
223827568|NCT03230383|DRUG|PF-06865571|Multiple ascending dose of PF-06865571 as extemporaneously prepared suspension for 14 consecutive days with total daily dose of 90mg, 300mg, 900mg, 1800mg, 3000mg and TBD.
223827569|NCT03230383|DRUG|PF-06865571|Multiple ascending dose of PF-06865571 as extemporaneously prepared suspension for 14 consecutive days with total daily dose of 90mg, 300mg, 900mg, 1800mg, 3000mg and TBD.
223827570|NCT03230383|DRUG|PF-06865571|Multiple ascending dose of PF-06865571 as extemporaneously prepared suspension for 14 consecutive days with total daily dose of 90mg, 300mg, 900mg, 1800mg, 3000mg and TBD.
223827571|NCT03230383|DRUG|PF-06865571|Multiple ascending dose of PF-06865571 as extemporaneously prepared suspension for 14 consecutive days with total daily dose of 90mg, 300mg, 900mg, 1800mg, 3000mg and TBD.
223827572|NCT03230383|DRUG|PF-06865571|Multiple ascending dose of PF-06865571 as extemporaneously prepared suspension for 14 consecutive days with total daily dose of 90mg, 300mg, 900mg, 1800mg, 3000mg and TBD.
223827573|NCT03230383|DRUG|Placebo|Matching Placebo for PF-06865571 for each cohort.
223827574|NCT01283321|DRUG|Human fibrinogen concentrate|4 g IV once, within 30 minutes of ACT \< 155 seconds, post CPB, with evidence of significant microvascular bleeding
223827575|NCT01283321|OTHER|apheresis platelets|A single apheresis platelet unit will be administered as an initial therapy within 30 minutes of ACT \<155 seconds post CPB with evidence of significant microvascular bleeding.
223827576|NCT03402373|DIETARY_SUPPLEMENT|Lycoderm|soft gel contains nutritional supplement
223827577|NCT03402373|DIETARY_SUPPLEMENT|Placebo|soft gel without active ingredients
223827578|NCT02327819|DIETARY_SUPPLEMENT|Branched-chain amoni acids (BCAA)|
223827579|NCT02327819|DIETARY_SUPPLEMENT|non-BCAA protein supplement|
223827580|NCT03453827|OTHER|no intervention|no intervention
223827581|NCT05501171|BEHAVIORAL|DREAMLAND|"DREAMLAND is self-administered psychological app for patients with AML that includes four modules, focused on:~1. Supportive psychotherapy strategies to help patients deal with the initial shock of diagnosis, cope with the loss of independence and abrupt life disruptions, and provide validation and reassurance.~2. Psychoeducation to manage expectations and enhance preparedness for extended hospitalization and mobilize social support.~3. Psychosocial skill-building to promote effective coping strategies and facilitate acceptance while living with uncertainty.~4. Self-care to promote positive health behaviors and enhance patients´ sense of control especially as they transition from the hospital to outpatient care.~Each module takes 20 minutes to complete. DREAMLAND also includes three optional models that also take 15 minutes to complete.~Other names BNT200"
223827582|NCT05501171|BEHAVIORAL|CERENA|"CERENA is a self-administered physical health app that includes 4 modules focused, focused on:~1. Education about general wellness.~2. Nutrition.~3. Exercise.~4. Cancer prevention.~Each module takes 20 minutes to complete. CERENA also includes three optional modules that also take 15 minutes to complete."
223827583|NCT03399149|OTHER|Systematic evaluation by an intensivist|implementation of a standardized procedure for patient care in ICU
223827584|NCT05492812|OTHER|Sedation and Nursing Management in EEG Recording in Children|Evaluation of the effect of sedative agents applied during EEG recording in children
223827585|NCT05492812|DRUG|Chloral Hydrate|Chloral Hydrate
223827586|NCT05492812|DRUG|Hydroxyzine|Hydroxyzine
223827587|NCT05492812|DRUG|Melatonin|Melatonin
223827588|NCT03762629|BEHAVIORAL|Exercise|Subjects were provided with energy-restricted diets of 1300-2200 kcal/day based on weight. The energy percentages provided by protein, fat and carbohydrate were 20%, 20% and 60%, respectively, while energy distributions at breakfast, lunch and dinner were 30%, 40% and 30%, respectively. Subjects performed a series of endurance exercise such as bicycling, walking, running, dancing and ball games for 5 hour/day, supplemented with resistance exercise. Training interventions were performed 5-6 day/week for 6 weeks. The exercise program was designed to result in an energy expenditure of 1500-2500 kcal/day.
223827589|NCT06204562|BEHAVIORAL|imitated laughter practice|"To imitate laughter, participants will practice Duchenne smile, which is reported to associate with positive emotion in people producing it If participants cannot imitate a Duchenne smile, they can hold a chopstick horizontally in their mouth tightly. To help timing the 3-minute and to enhance adherence, an audio recording with joyous music and vocal instruction will be played alongside the practice. Versions with or without laugh voice will be prepared for their preferences. A logbook will be given to each participant to record their practice. To remind participants to practise, a reminder will be made each day through the public announcement system of the respective nursing home, and the audio guide will be played."
223827590|NCT04140825|DEVICE|Resmon PRO FULL|Measurement of lung impedance by the Forced Oscillation Technique
223827591|NCT04052191|BIOLOGICAL|MCRcI® stem cells|Intra-Coronary Administration of MCRcI® stem cells
223827592|NCT04850287|BEHAVIORAL|Digital Sensors for Population Awareness about Health Issues using Social Media|A clustered randomized control trial will be conducted and ZIP Codes from each demographic environment will be randomly assigned to control and intervention arms. Digital educational materials about organ donation will be exposed to online users in social media belonging to ZIP Codes assigned to the intervention arm
223827593|NCT04644640|OTHER|Telerehabilitation Therapy|Rehabilitation services will be dispensed at patients' home utilizing video telecommunication services with real-time synchronous exchange of information - range of motion exercises for the knee, proprioception and balance training
223827594|NCT04644640|OTHER|In-person Rehabilitation Therapy|Range of motion exercises for the knee, proprioception and balance training
223827595|NCT04727476|DRUG|Lisdexamfetamine|Prescription of lisdexamfetamine sometime during til period from 1 April 2013 to 5 November 2019.
223827596|NCT03713021|DEVICE|TraceIT Tissue Marker|The maximum injection volume of TraceIT hydrogel, for a single location, is 1mL.
223827597|NCT05390398|BEHAVIORAL|Behaviour change guided lifestyle intervention|Participants in the intervention group receive personalized coaching from a lifestyle coach on adhering to the World Cancer Research Fund cancer prevention guidelines. The lifestyle coach is specialized in behaviour change techniques and uses these as the core of the lifestyle coaching. For each participant behavioural determinants will be assessed and targeted with specific applicable behaviour change techniques.
223827598|NCT05555160|DEVICE|PICC|Peripheral central venous catheterization (PICC) is mainly applied to patients with medium and long-term intravenous infusion, infusion of stimulant drugs and intermittent infusion of chemotherapy drugs. It is a catheterization technology to place PICC through peripheral veins and make its tip reach the central vein
223827599|NCT06396754|OTHER|AI-analysis on diagnostic and surgical specimens|The analysis will report a list of AI-based biomarkers to assess the tumour-immune spatial microenvironment as well as final spatial immune-ecology prognostic (SIPA) reports for every patient.
223827600|NCT04999371|BEHAVIORAL|Brief Alcohol Intervention|"The participants in the treatment group received free three-time counsel and constant multi-media messages about the topic of alcohol consumption for three months. One-to-one counseling services will be provided via a telephone call, which is based on World Health Organization (WHO) recommendations. A total of three counsels are conducted, which are set on the second week, sixth and tenth week after the baseline survey.~Brief intervention counselors are from the team of this study and trained by Hongkong University. All counselors are required to attend a full-day workshop before participant recruitment. The contents of the workshop include (1) knowledge of excessive drinking harms and benefits of controlling drinking; (2) overview of AUDIT; (3) alcohol reduction advice; (4) a standard procedure of brief intervention."
223827601|NCT04999371|BEHAVIORAL|Financial Incentive Intervention|The participants in financial Incentive intervention group were conducted by deducting money. Firstly, a certain amount of vouchers were given to the participants, which was equivalent to the reward for passing seven tests. Then, the voucher would be deducted according to every test result. Finally, the participants will receive cash according to the vouchers.
223827602|NCT06594679|DRUG|Niraparib Tosylate Monohydrate|Combination of niraparib and abemaciclib
223827603|NCT06291155|DRUG|SGLT2 inhibitor|All participants will be receive 100 mg/daily doses of Canagliflozin (INVOKANA) for 6 months. Canagliflozin is a Sodium-glucose cotransporter 2 (SGLT2) inhibitor
223827604|NCT03861507|DEVICE|Prostate Brachytherapy|High dose - rate (HDR) brachytherapy
223827605|NCT02269761|DEVICE|Nuvis Diagnostic Ultrasound System|Ultrasound of the chest
223827606|NCT06860529|DRUG|Serplulimab|Serplulimab is administered intravenously
223827607|NCT06860529|DRUG|Epirubicin|Epirubicin ivgtt
223827608|NCT06860529|DRUG|Albumin Paclitaxel|Albumin Paclitaxel ivgtt
223827609|NCT03367936|BEHAVIORAL|One-on-one Session|Participants will receive a 45-minute one-on-one behavioral lifestyle program for a healthful lifestyle and weight loss.
223827610|NCT03367936|BEHAVIORAL|Self-monitoring|Participants will receive an orientation on how to self-monitor using the smartphone and other devises
223827611|NCT03367936|BEHAVIORAL|Feedback|Participants will receive up to 4 daily feedback messages based on progress in attaining target behavior. The feedback messages will be delivered on a variable ratio schedule and tailored to data in subjects' dietary recordings
223827612|NCT06617104|OTHER|no intervention|no intervention
223827613|NCT06625840|DRUG|MK-1167|Oral Administration
223827614|NCT06625840|DRUG|Placebo|Oral Administration
223827615|NCT06623214|DEVICE|nebulyft|Micro Radiofrequency Skin Treatment Device(nebulyft)
223827616|NCT00079456|DRUG|temsirolimus|Given IV
223827617|NCT00079456|OTHER|pharmacological study|Correlative studies
223827618|NCT00079456|OTHER|laboratory biomarker analysis|Correlative studies
223827619|NCT06625814|DRUG|Levothyroxine|single oral dose
223827620|NCT06625814|DRUG|Enlicitide Decanoate|single oral dose
223827621|NCT03478462|DRUG|CLR 131|IV dose of CLR 131, increased/decreased by dose level; single or fractionated dose
223827622|NCT05597956|PROCEDURE|white defects|"With the previously cleaned tooth, the enamel will be prepared with a product that makes it more porous, thus eliminating the decalcified areas of the deepest part of the lesion. After completely removing the water from the surface, the resin will be applied infiltrating between the canaliculi of the enamel. When polymerized, it will form a framework that will seal the surface, thus improving surface resistance and aesthetics by modifying the refractive indices of the affected enamel, mimicking it with the remaining healthy enamel."
223827623|NCT05597956|PROCEDURE|yellow defects|"With the previously cleaned tooth, the enamel will be prepared with a product that makes it more porous, thus eliminating the decalcified areas of the deepest part of the lesion. After completely removing the water from the surface, the resin will be applied infiltrating between the canaliculi of the enamel. When polymerized, it will form a framework that will seal the surface, thus improving surface resistance and aesthetics by modifying the refractive indices of the affected enamel, mimicking it with the remaining healthy enamel."
223827624|NCT05597956|PROCEDURE|brown defects|"With the previously cleaned tooth, the enamel will be prepared with a product that makes it more porous, thus eliminating the decalcified areas of the deepest part of the lesion. After completely removing the water from the surface, the resin will be applied infiltrating between the canaliculi of the enamel. When polymerized, it will form a framework that will seal the surface, thus improving surface resistance and aesthetics by modifying the refractive indices of the affected enamel, mimicking it with the remaining healthy enamel."
223827625|NCT03391960|DEVICE|Passive disinfection device|Add use of passive disinfection cap to existing central line needleless connector infection control procedure
223827626|NCT06715007|DRUG|Clopidogrel|Patients will take Clopidogrel
223827627|NCT06715007|DRUG|Aspirin|Patients will take Rivaroxaban
223827628|NCT06715007|DRUG|Cilostazol + Isosorbide Mononitrate|Patients will take Cilostazol plus Isosorbide Mononitrate
223827629|NCT02142920|DRUG|PF-05212384|Single 89 mg Dose via 30 minute IV infusion
223827630|NCT04048070|DRUG|Flurbiprofen Axetil|One kind of NSAIDs, 200mg for 48 hours after surgery.
223827631|NCT04048070|DRUG|Sufentanil|One kind of opioid drugs, 1.5μg/kg, and recorded the drug consumption after surgery
223827632|NCT04048070|BEHAVIORAL|Extended perioperative counseling|The extended perioperative counseling contained additional information, including surgery procedures, importance of medicine treatment and medical help to relieve depression and anxiety about disease during peri-operation period.
223827633|NCT04048070|BEHAVIORAL|Shorter fasting food and water time before surgery|The patients in ERAS group were required to fast food for 6 to 8 hours and provided 12.6% maltodextrin carbohydrate supplement beverage for 2 hours before surgery
223827634|NCT04048070|BEHAVIORAL|Conventional perioperative counseling|THe conventional perioperative counseling included the risk of surgery and prognosis of disease and other things patients need to know.
223827635|NCT04048070|BEHAVIORAL|Regular fasting food and water time before surgery|The stricter control of preoperative fasting requirements, prohibiting solids and liquids from previous midnight to operation time.
223827636|NCT05392140|BEHAVIORAL|Health belief model-based smartphone-assisted nursing care program application will be installed on the phones of the patients who will be in the intervention group.|Health belief model-based smartphone-assisted nursing care program application will be installed on the phones of the patients who will be in the intervention group.
223827637|NCT05392140|BEHAVIORAL|Standart care|Standart care
223827638|NCT03545113|PROCEDURE|Upper arm arteriovenous graft surgery|Creation of arteriovenous graft vascular access for hemodialysis
223827639|NCT03545113|PROCEDURE|Upper arm arteriovenous fistula surgery|Creation of arteriovenous fistula vascular access for hemodialysis
223827640|NCT00380887|DRUG|Premarin|
223827641|NCT00893568|OTHER|resonance magnetic imaging (fMRI),|a cerebral study will be performed at the neuroanatomic and functional levels by resonance magnetic imaging (fMRI) realized in three times (before, one week and six months after treatment)
223827642|NCT01565018|DRUG|Rotigotine PR 2.1.4|Treatment B: Rotigotine transdermal patch (2 mg/24 h \[10 cm\^2\]). Reference; drug product PR 2.1.4. Single application of 1 patch for 24 hours.
223827643|NCT01565018|DRUG|Rotigotine PR 2.2.1|Treatment A: Rotigotine transdermal patch (2 mg/24 h \[10 cm\^2\]). Test; drug product PR 2.2.1. Single application of 1 patch for 24 hours.
223827644|NCT06108115|BEHAVIORAL|CueToSleep (Full Intervention Package)|Individuals will be randomly allocated to receive the full Health Rhythms package (CueToSleep) program on their smartphones. The package includes 24/7 behavioral sensing from the participant's smartphone using the global positioning system, accelerometer, and screen on/off state, as well as a series of psychoeducational learning screens about the relationship among alcohol, mood disturbance and sleep, and personalized suggestions for behavior change to improve sleep that will be sent to the participant every 3 to 4 days. These suggestions will be based on behaviors indicated by the individual participant's sensor data over the previous 3 to 4 days.
223827645|NCT00807690|DRUG|Tacrolimus ointment|Tacrolimus ointment 0.1%every night for at least 3 months, half body side
223827646|NCT01804673|DRUG|Fentanyl-ITS|Fentanyl Iontophoretic Transdermal (through the skin) System (ITS) will release fentanyl at the rate of 40 microgram (mcg) (1 dose) to maximum of 240 mcg per hour (6 doses) but not more than 3.2 milligram (mg) (80 doses) per 24 hours. The duration of study treatment will be 72 hours.
223827647|NCT01574430|PROCEDURE|PDT|30% or 50% verteporfin dose PDT was given to patients with CSC
223827648|NCT01855581|DRUG|pediatric sedation (propofol, ketamine, etc)|"Presedation assessment was performed by hospitalists and pediatric sedation was performed by protocol in the sedation unit.~Data on demographics, primary illness, ASA, snoring history, URI symptom, medications used, procedure and recovery times, medication doses, outcomes of anesthesia, airway interventions and adverse events were collected retrospectively."
223827649|NCT00462046|DRUG|Berberine|
223827650|NCT00899587|DRUG|enalapril|enalapril 5 mg every night
223827651|NCT00899587|OTHER|oxygen|oxygen 10 lit/min 1 hour twice a day at the first month, once a day at the second month and every other day at the third month
223827652|NCT00899587|DRUG|placebo|
223827653|NCT00884858|DRUG|Maraviroc|Maraviroc is administered BID according to the other drugs within HAART; dosage ranges from 150 mg to 600 mg bid.
223827654|NCT06001281|OTHER|plasma collection|Plasma samples will be prospectively collected at relevant time points during patient treatment.
223827655|NCT06122532|PROCEDURE|Stem cell preparation combined with Reticular skin|The dose of transplanted stem cells per wound (100cm2) is 1×10\^6, then cover the wound with autologous regular skin.
223827656|NCT06122532|PROCEDURE|Stem cell preparation combined with MEEK skin|The dose of transplanted stem cells per wound (100cm2) is 1 × 10 \^ 6, then cover the wound with autologous MEEK skin.
223827657|NCT06122532|PROCEDURE|Stem cell preparation combined with split-thickness skin|The dose of transplanted stem cells per wound (100cm2) is 1 × 10 \^ 6, then cover the wound with autologous split-thickness skin.
223827658|NCT06122532|PROCEDURE|autologous skin grafting|After cleaning the wound, use autologous skin (Reticular skin/MEEK skin/split-thickness skin) grafting and cover the wound surface。
223827659|NCT00818415|DRUG|Naproxen sodium ER (BAYH6689)|Extented release Naproxen sodium (660mg) administered once a day
223827660|NCT00818415|DRUG|Commercial Naproxen (Aleve, BAYH6689)|Immediate release Commercial Aleve (220mg) administered in a two ( 440 mg) plus one (220mg) dosing regime, 660 mg daily
223827661|NCT00087789|GENETIC|CERE-110: Adeno-Associated Virus Delivery of NGF|CERE-110 2.0 x 10\^10 vg, CERE-110 1.0 x 10\^11 vg, CERE-110 2.0 x 10\^11 vg
223827662|NCT00002708|PROCEDURE|surgical procedure|
223827663|NCT00002708|RADIATION|radiation therapy|
223827664|NCT00002708|RADIATION|stereotactic radiosurgery|
223827665|NCT04367402|OTHER|BioMedomics COVID-19 IgM-IgG Rapid Test|Qualitative test to aid in the diagnosis of COVID-19 novel coronavirus
223827666|NCT01219803|DRUG|High Dose GGQL Decoction|The drug was a kind of decoction extracted by Chinese herbs such as Huanglian etc,5 times thick of low dose GGQL Decoction, 150ml/bag, twice in a day
223827667|NCT01219803|DRUG|Mild dose GGQL Decoction|The drug was a kind of decoction extracted by Chinese herbs such as Huanglian etc,3 times thick of low dose GGQL Decoction, 150ml/bag, twice in a day
223827668|NCT01219803|DRUG|Low dose GGQL Decoction|The drug was a kind of decoction extracted by Chinese herbs such as Huanglian etc, 150ml/bag, twice in a day
223827669|NCT01219803|DRUG|Placebo|The placebo was a kind of decoction,which including 4.5% low dose GGQL Decoction to feel bitter taste as other drugs, 150ml/bag, twice in a day
223827670|NCT02328196|BEHAVIORAL|The Danish McGill Ingestive Skills Assessment (MISA-DK)|The MISA measures the performance of dysphagic patients during the patient's usual mealtime routine.
223827671|NCT04633083|OTHER|Data collection|"Clinical Data: Registration of patient identity, sex and birth year, Body Mass Index, generic score EQ-5D-3L, Tampa Schaal voor kinesofobia and shoulder specific score like Constant Score, PROMS, ADLER, SST and postoperative ROM.~Imaging Data: A preoperative and postoperative CT scan and 1-year postoperative radiograph (all three part of standard clinical practice) will be obtained. This data is used to extract the bone geometries and implant position.~Movement Analysis: The subject should stand still followed by different motion tasks in the gait lab with collection of shoulder girdle kinematics and kinetics using a 14-camera VICON System.~Stereo Radiographic EOS Measurements: Every subject included in the study will undergo a stereo radiographic EOS exam while quite standing with their arm in various positions (van Andel et al., 2008) .~ROM simulation: With the developed ROM software, we will simulate the ROM of the 2 patient groups based on the available CT scan data."
223827672|NCT04295746|OTHER|Serious Game ShopAut|"The serious game ShopAut, is a three-dimensional game conceptually based on classic 3D life simulation games. ShopAut aims to teach players the procedure of a shopping activity; to reinforce object categorization and recognition in a supermarket; to improve attention, orientation, and problem-solving skills; and to help the player engage in simple economic transactions.~The intervention provides a virtual training with ShopAut to train, experiment, and practice behaviours and actions that can be then transferred in real-life contexts."
223827673|NCT00000517|DRUG|warfarin|
223827674|NCT01936129|DRUG|Copaxone|
223827675|NCT01936129|DRUG|Placebo (buffered normal saline w/v)|
223827676|NCT04534335|DEVICE|SNOO Smart Sleep from Happiest Baby, Inc|Data related to the use of the SNOO itself (collected electronically) such as the amount of movement provided by the SNOO, etc., will be examined with the hemodynamic data obtained during the use of the SNOO. Clinical care data as it relates to the child will also be evaluated as it pertains to the use of the SNOO (this information will focus on the amount and frequency of narcotics administered to the infant). feasibility of use is the device intervention.
223827677|NCT03636360|DEVICE|Light|15 hours of light exposure
223827678|NCT00245375|DRUG|Tylenol #3|
223827679|NCT00245375|DRUG|Combination Tylenol and Ibuprofen|
223827680|NCT01533714|BIOLOGICAL|CDP6038 (olokizumab)|Biological/Vaccine: CDP6038 (olokizumab) 100 mg/mL solution for subcutaneous (sc) injection
223827681|NCT02500212|DRUG|ENVARSUS®|
223827682|NCT02500212|DRUG|ADVAGRAF®|
223827683|NCT03664739|DRUG|IDP-120 Gel|IDP-120 Gel, once-daily application
223827684|NCT03664739|DRUG|IDp-120 Vehicle Gel|IDP-120 Vehicle Gel, once-daily application
223827685|NCT03634137|DRUG|Afamelanotide Group 1|One 16 mg bioresorbable afamelanotide implant (Group 1) from the previous manufacturing process.
223827686|NCT03634137|DRUG|Afamelanotide Group 2|One 16 mg bioresorbable afamelanotide implant (Group 2) from the optimized final manufacturing process.
223827687|NCT04381767|DEVICE|EYE-SYNC|Evaluation of oculomotor performance using visual presentation and eye tracking analysis
223827688|NCT03475719|DRUG|HUG186-B and HUG186-D|Bazedoxifene acetate 22.6mg, Cholecalciferol 8.0mg(=800IU)
223827689|NCT03475719|DRUG|HUG186|Combination of Bazedoxifene acetate 22.6mg and Cholecalciferol 8.0mg(=800IU)
223827690|NCT02917044|PROCEDURE|Atrial Fibrillation Ablation|Procedure involving catheter ablation to produce pulmonary vein isolation. Pulmonary veins are isolated by assessing electrograms circumferentially around the PV using the Orion catheter.
223827691|NCT02917044|DEVICE|Catheters used to isolate pulmonary veins|Catheters transiently inserted into body via femoral veins in order to produce pulmonary vein isolation. These catheters are the same in each arm and comprise the Orion catheter (Boston Scientific) and the Tacticath (St Jude) which are used to produce pulmonary vein isolation and which are approved for use in standard EP procedures by the relevant authorities (CE marked). It is merely the protocol by which they are used that iffers in the two arms.
223827692|NCT02917044|PROCEDURE|Atrial Fibrillation Ablation with HD mapping to isolate PVs|Procedure involving catheter ablation to produce pulmonary vein isolation. Pulmonary veins are isolated by use of electroanatomical mapping with the Orion catheter around the sites ablation in order to target points of breakthrough.
223827693|NCT02917044|DEVICE|Rhythmia HD mapping|Mapping activation patterns using the Rhythmia system in conjunction with the Orion catheter
223827694|NCT02364453|DRUG|PACAP38|Giving doses of 4, 6 or 8 pg/kg/min on three separate trial days.
223827695|NCT06249620|DIETARY_SUPPLEMENT|Inmunoferon|The dosage regimen is two capsules (with the active ingredients) per day in a single dose.The study lasted 8 weeks, with 2 interventional visits at baseline and at 8 weeks. Blood samples are collected twice: once on day 0 of the study and again at the final visit.
223827696|NCT06249620|DIETARY_SUPPLEMENT|Placebo|The dosage regimen is two capsules (with inert ingredients) per day in a single dose.The study lasted 8 weeks, with 2 interventional visits at baseline and at 8 weeks. Blood samples are collected twice: once on day 0 of the study and again at the final visit.
223827697|NCT00599989|PROCEDURE|adjuvant therapy|
223827698|NCT00599989|PROCEDURE|conventional surgery|
223827699|NCT00599989|RADIATION|3-dimensional conformal radiation therapy|
223827700|NCT00599989|RADIATION|brachytherapy|
223827701|NCT00599989|RADIATION|intracavitary balloon brachytherapy|
223827702|NCT00599989|RADIATION|proton beam radiation therapy|
223827703|NCT00641849|BEHAVIORAL|Group A|Minimum Intervention Group A will fill out data forms at zero (0), two (2), four (4), and six (6) months.
223827704|NCT00641849|BEHAVIORAL|Group B|Maximum Intervention Group B will fill out data forms at zero (0), one (1), two (2), three (3), four (4), five (5), and six (6) months.
223827705|NCT05385328|DEVICE|EYEFUL: healthy people|"This kind of study implies that we do not require the use of any substance, medicine or therapeutic technique and neither imply any risk to the participants.~The data to be captured are exclusively video and audio recordings, and different signals from smart watches (mainly related to movement). Addittionaly, the clinical evaluation of the performance of these activities will be carried out according to the assessment scales to be defined in the project. The results of this evaluation will be exclusively used in the training of the automatic systems developed in the project and in order to establish a correlation between the captured observations (video, audio, smart watches signals) and the diagnostic assessment."
223827706|NCT05385328|DEVICE|EYEFUL: people with pathology|"This kind of study implies that we do not require the use of any substance, medicine or therapeutic technique and neither imply any risk to the participants.~The data to be captured are exclusively video and audio recordings, and different signals from smart watches (mainly related to movement). Addittionaly, the clinical evaluation of the performance of these activities will be carried out according to the assessment scales to be defined in the project. The results of this evaluation will be exclusively used in the training of the automatic systems developed in the project and in order to establish a correlation between the captured observations (video, audio, smart watches signals) and the diagnostic assessment."
223827707|NCT02662803|OTHER|high-intensive aerobe exercise|Aerobe bicycle ergometer training within 77-95% of maximum oxygen consumption; duration of each training session: 20 minutes; frequency of training: 6 sessions within 12 days
223827708|NCT02662803|OTHER|low-intensive aerobe exercise|Aerobe training below 70% of maximum oxygen consumption (including light stretching and simple exercises adapted from yoga figures); duration of training session: 20 minutes; frequency of training: 6 sessions within 12 days
223827709|NCT00642928|DRUG|Placebo|1 capsule per day during 4 weeks
223827710|NCT00642928|DRUG|BF 2.649 5 mg|one BF 2.649 capsule of 5 mg per day during 4 weeks
223827711|NCT00642928|DRUG|BF 2.649 10 mg|One BF 2.649 capsule of 10 mg per day during 4 weeks
223827712|NCT00642928|DRUG|BF 2.649 20 mg|One BF 2.649 capsule of 20 mg per day during 4 weeks
223827713|NCT00642928|DRUG|BF 2.649 40 mg|One BF 2.649 capsule of 40 mg per day during 4 weeks
223827714|NCT04384458|DRUG|Hydroxychloroquine|Oral hydroxychloroquine 400 mg twice a day on day 1, one 400 mg tablet on day 2, 3, 4, and 5, followed by one 400 mg tablets every 05 days until day 50th associated with 66 mg of zinc sulfate.
223827715|NCT04384458|DRUG|Ivermectin|Oral ivermectin dosage guidelines based on participant body weight, once on day for 2 consecutive days. This dose schedule should be repeated every 14 days for 45 days associated with 20 milligrams twice on day of active zinc.
223827716|NCT00345384|DRUG|Dexmedetomidine|Dexmedetomidine titrated over 24 hours
223827717|NCT00345384|OTHER|Placebo (Normal Saline)|
223827718|NCT01602757|DRUG|Synera|"Subjects received 4 Synera® patches for 2 hours in Session 1 and 4 patches for 12 hours in Session 4. During Study Session 2, subjects were randomly assigned to 4-hour applications of either 4 Synera® patches or 4 lidocaine/tetracaine patches without heat (no heat patches) and were crossed over during Study Session 3."
223827719|NCT02355522|DRUG|Intrauterine lidocaine|
223827720|NCT02355522|DRUG|Lidocaine gel|
223827721|NCT02355522|DRUG|KY jelly|
223827722|NCT02355522|DRUG|Intrauterine normal saline|
223827723|NCT01852656|BEHAVIORAL|Postcard and IVR Reminder Group|"IVR: Subjects in this reminder group will receive an automated telephone call to their primary telephone number. A total of 2 call attempts per member will be made. The IVR system will provide a message about the importance of annual influenza vaccination. The member can also request additional information about influenza vaccination and influenza vaccination locations and times.~Postcard: The postcard will be sent as a single postcard to each individual on the list. The postcard will be sent to the home address of the member. If the postcard is returned, the postcard will not be re-sent. The postcard does not identify that the member has a chronic health condition such as asthma or COPD. The postcard will be mailed during the last two weeks of September, 2012."
223827724|NCT01852656|BEHAVIORAL|Postcard Only Reminder Group|Postcard: The postcard will be sent as a single postcard to each individual on the list. The postcard will be sent to the home address of the member. If the postcard is returned, due to an inaccurate address, the postcard will not be re-sent. The postcard does not identify that the member has a chronic health condition such as asthma or COPD. The postcard will be mailed during the last two weeks of September, 2012.
223827725|NCT01852656|BEHAVIORAL|IVR Only Reminder Group|IVR: Subjects in this reminder group will receive an automated telephone call to their primary telephone number. A total of 2 call attempts per member will be made. The IVR system will provide a message about the importance of annual influenza vaccination. The member can also request additional information about influenza vaccination and influenza vaccination locations and times.
223827726|NCT04147182|DRUG|Hypertonic Saline 3%|3% and 5% Sodium Chloride Injection, USP is a sterile, nonpyrogenic, hypertonic solution for fluid and electrolyte replenishment in single dose containers for intravenous administration. The pH may have been adjusted with hydrochloric acid. It contains no antimicrobial agents.
223827727|NCT02997839|BEHAVIORAL|sleep disruption|"Group two will have interrupted sleep at time periods of 2 hours post operatively.~Group two will be woken every 2 hours, which is the standard NCCU protocol."
223827728|NCT03173781|DRUG|droxidopa|medication
223827729|NCT03173781|DRUG|Placebo|medication
223827730|NCT04408547|DEVICE|embryo transfer catheter|undergoing embryo transfer
223827731|NCT03748836|DRUG|ALPN-101|Single or multiple doses of ALPN-101 delivered via intravenous or subcutaneous injection. Ascending dose levels will be evaluated.
223827732|NCT03748836|DRUG|Placebo|Single or multiple doses of placebo delivered via intravenous or subcutaneous injection, matched to ALPN-101 cohorts.
223827733|NCT01421589|DRUG|Growth hormone treatment|Growth hormone 0.4 mg once daily (titrated to IGF-1) by sub-cutaneous injection for 12 weeks.
223827734|NCT02293525|DEVICE|ReLeaf catheter|Continuous infusion rate 10ml/hr (5ml/side)
223827735|NCT02293525|DRUG|Ropivacaine|
223827736|NCT02293525|DRUG|Saline|
223827737|NCT02293525|DRUG|Morphine|Patient-controlled analgesia (PCA) at 1mg every 6 minutes with a 4 hour lock out after 30mg
223827738|NCT02293525|DRUG|Oxycodone|10mg every 4-6 hours
223827739|NCT05124834|DIAGNOSTIC_TEST|blood glucose measurement, blood glucose monitor for personal use|measurement of the blood glucose concentration using the blood glucose monitor for personal use (TJ100)
223827740|NCT05124834|DIAGNOSTIC_TEST|blood glucose measurement, laboratory reference device|measurement of the blood glucose concentration using a laboratory reference device (YSI 2300 Stat Plus)
223827741|NCT01311362|DRUG|St. Johns wort|"* Administration of ambrisentan: 5 mg p.o. q.d. on day 1 and days 3-20~* Administration of SJW: 300 mg p.o. three times a day (t.i.d.) on days 11-20"
223827742|NCT03790514|OTHER|Heat Wrap|Commercially heat tapes ( without drugs) will be applied to patients.
223827743|NCT00251927|DRUG|esomeprazole|40 mg oral tablet administered daily
223827744|NCT00251927|PROCEDURE|Laparoscopic fundoplication (surgery)|Surgery
223827745|NCT03048032|PROCEDURE|Blood sampling|Besides routine clinical, laboratory and instrumental evaluation, blood samples will be taken within 4 hours of presentation to the hospital. Plasma samples, stored and frozen at -80°C, will be analyzed at the INSERM UMR942 institute in Paris. Up to 15 novel will be measured during the study: copeptine, proenkephalin, high sensitivity troponin T, troponin I, brain natriuretic peptide (BNP), N-terminal pro-BNP, adrenomedullin, soluble ST2, galectine 3, C-reactive protein, interleukine 6, procalcitonin, cystatin C, neutrophil gelatinase associated lipocalin.
223827746|NCT03048032|PROCEDURE|Echocardiography exam|A standard echocardiography as well as examination focused on right ventricle (RV) will be performed in a period of 48 hours of admission. Novel qualitative and quantitative parameters of right ventricle function and structure will be measured. These include RV diameter at base and midlevel, a measure of RV fractional area change (FAC), tissue doppler imaging derived tricuspid lateral annular systolic velocity wave (S'), tricuspid annular plane systolic excursion (TAPSE), velocity and gradient of tricuspid regurgitation, estimated systolic RV and RA pressure, RV wall strain and strain rate.
223827747|NCT05303597|DIAGNOSTIC_TEST|ultrasound-guided diagnostic nerve block with lidocaine|Patients with a trigger point in the posterior iliac crest will be evaluated by a second physician and diagnostic nerve block will be performed ultrasound-guided with the preliminary diagnosis of superior cluneal nerve entrapment. General Electric LogiqP5 model ultrasound device will be used and lidocaine will be applied between the posterior iliac crest and thoracolumbar fascia, which is viewed under the guidance of ultrasonography, for diagnosis and treatment.
223827748|NCT04204772|BIOLOGICAL|Activated charcoal and Tap Water|12 grams of AC mixed with Tap water or 25 grams of AC mixed with Tap water
223827749|NCT04204772|BIOLOGICAL|Activated Charcoal and Apple Juice|12 grams of AC with Apple Juice or 25 grams of AC with Apple Juice
223827750|NCT01576055|DEVICE|TIGRIS Vascular Stent|Implant
223827751|NCT01576055|DEVICE|BARD LifeStent|Implant
223827752|NCT06526377|DRUG|Natrunix|Natrunix is a monoclonal antibody preparation. Natrunix antibody is indistinguishable from a natural antibody isolated from a healthy human. Natrunix is expected to be the safest, most effective therapy for alleviating inflammatory pain and mitigating damage, mainly in the spine and sacroiliac joints, in AxSpA patients.
223827753|NCT06526377|DRUG|Placebo|Placebo
223827754|NCT01039350|DRUG|Darbepoetin alfa|Darbepoetin alfa will be initiated at a weekly (QW) subcutaneous dose of 300 mcg over 8 weeks.
223827755|NCT02153021|RADIATION|Phototherapy|"phototherapy: all patientes will received application of phototherapy after exercise session. The phototherapy will be applicated in abdominal and dorsal circumference/ quadriceps and biceps femoral.~Type Ga-Al-As Wavelength 808nm Frenquency Continue wave Optical output 100mW Spot diameter 0.6mm Power density 60W/cm2 Energy per minute 6J/point Number of Points 64points Total energy delivered 48J"
223827756|NCT02909023|BIOLOGICAL|blood samples are performed to measure active T cellular immune response during a routine visit|"During the visit 1 (V1), after signing the informed consent, 40 mL blood sampling are carried out and analyzed with the test ELISPOT to check if the patient shows a T immune response against HBV.~The visit 2 will be performed 4-8 weeks (depending on the availability of the patient) following V1 visit, in case the patient shows an immune response against HBV positive T following the sample taken at V1. 150 ml blood sampling are carried out at this visit."
223827757|NCT00047983|DIETARY_SUPPLEMENT|Canola oil|
223827758|NCT00047983|DIETARY_SUPPLEMENT|Arginine|
223827759|NCT00047983|DIETARY_SUPPLEMENT|Fish oil emulsion|
223827760|NCT04506996|BEHAVIORAL|Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management|see arm/group descriptions
223827761|NCT04506996|BEHAVIORAL|Monday-Focused Written Messages for Weight Management|see arm/group descriptions
223827762|NCT04506996|BEHAVIORAL|Educational Materials|After the baseline assessment and the 1st follow-up (\~8 weeks post randomization), participants received educational materials regarding physical activity and healthier diets. The study staff reviewed these materials with the participants
223827763|NCT02632019|DRUG|Gemcitabine|Gemcitabine 1000mg/m2, Physiological saline 100ml:IV (in the vein) once a week with a total of six times.
223827764|NCT02632019|BIOLOGICAL|Dendritic cell-precision T cell for neo-antigen combined with gemcitabine treatment|"Gemcitabine: Gemcitabine 1000mg/m2, Physiological saline 100ml: IV (in the vein) once a week with a total of six times before 60 days prior to the start of drawing blood. DC-PNAT: DC cell suspension (1×107 DC+ physiological saline + 0.25% human serum albumin) 1ml for each infusion, subcutaneous injection for each infusion, 3 cycles, each cycle received two infusions on day 19, 20; 40, 41; 61, 62.~PNAT cell suspension (1-6×109 PNAT + physiological saline + 0.25% human serum albumin) 300ml for each infusion, IV (in the vein) for each infusion, 3 cycles, each cycle received one infusions on day 21, 42, 63."
223827765|NCT00936520|DRUG|SAR 1118 0.1%|Daily eye drops (twice daily, \~50 microliter \[uL\] each drop) approximately 10 to 12 hours apart; morning and in the evening just prior to bedtime) to the study eye only for 8 consecutive days
223827766|NCT00936520|DRUG|SAR 1118 1.0%|Daily eye drops (twice daily, \~50 uL each drop) approximately 10 to 12 hours apart; morning and in the evening just prior to bedtime) to the study eye only for 8 consecutive days
223827767|NCT00936520|DRUG|SAR 1118 5.0%|Daily eye drops (twice daily, \~50 uL each drop) approximately 10 to 12 hours apart; morning and in the evening just prior to bedtime) to the study eye only for 8 consecutive days
223827768|NCT00857376|DIETARY_SUPPLEMENT|Alpha lipoic acid at 3 doses compared to placebo|This is a randomized study comparing the antioxidant effects of 3 doses of alpha lipoic acid (total of 600 mg daily, 1200 mg daily and 1800 mg daily) compared to placebo. These doses will be taken as 2 pills 3 times a day for 8 to 10 weeks.
223827769|NCT03263234|OTHER|8 weeks of circadian adjusted LED-based lighting (CALED)|The luminaires are installed before the beginning of either the control or the intervention period. During the control period (8 weeks) the luminaires have normal light. During the intervention period (8 weeks) the luminaires have CALED. Cromaviso will calibrate CALED to mimic circadian rhythm according to the latest knowledge about the light phase-response curve for elderly.
223827770|NCT03652194|OTHER|in vitro evaluation of epithelial immune response during C. glabrata infection|"1. study of the expression of genes coding for different proteins involved in the RTqPCR activation cascade~2. study of protein expression by the Western-Blot method"
223827771|NCT03652194|OTHER|study of the impact of resistance phenotype acquisition on the virulence of C. glabrata isolates|"1. in vitro evaluation by measuring cell invasion, cell adhesion and by determining epithelial cell cytotoxicity.~2. in vivo evaluation measured by a survival study on a CD-1 mouse model."
223827772|NCT00990301|DRUG|Moexipril HCl/ Hydrochlorothiazide 15mg/ 25mg Tablet, Paddock Laboratories, Inc.|test drug
223827773|NCT00990301|DRUG|Uniretic® 15mg/25mg Tablets|reference drug
223827774|NCT01224808|BIOLOGICAL|Biostate|Single bolus doses, administered intravenously. Frequency and dose will be determined by the Investigator based on the subjects clinical condition, previous VWF concentrate requirements, response to therapy, weight and reason for usage.
223827775|NCT01170884|DRUG|fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% ophthalmic solution; bimatoprost 0.03% ophthalmic solution|1 drop of fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% ophthalmic solution (Combigan®) taken approximately 12 hours apart, up to 2 times a day and 1 drop of bimatoprost 0.03% ophthalmic solution (Lumigan®) taken once every 24 hours.
223827776|NCT01170884|DRUG|bimatoprost 0.03% ophthalmic solution; hypromellose 0.2% eyedrops|1 drop of bimatoprost 0.03% ophthalmic solution (Lumigan®) taken approximately every 24 hours; mild lubricant eyedrops (Gen Teal® Mild) for masking purposes
223827777|NCT02694640|BEHAVIORAL|Reach Plus|"In Months 1-3, participants in this group will receive the previously tested telephone counseling for exercise. RTR volunteers or coaches will be asked to contact participants by telephone weekly over 3 months (12 calls). In months 4-9, participants will no longer receive calls from RTR coaches and will be encouraged to use the heart rate monitors and pedometers during exercise. Participants will continue to complete their exercise logs and receive feedback reports from study staff."
223827778|NCT02694640|BEHAVIORAL|Reach Plus Phone|"In Months 1-3, participants in this group will receive the previously tested telephone counseling for exercise. RTR volunteers or coaches will be asked to contact participants by telephone weekly over 3 months (12 calls). In months 4-9, these participants will have the opportunity to continue to receive support calls from their coach. Participants will also continue to complete their exercise logs and receive feedback reports from study staff."
223827779|NCT02694640|BEHAVIORAL|Reach Plus Message|"In Months 1-3, participants in this group will receive the previously tested telephone counseling for exercise. RTR volunteers or coaches will be asked to contact participants by telephone weekly over 3 months (12 calls). In months 4-9, participants will receive messages by email or text to motivate, prompt and reinforce continued exercise. Participants will also continue to complete their exercise logs and receive feedback reports from study staff."
223827780|NCT02696330|DRUG|clopidogrel|clopidogrel 75mg tablets with 300mg loading dose followed by 75mg oral tablets daily starting from day of hCG trigger till assessment of pregnancy by ultrasound
223827781|NCT02696330|DRUG|enoxaparin|enoxaparin 40 mg by subcutaneous injection once daily starting from day of hCG trigger till assessment of pregnancy by ultrasound
223827782|NCT02696330|DRUG|placebo|starch tablets with no active drug material is given daily starting from day of hCG trigger till assessment of pregnancy by ultrasound
223827783|NCT00683280|BEHAVIORAL|contingency management|Prize-based contingency management, with the opportunity to earn prizes for expired carbon monoxide levels reading 6ppm or less and urinary cotinine levels reading 30ng/ml or less for 4 weeks.
223827784|NCT00683280|OTHER|Standard of Care|varenicline (smoking cessation medication) 0.5mg po daily Days 1-3, 0.5mg po twice daily Days 4-7, 1.0 mg po twice daily Days 8-84.
223827785|NCT00683280|OTHER|Standard of Care|Twice weekly brief counseling based on public health service guidelines for quitting smoking.
223827786|NCT01199458|DRUG|alfentanil|20 mikrogr/kg
223827787|NCT01199458|DRUG|saline|The amount of saline will be equal the amount (in ml) of the study-drug (alfentanil)in order to keep it blinded.
223827788|NCT06442072|BEHAVIORAL|guided online self-help program|16 weeks of training and application of psychotherapeutic methods
223827789|NCT00071240|DRUG|Somatropin (recombinant human growth hormone)|3.0mg sc daily for 6 months, followed by 1.5mg sc daily for 6 months. Dose stopped, held or reduced by study investigators as indicated by adverse events
223827790|NCT01832415|DRUG|Bevacizumab|Observation of bevacizumab administration in first line ovarian cancer treatment
223827791|NCT04004572|DRUG|LEAP regimen|Patients will be given LEAP regimen every 3 weeks for 8 cycles.
223827792|NCT01044342|DRUG|AZD1446|capsule; single oral dose
223827793|NCT01044342|DRUG|AZD1446|capsule, single oral dose
223827794|NCT01044342|DRUG|donepezil|capsule, single oral dose
223827795|NCT01044342|DRUG|Placebo|capsule, single oral dose
223827796|NCT06106841|DRUG|400mg of TQB3909 tablets|TQB3909 tablets 400mg, TQB3909 tablets is a B-cell lymphoma (BCL)-2 inhibitor.
223827797|NCT06106841|DRUG|600mg of TQB3909 tablets|TQB3909 tablets 600mg, TQB3909 tablets is a B-cell lymphoma (BCL)-2 inhibitor.
223827798|NCT02864043|DEVICE|NvisionVLE with Real Time Targeting|Physician will complete a VLE scan of the esophagus and target areas of interest using the VLE optical marking probe
223827799|NCT02864043|PROCEDURE|esophagogastroduodenoscopy (EGD)|Standard of care EGD
223827800|NCT03753711|PROCEDURE|Multifidus muscle biopsy during minimally invasive back surgery|Bilateral biopsy of the multifidus muscle in patient with a unilateral disc hernia.
223827801|NCT01292174|BIOLOGICAL|ibalizumab (biologic/MAb) for SC Injection or placebo|ibalizumab or matching placebo administered by subcutaneous injection weekly at 120 mg
223827802|NCT01292174|BIOLOGICAL|ibalizumab (biologic/MAb) for SC Injection or placebo|ibalizumab or matching placebo administered by subcutaneous injection weekly at 240 mg
223827803|NCT01292174|BIOLOGICAL|ibalizumab (biologic/MAb) for SC Injection or placebo|ibalizumab or matching placebo administered by subcutaneous injection weekly at 480 mg
223827804|NCT03154203|OTHER|No intervention in this study|No intervention in this study
223827805|NCT02605382|DRUG|Chlorhexidine gluconate|
223827806|NCT02605382|DRUG|placebo|Solution chemical manufactured to mimic 0.12% chlorhexidine mouthwash
223827807|NCT04227860|OTHER|Balance exercise program|"Patients will be engaged in lower extremity kinesthesia and balance exercise program 3 time per week for 6 weeks.~Divided into 2 stages, stage 1 and 2, each stage 3 weeks. Patients who fulfill at least stage 1 of the program will be included in the study."
223827808|NCT04227860|OTHER|Strengthening exercise program|"Patients will be engaged in strengthening exercise program 3 time per week for 6 weeks.~Divided into 3 stages, stage 1, 2 and 3, each stage 2 weeks. Patients who fulfill at least stage 1 of the program will be included in the study."
223827809|NCT00077350|DRUG|triapine|Given IV
223827810|NCT00077350|DRUG|gemcitabine hydrochloride|Given IV
223827811|NCT00077350|OTHER|laboratory biomarker analysis|Correlative studies
223827812|NCT03729895|DEVICE|Adjustable Oral Appliance|Adjustable Oral Appliance consist of plastic maxillary occlusal splint，mandible occlusal splint and adjustable connecting rod.It could offer a non-invasive form of treatment but also achieve a good therapeutic effect
223827813|NCT05504213|DRUG|HS-10352 combined with fulvestrant (Stage 1)|"Drug: HS-10352 HS-10352 will be administered at escalating doses orally once daily on a continuous dosing schedule starting on Cycle 1 Day 1 (C1D1) in a 28 day cycle.~Drug: Fulvestrant Fulvestrant is administered at a dose of 500 mg intramuscular on Cycle 1 Day 1, Day 15, and Day 1 of every cycle thereafter (where a cycle is 28 days)."
223827814|NCT05504213|DRUG|HS-10352 combined with fulvestrant (Stage 2)|"Drug: HS-10352 participants will be enrolled into Cohort 2 (endocrine therapy-resistant) and Cohort 3 (endocrine therapy-sensitive or naïve) respectively and HS-10352 will be administered at the recommended dose identified in Part 1.~Drug: Fulvestrant Fulvestrant is administered at a dose of 500 mg intramuscular on Cycle 1 Day 1, Day 15, and Day 1 of every cycle thereafter (where a cycle is 28 days)."
223827815|NCT02222896|DRUG|Chlorhexidine Gluconate|2% CHG solution on cloth
223827816|NCT02222896|OTHER|Vehicle|Excipients of CHG product only
223827817|NCT02222896|DRUG|DynaHex-2|2% CHG solution
223827818|NCT02677363|OTHER|Resistance Exercise|Participants 60 and above aged (both females and males) will perform one hour of resistance exercise twice weekly for 8 weeks.
223827819|NCT00406120|PROCEDURE|Fine needle aspiration biopsy|
223827820|NCT03103932|OTHER|Biomarker guided discharge algorithm|participants randomized to the biomarker guided discharge algorithm will follow a pre-determined care pathway for treatment of heart failure symptoms based on admission NTproBNP levels
223827821|NCT05540093|OTHER|high power pain threshold ultrasound|After explaining the procedure, and the trigger points will be marked by a physical therapist that . Then, the hand placed next to the prone position with the head in the neutral position, and the hands placed next to the body. The frequency was set to 1 MHz, and the intensity increased from 0.5 to 2 until the patient reported an unpleasant sensation. The probe will be held there for 4 s; then, the intensity was reduced by 50%, and the probe was moved over and around the trigger point. This process is done several times for three minutes.
223827822|NCT05540093|OTHER|traditional therapy|the patients will receive traditional therapy in the form of postural correction exercise, active range of motion and stretching exercise for cervical muscles
223827823|NCT05435235|DRUG|Dapagliflozin 10mg Tab|One tablet daily starting 48h prior to PCI and continuing for 48h post-PCI.
223827824|NCT05298462|DIAGNOSTIC_TEST|Livzon Rapid Antibody Test for COVID-19|Point-of-care Rapid Antibody Test for COVID-19
223827825|NCT00179348|PROCEDURE|Quality-of-Life Assessment|Ancillary studies
223827826|NCT00179348|PROCEDURE|Yoga|Undergo a yoga-based rehabilitation program
223827827|NCT04815486|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|Active rTMS in 10 daily sessions in two weeks of sequential application of: 90% RMT at 1Hz, 1000 pulses/day, 25s inter train on M1 of lesioned hemisphere and 90% RMT at 10Hz, 1000 pulses/day, 50s inter train on M1 of healthy hemisphere.
223827828|NCT04815486|DEVICE|Motor Imagery (MI) through a Brain-Computer Interface (BCI) training platform in Virtual Reality (VR) with NeuRow|It will consist of a combination of the bilateral rTMS protocol and the MI-neurofeedback training. During this therapy, the patient received 10 consecutive daily sessions of bilateral rTMS (Monday to Friday, two weeks), with the same stimulation parameters as another therapy, and 12 non-consecutive sessions of MI-neurofeedback (three times a week for four weeks). The first 6 MI-neurofeedback sessions were carried out after bilateral stimulation with rTMS (i.e., rTMS as a priming method during the first two weeks), and the last 6 sessions, without rTMS as prior priming during the last two weeks.
223827829|NCT02220335|PROCEDURE|Pulmonary arterial denervation|Contrast pulmonary artery （PA) angiography was performed to localize the pulmonary artery bifurcation level and calculate the PA diameter.Once the anatomy was deemed acceptable, the radiofrequency ablation catheter was introduced into the distal bifurcation area of the main PA.This was then maneuvered within the PA to allow energy delivery to ensure that the electrodes were tightly in contact with the endovascular surface. About two to three ablations at 1-15 W for 240 seconds each point were performed in the distal bifurcation area of the main PA.
223827830|NCT02220335|DRUG|Standard treatment|Patients in the standard treatment group will take their baseline anti-heart failure medications at the original doses, without any changes except when medically required.The anti-heart failure drugs treatment is consistent in both arms.Patients in the standard treatment group will take one or combination of the following target drugs: endothelin receptor antagonist, 5'-PDE and prostacyclin. On the other hand, patients in the PADN group do not take any of the target drugs mentioned above.
223827831|NCT02058420|DRUG|Low tocotrienols group|300 mg tocotrienols daily
223827832|NCT02058420|DRUG|High tocotrienols group|600 mg tocotrienols daily
223827833|NCT00759772|DRUG|Placebo|sc daily for 6 months
223827834|NCT00759772|DRUG|Teriparatide|20 mcg sc daily for 6 months
223827835|NCT06229184|DIAGNOSTIC_TEST|Fecal Calprotectin Test|Fecal samples are taken fom obese and healthy adolescents for study
223827836|NCT02265029|OTHER|Immediate spa treatment|spa treatment in rheumatology with sedative and antalgique techniques and mobilizing techniques (rehabilitation in pool)
223827837|NCT02265029|OTHER|Late spa treatment|spa treatment in rheumatology with sedative and antalgique techniques and mobilizing techniques (rehabilitation in pool)
223827838|NCT05351138|DEVICE|TENS|In the study, CE certified tens device with Biolito brand, which is used specifically for incontinence treatment, will be used. The electrodes used during the intervention will be placed to the parasacral region (S2-S4). While the current is given, the power of the device will be gradually increased in 1 mA intervals. The lower value of the stimulation will be 10 mA and the upper value will be 25 mA, and the treatment will be continued with any value that the child can tolerate in this range.
223827839|NCT05351138|OTHER|Massage|The massage will be applied to the abdominal area between the subcostal lower border and the anterior superior of the spina iliaca. Massage techniques are as follows: Abdominal patting, colon patting, colon kneading, colon patting again, abdominal patting again. It will be advanced with deep abdominal strokes, then the starting point will be returned with transverse superficial strokes for the transversus abdominis muscle and oblique superficial strokes for the rectus abdominis muscle, and these strokes will be repeated 3 times each, a total of 6 times. Afterwards, 3 times column brushing, 3 times column kneading and 3 times column plastering will be done, respectively. At the end, a total of 6 abdominal strokes will be performed for both the transversus abdominis and oblique abdominal muscles as in the beginning.
223827840|NCT03354520|BEHAVIORAL|Tailored Videos|web-based OSA messages (videos featuring role models and coaching advice using motivational enhancement) addressing OSA barriers within a health literacy framework--to decrease cognitive load and render messages understandable and actionable. OSA messages were tailored based on focus group data in the previous study (group tailoring).
223827841|NCT03354520|BEHAVIORAL|OSA Treatment|Web-based platform delivering messages promoting OSA self-efficacy. . All patients will view the introductory video, followed by the video cluster: Sleep, Health, and Well-Being; Sleep-Heart Health; Lifestyle Changes; and Sleep Hygiene.
223827842|NCT03354520|BEHAVIORAL|Standard Videos|Patients in the control arm will also receive an iPad, providing access to standard online OSA health information (e.g., National Sleep Foundation) in an equivalent dose as in the intervention arm using pre-selected automatic alerts to access the website
223827843|NCT02978313|DRUG|Cetuximab|anti-EGFR monoclonal antibody
223827844|NCT02978313|DRUG|mFOLFOX6|Oxaliplatin+LV5FU2
223827845|NCT02978313|DRUG|FOLFIRI|Irinotecan+LV5FU2
223827846|NCT00213330|PROCEDURE|rectal distension|
223827847|NCT03782896|OTHER|acute postoperative pain|All patients assessed postoperative pain score in the recovery room and postoperative 2 month
223827848|NCT00002474|DRUG|carboplatin|
223827849|NCT00002474|DRUG|cyclophosphamide|
223827850|NCT00002474|DRUG|mitoxantrone hydrochloride|
223827851|NCT00002474|PROCEDURE|autologous bone marrow transplantation|
223827852|NCT00002474|PROCEDURE|bone marrow ablation with stem cell support|
223827853|NCT03306407|OTHER|Improved hand hygiene|The intervention group receives pre-travel advice with a special focus on improved hand hygiene including the use of hand gel sanitizer (Hartmann Sterillium) (bundle intervention)
223827854|NCT02226172|DRUG|Glasdegib (PF-04449913)|Oral daily dose of glasdegib (PF-04449913) 100 mg tablet in a continuous regimen of 28-day cycles.
223827855|NCT02226172|DRUG|Placebo|Oral daily dose of placebo 100 mg tablet in a continuous regimen of 28-day cycles.
223827856|NCT01865617|BIOLOGICAL|Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes|Given IV
223827857|NCT01989598|OTHER|Laboratory Biomarker Analysis|Correlative studies
223827858|NCT01989598|OTHER|Pharmacological Study|Correlative studies
223827859|NCT01989598|DRUG|Trametinib|Given PO
223827860|NCT01989598|DRUG|Uprosertib|Given PO
223827861|NCT04724720|DRUG|Famotidine|Standard or care treatment plus prescribed famotidine
223827862|NCT04724720|DRUG|Placebo|Standard of care treatment plus placebo
223827863|NCT04132570|DRUG|Budesonide|Participants will self-administer 2 nasal sprays of Budesonide (64 mcg/spray) once daily up to 10 +\\- 3 Days.
223827864|NCT04132570|OTHER|Placebo|Participants will self-administer 2 nasal sprays of matching placebo once daily up to 10 +\\- 3 Days.
223827865|NCT02161601|PROCEDURE|Cricoid Pressure|Correct Cricoid pressure applied against the cricoid cartilage, Incorrect Cricoid pressure applied against the thyroid cartilage and trachea
223827866|NCT03979950|BEHAVIORAL|Survey|Solid Organ Transplant patients will be recruited via social media. Co-investigators will reach out to the administrators of various social media networks to share information regarding the study with their networks on our behalf. Potential participants who are interested in participating, can then follow the link to the online survey tool, which includes the participant demographic information (age, ethnicity and highest level of education) and questionnaire. The questionnaire is 30 questions long and takes approximately 15 minutes to complete. This questionnaire will be a single, cross-sectional survey. No personal information will be documented on the questionnaire. All responses will be anonymous. Participants will be recruited for 6 months.
223827867|NCT03646227|OTHER|Standard of Care|There is no prescribed intervention for this study. Standard of care will be captured in the eCRF.
223827868|NCT03851874|PROCEDURE|Bariatric surgery|Bariatric surgery
223827869|NCT00000700|DRUG|Zidovudine|
223827870|NCT00380341|PROCEDURE|Instrument-applied spinal manipulative therapy|
223827871|NCT05445024|PROCEDURE|nalbuphine group|nalbuphine ED95, dexmedetomidine ED95 and ondansetron 16mg were added into normal saline to a total of 100ml
223827872|NCT05445024|PROCEDURE|sufentanil group|sufentanil (1/1000\* nalbuphine ED95), dexmedetomidine ED95 and ondansetron 16mg were added into normal saline to a total of 100ml
223827873|NCT05445596|BEHAVIORAL|Functional communication training|Functional communication training (FCT) is a behavioral approach to treating problem behavior. During FCT, children learn to use communication to access reinforcers, instead of using problem behavior.
223827874|NCT05366049|OTHER|using a medicine pacifier to give acetaminophen|While giving acetaminophen, the effect on the amount of taking the drug, pain and vital parameters are observed by using the drug pacifier.
223827875|NCT01466764|DRUG|Anakinra|An injection of 100 mg Anakinra was administered 1 hour prior to surgery and again 24 hours following surgery.
223827876|NCT01466764|OTHER|Normal Saline|An injection of normal saline was administered 1 hour prior to surgery and again 24 hours following surgery.
223827877|NCT05693467|DRUG|Dexamethasone palmitate emulsion(DXP) plus ropivacaine|The local infiltration solution in the dexamethasone palmitate emulsion(DXP) plus ropivacaine group will consist of ropivacaine and dexamethasone palmitate emulsion(DXP). For local infiltration, a total of 30mL solution will be prepared for each group, which will include 2mL of DXP(4mg per 1mL) added to 20.5 mL of saline and 7.5mL of 1% ropivacaine added to 15mL of saline for Group A . The surgeon will perform incision infiltration before the skin incision. A total of 10 mL of solution will be injected into each level. The study solution will be injected into the entire thickness of the planned incision site. The epidural space and intrathecal space will not be infiltrated.
223827878|NCT05693467|DRUG|Ropivacaine alone|The local infiltration solution in the ropivacaine alone group will consist of ropivacaine alone. For local infiltration, a total of 30mL solution will be prepared for each group, which will include 7.5mL of ropivacaine added to 22.5mL of saline for Group B . The surgeon will perform incision infiltration before the skin incision. A total of 10 mL of solution will be injected into each level. The study solution will be injected into the entire thickness of the planned incision site. The epidural space and intrathecal space will not be infiltrated.
223827879|NCT06339294|DRUG|Clotrimazole Cream|Single time application of clotrimazole ointment was done after aural toilet in external auditory canal via IV catheter
223827880|NCT06339294|DRUG|Povidone-Iodine|Gelfoam soaked pyodine solution was placed in external auditory canal after aural toilet
223827881|NCT05036889|DIAGNOSTIC_TEST|Mind.Px Report|Use of Mind.Px report as a reference for potential better matching of biologics to patients.
223827882|NCT03225521|BEHAVIORAL|HeartSteps: A just-in-time adaptive intervention for increasing physical activity amongst sedentary adults.|HeartSteps is an Android-based mHealth intervention that contains two main intervention components: contextually-tailored suggestions for activity and planning of the next day's activity. Activity suggestions provide individuals with actionable suggestions for how they can be active in their current context. Delivered suggestions are tailored based on time of day, user's location, day of the week (weekend/weekday), and weather. HeartSteps can deliver a user activity suggestions up to five times a day. Evening planning asks users to create or choose a plan of how they will be active on the following day. Planning can be delivered once a day, in the evening.
223827883|NCT01621958|BEHAVIORAL|Repeated perturbation training|One session consisting of 24 slips total interspersed with 16 nonslip trials (1 block of 8 slips, 3 non-slips, 2nd block of 8 slips, 3 non-slips, a mixed block consisting of 8 slips and 10 non-slips). Retest consisting of one slip exposure at either 6 months, 9 months or 12 months.
223827884|NCT01621958|BEHAVIORAL|Minimal perturbation training|One session consisting of a single slip exposure. Retest consisting of one slip exposure at either 6 months, 9 months or 12 months.
223827885|NCT06362343|DRUG|Rivaroxaban|Rivaroxaban
223827886|NCT04879498|DRUG|Monolithic zirconia|To assess the clinical performance and survival of posterior monolithic zirconia fixed partial dentures
223827887|NCT04879498|OTHER|Veneered zirconia|To assess the clinical performance and survival of posterior veneered zirconia fixed partial dentures
223827888|NCT04879498|OTHER|Metal-ceramic|To assess the clinical performance and survival of posterior metal-ceramic fixed partial dentures
223827889|NCT04099381|BIOLOGICAL|ASD CB-MNC infusion low level HLA compatibility.|CB-MNC infusion from different donors. One dose consists of 2-15х10\^7 cells per 1 kg of patient weight for each infusion. The protocol includes 2 infusions with an interval of 6-x months. HLA compatibility of the cord blood is 3 or fewer by A, B, DRB1 loci.
223827890|NCT04099381|BIOLOGICAL|ASD CB-MNC infusion high level HLA compatibility.|CB-MNC infusion from different donors. One dose consists of 2-15х10\^7 cells per 1 kg of patient weight for each infusion. The protocol includes 2 infusions with an interval of 6-x months. HLA compatibility of the cord blood is 4 or more by A, B, DRB1 loci.
223827891|NCT04099381|OTHER|Standard therapy.|The standard therapy can include drugs, special psychology training etc.
223827892|NCT00099489|DRUG|Interferon Beta-1a|
223827893|NCT00258440|DRUG|Weekly procrit dosing|The dose is standard of care, the investigational piece is the dosing schedule itself. Either weekly or Interval-dosing schedule subjects will get the study drug once every week until hematocrit is greater than 36% or Hemoglobin reaches a value of 12 g/dl, then they will get study drug once every other week.
223827894|NCT00258440|DRUG|Interval Dosing|The dosing of Procrit is standard of care, it is the schedule that is the investigational piece.
223827895|NCT04676711|DRUG|GFH312|Subjects are planned to be dosed in oral tablet, with single and multiple ascending doses
223827896|NCT04676711|DRUG|Placebo|Subjects are planned to be dosed in oral tablet, with single and multiple ascending doses
223827897|NCT03917810|OTHER|Diet|Macronutrient composition (specifically type and/or amount of carbohydrate) is manipulated
223827898|NCT00737061|DEVICE|Adiana Transcervical Sterilization System|Implantation of silicone matrix in fallopian tubes
223827899|NCT02169947|BEHAVIORAL|Weight loss core|The weight loss core is a culturally adapted version of the Diabetes Prevention Program core 16 week session program.
223827900|NCT02169947|BEHAVIORAL|Weight loss core plus maintenance|The intervention is a culturally adapted version of the Diabetes Prevention Program core 16 sessions plus 12 maintenance sessions.
223827901|NCT01406561|DRUG|OMS103HP-S|Proprietary concentration and formulation of OMS103HP in solution (OMS103HP-S) for injection into each 3 liter vehicle irrigation solution bag for use during meniscectomy surgery
223827902|NCT01406561|DRUG|Vehicle|3 Liter bags of vehicle irrigation solution for use during meniscectomy surgery
223827903|NCT01804543|DRUG|Ranolazine|ranolazine 500 mg, then 1000 mg twice a day
223827904|NCT02869269|DEVICE|Early stage|patients who classed as clinical stage 1 and 2
223827905|NCT02869269|DEVICE|Late stage|patients who classed as clinical stage 3 and 4
223827906|NCT02397486|DRUG|Pentoxifylline|
223827907|NCT02397486|DRUG|Vitamin E|
223827908|NCT02397486|DRUG|Cisplatin|
223827909|NCT02397486|RADIATION|Radiation therapy|
223827910|NCT06529354|BEHAVIORAL|Moderate-intensity Group|In water aerobics sessions, the exercises are performed at a moderate intensity, between 60% and 70% of the participant's maximum heart rate predicted by their age.
223827911|NCT06529354|BEHAVIORAL|High-intensity Group|In water aerobics sessions, the exercises are performed at a high intensity, between 80% and 90% of the participant's maximum heart rate predicted by their age.
223827912|NCT01347853|DRUG|Ketorolac tromethamine|30 mg intranasal post-surgery for up to 5 days total
223827913|NCT01347853|DRUG|Placebo|Intranasal post-surgery for up to 5 days total
223827914|NCT04039178|DEVICE|BQ|The BQ device (BrainQ Technologies Ltd., Israel), a Brain Computer Interface based stimulation device, uses machine learning tools to identify high resolution spectral patterns associated with motor functions in EEG measurements of healthy/non healthy subjects. These patterns are then translated into a tailored frequency dependent low intensity, non-invasive electro-magnetic treatment protocol.
223827915|NCT04039178|DEVICE|Sham|Sham BQ device
223827916|NCT00115219|DRUG|Etanercept|
223827917|NCT04112940|OTHER|Starch-based Thickened Liquids|Barium will be thickened to slightly, mildly, moderately and extremely thick consistences as defined by the International Dysphagia Diet Standardisation Initiative flow test.
223827918|NCT04112940|OTHER|Xanthan-gum Thickened Liquids|Barium will be thickened to slightly, mildly, moderately and extremely thick consistences as defined by the International Dysphagia Diet Standardisation Initiative flow test.
223827919|NCT06196580|DRUG|repaglinide; midazolam; SHR4640|repaglinide; midazolam; SHR4640
223827920|NCT06196580|DRUG|repaglinide; midazolam; SHR4640; SHR4640 placebo|repaglinide; midazolam; SHR4640; SHR4640 placebo
223827921|NCT06196580|DRUG|repaglinide; midazolam; SHR4640 placebo|repaglinide; midazolam; SHR4640 placebo
223827922|NCT03748238|PROCEDURE|Endometrial Injury with Hysteroscopy|All office hysteroscopy procedures will be done transvaginally under sedation with a 5 mm 30 degree lens supplied with a 5 F working channel continuous flow office hysteroscope (Bettocchi office hysteroscope, Karl Storz, Tuttlingen, Germany) without speculum or tenaculum. Briefly, following cervical passage and initial endometrial cavity investigation endometrial injury will be performed without energy modality (i.e. with scissors). Endometrial injury will perform first on the fundus by cutting into the endometrium (without injuring the myometrium) transversally. Later, vertical incisions will perform 0,5 cm apart each other, on the anterior and posterior walls of the uterus, 1-1.5 cm away from the fundus and one cut for each lateral wall
223827923|NCT01474447|BEHAVIORAL|Grinberg Method|The GM is a methodology of attention that teaches through expanding and focusing body attention to create a change and an improvement in pain and in quality of life. The method focuses on the way in which we experience pain, and offers an approach that trains people to use their attention and will in order to turn an unwanted experience that causes suffering, into a controlled experience in which they can take responsibility on the way they react to an existing pain. The method uses attention in order to learn the fixed ways in which we respond to pain in our body: where we focus our attention, what is the level of tension in our muscles, how we breathe and relax and more. It gives simple and effective tools to control all these, in order to create optimal conditions in the body to utilize its natural potential to recover and recuperate
223827924|NCT00075569|BIOLOGICAL|HspE7|500 micrograms of SGN-00101 (HspE7, Nventa, San Diego, CA) is a novel therapeutic vaccine consisting of a fusion protein containing an M. bovis BCG heat shock protein (Hsp65) covalently linked to the entire sequence of HPV 16 E7.
223827925|NCT05929365|PROCEDURE|colonoscopy|determine the mutation profile of resected colorectal neoplasia
223827926|NCT00439179|DRUG|cohort 1|Weekly gem + GW572016, 1000mg/day (combination)
223827927|NCT00439179|DRUG|cohort 2|Weekly gem + GW572016, 1500 mg/day (combination)
223827928|NCT00439179|DRUG|cohort 3|GEMOX + GW572016 1000 mg/day (combination)
223827929|NCT00439179|DRUG|cohort 4|GEMOX + GW572016 1500 mg/day (combination)
223827930|NCT05908890|DEVICE|Experimental Denture Adhesive|Adhesive will be applied to the partial denture(s) by a dental professional separate from the examiner and subject.
223827931|NCT05908890|DEVICE|Fixodent True Feel Denture Adhesive|Adhesive will be applied to the partial denture(s) by a dental professional separate from the examiner and subject.
223827932|NCT00088179|DRUG|pexelizumab in conjunction with CABG|
223827933|NCT04957732|DEVICE|Standard of Care (SoC)|SoC consisted of irrigation with normal saline, using the same proprietary abscess irrigation tip as the Irrisept arm. SoC was used at the initial visit and at each subsequent 48-hour visit interval (up to 96 hours) until abscess healing.
223827934|NCT04957732|DEVICE|Irrisept Delivery System|Irrisept is a manual, self-contained irrigation device capable of producing 7-8 psi of pressure for effective wound cleansing and irrigation. Irrisept contents include the Chlorhexidine Gluconate (CHG) solution, a 450 mL bottle, and Irriprobe applicator or an abscess irrigation tip. The bottle design allows users to control the pressure of the solution through manual bottle compression. The device had an option for use with an Irriprobe applicator or an abscess irrigation tip. Irrisept was used at the initial visit and at each subsequent 48-hour visit interval (up to 96 hours) until abscess healing.
223827935|NCT03148847|OTHER|Baseline care|
223827936|NCT03148847|OTHER|Referential's dissemination|
223835585|NCT05608941|OTHER|Respiratory muscle training|The training program will be carried-out with the Orygen Dual Valve. Individuals will perform a home-based intervention, split into two daily 20-min sessions (morning and afternoon), totaling 40 min per day, seven times a week, during eight weeks. Each daily session will be composed into four blocks of three minutes, with a two-minute rest between blocks. The initial training load for each participant will be set at 60% of his/her maximal baseline MIP and MEP for both inspiratory and expiratory strength training, respectively. Borg score of dyspnea and effort was also considered for adjusting training intensity, and scores from 4 to 6 were targeted. Once a week, a trained researcher will visit their homes, the MIP and MEP will be evaluated and the training load will be progressed to ensure that 60% of the new pressure values are maintained.
223827937|NCT03855410|BEHAVIORAL|S4E|The face-to-face version of S4E (i.e., Storytelling for Empowerment) is registered as a best-practice with the Substance Abuse and Mental Health Services Administration's (SAMHSA) National Registry of Evidence-Based Practices and Programs.The S4E mHealth app was developed in collaboration with youth in Southeast Michigan. Content produced for the application is based on scientific prevention principles in conjunction with youth input. To date, we have developed modules focused on youth alcohol and drug use, HIV and STIs. We now propose to develop modules focused on tobacco prevention and cessation. S4E aims to increase self-efficacy and communication about health risk behaviors. The face-to-face version of S4E has been shown to prevent and reduce substance use, including cigarette use, as well as increase (1) substance use prevention knowledge, (2) communication about health risk behaviors, and (3) perception of harm and self-efficacy in refusing licit and illicit substances.
223827938|NCT03855410|BEHAVIORAL|Attention-Matched Control Group|Participants in the Attention-Matched Control group will receive a PDF version of the tobacco module material, an enhancement to the usual care they would receive should they not join the study. Participants in this group will also receive usual care. The Clinic's usual care includes standard risk behaviors intake form, pamphlets highlighting resources on sexual, physical, and mental health, and other healthcare services.
223827939|NCT01035333|DRUG|Orlistat|60mg capsule three times a day for up to 6 months
223827940|NCT04310943|DRUG|Tislelizumab|Tislelizumab, 200mg, Q3W ,use until disease progression
223827941|NCT00994786|DRUG|pregabalin|pregabalin starting at 75 mg/day (at Study Week 0). Doses will be titrated up in 75 mg increments until a clinical response is achieved, as tolerated in the following manner: to 150 mg/day at the end of Study Week 1, to 225 mg/day at the end of Study Week 2, 300 mg/day at the end of Study Week 4, 450 mg/day at the end of Study Week 6 and to 600 mg/day at the end of Study Week 8. The maximum dose of pregabalin will be 600 mg/day.
223827942|NCT00994786|DRUG|Placebo|Placebo starting at 75 mg/day (at Study Week 0). Doses will be titrated up in 75 mg increments until a clinical response is achieved, as tolerated in the following manner: to 150 mg/day at the end of Study Week 1, to 225 mg/day at the end of Study Week 2, 300 mg/day at the end of Study Week 4, 450 mg/day at the end of Study Week 6 and to 600 mg/day at the end of Study Week 8. The maximum dose of pregabalin/placebo will be 600 mg/day.
223827943|NCT04570345|DRUG|ticagrelor monotherapy|• Drug: ticagrelor monothearpy after first 3 months dual therapy
223827944|NCT04570345|DRUG|Aspirin with P2Y12 receptor inhibitor|• Drug: aspirin plus ticagrelor dual therapy during 12 months
223827945|NCT03999905|BEHAVIORAL|Counseling training|Online training using Moodle.
223827946|NCT05761145|DIAGNOSTIC_TEST|Blood sample collection|Blood sample collection
223827947|NCT03395834|DEVICE|O3|O3 TM and INVOS® monitoring simultaneously in single patient during 3 min of vascular occlusion test
223827948|NCT01844115|DRUG|Placebo|
223827949|NCT01844115|DRUG|Vilazodone|Viibryd
223827950|NCT01072123|OTHER|Quest for the Code|interactive asthma-based computer program
223827951|NCT01873547|BIOLOGICAL|cell therapy|Mesenchymal stem cells derived from umbilical cord are transplanted directly into subarachnoid by Lumbar puncture.
223827952|NCT01873547|OTHER|rehabilitation|Patients only receive rehabilitation of limb function.
223827953|NCT00715663|DRUG|biphasic insulin aspart 30|No intervention is done. For study drug, start dose and frequency of administration to be prescribed by the physician as a result of normal clinical evaluation
223827954|NCT00758160|DRUG|OROS Methylphenidate|Participants will receive Osmotic Release Oral Delivery System (OROS) methylphenidate (MPH) 18 milligram (mg), 36 mg or 54 mg once daily for 8 weeks. Dose will be adjusted for each participant based on clinical responses and/or side effects.
223827955|NCT05686915|DIAGNOSTIC_TEST|MARS MRI|metal artifact reduction sequence (MARS) MRI to assess for fluid collections, ATLRs or other abnormalities
223827956|NCT05686915|DIAGNOSTIC_TEST|Titanium Labs|Labs to look at titanium levels in blood
223827957|NCT05686915|DIAGNOSTIC_TEST|Cobalt Labs|Labs to look at cobalt levels in blood
223827958|NCT05686915|DIAGNOSTIC_TEST|Chromium Labs|Labs to look at chromium levels in blood
223827959|NCT00038441|DRUG|DTI-015|DTI-015 injected through a catheter into center of brain tumor.
223827960|NCT01613027|BIOLOGICAL|Rituximab|Rituximab administered according to prescribing information and normal clinical practice.
223827961|NCT05100719|DRUG|alverine-citrate + simethicone and lactase|Patients who randomized in the first arm are treated with alverine-citrate + simethicone and lactase.
223827962|NCT05100719|DRUG|alverin-citrate + simethicone with placebo|Patients in the second arm receive alverin-citrate + simethicone with placebo without lactase.
223827963|NCT02220504|OTHER|Antipsychotic treatment discontinuation|Withdrawal of antipsychotic medication to stabilized patients.
223827964|NCT02220504|OTHER|Maintenance antipsychotic treatment|Maintenance antipsychotic medication to stabilized patients.
223827965|NCT05912114|DRUG|Mannitol|Mannitol, as an osmotic laxative, increases the colloid osmotic pressure in the intestinal lumen, which results in a hyperosmolar state in the intestine, thus allowing easy elimination of stools.
223827966|NCT05912114|DRUG|Polyethylene glycol electrolyte|Polyethylene glycol electrolyte is an inert polymer that cannot be absorbed by the body itself. Due to its high permeability, it retains water in the intestinal tract, increasing the amount of fluid retained in the intestine and softening the stool, thus acting as a diuretic.
223827967|NCT02084719|DEVICE|Oraquick HCV Rapid Antibody Test|
223827968|NCT02084719|DEVICE|Standard algorithm|
223827969|NCT03305224|DRUG|Ra-223 in combination with enzalutamide|Ra-223 (55 kBq/kg i.v.) 6 injections at 4 weeks interval in combination with enzalutamide 160 mg per a day
223827970|NCT00993317|DRUG|Placebo of CDP870|Given every 2 weeks until Week22 (SC)
223827971|NCT00993317|DRUG|CDP870 200mg|400mg CDP870 given at Week0, 2, 4 and thereafter 200mg CDP870 given every 2 weeks until Week 22(SC)
223827972|NCT00993317|DRUG|Methotrexate|"Received treatment with Methotrexate(MTX)for at least 24 weeks prior to the Baseline Visit.~The dose and route of administration of MTX had to have been stable for at least 8 weeks prior to the Baseline Visit. The minimum stable dose of MTX allowed is 10mg weekly."
223827973|NCT02712593|DIETARY_SUPPLEMENT|Niagen™ 100|
223827974|NCT02712593|DIETARY_SUPPLEMENT|Niagen™ 300|
223827975|NCT02712593|DIETARY_SUPPLEMENT|Niagen™ 1000|
223827976|NCT02712593|OTHER|Placebo|
223827977|NCT06495255|DIETARY_SUPPLEMENT|Human Milk Oligosaccharides (HMOs)|HMOs will be applied as a neutral-flavoured powder
223827978|NCT06495255|DIETARY_SUPPLEMENT|Control|will be applied as powder
223827979|NCT05774405|DRUG|Climara 0.1Mg/24Hr Transdermal System|Transdermal estradiol patch is used.
223827980|NCT05774405|OTHER|Hydrogel patch|Adhesive Hydrogel patch
223827981|NCT02265081|PROCEDURE|ultrasound|pelvic floor ultrasound
223827982|NCT02265081|PROCEDURE|uroflow-meter|uroflow meter: measurement of passed urine volume
223827983|NCT02691351|OTHER|Prospective Registry|"Survival and disease status follow-up at 1st primary treatment, 1st salvage treatment and 2nd salvage treatment~1. Regimen~2. Response Evaluation~3. SUSAR(Suspected, Unexpected, Serious, Adverse Reaction) collection"
223827984|NCT00002215|DRUG|Emivirine|
223827985|NCT00002215|DRUG|Nelfinavir mesylate|
223827986|NCT05075343|DEVICE|Custom foot orthoses|"3D printed custom foot orthoses (CFO) were designed by the same experimented podiatrist based on a detailed clinical and biomechanical examination and a 3D foot scan obtained for each participant. The degrees and types were adjusted at the CFO delivery according to each patient's comfort and tolerance.~The intervention period was 7weeks. The participants were taught to wear the CFO progressively during the first two weeks to allow for the lower limbs' muscles and structures to adjust to the CFO, and to wear the orthoses for the next 5 weeks, 7 days a week as often as they could."
223827987|NCT02710695|BEHAVIORAL|Control|This group will receive a standardized 10 minute discussion.
223827988|NCT02710695|BEHAVIORAL|Intervention|This group will receive a standardized 10 minute discussion
223827989|NCT00747526|DRUG|Rabeprazole sodium 5 mg|Type= exact number, unit= mg, number= 5, format= bead suspension formulation, route= oral use. Rabeprazole sodium 0.5 mg/kg (using increments of 1 mg dose) once daily from Day 1 to Day 5; possible extension using 5 mg once daily up to 28 consecutive days.
223827990|NCT00747526|DRUG|Rabeprazole sodium 10 mg|Type= exact number, unit= mg, number= 10, format= bead suspension formulation, route= oral use. Rabeprazole sodium 0.5 mg/kg (using increments of 1 mg dose) once daily from Day 1 to up to Day 14; possible extension using 10 mg once daily up to 28 consecutive days.
223827991|NCT00624663|DRUG|Rivastigmine|Administration 1 (A): 1 x 1.5 mg Exelon® Capsule (Novartis) + 1 x Placebo Capsule Administration 2 (B): 2 x 1.5 mg Exelon® Capsules (Novartis) Administration 3 (C): 2 x Placebo Capsules
223827992|NCT02579018|BEHAVIORAL|One hour supervised exercise session|All participants will participate in a one hour supervised exercise session. Participants will wear a physical activity monitor during the assessment for continuous monitoring of heart rate. Short, intense bouts of exercise will be interspersed with rest periods.
223827993|NCT02153359|DEVICE|High Efficiency Particulate Air Cleaner|
223827994|NCT02153359|DEVICE|Sham air cleaner|
223827995|NCT02238197|DRUG|Atrovent® Inhalation Solution|
223827996|NCT05024149|OTHER|infrared thermography (IRT)|The temperature and infrared thermography (IRT) images of the facial acupoints of three groups will be recorded by an infrared thermal-imaging camera.
223827997|NCT00056758|BIOLOGICAL|Autologous Dendritic Cell HIV Vaccination|
223827998|NCT05892523|PROCEDURE|THA|positioning the acetabular cup regarding abduction and anteversion angles with or without concern to spinal deformity
223827999|NCT04422639|RADIATION|SRS/SRT|Comparing pre-operative SRS/SRT to post-operative SRS/SRT
223828000|NCT01964521|DEVICE|Mepilex Transfer Ag|A soft silicone wound contact layer that absorbs and transfers exudate, maintains a moist wound healing environment and has antimicrobial properties.
223828001|NCT03377868|DIAGNOSTIC_TEST|Optic coherence tomography|Optic coherence tomography measures retinal layer thickness, macular volume , and cell inner plexiform layer.
223828002|NCT03377868|DIAGNOSTIC_TEST|Pulmonary function test|Pulmonary function test measures forced vital capacity and forced expiratory volume in one second.
223828003|NCT05434299|DRUG|TFX05-01|TFX05-01 for intravenous
223828004|NCT01108510|DRUG|COBI|Cobicistat (COBI) 150 mg tablet administered orally once daily
223828005|NCT01108510|DRUG|RTV|Ritonavir (RTV) 100 mg tablet administered orally once daily
223828006|NCT01108510|DRUG|ATV|Atazanavir (ATV) 300 mg capsule administered orally once daily
223828007|NCT01108510|DRUG|FTC/TDF|Emtricitabine (FTC) 200 mg/tenofovir disoproxil fumarate (TDF) 300 mg fixed-dose combination tablet administered orally once daily
223828008|NCT01108510|DRUG|COBI placebo|Placebo to match COBI administered orally once daily
223828009|NCT01108510|DRUG|RTV placebo|Placebo to match RTV administered orally once daily
223828010|NCT04924972|PROCEDURE|Blepharoplasty|90 patients undergoing bilateral upper eyelid blepharoplasty are randomly assigned to a suturing technique (running cutaneous or subcuticular Nylon (6-0 Prolene) sutures). Steri-strips will be used until suture removal 7 days after blepharoplasty for patient blinding.
223828011|NCT02796963|BEHAVIORAL|Crowdsourced intervention|The crowdsourced intervention is composed of three phases that cumulatively draw on crowd wisdom to engage the community: (1) a crowdsourcing contest to solicit optimal images/concepts/taglines; (2) a designathon to formulate optimal HIV testing campaigns; (3) a process of localization unique to each of the eight cities.
223828012|NCT02796963|BEHAVIORAL|Traditional intervention campaign|The pre-intervention period will include conventional HIV testing campaigns organized by local CDC, Community-Based Organization (CBO), and partners. These are typically designed by experts and social marketing companies.
223828013|NCT04246515|DEVICE|Blood Flow Restriction Training|Vascular occlusion of the injured limb.
223828014|NCT04246515|DEVICE|Sham Blood Flow Restriction Training|Blood Flow Restriction material will be attached to the limb without vascular occlusion.
223828015|NCT04246515|OTHER|Classic rehabilitation|Classic rehabilitation protocol after a hamstring injury consisiting out of stretching, strength, core stability,...
223828016|NCT00003415|DRUG|amifostine trihydrate|
223828017|NCT00003415|DRUG|topotecan hydrochloride|
223835586|NCT05608941|OTHER|Control|The control/sham group will underwent exactly the same protocol and weekly monitoring at home, but the participants will receive the devices without resistance of the spring.
223828018|NCT03096301|DEVICE|Low-intensity laser|Laser applications will be applied as initial treatment, with 2 sessions per week. A wave length of 780 nm, with an energy density of 25 J/cm2, a power of 50 mW and power density of 1.25 W/cm2, will be used for a duration of 20 seconds per point, resulting in a total energy of 1J per point. The laser will be applied at each point, using a conventional tip in contact with the skin, thus considering an area of 0.04 cm2
223828019|NCT03096301|DEVICE|occlusal plates|"The group undergoing treatment with occlusal plates will be instructed to use the device during sleep, 8 hours per night, for a period of 12 months. The plates will be made following the principles established by Okenson (1998).~Participants will be molded with alginate to obtain models. In the upper model, a 2 mm acetate plate will be made, to be later replaced with acrylic resin (STRINI et al., 2009), and these plates will be adjusted in centric relation, to promote occlusal stability and disocclusion guide.~Weekly follow-up and adjustments will be performed during the evaluation period, until the completion of treatment"
223828020|NCT03096301|DEVICE|Placebo|For the placebo group, all the measures described for the group 1 (LIL) will be adopted, however the laser equipment will remain switched off.
223828021|NCT06072820|DEVICE|Salivary Sampling|"Inclusion visit: After signature of the informed consent, all subjects will perform 3 consecutive Endotest® Diagnostic during the visit and 1 at-home.~Circadian circle visit: 6 included subjects will be asked to come back for a full day. They will have to perform 17 Endotest® Diagnostic: 14 on study site and 3 at home after the visit.~Repeatability-intermediate fidelity-stability-interferences visit: a maximum of 16 included subjects will be asked to come back for this visit. They will have to perform 17 Endotest® Diagnostic: 14 on study site and 3 at home after the visit."
223828022|NCT00592046|DRUG|ZIO-101 (Darinaparsin)|ZIO-101 (Darinaparsin) given for five consecutive days to be repeated every 28 days for up to six months. This is a dose escalation study.
223828023|NCT02454036|BEHAVIORAL|BBI intervention|Psychological intervention designed to reduce stress and enhance quality of life
223828024|NCT06038903|OTHER|caffeine consumption expectation|The group to which the Short-form caffeine expectation questionnaire (B-CaffeQ) was applied, which evaluated the expectations from caffeine consumption.
223828025|NCT01832103|DRUG|MK-7145|
223828026|NCT01167686|DIETARY_SUPPLEMENT|Gardemont Goldtrain Plus (GT+)|Four tablets of 760 mg of GT+ administered three times a day for seven consecutive days and similar placebo tablets given to the control arm
223828027|NCT01290536|DEVICE|Selective internal radiation therapy to the liver using Yttrium-90 glass microspheres (TheraSphere)|Administration of Yttrium-90 glass microspheres (TheraSphere) into the hepatic artery
223828028|NCT06236360|BEHAVIORAL|Mediterranean Diet Intervention|The primary goal is to evaluate whether tele-intervention can elevate the level of flavonoids, anthocyanins, proteins, omega-3 fatty acids, short fatty acids, fruits and vegetables, and fibers (all previously associated with a better response to immunotherapy) and limit foods with added sugars.
223828029|NCT05987501|DIAGNOSTIC_TEST|Multimodal ultrasound|Contrast enhanced ultrasound and shear wave elastography on target intestinal loop are perfomed before and at different timepoints after treatment induction
223828030|NCT04358796|DEVICE|Hyperbaric oxygent treatment|Subjects will enter the oxygen chamber. ATA will be elevated to 2 ATA. They will breath 100% oxygen while solving cognitive tests designed to assess their cognitive capacities
223828031|NCT04358796|DEVICE|Control hyperbaric oxygen treatment|Subjects will enter the oxygen chamber. ATA will be elevated to 1.2 ATA for a short while and the decreased back to 1 ATA. They will breath air while solving cognitive tests designed to assess their cognitive capacities
223835587|NCT05352451|BEHAVIORAL|Interventional Survey|Complete the surveys before and after attending coaching sessions. The two interviews each lasting for about one hour and will be done in-person or through video-conferencing meeting (depending on which is more convenient for you) with a study team member. The first interview, will ask about some basic information. In the second and last interview, will ask about experience of the coaching sessions and about how you feel about your decisions regarding your treatment and care. At each of the two time points, you and your caregiver will be interviewed separately. The video-conferencing, will be conducted through Zoom, which is a secure, widely used software which allows people to communicate remotely with computers, tablets, or smart phones. The software is available free of charge to you if you have a computer or other suitable device and internet.
223828032|NCT01900574|DRUG|Golimumab|Golimumab will be administered subcutaneously. For participants weighing less than 45 kg, the dose of golimumab at Week 0 will be 90 mg/m2 (up to 200 mg) and 45 mg/m2 (up to 100 mg) at Weeks 2, 6, and 10. For participants weighing 45 kg or more, the dose of golimumab at Week 0 will be 200 mg and 100 mg at Weeks 2, 6, and 10. From Week 14, the dose of golimumab will be 45 mg/m2 and 100 mg, every 4 weeks for participants weighing less than 45 kg and 45 kg or more, respectively. From Week 18, participants weighing 45 kg or more have the option to administer golimumab at home after being properly trained. At Week 14 or at any time after, the participants have the option to decrease their dose of golimumab to 50 mg (weighing 45 kg or more) or 22.5 mg/square meter (less than 45 kg) at the discretion of the investigator. A single dose increase back to 100 mg or 45 mg/m2 is permitted based on the investigator's assessment of an increase in a participant's ulcerative colitis disease activity.
223828033|NCT01258660|DRUG|EE 0.03 mg/DRSP 3 mg/Metafolin + folic acid placebo|Combination EE/DRSP/ Metafolin \[0.030 mg ethinylestradiol (EE) + 3 mg drospirenone (DRSP) + 0.451 mg Metafolin\] given orally in a cyclic regimen for 24 weeks (6 cycles) in combination with folic acid placebo tablets (encapsulated). Each treatment cycle consisting of once daily hormone and Metafolin treatment for 21-days followed by once daily hormone free, Metafolin only regimen for 7 days. This phase was followed by 20 weeks (5 cycles) folate elimination phase consisting of oral administration of Yasmin alone.
223828034|NCT01258660|DRUG|EE 0.03 mg/DRSP 3 mg (Yasmin) + folic acid|Yasmin \[0.030 mg ethinylestradiol (EE) + 3 mg drospirenone (DRSP)\] in combination with folic acid tablets 0.4 mg (encapsulated), given orally in a cyclic regimen for 24 weeks (6 cycles). Each treatment cycle providing once daily hormone and folic acid treatment for 21 days followed by once daily hormone free, folic acid only regimen for 7 days (encapsulated). This phase was followed by 20 weeks (5 cycles) folate elimination phase consisting of oral administration of Yasmin alone.
223828035|NCT01356992|DRUG|Enoxaparin|Drugs will be provided by the sponsor to the study's patients on the reference presentation: 40 mg/0.4mL, 60 mg/0.6 mL and 80 mg/0.8 mL (solution for injection of enoxaparin sodium, 1 mg/ kg Sanofi-Aventis) or Eurofarma enoxaparin sodium (1 mg/ kg). The patients will use the drug corresponding to the arm of the study to which they were allocated. The drug administration must be performed through subcutaneous via on the dose of 1 mg/kg every 12 hours for at least 2 days and kept until the patient is discharged.
223828036|NCT02867969|OTHER|Motor training|The motor training will comprise of demanding coordinative exercises based on commercially available developed by Microsoft Game Console (XBOX Kinect™) exergames that specifically target ataxia dysfunctions.
223828037|NCT05768724|BEHAVIORAL|intervention diet|"The Resmena diet: It was characterized by a higher meal frequency, consisting of seven meals/d (including breakfast, lunch, dinner, and two snacks in the morning and two snacks in the afternoon), and by a different macronutrient distribution; 40% total energy value from CHO, 30% from proteins and 30% from lipids. This pattern tried to reinforce high n-3 polyunsaturated FA (n-3 PUFA) and high natural antioxidant food consumption and promoted low GL CHO intake as well as a high adherence to the Mediterranean diet. It also maintained a healthy FA profile and a cholesterol content of less than 300 mg/day.~* Daily meal plans were created according to the energy intake of the participants and sent to the participants via social media every week. Participants were asked to keep 3-day diet records to evaluate their compliance with the diet and were invited to the research center once a month to be checked."
223828038|NCT05768724|BEHAVIORAL|control diet|"Control diet: It was based on the American Heart Association (AHA) guidelines, including 3-5 meals per day, a macronutrient distribution of 55% total energy value from carbohydrates, 15% proteins, and 30% lipids, a healthy fatty acids (FA) profile and a cholesterol consumption lower than 300 mg/day.~\- Daily meal plans were created according to the energy intake of the participants and sent to the participants via social media every week. Participants were asked to keep 3-day diet records to evaluate their compliance with the diet and were invited to the research center once a month to be checked"
223828039|NCT03103230|DEVICE|Cortical magnetic stimulation|Motor Evoked Potentials of lips and hand recorded after cortical magnetic stimulation
223828040|NCT04825860|DRUG|SEP-363856 50 mg|Subjects will take one tablet of study drug per day at approximately the same time each evening at bedtime. Study drug may be taken orally with or without food.
223828041|NCT04825860|DRUG|SEP-363856 75 mg|Subjects will take one tablet of study drug per day at approximately the same time each evening at bedtime. Study drug may be taken orally with or without food.
223828042|NCT04825860|DRUG|Placebo|Subjects will take one tablet of study drug per day at approximately the same time each evening at bedtime. Study drug may be taken orally with or without food.
223828043|NCT00040092|DRUG|Virulizin®|
223828044|NCT00781534|DRUG|Ginseng|Each of the 3 arms will be compared to determine if there is any clinical difference in blood sugars between the 3 groups
223828045|NCT00781534|DRUG|Ginseng|
223828046|NCT00781534|DRUG|ginsenoside RE|active metabolite of ginseng
223828047|NCT00781534|DIETARY_SUPPLEMENT|Placebo (sugar pill)|placebo group
223828048|NCT05046977|PROCEDURE|Single osteotomy|Single tibial osteotomy
223828049|NCT05046977|PROCEDURE|Double Osteotomy|Double Tibial Osteotomy
223828050|NCT04876651|OTHER|177Lu-DOTA-rosopatamb|Two single intravenous (IV) injections of 76 mCi each (equivalent to a 45 mCi/m2 dose in a standard 1.7m2 individual) of 177Lu-DOTA- rosopatamab, given 14 days apart, plus best SoC
223828051|NCT04876651|DRUG|Standard of Care|enzalutamide or abiraterone \[+ prednisone/prednisolone)\] or docetaxel
223828052|NCT06266702|OTHER|Experimental Oil with Phospholipids|Consumed on white bread
223828053|NCT06266702|OTHER|Control Polyunsaturated Oil Blend|Consumed on white bread
223828054|NCT00089713|DRUG|alagebrium chloride (ALT-711)|
223828055|NCT02829333|OTHER|general anesthesia and patient controlled intravenous analgesia|Patients receive general anesthesia intraoperative period and continuous intravenous analgesia postoperation
223828056|NCT02829333|OTHER|spinal anesthesia and continuous postoperative epidural analgesia|Patients receive spinal anesthesia intraoperative period and continuous epidural analgesia postoperation
223828057|NCT01933386|DEVICE|SoundBite|Non-surgical removable bone conduction device via the teeth.
223828058|NCT03791203|BEHAVIORAL|Calorie restriction (MACR)|This was a randomized, single-blind controlled trial with modified alternate-day calorie restriction (MACR) as the active intervention and normal habitual diet as control at Hospital University of Sains Malaysia.
223828059|NCT04192630|DEVICE|CVisc50 OVD|Bausch + Lomb CVisc50 Cohesive OVD
223828060|NCT04192630|DEVICE|ProVisc OVD|ProVisc OVD
223828061|NCT04192630|PROCEDURE|Cataract Surgery|Cataract Surgery
223828062|NCT03820791|DEVICE|Placement of a poster in patients' rooms|Patients and their caregivers will be exposed to the poster for one month
223828063|NCT03941743|DRUG|Fingolimod|Given PO
223828064|NCT03941743|DRUG|Fingolimod Hydrochloride|Given PO
223828065|NCT03941743|OTHER|Questionnaire Administration|Ancillary studies
223828066|NCT01193582|BIOLOGICAL|Prevenar|"Dosage form: intramuscular injection Dosage: 0.5 ml~Frequency:~4 doses starting from 121 to \< 212 days of age"
223828067|NCT01193582|BIOLOGICAL|Prevenar|"Dosage form: intramuscular injection Dosage: 0.5 ml~Frequency:~3 doses starting from 212 days to \< 12 months of age"
223828068|NCT01193582|BIOLOGICAL|Prevenar|"Dosage form: intramuscular injection Dosage: 0.5 ml~Frequency:~2 doses starting from 12 months to \< 24 months of age"
223828069|NCT01193582|BIOLOGICAL|Prevenar|"Dosage form: intramuscular injection Dosage: 0.5 ml~Frequency:~1 dose starting from 24 months to \< 72 months of age"
223828070|NCT01683240|DEVICE|cholangioscopy (Frimberger)|cholangioscopy with Frimberger duodenoscope system by the company of Karl Storz GmbH
223828071|NCT03154840|DRUG|Eutropin 4IU, Eutropin AQ 12IU, Eutropin Pen 36IU|Investigate the Relative Bioavailability among Different Eutropin Formulations
223828072|NCT02328976|OTHER|functional Magnetic Resonance Imaging (fMRI)|both chronic and episodic patients with migraine have a specific functional Magnetic Resonance Imaging (fMRI)
223828073|NCT02110524|DEVICE|Percutaneous Transluminal Angioplasty|
223828074|NCT01425632|DRUG|TAU-284|TAU-284 Low
223828075|NCT01425632|DRUG|TAU-284|TAU-284 High
223828076|NCT01425632|DRUG|Placebo|Placebo
223828077|NCT01339364|OTHER|Didactic Lecture|2 sessions of didactic lecture with PowerPoint presentations each delivered by a special lecturer. whole education period lasts 3 hours.
223828078|NCT01339364|OTHER|Interactive Lecture|2 sessions of brief interactive lectures followed by case discussion sections.
223828079|NCT01339364|OTHER|Lecture plus Small Group Education|A 1.5 hours session of didactic lecture followed by a session of small group education with 3 simulated patients.
223828080|NCT02512510|DRUG|TD-4208|
223828081|NCT02512510|DRUG|Placebo|
223828082|NCT05947123|BEHAVIORAL|Patient health care observational follow up after 2 prophylactic tratments|Real-life, observational, single-center cohort study to describe the efficacy of prophylactic treatment in patients after failure of at least 2 prophylactic treatments. Patients included in the study will be followed up in consultations or day hospitals according to their usual care, and will be asked to complete the MIDAS, HIT-6, PGIC, HAD and WPAI questionnaires at each visit. Data describing their care will be extracted from computerized patient records.
223828083|NCT02582164|DEVICE|Duke Biomedical Engineering's Long-working distance OCT|The long-distance SSOCT system designed by Duke University Biomedical Engineering Department allows the user to quickly image an eye at a much greater distance (typically 20-40 cm away but this could be longer or shorter). This could potentially be used while briefly attracting a child's attention to an illuminated image over the imaging lens. With this methodology, young patients would not need to place their eye close to the system and could be rapidly imaged during the short interval while they glance at the image from the correct distance.
223828084|NCT03349372|PROCEDURE|Hematopoietic stem cell transplantation|Hematopoietic stem cell transplantation
223828085|NCT01464255|DEVICE|ocufilcon D|Participants wear a first pair of lenses for one week and then crossover and wear an alternate second pair of lenses for one week.
223828086|NCT01464255|DEVICE|ocufilcon B|Participants wear a first pair of lenses for one week and then crossover and wear an alternate second pair of lenses for one week.
223828087|NCT01231503|BIOLOGICAL|GSK Biological's Investigational Malaria Vaccine 257049|3 doses, intramuscular (IM) route, in left antero-lateral thigh, as follows: 1) RTS,S Neo-10-14 Group at less than (=\<) 7 days, at 10 and 14 weeks (wks) of age; 2) RTS,S Neo-10-26 Group =\< 7 days, at 10 and 26 wks of age; 3) RTS,S 6-10-14 Group at 6, 10 and 14 wks of age; 4) RTS,S 6-10-26 Group at 6, 10 and 26 wks of age; 5) Engerix-B Neo/RTS,S 6-10-26 Group at 6, 10 and 26 wks of age; 6) RTS,S 10-14-26 Group at 10, 14 and 26 wks of age; 7) RTS,S 14-26-9M Group at 14 and 26 wks of age and at 9 months of age
223828088|NCT01231503|BIOLOGICAL|Engerix-B|1 dose, intramuscular route: left antero-lateral thigh at birth (=\< 7 days of age)
223828089|NCT01231503|BIOLOGICAL|Tritanrix HepB Hib|3 doses, intramuscular route: right antero-lateral thigh at 6, 10 and 14 weeks of age
223828090|NCT01231503|BIOLOGICAL|BCG|1 dose, intradermal route, in shoulder at birth (=\< 7 days of age)
223828091|NCT01231503|BIOLOGICAL|OPV|4 doses, orally, at birth (=\< 7 days of age) and at 6, 10 and 14 weeks of age
223828092|NCT01231503|BIOLOGICAL|Rouvax|1 dose, intramuscular (IM) route, in left antero-lateral thigh, at 9 months of age
223828093|NCT03126032|OTHER|GlycoCheck™-System|"Consecutive, sublingual measurements of endothelial glycocalyx with GlycoCheck™-System will be obtained at presentation, as well as during the inpatient treatment of the patients with suspected sepsis.~Blood sample will be drawn in all groups at time of assessment. Besides that, in patients with suspected sepsis blood samples will be drawn for further microbiologic and laboratory analysis at day 1 and day 7 of their hospital stay."
223828094|NCT04503382|OTHER|Kindness Media|As described above, the intervention is a series of short videos that display acts of kindness or ideas about kindness. These videos are edited together into one reel that was 8 minutes long.
223828095|NCT06106074|DRUG|Tolebrutinib|Tablet, oral
223828096|NCT06106074|DRUG|Placebo|Tablet, oral
223828097|NCT05811429|OTHER|Aerobic exercises|16 sessions for 8 weeks ,per week 2 sessions will be given.
223828098|NCT05811429|OTHER|Pilates exercises|16 sessions for 8 weeks ,per week 2 sessions will be given.
223828099|NCT01868074|DEVICE|Insole|Custom-molded arch-supporting insole
223828100|NCT00029575|DEVICE|Surgi-Vision Guidewire Coil|
223828101|NCT02663375|DEVICE|ACURATE TA™ Transapical Aortic Bioprosthesis|ACURATE TA™ Transapical Aortic Bioprosthesis is intended for subjects with severe symptomatic aortic stenosis and are considered high risk for surgical conventional Aortic Valve Replacement.
223828102|NCT06425978|DRUG|Cellular Matrix / A-CP-HA Kit|"For infiltration, a prior preparation of the region with anesthetic cream is performed, procaine 25 mg/g + lidocaine 25 mg/g (Emla 5% cream) in the vulvar area and vaginal introitus. Occlusion of the area with plastic film is performed for 20 minutes. After asepsis and antisepsis, infiltration is performed with mesotherapy needles 31G 4mm, using the technique of superficial point-to-point mesotherapy microinjections, in the vestibule and the first 3 cm of the posterior wall of the vagina."
223828103|NCT06425978|DRUG|Local estrogen therapy (Blissel, estriol 50 micrograms/g vaginal gel)|Blissel®, Estriol vaginal gel 50 micrograms/g, daily application for 15-21 days in a row, then two times a week for 24 weeks (6 months). Application instructions will be explained to the patients. The gel should be applied in the vagina using an applicator with the marked dose, the full applicator should be inserted into the vagina and emptied, preferably at night.
223828104|NCT04574154|PROCEDURE|FIB|FIB with ultrasound: Ropivacaine 0.5% 40 ml
223828105|NCT04574154|PROCEDURE|ESPB|ESPB (L4) with ultrasound: Ropivacaine 0.5% 40 ml
223828106|NCT04574154|PROCEDURE|spinal anesthesia|bupivacaine 0,5% 2.2 ml
223828107|NCT03982888|PROCEDURE|Deep Brain Stimulation|Stimulation of the nucleus accumbens via 2 electrodes implanted in the brain per patient to reduce self-injurious behaviours.
223828108|NCT03982888|DEVICE|DBS|"Use of the Medtronic DBS device. DBS device consists of 2 parts:~1. DBS lead, a thin wire with 2 electrical contacts implanted into pre-determined brain regions, and~2. Implantable pulse generator, a small device containing the batter and computer source placed under the skin of the chest to generate electrical pulses"
223828109|NCT01763528|OTHER|nutrition intervention|high protein diet
223828110|NCT05344989|DRUG|APNmAb005|Administered by IV infusion
223828111|NCT05344989|DRUG|Placebo|Administered by IV infusion
223828112|NCT00160160|DRUG|eprosartan/HCTZ|
223835588|NCT06195241|DRUG|DaxibotulinumtoxinA|Patients with Benign Essential Blepharospasm (BEB) or Hemifacial spasms (HFS) will be treated with DaxibotulinumtoxinA-Lanm (Daxxify) using a 2:1 conversion rate of Daxxify to Botox.
223828113|NCT05390138|BEHAVIORAL|Smart Sleep Apnea Self-management Support Programme (4S)|The experimental group will receive usual care and Smart Sleep Apnea Self-management Support Programme (4S). The 4S includes two interview sessions, instant messages, phone calls, continuous personalized chat-based messaging and phone call support and hotline services in relation to self-management. An e-platform will be used for self-monitoring and group sharing sessions will be conducted for experience sharing.
223828114|NCT05390138|BEHAVIORAL|General Hygiene Information (GH)|The control group will receive usual care and general hygiene information (GH). The GH includes two GH sessions, instant messages, phone calls, continuous personalized chat-based messaging and phone call support and hotline services in relation to general hygiene information. An e-platform will be used for self-monitoring and group sharing sessions will be conducted for experience sharing.
223828115|NCT05214014|BIOLOGICAL|Autologous Regulatory Т-cells|Autologous Regulatory Т-cells obtained from CD4+CD25+ cells isolated from PBMC and cultured with the cocktail of cytokines and antibodies to induce proliferation of Tregs
223828116|NCT05214014|OTHER|Standard treatment according to the clinical protocols|Standard treatment of Systemic Sclerosis according to the clinical protocols
223828117|NCT00002720|DRUG|tamoxifen citrate|
223828118|NCT00002720|PROCEDURE|conventional surgery|
223828119|NCT02904109|DRUG|Triflusal|Once daily oral administration of 600 mg triflusal Disgren® for 8 days.
223828120|NCT02904109|DRUG|Placebo|Once daily oral administration of placebo mannitol for 8 days.
223828121|NCT02112058|BEHAVIORAL|A Family-Strengthening Program for Low-Income Families|"The program's central and most intensive component was a series of relationship and marriage education workshops for groups of couples that was offered in the first four to five months of enrollment in the program.~Complementing the workshops was a second component, offered for the year after enrollment, that consisted of supplemental activities: educational and social events that were intended to build on and reinforce lessons from the curricula.~The third component, family support services, paired couples with a specialized staff member who maintained contact with them and facilitated their participation in the other two components throughout the duration of the program."
223828122|NCT00580229|DRUG|prednisone|prednisone 40mg by mouth 30-60 minutes prior to rituximab
223828123|NCT00301002|DRUG|Alefacept|
223828124|NCT06237374|BEHAVIORAL|Digital Vaccine Education Training & Patient-facing Chatbot Tool|The first part of the intervention is a digital training provided to CHWs, which includes videos and job aids on vaccine education to support patient communication. The second part of the intervention is a patient-facing chatbot designed to provide key information about routine immunization that CHWs can share with their patients through the social media and messenger application, WhatsApp.
223828125|NCT06237374|BEHAVIORAL|Standard Training|All CHWs in the study will receive the standard CHW training that is provided on an ongoing basis by Lwala Community Health Alliance.
223828126|NCT02394899|BEHAVIORAL|Play therapy|Short films that have been developed to deliver a series of child development messages will be shown at the monthly visits. Nine modules of approximate length 3 minutes each have been developed and cover the topics: Love, Comforting baby, Talking to babies and children, Praise, Using bath time to play and learn, Looking at books, Simple toys mothers can make, Drawing and games, and Puzzles. Nurses at the Sickle cell Unit (SCU) will be trained to discuss the video messages with the mothers/caregivers, demonstrate activities they can do with their children and how to make simple toys from household materials. Mothers/caregivers will practice some of the activities and they will be encouraged to make them part of their daily routine.
223828127|NCT02394899|OTHER|Problem solving skills|Problem solving therapy (PST) aims to empower patients or caregivers in attending to daily challenges. It is based on cognitive behavioural therapy and can be used in primary care settings. It encourages persons to use existing resources and skills to function better and find solutions to problems. It will be delivered in 6 sessions over the 6-week period and will last for about 30 minutes per session. The stages of PST are: identification of the problems; generating possible solutions; evaluating and implementing preferred solution; and evaluating to see if the solutions were successful. The parent/caregiver will be taught a process of problem solving with reference to general everyday problems as well as specific problems which may arise while parenting a child with SCD.
223828128|NCT04131959|DEVICE|CytoSorb 300 mL device|Intra-operative CytoSorb hemoadsorption of ticagrelor during cardiopulmonary bypass
223828129|NCT04642469|DRUG|Durvalumab|Intravenous administration of Durvalumab
223828130|NCT04642469|OTHER|Placebo|Placebo Comparator
223828131|NCT02359591|OTHER|text-based or multimedia|subjects fills in a questionnaire regarding whether the child meets the developmental milestones for his/her developmental age.
223828132|NCT02767700|GENETIC|NGS|Next generation sequencing
223828133|NCT04924140|DRUG|Aducanumab|Administered as specified in the treatment arm
223828134|NCT02622633|DEVICE|Epidural Electrode|Epidural electrode of high frequency (50Hz) stimulation in the dorsolateral prefrontal cortex.
223828135|NCT05592080|RADIATION|MRI|MRI-mDIXON-Quant examinations, anthropometric measures, body composition, hormonal and biochemical assays were performed in all participants, and the liver fat fraction (LFF) and muscle fat fraction (MFF) represented the fat content in the liver and skeletal muscle, respectively.
223828136|NCT01461993|BIOLOGICAL|rLP2086 and Gardasil|Gardasil vaccine and rLP2086 injection will be given to the subject concomitantly in Group 1 at Months 0, 2 and 6.
223828137|NCT01461993|BIOLOGICAL|rLP2086|Injections of rLP2086 and saline will be given to the subject concomitantly in Group 2 at Months 0, 2 and 6.
223828138|NCT01461993|BIOLOGICAL|Gardasil|Injections of saline and Gardasil vaccine will be given to the subject concomitantly in Group 3 at Months 0, 2 and 6.
223828139|NCT03309163|DRUG|Tramadol|Patient-controlled intravenous analgesia with Tramadol
223828140|NCT03309163|DRUG|Hydromorphone|Patient-controlled intravenous analgesia with Hydromorphone
223828141|NCT03309163|DRUG|Ropivacaine (Epidural analgesia)|Patient-controlled epidural analgesia with Ropivacaine.
223828142|NCT02228525|DRUG|selinexor (KPT-330)|
223828143|NCT00719303|BEHAVIORAL|Behavioral Dietary Intervention|Receive dietary intervention
223828144|NCT00719303|BEHAVIORAL|Compliance Monitoring|Complete daily fat gram and step diaries
223828145|NCT00719303|OTHER|Counseling|Undergo face-to-face and telephone counseling
223828146|NCT00719303|OTHER|Educational Intervention|Receive educational materials
223828147|NCT00719303|BEHAVIORAL|Exercise Intervention|Undergo physical activity intervention
223828148|NCT00719303|OTHER|Laboratory Biomarker Analysis|Correlative studies
223828149|NCT00719303|OTHER|Quality-of-Life Assessment|Ancillary studies
223828150|NCT00719303|OTHER|Questionnaire Administration|Ancillary studies
223828151|NCT00680056|DRUG|Formoterol plus Placebo (Tiotropium)|Formoterol 12mcg-capsules (2x/d) + Placebo (Tiotropium) (1x/d). Double-blind medication will be dispensed in HandiHalers and Aerolisers during 2 weeks.
223828152|NCT00680056|DRUG|Formoterol plus Tiotropium|Formoterol 12mcg-capsule (2x/dia) + Tiotropium 18mcg-capsule (1x/d). Double-blind medication will be dispensed in HandiHalers and Aerolisers during 2 weeks.
223828153|NCT03333174|DIAGNOSTIC_TEST|Cardiorespiratory monitoring|The investigators will use high resolution physiologic monitoring of Heart Rate, Respiratory Rate, Pulse oximetry, (and near-infrared monitoring as well as microcapnography in selected infants) to evaluate control of breathing (apnea, bradycardia, desaturations)
223828154|NCT05522920|OTHER|Therapy with and without spinal cord stimulation|Conventional therapy only will be followed with conventional therapy combined with electrical spinal cord stimulation.
223828155|NCT00219141|DRUG|Aliskiren 150/300 mg|Aliskiren 150 mg tablets
223828156|NCT00219141|DRUG|Losartan 50/100 mg|Losartan 50 or 100 mg capsules
223828157|NCT00219141|DRUG|Aliskiren placebo|Aliskiren 150 mg placebo tablet
223828158|NCT00219141|DRUG|Losartan 50/100 mg placebo|Losartan 50/100 mg placebo capsules
223828159|NCT03489005|DRUG|BIA 5-1058|"Subjects will receive BIA 5-1058 tablets (containing 100 mg) as single, oral doses 30 minutes after the start of a moderate mealas follows:~* 400 mg BIA 5 1058, as 4 × 100 mg tablets and 8 placebo tablets~* 1200 mg BIA 5 1058, as 12 × 100 mg tablets"
223828160|NCT03489005|DRUG|Placebo Oral Tablet|"Matching placebo tablets administered as follows:~\- placebo, as 12 × 0-mg tablets"
223828161|NCT03489005|DRUG|Moxifloxacin 400 mg|"Administered as follows:~\- 400 mg moxifloxacin, as 1 × 400-mg tablet"
223828162|NCT04763135|DRUG|Mirtazapine|"Orally disintegrating tablets of mirtazapine introduced at the dose of 15 mg and increased up to 45 mg per day during 56 days.~Doses escalation: based on symptom management and side effect assessment."
223828163|NCT04763135|DRUG|Escitalopram|"Orally disintegrating tablets of escitalopram introduced at the dose of 10 mg (or 5 mg for patients older than 65) and increased up to 20 mg per day during 56 days.~Doses escalation: based on symptom management and side effect assessment."
223828164|NCT01673360|DEVICE|Elevate PC|List of AMS prolapse products
223828165|NCT01673360|DEVICE|Mini Arc Pro|List of AMS Urinary Incontinence devices
223828166|NCT01673360|DEVICE|RetroArc|List of AMS Urinary Incontinence devices
223828167|NCT03957135|PROCEDURE|Laparoscopic distal pancreatectomy|Laparoscopic resection of the diseased portion of the pancreas for treatment of pancreatic cancer
223828168|NCT03957135|PROCEDURE|open distal pancreatectomy|Open resection of the diseased portion of the pancreas for treatment of pancreatic cancer
223828169|NCT02595177|PROCEDURE|Cataract surgery with intraocular lens implantation.|Phacoemulsification under topical anesthesia with intraocular lens implantation.
223828170|NCT06233123|BEHAVIORAL|the Medisafe android application (https://www.medisafe.com).|software for Android mobile phones that can remind the patient of his treatment on time
223828171|NCT01264029|BEHAVIORAL|Mindful Tai Chi Intervention|
223828172|NCT01264029|BEHAVIORAL|Mindfulness Meditation|
223828173|NCT01264029|BEHAVIORAL|Mall Walking|
223828174|NCT01264029|BEHAVIORAL|Weekly Discussion|
223828175|NCT00802828|DRUG|Famotidine Tablets, 40 mg|
223828176|NCT05273086|BEHAVIORAL|Sleep Intervention Group|"The intervention group will acquire skills to improve their quality of sleep such as:~* Acquisition of notions of chronobiology.~* Location of the nervous structures involved in biological rhythms.~* Awareness of the existence of three times that direct our biological rhythms, and of the need for them to be synchronized.~* Self-knowledge of the chronotype and the degree of adjustment of the three times.~* Knowledge of the variables that determine a good quality of sleep.~* Applications of chronobiology to the field of nursing. Recommendations for nurses and patients.~* Self-knowledge of the quality of sleep and the health status of the circadian system."
223828177|NCT06116214|OTHER|Vachellia Nelotica|As a root canal irrigant (herbal)
223828178|NCT06116214|OTHER|sodium hypochlorite|As a root canal irrigant
223828179|NCT04412252|DRUG|Tofacitinib|10 mg tofacitinib administered as two 5 mg tablets or solution taken orally twice daily for 14 days
223828180|NCT04412252|OTHER|Placebo|Tofacitinib-matching placebo administered as tablets or solution taken orally twice daily for 14 days
223828181|NCT02838628|DRUG|50 mg of KX2-391 Ointment 1%|Dose: 50 mg; Route of administration: Topical
223828182|NCT02838628|DRUG|50 mg of KX2-391 Ointment 1%|Dose: 50 mg; Route of administration: Topical
223828183|NCT02547571|DRUG|High volume PEG split-dose|Colyte® or PegLyte® will be provided to the subject who will be asked to drink 2L of the preparation starting at 7:00 PM the day before the procedure at a rate of 240 mL every 10 minutes until completed. The second dose of 2L of preparation will be taken the morning of the colonoscopy starting 4-5 hours prior to the planned procedural time at a rate of 240 mL every 10 minutes until completed.
223828184|NCT02547571|DRUG|Low volume PEG split-dose|Bi-PegLyte® will be provided to the subject who will be asked to ingest 3 tabs of Bisacodyl 5 mg (total 15 mg) at 2:00 PM the day before the procedure. After the first bowel movement, or if there is no bowel movement within 6 hours of taking the Bisacodyl tablets, the subject will be asked to drink 1L of the solution at a rate of 240 mL every 10 minutes until the solution is completed. The second dose of 1L of preparation will be taken the morning of the colonoscopy starting 4-5 hours prior to the procedure at a rate of 240 mL every 10 minutes. Use of antacids will not be permitted within one hour of taking bisacodyl.
223828185|NCT02547571|DRUG|High volume PEG non split, day before|Colyte® or PegLyte® will be provided to the subject who will be asked to drink 4L of preparation starting at 6:00 PM the day before the procedure, at a rate of 240 mL every 10 minutes until completed.
223828186|NCT02547571|DRUG|Low volume PEG non split, same day|Bi-PegLyte® will be provided to the subject, who will be asked to ingest 3 tabs of Bisacodyl 5 mg (total 15 mg) at 2:00 PM the day before the procedure and will drink 2L of preparation the morning of the colonoscopy starting 4 hours prior to the procedure at a rate of 240 mL every 10 minutes, until completed. Use of antacids will not be permitted within one hour of taking Bisacodyl.
223828187|NCT02547571|OTHER|Clear liquid diet|
223828188|NCT02547571|OTHER|Low residue diet|
223828189|NCT02547571|OTHER|Early colonoscopy (stratified)|"Early appointments: 7:30 AM to 10h30 AM"
223828190|NCT02547571|OTHER|Later colonoscopy (stratified)|"Later appointments: 10:30 AM to 4:30 PM."
223828191|NCT05490693|OTHER|Experimental group|Experimental group: 26 control group group: 26
223828192|NCT04000932|DRUG|Local platelet rich plasma (PRP) injection-T-Lab PRP kit|Platelet rich plasma (PRP) will be obtained by centrifugation of autologous anticoagulated whole blood. 1 ml PRP extract will be injected into the carpel tunnel (of the side with a diagnosis of carpel tunnel syndrome) via the distal wrist line using 23 gauge needle.
223828193|NCT04000932|DRUG|Local steroid injection-Diprospan ®, Schering Plough|The local steroid injection ((1 ml Diprospan ®, Schering Plough containing 6.43 mg of betamethasone dipropionate and 2.63 mg of betamethasone sodium phosphate) will be performed once into the carpal tunnel.1 ml Diprospan ®, Schering Plough extract will be injected by using 23 gauge needle from the distal wrist line through the carpal tunnel only once.
223828194|NCT01967264|DRUG|Udenafil|Udenafil tablets
223828195|NCT01967264|DRUG|Placebo|Placebo tablets
223828196|NCT05067946|BIOLOGICAL|GX-19N|DNA vaccine expressing SARS-CoV-2 S-protein antigen including the Nucleocapsid protein (NP) antigen
223828197|NCT05067946|OTHER|Placebo|GX-19N formulation buffer
223828198|NCT04976595|DRUG|Natesto|Nasal gel containing testosterone 11 mg/dose (5.5 mg/nostril) three times daily.
223828199|NCT02228473|DRUG|Glycopyrrolate|Glycopyrrolate will be administered.
223828200|NCT02228473|DRUG|Atropine|Atropine will be administered.
223828201|NCT03660033|DIAGNOSTIC_TEST|ECG in delivery room|See arm/group discussions
223828202|NCT01780493|PROCEDURE|The Direct Nipple Ureteroneocystostomy Technique|
223828203|NCT04540484|OTHER|Screening|Blood test screening for covid
223828204|NCT02817620|DIETARY_SUPPLEMENT|Spirulysat®|
223828205|NCT02817620|DIETARY_SUPPLEMENT|Placebo|
223828206|NCT05171868|BEHAVIORAL|Eye Movement Desensitization and Reprocessing (EMDR)|Each participant in the intervention group will receive 8 individual, weekly EMDR sessions over 8 weeks. Each session will take approximately 60-90 minutes. The sessions will be delivered at a place convenient to the participant. Trained EMDR therapists will deliver the intervention.
223828207|NCT01424059|OTHER|WEDQ-B (questionnaire)|Questionnaires are answered after delivery; within 48 hours and after five weeks
223828208|NCT04980768|PROCEDURE|Root canal treatment|Patients with apical periodontitis will undergo root canal treatment.
223828209|NCT02066532|DRUG|Ruxolitinib|25 mg bid, 20 mg bid, 15 mg bid, or 10 mg bid, (oral, twice a day) on days 1 through 21 of each 21 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
223828210|NCT02066532|DRUG|Trastuzumab|6 mg/kg every 3 weeks (cycle = 21 days). If no trastuzumab \> 28 days, patients will be initially re-loaded at 8 mg/kg, then 6 mg/kg.
223828211|NCT03511872|OTHER|Basic life support training|"A course design was made to be consistent with ERC guidelines with local modifications made by emergency professionals in duration, instructor-to-trainee ratio, course materials, methods to deliver these materials theoretically, and the type of the manikin used to practice CPR. One-day-course consisting of 75, 20, 20, 20 minutes for theoretical BLS, chocking, recovery position, the practical representation of BLS scenario respectively followed by 40-minute practical training on BLS skills for each subgroup. Both arms of the study follow the same timeline and no extra time is given to any group.~Same manikins were used for the training and the assessment. On the day of the experiment students in each arm are divided into 4 subgroups of maximum 9 students, each led by two trainers of BLS skills with a maximum ratio of 2 instructors to 9 students per group."
223828212|NCT00662493|BEHAVIORAL|Motor control retraining program|Specific retraining of VMO activation in a low-load situation,and progressed to integrate more functional positions. Use of dual channel biofeedback was incorporated
223828213|NCT00662493|BEHAVIORAL|Quadriceps strengthening program|4 exercises focused on quadriceps strengthening commencing at a resistance of 60% 1 repetition maximum. Each exercise was performed for 3 sets of 10 repetitions
223828214|NCT03499379|DEVICE|Mirena|A radio-opaque T-shaped polyethylene device containing 52mg of levonorgestrel dispersed in polydimethylsiloxane on its stem. The progestin is released at a rate of 15 mcg per day.
223828215|NCT03499379|DEVICE|Paraguard|A T-shaped polyethylene device with 380 mm2 of exposed surface area of fine copper wire wound around its arms and stem. Barium sulfate has been added to the polyethylene frame to make the device radio-opaque. A 3-mm plastic ball is located at the base of the IUD, through which the polyethylene monofilament string passes.
223828216|NCT03656731|OTHER|Breast cancer exercise intervention|"The exercise-based intervention is comprised of:~1. Supervised and group-based exercise training at the hospital setting two times a week. Each session will last approximately 60 minutes.The program consists of warm-up, exercises for balance and flexibility, progressive resistance training (seven resistance training exercises targeting the large muscle groups), and stretching and relaxation.~2. Home-based walking with activity tracker assessment. Evaluation and goal-setting in relation to activity (step counts) will be conducted once weekly.~3. Serving of a protein supplement (protein drink or bar) after each supervised training session."
223828217|NCT02631421|PROCEDURE|Blood Sampling|
223828218|NCT02631421|OTHER|Cardiac MRI|
223828219|NCT00002502|DRUG|busulfan|
223828220|NCT00002502|DRUG|cyclophosphamide|
223828221|NCT00002502|DRUG|cytarabine|
223828222|NCT00002502|PROCEDURE|allogeneic bone marrow transplantation|
223828223|NCT02481843|OTHER|2 hours of hyperoxia (FiO2 = 1)|Patients received 2 hours of hyperoxia at FiO2 = 1
223828224|NCT02011425|DEVICE|mandibular advancement appliance|mandibular advancement appliance
223828225|NCT00181038|DEVICE|Peri-Neuronal Catheter|
223828226|NCT04011332|OTHER|Integrated Care Model|The patients who are hospitalised due to a COPD exacerbation will be aligned to a nurse-led integrated care model for three months. The model constitutes a bundle of interventions that are commonly known as key elements in COPD management. In addition, the ANP-Team (Advanced Nursing Practice-Team) will coordinate the different health professionals within the hospital and across transitions within the three months.
223828227|NCT00073385|DRUG|Pivanex|
223828228|NCT00073385|DRUG|Docetaxel|
223828229|NCT03009721|DRUG|Other: Not applicable-observational study|
223828230|NCT03949088|OTHER|UF and Na profiling|Modulation of UF and dialysate sodium
223828231|NCT00132379|DRUG|ABR-217620|10.3, 16.5 or 22 mcg/kg, IV, daily 5 minute bolus injection for 4 consecutive day per cycle; up to 6 cycles
223828232|NCT00132379|DRUG|docetaxel|75mg/m\^2, IV, single 60 minute infusion, beginning on Day 5 then every third week
223828233|NCT06329674|DRUG|AJU-A51|Subjects take the investigational products once a day for 24 weeks.
223828234|NCT06329674|DRUG|A51R2|Subjects take the investigational products once a day for 24 weeks.
223828235|NCT06329674|DRUG|A51R3|Subjects take the investigational products once a day for 24 weeks.
223828236|NCT06329674|DRUG|AJU-A51 Placebo|Subjects take the investigational products once a day for 24 weeks.
223828237|NCT06329674|DRUG|A51R2 Placebo|Subjects take the investigational products once a day for 24 weeks.
223828238|NCT00994773|DRUG|Simvastatin|daily doses for 14 days
223828239|NCT00994773|DRUG|Tenofovir|
223828240|NCT00994773|DRUG|Entecavir|Entecavir
223828241|NCT03402880|BIOLOGICAL|Pembrolizumab|Given IV
223828242|NCT03402880|DRUG|Epacadostat|Given PO
223828243|NCT03402880|OTHER|Laboratory Biomarker Analysis|Correlative studies
223828244|NCT01265823|BIOLOGICAL|Adalimumab|Adalimumab was administered as follows: 80 mg at baseline, followed by 40 mg every other week (eow; starting at Week 1 until Week 15). The study drug was self-administered via subcutaneous (sc) injection.
223828245|NCT02173730|DRUG|BIBR 1048 MS|BIBR 1048 MS capsule 150 mg
223828246|NCT02173730|DRUG|Pantoprazole|Pantoprazole tablet 40 mg
223828247|NCT04707690|DEVICE|Intraurethral laser therapy|The laser will be applied according to the manufacturer's protocol. This includes a 2 step laser treatment using 2 different modes at 2 timepoints. The treatment takes about 15 minutes time.
223828248|NCT04707690|DEVICE|Intraurethral SHAM laser therapy|The laser will be applied according to the manufacturer's protocol. This includes a 2 step laser treatment using 2 different modes at 2 timepoints. The treatment takes about 15 minutes time.
223828249|NCT05281003|DRUG|Pembrolizumab|Biological: Pembrolizumab 200 mg administered IV Q3W on Day 1 of each 3-week cycle, up to 4 administrations in neoadjuvant setting.
223828250|NCT05281003|DRUG|Paclitaxel|Drug: Paclitaxel 150 mg/m\^2 administered IV Q3W on Day 1 of each 3-week cycle, up to 4 administrations in neoadjuvant setting.
223828251|NCT05281003|DRUG|Cisplatin|Drug: Cisplatin 80 mg/m\^2 administered IV Q3W on Day 1 of each 3-week cycle, up to 4 administrations in neoadjuvant setting.
223828252|NCT03915119|OTHER|GFT AI training|navigates a cluttered environment of stationary and moving/pursuing virtual obstacles to reach a way-point as quickly and efficiently as possible. Block order and difficulty, as well as the behavior of the obstacles in each block, will be driven by the AI and statistically weighted to specifically target the perceptual-motor and neuromechanical mechanisms based on each athlete's visit 1 performance
223828253|NCT02478125|DRUG|Burixafor Hydrobromide|Investigators will determine the kinetics of PCa cell release into the blood with four daily dosages of Burixafor hydrobromide alone or in combination with G-CSF
223828254|NCT02478125|DRUG|Docetaxel|Investigators will administer a single 75 mg/m2 IV dose of docetaxel. Twenty-one days later investigators will re-treat enrolled men with the optimal mobilization strategy + docetaxel IV. The second dose of docetaxel being given in combination with the optimal mobilization strategy will be chosen according to a standard 3+3 dose escalation schema, in which the dose of bruixafor +/- G-CSF will be held constant and the dose of docetaxel will escalate between three dose-levels: 1) docetaxel 30 mg/m2 IV, 2) docetaxel 60 mg/m2 IV, and 3) docetaxel 75 mg/m2
223828255|NCT02478125|DRUG|G-CSF|G-CSF will be given as a daily subcutaneous (SC) injection beginning 4 days prior to Burixafor hydrobromide and continuing through the 4 days of Burixafor hydrobromide treatment
223828256|NCT00715741|OTHER|FiO2 (fraction of inspired oxygen) 0.3 plus PEEP (positive end expiratory pressure) 3 -5 cm water|FiO2 (fraction of inspired oxygen) 0.3 plus PEEP (positive end expiratory pressure) 3-5 cm water
223828257|NCT00715741|OTHER|FiO2 0.3 without PEEP|FiO2 0.3 without PEEP
223828258|NCT00715741|OTHER|FiO2 >0.9 with 3-5 cm water PEEP|FiO2 \>0.9 with 3-5 cm water PEEP
223828259|NCT00715741|OTHER|FiO2 >0.9 without PEEP|FiO2 \>0.9 without PEEP
223828260|NCT04181840|DIAGNOSTIC_TEST|Blood and faeces tests|During V1 - Laboratory tests, particularly for calprotectin concentration assessment
223828261|NCT04181840|DEVICE|Impedance spectroscopy test|During V1 - the electrical impedance of anal sphincter muscles will be measured
223828262|NCT04181840|DIAGNOSTIC_TEST|Full gynecological and proctological examination|During V1 and V2 - Examination with a gynecological speculum, Two-handed examination, Rectal examination, and Anoscopy
223828263|NCT04181840|DIAGNOSTIC_TEST|Transanal ultrasonography|During V1 - reference diagnostic methods with documented effectiveness and safety; for comparison with impedance spectroscopy results.
223828264|NCT04181840|DIAGNOSTIC_TEST|Anorectal manometry|During V1 - reference diagnostic methods with documented effectiveness and safety; for comparison with impedance spectroscopy results.
223828265|NCT04181840|OTHER|Determining the degree of sphincter injury|During V2 - conducting the examination will finally determine the extent of sphincter damage, present the patient with therapeutic options and decide on the treatment or rehabilitation of sphincter.
223828266|NCT01356667|BEHAVIORAL|DARTNA|3-hour protocol provided 2x/week over 12 weeks
223828267|NCT01356667|BEHAVIORAL|Treatment-As-Usual|Participants will receive typical substance abuse behavior treatment interventions typically provided to patients including individual counseling, group therapy, and standard culturally-based interventions.
223828268|NCT02401958|OTHER|Resistance training|17 volunteers with RA and 17 without the disease, with a mean age of 54.7 + 6.63 underwent a resistance exercise session with a set of 12 repetitions at 50% of one repetition maximum (1RM ) and a set of 8 repetitions at 75% of 1RM. The exercises performed were: knee extension, knee flexion, hip abduction and hip adduction. Blood samples were obtained 30 minutes before, 5 minutes before, immediately after, 1 hour, 2 hours and 24 hours after the exercise session.
223828269|NCT01018563|DRUG|MORAb-003|Dose group to be determined by dose assigned in main study and patient's weight. Intravenous infusions are given every 3 weeks.
223828270|NCT02344537|BEHAVIORAL|Kundalini Yoga|Kundalini Yoga incorporates mindfulness practice with a triad of stretching, breathing, and meditation. The three components of treatment consist of muscular relaxation/stretching exercises, a meditation period characterized by a directed breathing exercise, and then a guided meditation.
223828271|NCT04107896|DRUG|Silodosin|Cap silodosin
223828272|NCT04107896|DRUG|Tamsulosin|Cap tamsulosin
223828273|NCT01031472|DRUG|GSK2248761 formulation 1|100mg GSK2248761 formulation 1- fasted 100mg GSK2248761 formulation 1 - with food (moderate fat meal)
223828274|NCT01031472|DRUG|GSK2248761 reference formulation|GSK2248761 100mg Gelucire reference capsule with food
223828275|NCT01031472|DRUG|GSK2248761 formulation 3|100mg GSK2248761 formulation 3 fasted 100mg GSK2248761 formulation 3 with food (moderate fat meal)
223828276|NCT01031472|DRUG|GSK2248761 formulation 2 or 4|100mg GSK2248761 formulation 2 or 4 - fasted 100mg GSK2248761 formulation 2 or 4 - with food (moderate fat meal)
223828277|NCT00798486|DEVICE|A1C Test Kit|Subjects tested 3 times with A1C test kits. Two tests were performed by the subject and the third test was performed by a healthcare professional (HCP). All results were compared to results from a laboratory glucose analyzer (TOSOH).
223828278|NCT03274154|DIETARY_SUPPLEMENT|Pre-Hyaluron 465 Innēov|Food supplement consisting og a tablet and a capsule, composed with a precursor of HA (glucosamine) and an enzymatic co-factor of HA synthesis (manganese)
223828279|NCT03781765|DRUG|Methylphenidate|stimulant medication
223828280|NCT03781765|DRUG|Atomoxetine|non-stimulant medication
223828281|NCT04446780|PROCEDURE|Mediolateral episiotomy|Cutting of the perineum during vaginal delivery in order to avoid obstetric anal sphincter injury
223828282|NCT05504382|DEVICE|naproxen phonophoresis|transmission of naproxen molecule by therapeutic ultrasound
223828283|NCT03857412|PROCEDURE|Capsular polishing|Capsular polishing taking place during cataract surgery
223828284|NCT03857412|OTHER|Non capsular polishing|No capsular polishing taking place during cataract surgery
223828285|NCT02161861|OTHER|cFFE increase the fusiogenic capacities of a gamete|
223828286|NCT03665883|PROCEDURE|Monopolar energy|Monopolar energy in TEP for inguinal hernia
223828287|NCT03665883|PROCEDURE|Blunt dissection|Blunt dissection in TEP for inguinal hernia
223828288|NCT04264234|DIAGNOSTIC_TEST|Vaginal Ultrasonography|Placenta previa cases will be evaluated at 32nd week by vaginal ultrasonography for invasion anomaly and preterm birth.
223828289|NCT04264234|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|Placenta previa cases will be evaluated at 32nd week by MRI for invasion anomaly and preterm birth.
223828290|NCT04517422|DIETARY_SUPPLEMENT|Probiotics|Combination of Lactobacillus plantarum CECT30292, Lactobacillus plantarum CECT 7484, Lactobacillus plantarum CECT 7485, and Pediococcus acidilactici CECT 7483
223828291|NCT04517422|OTHER|Placebo|Combination of maltodextrin (E1400, qs) in a vegetable hydroxymethylpropyl-cellulose capsule (HPMC) of size 0
223828292|NCT01863641|DRUG|calcitriol|Patients will receive calcitriol at a fixed dose of 0.25 µg (one oral pearl) daily.
223828293|NCT01863641|DRUG|placebo|Patients will receive placebo similar to intervention (shape, color and design) 1 oral unit daily.
223828294|NCT03016793|DRUG|Puerarin|purabone (puerarin) is a bone graft used for surgical repair of bony defects.
223828295|NCT03016793|DRUG|β- tricalcium phosphate|β- tricalcium phosphate is a bone graft used for surgical repair of bony defects
223828296|NCT03016793|DRUG|β- tricalcium phosphate alone|β- tricalcium phosphate is a bone graft used for surgical repair of bony defects
223828297|NCT00467922|DRUG|Hextend|Assessment of Goal-Directed Intraoperative Fluid Management in Hand Assisted Laparoscopic Colectomy: Standard Care versus Either Colloid and Crystalloid
223828298|NCT00467922|DRUG|Lactated Ringers|Assessment of Goal-Directed Intraoperative Fluid Management in Hand Assisted Laparoscopic Colectomy: Standard Care versus Either Colloid and Crystalloid
223828299|NCT00960752|DRUG|gp100|1 ml of gp100 peptide vaccine: 0.5 ml administered intradermally and the other 0.5 ml subcutaneously in the same extremity weekly (every 7 days +/- 2 days) for 8 weeks.
223828300|NCT00960752|DRUG|R848 gel|Applied to the gp100 vaccine injection site immediately following the injection, allowed to air dry for 30 minutes then covered with gauze dressing.
223828301|NCT00960752|DRUG|MAGE-3|1 ml of MAGE-3 peptide vaccine: 0.5 ml administered intradermally and the other 0.5 ml subcutaneously in the same extremity weekly (every 7 days +/- 2 days) for 8 weeks.
223828302|NCT04020159|OTHER|Patient Registry|No intervention/treatment
223828303|NCT05259774|DEVICE|Relizema cram|Relizema cream is a CE marked, Class IIa medical device, dermatological cream for topical use indicated for symptomatic treatment of dermatitis and erythema. Relizema cream is indicated for the treatment of itching and flushing associated with different types of dermatitis, including atopic dermatitis.
223828304|NCT01719601|DRUG|No intervention|This is an observational study. Immediate release tapentadol hydrochloride will be administered as per the recommended doses approved in Philippines. The recommended oral starting dose is 25 mg, 50 mg or 100 mg every 4 to 6 hours depending on the initial pain intensity and thereafter, the dose will be adjusted to maintain adequate analgesia with acceptable tolerability. The dosing regimen will be individualized according to the severity of pain being treated, the previous treatment experience, and the ability to monitor patients.
223828305|NCT00461292|BIOLOGICAL|botulinum toxin Type A (200U)|botulinum toxin Type A 200 U injection at Day 1 followed by botulinum toxin Type A 200 U injection \> Week 12; injections into detrusor
223828306|NCT00461292|BIOLOGICAL|botulinum toxin Type A (300U)|botulinum toxin Type A 300 U injection on Day 1 followed by botulinum toxin Type A 300 U injection \> Week 12; injections into detrusor
223828307|NCT00461292|OTHER|Normal saline (Placebo); botulinum toxin Type A (200U)|Placebo injection on Day 1 followed by botulinum toxin Type A 200 U injection \> 12 weeks; injections into detrusor
223828308|NCT00461292|OTHER|Normal saline (Placebo); botulinum toxin Type A (300U)|Placebo injection on Day 1 followed by botulinum toxin Type A 300 U injection \> Week 12; injections into detrusor
223828309|NCT02180438|DRUG|Stribild (Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF) 1 tablet daily X 48 weeks|
223828310|NCT02926664|OTHER|measurement of qSOFA|qSOFA will be measured at H0, H1 and H3
223828311|NCT05232435|OTHER|pilate mat exercise will be performed|pilate group:1- bridging 2- shoulder bridge 3- front support 4- spine stretch forward 5- spine twist plus standard treatment(stretch hamstring -stretch lower back - strength abdominal muscles - electrical heat pad)
223828312|NCT05232435|OTHER|MET|Will receive MET for hamstring and erectorspinae plus standard treatment
223828313|NCT05232435|OTHER|control group receive standard treatment|electrical heat pad - stretch hamstring - stretch lower back muscles - stregth abdominal muscles
223828314|NCT03176589|DEVICE|positive expiratory pressure (PEP)|Patients take a deep inspiration followed by PEP expiration with an expiratory pressure of 10-15 cm H2O
223828315|NCT03176589|DEVICE|Placebo comparator, Deep inspiration and expression in a placebo tube without resistance|Deep inspirations 3 times 10 and expiration in a placebo tube without expiratory resistance
223828316|NCT03176589|OTHER|Deep breathing maneuvers|deep breathing maneuvers 3 times 10 breahs without any device at expiration
223828317|NCT03387241|DRUG|Fluticasone/ Formoterol|See above
223828318|NCT03387241|DRUG|fluticasone/ salmeterol|See above
223828319|NCT01811940|DRUG|Adderall-ER|MAS-ER 60mg/day
223828320|NCT01811940|DRUG|Topiramate|Topiramate 100 mg bid.
223828321|NCT01811940|OTHER|Placebo|Placebo
223828322|NCT03547284|DRUG|sugarless gum|81 patients will receive 1 stick of sugarless gum(Samara gum) for 15 minutes every 2 hours
223828323|NCT02581176|DRUG|Apixaban|
223828324|NCT03115008|BEHAVIORAL|Video-based terminal feedback|Terminal feedback is given after skill performance using video-based coaching coupled with a validated polypectomy assessment tool
223828325|NCT01057108|OTHER|FOSTRAP Chewing Gum|20 mg BID
223828326|NCT01057108|OTHER|FOSTRAP Chewing Gum|40 mg BID
223828327|NCT01057108|OTHER|FOSTRAP Chewing Gum|20 mg TID
223828328|NCT01057108|OTHER|FOSTRAP Chewing Gum|20 mg TID
223828329|NCT01057108|OTHER|Placebo chewing gum|
223828330|NCT00042796|DRUG|decitabine|Given IV
223828331|NCT00042796|OTHER|pharmacological study|Correlative studies
223828332|NCT00042796|OTHER|laboratory biomarker analysis|Correlative studies
223828333|NCT01267981|DRUG|Standard diet|"After the lunch the day before the exploration, drink only clear liquids and stop solid food.~From 10 pm, stay fasting, don't drink except the usual drugs taken with mouthful of water until the exploration by video-capsule endoscopy."
223828334|NCT01267981|DRUG|Standard Diet + 500 ml of polyethyleneglycol|Apply the standard diet and drink 500 ml of polyethylene glycol 30 minutes after the endoscopy video-capsule ingestion.
223828335|NCT01267981|DRUG|Standard diet + 2 liters of polyethylene glycol the day before + 500ml of polyethylene glycol|apply the standard diet and drink 2 liters of polyethylene glycol between 19h and 21h the day before exploration. Then drink 500 ml of polyethylene glycol 30 minutes after the endoscopy video-capsule ingestion.
223828336|NCT04484766|OTHER|Primary data collection|"Primary data collection takes place via questionnaires outside the study centre.~All other investigations take place at the study centre:~* Physical examination: height, weight, BMI, blood pressure~* Cardiac examination: cardiac output~* Vascular measurements: Carotid intima media thickness, total peripheral resistance, blood pressure, flow-mediated vascular dilatation, critical flicker frequency, pulse wave velocity, augmentation index~* Serum analysis: basic laboratory, multiplex analysis (human vascular inflammation, human angiogenesis and adhesion molecule panel)"
223828337|NCT02664779|OTHER|Arrhythmia diagnosis with the 10 steps method|
223828338|NCT02664779|OTHER|Arrhythmia diagnosis with the 6 steps method|
223828339|NCT02664779|OTHER|Arrhythmia diagnosis with the 4 steps method|
223828340|NCT00180713|DRUG|Simvastatin|Simvastatin 40mg od for 1 month, then 80mg od for 11 months
223828341|NCT00180713|DRUG|Placebo|Placebo tablet once daily.
223828342|NCT06576115|DRUG|Nab paclitaxel|125 mg/m2 weekly, on days 1,8, and 15 or on days 1 and 15 as a 30-40 minute infusion administered first
223828343|NCT06576115|DRUG|Gemcitabine|1000 mg/m2 weekly, on day 1,8 and 15 or 1000 mg/m2 weekly, on day 1 and 15 over 30 minutes after nab- paclitaxel infusion
223828344|NCT06576115|DEVICE|TheraBionic P1|This treatment consists of delivering preset low levels of radio waves into the body with a spoon-shaped antenna placed in the mouth, three times a day, for an hour each time.
223828345|NCT05923086|DRUG|ORE001|Administration before major meal
223828346|NCT05923086|DRUG|Placebo|Administration before major meal
223828347|NCT03761082|OTHER|NA(observation study)|NA(observation study)
223828348|NCT05254444|BEHAVIORAL|Social marketing|Multi-tiered nutrition social marketing intervention focused on sustainable fish nutrition, dietary diversity and food safety.
223828349|NCT05254444|BEHAVIORAL|social marketing + gear modification|Multi-tiered nutrition social marketing intervention plus fishing gear modification (basket trap) and training.
223828350|NCT04963894|OTHER|Home functional balance physiotherapy|Experimental physiotherapy program is carried out at home to improve the balance of people with Parkinson's disease through exercises that simulate everyday functional contexts.
223828351|NCT04963894|OTHER|Conventional physiotherapy|Conventional control physiotherapy program is carried out face-to-face in a rehabilitation gym and in groups of 6 people. The conventional program of physiotherapy includes conventional therapeutic goals of rehabilitation in people with Parkinson's disease.
223828352|NCT04943263|OTHER|Tracheal Temperature|Temperature measured from the endotracheal tube compared with the esophageal temperature
223828353|NCT01979731|OTHER|Job rotation|The intervention group will perform rotation function, switching between tasks with low, moderate and high ergonomic risk and different requests for ergonomic body region added to ergonomic guidelines.
223828354|NCT01979731|OTHER|Guidelines ergonomics|Orientation about manual material handling, posture, furniture, rest break and others in general.
223828355|NCT06442540|PROCEDURE|Physical Agents|Hot pack
223828356|NCT06442540|PROCEDURE|Manipulation|HVLA manipulation of SI joint
223828357|NCT06442540|PROCEDURE|Core Stability Exercises|Supine abdominal draw-in Hold 8s 3s off x 2 Abdominal draw-in, with one knee drawn to the chest. Hold 8s 3s off x 2 Abdominal draw-in, with the heels sliding backward one after the other. 10 reps 3s off x 2 Abdominal draw-in, with both knees drawn to the chest. Hold 8s 3s off x 2 Supine twist 15 reps 3s off x 3 Prone bridging on elbows Hold 8s 3s off x 3 Side bridging on elbows Hold 8s 3s off x 3 Quadruped opposite arm-leg lift Hold 8s 3s off x 3 Advance to the stage 2 when the patient can hold 30 reps for an 8-sec hold.
223828358|NCT06442540|PROCEDURE|Intramusular electrotherapy|Intramuscular electrotherapy/ 3 sessions per week
223828359|NCT06442540|PROCEDURE|Soft tissue mobility|Stretching and Myofacial Release of piriformis and erector spinae
223828360|NCT04688593|DEVICE|MobileLink|Patients who receive a MobileLink hip prosthesis system will be followed-up for 10 years.
223828361|NCT03301090|OTHER|Placebo|Placebo
223828362|NCT03301090|BIOLOGICAL|REGN3048|REGN3048 is a fully monoclonal antibody (mAbs) which binds to the S protein of MERS-CoV.
223828363|NCT03301090|BIOLOGICAL|REGN3051|REGN3051 is a fully human monoclonal antibody (mAb) which binds to the S protein of MERS-CoV. It can reduce virus titers and ameliorate MERS-CoV-induced lung pathology when given post infection.
223828364|NCT04871035|DEVICE|Immunoadsorption|1 cycle, consisting of 5 sessions on 5 consecutive days with processing of the 0.7-fold individual plasma volume (maximum 2.5 l) each days with tryptophan adsorbers.
223828365|NCT04871035|DEVICE|Plasma Exchange|1 cycle, consisting of 5 sessions on 5 consecutive days with exchange of 0.7-fold plasma volume (maximum 2.5 l) each day with albumin solution as volume replacement solution.
223828366|NCT05403060|BEHAVIORAL|ALIADA: Alimentación, Adolescencia y Ambiente|The objective of the educational nutritional intervention is to promote in adolescents an increase in their consumption of vegetables and fruits and a decrease in their consumption of ultra-processed foods, through the application of the TSC constructs, with the use of education by pairs as the main strategy (peer leaders). It lasts two months, includes three exclusive sessions for peer leaders and five sessions for all participants, where the leaders, together with the researchers, will lead the activities of the sessions, as well as a general event for all high school students. Intervention activities include: electronic presentations, videos, food preparation and label reading workshops, individual and team reflection activities, goal setting and monitoring, board games, contests, among others. In addition, each participant is given a workbook, which contains key messages and activities for each educational session.
223828367|NCT01022801|DRUG|Entecavir|Capsule, P.O., 0.01, 0.1 or 0.5 mg, once daily for 24 weeks
223828368|NCT00507221|DRUG|Albendazole|"Every 3 months for 24 months (enrollment 3, 6, 9, 12, 15, 18, 21, and 24 months):~400mg/day X 3 days"
223828369|NCT00507221|DRUG|Praziquantel|At enrollment and 12 months: 25mg/kg X 1
223828370|NCT00507221|DRUG|Current standard of care in Kenya|Current standard of care for HIV patients in Kenya based on WHO guidelines.
223828371|NCT05626972|DRUG|Tenecteplase|Patients will be randomized 1:1 to standard dose tPA (0.9 mg/kg) or TNK (0.25mg/kg) before endovascular therapy (EVT)
223828372|NCT03218696|DEVICE|Cough Syrup for adults and children|The intervention product is a medical device in Europe due to its non-pharmacological mode of action, which makes the product compliant to the medical device definition. It is made of specific extracts of plants (plantago and thymus) which provide the product with protective characteristics of the oropharynx. These protective features enable the syrup to reduce the irritative cough promoting stimuli on the throat, which decrease urge to cough threshhold. In addition to these extract, honey completes the formula. The product does not contain any artificial component and no preservatives.
223828373|NCT03218696|DEVICE|Placebo|The placebo intervention is a syrup of same taste and colour without the natural protective components but with the necessary synthetic preservatives and other co-sweeteners to guarantee quality and safety. The placebo has, in fact, all the features of a cough syrup since true placebo syrup is not possible in cough. The lack of specific natural protective components is weighed against the presence of other necessary substances which may still have an effect on cough, but this effect is not envisaged to be a specific protective effect.
223828374|NCT00278382|DRUG|sorafenib tosylate|Given orally
223828375|NCT00278382|OTHER|laboratory biomarker analysis|Correlative studies
223828376|NCT01567865|BIOLOGICAL|Vaccine produced in existing facility|Live attenuated Japanese encephalitis vaccine SA 14-14-2 (LJEVac) produced in the existing facility by the Chengdu Institute of Biological Products (CDIBP), Chengdu, China
223828377|NCT01567865|BIOLOGICAL|Vaccine produced in new facility|Live attenuated Japanese encephalitis vaccine SA 14-14-2 (LJEVac) produced in the new facility by the Chengdu Institute of Biological Products (CDIBP), Chengdu, China
223828378|NCT03987230|DRUG|Sensitive Eyes® Plus Saline Solution|Sensitive Eyes® Plus Saline Solution
223828379|NCT03987230|OTHER|Oust™ Demodex® Wipes™|Oust™ Demodex® Wipes™
223828380|NCT03987230|OTHER|I-LID N LASH PLUS® Eyelid Cleanser|I-LID N LASH PLUS® Eyelid Cleanser
223828381|NCT03987230|OTHER|Blephadex Lid Wipes|Blephadex Lid Wipes
223828382|NCT03987230|OTHER|Eye Cleanse Lid Wipes|Eye Cleanse Lid Wipes
223828383|NCT03987230|OTHER|Blephademodex|Blephademodex
223828384|NCT02061696|DEVICE|Vascular Access Device|AXERA 2 Access System with Reduced Manual Compression
223828385|NCT02061696|PROCEDURE|Standard Manual Compression|Closure procedure by Manual Compression
223828386|NCT02750176|OTHER|Closed chain exercises|Closed-chain strengthening will be performed with the shoulder moving over a fixed hand. Resistance will be provided by body weight against gravity. To off-load and progress the amount of body-weight resistance, elastic bands will be used to support body weight using a exercise frame. Patients will perform 6 exercises.
223828387|NCT05591560|DRUG|Itraconazole capsule|Oral itraconazole 400 mg (4 capsules, each of 100 mg) for 5 days (two days before chemotherapy, the day of chemotherapy after receiving it, and two days after chemotherapy) Day 1, 8, and 15 repeated every 21 days for 6 cycles for group II
223828388|NCT05591560|DRUG|Placebo|4 placebo capsules for 5 days (two days before chemotherapy, the day of chemotherapy after receiving it, and two days after chemotherapy) Day 1, 8, and 15 repeated every 21 days for 6 cycles for group I
223828389|NCT01476488|DRUG|tacrolimus|
223828390|NCT00101335|DRUG|celecoxib|
223828391|NCT03643146|BEHAVIORAL|Lifestyle Management|Will use passive ubiquitous sensing through FitBit to 1)learn behavioral profiles of subjects who have pre-HTN/HTN and/or pre-diabetes /Diabetes 2) provide personalized recommendations through mobile based messaging app that will increase the likelihood of engaging in health diet/nutrition, physical activity and sleep practices
223828392|NCT03643146|BEHAVIORAL|Control Group|will receive standard medical care where research assistant will give pamphlets, with one size fits all recommendations for diet/nutrition, physical activity and sleep, to 10 subjects with comorbid HTN and T2D.
223828393|NCT02671318|DRUG|Drug conversion to sirolimus|Drug conversion to sirolimus: mycophenolate or azathioprine conversion to sirolimus, in a regimen with tacrolimus and prednisone.
223828394|NCT02671318|DRUG|Maintenance of the current regimen|Maintenance of the current regimen: mycophenolate or azathioprine maintenance, in a regimen with tacrolimus and prednisone.
223828395|NCT05996952|DRUG|RC48-ADC|Patients are treated with RC48-ADC at 2.0 mg/kg as an intravenous infusion over 30-90 minutes (60 minutes is recommended) once every 2 weeks for 12 weeks.
223828396|NCT02844491|OTHER|additional biological samples|blood and tissue samples
223828397|NCT05023967|PROCEDURE|Biospecimen Collection|Undergo collection of blood and tissue samples
223828398|NCT05023967|DRUG|Extended Release Metformin Hydrochloride|Given PO
223828399|NCT05023967|OTHER|Monitoring|Use continuous glucose monitoring system
223828400|NCT05023967|OTHER|Nutritional Assessment|Receive nutritional counseling
223828401|NCT05023967|OTHER|Short-Term Fasting|Perform intermittent fasting
223828402|NCT01420263|PROCEDURE|Re-feeding residuals|In the presence of significant gastric residuals (more than 1/3 of previous feed or \> 2ml), residual volumes will be re-fed if the physician decision is to continue feeds as scheduled in the absence of other clinical signs and symptoms of feeding intolerance. This practice will be continued until full enteral feeding is achieved and maintained for a minimum of 48 hours.
223828403|NCT01420263|PROCEDURE|Fresh Feeding Breastmilk or Formula only|In the presence of significant gastric residuals (more than 1/3 of previous feed or \> 2ml), residual volumes will be discarded and fresh breastmilk or formula will be fed if the physician decision is to continue feeds as scheduled in the absence of other clinical signs and symptoms of feeding intolerance. This practice will be continued until full enteral feeding is achieved and maintained for a minimum of 48 hours.
223828404|NCT02274649|BEHAVIORAL|one-to-one peer mentoring|Each patient received one-to-one peer mentoring each week during rehabilitation and for 90 days post discharge
223828405|NCT02274649|BEHAVIORAL|general peer support|General (traditional) peer support includes introduction and provision of support services upon request
223828406|NCT01051063|BIOLOGICAL|GSK Biologicals' recombinant WT1 Antigen-Specific Cancer Immunotherapeutic (ASCI) GSK2130579A|Intramuscular injection
223828407|NCT01393041|DEVICE|Angio-Seal VIP|Vascular Closure Device
223828408|NCT00231660|DRUG|topiramate|
223828409|NCT01928680|DRUG|Cisplatin/Capecitabine|Cisplatin/Capecitabine: Capecitabine 1000mg/m2 orally Bid on day 1 to day 14 plus Cisplatin 75mg/m2 on day1 of each 21 day cycle, until progression or untolerable toxicity
223828410|NCT00836654|BIOLOGICAL|Catumaxomab (Removab)|Puncture free survival
223828411|NCT00836654|PROCEDURE|paracentesis|
223828412|NCT04049292|OTHER|Better and safer return to sport (BEAST)|The RTS assessment includes a Lachman test, modified stroke test, side hop test, triple hop test, and quadriceps muscle power test. The sport-specific progression plans have 6 participation levels in practice and 6 participation levels in match play. A minimum of 2 weeks and 4 training sessions without pain or effusion must be completed before the athlete progresses to the next level. Criteria for full, unrestricted participation in practice: (1)at least 9 months from ACLR, (2)modified stroke test grade 0, (3)completed previous levels in the sport-specific progression plan, (4)negative Lachman test, (5)side hop test limb symmetry at least 90%, (6)triple hop test limb symmetry at least 90%, (7)quadriceps power symmetry at least 90%. The strength training and knee control exercise protocols each have 3-4 different exercises of 3-4 sets that are performed 3 days per week.
223828413|NCT04049292|OTHER|Usual care|Usual care is determined by the treating health care professional
223828414|NCT00192140|BIOLOGICAL|FluMist|A single intranasal dose of FluMist will be administered to approx. 300 subjects.
223828415|NCT01474837|BEHAVIORAL|Intervention: Exercise and motivational interviewing|12 sessions of exercise with MI
223828416|NCT02675140|DRUG|ZENTEL|Children in Group 2 (n=62) received 400 mg single-dose albendazole (helmintic treatment)
223828417|NCT02675140|DRUG|ZENTEL and Vitamin A Soft Capsules|Children in Group 3 (n=60) received a 200,000 IU vitamin A capsule combined with 400 mg single-dose albendazole once initially
223828418|NCT01815814|OTHER|Rolfing / Myofascial Structural Integration|"Rolfing is similar to deep massage. It is also known as myofascial structural integration."
223828419|NCT01007240|DEVICE|polyethylenimine (PEI) nanoparticles.|
223828420|NCT06272019|OTHER|Iodine gargle|Iodine gargle 0.2 %
223828421|NCT00790114|DRUG|AZD7325|Oral, day 1-12
223828422|NCT00790114|DRUG|Midazolam|single dose, twice during treatment
223828423|NCT00790114|DRUG|Caffeine|single dose, twice during treatment
223828424|NCT06114563|OTHER|Spirulina yogurt|High cardiometabolic risk volunteers will be asked to consume 2 yogurts with spirulina, each containing 2 g spirulina, daily for 8 weeks, without any other change in their dietary habits and physical activity.
223828425|NCT06114563|OTHER|Conventional yogurt|High cardiometabolic risk volunteers will be asked to consume 2 conventional yogurts (without spirulina), daily for 8 weeks, without any other change in their dietary habits and physical activity.
223828426|NCT03075956|DRUG|5 mg E4 single-dose|A single oral dose of 5 mg E4 will be administered during Period 1 of the study.
223828427|NCT03075956|DRUG|15 mg E4 single-dose|A single oral dose of 15 mg E4 will be administered during Period 1 of the study.
223828428|NCT03075956|DRUG|45 mg E4 single-dose|A single oral dose of 45 mg E4 will be administered once orally during Period 1 of the study
223828429|NCT03075956|DRUG|15 mg E4 multiple-dose|15 mg E4 will be administered once daily orally for 14 consecutive days during Period 2 of the study
223828430|NCT01783353|DIETARY_SUPPLEMENT|Zinc gluconate|
223828431|NCT01783353|DIETARY_SUPPLEMENT|Corn starch pill|
223828432|NCT02678325|OTHER|Standardized high protein enteral nutrition|A double-blind randomized controlled clinical trial of critically ill patients to explore values of high enteral protein administration on muscle breakdown and mortality.
223828433|NCT02678325|OTHER|Standardized normal protein enteral nutrition|double-blind randomized controlled clinical trial of critically ill patients to explore values of high enteral protein administration (compared to normal enteral protein administration) on muscle breakdown and mortality.
223828434|NCT05324930|DEVICE|Piscean collagen dressing|Piscean collagen dressing
223828435|NCT05324930|DEVICE|Saline infused dressing|Saline infused dressing
223828436|NCT02320643|DEVICE|Seratom® PA mesh|Partially absorbable mesh
223828437|NCT03857841|BIOLOGICAL|UNEX-42|UNEX-42 is a preparation of extracellular vesicles that are secreted from human bone marrow-derived mesenchymal stem cells suspended in phosphate-buffered saline.
223828438|NCT03857841|BIOLOGICAL|Phosphate-buffered saline|Phosphate-buffered saline
223828439|NCT02149602|RADIATION|Intensity modulated radiotherapy|Bilateral superficial lobe parotid sparing intensity modulated radiotherapy
223828440|NCT03055611|DRUG|ELOCTA|Extended half-life factor VIII product
223828441|NCT03055611|DRUG|ALPROLIX|Extended half-life factor IX product
223828442|NCT01052909|DRUG|Glimepiride|Glimepiride tablets 1 mg
223828443|NCT06617234|OTHER|Nurse-led Intervention Program|"Nurse-led Intervention Program: This intervention consists of a face-to-face educational session led by a nurse, focusing on the importance of cardiac rehabilitation. The session lasts 15-20 minutes and is tailored to the patient's medical condition and lifestyle, with follow-up reminders and personalized guidance for rehabilitation participation.~LINEbot Automated Robot System: This intervention uses the LINEbot system to send automated push notifications to participants, including educational messages, reminders for cardiac rehabilitation appointments, and health tracking prompts. Participants can log their daily health data through the system, which offers personalized advice on diet, exercise, and medication management."
223828444|NCT06617234|OTHER|LINEbot Automated Robot System|Participants in this group will use the \&amp;#34;LINEbot\&amp;#34; automated robot system, which sends push notifications through the LINE app. The system delivers education messages, exercise guidance, and health tracking prompts. It provides daily reminders for cardiac rehabilitation participation, as well as customized messages on health management, such as diet, medication, and self-care. The system also allows users to log health data like blood pressure and heart rate.
223828445|NCT06622785|BEHAVIORAL|Physical activity|Data were collected using a International Physical Activity Questionnaire-Short Form (IPAQ-SF)
223828446|NCT06622785|BEHAVIORAL|Exercise Benefits|Data were collected using a Exercise Benefits/Barriers Scale .
223828447|NCT04921969|DRUG|Ruxolitinib|The study cream will be applied topically twice a day for up to 52 weeks.
223828448|NCT04921969|DRUG|Vehicle Cream|Matching vehicle cream will be applied topically twice a day for up to 8 weeks.
223828449|NCT06897020|OTHER|(Group A: Bioflx crowns)|"prepartion:1.The mesiodistal width of the tooth will be measured using calipers and a closely fitted crown will be selected based on the measurements.~2.The tooth will be prepared similarly to stainless steel crowns (SSCs): • Occlusal reduction of approximately 1-1.5 mm will be done using a diamond bur.Mesial and distal reduction of no more than 1 mm will be performed using a No. 169L diamond bur.Depending on the tooth anatomy, either no buccal and lingual reduction will be needed, or a minimal reduction will be done. 3.All sharp line angles and corners will be smoothed to ensure proper crown fit. 4.The crown will be checked for proper fit before cementation. It will be positioned to extend 1 mm below the gingival margin. 5.The crown will be cemented using luting glass ionomer cement (GIC). The crown will be held with firm, constant pressure until the cement sets initially.~6.The marginal fit will be evaluated, and necessary adjustments will be made. 7.The occlusion will be checked."
223828450|NCT06897020|OTHER|(Group B: Preformed Zirconia crown|"1. Crown Selection: The mesiodistal dimension of the corresponding tooth will be measured . to select the appropriate size.~2. Occlusal Reduction: The marginal ridge of adjacent teeth will be used as a reference point and a 1.5-2 mm of occlusal reduction will be performed to allow proper crown seating.~3. Bucco-Lingual Reduction: The bucco-lingual wall will be reduced by approximately 1-1.5 mm using a flame-shaped diamond bur.~4. Interproximal Reduction: 1mm of interproximal reduction will be performed using a flame-shaped diamond bur such as a .368 or .330tapered carbide bur.~5. Feather Margin Preparation: Subgingival reduction of 1-2 mm will be done using a flame-shaped diamond bur, creating a feathered margin to achieve a passive fit.~6. Trial Fitting of the Crown: The crown will be tried in to ensure proper adaptation. until the crown fits passively and extends sub gingivally by 1-2 mm wit.~7. Glass ionomer cement will be used for cementation."
223828451|NCT02751736|DIETARY_SUPPLEMENT|CJLP243|Perioperative administration till postoperative weeks 3
223828452|NCT02751736|DIETARY_SUPPLEMENT|Placebo|Perioperative administration till postoperative weeks 3
223835589|NCT05577065|DIETARY_SUPPLEMENT|Probiotic|Single strain probiotic in the form of a sachet with a daily dose of 3E+9 Colony Forming Unit (CFU) per day for 26 weeks.
223828453|NCT03661229|DEVICE|CVInsight Monitoring|All participants (n=50) will receive CVInsight non-contact device and CVInsight contact device application during two of their regularly scheduled dialysis sessions.
223828454|NCT05718648|DRUG|BI 1015550|BI 1015550
223828455|NCT02446093|BIOLOGICAL|Aglatimagene besadenovec|Three courses of CAN-2409 + prodrug (valacylovir or acyclovir) will be delivered and timed with different phases of therapy: 1) after induction chemotherapy 2) during CR or post-SBRT, and 3) at time of surgery. Up to 2 additional courses of CAN-2409 + prodrug, if feasible, for subjects with disease progression or metastases.
223828456|NCT02446093|RADIATION|Chemoradiation|CR will start not more than 2 months after completion of induction chemotherapy. The chemotherapy component of CR may be selected as per institutional standard of care (SOC) and protocols for administration, and may include capecitabine, 5-FU, or gemcitabine. Radiation should consist of a total dose of 45-54 Gy in 1.8-2.0 Gy fractions concurrent with chemotherapy over 3-5.5 weeks.
223828457|NCT02446093|RADIATION|Stereotactic body radiation therapy|SBRT should start no more than 2 months after completion of induction chemotherapy. For SBRT, the radiation should consist of a total dose of 25-50 Gy in divided fractions over 1-2 weeks.
223828458|NCT02446093|PROCEDURE|Surgery|Surgical resection should be performed within 8 weeks after completing CR or SBRT.
223828459|NCT00000692|DRUG|Butyldeoxynojirimycin|
223828460|NCT02326844|DRUG|BMN 673 (talazoparib)|1 mg by mouth (p.o.) once daily on 28-day cycles until disease progression
223828461|NCT04944225|OTHER|Opioid Reduction Strategy|The intervention will involve a multi-faceted 3 component approach involving 1) opioid prescription caps (default maximum number of tablets for discharge prescriptions, as defined by evidence-based guidelines) 2) patient education tools (e.g. What is a normal pain trajectory? How to manage the pain? Benefits and potential harms of pharmacologic analgesia. Non-pharmacologic analgesia management? What to do if pain is excessive?), 3) provider education tools (e.g. including procedure-specific evidence-based recommendations for multi-modal analgesia; comparison of local baseline prescribing patterns with exemplary prescribing patterns; defining targeted reduction if baseline prescribing is at odds with best evidence; review of best evidence about optimal analgesia perioperatively), and 4) bi-weekly cumulative prescriber feedback on opioid prescribing patterns post-intervention and until end-of-study.
223828462|NCT00004928|DIETARY_SUPPLEMENT|calcitriol|
223828463|NCT00004928|DRUG|zoledronic acid|
223835590|NCT05577065|DIETARY_SUPPLEMENT|Placebo|Matching placebo in the form of a sachet once daily for 26 weeks
223828464|NCT01345643|OTHER|Maintenance of hemoglobin level not less than 10g/dL|The patient's hemoglobin level is maintained not less than 10g/dL perioperatively.
223828465|NCT01345643|OTHER|Transfusion trigger based on WCPTS|Determination of whether a patient needs red blood cell transfusion or which hemoglobin level should be maintained is based on WCPTS
223828466|NCT06280963|BEHAVIORAL|muscle energy technique|in muscle energy technique, the target is gluteus maximus muscle ( hip extension ) and repeat the method from three to five times .
223828467|NCT06280963|BEHAVIORAL|posterior innominate mobilization|in posterior innominate mobilization ( grade 3 mobilization ) , frequency of mobilizations is 30 oscillations , 3 sets per session ( every set has 30 oscillations )
223828468|NCT06280963|BEHAVIORAL|conventional treatment|"conventional treatment include~* TENS ( 45 minutes of conventional TENS )~* Ultrasound (pulsed mode 1:1 ,5 min .1.5W/cm2 )~* Stretching exercises ( hamstrings ,hip flexors and hip adductors)~* Strengthening exercises (lower abdomen and glutes muscles )~* Lumpopelvic stabilization exercise"
223828469|NCT00341640|PROCEDURE|Blood testing|
223828470|NCT02339649|PROCEDURE|Blood Sample|Blood Sample
223828471|NCT02339649|BEHAVIORAL|Neurocognitive Assessment|Neurocognitive Assessment
223828472|NCT02339649|OTHER|Resting State EEG|10-20 Minutes of Resting State EEG
223828473|NCT02339649|PROCEDURE|Lumbar Puncture|Lumbar Puncture
223828474|NCT02339649|OTHER|MRI|60 Minutes MRI
223828475|NCT05685771|DEVICE|Phase-targeted auditory stimulation|Bursts of pink noise (50 ms) played during deep non-REM sleep at specific phases of sleep slow waves.
223828476|NCT03630562|PROCEDURE|Aqueous humor samples collection|In addition to the routine examinations performed as part of the usual care of AMD patients, an anterior chamber puncture will be performed to collect the aqueous humor samples.
223828477|NCT01091428|DRUG|Alisertib|Alisertib tablets
223828478|NCT01091428|DRUG|Paclitaxel|Paclitaxel intravenous infusion
223828479|NCT04348682|DIAGNOSTIC_TEST|Positron Emission Tomography (PET) Imaging|A single dose activity of 5 mCi (accepted range of 3-7 mCi) of 68Ga-PSMA-11 will be intravenously administered to patient as a bolus injection. After 50-100 minutes of uptake time, the patient will undergo a whole body (skull to mid-thighs) PET/CT imaging.
223828480|NCT03863743|OTHER|integrated care pathway|Incidence of POUR after undergoing total hip or knee replacement and integrated care pathway will be evaluated.
223828481|NCT03863743|OTHER|physician's standard of care|Incidence of POUR will be evaluated in standard of care treatment.
223828482|NCT03386695|OTHER|Education by Pamphlets|Distribution of pamphlets with information of prevention and early detection of cervical cancer and written as well as pictorial depiction on how to collect cervical self sample for HPV detection.
223828483|NCT03386695|OTHER|Health education programme|Health education program explaining about prevention and early detection of cancer and education on method of collection of cervical self sample for HPV.
223828484|NCT06115850|PROCEDURE|Music|In the music intervention group, the patients received music intervention during RT for 10 consecutive days and listened to music for approximately 10-15 minutes in each session.
223828485|NCT04468243|OTHER|Nurse-led diabetes care|Nurse-led brief diabetes education, instructions on glucometer and Metformin use, patients receive prescriptions for Metformin and blood glucose testing kit
223828486|NCT05507489|DRUG|Jinzhen oral liquid or Jinhuaqinggan granules|Jinzhen oral liquid, for 3 years old, 10 ml once, twice a day; for 4 to 7 years old, 10 ml a time, 3 times a day; for 8 to 18 years old, 15 ml a time, 3 times a day.The dosage and usage of Jinhua Qinggan granules were determined by the researcher according to the patient's condition. The drugs were medicated for 14 days.
223828487|NCT01288781|DRUG|Acetazolamide|During a forty eight hour hypoxic exposure (3777m), subjects will be given either acetazolamide or placebo at hours fifteen, twenty and thirty two.
223828488|NCT01288781|DRUG|Lactose monohydrate|During a forty eight hour hypoxic exposure (3777m), subjects will be given either acetazolamide or placebo at hours fifteen, twenty and thirty two.
223828489|NCT03518658|OTHER|Evaluation Group|Patient receiving exposure to the MyCareLink Heart App during device pairing
223828490|NCT03518658|OTHER|Control Group (Historical)|Patients receiving exposure to the CareLink Monitor 2490 (Excluding wireless model 2490C). The patients' data will be extracted from Medtronic de-identified CareLink™ database.
223828491|NCT06134245|DEVICE|Entia Liberty|Home monitoring
223828492|NCT02531295|DRUG|Euphorbia kansui extract powder prepared as tea|1 g of Euphorbia kansui extract powder, measured and reconstituted in 4 fluid ounces of boiled water allowed to cool and administered as tea, taken by mouth daily
223828493|NCT06251726|DIAGNOSTIC_TEST|Immunoscore Colon Test|"Immunoscore Colon is an in-vitro diagnostic test, allowing the quantification of CD3 and CD8 positive cells in formalin-fixed paraffin-embedded (FFPE) tissue samples of primary colon cancer.~The test uses immunohistochemistry, digital pathology techniques and a dedicated image analysis software to determine CD3+ and CD8 + cell densities in the tumor ant in the invasive margin of the tumor."
223828494|NCT02338258|DEVICE|Anti-rotational plate|
223828495|NCT02338258|DEVICE|Exchanged Intramedullary nailing|
223828496|NCT03435458|COMBINATION_PRODUCT|Balloon catheter + oral misoprostol|The pharmacological cervical ripening will be administered just after the balloon catheter insertion (after coming back in her room) and will consist of misoprostol 25 micrograms given orally (oral prostaglandin E1). The same dose will be given every 2 hours until beginning of labor with a maximum of 8 administrations.
223828497|NCT03435458|DRUG|Oral misoprostol alone|Patients will receive a pharmacological cervical ripening alone that consist of Misoprostol 25 micrograms given orally (oral prostaglandin E1). The same dose will be given every 2 hours until beginning of labor with a maximum of 8 administrations.
223828498|NCT01154023|BEHAVIORAL|stimulus control therapy, sleep restriction therapy, multi-component treatment (stimulus control therapy, sleep restriction therapy)|Treatment was given weekly for 6 weeks. Sessions 1 - 4 were in a group format. Session 5 \& 6 were delivered individually by phone.
223828499|NCT02382510|DRUG|TRN-157|
223828500|NCT02382510|OTHER|Placebo|
223828501|NCT02382510|DRUG|Tiotropium|
223828502|NCT01167270|BEHAVIORAL|Child Safety Insights|A child safety intervention with messages focused on the infant's environment and interactions with parents. They will be guided by the American Academy of Pediatrics as well as the Academy's guide for health supervision, Bright Futures.
223828503|NCT01167270|BEHAVIORAL|Parenting Insights|Educational program contains messages to provide developmentally appropriate guidance to parents of infants on responsive parenting and healthy lifestyle that will prevent rapid weight gain in infancy and overweight at age 3 years.
223828504|NCT01315743|BEHAVIORAL|Team COOL|1\) a classroom-based experiential curriculum that incorporated school, family and community-linked activities to promote physical activity, healthy eating and limited television viewing, 2) environmental modifications of food and beverage offerings and physical activity opportunities at school and 3) a teacher-guided, youth-directed health advisory council to promote and support physical activity, healthy eating and limited television viewing.
223828505|NCT04857190|DEVICE|Parker Flex-it Directional Stylet|Parker Flex-it Directional Stylet
223828506|NCT04857190|DEVICE|Conventional Malleable Stylet|Conventional Malleable Stylet
223828507|NCT01060020|DRUG|Sildenafil|Single oral dose of 40mg or 80mg of Sildenafil
223828508|NCT03408834|OTHER|pulse variability index|fluid management with pulse variability index or conventional
223828509|NCT00030433|DRUG|gemcitabine hydrochloride|
223828510|NCT00030433|DRUG|irinotecan hydrochloride|
223828511|NCT02292810|DEVICE|Inspiratory muscle exercise|For inspiratory muscle exercise patients will breathe with a high load of 60% of MIP using a respiratory frequency of 15 breaths min and a prolonged duty cycle (TI/TTOT =0.7) until task failure. The blood flow, conductance and resistance arterial will be measured in the calf using plethysmography device. Arterial blood pressure and heart rate will be monitored continuously at the finger on a beat-by-beat basis by biopac equipment and the glucose levels will be captured by continuous glucose monitoring system.
223828512|NCT02292810|DEVICE|Inspiratory muscle exercise placebo|For inspiratory muscle exercise patients will breathe with a very low load of 2% of MIP using a respiratory frequency of 15 breaths min and a prolonged duty cycle (TI/TTOT =0.7) for 10 minute. The blood flow, conductance and resistance arterial will be measured in the calf using plethysmography device. Arterial blood pressure and heart rate will be monitored continuously at the finger on a beat-by-beat basis by biopac equipment and the glucose levels will be captured by using the continuous glucose monitoring system.
223828513|NCT03013699|BEHAVIORAL|Cruciferous and Dark Leafy Green Intervention|Participants receive individual dietary counseling from a Registered Dietitian who will focus on increasing intake of cruciferous and green leafy vegetables while addressing any disease- and treatment-related eating difficulties experienced by the participant.
223828514|NCT03013699|BEHAVIORAL|Usual Dietary Care|Participants receive standard educational materials that focus on healthy eating for cancer survivors and the opportunity to briefly discuss nutrition-related concerns with the Registered Dietitian weekly.
223828515|NCT00963989|DEVICE|Penumbra System|The Penumbra System is used to revascularize clotted cerebral blood vessels.
223828516|NCT02527837|DRUG|Sodium nitrite|Sodium nitrite, 240 micrograms/kg/hour for 2 hours
223828517|NCT02527837|DRUG|Sodium chloride|Sodium chloride, isotonic 0.9%, 25 ml/hour for 2 hours
223828518|NCT01941550|DRUG|Cabazitaxel chemotherapy|given in 6 cycles
223828519|NCT01183702|PROCEDURE|LASIK surgery|Participants have received LASIK surgery and their eyes are healthy.
223828520|NCT01183702|OTHER|No Intervention|Participant has healthy eyes not altered by LASIK surgery.
223828521|NCT05009706|OTHER|Self-care in Older frail Persons with Heart failure Intervention (SOPHI)|Patients who are randomized to the Self Care group will receive oral and written information, advice and support on following activities: excercise (from physiotherapist), nutrition (dietician) and symptom management (nurse), based on patient´s individual needs and abilities. The Self Care group will perform the activities daily at home. Once a week, patients come to the hospital to exercise with the support of a physiotherapist. Once a week or every other week patients will meet (at hospital or by phone) the dietician and nurse to solve possible problems and to follow-up food/nutrition intake and symptoms/symptom management.
223828522|NCT02171364|PROCEDURE|Virtual ablation in based 3D CT of patient who diagnosed AF|
223828523|NCT02171364|PROCEDURE|conventional ablation based on physician's personal experience|
223828524|NCT03743363|OTHER|Exergame 2/week|virtual training 2 times a week(8 week-long)
223828525|NCT03743363|OTHER|Exergaming 3/week|virtual training 3 times a week(8 week-long)
223828526|NCT03743363|OTHER|Healthy control / Exergaming 1/week|In the first 8 week-long only control group. For the next 8 weeks, the control group will do 1 workout per week.
223828527|NCT06031168|OTHER|Metformin gel coated implants|Patients will be treated with 1% concentrated metformin gel coated hydrophilic dental implant.
223828528|NCT06031168|OTHER|uncoated hydrophilic dental implants|Patients treated by uncoated implants
223828529|NCT00030368|DRUG|bortezomib|Given IV
223828530|NCT00030368|DRUG|paclitaxel|Given IV
223828531|NCT00030368|OTHER|laboratory biomarker analysis|Correlative studies
223828532|NCT04235868|BIOLOGICAL|Stem cell-derived derived pleiotropic factor|After debridement, the wounds in experimental group apply stem cell-derived lyophilized powder, and use foam dressing to wrap the wound; apply once every 2-3 days.
223828533|NCT04235868|BIOLOGICAL|fibroblast growth factor|After debridement, the wounds in control group apply fibroblast growth factor to the wound surface, and use foam dressing to wrap the wound; apply once every 2-3 days.
223828534|NCT05713812|PROCEDURE|Kinesiotaping|Kinesiotape will be applied
223828535|NCT05713812|PROCEDURE|Control Treatment|IFC + Hot pack for 20 minutes MDT (prone positioning) for 10 minutes. Lumbar SNAGs + lumbar rotation mobilization. Home exercise plan: MDT for 10 min + patient education to avoid flexion based activities.
223828536|NCT04216979|PROCEDURE|laparoscopy entry policy|"Patients will be randomly arranged in 2 groups Group (A):- Palmer's point is the primary entry site.~Group (B):- The umbilicus is the primary entry site."
223828537|NCT05731882|DEVICE|E-SeaLA, CardioPulse PFA system|First, pulmonary vein isolation(PVI) was performed with the novel hex spline PFA ablation catheter( CardioPulseTM PFA system, Hangzhou Dinova EP Technology Co., Ltd), then, pulsed field ablation and mechanical closure of the left atrial appendage were achieved by E-SeaLATM(Hangzhou Dinova EP Technology Co., Ltd) implantation.
223828538|NCT03953404|DIAGNOSTIC_TEST|SPLA2-IIA|bedside blood test
223828539|NCT05141981|DEVICE|inbody device|measure muscle mass
223828540|NCT01849120|DEVICE|EQUANOX Advance 8004CB sensor|The EQUANOX Advance 8004CB sensors placed in peripheral sites of neonates and infants will be used to detect peripheral perfusion and oxygen delivery.
223828541|NCT04262492|DRUG|Rivaroxaban|Rivaroxaban 10 mg or 15 mg or 20 mg OD Dabigatran 110 mg or 150 mg BID Apixaban 2.5 mg or 5 mg or 10 mg BID
223828542|NCT04645238|OTHER|Static Stretching|Static hamstring stretching exercise lasting 30 seconds and 10 repetitions under the supervision of the physiotherapist
223828543|NCT04645238|OTHER|PNF Stretching|PNF hold-relax stretching technique that consists of 10 seconds isometric contraction, 30 seconds hamstring stretching and 10 repetitions under the supervision of the physiotherapist
223828544|NCT01562002|PROCEDURE|Stem Cell with Amniotic Membrane Transplant|Single stem cell expansion in amniotic membrane transplant
223828545|NCT05932459|DRUG|Deuremidevir Hydrobromide for Suspension 100mg|Take it with 240ml water in fasted condition.
223828546|NCT05932459|DRUG|Deuremidevir Hydrobromide for Suspension 300mg|Take it with water in fasted condition or after taking infant formula.
223828547|NCT05932459|DRUG|Deuremidevir Hydrobromide for Suspension 25mg|Take it with 240ml water on an empty stomach.
223828548|NCT05932459|DRUG|Deuremidevir Hydrobromide tablets 100mg|Take it with 240ml water in fasted condition.
223828549|NCT06768957|OTHER|Single leg hop for distance|"Patients will have to perform a Single leg hop for distance.~A 10-minute warm-up is required beforehand, followed by three single-leg hop round trips over a distance of 6m to ensure that they are able to perform the exercise.~You start on the healthy side to understand the principles and reassure yourself. The distance covered is measured. This tells us something about the strength of the lower limb. The landing should be assessed qualitatively.~1\. Patient balanced on 1 foot, hands crossed over shoulders. 2. Jump as far as possible.~3\. Stabilise 1 time, keeping hands on shoulders."
223828550|NCT06768957|OTHER|Single leg hop for distance plus cognitive task|"Patients were asked to perform a single leg hop for distance in addition to a cognitive task.~A 10-minute warm-up is required beforehand, followed by three single-leg hop round trips over a distance of 6m to ensure that they are able to perform the exercise.~You start on the healthy side to understand the principles and reassure yourself. The distance covered is measured. This tells us something about the strength of the lower limb. The landing should be assessed qualitatively.~1. Patient balanced on 1 foot, hands crossed over shoulders.~2. Observe a sequence of 5 digits, appearing every 4 seconds, on the computer in front of you.~3. As soon as the 5th digit appears, jump as far as you can.~4. Stabilise 1 time, keeping your hands on your shoulders.~5. Replay the sequence of 5 numbers that appear on the screen, in reverse order."
223828551|NCT05442567|DRUG|Vedolizumab IV|Vedolizumab IV infusion
223828552|NCT05442567|OTHER|No Intervention|Participants will not receive any intervention in the Observational Cohort.
223828553|NCT05285917|DRUG|Hydroxyurea|Hydroxyurea has a narrow therapeutic window such that selection of the correct dose is essential to optimize benefits and avoid toxicity.
223828554|NCT01619657|DRUG|6% Hypertonic Saline (HS), 4mL|Administered via inhalation twice daily for 52 weeks. The delivery system is a PARI LC SPRINT® Junior nebulizer with a baby bend, size-adapted PARI® Baby face mask size 0-3, connection tubing (2.2m) and a PARI JuniorBOY® SX compressor.
223828555|NCT01619657|DRUG|0.9% Isotonic Saline (IS), 4mL|Administered via inhalation twice daily for 52 weeks. The delivery system is a PARI LC SPRINT® Junior nebulizer with a baby bend, size-adapted PARI® Baby face mask size 0-3, connection tubing (2.2m) and a PARI JuniorBOY® SX compressor.
223828556|NCT03884231|DEVICE|Infinity DBS System with MR Conditional labelling|Patients implanted with the Infinity DBS system with MR Conditional labeling
223828557|NCT01853254|DRUG|Peginterferon alfa-2a|Both combination and monotherapy for both genotype 2/3 and genotype non-2/3: 180 μg subcutaneously once weekly.
223828558|NCT01853254|DRUG|Ribavirin|For genotype 2/3, 800 mg orally daily, in 2 split doses for 24 weeks. For genotype non-2/3, 1000 mg orally daily for participants weighing \< 75 kg or 1200 mg orally daily for participants weighing ≥ 75 kg, in 2 split doses, for 48 weeks.
223828559|NCT02359149|PROCEDURE|intravitreal injections given by a nurse|
223828560|NCT02359149|PROCEDURE|intravitreal injections given by a physician|
223828561|NCT02359149|PROCEDURE|Intravitreal injections|
223828562|NCT02359149|DRUG|Anti-VEGF agents|
223828563|NCT06469073|PROCEDURE|Transversus thoracic muscle plane block or Erector spinal plane block|Transversus thoracic muscle plane block or Erector spinal plane block
223828564|NCT03753282|OTHER|questionnaires for patient reported outcome|"questionnaires with respect to outcomes:~* Reoperations~* Short term complications~* Long term complications~* EQ-5D (current)~* HOOS (current)~* disease related change of occupation~* use of walking aids~* comorbidities~* medication"
223828565|NCT03753282|OTHER|questionnaire for course of the disease|"questionnaires to assess course of the disease:~* from initial diagnosis of AVN to joint replacement as total hip arthroplasty (THA)~* therapeutic interventions"
223828566|NCT00398398|DRUG|Capecitabine, Oxaliplatin, Cetuximab|Xelox(Capecitbine, Oxaliplatin) and Cetuximab every three week; Capecitabine 1,000 mg/m2 was administered twice daily on days 1-14. Oxaliplatin 130 mg/m2 i.v. for 2 h was given on day 1 after cetuximab infusion. Cetuximab at an initial loading dose of 400 mg/m2 i.v. for 2 h and, thereafter, maintenance dose of 250 mg/m2 for 1 h every week.
223828567|NCT04762173|DEVICE|Online self-help intervention|Access to two online, self-guided programs available on the SilverCloud Health website.
223828568|NCT03279705|DEVICE|Water jet channel|The separate water jet channel was used for infusing water.
223828569|NCT03279705|DEVICE|Accessory channel|The accessory channel was used for infusing and/or suctioning water
223828570|NCT00650221|DRUG|Pravastatin|Single-dose 80 mg immediate-release oral tablet
223828571|NCT00650221|DRUG|Pravastatin|Single-dose 80 mg immediate-release tablet
223828572|NCT06219343|DEVICE|Non-invasive vagus nerve stimulation|Patient undergoes non-invasive vagus nerve stimulation during tachycardia episodes to see if reentry is possible
223828573|NCT04176133|DRUG|Entolimod|Intramuscular (IM) single dose administration. Entolimod is provided as a sterile, clear, colorless or slightly yellow liquid for IM injection.
223828574|NCT04176133|DRUG|Placebo|Intramuscular (IM) single dose administration, no active ingredient. A matching placebo is provided as a sterile, clear, colorless to slightly yellow liquid for IM injection in prefilled vials that are identical in appearance to the vials containing active drug.
223828575|NCT04176133|DRUG|Influenza vaccine|Intramuscular (IM) single dose administration. Fluzone, high-dose split virion influenza virus vaccine, Sanofi Pasteur
223828576|NCT01314781|DRUG|solifenacin|solifenacin 5mg tablet once daily
223828577|NCT01314781|PROCEDURE|PFMT and WBVT|pelvic floor muscle and whole body vibration training once a week
223828578|NCT04327908|OTHER|Questionaire TESS and MSTS|answering TESS and MSTS questionnaire
223828579|NCT06480643|OTHER|High load exercise type|Heavier load, fewer reps
223828580|NCT06480643|BEHAVIORAL|Low load exercise type|Lighter load, more reps
223828581|NCT03347864|DRUG|68Ga-NOTA-RM26|1.85 MBq per kilogram body weight of 68Ga-NOTA-RM26 were injected into the patients before the PET/CT scans
223828582|NCT03342781|DEVICE|high flow nasal oxygen therapy|Oxygen therapy using a high-flow nasal cannula (HFNC) is a high-flow oxygen delivery system that enhances the efficiency of respiration by using high flow rates to clear dead space and provide fresh oxygen. This system supplies oxygen at a high flow rate through a loose nasal cannula.
223828583|NCT03342781|DEVICE|Diffuser oxygen mask|diffuser mask is a low-flow delivery system, which is capable of delivering up to 90% of the fraction of inspired oxygen (FiO2) with low CO2 retention. In this system, the FiO2 can be adjusted by modifying the flow velocity to deliver the quantity of oxygen that the patient requires. Oxygen is supplied to the patient in a jet that flows from a device mounted on the oxygen mask. This ensures that a high concentration of oxygen is provided at a low flow rate.
223828584|NCT01755286|DRUG|OTO-201|Single intra-operative injection
223828585|NCT01755286|DRUG|Placebo|Single intratympanic injection
223828586|NCT01755286|DRUG|Sham|Simulated single intratympanic injection
223828587|NCT03140917|DIAGNOSTIC_TEST|Multimodal liver function assessment|HBS, MRI, CE-CT and ICG
223828588|NCT03442023|DRUG|Chlorhexidine gluconate at 2%|Mouth Rinse with Chlorhexidine gluconate at 2% every 12 hours, one week.
223828589|NCT03442023|DRUG|Chlorhexidine gluconate at 0.12%|Mouth Rinse with Chlorhexidine gluconate at 0.12% every 12 hours, one week.
223828590|NCT02891590|DRUG|DTRMWXHS-12|
223828591|NCT03652480|DRUG|MethylPREDNISolone Acetate 40 MG/ML|
223828592|NCT02520999|DEVICE|Auto PC(Acemedical, Goyang-si, Korea) - 0mmHg(control)|Blood pass through infusion set without external pressure.
223828593|NCT02520999|DEVICE|Auto PC(Acemedical, Goyang-si, Korea) - 150mmHg|Blood pass through infusion set under external pressure (150mmHg)
223828594|NCT02520999|DEVICE|Auto PC(Acemedical, Goyang-si, Korea) - 200mmHg|Blood pass through infusion set under external pressure (200mmHg)
223828595|NCT02520999|DEVICE|Auto PC(Acemedical, Goyang-si, Korea) - 250mmHg|Blood pass through infusion set under external pressure (250mmHg)
223828596|NCT02520999|DEVICE|Auto PC(Acemedical, Goyang-si, Korea) - 300mmHg|Blood pass through infusion set under external pressure (300mmHg)
223828597|NCT05200390|DEVICE|Continuous glucose monitor|FreeStyle Libre 2 system
223828598|NCT00555204|DRUG|ABT-089|10 mg - capsules once daily for 12 weeks
223828599|NCT00555204|DRUG|ABT-089|5 mg - capsules once daily for 12 weeks
223828600|NCT00555204|DRUG|ABT-089|15 mg - capsules once daily for 12 weeks
223828601|NCT00555204|DRUG|ABT-089|20 mg - capsules once daily for 12 weeks
223828602|NCT00555204|DRUG|ABT-089|30 mg - capsules once daily for 12 weeks
223828603|NCT00555204|DRUG|ABT-089|35 mg - capsules once daily for 12 weeks
223828604|NCT00555204|DRUG|placebo|placebo - capsules once daily for 12 weeks
223828605|NCT01017120|DRUG|Tazarotene Foam|Tazarotene foam once a day application to the face
223828606|NCT01017120|DRUG|Vehicle Foam|Vehicle Foam once a day application to the face
223828607|NCT01087723|DRUG|Bivalirudin|
223828608|NCT01087723|DRUG|Heparin|
223828609|NCT04539119|DRUG|Tenofovir|Participants will be given tenofovir 300mg (1 capsule) qd po two weeks before the first cycle of treatment. HBV DNA will be measured before each cycle of chemotherapy or immunotherapy. Tenofovir will be given until the copy count of HBV DNA drops below 1\*10\^3/L.
223828610|NCT04539119|DRUG|Entecavir|Participants will be given entecavir 0.5 mg (1 capsule) qd po from two weeks before the first cycle of treatment until one year after the end of treatment. HBV DNA will be measured before each cycle of chemotherapy or immunotherapy. Entecavir will be given until one year after the end of treatment.
223828611|NCT01095705|PROCEDURE|Conventional procedure|Local anaesthesia (Lidocaïne)
223828612|NCT01095705|PROCEDURE|Conventional procedure + Hypnosis|Local anaesthesia (Lidocaïne) + Hypnosis (20 minutes)
223828613|NCT05332574|BIOLOGICAL|GB263T|Participants will receive IV infusions of GB263T at increased dose level until maximum tolerated dose is reached or all planned doses are administered. Participants will receive GB263T at predefined dose levels and frequency, based upon observed safety and protocol defined criteria. The duration of each treatment cycle is 28 days.
223828614|NCT04873622|BEHAVIORAL|RESTORE: Recovering from Extreme Stressors Through Online Resources and E-health|RESTORE (www.restoreonline.ca) includes eight e-modules anticipated to be approximately 30-40 minutes each in length and intended to be completed over 4-8 weeks. The modules address cognitive and behavioural factors posited to cause and maintain psychological distress related to the COVID-19 pandemic. These include cognitions about the cause and meaning of stressors related to the pandemic, including self-blame, other blame and hindsight bias, as well as problematic beliefs related to safety, trust, and control. The modules also address the importance of: (1) expressing emotions that are natural to the events of the pandemic (e.g., sadness in the face of loss), (2) working through, rather than avoiding, thoughts, feelings and grief related to the pandemic, and (3) utilizing social supports. The modules consist of written materials, brief videos, and practice assignments delivered through the platform. RESTORE includes guidance via direct messaging and/or brief telephone calls.
223828615|NCT00806624|DRUG|DU-176b tablets|DU-176b tablets taken once daily for up to 3 months
223828616|NCT00806624|DRUG|DU-176b tablets|DU-176b tablets taken once daily for up to 3 months
223828617|NCT00806624|DRUG|Warfarin tablets|Warfarin tablets taken once daily for up to 3 months
223828618|NCT01918293|DEVICE|SMART ARM|The smartphone application for self-management of Asthma offers symptom diary, general information for asthma, the information of asthma drugs,the guideline for inhaler and the specific action plan according to daily symptom and FEV1.
223828619|NCT04746430|DRUG|Dexamethasone|6 mg dexamethasone prescribed during ten days and as a precaution combined with electronic monitoring of saturation and other signs and symptoms
223828620|NCT02550132|PROCEDURE|Spinal manipulation|Participants will lie down during the 45-minute experimental session. Vertebral displacements (cm) and muscle response amplitude (RMS value) will be recorded through kinematic markers (on T6, T7 and T8 spinous processes) and surface electromyography electrodes (on the left and right erector spinae at T6 and T8 vertebra level). Each SMT (4 per participant) will be delivered at T7 transverse processes by an apparatus. Responses during the thrust phase (duration equal to twice the time to peak force) and after the thrust (1,5s duration) will be compared between SMTs.
223828621|NCT02550132|DEVICE|Apparatus used to deliver spinal manipulations|An apparatus using a servo-controlled linear actuator motor (Linear Motor Series P01-48x360, LinMot Inc., Switzerland) will be used to deliver spinal manipulations.
223828622|NCT01615588|DIETARY_SUPPLEMENT|Manuka Honey|honey was weighed out to provide 25 g of available carbohydrate in 200 ml of water
223828623|NCT01158430|BEHAVIORAL|ACT group therapy|Group therapy (ACT) in groups of 9 patients in 9 weekly 3.5-hours sessions \& 1 booster session 1 month after 9th session, a total of 35.5 hours
223828624|NCT01702428|BIOLOGICAL|Priorix|Subjects receive 1 dose of MMR vaccine which is administered subcutaneously in the triceps region of the left arm.
223828625|NCT01702428|BIOLOGICAL|M-M-R II|Subjects receive 1 dose of MMR vaccine which is administered subcutaneously in the triceps region of the left arm.
223828626|NCT01702428|BIOLOGICAL|Varivax|Subjects receive 1 dose of VV vaccine which is administered subcutaneously in the triceps region of the right arm.
223828627|NCT01702428|BIOLOGICAL|Havrix|Subjects receive 1 dose of HAV vaccine which is administered intramuscularly in the anterolateral region of the right thigh.
223828628|NCT01702428|BIOLOGICAL|Prevnar 13|US subjects receive 1 dose of PCV-13 vaccine which is administered intramuscularly in the anterolateral region of the left thigh.
223828629|NCT04995497|DRUG|Intravenous Administration of Lidocaine Post Cardiac Surgery|Lidocaine will be administered via intravenously. Initial dose will be at 2 mg/kg ideal body weight followed by dosing at 2 mg/kg/hr for 48 hours
223828630|NCT04995497|DRUG|Administration of Lidocaine Post Cardiac Surgery via ESP Catheter|Lidocaine will be administered via ESP catheter. Initial dose will be at 2 mg/kg ideal body weight split between two catheters followed by dosing at 2 mg/kg/hr for 48 hours
223828631|NCT04958928|PROCEDURE|Catheter ablation|All patients received radiofrequncy ablation.
223828632|NCT00154063|DRUG|E2007|
223828633|NCT00154063|OTHER|Placebo|
223828634|NCT04155437|BEHAVIORAL|Health Facility Level Interventions|"* Intensified counseling on maternal dietary diversity and quality using job aids~* Counseling on purpose of IFA supplementation, managing side effects, and importance of adherence to daily consumption~* Distribution/prescription of IFA tablets at each ANC visit~* Use of pill card/reminders for pregnant women and their spouses~* Monthly IFA tablet stock monitoring to assure sufficient supplies~* Measurement of weight gain during each ANC visit and advise on healthy weight gain~* Checks for functioning scales and use of monitoring sheets~* Intensified counseling on early initiation of breastfeeding and exclusive breastfeeding using job aids~* Reminder on importance of early ANC attendance and 4+ visits"
223828635|NCT04155437|BEHAVIORAL|Community Level Interventions|"* Advocacy among community leaders (traditional and religious leaders, local associations, etc.) about ANC~* Gatherings among grandmothers, husbands, and other influencers about ANC and their roles~* Promotion of ANC service utilisation and the importance of early ANC visit during the first trimester.~* Early identification of pregnant women~* Support women's group discussions~* 2-3 home visits per pregnant woman by community health workers (Agent de santé a base communautaire; ASBC) which will include counseling on diet quality, breastfeeding, importance on adherence to daily IFA consumption and side effect management, etc."
223828636|NCT04155437|BEHAVIORAL|Health System Level Interventions|"* Training on nutrition interventions during ANC for all ANC providers and community health workers~* Semi-annual supervision by the Regional Health Directorate (Direction Regionale de la Santé; DRS)~* Quarterly supportive supervision of health facility staff by the health district management team~* Monthly supportive supervision of ASBCs~* Monthly review between health facilities and ASBCs~* Training and use of data registers~* Training and use of mother's cards to record up to 8 ANC visits and nutrition services~* Training on data utilization to improve coverage and quality"
223828637|NCT00072852|DRUG|Irinotecan|
223828638|NCT02091869|OTHER|Paper Asthma Action Plan|Participants will utilize a paper based asthma action plan to record asthma symptoms and medication usage.
223828639|NCT02091869|DEVICE|Mobile Phone|Participant will be able to log peak flow data, medications, and symptoms in their mobile phones utilizing the mobile app.
223828640|NCT01177202|BIOLOGICAL|HAC1 Vaccine|Subjects will come to the Clinical Trials Center up to 7 days prior to each vaccine dose to have blood drawn for research assays. The first dose of vaccine will be given on Day 0 and the second dose will be given 21 days later (± 3 days). Dose escalation will be staggered by at least 7 days as shown in Figure 1. Subjects from Groups G and H will be vaccinated with each of the other 6 groups. Two subjects from group A will be immunized on study day -1. The immunizations will be performed one hour apart with close monitoring. The remaining eight subjects from Group A will be immunized on study day 0. All subsequent immunizations for each group will occur on the same day. The principal investigator and the medical monitor will review all adverse events and make a determination on whether it is safe to proceed to the next higher dosage group. The control and reference vaccine groups can be vaccinated starting anytime after screening.
223828641|NCT01403389|DRUG|Eculizumab|1200 milligrams Eculizumab diluted in 0.9% NaCl to 5mg/mL for a total volume of 240 mL administered by IV infusion over 35 minutes in the operating room prior to organ reperfusion
223828642|NCT01403389|DRUG|Placebo|240 mL of 0.9% Sodium Chloride IV fluid given as placebo in the operating room prior to organ reperfusion
223828643|NCT04563442|OTHER|complication|complication co morbidities
223828644|NCT00239629|DRUG|Teriparatide|
223828645|NCT00239629|DRUG|Strontium ranelate|
223828646|NCT00239629|PROCEDURE|Transiliac bone biopsy|
223828647|NCT03483077|DRUG|BI 730460|tablets
223828648|NCT03483077|DRUG|Placebo|tablets
223828649|NCT02161900|OTHER|Yogic and routine exercises|All newly diagnosed cases with stage I-III of breast cancer who present to Tata Memorial Hospital will be randomly assigned to perform either a set of 'Yogic and Routine Exercises (referred to as exercise I) or Routine Exercises'(referred to as exercise II) . Patients will begin the exercises within a week of starting treatment.
223828650|NCT02451501|DEVICE|AKITA|
223828651|NCT04706741|DRUG|Izokibep|Izokibep is an Interleukin-17 Inhibitor that will be administered subcutaneously
223828652|NCT04706741|DRUG|Prednisone/Prednisolone|Background Corticosteroid
223828653|NCT06364241|OTHER|Focus group|During the focus group, the investigators will explore the cognitive deficits that people with lived experience with psychosis and their carers consider to be the most impairing.
223828654|NCT00004203|DRUG|oxaliplatin|
223828655|NCT03223272|DRUG|Reserpine|Open label reserpine 0.1 mg pill orally
223828656|NCT00451217|DRUG|Sugammadex|After the last dose of rocuronium or vecuronium, at reappearance of T2, a dose of 2.0 mg/kg sugammadex was to be administered
223828657|NCT00451217|DRUG|Neostigmine|After the last dose of rocuronium or vecuronium, at reappearance of T2, a dose of 50 ug/kg neostigmine was to be administered
223828658|NCT03747289|OTHER|performing exercises in a weight bearing posture|20 participants will perform exercises in a weight bearing posture
223828659|NCT03747289|OTHER|performing exercises in a non weight bearing posture|20 participants will perform exercises in a non weight bearing posture
223828660|NCT04668989|DEVICE|stenfilcon A - (Test lens)|Subjects will be randomized to wear test lenses for one week.
223828661|NCT04668989|DEVICE|kalifilcon A - (Control Lens)|Subjects will be randomized to wear control lenses for one week.
223828662|NCT01929330|DRUG|GI198745 0.1 mg|It is available as soft gelatin capsule to be administered as 5 X 0.1 mg capsules as single oral dose with approximately 250 mL of water.
223828663|NCT01929330|DRUG|GI198745 0.5 mg|It is available as soft gelatin capsule to be administered as 1 X 0.5 mg capsules as single oral dose with approximately 250 mL of water.
223828664|NCT00991614|DEVICE|EVOLUTION® Duodenal Stent|EVOLUTION® Duodenal Stent
223828665|NCT04386590|OTHER|Manual Therapy Plus Pulmonary Rehabilitation|Manual therapy combined with Pulmonary Rehabilitation
223828666|NCT04386590|OTHER|Sham Intervention|Detuned US plus Pulmonary Rehabilitation
223828667|NCT04882020|DIAGNOSTIC_TEST|cortisol, BDNF, s100B, IL-1B, IL-6, IL-10, TNF-alpha|compare both groups and evaluate the severity of obstructive sleep apnea modulates serum levels of inflammatory and neurocognitive markers in elederly.
223828668|NCT01622348|DRUG|IMO-3100 at 0.16 mg/kg|IMO-3100 at 0.16 mg/kg SC q wk x 4 wks based on body weight at screening, not to exceed 20 mg per injection
223828669|NCT01622348|DRUG|Saline for Injection|Saline for Injection 0.01 mL/kg SC q wk x 4 wk based on body weight at screening, not to exceed 1.25 mL
223828670|NCT01622348|DRUG|IMO-3100 at 0.32 mg/kg|IMO-3100 at 0.32 mg/kg SC q wk x 4 wks based on body weight at screening, not to exceed 40 mg per injection
223828671|NCT00007293|DEVICE|UV-B Lightsource and Fiber Optic Comb|
223828672|NCT00255658|DRUG|sorafenib tosylate|Given orally
223828673|NCT00255658|DRUG|temsirolimus|Given IV
223828674|NCT00255658|OTHER|laboratory biomarker analysis|Correlative studies
223828675|NCT00956540|PROCEDURE|Deflating tracheal cuff|Deflating tracheal cuff during ventilatory disconnections along the weaning phase in patients tracheostomized for prolonged weaning or ventilatory support.
223828676|NCT00956540|PROCEDURE|Deflating tracheal cuff 2|Deflating tracheal cuff during ventilatory disconnections along the weaning phase in patients tracheostomized for low level of consciousness or inability to adequate manage the airway.
223828677|NCT02392767|DIETARY_SUPPLEMENT|Verum|2400 mg L-arginine, 80 mg Pycnogenol, 45µg vitamine K2, 10 mg R (+) alpha lipoic acid, 8 mg vitamine B6, 500 µg vitamine B12, and 600 mg folic acid.
223828678|NCT02392767|DIETARY_SUPPLEMENT|Placebo|corn starch
223828679|NCT01805765|DRUG|Qing'E pills|composed of eucommia, psoralen, walnuts and garlic
223828680|NCT01805765|DRUG|Placebo|Containing 2% of Qing'E pills
223828681|NCT04877704|OTHER|Symprove (probiotic)|Symprove's unique water-based formula is packed full of live, active bacteria. It is a probiotic, not a drug.
223828682|NCT04877704|OTHER|Placebo|Matched placebo to Symprove probiotic
223828683|NCT00698321|BEHAVIORAL|HIV/STD prevention curriculum|The curriculum will include eight 1-hour HIV prevention modules administered weekly for 8 weeks. The modules will educate youth about risky sexual behaviors and will provide them with knowledge and skills necessary to reduce their risk of STDs, HIV, and pregnancy by abstaining from sex or using condoms if they choose to have sex. The curriculum is based on cognitive behavioral theories, focus groups, and the researchers' experience working with youth.
223828684|NCT00698321|BEHAVIORAL|General health promotion curriculum|The curriculum will include eight 1-hour general health modules administered weekly for 8 weeks. The curriculum will focus on teaching students healthful behaviors, including eating habits, physical activity, dental hygiene, and avoidance of cigarette smoking and substance abuse.
223828685|NCT01592695|DRUG|Nicotine replacement therapy - transdermal nicotine patch|Medication selection will be determined based on individual participant preferences, medical history, and contraindications.
223828686|NCT01592695|BEHAVIORAL|Tailored behavioral intervention|Participants will receive a standard six session cognitive behavioral intervention for smoking cessation combined with supplemental treatment modules based on individual need and preference.
223828687|NCT01592695|BEHAVIORAL|Tobacco quit line referral|Participants assigned to this condition will receive a referral to their state tobacco quit line. The specific behavioral treatment that is provided will differ slightly depending upon the services available through the participant's state of residence.
223828688|NCT01592695|DRUG|Nicotine replacement therapy - nicotine gum|Medication selection will be determined based on individual participant preferences, medical history, and contraindications
223828689|NCT01592695|DRUG|Nicotine replacement therapy - nicotine lozenge|Medication selection will be determined based on individual participant preferences, medical history, and contraindications
223828690|NCT01592695|DRUG|Bupropion Sustained Release|Medication selection will be determined based on individual participant preferences, medical history, and contraindications
223828691|NCT01592695|DRUG|Varenicline|Medication selection will be determined based on individual participant preferences, medical history, and contraindications
223828692|NCT01592695|DRUG|Combination pharmacotherapy - transdermal nicotine patch + nicotine gum|Medication selection will be determined based on individual participant preferences, medical history, and contraindications
223828693|NCT01592695|DRUG|Combination pharmacotherapy - transdermal nicotine patch + nicotine lozenge|Medication selection will be determined based on individual participant preferences, medical history, and contraindications
223828694|NCT01592695|DRUG|Combination pharmacotherapy - transdermal nicotine patch + bupropion|Medication selection will be determined based on individual participant preferences, medical history, and contraindications
223828695|NCT01592695|BEHAVIORAL|Alcohol use risk reduction|Participants engaging in risky alcohol use may receive this six-session telephone-based behavioral intervention for reducing alcohol use.
223828696|NCT01592695|BEHAVIORAL|Behavioral activation for the treatment of depression|Participants with elevated depressive symptoms may receive this six-session telephone-based behavioral activation intervention.
223828697|NCT01592695|BEHAVIORAL|Behavioral management of post-cessation weight gain|Participants with concerns about gaining weight after quitting smoking may receive this six-session telephone-based behavioral self-management intervention designed to help attenuate post-cessation weight gain.
223828698|NCT01629654|BEHAVIORAL|Health promotion program|"A 13 weeks organized program:~* One group session about poststroke fatigue involving both patient and relatives~* Two personal meetings, involving both patient and relatives~* Three telephone meetings, involving only patient"
223828699|NCT02584764|BEHAVIORAL|Cognitive behavior therapy|
223828700|NCT02584764|BEHAVIORAL|Internet support|
223828701|NCT04241874|OTHER|Mechanical Ventilation|Respiratory support through mechanical ventilator
223828702|NCT00432861|DRUG|PANCRECARB® (pancrelipase)|Capsules
223828703|NCT00432861|DRUG|Placebo|Capsules
223828704|NCT00563992|DRUG|Lithium|Participants may also be required to take the antidepressant paroxetine and/or the medication olanzapine for a portion of the study.
223828705|NCT00563992|DRUG|Valproic acid|Participants may also be required to take the antidepressant paroxetine and/or the medication olanzapine for a portion of the study.
223828706|NCT04515160|DIAGNOSTIC_TEST|Clinical Frailty Scale|Clinical fragility scale will be recorded in the first 24 hours of intensive care admissions.
223828707|NCT04515160|DIAGNOSTIC_TEST|Modified Frailty Index|Modified Frailty Index will be recorded in the first 24 hours of intensive care admissions.
223828708|NCT01085929|PROCEDURE|Incision and Drainage|Surgical incision of the skin surface followed by expression of purulence with or without debridement or manual exploration of abscess cavity.
223828709|NCT01085929|PROCEDURE|Ultrasound Guided Aspiration|Ultrasound is used to identify the abscess cavity. An 18 gauge needle is introduced into the abscess cavity and manual aspiration of the abscess contents is attempted.
223828710|NCT00467142|BIOLOGICAL|bevacizumab|
223828711|NCT00467142|DRUG|fluorouracil|
223828712|NCT00467142|DRUG|irinotecan hydrochloride|
223828713|NCT00467142|DRUG|leucovorin calcium|
223828714|NCT00467142|GENETIC|polymorphism analysis|
223828715|NCT00279994|PROCEDURE|Exercise therapy|
223828716|NCT00279994|DEVICE|Accelerometer (PAM; Personal Activity Monitor)|
223828717|NCT00279994|PROCEDURE|Oral Exercise Therapy advise|
223828718|NCT00919893|DRUG|Cernilton|Oral Cernilton, 2 capsules every 8 hours with the active substance consisting of 23 mg Extractum Pollens siccatum, 4 mg L-glutamate and 0.23 mg Stigmasterol per capsule for 12 weeks.
223828719|NCT00919893|DRUG|Placebo|Oral placebo, 2 capsules every 8 hours with identical capsulation and weight only containing the inactive substances in proportional doses as compared with Cernilton for 12 weeks.
223828720|NCT05050474|BIOLOGICAL|Recombinant SARS-CoV-2 Fusion Protein Vaccine|The product should be a milky-white suspension for injection. For prevention of SARS-CoV-2 infection.
223828721|NCT01034579|OTHER|Blood sampling|Subjects who had received Rebif® 44 microgram (mcg) three times a week for 96 weeks in study 24735 (NCT00078338) and not participated in the initial PGx sub-study will be enrolled in this retrospective cohort study wherein single blood sampling will be performed for pharmacogenetic markers analysis.
223828722|NCT01034579|OTHER|Blood sampling|Subjects who had received Copaxone® (Glatiramer Acetate) 20 milligram once daily for 96 weeks in study 24735 (NCT00078338) and not participated in the initial PGx sub-study will be enrolled in this retrospective cohort study wherein single blood sampling will be performed for pharmacogenetic markers analysis.
223828723|NCT03866772|DRUG|Misoprostol Oral Tablet|50 mcg oral consumption
223828724|NCT03866772|DEVICE|double balloon device for cervical ripening|insertion for 6 hours and followed by the above mentioned protocol
223828725|NCT04873778|DEVICE|Kinesio taping|Kinesio taping: Invented by Japan Dr.Kase, increase circulation by creating lifts skin,release pain and inflammation, stabilize joints
223828726|NCT04873778|DEVICE|Dynamic taping|Dynamic taping: Invented by Kendrick,elasticised with multi-directional rebound and with strong elastic resistance and recoil than KT
223828727|NCT01803295|DEVICE|40 mg MMC gel|A reverse thermal biodegradable gel (TC-3) (low viscosity at 5°C gel appearance at body temperature)for drug retention in the urinary bladder.
223828728|NCT01803295|OTHER|Standard of care MMC mixed with water|Standard of care 40mg MMC mixed with water
223828729|NCT01803295|DEVICE|80 mg MMC gel|A reverse thermal biodegradable gel (TC-3) (low viscosity at 5°C gel appearance at body temperature)for drug retention in the urinary bladder
223828730|NCT01982344|DEVICE|mini-exchange-room|
223828731|NCT01241253|OTHER|Whole cooked beans with rice meals|Three types of bean-and-rice meals all equal to 50 grams available CHO. Control treatment was 50 grams available CHO in the form of white rice alone.
223828732|NCT03893825|DRUG|TV-46000|TV-46000 will be administered per dose and schedule specified in the arm description.
223828733|NCT03893825|DRUG|Placebo|Placebo matching to TV-46000 will be administered per schedule specified in the arm description.
223828734|NCT05406960|DIETARY_SUPPLEMENT|Tea infusion|Herbal tea infusion will be administrated by the oral route before food
223828735|NCT02735733|DEVICE|Cold Bakri Balloon|In the room temperature arm, the bakri balloon will be inserted through the vagina and placed inside the uterus and filled with room temperature saline. In the cold arm, the same intervention will performed, however, the bakri balloon will be filled with cold saline at 32 degrees Fahrenheit.
223828736|NCT05622890|DRUG|Mirvetuximab Soravtansine|Mirvetuximab Soravtansine is an antibody drug conjugate designed to target folate receptor α (FRα). It consists of the humanized anti-FRα mAb M9346A attached via a cleavable disulfide linker to the cytotoxic maytansinoid, DM4.
223828737|NCT02406313|OTHER|CTS|Standardized Thermal Cure
223828738|NCT02406313|OTHER|ETP|Patient Therapeutic Education
223828739|NCT04422366|BIOLOGICAL|9-valent Human Papillomavirus (Types 6, 11, 16, 18,31,33,45,52 and 58) Recombinant Vaccine (Hansenula Polymorpha)|Subjects received 3 doses of 9-valent HPV vaccine according to a 0, 2, 6-month schedule.
223828740|NCT04422366|BIOLOGICAL|GARDASIL®|Subjects received 3 doses of Placebo according to a 0, 2, 6-month schedule
223828741|NCT02851160|OTHER|semi-structured interview conducted by a clinical psychologist|semi-structured interview conducted by a clinical psychologist
223828742|NCT02851160|OTHER|semi-structured interview conducted by a psychiatrist specialized in psycho-oncology|semi-structured interview conducted by a psychiatrist specialized in psycho-oncology
223828743|NCT04924686|OTHER|Observational studies, no intervention|Observational studies, no intervention
223828744|NCT02654223|BIOLOGICAL|MG56 Mannosylated 500 subcutaneous|Mixture of the following pollens: Phleum pratense, Dactylis glomerata, allergen extract with a concentration of 500 mTU (Mannosylated Therapeutic Units)/ml subcutaneous
223828745|NCT02654223|BIOLOGICAL|MG56 Mannosylated 1000 subcutaneous|Mixture of the following pollens: Phleum pratense, Dactylis glomerata, allergen extract with a concentration of 1000 mTU (Mannosylated Therapeutic Units)/ml subcutaneous
223828746|NCT02654223|BIOLOGICAL|MG56 Mannosylated 3000 subcutaneous|Mixture of the following pollens: Phleum pratense, Dactylis glomerata, allergen extract with a concentration of 3000 mTU (Mannosylated Therapeutic Units)/ml subcutaneous
223828747|NCT02654223|BIOLOGICAL|MG56 Mannosylated 5000 subcutaneous|Mixture of the following pollens: Phleum pratense, Dactylis glomerata, allergen extract with a concentration of 5000 mTU (Mannosylated Therapeutic Units)/ml subcutaneous
223828748|NCT02654223|BIOLOGICAL|MG56 Mannosylated 500 sublingual|Mixture of the following pollens: Phleum pratense, Dactylis glomerata, allergen extract with a concentration of 500 mTU (Mannosylated Therapeutic Units)/ml sublingual
223828749|NCT02654223|BIOLOGICAL|MG56 Mannosylated 1000 sublingual|Mixture of the following pollens: Phleum pratense, Dactylis glomerata, allergen extract with a concentration of 1000 mTU (Mannosylated Therapeutic Units)/ml sublingual
223828750|NCT02654223|BIOLOGICAL|MG56 Mannosylated 3000 sublingual|Mixture of the following pollens: Phleum pratense, Dactylis glomerata, allergen extract with a concentration of 3000 mTU (Mannosylated Therapeutic Units)/ml sublingual
223828751|NCT02654223|BIOLOGICAL|MG56 Mannosylated 5000 sublingual|Mixture of the following pollens: Phleum pratense, Dactylis glomerata, allergen extract with a concentration of 5000 mTU (Mannosylated Therapeutic Units)/ml sublingual
223828752|NCT02654223|BIOLOGICAL|Subcutaneous placebo|Comparison between placebo and active group
223828753|NCT02654223|BIOLOGICAL|Sublingual placebo|Comparison between placebo and active group
223828754|NCT05158439|BIOLOGICAL|AlloRx|cultured allogeneic adult umbilical cord derived mesenchymal stem cells
223828755|NCT05809349|DEVICE|transcranial magnetic stimulation|The stimulation intensity will be 80% resting motor threshold (RMT). The theta burst stimulation (cTBS) with a frequency at 50Hz, repeated at 5Hz, are delivered in a duration of 33.2s with the number of stimulation pulses of 600. Two groups of stimulation will be repeated in each cerebellar dentate nucleus with an interval of 5 min in each group. The treatment will last for 2 weeks, with 5 times per week.
223828756|NCT01448720|DRUG|Paliperidone palmitate|Type=exact number, unit=mg, number=150, 100, 75 mg equivalent (eq), form=suspension for injection, route=intramuscular use. One IM injection of 150 mq on Day 1, 100 mg eq. on Day 8 (+/- 4 days), and 75 mg eq. is recommended on Days 36, 64, and 92.
223828757|NCT01808976|OTHER|Problem Solving Therapy|this is a mobile app that participants use to solve problems. It will guide participants through a stepwise process for identifying a means for creating action plans.
223828758|NCT01808976|BEHAVIORAL|Evolution|This is a therapeutic video game that targets the cognitive control network, associated with depression. Participants are expected to play the game daily for 20 minutes over 4 weeks.
223828759|NCT01808976|BEHAVIORAL|Basic health push app|This is an app that send daily tips for improving your mood.
223828760|NCT00323713|BEHAVIORAL|Very low protein diet|0.3 g of proteins per kilo of body weight per day, supplemented with a mixture of essential aminoacids and chetoacids
223828761|NCT00323713|BEHAVIORAL|Low protein diet|0.6 g of protein per kilo of body weight per day
223828762|NCT06356727|DIAGNOSTIC_TEST|Thermodilution based assessment of coronary microcirculation|Coronary microvascular assessment with the derivation of CFR, IMR and MRR will be performed using a standard pressure/thermodilution guidewire.
223828763|NCT00464919|DRUG|Sorafenib|
223828764|NCT00464919|DRUG|tegafur/uracil (UFUR®)|
223828765|NCT02325232|DEVICE|Capsule endoscopy, double balloon enteroscopy sequential use|Small bowel capsule endoscopy followed by double-balloon enteroscopy with histological sampling in case of mucosal alterations
223828766|NCT00872469|DRUG|Tranexamic acid|1-2 grams by intravenous injection
223828767|NCT00872469|DRUG|Placebo [Saline]|Matched to active comparator
223828768|NCT04012814|DEVICE|Venus Bliss|The FDA cleared device (Venus Bliss™) is a non-invasive medical aesthetic device designed for body contouring. The device is comprised of a console, four 1060 nm diode laser applicators (60 mm x 60 mm). A belt is included to allow the operator to secure the laser applicators on the lipolysis treatment area, allowing hands free operation. The device uses vacuum assisted radiofrequency (RF) and PEMF (pulsed electromagnetic field) technology which has been shown in clinical studies to be safe and effective in body circumferential reduction and skin tightening.
223828769|NCT02089581|DRUG|Active comparator MR2XXX|comparison of two new oral formulations with existing formulation
223828770|NCT02089581|DRUG|MRXXX|MRXXX
223828771|NCT02089581|DRUG|MR1XXX|
223828772|NCT02089581|DRUG|MRXXX and MR1XXX|MRXXX and MR1XXX in fed and fasted state
223828773|NCT02183428|DRUG|BI 1356|
223828774|NCT02183428|DRUG|Glyburide|
223828775|NCT02183428|DRUG|BI 1356 + Glyburide|
223828776|NCT05206864|OTHER|Medical Food: SBD111|One capsule administered twice daily with morning and evening meals for 28 days
223828777|NCT05206864|OTHER|Placebo|One capsule administered twice daily with morning and evening meals for 28 days
223828778|NCT01275196|DRUG|Nilotinib|
223828779|NCT01275196|DRUG|Imatinib|
223828780|NCT02125032|DEVICE|Transcranial low voltage pulsed electromagnetic fields (T-PEMF)|
223828781|NCT02125032|DEVICE|Placebo Transcranial low voltage electromagnetic fields|
223828782|NCT05689814|DEVICE|Paraffin based Denture Fixative|Denture fixative applied in strips to secure dentures in place
223828783|NCT04432402|DRUG|Lenalidomide|Lenalidomide: 10mg、15mg、20mg、25mg qd PO day 1-7, Rituximab: 375 mg/m2 IV day0, Gemcitabine :1g/m2 IV day 1, oxaliplatin 100mg/m2 IV day1 (every 14 days as a cycle)
223828784|NCT02406261|DRUG|Lanabecestat|50 mg lanabecestat will be administered orally as 1 × 50-mg tablet
223828785|NCT02406261|DRUG|Simvastatin|20 mg simvastatin will be administered orally as 1 × 20-mg tablet
223828786|NCT02406261|DRUG|Midazolam|500 mcg midazolam will be administered orally as 0.25 mL of 2-mg/mL syrup
223828787|NCT02406261|DRUG|Midazolam|250 mcg midazolam will be administered intravenous (IV) as 0.25 mL of 1-mg/mL injection solution
223828788|NCT02406261|DRUG|Donepezil|5 mg donepezil will be administered orally as 1 × 5-mg tablet
223828789|NCT02406261|DRUG|Lanabecestat|50 mg lanabecestat will be administered orally as 1 × 50-mg tablet
223828790|NCT03165006|PROCEDURE|Mode of detection: Cancer detected at screening|Cancers detected as a result of screening mammograms.
223828791|NCT03165006|PROCEDURE|Mode of detection: Interval cancer|Cancers diagnosed after a negative screening mammogram and before the next screening invitation (2 years in Spain)
223828792|NCT03257293|BEHAVIORAL|Modified Cystoscopy|The objective of this study is to examine whether a non-pharmacologic modification in procedure of cystoscopies improves patient perception of pain and discomfort.
223828793|NCT03257293|BEHAVIORAL|Routine Cystoscopy|Routine cystoscopy as done as part of routine clinical practice
223828794|NCT00362102|DRUG|Cetuximab|
223828795|NCT02572817|BIOLOGICAL|High-titer anti-influenza plasma|Human plasma (FFP or FP24, 225-350 mL per unit or pediatric equivalent) with both an influenza A/H1N1 and A/H3N2 HAI titer of at least 1:80
223828796|NCT02572817|BIOLOGICAL|Low-titer anti-influenza plasma|Human plasma (FFP or FP24, 225-350 mL per unit or pediatric equivalent) with both an influenza A/H1N1 and A/H3N2 HAI titer of 1:10 or less
223828797|NCT04562103|DRUG|Epinephrine / Ropivacaine|In this group quadratus lomborum block was performed with 0.375% ropivacaine+100 mcg epinephrine.
223828798|NCT04562103|DRUG|Ropivacaine|In this group quadratus lomborum block was performed with plane 0.375% ropivacaine.
223828799|NCT04443439|DEVICE|GE Discovery MR750 3.0t superconducting MRI|T2WI, FLAIR, DWI, 3D BRAVO, 3D-ASL, rs-fMRI, DKI sequences to exclude other organic lesions
223828800|NCT03034317|DEVICE|NeuRx DPS|Patients who are diagnosed with ALS, have initiated NIV and choose to have the NeuRx DPS implanted.
223828801|NCT03862651|DRUG|Cangrelor|Cangrelor is an intravenous analog of adenosine triphospate with a potent, selective and specific affinity for P2Y12 receptors.
223828802|NCT04657549|PROCEDURE|Tonsillectomy|Tonsillectomy is done by monopolar electrocautery, bipolar scissors or cold instruments. First the mucosa of the anterior palatinal arch is incised and tonsillar capsule identified, then tonsillar tissue is removed along the capsule. Any bleeding is coagulated either with monopolar or bipolar electrocautery.
223828803|NCT04657549|PROCEDURE|Tonsillotomy|Tonsillotomy is done using monopolar electrosurgery, bipolar scissors or coblator device. Most of the tonsillar tissue is removed, exceeding the removal behind the line between anterior and posterior palatinal arch so that only thin layer of tonsil tissue is left over the tonsillar capsule.
223828804|NCT04022837|DRUG|Pantoprazole 40mg|effect of this drug on renal function
223828805|NCT00230321|DRUG|Darbepoetin alfa|During the induction phase, the investigational agent DARBEPOETIN ALFA will be initiated at a dose of 4.5 ug/kg/week subcutaneously.If patients do not achieve a major erythroid response by 6 weeks, the dose of DARBEPOETIN ALFA will be doubled to 9.0 ug/kg/week.
223828806|NCT05462652|DEVICE|Active Intervention|The active intervention is a 5-week program divided into 5 levels intended to be completed weekly. Each level is expected to take about 60 minutes to complete. Activities in each level may include reading text on the screen, answering multiple choice style questions, swiping or clicking a button to move through screens, dragging and dropping elements on screen, and completing tasks outside of the app. Certain on-demand resources can be accessed in the apps at any time, including crisis resources. Where appropriate, text entries in the app that match a database of concerning words/phrases will trigger an automated pop-up suggesting participants visit the in-app crisis resources if they need additional support. Text entries will also be monitored by study staff for safety, though not in real-time. Participants will be instructed to complete a weekly PHQ-8 assessment in the mobile app.
223828807|NCT02693886|OTHER|doctor experience|
223828808|NCT00497965|PROCEDURE|Chiropractic Manipulation|
223828809|NCT00497965|BEHAVIORAL|Balance Exercises|
223828810|NCT05428462|OTHER|Psychoeducation day on borderline personality disorder|Transmission of latest knowledge on borderline personality disorder
223828811|NCT00874289|OTHER|NGAL kit|Kit to test NGAL levels in heart failure patients
223828812|NCT05690061|DIETARY_SUPPLEMENT|Grain-Fed Beef Hamburger|Bowl of grain-fed beef hamburger cooked without seasonings. 250 grams of uncooked hamburger weighed out, then cooked in a non-stick pan for 8 minutes, no seasoning or oils were used and rendered fat was poured into serving bowl.
223828813|NCT05690061|DIETARY_SUPPLEMENT|Grass-Fed Beef Hamburger|Bowl of grass-fed, grass-finished beef hamburger cooked without seasonings. 250 grams of uncooked hamburger weighed out, then cooked in a non-stick pan for 8 minutes, no seasoning or oils were used and rendered fat was poured into serving bowl.
223828814|NCT05690061|DIETARY_SUPPLEMENT|Impossible BurgerTM|Bowl of plant-based Impossible burger cooked without seasonings. 250 grams of uncooked Impossible burger weighed out, then cooked in a non-stick pan for 8 minutes, no seasoning or oils were used and rendered fat was poured into serving bowl.
223828815|NCT04241575|DIAGNOSTIC_TEST|Simple fibrosis scores and electronic reminder messages|"For patients in the intervention group, we will calculate the fibrosis scores. For patients with increased fibrosis scores, we will type the following pop-up message in our electronic clinical management system:~This patient has high Fibrosis-4 index (and/or AST-to-platelet ratio index) of xxx suggestive of significant liver fibrosis. Please consider referring the patient to the hepatology clinic or arranging further test such as FibroScan.~The reminder message will pop up when physicians see the patient at the clinic and use the electronic clinical management system. The message will remain active for one year. Although the message is entered manually at this stage, the arrangement mimics an automated computer system. If the study results are positive, the next step is to modify the system to automate the process."
223828816|NCT00652262|DRUG|Levitra (Vardenafil, BAY38-9456)|Patients received BAY 38-9456 10 mg for the first 4 weeks of the treatment period, and then went on to receive 10 mg or 20 mg for the following 8 weeks.
223828817|NCT06349122|DIAGNOSTIC_TEST|Vaginal flora abnormalities screening and quantification using molecular biology technique|Vaginal self-sampling is a simple and validated method of sampling used for the molecular biology technique and the quantification of microorganisms involved in vaginal flora imbalance bacteriosis.The patient performs a self-sampling with a cotton swab transferred into a transport medium tube. The sample is sent to the laboratory where Multiplex Point of Care polymerase chain reaction (PCR) is performed.
223828818|NCT06349122|DRUG|Azithromycine|In case of Chlamydia trachomatis infections, as well as significant increase of Fannyhessea vaginae: 1 g per os in a single dose; In case of Neisseria gonorrhoeae infection: 2 g per os in a single dose (associated to ceftriaxone 1g IM)
223828819|NCT06349122|DRUG|Ceftriaxone|In case of Neisseria gonorrhoeae infections, 1g, associated to azithromycin 2 g per os in a single dose
223828820|NCT06349122|DRUG|Metronidazole|Metronidazole ovules: In case of Trichomonas vaginalis infection during the 1st trimester of pregnancy: 1 ovule morning and evening for 14 days (French Society of Dermatology Recommendations 2016); Metronidazole 500 mg tablets in case of Trichomonas vaginalis infection during the 2nd or the 3rd trimester of pregnancy in a single dose of 2 g
223828821|NCT06349122|DRUG|Clotrimazole, Vaginal|In case of Candida albicans infection in a single dose to be repeated up to 6 times if necessary.
223828822|NCT06349122|OTHER|Usual Care|Patients will not be screened using molecular biology techniques in this group. The management of these patients is a matter of routine for health professionals. They will be free to prescribe a standard vaginal swab if symptoms are present and to treat their patients according to their usual protocols. No routine sampling is recommended in the absence of a history
223828823|NCT02530138|DIETARY_SUPPLEMENT|synbiotic|2 symbiotics capsules per day for 28 weeks
223828824|NCT02530138|DIETARY_SUPPLEMENT|Placebo|2 placebo capsules per day for 28 weeks
223828825|NCT05468125|PROCEDURE|guidance|either follow the care bundle or the best evidence practice
223828826|NCT04548531|BEHAVIORAL|Shared Decision Making|"The decision aid is a paper information sheet presenting the pros and cons of three screening options (colonoscopy, stool-based tests, and postponing cancer screening until next year).~The decision coaching is a structured interview to help patients clarify their preference for screening test and to support them in implementation (whether scheduling colonoscopy, ordering stool test or seeking additional advice from specialist)."
223828827|NCT04746274|BEHAVIORAL|Online large-group one-session multicomponent positive psychological intervention|The intervention is aimed at enhancing positive mental health by using components from positive psychology or positive psychotherapy. These include for exapmle using character strengths, savoring the moment, goal setting and goal attainment. The intervention is conducted in an online group format via videoconference with a duration of approximately 3 and a half hours.
223828828|NCT04746274|BEHAVIORAL|Online large-group one-session cognitive intervention targeting dysfunctional thoughts|The intervention is aimed at reducing dysfunctional thoughts by applying strategies known from the cognitive therapy of depression. These include for example identification of automatic thoughts and cognitive biases as well as evaluating evidence for and against automatic thoughts. The intervention is conducted in an online group format via videoconference with a duration of approximately 3 and a half hours.
223828829|NCT06012565|DRUG|KAND567|2 x 125 mg capsules for oral administration. KAND567 (250 mg) was to be given every 12 hours for one week (7 days).
223828830|NCT06012565|DRUG|Microcrystalline cellulose|Capsules for oral administration, consisting of microcrystalline cellulose oral solid formulation in capsules. Placebo was to be given every 12 hours for one week (7 days).
223828831|NCT00432575|DRUG|surinabant (SR147778)|oral administration
223828832|NCT00432575|DRUG|placebo|oral administration
223828833|NCT03562169|DRUG|Ixazomib, thalidomide, & dexamethasone (ITD) re-induction|"4 - 6 ITD 28-day cycles as follows:~* Ixazomib 4mg capsule on days 1, 8 and 15~* Thalidomide 100mg capsule on days 1-28~* Dexamethasone 40mg tablets on days 1, 8, 15 and 22"
223828834|NCT03562169|DRUG|Conventional autologous stem cell transplant (ASCT-con)|Melphalan 200mg/m2 IV infusion on Day -1, followed by ASCT on Day 0.
223828835|NCT03562169|DRUG|Augmented autologous stem cell transplant (ASCT-aug)|Melphalan 100mg/m2 IV infusion on Day -3 and Day -2 plus ixazomib 4mg capsules on Day -4 and Day -1. ASCT will then be given on Day 0.
223828836|NCT03562169|DRUG|ITD consolidation and ixazomib maintenance vs. No further therapy|"Participants will be randomised to either 'no further therapy' or 'ITD consolidation and ixazomib maintenance'. Participants randomised to 'no further treatment' will not receive any further treatment but will be followed up at 8 weeks post randomisation 2 and at 3-monthly clinic visits until disease progression.~Participants randomised to ITD consolidation and ixazomib maintenance will receive:~Two 28-day cycles of ITD consolidation (same doses as in ITD re-induction). This will be followed by ixazomib maintenance as follows: Ixazomib 4mg capsule on days 1, 8 and 15 of each 28-day cycle until disease progression."
223828837|NCT01713790|DEVICE|Stochastic resonance whole-body vibration|Stochastic resonance whole-body vibration training program over 10 weeks, three times a week with 3 to 6 Hz, Noise 4.
223828838|NCT01713790|DEVICE|Exergame|training program over 10 weeks, three times a week.
223828839|NCT01713790|DEVICE|Leg press|training program over 10 weeks, three times a week.
223828840|NCT04205175|DRUG|Feiba|This is a single center, open label, dose escalation study of in vivo administration of Feiba in congenital hemophilia A patients with inhibitors who are on emicizumab.
223828841|NCT06400680|DEVICE|Spine Kinematic Assessment with Optoelectronic system|"All measurements will be obtained using an optoelectronic multicamera system for human motion analysis (with eight high-resolution cameras with infrared light and a sampling frequency of 100 Hz.~The experimental protocol require the positioning of markers (plastic spheres covered by reflecting film). Markers will be placed by clinical operators (physiotherapists with training in optoelectronic system for human motion analysis) after training and experience in recognition of the position of spinous and transversal processes, by manual identification.~During the data acquisition protocol, the subject perform five trial of walking barefoot on a 6 m distance at a self-selected normal-pace speed.~Every subject repeated this operations 2 times with 2 different operators."
223828842|NCT00636584|DRUG|sodium nitroprusside|sodium nitroprusside infusion at 1 microgram/kg/min dose during rewarming period of cardiac operations
223828843|NCT00636584|DRUG|placebo|placebo
223828844|NCT02761629|DRUG|Peg-Interferon Alpha-2A|Peg-IFN-Alpha-2A will be administered at 180 micrograms (mcg) once weekly via subcutaneous injection.
223828845|NCT02761629|DRUG|Ribavirin|Ribavirin will be administered as either 1000 milligrams (mg) (2\*200 mg tablets in morning and 3\*200 mg tablets in evening) for participants weighing less than (\<) 75 kilograms (kg) or as 1200 mg (3\*200 mg tablets in morning and 3\*200 mg tablets in evening) for participants weighing greater than or equal to (\>/=) 75 kg.
223828846|NCT00922844|DRUG|Sevoflurane and isoflurane|Patients will be randomized to a 10 minute treatment with isoflurane, followed by a wash-out period, followed by a 10 minute treatment with sevoflurane, or the other way round.
223828847|NCT03034213|DEVICE|Gentrix™ Surgical Matrix (Treatment)|Gentrix™ Surgical Matrix will be placed in the retrorectus space. The anterior midline fascia will be closed with long-acting absorbable suture either with a running or interrupted manner as per the surgeon's discretion.
223828848|NCT03034213|DEVICE|Permacol, Parietex, Progrip, Strattice Perforated, or Surgimend (Control)|A biological or prosthetic mesh (Permacol, Parietex, Progrip, Strattice Perforated, or Surgimend) will be placed in the retrorectus space. The anterior midline fascia will be closed with long-acting absorbable suture either with a running or interrupted manner as per the surgeon's discretion.
223828849|NCT03191929|OTHER|HIT Intervention|"Patients in the HIT intervention completed a multi-media, culturally adapted, mental health risk assessment tool in their preferred language prior to their baseline health care visit with their primary care provider. Patients' scores were transmitted to the provider prior to their clinic visit.~Providers in the HIT intervention received a web-based training developed by the Harvard Program in Refugee Trauma to train providers in delivering culturally competent, trauma-informed care to address mental health problems and other trauma-related medical issues in patients who experienced extreme war trauma. Providers also received ongoing clinical decision support through a mobile application to support the diagnosis and initiation of treatment for depression and/or PTSD."
223828850|NCT03191929|OTHER|Minimal Intervention Control Arm|"Patients in the Minimal Intervention Control Arm completed a multi-media, culturally adapted, mental health risk assessment tool in their preferred language prior to their baseline health care visit with their primary care provider; however, patients' scores in the Minimal Intervention Control Arm were only transmitted to the provider prior to their clinic visit if they showed evidence of being at risk to harm either themselves or others.~Providers in the Minimal Intervention Control Arm completed the online tutorial, A physician's practical guide to culturally competent care, which was provided by The Office of Minority Health, US Department of Health and Human Services Website."
223828851|NCT01982396|DRUG|ABC Twice Daily|
223828852|NCT01982396|DRUG|ABC Once Daily|
223828853|NCT01982396|DRUG|3TC Once Daily|
223828854|NCT01982396|DRUG|3TC Twice Daily|
223828855|NCT02348853|BEHAVIORAL|Healthy Weight for Living (HWL)|
223828856|NCT02348853|BEHAVIORAL|Current Best Practice (CBP)|
223828857|NCT02001974|DRUG|Paclitaxel+Reparixin|Association of Paclitaxel at fixed dosage with three increasing dosage of Reparixin
223828858|NCT04610762|DIAGNOSTIC_TEST|GeneXpert HCV VL Fingerstick test|The participants will have a molecular test (GeneXpert HCV VL Fingerstick, Cepheid) that quantifies hepatitis C virus (HCV) RNA levels directly from a fingerstick blood sample.
223828859|NCT01330693|DRUG|Atomoxetine|Atomoxetine is FDA-approved for the treatment of ADHD symptoms in children. Single dose of 0.5 mg/kg at baseline visit. Then dose adjusted in an open-label design afterwards.
224264567|NCT06187142|BEHAVIORAL|Initial phase: Personalized Chat Support (PCS)|Participants will receive three months of personalized chat support through WeChat. A total of 24 pre-set messages will be sent with the schedule of 3 times a week for 2 weeks, twice a week for the next 8 weeks and once a week for the last 2 weeks. These messages cover generic information about the benefits of quitting, methods to avoid/ manage craving or withdrawal symptoms, and hazards of smoking for chronic diseases experienced by different participants. Counsellors will respond to the participants' messages instantly. At the end of the initial phase (1-month), complete responders (quitters) will continue to receive PCS (subgroup PCS-1). Incomplete responders (smokers) will be randomly assigned to continue PCS (subgroup PCS-2) or receive PCS and MOS (subgroup PCS-3).
223828860|NCT01330693|DRUG|Sugar Pill|In-active sugar pill randomly assigned at baseline visit
223828861|NCT00957788|DRUG|NST-001|Comparison of different dosages of drug.
223828862|NCT01714102|DIETARY_SUPPLEMENT|Placebo|Placebo manufactured to mimic resveratrol tablet
223828863|NCT01714102|DIETARY_SUPPLEMENT|Resveratrol|Resveratrol PO BID for 30 days
223828864|NCT01830881|DRUG|Midazolam|5 mL oral midazolam oral syrup (2 mg/mL) 30-60 minutes prior to procedure
223828865|NCT01830881|DRUG|Ibuprofen|800 mg oral ibuprofen 30-60 minutes prior to procedure
223828866|NCT01830881|OTHER|Placebo-Cherry syrup|5 mL oral placebo-cherry syrup 30-60 minutes prior to procedure
223828867|NCT01830881|DRUG|Lidocaine|injection of 20 mL 1% lidocaine without epinephrine
223828868|NCT01475916|BEHAVIORAL|Educational program: consultation with paediatric pulmonologist|Longitudinal prospective study
223828869|NCT01476436|OTHER|Low carbohydrate dietary advice|Dietary advice
223828870|NCT01476436|OTHER|Continue usual diet|Dietary advice
223828871|NCT00119262|DRUG|doxorubicin hydrochloride|Given IV
223828872|NCT00119262|DRUG|cyclophosphamide|Given IV
223828873|NCT00119262|BIOLOGICAL|bevacizumab|Given IV
223828874|NCT00119262|DRUG|paclitaxel|Given IV
223828875|NCT00119262|BIOLOGICAL|filgrastim|Given SC
223828876|NCT00119262|BIOLOGICAL|pegfilgrastim|Given SC
223828877|NCT00119262|RADIATION|radiation therapy|Undergo radiation therapy
223828878|NCT00119262|DRUG|tamoxifen citrate|Given orally
223828879|NCT00119262|DRUG|aromatase inhibition therapy|Receive aromatase inhibition therapy
223828880|NCT00734214|DRUG|0.9% NaCl|"Intravenous Fluid~Isotonic Parenteral Fluid"
223828881|NCT00734214|DRUG|0.45%NaCl|"Intravenous Fluid~Hypotonic Parenteral Fluid"
223828882|NCT02038764|DRUG|Placebo|Placebo
223828883|NCT02038764|BIOLOGICAL|PF-06342674 Dose A|Multiple SC Doses
223828884|NCT02038764|BIOLOGICAL|PF-06342674 Dose B|Multiple SC Doses
223828885|NCT02038764|BIOLOGICAL|PF-06342674 Dose C|Multiple SC Doses
223828886|NCT02038764|BIOLOGICAL|PF-06342674 Dose D|Multiple SC Doses
223828887|NCT00953095|BEHAVIORAL|Joint Attention Intervention|Intervention in both conditions occurs once a week for 2 hours. Participants will be randomized to 1 of 2 interventions : (1) Caregiver Mediated Model (CMM):focuses on joint attention/engagement and involves individual meetings with the parents and children at their homes. Parents will be specifically taught techniques for altering the home environment and ways to enhance children's language, social, and play development. Parents will given guided practice (input/ coaching from the interventionist) as they implement these techniques with their child. (2) Caregiver Education Model (CEM): focuses on teaching parents information about autism, behavior modification, and community services. Parents will receive information on child development each week, and will be able to ask questions and discuss the information. Parents meet in a group (without their children) in a community-based setting to receive the intervention.
223828888|NCT05575115|BEHAVIORAL|Peer Comparison|"Peer comparison was an email-based intervention. Clinicians were ranked from highest to lowest inappropriate prescribing rate within each region using EHR data. Clinicians with the lowest inappropriate prescribing rates (the top-performing decile) were told via monthly email they were Top Performers. The remaining clinicians were told that they were Not a Top Performer in an email that included the number and proportion of antibiotic prescriptions they wrote for antibiotic-inappropriate acute respiratory tract infections, compared with the proportion written by top performers."
223828889|NCT03905590|PROCEDURE|Periapical surgery with amniotic membrane|periapical surgery will be done followed by amniotic membrane placement over the defect
223828890|NCT03905590|PROCEDURE|periapical surgery without amniotic membrane|periapical surgery will be done without placement of membrane over the defect.
223828891|NCT03590665|OTHER|Hand grip exercise and lower body negative pressure|For participants with Down syndrome, the first visit includes baseline measures and familiarization with the graded maximal exercise test protocol. If necessary, additional familiarization sessions will be scheduled for people with Down syndrome. The second visit, we perform the graded maximal exercise test and familiarize the participant with the procedures for the third visit: the hand grip exercise protocol and the lower body negative pressure (LBNP) box. The third visit we assess the peripheral blood flow during the hand grip exercise protocol without and with the LBNP. For control subjects, the first and second visit are combined. Their second visit is the same as the third visit for individuals with Down syndrome.
223828892|NCT03593993|PROCEDURE|Surgical Cohort|Blood, cerebrospinal fluid, and surgical tissue collected during procedure
223828893|NCT02179372|DIETARY_SUPPLEMENT|Eicosapentaenoic acid|30 subject with Crohn's Disease and/or Ulcerative Colitis in clinical remission but with fecal calprotectin value \>150 μg/g will recive 2 g/day of Eicosapentaenoic acid for 6 months treatment. At 3 months and 6 months, fecal calprotectin and clinical activity (CDAI for Crohn's Disease and SCCAI for Ulcerative Colitis) will be measured. The effect of Eicosapentaenoic acid on fecal calprotectin level will be monitored. Clinical relapses will be considered during the study.
223828894|NCT02179372|DIETARY_SUPPLEMENT|Medium chain fatty acid (placebo)|30 subject with Crohn's Disease and/or Ulcerative Colitis in clinical remission but with fecal calprotectin value \>150 μg/g will recive 2 g/day of medium chain fatty acids for 6 months treatment. At 3 months and 6 months, fecal calprotectin and clinical activity (CDAI for Crohn's Disease and SCCAI for Ulcerative Colitis) will be measured.
223828895|NCT06042868|OTHER|Nursing protocol|Emergency nursing protocol
223828896|NCT05658835|OTHER|Thrombi and blood analyses|Thrombi and blood will be collected during thrombectomy
223828897|NCT05348408|DRUG|platelet rich plasma|perineural PRP injection under ultrasound guidance in addition to medical treatment
223828898|NCT00664703|DRUG|Lobeline sulfate|Each laboratory day, participants will receive one capsule containing either methylphenidate HCl (15 or 30 mg) or placebo, and one sublingual tablet containing either lobeline (7.5, 15, or 30 mg) or placebo.
223828899|NCT00664703|DRUG|Methylphenidate HCl|Each laboratory day, participants will receive one capsule containing either methylphenidate HCl (15 or 30 mg) or placebo, and one sublingual tablet containing either lobeline (7.5, 15, or 30 mg) or placebo.
223828900|NCT00664703|DRUG|Placebo|Each laboratory day, participants will receive one capsule containing either methylphenidate HCl (15 or 30 mg) or placebo, and one sublingual tablet containing either lobeline (7.5, 15, or 30 mg) or placebo.
223828901|NCT02590068|DRUG|Zoster vaccine live|Single Zostavax vaccine, 0.65 ml dose, administered subcutaneously
223828902|NCT02826148|OTHER|RAADS-R scale|This scale is a self-administered questionnaire completed by the person himself assisted by a clinician
223828903|NCT04901364|BEHAVIORAL|Sensitivity and specificity of risk factors for degeneration of IPMNs|Measurement of high-grade dysplasia or invasive cancer on the histological analysis of the surgical specimen
223828904|NCT03632434|DEVICE|transcranial direct current stimulation|tDCS generates a small electric current which modulates how easy it is for active brain cells to discharge. The device is a neoprene cap worn over the head, and in the cap there are two electrodes, which are small metal discs, where the current comes from.
223828905|NCT01751113|DRUG|fluticasone propionate/salmeterol|250mcg fluticasone + 50 mcg salmeterol, twice daily 4 week treatment in each treatment sequence (crossover design)
223828906|NCT01751113|DRUG|tiotropium bromide|18 mcg tiotropium bromide, once daily 4 week treatment in each treatment sequence (crossover design)
223828907|NCT01751113|DRUG|fluticasone propionate/salmeterol plus tiotropium bromide|250mcg fluticasone + 50 mcg salmeterol, twice daily plus 18 mcg tiotropium bromide, once daily 4 week treatment in each treatment sequence (crossover design)
223828908|NCT03162757|PROCEDURE|Central venous catheterization|Central venous catheterization via either internal jugular vein or subclavian vein up to a maximum of two attempts.
223828909|NCT04855292|DRUG|TG103 injection|TG103 injection, SC, once weekly
223828910|NCT04855292|DRUG|Placebo|Placebo control, SC, once weekly
223828911|NCT06022718|OTHER|Taping|Kinesio taping and Rigid taping was applied.
223828912|NCT06461013|BEHAVIORAL|Blood flow restriction|A common clinical tourniquet (7cm \* 50cm in size) is placed in the middle section of the patient's thigh on the affected side, connected to a pressure gauge, observed and gradually pressurized to 160-170mmHg for about 10 minutes, then depressurized for 1 minute, and then re pressurized to 160-170mmHg. Each training session lasts for 20 minutes, once a day, five times a week, for a total of 8 weeks.
223828913|NCT01182727|DRUG|salsalate|Salsalate will be administered in 500 mg tablets. Salsalate will be administered in two divided doses of 2 grams in the morning and 2 grams in the evening. Salsalate will be administered for a total of 6 weeks. If a participant is not able to tolerate the target dose of 4 grams per day then 500 mg reductions will be made in a stepwise fashion until tolerated or a minimum dose of 2 grams per day is achieved.
223828914|NCT02218385|DEVICE|ForeCYTE Breast Aspirator|ForeCYTE Breast Aspirator used for bilateral collection of Nipple Aspirate Fluid (NAF) for cytologic testing
223828915|NCT01551303|DRUG|Oxytocin|Liquid metered-dose nasal spray, 30 IUs, administered once.
223828916|NCT01551303|DRUG|Placebo|Matched nasal spray placebo
223828917|NCT03648593|BEHAVIORAL|work recovery intervention|Recover! app: one hour weekly for two months
223828918|NCT03648593|BEHAVIORAL|waiting list control|no treatment during 6 months,then Recover! app
223828919|NCT04814927|DRUG|Copper IUD|Participants randomized to Copper IUD will receive Paragard IUD at Visit 2.
223828920|NCT04814927|DRUG|Etonogestrel implant|Participants randomized to ETG implant will receive the implant at Visit 2.
223828921|NCT04814927|DRUG|Levonorgestrel IUS|Participants randomized to LNG intrauterine system will receive the IUS at Visit 2.
223828922|NCT04814927|DRUG|DMPA Sub-cutaneous|Participants randomized to DMPA SC will receive the injection at Visit 2.
223828923|NCT02443025|BEHAVIORAL|Teens Against Tobacco Use|Teens Against Tobacco Use teen teachers develop and then deliver anti-tobacco presentations to the target population of younger students.
223828924|NCT02715895|DIETARY_SUPPLEMENT|Friso|Friso formula feeding on demand for 3 months
223828925|NCT02715895|DIETARY_SUPPLEMENT|Wyeth|Wyeth formula feeding on demand for 3 months
223828926|NCT02715895|DIETARY_SUPPLEMENT|Breast milk|Breast milk feeding on demand
223828927|NCT02433548|PROCEDURE|Fascia iliaca block|injection of 30 mLs below the fascia iliaca
223828928|NCT02433548|PROCEDURE|Sham injection|subcutaneous of 5 cc of normal saline
223828929|NCT02473887|DRUG|Ondansetron with1:1 ORA - sweet.|single dose of intravenous ondansetron form orally after being flavored with 1:1 ORA-sweet, the dose of ondansetron was determined based on the patient presenting weight.
223828930|NCT01013532|DRUG|Cilostazol|Cilostazol 100mg bid
223828931|NCT01013532|DRUG|Probucol|Probucol 250mg bid
223828932|NCT01013532|DRUG|Aspirin|Aspirin 100mg qd
223828933|NCT01013532|DRUG|placebo of cilostazol|same shape and size of active cilostazol
223828934|NCT01013532|DRUG|placebo of aspirin|same size and shape of active aspirin 100mg
223828935|NCT01013532|DEVICE|ankle-brachial index (ABI)|measurement of ABI every years during follow up
223828936|NCT01013532|DEVICE|intima-medial thickness (IMT)|ultrasound measured IMT of both common carotid arteries
223828937|NCT01013532|DEVICE|new asymptomatic brain hemorrhage|asymptomatic macrobleedings or microbleedings on GRE images
223828938|NCT01013532|DEVICE|new ischemic lesions on follow-up FLAIR images|any new ischemic lesions
223828939|NCT04526405|DIAGNOSTIC_TEST|SARS-CoV-2 S1/S2 IgG|SARS-CoV-2 S1/S2 IgG analysis
223828940|NCT04171830|OTHER|modified Hospital One-year Mortality Risk (mHOMR)|"Every inpatient will automatically be given the intervention (an mHOMR/HOMR Now! score) upon admission to hospital and considered for secondary interventions based on their score. Baseline threshold will be set as \>0.21 (59% sensitivity and 90% specificity for 12-month mortality with mHOMR).~At minimum each individual identified by the tool will receive two assessments to screen for severe symptoms and desire to engage in advance care planning (ACP):~1. Edmonton Symptom Assessment System Revised: scores \>6 will be flagged as severe. Clinical teams will address the symptoms as appropriate for the patient.~2. 4-item Advanced Care Planning Engagement Survey: Scores of 3-4 indicate readiness to discuss ACP. Clinical teams may choose to discuss ACP and goals of care themselves, activate a local ACP intervention, or distribute ACP documentation.~Both of these assessments will be done by a member of the treating team within 72 hours of the patient's hospital admission."
223828941|NCT06488560|DIETARY_SUPPLEMENT|commercial blenderized tube feed (CBTF)|Based on assessment by a dietician the participant will be fed the commercial blenderized formula to meet their caloric needs
223828942|NCT06488560|DIETARY_SUPPLEMENT|commercial formulas (CF)|Participant will be fed the commercial formula to meet their caloric needs per standard of care
223828943|NCT01350622|DRUG|PENNSAID|active treatment with PENNSAID and oral placebo. Subjects will apply 40 drops of Pennsaid to the affected ankle joint once, and will take a single placebo pill.
223828944|NCT01350622|DRUG|Diclofenac hydroxyethylpyrrolidine|active treatment oral Diclofenac and PENNSAID placebo. Patients will take a single 50mg dose of oral diclofenac and will apply 40 drops of placebo lotion (2.3% DMSO) to the affected ankle once.
223828945|NCT02638610|DEVICE|Cochet-Bonnet aesthesiometer|"The eyelid's sensation will be assessed at 6 points of the eyelid using the Cochet-Bonnet aesthesiometer (Luneau Ophtalmologie, Paris, France). Measurements will take place before surgery, and two weeks, three months and six months after surgery.~This instrument contains a 6 centimeters long, retractable, flexible monofilament. For any given length, when applied perpendicularly to a test surface, the filament will exert a precise pressure before visibly bending. The filament's length inversely corresponds to the pressure exerted by the aesthesiometer such that the shorter the filament length, the more pressure it exerts on the test surface."
223828946|NCT02848612|DRUG|anticoagulation by unfractionated heparin|anticoagulation by unfractionated heparin
223828947|NCT02465021|OTHER|Dietary intervention|All arms are given to all participants, in a randomized order
223828948|NCT04276662|DRUG|DS-3201b|1 dose of 50 mg DS-3201b
223828949|NCT04788069|DIETARY_SUPPLEMENT|Wholemeal bread|180g wholemeal bread/day + fixed portion at test day
223828950|NCT04788069|DIETARY_SUPPLEMENT|Sourdough bread|180g sourdough bread/day + fixed portion at test day
223828951|NCT04788069|DIETARY_SUPPLEMENT|Bread with sourdough|180g bread with sourdough/day + fixed portion at test day
223828952|NCT06528561|PROCEDURE|Sef-care program with exercise|Self-care program with physical exercise with aerobic and muscular strength components implemented progressively according to the participant's clinical evolution
223828953|NCT04173312|COMBINATION_PRODUCT|Bupivacaine infusion|Local systemic Infusion of anesthetic
223828954|NCT04173312|COMBINATION_PRODUCT|Saline|Local systemic infusion of saline
223828955|NCT02821832|PROCEDURE|Saliva collection|For biomarker assessments
223828956|NCT02821832|PROCEDURE|Urine collection|For biomarker assessments
223828957|NCT02821832|PROCEDURE|Sputum collection|For primary endpoint assessments and other biomarker assessments
223828958|NCT02821832|PROCEDURE|Blood Collection|For biomarker and eligibility assessments
223828959|NCT02821832|RADIATION|PET/CT Scan|Imaging of the lungs to establish disease extent and severity
223828960|NCT02821832|DRUG|Isoniazid, Rifampicin, Pyrazinamide and Ethambutol|Treatment-standard of care
223828961|NCT02857803|PROCEDURE|Virtual Reality|Intervention of 30 minutes, 3 times a week until reaching 12 sessions.
223828962|NCT02857803|PROCEDURE|Paper and Pencil|Intervention of 30 minutes, 3 times a week until reaching 12 sessions.
223828963|NCT02857803|PROCEDURE|Conventional Therapy|Intervention of 30 minutes, 3 times a week until reaching 12 sessions.
223828964|NCT03877705|DRUG|Listerine ready tabs|Technically, it's a rectangular-shaped, bilayer-compressed tablet that once chewed, creates just enough liquid to swish around your mouth to get a whole-mouth clean feeling.As manufacture claimed the tablet is easy to use just in three simple steps: chew (to activate), swish (to clean), then swallow as unlike mouthwashes which may contain alcohol and other ingredients not intended for ingestion, Listerine Ready Tabs are alcohol-free and safe to swallow which is highly suitable for bedridden patients.
223828965|NCT00676975|DRUG|Traditional Chinese Medicine|"A herbal extract 17g once daily for 8 weeks for lower dosage, and 34g for higher dosage.~The 20-herb formulation are Agastache rugosa,Fraxinus rhynchophylla, Angelica dahurica,Glycyrrhiza uralensis, Artemisia capillaris, Magnolia officinalis, Atractylodes macrocephala,Paeonia lactiflora, Aucklandia lappa, Plantago asiatica,Bupleurum chinense, Phellodendron amurense, Citrus reticulate, Poria cocos, Codonopsis pilosula, Saposhnikovia diraricata, Coix lacryma-jobi, Schisandra chinensis, Coptis chinensis, Zingiber officinale"
223828966|NCT00676975|DRUG|Traditional Chinese Medicine Placebo|Placebo once daily for 8 weeks
223828967|NCT02954900|OTHER|RealRisks|RealRisks is a web-based patient decision aid with modules that present information about risk assessment and chemoprevention.
223828968|NCT02954900|OTHER|BNAV|Breast Cancer Risk Navigation (BNAV) tool is a web-based decision support tool with modules that present pertinent information for primary care providers regarding breast cancer risk assessment and preventative measures for their patients.
223828969|NCT03745794|OTHER|Best Practice|Given standard of care
223828970|NCT03745794|DRUG|Quadratus Lumborum Block|Undergo QL block
223828971|NCT03745794|OTHER|Quality-of-Life Assessment|Ancillary studies
223828972|NCT03745794|OTHER|Questionnaire Administration|Ancillary studies
223828973|NCT01062412|DEVICE|LensAR Laser System|Laser treatment of the crystalline lens
224264568|NCT06187142|BEHAVIORAL|Second phase: Multi-component Optional Support (MOS)|For incomplete responders (subgroup PCS-3) randomized to MOS, the available intervention options include phone counseling, family/peer support group and financial incentive for nicotine replacement therapy. Participants will be guided by cessation counsellors at 1-month follow-up to choose any combination of MOS based on their prefer choice or combination of MOS. If MOS participants cannot be followed up at 1-month, they will continue PCS by default.
224264569|NCT06187142|BEHAVIORAL|Initial phase: Group Chat Support (GCS)|Participant will receive three months of group chat support through WeChat. In this group, participants can send 'No Smoking' and the smart quit-smoking assistant will record it. A smoking cessation clinic doctor in the group will respond to participants' questions about smoking cessation. At the end of the initial phase (1-month), complete responders (quitters) will continue to receive GCS (subgroup GCS-1). Incomplete responders (smokers) will be randomly assigned to continue GCS (subgroup GCS-2) or receive GCS and PCS (subgroup GCS-3).
224264570|NCT06187142|BEHAVIORAL|Second phase: Personalized Chat Support (PCS)|For incomplete responders (subgroup GCS-3) randomized to PCS, participants will receive the same intervention as Group PCS delivered at the initial stage. Participants will receive two months of personalized messages through WeChat. Please refer to Intervention Group 'Initial phase: Personalized Chat Support (PCS) for details.
224264571|NCT06187142|BEHAVIORAL|5A's / 5R's advice|5A's (Ask, Advise, Assess, Assist, Arrange) for smokers who are ready to quit, and 5R's (relevance, risks, rewards, roadblocks, and repetition) for smokers who are not ready to quit.
224264572|NCT06187142|BEHAVIORAL|health warning leaflet|The contents of the leaflet include the absolute risk of smoking, diseases caused by active and second-hand smoking, horrible pictorial warnings of the health consequences of active and second-hand smoking, and the benefits of quitting.
223828974|NCT04110366|BIOLOGICAL|Live attenuated influenza vaccine|Vaccination with live attenuated influenza vaccine (LAIV)
223828975|NCT04110366|OTHER|Vehicle control|Vehicle control nasal challenge
223828976|NCT05939817|BIOLOGICAL|umbilical cord-derived mesenchymal stem cells (UC-MSC)|Group 1 was injected UC-MSC 2 million cells/mL/cm3, given the same injection volume (1 mL) in every cm3 keloid volume using a 1 mL syringe and 27G needle. The injections were ultrasound-guided into the center of the lesion with a 30-45-degree angle using an in-plane technique, therefore the same pressure.
223828977|NCT05939817|BIOLOGICAL|umbilical cord-derived mesenchymal stem cells conditioned medium (UC-CM)|Group 2 was injected UC-CM 1 mL/cm3, given the same injection volume (1 mL) in every cm3 keloid volume using a 1 mL syringe and 27G needle. The injections were ultrasound-guided into the center of the lesion with a 30-45-degree angle using an in-plane technique, therefore the same pressure.
223828978|NCT05939817|DRUG|Triamcinolone Acetonide (TA)|Group 3 was injected TA 40 mg/mL/cm3, given the same injection volume (1 mL) in every cm3 keloid volume using a 1 mL syringe and 27G needle. The injections were ultrasound-guided into the center of the lesion with a 30-45-degree angle using an in-plane technique, therefore the same pressure.
223828979|NCT02886546|PROCEDURE|pneumoperitoneum|
223828980|NCT02886546|DEVICE|oesophageal Doppler monitor|
223828981|NCT02406989|DRUG|MS-553|Study Drug
223828982|NCT02406989|DRUG|Placebo|Matching placebo to MS-553
223828983|NCT05139641|BEHAVIORAL|Counseling to preserve fertility|Counseling to preserve fertility VS Control group
223828984|NCT04448431|DRUG|Vortioxetine|10 or 20 mg/day, capsules, orally
223828985|NCT04448431|DRUG|Desvenlafaxine|50 mg/day capsules, orally
223828986|NCT06278116|OTHER|Aligners cleansing with water|The product is masked in a spraying bottle without any labels. Once a day, for 14 days, the patient sprays the product on the aligner before cleaning it with a soft bristle toothbrush for 1 minute. Afterward, the aligner is rinsed under fresh running water.
223828987|NCT06278116|OTHER|Aligners cleansing with dish soap Svelto|the product is masked in a transparent bottle without any labels. Once a day, for 14 days, the patient puts the product on the aligner before cleaning it with a soft bristle toothbrush for 1 minute. Afterward, the aligner is rinsed under fresh running water.
223828988|NCT06278116|OTHER|Aligners cleansing with Polident Antibacterial Denture Cleaner|the product is masked by deleting all labels on the packaging with a black permanent marker. Once a day, for 14 days, the patient dissolves the tablet in a glass full of warm water (30-35 °C), then the aligner is placed inside it for 5 minutes. Afterward the aligner is rinsed under fresh running water.
223828989|NCT06278116|OTHER|Aligners cleansing with Invisalign Cleaning Crystals|the product is masked by deleting all labels on the packaging with a black permanent marker. Once a day, for 14 days, the patient dissolves the crystals in a glass full of warm water (30-35 °C) mixing with a spoon for 20 seconds; then, the aligner is placed inside the glass for 15 minutes. Afterward, the aligner is rinsed under fresh running water.
223828990|NCT06278116|OTHER|Aligners cleansing with Geldis|the product is masked by deleting all labels on the packaging with a black permanent marker. Once a day, for 14 days, the patient puts the product on the aligner before cleaning it with a soft toothbrush for 1 minute. Afterward, the aligner is rinsed under fresh running water.
223828991|NCT01002664|DRUG|MCS-2|30 mg/day (two 15 mg capsules) Qd for 12 weeks
223828992|NCT01002664|DRUG|Placebo|2 soft-gel placebo capsules Qd for 12 weeks
223828993|NCT02543021|DEVICE|Virtual chromoendoscopy|Digital / virtual chromoendoscopy with FICE
223828994|NCT02543021|PROCEDURE|Conventional chromoendoscopy|Conventional chromoendoscopy with indigo carmine dye spray
223828995|NCT01498913|DRUG|repaglinide|Prescription with NovoNorm® 0.5mg, 1mg or 2mg tablets according to product labelling in daily clinical practice at the discretion of the physician
223828996|NCT05104918|DRUG|Vortioxetine|10 mg tablets
223828997|NCT05104918|DRUG|Venlafaxine|75 mg tablets
223828998|NCT00981825|DRUG|Fluoride|Whole mouth brushing for 7 days
223828999|NCT00981825|DRUG|Triclosan/Fluoride|Brush whole mouth twice daily for 7 days
223829000|NCT02743793|PROCEDURE|Blood Draw|
223829001|NCT03543722|BEHAVIORAL|National Career Coach Program|Intensive employment services as described above.
223829002|NCT03543722|BEHAVIORAL|Local Community Resources Program|Usual employment services as described above.
223829003|NCT02697006|DEVICE|i-cor Synchronized Cardiac Assist Device|The i-cor Synchronized Cardiac Assist Device delivers pulsatile cardiac assist synchronized to the ECG during diastole and provides enhanced oxygenation through a membrane oxygenator.
223829004|NCT05887804|BIOLOGICAL|umbilical cord-derived mesenchymal stem cells (UC-MSC)|Group 1 was injected UC-MSC 2 million cells/mL/cm3, given the same injection volume (1 mL) in every cm3 keloid volume using a 1 mL syringe and 27G needle. The injections were ultrasound-guided into the center of the lesion with a 30-45-degree angle using an in-plane technique, therefore the same pressure.
223829005|NCT05887804|BIOLOGICAL|umbilical cord-derived mesenchymal stem cells conditioned medium (UC-CM)|Group 2 was injected UC-CM 1 mL/cm3, given the same injection volume (1 mL) in every cm3 keloid volume using a 1 mL syringe and 27G needle. The injections were ultrasound-guided into the center of the lesion with a 30-45-degree angle using an in-plane technique, therefore the same pressure.
223829006|NCT05887804|DRUG|Triamcinolone Acetonide (TA)|Group 3 was injected TA 40 mg/mL/cm3, given the same injection volume (1 mL) in every cm3 keloid volume using a 1 mL syringe and 27G needle. The injections were ultrasound-guided into the center of the lesion with a 30-45-degree angle using an in-plane technique, therefore the same pressure.
223829007|NCT03119571|PROCEDURE|Initial CCL admission|Admission to the cardiac catheterization lab to evaluated coronary artery disease and if present fix the culprit lesion/lesions
223829008|NCT03119571|DIAGNOSTIC_TEST|Initial ICU admission|Evaluate for additional testing and/or procedures
223829009|NCT03942874|BEHAVIORAL|Group Reward Retraining|Adapted behavioral activation group treatment for binge eating with values and cognitive skills integrated
223829010|NCT04237974|DEVICE|computed tomography pulmonary angiography|The radiological severity of pulmonary embolism will be assessed by using the computed tomography pulmonary arterial obstruction index (CT-PAOI)
223829011|NCT01146574|BIOLOGICAL|Sotatercept|Part 1: Sotatercept single dose 0.1mg/kg subcutaneous Part 2: Sotatercept starting dose groups of 0.3mg/kg, 0.5mg/kg or 0.7 mg/kg in a sequential design, dosed subcutaneously every 28 days for up to 8 doses
223829012|NCT01146574|BIOLOGICAL|Placebo|Placebo
223829013|NCT03969082|BEHAVIORAL|Bibliotherapy|Students will read to patients during 30 minutes. They will read aloud and pause regularly to encourage patients to reflect on what is being read, on the thoughts the poem or book has stirred or on how the reading matter relates to their own lives.
223829014|NCT05926128|DRUG|Discontinuing treatment with Tyrosine Kinase Inhibitor after enrolment|Discontinuing treatment with Tyrosine Kinase Inhibitor after enrolment with a scheduled molecular monitoring until month 24.
223829015|NCT03051659|DRUG|Eribulin Mesylate|Eribulin mesylate is developed from a natural substance found in a sea sponge. Eribulin mesylate works by preventing cancer cells from multiplying
223829016|NCT03051659|DRUG|Pembrolizumab|Pembrolizumab binds to PD-1, an inhibitory signaling receptor expressed on the surface of activated T cells, and blocks the binding to and activation of PD-1 by its ligands, which results in the activation of T-cell-mediated immune responses against tumor cells.
223829017|NCT01604811|DRUG|Permixon® 160 mg|Oral administration - 160 mg twice daily.
223829018|NCT01604811|DRUG|Tamsulosine Arrow LP|Oral administration - 0.4 mg daily.
223829019|NCT01604811|DRUG|Placebo matching Permixon® 160 mg|Oral administration - twice daily.
223829020|NCT01604811|DRUG|Placebo matching Tamsulosine Arrow LP|Oral administration - daily.
223829021|NCT02055573|OTHER|Ready To Learn (RTL)|See arm description
223829022|NCT02055573|OTHER|All Babies Cry (ABC)|See arm description
223829023|NCT05310032|DRUG|HSG4112|Once-daily oral adminstration
223829024|NCT05310032|DRUG|Placebo|Once-daily oral adminstration
223829025|NCT03535051|DEVICE|fractional carbon dioxide laser|Monthly fractional carbon dioxide laser sessions
223829026|NCT03535051|DRUG|Tacrolimus Oint 0.03%|topical daily tacrolimus ointment application
223829027|NCT06141304|DRUG|Plerixafor|Plerixafor was injected subcutaneously to participants twice per day for five consecutive days ten days post DLI.
223829028|NCT01076088|DRUG|Sitagliptin 50 mg|Sitagliptin 50 mg tablet twice a day, prior to the morning and evening meal, for 24 weeks.
223829029|NCT01076088|DRUG|Metformin 500 mg|Metformin 500 mg tablet twice daily, prior to the morning and evening meal, for 24 weeks.
223829030|NCT01076088|DRUG|Sitagliptin 100 mg|Sitagliptin 100 mg once daily for 24 weeks.
223829031|NCT01076088|DRUG|Placebo|Matching placebo tablets to sitagliptin or metformin for 24 weeks.
223829032|NCT01076088|DRUG|Metformin 850 mg|Metformin 850 mg tablet twice daily, prior to the morning and evening meal, for 24 weeks.
223829033|NCT05818059|DIAGNOSTIC_TEST|Diagnosis of Tuberculosis with computer-aided detection (CAD) software|"After enrolment, each subject will be assessed according to ARM 1 (assessment by clinician #1 without CAD) or ARM 2 (assessment by clinician #1 with CAD). Allocation to sequence ARM 1 or ARM 2 will be performed using a computer-generated random assignment list (with a 1:1 ratio), and assignments will be included in sealed opaque envelopes sequentially numbered.~Clinicians cannot be masked to the assessment method (with or without CAD) and cannot be masked to the further assessment (referral for microbiological diagnosis with stool and sputum Xpert) due to care process. However, the statistician will be masked to the assessment during data analysis."
223829034|NCT03053492|DEVICE|Duck Duck Punch Play|The behavioral intervention will include playing a hands-free video game custom designed for stroke survivors.
223829035|NCT03053492|BEHAVIORAL|Commercially Available Game Play|The behavioral intervention will include playing a hands-free video game available off-the-shelf.
223829036|NCT00786474|DRUG|Placebo|Normal saline solution, dosage determined by weight, self-administered by patient twice a day
223829037|NCT00786474|DRUG|Dalteparin|Low molecular weight heparin (LMWH), dosage determined by weight, self-administered by patient twice a day
223829038|NCT00282230|DRUG|FK778|
223829039|NCT00004399|DRUG|magnesium sulfate|
223829040|NCT00004399|DRUG|nimodipine|
223829041|NCT04851860|DRUG|sublingual immunotherapy|sublingual immunotherapy is the only disease modifying therapy preventing the evolution of AR to asthma
223829042|NCT02378064|DRUG|6-month treatment|
223829043|NCT03835637|DRUG|ORIC-101|Capsule or oral suspension
223829044|NCT00334425|DRUG|MENOPUR; GONAL-F|
223829045|NCT02342587|DRUG|Lapatinib|Patients will be treated with oral lapatinib 1250mg once daily for 21 days.
223829046|NCT00492804|PROCEDURE|Lichtenstein hernia repair|Lichtenstein hernia repair with tension free mesh
223829047|NCT00492804|PROCEDURE|Neurectomy|Neurectomy
223829048|NCT01544491|DRUG|RAD001|Everolimus (C0 trough level of 3-8 ng/mL) in combination with reduced dose tacrolimus and steroids withdrawal at 6 months after transplant
223829049|NCT01544491|DRUG|MMF|MMF (Cellcept®): 600mg/m2/dose twice daily (1200 mg/m2/day) in combination with tacrolimus (Prograf) and standard dose steroids
223829050|NCT02521324|DEVICE|DGB2|DGB guides its user in reducing breathing rate gradually from normal values (12-20 breaths/min) to slow rates (4-6 breaths/min) while increasing the relative duration of the exhalation phase. This is done by composing in real time musical tones from monitored respiration data with which the user synchronizes breathing .
223829051|NCT01501422|DRUG|Estrogen patch|50 microgram estrogen patch weekly
223829052|NCT01501422|DRUG|Placebo|Placebo patch for 8 weeks
223829053|NCT05592535|PROCEDURE|Coronary revascularization|Coronary revascularization performed by PCI in a vessel investigated with FFR or indication for surgery
223829054|NCT01254175|BIOLOGICAL|rHPIV3cp45 Vaccine|10\^5 TCID\^50 of rHPIV3cp45 vaccine, delivered as nose drops
223829055|NCT01254175|BIOLOGICAL|Placebo Vaccine|Placebo vaccine, delivered as nose drops
223829056|NCT06083103|DIAGNOSTIC_TEST|18-FDG PET-MRI|For this trial, 18-FDG PET-MRI will be conducted directly after PET-CT using a single dose of radiotracer
223829057|NCT02290717|DEVICE|Fractional CO2 laser|
223829058|NCT02290717|OTHER|NB-UVB therapy|NB-UVB therapy (according to the standard treatment protocol of the SNIP, which the patient is already been treated with) will be continued for both treated and control sites during 6 months.
223829059|NCT02290717|DRUG|Fluticasone Propionate Cream 0.05%|4 times a week (standard IPD protocol)
223829060|NCT05130788|BEHAVIORAL|WeChat Quit Coach|"WeChat Quit Coach intervention will be delivered via WeChat private groups for 6-12 weeks (\<30 seconds per day). During the intervention period, participants will receive a text message at a fixed point of time every day (e.g., 8:00 am). The messages are designed to build motivations and skillset to quit smoking. Participants will also receive a daily group discussion question (e.g., If you are to give one piece of advice to someone who has not made the decision to quit smoking, what would you say to his/her?), and be encouraged to respond to the question. Participants can comment on group members' responses and ask questions related to smoking and quitting either in group (so everyone in the group can see the message) or directly to the coach (so only the coach can see the message). The coach will respond to the questions within 24 hours. The PI and the RA will moderate group discussions."
223829061|NCT05130788|BEHAVIORAL|Leaflet|Participants in the control group will receive a leaflet with information about existing smoking cessation programs targeting Chinese American smokers.
223829062|NCT05130788|DRUG|Optional Nicotine Replacement Therapy (NRT) Patches or Lozenges|Participants in both groups will be offered a 4-week supply of NRT patches and lozenges but not forced to use the medications. The medications are free to participants. If participants want to try or use the medications, the study team will mail the patches and lozenges (with a Chinese version of the instruction) or deliver in person.
223829063|NCT05754138|DEVICE|Sport SICD|Follow up
223829064|NCT01428804|DEVICE|transcranial Direct Current Stimulation (tDCS)|Device: Eldith DC-Stimulator real or sham tDCS for 20 minutes at 2mA intensity over the left DLPFC (F3 according to the 10-20 system) Other Name: Eldith DC - Stimulator (neuroConn GmbH, Ilmenau, Germany)
223829065|NCT00967018|DRUG|Degarelix|
223829066|NCT00857441|DEVICE|Drug eluting balloon|Percutaneous transluminal coronary balloon angioplasty catheter eluting paclitaxel
223829067|NCT00857441|DEVICE|Liberté|Bare metal stent
223829068|NCT00857441|DEVICE|PTCA balloon catheter|Percutaneous transluminal coronary angioplasty catheter
223829069|NCT00857441|DEVICE|Taxus|Paclitaxel eluting stent
223829070|NCT03897205|DRUG|Imlifidase|Imlifidase is an immunoglobulin G (IgG) degrading enzyme of Streptococcus pyrogenes that cleaves all 4 human subclasses of IgG with strict specificity.
223829071|NCT03897205|OTHER|Plasma Exchange|The subject's plasma is removed and discarded and the subject receives replacement donor plasma, albumin, or a combination of albumin and saline. IA may be used instead of PE to the discretion of the investigator. IA is achieved by passing a subject's plasma over columns that bind immunoglobulins and then the plasma is passed back to the subject.
223829072|NCT05364918|DRUG|Jeksung combined with anti-radiation spray|Treat radiation stomatitis with Jeksung combined with anti-radiation spray
223829073|NCT05515718|OTHER|Standard pain management|Patients undergo ultrasound-guided femoral nerve blockperformed by a trained emergency physician, under strict aseptic conditions After the femoral nerve block is performed, the patient is monitored and (BP, HR, SpO2, ECG) during 90 minutes.
223829074|NCT05515718|OTHER|Femoral nerve block|Patients undergo ultrasound-guided femoral nerve blockperformed by a trained emergency physician under strict aseptic conditions, immediately after oral informed consent is obtained. After the femoral nerve block is performed, the patient is monitored and (BP, HR, SpO2, ECG) during 90 minutes.
223829075|NCT03268460|DIAGNOSTIC_TEST|Arterial blood gases|blood PH, HCO3
223829076|NCT03268460|DIAGNOSTIC_TEST|Blood anion gap|(Na+) - (Cl- + HCO3-)
223829077|NCT03268460|DIAGNOSTIC_TEST|serum electrolytes|Na+ , K+ , Cl- and calcium
223829078|NCT03268460|DIAGNOSTIC_TEST|renal function test|blood urea and serum creatinine
223829079|NCT03268460|DIAGNOSTIC_TEST|urine analysis|urine PH, specific gravity, aminoaciduria, glycosuria, phospaturia and 24 hr urine calcium
223829080|NCT01272882|DEVICE|Electrical Impedance Tomography monitoring|Chest belt with 16 electrodes connected to the EIT device
223829081|NCT02646111|DRUG|12 weeks without Ribavirin|12 weeks Triple Therapy: Ombitasvir, Paritaprevir, Ritonavir (25/150/100 mg dose) once daily and Dasabuvir 250 mg twice daily.
223829082|NCT02646111|DRUG|12 weeks with Ribavirin|12 weeks Triple Therapy: Ombitasvir, Paritaprevir, Ritonavir 25/150/100 mg dose once daily + Dasabuvir 250 mg twice daily + weight adjusted Ribavirin, daily dose: 1,000 mg weight \<75 kg, 1,200 mg weight\> 75 kg.
223829083|NCT02646111|DRUG|24 weeks with Ribavirin|24 weeks Triple Therapy: Ombitasvir, Paritaprevir, Ritonavir 25/150/100 mg dose once daily + Dasabuvir 250 mg twice daily + weight adjusted Ribavirin, daily dose: 1,000 mg weight \<75 kg, 1,200 mg weight\> 75 kg.
223829084|NCT01454180|DRUG|gemcitabine, or gemcitabine and capecitabine, or gemcitabine and erlotinib, or FOLFIRINOX, or FOLFOX, or FOLFIRI.|"* Gemcitabine 1000 mg/m2 weekly for 7 weeks, then weekly regimen of 3 weeks every 4 weeks.~* Gemcitabine - Capecitabine (GEM-CAP):Gemcitabine 1000 mg/m2 weekly for 3 weeks, Capecitabine 830 mg/m2 orally every 12 hours daily for 3 weeks; every 4 weeks.~* Gemcitabine-Erlotinib: Gemcitabine 1000 mg/m2 weekly for 7 weeks, then weekly regimen of 3 weeks every 4 weeks, Erlotinib 100 mg orally daily~* FOLFOXIRI: Oxaliplatin 85 mg/m2,irinotecan 180 mg/m2, folinic acid 400 mg/m2, 5'Fluouracilo 400 mg / m2, 5 'fluorouracil 2400 mg/m2 continuous intravenous infusion of 46 hours. Repeated every 14 days.~* FOLFOX: Oxaliplatin 85 mg/m2, folinic acid 400 mg/m2, 400 mg/m2 5'Fluouracilo, 2400 mg/m2 5'Fluouracilo continuous intravenous infusion of 46 hours. Repeated every 14 days.~* FOLFIRI: Irinotecan 180 mg/m2, folinic acid 400 mg/m2, 400 mg/m2 5'Fluouracilo intravenous bolus, 5'Fluouracilo 2400 mg / m2 continuous intravenous infusion for 46 hours. Repeated every 14 days."
223829085|NCT01454180|DRUG|Gemcitabine, Gemcitabine-Capecitabine, Gemcitabine-Erlotinib, FOLFOXIRI, FOLFOX, FOLFIRI|"* Gemcitabine 1000 mg/m2 weekly for 7 weeks, then weekly regimen of 3 weeks every 4 weeks.~* Gemcitabine - Capecitabine (GEM-CAP):Gemcitabine 1000 mg/m2 weekly for 3 weeks, Capecitabine 830 mg/m2 orally every 12 hours daily for 3 weeks; every 4 weeks.~* Gemcitabine-Erlotinib: Gemcitabine 1000 mg/m2 weekly for 7 weeks, then weekly regimen of 3 weeks every 4 weeks, Erlotinib 100 mg orally daily~* FOLFOXIRI: Oxaliplatin 85 mg/m2,irinotecan 180 mg/m2, folinic acid 400 mg/m2, 5'Fluouracilo 400 mg / m2, 5 'fluorouracil 2400 mg/m2 continuous intravenous infusion of 46 hours. Repeated every 14 days.~* FOLFOX: Oxaliplatin 85 mg/m2, folinic acid 400 mg/m2, 400 mg/m2 5'Fluouracilo, 2400 mg/m2 5'Fluouracilo continuous intravenous infusion of 46 hours. Repeated every 14 days.~* FOLFIRI: Irinotecan 180 mg/m2, folinic acid 400 mg/m2, 400 mg/m2 5'Fluouracilo intravenous bolus, 5'Fluouracilo 2400 mg / m2 continuous intravenous infusion for 46 hours. Repeated every 14 days."
223829086|NCT03739320|DRUG|Mepolizumab 100 MG Injection [Nucala]|100 milligrams subcutaneously once every 4 weeks
223829087|NCT00820820|BIOLOGICAL|ROUVAX|Measles vaccine (ROUVAX ®), Schwarz strain (\>1000 DICC 50) in 0.5 ml of water for injection. One single subcutaneous injection.
223829088|NCT00820820|BIOLOGICAL|placebo|Vehicle (water for injection), 0.5 ml, once
223829089|NCT03414697|OTHER|Control group|The control group received routine rehabilitation treatments including acupuncture, massage, Bobath therapy, and Vojat therapy.
223829090|NCT03414697|PROCEDURE|UC-MSCs|Injection of umbilical cord-derived mesenchymal stem cells (UC-MSCs) (at least 1×10\^7), once every 2 weeks, one course of treatment including two injections within 4 weeks, a total of two courses of treatment.
223829091|NCT01839968|OTHER|Ex vivo addition of normal platelet rich plasma to prasugrel-treated platelet rich plasma|
223829092|NCT01429506|PROCEDURE|Sleeve gastrectomy|Sleeve gastrectomy
223829093|NCT01429506|DRUG|Intensive medical management|Exenatide 10 mcg BD, Metformin 2-3 gm/day, 800 Kcal diet
223829094|NCT02773706|OTHER|Automated Psychology Services|The automated screening tool determines a positive or negative screen, then informs the clinician, and also automates a psychology visit.
223829095|NCT02773706|OTHER|Notification of Subspecialist|The automated screening tool determines a positive or negative screen, then informs the clinician.
223829096|NCT04658732|DRUG|Administration of Alprazolam , Gabapentin , Dexmedetomidine|Patients will be allocated into one of the 3 groups: Alprazolam (A group), Gabapentin (G group) and Dexmedetomidine (D group) as control group. Alprazolam group (n=15): patients in this group will receive 0.25 mg Alprazolam (2 tablets of Xanax 0.125 mg manufactured by Pfizer). Gabapentin group (n=15): patients in this group will receive 600mg Gabapentin (2 capsules of Neurontin 300 mg manufactured by Pfizer).Control group (n=15): patients in this group will receive 2 tablets of multivitamin (Vitamax manufactured by GlaxoSmithKline S.A.E) as placebo to ensure blindness of the study. The study drug will be received 120 minutes before the operation.
223829097|NCT01355874|DRUG|Iferanserin|0.5% iferanserin ointment (containing 10 mg of iferanserin) BID for 14 days during double blind.
223829098|NCT01355874|DRUG|Placebo|Placebo ointment BID for 14 days during double blind.
223829099|NCT01355874|DRUG|Iferanserin + Placebo|0.5% iferanserin ointment (containing 10 mg of iferanserin) BID for 7 days followed by placebo ointment BID for 7 days during the double blind.
223829100|NCT02733042|DRUG|Durvalumab|Administered as an IV infusion (250 mL) over approximately 1 hour in duration
223829101|NCT02733042|DRUG|Lenalidomide|Administered orally
223829102|NCT02733042|DRUG|Rituximab|Administered by intravenous infusion
223829103|NCT02733042|DRUG|Ibrutinib|Administered orally
223829104|NCT02733042|DRUG|Bendamustine|Administered as a 30-minute intravenous infusion
223829105|NCT00787722|PROCEDURE|Hematopoietic Stem Cell Transplantation|Infusion of participant's own stem cells
223829106|NCT00787722|DRUG|Cyclophosphamide|A medication used as chemotherapy and to suppress the immune system
223829107|NCT00787722|DRUG|G-CSF|A glycoprotein that stimulates the bone marrow to produce granulocytes and stem cells and release them into the bloodstream
223829108|NCT00787722|DRUG|rATG|A rabbit polyclonal antibody to lymphocytes
223829109|NCT00787722|DRUG|Mesna|A medication used in those taking cyclophosphamide or ifosfamide to decrease the risk of bleeding from the bladder
223829110|NCT00787722|DRUG|Rituximab|Monoclonal antibody therapy used to treat certain autoimmune diseases and types of cancer
223829111|NCT00787722|DRUG|Methylprednisolone|A corticosteroid medication used to suppress the immune system and decrease inflammation
223829112|NCT00403975|DRUG|diquafosol tetrasodium ophthalmic solution, 2%|
223829113|NCT03368924|OTHER|SCA patients (SS genotype)|"The clinical data relative to the patients will be collected in each of these stages (CVO, basic state).~Besides, to estimate the severity of the CVO, we shall use an index of severity of the episode ( IS2) adapted from the one who was validated by our group to stratify the severity of vasoocclusifs episodes at the drepanocytic child SS.~Main clinical parameters: taken of analgesic at home (level), temperature in the admission, SaO2 in the admission, number of painful sites, thoracic pain with or without associated cough, score EVA in the entrance, feeling of the patient of bigger gravity of the CVO with regard to its crises previous, heart rate to the admission, … Main biological parameters: rate of leukocytes, of polynucléaires neutrophiles, of réticulocytes, Lactate déshydrogénase, of haemoglobin, C-reactive Protein … The biological data can be studied according to their raw rate or according to their difference with their basic value (in the stable state)."
223829114|NCT00823732|OTHER|educational intervention|Undergo individualized interdisciplinary palliative care intervention
223829115|NCT00823732|OTHER|medical chart review|Ancillary studies
223829116|NCT00823732|OTHER|questionnaire administration|Ancillary studies
223829117|NCT00823732|PROCEDURE|end-of-life treatment/management|Undergo end-of-life treatment/management
223829118|NCT00823732|PROCEDURE|psychosocial assessment and care|Undergo psychosocial assessment and care
223829119|NCT00823732|PROCEDURE|quality-of-life assessment|Ancillary studies
223829120|NCT00823732|PROCEDURE|management of therapy complications|Undergo management of therapy complications
223829121|NCT00823732|PROCEDURE|assessment of therapy complications|Undergo assessment of therapy complications
223829122|NCT05047796|OTHER|Intervention Protocol|The intervention protocol will consist of visceral osteopathic techniques and will be performed by a professional who has 17 years of clinical experience in the field of Osteopathy.
223829123|NCT05047796|OTHER|Sham Protocol|The sham protocol will be performed by a professional who has 17 years of clinical experience in the field of Osteopathy. The sham protocol will consist of simulation of therapy, where the therapist will place his hands in the same regions of the intervention protocol, without therapeutic intent
223829124|NCT06058871|BEHAVIORAL|Regular messages|The EMI-I messages will be delivered in sequence over three months. The content, frequency, and timing of the messages will be determined by participant preferences, as determined during the baseline evaluation, as personalisation is central to such cognitive and behavioural changes. The messages will mainly be text-based, but other forms such as videos will also be used, depending on the needs of the participants.
223829125|NCT06058871|BEHAVIORAL|Nurse-led real-time support messages (chat type)|The nurse will initiate 10-15-minute chats via an online platform (e.g., WhatsApp) after all instant messages for each session have been delivered. The nurse will guide the participants to set goals for breastfeeding. Any anticipated barriers will be discussed. The participants can also initiate the chats. While there is no limit to the number of chat messages, nurse-led real-time support messages will be provided during working hours (i.e., 9 am-6 pm on weekdays).
223829126|NCT03522987|DRUG|Escitalopram 10mg|Participants will be given escitalopram 10mg by mouth daily and will be followed up at 2, 4, 6, 8, and 10 weeks. Medication will be adjusted if side effects occur. If unable to tolerate escitalopram, then venlafaxine XR (Effexor XR) 37.5mg will be substituted.
223829127|NCT01088529|DRUG|Abiraterone Acetate|1000 mg oral daily for 3 months followed by a prostatectomy.
223829128|NCT01088529|DRUG|Prednisone|5 mg orally daily.
223829129|NCT01088529|DRUG|LHRHa|LHRH analogue (either leuprolide or goserelin): Leuprolide is an intramuscular injection, and goserelin subcutaneous (under skin) of abdomen, given either 1 injection every 3 months or 1 injection each month for 3 months.
223829130|NCT05372887|DRUG|TNX-102 SL|Patients will take 2 tablets of randomly assigned study drug sublingually each day at bedtime starting on Day 1 for 12 weeks
223829131|NCT05372887|DRUG|Placebo|Patients will take 2 tablets of randomly assigned study drug sublingually each day at bedtime starting on Day 1 for 12 weeks
223829132|NCT06231290|OTHER|Adult full pulpotomy procedure|The adult pulpotomy procedure of mature molars will be carried out with the use of magnification (dental loupes or microscope) in healthy patients. The procedure will be performed either by postgraduate or undergraduate operators.
223829133|NCT05244590|OTHER|Consultation model for patients with palliative care needs|"Training in PC for GPs The training program for GPs will meet the main training needs of GPs according to our previous study and feedback from elements of the Palliative Care Study Group of the Portuguese Association of General and Family Medicine (GESPal). The training program will have a total duration of 24 hours and will consist of two modules.~Consultation model for patients Consultations will take place every 3 weeks for a total period of 12 weeks. The consultation model will be divided into five areas (Summarize clinical information, Objective symptoms' management, Assessment and coding of chronic diseases and symptoms, planning clinical approach, (other) problems/concerns) to be addressed during the assessment. The five areas were constructed to be intuitive for GPs, following the records' structure used in Portuguese primary care."
223829134|NCT03432949|DRUG|Dexamethasone plus Radium-223|Dexamethasone will be administered as 0.5 mg capsules by mouth per day during the duration of the Radium-223 treatment.
223829135|NCT03056859|DEVICE|Extravascular blood pressure transducer|Listed device is included in central venous catheter placement apparatus for consenting patients, according to manufacturer directions
223829136|NCT05045911|PROCEDURE|Endoscopic Barbed-clips Suturing|Endoscopic Barbed-clips Suturing
223829137|NCT05975437|OTHER|personalized surveillance plans (PSP) and personalized aftercare plans (PAP)|The PSP contains decisions on the surveillance trajectory based on individual risks and needs, assessed with the 'Breast Cancer Surveillance Decision Aid' including the INFLUENCE prediction tool. The PAP contains decisions on the aftercare trajectory based on individual needs and preferences and available care resources, which decision-making is supported by a patient decision aid.
223829138|NCT01821898|DRUG|Oral Budesonide|This group will receive oral viscous budesonide at a dose of 1 or 2 mg depending on the height divided twice a day
223829139|NCT01821898|OTHER|Elimination diet|This group will receive an elimination diet
223829140|NCT03016117|PROCEDURE|Pecs II block and parasternal block|The Pecs II block will be performed under ultrasound guidance, at fourth rib level, on the axillary line, into the fascial plane between pectoralis minor muscle and serratus muscle. The parasternal block will be performed under ultrasound guidance, at the second and fourth intercostal space, between the pectoralis major muscle and the intercostal muscles, near to the external intercostal membrane.
223829141|NCT04587531|DEVICE|Cranial Electrotherapy Stimulation|Alpha-Stim® AID microcurrent and cranial electrotherapy stimulator will be used. Daily one hour cranial electrotherapy stimulation (CES) treatment using ear clip electrodes with current set at fixed level of 100 uA (a subsensory current level), 0.5 Hertz will be used for active CES treatment group for 6 weeks. For the sham group the Alpha-Stim® AID ear clips will not emit electricity.
223829142|NCT03772106|DRUG|Propofol Fresenius|Propolipid 1% : IV
223829143|NCT03772106|DRUG|sevorane|sevorane Quick fill (sevoflurane) : inhalation
223829144|NCT04133428|DRUG|Sacubitril-Valsartan|"Evaluation of the Sacubitril-Valsartan treatment effectiveness.~As there are three possible doses, during the first 30 days of treatment 3 evaluations will be carried out (every 10 days) for dose titration based on safety and tolerability as well as a blood test the 30rd day of treatment.~Afterwards the patient will be evaluated after 3 and 6 months of treatment with a blood test and in the final visit (6 months) an echocardiography will be carried out and the final clinical evaluation will be made."
223829145|NCT05451511|OTHER|Door-In-The-Face Technique|Sequential request strategies will be applied as an intervention. For the Door-In-The-Face Technique, participants first receive a large request they are unlikely to accept, followed by a smaller request that is the true behavior of interest.
223829146|NCT05451511|OTHER|Foot-In-The-Door Technique|Sequential request strategies will be applied as an intervention. For the Foot-In-The-Door Technique, participants are shown an easier first request that they are likely to accept, followed by a larger request that is not the behavior of interest.
223829147|NCT02323893|DRUG|[18F]F-AraG|
223829148|NCT05447793|DEVICE|Fitostimoline plus|Formulation in gauzes and cream
223829149|NCT05447793|DEVICE|Connettivina bio plus|Formulation in gauzes and cream
223829150|NCT02689791|DIETARY_SUPPLEMENT|Resistant Starch Type 4|single dose 26g fiber given at the breakfast meal
223829151|NCT02518724|PROCEDURE|RIPC intervention exposure|placing a sphygmomanometer on the non-dominant hand and applying pressure of 200 mmHg for 5 min followed by 5 min without pressure X 4 repeats
223829152|NCT02518724|PROCEDURE|placebo intervention exposure|placing a sphygmomanometer on the non-dominant hand and applying pressure of 100 mmHg for 5 min followed by 5 min without pressure X 4 repeats.
223829153|NCT05753423|DIAGNOSTIC_TEST|Interview-based questionnaires & Clinical examination|Interview-based questionnaires will be conducted among Egyptian mothers attending Pediatric Dentistry and Dental Public Health outpatient clinic at Faculty of Dentistry, Ain Shams University by the principal investigator. Clinical examination of the oral health status of their preschool children aged 3-5 years will be conducted by the principal investigator.
223829154|NCT02341144|PROCEDURE|Pre-op percutaneous rectus sheath block|After induction of anesthesia, the attending anesthesiologist will use a portable ultrasound probe to locate the rectus sheath. A 22 gauge needle will be used to inject a predetermined volume of 0.2% ropivacaine (1cc/kg, max dose 10cc, divided into equal doses bilaterally). The analgesic will be injected percutaneously using ultrasound guidance between the rectus abdominis muscle and the posterior rectus sheath at the lateral border bilaterally.
223829155|NCT02341144|PROCEDURE|Intra-operative rectus sheath block|After the completion of the umbilical hernia repair, after fascial closure, but prior to skin closure, a predetermined volume of 0.2% ropivacaine (1cc/kg, max dose 10c, divided into equal doses bilaterally) will be administered under direct visualization into the rectus sheath bilaterally by the attending surgeon.
223829156|NCT02341144|DRUG|Ropivacaine|
223829157|NCT02349464|OTHER|Specialized Preterm Infant/Mother Dyad Lactation Support|Mother will receive home equipment and pediatric clinic lactation support.
223829158|NCT05177731|DRUG|Venetoclax|Orally by mouth
223829159|NCT05177731|DRUG|Decitabine for Injection|Intravenous infusion
223829160|NCT05177731|DRUG|Cytarabine|Intravenous infusion
223829161|NCT05177731|DRUG|Idarubicin|Intravenous infusion
223829162|NCT05177731|DRUG|Gilteritinib|Orally by mouth
223829163|NCT02917577|BIOLOGICAL|Avaxim Pediatric®|2 doses (0.5 mL each) 6 months apart of Avaxim Pediatric® vaccine.
223829164|NCT02917577|BIOLOGICAL|Avaxim ® (adult)|2 doses (0.5 mL each) 6 months apart of Avaxim ® (adult) vaccine.
223829165|NCT05342116|OTHER|Nestle Preload|1 sachet of Preload (50g) diluted with 400ml of water, to be consumed 2 to 4 hours prior to the endoscopy.
223829166|NCT05342116|OTHER|Water|400ml of water to be consumed 2 to 4 hours prior to the endoscopy.
223829167|NCT04938115|BIOLOGICAL|CD7 CART|Biological: CD7 CAR-T; Drug: Cyclophosphamide,Fludarabine; Procedure: Leukapheresis
223829168|NCT05882084|DIETARY_SUPPLEMENT|Astaxanthin 6 mg daily|Astaxanthin at 6 mg is given for daily ingestion and compared against placebo.
223829169|NCT05882084|DIETARY_SUPPLEMENT|Placebo|Placebo
223829170|NCT02579356|DRUG|Telmisartan|
223829171|NCT02579356|DRUG|Atorvastatin|
223829172|NCT03696875|OTHER|Multilevel Guided Discharge Planning|Clinical recommendations and resources activations + scheduling of early visit with the specialist + communication with primary care + written instruction sheet to the patient
223829173|NCT03696875|OTHER|Standard of care|Standard of care
223829174|NCT02222519|DRUG|Rocuronium|Rocuronium 0.6mg/kg iv single dose
223829175|NCT01885260|DRUG|ISIS-GCGRRx - Dose Level 1|3 doses on alternate days during the first week and then once weekly for 12 weeks
223829176|NCT01885260|DRUG|ISIS-GCGRRx - Dose Level 2|3 doses on alternate days during the first week and then once weekly for 12 weeks
223829177|NCT01885260|DRUG|Placebo|3 doses on alternate days during the first week and then once weekly for 12 weeks
223829178|NCT01416896|PROCEDURE|Hemodialysis using the standard venous needle|Hemodialysis using the standard venous dialysis needle
223829179|NCT01416896|PROCEDURE|"Hemodialysis using a new venous needle, the BME needle"|"Hemodialysis using a new venous dialysis needle or the BME needle"
223829180|NCT01416896|PROCEDURE|"Hemodialysis using a new venous needle, the BME needle"|"One hemodialysis using a new venous needle, the BME needle"
223829181|NCT01416896|PROCEDURE|Hemodialysis using the standard venous needle|One hemodialysis using the standard venous needle
223829182|NCT04882761|DEVICE|Dental implant|Comparative
223829183|NCT05410236|OTHER|3D bronchial tree model|A detachable 3D printed bronchial tree model
223829184|NCT05321706|DRUG|Dapagliflozin 10 mg|Participants will be randomized in a 1:1 fashion to receive 10 mg of oral dapagliflozin
223829185|NCT05321706|DRUG|Placebo|Participants will be randomized in a 1:1 fashion to receive a matching placebo once daily for one year.
223829186|NCT03383003|DRUG|Nexium|Esomeprazole ( Nexium )40 mg tid daily for 14 days in the high dose dual therapyarm and 40 mg bid daily for 7 days in the non-bismuth quadruple therapy
223829187|NCT03383003|DRUG|Amolin|Amoxicillin 750 mg qid daily for 14 days in the high dose dual therapy and amoxicillin 1 g bid daily for 7 days in the non-bismuth quadruple therapy
223829188|NCT03383003|DRUG|Klaricid|clarithromycin 500 mg bid daily for 7 days in the non-bismuth quadruple therapy
223829189|NCT03383003|DRUG|Flagyl|Metronidazole (Flagyl) 500 mg tid daily for 7 days in the non-bismuth quadruple therapy
223829190|NCT00337662|DRUG|olanzapine|10-20 milligrams (mg), oral, daily, 10 weeks.
223829191|NCT00337662|DRUG|risperidone|2-6 mg, oral, daily, for 10 weeks.
223829192|NCT00337662|DRUG|risperidone|2-6 mg, oral, daily, 10 weeks
223829193|NCT04834778|DRUG|HC-5404-FU|HC 5404-FU (hemi fumarate salt of HC 5404) is a novel, highly selective, and potent PERK inhibitor. Preclinical pharmacological studies demonstrated high specificity of HC 5404-FU to PERK and decreased viability of tumor cells. HC 5404-FU will be orally administered BID every day with food or within 30 minutes of completing a meal, starting at 25 mg, with doses escalating to 50, 100, 200, 400, 600, and 900 mg BID as safety allows for each 3-week treatment cycle.
223829194|NCT00410787|DRUG|OROS hydromorphone HCI (slow release)|
223829195|NCT03691948|OTHER|Responsible Opioid Prescriber Education (ROPES)|The ROPEs intervention is a self-guided, web-based continuing dental education intervention. Consistent with ADA recommendations, ROPEs consists of seven modules of active content: (1) Overview; (2) Background on the Opioid Epidemic; (3) Dental Pain Management and the Role of Opioids; (4) Universal Precautions Approach; (5) Screening, Monitoring, and PDMP use; (6) Providing Patient Education; and, (7) Case Vignettes. All key intervention content is delivered via video-based platform and includes downloadable practice aides and resources.
223829196|NCT03691948|OTHER|Active Comparator Control|An online PDF version of the Center for Disease Control Guideline for Prescribing Opioids for Chronic Pain.
223829197|NCT01381952|RADIATION|Low dose DSA (75% reduction compared to normal dose) with novel X-ray imaging technology.|Digital substraction angiography (DSA) with reduced dose settings (75% reduction expected) in combination with conventional X-ray imaging technology.
223829198|NCT01381952|RADIATION|Normal dose DSA with conventional X-ray technology|Digital substraction angiography (DSA) with normal dose settings in combination with conventional X-ray imaging technology.
223829199|NCT04795817|DEVICE|Transoral Robotic Surgery|Subjects will undergo TORS benign base of tongue resection procedures (i.e., partial glossectomy, epiglottoplasty, epiglottectomy, and/or lingual tonsillectomy) for the treatment of OSA. Concomitant non-robotic surgical procedures may also be performed as part of the subject's treatment for OSA, and can include one or more of the following: uvulopalatopharyngoplasty (UPPP), lateral pharyngoplasty, expansion sphincter pharyngoplasty, palatine tonsillectomy, or a modified uvulopalatoplasty. Nasal surgery such as septoplasty or turbinoplasty can be combined if it is needed.
223829200|NCT04325464|DEVICE|PEAR-003A|PEAR-003A delivers CBT-I through a decentralized clinical trial open to participants with chronic insomnia
223829201|NCT01007968|DRUG|LBH589|
223829202|NCT03178084|DRUG|Maraviroc (UK-427,857) QD + Zidovudine/Lamivudine BID|maraviroc (UK-427,857) 300 mg once daily added to zidovudine/lamivudine (300 mg/150 mg twice daily
223829203|NCT03178084|DRUG|Efavirenz QD + Zidovudine/Lamivudine BID|efavirenz (600 mg once daily) added to zidovudine/lamivudine (300 mg/150 mg twice daily)
223829204|NCT03178084|DRUG|Maraviroc (UK-427,857) BID + Zidovudine/Lamivudine QD|maraviroc (UK-427,857) 300 mg twice daily added to zidovudine/lamivudine (300 mg/150 mg twice daily
223829205|NCT02349724|BIOLOGICAL|Anti-CEA-CAR T|T cells modified with CEA targeted chimeric antigen receptor.
223829206|NCT02191384|DRUG|Orcinoside|oral, twice per day
223829207|NCT05877300|COMBINATION_PRODUCT|Cellspan™ Esophageal Implant-Adult (CEI)|The CEI is a combination product consisting of an engineered synthetic scaffold (device constituent) seeded and cultured with the patient's adipose derived mesenchymal stromal cells (biologic constituent), intended to stimulate regeneration of a structurally intact, living biologic esophageal conduit, in patients requiring full circumferential esophageal reconstruction up to 6 cm segment in length.
223829208|NCT00447044|BEHAVIORAL|Resistance Exercise|Subjects will lift weights with their legs.
223829209|NCT00447044|DIETARY_SUPPLEMENT|diet orange soda|Subjects drink diet orange soda 3x day for 2 days.
223829210|NCT00447044|DIETARY_SUPPLEMENT|essential amino acids|Subjects drink 15 grams of EAA mixed into diet orange soda 3x day for 2 days.
223829211|NCT01494714|DRUG|JNJ 10229570-AAA 1.2% cream|A patch containing the cream will be applied on the back and left for 48 hours on the left side, and 24 hours on the right side.
223829212|NCT01494714|DRUG|JNJ 10229570-AAA 2.4% cream|A patch containing the cream will be applied on the back and left for 48 hours on the left side, and 24 hours on the right side.
223829213|NCT01494714|DRUG|JNJ 10229570-AAA 3.6% cream|A patch containing the cream will be applied on the back and left for 48 hours on the left side, and 24 hours on the right side.
223829214|NCT01494714|DRUG|Color-matched vehicle in a cream formulation containing 0 mg of JNJ 10229570-AAA|A patch containing the cream will be applied on the back and left for 48 hours on the left side, and 24 hours on the right side.
223829215|NCT01494714|DRUG|Petroleum jelly|A patch containing the petroleum jelly will be applied on the back and left for 48 hours on the left side, and 24 hours on the right side.
223829216|NCT03344822|DIAGNOSTIC_TEST|68Ga-PSMA-11|radioactive tracer for PET-CT (68Ga-PSMA-11)
223829217|NCT03344822|DIAGNOSTIC_TEST|18F-Choline PET-CT|radioactive tracer for PET-CT (18F-Choline PET-CT)
223829218|NCT02477397|DRUG|Spiromax Budesonide/formoterol|1\. In Group A, Patients will be treated with Spiromax® budesonide/formoterol 160/4.5 μg two inhalations twice daily + Spiromax® budesonide/formoterol 160/4.5 μg as needed with a maximum of 8 additional inhalations daily.
223829219|NCT02477397|DRUG|Diskus Fluticasone/salmeterol|2\. In group B, Patients will be treated with Diskus® fluticasone/salmeterol 500/50 μg one inhalation twice daily + salbutamol 100 μg as needed with a maximum of 8 inhalations daily.
223829220|NCT04456335|GENETIC|Collection of supragingival plaque from caries free children|Supragingival plaque samples were collected from posterior molar teeth
223829221|NCT04545216|OTHER|Long-distance mountain running|Impact of a mountain race on the knee cartilage
223829222|NCT06167551|OTHER|mother lullaby group|mother's lullaby: the mother will be made to sing her own lullaby 5 minutes before the heel prick.
223829223|NCT06167551|OTHER|white noise group|white noise: 5 minutes before taking heel prick blood, white noise will be started to be played on an MP3 player with white noise. The MP3 player will be placed in the crib where the baby lies, at the baby's bedside, at least 20 cm away from the baby's head. After the MP3 player is turned on, the sound level will be measured at the baby's ear level with a decibel meter and adjusted so that it does not exceed 70 decibels.
223829224|NCT06167551|OTHER|classical music group|classical music: 5 minutes before heel prick, classical music will be started to be played from the MP3 player with white noise. The MP3 will be placed inside the crib where the baby lies, at the baby's bedside, at least 20 cm away from the baby's head. After the MP3 player is turned on, the sound level will be measured at the baby's ear level with a decibel meter and adjusted so that it does not exceed 70 decibels.
223829225|NCT06167551|OTHER|Contol Group|No intervation
223829226|NCT01468532|DRUG|docetaxel|Given IV
223829227|NCT01468532|DRUG|pasireotide|Given IM
223829228|NCT01468532|DRUG|prednisone|Given PO
223829229|NCT03106519|DRUG|Liposome bupivacaine + bupivacaine|
223829230|NCT02332018|RADIATION|Biplanar x-ray images|biplanar x-ray images with microdose and low-dose protocol
223829231|NCT01476917|DEVICE|Attune Sleep Apnea System|Observation of Attune Sleep Apnea System for use during sleep.
223829232|NCT05222425|DRUG|Xagrotin|A herbal compound
223829233|NCT05222425|DRUG|Green tea|Normal green tea
223829234|NCT05175534|PROCEDURE|monitoring|peroperative transesophageal echocardiography for monitoring in liver transplant surgery
223829235|NCT00589550|BIOLOGICAL|PEG-interferon alfa-2b|administered SC on day 1 of each week of therapy. This will most likely be a Monday or a Tuesday. Sorafenib will be initiated on day 15 (start of week 3) of the first course and continued daily without breaks.
223829236|NCT00589550|DRUG|Sorafenib|
223829237|NCT00589550|GENETIC|gene expression analysis|
223829238|NCT00589550|GENETIC|polymerase chain reaction|
223829239|NCT00589550|GENETIC|reverse transcriptase-polymerase chain reaction|
223829240|NCT00589550|OTHER|flow cytometry|
223829241|NCT00589550|OTHER|immunoenzyme technique|
223829242|NCT00589550|OTHER|laboratory biomarker analysis|
223829243|NCT02936622|DEVICE|Zilver® Paclitaxel-Eluting Peripheral Stent|Paclitaxel belongs to the Taxane drug class and coated on the stent at a much lower dose than when administered as a chemotherapy agent.
223829244|NCT02936622|DEVICE|Zilver® Paclitaxel-Eluting Peripheral Stent with slower-dissolving polymer-free paclitaxel coating|Paclitaxel belongs to the Taxane drug class and coated on the stent at a much lower dose than when administered as a chemotherapy agent.
223829245|NCT02936622|DEVICE|Zilver® Paclitaxel-Eluting Peripheral Stent with higher-dose polymer-free paclitaxel coating|Paclitaxel belongs to the Taxane drug class and coated on the stent at a much lower dose than when administered as a chemotherapy agent.
223829246|NCT01755520|DRUG|Ticagrelor|90mg twice daily dose
223829247|NCT01755520|DRUG|Aspirin|Aspirin 100mg once daily
223829248|NCT01755520|DRUG|Placebo - Ticagrelor|Placebo
223829249|NCT01755520|DRUG|Placebo - Aspirin|Placebo
223829250|NCT03441113|DRUG|MMB|Tablet(s) administered orally once daily
223829251|NCT04733196|DRUG|Essential oils|Participants were asked to rinse with 15 ml mouthwash twice daily for 21 days.
223829252|NCT04733196|DRUG|Essential oils in combination with chlorhexidine 0,12%|Participants were asked to rinse with 15 ml mouthwash twice daily for 21 days.
223829253|NCT04733196|DRUG|Placebo mouthwash|Participants were asked to rinse with 15 ml mouthwash twice daily for 21 days.
223829254|NCT04733196|DRUG|Chlorhexidine 0,20 % in combination with aroma oils|Participants were asked to rinse with 15 ml mouthwash twice daily for 21 days.
223829255|NCT04733196|DRUG|Prebiotic|Participants were asked to rinse with 15 ml mouthwash twice daily for 21 days.
223829256|NCT04733196|DRUG|Hydrogen peroxide 0,8 %|Participants were asked to rinse with 15 ml mouthwash twice daily for 21 days.
223829257|NCT03341650|BEHAVIORAL|High Pasta|Participants received a personalised diet program considering their food preferences and eating behaviour, based on the Italian guidelines for a healthy and Mediterranean diet and were encouraged to maintain their habitual consumption of pasta (at least 5 times/week). To encourage participants to prepare healthy meals by using high-quality ingredients, participants were provided with a recipe book and dietary guidelines and recommendations.
223829258|NCT03341650|BEHAVIORAL|Low Pasta|Participants received a personalised diet program considering their food preferences and eating behaviour, based on the Italian guidelines for a healthy and Mediterranean diet and were encouraged to maintain their habitual consumption of pasta (no more than 3 times/week). To encourage participants to prepare healthy meals by using high-quality ingredients, participants were provided with a recipe book and dietary guidelines and recommendations.
223829259|NCT04398693|DIETARY_SUPPLEMENT|Prebiotic|It shall be a double-blinded, randomized, placebo-controlled crossover study and treatment with prebiotic for 4 weeks. After a washout period of 4 weeks, the study protocol will be repeated in the other arm. Participants will receive supplementary diet based on high-amylose cornstarch, which releases large amounts of SCFA (acetate and butyrate) in a sachet with a powder that must be dissolved in a glass of liquid to your choice, during 4 weeks (20 g 2x/day). Participants will undergo anthropometric, biochemistry and GUT microbiota assessment, before and after the end of the first phase of the crossover study. Later, when the inversion of the treatment groups occur all participants will also be subjected to the same procedures before and after the end of the second phase of the study.
223829260|NCT01496508|DEVICE|mechanical ventilation (SLE 5000, Servo-i-Maquet)|Ventilation strategies for both groups were to emphasize lung recruitment and avoid atelectasis and over distention. The optimum lung volume was determined as expansion to 8 to 9.5 ribs for most infants, and 7 to 8 ribs for infants with air leak. HFOV setting were as follows: initial frequency was set between 11 and 15Hz; pressure amplitude of oscillation was initially adjusted to provide adequate chest wall movement and was subsequently titrated to maintain the PaCO2 between 40 and 55 mmHg; The initial mean airway pressure (MAP) was set at 8-10 cmH2O. MAP and FIO2 were set to maintain arterial oxygen saturation between 88 to 95%, an arterial pH of at least 7.25. Extubation was considered when MAP was ≤7 cmH2O and the pressure amplitude of oscillation reach 10 to 15 cmH2O.
223829261|NCT02146222|DRUG|VEGFR/PDGFR dual kinase inhibitor X-82|Given PO
223829262|NCT02146222|DRUG|docetaxel|Given IV
223829263|NCT02146222|OTHER|fluorine F 18 fluorothymidine|Undergo FLT PET/CT
223829264|NCT02146222|PROCEDURE|positron emission tomography/computed tomography|Undergo FLT PET/CT
223829265|NCT02146222|OTHER|pharmacological study|Correlative studies
223829266|NCT02146222|OTHER|laboratory biomarker analysis|Correlative studies
223829267|NCT03295266|DRUG|MK-3866|Single IV infusion of MK-3866 150 mg administered over 30 minutes at Hour 0 on Day 1 of treatment period.
223829268|NCT05667779|DRUG|QRL-101|Single-ascending doses of QRL-101 will be orally administered. The dose levels may change subject to available nonclinical, clinical, safety, and PK data.
223829269|NCT05667779|OTHER|Placebo|A placebo comparator will be administered at all dose levels.
223829270|NCT06480682|RADIATION|Dual x-ray scan|Annual whole body scan monitoring bone mineral density for whole body, radius, L1-4 and femur and body composition
224264573|NCT06187142|BEHAVIORAL|Self-help booklet|The contents include information about the benefits of quitting, methods to quit, how to handle withdrawal symptoms, misperceptions of quitting, etc.
224264574|NCT01438060|DRUG|Aripiprazole (BMS-337039)|"Acute Phase: Oral, Tablets (1 and 5 mg), Week 1-2: 2 mg, Week 3-4: 2 - 5 mg, Week 5-6: 2 - 10 mg, Weeks 7-10: 2 - 15 mg, Once daily, 10 weeks~Extension Phase: Oral, Tablets (1 and 5 mg), Week 11: 2 mg, Weeks 12-13: 2 - 5 mg, Weeks 14-15: 2 - 10 mg, Weeks 16-140: 2 - 15 mg, Once daily, 130 weeks"
224264575|NCT01438060|DRUG|Placebo|Acute Phase: Oral, Tablets, 0 mg, Once daily, 10 Weeks
223829271|NCT06480682|DIAGNOSTIC_TEST|Blood screen|Three times a year blood samples will be taken to measure: full blood count, ferritin, B12, folate, erythrocyte sedimentation rate (ESR), renal function, liver function, thyroid stimulating hormone (TSH), Free thyroxine (T4), luteinizing hormone (LH), oestradiol, testosterone, follicle-stimulating hormone (FSH), coeliac screen, vitamin D (25(OH)D), Leptin and Ghrelin
223829272|NCT06480682|OTHER|Questionnaires|Informed consent; Low energy availability questionnaires for males and females; General health including menstrual status (females)
223829273|NCT06480682|OTHER|Anthropometric measurements|Three times a year participant's measurements will be taken: stature, body mass and body composition (bio-impedence)
223829274|NCT06480682|PROCEDURE|Resting Metabolic rate|Resting metabolic rate will be measured by resting gas analysis. Each participant will lie down for a period of 15 minutes, in the final 5 minutes their expired gases are analysed using a breath-by-breath gas analyser (Cortex).
223829275|NCT06480682|OTHER|Energy expenditure|Energy expenditure was estimated using accelerometery (Genieactive) and activity logs in the participants' normal environment, assessed during 3 weekdays of scheduled dance training and 2 weekend days without scheduled dance training. Focus is on daily energy expenditure
223829276|NCT06280287|DIAGNOSTIC_TEST|FAPI PET|68Ga-FAPI PET/MR with high-resolution cardiovascular magnetic resonance vessel wall imaging for patients with carotid stenosis; 18FAl-FAPI PET/CT for patients with coronary artery disease
223829277|NCT00335205|DRUG|ropinirole|
223829278|NCT04180735|PROCEDURE|Liver transplantation|Liver transplantation
223829279|NCT02857660|OTHER|Whole body Electromyostimulation (exercise)|1.5 x 20 min/week (e.g. each Tuesday and every second Friday) with bipolar current, 85 Hz, 360 µs, rectangular mode, intermittent with 4 sec of current and 4 s of rest.
223829280|NCT02857660|DIETARY_SUPPLEMENT|Protein|up to 1.5-1.7 g/kg bodymass/d of protein (whey protein)
223829281|NCT03612518|BEHAVIORAL|Text and Voice Messages|Participants in this study arm will periodically receive information regarding antenatal- and postnatal care and family planning services through text and voice messages from the fifth gestational month until the post-partum period of 42 days.
223829282|NCT03612518|BEHAVIORAL|Interactive Phone Call|Participants in this study arm will receive information regarding antenatal- and postnatal care and family planning services through periodic interactive phone calls from the fifth gestational month until the post-partum period.
223829283|NCT04263298|DRUG|Fulvestrant|Fulvestrant 500mg Days 0, 14, 28, then every 28 days
223829284|NCT04263298|DRUG|Capecitabine Oral Product|Capecitabine 2000mg/m2 twice daily x 14 days followed by 7 days off
223829285|NCT05295303|DEVICE|Remote integrated post-MI management system|The home-based remote integrated post-MI management system comprises (1) a patch-based long-term Holter monitoring system HC3A250 (BISA Technologies (Hong Kong) Limited, Hong Kong SAR, China), (2) a handheld single-lead electrocardiogram (ECG) recorder (Comfit Healthcare Devices Limited, Hong Kong SAR, China), (3) a blood pressure monitor, (4) a patient-facing smartphone application specially designed for the study, and (5) a web-based clinical management system for clinicians
223829286|NCT03933332|OTHER|Diaphragm thickness|measured at apposition zone using ultrasonography in mm
223829287|NCT03933332|OTHER|Cross-sectional area of rectus femoris muscle|measured at lower one-third line between Spina iliaca anterior inferior (SIAI) and upper border femur patella using ultrasonography in cm\^2
223829288|NCT03933332|OTHER|Cross-sectional area of biceps brachii|measured at biceps brachii muscle using ultrasonography in cm\^2
223829289|NCT03933332|DIAGNOSTIC_TEST|C-Reactive Protein (CRP) Level|quantitative CRP using ELISA method in mcg/mL
223829290|NCT04109742|DRUG|phosphatidylcholine-curcumin complex supplement|a dietary curcumin supplement given at two different doses
223829291|NCT04109742|DRUG|Placebo curcumin capsule|matching placebo to active curcumin capsules
223829292|NCT03250351|OTHER|Neural mobilization group|See arm/group descriptions
223829293|NCT03250351|OTHER|Control group|See arm/group descriptions
223829294|NCT02693340|BIOLOGICAL|sampling|"• Sampling period(s):~* Blood: W0, W6, W14, W30 and W52 and relapse.~* Biopsies and fecal: W0, W14 and M52 and relapse."
223829295|NCT04725630|BEHAVIORAL|Healthy food incentive|$10.50/week/household member for 12 months to purchase healthy foods in participating supermarkets.
223829296|NCT04725630|BEHAVIORAL|Healthy food prescription|A one-time healthy food prescription pamphlet
223829297|NCT00479089|DRUG|Docetaxel|25 mg/m2 IV over 30 minutes for 4 weeks, followed by 2 weeks off therapy.
223829298|NCT00479089|DRUG|ZD1839|250 mg by mouth daily, without break.
223829299|NCT00479089|DRUG|Dexamethasone|"Course #1: 3 doses of prophylactic Dexamethasone 4mg orally every 12 hours, starting the night before the Docetaxel infusion.~Course #2: If no hypersensitivity reactions and no significant fluid retention during course 1, the Dexamethasone is reduced to 4mg orally twice daily on the day of therapy.~Course #3 and subsequent courses: If no hypersensitivity reactions and no significant fluid retention during course 2, the Dexamethasone is reduced to 4mg orally one hour before treatment."
223829300|NCT03784352|DEVICE|Virtual Reality|A calming virtual reality game will be played
223829301|NCT00405704|DRUG|Trimethoprim-Sulfamethoxazole|Cherry-flavored liquid suspension with 3 mg of trimethoprim plus 15 mg sulfamethoxazole per kilogram of body weight, taken once daily.
223829302|NCT00405704|DRUG|Placebo|Cherry flavored liquid suspension matched to active comparator.
223829303|NCT02323503|DEVICE|CRT-D device replacement|
223829304|NCT03133949|OTHER|Establish the clinical, biological and radiological characteristics of patients|Establish the clinical, biological and radiological characteristics of patients
223829305|NCT05728567|OTHER|whether the participants had T2DM|whether the participants had T2DM
223829306|NCT04281433|OTHER|Activa Bioactive|Before cavity preparation and restoration, masticatory muscles activity will be evaluated by using electromyography. An electromyography detects the electrical potential generated by muscle cells. A total of 40 posterior teeth will be selected for this study and grouped into 2 main groups (20 for each group)) according to presence of caries in one or both side in patient (unilateral or bilateral). Split mouth technique will be used. The affected teeth will be treated by removing the caries and restored tooth with bulk fill composite material, after restoring the affected teeth. Masticatory muscles activity will be evaluated by using electromyography to detect any changes in masticatory muscles activity before and after restoration.
223829307|NCT04959760|DIAGNOSTIC_TEST|The BinaxNOW™ Antibody Tests measure IgG antibodies against SARS-CoV-2.|The BinaxNOW™ Antibody Tests measure IgG antibodies against SARS-CoV-2 in fingestick capillary blood and plasma samples.
223829308|NCT03012061|DRUG|Placebo|Placebo is a white powder to be administered using ELLIPTA DPI which hold two individual blister strips, both of which contains lactose monohydrate blended with magnesium stearate.
224264576|NCT06166862|OTHER|Action observation and motor imagery therapy for rehabilitation|"Action observation; Patients will watch some exercises accompanied by music from a previously prepared video for 10 minutes. Exercises include 8-10 repetitions of abduction-adduction, horizontal abduction-adduction, flexion-extension and supination-pronation movements for the upper extremity, and stepping, forward-backward stepping, side stepping and ankle dorsiflexion movements for the lower extremity.~Motor imagery training; Patients will be asked to visualize the actions they watched in their minds for 10 minutes.~Then the patients will watch the video again and will be asked to perform the exercises while watching."
223829309|NCT03012061|DRUG|UMEC|UMEC is a white powder to be administered using ELLIPTA DPI which hold two individual blister strips, one of which contains GSK573719 blended with lactose blended with magnesium stearate and another one contains lactose monohydrate blended with magnesium stearate.
223829310|NCT03012061|DRUG|Fluticasone Furoate|FF is a white powder to be administered using ELLIPTA DPI which hold two individual blister strips, one of which contains GW685698 blended with lactose monohydrate and another one contains lactose monohydrate with magnesium stearate.
223829311|NCT03012061|DRUG|Albuterol/salbutamol|Albuterol/salbutamol is to be administered via metered-dose inhaler as a rescue drug on need basis throughout the study.
223829312|NCT03859401|DEVICE|EnMPC (Ensemble Model Predictive Control) AP Controller|This AP controller has the ability to anticipate exercise activity by use of trends seen during the Data Collection Period.
223829313|NCT03859401|DEVICE|rMPC (Naïve Model Predictive Control) AP Controller|This AP controller does not have the ability to anticipate exercise activity.
223829314|NCT05493384|OTHER|Telerehabilitation Group|The program will include stretching, strengthening, breathing, posture, proprioceptive, relaxation exercises and segmental extremity movements. Each exercise will be performed 10 times in a session for the first 4 weeks and 15 times for the last 4 weeks. Exercises will be performed progressively on the patients.
223829315|NCT06358911|OTHER|Poly amido amine dendrimer (PAMAM)|"Desensitizing agents was applied once after the bleaching procedure,as follows:~1-Bleaching/PAMAM group, patients received bleaching followed by the application of PAMAM for 30 minutes according to previous studies."
223829316|NCT06358911|OTHER|Manufacturer's desensitizing agent, Ultra EZ|"Desensitizing agents was applied once after the bleaching procedure, as follows:~2-Control group, where patients received hydrogen peroxide in-office bleaching followed by the application of manufacturer recommended desensitizing agent ( Ultra EZ) once for 60 minutes."
223829317|NCT06358911|OTHER|MI paste plus, desensitizing agent|"Desensitizing agents was applied once after the bleaching procedure, as follows:~3-Bleaching/MI Paste Plus group, patients received bleaching followed by the application of MI paste plus according to the manufacturer's instructions once for 3 minutes."
223829318|NCT06358911|OTHER|Hydroxyapatite and F (ReminPro), desensitizing agent|"Desensitizing agents was applied once after the bleaching procedure, as follows:~4-Bleaching/Hydroxyapatite and F (ReminPro), patients received bleaching followed by the application of Hydroxyapatite and F (ReminPro) according to the manufacturer's instructions once for 3 minutes"
223829319|NCT02574676|OTHER|non-interventional|
223829320|NCT02696902|DRUG|MEDI3902|Participants will receive a single IV dose of MEDI3902 500 mg and 1500 mg in MEDI3902 500 mg arm and MEDI3902 1500 mg arm, respectively.
223829321|NCT02696902|OTHER|Placebo|Participants will receive a single IV dose of placebo matched to MEDI3902.
223829322|NCT01003600|BEHAVIORAL|Questionnaire|The questionnaire will be administered by telephone and will take approximately 20-30 minutes. The questionnaire will elicit survivor responses along five domains: knowledge about diagnosis and treatment, knowledge about ongoing risks and recommended testing, history of health care utilization since the end of treatment, preferences for relevant information about these topics, and employment after the end of cancer treatment.
223829323|NCT03251560|DRUG|Fuke Qianjin capsule|Fuke Qianjin capsule 0.8g pills by mouth, three times daily
223829324|NCT03251560|DRUG|Placebo oral capsule|Placebo oral capsule 0.8g pill by mouth, three times daily
223829325|NCT05191641|OTHER|Individualized nursing care|Individualized nursing care based on the Professional Values Model for parents of pediatric oncology patients
223829326|NCT04022460|DIAGNOSTIC_TEST|Video clip assessment|Parents will take short video clips of their child sleeping at night. They will be asked to review the video clips and rate whether they think their child has obstructive sleep apnea (OSA), and if so, how severe it is. Two clinicians will review the video clips on a separate night.
223829327|NCT04022460|DIAGNOSTIC_TEST|Polysomnography (sleep study)|Children will undergo a polysomnography as the gold standard test to assess for OSA.
223829328|NCT04022460|OTHER|Educational webinar|After evaluating the video clips of their child sleeping, parents will watch an educational webinar on OSA in children with Down syndrome and how to recognize symptoms.
223829329|NCT03620643|DRUG|Crizotinib Oral Capsule [Xalkori]|Crizotinib 250 mg Crizotinib 200mg
223829330|NCT03620643|DRUG|Fulvestrant 50 MG/ML Prefilled Syringe [Faslodex or generic]|Fulvestrant (Faslodex or generic) is supplied as two 5-mL clear neutral glass (Type 1) barrels, each containing 250mg/5mL of fulvestrant solution for intramuscular injection and fitted with a tamper evident closure.
223829331|NCT00514046|DRUG|Vandetanib|once daily continuously (28 day cycles)
223829332|NCT05989165|DRUG|Minoxidil 5% Topical Solution|Patient will be given minoxidil 5% topical solution, twice a day for 12 weeks
223829333|NCT05989165|DEVICE|microneedling|Patient will be given microneedling treatment every 4 weeks
223829334|NCT00591123|DRUG|FOLFOX|Once every two weeks all patients will receive Oxaliplatin 85 mg/m2 IV, Leucovorin 400 mg/m2 IV and 5-FU 400 mg/m2 IV infusions
223829335|NCT00591123|DRUG|5-FU|5-FU 2400 mg/m2 IV will be given via pump for 46-48 hours at home.
223829336|NCT00591123|DRUG|Erlotinib|All patients will also be given Erlotinib, 100 mg orally daily for the first 4 weeks. Those patients who have not experienced toxicities will increase the dose level to 150 mg daily. Patients who have toxicities will remain at the 100 mg dose level or lower if necessary.
223829337|NCT00383240|DRUG|mometasone furoate/formoterol fumarate combination MDI 200/10 mcg BID|MF/F 200/10 mcg via a metered dose inhaler (MDI) twice daily for 26 weeks
223829338|NCT00383240|DRUG|Mometasone furoate MDI (MF MDI) 200 mcg|MF 200 mcg via metered dose inhaler twice daily for 26 weeks
224264577|NCT06166862|OTHER|Sham action observation and motor imagery therapy for rehabilitation|"Sham action observation; Patients will watch a video consisting of static nature photographs for 10 minutes with the same music.~Sham motor imaginary; Patients will think about the video they watched for 10 minutes.~Then, they will watch another video in which the exercises are performed only once, and they will be asked to do the exercises. They will be given enough time to do 8-10 repetitions."
224264578|NCT01215760|OTHER|Training with a mirror|Early sensory reeducation group, started at the first week postoperatively, using specific guidelines using the mirror training and stimulation of the contralateral side. Initially, the stimulation will be unilateral and later bilateral, after the removal of the splint in 4 weeks.
224264579|NCT01215760|OTHER|No mirror therapy|The classical group iniciates after 16 weeks postoperatively and follow a standard home protocol for sensory reeducation without the mirror. It begins with recognition of textures and objects, and specific rehabilitation, if any associated injuries.
224264580|NCT00177580|DRUG|Pravastatin|
224264581|NCT05136469|OTHER|NEURAL GLIDING|with Sciatic nerve gliding which is done by applying force on the proximal point and releasing the force distally and then reversing the process. This process was achieved for 30 seconds, 6 times on each leg for a total time of 3 minutes (360 seconds).
223829339|NCT00383240|DRUG|formoterol fumarate 10 mcg|F via metered dose inhaler 10 mcg twice a day for 26 weeks
223829340|NCT00383240|DRUG|Placebo|Placebo metered dose inhaler twice a day for 26 weeks
223829341|NCT02397265|DEVICE|Bi-hormonal closed loop pump|Using a bio-inspired artificial pancreas consisting of a bi-hormonal closed loop pump
223829342|NCT02397265|DEVICE|Standard opened loop pump|Using a standard opened loop pump
223829343|NCT02397265|DEVICE|Insulin closed loop|Using a closed loop
223829344|NCT02023879|DRUG|Alirocumab|Solution for injection in the abdomen, thigh, or outer area of the upper arm by self-injection or by another designated person using auto-injector (also known as pre-filled pen).
223829345|NCT02023879|DRUG|Placebo (for Alirocumab)|Solution for injection in the abdomen, thigh, or outer area of the upper arm by self-injection or by another designated person using auto-injector (also known as pre-filled pen).
223829346|NCT02023879|DRUG|Non-statin LMT|Ezetimibe or Fenofibrate at stable dose as background therapy.
223829347|NCT02023879|OTHER|Diet Alone|Stable cholesterol-lowering diet as background therapy.
223829348|NCT03233061|DIAGNOSTIC_TEST|cardiorespiratory fitness and daily physical activities evaluations|"The cardiopulmonary exercise testing is performed on a cycle ergometer connected to cardiovascular and respiratory software. Subjects have a facemask, which collected respiratory and metabolic variables.An incremental exercise test is performed up to exhaustion. ⩒O2 is recorded and heart rate is averaged by an electrocardiogram system.~Cardiopulmonary exercise testing during household activities Subjects have to perform 3 everyday life household activities: ironing,cleaning floor,walking and climbing stairs.A wearable ambulatory indirect metabolic system is used with Holter mode to record cardiorespiratory measures.Subjects have to breathe through the K4b2 facemask and turbine."
223829349|NCT02924389|DRUG|dolutegravir|Tivicay is a human immunodeficiency virus type 1 (HIV-1) integrase strand transfer inhibitor (INSTI) indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection. 50 mg of Tivicay (dolutegravir) will be taken orally once a day.
223829350|NCT02924389|DRUG|Triumeq|Triumeq is a fixed-dose combination drug for the treatment of HIV/AIDS. It is a combination of 600 mg abacavir, 50 mg dolutegravir and 300 mg lamivudine. Triumeq will be taken orally once daily.
223829351|NCT02924389|DRUG|Truvada|Truvada is a combination of emtriva and viread, both nucleoside analog HIV-1 reverse transcriptase inhibitors. Truvada is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection. One Truvada tablet (containing 200 mg/300 mg of emtricitabine and tenofovir disoproxil fumarate) will be taken orally once daily.
223829352|NCT00582530|OTHER|Whole Blood Draw|The plan is to obtain the research blood sample at the time of routine preoperative and postoperative blood testing, typically performed 1-2 weeks prior to surgery and then again 6 weeks to 12 months after surgery
223829353|NCT00896623|GENETIC|mutation analysis|
223829354|NCT00896623|GENETIC|polymorphism analysis|
223829355|NCT00896623|OTHER|surface-enhanced laser desorption/ionization-time of flight mass spectrometry|
223829356|NCT05952401|BEHAVIORAL|Usual Care|Usual care will be informed by practice guidelines (patient smoking cessation handout and brief advice).
223829357|NCT05952401|BEHAVIORAL|"Nudges"|"Patients in the experimental arm will receive practice guidelines (patient smoking cessation handout and brief advice) and Nudges to Quit, guideline-informed messages immediately following patient tobacco treatment needs assessment."
223829358|NCT02743715|DEVICE|Active tDCS (transcranial direct current stimulation)|An electrical current of 2mA is delivered to the cathode, positioned bilaterally in the cranial region corresponding to the supplementary motor cortex, with the anode positioned in the deltoid (neutral region), in 30-minute sessions, 5 days a week (Mondays through Fridays) for four consecutive weeks.
223829359|NCT02743715|DEVICE|Sham tDCS|The cathode is positioned bilaterally in the cranial region corresponding to the supplementary motor cortex, with the anode positioned in the deltoid (neutral region), in a 30-minute session, 5 days a week (Mondays through Fridays) for four consecutive weeks, without delivery of the electric current.
223829360|NCT04424290|DRUG|BI 764524|BI 764524
223829361|NCT04424290|DRUG|Sham control of BI 764524|Sham control of BI 764524
223829362|NCT03298607|DIETARY_SUPPLEMENT|Placebo|2 months treatment
223829363|NCT03298607|DIETARY_SUPPLEMENT|Serelys PMS|2 months treatment
223829364|NCT04671290|OTHER|Any intervention|No intervention
223829365|NCT03966690|DEVICE|Isokinetic leg extension/-flexion on a legpress device|Maximum strength and rate of leg-flexion /-extension during legpress exercise
223829366|NCT03966690|DEVICE|Isokinetic leg extension/-flexion on a legcurl device|Maximum strength and rate of leg-flexion /-extension during legcurl exercise
223829367|NCT02477891|DRUG|Daratumumab|Participants will receive daratumumab (16 milligram per kilogram \[mg/kg\]) as intravenous infusion on Day 1, 8, 15, and 22 of Cycles 1 and 2 (weekly dosing), on Day 1 and 15 of Cycles 3 to 6 (every 2 weeks dosing), and on Day 1 of Cycle 7 and subsequent cycles (every 4 weeks dosing) until documented progression, unacceptable toxicity, or study end. Each cycle is of 28 days.
223829368|NCT02011256|DEVICE|Implantable loop-recorder|All patients not diagnosed with atrial fibrillation with regular ECG or 72-hour Holter-monitoring will receive an ILR for 3 years.
223829369|NCT04854538|DRUG|Ekmasonid|1 extended release tablet contains 9 mg Budesonide
223829370|NCT04854538|DRUG|Uceris (first dose)|1 extended release tablet contains 9 mg Budesonide
223829371|NCT04854538|DRUG|Uceris (second dose)|1 extended release tablet contains 9 mg Budesonide
223829372|NCT06109506|PROCEDURE|Conservative treatment with antibiotics and eventual percutaneous image-guided drainage of the abscess|Patients with acute diverticulitis and abscess formation are commonly treated with a conservative approach that includes endovenous antibiotics and, for abscesses \> 4-5 cm, percutaneous image-guided drainage.
223829373|NCT03393403|DRUG|Dexmedetomidine|0.5mcg/kg intravenous(IV)continuous infusion for 30 minutes, or 0.5mcg/kg adding to local anesthetic for subcostal TAP block
223829374|NCT03393403|DRUG|0.9% Sodium-chloride|0.125ml/kg intravenously infusion in Dexmedetomidine\_adj group and control group
223829375|NCT04544228|PROCEDURE|Serratus Anterior Plane Block Technique|The patient will be placed in Lateral Decubitus with a surgical side upwards with arm abduction. A linear ultrasound transducer (6-13 MHz) will be placed on the patient's midaxillary line in the transverse plane, at the level of the fifth rib, with the indicator oriented toward the operator's left. With the rib, pleural line, and overlying serratus anterior and latissimus dorsi muscles visualized, local infiltration of the skin and subcutaneous tissue will be applied by 2-3ml of lidocaine 2%. Then, using ultrasound guidance, A 38-mm 22-gauge regional block needle will be advanced in-plane at an angle of approximately 45 degrees towards the fifth rib. The expecting depth for this block is 1-4 cm. After aspiration, injection 30ml local anesthetic mixture will be injected anteriorly to the rib and deep to the serratus anterior muscle.
223829376|NCT04544228|PROCEDURE|General anesthesia|"Induction of general anaesthesia will be performed using a regimen of IV 2 μg/kg fentanyl and propofol IV 2 mg /kg. Tracheal intubation will be facilitated using 0.5 mg/kg IV of rocuronium.~Anaesthesia will be maintained with inhaled sevoflurane 2-2.5% in oxygen enriched air (FiO2=0.5). Maintenance doses of rocuronium 0.1 m\\kg will be provided every 30 minutes.~The residual neuromuscular blockade will be reversed using neostigmine (0.05 mg/kg) and atropine (0.02 mg/kg), and extubation will be performed after complete recovery of the airway reflexes."
223829377|NCT04544228|DRUG|bupivacaine +ketamine|30 ml bupivacaine 0.25% + 1 ml ketamine (50mg) in Serratus Anterior Plane Block.
223829378|NCT04544228|DRUG|bupivacaine + neostigmine|30 ml bupivacaine 0.25% + 1 ml neostigmine (500 μg)in Serratus Anterior Plane Block.
223829379|NCT04544228|DRUG|bupivacaine +saline|30 ml bupivacaine 0.25% + 1 ml normal saline in Serratus Anterior Plane Block.
223829380|NCT06306560|DRUG|adebrelimab|adebrelimab IV
223829381|NCT06306560|DRUG|famitinib|famitinib PO
223829382|NCT06306560|DRUG|chemotherapy|chemotherapy IV
223829383|NCT01899118|RADIATION|Preoperative irradiation|50.4Gy/28F/5.5w
223829384|NCT01899118|DRUG|Nimotuzumab|400mg/w，0-5w
223829385|NCT01899118|DRUG|Oxaliplatin|130mg/m2 d1
223829386|NCT01899118|DRUG|Capecitabine|825mg/m2 bid d1-5/w,1-5w
223829387|NCT03434236|DIETARY_SUPPLEMENT|low dose Lipinova (30 mL daily)|Lipinova is a nutritional supplement containing concentrated n-3 PUFA (EPA and DHA) and metabolites
223829388|NCT03434236|DIETARY_SUPPLEMENT|Placebo|Placebo will have a similar appearance, smell and taste as the nutritional supplement
223829389|NCT03434236|DIETARY_SUPPLEMENT|high dose Lipinova (60mL)|Lipinova is a nutritional supplement containing concentrated n-3 PUFA (EPA and DHA) and metabolites
223829390|NCT05078684|PROCEDURE|Left ganglion stellate block|Ultrasound-guided anesthetic block of left ganglion stellate using 8ml of 5% bupivacaine.
223829391|NCT05078684|PROCEDURE|Sham left ganglion stellate block|Subcutaneous application of 0.5-1ml of 5% bupivacaine to the site of expected LGSB
223829392|NCT05672082|DRUG|[18F]DPA-714|Participant received one injection of 200 MBq of \[18F\]DPA-714
223829393|NCT04448236|DEVICE|Blood flow restriction resistance exercise|"Application the Blood flow restriction device over the proximal thigh to have 80% of the limb occlusion pressure to accumulate the metabolite generated during knee extension"
223829394|NCT04249336|DRUG|Fluoro-Calcium-Phospho-Silicate based dentifrices|Bio-Active glass based formulation
223829395|NCT04249336|DRUG|8% Arginine based dentifrices|Tubular occluding formulation
223829396|NCT04249336|DRUG|8% Strontium Acetate|Tubular occluding formulation
223829397|NCT04249336|DRUG|Sodium Fluoride|No claim of relieving Dentin Hypersensitivity
223829398|NCT01242176|DRUG|BI 10773 XX (Trial Formulation 2)|one single dose tablet in the morning
223829399|NCT01242176|DRUG|BI 10773 (Final Formulation)|one single film-coated tablet in the morning
223829400|NCT03452020|DEVICE|Temperature measurementsusing the Tyto thermometer, the standard of care thermometer and the predicate thermometer|Temperature measurements using the Tyto thermometer, the standard of care thermometer and the predicate thermometer
223829401|NCT03636945|OTHER|PET at 18F-FDOPA|18F-fluorodihydroxyphenylalanine (18F-FDOPA) PET imaging
223829402|NCT06077916|DRUG|Azithromycin|azithromycin is reconstituted and administered according to standard prescription indications in 250 mL saline solution
223829403|NCT06077916|DRUG|Saline solution|placebo consisting of saline solution 250 mL is administered
223829404|NCT03069820|DRUG|docetaxel and cisplatin|Patients receive TP (docetaxel and cisplatin) chemotherapy
223829405|NCT05444400|OTHER|Strengthening|Strengthening
223829406|NCT05444400|OTHER|Conventional protocol|Conventional protocol
223829407|NCT00612703|DRUG|ARQ 197|Treatment with ARQ 197 in combination with erlotinib
223829408|NCT02127320|DRUG|Rosuvastatin 20mg|
223829409|NCT02127320|DRUG|Ezetimibe 10mg|
223829410|NCT02127320|DRUG|Rosuvastatin 20mg + Ezetimibe 10mg|
223829411|NCT05769699|PROCEDURE|blood sample|blood sample
223829412|NCT02612896|DRUG|Mass drug administration, praziquantel 10mg/kg|see previous, in elimination study arm only
223829413|NCT02612896|BEHAVIORAL|Health education|in all study arms, using village meetings, posters, pamphlets.
223829414|NCT04103320|OTHER|Using different survey to evaluate pain|Survey will be at different time of the IVF protocol (at the first medical appointment in the medically assisted department, after stimulation, after oocytes retrieval, after embryo transfer, one month after the IVF protocol)
223829415|NCT00231998|DRUG|Pimecrolimus|Pimecrolimus cream 1 %
223829416|NCT01402167|PROCEDURE|Kyphoplasty|Patients will be treated via a balloon kyphoplasty surgical procedure
223829417|NCT01402167|PROCEDURE|Vertebroplasty|Patients will be treated via a transcutaneous vertebroplasty procedure.
223829418|NCT04228549|DEVICE|MyPADMGT|Online tracking and feedback to help patients adopt healthy lifestyles
223829419|NCT04228549|DEVICE|MyPADMGT + Nudging|Online tracking and feedback to help patients adopt healthy lifestyles plus nudging support to assist in making decisions
223829420|NCT01074632|DRUG|Lurasidone HCl|
223829421|NCT03390036|COMBINATION_PRODUCT|Cingal|Hyaluronic Acid with Triamcinolone Hexacetonide
223829422|NCT03390036|DEVICE|Monovisc|Hyaluronic Acid
223829423|NCT03390036|DRUG|Triamcinolone Hexacetonide|Triamcinolone Hexacetonide
223829424|NCT03010579|DRUG|erythropoietin|Erythropoietin will be administered subcutaneously (s.c.) at the dose of 10 000 IU, three times a week. If necessary,oral ferrous succinate vitamins B12 and folic acid will be administered.
223829425|NCT03010579|DRUG|iron supplementation|If necessary, oral ferrous succinate, vitamins B12 and folic acid will be administered.
223829426|NCT06018597|DRUG|Sevoflurane Baxter, 100%, Inhalation Vapour, Liquid 250 mL|No procedure was performed on the patient other than routine anesthesia management.We compared sevoflurane consumption amount in the patient undergoing general anesthesia with sevoflurane according to their metabolic age.
223829427|NCT04014478|DEVICE|Endovascular Denervation|A radiofrequency ablation catheter will be placed in abdominal aorta. At least 6 sites will be ablated with settings of temerature at 60 degree centigrade and time at 120 seconds.
223829428|NCT01614977|DRUG|Methylprednisoline|Methylprednisolone (Danalone) 1mg/Kg/dose twice daily for 14 days followed by 1mg/Kg/dose in the morning once daily for 14 days,
223829429|NCT02329106|DEVICE|Irreversible electroporation (IRE)|Irreversible electroporation (IRE) is a new, minimal-invasive image-guided treatment method for tumors not amenable for surgical resection or thermal ablation, due to vicinity near vital structures such as vessels,bile ducts and diaphragmatic dome.
223829430|NCT02443922|DRUG|Glimepiride|Glimepiride 2mg qam
223829431|NCT02443922|DRUG|Sitagliptin|Sitagliptin 100mg qam
223829432|NCT02443922|DRUG|Metformin|Metformin as prescribed
223829433|NCT00358215|DRUG|Darbepoetin alfa|Administered by subcutaneous injection
223829434|NCT00358215|DRUG|Placebo|Placebo subcutaneous injection
223829435|NCT00410631|BIOLOGICAL|filgrastim|
223829436|NCT00410631|DRUG|carboplatin|
223829437|NCT00410631|DRUG|cisplatin|
223829438|NCT00410631|DRUG|cyclophosphamide|
223829439|NCT00410631|DRUG|dacarbazine|
223829440|NCT00410631|DRUG|doxorubicin hydrochloride|
223829441|NCT00410631|DRUG|etoposide phosphate|
223829442|NCT00410631|DRUG|ifosfamide|
223829443|NCT00410631|DRUG|isotretinoin|
223829444|NCT00410631|DRUG|melphalan|
223829445|NCT00410631|DRUG|topotecan hydrochloride|
223829446|NCT00410631|DRUG|vincristine sulfate|
223829447|NCT00410631|DRUG|vindesine|
223829448|NCT00410631|PROCEDURE|autologous hematopoietic stem cell transplantation|
223829449|NCT00410631|PROCEDURE|conventional surgery|
223829450|NCT00410631|PROCEDURE|peripheral blood stem cell transplantation|
223829451|NCT00410631|RADIATION|iobenguane I 131|
223829452|NCT00410631|RADIATION|radiation therapy|
223829453|NCT04261738|DEVICE|Hyperbaric Oxygen|Volunteers will be given a standard hyperbaric oxygen treatment (2.4 ATA x 90 minutes)
223829454|NCT02240589|DRUG|Memantine|Day 1 to 3: 10 mg bid memantine. Day 3 to 21: 20 mg bid memantine. Day 21 to 168: 10 mg bid memantine.
223829455|NCT02240589|DRUG|Placebo|Day 1 to 3: 10 mg bid placebo. Day 3 to 21: 20 mg bid placebo. Day 21 to 168: 10 mg bid placebo.
223829456|NCT04328363|BEHAVIORAL|Intervention|Social prescription of health assets related to the practice of physical activity and a healthy eating pattern to modify lifestyles.
223829457|NCT04529720|BIOLOGICAL|Biological/Vaccine: Pertagen (aP BioNet)|"Pertagen (aP BioNet) was produced with a recombinant B pertussis strain that was genetically inactivated by the introduction of mutations (Arg9Lys and Glu129Gly) in the ptx operon of the S1 gene. Each 0.5 mL dose of Pertagen (aP BioNet) contained 5 µg PTgen, 5 µg FHA, and 0.3 mg as aluminium cation.~The study vaccine will be presented in a single-dose prefilled syringe. Each participant will be received one intramuscular injection in the non-dominant deltoid region."
223829458|NCT04529720|BIOLOGICAL|Biological/Vaccine: Boostagen (TdaP BioNet)|"Boostagen (TdaP BioNet) was produced with a recombinant B pertussis strain that was genetically inactivated by the introduction of mutations (Arg9Lys and Glu129Gly) in the ptx operon of the S1 gene. Each 0.5 mL dose of Boostagen (TdaP BioNet) contained 5 µg PTgen, 5 µg FHA, and 0.3 mg as aluminium cation. TdaP dose additional contained at least 7.5 Lf tetanus toxoid and at least 2.0 Lf diphtheria toxoid.~The study vaccine will be presented in a single-dose prefilled syringe. Each participant will be received one intramuscular injection in the non-dominant deltoid region."
223829459|NCT04529720|BIOLOGICAL|Biological/Vaccine: Adacel|"Comparator vaccine, Adacel (Sanofi-Pasteur, North York, ON, Canada) was produced chemically inactivated pertussis toxin. Each 0.5 mL dose of Adacel (as comparator vaccine) contained 2.5 µg PTchem, 5 µg FHA, 3 µg pertactin, 5 µg fimbriae types 2 and 3, 5.0 Lf tetanus toxoid, 2.0 Lf diphtheria toxoid and 0.33 mg as aluminium cation.~The study vaccine will be presented in a single-dose prefilled syringe. Each participant will be received one intramuscular injection in the non-dominant deltoid region."
223829460|NCT00285181|DRUG|Simvastatin|
223829461|NCT02471859|DRUG|GDC-3280|GDC-3280 at various doses, depending on the cohort and treatment period
223829462|NCT02471859|DRUG|Placebo|Placebo at various doses, depending on the cohort and treatment period
223829463|NCT02352662|OTHER|Perioperative blood samples collection|Collect blood samples at 3 different points intra-operatively. Each blood sample will be run using rotational thromboelastometry to assess intraoperative coagulation
223829464|NCT00631384|BEHAVIORAL|Couples VCT|Offer women coming to antenatal clinics to have their husbands come with them for couples VCT
223829465|NCT00631384|BEHAVIORAL|Individual VCT|Women to receive individual VCT
223829466|NCT06082531|DRUG|Sodium hyaluronate injection|The control group was injected into the joint cavity with sodium hyaluronate injection..
223829467|NCT01936610|OTHER|role play|In this method, researcher with two other co-researchers played 3 scenarios in 7 steps (for each scenario)including warm up, selecting participant, preparing the scene, preparing observers, play ,discussion and evaluation and generalization to education about advantages and disadvantages of normal delivery and cesarean section.
223829468|NCT01936610|OTHER|lecture|Describe advantages and disadvantages in one 90-min session
223829469|NCT04692844|DRUG|Propranolol|Patients will receive Propranolol in the course of their routine treatment. Results will be used to explore biological phenomena or disease processes.
223829470|NCT04692844|DRUG|Primidone|Patients will receive Primidone in the course of their routine treatment. Results will be used to explore biological phenomena or disease processes.
223829471|NCT05097118|DRUG|Ketamine Versus Bupivacaine|Drugs Ketamine versus Bupivacaine
223829472|NCT01801553|OTHER|Spinal manipulation|"-In the intervention group :~True Lumbopelvic manipulation in supine (A) or in lateral side lying (B) for subjects with LBP:~If for example, A is the best position for both patient-practitioner but after a maximum of two trials doesn't produce a pop sound then the practitioner will move to the B position for a maximum of two trials as well.~-In the control group:~Sham spinal manipulation will realize to mimic (i) the same time, (ii) interaction and (iii) action with the manual therapist but without any efficacy in the position B using the upper body of the patient to target the thoraco-lumbar hinge and not the lumbopelvic region and take the time of handling the patient like in a true SM and mimic a high velocity and short ROM action moving fast his body but with a minimal action on the patient's body."
223829473|NCT01801553|OTHER|sham spinal manipulation|
223829474|NCT01801553|OTHER|Usual medical care|
223829475|NCT02387437|BEHAVIORAL|SI recruitment|SI continuous positive airway pressure (CPAP) held at 40 cm H2O for 40 secs.
223829476|NCT02387437|BEHAVIORAL|IP recruitment|Incremental positive end-expiratory pressure (PEEP) with a fixed peak pressure (IP), PEEP increased in 5 cm H2O increments (allowing 30 secs/step) from a baseline PEEP of post-trial to 40 cm H2O while decreasing tidal volume to limit peak inspiratory pressure to 40 cm H2O. After CPAP of 40 cm H2O was held for 30 secs, PEEP was decremented in 5-cm H2O steps to the post-RM PEEP setting, while increasing tidal volume toward the baseline value of 10 mL/kg (as the 40 cm H2O peak pressure limit allowed).
223829477|NCT02387437|BEHAVIORAL|PCV recruitment|PCV peak pressure = 40 cm H2O, inspiratory to expiratory ratio = 1:2, and PEEP level = 15cm H2O for 2 min
223829478|NCT05461105|DRUG|rencofilstat, 75 mg|1 softgel capsule
223829479|NCT05461105|DRUG|rencofilstat, 150mg|2 softgel capsules
223829480|NCT05461105|DRUG|rencofilstat, 225 mg|3 softgel capsules
223829481|NCT06531135|BEHAVIORAL|T-CBSM|A 10-week remotely-delivered group, lasting about 120 minutes each session.
223829482|NCT06531135|BEHAVIORAL|Support group|Participants will receive weekly supportive-expressive group intervention for two hours per week for five weeks total.
223829483|NCT00167986|DRUG|vancomycin-resistant enterococci and ESBL|
223829484|NCT03273140|DEVICE|Gamification Diabetes Education Program (GDEP)|"Diabetic application focuses on diabetes management and consists of two gamelets and consist of story-telling, case scenarios with the integration of problem-based decision-making and solving skills in diabetes management. These scenarios created are familiar to the patients and nurses - to make the games more interactive and realistic to the players (participants). Immediate feedback will be given after they select their decision. The visual reward will appear after attaining one score for each correct question. Participants can easily access and play the games several times till contents are reinforced and knowledge is retained or at their own comfort level. This game mechanics aim to motivate and assist patients to achieve their desired result and self-efficacy behaviors. It addresses the deficits from the current literature review, by aiming to be up-to-date, reliable with new updated scenarios and platform."
223829485|NCT05641142|OTHER|monitoring the use of anticoagulant and/or antiplatelet therapy in patients with osler rendering disease|"Monitoring:~* hemoglobin and ferritin levels~* transfusion or intravenous iron~* hospitalization for bleeding or thrombose~* digestive bleeding and/or another haemorrhagic accident~* severity of epistaxis~* quality of life"
223829486|NCT02523313|DRUG|Nivolumab + Placebo|Nivolumab will be applied at a dose of 3 mg/kg given as IV infusion every 2 weeks for up to 1 year after initial dosing or until PD + Placebo instead of Ipilimumab on weeks 1, 4, 7 and 10 + Placebo instead of Nivolumab on weeks 4 and 10.
223829487|NCT02523313|DRUG|Nivolumab + Ipilimumab|Nivolumab (1 mg/kg) and Ipilimumab (3 mg/kg) will be applied as IV infusion every 3 weeks for 4 doses. Both study drugs are to be administered on the same day over the first 12 weeks + Nivolumab-Placebo on weeks 3, 5, 9 and 11. After week 12 Nivolumab is given as maintenance and will be applied at a dose of 3 mg/kg IV every 2 weeks for up to 1 year after initial dosing (of the combination) or until PD.
223829488|NCT02523313|DRUG|Double Placebo Control|Placebo instead of Nivolumab and Placebo instead of Ipilimumab will be applied as IV infusion every 3 weeks for 4 doses. Both placebos are to be administered on the same day over the first 12 weeks + Placebo instead of Nivolumab on weeks 3, 5, 9 and 11. After week 12 Placebo instead of Nivolumab is given as maintenance and will be applied intravenously every 2 weeks for up to 1 year after initial dosing (of the combination) or until PD.
223829489|NCT04658160|BEHAVIORAL|Longitudinal Tracking and Intervention Platform for Medicare Advantage Patients|access to/use of the tracking platform
223829490|NCT02423590|DRUG|Apatorsen (OGX-427)|Apatorsen (OGX-427) is a second generation antisense oligonucleotide designed to bind to Hsp27 mRNA
223829491|NCT02423590|DRUG|Gemcitabine|"Gemcitabine is an anti-cancer (antineoplastic or cytotoxic) chemotherapy drug. Gemcitabine is classified as an antimetabolite"
223829492|NCT02423590|DRUG|Carboplatin|"Carboplatin is an anticancer drug (antineoplastic or cytotoxic) chemotherapy drug. Carboplatin is classified as an alkylating agent."
223829493|NCT04169919|DRUG|Povidone-Iodine|Povidone-Iodine 5% eye wash
223829494|NCT04169919|DRUG|Normal Saline Flush|Normal Saline eye wash
223829495|NCT03621722|OTHER|Elequil Aromatabs|There will be a variety of different Aromatabs such as orange/peppermint or lavender
223829496|NCT05826522|OTHER|observationnal|cohort of blood collection and severals exams
223829497|NCT02354924|DEVICE|Biofinity soft contact lens|Biofinity soft contact lens on two eyes and follow up for 3 months (90 days). It is necessary to remove contact lenses every day and replace after 30 days.
223829498|NCT02354924|DEVICE|Visco soft contact lens|Viso soft contact lens on two eyes and follow up for 3 months (90 days). It is necessary to remove contact lenses every day and replace after 30 days.
223829499|NCT05744050|BEHAVIORAL|Low energy density lunch|Particpants will be provided with a lunch low in energy density (\~1.1kcal/g)
223829500|NCT05744050|BEHAVIORAL|Medium energy density lunch|Participants will be provided with a lunch medium in energy density(\~1.7kcal/g)
223829501|NCT05744050|BEHAVIORAL|High energy density lunch|Participants will be provided with a lunch high in energy density (\~3kcal/g)
223829502|NCT01432015|DRUG|fosaprepitant|Fosaprepitant for Injection 150 mg is administered intravenously on Day 1 only as an infusion over 20-30 minutes initiated approximately 30 minutes prior to chemotherapy. Patient will receive standard pre-medications
223829503|NCT01432015|DRUG|aprepitant|Aprepitant 125 mg orally 1 hour prior to chemotherapy treatment (Day 1) and 80 mg orally once daily in the morning on Days 2 and 3. patient will receive standard pre-medications
223829504|NCT01432015|OTHER|Oral Placebo|One pill administered on days 1-3 in conjunction with Fosaprepitant.
223829505|NCT01432015|OTHER|IV placebo|100 cc of IV placebo administered on day in conjunction with Aprepitant
223829506|NCT00263120|BEHAVIORAL|Pain Questionnaire|
223829507|NCT05634122|BEHAVIORAL|Acceptance and Commitment Therapy (ACT)|Group treatment protocol of 8 weeks of 90 minutes sessions Session 1: Presentation of the general ACT therapy concept. Session 2: Value analysis I. Session 3: Value analysis II. Session 4: Value analysis third Session 5: Values and feelings. Session 6: Drink one direction. Session 7: Dare and change. Session 8: Ready to act with ACT. Treatment as usual (TAU) Standard pharmacological treatment for patients with chronic pain.
223829508|NCT05634122|BEHAVIORAL|Treatment as Usual (TAU)|Standard pharmacological treatment for patients with chronic pain
223829509|NCT00262288|DRUG|i.v. recombinant human C1 inhibitor|
223829510|NCT02762383|DRUG|Peginterferon Alfa-2|Peginterferon alfa-2a will be administered as 90 micrograms (mcg) via subcutaneous (SC) injection once weekly.
223829511|NCT06268639|PROCEDURE|Osseodensification|The intervention, osseodensification, involves a surgical technique using specific drills (e.g., Densah burs) rotated in a counterclockwise direction to compact bone rather than remove it, thereby increasing bone density around the implant site. This method is aimed at improving the primary stability of dental implants by creating a denser bone environment, which theoretically should lead to better osseointegration and long-term success of the implant. The technique distinguishes itself from traditional drilling by preserving and enhancing bone structure, which is crucial for the success of dental implants in patients.
223829512|NCT05889819|DIETARY_SUPPLEMENT|Almond orange potato cookies for stunted under-five children|"Trained enumerator distributed 50 g cookies three times a week during 30 days to the treatment group.~Anthropometry measurement: weight and height measured at pre study, during study (once a week), and post study."
223829513|NCT04765592|DEVICE|WeFlow-Arch Modeler Embedded Branch Stent Graft System|The modular embedded aortic arch stent graft system consists of the embedded ascending aorta stent graft system, the arch aorta stent graft system and the branch stent system.
223829514|NCT05351060|OTHER|Custom Fabricated Splint|Participants will wear a customized splint on their affected hand(s)during the hours of sleep for the duration of the study.
224264582|NCT05136469|OTHER|DYNAMIC STRETCH|The stretch force was applied on the ankle in downward direction which was held for 30 seconds and was repeated 5 times total of 2.5 minutes (150 seconds). Stretch was given on both legs one at a time. Treatment was given for 3 weeks with 2 sessions per week
224264583|NCT05948072|DRUG|mFOLFOX6 + Cetuximab|Cetuximab + mFOLFOX6: Cetuximab (500mg/m2 IV ) will be given. Oxaliplatin (85 mg/m2 IV over 2 h on day 1), Leucovorin calcium (350 mg/m2 IV over 2 h on day 1) plus a bolus of 5FU (400 mg/m2) followed by a 46h-48h IV infusion of 5FU 2400 mg/m2 will be repeated for every 2 weeks. The regimens repeat every 2 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity.
224264584|NCT05948072|DRUG|mFOLFOX 6|mFOLFOX6: Oxaliplatin (85 mg/m2 IV over 2 h on day 1), Leucovorin calcium (350 mg/m2 IV over 2 h on day 1) plus a bolus of 5FU (400 mg/m2) followed by a 46h-48h IV infusion of 5FU 2400 mg/m2 will be repeated for every 2 weeks. The regimens repeat every 2 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity.
224264585|NCT01442376|DRUG|Palonosetron|Single dose Palonosetron IV 10 mcg/kg up to a maximum total dose of 0.75 mg
224264586|NCT01442376|DRUG|Palonosetron|Single dose Palonosetron IV 20 mcg/kg up to a maximum total dose of 1.5 mg
224264587|NCT01442376|DRUG|Ondansetron|Single three (every 4 hours) Ondansetron IV doses 0.15 mg/kg up to a maximum total dose of 32 mg
224264588|NCT01442376|DRUG|Placebo to Ondansetron|
224264589|NCT01442376|DRUG|Placebo to Ondansetron|
224264590|NCT01442376|DRUG|Placebo to Palonosetron|
223829515|NCT06104072|DEVICE|REHACOM Software|"It is a computer-based cognitive rehabilitation test that includes 32 cognition training tasks for attention/concentration, reaction behavior, memory , logical reasoning \& executive functioning with graded difficulty . It is composed of regular PC , 1G RAM , DVD drive, 100 GB hard drive with windows XP SP3, 128 MB RAM direct 3D graphic card , Screen at least 19 , regular PC keyboard or Rehacom panel \& printer .The Rehacom software version is (patientenpult (1990-1997) EN/ISO-13485-certified).~* For each Cognitive training domain there is one hundred levels of difficulty.~* Each patient is evaluated from level one(1) ang gradually increase the difficulty till we reach the level that will be used in the treatment sessions as the patient's performance improve we can proceed to the next level.~* The period of the session was chosen to be maximum (60 minutes) for each patient with five minutes rest in between each level."
223829516|NCT06104072|OTHER|A Designed Physical Therapy Program|A designed physiotherapy program consisted of aerobic exercise on treadmill, stretching exercise, Proprioceptive neuromuscular facilitation (PNF) techniques, Graduated active exercises, postural correction, gait training, balance training on different base of supports using static and dynamic balance training with reciprocal and weight shifting exercises.
223829517|NCT04329104|BIOLOGICAL|VRC-MALMAB0100-00-AB (CIS43LS)|Administered via one-time intravenous infusion
223829518|NCT04329104|OTHER|Normal saline|Administered via one-time intravenous infusion
223829519|NCT06076473|DIAGNOSTIC_TEST|Untargeted metabolomics|Pilot untargeted plasma metabolomics aiming to identify novel biomarkers for PA diagnosis and subtyping, which could be compared against existing biomarkers and taken forward to larger future studies.
223829520|NCT03849872|DRUG|ONO-5788|Investigational Drug
223829521|NCT03849872|DRUG|[14C]-ONO-5788|Investigational Drug
223829522|NCT00559910|DRUG|PH-797804|PH-797804 at four dose levels
223829523|NCT00559910|DRUG|Placebo|Placebo
223829524|NCT06345209|DEVICE|Sirolimus-coated Coronary Balloon Dilatation Catheter|During PCI, percutaneous transluminal coronary angioplasty is performed on the target lesion using the Sirolimus-coated Coronary Balloon Dilatation Catheter in the test group, subsequently completing the remaining procedure
223829525|NCT06345209|DEVICE|Drug-coated Coronary Balloon Dilatation Catheter|During PCI, percutaneous transluminal coronary angioplasty is performed on the target lesion using the Drug-coated Coronary Balloon Dilatation Catheter in the test group, subsequently completing the remaining procedure
223829526|NCT01349010|DRUG|Probucol|250mg (1 tablet) bid. p.o for 8 weeks
223829527|NCT01349010|DRUG|Placebo|1 tablet bid. p.o for 8 weeks
223829528|NCT00911924|DEVICE|iStent|Glaukos iStent, medication
224264591|NCT06070480|OTHER|Spinal Anesthesia Group|Effect of spinal anesthesia on intraocular pressure
224264592|NCT06070480|OTHER|Desflurane Group|Effect of general anesthesia with desflurane on intraocular pressure
224264593|NCT06070480|OTHER|Propofol Group|Effect of general anesthesia with propofol on intraocular pressure
224264594|NCT03499873|DRUG|Nepafenac 0.3% Oph Susp|Nepafenac 0.3% Ophthalmic suspension (experimental product)
224264595|NCT03499873|DRUG|Placebos|Placebo
224264596|NCT03499873|DRUG|Nepafenac 0.3% Oph Susp (reference)|Nepafenac 0.3% Ophthalmic suspension (Innovator)
224264597|NCT01717950|BIOLOGICAL|Na-APR-1 (M74)/Alhydrogel®|The Na-APR-1 (M74) candidate vaccine contains the recombinant Na-APR-1 (M74) protein expressed by Nicotiana plants. Purified Na-APR-1 (M74) was subsequently adsorbed onto aluminum hydroxide gel (Alhydrogel®) and suspended in a solution containing 10 mM imidazole, 150 mM sodium chloride and 0.3% Empigen BB, with pH 7.4 ± 0.1. The final concentration of Na-APR-1 (M74) in the drug product is 0.1 mg/ml, whereas that of Alhydrogel® is 0.8 mg/ml. Different doses of Na-APR-1 (M74) will be delivered by injecting different volumes of the 0.1 mg/ml Na-APR-1 (M74) preparation.
224264598|NCT01717950|BIOLOGICAL|Gluco-Pyranosylphospho-Lipid A Aqueous Formulation|GLA-AF contains a synthetic monophosphoryl lipid A (MPL) molecule that has Toll-Like Receptor-4 agonist activity. MPL is itself derived from the lipopolysaccharide (LPS) of Salmonella minnesota, a natural TLR4 agonist that is pyrogenic and can induce toxic shock. LPS, and more specifically, its lipid A component, has long been known for its strong adjuvant effects; however, its high toxicity has precluded its use in a vaccine formulation.
224264599|NCT04269122|OTHER|No Intervention|No intervention
224264600|NCT02711644|BEHAVIORAL|Supportive Lifestyle Counselling|Each participant will meet with the intervention Registered Dietitian twice in pregnancy and have two follow-up phone calls. Participants in this group will have on-going, supportive discussions with the intervention Registered Dietitian about healthy lifestyles in pregnancy. Discussion topics with the intervention Registered Dietitian at each visit will be participant-centered, allowing the participant to guide the conversation. These conversations will be reinforced at every future contact made throughout pregnancy.
224264601|NCT02711644|BEHAVIORAL|Standard Lifestyle Counselling|Each participant will meet in person with their respective Registered Dietitian twice in pregnancy and have two follow-up phone calls. At these visits, each participant will complete questionnaires and have anthropometric assessments (height/weight). From home, each participant will also complete online questionnaires at week 26, and week 34. Postpartum,each participant will complete an online questionnaire. Optional postpartum participation includes a focus group in the postpartum period and the option to meet with a Registered Dietitian postpartum.
224264602|NCT06428539|DIAGNOSTIC_TEST|T-reg cells|laboratory test
224264603|NCT06175364|OTHER|Health Professionals in the Field of Orthotics Prosthetics|Three data collection tools will be used as data collection methods for the research. These data collection tools; demographic information form, Health Sciences Evidence-Based Practice Survey and Information Literacy Self-Efficacy Scale.
224264604|NCT06202755|DRUG|Ticagrelor 90 MG|Efficacy and safety of 180 mg loading dose of ticagrelor administered within 24 hours of first-ever ischemic stroke followed by 90 mg bid for 3 months will be assessed through NIHSS, mRS, duration of hospital stay, new ischemic stroke, and possible adverse effects.
224264605|NCT06202755|DRUG|Cilostazol 100 MG|Efficacy and safety of 200 mg clopidogrel followed by 100 mg twice daily for 3 months will be assessed through NIHSS, mRS, duration of hospital stay, new ischemic stroke, and possible adverse effects.
224264606|NCT05128396|BEHAVIORAL|Cognitive Stimulation|During the initial session, a member of the research team will visit the subject's home and introduce the subject to the Cogmed training program (www.cogmed.com). Individuals will start at the same low difficulty level. As training proceeds, task difficulty will be individually adjusted based on performance by increasing/decreasing the number of items individuals have to remember, such that a participant reaches approximately 60% correct per day for each task. Each training session will start at the task difficulty level where the participant ended in the previous session. Performance and reaction time data will be continuously recorded while subjects are doing the task, and these data will be sent via the internet to the research team after each session. A member of the research team will communicate with each subject on a weekly basis (via phone call or email) to provide feedback and address any questions or concerns.
224264607|NCT05128396|BEHAVIORAL|Mindfulness training|"The mindfulness meditations will be narrated by one guide and the tasks will be narrated by a different guide. We will have 7 mindfulness tasks in total, whose order of presentation will be counterbalanced across sessions: 1. mindful observing of place, 2. mindful eating, 3. mindful observing of object, 4. mindful observing of person, 5. mindful walking, 6. mindful listening, and 7. mindful writing with the non-dominant and dominant hand.~At the end of each session, participants will write brief reflections stored via the website (e.g., an estimate of the amount of time subjects experienced their thoughts as wandering) both as an integral part of the mindfulness process and as a means of increasing the likelihood that subjects fully participate in each session. Each session will be structured as follows: Login, Mindfulness Meditation Session, Mindfulness Task 1, Mindfulness Task 2, Mindfulness Task 3, Write Log Reflection, Logout."
224264608|NCT05128396|BEHAVIORAL|Physical Activity|Aerobic exercises will include relatively low impact activities like walking, jogging, or running in place, which will aim to put limited demands on balance. Each exercise will be explained and demonstrated in the video. All exercises can be done standing, sitting, or next to a chair that provides balance support as demonstrated in the videos. After the first session, for each subsequent session the difficulty level will start at one level below the previous session's average difficulty level (e.g. if they exercise at the most difficult level for most of the time during one session, the next session will start at the medium difficulty level). Each exercise will be explained and demonstrated in the video.
223829529|NCT06475560|DIAGNOSTIC_TEST|CCE arm|Twice a week, patients will attend the in-hospital clinic in groups of five persons. They will bring their completed FIT sample, questionnaire, and the signed consent form. A project nurse will administer the capsules in the morning, and the patients can leave after. When the capsule investigation is completed, patients must return their belt and receiver to the Department of Surgery, OUH. After a few days, the patient will receive an electronic letter with the results and information regarding upcoming steps. Those with positive findings or an incomplete investigation will be given a new appointment according to the current clinical routine. A second questionnaire will be sent to the patient 2 weeks after the completed procedure.
223829530|NCT06475560|DIAGNOSTIC_TEST|OC arm|Patients will start bowel cleansing according to the instructions. They will bring their completed questionnaire and the signed consent form to the scheduled colonoscopy. They will continue to follow the routine clinical setup for outpatient colonoscopy and will only receive, by digital post, after 2 weeks from the procedure, an extra second questionnaire.
223829531|NCT01548014|DIETARY_SUPPLEMENT|VSL#3|children with severe Crohn's disease were assigned in a 1:1 ratio with either IFX 5 mg/kg q 12 weeks + concurrent immunomodulator + VSL#3 (4 sachets of 450 x 109 organisms per day) (Group A), or IFX 5 mg/kg q 8 weeks + concurrent immunomodulator (Group B).
223829532|NCT00145717|DRUG|Plant sterol enriched milk tea|
223829533|NCT04917380|OTHER||Retrospective clinical study，no intervention
223829534|NCT03420235|OTHER|Home monitoring program|The home monitoring program consists of 1) the use of an interactive internet tool to coach patients and enhance self-management 2) home-based pulmonary function testing with a handheld spirometer and 3) recording of patient-reported outcomes (PROs).
223829535|NCT02653014|DRUG|KBP-5074|
223829536|NCT02679768|BEHAVIORAL|Circadian Reinforcement Therapy|Circadian reinforcement therapy plus electronical monitoring. Circadian reinforcement therapy is a specialized psychoeducation working with strengthening of circadian rhythms.
223829537|NCT02679768|BEHAVIORAL|Standard treatment|Standard treatment plus electronical monitoring
223829538|NCT04055506|DRUG|BMS-986165|Dose 1
223829539|NCT04055506|DRUG|Ritonavir|100 mg
223829540|NCT02755454|DEVICE|Perfusion CT Imaging|
223829541|NCT01854294|DRUG|GM604|GM604 treated group subject will receive a slow IV bolus injection (\~1min) of 6.4 mL (320mg @50 mg/mL=6.4 mL) for each dose. A total of 6 doses will be administered over two weeks (on Mondays, Wednesdays and Fridays for the first 2 weeks).
223829542|NCT01854294|DRUG|Placebo comparator|Placebo comparator group subject will receive a slow IV bolus injection (\~1min) of 6.4 mL bacteriostatic saline for each dose. A total of 6 doses will be administered over two weeks (on Mondays, Wednesdays and Fridays for the first 2 weeks).
223829543|NCT03620903|DRUG|Ibrutinib / Bortezomib / Rituximab|Induction (Rituximab / Bortezomib / Ibrutinib), Maintenance I (Ibrutinib / Rituximab), Maintenance II (Ibrutinib)
223829544|NCT02903628|BEHAVIORAL|eye health education|give a lecture and issue knowledge manual for children and parents ,6 months once , 2.5 years
223829545|NCT03172117|BIOLOGICAL|human umbilical cord blood derived mesenchymal stem cells|"Low dose: 1 x 10\^7cells/2mL 3 repeated intraventricular administrations via an Ommaya Reservoir at 4 week intervals~High dose: 3 x 10\^7cells/2mL 3 repeated intraventricular administrations via an Ommaya Reservoir at 4 week intervals"
223829546|NCT03172117|OTHER|Normal saline 2mL|Normal Saline at 4 week intervals via an Ommaya Reservoir, for a total of 3 administrations
223829547|NCT01718236|DRUG|Rocuronium + sugammadex|Administration of rocuronium 1 mg/kg, intubation at decrease in Single Twitch to 10% of baseline event. by the disappearance of visible spikes event. in the 60th seconds after administration of muscle relaxants. Anesthesia with sevoflurane according to the MAC, neuromuscular blockade TOF count at 1-2.At the end of operation at PTC 1-2 sugammadex 4 mg/kg, at the TOF count 1-2, sugammadex 2 mg/kg, in the case of failure to achieve these values the anesthesiologist will wait until the minimum value of PTC 1-2 will be achieved. In can not intubate can not ventilate, and the failure of the introduction of laryngeal masks sugammadex 16mg/kg, immediately following the discovery of this fact and wait for the recovery of muscle strength. Time to recovery is recorded.
223829548|NCT01718236|DRUG|Succinylcholine + Neostigmine|1mg/kg succinylcholine iodide, intubation after decrease in Single Twitch to 10% of baseline event. after the disappearance of visible fasciculation event. in the 60th seconds after administration of muscle relaxants. Anesthesia with sevoflurane according to the MAC, at the moment of 20-30% of the original value of Single Twitch rocuronium 0.3 mg / kg, maintaining TOF Count at 1-2.At the end of operation at TOF Count 1-2 atropine 0.01 mg/kg and neostigmine 0.03 mg/kg. If TOF not 1-2 wait.In can not intubate can not ventilate, wait for the spontaneous recovery. Time to recovery of muscle strength is recorded.
223829549|NCT01463774|DRUG|Treatment A: Canagliflozin tablet|Type=exact number, unit=mg, number=100, form=tablet, route=oral use. One canagliflozin tablet taken orally (by mouth) on Day 1 of Treatment Period A.
223829550|NCT01463774|DRUG|Treatment A: Metformin IR tablets|Type=exact number, unit=mg, number=850, form=tablet, route=oral use. Two metformin IR tablets taken orally (by mouth) on Day 1 of Treatment Period A.
223829551|NCT01463774|DRUG|Treatment B: Canagliflozin/metformin fixed dose combination tablets|Type=exact number, unit=mg, number=50/850, form=tablet, route=oral use. Two canagliflozin/metformin IR tablets taken orally (by mouth) on Day 1 of Treatment Period B.
223829552|NCT04647019|DIETARY_SUPPLEMENT|Wild blueberry powder|22 g freeze-dried wild blueberry (Vaccinium angustifolium) powder consumed daily with 250 ml water. The powder is sealed in sachets and stored at -24 °C, except when transported. Participants are asked to store the sachets in a freezer until consumption.
223829553|NCT04647019|DIETARY_SUPPLEMENT|Placebo powder|22 g placebo powder matched for macronutrients, color, and flavor consumed daily with 250 ml water. The powder is sealed in sachets and participants are asked to store the sachets in a freezer until consumption.
223829554|NCT03823976|OTHER|Types of the dental procedures in general anaesthesia|Analysis of the mean number of preventive, prophylactic, therapeutic and rehabilitation procedures
223829555|NCT05471869|DIAGNOSTIC_TEST|Aneurysm diagnosis|Intelligent detection and diagnosis of aneurysm diagnosis by CTA
223829556|NCT03428061|OTHER|Integrated care for cardiovascular risk management|Disease management program for the prevention of cardiovascular diseases
223829557|NCT03674606|DRUG|Low dose aspirin|One 75 mg aspirin dose taken daily
223829558|NCT03106961|DEVICE|Bioresorbable vascular scaffolds, OCT, non-compliant ballooning|Measure the effect of high-pressure, NC ballooning on scaffold embedding by OCT
223829559|NCT02262611|DRUG|Micardis®|
223829560|NCT02262611|DRUG|MicardisPlus®|
223829561|NCT01339611|BEHAVIORAL|Educational program|Individual orientation (slides) during hospitalization period and telephone follow-up after discharge
223829562|NCT04520958|BEHAVIORAL|Mindfulness of Breath|Mindfulness of Breath consisted of instruction in focused attention on the breath and metacognitive monitoring and acceptance of discursive thoughts, negative emotions, and pain.
223829563|NCT04520958|BEHAVIORAL|Mindfulness of Pain|Mindfulness of Pain consisted of instruction in how to (1) zoom in to deconstruct pain into its constituent physical sensations and precisely map each sensation's spatial location, (2) use mindful breathing to zoom out and broaden the field of attention to include previously neglected sensory elements (i.e., spaces within the body that were absent of sensation and pleasant sensations), and (3) shift attention from unpleasant sensations to neutral/pleasant sensations or experiences.
223829564|NCT04520958|BEHAVIORAL|Cognitive-Behaviorally Based Pain Psychoeducation|Cognitive-Behaviorally Based Pain Psychoeducation consisted of psychoeducation about the link between thoughts, emotions, and behavior and provided instruction in the use logic to dispute maladaptive thoughts about pain that might otherwise exacerbate pain and distress.
223829565|NCT03932448|OTHER|The proposed study is not interventional.|The proposed study is not interventional. However, if a treatable microorganism is detected, e.g. Borrelia or Anaplasma, suitable therapy, e.g. doxycycline, will be in initiated if appropriate.
223829566|NCT05687617|DRUG|Indocyanine green|0,25mg/kg IV at the start of the surgery,
223829567|NCT01645332|DRUG|Placebo of DLBS3233|Placebo of DLBS3233 once daily for 12 weeks
223829568|NCT01645332|DRUG|DLBS3233|100 mg DLBS3233 once daily for 12 weeks
223829569|NCT01645332|OTHER|Lifestyle modification|Each study subject will be provided with and instructed to follow a lifestyle modification (particularly regarding dietary advice and exercise) during the subject's participation in the study.
223829570|NCT03135132|BEHAVIORAL|Control group|Recommend to consume usual diet during 12-week study period
223829571|NCT03135132|BEHAVIORAL|LCD group|Recommended to reduce calorie intake (a 300 kcal/day); educated to take out 1/3 of a bowl of rice from per meal a day for an easier application of 100kcal deficits, thereby reducing a 300kcal/3 meal/day
223829572|NCT01890902|DRUG|Ketoprofen 10% Cream|
223829573|NCT01890902|DRUG|Placebo|
223829574|NCT00280423|DRUG|GW679769|
223829575|NCT00003534|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|"Patients With Refractory Stage IV Prostate Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
223829576|NCT05010694|DRUG|GH35 Tablet|GH35 for oral administration at doses of Dose A, Dose B, Dose C, Dose D, Dose E and Dose F.
223829577|NCT06349785|DEVICE|rehabilitation of mechanically ventilated patients|"1. mechanical ventilation~2. silicon resuscitation bag (500ml) connected to pressure manometer with an oxygen flow of 10 l.min-1~3. Endotracheal closed suction with pressure control ventilation (PCV)"
223829578|NCT06349785|PROCEDURE|supportive care|\- Children in study group B will receive standard Physical therapy program including suction, percussion and vibration with total duration of session in group a will be 15 minutes, daily for successive two weeks
223829579|NCT06500182|OTHER|hippotherapy sessions|Patients benefit from the hippotherapy sessions in additional to continuing to receive traditional care.
223829580|NCT00164177|DRUG|HalfLytely|
223829581|NCT01730781|RADIATION|[11-C]OMAR|The radiotracer, \[11-C\]OMAR will be administered at no more than 10 micrograms at the beginning of each PET scan.
223829582|NCT00210665|DRUG|Trabectedin|Type= exact number, unit= mg/m2, number= 1.5, form= intravenous infusion, route= intravenous use. 1.5mg/m2 as 24hr infusion on day 1 of each 21 day cycle
223829583|NCT05583747|DEVICE|iTBS|rTMS involves direct stimulation of cortical neurons using externally applied, powerful, focused magnetic field pulses. iTBS is a briefer form of patterned rTMS that has been shown to be effective against MDD, despite a stimulation period of 1-3 min rather than 30-40 min.
223829584|NCT00936338|BEHAVIORAL|splint and joint mobilization self exercise|
223829585|NCT06458829|BEHAVIORAL|SEARCH-AF|SEARCH-AF program will include opportunistic screening among old adults during primary care visits and promoting strategies. Promoting strategies will be developed based on the Consolidated Framework for Implementation Research framework which may include leadership engagement, policy support, providing screening resources, atrial fibrillation screening and management training. General practitioner or nurse in each health care center will implement point-on-care screening. The intervention will last for six months and followed up for another six months.
223829586|NCT02977065|DRUG|Atorvastatin 20mg|PO daily for 4weeks
223829587|NCT02977065|DRUG|Atorvastatin 20 mg + CKD-519 50 mg|PO daily for 4weeks
223829588|NCT02977065|DRUG|Atorvastatin 20 mg + CKD-519 100 mg|PO daily for 4weeks
223829589|NCT02977065|DRUG|Atorvastatin 20 mg + CKD-519 200 mg|PO daily for 4weeks
223829590|NCT02977065|DRUG|Rosuvastatin 10 mg|PO daily for 4weeks
223829591|NCT02977065|DRUG|Rosuvastatin 10 mg + CKD-519 100 mg|PO daily for 4weeks
223829592|NCT06530524|DRUG|OnabotulinumtoxinA|Injection of onabotulinumtoxinA into the at-risk major salivary glands
223829593|NCT06530524|DRUG|Placebo|Injection of normal saline into the at-risk major salivary glands
223829594|NCT05054127|OTHER|foiiow up patients|observational study
223829595|NCT00284375|PROCEDURE|Registration of all big toe prostheses in Ghent University Hospital|Registration of all big toe prostheses in Ghent University Hospital.
223829596|NCT04764929|DEVICE|Helmet CPAP|Vyatil nonpowered oxygen tent system
223829597|NCT02717013|DIETARY_SUPPLEMENT|Placebo|Placebo capsules containing calcium lactate similar to the HMB capsules.
223829598|NCT02717013|DIETARY_SUPPLEMENT|HMB|HMB capsules supplying 3 grams per day of calcium beta-hydroxyl-beta-methylbutyrate.
223829599|NCT00079794|DRUG|Iscar|
223829600|NCT00079794|DRUG|mistletoe|
223829601|NCT04782310|DRUG|Pregabalin|Pregabalin 75mg two hour preoperatively, 12 hours postoperative and will continue for one week twice per day.
223829602|NCT04782310|DRUG|Duloxetine|Duloxetine 30mg two hour preoperatively …will be continued for one week once per day after breakfast .
223829603|NCT03836898|DEVICE|Presbyopic posterior chamber phakic intraocular lens IPCL|Presbyopic posterior chamber phakic intraocular lens IPCL (EyeolUK, United Kingdom) has a refractive optic and diffractive trifocal pattern on its anterior optical surface to correct both distance and near refractive errors. Presbyopic addition is manufactured in a range of +1.0 to + 4.0 diopters (D) in 0.5 D steps.
223829604|NCT05993195|DEVICE|Conduit Titanium Interbody Graft|The Concorde Bullet Device is compared with Conduit Titanium Interbody Graft for lumber fusion in terms of reoperation rates at 2 years.
223829605|NCT05993195|DEVICE|Concorde Bullet Device|This traditional device is to compare the clinical results of the new Conduit Titanium Interbody device for lumbar fusion
223829606|NCT00422370|DEVICE|lipid based additives based on vegetable oil & lecithin|
223829607|NCT05258747|DRUG|Olaparib tablets, 150 mg|Olaparib tablets, 150 mg of Lek Pharmaceuticals d.d., Slovenia
223829608|NCT05258747|DRUG|Lynparza® (olaparib) tablets 150 mg|Lynparza® (olaparib) tablets 150 mg Manufactured for: AstraZeneca Pharmaceuticals LP, Wilmington, Delaware (DE).
223829609|NCT06060834|DIETARY_SUPPLEMENT|Topical Botanical Agent|Cayenne Pepper, Coconut Water, Kelp, Lemon Juice, Oxynex LM, Potassium Sorbate, Red Palm Oil, Rose Water, Saw Palmetto, vitamin C
223829610|NCT00001010|DRUG|Zidovudine|
223829611|NCT00001010|DRUG|Acyclovir|
223829612|NCT01024959|OTHER|PCA3 Assay|Post-Digital Rectal Exam (DRE) urine collected prior to prostate biopsy
223829613|NCT04392232|DRUG|Convalescent Plasma|"• Investigational Product~o COVID-19 convalescent plasma will be obtained from an FDA-registered blood establishment (Hoxworth) that follows donor eligibility criteria and donor qualifications as outlined in section III.C.I of the Investigational COVID-19 Convalescent Plasma Guidance for Industry."
223829614|NCT00636792|DRUG|VELCADE|VELCADE administered as a 3- to 5-second intravenous (IV) bolus prior to Bendamustine and Rituximab on Days 1,8,15 and 22 of each cycle.
223829615|NCT00636792|DRUG|Bendamustine|Bendamustine administered IV over 30-60 minutes after VELCADE on Days 1 and 2 of each cycle
223829616|NCT00636792|DRUG|Rituximab|Rituximab administered by IV infusion after VELCADE and Bendamustine on Days 1, 8, 15 and 22 of Cycle 1, and on Day 1 of Cycles 2, 3, 4 and 5
223829617|NCT01414413|OTHER|Home assessment and initiation of ART|Home-based ART eligibility assessment (WHO staging, CD4 count measurement and educational treatment preparation) and initiation.
223829618|NCT01414413|OTHER|Clinic-based ART assessment and initiation|Participants who meet eligibility criteria and reside in a cluster that has been allocated to the control arm of this study will receive supported access to ART care through the primary care system for confirmation of HIV status and entry into HIV following disclosure to the resident community counsellor.
223829619|NCT01987596|BIOLOGICAL|filgrastim|Given SC once daily starting on day 1 after chemotherapy in Arm I (fixed) and on any day when ANC drops below 1000/mcl in Arm II (flexible)
223829620|NCT04813757|OTHER|exercise|each group will perform 2 shoulder strength exercise at the therapy session and 3 exercise at home session-2 strength exercise and one stretching exercise. they will perform the exercises 5 times per week
223829621|NCT04813757|OTHER|manual therapy|on each treatment session both group will receive 15 minutes of manual therapy which will include: massage,3-4 trigger point treatment posterior capsule stretch and mobilization with movement
223829622|NCT00709592|BIOLOGICAL|Thymoglobulin|Patients eligible for participation in this study will be randomized between receiving rabbit ATG for 3 days. Thymoglobulin will be administered according to VCU BMT standard of care starting day -9 and continued daily through day -7.
223829623|NCT00709592|RADIATION|Total-Body Irradiation|Undergo TBI
223829624|NCT00709592|PROCEDURE|Allogeneic PBSCT or BMT|Undergo allogeneic PBSCT or BMT
223829625|NCT00709592|DRUG|Tacrolimus|Given PO
223829626|NCT00709592|DRUG|Mycophenolate Mofetil|Given PO
223829627|NCT01129336|DRUG|Zoledronic acid|Patients with no bone metastasis (n=150) will receive Standard therapy plus Zoledronic acid administration 4 mg IV monthly during Months 1-18.
223829628|NCT01129336|DRUG|Standard Therapy|Standard Therapy, including chemotherapy and hormonal therapy, was determined at the discretion of the investigator.
223829629|NCT02351596|OTHER|Physiotherapy Core Stability Group Programme|"The aim of the intervention is to teach the participants active alignment and core stability, in order to influence their balance strategies. The exercises carried out will teach participants how and when to activate deep core stabilizing muscles. These exercises will be taught in a child-friendly way using imagery appropriate for the age of the participants. They will carry out activities like wall squats, 4-point kneeling, Transverses abdominis activation and gym ball sitting.~Participants will also be supplied with a Home Exercise Programme (HEP) sheet with explanations for exercises that they will be asked to carry out on their 'off' days over the 4 week period. They will be asked to keep a record of their compliance with this."
223829630|NCT02351596|OTHER|Control Group|The control group will partake in their usual physiotherapy care during the 4 week control period. They will not include core stability or balance specific exercises in their physiotherapy programme for the duration of the control period. If they are receiving active physiotherapy treatment during this time, the duration and frequency of this intervention is recorded
223829631|NCT05778331|PROCEDURE|Antagonist protocol for induction of ovulation|Full labs will be revised to exclude women with any chronic disease. Ultrasound to exclude any anatomical uterine problem.HSG.Women who will be categorized as Poseidon group 3 and Poseidon group 4.They will be given after that antagonist protocol with dose of HMG/FSH 300-450 I.U. per day: (Gonapure 150 I.U -follicle stimulating hormone FSH preparation of recombinant DNA technology- MinaPharm pharmaceuticals-Egypt) will be given from 2nd day of menstruation per day as starting dose then on 7th day (Cetrotide 0.25 -Cetrorelix, an anti-gonadotropin releasing hormone- MERCK SORONO-Germany) will be given daily till triggering . US will be done to evaluate follicular size from 7th day if it will be 1.8 cm or more for at least 2 follicles then (Chorimon 5000 i.u-Choriogonadotropin Alfa-IBSA-Switzerland )of total dose 10000 I.U. will be given then ovum pick up with be done after 35 h of triggering ovulation .Assessment of embryo quality
223829632|NCT00821132|OTHER|Genetic study of ALS families|Collection and analysis of genetic material, medical and family histories from families with ALS
223829633|NCT03978754|DIAGNOSTIC_TEST|ICG lymphography、CM、VD、Bioelectrical impedance technology、self-report|All of these methods are used for patients visiting the lymphedema clinic to assess whether they have developed lymphedema.
223829634|NCT03978754|DIAGNOSTIC_TEST|Bioelectrical impedance technology、CM|These two methods are routine evaluation methods for breast cancer patients before surgery
223829635|NCT03989635|DRUG|QAW039|QAW039 450mg
223829636|NCT00436176|BEHAVIORAL|Expanded Chronic Care Model|Intervention clinicians receive monthly performance feedback reports, cultural competency training, and health navigation training.
223829637|NCT06315764|PROCEDURE|Reflexology|"Following four weeks of treatment (post-1) and additional four weeks of treatment (post-2) the post evaluation was used (post-2).Before and after the foot reflexology, blood pressure was checked twice. Around 20 minutes is spent on foot reflexology .~Each patient in this study did 20 minutes of peddler aerobic training, with the first 5 minutes serving as a warm-up with intensity set at 60 - 65 percent of maximal heart rate, followed by another 10 minutes of peddler training with intensity gradually increased up to 70 - 75 percent, and the last 5 minutes serving as a cooling down with intensity set at 60 - 65 percent of maximal heart rate. After the warm-up and at the end of each training phase, the participants' heart rates were monitored. Finally, if the individual experienced pain, fainting, or shortness of breath, the training was promptly terminated as well as reflexology three times each week for eight weeks"
223829638|NCT00505167|DRUG|Memantine|Patients randomized to receive either memantine or donepezil
223829639|NCT00505167|DRUG|Donepezil|Patients randomized to receive either memantine or donepezil
223829640|NCT00358150|DRUG|Eliglustat tartrate|Eliglustat (Genz-112638) capsule as single 50 mg dose on Day 1 then eliglustat 50 mg twice daily (BID) from Day 2 to Day 19, then either eliglustat 50 mg BID (if Genz-99067\[active moiety of eliglustat in plasma\] trough plasma concentration was greater than or equal to \[\>=\]5 nanogram per milliliter \[ng/mL\] on Day 10) or eliglustat 100 mg BID(if Genz-99067 trough plasma concentration was less than \[\<\] 5 ng/mL), from day 20 to Year 4. After primary completion date (Week 52) participants underwent treatment interruption period of approximately 2 weeks before continuing same treatment through study completion (Year 9). Participant receiving 100 mg BID could be considered for further dose increase to 150 mg BID at Week 24 if they met certain criteria (for example, had been on treatment for at least 24 months, had not reached therapeutic goals established for participants receiving Cerezyme, and if all other causes for lack of treatment effect had been evaluated and ruled out).
223829641|NCT04403958|PROCEDURE|PRC|Total wrist arthrodesis with dorsal plate using proximal row of the wrist as bone graft
223829642|NCT04403958|PROCEDURE|TWA|Total wrist arthrodesis with dorsal plate using iliac crest as bone graft
223829643|NCT01980901|DEVICE|Ovation™/Ovation Prime™ Abdominal Stent Graft System|Single occurence permanent implant of AAA device.
223829644|NCT01812343|OTHER|Exercise test|
223829645|NCT00179010|DRUG|Adenosine|Adenosine intrarterial (intrabrachial) infusion at 3 diferent doses for 15 minutes each
223829646|NCT00179010|DRUG|Adenosine Mono Phosphate (AMP)|Intraterial infusion of AMP at 3 different doses for 15 minutes each (at equimolar doses as adenosine)
223829647|NCT06054620|DIETARY_SUPPLEMENT|Collagen and Vitamin C|Collagen-modelled crystalline amino acids (30g total, 8g glycine) and vitamin C (500 mg).
223829648|NCT06054620|DIETARY_SUPPLEMENT|Carbohydrate Placebo|Iso-caloric Placebo (30g maltodextrin).
223829649|NCT03765762|DRUG|GRF6019|GRF6019 for IV infusion
223829650|NCT03765762|OTHER|Placebo|Placebo for IV infusion
223829651|NCT01942655|OTHER|Blood sample and recto-colic biopsies|
223835591|NCT01929005|OTHER|Comprehensive Care|Patients will receive comprehensive medical care from their CCP in clinic and the hospital. For most patients, the ambulatory care provided by the CCP will be in our onsite medicine clinic, but for some patients with subspecialty needs the CCP may be a specialist who will care for the patient in a nearby ambulatory setting (e.g., nursing home, dialysis facility). The CCPs will also supervise the nurses, pharmacists, social workers, and others who are part of the multi-disciplinary care team. Daytime inpatient care will be provided by CCPs in conjunction with our inpatient advanced practice nurses (APNs). These APNs now work with our hospitalists, so they are experienced providing hospital care.
223829652|NCT04466332|DEVICE|LifeCath-CT PICC easy™ (Vygon)|"ECG electrodes are placed on patient's chest ensuring that there is a distinguishable P-wave.~Upper arm selection is based on vein diameter and dominance, ultrasound is used to identify a suitable vein.~The patient is prepared using a maximal sterile barrier approach. The catheter is inserted into one of the veins (75-90° arm abduction) using ultrasound and modified Seldinger technique.~The PICC is advanced into the central circulation and used as an intracavitary electrode (connection with Vygocard2™). Saline water instilled through the catheter ensures conductivity.~The ECG is then used until displayed intracavitary P-wave has a maximal height without negative deflexion. Catheter is left at this point (cavo atrial junction).~The PICC hub side is then trimmed and the catheter part connected. The PICC is caped with a neutral bidirectional valve.~The puncture site is dressed and catheter stabilized. Chest Xray is obtained immediately after insertion to assess the position."
223835592|NCT04517656|OTHER|Blood samples|"A peripheral blood sample will be taken and will include 2 EDTA tubes of 5 mL, for a total volume of 10 mL:~* Samples before the allograft,~* Samples at different times post-allograft: 15 days, 30 days, 60 days, 90 days, 180 days, 360 days,~* Samples in the event of the occurrence of concomitant events during the 12-month follow-up period: occurrence of acute Graft Versus Host Disease, chronic Graft Versus Host Disease, or relapse of the disease before the initiation of a new treatment."
223835593|NCT05125211|DRUG|GB001 recombinant peptide spray|administrated oral spray
223835594|NCT05125211|DRUG|Placebo|administrated oral spray
223829653|NCT04466332|DEVICE|PowerPICC-SOLO® (C.R. Bard)|"ECG electrodes are placed on patients chest ensuring that there is a distinguishable P-wave.~Upper arm selection is based on vein diameter and dominance, ultrasound is used to identify suitable vein.~The patient is prepared using a maximal sterile barrier approach. The catheter is inserted into one of the veins (75-90° arm abduction) using ultrasound and modified Seldinger technique.~The catheter's free end is cut to the anticipated length using anthropometric measurements (insertion/axillary crease+axillary crease/sternal notch+13cm) and the preloaded magnetic-tipped stylet (serving as intracavitary electrode) is put inside.~The PICC is advanced into central veins until intravascular ECG displays a P-wave with maximal height without negative deflexion. Catheter is left at this point (cavo atrial junction).~The puncture site is dressed and catheter stabilized. Chest Xray is obtained immediately after insertion to assess position."
223829654|NCT02484560|DRUG|Biological: Umbilical Cord Based Allogenic Mesenchymal Stem Cell|
223829655|NCT05162807|BEHAVIORAL|Psychoeducational Video on Palliative Care|The intervention is a psychoeducational video introducing palliative care and discussing its purpose, structure, benefits, and efficacy.
223829656|NCT05162807|BEHAVIORAL|Educational Video on Nutrition|The attention control is a video on nutrition and healthy eating during cancer survivorship.
223829657|NCT01762163|DRUG|Qizhitongluo Capsule|
223829658|NCT01762163|DRUG|Naoxintong Capsule|
223829659|NCT01762163|DRUG|Aspirin Enteric-coated Tablets|
223829660|NCT01762163|BEHAVIORAL|the routine recovery training|
223829661|NCT01762163|DRUG|placebo|
223829662|NCT02167152|OTHER|Ischemic preconditionin|Ischemic preconditioning will be accomplished through 4 cycles of alternating 5-minute inflation and 5-minute deflation of an upper-arm blood pressure cuff to the patient's systolic blood pressure plus 50% to induce ischemia and reperfusion.
223829663|NCT05125042|PROCEDURE|Amiodarone hydrochloride tablet + acupoint catgut embedding|Patients with persistent AF after undergoing catheter ablation take receive acupoint catgut embedding in Neiguan and Zusanli twice after and one month after surgery combined with amiodarone hydrochloride tablets 200mg bid, 1 month; 200mg qd,maintained to 3 months.All patients, who had no signs of recurrence three months after surgery, stopped taking medication.
223829664|NCT05125042|DRUG|Amiodarone hydrochloride tablet|Patients with persistent AF after undergoing catheter ablation only take amiodarone hydrochloride tablets 200mg bid, 1 month; 200mg qd,maintained to 3 months.All patients, who had no signs of recurrence three months after surgery, stopped taking medication.
223829665|NCT05401422|OTHER|treatment|types
223829666|NCT02381860|OTHER|Placebo|One bolus of less than 5% fruit cordial mixed with water, maltodextrin and whey protein isolate to match for carbohydrate and calorie content of the juice.
223829667|NCT02381860|DIETARY_SUPPLEMENT|60mL tart Montmorency cherry juice|One bolus of 60mL of tart Montmorency concentrate mixed with 100mL of water.
223829668|NCT01554943|OTHER|cardiac MRI|Patients will be submitted to extensive cardiac evaluation several years after completion of adjuvant chemotherapy
223829669|NCT04758221|OTHER|Treatment by composite coronal build-up|A total of (42) decayed or traumatized primary anterior teeth were treated with composite coronal build-up based on the micromechanical adhesive procedure of composite resin in addition to macro mechanical retentive grooves created on the lateral sides of the cervical one third of the roots of treated teeth.
223829670|NCT05663983|BEHAVIORAL|Description of therapeutical results|Comparison between two groups of patients treated in different realities (Pediatric Hospital or Adult General Hospital)
223829671|NCT02766673|DRUG|Albuterol Sulfate|Subjects will receive a dose of study medication every 4 hours for 24 total hours
223829672|NCT02766673|DRUG|Sterile Saline|Subjects will receive a dose of study medication every 4 hours for 24 total hours
223829673|NCT06527651|DRUG|Genicular blocks (dexamethazone and lidocaine)|Genicular blocks were applied bilaterally by another physiatrist who was experienced in ultrasonographic (US) interventional procedures more than 5 years. Total of 6mL solution consisting of 0.5 mg/2mL dexamethazone and 4mL %1 lidocaine for three branches of genicular nerves (superomedial, superolateral and inferomedial branches) was divided into three branches for each knee. Total of 12 mL solution was applied for each patient.
223829674|NCT01096199|DRUG|TS-ONE, Cisplatin, RAD001|
223829675|NCT03254693|COMBINATION_PRODUCT|1-step self-etch approach (SE)|Application mode - Do not use etchan. According to the manufacturer's instructions.
223829676|NCT03254693|COMBINATION_PRODUCT|selective enamel etching (SEE)|Application mode - Etch only on enamel for 15 s. Rinse for 15s. Air dry to remove excess water.According to the manufacturer's instructions.
223829677|NCT03254693|OTHER|1-step self-etch for double time (SE2X)|Application mode - Do not use etchan. According to the manufacturer's instructions, but for the double time (20 s) in the each application.
223829678|NCT03254693|OTHER|1-step self-etch additional layer (SE1+)|Application mode - Do not use etchan. According to the manufacturer's instructions, but apply tree times.
223829679|NCT05674084|DIAGNOSTIC_TEST|Capillary refill time|CRT will be measured by applying firm pressure to the ventral surface of the index finger distal phalanx with a glass microscope slide. The pressure will be increased until the skin is blank and then maintained for 10 seconds. The time for return of the normal skin color will be registered with a chronometer, and \> 3 seconds is defined as abnormal. Light and ambient temperature will be the same for all individuals.
223829680|NCT02120846|OTHER|Flywheel leg-press resistance exercise|
223829681|NCT03912480|BIOLOGICAL|Stem cells from human exfoliated teeth|Intravenous infusion of pulp mesenchymal stem cells
223829682|NCT03179631|DRUG|Ataluren|10, 20 mg/kg
223829683|NCT03179631|DRUG|PLACEBO|10, 20 mg/kg
223829684|NCT05773131|DEVICE|VR collaborative visualization system|Patients wear virtual reality head-mounted displays while family members using smart phones to interact in a same virtual space.
223829685|NCT00453479|DRUG|GSK233705B|
223829686|NCT01375959|DIETARY_SUPPLEMENT|resveratrol|resveratrol 500 mg capsules, 3 capsules (1500 mg) orally twice a day for 6 weeks
223829687|NCT01375959|DRUG|Placebo|3 placebo capsules orally twice a day for 6 weeks
223829688|NCT03498079|DIAGNOSTIC_TEST|3D ultrasound|3D ultrasound will be done to females complaining from primary infertility with mullerian anomalies
223829689|NCT00242463|DRUG|Nandrolone (anabolic steroid)|
223829690|NCT00242463|DRUG|Placebo|
223829691|NCT03774992|DEVICE|Orthokeratology lenses|Custom fit, form stable contact lenses
223829692|NCT00178256|DRUG|Paclitaxel|On Mondays, Wednesdays, and Fridays, paclitaxel infusion will begin early in the morning and complete before 10:30 am.
223829693|NCT00178256|PROCEDURE|Radiation Therapy|Thoracic XRT will be given in late afternoon, after 4:00 PM, if possible
223829694|NCT06115278|OTHER|survey|survey
223829695|NCT01763788|DRUG|Necitumumab|Administered IV
223829696|NCT01763788|DRUG|Gemcitabine|Administered IV
223829697|NCT01763788|DRUG|Cisplatin|Administered IV
223829698|NCT03567954|DIAGNOSTIC_TEST|Ultrasound examination of the rotator cuff tendons|An ultrasound scan of the rotator cuff tendons will be performed to determine the presence of a rotator cuff tear or not
223829699|NCT05540743|DRUG|biologic DMARDs|follow up the clinical response in Egyptian population to the drug
223829700|NCT01006317|BEHAVIORAL|clinical skills training|In addition to financial coverage (CMS) extensive in-service training of clinical skills (CS) to all doctors and MCH workers at the village and township level.
223829701|NCT01006317|BEHAVIORAL|health education|In addition to financial coverage extensive in-service training of health education (HE) to all doctors and MCH workers at the village and township level(Anhui, Chongqing and Shaan'xi provinces); In addition to financial coverage extensive in-service training of health education (HE) for Family planning (FP) staff at village level (Anhui).
223829702|NCT01006317|OTHER|financial|In addition to financial coverage of MCH care within the local reimbursement system (CMS) the coverage of ante- and postnatal care.
223829703|NCT02123537|DEVICE|Bioness L300 Foot Drop System|Participants will use the Bioness L300 Foot Drop System during waking hours for 12 weeks.
223829704|NCT00332683|PROCEDURE|Maintaining low (15mmHg) ETT cuff pressure|Manipulation of the ETT cuff pressure to hold a lower pressure of 15 mmHg
223829705|NCT00332683|PROCEDURE|Maintaining a normal pressure in the ETT cuff|No manipulation to maintain a low pressure of 15 mm Hg in the ETT cuff
223829706|NCT02354859|DRUG|Gallium nitrate|Study subjects will receive an infusion of either placebo or gallium nitrate.
223829707|NCT02354859|DRUG|Normal Saline|Study subjects will receive an infusion of either placebo (normal saline) or gallium nitrate.
223829708|NCT03008421|DIETARY_SUPPLEMENT|Astarte® (HSO Health Care GmbH, Vienna, Austria)|oral intake of Astarte® (HSO Health Care GmbH, Vienna, Austria) as described
223829709|NCT03008421|OTHER|Placebo|Identical-looking oral potato-maltodextrin-based placebo
223829710|NCT06436963|BEHAVIORAL|narrative medicine training combined with CBL training|The experimental group received narrative medicine training combined with CBL training.
223829711|NCT06436963|BEHAVIORAL|CBL training|The control group received normal CBL training.
223829712|NCT04139915|DRUG|Dactolisib|TORC1 inhibitor
223829713|NCT04139915|DRUG|Placebo|Placebo capsule
223829714|NCT01380301|DRUG|Miltefosine and antimony|Short course (half of each drug) administered simultaneously
223829715|NCT01380301|DRUG|Miltefosine alone|short course (half)
223829716|NCT03088358|DRUG|TeaRx|
223829717|NCT03088358|DRUG|Enoxaparin|
223829718|NCT00708305|DRUG|Sodium Fluoride (NaF)|Different fluoride toothpastes containing between 1400ppmF - 1450ppmF of fluoride as NaF
223829719|NCT00708305|DRUG|Placebo|Fluoride free toothpaste (0ppmF)
223829720|NCT04942860|DRUG|1% Methotrexate gel|1% methotrexate gel applied onto a predefined limb
223829721|NCT04942860|DRUG|0.5% Methotrexate gel|0.5% methotrexate gel applied onto a predefined limb
223829722|NCT02544269|PROCEDURE|Ropivacaine|Lumbosacral plexus blockade with ropivacaine.
223829723|NCT02544269|PROCEDURE|Bupivacaine|Regional anesthesia with bupivacaine titrated to the lowest effective dose
223829724|NCT00385450|DRUG|Nelfinavir/placebo|1250mg/twice each day/four days.
223835595|NCT05382858|DEVICE|Deep brain stimulation|active DBS with optimal stimulating parameters
223829725|NCT02771210|BIOLOGICAL|Secukinumab|Induction: Week 0,1,2,3 150 mg or 300 mg Secukinumab s.c. Maintenance: 150 mg or 300 mg Secukinumab s.c. every 4 weeks starting at Week 4
223829726|NCT02771210|DRUG|Secukinumab Placebo|Induction: Week 0,1,2,3 Secukinumab Placebo s.c. Maintenance: Secukinumab Placebo s.c. every 4 weeks starting at Week 4 until Week 24 followed by 150 or 300 mg Secukinumab s.c. every 4 weeks
223829727|NCT00139022|DEVICE|Continuous Positive Airway Pressure|
223829728|NCT05388994|OTHER|Exercise|The initial implementation for the 8-week combined exercise program consisted of a progressive aerobic exercise program with a lower extremity bike (Ergoline Ergoselect 200; Ergoline GMBH, Bitz, Germany). All sessions are individually supervised and conducted. Training intensity was started at 70% of maximum aerobic capacity and training intensity was increased by 5% of VO2peak every two weeks. Pedal speed was fixed at 50 rpm throughout 8 weeks of training. Exercise sessions; It started with a 5 minute warm-up period (30% of VO2peak), followed by a total of 40 minutes with a 30-minute load period and a 5-minute cool-down period (without resistance).
223829729|NCT00002793|DRUG|fluorouracil|
223829730|NCT00002793|DRUG|leucovorin calcium|
223829731|NCT03132493|DRUG|Nivolumab 10 MG/ML|nivolumab 3 mg/kg as an intravenous infusion every 2 weeks until progression
223829732|NCT00402545|DRUG|Cetuximab|Given intravenously on days 1, 8 and 15 of each 21-day cycle for three cycles
223829733|NCT00402545|DRUG|Docetaxel|Given intravenously on day 1 of each 21-day cycle for 3 cycles
223829734|NCT00402545|DRUG|Cisplatin|Intravenously on day 1 of each 21-day cycle for 3 cycles
223829735|NCT00402545|DRUG|5-Fluorouracil|Given by continuous infusion pump over a period of 96 hours(dosage wil vary depending upon when participant enrolls in trial)
223829736|NCT05056090|PROCEDURE|Patients will receive MV in PP|Putting the patient in a prone position
223829737|NCT01930435|DEVICE|Sterile Humidification Device|This is a personal humidification device. It is hand held and produces sterile warm vapor.
223829738|NCT00723424|DRUG|AZD5672|50 mg, for 13 days
223829739|NCT00723424|DRUG|Digoxin|0.5mg dose
223829740|NCT02826018|DRUG|ALN-HBV|Ascending doses of ALN-HBV by subcutaneous (sc) injection
223829741|NCT02826018|DRUG|Sterile Normal Saline (0.9% NaCl)|Calculated volume to match active comparator
223829742|NCT05765097|DEVICE|Artificial pancreas treatment|five to seven days treatment by artificial pancreas system
223829743|NCT01495182|OTHER|Dietary fiber|A proprietary fiber will be given to subjects
223829744|NCT03017989|DEVICE|NIRF imaging|By using a fluorescence imaging device (with an adapted light source and camera), a fluorescent dye can be made visible. By injecting the fluorescent dye intravenously, the vascularization will be visible. Thereby, structures with altered vascularization are expected to 'light up' differently than the surrounding.
223829745|NCT01269814|PROCEDURE|Gastroscopy|Gastroscopy
223829746|NCT03650595|DEVICE|"The TRANBERGCLS|Thermal Therapy"|"MRI Guided Focal Laser Ablation of Prostate Cancer by The Diode Laser System - The TRANBERGCLS\|Thermal Therapy"
223829747|NCT05819060|DRUG|Fuzuloparib Combination with Bevacizumab|For the first 6 patients, if DLT≤33.3%, Fuzuloparib 150mg/bid will be used for follow-up research; if DLT\>33.3%, Fuzuloparib will be used for follow-up research at 100mg/bid; Bevacizumab 7.5mg/kg, d1, Q3W.
223829748|NCT01560377|DEVICE|PINPOINT Endoscopic Fluorescence Imaging System|The PINPOINT system will be used to provide real-time endoscopic visible and endoscopic NIR fluorescence imaging. PINPOINT enables surgeons to perform routine visible light endoscopic procedures as well as further visually assess vessels, blood flow and related tissue perfusion with near infra-red imaging during minimally invasive surgery
223829749|NCT00326690|DEVICE|Blue Egg Device|
223829750|NCT03324737|DEVICE|Interactive Smartphone App|"There are six main components to the APP.~* Goal Setting: personalizes diet, activity, and weight loss goals for patients based on their starting point.~* Food choices and recommendations: App has an automated and immediate recommendation of foods if the choice selected from food database is not optimal. It has a calorie and nutrients tracker to enable patients to track their food intake.~* Activity and steps tracker: App has a pedometer to count physical activity and steps to enable patients to track their progress towards goals.~* Interactive video lessons: App has video lessons pushed weekly to the patient according to her needs. The videos encompass aspects of diet, lifestyle and behavior management.~* Healthcare Professionals Support: App has a chat channel to enable interaction between participants and healthcare professionals."
223829751|NCT02796547|DRUG|Levobupivacaine|Infiltration of the banks of the episiotomy done with Levobupivacaine
223829752|NCT02796547|OTHER|Physiological serum|Infiltration of the banks of the episiotomy done with physiological serum
223829753|NCT00849082|DRUG|cyproterone acetate|
223829754|NCT00849082|DRUG|goserelin acetate|
223829755|NCT00849082|RADIATION|radiation therapy|
223829756|NCT02932969|DRUG|BMS-986231|
223829757|NCT02932969|DRUG|BMS-986231 Placebo|
223829758|NCT02810691|DIETARY_SUPPLEMENT|Soluble fiber supplementation|Two different doses of psyllium powder will be diluted in 250 ml of orange-flavored water and drink in 5 minutes before breakfast.
223829759|NCT02810691|DIETARY_SUPPLEMENT|Placebo (for fiber supplementation)|Placebo will consist of 250 ml of orange-flavored water to be drink in 5 minutes before breakfast.
223829760|NCT04555915|OTHER|Monitoring of cerebral oxygenation|Modify cardio-respiratory support to avoid cerebral hypoxia
223829761|NCT04017702|DEVICE|Expiron respirator|Respiratory volume monitor (RVM) (ExSpiron, is a non-invasive FDA approved device that monitors minute ventilation (MV) and provides an early indication of respiratory status in non-intubated patients. The system consists of a lightweight monitor, a patient cable, and a disposable electrode PadSet, which detects changes in breathing.
223829762|NCT04350476|DIAGNOSTIC_TEST|VitalConnect Vital Sign Patch|"This patch provides continuous real-time monitoring of cardiac telemetry, heart rate, respiratory rate and oxygen saturation. Duration of monitoring is typically up to 7 days.~This patch is applied to the upper left side of the chest wall, attached with a hypoallergenic adhesive material. (This device is FDA approved for this indication)."
223829763|NCT03923218|OTHER|LL-37 levels in Gingival crevicular fluid|Collected gingival crevicular fluid
223829764|NCT03923218|OTHER|Serum Vitamin D3 levels|Collected serum
223829765|NCT03923218|OTHER|Clinical parameters|Recorded plague index, gingival index, probing depth, clinical attachment level
223829766|NCT00368862|DRUG|Ebixa (memantine hydrochloride)|
223829767|NCT00368862|DRUG|Cipralex (escitalopram)|
223829768|NCT03379714|DEVICE|WEB aneurysm embolization system|The WEB aneurysm embolization system is a class III device and consists of an implantable embolization device attached to a delivery device. The WEB is a mesh composed of single layers of braided nitinol tubes with platinum cores. The braids are held together by proximal and distal platinum/ iridium radiopaque markers.
223829769|NCT02546063|OTHER|Smartphone App|The GoCARB system is a smartphone application designed to support type 1 diabetic patients with carbohydrate counting by providing automatic, accurate and near real-time CHO estimation for non-packed foods.
223829770|NCT00199030|DRUG|Alemtuzumab (MabCampath)|
223829771|NCT00199030|DRUG|Cladribine|
223829772|NCT05444673|DRUG|Paprizumab combined with cisplatin and 5-FU|Patients with advanced temporal bone cancer were treated with pabulizumab combined with cisplatin and 5-FU
223829773|NCT02310126|DEVICE|etafilcon A (multi-focal)|Each subject will wear the soft contact lenses for 15 minutes then remove the lenses.
223829774|NCT02310126|DEVICE|etafilcon A (sphere)|Each subject will wear the soft contact lenses for 15 minutes then remove the lenses.
223829775|NCT06451575|DIAGNOSTIC_TEST|Blood collection|Blood collection
223829776|NCT01193543|DIETARY_SUPPLEMENT|calanus oil|1 gram twice daily
223829777|NCT01193543|DIETARY_SUPPLEMENT|olive oil|1 gram twice daily
223829778|NCT03680040|DIAGNOSTIC_TEST|Subjects previously implanted with a RESILIA aortic tissue valve.|Subjects to undergo multi-slice computed tomography and echocardiogram to assess predictors of valve durability in previously implanted Edwards aortic valves with RESILIA tissue.
223829779|NCT00590993|OTHER|MRI and MRSI|Compare treatment impact when using MRI and MRSI
223829780|NCT00227760|DRUG|Cediranib Maleate|Given PO
223829781|NCT00227760|PROCEDURE|Dynamic Contrast-Enhanced Magnetic Resonance Imaging|Correlative studies
223829782|NCT00227760|OTHER|Laboratory Biomarker Analysis|Correlative studies
223829783|NCT00227760|OTHER|Pharmacological Study|Correlative studies
223829784|NCT00832338|DRUG|Docetaxel with Cytoxan|Docetaxel 75 mg/m² plus cytoxan 600 mg/m² every 3 weeks for 6 cycles.
223829785|NCT00832338|DRUG|Dexamethasone|Dexamethasone 4 mg BID PO for 3 consecutive days starting 12-24 hours prior to each dose of docetaxel.
223829786|NCT00742105|DRUG|BGT226|
223829787|NCT02220686|BEHAVIORAL|Offer and Report Protocol|Physician advice to stop smoking, referral to state Quitline, and physician considers prescribing nicotine replacement therapy.
223829788|NCT04215393|DRUG|Conbercept eye drop|In the first stage, subjects will be receive Conbercept eye drop. In the second stage,subjests will revceive conbercept eye drop or placebo.
223829789|NCT04215393|DRUG|Placebo|In the second stage, subjects will be receive Conbercept eys drop or a placebo.
223829790|NCT05776082|OTHER|Questionnaire survey and specimen collection|Questionnaire survey, clinical follow-up and specimens collection.
223829791|NCT03781232|DEVICE|Prototype 0.3|Prototype 0.3 is a non-invasive glucose monitoring device using Raman spectroscopy
223829792|NCT03410914|DEVICE|Hemopatch|Application of hemopatch to the divided end of the pancreas during surgery.
223829793|NCT00239785|DRUG|FTY720|
223829794|NCT01578096|BEHAVIORAL|stress management|The study is a randomized, controlled,single-site, parallel group clinical trial comparing the effectiveness of CHW led diabetes education with CHW led diabetes education plus CHW led stress management in Latinos with Type 2 Diabetes.
223829795|NCT03860064|OTHER|Non intervention|Non
223829796|NCT04112472|DEVICE|EYESTAR 900|EYESTAR 900 is an optical biometry device used to create a geometrical representation of the eye by means of optical interferometry. The intervention are optical, non-contact examinations with the investigational device EYESTAR 900 and comparative device(s). Results of the examinations serve to compare the performance data of the investigational device with those of the comparative devices.
223829797|NCT00113893|DRUG|SCIO-469|SCIO-469 tablet will be administered orally at a dose of 30 mg thrice daily (90 mg per day) for 16 weeks. Participants with hematologic improvement at Week 16 and as per Investigator's discretion on clinical benefit from treatment will continue the treatment for additional 36 weeks.
223829798|NCT00113893|DRUG|SCIO-469|SCIO-469 tablet will be administered orally at a dose of 60 mg thrice daily (180 mg per day) for 16 weeks. Participants with hematologic improvement at Week 16 and as per Investigator's discretion on clinical benefit from treatment will continue the treatment for additional 36 weeks.
223829799|NCT00113893|DRUG|SCIO-469|SCIO-469 tablet will be administered orally at a dose of 90 mg thrice daily (270 mg per day) for 16 weeks. Participants with hematologic improvement at Week 16 and as per Investigator's discretion on clinical benefit from treatment will continue the treatment for additional 36 weeks.
223835596|NCT06088420|PROCEDURE|Intrathcal Morphine Group|intrathecal morphine (150 μg) in addition to standard spinal anesthetic drugs(10-12 mg 0.5% hyperbaric bupivacaine)
223829800|NCT00113893|DRUG|SCIO-469|SCIO-469 tablet will be administered orally at a dose of 120 mg thrice daily (360 mg per day) for 16 weeks. Participants with hematologic improvement at Week 16 and as per Investigator's discretion on clinical benefit from treatment will continue the treatment for additional 36 weeks.
223829801|NCT05092048|OTHER|questionnaire|PHQ-9 and GAD-7 questionnaire
223829802|NCT04005937|DIAGNOSTIC_TEST|H-reflex|Electrical stimulation of Group Ia afferent of muscle spindle
223829803|NCT02293174|DEVICE|Topcon TRC-NW400|Retinal Fundus Camera
223829804|NCT02293174|DEVICE|TRC-NW8|Retinal Fundus Camera
223829805|NCT02293174|DEVICE|TRC-NW400|Retinal Fundus Camera
223829806|NCT02293174|DEVICE|Canon-CR2|Retinal Fundus Camera
223829807|NCT02293174|DEVICE|Zeiss Visucam PRO|Retinal Fundus Camera
223829808|NCT04579120|DRUG|[11C]-Pittsburgh Compound B ([11C]PiB)|A dosage range between 6.0 - 20.0 mCi (222-740 MBq) is planned for \[11C\] PIB. A PET-certified medical professional will prepare and administer the \[11C\] PIB tracer. Prior to the administration, the dosage will be assayed in a dose calibrator and diluted with 0.9% sodium chloride (normal saline) up to a total 20 mL syringe volume. Participants will receive a maximum intravenous bolus injection of 20.0 mCi of \[11C\] PIB followed by a 10 mL 0.9% sodium chloride (normal saline) flush.
223829809|NCT04579120|DRUG|F 18 AV-1451 (Flortaucipir)|A dosage range between 6.5 - 10.0 mCi (240-370MBq) is planned for \[18F\] AV-1451. A PET-certified medical professional will prepare and administer the \[18F\] AV-1451tracer. Prior to the administration, the dosage will be assayed in a dose calibrator. The volume of 18F-AV-1451 dose should not be adjusted by adding normal saline to the syringe. Participants will receive a maximum intravenous bolus injection of 10.0 mCi of \[18F\] AV-1451 followed by a 10 mL flush of 0.9% sodium chloride (normal saline).
223829810|NCT05086822|DRUG|Irinotecan liposome|Irinotecan liposome
223829811|NCT05015660|DEVICE|Left bundle branch pacing lead (Select Secure 3830 lead)|Implantation of a left bundle branch pacing lead via sheath, to perform selective or non-selective pacing
223829812|NCT05015660|DEVICE|Right ventricular active fixation lead|Active fixation lead (standard)
223835597|NCT06088420|PROCEDURE|Quadratus Lumborum nerve block(QL) group|intrathecal morphine (150 μg) in addition to standard spinal anesthetic drugs (10-12 mg 0.5% hyperbaric bupivacaine) + bilateral QL block by injecting 20 ml of 0.25% isobaric bupivacaine bolus with 4 mg ) dexamethasone as an adjuvant
223829813|NCT03575689|DEVICE|Doyle Splint|Using Doyle splints following septoplasty is the standard of care and may help with stability of the septum in the immediate post op period. owever these splints are associated with morbidity in the post-op period. The quilting technique was developed to prevent complications and stabilize the septum. This study examines the efficacy of these splints in stabilizing the septum and preventing complications after septoplasty
223829814|NCT00855868|DRUG|florbetapir F 18|370 MBq (10 mCi), intravenous (IV) injection, single dose
223829815|NCT00855868|DRUG|[11C]-PIB|555 MBq (15 mCi), IV injection, single dose \[11C\]-PIB
223829816|NCT02439177|DEVICE|Blood glucose monitoring system (Omnitest 3)|
223829817|NCT02439177|DEVICE|Blood glucose monitoring system (Omnitest 5)|
223829818|NCT01622101|DIETARY_SUPPLEMENT|Thermogenic properties of Zantrex-3®|The present study was designed as a 2-arm randomised, placebo-controlled, double-blind crossover study. Each treatment was separated by \>7 d washout period. Both treatments were administered as tablets. The Zantrex-3® compound contained yerba maté, caffeine, guarana, damiana, green tea, kola nut, schizonepeta, piper nigrum, ginseng, maca root, and cocoa nut. The content of xantines (caffeine and caffeine-like stimulants) accounted for 365 mg per serving (2 capsules) or 1095 mg (6 capsules) if given as a daily dose. The placebo supplement contained rice flower and could not be distinguished from the Zantrex-3® compound with regard to colour, taste, smell or ap-pearance.
223829819|NCT02214823|DEVICE|FES-Cycling|
223829820|NCT02214823|OTHER|Standard Care|standard care physiotherapy including respiratory and rehabilitation with mobilisation activities such as sitting out of bed, marching on the spot, and mobility training.
223829821|NCT05769270|BEHAVIORAL|Peer Navigation and Coping Skills|Participants will receive 6 sessions of peer navigation and coping skills
223829822|NCT05769270|BEHAVIORAL|Treatment as Usual|Participants will receive referrals for PrEP and services
223829823|NCT04961736|OTHER|no intervention|This is an observation study, with no intervention
223829824|NCT01991249|OTHER|blood draw|
223829825|NCT03013686|PROCEDURE|Interval appendectomy|Laparoscopic appendectomy
223829826|NCT03013686|PROCEDURE|Follow-up with MRI|Abdominal MRI
223829827|NCT01948271|DRUG|Trichuris Suis Ova|During the treatment phase, study drug will be provided in a liquid form and will be administered every 2 weeks, starting with the Baseline visit, through Week 14.
223829828|NCT05251441|DIETARY_SUPPLEMENT|Breast Milk Fortifier supplements|Current information is recommended for breast milk supplementation in premature babies. However, there is no consensus on when it will start. For breast milk supplementation, we planned to supplement one group of our patients with enteral nutrition of 50 ml/kg/day and the other group when they reached 100 ml/kg/day.
223829829|NCT00932490|BEHAVIORAL|Nurse Coaching|Tailored adherence intervention that will be based on the particular needs of patients and advanced practice nurses will suggest individualized strategies to overcome barriers to adherence
223829830|NCT03324542|DRUG|Aflibercept [Eylea]|Anti-vascular endothelial growth factor (VEGF)
223829831|NCT02332330|DEVICE|VEST|
223829832|NCT00152490|DRUG|Certolizumab Pegol (CDP870)|
223835598|NCT06088420|PROCEDURE|Erector Spinae nerve block (ESP)group|intrathecal morphine (150 μg) in addition to standard spinal anesthetic drugs (10-12 mg 0.5% hyperbaric bupivacaine) + bilateral ESP block by injecting 20 ml of 0.25% isobaric bupivacaine bolus with 4 mg ) dexamethasone as an adjuvant
223835599|NCT01874093|DEVICE|The Ischemic Stroke System|SPG stimulation and standard of care
223835600|NCT01874093|DEVICE|Sham control|Sham stimulation and standard of care
223835601|NCT06275035|DRUG|Memantine Oral Tablet|Drug to preserve memory and neurocognitive dysfunction induced by radiation therapy
223829833|NCT03319186|PROCEDURE|EDIT Management|"EDIT management~1. Volumetric Pleural MRI for pre-aspiration pleural cavity volume~2. Large volume pleural aspiration with recording of intra-pleural pressure during aspiration~3. Volumetric Pleural MRI for post-aspiration pleural cavity volume~4. Computation of PEL250, defined as the rolling average of pleural elastance over the preceding 250ml aspirated.~   MaxPEL250 ≥ 14.5 cm H2O/L: allocated to 1st-line IPC MaxPEL250 \< 14.5 cm H2O/L: allocated to 1st-line TP~5. EDIT-directed 1st-line treatment to be delivered within 24 hours; if insufficient residual pleural fluid to allow standard Seldinger insertion technique then Boutin-type needle used for pneumothorax induction and guide wire insertion."
223829834|NCT03319186|PROCEDURE|Chest drain and talc pleurodesis|Intercostal chest drain insertion and talc slurry instillation according to British Thoracic Society guidelines
223829835|NCT01488864|BEHAVIORAL|Applied Relaxation (AR)|"AR is a technique influenced on cognitive behavioral therapy using coping mechanism and conditioning. AR focuses on muscle relaxation, where breathing is used for the conditioning of the relaxation. AR implies participation in 10 group sessions during a period of 12 weeks. A therapist will see the women assigned to AR in a group consisted of 6-8 women. The weekly sessions will last for 60 minutes each and are based on a scheme from Öst. The women will be told to practice each component daily.~During the first session a lecture about menopause and about theories of the mechanisms behind hot flashes will be given.~The aim of applying AR in view of coping with vasomotor symptoms will be discussed. The group is given a rationale of applying AR as a coping technique for handling sudden unanticipated symptoms by quick calming down, and thus gaining control over the situation."
223829836|NCT02803320|DRUG|SPF 50 Y65 110 (BAY 987516)|Subjects applied the assigned products to all sun-exposed areas of their face and body liberally and evenly, in accordance with instructions. Sun exposure was divided into two periods. Each period consisted of direct sun exposure (out of water; Cycle A) and water exposure (Cycle B). Cycles A and B were repeated two times before study closeout.
223829837|NCT05223842|BEHAVIORAL|Family Promoting Positive Emotions (F-PPE)|F-PPE is an 8-session dyadic intervention designed to enhance positive emotionality and buffer against the effects of stress on anhedonia in children. The intervention will be administered online through videoconferencing sessions with a clinician to mothers and their children.
223829838|NCT05223842|BEHAVIORAL|Written Information|Mothers assigned to the Written Information condition will receive email newsletters providing resources relevant to depression.
223829839|NCT01443429|DRUG|beraprost sodium(BPS)|
223829840|NCT02441946|DRUG|Abemaciclib|Administered orally
223829841|NCT02441946|DRUG|Loperamide|Administered orally
223829842|NCT02441946|DRUG|Anastrozole|Administered orally
223829843|NCT00974636|DIETARY_SUPPLEMENT|Low Salt Diet|Dietary sodium restriction of ≤2.0 g/day or ≤ 85 mmol/day
223829844|NCT00974636|DIETARY_SUPPLEMENT|Usual Salt Diet|Usual salt intake (approximately \>180-200 mmol/day in the average American diet).
223829845|NCT00074763|BIOLOGICAL|Platelet Transfusion|All receive both platelets frozen with Thrombosol and fresh random platelets (FRP), order received is randomized, i.e. receive either FRP then Thrombosol or Thrombosol then FRP.
223829846|NCT05034224|DEVICE|Swan-Ganz catheter placed in the coronary sinus - deflated|A normal Swan-Ganz catheter will be advanced in the coronary sinus. The Balloon will be kept deflated during sham intervention. The index of microvascular resistances will be measured using the Abbott Pressure Wire X as per instructions for use durng both interventions.
223829847|NCT05034224|DEVICE|Swan-Ganz catheter placed in the coronary sinus - inflated|A normal Swan-Ganz catheter will be advanced in the coronary sinus. The Balloon will be inflated to obtain coronary sinus occlusion during the active intervention. The index of microvascular resistances will be measured using the Abbott Pressure Wire X as per instructions for use durng both interventions.
223829848|NCT03237962|DEVICE|High Flow Nasal Cannula|High Flow Nasal Cannula (HFNC) is an oxygen device that increases oxygenation and washes out CO2 within the dead space, it was also clinically used to correct hypoxemia, hypercapnia and respiratory failure.By providing flow rate that is similar to or higher than the patient's inspiratory flow, HFNC is able to provide ventilatory support. To produce stable oxygen concentration, HFNC entrains less air in order to reach the preset value.
223829849|NCT03237962|DEVICE|Nasal Cannula|Nasal cannula is an oxygen therapy device that has been commonly used as treatment for patients with hypoxemia. With the adjustable flow of 1-6Lpm, the concentration of the oxygen differs as the breathing pattern of the patient changes.
223829850|NCT04932720|BEHAVIORAL|chıld yoga programme|"Yoga sessions were in the form of 6 sessions and were held as 2 sessions per week. The program was given by an expert yoga instructor who has an international Yoga Alliance approved child and adolescent yoga certificate.Consisting of the components of Hatha Yoga (HY), one of the yoga types known and widely practiced all over the world; Sessions consisting of asanas (yoga postures), pranayamas (breathing techniques), relaxation, relaxation exercises and meditation were prepared. Sessions are 45 minutes; For those who are new to yoga for the first 15 minutes; mental and physical preparation; asanas, pranayamas were taught, drama followed by breathing exercises and asanas in the next 30 minutes, relaxation techniques (imaginary journey) and meditation in the last 15 minutes."
223829851|NCT04314063|OTHER|nasal swap|nasal swap to detect prevalence of staph aureus in food handlers
223829852|NCT04392440|BEHAVIORAL|DIAL-SDM|Communication intervention for nephrologists and coaching intervention for patients.
223829853|NCT04392440|OTHER|usual care|regular nephrology care
223829854|NCT02111213|BEHAVIORAL|Virtual Advisor|The virtual advisor is named Carmen. She is an animated, computer-generated figure that speaks to participants and gives advice and support for physical activity.
223829855|NCT02111213|BEHAVIORAL|Promotora for physical activity|A promotora is a trained, lay health worker. Promotoras will be trained and supervised to provide advice, support and guidance to people to encourage them to be more physically active. They work with people face to face and by telephone to offer support and advice.
223829856|NCT03190863|BEHAVIORAL|Motor imagery combined with neurofeedback (MINF)|"7 individuals with C6-C7 tetraplegia randomize in the experimental group consisting in motor imagery practice combined with visual neurofeedback (NF - i.e. performance of the imagined movement).~Intervention consists in a total of 15 sessions repeated 3 times a week and lasting 5 weeks. Each session will last 45 minutes. An experienced physical therapist supervised all sessions. After each imagined movement, the NF based on brain activity measured by electroencephalography is display on a screen."
223829857|NCT03190863|BEHAVIORAL|Motor imagery (MI)|"7 individuals with C6-C7 tetraplegia randomized in the active comparator group consisting in motor imagery practice alone without visual NF. This means that the performance of the imagined movement is not displayed to the participants.~Intervention consists in a total of 15 sessions repeated 3 times a week and lasting 5 weeks. Each session will last 45 minutes. An experienced physical therapist supervised all sessions."
223829858|NCT03190863|BEHAVIORAL|Control (C)|"7 individuals with C6-C7 tetraplegia randomized in the sham comparator group consisting in imagining geometric shapes by visualization. Shapes are successively displayed on a screen.~Intervention consists in a total of 15 sessions repeated 3 times a week and lasting 5 weeks. Each session will last 45 minutes. An experienced physical therapist supervised all sessions."
223829859|NCT04876885|OTHER|Educational video|Three two-minute educational videos about COVID-19 vaccine development and dissemination
223829860|NCT06477367|OTHER|Video-Based Breathing Exercises|Researchers will present a 5-7 minute instructional video aimed at helping participants recall the technique for performing the exercises. These instructional videos will be sent to the researchers' mobile phones via WhatsApp. Participants will be instructed to perform the exercises three times a day for 15 minutes each, for a period of 30 days. To encourage regular exercise, participants will be provided with an exercise diary, and researchers will send reminder SMS messages at the same time every day. The control group will receive the clinic's routine dyspnea care protocol. After thirty days, final tests will be administered to both groups, and the research will be concluded.
223829861|NCT01581879|DRUG|Ziprasidone Hydrochloride|Ziprasidone HCL Capsules, 20 mg
223829862|NCT05706181|OTHER|Home-based leg heat therapy|Participants will be required to perform 8 weeks of leg heat therapy using water-perfused pants 4 times per week, with each session lasting 60 min. Skin temperature will be heated to about 40 °C. The pants heating system (consisting of pants and a water circulator/heater) can finely and uniformly control these designated skin temperatures. Participants will be randomly assigned to a group and provided with the pant heating system as well as a log book in which they are required to track the dates of each session. Participants will also measure their blood pressure and heart rate prior to, during, and immediately after each heating session using a portable oscillometric device provided by our laboratory.
223835602|NCT05977946|DEVICE|Volta System|The Volta System is a wearable, battery-operated, neurostimulation system designed to deliver tAN or taVNS. The device will be used to deliver two 30-minute sessions of active or sham therapy according to the participant's randomization group (taVNS or tAN).
223835603|NCT04221477|DRUG|Obinutuzumab|Obinutuzumab will be administered by IV infusion at a dose of 1000 mg at Baseline and Weeks 2, 24, 26, 50 (group 2: placebo), and 52 and subsequently from Week 80 and every 6 months thereafter, based on response.
223835604|NCT04221477|DRUG|MMF|MMF willl be administered at a target dose of 2.0 - 2.5 g/day in divided doses through Week 80.
223829863|NCT05706181|OTHER|Home-based sham therapy|Participants will be required to perform 8 weeks of leg heat therapy using water-perfused pants 4 times per week, with each session lasting 60 min. Skin temperature will be heated to about 40 °C. The pants heating system (consisting of pants and a water circulator/heater) can finely and uniformly control these designated skin temperatures. Participants will be randomly assigned to a group and provided with the pant heating system as well as a log book in which they are required to track the dates of each session. Participants will also measure their blood pressure and heart rate prior to, during, and immediately after each heating session using a portable oscillometric device provided by our laboratory.
223829864|NCT05956938|DEVICE|Stroboscopic Glasses|"A one-hour training session will be held, divided into 2 30-minute sessions over 2 days. Each session will take into account a gradual increase in the difficulty of the task, divided into three visuomotor and anticipation components (ball size, type of trajectory and distance from the stimulus).~The training sessions will consist of 2 series, and will be based on passing a ball between two people. Every 60 passes the flicker level of the glasses will increase, starting with level 1 (6hz) and ending at level 6 (1.75hz)"
223829865|NCT05956938|DEVICE|Action Video Game|A one-hour training session will be held, divided into 2 30-minute sessions over 2 days. Each session will take into account an increase in the difficulty of the task gradually based on the nature of the video game. The video game selected will be ContraIII: Alien Wars, from the Nintendo Mini Classic console.
223829866|NCT00095030|DRUG|muraglitazar|
223829867|NCT01629680|DRUG|Moxaverine|Moxaverine-hydrochloride, coated tablets containing 150 mg moxaverine (Kollateral forte, Ursapharm. Saarbrücken, Germany), dosage: 900 mg, administrated per os in three equal doses of 300 mg at two hour intervals
223829868|NCT01629680|DRUG|Placebo|coated tablets identical in number and appearance as the study drug
223829869|NCT02314741|PROCEDURE|POEM Procedure|The procedure is performed under anesthesia.The procedure involves endoscopic electrosurgical dissection with an Olympus triangular tip knife.The myotomy is usually \~6cm long \& averages 8-10cm. After the myotomy is performed the scope is withdrawn \& inserted into the lumen to inspect the mucosa, ensure mucosal integrity \& confirm easy passage of the endoscope through the LES consistent with an adequate myotomy. The mucosal entry site is usually 2-3cm long, \& is closed with 5-10 endoscopic clips. Patients are hospitalized after procedure for observation.The patient is given IV-nutrition until post-operative day 1. An esophagram is obtained. If no loss of mucosal integrity or leak is noted, a liquid diet is started, which is continued for several days before initiating a solid diet.
223829870|NCT06435949|DRUG|Fentanyl (as Citrate)|intravenous anesthesia with propofol with fentanyl (group Fentanyl) and propofol with oxycodone (group Oxycodone)
223829871|NCT03237013|BEHAVIORAL|Facial Morphing Intervention|Participants assigned to this condition were exposed to facial morphing technology that displays the progression of facial-ageing up to 72years, both with and without damage from UV exposure.
223829872|NCT03237013|BEHAVIORAL|Mindfulness Intervention|Participants assigned to this condition engaged in a self-guided mindfulness intervention audio tape. This intervention instructed participants to pay attention to the present moment, with a non-judgemental stance. For example, participants were instructed to notice their breath, thoughts, feelings, physical sensations, and to internally describe them, without passing judgement
223829873|NCT01359618|DRUG|TC-5214|Single dose, oral tablets
223829874|NCT01359618|OTHER|Placebo comparator|Single dose, oral tablets
223829875|NCT01359618|DRUG|Moxifloxacin|Single dose, oral encapsulated tablet
223829876|NCT01359618|OTHER|Moxifloxacin placebo comparator|Single dose, oral encapsulated tablet
223829877|NCT04266743|DEVICE|FeetMe Monitor|"For gait parameters' evaluation, the investigator asks the participant to move in a straight line over a 10-meter mat. The participant had to start the feet in line and then start walking at a comfortable speed. During this time, the investigator records the gait parameters from the FeetMe Monitor® and Gaitrite® system.~An operator asked the patient to repeat 3 trials. The same sequence was repeated by three other operators. The same measurement is done 7 days later.~A questionnaire is given to assess the ergonomics of the device"
223829878|NCT06228729|PROCEDURE|Endotracheal intubation|Inserting endotracheal tube into the trachea
223829879|NCT01694992|OTHER|Early mobilization|The Intervention Group - Early Mobilization - will follow the early physiotherapy program within the first 24 - 48 hours after acute ischemic stroke, five times per week for 30 minutes plus time to spent out of bed (sitting).
223829880|NCT02933463|OTHER|Embrace Wetbond|not require an additional bonding agent hydrophilic, fluoride releasing
223829881|NCT02933463|OTHER|Clinpro sealant|
223829882|NCT03300089|PROCEDURE|General anaesthesia|General anaesthesia
223829883|NCT03300089|PROCEDURE|Regional anaesthesia|Regional anaesthesia
223829884|NCT02240719|DRUG|everolimus|Given PO
223829885|NCT02240719|DRUG|bendamustine hydrochloride|Given IV
223829886|NCT03097003|DRUG|Apremilast|Psoriasis patients treated with Otezla® (Apremilast) in Belgium
223829887|NCT00210119|DRUG|Glivec|
223829888|NCT02554630|OTHER|Adjuvant|Blood will be incubated, ex-vivo, with one of the adjuvant therapies or no adjuvant and then, using microfluidic techniques the immune genomic profile and the functional capacity of immune cells will be assessed.
223829889|NCT02554630|OTHER|Blood Collection|Blood collection will be performed on all groups.
223829890|NCT02507882|BIOLOGICAL|IL28B Polymorphism|SNP rs12979860 and 4803217 will be determined in whole blood by allelic discrimination using specific probes by real time PCR.
223829891|NCT02507882|BIOLOGICAL|miRNA quantification|"RNAs will be extracted from serum using miRNeasy Mini Kit (Quiagen) according to the manufacturer's instruction.~The RNA purity will be assessed by the RNA concentration and quantified by NanoDrop ND-1000 (Nanodrop, United States).~cDNA will be obtained by miScript II Reverse Transcription Kits (Quiagen) A Preamplification will be performed using miScript PreAMP PCR Kits (Quiagen) Real Time PCRarray will be done using miScript miRNA PCR Arrays, with SYBR Green PCR Master Mix (Quiagen)."
223829892|NCT03971812|BIOLOGICAL|Blood sample|A blood sample of two 10 mL ethylenediaminetetraacetic (EDTA) tubes will be taken at the time of the visit. This sample will be centrifuged for isolation of peripheral blood mononuclear cells (PBMC).
223835605|NCT04221477|DRUG|Prednisone|Prednisone 0.5 mg/kg/day (maximum 60 mg/day) will be started on Day 2. Beginning on Day 15, prednisone will be tapered to 5 mg/day and continued until Week 80.
223829893|NCT01018641|BIOLOGICAL|SA3Ag vaccine|"In stage 1, each subject will receive 1 injection (0.5 mL) of one of the following doses:~Low dose level 10 μg of CP5 and CP8 and 20 μg of rClfAm Mid-dose level 30 μg of CP5 and CP8 and 60 μg of rClfAm High dose level 100 μg of CP5 and CP8 and 200 μg of rClfAm~In stage 2 the subject will receive 0.5 mL IM of the same dose level he/she received in stage 1."
223829894|NCT01018641|PROCEDURE|Blood draw|Blood for immunogenicity will be taken at timepoints throughout stage 1 and stage 2. Blood for hematology will be done in a select subset of subjects in stage 1.
223829895|NCT01018641|PROCEDURE|Colonization swab samples|Colonization swabs will be taken at timepoints throughout stage 1 and stage 2.
223829896|NCT01018641|BIOLOGICAL|SA3Ag followed by Placebo|"In stage 1, each subject will receive 1 injection (0.5 mL) of one of the following doses:~Low dose level 10 μg of CP5 and CP8 and 20 μg of rClfAm Mid-dose level 30 μg of CP5 and CP8 and 60 μg of rClfAm High dose level 100 μg of CP5 and CP8 and 200 μg of rClfAm~In stage 2 the subject will receive one injection of 0.5 mL IM of the placebo."
223829897|NCT01018641|PROCEDURE|Blood draw|Blood for immunogenicity will be taken at timepoints throughout stage 1 and stage 2. Blood for hematology will be done in a select subset of subjects in stage 1.
223829898|NCT01018641|PROCEDURE|Colonization swab samples|Colonization swabs will be taken at timepoints throughout stage 1 and stage 2.
223829899|NCT01018641|BIOLOGICAL|Placebo|In both stage 1 and stage 2, recipients will receive one injection (0.5 mL) IM of 150 mM (isotonic) NaCl for a total of 2 injections throughout the study.
223829900|NCT01018641|PROCEDURE|Blood draw|Blood for immunogenicity will be taken at timepoints throughout stage 1 and stage 2. Blood for hematology will be done in a select subset of subjects in stage 1.
223829901|NCT01018641|PROCEDURE|Colonization swab samples|Colonization swabs will be taken at timepoints throughout stage 1 and stage 2.
223829902|NCT01018641|BIOLOGICAL|SA3Ag with no booster in stage 2|"In stage 1, each subject will receive 1 injection (0.5 mL) of one of the following doses:~Low dose level 10 μg of CP5 and CP8 and 20 μg of rClfAm Mid-dose level 30 μg of CP5 and CP8 and 60 μg of rClfAm High dose level 100 μg of CP5 and CP8 and 200 μg of rClfAm~In stage 2 the subject will receive no vaccine."
223829903|NCT01018641|PROCEDURE|Blood draw|Blood for immunogenicity will be taken at timepoints throughout stage 1 and stage 2. Blood for hematology will be done in a select subset of subjects in stage 1.
223829904|NCT01018641|PROCEDURE|Colonization swab samples|Colonization swabs will be taken at timepoints throughout stage 1 and stage 2.
223829905|NCT01018641|PROCEDURE|Placebo with no booster in stage 2|"In stage 1, recipients will receive one injection (0.5 mL) IM of 150 mM (isotonic) NaCl.~In stage 2 the subject will receive no vaccine."
223829906|NCT01018641|PROCEDURE|Blood draw|Blood for immunogenicity will be taken at timepoints throughout stage 1 and stage 2. Blood for hematology will be done in a select subset of subjects in stage 1.
223829907|NCT01018641|PROCEDURE|Colonization swab samples|Colonization swabs will be taken at timepoints throughout stage 1 and stage 2.
223829908|NCT00003329|GENETIC|gene mapping|
223829909|NCT00988351|DEVICE|Continuous positive airway pressure|continuous positive airway pressure determined by polysomnography titration
223829910|NCT00988351|DEVICE|Auto-adjusting positive airway pressure treatment|Pressure range 4-18 centimeters of water (cm H2O)
223829911|NCT00431639|BEHAVIORAL|Animal Assisted Therapy|Every subject will be exposed to both treatment and comparison conditions.
223829912|NCT02136498|DRUG|Varenicline|Standard 12 week course of varenicline, provided in both arms
223829913|NCT02136498|BEHAVIORAL|Cognitive-behavioral self-help|Standard self-help education for smoking cessation, delivered via mobile-optimized website accessible via smartphone.
223829914|NCT02136498|BEHAVIORAL|MyMAP (My Mobile Advice Program)|Same standard self-help intervention as in control arm + automatically-tailored support and advice for managing nicotine withdrawal symptoms + secure messaging with cessation counselor
223829915|NCT04844918|DRUG|Tirzepatide|Administered SC
223829916|NCT04844918|OTHER|Placebo|Administered SC
223829917|NCT03477786|COMBINATION_PRODUCT|drug adjustment and behavioral modification|anti-hypertension drug prescription by physician and case management by health educator
223829918|NCT03653663|DRUG|Simvastatin 20 mg|Subjects are treated with 20 mg simvastatin for 8 weeks
223829919|NCT03653663|DRUG|Placebo Oral Tablet|Subjects are treated with placebo for 8 weeks
223829920|NCT01684995|BEHAVIORAL|Brief physician advice|Brief physician advice to quit smoking
223829921|NCT01684995|DRUG|nicotine patch|nicotine patch
223829922|NCT01684995|BEHAVIORAL|Individually Tailored Behavioral Skills training|Individually tailored behavioral skills training for smoking cessation
223829923|NCT01971190|DRUG|Intravitreal Aflibercept injection|"2mg intravitreal Aflibercept(Eylea) injection at baseline, at 1 month, and at 2 month.~At 3 month, 4 month, 5 month, and 6 month, PRN treatment of aflibercept injection or half-fluence photodynamic therapy may be done, if one of following conditions is fulfilled.~The PRN treatment method was decided by investigator's discretion.~Of patient who had persistent intra- or subretina fluid on SD-OCT~1. Central subfield thickness is not decreased to more than 50 micrometer compared with baseline central subfield thickness~2. Best-corrected ETDRS letter score dose not increased more than 5 letters than baseline (because of the persistent CSC).~3. Central subfield thickness is thicker than the previous exam~4. BCVA letter score is worse than the previous exam (because of the persistent CSC)"
223829924|NCT01971190|DRUG|Sham injection|"Sham injection at baseline, at 1 month, and at 2 month.~At 3 month, 4 month, 5 month, and 6 month, PRN treatment of aflibercept injection or half-fluence photodynamic therapy may be done, if one of following conditions is fulfilled.~The PRN treatment method was decided by investigator's discretion.~Of patient who had persistent intra- or subretina fluid on SD-OCT~1. Central subfield thickness is not decreased to more than 50 micrometer compared with baseline central subfield thickness~2. Best-corrected ETDRS letter score dose not increased more than 5 letters than baseline (because of the persistent CSC).~3. Central subfield thickness is thicker than the previous exam~4. BCVA letter score is worse than the previous exam (because of the persistent CSC)"
223829925|NCT01971190|PROCEDURE|Half-fluence photodynamic therapy|"At 3 month, 4 month, 5 month, and 6 month, PRN treatment of aflibercept injection or half-fluence photodynamic therapy may be done, if one of following conditions is fulfilled.~The PRN treatment method was decided by investigator's discretion.~Of patient who had persistent intra- or subretina fluid on SD-OCT~1. Central subfield thickness is not decreased to more than 50 micrometer compared with baseline central subfield thickness~2. Best-corrected ETDRS letter score dose not increased more than 5 letters than baseline (because of the persistent CSC).~3. Central subfield thickness is thicker than the previous exam~4. BCVA letter score is worse than the previous exam (because of the persistent CSC)"
223829926|NCT03209401|DRUG|Niraparib|an oral PARP inhibitor
223829927|NCT03209401|DRUG|Carboplatin|a platinum-based injection
223829928|NCT04055168|DRUG|AZD6615|AZD6615 (dose 1, dose 2, or dose 3) will be administered as a single dose to the randomized subjects.
223829929|NCT04055168|DRUG|Placebo|Placebo (dose 1, dose 2, or dose 3) will be administered as a single dose to the randomized subjects.
223829930|NCT03853122|OTHER|Best current practice exercise programme|"Therapeutic Physical Exercise programme based on the protocol of Afredson (for Achilles and patellar tendinopathies) and LEAP (for gluteal tendinopathy).~Achilles tendinopathy: ALFREDSON ECCENTRIC PROTOCOL: 3 sets of 15 repetitions of two eccentric exercises~Patellar tendinopathy: ALFREDSON ECCENTRIC PROTOCOL: 3 sets of 15 repetions of one eccentric exercise~Gluteal Tendinopathy: EXERCISE LEAP PROTOCOL: an exercise programme divided into stages with progression in different exercises, volumes and loads"
223829931|NCT03853122|OTHER|Experimental exercise programme|Therapeutic Physical Exercise programme structured in five stages oriented to specific neuromuscular adaptations based on the characteristics of the neuromuscular system, once daily, three times/week, sets, repetitions and load based on individually performed tests.
223829932|NCT01693003|DRUG|Indacaterol|150 µg d.o. during the first 3 weeks
223829933|NCT01693003|DRUG|Tiotropium|150 µg d.o. during 3 weeks
223829934|NCT01448421|DEVICE|Keystone Heart Embolic Deflection Device|The Keystone Heart Embolic Deflection Device is used in the aortic arch to deflect and to reduce embolic material (debris/thrombus) to the cerebral/carotid arteries during endovascular procedures.
223829935|NCT04800523|DEVICE|UroMonitor System|Implantable device to wirelessly and without catheters monitor the neurogenic bladder on an ambulatory basis
223829936|NCT00240526|BIOLOGICAL|Engerix™ -B|3 (Groups A and C) or 4 (Groups B and D) intramuscular injections during the primary study
223829937|NCT00240526|BIOLOGICAL|Hepatitis B immunoglobulin (HBIg)|1 intramuscular injections at birth (primary study)
223829938|NCT02976597|DRUG|Bupivacaine 0.25% 20ml on each side Sonar guided TAB|Bupivacaine 0.25% 20ml on each side Sonar guided TAP block. After careful aspiration injection of 20ml of 0.25% bupivacaine will be performed and hypoechoic layer will be detected on ultrasound then the maneuver will be repeated on the other side
223829939|NCT02976597|DRUG|Morphine 10mg|Morphine 10mg will be added to bupivacaine in sonar guided- TAP block divided into 5mg on each side.
223829940|NCT02976597|DRUG|Morphine 15mg|Morphine 15mg will be added to bupivacaine in sonar guided- TAP block divided into 7.5mg on each side.
223829941|NCT01908673|BEHAVIORAL|HRV biofeedback|
223829942|NCT01908673|BEHAVIORAL|ASTM|
223829943|NCT03550586|OTHER|Questionaires|Parturients will be assed for postpartum depression using the Edinburgh Postnatal Depression Scale (EPDS)translated into Hebrew . They will also be assed for PTSD using the validated PTSD questionnaire . Additionally in order to examine long term risk for chronic pain and backache parturients will be assed for persistent pain using the validated Brief Pain Inventory questionnaire ,and the validated Oswestry low back pain questionnaire .
223829944|NCT06489054|OTHER|Peer education|An initial assessment will be carried out to determine the socioeconomic, demographic profile and dental data and baseline data on literacy and attitudes related to oral health through questionnaires, after which participants will be invited to participate in a cycle of oral health education activities for three months on the experimental group (peer-based education). After the experimental stage, the literacy and attitudes questionnaires related to oral health will be reapplied, so that a comparative analysis can be carried out within and between groups.
223829945|NCT06489054|OTHER|Conventional education|An initial assessment will be carried out to determine the socioeconomic, demographic profile and dental data and baseline data on literacy and attitudes related to oral health through questionnaires, after which participants will be invited to participate in a cycle of oral health education activities for three months on the control group (dentist lecture). After the experimental stage, the literacy and attitudes questionnaires related to oral health will be reapplied, so that a comparative analysis can be carried out within and between groups.
223829946|NCT02861677|OTHER|pharmaceutical care|
223829947|NCT02307110|OTHER|cross-sectional observation|cross-sectional opthalmic examination
223829948|NCT01716208|DRUG|Ofatumumab + Fresh Frozen Plasma|
223829949|NCT00679484|DRUG|olmesartan medoxomil + candesartan cilexetil placebo|Dosage form: tablet; frequency: daily; duration: 24 weeks
223829950|NCT00679484|DRUG|olmesartan medoxomil placebo + candesartan cilexetil|Dosage form: tablets; frequency: daily; duration: 24 weeks
223829951|NCT02029040|DRUG|3% Hypertonic Saline|Within 5-15 minutes following the administration of the study drug, the Respiratory Distress Assessment Instrument (RDAI) score will be reassessed and study interventions are complete. The patient will be observed for one hour in the emergency department (ED). However, further treatments may be started immediately upon discretion of the treating physician. If the patient is discharged home study PI and/or research assistant will call the parents 7 days from the ED visit to check the number of visits to their primary doctor and/or EDs due to same illness.
223829952|NCT02029040|DRUG|0.9 % normal saline|Within 5-15 minutes following the administration of the study drug, the Respiratory Distress Assessment Instrument (RDAI) score will be reassessed and study interventions are complete. The patient will be observed for one hour in the emergency department (ED). However, further treatments may be started immediately upon discretion of the treating physician. If the patient is discharged home study PI and/or research assistant will call the parents 7 days from the ED visit to check the number of visits to their primary doctor and/or EDs due to same illness.
223829953|NCT01061918|DEVICE|Tecnis MF|20 patients in the Tecnis MF group.
223829954|NCT01061918|DEVICE|ReSTOR|20 patients in the ReSTOR group.
223829955|NCT02035813|DRUG|Ribociclib|Ribociclib/Everolimus in combination with endocrine therapy
223829956|NCT02035813|DRUG|Eribulin|
223829957|NCT01910727|BEHAVIORAL|Together on Diabetes-Hopkins|The Johns Hopkins Center for American Indian Health, with support from Bristol-Myers Squibb Foundation, Inc. is adapting a Family Health Coach model for diabetes prevention with four southwestern tribal communities. Specifically, Johns Hopkins Center for American Indian Health has designed a paraprofessional delivered pilot intervention aimed at improving the prevention and management of type 2 diabetes among American Indian youth. For Youth Participants, the pilot intervention consists of 12 sessions delivered during a 6-month intervention phase, plus 6 check-ins delivered during a 6-month follow-up phase. For Support Persons, the pilot intervention consists of 4 family skill building sessions delivered during the first 4 months of the Youth Participant's intervention phase.
223829958|NCT05900219|DRUG|HL-085+Vemurafenib|The treatment regimen was HL-085 9mg BID+ Vemurafenib 720mg BID oral administration for 21 days per cycle. The primary efficacy endpoint in this study was the ORR assessed by the Independent Review Committee (IRC) according to the RECIST 1.1
223829959|NCT01017653|DRUG|Irinotecan|Irinotecan: for those patients on an enzyme-inducing anti-epileptic drug (EIAED), irinotecan will be dosed at 340 mg/m2 every other week. For those not on an EIAED, irinotecan will be dosed at 125 mg/m2. Treatment on both drugs will continue until tumor progression or unacceptable toxicity.
223829960|NCT01017653|DRUG|Panitumumab|Panitumumab, 6 mg/kg, as an intravenous infusion every other week. Treatment on both drugs will continue until tumor progression or unacceptable toxicity.
223829961|NCT00211341|DIETARY_SUPPLEMENT|Vitamin A|Weekly single oral dose 7000 micrograms
223829962|NCT00862953|DIETARY_SUPPLEMENT|Normal protein energy-restricted|Normal protein diet energy restricted
223829963|NCT00862953|DIETARY_SUPPLEMENT|High protein energy-restricted|High protein diet, with either low or normal carbohydrate content
223829964|NCT01042990|OTHER|Adaptive Physical Activity|Structured gait, balance, and progressive walking program performed in a group gym setting 3x/week for 6 months
223829965|NCT00846833|BIOLOGICAL|Haploidentical NK cell|"1. Collection of PBMCs by leukapheresis~2. CD3+ depletion of apheresis product using CliniMACS®"
223829966|NCT00363896|DRUG|Aclidinium bromide|Aclidinium bromide 200 μg once-daily via inhalation via the Eklira Genuair® inhaler: 1 puff in the morning for 52 weeks
223829967|NCT00363896|DRUG|Placebo|Placebo once-daily via inhalation: 1 puff in the morning for 52 weeks
223829968|NCT05142410|DIAGNOSTIC_TEST|Analysis of post-translational histone modifications via mass spectrometry|"During the GrossHist study (NCT04205383), only 3 post-translational histone modifications available in ELISA at the time were quantified thanks to a collaboration with the VOLITION™ company \[Bouvier and Fortier et al. 2021\]. The development of a new mass spectrometry approach based on nucleosome enrichment of plasma, developed by collaborators at VOLITION™, has made it possible to consider the description of all post-translational histone modifications (about 40 post-translational modifications involving histones H2A, H2B, H3 and H4)."
223829969|NCT05833243|OTHER|modified diaphragmatic training|Modified diaphragmatic strength training prescriptions will be given based on the result of baseline assessment. The intensity is 60% from the maximum respiratory muscle strength from baseline and weekly remeasurement. Participants are asked to come for weekly follow-up and commit to do at least 20 sessions of exercise. The training is under supervision of physical medicine and rehabilitation specialist.
223829970|NCT05833243|OTHER|standard diaphragmatic training|"standard diaphragmatic strength training prescriptions will be given as daily routine, 3 times a day.~Participants are asked to come for weekly follow-up and commit to do at least 20 sessions of exercise. The training is under supervision of physical medicine and rehabilitation specialist."
223829971|NCT02351882|DRUG|Nabilone|Participants randomized to nabilone treatment arm, will undergo a one-week placebo washout, followed by 6 weeks of nabilone treatment (weeks 1-6). Participants will then receive a one-week placebo washout (week 7), before receiving 6 weeks of placebo treatment (weeks 8-14).
223829972|NCT02351882|DRUG|Placebo|Participants randomized to placebo arm, will undergo a one-week placebo washout, followed by 6 weeks of drug matched placebo (weeks 1-6). Participants will then receive a one-week placebo washout (week 7), before receiving 6 weeks of nabilone treatment (weeks 8-14).
223829973|NCT03422458|DEVICE|Alveolar Ridge Preservation|Insertion of a bone substitute material (BioOss Collagen) within the bony envelope at least to the level of the palatal/ lingual bone plate. Adaptation of a collagen matrix (Mucograft Seal) to the soft tissue borders.
223829974|NCT03657264|DRUG|P03277 0.1 mmol/kg|Single intravenous bolus injection at 2 mL/sec
223829975|NCT03657264|DRUG|Moxifloxacin 400mg|One tablet per os
223829976|NCT03657264|DRUG|NaCl 0.9%|Single intravenous bolus injection at 2 mL/sec
223829977|NCT03657264|DRUG|P03277 0.3 mmol/kg|Single intravenous bolus injection at 2 mL/sec
223829978|NCT02385578|OTHER|an educational intervention|"the first step of the train the trainer plan(TTT) ,which including the diagnosis and operation hand in hand teach by Professor Yano Takeshiin,and the case discussion,and so on"
223829979|NCT03555604|DIAGNOSTIC_TEST|Gastric ultrasound|Gastric ultrasound to measure antrum cross sectional area
223829980|NCT02619227|OTHER|Livelihood intervention|Participants will receive a livelihood intervention package consisting of a orientation and training and a loan package of chickens and associated implements to create poultry microenterprises.
223835606|NCT04221477|DRUG|Placebo|Placebo matching obinutuzumab will be administered by IV infusion at baseline and Weeks 0, 2, 24, 26, 50 and 52 and subsequently from Week 80 and every 6 months thereafter based on response.
223835607|NCT04221477|DRUG|Methylprednisolone|Methylprednisolone 80 mg IV will be administered as predmedication prior to infusions.
223835608|NCT04221477|DRUG|Acetaminophen|Acetaminophen 650-1000 mg will be administered as premedication prior to infusions.
223829981|NCT06420674|BEHAVIORAL|Unified Protocol for Transdiagnostic Treatment of Emotional Disorders|"The Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders is a psychological intervention that focuses on a wide range of emotional disorders (i.e., anxiety, depression and related disorders). It allows care for comorbid disorders, subclinical or unspecified symptoms reducing associated costs and improving response to treatment.~In our study, the Unified Protocol preventive program will be applied throughout 10 online modules. Women will have access to a web-page (moodle version) that includes audiovisual materials (e.g., written manual, videos, editable registers) and psychological assessments."
223829982|NCT00924469|DRUG|Abiraterone|Abiraterone acetate tablets will be administered orally at a total dose of 1000 milligram (mg) per day at least 1 hour before a meal or 2 hours after a meal for 24 weeks in Group 1 and from Week 13 to Week 24 for Group 2.
223829983|NCT00924469|DRUG|Leuprolide|Leuprolide acetate will be administered at a dose of 22.5 mg (dose adjusted as per Investigator's discretion) as intramuscular injection (injection of a substance into a muscle) once every 12 weeks in Group 1 and Group 2.
223829984|NCT00924469|DRUG|Prednisone|Prednisone tablets will be administered orally as 5 mg once daily for 24 weeks in Group 1 and from Week 13 to Week 24 for Group 2.
223829985|NCT04913818|BEHAVIORAL|BUDPA Program|The overall program includes 12 weekly 1-hour training class. Each session starts with a 10-minute warm-up period using stretching exercise and stationary mobilizing exercise for trunk and limb joints at both upper and lower bodies (e.g. shoulders, elbows, wrists, hips, knees and ankles), and followed by a session of four to six selected partnering exercise, with duration increase gradually from 20 minutes to 40minutes in four weeks' time. The Borg Rate of Perceived Exertion (Borg RPE) will be used to monitor the exercise intensity. The Research assistant will explain the Borg RPE scale to the subjects and instruct them to speed up or slow down their movements. The training session will end with a 10-minute cool down session with walking exercise and stationary trunk and limb mobilizing exercise involving joints of shoulders, elbows, wrists, hips, knees, and ankles.
223829986|NCT04913818|OTHER|Control arm (Usual care)|Active Comparator: Usual Care Activities will be provided by the elderly community center such as dementia or caregiver supporting service. They will be allowed to use the regular service provided such services are not related to physical activity or exercise training
223829987|NCT05938725|BIOLOGICAL|KYV-101 anti-CD19 CAR-T cell therapy|KYV-101 anti-CD19 CAR-T cell therapy
223829988|NCT05938725|DRUG|Standard lymphodepletion regimen|Standard lymphodepletion regimen
223829989|NCT04519541|DEVICE|Non-Invasive Thermal Ablation of the Medial Branch Nerves using the Neurolyser XR|Thermal ablation of the medial nerve branch using High Intensity Focused Ultrasound
223829990|NCT04950556|OTHER|Exercise|Pelvic floor muscle exercise will be given to the exercise group
223829991|NCT04950556|OTHER|Control|No intervention
223829992|NCT04573413|DEVICE|Inhibitory repetitive transcranial magnetic stimulation|"r-TMS Parameters: International 10/20 system for the location of the target area (left parietal cortex) 60% Power Frequency: 1 Hz 90 pulse trains with 10 pulses each (total 900 stimuli), resulted in a total stimulation period of 15 minutes.~Visual Scanning Visual-spatial training; Reading and copying training; Copying of line drawings on a dot matrix. Barrage"
223829993|NCT04573413|DEVICE|Sham Group|Sham stimulation and Visual scanning training Intervention: Device: SHAM
223829994|NCT03005093|OTHER|CAREGIVERS|The Turkish Feeding/Swallowing Impact Survey will be completed by the caregivers
223829995|NCT03005093|OTHER|CHILDREN OF CAREGIVERS|Chewing performance with Karaduman Chewing Performance Scale, tongue control with Tongue Thrust Rating Scale, dysphagia symptom severity with the Pediatric version of the Eating Assessment Tool will be evaluated. These assessments will be done before and after swallowing rehabilitation program.
223829996|NCT03623880|BEHAVIORAL|Unified Protocol|The unified protocol is a form of cognitive behavior therapy focused on helping the person reduce emotional distress through cognitive changes and behavioral skills. Exercises included confronting emotional-driven behaviors and mindfulness activities.
223829997|NCT03623880|BEHAVIORAL|Supportive Therapy|Supportive therapy seeks to improve self-esteem, aid the patient with problem solving, and provide structured support using empathetic listening.
223829998|NCT03504735|BEHAVIORAL|Therapeutic Lifestyle Change|Monthly consult with a dietitian and fitness instructor.
223829999|NCT03504735|DRUG|Caduet Pill|Take once daily.
223830000|NCT03504735|DRUG|Placebo|Take once daily.
223830001|NCT00361075|DRUG|transdermal estradiol patch (Vivelle), oral estrogen (Estrace), progesterone (Prometrium)|
223830002|NCT04058821|DIAGNOSTIC_TEST|Novel MRI scan - 7 days post injury|"* A turbo spin-echo localiser (20 seconds)~* Single-shot echo planar diffusion tensor imaging (7 minutes)~* 3D constructive interference in steady state (CISS, 6 minutes)~* Phase-sensitive inversion-recovery gradient echo with cardiac gating (4 minutes)"
223830003|NCT04058821|DIAGNOSTIC_TEST|Novel MRI scan - 14 days post injury|"* A turbo spin-echo localiser (20 seconds)~* Single-shot echo planar diffusion tensor imaging (7 minutes)~* 3D constructive interference in steady state (CISS, 6 minutes)~* Phase-sensitive inversion-recovery gradient echo with cardiac gating (4 minutes)"
223830004|NCT04058821|DIAGNOSTIC_TEST|Functional MRI scan - 6 months post brachial plexus exploration|"* Continuous whole brain echo-planar imaging~* High-resolution T1-weighted imaging of the brain~* Bilateral magnetic resonance spectroscopy (12 minutes)"
223830005|NCT04058821|DIAGNOSTIC_TEST|Functional MRI scan - 12 months post brachial plexus exploration|"* Continuous whole brain echo-planar imaging~* High-resolution T1-weighted imaging of the brain~* Bilateral magnetic resonance spectroscopy (12 minutes)"
223830006|NCT01993537|DRUG|Vitamin D|
223830007|NCT00630058|DRUG|MP-424(H), PEG-IFN-a-2b, RBV|MP-424 (three tablets of 250mg tablet at a time, every 8 hours) + PEG-IFN-a-2b + RBV for 12 weeks
223830008|NCT00630058|DRUG|MP-424 (L), PEG-IFN-a-2b, RBV|MP-424 (two tablets of 250mg tablet at a time, every 8 hours) + PEG-IFN-a-2b + RBV for 12 weeks
223830009|NCT01651936|DRUG|MK-8457 100 mg|MK-8457 100 mg dosed orally BID
223830010|NCT01651936|DRUG|Methotrexate|MTX dosed at the stable dose received upon study entry
223830011|NCT01651936|DRUG|Dose-match placebo|Dose-matched placebo dosed orally BID
223830012|NCT03044353|DRUG|GSK2315698 (CPHPC)|20mg/hour, IV (in the vein) for up to 72hours followed by 60mg three times daily subcutaneous injection for 11 days. Number of cycles: up to 6. Dose level and frequency adjusted according to renal function
223830013|NCT03044353|BIOLOGICAL|GSK2398852 (anti-SAP mAb)|Up to 1200mg, IV divided over days 1 and 3. Number of cycles: up to 6. Dose level adjusted based on tolerability.
223830014|NCT01079143|DRUG|Certican®|Certican® was supplied to the participating centers by Novartis for the whole duration of the study in the form of tablets containing 0.75, 0.5 and 0.25 mg and packaged in blister packs.
223830015|NCT01079143|DRUG|Neoral|Neoral® was also supplied to participating centers for the entire duration of the study in the form of soft capsules of 10 mg, 25 mg, 50 mg and 100 mg, and packaged in blister packs.
223830016|NCT01079143|DRUG|Myfortic|"Myfortic ® was supplied to the participating centers for the duration of the study in the form of 180 and 360 mg gastro-resistant, film-coated tablets. Myfortic® treatment was provided to patients preoperatively or within 24 hours post-transplantation according to the practices of the center. The starting dose was generally 1,440 mg/day, in 2 daily oral fractions, administered at 12 hour intervals up to randomization. Depending on the practices of the center and for the first 6 weeks post-transplantation, a maximum daily dose of 2160 mg of Myfortic® could be administered. In the Neoral® group, the daily dose of 1440 mg was maintained throughout the study.~In the Certican® group, the dose was halved (i.e. 720 mg/day) on introducing Certican® and maintained at 720 mg/day until the end of the study.~An increase in the daily dose of Myfortic® (in the Certican® group) was not authorized unless this was a temporary increase that did not exceed a period of 14 consecutive days."
223830017|NCT01079143|DRUG|Simulect®|The administration of Simulect® was part of the standard immunosuppressant therapy. This induction therapy was provided to patients in the form of commercial ampoules each containing 20 mg. Simulect® was administered to each patient at the dose of 20 mg on D0 and D4 post-transplantation.
223830018|NCT01079143|DRUG|Corticosteroids|An intravenous steroid treatment could be administered peri or intraoperatively according to local practice at each center. Oral steroid treatment was quickly introduced (in the week following transplantation) at a daily dose of 20 mg and was then reduced and continued throughout the study at a minimum dose of 5 mg/day.
223830019|NCT02162992|OTHER|No intervention|Observational
223830020|NCT06442020|PROCEDURE|Tadalafil (PDE5i)|Tadalafil at a dose of 5mg/day
223830021|NCT04001764|PROCEDURE|The radial artery cannulation over 2 cm of the wrist|The radial artery catheterization performed as short axis out-of-plane with USG over 2 cm of the wrist.
223830022|NCT04001764|PROCEDURE|The radial artery cannulation in the distal 3/4 area of the forearm|The radial artery catheterization will be performed in the distal 3/4 area of the forearm with ultrasound-guided short axis out of plane intervention.
223830023|NCT04001764|PROCEDURE|The radial artery cannulation in the distal 1/2 area of the forearm|The radial artery catheterization will be performed in the distal 1/2 area of the forearm with ultrasound-guided short axis out of plane intervention.
223830024|NCT02825953|DRUG|surfactant|the investigators attempt to administer surfactant in a more gentle way, i.e. by nebulization, by minimally invasive surfactant therapy, and endotracheal bolus application of natural surfactant
223830025|NCT02825953|DEVICE|nasal continuous positive airway pressure|each infant will be randomly assigned to nasal continuous positive airway pressure (NCPAP) or non-invasive intermittent positive-pressure ventilation (NIPPV). The infants will be stabilised on NCPAP (Neopuff; Fisher and Paykel, Auckland, New Zealand) in the delivery room and during transport to the NICU. NCPAP or NIPPV will be started within 30 min of birth immediately after randomisation. Both NCPAP and NIPPV will be delivered by a neonatal ventilator (Engström Carestation; GE Healthcare, Madison, USA) via short, binasal Cannula (RAM Cannula; Neotech, Valencia, CA).
223830026|NCT02825953|DEVICE|non-invasive intermittent positive-pressure ventilation|each infant will be randomly assigned to nasal continuous positive airway pressure (NCPAP) or non-invasive intermittent positive-pressure ventilation (NIPPV). The infants will be stabilised on NCPAP (Neopuff; Fisher and Paykel, Auckland, New Zealand) in the delivery room and during transport to the NICU. NCPAP or NIPPV will be started within 30 min of birth immediately after randomisation. Both NCPAP and NIPPV will be delivered by a neonatal ventilator (Engström Carestation; GE Healthcare, Madison, USA) via short, binasal Cannula (RAM Cannula; Neotech, Valencia, CA).
223830027|NCT02825953|DEVICE|Neopuff|Fisher and Paykel, Auckland, New Zealand
223830028|NCT02825953|DEVICE|neonatal ventilator|GE Healthcare, Madison, USA
223830029|NCT02053428|PROCEDURE|percutaneous image-guided gastrostomy|
223830030|NCT02141659|DRUG|TAK-385|TAK-385 Tablets.
223830031|NCT03893864|DIETARY_SUPPLEMENT|Administration of a product with Fitosomed Ubiquinone|Healthy runner athletes, \> 50 years old, without any chronic illness, without any other nutritional supplementation or drug intervention, took 100 mg/d of fitosomed Ubiquinone with lunch, daily, during one month, maintaining their usual training sessions.
223830032|NCT03893864|PROCEDURE|Coenzyme Q10 level in muscle biopsies|Determination of the muscle Ubiquinone concentration, the metabolic and structure characteristics of the muscle before and after one month of supplementation
223830033|NCT03893864|DIAGNOSTIC_TEST|Coenzyme Q10 level in plasma, blood cells, urine cells|Determination of Ubiquinone concentration in different tissues before and after one month of supplementation or not
223830034|NCT03893864|DIAGNOSTIC_TEST|Total antioxidant capacity after strenous exercise|Determination of the Total Antioxidant Capacity after strenous exercise in the Climate Chamber
223830035|NCT04708288|DEVICE|ARCHIMEDES Biodegradable Biliary and Pancreatic Stent|Pts that will receive ARCHIMEDES Biodegradable Biliary and Pancreatic Stent
223830036|NCT04329858|PROCEDURE|silver modified glass ionomer|occlusal cavity filled with silver modified
223830037|NCT04329858|PROCEDURE|zinc modified|occlusal cavity filled with zinc modified
223830038|NCT04329858|PROCEDURE|conventional glass ionomer|occlusal cavity filled with conventional glass ionomer
223830039|NCT01315405|BEHAVIORAL|Emotional facial expression recognition tests|"20 patients with an Idiopathic Parkinson's disease~\+ 20 paired healthy volunteers (on sex, age, and education)~After inclusion, patients are evaluated two times: they are studied without medication (MED OFF) and with medication (STIM ON) in a randomized order. The 2 evaluations should be spaced out 15 days to one month (J0 and J+15d)~Healthy subjects have only one visit J0 (inclusion and emotional facial expression recognition tests are made at the same time)"
223830040|NCT03558464|DIETARY_SUPPLEMENT|Intervention (integrated package)|"During whole study (pregnant women and offspring):~* Soap (for daily hand washing)~* Chlorine solution (for daily drinking water treatment)~* Life stage-appropriate (pregnancy, lactation, IYCF) monthly nutrition and WASH trainings~During pregnancy and up to when offspring turns 6 months old:~* LNS (Enov' Mum, 20g sachet daily)~* Anthelminthic treatment (single-dose mebendazole (500mg), once during second trimester of pregnancy)~Children 6-24 months of age~* MNP (MixMe, 1g sachet every three days)~* ORS + zinc~* 1 egg per day~All families in the intervention group will receive the same agriculture-focused package (see section 'control intervention' below) as those in the control group. All women will follow regular antenatal care as provided by the Kenyan government as part of their routine health system (e.g. intermittent preventive malaria treatment and iron-folic acid-supplements)."
223830041|NCT03558464|OTHER|Control|"Active control: The families living in the control clusters will receive the agriculture-focused package that is already in place in all participating clusters through the 1AF programme. This agriculture focused package consists of: - Agricultural training (every 2 weeks on average) for all - Free to enrol for the following products on credit: o Compost boosters~* Cook stoves o Seeds (onions, maize, indigenous greens, beans) o Maize storage bags o Drying tarps~* Trees o Solar lights o Fertilizer o Actellic dust (insecticide) o Re-usable sanitary pads"
223830042|NCT01247441|OTHER|Clinical data|
223830043|NCT00326768|DRUG|Telmisartan 40 mg/HCTZ 12.5 mg|
223830044|NCT00326768|DRUG|Telmisartan 40 mg|
223830045|NCT00326768|DRUG|Telmisartan 80 mg/HCTZ 12.5 mg|
223830046|NCT01927731|DRUG|Eltrombopag Olamine|Given PO
223830047|NCT01927731|OTHER|Laboratory Biomarker Analysis|Correlative studies
223830048|NCT02520180|DEVICE|Firehawk™ stent system|MicroPort Firehawk™ biodegradable polymer rapamycin target eluting stent
223830049|NCT02520180|DEVICE|Abbott Xience family Everolimus-Eluting Stent|Abbott Xience family Everolimus-Eluting Stent
223830050|NCT02125123|OTHER|Nutritional Supplement and Counseling|Ready-to-feed nutritional supplement and dietary counseling
223830051|NCT02125123|OTHER|Counseling|Dietary counseling
223830052|NCT01356173|DRUG|GDC-0349|Oral escalating dose
223830053|NCT00275496|PROCEDURE|Sentinel Lymph Node Dissection|Subject has wide excision and sentinel lymph node dissection for primary melanoma.
223830054|NCT00275496|PROCEDURE|Complete Lymph Node Dissection|Subject has wide excision, sentinel lymph node dissection, and complete lymph node dissection (if positive sentinel node found) for primary melanoma.
223830055|NCT00275496|PROCEDURE|Wide Excision|Subject has wide excision only for primary melanoma.
223830056|NCT03418935|DRUG|Remaxol (succinate + methionine + inosine + nicotinamide)|Solution for intravenous infusions, containing succinate, methionine, inosine, and nicotinamide in 400 ml glass bottle
223830057|NCT03418935|DRUG|Ringer's Solution|Intravenous infusion, 400 or 800 ml
223830058|NCT01388530|DEVICE|EMS 7500 Digital Muscle Stimulator|A standard FDA approved transcutaneous electrical nerve stimulation (TENS) unit will be used to apply low intensity stimulation to the trigeminal nerves during sleep.
223830059|NCT01812005|DRUG|alisertib|Given PO
223830060|NCT01812005|BIOLOGICAL|rituximab|Given IV
223830061|NCT01812005|OTHER|laboratory biomarker analysis|Laboratory correlative studies will be performed
223830062|NCT00305864|RADIATION|3-Dimensional Conformal Radiation Therapy|Undergo radiotherapy
223830063|NCT00305864|DRUG|Motexafin Gadolinium|Given IV
223830064|NCT00305864|DRUG|Temozolomide|Given orally
223830065|NCT01435044|DRUG|Sofosbuvir|Sofosbuvir 400 mg (2 × 200 mg tablets) administered orally once daily
223830066|NCT01435044|DRUG|GS-0938|GS-0938 300 mg (3 × 100 mg tablets) administered orally once daily
223830067|NCT01435044|DRUG|RBV|Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)
223830068|NCT01435044|DRUG|Placebo to match sofosbuvir|Placebo to match sofosbuvir administered orally once daily
223830069|NCT01435044|DRUG|Placebo to match GS-0938|Placebo to match GS-0938 administered orally once daily
223830070|NCT00171405|DRUG|aliskiren|
223830071|NCT02836613|BIOLOGICAL|Galcanezumab|Administered SC
223830072|NCT00976079|DEVICE|Transcutaneous electrical nerve stimulation (TENS)|Continuous TENS use
223830073|NCT00976079|DEVICE|Placebo TENS|Placebo TENS use
223830074|NCT05071274|DEVICE|Skinpen Prescision System|Skinpen Precision is an automated nonsurgical micro needling device designed for use by licensed health care practitioners or individuals directed by practitioners. The device incorporates a sterile Microneedle cartridge and Biosheath for single use only.
223830075|NCT03881059|OTHER|BMS-986165 Placebo|Participants will receive BMS-986165 matching placebo QD
223830076|NCT03881059|DRUG|BMS-986165 Dose A|Participants will receive BMS-986165 Dose A QD.
223830077|NCT03881059|DRUG|BMS-986165 Dose B|Participants will receive BMS-986165 dose B QD.
223830078|NCT03881059|DRUG|Ustekinumab|Participants will receive ustekinumab SQ injection QD.
223830079|NCT03881059|OTHER|Ustekinumab Placebo|Participants will receive ustekinumab SQ matching placebo QD
223830080|NCT05463614|DRUG|Propafenone and Propranolol|Propafenone Hydrochloride Tablets, 100-200mg, 1 or 2 times per day; Propranolol Hydrochloride Sustained-Release Capsules, 40mg, 1 times per day
223830081|NCT05284019|DRUG|Eptinezumab|Concentrate for solution for IV infusion
223830082|NCT05284019|DRUG|Erenumab|Solution for SC Injection
223830083|NCT05284019|DRUG|Onabotulinumtoxin-A|Solution for IM Injection
223830084|NCT05284019|DRUG|Fremanezumab|Solution for SC Injection
223830085|NCT05284019|DRUG|Galcanezumab|Solution for SC Injection
223830086|NCT05335772|BEHAVIORAL|Action Observation and following Action Execution|VR-AOT patients will observe, rehearse and execute specific upper limb motor task belonging to activities of daily living.
223830087|NCT05335772|BEHAVIORAL|Landscape Observation and following Action Execution|VR-LO participants will observe virtually explorable landscapes lasting for a matched duration. Then, they will be asked to actively perform the same set of hand actions requested to VR-AOT experimental groups.
223830088|NCT03499626|DRUG|ASLAN001|"Starting dose at 300mg BD Dose level +1: 400mg BD (which is the target dose for this study)~Dose reduction of ASLAN001 in event of adverse events grade 2 and above:~Dose level -1: 200mg BD Dose level -2: 100mg BD"
223830089|NCT02761889|RADIATION|IGRT 45 Gy in 5 fractions of 9 Gy|Previously untreated patients with prostate cancer will be treated with 45 Gy in five fractions of 9 Gy over 5 consecutive days.
223830090|NCT02761889|PROCEDURE|Image-guided, volumetric intensity-modulated arc radiotherapy (IGRT-VMAT)|Patients enrolled in the study will undergo IGRT-VMAT with state-of-the-art treatment-planning and quality assurance procedures with emphasis on normal tissue sparing and delivery accuracy via the use of devices that ensure stability and beam location reproducibility.
223830091|NCT02761889|DEVICE|Rectal balloon with air filling|A rectal balloon with air filling will be used for prostate target immobilization and anatomical reproducibility.
223830092|NCT02761889|DEVICE|Urethral catheter loaded with beacon transponders|A urethral catheter loaded with beacon transponders will be used to ensure set-up reproducibility and online target tracking.
223830093|NCT01465503|DRUG|Bivalirudin|Patients randomized to Bivalirudin group will be treated by bivalirudin before and during the procedure. Bivalirudin will be given as bolus of 0.75 mg/kg prior to the start of the intervention, followed by infusion of 1.75 mg/kg per hour for the duration of the procedure.The infusion will be lowered to 1.0 mg/kg per hour in patients with eGFR \<30 ml/min/1.73 m2.
223830094|NCT01465503|DRUG|Unfractionated Heparin|Patients randomized to the Control group will receive unfractionated heparn (UFH) before and during the procedure. UFH bolus will be of 70 UI/kg. If the activated clotting time measured 5 minutes after the study drug administration is lower than 270 seconds, an additional bolus of the randomised drug (UFH 20 U/kg) will be given.
223830095|NCT02065570|DRUG|Adalimumab|
223830096|NCT02065570|DRUG|Placebo|
223835609|NCT04221477|DRUG|Diphenhydramine|Diphenhydramine 50 mg will be administered as premedication prior to infusions.
223830097|NCT04577742|RADIATION|106 Ruthenium plaque brachytherapy|All patients, affected by uveal melanoma, were treated with 106 Ruthenium plaque brachytherapy to a total dose of 100 Gy to the tumor apex. The time of implant duration was calculated according to the conventional central-axis-point dose calculation
223830098|NCT02325726|PROCEDURE|Renal Resistive Index compared with NephroCheckTM|
223830099|NCT00259324|BEHAVIORAL|Diet and Activity|Diet and Activity
223830100|NCT02059772|DRUG|ranibizumab|
223830101|NCT02059772|PROCEDURE|micropulse diode laser|
223830102|NCT01266993|BIOLOGICAL|Nimenrix (GSK134612 vaccine)|Intramuscular, 1 dose
223830103|NCT01266993|BIOLOGICAL|Menjugate|Intramuscular, 1 dose
223830104|NCT01844193|DEVICE|Compex Rehab|"Participants in this arm will use a Compex® Rehab unit for neuromuscular electrical stimulation starting with postoperative at-home day 1 and continue using the unit twice a day, every day, until a 10-week follow-up is reached. The unit produces a 380 microsecond biphasic curve and utilizes a four phase process for the treatment (Warm-up, Work, Relaxation, and Recovery) for a total treatment time of 20 minutes and 5 seconds per session. All frequencies are delivered at the maximum subjective tolerable intensity. Participants will control this intensity and be asked to select a level that is tolerable although mildly uncomfortable; they will be instructed to increase this intensity as tolerated."
223830105|NCT02293837|DRUG|Tocilizumab (TCZ)|Subjects assigned to this group will receive tocilizumab intravenous (IV) infusions of either 8.0 mg/kg (body weight ≥ 30kg) or 10.0 mg/kg (body weight \<30kg) every 4 weeks for 24 weeks.
223830106|NCT02293837|DRUG|Placebo|Subjects assigned to this group will receive placebo intravenous (IV) infusions of either 8.0 mg/kg (body weight ≥ 30kg) or 10.0 mg/kg (body weight \<30kg) every 4 weeks for 24 weeks.
223830107|NCT02293837|OTHER|Standard of Care|Participants will also receive standard intensive diabetes management (in accordance with the American Diabetes Association guidelines \[Standard of Care, SOC\])
223830108|NCT01880060|BEHAVIORAL|INCENT weight loss program|Tangible incentives seem to be effective in enhancing short term, but not long-term weight loss. The monetary rewards are based on participant quarterly weigh-ins and the monetary amount of incentive will be identical to the percentage of body weight lost. Participants who lose 1, 2, 3, 4, or 5% of their body weight will then be compensated with 1, 2, 3, 4, or 5 dollars per month. Dollar amounts for participants that lose more than 5% of initial body weight then increase by increments of 5 (e.g., 5-9% weight loss = $5; 10-14%=$10; 15-19%=$15; \>20%=$20). These incentives will be based on quarterly weight and all percentage weight loss is calculated based on a participant's initial weight. commencement). Participants receive monthly checks that reflect the percent weight loss.
223830109|NCT01880060|BEHAVIORAL|Livin My Weigh|Livin My Weigh is an internet-delivered weight loss program without daily support or financial incentives. Participants receive quarterly newsletters with tips on weight loss, increasing physical activity, and menu suggestions, and optional quarterly educational sessions. Weight is measured in the same manner as the INCENT participants.
223830110|NCT06160713|DRUG|Itraconazole 65 MG|Two capsules of suba-itraconazole 65 mg twice daily for 6 months
223830111|NCT06160713|OTHER|Standard care|Standard care for bronchiectasis
223830112|NCT04779242|DRUG|Omadacycline|IV for injection, oral tablets
223830113|NCT04779242|DRUG|Moxifloxacin|IV solution, oral tablets
223830114|NCT02532322|DRUG|IV acetaminophen|IV acetaminophen 15 mg/kg (1.5 mL/kg) IV loading dose prior to incision, followed by a 15 mg/kg (1.5 mL/kg) dose given every 6 hours for the first 24 hours after surgery (total of 4 doses postoperatively)
223830115|NCT02532322|DRUG|normal saline|normal saline 1.5 mL/kg IV loading dose prior to incision, followed by a 1.5 mL/kg dose given every 6 hours for the first 24 hours after surgery (total of 4 doses postoperatively)
223830116|NCT01387503|PROCEDURE|Liver transplantation|Once randomized to Group 1, patients will be enlisted for liver transplantation at the recruiting Center. Prioritization is encouraged as a waiting time of more than 8 months could cause patients' drop-out from the study
223830117|NCT04001140|BEHAVIORAL|Enhancement of emotion regulation skills|Regarding the intervention, 7 sessions will be carried out. The main purpose is to help adolescents to enhance their emotion regulation, with the ultimate goal to decrease their risk of developing addictions and other psychopathology.
223830118|NCT04276818|PROCEDURE|PRP group|Demonstrating the effectiveness of dressing with PRP in the treatment of second-degree burns
223830119|NCT04276818|PROCEDURE|conventional treatment group|The effectiveness of conventional dressing containing silver sulfadiazine in the treatment of burns will be compared with the method of dressing with PRP.
223830120|NCT00035945|DRUG|ISIS 14803|
223830121|NCT00397267|DRUG|inhalation of corticosteroids|
223830122|NCT04864821|DRUG|Targeting CD276 CAR T cells|Targeting CD276 autologous chimeric antigen receptor T cells
223830123|NCT05392075|BIOLOGICAL|Pfizer COVID-19 mRNA vaccine|vaccinated people who received the Pfizer COVID-19 mRNA vaccine
223830124|NCT05392075|BIOLOGICAL|Moderna COVID-19 mRNA vaccine|vaccinated people who received the Moderna COVID-19 mRNA vaccine vaccine
223830125|NCT04193293|DRUG|Duvelisib|Phosphoinositide 3-kinase (PI3K) Inhibitor
223830126|NCT04193293|BIOLOGICAL|Pembrolizumab|Immunotherapy (programmed cell death protein 1 \[PD-1\] inhibitor)
223830127|NCT04374929|DEVICE|StealthTrac Temporary Pacing Lead Plus Negative Pressure Wound Therapy|Following fixation of the StealthTrac Lead, Negative Pressure Wound Therapy is applied over the incision site.
223830128|NCT04374929|DEVICE|StealthTrac Temporary Pacing Lead Plus Anti-Inflammatory Glucocorticoid|"• Methylprednisolone 125 mg administered over 30 minutes beginning at least 30 minutes prior to the incision and StealthTrac Lead insertion procedure. This intravenous dose can be repeated every 8 hours on day one of the insertion from 1-3 doses depending on the patient's ability to take oral medications. It can be administered daily thereafter until the patient is able to take oral dosing. In normal circumstances, post op day 2, commence oral glucocorticoid (see below for recommended oral dosing).~Oral (PO) glucocorticoid preparations and dosing:~* Prednisone 40-60 mg orally daily based on BMI category. BMI categories: Low (\<18); Medium (18-30); High (\>30). Low and medium are assigned 40 mg daily. High BMI is assigned 60 mg daily dose. This while the StealthTrac lead remains in place.~* Methylprednisolone 16-32 mg daily based on BMI (low, medium and high) while the StealthTrac Lead remains in place."
223830129|NCT04374929|DEVICE|Two StealthTrac Temporary Pacing Leads (Increased Electrode Spacing)|"Once the first StealthTrac Lead is placed using the procedure described in the AtaCor Temporary Pacing System Instructions for Use (DOC-10085), load a second StealthTrac Lead into the same MACH I Delivery Tool, unless it was damaged during insertion of the first StealthTrac Lead, in which case a new MACH I Delivery Tool should be used.~Insert the second StealthTrac Lead through (1) a different intercostal muscle path within the same intercostal space or (2) within an adjacent intercostal space. Increased electrode spacing is achieved by pacing between the leads."
223830130|NCT04374929|DEVICE|StealthTrac Lead Only (Control)|A single StealthTrac Lead is placed with no additional treatment.
223830131|NCT04676828|DIAGNOSTIC_TEST|Single-photon-emission CT scan|SPECT/CT scan is an established functional modality used in the diagnosis and monitoring of lung disease. SPECT/CT scan images pulmonary circulation, where perfused areas equate with normal functional lung
223830132|NCT04356339|DRUG|Interferon-beta-1b (BETASERON, BAY 86-5046)|Using the BETACONNECT autoinjector and myBETAapp as prescribed by the physician
223830133|NCT05962593|OTHER|Telephone call|The patients will be randomized for a postoperative telephone call
223830134|NCT01850082|PROCEDURE|Vein Harvesting Procedures|"Open Vein Harvesting is the traditional method of saphenectomy for CABG. It is performed under direct vision using a single long incision or, more commonly, multiple smaller incisions (referred to as bridging technique) along the course of the vein. This approach minimizes manipulation and direct trauma to the conduit but is associated with potential for discomfort and leg wound healing complications. Endoscopic Vein Harvesting is a minimally invasive procedure that was developed to eliminate the need for long incisions associated with OVH. EVH reduces the risk of wound infections and other leg wound complications but may be more traumatic to the conduit than OVH."
223830135|NCT01424436|BIOLOGICAL|GSK933776|1mg/kg dose group
223830136|NCT01424436|BIOLOGICAL|GSK933776|3mg/kg dose group
223830137|NCT01424436|BIOLOGICAL|GSK933776|6mg/kg dose group
223830138|NCT03936140|DRUG|Inhaled iloprost|Study drug was inhaled to ventilated lung through a nebulized system in inspiratory limb after one-lung ventilation in the lateral decubitus position.
223830139|NCT03936140|DRUG|Distilled water|Study drug was inhaled to ventilated lung through a nebulized system in inspiratory limb after one-lung ventilation in the lateral decubitus position.
223830140|NCT04324294|DRUG|EUS enhanced with contrast to evaluate pancreas|Patients will receive intravenous contrast during EUS to assess whether it improves the evaluation of pancreas.
223830141|NCT00005028|DRUG|bryostatin 1|
223830142|NCT00005028|DRUG|paclitaxel|
223830143|NCT04879316|OTHER|Resting Energy Expenditure measurement|Resting Energy Expenditure measurement using indirect calorimetry
223830144|NCT01680458|DRUG|Fluconazole|"Candidiasis infection: The recommended dosage in children is 3 mg/kg once daily.~Cryptococcal infection: The recommended dosage in children is 6 mg/kg once daily. A dosage of 12 mg/kg once daily may be used, based on medical judgment of the patient's response to therapy.~Prophylactic administration for deep mycosis on Hematopoietic stem cell transplantation: The recommended dosage in children is 12 mg/kg once daily.~Absolute doses exceeding 600 mg/day are not recommended."
223830145|NCT01756820|PROCEDURE|Single-portal Endoscopic Carpal Tunnel Release (Microaire®)|SmartRelease® ECTR endoscopic carpal tunnel release system of MicroAire (http://www.microaire.com/products/ectr-endoscopic-carpal-tunnel/smart-release-ctrs/).
223830146|NCT01756820|PROCEDURE|Knifelight|A mini-open single portal technique using the Knifelight® device (Stryker) according to the surgical technique as described by the manufacturer (antegrade approach)
223830147|NCT02225821|DRUG|Cephalozin|1000 mg Cephalozin
223830148|NCT02225821|OTHER|Sodium chloride|10 cc of NaCl 0.9%
223830149|NCT02495896|DRUG|Cisplatin|Given IV
223830150|NCT02495896|DRUG|Docetaxel|Given IV
223830151|NCT02495896|DRUG|Gemcitabine Hydrochloride|Given IV
223830152|NCT02495896|OTHER|Laboratory Biomarker Analysis|Correlative studies
223830153|NCT02495896|DRUG|Paclitaxel Albumin-Stabilized Nanoparticle Formulation|Given IV
223830154|NCT02495896|OTHER|Pharmacological Study|Correlative studies
223830155|NCT02495896|BIOLOGICAL|Recombinant EphB4-HSA Fusion Protein|Given IV
223830156|NCT04282590|DRUG|TRK-750/Placebo|Powder for oral solution
223830157|NCT04282590|DRUG|Placebo/TRK-750|Powder for oral solution
223830158|NCT02443506|DRUG|AMG 623|Single dose of AMG 623 administered as subcutaneous and intravenous doses
223830159|NCT02443506|DRUG|Placebo|Single dose of matching AMG 623 placebo administered as subcutaneous and intravenous doses
223830160|NCT05976113|OTHER|Observation only|Just obsrevation following standard of care (including surgery, chemotherapy and radiation when appropriate)
223830161|NCT00467064|BEHAVIORAL|Arthritis Quick Start|Two week, lay led, workshop focusing on goal setting, problem solving, and content specific to disease management.
223830162|NCT00467064|OTHER|Delayed treatment intervention|After four months delay, participants in Control Group receive Experimental workshop.
223830163|NCT00610064|RADIATION|Baseline neuroimaging|Baseline neuroimaging using PET and MRI of the brain in patients before sacral neuromodulation
223830164|NCT00610064|RADIATION|Neuroimaging during sacral neuromodulation|Neuroimaging during sacral neuromodulation using PET
223830165|NCT01515345|DRUG|prasugrel or ticagrelor|prasugrel 10mg od for 12 month ticagrelor 90mg td for 12 month
223830166|NCT01515345|DRUG|Clopidogrel|clopidogrel 75mg od for 12 month
223830167|NCT05438225|BEHAVIORAL|Automated text message reminder|Participants in the intervention group will receive monthly automated reminder text instructing them to discuss hearing issues with their PCPs, and to request a referral to audiology or otolaryngology if they have hearing loss.
223830168|NCT04485650|OTHER|music therapy|The music were chosen by a researcher under guidance of an expert and grouped as relaxing, classical, mystical, and Turkish folk music. One of them was chosen by the patients following the application of spinal anesthesia in the music group.
223830169|NCT04485650|OTHER|sedated group|Sedation was performed to the sedated group after spinal anesthesia based on the height and weight data and the doctor's decision. The number of participants:30
223830170|NCT04485650|OTHER|non-sedated group|The patients in the non-sedated group were followed without any procedure (sedation and music). The number of participants:30
223830171|NCT05929846|OTHER|Back to Living Well Program|The Back to Living Well program (BLW), a sustainable community-based program for persons with persistent mild to moderate LBP. The goal of the intervention is to provide an opportunity for community dwelling persons with persistent mild to moderate LBP to learn how to safely engage in exercise and become active self-managers. The 12-week program will engage participants in weekly exercise sessions, education and self management sessions, and encourage independent exercise at least 1x per week. All participants will be encouraged to complete an action plan and watch online education videos weekly.
223830172|NCT01040780|DRUG|Icotinib|125 mg three times daily (375 mg per day) by mouth
223830173|NCT01040780|DRUG|Gefitinib|250 mg every 24 hours by mouth
223830174|NCT05407168|OTHER|Best Practice|Receive standard of care
223830175|NCT05407168|OTHER|Health Promotion and Education|View decision aid
223830176|NCT05407168|OTHER|Questionnaire Administration|Ancillary studies
223830177|NCT04876560|OTHER|Application of CDSS to provide nutritional care in breast cancer patients from home|A personalised dietary plan was implemented by the CDSS. The CDSS estimated body mass index (BMI) and Total daily Energy Expenditure (TEE) according to individual's incorporated data. For overweight and obese patients, the CDSS produced a hypocaloric diet, in which daily energy intake was less than TEE by approximately -500 kcal/day. Nutrient distribution was in line with the Mediterranean dietary pattern. Patients received individual login passwords to CDSS allowing access to their personal profile from home. During the trial, patients were instructed to record food diaries in the CDSS every week, which were also made available to the dieticians. Visiting the CDSS, patients had the opportunity to track their progress e.g. monitoring goals of body weight, physical activity, consumption of fruits, vegetables, legumes.
223830178|NCT04876560|OTHER|General lifestyle advice to breast cancer patients by phone|General lifestyle guidelines were provided by phone and food diaries were sent via emails.
223830179|NCT00802737|DRUG|Ofatumumab|Eight once weekly infusions (1 x 300 mg + 7 x 2000 mg), then 2000 mg once monthly for two years
223830180|NCT02711072|DRUG|control group|spinal anesthesia with 10 mg hyperbaric Bupivacaïne 0,5% + 2,5 µ Sufentanyl + 100 µ of intrathecal Morphine+ infiltration catheter with saline 5 ml/h
223830181|NCT02711072|DRUG|infiltration group|spinal anesthesia with 10 mg hyperbaric Bupivacaïne 0,5% + 2,5 µ Sufentanyl + 1ml of saline + infiltration catheter with 5 ml/h of Bupivacaïne 0,125%.
223830182|NCT02955433|OTHER|Rideshare-based transportation|
223830183|NCT03677128|OTHER|mNavigator|Allied health providers at BMC will use mNavigator to facilitate compliance with protocol-driven treatment and reduce patient abandonment for patients diagnosed with Burkitt lymphoma, Diffuse large B-cell lymphoma or retinoblastoma.
223830184|NCT00890643|DRUG|prazosin hydrochloride|prazosin 1-20 mg/day in divided doses
223830185|NCT00890643|DRUG|placebo|placebo
223830186|NCT01706211|DRUG|BRL 49653C|BRL 49653C 2 mg bid or placebo bid through weeks 1 to 24.
223830187|NCT01706211|DRUG|Placebo|
223830188|NCT04435795|DRUG|Normal Saline intranasal and placebo inhaler|Normal Saline intranasal BID and Placebo 3 puff MDI inhaled BID
223830189|NCT04435795|DRUG|Ciclesonide|Ciclesonide 600mcg BID inhaled with aero chamber
223830190|NCT04435795|DRUG|Ciclesonide nasal|intranasal ciclesonide 200 mcg DIE
223830191|NCT03864926|DRUG|Envarsus XR|"Envarsus XR is FDA approved for the prophylaxis of organ rejection in kidney transplant recipients converted from tacrolimus immediate-release formulations, in combination with other immunosuppressants. Envarsus XR, is designed to deliver tacrolimus more smoothly over the whole day.~Envarsus XR, a calcineurin-inhibitor immunosuppressant, is available for oral administration as extended-release tablets containing the equivalent of 0.75 mg, 1 mg, or 4 mg of anhydrous tacrolimus USP. Inactive ingredients include hypromellose USP, lactose monohydrate NF, polyethylene glycol NF, poloxamer NF, magnesium stearate NF, tartaric acid NF, butylated hydroxytoluene NF, and dimethicone NF. Tacrolimus is the active ingredient in ENVARSUS XR."
223830192|NCT03864926|DRUG|Tacrolimus|Tacrolimus (generic; immediate release) is FDA approved for the prophylaxis of organ rejection in heart, kidney and liver transplant recipients.
223830193|NCT00445601|DRUG|gemcitabine hydrochloride|Given intravesically
223830194|NCT00445601|OTHER|placebo|Given intravesically
223830195|NCT05377710|PROCEDURE|sinus lift with lateral approach|Maxillary sinus floor augmentation or sinus lift is a surgical procedure, which provides a solution to the problem of sinus bone loss (too thin), and thus increases the thickness of the bone for immediate or subsequent implant placement in the premolars and molars (4). It consists of the elevation of the sinus mucosa that lines the maxillary sinus. The space thus freed will be filled with a bone filling material
223830196|NCT03764358|DEVICE|Arteriovenous Fistula|Surgical implantation of an arteriovenous fistula for hemodialysis
223830197|NCT03764358|DEVICE|Tunneled Cuffed Catheter|Placement of a tunneled cuffed catheter in surgical theatre
223830198|NCT02026713|OTHER|quit smoking for a 2 weeks period|evaluate the platelet reactivity after 15 days by quit smoking
223830199|NCT00074074|BIOLOGICAL|infliximab|
223830200|NCT04378634|BEHAVIORAL|Exercise|Sub-maximal exercise test
223830201|NCT04378634|OTHER|Mental Stress Test|Computerised mental arithmetic challenges and social evaluative threat tasks
223830202|NCT03260361|OTHER|Hypnosis, kinesitherapy, MEOPA|classical intervention
223830203|NCT03260361|OTHER|Usual practice|Usual practice with treatments and physio
223830204|NCT04683471|DEVICE|Stimulator|Neuromodulation
223830205|NCT04683471|DEVICE|Sham|Sham
223830206|NCT01150578|DRUG|No intervention|No intervention
223830207|NCT03340155|OTHER|Photo(chemo)therapy|Treatment with photo(chemo)therapy, including UVB, UVA, PUVA and photopheresis
223830208|NCT05638880|DRUG|Valsartan 80 mg|Valsartan is an angiotensin receptor blocker.
223830209|NCT05638880|DRUG|Empagliflozin 10 MG|Empagliflozin is an oral hypoglycemic drug.
223830210|NCT05638880|DRUG|Levocetirizine|Levocetirizine, Histamine-1 receptor antagonists provide a highly successful approach for controlling allergic and inflammatory conditions
223830211|NCT02895490|OTHER|educational intervention|Receive a DVD containing educational information and communication skills
223830212|NCT02895490|OTHER|communication skills training|Receive a DVD containing educational information and communication skills
223830213|NCT02895490|OTHER|educational intervention|Receive information about the LINC group
223830214|NCT02895490|OTHER|questionnaire administration|Ancillary studies
223830215|NCT02895490|OTHER|quality-of-life assessment|Ancillary studies
223830216|NCT03450213|DEVICE|Pentacam|Pentacam will be used to measure the magnitude and axis orientation of anterior and posterior corneal astigmatism.
223830217|NCT04481516|OTHER|Yoga|SKY Yoga
223830218|NCT05924490|BEHAVIORAL|Real-time strategy-based videogame training|Rise of Nation is a complex strategy-based video game, in which individualized-adaptive feedbacks are constantly given to players based on their performance.
223830219|NCT05924490|BEHAVIORAL|Semantic Knowledge training|Packages of various cross-word puzzles include word search, word ladder, and word wheel.
223830220|NCT02543723|BEHAVIORAL|Nurse Coach Intervention|Participants randomized to the intervention 2 group a tailored nurse coach component. Participants will receive an initial session conducted by the nurse coach, via phone or in-person. Participants will receive weekly phone calls from the nurse coach during the first month of the intervention, and then bi-monthly follow-up calls for the remainder of treatment or 6-month follow-up period (whichever occurs first). The nurse coach will modify the intervention plan to address identified barriers to adherence at this time.
223830221|NCT01300429|GENETIC|obtain tissue specimens|One core biopsy specimen will be placed in formalin and processed for cytogenetic and FISH analyses as well as DNA for ALK sequencing. The second core biopsy specimen will be immediately frozen in liquid nitrogen and stored in a -80 degree freezer for research specimen. Collection will be performed on-site at the time of the procedure.
223830222|NCT02259920|DRUG|KUC 7483 CL, immediate release tablet|
223830223|NCT02259920|DRUG|KUC 7483 CL, particulate formulation|
223830224|NCT02259920|DRUG|KUC 7483 CL, solution formulation|
223830225|NCT02259920|DEVICE|Enterion™ capsule|
223830226|NCT01326793|OTHER|Skype Consultation|One-hour Skype consultation with MA-licensed psychiatrist and a written summary of findings.
223830227|NCT02083003|DIETARY_SUPPLEMENT|Polyamine low-diet|
223830228|NCT02083003|DIETARY_SUPPLEMENT|Liberal alimentation|
223830229|NCT00273962|DRUG|ipratropium plus salbutamol UDV|
223830230|NCT00273962|DRUG|salbutamol UDV|
223830231|NCT02348437|PROCEDURE|Repair|An on-going suture technique with minimum four stitches.
223830232|NCT02348437|PROCEDURE|Non-repair|The PQ muscle will be placed so it covers the volar plate. No suture.
223830233|NCT00730990|OTHER|Positron Emission tomography|Positron Emission tomography scans. Part 1of the study : 4 subjects will receive 2 scans a day for 1 day with PET ligand administered in tracer quantities.
223830234|NCT00730990|DRUG|PET Scan with PF-03654746|If none of the data from Cohort 2 is informative, then: 2) an additional 3 subjects will receive 2 Scans on Day 1 and 1 scan on Day 2 following 3 different doses of PF-03654746. Doses will be determined based upon the outcome of the first intervention.
223830235|NCT00730990|DRUG|PET Scan with PF-03654746|If none of the data from the previous interventions are informative, then: 3) an additional 3 patients will receive 2 scans on Day 1 and 1 scan on Day 2 following three different doses of PF-0365476. Doses will be determined based upon the outcomes of the previous interventions.
223830236|NCT00730990|DRUG|PET Scan with PF-03654746|"Part 2 of the study will have 3 possible interventions:~1\) 3 subjects in Cohort 2 will receive 2 scans on Day 1 and 1 scan on Day 2 following 3 different doses of PF-03654746 (0.5 mg, 1.5 mg, 4 mg)."
223830237|NCT02450773|DRUG|Furosemide|40 mg furosemide on postpartum day 1-6
223830238|NCT02450773|DRUG|Potassium chloride|20 meq potassium chloride on postpartum day 1-6
223830239|NCT02450773|DRUG|Placebo #1|Placebo (for furosemide)
223830240|NCT02450773|DRUG|Placebo #2|Placebo (for KCl)
223830241|NCT03840837|DRUG|Rivastigmine transdermal patch|Titration of transdermal rivastigmine, as per arm description.
223830242|NCT01877096|BEHAVIORAL|Motivational Interviewing|A brief motivational interviewing session
223830243|NCT01877096|BEHAVIORAL|Attention Control|Participants will be asked to discuss the sources (e.g., the Internet) in which they receive information about their health. This group is designed to control for potential beneficial effects of meeting with an interventionist.
223830244|NCT04157790|OTHER|CARE score|CARE score calculation
223830245|NCT00556348|DRUG|bevacizumab|1.25mg
223830246|NCT01506492|BEHAVIORAL|CALM|Patients assigned to the intervention arm will receive 3-6 CALM therapy sessions over 3-6 months delivered by a trained therapist at our center.
223835610|NCT06074653|OTHER|Mulligan Bent Leg Raise technique|Treatment session will be conducted for 2 days a week for 4 weeks consecutively. In first week only 20 minutes session will be given to each group. Home exercise plan is also given.Pre and post intervention measurements will be taken at 2nd and 4th week. Both dominant and non-dominant legs will be checked
223830247|NCT01456858|OTHER|Insecticide Treated Polyethylene Sheeting|Insecticide Treated Polyethylene Sheeting is based on the standard polyethylene sheeting that is issued routinely as temporary shelter for people affected by emergencies. During manufacture the pyrethroid insecticide, deltamethrin, is extruded with the polyethylene into three-ply laminated sheets, comprising an inner low-density laminate and two, outer high-density laminates. The insecticide release characteristics enable the deltamethrin to diffuse slowly to the outer surfaces and to become available for pick-up by any insect that lands on the surface.
223830248|NCT01456858|OTHER|Untreated Plastic Sheeting|Standard polyethylene sheeting that is issued routinely as temporary shelter for people affected by emergencies. Standard untreated plastic sheeting is Identical to ITPS but without the incorporation of insecticide.
223830249|NCT04861922|DRUG|Unfractionated Heparin|10 unit/kgBW/hour continuous infusion for 5 days
223830250|NCT06203444|DRUG|Tenapanor|The study drug will be administered in dose of 50 mg bid
223830251|NCT02064621|DRUG|Candesartan 32mg|Candesartan 32mg 1T, PO, QD for 9days
223830252|NCT02064621|DRUG|Candesartan 32mg/Amlodipine 10mg|Candesartan 32mg 1T, PO, QD for 9days/Amlodipine 10mg 1T, PO, QD for 9days
223830253|NCT02391038|DRUG|MLN0264|MLN0264 IV.
223830254|NCT00911963|DRUG|VCH-222 or matching placebo|capsule, oral, 4 doses once daily or twice daily, 3 days
223830255|NCT00911963|DRUG|VCH-222 or matching placebo|capsule, oral, 400 mg twice daily or 750 mg twice daily, 12 weeks
223830256|NCT00911963|BIOLOGICAL|peginterferon alfa-2a|subcutaneous injection, 180 μg, once weekly, 48 weeks
223830257|NCT00911963|DRUG|ribavirin|tablet, oral, 1000-1200 mg daily based on body weight, 48 weeks
223830258|NCT05486208|DRUG|LY3844583|Administered SC and/or IV.
223830259|NCT05486208|DRUG|Placebo|Administered SC and/or IV.
223830260|NCT05416775|DRUG|SHR-8068；Adebrelimab|SHR-8068: Sterile Injection, 50mg/10mL, Intravenous Infusion Adebrelimab: injection, 600mg/12mL, intravenous infusion
223830261|NCT05416775|DRUG|SHR-8068；adebrelimab and platinum-based chemotherapy|SHR-8068: Intravenous Infusion Adebrelimab: injection, intravenous infusion Pemetrexed disodium for injection: , intravenous drip Paclitaxel for injection (albumin-bound): intravenous drip Paclitaxel injection: intravenous drip Carboplatin injection: intravenous drip Cisplatin injection: intravenous drip
223830262|NCT05416775|DRUG|Adebrelimab；platinum-based chemotherapy|Adebrelimab: intravenous infusion Pemetrexed disodium for injection: intravenous drip Paclitaxel for injection (albumin-bound): intravenous drip Paclitaxel injection: intravenous drip Carboplatin injection: intravenous drip Cisplatin injection: intravenous drip
223830263|NCT00966862|OTHER|Other: Dietary Fibers|
223830264|NCT04880915|OTHER|surgical smoke affects|The study, experimental type, was conducted to investigate the effects of five different methods on surgical smoke protection.
223830265|NCT05360758|OTHER|Evaluation of response to treatment with response-tailored Ibrutinib in patients with chronic lymphocytic leukemia|Evaluation of response to treatment with response-tailored Ibrutinib in patients with chronic lymphocytic leukemia using laboratory tests, abdominal ultrasound, general condition of the patient and bone marrow
223830266|NCT00680303|BEHAVIORAL|The Lidcombe Program for early stuttering|
223830267|NCT00680303|BEHAVIORAL|The Lidcombe Program for early stuttering|
223830268|NCT00680303|BEHAVIORAL|The Lidcombe Program for early stuttering|
223830269|NCT00632710|OTHER|phototherapy|The laser used was low-level Aluminum Gallium Arsenide (AlGaAs)diodo laser, at a wavelength of 785 nm (infrared), dose of 3 J/cm2, mean power of 70 mW, 3 sec. per point, laser beam of 0,06cm2, BIOSET brand - Indústria de Tecnologia Eletrônica Ltda -Rio Claro, Brazil.
223830270|NCT00632710|OTHER|phototherapy placebo|disconnected laser (same device - experimental group)
223830271|NCT02873286|BIOLOGICAL|MVA-BN-RSV|MVA-mBN294B
223830272|NCT02873286|OTHER|Placebo|Tris Buffered Saline, sterile
223830273|NCT05392387|OTHER|Standard antiviral therapy|pegylated interferon or/and nucleos(t)ide analogues
223830274|NCT03918239|DRUG|SHP643|Participants will receive injection of SHP643.
223830275|NCT02840396|DEVICE|rTMS|repetitive TMS (rTMS) can lead to temporary increases or decreases (depending on the protocol used) in excitability of the targeted area. This change in excitability has been shown to last beyond the duration of the stimulation.
223830276|NCT02840396|DEVICE|Sham rTMS|Sham rTMS (or placebo rTMS) refers to a control condition in which no physiological effect on the targeted cortical region occurs.
223830277|NCT04890522|DRUG|Triprilimab(JS001)|Maximum 6 cycles for combined therapy and maintenance for up to 2 years.
223830278|NCT04890522|DRUG|Cisplatin|Maximum 6 cycles for combined therapy.
223830279|NCT04890522|DRUG|5-Fluorouracil|Maximum 6 cycles for combined therapy.
223830280|NCT04890522|DRUG|Gemcitabine|Maximum 6 cycles for combined therapy.
223830281|NCT05828225|DRUG|CD19 CAR-T cells injection|CD19 CAR-T in the Treatment of Refractory Myasthenia Gravis
223830282|NCT00781742|DRUG|AZD6765|IV once per dosing day, multiple times during the treatment period
223830283|NCT00781742|DRUG|Placebo|0.9% saline IV once per dosing day multiple times during the treatment period
223830284|NCT01666054|OTHER|PSV|Pressure Support Ventilation will be used until patient is extubated
223830285|NCT01666054|OTHER|PAV|Proportional Assist Ventilation will be used until patient is extubated.
223830286|NCT00000174|DRUG|Rivastigmine|
223830287|NCT06349200|BEHAVIORAL|432 Hz music|Music tuned to the 432 Hz frequency, as compared with other frequencies, has the advantage of providing utter calm, pleasure, and peace to its listeners. It has proven to be effective for reducing stress and improving sleep quality
223830288|NCT06349200|BEHAVIORAL|Binaural beats|Binaural beats are defined as the sound that is born when two sounds of constant intensity but different frequencies are presented to both ears separately. The resultant sound perceived in the brain has a single tone and a frequency equivalent to the difference between the frequencies of the carrier sounds
223830289|NCT06349200|BEHAVIORAL|White noise|White noise is a type of random sound characterized by equal intensity across all frequencies within the audible range, resulting in a steady, uniform sound similar to the static from a television or radio tuned to an unused frequency.
223830290|NCT05964881|PROCEDURE|sacrospinous hysteropexy|sacrospinous hysteropexy
223830291|NCT01086605|DRUG|pixantrone dimaleate|Given IV
223830292|NCT01958177|BIOLOGICAL|Intravenous transfer of of Bone Marrow derived Mono Nuclear Stem Cell (BMMNCs)|Total 3 doses ,in 30 days ,in 7days interval Intravenous transfer of of Bone Marrow derived Mono Nuclear Stem Cell BMMNCs)
223830293|NCT03126305|OTHER|OC-Go|OC-Go, a HIPAA-compliant web-based clinician portal and patient-side mobile application that allows clinicians to create and push tailored treatment assignments to patients on their mobile devices
223830294|NCT00000206|DRUG|Buprenorphine|
223830295|NCT04020003|DRUG|Levosimendan|General treatment group: control the infection, remove or control the original disease, mechanical ventilation, small tidal volume, high PEEP mechanical ventilation strategy, strictly control the capacity, strengthen the airway management, timely nutrition support and intensive rehabilitation treatment. Levosimendan group: on the basis of routine group treatment, 12.5 mg of levosimendan 5% GS 50ml was given on the same day, and the micro-pump was continuously pumped for 24 hours. The initial dose was 0.5 ml/ h, and if the blood pressure was not significantly decreased, the blood pressure was gradually increased to 2.4 ml/ h at the maximum dose, until the pump was over. The above treatment is repeated every 7 days until the offline success or the patient leaves the ICU.
223830296|NCT01189890|DRUG|sitagliptin phosphate|Sitagliptin tablets, orally, at a dose of 100 mg or 50 mg QD for 30 weeks. The dose level to be administered will depend on the participant's estimated glomerular filtration rate (eGFR), calculated at Visit 3 and may be adjusted as medically indicated during the study.
223830297|NCT01189890|DRUG|Glimepiride|Glimepiride tablets, orally, starting at a dose of 1 mg QD, which may be gradually increased, as needed, to maximum dose of 6 mg QD for 30 weeks. The dose may also be decreased as medically indicated during the study.
223830298|NCT01189890|DRUG|Placebo to Sitagliptin|Matching placebo tablets to sitagliptin to allow for blinding.
223830299|NCT01189890|DRUG|Placebo to Glimepiride|Matching placebo tablets to glimepiride to allow for blinding.
223830300|NCT02140294|DIETARY_SUPPLEMENT|Polymeric nutritional supplements|
223830301|NCT02140294|DIETARY_SUPPLEMENT|Standard Nutrional Treatment|
223830302|NCT00803166|DRUG|Halobetasol Propionate 0.05% Cream-Reference Product|Small amount applied and evaluated over the course of three days
223830303|NCT00803166|DRUG|Halobetasol Propionate 0.05% Cream-Test product 1|Small amount applied and evaluated over the course of three days
223830304|NCT00803166|DRUG|Halobetasol Propionate 0.05% Cream-Test Product 2|Small amount applied and evaluated over the course of three days
223830305|NCT05406037|BIOLOGICAL|Venous sample|at Day 0, Day 3, Day 7, Day 14, Day 28 (7 ml blood sample collecting on dry tube) D0 = Diagnostic day
223830306|NCT04560205|DRUG|Tocilizumab|"4-8mg/kg with 400mg maximum dose of Tocilizumab will be given in 60 minutes I/V infusion, and dose will be repeated after 12-24 hours according to clinical as well as laboratory parameters.~Customized decision for Tocilizumab usage will be made by attending infectious diseases physician, comfort with Tocilizumab usage, bacterial co-infection and duration of Ventilation."
223830307|NCT01807221|DRUG|Finerenone (BAY94-8862)|
223830308|NCT01807221|DRUG|Placebo|
223830309|NCT01807221|DRUG|Inspra (eplerenone)|
223830310|NCT02609659|DRUG|ombitasvir/paritaprevir/ritonavir and dasabuvir|Tablet; ombitasvir coformulated with paritaprevir and ritonavir, dasabuvir tablet
223830311|NCT02609659|DRUG|ribavirin|Tablet
223830312|NCT00542841|PROCEDURE|Hydrocortisone withdrawal|This is considered a non-standard treatment. On Day 1, participants will receive one 10-mg pill of hydrocortisone. On Day 3, participants will receive intravenously a medicine called cosyntropin, a synthetic form of a hormone that the body makes. Participants will receive one last pill of hydrocortisone prior to the end of the study.
223830313|NCT00376441|PROCEDURE|Vaginal Surgery|patients undergoing vaginal surgery
223830314|NCT03906513|DEVICE|OMK2|OMK2 (including citicoline 2%, high molecular weight hyaluronic acid 0.2%, cyanocobalamin and 0.01% BAK, Omikron Italia SRL) is a Class IIa device CE marked registered in Medical Devices Database of Italian Ministry of Health (identification number of registration: 1170558).
223830315|NCT00824174|BEHAVIORAL|Questionnaire|1 questionnaire, about 15-20 minutes.
223830316|NCT03554161|BIOLOGICAL|Tocilizumab (TCZ)|Patients with refractory BD associated uveitis will receive Tocilizumab therapy, the efficacy and corticosteroids-tapering effects will be evaluated.
223830317|NCT00593554|RADIATION|Total Body Irradiation|8 Gy on Day -9
223830318|NCT00593554|DRUG|Thiotepa|5 mg/kg/d on Day -8 to -7
223830319|NCT00593554|DRUG|Fludarabine|40 mg/m2/d on Day -6 to -3
223830320|NCT00593554|BIOLOGICAL|Rabbit ATG|2.5 mg/kg/d on Day -5 to -2
223830321|NCT00593554|DRUG|Palifermin|60 ug/kg (actual body weight) on Day -9 to -7 and Day 0 to +2
223830322|NCT03976310|DRUG|48 weeks of Benralizumab|Benralizumab is administered for 48 weeks (week 0 to week 48) every 4 weeks for the first 3 injections (30 mg sc per injection), and then every 8 weeks for the following 5 injections.
223830323|NCT03976310|OTHER|Computed tomography|Computed tomography of the thorax is performed at the beginning (week 0), middle (week 24) and towards the end (week 48) of Benralizumab therapy. A sinus scan is also added on weeks 0 and 48.
223830324|NCT02338713|DRUG|Calcichew D3|Calcium 500 mg and vitamin D3 1000 IU chewable tablets
223830325|NCT02338713|DRUG|Noncarbonated Water|Noncarbonated water 200 mL
223830326|NCT05232149|DRUG|Orelabrutinib( lower dose)|Orelabrutinib is a white, round, uncoated tablet, will be taken lower dose QD by patients with persistent or chronic primary immune thrombocytopenia
223830327|NCT05232149|DRUG|Orelabrutinib( higher dose)|Orelabrutinib is a white, round, uncoated tablet, will be taken higher dose QD by patients with persistent or chronic primary immune thrombocytopenia
223830328|NCT02444585|DRUG|Denosumab|Intended to prevent periprosthetic loss of bone mineral density
223830329|NCT02054312|BEHAVIORAL|Family Based Interpersonal Psychotherapy (FB-IPT)|
223830330|NCT02054312|BEHAVIORAL|Client Centered Therapy (CCT)|
223830331|NCT01508143|DRUG|Misoprostol 400 micrograms|Misoprostol 400 micrograms each 6 hours for 8 dose
223830332|NCT01508143|DRUG|Misoprostol 800 micrograms|Misoprostol 800 micrograms each 12 hours for 4 doses
223830333|NCT03134378|DRUG|Rabeprazole Sodium 20mg|Twice daily
223830334|NCT03134378|DRUG|Clarithromycin 500mg|Twice daily
223830335|NCT03134378|DRUG|Amoxicillin 500 Mg|Twice daily
223830336|NCT04550273|BEHAVIORAL|aerobic treadmill exercise|The study group (n=20) received three sessions of aerobic exercise per week for 3 months. Every session was done on an electronic treadmill with no inclination started with 5 minutes warm-up then 30 minutes of moderate-intensity aerobic training with 60-75% of target heart rate then followed or ended by 5 minutes cool down.
223830337|NCT01714973|BIOLOGICAL|ST266|Patients will receive ST266 spray, to half the breast and saline to the other half (blinded) after each of ten consecutive radiation therapy treatments. ST266 and saline will be sprayed onto the breast to deliver 0.01 ml/cm2.
223830338|NCT04946305|OTHER|Lutathera|Prospective observational study. There is no treatment allocation. Patients administered Lutathera by prescription that have started before inclusion of the patient into the study will be enrolled.
223830339|NCT00960102|DEVICE|cochlear implant|Multichannel Nucleus cochlear implant
223830340|NCT00960102|DEVICE|hearing aid|Phonak hearing aid
223830341|NCT06371365|PROCEDURE|Free Flap surgery|No intervention, this is an observational study
223830342|NCT02086552|OTHER|Laboratory Biomarker Analysis|Correlative studies
223830343|NCT02086552|DRUG|Lenalidomide|Given PO
223830344|NCT02086552|DRUG|Sonidegib|Given PO
223830345|NCT06152523|DRUG|Monalizumab/MEDI5257|Phase II trial using an A'Hern design with a safety lead-in cohort to assess the safety/tolerability of the combination of monalizumab and MEDI5752 in patients with metastatic MSI/dMMR cancer
223830346|NCT04711460|BEHAVIORAL|Younger participants|Younger Participants 19-29 years received TAU + Tx over 5 weeks
223830347|NCT04711460|BEHAVIORAL|Older participants|older participants 30-54 years received TAU + Tx over 5 weeks
223830348|NCT04711460|BEHAVIORAL|TAU|Participants received TAU or Treatment As Ususal, Cognitive Behavior Therapy only
223830349|NCT04711460|BEHAVIORAL|TAU + MIndfulness practice|Participants received TAU + mindfulness training
223830350|NCT02761174|DRUG|Brimonidine|Patients receive brimonidine to half of their face, whereas the other half receives no treatment and thereby patients are their own control
223830351|NCT02761174|OTHER|IPL+air-cooling|IPL+air-cooling are applied to the whole face and the control side thereby only receives IPL+air-cooling
223830352|NCT02186080|DRUG|Gemigliptin|
223830353|NCT02186080|DRUG|Placebo|
223830354|NCT01810627|RADIATION|MVCT|Patients will receive an additional MVCT scan at their one month follow up visit.
223830355|NCT05973318|DRUG|Dorzotimol eye drops, 20 mg/mL + 5 mg/mL|Dosing schedule b.i.d.
223830356|NCT05973318|DRUG|Cosopt eye drops, 20 mg/mL + 5 mg/mL|Dosing schedule b.i.d.
223830357|NCT03180879|DRUG|Test - RB ibuprofen acid orodispersible tablets|RB ibuprofen acid orodispersible tablets, 2 x 200 mg, single dose, oral.
223830358|NCT03180879|DRUG|Reference - RB Nurofen ibuprofen acid tablets|RB Nurofen ibuprofen acid tablets, 2 x 200 mg, single dose, oral.
223830359|NCT03180879|DRUG|Comparator - Dolormin ibuprofen lysine tablets|Dolormin ibuprofen lysine tablets 2 x 342 mg (each 342 mg tablet contains 200 mg ibuprofen), single dose, oral.
223830360|NCT00424853|DRUG|Docetaxel and cisplatin followed by gemcitabine|docetaxel 75 mg/m2 day 1 + cisplatin 75 mg/m2 day1 repeated every 21 days for 3 cycles followed by gemcitabine 1200 mg/m2 day 1,8 repeated every 21 days for 3 cycles
223830361|NCT00424853|DRUG|docetaxel and cisplatin followed by gemcitabine|docetaxel 25 mg/m2 day 1,8,15 + cisplatin 25 mg/m2 days1,8,15 repeated every 28 days for 3 cycles followed by gemcitabine 1200 mg/m2 day 1,8 repeated every 21 days for 3 cycles.
223830362|NCT01211236|OTHER|application of wound dressing made of bio-bags (vitapads) containing maggots|
223830363|NCT01211236|OTHER|application of classical hydrogel/alginate wound dressing|
223830364|NCT05013996|BEHAVIORAL|MIDSA|Multidimensional Inventory of Development, Sex, and Aggression
223830365|NCT05013996|BEHAVIORAL|Usual methods of evaluation|Usual methods of evaluation of each of the participating centers (CMP / CRIAVS / private practitioners, etc.).
223830366|NCT03394261|BEHAVIORAL|Patient Decision Aid|PtDA-MAT will provide information on MAT treatment options and pros and cons of each treatment option, and will assess patients' preferred options.
223830367|NCT00004003|DRUG|cisplatin|
223830368|NCT00004003|DRUG|fluorouracil|
223830369|NCT00004003|DRUG|gemcitabine hydrochloride|
223830370|NCT00658697|DRUG|Docetaxel|Intravenously given at 75 mg/m2 on day 1 of every 3 weeks for 4 cycles
223830371|NCT00658697|DRUG|Bevacizumab|Intravenously given at (15 mg/kg) on day 1 of every 3 weeks for 8 cycles
223830372|NCT00658697|DRUG|ADT|Either subcutaneously or intramuscularly every three months for a total of 6 doses (total of 18 months)
223830373|NCT00658697|DRUG|Bicalutamide|Starting on day 84 orally once daily until hormone therapy is completed
223830374|NCT02080520|DIETARY_SUPPLEMENT|Nattokinase|
223830375|NCT02080520|OTHER|Placebo|
223830376|NCT03940235|DRUG|Androgen deprivation therapy (ADT)|SBRT + ADT
223830377|NCT03940235|RADIATION|SBRT|SBRT to all radiological documented lesions (bone or lymphnodes)
223830378|NCT00003143|DRUG|Amifostine|
223830379|NCT00003143|DRUG|DHAP|
223830380|NCT04418713|OTHER|active video-games|An intervention with active video-games to increase physical activity and improve body composition
223830381|NCT06049693|DRUG|Ferrous Gluconate 300 MG|Ferrous Gluconate 300 MG twice a day
223830382|NCT03022240|DRUG|Propofol|The child will be randomized via a block design to receive either a volatile anesthetic (induction: sevoflurane), or total intravenous anesthetic technique (induction: propofol)
223830383|NCT03022240|DRUG|Sevoflurane|The child will be randomized via a block design to receive either a volatile anesthetic (induction: sevoflurane), or total intravenous anesthetic technique (induction: propofol)
223830384|NCT03022240|DRUG|Ametop|Each patient will receive Ametop local anesthetic to the dorsum of both hands 30-45 minutes prior to induction.
223830385|NCT03022240|DRUG|Ondansetron|Each patient will receive the antiemetic ondansetron 0.1mg/kg IV.
223830386|NCT04397523|BIOLOGICAL|anti-SARS-CoV-2 convalescent plasma|Administration of convalescent plasma obtained from donors with prior documented SARS-CoV-2 infection
223830387|NCT02035215|DRUG|Atorvastatin 20mg|
223830388|NCT02035215|DRUG|Omega-3-acids ethylesters 90 4g|
223830389|NCT02035215|OTHER|Placebo(Omega-3-acids ethylesters 90)|
223830390|NCT02043262|BEHAVIORAL|Reablement|The intervention deals with improving function in daily activities the person defines as important in the areas of self-care, productivity and leisure.
223830391|NCT02043262|BEHAVIORAL|Standard treatment|The control intervention is standard home-based treatment/care in Norway.
223830392|NCT04860154|DRUG|Hematoporphyrin|Patients with negative skin test of hematoporphyrin Injection (3.0-5.0mg/Kg plus saline 250 mL intravenous drip, the drip was completed within 1 hour) and keep patients away from the light. The first PDT therapy was performed 24 hours after infusion of hematoporphyrin injection by ERCP. The biliary tumor necrosis was observed and the biliary tract was cleaned up 24 hours later and then PDT therapy showed again if necessary. Multiple plastic stents or bald metal stents will be placed. Follow up regularly after the procedure, PDT therapy would be given again in 3 months.
223830393|NCT00562068|BIOLOGICAL|alemtuzumab|
223830394|NCT00562068|DRUG|cyclophosphamide|
223830395|NCT00562068|DRUG|doxorubicin hydrochloride|
223830396|NCT00562068|DRUG|prednisolone|
223830397|NCT00562068|DRUG|vincristine sulfate|
223830398|NCT00562068|GENETIC|polymerase chain reaction|
223830399|NCT00562068|OTHER|flow cytometry|
223830400|NCT00562068|OTHER|laboratory biomarker analysis|
223830401|NCT00562068|OTHER|pharmacological study|
223830402|NCT02636894|DEVICE|Restylane Silk|
223830403|NCT04496414|DEVICE|Bactiseal Catheter|Bactiseal Catheter manufactured by Codman \& Shurtleff, Inc. in the United States is a silicon catheter impregnated in rifampicin and clindamycin.
223830404|NCT00535743|DRUG|Sugammadex|Sugammadex administered as a fast IV bolus dose (within 30 seconds) at 3 or 15 minutes following administration of Esmeron®, dosed at 2, 4, 8, 12 or 16 mg/kg according to participant actual body weight.
223830405|NCT00535743|DRUG|Placebo|0.9% NaCl administered as a fast IV bolus dose (within 30 seconds) at 3 or 15 minutes following administration of Esmeron®,
223830406|NCT00535743|DRUG|Esmeron®|Esmeron® administered at 1 or 1.2 mg/kg as a fast IV bolus (within 10 seconds), dosed according to participant actual body weight.
223830407|NCT06172218|OTHER|Flo|sterile, micronized human amniotic membrane product derived from placenta and umbilical cord
223830408|NCT06172218|OTHER|Saline|sterile, preservative free 0.9% NaCl
223830409|NCT00466258|DRUG|R-CHOP|"* Cyclophosphamide 750 mg/m2 i.v. day 1~* Adriamycin 50 mg/m2 i.v. day 1~* Vincristine 1,4 mg/m2 i.v. day 1~* Prednisone 100 mg i.v or oral. days 1-5."
223830410|NCT00466258|DRUG|Highly active antiretroviral therapy|Combined antiretroviral treatment (TARGA) wich include at lest 3 drugs. The combination should be accepted as an initial or rescue treatment.
223830411|NCT00466258|DRUG|Central nervous system (CNS) prophylaxis|methotrexate (12 mg) cytarabine (30 mg) hydrocortisone (20 mg)
223830412|NCT00466258|DRUG|Prophylaxis of opportunistic infections and support treatment|Pegfilgrastim
223830413|NCT05542992|DIAGNOSTIC_TEST|CT-based deep learning model|CT-based deep learning model for pure-solid nodules classifications
223830414|NCT00684762|DRUG|Cilostazol 100 mg Tablets|Cilostazol (1 x 100 mg tablet) administered after an overnight fast of at least 10 hours
223830415|NCT00684762|DRUG|Cilostazol (Pletal®) 100 mg Tablets|Cilostazol (Pletal® 1 x 100mg tablet) administered after an overnight fast of at least 10 hours.
223830416|NCT03900312|BEHAVIORAL|Asdzaan Be'eena' Program|The program will consist of 11 sessions conducted with girls ages 8-11 and their female caregivers. 5 of the 11 sessions will be taught to groups of 8-12 girls and their mothers, and 6 of the sessions will be taught to individual girl/female caregivers' dyads. The mix of group- and home-based lessons is based on findings from the formative phase about preference for certain topics to be taught in groups vs. individual dyads. Each of the sessions (group and individual) will be 60-90 minutes in duration and delivered by a trained Family Health Coach (FHC). Group sessions will take place at a local community center in a private room. Individual dyad sessions will take place in the girls'/female caregivers home or another private place of their choosing such as our local Johns Hopkins offices. The program will be conducted over 2.5-3 months with one session occurring every week for 11 weeks.
223830417|NCT03937323|OTHER|Blood lymphocyte subtypes and serum cytokines|Blood samples will be taken from the patients with biliary pancreatitis and healthy volunteers to perform flow-cytometric analysis and to determine the proinflammatory cytokines
223830418|NCT01394250|DEVICE|Buzzy|Cold, Vibrational Device
223830419|NCT01394250|DRUG|Topical Lidocaine 4% Cream|Applied to anticipated IV site at least 30 minutes prior to cannulation.
223830420|NCT06445855|BEHAVIORAL|Interpersonal relationship-based intervention program|An interpersonal relations-based intervention program will be implemented with an online intervention platform.
223830421|NCT04064554|DEVICE|BCG vaccination with MicronJet600|BCG vaccination with MicronJet600
223830422|NCT04064554|DEVICE|BCG vaccination with conventional needle|BCG vaccination with conventional needle
223830423|NCT05781386|DRUG|SIM1811-03 or in combination with Sintilimab injectiont|"SIM1811-03 is a first-in-class igG-1 based humanized anti-tumor necrosis factor type 2 receptor (TNFR2) monoclonal antibody for the treatment of malignant tumor.~Sintilimab is an IgG4 humanized monoclonal antibody against programmed cell death protein 1 (PD-1)"
223830424|NCT02300480|PROCEDURE|CTB group|CTB: A single injection of 1.0% 10ml ropivacaine by bile duct needle in calot's triangle when before surgical dissection.After surgery,participants in this group will also receive PCIA.
223830425|NCT02300480|PROCEDURE|PCIA group|The formula of the PCIA included tramadol 800 mg, flurbiprofen axetil 100mg with saline added up to a volume of 80 ml in total. The PCIA pump was set up with a 5 ml loading dose, a 2 ml bolus dose, a 15 min lockout interval and background infusion at a rate of 1 ml/h.
223830426|NCT01759680|DEVICE|Vibrosphère device|Vertical Sinusoidal vibration
223830427|NCT03870178|DEVICE|Transcranial direct current stimulation (tDCS)|The noninvasive and nonpharmacological weak electrical current applied to the scalp to modulate cortical excitability.
223830428|NCT01510613|DRUG|Pomalidomide and Dexamethasone|Pomalidomide: 2-4mg/day, every day in cycles of 28 days until progression or unacceptable toxicity Dexamethasone: 20-40mg/week, on days 1, 8, 15, 22 in cycles of 28 days until progression or unacceptable toxicity
223830429|NCT01210235|BEHAVIORAL|FLU-FIT Program|In the intervention, eligible patients aged 50-75 who come in for flu shots and are due for colorectal cancer screening will be offered FIT.
223830430|NCT02524054|DRUG|Furosemide|80 mg of Furosemide in 8ml saline will be aerosolized using ultrasonic screen nebulizers. Aerosol will be delivered using a clinical volume-control ventilator to regulate inspiratory flow and volume.
223830431|NCT02524054|DRUG|Aerosolized saline|8ml saline will be aerosolized using ultrasonic screen nebulizers. Aerosol will be delivered using a clinical volume-control ventilator to regulate inspiratory flow and volume.
223830432|NCT03385057|DRUG|Ibuprofen|Grape-flavored ibuprofen 100mg/5mL (Leader®) will be dispensed. Ibuprofen will be dosed at 10mg/kg (max dose 600mg) QID (roughly Q6 hours, however we left dosing QID to allow for some flexibility in the dosing schedule to accommodate patient sleeping schedules). The pharmacy will manipulate the volume of each medication using Ora Blend suspension so that for each child, weight-based dosing of each medication will be equivalent in volume. The first dose of study medication will be dispensed 4 hours after the preoperative acetaminophen dose. Thereafter, medication will be dosed QID (or roughly 6 hours apart). Surgeons, nursing staff, and patients and their families will be blinded regarding the type of medication administered.
223830433|NCT03385057|DRUG|Acetaminophen|Grape-flavored acetaminophen 160mg/5mL (Leader®) will be dispensed based upon the arm to which each participant has been randomized. Acetaminophen at 15mg/kg (max dose 650mg), dosing will be QID (roughly Q6 hours, however we left dosing QID to allow for some flexibility in the dosing schedule to accommodate patient sleeping schedules). The pharmacy will manipulate the volume of each medication using Ora Blend suspension so that for each child, weight-based dosing of each medication will be equivalent in volume. The first dose of study medication will be dispensed 4 hours after the preoperative acetaminophen dose. Thereafter, medication will be dosed QID (or roughly 6 hours apart). Surgeons, nursing staff, and patients and their families will be blinded regarding the type of medication administered.
223830434|NCT00000484|DRUG|chlorothiazide|
223830435|NCT00000484|DRUG|Rauwolfia alkaloids|
223830436|NCT03918538|BEHAVIORAL|Home rehabilitation exercise program|After pre-test, the intervention participants received a 60 minutes of teaching regarding the home rehabilitation exercise program, with a printed exercise manual. The intervention participants also received a weekly phone call from the interventionist to enhance their exercise adherence and helping to overcome exercise barriers.
223830437|NCT03953729|DRUG|Ibuprofen|"The child and his / her guardian shall immediately upon arrival for informed about the participation in the research, being evaluated on the criteria of inclusion and exclusion described above. Soon after the signature by the responsible for the child of the Informed Consent Form (Appendix A), the drug shall be administered at the dosage established by Clark's formula, according to the weight of each child. It will then be evaluated the degree of anxiety of the child in front of the dental treatment using the scale Children's Fear Survey Schedule-Dental Subscale (Barberio, 2017). After 30 minutes of drug administration, treatment will start."
223830438|NCT03953729|DRUG|Placebo|"The child and his / her guardian shall immediately upon arrival for informed about the participation in the research, being evaluated on the criteria of inclusion and exclusion described above. Soon after the signature by the responsible for the child of the Informed Consent Form (Appendix A), the placebo shall be administered at the dosage established by Clark's formula, according to the weight of each child. It will then be evaluated the degree of anxiety of the child in front of the dental treatment using the scale Children's Fear Survey Schedule-Dental Subscale (Barberio, 2017). After 30 minutes of drug administration, treatment will start."
223830439|NCT00654329|DRUG|Saline|Normal saline, given intranasally
223830440|NCT00654329|DRUG|Fentanyl|Fentanyl, nasal transmucosal, 2 micrograms/kilogram
223830441|NCT00654329|DRUG|Dexmedetomidine|Dexmedetomidine, transmucosal, 1 microgram/kilogram
223830442|NCT00654329|DRUG|Dexmedetomidine|Dexmedetomidine, 2 microgram/kilogram, transmucosal route
223830443|NCT02264496|BEHAVIORAL|Exercise|
223830444|NCT05421520|DEVICE|Artificial intelligence assisted system|A deep learning-based bile duct scanning system that can prompt endoscopists to scan standard stations, identify bile ducts and stones in real time
223830445|NCT00601718|DRUG|vorinostat|Given PO
223830446|NCT00601718|BIOLOGICAL|rituximab|Given IV
223830447|NCT00601718|DRUG|ifosfamide|Given IV
223830448|NCT00601718|DRUG|carboplatin|Given IV
223830449|NCT00601718|DRUG|etoposide|Given IV
223830450|NCT00601718|OTHER|pharmacological study|Correlative studies
223830451|NCT00601718|OTHER|laboratory biomarker analysis|Correlative studies
223830452|NCT00601718|GENETIC|gene expression analysis|Correlative studies
223830453|NCT02282319|DRUG|spinal dexmedetomidine 0.5 mcg|Administration of dexmedetomidine 0.5 mcg
223830454|NCT02282319|OTHER|spinal chloroprocaine 40 mg|spinal anesthesia with chloroprocaine 40 mg
223830455|NCT02282319|DRUG|IV dexmedetomidine 0.5 mcg/kg|intravenous administration of dexmedetomidine 0.5 mcg/kg
223830456|NCT02651285|OTHER|G-CSF medium|incubation of IVF embryos with a specific medium containing G-CSF
223830457|NCT02651285|OTHER|Control|incubation of IVF embryos with a medium without G-CSF
223830458|NCT03443596|BIOLOGICAL|Early intensive BP control|Participants in the early intensive BP control arm are treated with BP lowering medications, with an aim to bring the systolic BP to 140-160mmHg and maintain this level for 72 hours post-ictus
223830459|NCT02300389|RADIATION|Hypofractionated IMRT boost radiotherapy|All patients included into this arm are irradiated to 46 Gy a 2 Gy fraction to the whole pelvis and seminal vesicles and prostate gland (I phase) and than the boost dose is limited to the prostate gland with some part of seminal vesicles with hypofractionated dose of 7.5 Gy in two fractions (II phase) to the total dose of 61 Gy. Additionally all patients received neoadjuvant Androgen Deprivation Therapy (3-4 months prior starting radiotherapy) and during radiotherapy and during the follow-up up to 24 months.
223830460|NCT02300389|RADIATION|Conventional Fractionated IMRT boost radiotherapy|All patients included into this arm are irradiated to 46 Gy a 2 Gy fraction to the whole pelvis and seminal vesicles and prostate gland (I phase) and than the boost dose is limited to the prostate gland with some part of seminal vesicles with conventional fractionated dose of 2 Gy in 15 fractions (II phase) to the total dose of 76 Gy. Additionally all patients received neoadjuvant Androgen Deprivation Therapy (3-4 months prior starting radiotherapy) and during radiotherapy and during the follow-up up to 24 months.
223830461|NCT03936413|DEVICE|Bay Labs EchoGPS Echcoardiogram|An echocardiogram will be performed in this arm using the Bay Labs EchoGPS. The Bay Labs EchoGPS system is an ultrasound system which uses the techniques of computer vision to analyze echocardiography images in real time. It then provides feedback to the user to optimize the images, and once they meet a specific level of quality it automatically records the images.
223830462|NCT03936413|DEVICE|Native Terason Echocardiogram|An echocardiogram will be performed in this arm using a native Terason echocardiography system. This system will not have any artificial intelligence assistance in image optimization or selection.
223830463|NCT02479035|DIETARY_SUPPLEMENT|Red raspberry meal 1|\~125 g fresh weight (1 cup equivalent)
223830464|NCT02479035|DIETARY_SUPPLEMENT|Red raspberry meal 2|\~250 g fresh weight (2 cup equivalent)
223830465|NCT02479035|DIETARY_SUPPLEMENT|Control meal|0 g red raspberry
223830466|NCT03806504|OTHER|PEEP|performing 35 cm/H2O PEEP and 2-3 ml/kg tidal volume
223830467|NCT03806504|OTHER|control group|performing 6 cm/H2O PEEP and 6-8 ml/kg tidal volume
223830468|NCT00003288|BIOLOGICAL|filgrastim|
223830469|NCT00003288|DRUG|cyclophosphamide|
223830470|NCT00003288|DRUG|tirapazamine|
223830471|NCT01144221|PROCEDURE|Intramyocardial Cell therapy|Intramyocardial Cell therapy in patients with chronic ischemic heart disease after ICD CRT Implantation
223830472|NCT05812703|BEHAVIORAL|Cognitive Behavioral Therapy|The participants will attend one of the behavioral group treatments programs offered by the Stanford Pain Management Center. This class may be held online via Zoom, or in person based at the Stanford Pain Management Center. The class may be recorded for training purposes. No names or images/faces will be recorded for privacy reasons. The behavioral groups are 3 types, with or without exercise/movement. Current Evidence Based treatments that are provided as standard practice include: Cognitive Behavioral Therapy Group, with movement, Acceptance and Commitment Therapy Group, with or without movement. Group participants will learn different skills in each group and develop a personalized plan to use the skills after group ends. At the end of group participants will be given an anonymous survey about the class to evaluate satisfaction of the treatment. Movement in this portion of class is designed to low impact and restorative/gentle, with no significant increases in HR \> 50% HRmax.
223830473|NCT05812703|BEHAVIORAL|Acceptance and Commitment Therapy (ACT)|ACT is a 6 week behavioral group program led by a psychologist to improve psychological flexibility and reduce pain interference in patients with chronic pain.
223830474|NCT05812703|BEHAVIORAL|Moderate to high Intensity Group Exercise|Group exercise led by supervised clinician with Cardiovascular focus to increase HR into zones to see adaptations to improve cardiovascular fitness.
223830475|NCT03537261|BEHAVIORAL|Parent-based Crisis Prevention Institute (CPI) physical management training program (P-CPI)|Parents of children with ASD will be randomly assigned to the 6-hour P-CPI group training session, which includes nonverbal, paraverbal, verbal, and physical intervention techniques. Baseline measures will be administered on the day of training and follow-up measures at 2-week, 1-month, 2-month, and 3-month post baseline. The treatment group will also participate in an in-person follow-up group qualitative interview.
223830476|NCT03760822|DRUG|Ramucirumab|IV ramucirumab at 8 mg/kg on D1 and D15
223830477|NCT03760822|DRUG|Paclitaxel|IV paclitaxel at 80 mg/m² on D1, D8 and D15
223830478|NCT00123513|BEHAVIORAL|Diet|Environmental changes in the food and physical activity environment. Cafeteria and vending machine changes, food brought from home, walking routes, and awareness building.
223830479|NCT00123513|BEHAVIORAL|Exercise|Increase routing physical activity, walking routes, stairs intervention, etc.
223830480|NCT00123513|BEHAVIORAL|Environment|Cafeteria and vending machine changes and identification of opportunities of physical activity.
223830481|NCT00288873|DRUG|Ergocalciferol|
223830482|NCT00288873|DRUG|Cholecalciferol|
223830483|NCT00237562|PROCEDURE|Large loop electrosurgical excision|
223830484|NCT05508347|DRUG|Nituzumab/placebo|"Test group: 3 cycles of induction chemotherapy combined with 9 times of nituzumab targeted therapy followed by 2-3 cycles of synchronous radiotherapy and chemotherapy combined with 7 times of nituzumab targeted therapy, a total of 16 times of nituzumab targeted therapy, equivalent to the whole course targeted therapy.~Control group: 3 cycles of induction chemotherapy combined with 9 times of placebo treatment followed by 2-3 cycles of concurrent chemoradiotherapy combined with 7 times of nituzumab targeted therapy, a total of 7 times of nituzumab targeted therapy, only targeted therapy during concurrent chemoradiotherapy"
223830485|NCT02269618|OTHER|Home-based telehealth program|"Home-based telehealth program~* Scheduled calls initiated by nurse performed weekly; the nurse carried out a standardized interview on general clinical condition of the patients.~* Unscheduled calls initiated by patients or caregivers through the service centre(24h/24h) to report any clinical problems. in case of signs or symptoms~* Telemonitoring: during calls, patients can transmit via landline or mobile phone the recordings from the 1-lead ECG to a service centre, and talk to the nurse or doctor~* Home visit performed by therapist seven days after hospital discharge by setting the daily physical activity and other home visits in case of need~* Scheduled calls initiated by therapist performed weekly aimed at increasing workload and evaluating the proper execution of exercises."
223830486|NCT02269618|OTHER|Home-based rehabilitation|"Home-based rehabilitation Individual rehabilitative program including at least 3 sessions/week of mini-ergometer and exercises and 2 sessions/week of walking with pedometer~* Mini-ergometer: The personalized protocol will be structured at the beginning on the basis of data obtained from the assessment of the baseline exercise test, trying to get a training activity to the maximum value of around a Borg dyspnoea and motor equal to 6 (according to the protocol of Maltais)~* Walking: The patient will be encouraged to walk every day. Will be given a pedometer and will be asked to try to increase the amount of steps up to the maximal for the patient."
223830487|NCT02269618|OTHER|Usual care|Usual care All patients will be followed also in usual care manner by their GPs.
223830488|NCT01861756|OTHER|Diabetes Medication Choice decision aid|The Diabetes Medication Choice decision aid cards provide information about medications commonly used to treat type 2 diabetes mellitus. The tool was originally developed and successfully evaluated by Mayo Clinic researchers.
223830489|NCT00502996|DRUG|Methotrexate|\>=15 mg po/week
223830490|NCT00502996|DRUG|rituximab [MabThera/Rituxan]|1g iv on days 1 and 15
223830491|NCT01729728|DRUG|Tapentadol|Tapentadol oral solution single dose (1mg/kg body weight)
223830492|NCT03569917|OTHER|Rectal swab collection|Rectab swab collection will be performed at inclusion and 5 and 30 days later.
223830493|NCT03688789|OTHER|Hydrocortisone supplementation|"* Cortisol at T0 and T30 mins less than 550 nmol / L after ACTH 250 μG achieved during the last chemotherapy session~* Hydrocortisone supplementation in patients with biological adrenal insufficiency~* scale of quality of life estimated by EORTC QLQ-C30"
223830494|NCT01570179|DRUG|ideal BW based sugammadex reversal of moderate block|2 mg/kg sugammadex (based og ideal body weight)
223830495|NCT01570179|DRUG|real body weight based sugammadex reversal of moderate block|2 mg/kg sugammadex (based on real BW)
223830496|NCT01570179|DRUG|real body weight based sugammadex reversal of deep block|4 mg/kg sugammadex (based on real BW)
223830497|NCT01570179|DRUG|ideal body weight based sugammadex reversal of deep block|4 mg/kg sugammadex (based on ideal BW)
223830498|NCT06500520|OTHER|Resisted Exercise group|The resisted exercise training program targeted trunk, upper, and lower body segments with 10-12 repetitions at 30-65% intensity, lasting 50-60 minutes per session, 3 times weekly for 8 weeks. Participants determined their maximal repetition through trial training. Maximal power was assessed using concentric 1-maximal repetition (MT). Following a 2-3 minute rest and a 5-minute warm-up (walking), participants performed the 1-MT test to establish their heaviest lift with the correct technique, adjusting resistance levels accordingly. The circuit-style training spanned 9 stations with 2-3 sets per station, each circuit lasting 2-3 minutes with 90-second rests between sets. A 5-minute warm-up and cool-down (walking) preceded and followed each session. Exercises included bilateral elbow flexion, chest press, bilateral shoulder abduction, bilateral knee extension, back extension, sit-ups, knee flexion, hip abduction, and hip adduction.
223830499|NCT06500520|OTHER|Stretching Exercise group|The participants were made to perform stretching exercises, selected by reviewing the literature, under supervision 3 days a week for 8 weeks, and they were asked not to do any other exercises during this intervention period. They were asked to do exercises such as trunk flexion, pelvic elevation, squatting, trunk lateral flexion, lumbar extensor stretching, lower abdominal stretching, hip adduct stretching, piriformis stretching, and trunk flexor stretching (cobra pose). The holding time was 5 seconds, the rest time was 1 second, and the exercises were applied in 10 repetitions.
223830500|NCT01084590|BEHAVIORAL|Healthy Eating/Physical Activity|This intervention arm will include brief pediatrician counseling regarding the child's current BMI percentile status, recommendations for home environmental changes to achieve a healthy weight gain trajectory, and home safety and injury risk reduction environmental recommendations paired with a 12 month home-based program delivered via phone by a masters-level health behavior specialist to promote implementation of the obesity prevention home environmental strategies.
223830501|NCT01084590|BEHAVIORAL|Safety/Injury Prevention|This intervention arm will include the same brief counseling from the pediatrician paired with a 12 month home-based program delivered via phone by a masters-level health behavior specialist to promote implementation of the safety and injury prevention home environmental strategies.
223830502|NCT02444299|DEVICE|Shoulder hemi-arthroplasty|
223830503|NCT04843813|DIETARY_SUPPLEMENT|Lutein|Participants will consume daily soft gels containing the lutein supplement.
223830504|NCT04843813|DIETARY_SUPPLEMENT|Placebo|Participants will consume daily soft gels containing the safflower oil.
223830505|NCT06316219|DRUG|Nomegestrol Acetate/Estradiol 2.5mg/1.5mg|hysteroscopic polipectomy after starting 14-day treatment with oral Nomegestrol Acetate/Estradiol 2.5mg/1.5mg at any time of the menstrual cycle
223830506|NCT05374759|DIAGNOSTIC_TEST|neutrophil gelatinase-associated lipocalin|When the patient is diagnosed with sepsis and on the 3rd day of the follow-up, blood samples will be taken and NGAL levels will measured.
223830507|NCT05374759|DIAGNOSTIC_TEST|renal resistive index|When the patient is diagnosed with sepsis and on the 3rd day of the follow-up, renal resistive index will measure and record.
223830508|NCT04267614|DRUG|Etanercept|Patients who received etanercept for RA
223830509|NCT02526056|OTHER|Physiotherapists|This study is a usability design with qualitative and quantitative aspects. The therapeutic relevance and design features will be explored.
223830510|NCT02526056|OTHER|elderly people|In one part, with patients, physical strain and designs facets will be investigated. During their game playing process, different measurements will be done. They will be asked about their opinions about the game.
223830511|NCT01197989|DEVICE|TEPSO cloth|TEPSO stocks should be worn continuously for 4 weeks of the study and will be changed every 3 days without wearing again those already used (even after washing).
223830512|NCT01197989|DEVICE|Standard cloth|Standard cotton stocks should be worn continuously for 4 weeks of the study and will be changed every 3 days without wearing again those already used (even after washing).
223830513|NCT04622137|PROCEDURE|Kinesiotaping therapy|The investigators used kinesiotaping strips in formations such as the Y, I, X, fan, web, and donut formations ove fractured clavicula.
223830514|NCT03514407|DRUG|INCB059872|Part 1: Initial cohort of INCB059872 administered every other day (QOD) at the protocol-defined starting dose, with subsequent cohort dose escalation based on protocol-defined criteria. Part 2: Expansion with the recommended dose from Part 1.
223830515|NCT03684720|OTHER|Discover followed by direct instruction [DD]|The intervention group will be taught suturing using the principles of guided-discovery-learning. In its simplest form, this means allowing the participants to practice placing a simple interrupted suture using the materials needed, as well as a picture of a finished suture. They must then draw from their own learning experiences, as well as discover for themselves how to do it. After a discovery period, an instructor will then teach them, how to place a simple interrupted suture, and will them guide them, as they begin to practice again.
223830516|NCT01231243|PROCEDURE|in-office bleaching with/without light|Two clinical sessions of tooth bleaching will be performed in each patient with a 1-week interval between them. In each session, three 15-min applications of the gel will be done using one of the two concentrations under investigation. In half of the sample of each concentration, the gel will be activated with a LED/laser device for a total of 3 min, as specified by the DMC manufacturer.
223830517|NCT00183456|BEHAVIORAL|Peer-oriented intervention|The peer-oriented intervention program emphasized social identity and the goals of protecting family and community. The peer program also trained participants to provide HIV/STD education to their peers.
223830518|NCT00183456|BEHAVIORAL|Group cognitive behavioral therapy (CBT)|Group CBT will focus on teaching ways to modify thoughts and behaviors associated with risky sexual behaviors.
223830519|NCT03806946|DIAGNOSTIC_TEST|electroencephalography|diagnosis epileptic discharge
223830520|NCT03806946|DIAGNOSTIC_TEST|psychometric scales to diagnosis psychiatric disorders|to diagnosis intellectual disability, attention deficit hyperactivity disorder ,epilepsy,autism and other mental illness.
223830521|NCT03806946|OTHER|psychometric scales for assesment socioeconomic and behaviour problems|to assessment other behavioural comorbidity as aggression ,mood changes,etc and help in identify function impairment, social and economic burden
223830522|NCT01472913|DRUG|Fibrin sealant|Fibrin sealant is applied on the surfaces of bone and soft tissue of surgery after placement of the prothesis due to the randomised knee.
223830523|NCT01472913|DRUG|Saline water|Same procedure to the opposite knee (the same patient) performed with sprayed saline water (placebo).
223830524|NCT01518660|BEHAVIORAL|Training|Bi-weekly progressive resistance training
223830525|NCT02649322|DEVICE|J-Tip|"After sterile preparation, the J-tip injector will be placed on the skin at the selected site of the regional block needle introduction. Firm pressure will be placed with the J-tip injector on the site for the chosen block, the safety ring slid down, the trigger pressed and the tip held firmly on the skin for three seconds. One quarter of a milliliter of one percent lidocaine will be injected with the characteristic pop and hissing sounds inherent to the J-tip injector."
223830526|NCT02649322|DEVICE|Syringe and 25 gauge needle|The same initial timeout and sterile prep procedure will be followed for the use of local syringe and 25 gauge needle injection of 1% lidocaine ninety seconds prior to introduction of the regional block needle.
223830527|NCT02965118|DRUG|PAC-14028 cream 1.0%|topical application
223830528|NCT02965118|DRUG|PAC-14028 cream Vehicle|topical application
223830529|NCT03403777|DRUG|Avelumab|AVELUMAB will be administered intravenously 10mg/kg every 2 weeks.
223830530|NCT01606956|PROCEDURE|The cuff inflation by the resting volume|80 patients are randomly allocated into two groups : resting volume group (n=40), half the maximum volume group (n=40). In the resting volume group, the pilot balloon valve is connected to syringe without piston for keeping the valve open to the atmosphere and allowing the pressure within the cuff of LMA to equalize with atmospheric pressure. In the half the maximum volume group, the cuff of LMA is completely emptied and then the cuff is filled with the half the maximum volume.
223830531|NCT01606956|PROCEDURE|The cuff inflation by half the maximum volume|80 patients are randomly allocated into two groups : resting volume group (n=40), half the maximum volume group (n=40). In the resting volume group, the pilot balloon valve is connected to syringe without piston for keeping the valve open to the atmosphere and allowing the pressure within the cuff of LMA to equalize with atmospheric pressure. In the half the maximum volume group, the cuff of LMA is completely emptied and then the cuff is filled with the half the maximum volume.
223830532|NCT02701751|OTHER|Exercise session|A blood sample and fat biopsy will be obtained before and after the 60 minute moderate exercise session. There is no drug or device intervention in this study.
223830533|NCT00786201|DRUG|Placebo|Intravenous (IV) infusion every 4 weeks, from Week 0 through Week 48
223830534|NCT00786201|DRUG|CNTO 888 1 mg/kg|IV infusion every 4 weeks, from Week 0 through Week 48
223830535|NCT00786201|DRUG|CNTO 888 5 mg/kg|IV infusion every 4 weeks, from Week 0 through Week 48
223830536|NCT00786201|DRUG|CNTO 888 15 mg/kg|IV infusion every 4 weeks, from Week 0 through Week 48
223830537|NCT01572324|DRUG|Oxaliplatin, Fluorouracil, Leucovorin, Capecitabine|HAI of Oxaliplatin and Fluorouracil: Oxaliplatin 130mg/m2 in split daily doses for 3 days, Fluorouracil 3000 mg/m2 in split daily doses for 3 days. Intraarterial Oxaliplatin plus intravenous Leucovorin 200 mg/m2 simultaneously over 2 hours followed by intraarterial Fluorouracil over 22 hours on Days 1-3 of each cycle, repeat every 21 days. After 4-6 cycles of HAI, maintenance treatment continue, Maintenance of Oral capecitabine 1,000 mg/m2 twice a day from days 1-14, Cycles were repeated every 21 days.
223830538|NCT00432510|DRUG|C1 esterase inhibitor [human] (C1INH-nf)|
223830539|NCT03627611|DRUG|Levothyroxin|3 months
223830540|NCT03627611|DRUG|Liothyronine|3 months
223830541|NCT03728114|DEVICE|RIC|Adults allocated to the RIC group will undergo RIC procedure during which bilateral arm cuffs are inflated to a pressure of 200 mmHg over systolic blood pressure for five cycles of 5 min followed by 5 min of relaxation of the cuffs.
223830542|NCT03728114|DEVICE|sham RIC|Adults allocated to the sham group will undergo a sham RIC procedure during which bilateral arm cuffs are inflated to a pressure of 60 mmHg for five cycles of 5 min, followed by 5 min of relaxation of the cuffs.
223830543|NCT01467258|DRUG|Amantadine|Single dose
223830544|NCT01674595|BIOLOGICAL|AVANZ olea|Immunotherapy Olea europaea
223830545|NCT05359731|DRUG|Bupivacaine Hydrochloride|Patients will receive a total volume of 30 ml of bupivacaine 0.5% in an axillary block with a double puncture.
223830546|NCT05359731|DRUG|Bupivacaine Hydrochloride with Dexamethasone|Patients will receive a total volume of 30 ml of bupivacaine 0.5% with Dexamethasone 4 mg in an axillary block with a double puncture.
223830547|NCT03876938|DRUG|aprepitant|aprepitant 125 mg orally, dexamethasone 12 mg iv, ondansetron 8 mg iv before chemotherapy aprepitant 80 mg orally D2-4, dexamethasone 8 mg/day orally D2-4
223830548|NCT03876938|DRUG|olanzapine 10 mg|olanzapine 10 mg orally, dexamethasone 12 mg iv, ondansetron 8 mg iv before chemotherapy olanzapine 10 mg orally D2-4, dexamethasone 8 mg/day orally D2-4
223830549|NCT03876938|DRUG|olanzapine 5 mg|olanzapine 5 mg orally, dexamethasone 12 mg iv, ondansetron 8 mg iv before chemotherapy olanzapine 5 mg orally D2-4, dexamethasone 8 mg/day orally D2-4
223830550|NCT04479293|OTHER|Post COVID-19 Functional Satus Scale|scale from 0-64 assessing functional limitation
223830551|NCT01436123|OTHER|Stenting and micro-infusion of NP|Step 1 - IVUS, OCT-guided put in everolimus-eluting (drug-eluting-DES) stent + intravascular ultrasound (IVUS) mapping + harvesting stem cells with mesenchymal phenotype; Step 2 - culturing of stem cells in medium by gold nanoparticles with silica-iron oxide shells; Step 3 - micro-infusion of stem cells bearing NP into the lesion; Step 4 - detonation of nanoshells after migration of stem cells with NPs inside (until 7-10 days after transplantation). We expect 'melting' and 'burning' effects of PPTT, beneficial effects of bioactive products of stem cells lysis + benefits from further migration of stem cells from patch into the plaque
223830552|NCT01436123|DEVICE|Implantation of everolimus-eluting stent|Put stent in ischemia-related coronary artery by indications for PCI
223830553|NCT01223222|DRUG|LTX-109|Topical administration. 3 times daily. 5 days.
223830554|NCT01757067|DEVICE|PVC ablation|This will compare symptoms, safety between ablation procedure vs medical therapy. Biosense Catheter used is not indicated specifically for PVC ablations and will be evaluated
223830555|NCT02438150|BEHAVIORAL|Hospital fire video training|Participants will watch a video about hospital fire training which last for 30 minutes
223830556|NCT02438150|BEHAVIORAL|Non hospital fire video training|Participants will watch a video about volcanic eruption which last for 30 minutes
223830557|NCT05233722|OTHER|Exercise|1 hour of one-legged knee-extensor exercise followed by 4 hours of rest
223830558|NCT05233722|PROCEDURE|Insulin infusion|2 hours of Euglycemic Hyperinsulinemic Clamp
223830559|NCT05233722|DRUG|Placebo|Administration of 800 mg of calcium tablets
223830560|NCT05233722|DRUG|Rapamycin|Administration of 16 mg of Rapamycin tablets
223830561|NCT04103424|BEHAVIORAL|Short-term Exercise Training|Participants will perform 2-weeks of supervised exercise training on a stationary bike.
223830562|NCT05500027|DIAGNOSTIC_TEST|serum test|serum test of sCD58 and TGFbeta1
223830563|NCT04267575|DEVICE|Canady Helios Cold Plasma Scalpel|Device used to distribute cold plasma energy at the resected tumor margins.
223830564|NCT00206388|DRUG|Zolendric acid|IV, 2mg/m2/dose on day 0
223830565|NCT00206388|DRUG|Cyclophosphamide|fixed dose of 25mg/m2/dose days 0-27
223830566|NCT03382600|BIOLOGICAL|Pembrolizumab|200 mg Q3W on Day 1 by IV infusion
223830567|NCT03382600|DRUG|Oxaliplatin|130 mg/m\^2 Q3W on Day 1 by IV infusion
223830568|NCT03382600|DRUG|TS-1|40 to 60 mg orally according to Body Surface Area (BSA) BID Q3W on Days 1-14
223830569|NCT03382600|DRUG|Cisplatin|60 mg/m\^2 Q3W on Day 1 by IV infusion
223830570|NCT04206137|OTHER|Group A (PNF rhythmic initiation group )|Lifting of arms and push the head back through the pattern of flexion -abduction-external rotation and neck in extension to the left in opposition of therapist hand resistance will be asked to do. At the end range of motion extensor muscles of back will start to contract.Then, reversing of that movement pattern to extension-adduction-internal rotation and neck flexion to right against the therapist resisting hands will be asked. this will be repeated on both sides
223835611|NCT06074653|OTHER|PNF Contract Relax technique|Treatment session will be conducted for 2 days a week for 4 weeks consecutively. In first week only 20 minutes session will be given to each group. Home exercise plan is also given. Pre and post intervention measurements will be taken at 2nd and 4th week. Both dominant and non-dominant legs will be checked
223830571|NCT04206137|OTHER|Group B (Swiss ball exercises)|"Supine position: A ball will be placed under patient neck, and will be asked to bend hip and knee up to 90°. 5 times, 10 seconds hold Supine position: With a ball below the pelvis, knees bent, the ball press will be done with pelvis. 5 times, for 10 seconds hold.~Crawling position: With a ball below one knee while keeping toes away from contact with the floor, the patient will balance first to stabilize the posture and slowly raise the other lower limb. This exercise will be performed in turn for the two lower limbs 10 times, with 10 seconds hold.~Prone position: the patient will place a ball in front of pelvis and will repeatedly raise and lowered the two lower limbs alternately. There will be 10 repetitions, with 5 sets, taking 15 seconds rest between each set."
223830572|NCT01000376|DRUG|Eribulin alone|Group 1 Cycle 1 (28 days): Eribulin IV 1.4 mg/m\^2 alone on Day 1, then eribulin IV 0.7 mg/m\^2 plus oral ketoconazole 200 mg on Day 15 and oral ketoconazole 200 mg alone on Day 16. Subsequently, subjects were able to receive eribulin 1.4 mg/m\^2 on Days 1 and 8 every 21 days.
223830573|NCT01000376|DRUG|Eribulin plus Ketoconazole|Group 2 Cycle 1 (28 days): Eribulin IV 0.7 mg/m\^2 plus oral ketoconazole 200 mg on Day 1, then oral ketoconazole 200 mg alone on Day 2 and eribulin IV 1.4 mg/m\^2 alone on Day 15. Subsequently, subjects were able to receive eribulin 1.4 mg/m\^2 on Days 1 and 8 every 21 days.
223830574|NCT05235295|PROCEDURE|Ultrasound-guided sacroiliac joint injection|Using ultrasound the sacral hiatus in transverse position was identified. Then, sliding laterally and cephalad in transverse position, the posterior superior iliac spine and the posterior sacroiliac joint were identified. The needle was advanced toward the posterior joint space from medial to lateral, using an in-plane technique.
223830575|NCT05235295|PROCEDURE|Flouroscopy-guided sacroiliac joint injection|Using anterior posterior and contralateral oblique view the posterior joint line and inferior joint margin were identified and a needle was advanced at the point the posterior inferior joint line was most clearly seen.
223830576|NCT00715507|DEVICE|medication monitor|the medication monitor will aid in expertise and decision-making.
223830577|NCT06259162|PROCEDURE|LAG-3 expression / immune checkpoint protein expression|Evaluate the tissue and blood before and after chemotherapy
223830578|NCT00896454|DRUG|denosumab|120 mg subcutaneously (SC) every 4 weeks with a loading dose of 120 mg SC on study days 8 and 15.
223830579|NCT03108963|DRUG|L-carnitine and Metformin|L-carnitine plus Metformin was given Obese PCOS Women trying induction of ovulation with clomiphene citrate.
223830580|NCT03108963|DRUG|placebo|placebo was given Obese PCOS Women trying induction of ovulation with clomiphene citrate.
223830581|NCT01721395|DIETARY_SUPPLEMENT|Agave Syrup|
223830582|NCT04387838|DIAGNOSTIC_TEST|Anti-SARS-CoV2 Serology|A blood sample is collected by venipuncture at Day 0, Day 30 and Day 60. The anti-SARS-CoV2 serological status is measured by automated microplate ELISA technique on the EVOLIS analyzer (Biorad®), using reagent kits from EUROIMMUN France.
223830583|NCT04387838|OTHER|Questionnaire|"Data concerning personal exposure factors are collected in a questionnaire:~* Socio-demographic factors: sex, age~* Professional factors: Employment (type, pace, reception, service, care practices), wearing of personal protective equipment (type of equipment, frequency of use) and type of hospital~* Non-professional factors: Contact with infected individuals, carrying of professional equipment and compliance with barrier measures"
223830584|NCT05759312|DRUG|Zimberelimab|Zimberelimab 240mg IV every 2 weeks
223830585|NCT05759312|DRUG|Metformin Hydrochloride|Metformin 2000mg PO QD
223830586|NCT03693599|DRUG|carbetocin|single 100 µg IV dose of carbetocin diluted in 10 ml of Ringer's lactate solution (Pabal, Ferring Pharmaceuticals Ltd, West Drayton, UK).
223830587|NCT03693599|DRUG|Syntometrine|one ampoule of syntometrine (Novartis, Basel, Switzerland), which consisted of 5 IU of oxytocin and 500 microgram of ergometrine diluted in 10 ml of Ringer's lactate solution and was administered intravenously over 2 minutes
223830588|NCT03688711|DRUG|Dasiglucagon|Glucagon analogue
223830589|NCT03688711|DRUG|Placebo|Placebo for dasiglucagon
223830590|NCT06122181|DRUG|HS-10384 tablets|Multiple dosing of HS-10384 orally in a fasting state
223830591|NCT06122181|DRUG|HS-10384-matched placebo tablets|Multiple dosing of HS-10384-matched placebo orally in a fasting state
223830592|NCT05039775|DEVICE|EROS device|Eros is a small, hand-held device fitted with a removable, replaceable small plastic cup used as a natural way to initiate female sexual response. It was originally cleared by the FDA in April 2000 for the treatment of Female Sexual Arousal Disorder (FSAD), which includes problems with sexual arousal and orgasm.
223830593|NCT05039775|BEHAVIORAL|Psychosexual support|Strategies are suggested to improve the couple's emotional connection and communication, when couples are being consulted, they are encouraged to focus on the strengths as well as weaknesses in their relationship. Homework assignments are given for the couple to practice skills, such as turning the idea of sexual obligation into pleasure, learning to focus on sensations rather than anxieties and communicating openly with their partner.
223830594|NCT00253279|PROCEDURE|PET Scans|Healthy volunteers will undergo one PET Scan; bur patients will undergo a maximum of 3 PET scans over 2 years after injury; a maximum of 2 will be done while inpatient; one after d/c.
223830595|NCT02053545|DRUG|Conditioning Regimen & GVHD Prophylaxis|"Stratum 1 (Refractory disease, relapse after previous transplant): Radiation Therapy (if patient had prior Central Nervous System (CNS) disease), Clofarabine, Melphalan,Thiotepa, Stem Cell Transplant, Cyclophosphamide, Mesna, Tacrolimus and MMF~Stratum 2 (Myeloid in remission): Radiation Therapy (if patient had prior CNS disease), Busulfan, Fludarabine, Thiotepa, Stem Cell Transplant, Cyclophosphamide, Mesna, Tacrolimus, MMF~Stratum 3 (Lymphoid in remission): Radiation Therapy (if patient had prior CNS disease), TBI, Fludarabine, Thiotepa, Stem Cell Transplant, Cyclophosphamide, Mesna, Tacrolimus, MMF"
223830596|NCT01410461|DEVICE|quantitive sensory testing|Mechanical pain threshold: Threshold will be assessed, by using the von Frey filaments. The lowest gram weight capable of inducing pain in two of three trials will be considered as a pain threshold Heat pain threshold (HPT): HPT will be measured using thermal sensory analyzer
223830597|NCT01410461|DEVICE|Ultrasound testing|Morphological measures of the pelvic muscles: Using a 3D 4-8MHz abdominal probe ultrasound testing will be performed. The following parameters will be measured: (1) anteroposterior hiatal diameter; (2) lateral hiatal diameter; (3) levator ani thickness and length at 3 o'clock and 9 o'clock; (4) length of the obturator (5) length of the pubococcygeus muscle; (6) obturator thickness.
223830598|NCT03262090|DRUG|0.2ug/kg dexmedetomidine|subjects were randomly assigned to receive 0.2ug/kg intravenous dexmedetomidine before skin incision
223830599|NCT03262090|DRUG|0.4ug/kg dexmedetomidine|subjects were randomly assigned to receive 0.4ug/kg intravenous dexmedetomidine before skin incision
223830600|NCT03262090|DRUG|0.6ug/kg dexmedetomidine|subjects were randomly assigned to receive 0.6ug/kg intravenous dexmedetomidine before skin incision
223830601|NCT03262090|DRUG|0.8ug/kg dexmedetomidine|subjects were randomly assigned to receive 0.8ug/kg intravenous dexmedetomidine before skin incision
223830602|NCT03262090|DRUG|1.0ug/kg dexmedetomidine|subjects were randomly assigned to receive 1.0ug/kg intravenous dexmedetomidine before skin incision
223830603|NCT02441205|BEHAVIORAL|High Intensity Interval training|all subjects will undergo high intensity interval training 3 x per week for 10-12 weeks. the intervals of high-intensity (\~85% of maximal capacity) will be 5 to 10 bouts of 30 seconds at this intensity with rest periods in between intervals that range from 30 seconds to 2 minutes
223830604|NCT04396353|OTHER|Electronic questionnaire|Clinical, anthropometric, and sociodemographic variables to characterize the sample will be collected using the Google Form. The same tool will be used to collect clinical variables (outcomes), as well as to obtain data on the level of physical activity and sedentary behavior time (predictor variables) prior to SARS-CoV-2 contamination. For this, we will use the International Physical Activity Questionnaire (IPAQ).
223830605|NCT03454217|DRUG|Oxycodone|Postoperative pain treatment with oxycodone
223830606|NCT03454217|DRUG|Tramadol|Postoperative pain treatment with tramadol
223830607|NCT06369961|DRUG|transdermal fentanyl|Adult cancer pain patients switched from oral opioid to TDF
223830608|NCT01110720|DRUG|Davunetide|Davunetide Nasal Spray 30 mg BID IN 52 weeks
223830609|NCT01110720|DRUG|Placebo|Placebo Nasal Spray BID IN 52 weeks
223830610|NCT02874066|DRUG|PTV/r/OBV/DSV|Viekirax/Exviera for 12 weeks
223830611|NCT04675242|DRUG|NCX 4251|NCX 4251 Ophthalmic Suspension, 0.1% dosed once daily
223830612|NCT04675242|DRUG|Placebo|Vehicle of NCX 4251 Ophthalmic Suspension dosed once daily
223830613|NCT05975866|DIETARY_SUPPLEMENT|curcumin|Daily consumption of three 500 mg curcumin capsules with breakfast, lunch, and dinner
223830614|NCT05975866|BEHAVIORAL|Anti-inflammatory diet|The anti-inflammatory diet will be personalized based on each person's calorie intake in five meals. Achieving the goals of an anti-inflammatory diet by consuming only one type of food or following its principles in one meal is impossible and must be implemented consistently and regularly in a meal plan.
223830615|NCT02030275|DRUG|RXI-109|surgery.
223830616|NCT02030275|DRUG|Placebo|surgery.
223830617|NCT06480669|OTHER|Time Restricted Feeding|8 participants who practiced a 12/12 TRF (12 hours of fasting, from approximately 20:30 to 8:30 the following day).
223830618|NCT06480669|OTHER|Mediterranean Diet|A control group consisting of 9 participants who followed a standard Mediterranean diet.
223830619|NCT02903784|DEVICE|fMRI|Patient with grade 2 glioma and healthy volunteers use a brain imaging (fMRI)
223830620|NCT02903784|PROCEDURE|tractography|Patient with grade 2 glioma and healthy volunteers use a brain imaging (tractography)
223830621|NCT02903784|OTHER|neuropsychological examination|Patient with grade 2 glioma and healthy volunteers use a neuropsychological examination
223830622|NCT02923219|BIOLOGICAL|Adipose-derived stem cells|The adipose-derived stem cells therapy involve injection of patient's own adipose-derived stem cells. Local anesthetic will be applied to the face prior to the injection. For adipose-derived stem cells preparation, proper volume of fat cells will be collected from each patient just before each procedure. The stem cells will be injected into each standardized injection point in a superficial manner. The injections points are along the inferior border of cheek and mid-cheek and temple, where will be followed by 10-15 minutes of icing.
223830623|NCT03728192|OTHER|mangosteen extract|For Mangosteen group :DNA fragmentation assay is used to identify apoptosis.1×106 cells were harvested and treated with mangosteen pericarp extract for 48 h For Camptothecin group : Cells were also treated with standard anticancer drug Camptothecin to act as a positive control.
223830624|NCT00675545|DRUG|Docetaxel, Carboplatin|"Docetaxel Form: A white, lyophilized powder in vials of 50, 150, and 450 mg each, which should be stored at room temperature in a light-protected area.~Carboplatin Form: Taxotere is supplied as a sterile, non-aqueous, viscous solution with an accompanying sterile diluent (13% ethanol in water for injection). 20 and 80 mg strengths are available."
223830625|NCT03549611|DRUG|Multimodal Oral Drug Regimen|Regimen of 4 pharmacologic agents that provides analgesia by acting on 4 different physiologic pain pathways
223830626|NCT03549611|DRUG|Acetaminophen|Acetaminophen 975mg
223830627|NCT00100139|DRUG|Liposome Entrapped Paclitaxel Easy to Use (LEP-ETU)|
223830628|NCT00100139|DRUG|Paclitaxel for injection (Taxol)|
223830629|NCT02930564|OTHER|CDED + milk fat and gluten|CDED phase 1- induction phase a milk fat /emulsifier challenge (one scoop of ice cream and one slice of yellow processed cheese every day in the evening over 7 days), or a gluten/emulsifier challenge ( 3-4 slices of bread)
223830630|NCT00068666|DRUG|temozolomide|
223830631|NCT00068666|RADIATION|radiation therapy|
223830632|NCT04610151|OTHER|guided imagery|Guided Imagery CD: A guided imagery CD was prepared by a web designer with the recommendations of the researcher to include relaxing, soft and slow-paced, mixed nature sounds and photographs towards reducing pain in lower extremity surgical operation patients. The directives used for guidance, the audio recordings created as a result of literature review and the video lasted for 13 minutes (
223830633|NCT00320879|DRUG|irbesartan|
223835612|NCT05125016|DRUG|REGN4336|Administered once weekly (QW) by subcutaneous (SC) injection, or intravenous (IV) infusion
223835613|NCT05125016|DRUG|Cemiplimab|Administered concomitantly every 3 weeks (Q3W) by IV infusion
223835614|NCT05125016|DRUG|REGN5678|Administered concomitantly QW by IV infusion
223835615|NCT05125016|DRUG|Sarilumab|Administered once by IV infusion as prophylaxis prior to REGN4336 IV
223835616|NCT06610682|DRUG|Plixorafenib|Plixorafenib (900mg) daily co-administered with cobicistat (150mg daily) 7-28 days post-operatively, when clinically stable. Patients will take the drug daily by mouth under fasting conditions continuously for 28-day cycles until progressive disease or up to 24 cycles
223830634|NCT03263182|BEHAVIORAL|Introduction of the Safe Childbirth Checklist|"1. Adaptation of the SCC tool to Zambia: In order to produce a tool that is fully relevant to the Zambian context, a team of clinical experts from the MOH adapted the language of the SCC.~2. Training of trainers on the SCC by international experts: Ariadne Labs has designed a training-of-trainers (TOT) for coach training to support quality improvement initiatives, including the implementation of the WHO SCC. Members of the district mentorship team for Nchelenge District will receive this type of TOT training.~3. Following the TOT session, the district mentorship team will conduct facility-level training for health workers on using the SCC. Within target facilities, all public sector health workers will be invited to participate in the training.~4. Mentorship and support to facility-level health workers on using the SCC: The district mentorship team will carry out coaching and support visits to health facilities following the initial SCC training."
223830635|NCT02221895|OTHER|Postpartum follow up appointment 2-3 weeks after delivery|experimental arm
223830636|NCT02221895|OTHER|Postpartum follow up 6-8wk after delivery|control arm
223830637|NCT04401553|DRUG|cephalosporin|First tier antibiotics, cephalosporin, will be given before anesthesia induction in the subjects with a history of allergy-like event to beta-lactam
223830638|NCT04401553|DRUG|Second tier antibiotic (Vancomycin)|Second tier antibiotics, vancomycin, will be given before anesthesia induction for infection prevention in the subjects with a history of allergy-like event to beta-lactam (standard of care)
223830639|NCT01793246|DEVICE|probe based laser endomicroscopy (pCLE)|pCLE will be added to standard bronchoscopy for the purpose of characterizing lung cancer or for characterizing of acute rejection in transplanted lungs.
223830640|NCT03213015|DIAGNOSTIC_TEST|Ankle dorsiflexion measurement|It was used the test with WB, called Lunge Test, in which each evaluator marked a point 15 cm distal to the anterior tuberosity of the tibia (TAT) with a felt tip pen. After that the smartphone (app iHand) will be placed at this point. Between each measurement, the mark was removed with alcohol 70% The demarcated point served as a guide for positioning the smartphone. In order to standardize the smartphone positioning, BHome (home button on the iPhone), was aligned with the TAT pen mark. To ensure the same distance from the foot to the test, the distance of the hallux to the wall was measured (tape measure), recorded and reused for each test.
223830641|NCT01594658|PROCEDURE|Foam sclerotherapy|Foam application of 1% (Sklerol®, ICV Pharma, Bogota-Colombia), Reg INVIMA: 2002M-0001016, guided by ecography of insufficient superficial veins, doses from 10-40 cc of foam until obtaining endoluminal occlusion of the vein. The patient will rest for 8 minutes and then the leg will be covered with elastic bandage.
223830642|NCT01594658|PROCEDURE|conservative|This arm only has medical standard handling (healings performed by the nurse group)
223830643|NCT01037205|DRUG|DAS181 dry powder, formulation F02|10 mg delivered dose DAS181 in clear HPMC #3 Capsules
223830644|NCT01037205|DRUG|Respitose ML006 (DMV-Fonterra)|Lactose monohydrate
223830645|NCT04349761|DRUG|MyMD1|Isomyosamine 5mg capsules
223830646|NCT04349761|DRUG|Placebo|Placebo
223830647|NCT03141528|OTHER|Self-learning|Training without supervision
223830648|NCT03141528|OTHER|Instructor-led learning|Supervision by a tutor (either general practitioner or medical student, all trained in CPR teaching)
223830649|NCT03862989|PROCEDURE|Radiofrequency catheter ablation|A catheter is inserted into the heart and signals are recorded from the heart whilst at rest or whilst being stimulated by a catheter, in order to determine the site to ablate. Radiofrequency is then delivered to the target site in order to disrupt the pathological electrical activation which is causing the abnormal heart rhythm.
223830650|NCT02667444|DRUG|SB204 4%|Applied topically once daily
223830651|NCT02667444|DRUG|Vehicle Gel|Applied topically one daily
223830652|NCT01575782|DRUG|Chloroquine|Daily intake of Chloroquine during radiotherapy
223830653|NCT04930458|OTHER|Nanosilver fluoride|Nanosilver fluoride will be applied to the affected tooth in single application and then follow up after one and three months
223830654|NCT04930458|OTHER|Sodium fluoride with casein phosphopeptides amorphous calcium phosphate|Sodium fluoride with casein phosphopeptides amorphous calcium phosphatewill be applied to the affected tooth in single application and then follow up after one and three months
223830655|NCT04930458|OTHER|Sodium fluoride varnish|Sodium fluoride varnish will be applied to the affected tooth in single application and then follow up after one and three months
223830656|NCT05851911|BIOLOGICAL|sars-cov-2 vaccine or infection|Whether to vaccinate COVID-19 vaccine, or infect with sars-cov-2
223830657|NCT04982965|DRUG|Active Cannabis|400 mg of vaporized and inhaled active cannabis (5.1%)
223830658|NCT04982965|DRUG|Placebo Cannabis|400 mg of vaporized and inhaled placebo cannabis (\<.1%)
223830659|NCT01298180|DRUG|Growth hormone (Genotonorm® or Omnitrope®)|drug : the treatment will be begun in progressive dose by beginning by ¼ of the dose the first week, then ½ of the dose the second week, then 3/4 of the dose the third week and total dose the fourth week.
223830660|NCT01298180|PROCEDURE|DEXA, blood tests, H.G.P.O, osseous age.|"SPW, GHD, SPW-B :~blood tests : centralized dosage H.G.P.O : adjusted to children's age."
223830661|NCT01298180|PROCEDURE|biopsy|Biopsy : Cutaneous and fat tissue biopsy.
223830662|NCT04719013|DEVICE|Evoke radiofrequency device|Enrolled subjects will undergo up to 3 successive bi-weekly (every 2 weeks) treatments,
223830663|NCT01632332|BIOLOGICAL|HER-2/neu peptide vaccine|Given ID
223830664|NCT01632332|OTHER|laboratory biomarker analysis|Correlative studies
223830665|NCT06096220|PROCEDURE|Enucleation|Enucleation is complete removal of the cyst from the bony defect of the jaw affected by the lesion. Osteotomy is performed to allow access to the cyst, cystic wall is detached from the bone and removed completely.
223830666|NCT06096220|DIAGNOSTIC_TEST|incisional biopsy|Lesions clinically abd radiographically consistent with OKC will be submitted for histological examination to confirm the diagnosis of OKC
223830667|NCT06096220|DRUG|Application of 5-fluorouracil|5% 5-fluorouracil cream will be applied immediately after the enucleation to the cystic cavity for 24 hours
223830668|NCT06096220|DRUG|Application of Carnoy solution|Carnoy solution will be applied during the enucleation as described previously
223830669|NCT02004743|BEHAVIORAL|Intervention|"Psychological guidelines and PET~Patients will receive questionnaires at recruitment, 1 month, 3 months and 6 months based on the timeline of Diagnostic and Statistical Manual (DSM) -IV criteria for PTSD."
223830670|NCT02004743|OTHER|Treatment as usual|"Participants will experience treatment as usual.~Patients will receive questionnaires at recruitment, 1 month, 3 months and 6 months based on the timeline of Diagnostic and Statistical Manual (DSM) -IV criteria for PTSD"
223830671|NCT05963867|DRUG|BI 764532|BI 764532
223830672|NCT05963867|DRUG|[89Zr]Zr-BI 764532|\[89Zr\]Zr-BI 764532
223830673|NCT01609530|PROCEDURE|Liquid Nitrogen Cryotherapy|Every two weeks for a total of 5 treatments or until the patient clears, patients in the cryotherapy arm will be treated with 5-7 seconds of freeze time maintaining a 1mm freeze halo around the wart.
223830674|NCT01609530|PROCEDURE|Pulsed 1064nm Nd:YAG|Every 2 weeks for a total of five treatments or until the wart clears, patients in the laser arm will be treated with the Nd:YAG. The settings will be 180J, 20ms pulse width and 5mm spot size. For warts 3mm or less, a 3mm spot size will be used, 180J and 15ms. If the patient reports no response after treatment, including crusting or blistering, the energy will be increased by 10 J until 200J has been reached.
223830675|NCT00282360|DRUG|Trimetazidine|
223830676|NCT03696277|RADIATION|Stereotactic ablative body radiation (SABR)|SAbR treatment regimens including ≥25Gy x1 fraction, ≥12Gy x 3 fractions, or ≥8Gy x 5 fractions.
223830677|NCT00702182|DRUG|Vinorelbine (Navelbine)|Conventional Schedule Oral Vinorelbine on day 1 and day 8 of a 21 day schedule
223830678|NCT00702182|DRUG|Vinorelbine (Navelbine)|Metronomic Schedule Oral Vinorelbine 3 times a week
223830679|NCT00702182|DRUG|Erlotinib|Daily Oral Erlotinib 100 mg
223830680|NCT02885493|BEHAVIORAL|tests|
223835617|NCT06610682|DRUG|Cobicistat 150 MG [Tybost]|Plixorafenib (900mg) daily co-administered with cobicistat (150mg daily) 7-28 days post-operatively, when clinically stable. Patients will take the drug daily by mouth under fasting conditions continuously for 28-day cycles until progressive disease or up to 24 cycles
223830681|NCT02384005|OTHER|Self-anal exam arm|After a short pre-test the clinician will use a model to show a normal and diseased anal canal and then use pictures to show a self-DAE. The clinician will describe how to do a self-DAE for single men and partners. Next, the clinician will ask the participant to lower his pants for collection of anal human papillomavirus (HPV) DNA and cytology. The clinician will conduct a DAE and then participants will do self-DAE done in private. Then the research assistant will demonstrate the computer-assisted self-interview. When participants return to the clinician to receive the DAE results, the clinician will conduct a safety-related interview. The clinician will treat external anal disease, triage internal anal disease, and ask to be notified if a participant has any anus-related concerns in the following week. A complete appointment will require 70 minutes for singles and 105 minutes for couples. The PI will later conduct 3 focus groups.
223830682|NCT01421082|DEVICE|Lung Volume Reduction Coil (LVRC) (PneumRx, Inc.)|Lung Volume Reduction Coil (LVRC)
223830683|NCT00224523|DRUG|GW685698X|
223830684|NCT00224523|DRUG|mometasone furoate|
223830685|NCT04415385|DRUG|Camrelizumab|200mg, intravenous infusion for 30 minutes (including the time of the tube, the overall infusion time is not shorter than 20 minutes, no longer than 60 minutes), once every 2 weeks.
223830686|NCT04415385|DRUG|Apatinib|250 mg, orally once a day. Take about half an hour after a meal with warm water.
223830687|NCT00714350|BEHAVIORAL|New ICU Display Visualization|
223830688|NCT05033080|DRUG|VX-121/TEZ/D-IVA|Fixed-dose combination tablets for oral administration.
223830689|NCT05033080|DRUG|ELX/TEZ/IVA|Fixed-dose combination tablets for oral administration.
223830690|NCT05033080|DRUG|IVA|Tablet for oral administration.
223830691|NCT05033080|DRUG|Placebo (matched to VX-121/TEZ/D-IVA)|Placebo matched to VX-121/TEZ/D-IVA for oral administration.
223830692|NCT05033080|DRUG|Placebo (matched to ELX/TEZ/IVA)|Placebo matched to ELX/TEZ/IVA for oral administration.
223830693|NCT05033080|DRUG|Placebo (matched to IVA)|Placebo matched to IVA for oral administration.
223830694|NCT06033651|RADIATION|x-ray|AP view of pelvis
223830695|NCT04801745|OTHER|Healthy vegan diet|Participants will attend group lessons and individual nutrition counseling to help them adopt a healthy vegan diet.
223830696|NCT04801745|OTHER|My Plate - Low Purine|Participants will attend group lessons and individual nutrition counseling to help them adopt a balanced diet in accordance with my plate, and emphasis on choosing low purine options from the protein food groups.
223830697|NCT04801745|OTHER|Amla fruits|Participants will be provided with powdered amla fruits, and will be instructed to take 3g per day.
223830698|NCT01566305|DIETARY_SUPPLEMENT|Buttermilk without added egg-yolk|Buttermilk without added egg-yolk
223830699|NCT01566305|DIETARY_SUPPLEMENT|Buttermilk with added egg yolk|Buttermilk with added egg yolk
223830700|NCT01566305|DIETARY_SUPPLEMENT|Skimmed milk with added egg-yolk|Skimmed milk with added egg-yolk
223830701|NCT01566305|DIETARY_SUPPLEMENT|Skimmed milk without added egg yolk|Skimmed milk without added egg yolk
223830702|NCT03560245|DRUG|Bryostatin|The investigational drug product, bryostatin, is a sterile, pyrogen-free, lyophilized powder intended for IV infusion upon reconstitution and dilution.
223830703|NCT03560245|OTHER|Placebo|The placebo is a sterile, pyrogen-free, lyophilized powder identical in appearance to the experimental drug
223830704|NCT03270813|BEHAVIORAL|Relaxation training plus RAGE-Control|RAGE-Control is a biofeedback videogame in which players shoot at enemies while avoiding allies. The player's baseline heart rate is taken before the game and entered into the computer. During the game, the player wears a heart rate monitor, and if the player's heart rate rises above baseline, they are unable to shoot. The player must use relaxation skills to decrease their heart rate below the baseline before they can resume play. Participants will undergo relaxation training during each of 6 sessions, and then practice the skills they learned while playing the RAGE-Control videogame.
223830705|NCT03270813|BEHAVIORAL|Relaxation training plus Sham Videogame|The Sham videogame is a videogame in which players shoot at enemies while avoiding allies. The player wears a heart rate monitor during the game, but the heart rate does not affect the functioning of the game in any way. Participants will undergo relaxation training during each of 6 sessions, and then practice the skills they learned while playing the Sham videogame.
223830706|NCT04632732|DIAGNOSTIC_TEST|COVID-19 test|Nasal pharyngeal swab
223830707|NCT04632732|DIAGNOSTIC_TEST|Blood sampling|20cc of blood will be collected each 7 days during 28 days.
223830708|NCT03082833|DRUG|AZD2014|AZD2014 is a selective dual mTOR kinase inhibitor targeting both mTORC1 (rapamycin sensitive) and mTORC2 (rapamycin insensitive) complexes of mammalian Target Of Rapamycin (mTOR).
223830709|NCT02543190|BEHAVIORAL|compliance surveillance and improvement strategy|External monitor to ensure compliance with an educational protocol.
223830710|NCT03135457|PROCEDURE|Autologous RBC transfusion|Autologous RBC transfusion 300ml 10 ml/min
223830711|NCT03135457|PROCEDURE|Saline transfusion|Saline transfusion 300ml 10ml/min
223830712|NCT04096573|DRUG|LC51-0255|LC51-0255
223830713|NCT04096573|DRUG|Placebo|Placebo
223830714|NCT03675074|DEVICE|Neujia|Neujia devices endoscopically deployed for jejunoileal compression anastomosis
223830715|NCT01263106|DRUG|LY2216684|18-mg LY2216684 oral dose
223830716|NCT01263106|DRUG|Theophylline|200-mg theophylline oral dose
223830717|NCT00150384|DRUG|Amlodipine/Atorvastatin|
223830718|NCT03662360|OTHER|essential oils|Following a specific schema, the randomization will be perfomed. Patients enrolled in Group B will receive in environmental diffusion two essential oils, to define their possible effectiveness in the control of the psychological and behavioural disorders
223830719|NCT05053217|PROCEDURE|transforaminal epidural steroid injection|In the transforaminal approach, a small amount of drug is injected into the epidural space, and in previous studies, reduction in pain and improvement in functionality were found in patients with lumbar radicular pain in the short and medium term.
223830720|NCT03939247|OTHER|Active Tecaretherapy|"The Tecaretherapy: consists of using a specific device providing high frequencies (between 300 kHz and 1 MHz) supposed to accelerate the tissues healing process"
223830721|NCT03939247|OTHER|Inactive Tecaretherapy|"Inactive Tecaretherapy: the device will not provide any current."
223830722|NCT03939247|OTHER|CPT|Conventional physiotherapy treatment (massage, eccentric exercises, stretching)
223830723|NCT06448455|OTHER|Observation|Collect relevant data of patients
223830724|NCT00170937|DRUG|valsartan plus hydrochlorothiazide|
223830725|NCT03996044|OTHER|Teeth brushing and flossing|All participants will be instructed to brush with dentifrice containing amine fluoride in their composition (Elmex®) and floss with dental flossing, 3 times a day after meals for 30 days.
223830726|NCT03996044|OTHER|Tongue scraping|Tongue scraping will be performed by the same operator on all participants. Posterior-anterior movements will be performed with the scraper over the tongue dorsum, followed by cleaning the scraper with a gauze. This procedure will be performed ten times in each patient, in order to standardize the mechanical removal of the tongue coating.
223830727|NCT03996044|RADIATION|Antimicrobial Photodynamic Therapy (aPDT)|One session of aPDT will be performed with the photosensitizer (PS) urucum manipulated at a concentration of 20% (Fórmula e Ação®) in spray, to be applied in sufficient quantity to cover the middle third and back of the tongue (5 sprinkles) for 5 minutes for incubation. The excess will be removed with a sucker in order to keep the surface wet with the PS itself, without using water. Six points with a distance of 1 cm between them will be irradiated, considering the halo of light scattering and effectiveness of aPDT. The apparatus shall be precalibrated at wavelength 440-480nm for 60 seconds per point, irradiance of 450mW/cm and the light shall be irradiated so that a halo of 2cm diameter is formed per point.
223830728|NCT03996044|BIOLOGICAL|Probiotics|Pharmacy-manipulated capsules containing strains of Lactobacillus salivarius WB21 (6.7 x 108 CFU) and xylitol (280mg) will be used. Forty-two capsules will be delivered for each patient, who should take 1 capsule 3 times a day after meals for 14 days.
223830729|NCT01985477|DRUG|Lenalidomide|"Phase I All Patients - Induction: Lenalidomide starting dose 25 mg by mouth 1 time every day on Day 1-21.~Phase II Group A: Lenalidomide starting dose: Dose tolerated prior to enrollment.~Maintenance Therapy: Phase I and Phase II Group A: Maintenance therapy lenalidomide at dose level tolerated at completion of cycle 3 for 21/28 days.~Phase II Group B: Lenalidomide will be given as a single oral dose at the level patient was on at the time of progression on single agent lenalidomide prior to study enrollment."
223830730|NCT01985477|DRUG|Dexamethasone|"Phase I All Patients - Induction: Dexamethasone starting dose 40 mg by mouth on Days 1,8,15,22.~Phase II Group A: Dexamethasone starting dose: Dose previously on when progressing prior to study entry.~Maintenance Therapy: Phase I and Phase II Group A: Dexamethasone at last tolerated dose on Days 1, 8, 15 and 22."
223830731|NCT01985477|DRUG|All-Trans Retinoic Acid (ATRA)|"Phase I All Patients - Induction: ATRA starting dose 25 mg/m2 by mouth 2 times each day on Days 1-21.~Phase II Group A: ATRA starting dose: MTD from Phase I.~Maintenance Therapy: Phase I and Phase II Group A: ATRA at dose determined in Phase I for 14/28 days.~Phase II Group B: All-Trans Retinoic Acid (ATRA) starting dose: MTD from Phase I.~Maintenance Therapy Group B: ATRA at the dose determined in the Phase I portion of the trial for 14/28 days."
223830732|NCT00738452|OTHER|high performance liquid chromatography|Blood evaluation 0 minutes, 1 hour, 4 hours, 1 day, 2 days, 3-5 days and 6-7 days post start of antibody infusion. 24 hour urine sample evaluation daily for 5 consecutive days post antibody infusion.
223830733|NCT00738452|OTHER|pharmacological study|Blood evaluation 0 minutes, 1 hour, 4 hours, 1 day, 2 days, 3-5 days and 6-7 days post start of antibody infusion. 24 hour urine sample evaluation daily for 5 consecutive days post antibody infusion.
223830734|NCT00738452|PROCEDURE|radionuclide imaging|Approximately 1-3 hours, 1 day, 2 days, 3-5 days and 6-7 days post infusion.
223830735|NCT00738452|PROCEDURE|single photon emission computed tomography|Approximately 2 days and 3-5 days post infusion
223830736|NCT00738452|RADIATION|radiation therapy|3-6 mCi Indium-111 labeled cT84.66(5mg) and dose escalation (depending on toxicities observed from previous dosages) from a starting dose of 8mCi/m2 Y-90-cT84.66.
223830737|NCT00738452|RADIATION|yttrium Y 90 anti-CEA monoclonal antibody cT84.66|Dose escalation (depending on toxicities observed from previous dosages) from a starting dose of 8mCi/m2 Y-90-cT84.66.
223830738|NCT05666375|PROCEDURE|Percutaneous translumbar and transhepatic permcath|For selected ESRD patients who have exhausted all conventional access routes , translumbar and transhepatic insertion of long term hemodialysis catheters provide additional sites for access
223830739|NCT03228017|DRUG|Aspirin and/or Atorvastatin|This follow-up will allow us to assess how aspirin and/or atorvastatin affect platelet and endothelial function and inflammation.
223830740|NCT00819065|DRUG|Botulinum toxin type A from laboratory Lanzhou|Patients will receive botulinum toxin type A from laboratory Lanzhou either at time of allocation (arm BTA Lanzhou/Allergan) or three months later (arm BTA Allergan/Lanzhou), so that all patients will receive both drugs in a crossover model. Application will be performed according to standard protocol and respecting parameters of the patients former sessions (if there were any), by a trained investigator, unaware of the kind of TBA in use. Standard dilution will be employed, within the usual dose and application spots (for patients already in treatment) or standard (for patients yet to start treatment). Identical dose will be used, with 2ml of saline solution 0,9% dilution for each 100units, thus, there will be no difference for the patient or investigator concerning the applicated volume.
223830741|NCT00819065|DRUG|Botulinum toxin type A from laboratory Allergan|Patients will receive botulinum toxin type A from laboratory Allergan either at time of allocation (arm BTA Allergan / Lanzhou) or three months later (arm BTA Lanzhou /Allergan), so that all patients will receive both drugs in a crossover model. Application will be performed according to standard protocol and respecting parameters of the patients former sessions (if there were any), by a trained investigator, unaware of the kind of BTA in use. Standard dilution will be employed, within the usual dose and application spots (for patients already in treatment) or standard (for patients yet to start treatment). Identical dose will be used, with 2ml of saline solution 0,9% dilution for each 100units, thus, there will be no difference for the patient or investigator concerning the applicated volume.
223830742|NCT03479190|PROCEDURE|ultrasound guided injection of Platelet rich plasma|Platelet rich plasma (PRP) injection into trochanteric area under ultrasound guidance
223830743|NCT03479190|PROCEDURE|ultrasound guided injection of Normal Saline|ultrasound guided injection of Normal Salineinto trochanteric area under ultrasound guidance
223830744|NCT01397565|PROCEDURE|Laparoscopic cholecystectomy|Laparoscopic cholecystectomy
223830745|NCT01397565|PROCEDURE|Minilaparoscopic cholecystectomy|Laparoscopic cholecystectomy performed using minilaparoscopic instruments
223830746|NCT04809792|RADIATION|SBRT on the MR-Linac|Radiotherapy is performed on the 1.5 T MR Linac
223830747|NCT04992936|DIETARY_SUPPLEMENT|Extract from the wine industry|The product will be presented in powder format in a single container and with a measuring spoon of the daily dose.
223830748|NCT04992936|DIETARY_SUPPLEMENT|Placebo|The product will be presented in powder format in a single container and with a measuring spoon of the daily dose.
223830749|NCT03777865|BIOLOGICAL|13vPnC|All subjects receive a single dose (0.5mL) of 13vPnC
223830750|NCT02640976|DRUG|Human menopausal gonadotrophin (HMG)|\[Merional® 75 IU ampoules, IBSA institut\]
223830751|NCT02640976|DRUG|GnRH antagonist Cetrorelix|\[Cetrotide® 0.25 mg syringes, Merck Serono\]
223830752|NCT02640976|DRUG|Human chorionic gonadotrophin (hCG)|\[Choriomon® 5000 IU ampoules, IBSA institut\]
223830753|NCT05909787|OTHER|Auto-questionnaire|MCH (Montreal Children's Hospital) self questionnaire completed by the parents
223830754|NCT02611830|DRUG|Vedolizumab 300 mg IV|Vedolizumab intravenous infusion
223830755|NCT02611830|DRUG|Placebo IV|Vedolizumab intravenous infusion placebo
223830756|NCT02611830|DRUG|Vedolizumab 108 mg SC|Vedolizumab subcutaneous injection
223830757|NCT02611830|DRUG|Placebo SC|Vedolizumab subcutaneous injection placebo
223835618|NCT01083966|DRUG|Bevacizumab (Avastin)|"Super-Selective Intraarterial Intracranial Infusion of Bevacizumab in Vestibular Schwannoma~This phase I clinical research trial will test the hypothesis that Bevacizumab can be safely used by direct intracranial superselective intraarterial infusion up to a dose of 10mg/kg to ultimately enhance survival and hearing function of patients with VS"
223830758|NCT04842396|OTHER|Experimental:Motorized cycle ergometer|Cycling training on the MOTOmed Muvi for 20 minutes 3 days per week for 6 weeks. Moreover, control of adverse events throughout the trial was measured through the assessment and monitoring of vital signs before, during (within the first 10 minutes), and after the intervention sessions. Vital signs \[heart rate (per minute), systolic and diastolic blood pressure (in millimeters of mercury, mm Hg), and oxygen saturation (in percentage)\] were monitored by a nurse and a medical doctor using mobile finger pulse oximeters.
223830759|NCT02947607|PROCEDURE|Colon biopsies|
223830760|NCT00188318|PROCEDURE|hyperfractionated accelerated radiotherapy|
223830761|NCT00865111|DRUG|Bupropion 150 mg Extended-Released Tablet, single dose|A: Experimental Subjects received Abrika formulated products under fasting conditions
223830762|NCT00865111|DRUG|Wellbutrin SR® 150 mg Sustained-Release Tablet, single dose|B: Active comparator Subjects received GlaxoSmithKline formulated products under fasting conditions
223830763|NCT03508336|DIAGNOSTIC_TEST|Coma Recovery Scale-Revised|"Patients with disorders of consciousness were assessed by Coma Recovery Scale-Revised (CRS-R). In addition, we selected four stimuli: 1) only a command (as recommended in CRS-R), which was open your mouth; 2) only a spoon without a command; 3) a spoon and a command, the command was there is a spoon and open your mouth; 4) a spoon with water and a command, the command was there is a spoon with water and open your mouth. In brief, we presented these stimuli orderly in front of the patient's mouth and presented any one of them over 4 trials at 15 second intervals."
223835619|NCT01824914|DEVICE|McGrath Videolaryngoscope|A kind of portable videolaryngoscopes, produced by Aircraft Medical. It has been used for difficult airway.
223830764|NCT02058290|DRUG|IV morphine sulfate or Sponsor-approved equivalent|Patients in this group will receive IV morphine sulfate or Sponsor-approved equivalent via a patient-controlled analgesia (PCA) pump, as needed. The PCA pump will be set up postsurgically as soon as possible and prior to the patient leaving the post-anesthesia care unit (PACU) or immediately upon transfer to a floor if the stay in the PACU is less than one hour.
223830765|NCT02058290|DRUG|EXPAREL|"Patients will receive 266 mg EXPAREL diluted with preservative-free 0.9% normal saline to a total volume of 40 cc administered via wound infiltration prior to wound closure. When not contraindicated, 30 mg IV ketorolac will be given at the end of surgery. If not indicated, an IV non-steroidal anti-inflammatory drug (NSAID) may be substituted per the site's standard of care.~All patients will be offered rescue analgesia, as needed."
223830766|NCT05902221|DRUG|amoxicillin or moxifloxacin|Antibiotic treatment back bone during 12 weeks
223830767|NCT05902221|DRUG|amoxicillin or moxifloxacin + rifampicin|Antibiotic treatment back bone during 12 weeks + rifampicin
223830768|NCT05295914|DIAGNOSTIC_TEST|TREAT-B score|TREAT-B score: ALT(alanine transferase), HBeAg REACH-B score: sex, ALT, HBV viral load, age WHO-simplified score: ALT, cirrhosis
223830769|NCT05956548|PROCEDURE|external securement of scs leads during the scs trial period|two groups- one group will have an anchor device used alone to secure the leads, the second group will have an anchor device with a suture to secure the leads
223830770|NCT02578511|DRUG|Ixazomib|Patients who have been on stable doses of 6 - MP, vincristine, and methotrexate for a minimum of eight weeks and have at least six months remaining of maintenance are eligible to receive Ixazomib, which will be administered on days 1, 8 and 15.
223830771|NCT02626858|DEVICE|extra treatment planning CT-scan|Beside the standard post-operative CT-scan, an extra pre-operative CT-scan is performed.
223830772|NCT05605717|RADIATION|Fibroscan|Liver fibroscan and ultrasonography
223830773|NCT00210522|DRUG|RWJ 333369|Open-Label Extension: One 200 mg to 600mg tablet taken twice daily (up to a maximum of 1200mg/day) up to 1 year or the time that RWJ-333369 is available by prescription or the study is terminated by Sponsor.
223830774|NCT03751163|DRUG|Tranexamic Acid Oral Product|Encapsulated tranexamic acid 250 mg
223830775|NCT03751163|DRUG|Hydroquinone 4% Cream|Hydroquinone 4% Cream
223830776|NCT03751163|OTHER|Sunscreen|Sunscreen SPF 30
223830777|NCT03751163|DEVICE|Placebo|Encapsulated placebo
223830778|NCT03666884|DRUG|COE 2*1 (Restasis) + PFAT Refresh Single dose) 8*1|clinical improvement in oxford scale, ocular surface disease index, schirmers test, tear break up time, fluorescein staining of eye
223830779|NCT03666884|BIOLOGICAL|AS 50% eye drops 8*1|clinical improvement in oxford scale, ocular surface disease index, schirmers test, tear break up time, fluorescein staining of eye
223830780|NCT00000664|DRUG|Interleukin-2, Polyethylene Glycolated|
223830781|NCT00000664|DRUG|Zidovudine|
223830782|NCT02484079|PROCEDURE|Polypectomy|
223830783|NCT03421496|DRUG|Cannabidiol Oral Solution|An oral solution containing pharmaceutical grade cannabidiol (nonplant-based).
223830784|NCT03421496|DRUG|Placebo|Matching oral solution
223830785|NCT03421496|DRUG|Vigabatrin|Powder suspension
223830786|NCT06035614|DEVICE|exciplex|exciplex, excimer lamp 308nm produced by clarteis
223830787|NCT06035614|DRUG|Tacrolimus ointment|tacrolimus monohydrate ointment 0.1% TACRUS
223830788|NCT01357330|DRUG|SAR245408 (XL147)|Pharmaceutical form:capsule and tablet Route of administration: oral
223830789|NCT01357330|DRUG|MSC1936369B|Pharmaceutical form:capsule Route of administration: oral
223830790|NCT04810039|OTHER|Predict the outcome of the Glasgow Outcome Scale|Predict the outcome of the Glasgow Outcome Scale (GOS) score at 6 months compared to the actual outcome, in 20 anonymized records.
223830791|NCT05822921|BEHAVIORAL|In-person Psychoeducation (IP)|Parents will attend two 60-minute (i.e. one day per week, for the next two weeks), in-person psychoeducation sessions on the MAC, in or near their hometown. During these sessions, a clinician will discuss a series of psychoeducation topics supplemented with PowerPoint slides. Across the two sessions, the following topics will be covered: (1) signs/symptoms and epidemiology of ASD, (2) risk factors associated with developing ASD (e.g., genetics, neurobiology, environment, social motivation), (3) navigating the IEP process, and (4) evidence-based best practices recommended for their child's profile of ASD symptoms and co-occurring conditions. This delivery method will allow parents to ask questions and receive immediate, live, and detailed answers from an expert clinician, to focus on specific examples relevant to their child, and to foster ASD knowledge and efficacy in helping their child.
223830792|NCT05822921|BEHAVIORAL|Telehealth Psychoeducation (TH)|Parents in this group will attend two 60-minute sessions, remotely via a live video chat platform, rather than in-person. Otherwise, it will follow the same format and PowerPoint materials as the IP Group. Sessions will still be facilitated by a clinician, thus maintaining the option to ask questions, discuss personalized examples, etc. For families without computer and internet access, the family will be assisted with to connecting to internet access at a private and convenient location (e.g., a church, library, or local community services agency). In the event that this is not possible, the family will be randomized to one of the other two groups.
223835620|NCT02257255|PROCEDURE|Pfannenstiel cesarean section|Pain scales ( VAS and McGill ) 6, 12 and 24 hours after cesarean to pain assessment
223830793|NCT05822921|BEHAVIORAL|Psychoeducation as Usual (PAU)|Parents in this group will receive basic paper psychoeducation resources, distributed at their feedback session. It will be up to each parent how frequently and diligently these resources are reviewed. This should be akin to what a family might have access to at their pediatric or primary care office. To be consistent across study groups, the materials produced for these parents will be comprehensive and will include the same span of content as the PowerPoint slides used in the other two groups, but without structured sessions facilitated by a clinician. Upon distribution of materials, parents will be provided with our contact information and encouraged to reach out if any questions occur. Parents in the paper informational materials group will have the option to complete two in-person or video conference psychoeducation sessions after the end of the study, if preferred (i.e., 6 months later).
223830794|NCT05830435|BEHAVIORAL|Trier social stress test|TSST-VR-friendly: The assistant behind the desk asks the participant to prepare a small talk on their favourite holiday within 5 minutes. Then the participant is asked to tell about his holiday for 5 minutes. Then the participant is asked to do a simple math task: adding the number 5 to 0 for 5 minutes. The research assistant gives friendly gestures and verbal encouragements. TSST-VR-neutral: The assistant asks the participant to prepare a speech for a job interview in the upcoming 5 minutes. Then the participant is asked to deliver the speech for 5 minutes in front of two panelists and camera. Then the participant is asked to do a math task, subtracting the number 13 from 1022 for 5 minutes. During the performance the two panellist have neutral gestures and give neutral verbal instructions. TSST-VR unfriendly: The procedure of the TSST-VR unfriendly is the same as the neutral TSST-VR, with the addition that the two panellist give unfriendly gestures such as tapping on the table.
223830795|NCT00544544|DRUG|Riluzole|50 mg twice daily for 2 weeks 50 mg in the morning and 100 mg in the evening for 1 week 100 mg twice daily for 3 weeks
223830796|NCT00826163|DRUG|Budesonide|Inhaled budesonide 400 mcg twice a day for 2 weeks
223830797|NCT02853266|OTHER|laboratory biomarker analysis|Archived serum samples are analysed for measurement of biomarker NCRA
223830798|NCT03406702|DRUG|CX-8998|T-type calcium channel blocker
223830799|NCT03032354|DRUG|Lactobacillus rhamnosus GG and Bifidobacterium lactis BB12|Combination therapy of probiotics during 6 months
223830800|NCT03032354|OTHER|Placebo, (Placebo group)|Placebo during 6 months
223830801|NCT03763955|BEHAVIORAL|MIRT|"4 week MIRT provide:~1. front to front treatment (1 hour/day for 5 days/week)~2. treatment with robotic devices (1 hour/day for 5 days/week)~3. occupational therapy (1 hour/day for 5 days/week)"
223830802|NCT06474689|OTHER|EMDR|EMDR is based on the Adaptive Information Process (AIP) model, which posits that the traumatic event experienced by a subject is stored in memory along with the disturbing emotions, perceptions, cognitions, and physical sensations that characterized that moment. All this information is stored in a dysfunctional way within neural networks and unable to connect with other networks with useful information. The information enclosed in the neural networks, not being able to be processed, continue to cause discomfort in the subject, up to the onset of pathologies such as post-traumatic stress disorder (PTSD) and other psychological disorders. The goal of EMDR is to restore the adaptive processing of information in order to achieve the adaptive resolution by creating new and more functional connections.
223830803|NCT06474689|OTHER|CBT|CBT-E is based on the transdiagnostic theory for eating disorders. According to this theory, there is an overvaluation of shape, weight, eating and their control that people use to judge themselves which represents the core feature of maintaining eating disorder symptoms including binge eating. The goals of CBT-E are to increase the understanding of eating disorders, reduce weight concerns, and establish a pattern of regular eating by addressing the mechanisms that have been maintaining the eating disorder psychopathology including body image disturbances and reactions to life events and emotions. The goals of CBT-OB are to help patients to reach, accept and maintain a healthy weight loss by adopting a healthy lifestyle.
223830804|NCT01228422|BIOLOGICAL|Interferon alpha 2a|3MUI
223830805|NCT00004390|DRUG|desipramine|
223830806|NCT00004390|DRUG|methadone|
223830807|NCT00004390|DRUG|morphine|
223830808|NCT00004390|DRUG|nortriptyline|
223830809|NCT04520555|DEVICE|Laryngeal mask airway|LMA Flexible is a supraglottic airway device, which can be moved out of the surgical field without displacement of the cuff, or loss of seal for the anesthetist
223830810|NCT04520555|DEVICE|Endotracheal tube|Endotracheal tube is a plain tube, which is most commonly used in general anesthesia.
223830811|NCT00762021|DEVICE|SN60AT|Implantation with the AcrySof Intraocular Lens Model SN60AT following cataract removal.
223830812|NCT00762021|DEVICE|SN60WF|Implantation with the AcrySof Intraocular Lens Model SN60WF following cataract removal.
223830813|NCT01414426|DRUG|vandetanib|Given PO
223830814|NCT01414426|OTHER|placebo|Given PO
223830815|NCT01414426|OTHER|immunohistochemistry staining method|Correlative studies
223830816|NCT01414426|OTHER|laboratory biomarker analysis|Correlative studies
223830817|NCT01414426|PROCEDURE|biopsy|Correlative studies
223830818|NCT01414426|OTHER|pharmacological study|Correlative studies
223830819|NCT00601003|DRUG|Nifurtimox|30mg/kg/day PO divided into TID dosing q day
223830820|NCT00601003|DRUG|Cyclophosphamide|250 mg/m2/dose in normal saline, IV, infused over 30 minutes on days 1-5 of each cycle.
223830821|NCT00601003|DRUG|Topotecan|0.75mg/m2/dose, in normal saline, IV, infused over 30 minutes on days 1-5 of each cycle.
223830822|NCT04707911|BEHAVIORAL|Social Media Intervention|Social media based intervention using Instagram with up to 3 posts per day for 30 days
223830823|NCT01857622|DRUG|DU-176b 15mg|oral DU-176b 15mg once daily
223830824|NCT01857622|DRUG|DU-176b 30mg|oral DU-176b 30mg once daily
223830825|NCT01857622|DRUG|DU-176b 60mg|oral DU-176b 60mg once daily
223830826|NCT04866862|DRUG|Combination of Fruquintinib and Camrelizumab|Fruquintinib 5mg d1-21+Camrelizumab 200 mg d1
223830827|NCT05266014|DRUG|tinlarebant|"Phase 1b Portion: tinlarebant will be self-administered orally once daily for 2 cycles, 14 days per cycle.~Phase 2 portion: tinlarebant will be self-administered orally once daily for 24 months."
223830828|NCT05222035|DRUG|Camrelizumab|PD-1 inhibitor: Camrelizumab, 200 mg, intravenously (IV) , Day 1, Q3W, until progressive disease (PD) or unacceptable toxicity for a maximum of up to 35 cycles (up to approximately 2 years).
223830829|NCT05222035|DRUG|G-CSF|G-CSF: mecapegfilgrastim, 6 mg, subcutaneous injection, Day 1, Q3W, until stop using Camrelizumab, progressive disease (PD) or unacceptable toxicity.
223830830|NCT03341663|COMBINATION_PRODUCT|Coronary angiography,Canadian Cardiovascular Society angina pectoris classification for the severity of angina and electronic Von Frey instrument for testing the degree of acupoint sensitization|All the interventions were tested for only once
223830831|NCT00749801|DRUG|Nattokinase|2 capsules in the morning and before bed-time daily
223830832|NCT06087562|DRUG|Ropivacaine 0.5% Injectable Solution 20mL|Ultrasound-guided iPACK block with 20mL of 0,5% ropivacaine
223830833|NCT06087562|DRUG|0,9% normal saline 20mL|Ultrasound-guided placebo block with 20mL of 0,9% normal saline
223830834|NCT04959149|DEVICE|AirTraq videolaryngoscope|intubation of morbidly obese patient using Airtraq videolaryngoscope
223830835|NCT01291225|OTHER|Playground renovation and development|Playgrounds in Chillicothe will be renovated based on priorities determined by audits.
223830836|NCT01291225|BEHAVIORAL|Educational campaign|Educational materials will be developed and distributed in Ross County.
223830837|NCT06140563|OTHER|anticoagulation dosing|In one arm the normal amount of anticoagulation is administered at the dialysis start, while this is only a quarter of the normal amount of anticoagulation in the other arm.
223830838|NCT01267253|DRUG|Brivanib Alaninate|Given PO
223830839|NCT01267253|OTHER|Laboratory Biomarker Analysis|Correlative studies
223830840|NCT01450605|DRUG|No Intervention|Patients are previously on Reyataz® treatment or initiated Reyataz® for the first time
223830841|NCT04444687|DIAGNOSTIC_TEST|Test for SARS-CoV-2|"* As part of normal emergency evaluation due to symptoms or following standard operation procedure for patients heading to the operating theatre the status for SARS-CoV-2 is evaluated (gene expert, Roche)~* After intubation samples are acquired in the OR~  1. tracheal aspirate specimen directly after intubation (as part of standard operation procedures for CoVID-19 patients)~ 2. blood sample (as part of standard operation procedures for CoVID-19 patients)~ 3. fluid sample and smears from abdominal cavity as soon as this is accessed either by laparoscopy or laparotomy~ 4. Sample from laparoscopic smoke filters (Laparoshield™ Laparoscopic Smoke Filtration System)~* Fluid samples and smears are frozen at -80 degrees celcius for conservation in the OR."
223830842|NCT00014196|DRUG|cisplatin|
223830843|NCT00014196|DRUG|docetaxel|
223830844|NCT00014196|RADIATION|radiation therapy|
223830845|NCT05291182|DRUG|SY-4835|WEE1 inhibitor
223830846|NCT02768558|RADIATION|Radiation Therapy (RT)|2 Gy fractions once a day, 5 days per week, for a total of 60 Gy in 30 fractions.
223830847|NCT02768558|DRUG|Cisplatin|Concurrently with radiation therapy, 50 mg/m2, IV, on days 1, 8, 29, and 36, to begin with day 1 of radiation therapy.
223830848|NCT02768558|DRUG|Etoposide|Concurrently with radiation, 40 mg/m2, IV, on days 1-5 and 29-33, to begin with day 1 of radiation therapy.
223830849|NCT02768558|DRUG|Nivolumab|Beginning 4-12 weeks after chemoradiation, 240 mg, IV, every 2 weeks for 16 weeks, then 480 mg, IV, for 36 weeks.
223830850|NCT02768558|OTHER|Placebo|Beginning 4-12 weeks after chemoradiation, 240 mg, IV, every 2 weeks for 16 weeks, then 480 mg, IV, for 36 weeks.
223830851|NCT04318093|DRUG|BMS-986259|Specified dose on specified days
223830852|NCT04318093|OTHER|Placebo|Specified dose on specified days
223830853|NCT03470714|OTHER|Force Irradiation|For the force irradiation, while the subjects perform dominant elbow flexion at an angular velocity of 60°/s for concentric contractions, 30°/s for eccentric contractions, at 90° elbow flexion position for isometric contractions with a maximal effort level, electrical activity of the non-dominant biceps brachii and triceps brachii muscles are recorded.
223830854|NCT03470714|OTHER|Kinesiotaping|For kinesiotaping, the elbow positioned in 30°-45° flexion and kinesiotaping facilitation technique is applied origin to insertion of non-dominant biceps brachii muscle before 24 hours the experiment.
223830855|NCT02626221|OTHER|Non Interventional Study|Non Interventional Study
223830856|NCT00420758|DIETARY_SUPPLEMENT|Food supplement: fortified spread|Provision of fortified spread
223830857|NCT00420758|DIETARY_SUPPLEMENT|Food supplement: maize-soy flour|Provision of corn-soy blend (maize-soy flour)
223830858|NCT03219268|BIOLOGICAL|tebotelimab 1 mg|1 mg IV every other week
223830859|NCT03219268|BIOLOGICAL|tebotelimab 3 mg|3 mg IV every other week
223830860|NCT03219268|BIOLOGICAL|tebotelimab 10 mg|10 mg IV every other week
223830861|NCT03219268|BIOLOGICAL|tebotelimab 30 mg|30 mg IV every other week
223830862|NCT03219268|BIOLOGICAL|tebotelimab 120 mg|120 mg IV every other week
223830863|NCT03219268|BIOLOGICAL|tebotelimab 300 mg|300 mg IV every other wee
223830864|NCT03219268|BIOLOGICAL|tebotelimab 400 mg|400 mg IV every other wee
223830865|NCT03219268|BIOLOGICAL|tebotelimab 600 mg|600 mg IV every other week
223830866|NCT03219268|BIOLOGICAL|tebotelimab 800 mg|800 mg IV every other week
223830867|NCT03219268|BIOLOGICAL|tebotelimab 1200 mg|1200 mg IV every other week
223830868|NCT03219268|BIOLOGICAL|margetuximab|15 mg/kg IV every 3 weeks
223830869|NCT03222544|COMBINATION_PRODUCT|methylene blue|Continue treatment after 5mins suspension if the patient feels that the local temperature is too high to stand
223830870|NCT03222544|COMBINATION_PRODUCT|Photon therapy instrument|Continue treatment after 5mins suspension if the patient feels that the local temperature is too high to stand
223830871|NCT03018301|DRUG|Ketamine|will receive 0.25 mg/kg intravenous ketamine diluted with normal saline to 20 ml delivered over 10 minutes.
223830872|NCT03018301|OTHER|Normal saline|will receive intravenous 20 ml of normal saline, delivered over 10 minutes.
223830873|NCT03851913|PROCEDURE|TAI|transarterial chemoinfusion with mFOLFOX6 (oxaliplatin, calcium folinate, and 5-FU)
223830874|NCT05719623|OTHER|CUEVAS MEDEK EXERCISES|stretchings/strengthening
223830875|NCT05719623|OTHER|BALANCE AND POSTURAL|BALANCE AND POSTURAL
223830876|NCT02216747|DRUG|prednisone 60 mg/meter square Body Surface Area|treatment with prednisone 60 mg /meter square Body Surface Area to compare to other arms
223830877|NCT02216747|DRUG|prednisone 45 mg|treatment with 45 mg prednisone to compare with other arms
223830878|NCT02216747|DRUG|prednisone 30 mg|treatment with 30 mg prednisone to compare with other arms.
223830879|NCT01647308|DRUG|ISIS-APOCIIIRX|3 doses of ISIS ISIS-APOCIIIRX on alternate days during the first week and then once-weekly doses for 12 weeks.
223830880|NCT01647308|DRUG|Placebo|3 doses of placebo on alternate days during the first week and then once-weekly doses for 12 weeks.
223830881|NCT03254953|BEHAVIORAL|self-monitoring of body weight|\- weigh daily for 3 months and track their weight using the MyFitnessPal mobile app
223830882|NCT03254953|BEHAVIORAL|self-monitoring of diet|"* track their diet (food and drinks) daily using the MyFitnessPal mobile app~* when they are asked to track diet will vary based on the arm"
223830883|NCT03254953|BEHAVIORAL|weekly personalized feedback + lessons + action plans|\- these are additional evidence-based intervention components
223830884|NCT00786890|OTHER|observational, no intervention needed|observational, no intervention needed
223830885|NCT01664936|RADIATION|Cerenkov emissions from the PET tracer 18F-FDG and the radiotherapeutic 131I|We will image (i) patients who are receiving a PET/CT scan for tumors in the head / neck region and (ii) patients with thyroid cancer after 131I radioablation. Two scans will be completed per patient, one of the primary tumors, as well as a 'background' scan of the contralateral side or, if tumor is there as well, of the forearm. The device to be used is an intensified charge-coupled device camera (Stanford Photonics, Palo Alto, CA) connected to a laptop PC. The camera will use a Quartz high-UV transmission 50 mm 0.8f lens. The Imaging device will be placed approximately 5 cm from the area of the patient to be imaged.
223830886|NCT01409421|BEHAVIORAL|motivational interviewing|counseling intervention
223830887|NCT01409421|BEHAVIORAL|three phone calls to remind patients to take their eye drops|reminder phone calls
223830888|NCT03308760|OTHER|Questionnaire|Interview concerning the post-operative rehabilitation programme and a functional analysis using the American Orthopaedic Foot and Ankle Society questionnaire
223830889|NCT03308760|OTHER|Static stabilometry|on a force plate, in a double- then single-foot stance, with the eyes open and then closed
223830890|NCT03308760|OTHER|Isokinetic test|Isokinetic test of the flexors/extensors and invertors/evertors of the ankle
223830891|NCT02855164|DRUG|Tropifexor (LJN452)|Comparison of different doses of drug
223830892|NCT02855164|DRUG|Placebo|Comparator
223830893|NCT03229434|BEHAVIORAL|Mountain hiking|Compare arm description
223830894|NCT01156077|DRUG|TR-701 FA|Oral TR-701 FA 200 mg will be given as a single oral dose
223830895|NCT01156077|DRUG|TR-701 FA|TR-701 FA 200 mg will be given as a single 60 minute IV infusion in 250 cc saline
223830896|NCT00876460|DRUG|BIBF 1120 M + docetaxel M|BIBF 1120 Medium dose bid + docetaxel 60 mg/m2
223830897|NCT00876460|DRUG|BIBF 1120 M + docetaxel H|BIBF 1120 Medium dose bid + docetaxel 75mg/m2
223830898|NCT00876460|DRUG|BIBF 1120 H + docetaxel H|BIBF 1120 HIgh dose bid + docetaxel 75 mg/m2
223830899|NCT00876460|DRUG|BIBF 1120 L + docetaxel M|BIBF 1120 Low dose bid + docetaxel 60 mg/m2
223830900|NCT00876460|DRUG|BIBF 1120 H + docetaxel M|BIBF 1120 HIgh dose bid + docetaxel 60 mg/m2
223830901|NCT05660915|PROCEDURE|Intermediate approach|The area between superior mesenteric vein and superior mesenteric artery was defined as the intermediate area and dissection was performed in this area to achieve the removal of the uncinate process of pancreas.
223830902|NCT05660915|PROCEDURE|Standard approach|The key point of surgery in the standard approach group was to first reveal portal vein-superior mesenteric vein and gradually complete the the resection of the uncinate process of pancreas based on the reference of portal vein-superior mesenteric vein.
223830903|NCT03004313|PROCEDURE|Pet Scan|Subjects will undergo Pet Scanning for 90 minutes
223830904|NCT03004313|PROCEDURE|MRI scan|
223830905|NCT03004313|PROCEDURE|Quantitative Sensory Testing (QST)|
223830906|NCT03101124|DRUG|Tranexamic Acid 25 mg/ml for wound surface moistening|Wound surface moistened with 20 ml of tranexamic acid 25 mg/ml (total dose 500 mg) prior to wound closure
223830907|NCT03101124|DRUG|Tranexamic Acid 5 mg/ml as bolus in wound cavity|200 ml of tranexamic acid 5 mg/ml (total dose 1 g) as a bolus instilled into the wound cavity after wound closure, which will remain in the cavity until the activation of drains one hour later
223830908|NCT03101124|DRUG|Tranexamic Acid Injectable Solution|1 g of tranexamic acid administered intravenously in accordance with prevailing routines directly prior to planned surgical procedure.
223830909|NCT03100994|DRUG|Bupivacaine|injecting anesthetics to different local
223830910|NCT03100994|DEVICE|Ultrasound|Ultrasound guided nerve block
223830911|NCT03112200|PROCEDURE|Subchondroplasty with Arthroscopy|The Subchondroplasty® (SCP®) Procedure targets and fills bone defects with AccuFill® Bone Substitute Material utilizing an arthroscopic / percutaneous approach. Using intraoperative fluoroscopy, the bone defect is localized relative to MRI findings The appropriate AccuPort® Delivery Cannula is drilled to the bone defect. AccuFill® Bone Substitute Material is then injected into the subchondral bone defect. The calcium phosphate (CaP) fills the edematous void and hardens within the Bone Marrow Lesion. The CaP is resorbed over time and replaced with new bone during the healing process.
223830912|NCT03112200|PROCEDURE|Arthroscopy Alone|An endoscopic examination, therapy and surgery of the knee joint.
223830913|NCT00446940|DRUG|rosuvastatin|
223830914|NCT00446940|DRUG|atorvastatin|
223830915|NCT00715572|DRUG|thyroxine|monotherapy with thyroxine
223830916|NCT00715572|DRUG|thyroxine and triiodothyronine|combination with thyroxine and triiodothyronine
223830917|NCT04750993|DIAGNOSTIC_TEST|musculoskeletal ultrasonography|The presence of subclinic synovitis findings in the hand joints was evaluated with musculoskeletal ultrasonography.
223830918|NCT04381260|OTHER|No intervention|There is no intervention for patients included in this group as this is a retrospective data registry only.
223830919|NCT04381260|OTHER|Interview|Key Informant Interview
223830920|NCT04381260|OTHER|Survey|Stakeholder survey
223830921|NCT03313115|BEHAVIORAL|Sleep/Wake Protocol|"Day RN observes if completed per pt: no caffeine after 3 pm, encourage activities to prevent napping (chart % day spent napping), Lights on blinds/door open, Reasonable effort for some noise in room, Eye glasses hearing aids applied, Chair position/mobility at least 2x30 minutes.~Night RN observe if completed per pt: Appropriate pain control, Optimize room temp, Warm bath before 2200, TV off by 2200, Prevent extra alarms after 2200, Close room curtain by 2200, Dim room lights by 2200, Family out by 2200, Door half/fully closed after 2200, # RN interruptions after 2200, Offer eye mask/ear plugs, Meds administered for sleep (dilaudid, fentanyl oxycodone, haldol, quetiapine, propofol, melatonin, or other), Dim hallway lights by 2200, Nurses station quiet"
223830922|NCT02042638|DRUG|hCG 1500 IU three times a week|
223830923|NCT02042638|DRUG|Pregnyl (hCG) ampule 1500 IU/three times a week|
223830924|NCT02989896|DEVICE|perfusion index|
223830925|NCT03842553|OTHER|No Intervention: anonymous online survey|
223830926|NCT00004430|DRUG|Dihematoporphyrin derivative|
223830927|NCT00004430|DRUG|prednisolone|
223830928|NCT00004430|PROCEDURE|Laser surgery|
223830929|NCT05437042|OTHER|Medial calcaneal wedge|Immediate effect of medial calcaneal wedge for static balance and weight distribution
223830930|NCT02692950|OTHER|Honor My Decisions Advance Care Planning Video|Honor My Decisions is a commercial computer application which allows a person to record a video of his/her advanced care planning and legacy information.
223830931|NCT02692950|BEHAVIORAL|Post-video questionnaire|Questions regarding the video process, changes to previous answers and reaction received by others viewing the video
223830932|NCT01234766|DRUG|Bendamustine|90mg/m2, IV - Days 1 and 2 of every cycle
223830933|NCT01234766|DRUG|Rituximab|375mg/m2, IV - Cycle 1 only: Day -7 (+1 day) Day 1 of every cycle
223830934|NCT01234766|RADIATION|Y-90 ibritumomab|0.4mCi/kg, IV - Within 4 hours of rituximab, give over 10 minutes
223830935|NCT00136032|DRUG|Somatropin|Stratified based on age and estrogen status from 3 to 6 mcg/kg/day
223830936|NCT00136032|DRUG|Placebo|Dosage based on age and estrogen status ranging from 3 to 6 mcg/kg/day
223830937|NCT06250543|DRUG|AbobotulinumtoxinA 300 UNT|20 evenly distributed intradetrusor injections, 1 ml per site, were performed
223830938|NCT06250543|DRUG|IncobotulinumtoxinA 100 UNT|20 evenly distributed intradetrusor injections, 1 ml per site, were performed
223830939|NCT06250543|DRUG|Lidocain|30 minutes before the procedure the bladder was instilled with 40 ml of 1% lidocaine solution using a 16Fr urethral Foley catheter
223830940|NCT06250543|OTHER|placebo|30 minutes before the procedure the bladder was instilled with 40 ml of 0.9% NaCl solution
223830941|NCT00127413|BEHAVIORAL|Cognitive Behavioral Therapy - Pain|Pain treatment
223830942|NCT00127413|BEHAVIORAL|Cognitive Behavioral Therapy-Integrated|Integrated treatment
223830943|NCT00127413|BEHAVIORAL|Cognitive Processing Therapy - PTSD|Cognitive processing therapy
223830944|NCT00127413|BEHAVIORAL|Treat as Usual|Treatment as usual
223830945|NCT04100161|DIETARY_SUPPLEMENT|Protein supplementation|Daily dose of 40 g whey protein for 3 months
223830946|NCT04100161|DIETARY_SUPPLEMENT|Carbohydrate supplementation|Daily dose of 40 g maltodextrin for 3 months
223830947|NCT04100161|PROCEDURE|Active rehabilitation|Progressive rehabilitation following a muscle strain injury for 3 months
223830948|NCT04394091|DEVICE|ultrasensitive PET CT|A 194-cm-long total-body positron emission tomography/computed tomography (PET/CT) scanner (uEXPLORER), has been constructed to offer a transformative platform for human radiotracer imaging in clinical research and healthcare. Its total-body coverage and exceptional sensitivity provide opportunities for innovative studies of physiology, biochemistry, and pharmacology.
223830949|NCT06390930|OTHER|Acute Intermittent Hypoxia|During AIH, the participant will be equipped with a non-rebreathing face mask, and provided with the AIH intervention. The AIH intervention involves alternating breathing cycles. One cycle involves breathing air with lower oxygen concentration (9-10% oxygen) for 30 and 90 seconds, followed by breathing normal room air (21% oxygen) for a similar duration. This cycle is repeated 15 times in one session. Blood oxygen and heart rate are monitored throughout.
223830950|NCT06390930|OTHER|Sham Acute Intermittent Hypoxia|During Sham AIH, the participant will be equipped with a non-rebreathing face mask, and provided with the AIH intervention. The Sham AIH intervention involves alternating breathing cycles. One cycle involves breathing air closely resembling room air (\~21% oxygen) for 30 and 90 seconds, followed by breathing normal room air (21% oxygen) for a similar duration. This cycle is repeated 15 times in one session. Blood oxygen and heart rate are monitored throughout.
223830951|NCT00618462|BEHAVIORAL|Cognitive behavioral therapy (CBT)|CBT will include weekly 50-minute sessions for 8 weeks. The sessions will focus on learning skills to cope with urges to gamble and developing alternatives to gambling.
223830952|NCT00618462|BEHAVIORAL|Contingency management (CM)|CM will provide incentive, such as a gift certificate to a store or restaurant, for completing activities not related to gambling. Participants and their therapists will decide upon two potential alternative activities to gambling during each therapy session.
223830953|NCT00618462|BEHAVIORAL|Psychoeducation therapy|Psychoeducation therapy will include weekly 50-minute therapy sessions for 8 weeks. The sessions will focus on education about gambling and related problems.
223830954|NCT00618462|BEHAVIORAL|Case management|Case management will assist participants in obtaining additional services from the community as needed.
223830955|NCT00618462|BEHAVIORAL|Gamblers Anonymous (GA)|All participants will be referred to GA, a support group of people who are recovering from gambling addiction, and will be encouraged to attend meetings.
223830956|NCT00547911|DRUG|Droxidopa|
223830957|NCT00547911|DRUG|Carbidopa|
223830958|NCT00547911|DRUG|Entacapone|
223830959|NCT02254096|DRUG|BIRT 1696 BS|
223830960|NCT02254096|DRUG|Placebo|
223830961|NCT02254096|OTHER|Grapefruit juice (GFJ)|
223830962|NCT02254096|OTHER|High fat meal (HFM)|
223830963|NCT01539174|BIOLOGICAL|rituximab|Given IV
223830964|NCT01539174|DRUG|cyclophosphamide|Given IV
223830965|NCT01539174|DRUG|doxorubicin hydrochloride|Given IV
223830966|NCT01539174|DRUG|vincristine sulfate|Given IV
223830967|NCT01539174|DRUG|prednisone|Given PO
223830968|NCT01539174|OTHER|laboratory biomarker analysis|Correlative studies
223830969|NCT01539174|OTHER|pharmacological study|Correlative studies
223830970|NCT03241524|OTHER|Exercise program for pelvic muscle floor|Pelvic muscles of each participant was evaluated by PERFECT and Peritron methods in terms of strengthening as well as sexual function response using 3 questionnaires, before and after 4 and 8 weeks from the beggining of an exercise program prescribed according to individual ratings obtained in the previous evaluation.
223830971|NCT00655330|DRUG|Valsartan|Valsartan (160mg/day)
223830972|NCT00655330|DRUG|Placebo|Placebo
223830973|NCT00655330|DRUG|Probucol|Probucol (750mg/day)
223830974|NCT01483157|OTHER|vascular occlusion with exercise trainig|twelve weeks of resistance training with vascular occlusion twice a week
223830975|NCT01483157|OTHER|high intensity resistance training|twelve weeks of resistance training twice a week
223830976|NCT01644474|DRUG|Alirocumab|1 mL subcutaneous injection in the abdomen, thigh, or outer area of the upper arm by self-injection or by another designated person using the autoinjector.
223830977|NCT01644474|DRUG|Ezetimibe|One over-encapsulated tablet orally once daily at approximately the same time of the day with or without food.
223830978|NCT01644474|DRUG|Placebo (for Alirocumab)|1 mL subcutaneous injection in the abdomen, thigh, or outer area of the upper arm by self--injection or by another designated person using the autoinjector.
223830979|NCT01644474|DRUG|Placebo (for Ezetimibe)|One capsule orally once daily at approximately the same time of the day with or without food..
223830980|NCT02604732|PROCEDURE|Laparoscopic inguinal hernia repair with perioperative Aspirin|Patients undergoing laparoscopic inguinal hernia repair will continue on Aspirin perioperatively
223830981|NCT02604732|PROCEDURE|Laparoscopic inguinal hernia repair without perioperative Aspirin|Patients undergoing laparoscopic inguinal hernia repair will stop Aspirin 5-7 days before the surgery
223830982|NCT03787290|DRUG|Tocilizumab|participants will receive a single subcutaneous injection of tocilizumab (162 mg)
223830983|NCT03787290|DRUG|Placebo|participants will receive a single subcutaneous injection of saline
223830984|NCT03787290|DEVICE|Whole-Body Hyperthermia|subjects' core temperature will be increased to 38.5 degrees Celsius (typically 60-120 minutes) then they will begin a 60-minute cool-down phase
223830985|NCT04286230|BEHAVIORAL|Adherence to oral antibiotics assessed by Questionnaire|The purpose of the BIOTICA-questionnaire is to detect individual barriers preventing the optimal intake of oral antibiotics and thus, leading to inadequate adherence or persistence to the regimen.
223830986|NCT04286230|BEHAVIORAL|Persistence to oral antibiotics assessed by Questionnaire|The purpose of the BIOTICA-questionnaire is to detect individual barriers preventing the optimal intake of oral antibiotics and thus, leading to inadequate adherence or persistence to the regimen.
223830987|NCT05783674|OTHER|Brain Breaks® Video Exercises|A total of at least 140 Brain Breaks® videos, each 3-4 minutes long, aerobic exercises including wide joint movements, movements specific to different sports branches such as yoga and volleyball, basketball, football, tennis, karate, judo, and warm-up-cooling movements. It includes national dances of different cultures. Horon, Zeybek, Scarf dance, morning gymnastics in Ürgüp Göreme, dribbling (volleyball, basketball), Pilates ball, and core area exercises. In each session, 2 videos will be applied and each will be repeated 2-3 times, and a 3-minute rest break will be given between each video. The total session will last for 20-30 minutes on average and physical activity will be performed twice a week, for a total of 8 weeks, 16 sessions.
223830988|NCT05783674|OTHER|Posture training|All participants, as the BB Video Exercise and Control Group, will be given a 20-minute hands-on training on the importance of proper posture once at the beginning of the study, and breathing control training will be given to maintain proper sitting, standing, lying postures, and proper posture.
223830989|NCT04453397|DRUG|TNB-383B|TNB-383B is a bispecific antibody targeting BCMA on tumor cells and CD3 on T-cells.
223830990|NCT04213586|DIETARY_SUPPLEMENT|Whey protein supplementation|35 g of whey protein (7 d/wk) during a 10-wk resistance training program (3 d/wk; 3 sets of 8-12 repetitions with an interval of 1-2 minutes between sets and exercises) involving the leg press, leg extension, and arm flexion exercises. The load will be adjusted weekly.
223830991|NCT04213586|DIETARY_SUPPLEMENT|Collagen supplementation|35 g of collagen (7 d/wk) + 2 g of leucine during a 10-wk resistance training program (3 d/wk; 3 sets of 8-12 repetitions with an interval of 1-2 minutes between sets and exercises) involving the leg press, leg extension, and arm flexion exercises. The load will be adjusted weekly.
223835621|NCT02257255|PROCEDURE|Misgav-Ladach cesarean section|Pain scales (VAS and McGill) 6, 12 and 24 hours ater cesarean to pain assessment
223835622|NCT01342029|DRUG|Ranolazine|"This drug is approved by the U.S. Food and Drug Administration (FDA) for treatment of chronic angina.~500-1,000 mg po bid for 2 weeks"
223835623|NCT01342029|DRUG|Placebo|500-1,000 mg po bid for 2 weeks
223830992|NCT02751463|DRUG|Sunscreening Sport Spray Rest (BAY987519)|50 μl/ cm\*2 of the test article is applied directly to two sites on the skin and covered with the appropriate patch. 24 hours later, the patches are removed. The test sites are lightly wiped with a dry cloth/tissue and 3μl/ cm2 of test article is reapplied directly to the skin of the test site designated for irradiation, and lightly spread over the test site. 48 hours later the procedure is repeated to the same test sites. This process is repeated twice weekly for a total of six exposures.(Formulation Number - RB# Y51-002 )
223830993|NCT02751463|OTHER|Untreated skin|One site is patched without treatment as control
223830994|NCT01404611|DRUG|DF289|Ear drops
223830995|NCT01404611|DRUG|DF277|Ear drops
223830996|NCT01404611|DRUG|DF289 plus DF277|Ear drops
223830997|NCT03625505|DRUG|Venetoclax|tablet, oral
223830998|NCT03625505|DRUG|Gilteritinib|tablet, oral
223830999|NCT04138342|DRUG|Quantum dots coated with veldoreotide|The active group will receive Quantum dots coated with veldoreotide in different topical dosage forms as an anti-cancer drug.
223831000|NCT04138342|DRUG|Topical approved placebo|The placebo group will receive topical FDA approved in different dosage forms as a negative control drug.
223831001|NCT06382909|DIETARY_SUPPLEMENT|Inflammatory level|Quantification of C-reactive Protein (PCR) Quantification of serum cortisol Insulin quantification Prolactin quantification Fecal calprotectin dosage
223831002|NCT06382909|DIETARY_SUPPLEMENT|Cognitive assessment|Neurological assessment Psychiatric assessment
223831003|NCT06382909|DIETARY_SUPPLEMENT|Pedagogical assessment|Sociopedagogical assessment
223831004|NCT02044458|DEVICE|Stylette|use of stylette for successful insertion of foley catheter for induction of labor
223831005|NCT00880308|DRUG|LDE225|
223831006|NCT03141710|DIETARY_SUPPLEMENT|20 ml of prebiotic per day|12 volunteers will take 20ml of prebiotic per day for 12 weeks
223831007|NCT04667845|DEVICE|Home Ovulation Test|Digital read home ovulation test
223831008|NCT06512103|DIAGNOSTIC_TEST|Apical periodontitis group|Radiography of the patients were taken. Blood samples and gingival crevicular fluid samples were collected from those patient
223831009|NCT02386917|PROCEDURE|Gastric bypass|Weight loss surgery
223831010|NCT02386917|BEHAVIORAL|Very low calorie diet|Non-surgical weight loss procedure
223831011|NCT02625194|DRUG|Oxygen|Oxygen is supplied through suction port during bronchoscope-guided intubation.
223831012|NCT06625827|DRUG|Digoxin|Oral administration
223831013|NCT06625827|DRUG|Nemtabrutinib|Oral administration
223831014|NCT06625164|OTHER|exercise|core stabilization exercises
223831015|NCT06625996|DIETARY_SUPPLEMENT|carbohydrate loading|Preoperative carbohydrate loading
223831016|NCT06625749|DEVICE|Accurasee™ IOPCL|Intraocular pseudophakic capsular lens (IOPCL)
223831017|NCT02601937|DRUG|Tazemetostat|Tazemetostat (EPZ-6438) is a selective small molecule inhibitor of the histone-lysine methyltransferase EZH2 gene.
223831018|NCT01133574|DRUG|SLV354 capsules|20 mg
223831019|NCT01133574|DRUG|SLV354 capsules|60 mg
223831020|NCT01133574|DRUG|SLV354 capsules|120 mg
223831021|NCT01133574|DRUG|SLV354 capsules|250 mg
223831022|NCT01133574|DRUG|SLV354 capsules|500 mg
223831023|NCT01133574|DRUG|SLV354 capsules|750 mg
223831024|NCT01133574|DRUG|SLV354 capsules|1000 mg
223831025|NCT01133574|DRUG|SLV354 capsules|1250 mg
223831026|NCT01133574|DRUG|Placebo capsules|placebo
223831027|NCT01133574|DRUG|SLV354 capsules|low dose group 1
223831028|NCT01133574|DRUG|SLV354 capsules|high dose group 1
223831029|NCT01133574|DRUG|SLV354 capsules|low dose group 2
223831030|NCT01133574|DRUG|SLV354 capsules|high dose group 2
223831031|NCT01133574|DRUG|Placebo capsules|placebo
223831032|NCT02140346|DRUG|RV1729 28 day repeat dose|Safety and tolerability of repeat doses
223831033|NCT02140346|DRUG|RV1729 matching placebo 28 day repeat dose|Safety and tolerability of repeat doses
223831034|NCT06826066|OTHER|Blood samples|We propose to include patients who have been treated with radiotherapy and did not experience severe radiation-induced toxicity, after obtaining their informed consent. A blood sample will then be collected by the nursing staff from the Oncology-Radiotherapy department at Henri Mondor University Hospital. After the patient signs the consent form, each patient will have their clinical information recorded and a blood sample taken. The blood samples will be immediately transported, at room temperature, to the INSERM U955 i-Biot unit at Henri Mondor (serum, plasma, and PBMC). All samples will be frozen at -80°C for later analysis.
223831035|NCT06010511|OTHER|3T MRI scan|Conventional (3T) brain MRI scans will be used to determine global and functional markers of cerebral SVD, like WMH volume and presence of lacunes, microbleeds and superficial siderosis (3D T1, 3D FLAIR, SWI, DWI), hemodynamics (arterial spin labelling \& flow territory mapping) and white matter structural integrity (diffusion tensor imaging (DTI)). Furthermore, we want to measure structural integrity with a novel MR fingerprinting sequence and an inhomogeneous magnetization transfer (ihMT) MRI scan. We also want to apply a fMRI scan technique to measure CSF fluctuations in the 4th ventricle as a measure of brain glymphatics. Also the flow-territory mapping sequence is a non-standard sequence. Heart rate and respiratory signal will be measured during the scans (3T and 7T MRI) with standard vendor-supplied equipment.
223831036|NCT06010511|OTHER|7T MRI scan|Ultra-high field (7T) brain MRI scans will be used to determine WMH shape and other markers of cerebral SVD in or surrounding the WMH, like local enlarged perivascular spaces, (cortical) microinfarcts and microbleeds (T1, T2, FLAIR and T2\*) and vascular pulsatility (phase contrast MRI). Moreover, a recently implemented MRI technique to measure glymphatic flow in perivascular spaces will be used.
223831037|NCT06010511|BEHAVIORAL|Neuropsychological assessment|"* Mini-mental state examination~* Clock drawing~* 15-Word Verbal Learning Test, immediate and delayed~* Visual Association Test~* Stroop Color Word Test, 40 item version~* Trail Making Test A\&B~* Letter Digit Substitution Test~* Animal fluency test~* Hospital anxiety and depression scale~* Informant Questionnaire on Cognitive Decline in the Elderly"
223831038|NCT06010511|OTHER|General baseline data|"Baseline data, such as age, sex, psychiatric comorbidity and medication lists will be extracted from the patient files.~Age (Year of birth); Years of education; BMI (height \& weight); Sex; Verhage scale (education); Smoking status; Blood values; Sleep habits; Waste-hip ratio; Blood pressure; Current/general cardiovascular health; Psychiatric comorbidity; medical history related to cardiovascular health."
223831039|NCT03024320|BEHAVIORAL|M2M|An eHealth platform has been designed to deliver a home-based package using the extensive set of movement patterns that have been adapted for people with a range of physical/mobility disability, called Movement-To-Music (M2M). The M2M prescription will be based on the participant's baseline level of health, function and fitness. Each movement pattern will be available in three different positions - standing, standing with support (chair) and seated. The duration of each M2M session will be gradually increased during the Adoption phase from three 20-minute sessions (10 min. aerobic \& 10 min. strength) during weeks 1 to 3 (60 min/wk), to 45-min sessions (30 min. aerobic \& 15 min. strength) during weeks 4 to 6 (135 min/wk), and to 50-min sessions (150 min/week) during weeks 7 to 12 (excluding 5-min warmup and 5-min cool down).
223831040|NCT03024320|BEHAVIORAL|Attention Control|Telecoaching on health-based topics, not including physical activity.
223831041|NCT02366208|DRUG|PEG-Tα1|1.6 mg/ml, once a week, taken subcutaneously
223831042|NCT02366208|DRUG|Placebo to match PEG-Tα1|1ml, once a week, taken subcutaneously
223831043|NCT02366208|DRUG|Adefovir|10 mg, once daily, taken orally for 48 weeks
223831044|NCT04213989|DEVICE|Flexitouch Plus and Conservative Care|A segmental, programmable, gradient advanced pneumatic compression device. The system consists of a controller unit and garments, and provides in-home manual lymphatic drainage therapy in the legs for approximately 1 hour daily. Conservative care may include 30-40 mmHg graduated compression up to waist, dietary counseling, exercise, and/or referral for CDT.
223831045|NCT04213989|OTHER|Conservative Care|May include 30-40 mmHg graduated compression up to waist, dietary counseling, exercise, and/or referral for CDT.
223831046|NCT03055585|BIOLOGICAL|Wolbachia-infected Aedes aegypti mosquitoes|Deployment of Wolbachia-infected Aedes aegypti mosquitoes
223831047|NCT03055585|OTHER|standard practice dengue control|standard practice dengue control activities conducted by dengue control program
223831048|NCT00150410|DRUG|Inhaled insulin|
223831049|NCT01811563|DEVICE|Zimmer|
223831050|NCT01811563|DEVICE|Stryker|
223831051|NCT00047710|DRUG|Bevacizumab|Beginning 2 weeks prior to radiotherapy, dose of 5 mg/kg by vein then of 2.5 mg/kg during radiotherapy for four weeks every 2 weeks (three doses).
223831052|NCT00047710|DRUG|Capecitabine|650mg/m\^2 taken by mouth twice a day 15-52 during the radiotherapy.
223831053|NCT00047710|RADIATION|Radiotherapy|Radiography given once a day for 5 days at 50.4 Gy in 28 fractions over 5.5 weeks.
223831054|NCT05221203|BEHAVIORAL|TR-30|Bodyweight training exercises will be performed for 30 seconds and the training volume will be consisted of 1 repetition.
223831055|NCT05221203|BEHAVIORAL|TR-45|Bodyweight training exercises will be performed for 45 seconds and the training volume will be consisted of 1 repetition.
223831056|NCT04989530|DEVICE|Extracorporeal Shock Wave Therapy|different energy levels of ESWT
223831057|NCT04433793|BEHAVIORAL|Yoga therapy|"One yoga session will last one hour. It consists of physical exercises (asanas), conscious breathing (Pranayama) and deep relaxation (Savasana). The subsequent body exercises are structured from lying to sitting to standing. The following sequence of exercises will be repeated in each yoga unit: 1) Relaxation: conscious breathing, body scan, mindfulness 2) Vein pump 3) Pelvis and back rotation (adapted variation of the nakrasana) 4) Pelvis opening (adapted variation of the supta baddha konasana) 5) Shoulder bridge (setu bandha sarvangasana) 6) Forward folds (Paschimottanasana and variations with Pranayama) 7) Backbend: intense east stretch (Purvottasana) 8) Diagonal static yoga cat (Majariasana 1 and resting pose) 9) Standing exercise 10) Upward Salute(Urdhva Hastasana) 11) Warrior 1 (Virabhadrasana 1) 12) Warrior 3 (Virabhadrasana 3) 13) Tree (Vrkasana variation) 14) Relaxation (Savasana)."
223831058|NCT02816047|OTHER|Registry|Observational study to describe WCD indications, event rates, inappropriate shock rates and follow up (including ICD rate, shock rate, morbidity and mortality) in all Austrian WCD patients
223831059|NCT03257488|DEVICE|type IV portable monitoring (Somnocheck micro Weinmann)|Somnocheck micro Weinmann: a screening device for sleep disorders assessment. Somnocheck 2 Weinmann: a diagnostic device for obstructive sleep apnea.
223831060|NCT00329719|PROCEDURE|Conventional Surgery|Undergo surgery
223831061|NCT00329719|OTHER|Laboratory Biomarker Analysis|Correlative studies
223831062|NCT00329719|DRUG|Sorafenib Tosylate|Given PO
223831063|NCT00329719|DRUG|Temsirolimus|Given IV
223831064|NCT01946243|DRUG|Florbetapir F18|No Florbetapir F 18 will be administered in this study.
223831065|NCT05030935|DEVICE|mHealth App|In short, mHA contains three main functions for the user: a) a reminder for switching the patient position, b) training for preventive care habits and c) the possibility for patient evaluation in order to determine the need for the use of support surfaces.
223831066|NCT06783621|DRUG|OnabotulinumtoxinA|Intramuscular Injections
223831067|NCT06783621|DEVICE|JUVÉDERM|Injections
223831068|NCT06783621|DEVICE|CoolSculpting Elite System|CoolSculpting Elite Applicator
223831069|NCT06783621|OTHER|SkinMedica Products|Skincare Product
223831070|NCT06783621|DRUG|KYBELLA|Injections
223831071|NCT02552680|OTHER|Exercise|Physical Exercise
223831072|NCT02552680|OTHER|Guideline|Guideline on care and prevention of Work-Related Musculoskeletal Disorders in activities of daily living, especially those relating work activities.
223831073|NCT02552680|OTHER|Brochure|Manual/brochure containing information about general health
223831074|NCT03149263|BEHAVIORAL|distraction|Children will all benefit toxin injections with the same protocol. Only the distraction will be different during the session: either the children will have a distraction realized by the team of clowns / or children will benefit a classic distraction (TV, music, ...)
223831075|NCT00008437|DEVICE|high-intensity focused ultrasound ablation|
223831076|NCT05271682|DRUG|FHND6091|FHND6091 capsules
223831077|NCT02809508|DIETARY_SUPPLEMENT|Oily fish|A selection of oily fish, including salmon, herring and mackerel, provided for dinner and lunch
223831078|NCT02809508|DIETARY_SUPPLEMENT|Poultry|A selection of poultry, mainly chicken, provided for dinner and lunch
223831079|NCT04788290|OTHER|Observational|Rabone D®, Once daily administered per the locally approved product information
223831080|NCT05762536|DRUG|Darolutamide|Darolutamide 600 mg b.i.d. until the end of the last taxane cycle
223831081|NCT05762536|DRUG|Docetaxel or cabazitaxel|Docetaxel or cabazitaxel Q3W
223831082|NCT05103813|DRUG|Beraprost Sodium Tablets|Protective effect of Beraprost Sodium Tablets on coronary microcirculation function and ventricular remodeling after reperfusion therapy for acute ST segment elevation myocardial infarction
223831083|NCT04277741|DIETARY_SUPPLEMENT|RS4 bar|The RS4 group will consume one nutrition bar per day formulated using Fibersym® RW containing 20g fiber.
223831084|NCT04277741|DIETARY_SUPPLEMENT|Control bar|The control group will consume one native wheat starch bar per day.
223831085|NCT04399187|DRUG|Sodium hypochlorite gel application|Patients treated by scaling and root planing and Sodium hypochlorite gel application, meanwhile in patients of control group scaling and root planing alone was performed.
223831086|NCT02971384|DRUG|Echinaforce|
223831087|NCT02835443|DEVICE|Deep Brain Stimulation|Electrical stimulation of the dentate nucleus area of the cerebellum.
223831088|NCT03917160|DEVICE|EMS device|EMS treatment will be performed
223831089|NCT00231270|DEVICE|Cordis Nitinol Stent|
223831090|NCT00231270|DEVICE|PRECISE tapered stent|
223831091|NCT00231270|DEVICE|ANGIOGUARD XP Emboli Capture Guidewire (ECGW)|
223831092|NCT05303038|COMBINATION_PRODUCT|Cryoablation Combined with Tirelizumab and Bevacizumab|"Cryoablation of 1-2 typical metastatic lesions will be performed on D1 under general anesthesia and ultrasound guidance for two cycles.~200mg Tirelizumab ( IV Q3W) + Bevacizumab 7.5mg/kg ( IV Q3W) will be administered at D14 after cryoablation."
223831093|NCT05172830|DEVICE|Ovation Alto™ Abdominal Stent Graft System|Single occurrence permanent implantation of AAA device
223831094|NCT02930122|DRUG|anakinra (150mg)|intraarticular administration
223831095|NCT02930122|OTHER|Saline intraarticularly|intraarticular administration
223831096|NCT05774496|OTHER|Estimation of the occurrence of retinochoroiditis in women with congenital toxoplasmosis and previous retinochoroiditis lesions (recurrence) during pregnancy and postpartum.|All fundus examinations completed during pregnancy and postpartum in women with congenital toxoplasmosis and previous retinochoroiditis lesions are going to be checked.
223831097|NCT03936296|PROCEDURE|mpMR guided MR-US fusion transrectal prostate biopsy|mpMR images will be loaded to US fusion platform and registration of the will be performed. Suspicious lesions on MR which have PIRADS score 3 and above are targeted. Additional 2-4 cores biopsies will be taken them
223831098|NCT03936296|PROCEDURE|12 core standard transrectal prostate biopsy|Under the guidance of transrectal ultrasonography, 12 core biopsies taken from apex, apex lateral, mid, mid lateral, base and base lateral of right and left prostate lobe
223831099|NCT05857579|PROCEDURE|Microblepharoexfoliation|MBE was performed using the yokefellow instrument (Youke Electronic Corporation, Guangzhou, China), which contains a handpiece with a 1.80 mm diameter medical-grade diamond bur. Patients underwent MBE on the upper and lower lid margin of both eyes at 500 rpm until complete removal of accumulated biofilm debris, epithelial keratinization or capped meibomian glands. MBE was carried out only in the first combined treatment session.
223831100|NCT05857579|PROCEDURE|Intense pulse light|IPL treatment was carried out with Thermaeye Plus (MDS Medical Technologies SL, Barcelona, Spain). The procedure began by applying an ultrasound gel (Carmado SL, Alicante, Spain) to the patient's periocular areas and upper eyelids. In the periocular areas, 6 light pulses were applied; 4 light pulses on the skin below the lower eyelid (with handpiece placed horizontally in the first pass and vertically in the second pass) and 2 light pulses on the canthal area (with handpiece placed vertically in first and second pass). The parameters were as follows: (1) Filter: 650 nm; (2) fluence: 9 j/cm2; (3) pulses: 2; (4) duration: 3 ms; (5) Delay: 20 ms; and (6) Cooling: 70%. In the upper eyelids, 4 light pulses were applied; 2 light pulses in the first and second pass, respectively. The parameters were as follows: (1) Filter: 650 nm; (2) Fluence: 5 j/cm2; (3) pulses: 1; (4) duration: 3 ms and (5) Cooling: 70%.
223831101|NCT05857579|PROCEDURE|Meibomian gland expression|Finally, the MGX was performed on both upper and lower eyelids of each eye with a Collins forceps (Medi Instrument Inc, New York, USA).
223831102|NCT05857579|DRUG|Home-based therapy|Home-based therapy was based on Therapearl eye mask warming compress (Bausch \& Lomb, Madrid, Spain) twice a day and Eyestil synfo eyedrops (Sifi Iberica SL, Madrid, Spain) 4 times a day during the study
223831103|NCT05978648|DRUG|Trilaciclib|240 mg/m2, intravenous drip over 30 min within 4 hours before chemotherapy administration on the same day
223831104|NCT05978648|DRUG|Epirubicin|90 mg/m2, intravenous drip, d1, Q3W, 4 cycles.
223831105|NCT05978648|DRUG|Cyclophosphamide|600 mg/m2, intravenous drip, d1, Q3W, 4 cycles.
223831106|NCT05978648|DRUG|Paclitaxel|80 mg/m2, intravenous drip, d1,8,15, Q3W, 4 cycles.
223831107|NCT05978648|DRUG|Docetaxel|75 mg/m2, intravenous drip, d1, Q3W, 6 cycles.
223831108|NCT05978648|DRUG|Carboplatin|area under curve(AUC) = 6, intravenous drip, d1, Q3W, 6 cycles.
223831109|NCT05978648|DRUG|Trastuzumab|8 mg/kg in Cycle 1, 6 mg/kg in subsequent cycles, intravenous drip, d1, Q3W, for 1 year.
223831110|NCT05978648|DRUG|Pertuzumab|840mg in Cycle 1, 420mg in subsequent cycles, intravenous drip, d1, Q3W, for 1 year.
223831111|NCT01465139|DRUG|CDX-301|"CDX-301, administered in multiple dosages and frequencies depending on arm:~n=3-6 at between 1-75 μg/kg over 5 days~n=3-6 at 25 μg/kg over 7 days~n=3-6 at 25 μg/kg over 10 days"
223831112|NCT02256774|DRUG|BILR 355 BS|
223831113|NCT02256774|DRUG|Combivir®|
223831114|NCT02256774|DRUG|Ritonavir|
223831115|NCT00003792|BIOLOGICAL|MART-1 antigen|
223831116|NCT00003792|BIOLOGICAL|filgrastim|
223831117|NCT00003792|BIOLOGICAL|flu matrix peptide p58-66|
223831118|NCT00003792|BIOLOGICAL|gp100 antigen|
223831119|NCT00003792|BIOLOGICAL|recombinant MAGE-3.1 antigen|
223831120|NCT00003792|BIOLOGICAL|tyrosinase peptide|
223831121|NCT00003792|PROCEDURE|in vitro-treated peripheral blood stem cell transplantation|
223831122|NCT02319343|DRUG|Methylprednisolone|Comparison of preoperative single high dose of Methylprednisolone 125 mg iv. and isotonic Sodium Chloride (placebo)
223831123|NCT02319343|DRUG|Isotonic Sodium Chloride|Placebo
223831124|NCT05645289|DRUG|Minodronate|The minodronate group: The group will include thirty-six patients. Patients will take 1 mg of minodronate tablets orally with 200 mL of water in the morning. They can not lie flat for at least 30 minutes after taking the tablets, and they can not eat anything except water for at least 30 minutes after taking the tablets once a day for 12 weeks, for a total of 84 times.
223831125|NCT05645289|DRUG|Alendronate|The alendronate group: A total of 36 patients will be treated with alendronate. Patients will be orally given 10-mg alendronate tablets daily and 200 mL of water in the morning. They could not lie down and eat anything except water for at least 30 minutes after taking the tablets. The treatment lasted for 12 weeks, corresponding to a total of 84 doses.
223831126|NCT04971616|OTHER|Demographic data and range of motion.|The body parameters (BMI, age, gender), daily activities (daily steps, sedentary), work and rest time (sleep time, quality) were collected through wearable devices. The range of motion of neck and waist was collected through hand-held devices.
223831127|NCT01745315|DEVICE|Advanced bipolar devices|
223831128|NCT04284761|COMBINATION_PRODUCT|Bicalutamide implant|Biolen bicalutamide implant
223831129|NCT03414788|BIOLOGICAL|PF 06687234|Subjects will be given single, intravenous dose of PF 06687234 and \[124I\]IB PF 06687234 simultaneously
223831130|NCT03414788|BIOLOGICAL|[124I]IB PF 06687234|Subjects will be given single, intravenous dose of PF 06687234 and \[124I\]IB PF 06687234 simultaneously
223831131|NCT06044220|BEHAVIORAL|Intervention|The intervention group was given training on male reproductive health and testicular self-examination after the pretest. Posttest was administered after the training. He was reminded to perform TSE for 3 months after the training. After the reminders, a follow-up test was applied.
223831132|NCT06044220|OTHER|Control|Pretest and posttest were administered to the control group at the same time as the intervention group. After reminding the intervention group to perform TSI for 3 months, a follow-up test was performed in the control group.
223831133|NCT01681368|DRUG|Birinapant (TL32711)|47mg/m\^2 intravenous (IV) on days 1, 8 and 15 of each 28 day cycle
223831134|NCT01428921|BEHAVIORAL|Theory based education and brief motivation interview|"* Standard education programme as described above,~* Plus~  1. Face-to-face session (Part 1: Knowledge Enhancement Session, Part 2: Brief Motivation Interview Session) after the morning of CPAP titration~ 2. Follow-up phone call would be arranged within 1 week after using CPAP.~ 3. Video, slides and booklets would be used as education media."
223831135|NCT03464214|DEVICE|Neck Muscle Vibration|Local vibration device applied on neck muscles for 8 weeks
223831136|NCT03464214|BEHAVIORAL|Cervical Stabilization Exercises|Cervical stabilization exercises performed by healty individuals for 8 weeks
223831137|NCT06542757|RADIATION|1.5 T Elekta Unity MR-Linac system|Patients will receive 9 Gy/fraction (45 Gy total) for five fractions to the DIL, while the remainder of the prostate will be treated to 30 Gy in 5 fractions.
223831138|NCT06542757|DEVICE|Hydrogel rectal spacer (SpaceOAR)|A rectal spacer will be placed one week prior to simulation to achieve a separation of approximately 1 cm between the prostate and anterior rectal wall to further minimize rectal toxicity in these patients. The hydrogel will remain in the body for about 12 weeks.
223831139|NCT04384679|DEVICE|Hydrophilic polymer and potassium ferrate powder|Application with pressure until hemostasis is achieved
223831140|NCT01026909|DRUG|Aristospan 20mg|Triamcinolone hexacetonide injectable suspension, USP, 20mg/mL Parenteral. One single dose.
223831141|NCT03146481|DRUG|Aceclofenac|Aceclofenac 100 mg tablet given one hour before starting the root canal treatment
223831142|NCT03146481|OTHER|Placebo|Placebo tablet given one hour before starting the root canal treatment
223831143|NCT04732715|BEHAVIORAL|CaRE Course|Participants will complete the CaRE Course over a 6-8 week time period. The curriculum of the CaRE course will include topics addressing caregiving for a PLWD during a pandemic, navigating the healthcare system for a PLWD, guiding and managing daily life, and self care.
223831144|NCT06449885|OTHER|patients receive optimal treatment or follow-up according to the characteristics of the disease|Patients with MZL who are eligible for enrollment will be evaluated by the investigator and the enrolled patients will receive long-term follow-up after collecting medical history information, biological samples, and oncology data according to the study protocol. This study does not specify a detailed treatment modality, and patients receive optimal treatment or follow-up according to the characteristics of the disease.
223831145|NCT05928715|OTHER|Finger feeding|The newborn will receive every expressed breast milk or formula support during the day with the finger feeding method.
223831146|NCT04358419|DIAGNOSTIC_TEST|Aspergillus specific proteins in exhaled breath condensate (EBC)|The EBC will be collected by use of the RTube(R) system which is commercially available for the purpose of collection of EBC. As the patient breathes through a mouth piece, the exhaled breath is lead through a cooling chamber where the vaporous part of the exhaled breath condenses. The investigators aim at collecting a total minimum of 3.0 mL EBC per study participant in order to have sufficient amount of protein for the subsequent analysis.
224264609|NCT05128396|BEHAVIORAL|Control Group|Individuals in the control group will participate in the same computerized Cogmed training program as described above. The main difference is that for the control group task difficulty will remain at the same low starting level, rather than increasing over time. The instructions given to subjects will be identical to the ones used in the cognitive training intervention.
224264610|NCT00840281|DRUG|Cefzil® 500 mg tablets|1 x 500 mg, single-dose fasting
224264611|NCT00840281|DRUG|Cefprozil 500 mg Tablets|1 x 500 mg, single-dose fasting
224264612|NCT05080387|OTHER|Blood sample|Blood samples will obtained for measurement of neopterin level through ELIZA
224264613|NCT06627387|OTHER|Balance Training Using Augmented Reality|"The intervention will be carried out in two phases. The first phase will take place at Vall d\&amp;#39;Hebron Hospital, where patients will undergo balance training under the supervision of a physiotherapist. The scheduled dose will be 60 minutes daily, three days a week for four weeks. If the patients meet the inclusion criteria, the intervention will be extended for two more weeks at home. For this task, the involvement of a family member as a training partner will be essential. Relatives will receive training on using the system in the hospital and must be present whenever the patient undergoes the training at home. Three assessments will be carried out during the six weeks of the study. At the beginning of the intervention (Day 0 ), a second is once the hospital intervention has been carried out (Week 4 ), and the last is once the home intervention has been carried out (Week 6)."
224264614|NCT04941638|PROCEDURE|Distal radial access|Vascular access for primary PCI in patients with STEMI
224264615|NCT05492279|DIETARY_SUPPLEMENT|sheep ghee|natural sheep ghee, given to patient in a commercial box and intervention group 10 gr per day from sheep ghee
224264616|NCT05492279|DIETARY_SUPPLEMENT|sunflower oil|natural sunflower oil, given to patients in a commercial box and patient use 10 gr of it
224264617|NCT04706637|DRUG|Evogliptin|evogliptin 5mg + metformin, oral administration once a day for 48 weeks
224264618|NCT04706637|DRUG|Dapagliflozin|dapagliflozin 10mg + metformin, oral administration once a day for 48 weeks
224264619|NCT03170622|DIAGNOSTIC_TEST|Intervention group|This group will provide a stool sample that will be analysed for VOCs and followed up after 3 months
224264620|NCT00794547|DRUG|Calcitriol|Escalating dose of Calcitriol will be infused IV over 1 hour every 21 days.
224264621|NCT00794547|DRUG|Calcitriol|In this portion of the study, all patients will get the same dose of calcitriol (determined from the Phase I study) along with the standard chemotherapy
224264622|NCT00109954|DRUG|cisplatin|
224264623|NCT00109954|RADIATION|brachytherapy|
224264624|NCT00109954|RADIATION|yttrium Y 90 glass microspheres|
224264625|NCT02632253|PROCEDURE|HIIT|High-intensity interval training (HIIT) is performed on a cycle ergometer. It consists of a 10 min warm-up followed by 4 min intervals in Zone III (at 90-95% of peak heart rate), with each interval separated by 3 min of active pauses in zone I (at 50-70% of peak heart rate). The total duration of the HIIT training is 38 min. The HIIT group will perform two supervised HIIT trainings and one self monitored MICE training per week.
224264626|NCT02632253|OTHER|MICE|MICE is also performed on a cycle ergometer at an intensity of 70-75% of peak heart rate for 47 min (in order for the two training protocols to be isocaloric). The control group will perform two supervised and one self monitored MICE training per week.
224264627|NCT06561984|BEHAVIORAL|antenatal education|Giving educational sessions to the intervention group regarding modes of delivery
223831147|NCT04358419|DIAGNOSTIC_TEST|Pneumocystis jirovecii DNA in exhaled breath condensate (EBC)|The EBC will be collected by use of the RTube(R) system which is commercially available for the purpose of collection of EBC. As the patient breathes through a mouth piece, the exhaled breath is lead through a cooling chamber where the vaporous part of the exhaled breath condenses. The investigators aim at collecting a total minimum of 3.0 mL EBC per study participant in order to have sufficient amount of protein for the subsequent analysis.
223831148|NCT04691882|BEHAVIORAL|Diaphragmatic contraction|Sequential periods (30 s) of voluntary diaphragmatic contraction after meal ingestion
223831149|NCT04691882|BEHAVIORAL|Diaphagmatic relaxation|Sequential periods (30 s) of voluntary diaphragmatic relaxation after meal ingestion
223831150|NCT04896944|OTHER|No intervention|No intervention
223831151|NCT02831309|BEHAVIORAL|Light-Intensity Condition|The light-intensity condition consisted of 8 hours of sitting interrupted with 2--minute, light--intensity activity breaks performed at 25% of heart rate reserve (HRR) every 18 minutes. Standardized meals were provided.
223831152|NCT02831309|BEHAVIORAL|Moderate-Intensity Condition|The moderate-intensity condition consisted of 8 hours of sitting interrupted with 2--minute, moderate-intensity activity breaks performed at 50% of heart rate reserve (HRR) every 18 minutes. Standardized meals were provided.
223831153|NCT02831309|BEHAVIORAL|High-Intensity Condition|The high-intensity condition consisted of 8 hours of sitting interrupted with 2--minute, vigorous-intensity activity breaks performed at 75% of heart rate reserve (HRR) every 18 minutes. Standardized meals were provided.
223831154|NCT02831309|BEHAVIORAL|Sedentary Condition|The sedentary condition consisted of 8 hours of sitting interrupted with 2-minutes of screen time every 18 minutes. Standardized meals were provided.
224264628|NCT02064153|PROCEDURE|Cool dialysate|Each recruited patient undergoes a cool dialysate session ( 35.5ºC) and a warm dialysate session (37ºC). The sessions are minimum a week apart to remove the carryover effect.
224264629|NCT02064153|PROCEDURE|Warm dialysate|All recruited patients will undergo two study sessions - Cool dialysis (35.5ºC) and Warm dialysis (37ºC)
224264630|NCT04762251|OTHER|Time-restricted eating|Time restricted eating for a self-selected 9 hour window per day
224264631|NCT04762251|OTHER|Current Best Practice|Best practice guidelines to improve diet quality
224264632|NCT06559761|PROCEDURE|Hepatectomy|According to guideline recommended procedure of hepatectomy
224264633|NCT04033705|DEVICE|Freestyle Libre Pro glucose sensor|Participants will wear a Freestyle Libre Pro glucose sensor for approximately 2 weeks prior to elective surgery and then for 2 weeks following surgery.
224264634|NCT02050685|OTHER|All patients incoming in the sleep study centre for a PSG|All patients incoming in the sleep study centre for a PSG. Comparison between screening score and AHI derived from PSG.
224264635|NCT00685477|DRUG|Experimental Sequence ABC|Drug will be given over 15 minutes, followed by infusion over 30 minutes, followed by infusion over 60 minutes
224264636|NCT00685477|DRUG|Experimental Sequence ACB|Drug infused over 15 minutes, followed by infusion over 60 minutes, followed by infusion over 30 minutes
224264637|NCT00685477|DRUG|Experimental Sequence BAC|Drug will be given over 30 min infusion, followed by 15 minute infusion, followed by 60 minute infusion
224264638|NCT00685477|DRUG|Experimental Sequence BCA|Drug will be given over 30 min infusion, followed by 60 minute infusion, followed by 15 minute infusion
224264639|NCT00685477|DRUG|Experimental Sequence CAB|Drug will be given over 60 min infusion, followed by 15 minute infusion, followed by 30 minute infusion
224264640|NCT00685477|DRUG|Experimental Sequence CBA|Drug will be given over 60 min infusion, followed by 30 minute infusion, followed by 15 minute infusion
224264641|NCT04631562|DRUG|ALXN1820 SC|ALXN1820 SC will be administered as a manual SC push or SC infusion via a syringe pump. Doses will range from 12.5 milligrams (mg) to a maximum of 2250 mg. Multiple dosing duration will range from 3 to 5 weeks.
224264642|NCT04631562|DRUG|ALXN1820 IV|ALXN1820 IV (450 mg) will be administered as an IV infusion.
224264643|NCT04631562|DRUG|Placebo SC|Placebo SC will be administered as a manual SC push or SC infusion via a syringe pump.
224264644|NCT04631562|DRUG|Placebo IV|Placebo IV will be administered as an IV infusion.
224264645|NCT05313217|DIAGNOSTIC_TEST|Knee extension angle|"Knee Extension Angle (KEA):~* This test will be administered with an ankle-foot orthosis (AFO) maintaining the participants ankle in neutral.~* The participant will lie supine on the examination table with the contralateral lower extremity (LE) stabilized on the support surface using a mobilization strap.~* The hip of the lower being examined will be flexed to 90 degrees.~* The participant will then actively straighten their lower leg while maintaining upper leg in same position~* Once the participant feels they are at maximal knee extension (patient instructed to straighten leg as far as what is comfortable), the angle will be measured with iPhone Inclinometer.~* Participant asked to report any symptoms they are feeling and where (recorded for qualitative analysis)"
224264646|NCT05313217|DIAGNOSTIC_TEST|Straight Leg Raise|"Straight Leg Raise (SLR):~* Position the participant in supine on the plinth with knees extended and L LE strapped to the plinth~* The participant will keep the AFO donned on the R distal ankle to keep the ankle in neutral position.~* A researcher will passively lift the participant's right leg moving at a slow but consistent pace of approximately 15 degrees per second, while keeping it straight until a significant resistance is detected or the participant reports a production of symptoms, whichever occurs first.~* Measurement of the SLR angle will be assessed with iPhone inclinometer.~* Participant asked to report any symptoms they are feeling and where (recorded for qualitative analysis)"
224264647|NCT05313217|DIAGNOSTIC_TEST|Slump Test|"Slump Test Procedure:~* Participant will be instructed to sit upright with their legs over the edge of table~* AFO remains on R leg~* Participant will sequentially flex trunk, look down at the floor~* Participant will extend R knee until symptoms are felt. Measure of angle with iPhone inclinometer placed at superior aspect of medial malleolus~* Participant asked to report any symptoms they are feeling and where (recorded for qualitative analysis)"
223831155|NCT05063305|DIETARY_SUPPLEMENT|Probiotic|The probiotic to be used in the study is in capsule form and consists of 12 bacterial strains and 10-billion colony forming unit (CFU). The product consists of the following bacterial strains and species: Bifidobacterium infantis ATCC SD 6720, Bifidobacterium bifidum ATCC SD 6576, Bifidobacterium breve ATCC SD 5206, Bifidobacterium lactis ATCC SD 5220, Bifidobacterium longum ATCC SD 5588, Lactobacillus acidophilus DSM 32754, Lactobacillus casei ATCC SD5213, Lactobacillus paracasei ATCC SD 5275, Lactobacillus plantarum ATCC SD 5209, Lactobacillus reuteri ATCC SD 6689, Lactobacillus rhamnosus ATCC 53103, Lactobacillus salivarius ATCC SD 5208) in combination with the prebiotic, xylooligosacharide (XOS).
223831156|NCT05063305|DIETARY_SUPPLEMENT|Placebo|A placebo, that will be indistinguishable in appearance to the probiotic, will be provided to half of all study participants for the length of the trial. It will contain the following ingredients: Microcrystalline cellulose, magnesium stearate, a vegetarian capsule, and silicon dioxide. The probiotic will be manufactured by MeriCal.
223831157|NCT04963673|OTHER|calcineurin inhibitor dosage|The dosage of calcineurin inhibitors will be done as usual by the toxicology pharmacology laboratory of the CHU Amiens-Picardie. If the patient does not object, the determination of protein-bound uremic toxins from the rest of the collected blood tube will be performed using high performance liquid chromatography.
223831158|NCT04607915|BEHAVIORAL|Intervention for TECC Model|The Care Coordinator (CC) will provide brief coaching sessions (15 to 20 minutes) to each participant once per week for 8 weeks. Participants can identify topics for discussion and the CC and participant can decide if a video session via WebEx is required versus a phone call. Also, participants will be given peer support and will be indirectly monitored by a virtual care team of experts.
223831159|NCT01662427|OTHER|Questionaire to assess Noctural Parkinson's Disease Symptoms|Questionaire to assess Noctural Parkinson's Disease Symptoms and quality of life
223831160|NCT00001955|DRUG|Etanercept|
223831161|NCT00001955|DRUG|Celecoxib|
223831162|NCT05534880|OTHER|Binaural beats|Condition 02- will be used binaural beats, since they are referred through studies with the ability to drive neural oscillations in the beat frequency through differential hemispheric synchronization frequencies, it is expected that a neuromodulation and repercussion of the symptomatological reduction of CS.
223831163|NCT03198793|DRUG|QGC001|Twice daily (BID) administration of oral (PO) QGC001 (250 mg BID, 500 mg BID, and 500 mg BID + hydrochlorothiazide (HCTZ) 25 mg once daily \[QD\]) over 8 weeks.
223831164|NCT00519259|DRUG|Lobeline|
223831165|NCT01155388|DRUG|Ferumoxytol|Experimental: Ferumoxytol
223831166|NCT01155388|DRUG|Oral Iron|Active Comparator: Oral iron
223831167|NCT03710213|BEHAVIORAL|Text Message-based Intervention|The intervention consists of a series of educational and reminder text messages that a patient will receive in the week prior to a scheduled colonoscopy, in addition to two text messages at the time of enrollment explaining the texting program.
223831168|NCT01004250|DRUG|Pemetrexed|500 milligram per square meter (mg/m²) given intravenously on Day 1 of each 21-day cycle for four cycles of Induction Therapy, and continued in Maintenance Therapy until progression or unacceptable toxicity.
223831169|NCT01004250|DRUG|Cisplatin|75 mg/m² given intravenously on Day 1 of 21-day cycle for a maximum of 4 cycles
223831170|NCT01004250|DRUG|Bevacizumab|7.5 milligram per kilogram (mg/kg) given intravenously on Day 1 of 21-day cycle for four cycles of Induction Therapy, and continued in Maintenance Therapy until progression or unacceptable toxicity
223831171|NCT04192214|DRUG|BC 007|1350 mg of BC 007
223831172|NCT02891239|DEVICE|PicoWay|solid state laser capable of delivering energy at wavelengths of 1064 nm or 532 nm or wavelength of 785 nm that was added to the system
223831173|NCT04258085|OTHER|Early diagnosis program combined with electronic medical record|Implementation of early diagnosis approach targeting symptomatic women, combined with use of electronic medical record to facilitate documentation, patient tracking across levels of the health care system, and patient contact
223831174|NCT03943589|DRUG|Imlifidase|All subjects will receive imlifidase (Day 1) prior to standard care IVIg
223831175|NCT02710331|DRUG|Active Dronabinol|10 mg capsule of Dronabinol will be administered orally.
223831176|NCT02710331|DRUG|Placebo|Control: no alcohol, administered for \~80 minutes.
223831177|NCT02710331|DRUG|Placebo|Control: Placebo pill (no active cannabinoids) administered orally.
223831178|NCT02710331|DRUG|Active Ethanol|Target BrAC of 0.04% reached over 20 minutes and then clamped to maintain this dose for an additional 60 minutes. This dose is equivalent to consuming approximately 2 drinks over 1 hour. Administered over a total of 80 minutes.
223831179|NCT00889382|DRUG|OSI-906|Administered orally
223831180|NCT00889382|DRUG|Paclitaxel|Administered intravenously
223831181|NCT01875835|DEVICE|Xience™ V stent (Abbott Vascular, Santa Clara, California, USA)|
223831182|NCT01875835|DEVICE|Multilink-Vision stent(Abbott Vascular, Santa Clara, California, USA)|
223831183|NCT03806049|DRUG|Niraparib|given orally once daily
223831184|NCT03806049|DRUG|Bevacizumab|given as iv infusion every three weeks
223831185|NCT03806049|DRUG|TSR042|Given as IV infusion every three weeks
223831186|NCT03806049|DRUG|Carboplatin|given as iv infusion every three weeks
223831187|NCT03806049|DRUG|Paclitaxel|given as iv infusion every three weeks
223831188|NCT04096807|OTHER|Standard TEE exam including measurement of left upper pulmonary vein diameter and collapsibility, compared with PCWP measured continuously by a pulmonary arterial catheter|TEE takes part of the standard perioperative hemodynamic monitoring in cardiac surgery. Patients enrolled in the study are also monitored by a pulmonary arterial catheter
223831189|NCT03813095|DRUG|APH-1501|The investigational drug product APH-1501 is CBD encapsulated in biodegradable polymer nanospheres, is a lyophilized powder intended for oral administration.
223831190|NCT03813095|DRUG|Placebo|The placebo is a sterile pyrogen free lyophilized powder identical in appearance to the experimental drug product.
223831191|NCT03494374|DEVICE|UCBL orthosis|toe walking exercise
223831192|NCT01658488|OTHER|Non-fortified rice|Consumption of 2 servings of Non-fortified rice per day in women with iron deficiency anemia and measure serum iron and transferrin at baseline and end of study.
223831193|NCT01658488|OTHER|Iron-fortified Rice|Consumption of 2 servings of Iron-fortified rice per day in women with iron deficiency anemia and measure serum iron and transferrin at baseline and end of study.
223831194|NCT00900627|DRUG|AZD8931|Tablet Oral bid
223831195|NCT00900627|DRUG|Paclitaxel|IV once weekly for 3 weeks followed by a week off (repeated cycles)
223831196|NCT00900627|DRUG|Placebo|Oral bid (twice daily)
223831197|NCT04027790|DIAGNOSTIC_TEST|Epi proColon|Analysis of DNA methylation status for Septin9 and additional biomarkers
223831198|NCT03325335|DRUG|Midazolam premedication|Patients in Group P received midazolam (0.05 mg/kg, intramuscular injection) 30 minutes before induction of general anesthesia.
223831199|NCT03325335|DRUG|Remifentanil infusion|Target controlled infusion of remifentanil (4ng/ml) was used for induction of anesthesia based on the pharmacological models of Minto. After intubation, remifentanil (2 ng/ml) was infused until incision time. (Both groups)
223831200|NCT03325335|DRUG|Propofol infusion|Target controlled infusion of propofol (4.0 μg/ml) was used for induction of anesthesia based on the pharmacological models of Marsh. After intubation, propofol (3.0μg/ml) was infused until incision time. (Both groups)
223831201|NCT00373295|DRUG|Baclofen|Baclofen (60mg/day or 90 mg/day): Packaged medication in size 00 opaque capsules with riboflavin filler. Study capsules (0, 20, 30mg) were administered 3 times per day (0900, 1530, 2200).
223831202|NCT00373295|DRUG|Marijuana|Marijuana: Participants each received a single marijuana cigarette (provided by the National Institute on Drug Abuse) at each smoking occasion. Marijuana cigarettes were stored frozen in an airtight container and humidified at room temperature for 24 h prior to use.
223831203|NCT00373295|DRUG|Placebo|
223831204|NCT00830947|DEVICE|OrthoAccel Device|The OA device provides a light vibration at 0.25 Newtons and 30 Hz frequency for 20 minutes daily.
223831205|NCT00830947|DEVICE|Sham Device|Inactive sham device that is held in the mouth for 20 minutes.
223831206|NCT01306565|DRUG|Low dose Atorvastatin|80mg atorvastatin followed by two 20mg daily atorvastatin
223831207|NCT01306565|DRUG|High dose atorvastatin|80mg daily atorvastatin for 72 hours
223831208|NCT02462083|DRUG|IDP-118 Lotion|IDP-118 lotion will be applied as per the instructions provided by the investigational center staff.
223831209|NCT06232499|DEVICE|Intravenous Laser Irradiation of Blood|The different color lights for Intravenous Laser Irradiation of Blood are red light at 808nm and blue light at 415nm
223831210|NCT01270997|BIOLOGICAL|Etanercept|Subcutaneous injection (SC) Etanercept 25mg twice a week for 48 weeks
223831211|NCT01270997|BIOLOGICAL|Etanercept|Subcutaneous injection (SC) Etanercept 25mg twice a week for 48 weeks
223831212|NCT04908761|PROCEDURE|Transmuscular quadratus lumborum block|Patients assigned to the TQL block group receive the TQL block in a supine position with the surgical site facing up before recovery of general anesthesia after surgery. For the block, 30cc of 0.375% ropivacaine is used.
223831213|NCT04908761|PROCEDURE|Placebo|For patients assigned to the control group, 30cc of 0.9% normal saline is used for TQL block.
223831214|NCT03244592|DRUG|Minocycline|200 mg/day
223831215|NCT03244592|DRUG|Sugar pill|Matched placebo
223831216|NCT02291289|DRUG|Cetuximab|500 mg/m\^2 via IV infusion on Day 1 of every 2-week cycle
223831217|NCT02291289|DRUG|FOLFOX induction regimen|Administered per the Investigator's discretion in accordance with locally approved prescribing information.
223831218|NCT02291289|DRUG|Fluoropyrimidine (5-FU/LV or capecitabine)|Per Investigator's discretion: 5-FU 1600-2400 mg/m\^2 administered via 46-hour IV infusion on Day 1 of every 2-week cycle and LV 400 mg/m\^2 administered via a 2-hour infusion on Day 1 every 2 weeks or 1000 mg/m\^2 twice-daily capecitabine (BID) by mouth given days 1-14 every 2 weeks. The chosen fluoropyrimidine should be administered in accordance with local prescribing information.
223831219|NCT02291289|DRUG|Atezolizumab|800 mg atezolizumab via 60-minute IV infusion on Day 1 of every 2-week cycle, or a fixed dose of 840 mg
223831220|NCT02291289|DRUG|Vemurafenib|960 mg vermurafenib BID by mouth
223831221|NCT02291289|DRUG|Bevacizumab|5 mg/kg bevacizumab via 15-30 minute IV infusion on Day 1 of every 2-week cycle per local prescribing information
223831222|NCT02291289|DRUG|Trastuzumab|Initial loading dose of 8 mg/kg followed by 6 mg/kg for subsequent doses by IV infusion on Day 1 of every 3-week treatment cycle
223831223|NCT02291289|DRUG|Pertuzumab|Initial fixed loading dose of 840 mg followed by 420 mg for subsequent doses by IV infusion on Day 1 of each 3-week treatment cycle
223831224|NCT02291289|DRUG|Cobimetinib|60 mg orally once daily for 3 weeks followed by a 1-week treatment break
223831225|NCT02291289|DRUG|5-FU/LV|1600-2400 mg/m\^2 5-FU via 46-hour IV infusion in combination with 400 mg/m\^2 LV via 2-hour infusion on Day 1 of every 2-week cycle until disease progression per the Investigator's assessment using modified Response Evaluation Criteria in Solid Tumors or death from any cause, whichever occurs first. The fluoropyrimidine should be administered in accordance with local prescribing information.
223831226|NCT02291289|DRUG|Capecitabine|1000 mg/m\^2 twice-daily capecitabine (BID) by mouth given days 1-14 every 2 weeks. The fluoropyrimidine should be administered in accordance with local prescribing information.
223831227|NCT05742724|DRUG|Tetrahydrocannabinol-Cannabidiol Combination|Oral THC 0.1mg/kg and CBD 2.5mg/kg
223831228|NCT01304524|BIOLOGICAL|VGX 3100|1ml of VGX-3100 delivered IM followed by electroporation at Day 0, Week 4 and Week 12.
223831229|NCT01304524|BIOLOGICAL|Placebo|1ml of placebo delivered IM followed by electroporation at Day 0, Week 4 and Week 12.
223831230|NCT01304524|DEVICE|CELLECTRA™-5P|CELLECTRA™-5P is used for electroporation following IM delivery of VGX 3100 or placebo on Day 0, Week 4 and Week 12.
223831231|NCT05290103|BEHAVIORAL|Game intervention|"Game intervention consists of 15-30 minutes digital health game playing at school and 2 weeks free usage of the digital health game during free time. In addition, after the 2 weeks period of game playing, 30-minute debriefing sessions with a research are held.~The digital health game includes visualized elements with sound effects that aim at increasing understanding about the consequences of tobacco product use and supporting refusal skills. The health game includes different mini-games and also textual information.~The debriefing sessions with a researcher include small group and group discussions about the themes presented in the game. A researcher leads and teachers facilitate the discussions. The debriefing sessions aim to connect the game experience with daily life situations."
223831232|NCT00003238|DRUG|perillyl alcohol|
223831233|NCT01915147|DRUG|OXN PR followed by OxyPR tablets|
223831234|NCT01915147|DRUG|OxyPR followed by OXN PR tablets|
223831235|NCT02615756|BEHAVIORAL|Exercise|
223831236|NCT03076359|BEHAVIORAL|Traditional Healer Support Program|"Traditional Healers will provide the traditional healer support program assistance, as previously described, to all newly diagnosed patients."
223831237|NCT03076359|DRUG|Standard of Care|First-line ART will consist of two nucleoside reverse-transcriptase inhibitors (NRTIs) plus a non-nucleoside reverse-transcriptase inhibitor (NNRTI)- TDF + 3TC (or FTC) + EFV as a fixed-dose combination to be taken twice a day for the rest of the patient's life), clinic-based counseling, and community searches if lost to follow up.
223831238|NCT01545362|PROCEDURE|Total knee arthroplasty|Total knee arthroplasty
223831239|NCT06223477|OTHER|Platelet-rich Fibrin|PRF will be injected distal to the canine on the experimental side.
223831240|NCT06223477|OTHER|Vitamin D3|Vitamin Dꝫ will be injected distal to the canine on the experimental side
223831241|NCT02409160|PROCEDURE|Standard Roux-en-Y gastric bypass|
223831242|NCT02336581|BEHAVIORAL|Acceptance and Commitment Therapy (ACT)|individual + group + follow-up phone contacts
223831243|NCT02336581|BEHAVIORAL|Enhanced Treatment as Usual (eTAU)|individual + group + follow-up phone contacts
223831244|NCT00321256|PROCEDURE|human pancreatic islet transplantation|
223831245|NCT02590133|DRUG|Recombinant Human Endostatin Injection (Endostar)|15mg/m2/d, continuous intravenous infusion in 2ml/h for 30 days each cycle, 60 days as one cycle, 6 cycles in total
223831246|NCT02590133|DRUG|Fluorouracil (5-Fu)|200mg/m2/d, continuous intravenous infusion in 2ml/h for 30 days each cycle, 60 days as one cycle, 6 cycles in total
223831247|NCT02590133|DRUG|Nedaplatin|80mg/m2/d, intravenous drip on d1 and d28 each cycle, 60 days as one cycle, 6 cycles in total
223831248|NCT03498755|BEHAVIORAL|Mobile phone audio messaging|"Audio messages will be pushed to participants' mobile phones twice weekly on a set schedule in discrete modules that include basic information related to each of the four behavioral domains followed by an integration of the information across behaviors through relatable, character-driven narratives that enable message recipients to engage with the content through a real-world context."
223831249|NCT03498755|BEHAVIORAL|Peer-to-peer learning|Women participants in each community will meet twice monthly for peer-to-peer learning sessions to reinforce the content of audio messages. These sessions will further use women's empowerment approaches including critical examination of gender dynamics, and discussions of solutions for equitable decision-making and control of resources within households. These discussions will be facilitated with male household members and grandmothers in separate learning sessions that will be held three times throughout the intervention period.
223831250|NCT03498755|BEHAVIORAL|Conditional cash transfer|Participants will receive a conditional cash transfer to support their fish smoking business. The payment will be conditional on their participation in entrepreneurship trainings and the use of the investment into their fish smoking business.
223831251|NCT03498755|BEHAVIORAL|Entrepreneurship training|Entrepreneurship training will focus on commonly lacking business knowledge, with an emphasis on establishing fundamental entrepreneurial skills (i.e., customer care, accounting), sound business management and decision-making, building strong and sustainable business relationships, and encouraging the use of loans for their intended purposes. This training will be introduced during the credit and savings group (CSG) meetings that will occur twice per month.
223831252|NCT03498755|BEHAVIORAL|Market price information|Average market prices for fresh and processed fish at community, district, and regional markets will be disseminated via audio message calls (using Viamo's Infoline platform) to the mobile phones of women with the price information in their preferred language. These market prices will be collected twice weekly by Viamo field enumerators and sent to regional coordinators for validation. A second, independent validation will be carried out to ensure that there are no discrepancies.
223831253|NCT03498755|BEHAVIORAL|Improved smoke ovens|Local private sector artisans will construct and serve as suppliers of the new ovens. The promotion, uptake and impact of these improved Ahotor ovens will be tested among study participants. Awareness-raising workshops held in each community will promote the Ahotor in concert with a public retrofitting of a Chorkor stove. Immediately following this event, one month later, and three months later, study participants will receive additional one-on-one counseling to provide further support on the proper use of the smoke oven, as well as on optimal handling and smoking practices to enhance product quality.
223831254|NCT02040792|DRUG|TD-4208|
223831255|NCT02040792|DRUG|Placebo|
223831256|NCT01842087|OTHER|Control Food|For a period of 2 weeks, participants will consume control foods in addition to their usual diets.
223831257|NCT01842087|OTHER|Fiber Fortified Food|For a period of 4 weeks, participants will consume food fortified with fiber in addition to their usual diets.
223831258|NCT04217070|OTHER|Questionnaire|Questionnaire including demographic data, data regarding poisoning substance and outcomes of suicidal attempts
223831259|NCT02025452|OTHER|Rapid diagnostic|Specimens from rectal mucosa will be obtained using flocked swabs at enrolment. Those in 'rapid diagnostic' groups will have them tested using multiplex PCR the day of enrolment and participants with treatable pathogens will have antimicrobials provided. Those in 'delayed diagnostic' groups will have the swabs batched at tested at the conclusion of the study, being treated as per standard of care.
223831260|NCT02025452|DIETARY_SUPPLEMENT|Probiotic|Lactobacillus reuteri suspended in vegetable oil, 5 drops/day (1 x 10e8 CFU) x 2 months
223831261|NCT02025452|OTHER|Placebo|Identical in appearance to L. reuteri probiotic (same bottle), but simply vegetable oil. Dose is 5 drops/day x 2 months.
223831262|NCT04039074|BEHAVIORAL|Integrative Yoga|"A 12-week Integrative Yoga intervention which has meditative and psycho-educational components corresponding to traditional yoga practice."
223831263|NCT04039074|BEHAVIORAL|Iyengar Yoga|A 12-week established, predominantly body-oriented yoga intervention (Iyengar yoga).
223831264|NCT04039074|BEHAVIORAL|Mindfulness|A 12-week mindfulness intervention designed for the healthy handling of stress.
223831265|NCT03985163|OTHER|Patient Reported Outcomes Electronic Survey|This study does not include a drug, test, behavioral or medical procedure intervention; participants will be asked to complete three surveys
223831266|NCT02854306|PROCEDURE|Bariatric surgery|With mindfulness programm
223831267|NCT02854306|PROCEDURE|Bariatric surgery|Without mindfulness programm
223831268|NCT01649596|DEVICE|Warming Gown|Forced air warming Gown and portable warming unit that follows patient from pre-operative through surgery and into post-operative recovery.
223831269|NCT01649596|OTHER|Standard of care warming|The intervention is standard of care, placing warm blankets on the patient at time of pre operative preparation through the procedure and into recovery.
223831270|NCT04122560|DRUG|Fluconazole 200mg tab|PO dose of 400mg
223831271|NCT04122560|DRUG|Fluconazole 2 MG/ML|IV dose of 400mg
223831272|NCT00962585|DRUG|Placebo|
223831273|NCT00962585|DRUG|S-equol|"Eligible patients meeting all study entry criteria were randomly assigned to receive one of the following active treatments for 4 weeks:~* S-equol 10 mg BID (20 mg total daily dose)~* S-equol 50 mg BID (100 mg total daily dose)~* S-equol 150 mg BID (300 mg total daily dose)"
223831274|NCT00883103|DRUG|2% Lidocaine jelly|2% Lidocaine jelly will be applied onto the catheter and then the cotton swab during evaluation of postvoid residual and the Q-tip test.
223831275|NCT00883103|DRUG|Plain aqueous gel|Plain aqueous gel will be applied onto the catheter and then the cotton swab during evaluation of postvoid residual and the Q-tip test.
223831276|NCT06146309|DRUG|aflibercept (2mg/0.05ml)|Aflibercept is a medication used to treat and manage neovascular age-related macular degeneration, diabetic macular edema, myopic choroidal neovascularization, macular edema associated with retinal vein occlusion, and diabetic retinopathy. It is in the vascular endothelial growth factor-A (VEGF-A) and placental growth factor (PlGF) antagonist class of medications. Aflibercept acts as a soluble protein decoy for VEGF receptors to inhibit the predominant signaling pathway responsible for angiogenesis and vascular leakage. Aflibercept and other anti-VEGF inhibitors have become the gold standard in controlling neovascular (wet) age-related macular degeneration (NVAMD). T
223831277|NCT05666700|BIOLOGICAL|Combination Product: JNJ-68284528 (Cilta-cel) & 64Cu SPION dual PET-MR imaging agent|Cilta-cel is a cellular immunotherapy derived from autologous CD3+ T-cells that have undergone ex vivo modification to target B-Cell Maturation Antigen (BCMA) on the surface of plasma cells. Cilta-cel will be administered as two IV infusions, ≥70% unlabeled and ≤30% labelled. The dose will be based on the patient's weight (kg) at apheresis
223831278|NCT01281553|DRUG|Placebo|Suspension identical in appearance to cisapride q.i.d. for 8 weeks.
223831279|NCT01281553|DRUG|Cisapride|0.2 mg/kg suspension q.i.d.for 8 weeks.
223831280|NCT05909293|DRUG|Venclexta 100 MG Oral Tablet|"When there is a deficiency of neutrophils, G-CSF treatment may be necessary. The treatment is continued until the absolute neutrophil count (ANC) reaches either \>0.5×109/L and remains at that level for 3 consecutive days, or \>2×109/L. The purpose of G-CSF therapy in this context is to stimulate the production of neutrophils and restore their levels to a sufficient and stable range. This helps to strengthen the immune system and reduce the risk of infections associated with low neutrophil counts.~When experiencing Grade 3-4 thrombocytopenia, subcutaneous injection of IL-11 can be administered as a treatment.~When symptoms of infection occur, aggressive antimicrobial therapy and other supportive treatments should be administered.~All blood products should undergo irradiation when transfused, and all blood products must be filtered before infusion.~If gastrointestinal adverse reactions occur, antiemetic medications can be administered to alleviate symptoms."
223831281|NCT03503838|BEHAVIORAL|Online Yoga|12 weeks of online yoga; 60 min/week
223831282|NCT00415493|OTHER|Cold-dry air provocation|15 minute exposure to cold-dry air by nasal mask
223831283|NCT00415493|OTHER|Warm-moist air provocation|15 minute exposure to warm-moist air by nasal mask
223831284|NCT02743286|BEHAVIORAL|Frequent sit-to-stands|Participants will visit the clinic for a 6-hour monitoring period. Following a 1-hour sitting run-in period, participants will sit for an additional 5-hour period including 15 2-minute standing interruptions, 3 per hour. Baseline, mid-point, and end-of-visit bathroom breaks for urine sample collection will be conducted, with additional bathroom breaks allowed as needed.
223831285|NCT02743286|BEHAVIORAL|Walking breaks|Participants will visit the clinic for a 6-hour monitoring period. Following a 1-hour sitting run-in period, participants will sit for an additional 5-hour period including 5 2-minute walking interruptions, 3 per hour. Baseline, mid-point, and end-of-visit bathroom breaks for urine sample collection will be conducted, with additional bathroom breaks allowed as needed.
223831286|NCT02743286|BEHAVIORAL|Stand more|Participants will visit the clinic for a 6-hour monitoring period. Following a 1-hour sitting run-in period, participants will sit for an additional 5-hour period including 5 10-minute standing interruptions, 1 per hour. Baseline, mid-point, and end-of-visit bathroom breaks for urine sample collection will be conducted, with additional bathroom breaks allowed as needed.
223831287|NCT02279147|DRUG|neostigmine methylsulfate，raceanisodamine hydrochloride|The patients receive immediately raceanisodamine hydrochloride(10mg) by intramuscular injection after operation .From that date, for three consecutive days, the patients will be receive 50mg raceanisodamine hydrochloride and 0.15mg neostigmine methylsulfate in the 24h by slow injection of vein.
223831288|NCT05235763|OTHER|activity coach|The activity coach educates the patient about physical activity, offers means of manually tracking physical activity, and provides trends of registered activity. Furthermore, it provides weekly summaries of registered physical activity and provides means of setting goals for the following week.
223831289|NCT05235763|OTHER|sham activity coach|The visual appearance of Optilogg is changed as to make the patient aware that something has happened to it, hence not knowing if it is the real activity coach or not. No new functionality is added, however.
223831290|NCT04375982|DIAGNOSTIC_TEST|Venepuncture|Blood tube will be collected from standard venepuncture
223831291|NCT04375982|DIAGNOSTIC_TEST|Fingerstick|Capillary blood will be collected by fingerstick
223831292|NCT04328558|OTHER|Clavipectoral fascia plane block group|Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit.
223831293|NCT05464576|DIAGNOSTIC_TEST|MRI|Using the MRI in the diagnosis of the bladder cancer (invasive or not)
223831294|NCT01037959|DRUG|Norfloxacin|400 mg/day (per os) for 6 months
223831295|NCT01037959|DRUG|Placebo|1 pill/day (per os) for 6 months
223831296|NCT01231685|DRUG|Raltegravir|Subjects will maintain their nucleoside backbone and switch ritonavir-boosted protease inhibitor to Raltegravir 400 mg po BID for 48 weeks.
223831297|NCT01231685|DRUG|Ritonavir-boosted protease inhibitor|Subjects will maintain their nucleoside backbone and remain on a ritonavir-boosted protease inhibitor at standard doses for for 48 weeks
223831298|NCT04037995|OTHER|No intervation|No intervation
223831299|NCT05253690|PROCEDURE|balloon catheter insertion approach for labor induction|Parous women will be randomized to labor induction by view-guided approach using a speculum for catheter insersion versus manual guided catheter balloon insersion at cervical examination
223831300|NCT04375696|DRUG|Polyglucosamine L112|Polyglucosamine; Ascorbic Acid; Tartaric Acid
223831301|NCT04375696|OTHER|Placebo|Dicalcium Phosphate; Microcrystalline Cellulose; Iron Oxide (yellow, brown, and black); Magnesium Stearate; Silicon Dioxide
223831302|NCT00861796|DRUG|CYR-101|Experimental arm
223831303|NCT00861796|DRUG|Placebo|Placebo comparator
223831304|NCT00902941|DRUG|Azilect 1mg|1 mg daily orally for 120 days
223831305|NCT00902941|DRUG|Placebo|1 mg daily orally for 120 days
223831306|NCT00594906|DRUG|Teriparatide|Daily 20-mcg subcutaneous injections for the duration of the study (16 weeks)
223831307|NCT00594906|DRUG|Placebo|Daily 20-mcg subcutaneous injections for the duration of the study (16 weeks)
223831308|NCT03092960|BEHAVIORAL|Minimal intensity intervention|The minimal intensity intervention control includes the Group Lifestyle Balance (GLB) videos (DVD or online), standardized messages, and access to a lifestyle coach if initiated by the participant.
223831309|NCT03092960|BEHAVIORAL|HOMBRE|HOMBRE is a Group Lifestyle Balance (GLB)-based intervention tailored for men and available in 3 delivery modalities (coach-facilitated individual approach, coach-led online virtual groups, and coach-led in-person groups). A lifestyle coach will support men in making an informed choice of modality and will provide ongoing individualized feedback. All delivery modalities provide the same evidence-based curriculum and include self-monitoring and individualized feedback from the lifestyle coach.
223831310|NCT03492619|BEHAVIORAL|Intensive Intervention|an intervention focused on alleviating discouragement, food insecurity, and excess weight in women and targeted at the individual, family, and community levels
223831311|NCT03492619|BEHAVIORAL|Non-Intensive Intervention|Group sessions for healthy lifestyle
223831312|NCT00431002|BEHAVIORAL|Resistance training|See Detailed Description.
223831313|NCT05391321|OTHER|administration of the 4 quality of sexual life questionnaires|administration of the 4 quality of sexual life questionnaires
223831314|NCT02415218|BIOLOGICAL|Mucosal cell sheet transplantation|The subjects will have their oral mucosal tissues retrieved for cell sheet preparation. The mucosal cell sheet will be transplanted over the affected cornea.
223831315|NCT00272766|DRUG|pegaptanib sodium|
223831316|NCT01033773|DRUG|Antihyperglycemic medication guideline for management of uncontrolled hyperglycemia presenting to the ED using metformin, sulfonylurea and/or insulin|Diabetes medications (including sulfonylureas, metformin and/or insulin) were initiated and/or adjusted at each visit using the intervention algorithm per presenting blood glucose and prior diabetes medications.
223831317|NCT01033773|BEHAVIORAL|Diabetes survival skills self-management education|Survival skills DSME based upon current JCAHO and ADA joint recommendations for persons with diabetes prior to discharge to the outpatient setting was initiated in the ED and continued at the follow-up encounters.
223831318|NCT01972334|BIOLOGICAL|FMT|as explained in study arm
223831319|NCT01972334|BIOLOGICAL|placebo|salt water or saline will be given as placebo
223831320|NCT03306186|DEVICE|HemoSpec|Blood sampling for analysis
223831321|NCT06220786|DEVICE|Low-level laser therapy|Low-level laser therapy ca. 72 Joules per cm2
223831322|NCT06220786|DEVICE|"Fake low-level laser therapy"|Identical laser pen without production of low-level laser therapy
223831323|NCT02701946|PROCEDURE|Modified Robert Jones bandage|Modified Robert Jones bandage is defined as a three-layers of thick cotton wool and two-layers of elastic bandages. The wool layers are put on firmly and overlapped the previous one by half at each turn. The elastic layers were pulled snugly with more tension distally than proximally. Before wrapping in each turn, the elastic bandage was stretched approximately 2 and 1.5 inches at below and above tibial tuberosity level, respectively. The whole bandage attains a thickness of about two inches and extends above the ankle joint to six inches above the knee joint. Before applying this bandage, the sterile gauze pads were placed over the wound and followed by WebrilTM padding (Covidien, Mansfield, MA, US)
223831324|NCT02701946|PROCEDURE|Non compressive dressing|Non-compressive dressing is made by placing the sterile gauze pads over the wound and covering with the hypoallergenic self-adhesive, non-woven fabric tape.
223831325|NCT00839917|BIOLOGICAL|Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live (ProQuad™)|Single administration of 0.5 mL subcutaneous injection
223831326|NCT00839917|BIOLOGICAL|M-M-R™ II and Varivax™|Single administration of 0.5 mL subcutaneous injection
223831327|NCT04773886|DRUG|Mineral trioxide aggregate|Vital Pulpotomy will be done using Mineral trioxide aggregate (MTA) as pulp capping agent
223831328|NCT04773886|DRUG|Biodentine|Vital Pulpotomy will be done using Biodentine as pulp capping agent
223831329|NCT04773886|BIOLOGICAL|Platelet rich fibrin|"10 ml of blood was drawn from the peripheral vein in the selected patients with the help of sterilized disposable syringe and blood was collected in the pre-sterilized borosilicate glass test tube, without any addition of anticoagulant and was immediately centrifuged at 3000 rpm for 15 minutes in a centrifuge unit.~The product obtained after centrifugation consisted of three layers:~* Acellular platelet plasma- top most layer~* Platelet rich fibrin -middle layer~* Red blood corpuscles- bottom layer PRF was then separated from the red blood corpuscles base with the help of sterile tweezers and scissors and squeezed with the help of sterile gauze piece"
223831330|NCT00867490|DRUG|Candesartan+HCTZ - Phase 1|4 weeks treatment with candesartan 32 mg (two 16 mg tablets) plus hydrochlorothiazide 25 mg (two 12.5 mg tablets) taken orally with water in the morning between 7 and 10 am.
223831331|NCT00867490|DRUG|Aliskiren+HCTZ - Phase 2|Patients with uncontrolled mean sitting diastolic blood pressure (msDBP ≥ 90 mm Hg) at the end of Phase 1 were treated for 4 weeks with aliskiren 300 mg plus hydrochlorothiazide 25 mg in a single tablet taken orally with water in the morning between 7 and 10 am.
223831332|NCT00867490|DRUG|Aliskiren+HCTZ+amlodipine - Phase 3|The first 60 patients with uncontrolled mean sitting systolic or diastolic blood pressure (msDBP ≥ 90 mm Hg and/or msSBP ≥ 140 mm Hg) at the end of Phase 2 were offered 4 weeks treatment with aliskiren 300 mg plus HCTZ 25 mg in a single tablet plus an amlodipine 5 mg tablet taken orally with water in the morning between 7 and 10 am.
223831333|NCT00079443|DRUG|romidepsin|Given IV
223831334|NCT00079443|BIOLOGICAL|rituximab|Given IV
223831335|NCT00079443|DRUG|fludarabine phosphate|Given IV
223831336|NCT00079443|OTHER|laboratory biomarker analysis|Correlative studies
223831337|NCT03375684|OTHER|Conventional chest physiotherapy|Programme will include diaphragmatic breathing exercise, thoracic expansion exercises, incentive spirometer exercise (Triflo), oscillatory PEP (Flutter), postural drainage and coughing tecniques.
223831338|NCT03375684|OTHER|Inspiratory muscle training|Threshold IMT device will be used for the training. Training intensity will set at 30% of the maximum inspiratory pressure.
223831339|NCT05521295|OTHER|no intervention|no intervention in this study
223831340|NCT03246425|OTHER|Ventilator mode change|The enrolled subjects will be moved from the baseline mode to another mode of ventilation and the changes in the arterial pulse will be observed
223831341|NCT03246425|DEVICE|Monitoring of blood pressure variation|The changes in the blood pressure will be measured in the form of Stroke Volume Variation using SVV using Vigileo (Edward Life sciences) monitor
223831342|NCT01770249|PROCEDURE|Per-oral Endoscopic Esophagomyotomy (POEM)|The surgeon is cutting only through the innermost layers of muscles in the esophagus down to the stomach, leaving the outer layer intact.
223831343|NCT00472186|DRUG|Lansoprazole|If weight is less than 30 kg, 15 mg of Lansoprazole twice daily will be administered. If weight is greater than or equal to 30 kg, 30 mg of Lansoprazole twice daily will be administered.
223831344|NCT00472186|DRUG|Placebo|Placebo will also be administered based on weight.
223831345|NCT01254565|DRUG|Etelcalcetide|Administered intravenously (IV) at the end of hemodialysis
223831346|NCT01254565|DRUG|Placebo|Administered intravenously at the end of hemodialysis
223831347|NCT01389063|DRUG|Maraviroc|HAART of subjects enrolled in arm A will be intensified with maraviroc during week 1-8.
223831348|NCT02961855|DRUG|anesthesics plus antiinflammatory, CLIFE1|anesthesics plus antiinflammatory, CLIFE1 topical gel containing lidocaine plus diclofenac anesthesics plus antiinflammatory
223831349|NCT02961855|DRUG|local anesthesics, CLIFE2|local anesthesics, CLIFE2 topical gel containing lidocaine local anesthesics
223831350|NCT03545815|BIOLOGICAL|anti-mesothelin CAR-T cells|Cells will be infused on day 0.
223831351|NCT05334823|BIOLOGICAL|pCAR-19B cells|Drug: pCAR-19B cells； Administration method: intravenous infusion； Subjects will be treated with Fludarabine and Cyclophosphamide before cell infusion.
223831352|NCT02726399|DRUG|Ramucirumab|Ramucirumab 8mg/kg administered intravenously on days 1 and 8 ever 21 days
223831353|NCT02726399|DRUG|Trastuzumab|Trastuzumab (8 mg/kg loading dose; 6 mg/kg maintenance) administered intravenously every 21 days
223831354|NCT02726399|DRUG|Capecitabine|Capecitabine 850mg/m2 will be added, taken orally twice a day for fourteen days (days 1 through 14) followed by a 7 day rest period
223831355|NCT02726399|DRUG|Cisplatin|Cisplatin 80mg/m2 administered as an IV infusion every 21 days
223831356|NCT06073028|OTHER|20-minute gait training|All subjects undergo two 20-minute gait trainings using two different kinds of auditory cueing (temporal or spatial), one week apart (D1 and D8).
223831357|NCT04615208|DIAGNOSTIC_TEST|suspected of COVID-19 infection|suspected of COVID-19 infection
223831358|NCT03202030|PROCEDURE|Immediate dentoalveolar restoration|Block of bone removed from the tuber and placed in the buccal resorption of the socket together with an immediate implant
223831359|NCT03202030|PROCEDURE|Demineralized bovine bone|Block of demineralised bovine bone placed in the buccal resorption of the socket together with an immediate implant
223831360|NCT01594177|DRUG|Afatinib|20 mg daily for 17 weeks (first two weeks every second day).
223831361|NCT01594177|DRUG|Trastuzumab|First cycle: loading dose 8 mg/kg (day 1 q day 22), thereafter maintenance dose for 9 cycles: 6 mg/kg (day 1 q day 22).
223831362|NCT01594177|DRUG|Paclitaxel|80 mg/m² i.v. given weekly on day 1 q day 8 for 12 weeks.
223831363|NCT01594177|DRUG|Epirubicin|90 mg/m² i.v. given on day 1 q day 22 for 4 cycles.
223831364|NCT01594177|DRUG|Cyclophosphamide|600 mg/m² i.v. given on day 1 q day 22 for 4 cycles.
223831365|NCT04438096|DRUG|100 mg|One 100 mg pill and two placebo pills (QD) will be orally administered for 12 weeks
223831366|NCT04438096|DRUG|200 mg|Two 100 mg pills and one placebo pill (QD) will be orally administered for 12 weeks
223831367|NCT04438096|DRUG|300 mg|Three 100 mg pills (QD) will be orally administered for 12 weeks
223831368|NCT04438096|DRUG|Placebo|Three placebo pills (QD) will be orally administered for 12 weeks
223831369|NCT00433576|DRUG|resveratrol|Given orally
223831370|NCT00433576|OTHER|pharmacological study|Correlative studies
223831371|NCT00433576|OTHER|laboratory biomarker analysis|Correlative studies
223831372|NCT02693912|PROCEDURE|Bronchoscopy|Bronchoscopy will be implemented under sedation in both groups.
223831373|NCT06403241|OTHER|2000 meter ergometer test|Rowers performed 2000m ergometer test.A 2,000-m time trial is a standard test used to assess performance in rowers.
223831374|NCT00999401|DRUG|sapacitabine and seliciclib|sequential or concomitant administration of sapacitabine and seliciclib
223831375|NCT05652764|OTHER|Orem's Self-Care Deficit Theory Based Nursing Interventions for Immunotherapy Treated Cancer Patients|In this study, face-to-face patient education, giving patient education booklet, preparation of symptom management card, face-to-face and telephone counseling initiatives were planned to the experimental group.
223831376|NCT03110328|DRUG|MK3475|anti-PD1 immunotherapy
223831377|NCT00519675|DRUG|alitretinoin|
223831378|NCT03748979|DRUG|TAK-925|TAK-925
223831379|NCT03748979|DRUG|Placebo|TAK-925 Placebo
223831380|NCT02026973|DRUG|Fulvestrant|
223831381|NCT02026973|DRUG|Anastrozole|
223831382|NCT02026973|DRUG|Placebo|
223831383|NCT02026973|DRUG|Somatostatin|
223831384|NCT01335308|BEHAVIORAL|Standard Care|Practitioners will receive 2 hour obesity lecture and ½ day protocol training. Families recruited are given parent education materials. Outcomes will be collected at 1 year and 2 years after enrollment
223831385|NCT01335308|BEHAVIORAL|Moderate Dose Motivational Interviewing|Practitioners receive 2 days of Motivational Interviewing and Behavioral Therapy Training and ½ day protocol training. Families recruited receive 4 x MI visits with the pediatric practitioner. Outcomes will be collected at 1 year and 2 years after enrollment
223831386|NCT01335308|BEHAVIORAL|Higher Dose Motivational Interviewing|Practitioners receive 2 days of Motivational Interviewing and Behavioral Therapy Training and ½ day protocol training. Families recruited receive 4 x MI visits with the pediatric practitioner and 6 x visits (in phone or in person) with a Registered Dietitian, also trained in Motivational Interviewing. Outcomes will be collected at 1 year and 2 years after enrollment
223831387|NCT04253704|COMBINATION_PRODUCT|IDL lotion|IDL lotion is water-based (\> 80%) with isosorbide di-(linoleate/oleate) (2.0%), caprylic/capric triglycerides (5%), glycerin (3%), glyceryl stearate (2.5%), dimethicone (2.0%), steareth-20 (1.5%), cetyl alcohol (1.0%), and butyrospermum parkii (shea) butter (1.0%).
223831388|NCT04253704|COMBINATION_PRODUCT|Control lotion|Control lotion is water-based (\> 80%) with caprylic/capric triglycerides (5%), glycerin (3%), glyceryl stearate (2.5%), dimethicone (2.0%), steareth-20 (1.5%), cetyl alcohol (1.0%), and butyrospermum parkii (shea) butter (1.0%).
223831389|NCT01327937|DEVICE|Apligraf|Apligraf group - Applied at Day 0, Weeks 1-4 (maximum of 5 applications) Also cross-over at Week 4 for Control NPTH group - Apligraf applied at Week 4, Weeks 5-8 (maximum of 5 applications)
223831390|NCT01327937|OTHER|Standard of Care Dressing Group|Standard dressing regimen - Foam dressing (eg, Mepilex) and 4 layered compression system (eg, Profore)
223831391|NCT00189176|DRUG|Tetrathiomolybdate|
223831392|NCT04054895|DEVICE|Lead placed in the His-Purkinje system in order to achieve QRS shortening.|Physiologic pacing to achieve QRS shortening. If the patient has indication of stimulation (AV block), a backup lead will be implanted in the right ventricle. All patients will have a lead placed in the right atrium (except those that have permanent atrial fibrillation).
223831393|NCT04054895|DEVICE|Lead is placed in a tributary of the coronary sinus.|Biventricular Resynchronization Therapy is the use of a pacemaker with two endocardial leads placed in the right atrium and right ventricle. The third lead is placed in a tributary of the coronary sinus.
223831394|NCT02004860|DRUG|Protopic (R)|Protopic® 0.1% ointment - 2 applications per week for 6 months
223831395|NCT02004860|DRUG|Mycoster (R)|Mycoster 1% - 2 applications per week for 6 months
223831396|NCT01379820|DEVICE|OROTRACHEAL cpap WITH COMPENSATION BAG ( GREGORY CPAP)|USE OF OROTRACHEAL CPAP FOR RESPIRATORY DISTRESS SYNDROME IN NEWBORNS .
223831397|NCT02809586|BEHAVIORAL|SMI + I|This 8-week social media based intervention consists of e-coaches delivering positive content to facilitate peer interaction. Participants will earn incentives for interaction during the intervention (8 weeks).
223831398|NCT02809586|BEHAVIORAL|SMI|This 8-week social media based intervention consists of e-coaches delivering positive content to facilitate peer interaction. This group will NOT receive incentives for their participation in the secret group.
223831399|NCT04376411|DIAGNOSTIC_TEST|Flow-cytometric assay|100 µl of blood sample was incubated for 20 minutes at 4 C in the dark. Following incubation, red blood cells lysis, washing and analysis a specific software.Forward and side scatter histogram was used to define the lymphocytes population.
223831400|NCT04376411|DIAGNOSTIC_TEST|2D Echocardiographic analysis|Trans thoracic echocardiographic examination was performed through (PHILIPS -33) echocardiography device with broadband S5-1 transducer
223831401|NCT04376411|DIAGNOSTIC_TEST|Two-Dimensional speckle tracking echocardiography|Two-Dimensional speckle tracking echocardiography was performed on grey scale images of the left ventricle. For offline analysis digital storage software (Qlab 10.4) was used. The frame rate was adjusted to be 60-90 frame/second.
223831402|NCT02564055|DRUG|GSK2894512 1% Cream|1.0% (10 mg/g) GSK2894512 will be supplied as white to off-white cream to be applied topically
223831403|NCT02564055|DRUG|GSK2894512 0.5% Cream|0.5% (5 mg/g) GSK2894512 will be supplied as white to off-white cream to be applied topically
223831404|NCT02564055|DRUG|Vehicle cream|White to off-white vehicle cream base to be applied topically
223831405|NCT00697021|DRUG|Aspirin (200mg) and/or Plavix (150mg) dosage according to TEG|Non- responders to Aspirin or Plavix shown on TEG analysis will be treated by doubling of Aspirin (200mg) and/or Plavix (150mg) dosage
223831406|NCT00697021|DRUG|Aspirin 100mg and Plavix 75mg|Responders to standard dual antiplatelet therapy as observed by TEG analysis will continue standard doses of Aspirin and Plavix
223831407|NCT04127305|OTHER|No Intervention|No Intervention
223831408|NCT01599416|DIETARY_SUPPLEMENT|U-relax|Oral U-relax Day 1-5: 2 capsuals before sleep Day 6-360: 1 capsual before sleep
223831409|NCT04397302|DIAGNOSTIC_TEST|Role of Sacubitril/Valsartan in Hemodynamic and Echocardiographic Improvement of Heart Failure With Reduced Ejection Fraction|Reverse Remodeling is Associated With Hemodynamic Improvement and Stabilization in Outpatients With Heart Failure With Reduced Ejection Fraction Treated With Sacubitril/Valsartan: an Echocardiographic Study
223831410|NCT00773071|DEVICE|SPECT/CT guided LM/SL|Pre-operatively, SLNs will be detected by low-dose SPECT/CT (99mTc-cystein rhenium colloids, 1cc/1mCi). Intra-operatively, a blue-dye (Patent Blue, 2cc) and a gamma-probe guidance will be used to detect the SLN nodes. All blue-stained and/or hot lymph nodes with a radioactivity greater than 10% of the hottest node will be considered as SLNs. Serial sections of SLNs will be analyzed by H-E staining. In cases of negative H-E, the SLNs will be further analyzed by immunochemistry (CKAE1/CKAE3, and high molecular weight Cytokeratin 34BE12). Non-SLNs will be analyzed as usual in routine by H-E.
223831411|NCT04027205|OTHER|Physiotherapist-led exercise|A programme of physiotherapist-led exercise over approximately 12 weeks.
223831412|NCT04027205|PROCEDURE|Surgical repair|Surgical repair of the rotator cuff plus usual post-operative rehabilitation
223831413|NCT04747275|DRUG|Liquid stable levothyroxine (L-T4) Tirosint-SOL|Investigation of tolerability, palatability, and adherence of liquid levothyroxine (L-T4) for 8 weeks.
223831414|NCT04747275|DRUG|Oral tablet levothyroxine (L-T4)|Investigation of tolerability, palatability, and adherence of maintained oral tablet levothyroxine (L-T4) for 8 weeks
223831415|NCT00615602|DRUG|Docetaxel|Docetaxel 75 mg/m2 as an IV infusion over 1h every two weeks for 4 cycles
223831416|NCT00615602|DRUG|Trastuzumab|Trastuzumab 6 mg/Kg IV over 30 min every two weeks for 4 cycles. Subsequently,trastuzumab 6 mg/Kg IV over 30 min for 12 months
223831417|NCT00615602|DRUG|Epirubicin|Epirubicin 75 mg/m2 IV push on day 1 every 2 weeks for 4 cycles
223831418|NCT00615602|DRUG|Cyclophosphamide|Cyclophosphamide 700 mg/m2 IV push on day 1 every 4 weeks
223831419|NCT00615602|DRUG|5-fluoruracil|5-fluoruracil 700 mg/m2 IV push on day 1 every 4 weeks
223831420|NCT00615602|DRUG|Granulocyte-colony stimulating growth factor|rhG-CSF 5 μg/kg/d on days 3-10 after each cycle
223831421|NCT00615602|DRUG|Trastuzumab|Trastuzumab 6mg/Kg IV over 30 min every 2 weeks for 4 cycles. Subsequently, trastuzumab 6mg/Kg IV over 30 min for 6 months
223831422|NCT05912530|OTHER|no intervention|there is no intervention will done
223831423|NCT05351736|DRUG|Lurasidone|Treatment with lurasidone
223831424|NCT02360774|DRUG|Canagliflozin|Subjects will take one 300mg capsule of canagliflozin or identically dispensed placebo by mouth once daily, for 18 weeks.
223831425|NCT02360774|DRUG|Placebo|Subjects will take one 300mg capsule of canagliflozin or identically dispensed placebo by mouth once daily, for 18 weeks.
223831426|NCT00447330|DRUG|capecitabine (Xeloda), oxaliplatin and bevacizumab (Avastin)|"Capecitabine will be administered orally at a twice daily dose of 850 mg/m2 (equivalent to a total daily dose of 1700 mg/m2) given days 1-14 of the three week cycle.~Oxaliplatin will be administered at the dose of 130 mg/m2 given as a 2-hour intravenous infusion on day 1 of a three week cycle.~Bevacizumab will be administered at a dose of 15 mg/kg given as a 30-90 minute intravenous infusion on day 1 of a three week cycle following the administration of oxaliplatin."
223831427|NCT06002061|DEVICE|NovaResp MAPR System|"Baseline measurements will be taken while the subject is awake. Genioglossus activity with maximal tongue protrusion will be measured as well as the response to 1 to 2 pressure routines. Once the subject is sleeping, the operator will observe the PSG recording and determine sleep stage and respiratory phase (inspiration, expiration, between breaths). Test routines will be performed for each sleep stage and each respiratory phase. If the operator notices an apnea occurring, one of the routines will be applied. When all manual tests are complete, an automatic mode will be engaged for the remainder of the night. During this mode, a previously developed and trialled AI model will be used to predict if an obstructive apnea is upcoming. The operator will input which routine to test, and the routine will be automatically applied when a prediction occurs. There will be a minimum of 60 seconds between pressure routine applications."
223831428|NCT05498766|DRUG|Huaier granule|Huaier granule, oral administration, 10g each time, 3 times a day. Continuous medication until disease progression, the end of the study, intolerable toxicity, withdrawal from the study for any reason or death, or until the researcher determines that the participants will no longer benefit, whichever occurs first. After disease progression, whether to continue the medication or not should be determined by the researcher and participant together. Participants will start taking Huaier granule within 1 to 3 weeks after surgery.
223831429|NCT05498766|DRUG|Oxaliplatin|Participants will receive intravenous infusion of 130 mg/m² oxaliplatin on the first day of treatment cycle.
223831430|NCT05498766|DRUG|Tegafur, Gimeracil and Oteracil Potassium|Participants will receive oral Tegafur, Gimeracil and Oteracil Potassium (40 mg/m², twice a day) for 2 weeks, followed by 1 week of rest.
223831431|NCT00921297|PROCEDURE|Immediate Cataract Surgery|Cataract surgery, as part of standard of care, will be performed on 1/2 of the group under investigation.
223831432|NCT05675917|DEVICE|MacuTest platform|"The MacuTest platform will be used to collect the data needed to predict AMD risk. AMD risk prediction is evaluated by a mathematical algorithm based on the data collected and integrated into the platform.~The ophthalmologist will fill in the ophthalmologist questionnaire in the platform with data on the fundus and blood pressure, after examining the patient.~The patient will fill in the lifestyle questionnaires (nutrition, smoking, gender, year of birth, level of education) with his personal equipment (computer, smartphone or tablet)."
223831433|NCT00531011|DEVICE|XIENCE V® Everolimus Eluting Coronary Stent System|Coronary artery placement of a drug-eluting stent
223831434|NCT00531011|DEVICE|TAXUS® Liberté™ Paclitaxel Eluting Coronary Stent System|Coronary artery placement of a drug-eluting stent
223831435|NCT03268590|DRUG|Oxygen|Persons will undergo MRI, EEG, and complete computerized cognitive testing in baseline room air. Persons will then breathe 100% pure oxygen and undergo MRI, EEG, and complete computerized cognitive testing. Persons will serve as their own controls.
223831436|NCT05719285|DRUG|Single-Dose Antibiotic|"Allergy, prior urine culture resistance or another contraindication to first line antibiotic will result in the patient being prescribed second line antibiotic and so forth.~First line:~Arm 1: trimethoprim / sulfamethoxazole 800/160 mg once pre-procedure~Second line:~Arm 1: cefalexin 500 mg once pre-procedure~Third line:~Arm 1: nitrofurantoin 100 mg once pre-procedure~Fourth line:~Arm 1: ciprofloxacin 500 mg once pre-procedure"
223831437|NCT05719285|DRUG|Multi-Dose Antibiotic|"Allergy, prior urine culture resistance or another contraindication to first line antibiotic will result in the patient being prescribed second line antibiotic and so forth.~First line:~Arm 2: trimethoprim / sulfamethoxazole 800/160 mg once pre-procedure plus 800/160 mg every twelve hours for 6 total doses~Second line:~Arm 2: cefalexin 500 mg once pre-procedure plus 500 mg every twelve hours for 6 total doses~Third line:~Arm 2: nitrofurantoin 100 mg once pre-procedure plus 100 mg every twelve hours for 6 total doses~Fourth line:~Arm 2: ciprofloxacin 500 mg once pre-procedure plus 500 mg every twelve hours for 6 total doses"
223831438|NCT02139982|PROCEDURE|specific nerve block|specific nerve blocks of the musculocutaneous, radial, ulnar, or median nerves at axillary region
223831439|NCT02139982|DRUG|ropivacaine|Different concentration of ropivacaine
223831440|NCT01064583|OTHER|cocoa|dissolved in water twice-daily intervention
223831441|NCT04592536|DRUG|CVL-865 High dose|High dose CVL-865: Will be administered as 5mg BID for 2 days followed by 12.5mg BID for another 2 days during the Titration Phase. 25mg will be administered during the Maintenance Phase (3 days of BID and morning dose only on the 4th day)
223831442|NCT04592536|DRUG|Alprazolam 1mg XR|Alprazolam 1mg XR will be administered for 8 days BID (morning dose only on 8th day)
223831443|NCT04592536|DRUG|Placebo|Placebo, oral tablet/capsule will be administered for 8 days BID (morning dose only on 8th day)
223831444|NCT04592536|DRUG|CVL-865 low dose|Low dose CVL-865, oral tablets. Will be administered as 2.5mg BID for 2 days followed by 5mg BID for another 2 days during the Titration Phase. 7.5mg BID will be administered during the Maintenance Phase (3 days of BID and morning dose only on 4th day)
223831445|NCT02971891|DRUG|CLS006 (Furosemide) Topical Gel|
223831446|NCT02971891|DRUG|Vehicle Topical Gel|
223831447|NCT01777243|DRUG|GSK2398852|Unit dose strength: 100 mg/mL provided as 1 mL solution per vial. GSK2398852 dosage levels variable with the proposed starting dose level of GSK2398852 as 5 mg \[approximately equivalent to 0.1 mg/ kg\]. The next escalation dose levels are proposed as 1 mg/kg, 3 mg/kg, 10 mg/kg and 30 mg/kg.
223831448|NCT01777243|DRUG|GSK2315698|Unit dose strength: 200 mg/mL stock to be diluted. GSK2315698 will be administered at variable dosed until the concentration of the serum amyloid P component monoclonal antibody (SAP mAb) has fallen below 100 ng/mL.
223831449|NCT05119413|DRUG|New trio de Kligman|Once daily application in addition to the same sunscreen
223831450|NCT05119413|DRUG|Trio Kligman|Once daily application in addition to the same sunscreen
223831451|NCT03262337|OTHER|none, this is an observational study|none, this is an observational study
223831452|NCT02786043|DRUG|Propionyl-L-Carnitine Hydrochloride|1g twice a day on first 4 days and 1g/ day on day 5 during Phase III
223831453|NCT02919943|PROCEDURE|Percutaneous Coronary Intervention|OCT-guided Percutaneous Coronary Intervention.
223831454|NCT04117061|PROCEDURE|Observation|Patient after primary investigation is observed for 8-12 hours, (instead of being send directly to CT scan), after observation repeated clinical evaluation, laboratory tests and ultrasound examination are done , if final diagnosis stays unclear the patient is refered to CT scan.
223831455|NCT02929342|DRUG|Pitolisant|
223831456|NCT02929342|RADIATION|[14C]-Pitolisant|
223831457|NCT06010121|DIETARY_SUPPLEMENT|Liposomal Vitamin D|2000 IU of cholecalciferol in liposomal formulation
223831458|NCT06010121|DIETARY_SUPPLEMENT|Traditional Vitamin D|2000 IU of cholecalciferol in traditional formulation
223831459|NCT06475196|DRUG|Sintilimab (PD-1 inhibitor)|to evaluate the safety and efficacy of different cycles of sintilimab in combination with platinum-containing chemotherapy as preoperative neoadjuvant therapy in patients with resectable esophageal cancer.
223831460|NCT02565355|OTHER|Dietary Exclusion|The IgG antibody results will be disclosed ONLY to the patients in the lifestyle modification group by phone approximately one week after clinic visit.. 'Dietary Exclusion' will be advised by a dietitian. Patients are advised to eliminate a maximum of two foods as identified by high IgG antibody titres.
223831461|NCT02565355|OTHER|Standard Treatment|The standard therapy group will receive conventional treatment for Abdominal Pain as per usual practice at the Pediatric GI (PG) Clinic - counseling, reassurance, improving coping strategies and pain relievers as appropriate.
223831462|NCT05153278|BIOLOGICAL|Packed red blood cells|Standard treatment for iron deficiency anemia (control)
223831463|NCT05153278|DRUG|Intravenous drug|Experimental treatment for iron deficiency treatment
223831464|NCT02774343|DRUG|Pioglitazone|Subjects randomized to pioglitazone begin with a starting dose of 15 mg daily administered. The dose will be titrated up to 30mg on the second week and 45 mg on the third week of the study. Subjects will remain on 45 mg of pioglitazone until the end of week 12. At the end of week 12 the study medication will be discontinued.
223831465|NCT02774343|DRUG|Placebo|Subjects randomized to placebo receive placebo capsules once daily across all twelve weeks of the study.
223831466|NCT02774343|BEHAVIORAL|Therapy|Cognitive-behavioral therapy 1 hour per week
223831467|NCT02774343|BEHAVIORAL|Contingency Management|Prize-based contingency management for attendance
223831468|NCT03477461|DRUG|terlipressin|a continuous infusion of terlipressin (0.4 mg/kg/h) was initiated
223831469|NCT00179283|DRUG|sertraline|
223831470|NCT00179283|DRUG|venlafaxine XR|
223831471|NCT01705470|DRUG|furosemide|
223831472|NCT01705470|DRUG|placebo normal saline|
223831473|NCT00549419|DRUG|Ringers lactate, hydroxyethyl starch; norepinephrine, dobutamine|The Control group will be assessed using the standard care of traditional vital signs
223831474|NCT00549419|DRUG|Goal-directed hemodynamic therapy|Ringers lactate, hydroxyethyl starch; norepinephrine, dobutamine
223831475|NCT00549419|DRUG|Standard of care|Ringers lactate, hydroxyethyl starch; norepinephrine, dobutamine
223831476|NCT03817346|DRUG|GT-002|Single ascending dose
223831477|NCT03817346|DRUG|Placebo oral capsule|Comparator single ascending dose
223831478|NCT03701009|PROCEDURE|CBD stone removal via lithotripsy|Hold saline irrigation just after X-ray demonstrated no stone residue, a Spyglass explored.
223831479|NCT03701009|PROCEDURE|Saline 50ml|If not clean, intermittent saline irrigation 50ml, and Spyglass explored second time.
223831480|NCT03701009|PROCEDURE|Saline +50ml|If still have some stone fragments, intermittent saline irrigation another 50ml after the second Spyglass detection, Spyglass explored third time to evaluate stone clearance.
223831481|NCT00365495|PROCEDURE|Physical training (aerobic training)|
223831482|NCT04907487|DEVICE|MRI|"MRI of routine care includes at least the following sequences:~* 3D T1 TFE (2 minutes)~* T2 TSE (2 minutes)~* 3D FLAIR (3 minutes)~The sequences added by the research lasting 25 minutes are:~* SWI QSM 1.0iso 8 echoes (10 minutes)~* SWI QSM 1.0iso 8 echoes CS 6 (7 minutes)~* SWI QSM 1.0iso 8 echoes CS 9 (5 minutes)~* SWI QSM 1.0iso 8 echoes CS 12 (3 minutes)"
223831483|NCT05552729|DRUG|Vitamin D|The patients were given vitamin D supplementation 48 hours after surgery, and the two groups were given different doses of vitamin D supplementation until the postoperative discharge criteria were met. To scientifically evaluate the application effect of early postoperative vitamin D intervention in the improvement of perioperative cognitive function in patients with gastrointestinal tumors.
223831484|NCT05475769|DRUG|Clinical evaluation|Patients will receive treatments under the criteria of the responsible physician and the response to these treatments will be prospectively collected.
223831485|NCT02173535|DEVICE|etafilcon test contact lens Variant AP|Subject will complete a questionnaire regarding cosmetic effect of the lens post insertion, then remove the lens.
223831486|NCT02173535|DEVICE|etafilcon test contact lens Variant JG|Subject will complete a questionnaire regarding cosmetic effect of the lens post insertion, then remove the lens.
223831487|NCT02173535|DEVICE|etafilcon test contact lens Variant CS|Subject will complete a questionnaire regarding cosmetic effect of the lens post insertion, then remove the lens.
223831488|NCT02173535|DEVICE|etafilcon test contact lens Variant VC|Subject will complete a questionnaire regarding cosmetic effect of the lens post insertion, then remove the lens.
223831489|NCT02173535|DEVICE|etafilcon test contact lens Variant LA|Subject will complete a questionnaire regarding cosmetic effect of the lens post insertion, then remove the lens.
223831490|NCT03208400|BEHAVIORAL|virtual reality exposure|one-session exposure conveyed via virtual reality technology
223831491|NCT06067529|DRUG|hormone replacement therapy|hormone replacement therapy
223831492|NCT06359665|DRUG|Curcumin|500 mg capsule twice daily
223831493|NCT06359665|DRUG|Placebo|capsule twice daily
223831494|NCT03318952|DRUG|lidocaine|A buccal infiltration injection followed by 2-3 interpapillary injections and possibly more if needed of 2% lidocaine with 1:100,000 epinephrine will be administered.
223831495|NCT03318952|DRUG|articaine|A single buccal infiltration injection of 4% articaine with 1:100,000 epinephrine will be administered
223831496|NCT02821520|DRUG|conbercept|At baseline conbercept injection is administered.And thereafter is administered based on re-treatment criteria from month 1 to 11.The PRN conbercept re-injection should be monthly.
223831497|NCT02821520|PROCEDURE|Initial PDT|At baseline PDT with verteporfin is administered initially.And thereafter PDT is administered based on re-treatment criteria from month 3 to 11.The PRN PDT retreatment intervals should be no less than 3 months.
223831498|NCT02821520|PROCEDURE|Delayed PDT|PDT is administered based on re-treatment criteria from month 3 to 11.The PRN PDT retreatment intervals should be no less than 3 months.
223831499|NCT03064893|DEVICE|Alloderm|Reconstruction material
223831500|NCT03064893|DEVICE|Dermacell|Reconstruction material
223831501|NCT02682498|DRUG|(Bupivacaine Liposome Injectable Suspension)|Instead of injecting the standard joint injection for a case of total knee arthroplasty, Exparel-lipsomal bupivacaine will be administered at the end of the surgery.
223831502|NCT02682498|DRUG|Standard Preparation|A standard joint injection of 100ml (Clonidine 80 mcg, Epinephrine 0.5mg, Ketorolac 30mg, Ropivacaine 246.25mg, and Sodium Chloride 0.9% 48.45 ml) will be injected into the soft tissues around the joint after surgery.
223831503|NCT00283738|DEVICE|BioSTAR Septal Repair Implant System|PFO Closure
223831504|NCT00283738|PROCEDURE|Sham Procedure|Catheterization
223831505|NCT02763540|PROCEDURE|Lung cryobiopsy|Transbronchial cryobiopsy
223831506|NCT03100565|DRUG|local lidocaine spray|The lidocaine spray will be introduced to the cervix just before the biopsy procedure
223831507|NCT03100565|OTHER|forced coughing|The patients will be asked to forced coughing during the biopsy procedure
223831508|NCT03026569|OTHER|Orange juice (500 mL/d)|The patients were instructed to drink orange juice in two daily portions during eight consecutive weeks. Patients from both groups were asked to maintain their usual lifestyle, diet, and physical activity, and they were checked weekly by the researcher's team. Assessments of anthropometric data, dietary intake, as well as blood sample collection for biochemical analysis were performed in all participants on the first and last day of the experiment.
223831509|NCT01015261|PROCEDURE|Bone Marrow Transplantation|Allogenic Bone Marrow Transplantation
223831510|NCT01015261|PROCEDURE|Chemotherapy|"1. Cyclophosphamide 1200 mg/m2 D15~2. Daunorubicin 45 mg/m2 D15-D18~3. Vincristine 1 mg/m2 D15, D22~4. Dexamethasone 24 mg/d D12-D28"
223831511|NCT03841344|DEVICE|MRI|Evaluation of the utility of candidate endpoints in PAH trials
223831512|NCT03086122|DEVICE|Continuous positive airway pressure|Continuous positive airway pressure treatment for patients randomized to CPAP treatment group. Treatment duration: 3 months.
223831513|NCT03317210|DRUG|iron sucrose (200 mg VENOFER®)|According to hemoglobin level at the start of the therapy, the women were either treated with intravenous iron and rhEPO or with intravenous iron only twice weekly.
223831514|NCT03317210|DRUG|recombinant human erythropoietin (10,000 U EPREX®)|According to hemoglobin level at the start of the therapy, the women were treated with rhEPO twice weekly.
223831515|NCT00165269|PROCEDURE|Mantle irradiation|Limited to above the diaphragm
223831516|NCT05931705|OTHER|questionnaire|questionnaire
223831517|NCT02263144|PROCEDURE|virtual chromo-endoscopy using FICE Fujifilm Technology|For each polyps, any observer will use virtual chromo-endoscopy with FICE Fujifilm Technology
223831518|NCT00018161|DRUG|Mecamylamine|
223831519|NCT00018161|DRUG|Nicotine Patch|
223831520|NCT00018161|BEHAVIORAL|Cigarette brand switching|
223831521|NCT01754779|DIETARY_SUPPLEMENT|Placebo|3 tablets twice daily of matching placebo during the placebo phase.
223831522|NCT01754779|DIETARY_SUPPLEMENT|Citric Acid|3, 10 mEq tablets of H3Cit twice daily during the H3Cit phase (60 mEq H3Cit per day)
223831523|NCT01754779|DIETARY_SUPPLEMENT|Potassium Citrate|2, 10 mEq K3Cit tablets and 1 placebo tablet twice daily during the K3Cit phase (40 mEq K3Cit per day)
223831524|NCT04254679|DRUG|Opioid analgesics|"Current standard of care in the participating centers Prescription of around-the-clock non-opioid analgesics (acetaminophen and/or NSAIDs/COX-2) and a supply of opioids to be used as a rescue in case of breakthrough pain.~The specific round-the-clock analgesia and rescue opioid regimens will be determined by the patient's primary surgeon considering the surgical procedure, comorbidities and patient's preference."
223831525|NCT04254679|DRUG|Non-opioid analgesics|"Prescription of around-the-clock non-opioid analgesics (acetaminophen alone or combined with NSAIDs/COX-2).~The specific non-opioid analgesia regimens will be determined by the patient's primary surgeon considering the surgical procedure, comorbidities and patient's preference."
223831526|NCT06143657|DIAGNOSTIC_TEST|Automated Gram Staining Machine analysis|Measure urine and sputum specimens using this device.
223831527|NCT02823964|DRUG|Liprotamase|Oral, soluble, non-enterically coated, non-porcine, pancreatic enzyme replacement
223831528|NCT03786120|DRUG|Zolpidem|PO sleep aid in various doses
223831529|NCT03996941|BEHAVIORAL|Harm reduction of informal PrEP use|"Users attending the study center interested in PrEP use , as well as those who could benefit from it are invited to attend an information session in which issues are touched like the effectiveness and safety of PrEP, and the characteristics of the SeguiPrEP program. This program consists of periodic clinical controls (five during the first year and four in the following period) that include: physical examination, HIV and other STI screening, control of renal functions, estimation and promotion of PrEP adherence, monitoring of adverse events associated with PrEP and counseling.~Those who decide to use PrEP or who are already using PrEP are asked to schedule an initiation visit."
223831530|NCT03996941|OTHER|PrEP follow up based on point of care testing|The study center has a point-of-care technology based laboratory, which allows obtaining immediate results in order to reduce the loss of follow-up.
223831531|NCT05408000|DRUG|ketofol vs propofol|Patients planned for electroconvulsive therapy meeting the inclusion criteria and not having exclusion criteria will be randomized into two groups. Group K will receive titrated dose of Ketofol and Group P will receive titrated dose of Propofol for induction of anaesthesia
223831532|NCT01737060|DEVICE|Reverse total shoulder arthroplasty|
223831533|NCT01324219|BEHAVIORAL|Staff|Your participation will involve participating in video recordings of nursing care for a participating resident for 2-hour periods on 8 to 10 days. Communication training will be provided to staff in participating nursing homes during paid work hours regardless of their participation in the video recordings. The nursing home you work in may be randomly selected to receive the communication training at the start of the study or after a 3-month delay.
223831534|NCT01324219|BEHAVIORAL|Resident|Your participation will involve participating in video recordings of nursing care for 2-hour periods on 8 to 10. Communication training will be provided to staff in participating facilities during paid work hours regardless of their participation in the video recordings. Your nursing home may be randomly selected to receive the communication training at the start of the study or after a 3-month delay.
223831535|NCT03577808|OTHER|Biopsy|Patients with locally advanced rectal cancer will receive biopsy of the primary tumor before neoadjuvant chemoradiation.
223831536|NCT03954158|DRUG|Crisaborole ointment 2%|BID regimen
223831537|NCT03954158|DRUG|Vehicle|BID regimen
223831538|NCT03954158|DRUG|Crisaborole ointment 2%|QD regimen
223831539|NCT03954158|DRUG|Vehicle|QD regimen
223831540|NCT03424486|OTHER|Questionnaires|Evaluation of the prevalence of anxiety, depression and quality of life
223831541|NCT02489825|PROCEDURE|Augmentation vertebroplasty|Cement augmentation of fractured vertebral body
223831542|NCT02489825|PROCEDURE|Augmentation and prophylactic vertebroplasty|Cement augmentation of fractured vertebral body and prophylactic augmentation of both adjacent vertebral bodies
223831543|NCT04412564|DRUG|TQ-B3101|TQ-B3101 is a ALK inhibitor.
223831544|NCT05239416|PROCEDURE|Fat grafting|Under general or local anaesthesia, fat will be harvested from either abdomen or lower limb. After harvesting the fat by liposuction, the lipoaspirate will be injected underneath the healed ulcer area under complete aseptic operative setting
223831545|NCT04718714|DRUG|Midazolam|loading dose intravenous infusion of 0.2 mg/kg over 10 minutes followed by a maintenance dose of 0.02 -0.2 mg /kg/hr. over 24 hours.
223831546|NCT04718714|DRUG|Propofol|loading dose intravenous infusion of one mg/kg over 15 minutes followed by a maintenance dose of 20-80 microgram/kg/min. over 24 hours.
223831547|NCT04718714|DRUG|Dexmedetomidine|loading dose of dexmedetomidine of one µg/kg over 10 minutes followed by maintenance dose of 0.2 -1.5 µg/kg/hr. over 24 hours.
223831548|NCT00334867|DRUG|cyclophosphamide|Given IV
223831549|NCT00334867|DRUG|dexrazoxane hydrochloride|Given IV
223831550|NCT00334867|DRUG|doxorubicin hydrochloride|Given IV
223831551|NCT00334867|DRUG|etoposide|Given IV
223831552|NCT00334867|DRUG|ifosfamide|Given IV
223831553|NCT00334867|DRUG|topotecan hydrochloride|Given IV
223831554|NCT00334867|DRUG|vincristine sulfate|Given IV
223831555|NCT00334867|PROCEDURE|conventional surgery|Patients undergo surgery in week 18
223831556|NCT00334867|PROCEDURE|radiation therapy|Patients undergo radiation therapy in week 19
223831557|NCT05856240|BEHAVIORAL|Managing Stress & Emotions Group (MSEG)|The intervention consists of 6, 90-minute weekly sessions and includes the following components: providing education about psychological and emotional reactions to stress, introducing and practicing coping skills (e.g., mindfulness, emotional awareness, flexible thinking, behavioral modification), decreasing psychological avoidance using emotional exposure, and facilitating group support and discussion (see De Paul \& Caver, 2021 for original protocol description).
223831558|NCT00004286|DRUG|immune globulin|
223831559|NCT00441051|DRUG|Diclofenac sodium 1mg/g|
223831560|NCT03875495|DRUG|Temferon|Genetically modified autologous HSPCs
223831561|NCT04506580|PROCEDURE|DERMABOND™ PRINEO™(2-octyl Cyanoacrylate Adhesive and Polyester Mesh) vs subcuticular nylon suture|DERMABOND™ PRINEO™(2-octyl Cyanoacrylate Adhesive and Polyester Mesh) and subcuticular nylon suture are applied for each knee
223831562|NCT03570125|DIETARY_SUPPLEMENT|Prolon|The diet consists of natural ingredients, which are Generally Regarded As Safe (GRAS). In case the PROLON product will be unavailable at the time of the project we will design fasting mimicking diet without the usage of specifically designed commercial product
223831563|NCT00486915|PROCEDURE|Left Atrial Appendage Ligation|
223831564|NCT00390455|DRUG|Fulvestrant|Given IM
223831565|NCT00390455|OTHER|Laboratory Biomarker Analysis|Correlative studies
223831566|NCT00390455|DRUG|Lapatinib Ditosylate|Given PO
223831567|NCT00390455|OTHER|Placebo Administration|Given PO
223831568|NCT01148342|DRUG|MDMA|
223831569|NCT01148342|DRUG|(+/-)3,4-methylenedioxymethamphetamine Hydrochloride, MDMA HCI Capsules|0, 1.0 \&amp; 1.6 mg/kg
223831570|NCT03808441|OTHER|ctDNA analysis|Regular ctDNA analysis, which upon a decrease in mutant BRAF VAF (variant allele frequency) level of ≥80% the switch to N+I is triggered.
223831571|NCT02891044|DRUG|BAY987517|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation Code: Z44-040)
223831572|NCT05641077|OTHER|Virtual Visit|Patients randomized to this arm will be scheduled for and follow up with the surgeon or an advanced practice provider via a virtual visit using videoconference technology at 6 weeks after the anticipated date of surgery. If the surgery were to be rescheduled to a future date, the postoperative visit will be moved accordingly to ensure follow-up occurs at the 6-week postoperative period.
223831573|NCT05641077|OTHER|Office Visit|Patients randomized to this arm will be scheduled for and follow up with the surgeon or an advanced practice provider via an in-office visit at 6 weeks after the planned date of surgery. If the surgery were to be rescheduled to a future date, the postoperative visit will be moved accordingly to ensure follow-up occurs at the 6-week postoperative period.
223831574|NCT05398497|DEVICE|Cryoablation|Cryoablation will be performed under ultrasound guidance.
223831575|NCT00539903|BEHAVIORAL|Physical activity (PA) and immigrants|
223831576|NCT04800757|BEHAVIORAL|individual -Brief Motivational Intervention (BMI)|"A baseline survey will be administered prior to the session.Sessions will be initiated by exploring working conditions and psychosocial factors that may influence risk for work related injuries. If the LDL is motivated to change the target behavior, a 'change plan' will be developed which involves identifying reasons for change, goals in making change, specific actions and timelines, and others who may help the person change. The final step will be the development of a personal safety plan to reduce work place risks and a discussion of the following topics: (a) how they will know if their plan is successful, (b) potential obstacles, and (c) what the worker can do if the plan does not work. Finally,each worker will be asked to write and sign a personal pledge (Mi Promesa) to implement his own safety plan.Follow-up surveys will be conducted 4 weeks after the baseline survey."
223831577|NCT04800757|BEHAVIORAL|Group (Group Problem Solving)|Participants will be administered a baseline survey prior to session. The GPS intervention consists of a discussion between 2-5 LDLs and a trained group facilitator. The sessions will last 30-45 minutes and are intended to encourage and support Latino day laborers (LDL) to act to reduce work-related hazards and promote worksite safety. The intervention combines four participatory and group problem solving activities to engage in collaborative learning: an icebreaker, the risk identification, action planning, and Nuestra Promesa (Our Pledge). The last activity requires LDL to select a risk reduction behavior and then to fill out and sign a card detailing a pledge to implement a safety plan. Follow up surveys will be conducted four weeks post intervention, to assess participants' change in attitudes, beliefs, and risk reducing behavior and their implementation or their safety plan.
223831578|NCT04800757|BEHAVIORAL|Standard of Care (OSHA 10 Safety Cards)|Participant will be administered a baseline survey prior to the session.Participants in this standard of care control group will receive four wallet size cards with information about risk reduction strategies to deal with the four hazards responsible for most workplace fatalities in Texas: falls, struck by, heat exposure and cuts. The laminated cards are adapted from OSHA's website publicly available materials in Spanish for workers with limited literacy.
223831579|NCT00794820|DRUG|Fludarabine Phosphate|25 mg/m\^2 by vein over 5-30 minutes daily for 3 days (days 2-4)
223831580|NCT00794820|DRUG|Cyclophosphamide|250 mg/m\^2 by vein over 60 minutes daily for 3 days (days 2-4)
223831581|NCT00794820|DRUG|Rituximab|375 mg/m\^2 by vein for dose 1 (given 1 day prior to chemotherapy) and then 500 mg/m\^2 on days 2-3
223831582|NCT00671632|DRUG|Ramelteon, triazolam, and placebo (56 possible combinations total)|"Randomized sequence over eight consecutive days to include the following:~Ramelteon 16 mg, tablets, orally, one day only;~Ramelteon 80 mg, tablets, orally, one day only;~Ramelteon 160 mg, tablets, orally, one day only;~Triazolam 0.25 mg, capsules, orally, one day only;~Triazolam 0.50 mg, capsules, orally, one day only;~Triazolam 0.75 mg, capsules, orally, one day only;~Ramelteon placebo-matching tablets, orally, one day only, OR Triazolam placebo-matching capsules, orally, one day only;~Additional dose of study medication or placebo, tablets or capsules, orally, one day only."
223831583|NCT03542448|DEVICE|Swept source optical coherence tomography|Measurement of choroidal thickness in myopic patients
223831584|NCT00818909|OTHER|Systane|Systane prescription
223831585|NCT04789213|OTHER|Liver Transplantation|Liver Transplantation
223831586|NCT02966535|DEVICE|Adjustment of Mechanical Ventilator Inspiratory to expiratory time ratio (1:2 to 1:1)|Adjustment of Mechanical Ventilator Inspiratory to expiratory time ratio (1:2 to 1:1)
223831587|NCT02966535|DEVICE|Adjustment of Mechanical Ventilator Inspiratory to expiratory time ratio (1:1 to 1:2)|Adjustment of Mechanical Ventilator Inspiratory to expiratory time ratio (1:1 to 1:2)
223831588|NCT04708691|OTHER|Aerobic exercise|aerobic exercise
223831589|NCT00317174|BIOLOGICAL|DTPw-HBV/Hib-MenAC conjugate vaccine|
223831590|NCT04198532|OTHER|Contrast bath|Contrast bath (hot and cold therapy)
223831591|NCT00266474|OTHER|Assessment of upper and lower airway colonization, sinonasal symptoms, history, rhinoscopy and rhinomanometry.|
223831592|NCT02905019|BIOLOGICAL|R21 with Matrix-M1|Vaccine
223831593|NCT02905019|BIOLOGICAL|ChAd63 ME-TRAP|Vaccine
223831594|NCT02905019|BIOLOGICAL|MVA ME-TRAP|Vaccine
223831595|NCT02870504|PROCEDURE|Corneoscleral limbus group|Laser spot locates on the corneoscleral limbus
223831596|NCT02870504|PROCEDURE|one spot group|Laser spot locates on one spot away from the corneoscleral limbus
223831597|NCT02870504|PROCEDURE|two spots group|Laser spot locates on two spots away from the corneoscleral limbus
223831598|NCT00011830|DRUG|G-CSF|
223831599|NCT00011830|PROCEDURE|Apheresis|
223831600|NCT04076020|BEHAVIORAL|Relational agent/AliveCor Kardia - Intervention|Use of the relational agent and Kardia daily for 120 days.
223831601|NCT04076020|BEHAVIORAL|Usual Care|Use of the WebMD app daily for 120 days.
223831602|NCT05022602|DEVICE|Imagio|Imagio - both ultrasound probe and Duplex OA probe
223831603|NCT02208882|DRUG|BMS-986120|
223831604|NCT02208882|DRUG|Placebo|
223831605|NCT02208882|DRUG|Midazolam|
223831606|NCT02811289|DRUG|Mirbetriq (Mirabegron)|50mg of Mirabegron will be administered orally at time 0 in protocol A.
223831607|NCT02811289|OTHER|cold exposure|Acute cold exposure protocol using a water-conditioned cooling suit will be applied from time 120 to 300 min in protocol B
223831608|NCT02811289|RADIATION|injection of 18FDG|I.v. injection of 18-fluorodeoxyglucose (18FDG) will be performed at time 270 min, followed by 30 min dynamic PET/CT scanning
223831609|NCT02811289|RADIATION|injection of 11C-acetate|i.v. injection of 11C-acetate will be performed, followed by 20 min dynamic PET/CT scanning
223831610|NCT02811289|RADIATION|[3-3H]-glucose|i.v. administration of 1.5 uCi/min of \[3-3H\]-glucose
223831611|NCT02811289|OTHER|[U-13C]-palmitate|i.v. administration of 0.08 umol/kg/min of \[U-13C\]-palmitate
223831612|NCT02811289|OTHER|2H-Glycerol|i.v. administration of 0.05 µmol/kg/min of 2H-glycerol
223831613|NCT02500979|DRUG|Pramlintide acetate|Pramlintide acetate administered by a separate pump
223831614|NCT02500979|DRUG|Placebo|Placebo administered by separate pump
223831615|NCT02500979|DRUG|Lispro insulin U-100|Subjects will be stabilized on a separate insulin pump and administered lispro insulin throughout the study, except during both inpatient treatment periods (Visit 4 and Visit 5)
223831616|NCT02500979|DRUG|Regular insulin U-100|Use during two in-patient treatment periods (visits 4 and 5) and administered by separate pump
223831617|NCT06179589|DIETARY_SUPPLEMENT|VS002A|Amino acid based, glucose free ORS
223831618|NCT04159116|OTHER|Prophylactic suctioning when clinically indicated|Suctioned prophylactically when clinically indicated by copious secretions, coughing, choking or desaturatation
223831619|NCT00865475|DRUG|AZT+3TC+ABV (Trizivir)|Patients on treatment with TZV and viral suppression will be randomized to keep on TZV vs switching to LPV/r monotherapy
223831620|NCT00865475|DRUG|Switching to LPV/r monotherapy (Kaletra)|Patients on AZT+3TC+ABV with viral suppression will be randomized to keep on vs switching to LPV/r
223831621|NCT04039802|PROCEDURE|Single-stage surgery|In the test group, patients will be scheduled for bone-anchored hearing implant surgery using the single-stage procedure. The implant and abutment will be placed in one surgery.
223831622|NCT04039802|OTHER|Two-stage surgery|Two-stage surgery has already been performed, data will therefore be retrospectively collected
223831623|NCT00238862|PROCEDURE|Amniotic membrane transplantation|
223831624|NCT00238862|DRUG|Autologous serum/BSS 20%|
223831625|NCT05701722|DEVICE|Flourish HEC Vaginal Care System|BioNourish, a component of the Flourish HEC system, is a class II medical device. In addition to BioNourish, the system includes Balance intimate wash and BiopHresh homeopathic vaginal suppository with probiotics. All products are available over the counter and have been on the market for several years.
223831626|NCT05539521|DRUG|Remimazolam Besylate|sedation drugs
223831627|NCT05539521|DRUG|Propofol|Propofol
223831628|NCT02132533|DRUG|Nifedipine|Nifedipine 20 mg orally, then nifedipine 20 mg orally after 90 minutes if still contracting. Continue nifedipine 20 mg orally every 4 hours after the first dose for 48 hours.
223831629|NCT02132533|DRUG|Placebo|Placebo orally, then placebo orally after 90 minutes if still contracting. Continue placebo orally every 4 hours after the first dose for 48 hours.
223831630|NCT02132533|OTHER|Usual care|Usual evaluation, monitoring and care for women with preterm labor.
223831631|NCT03160300|DEVICE|Music with Binaural Beats|Relaxing music with embedded binaural beats at a frequency of 5 Hz
223831632|NCT03160300|DEVICE|Music|Relaxing music without a binaural beat component
223831633|NCT01603563|BEHAVIORAL|Stepped Care TF-CBT|Stepped Care TF-CBT patients will receive step one: 3 (1 hr.) in-office therapist-led sessions over 6 weeks, the parent-child workbook (Stepping Together), scheduled weekly phone meetings (15 minutes), and information from the National Child Traumatic Stress Network website (via web or paper for those without access). Children who do not meet responder status will receive step two: 9 (1 to 1.5 hr.) in-office therapist-directed sessions of TF-CBT over 6 to 8 weeks.
223831634|NCT01603563|BEHAVIORAL|Standard TF-CBT|Standard TF-CBT patients will receive 12 (1 to 1.5 hr.) standard weekly in-office therapist-directed sessions over 12 to 14 weeks (Phase II only). The 2 additional weeks allow for scheduling difficulty. Standard TF-CBT includes child, parent and conjoint parent-child sessions addressing the core trauma treatment components discussed in section a.3 (e.g. stress management, skill building, gradual exposure, \& trauma narrative etc.).
223831635|NCT00478764|DRUG|intraocular triamcinolone and gatifloxicin|
223831636|NCT00672958|DRUG|Vortioxetine|Encapsulated immediate-release tablets.
223831637|NCT00672958|DRUG|Placebo|Vortioxetine placebo-matching capsules.
223831638|NCT01380990|GENETIC|Infusion of autologous EFS-ADA LV CD34+ cells|Autologous EFS-ADA LV CD34+ cells (OTL-101\*) are infused intravenously
223831639|NCT01380990|OTHER|Haematopoietic Stem Cell Transplantation (HSCT)|Historical data from a database of ADA-SCID patients treated with allogeneic HSCT from GOSH will be collected as comparator group.
223831640|NCT01380990|DRUG|Busulfan|Busulfan is used for non-myeloablative conditioning
223831641|NCT01380990|DRUG|Peg-Ada|Peg-Ada enzyme replacement therapy is discontinued at Day +3- (-3/+15 days) after successful engraftment
223831642|NCT05092243|DEVICE|Transcranial direct current stimulation|A consecutive 5-days course of tDCS will be delivered. In treatment group, true stimulation will be administrated and sham stimulation will be delivered in control group.
223831643|NCT01836627|OTHER|Hyperinsufflation therapy|15 minutes twice a day of hyperinsufflation with Cough Assist® device
223831644|NCT03482817|DRUG|Ze 117|Subjects will be hospitalized to receive a probe drug cocktail alone and in combination with Ze 117.
223831645|NCT03482817|DRUG|Probe drug cocktail|Subjects will be hospitalized to receive a probe drug cocktail alone and in combination with Ze 117.
223831646|NCT00034645|DRUG|Posaconazole oral suspension|
223831647|NCT04595734|OTHER|No intervention due to observational methods of study|No intervention due to observational methods of study
223831648|NCT03118544|DEVICE|DyeVert System|The DyeVert System (Osprey Medical, Inc) consists of a Contrast Monitoring Wireless Display (CMW) and the DyeVert Plus Disposable Kit which is inclusive of a disposable single-use sterile Smart Syringe and DyeVert Plus Module.
223831649|NCT01161004|DRUG|Sugammadex - Nacl 9/00|"* Sugammadex: 4 mg/kg when post tetanic count shows at least 1 or 2 responses; 2 mg/kg when Train of four shows at least 2 responses.~* Nacl 9/00: same volume as Sugammadex"
223831650|NCT01161004|DRUG|Nacl 9/00 - sugammadex|"* Nacl 9/00: same volume as Sugammadex~* Sugammadex: 4 mg/kg when post tetanic count shows at least 1 or 2 responses; 2 mg/kg when Train of four shows at least 2 responses."
223831651|NCT01358448|BEHAVIORAL|growth monitoring|Caretakers will be encouraged to monitor child growth monthly.
223831652|NCT01358448|BEHAVIORAL|Growth Monitoring plus Family-based Behavioral Counseling|Caretakers will monitor growth monthly in addition participating in family-based behavioral counseling
223831653|NCT02587689|BIOLOGICAL|anti-MUC1 CAR T Cells|
223831654|NCT00110513|BIOLOGICAL|Recombinant human antithrombin (rhAT)|Up to 24 hours prior to the scheduled elective surgical procedure, caesarean section, or delivery induction, each patient will receive an initial intravenous loading dose followed by a continuous intravenous infusion of recombinant human antithrombin (rhAT) that will target and maintain an AT activity that is \> 80% and \< 120% of normal. The dosing objective for all study patients is maintenance of the AT activity at \> 80% and \< 120% of normal during the high-risk period for thromboembolic events. Dosing and dose adjustments will be based on the results of AT activity determinations performed prior to and during treatment.
223831655|NCT04037241|BIOLOGICAL|Anti-CEA CAR-T cells|Doses will be delivered by hepatic arterial infusions using a pressure enabled drug delivery (PEDD) device
223831656|NCT04037241|DRUG|gemcitabine/nab paclitaxel|systemic chemotherapy regimen
223831657|NCT04037241|DRUG|NLIR+FU/FA|systemic chemotherapy regimen
223831658|NCT04037241|DRUG|Capecitabine|systemic chemotherapy regimen
223831659|NCT02795260|BIOLOGICAL|Bacillus Calmette - Guerin|The participants are injection intradermally with 0.1ml ESAT6-CFP10(EC) in the right OR left arm and TB-PPD in the other arm(right OR left) after 12 weeks immunization of BCG .
223831660|NCT02795260|BIOLOGICAL|placebo of Bacillus Calmette - Guerin|The participants are injection intradermally with 0.1ml ESAT6-CFP10(EC) in the right OR left arm and TB-PPD in the other arm(right OR left) after 12 weeks immunization of placebo of BCG .
223831661|NCT05858489|OTHER|Mini-Mental State Examination (MMSE)|Each patient will be evaluated by MMSE then by the adapted version of MMSE
223831662|NCT02731313|BIOLOGICAL|Trastuzumab|Trastuzumab was not administered in this study. This study informs future trastuzumab treatment decisions.
223831663|NCT05752422|DEVICE|Niraxx G1 Headband Device including sham|Exploring effect of active t-PBM delivered by Niraxx G1 Headband versus sham condition
223831664|NCT04357002|DRUG|intravenous tranexamic acid|patients will be given a single bolus IV injection of 15 mg/kg of tranexamic acid (TXA) 20 minutes before surgical incision plus one vaginal placebo tablet 60 minutes before skin incision.
223831665|NCT04357002|DRUG|vaginal dinoprostone|patients will be given one vaginal dinoprostone tablet (3mg) 60 minutes before skin incision and a normal saline IV bolus 20 minutes before surgical incision
223831666|NCT04357002|DRUG|vaginal placebo|patients will be given one vaginal placebo tablet 60 minutes before skin incision and a normal saline IV bolus 20 minutes before surgical incision
223831667|NCT01429519|DRUG|RPh201, botanical drug product|topical, three times per week for a period of 4 consecutive weeks, followed by a single follow up visit 3 months post end of the last treatment day
223831668|NCT00651443|DRUG|Galiximab|Galiximab 500 mg/m2 IV once weekly times 4, followed by Galiximab 500 mg/m2 IV once monthly times 4 as an extended dosing regimen.
223831669|NCT04596787|PROCEDURE|Bilateral Thoracic paravertebral block|The blocks were performed at the T3-T4 level bilaterally to block the dermatomes between the T2 and T6 levels (breast innervation area).
223831670|NCT03562260|PROCEDURE|bipolar release|the bipolar release is the surgery that cut the origin and insertion of the sternocleidomastoid muscle that cause the torticollis from its contracture
223831671|NCT05261503|OTHER|HEP|The Homeostasis-Enrichment-Plasticity (HEP) intervention group will receive 45 minutes of face-to-face environmental enrichment-based intervention one day per week and online home support once a week for 12 weeks.
223831672|NCT05261503|OTHER|Traditional Phsical Therapy|The Traditional Physical Therapy group will receive a 45-minute intervention, two days a week for 12 weeks.
223831673|NCT03069560|DEVICE|SMS|SMS contact from the caregiver with patient after discharge in intervention group
223831674|NCT04600297|DEVICE|ELS Even Stronger (3D Printed Resin Composite)|Missing of one premolar cases will be restored using the 3D Printed resin composite (ELS Even Stronger, Saremco, Switzerland). The steps of the procedure: Preparation, scanning, colour determination, design of the restoration, printing the restoration, adjusting occlusion, finishing and polishing, cementation.
223831675|NCT04974879|DRUG|Osimertinib Oral Tablet|Osimertinib, 80mg, oral daily; bevacizumab (avastin), 15mg/KG body weight, erery 21 days, intravenously.
223831676|NCT01625624|OTHER|Carbohydrate Food Bar|Control Food Bar containing carbohydrate
223831677|NCT01625624|OTHER|Modified Carbohydrate Food Bar|Test Food Bar containing modified carbohydrate
223831678|NCT01598428|PROCEDURE|anterior capsule polishing|polish the anterior capsule and the equator of capsule extensively with a Whitman Shepherd Double-Ended Capsule Polisher
223831679|NCT03380884|DEVICE|Low-magnitude high-frequency vibration (LMHFV)|Low-magnitude high-frequency vibration (LMHFV) is a biophysical intervention that provides non-invasive, systemic mechanical stimulation and has been reported to have no adverse effect.
223831680|NCT01618396|DRUG|Sedation drug (Propofol and Midazolam)|Septic patients, after intubation, were initially sedated with propofol. During the second day of mechanical ventilation, propofol infusion was interrupted. When the patient awoke, the sedative drug was changed to midazolam. Sedation target was a Ramsay Scale score of 4 to 5.
223831681|NCT00245336|BIOLOGICAL|rThrombin|1000 U/mL applied topically in combination with absorbable gelatin sponge
223831682|NCT00245336|DRUG|bovine thrombin|1000 U/mL applied topically in combination with absorbable gelatin sponge
223831683|NCT02708238|DIETARY_SUPPLEMENT|Standardized extract of Chamomilla L., Melissa Officinalis L. and tyndallized L. Acidophilus (H122)|
223831684|NCT02708238|DIETARY_SUPPLEMENT|Lactobacillus reuteri DSM 17938 (108 CFU)|
223831685|NCT02708238|DRUG|Simethicone|
223831686|NCT05134389|PROCEDURE|One Anastomosis Gastric Bypass|Exposure to One Anastomosis Gastric Bypass
223831687|NCT01313923|DRUG|Sirolimus (formerly known as Rapamycin)|For low to moderate immunologic risk, the loading dose is 6mg immediately after transplantation, followed by 2mg PO Qday in conjunction with cyclosporine and corticosteroids. After 2-4 months, cyclosporine should be discontinued over 4-8 weeks while titrating sirolimus drug concentrations within the target-range with whole blood trough concentrations every 1-2 weeks. Monitoring is needed because cyclosporine inhibits the metabolism of sirolimus, and discontinuation of cyclosporine can lead to lower levels of sirolimus. In high immunologic risk patients, the loading dose is 15mg after transplantation, followed by 5mg PO Qday in conjunction with cyclosporine and corticosteroids for 12 months. A whole blood trough level is recommended between days 5 and 7 with adjustment to the daily dose.
223831688|NCT04731103|DRUG|Abacavir (ABC)|Tablets or oral solution
223831689|NCT04731103|DRUG|Lamivudine (3TC)|Tablet or oral solution
223831690|NCT04731103|DRUG|Abacavir (ABC)+Lamivudine (3TC)+Zidovudine (AZT)|Tablet or oral solution
223831691|NCT03352063|BEHAVIORAL|Prolonged sitting with exercise|Subjects will commit to sitting more than 11 hours per day and taking less than 5000 steps per day while participating in exercise training.
223831692|NCT03352063|BEHAVIORAL|Active walking with exercise.|Subjects will commit to sitting less than 5 hours per day and taking more than 10000 steps per day while participating in exercise training.
223831693|NCT03675841|DRUG|Pazufloxacin Mesilate ear drops|Pazufloxacin Mesilate ear drops of 0.1%，0.3%，0.5%
223831694|NCT02471404|DRUG|Dapagliflozin|10 mg, orally Green, plain, diamond-shaped, film-coated tablet
223831695|NCT02471404|DRUG|Saxagliptin|5 mg, orally Plain, yellow, biconvex, round, film-coated tablet
223831696|NCT02471404|DRUG|Glimepiride|1, 2, or 4 mg, orally Opaque gray capsule
223831697|NCT02471404|DRUG|Placebo for dapagliflozin|Does not contain active ingredient, orally Green, plain, diamond-shaped, film-coated tablet
223831698|NCT02471404|DRUG|Placebo for saxagliptin|Does not contain active ingredient, orally Plain, yellow, biconvex, round, film-coated tablet
223831699|NCT02471404|DRUG|Placebo for glimepiride|Does not contain active ingredient, orally. Opaque gray capsule
223831700|NCT04723251|BEHAVIORAL|taking photographs|"Participants will photograph images (using a cell phone) that invoke a feeling of gratitude. At least 1 photograph (at any time of the day) should be taken for a period of three weeks.~Once the photo images are captured, the participant should spend a moment looking at the image and reflecting on why they are grateful for the subject of the photograph."
223831701|NCT01676025|PROCEDURE|PRA|
223831702|NCT01676025|PROCEDURE|LA|
223831703|NCT05586854|PROCEDURE|Hydrolink NV membrane|"patient dialysis on a Hydrolink-NV® membrane with an anticoagulant dose decrease protocol.~Period 1 : conventional membrane with his usual anticoagulant for 4 weeks. Period 2 : Hydrolink-NV® membrane with maintenance of the previous doses of Orgaran® Period 3 : Hydrolink-NV® membrane with a decrease in Orgaran® Period 4 : Hydrolink-NV® membrane with the minimum effective dose of Orgaran® or without Orgaran® for a period of 3 months (M4, M5, M6)."
223831704|NCT02912156|DRUG|Vaway FC Tablets 200mg (Voriconazole)|
223831705|NCT02912156|DRUG|VFEND FC Tablets 200mg (Voriconazole)|
223831706|NCT00035503|DRUG|etiprednol dicloacetate|
223831707|NCT00114153|DRUG|capecitabine|
223831708|NCT00114153|DRUG|carboplatin|
223831709|NCT00114153|PROCEDURE|conventional surgery|
223831710|NCT00114153|RADIATION|radiation therapy|
223831711|NCT03989713|DRUG|MRD-triggered arm|"1. Salvage therapy:~   Quizartinib: 40mg, p.o., Days: 4 - 21 Cytarabine: 18-60yrs: 3g/m² bid / \>-60yrs: 1g/m² bid, i.v. 3h i.v. 3h, Days: 1,2,3; Mitoxantrone: 10mg, i.v. 30min: Days: 2,3;~2. Consolidation therapy:~   Cytarabine: 18-60yrs: 3g/m² bid, i.v. 3h / \>-60yrs: 1g/m² bid, i.v. 3h, Days: 1,2,3; Mitoxantrone: 10mg, i.v. 30min, Days: 2,3~3. Observation therapy:~No treatment"
223831712|NCT03989713|DRUG|Prophylactic Arm|"1. Salvage therapy:~   Quizartinib: 40mg, p.o., Days: 4 - 21 Cytarabine: 18-60yrs: 3g/m² bid / \>-60yrs: 1g/m² bid, i.v. 3h i.v. 3h, Days: 1,2,3; Mitoxantrone: 10mg, i.v. 30min: Days: 2,3;~2. Consolidation therapy:~   Quizartinib: 40mg, p.o., Days: 4 - 21 Cytarabine: 18-60yrs: 3g/m² bid, i.v. 3h / \>-60yrs: 1g/m² bid, i.v. 3h, Days: 1,2,3; Mitoxantrone: 10mg, i.v. 30min, Days: 2,3;~3. Maintenance therapy:~Quizartinib: Cycle 1, Days 1-15: 40mg, p.o. and Day 16-28: 60mg, p.o."
223831713|NCT05318846|DRUG|HRS4800 tablets|Dosing frequency: single dose; Route of administration: oral
223831714|NCT05318846|DRUG|Placebo tablets|Dosing frequency: single dose; Route of administration: oral
223831715|NCT01013935|OTHER|CARE+ Spanish computer counseling session|The computer will ask patients questions about taking HIV medicine. The computer will also ask patients questions about sexual and substance use activities. The computer will let patients look at short videos on various HIV medicine and HIV risk reduction topics and will then help patients create a health plan. Patients will get an anonymous print out at the end of the session and can choose to share with health care provider. There are questions about depression, suicide, or domestic violence. If a patient's answers indicate that they may be depressed, suicidal, or currently in an abusive relationship, we will refer them to a health worker at the clinic. We will repeat the session every 3 months up to 12 months total.
223831716|NCT01013935|OTHER|CARE+ Spanish brief computer risk assessment session|The computer will ask patients questions about taking HIV medicine. The computer will also ask patients questions about sexual and substance use activities. We will repeat the session every 3 months up to 12 months total.
223831717|NCT04315246|BIOLOGICAL|radiolabeled DPTA-omburtamab|Biological, radiolabeled DPTA-omburtamab
223831718|NCT01381744|BIOLOGICAL|Flagellin/F1/V|Flagellin/F1/V recombinant fusion protein vaccine administered by the intramuscular route on Days 0 and 28 at a dose of 1, 3, 6, or 10 micrograms (mcg). It is a clear, colorless solution.
223831719|NCT01381744|OTHER|Placebo|Phosphate buffered saline (PBS) used as diluent and placebo.
223831720|NCT04517370|DEVICE|Fractional/Pixel CO2 laser|"The treatment is done with a specialized vaginal applicator which allows treatment of vagina, using the Femilift fractional micro ablative CO2 laser system (Alma Lasers, Israel), according to the usual protocol (Laser mode: Pulse, Energy: 40-80 mj/pulse).~Before treatment, 5ml of topical anesthetic ointment (10% lidocaine in Vaseline base) will be spread in the vagina and on the vestibule for 30 minutes in both groups to avoid pain from the laser, as well as to allow the comparison between the groups (patients in both groups will not experience pain and therefore will remain blinded to their allocation)."
223831721|NCT00614198|OTHER|Gluten- and casein-free diet|Removal of foods containing gluten (cereal produce) and casein (dairy produce)
223831722|NCT01215708|DRUG|Tamsulosin|tamsulosin 0,4mg every night for 30 consecutive days
223831723|NCT04048252|OTHER|Focus group creation|Patients will join with researchers for a 2 hour recorded group discussion to highlight themes identified to require educational intervention
223831724|NCT04048252|OTHER|Workshop|Patients will attend 3-4 workshops on eg disease knowledge, medication management and side effects, adapted physical activity and nutrition
223831725|NCT05690789|OTHER|No treatment given|No treatment given
223831726|NCT05011916|DRUG|KDR2-2 suspension eye drops|All patients were instructed to instill one drop four times per day in the study eye for 6 weeks.
223831727|NCT02088775|PROCEDURE|PET scan|Undergo PET-CT scan
223831728|NCT02088775|PROCEDURE|CT Scan|Undergo PET-CT scan
223831729|NCT02088775|PROCEDURE|hepatic artery embolization|Undergo standard radioembolization
223831730|NCT02578225|OTHER|Non interventional study|
223831731|NCT00827151|DRUG|Estrogen|Estrogen 100 mcg patch twice weekly with 10 days of oral progesterone monthly for 12 months versus no medication
223831732|NCT02247414|DRUG|Warfarin|From postoperative day 3, patients will receive oral Warfarin 2.5mg qd with titration of dose to maintain a target INR of 2-3 for 1 year.
223831733|NCT02247414|DRUG|Dipyridamole|From postoperative day 3, patients will receive oral dipyridamole 25mg tid for three months.
223831734|NCT02247414|DRUG|Aspirin|From postoperative day 3, patients will receive oral Aspirin Enterie Ccoated Tablets 100mg qd for 1 year.
223831735|NCT02247414|DRUG|Low Molecular Weight Heparin|From postoperative day 3, patients will receive subcutaneous injection of Low Molecular Weight Heparin (4100 IU) once daily for first five days.
223831736|NCT00065468|DRUG|Interferon Alfa|Interferon alfa (Roferon) 3 MU given Sub Cutaneously three time /week for the first week, 9 MU given Sub Cutaneously three time /week for the second week, 18 MU given Sub Cutaneously three time /week thereafter.
223831737|NCT00065468|DRUG|CCI-779|25 mg of CCI-779 given Intra Venously once per week
223831738|NCT00065468|DRUG|Interferon Alfa and CCI-779|15 mg of CCI-779 given Intra Venously once per week; 6 MU of IFN alfa (Roferon) given Sub Cutaneously three time /week
223831739|NCT03741205|DEVICE|SPEAC System|Surface Electromyography (sEMG) based seizure monitoring and alerting system
223831740|NCT01169181|DEVICE|AMES + brain stimulation|Stroke survivors with plegia of affected upper extremity receive either AMES + rTMS or AMES + tDCS.
223831741|NCT03309124|OTHER|White bread|Toasted, with canola oil added to match for fat content of French fries (13.9 grams), as well as being matched for energy (280 kilocalories) and available carbohydrate content (33 grams) of potato treatments.
223831742|NCT03309124|OTHER|Baked potato with skin|Baked russet potato with canola oil added once baked to match for fat content of French fries, and also matched for the salt content of white bread (280 milligrams).
223831743|NCT03309124|OTHER|Mashed potatoes|Mashed potatoes prepared from frozen, with canola oil added to match for fat content of French fries, as well as being matched for energy and available carbohydrate content of the baked potato.
223831744|NCT03309124|OTHER|Fried French fries|Prepared from frozen, matched for energy and available carbohydrate content of baked potato and salt content of white bread.
223831745|NCT03309124|OTHER|Meal skipping|No food given
223831746|NCT01225835|DRUG|Menotrophin|Starting on Day 2 or 3 of the menstrual cycle, 150 IU (up to 300 IU) by subcutaneous injection once per day in the morning for up to 12 days until human chorionic gonadotropin (hCG) criteria are met.
223831747|NCT01225835|DRUG|Follitrophin alpha|Starting on Day 2 or 3 of the menstrual cycle, 150 IU (up to 300 IU) by subcutaneous injection once per day in the morning for up to 12 days until human chorionic gonadotropin (hCG) criteria are met.
223831748|NCT01225835|DRUG|Cetrorelix|Participants self-inject subcutaneously Cetrorelix in the morning at a daily dose of 0.25 mg/day from Day 5 of gonadotrophin administration on and continue throughout the period of gonadotrophin treatment up to day 12 as a maximum. The last dose of Cetrorelix is given on the day of ovulation induction.
223831749|NCT01225835|DRUG|Choriongonadotropin|10,000 IU administered by the Investigator or designated personnel in the evening of the day on which the hCG criterion is met (no later than Day 13). The criterion for hCG administration is three follicles \>+17 mm diameter as shown by pelvic ultrasound examination.
223831750|NCT01225835|DRUG|Progesterone|Vaginal gel progesterone is used once daily at a dose of 90 mg for a period of 30 days starting on the day of oocyte retrieval (approximately Day 14).
223831751|NCT05315830|BIOLOGICAL|HER2 Tumor Vaccine|B-cell epitope vaccine HER2 Tumor Vaccine 0.6 μg，Intramuscular injection on D1, D14 and D28
223831752|NCT05315830|BIOLOGICAL|HER2 Tumor Vaccine+ Standard of Care chemotherapy|B-cell epitope vaccine HER2 Tumor Vaccine 0.6 μg，Intramuscular injection on D1, D14 and D28 Standard of Care Chemotherapy cisplatin by intravenous administration at 80 mg/m2 on the first day of each cycle and either 5-FU, 4000 mg/m2 CIV (administered as 1000 mg/m2/day as continuous infusion for 96 hours on days 1 to 4 of each cycle) or capecitabine for 14 days at 2000 mg/m2/day, orally (administered as 1000 mg/m2 twice daily morning and evening for a total of 2000 mg/m2/day on days 1 to 14 of each cycle) or other standard of care chemotherapy
223831753|NCT01874574|DRUG|Hylan G-F 20|After full aseptic preparation, Single shot intra-articular injection either 6 mL of Hylan G-F 20 or 1 mL of 40 mg triamcinolone acetonide plus 5 mL of 1% xylocaine with adrenaline were injected into the joint cavity using the infero-lateral approach via a 21-gauge needle.
223831754|NCT01874574|DRUG|Corticosteroid|After full aseptic preparation, Single shot intra-articular injection either 6 mL of Hylan G-F 20 or 1 mL of 40 mg triamcinolone acetonide plus 5 mL of 1% xylocaine with adrenaline were injected into the joint cavity using the infero-lateral approach via a 21-gauge needle.
223831755|NCT02903589|OTHER|observational|
223831756|NCT04745104|DRUG|SHR-1707|SHR-1707 will be administered through IV infusion
223831757|NCT04745104|DRUG|Placebo|Placebo will be administered through IV infusion
223831758|NCT03085550|PROCEDURE|Fat grafting|Single treatment fat grafting infiltrated into diabetic ulcer wound
223831759|NCT03085550|PROCEDURE|Fat grafting + platelet rich plasma|Single treatment fat grafting mixed with autologous platelet rich plasma infiltrated into diabetic ulcer wound. Autologous PRP is obtained using the ANGEL(TM) Concentrated Platelet Rich Plasma (cPRP) Separation Device which is FDA-regulated and CE certified
223831760|NCT05699902|PROCEDURE|PECs block during mastectomy|The patients were randomised to receive a PECS block consisting of 30 ml of levobupivacaine 0.25% after induction of anaesthesia (PECS group) or a saline mock block (control group). The patients answered a 40-item QoR questionnaire (QoR-40) before and 1 day after breast cancer surgery. MAIN OUTCOME MEASURES
223831761|NCT05699902|PROCEDURE|Sham block|Female undergone mastectomy and have received conventional analgesic methods
223831762|NCT00332215|DRUG|Inhaled Sodium Pyruvate|
223831763|NCT01479491|OTHER|Data collection|Data source will be the Japan Medical Data Centre Company Limited (JMDC) - JMDC Medical Data Bank (JMDC-MDB) database. Aggregated data (age in months and years and gender) for all subjects recorded in the database and subject-level data for IS cases will be extracted from the database. This database will be reviewed to extract data for the period between January 2005 and April 2011. Cases of IS will be identified using the International Classification of Diseases-10 (ICD-10) diagnostic codes, examination codes and procedural codes.
223831764|NCT04349410|DRUG|Hydroxychloroquine, Azithromycin|FMTVDM Planar, SPECT, PET
223831765|NCT04349410|DRUG|Hydroxychloroquine, Doxycycline|FMTVDM Planar, SPECT, PET
223831766|NCT04349410|DRUG|Hydroxychloroquine, Clindamycin|FMTVDM Planar, SPECT, PET
223831767|NCT04349410|DRUG|Hydroxychloroquine, Clindamycin, Primaquine - low dose.|FMTVDM Planar, SPECT, PET
223831768|NCT04349410|DRUG|Hydroxychloroquine, Clindamycin, Primaquine - high dose.|FMTVDM Planar, SPECT, PET
223831769|NCT04349410|DRUG|Remdesivir|FMTVDM Planar, SPECT, PET
223831770|NCT04349410|DRUG|Tocilizumab|FMTVDM Planar, SPECT, PET
223831771|NCT04349410|DRUG|Methylprednisolone|FMTVDM Planar, SPECT, PET
223831772|NCT04349410|DRUG|Interferon-Alpha2B|FMTVDM Planar, SPECT, PET
223831773|NCT04349410|DRUG|Losartan|FMTVDM Planar, SPECT, PET
223831774|NCT04349410|DRUG|Convalescent Serum|FMTVDM Planar, SPECT, PET
223831775|NCT04160611|DRUG|Midazolam 7.5mg|The patient groups differ only in that respect that the intervention group will receive oral midazolam 7.5 g before oocyte aspiration.
223831776|NCT03169270|OTHER|Exercise training|All subjects performed a supervised 8-week, 5 days-week of endurance exercise training program in cycle-ergometer Each session included 5 minutes of warm-up and cool-down pedalling at 30% of peak work-rate (WR) and 50 minutes of interval training. The interval training combined 2 minutes of high-intensity pedalling and 3 minutes of active rest. Work-rate progress during the 8-week period was tailored on individual basis, according to subjects' symptoms, to maximize the training effect. During the first 2 weeks, high intensity pedalling interval was at least 70% of peak WR and active rest interval was at least 40% of peak WR. Thereafter, work-rate was increased by approximately 5% every week up to a maximum of 100% of peak WR during the last 2 weeks for the high intensity period and 50% of peak WR for the active rest. The cycling rate during the sessions was maintained at 60-70 rpm.
223831777|NCT01648179|DRUG|GSK1322322 (mesylate salt) Powder for Injection|1500 mg (mesylate salt) as free base, dissolved in sterile water for injection to a concentration of 100 mg/mL free base equivalent and sterilized via filtration. 15 mL of solution, equivalent to 1500 mg GSK 1322322, is the diluted into 0.9% Sodium Chloride Injection prior to infusion
223831778|NCT01648179|DRUG|GSK1322322 (freebase) tablets|500 mg tablets for a 1500 mg total single dose (3 tablets). Taken with 240 mL of water
223831779|NCT01648179|DRUG|GSK1322322 (mesylate salt) Powder for Oral Solution|1500 mg as a free base, dissolved in purified water to a concentration of 100 mg/mL free base equivalent. 15 mL of solution, equivalent to1500 mg GSK1322322 is administered orally with 225 mL of water
223831780|NCT01648179|DRUG|GSK1322322 (freebase) tablets FED|Drug 500 mg tablets for a 1500 mg total single dose (3 tablets) (FED moderate fat meal) Taken with 240 mL of water
223831781|NCT06187571|OTHER|CT+MWM|The MWM technique was applied to the MWM group in addition to the CT. The MWM technique was applied in flexion, abduction, internal rotation, and external rotation directions. The MWM technique was performed with 3 sets of 10 repetitions.
223831782|NCT06187571|OTHER|CT|Cold packs, electrotherapy modalities, scapular mobilization, stretching, and strengthening exercises were applied to the CT group.
223831783|NCT04280471|DRUG|Fecal Microbiota Transplantation Capsule|Receive OpenBiome FMT Capsule DE PO
223831784|NCT03053674|OTHER|Oral and written explanation|Oral and written explanation on importance of post-partum influenza vaccination for the health of their newborn infant
223831785|NCT03053674|OTHER|Follow-up questionnaire|Follow-up questionnaire to determine whether participants have receive post-partum vaccination
223831786|NCT03299062|DIAGNOSTIC_TEST|Cytology and Immunohistochemistry|Determine if nasal swabs can provide an adequate sample for evaluation using cytology and immunohistochemistry for alpha-synuclein, A-beta and p-tau staining.
223831787|NCT02480686|DRUG|SOF+PEG+RBV|Sofosbuvir (SOF) 400 mg tablet is administered orally once daily; Pegylated interferon alfa-2a (PEG) 180 μg was administered once weekly by subcutaneous injection; Ribavirin (RBV) was administered as a tablet orally according to body weight (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg).
223831788|NCT02749695|DRUG|Melsmon|Placental extract Melsmon® (Japan): 2 ml (100 mg), subcutaneously, every 2nd day for 2 weeks, then twice a week (30 injections for 4 months in total).
223831789|NCT02749695|OTHER|Placebo|2 ml subcutaneously, every 2nd day for 2 weeks, then twice a week (30 injections for 4 months in total).
223831790|NCT03285113|DEVICE|GiMer Medical MN 1000 External Stimulator|Trial stimulator to generate pulsed ultrahigh frequency (\>200KHz) electrical stimulation, delivered via lead around DRG, in treating pain. Similar with current market available Spinal Cord Stimulators but with a higher stimulation frequency (hundred KHz) range.
223831791|NCT03398915|PROCEDURE|Transpedicular Instrumentation|Transpedicular screw placement and instrumentation
223831792|NCT02643979|DRUG|Ketofol|50mg of Ketamine mixed with 100mg of Propofol
223831793|NCT02643979|DRUG|Propofol|100mg of Propofol
223831794|NCT02643979|DRUG|Saline|1mL of saline
223831795|NCT00849680|OTHER|Comparator: Placebo to the MRKAd5 HIV-1 gag/pol/nef vaccine|Placebo to the MRKAd5 HIV-1 gag/pol/nef vaccine.
223831796|NCT00849680|BIOLOGICAL|Monovalent MRKAd5 HIV-1 gag vaccine (1x10^9 vp/dose)|Monovalent MRKAd5 HIV-1 gag vaccine (1x10\^9 vp/dose)
223831797|NCT00849680|BIOLOGICAL|Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^6 vp/dose)|Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10\^6 vp/dose)
223831798|NCT00849680|BIOLOGICAL|Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^7 vp/dose)|Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10\^7 vp/dose)
223831799|NCT00849680|BIOLOGICAL|Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^8 vp/dose)|Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10\^8 vp/dose)
223831800|NCT00849680|BIOLOGICAL|Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^9 vp/dose)|Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10\^9 vp/dose)
223831801|NCT00849680|BIOLOGICAL|Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^10 vp/dose)|Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10\^10 vp/dose)
223831802|NCT00849680|BIOLOGICAL|Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (1x10^11 vp/dose)|Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (1x10\^11 vp/dose)
223831803|NCT00849680|BIOLOGICAL|Comparator: Placebo to MRKAd5 HIV-1 gag vaccine|Placebo to the MRKAd5 HIV-1 gag vaccine.
223831804|NCT01566786|DRUG|activated recombinant human factor VII|Starting dose of trial drug 10 mcg/kg, escalating up to five dose tiers: 20 mcg/kg, 40 mcg/kg, 80 mcg/kg, 120 mcg/kg and 160 mcg/kg. Administered within the first 4 hours after the insult
223831805|NCT01566786|DRUG|placebo|Starting dose of trial drug 10 mcg/kg, escalating up to five dose tiers: 20 mcg/kg, 40 mcg/kg, 80 mcg/kg, 120 mcg/kg and 160 mcg/kg. Administered within the first 4 hours after the insult
223831806|NCT03518164|PROCEDURE|Allograft|Bone graft
223831807|NCT03892369|OTHER|Ethanol|Ethanol administration
223831808|NCT01141335|DEVICE|polypropylene mesh|A Lichtenstein tension-free hernioplasty is performed using a polypropylene mesh will be fixed by sutures in Polypropylene 2/0.
223831809|NCT01141335|DEVICE|Infinit® PTFE mesh (WL Gore)|A Lichtenstein tension-free hernioplasty is performed using a PTFE mesh will be fixed by sutures in PTFE 2/0.
223831810|NCT04017741|DRUG|Combined Depo-Medrone and Lidocaine|"Patients will be randomised 1:1 to receive the active or placebo arm. The nerve is located along the superior nuchal line, where it bilaterally lies medial to the occipital artery. The scalp is prepped with alcohol and using 23G needle, the IMPs are injected at a 90 degrees angle till the bony endpoint is obtained. A combination of 2 mls of 2% lidocaine and 80mg methylprednisolone will be administered.~Patients who no longer receive any benefit will be crossed over to the placebo arm."
223831811|NCT04017741|DRUG|Sodium Chloride 0.9% Inj|Patients will be randomised 1:1 to receive the active or placebo arm. The nerve is located along the superior nuchal line, where it bilaterally lies medial to the occipital artery. The scalp is prepped with alcohol and using 23G needle the 4mls of normal saline (0.9%) are injected at a 90 degrees angle till the bony endpoint is obtained. Patients who no longer receive any benefit will be crossed over to the active arm.
223831812|NCT02522338|DRUG|iohexol|10 ml de l'iohexol (300 mgI/ml)
223831813|NCT01049074|OTHER|Acupuncture Treatment|Acupuncture is a technique of inserting and manipulating fine needles into specific points on the body to relieve pain or for therapeutic purposes.
223831814|NCT01049074|OTHER|Sham acupuncture|Sham acupuncture is inserting needles superficially, without manipulating, into specific points on the body.
223831815|NCT02989363|PROCEDURE|Device O-Arm in DBS|Deep brain stimulation surgeries with device O-Arm
223831816|NCT02989363|PROCEDURE|Device O-Arm in RAQUIS|Complex back surgeries with the device O-Arm
223831817|NCT02989363|PROCEDURE|Not device O-Arm in DBS|Deep brain stimulation surgeries without the device O-Arm
223831818|NCT02989363|PROCEDURE|Not device O-Arm in RAQUIS|Complex back surgeries without the device O-Arm
223831819|NCT01272986|DEVICE|ALOA IgG-Elisa|measurement of IgG Level in blood
223831820|NCT01272986|DEVICE|ALOA IgG-AtheroAbzyme|measurement of IgG in blood
223831821|NCT03509376|PROCEDURE|Suture repair|The diastasis is repaired with continous nylon suture
223831822|NCT03509376|PROCEDURE|Rolled mesh repair|Continuous nylon suture is done over a narrow strip of self gripping Rolled mesh to repair the diastasis
223831823|NCT04262102|BEHAVIORAL|SD_SF|Women will follow a personalized standard diet, described in National Diet Surveys. And their children will be spoon-fed during complementary feeding.
223831824|NCT04262102|BEHAVIORAL|SD_BLW|Women will follow a personalized standard diet, described in National Diet Surveys. And their children will follow a baby-led weaning approach for complementary feeding.
223831825|NCT04262102|BEHAVIORAL|HFV_SF|Women will follow personalized diet, high in fruits and vegetables. And their children will be spoon-fed during complementary feeding.
223831826|NCT04262102|BEHAVIORAL|HFV_BLW|Women will follow personalized diet, high in fruits and vegetables. And their children will follow a baby-led weaning approach for complementary feeding.
223831827|NCT03360279|DEVICE|Regular balloon|Randomization: to use regular balloon to treat stent graft restenosis
223831828|NCT03360279|DEVICE|DCB (paclitaxel-coated balloon)|Randomization: to use DCB (paclitaxel-coated balloon, Ranger, Boston-Scientific) to treat stent graft restenosis. The paclitaxel dose is 2 ug/mm2 delivered with the Ranger drug-coated balloon.
223831829|NCT05239871|DIAGNOSTIC_TEST|Ultrasound|Preoperative transvaginal/transabdominal ultrasonography done according to IDEA criteria.
223831830|NCT01187290|RADIATION|neoadjuvant chemoradiotherapy|Radiotherapy (3 weeks after last chemotherapy administration) 44 Gy in 22 fractions concomitant boost technique in 3 weeks
223831831|NCT00115362|DRUG|venlafaxine|
223831832|NCT02829710|BEHAVIORAL|Nurse-driven sedation protocol|The nurse-driven sedation protocol included the COMFORT-B scale. Initial doses were chosen by the physicians then all changes were made by the nurses with the aim of attaining an optimal range of analgesia and sedation, which was defined as values from 11 to 17 on the COMFORT-B score.
223831833|NCT05287334|DEVICE|Electrical impedance tomography measurement|During standard blood donation, donors' chest bioimpedance will be measured using electrical impedance tomography.
223831834|NCT01040286|DRUG|Flurbiprofen|2.0 mg
223831835|NCT01040286|DRUG|Chlorhexidine|2.5mg
223831836|NCT02207374|DRUG|semaglutide|Subject will receive either a dose of 0.5 or 1.0 mg of semaglutide once weekly (subcutaneous (s.c.) injection).Treatment duration 56 weeks.
223831837|NCT02207374|DRUG|DPP-4 inhibitor|Subjects will receive one DPP-4 inhibitor in addition to pre-trial OAD monotherapy, if any, for 56 weeks.
223831838|NCT02087150|DEVICE|Acclarent Eustachian Tube Balloon Catheter (ETBC)|
223831839|NCT03146858|DRUG|Enoxaparin|Enoxaparin is an anticlotting treatment that targets the other aspect of clot formation known as the coagulation cascade. Enoxaparin or an alternative is recommended as a single does to support PPCI procedure.
223831840|NCT02273505|DRUG|Asasantin (ER)|
223831841|NCT02273505|DRUG|Persantin|
223831842|NCT02273505|DRUG|Acetyl salicylic acid (ASA)|
223831843|NCT06130839|OTHER|Rocker board training|Then intervention will be applied to the perturbation group as mention below at Rocker board (50 x 45 cm).the group will perform 36 sessions (4 times per week over 8 weeks) and effects of interventions will be measured before treatment, at 4th and after8th week (pre, mid and post intervention). Trunk control exercises on Rocker Board in standing position first in medio-lateral direction for 10 min and then in anterio-posterior direction for 10 min with breaks in between.
223831844|NCT06130839|OTHER|Stable surface training|the group will perform 36 sessions (4 times per week over 8 weeks) and effects of interventions will be measured before treatment, at 4th and after 8th week (pre, mid and post intervention).
223831845|NCT00688090|BIOLOGICAL|Biological: MKC1106-MT|Cancer Vaccine, Immunotherapy
223831846|NCT00688090|BIOLOGICAL|Biological: MKCC1106-MT|Cancer Vaccine, Immunotherapy
223831847|NCT04866914|BEHAVIORAL|Acceptance and Commitment Therapy for Insomnia|ACT-I treatment group: Participants diagnosed with chronic insomnia will receive group treatment. The six sessions will be aimed at psychoeducation about sleep added to the therapeutic processes of acceptance, mindfulness, availability, values, defusion and commitment, used in ACT.
223831848|NCT04866914|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|Active control group CBT-I: Participants diagnosed with chronic insomnia will receive treatment in a group. The six sessions will be aimed at cognitive-behavioral components, such as education and sleep hygiene, stimulus control, sleep restriction and demystification / restructuring of belief beliefs.
223831849|NCT04864041|OTHER|Evaluation of global longitudinal strain using routinely recorded echocardiography images|There are no particular intervention performed in patients in this study, because echocardiography is part of the standard of care of patients hospitalised in the ICU for vaso occlusive crisis.
223831850|NCT01448044|DRUG|BMS-790052 (NS5A Replication Complex Inhibitor)|
223831851|NCT01448044|DRUG|Placebo matching BMS-790052|
223831852|NCT01448044|DRUG|Pegylated-interferon alfa 2a|
223831853|NCT01448044|DRUG|Ribavirin|
223831854|NCT03111758|DEVICE|Flow augmentation|Augmenting venous flow following deep venous stenting in patients with Postthrombotic syndrome
223831855|NCT02126436|OTHER|Acupuncture|"Participants will receive a course of traditional Chinese acupuncture. Acupuncture will be pragmatic but strict guidelines will be adhered to including:~using a combination of body and auricular acupuncture, treating the opposite limb to amputation and possibly the residual limb, using auricular acupuncture points such as shen men, sympathetic, points corresponding to the lower limb, using body acupuncture points around the stump (depending on tissue health and the patient), mirroring local and distal points by needling them on the opposite limb, points on the lower back taking a segmental approach to dermatomal pain, including points such as LI4 + LR3, LR3, GV20, SP10, electro-acupuncture may be used, retaining the needles for 20-30 minutes, treating twice weekly for four weeks."
223831856|NCT02126436|OTHER|Usual care|The group will receive usual care (including physiotherapy, occupational therapy, medical intervention and any other intervention as deemed appropriate by clinical staff).
223831857|NCT02189096|OTHER|NEWS and Sepsis Screening|Each Paramedic crew will continue to routinely document patient observations in an electronic Patient Report Form (ePRF) on every patient encounter. These physiological parameters will be used to calculate NEWS and screen for Sepsis (2 or more modified SIRS criteria and suspicion of infection). The NEWS will be available to the paramedic crew.
223831858|NCT02189096|OTHER|Point of care lactate measurement|Each Paramedic crew will continue to routinely document patient observations in an electronic Patient Report Form (ePRF) on every patient encounter. These physiological parameters will be used to calculate NEWS and screen for Sepsis (2 or more modified SIRS criteria and suspicion of infection). If NEWS is greater than or equal to 4 or the patient screens positive for Sepsis, then a Lactate will be measured on the CG4+ i-STAT cartridge.
223831859|NCT01902589|OTHER|Helicobacter Pylori Culture|"Biopsy specimens for histology will be fixed in formalin, embedded in paraffin and sectioned and stained with hematoxylin and eosin.~The microbiological workup will include an imprint of the biopsy on a slide followed by a gram stain for the purpose of demonstrating H. pylori in situ. Further the biopsies will be streaked out on chocolate agar, Sheep blood agar and H. pylori selective agar supplemented with Polymixin to suppress possible contaminants.~4 days of incubation in a micro aerophilic atmosphere will follow . Susceptibility testing of H pylori will be performed with E test on Mueller Hinton agar supplemented with defibrinated sheep blood using a MacFalrland 3.0 density of a bacterial suspension. Reading the susceptibility will take place following 72 hours of incubation in a micro aerophilic atmosphere."
223831860|NCT05581238|OTHER|TRACK-TCT|An extra variable will be added to an existing prediction model. It is hypothesized that the predictive ability will improve and that better distinction could be made between patients with an increased risk for receiving blood transfusions.
223831861|NCT03041454|OTHER|Novel systematic review format|A 2-page summary of systematic review content that has been designed in collaboration with policy makers and health care managers.
223831862|NCT05617547|DIAGNOSTIC_TEST|Pulse Oximeter (Massimo)|The Massimo LNCS (low noise cabled sensors) pulse oximeter will be used to estimate the oxygen saturation and compared to the gold standard, the arterial oxygen saturation in the blood as measured by co-oximetry. The pulse oximeters is FDA cleared for this purpose so patients will not be exposed to any interventions that are not standard of care.
223831863|NCT00004811|DRUG|itraconazole|
223831864|NCT00918216|GENETIC|fluorescence in situ hybridization|Additional histochemical, immunohistochemical, and fluorescence in situ stains may be performed to support the diagnosis or to better understand the spectroscopy results.
223831865|NCT00918216|OTHER|immunohistochemistry staining method|Additional histochemical, immunohistochemical, and fluorescence in situ stains may be performed to support the diagnosis or to better understand the spectroscopy results.
223831866|NCT00918216|OTHER|medical chart review|Patients' medical charts are reviewed to obtain clinical information
223831867|NCT00918216|PROCEDURE|fluorescence spectroscopy|The freshly excised breast tissue samples are analyzed ex vivo by fluorescence, reflectance, and/or Raman spectroscopy.
223831868|NCT00918216|PROCEDURE|histopathologic examination|Hematoxylin and eosin stained sections of the tissue samples are examined by light microscopy for histopathological analysis.
223831869|NCT00918216|PROCEDURE|light-scattering spectroscopy|The freshly excised breast tissue samples are analyzed ex vivo by fluorescence, reflectance, and/or Raman spectroscopy.
223831870|NCT03912220|DRUG|Nicotinamide riboside|The experimental arm will investigate the effects of nicotinamide riboside on nerve degeneration and regeneration.
223831871|NCT03912220|DRUG|Placebo Oral Tablet|Placebo drug that looks like the experimental drug, nicotinamide riboside tablets.
223831872|NCT05108727|DEVICE|Diode Laser|DL with a wavelength of 810±5 nm, a 400micron diameter, and a power of 1 watt in continuous mode was applied to the MWF at the test sites.
223831873|NCT05108727|PROCEDURE|Modified Widman Flap|Periodontal Surgery Technique
223831874|NCT02019433|DEVICE|Structan®|
223831875|NCT01165346|RADIATION|Fiducials|Implantation of fiducials
223831876|NCT01165346|RADIATION|CyberKnife|3 fractions over 8 to 10 days, 15 Gy/fraction
223831877|NCT01924143|DRUG|TD-9855|radiolabeled (100 µCi \[14C\]-Labeled) TD-9855 (20 mg)
223831878|NCT03973138|DRUG|Ranibizumab|DME patients who were diagnosed through fundus manifestations and FFA examination were treated by intravitreal injections of ranibizumab (0.5mg Lucentis®; Genentech, South San Francisco, CA) under the pro re nata (PRN) treatment regimen. The retreatment were conducted if BCVA was reduced by 0.1 logarithm of the minimal angle of resolution (logMAR) value or more from maximum acuity or if OCT central subfield thickness was more than 300μm.
223831879|NCT00972387|DIETARY_SUPPLEMENT|CHO, CHO-P, CHO-CHO, PLA|The CHO supplement will be administered during trial 1. The CHO-P will be administered during trial 2. The CHO-CHO supplement will be administered during trial 3. The PLA supplement will be administered during trial 4. This is the order of supplement administration for subjects randomly assigned to this order group.
223831880|NCT00972387|DIETARY_SUPPLEMENT|CHO-P, CHO-CHO, PLA, CHO|The CHO-P supplement will be administered during trial 1. The CHO-CHO will be administered during trial 2. The PLA supplement will be administered during trial 3. The CHO supplement will be administered during trial 4. This is the order of supplement administration for subjects randomly assigned to this order group.
223831881|NCT00972387|DIETARY_SUPPLEMENT|CHO-CHO, PLA, CHO, CHO-P|The CHO-CHO supplement will be administered during trial 1. The PLA will be administered during trial 2. The CHO supplement will be administered during trial 3. The CHO-P supplement will be administered during trial 4. This is the order of supplement administration for subjects randomly assigned to this order group.
223831882|NCT00972387|DIETARY_SUPPLEMENT|PLA, CHO, CHO-P, CHO-CHO|The PLA supplement will be administered during trial 1. The CHO will be administered during trial 2. The CHO-P supplement will be administered during trial 3. The CHO-CHO supplement will be administered during trial 4. This is the order of supplement administration for subjects randomly assigned to this order group.
223831883|NCT05018429|PROCEDURE|nerve sparing|When resect the bladder and prostate, the neurovascular bundles around the prostate will be preserved.
223831884|NCT02500316|DRUG|MOD-4023|Once weekly injection of long acting r-hGH (MOD-4023) provided as a solution for injection containing 20 or 50 mg/mL MOD-4023 in a single patient use, multi-dose, disposable pre-filled pen (PEN).
223831885|NCT05514574|OTHER|Music|"hussoni duseni  music"
223831886|NCT05514574|OTHER|Stress ball|Stress ball squeeze
223831887|NCT05216926|OTHER|Timing of preventive action based on prediction model|Timing of preventive action based on prediction model
223831888|NCT05216926|OTHER|Hypoglycaemia treatment at hypoglycaemia (usual care)|Hypoglycaemia treatment at hypoglycaemia (usual care)
223831889|NCT04091776|RADIATION|CT scan|"1. Quantitative CT scan to measure localized osteoporosis and detection of cortices comminution.~2. Blinded surgeon decision as regard to replace or to fix using DHS or PFN (depending on x-rays data only).~3. Pathological assessment of osteoporosis in retrieved bone in patients whom hip replacement was decided.~4. Assessment of fixation failure in fixed fractures if occurred.~5. Fixation failure is defined as:~5.1. Lag cut through 5.2. Lag cutout 5.3. Z-effect (lag penetration) 5.4. Non-union (within 6 months) 5.5. Loss of reduction with progressive varus deformity 5.6. Femoral fracture 5.7. Intra-operative fracture of lateral wall or anterior cortex"
223831890|NCT04221061|DRUG|18F-FluorThanatrace|18F-FluorThanatrace is a novel radiopharmaceutical which measure PARP-1 expression using a Positron Emission Tomography (PET/CT) scan.
223831891|NCT05895968|PROCEDURE|posterior cervical surgery|The patients were operated by the posterior cervical surgery, which were used with the barbed to suture the deep fascia.
223831892|NCT05725187|DEVICE|MobiCare|It is a 9.2g wearable electrocardiogram device, mobiCARE, in the form of a patch, and the model name is MC200M.
223831893|NCT05401435|OTHER|Resting measurement of blood pressure and heart rate|Simultaneous blood pressure and heart rate measurement every morning and evening during the duration of the experiment (28 days).
223831894|NCT03216902|DRUG|Vehicle of DE-126 Ophthalmic Solution, high dose of DE-126 Ophthalmic Solution|Vehicle of DE-126 Ophthalmic Solution dosed once daily for 6weeks, followed by high dose of DE-126 dosed once daily for 6 additional weeks
223831895|NCT03216902|DRUG|Topical ultra-low dose of DE-126 Ophthalmic Solution|Topical ultra-low dose of DE-126 Ophthalmic Solution dosed once daily for 12 weeks
223831896|NCT03216902|DRUG|Topical low dose of DE-126 Ophthalmic Solution|Topical low dose of DE-126 Ophthalmic Solution dosed once daily for 12 weeks
223831897|NCT03216902|DRUG|Topical medium dose of DE-126 Ophthalmic Solution|Topical medium dose of DE-126 Ophthalmic Solution dosed once daily for 12 weeks
223831898|NCT03216902|DRUG|Topical high dose of DE-126 Ophthalmic Solution|Topical high dose of DE-126 Ophthalmic Solution dosed once daily for 12 weeks
223831899|NCT03216902|DRUG|0.005% Latanoprost Ophthalmic Solution|0.005% Latanoprost Ophthalmic Solution dosed once daily for 12 weeks
223831900|NCT02913521|DRUG|Diclofenac Sodium Gel 1%|
223831901|NCT02913521|DRUG|Voltaren Gel|
223831902|NCT02913521|DRUG|Placebo|
223831903|NCT04415697|DIAGNOSTIC_TEST|Gene expression test using nanostring technology.|Evaluation of gene expression profile of a panel with 770 genes related to disease progression using nanostring technology
223831904|NCT05389527|DRUG|Pembrolizumab+Lenvatinib|"After enrollment, subjects receive pembrolizumab 200 mg via IV infusion on Day 1 of each 3-week cycle for 9 weeks: Lenvatinib 8 mg (body weight \<60 kg) or 12 mg (body weight ≥60 kg) orally once daily for 9 weeks.~Subjects conduct surgery 1 week after the last dose of Lenvatinib. 4 weeks after surgery, Pembrolizumab and Lenvatinib will restart as adjuvant treatment for up to 1 year."
223835624|NCT03867474|BEHAVIORAL|Mindfulness-Based Stress Reduction (MBSR)|The intervention group will be delivered in a group-based format, for one three-hour session per week for an 8-week period. Each session will consist of mindfulness practice (e.g. lying down body scan, sitting meditation, mindful eating, mindful movements such as walking and light hatha yoga movements) along with an inquiry about the practice. Strategies on stress reactivity, responding to stress, and some basic content on cognitive behaviour therapy principles will also be taught. Participants will be placed in dyads during the group. Homework practice will be given to complete on a daily basis for approximately 30-45 minutes. During week six participants will attend an all-day silent meditation retreat on a Saturday (Total of 10 sessions = 8 sessions, 1 orientation, and 1 all-day retreat).
223835625|NCT01107730|DRUG|Vitamin C|VitC intravenously (2g/day \[500mgX4\] for 2 days prior to surgery, and postoperatively for 4 days
223835626|NCT01107730|DRUG|L-Carnitine|L-Carnitine intravenously (2 gr/day \[1grX2\] for 2 days prior to surgery, and postoperatively for 4 days
223835627|NCT01107730|DRUG|Placebo|Placebo
223835628|NCT06348537|DIETARY_SUPPLEMENT|Olive Polyphenols|Patients with fibromyalgia of Group 1 will consume Olive Polyphenols daily during 60 days.
223835629|NCT06348537|DIETARY_SUPPLEMENT|Placebo|Patients with fibromyalgia of Group 2 will consume a placebo daily during 60 days.
223835630|NCT05796960|PROCEDURE|Thyroidectomy with or without lymphadenectomy or multivisceral resection|Lymph node dissection, as well as its surgical extension, was performed according to the surgeon's discretion. Multivisceral operations involved oesophagus, trachea and larynx.
223835631|NCT03981536|DRUG|AP-101|Administered by intravenous infusion (IV)
223835632|NCT00992160|DRUG|GW597599|GW597599 15mg tablet
223835633|NCT00992160|DRUG|Placebo|Placebo to match GW597599 15mg tablet
223835634|NCT00435903|DEVICE|Palm Pilot|
223835635|NCT05851690|PROCEDURE|Surgical treatment of pilonidal sinus disease|Advancement flap techniques in surgical treatment of pilonidal sinus disease.
223835636|NCT02040090|DRUG|Active rabies vaccine (US-FDA approved)|A 1.0 ml dose of active vaccine (2.5 IU/ml), will be given on 5 occasions, on Days 0, 3, 7, 14, and 28 On day 0, the day when the HRIG is given, the first vaccine dose could be given within few minutes from the time of HRIG injection was given and never be administered into the same anatomical site as the HRIG.
223835637|NCT01005628|DRUG|bortezomib|Injection into a vein 1.3 mg/m2 twice a week for 21 days
223835638|NCT03037229|DEVICE|Smartphone ECG|
223835639|NCT03037229|DEVICE|Standard 12-lead ECG|
223835640|NCT00001493|GENETIC|peripheral blood progenitor cells carrying MDR1|
223835641|NCT03086824|DEVICE|magnetic resonance-guided focused ultrasound|
223835642|NCT01978275|DEVICE|stimulong 100, pajunk, germany|simulating catheter
223835643|NCT01978275|DEVICE|plexolong 100, pajunk, germany|nonstimulating catheter
223835644|NCT04915703|PROCEDURE|Flushing of PTBD catheter|flushing of internal external PTBD catheter 3 times a day
223835645|NCT04648891|DRUG|Lidocaine|Subcutaneous injection 0.5cc 2% in 1:100,000 epinephrine
223831905|NCT00141687|PROCEDURE|Early ECV between 34 0/7 and 35 6/7 weeks|Early external cephalic version between 34 0/7 and 35 6/7 weeks of gestation
223831906|NCT00141687|PROCEDURE|Delayed ECV at or after 37 0/7 weeks|Delayed external cephalic version at or after 37 0/7 weeks of gestation
223831907|NCT00581113|RADIATION|Radiotherapy|Treatments are delivered through parallel opposed or 5 degree RAO/LAO fields that cover the entire cranial contents. There should be beam fall-f of at least 1 cm. The eyes must be excluded from the beam either by field arrangement or shielding.
223831908|NCT02775747|BIOLOGICAL|platelet rich plasma gel|Platelet rich plasma is prepared from fresh whole blood which is collected from a peripheral vein stored in acid citrare dextrose solution A (ACD-A)anticoagulant and processed to increase platelets by separating various components of blood
223831909|NCT02775747|BIOLOGICAL|saline|64 controlled women with recurrent cesarean section and fullfit to all inclusion and exclusion craiteria will reseve saline injection at time of wound closure
223831910|NCT04814017|PROCEDURE|Radial Shock-Wave Therapy|Radial shock-wave therapy was applied in 1.0-4.0 bar intensity, 10-15 hz frequency interval. 300-700 pulse for a trigger point, 1500-3000 pulse for a muscle. Intensity, frequency and pulse increased every session regularly beginning from minimal taking patients tolerance into consideration. Trigger points in the upper, middle and lower trapezius, supraspinatus, infraspinatus and levator scapula muscles were treated. Neck and upper back muscle static stretching exercises were teached to patients as home exercise program. The patients were asked to do each stretching exercise given as a home-based program every day, 3 times a day and 3 repetitions. The exercise program consisted of static neck lateral flexors stretching, shoulder posterior capsule stretching and apley stretching exercises. Exercise booklets were prepared and given to the patients.
223831911|NCT04814017|PROCEDURE|Control|Neck and upper back muscle static stretching exercises were teached to patients as home exercise program. The patients were asked to do each stretching exercise given as a home-based program every day, 3 times a day and 3 repetitions. The exercise program consisted of static neck lateral flexors stretching, shoulder posterior capsule stretching and apley stretching exercises. Exercise booklets were prepared and given to the patients.
223831912|NCT00619476|DRUG|GEn 1200mg/day|gabapentin enacarbil 1200mg/day
223831913|NCT00619476|DRUG|GEn 2400mg/day|gabapentin enacarbil 2400mg/day
223831914|NCT00619476|DRUG|GEn 3600mg/day|gabapentin enacarbil 3600mg/day
223831915|NCT00619476|DRUG|Placebo|placebo
223831916|NCT03753321|DIETARY_SUPPLEMENT|Whey protein|Whey protein isolate supplementation, individually adjusted to reach a total protein intake of 1.5 g/kg body weight/day for 10 days (7 days pre-loading and 3 days during trials 1 and 2)
223831917|NCT03753321|DIETARY_SUPPLEMENT|Soy protein|Soy protein isolate supplementation, individually adjusted to reach a total protein intake of 1.5 g/kg body weight/day for 10 days (7 days pre-loading and 3 days during trials 1 and 2)
223831918|NCT03753321|DIETARY_SUPPLEMENT|Placebo (maltodextrin)|Isoenergetic placebo (maltodextrin) for 10 days (7 days pre-loading and 3 days during trials 1 and 2
223831919|NCT06301659|BEHAVIORAL|routine rehabilitation therapy|The Participants with stable vital signs were scheduled for specialized rehabilitation training upon enrollment, and targeted rehabilitation programs were selected based on the patient's specific limb function impairment, conducted by experienced rehabilitation therapists.
223831920|NCT06301659|BEHAVIORAL|Modified mirror therapy|The patients were instructed to watch the recorded video and imitate the movements of their affected limbs. After the video ended, only the instructions and synchronized music were played. The patient was required to sit in front of a mirror table, with the mirror placed between both arms and facing the healthy side. The patient was required to recall the video based on the verbal instructions while using the healthy side to perform movement training. They were also asked to observe the reflected motion of the healthy limb in the mirror, simultaneously imagining the affected limb moving in sync (the patient focused on the front of the mirror, avoiding direct eye contact with the healthy hand, to create the sensation that it was the affected hand performing the movements).
223831921|NCT01062815|DIETARY_SUPPLEMENT|Parenteral Nutrition|Parenteral Nutrition infused over 20 hours cycled with dextrose solution over 4 hours compared to Parenteral Nutrition infused continuously over 24 hours.
223831922|NCT01820468|BEHAVIORAL|Adapted critical time intervention team|
223831923|NCT02711176|DRUG|Nexium|Patients in experimental group will receive the 14 day single dose of Nexium 40 mg daily
223831924|NCT02711176|DRUG|Tinafas|Patients in experimental group will receive the 14 day single dose regimen of Tinafas 1 g daily
223831925|NCT02711176|DRUG|Tavanex|Patients in experimental group will receive the 14 day single dose of Tavanex 500 mg daily
223831926|NCT02711176|DRUG|Lanzol|Patients in active comparator group will receive the 14 day lansoprazole (Lanzol) 30 mg twice daily
223831927|NCT02711176|DRUG|Klacid|Patients in active comparator group will receive the 14 day clarithromycin (Klacid) 500 mg twice daily twice daily
223831928|NCT02711176|DRUG|Iramox|Patients in active comparator group will receive the 14 day amoxicillin (Iramox) 1 g twice daily
223831929|NCT01783093|OTHER|Data Collection|Collection of data from existing medical records
223831930|NCT01564082|DEVICE|ETT First (GlideScope)|Patients will have the endotracheal tube (ETT) introduced into the pharynx under direct vision prior to GlideScope insertion. The ETT will then be advanced under GlideScope guidance into the trachea.
223831931|NCT04084743|OTHER|Virtual reality intervention|Virtual reality intervention includes: Maze game software
223831932|NCT04084743|OTHER|Dual task intervention|The intervention combined both motor and cognitive training which includes, walking 10 meter (1) Free walking (2) Walking carrying an emptying tray (3) Walking carrying a tray with 4 empty glasses (4) Digit calculations (Counting forward and backward, addition, subtraction, multiplication and division) during walking.
223831933|NCT04084743|OTHER|Conventional physiotherapy|"1. Gait training in parallel bar~2. Balance activities which includes, a. Forward direction activity b. Backward direction activity c. Sideways direction activity"
223831934|NCT04218760|DRUG|Isosorbide Mononitrate 60 MG Extended Release Oral Tablet [Imdur]|1 tablet Isosorbide Mononitrate 60 mg administrated orally.
223831935|NCT04218760|OTHER|Blood sample|3 blood samples from a periferal vein, two for RNA and one for metabolomics are taken right before administration of isosorbide mononitrate, 3 hours after administration of isosorbide mononitrate and again 5 hours after administration of isosorbide mononitrate.
223831936|NCT04170660|DIAGNOSTIC_TEST|Diagnostic test|During a vascular check-up usually prescribed, an additional blood sample is taken to allow the determination of the sFlt1/PlGf ratio.
223831937|NCT03673371|OTHER|Questionnaire|This is a questionnaire developed by DoD and VA researchers specifically for this study.
223835646|NCT04648891|DEVICE|Vibrating wand|a vibrating instrument held adjacent to the cricothyroid space
223835647|NCT05495061|DRUG|STN1012600 ophthalmic solution 0.002%|1 drop STN1012600 ophthalmic solution 0.002% once daily for 3 months
223835648|NCT05495061|DRUG|Latanoprost ophthalmic solution 0.005%|1 drop Latanoprost ophthalmic solution 0.005% once daily for 3 months
223831938|NCT05398354|BEHAVIORAL|Active retirement|"During the intervention, the sensorimotor training program will have a progressive increase in load, the exercises will be divided into 3 levels of intensity: easy (without external load, during the first 8 weeks), intermediate (application of external load: elastic bands, shin guards and free weights, from the 9th to the 16th week) and advanced (increased external load compared to the previous level, from the 17th to the 24th week).~During the sessions we will still assess the intensity through the subjective perception of effort (RPE) scale. In addition, adherence and control of the level of control through the Physical Activity Enjoyment (PACES) survey applied to participants."
223831939|NCT06139484|DEVICE|Transcranial Magnetic Stimulation|The stimulations were performed by Magstim RAPID.
223831940|NCT03715374|PROCEDURE|Periodontal Surgery with PRF+ABB|Patients will be treated by periodontal surgical flaps with the addition of PRF+ Anorganic Bovine Bone filling material
223831941|NCT03715374|PROCEDURE|Periodontal Surgery with Collagen Membrane +ABB|Patients will be treated by periodontal surgical flaps with the addition of Collagen Membrane + Anorganic Bovine Bone filling material
223831942|NCT01801384|BEHAVIORAL|Voucher-based incentives|
223831943|NCT06121518|DRUG|D064 and D702, QD|Experimental Group Subjects assigned to this group are treated with D064, D702
223831944|NCT06121518|DRUG|D064 and Placebo of D702, QD|Comparator Group Subjects assigned to this group are treated with D064, placebo of D702
223831945|NCT06121518|DRUG|Placebo of D064 and D702, QD|Comparator Group Subjects assigned to this group are treated with D702, placebo of D064
223831946|NCT03079115|DRUG|High-dose Atorvastatin|high-dose Atorvastatin (80 mg QD from 3 days before to 3 days after CAS, and thereafter 20mg QD until 30 days after CAS)
223831947|NCT03079115|DRUG|Conventional-dose Atorvastatin|conventional-dose Atorvastatin(20 mg QD from 3 days before to 30 days after CAS).
223831948|NCT06458660|BEHAVIORAL|LPP+: Mindfulness Meditation Delivered|During the 6-week intervention period, participants will receive reminder SMS text messages at a time selected by the participant at 48 and 24-hrs before each scheduled study visit. Within 24 hours after every session, participants will receive an SMS text reminder to complete a session satisfaction survey. If the satisfaction surveys are not completed within 48 hours after each session, participants will receive an additional SMS text message once per day for three consecutive days after each planned study visit. Twenty-four hours before each scheduled study visit after study visit number 1, participants will an SMS text requiring a one-character response (1= yes, 2=no), asking if participants practiced any mindfulness meditation techniques since the last session. Participants who have not interacted with the app during the previous week will receive an accountability call to assess barriers to participation.
223831949|NCT06458660|BEHAVIORAL|LP|LinkPositively is a culturally tailored, trauma-informed smartphone app for Black women living with HIV/AIDS affected by interpersonal violence. Core components of LinkPositively include: a) Virtual Peer Navigation that includes phone and text check-ins and 4 weekly one-on-one video sessions to build skills to cope with barriers and navigate care; b) Social Networking platform to receive peer support; c) Educational and Self-care database with healthy living and self-care tips; d) GPS-enabled Resource Locator for HIV care and ancillary support service agencies; and e) ART self-monitoring and reminder system.
223831950|NCT02334319|DRUG|Ganetespib|Given IV
223831951|NCT02334319|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
223831952|NCT02334319|OTHER|Laboratory Biomarker Analysis|Correlative studies
223831953|NCT01625910|BEHAVIORAL|Behavioral counseling|Counseling of parents to improve their child's diet and physical activity
223831954|NCT02873299|OTHER|10 Hz rTMS of the right dorsolateral prefrontal cortex|Ten sessions of 10 Hz rTMS of the right dorsolateral prefrontal cortex
223831955|NCT02873299|OTHER|20 Hz rTMS of the right dorsolateral prefrontal cortex|Ten sessions of 20 Hz rTMS of the right dorsolateral prefrontal cortex
223831956|NCT02959138|DRUG|Lanraplenib.|20 mg (2 X 10 mg) tablets administered orally in a fasted state on Day 1
223831957|NCT02158650|BEHAVIORAL|Video-Based Informed Consent|
223831958|NCT02880449|BEHAVIORAL|Intervention|A PA promoting intervention which provides education, social support and information about local opportunities for PA to pre-existing groups of older women living in socio-economically disadvantaged areas
223831959|NCT01463917|DRUG|Hypertonic solution|Use of Hypertonic solution 4 ml/Kg during left marginal branch CABG surgery.
223831960|NCT01463917|DRUG|Isotonic|Use of Isotonic solution 4 ml/Kg during left marginal branch CABG surgery.
223831961|NCT00006040|BIOLOGICAL|filgrastim|
223831962|NCT00006040|DRUG|etoposide|
223831963|NCT00006040|PROCEDURE|autologous bone marrow transplantation|
223831964|NCT00006040|PROCEDURE|peripheral blood stem cell transplantation|
223831965|NCT00006040|RADIATION|yttrium Y 90 monoclonal antibody M195|
223831966|NCT06455761|DRUG|68Ga-DOTA-NI-FAPI04|Intravenous injection of one dosage of 111-148 MBq (3-4 mCi) 68Ga-DOTA-NI-FAPI04. Tracer doses of 68Ga-DOTA-NI-FAPI04 will be used to detect tumors by PET/CT.
223831967|NCT06455761|DRUG|68Ga-FAPI/18F-FDG|Intravenous injection of one dosage of 111-148 MBq (3-4 mCi) 68Ga-FAPI or 3.7 MBq (0.1 mCi)/Kg 18F-FDG. Tracer doses of 68Ga-FAPI/18F-FDG will be used to detect tumors by PET/CT.
223831968|NCT02464111|OTHER|Treatment 1: Control|No supplement provided.
223831969|NCT02464111|DIETARY_SUPPLEMENT|Treatment 2: Bolus (LNS)|One LNS supplement provided in a single bolus dose in the morning
223831970|NCT02464111|DIETARY_SUPPLEMENT|Treatment 3: Divided Dose (LNS)|One LNS supplement provided in 3 separate portions throughout the study visit
223831971|NCT01912820|DIETARY_SUPPLEMENT|green tea extract|Given PO
223831972|NCT01912820|DRUG|quercetin|Given PO
223831973|NCT01912820|OTHER|placebo|Given PO
223831974|NCT01912820|PROCEDURE|therapeutic conventional surgery|Undergo prostatectomy
223831975|NCT01912820|OTHER|laboratory biomarker analysis|Correlative studies
223831976|NCT03693820|DRUG|the infiltration group|"* 15-20 ml periportal,~* 50 ml in gallbladder bed,~* The rest (about 150 ml in 70 Kg patient) will be intraperitoneal"
223831977|NCT03693820|DRUG|the control group|the 50 ml prepared for gallbladder bed infiltration will be replaced by saline.
223831978|NCT03660722|OTHER|blood and urinary samples|blood samples, rectal and urethral swabs , urine samples at inclusion, after 4 weeks then 12 weeks
223831979|NCT01327547|DRUG|Maraviroc|150mg, 300mg or 600mg twice daily x 144 weeks; dosing dependent on components of the current suppressive anti-HIV therapy
223831980|NCT01327547|DRUG|Placebo|150mg, 300mg or 600mg twice daily x 144 weeks; dosing dependent on components of the current suppressive anti-HIV therapy
223831981|NCT00832143|BEHAVIORAL|Referral Card with one-to-one counseling|A Referral Card (Neonatal Well-Being Card) along with one-to-one counseling to mothers within 48 hours of institutional delivery
223831982|NCT05305937|DEVICE|MRI scan|All patients will be scanned twice during the same MRI session, before and 2 hours after taking glucosamine orally. In addition to the CEST scans with glucosamine, patients will undergo MRI scans with the standard contrast agent of gadolinium. This procedure will be done following the CEST scan
223831983|NCT03918915|DRUG|SYD-101 Dose 1|Sterile topical ophthalmic solution
223831984|NCT03918915|DRUG|SYD-101 Dose 2|Sterile topical ophthalmic solution
223831985|NCT03918915|DRUG|Vehicle|Sterile topical ophthalmic solution without active ingredient
223831986|NCT02023138|OTHER|Focus group|Two hours focus group to allow the participants to modify a clinical practice guideline recommendation
223831987|NCT02023138|OTHER|Wiki|A specially tailored interactive communication website (Wiki) to allow the participants to modify a clinical practice guideline recommendation
223831988|NCT01373710|DRUG|Trastuzumab|One injection per week during 8 weeks by lumbar puncture or Ommaya Reservoir. 4 levels of doses are expected from 30 mg to 150 mg
223831989|NCT00440180|DRUG|Anastrozole|1 mg qd for 4 months
223831990|NCT00440180|DRUG|Placebo|Placebo Comparator
223831991|NCT05794919|DRUG|Calcium Hydroxybenzene Sulphonate Dispersible Tablets 0.25g|A generic product manufactured by Hainan Linheng Pharmaceutical Co., Ltd.
223831992|NCT05794919|DRUG|Calcium Hydroxybenzene Sulfonate Tablets（Doxium®) 250mg|Calcium Hydroxybenzene Sulfonate Tablets（Doxium®）produced by OM pharma S.A.
223831993|NCT04846205|DIAGNOSTIC_TEST|systematic etiological|"Theses following tests are made as usual practice :~* Ventilator polygraphy, or polysomnography between 1 month and 1 year after cryptogenic ischemic stroke.~* Transoesophageal ultrasound"
223831994|NCT00351923|BIOLOGICAL|MeMuRu-OKA (study vaccine)|
223831995|NCT06080230|BEHAVIORAL|Participants in the 8-week program|Psychological resilience program based on positive psychotherapy was applied to nurses
223831996|NCT04545294|DEVICE|Theta tACS|See detail in arm/group descriptions regarding the intervention.
223831997|NCT04532151|DIAGNOSTIC_TEST|Non-invasive skin imaging assessment|"Intervention Description : (Limit: 1000 characters) Do not repeat information already included in arm/group descriptions. Specify details not covered in associated Arm~One session of Non-invasive skin imaging assessment contained:~* an examination on LC-OCT~* an examination on LC-OCT-doppler~* a fluid silicone molding~* an examination on HD ultrasound~The measurements will be applied on 3 skin sites: the dorsal surface of the finger, the inner face and the outer surface of the forearm.~The imaging assessment lasts 30 minutes in a dimly lit room where the humidity and temperature are stable."
223831998|NCT01439087|DEVICE|MGH Optical Frequency Domain Imaging (OFDI) System|Imaging of Colonic Polyps with OFDI system
223831999|NCT01391143|BIOLOGICAL|MGA271|"Up to 9 dose escalation cohorts will be enrolled to determine the maximum tolerated dose of MGA271. Patients with evidence of clinical benefit will be allowed to continue therapy at the same dose once per week for 3 weeks out of every 4-week cycle until documented progression.~Patients treated in the Expansion Segment at the maximum administered dose will receive weekly, uninterrupted infusions of MGA271 in 8 week cycles for up to 12 cycles."
223832000|NCT05827666|DIETARY_SUPPLEMENT|2% milk beverage|Protein provided at 0.3 g/kg fat-free mass. All other conditions (almond, soy and rice milk alternative beverages) will be matched to the same energy content (i.e., isoenergetic). Macronutrient content of beverage (per 100 g): Calories: 52 kcal; Fat: 2.25 g; Carbohydrates: 4.8 g; Protein: 3.3 g.
223832001|NCT05827666|DIETARY_SUPPLEMENT|Almond milk alternative beverage|Matched to the same energy intake as 0.3 g/kg FFM of 2% milk. Macronutrient content of beverage (per 100 g): Calories: 24 kcal; Fat: 1.13 g; Carbohydrates: 3.1 g; Protein: 0.3 g.
223832002|NCT05827666|DIETARY_SUPPLEMENT|Soy milk alternative beverage|Matched to the same energy intake as 0.3 g/kg FFM of 2% milk. Macronutrient content of beverage (per 100 g): Calories: 39 kcal; Fat: 1.70 g; Carbohydrates: 3.0 g; Protein: 2.9 g.
223832003|NCT05827666|DIETARY_SUPPLEMENT|Rice milk alternative beverage|Matched to the same energy intake as 0.3 g/kg FFM of 2% milk. Macronutrient content of beverage (per 100 g): Calories: 49 kcal; Fat: 1.09 g; Carbohydrates: 9.8 g; Protein: 0.1 g.
223832004|NCT03751540|PROCEDURE|ostap|this block is performed under general anesthesia in this patients for postoperative analgesia.
223832005|NCT03751540|PROCEDURE|SIPB plus rectus sheath block|this block is performed under general anesthesia in this patients for postoperative analgesia.
223832006|NCT06320522|DIETARY_SUPPLEMENT|Ketone Monoester|Commercial dietary supplement intended raise blood ketone body levels
223832007|NCT06320522|DIETARY_SUPPLEMENT|Placebo|Placebo drink (2mM sucrose octaacetate) taste and volume matched to the ketone monoester drinks
223832008|NCT03093519|DRUG|KHK6640|Intravenous administration
223832009|NCT03093519|DRUG|Placebo|Intravenous administration
223832010|NCT03675724|DIETARY_SUPPLEMENT|Fisetin|Flavonoid Family
223832011|NCT03675724|DRUG|Placebo oral capsule|Placebo
223832012|NCT02338921|DRUG|Sitagliptin|"100mg qd per oral during 24months~compared with other treatment groups"
223832013|NCT02338921|DRUG|Dapagliflozin|"10mg qd per oral during 24months~compared with other treatment groups"
223832014|NCT02338921|DRUG|Lobeglitazone|"0.5mg qd per oral during 24months~compared with other treatment groups"
223832015|NCT02338921|DRUG|Glimepirde|
223832016|NCT02338921|DRUG|Metformin|
223832017|NCT05599880|DRUG|Bortezomib|Bortezomib is administered at 1.3mg/m2 iv or sc on each Cycly Day1, Days4, and Days8. Bortezomib is administered every 3 weeks for a total of 3 cycles. Thereafter, follow-up is scheduled for 12 months.
223832018|NCT01807143|OTHER|laboratory biomarker analysis|Correlative studies
223832019|NCT03635138|OTHER|Metal nanoparticles ( O Zn and Cu)|Np of OZn nanoparticles mixed with dental adhesive
223832020|NCT03635138|OTHER|Dental Adhesive pure|Dental Adhesive with commercial preparation
223832021|NCT01004419|DRUG|ZD6474 (vandetanib)|vandetanib (100 mg or 200 mg or 300 mg) by mouth once daily for 28 days
223832022|NCT01004419|DRUG|Faslodex (Fulvestrant)|Fulvestrant 500 mg intra-muscular injection on Day 1 and 250 mg Day 15 of cycle 1 Cycles 2 and beyond: Fulvestrant 500 mg intra-muscular injection on Day 1, every 28 days.
223832023|NCT00696085|BEHAVIORAL|Brief motivational intervention|The women who have positive alcohol screening questionnaires and a random sample of women who screen negative are entered into the next phase of the study. They have blood drawn for the markers of alcohol use, are told of the results and are given brief intervention about alcohol use.
223832024|NCT03891459|BEHAVIORAL|spray+ manipulation|Participants in spray+ group received placebo manipulation and were told they sprayed was oxytocin (in fact, it was saline);
223832025|NCT03891459|BEHAVIORAL|control manipulation|Participants in control group were told they sprayed saline (in fact, it was saline).
223832026|NCT05568485|OTHER|Telerehabilitation was applied to the group with rheumatism|Telerehabilitation was applied to the group with rheumatism in 3 sessions a week for 24 weeks via a social texting program. The intervention sessions consisted of 10 minutes of dance therapy-authentic movement, 40 minutes of exercises, and 10 more minutes of dance therap
223832027|NCT06190158|DIAGNOSTIC_TEST|Oral sodium suppression test|Oral sodium suppression test (\~2 grams of supplemental sodium for 3 days)
223832028|NCT06190158|DIAGNOSTIC_TEST|Saline suppression test|Saline suppression test (2 liters of saline)
223832029|NCT06190158|DIAGNOSTIC_TEST|Captopril suppression test|Captopril suppression test (50mg of captopril)
223832030|NCT06190158|DIAGNOSTIC_TEST|Dexamethasone suppression test|1mg of dexamethasone
223832031|NCT06190158|DIAGNOSTIC_TEST|Cosyntropin stimulation test|250mcg of cosyntropin
223832032|NCT01642186|DRUG|everolimus|
223832033|NCT01642186|DRUG|letrozole plus leuprolide|
223832034|NCT01642186|DRUG|combination of everolimus, letrozole and leuprolide|
223832035|NCT01511627|DRUG|General Anesthesia + Spinal anesthesia combined|"All patients will receive a preoperative multimodal analgesic regime:~* Tylenol® 975mg per os~* Naproxen® 500 mg per os~Patients will receive a spinal anesthetic with:~* Bupivacaine 0.5% 10 mg~* Fentanyl 10ug~* Epidural Morphine 150ug~After the spinal, a general anesthetic will be induced using:~* Midazolam 1 - 2 mg intravenously~* Fentanyl 1 - 2 ug/kg intravenously~* Propofol 1-3 mg/kg intravenously~* Rocuronium 0.3 - 0.9mg/kg intravenously~* followed by endotracheal intubation. Maintenance of anesthesia with sevoflurane, oxygen and air.~* Intraoperative Morphine 0 - 0.3mg/kg or Fentanyl 0 - 7.5ug/kg to maintain MAP and heart rate within 20% of baseline.~* Phenylephrine and Ephedrine can be used to support blood pressure and heart rate within 20% of baseline.~* Dexamethasone 4mg and Ondansetron 4mg intravenously~* Neostigmine 3mg and Glycopyrrolate 0.6mg intravenously Patients will receive a Morphine PCA to be initiated in the Post Anesthetic Care Unit (PACU)."
223832036|NCT01511627|DRUG|General Anesthesia (control group)|"All patients will receive a preoperative multimodal analgesic regime:~* Tylenol® 975mg per os~* Naproxen® 500 mg per os~Group I (General anesthetic) patients will receive a general anesthetic :~* Midazolam 1 - 2 mg intravenously~* Fentanyl 1 - 2 ug/kg intravenously~* Propofol 1-3 mg/kg intravenously~* Rocuronium 0.3 - 0.9mg/kg intravenously~* followed by endotracheal intubation. Maintenance of anesthesia with sevoflurane, oxygen and air.~* Intraoperative Morphine 0 - 0.3mg/kg or Fentanyl 0 - 7.5ug/kg. to maintain MAP and heart rate within 20% of baseline.~* Phenylephrine and Ephedrine can be used to support blood pressure and heart rate within 20% of baseline.~* Dexamethasone 4mg and Ondansetron 4mg intravenously~* Neostigmine 3mg and Glycopyrrolate 0.6mg intravenously~Patients will receive a Morphine PCA as per protocol that will be initiated in the Post Anesthetic Care Unit (PACU)."
223832037|NCT04802642|OTHER|Survey|Survey
223832038|NCT04316455|OTHER|Integrative Yoga Therapy|Participants having an hour in-person weekly session with qualified yoga therapist for 6-weeks. At each session, the personalised yoga practices including straightening and relaxing posture of yoga, yoga breathing, Combinations of sound and imagery yoga practices were given and asked to continue practice at home during the week.
223832039|NCT00451997|DRUG|Gleevec|600 mg (capsules) by mouth once daily
223832040|NCT00451997|DRUG|Ara-C|10 mg as an injection under the skin daily for 21 days of every 28 day cycle
223832041|NCT05652855|DRUG|MHB088C for Injection|MHB088C for Injection, an antibody drug-conjugated molecule (ADC)
223832042|NCT00124800|BEHAVIORAL|Tinnitus retraining therapy|Sound therapy and counseling
223832043|NCT00124800|DEVICE|Sound therapy|sound therapy and counselling
223832044|NCT01025661|OTHER|Chiropractic care|Clinical examinations and treatments were performed at the outpatient clinic. The patients were assessed and treated by research assistants and the clinical care was supervised by state registered chiropractors. The choice of therapy and modality was pragmatic and based on the analysis of different functions such as mobility, tenderness, muscle tension and tone, and each patient's relative symptoms. Chiropractic care included high-velocity and low-amplitude techniques, soft-tissue or myofascial techniques, and arthrokinematic stabilizing exercises or a combination of these. Patients were treated in 1-2 sessions per week during the trial.
223832045|NCT03459820|DIAGNOSTIC_TEST|18F-DCFPyL PET/CT|18F-DCFPyL Positron Emission Tomography/Computed Tomography Scan
223832046|NCT04107103|DRUG|Combination Product: Nivolumab with Pemetrexed|Nivolumab 3 mg/kg IV q.2 weekly in combination with pemetrexed 500mg/m2 q.6weekly. Treatment with nivolumab will continue every 14-days, and pemetrexed treatment will continue every 42-days. Treatment continues until disease progression or toxicity resulting in treatment discontinuation or until 2 years of treatment.
223832047|NCT02802020|DEVICE|Pancreatic fully-covered self-expanding metal stent (FCSEMS)|The WallFlex™ Pancreatic RX Fully Covered Soft Stent System consists of a flexible delivery system preloaded with a self-expanding pancreatic metal stent.
223832048|NCT00285090|DIETARY_SUPPLEMENT|Calcium, Vitamin D|
223832049|NCT00285090|DIETARY_SUPPLEMENT|Calcium,Vitamin D|
223832050|NCT00285090|DIETARY_SUPPLEMENT|Calcium, VitaminD|
223832051|NCT00285090|OTHER|Sugar Pill|
223832052|NCT01691989|DRUG|aleglitazar|150 mcg orally once a day for 26 weeks
223832053|NCT01691989|DRUG|placebo|oral doses once a day for 26 weeks
223832054|NCT05218122|OTHER|cross-sectional study without intervention|cross-sectional study without intervention
223832055|NCT00506285|DRUG|Methylphenidate Transdermal System (MTS)|MTS is an advanced patch product that provides methylphenidate evenly mixed with the adhesive. This formulation allows good adhesion and a wide range of dose sizes. MTS patch sizes of 12.5, 18.75, 25 and 37.5cm2 are equivalent to nominal doses over a 9-hour wear time of 10, 15, 20 and 30mg of MPH.
223832056|NCT00506285|OTHER|placebo patch|This patch is designed to appear identical to the actual intervention patch
223832057|NCT06150677|OTHER|Voluntary apnoea|Static apneas at high lung volume with a density of 30 seconds, followed by a normal breath of 10 seconds (9 cycles of 30s apnea - 10s normal breathing, until completing the 6 minutes).
223832058|NCT01089556|DRUG|Duloxetine|Administered orally
223832059|NCT01089556|DRUG|Pregabalin|Administered orally
223832060|NCT01089556|DRUG|Placebo|Administered orally, daily as a blind for duloxetine and/or pregabalin for 8 or 16 weeks
223832061|NCT05054829|BEHAVIORAL|PEERS®: program for the education and enrichment of relational skills|providing evidence-based social skills treatment to preschoolers, adolescents, and young adults with autism spectrum disorder (ASD)
223832062|NCT01238575|OTHER|placebo|Administered for up to 8 weeks.
223832063|NCT01238575|DRUG|extended-release guanfacine|1 mg tablets; flexible dosing up to 4 mg/day for up to 16 weeks
223832064|NCT02128503|OTHER|HBV DNA level monitoring|HBV DNV level being monitoring regularly
223832065|NCT04509765|RADIATION|Linac Based VMAT TBI|Use of linac based Volumetric Arc Therapy (VMAT) to deliver Total Body Irradiation (TBI). The study intervention is a VMAT based delivery technique using a 6 MV photon beam from a Varian TrueBeam® (Palo Alto, CA) equipped with a Millennium multi-leaf collimation (MLC) system3. TBI will be delivered using a Varian TrueBeam linear accelerator with photon beam VMAT capability. VMAT is a radiation technique combining dynamic photon fluence modulation using multi-leaf collimation (MLC) with gantry rotation to deliver a highly conformal dose distribution with improved target coverage and sparing of organs at risk (OARs).
223832066|NCT02137538|DRUG|Letrozole|
223832067|NCT02137538|DRUG|Anastrozole|
223832068|NCT01577030|DIETARY_SUPPLEMENT|Non-fat dairy|Add 4 daily servings per day of non-fat dairy (yogurt, milk, cheese) for a period of 4 weeks
223832069|NCT01577030|DIETARY_SUPPLEMENT|Add 4 servings fruit|Add 4 daily servings of fruit (fruit cup, apple sauce, orange juice) and remove all dairy for a period for 4 weeks
223832070|NCT02702258|BEHAVIORAL|MB-BP|MB-BP (Mindfulness-Based Blood Pressure Reduction) customizes Mindfulness-Based Stress Reduction (MBSR) to participants with prehypertension/hypertension. MB-BP will consist of nine 2.5-hour weekly group sessions and an 7.5-hour one-day session. Some of the unique areas of MB-BP are education on hypertension risk factors, hypertension health effects, and specific mindfulness modules focused on awareness of blood pressure determinants such as diet, physical activity, antihypertensive medication adherence, alcohol consumption, and stress reactivity. Students learn a range of mindfulness skills including body scan exercises, meditation and yoga. Homework consists of practicing skills for ≥45 min/day, 6 days/week.
223832071|NCT05193942|BEHAVIORAL|Intervention Our Plan|From day 1 to day 120 (i.e., entire 4 month duration) of the trial, participants randomized to the intervention arm will be granted access and instructed to use the Our Plan program as directed. The Our Plan program includes modules covering topics of communication, decision-making, HIV/STI prevention, and stigma and discrimination. Each module contains content, questions, and activities for the participant and couple to complete. One goal of OurPlan is to help both partners of the couple create and use a risk- reduction plan of evidence-based prevention strategies over time. Answers provided during the assessments will help determine whether participants/couples created a risk-reduction plan and used evidence-based strategies over time, including changes in their own confidence, intention, and perceived ability to use these strategies.
223832072|NCT05193942|BEHAVIORAL|Internation Informational Control|From day 1 to day 120 (i.e., entire 4 month duration) of the trial, participants randomized to the informational control condition will receive a webpage that contains information about HIV/STI prevention options and resources. This control condition represents the current equivalent of a standard of care for online HIV resources.
223832073|NCT03638856|DRUG|Misoprostol 200Mcg Tab|patient takes 2 tab of 200 mcg of Misoprostal 3 hr before hysteroscopy
223832074|NCT03449459|DIETARY_SUPPLEMENT|oral probiotics|"Culturelle™ DIGESTIVE HEALTH 30 CT(VCAP)(10 Billion Claim) which consists of 100% Lactobacillus rhamnosus GG, 1 tablet, q.d., for 3 months.~Subjects will take conventional therapy at the same time."
223832075|NCT03449459|DRUG|aerosol inhaled amikacin|"0.4g Amikacin sulfate injection + 5ml saline, aerosol inhalation, b.i.d., 5-7 days per month, for 3 months.~In order to observe and cope with adverse events timely, subjects will be admitted to the ward during the course of medication.~Subjects will take conventional therapy at the same time."
223832076|NCT03449459|BIOLOGICAL|combined vaccination|"Influenza Vaccine recommended by World Health Organization(WHO) in that year and imported 23-Valent Pneumococcal Polysaccharide Vaccine approved by China Food and Drug Administration(CFDA) are vaccinated at different body sites by professional nurses.~The interval between two vaccinations is 3-5 days to avoid the overlap of adverse events.~Subjects will take conventional therapy at the same time."
223832077|NCT02254421|DRUG|Presatovir|Presatovir 200 mg (4 × 50 mg tablets) administered orally or via nasogastric (NG) tube
223832078|NCT02254421|DRUG|Placebo|Placebo to match presatovir administered orally or via nasogastric tube
223832079|NCT05346796|BEHAVIORAL|Survivorship Care Plan-Personal Health Record (SCP-PHR)|The SCP-PHR tool is an online portal that is intended to help cancer survivors manage their survivorship care.
223832080|NCT03498014|OTHER|Pharmacogenetic analysis allowing personalized opioid prescription|Genotypic of patient to determine optimal opioid treatment (tramadol, codeine or oxycodone)
223832081|NCT03498014|OTHER|Standard opioid prescription|Opioid prescription made without reference to patient genetic profile (tramadol, codeine or oxycodone)
223832082|NCT03896451|DEVICE|Total knee endoprothesis|Total knee endoprosthesis after knee joint osteoarthritis
223832083|NCT04288674|OTHER|Retrospective data collection of demographics|Retrospective data collection of demographics from patients with leptospirosis and matching control group patients.
223832084|NCT04288674|OTHER|Retrospective data collection of underlying diseases|Retrospective data collection of underlying diseases from patients with leptospirosis and matching control group patients.
223832085|NCT04288674|OTHER|Retrospective data collection of duration of hospitalization|Retrospective data collection of duration of hospitalization from patients with leptospirosis and matching control group patients.
223832086|NCT06341517|DEVICE|iTBS|Intermittent Theta Burst Stimulation (iTBS) pattern consisting of 2 s trains of 3 pulses at 50 Hz, repeated at 5 Hz, every 10s for a total of 600 pulses for up to 8 sessions daily for 5 days
223832087|NCT05548959|DIAGNOSTIC_TEST|Pneumatonometry after microshunt implantation|Pneumatonometry was perfomed over 24 hours at 5 point in time (5 AM, 11 AM, 4 PM, 8 PM, and midnight) using a Pneumatonometer. The measurement was conducted in the habitual position.
223832088|NCT05548959|DIAGNOSTIC_TEST|Pneumatonometry after ab interno trabeculectomy|Pneumatonometry was perfomed over 24 hours at 5 point in time (5 AM, 11 AM, 4 PM, 8 PM, and midnight) using a Pneumatonometer. The measurement was conducted in the habitual position.
223832089|NCT04621136|DRUG|Ripasudil ophthalmic solution 0.4%|"Phase1 A total of three infants will receive ripasudil eye drops(0.4%) once daily for one week, followed by twice-daily drug administration for two weeks. The three infants who participate in Phase1 can continue to receive the eye drop treatment for additional 9 weeks(12 weeks in total)if the investigators determine that there are no safety issues with ripasudil. In addition, a data and safety monitoring board(DSMB)will be held two times to decide whether the new patients can be enrolled into phase1, and also if phase2 can begin.~Phase2:A total of 21 patients will receive ripasudil eye drops(0.4%)twice daily for 12 weeks."
223832090|NCT02165904|BIOLOGICAL|Adult Autologous Mesenchymal Bone Marrow Cell|Diagnosed patients with incomplete spinal cord injury and chronically established SCI will be treated with Adult Autologous Mesenchymal Bone Marrow Cells.
223832091|NCT01450280|BIOLOGICAL|ChAd63 CS|ChAd63 CS 5x10\^9 vp intra-muscularly Day 0
223832092|NCT01450280|BIOLOGICAL|ChAd63 CS, MVA CS|ChAd63 CS 5x10\^9 vp intra-muscularly Day 0; MVA CS 2x10\^8 pfu intra-muscularly Day 56
223832093|NCT01450280|BIOLOGICAL|ChAd63 CS|ChAd63 CS 5x10\^10 vp intra-muscularly Day 0
223832094|NCT01450280|BIOLOGICAL|ChAd63, MVA CS|ChAd63 CS 5x10\^10 vp intra-muscularly Day 0; MVA CS 2x10\^8 pfu intra-muscularly Day 56
223832095|NCT00252928|OTHER|Sodium dichloroisocyanurate (NaDCC) tablets|Intervention arm receives NaDCC tablets to use for to disinfect their household water for use for 20L of water. Ideally, disinfection occurs every day.
223832096|NCT00252928|OTHER|Placebo|Placebo
223832097|NCT02662595|OTHER|SMS reminder message|
223832098|NCT02662595|OTHER|Voice call + SMS message|
223832099|NCT03389685|BIOLOGICAL|Platelet Rich Plasma|Pure PRPII®, leukocyte-poor, platelet rich plasma
223832100|NCT03389685|OTHER|Saline Placebo|saline solution
223832101|NCT01398436|PROCEDURE|central venous catheter positioning in right atrium|A central venous catheter will be advanced for its entire length unless arrhythmias develop. Catheter position will be controlled by transesophageal echocardiography and/or by chest radiography
223832102|NCT01940653|DRUG|Progesterone|"Procedures Transvaginal ultrasound (US) and hormone analysis for FSH, LH, E2 and P on day 2 of the cycle will be performed. The artificial preparation of the endometrium consists of 7 days oestradiol valerate (Progynova®, Bayer-Schering Pharma AG, Berlin, Germany) 2 mg bid (bi-daily), followed by 6 days oestradiol valerate 2 mg tid (thrice daily). On day 13, the endometrium is measured. If endometrial thickness is more than 7 mm, patients are randomly assigned to group A or B. All patients with an endometrium less than 7 mm on day 13 of estrogen stimulation, are excluded.~Group A receives 5 days of micronized progesterone vaginally (Utrogestan® ((Utrogestan, Besins International), 3x200mg daily), group B receives 3 days of micronized progesterone vaginally. On the 5th (group A) or 3rd (group B) day of progesterone supplementation, the cryopreserved-thawed day 3 embryo is transferred."
223832103|NCT01950273|DRUG|BI 695500|BI695500, once a week for 4 weeks (4 administrations in total)
223832104|NCT01950273|DRUG|MabThera|MabThera, once a week for 4 weeks (4 administrations in total)
223832105|NCT00722813|OTHER|Survey|To determine patient preference for the two tests CT angiography (CTA) and catheter coronary angiography (CCA).
223832106|NCT01428674|OTHER|Interpersonal Mindful Compassion with Touch|A practitioner lightly touches the participant on the hands, arms, shoulders, lower legs and feet while extending loving kindness to the participant.
223832107|NCT01428674|OTHER|Reading while extending loving kindness|The practitioner sits in a room with the participant, pretending to read, while extending loving kindness to the participant.
223832108|NCT05583851|DEVICE|Acceptance and Commitment Therapy|Smartphone app guided and manualized version of acceptance and commitment therapy.
223832109|NCT05583851|OTHER|Psychoeducation Active Control|Set of 11 public seminar videos regarding depression and anxiety. Each are 15 minutes long.
223832110|NCT02230150|BEHAVIORAL|Adhesion-HF|The hypothesis that was investigated is whether the nursing consultation improves therapeutic strategies for membership, adherence to self-care, improved levels of NT-proBNP improves performance in 6-minute walk test, monitoring of biomarkers of laboratory tests (sodium , potassium, urea, creatinine and NT-proBNP) frequent occurrence of readmissions and mortality in patients with heart failure after 1 month.
223832111|NCT05238532|GENETIC|CT303|"Once a time, intravenous injection~* CT303 Starting Dose : 1.0\*10\^6 cells/kg~* CT303 Increasing Quantity Dose : 2.0\*10\^6 cells/kg"
223832112|NCT02418299|DEVICE|IncontiLase Er:YAG laser treatment|Each patient will receive 2-3 sessions of Er:YAG laser treatment for stress and mixed urinary incontinence (IncontiLase)
223832113|NCT04345198|PROCEDURE|Adrenal Artery Ablation|Intervention with adrenal artery ablation is performed in PA patients with resistant hypertension.
223832114|NCT02367014|DRUG|elamipretide (low dose)|elamipretide (0.01 mg/kg/hr) administered as single day intravenous infusion over 2 hours for 5 days
223832115|NCT02367014|DRUG|elamipretide (intermediate dose)|elamipretide (0.10 mg/kg/hr) administered as single day intravenous infusion over 2 hours for 5 days
223832116|NCT02367014|DRUG|elamipretide (high dose)|elamipretide (0.25 mg/kg/hr) administered as single day intravenous infusion over 2 hours for 5 days
223832117|NCT02367014|DRUG|Placebo|placebo (at each dose cohort) administered as single day intravenous infusion over 2 hours for 5 days
223832118|NCT05604287|DRUG|ID119031166M|The participants will receive a single oral dose of ID119031166M or once daily oral doses of ID119031166M for 14 days.
223832119|NCT05604287|DRUG|Placebo|The participant will receive a oral dose of Placebo.
223832120|NCT05872828|OTHER|No intervention|Observational study. No intervention will be adopted.
223832121|NCT02642718|DRUG|Ketorolac Tromethamine|In the operating room, the anesthesiologist administered ketorolac (30 mg) in 50 mL of 0.9 % saline intravenously to patients in the ketorolac group 30 minutes before surgical incision (a single dose).
223832122|NCT02642718|OTHER|Placebo|In the operating room, the anesthesiologist administered 50 mL of 0.9 % saline intravenously to patients in the control group 30 minutes before surgical incision
223832123|NCT05891418|BEHAVIORAL|Two informational emails with plan information|Informational emails about the benefits of Cost-Sharing Reduction Silver plans.
223832124|NCT05891418|BEHAVIORAL|Standard notice of eligibility determination|No extra outreach during intervention period.
223832125|NCT06208072|DRUG|Irbesartan 150mg|Irbesartan group will be treated with Irbesartan 150mg once daily for a total of 8 weeks.
223832126|NCT06208072|DRUG|Eplerenone 25 mg|Eplerenone group will be treated with Eplerenone 25mg twice daily for a total of 8 weeks
223832127|NCT03354637|DRUG|ATI-50002 high dose|Topical solution
223832128|NCT03354637|DRUG|ATI-50002 low dose|Topical solution
223832129|NCT03354637|DRUG|Placebo|Topical solution
223832130|NCT01074749|DEVICE|Accent Pacemaker|Implantation of pacemaker
223832131|NCT04554485|DRUG|Blinatumomab|Single cycle of blinatumomab followed by high-dose chemotherapy in the induction therapy for Ph-negative acute lymphoblastic leukemia in adults
223832132|NCT05571995|BEHAVIORAL|TRIMOSH|TRIMOSH will improve the knowledge, attitude and practice on occupational and health
223832133|NCT01154049|BIOLOGICAL|sm14 antigen plus adjuvant GLA|Healthy adults will receive 3 doses of the vaccine, on days 0, 30 and 60.
223832134|NCT02851836|BEHAVIORAL|image visualization and quotation|"two sets of 60 pictures are shown to the adolescents. we ask them to quote for their valence, hedonicity, arousal and to characterize the emotion elicited in each picture.~This evaluation takes approximately 1hour."
223832135|NCT04238403|BEHAVIORAL|Behavioral Parent Training (MATCH Protocol)|BPT. Behavioral Parent Training (BPT) is a well-established psychosocial intervention for the treatment for ADHD and related behavioral difficulties (e.g., oppositional problems). BPT is based on social learning and operant conditioning principles in which parents are instructed to utilize methods (e.g., praise, effective communication, reward systems, time-out from positive reinforcement) to facilitate positive behaviors in their child (e.g., compliance) and reduce challenging behaviors (e.g., opposition). BPT comes in several manualized, commercially available manuals. The version of BPT that we will be utilizing is from the MATCH protocol (Chorpita and Weisz, 2009), which consists of 10 components, delivered with individual families, typically over the course of 10-16 weekly individual meetings (total meetings depends upon parent availability and acquisition of BPT skills).
223832136|NCT00469365|BEHAVIORAL|pharmacist contact with the patient via telephone|
223832137|NCT00469365|BEHAVIORAL|Pharmacist contact with the patient's physician via fax|
223832138|NCT00469365|BEHAVIORAL|Usual care|
223832139|NCT02438462|OTHER|Soluble Fibrin|Calculating the area under the ROC curve of the Soluble Fibrin assay for the diagnosis of PE before evaluating the diagnostic performance of the assay.
223832140|NCT03871049|DRUG|Bupivacaine with dexamethasone|bupivacaine with dexamethasone
223832141|NCT03871049|DRUG|Bupivacaine|bupivacaine
223832142|NCT01650675|BEHAVIORAL|WIDUS computer-delivered, indirect brief intervention|A single 20-minute interactive computer-delivered intervention designed to promote motivation to change drug use and risky sexual behavior, if any, without presuming those risks to be specifically present.
223832143|NCT01650675|BEHAVIORAL|Nutrition time control/placebo intervention|This time-control intervention, designed in part to help promote RA blinding as to participant condition, focuses on proper infant nutrition using a computer-delivered, interactive format and videos.
223832144|NCT04005547|BEHAVIORAL|Promoting Awareness through Live Movement and Sound for youth with Autism Spectrum Disorder|Session 1 - Let's Talk About Relationships Session 2 - Let's Talk About Intimate Relationships Session 3 - Let's Talk About Sex Session 4 - Let's Talk About Protection Session 5 - Let's Talk About Communication \*Bring your Trusted Adult\* Session 6 - Let's Talk About Growing Up
223832145|NCT04192812|DRUG|PREOPERATİVE GnRHa THERAPY (LEUPROLIDE ACETATE) BEFORE SURGERY FOR UTERİN FIBROIDS|THE EFFICACY OF PREOPERATIVE USAGE OF GnRHa IN PATIENTS UNDERGOING TOTAL LAPAROSCOPIC HYSTERECTOMY DUE TO UTERIN FIBROIDS
223832146|NCT04192812|DRUG|NO GnRHa|THE EFFICACY OF PREOPERATIVE USAGE OF GnRHa IN PATIENTS UNDERGOING TOTAL LAPAROSCOPIC HYSTERECTOMY DUE TO UTERIN FIBROIDS
223832147|NCT00655395|DRUG|Laromustine (VNP40101M) and Ara-C|"1. Laromustine 300 mg/m2 (cohort 1), 400 mg/m2 (cohort 2), 500 mg/m2 (cohort 3) IV on day 1 over 30 - 60 minutes. Laromustine will be administered approximately 3-4 hours following the start of infusional Ara C.~2. Ara C at 100 mg/m2/day as a continuous infusion daily for 7 days. Appropriate antiemetics are given during the Ara C infusion."
223832148|NCT01979055|BEHAVIORAL|Self-regulation intervention|6 session educational intervention (3 telephone, 3 In-person), led by a health educator
223832149|NCT01979055|BEHAVIORAL|Telephone follow-up|Usual care group, will also receive 3 telephone calls to assess any questions they may have about asthma
223832150|NCT04999358|BEHAVIORAL|Protein education|The protein education session is pre-recorded and will describe in lay terms: the health issues associated with low protein intake, the amount of protein to eat in a day, and provide useful information to increase protein intake. This information will focus on the quality and amount of protein eaten, primarily using a whole-food approach. For example, the education sessions will give ideas for everyday foods that can be added to regular meals, favouring plant proteins, fish, lean meat, poultry, low fat dairy and eggs. The education session has been provided in conjunction with an NHS dietitian.
223832151|NCT04999358|BEHAVIORAL|Standard education|Dietary advice provided as part of standard cardiac rehabilitation will be pre-recorded and provided to the control group. This education session will be in addition to usual care.
223832152|NCT02206152|DRUG|N-acetyl cysteine|N-acetyl cysteine (or saline) IV infusion given as a 150 mg/kg loading dose over the first hour and then follow that with a 50 mg/kg maintenance dose infused over the next 4 hours during a controlled hyperinsulinemic hypoglycemic insulin clamp
223832153|NCT02206152|DRUG|Placebo|
223832154|NCT00478608|DRUG|Sirolimus (Rapamune®)|(1mg tablets): Initial loading dose of 6mg/day, followed by maintenance dose of 2mg/day, which was adjusted to specified trough level.
223832155|NCT03263143|OTHER|Palliative Care|Palliative Care Consultation within 24 to 48 hours after admission
223832156|NCT04315623|PROCEDURE|Regional citrate anticoagulation CRRT|Regional citrate anticoagulation Sodium citrate (4%) infusion before the filter in order to maintain post-filter ionCa2+ level between 0.25 to 0.35 mmol/L. Calcium gluconate supplementary after the filter to maintain serum ionCa2+ level between 1.0 to 1.2 mmol/L.
223832157|NCT04315623|PROCEDURE|No-anticoagulation CRRT|Patients accepted no-anticoagulation CRRT. Blood flow 200 ml/h. The replacement fluid was infused 50% predilution and 50% post-dilution.
223832158|NCT02474511|OTHER|general anesthesia and local anesthesia|the patient received generalanesthesia and local anesthesia randomly
223832159|NCT06294015|BIOLOGICAL|20% ASED + AT|Participants receive 20% Autologous Serum Eye Drops prepared by the hospital laboratory from the patients blood, diluted with sterile 0.9% sodium chloride to achieve the desired concentration. These drops are administered 6 times daily in one eye for two months. On top of this intervention is standard artificial tears therapy (Refresh Plus), applied four times daily.
223832160|NCT06294015|DRUG|0.9% NS + AT|Participants in the placebo group receive eye drops consisting of sterile 0.9% sodium chloride solution, which serves as the placebo. The placebo solution is administered 6 times daily in one eye for two months. Alongside the placebo drops, participants continue with standard artificial tears therapy (Refresh Plus), applied four times daily throughout the study duration.
223832161|NCT04188483|DIETARY_SUPPLEMENT|Selenium Supplementation|The selenium supplementation group will receive 200 μg selenium daily by taking two selenium-enriched yeast tablets (SelenoPrecise®, Pharma Nord) once daily for 60 days.
223832162|NCT04188483|BIOLOGICAL|Influenza vaccination|Subjects will receive standard seasonal influenza vaccination for the 2019-2020 season.
223832163|NCT06038812|DIAGNOSTIC_TEST|GCF sample collection|collecting GCF from deepest sites by paper points
223832164|NCT06038812|PROCEDURE|non-surgical periodontal treatment|performing scaling and root planning using ultrasonic device and manual curettes
223832165|NCT00005108|DRUG|Estradiol|
223832166|NCT00005108|DRUG|Progesterone|
223832167|NCT05275751|DRUG|TRPA1-inhibitor|Pharmacological inhibition of TRPA1 during intradermal injection of hot synthetic interstitial fluid
223832168|NCT05275751|DRUG|TRPV1-inhibitor|Pharmacological inhibition of TRPV1 during intradermal injection of hot synthetic interstitial fluid
223832169|NCT05275751|DRUG|TRPM3-inhibitor|Pharmacological inhibition of TRPM3 during intradermal injection of hot synthetic interstitial fluid
223832170|NCT05275751|DRUG|Placebo|No pharmacological intervention
223832171|NCT05275751|DRUG|Chloride-channel inhibitor|Pharmacological inhibition of a chloride channel during intradermal injection of hot synthetic interstitial fluid
223832172|NCT00850044|DRUG|ABT-450|capsules,QD, one dose, see Arm Descriptions for more information
223832173|NCT00850044|DRUG|ritonavir|capsules, QD, one dose, escalating doses, see Arm Descriptions for more information
223832174|NCT00850044|DRUG|placebo for ABT-450|capsules, QD, one dose
223832175|NCT00850044|DRUG|Placebo for ritonavir|capsules, QD, one dose
223832176|NCT02508766|PROCEDURE|Plantar stimulation|The manipulation was performed with the subject in the supine position. The intervention lasted ten minutes and consisted of four stages: 5 glide pressures focused on each interdigital space, that lasted 10 seconds in duration, 5 compression-decompression of each metatarsophalangeal joint, 5 glide pressures applied for 5 seconds each, on the region of metatarsal heads, 5 static pressures applied for 10 seconds each, focused on four points of the sole.
223832177|NCT04182607|PROCEDURE|kidney transplant|Clinical data will be collected from electronic medical records (EMRs) on donors and recipients who underwent a minimally invasive kidney transplantation procedure
223832178|NCT02941068|DRUG|fluconazole and caspofungin|
223832179|NCT03039543|DRUG|Rocuronium|Intravenous rocuronium was used to maintain moderate (TOF count of 1 or 2) neuromuscular blockade for patients with moderate neuromuscular blockade whereas intravenous rocuronium was used to maintain deep (TOF count of 0 with post-tetanic count of 2) neuromuscular blockade for patients with deep neuromuscular blockade.
223832180|NCT03039543|DRUG|Sugammadex|Patients in moderate neuromuscular blockade are reversed with 2 mg/kg sugammadex at a TOF count of 1 or 2 and patients in the deep neuromuscular blockade are reversed with 4 mg/kg sugammadex at post-tetanic count of 2.
223832181|NCT02561715|BEHAVIORAL|Questionnaires|Pre and post deep brain surgery questionnaires
223832182|NCT05554146|OTHER|Receipt of Coupon for Placebo Soft-Gel Capsule|The investigators will follow participants who were randomized to receive a coupon for placebo soft-gel capsule medical cannabis products by our collaborators at Vireo medical cannabis dispensary in a separate study
223832183|NCT05554146|OTHER|Receipt of Coupon for High THC Soft-Gel Capsule|The investigators will follow participants who were randomized to receive a coupon for high THC soft-gel capsule medical cannabis products by our collaborators at Vireo medical cannabis dispensary in a separate study
223832184|NCT05554146|OTHER|Receipt of Coupon for Equal THC and CBD Soft-Gel Capsule|The investigators will follow participants who were randomized to receive a coupon for equal THC and CBD soft-gel capsule medical cannabis products by our collaborators at Vireo medical cannabis dispensary in a separate study
223832185|NCT05554146|OTHER|Receipt of Coupon for High CBD Soft-Gel Capsule|The investigators will follow participants who were randomized to receive a coupon for high CBD soft-gel capsule medical cannabis products by our collaborators at Vireo medical cannabis dispensary in a separate study
223832186|NCT05921721|DEVICE|EOS|This modality simultaneously captures biplanar radiographs (anteroposterior and lateral images) through the whole-body slot scanning with patients in standing position with ultralow irradiation
223832187|NCT03821415|DRUG|RP101|17β-oestradiol-3-phosphate ophthalmic sterile solution
223832188|NCT05511740|RADIATION|Afternoon Radiation|Melatonin, a hormone of the pineal gland, which levels are characteristic of circadian patterns, regulated with low levels of excretion in the afternoon, rises gradually during the night, peaks at dawn, and falls back in the afternoon and late afternoon. Many studies prove the function and potential of melatonin as circadian biomarkers and well correlated with the development of cancer.The function of melatonin is as an antiproliferation substance or hormone, induces apoptosis, inhibits invasion and metastasis.
223832189|NCT04266171|BEHAVIORAL|Diet education based on CGMS data|Intervention group will receive diet education based on CGMS data, using post prandial glucose response, calculated by incremental area under curve of glucose level. Control group will receive conventional diabetes diet education without CGMS data.
223832190|NCT04266171|BEHAVIORAL|Conventional diet education|Control group will receive conventional diabetes diet education without CGMS data.
223832191|NCT00634322|DRUG|glucarpidase|IV dose based on weight, two doses given for 5 minutes, 24 hours apart
223832192|NCT00634322|DRUG|leucovorin|IV or po given every 6 hours
223832193|NCT00783120|OTHER|Repetitive transcranial magnetic stimulation|10 Hz rTMS of left dorsolateral prefrontal cortex (DLPFC) (15 sessions/3 weeks, 1000 stimuli per session, stimulation intensity 110 % related to the individual resting motor threshold); in total 15.000 stimuli.
223832194|NCT00783120|OTHER|Sham repetitive transcranial magnetic stimulation|placebo (sham)-rTMS of left DLPFC (15 sessions/3 weeks, 1000 stimuli per session; in total 15.000 stimuli
223832195|NCT01591460|DRUG|boceprevir|800 mg three times daily for 24, 32 or 44 weeks
223832196|NCT01591460|DRUG|peginterferon alfa-2a [Pegasys]|180 mcg subcutaneously once a week for 24, 32 or 44 weeks
223832197|NCT01591460|DRUG|peginterferon alfa-2a [Pegasys]|180 mcg subcutaneously once a week for 4 weeks
223832198|NCT01591460|DRUG|ribavirin (Copegus]|1000 mg or 1200 mg orally once a day for 24, 32 or 44 weeks
223832199|NCT01591460|DRUG|ribavirin (Copegus]|1000 mg or 1200 mg orally once a day for 4 weeks
223832200|NCT04142463|OTHER|Care pathway|A care pathway is a complex intervention for the mutual decision-making and organisation of care processes for a well-defined group of patients during a well-defined period. Care pathways can be used to optimise care processes when problems arise on communication, coordination, standardisation and monitoring of care for a specific group of patients. A care pathway for patients treated with OACD, should therefore consist of all relevant sustainable interventions that cover the continuum of the medicines' pathway with the aim to support self-management (e.g. consultations with doctors, contact moments with nurses, telephone follow-up, ...). The role of each stakeholder in the different interventions should be well-described including communication strategies between HCPs from primary and secondary care.
223832201|NCT00524238|DRUG|L-thyroxine|The hypothyroid patients receive usual treatment with L-thyroxine in our out patient clinic. The doctors there subscribe the medication, this study has no protocol regarding this, we observe the patients again after having been biochemically euthyroid for at least two months.
223832202|NCT05473091|OTHER|no intervention|retrospective analysis
223832203|NCT04376697|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|The treatment will be delivered by trained medical personnel.
223832204|NCT03230864|DRUG|Lu AF35700|10 mg/day, encapsulated tablets, orally
223832205|NCT03230864|DRUG|Risperidone|4-6 mg/day, encapsulated tablets, orally
223832206|NCT03230864|DRUG|Olanzapine|15-20 mg/day, encapsulated tablets, orally
223832207|NCT00464035|BEHAVIORAL|high calcium intake|
223832208|NCT03679013|DRUG|Oral Gabapentin and Intravenous Acetaminophen (IV APAP)|Scheduled multimodal pain regimen consisting of oral Gabapentin paired with intravenous Acetaminophen following cardiopulmonary bypass surgery.
223832209|NCT03679013|DRUG|Opiate based pain regimen.|Standard of care opiate based pain regimen.
223832210|NCT01930643|DEVICE|EMS|HELEX 573 : strength aggravation mode with middle frequency carrier(1500Hz), minimal voltage for visible muscle contraction(maximum output is 75mA) , 32 minutes per day.
223832211|NCT02780986|BEHAVIORAL|Female entertainment worker intervention group|"The following summarises the content of each session:~Session 1 (on-site): The peer educator will play 2 videos, demonstrating 5 sexy ways of putting on a condom in a pleasurable manner, and another one focusing on condom negotiation skills.~Session 2 (online): The peer educator will share an app game on condom usage and relevant online resources with the participants.~Session 3 (onsite): There will be discussion of common problems encountered in condom usage and condom negotiation by the participants. The peer educators will then conduct role plays with the participants to demonstrate the counter-strategies. In addition, the peer educators will get the participants who have been successful in condom negotiation to share their success stories.~Session 4 (online): The peer educator will share information about safe consumption of alcohol and tips to avoid getting drunk through the online platforms."
223832212|NCT02780986|BEHAVIORAL|Heterosexual men intervention group|"This will be delivered via 3 main activities:~1. Edutainment in the form of talk-shows based on 6 themes of sexual well-being and safe sex, held in the EE setting hosted by a famous female local comedian.~2. Web portal named THINK: This contains educational materials based on 6 themes of sexual health and safe sex, HIV risk profiling tool to calculate the risk of contracting HIV, videos on true life experiences of heterosexual men engaging in high risk sexual behaviour and another video on exit strategies to avoid casual or paid sex, online support for STI testing services and consultation with a clinical sexologist.~3. Public education event/photo booth: i. Distribution of pamphlets and brochures on sexual well-being and safe sex ii. Interactions with health promoters iii. Photo taking on safe sex messages iv. Free access to condoms and lubricants"
223832213|NCT04063111|DEVICE|vacuum assistant closure|Expose the open wound bed to negative pressure. This pressure removes edema or hemorrhage, mechanically pulls on the wound edges, decreases in wound surface area, improves circulation, and enhances proliferation of granulation tissue that filled the soft tissue defect.
223832214|NCT04063111|DEVICE|CONVENTIONAL DRESSING|CONVENTIONAL DRESSING for wound of open fracture of tibia grade III B
223832215|NCT00271869|PROCEDURE|Extracorporeal photoimmunotherapy|
223832216|NCT01414218|BEHAVIORAL|Humor as a Way of Life Seminar|One session per week lasting 2-3 hours per session for 4 months. Sessions will include the videotaping of humorous stories or situations and instruction related to strategies to incorporate humor into everyday life.
223832217|NCT02951650|DEVICE|Cyberonics VNS|Vagus nerve stimulation
223832218|NCT01948362|DRUG|Sulforadex|Active compound
223832219|NCT01948362|DRUG|Alpha cyclodextrin|Placebo control
223832220|NCT00432679|DRUG|Rosiglitazone (BRL49653C)|study drug
223832221|NCT00859508|DEVICE|SyntheCel|Patients will be clinically followed post-surgery until hospital discharge or within ten (10) days of the procedure and at one (1) month, three (3) months and six (6) months. The data up to and including the 6 month follow-up visit will be used in demonstrating the performance of SyntheCelTM Dura Replacement.
223832222|NCT00859508|DEVICE|Other FDA cleared dura replacements|Patients will be clinically followed post-surgery until hospital discharge or within ten (10) days of the procedure and at one (1) month, three (3) months and six (6) months. The data up to and including the 6 month follow-up visit will be used in demonstrating the performance of SyntheCelTM Dura Replacement.
223832223|NCT03790930|DIAGNOSTIC_TEST|deep learning|manually labeled samples will be used to train, validate and test deep learning algorithm, and then realize automatic classification.
223832224|NCT01528644|DIETARY_SUPPLEMENT|alginate beads containing ferrous gluconate|After insertion of the cannula and collection of baseline blood sample a single dose of approximately 20mg of iron as ferrous gluconate incorporated into alginate beads (approximately 22.2g)and added to cola jelly (200ml) will be given to the volunteer together with 3 placebo capsules (each containing 50mg of dextrose)and cola drink (200ml). Once consumed, further blood samples will be taken at specified time points during 6 hour cannulation time. A minimum of 7 days wash out period will take place prior next intervention.
223832225|NCT01528644|DIETARY_SUPPLEMENT|ferrous gluconate in a capsule|After insertion of the cannula and collection of baseline blood sample a single dose of approximately 20mg of iron as ferrous gluconate in a capsule and 2 placebo capsules (each containing 50mg of dextrose) followed by a cola jelly (200ml)and cola drink (200ml) will be given to the volunteer. Once consumed, further blood samples will be taken at specified time points during 6 hour cannulation time. A minimum of 7 days wash out period will take place prior next intervention.
223832226|NCT01528644|DIETARY_SUPPLEMENT|ferrous gluconate in a capsule in presence of calcium|After insertion of the cannula and collection of baseline blood sample a single dose of approximately 20mg of iron as ferrous gluconate in a capsule together with 2 calcium capsules (each containing 300mg of calcium phosphate)followed by cola jelly (200ml) and cola drink(200ml)will be given to the volunteer . Once consumed, further blood samples will be taken at specified time points during 6 hour cannulation time. A minimum of 7 days wash out period will take place prior next intervention.
223832227|NCT01528644|DIETARY_SUPPLEMENT|alginate beads with ferrous gluconate in presence of calcium|After insertion of the cannula and collection of baseline blood sample a single dose of approximately 20mg of iron as ferrous gluconate incorporated into alginate beads (approximately 22.2g)and added to cola jelly (200ml) will be given to the volunteer together with 2 calcium capsules (each containing 300mg of calcium as calcium phosphate, 1 placebo capsule (containing 50mg of dextrose)and cola drink (200ml). Once consumed, further blood samples will be taken at specified time points during 6 hour cannulation time. A minimum of 7 days wash out period will take place prior next intervention.
223832228|NCT03763396|DRUG|Ketoconazole (KCZ)|Oral Tablet
223832229|NCT03763396|DRUG|Posaconazole (PCZ)|Delayed Release Oral Tablet
223832230|NCT00229476|DRUG|sertraline (Zoloft)|
223832231|NCT00431977|PROCEDURE|coronary computed tomography angiography|
223832232|NCT04171804|DEVICE|Transcranial direct current stimulation|Participants will receive a total of 10 stimulation sessions on 5 consecutive days (twice a day with 3-4 hours interval). During each session, 2 milliAmpers (mA) of active or sham tDCS will be applied for 20 minutes over the dorsolateral prefrontal cortex (left anodal/right anodal).
223832233|NCT01744496|DRUG|Rotigotine|Patches will contain 4 mg / 24 h (20 cm\^2), 6 mg/ 24 h (30 cm\^2), or 8 mg /24 h (40 cm\^2) of Rotigotine. Application of study medication starts at the Baseline Visit. Rotigotine will be administered once daily starting at 4 mg / 24 h. Doses will then be up-titrated in weekly increments of 2 mg / 24 h until optimal or maximum dose (16 mg / 24 h) is reached and the Maintenance Period can be started. The duration of the Titration Period will vary from 1 to 7 weeks ± 3 days. The Maintenance Period will last 12 weeks ± 5 days. Thereafter, during the De-escalation Period, the dose of study medication will be decreased by 2 mg / 24 h every other day. The De-escalation Period may last up to 12 days.
223832234|NCT01744496|DRUG|Placebo|Placebo patches match the size of active patches 20 cm\^2, 30 cm\^2, or 40 cm\^2 and will contain Placebo. Application of Placebo patches starts at the Baseline Visit. Placebo patches will be administered once daily starting with the equivalent of 4 mg / 24 h. Doses will then be up-titrated in weekly equivalents to 2 mg / 24 h until either optimal dose or maximum dose is reached. The maximum dose is the equivalent to 16 mg / 24 h. The duration of the Titration Period will vary from 1 to 7 weeks. The Maintenance Period will last 12 weeks ± 5 days. During the De-escalation Period, the dose of Placebo will be decreased by the equivalent to 2 mg / 24 h every other day. The De-escalation Period may last up to 12 days.
223832235|NCT02037867|DEVICE|Fibrosis Biomarkers|Liver disease stratification with liver stiffness scan (Transient Elastography) Analysis of diagnostic performance of serum fibrosis markers (as listed above) Whole blood samples obtained for DNA analysis
223832236|NCT02312505|DEVICE|COPFX|cardiac Output by semi-invasive pulse contour analysis
223832237|NCT03987568|OTHER|Blood draws|Blood draws at two specified timepoints - the first is during the MRI and the second is scheduled during participant's prostatectomy.
223832238|NCT03987568|DIAGNOSTIC_TEST|Magnetic resonance imaging (MRI)|At the beginning of study magnetic resonance imaging MRI will be completed.
223832239|NCT05948462|DRUG|Lorlatinib|Participants will receive assigned dose of daily oral lorlatinib continuously for each cycle. Each cycle is 3 weeks.
223832240|NCT05948462|DRUG|Cisplatin or Carboplatin|Participants will receive standard of care intravenous Cisplatin or Carboplatin, both chemotherapy medications, on day 1 of each cycle every 3 weeks, for Cycles 1-4. Each cycle is 3 weeks.
223832241|NCT05948462|DRUG|Pemetrexed|Participants will receive intravenous Pemetrexed, a chemotherapy medication, on day 1 of each cycle. Each cycle is 3 weeks.
223832242|NCT04131868|BEHAVIORAL|Typical sleep opportunity|Typical sleep opportunity with consistent sleep timing for 1 week
223832243|NCT04131868|BEHAVIORAL|Extended sleep opportunity|Extended sleep opportunity by 90 min per night with consistent sleep timing for 1 week
223832244|NCT00600743|DRUG|GSKI181771X (CCK-1R agonist)|Drug one trial vs placebo
223832245|NCT00600743|BEHAVIORAL|Instructions to binge eat|Subjects will be instructed to binge eat and will also be given either drug or placebo
223832246|NCT00600743|BEHAVIORAL|Instructions to eat normally|Subjects will be instructed to eat normally and will also be given either drug or placebo
223832247|NCT00600743|DRUG|Placebo|Drug one trial vs placebo
223832248|NCT02578420|OTHER|open-label placebo|"Placebo Cream, openly described as Placebo"
223832249|NCT02578420|OTHER|deceptive placebo|"Placebo Cream, described as Voltaren, containing Diclofenac"
223832250|NCT06418035|BEHAVIORAL|Video modeling by scanning Qr code|The protocol activity carried out by the experimental group will involve the use of the QR Code: in the operator's presence, the child scans the code through a technological device and watches the video of the activity to be played later in the HomeLab.
223832251|NCT06418035|BEHAVIORAL|Modeling traditional method|The control group will carry out the protocol activities in a traditional way, without technological tools. The child observes the operator who shows the live activity inside the HomeLab.
223832252|NCT05674942|OTHER|Patients with urinary tract infection and chronic kidney disease|The data that will be collected from the electronic patient records at the clinics through a google form will include sociodemographic (age, sex, weight and occupation), comorbidities (e.g., HTN, DM), medications used, renal functions (serum creatinine, and CKD stage calculated by 2021 CKD-EPI creatinine equation), and in case of positive urine culture (type of microorganism and antibiogram).
223832253|NCT04126473|DRUG|ELX-02|ELX-02 is a small molecule, new chemical entity being developed for the treatment of genetic diseases caused by nonsense mutations. ELX-02 is a eukaryotic ribosomal selective glycoside (ERSG).
223832254|NCT04126473|DRUG|Ivacaftor|CFTR potentiator
223832255|NCT00799734|DRUG|EXD|Interventions: Intake of prepacked Chinese herbal medicine therapy (EXD), one sachet of granules (15g extracted granules) twice a day and placebo therapy of 15g granules with similar colour and taste.
223832256|NCT00014950|PROCEDURE|CF newborn screening|
223832257|NCT03708419|OTHER|Optimal diet|Based on a 7-points OGTT, participants will be classified as MIR or LIR. The hypothesized optimal diet for MIR has a moderate fat content which is high in mono- unsaturated fatty acids (HMUFA) with a macronutrient breakdown of 38 E% from fat (20% MUFA, 10% polyunsaturated fatty acids (PUFA), 8% saturated fatty acids (SFA)), 48 E% from carbohydrates (CHO, 35% complex), and 14 E% from protein (35-40% plant protein). The hypothesized optimal diet for LIR is low in fat, high in protein (LFHP) and increased fiber with a macronutrient breakdown of \<28 E% from fat (10% MUFA, 10% PUFA, 8% SFA), 48 E% from CHO (35% complex), and 24 E% from protein (35-40% plant protein), and an additional supplement of 6g of soluble fiber per day. Participants wil be randomly allocated to one of the two diets.
223832258|NCT03708419|OTHER|Suboptimal diet|"The optimal diet for the other metabolic phenotype will be considered as suboptimal/ control diet. For the MIR phenotype this is the high protein, high fiber, low fat diet; for the LIR phenotype this is the high monounsaturated fatty acid diet. See the description above."
223832259|NCT03326817|OTHER|Control Group|Patients receive standard care
223832260|NCT03326817|DEVICE|Soft Robotic Glove Group|This group will receive standard care and soft robotic therapy (continuous passive motion device developed by National University of Singapore).
223832261|NCT06393686|OTHER|yoga|The yoga intervention will be implemented every two weeks, with each session lasting 45 minutes and implemented for 10 weeks. Sessions will always be led by the same certified yoga instructor. Each session will include a variety of different yoga poses, as well as breathing techniques and deep relaxation methods.
223832262|NCT00037557|DRUG|BeneFIX|
223832263|NCT01257139|PROCEDURE|Dual-agent therapy or docetaxel alone or best supportive care|"ARM B: (245 patients)~Treatment if the SGS screening test is negative:~* non epidermoid tumor:~* Carboplatin ® AUC 5 on D1 and Alimta ®(pemetrexed) 500 mg/m² D1, D1=D21 with vitamin B9 and B12 supplementation. Maximum of four 3-week cycles.~* epidermoid tumor:~* Carboplatin AUC 5 on D1 and Gemcitabin 1000 mg/m² on D1 and D8, D1=D21. Treatment if SGS screening test is positive (cf.table 1): Vulnerable subjects will receive: Taxotere ® (Docetaxel) 38 mg/m² on D1 and D8, D1=D21. Maximum of four 3-week cycles Fragile subjects are patients considered to be at a high risk of complications during chemotherapy; they will therefore receive best supportive care (BSC) with appropriate geriatric management."
223832264|NCT02899871|OTHER|diagnosis of joint|"The diagnosis of joint pain will be established by a rheumatologist and completed:~* If necessary, by a clinically guided radiological assessment (plain x-rays, joint ultrasound, bone and joint MRI).~* serum assays of the anti-TNF administered, as well as screening for associated antibodies."
223832265|NCT06207643|PROCEDURE|carotid endarterectomy|removing carotid artery atheromatous plaque surgically
223832266|NCT03121534|DRUG|Blinatumomab|"Patients will receive blinatumomab as a continuous IV infusion, commencing on day 15 of cycle 1 and day 1 of cycle 2, for 2 courses of 4 weeks each separated by a 2 week .~blinatumomab will be initiated at 9mcg/day from day 15-21, followed by 28 mcg/day from day 22-28. This will be followed by 112 mcg/day from day 29-42. In cycle 2, patients will be admitted for the first 3 days.blinatumomab treatment-free interval."
223832267|NCT03121534|DRUG|Dexamethasone|Dexamethasone 20 mg by mouth or vein 24 hours prior to and within 1 hour before start of treatment in each treatment cycle. If treatment is interrupted for \>4 hours at any point, Dexamethasone treatment given before re-initiation of therapy. Dexamethasone 8 mg by mouth or vein every 8 hours given for 48 hours at the commencement of the infusion and after each dose increment.
223832268|NCT03121534|DRUG|Ibrutinib|Ibrutinib treatment will commence on cycle 1, day 1 at 420mg/d. Dose reductions to 280mg/d or 140mg/d are allowed per treating physician discretion, but the reason must be documented in the medical record. Ibrutinib will be given continuously until disease progression or toxicity.
223832269|NCT03121534|DRUG|Nivolumab|Patients will receive nivolumab for up to a total of 52 weeks. Dosing will be 240mg IV every 2 weeks, commencing on day 1 until 2nd response assessment, then 480mg IV every 4 weeks.
223832270|NCT02374593|DRUG|Levothyroxine|Levothyroxine dose will be adjusted at the first clinic visit based on thyroid anatomy on ultrasound.
223832271|NCT02374593|DEVICE|Ultrasound|
223832272|NCT03458559|DRUG|Radium-223 chloride|Intravenously 50 kBq/kg every 4 weeks. Total: 6 administrations
223832273|NCT03458559|DRUG|Rhenium-188-HEDP|Intravenously 40 MBq/kg every 8 weeks. Total: 3 administrations
223832274|NCT00579982|DRUG|Lamotrigine|Experimental formulation
223832275|NCT02603315|OTHER|marker CD74 and vascular endothelial growth factor VEGF|correlate the result of vascularity test done on paraffin blocks on both types of malignant pleural mesothelioma patients diagnosed and receive treatment and evaluated after treatment
223832276|NCT00865891|DRUG|Nifedipine Extended Release tablets 60 mg, single dose|A: Experimental Subjects received Abrica Pharmaceuticals LLLP formulated products under fasting conditions
223832277|NCT00865891|DRUG|ADALAT® CC Extended Release Tablets 60 mg|B: Active comparator Subjects received Bayer Pharmaceuticals Corporation, Bayer HealthCare formulated products under fasting conditions
223832278|NCT05404867|OTHER|fMRI|fMRI scan for 1 hour
223832279|NCT03847623|DIETARY_SUPPLEMENT|Curcumin|Natural compound, active ingredient of turmeric, in bi-daily dosing
223832280|NCT03847623|OTHER|Placebo|Placebo tablets at bi-daily dosing
223832281|NCT04827134|DRUG|TRIUMEQ|TRIUMEQ will be available as fixed dose combination (FDC) dispersible tablets to be administered orally as a dispersion.
223832282|NCT04827134|DRUG|DOVATO|DOVATO will be available as FDC dispersible tablets to be administered orally as a dispersion.
223832283|NCT02861898|DRUG|Intra-arterial Cetuximab|
223832284|NCT02861898|DRUG|Intra-arterial Mannitol|
223832285|NCT04874324|DRUG|WCK 2349 Oral|1 dose given orally twice daily at 12 hourly interval for five days.
223832286|NCT04874324|OTHER|Placebo Oral|Subjects will receive matching placebo
223832287|NCT01776684|DRUG|EGFR TKIs (gefitinib, erlotinib, afatinib, et al)|
223832288|NCT04399239|COMBINATION_PRODUCT|AuriNovo|AuriNovo is a patient-specific, biologically natural, supportive base for surgical reconstruction of the external ear (auricle) in people born with microtia Grades II-IV. The construct is a 3D-bioprinted collagen hydrogel scaffold encapsulating the patient's own auricular cartilage cells (chondrocytes). The construct is printed in a size and shape that matches the contralateral ear for implantation into the patient.
223832289|NCT04845295|OTHER|resistance training|Both experimental groups performed two exercises to target elbow flexor and knee extensor muscles: biceps curl on a Scott bench and parallel barbell squat, respectively. All sessions were performed at the same time (13-15 h), with a minimum 48 h rest between sessions on the same days during the week. For both groups, the intensity of load (1RM%) and number of sets were as follows: in the first three weeks the subjects exercises with ̴ 60% of 1RM in 3 sets, while during the next four weeks the load was set at ̴ 70% of 1RM in 4 sets. All repetitions were performed until muscular failure. The pause between sets was 2 minutes.
223832290|NCT01306175|DRUG|Digoxin plus BI 10773|Digoxin 0.5 mg as single dose, BI 10773 medium dose once daily
223832291|NCT01306175|DRUG|Digoxin|Digoxin 0.5 mg as single dose
223832292|NCT04830605|BEHAVIORAL|Internet-based treatment|The intervention is an internet-based psychotherapy treatment with eight modules based on acceptance and commitment therapy and with written therapist contact through eight weeks.
223832293|NCT02669303|DRUG|platelet-rich plasma group|"Once randomized to platelet-rich plasma arm, the study subject will have 30cc of blood drawn and centrifuged using the Recover(TM) Platelet Separation Kit (Biomet Biologics, Warsaw, Indiana, USA). The extracted platelet-rich plasma part will be re-injected into the subacromial space of the subject's affected shoulder."
223832294|NCT02669303|DRUG|Methylprednisolone group|Once randomized to Methylprednisolone arm, the study subject will have an injection with 2ml of Methylprednisolone (40mg/ml methylprednisolone acetate injectable suspension) (Pharmacia Upjohn, Kalamazoo, Michigan, USA) with 2ml of lidocaine hydrochloride 2% (Hameln Pharmaceuticals Ltd, Gloucester, UK) into the subacromial space of their affected shoulder.
223832295|NCT01990820|DEVICE|Acclarent Relieva Balloon Sinuplasty|"A rigid nasal endoscopy will be performed. After decongesting with oxymetazoline hydrochloride, the balloon catheter device will be inserted and the wire/balloon will be threaded through the maxillary sinus ostia. Confirmation of location will be per manufacturer's recommendation with either fluoroscopy or illumination. Following confirmation, the balloon will be dilated under visualization per manufacture's recommendation. After the visualization of the dilated ostia, cultures for aerobic/anerobic examination will be taken and irrigation with 10ml of isotonic sodium chloride will be performed.~Adenoidectomy will be performed using either the microdebrider or suction electrocautery in the usual manner."
223832296|NCT01990820|PROCEDURE|Adenoidectomy + Maxillary Sinus Irrigation|"A rigid nasal endoscopy will be performed. After decongesting with oxymetazoline hydrochloride, the maxillary sinuses will be entered via middle meati punctures using either a sterile spinal needle or a curved suction. Sinus contents will be aspirated and sent for aerobic/anaerobic cultures. Irrigation with 10ml of isotonic sodium chloride will be performed. If no material is aspirated initially, the sinus contents will be re-aspirated after irrigation and sent for aerobic/anaerobic cultures.~Adenoidectomy will be performed using either the microdebrider or suction electrocautery in the usual manner.~After adequate hemostasis, the patient will be awakened and brought to the recovery room. Depending on the recovery, the child will either be admitted or discharged home."
223832297|NCT02340754|BEHAVIORAL|Mindfulness-based Stress Reduction|
223832298|NCT02340754|BEHAVIORAL|MS Education Control|
223832299|NCT00004221|DRUG|Carboplatin|Given IV
223832300|NCT00004221|DRUG|Cyclophosphamide|Given IV
223832301|NCT00004221|BIOLOGICAL|Filgrastim|Given SQ
223832302|NCT00004221|DRUG|Paclitaxel|Given IV
223832303|NCT00004221|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo autologous peripheral blood stem cell transplantation
223832304|NCT00004221|DRUG|Topotecan Hydrochloride|Given IV
223832305|NCT00575068|DRUG|IDEC-114|Phase 1-A Group 1 - 125 mg/m2 x 4 infusions - Study Days 1, 8, 15, 22 Phase 1-A Group 2 - 250 mg/m2 x 4 infusions - Study Days 1, 8, 15, 22 Phase 1-A Group 3 - 375 mg/m2 x 4 infusions - Study Days 1, 8, 15, 22 Phase 1-B Group 4 - 500 mg/m2 x 4 infusions - Study Days 1, 8, 15, 22 Phase II-A \& II-B - Dosage start at the MTD (up to 375 mg/m2)
223832306|NCT06117748|OTHER|Pressure controlled ventilation-volume guaranteed|"Respiratory parameters will be set as: actual tidal volume 8 mL/kg actual body weight, respiratory rate 12 breaths/min, PEEP of five mmHg, oxygen flow 1 L/min, fraction inspired oxygen (FiO2) 0.6, and I:E ratio of 1:2.~Respiratory parameters will be kept constant if ETCO2 is \<45 mmHg. When ETCO2 exceed 45 mmHg, respiratory rate or tidal volume will be adjusted to maintain ETCO2 below 45 mmHg."
223832307|NCT06117748|OTHER|Volume controlled ventilation|"Respiratory parameters will be set as: actual tidal volume 8 mL/kg actual body weight, respiratory rate 12 breaths/min, PEEP of five mmHg, oxygen flow 1 L/min, fraction inspired oxygen (FiO2) 0.6, and I:E ratio of 1:2.~Respiratory parameters will be kept constant if ETCO2 is \<45 mmHg. When ETCO2 exceed 45 mmHg, respiratory rate or tidal volume will be adjusted to maintain ETCO2 below 45 mmHg."
223832308|NCT05270317|PROCEDURE|Bone Graft Cultivation and Harvesting|Participants will be randomly assigned preoperatively into three surgical groups depending on cultivation time: early-stage group, medium-stage group and late-stage group . Bone Graft Cultivation is a two-stage procedure aiming at generating new bone tissue for grafting by periosteal elevation . The first stage is the insertion of space-occupying implant which is responsible for keeping periosteal elevation for a defined time to stimulate new bone formation. The second stage is the extraction of woven bone that has been formed together with the implant.
223832309|NCT03410238|BEHAVIORAL|Saferteens Brief Intervention|A 30 minute private one-on-one brief motivational interviewing intervention administered by clinic staff. The goal of the intervention is to reduce and prevent youth violence using techniques to change behavior in a respectful, non-confrontational, and non-judgmental manner. This one-on-one counseling approach emphasizes individual choice and responsibility and differentiates between future goals/values and current behavior. In the 2 months following the intervention, participants will receive booster text messages tailored to their responses during the intervention.
223832310|NCT01898520|DRUG|Sativex|Oromucosal spray containing THC (27 mg/mL):CBD (25 mg/mL), in ethanol: propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring. Each 100 μL spray delivered THC 2.7 mg and CBD 2.5 mg. The maximum number of daily sprays was 12.
223832311|NCT01898520|DRUG|Placebo|Oromucosal spray containing ethanol: propylene glycol(50:50) excipients, with peppermint oil (0.05%) flavouring and colourings FD\&C Yellow No.5 (E102 tartrazine) (0.0260%), FD\&C Yellow No.6 (E110 sunset yellow) (0.0038%), FD\&C Red No. 40 (E129 Allura red AC) (0.00330%) and FD\&C Blue No.1 (E133 Brilliant blue FCF) (0.00058%). Each 100 μL spray administered to the sub-lingual or oral mucosa delivered the colourants plus excipients. The maximum daily dose was 12 sprays per day.
223832312|NCT03417882|BIOLOGICAL|GRN-1201 + Pembrolizumab|GRN-1201 will be administered in combination with Pembrolizumab
223832313|NCT00401674|DRUG|carboplatin|
223832314|NCT00401674|DRUG|paclitaxel|
223832315|NCT06339125|OTHER|Fall prevention algorithm|Algorithm generates fall prevention alerts to nurses in real time, using evidenced based electronic health record information regarding changes in care that may suggest the need for additional fall prevention strategies
223832316|NCT06339125|OTHER|Inspiren camera visualization|The Inspiren computer camera visualization is an additional strategy for nurses to employ when there is a change in a patient's fall risk.
223832317|NCT00633737|BEHAVIORAL|Stress reduction intervention|In addition to standard care, patients in the intervention group will receive a one-hour individually delivered programme administered once by a psychologist at least 3 days prior to surgery. This session aims to reduce stress and involves teaching relaxation and guided imagery exercises. Patients are provided a CD (or audiotape)of the relaxation instructions to take home and practice once a day.
223832318|NCT02018237|BEHAVIORAL|High fructose corn syrup diet|Subjects will consume a high fructose corn syrup diet for 4 weeks. The food will be prepared by the bio-nutrition kitchen, and meals will be picked up every 3-4 days.
223832319|NCT02018237|BEHAVIORAL|Standard diet (low in high fructose corn syrup)|Subjects will consume a standard diet (low in high fructose corn syrup) for 4 weeks. The food will be prepared by the bio-nutrition kitchen, and meals will be picked up every 3-4 days.
223832320|NCT02276378|DRUG|Telmisartan low|
223832321|NCT02276378|DRUG|Telmisartan high|
223832322|NCT02276378|DRUG|Hydrochlorothiazide (HCTZ)|
223832323|NCT02276378|OTHER|Japanese meal|
223832324|NCT03600038|BEHAVIORAL|Experimental smoking cessation smartphone app|The experimental arm includes an intervention using a novel/experimental smartphone smoking cessation app.
223832325|NCT03600038|BEHAVIORAL|Standard of care smoking cessation smartphone app|The control intervention uses a standard of care smartphone smoking cessation app.
223832326|NCT05280847|PROCEDURE|Erector spinae plane block|fascial plane injection using ultrasound and fluoroscopic guidance
223832327|NCT05853757|DRUG|Zzowin Nutra Tablet|1 Tablet daily half an hour before going to bed
223832328|NCT00004736|DRUG|Nelfinavir mesylate|
223832329|NCT00004736|DRUG|Ethambutol hydrochloride|
223832330|NCT00004736|DRUG|Isoniazid|
223832331|NCT00004736|DRUG|Pyrazinamide|
223832332|NCT00004736|DRUG|Lamivudine|
223832333|NCT00004736|DRUG|Rifabutin|
223832334|NCT00004736|DRUG|Stavudine|
223832335|NCT00004736|DRUG|Zidovudine|
223832336|NCT04870619|OTHER|High Intensity Gait Training|The intervention provided in this project is routinely delivered as a standard of care at the participating sites for patients after stroke that have a goal of walking improvement. The intervention consists of 45-60 minute, physical therapy sessions that occur five days per week (not weekends), focusing on prioritizing stepping practice at higher aerobic intensities during scheduled treatments (target training zone of 70-85% heart rate max (HRmax). Stepping is performed on treadmills and over ground, with safety harness systems and body weight support only as needed to ensure successful stepping. Tasks are progressed by increasing task difficulty as determined by the therapist. Accordingly, practice of non-walking tasks performed during physiotherapy, including bed mobility, transfers, and standing balance/ pre-gait activities, is limited.
223832337|NCT00287469|BIOLOGICAL|Hepatitis E vaccine, recombinant (Sar 56 kDa)|20mcg or rhE Sar 56 kDa/dose of 0.5 mL, aluminium hydroxide (0.5 mg/dose) and phenoxyethanol (2.5 mg/dose)
223832338|NCT00287469|OTHER|Placebo|PBS buffer placebo containing alum
223832339|NCT02666586|OTHER|Faba bean powder smoothie|Breakfast smoothie with 32 g whole faba bean powder (300g).
223832340|NCT02666586|OTHER|Faba bean protein concentrate smoothie|Breakfast smoothie with 32 g faba bean protein concentrate.
223832341|NCT02666586|OTHER|Faba bean starch smoothie|Breakfast smoothie with 33 g faba bean starch.
223832342|NCT02666586|OTHER|Faba bean protein isolate smoothie|Breakfast smoothie with 32 g faba bean protein isolate.
223832343|NCT02666586|OTHER|Non-pulse smoothie smoothie|Control smoothie with 32 g corn maltodextrin without added faba bean fractions.
223832344|NCT00307099|DRUG|Meropenem|Meropenem 1 gram intravenously every 8 hours for 3 days (9 doses), then an additional 5 days if the Clinical Pulmonary Infection Score is greater than 6.
223832345|NCT00307099|DRUG|Standard antibiotic therapy|Standard intravenous antibiotic therapy for a minimum of 8 days.
223832346|NCT03862703|DEVICE|mHealth intervention, PTSD Help app.|Experimental group will receive the app, PTSD Help.
223832347|NCT00124774|PROCEDURE|Nucleoplasty|
223832348|NCT06395389|BEHAVIORAL|Health Education (HealthEdu)|The Health Education condition is a 2-session brief intervention with each session lasting 40-50 minutes and separated by about 1 week (5-10 days). The first session focuses on providing in-depth information on good sleep hygiene and habits to improve sleep and information on positive eating habits, nutrition, and physical activity/functional exercise. The second session focuses on providing information about stress and social connection.
223832349|NCT06395389|BEHAVIORAL|Bloom|Bloom is a 2-session brief intervention with each session lasting 40-50 minutes and separated by about 1 week (5-10 days). The first session encourages participants to ask themselves what is important to them. This discussion emphasizes identifying values and ways to live in line with their values, as well as why they use cannabis and providing personalized feedback related to their reasons for use. The second session asks participants to reflect on information from session one and consider what they would like to do next to live in line with their values.
223832350|NCT00955006|BIOLOGICAL|VRC-HIVDNA-016-00-VP|Composed of six DNA plasmids in equal concentrations that encode Gag, Pol, and Nef from clade B (strains HXB2, NL4-3, NY5/BRU) and the HIV-1 Env glycoproteins from clade A (strain 92rw020), clade B (strains HXB2/BaL), and clade C (strain 97ZA012). Vaccine will be administered intramuscularly (IM) in the deltoid via needle-free Biojector.
223832351|NCT00955006|BIOLOGICAL|VRCHIVADV014-00-VP|A mixture of 4 recombinant serotype 5 adenoviral replication deficient vectors, each expressing HIV-1 proteins (clade B Gag-Pol fusion, clade A Env, clade B Env, clade C Env). Administered IM via needle and syringe.
223832352|NCT02763891|OTHER|Intervention group (Body body suspension and tilting exercises)|The body suspension and tilting exercise program (Chordata Method) involved suspending the body in the apparatus while performing tilting exercises. The Chordata apparatus consists of a steel structure with special springs and a harness specifically manufactured for practicing the Chordata Method. During the training sessions, the prescribed exercises emphasize the repetition of movements designed to promote different types of muscle contractions (concentric, eccentric, static) performed in different body positions and joint angles. Thus, when using the method, patients experience maximal functional performance beyond to the body mass centre, activating trunk antagonist muscles and motor memory evocation. Each session lasts 30 minutes.
223832353|NCT02763891|OTHER|Control group (global muscle stretching)|Subjects receiving submitted a global muscle stretching session twice a week for eight weeks. During this period. All participants are requested to don't engage in any additional type of exercise program or physical activity throughout the study period.
223832354|NCT02501135|PROCEDURE|Femoral nerve block with ropivacaine or bupivacaine|
223832355|NCT04531072|DRUG|Artemether-lumefantrine|Safety and efficacy evaluation during concurrent use of artemether-lumefantrine and atazanavir-ritonavir based antiretroviral therapy
223832356|NCT04531072|DRUG|Atazanavir-ritonavir 300/100 mg|Safety and efficacy evaluation during concurrent use of artemether-lumefantrine and atazanavir-ritonavir based antiretroviral therapy
223832357|NCT05892835|OTHER|Educative|A 2-hour training workshop was held where a theoretical explanation was given to recognize a cardiorespiratory arrest, the correct technique of chest compressions, ventilations and DESA management, in addition a practical class was carried out with CPR training models (Manikin for CPR practices Little Anne QCPR). Laerdal and AED simulation for CPR training (AED Practi-Trainer - Bilingual. WNL). Both theoretical and practical training were given by a basic life support instructor from the Spanish Society of Intensive Medicine and Coronary Units (SEMICYUC), the participants were instructed under the guidelines of the 2021 CKD recommendations.
223832358|NCT01034241|DIETARY_SUPPLEMENT|Control|Diet consists of 15 En% dairy protein and low GI, 55 En% carbohydrates and 30 En% fat
223832359|NCT01034241|DIETARY_SUPPLEMENT|High dairy protein|Diet consists of 25 En% dairy protein and low GI, 55 En% carbohydrates and 30 En% fat
223832360|NCT01034241|DIETARY_SUPPLEMENT|vegetable protein|Diet consists of 15 En% vegetable protein and low GI, 55 En% carbohydrates and 30 En% fat
223832361|NCT01034241|DIETARY_SUPPLEMENT|High GI|Diet consists of 15 En% dairy protein and high GI, 55 En% carbohydrates and 30 En% fat
223832362|NCT02342184|DRUG|GB-0998|
223832363|NCT01021163|DRUG|N-acetylcysteine, saline|Inject 100 mg/kg of N-acetylcysteine or the equivalent amount of saline for 15 minutes before the skin incision, then continuously inject 40 mg/kg/day of N-acetylcysteine or the equivalent amount of saline during the next 24 hours.
223832364|NCT06190574|OTHER|Telephone follow-up|Telephone follow-up
223832365|NCT02310893|BEHAVIORAL|Combined Contingency Management and Peer Navigation|
223832366|NCT02310893|BEHAVIORAL|Contingency Management|
223832367|NCT02310893|BEHAVIORAL|Peer Navigation|
223832368|NCT04256590|DIAGNOSTIC_TEST|Ultrasonography imaging|This study aimed to measure the tongue surface areas of the patients two times both of study and control groups with ultrasonography imaging to compare the tongue surface areas.
223832369|NCT00543218|DRUG|teriparatide 20 micrograms/day subcutaneous|
223832370|NCT00543218|DRUG|calcitonin 100 IU/day subcutaneous|
223832371|NCT00925782|DRUG|Melphalan HCL for Injection (Propylene Glycol-Free)/Alkeran for Injection|Patients will be randomized to receive 100 mg/m2 of Melphalan HCL for Injection (Propylene Glycol-Free) on Day -3 and Alkeran for Injection on Day -2 prior to ASCT.
223832372|NCT00925782|DRUG|Alkeran for Injection/Melphalan HCL for Injection (Propylene Glycol-Free)|Patients will be randomized to receive 100 mg/m2 of Alkeran for Injection on Day -3 and Melphalan HCL for Injection (Propylene Glycol-Free)on Day -2 prior to ASCT.
223832373|NCT06091618|PROCEDURE|new technique of ejaculatory preserving laser prostatectomy|"laser will be employed to preform vaporization. The ejaculatory preserving procedure will be done in the following steps:~Setting a mark cut 1 cm proximal of the verumontanum as orientation. Complete resection of the middle lobe to the abovementioned mark. Vaporization of lateral lobes to the capsule and the ventral side to the level of the verumontanum with avoidance of paracollicular digging.~Circular resection of the internal bladder neck. Apical resection utilizing the colliculus seminalis as a distal resection border and maintaining a 1cm safety area for preservation of ejaculation.~Total removal of prostate cuts and final check to confirm that there are no obstructive components."
223832374|NCT06091618|PROCEDURE|conventional technique of laser vaporization of the prostate|conventional laser vaporization of the prostate
223832375|NCT01584830|DRUG|Regorafenib (BAY73-4506)|Regorafenib BAY73-4506 will be given 3 weeks on/1 week off (160 mg od po.)
223832376|NCT01584830|DRUG|Placebo|Placebo will be given 3 weeks on/1 week off (160 mg od po.)
223832377|NCT00780442|DRUG|D-cycloserine|50 mg DCS
223832378|NCT00780442|DRUG|Placebo|Placebo
223832379|NCT01857830|BEHAVIORAL|Meditation Retreat|The intervention is a one week meditation and yoga retreat hosted at the La Costa Resort and Spa in Carlsbad, CA.
223832380|NCT01857830|BEHAVIORAL|Active Comparator Relaxation Group|Participants are randomized to stay at La Costa Resort and Spa for 6 days. Participants will receive daily meals similar to the meals for those in the retreat group. Participants will also receive a daily one hour lecture on topics related to longevity and health.
223832381|NCT00507026|DRUG|IV Diclofenac|IV Diclofenac q6h
223832382|NCT00507026|DRUG|IV ketorolac|IV ketorolac q6h
223832383|NCT00507026|DRUG|Placebo|Placebo q6h
223832384|NCT06381362|PROCEDURE|Minimally invasive pancreatic surgery|Minimally invasive pancreatic surgery
223832385|NCT05008159|BEHAVIORAL|3 month community-based mobility and health intervention|"12 weekly GROUP (10-15 adults per cohort) sessions + 3 INDIVIDUAL tailored system navigation sessions at beginning, midpoint, and end of program.~The 3-month GROUP program will include the following fixed components:~i) weekly interactive group-based health education sessions focused on:~* increasing knowledge, skills, and behaviours related to physical activity, healthy eating, and available community supports for older adults;~* socialization to foster peer and community connections, co-learning, and decrease social isolation~* skill-building to support independence and quality of life; and~ii) INDIVIDUAL tailored system navigation support"
223832386|NCT02372058|DEVICE|BiliCare|"Three non invasive measurements of TcB:~Two measurements with the BiliCare device and one measurement with a competitive FDA approved device"
223832387|NCT00658736|DRUG|Triamcinolone|Injection of bupivacaine and triamcinolone
223832388|NCT00658736|DRUG|Bupivicaine alone|Injection of bupivacaine
223832389|NCT05449574|DIAGNOSTIC_TEST|Scale for the Assessment of Sensory Integration in Adults|In people with MS and people with health of similar age, a test was performed to assess sensory integration in adults
223832390|NCT04141579|DRUG|Evolocumab 140 MG/ML [Repatha]|Evolocumab (also known as Repatha, formerly referred to as AMG 145) is a human monoclonal immunoglobulin G2 (IgG2) that specifically binds to proprotein convertase subtilisin/kexin type 9 (PCSK9) preventing its interaction with the low-density lipoprotein receptor (LDLR). The inhibition of PCSK9 by evolocumab leads to increased LDLR expression and subsequent decreased circulating concentrations of low-density lipoprotein cholesterol (LDL-C).
223832391|NCT04141579|DRUG|Placebo|Matching placebo
223832392|NCT00255697|PROCEDURE|psychosocial assessment and care|Patients undergo a 45-minute interview in person or by phone to provide demographic data and to complete quality of life questionnaires, including Functional Assessment of Cancer Therapy (FACT), Spiritual tool, Quality and Satisfaction with Treatment (QUEST), and Profile of Mood State (POMS), at baseline and at 3 and 12 months. Caregivers undergo a 20- to 30-minute interview in person or by phone to provide demographic data and complete quality of life questionnaires, including the Caregiver Reaction Assessment (CRA), Quest, and POMS, at baseline and at 3 and 12 months. Caregivers complete the Quality of Death and Dying (QODD) questionnaire 2-3 months after the patient's death.
223832393|NCT00255697|PROCEDURE|quality-of-life assessment|Patients undergo a 45-minute interview in person or by phone to provide demographic data and to complete quality of life questionnaires, including Functional Assessment of Cancer Therapy (FACT), Spiritual tool, Quality and Satisfaction with Treatment (QUEST), and Profile of Mood State (POMS), at baseline and at 3 and 12 months. Caregivers undergo a 20- to 30-minute interview in person or by phone to provide demographic data and complete quality of life questionnaires, including the Caregiver Reaction Assessment (CRA), Quest, and POMS, at baseline and at 3 and 12 months. Caregivers complete the Quality of Death and Dying (QODD) questionnaire 2-3 months after the patient's death.
223832394|NCT00457613|DRUG|bolus injection, followed by a continuous infusion ( 24 h) (Alkaline phosphatase)|
223832395|NCT04479098|OTHER|Resistance exercise training|The exercise training program will last 12 weeks, with a frequency of three sessions per week, held on Mondays, Wednesdays, and Fridays. Each session will last approximately 50 minutes. Whenever the maximum number of pre-established repetitions is successfully performed, the intensity will be increased by 5 to 10%. All sessions will be supervised by trained professionals.
223832396|NCT04479098|OTHER|Exercise detraining|The exercise detraining will last 12 weeks without exercise.
223832397|NCT03523871|DRUG|Mavyret|Patients will be on 8 weeks of Mavyret
223832398|NCT03395938|BEHAVIORAL|Proactive engagement|The engagements would include (1) a sealed envelope containing a cancer information sheet and an invitation letter directed towards siblings for them to contact the research team, (2) weekly phone reminders to the participants for a total of 4 weeks in a bid to remind participants of the need to convey the screening message to their siblings. The envelope will contain information on the various means for the siblings to contact the research team. These include communication means such as electronic mails (emails), telephone, hard copy returned mails through pre-paid envelopes, short messaging services (SMSs) or clinic consult.
223832399|NCT03395938|BEHAVIORAL|Current practice|This intervention depicts current practices by having the research team educate the participants on the Ministry of Health Singapore screening guidelines akin to counselling sessions carried out during the patient's clinical consultation. The research team would highlight that we would be happy to assist if necessary. The research team would then contact the patients in 4 weeks to check if they have communicated with their siblings and if they have gone for screening. We would also find out which method did they adopt to communicate with their siblings.
223832400|NCT03416504|BEHAVIORAL|Gradual Exposure (EXP-G)|In EXP-G, exposure proceeded hierarchically from mildly, to moderately, to highly intense stimuli so that exposure intensity gradually built between (but not within) sessions.
223832401|NCT03416504|BEHAVIORAL|Variable Exposure (EXP-V)|In EXP-V, exposure stimuli were chosen at random (i.e., pieces of paper with exposure stimuli written on them were pulled randomly from an opaque container) so that mild, moderate, and high intensity exposures could occur in any order during any of the sessions (the participant was not informed which level was coming next). This aimed to maximize (a) uncertainty, (b) variability in exposure intensity, and (c) variability in corresponding physiological arousal.
223832402|NCT06274580|DEVICE|embolization of the middle meningeal artery|Embolization of the MMA is occluded with PVA particles or liquid embolizing materials
223832403|NCT03856021|PROCEDURE|Microfracture with Bone Marrow Aspirate Concentrate|Bone Marrow Aspirate Concentrate harvested and prepared from the iliac crest
223832404|NCT03856021|PROCEDURE|Microfracture|All surgeons will use a 2 mm microfracture pick to perform the microfracture procedure. Using the 2 mm pick, surgeons will make 5 holes per 10 cm2.
223832405|NCT01952301|DEVICE|Xenogeneic Collagen Matrix|A type I and III porcine collagen matrix, as cleared by FDA (K012423)
223832406|NCT01952301|DEVICE|Free Gingival Graft|Autogenous, full-thickness soft tissue graft harvested from patient's palate.
223832407|NCT05193721|DRUG|SHR-1901|SHR-1901 dose escalation at 0.1 mg/kg or 0.3 mg/kg or 1 mg/kg or 3 mg/kg or 10 mg/kg
223832408|NCT03049657|DEVICE|Angiolite|Percutaneous coronary intervention
223832409|NCT03049657|DEVICE|Xience|Percutaneous coronary intervention
223832410|NCT01642134|DRUG|aspirin+clopidogrel (Duoplavin)|100 mg aspirin ;75 mg clopidogrel 3º months
223832411|NCT01482650|DEVICE|supraglottic airway placement and use|The investigators will place the device (Baska mask or LMA) according to a pre-defined protocol and monitor its performance intra and postoperatively.
223832412|NCT05175482|OTHER|Virtual Education|health belief model based virtual education
223832413|NCT00253409|DRUG|chemotherapy|
223832414|NCT00253409|PROCEDURE|adjuvant therapy|
223832415|NCT00253409|PROCEDURE|conventional surgery|
223832416|NCT00253409|PROCEDURE|neoadjuvant therapy|
223832417|NCT00253409|RADIATION|radiation therapy|
223832418|NCT04406337|DEVICE|Low intensity pulsed ultrasound|Low intensity pulsed ultrasound therapy will use ultrasound with frequency of 1.5 MHz, power intensity of 30 mW/cm\^2 (0.03 W/cm\^2 ) and 20% duty cycle.
223832419|NCT04406337|DEVICE|High intensity continuous ultrasound|High intensity continuous ultrasound therapy will use ultrasound with frequency of 1 MHz, power intensity of 3 W/cm\^2 and 100% duty cycle.
223832420|NCT02749058|PROCEDURE|Capsulectomy in Direct Anterior Total Hip Arthroplasty|Surgical intervention in which the surgeon will perform anterior capsulectomy during total hip arthroplasty.
223832421|NCT02749058|PROCEDURE|Capsulotomy in Direct Anterior Total Hip Arthroplasty|Surgical intervention in which the surgeon will perform anterior capsulotomy during total hip arthroplasty. Surgeon will repair the joint capsule.
223832422|NCT03266341|DIAGNOSTIC_TEST|Cultures|Take different samples anddetection of anaerobes on enriched blood agar and other selective anaerobic cultures
223832423|NCT00972179|DRUG|Placebo|Administered by subcutaneous or intravenous injection.
223832424|NCT00972179|DRUG|Tezepelumab|Administered by subcutaneous or intravenous injection
223832425|NCT01994720|DRUG|ticagrelor|ticagrelor, 180 mg (two tablets of 90 mg) loading dose on Day 1 followed by 90 mg twice daily.
223832426|NCT01994720|DRUG|Acetylsalicylic acid (ASA)|ASA, 300 mg (three tablets of 100 mg) on Day 1, followed by 100 mg once daily.
223832427|NCT03450421|DEVICE|Actamax™Adhesion Barrier|Actamax™Adhesion Barrier is a degradable hydrogel to be sprayed directly on surgically traumatized tissue. The aim of using the Actamax™ Adhesion Barrier (AB) in this way is to allow damaged and apposing tissue surfaces the opportunity to heal separately without becoming abnormally attached.
223832428|NCT00801424|DEVICE|humidified warmed CO2|Additional insufflation of humidified carbon dioxide (approx. 36-37ºC, approx. 80-100% relative humidity) via a humidifier with a heated tube (Fisher\&Paykel) connected to a gas diffuser (Cardia Innovation AB) that is able to create a local atmosphere of 100% carbon dioxide (humidified) in the wound cavity
223832429|NCT03949751|DRUG|Acne Crème Plus|The study specific intervention product is a combination of Benzoylperoxid and Miconazolnitrat (Widmer Acne Crème Plus, 47033 Swissmedic) to apply daily in the evening on the skin from the nipple-areola complex laterally to the medial margin of the scapula and from a horizontal line through the nipple-areola complex cranially over the shoulder and dorsally to the spina scapulae. The application should be done regularly for 7 days before shoulder surgery. The study specific intervention product is authorized by Swissmedic for use in the treatment of acne and is used standardly in clinical practice.
223832430|NCT05474443|OTHER|Myofascial gun with conventional therapy|"MYofascial gun was applied for the duration of 5 minutes over upper trapezius muscle. every week, on first two sessions frequency was set to 1-2 then for next two 3-4 and so on conventional therapy Hot Pack applied at the beginning of session for 10 minutes Muscle stretching of Upper Trapezius, Levator Scapulae and Pectoralis Major applied with holding time 20 seconds and 4 repetitions.~Cold pack was applied at the end of the session for few minutes"
223832431|NCT05474443|OTHER|Instrument Assisted Soft Tissue Mobilization with Conventional therapy|Graston's tool was applied over upper trapezius muscle from its origin to insertion kept at the angle of 45 Conventional Therapy Hot pack 10mins Upper Trapezius, Levator scapule and Pectoralis major muscle stretching(20s hold and 4 reps) Cold pack for few minutes
223832432|NCT03709875|DEVICE|TR Treatment|A virtual reality based system, consisting of two PC-based workstations, located at the patient's home and at the rehabilitation center, will be used. For the motor treatments the patient has to move the real end effector, following the trajectory of the corresponding virtual task displayed on his computer screen. The speech (mainly lexical based) and cognitive (attention focused) exercises will be delivered from the two Research Institutes to the patient's home. During the treatment at home, the patients will use wearable monitoring devices to monitor their status (speed, heart rate, respiratory rate, training load and single-lead ECG in real-time) and to provide real-time feedback during exercises.
223832433|NCT03054974|OTHER|Modern rehabilitation treatment|PT 1 hour per day and OT 30min per day
223832434|NCT03054974|OTHER|Modern rehabilitation &TCM|Traditional Chinese Medicine, including massage and medicated bath
223832435|NCT03054974|OTHER|modern rehabilitation &Baimai Ruangao|modern rehabilitation treatment with Baimai Ruangao and massage
223832436|NCT03054974|OTHER|modern rehabilitation &Tibetan medicine|modern rehabilitation treatment and Tibetan medicine(medicated bath with wuweiganlu and rub with baimairuangao)
223832437|NCT06071975|DRUG|Adezunap (AP707)|Sublingual spray with maximum application of 16 actuations per day or a maximum daily dose of 17,6mg THC distributed over 4 daily intakes.
223832438|NCT06071975|DRUG|Placebo|Sublingual spray with maximum application of 16 actuations per day distributed over 4 daily intakes.
223832439|NCT00604929|DIETARY_SUPPLEMENT|carbohydrate and protein|The intake of carbohydrate and protein during endurance type exercise
223832440|NCT02216422|DRUG|Ombitasvir/Paritaprevir/Ritonavir|Tablet; paritaprevir co-formulated with ritonavir and ombitasvir
223832441|NCT02216422|DRUG|Dasabuvir|Tablet
223832442|NCT02216422|DRUG|Ribavirin (RBV)|Tablet
223832443|NCT05814757|DRUG|OTX-DED|0.3mg dexamethasone ophthalmic insert
223832444|NCT05814757|DRUG|Controlled Insertion|Collagen Punctal Plug 0.2mm (Controlled Insertion)
223832445|NCT05814757|DRUG|Collagen Punctal Plug|Collagen Punctal Plug 0.2mm (Full Insertion)
223832446|NCT01171365|DRUG|Ciclesonide|Inhaled ciclesonide 320mcg twice daily
223832447|NCT01171365|DRUG|Placebo|Matched placebo inhaler two inhalations twice daily
223832448|NCT04285229|DRUG|Ixekizumab|Administered SC
223832449|NCT04285229|DRUG|Placebo|Administered SC
223832450|NCT02059317|OTHER|Flexion-extension in the sagittal plane|The movement required is a flexion - extension where the subject touches a target (adapted to his/her morphology) with both index fingers: the target is positioned in front of the subject, inline with his/her outstretched arms and at knee height. This movement simulates a lifting task without weight. The movement is repeated 30 times with a return to the initial position at a frequency of 0.32Hz.
223832451|NCT02059317|OTHER|Rotation in a transverse plane|The movement required of the subject is a rotational movement where the subject alternately touches with his/her left and right hands two targets. The latter are positioned horizontally on either side of the subject at shoulder height and at arm's length. The movement is repeated 30 times at a frequency of 0.28 Hz.
223832452|NCT02059317|OTHER|Complex movement in three dimensions|The subject is required to successively touch 4 targets situated (i) at knee height to the left of the subject, (ii) at shoulder height to the right of the subject, (iii) at shoulder height to the left of the patient, and (iv) at knee height to the right of the patient. The movement is repeated 30 times at a frequency of 0.16 Hz.
223832453|NCT04166695|DEVICE|Monolithic / facially veneered zirconia fixed partial denture|Participant receives one monolithic / facially veneered zirconia fixed partial denture retained by either teeth, implants or teeth and implants for the replacement of two neighbouring posterior teeth.
223832454|NCT04166695|DEVICE|Completely veneered CoCr fixed partial denture|Participant receives one completely veneered CoCr fixed partial denture retained by either teeth, implants or teeth and implants for the replacement of two neighbouring posterior teeth.
223832455|NCT04695158|DRUG|COVID-19 group (Group I)|Routine COVID-19 treatment
223832456|NCT04695158|DRUG|Type II Diabetes Mellitus and COVID-19 group (Group II)|Routine Type II Diabetes Mellitus and COVID-19 treatments
223832457|NCT02054078|DRUG|Bevacizumab|Bevacizumab200mg by intrapleural administration
223832458|NCT02054078|DRUG|Pulvis talci|Pulvis talci 4g by intrapleural administration
223832459|NCT01400464|DRUG|Prednisone therapy and pharmacokinetic|Prednisone therapy delivered in accordance with a 10 to 18 month pre-defined schedule. Pharmacokinetic and pharmacogenetic tests at 14 or 28 days. Monthly visit for the first 6 month, then every 8 weeks months thereafter for the remainder of the study with standard biologic monitoring , physical exam and medical and medication history .Also, participants will be asked to complete several questionnaires to assess quality of life and observance to therapy. Participants may have additional study visits if a disease flare or disease-related complications occur during the study.
223832460|NCT02061761|BIOLOGICAL|BMS-986016|Specified Dose on Specified Days
223832461|NCT02061761|BIOLOGICAL|BMS-936558|Specified Dose on Specified Days
223832462|NCT03906487|BEHAVIORAL|Assessment measures MINI, PCL5 and BDI-II and definition of 5 SDM|"This group will have two visits:~* the first to verify inclusion criteria and assessed psychotraumatic and depressive symptoms by completing assessment measures called MINI, PCL-5, BDI-II ;~* the last to characterize the SDM by defining 5 personal memories"
223832463|NCT03906487|BEHAVIORAL|Assessment measures MINI and definition of 5 SDM|"This group will have two visits:~* the first to verify inclusion criteria and assessed psychotraumatic and depressive symptoms by completing MINI questionary;~* the last to characterize the SDM by and defining 5 personal memories"
223832464|NCT02361593|PROCEDURE|assistance of a transparent cap|Patients will receive endoscopic injection of lauromacrogol with assistance of a transparent cap.
223832465|NCT02361593|PROCEDURE|without a transparent cap|Patients will receive routine endoscopic injection of lauromacrogol without use of transparent cap.
223832466|NCT02327910|OTHER|TOF unit TcPCO2 group|The patients of U group were extubated when TOF ratio greater than 0.9 and TcPCO2 recovery to preoprative(±5mmHg)
223832467|NCT02327910|OTHER|TOF group|The patients of T group were extubated when TOF ratio greater than 0.9.
223832468|NCT04374565|DRUG|High-Titer Anti-SARS-CoV-2 (COVID 19) Convalescent Plasma|Pathogen reduced SARS-CoV-2 convalescent plasma (1-2 units; \~200 mL each for a total of 200-400mls) given preferably in one day, but allowable to be given over 2 days if clinical circumstances delay infusions in 1 day), with titer to be determined after the unit has been infused.
223832469|NCT04015882|OTHER|Exercise therapy|The exercise therapy group will make by physiotherapist supervision.
223832470|NCT04777188|PROCEDURE|Percutaneous Intramyocardial Septal Radiofrequency Ablation for hypertrophic obstructive cardiomyopathy|Under transthoracic echocardiography (TTE) guidance, the puncture site is positioned at the apex. A guiding line is applied along the septal long axis and the radiofrequency ablation electrode needle(17G, Cool-tip™ RF Ablation System and Switching Controller;Medtronic, Minneapolis, MN, USA) pierced towards the hypertrophic anterior interventricular septum (AIVS) 8-10 mm from the subaortic valve. Each ablation lasts for up to 12 min and the ablation power is gradually increased from 30-40W. Then, the ablation needle is withdrawn 10 mm to prepare for the next application. Overall, 3-4 applications are performed in each patient. The ablation creates an area of thermal coagulative myocardial necrosis that appears as a hyperechogenic reflection detected by TTE. If deemed necessary, we repeat the procedure at the posterior interventricular septum (PIVS).
223832471|NCT04291170|OTHER|QDASH|completing the tasks on the QDASH: open jar, wash wall, carry shopping bag, wash back, cut food, hammer wood
223832472|NCT04291170|OTHER|KOOSJR|completing tasks on the KOOSJR: pivot, straighten, go up/down stairs, stand upright, rise from sitting, bend over
223832473|NCT02647047|PROCEDURE|Spinal analgesia|Administration of morphine 0.2 mg in subarachnoid space.
223832474|NCT02647047|PROCEDURE|Epidural analgesia|Bolus of ropivacaine 0.2% 4-6 mL followed by continuous epidural infusion of ropivacaine 0.2% 99 mL + sufentanil 50 mcg/mL 1 mL in epidural space
223832475|NCT02647047|PROCEDURE|Transversus Abdominis Plane block|Administration of ropivacaine 0.375% 20 mL in the plane between the internal oblique and the transversus abdominis muscles, bilaterally
223832476|NCT02647047|PROCEDURE|Surgical wound infiltration|Infiltration of the surgical wound with ropivacaine 0.75% 10- 20 mL
223832477|NCT02647047|DRUG|Acetaminophen|Administration of 1000 mg of acetaminophen 40 minutes before ending of surgery followed by intravenous administration of 1000 mg every 8 hours
223832478|NCT02647047|DRUG|Ketorolac|Administration of a non-steroidal antinflammatory drug (ketorolac 30 mg) as a rescue therapy
223832479|NCT02647047|DRUG|Ropivacaine|Epidural bolus of ropivacaine 0.2% 4-6 mL followed by continuous epidural infusion of ropivacaine 0.2% 99 mL
223832480|NCT02647047|DRUG|Sufentanil|Epidural continuous epidural infusion of sufentanil 50 mcg/mL 1 mL
223832481|NCT02647047|DRUG|Ropivacaine|Administration of ropivacaine 0.375% 20 mL in the plane between the internal oblique and the transversus abdominis muscles, bilaterally to obtain the transversus abdominis plane block
223832482|NCT02647047|DRUG|Ropivacaine|Infiltration of the surgical wound with ropivacaine 0.75% 10- 20 mL
223832483|NCT03257995|DRUG|Indacaterol maleate|150 μg via Concept1 device
223832484|NCT03257995|DRUG|Indacaterol acetate|150 μg via Concept1 device
223832485|NCT03257995|DRUG|Placebo|Capsule containing no active ingredients delivered via Concept1 device
223832486|NCT06211387|PROCEDURE|Resistance Exercise Training|Resistance Exercise Training for knee
223832487|NCT06211387|PROCEDURE|Joint Mobilization|Tibiofemoral and Patellofemoral Joint Mobilization
223832488|NCT03355105|OTHER|Objective adjustment of the MI/E exsuflation pressure and evaluation of cough effort|The exsufflation pressures will be progressively increased starting from -20 cmH2O with 10 cmH2O increments up. 3 coughing operations will be realised for each level, until obtention of 10% of AUC decrease or a PCF collapse of at least 10% over the last 2 levels and without exceeding -70 cmH2O. The selected landing will be the one allowing the largest PCF without presence of collapse. An intermediate bearing between 2 bearings may be tested in order to approach an optimum adjustment threshold less than 5 cmH2O.
223832489|NCT03355105|OTHER|Subjective adjustment of the MI/E exsuflation pressure and evaluation of cough effort|"The exsufflation pressures will be gradually increased from -20 cmH2O, with 10 cmH2O increments up to a maximum of -70 cmH2O. The selected level will be the one selected both by the patient and the clinician therapist and considered as making it possible to obtain the most effective cough according to the return of the patient."
223832490|NCT00346996|DRUG|insulin levemir / aspart|for subcutaneous injection
223832491|NCT00346996|DRUG|human insulin /insulin isophane|for subcutaneous injection
223832492|NCT03124628|OTHER|Flywheel resistance exercise|Flywheel resistance exercise, originally designed to maintain function, size and quality of skeletal muscle during spaceflight, employs iso-inertial technology rather than gravity dependent weights, which allows for coupled accommodated concentric and eccentric muscle actions, and brief episodes of eccentric overload.
223832493|NCT03124628|OTHER|Weight-stack resistance exercise|Conventional weight-stack resistance exercise
223832494|NCT03677882|BEHAVIORAL|Mind Body Bridging Group Session|Participants assigned to TAU + MBB will will receive treatment from the Suicide Prevention Team and the Mental Health Service, AND will be asked to participate in consisting of three to eight 60-minute sessions that will occur consecutively. Each group will be led by a trained MBB facilitator. Participants will receive a workbook at the beginning of the training that contains an explanation of all the major concepts involved in Mind Body Bridging. The workbook has homework assignments to be completed daily between group sessions.
223832495|NCT01642069|OTHER|laboratory biomarker analysis|Correlative studies
223832496|NCT05291884|DEVICE|Impella BTR|Subjects will be prepared for pump insertion procedure according to clinical site standard of care. Procedural preparations for insertion of the Impella BTR are identical to the insertion of the Impella 5.0/5.5 via the axillary artery. The Impella BTR remains in situ until the patient is sufficiently recovered for removal or is transitioned to another form of support. It is expected that the Impella BTR is in situ for a maximum of 28 days.
223832497|NCT00127972|DRUG|stavudine|
223832498|NCT00127972|DRUG|lamivudine|
223832499|NCT00127972|DRUG|nevirapine|
223832500|NCT00127972|DRUG|efavirenz|
223832501|NCT00127972|DRUG|trizivir|
223832502|NCT05401370|PROCEDURE|Methylene blue dye|For MB group, the staining of the glandular tissue will be obtained with 3-4 mL of 1% MB that will be introduced into the gland via the salivary duct several minutes before the surgery.The trans-oral catheterization of the Stensen's duct will be performed and the solution will be injected via intravenous cannula.The glandular tissue will turn dark blue.
223832503|NCT00747318|DRUG|SKP FlutiForm HFA pMDI|Each subject will receive SKP FlutiForm HFA pMDI 250/10 microgram twice daily for 60 weeks (two actuations of SKP FlutiForm HFA pMDI 125/5 microgram/actuation) for a total daily dose of 500 microgram fluticasone propionate and 20 microgram formoterol fumarate.
223832504|NCT05509712|BEHAVIORAL|Focus Groups to Refine MobileMen App Content|Participants are shown a clickable wireframe of the proposed new app features, including competition, animated badges, leaderboard, and incentives. Focus group members discuss perceptions, ease of use, and interest in the app design/features and identified additional or unnecessary features for adopting and maintaining physical activity (PA).
223832505|NCT05509712|BEHAVIORAL|Beta testing of MobileMen App Prototype|Project staff present the clickable wireframe prototype and have men navigate and test features using a structured script. Staff track participant responses in notes, as well as through both recording via a side profile and the device screen. At the conclusion of the session, participants complete surveys measuring satisfaction, helpfulness, and usability.
223832506|NCT02258464|DRUG|Radium-223 dichloride (Xofigo, BAY88-8223)|Up to 6 cycles of radium-223 dichloride 50kBq/kg body (55 kBq/kg after implementation of National Institute of Standards and Technology \[NIST\] update)
223832507|NCT02258464|DRUG|Placebo (saline)|Up to 6 cycles of saline injection
223832508|NCT02258464|OTHER|Background hormonal therapy|Prescribed by PI and was provided as long as patient can tolerate treatment. It must be prescribed as per local label in country participating.
223832509|NCT04723160|DIAGNOSTIC_TEST|Software assisted imaging diagnosis|In the test group, diagnoses are given with the help of the software.
223832510|NCT02779595|OTHER|Perioperative pulmonary function tests|Pulmonary electrical impedance tomography, spirometry, pulse oximetry and query performed preoperatively, at the the third, fifth and seventh postoperative day
223832511|NCT02138747|DRUG|Mirabegron|Oral
223832512|NCT02138747|DRUG|Tolterodine ER|Oral
223832513|NCT05970835|OTHER|Control group|Participants assigned to control group will receive the usual care provided by clinicians and physiotherapists from the Complexo Termal de Caldelas. Participants will have an educational session conducted by one of the researchers, and a paper sheet will be distributed with exercises and a written explanation of how to perform those exercises and the number of sets and repetitions. data collection will be conducted in moments t2 and t3 by a phone call.
223832514|NCT05970835|OTHER|Experimental group|"Experimental group evaluation: balance, functionality- 30 Second Sit To Stand Test, Modified Medical Research Council and functional status questionnaire, pain using VAS, cognitive variables-Montreal Cognitive Assessment and self-reported thermal water effects.After evaluation the App will display exercises related to data collected. Outcome measures will be collected at baseline, and 1 week, 1 month and 3 months after baseline.~After evaluation the App will display exercises related to data collected concerning participants condition improvement."
223832515|NCT04170296|DRUG|EN3835|Collagenase Clostridium Histolyticum (CCH)
223832516|NCT00932646|DRUG|BI 1744 (Olodaterol) Low Dose|BI1744 Respimat low dose once daily and placebo Foradil
223832517|NCT00932646|DRUG|BI 1744 (Olodaterol) Medium Dose|BI1744 Respimat medium dose once daily and placebo Foradil
223832518|NCT00932646|DRUG|Placebo|Placebo Respimat once daily and placebo Foradil
223832519|NCT00932646|DRUG|Foradil|12 mcg twice daily and placebo Respimat
223832520|NCT03381508|DEVICE|Brizzy continuous positive pressure device|Patients are treated with the Brizzy continuous positive pressure device, including pneumotachograph.
223832521|NCT02699541|BEHAVIORAL|Diabetes Self-Management Education|"This study will implement an individualized DSME program based on Information-Motivation-Behavioral (IMB) skills theory. IMB behavioral change theory assumption proposes that health-related behavior information, motivation and behavioural skills are primary determinants of promoting health behavior.~Researcher will use a previously validated educational toolkit (PRIDE) and will be delivered using motivational interviewing techniques through several sessions for each participant. Two face-to-face sessions (one at the beginning and one at the end of the 3 month period) and one phone call per week or per fortnight."
223832522|NCT01272713|OTHER|Oxygen therapy|"* Pre-hospital supplemental oxygen administered via Hudson mask at a flow rate of 8L/min~* In-hospital oxygen as per hospital protocol"
223832523|NCT01272713|OTHER|No oxygen therapy|No oxygen pre-hospital or in-hospital unless the oxygen saturation falls below 94% in which case oxygen will be administered via nasal cannulae (4L/min) or Hudson mask (8L/min) and titrated to achieve oxygen saturation of 94%.
223832524|NCT05282849|PROCEDURE|ultrasound guided fascia iliaca block|ultrasound guided fascia iliaca block anesthetizes variable combinations of the femoral nerve , lateral femoral cutaneous nerve , and obturator nerve, and is effective for many painful hip surgeries making it potentially useful for analgesia following Developmental Dysplasia of Hip (DDH) surgery.
223832525|NCT05282849|PROCEDURE|ultrasound guided quadratus lumborum block|ultrasound-guided quadratus lumborum (QL) block provides perioperative somatic, even visceral analgesia for patients including pediatrics, undergoing abdominal or hip surgery. The local anesthetic injected adjacently into the quadrates lumborum muscle spreads in a medial and cranial direction under the crura and arcuate ligaments of the diaphragm, then into the thoracic paravertebral space anesthetizing the hip region
223832526|NCT03826134|DRUG|[11C]PXT012253|Single intravenous bolus injection. The injected amount will be less than 5 μg. The radioactive dose is approximately 400 MBq per 70 kg body weight.
223832527|NCT01722318|DRUG|Plecanatide|
223832528|NCT01722318|DRUG|Placebo|
223832529|NCT06144268|DEVICE|ZyMōt Multi (850µL)|An amount of 850 µl untreated semen sample will be loaded into the inlet chamber with a help of a sterile insulin-type syringe. A volume of 750 µl of Sage Quinn's AdvantageTM Medium with Hepes + 5% HSA-solution medium will be placed on top of the membrane (outlet chamber). After 30 min of incubation in a humidified incubator (37°C), 500 µl of medium, containing the selected spermatozoa, will be retrieved from the upper side of the membrane (retrieval chamber). An amount of 400 µl will be necessary for the IUI procedure.
223832530|NCT06144268|OTHER|Density Gradient Centrifugation|"The gradient columns will be prepared by placing 1 ml 80% gradient media in a centrifuge tube and an additional 1 ml of 40% gradient layered on top.~The raw semen sample will be placed on top of the gradient (1ml semen/gradient tube) and centrifuged at 300xg for 20 minutes. The sperm pellet will be collected and washed 2 times for 5 min at 800xg in Sage Quinn's AdvantageTM Medium with Hepes + 5% HSA-solution.~The resulted pellet will be resuspended in the washing solution in a volume that will provide at least 1x106 forward motile spermatozoa in 400 µl, as this amount is necessary for IUI procedure."
223832531|NCT06100380|OTHER|Survey|Questionnaire
223832532|NCT00049686|DRUG|laromustine|
223832533|NCT06189430|OTHER|Yoga|Yoga practice was standardized throughout the study to avoid the risk of intervention variability. The basic structure of each yoga session is meditation, breathing exercises (pranayama), and after a warm-up, yoga practice includes asanas (postures) for strength, balance and mobility, and finally ends with relaxation. The yoga intervention we recommend was created within the framework of the asanas that the elderly can do in the literature and by taking the expert opinion of a sports physician.
223832534|NCT06189430|OTHER|Standard exercise|It is a type of exercise similar in intensity to vinyasa yoga. (50-70% MHR: maximum pulse rate)
223832535|NCT04265443|DEVICE|Percutaneous coronary intervention|PCI was performed using 2nd generation DES
223832536|NCT02126787|BEHAVIORAL|Intensive Group Analytic Psychotherapy|The form of intensive group analytic therapy to be used in the trial has been manualized by the research team for the study. It is rooted in group analysis tradition (Bion 1961; Foulkes \& Anthony, 1965). It is based on two recent group analytic psychotherapy manuals, one developed by Lorentzen (2014), the other by Garland (2010). The manual has been adapted to day treatment setting and also draws on polish psychoanalytical group experiences practiced in a public service. Like in other psychodynamic short-term therapies this approach is more structured and focused on issues relevant to symptoms relief. Thereby additional techniques are used: psychodrama, non-verbal techniques, movie therapy, memoir, summary or relaxation.
223832537|NCT02126787|BEHAVIORAL|Intensive transdiagnostic cognitive-behavioral group therapy|GCBT was designed for treatment in naturalistic settings of diagnostically mixed anxiety disorder patients with comorbid Personality Disorders (PD's) (Holas, Szaniawska, Suszek, Błażejewski, \& Kokoszka, in prep.). It is based on the transdiagnostic approach to emotional and particularly anxiety disorders that has been developed over the past ten years (Barlow, 2000; Barlow, Allen, \& Choate, 2004; Norton, 2006), additionally it includes interventions for personality disorders based of schema therapy and modes of personality disorders. This approach assumes a high overlap between anxiety disorders and is focused on the common aspects of them. Intensive GCBT developed by our group shares the classical assumptions of cognitive-behavioral therapy (Beck, 1976).
223832538|NCT01139905|OTHER|lopinavir/ritonavir|standard dose of lopinavir/ritonavir 100/25 mg tablet q 12 hour.
223832539|NCT05093751|OTHER|Observation|This study does not involve any intervention to subjects.
223832540|NCT06092541|DRUG|Intervention Group: pericervical anesthesia|"Patients assigned to the Intervention Group will receive Pericervical anesthesia before performing Hysteroscopy.~Specifically, for the administration of pericervical analgesia, Mepivacaine/Lidocaine 1.5% 10/15 ml (max dose 7 mg/kg) will be used and pericervical infiltration will be performed at 0.5 cm depth at 3 and 9 hours."
223832541|NCT06092541|OTHER|Nitroux Oxide anesthesia|Patients assigned to the Control Group will receive Nitrous Oxide anesthesia before hysteroscopy
223832542|NCT04196374|GENETIC|Genomic Sequencing|Whole Genome Sequencing and reporting of actionable genomic results for genes included on the ACMG secondary findings list.
223832543|NCT00004220|DRUG|gemcitabine hydrochloride|
223832544|NCT00004220|DRUG|oxaliplatin|
223832545|NCT05228093|PROCEDURE|Curative-intent endoscopic necrectomy followed by reconstruction using the posterior pedicle nasal septum and floor mucoperiosteum flap|"Radical endoscopic necrectomy was performed under general anesthesia using the endoscopic endonasal approach. And the reconstruction of the nasopharyngeal defect use the nasal septum and floor mucoperiosteum flap. Antibiotic therapy based on the result of bacterial cultivation before the surgery was administered for 5-7 days after surgery. Patients are prescribed regional perfusion with recombinant human epidermal growth factor derivative liquid (Watsin Genetech Ltd, Shenzhen, Guangdong, P.R. China) to keep the wound humid, and endoscopic nasal cleanup was performed every 2-4 weeks until the flap was completely epithelialized and the entire defect was relined.~Patients who were assessed as non-healing at 3 months after treatment will underwent salvage surgery."
223832546|NCT05228093|PROCEDURE|Conservative treatment|"Debridement guided by nasopharyngeal endoscopy and excision of the radiation-induced necrotic tissues were performed every 1 or 2 weeks. Patients are prescribed regional perfusion with recombinant human epidermal growth factor derivative liquid (Watsin Genetech Ltd, Shenzhen, Guangdong, P.R. China) to keep the wound humid. Other conservative treatment included daily nasopharynx rinsing with 2% aquae hydrogeniidioxide (5-10 mL each time) or saline (50-100 mL each time) and antibiotic therapy (metronidazole or ornidazole) guided by the culture results was also performed synchronously. Intravenous nutrition and systematic antibiotic therapy were also performed if indicated and necessary. In addition, patients can receive hyperbaric oxygen therapy when conditions permit.~Patients who were assessed as non-healing at 3 months after treatment will underwent salvage surgery."
223832547|NCT03766893|DRUG|Buprenorphine / Naloxone Oral Product|To treat opioid use disorder, buprenorphine/naloxone will be provided by a study pharmacist under a collaborative pharmacy practice agreement on a weekly (buprenorphine/naloxone) basis, unless the care plan specifies greater frequency of pharmacy visit. The median expected dose of buprenorphine/naloxone (sublingual film or tablet) is 8 to 24 mg daily, and may be adjusted per the collaborative pharmacy practice agreement.
223832548|NCT03766893|DRUG|injectable naltrexone|To treat opioid use disorder, injectable naltrexone will be provided by a study pharmacist under a collaborative pharmacy practice agreement on a monthly (injectable naltrexone) basis. The expected dose of injectable naltrexone will be approximately 380 mg. Injectable naltrexone will be dispensed and prepared by the pharmacist but administered by nursing staff for the pilot study.
223832549|NCT03766893|OTHER|Pharmacy maintenance addiction care|Patients on a stable dose of buprenorphine/naloxone or naltrexone will receive maintenance care at the pharmacy for one month. Patients will visit weekly for check-ins with a pharmacist. Patients on buprenorphine/naloxone will be dispensed their medication at study visits, whereas patients taking injectable naltrexone will be dispensed it once by the pharmacist during the pilot. All patients will visit the pharmacy at least weekly for addiction care (assessment, toxicological testing).
223832550|NCT04694482|OTHER|Psychometric scale administration|PTSD symptoms are assessed using a specific scale (IES-R) and compared between the two groups
223832551|NCT04529603|DEVICE|LungBrella marker implantation and VATS partial lobe resection|The enrolled patients will receive a plain chest CT scan,then the data be loaded into JediVision software. The JediVision software can navigate the location of nodule and facilitate the implantation of LungBrella marker in the operating room after general anesthesia,then the patients will receive VATS partial lobe resection .
223832552|NCT01706224|PROCEDURE|Blood sample|Samples will be tested to determine the presence of anti-pertussis antibodies.
223832553|NCT01706224|OTHER|Data collection|Electronic Case Report Forms (eCRF)
223832554|NCT01706224|OTHER|Data collection|Questionnaires, active questioning.
223832555|NCT03044262|OTHER|Standard adhesive strip|This is a standard adhesive strip (hydrocolloid) that is part of an ostomy device
223832556|NCT03044262|OTHER|New adhesive strip|This is a newly developed adhesive strip that in the future might be part of an ostomy device
223832557|NCT02800603|BEHAVIORAL|Family Check Up|"The FCU is an ecologically sensitive, evidence-based, targeted intervention that aims to reduce child EBP. Features of the FCU: 1) Assessment-driven: a multi-method, multi-informant assessment in which the consultant reviews strengths and difficulties across domains of contextual risk, family functioning and child health. A tailored intervention plan is then created based on results 2) Motivational interviewing: Caregivers engage in self-assessment about motivation and barriers to addressing factors that may perpetuate risk. The consultant and caregiver work to establish a menu of services 3) The family may be offered up to 6 sessions of the Everyday Parenting curriculum. The FCU has demonstrated effectiveness and cultural sensitivity across multiple US settings."
223832558|NCT03567993|BEHAVIORAL|Comparison|Participants randomized to the comparison arm will receive twice-monthly abstinence assessments from the text messaging system, with no motivational feedback. Those in the comparison arm are neither offered nor encouraged to participate in the intervention.
223832559|NCT03567993|BEHAVIORAL|Intervention|"Participants randomized to the intervention arm will receive:~1. Motivational Messages~2. Abstinence and Motivation to Use Services Assessments~3. Encouragement to access the Quitline~4. Encouragement to use Nicotine Replacement Therapy (NRT)~5. Provision of NRT, if requested~Intervention subjects are encouraged to access the Quitline and use NRT. However, these are not mandatory components of the intervention and subjects can choose if they would like to engage with the Quitline or use NRT."
223832560|NCT05858203|OTHER|ATAC-seq and ChIP-seq|CD138+ cells will be isolated from the bone marrow of MM patients and will be subjected to ATAC-seq and ChIP-seq analyses, by useing specific antibodies, to better understand the involvment of Che-1 in MM tumorogenesis.
223832561|NCT04410887|DRUG|PIPAC+SOX+OLAPARIB|SOX Chemotherapy regimen A cycle consists of Day 1: Oxaliplatin 130mg/M2 intravenous Day 1-14 Tegafur gimeracil oteracil potassium capsule 80mg/M2 oral (twice daily) Repeated every 21st day OLAPARIB Day 1-14: Olaparib 300mg BID PO
223832562|NCT02798029|RADIATION|Frameless Fractionated Stereotactic Radiation Therapy|
223832563|NCT06330636|OTHER|D-Allulose|Test breakfast
223832564|NCT06330636|OTHER|Sodium Saccharin|placebo breakfast
223832565|NCT02210910|DEVICE|InSpace™ system over repair|
223832566|NCT02210910|PROCEDURE|Best Repair of torn Rotator Cuff|
223832567|NCT01931579|DEVICE|confocal endo-microscopy|The intervention consists of the use of confocal endo-microscopy using the CELLVIZIO device and either the 1 mm CELLVIZIO miniprobe (ALVEOFLEX) or the 0.6 mm CELLVIZIO miniprobe (CHOLANGIOFLEX), during a navigational bronchoscopy procedure for the diagnostic of peripheral nodule. In this study, the navigational device - either radial endobronchial ultrasound (EBUS) or electromagnetic navigation (EMN) - will be moved to another location if the CELLVIZIO displays a non solid pattern, indicating that the nodule may not have been reached during the procedure. Three attempts of EBUS or EMN are allowed until the CELLVIZIO shows a solid pattern.
223832568|NCT00671996|DRUG|Mangafodipir|"Treatment will be undertaken with a ready-to-use investigative drug formulation identical to what is in diagnostic use as a contrast medium for MRI.~Formulation content: MnDPDP 10 mmol/ml~Administered dose per cycle: 2 μmol/kg b.w. Administration form: Ready-to-use formulation (solution). Mangafodipir or placebo (0.2 ml/kg b.w.) will be administered as an i.v. infusion over 5 min about 30 min prior to start of chemotherapy."
223832569|NCT00671996|DRUG|Placebo treatment (0.9% NaCl)|Intravenous infusion, 2 micromol/kg, pretreatment 30 minutes before the start of FOLFOX treatment (during the first three FOLFOX treatments)
223832570|NCT01378520|DRUG|ketoconazole|600 mg capsule oral once
223832571|NCT01378520|DRUG|inert powder|oral once
223832572|NCT02653924|OTHER|silk suture|each treatment will include 4 types of suture (as described above). all subjects will receive the same types of sutures. treatment plan is NOT influenced by the suture material used.
223832573|NCT02653924|OTHER|vicryl suture|each treatment will include 4 types of suture (as described above). all subjects will receive the same types of sutures. treatment plan is NOT influenced by the suture material used.
223832574|NCT02653924|OTHER|nylon suture|each treatment will include 4 types of suture (as described above). all subjects will receive the same types of sutures. treatment plan is NOT influenced by the suture material used.
223832575|NCT02653924|OTHER|polypropylene suture|each treatment will include 4 types of suture (as described above). all subjects will receive the same types of sutures. treatment plan is NOT influenced by the suture material used.
223832576|NCT06192355|DEVICE|Endoscopic hemostasis using a Esophagogastroduodenoscopy|performing an Esophagogastroduodenoscopy for diagnosis and therapy of possible bleeding sites
223832577|NCT03978390|BEHAVIORAL|behavioral priming|Priming the children with images of superheroes in order to behave desirably during the dental injection
223832578|NCT03978390|BEHAVIORAL|endowment effect|Giving the rewards to children before starting the dental treatment and telling children they can only keep it if they behave desirably during the dental procedure
223832579|NCT03978390|BEHAVIORAL|Positive reinforcement|Giving rewards to the children at the end if they cooperate desirably during the treatment
223832580|NCT00547105|DRUG|Erlotinib|Erlotinib is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) after failure of at least one prior chemotherapy regimen.
223832581|NCT00547105|RADIATION|SBRT|SBRT is a treatment method to deliver a high dose of radiation to the target, utilizing either a single dose or a small number of fractions with a high degree of precision within the body
223832582|NCT00594789|OTHER|Information letters|Information letters under Manitoba Health letterhead will be sent out to physician(s) and/or patient connected with a fracture that meets specific criteria. To address concerns over discontinuous care of patient seen at the time of fracture and for subsequent follow-up, the physician notification will specifically target the individual involved in the initial report to Manitoba Health as well as the primary care physician (using an algorithm developed by the Manitoba Centre for Health Policy). The notification will provide a general recommendation for osteoporosis assessment in addition to a copy of the BMD testing requisition since BMD testing is usually justified in this setting. The notification will not dictate what testing or treatment needs to be performed.
223832583|NCT03314623|BEHAVIORAL|Weight bearing as tolerated|If fracture is deemed stable the subjects will be allowed to weight bear immediately after surgery.
223832584|NCT02475044|BEHAVIORAL|Cognitive-Behavioral Therapy|16 Sessions of CBT.
223832585|NCT06420596|OTHER|Conventional Physiotherapy|Conventional physiotherapy is one prescription of 9 in person physiotherapy sessions (according to FMH Switzerland guidelines). The frequency of the physiotherapy sessions are at the discretion of the treating clinician, but the recommendation is 1 to 2 sessions per week.
223832586|NCT06420596|DEVICE|Akina Cloud|Akina Cloud is a digital health application that supports therapeutic exercises in people with musculoskeletal disorders. It is the first app-supported physiotherapy solution available in Switzerland.
223832587|NCT05544552|DRUG|TYRA-300|TYRA-300 is an oral, novel potent FGFR 3-selective tyrosine kinase inhibitor that targets tumors that contain activating gene alterations of FGFR3.
223832588|NCT05745428|OTHER|molecular and cellular analyses|sample blood
223832589|NCT02014090|OTHER|Hemodynamic and biological measurements|by MCE, PWA, Doppler, Multiplex, FACS
223832590|NCT04437147|DIETARY_SUPPLEMENT|Placebo|Fibers with vitamins and minerals will be administered for 30 days once a day in sachets
223832591|NCT04437147|DIETARY_SUPPLEMENT|3 Billion UFC strains of probiotics|Fibers with vitamins and minerals will be administered for 30 days once a day in sachets with 3 billion CFU strains of probiotics
223832592|NCT04437147|DIETARY_SUPPLEMENT|8 Billion UFC strains of probiotics|Fibers with vitamins and minerals will be administered for 30 days once a day in sachets with 8 billion CFU strains of probiotics
223832593|NCT05240833|DIAGNOSTIC_TEST|VExUS Score|"The VExUS-Guided Arm care team will be informed of the Day 0 VExUS immediately after the ultrasound is performed and given a suggested target for the following 48 hours as follows:~* VExUS 0: There is no evidence of venous congestion.~* VExUS 1: There is evidence of mild venous congestion. The investigators recommend targeting a net neutral or negative fluid balance with diuresis.~* VExUS 2-3: There is evidence of moderate to severe venous congestion. The investigators recommend targeting a fluid balance of negative 1-2L with diuresis.~* If the investigator cannot obtain ultrasound images of sufficient quality to calculate VExUS, the care team will be informed that there is no recommendation for that subject on that day."
223832594|NCT04650971|BIOLOGICAL|UniFluVec|Vaccination was performed intranasally (0.25 ml in each nostril) twice with an interval of 3 weeks
223832595|NCT04650971|BIOLOGICAL|Placebo|Vaccination was performed intranasally (0.25 ml in each nostril) twice with an interval of 3 weeks
223832596|NCT04023097|DEVICE|Toothwave toothbrush|Subjects get the device's box with the user manual and the device. However, they don't use the device, but only read the user manual and fill questionnaires.
223832597|NCT06226428|OTHER|Bed cyclo-ergonometry|The MotoMed Letto 2 device will be used, with a progressive pattern, starting at 5 minutes and lasting up to 30 minutes. It will be performed once a day, during weekdays (Monday to Friday) until discharge from the intensive care unit, and at a modified Borg intensity of 2-3 (Light).
223832598|NCT06226428|OTHER|Bed mobility activities (turning, pelvic elevation and sitting), standing, transfers and walking.|Bed mobility activities (turning, pelvic elevation and sitting), standing, transfers and walking.
223832599|NCT06226428|OTHER|Progressive upper and lower limb strength training|Performing isometric exercises, strengthening with multi-resistance elastic bands or multi-weight dumbbells.
223832600|NCT01755624|DEVICE|NovoTTF-100A device|
223832601|NCT01755624|OTHER|Best Standard of Care|
223832602|NCT00552773|DRUG|Cyclamen Europaeum|Nasal spray 10% (V/V),one spray per nostril daily for 7 days.
223832603|NCT03791385|BEHAVIORAL|Picture Exchange Communication System (PECS)|A communication system frequently used with non-verbal children with autism spectrum disorders (ASD) that uses a series of pictures that describe how a certain activity is done, in our case showing a structured method and technique for teeth brushing.
223832604|NCT06823557|DIETARY_SUPPLEMENT|Psychobiotic treatment|The dietary supplementation will follow established guidelines, recommending an intake of 16 g of prebiotic per day, distributed across three meals, for a duration of 12 weeks.
223832605|NCT06823557|OTHER|Placebo treatment|The control group will receive identical packaging that matches the experimental treatment in taste and appearance and will follow the same guidelines for consuming the placebo. For ethical reasons, after the end of the RCT, the control group will be given the option to receive the same prebiotic supplement.
223832606|NCT05741905|DRUG|Levofloxacin|Levofloxacin is a quinolone antibiotics and newly identified neuro-protective agent. Intravenous thrombolysis is one of the treatments for acute ischemic stroke.
223832607|NCT05741905|DRUG|Levofloxacin simulant|Levofloxacin simulant is placebo. Intravenous thrombolysis is one of the treatments for acute ischemic stroke.
223832608|NCT00903786|DRUG|perampanel|Patients will receive the same oral dosage (2 mg up to 12 mg once daily before bedtime) as used in the maintenance period of Study 231.
223832609|NCT00220961|DRUG|Pioglitazone|Pioglitazone tablets - 45 mg/day
223832610|NCT00220961|DRUG|Placebo|Placebo tablets similar to pioglitazone tablets - 1 tablet/day
223832611|NCT00006432|PROCEDURE|very low fat diet|
223832612|NCT03806868|OTHER|voucher for ordering foods (ONLY omega-3 rich foods)|A voucher will be provided weekly (4 times) for ordering only omega-3 rich foods. Groceries will be delivered to participants' home weekly.
223832613|NCT03806868|OTHER|voucher for ordering foods in general (any type of foods)|A voucher will be provided weekly (4 times) for ordering any type of food. Groceries will be delivered to participants' home weekly.
223832614|NCT00459303|DEVICE|aspherical intraocular lens|implantation of aspherical intraocular lenses(AMO Tecnis Z9000)during cataract suregry (small cornea incision phacoemulsification, deliver with Monarch II device, in the bag implantation)
223832615|NCT00459303|DEVICE|spherical intraocular lens|implantation of spherical intraocular lenses(Alcon SA60AT Acrysof)during cataract suregry (small cornea incision phacoemulsification, deliver with Monarch II device, in the bag implantation)
223832616|NCT00798356|OTHER|Yoga training|Yoga training for 12 weeks
223832617|NCT03651232|BEHAVIORAL|yoga|once weekly group yoga class for 12 weeks
223832618|NCT03651232|BEHAVIORAL|support group|once weekly group support class for 12 weeks
223832619|NCT02380508|DRUG|BCG SSI|Intradermal injection
223832620|NCT02380508|OTHER|No vaccination|
223832621|NCT02380508|DRUG|BCG Sii|intradermal injection
223832622|NCT06017388|BEHAVIORAL|Hypnosis|We will propose a hypnotic induction followed by a suggestion of mystical experience (based on Lynn \& Evans, 2017).
223832623|NCT06017388|BEHAVIORAL|Control|We will propose the neutral reading of a mystical expetience suggestion (based on Lynn \& Evans, 2017).
223832624|NCT04081519|DEVICE|active rTMS over DLPFC|15 sessions of active rTMS over DLPFC
223832625|NCT04081519|DEVICE|Add-on active rTMS over DLPFC|15 additional sessions of active rTMS over DLPFC
223832626|NCT04081519|DEVICE|Add-on active rTMS over LPC|15 additional sessions of active rTMS over LPC
223832627|NCT04081519|DEVICE|Add-on sham rTMS|15 additional sessions of sham rTMS over DLPFC or LPC
223832628|NCT06493123|OTHER|Conventional Cardiopulmonary Rehabilitation|Conventional cardiopulmonary applications including positioning, chest physiotherapy, in-bed normal joint movement exercises, sitting and walking, posture exercises
223832629|NCT06493123|OTHER|Bottle P.E.P. (Pozitive Expiratory Pressure)|"The device will be built according to the optimal design parameters for a positive expiratory pressure therapy bottle device established by Mestriner et al. According to this~Bottle-P.E.P. device:~* PEP: 10-20 cmH2O~* Inspiration: Expiration Ratio: 1:3-4~* Material Used: Open top plastic bottle, plastic pipe.~Plastic Bottle Specifications:~I. Material-Hard Plastic II. Dimensions-Weight- 40grams; Height- 25cm; Width- 10cm; Perimeter- 20cm III. Water column height- 13cm~Plastic Pipe Properties:~I. Material-Pipette II. Inner Diameter- ≥8mm III. Pipe Length- 30cm IV. Depth in the water column - 10cm; 3 cm above the bottom of the bottle surface.~\- The distal end of the tube used in the Bottle P.E.P. will be placed 10 cm below the surface, i.e. 10 cm water column and 3 cm above the bottom of the bottle, and the device will be placed on a table in front of the participant."
223832630|NCT06493123|OTHER|Early Mobilization|"The Maebashi mobilization protocol will be followed for early mobilization program. According to this protocol, the hemodynamic and respiratory parameters of the patient will be evaluated first and the patient who meets the criteria for the mobilization program will be started to the mobilization program according to the appropriate stage of the 5-stage mobilization protocol.~In Maebashi Mobilization protocol:~Level 1: No mobilization and in-bed passive exercise Level 2: Supported in-bed sitting and in-bed active/assistive-active exercise Level 3: Unassisted sitting on the edge of the bed Level 4: Active transfer to chair Level 5: Standing, stepping in place and supported walking about 10 meters (with support of 2 people)"
223832631|NCT01743794|DRUG|Ropivacaine|wound infusion, 0.2%, bolus 10mL followed by 8 mL/h infusion
223832632|NCT01743794|DRUG|Saline solution 0.9%|wound infusion, 0.9%, bolus 10mL followed by 8 mL/h
223832633|NCT04826874|BEHAVIORAL|Affect labeling|Short behavioral intervention teaching affect labeling
223832634|NCT03584776|DEVICE|Virtual Reality|Participants randomized to the VR condition will experience an an immersive guided relaxation VR experience during research visits in the post-operative period. They will also have the opportunity to choose additional VR games and relaxation experiences during their inpatient stay.
223832635|NCT03923010|DRUG|Itraconazole|Participants will receive itraconazole 200 mg orally once daily for 7 days and at the discretion of the treating physician on Day 14. Participants will also get their regular clinical care at the discretion of their treating physician.
223832636|NCT01352702|DRUG|Dabigatran|Patients assigned to this group will receive Dabigatran
223832637|NCT01352702|DRUG|Phenprocoumon|Patients assigned to this group will receive Phenprocoumon
223832638|NCT02379065|DEVICE|The Aerogen Aeroneb Solo©|
223832639|NCT02379065|DEVICE|Phillips Respironic© mask|
223832640|NCT00458913|DRUG|bortezomib|
223832641|NCT00458913|DRUG|cisplatin|
223832642|NCT06559943|OTHER|Traditional Physiotherapy + Placebo Kinesio Tape|"Following a total of 15 sessions of electrophysical agent and exercise training, 5 days a week, for 3 weeks, each session lasting 45 minutes, followed by traditional physiotherapy, 2 days a week, for 3 weeks, a total of 6 times, with 0% tension applied to the trapezius muscle in the neck region (I). Kinesiotape will be applied.~The tape will be applied twice a week in total, staying for 3 days and leaving one day free after each application."
223832643|NCT06559943|OTHER|Traditional Physiotherapy + Kinesio Tape Treatment with Inhibition Method|In addition to a total of 15 sessions of electrophysical agents and exercise training, 5 days a week for 3 weeks, each session lasting 45 minutes, kinesio tape will be applied 6 times in total, 2 days a week. Kinesiotape will be cut into an (I) shape (15 cm) with 50% tension and adhered laterally to the C7 joint. In acute cases such as overuse and muscle spasm, it is recommended to apply an inhibition technique that will inhibit the muscle. In the inhibition technique, the direction of the tape should be from the entry point of the muscle to the starting point and the application should be done with very light or light (15 - 25%) tension. In chronic cases, a facilitation technique should be applied to stimulate the weak muscle. The direction of the tape should be from the starting point of the muscle to the attachment point and the application should be done with light or moderate tension (25 - 50%).
223832644|NCT03091101|DEVICE|Scleral lens wearing keratoconics|Cohort of keratoconics fitted with scleral lenses and monitored over 6 months
223832645|NCT01629056|PROCEDURE|ablation|RF ablation to the left atrium of the heart, guided by ECI-contact information (active arm)
223832646|NCT01629056|PROCEDURE|RF ablation|RF ablation to the left atrium of the heart, without the use of ECI-contact information (control arm)
223832647|NCT05240378|OTHER|Surgery|Surgery for cancer as per the stage of the disease and protocol
223832648|NCT00811746|DRUG|Rozerem (Ramelteon)|8 mg taken orally 30 minutes before a split-night PSG
223832649|NCT00811746|DRUG|Lunesta (Eszopiclone)|3 mg taken orally 30 minutes before the start of a split-night PSG
223832650|NCT00811746|OTHER|Historical Controls|Chart review matched for demographics and comorbidities of the study drug groups.
223832651|NCT00401102|BEHAVIORAL|Interpersonal Psychotherapy for Depressed Adolescents|Open clinical trial of IPT-ASI for depressed and self-injuring adolescents, 12-18 years. Goal is to assess feasibility of using IPT-A protocol for teens with co-morbid depression and self-injury. All eligible participants receive 12 weeks of individual IPT-ASI with optional monthly booster sessions. IPT-ASI is a psychosocial intervention that focuses on the importance of interpersonal relationships in relation to psychological functioning. The first phase (4 weeks) includes a review of depression and self-injury symptoms, psycho-education about depression and self-injury, and a detailed assessment of the patient's important interpersonal relationships. The middle phase (weeks 5-9) involves interpersonal skill building, including communication skills, affect identification and expression, problem solving. The final phase ( weeks 10-12) involves review of skills, generalization of skills to other relationships, termination.
223832652|NCT00032344|PROCEDURE|Colonoscopy|Phase I - Cross-sectional; Phase II - 5 year follow-up; Phase III - 10 year follow-up
223832653|NCT02571946|RADIATION|Proton beam therapy|
223832654|NCT01246180|DRUG|Diclofenac|diclofenac 5% vs placebo (topical application) cutaneous blood flow measurement using laser Doppler
223832655|NCT01246180|DRUG|Amiloride|amiloride 1mM vs placebo (intradermal injection) cutaneous blood flow measurement using laser Doppler
223832656|NCT05582096|DRUG|LY3457263|Administered SC.
223832657|NCT05582096|DRUG|Tirzepatide|Administered SC.
223832658|NCT05582096|DRUG|Placebo|Administered SC.
223832659|NCT01597661|DRUG|Exposure to any bupropion during the first trimester|"The primary exposure group will be: any exposure to bupropion during the time period from 28 days prior to the last menstrual period through the fourth lunar month. The use of bupropion in combination with other anti-depressants, exposure to SSRI anti-depressants, and exposure to non-SSRI anti-depressants, including tricyclic anti-depressants, during this time period will be explored.~Mothers of identified infants are contacted within 6 months of delivery and invited to participate in the study by completing a telephone interview, conducted by trained study nurses. The interview addresses demographic, reproductive, and medical factors; medication and vitamin use; cigarette smoking, alcohol, and caffeine consumption, occupational exposures, and dietary intake. Exposure information is obtained directly from the mother in response to questions that focus both on indications for medication use and on medications themselves."
223832660|NCT01597661|DRUG|Exposure to bupropion alone during the first trimester|"The secondary exposure group will be: bupropion exposure alone during the time period from 28 days prior to the last menstrual period through the fourth lunar month.~Mothers of identified infants are contacted within 6 months of delivery and invited to participate in the study by completing a telephone interview, conducted by trained study nurses. The interview addresses demographic, reproductive, and medical factors; medication and vitamin use; cigarette smoking, alcohol, and caffeine consumption, occupational exposures, and dietary intake. Exposure information is obtained directly from the mother in response to questions that focus both on indications for medication use and on medications themselves."
223832661|NCT01597661|OTHER|Referent group: no exposure to any anti-depressant or anti-smoking drug during pregnancy|"The referent group will be defined as no exposure to any anti-depressant or anti-smoking drug at any time from 28 days prior to the last menstrual period through the end of pregnancy.~Mothers of identified infants are contacted within 6 months of delivery and invited to participate in the study by completing a telephone interview, conducted by trained study nurses. The interview addresses demographic, reproductive, and medical factors; medication and vitamin use; cigarette smoking, alcohol, and caffeine consumption, occupational exposures, and dietary intake. Exposure information is obtained directly from the mother in response to questions that focus both on indications for medication use and on medications themselves."
223832662|NCT02934477|OTHER|Hematopoietic Stem Cell Transplant|This observational study will compare outcomes of prospectively enrolled HCT recipients with outcomes of a cohort of age-matched non-HCT controls.
223832663|NCT04253197|DEVICE|Ultrasound|Pregnant women in 3rd trimester with anterior placenta previa and lower cesarean section scar. Ultrasound was done and according to parameters of the morbidly adherent placenta, a staging system was conducted.
223832664|NCT05805306|BEHAVIORAL|Entre Herman@s|The intervention unfolds as follows: (Week 1) the research team, Latino MSM, \& sibling will all engage in a PrEP Conversation followed by an individual Sibling Training for siblings to learn communication strategies for promoting health behaviors; (Week 2) we will send siblings reminders and a link to motivational interviewing techniques; (Week 3) we will conduct brief Follow-ups with siblings to determine if their brother changed his behavior; (Week 4) we will send a reminder to Latino MSM that they will have a follow-up the following week; (Week 5) we will conduct 30-day Follow-up with Latino MSM to determine if there was uptake of the new behavior change; (Week 7) same as week 5 above; (Week 10) send siblings information on motivational interviewing; (Week 12) final follow-up for both Latino MSM and siblings.
223832665|NCT05805306|BEHAVIORAL|Vaccines for Health|The intervention unfolds as follows: (Week 1) the research team, Latino MSM, \& sibling will all engage in a Health Conversation about vaccines for COVID, Hep A/B, or MPOX, followed by an individual Sibling Training for siblings to learn communication strategies for promoting health behaviors; (Week 2) we will send siblings reminders and a link to motivational interviewing techniques; (Week 3) we will conduct brief Follow-ups with siblings to determine if their brother changed his behavior; (Week 4) we will send a reminder to Latino MSM that they will have a follow-up the following week; (Week 5) we will conduct 30-day Follow-up with Latino MSM to determine if there was uptake of the new behavior change; (Week 7) same as week 5 above; (Week 10) send siblings information on motivational interviewing; (Week 12) final follow-up for both Latino MSM and siblings.
223832666|NCT05372679|DEVICE|Renal denervation|The TIVUS system will be used for renal denervation
223832667|NCT01550835|DEVICE|Emboshield NAV6® embolic protection system (Abbott Vascular, Santa Clara, CA)|Standard of care use of an embolic protection device
223832668|NCT01550835|DEVICE|Emboshield NAV6® embolic protection system (Abbott Vascular, Santa Clara, CA)|Aspiration thrombectomy following stent deployment and prior to embolic protection device removal
223832669|NCT04898842|OTHER|Dietary intervention|To determine whether a 4 stage bowel obstruction diet as a means of managing oral intake in patients symptomatic with malignant sub-acute bowel obstruction (SBO) is deliverable and effective in clinical practice.
223832670|NCT03457272|OTHER|New risk assessment|"Consists of a simple physiological scoring system and an assessment of patients who should assist healthcare professionals in identifying patients at risk of clinical deterioration earlier and support timely response and escalation of observation, care and treatment and thereby prevent the development of severe clinical deterioration.~The patients included in the study will be monitored using the new risk assessment tool with different intervals according to the patients' conditions. Underlying the tool are algorithms of action for intervention in the critically ill patient, inter professional guidelines and guidance for standardized monitoring, escalation plans and huddles."
223832671|NCT04970095|DEVICE|Maxillary Expander with Differential Opening (EDO)|The EDO is designed with two expansion screws positioned transversely. When more expansion is required between the canines, the anterior screw can be further activated. Both expansion screws can be activated to open in a parallel configuration. Pivoting corner screws allow for different amounts of expansion without significant risk of binding during activation.
223832672|NCT04970095|DEVICE|Petit Face Mask|"The face mask is anatomical, multi-adjustable, lightweight and an ideal therapeutic alternative for the correction of Class III malocclusion.~consist of forehead cap chin cap cross bar"
223832673|NCT01163747|BIOLOGICAL|tocilizumab|Intravenous repeating dose
223832674|NCT01163747|DRUG|methotrexate|A stable dose of between 7.5 and 25 mg/week, oral or parenteral.
223832675|NCT01163747|BIOLOGICAL|23-Valent Pneumococcal Polysaccharide Vaccine|Intramuscular or subcutaneous injection
223832676|NCT01163747|BIOLOGICAL|Tetanus Toxoid Adsorbed Vaccine|Intramuscular injection
223832677|NCT02392884|BEHAVIORAL|Cognitive Rehabilitation|Provide cognitive techniques and teach compensatory strategies that subjects can use to help them remember to attend appointments, take their medications regularly, increase attention (conversational and task) and concentration, increase cognitive flexibility, develop better problem-solving skills.
223832678|NCT02244099|OTHER|Controlled Substance|Patients will be identified using the reporting workbench in the EMR if they have been prescribed a controlled substance, carisoprodol, or tramadol at least 3 times in the last 6 months by one of the consenting resident physicians from Martha Morehouse General Internal Medicine Resident Continuity Clinic. Once identified, a comprehensive chart review for other important parameters based on best practice recommendations as described in the research protocol will be conducted in order to characterize the patient population for which the recommendations are being made to the physicians. Improvement in controlled substance, carisoprodol, and tramadol prescribing and adherence to the CSTA by the resident physicians will be tracked using a pre/post intervention comparison.
223832679|NCT03109340|OTHER|Supervised treadmill group (Group I)|An exercise prescription was developed for each woman on the basis of the data acquired from the baseline treadmill exercise test. Target HR corresponding to values of 50-70% VO2max (moderate-intensity) was determined by the submaximal treadmill test.The participants were instructed walking exercise at their target HR on a treadmill in Sports Rehabilitation Unit of Pamukkale University. HR was monitored by a Polar HR monitor (Polar Beat, Port Washington, NY).During 12 weeks, 5 days in a week and 30 minutes per day walking program was applied.
223832680|NCT03109340|DEVICE|ECE PEDO pedometer (Group II)|Following a 10-minute rest after treadmill test, the participants were instructed to walk on the treadmill while maintaining their target heart rate. The number of steps taken in a minute was calculated using a criterion pedometer when target HR responses were reached. In this way, we determined the steps per minute required to moderate intensity walking for each participant. Detected individual step numbers were recorded to ECE PEDO for each person. Then participants were given the walking program with ECE PEDO giving audible feedback in case of any deviation from the range of steps per minute.During 12 weeks, 5 days in a week and 30 minutes per day walking program was applied.
223832681|NCT04418414|DRUG|Gene therapy|CD34+ hematopoietic stem cells transduced with CD68-ET3 lentiviral vector (encoding human factor VIII gene) is administered by IV infusion following conditioning regimen with busulfan and anti-thymocyte globulin.
223832682|NCT04418414|OTHER|Biological|G-CSF and Plerixafor are administered by subcutaneous injection prior to apheresis.
223832683|NCT00991822|DRUG|Dorzolamide 2%|
223832684|NCT00991822|DRUG|Timolol 0.5%|
223832685|NCT00554333|BIOLOGICAL|Flu-ID 15μg|Inactivated Split-Virion Influenza Vaccine for Intradermal Route
223832686|NCT00554333|BIOLOGICAL|Inactivated adjuvanted Influenza Vaccine|Inactivated adjuvanted Influenza Vaccine for Intramuscular Route
223832687|NCT04906590|DRUG|[18F] PI-2620|Evaluation of the radiopharmaceutical imaging agent PI-2620 in detecting TAU brain burden.
223832688|NCT02101099|DEVICE|Colonoscopy Force Monitor|Use of Colonoscopy Force Monitoring device (CFM) to measure forces applied to the colonoscope during the procedure.
223832689|NCT00451568|DRUG|Metformin|500 mg 2 tablets 2 times a day
223832690|NCT00451568|DRUG|Desorelle|1 tablet/day in 21 days
223832691|NCT05433402|DRUG|ChlorproMAZINE 50 MG|The experimentall group will receive folinic acid, fluorouracil and oxaliplatin (mFOLFOX6) regimen every 14 days for (6-12 cycles) (6 months) (Day 1: 5-FU IV 400 mg/m2, leucovorin IV 400 mg/m2, oxaliplatin IV 85 mg/m2, 5-FU continuous IV infusion (CIVI) 1200 mg/m2/day x 2 days (over 46-48 hours) plus choloropromazine 50 mg daily for 6 months
223832692|NCT05433402|DRUG|Control|The control group will receive folinic acid, fluorouracil and oxaliplatin (mFOLFOX6) regimen every 14 days for (6-12 cycles) (6 months) (Day 1: 5-FU IV 400 mg/m2, leucovorin IV 400 mg/m2, oxaliplatin IV 85 mg/m2, 5-FU continuous IV infusion (CIVI) 1200 mg/m2/day x 2 days (over 46-48 hours)
223832693|NCT02758574|PROCEDURE|CDT without ultrasound acceleration|A pulmonary arteriogram will be performed. Upon confirmation of the pulmonary embolus a standard infusion catheter will be placed within the clot. The catheter will be used for infusion of thrombolytics to treat/dissolve the pulmonary embolus.
223832694|NCT02758574|PROCEDURE|CDT with ultrasound acceleration|A pulmonary arteriogram will be performed. Upon confirmation of the pulmonary embolus an infusion catheter that incorporates an ultrasound emitting wire will be placed within the clot. The catheter will be used for infusion of thrombolytics to treat/dissolve the pulmonary embolus. The wire will be connected to an ultrasound generating device.
223832695|NCT05929508|OTHER|Ischemic Preconditioning|A blood pressure cuff will be placed on the thigh of the intact/sound limb to restrict blood flow to the lower extremity for 5 minutes and then deflated for 5 minutes to allow for normal blood flow on a cycle for 50 minutes (5 times).
223832696|NCT03363659|DRUG|Disulfiram|Disulfiram is taken orally, twice daily.
223832697|NCT03363659|DIETARY_SUPPLEMENT|Copper gluconate|Copper gluconate is taken orally, twice daily
223832698|NCT03363659|DRUG|Temozolomide|Temozolomide is taken once daily
223832699|NCT01688960|DRUG|nesvacumab (REGN910/ SAR307746)|Dose level 1
223832700|NCT01688960|DRUG|nesvacumab (REGN910/ SAR307746)|Dose level 2
223832701|NCT01688960|DRUG|nesvacumab (REGN910/ SAR307746)|Dose level 3
223832702|NCT01688960|DRUG|aflibercept (ziv-aflibercept)|Dose level 1
223832703|NCT01688960|DRUG|aflibercept (ziv-aflibercept)|Dose level 2
223832704|NCT03417037|DRUG|BMS-986205|Administered orally daily, 100 mg
223832705|NCT03417037|BIOLOGICAL|Nivolumab|Specified dose on specified days
223832706|NCT03417037|DRUG|Chemotherapy|Platinum-based doublet chemotherapy
223832707|NCT06625541|DRUG|AJ302-IM|7 cohorts (7 dose levels) of participants are planned to be dosed.
223832708|NCT06625541|DRUG|Placebo|Matching placebo
223832709|NCT03872388|DRUG|Atorvastatin|"Patients will receive Atorvastatin per ASCVD guidelines dosed as either a moderate intensity (20mg/day) or high intensity statin (80mg/day). Tablets are available in either 20mg or 80mg and will be dispensed as per standard of care for up to 24 months as part of the study.~Patients may also receive capecitabine concurrently with Atorvastatin per physician discretion as standard of care. Standard of care dosing of Capecitabine is a 21 day cycle consisting 14 days on and 7 days off. The starting dosing will be per physician discretion, but may be up to 2500mg/m2 per day."
223832710|NCT03872388|DRUG|Capecitabine|Patients not eligible to receive atorvastatin in group II will be enrolled into non-statin observation group with/without capecitabine treatment. Capecitabine administration will be dosed as per standard of care. Standard of care dosing of Capecitabine is a 21 day cycle consisting 14 days on and 7 days off. The starting dosing will be per physician discretion, but may be up to 2500mg/m2 per day.
223832711|NCT06625736|DRUG|Xenical|The Xenical group will receive identical capsules 120mg (one capsule) to be taken three times daily with meals, equaling 360mg total daily dose, which aligns with the usage in adult female patients
223832712|NCT06625736|DIETARY_SUPPLEMENT|The dandelion extract|The dandelion extract group will receive 500 mg capsules of dandelion leaf extract, given 3 times per day before meals.
223832713|NCT06624917|PROCEDURE|Green Breast Surgery Protocol|A perioperative protocol aiming at reducing environmental impact of surgery, and fast recovery protocol to reduce hospitalization.
223832714|NCT03455296|OTHER|fluid therapy; crystalloid|maintenance fluid e.g. Ringer or Ringer acetate plus replacement fluid with crystalloids e.g. Ringer,or Ringer acetate or saline 0.9%, 500ml / 30 min. guided by ScVO2 with target value ≥ 70% versus lactate clearance (LCR) with target value ≤ 2mmol/L (or decline ≥ 10%) by the end of the study in group A \& group B respectively. Maintenance fluid without replacement will be initiated if ScVO2 or lactate value normalized.
223832715|NCT07032311|DEVICE|Behavioral Treatment|Description: ARM-2-G1: Patient subjects receiving standard care services without GLP-1 medication as part of the treatment regimen, and SIPPA Health behavioral intervention/therapy. ARM-2-G2: Patient subjects receiving standard care services that includes GLP-1 medication as part of the treatment regimen, and SIPPA Health behavioral intervention/therapy.
223832716|NCT07032324|DRUG|CAR T cells|chimeric antigen receptor T cells
223832717|NCT02527070|DEVICE|RESPeRATE (Paced Breathing)|The subjects will be guided by a digital metronome to breath at 15, 10, and 6 breaths/min for 2 minutes each using the metronome function of the device RESPeRATE (InterCure, Israel) that guides breathing using musical tones played at selectable rhythm.
223832718|NCT02527070|DEVICE|Quantum Warp10 (Red LED)|
223832719|NCT02527070|DEVICE|Omnilux new-U (Near Infrared LED)|
223832720|NCT02527070|OTHER|Heat/cold provocation|Immersion of one foot in a warm water bath ( 43-45 degrees C) for few seconds and then immersion of the same foot in cold water bath (5-7 degrees C) for 1 min.
223832721|NCT06718322|OTHER|Primary Cancer Prevention Implementation Toolkit (PCP-IT)|The PCP-IT is an online implementation support toolkit which aims to support implementation teams in improving the implementation of primary cancer prevention programs (PCPs). The PCP-IT builds upon the theory-base and the proven to be effective ItFits tool. The PCP-IT encompasses a total of six modules which are designed to guide implementers through the process of selecting and adapting PCP programs, identifying and addressing barriers, and developing and applying tailored implementation strategies. The toolkit includes: (1) a repository of PCP programs, (2) a repository of determinants of practice, (3) a repository of implementation strategies, (4) stakeholder consultation at all stages, (5) an online community of implementation practitioners, and (6) structured stepped process flows, instructions, examples and worksheets for working with the materials. https://global.itfits-toolkit.com/
223832722|NCT05574374|DRUG|DWP14012|Potassium-competitive acid blocker
223832723|NCT05574374|DRUG|DWC202202|Clopidogrel Bisulfate
223832724|NCT05574374|DRUG|DWC202203|Proton pump inhibitor
223832725|NCT03681639|DIAGNOSTIC_TEST|Serum Metal ion levels determined to monitor changes in chromium and cobalt levels|Analyses was performed pre-operatively, 6 months, 1 year, 2 years and 5 years post-operatively for all study subjects enrolled in this study, as well as, all revision study subjects receiving the Metasul LDH™ total hip system. To prevent intra-observer variation the metal ion concentrations was analysed by an approved Central Laboratory. The Central Laboratory provided specimen collection kits for the transfer of blood specimens to the Laboratory for analysis. The Laboratory provided the results to the Investigators. The cobalt and chromium was measured by induced coupled plasma mass spectrometry (ICP-MS). BUN, creatinine and GFR will be determined locally.
223832726|NCT00654940|DRUG|Pregabalin (Lyrica)|Oral, 75mg or 150mg capsules, BID
223832727|NCT00654940|DRUG|Placebo|Oral, matched capsules, BID
223832728|NCT06058689|DRUG|Pomalidomide 4 MG Oral Capsule|A single dose of 4 mg Pomalidomide per os, capsule, 4 mg, per period
223832729|NCT00092170|DRUG|MK0826, ertapenem sodium|
223832730|NCT00092170|DRUG|Comparator: Ticarcillin/Clavulanate|
223832731|NCT05018650|DEVICE|Route 92 Medical Reperfusion System|Mechanical thrombectomy for acute ischemic stroke patients with large vessel occlusions will be performed with direct aspiration consisting of navigating a large-bore catheter up to the face of the clot and initiating vacuum suction.
223832732|NCT05155280|OTHER|PET imaging using [11C]DASB radioligand.|Subjects will be asked to complete a food choice task in PET/MRI. During the task, PET and MRI scans will be acquired simultaneously. This will allow us to see in real time during food choices the brain activations of the subjects. For imaging we will inject the DASB tracer intravenously. This radio ligand is a tracer that allows us to see the cerebral serotoninergic transmission by positron emission tomography.
223832733|NCT05155280|BEHAVIORAL|Eye Tracker|"The second technique used is the eye tracker that will allow us to analyze food avoidance behaviors through the eyes. With a TOBII eye tracker we wil be able to follow the gaze of the subjects during the food preference task. It is a non-invasive approach."
223832734|NCT00994487|OTHER|High Energy Density Preload|Each child with a parent will attend a lunch session. In these sessions children will drink a liquid preload that is high in energy density and then they will consume an ad libitum lunch. The ad libitum lunch will be videotaped, and the videotapes will be coded for parental feeding styles
223832735|NCT00994487|OTHER|Low Energy Density Preload|Each child with a parent will attend a lunch session. In these sessions children will drink a liquid preload that is low in energy density and then they will consume an ad libitum lunch. The ad libitum lunch will be videotaped, and the videotapes will be coded for parental feeding styles.
223832736|NCT02965209|PROCEDURE|motorized spiral enteroscopy|Novel Motorized Spiral Enteroscopy (NMSE) represents a new technology which offers all of the advantageous options of spiral enteroscopy with a faster and less invasive approach. When the region of interest in the small bowel is reached by NMSE standard endoscopic techniques, e.g. argon plasma coagulation (APC), forceps biopsy or endoscopic mucosal resection (EMR) are performed for treatment and/or tissue acquisition.
223832737|NCT06180252|DIAGNOSTIC_TEST|PET with 11C MP4|Each subject will undergo a PET exam using 11C MP4 as a tracer. This is a specific ligand for the acetyl-choline esterase enzyme already used abroad both in healthy volunteers and in various patient groups.
223832738|NCT06494553|OTHER|cervical stabilization exercises|Neck stabilization exercises included the following: Chin tuck, cervical extension, Shoulder shrugs, Shoulder rolls, Scapular retraction
223832739|NCT06494553|DEVICE|Ultrasound therapy|The Chattanooga Intelect ultrasound made in America. Year of production: 2013. It was clinically proven to provide the best possible treatment outcomes by utilizing a high-quality transducer to ensure maximum ultrasound delivery to the treatment area. The output is a clean, culminated beam with the lowest available beam non-uniformity ratio
223832740|NCT06494553|OTHER|traditional treatment program|US, IR and therapeutic exercise program that consisted of Stretching exercises included the following: 1) stretching pectoralis muscle, placing both hands on the occipital area and pulling the elbows back up, and performing arm abduction and external rotation. 2) Stretching the cervical extensors, placing both hands on the occipital area in a sitting position followed by a flexed neck posture with the head down to stretch the cervical extensors.
223832741|NCT06494553|DEVICE|Infrared therapy|Infrared therapy is a non-invasive treatment modality that uses infrared light to promote healing, reduce pain, and improve circulation. It involves the application of infrared light, which penetrates deep into the tissues, providing therapeutic benefits.
223832742|NCT01941992|DRUG|SAMITAL®|
223832743|NCT01941992|DRUG|Placebo sachets|
223832744|NCT00590070|DRUG|adenosine|Adenosine (80 mcg as fast bolus followed by 2 mg given in 33cc of saline in 2 minutes as slow bolus)
223832745|NCT00590070|DRUG|nitroprusside|Nitroprusside (60 mcg as fast bolus followed by 100 mcg given in 33cc of 5% glucose in 2 minutes as slow bolus)
223832746|NCT00590070|DRUG|placebo|33 cc of heparinized saline given in 2 minutes as slow bolus
223832747|NCT04714216|DEVICE|The Omnipod 5/Horizon HCL system|"The Omnipod 5/Horizon HCL system, consists of a disposable insulin infusion pump (or pod), a built-in model predictive control (MPC) insulin dosing algorithm, and a remote Personal Diabetes Manager (PDM) interface, that interact with a Dexcom G6 continuous glucose monitor (CGM) to automatically control insulin delivery based upon real-time glucose values. The PDM component also enables remote interaction with the system, including glucose monitoring as well as insulin dosing management and adjustments."
223832748|NCT03541811|DIAGNOSTIC_TEST|3-d gait examination (level walking)|"Instrumented 3d-gait-analysis will be carried out in the movement lab of the FH (Fachhochschule; University of Applied Sciences) Campus Wien - University of Applied Sciences. The system used is a 10 camera T40S Vicon system with two floor-mounted AMTI OR6/7-2000 force plates. For assessing gait the Plug-in-Gait Lower Body Model with 14 mm retroreflective skin-mounted markers is implemented in the capturing software Vicon Nexus 2.2. The specific parameters will be extracted from the reporting software Vicon Polygon 4.2.~Markers will be placed by one experienced examiner. Subjects will be instructed to walk barefoot on a 10 meters walkway at self-paced walking speed until five right and five left valid first force plate strikes are captured."
223832749|NCT03541811|DIAGNOSTIC_TEST|Anthropometrics and body composition assessment|Body height will be measured with the stadiometer Seca 213 to the next 0.1cm. Body size and weight will be measured without shoes and outerwear. A correction of 1 kg will be subtracted for clothing. Body weight and body composition will be assessed with the medical body composition analyzer Seca mBCA 515 based on bioelectric impedance analysis.
223832750|NCT03541811|DIAGNOSTIC_TEST|Biomarkers|"Blood will be collected into Vacuette serum-separating tubes and will be kept at room temperature for 30 min. Samples will be centrifuged at 1500g for 10 min and serum aliquots will be stored at 80 C until use. Urine samples will be collected into Vacuette tubes containing no additive from non-fasted individuals between 8:00 and 12:00 a.m. Urine samples will be kept at 4 °C for a maximum of 8 h, and then aliquoted and stored at 80 °C.~All biomarkers (except vitamin D and CRP) will be measured in duplicates using standard enzyme-linked immunosorbent assay (ELISA) kits. Serum samples will be assessed for the level of sCOMP, sC1,2C, and sCS846, IL-6, IL-1, sTNFR1 and sTNFR2. Vitamin D and CRP will be measured using automated immunoassay. In urine samples uCTX-II will be determined and these levels will be corrected for creatinine levels (Jaffé method, in-house validated method)."
223832751|NCT03541811|DIAGNOSTIC_TEST|Clinical examination|Hemophilia joint health score (HJHS) will be assessed. Height will be measured with a stadiometer (SECA 213), weight with a medical scale (Marsden M-420) and leg length according to the Plug-in-Gait protocol with a measuring tape from the Anterior Spina Iliaca Superior to the distal aspect of the Medial Malleolus. Further anthropometrical parameters taken will be knee distance and malleoli distance by using a caliper. Gait relevant passive joint ROM of the knee, hip and ankle will be assessed by means of a handheld goniometer. The flexibility of hamstring muscles will be expressed as Popliteal Angle measured with a goniometer with the subjects supine and the hip in 90° flexion.
223832752|NCT03541811|DIAGNOSTIC_TEST|Habitual physical activity tracking (accelerometer based)|Participants will be instructed to wear an Actigraph wGT3X-BT tri-axial accelerometer permanently over a period of seven consecutive days with an elastic band on right hand sided hip. Data will be process with software ActiLife version 6.13. Cut-offs of at least 10 hours daily wear-time and a minimum of three valid weekdays and one valid weekend day will be applied for data cleaning. Count sampling epoch will be set at one minute. The so called Freedson Adult VM2 Cut-Offs will be applied to categorize physical activity intensities. The so called Freedson VM3 Combination will be applied for the estimation of activity energy expenditure.
223832753|NCT01238783|DRUG|AL-15469A 0.5% and AL-6515 0.3% Ophthalmic Suspension|Topical ocular dosed 3 times per day for 3 days
223832754|NCT01238783|DRUG|AL-15469A 0.5%|Topical ocular dosed 3 times per day for 3 days
223832755|NCT01238783|DRUG|AL-6515 0.3%|Topical ocular dosed 3 times per day for 3 days
223832756|NCT01238783|DRUG|Vehicle|Topical ocular dosed 3 times per day for 3 days
223832757|NCT04615858|DIETARY_SUPPLEMENT|Genepro Generation 3 Protein|Generation 3 Genepro Protein. Micronized protein. Zero lactose. No gluten. All Natural. No flavor. No Sugar. FODMAP Certified protein. 11g in weight, scoop.
223832758|NCT04615858|DIETARY_SUPPLEMENT|Whey Protein|Nutrition industries number 1 selling whey protein powder. No flavor. Gluten Free. 30g scoop.
223832759|NCT06484764|PROCEDURE|CT-fluoroscopy guided robot-assisted biopsy of thoracic and abdominal lesions|"During the procedure, the participant first undergoes a CT scan the radiologist plans the needle trajectory based on the registered preoperative CECT (contrast-enhanced computed tomography~) and intraoperative CT. After the participant is manually sterilised and given local anaesthesia, the radiologist will remotely control the robot to finish the needle insertion process under the CT-fluoroscopy guidance and simultaneously adjust the angular needle if necessary. The radiologist confirms whether the needle has reached the target area by CT-fluoroscopy image."
223832760|NCT06484764|PROCEDURE|Freehand CT-guided percutaneous needle biopsy of thoracic and abdominal lesions|Radiologists following the current clinical practice guidance to finish the freehand biopsy procedure under the CT guidance.
223832761|NCT01924403|PROCEDURE|Staple Closure|
223832762|NCT01924403|PROCEDURE|Vertical Mattress Closure|
223832763|NCT01924403|PROCEDURE|Running Subcuticular Closure|
223832764|NCT03506217|DEVICE|Vigileo Flo-trac device|A Vigileo Flotrac pulse counter invasive arterial cardiac output meter was used for cardiac output measurement. Heart rate, blood pressure, cardiac output, stroke volume variance (SVV), systemic vascular resistance (SVR) values were recorded.
223832765|NCT00608361|DRUG|Dasatinib|Given PO
223832766|NCT00608361|OTHER|Pharmacological Study|Correlative studies
223832767|NCT05764603|DRUG|MRI|MR ARTHROGRAPHY AND CT ARTHROGRAPHY IN PATIENT WITH KNEE OSTEOARTHRITIS
223832768|NCT05084261|DRUG|BT051 200 mg|Oral BT051 200 mg once daily for 28 days.
223832769|NCT05084261|DRUG|BT051 800 mg|Oral BT051 800 mg once daily for 28 days.
223832770|NCT05084261|DRUG|BT051 3200 mg|Oral BT051 3200 mg once daily for 28 days.
223832771|NCT05084261|DRUG|Matching Placebo|Placebo Matching BT051
223832772|NCT03670186|BEHAVIORAL|High-Intensity Interval Training (HIIT)|Participants perform high-intensity interval training (HIIT) on a cycle ergometer. The HIIT protocol consists of a 3-minute warm-up at 50W, ten 60-second high-intensity cycling intervals interspersed with 90 seconds of active recovery at 30% of their peak power output and a 2-minute cool-down at 50W for a total of 17.5 minutes.
223832773|NCT03403933|DRUG|Didrogyl|"Calcifediol will be administered at a dose of 10 drops per day (as indicated for use) for 6 months or until vitamin D levels\> 30 ng / ml are obtained.~Once these values have been obtained, the dosage can be reduced to a dosage of 4/5 drops of calcifediol (1 drop contains 5mcg of calcifediol) with the aim to maintain the plasma values of 25 (OH) D in a optimal range between 30-60 ng / ml during the 6 month of the duration of the study."
223832774|NCT05466474|BIOLOGICAL|Tislelizumab Injection|Efficacy of tislelizumab or tislelizumab combined with dacarbazine in the treatment of advanced malignant melanoma.
223832775|NCT03428568|OTHER|Herbal Melanin|Herbal melanin extracted from Nigella sativa seeds
223832776|NCT03428568|DRUG|Nexium|omeprazole
223832777|NCT03428568|DRUG|Amoxil|Antibiotic
223832778|NCT03428568|DRUG|Clarithromycin|Antibiotic
223832779|NCT06306950|DEVICE|Near infrared spectroscopy neuromonitor to prevent cerebral desaturation|patients were assigned into active treatment (intervention) or usual care (control) groups with cerebral oximetry monitoring using NIRS bilaterally (Root; Prime Medical Corporation, MASIMO, USA) \[17\]. After cleansing the adjacent skin area with alcohol, an adhesive optode pad was placed over each frontal to temporal area. Resting baseline rSO2 values were obtained after waiting at least 1 minute after the placement of the sensors.
223832780|NCT02358460|DEVICE|Ventilation delivered by SLE5000 ventilator|"In pressure-limited ventilation arm, ventilator settings as required to maintain appropriate oxygenation and carbon-dioxide elimination.~In volume-targeted ventilation arm, set target volume at 5ml/kg and wean rate. In both arms, aim to keep blood gases within normal limits."
223832781|NCT02810119|DRUG|LO2A|
223832782|NCT02810119|DRUG|Placebo|
223832783|NCT02471846|DRUG|Atezolizumab|Participants will receive atezolizumab at a fixed dose of 1200 milligrams (mg) via intravenous (IV) infusion on Day 1 of each 21-day cycle with the exception of biopsy cohort A, where atezolizumab administration will start on Cycle 2 Day 1.
223832784|NCT02471846|DRUG|GDC-0919|Participants will receive GDC-0919 by mouth (PO) twice daily (BID), specifically every 12 hours. During the dose-escalation stage, the first cohort will receive GDC-0919 at a starting dose of 50 mg PO BID. Dosing will commence on Day -1 for Cycle 1 and follow subsequent 21-day (Days 1 to 21) dosing cycles. The dose will be modified based upon evaluation of DLTs, with single dose escalations not to exceed 2.5-fold of the previous dose. The proposed dosages for evaluation are 50, 100, 200, 400, 600, and 1000 mg PO BID. During the expansion stage, selected solid tumor types will be treated at the MTD or MAD as determined during the dose-escalation stage.
223832785|NCT01625936|DRUG|CRLX101 (Cerulean)|CRLX101 is an innovative tumor-targeting nanopharmaceutical.
223832786|NCT01625936|DRUG|Bevacizumab|
223832787|NCT01461616|DRUG|NPH|equal doses of NPH insulin, insulin Detemir and insulin glargine injection
223832788|NCT01461616|DRUG|Detemir|equal doses of NPH insulin, insulin Detemir and insulin glargine injection
223832789|NCT01461616|DRUG|Glargine|equal doses of NPH insulin, insulin Detemir and insulin glargine injection
223832790|NCT02104856|DEVICE|Alair System (Bronchial Thermoplasty)|
223832791|NCT02864511|PROCEDURE|Nefertiti lift|
223832792|NCT06365606|DEVICE|iStatis Syphilis Ab Test|Capillary (fingerstick) blood, venous whole blood and plasma samples prospectively collected from the participants will be tested on the iStatis Syphilis Ab Test.
223832793|NCT00913679|PROCEDURE|Surgical approach (ReCap Hip Resurfacing System)|two different surgical approaches in hip resurfacing arthroplasty
223832794|NCT01818141|DRUG|Vancomycin|Vancomycin 125mg by mouth every 6 hours for 10 days
223832795|NCT01818141|DRUG|Fidaxomicin|Fidaxomicin 200mg by mouth every 12 hours for 10 days
223832796|NCT04329143|PROCEDURE|open completion cholecystectomy|open excision of cystic duct remnant
223832797|NCT04329143|PROCEDURE|lap completion cholecystectomy|lap excision of cystic duct stone
223832798|NCT05188963|PROCEDURE|Intermittent catheterization|Intermittent catheterization is performed as treatment for urinary retention. Treatment is stopped when postvoid urinary retention volume is below the threshold of each group.
223832799|NCT04319003|BEHAVIORAL|Sugar-reduction intervention|The intervention consisted of a) installation of a water filter at the school. b) each participant received a metal water bottle. c) a registered dietitian gave a 30-minute presentation on sugar reduction for the purposes of type 2 diabetes prevention
223832800|NCT01062906|DRUG|Lidocaine|1.5 mg/Kg as bolus and a continuous infusion of 2mg/Kg/hr until the end of surgery (closure of the skin)
223832801|NCT01062906|DRUG|Fentanyl|Fentanyl 3 mcg/Kg as bolus at the induction and a continuous infusion of normal saline (NaCl 0.9%) until the end of surgery (skin closure)
223832802|NCT01339325|PROCEDURE|Cholecystectomy|"Standard laparoscopic cholecystectomy The first cannula is inserted with an open laparoscopy technique. LCs are performed with either HF or US energized dissection, standard or fundus-first gallbladder dissection, closure of the artery by ligature/clip or US, closure of cystic duct by ligature/clip.~Laparo-endoscopic single site cholecystectomy~The TriPort device is inserted at the navel site through a 15 to 25 mm incision with an open laparoscopy technique. Two working instruments are inserted (one grasper and one energised device) through the TriPort. A further 1.8 or 3 mm instrument inserted through the larger gel valve, parallel to a 5 mm dissecting instrument, is used in some cases to enhance exposure. Gallbladder dissection is accomplished either after preparation of the cystic duct and artery or with a fundus-first technique, by means of HF electrosurgery or US shears.The cystic artery is divided between clips or by US scissors. The duct is divided between clips."
223832803|NCT04444375|DIAGNOSTIC_TEST|balance test|balance test
223832804|NCT01554982|DRUG|ferric citrate|Dose based on monthly serum phosphorus levels with goal of 3.5-5.5 mg/dL for all patients.
223832805|NCT00678444|OTHER|Educational video|Watching an educational video about clean intermittent self-catheterization prior to prolapse/incontinence surgery.
223832806|NCT02127905|BIOLOGICAL|CD34+ selected cells|Compassionate treatment of Fanconi Anemia patients with unrelated bone marrow or peripheral blood HSCT followed by the infusion of CD34+ selected cells using CliniMACS
223832807|NCT02986737|DEVICE|ACURATE neo™ and ACURATE TA™ LP|ACURATE neo™ Aortic Bioprosthesis and ACURATE TA™ LP Transapical Delivery System on patients with severe aortic stenosis where conventional aortic valve replacement (AVR) via open-heart surgery is considered to be high risk
223832808|NCT00641160|DRUG|vinorelbine tartrate|Dose Level #1 PO for at least 7 days
223832809|NCT00641160|DRUG|vinorelbine tartrate|Dose Level #2 PO for at least 7 days
223832810|NCT00641160|DRUG|vinorelbine tartrate|Dose Level #3 PO for at least 7 days
223832811|NCT00058903|DRUG|sertraline|
223832812|NCT01096732|DRUG|GDC-0449|Gelatine capsules of 150mg.Taken O.D. for 14 days.
223832813|NCT00807222|DRUG|lisdexamfetamine dimesylate|Subjects will receive Vyvanse 30, 50, or 70 mg per day or placebo capsules orally for up to (a maximum of) seven (7) weeks.
223832814|NCT04616274|DRUG|Venetoclax|This prospective study will draw blood from every patient to measure the venetoclax blood concentration. After blood concentration analysis by ultra-high performance liquid chromatography tandem mass spectrometry (UHPLC-MS/MS), the investigator will report the concentration to clinicians.
223832815|NCT00968838|PROCEDURE|White Blood Cell Transfusion|"4 Transfusions, each taking approximately 1 hour:~Patients \<50 years of age receive 4 standard transfusions before they are randomized to receive further radiated or non radiated transfusions.~Patients \>50 years of age are randomized to receive either radiated or non radiated transfusions."
223832816|NCT00742885|BIOLOGICAL|Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted|All subjects will receive 2 doses administered as an intramuscular (IM) injection.
223832817|NCT05180747|OTHER|Frequency of physical therapy sessions|Physical therapy sessions consisted of standard of care practice at our center of excellence i two different frequencies. All patients in both groups received 12 physical therapy sessions. Patients in the burst group received 2 physical therapy sessions per week in 6 weeks, while patients in the spaced group received 1 session every 2 weeks for 6 months.
223832818|NCT05071066|OTHER|ADHD+|"The group-based intervention is designed to reduce participants' ADHD and related symptoms. The content of the treatment will follow an established manual which is developed by an expert group comprised of psychiatrists and clinical psychologists. Core treatment components include internet use/addiction intervention, cognitive training, emotion management, social skills training, occupational training, emotion support/befriending, parenting training, and career guidance.~The main intervention lasts for 3 months, and the booster intervention lasts for another 3 months. The post- intervention assessments (3-month \[T1\], and 6-month \[T2\]) will be administered to all participants. During the period of intervention, all participants shall be clean from other forms of interventions to reduce any other possible confounders."
223832819|NCT04781647|DRUG|ABI-H0731|Participants will receive ABI-H0731 300 mg tablets orally once daily
223832820|NCT04781647|DRUG|ETV|Participants will receive ETV 0.5 mg tablets orally once daily
223832821|NCT04781647|BIOLOGICAL|Peg-IFNα|Participants will receive Peg-IFNα with a starting dose of 180 µg solution by subcutaneous injection once weekly
223832822|NCT00489723|DRUG|tamsulosin 0.4mg|
223832823|NCT04934774|BIOLOGICAL|CD7 CAR T cells|Non-gene edited anti-CD7 CAR T cells administered to patients, will be either fresh or thawed CAR T cells by IV injection after receiving lymphodepleting chemotherapy.
223832824|NCT04641624|OTHER|ultrasound assessment|soluble fms-like tyrosine kinase-1, proangiogenic protein placental growth factor, and niacin measurementswith a commercially available enzyme-linked immunosorbent assay (ELISA) kit.
223832825|NCT04535739|RADIATION|prophylactic cranial irradiation|25Gy/2.5Gy/10f were given for PCI patients
223832826|NCT02940769|DEVICE|light glasses|light glasses
223832827|NCT02940769|DEVICE|sham glasses (placebo)|sham light glasses
223832828|NCT02746536|OTHER|Slow chest compression|"During the SCC, the patient will remain in the sitting position; a bimanual slow compression on his/her upper chest will be performed always by the same evaluator, who will stand behind the patient. This compression will be done only in the expiratory phase, during one minute, in all respiratory cycles, respecting the chest mobility of each patient.~A standardized verbal command will be given: Exhale all the air."
223832829|NCT02746536|OTHER|No slow chest compression|"The patient will remain seated at rest for one minute after the 6MST. A standardized verbal command will be given: Exhale all the air."
223832830|NCT01755689|BIOLOGICAL|Meningococcal vaccine GSK134612|One dose administered intramuscularly (IM) in the deltoid of the right arm.
223832831|NCT01755689|BIOLOGICAL|Cervarix®|Three doses administered intramuscularly (IM) in the deltoid of the left arm.
223832832|NCT01755689|BIOLOGICAL|Boostrix®|One dose administered intramuscularly (IM) in the deltoid of the left arm.
223832833|NCT00050414|DRUG|Trabectedin|Trabectedin 0.58 mg/m2, administered as a 3-hour intravenous infusion, Days 1, 8, and 15 every 28 days for up to approximately 3 years in the absence of disease progression.
223832834|NCT00050414|DRUG|Dexamethasone|Dexamethasone 10 mg administered intravenously 30 minutes prior to each trabectedin infusion.
223832835|NCT05299489|OTHER|Direct restoration|Local anesthesia was achieved and the tooth were isolated using a rubber dam. Then, the entire caries and hypomineralized enamel were removed using diamond burs and removal the affected dentine caries by slow speed handpiece, the final preparation must be on intact enamel. The molars were wiped using 5.25% sodium hypochlorite followed by rinsing with water, etching using 37% phosphoric acid The surface of the restoration, bonding, applying composite and assessment of occlusion.
223832836|NCT05299489|OTHER|Indirect restoration|"Local anesthesia was achieved and the tooth were isolated using a rubber dam. Then, the entire caries and hypomineralized enamel were removed using diamond burs and removal the affected dentine caries by slow speed handpiece, the final preparation must be on intact enamel. Preparation walls were vertical according to the longitudinal axis of the tooth and the occlusal depth 2 mm. The impressions were taken for both jaws and the bite were recorded for the using red wax. The cavity in example were painted with insulating material. Indirect composite resin were applied, finishined and polished.~Cementation:~Tooth surface: The molars were wiped using 5.25% sodium hypochlorite followed by rinsing with water, etching using 37% phosphoric acid The surface of the restoration: application of silane coupling agent to enhance the formation of resin tags.~Dual cure resin cement was used for final cementation followed by an assessment of occlusion."
223832837|NCT03493113|DIAGNOSTIC_TEST|EEG|
223832838|NCT04800835|DEVICE|Gastric Balloon|implantation of two types of gastric balloons. Spatz3 Adjustable balloon will be implanted for 12 months and 6-month non adjustable balloon will be implanted for 6 months
223832839|NCT05926856|DRUG|Indocyanine green|Indocyanine Green 25mg kit for injection
223832840|NCT00385905|DEVICE|Excel Drug-eluting stent|
223832841|NCT06508099|DRUG|Vitamin A|300 000 IU single dose orally
223832842|NCT06508099|DRUG|Vitamin D3|100 000 IU single dose orally
223832843|NCT06003101|BIOLOGICAL|Bone marrow aspirate concentrate (BMAC)|Bone marrow aspiration from the body of the ilium will be performed through one of the arthroscopic portals.
223832844|NCT06003101|PROCEDURE|Control|Standard of care hip arthroscopy without bone marrow aspiration will be performed in these patients.
223832845|NCT03864289|BEHAVIORAL|Parent skills training|Parents of children with autism spectrum disorder attend the parental training course once a week, and there was a total of eight courses with each course lasting 3 hours
223832846|NCT02106689|DEVICE|Needle free system|Approximately 60 patients will be randomized in a 1:1 ratio to either receive their gonadotropin injections using the Comfort-in™ needle free system (treatment group), or through the standard needle and syringe (control group).
223832847|NCT02106689|DEVICE|Standard needle injection system|Approximately 60 patients will be randomized in a 1:1 ratio to either receive their gonadotropin injections using the Comfort-in™ needle free system (treatment group), or through the standard needle and syringe (control group).
223832848|NCT06224426|OTHER|Normobaric high-concentration oxygen|During endovascular therapy, eligible participants will receive FiO2=80% through endotracheal intubation, with a gas flow rate set at 4 L/min.
223832849|NCT06224426|OTHER|Normobaric low-concentration oxygen|During endovascular therapy, eligible participants will receive FiO2=30% through endotracheal intubation, with a gas flow rate set at 4 L/min.
223832850|NCT03693261|PROCEDURE|Coronary artery bypass grafting (CABG)|CABG, as part of the standard medical care
223832851|NCT03693261|PROCEDURE|Valve replacement|cardiac surgery for aortic or mitral valve replacement as part of their standard medical care
223832852|NCT03294213|DEVICE|aScope 4 Broncho|"Investigator is asked: In your memory, compare your daily bronchoscope and the aScope 4 Broncho just evaluated on patients admitted to the OR or ICU undergoing at least one bronchoscopy procedure Patients will not be asked to consent to participate in this study, as no patient data are obtained and the CE-marked aScope™ 4 Broncho is used within its intended use"
223832853|NCT04376983|BEHAVIORAL|Telerehabilitation for patients with a cardiac resynchronisation device|Using the device-measured physical activity to create tailored motivational messages and tips to the patients to increase physical activity
223832854|NCT05545462|DRUG|Doxycyclin|THE USE OF DOXYCYCLIN POWDER IN THE TREATMENT OF UMBILICAL GRANULOMA
223832855|NCT05545462|OTHER|COMMON SALT|THE USE OF COMMON SALT IN TREATMENT OF UMBILICAL GRANULOMA
223832856|NCT03702101|DEVICE|Auricular point detector|This device is only for auricular detection. No additional intervention will be delivered.
223832857|NCT01426906|DRUG|Ketoconazole|Period 1 : LC15-0444 Period 2 : LC15-0444 with ketoconazole
223832858|NCT01426906|DRUG|rifampicin|Period 1 : LC15-0444 Period 2 : LC15-0444 with rifampicin
223832859|NCT03906981|OTHER|Plaque from each subject will be collected but there will be no intervention|No intervention
223832860|NCT00279279|DEVICE|Implanted Device|
223832861|NCT03075293|OTHER|Determination of pain management|Determine of pain management given to children with appendicitis in ER according to their medical records
223832862|NCT02369315|BEHAVIORAL|Treatment (Invited entry 2012)|Entry to music program offered in September 2012
223832863|NCT02369315|BEHAVIORAL|Control (Invited entry 2013)|Entry to music program offered in September 2013
223832864|NCT01038674|DRUG|anti-IL-20|Anti-IL-20 injected subcutaneously (under the skin) with 1 dose once weekly during a 6 week period (in total 7 doses) at 2 dose levels.
223832865|NCT01038674|DRUG|placebo|Placebo injected subcutaneously (under the skin) with 1 dose once weekly during a 6 week period (in total 7 doses) at 2 dose levels.
223832866|NCT05951699|DEVICE|minimally invasive preoperative image-guided vacuum-assisted biopsy|minimally invasive preoperative image-guided vacuum-assisted biopsy of the breast and needle biopsy of axillary lymph node
223832867|NCT03630081|DRUG|WCK 4282 (FEP-TAZ) 4 g|WCK 4282 (FEP-TAZ) 4 g \[2 g FEP and 2 g TAZ\] IV q8h, infused over 90 min
223832868|NCT03630081|DRUG|Meropenem|1 g IV q8h, infused over 45 min
223832869|NCT03630081|DRUG|ciprofloxacin 500 mg Optional Oral Switch|ciprofloxacin 500 mg PO q12h
223832870|NCT03630081|OTHER|Infusion of normal saline|Infusion of normal saline over 45 min
223832871|NCT03670147|DEVICE|PF-SCS programming|In a blinded fashion, the study physician will ask subjects to switch their PF-SCS to the LAP.
223832872|NCT01567163|BIOLOGICAL|Ramucirumab|ramucirumab 10 milligrams/kilogram (mg/kg) intravenous infusion, administered on Day 1 of 3-week cycle
223832873|NCT01567163|DRUG|Docetaxel|docetaxel 75 milligrams/square meter (mg/m\^2) intravenous infusion administered on Day 1 of each 3-week cycle
223832874|NCT02937844|BIOLOGICAL|Anti-PD-L1 CSR T cells|Prescribed CSR T cells are infused intravenously to patients in a three-day split-dose regimen（day0,10%; day1, 30%; day2, 60%）.
223832875|NCT02937844|DRUG|Cyclophosphamide|250 mg/m\^2, d1-3
223832876|NCT02937844|DRUG|Fludarabine|25mg/m\^2, d1-3
223832877|NCT02787720|OTHER|Family centered empowerment model|The intervention was conducting Family-Centered Empowerment Model. The intervention package had three steps including pre intervention, during intervention and post intervention. The model has four stages including Perceived threat, Problem solving, Educational partnership, and Evaluation
223832878|NCT02787720|OTHER|Continuous care model|The intervention was conducting Family-Centered Empowerment Model. The intervention package had three steps including pre intervention, during intervention and post intervention. The model has four stages including Orientation, Sensitization, Control, and Evaluation
223832879|NCT03148080|PROCEDURE|Cognitive Assessment|Complete CogState
223832880|NCT03148080|OTHER|Questionnaire Administration|Complete Self-Report Questionnaire
223832881|NCT05349396|DRUG|Eszopiclone 3mg Test Drug T-1 Coated Tablets|Participants will receive one tablet of the test formulation T-1 containing Eszopiclone 3mg. The tablet will be taken with water and in a fasting condition.
223832882|NCT05349396|DRUG|Eszopiclone 3mg Test Drug T-2 Coated Tablets|Participants will receive one tablet of the test formulation T-2 containing Eszopiclone 3mg. The tablet will be taken with water and in a fasting condition.
223832883|NCT05349396|DRUG|Eszopiclone 3mg Reference Product Coated Tablets|Participants will receive one tablet of the Rerefence Product containing Eszopiclone 3mg. The tablet will be taken with water and in a fasting condition.
223832884|NCT03405662|DEVICE|Vielight Neuro Gamma|The Vielight Neuro Gamma is headset that delivers transcranial (through the scalp and skull) and intranasal (through the nose) near infrared (NIR) light. The device is engineered for increased efficacy and easy domestic use for comprehensive brain photobiomodulation (PBM). The NIR lights are pulsed at a 40 Hz rate, which correlates with electroencephalogram (EEG) gamma brain wave entrainment.
223832885|NCT03405662|OTHER|Sham Vielight Neuro Gamma|The Sham Vielight Neuro Gamma headset is identical to the active Vielight Neuro Gamma headset and intranasal light emitting diode (LED) except it has a power output of 0.
223832886|NCT00664664|DRUG|APD125|soft gelatin capsule, 20 mg, daily dosing for up to 3 weeks
223832887|NCT00664664|DRUG|APD125|soft gelatin capsule, 40 mg, daily dosing for up to 3 weeks
223832888|NCT00664664|DRUG|Placebo|soft gelatin capsule, daily dosing for up to 3 weeks
223832889|NCT00003009|BIOLOGICAL|aldesleukin|
223832890|NCT02415075|BEHAVIORAL|medical rehabilitation|Participants who will take part in the study are asked to fill out a questionnaire when arriving at the rehabilitation clinic and will be invited to participate in two motivational telephone interviews after six and 12 months.
223832891|NCT01608438|DEVICE|Customizing the Body-Machine Interface|The intervention compares two ways of customizing the body-machine interface which will be used for subjects for 40 sessions (spread over 8 months). In one case (SCI static), the body-machine interface is static. In the other case (SCI Machine Learning), there is a machine learning algorithm that adapts to the movements made by the subject.
223832892|NCT05063643|OTHER|High altitude|High altitude is defined as \>2000m.
223832893|NCT05649488|DEVICE|Intracoronary lithotripsy balloon catheter and Intracoronary lithotripsy apparatus|"Introduction: After the preparation, release the intracoronary lithotripsy balloon catheter to the area to be treated and release the shock wave pulse for treatment. After the balloon reaches the predetermined position, use angiography to lock the position and fill the balloon to 6 atm. After the shock wave pulse therapy, the balloon was expanded to 8 atm according to the balloon compliance table and lasted for 10s. After the treatment, unload the balloon pressure, wait for the blood flow to recover, and repeat the second treatment after an interval of one minute, two cycles, releasing a total of 20 shock wave pulses as a treatment cycle.~Therapeutic apparatus specification: IVL-HVG-C01； Specifications of balloon catheter: C20012, C20015, C22512, C22515, C25012, C25015, C27512, C27515, C30012, C30015, C32512, C32515, C35012, C35015, C37512, C37515, C40012, C40015"
223832894|NCT05649488|DEVICE|Dragonfly Opstar Imaging Catheter|OCT (optical coherence tomography) measurement using Dragonfly Opstar Imaging Catheter was performed in the OCT subgroup before or after the treatment of intracoronary lithotripsy balloon catheter and intracoronary lithotripsy therapeutic instrument, or after stent placement.
223832895|NCT01177813|DRUG|Placebo identical to BI10773 high dose|placebo tablets once daily
223832896|NCT01177813|DRUG|BI 10773|BI 10773 low dose tablet once daily
223832897|NCT01177813|DRUG|BI 10773 open label|Patients receive BI 10773 high dose tablets open label once daily
223832898|NCT01177813|DRUG|Placebo identical to BI10773 low dose|placebo tablets once daily
223832899|NCT01177813|DRUG|Placebo identical to BI10773 low dose|placebo tablets once daily
223832900|NCT01177813|DRUG|Placebo identical to BI10773 high dose|placebo tablets once daily
223832901|NCT01177813|DRUG|Placebo identical to Sitagliptin 100mg|placebo tablets once daily
223832902|NCT01177813|DRUG|Placebo identical to Sitagliptin 100mg|placebo tablets once daily
223832903|NCT01177813|DRUG|BI10773|BI 10773 high dose tablets once daily
223832904|NCT01177813|DRUG|Sitagliptin|Sitagliptin tablets 100 mg once daily
223832905|NCT01177813|DRUG|Placebo identical to Sitagliptin 100mg|placebo tablets once daily
223832906|NCT01177813|DRUG|Placebo identical to BI10773 low dose|placebo tablets once daily
223832907|NCT01177813|DRUG|Placebo identical to BI10773 high dose|placebo tablets once daily
223832908|NCT01225042|DIETARY_SUPPLEMENT|probiotics|Freeze-dried powder, dose 10E9 CFU twice daily for 4 weeks
223832909|NCT01225042|DIETARY_SUPPLEMENT|placebo|placebo consisting of carrier material powder of identical appearance
223832910|NCT05489029|OTHER|visual analog scale|Data collection was carried out at all stages of treatment: medical and nursing brigade, military mobile hospital, military medical clinical center, during rehabilitation, within 12 months of the injury.
223832911|NCT05250804|OTHER|Helfer Skin Tap Technique|Helfer Skin Tap Technique is a technique in which the researcher taps the Dorso gluteal muscle by counting 1-15 with the palmar aspect of fingers (non-dominant hand) in rhythmic manner before inserting the injection intra muscularly at 90 degree and remove the needle quickly again by tapping and counting 1-3.
223832912|NCT06120062|OTHER|swaddled|the 1st experimental group were swaddled
223832913|NCT06120062|OTHER|mother's breast milk odor|the 2nd experimental group were made to inhale mother's breast milk odor
223832914|NCT06120062|OTHER|both swaddled and made to inhale mother's breast milk odor|the 3rd experimental group were both swaddled and made to inhale mother's breast milk odor
223832915|NCT06120062|OTHER|No procedure|No procedure was applied to the infants in the control group.
223832916|NCT00581256|RADIATION|IMRT|All patients treated with the optimized plan will be treated to the entire target volume to 52.2 Gy in 1.74 Gy fractions, which is biologically equivalent to 50 Gy in 2 Gy fractions. This fractionation scheme will allow the boost of 10 Gy to be incorporated into the planning directive and to be delivered simultaneously with the treatment to the remaining target volume.
223832917|NCT00581256|RADIATION|3D|All patients treated using the best standard technique will receive 50 Gy in 2 Gy fractions or 50.4 Gy in 1.8 Gy fractions to the entire target volume delivering one treatment per day, five fractions per week (excluding holidays). A boost of 10 Gy to the tumor bed of an intact breast will be delivered. Patients treated to the chest wall will receive a 10Gy scar boost if mastectomy margins are positive in a patient with Stage II disease or if the patient was originally diagnosed with T3 or T4 (Stage III) disease
223832918|NCT06063655|DIETARY_SUPPLEMENT|Control: Water|Water will be provided to subject divided into 3 equal portions with each portion consumed over 10 minutes with 15 minutes between portions (rehydration period of 1 hour).
223832919|NCT06063655|DIETARY_SUPPLEMENT|Liquid IV hydration multiplier|Liquid IV hydration multiplier will be provided to subject divided into 3 equal portions with each portion consumed over 10 minutes with 15 minutes between portions (rehydration period of 1 hour).
223832920|NCT06063655|DIETARY_SUPPLEMENT|Liquid IV sugar-free hydration multiplier|Liquid IV sugar-free hydration multiplier will be provided to subject divided into 3 equal portions with each portion consumed over 10 minutes with 15 minutes between portions (rehydration period of 1 hour).
223832921|NCT00109928|DRUG|cisplatin|
223832922|NCT00109928|DRUG|etoposide|
223832923|NCT00109928|DRUG|gemcitabine|
223832924|NCT00109928|DRUG|methylprednisolone|
223832925|NCT00003944|BIOLOGICAL|filgrastim|
223832926|NCT00003944|DRUG|carboplatin|
223832927|NCT00003944|DRUG|cyclophosphamide|
223832928|NCT00003944|DRUG|paclitaxel|
223832929|NCT00003944|DRUG|topotecan hydrochloride|
223832930|NCT00003944|PROCEDURE|peripheral blood stem cell transplantation|
223832931|NCT01196104|DRUG|Technosphere® Insulin Inhalation Powder|
223832932|NCT01196104|DRUG|Insulin Aspart|Usual Care
223832933|NCT01196104|DRUG|Insulin Glargine|
223832934|NCT02676986|DRUG|Enzalutamide|Anti-androgen
223832935|NCT02676986|DRUG|Exemestane|Hormonal therapy (Licenced)
223832936|NCT06359795|DIAGNOSTIC_TEST|18F-AlF-FAPI PET/CT, 99mTc-DTPA SPECT/CT|Patients underwent 18F-AlF-FAPI PET/CT and 99mTc-DTPA SPECT/CT scans within 10 days.
223832937|NCT04149262|DRUG|Fiasp|Fiasp® used in a MiniMed 640G system equipped with SmartGuardTM technology and accompanied with EnliteTM Sensor and GuardianTM 2 Link transmitter
223832938|NCT04149262|DRUG|Novorapid|Novorapid® used in a MiniMed 640G system equipped with SmartGuardTM technology and accompanied with EnliteTM Sensor and GuardianTM 2 Link transmitter
223832939|NCT04149262|DEVICE|640G pump|MiniMed 640G system equipped with SmartGuardTM technology and accompanied with EnliteTM Sensor and GuardianTM 2 Link
223832940|NCT00014339|DRUG|Wobe-Mugos E|
223832941|NCT00014339|DRUG|melphalan|
223832942|NCT00014339|DRUG|prednisone|
223832943|NCT00014339|PROCEDURE|quality-of-life assessment|
223832944|NCT00610675|DRUG|Org 50081|One tablet daily
223832945|NCT05905887|DRUG|Rivoceranib Mesylate, Paclitaxel|"Paclitaxel will be administered at 80mg/m2/day every four weeks at Day 1, Day 8 and Day 15 per cycle. One cycle consists of 4 weeks (28 days).~Rivoceranib 400 mg orally once a day."
223832946|NCT00471575|PROCEDURE|ultra sound examination|
223832947|NCT04340674|OTHER|Telerehabilitation based on aerobic exercise|To perform different whole body aerobic exercises moderately intense according to Borg scale.
223832948|NCT02688374|OTHER|Treatment A: Nicorette 2 mg coated mint gum|Participants will be administered with 2 mg coated mint gum of Nicorette
223832949|NCT02688374|OTHER|Treatment B: Nicotinell 2 mg coated mint gum|Participants will be administered with 2 mg coated mint gum of Nicotinell
223832950|NCT02688374|OTHER|Treatment C: Nicotinell 2 mg coated fruit flavor gum|Participants will be administered with 2 mg coated fruit flavor gum of Nicotinell
223832951|NCT00267111|DRUG|Eucerin plus|1g, single application
223832952|NCT00267111|DRUG|Amethocaine gel 4%|1 g, single application
223832953|NCT05884021|OTHER|Postoperative analgesia|In patients who used intravenous PCA after surgery
223832954|NCT01023737|DRUG|Hydroxychloroquine|The HCQ study dose levels are defined as 400mg/day, 600mg/day, 800mg/day and 1000mg/day (oral dosing)during the phase I MTD determination. HCQ will be administered starting on Day 2 of Cycle 1 and will be continued daily thereafter until progression of disease or unacceptable toxicity develops.
223832955|NCT01023737|DRUG|Vorinostat|Oral administration of Vorinostat will be begin on Cycle 1 Day 1 at 300mg and will be continued daily thereafter until progression of disease or unacceptable toxicity develops.
223832956|NCT06385912|PROCEDURE|lymphadenectomy|Systematic pelvic and para-aortic lymphadenectomy during IDS in lymphadenectomy group
223832957|NCT03763188|OTHER|Use of daily urinary urea excretion|Weaning dialysis catheter
223832958|NCT02478086|DIETARY_SUPPLEMENT|use amine acids parenteral 3.5g|"Group A we administered standard doses of amino acids was administered (3.5gr) the study of renal function baseline urea, creatinine and BUN were measured within 24 h after birth in order to avoid any alteration cost by mother alter kidney function, afterwards the same markers were measured at the day 7, 14, 21 and 28. These markers were measure using orto-clinical diagnostic series 50-0278 USA.~The anthropometric measurements were assessed weekly by the same person to avoid bias (cephalic perimeter and height); weight was measured weekly using the same scale (SECA model 3741321009, Germany). All anthropometric and lab results were kept in a collection sheet."
223832959|NCT02478086|DIETARY_SUPPLEMENT|use amine acids parenteral 4g|"Group B we administered high doses of amino acids was administered (4 gr) the study of renal function baseline urea, creatinine and BUN were measured within 24 h after birth in order to avoid any alteration cost by mother alter kidney function, afterwards the same markers were measured at the day 7, 14, 21 and 28. These markers were measure using orto-clinical diagnostic series 50-0278 USA.~The anthropometric measurements were assessed weekly by the same person to avoid bias (cephalic perimeter and height); weight was measured weekly using the same scale (SECA model 3741321009, Germany). All anthropometric and lab results were kept in a collection sheet."
223832960|NCT02862847|OTHER|stool samples|
223832961|NCT01822028|DRUG|Treatment A|Florastor® placebo. Zavesca® capsules dosed at 300 mg daily (one 100 mg capsule three times per day).
223832962|NCT01822028|DRUG|Treatment B|"Florastor® capsules dosed at 1000 mg daily (two 250 mg capsules two times per day).~Zavesca® capsules dosed at 300 mg daily (one 100 mg capsule three times per day)."
223832963|NCT01316692|OTHER|laboratory biomarker identification and analysis|Correlative studies
223832964|NCT01316692|PROCEDURE|biopsy|Correlative studies
223832965|NCT01316692|OTHER|immunohistochemistry/tissue microarrays|Correlative studies
223832966|NCT01316692|GENETIC|TdT-mediated dUTP nick end labeling assay|Correlative studies
223832967|NCT01316692|OTHER|mass spectrometry|Correlative studies
223832968|NCT04537104|DEVICE|Coala Heart Monitor|ECG monitoring
223832969|NCT04592328|OTHER|Bacterial cultures taken during surgery.|Cultures taken from skin, subcutaneous tissue, surigal materials and surgical gloves at incision and after two hours.
223832970|NCT02856919|DRUG|brimonidine tartrate|Mirvaso® gel (5 mg/g brimonidine tartrate)
223832971|NCT00983619|DRUG|MEDI-551|MEDI-551 will be administered intravenously (IV) once every week in 4-week cycles until complete response, disease progression, toxicity, or another reason for treatment discontinuation will be observed.
223832972|NCT00983619|DRUG|Rituximab|Rituximab will be administered IV on Days 1, 8, 15, and 22 (28- day cycle). The treatment will be continued until the participants experiences unacceptable toxicity, disease progression, reaches complete response or withdraws consent.
223832973|NCT06343441|DEVICE|intraoral scan|intraoral scanning of the edentulous arch and scan body
223832974|NCT06343441|DEVICE|open tray impression|conventional method of impression making with silicone rubber material
223832975|NCT02368002|BEHAVIORAL|Behavioral weight loss therapy|All participants start with behavioral weight loss therapy which consists of 20 weekly meetings wtih a weight loss coach. Session components will include weekly weigh-in, discussion of progress and challenges and discussion of scheduled session topic. Dietary goals and physical activity goals are set. After their first session, participants are randomized to have their weight assessed at either their 3rd session or their 7th session. Both the participant and their coach are blinded to the randomization. If the participant has lost the expected amount of weight, they continue with behavioral weight loss therapy for the full 20 session.
223832976|NCT02368002|BEHAVIORAL|Portion-controlled meals|"Participants continue with behavioral weight loss therapy, but this is augmented with portion-controlled meals (PCM). Adherence to energy intake goals is facilitated by consuming pre-prepared meals specifically designed to meet caloric intake guidelines. PCMs reduce individuals' motivationally- and self-regulatory-dependent planning and decision making around eating. PCMs also serve as a teaching tool regarding the amount and type of food people should eat in order to produce weight loss."
223832977|NCT02368002|BEHAVIORAL|Acceptance-based treatment|Switching the therapeutic approach to an enhanced behavioral weight loss therapy teaching acceptance-based behavioral skills theoretically addresses the root problem of many weight loss challenges and boosts long-term capacity for self-regulation. Acceptance based strategies are designed to help participants identify and internalize values and lasting commitment to behavior consistent with these values. The strategies focus on increasing people's ability to forgo more pleasurable options (e.g., hedonic pleasure of food) in favor of behavior that is distinctly less pleasurable or even aversive (remaining hungry, anxious, bored). The inability to tolerate such distress is directly associated with failure of self-regulation.
223832978|NCT03772314|DRUG|Modafinil|Participants will received 100-400 milligrams (mg) per day of modafinil for 12 weeks.
223832979|NCT03772314|DRUG|Amphetamine-Dextroamphetamine|Participants will receive 10-40 mg/day of oral amphetamine salts for 12 weeks.
223832980|NCT00749619|OTHER|Catheter Lock Solution Taurolidine and Citrate|
223832981|NCT00749619|OTHER|Catheter Lock Solution :Taurolidine and Citrate and Heparin|
223832982|NCT00749619|OTHER|Catheter Lock Solution : Heparin|
223832983|NCT01333540|DRUG|TD-1211|Escalating doses
223832984|NCT01333540|DRUG|Placebo|Placebo once daily
223832985|NCT04967625|DRUG|Sintilimab|A humanized anti-PD-1 monoclonal antibody
223832986|NCT04967625|DRUG|Anlotinib hydrochloride|A tyrosine kinase inhibitor selectively targeting VEGFR-2
223832987|NCT01536145|DRUG|CP-751,871|CP-751,871 was given at doses ranging from 0.025 mg/kg up to 20 mg/kg IV every 4 weeks until disease progression or lack of tolerability
223832988|NCT02444234|DRUG|Tedizolid PO|Participants will be randomized to receive tedizolid oral 200mg once daily for 3 days and crossed over to IV after a 1 week washout.
223832989|NCT02444234|DRUG|Tedizolid IV|Participants will be randomized to receive tedizolid IV 200mg once daily for 3 days and crossed over to PO after a 1 week washout.
223832990|NCT01183650|DRUG|Tadalafil|5 mg, administered orally, daily for 10 days
223832991|NCT04683302|DEVICE|3DUS biplanar catheterization|biplanar view of both short and long axis view of the internal jugular vein improves anatomical awareness and potentially improves safety of venous catheterization
223832992|NCT04683302|DEVICE|2D US catheterization|2D short axis internal jugular vein catheterization
223832993|NCT00649493|DRUG|Rabeprazole Sodium Tablets 20 mg|20mg, single dose fed
223832994|NCT00649493|DRUG|Aciphex® Tablets 20 mg|20mg, single dose fed
223832995|NCT05743764|DRUG|HU007|cyclosporine 0.02%, trehalose 3%
223832996|NCT05743764|DRUG|Restasis|cyclosporine 0.05%
223832997|NCT05743764|DRUG|Moisview Eye drop|trehalose 3%
223832998|NCT00466674|DRUG|reduced intensity conditioning|reduced intensity conditioning for allogenic transplant
223832999|NCT03869645|DEVICE|CAPERE Thrombectomy System|Mechanical thrombectomy of acute thrombus in peripheral vasculature with the CAPERE Thrombectomy System
223833000|NCT02971059|DIETARY_SUPPLEMENT|Phenylalanine intake|Phenylalanine will be provided as graded intakes ranging from 7-40 mg/kg/day
223833001|NCT01284140|BEHAVIORAL|Sleep and circadian rhythm promotion|This multifaceted intervention attempts to enhance sleep and circadian rhythmicity through improved scheduling of nursing procedures, enforcement of a day/night routine, increased light exposure during the day, and decreased light and sound exposure during the night. The intervention began the morning after enrollment and enforced a specific period of enhanced light exposure from 9:00 a.m. to noon. The initial target of 5,000 lux administered by light box (Sunsation, SunBox Co.) was reduced to 400-700 lux after the first 10 subjects were enrolled in the study.
223833002|NCT01284140|BEHAVIORAL|Usual care|Usual care.
223833003|NCT01423864|DRUG|conventional ECMO with intravenous steroid|refractory acute respiratory distress syndrome and multi-organ dysfunction syndrome treated with intravenous steroid, Solu-Cortef 50mg q6h taper down when hemodynamic stable
223833004|NCT01423864|DRUG|solumedrol|Initially, intrapleural steroid administration was performed using 40 mg solumedrol q6h (for both the pleural cavities). If chest radiography showed an improvement in consolidation, i.e., 0.8 \> FiO2 ≥ 0.5 and 5 ≤ PEEP ≤ 10, the dosage of solumedrol was reduced to 40 mg q12h. When FiO2 was below 0.5 and the PEEP was below 10, the dosage of solumedrol was lowered to 40 mg qd for 3 days and then its administration was discontinued.
223833005|NCT03184090|DRUG|Palbociclib|palbociclib in combination with endocrine therapy (investigator's choice)
223833006|NCT03184090|DRUG|Endocrine therapy (non IMP)|Endocrine therapy (physician's choice based on prior administered agent including tamoxifen, exemestane, fulvestrant, anastrozole, or letrozole). Endocrine therapy must be different from previous treatment line.
223833007|NCT02556515|PROCEDURE|Interpositional arthroplasty (Burton-Pellegrini procedure)|Burton-Pellegrini procedure
223833008|NCT02556515|PROCEDURE|Total joint replacement|Total joint replacement
223833009|NCT02556515|DEVICE|Elektra prosthesis|Elektra prosthesis
223833010|NCT01654822|DRUG|topical application cervical spray|one time (2 puffs) topical application of 100µl AV2-DM antiviral spray( containing 50% AV2-DM and 50% olive oil)on the cervix
223833011|NCT01654822|DRUG|topical spray on the cervix|one time (2 puffs) topical spray of 100 µl (90% olive oil and 10% d-limonene) on the cervix
223833012|NCT01654822|PROCEDURE|cervical swab with Cervex-Brush-Combi at T0|
223833013|NCT01654822|PROCEDURE|cervical swab with Cervex-Brush-Combi at T1|
223833014|NCT01654822|PROCEDURE|cervical swab with Cervex-Brush-Combi at T0|
223833015|NCT01654822|PROCEDURE|cervical swab with Cervex-Brush-Combi at T1|
223833016|NCT02361060|DRUG|Neostigmine|40mcg/kg
223833017|NCT02361060|DRUG|Sugammadex|4mg/kg
223833018|NCT02361060|DRUG|Atropine|10 mcg/kg
223833019|NCT00088205|DRUG|enzastaurin|500 milligrams (mg), oral, daily, up to six 28-day cycles
223833020|NCT06026722|BEHAVIORAL|cognitive behavioral therapy for insomnia|CBT-I is a 4-session program built around 3 main axes: psychoeducation on sleep hygiene, cognitive therapy and behavioral stimulus control, sleep restriction and relaxation. Each of the 3 axes will be worked on over 3 sessions, the last one being a summary and consolidation session of the first 3. For ethical reasons, it has been decided that patients in the control arm will also follow CBT-I (on a waiting list). The control group will have the same follow-up as the experimental group, but will start the intervention 6 months after the experimental group. This will enable all patients to access CBT-I.
223833021|NCT06420102|DIAGNOSTIC_TEST|Biophysical and biochemical skin assessment|Measurements are taken from the skin surface including transepidermal water loss, skin hydration and pH. In addition, non-invasive biofluid (sebum) is sampled from the skin to profile local inflammation. Skin surface cells were also stripped to assess corneocyte properties over the pressure ulcer and surrounding healthy skin.
223833022|NCT03192215|DRUG|Apixaban|5 mg by mouth twice daily (2.5 mg for subjects meeting standard criteria for an adjusted dose).
223833023|NCT03192215|DRUG|Aspirin|Aspirin 81 mg by mouth once daily.
223833024|NCT02593032|DEVICE|Pre-filled trays|Randomized Control Trial Patients in the research treatment group receive pre-filled, 3x7 disposable trays that separate their medication by dose and time (e.g. morning, afternoon, evening). These pre-filled trays are inserted into a connected, weekly pillbox that detects when pills are removed from its wells.
223833025|NCT01160120|DRUG|generic FDC of TDF/3TC/EFV|Patients who were on individual TDF 3TC and EFV regimen before baseline will undergo TDM at baseline. Therapeutic drug monitoring (TDM) of generic FDC of TDF/3TC/EFV will be done after 4 weeks, to ensure steady state. At baseline and week 4 safety data will be obtained. In order to assess the efficacy and the long term safety of this drug, at week 12, 24 and 48 viral load, CD4 and safety parameters will be obtained.
223833026|NCT05199233|DEVICE|Muse S™ Headband system|Clinical grade, headband style, wireless EEG (electroencephalogram is a test used to evaluate the electrical activity in the brain) system and designed to interact with a mobile device (smartphone or tablet).
223833027|NCT00736073|DRUG|aprepitant|one dose of aprepitant (125 mg PO 4 hours) prior to their ERCP and one dose (80 mg PO) 18 hours after the first dose
223833028|NCT00736073|DRUG|Placebo|one dose of placebo (125 mg PO 4 hours) prior to their ERCP and one dose (80 mg PO) 18 hours after the first dose
223833029|NCT03951935|OTHER|Oswestry Disability Index (ODI) questionnaire|Participant's level of low back pain and the extent to which the pain impacts his/ her daily life activities and social life are estimated with the standardized Oswestry Disability Index questionnaire
223833030|NCT03951935|DIAGNOSTIC_TEST|self-paced walking test (SPWT)|walking back and forth at a self-selected pace along a hallway at the University Hospital until the onset of claudication, pain or until reaching the time limit of 30 minutes. Kinematic and electromyographic (EMG) data will be recorded every 3 minutes.
223833031|NCT03244241|DRUG|Insulin Degludec 100 UNT/ML [Tresiba]|Basal-bolus insulin regime
223833032|NCT01305096|OTHER|Yoga intervention|6 weeks of yoga postures, once a week for 60 minutes in a group session with a yoga teacher.
223833033|NCT01161693|DEVICE|TROOP® elevation pillow|Maternal Comfort after CSE during elective Cesarean Section in relation to adequate height of Anesthetic Block
223833034|NCT01161693|DEVICE|TROOP® elevation pillow|designed by an American bariatric anaesthesiologist Dr Craig Troop, plastic covered foam pillow with an elevation angle of 20 degrees which can simply be placed on the operating table
223833035|NCT01161693|DEVICE|TROOP® elevation pillow|designed by an American bariatric anaesthesiologist Dr Craig Troop, plastic covered foam pillow with an elevation angle of 20 degrees which can simply be placed on the operating table
223833036|NCT06226142|PROCEDURE|Percutaneous dilatational tracheostomy|Percutaneous dilatational tracheostomy
223833037|NCT01048606|BEHAVIORAL|Placebo + exercise|"Placebo: Non-active capsules of the same size and appearance than phytoestrogens capsules will be used as a placebo (same posology, i.e. 4 caps/day)~Exercise intervention: Three weekly 1h-sessions will be held on 3 non-consecutive days. Each session comprises a total of 60 min of aerobic exercise (on an ergometer device) and resistance exercise (with elastic bands, free weights, exercise ball, etc.), and a 5-min cool down. Cues regarding exercise intensity will be offered to maintain intensity in a range of 60 to 80% of maximal heart rate (with the use of a target pulse, etc.). The exercise sessions will be led by a physical activity specialist."
223833038|NCT01048606|DIETARY_SUPPLEMENT|Phytoestrogens without exercise|"Phytoestrogens: The phytoestrogen supplements will consist of 70 mg/day of soy isoflavones taken as 4 caps/day. More specifically, the daily dose of isoflavones contains 44 mg of diadzein, 16 mg of glycitein and 10 mg of genestein extracted from natural soy.~Without exercise: participants will be asked to do only their usual activities without being involved in any kind of structured exercise sessions."
223833039|NCT01048606|OTHER|Phytoestrogens + exercise|"Phytoestrogens: The phytoestrogen supplements will consist of 70 mg/day of soy isoflavones taken as 4 caps/day. More specifically, the daily dose of isoflavones contains 44 mg of diadzein, 16 mg of glycitein and 10 mg of genestein extracted from natural soy.~Exercise intervention: Three weekly 1h-sessions will be held on 3 non-consecutive days. Each session comprises a total of 60 min of aerobic exercise (on an ergometer device) and resistance exercise (with elastic bands, free weights, exercise ball, etc.), and a 5-min cool down. Cues regarding exercise intensity will be offered to maintain intensity in a range of 60 to 80% of maximal heart rate (with the use of a target pulse, etc.). The exercise sessions will be led by a physical activity specialist."
223833040|NCT01914978|OTHER|Food allergy handbook for parents|The food allergy handbook was designed to be a reliable resource to supplement physician management of food allergy, addressing key topics central to effective allergy management and maintenance of positive quality of life. The handbook includes evidence-based information about food allergies and their management, practical strategies for transferring allergy management skills into daily life, strategies for educating others about allergies, strategies for coping with common emotional challenges associated with food allergy, and strategies for teaching children and involving them in allergy management.
223833041|NCT01914978|OTHER|Food allergy treatment as usual|
223833042|NCT06207370|DRUG|Tafenoquine|Oral Tafenoquine
223833043|NCT06207370|OTHER|Placebo|Placebo
223833044|NCT03562455|OTHER|VRSim 3.0|VRSim 3.0 is a virtual reality training module.
223833045|NCT03562455|BEHAVIORAL|In-Person Wheelchair Training|A therapist will be used to train power wheelchair users.
223833046|NCT06545396|OTHER|Half-dose illumination protocol|Area will be treated according to the classic protocol, in a single session. First, the surface of the actinic keratoses will be scraped to remove scales and crusts. Using a spatula, a sufficient amount of photosensitizing cream will be applied to cover the treatment area (1 mm thick). The treated area will then be covered with an occlusive dressing for 3 hours. After this interval, the dressing will be removed and the area will be exposed to a red light source for 8 minutes with a spectrum of 630 nm and 18,5J/cm2, with the illumination intensity being less than 200 mW/cm2.
223833047|NCT06545396|OTHER|Full-dose illumination protocol|Area will be treated according to the classic protocol, in a single session. First, the surface of the actinic keratoses will be scraped to remove scales and crusts. Using a spatula, a sufficient amount of photosensitizing cream will be applied to cover the treatment area (1 mm thick). The treated area will then be covered with an occlusive dressing for 3 hours. After this interval, the dressing will be removed and the area will be exposed to a red light source for 8 minutes with a spectrum of 630 nm and 37J/cm2, with the illumination intensity being less than 200 mW/cm2.
223833048|NCT05853874|OTHER|Nutrition intervention (dietary protocol)|The nutrition intervention sought to improve participants' overall diet quality, taking into account a sufficient intake of carbohydrates, lipids, fibres and micronutrients (vitamins and minerals), promoting proper fruits and vegetables consumption and variety. About water intake, considering the high dehydration risk in older persons highlighted by the European Society for Clinical Nutrition and Metabolism (ESPEN) guidelines, its adequate consumption is recommended and encouraged.
223833049|NCT05853874|OTHER|Hospital standard of care|The standard clinical procedures following the malnutrition diagnoses will be implemented according to the routine of the two hospitals
223833050|NCT03300375|OTHER|Home exercise program|Home-based, progressive exercise program using resistance bands
223833051|NCT03300375|OTHER|Post Op instructions|Participants will follow all instructions provided to them by their physician and care team, but will be asked to refrain from starting any new strengthening exercise protocols or begin any new physical therapies during this time.
223833052|NCT02571621|DEVICE|Combitube|Intubation with Combitube
223833053|NCT00163891|BEHAVIORAL|Chest physiotherapy|
223833054|NCT03681483|DRUG|RO5126766|RO5126766 (CH5126766) is given 4mg twice weekly (Day 1 and Day 4 of each week) and should be taken by mouth on an empty stomach, either one hour before or two hours after a meal.
223833055|NCT05765188|OTHER|loop electrosurgical excision procedure|A retrospective study of 115 women who underwent both loop electrosurgical excision procedure (LEEP) and subse- quent pregnancy follow-up in a referral center was conducted.
223833056|NCT01601444|DEVICE|Pletysmograph|Pletysmograph electrodes are applied to the thoracic wall
223833057|NCT02246829|PROCEDURE|Intravitreal injection|2 mg intravitreal Aflibercept initiated with one injection every 4 weeks for three consecutive doses (loading dose) The duration of the follow-up is 12 weeks. This means 3 injections per patient should be given over the study period
223833058|NCT01654237|OTHER|questionnaires|185 industry workers divided in three sectors (factory, office and logistics) were assessed using the Nordic Musculoskeletal Questionnaire and lifestyle and work-related conditions questionnaires.
223833059|NCT05771194|DRUG|Routine preoperative and postoperative anti-infection therapy|received gatifloxacin eye drops (Otsuka Pharmaceutical Co., Ltd.) 4 times daily and gatifloxacin eye ointment once every night (Shenyang Xing Qi Pharmaceutical Co., Ltd) for 3 days before surgery. Postoperatively, gatifloxacin eye drops were administered 4 times daily, 0.1% fluorometholone (San Tian Pharmaceutical Co., Ltd., China) was administered 4 times daily, and pranoprofen (Qian Su Pharmaceutical Co., Ltd., Japan) was administered 4 times daily. The doses of the above three drugs were reduced each week. The compound tropicamide was administered once a day (Shentian Pharmaceutical Co., Ltd., China). All of the above procedures were stopped 1 month after surgery.
223833060|NCT05771194|DRUG|artificial tear therapy|given 0.1% sodium hyaluronate eye drops 4 times daily for 3 days before surgery (Jiang Xi, Zhen Shiming Pharmaceutical Co., Ltd.) and 3 months after surgery.
223833061|NCT05771194|PROCEDURE|Cleaning, hot compresses and massage of the meibomian gland|Group B used a steam eye mask (Your Ga Run Fang, Shang Hai Run Mu Industrial Co., Ltd.) for 20 minutes 3 days before surgery. Sterile cotton swabs were used to apply physiological saline to the eyelid for local cleaning, and the secretions and phosphorus debris on the surface of the eyelid margin were removed to fully expose the meibomian gland. Meibomian gland tweezers were used to squeeze from the root of the gland toward the opening to expel the secretions; each gland was expressed twice. After the operation, an appropriate amount of gatifloxacin cream (Shen Yang Xing Qi Pharmaceutical Co., Ltd.) was applied to the conjunctival sac to prevent infection. Hot towels (40°C) were applied to the eyes for 10 minutes every morning and evening for 3 days before the operation.
223833062|NCT00399425|DRUG|bemiparin (low molecular weight heparin)|
223833063|NCT05989867|DIAGNOSTIC_TEST|blood test|"Evaluation of islets function and insulin secretion pattern： Evaluating the venous plasma glucose, c-peptide, and insulin concentrations at 0h, 0.5h, 1h, 2h, and 3h after the SBMT in patients with chronic pancreatitis.~Characterization of pathophysiological features： Measuring intestinal hormones, exosomes, serum metabolites, and serum biochemical factors"
223833064|NCT05989867|DEVICE|Continuous Glucose Monitor|blood glucose will be monitored 24 hours a day from 7 to 14 days by wearing continuous glucose monitor(only for patients who had new-onset diabetes or poor glycemic control )
223833065|NCT00110760|DRUG|S-Caine™ Peel (lidocaine and tetracaine cream 7%/7%)|S-Caine Peel was composed of a 1:1 eutectic mixture of 7% lidocaine and 7% tetracaine and was applied topically. S-Caine Peel was applied with a uniform thickness of approximately 1 mm and remained on the treatment area for 30 minutes (+/- 2 minutes).
223833066|NCT00110760|DRUG|Placebo Peel|Placebo Peel applied topically with a uniform thickness of approximately 1 mm and remained on the treatment area for 30 minutes (+/- 2 minutes).
223833067|NCT04328818|DIAGNOSTIC_TEST|indwelling device biofilm identification|performance of the NGS-based identification technique in comparison with the conventional culture-based one, for the same indwelling device biofilm sample
223833068|NCT04380818|RADIATION|Low-dose radiotherapy|Bilateral low-dose lung irradiation: 0.5 Gy in a single fraction. Optionally, additional 0.5 Gy fraction 48h later
223833069|NCT04380818|DRUG|Hydroxychloroquine Sulfate|200 mg/12h for 5 days
223833070|NCT04380818|DRUG|Ritonavir/lopinavir|400/100 mg/12h for 7-10 days
223833071|NCT04380818|DRUG|Tocilizumab Injection [Actemra]|600 mg/day for 1-2 doses
223833072|NCT04380818|DRUG|Azithromycin|500 mg/24h for 3 days
223833073|NCT04380818|DRUG|Corticosteroid|Corticosteroids (methylprednisolone/dexamethasone/prednisone)
223833074|NCT04380818|DRUG|Low molecular weight heparin|low molecular weight heparin (LMWH) in prophylaxis of venous thromboembolism
223833075|NCT04380818|DEVICE|Oxygen supply|Oxygen
223833076|NCT01322438|DRUG|Regorafenib (BAY73-4506) + rifampin|Drug: BAY73-4506 A single 160-mg dose of BAY73-4506 will be administered in the fasted state on Day 1 as four 40 mg tablets. Drug: BAY73-4506 and rifampin 600 mg once a day doses of rifampin will be orally administered after overnight fasting from Day 15 to Day 23. A single 160-mg dose of BAY73-4506 will be administered in the fasted state on Day 21 as four 40 mg tablets.
223833077|NCT03137602|DEVICE|ATOMIC mobile app|(a) PA Coach, One-on-one Chats. Coaches will conduct three one-on-one phone or video conferencing sessions and will also conduct a text messaging session once per week to reinforce and follow-up on the one-on-one phone sessions during the course of the intervention. (b) PA-Self Monitoring. An activity tracker (Fitbit Charge 2) will be used to allow participants to monitor their activity behaviors (e.g. step counts). (c) PA Information. In addition the coach will send weekly tailored PA informational posts/messages aligned with Social Cognitive Theory (SCT) to all participants. (d) Educational Modules. MS specific web-based interactive PA modules will be provided to patients.
223833078|NCT04435392|DRUG|Jaktinib Hydrochloride Cream|Subjects in each group were scheduled to give the drug for 8 weeks.
223833079|NCT04435392|DRUG|Placebo|Placebo
223833080|NCT03614884|BEHAVIORAL|Gambling and Smoking Treatment|The treatment condition will have access to 7 treatment modules on content surrounding both gambling and smoking behaviours. Participants will have 8-weeks to complete them. The content of all modules is derived from Cognitive Behavioural Therapy and Motivational Interviewing. Through module engagement, participants will identify goals related to gambling and smoking behaviours, learn strategies to cope with cravings and triggers, and learn how to prevent relapse. Participants will have immediate access to all modules, and it will be recommended that they work through the modules sequentially. Participants in this condition will also be provided with nicotine replacement therapy (NRT) in the form of nicotine patches to use for the duration of the study.
223833081|NCT03614884|BEHAVIORAL|Gambling only treatment|The control condition will have access to 7 treatment modules on content surrounding gambling only. Participants will have 8-weeks to complete them. The content of all modules is derived from Cognitive Behavioural Therapy and Motivational Interviewing. Through module engagement, participants will identify goals related to gambling behaviours, learn strategies to cope with cravings and triggers, and learn how to prevent relapse. Participants will have immediate access to all modules, and it will be recommended that they work through the modules sequentially.
223833082|NCT03027505|DRUG|Ready to Use Therapeutic Food (RUTF)|"MUAC used as the primary admission and exit criteria for children with MUAC \<125mm and no medical complication.~Single treatment of RUTF for severe and moderate malnourished children and gradual reduction of doses according to the MUAC and the weight of the child during treatment. MUAC split into 3 categories:~* MUAC \<115 mm: 175 kcal /kg/day~* 115 \<MUAC \<120mm: 125kcal/kg/day~* 120 \<MUAC \<125mm: 75kcal/kg/day"
223833083|NCT02443103|DRUG|Guanabenz acetate|
223833084|NCT01369056|BEHAVIORAL|Advanced Adherence Counseling (AdvAdh)|AdvAdh consists of 3 individual sessions (study months 0, 3, 6) -- patient-centered, non-judgmental, Motivational Interviewing- and theory-based, semi-structured, brief, candid conversations with a trained clinical care nurse using Next Step Counseling (NSC) approach. The intervention targets: 1) accurate information about antiretroviral treatment (ART) (mechanisms of HIV and antiretrovirals) and the development of mental imagery around it; 2) promotion of perceived sense of ease and efficacy in working ART regimen into the context of one's daily life and present life circumstances that may challenge drug use persistence; 3) identification, refinement of skills promoting ease of adhering to one's ART regimen across the diverse and challenges contexts.
223833085|NCT05624723|DRUG|INCB054707|INCB054707 75 mg will be administered orally
223833086|NCT03173443|DEVICE|single lumen tube and bronchial blocker|fiberoptic intubation with single lumen tube and bronchial blocker
223833087|NCT03173443|DEVICE|double lumen tube|fiberoptic intubation with double umen tube
223833088|NCT02878070|BEHAVIORAL|Calls from a Peer Health Coach for 6 months|Weekly calls for 2 months, bi-weekly calls for 2 months, monthly calls for 2 months.
223833089|NCT03669094|DIETARY_SUPPLEMENT|Lactobacillus salivarius V4II-90|7 months intervention study: with a screening period of 12 weeks after which participants GBS+ women will be randomized and start the orally intake of 1 capsule per day of the Lactobacillus salivarius V4II-90 (1\*10E9 CFU) probiotic supplement over a 12 weeks period. A visit will then be completed one month after delivery.
223833090|NCT03669094|DIETARY_SUPPLEMENT|Placebo|7 months intervention study: with a screening period of 12 weeks after which participants GBS+ women will be randomized and start the orally intake of 1 capsule per day of the placebo supplement over a 12 weeks period. A visit will then be completed one month after delivery.
223833091|NCT01630590|DRUG|Cabozantinib|Starting dose of 60 mg by mouth every day of a 21 day cycle.
223833092|NCT01630590|DRUG|Androgen Ablation Therapy|Androgen ablation therapy, either by means of luteinizing hormone-releasing hormone super-agonist (of any formulation), LHRH antagonist, or surgical castration given upon decision of study doctor.
223833093|NCT02067351|BEHAVIORAL|Mindfulness|Meditation, body scan, yoga.
223833094|NCT02366936|DEVICE|Tortle Midliner|The Tortle Midliner is a breathable, knit beanie with two support rolls to help position the infant's head in midline while supine. It can also be worn sidelying or prone. The design includes Velcro adjustments and tabs for nasal cannula and feeding tubes. It is compatible with some ventilation devices, nasal CPAP, X-ray, and bilirubin shades. The beanie is designed to prevent dolichocephaly and provide passive stretch to cervical rotators if head preference has developed. It comes in three sizes and can fit preemies weighing 500 to 2500 g.
223833095|NCT01752413|DIETARY_SUPPLEMENT|Ferrous gluconate 325mg|Participants with low ferritin (\<30 micrograms/L (males) or \<20 micrograms/L (females)) will be asked to take two tablets of Ferrous Gluconate 325 mg (36 mg elemental iron) per day.
223833096|NCT01752413|BEHAVIORAL|Nutrition counseling|All blood donors receive current dietary counseling recommending iron rich foods
223833097|NCT04100460|DIETARY_SUPPLEMENT|7.25 grams of Arabinoxylan leaf fiber extract|Participants are given 7.25 grams of Arabinoxylan daily
223833098|NCT04100460|DIETARY_SUPPLEMENT|14.5 grams of Arabinoxylan leaf fiber extract|Participants are given 14.5 grams of Arabinoxylan daily
223833099|NCT04100460|DIETARY_SUPPLEMENT|Control - No Arabinoxylan|Participants are given no Arabinoxylan
223833100|NCT02934113|BEHAVIORAL|iOTA|The Individual Obesity Treatment Approach (iOTA) will assess individual behavior risks, collaborative goal-setting with a health coach, and the use of an interactive text system to provide ongoing support and self-monitoring of behavior change goals.
223833101|NCT02934113|BEHAVIORAL|HWPP|Work groups will participate in the Healthy Workplace Participatory Program (HWPP) to adapt and deploy interventions that change their work environments to support healthy eating and physical activity.
223833102|NCT02978989|PROCEDURE|nonsolo LC|This patient is scheduled to undergo nonsolo laparoscpic cholecystectomy.
223833103|NCT02978989|PROCEDURE|solo LC|This patient is scheduled to undergo solo laparoscpic cholecystectomy.
223833104|NCT00287248|DRUG|[123I] IMPY & SPECT Imaging|Subjects will be injected with 7mCi of \[123I\]IMPY, followed by SPECT imaging
223833105|NCT00656916|DRUG|Fluticasone Propionate|440 micrograms twice daily by oral inhalation.
223833106|NCT03479749|DEVICE|RegenoGel-OSP, RegenoGel|RegenoGel-OSP (A) and RegenoGel (B) are visco-supplements intended for the intra-articular treatment of OA.
223833107|NCT01555021|GENETIC|Genotyping assays|"Patients will provide blood samples at the beginning of the study. If the patient is in the AGT group (as opposed to the TAU group), their blood samples will be sent for genotyping immediately. AGT psychiatrists will be given the results of genotyping within 3-5 days in order to decide which antidepressants to use long-term and at what doses. Patients in the Treatment as Usual group will have their blood samples stored for future analysis. Both groups will provide saliva samples for GWAS analysis at a alter date; however, since the study was terminated early, GWAS testing for both groups and genotyping for the TAU group were not performed.~Patients will receive questionnaires to measure their mood, side effects, and symptoms.~Patients will be asked to participate in 3 follow-up phone calls (1 month, 3 months, and 6 months) to measure their mood."
223833108|NCT03358329|COMBINATION_PRODUCT|S8 Sinus Implant|In-office bilateral placement of the S8 Sinus Implant (mometasone furoate, 1350 mcg) in the ethmoid sinuses
223833109|NCT06393218|DEVICE|Intermittent Oro-esophageal Tube Feeding|Before each feeding, inside and outside of the tube was cleaned with water. During feeding, the patient should maintain a semi-reclining or sitting position with mouth opened, and the tube was inserted slowly and smoothly into the upper part of the esophagus by medical staffs while the appropriate depth of intubation was checked with the calibration markings on the tube wall. The distance from the incisors to the head part of the tube should be between 22-25 cm. However, the specific depth should be evaluated based on patients' feedback and adjusted accordingly. After insertion, the tail part of the tube should be put into a container full of water and the absence of continuous bubbles indicated a successful intubation. Then, the feeding was to be conducted three times per day with 50 ml per minute and 400-600ml for each feeding.
223833110|NCT06393218|BEHAVIORAL|Diaphragm Training|Diaphragm training includes both active and passive methods. Passive training involves placing weights on the participant's abdomen to provide resistance during breathing. Active training involves instructing participants to practice diaphragmatic breathing techniques.
223833111|NCT06393218|BEHAVIORAL|Routine rehabilitation|"Including： Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training.~Pulmonary function training, including standing training, cough training, and diaphragm muscle training."
223833112|NCT04994041|OTHER|Pelvic floor muscle plus adductor strengthening|20 sessions of pelvic floor muscle strengthening plus adductor is strengthening
223833113|NCT04994041|OTHER|Pelvic floor muscle exercises|20 sessions of pelvic floor muscle strengthening
223833114|NCT01682564|DRUG|Candemore tablet|"* Initial dose : 4mg/day if SBP\<140mmHg and/or DBP\<90mmHg, 8mg/day if SBP≥140mmHg and DBP≥90mmHg~* dose escalation : double dose if SBP≥100mmHg and DBP\>60mmHg (maximum dose 16mg/day)"
223833115|NCT01682564|DRUG|Atacand tablet|"* Initial dose : 4mg/day if SBP\<140mmHg and/or DBP\<90mmHg, 8mg/day if SBP≥140mmHg and DBP≥90mmHg~* dose escalation : double dose if SBP≥100mmHg and DBP\>60mmHg (maximum dose 16mg/day)"
223833116|NCT02088827|OTHER|Inactivity|Subjects will remain inactive (lying on a bed) for 4 hours.
223833117|NCT02088827|OTHER|Activity|Subjects will spend 4 hours of inactivity (lying on a bed) broken up by 2 minutes of moderate intensity biking (on a stationary bike) every 20 minutes.
223833118|NCT05197686|DEVICE|Oxygen theraphy with high flow nasal cannule|Oxygen theraphy with high flow nasal cannule
223833119|NCT05197686|DEVICE|Oxygen theraphy with mask with reservoir|Oxygen theraphy with mask with reservoir
223833120|NCT02982720|DRUG|Pembrolizumab|Pembrolizumab will be administered intravenously.
223833121|NCT02982720|DRUG|Sylatron|Sylatron will be administered subcutaneously.
223833122|NCT05993286|BEHAVIORAL|Exposure Therapy|"At Week 0, the homework was to expose oneself to these sounds for 20 minutes a day, three days a week for three weeks.~At the Week 3 interview, the frequency and severity of the homework were adjusted based on the degree of improvement in the symptoms and the person's adherence to the instructions."
223833123|NCT05993286|OTHER|Sound Therapy|Participants were asked to listen to specifically modulated music for twenty minutes a day, three days a week, for the first three weeks. At the Week 3 assessment, if the patient reported no or little benefit in their misophonia symptoms, the instruction was modified (intensified) to listening to the same music for forty minutes a day, three days a week.
223833124|NCT05993286|OTHER|Psychoeducation|A psychoeducation session, prepared by the research team was delivered by the investigator to each patient at the study intake.
223833125|NCT01952964|OTHER|JUC spray dressing|"Intervention group Care of Tenckhoff catheter exit site using spray dressing. The detailed procedures will be introduced by the nurse according to the protocol of the unit. Please refer to Appendix III for details.~Skin test with JUC spray will be carried out prior to the usage of JUC spray dressing for caring the exit site. For the first three days after patient has been discharged, study team members will perform telephone follow up. Patients are reminded to report for signs and symptoms of infection or physical damage of catheter noted. A routine follow up at the Renal Unit will be arranged at eight weeks intervals."
223833126|NCT02144519|BEHAVIORAL|Healthy Eating and Physical Activity|Create partnerships with ASPs to help facilitate changes in programming to meet the National Afterschool Alliance's HEPA Standards.
223833127|NCT05295563|OTHER|Evaluation|Gastrocnemius muscle morphology (cross-sectional area, muscle thickness, fascicle length, pennation angle), muscle stiffness, muscle vascularization and functionality of children with CP will be evaluated.
223833128|NCT01121718|DRUG|ICG Intervention|NIR-guided sentinel lymph node mapping with indocyanine green (ICG)
223833129|NCT06109844|OTHER|Standard of Care|Patients enrolled in this observational study receive standard of care. Treatment, ointments, compression and bandages will be registered at every visit.
223833130|NCT00750893|BIOLOGICAL|Rotarix or Rotarix liquid formulation|GSK Biologicals' oral live attenuated human rotavirus (HRV) vaccine (oral suspension or prefilled syringe).
223833131|NCT02374190|OTHER|Standard Hospital Care|We described patient characteristics using percentages for categorical data, means and SD or medians and IQRs for normally and non-normally distributed continuous variables, respectively. Statistical comparisons for differences in baseline characteristics among patients admitted during regular hours and off-hours were performed using χ2 tests for categorical variables, t-tests and Wilcoxon rank sum tests for normally and non-normally distributed continuous variables, respectively. DTB times were described using median and IQR based on time of admission. All p values were calculated as two-tailed analyses, using a significance level of 5%.
223833132|NCT03885856|OTHER|single row repair technique|single row repair technique
223833133|NCT03885856|OTHER|double row repair technique|double row repair technique
223833134|NCT03498326|DRUG|Gemcitabine|One group patients receive the standard gemcitabine treatment at 1,8,15 of the chemotherapy cycle after R0 resection at 1000mg/m2.
223833135|NCT03498326|DRUG|Gemcitabine|the other group patients receive the standard gemcitabine treatment at 1,8,15 of the chemotherapy cycle after R0 resection at 1000mg/m2, and receive additional celecoxib 200mg bid every days during chemotherapy period.
223833136|NCT02420327|DRUG|Placebo patch & placebo capsule|On this test day, cognition is assessed after administration of a placebo patch and a placebo capsule.
223833137|NCT02420327|DRUG|Placebo patch & galantamine capsule|On this test day, cognition is assessed after administration of a placebo patch and a galantamine capsule (4 mg p.o.).
223833138|NCT02420327|DRUG|Nicotine patch & placebo capsule|On this test day, cognition is assessed after administration of a nicotine patch (7 mg/24 hrs) and a placebo capsule.
223833139|NCT02420327|DRUG|Nicotine patch and galantamine capsule|On this test day, cognition is assessed after administration of a nicotine patch (7 mg/24 hrs) and a galantamine capsule (4 mg p.o.).
223833140|NCT06062576|DRUG|Yunnan Baiyao|On the basis of the optimal clinical treatment scheme, Yunnan Baiyao powder or ointment was used to treat the wound for 2 weeks
223833141|NCT01405794|DRUG|32ppm Silver Particle|Oral silver dose of 32ppm
223833142|NCT01405794|DRUG|Placebo|Sterile Water No Silver
223833143|NCT02462785|BEHAVIORAL|In-person Carbohydrate Counting Class|An in-person carbohydrate counting class led by a registered dietician. The in class session covers topics including the role of CHO in nutrition and diabetes, sources of CHO, different CHO and non-CHO foods, resources for CHO counting, label reading, and meal planning. This is the standard procedure for CHO counting education at SickKids.
223833144|NCT02462785|BEHAVIORAL|Online Carbohydrate Counting Tutorial|A web-based CHO counting tutorial that covers the same concepts reviewed during the standard in-person instructional session held at SickKids. A teen delivers the educational messages in short segments using techniques designed to maintain the viewer's attention (e.g., visuals of food portions and short segment highlights to emphasize important points). The online module includes brief interactive question/answer components for reinforcement. The secure online tutorial will be accessible for one week through a link provided by REDCap. Users will be able to repeat sessions, log on and off during sessions, and choose specific modules for repetition/review. The investigators will be able to capture the number of times patients log on and detail frequency and specifics of usage.
223833145|NCT04538807|DIAGNOSTIC_TEST|electromyography|Electromyography (EMG) is an electrodiagnostic medicine technique for evaluating and recording the electrical activity produced by skeletal muscles.
223833146|NCT04976569|DEVICE|STN-DBS stimulation pattern change|Deep brain stimulation (DBS) is an elective surgical procedure in which electrodes are implanted into certain brain areas.We use specific STN-DBS stimulation pattern to regulate sleep architecture.
223833147|NCT02589392|OTHER|Cetaphil® Restoraderm® moisturizer + Cetaphil® Restoraderm® body wash|
223833148|NCT02589392|OTHER|Cetaphil® Restoraderm® body wash|
223833149|NCT04676009|OTHER|Exercise arm :|"Patients will receive physical activity recommendations at inclusion.~At each treatment cure, patients will receive pre-exercise nutritional recommendations and an acute physical exercise prior to immunotherapy and chemotherapy. The acute physical exercise will last 35 minutes and will be intermittent and individualized based on the results obtained by the patient during an endurance test on a ergocyle performed prior to treatment.~3 blood sampling times (2 EDTAsx10 mL) will be specially added to the study and will take place before exercise (1), after exercise (2) and 12 hours after the start of treatment (3).~A nutritional assessment will be carried out during the first and last treatment cure.~They will also benefit a home walking program. These patients will have to wear an activity tracker tracker during all intervention (3 months).~They will have a phone follow-up every 10 days (± 3 days) after each treatment cure for the study duration."
223833150|NCT02965144|OTHER|no treatment|no treatment
223833151|NCT05987618|DEVICE|Oral appliance with elastic bands|"The elastic bands are attached to hooks on both the upper and lower appliance, and on both sides. The elastic bands will be carefully selected not to interfere with retention of the oral appliance. The strongest elastic bands that do not interfere with retention of the oral appliance will be chosen, probably within the range of 85-170 grams (3/8 - 3/16)."
223833152|NCT05987618|DEVICE|Oral appliance without elastic bands|The oral appliance without the elastic bands.
223833153|NCT03978026|BEHAVIORAL|Nap|Each participant is compared to himself in 4 conditions,
223833154|NCT03572829|DRUG|Aprepitant|Intensity-modulated radiotherapy was given to the patients with regimen of 69.96 Gy-73.92 Gy to the gross target volume of nasopharynx,69.96 Gy to the gross target volume of positive nodes, 60.06 Gy the high risk clinical target volume, 50.96 Gy to the low risk clinical target volume. Concurrent chemotherapy is administrated with cisplatin 100mg/m2 at d1, d22, d43 during radiotherapy. Patients receive concurrent aprepitant 125mg, dexamethasone 12mg, and ondansetron 8mg p.o. on day1. AND then patients received aprepitant 80mg, dexamethasone 8mg on day 2-5 at every chemotherapy cycle.
223833155|NCT02938936|OTHER|Pre-natal visit scheduling|This intervention will include a scheduled date and time for prenatal care follow-up visits. Women in the intervention group seeking care for their first ANC appointment will be offered several appointment slots on their return date by the nurse providing their first ANC visit. Women will be able select among the time options and will be provided an appointment card with their scheduled date and time. Staff will limit the number of scheduled women per hour by maintaining an appointment book. Clinic staff will be trained to differentiate between women returning for a scheduled visit from first prenatal visits, emergencies, and unscheduled return visits. First visits and emergencies will be seen during the first 2 hours after clinic opening and unscheduled women will be seen during a one-hour time slot midday. When women return on their date, they will be seen within one hour of their appointment time by clinic staff.
223833156|NCT05515679|BEHAVIORAL|The BRAIN App|The BRAIN App will be the first-ever artificial intelligence enabled cognitive stimulation therapy app, specifically designed for PWD. The goal of the app is to foster positive relationships between the care triad.
223833157|NCT01579617|BEHAVIORAL|BUtiful.|8 website sessions include themes that teach: gender empowerment, assertive communication skills, goal setting, pregnancy and STI/HIV risk, safer sex behaviors, proper condom use, positive attitudes and norms towards consistent condom use, contraception, partner involvement in safer sex, and responsibility for their own health.
223833158|NCT01579617|BEHAVIORAL|DIVAS.|Attention control arm: 8 website sessions that include topics on: healthy eating, choosing nutritional snacks, sugar and salt intake, physical activity, stress management, foods for beauty.
223833159|NCT00274170|DRUG|Octreotide|
223833160|NCT04509830|OTHER|hip strengthening|resistance training for hip abductor, hip extensor, and hip external rotator
223833161|NCT04509830|OTHER|quadriceps strengthening, stretch hamstring,cuff muscles|multi-angle isometric quadriceps strengthening and hamstring and cuff self stretch
223833162|NCT00393094|BIOLOGICAL|Bevacizumab|10 mg/kg intravenous injection
223833163|NCT00393094|DRUG|Irinotecan hydrochloride|125 mg/m\^2 if patient is on a non-enzyme inducing anti-epileptic drugs 340 mg/m\^2 if patient is on enzyme inducing anti-epileptic drugs every two weeks on a 4 week cycle
223833164|NCT06392061|DIETARY_SUPPLEMENT|Trilac|Trilac® is a dietary supplement developed by Surveal Pharma to support digestive health and overall well-being. This probiotic contains 4 strains of naturally-occurring bacteria including: Lactobacillus acidophilus, LA-5®, Bifidobacterium animalis, BB-12®, Streptococcus thermophiles, STY-31 and Lactobacillus delbrueckii subsp. Bulgaricus LBY-27 in concentration of 4.5 milliards CFU/capsule. Patients in the probiotic group will be instructed to take one tablet per day for a period of 8 weeks.
223833165|NCT04537338|GENETIC|1. Characterize the immune response after infection with SARS-CoV-2|1\. Characterize the immune response after infection with SARS-CoV-2 in terms of type of antibodies (IgM, IgG, IgA), seroconversion, maximum antibody levels, , and response to different viral proteins/antigens
223833166|NCT00322374|DRUG|Ixabepilone|Infusion, intravenous (IV), Cycle = 21 days. Dose escalation study.
223833167|NCT00322374|DRUG|Epirubicin|Infusion, intravenous (IV): 75 mg/m\^2. Cycle = 21 days, up to 10 cycles or cumulative dose of 800 mg/m².
223833168|NCT03133468|DRUG|AJM347|Oral administration
223833169|NCT03133468|DRUG|Placebo|Oral administration
223833170|NCT06309095|DEVICE|use of VDW Silver Endodontic motor|All patients will be subjected to local anesthesia with articaine hydrochloride (Maxicaine, Istanbul) containing 1:100,000 adrenaline. After the entrance cavities of the teeth are opened, a rubber dam will be applied to the relevant teeth for isolation from the oral environment. After the entrance cavity is opened, the working length of the canals will be determined with the help of a No. 10 K-file (Dentsply Maillefer, Ballaigues, Switzerland) canal file and an electronic apex finder (Woodpex III, Woodpecker Medical Instrument Co, Guilin, China). In both groups, it was planned to use the NiTi rotary instrument system using V Taper Gold (Fanta Dental Material, Shanghai, China) files with the help of VDW.Silver endomotor (VDW, München, Germany). The endodontic motor will be used to adjust different speed and torque values during root canal treatment. Post-operative pain caused by different speed and torque values will be compared.
223833171|NCT03557489|DEVICE|Mepilex Border Sacrum|Patients use gel pad(in usual) in addition to use Mepilex Border Sacrum foam pad during surgery.
223833172|NCT06410378|PROCEDURE|Erector Spinae Plane Block|Patient will receive 20 ml of bupivacaine 0.25 % through Erector Spinae Plane Block approach
223833173|NCT06410378|PROCEDURE|Serratus Anterior Plane Block|Patient will receive 20 ml of bupivacaine 0.25 % through Serratus Anterior Plane Block approach.
223833174|NCT06410378|PROCEDURE|controll group|patient will receive general anesthesia
223833175|NCT04388930|OTHER|Pre-operative assessment - blood, urine, & faecal sample|"Blood sample for multi-parametric flow cytometry. Blood and urine samples for identifying microbial-associated metabolite signature.~Urine and faecal samples for 16S rRNA gene sequencing"
223833176|NCT04388930|OTHER|Post-operative day 3 assessment - blood, urine, & faecal sample|"Blood sample for multi-parametric flow cytometry. Blood and urine samples for identifying microbial-associated metabolite signature.~Urine and faecal samples for 16S rRNA gene sequencing."
223833177|NCT04388930|OTHER|Post-operative week 4-6 assessment - blood, urine, & faecal sample|"Blood sample for multi-parametric flow cytometry. Blood and urine samples for identifying microbial-associated metabolite signature.~Urine and faecal samples for 16S rRNA gene sequencing."
223833178|NCT04388930|OTHER|Post-operative 3 month assessment - blood, urine, & faecal sample|"Blood sample for multi-parametric flow cytometry. Blood and urine samples for identifying microbial-associated metabolite signature.~Urine and faecal samples for 16S rRNA gene sequencing."
223833179|NCT04388930|OTHER|Pre-operative 6 month assessment - blood, urine, & faecal sample|"Blood sample for multi-parametric flow cytometry. Blood and urine samples for identifying microbial-associated metabolite signature.~Urine and faecal samples for 16S rRNA gene sequencing."
223833180|NCT04388930|OTHER|Post-operative month 12 recipient assessment - blood, urine, & faecal sample|"Blood sample for multi-parametric flow cytometry. Blood and urine samples for identifying microbial-associated metabolite signature.~Urine and faecal samples for 16S rRNA gene sequencing."
223833181|NCT03867708|RADIATION|ASD device closure|transcatheter secundum ASD device closure
223833182|NCT04230980|DRUG|Gabapentin|Gabapentin 600mg tablet
223833183|NCT04230980|DRUG|Placebo|Placebo tablet
223833184|NCT02839135|DRUG|Reformulated scopolamine patch|Reformulated scopolamine patch of 1.5 mg (+/- 0.3 mg) /system of 2.5 cm2 surface area with deliver approximately 1.0 mg over 72 hours
223833185|NCT02839135|DRUG|Marketed scopolamine patch|Marketed scopolamine patch of 1.5 mg (+/- 0.3 mg) /system of 2.5 cm2 surface area with delivery of approximately 1.0 mg over 72 hours.
223833186|NCT02157415|DEVICE|Uro-Tainer Polihexanide 0.02%|Catheters will be rinsed by gravity feed with 100ml solution of UT-P 0.02% once a day for a maximum of 5 instillations.
223833187|NCT05580640|PROCEDURE|OMT|For this proof-of-concept study we will use a series of case studies. This will allow us to determine if a single session of OMT can improve gait in subjects with prior knee surgery, whether multiple sessions are required to change chronic compensatory musculoskeletal issues, and whether subtle gait anomalies (or improvements), in patients with knee arthroscopy can be detected with the gait analysis system
223833188|NCT00792428|DEVICE|Real Transcranial Direct Current Stimulation|A direct current runs between two electrode positions and affects the excitability of the underlying brain tissue
223833189|NCT00792428|DEVICE|Sham Transcranial Direct Current Stimulation|A sham current runs between two electrode positions and might affect the underlying brain tissue.
223833190|NCT03654586|BEHAVIORAL|Sugary drink warning labels|The description of each intervention appears in the descriptions of the experimental arms.
223833191|NCT03870503|DRUG|oxytocin|The patient will be received oxytocin 20 IU by intravenous infusion
223833192|NCT03870503|DRUG|oxytocin plus misoprostol|The patient will be received oxytocin 20 IU by intravenous infusion plus 400 mic gm sublingual misoprostol
223833193|NCT03870503|DRUG|Carbetocin|The patient received Carbetocin 100 mic gm
223833194|NCT02674243|DRUG|Iodopovidone solution|In this group, iodopovidone solution will be used as pleurodesis substance
223833195|NCT02674243|DRUG|Talc|In this group, Talc will be used as pleurodesis substance
223833196|NCT00596024|DIETARY_SUPPLEMENT|lutein/zeaxanthin|daily supplementation of lutein and zeaxanthin at dose of 12 mg/day
223833197|NCT00596024|DIETARY_SUPPLEMENT|placebo|placebo capsules with the same size and coating as those of lutein/zeaxanthin supplements without active ingredients
223833198|NCT04758234|DRUG|LY3549492|Administered orally.
223833199|NCT04758234|DRUG|Placebo|Administered orally.
223833200|NCT02969031|BEHAVIORAL|Enhanced SCOPE training|Intervention is integrated into the American Board of Internal Medicine (ABIM) Maintenance Of Certification (MOC) process.
223833201|NCT02969031|BEHAVIORAL|Standard Communication training|Standard Communication training
223833202|NCT04478513|DRUG|AZD4635|During each treatment period subjects will receive a single dose of AZD4635 under fasting conditions.
223833203|NCT04478513|DRUG|Fluvoxamine|Daily oral single doses of fluvoxamine are planned to be administered to healthy volunteers in Treatment Period 2.
223833204|NCT04903834|DIAGNOSTIC_TEST|Soton hyperinflammation score|Score for hyperinflammation defined by blood parameters and other physiological measurements
223833205|NCT04903834|DIAGNOSTIC_TEST|HScore|Score for secondary haemophagocytic lymphohistiocytosis validated in prior publications
223833206|NCT02973360|DRUG|Docosahexaenoic Acid|Oral Capsule
223833207|NCT02973360|DRUG|Placebo|Oral Capsule
223833208|NCT01556763|DRUG|EVP-6124 (0.3 mg/day)|EVP-6124 was administered as one 0.3 mg capsule per day for 21 days.
223833209|NCT01556763|DRUG|EVP-6124 (1.0 mg/day)|EVP-6124 was administered as one 1.0 mg capsule per day for 21 days.
223833210|NCT01556763|DRUG|Placebo|Matching placebo was administered as one capsule per day for 21 days.
223833211|NCT01556763|DRUG|Antipsychotic therapy|Concomitant therapy with antipsychotic medication (aripiprazole \[10 to 30 mg/day\], olanzapine \[10 to 20 mg/day\], paliperidone \[3 to 12 mg/day\], or risperidone \[2 to 16 mg/day\]), taken at the same time each day as the EVP-6124 dose. Patients must have been taking concomitant therapy for at least 2 weeks at a stable dose to be eligible for the study.
223833212|NCT02107248|BEHAVIORAL|Sleep position: no restrictions|during the first eight weeks after total hip replacement following a posterolateral surgical approach
223833213|NCT02107248|BEHAVIORAL|Sleep position: supine|during the first eight weeks after total hip replacement following a posterolateral surgical approach
223833214|NCT02833662|OTHER|Measure of ODI and heart rhythm|Record nocturnal respiratory and cardiac parameters before and after surgery.
223833215|NCT04581902|DEVICE|rTMS therapy|rTMS treatment parameters will be determined by TMS care providers. Typical TMS settings for MDD involve rTMS applied at 10 Hz with an intensity of 120 % of resting motor threshold. Forty trains of 4 s duration with 11s of trains is typically applied (3000 pulses per day), resulting in approximately 90,000 pulses in a given treatment course.
223833216|NCT04963972|BEHAVIORAL|Behavioral Intervention|Participate in Lucid Lane therapy program
223833217|NCT04963972|OTHER|Best Practice|Receive standard of care opioid education
223833218|NCT04963972|OTHER|Questionnaire Administration|Ancillary studies
223833219|NCT05112211|DRUG|Doxycycline Hyclate|patients administrated with doxycycline tablets 100mg orally per day
223833220|NCT03012789|PROCEDURE|Surgery|Surgical excision
223833221|NCT00183443|DRUG|Divalproex-extended release (DVP-ER)|Divalproex ER will be given in 250 mg or 500 mg tablets. Dosing is once a day, every day, for the duration of study participation, either 12 or 26 weeks.
223833222|NCT00183443|DRUG|Lithium|Extended release lithium will be provided in 300 mg capsules. Participants will be dosed to a therapeutic blood level of lithium from 0.8 to 1.2 mcg/L.
223833223|NCT00183443|DRUG|Quetiapine|Quetiapine will be dosed to efficacy, provided in 50 mg, 100 mg, 200 mg, or 300 mg pills.
223833224|NCT00737984|PROCEDURE|Endometrial sampling|Endometrial sampling performed in the preceding cycle. It will be done in the follicular phase not later than day 10 of the cycle
223833225|NCT03687450|BEHAVIORAL|RISE yoga-based program|The RISE program developed by Kripalu Center for Yoga and Health includes yoga postures, mindfulness practices, meditation, breathing techniques, and education sessions about mindful approaches to daily living. The RISE program will be delivered as a 6-week yoga-based program on-site at Brigham and Women's Hospital in Boston, MA. The program will consist of six 60-90-minute weekly yoga-based RISE classes. Sessions will be lead by experienced instructors from Kripalu Center for Yoga \& Health. Subjects in this arm will also be asked to participate in 5-10 minutes of daily home practice with direction from the RISE curriculum.
223833226|NCT00776100|OTHER|clinical observation|Patients undergo observation for 6 weeks.
223833227|NCT00776100|RADIATION|radiation therapy|Patients undergo radiotherapy 5 days a week for 6 weeks.
223833228|NCT04793464|BEHAVIORAL|Promotores de Salud|The Promotores de Salud intervention is delivered by a paid Promotor(a) who is a trusted member of the community where the testing site is located. The intervention includes: (1) psychoeducation to increase knowledge about COVID-19 and the benefits of testing; (2) motivational interviewing (MI) strategies to explore personal, social, and behavioral barriers to testing and to discuss available resources to resolve these barriers; (3) emotional support to address testing-related concerns and anxieties that may dissuade Latinx individuals from getting tested; and (4) service navigation. When promotores are on-site at testing events, they will provide information about COVID-19 and preventive behaviors using in-person instruction on effective mask wearing, hand washing, and physical distancing, as well as the importance of repeated testing and vaccines.
223833229|NCT04793464|BEHAVIORAL|Services as usual|Services as usual, our control condition, includes strategies that are typically conducted by county and community-based organizations that serve under-represented groups to notify people of testing opportunities related to COVID-19. These include Facebook advertisements, email announcements, circulation to other community-based organizations and state agencies (e.g., Oregon Health Authority, county public health), and other flyer distribution means. This condition also includes a pamphlet about health behaviors and community resources handed out by testing facilitators at testing events.
223833230|NCT00203905|DRUG|5-Fluorouracil, Hydroxyurea-[FHX], Bevacizumab|Hydroxyurea at 500 mg PO q 12 hours x 6 days; Bevacizumab at 10 mg/kg as a 90-minute infusion; Infusion of 5-FU (600 mg/m2/day) X 5 days (120 hours)
223833231|NCT00203905|DRUG|5-Fluorouracil, Hydroxyurea-[FHX]|Hydroxyurea at 500 mg PO q 12 hours x 6 days; Infusion of 5-FU (600 mg/m2/day) X 5 days (120 hours)
223833232|NCT02488382|DRUG|Lonquek|Patients will be given a single fixed dose of Lonquek (Teva LTD), 12-mg subcutaneously.
223833233|NCT05656638|BEHAVIORAL|Speech and language therapy|"The treatment focuses on grammatical time marking. The aim of the treatment is to train underlying grammatical time marking processes, which were identified as deficient during a preliminary evaluation. The intervention is composed of 4 steps inspired by models and hypotheses from the literature on the subject. Step 1: temporal adverbial selection, subject must identify the tense encoded in sentences and select the correct adverbial among those proposed. Step 2: selection of inflected verb forms, subject must identify the tense encoded in the sentence and select the correct verb form among those proposed. Step 3: production of inflected verb forms, subject must identify the tense encoded in the sentence and produce inflected verbs. Step 4: semantic narration, subject must describe scenes using verbs inflected according to the previously defined reference time."
223833234|NCT00910806|DRUG|TMC207; nevirapine|
223833235|NCT04505995|DRUG|Azacitidine and homoharringtonine|Concommitant use of azacitidine and homoharringtonine
223833236|NCT02337205|DRUG|KX2-391 Ointment|KX2-391 Ointment will be applied at a predetermined concentration to the treatment area for a predetermined time period.
223833237|NCT02348320|BIOLOGICAL|Personalized polyepitope DNA vaccine|
223833238|NCT05923177|DRUG|SPECT|One single injection of \[123I\] I-(HE)3-G3, followed by gamma camera imaging directly postinjection and after 2, 4, 6, 24 and 48 hours.
223833239|NCT03948087|DEVICE|Vacuum Removable Rigid Dressing (VRRD)|Intra-operative application of device.
223833240|NCT05943275|DEVICE|Magnetic sensor|During the right heart catheterization procedure, measurement of hemodynamic pressures by the non-invasive experimental method (Magnetic sensor) and the invasive control method
223833241|NCT00416871|BIOLOGICAL|aldesleukin|
223833242|NCT00416871|BIOLOGICAL|recombinant interferon alfa|
223833243|NCT03018743|DRUG|Dapoxetine|Patients receive dapoxetine (taken 1-3 hours before sexual intercourse) 30mg as needed. A dose escalation to 60mg will be consented after 1 month in case of low efficacy. Patients will be re-evaluated 1, 3, 6, 12, and 24 months after initiating therapy regarding the treatment status and the reasons for treatment discontinuation in the case of discontinuation. If patients missed any visits, they will be contacted by telephone or mail to collect their treatment data.
223833244|NCT00316030|DRUG|Bexarotene|
223833245|NCT03129529|DEVICE|Focused shock wave|The outcome evaluation include ankle range of motion (ROM), modified Ashworth scale (MAS),modified Tardieu scale (MTS), baropodometric measurement, and gait speed.
223833246|NCT03129529|DEVICE|Radial shock wave|The outcome evaluation include ankle range of motion (ROM), modified Ashworth scale (MAS),modified Tardieu scale (MTS), baropodometric measurement, and gait speed.
223833247|NCT06442644|OTHER|Live music in the intensive care unit|To test a patient-tailored live music intervention's effect on stress reduction in adult, critically ill patients admitted to the intensive care unit.
223833248|NCT04499339|DRUG|SLAMF7 CAR-T|Single infusion of autologous SLAMF7 CAR-T cells
223833249|NCT04441424|BIOLOGICAL|Convalescent plasma|400 ml of convalescent plasma (plasma taken 2 weeks from the recovered COVID-19 patients) and was transfused over 1-2 hours to the recipients by blood donation set.
223833250|NCT04441424|DRUG|Hydroxychloroquin with Azithromycin|The control group of COVID-19 patients were given the conventional therapy approved in Iraq for COVID-19, namely Hydroxychloroquine 400mg PO twice per day for 5 days and Azithromycin once PO 500 mg per day for 5 days.
223833251|NCT02285595|DEVICE|Sonendo GentleWave™ System|
223833252|NCT00284908|DRUG|S-Tenatoprazole-Na (STU-Na)|30 mg, 60 mg, 90 mg and 120 mg of STU-Na for 5 days every morning
223833253|NCT06548789|DIETARY_SUPPLEMENT|Prebiotic Xnack Packouts|Prebiotic snack packouts (distributed every two weeks) and diet counseling to support increased consumption of prebiotic foods which provide dietary fiber, plant-based protein and other nutrients selectively fermented by the microbiome (e.g., pulses and legumes).
223833254|NCT01157741|BEHAVIORAL|C-C|Mx as H-C plus positioning follow up in the community clinic
223833255|NCT01157741|OTHER|C-SF|As C-C but with additional supplementary food (SF) (C-SF)
223833256|NCT01157741|OTHER|As C-C with additional psychosocial stimulation (PS) (C-PS)|Giving psychosocial stimulation
223833257|NCT01157741|OTHER|As C-C but with both SF & PS (C-SF+PS)|Giving both SF \& PS
223833258|NCT01157741|OTHER|H-C|Follow-up at Hospital
223833259|NCT01058330|OTHER|Plyometric training program|The intervention is a year long individualized plyometric exercise training program. Examples of plyometric activities include jumping, hopping, running, and throwing. The number of plyometric exercises will increase gradually to prevent over training to a total of five lower extremity exercises and five upper extremity exercises
223833260|NCT01535131|PROCEDURE|palatoplasty|procedure to close cleft palate
223833261|NCT05716841|OTHER|Ballistic exercises|stretching and then strengthening of the upper limb through ballistic six exercises from a moderate to intense manner with 3 sets of 10 repetitions with a 30sec gap between sets, 3 Sets of 15 repetitions with a 30sec gap between sets, and 3 sets of 20 repetitions with a 30sec gap between sets for 3 to 4 days per week for six weeks.
223833262|NCT02513992|PROCEDURE|intra-arterial injection of tracer|intra-arterial ictal injection of perfusion tracer
223833263|NCT02513992|DRUG|99m-Technetium Ethyl Cysteinate Dimer|administration of perfusion tracer 99m Tc-ECD during epileptic seizure
223833264|NCT02513992|DEVICE|intra-arterial catheter|placement of intra-arterial catheter via femoral artery
223833265|NCT02513992|DEVICE|pressure injector|the injection of the perfusion tracer will be delivered with a pressure injector
223833266|NCT02624206|DIETARY_SUPPLEMENT|Juice A|Subjects to be given juice daily for 3 weeks.
223833267|NCT02624206|DIETARY_SUPPLEMENT|Juice B|Subjects to be given juice daily for 3 weeks.
223833268|NCT04380896|OTHER|Blood test|Blood tests (8ml in total) 4ml blood for serological testing (measure the antibody titres to the SARS-CoV-2 nucleo-capsid protein (4ml) and 4ml EDTA to be stored for future research will be taken for each group.
223833269|NCT04380896|OTHER|Standardised questionnaires|It will be an online questionnaire about staff members health, symptoms of SARS-CoV-2 and contact with SARS-CoV-2. All participants will also be asked to complete a detailed symptom and electronic questionnaire prior to each appointment.
223833270|NCT05158881|DEVICE|Near-infrared spectroscopy|Near-infrared spectroscopy (NIRS) offers the non-invasive continuous monitoring of cerebral oxygenation and perfusion. Cerebral regional oxygen (crSO2) measured via NIRS represents a mixed tissue saturation value, thus enabling information on the balance of cerebral oxygen delivery and oxygen consumption.
223833271|NCT00195715|BIOLOGICAL|Adalimumab|Adalimumab 40 mg by subcutaneous injection every other week or every week
223833272|NCT02075190|OTHER|Therapeutic Computerized intervention|Remediation training intervention
223833273|NCT02075190|OTHER|Nontherapeutic computerized intervention|Online gaming intervention
223833274|NCT02290366|RADIATION|Focal prostate brachytherapy with Cesium-131|
223833275|NCT00284999|DRUG|Soothe|
223833276|NCT00284999|DRUG|Refresh Tears|
223833277|NCT00188396|DRUG|Citalopram|
223833278|NCT03844321|BEHAVIORAL|Mindfulness-Based Cognitive Therapy|8 sessions of online mindfulness-based cognitive therapy
223833279|NCT03844321|BEHAVIORAL|Brief Mindfulness|3 sessions of online mindfulness therapy
223833280|NCT05140213|DEVICE|Anti-infectious prescription support tool|"implementation of a pocket notebook with current anti-infectious recommendations in the emergency department Patients were kept under surveillance for at least one hour before discharge.~Patients were discharged home with a 7 day supply of acetaminophen 1000 mg orally every 6 h, ketoprofen 100 mg, orally twice a day, and muscle relaxant as needed. Patients were instructed to take tramadol 50 mg, orally every 6h as needed for low back pain, in case of insufficient relief."
223833281|NCT00230815|DEVICE|Follitropin alfa injected by Pen device|Follitropin alfa will be injected subcutaneously by Pen device at a dose of 75 International Unit (IU) and 150 IU in subjects aged 18-34 and 35-40 years, respectively, for 5 days. Dose will be adjusted on stimulation Day 6 until ovulation triggering criteria will met.
223833282|NCT00230815|DEVICE|Recombinant Human Choriogonadotropin (r-hCG)|Recombinant Human Choriogonadotropin (r-hCG) injection will be administered as a single dose of 250 microgram subcutaneously when at least 1 follicle, but not more than 3 follicles, reached a mean diameter greater than or equal to (\>=)17 mm and estradiol levels are approximately 150 picogram per milliliter (pg/mL) per mature follicle.
223833283|NCT00660920|DRUG|Ponatinib|Comparison of different dosages of drug given orally once per day.
223833284|NCT05387486|PROCEDURE|Anatomical Landmark technique|anatomical landmarks (sternocleidomastoid muscles, sternal notch, cricoid cartilage, carotid artery and clavicle) will be palpated. A 3cc syringe with 21 gauge needle (locator) will be used first to locate IJV at the apex of the triangle formed by the two heads of the sternocleidomastoid muscle. After successful location, an introducer needle of 18 gauge, attached with a 5 ml syringe, will be inserted at the same point. The introducer needle will be directed towards the ipsilateral nipple at an angle of 20-30° with the skin
223833285|NCT05387486|PROCEDURE|Ultrasound-guided pre location technique|In Group Ultrasound-guided pre location technique, venipuncture site will be determined using ultrasound probe which will be then removed and locator needle of 21 gauge will be used first to confirm IJV location. The cannulation or venipuncture will be performed at the marked point of locator needle by the use of 18 gauge introducer needle.
223833286|NCT05387486|PROCEDURE|Ultrasound-guided real-time technique|In Group Ultrasound-guided real-time technique, cannulation or venipuncture will be performed under real-time imaging using 18 gauge needle i-e ultrasound will be used for prelocation and puncturing of IJV and locator needle will not be used
223833287|NCT00002015|DRUG|Ganciclovir|
223833288|NCT05088967|DRUG|IBI110|R2PD d1 IV every 3 weeks
223833289|NCT05088967|DRUG|sintilimab|200mg d1 IV every 3 weeks
223833290|NCT04773249|DEVICE|Lateral Epicondylitis Bandage|The lateral epicondylitis bandage was first used by Ilfeld in 1965, and it is a non-elastic band that prevents the expansion of the muscles in the proximal forearm. A lateral epicondylitis bandage will be given to the patient for 6 weeks. The bandage will be positioned 5 cm distal to the lateral epicondyle to allow for elbow flexion. After the application, patients will be asked to punch and the belt on the band will be tightened. After the patients are asked to open the fist, the suitability of the pressure applied to the forearm will be evaluated. Patients will be asked to repeat this application while wearing the band. The patients will also be asked to use the bandage throughout the day, and to remove them during bathing and sleeping.
223833291|NCT04773249|DEVICE|Wrist Extension Splint|Wrist extension splint is an upper extremity orthosis that keeps the wrist at 15-20 degrees of extension with the polyethylene bar it contains. A wrist extension splint will be given to the patient for 6 weeks. The splint will be used to keep the wrist at 15-20 degrees of extension and to wrap the distal wrist and forearm without hindering finger movements. The patients will be asked to use the splint throughout the day, and to remove them during bathing and sleeping.
223833292|NCT03698864|DRUG|PCS499|PCS499 900mg twice a day with food
223833293|NCT05752643|OTHER|Online follow up|The online follow up will include screening for HIV and STIs (Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG) and Treponema pallidum (TP)) based in a self-sampling strategy
223833294|NCT02452866|DRUG|SYM-1219|Administered with 4 ounces of unsweetened applesauce, and 8 ounces of water
223833295|NCT06193759|BIOLOGICAL|Multi-tumor antigen specific cytotoxic T lymphocytes (TSA-T) directed against proteogenomically determined personalized tumor-specific antigens (TSA)|Young patients with embryonal central nervous system (CNS) malignancies typically are unable to receive irradiation due to significant adverse effects and are treated with intensive chemotherapy followed by autologous stem cell rescue; however, despite intensive therapy, many of these patients relapse. In this study, individualized TSA-T cells will be generated against proteogenomically determined tumor-specific antigens after standard of care treatment in children less than 5 years of age with embryonal brain tumors.
223833296|NCT00845871|DRUG|deferasirox:|Participants were administered daily with deferasirox starting dose of 20 mg/kg orally to a maximum dose of 40 mg/kg/day.
223833297|NCT03467308|GENETIC|Markers in tissue samples: (TIGAR , TRIM59, P53, AKT, GSH)|"The followings markers will be investigated in tissue samples:~1. TIGAR expression using quantitative real-time polymerase chain reaction (q Rt PCR) and immunohistochemistry.~2. TRIM59 expression using quantitative real-time polymerase chain reaction (q Rt PCR) and immunohistochemistry.~P53 expression using immunohistochemistry. P53 nuclear localization is essential for its normal function in growth inhibition or induction of apoptosis.~* Akt expression using western blot.~* GSH using chemical methods."
223833298|NCT02076074|RADIATION|accelerated partial breast irradiation|Undergo HG-PBI
223833299|NCT05080881|DIAGNOSTIC_TEST|phonocardiographic measurement: InnoVital Systems|The instrument consists of one or more low-profile microphones in plastic housings with nitrile or silicon diaphragms. These sensors convert heart sounds into analog signals that will be acquired by the BIOPAC data acquisition system.
223833300|NCT05080881|DIAGNOSTIC_TEST|phonocardiographic measurement: ThinkLabs StethOne|This device senses heart sounds and may be listened to using headphones and converted to an analog signal and saved using the BIOPAC data acquisition system.
223833301|NCT05080881|DIAGNOSTIC_TEST|physiological measurements: BIOPAC|Non-invasive blood pressure, electrocardiogram, heart rate, respiratory rate, and leg circumference - This is a commercially available device used regularly in health care settings to monitor continual blood pressure and heart rate.
223833302|NCT05080881|DIAGNOSTIC_TEST|physiological measurements: Masimo Radical-7|A commercially available device for pulse oximetry and continuous non-invasive hematocrit measurement.
223833303|NCT05080881|DIAGNOSTIC_TEST|physiological measurements: CoVa Monitoring System 2|This device will be used for thoracic bioimpedance and other physiological measures. This is a commercially available device. It also measures ECG, heart rate, heart rate variability, estimated stroke volume, and estimated cardiac output. The study team may measure either while body bioimpedance or thoracic bioimpedance.
223833304|NCT05080881|DIAGNOSTIC_TEST|Thoracic impedance|Thoracic impedance is measured using the Starling device (https://usstarling.baxter.com/starling-system). Baxter uses a series of proprietary algorithms to infer stroke volume and cardiac output from thoracis impedance. Calculated values will be recorded, but the main variable that will be recorded is simply the temporal profile of thoracic impedance during the manipulations in each group (changing lower body negative pressure or therapeutic phlebotomy).
223833305|NCT01542060|DRUG|biphasic insulin aspart 30|Administered via an insulin injection device. Dosages varied according to individual patients' medical requirement as determined by their attending clinician
223833306|NCT03380780|DRUG|Emicizumab|Participants will receive a single 1 milligram per kilogram of body weight (mg/kg) subcutaneous dose of emicizumab on Day 1.
223833307|NCT01374802|DRUG|Darunavir|400 mg tablet for oral administration
223833308|NCT01374802|DRUG|Ritonavir|tablet for oral administration
223833309|NCT01374802|DRUG|BI 201335|
223833310|NCT03061448|BEHAVIORAL|Internet-based cognitive-behavior therapy|Internet-based cognitive-behavior therapy on a safe internet platform. Treatment is divided into eight modules, each containing homework assignments . The participants will be assigned a therapist that they can contact through a message system in the platform and expect answer within 24 hours.
223833311|NCT03313258|DEVICE|Standard of Care Group|ZHF temperature monitor cable will be placed appropriately on the forehead by the care team under the direction of the research personnel. The research personnel will then connect this cable to a screen that is blinded to the care team but not to the research personnel.
223833312|NCT03313258|DEVICE|Active Warming Group|ZHF temperature monitor cable will be placed appropriately on the forehead by the care team under the direction of the research personnel. The research personnel will then connect this cable to a screen that is un-blinded to everyone so healthcare practitioners will be able to visually detect continuous temperature readings from the ZHF monitor.
223833313|NCT00345787|DRUG|Placebo|Corresponding placebo is applied for 12weeks
223833314|NCT00345787|DRUG|Buprenorphine Transdermal System|Buprenorphine Transdermal System 5, 10 or 20mg/patch is applied for 12weeks
223833315|NCT04660019|OTHER|Scalp and auricular acupuncture|Three scalp acupoints including Baihui (GV 20), bilateral Toulinqi (GB 15, stomach area) and four ear acupoints (Shenmen, thalamus, cardia, stomach). The study duration was 2 weeks with four sessions of scalp and auricular acupuncture treatment on day 1, 5, 9 and 14.
223833316|NCT04660019|OTHER|Seed acupressure|Three scalp acupoints including Baihui (GV 20), bilateral Toulinqi (GB 15, stomach area) and four ear acupoints (Shenmen, thalamus, cardia, stomach). The study duration was 2 weeks with four sessions of seed acupressure treatment on day 1, 5, 9 and 14.
223833317|NCT03694314|DIETARY_SUPPLEMENT|Omega-3 fatty acids|200 ml drink. The drink contains 840 mg total of omega-3 (360 mg of DHA, 240 mg of EPA, 200 mg of alpha-linolenic acid, and 40 mg of DPA).
223833318|NCT03694314|DIETARY_SUPPLEMENT|Placebo|200 mL placebo fruit juice with no effect on the hypothesized outcome.
223833319|NCT04070677|COMBINATION_PRODUCT|Ziverel|Patients in treatments with radiotherapy alone (RT) or radiochemotherapy (RT-CH) with acute radiation-induced esophagitis grade 2 or superior according to the most recent CTCAE will received support treatment with ZIVEREL®
223833320|NCT04424875|DRUG|3 mg melatonin|patients will remove impacted third molar and receive 3 mg melatonin into 2 ml hydroxyethyl cellulose gel 2%
223833321|NCT04424875|DRUG|Placebo|patients will remove impacted third molar and receive 2 ml hydroxyethyl cellulose gel 2%
223833322|NCT02500914|DRUG|SC-002|SC-002 will be administered by IV infusion over approximately 30 minutes every 3 weeks
223833323|NCT01117753|BEHAVIORAL|OutPatient Treatment for Adolescents (OPT-A)|
223833324|NCT01117753|BEHAVIORAL|Treatment As Usual|
223833325|NCT00406458|DRUG|SB-509|60 mg dose
223833326|NCT00406458|OTHER|Normal Saline|
223833327|NCT03380663|PROCEDURE|Remote Ischemic Conditioning (RIC)|"Remote Ischemic Conditioning (RIC) is a new treatment modality to attenuate reperfusion injury. Organ protection by RIC can be achieved simply by inducing 3 or 4 five-minute cycles of limb ischemia and reperfusion using a tourniquet or simple blood pressure cuff Ischemic resistance exercise training conducted as low-intensity blood flow restricted resistance exercise (BFRE), with a low occlusion pressure stimulus, which only compromises venous but not arterial blood flow. Much like RIC, BFRE is conducted as 3-5 cycles (sets of exercise) interspaced by short duration of recovery.~High intensity traditional resistance training (TRT) is performed by sets of 10-12 repetitions are performed in the knee extensor machine - load equaling 15RM and rest for 3 minutes)."
223833328|NCT01719900|DIETARY_SUPPLEMENT|Pulse fibre|Yellow pea hull fibre incorporated into a biscuit at 5 g/serving.
223833329|NCT01719900|DIETARY_SUPPLEMENT|Control|Control biscuit with no yellow pea hull fibre.
223833330|NCT03164915|BIOLOGICAL|LIV-GAMMA SN Inj.|
223833331|NCT03772951|OTHER|Cognitive Remediation Therapy|Through computer information technology, using error-free, procedural learning, speech enhancement and a series of targeted computer programmatic cognitive correction tasks, patients can gradually improve problem solving and information processing capabilities, thereby improving their recognition function.
223833332|NCT03772951|DRUG|Clozapine|the course of disease is more than 2 years, the condition is stable for more than one month
223833333|NCT00841516|OTHER|Placebo|Placebo was given the same way as a subcutaneous (just under the skin) injection.
223833334|NCT00841516|BIOLOGICAL|rBet v1-FV|Placebo was given the same way as a subcutaneous (just under the skin) injection.
223833335|NCT02559609|BEHAVIORAL|Contingency management for alcohol abstinence|Participants will earn reinforcement (incentives) for each alcohol negative breath test provided (when prompted to submit a test) during the 12-week intervention period.
223833336|NCT02559609|BEHAVIORAL|Contingency management for completing job related activities|Participants will earn reinforcement (incentives) for completing specific job-related activities during the 12-week intervention period.
223833337|NCT02559609|BEHAVIORAL|Job relelated activity contracting|Participants will complete job-related activity contracts each week with the goal of obtaining employment.
223833338|NCT02281396|BIOLOGICAL|2.5IU/ml in rabies vaccine （MRC-5 Cell) humans aged 10-20 years old|Freeze-dried Rabies Vaccine（MRC-5 Cell) of 2.5IU/ml,5 doses,4 weeks interval
223833339|NCT02281396|BIOLOGICAL|2.5IU/ml rabies vaccine （MRC-5 Cell) in humans aged 21-60 years old|Freeze-dried Rabies Vaccine（MRC-5 Cell) of 2.5IU/ml,5 doses,4 weeks interval
223833340|NCT02281396|BIOLOGICAL|2.5IU/ml rabies vaccine （MRC-5 Cell) in humans(from 10-20 years old)|Freeze-dried Rabies Vaccine（vero Cell) of 2.5IU/ml,5 doses,4 weeks interval
223833341|NCT02281396|BIOLOGICAL|2.5IU/ml rabies vaccine （MRC-5 Cell) in humans(from 21-60 years old)|Freeze-dried Rabies Vaccine（vero Cell) of 2.5IU/ml,5 doses,4 weeks interval
223833342|NCT04908124|DEVICE|Lubricant A|Water-based lubricant, which is suitable for oral, anal and vaginal sexual intercourse. Approximately 3g of lubricant will be considered a single application.
223833343|NCT04908124|DEVICE|Lubricant B|Water-based lubricant, which is suitable for oral, anal and vaginal sexual intercourse. Approximately 3g of lubricant will be considered a single application.
223833344|NCT04908124|DEVICE|Lubricant C|Water-based lubricant, which is suitable for oral, anal and vaginal sexual intercourse. Approximately 3g of lubricant will be considered a single application.
223833345|NCT04908124|DEVICE|Lubricant D|Water-based lubricant, which is suitable for oral, anal and vaginal sexual intercourse. Approximately 3g of lubricant will be considered a single application.
223833346|NCT04908124|DEVICE|Lubricant E|Water-based lubricant, which is suitable for oral, anal and vaginal sexual intercourse. Approximately 3g of lubricant will be considered a single application.
223833347|NCT02155959|DEVICE|toric intraocular lens|toric intraocular lens
223833348|NCT04376294|DEVICE|Extracorporeal Shockwave Therapy(ESWT)|Each session of Extracorporeal Shockwave Therapy(ESWT) consists of 2000 pulses with a pressure of 3 bars (equals an energy flux density of 0.1 mJ/mm²), and treatment frequency of 8 pulses/sec
223833349|NCT04376294|OTHER|Eccentric training of the calf muscle:|The patients were asked to stand with all their body weight on the injured leg on a wooden step. From an upright body position and standing with all body weight on the forefoot, with the ankle joint in plantar flexion. The calf muscle is loaded by having the patient lower the affected limb down by dorsiflexion the ankle until the plantar aspect of the heel lay below the level of the step, and the ankle is in maximum dorsiflexion.
223833350|NCT04376294|OTHER|Gastrocnemius, soleus, and hamstring stretch|Stretching every muscle for 30 seconds. Each stretch was performed 3 times (holding for 30 seconds and rest for 30 seconds). All these stretches were performed directly after the eccentric exercises twice/day for 7 days/week for weeks
223833351|NCT03116503|OTHER|diagnosis of bipolar disorder and comorbid depression|Evaluation of the number of diagnosis of bipolar disorder and comorbid depression
223833352|NCT01849796|DEVICE|tDCS|TDCS/sham will be delivered using the battery-operated device Phoresor II Auto with two saline-soaked sponge electrodes. To deliver excitatory (anodal) tDCS over the motor cortex, the main electrode will be placed over the motor cortex on the hemisphere contralateral to the major source of pain. The second electrode will be placed on the skin overlying the supraorbital region ipsilateral to the affected area. To deliver inhibitory (cathodal) tDCS, the main electrode will be placed over the somatosensory cortex on the hemisphere contralateral to the major source of pain. The second electrode will be placed on the skin overlying the supraorbital region ipsilateral to the affected area. The current will be delivered at the intensity of 2mA for 20 minutes. To deliver sham, the current will be delivered for 30 sec only to elicit tingling skin sensation but no cortical excitability changes.
223833353|NCT04152850|BEHAVIORAL|Lifestyle Medicine|Lifestyle intervention with components including physical activity, diet, relaxation/mindfulness, sleep and Traditional Chinese Medicine
223833354|NCT04096989|OTHER|Traditional Chinese medicine regimen-based lifestyle mobile health APP|The Experimental group receives TCM regimen-based lifestyle mobile health application intervention.
223833355|NCT04096989|OTHER|Lifestyle mobile health APP|Sham comparator group receives mobile health application, but there is no traditional Chinese medicine information.
223833356|NCT01091896|DRUG|Bevacizumab|1.25 mg of bevacizumab (0.05 ml) 7 days before vitrectomy
223833357|NCT01091896|DRUG|bevacizumab|1.25 mg of bevacizumab (0.05 ml) at the end of vitrectomy
223833358|NCT01865123|BEHAVIORAL|Transcendental Meditation|A standard 7 step course will be offered including an introductory and preparatory lectures, personal one-on-one instruction with a certified TM teacher followed by 3 consecutive days of classes on how to meditate correctly and effortlessly, how to understand mechanisms of stress release and sequential development to higher levels of human consciousness and enjoying ones full potential. Followup meetings will provide checking of TM practice, sharing of group experiences with the TM practice and knowledge to motivate and inspire continued regularity with the practice. The certified TM instructor will have experience with PTSD in this veteran population.
223833359|NCT01865123|BEHAVIORAL|Prolonged Exposure|Prolonged exposure therapy, a specific form of cognitive behavioral therapy, is considered the standard psychotherapy treatment for PTSD . The delivery of PE will be by a trained study therapist. There will be 16 individual sessions provided to each participant. Homework will include relaxation and breathing exercises and anxiety diaries.
223833360|NCT01865123|BEHAVIORAL|Educational control|This group will receive group-administered didactic health education specific to the PTSD veterans population. It will include emphasis on healthy lifestyle changes to promote more positive mental and physical health. The classes will be matched with the TM and PE interventions to control for time, instructor attention and other non-specific factors.
223833361|NCT00354133|DEVICE|Kinetra and Soletra (neurostimulator, Medtronic)|Patients in this arm were implanted with a neurostimulator (Kinetra and Soletra from Medtronic) are stimulated. Additionally the get best medical treatment.
223833362|NCT00354133|DRUG|Best Medical Treatment|Patients in this arm get best medical treatment only
223833363|NCT02333734|OTHER|Physical training|Performed supervised high intensity interval training 3 times a week over 8 weeks on a bicycle ergometer (with watt meter). During the training period, the trainee individually established program, each time with 10 × 60 sec. workout (interspersed with 60 sec. break) corresponding to a force which during the test cycle induces \~ 90% of the maximum heart rate. The time spent per session is expected to last \~ 25 minutes.
223833364|NCT00064025|OTHER|Laboratory Biomarker Analysis|Correlative studies
223833365|NCT00064025|DRUG|Medroxyprogesterone|Given IM
223833366|NCT00064025|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgical hysterectomy
223833367|NCT01209481|BEHAVIORAL|nutritional education group action|The educational group activities will consist of two-hour group dynamics and cooking workshops once a week and for five weeks.
223833368|NCT00095823|DRUG|Antidepressant + Placebo|Antidepressant Caps/Tablets Placebo Tablets, Oral, 2-20 mg Placebo, once daily, 6 weeks following an 8 week Prospective Treatment (Baseline) Phase.
223833369|NCT00095823|DRUG|Antidepressant + Aripiprazole|Antidepressant Caps/Tablets Aripiprazole Tablets, Oral, 2-20 mg Aripiprazole, once daily, 6 weeks following an 8 week Prospective Treatment (Baseline) Phase.
223833370|NCT02468934|DEVICE|SPRINT Peripheral Nerve Stimulation (PNS) System|"The SPRINT System is an Investigational Device which delivers mild electrical stimulation to nerves in the leg that underwent lead placement. The SPRINT System includes a small wire (called a Lead) that is placed through the skin in the upper leg. It also includes a device worn on the body that delivers stimulation (called the SPRINT Stimulator)."
223833371|NCT04641195|DIETARY_SUPPLEMENT|Vitamin D3 (cholecalciferol)|180,000 international units (IU) of vitamin D3 at enrollment, followed by 2000 IU once per day from enrollment to 8 weeks
223833372|NCT04641195|DIETARY_SUPPLEMENT|Zinc (zinc gluconate)|40mg of zinc gluconate taken once per day from enrollment to 8 weeks
223833373|NCT04641195|DIETARY_SUPPLEMENT|Zinc (zinc gluconate) & Vitamin D (cholecalciferol)|180,000 IU of vitamin D3 at enrollment, followed by 2000 IU of vitamin D3 and 40mg of zinc gluconate once per day from enrollment to 8 weeks
223833374|NCT04641195|OTHER|Placebo|Placebo vitamin D bolus at enrollment followed by placebo daily vitamin D maintenance doses and placebo daily zinc supplements.
223833375|NCT03277378|DEVICE|lead placement followed by BurstDR stimulation|lead placement followed by BurstDR stimulation
223833376|NCT04570813|OTHER|Artistic activies|12 workshops of artictic activities during 12 weeks
223833377|NCT02500875|DEVICE|PTNiA|
223833378|NCT02500875|DEVICE|PTNiB|
223833379|NCT02500875|DEVICE|PTN|
223833380|NCT03424720|DEVICE|PLE and BIS|Investigators attach the PLE and BIS sensors on the forehead of the patients undergoing facial nerve integrity monitoring during general anesthesia using total intravenous anesthetics
223833381|NCT00450515|DRUG|capecitabine|
223833382|NCT00450515|DRUG|vinflunine|
223833383|NCT06024629|DEVICE|cOCT and LC-OCT|"cOCT: conventional optical coherence tomography (cOCT) is an established imaging modality within dermatology that enables visualization of the architecture of the skin with a penetration depth of 1.0 - 1.5mm.~LC-OCT: Line-field confocal optical coherence tomography (LC-OCT) is a new emerging diagnostic modality within the field of dermatology. LC-OCT enables tridimensional imaging of the skin with a cellular resolution and BCC features on LC-OCT have been described. However, the penetration depth of LC-OCT (500µm), is limited compared to the penetration depth of cOCT (1.0-1.5mm)"
223833384|NCT00613613|DRUG|fenofibrate|Fenofibrate 145mg tablets once daily for 4 weeks
223833385|NCT00613613|DRUG|fenofibrate|Fenofibrate 145mg tablets once daily for 4 weeks
223833386|NCT01370603|DRUG|Atorvastatin|40 mg tablet administered orally once daily
223833387|NCT01370603|DRUG|Ezetimibe|10 mg tablet administered orally once daily
223833388|NCT01370603|DRUG|Ezetimibe/atorvastatin|Ezetimibe/atorvastatin 10 mg/40 mg combination tablet administered orally once daily
223833389|NCT01370603|DRUG|Placebo to atorvastatin|Administered orally once daily
223833390|NCT01370603|DRUG|Placebo to ezetimibe|Administered orally once daily
223833391|NCT01370603|DRUG|Placebo to ezetimibe/atorvastatin|Administered orally once daily
223833392|NCT03032874|PROCEDURE|Colonoscopy|They all had screening colonoscopy
223833393|NCT00829608|BIOLOGICAL|Human Papillomavirus Vaccine|0.5 mL of quadrivalent HPV vaccine will be given intramuscularly at three separate intervals. Dose 2 is given 2 weeks after dose 1 and dose 3 is given 4 weeks after dose 1 for a total of 3 doses over 2 months.
223833394|NCT01097213|DRUG|Ethanol|Intravenous infusion of 6% ethanol in half-normal saline for approximately 1 hour: The dosage is controlled by a physiologically-based pharmacokinetic (PBPK) model of alcohol distribution and elimination, developed by O'Connor and his associates at the Indiana Alcohol Research Center (IARC) (Ramchandani et al, 1999). PBPK Parameters that determine the dosage and frequency of the infusion for a specific individual are estimated by means of morphometric variables (age, height, weight and gender).
223833395|NCT01097213|DRUG|Placebo - half-normal saline|Intravenous infusion of half-normal saline for approximately 1 hour: The dosage is equal to the infusion dosage estimated by the PBPK model of alcohol distribution and elimination (Ramchandani et al., 1999) for the drug - ethanol condition.
223833396|NCT02963051|DRUG|Copper|1 mg, 3 mg, 5 mg or 7 mg intravenously on cycle 1 day 1, 8 and 15
223833397|NCT02963051|DRUG|Disulfiram|"80 mg three times a day~Source of disulfiram: Cantex Pharmaceuticals"
223833398|NCT02963051|DRUG|Copper gluconate|"1.5 mg three times a day~Source of copper gluconate: Cantex Pharmaceuticals"
223833399|NCT04774822|PROCEDURE|Color Fundus Photography|Stereoscopic Fundus photography
223833400|NCT04774822|DRUG|Mydriatics Agent|Eye dilating agent
223833401|NCT04774822|PROCEDURE|Optical Coherence Tomography (OCT)|Optical Tomographic imaging of retina
223833402|NCT06177236|DIAGNOSTIC_TEST|cervical cancer screening|The aim of this project was to determine the effect of clinic or self-sampling on attendance, attitudes, and anxiety in cervical cancer screening.
223833403|NCT03723135|DRUG|CC-486|Oral azacitidine administered as directed by treating physician.
223833404|NCT00518713|DRUG|Clobazam Low Dose|0.25 mg/kg/day; tablets; orally; for 15-18 weeks
223833405|NCT00518713|DRUG|Clobazam Medium Dose|0.5 mg/kg/day; tablets; orally; for 15-18 weeks
223833406|NCT00518713|DRUG|Clobazam High Dose|1.0 mg/kg/day; tablets; orally; for 15-18 weeks
223833407|NCT00518713|DRUG|Placebo|tablets; orally; daily for 15-18 weeks
223833408|NCT00997256|DRUG|Neurapas® balance (Herbal product (Hypericum, Passionflower, Valerian))|3 x 2 tablets / day over 3 days
223833409|NCT00997256|DRUG|film-coated sugar-pill|3 x 2 tablets / day over 3 days
223833410|NCT01722136|BEHAVIORAL|Low Dosage|Exercise dose of 8kcal/kg/week
223833411|NCT01722136|BEHAVIORAL|High Dosage|Exercise dose of 14kcal/kg/week
223833412|NCT04396925|OTHER|Point-of care Ultrasonography|GPs using POCUS and how it affects clinical judgement
223833413|NCT00641186|DRUG|sodium oxybate|4.5 to 9.0 grams per night
223833414|NCT00391014|DRUG|liposomal Amphotericine B|"AML patients in induction chemotherapy treatment will received prophylaxis with nebulized liposomal amphotericin B (24 mg/week). It will be maintained during the intensification chemotherapy and in periods between cycles.~If patient required ALO-TPH, the prophylaxis should be followed."
223833415|NCT01991444|OTHER|TAVI|no Intervention planned, Observation only
223833416|NCT01939782|OTHER|No Breakfast (NoB)|In both occasions the blood samples for glucose and insulin, cortisol triglycerides and intact GLP-1 will be taken after overnight fast at 8:30 and thenat 8:30, 9:00, 10:30, 12:00, 12:30, 14:00 and 15:30. The samples for clock genes and for DPP4 plasma activity will be taken at 8:30, 12:00 (before lunch) and at 15:30 (3 1/2 h after lunch).
223833417|NCT01939782|OTHER|Yes Breakfast (YesB)|In both occasions the blood samples for glucose and insulin, cortisol, triglycerides and intact GLP-1 will be taken after overnight fast at 8:30 and then at 8:30, 9:00, 10:30, 12:00, 12:30, 14:00 and 15:30. The samples for clock genes and for DPP4 plasma activity will be taken at 8:30, 12:00 (before lunch) and at 15:30 (3 1/2 h after lunch).
223833418|NCT03027713|PROCEDURE|weaning protocol|The patients were allocated in the NAVA weaning protocol group o in the PSV weaning protocol group
223833419|NCT00687661|DRUG|Bisphosphonate|35mg given orally once weekly for 24 months
223833420|NCT00687661|DRUG|Placebo|identical placebo pill once weekly for 24 months
223833421|NCT04623411|BEHAVIORAL|Neonatal resuscitation training with classical method and serious game simulation method|"After the theoretical training, the participants will be given technical information on the use of web-based neonatal resuscitation serious game simulation method.~Each participant will be asked to apply this method at least three times."
223833422|NCT04623411|BEHAVIORAL|Control Group|Neonatal resuscitation training with classical method
223833423|NCT03183557|DRUG|"Zoledronic acid, Reclast®"|To examine the efficacy of zoledronic acid in osteoporosis
223833424|NCT03183557|DRUG|"Zoledronic acid, Reclast® and active vitamin D, alfacalcidol®"|To examine the efficacy of zoledronic acid plus alfacalcidol in osteoporosis
223833425|NCT02922985|DRUG|Intravenous acetominophen|One dose if 1 gram intravenous to be given pre-surgery
223833426|NCT02922985|DRUG|Ketorolac, intramuscular|One dose of 60 mg Intramuscular to be given at time of skin closure
223833427|NCT02922985|DRUG|Bupivacaine, subcutaneous|Inject 20 mL of 0.25% bupivacaine at the site of anticipated skin incision.
223833428|NCT02922985|DRUG|Normal saline|Normal saline will be given intravenously, intra-muscularly, and subcutaneously in the same volume as the study drugs for the patients in the placebo group.
223833429|NCT03119337|OTHER|Text-based follow-up|2wT clients will receive automated daily texts from days 1-14. If a 2wT VMMC client responds that he suspects an AE, a VMMC nurse will exchange modifiable, scripted texts with clients to determine symptoms, frequency, and severity. Then, if deemed necessary, the client will be asked to return to clinic the following day or earlier. If 2wT patients do not respond to texts on Day 2 or Day 7, the same MoHCC tracing process will be activated, after which they will be considered LTFU. All study participants will be asked to come to the clinic for study-specific, Day 14 follow-up to review healing and verify adverse event reporting. At Day 42, we will implement a brief text-based survey with 2wT clients to ascertain complete healing, providing stronger inferences at study completion.
223833430|NCT02218489|DRUG|KPI-121|KPI-121 drug product will be supplied in 0.25% strength as a suspension in opaque dropper bottles. KPI-121 drug product is a sterile, aqueous, submicron suspension of loteprednol etabonate. Subjects randomized to placebo control arm will receive the same bottles containing all components at the concentrations used in the KPI-121 drug product with the exception of the active component, loteprednol etabonate.
223833431|NCT02218489|DRUG|Vehicle|The vehicle control has the same composition as KPI-121 0.25% ophthalmic suspension except it does not contain loteprednol etabonate. The vehicle is essentially isotonic and is buffered to maintain pH 5.0 - 7.0. It is a sterile, aqueous solution supplied in the same white, low-density polyethylene plastic dropper bottle with the same white, controlled-drop polyethylene tip and white polypropylene closure as KPI-121 0.25% ophthalmic suspension.
223833432|NCT00063817|DRUG|Conditioning Regimen|Cyclophosphamide 60 mg per kilogram (kg) of body weight per day intravenously (IV) on days -5 and -4 with respect to transplantation; humanized anti-CD2 monoclonal antibody (MEDI-507) 0.6 mg per kg on days -1, 0, and 1 (after test dose of 0.1 mg per kg on day -2); and cyclosporine A 5 mg per kg IV and thymic irradiation (700 cGy) on day -1. Hemodialysis was performed before and 14 hours after each dose of cyclophosphamide.Kidney transplantation was followed by IV infusion of donor bone marrow. Oral cyclosporine A was administered postoperatively, 8 to 12 mg per kg per day, with target trough blood levels of 250 to 350 ng per milliliter; the dose was tapered and discontinued over a period of several months. Protocol amendment that applied to participant 4 and 5: rituximab, 375 mg per square meter of body-surface area days -7 and -2; and prednisone, 2 mg per kg per day starting on the day of transplantation with tapering over the next 10 days.
223833433|NCT05221749|DRUG|Nanosilver Fluoride (NSF)|Optimized synthesis of Nanosilver Fluoride
223833434|NCT05221749|DRUG|Silver diamine fluoride|Silver Diamine Fluoride
223833435|NCT01099540|DRUG|Pazopanib|Pazopanib 800 mg qd daily
223833436|NCT02404493|DEVICE|EpiCeram Skin Barrier Emulsion|EpiCeram Skin Barrier Emulsion
223833437|NCT02404493|DRUG|1% Colloidal Oatmeal Balm|Experimental Product 1% Colloidal Oatmeal Balm
223833438|NCT00019006|DRUG|Detox-B adjuvant|
223833439|NCT00019006|DRUG|ras peptide cancer vaccine|
223833440|NCT06077435|DEVICE|AI|AI system
223833441|NCT03085251|DEVICE|Blood glucose monitoring systems for self-testing (BGMS)|"Measurement procedure~* Subjects will be asked to wash and dry their hands before the measurements.~* The measurement procedure for each reagent system lot of a BGMS will be as follows:~* Study personnel will collect a capillary blood sample from the subject's fingertip by skin puncture.~* Duplicate measurements on the sample will be consecutively performed with 2 test meters using reagent system units from the same vial / package.~* Capillary blood for measurements with all 3 test strip lots and for both comparison measurements will be taken from the same finger puncture.~* The sample will be applied to the reagent system units following specifications in the manufacturer's labelling."
223833442|NCT00214032|DRUG|Pycnogenol|pycnogenol 300 mg daily
223833443|NCT00214032|DRUG|Placebo|placebo 3 capsules daily
223833444|NCT01235130|DRUG|OMEGA-3|600mg, 2 caps, twice a day
223833445|NCT01235130|DRUG|Placebo soybean oil|600mg, 2caps twice a day
223833446|NCT02071550|DEVICE|FORESİGHT cerebral oxygen monitor and INVOS cerebral oxygen monitor|
223833447|NCT02071550|DEVICE|FORESIGHT and INVOS monitor|
223833448|NCT01207050|DRUG|Ramelteon|8mg capsule taken within one half hour of bedtime each night over the three night study period.
223833449|NCT01207050|DIETARY_SUPPLEMENT|Placebo|Control treatment
223833450|NCT01254890|DRUG|Azacitidine|75 mg/m\^2 subcutaneously (SQ) or by vein (IV) daily for 7 days per 28 day cycle.
223833451|NCT01254890|DRUG|Sorafenib|Starting dose level 200 mg by mouth two times a day in a 28 day cycle. In Phase II, Sorafenib administered per MTD dose from Phase I. Drug doses separated by approximately 12 hours.
223833452|NCT03320460|DRUG|Propionate clobetasol gel 0.05%|Patients will be treated with Propionate clobetasol gel 0.05% for 30 consecutive days and with placebo laser twice a week. Patients will be instructed to apply the propionate clobetasol gel 0.05% in the entire lesion three times/days. To prevent oral candidiasis, patients will use micostatin solution (Nystatin oral suspension 100,000 USP/ml) once a day during 4 weeks.
223833453|NCT03320460|DEVICE|Photobiomodulation|Patients will be treated with localized PBM with a diode laser with continuous wave (laser λ = 660 nm; power 100mW;radiant energy: 177J/cm2; 5-s exposure time per point and 0.5J of energy per point) applied directly to the surrounding oral mucosa and to the center of OLP, always by the same operator, twice a week for 4 weeks, totaling 8 session. The number of points will be variable according to the lesion size. The output power of the laser equipment will be evaluated using a power meter (Laser Check; MMOptics LTDA, São Paulo, Brazil) before treatment to confirm the effective mean power as well as the doses applied during the procedure.
223833454|NCT03320460|OTHER|Placebo gel|Placebo gel for 30 consecutive days to mask the treatment
223833455|NCT03320460|OTHER|Placebo Photobiomodulation|Laser device will be positioned over the lesion but will be switched off to mask the treatment.
223833456|NCT01340911|DRUG|SRT3025|SRT3025 will be supplied as hard gelatin capsules containing either 27.4 mg (25 mg SRT3025 free base equivalent) or 274 mg (250 mg SRT3025 free base equivalent) of SRT3025 HCl monohydrate drug substance.
223833457|NCT01340911|DRUG|Placebo|For placebo product, the SRT3025 drug substance will be replaced by Microcrystalline Cellulose (Avicel® PH 105) to match the SRT3025 investigational product.
223833458|NCT00050089|OTHER|No Antiretroviral Drug-Free Period (No ARDFP) vs ARDFP|Continuation or interruption of ART treatment
223833459|NCT00050089|DRUG|Standard ART vs Mega ART|Standard therapy vs Intensified therapy
223833460|NCT00050089|OTHER|No Antiretroviral Drug-Free Period (No ARDFP) vs ARDFP|Continuation or interruption of ART treatment
223833461|NCT00050089|DRUG|Standard ART vs Mega ART|Standard therapy vs Intensified therapy
223833462|NCT00050089|OTHER|No Antiretroviral Drug-Free Period (No ARDFP) vs ARDFP|Continuation or interruption of ART treatment
223833463|NCT00050089|DRUG|Standard ART vs Mega ART|Standard therapy vs Intensified therapy
223833464|NCT00050089|OTHER|No Antiretroviral Drug-Free Period (No ARDFP) vs ARDFP|Continuation or interruption of ART treatment
223833465|NCT00050089|DRUG|Standard ART vs Mega ART|Standard therapy vs Intensified therapy
223833466|NCT03746977|DIETARY_SUPPLEMENT|Protein|Protein supplementation 1.2 or 1.5 g/kg body mass/d
223833467|NCT03746977|BEHAVIORAL|Walking|Walking with a volume corresponding to 250 kcal/d
223833468|NCT03746977|BEHAVIORAL|WB-EMS application|WB-EMS application 1.5x 20 min/week
223833469|NCT05178264|DRUG|SARS-CoV-2 vaccines|All patients treated at least with 1 SARS-CoV-2 vaccine
223833470|NCT03636035|DIETARY_SUPPLEMENT|Tregocel®|Coated tablet (oral)
223833471|NCT06280456|DRUG|Tranexamic Acid Powder|10 mL of Tranexamic Acid(100 mg/mL) was injected into the joint at the end of the operation with different drainage clamping time.
223833472|NCT04364321|DRUG|Clonazepam 0.5 MG|Clonazepam 0.02 mg/kg only one dose
223833473|NCT04364321|DRUG|Diazepam Tablets|Diazepam 0.3 mg/kg every 8 hours for 3 doses. (24 hr)
223833474|NCT01097460|DRUG|MM-111 + Herceptin|For Phase 1: Dose escalation cohorts, MM-111 and Herceptin are administered weekly or bi-weekly via IV
223833475|NCT01630343|DRUG|Paracetamol tablet and Tramadol capsule|Panadol 500mg tablet Q4H prn Tramadol 50mg capsule Q4H prn
223833476|NCT01630343|DRUG|Panadol 500mg tablet, tramadol 50mg capsule|Regular Panadol 500mg tds with tramadol 50mg capsule tds for 3 weeks after injury
223833477|NCT04039503|DRUG|Tirzepatide|Administered SC as add-on to the pre-trial background medication.
223833478|NCT04039503|DRUG|Placebo|Administered SC as add-on to the pre-trial background medication.
223833479|NCT01185054|OTHER|½ strength apple juice|For each episode of diarrhea 10 ml/kg of fluid will be given and for each episode of vomiting 2 ml/kg will be given. If the child does not like the solution another fluid can be used.
223833480|NCT01185054|OTHER|Pediatric Electrolyte|For each episode of diarrhea 10 ml/kg of fluid will be given and for each episode of vomiting 2 ml/kg will be given. If the child does not like the solution another electrolyte maintenance fluid can be used. Fluids containing non-physiological concentrations of glucose and electrolytes (carbonated drinks, sweetened fruit juices, water) will be discouraged.
223833481|NCT01233167|DRUG|clopidogrel|clopidogrel 75 mg po per day for 12 months
223833482|NCT01233167|DRUG|placebo|placebo 75mg po per day for 12 months
223833483|NCT01233167|DRUG|clopidogrel and placebo|clopidogrel 50mg per day for 3 months,clopidogrel 25mg per day for 3 months,then placebo 75mg per day for 6 months
223833484|NCT01845948|BEHAVIORAL|parental training programme|In the experimental group, parents participated in the parental training programme approximately one month before the start of the academic year in primary school. Two social workers, who have minimum five- year experience in giving family counselling,implemented the interventions.
223833485|NCT01845948|BEHAVIORAL|Placebo Control|Parents had no intervention except that an information leaflet for parents on helping children to adapt the new primary school life published by Education Bureau was given to each parent in the control group at the end of data collection.
223833486|NCT03176043|PROCEDURE|IV Fluid Administration|Administration of 4% Dextrose in 0.18% Sodium Chloride, through an IV cannula via a volumetric infusion pump.
223833487|NCT02585791|OTHER|Propylene Glycol|inhaled Propylene Glycol (PG) by vaporing
223833488|NCT02585791|OTHER|vegetable glycerin|inhaled vegetable glycerin (VG) by vaporing
223833489|NCT02585791|OTHER|PG+VG|inhaled PG+VG by vaporing
223833490|NCT01615991|DRUG|Radiosynoviorthesis|Intraarticular administration from 111 to 222 Mbq yttrium-90 per joint
223833491|NCT02881177|DRUG|Oxytocin|40 IU
223833492|NCT02881177|DRUG|Placebo|40 IU
223833493|NCT00651469|DRUG|YAZ (DRSP 3 mg/EE 0.02 mg, BAY86-5300)|The study medication was packaged in 28-tablet blister packs. Each subject kit contained 6 blister packs plus 1 reserve blister pack.Subjects randomly assigned to the active treatment group received 24 consecutive days of hormonally active tablets (3mgDRSP/0.02mgEE) followed by 4 consecutive days of inactive tablets. The treatment period was 6 cycles (28 tablets per cycle).
223833494|NCT00651469|DRUG|Placebo|The subjects randomly assigned to the placebo group received 28 inert but identical-appearing, color-matched tablets. The treatment period was 6 cycles (28 tablets per cycle)
223833495|NCT05867485|OTHER|COVID-19 Discharge Education|"A discharge education brochure has been developed based on information from the literature to complement the verbal information provided to patients. The content of the education brochure includes the following:~1. Information about the spread of the virus and precautions to be taken.~2. Guidelines for cleanliness and disinfection of the environment.~3. Precautions regarding personal and wearable items.~4. Information about food and beverages.~5. Guidelines for personal hygiene practices.~6. Information about quarantine and isolation.~7. Guidelines for maintaining health and care (e.g., respiratory hygiene, cough etiquette, movement, range of motion exercises) (CDC, 2019; Ministry of Health of Turkey, 2020; CDC 2019 A-B-C-D)."
223833496|NCT05088837|OTHER|muscle energy technique|MET was performed in the form of post-isometric relaxation technique for iliopsoas, hamstrings, and erector spinae and quadratus lumborum muscles. the limb was taken very slightly beyond the restriction barrier and was held there for 10-30 seconds, it was done 3 times per session for 12 sessions.
223833497|NCT05088837|OTHER|ice and heat packs|Applying 20 minutes: 10 minutes hot,10 minutes cold on sacroiliac area, 3 times per week for 12 sessions
223833498|NCT01278108|DRUG|GLPG0778|single ascending doses, oral solution (10 to 800 mg/dose) and capsules (100 mg/dose)
223833499|NCT01278108|DRUG|placebo|single dose, oral solution or capsule (matching corresponding study medication)
223833500|NCT01278108|DRUG|GLPG0778|multiple dose, capsule, 7 days
223833501|NCT01278108|DRUG|placebo|multiple dose, capsule, 7 days
223833502|NCT02377713|DRUG|KHK6640|Single ascending dose administration
223833503|NCT02377713|DRUG|Placebo|Single ascending dose administration
223833504|NCT01542021|DRUG|degarelix injection|Treatment will consist of a single 240 mg injection of degarelix 4 ± 1 day before radical prostatectomy, depending on treatment arm.
223833505|NCT01542021|DRUG|degarelix injection|Treatment will consist of a single 240 mg injection of degarelix 7 ± 1 day before radical prostatectomy, depending on treatment arm.
223833506|NCT01542021|DRUG|androgen deprivation therapy|
223833507|NCT03122756|DRUG|Dexamethasone|Intravenous injection of dexamethasone 0.1 mg/kg maximum 8 mg (diluted with distilled water to 2 mL) just prior to administration of spinal anesthesia.
223833508|NCT03122756|OTHER|Normal Saline|Intravenous injection 2 mL intravenous normal saline (0.9 %) just prior to administration of spinal anesthesia.
223833509|NCT05835622|DEVICE|Keeogo|Keeogo is exoskeleton for walking assistance
223833510|NCT05835622|OTHER|adviced home practice|health tips for regular and appropriate physical activity
223833511|NCT05668936|DRUG|Cotadutide|Participants will receive a subcutaneous injection of cotadutide.
223833512|NCT05668936|DRUG|Cotadutide-placebo|Participants will receive a subcutaneous injection of cotadutide-placebo.
223833513|NCT05668936|DRUG|Moxifloxacin|Participants will receive a single oral dose of Moxifloxacin film-coated tablet.
223833514|NCT05668936|DRUG|Moxifloxacin-placebo|Participants will receive a single oral dose of Moxifloxacin-placebo film-coated tablet.
223833515|NCT03753776|DRUG|Placebo pills of Radium bromatum|Placebo pills of Radium bromatum will be taken since 48h before radiotherapy and until 15 days after the end of radiation, or until grade 2 or higher radiodermatitis apparition
223833516|NCT03753776|DRUG|Radium bromatum pills|Homeopathic Radium bromatum pills will be taken since 48h before radiotherapy and until 15 days after the end of radiation, or until grade 2 or higher radiodermatitis apparition
223833517|NCT03753776|DRUG|Radium bromatum/Apis mellifica/Belladonna placebo pills|Placebo pills of Radium bromatum, Apis mellifica and Belladonna will be taken since grade 2 or higher radiodermatitis and until 15 days after the end of radiation
223833518|NCT03753776|DRUG|Radium bromatum/Apis mellifica/Belladonna pills|Pills of Radium bromatum, Apis mellifica and Belladonna will be taken since grade 2 or higher radiodermatitis and until 15 days after the end of radiation
223833519|NCT04088474|DIETARY_SUPPLEMENT|Vigiis 101-LAB|examined the effects of the Vigiis 101-LAB capsules (5 billion CFU/day)
223833520|NCT04088474|DIETARY_SUPPLEMENT|Placebo|Maltodextrin was used as a placebo
223833521|NCT02307747|OTHER|blood samples|Blood samples will be collected every 4 hours during 24 h
223833522|NCT03609554|OTHER|Pilates|The Pilates exercise programme was implemented over 6 weeks, with 2 sessions/week (55 minutes/session). The Pilates programme was conducted by the Physical Education teacher, who was certified in Pilates training. The Pilates programme began at the basic level, incorporating more difficult principles and exercises gradually. The sessions were divided into the warm-up (7 min), the main part (41 min), and the cool down (7 min). Tt concentrated on basic Pilates exercises involving the principal regions of the body (spine flexions, extensions and rotations; hip flexions, extensions and rotations; and shoulder abductions, adductions and rotations).
223833523|NCT03663777|OTHER|Isometric handgrip training|Intervention period will last 12 weeks. Experimental group will perform three sessions per week of home-based handgrip exercise. The exercise protocol will consist of eight sets of bilateral handgrip contraction of two minutes of isometric contraction, with 30% of maximum voluntary contraction, and two minutes of interval between sets. Patients will receive a diary to record the sessions and report difficulties during the training. The patients be recommended to increase daily physical activity levels, and weekly, there will be phone contacts with the patients to reinforce the exercise recommendations.
223833524|NCT03663777|OTHER|Control Group|Intervention period will last 12 weeks. Patients will be recommended to increase daily physical activity levels, and weekly, there will be phone contacts to reinforce the recommendations.
223833525|NCT01216293|DRUG|Dexlansoprazole|Dexlansoprazole 60 mg capsules
223833526|NCT01216293|DRUG|Esomeprazole|Esomeprazole 40 mg capsules
223833527|NCT01216293|DRUG|Placebo|Placebo-matching capsules
223833528|NCT01080651|DRUG|Voriconazole|Day1: voriconazole 200 mg x 2, oral administration, Day2-7: rifampin 600 mg, once a day oral administration, Day8: voriconazole 200 mg x 2 + rifampin 600 mg, oral co-administration
223833529|NCT04496843|DIAGNOSTIC_TEST|HWA09 Measurement|Simultaneous recording of Withings HWA09 Device and PSG devices for the reference.
223833530|NCT02679534|OTHER|hand massage|
223833531|NCT02679534|OTHER|hand holding|
223833532|NCT02679534|OTHER|application of unscented hypoallergenic cream|
223833533|NCT02679534|OTHER|environmental adjustments|
223833534|NCT04676490|OTHER|RECORD-ED Card|Low-cost and low-tech recordable audio card containing language-concordant discharge instructions for families of children under age 10 presenting to the ED for asthma exacerbations with no or public insurance and a preference for English or Spanish. Recordable cards allow for multiple audio reviews of the instructions by multiple caregivers without dependence on access to the internet or smartphone technologies.
223833535|NCT04676490|OTHER|RECORD-ED Patient Portal|Audio recorded, language concordant discharge instructions via patient portal
223833536|NCT04590859|PROCEDURE|Block performed|Comparing block performed with penile blood flow
223833537|NCT04590859|DEVICE|LMA placement|Placement of LMA for airway securement
223833538|NCT01243073|DRUG|Imetelstat|
223833539|NCT06394661|DRUG|Serplulimab+NabPE|Serplulimab plus neoadjuvant nab-PE: Epirubicin 75mg/m2 ivgtt on Day 1+Albumin Paclitaxel 260mg/m2 ivgtt on Day 1+Serplulimab 4.5mg/Kg ivgtt on Day 3）
223833540|NCT05280405|DRUG|Infliximab|Infliximab
223833541|NCT05632536|PROCEDURE|SACRAL ESP AND CAUDAL BLOCK|Application of ultrasound-guided sacral erector spinae plane (ESP) block or ultrasound-guided caudal block with 1mL/kg 0.25% bupivacaine (local anesthetic) to patients
223833542|NCT01671748|DEVICE|MIST ultrasound therapy|Low frequency, non-contact ultrasound system delivering therapeutic ultrasound via a fine saline mist to the wound bed.
223833543|NCT01671748|OTHER|Standard Care|Compression bandaging, non-adherent dressing, and debridement if required.
223833544|NCT06524505|DEVICE|deep Transcranial Magnetic Stimulation (dTMS) -active|with the H1-coil device included 20-min sessions of 18 Hz (2-s trains separated by 20-s inter-train intervals, 55 trains totaling 1980 pulses/session).
223833545|NCT06524505|DEVICE|deep Transcranial Magnetic Stimulation (dTMS) -sham|The sham stimulation was performed using the same procedures, with the sham coil.
223833546|NCT06609330|BEHAVIORAL|Countering Chronic Anger and Aggression Related to Trauma and Transgressions (CART)|Countering Chronic Anger and Aggression Related to Trauma and Transgressions (CART), a novel intervention for reducing chronic anger and aggression and improving interpersonal relationships, in military personnel who have experienced military-related betrayal delivered in 14 treatment modules twice a week.
223833547|NCT06376981|DRUG|Hyaluronic acid injection|An injection of 2 ml of Acid hyaluronic
223833548|NCT06376981|DRUG|Corticosteroid injection|An injection of 1 ml of corticosteroids
223833549|NCT06376981|DRUG|Placebo injection|An injection of 2 ml of placebo (physiological serum)
223833550|NCT00697554|BIOLOGICAL|HBV-MPL vaccine 208129|2-dose primary vaccination followed by 1 booster vaccination by intramuscular injection
223833551|NCT00697554|BIOLOGICAL|Engerix™-B|3-dose primary vaccination followed by 1 booster vaccination by intramuscular injection of double doses
223833552|NCT01974466|OTHER|Goal A|controled fluid therapy：10\~5ml/kg/h，crystalloid vs colloid 2:1 resuscitation target： fulfillment of two or more of four criteria:1. HR \<120 beats/min, 2.MAP 65-85 mm Hg, 3. urine output ≥1 ml/kg /h 4. HCT ≤35%.
223833553|NCT01974466|OTHER|Goal B|"controled fluid therapy：10\~5ml/kg/h，crystalloid vs colloid 2:1 resuscitation target： fulfillment of all of the following criteria:~1 CVP 8-12 mmHg , 2.MAP 65-85 mm Hg, 3. urine output ≥0.5 ml/kg/h 4. ScvO2 ≤70%"
223833554|NCT06624423|OTHER|corn silk tea|Corn Silk Tea
223833555|NCT04703803|COMBINATION_PRODUCT|1% lidocaine injection in trigger points|The trigger point injection procedure with 1% lidocaine will be e (the sum of all needled trigger points will have a maximum of 10 ml), in a single intervention
223833556|NCT06710535|OTHER|Manual Manipulation|The participants will receive one session of manipulation if in the experimental group. It should be mentioned that the technique will be carried out by a physiotherapist with a history of more than 10 years of manual therapy. For instance, to correct right anterior innominate rotation, the participant will be made to lie on the side so that the affected side is upward. The physiotherapist will stand in front of the participant; first we will put their shoulders, pelvis and lower limbs in neutral position and place the right hand on the anterior superior iliac spine (ASIS) and the left hand on the ischium tuberosity and with a rotational movement of the hands, the physiotherapist will rotate the ilium posteriorly. At the end of the range, we will replace the position of hands and place the left forearm on the ischium tuberosity and place the right hand on the upper participant's shoulder and will move it toward the bed at the end of the range in exhalation a thrust will be executed.
223833557|NCT06710535|OTHER|Sham Manipulation|The participants will receive one session of sham manipulation if in the sham group. For instance, to correct right anterior innominate rotation, the participant will be made to lie on the side so that the affected side is upward. The physiotherapist will stand in front of the participant; first we will put their shoulders, pelvis and lower limbs in neutral position and place the right hand on the anterior superior iliac spine (ASIS) and the left hand on the ischium tuberosity and with a rotational movement of the hands, the physiotherapist will rotate the ilium posteriorly. At the end of the range, we will replace the position of hands and place the left forearm on the ischium tuberosity and place the right hand on the upper participant's shoulder and will move it toward the bed at the end of the range in exhalation, the physiotherapist will pretend to execute a thrust.
223833558|NCT05359900|OTHER|Pain neuroscience education|Pain neuroscience education lecture
223833559|NCT05359900|OTHER|Red Flag Education|Red Flag education lecture
223833560|NCT05921630|OTHER|Education|Patient education before pulmonary function test
223833561|NCT02229903|DEVICE|Active DTMS Treatment|H-coil Deep TMS 29 TMS treatments over 6 weeks.
223833562|NCT02229903|DEVICE|Sham Treatment|29 treatments over 6 weeks.
223833563|NCT05793762|DEVICE|Left virtual mirror therapy task|the participant is seated on a chair facing the screen of the virtual mirror therapy device. both hands resting under the screen. The participant is asked, for each block of 20 seconds, to observe the visual feedback of the virtual left hand on the screen (flexion / extension movements of the fingers at 0.5 Hz).
223833564|NCT05793762|DEVICE|Right virtual mirror therapy task|the participant is seated on a chair facing the screen of the virtual mirror therapy device. both hands resting under the screen. The participant is asked, for each block of 20 seconds, to observe the visual feedback of the virtual right hand on the screen (flexion / extension movements of the fingers at 0.5 Hz).
223833565|NCT01884987|DRUG|GM1|This group will be treated with GM1 80mg daily for 14 days, and then followed with GM1 40mg daily for 46 days.
223833566|NCT02725281|OTHER|Stress ball|"The patients in this group were given stress ball into both their palms 5 minutes before ESWL. Participants were instructed to squeeze the balls twice after counting up to ten and repeat it until the end of the procedure. This ball was medium hard and has been made of high quality silicon."
223833567|NCT02725281|OTHER|Music|The patients in this group were also listened to the music chosen by them with a headset from 5 min before until the end of lithotripsy. Types of music played for the patients were Turkish folk music, Turkish art music, Turkish arabesque music, Turkish pop music, foreign pop music, rock music, and classical music.
223833568|NCT05291013|PROCEDURE|Gastric byspass|Test will be before and 9-12 month after gastric bypass
223833569|NCT05400720|BEHAVIORAL|Mentoring|At least one meeting between the mentor and mentee will occur to share experiences and see if the mentee would like to continue meeting with a mentor
223833570|NCT02112734|DRUG|Vitamin D|400 IU/daily until age 12 months
223833571|NCT02112734|DRUG|placebo|identical placebo daily
223833572|NCT06474117|OTHER|Gait analysis coupled with ultrasound|Measure the lengths of the Achilles tendon and gastrocnemius medialis muscle
223833573|NCT06474117|OTHER|Isokinetic dynamometer with simultaneous ultrasound|Measure the force/length profile of the gastrocnemius medialis muscle
223833574|NCT03428282|PROCEDURE|VR Box|Distraction will be made during the injection of the drug using this method.
223833575|NCT03428282|PROCEDURE|Tablet Device|Distraction will be made during the injection of the drug using this method
223833576|NCT03428282|DRUG|Anesthesia|Anesthesia will be obtained by injecting the drug into the oral mucosa before performing the dental treatment.
223833577|NCT03139838|BEHAVIORAL|EHR-Based Intervention A|Intervention A will be a prompt for clinicians to document an estimated prognosis for patients at 6 months, and an assessment of predicted functional outcome if expected to survive.
223833578|NCT03139838|BEHAVIORAL|EHR-Based Intervention B|Intervention B will entail a prompt for clinicians to provide a reason for not offering patients and their families the alternative of care focused entirely on comfort despite recommendations from critical care professional societies to do so for patients at high risk for death or severely impaired functional recovery.
223833579|NCT01222832|DRUG|Bacitracin|Bacitracin soaked nasopore sponge
223833580|NCT03444220|BIOLOGICAL|Anaerobically Cultivated Human Intestinal Microbiota|30ml ACHIM will be administrated at week 0 and 2 with 14 days apart
223833581|NCT03444220|BIOLOGICAL|Anaerobically Cultivated medium|30ml medium will be administrated at week 0 and 2 with 14 days apart
223833582|NCT04238221|DRUG|Doxofylline|Patients will receive a 4-week treatment with doxofylline 400 mg bid, in addition to their chronic usual inhalation therapy.
223833583|NCT03059693|DRUG|HAT1 topical cream|
223833584|NCT03059693|DRUG|Vehicle cream|
223833585|NCT00027690|DRUG|Gefitinib|Given orally
223833586|NCT00027690|OTHER|Laboratory Biomarker Analysis|Correlative studies
223833587|NCT03242603|BIOLOGICAL|Anti-GD2 in combination with NK cells|Haploidentical donor NK cells will be expanded over 10 days and infused in combination with anti-GD2. Anti-GD2 will be given as daily infusion for 5 days ; D-1, 0,+1, +2 and +3. NK cells will be infused at single dose on day 0. The patient will receive cyclophosphamide 60mg/kg on day -3 and day -2 prior to the NK cell infusion. IL- 2 will be given subcutaneously for 6 doses every alternate day starting on day -1, for NK cell survival.
223833588|NCT03749382|OTHER|AprilAge- facial morphing appearance based intervention for smoking|"Appearance-based intervention: The intervention is a software that ages an individual's face with and without the effects of smoking. Participants have their photo taken on a laptop webcam, they are then asked to report their age and ethnicity in order to calibrate the software, the participants picture is then matched to a stock image. The participants will see two images on the screen, on the left is there face aged without the effects of smoking and one the right aged with the effects of smoking. Participants will be led through a series of morphing sequences (1-5). In-between each of the morphing sequences (Morph1 to Morph5) the participant will be asked to comment on the differences they can see between the two images.~General stop smoking intervention: The General stop smoking intervention comes in the form of a NHS stop smoking information leaflet. The participants will be given the leaflet on a laptop screen and asked to read through the whole document."
223833589|NCT02011958|DRUG|Liposomal Amphotericin B|"40 mg/kg total dose: IV infusion of 5mg/kg per day on day 1 to 5, 10,17,24 (when administered as a monotherapy)~30 mg/kg total dose: IV infusion 5 mg/kg per day on day 1, 3, 5, 7, 9, 11 (when administered in combination with Miltefosine)"
223833590|NCT02011958|DRUG|Miltefosine|"Orally taken every day during 28 days~* 1 x 50 mg capsule per day if the patient weights less or equal to 25 kg~* 2 x 50 mg capsules per day if the patient weights more than 25 kg (1 capsule in the morning / 1 capsule in the evening)"
223833591|NCT02358590|BEHAVIORAL|HAPA menu-based mini-video|The intervention will be a multi-target menu-based mini-videos designed to deliver information about vitamin D adherence and its effect on osteoporosis
223833592|NCT02358590|BEHAVIORAL|Standard care|The treating physician will advice participants to take vitamin D
223833593|NCT02169830|DRUG|nortriptyline|The nortriptyline will be given in an escalating fashion, starting at 25 mg PO qhs for 2 weeks, followed by 50 mg PO qhs for 2 weeks, and finally 75 mg PO qhs. Patients will be encouraged to use the lowest effective dose and to self-titrate their medication.
223833594|NCT02169830|DRUG|Topiramate|Topiramate dosing will be 25 mg PO qhs for 1 week, followed by 25 mg BID for 1 week, followed by 25 mg in the morning and 50 mg qhs for 1 week, and finally 50 mg BID
223833595|NCT02169830|BEHAVIORAL|Diet Modification|Emphasis will be given to cessation of known migraine triggers such as caffeine, sodas, chocolates, alcohol (especially red wine) and aged cheeses. Patients who have complete control of their symptoms with diet and behavior modification alone will be followed for a total of 4 months to determine the durability of symptom relief.
223833596|NCT02626403|DEVICE|Anodal tDCS|Patients will receive anodal tDCS during 20 minutes preceded and followed by a behavioral assessment (Coma Recovery Scale Revised) and an EEG. The anodes will be placed over F3, F4, CP5, and CP6 in order to stimulation the fronto-parietal cortex bilaterally.
223833597|NCT02626403|DEVICE|Sham tDCS|Identical to anodal tDCS, except that the stimulation will be stopped after 15 seconds.
223833598|NCT05475938|OTHER|Painting therapy and psychoanalysis|Pathologically confirmed children with malignant bone tumors, painting therapists to explain the requirements and purpose of painting. After the patient completes the painting, the therapist makes a targeted and individualized analysis and provides psychological counseling by reflecting the patient's psychological state through painting.
223833599|NCT03204695|DEVICE|Percutaneous LAA Closure|LAA Closure with the WaveCrest LAA Occlusion System (study device)
223833600|NCT03204695|DRUG|Anticoagulation or Clopidogrel|Subjects either continue on anticoagulation or receive clopidogrel
223833601|NCT04596527|DRUG|18F-FMPP|18F-FMPP were injected into the patients at rest (2.5 mCi) and during stress (6.0 mCi) for an individual subject before PET/CT scans.
223833602|NCT03800966|OTHER|Leaflet|Leaflets for both groups will be printed in colour. Leaflet in each group contains 8 pictures and 8 statement, whose sequences will be scrambled. Primary school students need to do the matching, to ensure they read the statements.
223833603|NCT03241043|DRUG|Treatment 2 weeks Envarsus followed by 2 weeks Advagraf|
223833604|NCT03241043|DRUG|Treatment 2 weeks Advagraf followed by 2 weeks Envarsus|
223833605|NCT04019600|OTHER|Echocardiography|Demographic data and health risk factors will be collected on day of screening, together with the above tests. Right heart catheterization will be separately arranged in patients with a high echocardiographic probability of PAH. For those with a low-intermediate echocardiographic probability, screening will be repeated within 1 year to ensure true negativity of the original scan.
223833606|NCT04834362|DRUG|Analog Insulin|"For a patient who is known to have diabetes but were not getting insulin previously (or previous insulin dosage is not known), insulin therapy will be started at a total daily dose of 0.3-0.4 units/kg/day for an admission BG between 10-15 mmol/L or 0.5-0.6 units/kg/day for a BG \>15 mmol/L. In previously insulin treated patients, ongoing total daily dose of insulin will be started. If there is history of poor glycemic control with ongoing insulin dose, then 10-20% increase of daily dose of insulin will be considered.~For a patient who is not known to have diabetes, insulin therapy will be started if admission BG is \>10 mmol/L in two or more occasions. A total daily dose of 0.3-0.4 units/kg/day will be started if admission BG is 10-15 mmol/L and 0.5-0.6 units/kg/day for a BG \>15 mmol/L."
223833607|NCT04834362|DRUG|Human insulin|Patients treated with human insulin regimen will receive 50% of total daily dose as NPH insulin at around 6 am and 6 pm, while the rest 50% regular human insulin three times a day in 3 equally divided doses at around 6 am, 12 pm and 6 pm.
223833608|NCT06396195|OTHER|bioflx crown|The Bioflx crowns are characterized by their flexibility, durability, and adaptability. These crowns are preformed pediatric crowns designed for aesthetics, combining properties found in both stainless steel and zirconia crowns.
223833609|NCT06396195|OTHER|stainless steel crown|"Stainless steel crowns continue to be considered the Gold Standard for posterior full coverage restorations in primary molars"
223833610|NCT00081471|DRUG|darbepoetin alfa|0.45 micrograms/kg sc (starting dose) weekly
223833611|NCT00081471|DRUG|methoxy polyethylene glycol-epoetin beta [Mircera]|0.6 micrograms/kg sc (starting dose) once every 2 weeks
223833612|NCT03990714|PROCEDURE|Right hemicolectomy|It is the resection of the right colon by a tumor and the reconstruction by an ileocolic anastomosis: intracorporeal or extracorporeal
223833613|NCT01868789|RADIATION|Weightbearing CT|
223833614|NCT01316497|PROCEDURE|Remote ischemic preconditioning (RIPC)|RIPC was performed by applying a blood pressure cuff around the child's leg. The cuff was inflated to 40 mmHg above the systolic pressure in 4 cycles of 5 minutes. Every cycle of ischemia was followed by 5 minutes of reperfusion. The first RIPC cycle started after anesthesia induction when invasive arterial blood pressure was monitored. Appropriate cuff size was used choosing between four sizes. For reproducibility RIPC was performed on the right leg with only a few exceptions, when the leg was used for invasive catheters.
223833615|NCT01316497|PROCEDURE|Control|The cuff was applied on the leg without inflation in the control group.
223833616|NCT05536674|BEHAVIORAL|SMS reminder for the HPV vaccination|A BI-informed SMS reminder to remind caregivers of girls between 10-12 years that their daughter is due the first dose of her HPV vaccination and share information about the vaccine.
223833617|NCT03788148|DEVICE|Stent, red blood cell transfusion|BMS (Bare Metal Stent) and DES (drug-eluting stent) transplants with periprocedural red blood cell transfusion
223833618|NCT01349829|BIOLOGICAL|HAVpur Junior|"≥12 International Units (IU) hepatitis A antigen coupled to virosomes, intramuscularly (i.m.), anterolateral thigh (M. vastus lateralis) or deltoid (M. deltoideus)~Vaccination schedule: single doses at 0 and 6 months"
223833619|NCT01349829|BIOLOGICAL|Havrix 720 Junior|"≥720 ELISA Units (EU) hepatitis A antigen adsorbed to aluminium hydroxide, intramuscularly (i.m.), anterolateral thigh (M. vastus lateralis) or deltoid (M. deltoideus)~Vaccination schedule: single doses at 0 and 6 months"
223833620|NCT02555371|BIOLOGICAL|Mepolizumab 100mg|Mepolizumab is a fully humanised Immunoglobulin (IgG) antibody (IgG1, kappa) with human heavy and light chain frameworks. Mepolizumab will be provided as a lyophilised cake in sterile vials for individual use.
223833621|NCT02555371|DRUG|Placebo|The placebo will be 0.9% sodium chloride solution and will be provided by the study site.
223833622|NCT04784273|PROCEDURE|Tibiotalocalcaneal Arthrodesis|Tibiotalocalcaneal (TTC) arthrodesis with a novel dynamic compression intramedullary nail.
223833623|NCT04784273|DEVICE|DynaNail|Utilization of a novel dynamic compression pseudoelastic intramedullary nail
223833624|NCT01859650|OTHER|MR and CT imaging|
223833625|NCT03095599|BIOLOGICAL|IVACFLU-S|"IVACFLU-S is seasonal inactivated, split virion, trivalent influenza vaccine (A/H3N2, A/H1N1, and B), produced in GCP facility by IVAC uses embryonated chicken eggs. This vaccine is purified by sucrose gradient ultracentrifugation (Alfa Wassermann, West Caldwell, NJ), and inactivated with formaldehyde. Each 0.5 mL dose of vaccine contains~* NYMC X-179A (A/California/7/2009) (H1N1) - 15μg hemagglutinin (HA)~* NYMC X-263B (A/HongKong/4801/2014) (H3N2) - 15μg HA~* NYMC BX-35 (B/Brisbane/60/2008) (B) - 15μg HA"
223833626|NCT03095599|OTHER|Placebo|Phosphate buffered saline with pH 7.2; 0.5 ml/per dose
223833627|NCT00104182|DRUG|insulin detemir|
223833628|NCT00104182|DRUG|insulin NPH|
223833629|NCT00299689|DRUG|Denileukin diftitox|12 mcg/kg IV (in vein) over 30 minutes on days 1 through 4 of each 21 day cycle for 4 cycles.
223833630|NCT05830916|DIAGNOSTIC_TEST|Antiphospholipid antibodies|Antiphospholipid (aPL) antibodies are a heterogeneous group of autoantibodies with high affinity for phospholipids such lupus anticoagulant (LA), β2glycoprotien І (β2GPІ), and anticardiolipin (anti-CL). They interfere with physiological mechanisms of coagulation and fibrinolysis, leading the haemostatic balance towards coagulation. Moreover, it seems to affect the physiological function of various cells such as platelets and endothelial cells
223833631|NCT03116763|BEHAVIORAL|iPeer2Peer Mentorship|10 sessions of 20-30 minute Skype calls conducted over 5-12 weeks.
223833632|NCT03116763|OTHER|Active Comparator: Control Group|The control group will receive standard care but without the iPeer2Peer program.
223833633|NCT01379235|OTHER|Pilatis exercise|12 weeks of pilatis exercise 3 times a week.
223833634|NCT00513019|DRUG|Lamictal (lamotrigine)|once daily from beginning to end of study. Dosage varies.
223833635|NCT00513019|DRUG|Placebo|daily
223833636|NCT03184714|DEVICE|NIPPV|BiPAP treatment for 3 years
223833637|NCT05733923|PROCEDURE|Traditional Escavation|"Patients will receive an operative procedure to remove dental caries by traditional excavation using Carbide burs on a micromotor handpiece at low speed with air and water cooling.~\- Group 6: 15 carious teeth will be excavated chemo-mechanically using Selecti-solve."
223833638|NCT05733923|PROCEDURE|Excavation with Sodium Hypochlorite Gel 2.5%.|Patients will receive an operative procedure to remove dental caries by traditional excavation using Carbide burs on a micromotor handpiece at low speed with air and water cooling. In addition, teeth will be excavated chemo-mechanically using Sodium Hypochlorite Gel 2.5%.
223833639|NCT05733923|PROCEDURE|Excavation with Papacarie Duo|Patients will receive an operative procedure to remove dental caries by traditional excavation using Carbide burs on a micromotor handpiece at low speed with air and water cooling. In addition, teeth will be excavated chemo-mechanically using a Papacarie Duo.
223833640|NCT05733923|PROCEDURE|Excavation with Brix3000|Patients will receive an operative procedure to remove dental caries by traditional excavation using Carbide burs on a micromotor handpiece at low speed with air and water cooling. In addition, teeth will be excavated chemo-mechanically using a Brix3000.
223833641|NCT05733923|PROCEDURE|Excavation with Selecti-solve|Patients will receive an operative procedure to remove dental caries by traditional excavation using Carbide burs on a micromotor handpiece at low speed with air and water cooling. In addition, teeth will be excavated chemo-mechanically using a Selecti-solve.
223833642|NCT00931203|DRUG|Celecoxib|Celecoxib (400 mg/d) will be continued from day 1 to 65
223833643|NCT01714596|OTHER|PO versus IV antibiotics Route of administration evaluation|This is a study of oral (per os, (PO)) antibiotic therapy versus intravenous (IV) antibiotics in the treatment of acute infection after fixation of fractures and joint fusions. This is not a study of an experimental drug but a study of route of administration of standard use antibiotics. Antibiotic regimen options decision will be made by the Study Surgeon at each site in consult with local Infectious Disease experts based on local standard practices and bacterial susceptibilities.
223833644|NCT01054872|BIOLOGICAL|HIV-1 DNA plasmid vaccine|4 mg injection administered as 1 mL intramuscularly via Biojector in deltoid
223833645|NCT01054872|BIOLOGICAL|HIV-1 recombinant Ad5 vaccine|1 x 10\^10 particle units (PU) administered as 1 mL intramuscularly by needle and syringe in deltoid
223833646|NCT03923296|DEVICE|Blood measurement and monitoring|Blood from a single fingerprick will be used to used to measure and monitor patients blood parameters.
223833647|NCT03923296|BEHAVIORAL|Interviews|Focus group interviews
223833648|NCT04575649|OTHER|Gastrointestinal anomalies|Infants born late preterm (at or above 35 weeks gestation) and term infants admitted to the NICU with congenital gastrointestinal anomalies, including gastroschisis, omphalocele, esophageal and bowel artesias, tracheoesophageal fistulas, Hirschsprung's disease, or congenital diaphragmatic hernias.
223833649|NCT04461925|PROCEDURE|Placenta-Derived MMSCs; Cryopreserved Placenta-Derived Multipotent Mesenchymal Stromal Cells|i/v infusions
223833650|NCT04461925|DRUG|Antibiotics|per os
223833651|NCT04461925|DRUG|Hormones|a moderate amount of dexamethasone i/v
223833652|NCT04461925|DRUG|Anticoagulant Therapy|Sub-Q
223833653|NCT04461925|DEVICE|Оxygen therapy|Оxygen therapy, mechanical ventilation and other supportive therapies
223833654|NCT01995357|DEVICE|Coloplast Test A|Coloplast Test A is a newly developed ostomy appliance
223833655|NCT01995357|DEVICE|Coloplast Test B|Coloplast Test B is a newly developed ostomy appliance.
223833656|NCT01995357|DEVICE|Standard product|Standard product is the subjects usual product. Only subjects that usually use the CE-marked commercially available SenSura 1-piece flat and SenSura Mio 1-piece are included in the investigation.
223833657|NCT04086979|BEHAVIORAL|Parental Friendship Coaching|In this condition, therapists instructed parents in ways to coach their children to display better friendship behaviors using skills teaching, role play, active practice, and homework. This is a 10 week group intervention.
223833658|NCT04086979|BEHAVIORAL|Coping with ADHD through Relationships and Education|In this condition, the therapist provided parents with psychoeducation about ADHD and friendship difficulties, and encouraged them to apply this information to their child and to support one another with tips about how to address these problems. This is a 10 week group intervention.
223833659|NCT05266105|DRUG|Palazestrant|Complete Estrogen Receptor Antagonist
223833660|NCT05266105|DRUG|Palbociclib|Palbociclib is an approved CDK 4/6 Inhibitor drug
223833661|NCT06330818|DIAGNOSTIC_TEST|MRI|Patients will get special MRI sequences (CO2-triggered BOLD MRI, Vessel-wall imaging, resting state BOLD MRI) to identify cerebral vasoreactivity and disease activity.
223833662|NCT06330818|DIAGNOSTIC_TEST|H2 15O PET/CT|Patients will get H2 15O PET/CT with acetazolamide challenge to define the cerebral vasoreserve for comparison with fMRI Images
223833663|NCT06330818|OTHER|Biosampling|Patients do get a venous puncture for blood analysis on circulating endothelial cells and virus PCR analysis
223833664|NCT04201951|DRUG|Tranexamic acid injection|Participant in group A will receive 2 ampules of 5 milliliters (mL) Tranexamic acid applied to 20 mL of 5% glucose water slowly intravenously immediately after the delivery of the fetus
223833665|NCT04201951|OTHER|Glucose water 5%|Group B will receive 30 mL of 5% glucose water slowly intravenously immediately after the delivery of the fetus
223833666|NCT04860128|BEHAVIORAL|Sports technology application|Each of the intervention groups will use in after-school hours a different mobile app for 12 weeks, with a frequency and duration of 60 minutes of training, at least three times a week. A weekly record will be kept by the adolescents in which they will have to indicate the weekly practice frequency, the duration of the activity and the kilometers covered through a report that the adolescents will deliver to the teacher at the end of each week.
223833667|NCT01184001|DRUG|Treatment A|Single dose of tasocitinib (CP-690,550) 10 mg under fed conditions.
223833668|NCT01184001|DRUG|Treatment B|Single dose of tasocitinib (CP-690,550) 10 mg under fasted conditions.
223833669|NCT01184001|DRUG|Treatment B|Single dose of tasocitinib (CP-690,550) 10 mg under fasted conditions.
223833670|NCT01184001|DRUG|Treatment A|Single dose of tasocitinib (CP-690,550) 10 mg under fed conditions.
223833671|NCT04793932|DRUG|PAXG|Nab-paclitaxel, cisplatin and gemcitabine drugs will be administered on day 1 and 15 every 28 days. Capecitabine tablets will be taken orally on days 1 to 28, every 28 days
223833672|NCT04793932|DRUG|mFOLFIRINOX|Oxaliplatin, folinic acid, irinotecan and 5-Fluoruracil will be administered on day 1 and 15 every 28 days
223833673|NCT04793932|DRUG|short-course chemotherapy|other two months of chemotherapy after surgery
223833674|NCT04793932|DRUG|long-course chemotherapy|other two months of chemotherapy before surgery
223833675|NCT05107245|DIAGNOSTIC_TEST|1test1|Loss of bacterial diversity diagnosis
223833676|NCT06116110|OTHER|Long-term Follow-Up|No intervention
223833677|NCT02455479|BIOLOGICAL|dAd5GNE Vaccine|dAd5GNE Vaccine or Placebo dAd5GNE Vaccine
223833678|NCT02455479|BIOLOGICAL|Placebo|dAd5GNE Vaccine or Placebo dAd5GNE Vaccine
223833679|NCT06452706|DRUG|TQB2102 for injection|TQB2102 for injection is a HER2 dual-antibody-drug conjugate (ADC).
223833680|NCT06581640|BIOLOGICAL|CAR-T treatment|Peripheral blood lymphocyte collection, PBMC separation, BCMA CAR-T cell preparation/storage, lymphodepletion chemotherapy pretreatment for the subject, and BCMA CAR-T cell infusion.
223833681|NCT01490515|PROCEDURE|non-invasive metabolomic profiling|non-invasive metabolomic profiling of IVF human embryos
223833682|NCT01490515|OTHER|morphological evaluation|Simple microscopic observation of embryos and evaluation of morphological characteristics
223833683|NCT04082182|BIOLOGICAL|Dendritic cell immunotherapy|Intravenous infusions of MIDRIX4-LUNG DCs every 2 weeks, using an intra-patient dose escalation scheme progressing along the following range: 10 x10E6 DCs (minimal dose), 20 x 10E6 DCs, 40 x 10E6 DCs, 80 x 10E6 DCs, 100 x 10E6 DCs (maximal dose), until exhaustion of the batch or occurrence of grade ≥3 toxicity event
223833684|NCT04082182|BIOLOGICAL|Antigen-specific DTH|Intradermal injection of 1 x 10E6 MIDRIX4-LUNG DCs at baseline and after completion of all i.v. DC vaccination rounds. This is used for assessment of induction of antigen-specific immune responses as part of in vivo immunomonitoring (delayed-type hypersensitivity cutaneous reaction as test read-out)
223833685|NCT04082182|BIOLOGICAL|Control DTH|Intradermal injection of 1 x 10E6 MIDRIX-CTRL DCs at baseline and after completion of all i.v. DC vaccination rounds. This is used for assessment of background (i.e. non-antigen-specific) reactivity (delayed-type hypersensitivity cutaneous reaction as test read-out)
223833686|NCT00130650|DEVICE|Pain Ease|
223833687|NCT02156362|OTHER|follow up visit|At least 1 follow up visit per year will be done and an additional visit if needed.
223833688|NCT01949675|BIOLOGICAL|Shanchol™: Oral Cholera Vaccine Killed Bivalent (O1 and O139) Whole Cell|1.5 mL, Oral administration
223833689|NCT01949675|BIOLOGICAL|Shanchol™: Oral Cholera Vaccine Killed Bivalent (O1 and O139) Whole Cell|1.5 mL, Oral administration
223833690|NCT01949675|BIOLOGICAL|Shanchol™: Oral Cholera Vaccine Killed Bivalent (O1 and O139) Whole Cell|1.5 mL, Oral administration
223833691|NCT03750279|OTHER|Exercise therapy|"* 5 min. warm up with light exercises for the lower limb prior to strength/endurance exercise therapy.~* Strength/endurance exercise therapy including level 1 or 2 per session:~Level 1: Pelvic lifts (2x15 rep.), one-legged knee bends (2x10 rep. per leg), hip abductions (2x10 rep. per leg). The participants may progress from level 1 to level 2.~Level 2: Pelvic lifts (3x15 rep.), one-legged knee bends (3x10 rep. per leg), hip abductions (2x10 rep. per leg), sideways slide (2x10 rep. per leg), and backwards slide (2x10 rep. per leg). The participants may regress from level 2 to level 1."
223833692|NCT03750279|OTHER|LLLT|\- LLLT (60 mW mean output per probe, 904 nm wavelength) applied to the knee in adherence with the recommendations by World Association for Laser Therapy, in terms of dosage per treatment spot.
223833693|NCT03750279|OTHER|Sham LLLT|\- Same procedure as in the LLLT group with the exception of laser irradiation (0 mW mean output power).
223833694|NCT03359681|DRUG|Metformin Hydrochloride|metformin 500mg three times a day 20 days before colon cancer surgery and 10 days after.
223833695|NCT03359681|DRUG|Placebo oral capsule|placebo 500mg three times a day 20 days before colon cancer surgery and 10 days after.
223833696|NCT06267274|DRUG|Bimatoprost Ophthalmic Solution, 0.01%|1 drop of ophthalmic solution instill in both eyes every night at 10:00 pm (±1 hours) for 42 days (6 weeks) (± 4 days) as per the randomization schedule.
223833697|NCT06267274|DRUG|LUMIGAN® (bimatoprost ophthalmic solution) 0.01%|1 drop of ophthalmic solution instill in both eyes every night at 10:00 pm (±1 hours) for 42 days (6 weeks) (± 4 days) as per the randomization schedule.
223833698|NCT00798395|DRUG|Org 50081|1.5 mg on day 1-7
223833699|NCT00798395|DRUG|Org 50081|4.5 mg on Day 1-7
223833700|NCT00798395|DRUG|Placebo|Once daily on Day 1-7
223833701|NCT00798395|DRUG|zopiclone|Single dose of 7.5 mg
223833702|NCT01548443|DEVICE|Medifoam H dressing|"Cover medifoam H on the wound for a week."
223833703|NCT01548443|DEVICE|Duoderm THIN dressing|"Cover Duoderm THIN on the wound for a week"
223833704|NCT03615482|BIOLOGICAL|V114|Single 0.5 mL injection
223833705|NCT03615482|BIOLOGICAL|QIV|Single 0.5 mL injection
223833706|NCT03615482|BIOLOGICAL|Matching Placebo for V114|Single 0.5 mL injection
223833707|NCT00005611|DRUG|BMS-188797|
223833708|NCT03987035|DEVICE|BeGraft Peripheral (BGP) Stent Graft System as bridging stent|BGP Stent Graft System as bridging stent
223833709|NCT05798728|PROCEDURE|Outpatient transcervical foley balloon|These participants will receive a 16-French Foley catheter which will be placed by a physician present in the clinic. The balloon will be inflated with 40 mL of sterile water, and the catheter will then be gently withdrawn so that the balloon applies pressure against the internal os. The catheter will then be taped to the inner thigh.
223833710|NCT05798728|PROCEDURE|Inpatient Vaginal Misoprostol|These participants will receive 25 micrograms of Misoprostol (100- microgram tablet cut into fourths by the hospital pharmacist) inserted vaginally into the posterior fornix every 4 hours and repeated up to a maximum of six doses per our standard hospital protocol.
223833711|NCT02845505|OTHER|Intravascular Ultrasound, coronary computed tomography angiography|
223833712|NCT03521921|DEVICE|Mitraclip|Edge-to edge mitral valve repair
223833713|NCT03248570|DRUG|Pembrolizumab|All subjects will receive pembrolizumab 200mg IV every 3 weeks until disease progression or unacceptable toxicity.
223833714|NCT03248570|DRUG|Chemotherapy|At time of progression, all subjects will also have the option of receiving taxane-based chemotherapy followed by repeat pembrolizumab for those who have a clinical response to chemotherapy. Chemotherapy regimen will be at the discretion of the treating physician, and may consist of docetaxel or cabazitaxel with or without a platinum agent (e.g. carboplatin). A minimum of 4 cycles and a maximum of 8 cycles of chemotherapy will be given.
223833715|NCT04576780|OTHER|Integrated Large Complex Polyp Referral Pathway|"The referring doctor will use a standardized template to send the referral along with its associated video or high-resolution photographs.~Referrals will be reviewed in a consensus fashion by at least 2 expert physicians at St. Michael's Hospital (SMH) on a bi-weekly basis. Polyps will be scored using a standardized evaluation form that documents relevant polyp features to assist the determination of whether a lesion is amenable to curative endoscopic resection.~Cases will be triaged as being: (1) a standard polyp suitable for local removal in the community; (2) a complex polyp requiring expert removal at SMH with priority assigned based on the suspected risk of invasive disease; (3) a polyp that is not amenable to endoscopic resection or that is suspicious for cancer will that be recommended for surgical resection."
223833716|NCT00897611|PROCEDURE|DNA methylation analysis|
223833717|NCT00897611|PROCEDURE|polymerase chain reaction|
223833718|NCT00897611|PROCEDURE|computed tomography|
223833719|NCT00897611|PROCEDURE|magnetic resonance imaging|
223833720|NCT01295346|OTHER|Head CT scan and blood draw|
223833721|NCT02309528|OTHER|Educational computerized digital stories|computerized digital stories made by American Indians
223833722|NCT02922413|BIOLOGICAL|Hemin for injection|Panhematin 4 mg/kg body weight reconstituted with 25% human albumin infused intravenously over at least 1 hour.
223833723|NCT02922413|OTHER|Placebo|Saline infusion
223833724|NCT00979173|DRUG|AC480|Subjects will be initiated on AC480 300mg orally BID for 14 (+/-2 days) before surgery. After surgery, subjects will continue to be dosed with AC480 until either disease progression or intolerance, and will be evaluated every other cycle (i.e., every 4 weeks).
223833725|NCT03078387|DIAGNOSTIC_TEST|imaging|imaging before and after treatment
223833726|NCT01492517|OTHER|Ozone exposure|Exposure to 0.3ppm ozone for 2 hours
223833727|NCT01492517|OTHER|Diesel exhaust|Diesel exhaust generated from a diesel generator delivered to the exposure at a target concentration of 300 μg/m3
223833728|NCT01492517|OTHER|Ozone18|Exposure to ozone generated using the heavy non-radioactive isotope of oxygen (18O).
223833729|NCT01492517|OTHER|Clean Air|Exposure to air which has been scrubbed to remove air pollutants including ozone and particles.
223833730|NCT01161017|DRUG|Amitriptyline|Initial dose of 12.5mg will be given for 2 days. Then, daily 25mg will be taken for additional 8 weeks
223833731|NCT01161017|DRUG|Topiramate|For the first 5 days of treatment 25mg is prescribed and should be ingested in one evening dose. For another 5 days, 25g dose should be taken twice a day (morning and evening). For the next 5 days, morning dose will be 25mg; evening dose will be 50mg. For the remaining 6 weeks of treatment, a dose of 50mg twice a day will be advised
223833732|NCT02377765|DEVICE|Transcutaneous Stimulation|TPTNS through a TENS unit is a non-invasive technique, easily manageable by patients, which lacks some adverse side effects reported with the use of PTNS, such as bleeding and/or pain at the site of needle insertion. As the technique is self-administered, the associated costs might be substantially lower when compared to PTNS, which involves repeated Hospital appointments for maintenance therapy.
223833733|NCT02377765|PROCEDURE|Percutaneus Stimulation|PTNS aims to stimulate the sacral nerve plexus (origin to the parasympathetic innervations to the bladder) through the afferent fibres of the posterior tibial nerve, a mixed nerve containing L5-S3 fibres (Slovak, Chapple and Barker, 2014). This is achieved by a needle electrode inserted above the medial malleolus. Interestingly, this anatomical area is known as acupuncture point Spleen6 (Sp6).
223833734|NCT05491005|BEHAVIORAL|Total diet replacement|Total diet replacement (850 kcal/day) for 3 months followed by weight maintenance for 21 months.
223833735|NCT05491005|BEHAVIORAL|eHealth|All follow-up through an eHealth application and video meetings.
223833736|NCT05491005|BEHAVIORAL|Face-to-face|All follow-up through face-to-face meetings.
223833737|NCT05616182|OTHER|LARS ligament and bone prosthesis replacement was performed|To report the postoperative complications and limb function of patients who underwent LARS ligament and bone prosthesis replacement in Henan Cancer Hospital.
223833738|NCT01500226|DRUG|Rolapitant|(4 X 50 mg capsule) 200 mg PO
223833739|NCT01500226|DRUG|Granisetron|2 mg PO
223833740|NCT01500226|DRUG|Dexamethasone|20 mg PO
223833741|NCT01500226|DRUG|Placebo|(4 X 0 mg capsules) 0 mg PO
223833742|NCT06176456|DIAGNOSTIC_TEST|rTMS|Active regiment
223833743|NCT06176456|OTHER|Placebo|Tactile artefacts without magnetic pulses
223833744|NCT05096390|DRUG|Axitinib Oral Tablet [Inlyta]|Axitinib 5 up to 10mg twice a day
223833745|NCT05096390|DRUG|Pembrolizumab Injection [Keytruda]|Pembrolizumab intravenously over 30 min minutes at 200 mg every 3 weeks
223833746|NCT02955277|OTHER|TECH: Tablet Enhancement of Cognition and Health protocol|Cognitive training using touchscreen tablets (TECH protocol)
223833747|NCT02955277|OTHER|Standard care or active standard care|standard occupational therapy or 6-weekly group sessions playing board games and puzzles.
223833748|NCT02754609|OTHER|Gluten micro-challenge|From week 12 to week 24, all participants will start a gluten micro-challenge from 10mg/day for the first 2 weeks escalating over the this period to 50mg/day at the end of week 24.
223833749|NCT02754609|OTHER|Inadvertent gluten challenge|From week 24 to week 36, all participants will be on gluten 50mg/day and 1g twice weekly.
223833750|NCT02754609|OTHER|Moderate gluten challenge|From week 36 to week 42, all participants will be on gluten 2g/day.
223833751|NCT02754609|OTHER|Liberal diet|From week 42, all participants will be unblinded and those who have received hookworm therapy have the option to go on a liberal diet of more than 10g of gluten/day from week 42 to week 94.
223833752|NCT02754609|OTHER|Necator americanus-hookworm larvae L3-10|A total of 40 participants at week 0 and week 8 will have hookworms L3-10 present in 2-3 drops of water applied to their skin and then covered in a light dressing.
223833753|NCT02754609|OTHER|Tabasco® Sauce|Arm: Placebo Comparator: Tabasco® Sauce A total of 10 participants at week 0 and week 8 will have Tabasco® Sauce present in 2-3 drops of water applied to their skin and covered in a light dressing
223833754|NCT02754609|OTHER|Necator americanus-hookworm larvae L3-20|A total of 40 participants at week 0 and week 8 will have hookworms L3-20 present in 2-3 drops of water applied to their skin and then covered in a light dressing.
223833755|NCT02754609|OTHER|Gluten free diet|From week 0 to week 12, all participants will be on a gluten free diet.
223833756|NCT03620071|OTHER|GoalKeeper|Mobile-health communication tool for parents of children with medical complexity
223833757|NCT03620071|OTHER|Standard Care|Standard Clinical Care
223833758|NCT00387192|DRUG|Optivate|Plasma-derived Factor VIII
223833759|NCT05729815|OTHER|Relaxation|Sessions focused on relaxations activities (Jacques Choque Method).
223833760|NCT05729815|OTHER|Loose parts play|Loose parts play-based sessions, with open-ended materials.
223833761|NCT05729815|OTHER|Combined|Sessions focused on loose parts play and relaxation activities.
223833762|NCT01973465|BIOLOGICAL|Stool|Implanting fecal matter via colonscope
223833763|NCT00225420|DRUG|docetaxel|Docetaxel will be administered per the designated cohort starting at 10 mg/m2 intravenously over 1 hour weekly for eight weeks, for a total of eight treatments.
223833764|NCT00225420|DRUG|leuprolide acetate|Leuprolide acetate will be administered at 22.5 mg IM and will be initiated 2 to 3 months prior to radiotherapy and chemotherapy with docetaxel.
223833765|NCT00225420|RADIATION|radiation therapy|The total dose will be 7800 cGy in 200 centigray (cGy) per fraction for a total of 39 treatments.
223833766|NCT00360555|DRUG|flibanserin|flibanserin 25 mg b.i.d
223833767|NCT00360555|DRUG|flibanserin 50mg|flibanserin 50mg qhs/b.i.d.
223833768|NCT00360555|DRUG|flibanserin 100mg|flibanserin 50 mg b.i.d/100mg qhs
223833769|NCT00360555|DRUG|placebo|placebo comparator
223833770|NCT02836977|DRUG|tegafur-uracil|Eligible patients will receive tegafur-uracil orally at a dose of 400mg/day (100mg/Cap., 2 capsules each time, twice a day) and folinic acid 30mg/day (15mg/Tab., 1 tablet each time, twice a day) for one year.
223833771|NCT00147979|DEVICE|Bridging by PTFE with bounded heparin|Bridging by PTFE with bounded heparin
223833772|NCT00147979|DEVICE|Bridging by PTFE without bounded heparin|Bridging by PTFE without bounded heparin
223833773|NCT02748564|BIOLOGICAL|Aldesleukin|Given IV
223833774|NCT02748564|OTHER|Laboratory Biomarker Analysis|Correlative studies
223833775|NCT02748564|BIOLOGICAL|Pembrolizumab|Given IV
223833776|NCT03597893|DRUG|Oxytocin|intranasally administrated
223833777|NCT03597893|DRUG|Placebo|intranasally administrated
223833778|NCT03188328|DRUG|AvidinOX|"AvidinOX vial containing 22.5 mg AvidinOX~\+ vials containing 10 ml of water for injection (WFI) for the reconstitution in a clear solution with an AvidinOX concentration of 3 mg/ml. One Intralesion administration of a volume of reconstituted AvidinOX equal to about 15 % of the estimated lesion volume"
223833779|NCT03188328|DRUG|177Lu-ST2210|177Lu-ST2210 dose starting at 7.5 Gigabequerel (GBq) ±10%with escalation steps of 2.5 GBq up to 15 GBq ±10%, approximately 1 mg ST2210
223833780|NCT03188328|DRUG|177Lu-ST2210|Second dose of 177Lu-ST2210 dose (14 days after the first dose) starting at 7.5 Gigabequerel (GBq) ±10%with escalation steps of 2.5 GBq up to 15 GBq ±10%, approximately 1 mg ST2210
223833781|NCT06228235|DEVICE|Repetitive transcranial magnetic stimulation (rTMS)|"rTMS: rTMS is a form of non-invasive brain modulation. High-frequency rTMS will be administered. Pulses will be delivered at the frequency of 20Hz, in 50 trains of 40 pulses, 2000 pulses in total.~Behavioral priming with regulation of craving: During rTMS, participants will look at pictures either related or unrelated to smoking. When looking at pictures related to smoking, participants will either upregulate cravings by thinking about the immediate positive experience of smoking or downregulate cravings by thinking about long-term negative consequences of smoking. When looking at neutral pictures unrelated to smoking, participants will not regulate their cravings."
223833782|NCT05140993|BEHAVIORAL|extended emotional and orientation support|extended emotional and orientation support
223833783|NCT00005594|DRUG|ISIS 2503|Beginning dosage of ISIS 2503 is 6 mg/kg/day given as a continuous i.v. infusion over the first 14 days of a 21-day treatment cycle. This will be repeated for the first two weeks of every three-week treatment cycle.
223833784|NCT01109303|PROCEDURE|TightRope System- Arthrex® / Dynamic Implant|Patients are operated on using a dynamic implant, the TightRope System by Arthrex®. The ankle is immobilized in a plaster boot for 6 weeks.
223833785|NCT01109303|PROCEDURE|Screw fixation - Synthes® / Static Implant|Patients are operated on using a static implant, the rigid four-cortices 3,5 mm screw fixation by Synthes®. The ankle is immobilized in a plaster boot for 6 weeks.
223833786|NCT01809210|DRUG|selumetinib|2 x 25mg capsules bd continuously in cohort 1 (with gemcitabine and cisplatin). If tolerated - next cohort 3 x 25mg capsules bd continuously. if higher doses are explored, required number of capsules will be provided. Option to administer on D2-19 of each 21 day cycle if required to assess tolerability of combinations with chemotherapy
223833787|NCT01809210|DRUG|gemcitabine|1250 mg/m2 iv on Day 1 and 8 of each 21 day cycle. If combination not tolerated, option to give 1000 mg/m2 iv on Day 1 and Day 8 of each 21 day cycle
223833788|NCT01809210|DRUG|cisplatin|75 mg/m2 iv on Day 1 of each 21 day cycle. If combination not tolerated, option to give 50 mg/m2 iv on Day 1 or 25mg/m2 iv on Day 1 and Day 8 of each 21 day cycle
223833789|NCT01809210|DRUG|carboplatin|If it is not possible to identify a tolerable combination of selumetinib, gemcitabine and cisplatin, cisplatin may be replaced with carboplatin (AUC5) iv on Day 1 of each 21 day cycle
223833790|NCT01809210|DRUG|pemetrexed|Gemcitabine may be replaced with pemetrexed 500 mg/m2 iv on Day 1 of each 21 day cycle.
223833791|NCT02500511|BIOLOGICAL|NmVac4-A/C/Y/W-135-DT™|no intervention in this study, received test vaccine in trial JN-NM-002
223833792|NCT01668147|DRUG|[11C] desmethyl-loperamide|IV administration of 10-14 mCi of \[11C\] desmethyl-loperamide with PET/CT imaging
223833793|NCT01668147|OTHER|Control - no pretreatment|Session 1: IV administration of 10-14 mCi \[11C\] desmethyl-loperamide (dLop) with PET/CT imaging and brain MRI
223833794|NCT01668147|DRUG|Oral ritonavir|Session 2: Pretreatment with oral ritonavir for 3 days followed by IV administration of 10-14 mCi \[11C\]dLop with PET/CT imaging and brain MRI
223833795|NCT01668147|DRUG|Oral efavirenz|Session 3: Pretreatment with oral efavirenz for 14 days followed by IV administration of 10-14 mCi \[11C\]dLop with PET/CT imaging and brain MRI
223833796|NCT00791622|DRUG|Paliperidone ER|
223833797|NCT06168656|BEHAVIORAL|Mobile Application|"The mobile application will include the following features:~Direct Message Section: This section will allow expectant fathers to ask specialized questions directly to experts or specialists.~Forum Section: Expectant fathers can use this section to engage in discussions and connect with each other.~Education Section: This section is specifically designed to cater to the educational needs of expectant fathers."
223833798|NCT03567083|BEHAVIORAL|Problem Management Plus (PM+)|This intervention is based on the WHO treatment guidelines for conditions related to stress (WHO, 2013). It is a 5-session intervention that is delivered by trained non-specialized workers or lay people, and is available in individual and group delivery formats for both children and adults. PM+ includes evidence-based techniques such as; problem solving, stress management, behavioral activation, and accessing social support. It has proved to be effective by two randomized controlled trials (RCTs) in Kenya and Pakistan (Bryant, Dawson, Schafer, Sijbrandij, \& van Ommeren, 2016; Rahman, Hamdani, Awan, Bryant, Dawson, Khan, Mukhtar-ul-Haq Azeemi, et al., 2016).
223833799|NCT03557983|DRUG|Fenofibrate|Fenofibrate is dissolved in Saline and topically spread three times per day at the irradiated areas, with a concentration of 400 μg/mL for week.
223833800|NCT03557983|DRUG|Saline|Saline is topically spread three times per day at the irradiated areas for one week.
223833801|NCT01808443|OTHER|Cryotherapy|up to a maximum of four treatments every 21-28 days
223833802|NCT01808443|OTHER|laser|up to a maximum of four treatments every 21-28 days
223833803|NCT02717598|PROCEDURE|cold snare polypectomy|CSP was performed by using a disposable oval snare with a diameter of 10 mm under gentle suction to reduce colon wall tension. The tip of the endoscope was deflected toward the polyp base to ensnare 1 to 2 mm of normal mucosa surrounding the polyp. Afterward, additional EMR was performed at the polypectomy site to evaluate for the presence of residual polyp tissue,including an additional 1 to 2 mm clear margin, was resected by the snare and Endocut current after submucosal injection of a mixed solution.In the event that no tissue could be removed or if EMR failed to get in situ mucosal specimens. At least four cold biopsies using forceps on the remaining margins were obtained.After each procedure, the polypectomy site was observed for 30 seconds to confirm the absence of immediate bleeding.Cross-sections of the EMR specimens were collected at 1-mm intervals.
224264648|NCT05313217|DIAGNOSTIC_TEST|Extended slump test|"Extended Slump Procedure:~* Participant will be instructed to sit upright with their legs over the edge of table~* AFO remains on R leg~* Participant is asked to arch their lower back into maximal extension in sitting, stabilized to research bench to maintain hyper-lordosis posture.~* The participant is asked first flex cervical spine, then to extend their knee until it reaches full ROM or symptoms are felt that limit ROM.~* Knee extension ROM is assessed with iPhone inclinometer at superior aspect of medial malleolus.~* Participant asked to report any symptoms they are feeling and where (recorded for qualitative analysis)"
223833804|NCT02717598|PROCEDURE|hot snare polypectomy|HSP, which is using electrocoagulation on the basis of using cold snare.After HSP, another independent endoscopic surgeon judged whether the endoscopic eradication was successful. Afterward, additional EMR was performed at the polypectomy site to evaluate for the presence of residual polyp tissue,including an additional 1 to 2 mm clear margin, was resected by the snare and Endocut current after submucosal injection of a mixed solution.In the event that no tissue could be removed or if EMR failed to get in situ mucosal specimens. At least four cold biopsies using forceps on the remaining margins were obtained.After each procedure, the polypectomy site was observed for 30 seconds to confirm the absence of immediate bleeding, the specimens were retrieved and stored in formalin. Cross-sections of the EMR specimens were collected at 1-mm intervals; accurate tissue section of the marked site was ensured.
223833805|NCT00192283|BIOLOGICAL|CAIV-T|The total single-dose volume of 0.2 mL was administered intranasally with the spray applicator intended for commercial use (approximately 0.1 mL into each nostril).
223833806|NCT00192283|OTHER|Placebo|A single dose of placebo volume of 0.2 mL was administered intranasally with the spray applicator intended for commercial use (approximately 0.1 mL into each nostril).
223833807|NCT03664167|DIETARY_SUPPLEMENT|intensive weight loss diet, with Cambridge weightplan products, and visits to a dietician.|intensive weight loss diet, with Cambridge weightplan products, and visits to a dietician.
223833808|NCT04141111|DEVICE|Continuous Glucose Monitoring (CGM)|"On each visit (baseline, 4, 8, and 12 months), participants received an iPro2 CGM device (MiniMed Medtronic), placed according to the manufacturer's standard procedure. The iPro2 was used each time for 7-days. During this period, patients were asked to perform 4 SMBG measurements daily for calibration (fasting, lunch, dinner, and before bed). Patients received a diary to register food intake, physical activity and medication, SMBG values, and any diabetes-related event (extra consultations, phone calls, etc) in the previous 4 months.~Each time, CGM data was interpreted by an expert clinician, and a report was delivered, within one week, to the respective healthcare team. This report was discussed together by the patient and one member of the healthcare team, either in consultation or by phone, agreeing on any necessary therapeutic changes. If necessary, extra consultations for nutrition, nursing, or education, were scheduled, to address specific needs identified during rCGM review."
223833809|NCT03760315|DIAGNOSTIC_TEST|blood mNGS (IDSeqTM Ultra); blood Culture|take blood samples for mNGS and Culture at the same time in sepsis patients. No intervention on the treatment of the patients.
223833810|NCT00061100|BEHAVIORAL|Behavior Therapy-RISE|manually-guided HIV intervention RISE: Reduce high risk Intravenous drug use and unsafe Sexual Encounter
223833811|NCT00061100|BEHAVIORAL|Standard prevention Education|standard psychosocial Education for HIV/hepatitis prevention
223833812|NCT06186505|DEVICE|AirGlove|AirGlove is a unique warming system developed to enable access to the veins in a patients arm for the delivery of intraveneous drugs by gently heating the patients arm up as it forces warm air through a double walled polythene glove. In this study, the device will be used on the leg of the participants as means of encouraging circulation to the area.
223833813|NCT04122053|BEHAVIORAL|Intervention group with genotype information|Results of genotyping will be translated into personalised dietary recommendations. Subjects will be informed about their genotypes from the beginning of the study. The importance of personalised recommendations will be explained.
223833814|NCT04122053|BEHAVIORAL|Control group without genotype information|Subjects will receive personalised dietary recommendations, but at the beginning they will not be informed about their genotypes and the meaning of personalisation. Information about their genotype will be given to the participants at the and of study.
223833815|NCT05852769|DRUG|BMS-986196|Specified dose on specified days
223833816|NCT05852769|DRUG|Caffeine|Specified dose on specified days
223833817|NCT05852769|DRUG|Montelukast|Specified dose on specified days
223833818|NCT05852769|DRUG|Flurbiprofen|Specified dose on specified days
223833819|NCT05852769|DRUG|Omeprazole|Specified dose on specified days
223833820|NCT05852769|DRUG|Midazolam|Specified dose on specified days
223833821|NCT05852769|DRUG|Digoxin|Specified dose on specified days
223833822|NCT05852769|DRUG|Pravastatin|Specified dose on specified days
223833823|NCT02372331|OTHER|ERAS perioperative management|"* Preop Counseling~* Preop biliary drainage (X) when Serum Total bilirubin \< 14.62mg/dl and cholangitis (-)~* Preop enteral nutrition~* Oral bowel preparation (mechanical bowel preparation ) (X)~* Preop fasting \< 6 hours~* Prevention of postoperative nausea and vomiting (PONV) (O)~* Nasogastric intubation (X)~* Near-zero fluid balance~* Somatostatin analogues (X)~* Postop routine artificial nutrition (X), soft diet at POD #2~* Audit~* Other items are same as conventional"
223833824|NCT06040463|BEHAVIORAL|Diabetes Self-Management Training (DSMT)|The American Diabetes Association endorses the use of small-group diabetes self-management training (DSMT), for people living with diabetes to improve lifestyle, HbA1c levels, and overall quality of life. A certified diabetes care and education specialist will teach a four-part series of one-hour sessions providing culturally competent group education and discussion for groups of 5-8 patients: Session 1 - Living with diabetes - physiology of diabetes, integrating diabetes into your daily life, long term outcomes of diabetes; Session 2 - Culturally competent food education \& portion control; Session 3 - Tips \& Tricks for dining out and special occasions; Session 4 - Advanced tools and psychosocial implications of living with diabetes. While patients will be encouraged to move through the series together as a cohort, there will be make-up sessions and flexibility to ensure high-quality participation.
223833825|NCT06040463|BEHAVIORAL|Remote Glucose Monitoring (RGM)|Remote Glucose Monitoring (RGM) is an automated process of transmitting glucose levels directly from a personal smartphone device to a healthcare provider using a remote data transmitter. Since 2020, Sinai has worked with Glooko Inc. to provide the RGM platform and technical assistance to patients and for Sinai providers to access data remotely. Via the app, patients can: document their glucose levels; sync data from a meter, insulin pump, pen or continuous glucose monitoring device; track their weight; log food and meals; access educational resources; track steps; and track blood pressure. Remotely uploading data provides patients with a direct line to their provider for regular feedback on progress and answers to questions between clinic visits. Patients also receive one one-hour education session on RGM and the Glooko application.
223833826|NCT06040463|BEHAVIORAL|Community Health Worker tailored support|CHWs are frontline public health workers who are trusted members of and/or have an unusually close understanding of the community served. The Center has two bilingual (Spanish/English) CHWs; additional bilingual CHWs will be added to the team to support the proposed study. While approaches will differ slightly depending on the patient and study condition, all patients paired with a CHW will be screened for social needs utilizing a standard social determinants of health (SDoH) screening tool, receive referrals to resources to address unmet social/health needs, and aided in navigating health and social systems.
223833827|NCT03833011|PROCEDURE|Osteopathic Manipulation|Osteopathic manipulation
223833828|NCT04640480|DRUG|SNB-101|SN-38 dosage ranges from 1 to 7 will be determined by Safety Review Committee meeting
223833829|NCT00827944|DEVICE|Parietex Progrip|"Surgical technique:~Self-gripping lightweight Polyester and Polylactic acid meshes providing a sutureless fixation."
223833830|NCT00827944|DEVICE|Low weight polypropylene mesh|"Surgical technique:~Lichtenstein repair with lightweight polypropylene mesh (inferior to 70gr/m2) secured to the posterior inguinal wall with sutures"
223833831|NCT04399564|DEVICE|temporary hemodialysis catheters|Vascular access using temporary vs.long-term hemodialysis catheters
223833832|NCT04399564|DEVICE|long-term hemodialysis catheters|long-term hemodialysis catheters
223833833|NCT00709891|DEVICE|cobas® 4800 HPV Test|
223833834|NCT00401466|DEVICE|Implantable Cardioverter Defibrillator|ICD with Biotronik Home Monitoring capability
223833835|NCT04071691|DIAGNOSTIC_TEST|PET-MRI|SST2 PET-MRI scan
223833836|NCT03839472|PROCEDURE|CBI|CBI with 5 liters normal saline in 1 liter increments up to 2 hours after TURBT procedure.
223833837|NCT03699124|BIOLOGICAL|FD MVA-BN|Vaccinations with a 0.5 mL dose of vaccine containing at least 0.5 x 10E8 Infectious Units (Inf.U)
223833838|NCT03644134|BEHAVIORAL|Assessment of physiological stress and sleep pattern|The personalized intervention consists of (i) information session (ii) pre-assessment (first assessment) of stress and recovery levels, and sleep patterns (iii) individual feedback sessions and action plans based on the outcomes of the initial assessment (iv) monitoring and follow-ups (v) post-assessment (second assessment) of stress and recovery levels and sleep patterns.
223833839|NCT01346761|BEHAVIORAL|Telephone Genetic Counseling|Participants will complete a pre-test session and a test results disclosure session (if tested) with a licensed, board-certified genetic counselor over the telephone. Counseling sessions will be audiotaped for quality control of intervention.
223833840|NCT01346761|BEHAVIORAL|In-Person Genetic Counseling|Participants will complete a pre-test session and a test results disclosure session (if tested) with a licensed, board-certified genetic counselor in person. Counseling sessions will be audiotaped for quality control of intervention.
223833841|NCT05435183|DEVICE|Non-invasive high-frequency oscillatory ventilation|Non-invasive high-frequency oscillatory ventilation generates high-frequency pressure fluctuations in the airway caused by the opening and closing of a solenoid valve.
223833842|NCT05435183|DEVICE|Noninvasive Bilevel Positive Pressure Ventilation|Noninvasive Bilevel Positive Pressure Ventilation
223833843|NCT00260156|DRUG|vildagliptin|
223833844|NCT00260156|DRUG|placebo|
223833845|NCT01474512|DRUG|80 mg Ixekizumab Dosing Regimens 1, 2, and 3|Administered SC
223833846|NCT01474512|DRUG|Placebo|Administered SC
223833847|NCT00699543|DEVICE|Coroflex Please stent implantation|Use Coroflex Please stent in the treatment of coronary stenosis
223833848|NCT00699543|DEVICE|Taxus stent implantation|Use Taxus stent in the treatment of coronary stenosis
223833849|NCT03888885|BEHAVIORAL|Sport Education Model|A total number of 25 lecturers participated in the 12-hour CPD workshop on Sport Education curriculum on June 2018. The content of the workshop focused on the development of a Sport Education season, the changing roles of teachers and students, the assessment of personal and social responsibility, and the application of sport education season and related pedagogies on handball, badminton, swimming and physical conditioning. The Sport Education courseware and class materials were then designed by the eligible lecturers. The intervention was lasted for 10-lesson, 1-day per week and the duration for each lesson was around 90 minutes. The specific five phases in Sport Education model of team selection, teacher-directed, pre-season, formal competition and cumulating event were included. The eligible lecturers led the lessons according to the designated course wares and lesson plans for each sport.
223833850|NCT05484258|BEHAVIORAL|Shared Medical Visit|Group visit wherein physician and Social Worker, would be discussing topics relevant to the population.
223833851|NCT04773002|OTHER|Different anesthesia methods|Total intravenous anesthesia (TIVA)and volatile anesthesia
223833852|NCT01118962|DRUG|Lacosamide|Lacosamide was supplied as 50 mg and 100 mg tablets. The starting Lacosamide dose was the same dose reached by a subject at the end of SP0961 (NCT01118949). At the beginning of SP0962, the dose may be maintained, or increased or decreased by 100 mg /day, as deemed clinically appropriate to optimize tolerability and seizure reduction. Dose increases should be no faster than 100 mg/ day per week up to a maximum of 800 mg/ day. Lacosamide was administered twice daily (approx. 12 hours apart, once in the morning and once in the evening) in 2 equally divided doses for up to a 56-week Treatment Phase. The Treatment Phase was followed by a 5-week End-of-Study Phase, during which subjects had to be tapered off Lacosamide at a recommended decrease rate of 200 mg/ day per week.
223833853|NCT05894759|BEHAVIORAL|Psychological stress relief techniques|Psychological stress relief techniques
223833854|NCT02187211|DRUG|Minocycline|
223833855|NCT02187211|DRUG|Placebo (for Minocycline)|
223833856|NCT03708380|BEHAVIORAL|Dietary intervention|Over a 60-day period, participants will receive healthy lunches that provide a hand-delivered healthy alterative to their current diets.
223833857|NCT02127684|DRUG|ranibizumab|ranibizumab 0.3mg intravitreally monthly
223833858|NCT02127684|DRUG|ranibizumab|ranibizumab given every 2 weeks for 8 weeks then monthly as needed
223833859|NCT04689165|BIOLOGICAL|Experimental Group A meningococcal polysaccharide vaccine|Two doses of Experimental Group A meningococcal polysaccharide vaccine at the vaccination schedule of week 0, 12
223833860|NCT04689165|BIOLOGICAL|Control Group A meningococcal polysaccharide vaccine|Two doses of Control Group A meningococcal polysaccharide vaccine at the vaccination schedule of week 0, 12
223833861|NCT02724072|DEVICE|Thoraflex™ Hybrid Device|Single-use medical device sterilized by ethylene oxide which is pre-loaded into a delivery system. The device comprises a gelatin sealed vascular graft combined with a stented graft.
223833862|NCT05931562|OTHER|Fermented Foods|Participants will recieve dietary education to include 4 to 6 portions of fermented foods to their normal diet.
223833863|NCT05931562|OTHER|High Fibre|Participants will recieve dietary education to increase their fibre intake to 24-35g/day in their normal diet.
223833864|NCT05931562|OTHER|Combined Diet|Participants will recieve dietary education to increase their fibre intake to 25-30g/day and include 3 to 4 portions of fermented foods to their normal diet.
223833865|NCT05931562|OTHER|Control|Participants will recieve dietary education based on the Irish healthy food pyramid.
223833866|NCT00386711|BEHAVIORAL|training on identification of suicide risk and depression|
223833867|NCT03985098|BEHAVIORAL|Motivational interviewing intervention arm|The intervention will be a phone call by a pharmacy student that will use MI strategies to identify and address the adherence barrier(s) and 5 monthly follow up calls
223833868|NCT00790829|DRUG|transdermal nicotine patch|Generic seven-milligram nicotine patches for 24hours, placebo patch for 24 hours
223833869|NCT02749708|DRUG|IRX5183|IRX5183 will be administered orally daily on days 1-28 of each cycle for 2 cycles of induction. In the phase I part of the study, there will be 3 dose levels (dose level 1 \[DL1\] with 50 mg, DL2 with 75 mg, and DL3 with 100 mg), with 1 additional dose level to be only used if excessive toxicity noted at the DL1. There will be no intra-patient dose escalation. A phase II portion of the study was originally planned, but the study was terminated prior to phase II enrollment.
223833870|NCT03478423|DRUG|Codeine|30mg tablets. Patients will be instructed to take 1 tablet every 4 hours as needed for moderate to severe pain if you continue to have pain despite taking acetaminophen.
223833871|NCT03478423|DRUG|Oxycodone|5mg tablets. Patients will be instructed to take 1 tablet every 4 hours as needed for moderate to severe pain if you continue to have pain despite taking acetaminophen.
223833872|NCT03478423|DRUG|Hydromorphone|1mg tablets.Patients will be instructed to take 1 tablet every 4 hours as needed for moderate to severe pain if you continue to have pain despite taking acetaminophen.
223833873|NCT00514605|OTHER|Behavioral counseling|Standard-of-Care counseling at the Point-of-Care.
223833874|NCT00514605|DEVICE|HIV-1 Antibody Test Kit|Assay to detect HIV antibodies
223833875|NCT00487422|DRUG|prucalopride|2 mg o.d.
223833876|NCT00487422|DRUG|Prucalopride|4 mg o.d.
223833877|NCT00487422|OTHER|Placebo|o.d.
223833878|NCT01635894|BEHAVIORAL|Training|Women in both the practice nurse and specialist nurse groups were given supervised pelvic floor exercise training. After the initial training they were given a daily exercise regimen and seen at monthly intervals for three months. The practice nurses had attended a study day on supervising Pelvic Floor Muscle Training(PFMT)followed by practice sessions with patients overseen by the nurse specialist.
223833879|NCT01043731|PROCEDURE|Laparoscopic transvaginal hybrid anterior resection|Transvaginal Hybrid Anterior Resection: three 5mm trocars are placed transabdominally (one trans-umbilical, the other two in the lower abdomen). Identification of the inferior mesenteric vein and artery. Clipping of the vein. Then placement of a 12mm trocar through the posterior fornix of the vagina for stapling of the inferior mesenteric artery. After mobilisation of the colon descendens and the splenic flexure stapling of the proximal rectum through the 12mm trocar placed vaginally. Afterwards the colpotomy is performed and the mobilised left hemi-colon is extracted transvaginally. The proximal colonic resection is performed extracorporeally in the conventional fashion with placement of a purse-string suture and insertion of the circular stapling anvil into the proximal end of the bowel. The bowel is then replaced into the abdominal cavity. The colpotomy is then closed. A circular stapler is inserted transanally and the end-to-end anastomosis is performed.
223833880|NCT00772798|DRUG|Paclitaxel, Carboplatin and Vorinostat|Intravenous paclitaxel (175 mg/m2) and carboplatin (AUC 5) and oral vorinostat 400 mg day 1-14 every three weeks.
223833881|NCT05373602|DIAGNOSTIC_TEST|LARS questionnaire|Eligible participants were issued with LARS questionnaire (Chinese version) by E-mail, message, phone or face to face interview.
223833882|NCT00000556|DRUG|amiodarone|
223833883|NCT00000556|DRUG|sotalol|
223833884|NCT00000556|DRUG|propafenone|
223833885|NCT00000556|DRUG|flecainide|
223833886|NCT00000556|DRUG|quinidine|
223833887|NCT00000556|DRUG|moricizine|
223833888|NCT00000556|DRUG|disopyramide|
223833889|NCT00000556|DRUG|procainamide|
223833890|NCT00000556|DRUG|adrenergic beta antagonists|
223833891|NCT00000556|DRUG|verapamil|
223833892|NCT00000556|DRUG|diltiazem|
223833893|NCT00000556|DRUG|digoxin|
223833894|NCT00000556|PROCEDURE|catheter ablation|
223833895|NCT00000556|DEVICE|pacemaker, artificial|
223833896|NCT01305356|DEVICE|Augment® Injectable Bone Graft|Implantation of up to 9cc of Augment® Injectable Bone Graft
223833897|NCT01305356|PROCEDURE|Autologous bone graft|Implantation of up to 9cc of autologous bone graft
223833898|NCT01023308|DRUG|Panobinostat|Panobinostat was administered 3x week ( 2 weeks on 1 week off)
223833899|NCT01023308|DRUG|Bortezomib|Bortezomib was administered 2 x week ( 2weeks on 1 week off)
223833900|NCT01023308|DRUG|Dexamethasone|Dexamethasone was adminstered on day of Bortezomib and the day after Bortezomib administration
223833901|NCT01023308|DRUG|Placebo|Placebo was administered 3x week ( 2 weeks on 1 week off)
223833902|NCT02060253|DRUG|ganetespib|Given IV
223833903|NCT02060253|DRUG|paclitaxel|Given IV
223833904|NCT02060253|BIOLOGICAL|trastuzumab|Given IV
223833905|NCT02060253|BIOLOGICAL|pertuzumab|Given IV
223833906|NCT01409174|DRUG|Ipilimumab|"Phase I Starting dose: 1 mg/kg by vein over 90 minutes on Day 1 of each 3 week cycle for Induction 12 weeks, then Day 1 of Cycle 1 for Consolidation 12 weeks and Day 1 of each 12 week cycle in Maintenance.~Phase II dose: Maximum tolerated dose (MTD) from Phase I."
223833907|NCT01409174|DRUG|Temozolomide|200 mg/m\^2 by mouth 1 time a day on Days 2-5 of each Induction cycle (four 3 week cycles).
223833908|NCT01409174|DRUG|Cisplatin|25 mg/m\^2 by vein over 1 hour on Days 2-4 of each Induction cycle (four 3 week cycles).
223833909|NCT01409174|DRUG|Interferon Alfa-2b|5 million U/m2 subcutaneously on Days 2-6 of each 3 week Induction cycle (four 3 week cycles) and each 4 week Consolidation cycle (three 4 week cycles).
223833910|NCT01409174|DRUG|Interleukin-2|9 million IU/m\^2 by vein as a continuous infusion on Days 2-5 of each 3 week Induction cycle (four 3 week cycles) and each 4 week Consolidation cycle (three 4 week cycles).
223833911|NCT01697761|OTHER|Treatment Group|patients receive herbs-partitioned moxibustion for 2 cones and acupuncture for 30 minutes，3 times a week for 12 weeks
223833912|NCT01697761|OTHER|Control Group|patients receive shallow needing and bran-partitioned moxibustion with the stimulation same to the treatment group.
223833913|NCT02152436|OTHER|Simulation - based curriculum|Operating room medical and non-medical members will be asked to carry out a simulation session preceded by an educational maze with videos. Outcomes will be compared and correlated after and before this curriculum
223833914|NCT00337415|DRUG|MK0354|
223833915|NCT00855192|BEHAVIORAL|mindful meditation|interpersonal and psycho-educational
223833916|NCT00855192|BEHAVIORAL|interpersonal therapy|psycho-educational
223833917|NCT02772250|BEHAVIORAL|telephone re-education(TRE)|Subjects who are randomized into this group receive regular instructions at the time of their appointment to discuss colonoscopy (a nurse provides education of 5 minutes and meanwhilet sent a bookle to the patient) and a TRE which was conducted by one investigator at 15:00-17:00 on the day before colonoscopy.
223833918|NCT02772250|BEHAVIORAL|face-to-face re-education (FFRE)|Subjects who are randomized into this group receive regular instructions on the day of their appointment to discuss colonoscopy and also a FFRE which was conducted by a investigator on the same-day of procedure at hospital.
223833919|NCT02687503|DIETARY_SUPPLEMENT|Probiotic|All children will receive a daily dose of probiotic (10⁹ cfu of L.acidophilus NCFM and B. lactis, Bi-07), a commercially available probiotic. Parents will give probiotic in 1 ounce of milk or water once a day for 30 days in an open label fashion.
223833920|NCT03437798|OTHER|Disease status|Women who reported periodontal disease diagnosis/condition
223833921|NCT05338983|DRUG|Topical anesthetic|20% Benzocaine gel will be applied on the area of infiltration
223833922|NCT05338983|DEVICE|Avent baby bottle warmer|Warming device
223833923|NCT05338983|DRUG|Sodium bicarbonate|0.1ml of 8.4% of sodium bicarbonate will be removed from the 50ml vial by one ml insulin syringe , directly injected into the local anesthetic cartridge and will be shacked 5 times to mix the solution.
223833924|NCT05338983|DEVICE|Buzzy device|"Bee-shaped apparatus consisting of two parts: the main vibrating body of a bee and detachable ice wings.~External application of Buzzy device during administration of dental anesthetic."
223833925|NCT05338983|DRUG|Mepivacaine Hydrochloride|Mepivacaine HCL 2% with Epinephrine 1:100,000 Local Anesthetic. Local Dental anesthetic infiltration
223833926|NCT02089451|DRUG|Faster-acting insulin aspart|Drug: insulin aspart (faster acting insulin aspart) Subjects will receive five single dose level of faster acting insulin aspart. Three single dose s.c under the skin (abdomen, deltoid/upper arm, thigh), one single dose i.m. (intramuscularly, into the muscle) and one single dose i.v. (intravenously, into the vein)
223833927|NCT02809027|DRUG|Ginger|
223833928|NCT02809027|DRUG|Placebo|
223833929|NCT06424379|OTHER|Histopathological analysis|"Morphological analysis will include the description of architectural patterns and cytological features on formalin-fixed and paraffin-embedded (FFPE) tissue samples retrieved from the routine diagnostic archives of the Pathology Department of the University Hospital Lyon Sud.~A panel of immunohistochemical staining will be analyzed including CD20, CD3, CD10, Bcl-6, Bcl-2, CD5, CD23, CD38, MUM1, Ig kappa, Ig lambda, MEF2B, LMO2, MNDA, IRTA1, P53, CMYC and Ki67 . /MIB1. Diffuse large B-cells lymphomas will be classified into two distinct subgroups: centro-germinative (GC) and non-centro-germinative (nGC), using the Hans algorithm."
223833930|NCT06424379|GENETIC|Molecular analysis|"Next-generation sequencing (NGS) analysis will be performed on FFPE tissue samples retrieved from the routine diagnostic archives of the Pathology Department of the University Hospital Lyon Sud. A panel of 73 genes dedicated to lymphoma diagnosis determined by a consensus of French Lysa experts will be used. The identification of genetic variants will be followed by the attribution of pathogenicity class in accordance with the guidelines for validation of NGS-based oncology panels.~RNA extraction will classify DLBCLs into two distinct subgroups: germinal-centre B-cell-like (GCB-DLBCL) and activated B-cell-like (ABC-DLBCL)."
223833931|NCT01383993|DRUG|Voriconazole|"Study Days 1: IV voriconazole 9 mg/kg q12h. Study Days 2 to 7: IV voriconazole 8 mg/kg q12h. Study Days 8 to 14: Oral voriconazole (POS) 9 mg/kg q12h with a maximum of 350 mg q12 h.~Notes:~If unable to switch to oral medication on Day 8, subjects can continue with IV treatment up to Day 20 before switching to oral dose.~Only morning oral dose will be given on Day 14 (or the seventh day of oral dosing if IV regimen is extended). However, if clinically indicated, voriconazole treatment may be continued up to Day 30.~(IV = Intravenous; POS = Powder for oral suspension)"
223833932|NCT01383993|DRUG|Voriconazole|"Study Days 1: IV voriconazole 6 mg/kg q12h. Study Days 2 to 7: IV voriconazole 4 mg/kg q12h. Study Days 8 to 14: Oral voriconazole (POS) 200 mg q12h.~Notes:~If unable to switch to oral medication on Day 8, subjects can continue with IV treatment up to Day 20 before switching to oral dose.~Only morning oral dose will be given on Day 14 (or the seventh day of oral dosing if IV regimen is extended). However, if clinically indicated, voriconazole treatment may be continued up to Day 30.~(IV = Intravenous; POS = Powder for oral suspension)"
223833933|NCT04689022|BEHAVIORAL|Mississippi Scale for Combat-Related PTSD (M-PTSD)|The treatment outcome rate was assessed by the Mississippi Scale for Combat-Related PTSD (M-PTSD). A positive outcome rate is represented with the patient post-discharge positive coping, which corresponds to 94-58 points, observed in 39 patients (17.9%). A treatment failure is regarded as the absent PTSD treatment effect after discharge, which corresponds to 148-113 points, observed in 5 patients (2.3%) and psychic disorders, which correspond to 112-95 points, observed in 174 patients (79,8%).
223833934|NCT04689022|DIAGNOSTIC_TEST|visual analogue scale (VAS)|pain intensity
223833935|NCT04689022|DIAGNOSTIC_TEST|Douleur Neuropathique 4 questions (DN4)|neuropathic pain component
223833936|NCT03671720|BIOLOGICAL|personalized DC vaccine|personalized vaccine comprised of autologous dendritic cells (DC) loaded in vitro with lysate from autologous tumor cells, administered intranodally on day 1,8,15, with a combination of oral cyclophosphamide (50mg) every day except the day of vaccine administrations.Cycles are repeated every 21 days. Treatment is continued until disease progression or exhaustion of vaccine supply, whichever comes first.
223833937|NCT00414869|DRUG|NCX-1000|500 mg powder sachets to be taken as 1, 2, or 4 sachets twice daily, PO x 16 days
223833938|NCT00414869|DRUG|Placebo|Inactive powder matching NCX-1000
223833939|NCT03010735|DIETARY_SUPPLEMENT|probiotics|Daily take 4.0E+10 CFU of probiotics
223833940|NCT03010735|DIETARY_SUPPLEMENT|Placebo|
223833941|NCT03544528|PROCEDURE|Regeneration|Apical bleeding will be induced by passing a hand instrument beyond the apical foramen to allow blood filling in the canal. Mineral trioxide aggregate will be placed directly over the coagulated blood clot.
223833942|NCT00218985|BEHAVIORAL|Exercise training|Intensity controlled exercise training before the scheduled bypass surgery
223833943|NCT03453632|DRUG|Botulinic toxin|"Clinical photographs of the soles Standardized anesthesia protocol (lidocaine, prilocaine on soles, cryo-spray, oral administration of paracetamol and only if necessary oxycodone and hydroxyzine).~Cleaning and antiseptic on the soles Injections of botulinic toxin (200 UI) on right or left foot"
223833944|NCT03453632|DRUG|Placebo|"Clinical photographs of the soles Standardized anesthesia protocol (lidocaine, prilocaine on soles, cryo-spray, oral administration of paracetamol and only if necessary oxycodone and hydroxyzine).~Cleaning and antiseptic on the soles Injections of physiological serum (200 UI) on right or left foot"
223833945|NCT04485780|BIOLOGICAL|botulinum toxin type A|In the outpatient department, patients who need hemorrhoidectomy were randomly assigned to two groups at a 1:1 ratio using a computer-generated list of random numbers (Microsoft Excel). One group received Botulinum toxin injection during the outpatient clinic one week before the operation(experimental group, EG), and the other group received injection during the operation(control group, CG). The two groups were compared for the influence of postoperative pain control and wound healing rate.
223833946|NCT02646553|OTHER|Children refered to the obesity clinic|Compere if urine cortisol is as good as saliva cortisol as a screening for hypercortisolism in children.
223833947|NCT05173051|OTHER|Solid Medication intake vs. crushed medication intake|The swallowing ability for solid and crushed medications in stroke patients is evaluated.
223833948|NCT04201522|OTHER|Normocapnic hyperpnoea intervention|Patients will perform for 6-weeks, 15 min twice daily, 5 days a week at 60% of the peak of minute ventilation, at home by means of a respiratory device (SpiroTiger, Idiag, Fehraltorf, CH).
223833949|NCT04201522|OTHER|Sham intervention|Patients will perform for 6-weeks, 15 min twice daily, 5 days a week at rest's minute ventilation, at home by means of a respiratory device (SpiroTiger, Idiag, Fehraltorf, CH).
223833950|NCT05049044|OTHER|Quality of Life Questionnaire-Core 30 (QLQ-C30)|The HR-QoL evaluation is based on three self-assessment questionnaires distributed to the patients according to the pre-specified data collection schedule. Patients will also complete an additional questionnaire on socio-economic and occupational outcomes
223833951|NCT01330043|DRUG|Bupropion|Both groups received the same pharmacotherapy per protocol. During open label treatment, all received CBT and bupropion and NRT patch. At week 10 those who continued to smoke were switched to varenicline through week 26. At week 10 those who are abstinent and reported low levels of craving and low levels of depression symptoms were withdrawn from study medications. Those who were abstinent but reported difficulty with craving or depression symptoms remained on bupropion and NRT through week 26. Medication was not available after week 26.
223833952|NCT01330043|DRUG|Nicotine patch|Both groups received the same pharmacotherapy per protocol. During open label treatment, all received CBT and bupropion and NRT patch. At week 10 those who continued to smoke were switched to varenicline through week 26. At week 10 those who are abstinent and reported low levels of craving and low levels of depression symptoms were withdrawn from study medications. Those who were abstinent but reported difficulty with craving or depression symptoms remained on bupropion and NRT through week 26. Medication was not available after week 26.
223833953|NCT01330043|DRUG|Varenicline|Both groups received the same pharmacotherapy per protocol. During open label treatment, all received CBT and bupropion and NRT patch. At week 10 those who continued to smoke were switched to varenicline through week 26. At week 10 those who are abstinent and reported low levels of craving and low levels of depression symptoms were withdrawn from study medications. Those who were abstinent but reported difficulty with craving or depression symptoms remained on bupropion and NRT through week 26. Medication was not available after week 26.
223833954|NCT05969522|DRUG|GlucoCorticoid|The high-risk group: methylprednisolone intravenous 15-30mg/kg/d (Max.500mg/d)\*3 days , with 2 courses, interval 5-7 days;Oral prednisone acetate 1.5-2mg/kg/d (Max. 60mg/d) during methylprednisolone impact interval and later stage, with the first reduction after 2-4 weeks. The dose was reduced once every 3 weeks in the first 3 months, and once every 4 weeks in the next 3 months, with a reduction of 5-10mg/ day each time; Rituximab：375 mg/m2/ time, once a week for 4 times;Intravenous cyclophosphamide 7.5-10mg/kg.d\*2 days(Max.500mg/d), once every 4 weeks, twice in total, at the 8th and 12th week.The medium-low risk group: methylprednisolone was the same dose as before, but only with 1 course, then followed by oral prednisone acetate 1.5-2mg/kg/d (Max. 60mg/d), divided into three times for 3 weeks, and then changed to morning daily; The dose was reduced as the high-risk group ;Rituximab was the same dose as before.
223833955|NCT06493500|DRUG|Eggshell derived Nano-hydroxyapatite (n-HAp) with a Fluoride containing toothpaste|patients would be instructed to treat their teeth for 5 min twice a day with the provided toothpaste.
223833956|NCT06493500|DRUG|Eggshell derived Nano-hydroxyapatite (n-HAp) without a Fluoride containing toothpaste|patients would be instructed to treat their teeth for 5 min twice a day with the provided toothpaste.
223833957|NCT00521872|PROCEDURE|STARR Operation|
223833958|NCT06163716|BEHAVIORAL|Multidomain intervention (MD-Int) group|The MD-Int program included: 1) individual follow-up visits every three months for cardiovascular risk factor monitoring and nutritional counselling with primary health care providers; 2) two nutritional workshops led by a nutritionist; 3) 20 hours of cognitive stimulation delivered through group sessions and 4) 40 hours of individual cognitive training exercises. Participants in the MD-Int group received recommendations to practice 2 to 6 hours of physical exercise per week and get involved in sports activities. Social stimulation was promoted through group activities.
223833959|NCT04443920|DRUG|Tranexamic acid (TXA)|Randomly assigned \[1:1 ratio\] using a computer generated table of random numbers to 1 of the 2 intervention groups
223833960|NCT04443920|DRUG|Placebo Normal Saline (NS)|Randomly assigned \[1:1 ratio\] using a computer generated table of random numbers to 1 of the 2 intervention groups
223833961|NCT04708184|DRUG|GLPG3970 oral solution|GLPG3970 for oral administration
223833962|NCT04708184|DRUG|GLPG3970 tablet|GLPG3970 for oral administration
223833963|NCT03503994|DRUG|Inhaled Beclomethasone Dipropionate Monohydrate|"Beclomethasone Dipropionate (HFA-BDP, QVAR\*) in the following doses will be evaluated:~1. 200 mcg bid~2. 400 mcg bid~3. 600 mcg bid~4. 800 mcg bid"
223833964|NCT04372511|DEVICE|Binaural Beats|Device: Sound with Binaural Beats at acoustic frequencies of 256 Hz in one ear and 260 Hz in the opposite ear producing a binaural beat of 4 Hz with a white background noise
223833965|NCT06213012|DEVICE|Transcutaneous Spinal cord Stimulation|Delivered using a constant-current stimulator
223833966|NCT06213012|DEVICE|Epidural Spinal Stimulation (ESS)|"The device used for ESS, the CoverEdgeX 32 Surgical Lead system (Boston Scientific, USA), is a device approved by the FDA used in the treatment of severe pain and is approved for individuals to manage chronic pain when other treatments have not been effective.~If you are in the ESS group, you will have surgery to have the stimulator placed and the stimulator will be removed at an office visit towards the end of the study."
223833967|NCT03172741|DRUG|Medical Marijuana|1-gram marijuana cigarette smoked once per day for 3 months
223833968|NCT03172741|DRUG|Placebo|Matching 1 gram placebo cigarette smoked once per day for 3 months
224264649|NCT04306952|BEHAVIORAL|Brief MBI|The brief MBI consists of four weekly group sessions that are two hours each and one all day mediation retreat. The rationale for testing the short MBI is to evaluate a low-dose (8 hours of contact) MBI that optimizes cost-effectiveness and minimizes patient burden.
224264650|NCT04306952|BEHAVIORAL|Standard MBI|The standard MBI consists of eight weekly group sessions that are approximately two hours each and one all day meditation retreat. The length of this package is based on the standard length of MBSR as an 8-week program. The rationale for testing the standard MBI is to provide a comparison to a dose (16 hours of contact) that is most similar to the length of MBSR and has the fewest modifications, making it easier to train MBI providers.
223833969|NCT05828784|DEVICE|Intersomatic arthrodesis|"Arthrodesis is an operative modality also used in the treatment of multiple recurrences of herniated discs, stenosis (narrowing) of the spinal anal, degenerative and malformative spondylolisthesis.~The procedure can be performed with different surgical techniques, but in all cases it aims to achieve the same goal: to re-establish, through the use of spacers, the correct distance between two vertebral somes, in cases of disc degeneration, that are no longer able to fulfill their function; that is, they no longer absorb mechanical stresses and/or compress the nerve structures of the spine causing almost always unbearable (disabling) pain."
223833970|NCT00805636|DRUG|2-(5-fluoro-pentyl)-2-methyl-malonic-acid ([18F]-ML-10)|\[18F\]-ML-10 will be radiolabeled at the PET Radioactive Drug Production (RDP) facility at or in close proximity to each clinical site, and will be administered as an intravenous bolus injection (in 3-10 ml sterile saline solution, containing no more than 10% ethanol by volume). The dose concentration selected for \[18F\]-ML-10 will be 7 MBq/Kg or 0.19 mCi/Kg. The radioactivity dosage of \[18F\]-ML-10 administered at each PET/CT session will be at least 300 MBq (8.1 mCi) and not more than 500 MBq (13.5 mCi).
223833971|NCT00805636|RADIATION|Stereotactic Radio-Surgery (SRS) therapy|SRS will be administered according to the standard of care using a radiation dose of 14-24 Gy to each lesion.
223833972|NCT00805636|PROCEDURE|Positron Emission Tomography|Each patient will undergo 2 PET/CT sessions, each following intravenous administration of \[18F\]-ML-10, to assess tracer uptake by the brain metastases treated by SRS. The PET/CT scan will be directed to the brain and will include one bed position. The PET/CT sessions will be performed at baseline, i.e., before the radiation treatment, and on the day after, within 24h after SRS treatment.
223833973|NCT00262743|BIOLOGICAL|Polyphenon E|"Phase I Dose Escalation:. 400 mg orally twice a day to 2000 mg orally twice a day~Phase II: 2000 mg orally twice a day"
223833974|NCT02040233|DRUG|BAY1067197 (10 mg)|10 mg BAY1067197 for 7 d treatment once daily as oral application
223833975|NCT02040233|DRUG|BAY1067197|The dose escalation to the second dose step will proceed only if the previous dose step has shown acceptable safety and tolerability 5 mg / or 10 mg / or 20 mg BAY1067197 for 7 d treatment as oral application.
223833976|NCT02040233|DRUG|Placebo (10 mg)|10 mg Placebo for 7 d treatment once daily as oral application
223833977|NCT02040233|DRUG|Placebo|5 mg / or 10 mg / or 20 mg Placebo for 7 d treatment once daily as oral application
223833978|NCT05594355|DRUG|TEBOFORTAN|TEBOFORTAN 240 mg is administrated 1 tablet per day
223833979|NCT04966156|BEHAVIORAL|CaRE-4-alloBMT plus usual care group|CaRE-4-alloBMT uses emerging eHealth technologies to reduce barriers to accessing and providing cancer rehabilitation which includes: 1) Individualized progressive exercise prescriptions that allows customizable exercise prescriptions, tracking of exercise completion, and video tutorials; 2) Individualized nutrition plans and stepped stratified care such as education, counselling, intervention based on nutritional status and delivered by registered dietitians; 3) On-line e-modules provide interactive education to promote self-management skills for stress management, nutrition, managing common symptoms, etc.; 4) Remote monitoring using FitbitTM devices to monitor patients physical activity, caloric intake, and sleep for duration of the program. CRS and alloBMT clinicians will have access to real-time Fitbit data through our clinical dashboard; 5) Remote clinical support: check-ins and health coaching sessions with a member of the CRS team (phone or MS Teams video).
223833980|NCT05361746|DEVICE|Scotchbond Universal Plus Adhesive|Eligible teeth with Class-V NCCLs randomized to the SBU+ treatment group will undergo restoration(s) using Scotchbond Universal Plus (SBU+) Adhesive using total-etch mode and Filtek Universal Restorative material.
223833981|NCT05361746|DEVICE|Scotchbond Universal Adhesive|Eligible teeth with Class-V NCCLs randomized to the SBU Control group will undergo restoration(s) using Scotchbond Universal Plus (SBU) Adhesive using total-etch mode and Filtek Universal Restorative material.
223833982|NCT05691569|OTHER|doll therapy|empathy dolls
223833983|NCT02702349|OTHER|penicillin test|children are tested for penicillin allergy and then challenged with penicillin P.O.
223833984|NCT05887284|RADIATION|low dose radiotherapy (0.5 Gy)|12 times 0.5 Gy
223833985|NCT05887284|RADIATION|mock radiation treatment|6 times 0.0 Gy
223833986|NCT05887284|RADIATION|low dose radiotherapy (1.0 Gy)|6 times 1.0 Gy
223833987|NCT06176820|DRUG|Vaginal Gel|Arm 1 will apply 2.5 gram of VHAL gel intravaginally using vaginal applicator 2 times per week for 3 months
223833988|NCT06176820|DRUG|Vaginal lubricant|Arm 2 will apply 2.5 gram of vaginal lubricant intravaginally using vaginal applicator 2 times per week for 3 months
223833989|NCT02268318|OTHER|1-Fermented Dairy Product with Phytosterols (test)|1- 1 bottle of test product/day
223833990|NCT02268318|OTHER|2-Fermented dairy Product with No Phytosterols (control)|2-1 bottle of control product/day
223833991|NCT02701582|DRUG|Phenylephrine|if Mean arterial pressure (MAP) is \< = 65, Stroke volume variation (SVV) \< 13 and Cardiac Index is \>=2.2 Phenylephrine is administered
223833992|NCT02701582|DRUG|Epinephrine|if Mean arterial pressure (MAP) is \< = 65, Stroke volume variation (SVV) \< 13 and Cardiac Index is \< 2.2 Epinephrine is administered
223833993|NCT02701582|OTHER|Albumin|if Mean arterial pressure (MAP) is \< = 65, Stroke volume variation (SVV) \> = 13, fluids are administered --OR-- if Mean arterial pressure (MAP) is \> 65, Stroke volume variation (SVV) \> = 13 and Cardiac Index is \<2.2 fluids are administered.
223833994|NCT02701582|OTHER|Voluven|if Mean arterial pressure (MAP) is \< = 65, Stroke volume variation (SVV) \> = 13, fluids are administered --OR-- if Mean arterial pressure (MAP) is \> 65, Stroke volume variation (SVV) \> = 13 and Cardiac Index is \<2.2 fluids are administered.
223833995|NCT02701582|OTHER|Normal Saline|if Mean arterial pressure (MAP) is \< = 65, Stroke volume variation (SVV) \> = 13, fluids are administered --OR-- if Mean arterial pressure (MAP) is \> 65, Stroke volume variation (SVV) \> = 13 and Cardiac Index is \<2.2 fluids are administered.
223833996|NCT02701582|OTHER|Packed Red Blood Cells|if Mean arterial pressure (MAP) is \< = 65, Stroke volume variation (SVV) \> = 13, fluids are administered --OR-- if Mean arterial pressure (MAP) is \> 65, Stroke volume variation (SVV) \> = 13 and Cardiac Index is \<2.2 fluids are administered.
223833997|NCT02701582|DEVICE|FloTrac Monitor|FloTrac monitor is connected for all patients, but only visible to the anesthesiologist for half. Based on a decision tree and the data from monitor, choices of interventions are used.
223833998|NCT00951860|OTHER|Autonomic Nervous System activity|Autonomic activity measured at birth and at 6, 12, 18 and 24 months is represented by time-domain indices (SDNN index, SDANN, pNN50) and frequency- domain indices(PTOT, VLF, LF, HF, ratio LF / HF, LFnu, HFnu), which reflect the short-term variability (parasympathetic branch) and medium term (ortho and parasympathetic branch) of the vegetative balance. This subtle technical assessment of autonomic functioning has been validated in the literature for two decades
223833999|NCT05582213|DIAGNOSTIC_TEST|induction of anesthesia|This group includes (20) patients will receive induction by sevoflurane 3% using open circuit (modified Ayre's T-piece) till loss of consciousness and will be maintained on oxygen mask on the same concentration of sevoflurane and connected to capnogram
223834000|NCT02123290|DRUG|DSM265 400mg|
223834001|NCT02123290|DRUG|DSM265 xmg|Dose of DSM265 to be determined based on the results of the first cohort
223834002|NCT02123290|DRUG|DSM265 ymg|Dose of DSM265 to be determined based on the results of the second cohort
223834003|NCT02391285|DEVICE|dynamometer (Auckland vaginal elastometer)|"The elastometer is a modified vaginal speculum which captures pelvic muscle tone over 3 minutes and records this on an attached computer. In addition to the elastometer test, there are three further related tests, which patients would be suitable to participate in.~I. a questionnaire to fill in so as to obtain some feedback from patients regarding what they thought of the test and the device.~II. The investigators would like to repeat the elastometer measurement within a week of the first test to determine the reliability and accuracy of repeating the measurement after a few days.~III. The investigator would like to request that the patient have an MRI scan of the pelvic muscles to check whether the elastometer can pick up functional muscle weakness that would not otherwise be recognised except by performing an MRI scan. The investigators will therefore compare elastometer readings to the MRI scan findings."
223834004|NCT02161328|OTHER|EIT belt|
223834005|NCT01734837|DEVICE|DS-Ligature Clip|
223834006|NCT02589041|PROCEDURE|intraneural sciatic nerve injection|"A popliteal intraneural sciatic nerve block will be performed under ultrasound guidance. Minimal effective volume will be evaluated performing a randomization based on the Up-and-down methodology.~A baseline and postoperative electrophysiological study will assess the presence of any neurological complication."
223834007|NCT02589041|DRUG|Ropivacaine 1%|
223834008|NCT00061360|DRUG|ATG+Rapamune+cyclosporine|ATG+Rapamune+cyclosporine
223834009|NCT00061360|DRUG|ATG+cyclosporine|ATG+cyclosporine
223834010|NCT04507672|DRUG|Fluid resuscitation|Use the choice of crystalloid for resuscitation during the first 72 hours after enrollment
223834011|NCT04684927|DEVICE|MID-C System -Minimal invasive deformity correction system for the treatment of AIS|"A 5 years follow-up will be performed for all patients who underwent AIS repair surgery using the MID-C System. The follow-up in order to assess safety and efficacy measurments. Eligible Patients will be followed and assessed at the following time points: Immediate Post-op up to 6 weeks, 6 months, 12 months, and then annually out to 5 years post-implantation.~During the study, the following rating scales and assessments will be conducted to assess the probable benefit and safety of the treatment: Physical exam,X-rays,Cobb angle measurements,Adverse Events (AEs) and Scoliosis research society (SRS-22) questionnaire: The questionnaire is commonly used to assess health related quality of life in children with AIS."
223834012|NCT00492843|DRUG|Ibandronate (Bondronat)|Intravenous infusion of either 6mg Bondronat on three consecutive days or 6mg Bondronat on one day.
223834013|NCT04016051|DRUG|Clarithromycin DST (125 mg)|Clarithromycin DST (125.0 mg clarithromycin / straw).
223834014|NCT04016051|DRUG|Clarithromycin DST (187.5 mg)|Clarithromycin DST (187.5 mg clarithromycin / straw).
223834015|NCT04016051|DRUG|Clarithromycin DST (250 mg)|Clarithromycin DST (250.0 mg clarithromycin / straw).
223834016|NCT04016051|DRUG|Clarithromycin Syrup (125 mg)|Clarithromycin Syrup 2.5 ml (125 mg).
223834017|NCT04016051|DRUG|Clarithromycin Syrup (187.5 mg)|Clarithromycin Syrup 3.75 ml (187.5 mg).
223834018|NCT04016051|DRUG|Clarithromycin Syrup (250 mg)|Clarithromycin Syrup 5 ml (250 mg).
223834019|NCT02653040|OTHER|Dynamic lighting|"Intervention is rooms with light settings imitating natural light conditions with white light at day and low-lux no-blue light at night:~07am-10am: white light, increasing intensity 10am-07pm: white light, full intensity 07pm-11pm: no blue wavelength, low intensity 11pm-07am: no blue wavelength, very low intensity"
223834020|NCT00948259|DRUG|NP031112|unidose sachets containing dry powder for oral suspension, once daily dosing 400 mg (4 to 20 weeks), 600 mg(4 to 16 weeks),800 mg (6 to 12 weeks), 1000 mg (6 weeks)
223834021|NCT00948259|DRUG|Placebo|unidose sachets containing dry powder for oral suspension, once daily dosing 400 mg (4 to 20 weeks), 600 mg(4 to 16 weeks),800 mg (6 to 12 weeks), 1000 mg (6 weeks)
223834022|NCT02151019|RADIATION|IMRT|IMRT will be given to some patients to enable comparison of the acute grade 2 GI toxicities compared to those patients receiving their radiotherapy by 3-DCRT
223834023|NCT03030547|DEVICE|SenseWear activity monitor|Individuals will wear SenseWear activity monitors on right triceps muscle for 5 days. The data stored on the device will be recorded in computer using the software. Individuals will be given information of the resulting data (total number of steps, total energy expenditure, the number of daily steps and energy expenditure, physical activity duration in different intensity).
223834024|NCT02502305|BEHAVIORAL|liveonline course|physical activity and healthy diet are targeted and should be enhanced, health literacy (HL) in older people should be improved
223834025|NCT01182168|DRUG|gemcitabine and split-dose cisplatin plus escalating doses of continuous Everolimus (RAD001)|Patients will receive gemcitabine IV and cisplatin IV on days 1 and 8. Everolimus orally will be administered continuously (one cycle = 21 days). Everolimus will be escalated at the following dose levels: 5mg every-other-day, 5mg daily, and 10mg daily. Patients will receive a total of 6 cycles of gemcitabine and cisplatin in combination with Everolimus unless disease progression or unacceptable toxicity occurs.
223834026|NCT02490696|DEVICE|Miso PET scan|2 PET scans will be performed before surgery : the first one with F-Miso tracer and the second, 24 hours later, with FAZA tracer
223834027|NCT02490696|DEVICE|FAZA PET scan|2 PET scans will be performed before surgery : the first one with FAZA tracer and the second, 24 hours later, with F-Miso tracer
223834028|NCT02774265|DRUG|VTE prophylaxis with Enoxaparin 30mg BID|Patients will receive Enoxaparin 30mg BID for DVT prophylaxis and will be followed to determine the efficacy, safety and cost when used for VTE prophylaxis in high-risk orthopedic traumas administered for the length of time indicated by standard of care based on the injury.
223834029|NCT02774265|DRUG|VTE prophylaxis with Aspirin 81mg BID|Patients will receive Aspirin 81mg BID for DVT prophylaxis and will be followed to determine the efficacy, safety and cost when used for VTE prophylaxis in high-risk orthopedic traumas administered for the length of time indicated by standard of care based on the injury.
223834030|NCT04672109|DEVICE|Transcranial direct current stimulation|Dual/Cathodal/Anodal/Sham tDCS will be applied in 2 mA, 20 mins. All experiments will be performed in random order for each subject.
223834031|NCT01388374|OTHER|Other, care provided by Nurse Practitioners|Patients will receive care at the Primary Out of Hours Emergency Service by a Nurse Practitioner instead of a General Practitioner (substitution of care from physicians to nurses).
223834032|NCT00912821|DRUG|6 L dialysate|6 L peritoneal dialysis solution
223834033|NCT00912821|DRUG|8 L dialysate|8 L peritoneal dialysis solution
223834034|NCT02678520|RADIATION|3-D Conformal Radiation Therapy|"Radiation delivered after surgery to remove the prostate, using 3-D Conformal Radiation Therapy. Radiation will be delivered to prostatic fossa / surgical bed including any suspected regions of microscopic disease such as positive margins, extracapsular extension and/or seminal vesicle involvement.~The total dose of radiation will be 6600 centigray (cGy) at 200 cGy/fraction (fx) given once daily ."
223834035|NCT02678520|RADIATION|Intensity Modulated Radiation Therapy|"Radiation delivered after surgery to remove the prostate, using Intensity Modulated Radiation Therapy. Radiation will be delivered to prostatic fossa / surgical bed including any suspected regions of microscopic disease such as positive margins, extracapsular extension and/or seminal vesicle involvement.~The total dose of radiation will be 6600 centigray (cGy) at 200 cGy/fraction (fx) given once daily ."
223834036|NCT02678520|DRUG|Casodex, Zoladex , Lupron|"Hormonal Therapy (6 Months): Required for High Risk Groups, and as per Standard of Care for Low Risk Groups.~Hormonal therapy protocol regimen for the high risk adjuvant and salvage groups will consist of Casodex (50 mg/day po for 6 months) and Zoladex (10.8 mg subcutaneously once every 3 months x 2) or Lupron (22.5 mg given intramuscularly once every 3 months x 2 injections or 7.5 mg IM q once monthly x 6) to start on day 1 of the clinical trial.~Hormonal therapy will typically begin 2 months prior to radiation and continue for a total of 6 months."
223834037|NCT01427621|PROCEDURE|remote ischemic pre and postconditioning (RIPC)|RIPCcom group: combined intervention of remote ischemic pre- and postconditioning consisted of three 10-minute cycles of right lower limb ischemia, which was induced with an automated cuff-inflator placed on the right upper leg and inflated to 250 mmHg, with an intervening 10 minute of reperfusion during which the cuff was deflated. This intervention were performed at 10 minutes after induction of anesthesia and then 10 min after weaning from CPB.
223834038|NCT01284777|GENETIC|blood sample, thoracocentesis|20ml of blood only one thoracocentesis (the same that one for diagnostic)
223834039|NCT04910906|DEVICE|Ectoin® Vaginal Gel|"Ectoin® Vaginal Gel is a clear, non-hormonal moisturizing gel containing only active ingredient Ectoin® for the relief of vaginal dryness/vaginal atrophy.~Other excipients in the formulation include:~Hydroxyethylcellulose (Gelling agent) Lactic acid (90 %) (pH stabiliser) DL-Sodium lactate (Buffer substance) Sodium benzoate (preservative) Propylene glycol (Humectant)"
223834040|NCT04430335|BEHAVIORAL|Telephone interview|Interested participants will complete a telephone interview to determine eligibility for the study. If found to be eligible for the study, participants will be registered and set up a time to speak with an assigned study coach.
223834041|NCT04430335|BEHAVIORAL|Cognitive Behavioral Therapy|Participants will speak with their assigned coach over the phone for 12 weeks to discuss the cognitive behavioral therapy (CBT) study workbook and provide feedback. CBT is a type of treatment that teaches people different ways to handle anxiety and/or depressive symptoms, such as by relaxing the body, changing thoughts, and solving problems. Participants will receive a workbook focused on teaching these strategies.
223834042|NCT02071563|DIETARY_SUPPLEMENT|CSB14|
223834043|NCT02071563|DIETARY_SUPPLEMENT|RUSF1|
223834044|NCT02071563|DIETARY_SUPPLEMENT|SC+|
223834045|NCT04004793|BEHAVIORAL|Intensive lifestyle intervention|Participants were will be asked to follow a weight management programme, in accordance with the American Diabetes Association guidelines. Weight loss will be induced with a diet replacement phase using an energy restriction diet (energy deficit by 500\~750 kcal/day) for 3 months, with \<35% as fat, \>15% as protein. The minimum energy intake is 1200kcal/day for men and 1000kcal/day for women.. Additionally, participants were encouraged to increase physical exercise (≥150 minutes of brisk walking every week or ≥10000 steps per day).
223834046|NCT04004793|DRUG|Dapagliflozin 10 MG Oral Tablet|The treatment of Dapagliflozin (Forxiga®) will be initiated and maintained at 10mg every morning until the completion of the study.
223834047|NCT04004793|DRUG|Placebo Oral Tablet|The treatment of placebo will be initiated and maintained at 10mg every morning until the completion of the study.
223834048|NCT04668287|BEHAVIORAL|Increasing self-esteem|During 5 weeks, participants will be part of one of the working groups in which they'll be taught by a counselor about how a low self-esteem develops and what have to be done for improving self-esteem, based on the Melanie Fennel' model.
223834049|NCT03249376|DRUG|Lumateperone|Lumateperone 42 mg (ITI-007 60 mg tosylate)
223834050|NCT03249376|OTHER|Placebo|Placebo
223834051|NCT06395077|DIAGNOSTIC_TEST|CBCT low-dose protocol|The patient underwent two CBCT examinations (Accuitomo 170; J Morita Corp., Kyoto, Japan): one examination followed the clinical standard-dose protocol (exposure settings: 90 kV, 5 mA, and 9.4 s), and one, the low-dose protocol (90 kV, 2 mA, 9.4 s).
223834052|NCT04916899|DRUG|Rifampicin/ Isoniazid/ Pyrazinamide/ Ethambutol|Form: Tablets Dosage: 150 mg / 75 mg / 400 mg / 300 mg Adminstration way: Oral
223834053|NCT01958762|OTHER|Invitation for oral cavity cancer screening|
223834054|NCT02375763|OTHER|Software instruction|
223834055|NCT01154036|DRUG|ezetimibe 10 mg|
223834056|NCT01154036|DRUG|atorvastatin|
223834057|NCT01154036|DRUG|Comparator: rosuvastatin|
223834058|NCT00583180|DRUG|Capsaicin|instillation of sterile water or 1000 micrograms of capsaicin into the wound at the end of open groin hernia surgery in previous study.no new intervention will be performed in the current study.
223834059|NCT06352515|DIAGNOSTIC_TEST|Flow cytometry|flow cytometry to study distribution of T lymphocyte subsets in ulcerative colitis patients
223834060|NCT00165620|DRUG|Iomeprole|
223834061|NCT05679700|OTHER|Rigid Taping|Rigid taping was applied to stroke patients with knee hyperextension.
223834062|NCT01985698|PROCEDURE|Robotic-assisted resection.|Robotic-assisted abdominoperineal resection.
223834063|NCT01985698|PROCEDURE|Laparoscopic resection|Laparoscopic abdominoperineal resection
223834064|NCT01842243|PROCEDURE|Apical pacing|Pacemaker set to pace at right ventricular apex initially.
223834065|NCT01842243|PROCEDURE|Septal pacing|Pacemaker set to pace at right ventricular septum initially.
223834066|NCT01842243|DEVICE|Pacemaker|MR conditional Pacemaker implanted in all study patients
223834067|NCT03993899|DEVICE|FineHearing strategy or HDCIS strategy|Cochlear implant with FineHearing strategy or HDCIS strategy
223834068|NCT03086915|DRUG|Neuromuscular Blocking Agent|Administration of neuromuscular blockers during anesthesia
223834069|NCT01611103|PROCEDURE|transcranial direct current stimulation|delivery of transcranial direct current stimulation or sham stimulation for 20 to 60 minutes
223834070|NCT04676230|PROCEDURE|Experimental group|Caries management based on the ICCMSTM: Patient intervention according to the caries risk likelihood: high, moderate or low. Surfaces intervention according to the surface diagnosis decision matrix (ICCMSTM): Mi: Initial caries management, Mm: Moderate caries management, and Me: Extensive caries management.
223834071|NCT04676230|PROCEDURE|Control group|Systematic patient caries risk intervention (all managed as high risk patients). Surfaces intervention with conventional caries management of cavitated/dentin caries lesions (restorative treatment).
223834072|NCT00906503|DRUG|dexamethasone|Four 4 mg dexamethasone tablets by mouth after food 40, 28, 16 and 4 hrs before the scan
223834073|NCT00906503|PROCEDURE|PET/Computed Tomography (CT)|Radioactive tracer (18F-FDG), approx. 1 ml (1/5 of a tsp.); Scanned for about 15 minutes for imaging the lungs
223834074|NCT00906503|RADIATION|fludeoxyglucose (18F)|Radioactive tracer (18F-FDG), approx. 1 ml (1/5 of a tsp.); Scanned for about 15 minutes for imaging the lungs
223834075|NCT00001450|DRUG|paclitaxel|
223834076|NCT00001450|DRUG|cisplatin|
223834077|NCT03113162|BIOLOGICAL|Autologous Hematopoietic Stem Cell|
223834078|NCT03113162|DRUG|BEAM Regimen|Reduced-intensity BEAM for Immunoablation
223834079|NCT02339389|OTHER|Labor analgesia|Measuring maternal ventilation after placement of epidural analgesia compared to baseline
223834080|NCT05952115|OTHER|lumbar motor control exercises|"the patients will receive lumbar motor control exercises in the form of three exercises (Abdominal draw in maneuver, side-bridge, and quadruped) and the level of difficulty increased each week. For all exercises, the number of repetitions stayed the same, but the difficulty increased each week, and we progressed to the advanced level of each of the three exercises.~This training achieves co-contraction of the local/deep stabilizing muscles (Transversus abdominis and multifidus) and strengthening the global/large spinal stabilizers (erector spinae and obliques)."
223834081|NCT05952115|OTHER|Cervical stabilization exercises|The exercise program consisted of an axial elongation exercise, cranio-cervical flexion exercise, cervical extension exercise, and cervical-scapulothoracic strengthening exercise. The exercise program progressed based on the exercise tolerance of the patients by increasing the repetition of the exercise (10 reps to 15 reps to 20 reps). And for the resistive exercise, the participants change to an elastic band with greater resistance (progress to the next color resistance band). Exercises were performed for 20 min/session, and an exercise log recording the date and repetition of the exercises was maintained by the therapist for each participant.
223834082|NCT02158624|DRUG|Intravitreal Lucentis 0.5mg|
223834083|NCT05350085|DRUG|Remimazolam besylate|① initial dose: use a micro injection pump to pump remimazolam at the rate of 50mg/h, and observe for 4 \~ 8 minutes until Ramsay Sedation grade III，then start dental operation ; ② Maintenance dose: maintain the pump speed at 5 \~ 10mg/h，adjust the pump dose to maintain the patient at Ramsay Sedation grade III. ③ Additional dose: During the operation, if the patient has body movement reaction or cannot cooperate with the dentist, local anesthetics shall be given as remedy. ④ After the operation, stop the microinjection pump.
223834084|NCT05350085|DRUG|Midazolam|① initial dose: use a micro injection pump to pump remazolam at the rate of 30mg/h, and observe for 4 \~ 8 minutes until Ramsay Sedation grade III，then start dental operation; ② Maintenance dose: maintain the pump speed at 3 \~ 6mg/h，adjust the pump dose to maintain the patient at Ramsay Sedation grade III. ③ Additional dose: During the operation, if the patient has body movement reaction or cannot cooperate with the dentist, local anesthetics shall be given as remedy. ④ After the operation, stop the microinjection pump.
223834085|NCT03757611|DIETARY_SUPPLEMENT|Tabetri capsule|1,000 mg/capsule (Taheebo extract 600 mg/day)
223834086|NCT03757611|DIETARY_SUPPLEMENT|Placebo capsule|1,000 mg/capsule
223834087|NCT01010893|BIOLOGICAL|Vaccination with Fluval P and Fluval AB influenza vaccines|Vaccination with Fluval P monovalent influenza vaccine with 6 μg HA/0.5 ml active ingredient content and aluminium phosphate gel adjuvant (dose: 0.5 ml /total 6 μg HA/ in both age groups, single dose) AND with Fluval AB trivalent influenza vaccine with 15 μg HA/0.5ml/strain active ingredient content and aluminium phosphate gel adjuvant (dose: 0.5 ml /total 3x15 μg HA/ in both age groups, single dose).
223834088|NCT01010893|BIOLOGICAL|Vaccination with Fluval P monovalent influenza vaccine|Fluval P monovalent influenza vaccine with 6 μg HA/0.5 ml active ingredient content and aluminium phosphate gel adjuvant
223834089|NCT06034574|DEVICE|Continuous glucose monitoring|Assessment of accuracy of two different continuous glucose monitoring devices during exercise
223834090|NCT02265380|DEVICE|Placement of IV catheter|
223834091|NCT00187317|BEHAVIORAL|Balance training (exercise)|Perturbation-based balance training. 30-minute sessions three times per week for six weeks.
223834092|NCT00187317|OTHER|Flexibility and relaxation exercise|30-minute sessions, three times per week for six weeks.
223834093|NCT00830986|DEVICE|Total Knee Arthroplasty Implant (Scorpio®)|Implantation of a Total Knee Arthroplasty using Conventional Intramedullary Instrumentation
223834094|NCT00830986|DEVICE|Total Knee Arthroplasty Implant (Scorpio®)|Implantation of a Total Knee Arthroplasty using a Computer Assisted Software, without Intramedullary Instrumentation
223834095|NCT01824082|DRUG|Perineural infusion [continuous peripheral nerve block(s)]|Electronic, programmable, portable infusion pumps will be used to administer perineural study solution at fixed rates for over 6 days. Subjects will receive a total of 1,100 mL of study fluid from either one (upper extremity) or two (lower extremity) pump and external reservoir combinations. The continuous basal infusion rate will be determined by catheter location: femoral 2.5 mL/h; popliteal-sciatic 5 mL/h; and infraclavicular 7.5 mL/h (37.5 mg/h for both upper and lower extremity subjects). No patient-controlled bolus dose will be included. Subjects will have the option of returning 4-16 weeks later for a second infusion of the alternate treatment solution.
223834096|NCT05993871|DIAGNOSTIC_TEST|Clinical Evaluation/Questionnaires|Anthropometric measures, somatosensory assessment (NPS, UENS, TCNS), autonomic assessment (COMPASS-31, Ewing battery), and severity and quality of life evaluation (NPS, TCNS, COMPASS-31, and EuroQOL-5D-5L index score)
223834097|NCT05993871|DIAGNOSTIC_TEST|Nerve Conduction Study|Routine Nerve Conduction Study.
223834098|NCT05993871|DIAGNOSTIC_TEST|Small fiber electrodiagnostic tests|R-R interval analysis, Cutaneous Silent Period and Sympathetic Skin Response.
223834099|NCT05993871|DIAGNOSTIC_TEST|Nerve Ultrasound|Bilateral vagal, left median, right ulnar, left tibial and right sural nerves ultrasound.
223834100|NCT05993871|DIAGNOSTIC_TEST|Skin Biopsy|distal leg 3mm punch skin biopsy
223834101|NCT06235164|DRUG|immune checkpoint inhibitors: sintilimab, nivolumab, and camrelizumab|"Drug: Sintilimab, Nivolumab, and Camrelizumab，One course will last 21 days.Given once every 3 weeks at a dose of 200 mg. Drug: nab-paclitaxel nab-paclitaxel one course will last 21 days#Given twice every 3 weeks at a dose of 125 mg/m2. Drug:oxaliplatin Oxaliplatin one course will last 21 days#Given once every 3 weeks at a dose of 130 mg/m2.~Drug:docetaxel docetaxel one course will last 21 days#Given once every 3 weeks at a dose of 40mg/m2.~Drug:fluorouracil fluorouracil one course will last 14 days#Given once every 2 weeks at a dose of 2800mg/m2.~Drug: Capecitabine Capecitabine was calculated according to body surface area every 3 weeks at a dose of 1000 mg/m2, P.O., bid, d1-d14 Drug: S1 S-1 was calculated according to body surface area, P.O., bid, d1-d14#And the dosage according body surface area:\<1.25m2, 40mg everytime;1.25-1.5m2,50mg every time; \>1.5m2, 60mg every time"
223834102|NCT05293535|OTHER|Prognostic study|No intervention... as it is a prognostic study and no intervention done on patients.
223834103|NCT00176865|PROCEDURE|Stem Cell Transplant|IV on Day 0
223834104|NCT00176865|DRUG|Fludarabine|30mg/m\^2 IV Day -7 through Day -3
223834105|NCT00176865|DRUG|Melphalan|140 mg/m\^2 IV Day -1
223834106|NCT00176865|DRUG|Anti-thymocyte globulin (ATG)|30 mg/kg IV Day -5 through Day -1
223834107|NCT00176865|DRUG|Campath 1H|0.2 mg/kg IV X 5 days (used as an alternative to Anti-thymocyte globulin (ATG) if unable to tolerate ATG) Day -10 through Day -6
223834108|NCT00176865|DRUG|Cyclosporin A|2.5 mg/kg IV every 12 hours (adults) or every 8 hours (children \<40 kg) maintaining a level of \>200mg/L Day -3 until Day +180 when, if no GVHD, the dose will be tapered 10% per week beginning on day 181
223834109|NCT00176865|DRUG|Mycophenolate mofetil|15 mg/kg IV or orally bid and discontinued on Day +45 unless GVHD is present
223834110|NCT00176865|DRUG|Intravenous immunoglobulin (IVIG)|500 mg/kg IV weekly beginning on Day +7 until Day +100
223834111|NCT05218564|DRUG|Oxygen Therapy|During the 6 Minute Walking Test (6MWT), the participant will be required to walk as fast as possible on a flat, straight surface on the ward (e.g. corridor) in six minutes, including as many breaks as he/she deems necessary. The performance of this test will be monitored continuously by a Respiratory Physiotherapist and will include the presence of a Physician, who will be ready to assist as needed. The sequence of use of compressed medical air and oxygen used during the 6MWT in the first group will then be characterised as follows: ABC (A=Baseline, B=Air, C=Oxygen). The sequence of the second group will be characterised as follows: ACB (A=Baseline, B=Air, C=Oxygen).
223834112|NCT05218564|OTHER|Compressed Medical Air|During the 6 Minute Walking Test (6MWT), the participant will be required to walk as fast as possible on a flat, straight surface on the ward (e.g. corridor) in six minutes, including as many breaks as he/she deems necessary. The performance of this test will be monitored continuously by a Respiratory Physiotherapist and will include the presence of a Physician, who will be ready to assist as needed. The sequence of use of compressed medical air and oxygen used during the 6MWT in the first group will then be characterised as follows: ABC (A=Baseline, B=Air, C=Oxygen). The sequence of the second group will be characterised as follows: ACB (A=Baseline, B=Air, C=Oxygen).
223834113|NCT05397938|DRUG|JMT103|JMT103, subcutaneous injection, once every 6 months (Q6M)
223834114|NCT05397938|DRUG|Alendronate sodium|Alendronate sodium tablet, once every week (QW)
223834115|NCT05397938|DRUG|JMT103 placebo|JMT103 placebo, subcutaneous injection, once every 6 months (Q6M)
223834116|NCT05397938|DRUG|Alendronate sodium placebo|Alendronate sodium tablet placebo, once every week (QW)
223834117|NCT02542514|DRUG|Ibrutinib|p.o. 560 mg once a day (four 140 mg capsules) for one year (12 cycles of 28 days)
223834118|NCT06121115|DRUG|Norepinephrine|Norepinephrine administered in midline catheter according to clinical routine
223834119|NCT05676398|DIAGNOSTIC_TEST|Ambulatory rhythm recording|Ambulatory rhythm recording by use of a wearable patch-type device.
223834120|NCT00534911|BEHAVIORAL|Cognitive Behavioral Therapy|"Participants will receive 12 weeks of CBT designed for youth with IBD. During sessions, participants will learn new ways of thinking (e.g., reconstruction of personal physical illness narratives, coping strategies, social skills) and behaving (e.g., positive activities, family communication, sleep hygiene, relaxation) to improve emotional and physical outcomes. Parent sessions will be provided at the beginning, middle, and end of the treatment to improve family understanding and communication about the physical illness and about risks of developing depression. There will also be 6-month booster sessions during follow-up.~Other Name: Primary and secondary coping enhancement training (PASCET)"
223834121|NCT00534911|BEHAVIORAL|Supportive Non-directive Therapy (SNDT)|SNDT is a 12-week non-directive therapeutic intervention. Participants will receive social support and quality information about the warning signs and risk factors for depression. Parent sessions will be provided at the beginning, middle, and end of the treatment to improve family understanding and communication about the physical illness and about risks of developing depression. There will also be 6-month booster sessions during follow-up.
223834122|NCT04153513|DRUG|Lanolin|Lanolin will be applied by hand in a thin layer to the nipple and areola after every breast feed (approximately every 2 to 3 hours) for a maximum of 7 days or until the symptoms of pain and signs of nipple damage have ceased (if noted before 7 days).
223834123|NCT04153513|OTHER|Mother's milk|After each breast feed (approximately every 2 to 3 hours), a few drops of breast milk will be applyed to the nipple and areola by hand and allow them to air dry. The treatment will last for up to 7 days or until the symptoms of pain and signs of nipple damage have ceased (if noted before 7 days).
223834124|NCT06364319|DRUG|anti-CD25 rhMAb|1 mg/kg/day administered IV day 1, 4, and 8, then weekly for 6 doses. For patients achieving partial remission, an extra dose of Anti-CD25 rhMAb can be given on days 39 and 49.
223834125|NCT06364319|DRUG|Prednisone|Maintain pre-screening dose
223834126|NCT06364319|DRUG|Ruxolitinib|10mg, BID PO
223834127|NCT06364319|DRUG|Cyclosporine|1.25mg/kg, BID PO/IV, target:150-250ng/ml
223834128|NCT00654693|OTHER|Rapid Response Team|If the subject is experiencing a life threatening change in their vital signs, the Rapid Response Team will be initiated per VUMC protocol.
223834129|NCT03490890|OTHER|Microwave ablaton|Patients with pathology verified GGO were treated with MWA.
223834130|NCT02426385|DEVICE|FineVision Toric|Posterior chamber IOL which consists in a small plastic lens with plastic side struts, called haptics, to hold the lens in place within the capsular bag inside the eye
223834131|NCT03857581|DRUG|Clozapine|Subjects will be randomly assigned to clozapine or olanzapine and followed for up to 12 weeks with weekly visits.
223834132|NCT03857581|DRUG|Olanzapine|Subjects will be randomly assigned to clozapine or olanzapine and followed for up to 12 weeks with weekly visits.
223834133|NCT00279422|DRUG|visilizumab|
223834134|NCT00279422|DRUG|visilizumab|
223834135|NCT04463043|DEVICE|SelfBACK app|The selfBACK is an evidence-based and data-driven decision support system (DSS) to support self-management of low back and neck pain delivered via a smartphone app. The selfBACK app provides individually tailored self-management plans to participants on a weekly basis by matching the participant's health information with targeted educational messages, physical activity advices and exercise recommendations via the DSS.
223834136|NCT04463043|OTHER|e-Help webpage|The e-Help is an evidence-based web-based resource to support self-management of low back and neck pain. The e-Help webpage provides evidence-based self-management content equivalent to the selfBACK including educational messages, physical activity and exercise recommendations. Instructions on how to compose exercise programs will be given to participants, however no tailored self-management support will be offered in this solution.
223834137|NCT04463043|OTHER|Usual care|Usual care refers to seeking care or receiving treatments or help as usual.
223834138|NCT01190384|OTHER|Couscous plus fiber|Soup with added fiber to equal Bean soup. Subjects' serving size is isocaloric to the experimental Bean soup.
223834139|NCT01190384|DIETARY_SUPPLEMENT|Grape seed extract|300 milligrams of grape seed extract in capsule form will be consumed with the low ORAC value soup.
223834140|NCT01190384|OTHER|Bean Soup|Experimental soup with a high fiber content and ORAC value. The ORAC value is the Oxygen Radical Absorbance Capacity (ORAC) score which is a measure of the antioxidant levels of food and is expressed as Trolox Equivalents. The antioxidants in the soup are derived from beans.
223834141|NCT02334943|BIOLOGICAL|Blood test|Blood test
223834142|NCT06024499|DRUG|HY209GEL Active|Selected two among four doses (HY209GEL 0.5% or 1% or 2% or 4%) in PART1
223834143|NCT06024499|OTHER|Placebo|Placebo
223834144|NCT04011384|BEHAVIORAL|Behavioral economic intervention of online purchasing at a food pantry|This intervention includes multiple behavioral economic interventions, healthy food shopping cart defaults, healthy placement choice architecture, traffic light nutrition labels, social norms messaging, and healthy swaps.
223834145|NCT05264233|DIETARY_SUPPLEMENT|Coconut oil|50 g of coconut oil will be added to the test meal for breakfast and 30 g of coconut oil will be added to the test meal for lunch
223834146|NCT05264233|DIETARY_SUPPLEMENT|Butter|50 g of butter will be added to the test meal for breakfast and 30 g of butter will be added to the test meal for lunch
223834147|NCT05264233|DIETARY_SUPPLEMENT|Vegetable oil|50 g of vegetable oil will be added to the test meal for breakfast and 30 g of vegetable oil will be added to the test meal for lunch
223834148|NCT01686932|DRUG|Vildagliptin|vildagliptin 50mg BID for 8 weeks
223834149|NCT01686932|DRUG|Sitagliptin|sitagliptin 100mg QD for 8 weeks
223834150|NCT06564025|BEHAVIORAL|Pilot program study|To assess program feasibility, acceptability, and preliminary efficacy, we will pilot the intervention with a purposive sample of 50 father-teen pairs (100 participants total). All participants will receive the program.
223834151|NCT02757222|RADIATION|Escalated Dose|"Boost Target Volume (BTV): The PET CT GTV (thresholding at 40% of SUV max) with a 3mm margin will form the BTV.~CTV1: A 3mm area around the BTV avid primary or 2mm area around the node will form the CTV1.~CTV 2: This (CTV 2) includes the area around the primary or nodal levels at risk of harbouring microscopic primary or microscopic nodal metastatic disease and not already included in CTV1.~Planning Target Volume: PTV - A margin of 5mm will be added to each of the CTV to obtain the PTV.~BTV receives 73.5Gy in 30 fractions. PTV 1 receives 63Gy in 30 fractions. PTV 2 receives 54 Gy in 30 fractions.~All patients receive concurrent platinum chemotherapy."
223834152|NCT02757222|RADIATION|Standard Dose|"CTV 1 includes 6mm isotropic margin around the entire PET-CT avid (thresholding at 40% of SUV max) larynx/ hypopharynx /oropharynx and 5mm isotropic margin around nodes.~CTV 2: This (CTV 2) includes the area around the primary or nodal levels at risk of harbouring microscopic primary or microscopic nodal involvement, or at risk nodal areas, and not already included in CTV1.~Planning Target Volume: PTV - A margin of 5mm will be added to each of the CTV to obtain the PTV.~PTV 1 receives 66Gy in 30 fractions. PTV 2 receives 54 Gy in 30 fractions.~All patients receive concurrent platinum chemotherapy."
223834153|NCT06641219|DRUG|One single intravenous injection of [177Lu]Lu-BQ7876|One single intravenous injection of 600-800 MBq \[177Lu\]Lu-BQ7876 in prostate cancer patients.
223834154|NCT06566482|DRUG|Dexmedetomidine-esketamine combination|Patient-controlled analgesia is established with dexmedetomidine (1 μg/ml), esketamine (1 mg/ml), and sufentanil (1 μg/ml) in a total volume of 100 ml. The pump is programmed to deliver 2-ml boluses at 6 to 8-minute lockout intervals with a background infusion rate at 1 ml/h. Patient-controlled analgesia is provided for at least 24 hours but no more than 48 hours after surgery.
223834155|NCT06566482|DRUG|Placebo|Patient-controlled analgesia is established with sufentanil (1 μg/ml) in a total volume of 100 ml. The pump is programmed to deliver 2-ml boluses at 6 to 8-minute lockout intervals with a background infusion rate at 1 ml/h. Patient-controlled analgesia is provided for at least 24 hours but no more than 48 hours after surgery.
223834156|NCT01782040|OTHER|Auriculotherapy group|It was used semipermanent needles (1.5mm) to stimulate points, once on a week, during 8 sessions.
223834157|NCT05668364|OTHER|Outdoor cold air exposure|Exposure to outdoor cold air (\<10°C or \<50°F, intervention group) for 30 minutes. On completion of the intervention, participants remained under observation at indoor ambient air from 30 minutes to 60 minutes from the intervention.
223834158|NCT03568721|DRUG|Ibuprofen|prescription of ibuprofen 400 mg
223834159|NCT03568721|DRUG|Acetaminophen|prescription of acetaminophen 500 mg
223834160|NCT03568721|OTHER|Chewing gum|prescription of one tablet of chewing gum
223834161|NCT02338518|DRUG|oxaliplatin|"oxaliplatin 100 mg/m2 was administered from the celiac artery on day 1 of every cycle in SEEOX group and SOX group.~Intravenous oxaliplatin 130 mg/m2 was administered on day 1 of every cycle in SOX group."
223834162|NCT02338518|DRUG|etoposide|etoposide 80 mg/m2 was administered from the celiac artery on day 1 of every cycle in SEEOX group.
223834163|NCT02338518|DRUG|pharmorubicin|pharmorubicin 30 mg/m2 was administered from the celiac artery on day 1 of every cycle in SEEOX group.
223834164|NCT02338518|DRUG|S-1|80\~120 mg of oral S-1 per square meter of body-surface area per day was given for 2 weeks in both SEEOX and SOX groups.
223834165|NCT00472537|PROCEDURE|Retromuscular Mesh repair of midline incisional hernia|
223834166|NCT00472537|PROCEDURE|Laparoscopic repair of midline incisional hernia|
223834167|NCT01965964|PROCEDURE|Questionnaire|
223834168|NCT02092246|DEVICE|Ultrasound machine|Use of ultrasound machine guidance for accurate needle placement into the knee joint
223834169|NCT02092246|DEVICE|Unguided injection|Needle placement will take place without ultrasound machine guidance
223834170|NCT06255847|DRUG|Pomalidomide, cyclophosphamide combined with dexametha|The starting dose of pomalidomide was 2 mg in all cases，the starting dose of cyclophosphamide was 50 mg/day.If the adverse event is attributable to a specific study drug, the dose is reduced accordingly for that drug; if the adverse event is associated with multiple drugs, the dose is reduced appropriately for one of the predominantly associated drugs at the discretion of the investigator; and if multiple adverse events occur concurrently, the dose should be adjusted according to the guidelines for the most severe toxicity.
223834171|NCT00057603|PROCEDURE|Deep Brain Stimulation|Deep brain stimulation sends electrical signals to specific parts of the brain, which block the impulses that cause neurological dysfunction.
223834172|NCT02563834|DRUG|thiapalmitate tracer|Radiolabeled tracer infusion; occurs in all treatment arms
223834173|NCT02563834|DRUG|Saline|Saline infusion for control
223834174|NCT02563834|DRUG|Insulin|Insulin infusion for insulin/glucose clamp procedure
223834175|NCT01364727|DRUG|Amrubicin|35 mg/m2; IV on days 1-3 each 3 week cycle
223834176|NCT05072522|DRUG|SKLB1028|SKLB1028 capsules, oral, once daily in continuous 28-day cycles
223834177|NCT04513457|OTHER|Liver resection and Neoadjuvant chemotherapy|
223834178|NCT04513457|OTHER|Liver resection and Adjuvant chemotherapy|
223834179|NCT04513457|OTHER|Liver resection, Neoadjuvant chemotherapy and Adjuvant chemotherapy|
223834180|NCT04513457|PROCEDURE|Liver resection|
223834181|NCT02343588|BEHAVIORAL|The Health Lifestyles Interventions|"1. Creating supportive school and family environment, whole intervention periods;~2. Health lifestyles educational strategies, 30min/week for education lessons and six times education activities;~3. Instruct and promote school physical education, whole intervention periods;~4. The monitoring and instruction of obesity related behaviors, once a week for physical activity and dietary behavioral log and once a month for parental monitor"
223834182|NCT01165710|OTHER|Patients with Atrial Fibrillation (AF)|Treatment patterns of AF according to patient demographics, clinical factors, risk stratification, and geographic regions.
223834183|NCT02430922|DEVICE|iVolution nitinol stent|
223834184|NCT01101139|DRUG|Sugammadex|Sugammadex (single intravenous injection 0.25 mg/kg)
223834185|NCT01101139|DRUG|Placebo|Placebo: single intravenous injection Saline 0.9%
223834186|NCT02984956|DEVICE|pleth variability index|
223834187|NCT00064272|DRUG|ginger extract|Given orally
223834188|NCT00064272|OTHER|placebo|Given orally
223834189|NCT04730063|DEVICE|VQm PHM™|Procedure: Non-invasive measurements obtained with the VQm PHM™
223834190|NCT02500485|DRUG|SHR3824, SP2086|One 100-mg tablet of SP2086 once daily on Day 1,2,3,4 followed by two 10-mg tablets of SHR3824 once daily on Day 11,12,13,14, followed by one 100-mg tablet of SP2086 and two 10-mg tablets of SHR3824 on Day 15,16,17,18.
223834191|NCT02618057|DRUG|Prednisolone|PO prednisolone, 1 mg/kg/day, for 5 days
223834192|NCT02618057|DRUG|Levofloxacin|Levofloxacin, 10mg/kg/day, IV, for 5days
223834193|NCT04716881|DRUG|Naltrexone 380 MG|Vivitrol (naltrexone) 380 mg delivered intramuscularly every 28 days
223834194|NCT04398784|DIETARY_SUPPLEMENT|Freeze Dried Blueberry Powder - 71717|Single serve packets containing 22.5 grams of powdered freeze-dried whole blueberries; A mix of 2 species, Vaccinium virgatum (ashei)/Vaccinium corymbosum, provided by U.S Highbush Blueberry Council (USHBC). Powders are sealed in single serve packets to protect from light and moisture. Packets are refrigerated except for when distributed to participants; participants are asked to store packets in refrigerator until consumption.
223834195|NCT04398784|DIETARY_SUPPLEMENT|USHBC Blueberry Placebo Formula #114|Blueberry flavor- and color-matched placebo powder.
223834196|NCT01085565|DEVICE|ExAblate 2100|Conformal Bone System
223834197|NCT04299633|DRUG|Vadadustat|2 x 150 mg oral tablets
223834198|NCT04299633|DRUG|Sevelamer carbonate|2 x 800 mg oral tablets
223834199|NCT04299633|DRUG|Calcium acetate|2 x 667 mg oral gelcaps
223834200|NCT04299633|DRUG|Auryxia®|2 x 1 gram tablets (210 mg ferric iron equivalent to 1000 mg ferric citrate)
223834201|NCT02561351|OTHER|FeNO measurement|FeNO was performed repeatedly every 3 months in every cases. exacerbations were recorded each visit
223834202|NCT04288362|OTHER|Intervention Group|Participants in this arm will undergo the new care model for management of diabetes mellitus polyclinics.
223834203|NCT04288362|OTHER|Control Group|Participants in this arm will continue to undergo the existing care model for management of diabetes mellitus in the polyclinics.
223834204|NCT05943418|BEHAVIORAL|Wysa for Worry|"The Wysa for Worry cCBT program is a week-based cCBT programme consisting of specialised cognitive behavior therapy (CBT) interventions delivered through a conversational agent.~Each week of the programme focuses on a different CBT technique or intervention, which is explained in a short weekly video. Following each video, the technique or intervention is discussed and practiced with Wysa's AI chatbot."
223834205|NCT05943418|BEHAVIORAL|App-based Psychoeducation|The control will include the weekly delivery of active psychoeducational resources.
223834206|NCT02892682|OTHER|BLOOD TEST|
223834207|NCT01426490|DIETARY_SUPPLEMENT|Vitamin C|Vitamin C, 100 mg/d
223834208|NCT01426490|DIETARY_SUPPLEMENT|Vitamin B6|Vitamin B6, 50mg/d
223834209|NCT01426490|DIETARY_SUPPLEMENT|Folic acid|Folic acid 400 microgram/d
223834210|NCT01426490|DIETARY_SUPPLEMENT|Vitamin B6 plus folic acid|Vitamin B6, 50 mg; folic acid, 400 microgram
223834211|NCT02223247|DRUG|TVB-2640|
223834212|NCT01558674|DRUG|MK-7145|
223834213|NCT01558674|DRUG|Furosemide|
223834214|NCT01558674|DRUG|Torsemide|
223834215|NCT04454905|DRUG|Camrelizumab|Camrelizumab (Jiangsu HengRui Medicine Co., Ltd.) is a recombinant anti-human PD-1 IgG4 monoclonal antibody.
223834216|NCT04454905|DRUG|Apatinib|Apatinib is a novel angiogenesis inhibitor vascular endothelial growth factor 2.
223834217|NCT04147260|DRUG|BI 730357|Film-coated tablet
223834218|NCT04147260|DRUG|Placebo to match BI 730357|Film-coated tablet
223834219|NCT04147260|DRUG|Ciprofloxacin|Film-coated tablet
223834220|NCT06275672|OTHER|Adapted version of the mhGAP-IG|An Ugandan adapted version of the mhGAP-IG CAMH module for identification, assessment, and management of common mental disorders in children and adolescents. The mhGAP-IG CAMH module further details six different protocols for the management of these mental health problems, primarily based on psychosocial and systemic interventions. The described psychosocial interventions can also be provided as general prevention for children with subclinical problems. Lastly, the module guides further follow-up assessment. Experts identified by the Ministry of Health will train trainers who train and follow-up teachers and health personnel receiving the intervention.
223834221|NCT04980716|DRUG|"Multiple cardiovascular drugs related to Golden Triangle"|Based on impedance cardiography results at each timepoints, cardiovascular drug treatment and exercise plan will be given in the intervention group.
223834222|NCT01531192|DIETARY_SUPPLEMENT|Lactobacillus reuteri|Lactobacillus reuteri 100 million CFU/day for 3 months
223834223|NCT01531192|DRUG|Nystatin|50000 unit/3 times a day, both for orally and by orogastric route
223834224|NCT00259493|PROCEDURE|Off-Pump Coronary Artery Bypass Graft Surgery|
223834225|NCT00445263|DRUG|TIROFIBAN|intravenous infusion
223834226|NCT00445263|PROCEDURE|CORONAROGRAPHY|standard procedure of coronarography
223834227|NCT01191684|OTHER|laboratory biomarker analysis|Correlative studies
223834228|NCT01191684|OTHER|enzyme-linked immunosorbent assay|Correlative studies
223834229|NCT01191684|OTHER|flow cytometry|Correlative studies
223834230|NCT01191684|OTHER|immunoenzyme technique|Correlative studies
223834231|NCT01191684|BIOLOGICAL|modified vaccinia virus ankara vaccine expressing p53|Given SC
223834232|NCT04093141|PROCEDURE|IRE|in situ irreversible electroporation
223834233|NCT02869113|DRUG|BAY98751 (Y65-110)|10 µL in one eye
223834234|NCT02869113|DRUG|BAY 98751 (Y65-102)|10 µL in one eye
223834235|NCT02869113|DRUG|BAY 98751 (Y65-106)|10 µL in one eye
223834236|NCT02869113|DRUG|Standard shampoo mixture (Control)|10 µL in other eye
223834237|NCT02117674|PROCEDURE|standard forward-viewing colonoscopy|examination of the colon with a conventional colonoscope
223834238|NCT02117674|PROCEDURE|full-spectrum colonoscopy|examination of the colon with full-spectrum colonoscope
223834239|NCT02117674|PROCEDURE|right colon retroflexion|examination of the right colon with scope retroflexion (both with conventional and fuse scope)
223834240|NCT03519698|OTHER|Warm water|Footbaths were prepared with 12 liters of warm water (40 °C)
223834241|NCT03519698|OTHER|Mustard|12 l footbath with warm water (40 °C) and 80 g mustard flour (Sinapis nigrea semen plv.)
223834242|NCT03519698|OTHER|Ginger|12 l footbath with warm water (40 °C) and 80 g ginger flour (Zingiberis rhizoma plv.)
223834243|NCT01872780|DRUG|Rosiglitazone|single oral administration of 4mg of rosiglitazone
223834244|NCT01872780|GENETIC|CYP2C8 genotype|CYP2C8\*11.
223834245|NCT02343575|DRUG|Valproic Acid|"1\.~Start:~VPA PO/NGT 500 mg BID~2\.~If need to increase in 24 or more hours:~VPA 500 mg PO/NGT q am, 1000 mg PO/NGT QHS~3\.~If need to increase in 24 or more hours:~VPA 500 mg PO/NGT q am, 1500 mg PO/NGT QHS~4.If need to increase in 24 or more hours:~VPA 500 mg PO/NGT Q am, 2000 mg PO/NGT QHS"
223834246|NCT02343575|DRUG|Placebo|Placebo 500 mg matched to VPA BID PO/NGT
223834247|NCT02343575|DRUG|Haloperidol|Both arms (intervention VPA and placebo) will receive flexible as needed haloperidol: Rescue: HAL IV 2-5 mg Q4hr PRN
223834248|NCT01734850|DRUG|Busulfan|Intravenous busulfan
223834249|NCT01734850|BIOLOGICAL|Cal-1 modified HSPC|Hematopoietic progenitor/stem cells (HSPC) modified with LVsh5/C46 (Cal-1)
223834250|NCT01734850|BIOLOGICAL|Cal-1 modified CD4+ T lymphocytes|CD4+ T lymphocytes modified with LVsh5/C46 (Cal-1)
223834251|NCT05955521|PROCEDURE|exosome and ctDNA evaluation|Serial exosome and ctDNA evaluation during follow up period between neoadjuvant chemotherapy and surveillance after curative surgery.
223834252|NCT05480033|BEHAVIORAL|Imagery Technique|The stages of the imagery technique included preparation of a suitable environment, preparation of the students, setting the background music (ney sound), relaxation, focusing on the technique, visualising the situation to be imagined, loading positive and constructive expressions on the individual, distracting the student from the imagined situation, relaxation and ending the session.
223834253|NCT00747058|DRUG|PF-3864086|The dosage form is POS (powdered oral suspension). Each subject will have 5 periods and the frequency (and duration) is once per period. The doses have been left flexible within the protocol but are listed as: 3, 10, 30, 60, 120, 240, 480 and 720 mg with an option to insert an additional dose cohort as well.
223834254|NCT00747058|DRUG|Placebo|Placebo
223834255|NCT02204293|DRUG|Canakinumab|Canakinumab, single-dose 4 mg/kg up to 300 mg administered subcutaneously.
223834256|NCT02204293|DRUG|Placebo|Matching placebo administered subcutaneously.
223834257|NCT01196130|BEHAVIORAL|Cancer Symptom Questionnaire|5 minute questionnaire(s) completed at each study visit.
223834258|NCT01196130|OTHER|Biomarker Testing|Blood draw at each study visit for biomarker and cytokine testing.
223834259|NCT02576834|BEHAVIORAL|Cognitive Therapy for Suicide Prevention|10 sessions of cognitive therapy for suicide prevention provided, along with optional 9 booster sessions + SAU
223834260|NCT02576834|OTHER|Services as Usual|Services as usually provided in the community
223834261|NCT03160482|DIAGNOSTIC_TEST|Immunohistochemistry|Immunohistochemistry procedure on the formalin-fixed, paraffin-embedded tissue.
223834262|NCT02019602|PROCEDURE|Blood sampling from mother|A blood sample from the mother will be taken within 24 hours before/after the delivery.
223834263|NCT02019602|PROCEDURE|Blood sampling from infant|Blood samples from the infant will be taken within 24 hours after birth, at Week 4 and at Week 8.
223834264|NCT02019602|PROCEDURE|Blood sampling from umbilical cord|A blood sample from the umbilical cord will be taken directly (within 1 hour ) after delivery.
223834265|NCT02019602|BIOLOGICAL|Certolizumab Pegol|"Mothers who decided to continue on, or to start treatment with, CZP for an approved indication with their treating physician prior to participation into this study. The mother is responsible for procuring her own supply of commercial CZP. The CZP dose and administration schedule will be as per the locally approved label.~* Active Substance: Certolizumab Pegol~* Pharmaceutical Form: Solution for injection~* Concentration: 200 mg/ml~* Route of Administration: Subcutaneous Use"
223834266|NCT05407532|PROCEDURE|Group with oral management|The investigators provided information on oral health care plus oral exercises before meals, including salivary glands massage methods.
223834267|NCT05407532|PROCEDURE|Group with oral care|The investigators taught and monitored patients or caregivers to do oral care after meals and before sleep.
223834268|NCT00652925|DRUG|Celecoxib|Higher dose, 6 mg/kg/dose BID
223834269|NCT00652925|DRUG|Celecoxib|Active drug at lower dose
223834270|NCT00652925|DRUG|Naproxen|Control comparator, 15 mg/kg/dy target dose
223834271|NCT03124030|PROCEDURE|simple dental extraction|dental extraction is performed by an expert oral surgeon within 20 minutes. Non-resorbable suture are applied
223834272|NCT06531148|OTHER|Chemo-mechanical caries removal|Chemo-mechanical were be used as a Chemo-mechanical caries removal agent for one side of the bilateral carious teeth (selected randomly). Application of the material were be done according to the manufacturer's instructions (20). The material will be applied with a blunt spoon excavator and left for 2 minutes allowing the chemistry to work. The decayed dentin which becomes soft (due to the action of the material) was being scraped away using a blunt excavator in a pendulum movement without pressure. If necessary, the procedure will be repeated to get healthy dentin. The cavity will be visually inspected by caries detector dye to assess the complete removal of the carious dentin.
223834273|NCT01710774|PROCEDURE|Telemedicine follow-up care|Telemedicine follow-up care for people with diabetes-related foot ulcers in municipal primary health care in collaboration with specialist health care
223834274|NCT04311242|OTHER|Diet|Ketogenic diet
223834275|NCT04598737|PROCEDURE|Ultra-translucent multilayer zirconia|Ultra-translucent multilayer zirconia laminate veneer treatment
223834276|NCT04598737|PROCEDURE|Lithium disilicate|Lithium disilicate laminate veneer treatment
223834277|NCT00026637|DRUG|sertraline|Sertraline: 25-200mg PO (orally); Subjects begin at 25mg for week 1 and increase to 50mg at the beginning of week 2. Sertraline is increased in 50mg increments when subjects score in the depressed range on the CES-D, a questionnaire that is administered every 2 weeks over the 16 week intervention period. Subjects may reduce dosage if toxicity occurs.
223834278|NCT00026637|BEHAVIORAL|cognitive behavior therapy|CBT (Cognitive Behavior Therapy) - CBT is a psychotherapy based on modifying cognitions, assumptions, beliefs and behaviors, with the aim of influencing disturbed emotions. Subjects will meet with a trained CBT therapist for 1 hour each week over the 16 week intervention period and will be given assignments to work on each week.
223834279|NCT03001401|OTHER|iDesign|One group will under go standard LASIK using iDesign platform (J\&J, USA). Visual acuity, tomography outcomes, biomechanical outcomes and inflammation in myopic eyes treated with iDesign and SMILE are proposed to be evaluated under the study.
223834280|NCT03001401|OTHER|SMILE|The other group will undergo SMILE for treatment refractive error (Carl Zeiss, Germany). isual acuity, tomography outcomes, biomechanical outcomes and inflammation in myopic eyes treated with iDesign and SMILE are proposed to be evaluated under the study.
223834281|NCT02503462|DRUG|Darunavir|darunavir 800 mg once daily will be first given together with ritonavir 100 mg once daily for one month (period 1) and then darunavir 800 mg once daily will be given together with cobicistat 150 mg once daily for one month (period 2). Afterwards, all patients will be switched back to darunavir/ritonavir (800/100 mg once daily).
223834282|NCT02503462|DRUG|ritonavir|ritonavir 100 mg once daily will be used to boost darunavir 800 mg once daily (period 1).
223834283|NCT02503462|DRUG|cobicistat|cobicistat 150 mg once daily will be used to boost darunavir 800 mg once daily (period 2).
223834284|NCT05956977|DEVICE|resection with help of 3D ultrasound|see above
223834285|NCT05349318|DEVICE|Hyperbaric oxygen therapy|Each session will include exposure of 90 minutes to 100% at 2 ATA, with 5 minutes air breaks every 20 minutes
223834286|NCT05349318|DEVICE|Sham|Each session will include exposure of 90 minutes to 21% at 1.2 ATA during the first five minutes of the session with the noise of circulating air, and then decrease slowly during the next five minutes to 1.03 ATA
223834287|NCT02329990|DIETARY_SUPPLEMENT|phosphorus|phosphorus supplement
223834288|NCT03615625|BEHAVIORAL|Power Training Session|"3 sets of 8-10 repetitions of 5 exercises performed in the following order: leg press, bench press, knee extension, upright row, and knee flexion, using an intensity corresponding to 50 % of 1-RM and two-minute intervals between sets and exercises. The concentric phase of exercises during each repetition was performed as fast as possible while the eccentric phase lasted 1-2 seconds."
223834289|NCT01162941|OTHER|Steroid refractory ITP|a platelet count less than 20X109/L despite of treatment with full dose of steroid (prednisolone 1mg/kg for at least 4 weeks)
223834290|NCT00463541|DRUG|solifenacin succinate|oral
223834291|NCT03548636|BEHAVIORAL|Single-Arm Feasibility Study|Groups of 8 to 12 participants, consisting of \>50% breast cancer survivors, were invited to apply for up to $2000 to enable access to equipment, resources, facilities, instruction and/or transportation to implement a physical activity intervention. Applicants were assessed by a Grant Review Panel. Successful applicants were informed that they would receive an additional $500 incentive if they increased their group's mean physical activity at six month follow-up (assessed via accelerometry).
223834292|NCT03335891|PROCEDURE|Core Stabilization Exercises|Volunteers received an asthma education program and trained for diaphragmatic, pursed lip breathing exercises as well as participated in the core stabilization exercises program.
223834293|NCT03335891|PROCEDURE|Control|Volunteers received an asthma education program and trained for diaphragmatic andpursed lip breathing exercises
223834294|NCT04668664|DEVICE|EchoTip® Insight™ Portosystemic Pressure Gradient Measurement System (EchoTip® Insight™)|Measuring the portal pressure gradient in patients with cirrhosis who are referred for an esophagogastroduodenoscopy (EGD) and/or endoscopic ultrasound (EUS).
223834295|NCT06460415|DEVICE|photobiomidulação|The volunteers in the GFBM group will undergo 8 sessions of a combined red and infrared laser protocol with 4J of infrared power and 4J of red power. Being applied at 8 points (4 red and 4 infrared) in the vulvar region and 8 points (4 red and 4 infrared) points in the intravaginal pelvic floor region. The MMO semiconductor laser device (GaA1As and InGaAlP) will be used with an area of the output laser beam at the NOZZLE of the laser pen of 3mm2 and wavelengths of 660nm (Red Laser) and 808nm (Infrared Laser) with a power of 100mW. The application will be carried out with the volunteers on a stretcher, in the supine position, gynecological position, with the knees and hips flexed and in abduction, feet supported on the stretcher.
223834296|NCT06460415|OTHER|Placebo|The placebo control will be administered using the same device as the GFBM, but without any therapeutic dose delivery. Furthermore, the irradiated sites and irradiation time will be the same as PBMT. Volunteers will receive a total dose of 0 J in placebo mode. This treatment was also carried out in 8 sessions.
223834297|NCT01058863|DRUG|Albuterol Spiromax®|Albuterol Spiromax® delivers 90 mcg albuterol per inhalation. Doses of 180 mcg require two inhalations. Intervention given as double-blind medication on 2 of 5 treatment days, once at 90 mcg and once at 180 mcg.
223834298|NCT01058863|DRUG|ProAir® HFA|ProAir® HFA delivers 90 mcg of albuterol per inhalation. Doses of 180 mcg require two inhalations. Intervention given as double-blind medication on 2 of 5 treatment days, once at 90 mcg and once at 180 mcg.
223834299|NCT01058863|OTHER|Placebo Inhaler|Placebo delivered in both the Spiromax® and HFA inhalers to maintain the blind and also to support the placebo treatment arm.
223834300|NCT03753607|OTHER|No intervention|No intervention
223834301|NCT05043311|BIOLOGICAL|SCTV01C|intramuscular injection
223834302|NCT05043311|OTHER|Placebo|intramuscular injetion
223834303|NCT03653416|DEVICE|Ipack|IPACK block - local anesthesia injected safely under ultrasound guidance in the interspace between the popliteal artery and capsule of the knee.
223834304|NCT03653416|DRUG|Bupivacaine|20 cc of bupivacaine(o.25%) injection
223834305|NCT03653416|PROCEDURE|Peri Articular Infiltration|Adductor Canal Catheter and Peri Articular Infiltration
223834306|NCT02712112|DRUG|Imatinib Mesylate|
223834307|NCT02254850|PROCEDURE|Flow Mediated Dilation|"Patients performed FMD by an high-resolution ultrasound linear probe in a supine decubitus and conditioned room.The probe was placed on humeral artery and connected to a mechanically arm. Then were performed several measurement s of the internal diameter of the vessel (edge to edge distance), on the R wave of the ECG, and software calculated the average value.The post-ischemic vasodilation was induced using a sphygmomanometer placed on the forearm, distal to the elbow crease, kept inflated to 250 mmHg for 5 minutes. The flow rate was recorded immediately after the desufflation; the diameter of the brachial artery was measured several times after desufflation (for 60-90 seconds). Nextly, the FMD was calculated as the percentage difference between the maximum diameter of the post-ischemic reached and the mean diameter of the vessel."
223834308|NCT02254850|DRUG|Mesoglycan|The Patients firstly underwent to intramuscular administration of 1 vial only, containing: Mesoglycan 30mg/ml.
223834309|NCT02254850|DRUG|Mesoglycan|The patients underwent to oral treatment with 1 capsule, administered bis in die for a period of 90 days, containing: Mesoglycan 50 mg.
223834310|NCT02254850|DRUG|Placebo|The Patients firstly underwent to intramuscular administration only of 1 vial containing inactive ingredients: sodium chloride, chlorocresol, water for injections.
223834311|NCT02254850|DRUG|Placebo|The patients underwent to oral treatment with 1 capsule, administered bis in die for a period of 90 days, containing inactive ingredients: lactose monohydrate, corn starch, croscarmellose sodium, magnesium stearate, gelatin, titanium dioxide, erythrosine.
223834312|NCT00086086|DRUG|Darbepoetin Alfa|
223834313|NCT01925261|DRUG|TPX-100 50mg|
223834314|NCT01925261|DRUG|TPX-100 100mg|
223834315|NCT01925261|DRUG|TPX-100 200mg|
223834316|NCT01925261|DRUG|TPX-100 20mg|
223834317|NCT01925261|DRUG|Placebo|
223834318|NCT05540691|DEVICE|Wear noise-cancelling earphones|Intervention of wearing noise-canceling earphones after general anesthesia
223834319|NCT00598481|GENETIC|Gene Therapy|Infusion of autologous CD34+ cells transduced with retroviral vector encoding ADA after non-myeloablative conditioning with busulfan
223834320|NCT00598481|DRUG|Busulfan|Busulfan is used for non-myeloablative conditioning
223834321|NCT00673634|PROCEDURE|Standard preoxygenation|Spontaneous breathing of 100% oxygen in a facemask for 3 minutes.
223834322|NCT00673634|PROCEDURE|BiPAP assisted preoxygenation|Spontaneous breathing of 100% oxygen in a facemask with application of an inspiratory pressure of 4cm H2O and a positive end-expiratory pressure of 4cm H2O, for 3 minutes.
223834323|NCT05758155|OTHER|mental health literacy training supported by creative drama|nursing students will be given two hours of mental health literacy training supported by creative drama one day a week for 4 weeks.
223834324|NCT05758155|OTHER|mental health literacy training supported by classroom instruction|nursing students will be given mental health literacy training supported by two hours of classroom instruction one day a week for 4 weeks.
223834325|NCT01397929|DRUG|BAL101553|Intravenous administration
223834326|NCT04456582|PROCEDURE|Shear wave elastography|The elastographic technique by ultrasound (USE), shear waves or shear wave elastography (SWE), quantitatively evaluates tissue stiffness by mapping the propagation of acoustic waves (shear waves), in a non-invasive manner and without emission of ionizing radiation. Their speeds are tracked by the ultrasound equipment after tissue deformation occurs, generated by pulses of acoustic radiation (ARFI) of the transducer itself. Assuming the correlation between tissue stiffness and increased acoustic propagation speeds, it is possible to describe mathematically the elasticity of tissues by measuring specific acoustic waves.
223834327|NCT05461560|DIETARY_SUPPLEMENT|Sucrose solution|50 g of sucrose dissolved in 500 ml of tap water
223834328|NCT05461560|DIETARY_SUPPLEMENT|Seaweed extract in sucrose solution|1 g of seaweed extract in solution of 50 g of sucrose in 500 ml of tap water
223834329|NCT02306395|PROCEDURE|Endometrial local injury|The way of intervention is to scratch the uterine cavity two cycles by a small spatula in the first 3-5 days after menstrual period.
223834330|NCT03073629|DIAGNOSTIC_TEST|Clinical Pathway|Patients will be evaluated and managed in a specialized cardiovascular clinic to determine the etiology of right heart failure and begin treatment.
223834331|NCT02212938|DRUG|BI 14332 CL|
223834332|NCT02212938|OTHER|high fat breakfast|
223834333|NCT05490069|OTHER|iCBT-based EMI|Consists of brief iCBT for psychological support (mandatory), stroke care education (optional), and real-time chat-based support messages, delivered according to participants' preferences.
223834334|NCT00743743|DIETARY_SUPPLEMENT|Longevinex brand resveratrol supplement|1 capsule daily for 52 weeks containing 215 mg of resveratrol active ingredient
223834335|NCT00743743|DIETARY_SUPPLEMENT|placebo|1 capsule of placebo daily for 52 weeks
223834336|NCT05179044|DEVICE|Guardian Sport Rehabilitator knee brace|The Guardian Sport Rehabilitator knee brace has pneumatic condyles that can be used to support and control the knee joint as well as an extension swing assist design which automatically assists in extending the knee when the patient themselves may guard against it. The Guardian Rehabilitator Knee Brace is considered by the FDA as a Class I external medical device. It is used on label and therefore exempt from IDE requirements.The Guardian Brace FDA registration to manufacturer external limb devices is attached for reference.
223834337|NCT03240939|DRUG|Dutasteride 0.5 mg|single dose
223834338|NCT03240939|DRUG|Tadalafil 5 mg|single dose
223834339|NCT03240939|DRUG|YY-201|single dose
223834340|NCT00571779|DEVICE|AtriCure Bipolar System|
223834341|NCT03435601|DRUG|Anifrolumab|"IV Administration of Anifrolumab 300 mg every 4 weeks from week 0 to week 20 for a total of 6 doses.~At week 24 patients will continue the current study for another 8 weeks to complete a 12-week safety follow-up after the last dose of investigational products (last dose of investigational product will be given at week 20).~The total study duration could be up to approximately 36 weeks (including the screening period)."
223834342|NCT03435601|DRUG|Placebos|"Placebo IV administration Q4W, a total of 6 doses At week 24 patients will continue the current study for another 8 weeks to complete a 12-week safety follow-up after the last dose of investigational products (last dose of investigational product will be given at week 20).~The total study duration could be up to approximately 36 weeks (including the screening period)."
223834343|NCT04840888|DRUG|LY3484356|Administered orally.
223834344|NCT04840888|DRUG|Omeprazole|Administered orally.
223834345|NCT04840888|DRUG|Itraconazole|Administered orally.
223834346|NCT04840888|DRUG|Carbamazepine|Administered orally.
223834347|NCT01159639|DRUG|Clopidogrel|patients with inappropriate response to aspirin 300 mg after CABG, assessed by multiple electrode aggregometry are randomized to receive clopidogrel 75 mg daily dose
223834348|NCT00798031|DEVICE|A minimum of two but up to three Astra Tech Dental Implant, Fixture Osseospeed will be placed in the posterior upper jaw of 20 eligible subjects.|A minimum of 2 but up to three dental implants will be placed in the posterior upper jaw of 20 subjects. The dental implants are produced by Astra Tech AB (Fixture Micro Thread OsseoSpeed TM Astra Tech AB. The study will include 15 clinic visits and interim analysis will occur at 6 months, 1, 2, and 3 years after loading of the temporary prosthesis.
223834349|NCT00798031|DEVICE|Placement of dental implant|"Device: A minimum of two but up to three Astra Tech Dental Implant, Fixture Osseospeed will be placed in the posterior upper jaw of 20 eligible subjects.~A minimum of 2 but up to three dental implants will be placed in the posterior upper jaw of 20 subjects. The dental implants are produced by Astra Tech AB (Fixture Micro Thread OsseoSpeed TM Astra Tech AB. the study will include 15 clinic visits and interim analysis will occur at 6 months, 1, 2, and 3 years after loading of the temporary prothesis."
223834350|NCT00798031|DEVICE|dental implant|Subjects will have a complete diagnostic work-up performed and assessment for eligibility in the study by both a Prosthodontist and Surgeon. Subjects will then have two and up to three dental implants placed in an out patient basis at the University of Iowa College of Dentistry
223834351|NCT02905123|BEHAVIORAL|Check Your Drinking|
223834352|NCT00474721|DRUG|ibuprofen|
223834353|NCT00474721|DRUG|acetaminophen with codeine|
223834354|NCT01487304|DRUG|Marketed low dose hormone replacement therapy|A low dose of marketed HRT products prescribed at the discretion of the treating physician
223834355|NCT03037879|OTHER|SPT|Participants in the SPT group will receive 10 training sessions over 5 weeks.
223834356|NCT03037879|OTHER|SPT Control|Participants in the SPT control group will receive 10 computer-based control sessions over a five-week period during which they will engage in computer-based training. However, they will not be exposed to the training materials central to the SPT.
223834357|NCT03037879|OTHER|mSMT|Participants in the mSMT group will meet with the trainer twice per week for five weeks. Sessions last 45-60 minutes each and are spread over 5 weeks.
223834358|NCT03037879|OTHER|mSMT Control|Participants in the mSMT control group will meet with the therapist at the same frequency and for the same duration as those in the mSMT experimental group. However, subjects will not be exposed to the training materials central to the mSMT.
223834359|NCT05172882|PROCEDURE|Wound site infiltration|Block fluids that were prepared as 20 ml 0.25% bupivacaine before the intervention, will be applied through the upper and lower incision lips on the suprainguinal surgical site.
223834360|NCT05172882|PROCEDURE|Transversalis fascia plane block|External, internal oblique, and transversus abdominis muscles will be visualized by the ultrasound device. After transversalis fascia will be seen, transversalis fascia plane block will be performed. As a block fluid 20 ml 0.25% bupivacaine will be applied.
223834361|NCT01265589|DRUG|surfactant|Intratracheal Surfactant Administration without Vitamin A for Newborn Respiratory Distress Syndrome
223834362|NCT01265589|DRUG|surfactant+vitamin A|Intratracheal Surfactant Administration with Vitamin A for Newborn Respiratory Distress Syndrome
223834363|NCT00417014|DRUG|chlorambucil|
223834364|NCT00417014|DRUG|prednisolone|
223834365|NCT00417014|DRUG|procarbazine hydrochloride|
223834366|NCT00417014|DRUG|vinblastine sulfate|
223834367|NCT00417014|RADIATION|radiation therapy|
223834368|NCT05787938|DEVICE|MRI|A procedure that uses radio waves, a powerful magnet, and a computer to make a series of detailed pictures of areas inside the body. A contrast agent, such as gadolinium, may be injected into a vein to help the tissues and organs show up more clearly in the picture. MRI may be used to help diagnose disease, plan treatment, or find out how well treatment is working. It is especially useful for imaging the brain and spinal cord, the heart and blood vessels, the bones, joints, and other soft tissues, the organs in the pelvis and abdomen, and the breast. Also called magnetic resonance imaging, NMRI, and nuclear magnetic resonance imaging.
223834369|NCT06493838|DRUG|intravenous 50 mL of saline injection of 0.9% after umbilical cord clamping.|intravenous 50 mL of saline injection of 0.9% after umbilical cord clamping.
223834370|NCT06493838|DRUG|Neostigmine 20μg/kg (Neostigmine Methylsulphate 0.5 mg, Amriya Pharm.Ind.) and atropine 0.01 mg/kg (diluted in 50 ml saline; 0.9% for 10 min) following umbilical cord clamping.|Neostigmine 20μg/kg (Neostigmine Methylsulphate 0.5 mg, Amriya Pharm.Ind.) and atropine 0.01 mg/kg (diluted in 50 ml saline; 0.9% for 10 min) following umbilical cord clamping.
223834371|NCT00000782|BIOLOGICAL|gp160 Vaccine (Immuno-AG)|
223834372|NCT00000782|BIOLOGICAL|gp160 Vaccine (MicroGeneSys)|
223834373|NCT02388074|DEVICE|CyPath®|CyPath® diagnostic assay for the early detection of lung cancer using sputum
223834374|NCT00003050|DRUG|cyclophosphamide|
223834375|NCT00003050|DRUG|doxorubicin hydrochloride|
223834376|NCT00003050|DRUG|paclitaxel|
223834377|NCT00003050|DRUG|tamoxifen citrate|
223834378|NCT00003050|PROCEDURE|surgical procedure|
223834379|NCT00003050|RADIATION|radiation therapy|
223834380|NCT00915902|DRUG|Omega-3-acid ethyl esters|Omega-3-acid ethyl esters (Lovaza), two 1-gram capsules taken twice daily for 8 weeks
223834381|NCT00915902|DRUG|Placebo|Placebo (corn oil), two 1-gram capsules taken twice daily for 8 weeks
223834382|NCT03464604|DIAGNOSTIC_TEST|active|Pre-screening for melanoma by qualified nurse
223834383|NCT00003458|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|Children with a brain tumor will receive Antineoplaston therapy (Atengenal + Astugenal).
223834384|NCT02133924|DRUG|natalizumab|Natalizumab 300mg on days 0 and 14.
223834385|NCT02133924|DRUG|steroids|Prednisone 2mg/kg/d (or methyl-prednisolone IV equivalent)
223834386|NCT02773264|DEVICE|Ultrasound|Ultrasound Elastography of soft tissue and organ lesions
223834387|NCT01213862|BEHAVIORAL|Home Based Education|There will provided education about what is heart failure, its causes, how to recognize signs and symptoms, monitoring of weight and blood pressure, the importance of compliance to treatment. Patients will be instructed about the medications; a guide to rest and exercise, sexual activity, vaccines, travel and diet will be provided. The involvement of the family will be encouraged; the contact with the team should be done when: patient observes an increase of 1 or 2 kg of weight in 2-3 days, worsening of dyspnea on effort, edema in legs / abdomen, worsening of cough, persistent vomiting, syncope, sputum with blood, fever, persistent tachycardia. In phone calls made between home visits, the compliance to treatment will be evaluated and reinforced.
223834388|NCT04183673|PROCEDURE|Laser therapy-cryo thermal therapy|5 days per week, 3 weeks, sessions including laser therapy + cryo therapy followed by usual rehabilitation
223834389|NCT04183673|PROCEDURE|Usual care|5 days per week, 3 weeks, sessions of usual rehabilitation
223834390|NCT01398501|DRUG|Sorafenib|Oral, 200 to 400 mg QD or BID
223834391|NCT04157686|DRUG|MT10109L Dose 1|MT10109L Dose 1 will be injected into the GL area
223834392|NCT04157686|DRUG|MT10109L Dose 2|MT10109L Dose 2 will be injected into the LCL area
223834393|NCT04157686|DRUG|MT10109L Dose 1 + Dose 2|MT10109L Dose 1 will be injected into the GL area plus MT10109L Dose 2 will be injected into the LCL area
223834394|NCT04112264|PROCEDURE|Monopolar radiofrequency ablation|a radiofrequency cannula is advanced under USG guidance towards the nerve. The final position will be confirmed by using nerve stimulator with elicitation of paraesthesia along the area of knee joint supplied by that respected genicular nerve by stimulation at 50 Hz current of \<0.5 mV. The motor stimulation will be negative at all instances. For each genicular nerve, two conventional RF lesions are done for 120s at 80° of temperature using the Neurotherm 1100 RF generator.
223834395|NCT04112264|PROCEDURE|Bipolar radiofrequency ablation|Two radiofrequency cannula are advanced under USG guidance towards the nerve. The final position will be confirmed by using nerve stimulator with elicitation of paraesthesia by stimulation at 50 Hz current of \<0.5 mV. The motor stimulation will be negative at all instances. For each genicular nerve, two conventional RF lesions are done for 120s at 80° of temperature using the Neurotherm 1100 RF generator.
223834396|NCT04156152|OTHER|DEENSIBILIZING TOOTHPASTE BASED ON NANOCRISTALS OF HYDROXIAPATITA / 5% POTASSIC NITRATE / SODIUM MONOFluORPHOSPHATE 1450 PARTS PER MILLION|The toothpastes will be delivered by the researchers and will be applied with a manual toothbrush, with soft bristles and straight handle, by the patient.The 2nd, 3rd, 4th session (2nd, 4th, 6th week of follow-up) will be the application of tests and reinforcement of oral hygiene instruction. In the 5th session (8th week of follow-up) the pastes will be requested to verify compliance.
223834397|NCT04156152|OTHER|5% POTASSIC NITRATE / SODIUM FLUORIDE 1426 PARTS PER MILLION TOOTHPASTE|The toothpastes will be delivered by the researchers and will be applied with a manual toothbrush, with soft bristles and straight handle, by the patient.The 2nd, 3rd, 4th session (2nd, 4th, 6th week of follow-up) will be the application of tests and reinforcement of oral hygiene instruction. In the 5th session (8th week of follow-up) the pastes will be requested to verify compliance.
223834398|NCT01564745|OTHER|Functional respiratory evaluation|Each enrolled patients has a pulmonary function test before and after extubation, and repeatedly at D1, D3, D5 (if they are always hospitalized)
223834399|NCT00218803|BEHAVIORAL|Nurse asthma education intervention|Asthma Education
223834400|NCT00218803|BEHAVIORAL|Control Group|Asthma Education
223834401|NCT04823559|OTHER|ThinkCancer workshop|The proposed intervention, the ThinkCancer! Workshop, is practice-based and consists of themed sessions for both clinical and non-clinical staff, the co-production of a Cancer Safety Netting Plan (CSNP) and the appointment of a Cancer Safety Netting Champion (CSNC). The workshop aims to raise awareness and increase knowledge around current cancer diagnosis guidance and will be delivered over half a day during GP protected time in the form of face-to-face educational sessions. Sessions will consist of a series of interactive activities exploring existing processes within practices and developing plans for change to implement each component.
223834402|NCT05271838|DIETARY_SUPPLEMENT|Magnesium acetate mixture (30 mmol/ml)|Patients with a magnesium retention test \>25% and randomized to intervention receive magnesium acetate oral mixture (30 mmol/ml) 20 ml x 3/day for a period of three weeks.
223834403|NCT05271838|DIETARY_SUPPLEMENT|High-protein diet (2 g/kg/day)|Nutritional counseling and protein supplementation to establish an intake of 2 g protein kg/day during admission and three weeks after discharge.
223834404|NCT05438615|OTHER|Corneal Refractive Therapy-spherical|A comparison of two different designs of Corneal Refractive Therapy contact lenses will be done. Each will be worn for two weeks. The sponsor will mask which lens will be first or second in the trial.
223834405|NCT05438615|OTHER|Corneal Refractive Therapy-aspherical|A comparison of two different designs of Corneal Refractive Therapy contact lenses will be done. Each will be worn for two weeks. The sponsor will mask which lens will be first or second in the trial.
223834406|NCT06328062|DRUG|Mirogabalin|Participants will receive 5 mg of mirogabalin, taken as half a tablet, every day twice a day, after breakfast and dinner, for 6 weeks.
223834407|NCT06328062|DRUG|Pregabalin|Participants will receive 50 mg of pregabalin, taken as a tablet, every day twice a day, after breakfast and dinner, for 6 weeks.
223834408|NCT06893055|OTHER|Strength-Endurance Training|"The intervention for the experimental Strength-Endurance group includes warm-up, three laps of strength and endurance exercises and cool-down.~The training program lasts 3 months and includes two 1-hour training sessions per week, for a total of 24 sessions."
223834409|NCT06893055|OTHER|Endurance Training|The intervention for the control Endurance training group includes warm-up, three laps of endurance exercises and cool-down. The training program lasts 3 months and includes two 1-hour training sessions per week, for a total of 24 sessions.
223834410|NCT04315415|DEVICE|Silk Voice|Silk Voice comprised of silk protein and cross-linked hyaluronic acid (HA)
223834411|NCT04212169|DRUG|MEDI3506|multiple doses
223834412|NCT04212169|DRUG|Placebo|multiple doses
223834413|NCT01603940|DRUG|Benazepril|Patients in this group will receive 20 mg of benazepril per day, orally, during 12 weeks.
223834414|NCT01603940|DRUG|Losartan|Patients in this group will receive 100 mg of losartan per day, orally, during 12 weeks.
223834415|NCT02018861|DRUG|Parsaclisib|
223834416|NCT02018861|DRUG|Itacitinib|
223834417|NCT02018861|DRUG|Rituximab|
223834418|NCT02018861|DRUG|Ifosfamide|
223834419|NCT02018861|DRUG|Carboplatin|
223834420|NCT02018861|DRUG|Etoposide|
223834421|NCT03135353|DEVICE|3D saline infusion sonohysterography|instillation of saline in the uterine cavity using pediatric foley's catheter, then performing 3D ultrasound scan of the uterus and adenexae
223834422|NCT03135353|DEVICE|Office Hysteroscopy|an outpatient procedure done to assess the uterine cavity using the office hysteroscopy
223834423|NCT02529865|BIOLOGICAL|Periurethral injection of autologous ADRCs and adipose tissue|1 mL of the isolated ADRC is injected into the region of the external urethral sphincter, and another 4 mL of the ADRC and 16mL autologous adipose cells is injected under the urethral mucosa.
223834424|NCT05210140|DRUG|Escitalopram|"Escitalopram, a selective serotonin reuptake inhibitor (SSRI), is commercially known as ELORYQA®, Elicea®, Escital®,PRAMES® or Lata® in Serbia. The recommended dose for Major depressive disorder is 10mg/day. Based on the individual response, dose can be adjusted and the maximum dose is 20 mg/day; 5 mg/day dose is also available. Escitalopram is also indicated for treatment of Obsessive-compulsive disorder, Generalized anxiety disorder, Social anxiety disorder (Social phobia) and Panic disorder (with or without agoraphobia) by Medicines and Medical Devices Agency of Serbia.~In known CYP2C19 poor metabolizers, initial dose should be 5mg/day during first 2 weeks, and based on the individual response it can be increased up to maximum of 10 mg of escitalopram per day, according to the guidelines of Medicines and Medical Devices Agency of Serbia."
223834425|NCT04574245|PROCEDURE|Gastrectomy; Hepatectomy|
223834426|NCT00504348|DRUG|Tacrolimus|Start at the standard starting dose of 0.075mg/kg/day divided into two doses, then adjust doses based on clinical response and tolerability, but maintain whole blood trough levels between 5 to 10 ng/mL and total daily doses equal to or below 0.3mg/kg.
223834427|NCT05248464|OTHER|The Patient Dignity Inventory instrument (PDI)|The PDI is an instrument made up of 25 items integrated into 5 factors that include: symptoms, existential anguish, dependency, peace of mind, and social support, prior to its application, adaptation, and validation will performer
223834428|NCT05248464|OTHER|WHOQOL-BREF (quality of life) instrument|The WHOQOL-BREF is a self-report questionnaire which assesses 4 domains of quality of life (QOL): physical health, psychological health, social relationships, and environment, it consists of 24 items.
223834429|NCT00151008|DRUG|Bexarotene/NBUVB vs placebo NBUVB|
223834430|NCT02468505|BEHAVIORAL|STEPS|time-limited behavioral counseling, online materials, training
223834431|NCT02968940|BIOLOGICAL|Avelumab|Avelumab 10 mg/kg intravenously (IV) every 2 weeks
223834432|NCT02968940|RADIATION|Hypofractionated radiation therapy (HFRT)|Hypofractionated radiation therapy to a total dose of 30 Gy, delivered in 6 Gy per fraction for 5 consecutive daily fractions
223834433|NCT03869710|DEVICE|Ultrasound-guided Dry-Needling Therapy|The needle will be insert under ultrasound guidance to elicit the myofascial response on the neck of the patients
223834434|NCT02718417|DRUG|carboplatin|Given Q3W during chemotherapy phase
223834435|NCT02718417|DRUG|paclitaxel|Investigator choice of weekly or Q3W during chemotherapy phase
223834436|NCT02718417|DRUG|Avelumab|Given Q3W in combination with carboplatin/paclitaxel during chemotherapy portion
223834437|NCT02718417|DRUG|Avelumab|Given as single agent in maintenance portion Q2W
223834438|NCT02938728|OTHER|Biopsies|
223834439|NCT05835492|DEVICE|myCOPD|myCOPD is a digital self-management application (app), that supports all elements of managing COPD by creating a supported self-help environment, and in turn reduce medical visits, and hospital admissions and re-admissions. myCOPD allows for key aspects of disease management, such as PR, to be provided remotely, based on a person's self-assessment. Furthermore, it can help people with COPD manage their condition at home, or anywhere away from a clinical setting. Successful implementation of myCOPD provides an opportunity to build capacity in primary and secondary care, and community teams where a blended approach with traditional PR and myCOPD is used. Studies have shown myCOPD is able to deliver similar improvements in symptoms and exercise tolerance compared to PR exercise-classes and helps patients admitted to hospital recover more quickly at home(5)(6). myCOPD is widely deployed across the NHS and is being used by patients in different areas of the UK.
223834440|NCT05881083|BEHAVIORAL|1-week nicotine replacement therapy sampling|Participants will be given an 1-week sample of nicotine replacement therapy (patch or gum) with brief instructions on how to use the product
223834441|NCT05881083|BEHAVIORAL|Brief cessation advice|"Participants will receive brief cessation advice following the AWARD (ask, warn, advise, refer, do-it-again) model:~A: Ask about the tobacco use status; W: Warn about the hazards of tobacco use; A: Advise the smokers to quit; R: Refer the smokers to cessation services; D: Do-it-again"
223834442|NCT02353117|BEHAVIORAL|Congenital Syphilis Intervention Group|
223834443|NCT01220674|OTHER|cognitive testing|computer-based cognitive assessment
223834444|NCT05854940|DIAGNOSTIC_TEST|Serum Raman spectroscopy intelligent diagnostic system|Intelligent diagnostic system based on Raman spectrum of serum
223834445|NCT06029218|RADIATION|Proteus ONE one daily beam|A single daily beam is used, doubling the dose delivered for this treatment incidence.
223834446|NCT06029218|RADIATION|Proteus ONE two daily beam|two daily beams are used, in accordance with the initial treatment plan and the patient's standard of care
223834447|NCT01938664|DRUG|Candesartan with CBT|8 mg, po (by mouth)
223834448|NCT01938664|OTHER|Placebo with CBT|
223834449|NCT02486705|BEHAVIORAL|PTSD Family Coach Full|PTSD Family Coach mobile app is an iOS mobile phone application designed to provide information, support resources, tools for coping with caregiver-related stress, and tools for self-monitoring stress symptoms.
223834450|NCT02486705|BEHAVIORAL|PTSD Family Coach Basic|PTSD Family Coach mobile app is an iOS mobile phone application designed to provide information and support resources,
223834451|NCT06501300|BEHAVIORAL|Emotion-focused: Tuning in to Kids in School|The aim of the TIKiS is to improve emotion coaching and reduce emotion dismissing in elementary school teachers through six x 90-minute group sessions.
223834452|NCT03040219|DRUG|Folic Acid|Tablets
223834453|NCT00551213|BIOLOGICAL|Robatumumab|
223834454|NCT00551213|DRUG|Irinotecan|
223834455|NCT00551213|BIOLOGICAL|Cetuximab|
223834456|NCT00551213|DRUG|Capecitabine|
223834457|NCT00551213|DRUG|FOLFOX|Leucovorin calcium (folinic acid)(FOL) + 5-fluorouracil (F)+ oxaliplatin (OX)
223834458|NCT00551213|DRUG|CAPEOX/XELOX|Capecitabine (CAPE) or Xeloda® (XEL) + oxaliplatin (OX)
223834459|NCT00551213|DRUG|FOLFIRI|Leucovorin calcium (folinic acid)(FOL) + 5-fluorouracil (F)+ irinotecan (IRI)
223834460|NCT01093261|DRUG|Placebo|"Placebo:~continuous intra venous infusion of placebo n°1 for 10 days. enteral administration of placebo n°2 for 10 days."
223834461|NCT01093261|DRUG|Hydrocortisone Fludrocortisone|HYDROCORTISONE: 200 mg.day-1 for 7 days, 100 mg.day-1 on day 8 and 9, 50 mg on day-10 (continuous intravenous infusion) FLUDROCORTISONE: 50 microg.day-1 for 10 days (per os)
223834462|NCT04908163|BEHAVIORAL|Mediterranean diet-based nutritional education intervention|The patients in the nutritional intervention group will receive dietary advice on how to follow a Mediterranean diet. The dietary recommendations will be given at the beginning of the study by nutritionists using comprehensive written material.
223834463|NCT04908163|BEHAVIORAL|Mediterranean diet-based culinary intervention|The culinary intervention will be developed integrating eight culinary and nutritional workshops that will be given every week, twice per week, during one-month intervention. The duration of each culinary and nutritional workshop will be 1 hour, thus, the program will provide a total of hours of nutritional education and a total of 8 hours of nutritional and cooking training. The courses will take place in a well-equipped kitchen from the Basque Culinary Center and participants will be connected online in order to be able to cook and practice at the same time. All cooking classes will begin with a theoretical introductory part that aim to explain the main take-home messages from the workshop. Subsequently, every class will be characterized by a hands-on part that will include the demonstration and practical preparation of different elaborations based on the use specific cooking techniques and healthy ingredients.
223834464|NCT00900289|GENETIC|DNA methylation analysis|
223834465|NCT00900289|GENETIC|microarray analysis|
223834466|NCT00900289|GENETIC|polymerase chain reaction|
223834467|NCT00900289|OTHER|immunohistochemistry staining method|
223834468|NCT00900289|OTHER|laboratory biomarker analysis|
223834469|NCT01890967|DRUG|LY3015014|Administered SC
223834470|NCT01890967|DRUG|Placebo|Administered SC
223834471|NCT01890967|DRUG|Statin|Administered orally
223834472|NCT01890967|DRUG|Ezetimibe|Administered orally
223834473|NCT01861301|OTHER|Laboratory Biomarker Analysis|Correlative studies
223834474|NCT01861301|DRUG|Tivantinib|Given PO
223834475|NCT05440799|DRUG|BI 1819479|BI 1819479
223834476|NCT05440799|DRUG|BI matching placebo|BI matching placebo
223834477|NCT03350477|DEVICE|Cancer ablation|Tumors bigger than 2 cm are fit for ablation therapy, percutaneously under CT scan or ultrasound.
223834478|NCT03350477|DRUG|Life information rehabilitation therapy|Each treatment: one bottle solution each day, consecutive 3 months, oral administration
223834479|NCT00255814|RADIATION|radiation therapy|
223834480|NCT01015573|DEVICE|magnetic sensor system to measure the movements of finger tapping|
223834481|NCT04612114|DIAGNOSTIC_TEST|Belun Ring|Simultaneous recording of Belun Ring data (pulse oximeter, pulse rate and actigraphy) and standard of care PSG will be performed for one night.
223834482|NCT03801720|OTHER|Ultrasound|Using ultrasound stimulation to induce micturition.
223834483|NCT06373848|DRUG|Receive 30 mg of Coq10|A total of 120 individuals diagnosed with chronic periodontitis were selected for this study. These participants were randomly assigned to two different groups. The purpose of the study was to measure the periodontal parameters of the two molars adjacent to the mandible using a periodontal probe. All of the patients received scaling and root planing (SRP) as part of their treatment. However, the treatment groups differed in terms of the supplements they received. Group A was given a daily dose of Coq10 at 30 mg, while Group B received a daily dose of Vitamin E at 400 mg; Furthermore, group C did not receive any supplements. The periodontal examination involved a total of 300 teeth across the three groups. In addition to this, 2 ml of unstimulated saliva was collected from each patient both before and after 2 months. The purpose of collecting the saliva samples was to evaluate the total antioxidant capacity and determine if there were any changes over time.
223834484|NCT04653896|DEVICE|Keeogo|The Keeogo is the only commercially available (in Canada) robotic exoskeleton for a non-paralyzed population who can stand and initiate a stepping action, but have impaired mobility for functional tasks. Keeogo provides active assistance during stance and swing phases and assists users to perform functional mobility tasks including walking, stair climbing, sit-to-stand, bending, squatting, and kneeling.
223834485|NCT00675727|BIOLOGICAL|CADI-05|Two intradermal treatments each week for first 4 weeks followed by one intradermal treatment per week for second 4 weeks.
223834486|NCT02928094|BIOLOGICAL|Ad5FGF-4|Ad5FGF-4 administered via intracoronary infusion using standard balloon catheter, and under conditions of transient ischemia.
223834487|NCT02928094|BIOLOGICAL|Placebo|Placebo buffer administered via intracoronary infusion using standard balloon catheter, without transient ischemia.
223834488|NCT05545969|DRUG|Pembrolizumab|Pembrolizumab is a potent and highly selective humanized monoclonal antibody (mAb) of the IgG4/kappa isotype designed to directly block the interaction between PD-1 and its ligands, PD-L1 and PD-L2.
223834489|NCT05545969|DRUG|Lenvatinib|Lenvatinib is an oral potent multiple RTK inhibitor that selectively inhibits VEGF receptors, VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4), fibroblast growth factor receptor (FGFR1-4), platelet derived growth factor (PDGFRα), stem cell factor receptor (KIT), and rearranged during transfection (RET)
223834490|NCT03251404|OTHER|Injury prevention exercise programs|The two intervention programs contain exercises aiming to increase lower extremity strength, core stability, balance and neuromuscular function.
223834491|NCT01093300|DEVICE|Paclitaxel-eluting balloon catheter|
223834492|NCT01093300|DEVICE|Everolimus-eluting stent|
223834493|NCT03572010|DIETARY_SUPPLEMENT|FeFum fortified maize test meal|Maize porridge extrinsically labeled with 2 mg ferrous fumarate (58FeFum); only for iron deficient children (defined by plasma ferritin \<40 mikrogramm/L and/or sTfR \>8.3 mg/L); cereal staple foods, like maize, depending on milling, may be high in phytic acid, a potent iron absorption inhibitor
223834494|NCT03572010|DIETARY_SUPPLEMENT|FeSO4 fortified LNS|self-made Lipid-based nutritional supplement (LNS) extrinsically fortified and labeled with 6 mg ferrous sulfate (57FeSO4); only for iron deficient children (defined by plasma ferritin \<40 mikrogramm/L and/or sTfR \>8.3 mg/L); LNS may be a better food matrix for iron supplementation compared to maize-based porridge; contains canola oil, peanut paste, milk powder, sugar, maltodextrin and palm stearin
223834495|NCT03572010|DIETARY_SUPPLEMENT|FeSO4 supplement|170 mg iron tablets as FeSO4 (containing 55 mg of elemental iron) with 6 mg extrinsically labeled 57Fe; will be given together with a glass of water; only for iron deficient children (defined by plasma ferritin \<40 mikrogramm/L and/or sTfR \>8.3 mg/L);
223834496|NCT03572010|DIETARY_SUPPLEMENT|FeSO4 fortified fruit juice|Fruit juice labeled with 12 mg 57Fe as FeSO4; in the group for iron sufficient children
223834497|NCT01492855|PROCEDURE|Arthroscopy|Arthroscopy is offered for the patients who do not benefit from conservative treatment.
223834498|NCT01492855|BEHAVIORAL|Non-invasive treatment|All patients will receive information and supervised exercises by a physiotherapist.
223834499|NCT01668875|OTHER|Head down 30 degree postural drainage position|supine head down 30 degree on tilt table (intervention period in the treatment condition)
223834500|NCT01668875|OTHER|Horizontal supine lying|horizontal supine lying on tilt table (intervention period in the sham condition)
223834501|NCT04524182|OTHER|control group|"There was no intervention in the control group during study.~At the end of study all patients were received home-based exercise tailored to each individual's needs which include stretching, strengthening, balance and gait exercise and posture exercise"
223834502|NCT04524182|OTHER|mobilization group|"Lumbosacral mobilization for 10 minutes in the study group (pelvis forward and backward distraction, passive rotation of the lower body, short lever rotation, long lever rotation, lumbar central posterior-anterior, lumbar unilateral posterior-anterior, anterior rotation-posterior superior iliac spine- down, posterior rotation-posterior superior iliac spine-up were applied.~At the end of study all patients were received home-based exercise tailored to each individual's needs which include stretching, strengthening, balance and gait exercise and posture exercise"
223834503|NCT04964765|DIAGNOSTIC_TEST|Mapping|CardioInsightTM Cardiac Mapping System is a non-invasive single beat cardiac mapping system that provides three-dimensional electroanatomic maps of the heart. The CIT vest is attached to the patient's torso for non-invasive mapping. To ensure correct and rapid mapping of the NOAF by the CIT device, it is essential to briefly slow down the patient's heart rate below 50bpm for a few seconds. Therefore 6mg adenosine as a rapid i.v. bolus will be administered. The adenosine application will slow down the patient's heart rate and allow for correct mapping by the CIT device. Medical therapy of atrial fibrillation is started immediately according to local protocol. Since non-invasive mapping is performed within a few minutes, the therapy of atrial fibrillation will not be critically delayed. Consecutively, a low-dose thoracic computed tomography (CT) scan (neck to upper abdomen) will be performed independent from the patient's rhythm.
223834504|NCT04964765|DIAGNOSTIC_TEST|Computed tomography scan|The CT scans will follow a standardised protocol as predefined by the manufacturer of the CIT vest, Medtronic (Dublin, Ireland). After the sensor array has been placed on the patient, the patient is ready to undergo a CT scan to register each electrode's locations with respect to the body surface. All CT scans cover a body region from neck to the upper abdomen, have no cardiac gating performed or any contrast agent given. The CT scans are acquired on 3 CT scanners manufactured by Siemens Corporation (Berlin, Germany) with a fixed tube voltage of 80 kVp and 250 effective mAs (=mAs/pitch). The reconstruction parameters are of 3 mm slice thickness and of 1.5 mm increment (slice overlap) The estimated effective dose (ED) is 3.2 mSv per patient.
223834505|NCT05536427|BIOLOGICAL|IPM001|IPM001 will be used against tumor cells
223834506|NCT01556841|BIOLOGICAL|TroVax®|"Pre-amendment 10:~Patients will be randomised to receive either TroVax® 1 x 10↑9 TCID50/mL in 1mL (experimental arm) or matched placebo (control arm) on a 1:1 basis. A single dose will be given by intramuscular injection during the following weeks: 2, 4, 7, 10, 13, 19, 25, 31, 37, 43 and 49. No further treatment will be given beyond week 49.Treatment will be stopped early if confirmed progression or unacceptable toxicity.~Post-amendment 10:~Patients will be registered to receive TroVax 1 x 10↑9 TCID50/mL in 1mL only. A single dose will be given by intramuscular injection during the following weeks: 2, 4, 7, 10, 13, 19 and 25. No further treatment will be given beyond week 25.Treatment will be stopped early if confirmed progression or unacceptable toxicity."
223834507|NCT01556841|BIOLOGICAL|Placebo|"Pre-amendment 10:~Matched placebo will be administered as above.~Post-amendment 10:~TRI-70 onwards received TroVax only."
223834508|NCT00004645|PROCEDURE|Plasma exchange|
223834509|NCT04270513|OTHER|Endovascular treatment by Flying Intervention Team|After telemedicine-assisted decision for endovascular treatment, the Flying Intervention Team is transferred via helicopter to the primary stroke center and performs endovascular treatment in the local angiography suite.
223834510|NCT04559399|PROCEDURE|smiley face shape rod|For treatment of isthmic spondylolithesis a transpedical screws for the same level and rod revolve around spinal process to stabilization of pars interarticularis of the same segment after removes bone at the margine of defects pars till reach to healthy bleed margine then put bone graft at the defect then stablizing pars and bone graft by rods.
223834511|NCT03796689|DEVICE|Smartphone-linked HBPM and associated app|Participants in the Smartphone-linked arm of the study will receive an Omron 786N Home Blood Pressure Monitor (HBPM) that can be linked to the Omron Connect app via Bluetooth. They will also receive instructions about how to use their device and download the app and will be provided with publicly available guidelines for HBPM. Participants will be instructed to use their device and app to take readings which they can track over time and share with their provider using the app.
223834512|NCT03796689|DEVICE|Standard HBPM|Participants in the Standard arm of the study will receive an Omron 785N Home Blood Pressure Monitor (HBPM), instructions about how to use their device and publicly available guidelines for HBPM. They will be instructed to use their device to take readings which they can track over time and share with their provider.
223834513|NCT03685747|DRUG|Vancomycin|Vancomycin one-time 20 mg/kg intraperitoneal dose.
223834514|NCT05205447|DRUG|LY3410738|Oral LY3410738
223834515|NCT05205447|DRUG|Itraconazole|Oral Itraconazole
223834516|NCT05205447|DRUG|Carbamazepine|Oral Carbamazepine
223834517|NCT01962064|BEHAVIORAL|Cognitive assessment|
223834518|NCT01962064|OTHER|Brain imaging examination MRI|
223834519|NCT00795132|DRUG|Busulfan|This drug is a bifunctional alkylating agent. Busulfan is highly toxic to noncycling or slowly-cycling cells. Pharmacokinetic studies of the IV formulation in pediatrics have shown that using a dose of 0.8mg/kg IV q6 hours most patients will achieve AUC levels between 800 and 1300 uM/min, representing steady state levels between 600-900ug/ml. The manufacturer recommends higher doses, 1.1mg/kg for children less than 12kg. Because this is a reduced intensity study and infants on the study will be very heavily pretreated we will use the lower dose of 0.8mg/kg q6 hours for a total of 8 doses for all patients.
223834520|NCT00795132|DRUG|Anti-Thymocyte Globulin|"Thymoglobulin will be administered at a dose of 2.5 mg/kg recipient body weight intravenously on each of 4 successive mornings (Days -4, -3,-2,-1) for patients receiving unrelated grafts and at a dose of 2.5mg/kg as a single dose on d-1 for patients receiving related marrow grafts. ATG is infused over a minimum of 4 hours, but is generally better tolerated over 6-8 hours. Suggested premedications are acetaminophen (10 mg/kg/dose), diphenhydramine (1 mg/kg/dose), and methylprednisolone. The methylprednisolone should be given at a dose of~1mg/kg 30 minutes prior to the ATG, with another 1mg /kg four hours into the infusion (total 2mg/kg/d). Patients are observed continuously for possible allergic reactions throughout the infusion."
223834521|NCT00795132|DRUG|Fludarabine|Administration and Dosage: Fludarabine will be administered at a dose of 30 mg/m2 in 100 ml of D5W intravenously over one hour on each of six consecutive days -10 through -5 for unrelated grafts or d-7 through d-2 for related grafts. Fludarabine is a fluorinated nucleotide analog of the antiviral agent vidarabine, 9-beta-D-arabinofuranosyladenine. Fludarabine phosphate is rapidly dephosphorylated to 2-fluoro-ara-A and then phosphorylated intracellularly by deoxycytidine kinase to the active triphosphate, 2-fluoro-ara-ATP. The half-life of 2-fluoro-ara-A is approximately 10 hours. The mean total plasma clearance is 8.9 L/hr/m2 and the mean volume of distribution is 98 L/m2. Approximately 23% is excreted unchanged. This metabolite appears to act by inhibiting DNA polymerase alpha, ribonucleotide reductase and DNA primase, thus inhibiting DNA synthesis.
223834522|NCT00795132|DRUG|Cyclosporine|"Cyclosporine is a potent immunosuppressive agent that in animals prolongs survival of allogeneic transplants involving skin, kidney, liver, heart, pancreas, bone marrow, small intestine, and lung. The effectiveness of cyclosporine results from specific and reversible inhibition of immunocompetent lymphocytes in the G 0 - and G~1 -phase of the cell cycle. Administration and Dosage: Cyclosporin start on day -3 initially at a dose of 2.5mg/kg IV q12 hours or 3mg/kg/dose (neoral equivalent) PO q12 hours targeting suggested troughs of 250 to 350 ng/ml. Continuous infusion cyclosporin may be allowed per institutional preference. 3x daily dosing may be used for younger children to achieve therapeutic levels. PBMTC Protocol #ONC0313 19 Continuous infusion cyclosporin may be allowed per institutional preference."
223834523|NCT00795132|DRUG|Mycophenolate mofetil|MMF is a potent, selective, uncompetitive, and reversible inhibitor of inosine monophosphate dehydrogenase (IMPDH), and therefore inhibits the de novo pathway of guanosine nucleotide synthesis without incorporation into DNA. Administration and Dosage: Initial dosage will be IV or PO with switch to PO when tolerated. Starting doses will be 15 mg/kg/day bid (total dose 30mg/kg/d, IV same as PO dose) beginning day 0 with the first dose given approximately 4-6 hours after the stem cell infusion. This dose will stop on day +30 for patients receiving matched sibling BM/PBSC and UCB grafts, but will continue until day +40 and then taper at approximately 11%/wk over 8 weeks until patients are off at day +96.
223834524|NCT00002956|BIOLOGICAL|allogeneic Epstein-Barr virus-specific cytotoxic T lymphocytes|
223834525|NCT03082300|DRUG|naquotinib|Oral
223834526|NCT04234243|PROCEDURE|cytoreduction and HIPEC|cytoreduction CCR 0-1, and HIPEC close technique
223834527|NCT02883322|OTHER|Cross cultural adaptation of patient reported outcomes (PRO)|Process used to adapt a questionnaire from one cultural setting to another
223834528|NCT03642002|OTHER|Toning|"Music therapist will begin gentle breathing and toning on a descending Ah vowel to stimulate vibration in the chest and increase awareness of the breath. The patient will be encouraged to join the music therapist as is comfortable"
223834529|NCT03642002|OTHER|Ocean drum & SOK melody|Music therapist will introduce ocean drum to mimic breathing sounds and will hum the melody of Song of Kin to begin entrainment process. Patient will be invited to join the music therapist in humming as is comfortable
223834530|NCT03642002|OTHER|SOK|Music therapist will introduce sung lyric content of Song of Kin accompanied on guitar. Patient will be invited to sing with music therapist as is comfortable.
223834531|NCT03642002|BEHAVIORAL|Process|Music therapist will process patient experience and provide psycho-education on strategies for using music to promote comfort and enhance breath.
223834532|NCT03642002|OTHER|Holding Harmonic Container|"Music therapist will provide a holding harmonic container of IM7 - IVM7 and will improvise a repeating melody on ah based on the ambient sounds in the patient's immediate environment"
223834533|NCT01547104|DRUG|Linagliptin|Linagliptin dosed 5 mg as add on therapy to an existing metformin therapy
223834534|NCT01547104|DRUG|Glimepiride|Glimepiride 1-4mg (individually dosed) as add on therapy to an existing metformin therapy
223834535|NCT05523622|DEVICE|Tono-Vera tonometer|The tonometer measures intraocular pressure with a small rebound probe, similar to those used with other tonometers currently on the market, such as the iCare.
223834536|NCT05523622|DEVICE|Goldman Applanation Tonometry|This is the current gold standard for measuring eye pressure.
223834537|NCT05572151|PROCEDURE|lymph node number|Lymph nodes were harvested during surgical resection of rectal cancer
223834538|NCT00839228|DRUG|Perhexiline|100mg o bd for 3 months
223834539|NCT00839228|DRUG|Placebo|Placebo one tablet bd for 3 months
223834540|NCT06297824|BEHAVIORAL|ERGT-A|Emotion regulation group therapy for adolescents
223834541|NCT02561455|DRUG|Gilteritinib|oral tablet
223834542|NCT01050075|OTHER|acupuncture therapy|acupuncture therapy
223834543|NCT01050075|OTHER|questionnaire administration|Ancillary study
223834544|NCT01050075|OTHER|management of therapy complications|To be determined by the treating physician
223834545|NCT06187181|PROCEDURE|implant overdenture|. Videofluoroscopy swallowing evaluation was done using 10 ml of thin liquid bolus at three different oral conditions: Without dentures (WOD), with the conventional complete denture (CDs) and with mandibular implant retained overdenture (IODs).
223834546|NCT06187181|RADIATION|videofluroscopy|videofluroscopy evaluation of swallowing function
223834547|NCT03677024|PROCEDURE|SLN arm|Intra-operative SN mapping with indocyanin green: Intracervical injection will be performed by the surgeon. Sub-mucous injections will be performed with 50% diluted dye at 3 and 9 o'clock positions. 1ml injection contained infracyanine green will be injected deeply into the stroma of the cervix (1cm-depth), and another 1ml will be injected superficially (2mm-depth). The time between the injection and the search for SLN must be as soon as possible.
223834548|NCT01290016|BEHAVIORAL|2 servings dairy + exercise|Subjects in this group will receive family based counseling to maintain the intake of 2 servings of dairy per day and also receive instruction on how to improve their physical activity.
223834549|NCT01290016|BEHAVIORAL|4 servings dairy + exercise|Subjects in this group will receive family based counseling to increase intake of dairy to 4 servings per day and also receive instruction on how to improve their physical activity.
223834550|NCT01290016|BEHAVIORAL|Control|The group will receive information during the study about diet and exercise but will not receive the intervention until 6 months into the study protocol.
223834551|NCT06117995|OTHER|Assessment the pre-washed sperm motility before IUI|The pre-washed sperm motility will be assessed by using WHO 2021 guidelines, stratified into four groups.
223834552|NCT03482674|BEHAVIORAL|DIMINI lifestyle intervention|DIMINI lifestyle intervention consists of the DIMINI-kit which contains health information, a list of food recommendations with additional information on calories, serving size and weight (traffic light rating system), a nutrition and an exercise diary. Participants in the intervention group can choose between a paper-based version or an app-based version of the DIMINI-kit. In addition, the kit includes an elastic exercise band with exercise poster, a measuring tape for self-control of the waist size and a pedometer.
223834553|NCT06174974|OTHER|Education|The education was designed to cover the environmental stressors of the intensive care unit and the practices performed to reduce these stressors. The education content was created according to the Activities of Daily Living (ADL) Theory based on the institution's cardiovascular surgical intensive care unit protocols (Cardiovascular surgical intensive care unit visitor entry-exit rules information form) and the literature (included at the end of the presentation). Expert (intensive care nurses, ward nurses, cardiovascular surgeons and academic nurses) opinions were obtained. Patient-friendly and simple language was used to ensure that the content of the information presentation was acceptable and interesting.
223834554|NCT04925921|DEVICE|SR-1 Laser|3-4 treatments at 4-6 week intervals
223834555|NCT05799924|DEVICE|Transcutaneous electrical acupoint stimulation|The transcutaneous electrical acupoint stimulator applied alternating current (including sine wave, pulse wave and modulation wave) with frequency of 2 \~ 100Hz and intensity of 10-20mA to stimulate corresponding acupoints through skin electrodes. The stimulated acupoints include Hegu acupoints, Luogong acupoints, Neiguan acupoints and Waiguan acupoints.
223834556|NCT05799924|DRUG|non steroidal anti inflammatory drugs|Hormonal contraception can suppress ovulation, NSAIDS can ease pain
223834557|NCT00042393|DRUG|Adefovir Dipivoxil|
223834558|NCT06478823|OTHER|Stools donation|"Healthy volunteer donors included in the selection process to donate stool for the preparation of a TMF as part of research projects.~Donors will be followed from their selection until 6 months after their last valid stool donation."
223834559|NCT02451930|DRUG|Necitumumab|Administered IV
223834560|NCT02451930|DRUG|Pembrolizumab|Administered IV
223834561|NCT02341911|DRUG|Gemcitabine,cisplatin|Gemcitabine 1250 mg/m2, IV drip 30 minutes, D1, D8 Cisplatin 75 mg/m2, IV drip 120 minutes, D1
223834562|NCT02341911|DRUG|Gemcitabine,carboplatin|Gemcitabine 1000 mg/m2, IV drip 30 minutes, D1, D8 Carboplatin AUC 2, IV drip 120 minutes, D1
223834563|NCT05616208|BIOLOGICAL|Bioengineered Internal Anal Sphincter|Autologous Bioengineered Internal Anal Sphincter
223834564|NCT00337116|DRUG|iso sorbide dinitrate iv bolus or s/l|
223834565|NCT05156801|DEVICE|ArchSinus stent|Post FESS unilateral placement of the ArchSinus stent into the randomized ethmoid sinus cavity.
223834566|NCT00000286|DRUG|Nefazodone|
223834567|NCT03406429|DEVICE|Active rTMS|All study participants will receive one block of active rTMS. Each block will consist of daily sessions of 20Hz active rTMS delivered to the left dorsolateral prefrontal cortex (dlPFC) over five days (Monday through Friday).
223834568|NCT03406429|DEVICE|SHAM rTMS|All study participants will receive one block of SHAM rTMS. Each block will consist of daily sessions of 20Hz SHAM rTMS delivered to the left dorsolateral prefrontal cortex (dlPFC) over five days (Monday through Friday).
223834569|NCT05483842|OTHER|Reiki|"Consisting of the words rei meaning spirit and ki meaning universal life force, Reiki means spiritually directed life force energy. Reiki practice has an important place in modern medicine and the nursing profession because it cures many diseases resistant to known treatments, has no side effects, is easy to apply, is safe, effective and economical.~In the Reiki method, which is one of the complementary and alternative methods, energy is transferred through the hands. Its basis is based on the principle that when there is a blockage in an energy center, disease occurs and the energy transferred by touching, strengthens and heals the body's self-healing ability by opening the blockages. Reiki practitioners who have received training and initiation perform the practice by holding their hands in certain positions on the recipient's body."
223834570|NCT05483842|OTHER|Sham Reiki|Sham means to pretend; therefore, in this study, the sham Reiki placebo provider pretended to perform a Reiki session by moving her hands on the patient's body in a specific order for a 30-minute period following strictly operationalized measures.
223834571|NCT03704311|PROCEDURE|Muscle biopsy|Local anesthesia was applied to the superficial skin covering the MTrP of each participant. Percutaneous biopsy sampling optimized with a suction-enhancement technique was used to obtain muscle biopsies of the m. trapezius MTrP or the m. gluteus medius MTrP from each participant using small Bergstrom muscle biopsy needle, 8 swg (4.0mm) x 100 mm (Dixons Surgical Instruments, Essex, United Kingdom).
223834572|NCT02991287|PROCEDURE|Inguinal hernia repair|
223834573|NCT02991287|PROCEDURE|Abdominal hysterectomy|
223834574|NCT02991287|PROCEDURE|Vaginal hysterectomy|
223834575|NCT02991287|PROCEDURE|Thoracotomy|
223834576|NCT01395771|BEHAVIORAL|Phone call intervention, no phone call intervention|Biweekly phone call intervention +routine service will be assigned to intervention group of new cases and old cases. Only routine service will be assigned to the control group of abovementioned two kind of cases.
223834577|NCT03112122|BIOLOGICAL|autologous bone marrow concentrate|injection of autologous bone marrow concentrate
223834578|NCT03112122|BIOLOGICAL|bone substitute i-FactorTM|subchondral injections of i-FactorTM
223834579|NCT03112122|PROCEDURE|core decompression|subchondral anterograde drilling
223834580|NCT02580682|DRUG|Sanfu herbal patch|The formula of the patch consists of Huang Qi (Astagalus Membranaceus), Fu Zi (Aconiti Lateralis Radix Praeparata), Yan Hu Suo (Rhizoma Corydalis), Xi Xin (Herba As5ari), Bai Jie Zi (Semen Sinapis Albae) and Rou Gui(Cortex Cinnamomi), in a proportion of 2:2:1:1:2:1.
223834581|NCT02580682|DRUG|Sanfu moxibustion|Moxibustion is a kind of thermal therapy without any feeling of pain or swell.Moxibustion exerts its therapeutic effect by thermal power and the application of moxa.
223834582|NCT02580682|DRUG|Sanfu herbal patch and moxibustion|use Sanfu moxibustion followed by Sanfu herbal patch
223834583|NCT03749356|DRUG|TacroBell SR cap.|"* Orally, once-daily in the morning~* After first dose 0.2mg/kg, check the blood concentration of tacrolimus at each visit and adjust the dose to acheive the blood concentration maintaining at 3\~12ng/ml for 0 to 3months and then at 3\~8ng/ml for 3 to 6months of study treatment."
223834584|NCT03623711|DRUG|Escitalopram|participants take escitalopram tablets based on their severity of depression (10-20mg/day) at least for 12 weeks.
223834585|NCT03623711|DRUG|Duloxetine|participants take Duloxetine capsule based on their severity of depression (60mg/day) at least for 12 weeks.
223834586|NCT03623711|DRUG|Bupropion|participants take Bupropion tablets based on their severity of depression (75-300mg/day) at least for 12 weeks.
223834587|NCT03623711|OTHER|Healthy control|Healthy control take placebo tablets
223834588|NCT03206294|OTHER|pharmacist assessment|St Joseph Hospital pharmacist assess every diabetic patient hospitalized in cardiology service in term of antidiabetic treatment during the hospitalization
223834589|NCT05656313|DEVICE|Measures of speech intelligibility in a noisy situation with speech from the side and from behind (measured with CC-OLSA Test)|"The Concurrent OLSA test (CC-OLSA) is a speech recognition test with three turn-taking talkers presenting sentences of the Oldenburg sentences test at fixed signal-to-noise ratios.~CC-OLSA is the only one-talker-at-a-time speech test that is sensitive at the desired SNR and uses sentences with an intelligibility function with slopes of 10-17 %/dB."
223834590|NCT05656313|DEVICE|Measures of the subjective speech recognition threshold in a noisy situation with speech from the side and from behind (measured with HEISS test)|The measure of the subjective speech recognition threshold is an alternative procedure to evaluate the subjective speech intelligibility in different listening conditions. The subjective speech recognition threshold is defined as the speech presentation level of running speech needed to just follow conversation. Subjects have to adjust the presentation level of speech so that they are just able to understand the speech, using a slider on a touch screen. This adjustment is repeated 10 times. Each adjustment results in a value for the subjective speech recognition threshold in dB SNR. The outcome measure is the mean value of the 10 repetitions. The HEISS-Test will be repeated four times for the secondary objective: test for 2 test conditions (Reference, novel approach) against 2 target directions (better ear side, back).
223835649|NCT05822297|DEVICE|Neuromuscular electrical stimulation|NMES will consist of a 12 week electrical stimulation program, three times a week. Electrical stimulation will be done on the quadriceps muscles of both legs simultaneously. For each leg, one electrode is placed on the proximal side and one on the distal side of the quadriceps muscle. Electrical stimulation sessions will take 30min, at a stimulation frequency of 50Hz, an intensity where we can at least see a visible or palpable contraction with a maximum intensity of 100mA (we will choose the highest intensity that is easily supported by the participant without inducing discomfort) and a pulse width of 400μs. The activation within the activation-rest cycle consists of a 1s ramp-up, 7s full activation and 1s ramp-down, followed by 18s rest. Every 4 weeks the rest period will be diminished with 3s until a total of 9s.
223834591|NCT05656313|DEVICE|Ability to multitask in the auditory and visual domains in noisy situation with speech from the side and from behind (Multitask test)|This test uses a dual-task-paradigm assessing vigilance for auditory and visual triggers concurrently. The primary task is to listen to a novel (Harry Potter) and respond on two trigger words by pressing the appropriate button (one in each hand). The secondary task is to observe a monitor showing a sequence of random signs and respond on a target sign by pressing both buttons. The test includes at least 100 triggers (50 auditory, 50 visual) and takes 10 minutes per condition (side vs. back; novel approach vs. reference; 40 minutes in total). The multitask test will be repeated four times for the secondary objective: 2 conditions (Refrence, novel approach) against 2 target directions (better ear side, back). Following data are provided from each multitask Test measure: (1) subjective rating of the perceived ability to perform the visual and the auditory test simultaneously. (2) reaction times to auditory and visual tasks, and (3) accuracy.
223834592|NCT05656313|DEVICE|Measure of subjective speech intelligibility and listening effort in noisy situation with speech from the side and from behind (subjective assessment; 100-point scale)|"In addition to the tests mentioned above a subjective assessment will be used to determine the subjective perception as this measure is often a good indication for clinical relevance.~For this purpose, the same speech material as used in the HEISS-test is presented by a loudspeaker in the same noisy environment as in the other three tests. The subjects rate his/her perception of the presented speech using a questionnaire on the dimensions listen effort and speech intelligibility. The subject will rate his perception on the 100 point scale with pencils with different colors to get either absolute and relative ratings.~The subjective assessment will be repeated four times for the secondary objective: 2 test conditions (Rference and novel approach) against 2 target directions (better ear side, back). Following data are provided from assessment: rating on a 100-point scale per condition and per dimension."
223834593|NCT05727683|BIOLOGICAL|CD19-targeted Chimeric Antigen Receptor (CAR) T Cells|Subjects will receive Lymphodepleting chemotherapy with intravenous (IV) fludarabine (25 mg/m2/day for 3 days) plus cyclophosphamide IV (250 mg/m2/day for 3 days) (flu/cy) concurrently, followed by JWCAR029 cells infusion. Phase 1 will evaluate up to 4 JWCAR029 cells dose levels.
223834594|NCT06550830|BIOLOGICAL|Sinovac PCV24 formulation 1|One dose of Sinovac PCV24 formulation 1(0.5mL)
223834595|NCT06550830|BIOLOGICAL|Sinovac PCV24 formulation 2|One dose of Sinovac PCV24 formulation 2(0.5mL)
223834596|NCT06550830|BIOLOGICAL|Prevenar13®|One dose of PCV13 manufactured by Pfizer
223834597|NCT00895479|PROCEDURE|Graft placement surgery plus Trinam therapy|"Trinam arm: graft placement surgery plus 1ml perivascular administration of Trinam vector.~Control arm: graft placement surgery"
223834598|NCT02818816|DRUG|brimonidine tartrate 0.2%|Alpha adrenergic receptor agonist
223834599|NCT02818816|OTHER|Carboxymethylcellulose Eye Drops|Ocular lubricants
223834600|NCT04218136|BIOLOGICAL|Blood samples|A minimum of 4 blood samples and a maximum of 6 blood samples will be collected. Venous return blood samples collected as part of routine monitoring of patients for bioclinical parameters. Samples will be collected before start of the infusion and end of the infusion
223834601|NCT00372307|DRUG|Application of pimecrolimus|
223834602|NCT06431698|DEVICE|Custom-made silicone device|Correction of deformation using the custom-made silicone device
223834603|NCT06431698|DEVICE|adjustable Earwell device|Correction of deformation using the adjustable Earwell device
223834604|NCT04708821|DRUG|Dexamethasone ophthalmic insert 0.4Mg|Dextenza 0.4Mg Ophthalmic Insert
223834605|NCT04708821|DRUG|0.2% loteprednol etabonate ophthalmic suspension|0.2% loteprednol etabonate ophthalmic suspension
223834606|NCT04708821|DRUG|olopatadine hydrochloride ophthalmic solution 0.7%|olopatadine hydrochloride ophthalmic solution 0.7%
223834607|NCT04463082|PROCEDURE|Intravenous administration of fluids|Intravenous administration of fluids (20ml/kg, but the maximum volume will be limited up to 500ml) within 60 minutes.
223834608|NCT04027569|OTHER|Patient Specific Functional Scale|A validated patient reported outcome measure that asks patients to write down activities and score them 0 to 10.
223834609|NCT04027569|OTHER|PROMIS PF|A computer adaptive, validated patient reported outcome measure that measures physical function on a 1 to 100.
223834610|NCT05348330|PROCEDURE|Thoracic intervertebral foramen block|Under ultrasound guidance the continuous thoracic intervertebral foramen block, will be provided to achieve analgesia in polytraumatic patients with rib fractures. A set for continuous peripheral nerve block will be used. The infusion rate of analgesic solution (levobupivacaine 0.25% combined with dexamethasone 16 mg) will be titrated to patient perceived pain. The block will be performed close, by considering the level of rib fractures.
223834611|NCT05348330|PROCEDURE|Mid-point to pleura transverse process block|Under ultrasound guidance the continuous mid-point to pleura transverse process block, will be provided to achieve analgesia in polytraumatic patients with rib fractures. A set for continuous peripheral nerve block will be used. The infusion rate of analgesic solution (levobupivacaine 0.25% combined with dexamethasone 16 mg) will be titrated to patient perceived pain. The block will be performed close, by considering the level of rib fractures.
223834612|NCT04236128|OTHER|Mobile App|"The app will be provided to patients in hospital on post-operative day 3. On the day of discharge, the patient will be emailed a Daily Health Check and receive subsequent Daily Health Check emails on Day 1-14, 21 and 30 days following discharge. The Daily Health Check is a tailored questionnaire to elicit their symptoms and status of post-operative recovery. After the patient has completed the Daily Health Check, a Daily Health Check Summary is emailed to the patient that summarizes their responses and provides appropriate action recommendations based on their responses ranging from: (i) suggestions for educational modules, (ii) expect a call from your health care team in the next 24 hours, (iii) call your surgeon's office today or (iv) go to the nearest emergency room. The patient's Daily Health Check responses are displayed in real time on a secure website that automatically red flags extreme responses to alert the health care team to contact the patient by telephone."
223834613|NCT04474964|RADIATION|Low dose Craniospinal Irradiation plus Focal Radiotherapy|The intervention arm of the study is to prospectively evaluate disease-related outcomes of low-dose CSI plus focal radiotherapy without concurrent chemotherapy followed by standard 6-cycles of adjuvant systemic chemotherapy in WNT-pathway medulloblastoma.
223834614|NCT02733133|DRUG|Testagen® TDS Testosterone 5% HypoSpray®|Topically applied Testosterone Hormone Replacement Lotion
223834615|NCT06040645|OTHER|APP Co-management|"To reduce additional burden of care on the PCPs, the investigators will incorporate Advanced Practices Providers into the patient education and self-management portion of care. The APPs will be trained together with the intervention physicians, but they will also undergo additional standardized training on patient education, UI knowledge, providing instruction on Kegel exercises, shared decision making, and self management.~Patients will then be scheduled for a UI education and self-management session with the APP by telemedicine (video visit or telephone visit) within one month of their initial visit. For patients in need of an annual pelvic examination, and if the patient's PCP prefers to have the APP conduct the pelvic exam, a separate visit will be scheduled with the APP. A followup televisit will then be scheduled within three months of the initial APP visit, in order to assess the outcome of non-surgical treatment and determine if a specialist referral is indicated."
223834616|NCT06040645|OTHER|E-consult|"In implementing the electronic consultation system in the private sector, the investigators will model the Expected Practice developed by the Los Angeles County Specialty-Primary Care Work Group. This eConsult system utilizes a kickback mechanism by which a specialist, who reviews the referral, can return it if it has not met certain baseline criteria (e.g. for a woman with OAB/urinary urgency: document negative UA, scheduled voids, titrate fluids to thirst, Kegels, antimuscarinics, optimize diuretic control, adjust any diuretics)."
223834617|NCT06388070|DRUG|HUC3-053|drops in each eye five to six times a day for 12 weeks
223834618|NCT06388070|DRUG|Hyalein Mini Drops|drops in each eye five to six times a day for 12 weeks.
223834619|NCT06518499|PROCEDURE|Pilonidal sinus surgery|Bascom's Pit-Pick procedure, Primary Closure, Karydakis procedure
223834620|NCT05584657|DRUG|Sulopenem etzadroxil/probenecid|Oral sulopenem twice daily for 5 days
223834621|NCT05584657|DRUG|Amoxicillin/clavulanate|Oral Augmentin twice daily for 5 days
223834622|NCT05801159|DIAGNOSTIC_TEST|Positron Emission Tomography-Computerised Tomography (PET-CT)|Injection of the 18F-fluoropivalate (18F-FPIA) radiotracer followed by a whole brain static PET-CT scan.
223834623|NCT05070650|DRUG|Acetylcysteine|200 mg/500 mg/10 mg granules for oral solution: one sachet three times per day
223834624|NCT05070650|DRUG|Paracetamol|500 mg/10 mg granules for oral solution: one sachet three times per day
223834625|NCT05070650|DRUG|Phenylephrine|500 mg/10 mg granules for oral solution
223834626|NCT00002730|DRUG|buthionine sulfoximine|
223834627|NCT00002730|DRUG|melphalan|
223834628|NCT01024647|BIOLOGICAL|certolizumab pegol|certolizumab pegol 200 mg every 2 weeks
223834629|NCT01024647|BIOLOGICAL|certolizumab pegol|certolizumab pegol 400 mg every 2 weeks
223834630|NCT01024647|BIOLOGICAL|certolizumab pegol|certolizumab pegol 400 mg every 4 weeks
223834631|NCT01024647|BIOLOGICAL|certolizumab pegol|certolizumab pegol 400 mg every 2 weeks
223834632|NCT03585114|DRUG|[F-18] DCFPyL|\[18F\]DCFPyL will be used for study imaging. It will be administered intravenously on the day of imaging. Subjects will receive a bolus injection of 9mCi (331 MBq) of \[18F\]DCFPyL through a peripheral IV catheter. 60 to 120 minutes after injection, a whole body (toes to vertex) lowdose CT will be obtained (120 kVp, 80 mA maximum).
223834633|NCT03585114|PROCEDURE|PET/CT imaging|As per standard of care, acquisition will be performed on PET/CT scanner (Siemens, Germany) operating in 3D emission mode with CT-derived attenuation correction.
223834634|NCT00684268|DRUG|Silibinin|"comparison of different dosing schedule of Silibinin infusions (20 mg/kg/d infused over 2 hours) A: 3x5days B: 14 days C: 21 days D: 28 days~sequential the infusion duration will be shortened - 2 hours, then 1 hr and then 1/2 hr/infusion"
223834635|NCT00684268|DRUG|Silibinin|20 mg/kg Silibinin iv /d /21 days, antiviral combination therapy will be continued
223834636|NCT00005991|DRUG|gemcitabine hydrochloride|
223834637|NCT00005991|DRUG|pegylated liposomal doxorubicin hydrochloride|
223834638|NCT00778063|DRUG|dexmedetomidine|2 mcg/kg intranasally 30 minutes prior to surgery
223834639|NCT00778063|DRUG|saline|a volume of intranasal saline, calculated based on body weight, will be given 30 minutes prior to surgery
223834640|NCT01406860|DRUG|Droperidol|Droperidol 1.25 mg IV x 1, may repeat 0.625 mg if needed at 60 minutes
223834641|NCT01406860|DRUG|Metoclopramide + diphenhydramine|Metoclopramide 20 mg IV infusion q30 minutes as needed with a maximum of 4 doses + Diphenhydramine 25 mg IV injection x 1 given with the first dose of metoclopramide IV infusion and repeated x 1 given with the third metoclopramide IV infusion.
223834642|NCT00931450|DRUG|exemestane|Given orally
223834643|NCT00931450|DRUG|sunitinib malate|Given orally
223834644|NCT00931450|OTHER|placebo|Given orally
223834645|NCT00763932|BIOLOGICAL|Myozyme|10 mg/kg or 20 mg/kg qw OR 20 mg/kg or 40 mg/kg qow
223834646|NCT06385210|OTHER|Semi structured interviews|Participants will be interviewed concerning perceived barriers to routine surgical video recording
223834647|NCT02727868|GENETIC|blood samples|
223834648|NCT04572490|DIAGNOSTIC_TEST|periapical radiograph|alveolar bone loss measurement on standardized parallel periapical radiograph
223834649|NCT00126204|DRUG|Doxycycline|
223834650|NCT05730218|DRUG|ONL1204 Ophthalmic Solution|ONL1204 Ophthalmic Solution at one of two doses delivered via intravitreal injection
223834651|NCT05730218|DRUG|Sham treatment|Sham injection is performed by touching the eye surface with a syringe without a needle
223834652|NCT02922673|DRUG|Aspirin|
223834653|NCT02922673|DRUG|Placebo|
223834654|NCT03930966|DIAGNOSTIC_TEST|PDEQ, PCL-5 and demographic survey|Questionnaires
223834655|NCT02640651|DEVICE|DC-Stimulator (PLUS version)|transcranial direct current stimulation
223834656|NCT06378502|DRUG|Amoxicillin Short|Short Span
223834657|NCT06378502|DRUG|Amoxicillin Long|Long span
223834658|NCT01613820|DRUG|Ketamine|ketamine IV 0.25mg/kg infusions twice a week for 3 weeks as augmentation of ongoing antidepressant regimen.
223834659|NCT01613820|DRUG|Scopolamine|Scopolamine 2ug/kg over 15 minutes twice a week for 3 weeks as augmentation of ongoing antidepressant regimen
223834660|NCT02291224|BEHAVIORAL|Interactive multimedia platform|An interactive platform that includes video vignettes of young women who are choosing dual protection strategies (based on a synthesis of focus group data from members of the TSC patient population), as well as true/false questions to build knowledge about dual protection and dispel common myths about contraceptive strategies. There will also be reflection questions that encourage participants to consider values and priorities in their own lives that may influence their dual protection strategy selection.
223834661|NCT02291224|BEHAVIORAL|Intervention arm counseling|Counseling for the intervention group will follow carefully developed guides and incorporate the participants' answers to the reflection questions in the interactive multi-media component. This counseling has a set structure (set forth in separate counseling guides for health care providers and nurse educators), incorporates motivational interviewing techniques, includes multiple opportunities for role play, and is designed to be patient-centered.
223834662|NCT02291224|BEHAVIORAL|Standard of care counseling|Standard of care counseling is provided by health care providers and health educators at TSC. It incorporates extensive counseling on methods to prevent both unintended pregnancy and sexually transmitted infections, however the structure of the counseling and techniques used are dependent on the standard practice of each provider or educator. This counseling does not incorporate answers to reflection questions from the multi-media platform because control arm participants will not view this content.
223834663|NCT05640076|OTHER|24/7 Telephonic Palliative Care Service availability|"Metropolitan Palliative Care Service-implemented 24/7 telephonic availability service for the patients, their relatives, the EMS and Primary Care physicians taking care of them.~After consultation, if the information and medical suggestions are not sufficient, an urgent ambulatory or home visit could be planned."
223834664|NCT00573950|DRUG|cilostazol|50 mg two times a day for 2 weeks and then 100mg two times a day for 6 weeks
223834665|NCT00573950|DRUG|Placebo|Placebo tablet comparable to 50mg cilostazol two times a day for 2 weeks and then placebo tablet comparable to 100mg cilostazol two times a day for 6 weeks
223834666|NCT02807246|BIOLOGICAL|Maflor®, Mamsel Pharmaceuticals, Turkey|"Dietary Supplement: Probiotics probiotics at a dose of 1x109 CFU/day. (Maflor®, Lactobacillus rhamnosus GG 109 CFU, Mamsel Pharmaceuticals, Turkey)~Other Name: Maflor®"
223834667|NCT02807246|OTHER|drops of saline|Dietary Supplement: Breast milk +drops of saline
223834668|NCT00245596|DRUG|sildenafil|
223835650|NCT03591861|PROCEDURE|Ketogenic diet|"* Children under 2 years will immediately start on a full calorie classical 3:1 ketogenic diet. The 3:1 ratio indicates that the diet contains 3 g of fat for every 1 g of protein + carbohydrate, which results in about 87% of calories coming from fat.~* Children 2 years or older will skip breakfast and lunch on the day of admission but start a full calorie 3:1 ketogenic diet at dinner."
223835651|NCT03591861|DRUG|BCNU|-Standard of care
223835652|NCT02890056|BEHAVIORAL|H2GO!|
223834669|NCT05586191|OTHER|Action observation at home|"Exercises included will contain four stages of exercises. Each stage will be followed for 2 weeks i.e. stage 1 for 1st and 2nd week, second stage for 3rd and 4th week, third stage for 5th and 6th week and fourth stage for 7th and 8th week of treatment. Each component of every stage will be played for 1 minute in front of participants, followed by 1 minute rest and then these exercises will be performed for 5 minutes.~All participants will perform AOT 3 times/week for up to 8 weeks along with functional training for the rest of the weeks. Functional training will include stretching and isometric exercises (stretching of hamstring and calf muscle while quads isometric). Assessment will be done by using the tools at baseline and after 8 weeks of intervention. A final reading will be taken after 12 weeks to check the maintenance of training effects."
223834670|NCT05586191|OTHER|Action Observation therapy at hospital|"Exercises included will contain four stages of exercises. Each stage will be followed for 2 weeks i.e. stage 1 for 1st and 2nd week, second stage for 3rd and 4th week, third stage for 5th and 6th week and fourth stage for 7th and 8th week of treatment. Each component of every stage will be played for 1 minute in front of participants, followed by 1 minute rest and then these exercises will be performed for 5 minutes.~All participants will perform AOT 3 times/week for up to 8 weeks along with functional training for the rest of the weeks. Functional training will include stretching and isometric exercises (stretching of hamstring and calf muscle while quads isometric). Assessment will be done by using the tools at baseline and after 8 weeks of intervention. A final reading will be taken after 12 weeks to check the maintenance of training effects."
223834671|NCT03373474|OTHER|local distribution points association|"Participants will receive acupuncture treatments using the local points set plus the local-addition points set (local distribution association) described below. Warming acupuncture will be applied at HT2, LI11, and TE9 if permitted.~Local points set: TE5, LI11, TE9, HT3, TE13, and Xiajiquan on the affected arm. Local-addition points set: LU5, PC3, SI7, TE4, TE3, HT2, TE10, LI15, and 2 other points according to the symptom on the affected arm."
223834672|NCT03373474|OTHER|local-distal points association|"Participants will receive acupuncture treatments using the local points set plus the distal points set (local-distal association) described below. Warming acupuncture will be applied similarly to the local distribution group, with the addition of Ren6, Ren9, bilateral SP9, and LI11 on the unaffected arm.~Local points set: TE5, LI11, TE9, HT3, TE13, and Xiajiquan on the affected arm. Distal points set: TE5, LI11, HT3, TE13 on the unaffected arm; CV4, CV6, CV9, CV12, bilateral SP6 and SP9."
223834673|NCT00002214|DRUG|Capravirine|
223834674|NCT01300559|DEVICE|Tissuelink device|Tissuelink device plus Unipolar electrocautery
223834675|NCT03685708|BIOLOGICAL|HEPLISAV-B|HEPLISAV-B (Hepatitis B Vaccine \[Recombinant \], adjuvanted) vaccine - A series of 2 doses (0.5 ml each) will be given on a 0- and 3- month schedule via intramuscular injection.
223834676|NCT03565770|OTHER|individual coaching|coaching on the phone or with messages on line twice a month in order to help patients to adjust their insulin doses and fill in their self-assessment test.
223834677|NCT03565770|OTHER|Standard care|completion of the self-assessment test at inclusion, at M6 and M12 for all study participants
223834678|NCT00936494|PROCEDURE|Cold ablation inferior turbinate reduction|The procedure usually takes 30 minutes and involves the surgeon inserting the coblation inferior turbinate reduction wand into the inferior turbinates and allowing for the radiofrequency cold ablation to ablate soft tissues, with a resultant thermal lesion allowing for additional soft tissue attenuation and contracture with time.
223834679|NCT00065416|PROCEDURE|massage|
223834680|NCT05188391|DIAGNOSTIC_TEST|Deltoid Gap Sign|At first deltoid sign test will be performed and the result of the test will be noted for the patients who are already scheduled open medial ankle surgery due to diagnosed as ankle fracture. During the open surgery, the test results will be evaluated.
223834681|NCT01286974|DRUG|[14C]linifanib|\[14C\]linifanib, single administration, oral liquid
223834682|NCT01286974|DRUG|ABT-869, linifanib|linifanib once a day (QD), oral tablet
223834683|NCT04773574|DEVICE|Corneal topography, Optical coherence tomography (OCT) and Optical coherence tomography angiography (OCTA)|"Ocular investigations were performed in each trimesters and at 6 weeks after childbirth.~1. st trimester : gestational age 8-12 weeks~2. nd trimester : gestational age 24-28 weeks~3. rd trimester : gestational age 34-38 weeks"
223834684|NCT04006366|BEHAVIORAL|Time restricted feeding|We propose a pilot and feasibility trial of a 10 hour time restricted eating intervention among post-bariatric surgery patients.
223834685|NCT03479060|PROCEDURE|Wet Cupping|cupping technique procedure was conducted in five phases:Primary suction,Area disinfection,Scarification,Bloodletting and secondary suction and Removing and dressing
223834686|NCT05313893|BIOLOGICAL|Quadrivalent influenza vaccine|Subjects receive two doses of quadrivalent influenzavaccine administered 4 weeks apart by intramuscularinjection. Each 0.5-ml dosecontained 15 μg of hemagglutinin per strain.
223834687|NCT01080196|BEHAVIORAL|RENEW|"RENEW will occur on a recumbent ergometer that appears like a normal stepper ergometer. While resisting the foot pedal movement the participant experiences eccentric muscle contractions about the knee and hip while performing negative work. The progression of the 3 x/week (every other day), 12 week RENEW program will be determined as a function of the rating of perceived exertion (RPE) using a target workload on the monitor. RENEW will be increased very slowly over the first 3 weeks and, subsequently, to maintain an 11-13 perceived exertion. During the formal RENEW training regimen the participants become fully acclimated to the device (week 3-4) the total RENEW load will increase weekly with no increase in their RPE."
223834688|NCT05721027|DRUG|Ibuprofen 400 mg|Ibuprofen 400 mg PO every 8 hours as needed for 7 days
223834689|NCT05721027|DRUG|Dexamethasone Oral|Dexamethasone 16 mg PO during ED visit and next day
223834690|NCT05721027|BEHAVIORAL|Educational Intervention|Research personnel will provide each patient with a 15-minute educational intervention. This will be based on National Institute of Arthritis and Musculoskeletal and Skin Diseases Handout on Health: Back Pain information
223834691|NCT03988374|DRUG|Dentifrices|Dentifrice on plaque, gingivitis, and bleeding.
223834692|NCT05743192|OTHER|Stop performing an antibiotic susceptibility test|Intervention = Stop performing an antibiotic susceptibility test for enterococcus faecalis in urine cultures. It defines two groups : one before and one after the intervention
223834693|NCT02698280|DRUG|Bevacizumab|Bevacizumab is administered intravenously at 5mg/kg every 3 weeks.
223834694|NCT02698280|DRUG|Nimustine|Nimustine is administered intravenously at 90mg/m\^2 to 110mg/m\^2 every 6 weeks.
223834695|NCT02260089|DRUG|Low dose of telmisartan|
223834696|NCT02260089|DRUG|High dose of telmisartan|
223834697|NCT02260089|DRUG|Placebo|
223834698|NCT00002813|DRUG|cisplatin|
223834699|NCT00002813|DRUG|vinorelbine tartrate|
223834700|NCT01151982|BEHAVIORAL|Psychosocial Intervention|"The intervention we propose to test has 3 actives components. The first one is the fact of giving information to the GPs about the level and risk profile of depression of their patients. The second one is the transmission of this information from the GP to the patient. The third one is the interaction GP/Patient once both have the information about the risk profile of depression and the psychoeducational intervention that the GP will provide to the patient.~We will develop psychoeducational booklet, DVDs and websites for patients included in the intervention group.~The psychoeducative intervention will be tailored to each patient based on his/her profile, risk level and patients' risk factors.~The GPs will receive a 20-hours training course in the intervention. Moreover, we will assume a communitarian view, considering the patient as an active agent for change (empowerment). That is, GPs and patients will work together in order to promote patients' resources."
223834701|NCT03767478|DEVICE|Revitive Medic Coach (Actegy Ltd)|Use the device for two 30-minute sessions per day, a minimum of five hours per week for 12 weeks at suprathreshold (2 x motor threshold).
223834702|NCT03767478|DEVICE|Sham Revitive Medic Coach (Actegy Ltd)|Use the device for two 30-minute sessions per day, a minimum of five hours per week for 12 weeks at suprathreshold (2 x motor threshold).
223834703|NCT03887104|DEVICE|SD-OCT|Spectral Domain Optical Coherence Tomography for non-invasive, light-based, cross-sectional imaging of ocular structures
223834704|NCT05674968|BEHAVIORAL|Managing Challenging Behaviors in ADHD; Psychosocial program|MCB-ADHD is a brief Behavioral Parent Training (BPT) program delivered to caregivers and children together. THe researchers have specially designed this program to be flexible so that it can be delivered over telehealth and/or in-person. All sessions are guided by web-based tool to provide parent support materials and direct the work to be completed in session. MCB-ADHD combines brief BPT skills modules adapted from an established evidence-based BPT called Helping the Noncompliant Child (HNC; McMahon \& Forehand, 2003) with high quality psychoeducation and advocacy training that were developed by the investigators specifically for use in this project. Families receive 4 sessions adapted from HNC focused on behavior management and 2 sessions focused on education and empowerment.
223834705|NCT04403061|DIAGNOSTIC_TEST|Cytokines measurement|Quantification of plasma cytokine levels of human GM-CSF, IFN-α, IFN-γ, IL-2, IL-4, IL-5, IL-6, IL-9, IL-10, IL-12p70, IL-17A, and TNF-α using multiplex technol-ogy (quantitative measure).
223834706|NCT04403061|DIAGNOSTIC_TEST|Cellular response|SARS-CoV-2 peptides (Prot-S, Pros-N and Port-M) will be used to activate CD4 and CD8 T cells. Cytokines released, such as IFNg, TNFa, IL4, IL17A, and IL2, from each cell subset will be measured by flow cytometry (quantitative measure).
223834707|NCT04403061|DIAGNOSTIC_TEST|TLRs activation measurement|After specific cell activation through TLR7/8 receptors, such as resiquimod, ORN R-0002, ORN R-0006, ORN R-1263, ORN R-2336, and controls as Poly (I:C), the release of IFNa, IFNg, TNFa, IL12, and IL6 will be analyzed (quantitative measure).
223834708|NCT04403061|DIAGNOSTIC_TEST|KIR phenotype evaluation|Characterization of the presence of 14 genes plus 2 pseudogenes of KIR gene family (qualitative genotyping) by PCR, mRNA expression profiling (quantitative measures) by RT-PCR, and phenotyping of human NK cells analyzing different KIR receptors (quantitative measure) by flow cytometry, will be analyzed.
223835653|NCT02554435|DEVICE|EAM|The monitor provides the participant feedback on their daily steps, active time, idle time, burned calories, and distance traveled through the mobile application (app). Participants can review all of their feedback while in the intervention. If the participants chose, they are also able to monitor their sleep and dietary intake. The app also provides health tips and daily challenges. The participants will also have the opportunity to interact with other participants through the social features of the app.
223834709|NCT05530967|OTHER|TT|"This intervention uses questionnaire at three-time intervals (i.e., days 5, 10, and 30) and abstraction of PAP use data (days 1 - 35). Consecutive adults with moderate-severe OSA and recommended to PAP treatment will be invited to the study. Once the patient has been prescribed PAP therapy a research associate will call the patient before receiving their new PAP device. The research associate will utilize an IRB approved telephone script to discuss study details, conduct eligibility screening (inclusion/exclusion criteria), and to ask whether the patient is interested in participating.~The research associate will then send the patient an IRB approved digital information sheet. The information sheet will provide the patient an option to mark Yes if they are willing to participate in the study or No if they are not willing. Patients who indicate their willingness to participate will receive the Triage Tool in accordance with the study protocol."
223834710|NCT05530967|OTHER|VE|A randomly selected sub-group of participants (n=30) will also receive an animated education video that provides targeted information and encouragement for self-managing your PAP problem(s). Patients in this sub-group will be asked to view a maximum of 2 different videos that are less than 2 minutes in duration. These videos are aligned with practice guideline recommendations for addressing PAP problems early in treatment. The videos will be sent digitally from Somnoware™.
223834711|NCT00627042|BIOLOGICAL|Ramucirumab (IMC-1121B)|Participants will receive ramucirumab (IMC-1121B) at 8 milligrams per kilogram (mg/kg) administered over 1 hour every other week (every 14 days). Treatment will continue until there is evidence of disease progression, intolerable toxicity, or other withdrawal criteria are met.
223834712|NCT03950219|OTHER|Group course|Education and support
223834713|NCT05226845|OTHER|prescribed exercise|the therapist chooses the five exercises to do
223834714|NCT05226845|OTHER|chosen exercise|the patient chooses the five exercises to perform among fifteen possibilities
223834715|NCT02268552|DRUG|branaplam|
223834716|NCT04266990|OTHER|Planned Sweat collection|Four times a day at fixed time points (9:30, 11:30, 13:30, 15:30), a researcher will ask the volunteers to wash their hands with non-scented soap and then place a sterile cotton gauze in the palm of their non-dominant hand. After 10 minutes, the gauze will be retrieved by the researcher.
223834717|NCT04266990|OTHER|Spontaneous Sweat collection|As the patient will be under continuous monitoring, sweat and saliva samples will be also collected during and/or right after a seizure occurs if the volunteer is not holding a gauze at that time. The sweat samples will be collected by the researcher by applying a sterile gauze to the patients hands, either during or immediately following a seizure during 10 minutes.
223834718|NCT04266990|OTHER|Healthy volunteers sweat collection|A researcher will ask the volunteers to wash their hands with non-scented soap and then place a sterile cotton gauze in the palm of their non-dominant hand. After 10 minutes, the gauze will be retrieved by the researcher. The healthy samples will be collected on the same floor of Ghent University Hospital and as close as possible to where patients reside
223834719|NCT02728518|DRUG|Nebulized Amikacin|400mg twice daily nebulized amikacin
223834720|NCT02728518|DRUG|Intravenous Amikacin|20mg/kg once daily intravenous amikacin
223834721|NCT05506267|DEVICE|Trachea Sound Sensor (TSS)|Use the TSS and commercial vital sign monitors to develop a diagnostic algorithm that detects and predicts hypoventilation due to opioids and anesthetic medication
223834722|NCT00000836|DRUG|Sevirumab|
223834723|NCT04121221|DRUG|GA Depot|Long acting intramuscular injection of glatiramer acetate, once every 4 weeks
223834724|NCT04121221|OTHER|Placebo|IM injection once every 4 weeks
223834725|NCT00146211|DRUG|Ethyl-EPA (Miraxion™)|
223834726|NCT04314128|DIAGNOSTIC_TEST|TOS and TCD|TOS: Transorbital sonography TCD: Transcranial Doppler
223834727|NCT00056290|BIOLOGICAL|VEGF|3 sets of injections, at 2 week intervals
223834728|NCT00056290|BIOLOGICAL|VEGF|3 sets of injections, at 2 week intervals
223834729|NCT03692988|BEHAVIORAL|Dignity Therapy|Dignity Therapy (DT) invites individuals with life-limiting illnesses to reflect on matters of importance to them and compiles them in a narrative document for the patient to share.
223834730|NCT05126446|DEVICE|the Aorta Arch Stent Graft System combined with the Endovascular Needle System|Patients who meet all the inclusion criteria and don't meet the exclusion criteria will be implanted with device
223834731|NCT00623415|DRUG|Flupirtine|300 mg daily (divided in two doses)
223834732|NCT00623415|DRUG|Placebo|twice daily
223834733|NCT01537653|DRUG|SAR231893 (REGN668)|Pharmaceutical form:Solution in a vial Route of administration: Subcutaneous injection
223834734|NCT01537653|DRUG|placebo|Pharmaceutical form:Solution in a vial Route of administration: Subcutaneous injection
223834735|NCT00997243|BIOLOGICAL|lintuzumab|Cycle 1 600mg as an IV infusion (flat dose for all), given on days 2, 7, 15, and 22. Subsequent Cycles (cycles to be repeated every 28 days) 600mg as an IV infusion, given every other week, twice during each cycle, including one dose given during AZA therapy. Doses should be given at least 12 days apart. By convention, dosing on days 7 and 22 of each cycle will be encouraged, but due to expected issues of patient convenience (time, travel, etc.), the study requirements are every other week, twice during each cycle, with one dose during AZA treatment.
223834736|NCT00997243|DRUG|5-azacytidine|75mg/m2 IV/SC daily on days 1-7.
223834737|NCT06048874|PROCEDURE|Sono-guided injection|After spinal anesthesia, patients will be injected around femoral nerve using ultrasonography.
223834738|NCT06048874|DRUG|Ropivacaine injection|After spinal anesthesia, patients will be injected 20ml ropivacaine around femoral nerve.
223834739|NCT06048874|DRUG|Saline injection|After spinal anesthesia, patients will be injected 20ml 0.9% saline around femoral nerve.
223834740|NCT02537353|DEVICE|Metal clips|The group will be shot of adrenaline 1: 10,000 in four quadrants, associated with application of metal clips.
223834741|NCT02537353|DRUG|Hemospray|The group will be shot of adrenaline 1: 10,000 in the four quadrants associated with application adsorption powder, marketed under the name Hemospray.
223834742|NCT02537353|PROCEDURE|Endoscopy Exam|All patients will be submitted to endoscopy exam in 12 to 24 hours after the therapeutic procedure to confirm the success of the therapy and measure if there the presence of rebleeding.
223834743|NCT02537353|DRUG|Adrenaline|The injection of adrenaline solution with 50% glucose at a proportion of 1: 10000 in four quadrants.
223834744|NCT02184897|DRUG|lenograstim 10 microgram/kg/day|
223834745|NCT03069794|DIAGNOSTIC_TEST|Use of stable force platform|Use of stable force platform to appreciate the posture before and after spinal surgery
223834746|NCT02261415|DRUG|Tranexamic acid (TXA)|1 g TXA bolus injection + 1 g TXA infusion from induction over 8 hours
223834747|NCT02261415|DRUG|Normal saline|1 g saline bolus injection + 1 g saline infusion from induction over 8 hours
223834748|NCT02273011|PROCEDURE|caesarean section|elective caesarean section under regional anesthesia
223834749|NCT02602249|BIOLOGICAL|MUC1-gene-DC-CTL|MUC1-gene-DC-CTL will be used against tumor cells.
223834750|NCT02602249|BIOLOGICAL|MUC1-peptide-DC-CTL|MUC1-peptide-DC-CTL will be used against tumor cells.
223834751|NCT03641833|DIAGNOSTIC_TEST|blood sample for brain biomarkers|Transcranial Doppler will be performed to evaluate a.cerebri media blood flow speed during surgery.
223834752|NCT02948946|PROCEDURE|NETest|5 mL of blood will be drawn from participants for testing.
223834753|NCT02900781|DEVICE|Steprite™|Steprite™ Device shoe insert monitoring device
223834754|NCT02900781|OTHER|Standard of care|No Device. Standard of care physical therapy
223834755|NCT02862704|BIOLOGICAL|MG7-CART|Ultrasound-guided intra-tumor injection as the route of T cell delivery, so that more T cells gathered at the tumor site, less migrate to the normal tissue, thereby enhancing the efficacy of anti-tumor, reducing the potential of side effects. And MG7-CART is a 2nd CAR, with MG7 as the target protein, 4-1BB as co- stimulator
223834756|NCT02472314|DRUG|1.3% Liposomal Bupivacaine|local tissue infiltration of Liposomal Bupivacaine during surgery
223834757|NCT02472314|DRUG|0.125% Bupivacaine|Continues nerve block with Bupivacaine during surgery and postoperatively
223834758|NCT03756779|OTHER|Dietary intervention|Dietary intervention with dietary modification of fat intake.
223834759|NCT00321477|DRUG|GW679769 oral tablets|
223834760|NCT01235273|DRUG|Growth Hormone|growth hormone administration
223834761|NCT01235273|OTHER|Placebo|standard placebo
223834762|NCT02889042|OTHER|MRI and biological assessment|performing a MRI and a biological assessment
223834763|NCT06357364|BEHAVIORAL|Psychoeducation and cognitive modules|Psychoeducation and cognitive modules: what is procrastination, role of rewards, work environment, belief identification, cognitive restructuring, relapse prevention.
223834764|NCT06357364|BEHAVIORAL|Behavioral module: Starting on Time and Planning Realistically|Learning of realistic planning, and timely starting of work.
223834765|NCT06357364|BEHAVIORAL|Behavioral module: Working Time Restriction|Restriction of allowed time for work, and gradual increase of allowed time, if previous time windows where effectively used.
223834766|NCT04947969|DEVICE|laser acupuncture|This study will use German-made low-level laser pen (Al-Ga-As diode laser, 810nm, NIR, Physiolaser Olympic Basic, RJ laser). The parameters are power of 100mW, frequency of Bahr, apply on acupoint. Well will irradiate each point for 2 J. Each patient will receive this treatment six times for one week.
223834767|NCT04499742|RADIATION|Using Isotope (Tc99m-Sulfur Colloid) to label glucose and administer this directly into duodenum.|Patients will be undergoing Standard of Care procedure EAGBT for collection of duodenal fluid (aspirate and culture) and placement of a catheter into the duodenum. This catheter will be used for infusion of glucose isotope into the small bowel. Subsequently Standard of Care nuclear medicine imaging will be used to track the location of the isotope in the gut.
223834768|NCT01433653|BEHAVIORAL|Cognitive Behavioral Therapy for Complicated Grief|Manualized CBT with 25 sessions, once a week. Key elements are exposition and cognitive restructuring.
223834769|NCT01349907|DRUG|Asenapine|One flavored asenapine sublingual tablet (containing either 2.5, 5 or 10 mg asenapine) twice daily (BID), starting at 2.5 mg on Day 1 for three consecutive days. Normally on Day 4, the dose will increase to 5 mg BID beginning with the evening dose. Normally on Day 7, the dose will increase to 10 mg BID beginning with the evening dose. The dose may be up-titrated earlier than Days 4 and 7 at the investigator's discretion. Beginning on Day 8 (or after at least 1 day on 10 mg BID), asenapine dosing will be flexible (2.5, 5, or 10 mg BID) until up to Week 50.
223834770|NCT01349907|DRUG|Rescue medication|For participants whose symptoms worsen or are not adequately controlled on assigned treatment, rescue medication may be administered during the trial in the following circumstances. For the control of agitation, anxiety, insomnia, restlessness, or akathisia and extrapyramidal symptoms (EPS) some benzodiazepines (i.e., lorazepam \[up to 4 mg/day\] or an equivalent dose of short-acting benzodiazepines) and EPS medications (i.e., anticholinergics) are allowed. Benadryl (diphenhydramine) and beta blockers are also permitted, provided that they are not taken within 8 hours of efficacy assessments.
223834771|NCT04963764|DRUG|Amoxicillin|Participants will be randomized to receive oral amoxicillin for a standard course (10 days)
223834772|NCT04963764|DRUG|Placebo|Participants will be randomized to receive oral placebo for a standard course (10 days)
223834773|NCT02557906|PROCEDURE|Breast reconstruction - implant and an ADM (SurgiMend)|Skin or nipple sparing mastectomy and immediate breast reconstruction with implants and SurgiMend
223834774|NCT02557906|PROCEDURE|Breast reconstruction- autologous tissue|Skin or nipple sparing mastectomy and immediate breast reconstruction with autologous tissue
223834775|NCT02557906|PROCEDURE|Breast reconstruction- implant + dermal sling/LD flap|Skin or nipple sparing mastectomy and immediate breast reconstruction using an implant and a dermal sling or a latissimus dorsi flap
223834776|NCT02460081|DRUG|PDA-002|
223834777|NCT02460081|DRUG|Placebo|
223834778|NCT00344370|DRUG|Pitavastatin|Pitavastatin 4 mg QD
223834779|NCT00344370|DRUG|Atorvastatin|Atorvastatin 40 mg
223834780|NCT03226457|DRUG|Empagliflozin 25mg|Empagliflozin (SGLT2 inhibitor) 25 mg once daily for 6 weeks
223834781|NCT03226457|DRUG|Placebo oral capsule|Capsules containing microcrystalline cellulose Ph Eur over encapsulated in a hard gelatine capsule shell to match the active comparator once daily for 6 weeks
223834782|NCT03226457|DRUG|Frusemide|Renal Physiology Test (RPT) days will be performed at week 1 and week 6 on each arm of this crossover trial. On these RPT days participants will undergo oral water loading (15mls/kg) and frequent urination at 30 minute intervals to gain a steady state diuresis. At a set time point, an intravenous bolus of furosemide at a dose of half the participant's usual loop diuretic dose will be administered.
223834783|NCT03413358|DRUG|Sheng Bai oral liquid|"Drug: Sheng Bai oral liquid 40 mL, oral use, thrice daily after screening on the same day in the second course of the chemotherapy.~Subjects will be treated for 2 courses"
223834784|NCT03413358|DRUG|Platinum-based two medicine (carboplatin / cisplatin) .|Using Platinum-based two medicine (carboplatin / cisplatin)
223834785|NCT04980235|DIAGNOSTIC_TEST|transperineal 3D ultrasound|All ultrasound volumes were acquired 7days after delivery and another examination 6weeks post-delivery by one experienced sonographers using a GEVoluson p8 (GE Healthcare) equipped with a 4-8-MHz curved array 3Dultrasound transducer
223834786|NCT05886686|DEVICE|Validation of the accuracy of a combined oximeter, thermometer and heart rate measurement device|Validation of the combined device measurements compared with standard of care devices
223834787|NCT00739635|DRUG|Neramexane mesylate|Double-blind treatment period of 17 weeks up to 75 mg Neramexane mesylate per day
223834788|NCT00739635|DRUG|Placebo|Double-blind treatment period of 17 weeks placebo
223834789|NCT03583541|BEHAVIORAL|HIV Risk Reduction|This is an intervention comprised of 4 sessions provided twice per week for 2 weeks of an evidence-based, HIV/STI risk reduction intervention.
223834790|NCT03583541|BEHAVIORAL|Financial Literacy|This evidence-based Financial Education Core Curriculum addresses the importance of savings, banking services, budgeting debt management. Undarga adaptation for FSWs included shortening and simplifying sessions while retaining core elements; adding weekly check-ins due to safety concerns FSWs share related to intervention participation, and safety planning as needed. We will further adapt sessions in months 1-6 to assure language and illustrative examples are culturally consonant, and to infuse BE principles consistent with HIVRR. During sessions 1 \& 2 we will include information on delay discounting, for example, learning to understand the tendency to prefer small immediate rewards over larger available at a later time; sessions 3 \& 4 will include details on economic utility; sessions 5 will contain information on salience (e.g. understanding occasions when women may minimize triggers to unsafe sex); and session 6 will address loss aversion.
223834791|NCT03583541|BEHAVIORAL|Mentorship|Mentorship. Mentorship to bridge the transition from FL and savings to a vocational change is a critical component of this intervention. These sessions are intended to support the transition -equipped with financial literacy and savings -to vocational, educational, employment or small business development training using matched savings. The mentorship sessions are adapted from the pilot study and integrate components (e.g., referral and linkage, coaching, exchange visits to model farmers) from income-generating activities provided by our collaborating partner, RTY. All sessions include check-in and individual attention. The first 4 sessions focus on identifying options for vocational, educational, employment or business development training. The second 4 sessions include invited experts in identified areas of interest by group members for more intensive time and attention to individualized needs to make the transition.
223834792|NCT03583541|BEHAVIORAL|Matched savings individual development account|A matched savings individual development account (hereafter IDA) is a savings account held at a local bank whereby deposits made by the woman are matched by the intervention to encourage savings and investment in skills and asset development. The accounts introduce women to financial management skills, introduce them to formal financial institutions, and by matching their deposits, incentivize women to save small amounts. Each woman will receive an IDA held in her own name. Women will be allowed and indeed encouraged to contribute up to 50,000 shillings (\~15 USD) per month towards their IDAs. The maximum amount of women's contribution to be matched will be an equivalent of US$15 per month for 10 months. During the intervention, monthly account statements will be generated for women to note their accumulated savings. During the intervention, women will have direct access to both their personal savings deposited in the accounts and the match provided by the study.
223834793|NCT01541618|OTHER|MSDX Complex-1 Biomarker test|MSDX Complex-1 Biomarker test
223834794|NCT05316168|DRUG|Bupivacaine HCl 0.5% Injectable Solution|During adductor canal block participants will receive 20cc of Bupivacaine HCl 0.5%
223834795|NCT05316168|DRUG|Dexamethasone|During adductor canal block participants will receive 2mg Dexamethasone
223834796|NCT05316168|PROCEDURE|Infiltration between Popliteal Artery and Capsule of the knee (iPACK)|Prior to closing the surgical wound participants will receive a local injections of 20cc 0.5% bupivacaine mixed with 2mg dexamethasone
223834797|NCT05316168|DRUG|Percocet 5Mg-325Mg Tablet|Participant will receive 20 Percocet 5/325mg tablets post surgery for pain control
223834798|NCT04102540|OTHER|Infographic intervention|Information visualizations (infographics) will be used to teach participants about HIV during study visits immediately following their normal clinic visits.
223834799|NCT03507829|DRUG|Human insulin isophane, Humulin N (Eli Lilly)|Human insulin isophane, Humulin N (Eli Lilly)
223834800|NCT03507829|DRUG|Standard of care|Sliding scale short acting insulin for hyperglycemia; Sulphonylurea for NODAT
223834801|NCT03507829|DRUG|Insulin lispro, Humalog (Eli Lilly) in insulin pump|Insulin lispro, Humalog (Eli Lilly) in insulin pump
223834802|NCT00649974|DRUG|Valacyclovir Hydrochloride Tablets 1000 mg|1000mg, single dose fasting
223834803|NCT00649974|DRUG|Valtrex® Tablets 1000 mg|1000mg, single dose fasting
223834804|NCT02460471|RADIATION|palliative radiation therapy|thermoplastic mask immobilization. CT in treatment position. radiation dose of 25 Gy in 5 daily fractions over one week 6 MV photons by intensity modulation. Target volume is the symptomatic tumour volume with a 5 mm margin
223834805|NCT05220124|DRUG|Live Combined (Bifidobacterium,Lactobacillus and Enterococcus Capsules)|420mg Live Combined (Bifidobacterium,Lactobacillus and Enterococcus Capsules) bid for 4 treatment cycles.
223835654|NCT02554435|BEHAVIORAL|5 A's counseling|Brief counseling to encourage behavioral change. The counseling is intended to be administered by a health care provider. The component of the counseling are assess, advise, agree, assist, and arrange.
223834806|NCT05140174|OTHER|Radical Healing and Internalized Stigma (RHIS) Training|8-hour RHIS training includes, readings that discuss radical healing and internalized stigma, access to didactic information regarding radical healing and internalized stigma. Therapists will role play certain scenarios that may involve minority stress experiences and discuss with the trainers different types of responses that could be therapeutic. The training will focus on the most up to date research regarding transgender mental health, minority stress, radical healing, and role-plays that focus on these processes.
223834807|NCT06363435|DEVICE|AI-based detection and quantification of suspected tumour/metastases in PSMA PET/CT scans|Tumour burden will be automatically calculated and stored in a database. The result of the AI-based measurements will not involve the handling of the patients
223834808|NCT04273503|BEHAVIORAL|Mentoring/educational session|12 mentoring/educational sessions focused on physical activity and healthy nutrition by Mayo Clinic experts.
223834809|NCT05950048|OTHER|The web-based breastfeeding counseling|To the web-based breastfeeding counseling/experimental group (n =33), during the first 6 months after birth, they will be directed to the web-based breastfeeding consultancy website. On this page, mothers will receive counseling on breastfeeding (written, visual, audio materials and telephone counseling) from birth. In addition, the Web-based breastfeeding counseling/experimental group will fill out data collection forms in the first 24 hours, 1st, 2nd, 4th and 6th months after delivery.
223834810|NCT02244593|OTHER|FAST MRI and mammography screening|Patients in this group will receive Breast MRI and annual mammography. Participants will complete 4 questionnaires at 3 time points: enrollment; 2 weeks after they receive their mammogram; 6 months after their mammogram.
223834811|NCT04079374|DRUG|Etanercept|Subcutaneous injections
223834812|NCT04079374|DRUG|Enbrel|Subcutaneous injections
223834813|NCT01821443|OTHER|Stereotactic radiosurgery (SRS)|"Dose \& prescription The dose will be prescribed to the isodose surface, which encompasses the margin of the metastasis (50-90% \[maximum=100%\]), as defined by target delineation on the imaging studies.~The prescribed dose is dependent on the prescription isodose volume (IDV). The prescription IDV is defined as the volume (cm3) that is encompassed by the prescription isodose line (IDL)."
223834814|NCT03142217|OTHER|Study of dysarthria in patients with Huntington's disease|Study of dysarthria in patients with Huntington's disease
223834815|NCT03372486|DRUG|Bupivacaine plus naloxone|Patients received 20 mL bupivacaine 0.5% plus 100 ng naloxone (1ml) in 2ml saline.(naloxone ampoule 0.4mg will dilute in 400ml of saline then 1ml of it will dilute in 10 ml saline, so each ml will have 100ng naloxone)
223834816|NCT03372486|DRUG|Bupivacaine|Patients will be injected ultrasound guided in their brachial plexus by 20 mL bupivacaine 0.5% plus 3 ml of saline
223834817|NCT00479037|DRUG|Full Length Parathyroid Hormone, PTH(1-84)|Once daily subcutaneous injection in the abdomen by self administration
223834818|NCT00479037|DRUG|Strontium Ranelate|The daily dose of 2 g (one sachet) strontium ranelate was to be mixed in a glass of water and taken immediately after mixing at bedtime at least 2 hours before or after intake of calcium, any food or drinks, other than water
223834819|NCT00280293|DRUG|Lamotrigine|Lamotrigine
223834820|NCT00280293|DRUG|Placebo|Placebo
223834821|NCT05655481|OTHER|Aerobic and Resistance training with rehabilitation|Effects of home telerehabilitation program improve functional capacity variables
223834822|NCT05655481|OTHER|Health education|Telehealth and guidelines for the practice of physical activity and health education
223834823|NCT00588003|DRUG|anastrozole|anastrozole 1mg/day 11 days before their surgery and to take the last dose of the oral endocrine agent (anastrozole) on the day before their surgery.
223834824|NCT00588003|OTHER|Placebo|No medication before surgery
223834825|NCT00178022|BEHAVIORAL|Case management and problem solving therapy|
223834826|NCT06504576|DRUG|Cilostazol 50 MG Oral Tablet|Two consecutive weeks of Cilostazol (50mg BID) two days after admission
223834827|NCT06504576|PROCEDURE|Conventional internal medicine treatment|Receives only conventional internal medicine treatment
223834828|NCT06478875|COMBINATION_PRODUCT|[68Ga]Ga-PentixaFor PET imaging|PET imaging of adrenal glands
223834829|NCT02981485|DEVICE|Fat Grafting|Treatment of breast cancer related lymphedema by fat grafting
223834830|NCT04934319|BEHAVIORAL|Balance and Proprioceptive Training|"* Step-by-step training (5 levels)~* 30 minute per training~* 3 times per week~* Four weeks"
223834831|NCT01375712|DIETARY_SUPPLEMENT|Fermented milk containing Lactobacillus casei strain Shirota|A fermented milk containing Lactobacillus casei strain Shirota, 65 ml for oral administration, 1 bottle per day for 8 weeks (56 days). One bottle of the drink contains: 42.9 kcal/182 kJ; less than 0.1 g of fat; 9.6 g of carbohydrate; 0.01 g of sodium; 0.9 g of protein; and at least 6.5 x 10\^9 colony-forming units of Lactobacillus casei strain Shirota.
223834832|NCT01375712|DIETARY_SUPPLEMENT|Placebo|Non-fermented milk without Lactobacillus casei strain Shirota, 65 ml for oral administration, 1 bottle per day for 8 weeks (56 days). One bottle of the drink contains: 42.9 kcal/182 kJ; less than 0.1 g of fat; 9.6 g of carbohydrate; 0.01 g of sodium; and 0.9 g of protein.
223834833|NCT03430128|DIETARY_SUPPLEMENT|IMPACT immunotherapy|Powdered formula that is pre-packaged in individual packets which the patients will be instructed to mix with water before consumption.
223834834|NCT03430128|DIETARY_SUPPLEMENT|ENSURE|Liquid milk formula available over the counter
223834835|NCT06302790|OTHER|Molli Suit Apply|Exopulse Mollii Suit is a neuromodulation application that has been extensively evaluated and is a reliable technique in patients with spasticity. Unlike many neurostimulation techniques that focus only on symptomatic muscles, Suit relieves spasticity and associated pain by stimulating the weakened antagonist of the spastic muscle. Its wearable structure is designed to manage spasticity and associated pain in both upper and lower extremities.
223834836|NCT03012217|OTHER|Observational Study|
223834837|NCT04450433|DIAGNOSTIC_TEST|aortic dissection and healthy people|Differential expression of metabolites in patients with aortic dissection and healthy people
223834838|NCT02834715|DIETARY_SUPPLEMENT|Stevia rebaudiana liquid extract|Sweetener made of liquid stevia self administered daily for 30 days
223834839|NCT03252678|OTHER|a book and videos about ACP|A book and three videos about advanced care planning are provided for self-education
223834840|NCT03252678|OTHER|a book and videos about pain control|A book and three videos about pain control for cancer patients are provided for self-education
223834841|NCT01273649|DEVICE|cryotherapy|cryotherapy is given with other physical training
223834842|NCT01458249|DRUG|eribulin mesylate|Administration of eribulin mesylate at a dose of 1.4 mg/m\^2 as an IV bolus infusion over 2-5 minutes on Days 1 and 8 of every cycle, where the duration of each cycle is 21 days.
223834843|NCT02116140|OTHER|[C11]Acetate and HED PET|
223834844|NCT04583319|DIAGNOSTIC_TEST|EasyCov POC|Saliva samples will be collected according to the sampling protocol defined each for EASYCOV test. The EasyCoV test will be performed at the beginning of the study before obtaining the routine RT- PCR test results. The operators performing this test will be blinded from the routine RT-PCR results.
223834845|NCT01348854|DEVICE|iFS Femtosecond Laser System|arcuate incisions placed with the iFS femtosecond laser
223834846|NCT05089110|PROCEDURE|blood sample|5 cm blood sample from COVID-19 patients
223834847|NCT04280328|DRUG|Ciforadenant|100 mg orally twice daily for 28-day cycles
223834848|NCT04280328|DRUG|daratumumab|"16 mg/kg administered intravenously as follows based on 28-day cycles:~* Cycles 1 - 2: Days 1, 8, 15, and 22~* Cycles 3 - 6: Days 1 and 15~* Cycles 7 - 24: Day 1"
223834849|NCT01345461|DEVICE|transcutaneous electrical muscle stimulation, (model DS7A, Digitimer, Welwyn, Garden City, Hertfordshire, UK)|two constant current high voltage stimulators delivered ten single stimuli twitches with biphasic square pulses at widths of 300 μs. A train generator was then switched on, triggering the delivery a 35 Hz current in bouts of 3 seconds periods separated by 1-second pause for a total of 40 tetanic contractions. In immediate succession to the tetanic contractions a second series of ten single twitch stimuli ended the protocol.
223834850|NCT06460012|BEHAVIORAL|STELLA-R Curriculum|The STELLA-R curriculum is presented utilizing the ABC analytic approach to address care recipient's distressing behaviors. Using the scaffold of the ABC pyramid, they will receive video instructions on how to fully define the Behaviors they want to address by observing, describing, and writing about them. The care partners will learn to identify the Activators, the triggers for the behaviors. Next, care partners will learn to consider what happens after the behaviors, the Consequences. This is an 8-week self-directed, online weekly curriculum.
223834851|NCT06460012|BEHAVIORAL|Unrestricted Access|Following the STELLA-R curriculum, care partners will receive 8 weeks of unrestricted access to all lessons and resources.
223834852|NCT06460012|BEHAVIORAL|Limited Access|Experimental and Waitlist Control group will experience 8 consecutive weeks of limited access to the STELLA-R website and resources. Waitlist Control will experience this from Week 1 to Week 8 while the Experimental Group will reach this phase from Week 17 to Week 24.
223834853|NCT04798105|BEHAVIORAL|Effects of tDCS of dlPFC on Probabilistic Selection Task|Predictors of Probabilistic Selection Task Performance including anodal tDCS of dlPFC, eye blink rate, extraversion and impulsiveness
223834854|NCT02064725|DRUG|Sodium cridanimod|Eligible patients will be enrolled into the study and administered sodium cridanimod (500 mg i.m./ twice a week) in combination with megestrol acetate (160 mg p.o./ day) or medroxyprogesterone acetate (200 mg p.o./ day).
223834855|NCT00684983|DRUG|Capecitabine|Given PO
223834856|NCT00684983|BIOLOGICAL|Cixutumumab|Given IV
223834857|NCT00684983|DRUG|Lapatinib Ditosylate|Given PO
223834858|NCT00684983|OTHER|Quality-of-Life Assessment|Ancillary studies
223834859|NCT03366883|COMBINATION_PRODUCT|Paclitaxel, Cisplatin Plus 5-FU (TCF)|preoperative chemotherapy with three cycles of TCF(Paclitaxel 135mg/m2 D1;Cisplatin 60mg/m2 D1 or 20mg/m2 D1-D3;5-fluorouracil 600mg/m2 D1-D5；repeated every 3 weeks)
223834860|NCT03366883|RADIATION|radiochemotherapy|preoperative radiochemotherapy (41.4 Gy/23 fractions or 40 Gy/20 fractions) with four cycles of TP(Paclitaxel 45mg/m2 on D1 and Cisplatin 20mg/m2 D1,repeated every week)
223835655|NCT02554435|DEVICE|Pedometer|The pedometer provides the participant feedback on their daily steps, activity time, distance traveled, and calories burned. Participants can review the feedback for the past 7 days.
223834861|NCT03807193|BEHAVIORAL|Self-selected treatment|The participants will select their own treatment material with the help of a written manual. The interventions possible to choose are all interventions used in standard cognitive behavior therapy for anxiety and depression.
223834862|NCT03807193|BEHAVIORAL|Predetermined treatment|The participants will be given a treatment program designed to address worry and generalized anxiety disorder. The program are based on newer forms of cognitive behavior therapy and include mindfulness and acceptance.
223834863|NCT03807193|BEHAVIORAL|Weekly support|The participants will have scheduled weekly support, once a week, during the treatment. The support till be delivered by students in clinical psychology.
223834864|NCT03807193|BEHAVIORAL|Support on demand|The participants will have support if and when they ask for it by themselves. If asked for the support will be delivered by students in clinical psychology.
223834865|NCT05015777|OTHER|Emil Jaques-Dalcroze's Eurhythimcs Exercise Program|"Training sessions took place twice a week for 45 minutes each over a period of 12 weeks. Each training included rhythmic exercises using the Jaques-Dalcroze Eurhythmics (JDE) method with piano accompaniment and electronically played music. Training sessions were conducted by a JDE specialist.~Exercises with the use of this method consist mainly in the repetition of preset musical sequences using body movements. In addition to the physical layer, the cognitive layer was equally important: while performing a given movement exercise, participants often had to focus in order to react appropriately to additional tasks, such as changes in sound pitch and rhythm of the piece."
223834866|NCT05452629|BEHAVIORAL|Mindfulness induction (MI)|In the MI condition, participants were guided to focus on present experiences regarding the thoughts, emotions and sensations through the three classic mindfulness exercises (i.e., focused breathing, meditation, and body scanning). The duration of MI was 30-minutes.
223834867|NCT05452629|BEHAVIORAL|Relaxation (RI)|In the RI condition, participants were guided to relax each muscle group following the audio for 30-minutes.
223834868|NCT06396390|DRUG|Progestin|In this regimen, Dydrogesterone (Duphaston©; 10mg; Deva Holding, Tekirdag/Turkiye) 3x1 PO will be started on day 2 of menstrual cycle and will be continued until the trigger day. The patient's dosage will be tailored based on their BMI, AMH value, and the number of follicles observed during the ultrasound examination on the 2nd day of the menstrual cycle. For triggering, Choriogonadotropin-α (Ovitrelle©, 250 mcg/0.5 mL, Merck Serono S.p.A., Bari/Italy) 1 amp SC + Triptorelin Acetate (Gonapeptyl©, 0.1mg/mL, Ferring GmbH, Kiel/Germany) 2 amp SC will be used. All oocytes picked-up will be frozen.
223834869|NCT06396390|DRUG|GnRH antagonist|In this regimen, Cetrorelix (Cetrotide©, 250 mcg/mL, Pierre Fabre Medicament Production, Idron, France) 1x1 SC will be started on day 7 of menstrual cycle and will be continued until the trigger day. For triggering, Choriogonadotropin-α (Ovitrelle©, 250 mcg/0.5 mL, Merck Serono S.p.A., Bari/Italy) 1 amp SC + Triptorelin Acetate (Gonapeptyl©, 0.1mg/mL, Ferring GmbH, Kiel/Germany) 2 amp SC will be used. All oocytes picked-up will be frozen.
223834870|NCT02973126|PROCEDURE|FFRct and SPECT|enable the comparison of diagnostic performance of FFRct and SPECT in subjects with suspected stable CAD after abnormal SPECT imaging who have no contraindications to coronary computed tomography angiography (CCTA).
223834871|NCT00514072|BIOLOGICAL|BCG vaccine|given intradermally
223834872|NCT00514072|BIOLOGICAL|prostate cancer vaccine ONY-P1|given intradermally
223834873|NCT00514072|OTHER|placebo|given intradermally
223834874|NCT03093090|DIETARY_SUPPLEMENT|Water|6 oz
223834875|NCT03093090|DIETARY_SUPPLEMENT|Parmalat™ Whole Milk|6 oz
223834876|NCT03093090|DIETARY_SUPPLEMENT|Similac Pro-Advance™|6 oz
223834877|NCT03093090|DIETARY_SUPPLEMENT|Ensure Plus™|6 oz
223834878|NCT03093090|DRUG|Furosemide 20 MG|Furosemide is a loop diuretic (water pill) that prevents your body from absorbing too much salt.
223834879|NCT00050401|DRUG|MERREM I.V. 2g as a 3 hour infusion every 8 hours|
223834880|NCT00050401|DRUG|vancomycin I.V. 1 g every 12 hours|
223834881|NCT00050401|DRUG|tobramycin I.V. 5 mg/kg every 24 hours|
223834882|NCT00050401|DRUG|MERREM I.V. 1g as a 30 minute infusion every 8 hours|
223834883|NCT00050401|DRUG|MERREM I.V. 500 mg as a 3 hour infusion every 8 hours|
223834884|NCT00594932|DRUG|mycophenolate mofetil|First treatment month: mycophenolate mofetil ascending doses orally Second treatment month to end of study: mycophenolate mofetil 3 gms/day (or less if tolerance issues arise)
223834885|NCT00594932|OTHER|placebo|"oral placebo will be given in ascending doses during the first month and at full dose during the second and third month (or at lower dose if tolerance issues warrant). During the fourth month mycophenolate mofetil will be given in ascending doses to 3 gms/day (or less if tolerance issues arise) and continues until the end of the study at 6 months."
223834886|NCT01094171|BIOLOGICAL|Poliorix TM|Intramuscular administration, 3 doses
223834887|NCT01094171|BIOLOGICAL|Infanrix TM|Intramuscular administration, 3 doses
223834888|NCT04571632|DRUG|Avelumab|"Avelumab (200mg/10mL solution) will be administered by intratumoral injection at a maximum total dose of 40 mg (= 2 ml of a 200mg/10ml solution) on day 1 followed by a subsequent intratumoral injections on day 15, 29, 43, 57 and 71.~Total administered dose of avelumab (200mg/10mL solution) will be up to 2.0 mL per treatment. Injected volume per lesion will range from 0.05 mL for lesions \< 0,5 cm to 2.0 mL for lesions \> 5 cm in longest diameter.~Injection of all lesions in individual patients will not be required."
223834889|NCT04571632|DRUG|Ipilimumab 5 MG/ML|"Ipilimumab (50mg/10mL solution) will be administered by intratumoral injection at a maximum total dose of 10 mg (= 2 ml of a 50mg/10ml solution) on day 1 followed by a subsequent intratumoral injections on day 15, 29, 43, 57 and 71.~Total administered dose of ipilimumab (50mg/10mL solution) will be up to 2.0 mL per treatment. Injected volume per lesion will range from 0.05 mL for lesions \< 0,5 cm to 2.0 mL for lesions \> 5 cm in longest diameter.~Injection of all lesions in individual patients will not be required. Determination of ipilimumab (50mg/10mL solution) injection volume based on lesion size"
223834890|NCT04571632|DRUG|Pembrolizumab 100 MG in 4 ML Injection|The first administration of pembrolizumab 200 mg (100 mg/4mL solution) by the intravenous route during 30 minutes will be administered on day 1. The second administrations of pembrolizumab 200 mg will be administered by a 30 minutes intravenous infusion on day 21, and thereafter every 21 days (or up to ± 3 days before or after the scheduled date if necessary) days.
223834891|NCT04571632|OTHER|CD1c (BDCA-1)+ / CD141 (BDCA-3)+ myDC|"CD1c (BDCA-1)+ / CD141 (BDCA-3)+ myDC will be administered by intratumoral injection in the lesions that were injected by avelumab en ipilimumab on day 1 (approximately 24 hours after intratumoral injection of avelumab en ipilimumab).~The total administered CD1c (BDCA-1)+/ CD141 (BDCA-3)+ myDC volume will be up to 4.0 mL per intratumoral treatment session. Injected volume per lesion (skin-, soft tissue or lymph-node metastases) will range from 0.1 mL for lesions \< 0,5 cm to 4.0 mL for lesions \> 5 cm in longest diameter. Injection of all lesions in an individual patient will not be required.~The determination of CD1c (BDCA-1)+ / CD141 (BDCA-3)+ myDC injection volume is based on lesion size.~When lesions are clustered together, they are injected as a single lesion according to the table for determination of CD1c (BDCA-1)+ / CD141 (BDCA-3)+ myDC injection volume based on lesion size."
223834892|NCT05426382|DEVICE|A digital care solution for patients with NAFLD|A digital solution that provides remote symptom monitoring and support of healthy lifestyle choices through tasks that are made more attractive with gamification and rewards.
223834893|NCT06237868|DEVICE|rTMS Active|The participants undergo Active rTMS, approximately 10-15 min and then complete tasks and questionnaires.
223834894|NCT06237868|DEVICE|rTMS Sham|The participants undergo Sham rTMS, approximately 10-15 min and then complete tasks and questionnaires.
223834895|NCT06081530|DRUG|BI 3802876|BI 3802876
223834896|NCT06081530|DRUG|Placebo matching BI 3802876|Placebo matching BI 3802876
223834897|NCT05813925|DRUG|Cagrilintide|Participants will receive 2.4 mg cagrilintide s.c. OW after a dose escalation period of 16 weeks for 52 weeks
223834898|NCT05813925|DRUG|Semaglutide|Participants will receive 2.4 mg semaglutide s.c. OW after a dose escalation period of 16 weeks for 52 weeks
223834899|NCT05813925|DRUG|Placebo Semaglutide|Participants will receive placebo matched to semaglutide
223834900|NCT00319605|DRUG|Levetiracetam|
223834901|NCT00005973|DRUG|BMS-214662|Given IV
223834902|NCT00005973|OTHER|laboratory biomarker analysis|Correlative studies
223834903|NCT01219595|OTHER|Sweetened, dried cranberries|Women in Arm 1 will consume one serving (1/3 cup; 42 g) of sweetened, dried cranberries each day for two weeks.
223834904|NCT01219595|OTHER|Strawberry Fruit Pieces|1 serving (1/3 cup; 42 g) of strawberry fruit pieces each day for three separate, two-week periods. Each two week period will be separated by a two-week interval.
223834905|NCT01219595|OTHER|Sweetened, dried cranberries|1 serving (1/3 cup; 42 g) of sweetened, dried cranberries each day for three separate, two-week periods. Each two week period will be separated by a two-week interval.
223834906|NCT01219595|OTHER|Sweetened, dried cranberries|1 serving (1/3 cup; 42 g) of sweetened, dried cranberries each day for one 4-week period.
223834907|NCT01219595|OTHER|Strawberry Fruit Pieces|1 serving (1/3 cup; 42 g) of strawberry fruit pieces each day for one 4-week period.
223834908|NCT01219595|OTHER|Observation|Subjects in the non-UTI susceptible group will have one visit where one vaginal and one rectal swab will be collected.
223834909|NCT01927718|DRUG|Thalidomide|100 mg by mouth daily for 28 days in a 28 day cycle.
223834910|NCT01927718|DRUG|Lenalidomide|Lenalidomide continued by mouth at the previous dose of 5 mg daily for 21 days on a 28 day cycle, 5 mg daily for 28 days on a 28 day cycle, 10 mg daily for 28 days on a 28 day cycle, or 15 mg daily for 28 days on a 28 day cycle.
223834911|NCT01927718|BEHAVIORAL|Questionnaires|Questionnaire completion at screening, once a month for the first 6 months, then every other month while on study.
223834912|NCT00730301|PROCEDURE|Bronchoscopic Lung Volume Reduction (BLVR)|Procedure under general anesthesia.
223834913|NCT01009047|DRUG|Paliperidone extended release (ER)|Paliperidone ER will be administered as oral capsule at a dose of 6 mg for 1 week and then will be administered at a dose of either 3, 6 or 9 mg up to Week 26, once daily in the morning.
223834914|NCT01009047|DRUG|Aripiprazole|Aripiprazole will be administered as oral capsule at a dose of 2 mg on Days 1 and 2, 5 mg on Days 3 and 4, 10 mg Days 5, 6 and 7; and then will be administered as a dose of either 5 or 10 or 15 mg up to Week 26, once daily in the morning.
223834915|NCT06303336|OTHER|NMES with Dynamic Bracing|The group will receive NMES along with dynamic bracing
223834916|NCT06303336|OTHER|NMES without Dynamic Bracing|The participants will receive NMES on the lower extremity
223834917|NCT06303336|OTHER|Dynamic Bracing Only|This group will receive dynamic bracing only on the lower limb.
223834918|NCT05758363|DIETARY_SUPPLEMENT|Consumption of dietary supplement.|Consumption of a dietary supplement rich in glutathione, selenium, zinc, vitamin D and EPA/DHA. 1 capsule per day of the dietary supplement with breakfast.
223834919|NCT05758363|OTHER|Consumption of control product|Consumption of 1 capsule per day of control product of identical appearance with breakfast.
223834920|NCT01676220|DRUG|HOE901-U300 (new formulation of insulin glargine)|HOE901-U300 (new insulin glargine 300 units per milliliter \[U/mL\]) subcutaneous (SC) injection once daily (evening) for 12 months on top of non-insulin antihyperglycemic drug(s). Dose titration seeking fasting plasma glucose 4.4-5.6 millimole per liter (mmol/L) (80 - 100 milligram per deciliter \[mg/dL\]).
223834921|NCT01676220|DRUG|Lantus (insulin glargine)|Lantus (HOE901-U100, insulin glargine 100 U/mL) SC injection once daily (evening) for 12 months on top of non-insulin antihyperglycemic drug(s). Dose titration seeking fasting plasma glucose 4.4-5.6 mmol/L (80 - 100 mg/dL).
223834922|NCT03575637|DRUG|Olanzapine|Patients who have failed first-line treatment of advanced gastric cancer receive second-line treatment with paclitaxel regimen and olanzapine 5 mg QD.
223834923|NCT04394741|DEVICE|Intervention-Dry Needling|"Deep Dry Needling into the site of the latent Trigger Point of the upper trapezius muscle.~1 session in upper trapezius muscle moving the needle up and down ten times."
223834924|NCT04394741|DEVICE|Control-Dry Needling|"Sham Dry Needling into the site of the latent Trigger Point of the upper trapezius muscle with non-penetrating needles~1 session in upper trapezius muscle moving the needle up and down ten times."
223834925|NCT01557972|PROCEDURE|Blood pressure measurement based on HBP or CBP|To clarify which of HBP or CBP provides the stronger prediction power for the outcomes.
223834926|NCT01557972|PROCEDURE|Blood pressure measurement based on HBP or CBP|To clarify which of HBP or CBP provides the stronger predictive power for the outcomes
223834927|NCT03511079|BEHAVIORAL|Music|Music will be delivered through Pandora Plus radio via patient's computer or smartphone. The patient will choose a favorite song to create a playlist which will be used for the duration of the entire study. The subgenre of the initial song will be recorded.
223834928|NCT00158522|DRUG|pegylated interferon alpha2a|
223834929|NCT05918315|PROCEDURE|Buccal mucosa substitution urethroplasty|Use of buccal mucosa as a substitution for urethroplasty
223834930|NCT01366651|DRUG|Doripenem|Type=exact number, unit=mg/kg, number=30, form=solution for injection, route=intravenous use, every 8 hours for 2 days (total of 5 doses) for patients 12 weeks to \<1 year of age.
223834931|NCT01366651|DRUG|Doripenem|Type=exact number, unit=mg/kg, number=10, form=solution for injection, route=intravenous use, every 8 hours for 2 days (total of 5 doses) for patients \<12 weeks of age.
223834932|NCT02242240|DRUG|Formoterol twice daily|
223834933|NCT02242240|DRUG|Formoterol once daily|
223834934|NCT02242240|DRUG|Tiotropium once daily|
223834935|NCT02242240|DRUG|Placebo|
223834936|NCT04136652|PROCEDURE|CO2 laser- treatment (DEKA SmartXide2 Laser System, MonaLisa Touch|women will receive a series of three treatments using a fractional (pulsed) CO2 laser system (SmartXide2 MonaLisa Touch, DEKA M.E.L.A Srl, Florence, Italy), each performed in an outpatient setting without analgesia. A tubular laser-probe is inserted in the vaginal canal until reaching the vaginal vault. A burst of laser pulses is transmitted through the probe and deflected at 90degrees in four directions towards the vaginal wall, then rotated 45degree for a second burst of pulses. Guided by markings on the probe, it is withdrawn 4mm and the procedure is repeated until reaching the introitus. Treatment parameters include power 30W, dwell time 1000us, 1000um spacing, using normal scan mode, with Smartstack setting for 1 at first application and 3 for the next two applications.
223834937|NCT06339151|DRUG|Dexamethasone before surgery|Dexamethasone 0.15 mg/kg IV before surgery
223834938|NCT06339151|DRUG|Dexamethasone before and 12 hours after surgery|Dexamethasone 0.15 mg/kg IV before surgery Dexamethasone 0.15 mg/kg IV at 12 hours post operation
223834939|NCT06339151|DRUG|Dexamethasone before and 24 hours after surgery|Dexamethasone 0.15 mg/kg IV before surgery Dexamethasone 0.15 mg/kg IV at 24 hours post operation
223834940|NCT00000719|DRUG|Zidovudine|
223834941|NCT00000719|DRUG|Zalcitabine|
223834942|NCT01448525|DRUG|bimatoprost ophthalmic solution 0.03%|One drop of bimatoprost ophthalmic solution 0.03% applied to the upper eyelid margin of both eyes once daily in the evenings for 16 weeks.
223834943|NCT01448525|DRUG|bimatoprost vehicle solution|One drop of bimatoprost vehicle solution applied to the upper eyelid margin of both eyes once daily in the evenings for 16 weeks.
223834944|NCT03875911|DRUG|Mitomycin C|Three delivery methods of Mitomycin-C in Trabeculectomy
223834945|NCT03508804|DRUG|Lidocaine-Prilocaine Cream|10ml of vaginally self-administered cream composed of an eutectic mixture of 2.5% lidocaine, 2.5% prilocaine
223834946|NCT03508804|DRUG|Placebo Cream|10ml of vaginally self-administered placebo cream
223834947|NCT03508804|DRUG|1% Lidocaine Paracervical Block|Paracervical block of 10ml of 1% lidocaine
223834948|NCT00119119|DRUG|pentoxyphilline|
223834949|NCT00119119|DRUG|tocopherol|
223834950|NCT05595330|BEHAVIORAL|Lymphedema prevention protocols|"Coming for surgery: A PPT lecture; 2. A seminar; 3. Patients were given a lymphedema prevention brochure; 4. Diary cards for exercise is given and instruct patients to fill out daily; 5. Establish a WeChat group.~The first chemotherapy:1. Review diary card and provide guidance and education. 2. A PPT lecture; 3. A seminar; 4. Play functional exercise videos in the recovery room; 5. Rehabilitation volunteers come to the ward to form mutual help groups with patients under the guidance of subject team members; 6. Instruct regular exercise and avoid behaviors that can lead to lymphedema. 7. Ask about the exercise and whether there is any swelling and discomfort and give guidance.~The second chemotherapy: 1. A PPT lecture; 2. A seminar; 3. Play functional exercise videos in the recovery room.~The third chemotherapy: 1. Routine nursing; 2. Assess patients' knowledge of lymphedema prevention and exercise compliances; 3. Play functional exercise videos in the recovery room."
223834951|NCT03824938|DRUG|Aspirin 650mg Oral Capsule|A 650mg dose of aspirin is administered in the laboratory one hour before participant completes a maximal exercise test.
223834952|NCT03824938|DRUG|Acetaminophen Tablet 650mg|A 650mg dose of acetaminophen is administered in the laboratory one hour before participant completes a maximal exercise test.
223834953|NCT03824938|OTHER|Placebo|A placebo pill is administered in the laboratory one hour before participant completes a maximal exercise test.
223834954|NCT05126459|COMBINATION_PRODUCT|Regimen 1|Administer orally after informed consent obtained prior to any dental procedure. Hydroxyzine (1.5- 2mg/kg) + Meperidine (1.5 -2 mg/kg) + Midazolam (0.5- 0.75 mg/kg) In combination with oral drugs stated above, administeration via inhalation of Nitrous oxide/oxygen (30-50% N2O/ 70-50% O2) via inhalation.
223834955|NCT05126459|COMBINATION_PRODUCT|Regimen #2|Administer orally after informed consent obtained prior to any dental procedure. Hydroxyzine (1.5 - 2mg/kg) + Meperidine (1.5 -2 mg/kg). Administer Nitrous oxide/oxygen (30-50% N2O/ 70-50% O2) via inhalation.
223834956|NCT05126459|COMBINATION_PRODUCT|Regimen #3|Administer orally after informed consent obtained prior to any dental procedure. Hydroxyzine (1.5 - 2mg/kg) + Midazolam (0.5- 0.75 mg/kg). Administer Nitrous oxide/oxygen (30-50% N2O/ 70-50% O2) via inhalation.
223834957|NCT04874064|OTHER|Liquid Biopsy|Blood collection and access to residual tumor.
223834958|NCT01304043|DRUG|chemotherapies protocols|Cisplatine 20 mg/m² IV Etoposide 100 mg/m² IV Bléomycine 30 mg IV
223834959|NCT01990300|DRUG|Alogliptin/Pioglitazone|Alogliptin/Pioglitazone combination tablets
223834960|NCT00720005|DEVICE|Aspheric Acrysof ReSTOR intraocular lens|Bilateral implantation of Aspheric Acrysof ReSTOR
223834961|NCT00953420|DRUG|Docetaxel|60 mg/m2 IV on Day 1
223834962|NCT00953420|DRUG|Carboplatin|Target AUC of 5 (mg/ml x min) on Day 1
223834963|NCT00953420|DRUG|Dexamethasone|5 mg/m2/dose (max of 8 mg/dose) po q hs on Day 0, and q am and hs on Day 1
223834964|NCT00953420|BIOLOGICAL|EBV-specific cytotoxic T lymphocytes|1 x 10e8 cells/m2 IV over 1 to 5 min
223834965|NCT00953420|BIOLOGICAL|G-CSF or Peg-GCSF|If needed per dose modification guidelines: Peg-GCSF 0.1 mg/kg ≤ 45 kg; 6 mg for \> 45 kg subcutaneous on Day 2 or GCSF 5 mcg/kg/day (max of 600 mcg) subcutaneous to start 24 hours after carboplatin administration until ANC \> 2500 cells/ul x 2 days after nadir.
223834966|NCT00255229|DRUG|Glutamine|Glutamine 10 g four times daily starting two days before treatment for six days in total
223834967|NCT00255229|OTHER|Placebo|Glutamine placebo
223834968|NCT03296618|DRUG|NSI-566|Dosing will consist of a one-time stereotactic, intracranial injection of a hNSC line, NSI-566, ranging from 1.2×107 cells to 8×107 cells, as tolerated.
223834969|NCT02571439|PROCEDURE|Surgical TAP block|surgeon administered TAP block
223834970|NCT02571439|PROCEDURE|Conventional TAP block|Anesthesiologist administered TAP block
223834971|NCT02571439|DRUG|0.5% ropivacaine|20ml of 0.5% ropivacaine is used to perform the TAP block
223834972|NCT01719640|DRUG|infusion of MSCs|infusion of MSCs
223834973|NCT01719640|DRUG|infusion MCs|infusion of MCs
223834974|NCT01719640|DRUG|insulin|intensive insulin care
223834975|NCT04607473|DEVICE|automated breast ultrasound (ABUS)|Both HHUS and ABUS will be performed on each patient for preoperative staging. Breast radiologists each independently will read HHUS and ABUS images obtained from one patient. The radiologists will be blinded to the findings of the other US mode.
223834976|NCT01250249|BIOLOGICAL|BCG Vaccine IP - Serum Institute of India|0.1 ml for adults and children aged 1 month and over 0.05 ml for infants under 1 month of age
223834977|NCT04056728|BIOLOGICAL|Eupenta Inj.|fully liquid pentavalent vaccine, Adsorbed Diphtheria-Tetanus-whole-cell Pertussis-Hepatitis B (rDNA \[recombinant-deoxyribonucleic acid\])-Haemophilus influenzae type b conjugate vaccine single dose 0.5 mL/vial The vaccine is given at 6, 10 and 14 weeks of age in infants.
223834978|NCT00555789|DRUG|AEB071|200mg oral b.i.d.
223834979|NCT00555789|DRUG|mycophenolic plus tacrolimus|720mg b.i.d. 2yrs
223834980|NCT04496167|DRUG|EN3835|Collagenase clostridium histolyticum
223834981|NCT04496167|DRUG|Placebo|Placebo comparator
223834982|NCT03085121|PROCEDURE|Distal femoral resection in total knee arthroplasty|EM and IM alignment systems are used to make the distal femoral cut in a random order.
223834983|NCT06381037|BEHAVIORAL|"How to improve your strengths and quality of life."|"The intervention program How to improve your strengths and quality of life consists of 8 individual sessions. The sessions take place weekly, so the total duration of the program is 8 weeks. Each session lasts approximately 1 hour. The sessions will be held both in person and online.~The sessions are:~* Session 1: Introduction to quality of life and personal strengths.~* Session 2: Self-fulfillment.~* Session 3: Pleasure.~* Session 4: Autonomy and control.~* Session 5: Family functioning and assertive communication.~* Session 6: Resilience.~* Session 7: Experiential acceptance.~* Session 8: Gratitude and closing of the workshop."
223834984|NCT03386760|DEVICE|Laser Utilisation PicoSecond|"Laser utilisation for tattoo depigmentation~1 session every month for a total of 3 sessions"
223834985|NCT03386760|DEVICE|Laser Utilisation Nano-second|"Laser utilisation for tattoo depigmentation~1 session every month for a total of 3 sessions"
223834986|NCT02712840|PROCEDURE|Freeze-All Protocol|All good morphologic quality blastocysts are vitrified on day 5 or 6. The best quality vitrified blastocyst frozen on day 5 will be warmed and transferred in a subsequent cycle.
223834987|NCT02712840|PROCEDURE|Fresh Protocol|Participants receive fresh embryo transfer of best morphologic quality blastocyst on day 5 and vitrification of all good quality supernumerary blastocysts.
223834988|NCT00925340|BEHAVIORAL|Family Check Up|The Family Check-Up provides a thorough assessment of individual family strengths and weaknesses and utilizes principles of motivational interviewing to encourage families to change.
223834989|NCT00925340|BEHAVIORAL|Psychoeducation|Psychoeducation regarding teen alcohol and drug use in general, along with ways parents can help their children stay safe from using alcohol or drugs.
223834990|NCT03869060|BIOLOGICAL|Dengue-1 Virus-Live Virus Human Challenge (DENV-1-LVHC)|Dengue subtype 1 Challenge Virus (DENV-1) strain 45AZ5
223834991|NCT02298205|OTHER|Asthma controller medication (Beclomethasone) adjustment strategy|The participant will adjust the dose of Beclomethasone based on symptoms
223834992|NCT02298205|OTHER|Provider-based adjustment|The provider will adjust the dose of Beclomethasone based on the participant's asthma control at their encounter with them
223834993|NCT03559439|BIOLOGICAL|CD19 CAR T|CD19 CAR T cells transduced with a lentiviral vector to express anti-CD19 scFv CD3z:CD28 administered by IV infusion. Subjects will receive 0.1-10 x 10\^6 transduced CAR T cells as a split dose over three days as follows:Day 1, 10% fraction, Day 2, 30% fraction, Day 3, 60% fraction.
223834994|NCT02560740|DIETARY_SUPPLEMENT|PerOx Quench|By 1 week pretreatment of PerOx Quench and following 4 weeks taken to decrease the CIPN incidence.
223834995|NCT02560740|DIETARY_SUPPLEMENT|PerOx Quench Placebo|By 1 week pretreatment of Placebo and following 4 weeks taken to record the CIPN incidence.
223834996|NCT02514980|DRUG|Bupivacaine|Infraorbital nerve block using bupivacaine 0.25% on each side.
223834997|NCT02514980|DRUG|Ketamine|Infraorbital nerve block using 0.5mg/kg ketamine on each side.
223834998|NCT00681187|DRUG|lanreotide (Autogel formulation)|90 mg or 120 mg once every 28th day
223834999|NCT03508102|DRUG|remifentanil|the effects of remifentanil on the average value of BIS at the time period of before induction , induction , intubation , skin incision, peritoneum incision, uterine incision, and delivery
223835000|NCT02210962|DIETARY_SUPPLEMENT|essential fatty acids|Yellow capsules containing eicosapentaenoic acid, docosahexaenoic acid (active)
223835001|NCT02210962|DIETARY_SUPPLEMENT|olive oil|Yellow capsules containing olive oil (placebo)
223835002|NCT04893070|OTHER|Questionnaires COVID+|"* 1 questionnaire on COVID-19 symptomatology and quality of life 12 months after COVID-19 first symptoms~* 1 questionnaire on quality of life 18 months after COVID-19 first symptoms"
223835003|NCT04893070|OTHER|Questionnaires COVID-|"* 1 questionnaire on quality of life at enrollment~* 1 questionnaire on quality of life 6 months after enrollment"
223835004|NCT03647839|DRUG|Nivolumab 10 MG/ML|Nivolumab will be supplied free of charge by Bristol-Myers Squibb (BMS) as sterile liquid in 10mL glass vials.
223835005|NCT03647839|DRUG|BNC 105|BNC105 will be provided free of charge by Bionomics, as a sterile solution of BNC105P. BNC105P is a clear, colorless to yellow liquid presented in a clear glass vial and is intended to be diluted with commercially available sterile 0.9% saline prior to IV administration.
223835006|NCT03647839|DRUG|BBI608|BBI-608 will be supplied free of charge by Boston Biomedical as capsules.
223835007|NCT05345912|DRUG|CG-745 IV Solution|CG-745 IV: Supplied as 125 mg/vial Administered intravenously, once, approximately 9 AM local time in fasted condition, over 60 min infusion
223835008|NCT05345912|DRUG|CG-750 125mg capsule|CG-750 capsule: Supplied as 125 mg/capsule Administered orally, once, approximately 9 AM local time in fasted condition except for fed condition in Cohort 2, period 3
223835009|NCT05345912|OTHER|PO Placebo|PO Placebo: Supplied as placebo capsule (same appearance as in CG-750 Administered orally, once, approximately 9 AM local time in fasted condition except for fed condition in Cohort 2, period 3
223835010|NCT05345912|OTHER|IV Placebo: 0.9 % normal saline|IV Placebo: 0.9 % normal saline Administered intravenously, once, approximately 9 AM local time in fasted condition, over 60 min infusion
223835011|NCT00416923|BIOLOGICAL|rituximab|
223835012|NCT00549822|DRUG|Letrozole|Treatment is intermittent with possible breaks between each 28 day treatment cycle if CA 15-3 or CA 27.29 level that has decreased by at least 50% of that individual patient's baseline or peak level on firstline letrozole or anastrozole therapy or has decreased into the normal reference range per institutional parameters. Letrozole or anastrozole therapy will be interrupted until CA 15-3 or CA 27.29 levels rise by at least 25% above trough CA 15-3 or CA 27.29 level. If the trough level is in the normal reference range then the CA 15-3 or CA 27.29 must rise into the normal reference range.
223835013|NCT00166634|PROCEDURE|Ambulatory Blood Pressure Monitoring (ABPM)|
223835014|NCT04019119|BEHAVIORAL|Digital intervention|The information group will receive through a mobile application tips to reduce sedentary lifestyle and promote healthy living habits.
223835015|NCT06344611|OTHER|Other|It is an observational study. Subjects will receive the treatment as per institute protocol.
223835016|NCT00182663|DRUG|clarithromycin|Given PO
223835017|NCT00182663|DRUG|thalidomide|Given PO
223835018|NCT00182663|DRUG|dexamethasone|Given PO
223835019|NCT04948879|PROCEDURE|Vascular resection/reconstruction|The resection of a major blood vessel with or without reconstruction
223835020|NCT00743522|DEVICE|ICD/ CRT-D|Cardiac device
223835021|NCT06279754|DRUG|Recombinant Human Endostatin Injection|Recombinant Human Endostatin Injection：210 mg, intravenous infusion for 72 hours, once every three weeks cycle Evafolimab Injection：Subcutaneous injection on day 1, 8, and 15, once every three weeks cycle
223835022|NCT02788006|DRUG|Regorafenib 160 mg|
223835023|NCT05047562|OTHER|Pilates Group|16 Pilates exercise sessions twice a week for 2 months.
223835024|NCT05047562|OTHER|Segmental Stabilization group|16 sessions of segmental stabilization exercises, 2 times a week for 2 months.
223835025|NCT02951299|DRUG|Pentoxifylline 400Mg Tablet|Investigators with AKI will received oral pentoxifylline (400 mg) three times a day for 14 days or no pentoxifylline according to their decision.
223835026|NCT05521594|PROCEDURE|Fine Needle Aspiration Cytology|Comparison between FNAC and post operative specimen after thyroid surgery
223835027|NCT03859336|DEVICE|Transdermal Neuromodulation Stimulation|The TEN device administers a tuned high frequency electrical stimulation delivered to the cervical plexus (C2-C4) on the back of the neck for 20 minutes. This stimulation will activate common trigeminovagal pathways modulating noradrenergic signaling to attenuate sympathetic activity. This stimulation can subsequently regulate the activity of several deep-brain nuclei within the ascending reticular activating system (RAS). Nuclei in the RAS regulate powerful neuromodulators like norepinephrine (NE), acetylcholine (ACh), and serotonin (5-HT). The investigators will examine whether this modulation from TENS will decrease anxiety and improve sleep quality in the study participants.
223835028|NCT05375136|OTHER|Non-interventional|No intervention will be administered.
223835029|NCT04696848|DRUG|CKD-516 plus Durvalumab|"Stage 1 : dose escalation durvalumab (1500 mg Q4W) in combination with CKD-516 at 1 of 3 planned dose levels (9, 11, or 13 mg/m2 twice a week for 3 weeks in each cycle, Q4W).~Stage 2 : durvalumab (1500 mg Q4W) in combination with CKD-516 at recommended phase 2 dose (twice a week for 3 weeks in each cycle, Q4W)."
223835030|NCT03927872|OTHER|blood biomarkers|assessment of serum BNP, D-Dimer and CK-MB and CRP and globulin /albumin ratio stroke outcome
223835031|NCT02269943|DRUG|CC-486|
223835032|NCT02694614|BEHAVIORAL|smartphone-assisted dietary coaching|
223835033|NCT00570258|DRUG|Fulvestrant|Fulvestrant: 250 mg IM Q 4 weeks
223835034|NCT00570258|DRUG|erlotinib|150 mg PO QD
223835035|NCT00570258|DRUG|Fulvestrant|250 mg IM Q 4 weeks
223835036|NCT00570258|DRUG|Placebo|Placebo 150 mg PO QD
223835037|NCT02145481|BEHAVIORAL|Decision Aid|Decision aid describing treatment choices for patients with coronary artery disease.
223835038|NCT02145481|BEHAVIORAL|CAD Education|Education for patients with coronary artery disease
223835039|NCT00422396|DRUG|Fenofibrate (drug)|
223835040|NCT03436121|DRUG|Ketamine|"Ketamine is a medication approved by the US Food and Drug Administration (FDA) for anesthesia, sedation, and post-surgical pain treatment. It is not approved for emergency patients complaining of pain but is often used off-label. Ketamine may be useful for acute pain management and in treatment of depressed mood. The purpose of this study is to determine whether a single low dose of ketamine can relieve pain and reduce negative mood for 2 weeks after emergency department (ED) treatment."
223835041|NCT03436121|DRUG|Midazolam|In this study, all patients will also receive midazolam. Midazolam is a sedative that typically makes people feel relaxed and is intended to increase comfort with ketamine and reduce anxiety.
223835042|NCT03436121|DRUG|Placebo|In this study, patients in the active comparator group will receive midazolam first, then placebo. A placebo is an inactive solution that looks like the study drug, but contains no active ingredients.
223835043|NCT06309030|DRUG|Bushen quhan zhiwang decoction|Treatment with 100ml of Bushen quhan zhiwang decoction twice a day for 3 months.
223835044|NCT06309030|DRUG|Bushen quhan zhiwang decoction placebo|Treatment with 100ml of Bushen quhan zhiwang decoction placebo twice a day for 3 months.
223835045|NCT03050398|DRUG|Ribociclib|ribociclib + letrozole
223835046|NCT03050398|DRUG|letrozole|ribociclib + letrozole
223835047|NCT01723553|DRUG|C-11 PiB|One time intravenous administration of \~740 megabecquerel (MBq) of \[N-methyl-C-11\]2-(4'-methylaminophenyl)-6-hydroxybenzothiazole (PiB) (range 370 - 740 MBq).
223835048|NCT04455334|OTHER|Error-augmented treadmill training|walk on split-belt treadmill
223835049|NCT04455334|OTHER|active control group|walk on tie-belt treadmill
223835050|NCT04455334|OTHER|Error-augmented concept combined physical therapy group|Error-augmented concept combined physical therapy
223835051|NCT04455334|OTHER|conventional physical therapy group|conventional physical therapy
223835052|NCT04455334|OTHER|NO INTERVENTION|NO INTERVENTION
223835053|NCT04387539|DRUG|SOF/SMV/DCV/RBV|SOF was given orally at a dose of 400 mg/day DCV was given orally at a dose of 60 mg/day SMV was given orally at a dose of 150 mg/day. RBV was given in a total daily oral dose of 600 mg/day up to 1,200 mg/day according to the participant's weight and tolerability.
223835054|NCT02778282|OTHER|MySafeRx™|The MySafeRx™ platform is a combination of several key components, including daily videoconferencing check-ins with motivational interviewing-based recovery coaching, text-messaging reminders, secure storage of buprenorphine medication within a secure electronic pill dispenser, and a standardized protocol for supervising self-administration of medication via videoconferencing.
223835055|NCT04726475|BEHAVIORAL|Interoceptive Aversive Memory Reactivation|In order to reactivate interoceptive aversive memory, participants will be asked to breathe a medical grade 35% CO2/65% O2 gas mixture which produces somatic perturbations. The 35% CO2 challenge is a widely used and safe symptom induction technique that has been utilized in our laboratory in several experiments. Participants will be informed that breathing the gas is safe, but that it will likely cause changes in their physical sensations. Participants will specifically be asked to breathe the gas mixture normally with their mouth open through an oxygen mask for 10 seconds.
223835056|NCT04726475|DIETARY_SUPPLEMENT|Cannabidiol (CBD)-Rich Broad Spectrum Hemp Extract Oil|300mg CBD-rich hemp-derived formulation in MCT coconut oil.
223835057|NCT04726475|DIETARY_SUPPLEMENT|Placebo Oil|3ml oral dose of MCT coconut oil.
223835058|NCT03288389|DIETARY_SUPPLEMENT|NTFactor Lipids®|Membrane Lipid Replacement with NTFactor Lipids wafers
223835059|NCT03288389|DIETARY_SUPPLEMENT|Placebo|Placebo wafers
223835060|NCT01071889|DRUG|Flumazenil|Flumazenil- 0.4 mg per 100 µl in a sublingual spray administration
223835061|NCT01071889|DRUG|Placebo|Placebo - only excipients with no API
223835062|NCT05538299|BEHAVIORAL|questionnaire, KAP|Diagnostic studies including questionaire, CXR, spirometry, clinical assesment, occupational safety training
223835063|NCT02838225|DRUG|Docetaxel, Doxorubicin|
223835064|NCT02838225|DRUG|Docetaxel, Doxorubicin, Cyclophosphamide|
223835065|NCT05740475|DRUG|9MW3811 injection|Single dose intravenously infused on day 1
223835066|NCT05740475|DRUG|Placebo|Single dose of matching placebo intravenously infused on day 1
223835067|NCT02552849|OTHER|No intervention|
223835068|NCT00558324|PROCEDURE|LASIK|Mechanical microkeratome Hansatome 160 microns
223835069|NCT00558324|PROCEDURE|LASIK|Mechanical microkeratome K 3000 130 microns
223835070|NCT00558324|PROCEDURE|LASIK|Femtoseconds laser 100 microns
223835071|NCT05472220|DRUG|Alpelisib|Given orally
223835072|NCT05472220|DRUG|Carboplatin|Given IV during imaging
223835073|NCT05472220|DRUG|Hyperpolarized Carbon-13 (13C) Pyruvate|Given IV
223835074|NCT05472220|DEVICE|Continuous Glucose Monitor (CGM)|Self-applied devices that sit partially beneath the skin
223835075|NCT00126685|BIOLOGICAL|autologous tumor cell vaccine|
223835076|NCT00126685|BIOLOGICAL|therapeutic autologous dendritic cells|
223835077|NCT01386710|DRUG|Bevacizumab and Carboplatin|"Day 0: Intraarterial Bevacizumab single dose (15mg/kg) plus Intraarterial Carboplatin (150mg/m2) after Mannitol to open the blood brain barrier~Day 28: Intravenous Bevacizumab (10mg/kg) plus Carboplatin (AUG5) every two weeks thereafter until disease progression on MRI scan.~If progression occurs, repeat intraarterial Bevacizumab single dose (15mg/kg) plus intraarterial Carboplatin (150mg/m2) to area of progression and wait 28 days and then restart Intravenous Bevacizumab (10mg/kg) plus Carboplatin (AUG5) every two weeks thereafter until progression on MRI scan.~Repeat Cycle"
223835078|NCT01386710|DRUG|Bevacizumab and Carboplatin|"Day 0: Intraarterial Bevacizumab single dose (15mg/kg) plus Intraarterial Carboplatin (150mg/m2) after Mannitol to open the blood brain barrier~Day 28: No biweekly IV Bevacizumab plus Carboplatin treatment~If MRI shows progression then repeat intraarterial Bevacizumab single dose (15mg/kg) plus intraarterial Carboplatin (150mg/m2) to area of progression Repeat Cycle"
223835079|NCT02309606|OTHER|PET scan with 5-HT receptor ligands|Interictal episodic migraine patients and healthy controls will be scanned with a 5-HT1B and a 5-HT4 receptor radioligand. Episodic migraine patients will further be scanned during a cilostazol induced migraine attack and after treatment with sumatriptan. Chronic migraine patients will be scanned with only the 5-HT4 receptor radioligand.
223835080|NCT04515563|BEHAVIORAL|Stretching exercise|Control Group
223835081|NCT04515563|BEHAVIORAL|Low-frequency, moderate-intensity walking group|once-a-week walking exercise at moderate intensity
223835082|NCT04515563|BEHAVIORAL|High-frequency, moderate-intensity walking group|thrice-a-week walking exercise at moderate intensity
223835083|NCT04515563|BEHAVIORAL|Low-frequency, vigorous-intensity walking group|once-a-week walking exercise at vigorous intensity
223835084|NCT04515563|BEHAVIORAL|High-frequency, vigorous-intensity walking group|thrice-a-week walking exercise at vigorous intensity
223835085|NCT03018106|DRUG|Ospemifene|Ospemifene is a selective estrogen receptor modulator (SERM), and it is the only SERM approved in the United States to treat moderate to severe dyspareunia associated with VVA. It is an oral medication that is taken as a 60mg tablet once daily. Food intake increases its absorption by 2 to 3-fold, and this is not impacted by the fat or calorie content of the food. It is metabolized primarily in the liver, and is excreted in feces.
223835086|NCT03018106|DRUG|Vaginal conjugated estrogens|Conjugated estrogens are a mixture of several different estrogen salts derived from natural sources and blended to approximate the composition of estrogens in the urine of pregnant horses. The main components are sodium estrone sulphate and sodium equilin sulfate. Vaginal estrogen is considered the medication of choice for treating vulvovaginal atrophy (VVA).
223835087|NCT01274130|DRUG|Metformin|Diavex 1000mg on Day1 and 750mg on Day2
223835088|NCT03055832|DEVICE|iLux 2020 System|Medical device that applies localized heat and pressure therapy to the eyelid in order to express melted meibum from obstructed glands
223835089|NCT03055832|DEVICE|LipiFlow Pulsation System|Medical device that applies a combination of heat and pressure to the inner eyelid to remove gland obstructions and stagnant gland content
223835090|NCT01854333|OTHER|ADOS module 1-4 or ADI-R|
223835091|NCT00443469|DEVICE|magnetic stimulation|SMS was delivered with a repetitive magnetic stimulator connected to a figure of eight coil capable of delivering a maximum output of 2 Tesla per pulse. The coil measured 90 mm in each wing and was centered over the surface landmark corresponding to the cauda equina region. SMS was performed with the patient lying comfortably in the prone position and a soft pillow supported the lower abdomen. The coil was placed flat over the back with the handle pointing cranially. Each patient on active treatment received 200 trains of 5 pulses delivered at 10 Hz, at an interval of 5 s between each train. As this was a pilot study, each only received 1000 pulses in a single session.
223835092|NCT00443469|DEVICE|Magnetic Stimulation with tilted coil|The placebo arm consisted of 'sham' SMS delivered with the coil angled vertically and one of the wing edges in contact with the stimulation point. As this coil type allows maximum magnetic flux at the center of the intersection, we believe minimum or no stimulation was effected at the edge of the coil in contact with the patient. Stimulation parameters and duration were unchanged in this arm.
223835093|NCT03108287|DRUG|RAK therapy|rabeprazole 20mg, amoxicillin 1g and clarithromycin 500mg twice-daily
223835094|NCT03108287|DRUG|RBAK therapy|rabeprazole 20mg, amoxicillin 1g and clarithromycin 500mg, bismuth subcitrate 360mg twice-daily
223835095|NCT04739683|DEVICE|Foley bulb placement|A 16 F Foley catheter with a 30-mL balloon and stylet is inserted into the endocervical canal under direct visualization by sterile speculum exam or by digital palpation. The Foley catheter is advanced to or past the internal os, and the balloon is filled with 30-40 mL of sterile water. The catheter is then placed on genital traction by taping the end of the catheter to the medial portion of the thigh.
223835096|NCT04739683|DEVICE|DILAPAN-S® placement|A bivalve speculum will be used to visualize and prepare the cervix with an antiseptic solution. The DILAPAN-S® (4 x 65 mm) will be inserted in the cervical canal until it traverses the internal os. As many dilators as needed to achieve the desired effect should be inserted. Specific number of pieces always depends on decision and clinical judgement of physician and indications. A gauze pad moistened with sterile water or saline may be inserted into the vagina to help keep the DILAPAN-S® in place, if needed
223835097|NCT03217734|BIOLOGICAL|Adalimumab|Subcutaneous Injection
223835098|NCT03217734|DRUG|Methotrexate|Oral Tablet
223835099|NCT03217734|DRUG|Placebo|Oral Tablet
223835100|NCT03505411|DIETARY_SUPPLEMENT|melatonin supplementation|
223835101|NCT03619174|DEVICE|Viveve Treatment|The Viveve system is a monopolar radiofrequency system that uses surface cooling and radiofrequency (RF) energy delivery to provide a non-surgical and minimally-invasive approach to generate heat within the submucosal layers of vaginal tissue while keeping the surface cool.
223835102|NCT00312975|DRUG|CP-675,206|Given intravenously every 3 months
223835103|NCT00312975|DRUG|best supportive care|As per investigator discretion. Excludes chemotherapy or other anti-cancer therapy
223835104|NCT03354988|OTHER|Physical exercise group|For the exercise group, systematic physical activity programs consisting of range-of-motion exercises with gentle compression, extension and flexion of all joints of both bilateral upper extremities; including the shoulder, elbow, and wrist and lower extremities; including the hip, knee and ankle, with a total of 12 joints. Each activity was about 10 min a day and was carried out 5 times per week for 4 weeks. This program was started after 1 week of birth. Physical activity continued until discharge from hospital
223835105|NCT03354988|OTHER|Control group|Other routine care activities such as bathing (every day) and kangaroo care (30 minutes/day), will be done for both the control
223835106|NCT00059254|DIETARY_SUPPLEMENT|Oleic acid (OA)|OA-enriched (HI OA; fat, 40%; PA, 1.7%; OA, 31.4%)
223835107|NCT00059254|DIETARY_SUPPLEMENT|Palmitic Acid (PA)|PA-enriched (HI PA; fat, 40% of energy; PA, 16.8%; OA, 16.4%)
223835108|NCT06423586|DIETARY_SUPPLEMENT|Curcuma longa and Boswellia serrata extracts|Participants received 500 mg of Curcuma longa and 150 mg of Boswellia serrata extracts (Meriva™ and Casperome™) twice daily for 30 days.
223835109|NCT06380595|PROCEDURE|Complex endovascular aortic repair (cEVAR)|Complex endovascular aortic repair (cEVAR) collectively refers to the use of fenestrated/branched EVAR (f/bEVAR) or other EVAR variations allowing alternative visceral incorporation approaches, such as laser or radiofrequency (RF) fenestration or parallel endografts (snorkel, periscope, chimney or sandwich EVAR) to enable repair of perivisceral AAA (pvAAA), thoracoabdominal aortic aneurysms (TAAA), and aortic arch aneurysms.
223835110|NCT05552690|PROCEDURE|blood draw|10 ml of blood will be draw to genetic analysis (sequencing)
223835111|NCT03779451|DRUG|17-OHPC|received weekly 250 mg 17 alpha-hydroxyprogesterone-caproate (cidolut depot) intramuscular injections started at 26-28 week and up to 37-weeks' gestation or delivery.
223835112|NCT03779451|DRUG|vaginal progesterone|vaginal progesterone suppositories (Cyclogest vaginal suppository) in a dose of 400 mg daily starting at 26-28 weeks of gestation till 37 weeks of gestation or delivery
223835113|NCT01850966|DRUG|Iguratimod|The usual adult dosage for oral use of 25 mg tablet of iguratimod once daily for 4 weeks or more, after which the dosage should be increased to one 25 mg tablet taken twice daily.
223835114|NCT01276249|DEVICE|Fortevo Endograft|The Fortevo Endograft, Main Body and Iliac Lumen Delivery System are indicated for the endovascular treatments of patients with infrarenal abdominal aortic aneurysms or aortic-iliac aneurysms having suitable morphology for endovascular repair.
223835115|NCT04305899|DRUG|BMS-986165 Tablet formulation 1|Specified dose on specified days
223835116|NCT04305899|DRUG|BMS-986165 Tablet formulation 2|Specified dose on specified days
223835117|NCT01991197|DRUG|Sitagliptin|"Week 0-16: Two 50mg tablets (or one 50mg tablet for participants with moderate kidney disease) once daily for 16 weeks during the double-blind phase.~Week 16-32: Then two 50mg tablets (or one 50mg tablet for participants with moderate kidney disease) once daily for 16 weeks during the open-label phase of the trial."
223835118|NCT01991197|DRUG|Gliclazide|"Double-blind phase (week 0-16):~One 80mg capsule once daily for 4 weeks. The if no severe hypoglycaemic episodes one 80mg capsule twice daily for 4 weeks.~Then if no severe hypoglycaemic episodes two 80mg capsules twice daily for 8 weeks."
223835119|NCT01991197|DRUG|Sitagliptin matched placebo|Week 0-16: Two tablets (or one tablet for those with moderate kidney disease) daily for 16 weeks during the double-blind phase.
223835120|NCT01991197|DRUG|Gliclazide matched placebo capsule|"Double-blind phase (week 0-16):~One capsule daily for 4 weeks. Then if no severe hypoglycaemic episodes one capsule twice daily for 4 weeks. Then if no severe hypoglycaemic episodes two capsules twice daily for 8 weeks."
223835121|NCT05468671|DRUG|Remimazolam|Remimazolam is a new drug innovation in anesthesia. It combines the properties of two unique drugs already established in anesthesia - Midazolam and remifentanil. It acts on GABA receptors like midazolam and has organ-independent metabolism like remifentanil.
223835122|NCT05468671|DRUG|Propofol|Propofol is used to put you to sleep and keep you asleep during general anesthesia for surgery or other medical procedures.
223835123|NCT05468671|DRUG|Rocuronium|Rocuronium is a non-depolarizing neuromuscular blocker
223835124|NCT05468671|DRUG|Remifentanil|Remifentanil is an esterase-metabolized opioid
223835125|NCT05468671|DRUG|oxycodone|Oxycodone is an opiate painkiller.
223835126|NCT05468671|DRUG|Sugammadex Sodium|Sugammadex sodium is an organic sodium salt that is the octasodium salt of sugammadex. Used for reversal of neuromuscular blockade induced by rocuronium and vecuronium in adults undergoing surgery
223835127|NCT05468671|DRUG|Flumazenil|Flumazenil is used to reverse the effects of a benzodiazepine
223835128|NCT03640689|DEVICE|Endovenous ablation + iliac US +/- iliac stenting|Concomitant Ablation of the GSV with endovenous therapy with associated iliac vein interrogation and stenting if required
223835129|NCT03640689|DEVICE|Endovenous ablation of Great Saphenous Vein|Ablation of the Great Saphenous Vein and subsequent Graduated Compression
223835130|NCT02909361|DRUG|Fulvestrant|500 mg on days 0, 14, and 28, and every 28 days thereafter
223835131|NCT05608733|DRUG|Epidural catheter|Bony landmarks and the space between the lower lumbar vertebrae are identified. Subsequently, infiltration of the skin and subcutaneous cellular tissue with local anesthetic (Lidocaine 2% without epinephrine) is performed at the site to be punctured. A 17G Tuohy needle is inserted 2-4 cm through the skin, then the mandrel is removed, the low-resistance syringe is connected, and the loss of resistance is checked using the air or liquid technique, depending on the preference of the anesthesiologist. . Appreciating the loss of resistance in the embolus, the mandrel is then withdrawn and the epidural catheter is advanced to leave it an additional 5 cm inside the epidural space.
223835132|NCT05608733|DRUG|Continuous sciatic nerve block|The patient is placed in the prone or supine position with the limb to be blocked flexed at 90°. Using a high-frequency linear transducer and using sterile technique, the popliteal sciatic nerve is identified in an axial axis. A 17G Tuohy needle is inserted plane and medial. Saline solution (5 ml) is applied to open the perineural space. Adequate hydrodissection and donut sign in the nerve are observed..A perineural catheter is then advanced 5 cm beyond the tip of the needle. The catheter is fixed with stitches and a transparent sterile dressing is placed.
223835133|NCT04763538|OTHER|Standard of care|Patients are treated according to the standard of care for each individual disease.
223835134|NCT03863899|PROCEDURE|Nerve block|drug mixture: 10-15 ml 0.5% ropivacaine plus 5 ml 1% lidocaine plus 1 mg dexamethasone plus 50 ug adrenaline
223835135|NCT03863899|PROCEDURE|Local infiltration|15-20 ml of mixture of 0.5% bupivacaine and 1% lidocaine (1:1)
223835136|NCT03863899|PROCEDURE|TAVI|Insertion of an aortic valve prothesis through the aorta accessed through femoral artery
223835137|NCT03863899|DRUG|Additional intraoperative analgesia|Administration of any analgesics during the operation
223835138|NCT03863899|DRUG|Additional postoperative analgesia|Administration of any analgesics within first 24 hours after the operation
223835139|NCT00949962|DRUG|antiandrogen therapy|Given systemically
223835140|NCT00949962|DRUG|leuprolide acetate|Given subcutaneously
223835141|NCT00949962|RADIATION|3-dimensional conformal radiation therapy|Undergo radiotherapy
223835142|NCT05535686|OTHER|Rheumatoid Arthritis|Rheumatoid Arthritis Disease (R.A)
223835143|NCT03938948|DEVICE|low-level laser/light therapy|Participants will wear light therapy devices for 14 weeks
223835144|NCT00004189|BIOLOGICAL|filgrastim|
223835145|NCT00004189|DRUG|becatecarin|
223835146|NCT00004189|DRUG|cisplatin|
223835147|NCT01010217|DRUG|Cyclophosphamide|50 mg/kg/day intravenous (IV) over 3 hours on Days 3 and 4.
223835148|NCT01010217|DRUG|Fludarabine|40 mg/m\^2 IV over 1 hour on Days -6, -5, -4, and -3.
223835149|NCT01010217|DRUG|Melphalan|140 mg/m\^2 IV (or 100 mg/m\^2 with reduced intensity Regimen 2) over 30 minutes on Day -8.
223835150|NCT01010217|DRUG|Mesna|10 mg/kg IV every 4 hours for a total of 10 doses starting just prior to first dose of Cyclophosphamide on Days 3 and 4.
223835151|NCT01010217|DRUG|Rituximab|CD20+ lymphoid malignancies: 375 mg/m2 on Day -13 followed by 1000 mg/m2 on Day -6, +1, and +8.
223835152|NCT01010217|PROCEDURE|Stem Cell Transplantation|Infusion of donor's stem cells by vein on Day 0, may last anywhere from 15 minutes to several hours.
223835153|NCT01010217|DRUG|Thiotepa|5 mg/kg Regimen 1 (or 5 mg/kg with reduced intensity Regimen 2) IV over 4 hours on Day -7.
223835154|NCT01010217|DRUG|Tacrolimus|0.015 mg/kg by vein or orally daily starting on Day +5 for 3 months
223835155|NCT01010217|DRUG|Mycofenolate mofetil|15 mg/kg/dose orally three times a day starting on Day +5 to Day +100 or otherwise indicated
223835156|NCT01010217|DRUG|G-CSF|5 mcg/kg/day subcutaneously starting Day 7 once a day daily until neutrophil recovery \> 1000/mcl.
223835157|NCT00082290|OTHER|massage therapy|
223835158|NCT00082290|OTHER|visit with a volunteer|
223835159|NCT00082290|OTHER|period of quiet time|
223835160|NCT00082290|BEHAVIORAL|questionaire about pain|
223835161|NCT02677103|DEVICE|radial extracorporeal shock wave therapy|he RSWT was delivered at 2 Hz with 2000 shock waves and the energy level of 0.26mJ/mm2 in calcific tendinitis of shoulder.
223835162|NCT02677103|PROCEDURE|ultrasound-guided needle puncture|After injecting 3cc 1% Xylocain in the subcutaneous tissue, muscle layer and subdeltoid bursa, multiple back-and-forth puncture about 10-20 times (depending on the size of the plaques) within the calcific plaques will be performed.
223835163|NCT02677103|PROCEDURE|RSWT and USNP|each subject will receive radial shock wave therapy after ultrasound-guided needle puncture, as described in the previous paragraphs.
223835164|NCT00941278|DRUG|PH-10 (0.001% Rose Bengal)|PH-10 will be applied daily for 28 days to skin areas affected by mild to moderate psoriasis.
223835165|NCT00605371|DRUG|Lamotrigine tablet|Lamotrigine extended release single dose tablet will be available with dosing strengths of 200 milligrams and 50 milligrams intended to be administered orally in fasted state. It will be a round standard convex shape tablet.
223835166|NCT00605371|DRUG|Lamotrigine caplet|Lamotrigine extended release single dose caplet will be available with dosing strength of 200 milligrams and 50 milligrams intended to be administered orally in fasted and fed state.
223835167|NCT04745858|OTHER|Bowen's Technique|In Bowen's Technique, sequence of short gentle moves are applied over Hamstrings. Skin slack is taken to the lateral side of muscle. The muscle is hooked by the thumbs from its lateral edge. Skin is carried along and thumb is flattened in a medial direction, the muscle plucks under the thumbs. Three alternate sessions per week are given for 4 weeks. The treatment time for each session is 20 minutes.
223835168|NCT04745858|OTHER|Muscle Energy Technique|Isometric contraction of hamstrings is performed by the patient being employing 20% of the strength. This contraction is resisted by the practitioner for 7-10 s. A three second relaxation period is given. This technique is repeated for three times. Three alternate sessions per week is given for 4 weeks.
223835169|NCT01439711|DRUG|letrozole|
223835170|NCT01439711|PROCEDURE|MRI|
223835171|NCT01439711|PROCEDURE|conventional surgery|
223835172|NCT02366585|DRUG|Ciclosporin|Ciclosporin gel applied to two periodontal pockets
223835173|NCT04242875|DIAGNOSTIC_TEST|Angle Kappa|Angle kappa will be measured using the OPD III scan.
223835174|NCT04242875|OTHER|Visual disturbance questionnaire.|Questionnaire evaluating visual disturbances.
223835175|NCT05212493|DRUG|Cannabis oil|Cannabis oil 20:1 CBD:THC ratio
223835176|NCT02397460|DRUG|Gefapixant|Gefapixant tablets administered orally as a single dose of 50 mg (1 tablet) or 300 mg (6 tablets)
223835177|NCT02397460|DRUG|Placebo|
223835178|NCT01759875|DRUG|Ritonavir-boosted Atazanavir|Ritonavir (100mg) PO x1 and Atazanavir (300mg) PO x1
223835179|NCT01759875|DRUG|Ritonavir-boosted Atazanavir plus Rabeprazole|Rabeprazole (20mg) PO twice daily (Days 1-3); Ritonavir (100mg) PO x1 and Atazanavir (300mg) PO x1 (Day 4)
223835180|NCT01759875|DRUG|Ritonavir-boosted Atazanavir plus Rabeprazole AND Betaine Hydrochloride|Rabeprazole (20mg) PO twice daily (Days 1-3); Betaine Hydrochloride (1500mg) PO x1 AND Ritonavir (100mg) PO x1 and Atazanavir (300mg) PO x1 on Day 4
223835181|NCT05994599|COMBINATION_PRODUCT|EVE119 vaginal ring|EVE119 (ethinyl estradiol/etonogestrel) vaginal ring delivering 0.015 mg/0.12 mg dose per day
223835182|NCT05994599|COMBINATION_PRODUCT|Nuvaring vaginal ring|Nuvaring® (ethinyl estradiol/etonogestrel) vaginal ring delivering 0.015 mg/0.12 mg dose per day
223835183|NCT04729140|DRUG|Ivermectin Tablets|Double-blinded, prospective, placebo controlled outpatient randomized clinical trial.
223835184|NCT04729140|DRUG|Doxycycline Tablets|Double-blinded, prospective, placebo controlled outpatient randomized clinical trial.
223835185|NCT04729140|DRUG|Placebo|Double-blinded, prospective, placebo controlled outpatient randomized clinical trial.
223835186|NCT00372333|DRUG|IDEA-033|
223835187|NCT01531140|DRUG|polyethylene glycol +Bisacodyl|Polyethylene glycol (Fortrans) p.o. 30 ml/kg/2days + Bisacodyl p.o.10-15 mg/day for 2 days
223835188|NCT01531140|DRUG|Polyethylene glycol|Polyethylene glycol p.o.: 60 ml/kg/days
223835189|NCT01531140|DRUG|Sennosides|Sennosides 1tbl/8kg for 2 days
223835190|NCT04415892|OTHER|Cinnamaldehyde and capsaicin|Topical application of cinnamaldehyde and capsaicin on the fingers
223835656|NCT05576259|OTHER|oVRcome phone app with headset|The intervention oVRcome is self-help VRET for social anxiety, that is delivered through a smartphone application (app) in combination with headset that holds the smartphone and uses 360º video. oVRcome includes 6 modules of psychoeducation, relaxation, mindfulness, cognitive techniques, exposure through VR, and a relapse prevention module which are aimed to be completed weekly.
223835657|NCT06647043|DIETARY_SUPPLEMENT|SMT04 Pro|Consists of a blend of food-grade Bifidobacterium as active probiotics
223835191|NCT00747773|DEVICE|CryoSpray Ablation System|"CSA Medical, Inc. (formerly CryMed Technologies, Inc.) received FDA market clearance for the CSA System (CryoSpray AblationTM System, formally Cryo Ablator System) on April 21, 2006. It is a Class II device intended to be used as a cryosurgical tool for the destruction of unwanted tissue in the field of general surgery, specifically for endoscopic applications (K070893). As defined by the FDA, the CSA System is a cryosurgical unit with a liquid nitrogen cooled cryocatheter and accessories used to destroy tissue during surgical procedures by applying extreme cold"
223835192|NCT03308903|DIAGNOSTIC_TEST|DEXA scan|The participant will undergo a whole-body DEXA (DEXA; GE Medical Systems, Chalfont St Giles, UK) scan, lasting approximately 5 minutes. This scan will produce body composition data, including estimates of lean body mass (LBM), appendicular lean mass (aLM) and body fat percentage (BF%).
223835193|NCT04165161|DIAGNOSTIC_TEST|search for a patent foramen ovale|Injection of a contrast solution A - In the upper cellar territory with controlled ventilation without positive tele-expiratory pressure; B - In the upper cellar territory in controlled ventilation with a positive end-to-expiratory pressure of 10cm H2O; C - In the lower cellar territory with controlled ventilation without positive tele-expiratory pressure; D - In the lower cellar territory in controlled ventilation with a positive end-to-expiratory pressure of 10cm H2O;
223835194|NCT00636714|BEHAVIORAL|Nursing judgement|Based on the nursing judgement, titrate insulin infusion and determine glucose check frequency to achieve a target glucose of 5-8 mmol/L
223835195|NCT00636714|BEHAVIORAL|Nomogram|A preprinted order outlining a nomogram with instructions for how insulin infusion should be changed based on measured glucose values and how frequent the glucose checks should be
223835196|NCT03810079|DEVICE|Anodal transcranial direct current stimulation|Neuromodulation of bilateral prefrontal areas using 2 mA tDCS delivered during 20 minutes via sponge electrodes on the scalp
223835197|NCT00306514|BIOLOGICAL|CYT004-MelQbG10|
223835198|NCT01406717|DRUG|SPIL1033|5 mcg twice daily for the first 4 weeks and 10 mcg twice daily for the remaining 20 weeks. To be self-administered twice daily.
223835199|NCT01406717|DRUG|Placebo|5 mcg twice daily for the first 4 weeks and 10 mcg twice daily for the remaining 20 weeks. To be self-administered twice daily.
223835200|NCT01222611|DRUG|Fosamprenavir|HAART including fosamprenavir boosted with ritonavir
223835201|NCT01375894|DEVICE|"imitation assessment using the 5-dt data glove."|measuring the speed of the hand during imitation
223835202|NCT03120208|BEHAVIORAL|• The Edinburgh postnatal depression scale (EPDS), validated in French, with a discrimination threshold ≥ 11.|The Edinburgh postnatal depression scale (EPDS), validated in French, with a discrimination threshold ≥ 11.
223835203|NCT03120208|BEHAVIORAL|The GAD-7 with a discrimination threshold ≥10.|The GAD-7 with a discrimination threshold ≥10.
223835204|NCT03120208|BEHAVIORAL|• Spielberger's State-Trait anxiety inventory, Form Y (validated in French), with a STAI (form Y-A) discrimination threshold ≥ 46|Spielberger's State-Trait anxiety inventory, Form Y (validated in French), with a STAI (form Y-A) discrimination threshold ≥ 46
223835205|NCT03120208|BEHAVIORAL|The IES-R, validated in French, with a discrimination threshold ≥ 30.|The IES-R, validated in French, with a discrimination threshold ≥ 30.
223835206|NCT03120208|BEHAVIORAL|EPDS, MINI, STAI-A and B, IES-R and QEVA (experience)|For the partners
223835207|NCT01168674|DRUG|ziprasidone|Ziprasidone will be administered as a pill. The once-daily total daily dose will be 80-160 mg/d of ziprasidone. Dosing will begin at 20 mg BID with an escalation strategy based on target symptoms and tolerability, with a target dose range of 80-160 mg/d. Dose escalations will occur by increments of 20-40 mg weekly.
223835208|NCT01168674|DRUG|Sugar pill|The once-daily total daily dose will be 80-160 mg/d of the sugar pill. Dosing will begin at 20 mg BID with an escalation strategy based on target symptoms and tolerability, with a target dose range of 80-160 mg/d. Dose escalations will occur by increments of 20-40 mg weekly.
223835209|NCT01112696|DEVICE|Sensor wear|All subjects to wear sensors
223835210|NCT03259529|DRUG|Bendamustine hydrochloride|70 mg/m2 by intravenous (IV) infusion for up to 2 cycles
223835211|NCT03259529|DRUG|Gemcitabine 500 mg|500 mg/m2 by intravenous (IV) infusion on day 1,8,15 for up to 2 cycles
223835212|NCT03259529|DRUG|Gemcitabine 700 mg|700 mg/m2 by intravenous (IV) infusion on day 1,8,15 for up to 2 cycles
223835213|NCT03259529|DRUG|Gemcitabine 1000 mg|1000 mg/m2 by intravenous (IV) infusion on day 1,8,15 for up to 2 cycles
223835214|NCT03259529|DRUG|Nivolumab|1 mg/kg by intravenous (IV) infusion on day 1,15 for up to 2 cycles
223835215|NCT03259529|DRUG|Rituximab|375 mg/m2 by intravenous (IV) infusion on day 0 for up to 2 cycles
223835216|NCT02584855|DRUG|Ixekizumab|Administered SC
223835217|NCT02584855|DRUG|Placebo|Administered SC
223835218|NCT00039156|DRUG|ortataxel|
223835219|NCT05208619|PROCEDURE|Regional anaesthesia|Patients receive either a thoracic epidural analgesia or paravertebral block as an regional anaesthetic adjunct to general anaesthesia for thoracic surgery
223835220|NCT02337478|DRUG|Vincristine Sulfate Liposome|Given via injection
223835221|NCT02337478|OTHER|Laboratory Biomarker Analysis|Correlative studies
223835222|NCT03527693|DEVICE|Lipogems injection|Micro-fragmented adipose tissue (10 cc) was injected intra-articular after the arthroscopic procedure (shaving or shaving + meniscectomy).
223835223|NCT04431687|DRUG|CKD 501|QD, PO
223835224|NCT04431687|DRUG|D759, D150|QD, PO
223835225|NCT04431687|DRUG|CKD-501, D759, D150|QD, PO
223835226|NCT02025348|DRUG|IntelliCap|Drug release from the IntelliCap® system will be actuated post-gastric emptying of IntelliCap® capsule.
223835227|NCT01164163|DRUG|ruxolitinib phosphate|
223835228|NCT01164163|OTHER|laboratory biomarker analysis|
223835229|NCT01164163|OTHER|pharmacological study|
223835230|NCT03913728|OTHER|Drug level blood tests|All information included previously.
223835231|NCT03913728|OTHER|Telephone Interview|All information included previously.
223835232|NCT01046461|DRUG|Ramosetron, Aprepitant, Dexamethasone|"Day 1:~Aprepitant 125 mg PO, 1 hour before chemotherapy Ramosetron 0.6 mg IV, 30 min before chemotherapy Dexamethasone 12 mg PO, 30 min before chemotherapy~Day 2 - 3:~Aprepitant 80 mg PO. in the morning Dexamethasone 8 mg PO. in the morning~Day 4 Dexamethasone 8 mg PO. in the morning"
223835233|NCT05914428|OTHER|ALDH2 rs671 mutation|We selected blood samples from sepsis patients from the biological bank of Qilu hospital and tested their genotypes. The intervention group was ALDH2 rs671 mutation patients
223835234|NCT03504865|DRUG|Liposomal bupivacaine|Given at the end of the operation.
223835235|NCT03504865|DRUG|Standard bupivacaine|Given at the end of the operation.
223835704|NCT04259775|DEVICE|Automated Insulin Dose Adjustment|The system originally developed at Boston Children's Hospital, obtains CGM, insulin delivery, and activity data, from the cloud each day at approximately 8:00 PM using an Application Program Interface (API) calls to commercial companies (primarily Glooko and Tidepool) that aggregate data from different devices used to manage glucose levels in individuals. A detailed statistical and control analysis (see preliminary data study 1 for algorithm details) of the data are then conducted to determine if a change in therapy is required. If the analysis indicates a change in therapy is required, the patient or parent is notified by text or email directing then to a web portal detailing the change. The patient or parent can accept or modify the recommended change. If a change is made, the AIDA system confirms that the change is correctly implemented into the patient's pump or Bluetooth enabled pen when the patient next uploads the device data to the cloud.
223835705|NCT04259775|DEVICE|Control|Standard Care - change in therapy settings effected at regularly scheduled patient visits
223835706|NCT01614574|BIOLOGICAL|velaglucerase alfa|60 U/kg every other week intravenous infusion
223835707|NCT04451343|OTHER|biographical interviews|A sociologist trained in the sociology of cancer, to enable participants to talk about their experiences and clearly distinguish the experiences of each individual
223835708|NCT05095129|GENETIC|SNP analysis of the DNA|SNP analysis of the DNA obtained from peripheral blood sample
223835709|NCT00492934|DRUG|human menopausal gonadotrophins|Daily subcutaneous injections, dose 37.5 IU or 75 IU, start on day 2 of the menstrual cycle until ovulation
223835710|NCT02836327|OTHER|Magnetic Resonance Imaging|Magnetic Resonance Imaging
223835711|NCT05408923|DRUG|saline 0.9%|Control group will get normal saline for irrigation throughout the case.
223835712|NCT05408923|DRUG|(0.05% chlorhexidine gluconate (CHG) in sterile water)|Intervention group will get Irrisept irrigation (0.05% CHG in sterile water) throughout the case.
223835713|NCT05763992|DIETARY_SUPPLEMENT|Control diet (ARM A) or Fasting-Like Approach (FLA, ARM B)|Each FLA cycle will consist of 5 consecutive days of a specific FLA scheme, which will be repeated with a three-week interval. The FLA will consist of a plant-based, low-calorie (about 600 Kcal on day 1; about 300 Kcal on day 2 to 5), low-protein, low-carbohydrate diet. The first FLA cycle will start two days prior to the day of first chemo-immunotherapy cycle administration and will continue for two more days after chemotherapy. In the absence of significant contraindications or severe adverse events, subsequent FLA cycles will recur with three-week intervals and will maintain the same timing with respect to chemo-immunotherapy administration.
223835714|NCT04669912|OTHER|glucose control and sensor usage|Data related to glucose control and sensor usage collected from the Libreview platform
223835715|NCT01923428|DRUG|AZD1722|
223835716|NCT01923428|DRUG|Placebo|
223835717|NCT02409303|BEHAVIORAL|Screen-Refer-Treat Intervention|This intervention is healthcare system intervention that trains providers on validated screening tools (Online M-CHAT-R/F and STAT) and an evidence-based behavioral intervention (RIT). PCPs receive a 2-hour training workshop on the Online M-CHAT-R/F and EI Providers receive 2 day-long training workshops, one on the STAT/expedited assessment and one RIT.
223835718|NCT02550873|BIOLOGICAL|PRM-151|PRM 151 10 mg/kg IV infusion over 60 minutes days 1, 3, and 5, then one infusion every 4 weeks
223835719|NCT02550873|OTHER|placebo|Placebo IV infusion over 60 minutes on days 1, 3, and 5, then one infusion every 4 weeks
223835720|NCT05625919|DRUG|Sirolimus for Injection (Albumin Bound)|Sirolimus for injection (Albumin-bound), intravenously, once a week, 21 days per cycle (two weeks-on and one week-off)
223835721|NCT04653298|OTHER|Evaluation of quality of life, comorbidities and return to work status|Quality of life will be evaluated thanks to several methods: Short Form 36, EQ 5D 5L and return to work status Questionnaires will be evaluated through postal and phone call at least 12 months after ECMO.
223835722|NCT04657523|DEVICE|Investigational Liver Fat Quantification Software|All subjects enrolled in this study will undergo two abdominal ultrasound examinations using the investigational Liver Fat Quantification feature on the Philips EPIQ Ultrasound System. In addition, all subjects will also undergo one MRI-PDFF examination according to the clinical standard of care.
223835723|NCT00895843|DRUG|Brufen retard|Single dose 2 x 800mg tablets 2 hours prior to surgery
223835724|NCT00895843|DRUG|ibuprofen|Single dose ibuprofen 2 x 200mg tablets 2 hours prior to surgery
223835725|NCT00895843|DRUG|Bupivacaine|Up to 10ml of Bupivacaine 0.5% with 1:200,000 Adrenaline given prior to surgical incision as inferior alveolar nerve block and long buccal nerve infiltration.
223835726|NCT04717063|DRUG|Peroxyl Oral Product|mouth wash
223835727|NCT04717063|DRUG|Placebo|placebo mouth wash
223835728|NCT04702100|OTHER|instrument assisted soft tissue mobilization|the patients will receive instrument-assisted soft tissue mobilization:The subject was seated in a relaxed sitting position. M2T blade was used to find specific areas of restriction on RT upper trapezius. Then treatment plane 1 - 2 and 3 were used.The lubricant (Vaseline) was applied to the skin around the neck area prior to treatment and the tool was cleaned with an alcohol preparation pad. Then by using M2T blade with angle 45, we were giving long slow strokes without causing any discomfort or pain over muscle starting from its insertion up to its origin approximately for 2 to 3 min repeated two times.
223835729|NCT04702100|OTHER|integrated neuromuscular inhibition technique|will receive integrated neuromuscular inhibition technique: from supine lying position.we the patients will perform ischemic compression at trigger points then positional release technique and finally muscle energy technique.
223835730|NCT04702100|OTHER|conventional therapy|the patients will receive hot back for 10 minutes, active range of motion exercise, chin tuck, stretches
223835731|NCT00284765|PROCEDURE|flector|
223835732|NCT05106985|DEVICE|ApplTree reminder app|The reminder app will be introduced to participants to support adherence to chosen goal-related tasks. Reminder app will be introduced following a baseline phase of 10, 16 or 22 days. The duration of the baseline phase will be randomly assigned using an online random number generator.
223835733|NCT05966376|DEVICE|Hemostatic device for distal radial approach.|Hemostasis after distal radial approach is done with one of two devices, one of them is designed specifically for the distal radial approach; the other is not but a modified technique with the last one could be helpful.
223835734|NCT02637050|OTHER|Standard of care|At the discretion of the attending physician.
223835735|NCT01260857|DRUG|Aldazide|Aldazide 25 mg OD
223835736|NCT00039182|DRUG|erlotinib hydrochloride|Given orally
223835737|NCT00039182|OTHER|laboratory biomarker analysis|Correlative studies
223835738|NCT02304328|OTHER|Clinical assessment|Patients will be clinically assessed whether they present clinical signs of brain herniation syndromes
223835739|NCT02406118|PROCEDURE|Transanal total mesorectal excision|Subjects will have their rectal cancer removed using a technique combining surgery through the anus and standard laparoscopy. Transanal visualization will be using endoscopy. At the end of the procedure, the rectum will be removed though the anus or ileostomy formation site, the bowel will be re-connected to the anus, and a temporary diverting stoma will be created, which is standard of care following surgery for this type of cancer.
223835740|NCT01977001|DEVICE|MigraineBoxTM|
223835741|NCT02988206|BEHAVIORAL|Personalized Objects|personalized objects are based on the observation or the reports from family
223835742|NCT02988206|BEHAVIORAL|non-personalized Objects|non-personalized objects are based on the suggestion in CRS-R,which are comb and cup
223835743|NCT05681403|DRUG|Improved BEAM regimen|Mitoxantrone hydrochloride liposome, carmostine, etoposide and cytarabine will be used as conditioning regimen for ASCT in the lymphoma patients.
223835744|NCT06379230|OTHER|This study is purely descriptive study.|This study is purely descriptive study.
223835745|NCT02868437|DEVICE|intrauterine self-cross-linked hyaluronic acid gel|intrauterine self-cross-linked hyaluronic acid gel will apply after curettage for retained product after second trimester abortion
223835746|NCT00850720|OTHER|Blood draws|Samples of blood to be drawn before surgery, and nine hours after surgery.
223835747|NCT04374500|DRUG|Leptin infusion plus vasodilators in healthy men|This applies only to protocol 2 with two arms (leptin or saline) where four vasodilatators (bradykinin, acetylcholine, sodium nitroprusside and verapamil) were infused concomitantly
223835748|NCT04374500|DRUG|Leptin infusion in healthy men|This applies only to protocol 1 when only leptin was given
223835749|NCT04374500|DRUG|Vasodilators in CAD patients|This applies only to protocol 3
223835750|NCT02950935|DRUG|Progesterone|subcutaneous injection of progesterone solution will be performed twice à day from onset of threatened abortion symptoms until week 12 of pregnancy.
223835751|NCT02950935|DRUG|Placebo|subcutaneous injection of placebo solution will be performed twice à day from onset of threatened abortion symptoms until week 12 of pregnancy.
223835752|NCT04963062|DEVICE|Holmium laser with Moses lasers|The holmium laser with Moses is FDA approved. It emits two separate laser pulses with a short time interval between them. The first pulse divides the water between the laser fiber tip and the stone and the second pulse hits the stone unobstructed. The goal is to increase stone ablative volume and decrease retropulsion of the stone.
223835753|NCT04963062|DEVICE|Holmium laser with thulium lasers|The holmium laser with thulium laser is FDA approved. It has a different wavelength then the holmium laser with Moses and thus has slightly different energy properties. It has also been shown to increase ablative volume and decrease retropulsion without any safety concerns
223835754|NCT01482949|DRUG|AGS-003|Autologous Dendritic Cell Immunotherapy
223835755|NCT04063579|DIAGNOSTIC_TEST|Cardiac Magnetic Resonance, Echocardiogram, Blood investigation (NT-proBNP), cardiac catheterization|Imaging, blood tests, LV pressure measurement
223835756|NCT04063579|DIAGNOSTIC_TEST|Cardiac Magnetic Resonance, Echocardiogram, Blood investigation (NT-proBNP)|Imaging and Blood tests
223835757|NCT03873246|DRUG|OC-01 0.1% 0.6 mg/ml|OC-01 (varenicline) nasal spray: 0.1 % (0.6 mg/ml)
223835758|NCT03873246|DRUG|OC-01 (varenicline) nasal spray: 0.2 % (1.2 mg/ml)|OC-01 (varenicline) nasal spray: 0.2 % (1.2 mg/ml)
223835759|NCT03873246|OTHER|placebo comparator|vehicle control
223835760|NCT01857323|DRUG|Albuterol Spiromax®|Albuterol Spiromax delivers 90 mcg of albuterol base from the mouthpiece per triggered dose. Participants took doses of 2 inhalations each twice a day (morning and evening) for a total daily dose of 360 mcg. The first 45 enrolled participants constituted a subgroup who were dosed for 35 days, while most participants were dosed for 50 days.
223835761|NCT03752736|BEHAVIORAL|"I wear sunscreen everyday song-based video"|"All four classes (arms) will be shown (sitting on carpet, not participating) a 2-3 minute song-based video titled I wear sunscreen everyday in which they observe elementary age children applying sunscreen in a systematic fashion. Following the viewing, classes will be administered this video guided, song- based intervention while their teacher documents their independent participation using our classroom map data collection sheet."
223835762|NCT05128292|DIETARY_SUPPLEMENT|CoQ10 plus Selenium|400 mg/day CoQ10 soft gel capsula (Bio-Quinone active 100 mg b.i.d) plus 200 microgram organic selenium yeast tablet (SelenoPrecise 100 microgram b.i.d.) over 8 weeks
223835763|NCT03250598|DRUG|AG-348|50 mg single-dose
223835764|NCT03250598|DRUG|AG-348|5 mg single-dose
223835765|NCT03250598|DRUG|AG-348|200 mg single-dose
223835766|NCT06529211|DIETARY_SUPPLEMENT|Low caloric diet|Low caloric diet: the participants will receive low caloric diet program (1500 Kcal/ day) for 6 weeks as follows: 45% carbohydrate, 20% fat and 35% proteins of total calorie intake.
223835767|NCT06529211|DEVICE|Ultrasound cavitation|"Ultrasound cavitation + Low caloric diet Low caloric diet program (1500 Kcal/ day): for 6 weeks.~Ultrasound cavitation: It will be on abdomen for 30 minutes/session, 2 sessions/week for 6 weeks as follows:~* The participants will be in supine lying position and the abdomen is divided into two sides right and left from the midline.~* The Ultrasound pulsed waves will be set with power input (AC100/ 240V), frequency (40 KHz), and Power output (45W). This will be for 15 minutes on each abdominal side."
223889065|NCT05629156|OTHER|No intervention implemented. Observational study only|Observational study only. Injuries and illnesses and exposure is registered using standardized paper forms.
223835768|NCT06529211|DEVICE|Whole body vibration|"Whole body vibration + Low caloric diet Low caloric diet program (1500 Kcal/ day) for 6 weeks.~Whole body vibration: for 30 minutes/session, 2 sessions/week for 6 weeks as follows:~* The participants will begin with a brief warm-up for 5 minutes by doing deep breathing exercises.~* Then they will stand with feet shoulder-width apart on the platform while holding handrails to maintain balance and stability. They will be instructed to relax and allow the vibrations to pass through her body. This will be applied for 20 minutes per session.~* The vibration will be started with lower settings and gradually will be increased till the desired frequency and amplitude (45 HZ) will be reached.~* After the session will be completed, the participant will be instructed to cool down gradually by doing deep breathing for 5 minutes to help their body to return to a resting state. They will be advised to drink plenty of water to be hydrated and recovered after the WBV session."
223835769|NCT00541957|BEHAVIORAL|behavior therapy|10 sessions over 4 months
223835770|NCT00541957|DRUG|Medication prescribed by PCP|Can include any antidepressant medication
223835771|NCT05357807|PROCEDURE|Standard RYGB|Roux-en-Y Gastric bypass
223835772|NCT05357807|PROCEDURE|Extended Pouch RYGB|Roux-en-Y gastric bypass with an extended pouch
223835773|NCT05357807|PROCEDURE|Banded extended pouch RYGB|Roux-en-Y gastric bypass with a banded extended pouch
223835774|NCT00404482|DRUG|Cyclosporine A|
223835775|NCT03922828|DIAGNOSTIC_TEST|CT scans|CT surveillance, Lung biopsy, Lung resection
223835776|NCT04678869|DRUG|Ciprofloxacin|prophylactic ciprofloxacin (10mg/kg BD, enteral/IV)
223835777|NCT04678869|DRUG|Antibiotic|Standard of care antibiotic as per local policy
223835778|NCT03854240|OTHER|Classic block (Group C) and modified block (Group M) groups|Classic block (Group C) and modified block (Group M) will be performed following induction of general anesthesia, with patients in the prone position by using ultrasound device
223835779|NCT03208309|DRUG|Diacerein|
223835780|NCT03208309|DRUG|Placebo|
223835781|NCT06291077|DRUG|Belatacept|Changing of anticalcineurins by Belatacept
223835782|NCT06291077|DRUG|anticalcineurins|Keeping of anticalcineurins
223835783|NCT01607411|DRUG|Fluoride|Fluoride Toothpaste
223835784|NCT01607411|DRUG|Placebo|Fluoride free toothpaste
223835785|NCT03888508|OTHER|SIT|"sensory integration therapy along with standard therapy.~Primary care giver will be trained to perform sensory integration therapy at home.~. Sensory interventions will include maneuvers for both hypo and hyper-reactive behaviors in five senses as tactile, vestibular, proprioception, vision and auditory using a sensory integration kit and other items available at home~Daily sessions of approx 60 minutes/ day with each sensory stimulus given for 10-30 minutes 6 days in a week will be done."
223835786|NCT05697432|DIAGNOSTIC_TEST|Oral Examination|A complete examination of oral and dental hygiene any health problems will be registered
223835787|NCT05697432|DIAGNOSTIC_TEST|PUFA index|An assessment of the presence of oral conditions resulting from untreated caries. P=Pulpal involvement, U=ulceration, F=fistula, A=abscess index
223835788|NCT05697432|DIAGNOSTIC_TEST|Plaque index|An assessment of the amount of dental plaque visible on the vestibular and lingual surfaces of all teeth. The index varies between 0-4.
223835789|NCT05697432|DIAGNOSTIC_TEST|Streptococcus mutans screening|A strip test for specific bacteria named streptococcus mutans, which plays an important role in caries formation, from patients' collected saliva
223835790|NCT05697432|BEHAVIORAL|Education|Education on correct toothbrushing technique, oral hygiene, dietary education on foods detrimental for dental hygiene.
223835791|NCT05379140|BEHAVIORAL|Three Weekly Therapeutic Chinese Massage Sessions|Participants in the therapeutic Chinese massage group received three weekly 25-minute therapeutic Chinese massage sessions. The intervention included acupressure to points along the distal lower extremity acupuncture points of the Gall Bladder Channel (GB 40 and then 34). Further Chinese Massage incorporates kneading, rolling, movement of the ankle, rotating, pulling, and scrubbing to the lower extremity.
223835792|NCT05379140|BEHAVIORAL|Three Weekly Placebo Massage Sessions|The placebo massage group received three weekly 25-minute placebo massage that included gentle rubbing to the foot and toes without point stimulation or other techniques of Chinese Massage. The control group had the opportunity to receive the treatment after the study was completed.
223835793|NCT04436081|DRUG|THC-free CBD Oil|Hemp-based CBD oil Gelcaps
223835794|NCT04436081|DRUG|Placebo|Placebo Gelcaps
223835795|NCT00885495|DRUG|darunavir, ritonavir, rosuvastatin|darunavir 600 mg twice daily for 7 days ritonavir 100 mg twice daily for 7 days rosuvastatin 10 mg once daily for 7 days Combination of all three drugs for 7 days
223835796|NCT00885495|DRUG|rosuvastatin, darunavir, ritonavir|rosuvastatin 10 mg daily for 7 days; darunavir 600 mg twice daily for 7 days with ritonavir 100 mg twice daily for 7 days; Combination of all three for 7 days
223835797|NCT01839643|DRUG|Meloxicam 2.4 g|2.4 g in Vaginal Ring
223835798|NCT01839643|DRUG|Meloxicam 3.0 g|3.0 g in Vaginal Ring
223835799|NCT01400893|DEVICE|SCD|The selective cytopheretic device (SCD) is comprised of tubing, connectors and a hemofilter cartridge. The device is connected in series to a commercially available Continuous Renal Replacement Therapy (CRRT) device. Blood from the CRRT circuit is diverted after the CRRT hemofilter through to the extra capillary space (ECS) of the SCD. Blood circulates through this space and is returned to the patient via the venous return line of the CRRT circuit. Regional citrate anticoagulation is used for the entire CRRT and SCD blood circuits.
223835800|NCT02739243|BEHAVIORAL|Tailored group intervention (PREPARE)|
223835801|NCT02739243|BEHAVIORAL|Individual treatment as usual|
223835802|NCT00184613|DEVICE|pump|
223835803|NCT00184613|DRUG|insulin glargine|
223835804|NCT00184613|DRUG|insulin aspart|
223835805|NCT04381702|PROCEDURE|Pancreatoduodenectomy|Open or laparoscopic pancreato-duodenectomy with pancreatojejunal anastomosis
223835806|NCT02528955|RADIATION|A: De-Intensification RT primary tumor region|"A:~* Reduction of radiation dose in the primary tumor region to 56 Gy,~* Elective Radiotherapy of both neck sides"
223835807|NCT02528955|RADIATION|B: De-Intensification RT contralateral lymph nodes|"B:~* No dose reduction in primary tumor region (prescribed dose in primary tumor region: 64 Gy)~* Reduction of target volume: only elective radiotherapy of the ipsilateral neck, no contralateral neck irradiation"
223835808|NCT02528955|RADIATION|C. De-Intensification RT primary tumor region AND contralateral lymph nodes|"C:~* Reduction of radiation dose in the primary tumor region to 56 Gy, AND~* Reduction of target volume: only elective radiotherapy of the ipsilateral neck, no contralateral neck irradiation"
223835809|NCT05165875|DRUG|Hydrocortisone-Lidocaine|"Intervention will be done on the same day based on the randomization.~For the steroid injection group, a 1ml injection of a mixture of 0.5ml triamcinolone acetonide (50mg/5ml) and 0.5ml 1% lignoacaine is given intra-thecally into the first extensor compartment.~For both groups, routine analgesia is not prescribed but the use is not restricted to the participants."
223835810|NCT05165875|OTHER|Splint|"Intervention will be done on the same day based on the randomization. For the splint group, a long thumb spica thermoplastic splint (wrist neutral, 30º CMCJ flexion, 30º thumb abduction, IPJ free) will be customized and intermittent active range of motion exercises will be taught for 4 weeks. Subsequently, the splint will be weaned and passive range of motion exercises taught.~For both groups, routine analgesia is not prescribed but the use is not restricted to the participants."
223835811|NCT02093143|DRUG|Remifentanil|Target-controlled infusion of remifentanil 50 µg/ml using the pharmacologic model of Minto et al. to achieve a theorical brain concentration of 1.5 ng/ml.
223835812|NCT05806099|DRUG|MBS303|"Phase I: The patients confirming to the eligibility criteria will be assigned to one of the 7 dose groups (0.05/0.15/0.45 mg \~ 1.5/6/60 mg, respectively) based on the sequence of inclusion. Each patient will receive MBS303 as per the schedule specified in the respective arms. Based on the safety data of the previous dose groups, if pretreatment with MIL62 is required after disussion by the sponsor and the investigators, the subject should be given an IV infusion of MIL62 1000 mg single dose on the D-7.~Phase Ⅱ: One or two recommended doses will be selected based on the results of Phase I. Each patient will receive one of the two recommended doses MBS303 as step-up doses on D1 (low dose) and D8 (intermediate dose) of C1 and at the target dose on D1 of C2-17 (21-day cycles). Based on the previous safety data, if pretreatment with MIL62 is required after disussion by the sponsor and the investigators, the subjects should be given an IV infusion of MIL62 1000 mg single dose on the D-7"
223835813|NCT01920776|OTHER|ultrasound examination|
223835814|NCT01920776|OTHER|Ultrasound group|Ultrasound group will receive ultrasound examination at least once a day, the results will be noted to the attending who is in charge of the treatment.
223835815|NCT03615209|DEVICE|Transauricular vagus nerve stimulation|Stimulation will be performed for 150 minutes (throughout the entire OGTT).
223835816|NCT03615209|DEVICE|Transauricular sham stimulation|Sham stimulation will be performed for 150 minutes (throughout the entire OGTT)
223835817|NCT03262701|DRUG|Hydrogen Peroxide Gel, 13 weeks|13 weeks of twice-daily use of custom tray application of 1.7% peroxide gel as an adjunct to scaling and root planing in the treatment of chronic periodontitis.
223835818|NCT03262701|DRUG|Hydrogen Peroxide Gel, 26 weeks|26 weeks of twice-daily use of custom tray application of 1.7% peroxide gel as an adjunct to scaling and root planing in the treatment of chronic periodontitis.
223835819|NCT03262701|OTHER|Scaling and Root planing group|Subjects will receive the standard of care which is conventional non-surgical therapy for chronic periodontitis without custom tray application of 1.7% peroxide gel
223835820|NCT05183009|DEVICE|eXciteOSA|eXciteOSA
223835821|NCT03423459|DEVICE|TAVR|Transcatheter Aortic Valve Replacement
223835822|NCT02031744|DRUG|erlotinib [Tarceva]|150 mg oral administration once daily
223835823|NCT02031744|DRUG|Placebo|15 mg/kg intravenous administration every 3 weeks
223835824|NCT02031744|DRUG|Onartuzumab [MetMAb]|15 mg/kg intravenous administration every 3 weeks
223889066|NCT05980000|DRUG|Ramucirumab|Ramucirumab is administered at a dose of 10 mg/kg over 60 minutes.
223835825|NCT05991050|DIETARY_SUPPLEMENT|energy-restricted diet|Meal plan that creates an energy deficit of 500 to 1000 Kcal per day less than the individual's average daily intake was suitable for weight reduction.Each post-menopausal woman followed Dietary Approaches to Stop Hypertension (DASH) which : low in total fat, cholesterol, red meat, sweets and sugar containing beverages, emphasize fish, nuts, fruits, vegetables and whole grains and it also rich in Potassium(6900mg), Calcium(1200-1500mg) and Magnesium, as well as vitamins A, C and E.
223835826|NCT05991050|DEVICE|Whole body vibration|"For 8 weeks, WBV participants completed 3 supervised training sessions a week. The exercises were consisted of dynamic squats starting from upright position into the assigned degree of knee ﬂexion squats with 90° knee angle, semi-squats with 120° knee angle and heel elevation (calf-raise), each exercise was performed for 3 sets and each set consisted of 5 repetitions."
223835827|NCT03868319|PROCEDURE|lung protective ventilation strategy|low tidal volumes and positive end-expiratory pressure mechanical ventilation during robot-assisted laparoscopic radical cystectomy for bladder cancer
223835828|NCT03868319|PROCEDURE|nonprotective ventilation|large tidal volume and zero PEEP mechanical ventilation during robot-assisted laparoscopic radical cystectomy for bladder cancer
223835829|NCT03724461|BEHAVIORAL|High Intensity resistance training (12 weeks)|High intensity resistance training (80% of 1 repetition maximum), 2 d/wk (Longitudinal)
223835830|NCT03724461|BEHAVIORAL|Light-moderate intensity resistance training (12 weeks)|Light-moderate intensity resistance training (40% of 1 repetition maximum), 2 d/wk (Longitudinal)
223835831|NCT03724461|BEHAVIORAL|Control (12 weeks)|No resistance training during the intervention period.
223835832|NCT03724461|BEHAVIORAL|One High Intensity resistance training session|High intensity resistance training, 1 training session
223835833|NCT03724461|BEHAVIORAL|One Light-moderate intensity resistance training session|Light-moderate intensity resistance training, 1 training session
223835834|NCT02589925|DEVICE|Vercise deep brain stimulation|implantation of a Vercise neurostimulation system
223835835|NCT02589925|PROCEDURE|subthalamic nucleus (STN) stimulation|bilateral high-frequency neurostimulation of the subthalamic nucleus using a Vercise neurostimulation system
223835836|NCT02589925|PROCEDURE|NBM stimulation|bilateral low-frequency neurostimulation of the subthalamic nucleus using a Vercise neurostimulation system
223835837|NCT02589925|PROCEDURE|sham stimulation|ineffective neurostimulation by setting 0mA output at the Vercise neurostimulation system
223835838|NCT04769882|DEVICE|Er:YAG Laser|"Selected Er:YAG settings: enamel removal program for adult, with normal modality (frequency: 20 Hz, energy: 400 mJ, power: 8.0 W, air: 80%, water: 60%) and dentin removal program for adult, with normal modality (frequency: 20 Hz, energy: 200 mJ, power: 4.0 W, air: 90%, water: 30%)"
223889067|NCT05980000|DRUG|Pembrolizumab|Pembrolizumab is administered at a flat dose of 200 mg over 30 minutes.
223835839|NCT03862443|BEHAVIORAL|Fixed Incentive|The Fixed Incentive intervention is a fixed reward, in which participants are eligible for fixed weekly payments based on toothbrushing performance collected through smart powered toothbrush synced to a smartphone app.
223835840|NCT03862443|BEHAVIORAL|Drawing Incentive|The Drawing Incentive intervention is a drawing reward, in which participants are eligible for weekly payments based on toothbrushing performance collected through smart powered toothbrush synced to a smartphone app.
223835841|NCT06310122|DEVICE|Extracorporeal shockwave therapy|"Devices used to improve foot function pain and gait pattern~Patients will be placed in prone position, therapist locate the point of maximum tenderness. treatment area will be prepared with coupling gel to minimize the loss of shockwave therapy at the interface between applicator tip and skin. Each patient will receive 2000 impulses ,3 bar energy,15mm depth applicator at frequency (10 HZ) per session / week for 4 weeks"
223835842|NCT06310122|DEVICE|ultrasound|"Devices used to improve foot function pain and gait pattern~Participants in the study group will be treated with 5 minutes of therapeutic ultrasound at a frequency of 1 MHz and continuous current at a pulse intensity of 1.8 W/cm2 (when the sensitivity level was too high and the procedure hurt the patient, the therapist reduced the intensity . 3 sessions /week for 4 weeks"
223835843|NCT06312631|DEVICE|Putting on the gripping glove|taking measurements and putting the gripping glove on the patient
223835844|NCT06312631|OTHER|ULPA questionnaire|"The evaluation of the effectiveness of the gripping glove on the performance of the upper limb in daily life will be evaluated using the ULPA score.~The investigator asks the patient to perform a task and the ULPA collects the total number of errors made by the patient (inability/omission, imprecision, repetition, time to complete the task)"
223835845|NCT06312631|OTHER|Motor Activity Log (MAL) Questionnaire|"The MAL is a self-assessment of the integration of the upper limb into daily life. This measurement allows a quantified evaluation of the perceived performance of the use of the upper limb in the actions of daily life.~The patient will answer 30 questions about daily life and for each item, rate the quantity from 0 to 5: 0 = never uses the hemiplegic arm and 5 = uses as much as before the accident"
223835846|NCT06312631|OTHER|Fugl-Meyer Assessment Upper Extremity (FMA-UE) questionnaire|This questionnaire assesses the motor selectivity of the upper limb. Several questions are asked about the movements that the patient can perform and to each question, the patient can answer either 0 (minimum) and 2 (maximum).
223835847|NCT06312631|OTHER|Score Action Arm Research Test|"This questionnaire evaluates 4 different actions: Grasping an object (6 different objects to grasp), holding an object (4 different objects), pinching an object (6 different objects) and the overall movements made by the patient (3 different overall movements).~For each item, each object or each movement evaluated, the patient must rate the task on a scale of 0 to 3 (0=cannot perform any part of the test and 3=performs the test normally)"
223835848|NCT06312631|OTHER|EuroQol five-level (EQ-5D-5L) questionnaire|This questionnaire assesses the patient's state of health. 5 items are proposed (mobility, autonomy, current activity, pain, anxiety) and for each the patient must check one of the 5 propositions (no problem, mild problems, moderate problems, severe problems, incapable). The patient must also rate their state of health on a scale of 0 to 100.
223835849|NCT06312631|OTHER|Quebec User Evaluation of Satisfaction with Assistive Technology|This questionnaire assesses satisfaction with the technical aid (here the gripping glove) and the related services. The technique and related services will be evaluated by items provided to the patient and he will have to rate for each of them a score between 1 and 5 (1 = not satisfied at all and 5 = very satisfied)
223835850|NCT06312631|OTHER|Psychosocial Impact of Assistive Devices Scale (PIADS)|This questionnaire measures the effect of technical aids on the psychosocial level. 26 sentences or words are offered to the patient concerning his psychological state and the patient must evaluate them between -3 and 3 (-3 = decreased and +3: increased)
223835851|NCT06312631|OTHER|Goal Attainment Scale (GAS)|Carrying out an activity in the patient's real context is assessed using the Goal Attainment Scale (GAS). The doctor gives the patient objectives to achieve and the patient must give the quotation for each objective between initial state (-2), expected result (0) and best possible result (2)
223835852|NCT06312631|OTHER|installation and collection of accelerometers|The accelerometer quantitatively reports the spontaneous use of the upper limb in daily life. It counts the number of voluntary movements of the upper limbs. The amount of movement of the paretic upper limb will be expressed as a percentage of the movements of the non-paretic limb.
223835853|NCT01368211|BIOLOGICAL|2-4-day-old Mirasol-treated Platelets Transfusion|"2-4-day-old Mirasol-treated Platelets Units with:~* Platelet yield between 2.4x10e11 and 4.5x10e11~* Plasma carryover of \>32%~* Cell count \> 800x103/µL"
223835854|NCT01368211|BIOLOGICAL|2-4-day-old Untreated Platelets Transfusion|"2-4-day-old Untreated Platelets Units with:~* Platelet yield between 2.4x10e11 and 4.5x10e11~* Plasma carryover of \>32%~* Cell count \> 800x103/µL"
223835855|NCT03318211|DRUG|Magnesium Sulfate|Intravenous ampules of MgSo4 was given to only to control group after delivery
223835856|NCT02085343|BEHAVIORAL|EXP|Participants will receive one-session exposure therapy consisting of six-6 minute trials of exposure to heights, involving ascending a 9-landing flight of outdoor stairs. Participants will be asked to ascend, accompanied by the therapist who will provide verbal encouragement throughout supporting efforts at exposure. An instructional set will be provided prior to treatment presenting the rationale for exposure as an effective means of reducing pathological fear.
223835857|NCT02085343|BEHAVIORAL|EXP + SBF|Participants will receive one-session exposure therapy consisting of six-6 minute trials of exposure to heights, involving ascending a 9-landing flight of outdoor stairs. Participants will be asked to ascend, accompanied by the therapist who will provide verbal encouragement supporting efforts at exposure. An instructional set will be provided prior to treatment explaining how safety behaviors serve to maintain fear, and how their elimination may enhance fear reduction. Additionally, the therapist will identify safety behaviors and prompt participants to reduce their utilization of them during treatment.
223835858|NCT02085343|BEHAVIORAL|EXP + SBF + AA|Participants will receive one-session exposure therapy consisting of six-6 minute trials of exposure to heights, involving ascending a 9-landing flight of outdoor stairs. Participants will be asked to ascend, accompanied by the therapist who will provide verbal encouragement supporting efforts at exposure. An instructional set will be provided explaining the rationale for eliminating safety behaviors, and how engagement in anti-phobic actions may enhance fear reduction. Additionally, the therapist will identify safety behaviors and prompt participants to reduce their utilization of them during treatment, and will instruct participants to enact a series of progressively challenging anti-phobic actions which oppose the prototypical fear response.
223835859|NCT01349660|DRUG|Bevacizumab|Bevacizumab 10 mg/kg IV every 2 weeks
223835860|NCT01349660|DRUG|BKM120|BKM120 orally (PO) once daily
223835861|NCT03746756|BEHAVIORAL|SBIRT|"As part of regular practice FQHC screen patients at least once a year with the Alcohol Use Disorders Identification Test (AUDIT) to identify alcohol problems and Drug Abuse Screening Test (DAST) to identify drug problems. Those who are the most severed and referred to treatment are approached about participating in the study."
223835862|NCT03746756|BEHAVIORAL|SBIRT+RMC-PC|In addition to SBIRT, those randomly assigned to the experimental condition will also receive Recovery Management Checkups for Primary Care (RMC-PC) at the time of referral/study enrollment and quarterly for 12 months. RMC-PC involves a linkage manager reviewing the assessment data and using motivational interviewing to encourage the person to go to treatment and identify barriers to entering or staying in treatment. It also involves problem solving on how to address common issues (e.g., transportation, scheduling), staying in regular contact for the first two weeks to make sure they stay in treatment, and checking in on continuing care compliance at later checkups.
223835863|NCT03281278|OTHER|standard treatment|standard medical treatment
223835864|NCT05274308|PROCEDURE|Blood sampling|Blood sampling from all eligible transplantation patients according to the protocol
223835865|NCT05200637|DEVICE|Orsiro stent|Orsiro stent
223835866|NCT05200637|DEVICE|Xience stent|Xience stent
223835867|NCT05200637|DEVICE|Any drug-eluting stent|Any drug-eluting stent
223835868|NCT02535559|BEHAVIORAL|Teens Against Tobacco Use|Teens Against Tobacco Use teen teachers develop and then deliver anti-tobacco presentations to the target population of younger students.
223835869|NCT05353543|DRUG|SSRIs|In this study, SSRIs antidepressants will be used, and the oral dose will be determined by the clinical specialist. Once-daily for 6 weeks.
223835870|NCT05353543|PROCEDURE|acupuncture (strong reaction acupoints)|This study will use the intradermal needle as an acupuncture intervention. Strong reaction acupoints selected in the first part of the study will be stimulated. According to the position of the acupoints, choose a needle of φ0.20\*1.5m or φ0.20\*1.2mm. Press the needle to insert the acupoint vertically and retain it in the skin. After the intervention, the needle will be retained for 72 hours with a day of rest after removal. During needle retention, participants will be instructed to press the acupoints 3-4 times a day for about 1 minute each time, with the amount of stimulation as much as the patient can tolerate, at an interval of about 4 hours. A total of 10 treatment sessions will be performed for 6 weeks.
223835871|NCT05353543|PROCEDURE|acupuncture (weak reaction acupoints)|This study will use the intradermal needle as an acupuncture intervention. Weak reaction acupoints selected in the first part of the study will be stimulated. According to the position of the acupoints, choose a needle of φ0.20\*1.5m or φ0.20\*1.2mm. Press the needle to insert the acupoint vertically and retain it in the skin. After the intervention, the needle will be retained for 72 hours with a day of rest after removal. During needle retention, participants will be instructed to press the acupoints 3-4 times a day for about 1 minute each time, with the amount of stimulation as much as the patient can tolerate, at an interval of about 4 hours. A total of 10 treatment sessions will be performed for 6 weeks.
223835872|NCT05353543|PROCEDURE|sham acupuncture|Sham acupuncture will use the same size, color, and material as the verum intradermal needle with a thin silicone pad in the middle instead of the needle body. The sham acupuncture will be needled on the points 1cm lateral to strong reaction acupoints. After the intervention, the needle will be retained for 72 hours with a day of rest after removal. A total of 10 sessions will be performed for 6 weeks.
223889068|NCT03315754|DRUG|TOOKAD Soluble 4 mg/kg|Vascular targeted photodynamic therapy using TOOKAD Soluble
223889069|NCT06123611|BEHAVIORAL|Adopting Comprehensive Training for FireArm Safety in Trauma centers|Firearm access screening, brief firearm safe storage intervention, and referral to community and preventive health resources
223835873|NCT02826304|PROCEDURE|Vaginal hysterectomy|"All the cases were performed by the same surgical team~1. Incision is made at the anterior cervical lip below the bladder reflection~2. Anterior peritoneal entry .~3. Douglas pouch entry.~4. The uterosacral ligaments and the cardinal ligaments are clamped, divided and ligated .~5. Uterine artery clamping division and ligation~6. After securing the uterine A., debulking procedures was performed in the form of bisection, coring or myomectomy~7. Utero-ovarian and round clamping-division and ligation ( in cases where oophorectomy was performed this part was done at the level of the infundibulo-pelvic ligament).~8. Hemostasis~9. The vaginal vault is closed after insertion of intraperitoneal drain and"
223835874|NCT02826304|PROCEDURE|Laparoscopic assisted vaginal hysterectomy|"1. Uterine manipulator was inserted through the cervix to mobilize the uterus~2. Veress needle was inserted through the base of the umbilicus~3. creation of pneumoperitoneum~4. Insertion of 4 trocars one at the base of umbilicus for the camera and 3 lateral trocars~5. The round and the utero-ovarian ligament are coagulated and divided.~6. Dissection through the vesico-uterine space to displace bladder away from the cervix.~7. Uterine artery was coagulated and divided laparoscopically~8. anterior colpotomy over the cup of the uterine elevator.~9. Vaginal part starts with opening of douglas pouch and clamping , division and ligation of uterosacral and cardinal ligaments followed by removal of the uterus and closure of the vault. reinflation to ensure proper hemostasis."
223835875|NCT05666102|BEHAVIORAL|Transgender men's perspectives on HIV risk and HIV prevention interventions|Investigators will enroll 30 TMSM in 5 focus groups where they will examine the unique contexts in which risk for HIV acquisition occurs for TMSM, and explore participant preferences for HIV prevention services. Focus group questions will focus on five areas: 1) Gathering information related to partner selection and sorting among TMSM; 2) assessing TMSM's perceptions of HIV risk in their lived experiences; 3) exploring the various types of sexual behavior TMSM are engaging in; 4) understanding the various HIV prevention strategies currently being deployed by TMSM; and 5) examine the preferences TMSM have for receiving information related to sexual health and HIV prevention information.
223835876|NCT05906303|DRUG|Caffeine and Sodium Benzoate Injection|Provide caffeine to shorten second stage of labor and augment pushing efforts
223835877|NCT05906303|DRUG|Normal Saline|Provide normal saline to serve as a placebo
223835878|NCT03240341|BEHAVIORAL|Patient Activation Measure Questionnaire|Measure the level of patient engagement in cancer care pathway
223835879|NCT02337712|RADIATION|q.d. RT|65 Gy in 26 fractions
223835880|NCT02337712|RADIATION|b.i.d.RT|45 Gy in 30 fractions
223835881|NCT02337712|DRUG|etoposide and cisplatin|etoposide and cisplatin concurrent with radiotherapy
223835882|NCT01212406|DRUG|Vitamin D|Every month 100.000 units of vitamin D in syringe Exacta-Med Oral Dispenser during 2 years and re-evaluation after 3 years
223835883|NCT00519636|DRUG|FPNS|fluticasone propionate nasal spray
223835884|NCT00519636|DRUG|FFNS|fluticasone furoate nasal spray
223835885|NCT00519636|DRUG|placebo FFNS|placebo nasal spray matching fluticasone furoate nasal spray
223835886|NCT00519636|DRUG|placebo FPNS|placebo nasal spray matching fluticasone propionate nasal spray
223835887|NCT03449537|DIETARY_SUPPLEMENT|extensively hydrolyzed casein formula + LGG|Hypoallergenic formula based on extensively hydrolyzed casein supplemented with the probiotic Lactobacillus rhamnosus GG
223835888|NCT03449537|DIETARY_SUPPLEMENT|Hypoallergenic formula based on amino-acid based formula|Hypoallergenic formula for cow milk allergy treatment based on amino acids
223835889|NCT01611818|OTHER|Low Intensity Internet-delivered psychotherapy|Patients will be contacted by a researcher trained in psychotherapy. Patients can ask for questions or advice to psychotherapists during the study
223835890|NCT01611818|OTHER|Self-guided Internet delivered psychotherapy|No contact with the therapists over the treatment period will be done.
223835891|NCT01611818|OTHER|Improved treatment as usual|Any kind of treatment administered by the GP to the patient with depression
223835892|NCT04436796|DEVICE|interoperable Artificial Pancreas System (iAPS)|Use of the iAPS at home for 13 weeks, with weekly adaptation of insulin delivery settings occurring automatically in the iAPS.
223835893|NCT04436796|OTHER|Sensor-Augmented Pump (SAP)/Predictive Low Glucose Suspend (PLGS)|Use of personal pump with study CGM \& glucometer at home for 13 weeks.
223835894|NCT03136835|DRUG|Maternal Hyperoxygenation|Oxygen via nasal prongs at up to 4L/min continuously during 2nd and 3rd trimester of pregnancy until birth
223835895|NCT00462644|DRUG|RSI sedation with etomidate/succinylcholine|etomidate 0.3 mg/kg IV plus succinylcholine 1 mg/kg IV
223835896|NCT00462644|DRUG|RSI sedation with fentanyl/midazolam/succinylcholine|100 micrograms fentanyl IV, plus 5 mg midazolam IV, plus 1 mg/kg succinylcholine IV
223835897|NCT03407261|PROCEDURE|micro-osteoperforations|Three vertical micro-osteoperforations, using Excellerator, in the buccal extracted site were executed following the aseptic procedure and local anesthesia
223835898|NCT02964715|DRUG|Empagliflozin|25 mg daily for 6 months
223835899|NCT02846558|OTHER|Frequent Patient Interaction|Weekly informational and supportive text messages will be sent to patients, encouraging adherence to the calorie restriction diet.
223835900|NCT02846558|BEHAVIORAL|Timing Restriction|Patients continue to follow their normal diet, but limit food intake to an 8-hour period during the day.
223835901|NCT02846558|DEVICE|LoseIt! Smartphone Application|Patients will be trained by study staff to download the LoseIt! application, and use it to log all food intake throughout the study duration. Data collected from the application will be the primary measure of adherence to dietary changes.
223835902|NCT00744081|DRUG|Glivec|
223835903|NCT00744081|DRUG|Mitoxantrone|
223835904|NCT00744081|DRUG|Topotecan|
223835905|NCT00744081|DRUG|AraC|
223835906|NCT01728805|BIOLOGICAL|KW-0761|1.0 mg/kg weekly x 4 in cycle 1 then every other week until progression
223835907|NCT01728805|DRUG|Vorinostat|
223835908|NCT05264493|DRUG|NaxRedy ™|5 mg (5 mg/0.5 mL) IM autoinjector injection into lateral thigh
223835909|NCT05264493|DRUG|Naloxone Hydrochloride Injection, USP|2 mg IM (2mg/2 mL) injection into gluteal muscle
223835910|NCT05264493|DRUG|Naloxone Hydrochloride Injection, USP|2 mg bolus IV (2mg/2 mL)
223835911|NCT04228328|DIAGNOSTIC_TEST|The 6-minutes Walk Test|To walk for 6 minutes
223835912|NCT06236581|BEHAVIORAL|GEM Intervention|Lifestyle coaching
223835913|NCT06109415|DRUG|HTX-011|400 mg
223835914|NCT06109415|DRUG|Bupivacaine Hydrochloride|100 mg
223835915|NCT06109415|DRUG|Ibuprofen|400 mg
223835916|NCT06109415|DRUG|Acetaminophen|1 g
223835917|NCT06109415|DEVICE|Luer lock applicator|Applicator for instillation
223835918|NCT03799679|DRUG|Chemotherapeutic Agent|"Drug: Nanoparticle Albumin-Bound Paclitaxel Nanoparticle Albumin-Bound Paclitaxel 125mg/m2, iv, d1. Patients will receive this as a single-agent for the first twelve weeks, then followed by epirubicin in combination with cyclophosphamide.~Drug: Epirubicin 90 mg/m² given IV~Drug: Cyclophosphamide 600 mg/m² given IV"
223835919|NCT04174235|DEVICE|Ultrasound scan|A full history taking was obtained according European surveillance of congenital anomalies EURO-CAT core data. All women underwent abdominal and transvaginal US (Toshiba Xario 200 unit)
223835920|NCT00205231|DRUG|etanercept|
223835921|NCT06307340|BEHAVIORAL|Skills Training in Affective and Interpersonal Regulation with Narrative Therapy (STAIR-NT)|Adapted version of evidence-based behavioral PTSD intervention.
223835922|NCT06307340|BEHAVIORAL|Treatment as Usual|Treatment as usual.
223835923|NCT00000561|DEVICE|pacemaker, artificial|
223835924|NCT06812221|DRUG|Sublingual administration|Participants will receive a sublingual dose of 5-MeO-DMT or placebo, once a week for four consecutive weeks.
223835925|NCT06812221|PROCEDURE|Electroencephalography|Conducting baseline electroencephalography and during the consumption of the corresponding dose.
223835926|NCT06812221|DIAGNOSTIC_TEST|Biochemical mesurements|Biochemical determinations will be performed to assess hematological, renal, hepatic, cardiac, and cellular lysis functions. The biochemical markers that will be measured include red blood cells, hematocrit, hemoglobin, glycated hemoglobin, white blood cells, microalbuminuria (urine albumin/creatinine ratio), and various serum markers such as cortisol, glucose, urea, serum creatinine, total cholesterol, HDL, LDL, triglycerides, AST, ALT, lactate dehydrogenase (LDH), creatine kinase (CK), CK-MB, and C-reactive protein.
223835927|NCT06812221|DIAGNOSTIC_TEST|Acute Subjective Ratings of Psychedelic Effects|To determine the intensity of the acute effects experienced by subjects, retrospective ratings will be collected 1 hour after 5-MeO-DMT or placebo exposure. Subjective ratings will include the Peak Experience Scale (PES), the Ego Dissolution Inventory (EDI), and the Mystical Experiences Questionnaire (MEQ).
223835928|NCT06812221|DIAGNOSTIC_TEST|Vital signs|Vital signs, including blood pressure, heart rate, oxygen saturation, respiration rate, body temperature, and electrocardiograms (ECGs), will be monitored over the six weeks of the treatment.
223835929|NCT06812221|DIAGNOSTIC_TEST|Cognitive Assessments|Cognitive assessments will evaluate the effects of sublingual 5-MeO-DMT on cognitive functions. Participants will complete the Phonological Verbal Fluency Test (FAS) to assess executive function, the Paced Auditory Serial Addition Test (PASAT) to evaluate processing speed, and the Digit Span Scale (DSS) to measure attention span and working memory. These tests will be administered at baseline, during treatment, and post-treatment to monitor any cognitive changes in response to either a 6 mg dose of 5-MeO-DMT or placebo. This will help determine how the intervention may affect cognitive processing, memory, and attention.
223835930|NCT06812221|DIAGNOSTIC_TEST|Psychiatric Assessments|Psychiatric evaluations will be conducted to assess the emotional and psychological effects of sublingual 5-MeO-DMT. Participants will complete the Beck Depression Inventory II (BDI II) to measure mood and depressive symptoms, the State-Trait Anxiety Inventory (STAI) to evaluate state anxiety, and the Depression, Anxiety, and Stress Scale (DASS-21) to assess stress levels. Additionally, the Suicidal Ideation Scale (SSI) will be used to monitor any changes in suicidal ideation throughout the study. These psychiatric assessments will be administered at multiple time points during the study to evaluate the potential therapeutic effects of 5-MeO-DMT in improving mood, anxiety, and overall psychological well-being.
223835931|NCT05728593|OTHER|parent-based occupational therapy|Parent-based occupational therapy intervention While the therapist, parent and child were in the therapy area in the first session, the child received the same standard occupational intervention as the control group, and during this process, the parents recorded the therapy with a video recorder. In the second 20 minutes, three activities (such as eating, dressing or mobility activities), which had been decided and planned by the parent and the therapist before the session, were performed by the child and helped by the parent and video-recorded by the occupational therapist.
223835932|NCT05728593|OTHER|Standard occupational therapy intervention|"The sessions in this intervention included the creation of a client-based programme to increase each child's individual skills, functions and social participation. Each session lasted 45 minutes and took place twice a week until 10 sessions had been completed.~Various materials such as toys, blocks, paper and pencils were used to increase the child's participation in daily living, leisure and play activities."
223835933|NCT01222221|BIOLOGICAL|glioblastoma multiforme multipeptide vaccine IMA950|
223835934|NCT01222221|BIOLOGICAL|sargramostim|
223835935|NCT01222221|DRUG|temozolomide|
223835936|NCT01222221|OTHER|laboratory biomarker analysis|
223835937|NCT01222221|OTHER|pharmacological study|
223835938|NCT01222221|PROCEDURE|adjuvant therapy|
223835939|NCT01222221|RADIATION|radiation therapy|
223835940|NCT03776994|BIOLOGICAL|Vaccinations on Day 0, Day 28, and Day 140|The monovalent VEE VLP vaccine (the same VEE VLP study agent which comprises the VEE portion of the NIAID trivalent alphaviral VLP vaccine) will use the same vaccination regimen (Day 0, Week 4 \[Day 28\], and Week 20 \[Day 140\]) and the vaccine dosages (2 μg, 10 μg, and 20 μg)
223835941|NCT06858436|DRUG|Canagliflozin 100mg|receiving Canagliflozin 100mg QD
223835942|NCT05064111|DIAGNOSTIC_TEST|TRUS biopsy|The biopsy procedure will be completed using an FDA-approved ultrasound machine with the addition of an investigational (non-FDA approved) image fusion software.
223835943|NCT01017978|PROCEDURE|MRI Scan of soft tissue tumor|MRI scan will be completed at baseline (prior to start of subject's clinically ordered chemotherapy treatments.
223835944|NCT01338558|DRUG|bevacizumab [Avastin]|5 mg/kg iv on Day 1 of each 2-week cycle until disease progression, unacceptable toxicity or withdrawal of consent
223835945|NCT01338558|DRUG|cetuximab|400 mg /m2 iv on Day 1, followed by 250 mg/m2 every week until disease progression, unacceptable toxicity or withdrawal of consent
223835946|NCT01338558|DRUG|mFOLFOX6|Standard mFOLFOX6 chemotherapy, 2-week cycles until disease progression, unacceptable toxicity or withdrawal of consent
223835947|NCT05443100|OTHER|Whole-body cryostimulation (WBC)|Multidisciplinary rehabilitation program consisting of 10 WBC sessions.
223835948|NCT05443100|OTHER|Rehabilitation program|Multidisciplinary rehabilitation program consisting of diet and physical exercise.
223835949|NCT06918691|BEHAVIORAL|technology addiction prevention program|technology addiction prevention program
223835950|NCT06544096|BEHAVIORAL|intervention group (WeChat platform + healthcare)|The study will implement the WeChat-based Neonatal Home Skin Care Management System, designed based on neonatal skin characteristics and evidence-based care guidelines. The intervention materials included a WeChat platform functional module (comprising a newborn information registration interface, online consultation, and questionnaire features) along with standard educational brochures used in the control group. During hospitalization, study group healthcare providers will deliver standard health education (identical to the control group) while additionally guiding mothers through platform registration and data entry, with demonstrations of system functionality. Post-discharge, the system automatically will deliver stage-appropriate skin care recommendations based on neonatal age with read reminders prompting parental engagement. Parents can access educational materials or submit queries at any time, while researchers utilize the platform for survey distribution.
223835951|NCT06544096|BEHAVIORAL|control group (routine health education)|When the parturient is discharged from the hospital, the medical staff of the control unit will give the parturient health education about the discharge of the newborn. The contents of the education include neonatal jaundice, umbilical care, vaccination, 42-day follow-up, breastfeeding and so on, which are not included in the system.
223835952|NCT02800486|DRUG|Intra-arterial Cetuximab|
223835953|NCT02800486|DRUG|Intra-arterial Mannitol|
223835954|NCT02800486|RADIATION|Hypofractionated re-irradiation|
223835955|NCT01779713|GENETIC|Case-control transcriptomic study|No intervention
223835956|NCT06618105|DRUG|Albuterol Sulfate 90 MCG/INHAL Metered Dose Inhaler, 200 Actuations|Albuterol sulfate HFA Inhalation Aerosol (E.Q. 90 mcg of albuterol Base/Inh) (of Macleods Pharmaceuticals Ltd.)
223835957|NCT06618105|DRUG|Test Placebo|Matching Placebo of T inhalation aerosol
223835958|NCT06618105|DRUG|Reference Placebo|Matching Placebo of R inhalation aerosol
223835959|NCT06618105|DRUG|Albuterol Sulfate 90 MCG/INHAL Metered Dose Inhaler, 200 Actuations|Albuterol sulfate HFA Inhalation Aerosol (E.Q. 90 mcg of albuterol Base/Inh) (distributed by Teva Pharmaceuticals USA, Inc.)
223835960|NCT06622278|BEHAVIORAL|Flipped Classroom|The flipped classroom educational model requires participants to independently review educational material before class, and class time with the health educator is spent engaging in group and individual skills-based activities and problem-solving assignments. The theoretical basis for the development of active learning is to elicit higher cognitive learning, according to the revised Bloom's taxonomy and shift independent student time to passive learning (remembering and understanding) and collaborative student and educator time to active learning (applying, analyzing, evaluating, and creating). Thus, the weight management education will include: case vignettes, group debates/discussions, think-pair-share activities, gamification of health-related topics, creation of meal and physical activity, problem-solving barriers to a healthy diet and physical activity, and hands-on worksheets.
223835961|NCT05516017|DEVICE|Vestibular Electrical Stimulator and Pinhole Glasses|"It is applied with a vestibular electrical stimulation device for 20 msec with 2 Hz, 1-4 mA, 1 mA increments. Very high frequencies can cause auditory perceptions such as 0.5 - 20 kHz, should be avoided.~The pinhole glasses are made of 2 pieces of opaque black plastic material with a total of 113 holes on each side. The opaque black plastic is 1.7 mm thick, 4.5 cm wide, and 5.5 cm long.~The holes in the opaque black material are arranged horizontally in 11 rows from top to bottom. The diameter of each hole is 1.1 mm, the horizontal distance of the holes from each other is 4.5 mm, and the vertical distance is 3.5 mm."
223835962|NCT05516017|DEVICE|Vestibular Electrical Stimulator|It is applied with a vestibular electrical stimulation device for 20 msec with 2 Hz, 1-4 mA, 1 mA increments. Very high frequencies can cause auditory perceptions such as 0.5 - 20 kHz, should be avoided.
223835963|NCT06625853|OTHER|Mtwo R files with Xp-Endo finisher file|"XP-endo Finisher file will be inserted without rotation into the root canals filled with 2.5% NaOCl and will be activated (800 rpm; torque of 1 N.cm) for~1 min in each canal using slow and gentle 7-8 mm lengthwise movements."
223835964|NCT06625853|OTHER|Mtwo R files|obturation material will be removed using Mtwo R (VDW, Munich, Germany)files attached to an endodontic motor (Ecube, seachin, Korea) with a constant speed of 280 rpm, as suggested by the manufacturer. Mtwo R 25/0.05 will be used to empty the coronal and middle thirds of the root. Mtwo R 15/0.05 will be used to reach the working length.
223835965|NCT06625879|PROCEDURE|Serratus Anterior Plane Block (SAPB)|"Group I: (Serratus Anterior Plane Block (SAPB) Group) (n=15):~The patient will lay on her side with arm brought forward, the linear US transducer probe (10-12 MHz) will be placed in the midaxillary line and then moved caudal from second rib until the sixth intercostal space. At this point, the subcutaneous tissue and serratus muscle will be identified in the superficial plane, whereas the external intercostal muscles will be identified in the intermediate plane and finally in the deep plane the ribs, pleura and lung will be identified. The needle will be advanced from caudal to cranial direction. In-plane technique will be used until the tip of the needle placed between the serratus anterior muscle and the external intercostal muscle (deep SABP) . A volume of titrated bolus of 20 ml of bupivacaine 0.5% will be injected after aspiration to avoid intravascular injection."
223835966|NCT06625879|PROCEDURE|Midpoint transverse process to pleura (MTP) block|In the lateral postion, the T4 spine will be counted by ultrasound, and high frequency linear US transducer probe (10-12 MHz) will be placed longitudinally, approximately 2.5 cm lateral to the midline the needle will be advanced in plane from cranial to caudal direction. The desired end point for the needle tip will be the midpoint of the line between the posterior border of the transverse process of T4 and the pleura(injection will be deep (anterior) to the posterior aspect of the vertebral transverse process but superficial to the superior costotransverse ligment),the needle tip dose not enter the paravertebral space , a volume of titrated bolus of 20 ml of bupivacaine 0.5% will be injected after aspiration to avoid intravascular injection,pleural displacement and bowing of erector spinae will be observed at the side of injection .
223835967|NCT06626217|OTHER|Resting conditions|The volunteers hand is at rest and Perfusion index readings are taken for six minutes from pulse oximeter and smartwatch
223835968|NCT06626217|OTHER|Movement artifacts|The volunteer periodically spreads his/her fingers and clenches them into a fist, and Perfusion index readings are taken for six minutes from pulse oximeter and smartwatch.
223835969|NCT06626217|OTHER|Circulation constriction|The volunteers arm is constricted using a cuff to measure non-invasive blood pressure. The perfusion index value is monitored during the time of cuff pressure and cuff release. The measurement is followed by a 4-minute pause to allow the vascular supply to stabilize. The measurement is repeated three times.
223835970|NCT06626217|OTHER|Physical exercise|The volunteer is seated on the exercise bike, rests his forearms on the handlebars and is instructed not to move his arms. The volunteer\&#39;s heart rate is controlled to increase to 120 beats per minute. For five minutes, the perfusion index is recorded from a pulse oximeter and smartwatch.
223835971|NCT06626178|DIAGNOSTIC_TEST|Computed tomography (CT) scan low dose|The radiological investigation will be done with multi-detector-row (64 or more) computed tomography (CT) scanners at low-dose protocol. The low-dose spiral CT consists of a CT study of the chest, without the need for injection of contrast medium, characterized by less radio exposure than the standard CT of the chest with high sensitivity in detecting pulmonary nodules.
223835972|NCT06626178|PROCEDURE|Blood sampling|Peripheral venous blood sampling (20 ml)
223835973|NCT06626178|PROCEDURE|Tissue sampling (lung)|sampling of tumor and healthy tissue during surgery
223835974|NCT06626178|OTHER|Spirometry|Spirometry measurement using spirometer
223835975|NCT06626178|OTHER|Questionnaires|Compilation of epidemiological questionnaire, quality of life questionnaires
223835976|NCT06626178|OTHER|Smoking cessation program|Study guarantee valid support for quitting smoking, which for a smoker is a more effective intervention to reduce the risk of developing lung cancer, myocardial infarction and other smoking-related diseases
223835977|NCT06626178|OTHER|Carbon monoxide measurment|Measurment of Carbon monoxide (CO)
223835978|NCT06626178|OTHER|Cardiovascular primary prevention|Intervention done in order to find the presence of coronary calcifications
223835979|NCT06863662|DRUG|Etoricoxib + Tizanidine fixed dose|One sachet with 120 mg / 4 mg, dissolved in 100 mL of water
223835980|NCT06863662|DRUG|Etoricoxib fixed dose|One sachet with 120 mg, dissolved in 100 mL of water
223835981|NCT06624852|OTHER|Screening for coronary artery revascularization based on TMT-ECG|Screening for coronary artery revascularization based on TMT-ECG with and without the assistance of PROPECG-TMT
223835982|NCT06626386|DIAGNOSTIC_TEST|PSA testing|PSA Testing in venipunctate and capillary blood
223835983|NCT06625294|PROCEDURE|Task -oriented training with bilateral functional task training exercises|"Task oriented training approach with BFTT will consists of different tasks including:~Hand Movements:~1. Fold a small cloth towel with both hands with initially putting the towel flat on the table and gradually folding it into a large towel roll.~2. Put a small amount of putty on patient's table and instruct to roll it with the help of rolling pin moving it back and forth using both the hands.~3. Place a jar with a removable lid on the table and instruct the patient to remove lid from the jar completely by holding the jar with either hand and remove the lid with the alternate hand.~4. Pouring water: Pour water from jug while holding the jug in unaffected hand to cup/glass that is held in affected hand and activity can be done the other way round as well.~5. Pour water from one hard plastic cup to another while alternatively involving both the hands (we must not allow deformation of the cup)~6. Plunging action with coffee maker against water resistance:Fill the coffee maker with water."
223835984|NCT06625294|PROCEDURE|Task Oriented Training with CIMT|"• Hand Movements:~1. Sitting at a table (Wrist Extension): Affected forearm resting on table. Place cylindrical object in palm of patient's hand. Patient asked to move the hand towards the forearm (dorsiflexion) by extending the wrist - no elbow flexion allowed.~2. Sitting at a table (Radial Deviation of Wrist): Therapist should place forearm with ulnar side on table in mid-pronation / supination position. Thumb in line with forearm and wrist in extension. Fingers around cylindrical object. Patient is asked to lift hand off table. No wrist flexion or extension.~Advanced Hand Activities:~1. Have the patient reach forward to pick up the top of a pen with their affected hand, bring the affected arm back to their side and put the pen cap down in front of them.~2. Place (beans), in a teacup an arm's length away on the affected side. Place another teacup an arm's length away on the intact side. Have the patient pick up one beans with their affected hand and place the beans in the cup on the"
223835985|NCT05314556|BEHAVIORAL|Group psychotherapy|Additional group psychotherapy for patients with narcolepsy type 1 with standard medication
223835986|NCT06687148|OTHER|Manual manipulation|The participants will receive one session of manipulation if in the experimental group. It should be mentioned that the technique will be carried out by a physiotherapist with a history of more than 10 years of manual therapy. For instance, to correct right anterior innominate rotation, the participant will be made to lie on the side so that the affected side is upward. The physiotherapist will stand in front of the participant; first we will put their shoulders, pelvis and lower limbs in neutral position and place the right hand on the anterior superior iliac spine (ASIS) and the left hand on the ischium tuberosity and with a rotational movement of the hands, the physiotherapist will rotate the ilium posteriorly. At the end of the range, we will replace the position of hands and place the left forearm on the ischium tuberosity and place the right hand on the upper participant's shoulder and will move it toward the bed at the end of the range in exhalation a thrust will be executed.
223835987|NCT06687148|OTHER|Sham manipulation|The participants will receive one session of sham manipulation if in the sham group. For instance, to correct right anterior innominate rotation, the participant will be made to lie on the side so that the affected side is upward. The physiotherapist will stand in front of the participant; first we will put their shoulders, pelvis and lower limbs in neutral position and place the right hand on the anterior superior iliac spine (ASIS) and the left hand on the ischium tuberosity and with a rotational movement of the hands, the physiotherapist will rotate the ilium posteriorly. At the end of the range, we will replace the position of hands and place the left forearm on the ischium tuberosity and place the right hand on the upper participant's shoulder and will move it toward the bed at the end of the range in exhalation, the physiotherapist will pretend to execute a thrust.
223835988|NCT04147767|DIETARY_SUPPLEMENT|Cholesterol Reducing Strawberry Yogurt Drink (Tesco Ltd)|"Ingredients: Skimmed Milk, Strawberry Juice from Concentrate (5%), Plant Sterols Ester (3.4%)\*\*\*, Sugar, Maize Starch, Flavourings, Colour (Anthocyanins), Starter Culture including Bifidobacterium (Milk), Thickener (Carob Gum), Sweetener (Sucralose), Milk Proteins.~\*\*\* Equivalent to 2% Free Plant Sterols"
223835989|NCT04147767|DIETARY_SUPPLEMENT|Low Fat Strawberry Yogurt Drinks (Morrisons Ltd)|Ingredients: Yogurt (Milk), Water, Sugar, Strawberry Purée (1%), Modified Maize Starch, Carrot Concentrate, Flavouring, Acidity Regulator (Citric Acid), Vitamin C, Colour (Paprika Extract), Sweetener (Sucralose), Vitamin D, Vitamin B6.
223835990|NCT01803841|PROCEDURE|Transradial coronary angiography and intervention|
223835991|NCT01803841|PROCEDURE|Transfemoral coronary angiography and intervention|
223835992|NCT05244148|DEVICE|IP1 - Stérimar BLOCKED NOSE Baby nasal spray|1 to 2 sprays per nostril at least 2 twice a day and, as needed, up to a maximum of 6 times a day.
223835993|NCT05244148|DEVICE|IP2 - Stérimar Stop & Protect Cold Baby + standard of care|1 to 2 sprays per nostril at least 2 twice a day and, as needed, up to a maximum of 6 times a day.
223835994|NCT05244148|BEHAVIORAL|Standard of Care|hydration + rest at home + if needed paracetamol
223835995|NCT06002906|DRUG|Indocyanine green|Indocyanine green (ICG) is a safe, sterile, water-soluble molecule that binds to plasma proteins and can be injected intravenously. ICG will be injected intravenously based on the patient's weight prior to and after making the GJ anastomosis and a 10 mL bolus of normal saline will be immediately followed the injection of indocyanine green by an anesthesiologist. A subjective score of 1-5 for perfusion will be assigned by operating surgeons. The RYGB will then be completed by the operating surgeon in their routine fashion.
223835996|NCT06002906|DEVICE|Stryker 1688 AIM system|The Stryker 1688 AIM system used during laparoscopic surgery which is sensitive in the visible and infrared spectrum. ICG (SPY AGENT™ GREEN) is used with the SPY mode in the Stryker 1688 AIM fluorescence imaging system to perform intraoperative fluorescence angiography.
223835997|NCT03239405|DEVICE|Suction callibrated system|One-step suction callibrated SG system
223835998|NCT05902533|RADIATION|Radiation (reduced elective nodal dose (30.6 Gy)|28-30 fractions Monday through Friday of intended chemoradiation depending on the total dose required (50.4-54 Gy) which will occur over approximately 5.5 to 6 weeks.
223835999|NCT05902533|DRUG|Capecitabine|825 mg/m2 BID (Oral Twice daily on days with RT)
223836000|NCT05902533|DRUG|Mitomycin c|10 mg/m2 slow IV push Day 1 and 29
223836001|NCT02841267|DRUG|PF 06252616|
223836002|NCT05771974|DEVICE|Compression therapy using surgical gloves|Intervention group wear two-layer of normal-sized surgical gloves on both hands during chemotherapy infusion
223836003|NCT06695195|DRUG|Cannabidiol (CBD)|25 mg capsule twice daily
223836004|NCT06695195|DRUG|Placebo|25 mg capsule twice daily
223836005|NCT06686303|OTHER|High frequency Segmental Vibrator|Segmental vibrations of high frequency was used on each flexor and extensor interspersed with a 1 minute break.
223836006|NCT06686303|OTHER|Combined effects of high frequency segmental vibrator and neuromuscular electrical stimulation.|Segmental vibrations of high frequency with Neuromuscular Electrical Stimulation was given on each flexor and extensor.
223836007|NCT06710379|DRUG|ADRX-0405|Antibody Drug Conjugate targeting STEAP1
223836008|NCT06698809|DEVICE|Active tPBM|tPBM is a neuromodulatory treatment that uses red and/or near infrared light to penetrate the cortex and can alter both cerebral metabolism and blood flow. Subjects will receive treatment for approximately 12 minutes per treatment.
223836009|NCT05650307|DIAGNOSTIC_TEST|MRI|The magnetic field exposure for MRI in this study is similar to standard clinical MR procedures. The powers of all radio frequency fields in this study are at or under FDA guidelines. The CMR techniques performed here have been used in the literature and in our own clinical cardiac MRI service extensively for several years and have an excellent safety profile in our institution.
223836010|NCT06883006|BEHAVIORAL|Sleep Extension|A 1.5-hour nap opportunity compared to a neutral 1.5 hour waking activity (e.g., puzzle completion) prior to task. Participants will either nap or not prior to the emotion regulation task. These two conditions will be counter-balanced within gender and participants will complete them 1 week apart. If they are in the nap condition, they will nap for 1.5 hours with PSG in a dark, soundproofed room with optional fan, white noise, or music. If they are in the no nap condition, they will work on puzzles for 1.5 hours in the same room but with the lights on.
223836011|NCT06920446|BIOLOGICAL|UCAR T-cell group|A single injection of UCAR T-cells, referred to as universal allogeneic anti-CD19/BCMA CAR T-cells
223836012|NCT06739590|BEHAVIORAL|Learning with CT scans|The average performance improvement in this group will serve as the baseline for learning achievable through conventional CT and MR imaging alone.
223836013|NCT06739590|BEHAVIORAL|Learning with 3D visualization models|Learning anatomical structures using three-dimensional visualization models displayed on a computer.
223836014|NCT06739590|RADIATION|Learning with 3D-MR visualization models|Viewing and manipulating 3D visualization models to learn anatomical structures using the MR headset.
223836015|NCT06744062|DRUG|BR1015|One tablet administered alone
223836016|NCT06744062|DRUG|BR1015-1|One tablet administered alone
223836017|NCT06744062|DRUG|BR1015-2|One tablet administered alone
223836018|NCT06887517|DRUG|Antimalarial with or without oral glucocorticosteroid|"Intervention one: Antimalarial and Oral Glucocorticosteroid, Prednisone or equivalent dose of glucocorticoid tapering: 0.5\~0.6mg/kg/d(week 0\~2), 0.3\~0.4mg/kg/d(week 3\~4), 15 mg/d(week 5\~6), 10 mg/d(week 7\~8), 7.5 mg /d(week 9\~10), 5 mg/d(week 11\~12), 2.5 mg/d(week 13\~24), \<2.5 mg/d(after week 24)；Hydroxychloroquin 6.5mg/kg/d but no more than 400mg/d for initial therapy, and reduce to 4\~5mg/kg/d for maintenance therapy~Intervention two: Antimalarial only. Hydroxychloroquin 6.5mg/kg/d but no more than 400mg/d for initial therapy, and reduce to 4\~5mg/kg/d for maintenance therapy"
223836019|NCT04894578|PROCEDURE|reverse distal metatarsal minimal-invasive osteotomy|minimal-invasive oblique osteotomy of the two or three metatarsal bones using a straight burr
223836020|NCT04894578|PROCEDURE|tarsometatarsal fusion|open procedure with fusion and screw and plate fixation of two to three tarsometatarsal joints
223836021|NCT04321993|DRUG|Baricitinib (janus kinase inhibitor)|Baricitinib will be administered as 4 mg po daily for 14 days or until hospital discharge, whichever is sooner.
223836022|NCT04321993|DRUG|Remdesivir (antiviral) + barictinib (janus kinase inhibitor)|"Remdesivir will be administered as a loading dose of 200 mg IV over one hour on day 1 followed by 100 mg IV daily over one hour on days 2-5 (with a possibility to extend to up to 10 days total).~Baricitinib will be administered as 4 mg po daily for 14 days or until hospital discharge, whichever is sooner."
223836023|NCT04321993|DRUG|Remdesivir (antiviral)|Remdesivir will be administered as a loading dose of 200 mg IV over one hour on day 1 followed by 100 mg IV daily over one hour on days 2-5 (with a possibility to extend to up to 10 days total).
223836024|NCT04321993|DRUG|Tocilizumab (interleukin 6 inhibitor)|Tocilizumab will be administered as a single IV infusion over one hour. Dosage will be 8 mg/kg total bodyweight up to a maximum of 800 mg.
223836025|NCT02635087|DEVICE|miRNA tool|patients to be assessed by the miRNA tool. MicroRNA tool contains miRNA of miR-21、miR-20a-5p、miR-103a-3p、miR-106b-5p、miR-143-5p and miR-215. Investigators evaluate these miRNA status of surgical specimens using qRT-PCR and calculate their risk score(risk score =(0.108×status of miR-21-5p)+(0.086×status of miR-20a-5p)+(0.240×status of miR-103a-3p)+(0.095×status of miR-106b-5p)- (0.238×status of miR-143-5p)-(0.237×status of miR-215),low expression status equals 0 and high expression status equals 1.Then we determine the patients who with a score higher than 1 as exposed patient.
223836026|NCT06842927|OTHER|data collection|"An additional collection of peritoneal dialysate and spot urine samples will be collected.~Participants randomized to the training/validation arm will have their data used for model development, including the training and validation phases."
223836027|NCT06842927|OTHER|data report|An additional collection of peritoneal dialysate and spot urine samples will be collected. Participants randomized to the test arm will have their data isolated and reserved exclusively for evaluating the performance of the final AI model
223836028|NCT06744933|COMBINATION_PRODUCT|Self-administered auricular acupressure integrated with a smartphone application|"6 to 8 Vaccariae Semen ear patches will be affixed on one ear of the patient. The patient will be required to press on the ear patches 3 times a day, and 30 minutes before a meal. Every 3 to 4 days, the patient will visit the clinic to change a new set of ear patches on the same auricular acupoints of the opposite ear alternately. The whole course of intervention will be 8 weeks. The smartphone app will send scheduled pop-up notifications to remind patients to press on the ear patches. The patient will be required to enter the number of times pressing and of defaecation every day on the smartphone application. The smartphone application will send more notifications to the patient if he/ she has a low compliance. When the participants record the number of times pressing on the auricular acupoints, positive reinforcement messages will pop-up, such as Excellent job! for those with good compliance while You are almost there! Keep going! for those with poor compliance."
223836029|NCT06909708|PROCEDURE|SIRT|Y-90 administered
223836030|NCT06909708|PROCEDURE|cTACE|cTACE administered
223836031|NCT05971823|OTHER|Tobacco product administration and assessment|Subjective measures 1 is followed by product sampling that includes 5 self-directed ECIG/own brand cigarette puffs over 10 minutes. After sampling is complete participants complete subjective measures 2. Ten minutes after their sampling has been completed, they complete subjective measures 3 and the behavioral economic task(s). These activities are preceded and followed by cardiovascular response assessment.
223836034|NCT06583122|PROCEDURE|Ultrasound Guided Approach|All enrolled patients will receive the new ultrasound-guided approach to occipital nerve radiofrequency ablation
223836035|NCT07102628|DRUG|Placebo|The participants will receive placebo subcutaneous at randomization (Day 1, Baseline visit) and Day 90
223836036|NCT07102628|DRUG|Inclisiran|The participants will receive Inclisiran sodium 300 mg subcutaneous at randomization (Day 1, Baseline visit) and Day 90
223836037|NCT07102602|DEVICE|high intensity laser therapy|The high-intensity laser used in this study is approved by the Ministry of Health and Welfare, Taiwan (No. 032670). It operates at a wavelength of 940 nm. For the active treatment (HILT), the laser delivers 900 joules to the quadriceps at a power output of 3 W for 5 minutes and is applied along the length of the quadriceps muscle
223836038|NCT07102602|DEVICE|Sham laser therapy|In the sham condition (SHAM), the output is set to 0 W for 5 minutes, resulting in no energy delivery.
223836039|NCT06915051|DIAGNOSTIC_TEST|Determining the relationship between the coiling number and fetal echocardiography findings.|Fetal echocardiography findings to be performed simultaneously with the determination of the coiling number.
223836040|NCT06919913|DIETARY_SUPPLEMENT|Culturelle Digestive Daily Probiotic Capsule|Each capsule contains 10 billion colony-forming units (CFU) of Lactobacillus rhamnosus GG. Subjects will self-administer 1 oral capsule daily for 6 weeks post operatively.
223836041|NCT06918717|PROCEDURE|Direct Laryngoscopy-to-VideoLaryngoscopy sequence|Participants will proceed with a double intubation technique sequence, first performing an initial direct laryngoscopy without looking at the video screen until they reached the epiglottis, then performing an indirect lryngoscopy for intubation.
223836042|NCT06918717|PROCEDURE|Free use of videolaryngoscopy|Participants are free to use of the videolaryngoscope as they intended
223836043|NCT06919900|BEHAVIORAL|Perturbation Training|Unexpected slips blended with trips and unperturbed walking trials on a treadmill. A safety harness will be worn at all times.
223836044|NCT06919900|BEHAVIORAL|Treadmill Walking|Treadmill walking for the same amount of time as the training group without perturbation. A safety harness will be worn at all times.
223836045|NCT06918470|OTHER|Standard monitoring techniques|（3）atients were given the same anesthesia regimen. Standard monitoring techniques include electrocardiogram, pulse oximeter, heart rate and blood pressure monitoring, continuous monitoring of bispecific index of electroencephalography, and the use of remifentanil (0.3 mg/kg) Rapid sequence induction was performed using sufentanil (0.3 μ g/kg), propofol (2.5mg/kg), and rocuronium bromide (0.6 mg/kg). Anesthesia was maintained using remifentanil (0.1-0.2 μ g/0kg/min), inhaled sevoflurane (1%), and intravenous propofol (1-4 mg/kg/h) to maintain BIS 40-60, with heart rate and blood pressure within 20% of baseline values.
223836046|NCT06918470|OTHER|noise cancelling headphones|The treatment group started wearing noise cancelling headphones until the end of the surgery in the general anesthesia induction group to isolate intraoperative environmental noise,patients were given the same anesthesia regimen. Standard monitoring techniques include electrocardiogram, pulse oximeter, heart rate and blood pressure monitoring, continuous monitoring of bispecific index of electroencephalography, and the use of remifentanil (0.3 mg/kg) Rapid sequence induction was performed using sufentanil (0.3 μ g/kg), propofol (2.5mg/kg), and rocuronium bromide (0.6 mg/kg). Anesthesia was maintained using remifentanil (0.1-0.2 μ g/0kg/min), inhaled sevoflurane (1%), and intravenous propofol (1-4 mg/kg/h) to maintain BIS 40-60, with heart rate and blood pressure within 20% of baseline values.
223836047|NCT06917807|PROCEDURE|Pericapsuler nerve group block|A single shot pericapsular nerve group block preformed under ultrasound guidance with a local anesthetic agent ( Marcaine )
223836048|NCT06917807|PROCEDURE|Quadratus lumborum block|A single shot Quadratus lumborum block preformed under ultrasound guidance with a local anesthetic agent ( Marcaine )
223836049|NCT06918197|PROCEDURE|PAS Technique|"PAS Technique Protocol:~The following steps outline the PAS Technique. While the example below uses 6 injection sites, the approach can be adapted for different pain management procedures with a different number of needle injection sites as needed.~Timer: Begin stopwatch for entire procedure from start to medication insertion. Positioning: The patient is placed in a prone position on the fluoroscopic table. Time out was performed.~Skin Preparation: Clean the injection site with an antiseptic solution and drape it to maintain sterility.~Anesthesia: Administer intravenous sedation Identification of Anatomical Landmark:The spinous process was located and marked as the reference point (SP), which was then used as a guide for the following steps.~Marking Target Points: Using the spinous process (SP) as the anatomical landmark and X-ray guided fluoroscopy, Target Point 1 (TP1) was identified and its position verified. The X value (the horizontal distance from the SP to TP1) was measured."
223836050|NCT06918197|PROCEDURE|Standard Technique|"In the Standard or Traditional technique, the spinal needles are used to localize the anatomical objective using fluoroscopic guidance for each needle placement. Traditionally, each needle is placed individually with a spot radiological view before placement and after placement of each needle to confirm the localization."
223836051|NCT06919523|DRUG|Dapagliflozin 5mg|Dapagliflozin 5m orally once daily for 3 months plus standard care (diuretics and Large volume paracentesis)
223836052|NCT06919523|DRUG|Standard care treatment|Diuretics and Large volume paracentesis as indicated
223836053|NCT06919328|DIETARY_SUPPLEMENT|Niagen®|nicotinamide riboside
223836054|NCT06919328|OTHER|NAD+|Nicotinamide adenine dinucleotide
223836055|NCT06919328|OTHER|Placebo|bacteriostatic water
223836056|NCT06917911|PROCEDURE|Biospecimen Collection|Undergo optional buccal cell collection and/or blood sample collection
223836057|NCT06917911|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
223836058|NCT06917911|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
223836059|NCT06917911|DRUG|Cytarabine|Given IV
223836060|NCT06917911|DRUG|Daunorubicin Hydrochloride|Given IV
223836061|NCT06917911|PROCEDURE|Echocardiography Test|Undergo echocardiography
223836062|NCT06917911|DRUG|Gemtuzumab Ozogamicin|Given IV
223836063|NCT06917911|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA scan
223836064|NCT06917911|DRUG|Venetoclax|Given PO
223836065|NCT06918171|PROCEDURE|Clinical Efficacy of Open Reduction and Anchor Suture Bridge Fixation|Under general anesthesia, patients were positioned prone, and a midline posterior incision was made at the level of the popliteal fossa. After incising the fascia, careful dissection was undertaken to expose the posterior joint capsule and fracture fragment, with particular attention to safeguarding the neurovascular structures. Once the fracture site was fully exposed, hematoma and any interposing soft tissue were meticulously cleared to prepare for reduction. The avulsed bone fragment, located at the PCL insertion site, was identified and prepared for fixation. A suture anchor (Johnson \& Johnson, USA) was carefully implanted into the prepared osseous bed. The suture threads were passed anteriorly around the PCL and configured in a figure-of-eight pattern to achieve precise anatomical reduction of the fracture fragment. To enhance fixation stability, two extracortical anchors (Johnson \& Johnson, USA) were additionally positioned approximately 2 cm distal to the fracture site, securing
223836066|NCT00153387|BEHAVIORAL|Women's health|
223836067|NCT06919575|COMBINATION_PRODUCT|Multicomponent frailty intervention|"First, the underlying causes of the patient's frailty should be analyzed. Individualized goals should be established using Goal Attainment Scaling (GAS), followed by implementation of tailored measures. For patients presenting with malnutrition or mood-related disorders, comprehensive nutritional and psychological assessments must be conducted, with subsequent nutritional support or pharmacological treatment initiated when clinically indicated.~The patients of the intervention group with poor physical function would receive exercise prescription tailored to the subjects' physical ability from a trained specialist. For Participants requiring exercise-based interventions, a moderate and gradually increasing intensity exercise regimen home-basethree times a week, over a 12-week duration will be administer under telehealth-based monitoring."
223836068|NCT04627103|DEVICE|Self Forming Magnetic (SFM) Anastomosis System|The SFM will be placed using an endoscope in the duodenum and laparoscopically into the ileum. A compression anastomosis will be created in each of the subjects and the diversion of enteral flow from the duodenum to ileum will create a metabolic effect that will induce weight loss and impact Type 2 Diabetes. Following the diversion being created, a gastric sleeve will be created according to standard technique.
223836069|NCT00583505|DEVICE|Device closure with the AMPLATZER Membranous VSD Occluder|Device closure with the AMPLATZER Membranous VSD Occluder
223836070|NCT05696730|OTHER|Communication intervention about sexuality in people with COPD|"COSY is a communication intervention which consists of one face to face counselling (75 min) and two 30-min telephone call counselling.~Patients assigned to the intervention group will get the COSY communication intervention with a special focus on the positive impact of sexuality on wellbeing plus specific motivation for physical activity. Together with the patient, a personalized re-enforcement instrument, the COSY-Compass, is elaborated to set individual goals and motivation for physical activity over the whole intervention period (3 months).~Participants will learn to understand the positive effect of regular physical activity on physical, mental, and cognitive wellbeing and a more fulfilling sex life as well as get inspiration about the spectrum and possible expressions and manifestations of caring and intimacy with oneself."
223836071|NCT02408419|DRUG|Bupivacaine|Bupivacaine is injected proximally to anesthetize the obturator nerve
223836072|NCT02408419|DRUG|Saline|Saline is injected as a placebo
223836073|NCT00252681|PROCEDURE|laparotomy|
223836074|NCT00252681|PROCEDURE|primary peritoneal drainage|
223836075|NCT00035958|DRUG|Prednisone|
223836076|NCT00035958|DRUG|Methotrexate|
223836077|NCT00035958|DRUG|Etanercept|
223836078|NCT05956834|DEVICE|PAMSys|Wearable accelerometer and gyroscope for measuring movement
223836079|NCT05956834|DEVICE|LEGSys|Wearable accelerometer and gyroscope for measuring movement
223836080|NCT05196633|OTHER|radial extracorporeal shock wave therapy|rESWT (Endopuls 811; Enraf Nonius B.V. Va-reseweg 127, 3047 AT Rotterdam MedTech, Wessling, Germany) will be applied on the myotendinous junction of both the gastrocnemius and the soleus muscles in post-stroke spasticity patients. 2000 shots will be applied on the gastrocnemius and soleus myotendinous junction with a frequency of 10 Hz and energy density of 60 mJ (1 bar) within tolerable pain limits.
223836081|NCT05196633|OTHER|sham radial extracorporeal shock wave therapy|The control group will receive sound over the myotendinous junction of gastrocnemius and soleus with transducer-like contact.
223836082|NCT04305678|DRUG|Mepolizumab|Mepolizumab (Nucala) 400 mg SC every 4 weeks x 24 weeks
223836083|NCT05041634|BEHAVIORAL|IHOPE|Integrating Healthy Habits Optimized by Community Participation and Engagled Learning
223836084|NCT04068727|OTHER|Clinical Pharmacist Intervention|After randomization, the pharmacist calls patients to assess drug choice and dose. Staff distribute manufacturer coupons and help patients apply for medication payment assistance. Pharmacist discusses DOAC alternatives with prescribe and provides DOAC education by discussing potential adverse effects, medication interactions, alarm symptoms, and lab work. Staff mail educational materials. Pharmacist documents concerns in the electronic health record and messages prescriber about missing lab work. Patients share medication-related concerns. Patients are provided with a phone number for non-education calls to discuss their medications from 6 AM - 10 PM on any day. The pharmacist offers dose de-escalation instructions based on the DOAC prescription. The pharmacist advises the continuity provider on DOAC duration and monitoring. For follow-up/perioperative support, the pharmacist reviews and recommends lab monitoring and gives DOAC interruption/resumption recommendations.
223836085|NCT01682538|DRUG|Nitisinone, capsule|
223836086|NCT01682538|DRUG|Nitisinone, suspension|
223836087|NCT01686594|DRUG|8-methoxypsoralen|8-methoxypsoralen 10mg per 20 kg body weight 1 hour before UVA exposure
223836088|NCT05455463|BEHAVIORAL|Online aphasia-adapted physical activity class|Online 50-minute physical activity sessions, two to three times weekly for 10-11 weeks. The activity instructions will be modified to be aphasia-friendly (simplified language, multimodality support).
223836089|NCT02283099|BIOLOGICAL|rVSVΔ-ZEBOV-GP|single dose of rVSVΔ-ZEBOV-GP (3x10\^6 pfu, 2x10\^7 pfu or 3x10\^5)
223836090|NCT03575442|BEHAVIORAL|"3 session program of art therapy"|With this program, we expect to offer socio-emotional well-being in the psychiatric context, and creative self-expression through painting. In addition, we hope to provide contributions towards the creation of quality standards of the professional practice of nurses, within the context of implementing psychosocial programs in mental health.
223836091|NCT03133143|BEHAVIORAL|Cognifit|CogniFit is an Internet browser-based digital brain training program, to improve cognitive abilities based on a personalised brain training regimen. Participants are instructed to play all games assigned by cognifit from three categories (memory, spatial perception, and mental planning) during each training session. After playing the games in these three categories, they are free to choose which exercises they wish to play.
223836092|NCT03133143|BEHAVIORAL|SIMS 4 (Maxis, Inc)|The Sims 4 is a life simulation PC game. It is purely an entertainment game without known cognitive or health-related outcomes. Does not iclude high-intensity action and competition. This specific game and non-competitive games like it in general do not improve attention, working memory, or other cognitive abilities despite being engaging and fun.
223836093|NCT02929290|DRUG|BPI-9016M|"Part I：Four dose cohorts will be evaluated, including 300mg, 450mg, 600mg, 800mg. BPI-9016M Tablet will be administered orally to patients once daily for each dose cohort.~Part II：400mg BPI-9016M Tablet will be administered orally to patients twice a day."
223836094|NCT00528190|DRUG|Itraconazole|Oral Itraconazole 5mg/kg/day or identical placebo for 24 weeks
223836095|NCT01870817|DIETARY_SUPPLEMENT|Home jejunostomy feeding|
223836096|NCT03312985|PROCEDURE|ACAF surgery|The main surgical procedures include discectomy of the involved levels, thinning of the anterior part of the involved vertebrae, intervertebral cages, anterior plate and screws installation, bilateral osteotomies of the vertebrae, and antedisplacement of the vertebrae-OPLL complex
223836097|NCT03312985|PROCEDURE|ACCF surgery|Removal of the vertebral body，exposed ossification of the posterior longitudinal ligament，and then removed
223836098|NCT05786586|DEVICE|650 nm low-level red-light|650 nm low-level red-light is a kind of laser, concentrated into a beam, to repeatedly irradiate the retina
223836099|NCT04129580|DEVICE|reSET-O app|The reSET-O app, owned by Pear Therapeutics, Inc., is designed to work as cognitive behavioral therapy, adjunctive to medication assisted treatment, for opioid use disorder. The app provides psychoeducation related to opioid use and dependence, coping skills, and skills to avoid relapse,
223836100|NCT06788236|DRUG|AVTR101|three times daily
223836101|NCT06788236|DRUG|Placebo|three times daily
223836102|NCT03757169|OTHER|Hand grip isometric contraction|The patients at the Hand Grip group will perform 12 weeks of hand grip exercises, three times/week for 16 minutes with time to rest.
223836103|NCT03757169|OTHER|Control|The patients will receive verbal orientations about the OSA and the arterial hypertension.
223836104|NCT00394875|PROCEDURE|Treated and educated by nurses specialized in diabetes.|
223836105|NCT03878082|DRUG|Propacetamol 1g|pain control with IVPCA and propacetamol 1g every 6 hours for 2 days
223836106|NCT03878082|DRUG|Propacetamol 2g|pain control with IVPCA and propacetamol 2g every 6 hours for 2 days
223836107|NCT03878082|DRUG|IVPCA|pain control with IVPCA
223836108|NCT05365074|DRUG|Chloroprocaine Injection|Spinal anesthesia with 50 mg of 1% Chloroprocaine
223836109|NCT00895973|OTHER|Stirrups delivery vs bed delivery|Position of legs at time of vaginal delivery (bed vs stirrups)
223836110|NCT04312828|PROCEDURE|Orthopedic management of the Z-foot|Orthopedic treatment with femoropedic plasters and slotted splints in 1st intention
223836111|NCT02654067|PROCEDURE|photograph|photograph of airway
223836112|NCT03038074|DEVICE|Pulse Oximeter with respiration rate sensor|
223836113|NCT03159650|DEVICE|intravascular ultrasonography|intravascular ultrasonography will be used during the study for the resolving proximal cap ambiguity of chronic total occlusion, facilitating re-entry into the true lumen after subintimal crossing and confirming distal true lumen guidewire position
223836114|NCT01361815|DEVICE|H-Coil Deep TMS in combination with SSRIs|The study group will receive DTMS treatment three times a week for four weeks in combination with SSRI medications.
223836115|NCT05923268|DRUG|[99mTc]Tc-G3-(G3S)3C|One single injection of \[99mTc\]Tc-G3-(G3S)3C, followed by gamma camera imaging directly postinjection and after 2, 4, 6 and 24 hours
223836116|NCT06268353|OTHER|blood sampling|Measure CAPGDF15 in plasma of 3 pregnant and 3 non-pregnant women
223836117|NCT04351490|DIETARY_SUPPLEMENT|Zinc gluconate|Zinc gluconate capsule 15 mg x 2 per day during 2 months
223836118|NCT04351490|DIETARY_SUPPLEMENT|25-OH cholecalciferol|25-OH cholecalciferol drinkable solution 10 drops (2000 IU) per day during 2 months
223836119|NCT06410443|DRUG|Dexamethasone|Retention enema with 10mg dexamethasone, once a day, the total course of treatment for 1 week.
223836120|NCT06410443|DRUG|Antibiotics, probiotics, vitamins, antidiarrheal drugs, enteral nutrition, and endoscopic argon plasma coagulation|Treatment according to guideline of radiation-induced intestinal injury.
223836121|NCT02435511|OTHER|HealtheRx|The HealtheRx is an informational intervention. The HealtheRx is generated and administered at the point of care. It includes a list of community resources, tailored to a patient's needs based on diagnoses, that are located near the patient's home. A health care provider and/or administrative staff administers and reviews the HealtheRx with the patient.
223836122|NCT06423261|DRUG|GB002 Recombinant Peptide Inhalation Solution|Inhalation administration
223836123|NCT06423261|DRUG|Placebo|Inhalation administration
223836124|NCT02643771|PROCEDURE|Full Mouth Scaling and Root Planing|This procedure was performed as described by Quirynen et al. 2005 with some modifications
223836125|NCT01710293|BEHAVIORAL|Communication of Patients Lost to Follow-up to Providers|"The investigators will query the VA's database weekly to identify possible lost to follow-up events for a random sample of about half of the providers at our study sites. The queries will use the trigger criteria developed in our previous work for colorectal cancer, lung cancer, hepatocellular carcinoma, breast cancer, and bladder cancer. The list of trigger positive patients will be transmitted to a facility-level recipient who will either disseminate the information to existing facility individual cancer care coordinators/trackers or will review the charts of the triggered patients in order to determine whether these patients have been truly lost to follow-up or not. If patients are found to be lost to follow-up, the Facility Recipient or cancer care coordinator/tracker will communicate the need for follow-up to the PACT or primary care provider, using secure emails, phone calls, or in person, depending on which method of communication they deem most appropriate and effective."
223836126|NCT00322868|DRUG|pioglitazone|All subjects treated for 28 days with pioglitazone, 30 mg orally, once daily.
223836127|NCT03290469|OTHER|clinical whole genome sequencing (cWGS)|Clinical Whole Genome Sequencing (cWGS) consists of the sequencing, analysis and interpretation of subjects samples and a return of the result to the ordering physician.
223836128|NCT01766518|DRUG|Mycophenolate mofetil|MY-REPT capsule 500\~1500mg/day, per oral, capsules twice a day with Tacrolimus, Corticosteroids, Basiliximab post liver transplantation
223836129|NCT04646447|DIETARY_SUPPLEMENT|L-serine|"L-Serine Arm L-serine is considered as GRAS (generally recognized as safe) by the FDA and has been approved as a normal food additive under CFR172.320.~All patients will receive the same L-serine dose treatment over 12 months. Arm: Experimental: L-Serine 250 mg / kg / day during the first two weeks. From week 3 to 52, 500 mg / kg / day. L-serine orally administered, divided into three doses a day.~The L-Serine will be manufactured, packaged, labeled and/or distributed by NUTRICIA or delegated contractors. It will be presented in a powdered form of 100 gr of the amino acid L-serine. For oral use.~Sufficient L-serine will be dispensed at home considering the dose according the weight of the patient."
223836130|NCT01332240|PROCEDURE|Endoscopic ultrasonography|in order to stage the mediastinum
223836131|NCT02875678|DRUG|ABX-1431|Single-dose ABX-1431
223836132|NCT02875678|DRUG|Placebo|Single-dose matching placebo
223836133|NCT05488379|OTHER|Group well child care|Beginning with the 1-month well child care visit, mother-infant dyads will participate in well child care together, with subsequent visits occurring at the American Academy of Pediatrics recommended intervals (2, 4, 6, 9, 12, 15, and 18 months of age).
223836134|NCT00483821|OTHER|medical chart review|medical chart review
223836135|NCT02629445|DEVICE|Cardiac Resynchronisation Defibrillator|Defibrillation testing of cardiac defibrilator
223836136|NCT03739385|OTHER|Exercise Intervention|The training interventions of all three groups (intergenerational group, peer group seniors, peer group children) will occur under professional supervision twice a week lasting over a 25-week period with training sessions lasting 45 minutes each. Control groups (control group seniors, control group children) receive no intervention.
223836137|NCT05187598|OTHER|Effective communication training in perinatal patient safety|Students will be given theoretical training, group discussion will be made over sample videos, and students will participate in the standard participant practice and a post-analysis session will be held.
223836138|NCT02606747|OTHER||routine blood sugar control
223836139|NCT02079207|BIOLOGICAL|NBP606|13-valent peumococcal conjugate vaccine(13vPnC)
223836140|NCT02079207|BIOLOGICAL|Prodiax-23|23-valent peumococcal polysaccharide vaccine(23vPS)
223836141|NCT05148624|PROCEDURE|embryo transfer|immediate ambulation after embryo transfer
223836142|NCT02078310|DRUG|ITI-007|ITI-007 for Part 1
223836143|NCT02078310|DRUG|Placebo|ITI-007 for Part 1
223836144|NCT02078310|DRUG|ITI-007|ITI-007 for Part 2
223836145|NCT02078310|DRUG|Placebo|Placebo for Part 2
223836146|NCT04911114|BEHAVIORAL|Be-Balanced|The BE-BALANCED program will run for 12-weeks, with participants attending group-based virtual supervised exercise sessions twice weekly. Participants will complete an individual in-person assessment at baseline and again at end of intervention to collect physical outcome measures and will complete questionnaires electronically using REDCap, (or mailed version). Follow-up assessments will be administered electronically to each participant using REDCap at 3-months after program completion (24 weeks post-baseline).
223836147|NCT04227925|BIOLOGICAL|Trichuris trichiura|Infective eggs from human whipworm, Trichuris trichiura
223836148|NCT00224133|DRUG|Silodosin|8 mg daily
223836149|NCT06258239|OTHER|Communication between nursing staff and participants|The analgesic treatment that will be given are part of clinical routine - the participants will get the same exact treatment regardless if they entered the study and to which study arm they entered. The effect that we are interested to capture is the potential added value of communication between the nursing staff and participants while administrating analgesics.
223836150|NCT00000764|DRUG|Isotretinoin|
223836151|NCT00000764|DRUG|Interferon alfa-2a|
223836152|NCT02372175|BIOLOGICAL|Dengue-1 Virus-Live Virus Human Challenge (DENV-1-LVHC)|Dengue subtype 1 Challenge Virus (DENV-1) strain 45AZ5 administered as a single injection.
223836153|NCT01639261|DRUG|Interferon gamma 1b|Initial dose: 50µg s.c. three times/week, without fever \>38,5 dose increase: 50µg/m² BSA three times/week
223836154|NCT04896905|OTHER|Rehabilitation|Rehabilitative procedures in isolation ward
223836155|NCT01700504|DRUG|Axillary lavage with gentamicin solution|Patients undergoing an axillary lavage with 500ml of normal saline followed by 500ml gentamicin solution
223836156|NCT03908281|BEHAVIORAL|Fasted Exercise|Exercise training will take place 3 times per week and will progress to 60 minutes at a workload corresponding to 80% of Ventilatory Threshold.
223836157|NCT03908281|BEHAVIORAL|Postprandial Exercise|Exercise training will take place 3 times per week and will progress to 60 minutes at a workload corresponding to 80% of Ventilatory Threshold.
223836158|NCT01702389|DRUG|Remifentanil|
223836159|NCT01897857|DEVICE|duplex Doppler ultrasonography|
223836160|NCT03518736|BEHAVIORAL|Supporting Play Exploration and Developmental Intervention (SPEEDI)|Physical Therapy intervention
223836161|NCT05611619|RADIATION|Tyre noise - continuous flow|Tyre noise from continuous traffic, throughout the night
223836162|NCT05611619|RADIATION|Tyre noise - discrete events|Tyre noise from few, discrete traffic events, occurring throughout the night
223836163|NCT05611619|RADIATION|High noise level|Tyre noise corresponding up to 65 dB LAEq,24h
223836164|NCT05611619|RADIATION|Moderate noise level|Tyre noise corresponding up to 60 dB LAEq,24h
223836165|NCT05611619|RADIATION|Low noise level|Tyre noise corresponding up to 55 dB LAEq,24h
223836166|NCT05611619|RADIATION|Air-filled tyres|Tyre noise from traditional, air-filled tyres
223836167|NCT05611619|RADIATION|Composite tyres|Tyre noise from newly designed, airless composite tyres
223836168|NCT03645486|GENETIC|Infusion of lentiviral TYF-CGD-modified autologous stem cells|Infusion of lentiviral TYF-modified autologous stem cells at 1\~10x10\^6 gene-modified cells per kg body weight
223836169|NCT01041508|DRUG|Clofarabine|Clofarabine will be given as an intravenous infusion over 2 hours on days -6 though -2. The dose of Clofarabine will be assigned at study entry (30, 40 or 52 mg/m2).
223836170|NCT01041508|RADIATION|Total Body Irradiation|"Low dose (2 Gy) TBI will be administered from a linear accelerator at ≤ 20 cGy/min on day 0 according to institutional guidelines."
223836171|NCT01041508|OTHER|Stem Cell Transplantation|Patients will be infused with 'unmanipulated' hematopoietic stem cells from a related or unrelated donor on day 0 of the treatment regimen according to institutional practice guidelines.
223836172|NCT01041508|DRUG|Cyclosporine|"Cyclosporine is given IV based on body weight at:~* Age ≤ 6 years old: 6 mg/kg IV QD. in divided doses (e.g. 2 mg/kg q8hrs).~* Age \> 6 years old: 3 mg/kg IV QD in divided doses (1.5mg/kg q12hrs)~Cyclosporine should be started on day -1 after completion of Clofarabine. Levels should be maintained between 300-400 ng/ml."
223836173|NCT01041508|DRUG|Mycophenolate Mofetil|MMF will be at 15 mg/kg, based on adjusted body weight, q 8 hours (45 mg/kg/day; max.3g/day) PO, or IV if indicated, from the evening of day 0 (i.e. first dose 4-6 hours following stem cell infusion) to day +40 post-transplant. Oral doses will be rounded to the nearest 250 mg (capsules are 250 mg). MMF is also available in oral suspension form. MMF will be given until day +40 post transplant and then tapered by 10% per week to be discontinued by day +90.
223836174|NCT03033121|DRUG|Growth Hormone|
223836175|NCT06479993|DIETARY_SUPPLEMENT|Chlorella supplementation|Supplementation with chlorella (6g/day for 3-weeks)
223836176|NCT06479993|DIETARY_SUPPLEMENT|Placebo supplementation|Supplementation with placebo - microcrystalline cellulose (6g/day for 3-weeks)
223836177|NCT04690296|DEVICE|cathetherization approach|real time ultrasound guidance versus anatomical landmarks subcalvain vein catheterization
223836178|NCT05981729|OTHER|Technology enriched stroke rehabilitation|In order to increase time spent in rehabilitation activity, participants will be prescribed and supported to use (by NHS staff) commercially available technology, such as robotics, adapted treadmills, virtual reality, and mobile digital devices such as smartphones, tablets, and wearable sensors.
223836179|NCT05625841|OTHER|Honey product|Bee products intervention from the first day of radiation to the end of radiation therapy duration 8-12 weeks.
223836180|NCT05625841|OTHER|propolis|propolis
223836181|NCT05625841|OTHER|Usual care|Usual care
223836182|NCT00503828|DRUG|Derris scandens Benth extracts|Derris scandens Benth extracts (oral) 400 mg twice per day for 4 weeks
223836183|NCT00503828|DRUG|naproxen|Naproxen 500 mg/day for 4 weeks
223836184|NCT02056119|DEVICE|Vibrating Mesh Nebulizer Arm|"* Physician order received for subject, randomization to vibrating mesh nebulizer occurred.~* Aeroneb® Solo (Aerogen, Galway, Ireland) vibrating mesh nebulizer to be placed before the heater on the dry side of the heater water chamber on the inspiratory ventilator circuit.~* Aerosol treatment delivered per physician order.~* Mesh nebulizer to be replaced every 30 days per hospital protocol. a. Prior to every nebulizer change or every 3 days, study staff to be notified in order to obtain cultures."
223836185|NCT02056119|DEVICE|Jet Nebulizer Arm|"* Physician order received for subject, randomization to jet nebulizer occurred.~* Jet nebulizer, Misty Max 10™ (Carefusion, CA), placed into spring loaded t-piece between the humidifier and the ventilator (approximately 15 cm from the gas outlet).~* Aerosol treatment delivered per physician order at flow rates of 8-10 L/min.~* Jet nebulizer to be replaced every 3 days per hospital protocol. a. Prior to every nebulizer change or every 3 days, study staff to be notified in order to obtain cultures."
223836186|NCT03220737|BIOLOGICAL|VAXCHORA (Cholera Vaccine, Live, Oral)|VAXCHORA (Cholera Vaccine, Live, Oral) is a live, attenuated bacterial vaccine suspension for oral administration containing the V. cholerae strain CVD 103-HgR.
223836187|NCT03220737|OTHER|Placebo|Placebo control for this study is normal (0.9%) saline.
223836188|NCT05629442|OTHER|ctDNA|initial research biopsy, quality of life assessments and ctDNA collection
223836189|NCT05058586|OTHER|The Effects of Aerobic Exercise Training on Cardiorespiratory Fitness, Functional Capacity, Balance and Ventricular Repolarization Indices in Stroke Patients|Seventy patients with history of stroke admitted to our center between July 2017 and January 2018. Subjects participated in the study were randomly assigned to anti-gravity treadmill training, underwater walking therapy and control group. We examined aerobic capacity of participants by using 6-minute walk test and cycle ergometer testing before starting the treatment along with one month follow up. Patient's balance examined by using the Berg Balance Scale (BBS).
223836190|NCT04698889|DIETARY_SUPPLEMENT|natural cow|
223836191|NCT04698889|DIETARY_SUPPLEMENT|high protein cow milk|
223836192|NCT04698889|DIETARY_SUPPLEMENT|natural human|
223836193|NCT04698889|DIETARY_SUPPLEMENT|low protein cow milk|
223836194|NCT01712789|DRUG|Pomalidomide|Oral Pomalidomide at the starting dose of 4 mg on Days 1-21 of a 28-day cycle
223836195|NCT01712789|DRUG|Dexamethasone|Oral Low dose Dexamethasone at the starting dose of 40mg/day (≤ 75 years old) or 20 mg/day (\> 75 years old) on Days 1, 8, 15 and 22 of a 28-day cycle.
223836196|NCT04199715|BIOLOGICAL|Heplisav-B|This is an FDA-approved vaccine for Hepatitis B that is made by Dynavax Technologies.
223836197|NCT04783324|BEHAVIORAL|E-Mobile Health Application|The e-mobile health application prepared by the researcher will be used. E-mobile health application include information about postpartum care.
223836198|NCT05331820|OTHER|weekly mobile reminder|a weekly reminder will be sent to participants in the intervention group via mobile internet applications
223836199|NCT00283465|DRUG|Epoetin alfa|
223836200|NCT02938741|DRUG|Anti-human Thymoglobulin|r-ATG 2.5MG/KG\*4days were used in the conditioning
223836201|NCT02938741|DRUG|Placebo|r-ATG 2.5MG/KG\*4days were not used in the conditioning
223836202|NCT00620165|DRUG|levetiracetam|Subjects will receive levetiracetam titrated up over 6 weeks to a maximum dose of 3000 milligrams (mg) per day, and then continue at 1500 mg twice daily for an additional 6 weeks.
223836203|NCT00620165|DRUG|placebo|Subjects will receive identical placebo titrated up over 6 weeks to a maximum daily dose, and then continue twice daily for an additional 6 weeks.
223836204|NCT03963882|DRUG|Two cycles of neoadjuvant chemotherapy|Two cycles of neoadjuvant chemotherapy (paclitaxel 175 mg/m2 and cisplatin 70 mg/m2, on day 1, once for three weeks).
223836205|NCT03963882|DIAGNOSTIC_TEST|First imaging evaluation|First imaging evaluation consists of pelvic magnetic resonance imaging (MRI) and positron emission tomography (PET)
223836206|NCT03963882|DIAGNOSTIC_TEST|Second imaging evaluation|Second imaging evaluation consists of pelvic magnetic resonance imaging
223836207|NCT03963882|DRUG|The third cycles of neoadjuvant chemotherapy|The third cycles of neoadjuvant chemotherapy (paclitaxel 175 mg/m2 and cisplatin 70 mg/m2, on day 1, once for three weeks).
223836208|NCT03963882|PROCEDURE|RH|Radical hysterectomy
223836209|NCT03963882|RADIATION|Radiochemotherapy|Concurrent radiochemotherapy
223836210|NCT03963882|DIAGNOSTIC_TEST|Pathologic evaluation|Pathologic evaluation for RH patients
223836211|NCT03486899|DRUG|BMS-986036|Specified dose on specified days.
223836212|NCT03486899|OTHER|Placebo|Specified dose on specified days.
223836213|NCT03553940|BIOLOGICAL|Influenza Virus Monovalent A/H3N2/Bris 10 M2SR Live Vaccine|Live monovalent influenza A/H3N2-based M2SR (M2 defective Single Replication vaccine), comprised of 5 out of 8 gene segments on the donor virus influenza A/Puerto Rica/8/34. HA and NA derive from an A/Brisbane/10/2007-like virus. Administered intranasally as s single dose.
223836214|NCT03553940|OTHER|Placebo|H3N2 M2SR vaccine placebo (normal saline). Administered intranasally as a single dose.
223836215|NCT03553940|BIOLOGICAL|Quadrivalent MDCK Inactivated Influenza Vaccine|A quadrivalent cell culture inactivated vaccine (ccIV4) is an inactivated subunit influenza vaccine prepared from virus propagated in Madin Darby Canine Kidney (MDCK) cells indicated for the prevention of influenza disease caused by influenza virus subtypes A and type B contained in the vaccine. Administered intramuscularly as a single dose.
223836216|NCT02362113|OTHER|GI/GL|GI and GL would be categorized as tertile. due to cross-sectional design of this study, intervention would not be applicable.
223836217|NCT03685279|BEHAVIORAL|Nurtured Heart Approach|Based on three stands designed to reduce negative reactivity from parents/guardians, increase positive interactions, and set firm, clear limits.
223836218|NCT02278575|DRUG|Atenativ|intravenous transfusion
223836219|NCT03725943|DIAGNOSTIC_TEST|Dreem|Dreem Band to be worn by each participant while undergoing in-lab sleep study with PSG.
223836220|NCT05390892|DRUG|SGLT2 inhibitor|Empagliflozin, dapagliflozin, or canagliflozin
223836221|NCT05390892|DRUG|GLP-1 receptor agonist|Dulaglutide, liraglutide, semaglutide
223836222|NCT00955903|BEHAVIORAL|Exercise|Participants will participate in supervised exercise sessions
223836223|NCT00955903|BEHAVIORAL|Reduced Calorie Diet|Participants will follow a reduced calorie diet
223836224|NCT00955903|BEHAVIORAL|Weight Maintenance Diet|Participants will follow a weight maintenance diet
223836225|NCT01190033|DEVICE|Neurotome OFF|In this intervention the neurotome will be unconnected.
223836226|NCT01190033|PROCEDURE|neurolysis|In this procedure the neurotome will be connected
223836227|NCT05447247|OTHER|Acupuncturing Ba Liao point under ultrasound guidance|Acupuncturing Ba Liao point under ultrasound guidance
223836228|NCT00401921|DRUG|Minocycline|100 mg, 1 capsule PO BID starting 36 hours prior to surgery. 2 capsules the morning of surgery
223836229|NCT00401921|DRUG|Placebo oral capsule|1 capsule PO BID starting 36 hours prior to surgery. 2 capsules the morning of surgery.
223836230|NCT04920461|DEVICE|Additional MRI sequences|Additional MRI sequences (3D T2 SPACE sequence, 4/5 minutes approximatively)
223836231|NCT04920461|OTHER|Neuropsychological assessment|Neurovisual function assessed with neuropsychological tests
223836232|NCT05725343|DRUG|Canakinumab|Canakinumabwill be administered up to three years, or until lung cancer diagnosis, unacceptable toxicity or physician/subject's decision to withdraw, whichever comes first.
223836233|NCT05725343|DRUG|Placebo|placebo will be administered up to three years, or until lung cancer diagnosis, unacceptable toxicity or physician/subject's decision to withdraw, whichever comes first.
223836234|NCT00515164|DRUG|Biologic Lung Volume Reduction (BLVR) - 20 mL Hydrogel|20 mL Hydrogel
223836235|NCT05186844|BEHAVIORAL|survey application|Scales and questionnaires were applied to children and their parents according to age groups.
223836236|NCT01544621|OTHER|Smoking cessation|Smoking cessation
223836237|NCT04025372|DRUG|Bicalutamide|Bicalutamide is categorized as an antiandrogen. Antiandrogens are substances that block the effects of testosterone. Cancer of the prostate depends on the male hormone testosterone for its growth. If the amount of testosterone is reduced it is possible to slow down or shrink the cancer.
223836238|NCT04025372|DRUG|GnRH Agonist|In men, GnRH agonists cause the testicles to stop making testosterone. Some GnRH agonists are used to treat prostate cancer.
223836239|NCT04025372|RADIATION|Radiation Therapy|Radiation Therapy is a cancer treatment that uses high doses of radiation to kill cancer cells and shrink tumors.
223836240|NCT04025372|DRUG|Darolutamide|Darolutamide belongs to a class of drugs called androgen receptor inhibitors. In the body, these agents compete with androgens for binding to the androgen receptor, which reduces the ability of androgens to promote the growth of prostate cancer cells
223836241|NCT02210819|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|"Cohort participants are classified as rivaroxaban patient, if the patient receives initial rivaroxaban VTE treatment. Dosing according to daily clinical routine"
223836242|NCT02210819|DRUG|Recommended VTE pharmacological treatments according to international guidelines|"Cohort participants are classified as Standard of care patients, if the patient receives recommended VTE pharmacological treatments according to international guidelines, e.g. unfractionated heparin, LMWH, fondaparinux, VKA, if these are also approved pharmacological treatments for VTE in the respective country. Dosing according to daily clinical routine."
223836243|NCT01848834|BIOLOGICAL|Pembrolizumab|IV infusion
223836244|NCT02865057|PROCEDURE|Vaginal assessment|Vaginal assessment of position prior to delivery
223836245|NCT01050101|DIETARY_SUPPLEMENT|No fiber|"The High GI low fiber meal consists of 0 grams fiber with total kcal of 573 with 63% energy from carbohydrates, 24% energy from fat and 13% energy from protein.~Test meal consists of breakfast meals containing muffins and yogurt beverage/shake."
223836246|NCT01050101|DIETARY_SUPPLEMENT|Low GI high fiber viscous meal|"Test meal consists of 12 grams of fiber (9 grams soluble and 3 grams insoluble). The ratio is 80:20 ratio of viscous polysaccharide fiber source (psyllium husk) to insoluble non-viscous producing fiber source (cellulose).~Total kcal provided as 560 kcal with 63% energy from carbohydrates, 24% energy from fat and 13% energy from protein. Test meal consists of breakfast meals containing muffins and yogurt beverage/shake."
223836247|NCT01050101|DIETARY_SUPPLEMENT|Low GI high fiber non-viscous|"Test meal consists of 11 grams of fiber (3 grams soluble and 8 grams insoluble). The ratio is 20:80 of viscous polysaccharide fiber source (psyllium husk) to insoluble non-viscous producing fiber source (cellulose).~Total kcal provided as 560 kcal with 63% energy from carbohydrates, 24% energy from fat and 13% energy from protein. Test meal consists of breakfast meals containing muffins and yogurt beverage/shake."
223836248|NCT00999973|DRUG|Mitomycin C 0.02%|
223836249|NCT00999973|DRUG|Placebo|
223836250|NCT02543593|DEVICE|Active tDCS or Sham tDCS|tDCS is a painless technique which consists in applying low direct-current through electrodes (one electrode serving as an anode, the other as a cathode) placed on the scalp to target the cerebral cortex. In patients with chronic pain, the anode is commonly placed over the motor cortex (M1) (Valeriani et al., 1999).
223836251|NCT04908436|DRUG|Finerenone (BAY94-8862)|10 mg BAY94-8862 immediate release (IR) tablet, administered orally
223836252|NCT00972946|BIOLOGICAL|Administration of autologous Endorem-labelled mononuclear cells intravenously|single dose
223836253|NCT00972946|DRUG|Administration of Endorem|single dose, intravenous
223836254|NCT02638064|PROCEDURE|Surgiflo injection|Curettage of sinus cavity then injection of surgiflo material
223836255|NCT04807829|DRUG|Nabilone|Nabilone is a synthetic endocannabinoid and CB1 agonist.
223836256|NCT04807829|DRUG|Placebo|Inactive placebo comparator
223836257|NCT06428253|DEVICE|HMM1-022|intradermal injection
223836258|NCT03259373|BEHAVIORAL|Early Patient-Level and Provider-Level Educational Intervention|"Letters to patients that (1) explain to the patient that he or she appears to have AF, characterize the risk of stroke, and emphasize that although there may be a medical reason, the patient does not seem to be on an anticoagulant and (2) encourage the patient to discuss this with his or her provider to ask if he or she might benefit from OAC therapy to prevent stroke.~Early intervention letters to providers explain this project, the nature of the problem, and identify a list of the provider's patients who have been contacted, as the provider and patient letters will be sent at approximately the same time; describe evidence and guidelines regarding oral anticoagulation."
223836259|NCT03259373|BEHAVIORAL|Delayed Provider-Level Educational Intervention|Delayed intervention letters to patients' providers, where they may be identified, that explain this project, the nature of the problem, and identify a list of their patients who are flagged as at risk for stroke and have not been treated with an oral anticoagulant; describe evidence and guidelines regarding oral anticoagulation.
223836260|NCT03567356|OTHER|"MAT-PLUS Helping Hands"|"1\) Significant other engagement through the Helping Hands approach empowers designated concerned helpers, providing concrete guidance for monitoring, supervision, and improving adherence for their loved one in treatment; 2) Care coordination and case management by counselors to enhance adherence to XRNTX ; 3) Assertive outreach incorporates frequent multi-channel outreach with the goal of achieving XRNTX dosing."
223836261|NCT04919434|OTHER|IRECO|During 5 days, women included in the study will have to only use personal care product distributed by the research team.
223836262|NCT04798378|DEVICE|Neurosleeve|Myoelectric devices for restoration of independent arm function
223836263|NCT05951296|DRUG|Leramistat|Drug: Leramistat
223836264|NCT05951296|DRUG|Placebo|Placebo comparator
223836265|NCT05960604|DIAGNOSTIC_TEST|Passive leg raising|"All patients who met the inclusion criteria will be placed head down flat and feet up at a 45° angle for 30 seconds.~Hemodynamic parameters and analysis by pressure recording analytical method obtained with the MostCare will be collected before, during and after the test until the end of the surgery.~The total duration of the intervention (passive leg raising) is 30 seconds. The total duration of hemodynamic parameters recording is expected to be 60-600 minutes."
223836266|NCT06041763|PROCEDURE|Meniscal Repair Procedure|All meniscal repairs will be performed by the surgeons who are listed as investigators for the study. Meniscal repair consists of arthroscopic suturing of torn fragments. This takes approximately 20 minutes. In the interventional group, the BEAR implant will be inserted through preexistent arthroscopic portals after repair is complete. This will take an additional 2 minutes.
223836267|NCT06041763|DEVICE|BEAR Implant|The BEAR Implant (22 mm in diameter and 45mm in length) is cylindrical in shape and comprised of collagen and extracellular matrix derived from bovine connective tissue, which has been cleaned, disinfected and processed by a proprietary manufacturing method. The implant has been terminally sterilized by electron-beam inadiation and is intended to be used with up to 10 ml of autologous blood drawn during the surgical implantation procedure. The BEAR Implant is resorbed within 8 weeks and replaced with a fibrovascular repair tissue.
223836268|NCT03213002|DRUG|Capecitabine|Capecitabine at 1500 mg/m2
223836269|NCT03213002|DRUG|Temozolomide|Temozolomide at 150 mg/m2 - 200 mg/m2
223836270|NCT05687071|DRUG|180mg of ETC-1002(bempedoic acid)|180mg, tablet, once daily, for 52 weeks
223836271|NCT06238648|PROCEDURE|Biopsy|Undergo biopsy
223836272|NCT06238648|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
223836273|NCT06238648|PROCEDURE|Computed Tomography|Undergo PET/CT and/or CT
223836274|NCT06238648|BIOLOGICAL|Epcoritamab|Given SC
223836275|NCT06238648|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223836276|NCT06238648|OTHER|Patient Observation|Undergo observation
223836277|NCT06238648|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
223836278|NCT05742230|DRUG|Henagliflozin 10 mg|Participants will receive 10 mg single oral tablets orally once daily.
223836279|NCT05742230|DRUG|blank control|standard treatment
223836280|NCT05580159|BIOLOGICAL|SW-BIC-213|The patient will take a single 25 μg dose mRNA vaccine SW-BIC-213.
223836281|NCT05580159|BIOLOGICAL|SARS-Cov-2 Vaccina(Vero Cell ) Inactivated|The patient will take a third dose of COVID-19 Inactivated vaccine.
223836282|NCT06343337|DIAGNOSTIC_TEST|Evaluation of DMFT index, CPI scores, salivary pH and flow rate in pregnant and non-pregnant woman|Total 198 volunteer (51 women for control, 47 women for 1st trimester, 51 women for 2nd trimester, and 49 women for 3rd trimester) were included. The data about sociodemographic characteristics, dental and systemic health conditions were recorded. Unsitumulated saliva samples were collected for 5 minutes by spitting method. The pH of saliva was measured by a portable pHmeter. The salivary flow rate was determined by the weight measurement method. DMFT index and CPI scores were determined. The statistical differences were evaluated by Kruskal-Wallis, Mann Whitney U and Chi Square tests (α=.05).
223836283|NCT03786484|DRUG|PBF-999|Phosphodiesterase 10 inhibitor (PDE10i)
223836284|NCT02894320|BEHAVIORAL|Behavioral observation|
223836285|NCT02875561|DEVICE|Sonopet Ultrasonic Aspirator|To evaluate the incident of recurrence of VIN dysplasia events in women treated for VIN with the sonopet ultrasonic aspirator compared to CO2 Laser Ablation
223836286|NCT02875561|DEVICE|CO2 Laser Ablation|To evaluate the incident of recurrence of VIN dysplasia events in women treated for VIN with the sonopet ultrasonic aspirator compared to CO2 Laser Ablation
223836287|NCT03329430|OTHER|Foot orthoses|Customized foot orthoses
223836288|NCT03587844|DRUG|brentuximab vedotin|MF/SS Brentuximab vedotin 0.9 mg/kg 0R 1.2 mg/kg.
223836289|NCT03587844|DRUG|brentuximab vedotin|LyP Brentuximab vedotin 0.9 mg/kg2
223836290|NCT03587844|DRUG|brentuximab vedotin|MF/SS prior brentuximab vedotin-Brentuximab vedotin dose to be determined from Cohort 1
223836291|NCT03230422|DEVICE|normal airway|The Time interval between the laryngoscope blade passing the teeth/gums to the announcing of the first ventilation was recorded as the time to ventilation with the Video laryngoscopy (VL) or conventional direct laryngoscopy (DL)
223836292|NCT03230422|DEVICE|difficult airway|The Time interval between the laryngoscope blade passing the teeth/gums to the announcing of the first ventilation was recorded as the time to ventilation with the Video laryngoscopy (VL) or conventional direct laryngoscopy (DL)
223836293|NCT01822353|DIETARY_SUPPLEMENT|Dietary supplement|Milk, egg or nut oral immunotherapy
223836294|NCT05323214|DRUG|Control Analgesic regimen|testing the efficiency of bupivacaine without adjuvant drugs in epidural analgesia
223836295|NCT05323214|DRUG|Fentanyl Analgesic regimen|testing the efficiency of Fentanyl as an adjuvant drug to bupivacaine in epidural analgesia
223836296|NCT05323214|DRUG|Dexmedetomidine Analgesic regimen|testing the efficiency of Dexmedetomidine as an adjuvant drug to bupivacaine in epidural analgesia
223836297|NCT05409196|BIOLOGICAL|ShigETEC live, attenuated, oral vaccine|Vaccine or placebo will be delivered orally as a single dose in Stage 1 and between 2 and 4 doses at 3-day intervals in Stage 2 of the Study.
223836298|NCT05409196|DRUG|Placebo|Vaccine or placebo will be delivered orally as a single dose in Stage 1 and between 2 and 4 doses at 3-day intervals in Stage 2 of the Study.
223836299|NCT00306904|DRUG|bevasiranib|
223836300|NCT00563849|DRUG|Leflunomide|concomitantly leflunomide (no loading dose, 10 mg/day) and methotrexate (starting at 7.5 mg/week and titrating up to 15 mg/week) for 20 weeks.
223836301|NCT05957757|DRUG|RC48|"RC48 was scheduled to be administered at a dose of 2.0mg/kg every 2 weeks, with the first dose on day 1 of the first cycle.~The drug is diluted with normal saline and administered by intravenous drip for one hour."
223836302|NCT05957757|DRUG|Tislelizumab|"Tislelizumab was administered at a dose of 200 mg every 3 weeks, with the first dose on day 1 of the first 21-day cycle.~The drug is diluted with normal saline and administered by intravenous drip for one hour."
223836303|NCT04334785|DEVICE|cryo-ablation|Under the guide of ultrasound, cryo-ablation for the lump of early invasive breast cancer will be conducted.
223836304|NCT06489093|DRUG|NSF|Prior to treatment the working field is isolated with cotton rolls. Gingival barrier is used for soft tissue protection. Application of NSF using a microapplicator on the carious lesion for 1 minute. Excess material and gingival barrier are removed. Participants receive oral hygiene instructions.
223836305|NCT06489093|DRUG|SDF+KI|Prior to treatment the working field is isolated with cotton rolls. Gingival barrier is used for soft tissue protection. Application of 38% silver diamine fluoride (Riva star 38%, SDI) using a microapplicator on the carious lesion. Immediately afterwards, potassium iodide is applied as a reducing agent. Excess material and gingival barrier are removed. Participants receive oral hygiene instructions.
223836306|NCT06489093|OTHER|Control group|Subjects will receive oral hygiene instructioins to apply fluoridated toothpaste to a toothbrush and brush teeth thoroughly for at least 2 minutes, then expectorate and rinse.
223836307|NCT03587350|DEVICE|Shimmer monitoring|The shimmer monitor, monitors movement and the range of movement.
223836308|NCT02329600|DRUG|green tea tablets (Green tea extract 5:1) 200 mg|Green tea is a product made from the Camellia sinensis plant. The fresh leaves are used to make medicine. the green tea extract is presented in a form of tablets 200 mg and is taken orally.
223836309|NCT02329600|DRUG|Triamcinolone Acetonide|topical corticosteroids (Kenalog in orabase: Bristol-Myers, Squibb, Spain) applied topically 4 times a day i.e. following each meal and at bed time for one month
223836310|NCT00115375|DRUG|Clopidogrel (SR25990)|
223836311|NCT04395768|DIETARY_SUPPLEMENT|Vitamin C|In addition to the active comparator, which is a combination of 2 drugs and 3 dietary supplements, the experimental treatment arm will also receive Vitamin C (intravenous or oral)
223836312|NCT04395768|DRUG|Hydroxychloroquine|Active comparator group will receive: a combination of 2 drugs and 3 dietary supplements
223836313|NCT04395768|DRUG|Azithromycin|Active comparator group will receive: a combination of 2 drugs and 3 dietary supplements
223836314|NCT04395768|DIETARY_SUPPLEMENT|Zinc Citrate|Active comparator group will receive: a combination of 2 drugs and 3 dietary supplements
223836315|NCT04395768|DIETARY_SUPPLEMENT|Vitamin D3|Active comparator group will receive: a combination of 2 drugs and 3 dietary supplements
223836316|NCT04395768|DIETARY_SUPPLEMENT|Vitamin B12|Active comparator group will receive: a combination of 2 drugs and 3 dietary supplements
223836317|NCT02425475|DEVICE|LIMES|All patients will undergo dermoscopic diagnosis and be documented with a video image storing. The diagnosis based on dermoscopy will be immediately documented. Then, as a second diagnostic procedure, fluorescence diagnostics based on the two photon excitation from a dye-laser will be performed. The classification as non-melanoma or malignant melanoma by the medical device LIMES will also be documented immediately. Afterwards, the lesion will be excised and undergo histo-pathologic examination by the respective histopathologist of the participating centers. The histopathologic diagnosis will serve as gold standard for subsequent evaluations of the diagnostic accuracy.
223836318|NCT01469793|DRUG|DMOT4039A|DMOT4093A will be administered by intravenous infusion on either a Q3W or a Q1W dosing schedule, in 21-day cycles.
223836319|NCT06029530|DRUG|Atropine Ophthalmic|eye drops to be administered once daily
223836320|NCT01140022|OTHER|CT Screening|Patients will use a kiosk module that will provide information about CT screening and assess their risk for CT. Patients choosing to get a CT screening will receive a printout instructing the provider or nurse to collect a urine sample for CT screening.
223836321|NCT03658811|DEVICE|intense pulsed light|Use of 6 mm SapphireCool light guide to treat upper lid margins from tragus to tragus including the nose
223836322|NCT00988585|DIETARY_SUPPLEMENT|EPA 600|EPA 600 mg/day for 6 weeks
223836323|NCT00988585|DIETARY_SUPPLEMENT|EPA 1800|1800 mg/day for 6 weeks
223836324|NCT00988585|DIETARY_SUPPLEMENT|Olive Oil|600 mg/day for 6 weeks
223836325|NCT00988585|DIETARY_SUPPLEMENT|DHA|600 mg/day for 6 weeks
223836326|NCT05560516|DRUG|Qutenza|Capsaicine patch: Qutenza 8% patch will be applied to the skin according to the instruction of the manufacturer. After application of local anesthetics on the skin, a Qutenza 8% patch will be placed. 1-4 patches will be placed and can be adjusted to the right size, depending on the surface of the CIPN. The patch(es) will be removed after 30-60 minutes. The effect will last about 12 weeks.
223836327|NCT05560516|DRUG|Duloxetine|Duloxetine tablets: In week 1 patients will receive 30 mg duloxetine one time per day. In week 2 the dose will be increased to 60 mg one time per day. In case of inacceptable adverse events the patient is allowed to reduce the dose to 30 mg one time per day after consultation with the researcher or physician.
223836328|NCT00946647|DRUG|Panobinostat (LBH589)|Panobinostat was supplied by Novartis as immediate-release hard gelatin capsules in strengths of 5 mg, 10 mg, and 20 mg packaged in high density polyethylene bottles.
223836329|NCT00946647|DRUG|5-Azacytidine|
223836330|NCT00471263|DRUG|Casigold|
223836331|NCT00471263|DRUG|Casimax|
223836332|NCT00471263|DRUG|Placebo|
223836333|NCT06129695|PROCEDURE|Zygomatic implants|the ideal way to support implant-based restorative procedures for full and partially edentulous patients who are missing bone in the upper posterior maxilla.
223836334|NCT05770596|DRUG|vitamin C group|patients in this group will receive 2 gm vitamin C orally 1 hour before surgery and will receive 0.5 gm vitamin C per day orally for 50 days starting from the 2nd postoperative day.
223836335|NCT05770596|OTHER|placebo group|patients in this group will receive placebo tablets with the same manner; orally 1 hour before surgery and for 50 days starting from the 2nd postoperative day.
223836336|NCT04387162|BEHAVIORAL|Prism Adaptation Treatment|Spatial retraining treatment
223836337|NCT04222309|PROCEDURE|Laparoscopically harvested omental free flap|Laparoscopically harvested omental free flap into the resection cavity of recurrent glioblastoma multiforme (GBM) patients.
223836338|NCT03227484|DRUG|Empagliflozin 25mg|Once daily over 8 weeks
223836339|NCT03227484|DRUG|Placebo Oral Tablet|Once daily over 8 weeks
223836340|NCT04430296|PROCEDURE|Cyclophotocoagulation|"High Intensity Focused Ultrasound Cyclophotocoagulation (HIFU): parameters: 21 MHz frequency, 2.45 W acoustic power, with the activation of each transducer lasting 6 seconds MicroPulse cyclophotocoagulation (MP-CPC):Laser settings of 2 Watts (W) will be applied for a 90 seconds treatment time for each 180 degrees, with a duty cycle of 31.3%, which consists of 0.5ms on time and 1.1 ms off-time and delivering a total of 112,7 Joules Continuous Wave cyclophotocoagulation (CW-CPC): The laser settings used will be 1.250 W, 4s exposure time per burn, 22-24 burns per eye."
223836341|NCT05012423|DRUG|Placebo|Matching Placebo will be administered as oral capsules.
223836342|NCT05012423|DRUG|ECC0509|ECC0509 1 mg and 10 mg capsules. ECC0509 will be administered as oral capsules.
223836343|NCT05012423|DRUG|Placebo|Matching Placebo will be given orally during each dosing day.
223836344|NCT05012423|DRUG|ECC0509|ECC0509 1 mg and 10 mg capsules
223836345|NCT01638468|DEVICE|AngioJet Ultra PE Thrombectomy System|Thrombectomy with or without lytic delivery using the AngioJet Ultra PE Thrombectomy System
223836346|NCT03171168|DEVICE|AposTherapy|AposTherapy is a home-based exercise program utilizing footwear that causes exercise with normal daily activity that may significantly improve function in patients with knee pain in general, and specifically knee osteoarthritis (OA).
223836347|NCT03171168|OTHER|Traditional Physical Therapy|Up to 20 sessions of traditional physical therapy
223836348|NCT05672004|OTHER|PUMP-fit strategy (implementation toolbox)|"Healthcare professionals will receive the ProMuscle training from one of the researchers during a one-hour online meeting (during the control period).~Healthcare professionals will be informed about the platform and toolbox. Healthcare professionals receive a personal log-in for the online platform. Healthcare professionals receive a questionnaire about their readiness for implementation. The results of this questionnaire are directly visible on the platform Within the separate environment of the online platform, healthcare professionals can access their implementation toolbox. The toolbox is tailored to their personal context based on the results of the 'Readinesstool'."
223836349|NCT05672004|OTHER|Implementation as usual|"First, healthcare professionals will receive the ProMuscle training from one of the researchers during a one-hour online meeting.~At the end of the training healthcare professionals are informed about the mandatory conditions to implement ProMuscle (champion, material, approval of management).~Healthcare professionals receive a questionnaire about their readiness for implementation. The results of this questionnaire are directly visible. Results contain a graph of possible barriers for implementation in their practice.~Hereafter they will be instructed to start with implementation as usual."
223836350|NCT01090037|DRUG|TRK-100STP high dose|
223836351|NCT01090037|DRUG|TRK-100STP low dose|
223836352|NCT01090037|DRUG|Placebo|
223836353|NCT05553132|COMBINATION_PRODUCT|Autologous Chondrocytes in their Pericellular Matrix (Chondrons) Coimplanted with Allogeneic Adipose-Derived Mesenchymal Stromal Cells (AMSCs) in a Fibrin Glue Carrier|Cartilage cells are being used from the rim of the defect in the hip and recycled to help make new cartilage in the hip. There are not enough cartilage cells to fill the defect so cartilage cells need to be mixed with MSCs. MSCs or Mesenchymal Stem Cells are naturally occurring cells that provide growth factors and cell signals that play a role in tissue repair. MSCs can be found in bone marrow and in the fatty tissues (i.e., area under the skin of the belly or breast) of patients. Fibrin glue is a product made from the naturally occurring compounds in blood which cause clotting. This glue hardens into a gel-like substance into which cells such as cartilage cells (chondrons) and AMSCs can be placed.
223836354|NCT03786094|DRUG|Eribulin|Eribulin alone
223836355|NCT03786094|DRUG|Balixafortide|Balixafortide + Eribulin
223836356|NCT00670982|DRUG|bevacizumab|Given intravenously every 2 weeks
223836357|NCT00670982|DRUG|vinorelbine|Given intravenously once a week
223836358|NCT00670982|DRUG|trastuzumab|Given intravenously once a week
223836359|NCT05398263|BIOLOGICAL|Tezepelumab|Tezepelumab subcutaneous injection
223836360|NCT05398263|OTHER|Placebo|Placebo subcutaneous injection
223836361|NCT06290167|DEVICE|360° media|sessions with head mounted display in hospital and sessions with tablet at home
223836362|NCT06290167|OTHER|Treatment As Usual (TAU)|sessions of TAU rehabilitation in hospital and sessions TAU rehabilitation at home
223836363|NCT06290167|OTHER|In hospital sessions|sessions will be carried out under the supervision of a therapist
223836364|NCT06290167|OTHER|at home sessions|sessions will be carried out without the supervision of a therapist
223836365|NCT06290167|OTHER|Mild Cognitive Impairment|half of this group will perform the protocol with 360° videos and the other half will perform the TAU
223836366|NCT06290167|OTHER|Subjective Memory Complain|half of this group will perform the protocol with 360° videos and the other half will perform the TAU
223836367|NCT05763732|BEHAVIORAL|Rhythmic Auditory Stimulation (RAS)|"Rhythmic auditory stimulus (RAS) is a Neurologic Music Therapy (NMT) technique that utilizes an auditory rhythmic cue to entrain gait to a specific rhythm.~RAS, as an anticipatory time cue, can be used as both an immediate entrainment stimulus, providing rhythmic cues during movement, and as a facilitating stimulus for planning and executing a movement to achieve more functional gait patterns. Cadence, gait velocity, and stride length are the commonly used parameters to monitor changes in a patient's gait."
223836368|NCT06827496|DRUG|Oral antibiotic treatment|"Initial antibiotics:~Below 5 years: High-dose amoxicillin-clavulanate (8:1 ratio; 100/12.5 mg/kg/day in 3 doses) until clinical improvement and decrease in CRP, followed by dose reduction (4:1 ratio) to 50/12.5 mg/kg/day in 3 doses).~5 years and above: High-dose anti-staphylococcal penicillin (200 mg/kg/day in 4 doses) until clinical improvement and decrease in CRP, with dose reduction (100 mg/kg/day in 4 doses) after clinical improvement~Treatment duration of follow-up therapy (after initial high-dose antibiotics): One week for uncomplicated joint infections, three weeks for bone infections, and four weeks for spondylodiscitis"
223836369|NCT05989321|PROCEDURE|PVI alone|pulmonary vein isolation
223836370|NCT05989321|PROCEDURE|PVI + SPs ablation|pulmonary vein isolation + SPs ablation
223836371|NCT05895058|DEVICE|Gastric bypass surgery with 2D 4K laparoscopic imaging|All patients involved in the investigation will receive a laparoscopic Roux-en-Y gastric bypass (LRYGB). The interventions are performed by three defined surgeons.
223836372|NCT05895058|DEVICE|Gastric bypass surgery with 3D HD laparoscopic imaging|All patients involved in the investigation will receive a laparoscopic Roux-en-Y gastric bypass (LRYGB). The interventions are performed by three defined surgeons.
223836373|NCT03749460|BIOLOGICAL|Nivolumab|Given IV
223836374|NCT03749460|BIOLOGICAL|Ipilimumab|Given IV
223836375|NCT03749460|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
223836376|NCT03396536|OTHER|Evaluation of KM|"KM will be evaluated. The alveolar mucosa will be stained with Lugol's solution, by means of a cotton swab. A cotton roll will be soaked in the solution and gently applied on the mucosa around the implant. Since Lugol's solution is selective to the glycogen present in AM, the muco-gingival junction as the borderline between the blue-stained alveolar mucosa and KM can be easily identified.~A manual periodontal probe with 1 mm markings will measure the distance from the peri-implant margin and the muco-gingival junction.~Mucosal thickness (MT) will be measured after topical application of the anesthetics. MT will be evaluated inserting a 27G needle with a rubber stop 1 mm below the peri-implant mucosal margin at the mid-buccal aspect, until the abutment is engaged. The needle will be removed and the distance between the rubber stop and the point of the needle will be measured with a manual periodontal probe."
223836377|NCT04367194|BEHAVIORAL|Neurorehabilitation|After examination of the patients, the patients undergo neurorehabilitation. We use virtual reality therapy. Patients perform a submaximal load that is monitored by a polar clock. We develop endurance, coordination, sensory integration, visual and acoustic input, vestibular training, proprioception training.
223836378|NCT03883958|PROCEDURE|Erector Spinae Plane Block|ESPB will be performed in sitting or lateral decubitus position. The target vertebral level will be correspond to the approximate mid-point of the extent of fractured ribs. The tip of the transverse process of the target vertebra will be identified using the high-frequency linear placed in cephalocaudal orientation about 3 cm to the spinous process. The skin and subcutaneous tissue will be infiltrated with 2-3 ml of 2% lignocaine. With the transducer fixed over the targeted TP, a 22-gauge 88-mm needle (Spinocan, B. Braun, Germany) will be advanced in-plane to the ultrasound beam in a cephalo-caudal direction to contact the TP. Correct needle tip position will be confirmed by doing alternating aspiration to confirm lack of inadvertent vascular puncture with injection of 1-2 ml of saline and visualizing linear fluid spread deep to erector spinae muscle, separating it from the TP. A bolus dose (2ml/segment) of plain bupivacaine 0.5% plus 4mg of Dexamethasone will be injected.
223836379|NCT03883958|PROCEDURE|Paravertebral Block|TPVB will be performed at a spinal level midway between the uppermost and the lowest fractured rib with the patient in sitting or lateral decubitus position (with patients lying on their unaffected side). The ultrasound-guided technique will be used. A high-frequency linear transducer will be used to confirm the levels of the fractured ribs. The most cephalad and most caudad fractured ribs will be identified first. The fractured rib in the middle will be then identified, and the rib will be then traced back medially. After skin and subcutaneous tissue infiltration with 2-3 ml of 2% lignocaine, a 22-gauge 88-mm needle (Spinocan, B. Braun, Germany) will be inserted in a lateral-to-medial direction until the needle tip entered the paravertebral space. 1-2 ml of Saline will be injected into the paravertebral space while observing the pleura being moved deeply. A bolus dose (2ml/segment) of plain bupivacaine 0.5% plus 4mg of Dexamethasone will be injected.
223836380|NCT00389090|DRUG|Temozolomide and O6-Benzylguanine|O6BG + Temozolomide
223836381|NCT03315819|PROCEDURE|Bankart repair|Arthroscopic repair of anterior capsulo-labral lesions using the Bankart technique.
223836382|NCT03315819|PROCEDURE|Immobilization interne rotation|Immobilisation in rotation Internal (Dujarrier) 3 weeks then rehabilitation
223836383|NCT01513967|DRUG|RPh201, botanical drug product|SC administration at varying doses
223836384|NCT01513967|DRUG|Placebo|SC administration at varying doses
223836385|NCT06004752|DRUG|Ciclosporin|Cyclosporine was taken orally at 3-5mg/kg bid was administered to maintain the trough concentration at 100-200 μg/ml
223836386|NCT06004752|DRUG|Avatrombopag|Avatrombopag was administrated at 40 mg/d and increased by 20 mg/d during the biweekly follow-up if platelet was not 20 × 109/L higher than baseline. AVA dose was gradually reduced if PLT ≥ 150 × 109/L. The maximum dose was 60 mg/d, while the minimum was 20 mg/week.
223836387|NCT03400904|OTHER|Patients with brain injury and mechanical ventilation exposed to extubation/tracheostomy|Extubation and/or tracheostomy if applicable
223836388|NCT04752540|DRUG|Olorofim|single oral dose
223836389|NCT05884190|OTHER|Remote Medical Model (RMM)|Remote home blood pressure (BP) monitoring once a day for the first 7 days and then at least weekly or more frequently as per a standardized blood pressure protocol up to six weeks and weekly virtual visits for 6 weeks and up to 12 weeks as needed by a physician extender (e.g. Nurse Practitioner, Pharmacist, etc.), and screening for social determinants of health and anxiety/ depression with referral for services if positive
223836390|NCT05884190|OTHER|Community Health Model (CHM)|Utilization of community health workers trained in a strength-based trauma informed dyadic evidence-based approach.
223836391|NCT05884190|OTHER|SoC|SoC for Postpartum Hypertension
223836392|NCT01548859|DRUG|Midazolam|0.2 mg/kg/saat continuous infusion of midazolam received during anaesthesia
223836393|NCT01548859|DRUG|Sevoflurane|end tidal concentration of % 0,5-8
223836394|NCT02711826|BIOLOGICAL|Polyclonal Regulatory T Cells|Participants randomized to polyTregs group will receive a single infusion of 550 ± 450 x 10\^6 polyTregs.
223836395|NCT02711826|DRUG|Everolimus|
223836396|NCT02711826|DRUG|Tacrolimus|
223836397|NCT02711826|DRUG|Mycophenolate mofetil|All enrolled participants will be on MMF (or MPA below) at the time of study entry at a minimum dose of 1000mg per day.
223836398|NCT02711826|DRUG|Mycophenolic acid|All enrolled participants will be on MPA (or MMF above) at the time of study entry at a minimum dose of 720mg per day.
223836399|NCT02711826|DRUG|Acetaminophen|650 mg acetaminophen, administered 30-60 minutes prior to infusion as pre-medication.
223836400|NCT02711826|DRUG|Diphenhydramine|25-50 mg diphenhydramine intravenously or by mouth, administered 30-60 minutes prior to infusion as pre-medication.
223836401|NCT02711826|PROCEDURE|Biopsy, Kidney|
223836402|NCT02711826|PROCEDURE|Blood Draw|
223836403|NCT02711826|PROCEDURE|Leukapheresis|
223836404|NCT02711826|PROCEDURE|IS regimen conversion|Conversion from Tacrolimus, a calcineurin inhibitors (CNI), to Everolimus, an mTOR inhibitor.
223836405|NCT02710994|DRUG|CDFR0209|Immediate release omeprazole 40 mg and sodium bicarbonate 1,100 mg
223836406|NCT02710994|DRUG|Losec|Losec 40 mg
223836407|NCT05138484|DRUG|experimental group 10% mouthwash of M. sylvestris extract|To each patient was delivering a 150 ml bottle with the corresponding mouthwash. The indications for posology were: rinse with 10 ml of mouthwash for 1 minute in the mouth, every 12 hours for 7 days. To the follow-up of the intervention, was made telephone calls at least once a day to remember the rinse.
223836408|NCT02906202|GENETIC|LentiGlobin BB305 Drug Product|LentiGlobin BB305 Drug Product is administered by IV infusion following myeloablative conditioning with busulfan.
223836409|NCT02169037|PROCEDURE|FIRM Ablation|Substrate ablation for AF, via ablation of rotors and focal sources alone.
223836410|NCT02169037|PROCEDURE|Conventional AF ablation with PVI|Trigger Based Ablation for AF, using Pulmonary Vein Isolation alone.
223836411|NCT03930134|PROCEDURE|sparse uterine suture|The slowly absorbed Vicryl 1 suture with a large round needle is introduced intramyometrially right above the endometrium. The suture starts in one corner and proceeds along the lower then the upper edge returning back to the incision point. Subserous layer is closed upon using the same thread in order to cover the purse suture and to complete the haemostasis while increasing the wound thickness.
223836412|NCT03930134|PROCEDURE|one layer uterine closure|one layer classical continious uterine closure using slowly absorbed Vicryl 1
223836413|NCT01674257|OTHER|USPIO (ferumoxytol)-enhanced MRI scan|Two separate MRI scans will form this intervention. A baseline scan followed by an infusion of USPIO (ferumoxytol), followed by another MRI scan.
223836414|NCT01674257|RADIATION|18f-Fluoride PET/CT scan|
223836415|NCT01674257|RADIATION|18F-Flurodeoxyglucose PET/CT scan|
223836416|NCT04968028|PROCEDURE|ACAF|(1)A standard right-side Smith-Robinson approach is performed. (2) The involved disc tissues are removed. The posterior longitudinal ligament is cut down at the levels cephalic and caudal to OPLL. (3) The anterior portion of the middle vertebral bodies is removed according to the thickness of ossification. Suitable cages are placed into each intervertebral space. (4) On the left side of the vertebra, a 2-mm-wide groove is created at the medial border of the transverse foramina. After that, an curved plated is fixed with screws. (5) On the right side of the vertebrae, a similar groove was also created. (6) Finally, tightening the screws to achieve a gradual evaluation of the vertebrae with OPLL.
223836417|NCT04968028|PROCEDURE|Laminoplasty|(1) In the prone position, the skin and nuchal ligament were cut through the posterior median incision, and the paravertebral muscles were stripped layer by layer to expose the bilateral vertebral lamina, lateral mass and articular process.（2) Part of spinous process were removed with bone biting forceps. The side with more severe symptoms was selected as the open side, bone groove was performed at 2-3 mm of the medial edge of bilateral facet joints with the medial cortex was reserved at the shaft side.（3) Slowly lift the lamina and maintained.（4)Determining the opening width of each segment by trial, and selecting the appropriate size Arch miniplate, and fixed with screws.
223836418|NCT02806284|BIOLOGICAL|PPSV23, Act-HIB|"described in Arm description"
223836419|NCT04802226|OTHER|self exclusion procedure|self exclusion procedure( responsible gambling tool)
223836420|NCT01987830|DEVICE|MRI-PET|"* \[11C\] temozolomide for PET scan and a contrast dye for the MRI scan~* Drawing blood to assess the radioactivity of \[11C\] temozolomide"
223836421|NCT01987830|DEVICE|TMZ-PET|The PET scan will take approximately 90 minutes. You will receive one injection of \[11C\] temozolomide. Following the injection of the radioactive substance, blood samples will be taken from the second IV line.
223836422|NCT03990363|DRUG|Verinurad|"Study treatments will be titrated in 3 steps for target low dose (3 mg), intermediate dose ( 7.5 mg) and High Dose (12 mg) Verinurad.~As per Protocol Version 5.0, Patients from 3 mg dose will be switched to 24 mg at visit 9"
223836423|NCT03990363|DRUG|Allopurinol|Study treatments will be titrated in 3 steps: Low dose (100 mg), intermediate (200 mg) and High Dose ( 300 mg) Allopurinol
223836424|NCT03990363|DRUG|Placebo for Verinurad|Matching Capsule
223836425|NCT03990363|DRUG|Placebo for Allopurinol|Matching tablet
223836426|NCT00566358|PROCEDURE|Duodenal exclusion surgery|Under open laparotomy, a duodenum section 2cm below the pylorus and a jejunum section below Treitz's Angle to create an excluded biliopancreatic limb of 150cm. A Roux-in-Y retrocolic anastomosis of the alimentary limb promotes the gastrojejunal continuity and the anastomosis of the excluded biliopancreatic limb is done 100cm below the jejunal-pyloric union.
223836427|NCT02171182|DRUG|Qutenza|capsaicin patch
223836428|NCT04453059|DRUG|Iopamidol|Previously administered Isovue-300 (300 mgI/mL) PO at a dilution of 2-3% (6-9 mgI/mL)
223836429|NCT00043888|DRUG|fosamprenavir|
223836430|NCT00043888|DRUG|COMBIVIR|
223836431|NCT00043888|DRUG|ritonavir|
223836432|NCT00043888|DRUG|TRIZIVIR|
223836433|NCT00008047|DRUG|fluorouracil|
223836434|NCT00008047|DRUG|hydroxyurea|
223836435|NCT00008047|DRUG|paclitaxel|
223836436|NCT00008047|PROCEDURE|conventional surgery|
223836437|NCT00008047|RADIATION|radiation therapy|
223836438|NCT00428064|DRUG|Sirolimus|
223836439|NCT00428064|DRUG|cyclosporine|
223836440|NCT03881033|OTHER|Peep 5cmH2O|Face mask ventilation with peak inspiratory pressure according to the group P7+5 means face mask ventilation with peak inspiratory pressure 7cmH2O plus PEEP 5 cmH2O.
223836441|NCT03881033|OTHER|Peak inspiratory pressure|Face mask ventilation with peak inspiratory pressure according to the group P12 means face mask ventilation with peak inspiratory pressure 12cmH2O without PEEP.
223836442|NCT02313896|BEHAVIORAL|Phone calls|Phone calls from medical staff assess confusion of the patient, and recommend immediate changes to dosage of lactulose.
223836443|NCT04299802|DRUG|Leukocyte-Rich Platelet-Rich Plasma|LR-PRP will be a concentration of PRP with the addition of leukocytes. Studies have shown that LR-PRP is more effective in treating tendinopathy than leukocyte-poor platelet-rich plasma.
223836444|NCT04299802|PROCEDURE|Percutaneous Ultrasonic Tenotomy|Discussed in Percutaneous Ultrasonic Tenotomy Arm section
223836445|NCT02476097|DRUG|Esomeprazole: Nexium® 20mg, Astra Zeneca|Comparison of the prevalence of clinical symptoms of acid rebound, between patients with progressive (esomeprazole ) or sudden (placebo) discontinuation of Proton pump inhibitors.
223836446|NCT02476097|OTHER|CYP2C19 phenotypical analysis|All patients included will undergo an assessment of the CYP2C19 activity by the administration of omeprazole 40mg and following measurement of omeprazole metabolic ratio respectively, once during the study.
223836447|NCT02476097|DRUG|Placebo|Comparison of the prevalence of clinical symptoms of acid rebound, between patients with progressive (esomeprazole ) or sudden (placebo) discontinuation of Proton pump inhibitors.
223836448|NCT04478227|DRUG|Romiplostim|Nplate is a thrombopoietin receptor agonist indicated for the treatment of thrombocytopenia in patients with chronic immune (idiopathic) thrombocytopenic purpura (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy.
223836449|NCT01133860|DRUG|eltrombopag|Eltrombopag, administered orally, 50 mg/daily for 21 days. Patients with platelet counts between 100 and 150x10e9/L at day 21 will continue eltrombopag 50 mg/daily for 21 additional days. Patients with platelet count lower than 100x10e9/L at day 21 will receive eltrombopag 75 mg/daily for additional 21 days. Patients with more than 150x10e9 platelets/L at day 21 will stop therapy.
223836450|NCT03017144|OTHER|Pit crew model education|A pit crew model for resuscitation is educated to all resuscitation team members.
223836451|NCT01079624|OTHER|Glucose-insulinotropic peptide, Glucagon-like peptide-1|GIP 2 and 5 pmol/kg min GLP-1 0.7 pmol/kg min
223836452|NCT02406209|DRUG|NS2|NS2 ophthalmic drops (0.5%)
223836453|NCT02406209|DRUG|Prednisolone acetate ophthalmic suspension (1%)|
223836454|NCT01500746|PROCEDURE|Pulse lavage treatment|A pulse lavage machine will be used to irrigate the wound with a total of 4 liters of water, twice daily, for a total of 4 days (8 treatments).
223836455|NCT01500746|OTHER|Dressing changes|Wounds will be treated with moist gauze dressing changes twice daily for a total of 4 days (8 treatments).
223836456|NCT02283437|BEHAVIORAL|Problem-solving Based Bibliotherapy Program|The PSBPF will complete the bibliotherapy (self-help) and problem-solving manual developed by the research team for caregivers of people with schizophrenia spectrum disorders.
223836457|NCT02283437|BEHAVIORAL|Behavioral Management and Education Program|Two trained advanced practice psychiatric nurses who are experienced in psychiatric rehabilitation and group programs will lead the behavioral management and education group, which is guided by a validated treatment protocol based on the research team's (Chien and Wong, 2007) and McFarlane et al.'s (2001) family management programs for schizophrenia.
223836458|NCT04052230|OTHER|ultrasound measure|Admission to the intensive care unit, and setting up an ECMO Daily monitoring from D1 to D7, follow up at D60
223836459|NCT03195920|DEVICE|Enhanced Lithotripsy System|The Enhanced Lithotripsy System is a type of lithotripsy system comprising a console, treatment head, and Acoustic Energy Focusing material. Operation of the Enhanced Lithotripsy System entails combined action of extracorporeal insonation and Acoustic Energy Focusing material to fragment urinary stones.
223836460|NCT06353659|DIAGNOSTIC_TEST|Contrast-enhanced Ultrasound|Patients with acute kidney injury high risk factors (KDIGO 2012) will undergo a contrast-enhanced ultrasound within 24 hours of admission to the ICU
223836461|NCT05322135|DRUG|18F-FSPG|Given by vein (IV)
223836462|NCT05322135|DRUG|11C-Glutamine|Given by vein (IV)
223836463|NCT01622712|DEVICE|Rebound HRD Mesh|Patients with unilateral inguinal hernia receive a nitinol containing large pore polypropylene mesh.
223836464|NCT02092818|DRUG|Riociguat (Adempas, BAY63-2521)|The decision on clinical management of the patient including the actual treatment duration will be determined solely by the physician not by the clinical study protocol (CSP)
223836465|NCT03677063|OTHER|No dressing|Then, care is the same and exit-site remains covered with an occlusive dressing to promote tunnel epithelialization and healing. The shower is forbidden during this period.
223836466|NCT00099216|DRUG|Rivastigmine|
223836467|NCT04193748|DRUG|Topical pomegranate seeds and peel extracts|Topical pomegranate seeds and peel extracts in the form of gel
223836468|NCT02431728|DIETARY_SUPPLEMENT|Melatonin|5 mg capsule p.o. at bedtime daily
223836469|NCT02431728|DIETARY_SUPPLEMENT|Matched Placebo|5 mg capsule p.o. at bedtime daily
223836470|NCT05266651|DRUG|Tadalafil 5mg|oral tablets for one month duration
223836471|NCT05266651|DRUG|Placebo|oral tablets for one month duration
223836472|NCT02334527|DRUG|Palbociclib|125 mg capsule will be taken once per day orally and continuously for 3 weeks followed by 1 week off.
223836473|NCT01706965|DRUG|Kuvan|20mg/kg using a daily dosing schedule. To increase tolerability, treatment will be initiated at 10mg/kg for the first week of the study. Given the short length of the trial, no dose adjustments will be made for changes in weight
223836474|NCT01706965|DRUG|Multivitamin|Multi-vitamin will be used as an active control in this study. Will be dosed daily
223836475|NCT03944980|DRUG|Docetaxel|Docetaxel injection
223836476|NCT03944980|BIOLOGICAL|PD1-T cells|PD1-T cells injection
223836477|NCT02451813|PROCEDURE|Apposition of needle bevel against femoral nerve|Indentation of femoral nerve and fascia iliaca by block needle and measurement of opening injection pressure during the controlled injection of 1 ml of dextrose (D5W) solution
223836478|NCT06161103|PROCEDURE|3D Printed Prefabricated Composite Resin Crown Group|3D Crown application: After preparing the molars, the crown was cemented by passive seating with modified glass ionomer cement (GC FujiCEM Evolve, GC America, Alsip, USA).
223836479|NCT06161103|PROCEDURE|Prefabricated stainless steel crown group|Stainless steel crown application: After preparing the molars, the crown was filled with type-1 glass ionomer cement (Aqua Meron, Voco, Cuxhaven, Germany) and cemented.
223836480|NCT02814110|DRUG|Granulocyte colony-stimulating factor (Filgrastim)|Drug administration
223836481|NCT05216224|DRUG|ATI-450|Oral, small molecule MK2 inhibitor
223836482|NCT05216224|DRUG|Placebo oral tablet|Placebo tablet manufactured to match ATI-450 in appearance
223836483|NCT05551429|BEHAVIORAL|Invitation to the CR|"1. Oral and written information emphasise the benefits of cardiac rehabilitation in terms of treatment of heart diseases, increasing functional capacity, reducing morbidity and mortality, and enhancing secondary prevention.~2. Introducing the scope and method of administration of CR to patients.~3. Setting up the appointment for the initial CR session four weeks later."
223836484|NCT00518141|DRUG|Acetyl Salicylic Acid and Terbutalin|ASA 75 mg, Terbutalin 5mg
223836485|NCT00057811|DRUG|doxorubicin hydrochloride|Given IV, IT, or orally
223836486|NCT00057811|DRUG|cyclophosphamide|Given IV
223836487|NCT00057811|DRUG|methotrexate|Given IV or IT
223836488|NCT00057811|DRUG|rasburicase|Given IV
223836489|NCT00057811|DRUG|leucovorin calcium|Given IV or orally
223836490|NCT00057811|DRUG|prednisone|Given IV or orally
223836491|NCT00057811|DRUG|methylprednisolone|Given IV or orally
223836492|NCT00057811|BIOLOGICAL|filgrastim|Given subcutaneously
223836493|NCT00057811|BIOLOGICAL|rituximab|Given IV
223836494|NCT00057811|DRUG|cytarabine|Given IT
223836495|NCT00057811|DRUG|etoposide|Given IV
223836496|NCT00057811|DRUG|vincristine sulfate|Given IV
223836497|NCT00057811|DRUG|hydrocortisone sodium succinate|Given IT
223836498|NCT00057811|OTHER|laboratory biomarker analysis|Correlative studies
223836499|NCT00556374|DRUG|Placebo|
223836500|NCT00556374|BIOLOGICAL|Denosumab|Administered as a subcutaneous injection
223836501|NCT00556374|DRUG|Non-steroidal aromatase inhibitor therapy|An approved non-steroidal aromatase inhibitor therapy (eg, anastrazole) in the adjuvant setting
223836502|NCT00556374|DRUG|Zoledronic Acid|5 mg zoledronic acid administered at a constant infusion rate
223836503|NCT00556374|OTHER|Standard of Care|Standard of care (SoC) as recommended by the treating physician, depending on individual factors such as bone density, lifestyle recommendations by the Investigator such as diet, physical activities and sun exposure, as well as local treatment standards.
223836504|NCT05278923|DEVICE|SALAD simulation device|An airway CPR manikin was modified to simulate regurgitation during CPR . A manual pump was fixed on the bottom of the torso to simulate the stomach. A clear vinyl tube was connected the manikin's oesophagus and the outflow port of the pump. A water container outside the manikin was filled with simulated gastric content and connected to the inflow port of the pump through another vinyl tube. The manikin's left main bronchus was occluded using a red cap provided by the manufacturer. The lung was simulated by an anaesthesia breathing bag placed outside the manikin and connected to the manikin's right main bronchus via a breathing circuit. A compression pad was attached to the bottom of the manikin's compression plate. During chest compression, the compression pad squeezed the pump to regurgitate gastric contents into the oropharynx
223836505|NCT05733806|OTHER|chemotherapy, surgery|this is an observational prospective study, therefore no intervention is planned. Patients perform medical and surgical treatment as per standard of case.
223836506|NCT03524274|BIOLOGICAL|Activated CIK and CD3-MUC1 Bispecific Antibody in Treating colorectal cancer|CIK cells was activated by PD-1 inhibitor and bispecific antibody of anti-CD3/MUC1
223836507|NCT03524274|PROCEDURE|Cryotherapy|the maximum tumor length≥2 cm，cool down the lesion,result in degeneration, necrosis or loss of the lesion.
223836508|NCT02169219|DRUG|Glucocorticoids|"Patients will begin prednisone therapy at a dose selected by the investigator or the treating physician with oral prednisone 60mg or 1mg/kg (if weight less than 60kg) or intravenous methylprednisolone, up to 1g/day for three days.~Prednisone will be tapered over 8 weeks as follows:~* 60mg for 2 weeks~* 40mg for 2 weeks~* 30mg for 1 week~* 20mg for 1 week~* 10mg for 1 week~* 5mg for 1 week"
223836509|NCT02169219|DRUG|Rituximab|Rituximab will be administered in four weekly doses at 375mg/m2
223836510|NCT02672163|PROCEDURE|CABG surgery|Elective CABG surgery
223836511|NCT02672163|PROCEDURE|AADC therapy|Atrial appendage derived cells are placed on the site of a infarct scar with matrix sheet
223836512|NCT00255567|DRUG|Sodium Stibogluconate|Sodium Stibogluconate 20mg/kg/day for 30 days
223836513|NCT00255567|DRUG|Paromomycin sulphate|Paromomycin sulphate
223836514|NCT00255567|DRUG|SSG and Paromomycin sulphate|SSG and Paromomycin Sulphate 17 days
223836515|NCT04039880|DRUG|Olorofim|single oral dose (120 mg, 3.7 MBq)
223836516|NCT05721339|BEHAVIORAL|Acceptance and Commitment Therapy|"ACT will be applied through 8 sessions by the psychological flexibility processes, which were grouped into three response styles: open, aware, and active. Openness is reflected by acceptance, which means the conscious embrace of psychological events without unnecessary attempts to change their frequency. Defusion means untangling unhelpful thoughts and responding to mental experiences as experiences rather than guides to action. The awareness set, which is reflected by applying self-as-context, which means a continuous and secure I from which events are experienced but distinct from those events. A present moment means ongoing, nonjudgmental contact with internal and external events as they occur in the present moment. The active set, which was reflected by making the intern nurses embrace their desired and chosen life values directions, and commit action to selected values."
223836517|NCT00026520|BIOLOGICAL|recombinant interferon alfa|
223836518|NCT00026520|DRUG|thalidomide|
223836519|NCT01028521|DRUG|CM3.1-AC100|Solution for sc injection, single ascending doses
223836520|NCT01028521|DRUG|Placebo|Solution for sc injection
223836521|NCT02089815|BEHAVIORAL|Home based exercise|modified Otago exercise program to simple designed home based exercise program
223836522|NCT02089815|OTHER|fall prevention education and counseling|
223836523|NCT02231372|DRUG|Berodual® Respimat® solution for inhalation|
223836524|NCT05427513|DRUG|Tranexamic acid injection|will inject tranexamic acid in limb salvage surgery of sarcoma patient to check its efficacy in preventing blood loss
223836525|NCT05427513|OTHER|normal saline|normal saline will be injected to ensure placebo
223836526|NCT06013332|DEVICE|PBF PLLA microsphere (injectable poly-L-lactic acid)|Poly-L-lactic acid (PLLA) is a collagen stimulator, helps restore the deep, underlying structure of the skin to diminish facial wrinkles. PLLA microparticles are absorbable for human body, and it works with human body within the deep dermis to help revitalize collagen production and help restore human skin's inner structure and volume. PLLA can rebuilt collagen strands begin gradually helping to restore facial volume and the look of fullness to wrinkles and folds.
223836527|NCT06013332|DEVICE|Sculptra®|Sculptra®
223836528|NCT05559437|DRUG|Levo-bupivacaine 0.25|The blockade of ilioinguinal/iliohypogastric nerves in the anterior abdominal wall has improved postoperative analgesia after open inguinal hernia repair. Other new blocks needs to be investigated
223836529|NCT04088318|DRUG|OQL011|OQL011 is an ointment containing active ingredient.
223836530|NCT04088318|DRUG|Vehicle Ointment|Vehicle ointment is an ointment containing no active ingredient.
223836531|NCT03434613|DRUG|Rosuvastatin|Rosuvastatin 5mg 1T daily for 6 months
223836532|NCT03434613|DRUG|Rosuvastatin/ezetimibe combination|Rosuvastatin 5mg / Ezetimibe 10mg combination 1T daily for 6 months
223836533|NCT05217823|DEVICE|Er:YAG laser|
223836534|NCT05217823|OTHER|hand instruments|
223836535|NCT02934516|PROCEDURE|Cesarean section|"Abdominal disimpaction with lower uterine segment support: the edge of the lower uterine segment is grasped by 3-4 modified Allies forceps (with broader jaws) applied along the lower edge of the incision until it is completely supported. These forceps are handled by the assistant, and gentle traction is applied upward, perpendicular to the uterine surface and away from the fetal head without excessive force. Accordingly, the hand of the surgeon could be inserted into the uterine cavity, and adequate space for manipulations is available without applying pressure on the lower segment. The fetal head is eventually grasped and delivered.~Classic push method: delivering the head with assistance by pushing the fetal head vaginally"
223836536|NCT00238420|DRUG|Paclitaxel|Given IV
223836537|NCT00238420|RADIATION|Radiation Therapy|Undergo radiation therapy
223836538|NCT00238420|BIOLOGICAL|Trastuzumab|Given IV
223836539|NCT06195124|DRUG|RGL-193（low-dose）|Each side of the putamen received 150 μL of RGL-193, with a unilateral dose of 1.5×10\^11 VG and a bilateral dose of 3.0×10\^11 VG.
223836540|NCT06195124|DRUG|RGL-193（high-dose）|Each side of the putamen received 200 μL of RGL-193, with a unilateral dose of 5.0×10\^11 VG and a bilateral dose of 1.0×10\^12 VG.
223836541|NCT00338793|DRUG|prednisolone|
223836542|NCT05768516|OTHER|Implementation of best practice for low back pain in primary care|"1. Stratified care: GPs will use a simple algorithm based on the risk of chronicity to determine the management plan. The risk level bas will be based on the Start Back Tool (SBT) and other variables that have been shown to improve the classification, such as work capacity.~2. Healthcare professional education: GPs will receive education to improve their knowledge about low back pain guidelines, diagnostic triage, patient education, stratified care and best practice.~3. Patient education: An education booklet Understanding My Low Back Pain will be used by GPs during their consultations. Second, GPs, PTs and OTs will provide similar reassuring messages and direct patients to the website www.infomaldedos.ch.~4. Interprofessional collaboration: A structured assessment form and a facilitated contact will be implemented between healthcare providers."
223836543|NCT00108121|DRUG|PEP005|
223836544|NCT04772690|OTHER|A resource-oriented intervention|The intervention is delivered by an interdisciplinary team of occupational therapist, physiotherapist, nurse, psychologist, physician and social worker. It consists of a five-day residential stay at REHPA and a two-day follow-up stay after seven weeks at home. The residential stays include both workshops and engagement in physical and creative activities.
223836545|NCT00442286|DEVICE|Rheos® Baroreflex Hypertension System|Electrical activation of the Carotid Baroreflex
223836546|NCT05733819|DEVICE|Subject-specific optimized RAS|Walking with metronome-based RAS cueing
223836547|NCT05733819|BEHAVIORAL|Active Walking|Walking without RAS cueing
223836548|NCT03666910|DIAGNOSTIC_TEST|Audiometer|detection of hearing problems
223836549|NCT02450019|PROCEDURE|Traditional to protective ventilation|Traditional ventilation will be set with 9 ml/kg with predicted body weight of tidal volumes and no PEEP and switched to protective ventilation after intracranial pressure measurement.
223836550|NCT02450019|PROCEDURE|Protective to traditional ventilation|Protective ventilation will be set with 7 ml/kg tidal volume, 5 cm H2O PEEP, and 0.4 inspired O2 fraction (FiO2), and switched to traditional ventilation after intracranial pressure measurement.
223836551|NCT00859131|DRUG|Rabbit Antithymocyte globulin|1.5 mg/kg IV pre-op, day 1, day 2, day 3, day 4
223836552|NCT00859131|DRUG|Daclizumab|1.0 mg/kg pre-op and 1.0 mg/kg on Day 7
223836553|NCT00425217|DRUG|Rituximab|
223836554|NCT00663962|DRUG|Pregabalin|"PHASE 1 (N=3) Pregabalin 150mg administered one hour prior to surgery and 12 hours after surgery, then continued BID until day 7 post-op.~PHASE 2 (N=4) Pregabalin 300mg administered one hour prior to surgery and 12 hours after surgery, then continued BID until day 7 post-op."
223836555|NCT00663962|DRUG|Placebo|An identical placebo administered one hour prior to surgery and 12 hours after surgery, then continued BID until day 7 post-op (N=8)
223836556|NCT05364619|DRUG|Qingre Huashi Granules combined the modified dual therapy|Qingre Huashi Granules combined the modified dual therapy for 14 days
223836557|NCT05364619|DRUG|Bismuth containing quadruple therapy|Bismuth containing quadruple therapy for 14 days
223836558|NCT02754414|PROCEDURE|Apheresis platelet collection|A single apheresis platelet unit will be collected from a healthy adult volunteer subject using the Trima Accel® Automated Blood Collection System. Concurrent plasma will be collected.
223836559|NCT02754414|OTHER|Refrigerated storage of apheresis platelets in PAS/plasma|The apheresis platelet unit will be stored, without agitation, at 4°C, for up to 20 days.
223836560|NCT02754414|RADIATION|Infusion of aliquot of autologous radiolabeled platelets|Fresh and stored aliquots will be labeled with Indium-111. We are administering ≤30 microcuries in both infusions for a total dose of 0.8 mSv.
223836561|NCT02754414|OTHER|In vitro tests|Tests to evaluate platelet function will be performed on the platelet unit on day of collection and end of storage
223836562|NCT03509792|BEHAVIORAL|Simple cognitive task|"A memory cue followed by playing the computer game Tetris on own smartphone. Options to engage in self-administered booster sessions after day 1."
223836563|NCT03509792|BEHAVIORAL|Attention placebo|Smartphone activity for same amount of time.
223836564|NCT01119339|DRUG|LAS 41004|LAS 41004 dosage 1, once daily
223836565|NCT01119339|DRUG|LAS 41004|LAS 41004 dosage 2, once daily
223836566|NCT01119339|DRUG|LAS 41004|LAS 41004 dosage 3, once daily
223836567|NCT01119339|DRUG|LAS 41004|LAS 41004 dosage 4, once daily
223836568|NCT01119339|DRUG|LAS 41004|LAS 41004 , dosage 5, once daily
223836569|NCT01119339|DRUG|LAS 41004 dosage 6|LAS 41004, dosage 6, once daily
223836570|NCT01119339|DRUG|Placebo|Placebo, once daily
223836571|NCT01119339|DRUG|Reference|Reference, once daily
223836572|NCT05896917|DEVICE|3D Printed Foot Orthosis|3D printed foot orthoses designed and fabricated at the Taibah University
223836573|NCT05896917|DEVICE|Prefabricated Foot Orthosis|Generic foot orthoses available commercially
223836574|NCT05343117|DRUG|Palbociclib based-therapy as initial endocrine therapy|Palbociclib + aromatase inhibitor/fulvestrant (initial endocrine therapy)
223836575|NCT05343117|DRUG|Palbociclib based-therapy after chemotherapy|Palbociclib + aromatase inhibitor/fulvestrant (after chemotherapy)
223836576|NCT03428815|DEVICE|Prosthesis suspension liner|Liners out of phase change material will be fitted
223836577|NCT04499417|DEVICE|Electromyostimulation Whole-Body-Workout|Electromyostimulation - intensity 5 (muscle stimulation)
223836578|NCT04499417|DEVICE|Electromyostimulation Sham Whole-Body-Workout|Electromyostimulation - intensity 0 (no muscle stimulation)
223836579|NCT02933190|PROCEDURE|transvaginal surgery；UAE and D&C|For cesarean scar pregnancy treatment
223836580|NCT02102464|DEVICE|LipiFlow treatment|The LipiFlow® Thermal Pulsation System is a prescription device intended for the application of localized heat and pressure therapy in adult patients with chronic cystic conditions of the eyelids, including meibomian gland dysfunction, also known as evaporative dry eye or lipid deficiency dry eye.
223836581|NCT01700348|DEVICE|Airflosser|Use of Philips Airflosser
223836582|NCT01700348|DEVICE|Manual Floss|Active Comparator
223836583|NCT04140890|BEHAVIORAL|Habit Formation|Treatment sessions consist of 12 weekly health coaching sessions at participants' home. During the intervention period, an occupational therapist will help the participant to commit to developing new simple habits (dietary habits or physical activity habits) in each 60-minute session.
223836584|NCT04140890|BEHAVIORAL|Education|In the education group, participants will receive newsletters containing general healthy aging materials over 12 weeks. A trained research assistant will call participants to verify receipt of the newsletter, and answer their questions about the materials. Each phone call will last \~15 minutes.
223836585|NCT01053637|DRUG|hydrocodone/acetaminophen|0.17 mg/kg hydrocodone component to max of 10 mg. If dose is vomited within 5 minutes, second dose may be administered.
223836586|NCT01053637|DRUG|Sugar water|An equal volume of sugar water will be dispensed, as for the weight based 0.17 mg/kg hydrocodone solution given for the study drug
223836587|NCT03580460|BEHAVIORAL|Computer delivered smoking cessation counseling|15 to 20 minute computer-delivered interactive smoking cessation counseling
223836588|NCT05709691|OTHER|Oculomotor therapy|Visual exercise to improve oculomotor behavior.
223836589|NCT05709691|OTHER|Adapted yoga|Muscular Stretching Therapy, postural control, respiratory physiotherapy.
223836590|NCT03691285|PROCEDURE|Mandibular Overdenture|Placement of 1 or 2 implants in the anterior region of the edentulous mandible.
223836591|NCT02378818|BEHAVIORAL|Force task, preference task, discount task, learning task.|Force task, preference task, discount task, learning task.
223836592|NCT03530046|COMBINATION_PRODUCT|High SID fluid|The fluid will be given to the patient at a rate prescribed by the treating physician according to clinical response for a period of 2 hours or up to maximum 30ml/kg fluid is given, whichever is earlier.
223836593|NCT03530046|COMBINATION_PRODUCT|Hartmann's solution|The fluid will be given to the patient at a rate prescribed by the treating physician according to clinical response for a period of 2 hours or up to maximum 30ml/kg fluid is given, whichever is earlier.
223836594|NCT03713255|PROCEDURE|PVB group|Patients in this group will receive preoperative ultrasound-guided thoracic paravertebral block using ropivacaine 0.5% with epinephrine 2.5 mcg/mL, and supplemental standardized anesthetic/analgesic regimen (Acetaminophen / NSAIDs / opioids for breakthrough pain).
223836595|NCT03713255|PROCEDURE|MTP block group|Patients in this group will receive preoperative ultrasound-guided mid-point transverse process to pleura block using ropivacaine 0.5% with epinephrine 2.5 mcg/mL, and supplemental standardized anesthetic/analgesic regimen (Acetaminophen / NSAIDs / opioids for breakthrough pain).
223836596|NCT03713255|PROCEDURE|Control Group|Patients in this group will receive preoperative ultrasound-guided sham block with subcutaneous local anesthetic injection using lidocaine 1%, and supplemental standardized anesthetic/analgesic regimen (Acetaminophen / NSAIDs / opioids for breakthrough pain).
223836597|NCT00822315|DRUG|efavirenz|tenofovir 245 mg / lamivudine 300 mg / efavirenz 600 mg
223836598|NCT00822315|DRUG|raltegravir|tenofovir 245 mg / lamivudine 300 mg / raltegravir 400 mg
223836599|NCT00822315|DRUG|raltegravir|tenofovir 245 mg / lamivudine 300 mg / raltegravir 800 mg
223836600|NCT02722317|BEHAVIORAL|psychological support|psychological support was given to men by the service, the researcher didn't interfered in the intervention, just ask questions about it.
223836601|NCT04814875|DRUG|ATX-101 + Carboplatin + Pegylated liposomal doxorubicin (ACD)|"Pegylated liposomal doxorubicin (30 mg/m²) will be administered intravenously on Day 1 of each 28-day cycle; carboplatin (AUC5) will be administered intravenously on Day 1 of each cycle.~ATX-101 will be administered intravenously on Day 2 of each cycle in three escalation cohorts: 20, 30, and 45 mg/m² according to a 3+3 design."
223836602|NCT05222438|DRUG|loncastuximab tesirine|loncastuximab tesirine for maintenance therapy between day 30 and 60 following autoSCT and will receive a total of 6 months of therapy (8 cycles).
223836603|NCT02181972|DRUG|Gingko biloba|
223836604|NCT02181972|DRUG|Placebo|
223836605|NCT03427086|DRUG|Biotin|High dose biotin
223836606|NCT03427086|DRUG|Placebo Oral Tablet|Placebo tablet similar in shape and size to the biotin tablet
223836607|NCT05552274|DRUG|ECC4703|ECC4703 will be administered as 1 mg, 10 mg and 40 mg capsules. ECC4703 will be administered as oral capsules during each dosing day.
223836608|NCT05552274|DRUG|Placebo|Matching Placebo will be administered as oral capsules. Matching Placebo will be given orally during each dosing day.
223836609|NCT04729283|PROCEDURE|Sigmoidectomy|The sigmoid resection surgery, realized by laparoscopy or laparotomy, with anastomosis.
223836610|NCT01270763|BEHAVIORAL|Intensive lifestyle intervention|Lifestyle intervention focused on weight loss through diet and physical activity
223836611|NCT01270763|BEHAVIORAL|Diabetes support and education|Behavioral intervention focused on diabetes support and education
223836612|NCT03655873|DRUG|HEC30654AcOH capsule|"single ascending-dose study: 5-、10-、15-、30-、60-、90-、120mg HEC30654AcOH capsule in day1.~Multiple ascending-dose study:~15-、30-、60mgHEC30654AcOH capsule in day1-day7，2 times everyday."
223836613|NCT03655873|DRUG|Placebo capsule|"single ascending-dose study: 5-、10-、15-、30-、60-、90-、120mg placebo capsule in day1.~Multiple ascending-dose study:~15-、30-、60mg placebo capsule in day1-day7，2 times everyday."
223836614|NCT03796013|DRUG|Entrectinib Form A|Participants will receive a single oral dose of entrectinib form A under fasted conditions.
223836615|NCT03796013|DRUG|Entrectinib Form C|Participants will receive a single oral dose of entrectinib form C under fasted conditions.
223836616|NCT01209338|BEHAVIORAL|Health education|Health education about HPV infection, HPV vaccine and cervix cancer.
223836617|NCT03958630|DRUG|11C-ER176|PET biomarker for inflammation
223836618|NCT03958630|DRUG|11C-PIB|PET biomarker for amyloid
223836619|NCT03958630|DIAGNOSTIC_TEST|Positron Emission Tomography (PET) Scan|Participants underwent PET scan with \[11C\]ER176 and/or 11C-PIB
223836620|NCT00670696|DRUG|Rapydan|Topical anaesthetic plaster
223836621|NCT00670696|DRUG|tetracaine gel|Topical tetracaine gel
223836622|NCT01941004|DRUG|fingolimod|Randomized to 6 month (180 days) 0.5 mg fingolimod + 6 month (180 day) open label 0.5mg fingolimod capsules for oral administration once daily
223836623|NCT01941004|DRUG|Placebo (6mos) + open label fingolimod (6 mos)|Randomized to 6 month (180 days) matching placebo + 6 month (180 day) open label 0.5mg fingolimod capsules for oral administration once daily
223836624|NCT01715623|BIOLOGICAL|a blood sample|Dosage of Ig
223836625|NCT04370743|OTHER|No intervention|
223836626|NCT03676036|DRUG|DS107E|
223836627|NCT03676036|DRUG|Vehicle|
223836628|NCT05433896|DRUG|Dasatinib ASD|XS004 Dasatinib Amorphous Solid Dispersion Film-Coated Tablet, 90 mg Test Formulation
223836629|NCT05433896|DRUG|Omeprazole 40 MG|Omeprazole Delayed Release Capsules, USP 40 mg
223836630|NCT04250961|OTHER|postoperative early shower|The shower group showered in 48-72 hours after median sternotomy with tap water.
223836631|NCT01628380|PROCEDURE|Cytoreductive Surgery and HIPEC|"CRS: radical surgery, associated to any surgical procedure needed to obtain a zero or ≤ 0.25cm residual tumor (peritonectomy, bowel resection, diaphragmatic stripping, gastric resection, etc.).~HIPEC: Cisplatin (CDDP) (100 mg/m2 of body surface area) + Paclitaxel (175mg/m2 of body surface area). Closed/open technique, as preferred. Duration: 90 minutes. Mean Intra-abdominal Temperature: 42°C."
223836632|NCT01628380|PROCEDURE|CRS alone|CRS: radical surgery, associated to any surgical procedure needed to obtain a zero or ≤ 0.25cm residual tumor (peritonectomy, bowel resection, diaphragmatic stripping, gastric resection, etc.)
223836633|NCT05409274|OTHER|No Intervention|No Intervention
223836634|NCT06159296|DEVICE|Hydroxy gas|Hydroxy gas is a combination of hydrogen and oxygen together.
223836635|NCT05471258|OTHER|Experimental: monopolar dielectric diathermy|The Experimental Group formed by 30 subjects will undergo an application of monopolar electrical diathermy by radiofrequency emission (MDR) using the Physicalm® device developed by the electro-medicine company Biotronic Advance Develops SL, on the lumbar muscles by means of rotary movements and translation, adapting to the muscle fibers of the lumbar area. A pulsed emission of 840 KHz and 30v will be made dynamically during a treatment time of 20 minutes. 3 weekly sessions will be performed for 3 weeks, a total of 9 treatment sessions.
223836636|NCT05471258|OTHER|Control: Placebo|"The 30 participants in the control group will receive a placebo treatment, consisting of the same execution protocol as the EG, but with a non-emitting device whose software and hardware will be exactly the same as that used in the EG. The intervention will be simulated for 20 minutes.~3 weekly sessions will be held for 3 weeks, a total of 9 treatment sessions."
223836637|NCT03758924|DRUG|ANAVEX2-73|Liquid oral solution
223836638|NCT03758924|DRUG|Placebo|Liquid oral solution
223836639|NCT01736358|DRUG|Intranasal Ketoralac|15.75 mg of Sprix in each nostril 20 minutes before end of surgery
223836640|NCT01736358|DRUG|Placebo|15.75 mg of placebo will be administered in each nostril 20 minutes before the end of surgery
223836641|NCT00799071|DRUG|posaconazole (PSZ)|Intake of PSZ oral suspension 40mg/ml twice daily with food. Starting dose is based on bodyweight. The dosage will be adjusted if the exposure is not adequate based on PSZ trough level on Day 10 and 20.
223836642|NCT01824472|DEVICE|CPAP|Treatment for sleep apnea
223836643|NCT01824472|BEHAVIORAL|CBT|Treatment for insomnia
223836644|NCT01824472|DEVICE|sham CPAP|Placebo for sleep apnea
223836645|NCT01824472|BEHAVIORAL|CC|Placebo (sham) for insomnia
223836646|NCT06328920|DEVICE|Intermittent Oro-esophageal Tube Feeding|The observation group was given enteral nutritional support with Intermittent Oro-esophageal Tube according to the following procedure: Before each feeding, inside and outside of the tube was cleaned with water. During feeding, the patient should maintain a semi-reclining or sitting position with mouth opened, and the tube was inserted slowly and smoothly into the upper part of the esophagus by medical staffs while the appropriate depth of intubation was checked with the calibration markings on the tube wall. The distance from the incisors to the head part of the tube should be between 22-25 cm.
223836647|NCT06328920|DEVICE|Nasogastric Tube Feeding|The control group was given enteral nutritional support with Nasogastric Tube Feeding according to the relevant guidelines. Within 4 hours after admission, the placement of the feeding tube was conducted by professional medical staffs and after intubation, the tube was secured to the patient's cheek with medical tape. The feeding was conducted once every 3-4 hours, with 200-300ml each time.
223836648|NCT04956263|DRUG|YG1699|"YG1699 is a novel investigational dual inhibitor of sodium-dependent glucose cotransporters, SGLT1 and SGLT2, indicated as an adjunct to diet and exercise to improve glycemic control and weight loss in adults with T2DM. A subsequent indication will be developed for YG1699 to improve glycemic control in adults with T1DM.~The proposed dosage form is a yellow, film-coated tablet for oral administration. The proposed tablet strengths for the current clinical research are 5 mg and 25 mg. The tablets are packaged in high-density polyethylene (HDPE) bottles with HDPE caps and desiccant inserters. Each HDPE bottle contains 30 tablets of drug product.~The study drug YG1699 is manufactured by Youngene Therapeutics Inc., Ltd., China."
223836649|NCT04956263|DRUG|Dapagliflozin|Farxiga® is a sodium-glucose cotransporter 2 (SGLT2) inhibitor. Faxiga® is available as a film-coated tablet for oral administration containing the equivalent of 5 mg dapagliflozin as dapagliflozin propanediol and the following inactive ingredients: microcrystalline cellulose, anhydrous lactose, crospovidone, silicon dioxide, and magnesium stearate. In addition, the film coating contains the following inactive ingredients: polyvinyl alcohol, titanium dioxide, polyethylene glycol, talc, and yellow iron oxide.
223836650|NCT05181813|PROCEDURE|Ginge-Cal|Fill the infected root canal of of primary teeth with Gingerols extract and Calcium Hydroxide (Ginge-Cal)
223836651|NCT05181813|PROCEDURE|Metapex|Fill the infected root canal of of primary teeth with Metapex
223836652|NCT04939311|DRUG|VB-201|One dose of VB-201 80 mg (1 tablet) will be administered orally once daily for 52 weeks.
223836653|NCT04939311|DRUG|Placebo|One dose of placebo 80 mg (1 tablet) will be administered orally once daily for 52 weeks.
223836654|NCT04969744|DEVICE|ICE|Intermittent Cooling Exposure using cooling garment for 1-2 hours
223836655|NCT03760471|OTHER|Evidenced-based symptom management and coping intervention|The intervention visits will focus on coping and the following symptoms prevalent during CRT: (1) pain and mucositis, (2) nausea, (3) constipation, (4) fatigue, (5) sleep disturbances, (6) xerostomia, (7) thick mucus, and (8) depression
223836656|NCT01695122|DRUG|Valproic Acid|
223836657|NCT01132196|DRUG|Divalproex Sodium|Divalproex Sodium DR Tablets 500 mg
223836658|NCT01815736|DRUG|E/C/F/TAF|150/150/200/10 mg FDC tablet administered orally once daily
223836659|NCT01815736|DRUG|E/C/F/TDF|150/150/200/300 mg FDC tablet administered orally once daily
223836660|NCT01815736|DRUG|EFV/FTC/TDF|600/200/300 mg FDC tablet administered orally once daily
223836661|NCT01815736|DRUG|RTV|100 mg tablet administered orally once daily
223836662|NCT01815736|DRUG|ATV|300 mg capsule administered orally once daily
223836663|NCT01815736|DRUG|FTC/TDF|200/300 mg tablet administered orally once daily
223836664|NCT01815736|DRUG|COBI|150 mg tablet administered orally once daily
223836665|NCT01147211|DRUG|MK2206|MK-2206 will be administered orally in a starting dose level of 135 mg on a schedule of Qwk in repeating 3-week treatment cycles in combination with gefitinib in continuous 21-day cycles for the duration of the study
223836666|NCT03694457|PROCEDURE|Reversed total shoulder arthroplasty|Replacement of the proximal humeral head by a reversed prosthesis through an anterior approach
223836667|NCT03694457|PROCEDURE|lateral approach|Replacement of the proximal humeral head by a reversed prosthesis through a lateral approach
223836668|NCT05389969|OTHER|digital arch scanning|"Scanning of the maxillary and mandibular dental arch will be performed for the same group of patients twice. The first time is before bracket positioning using two different scanners and the three different techniques. The second time is after brackets positioning using the same two different scanners and the same three different scanning techniques.~Then these scans will be compared to by superimposition techniques and linear measurement techniques."
223836669|NCT06204328|OTHER|Benson relaxation technique and mHealth psychoeducation|"Benson relaxation technique \& mHealth psychoeducation (combined intervention) will receive: 6 months.~Benson relaxation technique: Definition, benefits, and instruction about the Benson relaxation technique will be provided through recorded video, and a nurse will guide individuals face-to-face after receiving training from a physiotherapist.~mHealth psychoeducation: There will be six sessions in a total of six months of intervention, and every session will be conducted at the beginning of each month. During each session, recorded videos based on the self-determination theory (symptom management, maintaining and enhancing relationships, problem-solving, stress and coping, self-care, and effective communication) will be provided face-to-face to the intervention group via smartphones, tablets, or handheld computers. As well as phone calls and SMS reminders will continue every week for follow-up and question and answer sessions."
223836670|NCT03656393|DRUG|Gefitinib|Gefitinib (250 mg, orally, every day) for 56 days
223836671|NCT03656393|DRUG|Vinorelbine|Vinorelbine (60 mg/m2, orally, Once every three weeks) for 6 weeks
223836672|NCT03656393|DRUG|Carboplatin|Carboplatin (AUC5, intravenously drip, once a week) for 6 weeks
223836673|NCT02912429|DEVICE|Patellofemoral Arthroplasty|
223836674|NCT00429260|DRUG|Saredutant|
223836675|NCT02413684|BEHAVIORAL|Patient engagement toolkit|"Pack Health LLC and Duke will develop a patient engagement toolkit known as Packs to help empower and engage patients. These disease-specific, evidence-based kits are scientifically designed to improve patient involvement in their own care"
223836676|NCT05211375|PROCEDURE|Duodenojejunal bypass|Sleeve gastrectomy will be performed in the same manner as in the SG group. DJB will be performed by transection of the duodenum and bypassing 250 cm of the proximal jejunum. The handsewn suture will be used for duodenojejunal anastomosis, and the size of anastomosis will be 1.5 - 2 cm. Single anastomosis will be performed rather than Roux-en-Y fashion.
223836677|NCT05211375|PROCEDURE|Sleeve gastrectomy|Sleeve gastrectomy will be performed using 36-38 Fr bougie. The initial stapling start point will be between 4-6 cm from the pylorus, and the last stapling will be performed at least 1 cm away from His angle. The height of the automatic stapler will be selected based on the researcher's discretion.
223836678|NCT01954524|DRUG|IV bolus injection of Sildenafil|"Dose escalation will be performed (in different participants). The doses will be as follows:~CTP class B cirrhosis: A single 5 and 10 mg IV bolus injections of Sildenafil. CTP class C cirrhosis: A single 2.5, 5, 8 and 10 mg IV bolus injections of Sildenafil."
223836679|NCT01282320|BEHAVIORAL|Physical activity intervention program|Individually tailored exercise programme (combination of pilates and aerobe training) with one hour activity sessions two-three times per week in 16 weeks.
223836680|NCT01518114|BEHAVIORAL|Exercise Training|Exercise will be performed under continuous telemetry monitoring and medical supervision. Each session will include 5-10 worm-up, 30 min of aerobic activity on treadmill or bicycle ergometer followed by 10-15 min of stretch and relaxation exercise. Blood pressure will be obtained before the onset and at the end of each session. Participants will be requested to rest and observed 15-30 min before going home. The exercise intensity will be monitored and adjusted, per protocol, according to RPE using the Borg scale.
223836681|NCT02398162|PROCEDURE|Multi Blood Collections|At baseline (the day of presentation to hospital), 2 weeks, 12 weeks and 1 year later.
223836682|NCT02398162|PROCEDURE|Single Blood Collection|On the enrollment day
223836683|NCT04005729|DRUG|Cangrelor 50 MG|30 mcg/kg bolus, then 4h infusion 4 mcg/kg/min
223836684|NCT02429921|DIETARY_SUPPLEMENT|high-selenium lentils|lentils grown on naturally selenium-rich soils in the Canadian Prairies
223836685|NCT02429921|DIETARY_SUPPLEMENT|Low-Se lentils|lentils grown on selenium-deficient soils in Idaho, USA.
223836686|NCT06119906|DEVICE|Hyper-Spectral Endoscopy|We have developed a custom hyperspectral endoscopy approach based around a commercially available endoscopy system. An Olympus gastroscope (GIF-H260) and video processor and display are used with a modified light source that incorporates a laser with tunable wavelength for illuminating the scene through the endoscope. A live video feed from the gastroscope is displayed on the endoscopy monitors and can be acquired and saved in the native video acquisition system. The spectral imaging data is also saved within this video feed, where imaging wavelength corresponds to a given timestamp in the video.
223836687|NCT01369173|OTHER|Mexican or American foods|Participants will be randomized to an isocaloric Indigenous Mexican or a Western diet for 24 days. All foods and beverages will be prepared by the Human Nutrition Laboratory at the Fred Hutchinson Cancer Research Center. After a 4-week wash-out period, participants will cross over to the other arm and be given the alternate diet for 24 days. Blood and urine specimens will be collected before and after each feeding period to test baseline and post-intervention metabolic response as defined by various inflammatory and cancer susceptibility biomarkers including insulin-like growth factor 1 (IGF1), insulin-like growth factor binding protein 3 (IGFBP3), leptin, adiponectin, interleukin-6 (IL-6), C-reactive protein (CRP) and SAA (serum amyloid-A). DNA extracted from whole blood will be used to test whether a panel of 128 Ancestry Informative Markers (AIMs) is associated with metabolic response to the diets and other phenotypic traits of obesity, which relate to breast cancer risk.
223836688|NCT05107778|DRUG|ASC42 10mg|ASC42 10mg orally once daily;
223836689|NCT05107778|DRUG|ASC42 15mg|ASC42 15mg orally once daily.
223836690|NCT05107778|DRUG|ih PEG-IFN α-2a|ih PEG-IFN α-2a 180μg subcutaneous injection once a week.
223836691|NCT05107778|DRUG|Entecavir|Entecavir 0.5 mg orally once daily.
223836692|NCT05107778|DRUG|Placebo|Placebo orally once daily.
223836693|NCT00438867|GENETIC|Ad5FGF-4|Adenovirus serotype-5 mediated human fibroblast growth factor-4 gene transfer
223836694|NCT00438867|GENETIC|Placebo|Control group
223836695|NCT04261361|BEHAVIORAL|CBCBT intervention|8 group CBT sessions and 4 weekly follow-up calls
223836696|NCT04261361|BEHAVIORAL|Adherence counseling|All participants in both CBCBT and ETAU groups will have one session of Life-Steps, a stand-alone CBCBT intervention designed to improve adherence to medical recommendations and individualized DM self-management goals.
223836697|NCT04261361|BEHAVIORAL|Psycho-education package|Printed materials of a DM self-management education program will be delivered to both the CBCBT and ETAU groups.
223836698|NCT03040687|BIOLOGICAL|Anti CS6 BSIgG product (Lot PD1601105CS)|
223836699|NCT03040687|BIOLOGICAL|Anti B7A BSIgG product (Lot PD1601132ET)|
223836700|NCT03040687|BIOLOGICAL|Bovine Immunoglobin Negative Control (Lot PD161071NC)|
223836701|NCT03040687|BIOLOGICAL|B7A- CS6-expressing ETEC challenge strain|
223836702|NCT05631990|DRUG|AD-209|PO, Once daily(QD), 8weeks
223836703|NCT05631990|DRUG|AD-209-1A|PO, Once daily(QD), 8weeks
223836704|NCT05631990|DRUG|AD-209-1B|PO, Once daily(QD), 8weeks
223836705|NCT05631990|DRUG|AD-209-1C|PO, Once daily(QD), 8weeks
223836706|NCT05631990|DRUG|AD-209 placebo|PO, Once daily(QD), 8weeks
223836707|NCT05631990|DRUG|AD-209-1 placebo|PO, Once daily(QD), 8weeks
223836708|NCT03317379|BEHAVIORAL|Peer mentorship|Weekly meetings with a recovered peer mentor once per week. Dyads discuss eating disorder symptoms and how to overcome them.
223836709|NCT03317379|BEHAVIORAL|Social support mentorship|Weekly meetings with a social support mentor who has not personally struggled with an eating disorder, once per week. Dyads engage in activities unrelated to the eating disorder (e.g., a movie, a community event, volunteer work).
223836710|NCT03317379|BEHAVIORAL|Recovery Record use with mentor|Recovery Record is a smart phone or web-based application designed to provide recovery support to eating disorder patients. Includes a number of features aimed to promote recovery, such as a meal tracking, prompts for completing meals/snacks, tracking for additional symptoms such as stress and mood, motivational messages, information about coping strategies, and capacity to share logged data with clinicians and mentors.
223836711|NCT00003384|OTHER|Cervical Papanicolaou Test|Undergo Pap smear
223836712|NCT00003384|PROCEDURE|Conization|Undergo cone biopsy
223836713|NCT00003384|OTHER|Laboratory Biomarker Analysis|Correlative studies
223836714|NCT00872014|DRUG|AMG 386|Two doses of AMG 386 (15 mg/kg) IV QW will be studied
223836715|NCT00872014|DRUG|AMG 386|Two doses of AMG 386 (10 mg/kg) IV QW will be studied
223836716|NCT00872014|DRUG|Sorafenib|Sorafenib 400 mg PO BID orally twice daily in an every 4 week dosing schedule for 15mg/kg cohort \& 10mg/kg cohort
223836717|NCT03241264|DRUG|ND-L02-s0201|Specified dose on specified day
223836718|NCT01635361|OTHER|New Medicine Service|The New Medicine Service is an intervention where patients prescribed a new medicine receive followup consultations with the pharmacist 7-14 days and 14-21 days after receiving the new prescription item
223836719|NCT02661854|BIOLOGICAL|MM09 Mannosylated 5.000 subcutaneous|Mixture of the following mites: Dermatophagoides pteronyssinus and Dermatophagoides farinae, allergen extract with a concentration of 5.000 MTU (Mannosylated Therapeutic Units)/ml subcutaneous
223836720|NCT02661854|BIOLOGICAL|MM09 Mannosylated 10.000 subcutaneous|Mixture of the following mites: Dermatophagoides pteronyssinus and Dermatophagoides farinae, allergen extract with a concentration of 10.000 MTU (Mannosylated Therapeutic Units)/ml subcutaneous
223836721|NCT02661854|BIOLOGICAL|MM09 Mannosylated 30.000 subcutaneous|Mixture of the following mites: Dermatophagoides pteronyssinus and Dermatophagoides farinae, allergen extract with a concentration of 30.000 MTU (Mannosylated Therapeutic Units)/ml subcutaneous
223836722|NCT02661854|BIOLOGICAL|MM09 Mannosylated 50.000 subcutaneous|Mixture of the following mites: Dermatophagoides pteronyssinus and Dermatophagoides farinae, allergen extract with a concentration of 50.000 MTU (Mannosylated Therapeutic Units)/ml subcutaneous
223836723|NCT02661854|BIOLOGICAL|MM09 Mannosylated 5.000 sublingual|Mixture of the following mites: Dermatophagoides pteronyssinus and Dermatophagoides farinae, allergen extract with a concentration of 5.000 MTU (Mannosylated Therapeutic Units)/ml sublingual
223836724|NCT02661854|BIOLOGICAL|MM09 Mannosylated 10.000 sublingual|Mixture of the following mites: Dermatophagoides pteronyssinus and Dermatophagoides farinae, allergen extract with a concentration of 10.000 MTU (Mannosylated Therapeutic Units)/ml sublingual
223836725|NCT02661854|BIOLOGICAL|MM09 Mannosylated 30.000 sublingual|Mixture of the following mites: Dermatophagoides pteronyssinus and Dermatophagoides farinae, allergen extract with a concentration of 30.000 MTU (Mannosylated Therapeutic Units)/ml sublingual
223836726|NCT02661854|BIOLOGICAL|MM09 Mannosylated 50.000 sublingual|Mixture of the following mites: Dermatophagoides pteronyssinus and Dermatophagoides farinae, allergen extract with a concentration of 50.000 MTU (Mannosylated Therapeutic Units)/ml sublingual
223836727|NCT02661854|BIOLOGICAL|Subcutaneous placebo|Comparison between placebo and active group
223836728|NCT02661854|BIOLOGICAL|Sublingual placebo|Comparison between placebo and active group
223836729|NCT04408001|OTHER|Clinical interview|At each study visit, participants will be questioned by a physician about their persistent symptoms or the existence of intercurrent infections that may resemble COVID-19.
223836730|NCT04408001|BIOLOGICAL|Blood collection|"At each study visit,~* 1 EDTA tube for complete blood count~* 3 dry tubes with gel for serology, serum neutralisation test and serum library~* 1 cell preparation tube for the separation of immune cells within the circulating blood will be collected."
223836731|NCT04408001|BIOLOGICAL|Saliva collection|At each study visit, a saliva sample will be collected for the determination of IgA antibodies.
223836732|NCT00550173|DRUG|pemetrexed|500 milligrams per meter squared (mg/m\^2), intravenous (IV), every (q) 21 days until progression or unacceptable toxicity develops
223836733|NCT00550173|DRUG|erlotinib|150 mg, orally, once daily until progression or unacceptable toxicity develops
223836734|NCT03066570|BEHAVIORAL|Graded Exposure|Graded Exposure in vivo (GEXP) is a second-generation cognitive-behavioural intervention, and is characterized by systematic and repeated exposure to feared movements, activities and/or sensations in order to decrease fear and subsequently increase physical activity.
223836735|NCT05967104|OTHER|Education based on the PLISSIT model|Training to the intervention group was carried out in 3 sessions of 45 minutes each week, organized by the first author (AD). In each session, training was organized based on the PLISSIT framework.
223836736|NCT03067103|DRUG|Tramadol|Patients will receive injections in peritonsillar fossa of tramadol (2 mg/kg-2 ml)
223836737|NCT03067103|DRUG|Ketamine|Patients will receive injections in peritonsillar fossa of ketamine prior to surgery
223836738|NCT03067103|DRUG|Placebos|Patients will receive 2mL of saline solution in peritonsillar fossa prior to surgery
223836739|NCT02018315|DRUG|Triheptanoin|Triheptanoin is a 7-carbon medium chain triglyceride
223836740|NCT06250166|BEHAVIORAL|iPLANT diet plan and diet counselling|A diet plan which mainly consists of plant-based food will be designed based on participants' energy and protein needs. The counselling covers (1) guidance to achieve energy and protein requirement (2) advice on food to be included in iPLANT diet plan (Mediterranean diet: increase intake of fish and legumes; moderate intake of eggs, dairy, nuts, poultry; limit intake of red meat).
223836741|NCT06250166|BEHAVIORAL|Usual diet counselling|General dietary advices on how to improve oral intake and maintain healthy weight will be provided.
223836742|NCT04998695|OTHER|Olive pomace oil|Volunteers consumed during 4 weeks 45 g/d of olive pomace oil as the only source of dietary fat, used for cooking, salad dressing, toasts, etc.
223836743|NCT04998695|OTHER|Sunflower oil|Volunteers consumed during 4 weeks 45 g/d of sunflower oil as the only source of dietary fat, used for cooking, salad dressing, toasts, etc.
223836744|NCT02522975|DRUG|EPIAO®|"Recombinant human erythropoietin falls under the pharmacological class of haematopoietic / anti anaemic agents. It has been developed for the treatment of anaemia in subjects with chronic kidney disease.~Erythropoietin, also known as EPO, is a glycoprotein hormone that controls erythropoiesis, or RBC production. It is a cytokine (protein signalling molecule) for erythrocyte precursors in the bone marrow. Human EPO has a molecular weight of 34,000."
223836745|NCT02522975|DRUG|EPREX®|"Recombinant human erythropoietin falls under the pharmacological class of haematopoietic /anti anaemic agents. It has been developed for the treatment of anaemia in subjects with chronic kidney disease.~Erythropoietin, also known as EPO, is a glycoprotein hormone that controls erythropoiesis, or RBC production. It is a cytokine (protein signalling molecule) for erythrocyte precursors in the bone marrow. Human EPO has a molecular weight of 34,000."
223836746|NCT02769299|RADIATION|Radiation Therapy|less than 1 Gy with protons to 4-8 Gy with photons
223836747|NCT02359383|OTHER|Chest physiotherapy|Depending on the location of the pleural effusion different techniques are performed: 1. Postural control techniques; 2. Secretions drainage techniques; 3. Thoracic expansion techniques; 4. Diaphragmatic mobility techniques.
223836748|NCT02610712|DRUG|Ketamine|
223836749|NCT04366570|OTHER|clinical assessment of the shoulder and the cervical spine includes stress guideline tests|As a result of statistical processing, we are planning to obtain the most sensitive and specific tests from the clinical examination protocol
223836750|NCT01725997|PROCEDURE|hook plate|Surgery with hook plate followed by physiotherapy
223836751|NCT01725997|OTHER|Physiotherapy|Patients will be following a program specific for AC joint dislocations
223836752|NCT05934097|DRUG|FT596|Dosing to be initiated at a dose no higher than highest tolerable dose in study FT596-101, intravenously
223836753|NCT05934097|DRUG|Cyclophosphamide|750 mg/m\^2 intravenously
223836754|NCT05934097|DRUG|Doxorubicin|50 mg/m\^2 intravenously
223836755|NCT05934097|DRUG|Vincristine|1.4 mg/m\^2 (maximum dose 2 mg) intravenously
223836756|NCT05934097|DRUG|Prednisone|100 mg orally
223836757|NCT05934097|DRUG|Rituximab|375 mg/m\^2 intravenously
223836758|NCT05934097|DRUG|Bendamustine|90 mg/m\^2 IV infusion
223836759|NCT00721331|DRUG|nortriptyline HCl + loratadine|Topical
223836760|NCT00721331|DRUG|nortriptyline HCl + loratadine|Topical
223836761|NCT00721331|DRUG|nortriptyline HCl|Topical
223836762|NCT00721331|DRUG|mometasone furoate|Topical
223836763|NCT00721331|DRUG|Active ingredient free vehicle cream of CRx-197|Topical
223836764|NCT03499574|BEHAVIORAL|Dysphagia therapy using surface EMG as biofeedback|10 x 45 minute sessions over 14 days
223836765|NCT03499574|BEHAVIORAL|Usual Care|Usual care may include the following Speech and Language Therapy interventions; assessment, review, therapy, patient/family education etc.. Dose will vary.
223836766|NCT03911193|DRUG|Cabozantinib|Patients will be treated with cabozantinib 60 mg/daily (cycles each 28 days) until progression, toxicity or patient refusal.
223836767|NCT05690022|PROCEDURE|sleeve gastrectomy|Patients will be recruited for a sleeve gastrectomy according to the guidelines of the National Institute of Health.
223836768|NCT03292042|BEHAVIORAL|Physical health promotion program|"The program has 24 sessions. Each session has two parts:~* first part: half an hour of theoretical content, about the Metabolic syndrome, the effect of unhealthy lifestyle, toxic habits such as smoking or drinking alcohol, dietary habits or physical activity.~* Second part: 1 hour of physical activity (walk)"
223836769|NCT01899495|OTHER|High sodium diet and low sodium diet|Isocaloric diet with 60 mEq of potassium and 1gm protein/kg body weight with high sodium 300mEq; low sodium 10 mEq.
223836770|NCT00810641|PROCEDURE|Gufoni maneuver|For Gufoni maneuver,16,18 the patient was quickly brought down to the side-lying position on the affected ear from the sitting position. After one minute in this position, the head of the patient was quickly turned 45O upward, so that the nose directed upward. Approximately 2 minutes later, the patient was returned to the upright position (Figure 2A).
223836771|NCT00810641|PROCEDURE|Head-shaking maneuver|For head-shaking maneuver,15 patients were brought into a sitting position. After pitching the head forward by approximately 30O, we moved the head sideways in a sinusoidal fashion at an approximate rate of 3 Hz for 15 seconds.
223836772|NCT00810641|PROCEDURE|sham maneuver|For the sham maneuver, patients quickly lied on the unaffected side, and returned to the sitting position after one minute.
223836773|NCT01843075|DRUG|Liraglutide|Daily subcutaneous injection
223836774|NCT01843075|DRUG|Placebo|Daily subcutaneous injection
223836775|NCT03160911|DEVICE|Over-the-scope clip (OTSC)|The device provides a robust and strong tissue apposition. The system was developed to close perforations and treat bleeding in the gastrointestinal tract. In chronic ulcers, an anchor device can be used to pull the ulcer base toward the aspiration cap to facilitate accurate clip application. Endoscopic haemostasis would be achieved with the use of this device and/or injection of adrenaline
223836776|NCT03160911|DEVICE|Conventional Endoscopic Haemostasis|This includes the use of heater probe, endoscopic clipping and injection of adrenaline for endoscopic haemostasis
223836777|NCT01556243|PROCEDURE|therapeutic conventional surgery|
223836778|NCT01556243|RADIATION|whole breast irradiation|
223836779|NCT03703206|DRUG|ultrasound guided injection of local anesthetic between the popliteal artery and the capsule of the knee (iPACK)|nerve block for posterior knee pain after a TKA.
223836780|NCT00408161|BEHAVIORAL|Contingency Management|prize contingency management (CM) -- 6-month treatment plus standard case management treatment and follow-ups at 9, 12, and 18 months after intake
223836781|NCT00408161|BEHAVIORAL|standard case management treatment|6-month treatment standard case management treatment, and follow-ups scheduled at 9, 12, and 18 months after intake.
223836782|NCT02325713|DRUG|Oral dispersible tablet of praziquantel (ODT-PZQ)|Treatment A (test): ODT-PZQ (MSC1028703A) at a single dose of 40 milligram per kilogram (mg/kg) orally dispersed in water after meal.
223836783|NCT02325713|DRUG|Cysticide|Treatment B (reference): Cysticide tablet at a single dose of 40 mg/kg will be given with water orally after a meal.
223836784|NCT02325713|DRUG|ODT-PZQ|Treatment C1 (test): ODT-PZQ (MSC1028703A) at a single dose of 20 mg/kg orally dispersed in water after a meal.
223836785|NCT02325713|DRUG|ODT-PZQ|Treatment C2 (test): ODT-PZQ (MSC1028703A) at a single dose of 60 mg/kg orally dispersed in water after a meal.
223836786|NCT02325713|DRUG|ODT-PZQ|Treatment D1 (test): ODT-PZQ (MSC1028703A) at a single dose of 40 mg/kg orally dispersed in water without a meal.
223836787|NCT02325713|DRUG|Cysticide|Treatment D2 (reference): Cysticide crushed tablets at a single dose of 40 mg/kg will be given with water orally after a meal.
223836788|NCT03492996|DRUG|LCB01-0371 dose with a [14C]-LCB01-0371-tracer dose|To assess the absorption, metabolism, excretion of LCB01-0371 after a single oral LCB01-0371 dose with a \[14C\]-LCB01-0371-tracer dose to healthy subjects
223836789|NCT04532437|OTHER|artificial intelligence-based skin aging simulation|Photographs of the volunteers' facial skin will be taken in the Department of Dermatology at baseline using a modern skin analysis photo system (VISIA®, Canfield Scientific, Parsippany, NJ, USA) and afterwards a simulation of the participants' facial skin aging will be performed with the VISIA® photo analysis System.
223836790|NCT04532437|OTHER|electronic questionnaire 1|Electronic questionnaire about current sun-related knowledge and protective behaviours via link with smartphone before and after the skin aging simulation.
223836791|NCT04532437|OTHER|electronic questionnaire 2|Participants report their perception of the interventions and their motivation for improved sun protection by completing an electronic questionnaire after the skin aging simulation.
223836792|NCT05967676|DIAGNOSTIC_TEST|Turkish adaptation, validity and reliability|"This study was conducted as test-retest design and the psychometric properties of PRIA-RS were examined in injured athletes"
223836793|NCT01947595|BEHAVIORAL|intensified lifestyle intervention|"* physical activity 6 hours per week, 50% guided activity~  * recorded by an accelerometer (Aipermotion 440)~* 16 sessions per year with a lifestyle advisor~  * nutritional advice (target weight: 5% less, if BMI \> 25kg/m², less than 30% fat per caloric intake, less than 10% fatty acids per caloric intake, more than 15 g fibre per 1000 kcl)"
223836794|NCT01947595|BEHAVIORAL|normal lifestyle intervention|"* physical activity 3 hours per week~  * recorded by an accelerometer (Aipermotion 440)~* 8 sessions per year with a lifestyle advisor~  * nutritional advice (target weight: 5% less, if BMI \> 25kg/m², less than 30% fat per caloric intake, less than 10% fatty acids per caloric intake, more than 15 g fibre per 1000 kcl)"
223836795|NCT01947595|BEHAVIORAL|Single lifestyle advice|"\- Single Health care advice and lifestyle advice (30 minutes) at the beginning~* recommend the individual target weight (5% less, if BMI 25\> kg/m²)"
223836796|NCT01337830|OTHER|Ariva® Silver Wintergreen|Study product containing 6 mg silver salt and 2 mg nicotine per dissolvable lozenge, administered orally as a single dose.
223836797|NCT01337830|OTHER|Silver Wintergreen|Comparator product containing 6 mg silver salt and no tobacco (i.e., no nicotine), administered orally as a single dose.
223836798|NCT00761917|DEVICE|Tear Film Analyzer|tear film images
223836799|NCT06050291|DRUG|Fixed-Dose Combination (FDC) Tablet|Obicetrapib/Ezetimibe FDC tablet
223836800|NCT04493918|COMBINATION_PRODUCT|Mesenchymal Stem cell + Nacl 0.9%|Patient who undergo surgery, debridement, decompression and posterior stabilization injection with Nacl 0.9% 2 ml + MSC 30 million unit
223836801|NCT04493918|COMBINATION_PRODUCT|NaCl 0.9%|Patient who undergo surgery, debridement, decompression and posterior stabilization injection with Nacl 0.9% 2 ml
223836802|NCT00012181|DRUG|alvocidib|Given IV
223836803|NCT00012181|OTHER|pharmacological study|Correlative studies
223836804|NCT04912622|DIAGNOSTIC_TEST|Clinical Trial|Retinal image acquisition with Cellularis version 2.0
223836805|NCT02398682|OTHER|Rapid diagnosis of AKI cause|"The Outreach team will advise on an evidence-based package of care:~1\) Rapidly establish a credible diagnosis of the cause of AKI including:~1. Improved assessment of volume status~2. Standardised use of urine dipstick .~3. Appropriate sepsis investigations.~4. Urgent ultrasound with suspected obstruction."
223836806|NCT02398682|OTHER|Rapid treatment of AKI cause|Rapid, limited treatment of hypovolaemia, with avoidance of iatrogenic fluid overload, recently recognised as a significant cause of mortality in AKI. Rapid sepsis therapy. Urgent relief of urinary tract obstruction.
223836807|NCT02398682|OTHER|Stopping 'nephrotoxic' drugs|Cessation of all potentially nephrotoxic drugs.
223836808|NCT02398682|OTHER|Early nephrology followup for stage 3 AKI|A rapid followup at discharge in an AKI clinic for survivors of stage 3 AKI, within 7 days of discharge for those in hospital, or within 7 days of the Alert for those not admitted to hospital.
223836809|NCT02398682|OTHER|Preventing recurrent AKI|Patients with AKI in the Intervention arm will receive information on preventing AKI during the study.
223836810|NCT02398682|OTHER|Good standard care|Good standard care will be provided for all patients in non Experimental arms; clinicians will continue to be able to rapidly refer patients for Nephrology advice or review; online guidance will be available for all clinicians and noted in the alerts for all cases of AKI.
223836811|NCT02870946|PROCEDURE|Simultaneous RRT|The patients in the simultaneous RRT arm will receive RRT when ECMO is commenced. (see Study Description)
223836812|NCT02870946|PROCEDURE|Standard care|The patients in the standard care arm will not receive RRT when ECMO is commenced. Only when a patient demonstrates AKI and fulfills any one of the criteria of the conventional RRT indication, RRT would be delivered.
223836813|NCT05790564|OTHER|Almond|Daily consumption of 2 ounces of unsalted, dry roasted almonds for 12 weeks
223836814|NCT05790564|OTHER|Crackers|Daily consumption of non-whole grain crackers for 12 weeks (caloric equivalent to 2 ounces of dry roasted almonds)
223836815|NCT06652737|BIOLOGICAL|PfSPZ-LARC2 Vaccine|The PfSPZ comprising PfSPZ-LARC2 Vaccine contain a double genetic deletion, of the Mei2 and LINUP genes, and undergo developmental arrest in the late liver stages without releasing merozoites into the blood stream (no blood stage parasites are produced)
223836816|NCT06652737|BIOLOGICAL|Normal Saline (Placebo)|Normal Saline Placebo
223836817|NCT06331299|DRUG|UGN-103|UGN-103 consists of mitomycin and sterile hydrogel (a proprietary thermally responsive gel) that is used to reconstitute mitomycin before instillation. The reverse thermal properties of UGN-103 allow for local administration of mitomycin as a liquid under chilled conditions, with subsequent conversion to a semi-solid gel depot following instillation into the bladder.
223836818|NCT00001125|BIOLOGICAL|Varicella Virus Vaccine (Live)|
223836819|NCT06654986|DRUG|Salmeterol + amino acid availability|The participants will be administered 200 µg salmeterol (8 puffs) from a MDI device and 40 g amino acid availability (clear whey in a shaker with water) daily during a 6-week intervention. Participants will be instructed to provide documentation of both the inhalation and the shaker intake via video.
223836820|NCT06654986|DRUG|Salmeterol + placebo|The participants will be administered 200 µg salmeterol (8 puffs) from a MDI device. Furthermore they will be administered 80 g placebo (carbo fuel in a shaker with water) daily during a 6-week intervention. Participants will be instructed to provide documentation of both the inhalation and the shaker intake via video.
223836821|NCT06654986|DRUG|Placebo + placebo|The participants will be administered placebo (8 puffs) from a MDI device. Furthermore they will be administered 80 g placebo (carbo fuel in a shaker with water) daily during a 6-week intervention. Participants will be instructed to provide documentation of both the inhalation and the shaker intake via video.
223836822|NCT05694975|DRUG|Vitamin C|The total dosage of vitamin C for the treatment group is 24 g per day.
223836823|NCT05694975|DRUG|Placebo|The total dosage of placebo(5% glucose) for the control group is 24 g per day.
223836824|NCT05727033|BEHAVIORAL|Participatory teaching group|"The intervention will be called FEDE-ITS® methodology. This methodology is self-designed and self-developed and draws on previous work in equivalent populations. It is based on teaching in a participatory way knowledge and healthy attitudes related to the five most prevalent STIs in the province of Barcelona and Lleida, the methods to avoid contagion, and the health resources that can be consulted in case of infection, contact with an infected person or concerns. In addition, a gender perspective is incorporated to contribute to freer and more egalitarian relationships and reduce the likelihood of violence against women which develops in adolescence.~The cross-cutting themes of the training are: health, pleasure, self-esteem, knowledge-based freedom of choice, equality between people and respect for sexual freedom. Therefore, the ultimate goal is to prevent abusive power relations and macho violence."
223836825|NCT05727033|BEHAVIORAL|Sham control group|"The Health and School program was implemented to promote health in schools, and for this reason the program's nurse attends annually to address problems related to sexual affective health within the curricular itinerary of each school, but not specifically on sexually transmitted infections or gender perspective."
223836826|NCT05538481|OTHER|Semi-structured interview|A collection of individual cultural values and palliative care preferences within the focus group meetings
223836827|NCT05538481|OTHER|Developed survey completion|A collection of individual responses to a survey created after focus group completion and analysis
223836828|NCT05538481|OTHER|Systems of Belief Inventory (SBI-15R)|A 15-item questionnaire designed to measure religious and spiritual beliefs and practices and the social support derived from a community sharing those beliefs.
223836829|NCT02684903|BEHAVIORAL|Parent Child Interaction Therapy|PCIT is a 16-20 session live-coaching parenting intervention. PCIT for Child Welfare families is delivered in two sequential treatment phases following a motivational enhancement training: Phase 1, Child-Directed Interaction (CDI) to enhance positive parenting and interrupt harsh aversive parenting, and Phase 2, Parent-Directed Interaction (PDI) to coach effective parent commands and a consistent time-out protocol when child disobeys.
223836830|NCT03617159|DEVICE|Magnetic Resonance Imaging|Diagnostic Modality
223836831|NCT00216762|DRUG|Rituximab|Rituxan ® 1000 mg IV x 2 infusions, 2 weeks apart
223836832|NCT06662695|DIETARY_SUPPLEMENT|Ginger-based supplement|Ginger-based supplement in a dosage of 1500 mg
223836833|NCT06662695|DIETARY_SUPPLEMENT|Placebo|Capsules containing corn flour
223836834|NCT01354106|DEVICE|Skin Trauma|Each participant completed received both treatment arms, the 3M Micropore and 3M Kind Removal Silicone Tape.
223836835|NCT06603961|DEVICE|CPG-EB group|Customized-pressure guided elastic bandage group
223836836|NCT06609473|BEHAVIORAL|CHEF Intervention Program|Poverty-targeted intervention utilizing direct resource provision of healthy meal kits and groceries, as well as assisted referral and enrollment in government nutrition assistance benefits, SNAP (Supplement Nutrition Assistance Program) and/or WIC (Woman, Infants, and Children Program). Meal kits will be delivered by a commercial meal kit vendor. Grocery gift cards will be delivered via email, mail, or in-person. Kitchen equipment will be delivered to caregiver residence.
223836837|NCT03726021|DRUG|Irinotecan,Oxaliplatin, and S1|"Drug: Irinotecan is a chemotherapy agent. Chemotherapy agents are medicines that kill cancer cells.~Drug: Oxalipatin Oxaliplatin is a chemotherapy agent. Chemotherapy agents are medicines that kill cancer cells~Drug: S1 is a chemotherapy agent. Chemotherapy agents are medicines that kill cancer cells"
223836838|NCT06916585|DRUG|AS1501 for injection|Single administration, after 20 days of elution, enter continuous administration, once a week for 4 consecutive weeks
223836839|NCT06918951|RADIATION|Stereotactic ablative radiotherapy (SABR)|SABR is a safe and effective modality for metastasis-directed therapy, delivering a high dose of radiotherapy to a small target using conformal techniques. Emerging evidence suggests that SABR for oligoprogressive cancer may extend the duration of systemic therapy, and result in improvements in Progression Free Survival (PFS) and Overall Survival (OS) compared to historic controls.
223836840|NCT06918951|RADIATION|Palliative radiotherapy|"Radiotherapy will consist of 8 Gy in 1 fraction to all sites of oligoprogression.~Participants will continue their current systemic therapy (if already on systemic therapy at the time of oligoprogression event) or continue off systemic therapy (if the participant was not on systemic therapy at the time of the oligorecurrence event)."
223836841|NCT05204550|DRUG|unfractionated heparin|intranasal
223836842|NCT05204550|DRUG|0.9%sodium chloride|intranasal
223836843|NCT02902029|DRUG|Vemurafenib|960 mg vemurafenib BID until progression or unacceptable toxicity develops
223836844|NCT02902029|DRUG|Cobimetinib|60 mg cobimetinib QD, 21/7 until progression or unacceptable toxicity develops
223836845|NCT02902029|DRUG|Atezolizumab|1200 mg atezolizumab administered intravenously on day 1 of each 21 day-cycle. Will be given until progression or unacceptable toxicity develops
223836846|NCT04031430|DEVICE|Telemonitoring|Women who are allocated to the PSM groep, will receive a connected blood pressure monitor. They have to measure their blood pressure twice a day and fill in their weight once a week in the App. These data are automatically transmitted via Bluetooth and Wi-Fi to the hospital, but the caregiver will not see those data, and can not react to it.
223836847|NCT04031430|OTHER|Longitudinal CV profiling during pregnancy and before and after the start/switch of antihypertensive medication|Longitudinal CV profiling during pregnancy and before and after the start/switch of antihypertensive medication Registration of medication usage in the Medisafe app Assessment of their beliefs about medicine in general and during pregnancy and their perceptions regarding medication adherence by means of the 'Beliefs about Medicine Questionnaire' and the 'Probabilistic Medication Adherence Scale' at baseline and postpartum.
223836848|NCT04031430|OTHER|CV profiling before and after the start/switch of antihypertensive medication|CV profiling before and after the start/switch of antihypertensive medication Registration of medication usage in the Medisafe app Assessment of their beliefs about medicine in general and during pregnancy and their perceptions regarding medication adherence by means of the 'Beliefs about Medicine Questionnaire' and the 'Probabilistic Medication Adherence Scale' at baseline and postpartum.
223836849|NCT02344394|DEVICE|Medtronic Cryoballoon|For endocardial pulmonary vein Isolation, an Arctic Front Advance Cardiac CryoAblation catheter (Medtronic, Mounds view, MN, USA) will be used.
223836850|NCT02344394|DEVICE|Thermocool Catheter|For mapping and ablation from endocardium a 3.5 mm irrigated tip catheter (Navistar Thermocool SmartTouch Unidirectional Navigation Catheter, Biosense Webster, Diamond Bar, CA, USA) will be used.
223836851|NCT02344394|DEVICE|nContact|For Epicardial Ablation (the surgical portion of the Hybrid procedure), we will use the VisiTrax cardiac ablation device (nContact, Morrisville, NC, USA).
223836852|NCT06625580|PROCEDURE|transverse thoracic muscle plane and serratus anterior plane block|ultrasound guided transverse thoracic muscle plane block and serratus anterior plane block will be performed with 0.25% bupivacaine
223836853|NCT06625580|PROCEDURE|erector spinae plane block|ultrasound guided erector spinae plane block will be performed with 0.25% bupivacaine
223836854|NCT06624501|OTHER|Observational cohort study|
223836855|NCT06625866|BEHAVIORAL|Feedback and information|"The healthcare professionals in the intervention arm will be exposed to feedback and information behavioral strategies. Namely, interns, residents, obstetricians/gynecologists, and nurses will receive written feedback about the episiotomy rates in the hospital each month during the study period. Moreover, at least two academic sessions will be designed to outline the indications, surgical technique, complications, and surgical ethics for the procedure (i.e., episiotomy). Likewise, each session will also include a patient testimonial about their experience during delivery and their follow-up when an episiotomy was performed.~The feedback intervention will be provided for 2 months, and the feedback intervention + the information intervention will be provided for 2 additional months."
223836856|NCT03824535|DIAGNOSTIC_TEST|Computed Tomography|Undergo PET/CT
223836857|NCT03824535|DRUG|Fludeoxyglucose F-18|Given IV
223836858|NCT03824535|DRUG|Fluorine F 18 L-glutamate Derivative BAY94-9392|Given IV
223836859|NCT03824535|DIAGNOSTIC_TEST|Positron Emission Tomography (PET/CT)|Undergo PET/CT
223836860|NCT06625450|DRUG|Tofacitinib|Tofacitinib alone will be continued at a dose of 11 mg once a day
223836861|NCT06625450|DRUG|Tofacitinib plus mesalamine|Both tofacitinib 11 mg once a day and mesalamine will be continued
223836862|NCT06624332|BEHAVIORAL|e-SBI main session|Single 20-minute e-SBI session that includes screening followed by brief motivational intervention.
223836863|NCT06624332|BEHAVIORAL|e-SBI Booster Session|A 20-minute booster e-SBI session that reinforces content from the main e-SBI session.
223836864|NCT06624332|BEHAVIORAL|Text messaging|4 weeks of daily automated text messages that reinforce content from the e-SBI main session.
223836865|NCT06625125|BEHAVIORAL|Mindfulness-based intervention|"The mindful mediators are asked to act as neutral observers who quietly attend to, notice, and let go of internal and external stimuli (present experiences) such as thoughts, feelings, physical sensations, and sounds without reactions, evaluation, and judgments. (Smith, 2005).~The subjects in the mindfulness-based intervention (MBI) group will receive 30 minutes individually administered, guided, chairside interventions during their hemodialysis sessions, three times a week over eight weeks (Alhawatmeh et al., 2022; Thomas et al., 2017). Subjects in this group will receive their assigned intervention developed by the principal investigator (PI) according to the Smith's MBI protocol that will provide intervention instructions. During the eight weeks and at bedtime at night, the subjects will be optionally encouraged to practice the intervention at home."
223836866|NCT06625125|BEHAVIORAL|Progressive muscle relaxation|"he progressive muscle relaxation (PMR) group will receive the ABC version of PMR (Smith, 2005). This abbreviated version of PMR involves a tense-let go exercise of 11 muscle groups including hand, arm, arm and sides, back, shoulder, face, front of neck, stomach, chest, leg, and foot.~As the MBI group, the subjects in the PMR group will receive 30 minutes individually administered, guided, chairside interventions during their hemodialysis sessions, three times a week over eight weeks. Subjects in this group will receive their assigned intervention developed by the principal investigator (PI) according to the Smith's PMR protocol that will provide intervention instructions. During the eight weeks and at bedtime at night, the subjects will be optionally encouraged to practice the intervention at home."
223836867|NCT06874413|BEHAVIORAL|Prehabilitation|Physical prehabilitation or exercise conducted through the YMCA's Silver Sneaker's program prior to receiving surgery that will be assessed through the use of wearable activity monitors.
223836868|NCT06874413|OTHER|Standard of Care (SOC)|Patients will receive standard of care preoperative instructions.
223836869|NCT06875895|OTHER|Traditional Physiotherapy|Hotpack, Tens and Ultrasound application
223836870|NCT06875895|OTHER|Motor Imagery Training|Kinesthetic and visual motor imagery will be applied.
223836871|NCT06692452|DRUG|Tazemetostat|EZH2 inhibitor, 200 mg tablet, taken orally per protocol.
223836872|NCT06692452|DRUG|Doxorubicin|Anthracycline antibiotic, 10, 20, 50, 100, and 200 mg vials, via intravenous (into the vein) infusion per institutional standard of care.
223836873|NCT06692452|DRUG|Vincristine|Vinca Alkaloid, 1, 2, and 5mL vials, via intravenous (into the vein) infusion per institutional standard of care.
223836874|NCT06692452|DRUG|Prednisone|Corticosteroid, 1, 2.5, 5, 10, 20, 25, and 50 mg tablets, taken orally per institutional standard of care.
223836875|NCT06692452|DRUG|Cytoxan|Alkylating agent, 100mg, 200 mg, and 500mg vials, and 1 and 2 gram vials, via intravenous (into the vein) infusion per institutional standard of care.
223836876|NCT06692452|DRUG|Carmustine|Alkylating agent, 100 mg single dose vials, via intravenous (into the vein) infusion per institutional standard of care.
223836877|NCT06692452|DRUG|Etoposide|Topoisomerase II inhibitor, 100mg single dose vial, via intravenous (into the vein) infusion per institutional standard of care.
223836878|NCT06692452|DRUG|Cytarabine|Antineoplastic, 20mg single dose vial, via intravenous, intrathecal, or subcutaneous injection per institutional standard of care
223836879|NCT06692452|DRUG|Melphalan|Alkylating agent, 90 mg multi-dose vial, via parenteral infusion per institutional standard of care.
223836880|NCT03873636|OTHER|Stimulation via noninvasive brain stimulation systems|Active (at or below 2mA) stimulation targeting brain regions engaged in task-switching and dual-tasking for 30-40 minutes. Local IRB has determined the Soterix, Neuroelectrics, \& Halo devices to be non-significant risk (NSR) devices via abbreviated investigational device exemption (IDE) procedure.
223836881|NCT06703580|DRUG|Hyperbaric prilocaine 2% 40 mg|this arm will include 50 patients who will receive intrathecal hyperbaric prilocaine 2% in a dose of 40 mg.
223836882|NCT06703580|DRUG|hyperbaric prilocaine 2% 50 mg|comparison of 3 different doses of prilocaine
223836883|NCT06703580|DRUG|hyperbaric prilocaine 2% 60 mg|this study compare 3 different doses of prilocaine
223836884|NCT06918821|BEHAVIORAL|Healthy Toddler Parent Group (HTPG)|Parent education class
223836885|NCT06918821|BEHAVIORAL|Families Understanding Nutrition and Physically Active Lifestyles (FUNPALs) Playgroup|Family playgroup
223836886|NCT06500611|OTHER|Sensory Integration and Vestibular Exercise with Routine Physical Therapy|"1. Stand with feet hip-width apart 5 rep~2. Sit in chair without backrest 5 rep~1.Stand with feet hip -width apart 5 rep~2.Sit to stand sit on chair without backrest and perform sit to stand repeatedly 5 rep~1.Tandem Walk one foot directly in front of the other.2 sets 5 steps forward and backward~2.Patientwalk forward cross an obstacle, continue walk. Walk Lateral Walk Backward 2 sets~1. Stand and slowly move head side to side and up down 10 repetition~2. Fix gaze and move head side to side or up and down 10 repetitions~1\. Stand on one leg for 10 seconds hold on. Repeat 5 times on each leg.~2\. Stand and rotate body to right and left 10 rotations~1. Walk on straight line , zigzag pattern, walk while looking your shoulder 5 rep~2. Sit and swing your legs back and forth 5rep~3. Play catch in standing. 2 sets 5-8 catches.~Static stretching 30 sec hold 5 times"
223836887|NCT06500611|OTHER|Vestibular Exercise with Routine Physical Therapy|"Vestibular exercise~1\. Stand with feet hip -width apart and slowly move head side to side and up down.10 repetitions for each direction.~2 .Fix your gaze on object while moving your head side to side or up and down. 10 repetitions for each movement.~1.Patient will stand on one leg for 10 second. Hold onto a stable support if needed. 5 times on each leg.~2\. Stand with feet hip-width apart and rotate body to the right and left. 10 rotations in each direction.~1. Walk on a straight line or in a zigzag pattern or walk while looking over your shoulder. (5 rep)~2. Sit on a stable chair and swing your legs back and forth, similar to a pendulum. (5rep)~3. Catch and Throw play catch with a partner while standing. 2 sets of 5-8 catches.~Routine Physical Therapu Static stretching exercises for 30 sec hold with 30 sec rest. 5 times for each muscle group"
223836888|NCT06744127|DRUG|BR1015|One tablet administered alone
223836889|NCT06744127|DRUG|BR1015-1|One tablet administered alone
223836890|NCT06744127|DRUG|BR1015-2|One tablet administered alone
223836891|NCT05623137|DEVICE|Acu-TENS|A dual-channel TENS stimulator will be used (ECS300A; Neurotrac, Verity Medical LTD, Ireland). Electrodes will be placed over selected acupoints (i.e., bilateral Sanyinjiao (SP6), Neiguan (PC6), Shenmen (HT7), Hegu (LI4), Zusanli (ST36) and Quchi (LI11)) and connected to the TENS stimulator. These acupoints are selected according to the traditional Chinese medicine and results of previous studies. The stimulation will be lasted 30-min for each session. The frequency of the stimulation parameter's waveform will be set to 100 Hz and the square pulses will be set to 0.2-ms. The intensity of the stimulation will be below motor threshold and lower than the intolerable level, and hence, participants will feel a pleasant and mild aching sensation.
223836892|NCT05623137|DEVICE|Sham Acu-TENS|A dual-channel TENS stimulator will be used (ITO Physiotherapy \& Rehabilitation, Co, Ltd, Tokyo, Japan). Electrodes will be placed over selected acupoints (i.e., bilateral Sanyinjiao (SP6), Neiguan (PC6), Shenmen (HT7), Hegu (LI4), Zusanli (ST36) and Quchi (LI11)) and connected to the TENS stimulator. These acupoints are selected according to the traditional Chinese medicine and results of previous studies. The stimulation will be lasted 30-min for each session. The frequency of the stimulation parameter's waveform will be set to 100 Hz and the square pulses will be set to 0.2-ms. The intensity of the stimulation will be below motor threshold and lower than the intolerable level, and hence, participants will feel a pleasant and mild aching sensation.
223836893|NCT05623137|OTHER|SHP|SHP is a set of instructions designed to help with sleep and promote healthy sleeping habits. The sleep guide contains information on how much sleep is needed by every individual daily, factors that could affect sleep, and risk factors for sleep disorders. It also contains information on the types of sleep disorders, delayed sleep syndrome, insomnia-producing behavior that could affect sleep quality, and suggestions for inducing sleep. The participants will be instructed to read the guide after the baseline assessment (T0). Those instructions will be reinforced by the research practitioner after each treatment session, in order to maintain the healthy sleeping habits.
223836894|NCT06902402|DIETARY_SUPPLEMENT|Supportan® Drink, flavour Tropical Fruits|flavour Tropical Fruits
223836895|NCT06902402|DIETARY_SUPPLEMENT|Supportan® Drink, flavour Cappuccino|flavour Cappuccino
223836896|NCT06902402|DIETARY_SUPPLEMENT|Supportan® Drink, flavour Pineapple-Coconut|flavour Pineapple-Coconut
223836897|NCT05940298|DRUG|Intravenous injection of [99mTc]Tc-DB8|One single intravenous injection of \[99mTc\]Tc-DB8, followed by gamma camera imaging after 2, 4, 6 and 24 hours.
223836898|NCT06912308|OTHER|Active Physiotherapy|Involves patient-driven exercises such as verticalization, sitting on the edge of the bed, and active breathing exercises.
223836899|NCT06912308|OTHER|Passive Physiotherapy|Employs methods like passive movements and electrostimulation of the diaphragm, providing therapeutic benefits without requiring active patient engagement.
223836900|NCT06920173|PROCEDURE|Experiemental: Peripheral Venous Catheter|Patients older than 18 years of age who present with shock requiring vasopressors at the following minimum doses: norepinephrine 5 mcg/min, phenylephrine 50 mcg/min, epinephrine 5 mc/min, dobutamine 5 mcg/kg/min. Vasopressors are infused through a peripheral venous catheter (18 gauge or larger); however, patients are crossed over to the central venous catheter group if the maximum vasopressor dose is reached or more than two vasopressors.
223836901|NCT06917924|DIAGNOSTIC_TEST|lumbar puncture|Standard of care of LP
223836902|NCT06915155|DEVICE|Swing-Mesh™|A lightweight, macroporous, three-dimensional polypropylene mesh implant developed by THT BioScience™ and distributed by B. Braun™, used in laparoscopic-endoscopic inguinal hernia repair without fixation. The mesh is designed to conform to the anatomical shape of the myopectineal orifice and is available in two sizes (15×11 cm or 16×12 cm).
223836903|NCT02752152|BEHAVIORAL|Computer-assisted counseling|The counselor opens the computer-assisted information/educational interactive counseling program on the tablet computer and invites the participant to use the program.
223836904|NCT02752152|BEHAVIORAL|On-demand counseling|The counselor only invites the participants to ask questions about HIV and other STIs.
223836905|NCT02752152|BEHAVIORAL|Standard counseling|The counselor gives face-to-face general information/education
223836906|NCT02752152|BEHAVIORAL|Appointment + reminder|Has an appointment and receive reminders for further testing
223836907|NCT02752152|BEHAVIORAL|Reminder|Only receive reminders for further testing
223836908|NCT02752152|BEHAVIORAL|No appointment and no reminder|No appointment and no reminders for further testing
223836909|NCT02176928|DEVICE|AutoPAP|"PAP will be delivered by an auto-titrating device (IntelliPAP AutoAdjust®). These devices automatically set the level of delivered pressure to ensure upper airway patency, to treat detected apneas and hypopneas.~AutoPAP treatment 7 nights a week for four months (16 weeks)."
223836910|NCT02176928|DEVICE|Sham PAP|"Sham PAP treatment will be delivered by an auto-PAP device (IntelliPAP AutoAdjust®) that is set to a fixed low pressure of 3 cmH20 without an ability to titrate according to detected respiratory events. The pressure is too low to eliminate respiratory events and serves as sham or sub-therapeutic PAP.~Sham PAP treatment 7 nights a week for four months (16 weeks)./"
223836911|NCT02162693|BIOLOGICAL|Mesenchymal progenitor cells|Administrated for intra-articular injection
223836912|NCT02162693|BIOLOGICAL|Sodium Hyaluronate|
223836913|NCT03114995|DRUG|Tirofiban|
223836914|NCT00900536|GENETIC|mutation analysis|
223836915|NCT00900536|GENETIC|polymorphism analysis|
223836916|NCT00900536|GENETIC|protein expression analysis|
223836917|NCT00900536|OTHER|immunohistochemistry staining method|
223836918|NCT00900536|OTHER|laboratory biomarker analysis|
223836919|NCT05151861|OTHER|Complete removal of pharmacological treatment|Removal of treatment
223836920|NCT05151861|DRUG|Control|Maintenance of pharmacological treatment
223836921|NCT00973947|OTHER|questionnaire administration|
223836922|NCT00973947|RADIATION|3-dimensional conformal radiation therapy|
223836923|NCT00973947|RADIATION|radiation therapy treatment planning/simulation|
223836924|NCT01668485|PROCEDURE|Hypoglycemic and euglycemic glucose clamp|Each study participant will be subjected to a continuous infusion of insulin at a rate of 0.8 mU·kg-1·min-1 to induce hypoglycemia (blood glucose 2.8-3 mmol/l) for 30 minutes. At least two weeks later an identical insulin infusion will be administered and euglycemia (blood glucose 5 mmol/l) will be targeted. The order of these interventions will be subject to randomization.
223836925|NCT01549691|DRUG|Zopiclone|7.5 mg before sleep, the evening before surgery
223836926|NCT01549691|DRUG|Alprazolam|0.5 mg at awakening, the day of surgery
223836927|NCT01549691|DRUG|placebo|given night before surgery and at awakening, the day of surgery
223836928|NCT06696612|DIAGNOSTIC_TEST|Dermoscopy|Dermoscopic examination of the nails
223836929|NCT02580825|BEHAVIORAL|Biofeedback gait retraining|Each session will include a continuous exercise in which the patient will do walking, walking pace and running (3 minutes each section). During the meeting, participant will receive biofeedback that will displayed on a computer screen that shows the forces that develop in the knee joint so that the patient can see graphically the forces that develop around the knee joint and will be guided / try to reduce the values of the graph by changing the intensity of his landing on the tracks. In all training the time that the biofeedback is shown will be reduced.
223836930|NCT02580825|BEHAVIORAL|Exercise|Each session will include a continuous exercise in which the patient will do walking, walking pace and running (3 minutes each section).
223836931|NCT00835874|DRUG|Probiotics|Lactobacillus acidophilus, b.lactis capsule. Once daily.2X 10 by the power of 10 bacteria per dose.
223836932|NCT03681340|OTHER|Hydroxyapatite toothpaste|If in a subject a significant increase of carious lesions will be observed, her/his parents are informed about the necessity for further caries preventive measures (e.g. dietary changes, use of fluoride products, reduction of cariogenic microflora with chlorhexidine, xylitol chewing gum, etc.) and caries preventive treatment (removing caries and placing a restoration) by the study centers is offered.
223836933|NCT03681340|OTHER|Fluoridated toothpaste|If in a subject a significant increase of carious lesions will be observed, her/his parents are informed about the necessity for further caries preventive measures (e.g. dietary changes, use of fluoride products, reduction of cariogenic microflora with chlorhexidine, xylitol chewing gum, etc.) and caries preventive treatment (removing caries and placing a restoration) by the study centers is offered.
223836934|NCT04344834|DIAGNOSTIC_TEST|A questionnaire or scales|A questionnaire or scale to assess the participants mental health.
223836935|NCT03655496|DEVICE|Home-based tool|The tool consists of a tablet computer and a Bluetooth connected weight scale. The patient is encouraged to use the tool daily. The weight is titrates the dose of diuretics and a short tip about how to improve living with heart failure, this is presented on the screen. Every five days the patient assess their self-perceived symptoms on the tablet computer. If the weight increases by 2kg or more in 3 days or less, the high dose is recommended for two days, after which the effect on the weight is assessed. If the weight increased was reverted, the dose is returned to normal and if it is still elevated, an alert on the table computer. If the self-assessed symptoms deteriorate, the same type of alert will appear on screen, urging the patient to contact the health care provider.
223836936|NCT05389358|BEHAVIORAL|Asiphephe health worker training|Lay health workers are already employed by the Department of Health and are trained in-service (30 hours) and receive monthly supervision (total of approximately 6 one-on-one hours; 15 group hours).
223836937|NCT05389358|BEHAVIORAL|Asiphephe therapeutic sessions|Asiphephe sessions are manualized using illustrated job aids, a participant workbook, session checklists, and an intervention manual. The model is informed by problem-solving therapy (Lund, 2018), trauma-informed coping (Sikkema, 2018) and safety planning (Garcia-Moreno, forthcoming) and was piloted with 12 health workers with input from 3 global mental health experts.
223836938|NCT05389358|OTHER|IPV assessment|IPV intensity as measured by WHO Multicountry Study Instrument at a cut-off of any past-year physical/sexual/psychological violence exposure vs. none
223836939|NCT05389358|OTHER|Referral for IPV or Mental Health|Study staff are trained to recognize signs or symptoms of distress and to make appropriate referrals to appropriate community-based services, if necessary. Experienced mental health professionals on the investigative can be consulted or referred to should a participant exhibit severe symptom of mental distress.
223836940|NCT03826563|DRUG|oral melatonin tablets (NatureMade brand)|melatonin tablets
223836941|NCT03826563|OTHER|Placebo|pill placebo
223836942|NCT00677456|PROCEDURE|R-Y reconstruction after total gastrectomy|Following curative total gastrectomy and systematic lymphadenectomy, the jejunum was divided 20 cm distal to the Treitz ligament with preservation of the nerve along the marginal vessels. The distance of the esophagojejunostomy to the jejunojejunostomy was 40 cm for the R-Y.
223836943|NCT00677456|PROCEDURE|P-Y reconstruction after total gastrectomy|Following curative total gastrectomy and systematic lymphadenectomy, the jejunum was divided 20 cm distal to the Treitz ligament with preservation of the nerve along the marginal vessels. The distance of the esophagojejunostomy to the jejunojejunostomy was 40 cm for the P-Y.
223836944|NCT00677456|PROCEDURE|Pouch reconstruction after total gastrectomy|Following curative total gastrectomy and systematic lymphadenectomy, the jejunum was divided 20 cm distal to the Treitz ligament with preservation of the nerve along the marginal vessels. To make the jejunal pouch, jejunojejunostomy was done with a linear stapler at the antimesenteric border, the distance of the esophagojejunostomy to the jejunojejunostomy was 40 cm for the R-Y.
223836945|NCT00677456|PROCEDURE|P-I reconstruction after total gastrectomy|Following curative total gastrectomy and systematic lymphadenectomy, the jejunum was divided 20 cm distal to the Treitz ligament with preservation of the nerve along the marginal vessels.To make the jejunal pouch, jejunojejunostomy was done with a linear stapler at the antimesenteric border,The pouch was 20 cm long, with a 10-cm jejunal loop with the P-I.
223836946|NCT01387256|DRUG|medical abortion|pregnancy termination with drugs
223836947|NCT06279429|DIETARY_SUPPLEMENT|Sideral® Sucrosomial Iron|Sucrosomial Iron 30mg
223836948|NCT06279429|DIETARY_SUPPLEMENT|Iron chewable tablet|Iron chewable tablet 100mg
223836949|NCT00788424|DRUG|AS101 Cream|4% AS101 Cream or Placebo cream, twice a day for 12 weeks
223836950|NCT06036394|DIAGNOSTIC_TEST|The images (CT, MRI, PET) used for RT planning, mid-treatment imaging as part of IGRT or disease evaluation, and response assessment/ surveillance post-RT|The radiation plans and dose-volume histogram will be obtained from TPS. All the images and radiation-related data will be downloaded from the PACS and TPS, applying anonymization filters. Clinical features (patient, disease, treatment-related characteristics, and outcomes) will be extracted by review of electronic medical records. Imaging pre-processing will be done, which will include skull stripping and registration across different modalities (e.g., MRI and CT) or different sequences(e.g., T1C, T2W, ADC) will be done using rigid or deformable algorithms as suited best for the modality
223836951|NCT00886470|BIOLOGICAL|ST266|ST266 is a clear liquid containing more than 200 proteins, cytokines, and growth factors in solution. Patients will be treated for 21 days unless both wounds have healed prior to 21 days, at which time a punch biopsy of the epithelialized area of each wound will be performed. A study evaluation visit for assessment of the biopsy site will occur on day 28 or within 7 days of the punch biopsies, whichever occurs first. Six months after the punch biopsy, the patient will return to the burn center for a final examination and photographs of the study wounds.
223836952|NCT04128033|OTHER|Puncture of the RP6 point|"Puncture of RP6 San Yin Jiao point, located just behind the posterior edge of the tibia 3 cm above the end of the inner malleolus."
223836953|NCT04128033|OTHER|Puncture of the placebo point|"Puncture of a placebo point outside the meridian, with no effect"
223836954|NCT04763083|DRUG|NVG-111|Open label, continuous iv infusion, escalating doses of NVG-111 for minimum 3 cycles
223836955|NCT06413550|BIOLOGICAL|Hibiscus Sabdariffa|The fresh red Roselle plant was obtained; the red calyxes of Hibiscus Sabdariffa were separated from the plant and dried for a week at 25°C. The dried calyxes were ground to powder, kept in a sealed container, and stored in a refrigerator (4°C) until used. Aqueous Roselle calyx extract was prepared by adding 10 gm of the previously prepared powder to 100 ml of boiling water and then heated on a hot stirrer plate for 30 min. To remove the remnants, the mixture was filtered via Whatman No 1 filter paper (Whatman products, Springfield Paper Mill, Maidstone, UK). The water content of the filtered solution was evaporated using an air recirculation oven and then kept at 4°C in the dark until used to determine antibacterial effectiveness \[20\].
223836956|NCT05961813|BEHAVIORAL|Intensive intervention for smoking cessation|Patients will be given a brochure and presentation on smoking cessation and will complete 6 visits (2 before surgical intervention, 4 visits within the following 12 months), as well as follow up phone calls for progressi monitorization.
223836957|NCT05961813|BEHAVIORAL|Brief intervention for smoking cessation|Patients will be given a brochure and presentation on smoking cessation 4 weeks before surgery, as well as follow up phone calls for progressi monitorization.
223836958|NCT00980109|DRUG|active oseltamivir|Oseltamivir capsules (75 mg per capsule), one capsule daily by mouth (PO) for 112 days. The dose should be administered at approximately the same time each day.
223836959|NCT00980109|DRUG|placebo capsule|Placebo capsules, one capsule daily for 112 days. The capsule should be administered at approximately the same time each day.
223836960|NCT00980109|DRUG|zanamivir for inhalation|Zanamivir for inhalation, (5 mg per inhalation), two inhalations, once daily using a ROTADISK/DISKHALER for 112 days. The dose should be administered at approximately the same time each day.
223836961|NCT00980109|DRUG|placebo for inhalation|Placebo (lactose powder), two inhalations, once daily using a ROTADISK/ DISKHALER for 112 days. The dose should be administered at approximately the same time each day.
223836962|NCT05843630|DIAGNOSTIC_TEST|without|without
223836963|NCT04936490|DRUG|Crocin|15 mg/d
223836964|NCT04936490|DRUG|Placebo|15 mg/d
223836965|NCT06446843|COMBINATION_PRODUCT|(Arthrocentesis followed by i-PRF +HA)|Intra-articular I-PRF with HA will be injected in the joint,1 ml of I-PRF will be injected inside the joint, Then from 25mg/ml of HA , 1ml will be injected into the superior joint space
223836966|NCT05609019|DRUG|SYHX2005|Tablets. Take orally.
223836967|NCT03215121|PROCEDURE|One handed mask airway, switch to two hands|"Prior to the induction of anesthesia, a shoulder role will be used to have the child's head in sniffing position for induction. Horizontal alignment of the external auditory meatus with the sternum, will be used as a marker for, proper positioning.~Oxygen and nitrous oxide for 10-15 seconds will be administered and sevoflurane will then be commenced.The provider will hold the mask as randomized, one hand mask airway with switch to two hand for Group 1 patients. Any changes in airway patency when mask is held by one hand versus two hands will be observed and documented by various parameters. The initial mask management will be performed for 20 seconds.~After another 20 seconds (50 seconds from the start of induction), in Group one, the mask holding will switch to two hands for 20 seconds."
223836968|NCT03215121|PROCEDURE|Two handed mask airway + jaw thrust|"Prior to the induction of anesthesia, a shoulder role will be used to have the child's head in sniffing position for induction. Horizontal alignment of the external auditory meatus with the sternum, will be used as a marker for, proper positioning.~Oxygen and nitrous oxide for 10-15 seconds will be administered and sevoflurane will then be commenced.The provider will hold the mask as randomized, two hands for Group two patients. Any changes in airway patency when mask is held by one hand versus two hands will be observed and documented by various parameters. In Group 2 patient's mask will be held with two hands first for 40 seconds."
223836969|NCT03215121|PROCEDURE|Two handed mask airway, switch to one hand|"Prior to the induction of anesthesia, a shoulder role will be used to have the child's head in sniffing position for induction. Horizontal alignment of the external auditory meatus with the sternum, will be used as a marker for, proper positioning.~Oxygen and nitrous oxide for 10-15 seconds will be administered and sevoflurane will then be commenced.The provider will hold the mask as randomized, two hands for Group 3 patients. Any changes in airway patency when mask is held by one hand versus two hands will be observed and documented by various parameters. The initial mask management will be performed for 20 seconds.~After another 20 seconds (50 seconds from the start of induction), in Group 3, the mask holding will switch to one hand for 20 seconds."
223836970|NCT01440049|OTHER|Prospective Observational|this is an observational study non interventional
223836971|NCT00540605|DRUG|Tenofovir 1% vaginal gel|topical gel containing 1% tenofovir
223836972|NCT03433092|OTHER|serum carotenoids|In each study, the serum concentrations of carotenoids were detected by high performance liquid chromatography
223836973|NCT02696720|DRUG|Lidocaine|
223836974|NCT02696720|OTHER|Sham|
223836975|NCT00671541|DRUG|Merogel Nasal Stent and Nasopore Stent|Merogel Nasal Stent and Nasopore Stent
223836976|NCT00671541|DRUG|Nasopore Stent and either Gentamycin or Bacitracin|Nasopore Stent with Bacitracin (100,000 units in 10cc(NSS)or Gentamycin(80mg in 10cc NSS)
223836977|NCT04329052|BEHAVIORAL|Adventure-based training with health educational talk|Participants need to attend an adventure-based training with various experiential learning activities with a health educational talk on mental health.
223836978|NCT01476579|DEVICE|Cardiac Computer Tomography|Compare Cardiac CT with reference standard wich is conventional invasive coronary angiography.
223836979|NCT01386840|OTHER|Severe Pneumonia - Home Management|"For those randomized to home management, first dose will be administered by the mother/caretaker under supervision at health facility. The health personnel will assess the parameters like temperature, Respiratory rate, Lower chest indrawing, Pulse rate, clinical deterioration, Other signs eg. co-morbid conditions, Assessment of adherence, Adverse event when they visit the home after 24 hours, 72 hours and on day 8th.~Mothers will be advised to return to the healthcare facility at their scheduled times and any time during the study period if there is clinical deterioration. The symptoms and signs of clinical deterioration will be discussed with the mother as described in the patient discharge counselling checklist. Mothers will be given a study patient data card with contact Numbers."
223836980|NCT03617874|OTHER|PC4PrEP- Intervention Clinics|PC4PrEP is a comprehensive, multi-level, structural and sustainable intervention designed to address barriers at system, provider, and user levels to increase PrEP uptake.
223836981|NCT03617874|OTHER|Standard of Care Clinics|The standard of care model is the model approved by the health system for their health care clinics.
223836982|NCT02224014|DRUG|Lendormin D tablets|
223836983|NCT01999660|DEVICE|SpaceOAR™ implantation|
223836984|NCT01587729|DRUG|Tricyclic AD (TCAs) and selective serotonin re-uptake inhibitors (SSRIs) antidepressants|TCA or SSRI prescription during the study period between January 1, 2001 and December 31, 2009. The TCAs and SSRIs administered to the patients include paroxetine and escitaloprim.
223836985|NCT02602457|BEHAVIORAL|moderate-intensity continuous exercise training|Participants will complete supervised exercise sessions. Moderate-intensity continuous exercise training will follow cardiovascular rehabilitation guidelines. Participants will attend on-site moderate-intensity continuous exercise training two times weekly for 12 weeks.
223836986|NCT02602457|BEHAVIORAL|high-intensity interval training|Participants will complete supervised exercise sessions. Participants will attend on-site high-intensity interval training two times weekly for 12 weeks.
223836987|NCT02794961|BIOLOGICAL|CD22 CAR-T|Autologous CAR-T cells with average 1\*10\^6 cells/kg body weight
223836988|NCT03090217|BEHAVIORAL|Pelvic Physiotherapy|1\) daily pelvic floor muscle training (PFMT).
223836989|NCT03090217|BEHAVIORAL|Standard care (SC)|1\) daily vaginal dilator therapy (10 to 15 minutes) and 2) usual care management.
223836990|NCT03795805|PROCEDURE|total knee arthroplasty|Total knee arhroplasty
223836991|NCT03795805|PROCEDURE|Tourniquet limb cuff|Tourniquet limb cuff and regular anesthesia
223836992|NCT03795805|DRUG|Intaarticular lidocain|20 ml of 2% lidocain application intraarticular before surgery (intraarticular lidocain)
223836993|NCT00110201|DRUG|Nesiritide|
223836994|NCT04572542|DRUG|Camrelizumab|Camrelizumab One course will last 21 days.Given once every 3 weeks at a dose of 200 mg
223836995|NCT04572542|DRUG|Apatinib Mesylate|Apatinib One course will last 21 days.Oral administration at a dose of 250 mg everyday
223836996|NCT04572542|DRUG|nab-paclitaxel|nab-paclitaxel One course will last 21 days。Given twice every 3 weeks at a dose of 125 mg/m2
223836997|NCT00412867|DRUG|Alteplase|0.6 mg/kg of Alteplase is intravenously administered
223836998|NCT02453087|DRUG|DCDS0780A|Participants will receive escalating doses of DCDS0780A as intravenous infusion.
223836999|NCT02453087|DRUG|Rituximab|Participants will receive rituximab at a dose of 375 mg/m\^2 of body surface area as intravenous infusion.
223837000|NCT02453087|DRUG|Obinutuzumab|Participants will receive obinutuzumab at a dose of 1000 milligrams (mg) as intravenous infusion.
223837001|NCT03149211|DRUG|UB-421|Subjects will receive 13 doses of the UB-421 by intravenous infusion at 25 mg/kg bi-weekly (Cohort 2, 26 weeks).
223837002|NCT03149211|DRUG|current standard HAART treatment|Subjects will receive current standard HAART treatment as the active control group.
223837003|NCT03631147|DRUG|Rifaximin|400mg bid for 8 weeks
223837004|NCT06417905|OTHER|Supervised exercises|strengthening deep neck flexors, serratus anterior middle and lower trapez stretchening upper trapezius, levator scapula
223837005|NCT06417905|OTHER|video based exercises|strengthening deep neck flexors, serratus anterior middle and lower trapez stretchening upper trapezius, levator scapula
223837006|NCT03391713|BEHAVIORAL|Poster|The poster includes the FAST symptoms but translated to the Malay language (Ce.P.A.T) Cakap tak jelas (slurred speech - Speech slurring) Perubahan muka (face changes - Face drooping) Anggota lemah (weak limbs - Arm weakness) Terus ke Hospital (straight to the hospital - Time to call 911
223837007|NCT00090272|DRUG|MK0826, ertapenem sodium|
223837008|NCT00090272|DRUG|Comparator: cefotetan|
223837009|NCT03415022|BEHAVIORAL|computer-based treatment|30 minute sessions of free viewing of faces and listening to music
223837010|NCT04466618|BIOLOGICAL|Saline|Saline infused during the study
223837011|NCT04466618|BIOLOGICAL|Exendin-9,39|Exendin-9,39 infused during the study
223837012|NCT04466618|BIOLOGICAL|Saline + Intralipid/Heparin|Saline infused during acute insulin resistance
223837013|NCT04466618|BIOLOGICAL|Exendin-9,39 + Intralipid/Heparin|Exendin-9,39 infused during acute insulin resistance
223837014|NCT04730934|OTHER|Perceived stress scale|Perceived stress scale (PSS) : The PSS is a validated 10-item self-report questionnaire which asks individuals to indicate how often they have found their lives unpredictable, uncontrollable, and overloaded in the last month. The higher scores indicating greater perceived stress.
223837015|NCT04730934|OTHER|Fibromyalgia impact questionnaire|Fibromyalgia impact questionnaire (FIQ): The FIQ is composed of 10 items. The first item contains 11 questions related to physical functioning - each question is rated on a 4 point Likert type scale. Items 2 and 3 ask the patient to mark the number of days they felt well and the number of days they were unable to work (including housework) because of fibromyalgia symptoms. Items 4 through 10 are horizontal linear scales marked in 10 increments on which the patient rates work difficulty, pain, fatigue, morning tiredness, stiffness, anxiety and depression.
223837016|NCT04730934|OTHER|The drugs used before and during the pandemic, the patient's job status, physical activity conditions, pain status|"Drug using: Antidepressant, SNRI, gabapentin, SSRI, myorelaxan, nsaid, paracetamol, pregabalin, tramadol, food supplement.~Job status: Participants were questioned about their occupational status before and during the pandemic as I am a housewife, I quit my job, I worked from home, I worked part-time and there was no change in my job.~Physical activity: I do not have physical activity, I do my daily work at home, I do daily walks, I exercise regularly.~Pain status: Participants were questioned that their pain conditions before and during the pandemic were much worse, worse, a little bad, no change, a little good,  better, It was questioned as much better."
223837017|NCT05543421|DEVICE|TMS|rTMS (30sessions) or iTBS (40sessions)
223837018|NCT02949518|OTHER|Enhanced Recovery Pathway (ERP) for Spine|The study team emphasizes that all components of the ERP are considered standard of care at this institution. The objective of this study is to ensure that the study patients assigned to the ERP will receive these standard of care components.
223837019|NCT04439487|DIAGNOSTIC_TEST|Anthropometric measurements during routine preoperative visit|During routine preoperative anaesthetic visit and physical examination the following predictive test measurements are obtained by a research team member not involved in the further assessment of laryngoscopy: score in modified Mallampati test, Thyromental height, Sternomental distance, Thyromental distance, Neck circumference, Mouth opening distance
223837020|NCT04439487|OTHER|Assesment of intubation parameters during induction of general anaesthesia|During induction of general anaesthesia and intubation research team member not involved in obtaining anthropometric measurements notes Number of intubation attempts, Intubation time, Subjective intubation difficulty, Use of bougie and Need of technique modification.
223837021|NCT04027920|DRUG|Shenghua Decoction|Three days' shenghua decoction treatment
223837022|NCT04897087|OTHER|patient safety event|This study will explore the perceptions of patients, carers and relatives who have experienced a patient safety event. Telephone interviews will be undertaken lasting up to 60 minutes This study involves NHS patients, their carers or relatives. We will ask participants about their experience of being involved a patient safety event and the barriers and enablers to participation in the review. We will ask what 'good' patient involvement in patient safety reviews should look like from those with lived experience. This is because we wish to understand from their perspective what matters to them when things go wrong and how best to involve them.
223837023|NCT02096081|DRUG|IncobotulinumtoxinA|20U injection: equal aliquots of 0.1 mL (4U) to 5 injection points; mode of application: intramuscular injection
223837024|NCT02096081|DRUG|OnabotulinumtoxinA|20U injection: equal aliquots of 0.1 mL (4U) to 5 injection points; mode of application: intramuscular injection
223837025|NCT00004767|DRUG|Sodium Benzoate|
223837026|NCT00004767|DRUG|Sodium Phenylacetate|
223837027|NCT00004767|DRUG|Sodium Phenylbutyrate|
223837028|NCT00004767|BEHAVIORAL|Dietary Intervention|
223837029|NCT02059915|DRUG|Oxycodone|One capsule of 40 mg PF-00345439 Formulation X, single dose, under fed conditions
223837030|NCT02059915|DRUG|Oxycodone|One capsule of 40 mg PF-00345439 Formulation K, single dose, under fed conditions
223837031|NCT02059915|DRUG|Oxycodone|One capsule of 40 mg PF-00345439 Formulation X, single dose, under fasting conditions
223837032|NCT02059915|DRUG|Oxycodone|One capsule of 40 mg PF-00345439 Formulation K, single dose, under fasting conditions
223837033|NCT00884286|DRUG|Aplidin®|Aplidin® will be administered at a starting dose of 3.2 mg/m2, as a 1-hour intravenous infusion, on days 1, 8 and 15, every 28 days cycle.
223837034|NCT01684488|BEHAVIORAL|YRI|The YRI brings together six empirically-supported practice elements shown to be efficacious across different mental health interventions, as well as methods intended to socialize youth and improve self-efficacy. Practice elements address the broad scope of problems evidenced in Sierra Leonean war-affected youth and enhance the YRI's pacing, which progresses through three phases traditionally used in trauma treatments (stabilization, integration, connection). The weekly intervention takes place over 10 sessions lasting approximately one hour and a half. Groups are divided by gender and age. Each group is paired with two interventionists of the same gender.
223837035|NCT01684488|OTHER|EducAid educational programming|EducAid is a charitable trust that provides free year-round education to over 1,500 youth, along with food, medicine, and shelter when needed. EducAid's education model aims to improve academic knowledge, self-efficacy, and attitudes toward school. Additionally, it aims to nurture hope for the future and a sense of normalcy through interactions with teachers, mentors, and peers.
223837036|NCT00264043|DEVICE|emboli capturing guidewire device combined with stent|AngioGuard™ device and Bx Velocity™ stent
223837037|NCT04600622|BEHAVIORAL|Rural Diabetes One-Day Education and Care program (R-D1D)|One time, 5.5-hour multi-disciplinary diabetes self-management education and support intervention delivered via telehealth.
223837038|NCT04600622|BEHAVIORAL|Diabetes Education Materials|Diabetes Education Materials
223837039|NCT02424331|OTHER|Pursed Lips Breathing|Pursed Lips Breathing for six minutes.
223837040|NCT02424331|OTHER|Quiet Breathing|
223837041|NCT01285219|DRUG|pegylated filgrastim and ﬁlgrastim|patients were administered pegylated filgrastim 100 ug/kg in cycle 1 and ﬁlgrastim 5 ug/kg/d in cycle 2
223837042|NCT01285219|DRUG|ﬁlgrastim and pegylated filgrastim|patients received ﬁlgrastim 5 ug/kg/d in cycle 1 and pegylated filgrastim 100 ug/kg in cycle 2
223837043|NCT02395705|DRUG|cisplatin and paclitaxel|"1. Paclitaxel, 175mg/m2, d1, Cisplatin, 25mg/m2, d2-d4, 3 week, 2 cycles.~2. Paclitaxel, 87.5mg/m2, d1,d8, Cisplatin, 25mg/m2, d2-d4, 3 week, 2 cycles.~3. Paclitaxel, 175mg/m2, d1, Cisplatin, 75mg/m2, d1, 3 week, 2 cycles."
223837044|NCT01720797|DEVICE|Micro-osteoperforation|Minimally invasive micro-osteoperforation procedure used to achieve rapid orthodontic tooth movement.
223837045|NCT01720797|DRUG|Anesthestic|Topical or local anesthetic will be delivered in the area to be treated in accordance with standard practice.
223837046|NCT01720797|OTHER|Chlorhexidine|Prior to intervention subject will swish 5cc of chlorhexidine for one minute, twice. Following procedure Chlorhexidine rinses are to begin twice a day for a week.
223837047|NCT00178620|DRUG|Reteplase 10 Units (U) plus a second dose of reteplase 10 U|Thrombolytic-clot busting drug Retavase IV Bolus, 10 U followed by a second 10U dose
223837048|NCT00178620|DRUG|Reteplase 10 U|Thrombolytic-clot busting drug Retavase IV Bolus in one 10U dose
223837049|NCT00178620|PROCEDURE|Urgent Percutaneous Coronary Intervention (PCI)|
223837050|NCT00178620|PROCEDURE|Primary Percutaneous Coronary Intervention (PCI)|
223837051|NCT03605017|BEHAVIORAL|Virtual Reality Executive Function Training (VREFT)|
223837052|NCT00043940|DRUG|bivalirudin|Bivalirudin therapy will be given as a 0.75-mg/kg intravenous bolus and 1.75-mg/kg/h intravenous infusion during procedure and up to 4 hours.
223837053|NCT04524104|BEHAVIORAL|Lumen Treatment|the virtual AI agent, Lumen, via an iPad-based application. Each participant will receive a locked, encrypted study iPad installed with Lumen. They will complete 8 problem solving therapy (PST) sessions beginning with 4 weekly and then 4 biweekly intervals over 12 weeks on their assigned iPad.
223837054|NCT04814485|DRUG|SHR-1020+albumin-bound paclitaxel|SHR-1020 combined with albumin-bound paclitaxel for advanced pancreatic cancer
223837055|NCT02790762|BIOLOGICAL|Human umbilical cord mesenchymal stem cells|A single dose of 2×107 hUC-MSC will be implanted to patients by intravenous infusion, and repeated every week for four times.
223837056|NCT02303340|RADIATION|Dual Energy X-ray Absorptiometry|
223837057|NCT01013480|DRUG|Arbaclofen|A flexible dose titration will be utilized during the first four weeks to define the optimal titrated dose (OTD) for each subject. Investigators will use clinical judgment to adjust doses to the OTD. The starting dose will be 1 mg BID. The dose may be increased every four to five days to 2 mg BID, 3 mg BID, 5 mg BID and then 10 mg BID
223837058|NCT04841044|DIETARY_SUPPLEMENT|Cetoleic acid|Very long monounsaturated fatty acid ( C22:1n-11)
223837059|NCT04841044|DIETARY_SUPPLEMENT|Control Oil|Control oil consisting of: mix of anchovy oil, olive oil, high-oleic sunflower oil and rapeseed oil
223837060|NCT05103774|DIAGNOSTIC_TEST|T3-T4-TSH|thyroid function tests
223837061|NCT00994136|DRUG|normal saline|Ten milliliters of normal saline will be injected at the end of the intravenous therapy. Injection is performed with the start/stop method and with the positive pressure technique (clamping the catheter while injecting the last milliliters of normal saline)
223837062|NCT05284188|PROCEDURE|Open or arthroscopic Modified Broström operation|Patients with CLAI and GJL were randomly allocated to accept the open or arthroscopic Modified Broström operation.
223837063|NCT06204523|DIAGNOSTIC_TEST|investigated biomarkers regarding the efficacy of first-line chemotherapy|The present study was designed to generate solid evidence on the predictivity of the investigated biomarkers regarding the efficacy of first-line chemotherapy in patients with GC
223837064|NCT00409240|OTHER|MEDIC|Multidisciplinary Education and Diabetes Intervention for Cardiac risk reduction (MEDIC; a pharmacist-led behavioral and pharmacologic intervention in groups.
223837065|NCT02620189|DRUG|Anti-TNF Biologics Therapy|
223837066|NCT04655313|DRUG|ARQ-151 cream 0.3%|ARQ-151 cream 0.3% applied to chronic plaque psoriasis lesions once a day for 4 weeks
223837067|NCT02243072|BEHAVIORAL|Fit Families plus Standard Medical Care|Adolescents will receive the Fit Families plus Standard Medical Care which consists of twice weekly home-based, family psychotherapy from a CHW for 6 months
223837068|NCT00675961|BEHAVIORAL|Brief Counseling Intervention (BCI)|Two-tiered BCI characterized by both primary and secondary interventions. Primary BCI treatment format consists of 6 discussions delivered monthly in the first 6 months of standard TB treatment. 10-15 minutes long. Secondary BCI is delivered on a monthly basis while receiving TB treatment. 5-10 minutes long.
223837069|NCT00675961|DRUG|Naltrexone|Opioid antagonist, which decreases the pleasurable response to and craving for alcohol consumption. Oral; single daily dose of 50 mg per day for 6 months.
223837070|NCT00675961|OTHER|BCI + Naltrexone|Combination of the two previous interventions
223837071|NCT00675961|BEHAVIORAL|Treatment as Usual|Services provided by psychologists and narcologists (additions specialists) employed by the Tomsk Oblast TB Services.
223837072|NCT03781960|DRUG|Abemaciclib|Abemaciclib will be given at a dose of 150mg by mouth twice daily continuously for the duration of trial therapy.
223837073|NCT03781960|DRUG|Nivolumab|Nivolumab will be administered at a dose of 480mg IV every 28 days. Treatment with nivolumab will begin after an initial 7-day treatment period with abemaciclib monotherapy.
223837074|NCT00647413|BEHAVIORAL|bio-chemical feedback and expert system intervention ETS|"Urinary cotinien will be measured using urine collected from the infants diaper. It will be analysed and the result will be explained to the participant in a written letter approximately 2 weeks after the intervention.~The intervention will also be a counselling session about the consequences of ETS to the infant. The counselling will be guided by the principles of motivational intervieweing and an expert system letter tailored to the data assessed will be send to the participants"
223837075|NCT01060566|DRUG|VX-770|In period 1, subjects will receive a single oral dose of midazolam (2 mg) and on Day 1 and Day 8. Subjects will receive single oral dose of rosiglitazone 4 mg and on Day2 and Day 9. Subjects will receive multiple doses of VX-770 150 mg q12h Day 3-10.
223837076|NCT01060566|DRUG|VX-770|In period 2, subjects will receive 150 mg VX-770 q12h orally from Day 1 through the morning of Day 8. On the morning of Period 2 Day 1, subjects will receive a 400 mg loading dose of fluconazole. Thereafter, subjects will receive 200 mg fluconazole qd orally from Day 2 through Day 9.
223837077|NCT05565222|DRUG|Piperacillin/tazobactam or temocillin|"Piperacillin/tazobactam : 4.5 g by intravenous route every 6 hours (adjusted in case of renal failure).~Temocillin : 6g/24 hours infused continuously by intravenous route after 2 g loading dose (adjusted in case of renal failure)"
223837078|NCT05565222|DRUG|Meropenem|2 g every 8 hours by intravenous route (adjusted in case of renal failure)
223837079|NCT00591747|BEHAVIORAL|Resistance Exercise|60 minute sessions 3 times a week of moderate-vigorous lower and upper body free-weight strength training plus impact training (jumps). Two of the three sessions are conducted in a supervised setting at a university fitness facility and the third session is a modified version of the exercise program performed at home. Participants are in the exercise program for 12 months
223837080|NCT00591747|BEHAVIORAL|Flexibility Training|60 minute session 3 times a week focusing on whole body flexibility (stretching) and relaxation (progressive neuromuscular relaxation, focused breathing) exercises. Exercises are selected to be non-weight bearing and require minimal muscle strength in order to provide a contrast to the intervention arm. Two sessions are conducted in a supervised setting at a university fitness center and the third is a home-based version of the program performed at home.
223837081|NCT06339047|OTHER|Projector Kaleidoscope|Children in the projector kaleidoscope group will be watched for approximately 5 minutes before induction in the operating room.
223837082|NCT06339047|OTHER|Cartoon|Children in the cartoon group will be asked which cartoon they want to watch from the cartoon pool and will be shown the cartoon they want. The cartoon duration is approximately 5 minutes.
223837083|NCT03794349|BIOLOGICAL|Dinutuximab|Given IV
223837084|NCT03794349|DRUG|Eflornithine Hydrochloride|Given PO or via NG or G tube
223837085|NCT03794349|DRUG|Irinotecan Hydrochloride|Given IV
223837086|NCT03794349|BIOLOGICAL|Sargramostim|Given SC or IV
223837087|NCT03794349|DRUG|Temozolomide|Given PO or via NG or G tube
223837088|NCT03821701|DRUG|Entresto|Sacubitril Valsartan Sodium Tablets, 100mg bid, among whole study
223837089|NCT03821701|DRUG|ACEI/ARB|Choose one of ACEI/ARB according to the clinical condition among the whole study.
223837090|NCT00249093|DRUG|oxygen|
223837091|NCT04028115|DRUG|Ixazomib|Scheduled visits: Patients included in the trial will be treated with Ixazomib 4 mg on day 1, 8, and 15 in a 28-day cycle for up to 24 cycles. Patients will be evaluated every 4th week by a medical doctor, prior to initiation of a new cycle of Ixazomib.
223837092|NCT05866250|DIAGNOSTIC_TEST|Doppler-based renal resistive index|The kidney's interlobular or arcuate artery was preferentially selected and measured by pulse-wave Doppler.
223837093|NCT00878358|OTHER|Hydrotherapy|
223837094|NCT00878358|OTHER|Physiotherapy|
223837095|NCT00060463|BEHAVIORAL|Increased access to emergency contraceptive pills|
223837096|NCT00678990|PROCEDURE|Transplantation of islets with heparin coating|Transplantation of islets with heparin coating
223837097|NCT00192621|DRUG|Combivir (zidovudine [AZT] / lamivudine [3TC])|
223837098|NCT00192621|DRUG|Kaletra (lopinavir [LPVr])|
223837099|NCT05125120|OTHER|COGNİTİVE ORİENTATİTON DAİLY OCCUPATİONAL PERFORMANCE APPROACH|Polatajko et al. (2001) developed the CO-OP approach, which is an occupation-oriented problem-solving approach that combines cognitive strategies to help children acquire motor abilities throughout daily tasks (9, 29). The CO-OP approach of therapy focuses on the goal or task at hand rather than the acquisition of functions in occupational performance. CO-OP is a 'deductive' or 'occupational performance-oriented' approach that focuses on the activity target selected throughout the therapy, as opposed to 'inductive' or 'impairment-focused' alternatives (13). As a verbal approach, CO-OP focuses on skill acquisition at the activity level and strives to provide children with global problem-solving skills. Necessary performance strategies specific to the child and the activity are determined with a customised programme (12, 30). Skill acquisition, cognitive strategy development, and adapting and transferring these acquired skills to daily life are the three key goals of the approach.
223837100|NCT00688259|BEHAVIORAL|Supportive Therapy (ST)|approximately 20 sessions of manualized psychotherapy to promote a strong alliance between the therapist and the participant in order to provide a safe place to discuss issues pertaining to recovery
223837101|NCT00688259|BEHAVIORAL|Cognitive Behavioral Therapy for Psychosis (CBTp)|approximately 20 sessions of individual manualized psychotherapy in which participants are taught to evaluate the data supporting beliefs that may interfere with recovery
223837102|NCT05403359|DRUG|Steroids|"Description of the intervention in each of the work packages:~* WP1A admission: Steroid dose \>6mg/day dexamethasone equivalent will be compared to control (steroid = 6mg/day dexamethasone or equivalent steroid).~* WP1B late: After 10 days of dexamethasone therapy patients are stratified in high-dose steroids (\> 6 mg dexamethasone or equivalent steroid) or no steroids up to day 28.~* WP2 ICU admission: High-dose steroids (dexamethasone \>6 mg daily or equivalent corticosteroids) compared to dexamethasone 6 mg up to 72 hours after admission~* WP3 ICU late: After dexamethasone 6 mg for 10 days patients are stratified in high-dose steroids (dexamethasone \>6 mg daily or equivalent corticosteroids) or no steroids up to day 28."
223837103|NCT00939796|DEVICE|Acclarent Tympanostomy Tube Delivery System|A device which provides a means to create a myringotomy with insertion of a proloaded tympanostomy tube (TT) for placement of the TT in patients indicated for such treatment for Otitis Media
223837104|NCT05983471|DRUG|ME-015 (Suplatast Tosilate)|Oral capsule form, 200 mg t.i.d. (total 600 mg per 24 hours)
223837105|NCT05983471|OTHER|Identical placebo|Without active component
223837106|NCT01220141|DRUG|activated recombinant human factor VII|Administration of room temperature stable NovoSeven® (activated recombinant human factor VII) in dosages prescribed by the treating physician according to the product labelling text approved in his country.
223837107|NCT01310868|DRUG|5-ALA|5-ALA is used to generate tumour specific fluorescence as an aid to surgical resection of GBM, prior to the insertion of Gliadel wafers
223837108|NCT01310868|DRUG|Gliadel wafers|The implantation of Carmustine Wafers (Gliadel) delivers carmustine- (3-bis 2-chloroethyl 1-1-nitrosourea (BCNU)) directly into the surgical cavity created after tumour resection.
223837109|NCT01310868|RADIATION|Radiotherapy as normal based on standard clinical protocols determined by the neuro-oncologist|60Gy in 30 fractions (2Gy per fraction given once daily, five days per week (Monday-Friday) over 6 weeks. Radiotherapy delivered to gross tumour volume with 2-3cm margin. Standard treatment following neurosurgery for glioblastoma
223837110|NCT01310868|DRUG|Concomitant chemotherapy as normal based on standard clinical protocols determined by the neuro-oncologist|temozolomide given alongside the radiotherapy at 75mg/m2 daily from the first day of radiotherapy, until the last day of radiotherapy, but for no longer than 49 days. Standard treatment following neurosurgery for glioblastoma
223837111|NCT01310868|DRUG|Adjuvant chemotherapy as normal based on standard clinical protocols determined by the neuro-oncologist|Following a 4 week break after contomitant chemo/RT, temozolomide given 150-200mg/m2 TMZ 5/28 days for 6 cycles (dosage increase to 200mg/m2 on second and subsequent cycles dependent on haematological toxicity. Sites should follow local guidelines if different.). TMZ to be given on 5 consecutive days followed by 23 days with no TMZ, per cycle. Standard treatment following neurosurgery and concomitant chemo/RT for glioblastoma
223837112|NCT00109551|DRUG|zinc sulphate dietary supplement|
223837113|NCT00109551|DRUG|iron sulphate-folic acid dietary supplement|
223837114|NCT00023439|OTHER|Nucleic Acid Amplification Methods for diagnosis|no intervention
223837115|NCT02496494|DRUG|Tacrolimus|Tacrolimus for maintenance immunosupression in kidney transplant recipients
223837116|NCT05170035|PROCEDURE|MMS + Autologous patch|A patch of consisting of platelets, leucocytes and fibrin, formed by the patients own blood sample.
223837117|NCT05170035|PROCEDURE|MMS and secondary intention healing|Mohs micrographic surgery (standard of care) (wounds will heal by secondary intention healing)
223837118|NCT02411591|DRUG|Necitumumab|Administered IV.
223837119|NCT02411591|DRUG|Abemaciclib|Administered orally.
223837120|NCT02131714|BEHAVIORAL|counseling and exercises|These individuals were asked about parafunctional habits and the treatment was applied by providing an explanation concerning the role of pain, possible aetiological factors of the patient's TMD, the relationship between chronic pain and psychosocial distress, and its benign character. They also had to perform once daily application of hot packs on both sides of the face for 20 minutes and after that they must perform active free therapeutic exercise of mouth opening for 10 times
223837121|NCT02131714|BEHAVIORAL|lifestyle counseling|
223837122|NCT00280475|DEVICE|Whole brain radiation therapy arm|Whole brain radiation therapy arm
223837123|NCT00280475|DEVICE|Salvage stereotactic radiosurgery arm|Salvage stereotactic radiosurgery arm
223837124|NCT00000736|DRUG|Zidovudine|
223837125|NCT03994575|OTHER|Guideline recommended feedback|The ACS Reflective III Pilot program is a quality assurance program where the decision to follow the recommendations and all treatment decisions related to patient care are left to the physician's discretion and feedback to the physician with their aggregate and individual patient data is intended as a quality assurance undertaking
223837126|NCT02491892|DRUG|Pertuzumab|Participants will receive one of two IV treatment regimens with pertuzumab: either 420 mg every 3 weeks, with an initial 840-mg loading dose, or 1050 mg every 3 weeks with no loading dose administered.
223837127|NCT04227340|DEVICE|Photobiomodulation Therapy (PBM)|The PBM will be delivered through application of the LED Cluster Probe externally to the right external buccal, left external buccal, mid face with mouth open and submandibular and left/right cervical. Patients who develop an oral lesion, intra-oral directed therapy will be administered with the dental light probe. For patients that can tolerate, an intraoral probe will deliver light directly onto the oral mucosa, this will then replace the mid face application with mouth open. Each laser application will be timed at 60 seconds.
223837128|NCT04227340|OTHER|Pain and Oral Function Assessment|After the 6-minute laser/ treatment session the child and parent will complete the mucositis evaluation scale on paper or ipad which includes self-report oral function specific to ability to swallow, eat and drink, as well as the patient's self-reported need for medication specific to mouth pain.
223837129|NCT04227340|OTHER|Parent-Reported Satisfaction Survey|A parent-reported satisfaction survey will be administered via paper questionnaire after the initial LLLT treatment. Parent satisfaction will be reported by parents on a 5-point Likert scale to questions adapted from a parent satisfaction survey used in a study regarding child life services in pediatric imaging.
223837130|NCT01154803|DIETARY_SUPPLEMENT|Ready to Use Therapeutic Food (RUTF)|1 sachet/day, 500 kcal and multi micronutrients (fortified high quality food(RUTF),for 2 weeks after an illness (malaria, diarrhoea, pneumonia)
223837131|NCT01154803|DIETARY_SUPPLEMENT|Micronutrient Powder (MNP)|2 sachets / day for 14 days after an illness (diarrheoea, malaria, pneumonia)
223837132|NCT02488694|DRUG|Afatinib|40 mg/d
223837133|NCT02488694|DRUG|Pemetrexed|500 mg/m² i.v. on d1 of each 21-day cycle
223837134|NCT03943303|RADIATION|Natural gamma radiation from the monazite sands|Patients selected for the study will have their knee (s) affected by osteoarthrose fully submerged in the monazite beach sand 2 (two) times per week for 30 (thirty) minutes each session at the same location and at the same time of day.
223837135|NCT03943303|RADIATION|Normal sands exposure patients|Patients selected for the study will have their knee (s) affected by osteoarthrose fully submerged in the no-monazite beach sand 2 (two) times per week for 30 (thirty) minutes each session at the same location and at the same time of day.
223837136|NCT06027775|DRUG|Targeted agent|The two cohorts received different adjuvant therapy regimens, with the CT group receiving chemotherapy plus targeted therapy; the CA group received chemotherapy alone.
223837137|NCT01994733|DRUG|Calcium carbonate ( Intensive phosphate control)|Individuals randomized to this arm will be exposed to a treatment strategy that targets a P of \< 1.50 mmol/L, reflecting the recommendations of current guidelines. Titration of the calcium carbonate dose will be the core of this approach and this will be complemented by usual recommendations regarding dietary P restriction. Dietitians will be available to provide counseling with regards to any aspect of the end-stage renal disease diet, as per usual dialysis unit practice
223837138|NCT01994733|DRUG|Calcium carbonate (Liberalized phosphate control)|"Individuals in this arm will be exposed to a treatment strategy that allows P to rise above 2.00 mmol/L. This will be accomplished through structured reduction of P binders already in use (as per the algorithm detailed below). Rescue P binding will be instituted if P rises above 2.50 mmol/L. Dietitians will be available to provide counseling regarding any aspect of the end-stage renal disease diet, as per usual dialysis unit practice, but will not provide counseling on dietary P restriction unless the P rises above 2.50 mmol/L."
223837139|NCT01018823|DRUG|Ertugliflozin|Ertugliflozin oral dosing 1 mg, 5 mg, 25 mg, or 100 mg solutions/suspensions administered once daily for 14 days immediately after breakfast
223837140|NCT01018823|DRUG|Placebo to Ertugliflozin|Placebo oral dosing solutions/suspensions administered once daily for 14 days immediately after breakfast
223837141|NCT02809274|OTHER|questionnaires|• Influence of iron parameters on Patient-reported symptoms as assessed by Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score (MPN-SAF TSS) for assessment of the severity of symptoms, Quality of life evaluation by The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) and fatigue assessment by PROMIS Fatigue Scale: Short Form
223837142|NCT00658671|DRUG|ENMD-2076|Capsules, daily dosing in 28 day cycles
223837143|NCT01820533|OTHER|Cell Phone Survey|Eight item survey for smokers being treated in the YNHH Emergency Dept. The survey asks about the type of cell phone(s) subjects have, how much they pay for cell service monthly, housing status, and if they receive any benefit that would qualify them for the Lifeline program.
223837144|NCT05925959|OTHER|Preoperative Weight Management Program|The medical obesity intervention is comprised of monthly visits with an obesity medicine (OM) provider +/- a registered dietitian (in person or virtual). Lifestyle modifications (nutrition, physical activity, stress, sleep), appetite control, and medication side effects will be addressed in all visits. At initial visit, patients will evaluated in person by an OM provider +/- registered dietitian. An individualized intense lifestyle intervention will be implemented with the addition of an anti-obesity medication (phentermine, naltrexone/bupropion, phentermine/topiramate, liraglutide, semaglutide, etc). Medication use will be based on disease risk, patient preference, severity of obesity, contraindications, potential drug interactions and insurance coverage. A diet recommendation will be tailored to the patient's medical and food allergy history. Weight and vital signs will be monitored at each visit. Participants will have a total of 5 follow-up monthly encounters, every 30 +/- 7 days.
223837145|NCT03529903|BEHAVIORAL|Health Coaching|Our trained health coaches will use the Way To Health platform to track patient health behaviors, and will communicate with patients via both SMS text messaging (up to four messages per week) and biweekly phone calls (up to one hour). During these interactions, health coaches will connect the patient to helpful resources and to help them reflect on previous goals and to set realistic, achievable goals for the upcoming weeks.
223837146|NCT03904342|BEHAVIORAL|Sophie CBT System|The Sophie CBT system is a tablet-based system that delivers self-paced cognitive behavioral therapy educational curriculum in the format of 6 discrete modules.
223837147|NCT03904342|BEHAVIORAL|iHope CBT|Licensed therapists will use the iHope HIPAA-compliant telemedicine platform to deliver cognitive behavioral therapy to patients via telephone, videoconferencing, and/or text chat.
223837148|NCT04729049|PROCEDURE|Erector Spinae plane Block|Ultrasound-guided interfascial technique, aiming to block the anterior and posterior branches of the spinal nerves for multi-dermatomal analgesia. Injection of local anesthetic in the plane deep to the erector spinae muscles and superficial to the transverse processes, to achieve a craniocaudal distribution along several vertebral levels.
223837149|NCT04729049|DRUG|Patient controlled analgesia with intravenous morphine|Patient-controlled intermittent boluses of morphine 1 mg (maximum once every 15 minutes).
223837150|NCT00305682|BIOLOGICAL|anti-thymocyte globulin|Equine ATG dose is 15 mg/kg intravenously (IV) every 12 hours for 6 doses on days -6, - 5, and -4.
223837151|NCT00305682|DRUG|cyclophosphamide|Cyclophosphamide 50mg/kg x 1 to be administered IV over 2 hours with high volume fluid flush on day -6.
223837152|NCT00305682|DRUG|Fludarabine|Fludarabine 40 mg/m2/day or 30 mg/m2/day intravenously (IV) as one hour infusion x 5 days, on day -6 to -2.
223837153|NCT00305682|DRUG|mycophenolate mofetil|Mycophenolate mofetil (MMF) 3 gram/day for patients who are ≥ 40 kg divided in 2 or 3 doses. Pediatric patient (\<40 kilograms) will receive MMF at the dose of 15 mg/kg/dose every 8 hours.
223837154|NCT00305682|PROCEDURE|umbilical cord blood transplantation|One or 2 UCB units may be infused to achieve the required cell dose.
223837155|NCT00305682|RADIATION|total body irradiation|Administered Day -1, 200 cGy
223837156|NCT00305682|DRUG|Sirolimus|Sirolimus will be administered starting at day -3 with 8mg-12mg mg oral loading dose followed by single dose 4 mg/day with a target serum concentration of 3 to 12 mg/mL. Levels are to be monitored 3 times/week in the first 2 weeks, weekly until day +60, and as clinically indicated until day +100 post-transplantation. In the absence of acute GVHD sirolimus may be tapered starting at day +100 and eliminated by day +180 post-transplantation.
223837157|NCT04543370|DRUG|Edasalonexent 2000 mg TID|CAT-1004 capsules
223837158|NCT04543370|DRUG|Midazolam 2 MG/ML|2 mg/ml syrup
223837159|NCT04543370|DRUG|Deflazacort 36Mg Tab|36 mg tablets
223837160|NCT01112150|DEVICE|NormaTec Pump|Normatec Pump
223837161|NCT04562506|DEVICE|rTMS with H-coil|Deep repetitive transcranial manetic stimulation or sham stimulation with H-coil
223837162|NCT04562506|DEVICE|Sham rTMS stimulation with H-coil|Sham rTMS stimulation
223837163|NCT04895020|BIOLOGICAL|9-valent HPV vaccine|9-valent HPV recombinant vaccine (Hansenula Polymorpha) All subjects aged 9 to 45 years received 3 doses of 9v HPV vaccine at 0,2,6 month scehdule
223837164|NCT00661258|BEHAVIORAL|Electronic drug monitoring feedback data|All patients were given electronic drug monitors that can monitor pill-taking behavior. In the intervention arm, patients and their attending doctors were given the electronic drug monitoring data on pill bottle openings at each monthly visit for use in adherence counseling sessions. Control arm patients were not given their electronic drug monitoring feedback data and their counseling sessions were based on self-reported adherence, as per standard of care in Dali.
223837165|NCT04047004|DRUG|Doxorubicin|Conventional PIPAC with doxorubicin (2.1 mg/m2 body surface in 50ml saline) is performed through the CE-certified nebulizer by certified PIPAC surgeons directly after the completion of the laparoscopic gastric resection and reconstruction using the remaining relevant ports. Chemotherapy is installed at a rate of 0.5-0.8 ml/s with a maximum pressure of 300 pressure per square inch and 30 minutes of simple diffusion.
223837166|NCT04047004|DRUG|Cisplatin|Conventional PIPAC with cisplatin (10.5 mg/m2 body surface in 150ml saline) is performed through the CE-certified nebulizer by certified PIPAC surgeons directly after the completion of the laparoscopic gastric resection and reconstruction using the remaining relevant ports. Chemotherapy is installed at a rate of 0.5-0.8 ml/s with a maximum pressure of 300 pressure per square inch and 30 minutes of simple diffusion.
223837167|NCT04539379|DRUG|Magnesium sulfate|intravenous infusion
223837168|NCT04539379|DRUG|Labetolol|intravenous infusion
223837169|NCT01259336|DRUG|Itraconazole|Tablet 200 mg twice daily for 6 months
223837170|NCT01259336|DRUG|treatment in cavitary pulmonary aspergillosis|Anti-tussive, blood transfusion, surgical resection and bronchial artery embolisation(BAE)
223837171|NCT01628874|DEVICE|J-Tip|Used once for both arms prior to lumbar puncture. The Experimental arm will receive 0.5 mL (5mg) of 1% Lidocaine. The Active Comparator arm will receive normal saline. This will occur after the cream has been placed for 30 minutes and wiped away and prior to the lumbar puncture.
223837172|NCT01628874|DRUG|EMLA|In the Active Comparator arm, lidocaine 2.5% and prilocaine 2.5% cream placed over area where lumbar puncture will occur for at least 30 minutes. This same procedure will occur for the Experimental arm with a placebo cream instead. This will occur once prior to the J-Tip injection and lumbar puncture.
223837173|NCT01628874|DRUG|Lidocaine|5 mg given via J-Tip once, repeat dosing as needed in the Experimental group. A placebo will be given in the Active Comparator group.
223837174|NCT02622971|OTHER|PBMT|Effects of phototherapy isolated and/or combined with cryotherapy in post-exercise skeletal muscle recovery.
223837175|NCT02622971|OTHER|Cryotherapy|Effects of cryotherapy isolated and/or combined with phototherapy in post-exercise skeletal muscle recovery.
223837176|NCT03496415|DEVICE|remote ischemic conditioning|Remote ischemic conditioning is performed by using an electric autocontrol device with cuffs that inflated to a pressure of 200 mm Hg during the ischemic period (Patent No. CN200820123637.X, China)
223837177|NCT03496415|DEVICE|sham remote ischemic conditioning|sham remote ischemic conditioning is performed by using an electric autocontrol device with cuffs that inflated to a pressure of 60 mm Hg
223837178|NCT02696278|OTHER|Lesson about vegetables|During the introductory period, children will receive a lesson about vegetables 3 days a week for 3 weeks.
223837179|NCT02696278|OTHER|Vegetables|During the introductory period, children will be served vegetables 3 days a week for 3 weeks during snack time at their daycare center. During the intervention period, children will receive vegetables everyday for 3 weeks during snack time at their daycare center.
223837180|NCT02696278|OTHER|Hummus|During the introductory period, children will be served hummus, depending on their group assignment, 3 days a week for 3 weeks during snack time at their daycare center. During the intervention period, children will receive hummus, depending on their group assignment, everyday for 3 weeks during snack time at their daycare center.
223837181|NCT00248443|PROCEDURE|Fiberoptic bronchoscopy and bronchoalveolar lavage|
223837182|NCT00545142|DRUG|Abilify(Aripiprazole)|co-administration of Abilify with Depakote in the 6-week treatment of acute mania in patients with bipolar disorder
223837183|NCT00545142|DRUG|Depakote(Divalproate)|co-administration of Abilify with Depakote in the 6-week treatment of acute mania in patients with bipolar disorder
223837184|NCT04802863|DRUG|XNW4107, Imipenem/Cilastatin|Five doses of 250 mg XNW4107 in combination with 500 mg imipenem/500 mg cilastatin
223837185|NCT05345093|DEVICE|Ialuxid gel|"Ialuxid® Gel is intended for topical external use. It is formulated with the appearance of white to pale yellow coloured consistent gel.~Ialuxid® Gel will be used for 8 weeks, 2-3 times a day."
223837186|NCT03722212|DIAGNOSTIC_TEST|METAglut1|A blood draw is performed on each patient for the METAglut1 test, and sent to Laboratoire CERBA, Saint-Ouen l'Aumône, France, for sample analysis.
223837187|NCT01253382|BIOLOGICAL|ecallantide|10 - 30mg subcutaneous injection.
223837188|NCT05414721|DRUG|Low flow desflurane anesthesia (Group D)|When the MAC value of desflurane was 1, fresh gas flow was decreased to 0.5 L/min (60% O2+40% air). Hemodynamic parameters, SpO2 and BIS values were recorded after induction, at the beginning of low flow/normal flow anesthesia and every 5 minutes during surgery. The patients were observed in terms of side effects and complications during the operation and in the postoperative period. To research the liver and the kidney functions, blood samples were taken pre-induction, post-surgery, and at the postoperative 24th hour by venous route.
223837189|NCT03753971|OTHER|Sound stimulation|Short sound stimulations will be emitted through a head band during sleep apneas
223837190|NCT00683449|DRUG|Dose Group 1|IV infusion of MN-221 16 mcg/min for 15 min; total dose of 240 mcg
223837191|NCT00683449|DRUG|MN-221 placebo|i.v. infusion of placebo for 15 minutes
223837192|NCT00683449|DRUG|Dose Group 2|i.v. infusion of MN-221 30 mcg/min for 15 minutes (total dose of 450 mcg)
223837193|NCT00683449|DRUG|Dose Group 3|i.v. infusion of MN-221 16 mcg/min for 15 minutes followed by 8 mcg/min for 105 minutes (total dose = 1,080 mcg)
223837194|NCT01866241|DRUG|Misoprostol|Is a prostaglandin
223837195|NCT01899248|DRUG|Sevoflurane|
223837196|NCT01899248|DRUG|Desflurane|
223837197|NCT04831762|BEHAVIORAL|Attention Network task (computerized)|Computer-based game challenging orienting and executive attention. The subject must chose which side an animal is going, using left and right buttons, depending on the validity of a cue and the congruency of flankers.
223837198|NCT04831762|BEHAVIORAL|Head-toes-knees-schoulders|Following motor commands such as touch your head when they are congruent or incongruent.
223837199|NCT04831762|BEHAVIORAL|Laby 5-12|Test of motor planning using labyrinths
223837200|NCT04831762|BEHAVIORAL|M-ABC 2|Test of motor functions using various subtests of gross and fine motor function.
223837201|NCT04831762|BEHAVIORAL|Stroop animals|Stroop test for preK children using animals instead of words
223837202|NCT01200719|DEVICE|transcranial alternating current stimulation (tACS)|Patients in the tACS group received a total of 15 sessions of brain stimulation. The sessions were conducted on weekdays (from Monday to Friday) for three consecutive weeks. Each session lasted 30 minutes. The alternating current stimulations were generated by a CVFT-MG201 machine. Stimulations were delivered by two U-shaped electrodes (approximately 7 cm2) fixed on the patient's left and right mastoid regions (anode or cathode varied depending on polarity of the alternating current). The frequencies (supra-slow waves: \< 1 Hz; theta to gamma), levels of intensities (0 to 3mA), and density function (follows a bell-shaped curve; mean intensity \~ 2.1mA) of the current were delivered according to the manufacturer's pre-set random protocol.
223837203|NCT00113698|DRUG|Enalapril|Up-titration period is to reach the highest tolerated dose up to a maximum of 0.4 mg/kg/day
223837204|NCT00113698|OTHER|Placebo|Placebo An inert preparation with similar appearance and taste to the drug
223837205|NCT01991717|DEVICE|Victus|The anterior capsulotomy and lens fragmentation will be performed by means of femtosecond laser surgery
223837206|NCT01991717|DEVICE|Conventional Phaco|The capsulotomy as well as the lens fragmentation is performed manually.
223837207|NCT06312527|DEVICE|Silicone dressing|"Participant will apply silicone dressing at 2 weeks after TKA on one side of knee.~Silicone dressing will change every week until 12 week postoperative."
223837208|NCT01600950|DRUG|LY2963016|Single 0.3 U/kg dose administered subcutaneously
223837209|NCT01600950|DRUG|Lantus|Single 0.3 U/kg dose administered subcutaneously
223837210|NCT00007930|PROCEDURE|conventional surgery|
223837211|NCT00007930|PROCEDURE|laparoscopic surgery|
223837212|NCT00156338|PROCEDURE|fluid management|volume and sodium restriction
223837213|NCT00156338|PROCEDURE|fluid management|volume restriction
223837214|NCT00156338|PROCEDURE|fluid management|liberal fluid management
223837215|NCT02339701|RADIATION|IMRT|
223837216|NCT02339701|RADIATION|SBRT|
223837217|NCT00982982|DRUG|THC and Iomazenil|"* Iomazenil: 3.7 μg/kg intravenously over 10 minutes~* Delta-9-THC (0.015 mg/kg = 1.05 mg in a 70kg individual), dissolved in alcohol. This dose is roughly equivalent to smoking approximately 1/4th of a marijuana cigarette, or joint. It is administered intravenously for 10 minutes."
223837218|NCT00982982|DRUG|Placebo (control)|Control: small amount of alcohol intravenous (quarter teaspoon), with no THC
223837219|NCT02550275|BEHAVIORAL|neuropsychological test|
223837220|NCT02550275|RADIATION|MRI|
223837221|NCT00451815|DRUG|active drug (BIIB014) at 10, 30, 100, or 300 mg once daily.|
223837222|NCT00451815|DRUG|placebo|
223837223|NCT02711722|DEVICE|Neurally adjusted ventilatory assist|"Ventilation supported by NAVA~* Blood gas analysis~* Respiratory Parameters At the end of the study step Neuro-Ventilatory Efficiency and Neuro-Mechanical Efficiency are measured."
223837224|NCT02711722|DEVICE|PScli1|Pressure support set by clinicians prior to inclusion
223837225|NCT02711722|DEVICE|PScli2|Pressure support at the same level as prior to the study
223837226|NCT03541642|BEHAVIORAL|Enhanced Intervention|Targeted PrEP counseling; targeted written/visual materials; follow up supportive text messages; distribution of PrEP at the syringe exchange
223837227|NCT03541642|BEHAVIORAL|Basic Intervention|General messaging from medical personnel; reminder text messages; distribution of PrEP at the syringe exchange
223837228|NCT02255630|OTHER|Cycling Exercise|
223837229|NCT00002750|DRUG|melphalan|
223837230|NCT02498743|PROCEDURE|echocardiography|TV was connected to display the cartoon video during the echocardiography: the episode number 125 of 'Dora the Explorer': 'Baby Winky Goes Home!' was reproduced during the echocardiography.
223837231|NCT02498743|BEHAVIORAL|Watching Animated cartoons|
223837232|NCT02682563|DRUG|Dapagliflozin 10mg QD|Dapagliflozin 10mg once daily for 12 weeks
223837233|NCT02682563|DRUG|Gliclazide 30mg QD|Gliclazide30mg once daily for 12 weeks
223837234|NCT05898737|DEVICE|NOL-Index|NOL Index monitoring with the PMD100™ (Medasense Biometrics Ltd.)
223837235|NCT02136485|BEHAVIORAL|Mindfulness-based stress reduction (MBSR)|8 sessions of MBSR
223837236|NCT02136485|OTHER|waiting list control|
223837237|NCT05015673|DRUG|SEP363856|
223837238|NCT05015673|DRUG|Placebo|
223837239|NCT06264934|DEVICE|Breast scan using the Z-scanner|Four repeated scans of both breasts using the Z-scanner.
223837240|NCT06264934|DEVICE|Breast scan using the Z-scanner|A scan of both breasts using the Z-scanner.
223837241|NCT03088137|DRUG|Follitropin alfa (Gonal-f)|Subcutaneous injection, fixed starting dose 150 IU for 5 days, maximum of 16 days of ovarian hyperstimulation
223837242|NCT03088137|DRUG|Follitropin alfa (Primapur)|Subcutaneous injection, fixed starting dose 150 IU for 5 days, maximum of 16 days of ovarian hyperstimulation
223837243|NCT02433093|DRUG|Basimglurant|Participants will receive once-daily oral basimglurant capsules in a multiple ascending dose regimen. Basimglurant dose will be titrated over 22 days; dose escalations will be separated by at least 4 days, with the final dose administered for a minimum of 14 days. The minimum starting dose will be 1.5 mg, which can be titrated up to a maximum dose of 4.0 mg. Intrapatient dose increments will not exceed 1.0 mg every 4 days.
223837244|NCT02433093|DRUG|Placebo|Participants will receive 22 days of once-daily oral matching placebo capsules.
223837245|NCT06126419|DRUG|High-Dose Insulin Therapy|A baseline blood glucose value will be obtained. Two units of insulin will be administered IV if the blood glucose is \> mmol/L. An insulin infusion of 0.12 units/kg/hr will be started. Ten minutes after starting the insulin, and when the blood glucose is \< 6 mmol/L, dextrose 20% supplemented with phosphate (30 mmol/L) will be infused. Blood glucose levels will be measured every 15 minutes, and the dextrose infusion rate adjusted to maintain glycemic levels between 4 and 6 mmol/L for a duration of 6 hours. At the end of the 6 hour period, the insulin will be stopped and the dextrose will be weaned off.
223837246|NCT01026675|PROCEDURE|50 g oral glucose challenge test - 75 g oral glucose tolerance test|50 g oral glucose challenge test at 6-13 weeks of gestation and 75 g oral glucose tolerance test at 24-28 weeks of gestation.
223837247|NCT03699046|PROCEDURE|Subchondroplasty and Knee Arthroscopy|Subchondroplasty® (SCP®) is a procedure performed along with minimally-invasive arthroscopy. The bone marrow lesion(s) will be located using pre-operative MRI combined with fluoroscopy (intra-operative X-ray) and a small, drillable AccuPort® Delivery Cannula will be placed in the appropriate position. The cannula will then be drilled into the bone marrow lesion(s) and a flowable, synthetic, calcium phosphate bone substitute (AccuFill® Bone Substitute Material, Zimmer Biomet) will be injected into the lesion(s). The calcium phosphate bone substitute will then harden, improve the structural integrity of the damaged subchondral bone, and will gradually be resorbed and replaced with new bone.
223837248|NCT03699046|PROCEDURE|Knee Arthroscopy Alone|Knee arthroscopy is a surgical procedure that involves the orthopaedic surgeon making small incisions in the knee and then inserting a small camera into the joint. Following the insertion of the camera, multiple procedures can be completed to treat a number of different conditions such as repair or partial/complete removal of the meniscus, debridement, lavage, removal of a loose body among others.
223837249|NCT03699046|BIOLOGICAL|Subchondroplasty|Subchondroplasty® (SCP®) is a procedure performed along with minimally-invasive arthroscopy. The specific biological component of the procedure involves the injection of the AccuFill® Bone Substitute Material (Zimmer Biomet), which is a a flowable, synthetic, calcium phosphate bone substitute, into the bone marrow lesion(s).
223837250|NCT01987375|DRUG|Cetuximab-IRDye800|a single dose of the study drug following a single loading dose of unlabeled cetuximab
223837251|NCT06341257|RADIATION|Stereotactic Central/Core Ablative Radiation Therapy (SCART)|The patient will receive a dose of 21 Gy in 3 fractions, with the dose maintained at 5 Gy per fraction for the entire tumor GTV boundary.
223837252|NCT03070314|DRUG|Echinaforce junior|Echinacea Purpurea Extract Pill, sweetened and with orange flavour
223837253|NCT00000242|DRUG|Carbamazepine|
223837254|NCT00303082|DRUG|Lactobacillus rhamnosus GR1 and Lactobacillus reuteri RC-14|
223837255|NCT03265379|OTHER|FACT-B and Brief Pain Inventory|Quality of Life Questionnaires
223837256|NCT03198260|OTHER|Fascial manipulation|Deep frictional massage
223837257|NCT00274911|DRUG|cisplatin|
223837258|NCT00274911|DRUG|lomustine|
223837259|NCT00274911|DRUG|vincristine sulfate|
223837260|NCT00274911|PROCEDURE|adjuvant therapy|
223837261|NCT00274911|RADIATION|radiation therapy|
223837262|NCT03870087|DEVICE|Robotic-assisted PCI|The CorPath GRX is intended for use in the remote delivery and manipulation of guidewires and rapid exchange balloon/stent catheters, and remote manipulation of guide catheters during percutaneous coronary intervention (PCI) procedures.
223837263|NCT04612049|DEVICE|Immersive virtual reality visuo-motor skill assessment|Visuo-motor skill assessment in an immersive 3D virtual environment using a head-mounted display.
223837264|NCT02826564|DRUG|pembrolizumab|
223837265|NCT02522546|OTHER|nasopharyngeal swab|nasopharyngeal swab
223837266|NCT00918749|DRUG|150 mg|150 mg immediate release (IRBB) risedronate tablet administered orally at least 30 minutes before breakfast.
223837267|NCT00918749|DRUG|75 mg|75 mg delayed release (DRFB) risedronate tablet administered orally immediately after ingesting breakfast
223837268|NCT00918749|DRUG|100 mg|100 mg delayed release (DRFB) risedronate tablet administered orally immediately after ingesting breakfast
223837269|NCT01951092|OTHER|Text messaging|
223837270|NCT04786470|DRUG|Ropivacaine|Ropivacaine infusion via transversus abdominis plane catheter.
223837271|NCT04786470|DRUG|Saline|Saline infusion via transversus abdominis plane catheter.
223837272|NCT00072163|DRUG|temozolomide|Given orally
223837273|NCT00072163|DRUG|thalidomide|Given orally
223837274|NCT00101569|DRUG|Aripiprazole|Tablets, Oral, 15 -30 mg, once daily, 2 weeks (days 1 -14).
223837275|NCT00101569|DRUG|Aripiprazole|Oral Solution, Oral, 15-30 ml, once daily, 1 week (days 15 -21).
223837276|NCT04592133|DIAGNOSTIC_TEST|Ultrasonography|Ultrasonography Examination
223837277|NCT03587987|DEVICE|Neopff|manual ventilation
223837278|NCT03587987|DEVICE|rPap|Manual ventilation
223837279|NCT03729349|BIOLOGICAL|Golimumab|Participants will receive golimumab as a part of clinical practice.
223837280|NCT04049721|PROCEDURE|HBO|2.5 atmospheres absolute (ATA) with 90 minutes of hyperbaric oxygen will be given over the course of two weeks.
223837281|NCT04049721|OTHER|Standard of Care|20 patients will be included in the retrospective review arm. The retrospective chart review will be performed to determine the outcomes of patients with crush injuries treated at NYU Winthrop Hospital without HBO from 1/1/2012-12/31/2018.
223837282|NCT01610973|PROCEDURE|Endothelial descemet membrane graft|Standard Endothelial descemet membrane graft
223837283|NCT01610973|PROCEDURE|Endothelial descemet membrane graft|Standard Endothelial descemet membrane graft
223837284|NCT06529562|RADIATION|Surgery combined with Target-reduction intensity-modulated radiotherapy|in control arm
223837285|NCT06529562|RADIATION|Surgery combined with Dose-reduction intensity-modulated radiotherapy|in experimental arm
223837286|NCT00873093|DRUG|L-asparaginase|Given IM 6000 IU/m2/dose Days 2 and 9
223837287|NCT00873093|DRUG|doxorubicin hydrochloride|Given IV 60 mg/m2/dose on Day 1
223837288|NCT00873093|DRUG|therapeutic hydrocortisone|Given IT (8mg - 15mg) Age-based dosing Block 1: Days 8,15, 22 and 29 Block 2: Days 1 and 22
223837289|NCT00873093|DRUG|vincristine sulfate|Given IV 1.5 mg/m2 (max 2 mg) on Days 1, 8, 15 and 22
223837290|NCT00873093|DRUG|cytarabine|Given IT or IV 3,000 mg/m2/dose on Days 1, 2, 8 and 9
223837291|NCT00873093|DRUG|prednisone|Given PO or IV 40 mg/m2/day on Days 1-28
223837292|NCT00873093|DRUG|bortezomib|Given IV 1.3 mg/m2/dose Block 1: Days 1, 4, 8 and 11 Block 2: Days 1, 4 and 8
223837293|NCT00873093|DRUG|pegaspargase|Given IM or IV (over 2 hours) 2500 IU/m2/dose on days 2, 8,15 and 22
223837294|NCT00873093|DRUG|methotrexate|Given IT (8mg - 15mg) Age-based dosing Block 1: Days 15 and 29 Block 2: Days 1 and 22
223837295|NCT00873093|DRUG|etoposide phosphate|Given IV 100 mg/m2/dose on Days 1-5
223837296|NCT00873093|DRUG|cyclophosphamide|Given IV 440 mg/m2/dose on Days 1-5
223837297|NCT00873093|BIOLOGICAL|filgrastim|Given IV or SC 5 micrograms/kg/dose Only on Day 6
223837298|NCT00873093|DRUG|leucovorin calcium|Given PO or IV 15mg/m2/dose q6h x 3 doses
223837299|NCT00873093|OTHER|laboratory biomarker analysis|Correlative studies
223837300|NCT00873093|DRUG|High Dose MTX|IV 5000 mg/m2/dose Block 2: Day 22
223837301|NCT01708187|BIOLOGICAL|Clarix™1k graft|"Group 1 will have standard peroneal repair surgery with the addition of the Clarix™1k tissue.~Group 2 will have standard peroneal repair surgery without the use of the Clarix™1k tissue."
223837302|NCT00788255|DRUG|Final exogenous oxytocin concentration=22.5 μU/mL|Citrated whole blood 1mL + 23μU oxytocin. After mixing by inversion 8-10 times, 360μL kaolin-activated blood of each study solution was pipetted into a plastic cup in a prewarmed Thromboelastograph® (37°C). Each sample was recalcified in a plastic cup with 10μL of CaCl2 6.45%, and TEG® analysis was commenced within 1 minute of reconstituted sample preparation.
223837303|NCT00788255|DRUG|Final exogenous oxytocin concentration=30.1μU/mL|Citrated whole blood 1mL + 31μU oxytocin. After mixing by inversion 8-10 times, 360μL kaolin-activated blood of each study solution was pipetted into a plastic cup in a prewarmed Thromboelastograph® (37°C). Each sample was recalcified in a plastic cup with 10μL of CaCl2 6.45%, and TEG® analysis was commenced within 1 minute of reconstituted sample preparation.
223837304|NCT00788255|DRUG|Final exogenous oxytocin concentration=32.9μU/mL|Citrated whole blood 1mL + 34μU oxytocin. After mixing by inversion 8-10 times, 360μL kaolin-activated blood of each study solution was pipetted into a plastic cup in a prewarmed Thromboelastograph® (37°C). Each sample was recalcified in a plastic cup with 10μL of CaCl2 6.45%, and TEG® analysis was commenced within 1 minute of reconstituted sample preparation.
223837305|NCT03584685|DEVICE|Mask|All participants will initially be treated without the mask. In the next appointment, half will be treated with the mask.
223837306|NCT03584685|PROCEDURE|Routine wound treatment|All participants will initially be treated for their wounds without the mask. In the next appointment, half will again be treated for their wounds without the mask.
223837307|NCT02053779|DRUG|Triptorelin 0.1mg|Triptorelin 0.1 mg administered subcutaneously 6 days after ovum pick-up (OPU) in IVF/ICSI cycles triggered by triptorelin 0.2 mg followed by hCG 1500 iu the day of OPU.
223837308|NCT00459511|PROCEDURE|Blood AM, IL-6, ACTH, Cortisol, Glucose and Insulin|
223837309|NCT00734890|BIOLOGICAL|bevacizumab|
223837310|NCT00734890|DRUG|vandetanib|
223837311|NCT00734890|OTHER|laboratory biomarker analysis|
223837312|NCT00734890|OTHER|pharmacological study|
223837313|NCT05586074|DRUG|Clifutinib|tablet, oral
223837314|NCT05586074|DRUG|LoDAC|subcutaneous (SC) or intravenous (IV) injection
223837315|NCT05586074|DRUG|Azacitidine|SC or IV
223837316|NCT05586074|DRUG|Decitabine|IV
223837317|NCT05586074|DRUG|Ara-C±IDA|SC and IV
223837318|NCT05586074|DRUG|FLAG-IDA|SC and IV
223837319|NCT00917228|DEVICE|recordings with device equipped|
223837320|NCT00917228|DEVICE|Control|Recording without device equipped
223837321|NCT05553574|BEHAVIORAL|Stop signal food task|The participants need to classify pictures of food and not food. They were asked to hold their response if they see a white frame around the picture.
223837322|NCT03509922|DRUG|Anplag Tab. 100mg bid|sarpogrelate hydrochloride 100mg bid for 24 weeks
223837323|NCT03509922|DRUG|Anplag Tab. 100mg tid|sarpogrelate hydrochloride 100mg tid for 24 weeks
223837324|NCT05249296|OTHER|Nature based solution for stress reduction|participation in nature activities: daily 30 min walking in nature
223837325|NCT06304311|PROCEDURE|Routine Obstetrics care & Lamaze breathing techniques and backside massage|"Lamaze breathing techniques Five breathing patterns were introduced namely- cleansing breathing for relaxation, slow-paced breathing, modified-paced breathing and patterned- paced breathing. These patterns were used during and following contractions. Gentle pushing, and breath-hold during pushing were instructed during the second stage of labor which encouraged descent of the baby.~Backside massage during 2nd stage of labor by the trained massage therapist."
223837326|NCT01898975|OTHER|500ml fluid loading|Fluid loading to evaluate fluid responsiveness
223837327|NCT00904228|OTHER|placement of plastic cap during delivery room stabilization|placement of plastic cap during delivery room stabilization
223837328|NCT00904228|OTHER|placement of routine cap during delivery room stabilization|
223837329|NCT00655070|DEVICE|Timi3 Transthoracic ultrasound|Low frequency ultrasound over the chest using Timi3 ultrasound device
223837330|NCT05034510|DEVICE|Deep Brain Stimulation|modification in stimulation parameters
223837331|NCT05307900|OTHER|Confirmation of feeding tube placement in critically ill patients|Confirmation of feeding tube placement using ultrasonography
223837332|NCT00136916|DRUG|Inhaled Insulin|Inhaled insulin with dose adjusted according to premeal blood glucose
223837333|NCT00136916|DRUG|Subcutaneous insulin|Subcutaneous insulin with dose adjusted according to premeal blood glucose
223837334|NCT01529190|DRUG|Pregabalin|Effect of Preoperative Pregabalin on Pain Intensity. 300mg of pregabalin before surgical incision
223837335|NCT01529190|DRUG|Placebo|placebo
223837336|NCT01585922|PROCEDURE|noninvasive positive pressure ventilation (NPPV)|Use NPPV to treat the ARDS patients,and we choose the NPPV ventilators in which the FiO2 can be fixed, for example: the BiPAP Vision or V60 of Phillip Respironics.
223837337|NCT01585922|PROCEDURE|invasive mechanical ventilation|Intubate and give invasive mechanical ventilation to the other group patients when they are allocated at once.
223837338|NCT00232843|DEVICE|stent|Cordis SMART™ nitinol self-expanding stent.
223837339|NCT00232843|DEVICE|angioplasty|balloon angioplasty
223837340|NCT01152554|DRUG|TC-5214|Tablet, oral, twice daily for 52 weeks
223837341|NCT01152554|DRUG|Placebo|Tablet, oral, twice daily for 52 weeks
223837342|NCT00897728|OTHER|laboratory biomarker analysis|
223837343|NCT06355908|BIOLOGICAL|IL13Rα2 CAR-T|The IL13Rα2 CAR-T cells will be administered via intraventricular infusion every 2 weekly via an Ommaya reservoir.
223837344|NCT00029627|DRUG|Yohimbine|
223837345|NCT00801593|PROCEDURE|Steroid injection into the TMJs.|In case of otherwise noncontrollable TMJ involvement steroids are injected into arthritic TMJs under MRI guidance.
223837346|NCT00268229|DRUG|cytarabine|300 mg/m2/day
223837347|NCT00268229|DRUG|daunorubicin hydrochloride|45 mg/m2/day
223837348|NCT00268229|DRUG|imatinib mesylate|dose escalation (300 mg/day to 800 mg/day).
223837349|NCT01071265|PROCEDURE|Remote Ischemic Preconditioning|Occlusion of leg blood flow using a pneumatic tourniquet on the thigh. Tourniquets are inflated to 300 mmHg for 5 minutes followed by deflation for 5 minutes then repeated for a total of 3 inflations.
223837350|NCT01071265|PROCEDURE|Sham|Sham procedure. A pneumatic tourniquet is placed on an upper arm and/or thigh but not inflated.
223837351|NCT01620736|DRUG|Raltegravir|Raltegravir 400 mg po bid
223837352|NCT04212481|PROCEDURE|uniport video-assisted thoracoscopic surgery|video-assisted thoracoscopic surgery for NSCLC using single port or two ports or three ports
223837353|NCT04212481|PROCEDURE|two ports video-assisted thoracoscopic surgery|video-assisted thoracoscopic surgery for NSCLC using two ports
223837354|NCT04212481|PROCEDURE|three ports video-assisted thoracoscopic surgery|video-assisted thoracoscopic surgery for NSCLC using three ports
223837355|NCT00002354|DRUG|Indinavir sulfate|
223837356|NCT00002354|DRUG|Stavudine|
223837357|NCT02117544|DEVICE|Lotrafilcon B multifocal contact lenses (new)|
223837358|NCT02117544|DEVICE|Lotrafilcon B multifocal contact lenses|
223837359|NCT02967211|DRUG|insulin glargine (U300)|"Pharmaceutical form: solution~Route of administration: subcutaneous"
223837360|NCT02967211|DRUG|insulin glargine (U100)|"Pharmaceutical form: solution~Route of administration: subcutaneous"
223837361|NCT02967211|DRUG|NPH insulin|"Pharmaceutical form: solution~Route of administration: subcutaneous"
223837362|NCT02967211|DRUG|insulin detemir|"Pharmaceutical form: solution~Route of administration: subcutaneous"
223837363|NCT02967211|DRUG|insulin degludec|"Pharmaceutical form: solution~Route of administration: subcutaneous"
223837364|NCT01693939|DEVICE|FS200 Femtosecond Laser|
223837365|NCT05459220|DRUG|SHR0410 Injection|SHR0410 Injection（Low Dose）
223837366|NCT05459220|DRUG|SHR0410 Injection|SHR0410 Injection（High Dose）
223837367|NCT05459220|DRUG|Placebo|Placebo for SHR0410 Injection.
223837368|NCT02718352|OTHER|Naturalistic Prospective Cohort|Follow subjects through 1 year of naturalistic buprenorphine treatment
223837369|NCT04957940|DRUG|SMOFlipid|Intravenous fish-oil-based lipid (SMOF lipid 20%) (Fresenius Kabi, Bad Homburg, Germany) emulsion supplementation to standard enteral nutrition in a dose of 100 ml/day at a rate of 12.5 ml/h over 8 h daily for 5 days.
223837370|NCT04957940|OTHER|0.9% saline|Receive standard enteral nutrition plus 100 ml/day 0.9% normal saline at a rate 12.5 ml/h over 8 h for 5 days
223837371|NCT03682822|PROCEDURE|Early Artificial rupture of membranes|Women in this arm will undergo artificial rupture of membranes before 4 cm of cervical dilation is reached during induction of labor as long as the procedure is deemed clinically safe and feasible.
223837372|NCT03682822|PROCEDURE|Delayed Artificial rupture of membranes|Women in this arm may undergo artificial rupture of membranes performed only after 4 cm of cervical dilation is reached during induction of labor. Rupture may also be performed after 10 hours of oxytocin administration with no cervical change.
223837373|NCT05905471|OTHER|Interview|Interview study
223837374|NCT02769611|DRUG|Ruboxistaurin|Dose escalation trial. 1st ten patients to receive 64 mg, next 10 patients to receive 128 mg, next 10 patients to receive 256 mg.
223837375|NCT03911375|OTHER|Mindfulness Based Stress Reduction (MBSR)|"Psycho-educational program of stress reduction based on mindfulness. Program of 30 hours of duration divided into 9 sessions with a weekly frequency of 2.5 h and an intensive session between week 6 and 7 of the program with a duration of 7.5 hours.~Each week the theoretical contents necessary to understand the attention development practices proposed in mindfulness-based interventions will be covered. In addition, basic concepts of the psychobiology and psychology of stress and pain are explained. The subjects will have a homework load of approximately 45 minutes per day during the duration of the intervention."
223837376|NCT03289546|BEHAVIORAL|Mindfulness training|"The mindfulness training protocol will include the following basic components of traditional mindfulness-based stress reduction training: 1) training in awareness of sensations (body scan); 2) training in the awareness of the sensations of breathing; 3) training in directing the attention to simple activities of daily life, and in recognizing when the attention is no longer focused on a specific object of attention; and 4) training in 'open awareness'."
223837377|NCT03289546|BEHAVIORAL|Aerobic training|Exercise sessions will be led by CPR- and exercise-certified YMCA instructors and supervised by the senior research assistant. Sessions will consist of 10 minutes of warm-up, 40 minutes of aerobic exercise (walking on a treadmill), 10 minutes of cool down and stretching. Participants will receive heart monitors at the beginning of the study and will be trained by the senior research assistant to exercise targeting heart rates at 65-75% of the age predicted max heart rate or at an intensity of 12-13 in the Borg scale of the rate of perceived exertion.
223837378|NCT04323319|DEVICE|ESWT, Graston Technique|"The treatment period for each group was determined as 4 weeks. Stretching program for each group will be given as home exercise program. Stretching exercises will be completed in 3 sets, 2 sets per day, stretching for 30 seconds.~Graston Technique Group will take treatment 2 times per week, ESWT group will take treatment 1 time per week."
223837379|NCT02321085|PROCEDURE|Sinus Rhythm control|
223837380|NCT02321085|PROCEDURE|Pulse Rate control|
223837381|NCT06175117|DRUG|compound E Jiao Jiang(cEJJ)|compound E Jiao Jiang(cEJJ)：20ml (1 bottle) at a time, 3 times a day, should be taken orally before morning, lunch and dinner.
223837382|NCT06175117|DRUG|compound E Jiao Jiang(cEJJ) placebo|"compound E Jiao Jiang(cEJJ) placebo：20ml (1 bottle) at a time, 3 times a day, should be taken orally before morning, lunch and dinner.~ferrous succinate tablet：1 tablet at a time, 2 times a day, should be taken in the morning, after dinner or during meals."
223837383|NCT04962893|BIOLOGICAL|SARS-CoV-2 VLP Vaccine-Wuhan|Alum adsorbed, CpG ODN adjuvanted VLP vaccine expressing HexaPro-S, M, N, E proteins of the virus
223837384|NCT04962893|BIOLOGICAL|SARS-CoV-2 VLP Vaccine-Alpha (British) variant|Alum adsorbed, CpG ODN adjuvanted VLP vaccine expressing HexaPro-S, M, N, E proteins of the virus
223837385|NCT04962893|BIOLOGICAL|SARS-CoV-2 VLP Vaccine-Wuhan+Alpha variant|Alum adsorbed, CpG ODN adjuvanted VLP vaccine expressing HexaPro-S, M, N, E proteins of the Wuhan or Alpha variants
223837386|NCT05968521|BEHAVIORAL|Cardiac Rehabilitation (CR): Experimental|CR will consist of six sessions lasting 90 minutes of a structured exercise programme, educational and lifestyle modules, and a psychological component. Sessions include group discussions, experiential learning and homework tasks that participants are asked to complete between sessions. Participants in this treatment arm will also receive routine clinical outpatient management alongside CR.
223837387|NCT05968521|BEHAVIORAL|Treatment as usual: Control|Treatment as usual will include routine clinical outpatient management.
223837388|NCT03369288|DIAGNOSTIC_TEST|PET MRI|18F-fluoride PET-MRI
223837389|NCT03066388|OTHER|Pulse pressure variations|Stroke volume and, pulse pressure variations obtained by noninvasive (ΔPPCNAP) and invasive (ΔPPART) devices are recorded immediately before and after volume expansion (VE), performed as a 30-minute infusion of 500 mL of 4% gelatin.
223837390|NCT05620017|DRUG|BAT8008 for Injection|Intravenous infusion, once every 2 weeks (Q2W). It is recommended that the infusion time of the first cycle should be ≥ 3 hours. If no infusion reaction occurs, the subsequent circulation can be completed within 1-2 hours.
223837391|NCT05856474|OTHER|pancreatectomy|pancreaserving surgery, using end to side or end to end, pancreaticojejunostomy
223837392|NCT01236027|OTHER|no intervention|not applicable-no intervention
223837393|NCT03781011|BEHAVIORAL|Vegetarian diet intervention|Patients will received dietary education and supervision by dietician to avoid high carnitine/choline foods including red meat, eggs...etc.
223837394|NCT05752578|OTHER|Neuropsychological testing|During the session the patient will be administered the Memory for Intentions Screening Test (MIST; Raskin et al., 2010) with the purpose of investigating prospective memory ability. Then during the same meeting the following tests will be offered to the patient: Montreal Cognitive Assessment (MOCA; Nasreddine. Translation Pirani et al 2006) investigating global cognitive performance; - Interpersonal Reactivity Index (IRI; Davis, 1980;1983- Italian version edited by Bonino et al, 1998) with the purpose of assessing cognitive and affective empathy (Hot cognition); Modified Five Point Test (Ruffi et al 1987) aimed at assessing figurative fluency (Cold cognition).
223837395|NCT04123873|DRUG|Paracetamol|1g x 4 p.o.
223837396|NCT04123873|DRUG|Ibuprofen|400mg x 4 p.o.
223837397|NCT04123873|DRUG|Dexamethasone|24mg IV x 1 after induction om anaesthesia
223837398|NCT04123873|DRUG|Placebo oral capsules|p.o. x 4
223837399|NCT04123873|DRUG|Placebo IV|IV x 1
223837400|NCT03508128|OTHER|surgical procedure|Surgical procedure
223837401|NCT00309920|BIOLOGICAL|darbepoetin alfa|
223837402|NCT00309920|DRUG|cyclophosphamide|
223837403|NCT00309920|DRUG|docetaxel|
223837404|NCT00309920|DRUG|doxorubicin hydrochloride|
223837405|NCT00309920|DRUG|epirubicin hydrochloride|
223837406|NCT00309920|DRUG|fluorouracil|
223837407|NCT03908242|DRUG|salvianolic acid A|salvianolic acid A/Placebo 90 mg bid; salvianolic acid A/Placebo 180 mg qd
223837408|NCT03908242|DRUG|Placebo|salvianolic acid A/Placebo 90 mg bid; salvianolic acid A/Placebo 180 mg qd
223837409|NCT01720017|OTHER|Preclinical Manikin Training|During the preclinical manikin training, each subject will perform 10 intubations in a manikin with a difficult airway simulated by swelling the manikin tongue and placing it in a cervical collar.
223837410|NCT01720017|OTHER|Inservice Training|Inservice training will include review of a product information handout and a video demonstration.
223837411|NCT05542017|PROCEDURE|Surgical Ablation for Atrial Fibrillation|Surgical ablation in combination with other cardiac procedures through a median sternotomy or thoracotomy. Main procedures were valve surgery (i.e. repair, replacement) and/or coronary artery bypass grafting (CABG). Surgical ablation procedures for atrial fibrillation were divided into three different groups according to Heart Rhythm Society (HRS) expert consensus 2017: (1) Pulmonary vein isolation alone; (2) Pulmonary vein isolation combined with left atrial lesion sets; (3) and biatrial procedure.
223837412|NCT02559817|DRUG|Linaclotide Dose A|
223837413|NCT02559817|DRUG|Linaclotide Dose B|
223837414|NCT02559817|DRUG|Linaclotide Dose C|
223837415|NCT02559817|DRUG|Linaclotide Approved Adult Dose|
223837416|NCT02559817|DRUG|Matching Placebo|
223837417|NCT06128317|OTHER|no intervention is intended.|no intervention is intended.
223837418|NCT00003840|BIOLOGICAL|DTGM fusion protein|
223837419|NCT00030654|DRUG|bicalutamide|
223837420|NCT00030654|DRUG|docetaxel|
223837421|NCT00030654|DRUG|doxorubicin hydrochloride|
223837422|NCT00030654|DRUG|estramustine phosphate sodium|
223837423|NCT00030654|DRUG|flutamide|
223837424|NCT00030654|DRUG|ketoconazole|
223837425|NCT00030654|DRUG|paclitaxel|
223837426|NCT00030654|DRUG|releasing hormone agonist therapy|
223837427|NCT00030654|DRUG|vinblastine sulfate|
223837428|NCT06386224|BEHAVIORAL|Internet-delivered pain self-management (CBT Condition)|Participants will login to the website for 15-20 minutes per week, and complete 5 modules focused on different skills delivered over 8 weeks (e.g., symptom identification, changing negative thoughts, activity pacing)
223837429|NCT06386224|BEHAVIORAL|Education Program|Participants will login to the website for 15-20 minutes per week, and complete 5 modules focusing on pancreatitis pain topics, including: an introduction to pancreatitis, treatment options, specific therapies, surgical procedures.
223837430|NCT04026282|PROCEDURE|GnRH-ant protocol|Recombinant FSH (Gonal-f®) will be administrated as routinely practiced by investigators. FSH doses will be adjusted according to the clinical experiences of investigators.The GnRH-ant (Cetrotide®) will be initiated in a fixed protocol on stimulation days 5 or 6 per the investigator's ART protocol.
223837431|NCT04026282|PROCEDURE|GnRH-a long protocol|The GnRH-a (Diphereline® or Decapetyl®) 0.1mg will be administered for about14 to 20 days for down-regulation. Gonal-f® will be administrated as routinely practiced by investigators. GnRH-a types, GnRH-a and FSH doses will be adjusted according to the clinical experiences of investigators in each site.
223837432|NCT03374345|DRUG|Sipjeondaebo-tang Granule|3g, three times a day, each taken before or between meals Manufacturing company: HANPOONG PHARM \& FOODS Co. Ltd.
223837433|NCT03374345|DRUG|Placebo|3g, three times a day, each taken before or between meals Manufacturing company: HANPOONG PHARM \& FOODS Co. Ltd.
223837434|NCT03328052|DEVICE|MYnd Analytics PEER Online directed antidepressant therapy|"PEER Online is similar to a standard QEEG in that it uses QEEG output variables, but differs from a standard QEEG in that it references the QEEG to a normative and then symptomatic database. By comparing a given patient's QEEG to a database of QEEGs of subjects who have tried and responded to a specific medication, PEER Online can provide useful information regarding the response of neuro-physiologically similar patients to a wide number of medications. PEER Online may thus have the advantage of providing physicians with useful information as to medication outcomes before a medication regime is started. It has also been used to help select the medication that best matches the QEEG brainwave pattern, regardless of symptom clusters, currently used for diagnostic nomenclature. Patients will receive anti-depressant therapy guide by the results of the PEER Online algorithm."
223837435|NCT03328052|OTHER|Conventional antidepressant therapy|Anti-depressant therapy chosen based on physician best judgement.
223837436|NCT00004643|DRUG|cytarabine|
223837437|NCT05825729|DIAGNOSTIC_TEST|Dry suction technique (A)|"Using a linear echoendoscope, such as Pentax or Olympus, after identifying the lesion and deciding where to perform the EUS-FNB, always checking that there are no vessels on the eco-Doppler that would prevent puncture, a 22G Cook Echo-Tip Procore histology needle will be used to perform the following techniques of the described arms.~\- Dry suction puncture: Once the lesion is located and punctured, the stylet will be completely removed, and a 10 mL syringe with a vacuum of 10 mL will be attached. In each pass, the needle will be advanced and retracted 20-30 times according to the standard technique. The suction will then be closed, and the needle will be removed. The fanning technique will be performed whenever possible."
223837438|NCT05825729|DIAGNOSTIC_TEST|Slow-pull technique (B)|"Using a linear echoendoscope, such as Pentax or Olympus, after identifying the lesion and deciding where to perform the EUS-FNB, always checking that there are no vessels on the eco-Doppler that would prevent puncture, a 22G Cook Echo-Tip Procore histology needle will be used to perform the following techniques of the described arms."
223837439|NCT05825729|DIAGNOSTIC_TEST|Wet suction technique (C)|"Using a linear echoendoscope, such as Pentax or Olympus, after identifying the lesion and deciding where to perform the EUS-FNB, always checking that there are no vessels on the eco-Doppler that would prevent puncture, a 22G Cook Echo-Tip Procore histology needle will be used to perform the following techniques of the described arms.~\- Wet suction technique: Prior to puncture, the stylet should be removed and the needle should be flushed with 1-2 ml of physiological saline and a 10 ml vacuum syringe with 3-5 ml of saline should be attached. In each pass, the needle should be moved forward and backward 20-30 times. Aspiration should be opened as the needle advances and closed as it is withdrawn. Afterwards, the aspiration should be closed and the needle should be removed. The fanning technique should be performed whenever possible."
223837440|NCT05188365|OTHER|true acupuncture|"different body acupuncture points will be selected to be manually punctured in addition to 4 acupoints on the skin of abdominal surface (the four points will be electrical stimulated during acupuncture). the session (20 minutes) will repeated thrice weekly. the total duration of the study will be 60 days.~The points that will be manually acupunctured all over the body of every patient will be: SJ(3)/SJ(5)/SJ(17)/SJ(18)/SJ(19)/SJ(20)/SJ(21)/SJ(22)/GB(2)/GB(8)/GB(20)/LI(4)/LI(11)/KI(3)/SP(6)/ST(36)/REN(4)/REN(9)/REN(12)~The acupuncture points that will be electrically stimulated on the abdomen of every patient will be: bilateral Stomach 25 in addition to gallbladder 28 acupoints."
223837441|NCT05188365|OTHER|sham acupuncture|different body acupuncture points will be selected to be manually punctured in addition to 4 acupoints on the skin of abdominal surface (the four points will be electrical stimulated during acupuncture). opposite to group A, in this group, the acupuncture needles will be inserted manually and very adjacent to the real location of group-A acupoints (sham acupuncture). The electrical stimulator will connected to abdominal acupoints (bilateral Stomach 25 in addition to gallbladder 28 acupoints) but it will be turned off during the sessions. the session will repeated thrice weekly. the total duration of the study will be 60 days
223837442|NCT05946382|BEHAVIORAL|RNT-ACT Protocol|Swedish Translation of the 2\*60 minute Acceptance and Commitment Protocol for Repetitive Negative Thinking.
223837443|NCT05946382|BEHAVIORAL|iCBT Treatment|Internet-based Cognitive Behavioral Therapy as mandatory routine care in Swedish Primary care and therefore considered Treatment as usual.
223837444|NCT00597870|DEVICE|Endoluminal treament of thoracic lesions|Endoluminal treament of thoracic lesions with a thoracic stent-graft
223837445|NCT04207684|DRUG|Testosterone injection|250 mg of testosterone cypionate (equivalent to 174,8 mg of testosterone) administered via intramuscular injection in a single dose (2 mL)
223837446|NCT05962840|DRUG|Telitacicept|Patient will be treated with Telitacicept (Taiai the commercial name) 80 mg every week subcutaneously for 12 months
223837447|NCT05962840|OTHER|Placebo of Telitacicept|Patient will be treated with placebo of Telitacicept (Taiai the commercial name) 80 mg every week subcutaneously for 12 months
223837448|NCT04183192|BIOLOGICAL|Mepolizumab|Mepolizumab 3 mg administered SC
223837449|NCT04183192|BIOLOGICAL|Mepolizumab|Mepolizumab 6 mg administered SC
223837450|NCT04183192|BIOLOGICAL|Mepolizumab|Mepolizumab 12 mg administered SC
223837451|NCT04183192|BIOLOGICAL|Mepolizumab|Mepolizumab 24 mg administered SC
223837452|NCT04183192|BIOLOGICAL|Reslizumab|Reslizumab 0.1 mg/kg administered IV
223837453|NCT04183192|BIOLOGICAL|Reslizumab|Reslizumab 0.2 mg/kg administered IV
223837454|NCT04183192|BIOLOGICAL|Reslizumab|Reslizumab 0.4 mg/kg administered IV
223837455|NCT04183192|BIOLOGICAL|Reslizumab|Reslizumab 0.8 mg/kg administered IV
223837456|NCT04183192|BIOLOGICAL|Placebo|Placebo (administered either IV or SC)
223837457|NCT01806415|DRUG|Fenobam|Oral administration of 50, 100, or 150mg of Fenobam or placebo (lactose)
223837458|NCT01806415|DRUG|Placebo|Oral administration of placebo or lactose 150 mg
223837459|NCT00070629|DRUG|CPG 7909|CPG 7909 Injection will be administered subcutaneously at a starting dose of 0.20 mg/kg at the beginning of Weeks 2 and 3 of the three-week cycle.
223837460|NCT00070629|DRUG|Chemotherapy|"A taxane and a platinum compound given on week one of three-week cycles:~Regimen A: Paclitaxel 175 mg/m2 over 1 - 3 hrs, Cisplatin 75 mg/m2 Regimen B: Paclitaxel 175 mg/m2 over 1 - 3 hrs, Carboplatin AUC of 6 Regimen C: Docetaxel 75 mg/m2, Cisplatin 75 mg/m2 Regimen D: Docetaxel 75 mg/m2, Carboplatin AUC of 6"
223837461|NCT00070629|DRUG|Chemotherapy|"A taxane and a platinum compound given on week one of three-week cycles:~Regimen A: Paclitaxel 175 mg/m2 over 1 - 3 hrs, Cisplatin 75 mg/m2 Regimen B: Paclitaxel 175 mg/m2 over 1 - 3 hrs, Carboplatin AUC of 6 Regimen C: Docetaxel 75 mg/m2, Cisplatin 75 mg/m2 Regimen D: Docetaxel 75 mg/m2, Carboplatin AUC of 6"
223837462|NCT03888703|DEVICE|Fractional ablative CO2 laser|Three treatments with a fractional ablative CO2 laser 8 weeks apart
223837463|NCT02492217|DRUG|Adalimumab|
223837464|NCT00577720|DRUG|risedronate|35mg immediate release risedronate tablet before breakfast, once a week for 13 weeks
223837465|NCT00577720|DRUG|risedronate|35mg delayed release risedronate tablet following breakfast, once a week for 13 weeks
223837466|NCT00577720|DRUG|risedronate|50mg delayed release risedronate tablet following breakfast, once a week for 13 weeks
223837467|NCT00577720|DRUG|risedronate|50mg delayed release risedronate tablet before breakfast, once a week for 13 weeks
223837468|NCT01000870|DRUG|MNI-513-01|Subjects will be administered a single IV injection of IMP with a total activity amounting to 300MBq (8.1 mCi) +/- 20% of MNI-513 followed by PET imaging.
223837469|NCT03100838|DRUG|Nifedipine 60 MG Extended Release Oral Tablet|Reference Drug (Brand)
223837470|NCT03100838|DRUG|Nifedipine 60 MG Extended Release Oral Tablet|Test Drug (Generic)
223837471|NCT03100838|DRUG|omeprazole/sodium bicarbonate|Proton Pump Inhibitor/Antacid for drug-drug interaction
223837472|NCT03100838|DEVICE|SmartPill (TM)|Gastric pH measurement using SmartPill (TM) Technology
223837473|NCT06021210|DRUG|Letermovir Pill|Letermovir is the world's first and only new drug approved for the prevention of CMV infection. In 2017, it was approved by the U.S. Food and Drug Administration (FDA) for the prevention of CMV infection and disease in CMV-seropositive adult recipients (R+) of allogeneic hematopoietic stem cell transplantation (allo-HSCT). It was approved in China on December 31, 2021.
223837474|NCT01182922|BEHAVIORAL|Invitation letter|Invitation letter sent 6 weeks prior to prespecified screening colonoscopy appointment date and followed by reminder letter within 3 weeks if no response is received.
223837475|NCT02053311|DRUG|Orteronel|300mg orteronel
223837476|NCT02053311|DRUG|Placebo|Placebo
223837477|NCT02554513|DEVICE|EPG Tx|behavioral intervention that incorporates a device that provides visual biofeedback
223837478|NCT02554513|BEHAVIORAL|SPT|A treatment hierarchy involving integral stimulation
223837479|NCT03092544|DRUG|dimethyl fumarate|Active drug
223837480|NCT05702203|OTHER|Creative Music Therapy|Creative Music Therapy 3x20 minutes per week during admission, at least 10 session during admission, after discharge once every other week until 6 months of age.
223837481|NCT05565755|OTHER|Motivational interview|Motivational interview Training
223837482|NCT06086002|DEVICE|Microwave ablation|Microwave ablation will be performed by using single antenna (Emprint, Medtronic) with overlapping ablation or two antennas (Starwave, STARmed) with simultaneous ablation.
223837483|NCT06337643|BIOLOGICAL|MVX01|Pneumococcal Vaccine Candidate
223837484|NCT06337643|BIOLOGICAL|MVX01 Placebo|Placebo
223837485|NCT06340529|OTHER|Clinical Simulation|Carrying out a total of 9 clinical simulation in three days, one day every two weeks, where the student resolves a situation by taking on the role of a physiotherapist with a simulated patient.
223837486|NCT04858620|DRUG|Xlear Nasal Spray|Xylitol plus Grapefruit Seed Extract (Xlear) nasal spray, 2 puffs per nostrils, every 6 hours
223837487|NCT04858620|DRUG|Placebo|Saline nasal spray, 2 puffs per nostrils, every 6 hours
223837488|NCT02703285|OTHER|Sound|task of the participants in the study to determine the chest sound based on specific sounds: Vesicular - Diminished; Expiratory Wheeze; Bronchovesicular; pneumonia; pulmonary Oedema; Stridor; Agonal respiration
223837489|NCT01029600|PROCEDURE|Arthroscopic capsular release|Surgical division of thickened capsule in the shoulder
223837490|NCT01029600|PROCEDURE|Distention with steroid|Intraarticular distention with steroid, saline, contrast and local anaesthetic
223837491|NCT02129569|OTHER|Psychoeducational intervention|Receive information about strategies for cognitive self-management of distress
223837492|NCT02129569|BEHAVIORAL|behavioral intervention|Receive individualized walking prescription and wear pedometer
223837493|NCT02129569|OTHER|counseling intervention|Receive supplemental counseling support over the phone
223837494|NCT02129569|OTHER|educational intervention|Receive NCI educational booklets and a link to the ACS website
223837495|NCT02129569|OTHER|telephone-based intervention|Receive calls that are primarily social in nature
223837496|NCT02129569|OTHER|questionnaire administration|Ancillary studies
223837497|NCT02129569|OTHER|quality-of-life assessment|Ancillary studies
223837498|NCT01944982|BIOLOGICAL|Expanded haploidentical natural killer cells (NKAEs)|
223837499|NCT04019821|DRUG|Insulin Glulisine|A type of bolus insulin will be insulin glulisine if participant used insulin glulisine before entering the trial.
223837500|NCT04019821|DRUG|Insulin Aspart|A type of bolus insulin will be insulin aspart if participant used insulin aspart before entering the trial.
223837501|NCT04019821|DRUG|Insulin Lispro|A type of bolus insulin will be insulin lispro if participant used insulin lispro before entering the trial.
223837502|NCT00184028|DRUG|Taxotere|Taxotere is given at 60 mg/m2 as a 1-hour intravenous infusion.
223837503|NCT00184028|DRUG|Oxaliplatin|Oxaliplatin will be administered intravenously over 2 hours at a rate of 10mg/m2/min. on day 1 every 3 weeks.
223837504|NCT05145556|DEVICE|Videolarygoscopy|In a randomised order we evaluate the first pass success rate of the tracheal tube into the trachea.
223837505|NCT05145556|DEVICE|conventional laryngoscopy|In a randomized order we evaluate the first pass success rate of the tracheal tube into the trachea.
223837506|NCT02760862|DRUG|hydrocortisone 100mg.|Group (I), received hydrocortisone 100mg, dissolved in 2ml normal saline, intravenously/8 hours for 48 hours
223837507|NCT02760862|DRUG|mannitol 20% intravenous fluid|group (II), received mannitol 20% 100ml intravenously which was given over 30 minutes and followed by 100 ml on a 12hour basis. Urinary catheter was inserted for patients in group (II) under complete aseptic conditions by the anesthesia resident before the start of mannitol infusion and removed after its discontinuation, accompanied by the intravenous fluid infusion over 48 hours of 500ml of normal saline or Ringer's solution every 8 hours and the input/output fluid chart for evaluation of fluid balance.
223837508|NCT00191685|DRUG|duloxetine|
223837509|NCT00908856|BIOLOGICAL|autologous bone marrow mononuclear cell transfusion|a single intravenous transfusion approximately 2 days after bone marrow aspiration, and 4 days after stroke onset; the full amount of autologous mononuclear cells derived from 30 cc of bone marrow
223837510|NCT00908856|BIOLOGICAL|marrow stromal cells|a single intravenous transfusion approximately 21 days after bone marrow aspiration, and 23 days after stroke onset; the full amount of marrow stromal cells cultured over 21 days from 30 cc of bone marrow (expected to be approximately 1,000,000 cells/kg body weight)
223837511|NCT00908856|DRUG|placebo|a single intravenous transfusion of saline, approximately 2-21 days after bone marrow aspiration, and 4-23 days after stroke onset; the full amount of mononuclear cells derived from 30 cc of bone marrow
223837512|NCT01803932|BEHAVIORAL|Male-focused group violence prevention intervention|
223837513|NCT00256139|DRUG|Raptiva|
223837514|NCT02179645|DRUG|GRC 27864|
223837515|NCT02179645|DRUG|Celecoxib|
223837516|NCT02179645|DRUG|Placebo|
223837517|NCT06252389|PROCEDURE|Achilles Tendon Repair augmented with Bioinductive Collagen Patch|Standard Achilles Tendon Repair augmented with Bioinductive Collagen Patch. Standard Rehabilitation Protocol.
223837518|NCT00037700|DRUG|anakinra|
223837519|NCT00037700|DRUG|pegsunercept|
223837520|NCT04879355|DEVICE|Spinal needle (25G)|Fine needle aspiration from thyroid nodules using a 25G spinal needle.
223837521|NCT04879355|DEVICE|Conventional fine needle (25G)|Fine needle aspiration from thyroid nodules using a conventional 25G fine needle
223837522|NCT01354938|DRUG|Clarithromycin modified release 500 mg|Clarithromycin modified release 500 mg was prescribed. The dosage given was either 1 tablet or 2 tablets once a day, depending on the severity of the treatment.
223837523|NCT03691584|DRUG|TP-6076|The dose planned to be administered in this study is an iv infusion of 30 mg TP 6076 q24h for 4 consecutive days (starting on Day 1 and ending on Day 4).
223837524|NCT03691584|PROCEDURE|Bronchoalveolar lavage|Subjects will be randomized to undergo a BAL at a single time point: either 2, 4, 8, or 24 hours after the start of the final TP-6076 iv infusion on Day 4.
223837525|NCT04424485|PROCEDURE|Total thyroidectomy (TT)|Standard TT procedure for thyroid carcinoma, for both groups
223837526|NCT04424485|PROCEDURE|Central lymph node dissection (CLND)|Standard CLND for thyroid carcinoma, for both groups
223837527|NCT04424485|DIAGNOSTIC_TEST|Sentinel lymph node (SLN) bopsy|Intrathyroidal injection of ICG for SL biopsy, for only experimental group
223837528|NCT04424485|DIAGNOSTIC_TEST|Identification of parathyroid glands (PGs)|Near-infrared (NIR) fluorescence visualization of PGs, for only experimental group
223837529|NCT06488729|OTHER|Foot massage|Foot massage
223837530|NCT06441019|DRUG|HAIC（Oxaliplatin+ Raltitrexed）、TQB2868、Ramucirumab|The patient will receive combined treatment with HAIC, TQB2868, and Ramucirumab. After enrollment, the patient will undergo routine hepatic artery angiography via femoral artery catheterization and placement of a hepatic artery catheter，they will then receive 150ml of 5% sodium bicarbonate + Oxaliplatin (85mg/m2) for 4-6 hours + Raltitrexed (2mg/m2) for 2-4 hours . This will be done every 3-4 weeks for at least 2 cycles. Systemic treatment will be administered every 21 days, with TQB2868 injection given on the first day of each cycle (1-7 days after HAIC). The fixed dose of TQB2868 will be 300mg, and Ramucirumab will be given at a dose of 500mg (initial intravenous infusion for 60 minutes, followed by 30 minutes if tolerated).
223837531|NCT05843175|OTHER|Exercise and meal testing (acute stimuli)|"Pre-meal exercise: 1º milkshake intake + 2º exercise test~Post-meal exercise: 1º exercise test + 2º milkshake intake~Non-exercise meal: Only milkshake intake"
223837532|NCT01539434|BEHAVIORAL|Behavioural intervention|Patients in the behavioural intervention group will get a personal meeting with the physiotherapist and get advice about the value of physical activity and also get recommendations on how to be physically active. The behavioural intervention to support physical activity behaviour includes weekly motivational interviewing telephone calls for the first month, two telephone calls for the following two months and thereafter monthly telephone calls.
223837533|NCT01539434|BEHAVIORAL|Usual care group|Patients in the usual care group will get a personal meeting with the physiotherapist and get advice about the value of physical activity and also get recommendations on how to be physically active.
223837534|NCT05197075|DRUG|DRV/COBI FDC|DRV/COBI FDC tablet dispersed in water will be administered orally.
223837535|NCT05210842|OTHER|Endoscopy|The procedures are performed using a flexible therapeutic linear array echoendoscope.
223837536|NCT02806336|BEHAVIORAL|Multi Modal Balance Training (MMBI)|Group balance class, obstacle course, strengthening exercises
223837537|NCT02806336|BEHAVIORAL|Weight Loss (WL)|Nutritional counseling to achieve 500 kcal standard hypocaloric diet
223837538|NCT01916317|DRUG|0.5% lignocaine 60mM|
223837539|NCT06222554|DEVICE|MoveMend Health|Software-based therapeutic tool that offers gamified exercises and activities. The device is designed for deployment on tablets. The core purpose of the device is to augment patient engagement and participation in their own rehabilitation by providing additional therapeutic interventions between formal occupational therapy sessions.
223837540|NCT04225949|OTHER|survey 1|survey with one version of depiction
223837541|NCT04225949|OTHER|survey 2|survey with one version of depiction
223837542|NCT03983993|DRUG|Niraparib|Given PO
223837543|NCT03983993|BIOLOGICAL|Panitumumab|Given IV
223837544|NCT01504451|DEVICE|ILR insertion|Insertion of implantable loop recorder
223837545|NCT01504451|PROCEDURE|AF ablation|AF ablation
223837546|NCT02774213|OTHER|Questionnaires completion|
223837547|NCT02774213|OTHER|Clinical Pain Assessments|
223837548|NCT02999971|OTHER|circuit class therapy in water|The circuit, the main part of the session, include a series of 10 different workstations, arranged to progress in complexity, in order to work several segments of the body, oriented towards a functional recovery objective. These stations will be made up of task-specific activities for gait, balance and dexterity. Time in each workstation will be 5 minutes divided as follows: 4 minutes work period and 1 minute rest period, of these, last 30 seconds will be change period for crossing from one workstation to the next. After 50 minutes, each patient will have covered the 10 workstations, thus working in all of the objectives pursued in the realization on this CCT: gait, balance and dexterity.
223837549|NCT02999971|OTHER|circuit class therapy on land|The circuit, the main part of the session, include a series of 10 different workstations, arranged to progress in complexity, in order to work several segments of the body, oriented towards a functional recovery objective. These stations will be made up of task-specific activities for gait, balance and dexterity. Time in each workstation will be 5 minutes divided as follows: 4 minutes work period and 1 minute rest period, of these, last 30 seconds will be change period for crossing from one workstation to the next. After 50 minutes, each patient will have covered the 10 workstations, thus working in all of the objectives pursued in the realization on this CCT: gait, balance and dexterity.
223837550|NCT00892268|PROCEDURE|acupuncture therapy|Undergo acupuncture
223837551|NCT00892268|PROCEDURE|pain therapy|Receive standard care
223837552|NCT00043095|DRUG|gemcitabine hydrochloride|
223837553|NCT00043095|DRUG|ixabepilone|
223837554|NCT03795779|BIOLOGICAL|CLL1-CD33 cCAR T cells|CLL1-CD33 cCAR T cells transduced with a lentiviral vector to express two distinct units of anti-CLL1 and CD33 CARs.
223837555|NCT00487786|DRUG|OGX-427|OGX-427 injection at 200mg, 400mg, 600mg, 800mg or 1000mg once a week until withdrawn
223837556|NCT00487786|DRUG|Docetaxel|injection - 75 mg/M2 IV on Day 1 every 21 days for cohorts 6 \& 7 only, together with appropriate dose of OGX-427 until withdrawn from study
223837557|NCT02595229|PROCEDURE|Pronator quadratus repair|Suturing of the pronator quadratus muscle
223837558|NCT06413849|OTHER|Telephone coached graphic narrative bibliotherapy|Eight weekly sessions of telephone coached graphic narrative bibliotherapy
223837559|NCT06413849|OTHER|Control group|Reading educational booklet
223837560|NCT06509464|DEVICE|High intensity interval training|High intensity interval training on treadmill
223837561|NCT06509464|DIETARY_SUPPLEMENT|Caloric restricted diet|Caloric restricted diet
223837562|NCT05407311|DRUG|64Cu-SAR-BBN|64Cu-SAR-BBN
223837563|NCT01540396|BEHAVIORAL|Dietary modification and medications|Patients diagnosed with gestational diabetes will receive dietary advice and instruction on blood glucose monitoring from their regular prenatal doctors, consistent with standard of care practices. Medications (glyburide, insulin) will be used as needed to assist with blood glucose control.
223837564|NCT05995431|PROCEDURE|scaling and root planing|All the participants will undergo scaling and root planing
223837565|NCT05995431|PROCEDURE|Subgingival instrumentation|All the participants will undergo subgingival instrumentation
223837566|NCT02172456|DRUG|99mTc-radiolabelled tiotropium|
223837567|NCT02172456|DRUG|non-radiolabelled tiotropium|
223837568|NCT01770990|BEHAVIORAL|Tel-PT including mail|Patients receive telephone-based psychotherapy and one letter after each telephone session.
223837569|NCT01770990|BEHAVIORAL|Tel-PT without mail|Patients receive telephone-based psychotherapy without additional letters.
223837570|NCT01792362|OTHER|Weight loss diet|Control the patients diet to make them loosing weight
223837571|NCT01354275|OTHER|To compare the IVF/ICSI outcomes of GnRH Antagonist cycle versus GnRH agonist cycle|150 IU FSH dose and OCP plus GnRH Agonist (long luteal) IVF/ICSI cycle and 150 IU FSH dose and OCP plus GnRH Antagonist (Fixed protocol) IVF/ICSI Cycle
223837572|NCT01354275|OTHER|GnRH Antagonist|GnRH Antagonist cycle; 150 IU FSH and sixth day Antagonist will be administered
223837573|NCT03989791|DIETARY_SUPPLEMENT|absolute diet|Patients in absolute diet group were fasted from any food with intravenous infusion of 5% glucose and sodium chloride instead in the first 24 hours. Then, the patients will be given soup for the next 24 hours if there was no delayed complication or discomfort during the fasting. Finally, they will gradually transit from soup to normal diet such as porridge, noodles and rice in the third 24 hours.
223837574|NCT03989791|DIETARY_SUPPLEMENT|normal diet|Patients in normal diet group were directly given normal diet such as porridge, noodles and rice as usual after polypectomy. Meanwhile, all the patients in two groups were given PPI for 3 days intravenously and restricted from vigorous exercise for 14 days.
223837575|NCT00003509|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Stage IV Melanoma will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
223837576|NCT05270382|OTHER|cetylpyridinium chloride|The mouthwash is used to see the effects on wound healing and the oral microbiome.
223837577|NCT03734159|DRUG|Ropivacaine|Injection of 60 ml of ropivacaine 0.25% divided into 4 injections of 15 ml (2 per side, between ribs 2 and 3 and between ribs 4 and 5)
223837578|NCT03734159|DRUG|sodium chloride 0.9%|Injection of 60 ml of sodium chloride 0.9% divided into 4 injections of 15 ml (2 per side, between ribs 2 and 3 and between ribs 4 and 5)
223837579|NCT06058143|PROCEDURE|CLIF-LP|CLIF-LP surgery method was applied
223837580|NCT06058143|PROCEDURE|TLIF|TLIF surgery method was applied
223837581|NCT02658292|DRUG|Naftifine hydrochloride foam, 3%|Apply NAFT900 foam twice daily to the affected area(s) plus half-inch around each affected area for 4 weeks
223837582|NCT02658292|DRUG|Vehicle|Apply vehicle foam twice daily to the affected area(s) plus half-inch around each affected area for 4 weeks
223837583|NCT06199947|OTHER|Biopsies and Blood collection|Each participant will have 2 additionnal biopsies during his/her diagnostic endoscopy plus two blood test during his/her inclusion
223837584|NCT02099435|DEVICE|Hemospray|The Hemospray™ device comes in a 7F kit and a 10F kit. Each kit includes two 220 cm Teflon application catheters, a handle with CO2 cartridge and a syringe containing approximately 20 g of the Hemospray™ material. Hemospray™ is a proprietary inorganic mineral powder that acts as a mechanical barrier when sprayed over a bleeding lesion and the surrounding mucosa.
223837585|NCT00488215|DRUG|prucalopride|The dose will be consecutively escalated in 2 mg steps per day, starting from 2 mg up to 20 mg once daily or until severe drug-related adverse events occur (= individual maximum tolerable dose, on decision of the subject and/or investigator).
223837586|NCT00488215|OTHER|Placebo|During the placebo session, the number of placebo tablets will be consecutively escalated in an identical way as described for prucalopride. This means 1 tablet more every day, up to 10 tablets.
223837587|NCT06083311|DIETARY_SUPPLEMENT|Probiotic|Participants in this arm will receive a daily dose of 3x10\^9 Colony Forming Units (CFU) of a live bacterium, corresponding to 1 capsules daily for 28 days
223837588|NCT06083311|DIETARY_SUPPLEMENT|Placebo|Participants in this arm will receive an equivalent placebo for 28 days
223837589|NCT01563978|DRUG|fostamatinib|fostamatinib 100 mg twice daily
223837590|NCT01563978|DRUG|placebo|placebo
223837591|NCT05764239|DRUG|SYNB1934v1|SYNB1934v1 consisted of powder for oral suspension packaged in sachets. During dose preparation, the powder was resuspended in water or apple juice prior to administration.
223837592|NCT05764239|DRUG|Placebo|Placebo was manufactured using an inactive powder that was color matched to the SYNB1934v1 drug product. In order to maintain study blinding during the RWP, placebo was packaged, labeled, stored, and administered in an identical manner to SYNB1934v1.
223837593|NCT03832725|OTHER|High Protein (HP) weight loss diet|"Newly diagnosed Type 2 Diabetic (NT2DM) subjects will be placed on a HP diet for 6 months with all food provided for weight loss and remission of NT2DM.~Intervention with the HP diet will be 6 months. If subjects have not had remission of Type 2 Diabetes by the end of the 6 months, they will be referred to an endocrinologist for pharmaceutical treatment"
223837594|NCT03832725|OTHER|High carbohydrate (HC) weight loss diet|"Newly diagnosed Type 2 Diabetic (NT2DM) subjects will be placed on a HC diet for 6 months with all food provided for weight loss and remission of NT2DM.~Intervention with the HP diet will be 6 months. If subjects have not had remission of Type 2 Diabetes by the end of the 6 months, they will be referred to an endocrinologist for pharmaceutical treatment"
223837595|NCT00003639|BIOLOGICAL|recombinant interferon alfa|
223837596|NCT00003639|DRUG|chlorambucil|
223837597|NCT00003639|DRUG|dexamethasone|
223837598|NCT00003639|DRUG|idarubicin|
223837599|NCT02465333|PROCEDURE|Heel Fat Grafting|"Fat grafting is widely used by plastic surgeons and is considered a standard of care procedure in plastic surgery. Fat tissue to be used for grafting is harvested with a small liposuction cannula. The fat is then centrifuged, cleaned, and loaded into 1cc syringes and injected into the heel fat pad using specialized cannulas.~Postoperatively, the foot will be bandaged for twenty-four hours and the subject will be advised to limit ambulation. Over the next three weeks, the patient will be instructed to wear a cushioned, supportive sneaker and participate in only activities of normal daily living, with no excessive aerobic activity."
223837600|NCT03314649|OTHER|Observational study|Lavage of the Peritoneal Cavity
223837601|NCT06016374|OTHER|telerehabilitation|"During this study, the patient will be asked to use the TeleRé programme at least 5 times a week for 30 minutes for one month. Through the programme, they will have access to exercises in video format and thus self-rehabilitation as well as serious therapeutic games. The self-education games and videos target the functional and motor recovery of the upper limb. In addition, cognitive functions (attention, memory, etc.) will also be stimulated via the programme. Therapeutic education modules and PROMS assessments will also be available."
223837602|NCT01621282|OTHER|Education|A 6-month interactive course on critical appraisal
223837603|NCT01621282|OTHER|Conventional|Conventional method/no intervention
223837604|NCT02797223|BEHAVIORAL|Semi-structured interviews|Qualitative phenomenological study. Data collection will be done through semi-structured interviews. Each interview will last between 60 and 90 minutes. It will be the same researcher who interviewed and analyze them.
223837605|NCT02788136|DRUG|human chorionic gonadotropin|At 08 AM of day 0, all subjects underwent to a single intramuscular injection of hCG of 5000 IU
223837606|NCT00028314|DRUG|Abacavir sulfate|
223837607|NCT00028314|DRUG|Atazanavir/Ritonavir|
223837608|NCT00028314|DRUG|Lopinavir/Ritonavir|
223837609|NCT00028314|DRUG|Nevirapine|
223837610|NCT05760430|COMBINATION_PRODUCT|PVE+cTACE+Camrelizumab+Apatinib|After cTACE, 3 mg/kg of Camrelizumab was injected intravenously once every three weeks+250 mg of Apatinib mesylate tablets were taken orally once a day. PVE was performed on the half liver with the largest tumor load 2 weeks after CTACE.
223837611|NCT05760430|COMBINATION_PRODUCT|cTACE+Atirizumab+Bevacizumab|After cTACE, 1200 mg of Atirizumab+15 mg/kg of Bevacizumab was injected intravenously every three weeks.
223837612|NCT02999893|DRUG|APR-246|APR-246 (also known as PRIMA-1MET), a first-in-class agent targeting mutant p53 resulting in re-expression of wild-type p53 activity.
223837613|NCT04860843|DRUG|Thoracic paravertebral block|Participants will receive a thoracic paravertebral with local anesthetic infiltrate (30ml of 0.35% ropivacaine with 1:400K epinephrine).
223837614|NCT04860843|DRUG|Pecs block|Participants will receive a pecs block with local anesthetic infiltrate (30ml of 0.25% ropivacaine with 1:400K epinephrine).
223837615|NCT04860843|DRUG|Sham Pecs block|Participants will receive a and a pecs block with saline infiltrate (30ml normal saline; 0.9% NaCl).
223837616|NCT04239456|DEVICE|RehaCom (software)|RehaCom software has gamified, interactive modules that will help participants practice the application of various memory strategies at custom, increasingly more difficult levels. Instructor will also use the software to teach and demonstrate the use of memory strategies with the domains targeted (i.e., list learning, remembering written/verbal information, and memory for names/faces).
223837617|NCT05085743|DIAGNOSTIC_TEST|Deep convolutional neural networks analysis|using Deep convolutional neural networks to analyze pre-intubation chest radiographs along with patients' data to predict the proper depth of ETT fixation
223837618|NCT03356873|DRUG|Vitamin D|Vitamin D supplementation
223837619|NCT03356873|OTHER|Placebo|Placebo
223837620|NCT06227325|DRUG|RC48 combined with Sintilimab and XELOX|RC48: 2.5 mg/kg, iv, d1, repeat every 2 weeks; Sintilimab: 200mg, iv, d1, repeat every 3 weeks; XELOX: Oxaliplatin 130mg/m2, iv, d1；Capecitabine1000 mg po, bid, d1-14, repeat every 3 weeks
223837621|NCT03857711|PROCEDURE|Conventional CABG|Coronary artery bypass grafting
223837622|NCT03857711|PROCEDURE|CABG+ PVI|CABG+ prophylactic epicardial bipolar radiofrequency isolation of the pulmonary veins
223837623|NCT03857711|PROCEDURE|CABG+ PVI+amiodarone|CABG+PVI+amiodarone (CABG+RFA + class III antiarrhythmic drug- amiodarone)
223837624|NCT03857711|PROCEDURE|CABG+amiodarone|
223837625|NCT00518505|OTHER|Symptom questionnaire|This questionnaire will assess patient outcomes before and after surgery for gastroesophageal reflux disorder.
223837626|NCT04628416|DEVICE|PICO dressing|Use of a portative miniature negative pressure dressing system named PICO® on the split-thickness skin graft of fibula free flap donor sites
223837627|NCT04628416|DEVICE|Conventional dressing|use of a conventional dressing (parrafin gauze) on the split-thickness skin graft of fibula free flap donor sites
223837628|NCT05075655|DEVICE|Endobronchial ultrasound guided miniforceps biopsy and transbronchial needle aspiration|"Mediastinal node is sampled using three path of classic ultrasound guided transbronchial needle aspiration (EBUS-TBNA).~A reduce size forceps is then inserted inside the mediastinal node via the duc EBUS-TBNA made and biopsies (EBUS-MFB) are made using real time ultrasound guidance."
223837629|NCT01034761|BEHAVIORAL|Pop-up alert|Pop-up alert in the electronic medical record whenever the provider enters an order for a specified high risk medication from the Beers list.
223837630|NCT02344836|BEHAVIORAL|Podcast + mobile diet app|Use of a mobile app to track behaviors related to weight loss as well as receive study-related weight loss information via podcast.
223837631|NCT02344836|BEHAVIORAL|Podcast + theory-based mobile diet app|Use of a theory-based mobile app to track behaviors related to weight loss as well as receive study-related weight loss information via podcast.
223837632|NCT02044419|DRUG|lomitapide|
223837633|NCT04946448|OTHER|FIT diet|Dietary intervention as add-on therapy to biologicals
223837634|NCT03816592|PROCEDURE|Opioid free anaesthesia|patient anesthtesized with lidocaine, ketamine and dexamethasone
223837635|NCT03816592|PROCEDURE|Opioid anaesthesia|patients anesthetized with sufentanil ketamine and dexamethasone
223837636|NCT06307483|BEHAVIORAL|Taichi group|Participants in the Tai chi group were regular Tai chi practitioners who had practiced Tai chi for at least 3 months, at least three times a week for at least 30 minutes each time.
223837637|NCT06307483|BEHAVIORAL|Exercise group|The subjects in the exercise group had regular exercise habits, and insisted on non-Tai chi exercise for at least 3 months, at least three times a week, at least 30 minutes each time.
223837638|NCT01933347|DRUG|Gefitinib|Subjects will receive the oral administration of gefitinib 250mg/d until the tumor progression.
223837639|NCT04562779|DRUG|Naltrexone 380 MG|XR naltrexone to be given once prior to hospital discharge
223837640|NCT04562779|DRUG|Ketamine Hydrochloride|IV ketamine infusion to be given once prior to hospital discharge
223837641|NCT04562779|BEHAVIORAL|Enhanced linkage|Includes in-hospital intake at outpatient addiction clinic plus contingency management related to follow-up
223837642|NCT05332951|OTHER|Interpersonal Reactivity Index|Questionnaire to be completed by the patient
223837643|NCT00333138|DRUG|FTY720|FTY720 capsule was taken orally once a day
223837644|NCT00333138|DRUG|Placebo|Placebo 1.25 mg capsule was given once daily
223837645|NCT05103254|DRUG|Bempedoic Acid|Bempedoic Acid 180 MG
223837646|NCT05103254|DRUG|Bempedoic Acid / Ezetimibe|Bempedoic Acid 180 MG / Ezetimibe 10 MG
223837647|NCT02654379|BIOLOGICAL|Rituximab|Rituximab use in non-oncology indications
223837648|NCT04581239|OTHER|Active neural mobilization|"Active neural mobilization Base line treatment followed heating pad 10 minutes, lumber traction with 50 %of body weight in accordance with tolerance. 15 to 20 Lumber segmental mobilization.~Active oscillatory nerve mobilization was given in 3 sets of 10 repetition in each set with 20 sec rest time between set"
223837649|NCT04581239|OTHER|passive neural mobilization|"Base line treatment followed heating pad 10 minutes, lumber traction with 50 %of body weight in accordance with tolerance. 15 to 20 Lumber segmental mobilization~Passive neural mobilization This oscillatory nerve mobilization was given in 3 sets of 10 repetition in each set with 20 sec rest time between set. Both groups received total 18 session 3 session per week for consecutive 6 weeks"
223837650|NCT02541539|DIETARY_SUPPLEMENT|Lactobacillus casei Zhang|This project aims to study the benefits of probiotics namely Lactobacillus casei Zhang in prevention of upper respiratory and gastrointestinal illnesses, among adults in Malaysia aged from 18-81 years.
223837651|NCT02541539|DIETARY_SUPPLEMENT|Placebo|This project aims to study the benefits of probiotics namely Lactobacillus casei Zhang in prevention of upper respiratory and gastrointestinal illnesses, among adults in Malaysia aged from 18-81 years.
223837652|NCT02721199|OTHER|Neural Respiratory Drive Automated EMGpara assessment|Neural respiratory drive will be measured using surface electrodes and nasal cannula . The 2nd intercostal space will be identified by bony landmarks and skin preparation will be performed using detergent wipes, followed by EMG preparation gel with final cleaning to remove exfoliated skin. Wet gel electrodes will be placed immediately adjacent to the sternal border in the 2nd intercostal space and will be connected to the automated EMG analysis system. Electrodes will remain in place for the duration of the study. A nasal cannula will be placed in the nose and detect pressure changes during respiration in order to ensure accurate detection of inspiratory cycle. In addition, an accelerometer will be attached to the thorax of the patient
223837653|NCT05190068|DRUG|HMPL-760|HMPL-760 was administered continuously as a single agent orally every day in sequential 28-day cycles.
223837654|NCT05654272|DIAGNOSTIC_TEST|MRI|Cardiac MRI
223837655|NCT04630756|DRUG|AZD4573|AZD4573 will be administered as an absolute (flat) dose, 2-hour (± 15 minutes) IV infusion once weekly (as monotherapy for Module 2 only) and in combination with orally administered acalabrutinib twice daily continuously. For both Part A and Part B of this study, Cycle 1 consists of 5 weeks, with a dose ramp-up. Subsequent cycles are 21 days (3 weeks) with once weekly dosing of AZD4573 in combination with acalabrutinib twice daily continuously (in Module 1 and Module 2, period 2).
223837656|NCT04630756|DRUG|Acalabrutinib|Oral Acalabrutinib capsule will be administered twice daily continuously from Day 1 of Cycle 1 Week 1 in combination with AZD4573.
223837657|NCT06004596|DIAGNOSTIC_TEST|13C-Spirulina Gastric Emptying Breath Test (GEBT)|Diagnostic test
223837658|NCT06004596|DIAGNOSTIC_TEST|13C-Spirulina Gastric Emptying Breath Test (GEBT) - repeat|Diagnostic test - repeat for biological variability deterination
223837659|NCT06373588|BEHAVIORAL|Patient Navigator|The patient navigator will meet the following requirements: a bachelor's degree in health or social sciences, or equivalent experiences; strong knowledge of the local health and social services system; trauma-informed care and cultural safety; strong interpersonal skills, ability to problem-solve, and autonomy; have prior experiences with migrant communities (including lived experiences) and working in healthcare setting. The navigator will be trained on topics related to their role, through case discussions, and role playing, as done in other navigator trials. Topics will include Indigenous cultural safety as applied to migrant health, systems navigation, care coordination, family-centred care, social determinants of health (health insurance, income supplements, etc.) and inequities, advanced communication and helping skills (e.g., motivational interviewing), ethics, privacy, and confidentiality, and others as determined through our co-design process.
223837660|NCT05004064|DRUG|Acalabrutinib|Patients will receive acalabrutinib 100mg twice daily for up to six 28 day cycles. Patients can receive 100mg once daily for cycle 1, day 1 to day 7, according to the investigator's discretion.
223837661|NCT05004064|DRUG|Rituximab|Patient will receive rituximab 375 mg/m2 IV on day 1 (+/- 3 days) of each cycle, for a maximum of 6 cycles
223837662|NCT03502603|DIAGNOSTIC_TEST|Railroad Test|This is a test designed to evaluate visual perception capacities and requires the participant to match photographs with railroads as a central theme. The participant is presented with a photograph image at the top of the screen and is asked to match it to one of the two, three or four choices in the lower portion of the display.
223837663|NCT03502603|DIAGNOSTIC_TEST|Swamp Test|This is a test of immediate visual memory/attention for photographs with swamp wetlands as a central theme. The participant is briefly presented with a photograph which is replaced by two, three or four choices, one of which the participant is asked to select as the initially presented image.
223837664|NCT03502603|DIAGNOSTIC_TEST|Presidents Recognition Test|This is a test of history knowledge and facial recognition using pictures of US presidents and non-president distractors. The participant is presented with two photographs and is asked to identify which is the picture of a US president
223837665|NCT03502603|DIAGNOSTIC_TEST|Judgment of Line Orientation|This test requires participants to visually match the orientation of line segments. This is a test of visual perception and was included as a relative equivalent of the Railroad Test.
223837666|NCT03502603|DIAGNOSTIC_TEST|Symbol Span subtest of the Wechsler Memory Scale-IV|This test requires participants to immediately recall a sequence of designs after a brief presentation. This is a test of immediate visual memory/attention and was included as a relative equivalent of the Swamp Test
223837667|NCT03502603|DIAGNOSTIC_TEST|Information subtest of the Wechsler Adult Intelligence Scale-IV:|This test requires participants to answer factual knowledge questions. This is a test of fund of knowledge and was included as a verbal equivalent for the non-verbal Presidents Recognition Test.
223837668|NCT03502603|DIAGNOSTIC_TEST|Digit Span subtest of the Wechsler Adult Intelligence Scale-I|This test requires the participant to repeat sets of digits forward, backward, and to sequence digits in ascending order. This is a test of immediate memory/attention and was included to investigate possible attentional correlates of the Swamp Test. This test includes a performance validity indicator that will permit analyses of validity indicators included with the experimental tests
223837669|NCT03502603|DIAGNOSTIC_TEST|Reading subtest of the Wide Range Achievement Test|This test requires participants to read words printed on a card. This is a test of word knowledge/academic achievement and was included to investigate the academic achievement concomitants of the Presidents Recognition Test.
223837670|NCT03502603|DIAGNOSTIC_TEST|Symbol Digit Modalities Test:|This test requires participants to visually match abstract symbols with numbers within a certain time period. The participant either verbalizes or writes the response on an answer sheet. This is a test of speed of information processing and was included to assess speed of response factors pertaining to all of the experimental tests as reflecting speed of information processing.
223837671|NCT03502603|DIAGNOSTIC_TEST|Dot Counting Test|This test requires participants to count arrays of dots presented on a card while being timed. This is a performance validity test and was included to ascertain validity factors pertaining to each of the experimental tests.
223837672|NCT05289934|BEHAVIORAL|Music Stimuli|Nine-minute-long Mozart K.448 (1st movement) and instrumental age-appropriate songs will be played via single-use earbuds with 10 minutes wash-out in between music stimuli.
223837673|NCT05965167|DRUG|EBP05|Oral tablets
223837674|NCT05965167|DRUG|Forteo 20 mg|Subcutaneous injection
223837675|NCT05965167|DRUG|EBP11|Oral tablets
223837676|NCT05965167|DRUG|EBP22|Oral tablets
223837677|NCT06219486|DIAGNOSTIC_TEST|D-dimer|The investigators will measure a D-dimer test on participants and randomize on informing the physician on the value.
223837678|NCT03841708|DEVICE|Pleth variability index|The utility of a early goal directed therapy will be evaluate by the pleth variability index (PVI). If above\>13% in a well sedated patients perfectly synchronized with the ventilator providing at least 6ml/kg of ideal body weight, a fluid challeng with 10ml/kg of NaCl 0,9% will be administrated. Patient will be constantly re-assessed until the hemodynamic goals of a mean arterial pressure above 65 mmHg, a capillary refill time below 3 seconds, a decreasing trend on lactates and a urinary output above 0.5/ml/kg/h will be achieved. The second fluid challenge will always be performed with 100 ml of albumin 20%. The third fluid challenge if necessary will be performed with 10 ml/kg of NaCl 0.9%.
223837679|NCT03841708|DEVICE|Standard non invasive monitoring|In the control group patients will be hemodynamically resuscitated in the early phases after ROSC based on standard non invasive monitoring such as SatO2, EtCO2, non invasive blood pressure and continuous ECG. If deemed necessary by the treating physician a fluid challenge of 10ml/kg of NaCl 0,9% will be administrated. Patient will be constantly re-assessed until the hemodynamic goals of a mean arterial pressure above 65 mmHg, a capillary refill time below 3 seconds, a decreasing trend on lactates and a urinary output above 0.5/ml/kg/h will be achieved. The second fluid challenge will always be performed with 100 ml of albumin 20%. The third fluid challenge if necessary will be performed with 10 ml/kg of NaCl 0.9%.
223837680|NCT01412814|DEVICE|AposTherapy Biomechanical System|The device is comprised of four adjustable modular elements attached to foot-worn platforms that are capable of manipulating the foot's center-of-pressure and applying perturbation training throughout the gait cycle. The device allows for neuromuscular training during dynamic loading.
223837681|NCT01412814|OTHER|Physical Therapy Program|Their therapy program will be similar to the experimental group, but without the treatment device (placebo walking shoe).
223837682|NCT04925596|BEHAVIORAL|ePrimaPrescribe online educational program|online training program aiming to change general practitioners' benzodiazepine prescription
223837683|NCT04925596|BEHAVIORAL|ComunicaSaudeMental online educational program|online training program aiming to improve general practitioners' communication with mentally ill patients
223837684|NCT01717183|DEVICE|Urgo 310 3113|URGO 310 3113 dressing may be changed every 2 to 4 days, and left in place for up to 7 days, depending on the level of exudate and the wound condition
223837685|NCT01717183|DEVICE|Placebo URGO 310 3113 dressing|
223837686|NCT03027687|DEVICE|tDCS|tDCS is an electrical brain stimulation method
223837687|NCT06327763|PROCEDURE|ilioinguinal nerve section|patients operated on by open inguinal hernioplasty with ilioinguinal neurectomy
223837688|NCT03764423|DIETARY_SUPPLEMENT|Salmon fishmeal|Salmon fishmeal with high protein content
223837689|NCT03764423|DIETARY_SUPPLEMENT|Microcrystalline cellulose|Microcrystalline cellulose contain no energy and is less fermented in the gut than other dietary fibers.
223837690|NCT02862041|DEVICE|Echogenic needle - Pajunk sonoplex echogenic needle|Ultrasound guided infraclavicular brachial plexus block for upper extremity surgeries
223837691|NCT02862041|DEVICE|Non Echogenic needle - Stimuplex Braun Nonechogenic needle|Ultrasound guided infraclavicular brachial plexus block for upper extremity surgeries
223837692|NCT04464837|DEVICE|Cold Snare Polypectomy of intermediate sized polyps (10-15 mm)|If an eligible polyp (10-15mm) is found, cold snare polypectomy is performed with the Olympus SnareMaster® Plus Snare
223837693|NCT04533776|BEHAVIORAL|Celiac Disease Definition, Symptoms and Treatment|"* Adolescents share their knowledge about the disease~* Emphasizing the definition and symptoms of celiac disease~* Discussion of the treatment of celıac disease Expression Question-Answer Discussion Summarizing"
223837694|NCT04533776|BEHAVIORAL|Difficulties Due to Celiac Disease|"* Determining what experience living with celiac is fot the patient (What do I think about the disease, how do I feel about the disease,how do I perceive the disease, how does the disease affect me)~* Determining the difficulties encountered in Daily life due to illness (How do I deal with difficulties)~* Determining how the disease affects life Expression Question-Answer Discussion Summarizing"
223837695|NCT04533776|BEHAVIORAL|Gluten Free Diet in Celiac Disease|"* Evaluating dietary information~* Identifying the difficulties in diet therapy Expression Question-Answer Discussion Summarizing Case Study Presentation (Transfer of life experience of an individual who is 22 years old with celiac disease)"
223837696|NCT04533776|BEHAVIORAL|Difficulties Related to Disease in School and Social Life|"* Assessment of difficulties encountered in school and social life~* Evaluation of the solution suggestions fort he difficulties encountered Expression Question-Answer Discussion Summarizing Örnek Olay Sunumu (Transfer of life of experience of a 23 years old dietician with celiac disease)"
223837697|NCT04533776|BEHAVIORAL|Celiac Disease and Its Effects on Acamdemic Success Peer Relations|"* Evaluation of the effects of the disease on academic success~* Evaluation of the effects of the disease on peer relationships in the school enviroment~* Difficulties experienced in peer relations and evaluation of relationships (exclusion) Expression Question-Answer Discussion Summarizing"
223837698|NCT04533776|BEHAVIORAL|Celiac Diseae anf Future Goals|"* General summary of all sessions so far~* Summarizing the topics discussed in the previous session~* Evaluating the future goals of the participants Expression Question-Answer Discussion Summarizing"
223837699|NCT04533776|OTHER|No Intervention: routine health care- control group|Peer interactive group support was not provided to the control group. After all the sessions of the peer interactive group support of the study were completed, a separate training meeting was held for the control group.
223837700|NCT05593211|DEVICE|Kronos Electrocautery Device|The Kronos Electrocautery Device is a disposable electrocautery device that can cauterize deep tissue through a standard biopsy procedure guide needle. This device is intended to coagulate the tissue surrounding the core biopsy channel during withdrawal to reduce or eliminate significant post-procedural bleeding. Currently, the Kronos Electrocautery Device consists of one (1) size. As such, the existing Kronos Electrocautery Device is chosen as the worst-case condition
223837701|NCT00859092|DIETARY_SUPPLEMENT|Simply Thick|Simply Thick® added to each bottle of formula or beast milk to create nectar or honey consistency
223837702|NCT04343222|DRUG|Bromfenac|An NSAID used to treat eye pain and swelling
223837703|NCT04343222|DRUG|Artificial tears|eye drops to lubricate the eye and maintain moisture
223837704|NCT03077620|DRUG|Suvorexant|Participants will be given a sleep aid (10mg or 20mg suvorexant) at bedtime for two consecutive nights that they are spending in a research unit.
223837705|NCT03077620|DRUG|Placebo|Participants will be given a placebo at bedtime for two consecutive nights that they are spending in a research unit.
223837706|NCT00454428|PROCEDURE|pulsatile intra-aortic balloon pump|
223837707|NCT05092425|OTHER|no intervention|no intervention
223837708|NCT03225846|DRUG|WVE-120102|WVE-120102 is a stereopure antisense oligonucleotide (ASO)
223837709|NCT03225846|DRUG|Placebo|0.9% Sodium Chloride
223837710|NCT03072758|BEHAVIORAL|Men's Club|"Interactive session: This will be a one-day five-hour session that will take place at the church, and will be facilitated by trained lactation nurses. This will involve a maximum of 10 male participants and will occur during the female partner's 3rd trimester. Male partners will (a) complete a structured questionnaire to determine baseline knowledge, attitudes and beliefs about breastfeeding practices, and (b) actively engage in educational information on the benefit of exclusive breastfeeding. At the end of the session, the participants will receive educational pamphlets on breastfeeding to reinforce all the information that had been provided.~Phone call reminders: Participants will receive weekly robocalls during the first six weeks following the birth of the infant to reinforce the benefits of exclusive breastfeeding. This will be an automated service that will deliver the calls at a specific time of the day the participants have indicated on their questionnaire."
223837711|NCT00996580|DRUG|DR-103|"One tablet daily.~Four 91-day cycles of the DR-103 regimen:~42 days combination therapy of 20 mcg ethinyl estradiol (EE) /150 mcg levonorgestrel (LNG) followed by; 21 days combination therapy of 25 mcg EE/150 mcg LNG followed by; 21 days combination therapy of 30 mcg EE/150 mcg LNG followed by; 7 days of 10 mcg EE."
223837712|NCT03655522|DRUG|NAVX-010|Dose levels of NAVX-010 were 2, 8, 25, 50, and 75 mcg. Four patients per active group. Each subject participated in only 1 treatment period.
223837713|NCT03655522|DRUG|Placebo|There were two Placebos per group.
223837714|NCT04756011|OTHER|Health related quality of life|Confidence in diabetes self care questionnaire the socioeconomic level of the family scale MINI-KID the Peds-QL
223837715|NCT00354367|DRUG|Certolizumab pegol|
223837716|NCT02980796|BEHAVIORAL|Exercise|Each experimental day participants will complete an acute bout of exercise on a recumbent bike.
223837717|NCT02980796|BEHAVIORAL|Practice|Each experimental day participants will complete a session of skilled motor practice.
223837718|NCT02718534|BEHAVIORAL|stroke rehabilitation|Physical rehabilitation exercise between 24 and 48 hours and after 48 hours
223837719|NCT04248465|DRUG|Placebo|Single loading dose via intravenous infusion, followed by regular maintenance dosing, based on weight.
223837720|NCT04248465|BIOLOGICAL|Ravulizumab|Single loading dose via intravenous infusion, followed by regular maintenance dosing, based on weight.
223837721|NCT00553020|DRUG|Insulin glargine|"Lantus (commercial formulation, Reference):~10 mL vials (100 IU/mL) solution Dose: 0.3 IU per kg BW injected subcutaneously in the patients usual injection site (either abdomen or thigh)~NPH-insulin (Protaphan) (Test):~10 mL vials (100 IU/mL) solution Dose: 0.3 IU per kg BW injected subcutaneously in the patients usual injection site (either abdomen or thigh)"
223837722|NCT03084939|BIOLOGICAL|Trastuzumab Emtansine|Trastuzumab emtansine 3.6 milligrams per kilogram (mg/kg) was administered intravenously on Day 1 of each 21-day cycle.
223837723|NCT03084939|DRUG|Lapatinib|Lapatinib 1250 mg was administered orally once per day of each 21-day cycle.
223837724|NCT03084939|DRUG|Capecitabine|Capecitabine 1000 milligrams per square meter (mg/m\^2) was administered orally twice daily on Days 1-14 of each 21-day cycle.
223837725|NCT05708846|OTHER|Telemonitoring|"All patients will be telemonitored in order to create a labeled and diverse dataset that will include the following data:~Physiological parameters (measured periodically), socio-demographic data, risk factors, medication tracking, symptomatology questionnaire for patients, NYHA-class, clinical interventions, health questionnaire answers, classified alarms with their respective timestamp and annotation by the MD, and measurement ranges for each personalized alarm and their changes"
223837726|NCT00696163|DRUG|biphasic insulin aspart 30|Being an observational study, dose of NovoMix 30 will be according to treating physician's discretion
223837727|NCT03161119|DEVICE|Ultrasound guided embryotransfer with Cook K-Jets-551910-S|"On the day of ET, patient will be asked to come with full bladder. ET will be done with patient in lithotomy position. No anesthesia will be used for the procedure. Under sterile condition, vaginal parts will be cleaned with saline and draped and speculum inserted to expose cervix. Cervical mucus and cervix will be cleaned with sterile media.~The Et procedure itself is standardized as far as possible amongst the participating physicians to eliminate bias."
223837728|NCT03161119|DEVICE|Ultrasound guided embryotransfer with Cook k-soft-5000 (or K-J-SP-681710 and K-J-SPPE-681710)|"On the day of ET, patient will be asked to come with full bladder. ET will be done with patient in lithotomy position. No anesthesia will be used for the procedure. Under sterile condition, vaginal parts will be cleaned with saline and draped and speculum inserted to expose cervix. Cervical mucus and cervix will be cleaned with sterile media.~The Et procedure itself is standardized as far as possible amongst the participating physicians to eliminate bias."
223837729|NCT04013490|DIETARY_SUPPLEMENT|Cassava dietary fiber capsule|Cassava dietary fiber capsule or placebo will be consumed once daily at the recommended doses of each group.
223837730|NCT00253539|DRUG|arzoxifene hydrochloride|Given orally
223837731|NCT00253539|DRUG|tamoxifen citrate|Given orally
223837732|NCT00253539|OTHER|placebo|Given orally
223837733|NCT03621982|DRUG|ADCT-301|intravenous infusion
223837734|NCT03621982|BIOLOGICAL|Pembrolizumab|intravenous infusion
223837735|NCT04547426|OTHER|Wine with or without alcohol and snuff with or without nicotine|Two by two factorial of wine and snuff with meals
223837736|NCT01157143|DRUG|XRP0038 (NV1FGF)|"Pharmaceutical form : solution~Route of administration : intramuscular"
223837737|NCT02036515|DRUG|Ertugliflozin 5 mg|Ertugliflozin, oral, 5 mg tablet once daily for 52 weeks
223837738|NCT02036515|DRUG|Ertugliflozin 15 mg|Ertugliflozin, oral, 5 mg and 10 mg tablet once daily for 52 weeks
223837739|NCT02036515|DRUG|Placebo for ertugliflozin 5 mg|Matching placebo for ertugliflozin 5 mg, oral, once daily for 52 weeks
223837740|NCT02036515|DRUG|Metformin|Participants are to remain on their stable doses of metformin (oral, \>=1500 mg/day) while receiving blinded investigational product during the double-blind treatment period.
223837741|NCT02036515|DRUG|Sitagliptin|Participants are to remain on their stable doses of sitagliptin (oral, 100 mg once daily) while receiving blinded investigational product during the double-blind treatment period.
223837742|NCT02036515|DRUG|Glimepiride|Glimepiride rescue medication, oral, once daily, open-label glimepiride; dose determined per the investigator's discretion
223837743|NCT02036515|BIOLOGICAL|Insulin|Insulin glargine rescue medication, injectable, as required. In the event that an investigator considers use of glimepiride to not be appropriate for a participant meeting protocol specified glycemic rescue criteria, insulin glargine can be initiated as the rescue medication, and managed by the investigator according to clinical practice guidelines of the local country.
223837744|NCT02036515|DRUG|Placebo for ertugliflozin 10 mg|Matching placebo for ertugliflozin 10 mg, oral, once daily for 52 weeks
223837745|NCT02166151|DRUG|Omalizimab|Omalizimab 150 mg S.C. once a month for consecutive 3 months
223837746|NCT03722719|OTHER|the Knack|The Knack consists of voluntary PFM contractions before and during activities that increase abdominal pressure. Such contraction elevates the pelvic floor cranially, with consequent closure of the urethra, vagina and rectum, stabilization of the pelvic floor and avoidance of urine leakage.
223837747|NCT03722719|OTHER|PFMT|The rationale underlying intensive PFM strength training is that it might develop the structural support of the pelvis by raising the levator plate to a permanent, higher position within the pelvis and promoting PFM and connective tissue hypertrophy and stiffness. These conditions facilitate automatic and more efficacious activation of motor units (neural adaptation), which impedes descent during activities that increase abdominal pressure.
223837748|NCT03722719|OTHER|The Knack + PFMT|These participants will perform the exercises described for both the Knack and PFMT groups at the outpatient clinic and at home.
223837749|NCT06378762|BEHAVIORAL|Endurance Exercise|30 minutes of running at an intensity corresponding to the heavy-domain (between the first and second ventilatory thresholds)
223837750|NCT06378762|BEHAVIORAL|Strength Exercise|Combination of strength and power exercises Weeks 1-5 focus on building maximal strength Weeks 6-11 focus on maintaining maximal strength and improve muscle power
223837751|NCT06378762|BEHAVIORAL|Concurrent Exercise|Combining both strength and endurance training programs, with strength preceding endurance, incorporating a 20-min rest period between each modality
223837752|NCT04939207|DIAGNOSTIC_TEST|CT-FFR|CT-images will be processed by an algorithm to calculate FFR-values of the full coronary tree
223837753|NCT04939207|DIAGNOSTIC_TEST|Angiography-derived FFR|FFR-values are calculated during coronary angiography based on the acquired images of the coronary arteries
223837754|NCT04939207|DIAGNOSTIC_TEST|Angiography with invasive FFR-measurements|during coronary angiography, a specialized pressure wire is passed through the coronary stenosis to calculate FFR based on the difference between the actual pressure and the expected pressure in the hypothetical healthy coronary artery.
223837755|NCT05339906|DEVICE|ZOV.ai digital therapy candidate|ZOV.ai is a novel auditory neuro modulating technology that leverages euphonic music tracks with broad-spectrum binaural beats to induce selective EEG spectral power changes to improve stuttering symptoms
223837756|NCT04635878|OTHER|Blood collection|Blood collection (at admission, two days, one week and at discharge) to analyze the activation of NLRP3 inflammasome in platelets and leukocytes
223837757|NCT00394095|DRUG|Topiramate|Oral topiramate 300-400mg/day for 12 weeks
223837758|NCT00394095|DRUG|Placebo|Matched placebo to Experimental arm
223837759|NCT05820074|DIAGNOSTIC_TEST|Neural Activity Recording|Neural Activity is measured using EEG in all groups. Additionally, in Parkinson's patients, local-field-potentials from deep brain stimulation electrodes are recorded.
223837760|NCT05820074|DIAGNOSTIC_TEST|Movement Parameter Recording|Gait-related movement parameters are non-invasively recorded using motion capture, accelerometers and electromyography.
223837761|NCT05820074|OTHER|Neuromodulation|Neural signals are recorded with the electrodes of the deep brain stimulation device. Parkinson's patients are asked to modulate their neural activity by observing the streamed neural activity and applying mental strategies.
223837762|NCT01034475|DRUG|CPI-613|"This is a Phase I open label trial using a 2-stage dose-escalation scheme (single-patient \& traditional stages):~Single-Patient Dose-Escalation Stage: In the single-patient stage, a single patient will be accrued per dose level. The starting dose will be 420 mg/m². Dose level will be escalated (by doubling the previous dose) if there is no toxicity or if the toxicity is grade 1 or less. If toxicity is \>Grade 1, the traditional dose-escalation stage will be triggered.~Traditional Dose-Escalation: All dose escalations conducted in this Traditional Dose-Escalation stage will be escalated according to the modified Fibonacci Dose-Escalation scheme."
223837763|NCT02174198|DEVICE|BioOss Collagen at the time of implant placement|Experimental: placement of BioOss Collagen No intervention: no BioOss Collagen
223837764|NCT03565861|DRUG|Placebo|Intravenous vehicle
223837765|NCT03565861|DRUG|NP10679|NP10679
223837766|NCT00309335|DRUG|Phentolamine Mesylate (NV-101)|
223837767|NCT00862875|DRUG|Detemir or Glargine|Initial dose of 10 units of insulin at bedtime. The insulin dose will be increase by 1 unit per day until fasting plasma glucose (FPG) levels are 5.0 mmol/L.
223837768|NCT04125511|DRUG|68Ga-FAPI|Intravenous injection of one dosage of 74-148 MBq (2-4 mCi) 68Ga-FAPI. Tracer doses of 68Ga-FAPI will be used to image lesions of IgG4-RD by PET/CT.
224078756|NCT02495922|DRUG|Dexamethasone|"20 mg per os on day 1,2 and 4,5 and 8,9 and 11,12 and 15 in induction cycles 1 and 2. 20 mg per os on day 1,2 and 4,5 and 8,9 and 11,12 in induction cycles 3 and 4 (Arms A1 and A2).~8 mg per os and 12 mg i.v. on day 1, 8 and 15 and 20 mg per os on days 2,4,5, 9, 11 and 12 in induction cycles 1 and 2. 8 mg per os and 12 mg i.v. on day 1, and 11, 20 mg per os on days 2,4,5,8, 9, and 12 in induction cycles 3 and 4 (Arms B1 and B2).~20 mg per os on days 1,2, 8,9, 15 and 16 in both cycles of consolidation (Arms A1 and B1). 8 mg per os and 12 mg i.v. on days 1, 8 and 15 and 20 mg per os on days 2, 9 and 16 in both consolidation cycles (Arms A2 and B2).~12 mg per os on day 1 and 15 in maintenance cycles 1-6, 12 mg per os on day 1 of maintenance cycles 7 and following (Arms A1 and B1). 4 mg per os and 8 mg i.v. on day 1 and 15 in maintenance cycles 1-6, 4 mg per os and 8 mg i.v. on day 1 of maintenance cycles 7 and following (Arms A2 and B2)."
223837769|NCT06082128|BEHAVIORAL|FOCUSau|"FOCUSau is a self-administered web-based intervention and completed autonomously via the internet by the dyad. Delivery encompasses the completion of four prescribed consecutive FOCUSau sessions (with three weeks between each session) over a period of 12 weeks.~The sessions are completed simultaneously by the patient and family carer, together at a computer. The intervention sessions can be completed at any time within the 12-week timeframe. Participants receive tailored individual and dyadic messages according to the information provided at study enrollment and their responses to questions within the sessions. Dyads are also provided with an online personal workbook containing the results of interactive exercises completed during the internet sessions. Any information sheets that the dyad indicated as 'of interest to them' during the internet sessions are included as a hyperlink in their personal workbook which also contains evidence-based local advanced cancer related resources."
223837770|NCT04404257|RADIATION|ControlRad System|Cardiac Catheterization or electrophysiology implant procedures with Control Rad system device installed in the cath lab room #5.
223837771|NCT04404257|RADIATION|Without ControlRad System|Cardiac Catheterization or electrophysiology implant procedures in cath lab room 5 without the ControlRad system device.
223837772|NCT00107380|BIOLOGICAL|rituximab|
223837773|NCT00107380|DRUG|cyclophosphamide|
223837774|NCT00107380|DRUG|doxorubicin hydrochloride|
223837775|NCT00107380|DRUG|prednisone|
223837776|NCT00107380|DRUG|vincristine sulfate|
223837777|NCT00107380|RADIATION|tositumomab and iodine I 131 tositumomab|
223837778|NCT03673098|BEHAVIORAL|Adapted 3RP|The 3RP blends stress management principles, cognitive behavioral therapy, and positive psychology. The 3RP focuses on 3 major areas: (1) eliciting the relaxation response; (2) increasing stress awareness; and (3) promoting adaptive strategies. The adapted 3RP intervention consists of 10, 90-minute weekly group sessions. Content specific to older women living with HIV, including self-compassion exercises, was added to the intervention in the first phase of this study (open pilot).
223837779|NCT01917734|OTHER|Therapeutic feeding for children with SAM|Comparison of outcomes between children with complicated SAM and children with uncomplicated SAM as well as comparisn of outcomes against national and internationally agreed upon standards of care
223837780|NCT04058210|DRUG|ELX/TEZ/IVA|Fixed-dose combination tablet for oral administration.
223837781|NCT04058210|DRUG|IVA|150-mg tablet for oral administration.
223837782|NCT04223154|DEVICE|Real iTBS to the dlPFC|This will be delivered with the Magventure Magpro system; 600 pulses with the active sham coil (double blinded using the USB key).
223837783|NCT04223154|DEVICE|Sham iTBS to the dlPFC|This will be delivered with the Magventure Magpro system; 600 pulses with the active sham coil (double blinded using the USB key).
223837784|NCT00987792|DRUG|Moxifloxacin (Avelox, BAY12-8039)|Hospitalized patients receiving Avelox according to local drug information
223837785|NCT00739583|DRUG|CHG 2% w/v and IPA 70% v/v|Skin preparation of the surgical site per label of the product. The area for surgery will be prepared for 30 seconds
223837786|NCT00739583|DRUG|Iodophor 0.7% and IPA 74% w/w|Skin preparation of the surgical site per product labeling. The area will be painted with the solution.
223837787|NCT02249481|PROCEDURE|Adductor Canal catheter delivering 0.0625% L- Bupivacaine|Adductor canal catheter: Blockade at mid-thigh. Identify sartorius at mid thigh - find point where the femoral artery begins to descend from sartorius. In plane technique, hydro-dissect space between sartorius and femoral artery. Catheter threaded and 2-4cm left in situ (bevel orientated cephalad). Bolus 20 mls via needle and 5 mls via catheter to confirm spread under ultrasound guidance. Glue/Lockit dressing.
223837788|NCT02249481|PROCEDURE|Femoral nerve catheter delivering 0.0625% L- Bupivacaine|Femoral nerve catheter: Blockade at level of Femoral crease. Identify femoral nerve. In plane lateral approach. Bolus 20 mls via needle. Catheter threaded and 2-4cm left in situ (bevel orientated cephalad).and 5 mls injected via catheter to confirm spread under ultrasound guidance. Glue/Lockit dressing.
223837789|NCT02662244|DEVICE|Nd:YAG laser|Long-Pulsed 1064 NM ND:Yag Laser Treatment Of Basal Cell Carcinoma
223837790|NCT00548275|BEHAVIORAL|Enhanced Sexual Risk Management|management of sexual risk
223837791|NCT00548275|BEHAVIORAL|Standard Sexual Risk Management|management of sexual risk
223837792|NCT06431802|OTHER|Conventional intervention|A nursing specialist with extensive clinical and teaching experience will provide on-site course training. The training will cover topics related to pain and pain assessment, such as: pain definition, types, physiological mechanisms, performance, pain assessment tools, and frequency of pain assessment. Interventions will be provided once a week for 4 weeks.
223837793|NCT06431802|BEHAVIORAL|Platform intervention|Using a pre-assigned account to log in to the platform, read the guidance instructions and enter the platform to start training. Basic knowledge of pain and pain assessment can be learnt through the Learning Resources module on the platform, and pain assessment training can be conducted through the Pain Assessment Exercise module. During pain assessment training the platform provides instant feedback based on the participant's exercises. Interventions will be completed in 4 weeks.
223837794|NCT04699448|OTHER|Nutritional intervention.|Diets designed for body weight loss, based on different macronutrient content.
223837795|NCT01155726|DEVICE|Nelfilcon A contact lens|Commercially marketed, soft, hydrogel contact lens for daily wear, daily disposable use. Blister pack label and lens packaging visible to participant. Lenses inserted and removed by participant.
223837796|NCT01155726|DEVICE|Nelfilcon A contact lens with comfort additive (DACP), unmasked|Commercially marketed, soft, hydrogel contact lens with comfort additive for daily wear, daily disposable use. Blister pack label and lens packaging visible to participant. Lenses and removed inserted by participant.
223837797|NCT01155726|DEVICE|Nelfilcon A contact lens with comfort additive (DACP), masked|Commercially marketed, soft, hydrogel contact lens for daily wear, daily disposable use. Blister pack label and packaging not visible to participant. Lenses inserted and removed by the investigator.
223837798|NCT01155726|DEVICE|Nelfilcon A contact lens with comfort additive (DACP), partially masked|Commercially marketed, soft, hydrogel contact lens for daily wear, daily disposable use. Lens name and manufacturer on blister pack label concealed from participant. Lenses inserted and removed by the participant.
223837799|NCT01155726|DEVICE|Etafilcon A contact lens|Commercially marketed, soft, hydrogel contact lens for daily wear, daily disposable use. Blister pack label and lens packaging visible to participant. Lenses inserted and removed by participant.
223837800|NCT01155726|DEVICE|Etafilcon A contact lens with comfort additive (1DAVM), unmasked|Commercially marketed, soft, hydrogel contact lens with comfort additive for daily wear, daily disposable use. Blister pack label and lens packaging visible to participant. Lenses inserted and removed by participant.
223837801|NCT01155726|DEVICE|Etafilcon A contact lens with comfort additive (1DAVM), masked|Commercially marketed, soft, hydrogel contact lens for daily wear, daily disposable use. Blister pack label and packaging not visible to participant. Lenses inserted and removed by the investigator.
223837802|NCT01155726|DEVICE|Etafilcon A contact lens with comfort additive (1DAVM), partially masked|Commercially marketed, soft, hydrogel contact lens for daily wear, daily disposable use. Lens name and manufacturer on blister pack label concealed from participant. Lenses inserted and removed by the participant.
223837803|NCT06242509|DIAGNOSTIC_TEST|Biological samples|"Plasma sampling ans stool sampling~* at inclusion~* at 1 month~* at 3 months~* at progression within the 3 months"
223837804|NCT04307602|OTHER|Exercise - High Intensity Interval Training (HIIT)|Exercise in the walk aid Innowalk for children for children with CP GMFCS IV-V, Exercise on spinning bike for children with CP GMFCS I-II and non-disabled children
223837805|NCT04307602|OTHER|Exercise - Submaximal Steady State Training (SST)|Exercise in the walk aid Innowalk for children for children with CP GMFCS IV-V, Exercise on spinning bike for children with CP GMFCS I-II and non-disabled
223837806|NCT04464941|BEHAVIORAL|a composite intervention with both group and individual components for oral health promotion program|"The group intervention consisted of:~1\. Group oral health education 2. Display of Bass tooth-brushing methods 3. Broadcasting of songs as tooth-brushing reminders; The individual interventions included:~1\. Instruction in the Bass tooth-brushing method, 2. Individual behavioral modification method"
223837807|NCT00157586|DRUG|Delapril, Delapril-Manidipine Fixed combination|
223837808|NCT00318825|DRUG|Nitrous oxide|
223837809|NCT03639675|DRUG|Aflibercept (EYLEA, BAY86-5321)|2 mg (0.05 mL), Intravitreal injection (IVT), single dose.
223837810|NCT03639675|DRUG|Topical IOP-lowering drugs|A combination of at least 3 topical IOP-lowering drugs will be administered during a run-in phase before treatment and should be kept unchanged until IOP evaluation at Week 1, after which they may be reduced according to the investigator's opinion
223837811|NCT01760655|DRUG|Fludarabine phosphate|Given IV
223837812|NCT01760655|DRUG|Busulfan|Given IV
223837813|NCT01760655|RADIATION|Total-Body Irradiation|Undergo TBI
223837814|NCT01760655|BIOLOGICAL|Therapeutic Allogeneic Lymphocytes|Undergo DLI
223837815|NCT01760655|DRUG|Cyclophosphamide|Given IV
223837816|NCT01760655|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic PBSCT
223837817|NCT01760655|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo allogeneic PBSCT
223837818|NCT01760655|DRUG|Tacrolimus|Given IV
223837819|NCT01760655|DRUG|Mycophenolate Mofetil|Given IV
223837820|NCT01760655|OTHER|Laboratory Biomarker Analysis|Correlative studies
223837821|NCT04078100|PROCEDURE|Transseptal approach.|surgical approach to the mitral valve through the Fossa Ovalis by way of the right atrium.
223837822|NCT03701425|DIETARY_SUPPLEMENT|Mediterranean diet and exercise plan|"Mediterranean diet:~Diet: according to the definition, with the following distribution of macro nutrients:~Protein contribution 0.8-1.2 Carbon Hydrates 45-50% Lipids 30%"
223837823|NCT05599633|DIETARY_SUPPLEMENT|Sago starch drink|Sarawak sago starch drink will be provided by CRAUN throughout the study. The starch drink will be supplied in sealed aluminium sachets. Each sachet contains 25g of study starch with cocoa flavouring.
223837824|NCT05599633|DIETARY_SUPPLEMENT|Corn starch drink|Corn starch drink will be provided by CRAUN throughout the study. The starch drink will be supplied in sealed aluminium sachets. Each sachet contains 25g of study starch with cocoa flavouring.
223837825|NCT02459587|BEHAVIORAL|Crisis Line Facilitation (CLF)|This single session therapist-delivered intervention addresses Veterans' perceived barriers and facilitators of crisis line use during periods of suicidal crisis. The CLF session culminates with the Veteran calling the Crisis Line with the therapist in the room as a way for the Veteran to practice the logistics of making the call and to have direct experiences that may counter any negative beliefs about Crisis Line use.
223837826|NCT02459587|BEHAVIORAL|Enhanced Usual Care (EUC)|Those in the EUC condition received the same promotional items and information about the Veterans Crisis Line (VCL) as the CLF condition. Participants were encouraged to seek help via a provider or the VCL if they felt suicidal in the future. Research staff briefly explained key information about the VCL to those in the EUC condition (e.g., the links between the VCL and the VA, the 24/7/365 availability, etc.).
223837827|NCT02719951|DRUG|[18F]FPEB PET imaging|PET exam
223837828|NCT02719951|OTHER|Biological samples|blood sample and urine sample
223837829|NCT02719951|OTHER|MRI|MRI exam
223837830|NCT02485353|DRUG|Vosaroxin and Cytarabine|
223837831|NCT06011967|OTHER|Intubation using C-MAC D blade videolariyngoscope|all patients were intubated using the C-MAC D-Blade videolaryngoscope but for each group the intubation tubes were angled in different degrees. First group was intubated using the stylet of 60 degrees, second group was intubated using the stylet of 80 degrees and the third group was intubated using the stylet of 90 degrees.
223837832|NCT02883504|PROCEDURE|Echo-Doppler examination and left heart catheterization|
223837833|NCT01021332|DRUG|tamsulosin hydrochloride/solifenacin succinate fixed dose combination (0.4 mg/6 mg)|oral
223837834|NCT01021332|DRUG|tamsulosin hydrochloride/solifenacin succinate fixed dose combination (0.4 mg/9 mg)|oral
223837835|NCT01746394|BEHAVIORAL|Parents as Teachers Enhanced|Participants will receive the same monthly Parents as Teachers (PaT) lessons and materials at each home visit as the PaT arm. Additionally, these mothers will receive the enhanced nutrition and physical activity lessons and materials which will follow the family well-being format of the PaT lessons. The StartSmart lessons will focus on healthy gestational weight gain, diet, physical activity, breastfeeding, weight management, healthy eating, food shopping, meal preparation, physical activity, proper infant feeding, and infant activity time.
224078757|NCT01960322|BEHAVIORAL|Telemetric|A manualized behavioral management approach focusing on avoidance and addressing barriers to adherence, delivered via telephone or internet chat applications.
223837836|NCT01746394|BEHAVIORAL|Parents as Teachers|Participants will receive monthly Parents as Teachers (PaT) lessons and materials at each home visit. The Parent Educator will first connect with the mother by discussing or reviewing content from the prior visit; reflect on the mother's experience with continuing the parent-child activity from the prior visit; and agree on what will happen during the current visit. For the lesson plan, the Parent Educator will cover the following three areas using discussion, activities, and handouts: parent-child interaction, develop-centered parenting, and family well-being. In closing, the Parent Educator will review and evaluate the visit, talk about the mother's next step, and plan for the next visit.
223837837|NCT01358916|OTHER|Mailing of antibiotic therapy guidelines to the sentinel physicians|Mailing of antibiotic therapy guidelines to the sentinel physicians and regular feedback on antibiotic prescription
223837838|NCT06297096|DRUG|Tocilizumab|Tocilizumab 162 mg s.c./week
223837839|NCT06297096|DRUG|Nintedanib|Nintedanib - established doses of nintedanib for adults in the treatment of ILD, also SSc-ILD: 2 x 150 mg daily, in the event of e.g. increased liver enzyme levels, poorer treatment tolerance (e.g. diarrhea), the dose can be reduced to 2 x 100 mg
223837840|NCT06297096|DRUG|Standard therapy|mycophenolate mofetil stable dose from 1000 - 3000 mg daily tablet 500 mg or 250 mg regardless of the preparation (Mycofit, CellCept, Mycophenolate mofetil, Myfenax) or methotrexate 10-25 mg/week orally or subcutaneously as above, regardless of the preparation
223837841|NCT06109259|DRUG|DWJ1567|One tablet of DWJ1567
223837842|NCT06109259|DRUG|DWC202312|One tablet of DWC202312
223837843|NCT04489784|DEVICE|Infrared Laser|An aluminum gallium arsenide (AlGaAs) diode laser device (Twin laser, MMOptics, São Carlos, SP, Brazil) was used. The irradiation parameters were as follows: infrared laser (808 nm wavelength) with a spot area of 0.04 cm2, and an average optical power of 100 mW operated in a continuous mode during 1 minute per point, leading to an irradiance of 2,500 mW/cm2, energy of 6 J and fluence of 125 J/cm2 per point. The laser was applied on ballerina's feet twice a week during three months.
223837844|NCT05845073|DIETARY_SUPPLEMENT|Probiotic|Participants in this arm will receive a daily dose of 2x10\^9 Colony Forming Units (CFU) of a multi strain probiotic (live bacterium), corresponding to 2 capsules twice daily, for the duration of antibiotic therapy, and 14 days thereafter.
223837845|NCT05845073|DIETARY_SUPPLEMENT|Placebo|Participants in this arm will receive an equivalent placebo for for the duration of antibiotic therapy, and 14 day thereafter.
223837846|NCT04744662|DRUG|ONL1204 Ophthalmic solution|Liquid formulation administered by intravitreal (IVT) injection
223837847|NCT04744662|PROCEDURE|sham injection|sham injection is done by touching the eye surface with a syringe without a needle
223837848|NCT00234559|DEVICE|VAC® Therapy System|
223837849|NCT05636436|BIOLOGICAL|Low Dose Recombinant Herpes Zoster Vaccine (CHO cells)|0.5 mL per dose, containing a total of 50 µg recombinant varicella zoster virus glycoprotein E, adjuvanted with low dose MA105.
223837850|NCT05636436|BIOLOGICAL|High Dose Recombinant Herpes Zoster Vaccine (CHO cells)|0.5 mL per dose, containing a total of 50 µg recombinant varicella zoster virus glycoprotein E, adjuvanted with high dose MA105.
223837851|NCT05636436|BIOLOGICAL|Low dose adjuvant|0.5 mL per dose, containing low dose MA105 adjuvant.
223837852|NCT05636436|BIOLOGICAL|High dose adjuvant|0.5 mL per dose, containing high dose MA105 adjuvant.
223837853|NCT05636436|BIOLOGICAL|Positive control|0.5 mL per dose, containing a total of 50 µg recombinant varicella zoster virus glycoprotein E, adjuvanted with AS01B.
223837854|NCT05636436|BIOLOGICAL|Placebo|0.5 mL per dose, containing 4.5 mg sodium chloride.
223837855|NCT04731714|DEVICE|Rhythmic median nerve stimulation|Square-wave 200 µs pulses triggered by computer at 12 Hz, at the threshold for thumb movement (expected \~2-15mA), applied to surface electrodes over the median nerve at the right wrist (conductive gel, 30 mm apart center-to-center, anode distal). This is a non-significant risk device study.
223837856|NCT04731714|DEVICE|Arrhythmic median nerve stimulation|Square-wave 200 µs pulses triggered by computer at random intervals with a mean rate of 12 Hz (as described in Morera Maiquez et al., 2020), at the threshold for thumb movement (expected \~2-15mA), applied to surface electrodes over the median nerve at the right wrist (conductive gel, 30 mm apart center-to-center, anode distal). This is a non-significant risk device study.
223837857|NCT03487666|DRUG|Nivolumab|Nivolumab is a human programmed death receptor-1 (PD-1) antibody currently approved in different diseases.
223837858|NCT03487666|DRUG|Capecitabine|Capecitabine was selected for Arm B given the recent results from CREATE-X trial and the increasing use by the community (feasibility). Importantly, available data from other scenarios indicates that capecitabine does not have immunosuppressive effects
223837859|NCT06434051|OTHER|Traditional Chinese cervical manipulation|The CMP will first palpate the transverse processes of C1 and C2. The transverse process with apparent tenderness will be regarded as the pain side. The right side will be the painful side for the following example). During the manipulation, the CMP will use his left hand to support the lower jaw and passively rotate the neck to the left side by 70-75 degrees (or to the maximum angle without discomfort). The physician's right-hand fingers will support the left-side transverse processes of C1 and C2, and the thumb and thenar muscle will be placed on the spinous process and occipital area. While maintaining a passive left neck rotation, the physician will increase the rotation angle by 5-10 degrees with both hands under a sudden pulling force. The above procedure will be repeated on the right side (pain side).
223837860|NCT06434051|OTHER|Sham manipulation|The posture and position of the participant and the practitioner and the procedure are the same as the CCM technique. The right side will be regarded as the pain side once again. When performing the sham technique, the CMP uses the left hand to support the lower jaw position and passively rotates the neck to the left side by 70-75 degrees or to the maximum angle. The right hand presses the upper inner corner of the right scapula. While maintaining the passive left rotation of the neck, the right hand slowly exerts force downwards and outwards on the inner side of the scapula. The left hand only maintains the left rotation of the neck without any pulling force. After completion, repeat the above actions on the right side. After the technique is completed, participants can get up after resting for 5-10 minutes.
223837861|NCT04758403|RADIATION|Navigation Bronchoscopy|Navigation Bronchoscopy procedure will be performed per product instructions and the institution's standard practice.
223837862|NCT04758403|RADIATION|Cone beam computed tomography (CBCT)|Per Protocol
223837863|NCT04545593|BEHAVIORAL|Positive Minds Strong Bodies Enhanced|The Positive Minds Strong Bodies Enhanced intervention (PMSB-E) was designed to provide a single, integrated program that could address the dual challenges of mental health and disability among minority elders. PMSB-E seeks to improve mood symptoms, identify and correct negative distortions or cognitions, promote behavioral activation through engaging the participant in pleasant activities, and encourage developing supportive relationships. All sessions are tailored to the participant's needs using a collaborative approach.
223837864|NCT04545593|BEHAVIORAL|Enhanced Usual Care|Participants in this arm will receive a booklet about anxiety and depression in Spanish, English, or Mandarin/Cantonese. Research staff will call the participant 4 times over the course of 6 months to administer mental health items, a suicide questionnaire, and a question about medication side effects to mimic the administration schedule in the intervention group.
223837865|NCT06299605|DRUG|Vonoprazan-Amoxicillin-Tetracycline-Bismuth quadruple regimen for 14 days|Vonoprazan 20mg bid + Amoxicillin 1000mg bid + Tetracycline 500mg qid + Bismuth 220mg bid for 14 days
223837866|NCT06299605|DRUG|Vonoprazan-Amoxicillin-Tetracycline triple regimen for 14 days|Vonoprazan 20mg bid + Amoxicillin 1000mg bid + Tetracycline 500mg qid for 14 days
223837867|NCT06299605|DRUG|Vonoprazan-Amoxicillin-Tetracycline triple regimen for 7 days|Vonoprazan 20mg bid + Amoxicillin 1000mg bid + Tetracycline 500mg qid for 7 days
223837868|NCT05343455|DRUG|DFD-29|DFD-29 (40 mg) extended release capsules
223837869|NCT05343455|DRUG|Doxycycline|Doxycycline 40 mg capsules
223837870|NCT05343455|DRUG|Placebo|Placebo capsules
223837871|NCT05929807|DRUG|TransCon CNP|TransCon CNP drug product is a lyophilized powder in a single-use vial. Prior to use, the lyophilized powder is reconstituted with sterile water for injection and administered by subcutaneous injection via syringe and needle.
223837872|NCT04600180|PROCEDURE|sigmoidoscopies and and venous blood sampling|Sigmoidoscopies will be performed at baseline and during immunotherapy. During these procedures biopsies will be taken from the sigmoid and rectum. At the same timepoints, venous blood samples will be taken.
223837873|NCT04411940|DRUG|Haloperidol Tablets, Mylan Pharmaceuticals Inc.|single dose, 2 mg Haloperidol tablet
223837874|NCT04411940|DRUG|Haloperidol Tablets, Cycle Pharmaceuticals Ltd|single dose, 2 mg Haloperidol tablet
223837875|NCT05061771|DRUG|nomacopan (rVA576)|Nomacopan an inhibitor of complement C5 and LTB4
223837876|NCT05061771|OTHER|Placebo|Placebo
223837877|NCT06121791|OTHER|Normal values of abdominal level muscle areas of Turkish children|age, sex, L3-L4 LEVEL: Psoas muscle area, Paraspinal muscle area, Abdominal muscle area, L4-L5 LEVEL: Psoas muscle area, Paraspinal muscle area, Abdominal muscle area
223837878|NCT05138796|DRUG|TP-05 (lotilaner oral capsules)|TP-05 (lotilaner oral capsules)
223837879|NCT05138796|DRUG|Placebo|Placebo to match TP-05 (lotilaner oral capsules)
223837880|NCT00002896|DRUG|chemotherapy|
223837881|NCT00002896|DRUG|fluorouracil|
223837882|NCT00002896|DRUG|leucovorin calcium|
223837883|NCT00002896|PROCEDURE|conventional surgery|
223837884|NCT00002896|RADIATION|low-LET cobalt-60 gamma ray therapy|
223837885|NCT00002896|RADIATION|low-LET photon therapy|
223837886|NCT03498040|OTHER|Study of the occurrence of Carcinoid Heart Disease|"Patient at high risk of Carcinoid Heart Disease (metastatic ileum or bronchial well-differentiated neuroendocrine tumors, patients with high level of urinary 5HIAA or with carcinoid syndrome) are followed with annual echocardiography to detect the occurrence of carcinoid heart disease.~In case of documented Carcinoid Heart Disease, a six or three months' cardiac follow-up is necessary to evaluate the progression and the severity of the disease.~Investigators collect the data of clinical parameters (flushes, diarrhea, …) biological parameters (urinary 5HIAA, NT-ProBNP …) and cardiac parameters that may influence the occurrence, severity and progression of Carcinoid Heart Disease."
223837887|NCT04864496|DRUG|Prescribe N-acetylcysteine tablets|N-acetylcysteine tablets ,1200 mg two times daily
223837888|NCT04864496|DRUG|Prescribe placebo tablets|manufactured by Daroo Salamat Pharmed, two times daily
223837889|NCT04761419|BEHAVIORAL|Parents' longer presence beside their infant|They are not intervention. We will collect data about these items.
223837890|NCT02722941|DRUG|Panobinostat|Maintenance therapy dosing as outlined in Cohorts A and B.
223837891|NCT04223596|DRUG|Brigatinib|Brigatinib 90 mg for the first 7 days (D1-7 at cycle 1) and then 180 mg daily thereafter for QW4 cycles of duration (28 days+-3 days)
223837892|NCT04171726|DRUG|Edoxaban|A non-vitamin K antagonist (VKA) oral anticoagulant that selectively inhibits factor Xa.
223837893|NCT00027768|PROCEDURE|adjuvant therapy|
223837894|NCT00027768|RADIATION|iodine I 131 ethiodized oil|
223837895|NCT00003928|DRUG|cisplatin|Cisplatin IV over 60 minutes on day 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
223837896|NCT00003928|DRUG|gemcitabine hydrochloride|Gemcitabine IV over 30 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
223837897|NCT02510066|DEVICE|Acupuncture|Disposable stainless steel filiform needles (40mm in length and 0.30mm in diameter) are inserted perpendicularly into T8-T12 Jiaji (Ex-B2) points bilaterally to a depth of 25 mm. After De Qi sensation is achieved, the handles of needles on homolateral T8 and T12 Jiaji are respectively connected to the Han's acupoint nerve stimulator at a frequency of 2/100 Hz and a current of 1mA with a disperse-dense waveform for 30 minutes.
223837898|NCT02510066|DEVICE|Placebo acupuncture|Placebo acupuncture needles (Dongbang AcuPrime Acupuncture Inc., South Korea) are used on the non-point points at the same level as T8 and T12 Jiaji, 4.5 cun lateral to the posterior median line. The needles with blunt tips are quickly put onto points without inserting into the skin. The needles on homolateral points at the same level as T8 and T12 Jiaji are then connected to the electric stimulator, but with zero frequency and electric current.
223837899|NCT01212263|DRUG|Step-up HP u FSH|HP u FSH (Fostimone 75 IU ,IBSA Institut Biochimique SA-CH 6903 Lugano) in doses of 37.5 IU (half ampole) im /day statrted from second day of the cycle for 7 days ,then increased to 75 IU for another 7 days ,then to 112.5 IU (one and half ampoule) untilleading follicle mean diameter reaches 18 mm
223837900|NCT01212263|DRUG|Clomiphine citrate plus low dose uFSH|Clomiphene citrate 50 mg tab oral tablets(Clomid 50 mg tablets Global Napi , Egypt) two tablets(100 mg) /day are started from the 2nd day of cycle for 5 days togeteher with 37.5 IU HP uFSH (Fostimone 75 IU IBSA)/day for 8 days and may be extended to 10-12 days until leading follicle diameter reaches 18 mm
223837901|NCT02451904|OTHER|Observation|
223837902|NCT06526208|DRUG|MB-IMP|MB-IMP is a marijuana-based investigational medical product. It contains a 23:1 ratio of CBD to THC, is an oil-based tincture that is taken orally.
223837903|NCT06526208|OTHER|Placebo|Does not contain CBD or THC
223837904|NCT05441475|DRUG|ABSK-011 180 mg QD combined with atilizumab 1200 mg q3w|All subjects will receive continuous oral administration of absk-011 once a day (QD) or twice a day (bid) with an initial dose of 180 mg, and intravenous infusion (IV) of 1200 mg of atilizumab every 21 days (q3w).
223837905|NCT05149079|DIETARY_SUPPLEMENT|Cod protein hydrolysate|Rest raw materials (RRM) from cod (Fjordlaks AS, Norway) are used for the hydrolysis production (Food Grade). Freshly minced RRM is treated wth enzymes optimized to generate bioactive hydrolysates using facilities and techniques approved for human consumption.
223837906|NCT05149079|DIETARY_SUPPLEMENT|Placebo|Whey protein powder, commercially available
223837907|NCT02977975|OTHER|Raw sauerkraut|Sauerkraut fermentations have been shown to contain a broad range of microorganisms, including Leuconostoc mesenteroides, Lactobacillus plantarum, Leuconostoc citreum, Leuconostoc argentinum, Lactobacillus paraplantarum, and Lactobacillus coryniformis. Some of these bacteria, such as Lactobacillus plantarum, are classified as probiotics.
223837908|NCT02977975|OTHER|Pasteurized sauerkraut|Sauerkraut without live bacteria.
223837909|NCT03826212|DIETARY_SUPPLEMENT|Soybean Germ Extract|Soybean Germ Extract 1,600 mg/day for 12 weeks.
223837910|NCT03826212|DIETARY_SUPPLEMENT|Placebo|Placebo 1,600 mg/day for 12 weeks.
223837911|NCT03589924|PROCEDURE|Immediate IBBR+TiLoop®Bra|Patients will receive immediate implant reconstruction following mastectomy using TiLoop®Bra
223837912|NCT03589924|PROCEDURE|Immediate-delayed IBBR+TiLoop®Bra|Patients will receive immediate-delayed implant reconstruction following mastectomy using TiLoop®Bra
223837913|NCT02748512|DRUG|FAI Insert administered using the Mk II inserter|
223837914|NCT02748512|DRUG|FAI Insert administered using the Mk I inserter|
223837915|NCT03344614|DRUG|raltitrexed combined with apatinib|raltitrexed, 3 mg/㎡, ivgtt, d1, apatinib 500 mg, QD po, d1-21, Every 3 weeks for 1 cycles
223837916|NCT02990728|DRUG|Metformin|The enrolled patient is allocated to either LNG-IUS only or LNG-IUS + metformin by central randomization with study site allocation. A 90-100 days of continuous treatment before first histologic assessment of treatment response is required. The patient will receive endometrial curettage or hysteroscopic evaluation and resection of suspected lesion after 90-100 days of treatment. Patients with good response to assigned treatment will continue the treatment for another 90-100 days and second histologic assessment will be performed. Patients with poor response to assigned treatment at first assessment will receive additive oral progestin therapy, along with the assigned regimen(s) as, Oral progestin, either medroxyprogesterone acetate 500 mg daily or oral megestrol acetate 160 mg daily After a total of at least 6 months treatment period, the patient with good response at first assessment is suggested to keep the Mirena for maintenance until plan to get pregnant
223837917|NCT02990728|DEVICE|Mirena®|
223837918|NCT04012320|OTHER|No intervention, observational study|No intervention, observational study
223837919|NCT00787943|DRUG|Topical benzoyl peroxide 10.0% cream - Formulation 1|Formulation 1 will be applied to the randomly-assigned single (left or right) side of the face twice daily.
223837920|NCT00787943|DRUG|Topical benzoyl peroxide 10.0% cream - Formulation 2|Formulation 1 will be applied to the randomly-assigned single (left or right) side of the face twice daily.
223837921|NCT05034575|OTHER|Eye Tracking Technology Sensor|Eye tracking will be performed using Tobii Pro eye tracking technology sensor (Tobii Pro Fusion, Stockholm, Sweden), providing binocular eye tracking up to 250 Hz. The sensor, positioned on the inferior aspect of the computer monitor, reflects infrared (IR) light beams off of each cornea and are subsequently captured.
223837922|NCT05830461|BEHAVIORAL|Online psychological care program to reduce psychological distress in women who attend a breast clinic|"The intervention will be online and self-applied. It will consist of 3 stages, according to the patient's situation: 1) without suspicion of cancer (A1), 2) with suspicion of cancer (A2), and 3) with confirmed diagnosis of cancer (B).~Stage 1 includes modules related to the prevention and timely detection of breast cancer. Stage A2 consists of emotional management in the face of suspicion of breast cancer. In stage B, medical information about breast cancer is provided, as well as psychological strategies to face the diagnosis.~Psychological techniques based on the cognitive behavioral model, mindfulness, acceptance and commitment therapy, and health beliefs are included."
223837923|NCT05830461|BEHAVIORAL|Psychological care program to reduce psychological distress in women who attend a breast clinic|"The intervention will be delivered through printed materials. It will consist of 3 stages, according to the patient's situation: 1) without suspicion of cancer (A1), 2) with suspicion of cancer (A2), and 3) with confirmed diagnosis of cancer (B).~Stage 1 includes modules related to the prevention and timely detection of breast cancer. Stage A2 consists of emotional management in the face of suspicion of breast cancer. In stage B, medical information about breast cancer is provided, as well as psychological strategies to face the diagnosis.~Psychological techniques based on the cognitive behavioral model, mindfulness, acceptance and commitment therapy, and health beliefs are included."
223837924|NCT04003311|DEVICE|Comprehensive Primary Micro Stem|Patients that have been implanted with the Comprehensive Primary Micro Stem to repair shoulder malfunction/disease.
223837925|NCT04003311|DEVICE|Comprehensive Anatomic Versa-Dial Titanium Humeral Head|Patients that have been implanted with the Comprehensive Anatomic Versa-Dial Titanium Humeral head to repair shoulder malfunction/disease.
223837926|NCT01314092|BIOLOGICAL|Autologous cultured adipose derived stem cells(low dose group)|low dose group: 1x10e7 cells/mL At 6 weeks after first stem cell injection, fistula closing was assessed. If it is not completely closed, second injection would be applied in 2 weeks. Additional dosage would be doubled to first dosage.
223837927|NCT01314092|BIOLOGICAL|Autologous cultured adipose derived stem cells(high dose group)|high dose group: 2x10e7 cells/mL At 6 weeks after first stem cell injection, fistula closing was assessed. If it is not completely closed, second injection would be applied in 2 weeks. Additional dosage would be doubled to first dosage.
223837928|NCT00298935|PROCEDURE|Osteopathic manipulative treatment (OMT)|
223837929|NCT02585310|OTHER|Packed red blood cell transfusion|Record number of PRBC transfusion during perioperative period.
223837930|NCT00950209|DIETARY_SUPPLEMENT|saline infusion|"In the first step of the protocol, all the patients will have a kinetic study of the TRL-apoB48 in conditions of a saline infusion to measure the basal production and clearance rates of the TRL-apoB48"
223837931|NCT00950209|OTHER|euglycaemic hyperinsulinic clamp|an euglycaemic hyperinsulinic clamp to maintain plasma glucose around 1g/l
223837932|NCT00950209|DIETARY_SUPPLEMENT|infusion of Endolipide and heparin|an infusion with Endolipide 20 % (12,5 ml/h) and heparin (250 U/h) to prevent the suppressive effect of insulin on plasma free fatty acids
223837933|NCT00950209|OTHER|hyperglycaemic hyperinsulinic clamp|a hyperglycaemic hyperinsulinic clamp to maintain plasma glucose around 2 g/l to prevent the decreasing effect of insulin on plasma glucose.
223837934|NCT06367062|OTHER|MRI|MRI is used to assess of brain development.
223837935|NCT04415593|DIETARY_SUPPLEMENT|High dose of peanuts|Patients will receive a high dose of ground peanuts (300 mg) mixed with apple mousse (supposing child tolerates apple). For the transparency of the study all patients will receive the same commercially prepared apple product
223837936|NCT04415593|DIETARY_SUPPLEMENT|Low dose of peanuts|Patients will receive a low dose of ground peanuts (150 mg) mixed with apple mousse (supposing child tolerates apple). For the transparency of the study all patients will receive the same commercially prepared apple product
223837937|NCT04066543|DEVICE|TACE|The modified Seldinger puncture was used to puncture the cutaneous-femoral artery, insert the catheter and perform hepatic artery angiography. The location, morphology and blood supply of liver tissue lesions were comprehensively understood. The use of chemotherapeutic drugs and the dosage of iodized oil as the embolic agent were determined according to the general situation. The catheter was injected into the supply vessel of the tumor, and 5-FU and adriamycin were injected according to the situation. The embolic agent was injected with iodized oil as carrier, mixed with chemotherapeutic drugs at the same time, and then assisted with gelatin sponge for embolization. Antiemetic drugs were given before treatment and hepatoprotective drugs were given after operation. Until the disease progresses.
223837938|NCT04066543|DRUG|Anlotinib Hydrochloride|Anlotinib hydrochloride capsule, according to the recommended dose, po, qd, continuous oral 2 weeks stop for 1 week, 3 weeks for a cycle.
223837939|NCT01837043|DRUG|Belatacept|
223837940|NCT01837043|DRUG|Calcineurin Inhibitor|
223837941|NCT03930186|DRUG|Apremilast|Tablets for oral administration
223837942|NCT03930186|DRUG|Topical Therapy|Participants continued to use their existing topical treatment for psoriasis for the first 16 weeks. After 16 weeks, participants could decrease the use of topical therapy at their discretion under the direction of their physician.
223837943|NCT06343961|PROCEDURE|Intraoperative Fluorescein Angiography|Targeted laser photocoagulation under the guidance of intraoperative fluoroscopy
223837944|NCT05471921|BEHAVIORAL|SBIRT|SBIRT is an evidence-based treatment for unhealthy alcohol and other drugs (AOD) use in non-humanitarian settings and can efficiently provide individuals with an appropriate level of care based on their symptoms. Participants randomized to SBIRT will receive an on-the-spot alcohol brief intervention (CETA-BI) and be categorized as low or moderate/high severity using the AUDIT scale. Participants who are moderate/high severity will be connected to a counselor and will begin full CETA treatment. CETA is a transdiagnostic approach that combines motivational interviewing with cognitive behavioral therapy to assist clients in considering changing their rates of AOD use. The intervention lasts 30-40 minutes and consists of 6 components including 1) screening; 2) identifying the impacts of unhealthy AOD use; 3) talking about change/goal-setting; 4) understanding the primary reason for drinking; 5) skill-building; and 6) referral for services.
223837945|NCT05471921|BEHAVIORAL|Treatment as usual|Mantapala health workers and supervisors were trained in mental health gap action program-humanitarian intervention guide (mhGAP-HIG), which is a mental health service provision guide for use in humanitarian settings; this training was led by staff from United Nations High Commissioner for Refugees. This training did not include evidence-based psychological interventions (e.g., CETA). Participants randomized to TAU will be referred to the existing services that exist in the health clinic located in Mantapala refugee settlement. More specialized services are referred to the District Hospital in Nchelenge.
223837946|NCT06273189|DEVICE|Conventional|In conventional group, contralateral side mandibular osteotomies were performed with Lindeman and round bur (Karl Storz, Tuttlingen, Germany)
223837947|NCT06273189|DEVICE|Bone Scalpel|In ultrasonic device group, osteotomies one side of the mandible were performed unilaterally using an ultrasonic bone scalpel (BoneScalpel; Misonix, Farmingdale, NY) with a serrated standard blade
223837948|NCT00938899|DRUG|TMC435350; Placebo|
223837949|NCT04576195|OTHER|Real PENS|"The technique will be performed ultrasound-guided on the radial nerve, the places of the needle's insertions will be the following:~Needle will be placed at under the lateral intermuscular septum between the triceps brachii and brachialis, approximately 10cm superior to the lateral epicondyle Needle will be placed at the upper third of the forearm on the posterior interosseous nerve after passing the arcade of Frohse's~The percutaneous electrical stimulation will be realized with a transcutaneous electric nerve stimulation (TENS) current:~TENS Frequency 2 Hz TENS Pulse width - 250 microseconds Duration - 30 minutes. TENS Intensity - Increased at an intensity of visible motor response of the innervated musculature and maximal tolerable intensity.~Administration - One single session."
223837950|NCT04576195|OTHER|Sham PENS|"The technique will be performed ultrasound-guided on the radial nerve, the places of the needle's insertions will be the following:~Needle will be placed at under the lateral intermuscular septum between the triceps brachii and brachialis, approximately 10cm superior to the lateral epicondyle Needle will be placed at the upper third of the forearm on the posterior interosseous nerve after passing the arcade of Frohse's~The electrical current will not be working, and the needles will be placed during 30 minutes:~\- Administration - One single session"
223837951|NCT04187911|BEHAVIORAL|Dyadic Developmental Psychotherapy (DDP)|DDP involves approximately twenty 1 hour sessions (usually over 6-9 months) with the adoptive parent/foster carer and child, facilitated by a specifically trained therapist. The role of the therapist during sessions is to maintain an attuned relationship with both child and parent - modelling and encouraging development of a similarly attuned relationship between the child and parent. Therapists are trained to use Playfulness, Acceptance, Curiosity and Empathy (PACE). Our research suggests that key mechanisms of action in DDP might include the active participation of the parents and increased carer empathy and emotional warmth for the child. DDP experts believe this helps build parental capacity for attuned dialogue with the child, co-creation of the meanings underlying child behaviour, and co-regulation of experienced emotions aiming to address four main problem areas: 1. child emotional regulation 2. parental stress 3. the parent-child relationship 4. child mental health.
223837952|NCT04187911|BEHAVIORAL|Services as Usual (SAU)|"SAU tends to be case-dependent with therapists and social workers attempting to respond to the sometimes changeable needs of the family as needs arise. At the time of our UK mapping and modelling work, these services were usually CAMHS based. This may have changed, at least for adoptive families, with the advent of the Adoption Support Fund, which, since May 2015, has allowed local authorities / adoption agencies to apply for funding for essential therapeutic services. A wide range of interventions, many with a scant evidence base, have been purchased - sometimes from private practitioners - since 2015. In addition, relevant NICE guidelines, particularly those on Looked After and Accommodated Children, Attachment and Child Abuse and Neglect, have been published or updated.Our detailed qualitative and quantitative process evaluation throughout all study Phases will be crucial to carefully characterise SAU in all study sites."
223837953|NCT00379249|DRUG|Rosuvastatin|
223837954|NCT01639274|OTHER|COPD prevalence|Determine prevalence of COPD
223837955|NCT02033993|DRUG|Nab-Paclitaxel|
223837956|NCT02033993|DRUG|Paclitaxel|
223837957|NCT03140293|DRUG|Lidocaine injection|Injectable anesthesia is 1-2mL of 2% lidocaine via a 22 gage needle, given at the anticipated site of CVS needle puncture immediately before procedure.
223837958|NCT03140293|DRUG|Gebauer Ethyl Chloride Spray|Gebauer Ethyl Chloride Spray is a topical anesthetic spray which is sprayed continuously for 3-7 seconds from a distance of 3-9 inches at the site where the chorionic villus sampling is expected to take place.
223837959|NCT04302090|OTHER|Regulated expiratory method|This method was originally a postpartum abdomino-perineal rehabilitation technique. It allows a functional abdominal rehabilitation by combining a regulated breath in a specific mouthpiece and an abdominal stimulation triggered by this same breath. The use of this method was extended to labor and childbirth. In fact, the application of the method during labor is based on the use of a flow regulating device (Winner Flow + URO-MG®). By regulating the flow of breath during a uterine contraction, it allows better pain management.
223837960|NCT00507611|PROCEDURE|Sentinel node mapping|Patients will undergo preoperative lymphoscintigraphy in the nuclear medicine department to access axillary and extra-axillary sites of localization. Intraoperatively, patients will also be injected with approximately 4 to 5 mL of 1% isosulfan blue dye (by intradermal, intraparenchymal, or subareolar route). Patients will undergo intraoperative identification and biopsy of all SLN candidates. A confirmatory axillary lymph node dissection will then be performed on all patients.
223837961|NCT00375128|BIOLOGICAL|FP9-PP (FP9 polyprotein)|
223837962|NCT00375128|BIOLOGICAL|MVA-PP (Modified Virus Ankara polyprotein)|
223837963|NCT05173493|DRUG|Amoxicillin,Furazolidone|Amoxicillin-Furazolidone-containing quadruple group
223837964|NCT05173493|DRUG|Amoxicillin,Levofloxacin|Amoxicillin-Levofloxacin-containing quadruple group
223837965|NCT05173493|DRUG|Tetracycline,Furazolidone|Tetracycline-Furazolidone-containing quadruple group
223837966|NCT05665309|PROCEDURE|3D anatomical model of aneurysm|Surgery prepared with 3D anatomical model of aneurysm
223837967|NCT00926965|DRUG|amisulpride|amisulpride tablet 100-1200mg/day for 24 months
223837968|NCT00926965|DRUG|Olanzapine|Olanzapine tablet 2.5 to 30 mg/day for 24 months
223837969|NCT00926965|DRUG|Conventional antipsychotics|the subjects were randomized to the conventional antipsychotic group to maintain their original conventional antipsychotics
223837970|NCT00003431|BIOLOGICAL|recombinant flt3 ligand|
223837971|NCT02264574|DRUG|Ibrutinib|Ibrutinib will be supplied as 140 mg hard gelatin capsules for oral (PO) administration.
223837972|NCT02264574|DRUG|Obinutuzumab|Obinutuzumab will be supplied as 1000 mg/40 mL solution in a single-use vial for intravenous (IV) administration
223837973|NCT02264574|DRUG|Chlorambucil|Chlorambucil will be supplied as 2 mg film-coated tablets for oral (PO) administration
223837974|NCT02181959|DRUG|Pharmaton® with DMAE|
223837975|NCT02181959|DRUG|Pharmaton® without DMAE|
223837976|NCT02181959|DRUG|Placebo|
223837977|NCT04621071|DIETARY_SUPPLEMENT|Probiotics (2 strains 10x10^9 UFC)|Probiotic vs Placebo (1:1)
223837978|NCT04621071|DIETARY_SUPPLEMENT|Placebo (potato starch and magnesium stearate)|Probiotic vs Placebo (1:1)
223837979|NCT02622425|DIETARY_SUPPLEMENT|Placebo|maltodextrin
223837980|NCT02622425|DIETARY_SUPPLEMENT|PD01|Carotenoid-producing Bacillus strain PD01
223837981|NCT02521259|DEVICE|BIS|BIS monitoring provides the patient's depth of consciousness, enables us to monitor safe, optimal anesthesia for each patient.
223837982|NCT05719636|OTHER|Conventional treatment|Conventional protocol that involves simple active and passive range of motion exercises of lower limb with positioning for assistive devices was provided
223837983|NCT05719636|OTHER|Progressive resistance exercise|The protocol that was applied on the members of (experimental group) are progressive resistance exercises. These passive resistance exercises included Flexion, Extension, Abduction, Adduction of hip; Flexion, Extension of knee; with minimum time in start and minimum quantity of loads, with Thera bands and sandbags,.
223837984|NCT01244009|DRUG|MK-4827|MK-4827 will be administered daily as an oral formulation in continuous 21-day cycles.
223837985|NCT03454932|OTHER|Blood sampling|
223837986|NCT02900911|OTHER|Early rehabilitation|"Early swallowing exercises and respiratory muscle training: Standard swallow therapy and instructions for training submental muscles involved in swallowing function and expiratory strength starting 2 weeks before radiotherapy~Expiratory/Inspiratory training: the training load is the maximum inspiratory/expiratory load defined according to patient tolerance. This load will be equivalent to 10 maximal repetitions (RM) as 10 consecutive inspirations (x 5 sessions), three times a day.~All sessions will be conducted under the supervision of an expert physiotherapist/swallowing therapist. The total duration of the training program is 6 months."
223837987|NCT02900911|OTHER|Late rehabilitation|Late swallowing exercises and respiratory muscle training: Standard swallow therapy and instructions for training submental muscles involved in swallowing function and expiratory strength starting after completing radiotherapy
223837988|NCT00765661|DRUG|Tacrolimus (Tacro™)|"The initial dose at 0.14 mg/kg (daily dose for African-American is 0.17 mg/kg), oral in the morning (before noon) within 12 hours after transplantation. Subsequent doses adjusted to maintain a target tacrolimus trough level of 7 - 20 ng/mL for (PK) phase of the study (through Study Day 14). Post PK maintenance phase of the study and remain on assigned study drug until Study Day 360. Dose of study drug was adjusted to maintain tacrolimus trough levels between 5 - 20 ng/mL from Day 15 until Day 90 and then between 5 - 15 ng/mL for the remainder of the study according to local standard of care.~Other Names:~Tacrolimus modified-release"
223837989|NCT00765661|DRUG|Prograf|"Prograf® capsules, twice daily: Starting total daily dose of 0.10 mg/kg administered in two equally divided doses, morning and evening, per product labeling. Subsequent doses adjusted to maintain a target whole blood tacrolimus trough level of 7 - 20 ng/mL for the remainder of the pharmacokinetic (PK) phase of the study (through Study Day 14). Post PK patient enter the maintenance phase of the study and remain on assigned study drug until Study Day 360. Dose of study drug was adjusted to maintain tacrolimus trough levels between 5 - 20 ng/mL from Day 15 until Day 90 and then between 5 - 15 ng/mL for the remainder of the study according to local standard of care.~Other name: tacrolimus"
223837990|NCT01697137|BEHAVIORAL|Participant Video and Provider Cueing|Participants will watch a 5-minute video and then select a question about donation to discuss with their primary care provider (provider cueing).
223837991|NCT02593175|DRUG|Carboplatin|Given IV
223837992|NCT02593175|DRUG|Paclitaxel|Given IV
223837993|NCT02593175|BIOLOGICAL|Panitumumab|Given IV
223837994|NCT05874999|OTHER|Supramaximal High-Intensity Interval Training at 60% of MPO6|"Supramaximal HIIT is performed as 10×6 second intervals against a load of 60% of maximum mean power output for 6 seconds (MPO6) with a 54 second recovery between intervals. The MPO6 was estimated from the BCST.~Duration supramaximal HIIT: 10 minutes~Warm-up and cool-down: 5 minutes at 30% of maximum aerobic power (MAP) obtained during maximal incremental cardiopulmonary exercise test (CPET) on a stationary bicycle."
223837995|NCT05874999|OTHER|Moderate-Intensity Continuous Training|"MICT is performed against a load of 60% of MAP obtained during a maximal incremental CPET on a stationary bicycle.~Duration MICT: 20 minutes~Warm-up and cool-down: 5 minutes at 30% of MAP obtained during maximal incremental CPET on a stationary bicycle."
223837996|NCT05874999|OTHER|Supramaximal High-Intensity Interval Training at 80% of MPO6|"Supramaximal HIIT is performed as 10×6 second intervals against a load of 80% of MPO6 with a 54 second recovery between intervals. The MPO6 was estimated from the BCST.~Duration supramaximal HIIT: 10 minutes~Warm-up and cool-down: 5 minutes at 30% of MAP obtained during maximal incremental CPET on a stationary bicycle."
223837997|NCT01587833|DRUG|Benzodiazepine (BZD) use, defined by ATC codes|BZD prescription during the study period between January 1, 2001 and December 31, 2009
223837998|NCT00311792|BEHAVIORAL|LapSimGyn training until expert proficiency level is reached|Two consecutive simulations reaching predefined expert level
223837999|NCT00311792|BEHAVIORAL|Traditional clinical education|
223838000|NCT00641953|DRUG|IMX-150|(0.3%) 0.5g topically BID to each foot for 4 weeks
223838001|NCT00641953|DRUG|IMX-150|(0.6%) 0.5g topically BID to each foot for 4 weeks
223838002|NCT00641953|DRUG|Placebo|0.5 g topically BID to each foot for 4 weeks
223838003|NCT03219437|DRUG|risankizumab|subcutaneous (SC) injection
223838004|NCT03219437|DRUG|methotrexate|capsule
223838005|NCT03291275|OTHER|Follow-up for death and recurrence|All patients are followed up to determine definite date of diagnosis, recurrence and death.
223838006|NCT02354248|PROCEDURE|Triple stimulation technique|Evoked motor potentials obtained by magnetic transcranial stimulation are usually used, in standard practice, to evaluate the corticospinal tract. This procedure combines two techniques: the magnetic stimulation and the electroneuromyography. It is based on the double collision principle between the descending central stimulation (magnetic) and the ascending peripheric stimulation, hereby suppressing the issue of desynchronisation of evoked motor potentials. The Triple stimulation technique allows a better quantification of the proportion of motor units activated by the transcranial stimulation.
223838007|NCT05460130|BEHAVIORAL|Simplified Hepatitis C Virus (HCV) Treatment Protocol|A simplified, low-barrier, locally contextualized, HCV treatment protocol delivered by trained front-line health care providers (primary care physicians and mid-level providers) serving hard-to-reach-populations.
223838008|NCT02658721|DRUG|Lidocaine|
223838009|NCT02658721|DRUG|lidocaine+adjunct tramadol|IVRA was performed with 3 mg/kg lidocaine (10% Lidocaine) plus 50 mg tramadol, which were administered after diluting with saline to 40 mL. While performing IVRA, 30 mL saline was simultaneously administered to the systemic circulation
223838010|NCT02658721|DRUG|lidocaine+systemic tramadol|IVRA was performed with 3 mg/kg lidocaine, which was diluted with saline to 40 mL. While performing IVRA, 50 mg tramadol diluted with saline to 30 mL was simultaneously administered to the systemic circulation
223838011|NCT02658721|DRUG|Fentanyl|If the patient had a VAS score of \>4 and if required, 1 μg/kg fentanyl was administered for analgesia and the dosage and time were recorded.
223838012|NCT02658721|DRUG|Atropine|"The patients received premedication 45 min before the surgery with intramuscular 0.01 mg/kg atropine.~In case of bradycardia (HR \<50/min), 0.5 mg intravenous atropine was administered."
223838013|NCT02658721|DRUG|Midazolam|The patients received premedication 45 min before the surgery with intramuscular 0.07 mg/kg midazolam
223838014|NCT02658721|DRUG|Diclofenac sodium|The patients with a VAS score of \>4 were administered with 75 mg diclofenac sodium via intramuscular route.
223838015|NCT02658721|DRUG|Ephedrine|In the event of hypotension (systolic arterial pressure \<90 mmHg or a decrease of more than 50 mmHg from the normal value) during the surgery, 5 mg intravenous ephedrine was administered.
223838016|NCT02658721|DRUG|Ondansetron|Intravenous 4 mg ondansetron was administered for nausea and vomiting.
223838017|NCT06475599|DRUG|Anlotinib hydrochloride capsule + TQB2450 injection|"Anlotinib hydrochloride capsule is a multi-target tyrosine kinase inhibitor, which targets VEGFR (VEGFR-1, VEGFR-2 and VEGFR-3), PDGFR, FGFR and c-Kit, etc. It can inhibit tumor progression by inhibiting angiogenesis and tumor growth at the same time.~TQB2450 injection is a humanized monoclonal antibody targeting programmed death ligand 1 (PD-L1) that prevents the binding of PD-L1 to the PD-1 and B7.1 receptors on the T-cell surface, allowing T-cell reactivation and thus enhancing the immune response."
223838018|NCT06475599|DRUG|Chemotherapy drug|Based on each patient's condition and previous treatment history, the investigator will select one of the chemotherapy drugs (including Paclitaxel, Albumin, Doxorubicin and Doxorubicin hydrochloride) for treatment.
223838019|NCT03522428|DIETARY_SUPPLEMENT|vitamin b12|Vitamin B12 has been added to the experimental group of pregnant women, at a dose of 5 μg / 100 days
223838020|NCT03501238|OTHER|Chocolate Milk|Chocolate bovine milk will be consumed everyday for 1 week. Milks will be store-bought, with added sucrose and added cocoa powder.
223838021|NCT03501238|OTHER|Chocolate milk substitute|Chocolate milk substitute will be consumed everyday for 1 week. Milks will be store-bought, with added sucrose and added cocoa powder.
223838022|NCT03501238|OTHER|Chocolate milk substitute with gelatin|Chocolate milk substitute with gelatin added will be consumed everyday for 1 week. Milks will be store-bought, with added sucrose and added cocoa powder.
223838023|NCT04436003|BEHAVIORAL|Muscle and articulation chains GDS method|"A physiotherapy method adapting treatment to patient's terrain, or psychomorphology, using chosen techniques to balance tension between muscle chains, thus optimalizing posture and mouvement."
223838024|NCT05915871|DRUG|Tegoprazan|Tablet for oral administration
223838025|NCT05915871|DRUG|Bismuth|Capsule for oral administration
223838026|NCT05915871|DRUG|Amoxicilli|Capsule for oral administration
223838027|NCT05915871|DRUG|Clarithromycin|Tablet for oral administration
223838028|NCT02690402|BEHAVIORAL|adapted physical activity|The study begins with an evaluation of physical strenght and cognitive and psychometric assessment.Then, a personalized care will be offered in terms of adapted physical activity. The evaluation protocol will be performed again to measure the impact of physical activity three months after the first assessment.
223838029|NCT00421694|DRUG|Bicalutamide|
223838030|NCT05724212|DIAGNOSTIC_TEST|Interferon gamma release assay (IGRA)|in vitro test
223838031|NCT04551703|DRUG|Adrenaline saline irrigation|The surgical field is flushed with 20 cc of Adrenaline saline irrigation. This is in contrast to the standard of care, normal saline irrigation.
223838032|NCT06063369|DRUG|Palmitoylethanolamide|"Dose: PEA 1200 mg given in 400 mg capsules (3 capsules per day) or Placebo Route of administration: oral Duration and frequency: study medication will be provided to patients in bottles every two weeks for the duration of the study (three dispensations).~Formulation: PEA and placebo in identical capsules. Dosing scheme: Patients will be instructed to take two capsules twice daily for the 42 days of the study."
223838033|NCT04271592|DRUG|ABI-H3733 Liquid Oral Dosage Form|ABI-H3733 liquid oral dosage form
223838034|NCT04271592|DRUG|ABI-H3733 Solid Oral Dosage Form|ABI-H3733 solid oral dosage form
223838035|NCT04271592|DRUG|Placebo to ABI-H3733 Liquid Oral Dosage Form|Placebo to ABI-H3733 liquid oral dosage form
223838036|NCT04271592|DRUG|Placebo to ABI-H3733 Solid Oral Dosage Form|Placebo to ABI-H3733 solid oral dosage form
223838037|NCT02915380|BIOLOGICAL|Evaluation of pituitary endocrine function|"The basal thyroid hormone and test to perform will be: TSH, fT4, fT3.~When available, the following hormones will be tested:~FSH, LH, estradiol (in women), testosterone (in men), sex hormone-binding globulin (SHBG), ACTH, cortisol, prolactin, Na, K; serum levels of GH and IGF-1; and serum and urine osmolality.~Adrenal function will be evaluated through ACTH-stimulation testing . Adrenal or GH insufficiency will be evaluated by insulin tolerance testing (ITT)"
223838038|NCT02915380|BEHAVIORAL|Evaluation of clinical outcome|Patients' outcome will be assessed as modified Rankin Scale (mRS) at discharge from the hospital, at 3, 6 and 12 months.
223838039|NCT02915380|BEHAVIORAL|Evaluation of neuropsychological function|Neuropsychological examination will be conducted focusing on verbal comprehension (Token Test) and visual neglect. Verbal and visual short term and working memory visuospatial construction and figural memory will be performed through Rey Osterrieth Complex figure test, and psychomotor speed attention and concentration through Trail Making Test.
223838040|NCT06358742|OTHER|ZCT toothpaste|
223838041|NCT06358742|OTHER|Control toothpaste|
223838042|NCT03383185|DEVICE|Intrauterine device|Use of Intrauterine device during the follow-up period
223838043|NCT03383185|DRUG|Combined Oral Contraceptive|Use of combined oral contraceptive during the follow-up period
223838044|NCT03383185|DRUG|Progestin-only pills|Use of progestin-only pills during the follow-up period
223838045|NCT03383185|DRUG|Depot-Medroxyprogestereone Acetate|Use of depot-medroxyprogesterone acetato during the follow-up period
223838046|NCT04499040|BIOLOGICAL|Blood sample|Blood samples to assess biological parameters such as:
223838047|NCT04499040|OTHER|Fecal samples|Microbiota analysis
223838048|NCT04499040|BEHAVIORAL|Neuropsychological|Neuropsychological assessment
223838049|NCT00576602|DRUG|methoxy polyethylene glycol-epoetin beta [Mircera]|Recommended starting dose of 0.6 micrograms/kg sc every 2 weeks
223838050|NCT00576602|DRUG|Supportive treatment|As prescribed
223838051|NCT05528887|BIOLOGICAL|Autologous CAR-T cells|D0: CAR-T cells will be infused intravenously.
223838052|NCT05528887|DRUG|Fludarabine|D-5 to D-3: Fludarabine (30 mg/m\^2/day) will be administered intravenously for 3 days.
223838053|NCT05528887|DRUG|Cyclophosphamide|D-5 to D-3: Cyclophosphamide (500 mg/m\^2/day) will be administered intravenously for 3 days.
223838054|NCT00107185|BIOLOGICAL|therapeutic autologous dendritic cells|
223838055|NCT02716597|DRUG|25% Albumin|
223838056|NCT02716597|DRUG|Placebo|
223838057|NCT03548545|DEVICE|tDCS|subjects will receive a total of 8-structured CBT sessions administered by a certified therapist(according to the NICE guidelines).In the first two weeks, participants will undergo 6-sessions of CBT every other day(3 CBT sessions per week) and 10 daily sessions of either active or sham tDCS(2 mA, 30 minutes).They will undergo additional booster sessions of the same intervention(active or sham tDCS followed by CBT) by week 4 and 6.
223838058|NCT05804864|DRUG|KM501|1a: The program evaluated six dose levels, i.e., 0.1, 0.3, 0.6, 1.2, 1.8, 2.4 mg/kg, An accelerated titration was performed in the 0.1 and 0.3 mg/kg dose groups, and then a Bayesian optimal interval design was used to determine MTDS for four subsequent dose levels. Ib: The antitumor activity of KM501 monotherapy in subjects with specific types of tumors that are HER2-positive or express, amplify, or mutate will be evaluated at the RP2D dose level
223838059|NCT04105985|DRUG|Kovanaze Nasal Spray|Intra-nasal local anesthetic
223838060|NCT04105985|DRUG|Articaine Injection|Local anesthetic
223838061|NCT01521949|DRUG|Acai Juice Product|2 ounces of Acai Juice Product twice daily.
223838062|NCT02886728|DRUG|Filgotinib|Tablet(s) administered orally once daily
223838063|NCT02886728|DRUG|Placebo to match filgotinib|Tablet(s) administered orally once daily
223838064|NCT02886728|DRUG|MTX|Capsule(s) administered orally once weekly
223838065|NCT02886728|DRUG|Placebo to match MTX|Capsule(s) administered orally once weekly
223838066|NCT04770597|DEVICE|Aranet4 Home CO2 monitor|The sensor is placed in the room at a height between 1 and 2 meters and not near the window or door.
223838067|NCT06169761|OTHER|Assessment of motor skills of the tongue and others muscles, see below) and risk for sleep apnea|"The following items will be assessed:~1. Risk for sleep apnea, through the STOP-BANG Questionnaire.~2. Anthropometric data: Height, weight, neck circumference, maximal mouth opening and maximal mouth opening with tongue to palate (with the Quick Tongue-Tie Assessment tool).~3. Tongue peak pressure (i.e., the maximal pressure - Pmax - exerted against the IOPI bulb in kPa) during 3 sec. of tongue protrusion and elevation.~4. Tongue endurance (i.e., the time to task failure in maintaining a pressure equal to a fixed percentage of Pmax against the IOPI bulb) during tongue protrusion and elevation~5. Tongue mobility restriction measured with the Quick Tongue-Tie Assessment Tool~6. Maximum inspiratory and expiratory pressures measured with MicroRPM in cmH2O~7. Handgrip strength (measured with a JAMAR dynamometer in kg)~Tongue skills measurements will be repeated 2 to 4 weeks after baseline to assess the reliability of these measurements."
223838068|NCT00422721|PROCEDURE|realization of a family tree|
223838069|NCT00422721|PROCEDURE|refractometry|
223838070|NCT00422721|PROCEDURE|evaluation of the presence of a nystagmus|
223838071|NCT00422721|PROCEDURE|ocular behavior|
223838072|NCT00422721|PROCEDURE|test of baby vision|
223838073|NCT00422721|PROCEDURE|test of keenness|
223838074|NCT00422721|PROCEDURE|reading test|
223838075|NCT00422721|PROCEDURE|visual field|
223838076|NCT00422721|PROCEDURE|color vision|
223838077|NCT00422721|PROCEDURE|electroretinographical activity|
223838078|NCT00422721|PROCEDURE|biomicroscopical test|
223838079|NCT00422721|PROCEDURE|retinal imaging|
223838080|NCT00422721|PROCEDURE|retinal autofluorescence|
223838081|NCT00422721|PROCEDURE|genotyping|
223838082|NCT03650738|DRUG|Apatinib|Neoadjuvant program: apatinib 250mg oral d1-21; albumin paclitaxel 260mg/m2 intravenous drip d1; carboplatin AUC=5-6 intravenous drip d1; 21 days for 1 cycle. The treatment regimen was used for a total of 6 cycles, or to PD, or the toxicity was not tolerated.
223838083|NCT01429961|DRUG|SOX|TS-1, Oxaliplatin regimen (3week) Oxaliplatin 130 mg/m2 IV Day 1 S-1 40 mg/m2 b.i.d. Day1\~14
223838084|NCT03819569|PROCEDURE|Small Renal Mass Biopsy|Subjects will receive a small renal mass biopsy prior to making a treatment decision
223838085|NCT03819569|OTHER|No Small Renal Mass Biopsy|Subjects will not receive a small renal mass biopsy prior to making a treatment decision
223838086|NCT04525274|DRUG|normal saline|"At the end of surgery, patient will be shifted to Trendelenburg position and intraperitoneal instillation of 40 ml bupivacaine 0.25% + 5 ml normal saline will be done guided by the camera and sprayed uniformly into the peritoneal cavity by the surgeon.~The patient will be maintained in Trendelenburg position for 5-10 minutes after drug instillation and the abdomen will be deflated by passive exsufflation using gentle abdominal pressure."
223838087|NCT04525274|DRUG|dexmedetomidine|"At the end of surgery, patient will be shifted to Trendelenburg position and intraperitoneal instillation of the study drug(40 ml bupivacaine 0.25% + 1 µg/kg dexmedetomidine diluted in 5 ml normal saline) will be done guided by the camera and sprayed uniformly into the peritoneal cavity by the surgeon.~The patient will be maintained in Trendelenburg position for 5-10 minutes after drug instillation and the abdomen will be deflated by passive exsufflation using gentle abdominal pressure."
223838088|NCT04525274|DRUG|Ketamine|"At the end of surgery, patient will be shifted to Trendelenburg position and intraperitoneal instillation of the study drug(40 ml bupivacaine 0.25% + 0.5 mg/kg ketamine diluted in 5 ml normal saline) will be done guided by the camera and sprayed uniformly into the peritoneal cavity by the surgeon.~The patient will be maintained in Trendelenburg position for 5-10 minutes after drug instillation and the abdomen will be deflated by passive exsufflation using gentle abdominal pressure."
223838089|NCT05527470|DRUG|Gemcitabine,Cisplatin|Induction chemotherapy: Patients receive 1000 mg/m2 gemcitabine intravenously on day 1and day 8， 80mg/m2 cisplatin intravenously on day 1 to 3, three cycles were administered at intervals of 3 weeks.
223838090|NCT05527470|RADIATION|Intensity-modulated radiation therapy (IMRT)|IMRT is given as 2.0-2.3 Gy per fraction with five daily fractions per week for 6-7 weeks, Cumulative doses were \> 66 Gy to the primary tumor and \> 50 Gy to the bilateral cervical lymph nodes and potential sites of local infiltration.
223838091|NCT05527470|DRUG|Cisplatin|Concurrent chemotherapy: Patients received 100mg/m2 cisplatin intravenously on day 1 to 3, three cycles were administered at intervals of 3 weeks.
223838092|NCT02958761|BIOLOGICAL|intraarticular injections of platelet lysate|
223838093|NCT02958761|DRUG|hyaluronic acid|intraarticular hyaluronic acid (20 mg/2 mL; Hyalgan, Fidia, Abano Terme, Italy) injections at the same intervals
223838094|NCT00074243|DRUG|CC-8490|
223838095|NCT01785641|DRUG|ceftazidime+ciprofloxacin|2 synergistic antibiotics: ceftazidime IP + ciprofloxacin po for gram negative bacterial peritonitis
223838096|NCT01785641|DRUG|ceftazidime monotherapy|ceftazidime IP for gram negative bacterial peritonitis
223838097|NCT01785641|DRUG|cefazolin+gentamicin|cefazolin IP + gentamicin IP for gram positive bacterial peritonitis
223838098|NCT01785641|DRUG|cefazolin monotherapy|cefazolin IP for gram positive bacterial peritonitis
223838099|NCT03100695|OTHER|Concentrated autologous PRP-BMA|Injection of autologous, concentrated platelet-rich plasma and bone marrow aspirate at the site of fixation.
223838100|NCT02270073|BEHAVIORAL|Cognitive behavior therapy of trainee therapists|In all three treatment arms, trainee therapists perform a cognitive behavior therapy (CBT) under conditions of the German health care system. This treatment is not a manualized intervention, but rather based on individualized treatment plans that have been developed together with expert supervisors during a five session diagnostic stage. Treatment duration is 25 sessions, while on average every fourth is supervized by an CBT expert therapist.
223838101|NCT04934553|BEHAVIORAL|Amplification of Positivity Training|12 90-minute, clinician-administered treatment sessions focused on presenting rationale and instructions for completing positive activity exercises (e.g., gratitude, acts of kindness) designed to increase positive emotions, cognitions, and behaviors.
223838102|NCT04934553|BEHAVIORAL|Cognitive-behavioral Therapy|12 90-minute, clinician-administered treatment sessions focused on strategies to alter cognitions and behavior related to alcohol use.
223838103|NCT00538408|PROCEDURE|Whole body magnetic resonance angiography (dotarem)|
223838104|NCT00538408|DEVICE|Whole body magnetic resonance angiography (vasovist)|
223838105|NCT00180687|DRUG|Nebulised Bupivacaine intraperitoneally|Nebulised Marcaine (Bupivacaine)
223838106|NCT00180687|DRUG|Normal Saline|Nebulised Normal Saline
223838107|NCT00180687|DRUG|Injected Bupivacaine intraperitoneally|Injected Marcaine directly into the peritoneal cavity
223838108|NCT00180687|OTHER|No Intraperitoneal Therapeutics|No Intraperitoneal Therapeutics given
223838109|NCT05059574|BEHAVIORAL|Breast Crawling|The mother's first breast-feeding of her baby is not routine biological breast-feeding, but as a cradle to the breast.
223838110|NCT01015183|DRUG|Zinc Sulfate|Zinc Sulfate: 100 mg of zinc element, per day, bid for two weeks start with chemotherapy
223838111|NCT01015183|DRUG|Placebo|Placebo: as the same of intervention group
223838112|NCT03352050|DIETARY_SUPPLEMENT|mushroom|
223838113|NCT03352050|OTHER|ground beef|
223838114|NCT01084122|DRUG|Iron sucrose|Iron sucrose FERIV® (20 mg/ml). Dilution: 10 ml in 100 ml SF 0.9%. 25 ml in 15 minutes and the rest in others 15 minutes.
223838115|NCT04990440|DRUG|Bermekimab|Participants will receive bermekimab IV.
223838116|NCT04990440|DRUG|Placebo|Participants will receive placebo IV.
223838117|NCT03048110|DRUG|BAY1841788 (ODM-201)|In Period 1, 600 mg single dose administered as 2x300 mg tablets on Study Day 1, In Period 2, 600 mg single dose administered as 2x300 mg tablets on Study Day 5, In Period 3, 600 mg single dose administered as 2x300 mg tablets at Study Day 8.
223838118|NCT03048110|DRUG|Itraconazole|200 mg twice daily (BID) administered as 2 x 100 mg capsules per dose in treatment period 2 on Study Day 1, 200 mg once daily (QD) administered as 2 x 100 mg capsules per dose in treatment period 2 on Study Days 2 to 7.
223838119|NCT03048110|DRUG|Rifampicin|600 mg QD administered as 1 x 600 mg tablet per dose in treatment period 3 on Study Days 1 to 10.
223838120|NCT04537351|BIOLOGICAL|CYP-001|The active agent in CYP-001 is Cymerus mesenchymal stem cells (MSCs), which are derived through a proprietary induced pluripotent stem cell (iPSC) and mesenchymoangioblast (MCA)-derived production process.
223838121|NCT03712098|DRUG|Liraglutide|Liraglutide 3.0 mg is an injectable medicine that may help some adults with excess weight (BMI ≥27) who also have weight-related medical problems or obesity (BMI ≥30) lose weight and keep the weight off. Liraglutide is approved by the U.S. Food and Drug Administration (FDA) for chronic weight management when combined with a reduced-calorie meal plan and physical activity.
223838122|NCT03712098|DRUG|Placebo|The placebo is an inactive substance that is designed to look like liraglutide but contains no medication.
223838123|NCT03712098|BEHAVIORAL|Smoking Cessation Counseling|All participants receive manual-based counseling from a trained smoking cessation counselor. The counseling sessions are designed to enhance awareness of the harmful effects of smoking, assist the participant in developing skills to quit, and avoid relapse.
223838124|NCT01609153|DRUG|Olanzapine|Coated tablet 5-20 mg milligram(s) per day for 16 weeks
223838125|NCT01609153|DRUG|Amisulpride|200-800 mg milligram(s)per day for 16 weeks
223838126|NCT01609153|DRUG|Olanzapine and Amisulpride|"Zyprexa:~Coated tablet 5-20 mg milligram(s) per day for 16 weeks~Amisulpride:~Coated tablet 200-800 mg milligram(s)per day for 16 weeks"
223838127|NCT00498277|PROCEDURE|Magnetic Resonance Imaging|One MRI sequence done to look for relative fat, and a second extra MRI sequence done to look for the diffusion.
223838128|NCT02724761|DRUG|Racemic Epinephrine|1 inhalation of 0.5 mL of 2.25% Nebulized Racemic Epinephrine every 8 hours for 24 hours after surgery
223838129|NCT02724761|DRUG|Placebo (for racemic epinephrine)|0.5 mL of normal saline will be prepared in an identical amber syringe as the drug intervention (racemic epinephrine)
223838130|NCT05000775|DIETARY_SUPPLEMENT|G-Niib|G-NiiB®, a patent-protected microbiome immunity formula, composed of naturally occurring food-grade bacteria approved by health authorities, has been developed by a group of CUHK gastroenterology experts.
223838131|NCT05000775|DIETARY_SUPPLEMENT|Placebo|Placebo
223838132|NCT06304844|DIAGNOSTIC_TEST|transient elastography (Fibroscan)|conduct fibroscan for patients with (MAFLD by abdominal ultrasonography)
223838133|NCT04157764|DEVICE|HomeChoice Claria APD machine with SHARESOURCE|HomeChoice Claria APD machine with SHARESOURCE software. SHARESOURCE is a software can telemonitor patients' compliance
223838134|NCT03291795|OTHER|Exercise Intervention|Study patients will undergo a program of prehabilitation exercise for 6 days per week prescribed for them by an exercise physiologist, for up to 4 weeks prior to surgery.
223838135|NCT02310490|DEVICE|DA-13-007 right with left side Sculptra left side|The treatment phase will consist of one to three visits at 3 week intervals during which eligible subjects will receive bilateral injections of study material in the left and right nasolabial fold wrinkles, including visits at weeks 3 and 6 for touch ups if needed
223838136|NCT02310490|DEVICE|DA-13-007 left with left side Sculptra right side|The treatment phase will consist of one to three visits at 3 week intervals during which eligible subjects will receive bilateral injections of study material in the left and right nasolabial fold wrinkles, including visits at weeks 3 and 6 for touch ups if needed
223838137|NCT02539758|OTHER|ocular massage|ocular massage could be applied over the globe over the closed eyelids with moderate massage strength for 15 minutes. The compression of the globe was given with finger, and press for 2 seconds, then by a 2 seconds release, with a frequency of 15 presses/minute.
223838138|NCT02539758|DEVICE|LenstarLS900|observed changes of anterior chamber depth before and after ocular massage by LenstarLS900
223838139|NCT02539758|DEVICE|Goldmann tonometer|observed changes of intraocular pressure before and after ocular massage by Goldmann tonometer
223838140|NCT05121870|BIOLOGICAL|UC-MSCs|3 does of UC-MSCs(6.0×10E7cells per time) intravenously at week 0, week 4, week 8.
223838141|NCT05121870|BIOLOGICAL|Saline containing 1% Human serum albumin（solution without UC-MSCs）|3 does of placebo intravenously at week 0, week 4, week 8.
223838142|NCT03937271|DIAGNOSTIC_TEST|Traditional Chinese Medicine pattern|Autoimmune disease (AID) as Sjögren's syndrome (SJS), Systemic lupus erythematosus (SLE), Rheumatoid Arthritis (RA), Systemic Sclerosis (SSc), Ankylosing spondylitis (AS) for comparing with the Dry eye syndrome (DES) subjects will take the Traditional Chinese Medicine pattern.
223838143|NCT03937271|DIAGNOSTIC_TEST|Traditional Chinese Medicine tongue diagnosis|Autoimmune disease (AID) as Sjögren's syndrome (SJS), Systemic lupus erythematosus (SLE), Rheumatoid Arthritis (RA), Systemic Sclerosis (SSc), Ankylosing spondylitis (AS) for comparing with the Dry eye syndrome (DES) subjects will take the Traditional Chinese Medicine tongue diagnosis.
223838144|NCT03937271|DIAGNOSTIC_TEST|Traditional Chinese Medicine pulse diagnosis|Autoimmune disease (AID) as Sjögren's syndrome (SJS), Systemic lupus erythematosus (SLE), Rheumatoid Arthritis (RA), Systemic Sclerosis (SSc), Ankylosing spondylitis (AS) for comparing with the Dry eye syndrome (DES) subjects will take the Traditional Chinese Medicine pulse diagnosis.
223838145|NCT03937271|DIAGNOSTIC_TEST|Heart rate variability|Autoimmune disease (AID) as Sjögren's syndrome (SJS), Systemic lupus erythematosus (SLE), Rheumatoid Arthritis (RA), Systemic Sclerosis (SSc), Ankylosing spondylitis (AS) for comparing with the Dry eye syndrome (DES) subjects will take the Heart rate variability.
223838146|NCT03937271|DIAGNOSTIC_TEST|Schirmer's test|Autoimmune disease (AID) as Sjögren's syndrome (SJS), Systemic lupus erythematosus (SLE), Rheumatoid Arthritis (RA), Systemic Sclerosis (SSc), Ankylosing spondylitis (AS) for comparing with the Dry eye syndrome (DES) subjects will take the Schirmer's test.
223838147|NCT02537444|DRUG|Acalabrutinib|
223838148|NCT02537444|DRUG|acalabrutinib and pembrolizumab combination|
223838149|NCT04145336|DEVICE|5cm 5-Fr PDS|High-risk patients receive 5cm 5-Fr PDS
223838150|NCT04145336|DEVICE|7cm 5-Fr PDS|High-risk patients receive 7cm 5-Fr PDS
223838151|NCT04145336|DRUG|Indomethacin|All patients without contraindications should be administrated with rectal indomethacin within 30 min before ERCP.
223838152|NCT02724020|DRUG|Everolimus|Everolimus capsules.
223838153|NCT02724020|DRUG|MLN0128|MLN0128 capsules.
223838154|NCT02724020|DRUG|MLN1117|MLN1117 capsules.
223838155|NCT03016013|BIOLOGICAL|Placebo plus MTX|The trial was divided into two groups: (1) placebo + MTX; (2) telitacicept 160 mg + MTX. MTX was used as the basic treatment, the dose of MTX was stable during the trial, and could not be adjusted. Telitacicept or placebo was administered once a week for the first 24 weeks. Beginning at week 24, subjects in the placebo group will enter the RC-18 treatment group. All subjects received RC-18 treatment once a week from week 24 to week 48.
223838156|NCT03016013|BIOLOGICAL|RC18 160 mg plus MTX|The trial was divided into two groups: (1) placebo + MTX; (2) telitacicept 160 mg + MTX. MTX was used as the basic treatment, the dose of MTX was stable during the trial, and could not be adjusted. Telitacicept or placebo was administered once a week for the first 24 weeks. Beginning at week 24, subjects in the placebo group will enter the RC-18 treatment group. All subjects received RC-18 treatment once a week from week 24 to week 48.
223838157|NCT04808869|OTHER|Exercise|Cycling 3 times a week for 15 minutes at 70 rpm using blood flow restriction cuffs at different occlusions.
223838158|NCT04704401|OTHER|Questionnaire|Structured questionnaire to collect cardiovascular and metabolic events, incident cancers and deaths that have occured, as weel as information on CPAP, through telephone interview.
223838159|NCT05602337|OTHER|Observational Study Only|Non-invasive Skin Sampling
223838160|NCT05539690|BEHAVIORAL|Balance training|"* Step-by-step training (5 levels)~* 30 minute per training~* 3 times per week~* 4 weeks"
223838161|NCT01066156|DRUG|Seroquel|This study will investigate therapeutic responses to Seroquel pharmacotherapy in PTSD
223838162|NCT06048796|OTHER|Early cessation of sedation and TTM|Early cessation of sedation and TTM, with subsequent weaning from mechanical ventilation if appropriate
223838163|NCT01700673|DRUG|Azacitidine|Azacitidine will be administered days 1-5 of a 28 day cycle. Treatment is planned for a total of 12 cycles.
223838164|NCT01700673|BIOLOGICAL|Sargramostim|Sargramostim will be administered days 1-10 of a 28 day cycle. Treatment is planned for a total of 12 cycles.
223838165|NCT03890120|DRUG|Cilofexor|100 mg tablet administered orally once daily
223838166|NCT03890120|DRUG|Placebo|Tablet administered orally once daily
223838167|NCT01133509|DRUG|Gardasil|0.5ml IM for three doses, Second and third dose to be given at 2 months and 6 months
223838168|NCT04785183|DIETARY_SUPPLEMENT|Melatonin drops|Melatonin oral administration
223838169|NCT04785183|OTHER|Placebo|Oral 5% glucose
223838170|NCT02424461|DRUG|Ceftriaxone|1 injection 1 g per day for 2 days
223838171|NCT02424461|DRUG|Ofloxacine|400 mg/jour (200 mg/ jour in case of renal failure) for seven days
223838172|NCT02424461|DRUG|Ofloxacine|400 mg/jour (200 mg/ jour in case of renal failure) for 14 days
223838173|NCT02424461|DRUG|Placebo of ofloxacine|Placebo of ofloxacine for 7 days
223838174|NCT04047069|BEHAVIORAL|Awareness Training and Person-Centered Occupational Therapy Intervention|Exp. identifying the activities the person wants to do, suggestions to facilitate the activity, arranging the activity according to the needs of the person, arranging the environment so that the environment can be a facilitating factor in the activities the person wants to do.
223838175|NCT04047069|BEHAVIORAL|Awareness Training|"Exp.~* General information about HD~* Approaches to Coping with HD Symptoms~* Self care skills (eg hygiene)"
223838176|NCT03112278|PROCEDURE|Ceramic ultrathin occlusal veneers|Severely eroded teeth will be restored with ultrathin occlusal veneers made of ceramic (e.max CAD/Ivoclar Vivadent) by technology CAD-CAM bonded to the teeth (0.6 - 1.2 mm thick).
223838177|NCT03112278|PROCEDURE|Composite resin ultrathin occlusal veneers|Severely eroded teeth will be restored ultrathin occlusal veneers made of composite resin (Lava Ultimate/3M Espe) by technology CAD-CAM bonded to the teeth (0.6 - 1.2 mm thick).
223838178|NCT06116643|DIETARY_SUPPLEMENT|Soluble protein hydrolysate (SPHi)|Participants that are already on stable maintenance therapy for ulcerative colitis will continue with their therapy regimen and the addition of 10g of SPHi in 100ml of water every day for 12 weeks.
223838179|NCT01016990|DRUG|valproic acid|
223838180|NCT01016990|GENETIC|western blotting|
223838181|NCT01016990|OTHER|laboratory biomarker analysis|
223838182|NCT01016990|OTHER|pharmacological study|
223838183|NCT02335268|DRUG|N-Plate / romiplostim|medical intervention in 3 patient groups (MDS patients with IPSS Low/Int-1) that are stratified according to their baseline TPO-Level and previous transfusions
223838184|NCT05465694|PROCEDURE|2-minute-time interval of per oral 24% sucrose|Experiment began with a five-minute observation period of all outcome measures while infant was resting in an incubator. Later, attendant nurse gave 1 ml of 24% sucrose solution on neonate's tongue. In the 2-two minute-time interval prior to heel lance intervention, following two minutes of waiting period, heel lance procedure was applied to infant's foot. In no time interval of sucrose given immediately prior to heel lance intervention, attendant nurse performed heel lance procedure immediately after giving 1 ml of 24% sucrose solution sucrose on tongue. Infant's facial actions and heart rate, and oxygen saturation were recorded by using two video cameras. Recording was carried out by a nurse during whole procedure. After collecting data, researcher watched videos separately and scored them by using PIPP-R. Measurement of study outcome relied on data collection strategies: Neonatal close-up video recording of infant facial actions, pulse oximeter, observation for adverse events.
223838185|NCT05465694|PROCEDURE|no time interval of per oral 24% sucrose|no time interval of per oral 24% sucrose
223838186|NCT00000195|DRUG|Naltrexone|
223838187|NCT02706626|DRUG|brigatinib|Single arm phase 2 trial to investigate the clinical activity in patients with advanced non-small cell lung cancer
223838188|NCT03670745|BEHAVIORAL|An electronic self-administered pre-visit planning tool.|An electronic self-administered pre-visit planning tool allowing adolescents to list areas of concern to support shared decision-making during an office visit.
223838189|NCT03670745|BEHAVIORAL|Control group|No planning tool
223838190|NCT01879878|DIETARY_SUPPLEMENT|Verum, broccoli sprout grain|Patients will be randomly classified into two groups - verum and placebo. The patients in the experimental arm will receive capsules with broccoli sprout grain containing a total of 90mg sulforaphane active substance per day over one year as nutrition supplement whereas patients assigned to the placebo group will receive inactive substance (methylcellulose) with identical capsule and portion distribution.
223838191|NCT01879878|DIETARY_SUPPLEMENT|placebo|Patients assigned to the placebo group will receive inactive substance (methylcellulose) with identical capsule and portion distribution as the experimental arm.
223838192|NCT00843362|DRUG|Dinoprostone vaginal pessary|10 mg controlled-release dinoprostone pessary applied for 24 hours
223838193|NCT00843362|DRUG|Dinoprostone vaginal gel|2 mg vaginal dinoprostone gel, two daily doses with a 6 hours interval
223838194|NCT03065790|DIAGNOSTIC_TEST|2-Deoxy-2-[18F]fluoro-D-glucose (FDG)|2-Deoxy-2-\[18F\]fluoro-D-glucose (FDG)
223838195|NCT02938390|PROCEDURE|Ultrasound for localizing intercostal perforating vessels|Use of an Intra-operative ultrasound during nipple sparing mastectomy to localize intercostal perforating vessels.
223838196|NCT00547664|DRUG|Hylenex recombinant , morphine, saline|Subcutaneous infusion of morphine and hydromorphone (Dilaudid) with or without the preceded co-injection of Hylenex. Hospice patients include both home-bound patients as well as those under intensive care in hospice houses.
223838197|NCT00547664|OTHER|Saline|Subcutaneous infusion of morphine and hydromorphone (Dilaudid) with the preceded co-injection of saline.
223838198|NCT04889885|DEVICE|High-intensity laser therapy (HILT)|"HILT was done by Multiwave Locked System (MLS) laser therapy combining 2 laser wavelengths (808 and 905 nm) in order to strengthen the effects of HILT. The laser was applied on medial, lateral and posterior parts around the knee joint. The total energy per session was 562.5 Joules (J) which was done 2-3 times a week for a total of 10 sessions.~Additionally, the participants received conservative treatment for knee OA such as education about the disease, proper activities, and exercise."
223838199|NCT04889885|DEVICE|Sham laser|The control group received a sham laser (2-3 times a week for a total of 10 sessions) plus conservative treatment as in the intervention group. The laser machine was the same as in the intervention group; however, the laser was applied without releasing laser energy to the knee joint.
223838200|NCT03207425|DRUG|EDP 305|Each subject will receive a single dose of EDP 305 on Day 1.
223838201|NCT03423901|OTHER|Blood sampling|Descriptive analysis of clinical, biological and histological of 3 arms: ABO incompatible, HLA incompatible, and ABO/HLA incompatible kidney transplantation (1 and 5 years posttransplantation in each groups)
223838202|NCT00190346|DEVICE|Humidification devices: HH vs HME|
223838203|NCT03460717|OTHER|Peripheral Nerve Field Stimulation by Thermal Micro-Cautery|The most painful points over the knee received an intense heat by a metal rod for 0.5 seconds.
223838204|NCT01192295|DRUG|Oxycodone HCl controlled-release tablets|Oxycodone HCl controlled-release tablets at strengths of 10, 15, 20, 30, or 40 mg (20 mg - 240 mg daily) every 12 hours.
223838205|NCT04682574|DRUG|Vitamin C|mega dose is given to the selected critically ill patients
223838206|NCT01444976|DRUG|local anesthesia|patients will receive only topical anesthesia with 1% lidocaine
223838207|NCT01444976|BEHAVIORAL|hypnosis|Hypnosis will be performed by the same anesthesiologist according to indirect Erickson's method
223838208|NCT01444976|DRUG|Midazolam|Before insertion of the probe, the patients will be sedated with midazolam at a dose of 0,.05 mg/kg iv (to achieve a Ramsay Sedation Score of 2-3). If needed, additional iv doses (0.005 mg/kg) were given during the procedure.
223838209|NCT03785340|DRUG|Brimonidine Tartrate|Brimonidine Tartrate Nanoemulsion Eye Drops 0.20% given 2 times a day for 4 weeks.
223838210|NCT03785340|DRUG|Placebos|Ophthalmic buffered saline Eye Drops given 2 times a day for 4 weeks.
223838211|NCT02859597|DEVICE|High flow nasal cannula|High flow nasal cannula at 50 liters per minute and 50% oxygen will initially be used for oxygenation.
223838212|NCT02859597|DEVICE|Nasal Cannula|Control group will receive oxygen via standard flow nasal cannula at 5 liters per minute (approximately an FiO2 of 0.35)
223838213|NCT02605499|OTHER|UV-C light disinfection|UV-C light disinfection will be used in hospital patient rooms as an adjunct to routine daily and discharge cleaning.
223838214|NCT00461448|DIETARY_SUPPLEMENT|Potassium supplement|Patients were randomly allocated to receive either an EGJ containing 234.5 mmol microcrystalline KCl a total of 6000 mg of K in 2 EGJ, but split into 2 intakes daily) or PGJ for 28 days.
223838215|NCT02519179|BEHAVIORAL|Opaque, weighted bottle|This is the experimental condition; mothers will be asked to feed their infants from an opaque, weighted bottle.
223838216|NCT02519179|BEHAVIORAL|Clear, conventional bottle|This is the control condition; mothers will be asked to feed their infants from a clear, conventional bottle.
223838217|NCT03281564|OTHER|Quality of life after Essure® removal|Questionnaire to assess the quality of life 1, 3, 6 and 12 months after laparoscopic removal of Essure® device
223838218|NCT06417645|DRUG|fixed propofol infusion 15 mg/kg/h until 1% BSR (burst suppression ratio)|after a slow induction with propofol to loss of consiousness (LOC), we proceed to give remifentanil TCI and rocuronium and intubate the patient. After 5 min we infuse 15 mg/kg/h until 1%BSR observe in the BIS monitor. Then we reduce the TCI LOC predicted concentration.
223838219|NCT06086808|OTHER|Resistance Training|A resistance training program will be used as a progressive, high-intensity protocol. The training stimulus will be provided using free weights. The exercises will consist of bench presses, biceps curls, triceps extensions, Latissimus Dorsi pull-down exercises, hamstring curls, and calf raises. The intensity of the training stimulus will be at a working range of 6 to 8 repetitions (2 sets). The training stimulus will subsequently be increased using the 7-RM (repetition maximum) method when 2 sets of 6 to 8 repetitions are completed with proper form and without discomfort. Other key strength exercises will include mini-squats, mini-lunges, and lunge walks. The number of sets completed and the load lifted for each exercise will be recorded for each participant in every class.
223838220|NCT06086808|OTHER|General Fitness and Toning|The general fitness and toning program will consist of stretching exercises, range-of-motion exercises, basic core-strengthening exercises, balance exercises, and relaxation techniques. Key balance exercises will include tandem stand, tandem walking, and single leg stance (eyes opened and closed). No additional loading (e.g., hand weights or resistance bands) will be applied to any of the exercises. This group will serve to control for confounding variables such as physical training received by traveling to the training centers, social interaction, and changes in life style secondary to study participation.
223838221|NCT00737308|OTHER|ceramic crown|Zirconia
223838222|NCT04127344|BEHAVIORAL|Music Therapy Intervention|Patients randomized to a music therapy intervention will receive an individualised music therapy intervention. The sessions will last 10-20 minutes and they will be done by music therapist and musician.
223838223|NCT04253821|OTHER|muscle tonus, stiffness and elasticity,six-minute walk test, Pulmonary function tests, The neck disability index|The muscle tonus, stiffness and elasticity of upper trapezius (UT), semispinalis capistis (SSC), pectoral muscles (PM) and sternocleidomastoideus muscles (SCM) were measured by using MyotonPro® device. Functional capacity was measured with six-minute walk test. Pulmonary function tests was evaluated with spirometer. The neck disability index (NDT) was applied. The forward head posture was determined by measurements of craniovertebral angle (CVA). Physical activity levels of participants were evaluated by Physical Activity Index (FIT).
223838224|NCT03746444|OTHER|General Anesthesia|The patients in general anesthesia group will undergo general anesthesia
223838225|NCT03746444|OTHER|Regional Anesthesia|The patients in Group R will be given combined spinoepidural anesthesia
223838226|NCT05049525|DRUG|Itraconazole 400 mg/day and terbinafine 500 mg/day administered orally.|Itraconazole capsules of 100 mg, antifungal agent. Terbinafine tablets 250 mg (as terbinafine hydrochloride), antifungal agent.
223838227|NCT05049525|DRUG|Itraconazole's matching placebo 400 mg/day and terbinafine's matching placebo 500 mg/day administered orally.|Matching placebo of itraconazole capsules of 100 mg, antifungal agent. Matching placebo of terbinafine tablets 250 mg, antifungal agent.
223838228|NCT02452229|OTHER|Review of the Literature for Human Herpes Virus infections|"Review of the Medline database (PubMed and Ovid interface) for human herpes virus infections in burns as well as Web of Science interface.~PRIMSA (preferred reporting items for systematic reviews and meta-analyses) guidelines and checklist were used."
223838229|NCT00147654|DRUG|Tolterodine ER 4 mg QD|
223838230|NCT00147654|DRUG|Tamsulosin 0.4 mg QD|
223838231|NCT02923895|OTHER|Stannous fluoride|0.454% weight by weight (w/w) stannous fluoride containing 1100 parts per million (ppm) fluoride
223838232|NCT02923895|OTHER|Sodium monofluorophosphate|0.76% w/w sodium monofluorophosphate containing 1000 ppm fluoride
223838233|NCT04044079|DRUG|Dinoprostone|1 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia \& Upjohn, Puurs, Belgium) inserted by the patient 12 hours before the scheduled office hysteroscopy.
223838234|NCT04044079|DRUG|Misoprostol|Misoprostol (200µg) will be administered vaginally 12 hours before office hysteroscopy.
223838235|NCT04044079|DRUG|Placebo|one tablet of placebo inserted by the patient 12 hours before the scheduled office hysteroscopy.
223838236|NCT06206044|DRUG|Intrathecal 1.6 ml 0.75% bupivacaine in 8.25% dextrose combined with 15 mcg fentanyl and 150 mcg preservative-free morphine|Patients will receive standard intrathecal medications for urgent and scheduled cesarean delivery at the study site. All study subjects will receive bupivacaine, fentanyl, and morphine.
223838237|NCT02463162|OTHER|Conversations Matter videos|2 videos about Advance Care Planning and Goals of Care Designations respectively. These 2 videos were developed by Alberta Health Services and are each 8 minutes long.
223838238|NCT03708068|OTHER|Early exclusive enteral nutrition|Infants will be fed at least 80% of reference daily fluid intake from day one. Feeds will be advanced by 20-30 ml/kg per day on second day onwards to meet reference daily fluid intake until infant reaches full enteral feed.
223838239|NCT01627236|DRUG|methylprednisolone|methylprednisolone 1mg/kg intravenous drip qd，for 3 days glucocorticoid
223838240|NCT03589482|DEVICE|Electrical Impedance Tomography|Electrical impedance tomography (EIT) is a new technique that enables real-time visualization of the distribution of ventilation at the bedside. This technique allows clinicians and investigators to immediately determine how applying higher or lower PEEP levels affect stress and strain in the lung. The investigators propose to apply this new technique to test a strategy for finding the optimal level of PEEP that prevents lung injury and improves outcomes in critically ill patients.
223838241|NCT03589482|OTHER|ExPRESS-derived PEEP level|The ExPRESS algorithm is a traditional approach to selecting PEEP based on respiratory mechanics.
223838242|NCT05727059|DEVICE|The Elevate™ System|The Magenta Elevate™ is a temporary (≤ 6 hours) ventricular support device indicated for use during high-risk percutaneous coronary interventions (PCI) performed electively or urgently in hemodynamically stable patients, with severe coronary artery disease.
223838243|NCT06063317|BIOLOGICAL|CF33-CD19 IT Monotherapy|Safety Run-In Phase: CF33-CD19 will be administered intratumorally on Days 1 and 8 of Cycle 1 and Day 1 of each subsequent 21-day cycle.
223838244|NCT06063317|BIOLOGICAL|CF33-CD19 IV Monotherapy|Safety Run-In Phase: CF33-CD19 will be administered intravenously on Days 1 and 8 of Cycle 1 and Day 1 of each subsequent 21-day cycle.
223838245|NCT06063317|BIOLOGICAL|CF33-CD19 IT Combination|Dose Escalation Combination Phase: CF33-CD19 will be administered intratumorally on Days 1 and 15 of each 28 day cycle.
223838246|NCT06063317|BIOLOGICAL|CF33-CD19 IV Combination|Dose Escalation Combination Phase: CF33-CD19 will be administered intravenously on Days 1 and 15 of each 28 day cycle.
223838247|NCT06063317|DRUG|Blinatumomab|Blinatumomab will be infused via a 7-day continuous infusion from Days 2-9 and Days 16-23 of each 28-day cycle.
223838248|NCT06063317|DRUG|Hydroxyurea|Hydroxyurea will be orally administered daily.
223838249|NCT04245033|DRUG|Dihydroartemisinin-Piperaquine (DP)|Dihydroartemisinin-Piperaquine (DP) for intermittent preventive treatment of malaria in school children (IPTsc).
223838250|NCT06094933|BEHAVIORAL|Mobile Anger Reduction Intervention (MARI)|This is a mobile intervention that uses interpretation bias modification (IBM) techniques to reduce the hostile interpretation bias. Participants will download the MARI app and be instructed to complete at least 5 treatment sessions each week for a period of 4 weeks. Each session takes approximately 10 minutes. The app also includes a Nightly Diary to track symptoms, a calendar to program session reminders, and a My Progress feature to track use and performance.
223838251|NCT06094933|BEHAVIORAL|Health Education Condition (HED)|This is a mobile application that delivers videos with psychoeducation about healthy habits and selfcare for general wellness. Participants will download the HED app and be instructed to use it at least 5 times a week for a period of 4 weeks.
223838252|NCT05832580|DRUG|Etidronate|Etidronate in capsules of 200 mg or 400 mg.
223838253|NCT05832580|DRUG|Placebo|Placebo in similar capsules
223838254|NCT05526235|BEHAVIORAL|Doing What Matters (DWM)|The original DWM program consists of a self-help guide called 'Doing What Matters in Times of Stress', that is complemented with pre-recorded audio exercises. The audio material imparts key information about stress management and guides participants through individual exercises. Additionally, participants are guided by a briefly trained helper. In this study, DWM will be delivered as an online intervention. The DWM intervention, i.e. both the audio recordings and the self-help guide, has been adapted for use on a smartphone or other device with internet access. The format of DWM is innovative in that it seeks to ensure that key intervention components are delivered as intended through the use of pre-recorded audio, without the burden of extensive training and supervision. In the online application tool a new module is released every week so participants will be asked to go through the entire DWM intervention within 5 weeks with weekly guidance from a helper.
223838255|NCT05526235|BEHAVIORAL|Problem Management Plus (PM+)|PM+ is a new, brief, psychological intervention program based on cognitive behavioral therapy (CBT) techniques. The manual involves the following empirically supported elements: problem solving plus stress management, behavioral activation, facing fears, and accessing social support. Across the five 90-minute sessions participants may talk to trained non-professional. PM+ has four core features, and it is brief. In this study, the delivery mode of the PM+ intervention will be flexible, with remote delivery in phases of the pandemic when physical distancing rules apply. This is a future-oriented attempt towards a more holistic mental health care system that can flexibly switch between modes of delivery (e.g. remotely (e.g. Zoom) or face-to), depending on the needs and the specific containment measures that apply, and the specific preferences and needs of the participant.
223838256|NCT05526235|BEHAVIORAL|Psychological First Aid (PFA)|PFA is a brief intervention consisting of a 15-min call that assess the immediate concerns and needs of an individual in order to connect individuals to help and resources.
223838257|NCT05377086|OTHER|Schroth 3-Dimensional scoliosis exercise|Schroth 3-Dimensional scoliosis exercises
223838258|NCT05377086|OTHER|conventional scoliosis exercise|conventional scoliosis exercise
223838259|NCT00813111|DRUG|SKY0402|600mg SKY0402 instilled into breast pocket during surgery
223838260|NCT00813111|DRUG|Bupivacaine HCl|200mg Bupivacaine HCl instilled into breast pocket during surgery
223838261|NCT06013488|BEHAVIORAL|Character Strengths Based Coaching Support|Residential (five day) workshop and remote (weekly) telephonic support for 8 to 10 weeks
223838262|NCT06013488|BEHAVIORAL|Routine Supervision|Weekly face-to-face supervision by supervisor in groups of \~20 (1 supervisor for \~20 health workers)
223838263|NCT04634357|DRUG|ET140203 T Cells|"Biological/Vaccine: ET140203 autologous T-cell product~Autologous T cells transduced with lentivirus encoding an ET140203 expression construct"
223838264|NCT05601232|RADIATION|BNCT|Patients will be infused SPM-011 intravenously at a dose of 200mg/kg/hr over 2 hours. Thereafter, patient will be infused SPM-011 intravenously at a dose of 100mg/kg/hr and will receive neutron irradiation simultaneously for a certain period of time based on his Boronophenylalanine (BPA) concentration in the blood.
223838265|NCT05087095|BEHAVIORAL|CALM Intervention|"The CALM intervention includes 6 individual therapy sessions, each approximately 45-60 minutes in length, delivered over 3 months. Participants will be asked to complete self-report surveys of behavioral and psychological variables surveys at the following timepoints:~* Within one week before initiating the CALM intervention therapy~* Within one week after its completion,~* 3 months after the CALM intervention is complete~  * After each intervention session, participants will complete a brief post-session survey to assess acceptability of CALM session components"
223838266|NCT03998462|BEHAVIORAL|Mindfulness Based Stress Reduction|MBSR consists of 6-10 individuals with PD and led by a trained instructor who is not involved in the clinical care or assessment of these participants.
223838267|NCT03998462|BEHAVIORAL|Creative Education Care|Creative Education Care consists of 6-10 individuals with PD and led by a trained instructor who is not involved in the clinical care or assessment of these participants.
223838268|NCT03892785|DRUG|Prednisone treatment|tapering prednisone regimen
223838269|NCT03892785|DRUG|Tocilizumab treatment|Tocilizumab 162 mg/week subcutaneous from W0 to W51 (52 injections)
223838270|NCT03892785|DRUG|Methotrexate treatment|"Methotrexate subcutaneous from W0 to W51 (52 administrations).~* W0: 7.5 mg/week~* W1: 0.2 mg/Kg/week~* W2 to W51: 0.3 mg/Kg/week (without exceeding 20 mg/week) Folic acid 10 mg/week, 48h after taking Methotrexate, from W0 to W51"
223838271|NCT03892785|OTHER|Questionnaires|HAQ, SF-36, FACIT-fatigue
223838272|NCT03892785|BIOLOGICAL|Blood samples|Additionnal blood samples for immunomonitoring
223838273|NCT06668285|BEHAVIORAL|parental presence|parental presence in PICU
223838274|NCT01670500|DRUG|Cisplatin|administered intravenously every 3 weeks for 4 doses
223838275|NCT01670500|DRUG|Cyclophosphamide|administered with doxorubicin intravenously every 2 or 3 weeks for 4 doses
223838276|NCT01670500|DRUG|Doxorubicin|administered with Cyclophosphamide intravenously every 2 or 3 weeks for 4 doses
223838277|NCT05940844|DRUG|OB-002|The patients will be dosed once weekly (Days 1, 8, 15 and 22) over a 4-week treatment cycle with a 28 day dose-limiting toxicity (DLT) observation period.
223838278|NCT03588026|DRUG|rVA576|6 months of treatment, rVA576 plus SOC. Followed by a further 3 months of rVA576 plus SOC. In total, 9 months on rVA576 plus SOC.
223838279|NCT03588026|OTHER|Standard of care (SOC)|6 months on SOC followed by 3 months of treatment with rVA576 plus SOC. In total, 3 months on rVA576 plus SOC.
223838280|NCT06368687|OTHER|Anorexia nervosa plus autism|In the inpatient care the treatment model takes into account the patient's perception disorders, meaning e.g. an adapted mealtime situation where the patient can eat separately or wear hearing protection if necessary. The patients have an adapted meal plan regarding difficulties with specific textures or foods. To meet their need for continuity, they have the same contact persons throughout the entire period of care. The healthcare staff receive training in working with the specific subgroup and have regular exchanges of experience regarding the patient group, 15 minutes every or every two weeks.
223838281|NCT06443697|OTHER|No intervention|This is a secondary analysis and no intervention is implemented.
223838282|NCT06110117|DEVICE|Sterimar Stop & Protect Irritation & Dryness|One or two nasal sprays will be administered to each nostril for a minimum of 2 times per day up to a maximum of 6 times per day for seven days.
223838283|NCT04489693|BEHAVIORAL|Ambulatory Care Coordinator Team (ACCT)|See arm description
223838284|NCT04489693|BEHAVIORAL|Comprehensive Care Physician Program (CCP)|see arm description
223838285|NCT04489693|BEHAVIORAL|Comprehensive Care Community & Culture Program (C4P)|see arm description
223838286|NCT02120885|BEHAVIORAL|physical activity intervention|Exercise program is scheduled to be conducted in three phases. Phase I is in-hospital exercise program. This program will be conducted in hospital during 1 week after surgery. Phase II is home-exercise program that will be performed at home during 1 week after discharge. Phase III is main-exercise program that will be conducted the fitness center nearby hospital during 8 weeks after phase II program. Main-exercise program is focused on the functional recovery.
223838287|NCT04780217|BIOLOGICAL|T3011|T3011 will be administered through IV drip or pumping.
223838288|NCT04029558|DIETARY_SUPPLEMENT|Combination of Plant Extracts (BSL_EP025)|Each participant will consume 2 capsules daily at lunch for 8 weeks.
223838289|NCT04029558|DIETARY_SUPPLEMENT|Placebo|Each participant will consume 2 capsules daily at lunch for 8 weeks.
223838290|NCT00211601|BEHAVIORAL|Disease Management Assessment|
223838291|NCT00469781|DRUG|2. Xibrom (Bromfenac)|Group 1 and 2: 1 drop(Instill one drop in the eye that was operated on twice daily)3 days prior to surgery and 4 doses during dilation immediately before the procedure. Use for 4 weeks after surgery.
223838292|NCT00469781|DRUG|1. Pred Forte|"Group 1 Instill one drop in the eye that was operated on four times a day starting on day of surgery and use for four weeks.~Group 2 Instill one drop in the eye that was operated on twice a day starting on day of surgery and use for four weeks."
223838293|NCT03997058|OTHER|Auricular point pressure therapy|Use a hard and smooth pill to adhere to the center of the 0.7×0.7cm tape. Hold the puncture clip on the part of the ear which is selected, and give appropriate pressure (揉) to make the patient have heat, hemp, Swelling and painful feeling; patients with sputum press 3-5 times a day, each time 1-2 minutes per hole, and must be pressed once every 15-30 minutes before going to bed every night. Press the point pressure method (press the ear point with a fingertip and press it loosely, each interval is 0.5 seconds. It is better for the patient to feel the swelling and slightly heavy tingling, and the force should not be too heavy. Generally, each time the hole can be pressed 27 times. Each time one side of the ear is selected, the two ear points are used alternately, staying in the summer for 1-3 days, and staying in the winter for 3-7 days.It is not appropriate to have local inflammation of the auricle, frostbite or surface skin ulceration.
223838294|NCT03997058|DRUG|Oral estazolam medication|The first dose was started from 0.5mg, qn, and taken at 30min-1h before going to bed. If the dose is not effective, gradually increase the amount to 2mg, qn. If the patient has drug-induced liver damage and respiratory depression, it is necessary to stop the drug immediately. Hemorrhoids avoid drinking alcohol during medication.
223838295|NCT02076685|DRUG|isoniazid|dose adjustment according to the pharmacogenomic results
223838296|NCT03675243|DIAGNOSTIC_TEST|sphincterometry|Sphincterometry is a method of the spincter function examination, which allows to assess the state of the anal sphincter muscle and its function
223838297|NCT04268953|DRUG|Tricaprilin|Tricaprilin formulated as AC-SD-03 mixed in 300mL water
223838298|NCT04320615|DRUG|Tocilizumab (TCZ)|Participants will receive 1 dose of IV TCZ. 1 additional dose may be given if clinical symptoms worsen or show no improvement.
223838299|NCT04320615|DRUG|Placebo|Participants will receive 1 dose of IV placebo matched to TCZ. Up to 1 additional dose may be given if clinical symptoms worsen or show no improvement.
223838300|NCT03003546|OTHER|Laboratory Biomarker Analysis|Correlative studies
223838301|NCT03003546|DRUG|Nab-paclitaxel/Rituximab-coated Nanoparticle AR160|Given IV
223838302|NCT03003546|OTHER|Pharmacological Study|Correlative studies
223838303|NCT06206980|OTHER|Physical Activity Promotion|"This intervention includes a hospital-based and a home-based intervention. During the hospital stay, the patients were provided with a health education which included information about pneumonia pathophysiology, healthy-lifestyle habits, benefits of being physically active, and any questions patients may have would be answered.~Additionally, an exercise program is provided, which includes resistance and aerobic exercise.~At the end of the hospital stay, a diary is provided to patients for recording the physical activity that performing the following 3 months. This diary is accompanied by phone calls at 15 days, 1 and 2 months of the hospital stay. During the phone calls, patients are motivated to increase their activity levels, and any questions patients may have, are answered."
223838304|NCT06206980|OTHER|Control Intervention|Patients received an informational brochure in a consultation with a health professional. The brochure explained the importance of physical activity to improve the health condition of these patients. Patients had the opportunity to ask any questions to the healthcare professional
223838305|NCT01435057|PROCEDURE|exercise training|comparison of strength versus endurance training (two or three times a week, 60 minutes per training session) over 24 months
223838306|NCT01226628|BIOLOGICAL|CNTO 2476|
223838307|NCT01226628|PROCEDURE|iTrack Model 275 micro catheter|CNTO 2476 will be administered subretinally using the iTRACK microcatheter in participants with visual acuity impairment. During surgery, the portion of microcatheter distal to the flexible blue hub is inserted into the subretinal space via a peripheral scleral cutdown and choroidal fistula.
223838308|NCT01427335|DRUG|calcium|"intravenous infusion of 10 % calcium gluconate 10 mL in 200 mL of physiologic saline on the day of ovum pickup, day 1,day 2, and day 3 after ovum pickup were administered in study group.~Intravenous infusion was performed within 30 minutes"
223838309|NCT01427335|DRUG|0.9 % saline|0.9 % saline intravenous infusion
223838310|NCT03684005|OTHER|MyPatientPal smartphone app|All patients in this single-arm study will use a smartphone-based app, MyPatientPal, to enter symptoms and track medications related to their cancer treatment. No drugs will be administered for the purposes of this behavioral study.
223838311|NCT03269448|DIAGNOSTIC_TEST|Peripheral venous blood sampling|Blood collected from peripheral venous (extremities) and central venous (central catheter) for blood gas analyses
223838312|NCT01023880|DRUG|CEP-18770|CEP-18770 beginning at a dose of 1.5 mg/m2. Patients will receive I.V. administration on days 1, 8, 15 (up to 8 cycles of 28 days each). When the MTD is established, additional patients will be treated at the MTD.
223838313|NCT03356860|DRUG|Paclitaxel|80mg/m2 IV weekly from week 1 to week12
223838314|NCT03356860|DRUG|Epirubicin|90 mg/m2 IV Q 2 weeks from week 14 to week 20
223838315|NCT03356860|DRUG|Cyclophosphamide|600 mg/m2 IV Q 2 weeks from week 14 to week 20
223838316|NCT03356860|DRUG|Durvalumab|Durvalumab 1500 mg IV at week 14 and 18
223838317|NCT03752762|DIETARY_SUPPLEMENT|SQ-LNS|SQ-LNS is a peanut-based ready to use home fortification product to improve diet quality in children 6-24 months of age. It includes peanuts and other ingredients such as vegetable fat, powdered milk and several micronutrients. The formulation designed for this study will not include sugar.
223838318|NCT03752762|BEHAVIORAL|SPOON behavioral change strategy|An innovative behavioral change strategy designed using ethnographic and marketing methods to promote adequate infant and young child feeding practices and the use of SQ-LNS. The strategy will be delivered to mothers or caregivers through individual home-visits and group sessions.
223838319|NCT06316505|BEHAVIORAL|Oral hygiene motivation with individual oral photograps|Oral photograps was taken at control sessions.
223838320|NCT01449721|DRUG|Intravenous fluid|0.9% Sodium chloride intravenous fluid
223838321|NCT05229172|DEVICE|Volume Targeted Ventilation|There is no study specific intervention planned. Procedures will be conducted according to standard of care of each participating hospital and the instructions for use of the study device.
223838322|NCT01907412|BEHAVIORAL|Family Foundations Coparenting Program|"Family Foundations, a program for adult couples expecting their first child, is designed to help them establish positive parenting skills and adjust to the physical, social, and emotional challenges of parenthood. Program topics include coping with postpartum depression and stress, creating a caring environment, and developing the child's social and emotional competence.~Family Foundations is delivered to groups of couples through four prenatal and four postnatal classes of 2 hours each. Prenatal classes are started during the fifth or sixth month of pregnancy, and the postnatal classes end when the children are 6 months old.~Family Foundations is delivered in a community setting by childbirth educators who have received 3 days of training from Family Foundations staff."
223838323|NCT04159961|DRUG|DWJ211|Inject the Drug into submental fat and abdominal fat via subcutaneous
223838324|NCT03822624|DIETARY_SUPPLEMENT|Probiotic|Probiotic mixture with three bacterial strains with maltodextrin as a carrier.
223838325|NCT03822624|OTHER|Placebo|Placebo comparator with maltodextrin as a carrier.
223838326|NCT03171558|PROCEDURE|Gastric Pull Up|Using gastric tissue to reconstruct the esophagus and pharynx after pharyngo-esophagectomy.
223838327|NCT03171558|PROCEDURE|Free Flap Surgery|Using radial forearm free flap or anterolateral thigh free flap to reconstruct the cervical esophagus and pharynx after pharyngectomy and cervical esophagectomy.
223838328|NCT03490903|DEVICE|Virtual Reality|Subjects undergoing the Virtual Reality Intervention will be fitted with a VR headset and headphones, and undergo an immersive meditation experience provided by AppliedVR, Inc. The headphones will not be noise-cancelling, and the subject will be able to communicate with the physician or circulating nurse if needed.
223838329|NCT03490903|DRUG|Fentanyl Injection|Fentanyl is commonly administered to treat pain during invasive procedures such as coronary angiography. Intravenous fentanyl injection dosages are determined by the physician operator, and administered by the circulating nurse.
223838330|NCT03490903|DRUG|Midazolam injection|Midazolam is commonly administered to treat anxiety during invasive procedures such as coronary angiography. Intravenous midazolam injection dosages are determined by the physician operator, and administered by the circulating nurse.
223838331|NCT02915718|PROCEDURE|protein A immunoadsorption|protein-A immunoadsorption for 5 days and i.v. IgG（0.5g/kg Body weight）substitution
223838332|NCT00579540|DIETARY_SUPPLEMENT|Flax Seed Oil|Subject will follow their usual diet for 4 weeks, at week 6 they will be randomized to receive either flax seed oil, fish oil, or soybean oil capsules for 6 weeks. They will take six capsules orally six times a day for a total of six weeks.
223838333|NCT00579540|DIETARY_SUPPLEMENT|Fish Oil|Subject will follow their usual diet for 4 weeks, at week 6 they will be randomized to receive either flax seed, fish oil, or soybean oil capsules for 6 weeks. They will take six capsules orally six times a day for a total of six weeks.
223838334|NCT00579540|DIETARY_SUPPLEMENT|Soybean Oil|Subject will follow their usual diet for 4 weeks, at week 6 they will be randomized to receive either flax seed, fish oil, or soybean oil capsules for 6 weeks. They will take six capsules orally six times a day for a total of six weeks.
223838335|NCT01216982|DRUG|Lovaza, omega-3 fatty acid ethyl ester|Three 1g capsules/day for three months; this corresponds to a total of 2520mg EPA+DHA/day
223838336|NCT01216982|DRUG|Placebo, visually identical to Lovaza|Three 1g corn oil capsules/day for three months
223838337|NCT02793635|DEVICE|Indego Powered Exoskeleton|Subjects who have Spinal Cord Injury will wear the Indego device which will include being trained and evaluated for fifteen (15) sessions.
223838338|NCT05748782|OTHER|Baska Mask|The Baska mask (Logikal Health Products PTY Ltd., Morisset, NSW, Australia) is a supraglottic airway device introduced in 2012 with many innovations that might be expected to overcome these derangements.
223838339|NCT05748782|DEVICE|Endotracheal tube|BASKA Mask
223838340|NCT04600401|OTHER|Mentis Plus+ (Experimental Group)|"Each factor can be considered a module, so it is a modular program. So, each module has 3 sessions to be carried out in full. It is a systematic program, so the order of the sessions is regulated by the letters A, B and C for each module. The modules to be worked on correspond to the low-level or languising factors identified after the application of the positive mental health questionnaire (PMHQ). After the application of the PMHQ, people are grouped with the same module to work."
223838341|NCT00491725|DRUG|repaglinide|
223838342|NCT00491725|DRUG|metformin|
223838343|NCT02654795|RADIATION|computed tomography|CT angiography will be performed with a dual-source CT scanner using prospective ECG gating, with detector collimation of 128x0.6 mm, a gantry rotation time of 280 ms, tube voltage of 100-120 kV, tube current of 280-380 mAs depending on the patient's body mass.
223838344|NCT05441358|PROCEDURE|Open Heart Surgery|Blood collection at 4 timepoints (prior to anesthesia induction, immediately post-protamine, 1-2 hours post protamine, and up to 48 hours post-surgical completion) to assess platelet function.
223838345|NCT05810675|BEHAVIORAL|Telehealth Early Intervention Program (TEIP)|The Telehealth Early Intervention Program (TEIP) that will be carried out by parents at home when interact with their children; and to train parents in delivering developmental and behavioral techniques to their children. The participating families will be randomized in parallel to treatment and comparison groups for teaching the knowledge and techniques: (1) Treatment group: providing the training of TEIP for parents via telehealth modalities as they learn critical skills with their child with the goal of increasing multidimensional child developments. Intervention provider will provide the training for parent-child dyad interaction to work with parents to implement these strategies at home environment.
223838346|NCT03334760|OTHER|Danish National Birth Cohort|DNBC is a nationwide cohort study of pregnant women and their offspring. The women were enrolled early during pregnancy between 1996 and 2002. They provided information on exposures during and after pregnancy by means of four computer-assisted telephone interviews in gestational weeks 12 and 30 and post-partum when the child was 6 and 18 months old.
223838347|NCT05353738|BIOLOGICAL|Blood sample for research of anti-xoprs netralizing anti spike|"The evaluation of the ex vivo efficacy of the Moderna vaccine by the search for anti Spike AcN at 6,24, 40 and 52 or 64 weeks after the second injection of the vaccine.~The effectiveness of vaccination of CANNEMUSS patients will be evaluated by comparing the antibodies anti-S neutralizers from patients in the CANNEMUSS study to those from patients whose sample was carried out before the pandemic (negative control group) and those of patients infected with the omicron virus (positive control group)."
223838348|NCT05353738|OTHER|Questionnaire|Evaluation of vaccine efficacy in real life by filling out questionnaires
223838349|NCT01672450|DRUG|Intratumoral Ipilimumab and Interleukin-2|Only 1 lesion, 0.5 -2 cm, will be treated. Interleukin-2, 3 mIU IT TIW x 2 weeks (days 1, 3 and 5), then BIW x 6 weeks (days 1 and 4). Escalating doses of Ipilimumab (0.1, 0.25, 0.5, 1, 2, mg) IT weekly x 8 weeks
223838350|NCT04055285|PROCEDURE|Sympathetic Renal Denervation|Catheter-based sympathetic renal denervation (RDN) using radiofrequency, ultrasound, or perivascular injection of neurotoxic agents such as alcohol has been introduced as a minimally invasive alternative treatment option for patients with resistant hypertension. RDN consists of endovascular catalysis of the kidney sympathetic nerves running in the wall of the renal arteries.
223838351|NCT04055285|DEVICE|Implantable Loop Recorder|Implantable Loop Recorders (ILRs) are small, subcutaneously implanted devices that are able to detect and store atrial fibrillation episodes lasting longer than 2 minutes with high sensitivity (96.1-100%) and good specificity (67-85.4%) for a period of up to three years.
223838352|NCT02168920|DRUG|2 mg/day|Once daily for 10 weeks
223838353|NCT02168920|DRUG|3 mg/day|Once daily for 10 weeks
223838354|NCT02168920|DRUG|6 mg/day|Once daily for 10 weeks
223838355|NCT02168920|DRUG|Placebo (0 mg/day)|Once daily for 10 weeks
223838356|NCT00129675|DRUG|[123I]ß CIT|"Single Photon Emission Computed Tomography~SPECT imaging uses the single photon emissions from radioactive compounds that are (most commonly) injected into a patient and are metabolized by specific organs or body systems. SPECT imaging is performed by using a gamma camera to acquire multiple 2-D images (also called projections), from multiple angles. A computer is then used to apply a tomographic reconstruction algorithm to the multiple projections, yielding a 3-D dataset. This dataset may then be manipulated to show thin slices along any chosen axis of the body, similar to those obtained from other tomographic techniques, such as MRI, CT, and PET. The resulting SPECT images reflect body/organ function as opposed to specific anatomy of other imaging modalities such as CT or MRI."
223838357|NCT06139263|DEVICE|a percussion massage gun (Compex Fix 2.0)|Vibration application will be applied to the individuals in this group in addition to conventional methods. Vibration application will be applied to the trapezius, levator scapula and cervical paravertebral muscles with a percussion massage gun (Compex Fix 2.0) along the origo-insersio line for 3 minutes for each muscle group. Vibration application will be made with the soft head of the percussion massage gun. Vibration therapy will be applied 3 days a week for 3 weeks.
223838358|NCT06139263|OTHER|conventional treatment program|In the conventional treatment program, heat will be applied to the neck area for 20 minutes and TENS (100 Hz) will be applied to the painful area. Additionally, patients will be given joint range of motion (ROM) exercises under the supervision of a physiotherapist. Patients will be asked to perform ROM exercises in 2 sets of 10 repetitions, holding for 2 seconds at the end point in all directions. As a strengthening exercise, isometric exercises will be given in the flexion extension, right and left lateral flexion directions by waiting for 6 seconds at the end point. Isometric exercises will be performed in 2 sets of 10 repetitions with 1 minute rest between sets.
223838359|NCT04333173|PROCEDURE|endovascular procedure|Endovascular therapies for erectile dysfunction
223838360|NCT02120989|BEHAVIORAL|Partner-Assisted Cognitive Behavioral Therapy for Insomnia|Study treatment includes partner-assisted Cognitive Behavioral Therapy for Insomnia (CBT-I) and consists of 7-8 weekly group therapy sessions of 2 hours each. Partner-assisted CBT-I focuses on altering patients' sleep schedules and changing their behaviors and patterns around sleeping in order to help them sleep in a single block of time overnight. As part of this treatment, participants will be asked to change, possibly reduce, the amount of time spent in bed and to maintain a specific bed time and wake time, as well as other potential changes depending on his/her specific insomnia pattern. This treatment has been shown to be safe and efficacious for a wide range of patients.
223838361|NCT05515029|COMBINATION_PRODUCT|GVHD prevention: post-transplantation cyclophosphamide, abatacept, vedolizumab, calcineurin inhibitor|Cyclophosphamide 100 mg/kg/course on the days +3, +4 Abatacept 10 mg/kg/day on the days +5, +14, +28, +45, +60, +90, +120 Vedolizumab 10 mg/kg/day, max. 300 mg on the days -1, +14, +28
223838362|NCT03285711|DRUG|Filgotinib|200 mg tablet administered orally once daily
223838363|NCT03285711|DRUG|Lanraplenib|30 mg tablet administered orally once daily
223838364|NCT03285711|DRUG|Filgotinib placebo|Tablet administered orally once daily
223838365|NCT03285711|DRUG|Lanraplenib placebo|Tablet administered orally once daily
223838366|NCT03964025|DEVICE|Wearing Cardioskin™ for 14 days|The current standard of care for diagnosing AF is through the use of a 24 hour Holter device. In this study, in addition to wearing the 3-lead Holter recorder for 24 hours, the subject will be wearing the Cardioskin™ for a period of 24 hours as well, after which the subject will continue wearing the Cardioskin™ alone for an additional period of 13 days.
223838367|NCT00865644|DRUG|Imiquimod 5% Cream|Applied topically to three tumors 5 times per week for a full 6 weeks
223838368|NCT02935855|DRUG|Dabigatran|
223838369|NCT02935855|DRUG|Apixaban|
223838370|NCT02935855|DRUG|Rivaroxaban|
223838371|NCT02935855|DRUG|Edoxaban|
223838372|NCT02935855|DRUG|Warfarin|
223838373|NCT02935855|DRUG|Acenocumarole|
223838374|NCT00085059|DRUG|boronophenylalanine-fructose complex|
223838375|NCT02053194|BEHAVIORAL|Pharmacist-led educational intervention|1\) Educational material to participants in the form of a written educational brochure on inappropriate prescriptions that was developed and tested during the EMPOWER study. 2) Evidence-based pharmaceutical opinions sent to the treating physicians.
223838376|NCT00122161|BEHAVIORAL|ATHENA Decision Support System, An Automated Clinical Decision Support System for Health Care Providers|
223838377|NCT00122161|BEHAVIORAL|Profiling performance|
223838378|NCT06520033|DEVICE|humanoid robot|"The humanoid robot will execute an educational hydration plan that will be integrated into the usual dynamics of the residence. In order to increase the fluid intake of the residents, stimulation activities will be proposed that will be carried out by the robot such as reminders, interactive activities and positive reinforcement. It will also allow the daily recording fluid intake of each residents.~This intervention will last two months."
223838379|NCT06520033|OTHER|Usual care|The center's usual hydration plan
223838380|NCT02431533|DIETARY_SUPPLEMENT|PX0612|PX0612 is a probiotic contained in a veggie capsule.
223838381|NCT02431533|DIETARY_SUPPLEMENT|Di-Calcium Phosphate|Patients in the 'placebo' group will receive the placebo capsules. The main ingredient in the placebo capsule is Di-Calcium Phosphate
223838382|NCT00281944|DRUG|oxaliplatin|Given IV
223838383|NCT00281944|DRUG|fluorouracil|Given IV
223838384|NCT00281944|DRUG|leucovorin calcium|Given IV
223838385|NCT00281944|OTHER|pharmacological study|Correlative studies
223838386|NCT00281944|PROCEDURE|positron emission tomography|Undergo PET scan
223838387|NCT00281944|PROCEDURE|computed tomography|Undergo PET/CT scan
223838388|NCT02107443|BEHAVIORAL|Geriatric Assessment Summary|Complete summary of results from the Geriatric Assessment
223838389|NCT02107443|BEHAVIORAL|Geriatric Assessment Targeted Recommendations|"Recommendations are made based on areas patients were impaired in on the Geriatric Assessment. They include referrals, tests, medication review, instructions, and support services. The choice of which recommendation to implement is left to the discretion of the physician.~Treatment modifications"
223838390|NCT02107443|BEHAVIORAL|Geriatric Assessment (GA)|A GA measures the issues important to older patients, including function, psychological status, cognitive abilities, social support, and the impact of medical problems on quality of life.
223838391|NCT04354311|DEVICE|ANI|Under steady state total intravenous anaesthesia with propofol and remifentanil at constant dosage, tetanus stimulation of the ulnar nerve was performed followed by orotracheal intubation. The variation of ANI and hemodynamic parameters as well as the somatic response associated with both maneuvers were collected.
223838392|NCT02351895|OTHER|Copper impregnated linen|Copper impregnated linen was used in place of regular linen on one ward (out of two) for each period of the study. Each study period lasted for 23 weeks. After the washout period (3 weeks) the wards were switched.
223838393|NCT03956576|OTHER|[Pyr]apelin-13|Peptide \[Pyr\]apelin-13 infusion
223838394|NCT03656016|DEVICE|Magnetic Resonance Imaging|Phase contrast magnetic resonance imaging technique
223838395|NCT00333788|BIOLOGICAL|Certolizumab pegol (CDP870)|400 mg subcutaneous (sc) injection of Certolizumab pegol (CDP870) every 2 (Q2W) or 4 (Q4W) weeks
223838396|NCT00630214|DIETARY_SUPPLEMENT|Oral calcium plus vitamin D|calcium supplementation took 3 g/day oral calcium (1 g every 8 h) plus 1 mcg/day vitamin D (0.5 mcg every 12 h), beginning on the night of surgery and continuing for 14 days.
223838397|NCT00630214|DIETARY_SUPPLEMENT|Oral calcium alone|calcium carbonate (3 g/day, 1 g every 8 h)
223838398|NCT01791634|PROCEDURE|proximal chevron osteotomy|
223838399|NCT01791634|PROCEDURE|proximal open wedge osteotomy with LPS system|
223838400|NCT01521325|DRUG|Amatuximab|Subjects will receive one infusion of radiolabeled amatuximab.
223838401|NCT01248520|OTHER|influenza and general health information|Subjects assigned to the influenza information group will receive health text messages from the time they enroll until they deliver. These messages will contain general health information as well as information regarding influenza and the importance of vaccination during pregnancy.
223838402|NCT01248520|OTHER|general health information|Subjects assigned to the influenza information group will receive health text messages from the time they enroll until they deliver.
223838403|NCT01194882|DRUG|HUMAN INSULIN (BIOSYNTHETIC)|Pharmaceutical form: solution for infusion Route of administration: Intraperitoneal use Dose regimen: 400 IU/ml
223838404|NCT01194882|DRUG|Insuplant|"Pharmaceutical form:solution for infusion Route of administration: Intraperitoneal use~Dose regimen:"
223838405|NCT05039034|OTHER|Advice according to primary prevention guidelines on stroke of China|
223838406|NCT02601586|DRUG|PR Oxycodone|PR Oxycodone
223838407|NCT02601586|DRUG|Levodopa|Levodopa
223838408|NCT02601586|DRUG|Oxycodone Placebo|Placebo of PR Oxycodone
223838409|NCT02601586|DRUG|Levodopa placebo|
223838410|NCT06392685|OTHER|Silane coupling agent|Silane coupling agent (Porcelain primer) will be applied following the acid etch rinsing and drying step, for 30 seconds and then it will be thoroughly dried using air syringe then universal adhesive with regular silane will be actively applied for 20 seconds and then it will be light cured for 20 seconds and final restoration will be done
223838411|NCT06392685|OTHER|Adhesive containing silane.(Intervention 1 )|Universal adhesive with regular silane will be applied for 20 seconds, air thinned for 10 seconds and then it will be light cured for 20 seconds and final restoration will be done using same resin composite material
223838412|NCT06392685|OTHER|Acid resistance silane containing adhesive.(Intervention 2)|Acid resistance silane containing adhesive will be applied for 20 seconds, dry with gentle air for 3 seconds, then with stronger air and light cured for 10 seconds and final restoration will be done
223838413|NCT04672356|BIOLOGICAL|IBI939|IBI939 injection
223838414|NCT04672356|BIOLOGICAL|Sintilimab|Sintilimab injection
223838415|NCT02766998|PROCEDURE|Preserved umbilical vein as shunt/conduit|All subjects will have umbilical vein harvested and stored for use in first cardiac surgery requiring shunt or conduit.
223838416|NCT01799772|BEHAVIORAL|Comprehensive Behavioral Intervention|"1. Evidence-based exercise program - Combination of high intensity lower extremity strengthening, endurance on the treadmill, functional task-oriented exercises, and balance techniques. During 12 sessions, subjects will be instructed to become independent in performing the exercises at home.~2. Physical activity promotion - Instructions to engage in moderate intensity exercise 5 days/week will be delivered along with the exercise program.~3. Healthy nutrition guidance - Instructions on healthy nutrition delivered by a dietitian.~4. Self-management - Basic self-management skills advocated by the Arthritis Foundation Self-Help Program and behavioral strategies (self-monitoring, problem solving, relapse prevention, and goal-setting) and feedback into approaches a, b and c."
223838417|NCT01799772|OTHER|Standard of Care Exercise Program|Typical rehabilitation after TKA surgery
223838418|NCT05470413|DRUG|SHR0302|SHR0302 4 mg
223838419|NCT05470413|DRUG|SHR0302|SHR0302 8 mg
223838420|NCT05470413|DRUG|Placebo|Placebo
223838421|NCT00884520|DRUG|[F-18] VM4-037|"The individual doses of \[F-18\]VM4-037 contain a maximum of 20 mCi for normal volunteers and 10 mCi for cancer subjects.~The single IP dose is administered to the study subject immediately prior to the start of PET imaging."
223838422|NCT00729690|DRUG|Pregabalin|"Group 1 (n=16, multi-dose pregabalin): patients receive pregabalin 150 mg orally 1 hour prior to surgery and then repeat 150 mg doses at 12 and 24 hours after initial dose.~Group 2 (n=16, single dose pregabalin): patients receive pregabalin 150 mg orally 1 hour prior to surgery, and then placebo doses at 12 and 24 hours after initial dose.~Group 3 (n=16, placebo): patients receive matching placebo at the same 3 time points as Groups 1 and 2."
223838423|NCT00729690|DRUG|Pregabalin|Group 2 (n=16, single dose pregabalin): patients receive pregabalin 150 mg orally 1 hour prior to surgery, and then placebo doses at 12 and 24 hours after initial dose.
223838424|NCT00729690|DRUG|Placebo|Group 3 (n=16, placebo): patients receive matching placebo at the same 3 time points as Groups 1 and 2.
223838425|NCT05800119|BEHAVIORAL|Brain-level condition|Participants will receive a brief reading passage about the neurobiological effects of psychotherapy.
223838426|NCT05800119|OTHER|Mind-level condition|Participants will receive an active control consisting of a brief reading passage about the effectiveness of psychotherapy.
223838427|NCT00168051|DRUG|ReFacto|
223838428|NCT00168051|DRUG|Advante|
223838429|NCT01591161|DRUG|Mapracorat|1 drop of study medication into the study eye QID for 14 days
223838430|NCT01591161|DRUG|Placebo|1 drop of vehicle into the study eye QID for 14 days.
223838431|NCT01048203|DRUG|ABR-215050|1 mg ABR-215050
223838432|NCT02117336|DRUG|P1446A-05|"The study have dose escalation phase, followed by a dose extension phase.~* Dose escalation phase: five Dose Levels will be evaluated in the 'dose escalation' phase. The Dose Levels selected are 50 mg (Dose Level 1), 75 mg (Dose Level 2), 125 mg (Dose Level 3), 200 mg (Dose Level 4) and 275 mg (Dose Level 5), once daily. If required, a 25 mg once daily dose (Dose Level -1) will also be studied. For Dose Levels 1, 2 and 3 there will be 2- dosing periods: Single Dose and Continuous Dose. At least 3-patients will be enrolled at each Dose Level. Dosing regimens planned for Dose Level 4 and 5 are 200 and 275 mg once daily. In the continuous dose period, patients will receive P1446A-05 on a 28-day cycle, until the occurrence of disease progression or unacceptable toxicity.~* Dose Extension Phase: Up to a total of 14 patients will be treated at the MTD of P1446A-05, determined in the dose escalation phase, until the occurrence of disease progression or unacceptable toxicity or death."
223838433|NCT06183515|PROCEDURE|CPAP group: postoperative CPAP support, non-CPAP group: oxygen 3 liters per minute (L/min) either via mask for those who were extubated or through a T-piece for those with a trash|The effect of CPAP was prevent atelectasis after apnoeic ventilation during the procedure and to reduce post-procedural airway problems.
223838434|NCT03524313|DIAGNOSTIC_TEST|End tidal carbon monoxide|"* Evaluation of cardiac output estimated by transthoracic echocardiography and end tidal carbon monoxide~* Evaluation of cardiac output estimated by transthoracic echocardiography and portal veinous velocity~* Evaluation of femoral veinous velocity"
223838435|NCT04019561|DRUG|MEDI0382 high dose|MEDI0382 high dose administered subcutaneously
223838436|NCT04019561|DRUG|Placebo for MEDI0382 high dose|Placebo for MEDI0382 high dose administered subcutaneously
223838437|NCT04019561|DRUG|MEDI0382 low dose|MEDI0382 low dose administered subcutaneously
223838438|NCT04019561|DRUG|Placebo for MEDI0382 low dose|Placebo for MEDI0382 low dose administered subcutaneously
223838439|NCT04842279|OTHER|FACE-Q scale|"FACE-Q is a recently developed and validated patient reported outcome measure (PROM) tool that allows clinicians to assess patient perspectives after skin cancer surgery of the face.The PROM is used to assess the perspective and impact of skin cancer as well as its treatment on the patient's quality of life (QoL). Patients with skin cancer may have increased anxiety, social isolation, and cosmetic concerns after surgery. The FACE-Q utilizes five scales to measure the psychometric, QoL, patient experience, and cosmetic outcomes. Raw scores are transformed to a 0-100 scale with a higher score indicating a better outcome.~Any studies using FACE-Q for facial surgery reconstruction at our center may be eligible for inclusion in the database"
223838440|NCT00290082|DRUG|loxapine, midazolam|agitated patients received loxapine 1 ml/ kg body weight ( loxapine 25mg/ml) or midazolam 1 ml/ kg body weight ( midazolam 1mg/ml) if patients were still agitated 20 min after the first treatment, they received loxapine 0.5 ml/ kg body weight ( loxapine 25mg/ml) or midazolam 0.5 ml/ kg body weight ( midazolam 1mg/ml)
223838441|NCT00290082|BIOLOGICAL|blood sample|was evaluated in patients sedated, alcohol level, blood sugar
223838442|NCT00290082|OTHER|patient monitoring|Till his coming out the emergency service, patient had an hemodynamic, respiratory and neurologic monitoring as well as an agitated score monitoring The occurence of a complication during the 15 days after leaving the emergency department was prospected.
223838443|NCT00290082|DRUG|Loxapine|Loxapine 1 mL / 10 kg
223838444|NCT00290082|DRUG|Midazolam|Midazolam 1 mL / 10 Kg
223838445|NCT03390361|DEVICE|Femtosecond Laser-assisted|Laser cataract surgery will be performed in one eye
223838446|NCT03390361|PROCEDURE|Manual Cataract Surgery|Manual cataract surgery will be performed in contralateral eye
223838447|NCT02886936|DEVICE|iFIT Transtibial Prosthesis|Transtibial amputee volunteers will be fit with the iFIT device and instructed on its use. Patient will wear the iFIT device for a two week time period according to a provided wear schedule. At the end of this time patient will rate it for comfort, stability and ease of use.
223838448|NCT02886936|DEVICE|iFIT Transfemoral Prosthesis|Transfemoral amputee volunteers will be fit with the iFIT device and instructed on its use. Patient will wear the iFIT device for a two week time period according to a provided wear schedule. At the end of this time patient will rate it for comfort, stability and ease of use.
223838449|NCT02320721|DRUG|Insulin Glargine (HOE901 - U300)|Self-administered by subcutaneous (SC) injection in the evening using a pre-filled pen. Dose titration to achieve fasting self-monitored plasma glucose (SMPG) from 90 to 130 mg/dL (5.0 to 7.2 mmol/L).
223838450|NCT02320721|DRUG|Insulin Glargine (HOE901 - U100)|Self-administered by SC injection in the evening using a pre-filled pen. Dose titration to achieve fasting SMPG from 90 to 130 mg/dL (5.0 to 7.2 mmol/L).
223838451|NCT02320721|DRUG|Background therapy|Non-insulin anti-diabetic drugs with the exception of thiazolidinediones.
223838452|NCT05557383|BEHAVIORAL|use peanut ball|The peanut ball was placed between the legs of a woman in the intervention group immediately after she received her epidural and consented to participate in the study.
223838453|NCT00110682|DRUG|Imiquimod used as an adjunct to cryotherapy|
223838454|NCT05824221|DEVICE|rTMS|Non invasive brain stimulation in Cocaine Use Disorder
223838455|NCT03839121|DEVICE|Cardiac Resynchronization Therapy (CRT)|Observation and documentation of CRT patients
223838456|NCT04131907|DEVICE|Optilume BPH Catheter System|The Optilume™ BPH, Prostatic Dilation DCB Catheter is a dilation catheter used to exert radial force to dilate the prostatic urethra resulting in a commissurotomy. The distal end of the catheter has a semi-compliant inflatable double lobe balloon that is coated with a proprietary coating containing the active pharmaceutical paclitaxel.
223838457|NCT04131907|DEVICE|Optilume Sham Device|21 Fr sheathed Optilume™ BPH Prostatic Pre-dilation Catheter (modified to prevent inflation)
223838458|NCT01297530|DRUG|BAY87-2243|Oral administration once daily in a continuous schedule. Starting dose will be 5 mg and dose will be escalated dependent on any dose limiting toxicities.
223838459|NCT01730014|DRUG|148-0287-A-4.2mM-cartridge|In a dose-escalating design, healthy subjects will receive a single dose, injected subcutaneously.
223838460|NCT01730014|DRUG|placebo|In a dose-escalating design, healthy subjects will receive 148-0287-A-placebo-cartridge, injected subcutaneously.
223838461|NCT01730014|DRUG|148-0287-A-4.2mM-cartridge|In a dose-escalating design, subjects with type 1 diabetes will receive a single dose, injected subcutaneously. Subjects will only be randomised to receive either treatment A or B.
223838462|NCT01730014|DRUG|placebo|In a dose-escalating design, subjects with type 1 diabetes will receive 148-0287-A-placebo-cartridge in a single dose, injected subcutaneously. Subjects will only be randomised to receive either treatment A or B.
223838463|NCT01730014|DRUG|insulin glargine|In a dose-escalating design, subjects with type 1 diabetes will receive insulin glargine once daily, injected subcutaneously. Subjects will only be randomised to receive either treatment A or B.
223838464|NCT01730014|DRUG|sodium chloride 0.9% w/v|In a dose-escalating design, subjects with type 1 diabetes will receive sodium chloride 0.9% w/v, injected subcutaneously daily. Subjects will only be randomised to receive either treatment A or B.
223838465|NCT01874327|BEHAVIORAL|Baby JASPER|Intervention focuses on core deficits of joint attention, play, engagement, and regulation embedded within AEPS curriculum
223838466|NCT01874327|BEHAVIORAL|Standard Baby Classroom|Assessment, Education and Programming System (AEPS) for Infants and Children curriculum focused on early developmental milestones in fine and gross motor, cognitive, adaptive and social areas
223838467|NCT01670227|BEHAVIORAL|PARENTCORPS|ParentCorps is a culturally-informed, universal intervention (for all children enrolled in Pre-K within an elementary school) designed to promote positive behavioral supports for children at home and in the classroom. ParentCorps includes two complementary components: 1) parent and child group intervention (13 2-hour sessions after school) for Pre-K students and their families; 2) professional development and individual consultation for early childhood teachers.
223838468|NCT02357680|OTHER|Diary|"The intervention is a notebook in which the relative will be asked to keep a diary of the time when the patient is critically ill in the ICU. At least two photos of the patient will be added to the diary upon full consent from the patient.~The diary contains a written description on how to use the diary during and after the patients stay in the ICU."
223838469|NCT01346670|DRUG|LipoCol and Mevacor|To evaluate the relative bioavailability of lovastatin and its ß-hydroxy acid of 600 mg LipoCol Forte® Capsules compared to that of one 20 mg Mevacor® Tablet after single oral administration in healthy subjects using a 2x2 crossover design.
223838470|NCT04201496|COMBINATION_PRODUCT|Empagliflozin + Control-IQ x 4 wks then Basal-IQ x 2 wks|Participants with be provided with Empagliflozin to take daily for approximately 10 weeks. Along with the study medication, participants will initially use the Tandem t:slim insulin pump with Control-IQ Technology for 4 weeks. Participants will then transition to using the Tandem t:slim insulin pump with Basal-IQ Technology for 2 weeks.
223838471|NCT04201496|COMBINATION_PRODUCT|Empagliflozin + Basal-IQ x 2 wks then Control-IQ x 4 wks|Participants with be provided with Empagliflozin to take daily for approximately 10 weeks. Along with the study medication, participants will initially use the Tandem t:slim insulin pump with Basal-IQ Technology for 2 weeks. Participants will then transition to using the Tandem t:slim insulin pump with Control-IQ Technology for 4 weeks.
223838472|NCT04201496|DEVICE|No Empagliflozin + Control-IQ x 4 wks then Basal-IQ x 2 wks|Participants will initially use the Tandem t:slim insulin pump with Control-IQ Technology for 4 weeks. Participants will then transition to using the Tandem t:slim insulin pump with Basal-IQ Technology for 2 weeks. Empaglizflozin will not be provided to this group.
223838473|NCT04201496|DEVICE|No Empagliflozin + Basal-IQ x 2 wks then Control-IQ x 4 wks|Participants will initially use the Tandem t:slim insulin pump with Basal-IQ Technology for 2 weeks. Participants will then transition to using the Tandem t:slim insulin pump with Control-IQ Technology for 4 weeks. Empaglizflozin will not be provided to this group.
223838474|NCT06210763|BEHAVIORAL|Threshold IMT and traditional physical therapy program|twenty ICU-acquired weakness elderly patients will receive chest physiotherapy (cough training, vibration, percussion, rib springing, and postural drainage), 30 minutes of resisted training on upper- and lower-limb muscles (15 min on upper limb and 15 min on lower limb), and 30 minutes of neuromuscular electrical stimulation of lower- and upper-limb muscles (triceps and wrist extensors, dorsiflexors, and quadriceps). sessions will be executed 5 times weekly). this Group will receive 3-set IMT (two sessions daily via threshold IMT, the set contain 10 repetitions) 5 times weekly. The study duration will be 1 month.
223838475|NCT06210763|BEHAVIORAL|traditional physiotherapy program|twenty ICU-acquired weakness elderly patients will receive chest physiotherapy (cough training, vibration, percussion, rib springing, and postural drainage), 30 minutes of resisted training on upper- and lower-limb muscles (15 min on upper limb and 15 min on lower limb), and 30 minutes of neuromuscular electrical stimulation of lower- and upper-limb muscles (triceps and wrist extensors, dorsiflexors, and quadriceps). sessions will be executed 5 times weekly).
223838476|NCT01778062|DRUG|Indacaterol|Indacaterol 150µg once daily oral inhalation
223838477|NCT01778062|DRUG|Control|Placebo once daily oral inhalation
223838478|NCT05667259|OTHER|Surgical resection for cancer rectum|Curative resection for cancer recum
223838479|NCT01632358|DRUG|TAP311 capsules|
223838480|NCT01632358|DRUG|Placebo|
223838481|NCT01117597|RADIATION|low RF exposure level|Exposure with 1.5 W/kg
223838482|NCT01117597|RADIATION|sham exposure|intervention with sham RF exposure
223838483|NCT01117597|RADIATION|high RF exposure|intervention with high RF exposure
223838484|NCT02834572|BEHAVIORAL|All About Me|Assessment and algorithm to determine recommended HIV testing approach
223838485|NCT02834572|BEHAVIORAL|Control|HIV testing information
223838486|NCT04323644|PROCEDURE|Surgery|Emergency or elective surgery
223838487|NCT04421937|BEHAVIORAL|Procedure: Traditional Dysphagia Therapy (TDT)|"Traditional dysphagia therapy includes diet modification training, teaching postural compensatory methods, training of oral motor control exercises and tongue root exercises, training of swallowing maneuvers, and practice of chin-resistance exercise, which is the exercise of opening the upper esophageal sphincter.~Traditional Dysphagia Therapy will be applied for 45 minutes a day, 5 days a week for 3 weeks."
223838488|NCT04421937|DEVICE|Procedure: Neuromuscular Electrical Stimulation with TDT|The skin to be treated will be cleaned and dried. NMES will be implemented with signals received from two channels. In the first channel, the upper electrodes will be placed horizontally just above the hyoid bone. This is the place where the cupping is felt when the finger is pressed right under the chin. In the second channel, the lower electrodes will be placed horizontally, just above the thyrohyoid muscle. This is the place where you can feel a cupping when pressed with your finger, on both sides of the apple in the larynx. The device will be set to start at the lowest power, with very short pulses of approximately 700 microseconds, at intervals of 1 second. The power will be gradually increased according to the device and the power that the patient feels vibration will be stopped. The power to be applied will not exceed 25 milliamps. NMES application and Traditional Dysphagia Therapy will be applied for 45 minutes a day, 5 days a week for 3 weeks.
223838489|NCT03418896|DRUG|human chorionic gonadotropin|a single injection of a standard dose
223838490|NCT05299879|DIAGNOSTIC_TEST|Cardiopulmonary exercise test, NT-proBNP, Echocardiography, 6 minute walk test, Right heart catheterization|Screening for advanced HF with modified criteria from the Heart Failure Association of the European Society of Cardiology
223838491|NCT06398028|DRUG|Indocyanine green|Indocyanine green has a sharply defined spectral peak absorption of near-infrared light at 800 nm in blood plasma or blood. This is the same wavelength at which the optical density of oxygenated hemoglobin in blood approximately equals that of reduced hemoglobin. Therefore, this coincidental light absorption makes it possible to measure indocyanine green concentrations in blood, plasma and serum in terms of its optical density at 800 nm, independent of variations in oxygen saturation level
223838492|NCT06529601|DEVICE|CAD/CAM mandibular fixed retainer|Keeppy is a Class IIa custom-made medical device manufactured by Digital Service Leone s.r.l. - via Pratese 160/b, Florence, Italy. The Keeppy is an individualized fixed retainer, made of a Nickel-free Chrome Cobalt alloy, produced with a CAD-CAM procedure starting from a digital impression made with an intraoral optical scanner (3 Shape), which allows a perfect adaptation to the lingual surfaces of the 6 lower anterior teeth on which it is bonded. The device is characterized by the presence of applicators that can be placed temporarily on the buccal surface of the canines, which facilitate the clinician in the precise application of the device and which are removed as soon as the bonding phase of the retainer is complete. Bonding is performed using classic composite resins following a preparation phase of the lingual surface of the tooth consisting of the application of etchant (37% orthophosphoric acid) for 30 seconds and adhesive (primer-bonding).
223838493|NCT06529601|DEVICE|Conventional mandibular fixed retainer|The standard control device, which is among the most commonly used in routine clinical practice, consists of a steel braided wire. The device selected for the Class IIa investigation is the Ortho Flex Tech manufactured by Reliance Orthodontic Products, Inc. 1540 West Thorndale Ave. Itasca, IL 60143 USA. The Ortho Flex Tech steel braided wire is manually shaped by the clinician and cut with a wire cutter so that it has the proper length to extend over the 6 dental elements. Once the correct length has been defined, it is then held in place on the lingual surface of the teeth by the use of 2 interdental wires passing doubly through the interdental area (between the lateral incisor and canine on one side and the other). This allows the device to be bonded using composite resin after etching the lingual surfaces of the lower anterior teeth.
223838494|NCT03387514|DRUG|PSMA-based 18F-DCFPyL PET tracer for PET/CT exams|"18F-DCFPyL whole body PET/CT scan administered at the following timepoints:~PET1 - Prior to scheduled nephrectomy~PET2 - to establish a new baseline PET before systemic therapy~* PET2A - Post-surgery and prior to start of standard of care systemic therapy~* PET2B - 12-16 weeks from start of first line systemic therapy (immune-based or anti-angiogenic)~PET3 - If first line systemic therapy did not include anti-angiogenesis therapy and new systemic therapy does include anti-angiogenesis therapy~* PET3A - Prior to start of additional anti-angiogenesis therapy~* PET3B - 12-16 weeks from the start of additional anti-angiogenesis therapy~PET4 - obtained at clinical progression or 2 years following initial systemic therapy"
223838495|NCT03993405|OTHER|Ultrasonographic evaluation|Ultrasonographic measurement is assessment method to diagnosis of sarcopenia
223838496|NCT02202694|BEHAVIORAL|Culturally Adapted Cognitive behavior therapy|This 12 session Multimodal Psychosocial Intervention will include a supportive component, an educational component, psychosocial component
223838497|NCT01159535|BEHAVIORAL|Mindfulness Based Relapse Prevention|The MBRP intervention comprises 8 weekly, 2-hour sessions delivered in small group format (10-14 participants) by two therapists (Bowen, et al., 2009). In MBRP, therapists facilitate discussions and exercises and introduce the meditation practice component.Group sessions include discussions of mindfulness as a means of coping with craving and painful cognitions/sensations that precipitate relapse, role-playing exercises, meditation practice, and homework assignments.
223838498|NCT01159535|BEHAVIORAL|Relapse Prevention|intervention is composed of 8 weekly 2-hour sessions delivered in small group format (10-14 participants)
223838499|NCT01159535|BEHAVIORAL|Treatment as Usual|All participants will be enrolled in continuing care services (including attendance at AA, NA, or other self-help groups) as recommended by their treatment providers. Thus, TAU participants will have ongoing support and monitoring by their continuing care providers on a regular basis.
223838500|NCT00118144|DRUG|bortezomib|Given IV
223838501|NCT04069221|DRUG|Single oral dose of 800 mg OZ439|Single oral dose of 800 mg OZ439
223838502|NCT04069221|DRUG|Single oral dose of 400 mg OZ439|Single oral dose of 400 mg OZ439
223838503|NCT04069221|DRUG|Single oral dose of cobicistat|Single oral dose of 150 mg cobicistat
223838504|NCT04069221|DRUG|iv infusion of [14C]-OZ439|15-minute 10-mL iv infusion of 100 μg \[14C\]-OZ439
223838505|NCT04701593|DRUG|Triamcinolone Acetonide 40mg/mL|Sub-tenon irrigation 1cc
223838506|NCT00245011|BIOLOGICAL|filgrastim|Filgrastim will be administered post post chemotherapy until target WBC (white blood cell) count is achieved.
223838507|NCT00245011|DRUG|ifosfamide|Ifosfamide administered IV.
223838508|NCT00245011|PROCEDURE|peripheral blood stem cell transplantation|Peripheral blood stem cell transplantation is done 14 days after 2nd dose of Samarium is delivered
223838509|NCT00245011|RADIATION|Sm-EDTMP (low dose)|Sm-EDTMP (low dose) administered after autologous stem cell collection
223838510|NCT00245011|RADIATION|sm-EDTMP (higher dose)|Upon blood cell count recovery from Sm-EDTMP (low dose), Sm-EDTMP (higher dose) is administered followed in 14 days by peripheral blood stem cell transplantation.
223838511|NCT04877574|PROCEDURE|ANI-guided intraoperative analgesia|Intraoperative analgesia is performed by controlling the effect-site concentration of remifentanil to maintain 50-70 of ANI.
223838512|NCT04877574|PROCEDURE|Conventional intraoperative analgesia|Intraoperative analgesia is performed by controlling the effect-site concentration of remifentanil at the discretion of attending anesthesiologists based on hemodynamic parameters.
223838513|NCT03050437|DRUG|Cisplatin|cisplatin is added to Pem/cis arm
223838514|NCT03050437|DRUG|Pemetrexed|Pem is applied to both arms
223838515|NCT05744882|PROCEDURE|coronectony|root canal treatment
223838516|NCT05744882|PROCEDURE|root canal treatment|root canal treatment
223838517|NCT05028010|BEHAVIORAL|Capacity building|Four days of training on the promotion of maternal and child nutrition will be given. The training will be based on Pender's health promotion model. Supportive supervision will be conducted.
223838518|NCT02427555|OTHER|Barley kernel bread|3 days intervention with barley kernel bread
223838519|NCT02427555|OTHER|white wheat bread|3 days intervention with white wheat bread
223838520|NCT05429359|OTHER|CPET: CardioPulmonary Exercise Test for CSII users|"* Baseline~* VO2peak measurement~* Breakfast~* 100% bolus insulin~* CSII users: 100% basal"
223838521|NCT05429359|OTHER|AEX1: Aerobic Exercise Test 1 for CSII users|"* 90min~* 40-45% VO2peak~* Breakfast~* 50% bolus insulin~* CSII users: -2h target 150 mg/dL"
223838522|NCT05429359|OTHER|AEX2: Aerobic Exercise Test 2 for CSII users|"* 90min~* 40-45% VO2peak~* Breakfast~* 50% bolus insulin~* CSII users: -1h target 150 mg/dL"
223838523|NCT05429359|OTHER|CPET: CardioPulmonary Exercise Test for MDI users|"* Baseline~* VO2peak measurement~* Breakfast~* 100% bolus insulin~* MDI users: 100% basal"
223838524|NCT05429359|OTHER|AEX1: Aerobic Exercise Test 1 for MDI users|"* 90min~* 40-45% VO2peak~* Breakfast~* 50% bolus insulin~* MDI users: 50% basal"
223838525|NCT05429359|OTHER|AEX2: Aerobic Exercise Test 2 for MDI users|"* 90min~* 40-45% VO2peak~* Breakfast~* 50% bolus insulin~* MDI users: 80% basal"
223838526|NCT03377673|DIAGNOSTIC_TEST|CMR|CMR is performed using a 1,5T whole-body system (Siemens Aera, Siemens Medical Solutions; Erlangen, Germany)
223838527|NCT03461250|DIAGNOSTIC_TEST|HCV serology|Apply CRF to identify risk factors for HCV infection. In patients with positive HCV serology measure the level of viral load and HCV genotype by PCR Abbott-real time and determine the stage of liver fibrosis by elastography (Fibroscan)
223838528|NCT02708602|GENETIC|β2AR polymorphism|
223838529|NCT04681430|BIOLOGICAL|Convalescent plasma|transfusion of convalescent plasma (CP) with neutralizing antibodies against anti-SARS-CoV-2 ((titer of at least 1:160)
223838530|NCT04681430|DRUG|Camostat Mesilate|Tablets over 7 days, daily dose of 600 mg split into 3 doses
223838531|NCT04681430|DRUG|Placebo for Camostat Mesilate|Placebo Tablets over 7 days, split into 3 doses
223838532|NCT04681430|OTHER|Standard of Care (SoC)|Control Arm for convalescent plasma (CP)
223838533|NCT00075803|DRUG|Fluconazole|Fluconazole will be administered orally once daily. Fluconazole capsules should be taken at least one hour before or one hour after a meal. If oral drug is not possible, it will be given intravenously once daily in a total volume of 200 mL in patients \> 12 years. For adults, each 200 mL infusion will be administered over 2 hours. In patients \< 12 years, intravenous doses will be prepared.
223838534|NCT00075803|DRUG|Voriconazole|Voriconazole will be administered orally twice daily. Voriconazole capsules should be taken at least one hour before or one hour after a meal. Taken concomitantly with food, bioavailability of voriconazole is reduced. If oral drug is not possible, it will be given intravenously at a dosage of 200 mg every 12 hours over two hours in patients \> 12 years. Each voriconazole dose will be diluted to a total volume of 200 mL in patients \> 12 years. Volumes of the formulation required to provide 4 mg/kg doses for children age \< 12 years.
223838535|NCT01372358|DRUG|CIPRO®XR|Ciprofloxacin 1000 mg Tablets Dr. Reddy's Laboratories Limited
223838536|NCT00650494|DRUG|Valacyclovir Hydrochloride Tablets 1000mg|1000mg, single dose fed
223838537|NCT00650494|DRUG|Valtrex® 1000 mg|1000mg, single dose fed
223838538|NCT01740011|PROCEDURE|Laparoscopic surgery|
223838539|NCT02218021|DRUG|Samidorphan|
223838540|NCT02218021|DRUG|Placebo|
223838541|NCT02218021|DRUG|Oxycodone|
223838542|NCT03496025|DEVICE|Electrical muscle stimulation|The intervention consists of activating paralyzed facial muscles with electrical stimulation.
223838543|NCT05724524|OTHER|Stool sample collection|50mg stool sample taken for protein extraction
223838544|NCT05724524|OTHER|Blood sample collection|Venous blood sample taken for analysis of serum and plasma
223838545|NCT06336499|OTHER|Multi-parametric MRI and image analysis by deep learning or machine learning algorithms|Diagnosis models are established using quantitative features extracted from the multi-parametric MRI images and further processed by appropriate deep learning or machine learning algorithms.
223838546|NCT01910558|DIETARY_SUPPLEMENT|Alpha-cyclodextrin and digestible starch|Weight maintaining diet (40% fat, 30% protein, and 30% carbohydrate) supplemented with 3 gram alpha-cyclodextrin and 3 gram of starch
223838547|NCT01910558|DIETARY_SUPPLEMENT|Alpha-cyclodextrin|Weight maintaining diet (40% fat, 30% protein, and 30% carbohydrate) supplemented with 6 grams alpha-cyclodextrin
223838548|NCT01910558|DIETARY_SUPPLEMENT|Digestible starch|Weight maintaining diet (40% fat, 30% protein, and 30% carbohydrate) supplemented with 6 grams digestible starch
223838549|NCT01438671|PROCEDURE|Nintendo Wii Fit|The Nintendo Wii Fit is an accessory for the Nintendo Wii video game system that utilizes a balance board peripheral. The subject stands on the balance board and engages in video games that require weight shifting and balancing in order to interact with the game. This intervention will be administered for 30 minutes, 3 to 5 times per week (as tolerated by subject), for a two week period.
223838550|NCT01438671|PROCEDURE|Traditional balance training|This physical therapy intervention involves gait training, balance education on various surfaces, activities involving limited and changing bases of support, and dynamic interaction with the subject's environment. This intervention will be administered 30 minutes per day, 3 to 5 days per week (by subject's tolerance), for a two week period.
223838551|NCT01443975|PROCEDURE|x-pander|Measurement of the size and quality of the bony acetabulum before mounting the artificial hip socket.
223838552|NCT02812212|DEVICE|ultrasonography|bilateral ultrasonography to measure the antero-posterior renal pelvic diameter (APRPD) in both positions.
223838553|NCT02812212|DEVICE|diuretic renography|diuretic renography to measure the cortical transit time.
223838554|NCT03740074|BEHAVIORAL|PAI|"Consenting subjects will be given a Mio Slice, along with instructions on how to utilize the device.~They will register on line with PAI Health, and will be asked to sync their device at least once every 7 days. They will be encouraged to look at the device app on their smart phone at least once daily.~After 1 week of obtaining baseline data, subjects will be encouraged to try to obtain a PAI score of at least 30 initially. Once they obtain a score of 30 consistently, they will be encouraged to increase the score toward 50. If they consistently obtain 50, they can increase their goal sequentially toward a maximum goal of 100. The duration of the study will be 12 weeks."
223838555|NCT01625039|BEHAVIORAL|Employee wellness programme|The experimental group was subjected to a wellness programme based on the principles of cognitive behaviour therapy (CBT) as well as weekly supervised exercise classes over six weeks.
223838556|NCT01625039|BEHAVIORAL|Comparator (Once off educational session and educational materials)|Once off educational session and educational materials
223838557|NCT03044496|DRUG|Supraclavicular nerve block|Supraclavicular nerve block using ultrasound and 10ml ropivacaine 0.5% with 20ml mepivacaine 1%
223838558|NCT04308538|PROCEDURE|Standard Recession|Bilateral lateral rectus muscle recession will be performed through fornix approach using standard tables
223838559|NCT04308538|PROCEDURE|Reduced Recession|Bilateral lateral rectus muscle recession will be performed through fornix approach using reduced numbers
223838560|NCT02868580|DRUG|Triumeq|Triumeq, a combination of dolutegravir, abacavir and lamivudine is an anti-retroviral therapy indicated for people with HIV-1 infection.
223838561|NCT01287793|DRUG|tigecycline|intravenous, 200 mg, single dose
223838562|NCT01287793|DRUG|tigecycline|intravenous, 50 mg, single dose
223838563|NCT01287793|DRUG|moxifloxacin|oral tablet, 400 mg, single dose
223838564|NCT01287793|DRUG|100 mL 0.9% Sodium Chloride intravenous|intravenous fluid, 100 mL, single dose
223838565|NCT01287793|DRUG|placebo|0.9% Sodium Chloride intravenous 100mL, single dose
223838566|NCT05050370|BEHAVIORAL|Brief messaging and personalized support|Patients will receive (i) a face-to-face group session and a package of instant messages related to lifestyle-integrated exercise (including breathing, balance, aerobic, strength, stretching exercises), cancer-related care information and support.
223838567|NCT03079505|DRUG|Dasatinib 100 MG [Sprycel]|Dasatinib (Sprycel) 100 milligram, once-daily (QD) will be given to 25 patients orally
223838568|NCT03079505|DRUG|Nilotinib 150mg oral capsule [Tasigna]|Nilotinib (Tasigna) 300 milligram, twice-daily (BID) will be given to 25 patients orally
223838569|NCT04445155|BEHAVIORAL|Modified DECIDE Parent and Provider Intervention|The parent component will include up to three 60 minutes sessions. Session 1 (Decisions and Agency) is designed to increase awareness of their role in clinical interactions and encourage participation and decision making in care. Session 2 (the Who, How, and Why of Decisions) teach skills for understanding treatment decisions in terms of roles, processes, and reasons involved. Session 3 (Self-efficacy and Consolidation) encourages parents to ask questions about their adolescents' behavioral health and health care and treatment options. The provider component is designed to improve provider communication in three key areas: 1) perspective taking to understand circumstances and perceptions; 2) attributional errors or attributing negative parent behaviors to character traits; and 3) receptivity to parent participation and collaboration.
223838570|NCT00366262|DRUG|PLA-695|
223838571|NCT00366262|DRUG|Naproxen|
223838572|NCT00366262|DRUG|Placebo|
223838573|NCT01103986|BEHAVIORAL|Motivational/health literacy education (Test group)|"Attend a 1-hour class to learn how to use the book What to Do When Your Child Gets Sick."
223838574|NCT04131283|DRUG|Epinephrine|Vasoconstrictor solution is applied on the surface of the attached gingiva and on the gingival sulcus.
223838575|NCT01473511|BEHAVIORAL|Strongest Families Intervention (formerly Family Help)|Distance HEALTH education intervention focussed on skill learning for parents
223838576|NCT00107744|DIETARY_SUPPLEMENT|Soy protein-milk protein-carbohydrate|40 grams of soy protein per day for 8 weeks, 40 grams of milk protein per day for 8 weeks, and 40 grams of carbohydrate per day for 8 weeks
223838577|NCT00107744|DIETARY_SUPPLEMENT|Milk protein-carbohydrate-soy protein|40 grams of milk protein per day for 8 weeks, 40 grams of carbohydrate per day for 8 weeks, 40 grams of soy protein per day for 8 weeks.
223838578|NCT00107744|DIETARY_SUPPLEMENT|Carbohydrate-soy protein-milk protein|40 grams of carbohydrate per day for 8 weeks, 40 grams of soy protein per day for 8 weeks, 40 grams of milk protein per day for 8 weeks.
223838579|NCT00488241|DEVICE|Zarzenda|Topically applied daily for 2 weeks
223838580|NCT00564590|DRUG|Melatonin|4 mg of Melatonin once a day for 3 months
223838581|NCT00564590|OTHER|omeprazole|omeprazole 20 mg once a day
223838582|NCT00564590|DRUG|Placebo|Placebo once a day
223838583|NCT02385617|DRUG|Octreotide|Octreotide 100mcg (1mL) single dose, subcutaneously, into the lower abdomen, 50 minutes prior to eating
223838584|NCT02385617|DRUG|Placebo|0.9% saline (1mL) single dose, subcutaneously, into the lower abdomen, 50 minutes prior to eating
223838585|NCT01875861|OTHER|Evidence-Based Quality Improvement Plus Facilitation|The intervention involves researchers partnering with clinical stakeholders, offering tailoring in local implementation strategies to address barriers to metabolic side-effect monitoring and management. External facilitation to support, problem-solve and refine implementation will be provided for a six-month implementation phase.
223838586|NCT05532020|DRUG|DCCR (diazoxide choline) extended-release tablets|All participants will be titrated over a four week period to the maintenance dose. Participants will take DCCR daily for up to 52 weeks.
223838587|NCT05261750|BIOLOGICAL|Auto-Dendritic Adjuvant Therapy|Treatment with standard medical therapy (radiotherapy or chemoradiation) and auto-dendritic adjuvant therapy via intramuscular 3 times injection every 1 week.
223838588|NCT05261750|BIOLOGICAL|Allo-Dendritic-Secretome Adjuvant Therapy|Treatment with standard medical therapy (radiotherapy or chemoradiation) and allo-dendritic-secretome adjuvant therapy 2 cc 1 times injection, and then followed by auto-dendritic therapy via intramuscular 3 times injection every 1 week.
223838589|NCT01835561|DRUG|Pomalidomide|Single oral dose of 4-mg capsule
223838590|NCT01835561|DRUG|Pomalidomide|4-mg capsule
223838591|NCT06198660|OTHER|positional release technique|positional release techniques in addition to conventional therapy two sessions per week for 6 weeks
223838592|NCT06198660|OTHER|cognitive behavioral therapy|cognitive behavioral therapy in addition to conventional therapy two sessions per week for 6 weeks
223838593|NCT06198660|OTHER|conventional therapy only|conventional therapy two sessions for 6 weeks
223838594|NCT02062190|DRUG|resveratrol|"100mg 2x/day~1 month"
223838595|NCT01388543|DRUG|Atazanavir|Atazanavir 400mg once daily for 7 days followed by atazanavir 300mg plus ritonavir 100mg for 7 days
223838596|NCT03540979|PROCEDURE|endometrial preparation for frozen blastocyst transfer|medical endometrial preparation for frozen blastocyte transfer
223838597|NCT03540979|DRUG|Letrozole|Aromatase inhibitor - 2.5mg/d for 5 days
223838598|NCT03540979|DRUG|Ovidrel|recommbinant hCG 250 mcg- single sc injection to induce ovulation
223838599|NCT03540979|DRUG|Estrofem|Estrofem 2mg\*3/d for endometrial preparation
223838600|NCT03540979|DRUG|Endometrin 100Mg Vaginal Insert|vaginal tab for lutheal support
223838601|NCT02948543|BIOLOGICAL|Bacillus of Calmette-Guerin (BCG)|A strain of tubercle bacillus which modifies biologic response.
223838602|NCT02948543|DRUG|Mitomycin (MM)|An antibiotic produced by a soil actinomycete which inhibits DNA synthesis.
223838603|NCT00099450|DRUG|INS50589 Intravenous Infusion|
223838604|NCT02359019|BIOLOGICAL|Pembrolizumab|Given IV
223838605|NCT02359019|OTHER|Laboratory Biomarker Analysis|Correlative studies
223838606|NCT05774028|DRUG|Pegaspargase Combined With Gemcitabine, Etoposide, Liposomal Mitoxantrone Hydrochloride and Dexamethasone (P-GEMD) regimen|P-GEMD regimen (Every 3 weeks as a cycle, a total of 6 cycles) : Pegaspargase 3750 IU, d2; Gemcitabine 1000mg/m2, d1; Etoposide 65mg/m2, d2-d4; Mitoxantrone hydrochloride liposome 12mg/m2, d1; Dexamethasone 40mg/d, d1- d4.
223838607|NCT01421485|BEHAVIORAL|Integrated treatment program|CBT, psychopharmacological treatment, family treatment, HIV prevention, case management
223838608|NCT01421485|BEHAVIORAL|Treatment as Usual|Treatment in community, case management
223838609|NCT06918054|DIETARY_SUPPLEMENT|Dietary modification|Patients will follow Mediterranean Diet (MD), this diet is characterized by a high intake of vegetables, fruit, whole cereals, legumes, nuts, and fish and a low intake of red meat and homemade desserts. The main added fat was extra virgin olive oil, with 35-40% kcal from fat (\<10% from saturated fat), 40-44% kcal from carbohydrate, and 20% kcal from protein
223838610|NCT06918054|DIETARY_SUPPLEMENT|Supplementation of omega 3 fatty acids|Supplementation of omega 3 fatty acids ( dose based on weight: \<40 kg-450 mg/day, 40-60 kg-900 mg/day, \>60 kg-1300 mg/day)
223838611|NCT06914960|PROCEDURE|2-point Radiofrequency Ablation|"For the radiofrequency ablation (RFA) procedure, a 10 cm long, 22 gauge RF cannula with a 10 mm active tip (Model SC-K, Top Neuropole, MPS Medical Product Service GmbH, Germany) will be used.~In order to increase the accuracy of the location determined by ultrasound, sensory stimulation will be applied at a frequency of 50 Hz and with a threshold value lower than 0.6 volts. In order to prevent the motor nerves from being affected, the absence of lower extremity muscle fasciculations in the relevant area will be confirmed with 2 volt stimulation at 2 Hz frequency. Patients in 2 nerve groups (SM and IM) will undergo 2-point RFA at 42°C using a 120-second pulse RFA generator (TOP Lesion Generator TLG-20, MPS Medical Product Service GmbH, Germany).~To address any discomfort that may occur after the procedure, a total of 2 cc of betamethasone (5 mg+2 mg/1 cc) and %2 lidocaine (1 cc) will be injected into the points where RFA is applied, after aspiration."
223838612|NCT06914960|PROCEDURE|3-point Radiofrequency Ablation|Description: For the radiofrequency ablation (RFA) procedure, a 10 cm long, 22 gauge RF cannula with a 10 mm active tip (Model SC-K, Top Neuropole, MPS Medical Product Service GmbH, Germany) will be used. In order to increase the accuracy of the location determined by ultrasound, sensory stimulation will be applied at a frequency of 50 Hz and with a threshold value lower than 0.6 volts. In order to prevent the motor nerves from being affected, the absence of lower extremity muscle fasciculations in the relevant area will be confirmed with 2 volt stimulation at 2 Hz frequency. 3-point RFA will be applied to patients in 3 nerve groups (SM, SL and IM) using a generator (TOP Lesion Generator TLG-20, MPS Medical Product Service GmbH, Germany) in the form of 120-second pulse RFA at 42°C. To address any discomfort that may occur after the procedure, a total of 2 cc of betamethasone (5 mg+2 mg/1 cc) and %2 lidocaine (1cc) will be injected into the points where RFA is applied, after aspiration.
223838613|NCT06914960|PROCEDURE|5-point Radiofrequency Ablation|Description: For the radiofrequency ablation (RFA) procedure, a 10 cm long, 22 gauge RF cannula with a 10 mm active tip (Model SC-K, Top Neuropole, MPS Medical Product Service GmbH, Germany) will be used. In order to increase the accuracy of the location determined by ultrasound, sensory stimulation will be applied at a frequency of 50 Hz and with a threshold value lower than 0.6 volts. In order to prevent the motor nerves from being affected, the absence of lower extremity muscle fasciculations in the relevant area will be confirmed with 2 volt stimulation at 2 Hz frequency. 5-point RFA will be applied to patients in 5 nerve groups (SM, SL and IM, recurrent fibular nerve-RFN, infrapatellar branch of saphenous nerve-IPBSN) via same generator in the form of 120-second pulse RFA at 42°C. To address any discomfort that may occur after the procedure, a total of 2cc of betamethasone (5mg+2mg/1cc) and %2 lidocaine (1cc) will be injected into the points where RFA is applied, after aspiration.
223838614|NCT02990221|DRUG|Ingenol mebutate|150 mcg / g per day, to be applied on a predetermined area of 25 cm2 of skin of the face or scalp, for 3 days consecutive
223838615|NCT02990221|PROCEDURE|cryotherapy|application with 5 seconds of freezing time of each lesion located in a predetermined skin area of 25 cm2 of the face or scalp
223838616|NCT04660968|BEHAVIORAL|Dyadic health behaviour change intervention|The dyadic behaviour change intervention adopts a dyadic coping perspective wherein appraisal of shared responsibility, agreement on tasks, and collaboration are fostered throughout the intervention. The intervention will target four behaviour goals: reducing overall caloric intake, substituting empty calorie foods with healthier alternatives, reducing sedentary behaviour, and increasing physical activity. The specific behavioural change strategies will include motivational interviewing, self-monitoring, goal setting, stimulus control, problem solving, and relapse prevention. Each session will also include a short education component on healthy eating to improve participants' adherence to the updated Canada's Food Guide. Participants will have access to web-based exercise training sessions. Intervention sessions will be delivered online.
223838617|NCT04660968|BEHAVIORAL|Dyadic nutrition counselling intervention|The couples-based education nutrition intervention will provide extensive information on healthy eating. However, it will not include any behavioural change principles. Topics will be based on Dietitians of Canada's Practice-based Evidence in Nutrition (PEN) discussions in the database that focus on healthy eating for older adults. The topics covered will include increasing fruits and vegetables, hidden (empty) calories, how to read food labels, portion control, reducing salt and saturated fat, plant-based proteins, and eating for healthy bones. Participants in this group will also be told to increase their levels of physical activity to 150 minutes of moderate to vigorous physical activity per week, as per the Canadian Guidelines. Participants will have access to web-based exercise training sessions. However, physical activity will not be discussed explicitly during the intervention. Intervention sessions will be delivered online.
223838618|NCT03606135|OTHER|The Pneumonia Group|
223838619|NCT03606135|OTHER|The Control Group|
223838620|NCT00413608|DRUG|Clopidogrel|Clopidogrel
223838621|NCT04049201|PROCEDURE|elective surgery|investigators will compare the effect of interactive tablet on preoperative anxiety in children to the effect ofMidazolam in elective surgery
223838622|NCT04049201|DRUG|Midazolam|Oral Midazolam
223838623|NCT04049201|DEVICE|Interactive Tablet|interactive Tablet containing many cartoon's videos
223838624|NCT02114281|OTHER|Care|
223838625|NCT02114281|OTHER|Not care|
223838626|NCT04106687|PROCEDURE|Ultrasound Guided Caudal Block|Postoperative pain procedure
223838627|NCT04106687|PROCEDURE|Sacral Erector Spinae Block|Postoperative pain procedure
223838628|NCT02187822|DRUG|TPI 287|TPI 287 is an infusion given through veins. Dose escalation will begin at 14 mg/m\^2/dose. Dose expansion will begin at the maximum tolerated dose (MTD).
223838629|NCT02187822|PROCEDURE|Fractionated Stereotactic Radiotherapy (FSRT)|The prescription dose will be 25 gray (Gy) in 5 daily fractions delivered to the planning target volume (PTV).
223838630|NCT00542945|DEVICE|ICD|Implantation of an ICD
223838631|NCT00542945|OTHER|Optimal medical treatment|ACE-inhibitors or ARB Beta-blocker Optional aldosterone antagonist
223838632|NCT01941914|DRUG|Calcium chloride|
223838633|NCT04288973|DIAGNOSTIC_TEST|Microsoft Kinect Detection during mother child interaction|methodology based on RGB-D sensors applied to the setting of free parent-infant interaction
223838634|NCT00283309|DRUG|Memantine|
223838635|NCT00283309|DRUG|Riluzole|
223838636|NCT03564938|DRUG|Regorafenib (Stivarga, BAY73-4506)|The recommended dose of regorafenib is 160 mg (consisting of 4 tablets, each containing 40 mg of regorafenib) for 3 weeks of every 4 week cycle, (ie. 3 weeks on therapy, 1 week off therapy).
223838637|NCT06244147|DIETARY_SUPPLEMENT|KSM-66 Ashwagandha Root Extract|Participants will take KSM-66 Ashwagandha root extract 300mg twice a day for the duration of the study.
223838638|NCT01982071|DRUG|Micafungin|Intravenous (IV)
223838639|NCT06440174|PROCEDURE|endoscopic ultrasound|EUS is an invasive procedure combining upper gastrointestinal endoscopy with ultrasonography. An ultrasound probe located at the end of the endoscope allows direct visualisation of the oesophageal wall layers and adjacent tissues providing local assessment of the depth of tumour invasion and lymph nodes. This assessment informs local tumour (T-) and node (N-) staging which are important prognostic indicators of survival. Patients undergoing EUS require sedation and there are risks of complication. EUS is a specialist investigation requiring many years of dedicated training to perform competently.
223838640|NCT06287450|BIOLOGICAL|Bivalent RSV Vaccine (IN006)|Formulation for injection
223838641|NCT06287450|BIOLOGICAL|Placebo|0.9% sodium chloride (normal saline) injection
223838642|NCT04339218|DEVICE|Cryoablation|"Cryoablation will be performed by a specialized radiologist, percutaneously, ie through the skin. The operation is performed under general anesthesia, under the guidance of the scanner. The images from the scanner make it possible to precisely insert and place a needle at the level of the tumor to be treated. Intense cold will be produced by the needle and will destroy the cancer cells by freezing (temperatures of -40 °C). Freezing is localized to the tumor, the rest of the organ will not suffer from the cold.~The aftermath of the intervention causes only minimal pain and in most cases does not require pain treatment. As the operation is minimally traumatic, the risk of complications is low. Hospitalization is around twenty-four hours and usual or professional activities can be resumed very quickly."
223838643|NCT04339218|DRUG|Pembrolizumab|Pembrolizumab will be prescribed and administered at the dose recommended by market authorization.
223838644|NCT04339218|DRUG|Pemetrexed|Pemetrexed will be prescribed and administered at the dose recommended by market authorization.
223838645|NCT04339218|DRUG|Carboplatin|Carboplatin will be prescribed and administered at the dose recommended by market authorization.
223838646|NCT03381794|PROCEDURE|Corneal transplantation|PKP: Penetrating Keratoplasty DALK: Deep Anterior Lamellar Keratoplasty DMEK: Descemet Membrane Endothelial Keratoplasty DSAEK: Descemet's Stripping Automated Endothelial Keratoplasty
223838647|NCT00731042|DRUG|Avagard|Topical solution, 6 mL, 6 applications/day for 14 days.
223838648|NCT00731042|DRUG|Purell Surgical Scrub|Topical solution, 4 mL, 6 applications/day for 14 days.
223838649|NCT05474664|DRUG|Camostat mesylate|"1. 4\~12 years old: Camostate mesylate 100 mg, 2 times a day~2. greater than 13 years old: Camostate mesylate 100 mg, 3 times a day"
223838650|NCT06068738|OTHER|Biological sample collection|Collection of ascites, blood and fresh tumour tissues (if available)
223838651|NCT05417204|BEHAVIORAL|Abdominothoracic biofeedback|A standard biofeedback technique (3 sessions over a 4-week period) directed at controlling the muscular activity (postural tone) of the abdominal walls, will serve as active intervention in the experimental group, and as a sham intervention in the active comparator group.
223838652|NCT04213846|BEHAVIORAL|Experimental: Mobile Alcohol Expectancy Intervention|Participants randomized to the intervention condition will receive daily intervention messages two times a day for three weeks in the mobile app. The intervention uses participants' own daily responses to personalize messages, when appropriate, that challenges their personal expectations of alcohol's positive effects on mood, social facilitation, and tension reduction, as well as aggression and risk-taking. The intervention messages also focus on intentions to drink and pharmacologically-delayed negative effects. Intervention Messages in general will include feedback based on selected assessment items, weekly summaries generated from the daily assessments, general psycho-educational messages and videos about alcohol, and a toolbox with supplemental information (e.g., personal BAC calculators, resources).
223838653|NCT04423393|BIOLOGICAL|VIR-3434|VIR-3434 given by subcutaneous injection or intravenous infusion.
223838654|NCT04423393|OTHER|Placebo|Sterile normal saline (0.9% NaCl) given by subcutaneous injection or intravenous infusion.
223838655|NCT02867839|DRUG|Oxaliplatin plus S-1|8 cycles of adjuvant chemotherapy with Oxaliplatin plus S-1
223838656|NCT02867839|DRUG|S-1 only|16 cycles of adjuvant chemotherapy with S-1 only
223838657|NCT03104569|PROCEDURE|Injection of 37℃ contrast agent|Nonionic contrast agent is heated to 37℃ in a incubator when injection of contrast agent
223838658|NCT02459509|DRUG|Dexmedetomidine|Either 2mcg/kg or 4mcg/kg of intranasal dexmedetomidine will be given to assess efficacy of preoperative sedation
223838659|NCT00149721|PROCEDURE|Ventriculo-peritonal shunting|
223838660|NCT01277237|DRUG|Omacor|Active comparator: omacor 4g/day
223838661|NCT01277237|DRUG|lactose tablet|placebo: lactose tablet 4g/day
223838662|NCT03302065|DRUG|Tiotropium|
223838663|NCT04769024|DEVICE|LUMEEN Virtual Reality sessions|"It will consist in carrying out 12 virtual reality sessions in groups of 6 participants, at a rate of 2 per week for approximately 6 weeks, using the LUMEEN EVASION module. Each session lasts approximately 45 minutes. This module allows the simultaneous broadcasting in virtual reality headsets of 360° videos accompanied by music about different themes: nature, animals, travel, art and live performance.~The course of an EVASION session is as follows:~1. The participants are seated in armchairs in an open environment and sufficiently spaced so that they can move their arms without bumping into each other.~2. The facilitator announces the immersion theme of the session~3. Participants are equipped with virtual reality head-mounted displays.~4. Participants watch the content.~5. The head-mounted displays are removed.~6. A group discussion encouraging participants to share their feelings and what they have learned from the immersion is conducted by the facilitator."
223838664|NCT04769024|BEHAVIORAL|Control/non-digital stimulation sessions|It will consist in non-digital stimulation (sensory, social, cognitive, creative) group sessions offering various typical pen-and-paper activities for this public which mainly stimulate language, immediate memory, semantic memory, and visual recognition (e.g., definitions, games of 7 differences, reconstruction of proverbs, quizzes…). A set of activities with instructions will be provided to the investigating centres but the choice of activities in each session will be left to the facilitator's decision in order to adapt the sessions to the participants' desires and abilities, as is usually done in such stimulation groups. The sessions will last 45 minutes and will be offered twice a week for 6 weeks by a facilitator or a caregiver with group care training. The sessions will be organized in groups of 6 participants to match the group size of the intervention groups.
223838665|NCT00906295|OTHER|Allowed drop in hemoglobin to 4.5-5.5 mmol/L|Transfusion with red blood cells to hemoglobin between 4.5-5.5 mmol/L (Transfusion threshold of 4.5 mmol/L)
223838666|NCT00906295|OTHER|Allowed drop in hemoglobin to level between 5.6-6.5 mmol/L|Transfusion with red blood cells to between hemoglobin 5.6-6.5 mmol/L (Transfusion threshold of 5.5 mmol/L)
223838667|NCT01419301|BEHAVIORAL|Mindfulness based stress reduction (MBSR)|Mindfulness based stress reduction (MBSR) is program based on daily meditation practice that guides an individual towards increased awareness and self-regulation of thoughts and actions. MBSR is easier to implement and may be shown to be more effective than cognitive-behavioral stress reduction, and is more applicable to patients with chronic illness.
223838668|NCT03613584|DRUG|Von Willebrand Factor|Bolus and continuous infusion of the Investigational Medicinal Product (IMP) during extracorporeal membrane oxygenation (ECMO)
223838669|NCT03613584|DRUG|Saline Solution|Bolus and continuous infusion of the Investigational Medicinal Product (IMP) during extracorporeal membrane oxygenation (ECMO)
223838670|NCT03374072|BEHAVIORAL|Siblings FORWARD program|Siblings will participate in a program developed by the researchers designed to engage adults with their autistic sibling and other family members to plan for the future. The Siblings FORWARD program will be implemented by community service providers already working with autistic adults. The program will involve a series individual and joint sessions with siblings and autistic adults using Zoom.
223838671|NCT03374072|BEHAVIORAL|Information Only Condition|Siblings will be provided with online information about services for adults with ASD and future planning.
223838672|NCT02692235|DIETARY_SUPPLEMENT|carnitine|1500 mg/d l-carnitine-l-tartrate
223838673|NCT02692235|DIETARY_SUPPLEMENT|placebo|isonitrogenous
223838674|NCT01219465|BIOLOGICAL|umbilical cord mesenchymal stem cells|Transfusion of the umbilical cord mesenchymal stem cells (2 x 107 cells) intravenously.
223838675|NCT00802841|DRUG|nilotinib|Supplied as 200 mg tablets
223838676|NCT00802841|DRUG|imatinib|Supplied as 100 mg and 400 mg tablets
223838677|NCT01968005|DRUG|Etoreat®(Etodolac-Lidocaine Topical Patch)|
223838678|NCT01968005|DRUG|Placebo|
223838679|NCT05090982|OTHER|Audio recordings during the consultations|50 patients with audio recordings of the consultation
223838680|NCT05090982|OTHER|Audio recordings during the consultations and test of the shared medical decision-making tool for modification|50 patients with audio recording of the consultation and Test of the shared medical decision-making tool for modification
223838681|NCT05090982|OTHER|Audio recordings during the consultations and test of the shared medical decision-making tool for validation|50 patients with audio recording of the consultation and test of the shared medical decision-making tool for validation.
223838682|NCT05498974|OTHER|Standard type 1 diabetes management model constructed by China Alliance for Type 1 Diabetes in each center|Standard type 1 diabetes management model constructed by China Alliance for Type 1 Diabetes in each center
223838683|NCT02391220|OTHER|LCA symbiotic fermented milk|LCA symbiotic fermented milk with the probiotic cultures Lactobacillus acidophilus La-5® and Bifidobacterium animalis ssp. lactis BB-12® and the Beneo dietary fibers.
223838684|NCT02391220|OTHER|heat-treated fermented milk|heat-treated fermented milk without probiotic cultures and dietary fibres
223838685|NCT01939860|OTHER|Written and verbal patient education on hypertension and its treatment|
223838686|NCT03303274|PROCEDURE|Ipsilateral tilt|The operation table will be tilted 20 degrees right laterally.
223838687|NCT01901549|PROCEDURE|Renal denervation|The treatment catheter is introduced into each renal artery and is applied discrete, radiofrequency ablations lasting up to 2 min each and of 8 watts or less to obtain up to six ablations separated both longitudinally and rotationally within each renal artery. During ablation, the catheter system monitored tip temperature and impedance, altering radiofrequency energy delivery in response to a predetermined algorithm. After the procedure the control arterial angiogram should be done.
223838688|NCT01901549|DRUG|Metoprolol|Beta-blockers. Optimal mediсal therapy will be assigned according to ACS and STE guidelines.
223838689|NCT01901549|DRUG|Lisinopril|ACE inhibitors. Optimal mediсal therapy will be assigned according to ACS and STE guidelines.
223838690|NCT02720887|PROCEDURE|Nanoparticles load|Pregnant women will have a sampling of amniotic fluid to measure load and composition of nanoparticles.
223838691|NCT02711995|DRUG|RenuGel|Injection augmentation is the injection of a filler material (Brand: RenuGel; generic: Carboxymethylcellulose) into the vocal cords through the skin of the neck, guided by the view from a flexible laryngoscope inserted through the nostril. The flexible laryngoscopy is identical to the procedure that the doctor has used to examine your vocal cords in the past. It is the routine diagnostic evaluation technique of voice disorders.
223838692|NCT02711995|DRUG|Botulinum Toxin|Botulinum toxin treatment is the injection of botulinum toxin into the muscles of the vocal cords through the skin of the neck. This is identical to the injections you may have received in the past for your disorder.
223838693|NCT00377741|DRUG|valganciclovir [Valcyte]|900mg po
223838694|NCT03094897|DRUG|18F-Al-NOTA-MATBBN PET/CT|18F-Al-NOTA-MATBBN(PET imaging agent) given by vein before PET scans.Perform PET/CT for each enrolled volunteer or patient at 60-90min.
223838695|NCT03094897|DEVICE|PET/CT|Imaging with 18F-Al-NOTA-MATBBN PET/CT.
223838696|NCT06314191|OTHER|blood sampling|blood sampling with analyses
223838697|NCT06314191|OTHER|knee radiography|radiography of both knees in Schuss
223838698|NCT00940134|BIOLOGICAL|PYY 3-36|0.8 pmol/kg/min x 3 hours
223838699|NCT00940134|BIOLOGICAL|GLP-1|1.0 pmol/kg/min x 3 hours
223838700|NCT00940134|BIOLOGICAL|saline infusion|saline infusion x 3 hours
223838701|NCT01329120|PROCEDURE|Minimally invasive repair of pectus excavatum|Minimally invasive surgical technique basically consisting of inserting one or more convex steel bars under the sternum through small bilateral incisions in the thoracic wall
223838702|NCT01329120|PROCEDURE|Open surgical repair of pectus carinatum|Open surgical removal the affected cartilages bilaterally and the excess cartilage over the sternum
223838703|NCT04006795|OTHER|Serum|Participants will be topically applied adhesive patch containing developmental serum
223838704|NCT04006795|OTHER|Lotion|Participants will be topically applied adhesive patch containing developmental lotion
223838705|NCT04006795|OTHER|Cream|Participants will be topically applied adhesive patch containing developmental cream
223838706|NCT04006795|OTHER|Normal Saline|Participants will be topically applied adhesive patch containing normal saline
223838707|NCT05370989|OTHER|Technology-Based Parent School Program|The program will be continued for 10 weeks in the intervention group and will be included five web-based modules, five online group interactions after each module, and consultation throughout the program and the follow-up period.
223838708|NCT05370989|OTHER|ongoing treatment|Health service of the control group will ongoing.
223838709|NCT03064503|BIOLOGICAL|Blood sampling|Blood sampling will be performed at inclusion to investigate some biological eligibility criteria, and the day of MRI in order to analyse fibrosis biomarkers and collagen synthesis biomarkers
223838710|NCT03064503|DEVICE|MRI|MRI will be performed to measure interstitial fibrosis
223838711|NCT03064503|BIOLOGICAL|Skin auto-fluorescence|Skin auto-fluorescence measures will be performed to measure advanced glycation end-products (AGE) produced by collagen degradation
223838712|NCT04192942|OTHER|protocol of management of major burn in intensive care unit|primary assessment first aid management laboratory investigation radiological investigation surgical intervention
223838713|NCT02703961|DRUG|concurrent chemotherapy with cisplatin|in experimental group: cisplatin 60mg/m2, d1,d22;
223838714|NCT02703961|DRUG|concurrent chemotherapy with docetaxel|in experimental group: docetaxel 60mg/m2, d1,d22;
223838715|NCT02703961|RADIATION|pelvic radiotherapy|external beam radiotherapy for whole pelvix with 50Gy/25f boost radiotherapy for pelvic lymph node metastasis with 12-14Gy/4-7f.
223838716|NCT02703961|RADIATION|brachytherapy|CT/MRI guided brachytherapy or x-ray guided brachytherapy
223838717|NCT02703961|DRUG|adjuvant chemotherapy with cisplatin and docetaxel|cisplatin 75mg/m2, d43,d64; docetaxel 75mg/m2, d43,d64
223838718|NCT06349486|DRUG|vonoprazan, amoxicillin, tripotassium dicitrate bismuthate|bismuth-amoxicillin-vonoprazan triple therapy
223838719|NCT06349486|DRUG|vonoprazan, amoxicillin|vonoprazan-amoxicillin dual therapy
223838720|NCT06349486|DRUG|rabeprazole, amoxicillin, clarithromycin|proton pump inhibitor-based standard triple therapy
223838721|NCT05229510|DRUG|50 mg/mL Virazole Inhalant Product|50 mg/mL Virazole (10 or 20 ml total volume) aerosolized and administered until solution depleted
223838722|NCT05229510|DRUG|100 mg/mL Virazole Inhalant Product|100 mg/mL Virazole (10 or 20 ml total volume) aerosolized and administered until solution depleted
223838723|NCT05229510|DRUG|Placebo|Placebo (10 or 20 ml total volume) aerosolized and administered until solution depleted
223838724|NCT01454336|BIOLOGICAL|Cell injection|MSCs introduced into portal vein
223838725|NCT05501132|DEVICE|transcranial direct current stimulation|Patients will receive 10 sessions of 20 minutes of either 1 mA, 2 mA or sham electrical stimulation on 5 consecutive days
223838726|NCT00315627|DRUG|Islet transplantation|Islet transplantation
223838727|NCT01115998|OTHER|Power wheelchair|Children used power wheelchairs for one year. They continued to receive their usual early intervention services.
223838728|NCT01115998|OTHER|No power wheelchairs|Children in the control group did not use power wheelchairs. They continued to receive their usual early intervention services.
223838729|NCT00915850|DRUG|DCF|docetaxel, Cisplatin and 5-FU
223838730|NCT04428970|PROCEDURE|Invasive ICP monitoring|Insertion of a parenchymal pressure measuring probe
223838731|NCT05645913|DRUG|Oral anticoagulant|Oral anticoagulant that was continued at least 25days, inculding warfarin and new oral anticoagulant (NOAC)
223838732|NCT06270290|OTHER|Exposure to contact sports or history of concussions|History of contact sports practices or of concussions
223838733|NCT03138083|DRUG|OMO-1|OMO-1 is a small molecule inhibitor of the enzymatic activity of the MET receptor tyrosine kinase
223838734|NCT01214447|OTHER|No intervention|Observational study - no intervention
223838735|NCT02819479|DRUG|25% Mannitol|"Route of administration:~In this study, the first step of the treatment will be performing osmotic blood-brain-barrier disruption with administration of intra-arterial 25% Mannitol into the appropriate cervical artery."
223838736|NCT02819479|DRUG|Low-dose Intra-arterial Bevacizumab|"Route of administration:~In this study, the second step of the treatment will be administering intra-arterial targeted bevacizumab into the appropriate cervical artery."
223838737|NCT02174679|DRUG|68Ga DOTATATE|Patients with somatostatin receptor positive tumors will be evaluated with 68Ga-DOTATATE PET/CT.
223838738|NCT00196911|PROCEDURE|Implantation of stimulation electrodes in the STN|
223838739|NCT02110927|DEVICE|Transcutaneous microcurrent|Microcurrent in the abdominal region with four transcutaneous electrodes in a parallel position, intensity below the sensitivity threshold and a maximum of 1 mA. Every 15 minutes changed from 25 Hz to 10 Hz.
223838740|NCT02110927|DEVICE|Aerobic exercise|50 minutes of aerobic moderate-intensity exercise (45-55% of maximal oxygen consumption (VO2 max)) using Karvonen´s formula, performed on a cycloergometer. Were used Borg scale (12-13), Polar® heart monitors to control heart rate and K4b2 to analyze the quantity of oxygen (O2) consumption and carbon dioxide (CO2) produced during exercise.
223838741|NCT01097980|DRUG|Trazodone|50 mg/d trazodone was upwardly titrated to 100 mg/d over one week and then maintained
223838742|NCT01097980|DRUG|Placebo|Placebo
223838743|NCT00029809|BEHAVIORAL|Chinese exercise modalities|
223838744|NCT02135393|DIETARY_SUPPLEMENT|13C5-folic acid or 13C5-6S-5-FormylTHF|Subjects with an insitu transjugular intrahepatic porto systemic stent shunt assigned to receive either a physiological 500 nmol (220 µg folic acid equivalent) dose of 13C5-folic acid or 13C5-6S-5-FormylTHF at the time of routine shunt venography to check patency followed by portal venous sampling at pre defined time points for 85 minutes and then given 13C5-6S-5-FormylTHF ator 13C5-folic acid at their next annual venography patency check with portal venous sampling at pre defined time points for 85 minutes
223838745|NCT02578602|DRUG|Gadoxetate Disodium|Given IV
223838746|NCT02578602|DEVICE|Magnetic Resonance Imaging|Undergo MRI with gadoxetate disodium
223838747|NCT03531905|DRUG|Bempedoic acid + Ezetimibe FDC Oral Tablet|Experimental therapy of bempedoic acid 180 mg + ezetimibe 10 mg FDC tablet
223838748|NCT03531905|DRUG|Ezetimibe 10 mg Oral Tablet|Ezetimibe 10 mg tablet, overencapsulated for blinding purposes
223838749|NCT03531905|DRUG|Placebo Oral Tablet|Placebo tablet, matched for the FDC product for blinding purposes
223838750|NCT03531905|DRUG|Placebo oral capsule|Placebo over-encapsulated for blinding purposes
223838751|NCT01120574|OTHER|Home mechanical ventilation|Home mechanical ventilation will be performed with a bilevel pressure ventilator.
223838752|NCT02294162|DRUG|Ketamine i.v|
223838753|NCT05732948|DRUG|autologous T cells & cyclophosphamide|This is a phase I dose escalation study to assess the safety and tolerability using increasing doses of PD-1(programmed death 1)silent PSMA(prostate-specific membrane antigen)/PSCA(prostate stem cell antigen)targeted CAR-T administered one day after pretreatment with cyclophosphamide.
223838754|NCT02477943|DEVICE|BrainScope Ahead 200iD|The BrainScope Battery evaluation will consist of 4 tests to aid in the assessment of concussion: History, Physical, signs and symptoms (SAC, SCAT3), Electrophysiological Function; Neurocognitive Performance Assessment and a balance/sway measurement. BrainScope Ahead 200iD device will be used to perform EEG.
223838755|NCT02477943|DEVICE|Advanced MRI Neuroimaging|Diffusion tensor imaging (DTI) is a magnetic resonance imaging technique that enables the measurement of the restricted diffusion of water in tissue in order to produce neural tract images instead of using this data solely for the purpose of assigning contrast or colors to pixels in a cross sectional image.
223838756|NCT06292702|PROCEDURE|Traditional Burch colposuspension|Peforming two stitches between the anterior vaginal wall and Cooper's ligament.
223838757|NCT06292702|PROCEDURE|Modified Burch colposuspension|Performing lateral tension for the anterior vaginal wall towards the intersection point of the arcus tendineus and the lower edge of the pubic bone then performing two stitches between the anterior vaginal wall and Cooper's ligament.
223838758|NCT01142999|DRUG|Sunflower oil|One group will be instructed to use FDA-approved moisturizers and soap substitutes on their newborn infants.
223838759|NCT01142999|DRUG|Control group|This group will be asked NOT to use any skin moisturizers and use only soap substitutes on their infants.
223838760|NCT01142999|DRUG|Aquaphor ointment|One group will be instructed to use FDA-approved moisturizers and soap substitutes on their newborn infants.
223838761|NCT01142999|DRUG|Cetaphil cream|One group will be instructed to use FDA-approved moisturizers and soap substitutes on their newborn infants.
223838762|NCT03147092|DRUG|Captopril 25Mg, Hydrochlorothiazide 25Mg Oral Tablet,|Treatment of hypertensive subjects
223838763|NCT03147092|DRUG|Atenolol|Treatment of hypertensive subjects
223838764|NCT03147092|DRUG|Losartan potassium 50mg|Treatment of hypertensive subjects
223838765|NCT03147092|DRUG|Clonidine|Treatment of hypertensive subjects
223838766|NCT03805360|DRUG|Ropivacaine|Ropivacaine is a local anesthetic that is expected to provide numbness to the chest wall when injected into the erector spinae plane.
223838767|NCT03805360|DRUG|Normal Saline Flush, 0.9% Injectable Solution|Normal Saline Flush, 0.9% Injectable Solution is not expected to provide numbness to the chest wall when injected into the erector spinae plane.
223838768|NCT02516579|DRUG|Siklos|
223838769|NCT00624104|DIETARY_SUPPLEMENT|Food (fat free meal)|Fat free meal (40% of REE)
223838770|NCT02343614|DRUG|Celecoxib|
223838771|NCT06490094|BEHAVIORAL|Inquiry Based Stress Reduction (IBSR)|"The 8-week IBSR program is a clinical intervention based on The Work method, developed by Byron Katie and run in the US and Europe for 35 years. The IBSR intervention will involve weekly group meetings (3 hours/meeting) throughout 8 weeks. Home practice between sessions will be supported by facilitator assistants (1-hour session per week). All sessions will be standardized according to the IBSR certification program guidelines and will be assessed to maintain consistency in the program, as in previous studies. ."
223838772|NCT03348826|DRUG|Sodium Bicarbonate 8.4% Solution for Injection|3 mL injection into line with up to 2 injections administered
223838773|NCT03348826|DRUG|Alteplase Injectable Solution|2 mL injection into line with up to 2 injections administered
223838774|NCT03905811|DRUG|Terazosin 5 MG|5 milligrams by mouth daily at bedtime
223838775|NCT03905811|DRUG|Placebo oral capsule|1 capsule by mouth daily at bedtime
223838776|NCT04975789|OTHER|InfoViz|The pain InfoViz tool is a two-page paper tool that consists of an explanation of how to use the tool in both Hmong and English, a culturally-appropriate Faces pain severity scale, pain body diagram, and 13 pain qualities in the form of icons representing each pain quality metaphor. The interpreter explains the instructions in Hmong, then marks the body areas corresponding to the location of pain reported by the participant, and marks the pain qualities expressed by the metaphors selected by the Hmong patient. In the clinic appointment, the interpreter communicates to the physician, in English, the pain location and qualities identified by the participant, using the medical terms identified on the InfoViz tool.
223838777|NCT01646320|DRUG|Dapagliflozin|Tablets, Oral, 10 mg, Once daily, Up to 52 weeks
223838778|NCT01646320|DRUG|Placebo matching with Dapagliflozin|Tablets, Oral, 0 mg, Once daily, Up to 52 weeks
223838779|NCT01646320|DRUG|Saxagliptin|Tablets, Oral, 5 mg, Once daily, Up to 52 weeks
223838780|NCT01646320|DRUG|Metformin immediate release (IR)|Tablets, Oral, ≥ 1500 mg, Twice daily, Up to 52 weeks
223838781|NCT06449235|DRUG|Omarigliptin|"Chemical name: MK-3102 Class: Dipeptidyl peptidase-4 (DPP-4) inhibitor~Mechanism of Action:~Inhibits DPP-4 enzyme, thereby increasing incretin levels. Enhances glucose-dependent insulin secretion. Suppresses glucagon secretion. Improves β-cell function of the pancreas. Reduces hepatic glucose output. Administration: Once-weekly oral dosing."
223838782|NCT06449235|DRUG|Sulphonylureas|"Chemical Name: Sulphonylureas Class: Sulphonylureas~Mechanism of Action:~Stimulates insulin release from pancreatic beta cells. Enhances the sensitivity of beta cells to glucose. Reduces hepatic glucose production. Increases peripheral glucose uptake and utilization. Administration: Typically administered once or twice daily, depending on the specific medication and patient needs."
223838783|NCT06449235|DRUG|Metformin|"Chemical Name: Metformin Class: Biguanide~Mechanism of Action:~Decreases hepatic glucose production. Improves insulin sensitivity in peripheral tissues. Enhances peripheral glucose uptake and utilization. Reduces intestinal absorption of glucose. Administration: Administered orally, usually once or twice daily with meals."
223838784|NCT06449235|DRUG|Other DPP4-i|"Chemical Names: Sitagliptin, Vildagliptin, Saxagliptin, Linagliptin, Alogliptin Class: Dipeptidyl Peptidase-4 (DPP-4) Inhibitors~Mechanism of Action:~Inhibits DPP-4 enzyme, thereby increasing incretin levels. Enhances glucose-dependent insulin secretion. Suppresses glucagon secretion. Improves β-cell function of the pancreas. Reduces hepatic glucose output. Administration: Typically administered orally once daily. Dosage may vary depending on the specific medication and patient needs."
223838785|NCT06449235|DRUG|Thiazolidinediones|"Chemical Name: Thiazolidinediones (e.g., Pioglitazone, Rosiglitazone) Class: Thiazolidinediones (TZDs)~Mechanism of Action:~Activates peroxisome proliferator-activated receptor-gamma (PPAR-γ) in adipose tissue, muscle, and liver.~Increases insulin sensitivity in peripheral tissues. Enhances glucose uptake and utilization in muscle and adipose tissue. Reduces hepatic glucose production. Administration: Administered orally, typically once daily. Dosage may vary based on the specific medication and patient response."
223838786|NCT06449235|DRUG|Alpha-Glucosidase Inhibitor|"Chemical Name: Alpha-Glucosidase Inhibitors (e.g., Acarbose, Miglitol) Class: Alpha-Glucosidase Inhibitors~Mechanism of Action:~Inhibits alpha-glucosidase enzymes in the small intestine. Delays the breakdown and absorption of complex carbohydrates. Reduces postprandial blood glucose levels. Administration: Administered orally, typically taken with the first bite of each main meal. Dosage may vary based on the specific medication and patient response."
223838787|NCT06449235|DRUG|Glucagon-Like Peptide-1|"Chemical Name: Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists (e.g., Exenatide, Liraglutide, Dulaglutide, Semaglutide) Class: GLP-1 Receptor Agonists~Mechanism of Action:~Mimics the action of endogenous GLP-1. Enhances glucose-dependent insulin secretion. Suppresses glucagon secretion. Slows gastric emptying. Promotes satiety and reduces food intake. Improves β-cell function of the pancreas. Administration: Administered via subcutaneous injection, with frequency varying from twice daily to once weekly, depending on the specific medication."
223838788|NCT06449235|DRUG|Receptor Agonists (GLP1RA)|"Chemical Name: GLP-1 Receptor Agonists (GLP1RA) (e.g., Exenatide, Liraglutide, Dulaglutide, Semaglutide) Class: Glucagon-Like Peptide-1 Receptor Agonists~Mechanism of Action:~Activates GLP-1 receptors. Enhances glucose-dependent insulin secretion. Suppresses glucagon secretion. Slows gastric emptying. Promotes satiety and reduces food intake. Improves β-cell function of the pancreas. Administration: Administered via subcutaneous injection, with frequency varying from twice daily to once weekly, depending on the specific medication."
223838789|NCT06449235|DRUG|SGLT2 inhibitors|"Chemical Name: Sodium-Glucose Co-Transporter-2 (SGLT2) Inhibitors (e.g., Canagliflozin, Dapagliflozin, Empagliflozin, Ertugliflozin) Class: SGLT2 Inhibitors~Mechanism of Action:~Inhibits SGLT2 in the proximal renal tubules. Reduces reabsorption of filtered glucose from the renal tubules. Increases urinary glucose excretion. Lowers blood glucose levels independently of insulin. Administration: Administered orally, typically once daily. Dosage may vary based on the specific medication and patient response."
223838790|NCT01489020|BIOLOGICAL|subcutaneous immunotherapy with DPT extract|Increasing doses of subcutaneous immunotherapy in three different scales up to the maximum dose of 500 TSU (Treatment Standardized Units)
223838791|NCT01489020|BIOLOGICAL|Subcutaneous depot placebo|Increasing doses of subcutaneous depot placebo in three different scales
223838792|NCT04610424|BEHAVIORAL|"Cooperative Parent Mediated Therapy (CPMT)"|CMPT usually last 6 months, for a total amount of 15 sessions of 90 min; twelve core sessions (one session per week) are delivered in the first 3 months, followed by 3 monthly booster sessions. Each weekly core session had a specific focus and specific intervention strategies based on active parent coaching during parent-child interaction, and included the parent-child dyad with the parent being actively coached by a trained therapist. Live active coaching increases parents' competence in implementing strategies to enhance child development, and at the same time increases their confidence. This intervention has demonstrated evidence of effectiveness in socio-communicational improvement as measured by ADOS-G (Valeri, 2019) in a randomized controlled trial (RCT).
223838793|NCT04610424|BEHAVIORAL|As usual|Speech Language Therapy and Occuapational Therapy provided as usual by National Health Services
223838794|NCT05935280|OTHER|Room temperature|Room temperature injection
223838795|NCT05935280|OTHER|Cold temperature|Cold temperature injection
223838796|NCT05935280|DRUG|Lidocain|Unspecific sodium channel blocker
223838797|NCT05935280|DRUG|PF-05105679|Specific antagonist of the TRPM8 ion channel
223838798|NCT05935280|DRUG|A967079|Specific antagonist of the TRPA1 ion channel
223838799|NCT05935280|DRUG|PF-05089771|Specific antagonist of the Nav1.7 sodium channel
223838800|NCT05935280|DRUG|PF-06305591|Specific antagonist of the Nav1.8 sodium channel
223838801|NCT00258713|DRUG|voclosporin|voclosporin 0.2, 0.3, or 0.4 mg/kg BID
223838802|NCT00375856|DEVICE|DePuy P.F.C.® Sigma Rotating Platform Knee|no details
223838803|NCT04460443|DRUG|sofosbuvir|Sofosbuvir once daily
223838804|NCT04460443|DRUG|Sofosbuvir ledipsavir|Sofosbuvir ledipsavir once daily
223838805|NCT04460443|DRUG|Daclatasvir|Daklatasuvir tablets
223838806|NCT06696950|OTHER|Mutimodal gait training includes unilateral step training, inclined treadmill training, over ground training with rhythmic auditory stimulation|Unilateral step training, inclined treadmill training, over ground training, repetitive isochronous pulses via metronome
223838807|NCT06696950|OTHER|Multimodal gait training|Unilateral step training, inclined treadmill training, over ground training,
223838808|NCT05980221|DIAGNOSTIC_TEST|Metabolomics|Plasma samples taken for the investigation of the metabolome
223838809|NCT05980221|DIAGNOSTIC_TEST|13C MTGT|sequential breath samples taken for investigation of PEI (reference test)
223838810|NCT06696846|BIOLOGICAL|CD70 CAR-NK|"CAR - NK cells constructed by using genetic engineering technology retain the original extensive tumor - killing ability of NK cells. By using their unique target cell recognition mechanism, the target is accurately locked on specific antigen proteins, thereby enhancing the anti - tumor effect. Cord blood-derived CAR - NK cell products shorten the treatment time and are inexpensive. Multiple studies have confirmed the feasibility of CAR - NK cells in treating hematological tumors.~Blocking the CD70/CD27 signaling pathway plays an important role in inhibiting CD70 - positive tumors, such as refractory/relapsed T - cell lymphoma and acute myeloid leukemia. Pre - clinical studies in our laboratory have proved that CD70 CAR - NK can effectively inhibit the in - vivo and in - vitro proliferation of T - cell lymphoma and prolong survival."
223838811|NCT01540435|DRUG|Bevacizumab|Bevacizumab at a dose of 5 mg/kg iv over 30 to 90 min (day 1) + FOLFOXIRI in a biweekly schedule, 6 cycles preoperatively, 6 cycles postoperatively
223838812|NCT05417997|DIETARY_SUPPLEMENT|Kunamin®|Grape juice, seed, stem and rice extracts supplement containing KH good healthy cells (proteins)
223838813|NCT05417997|DRUG|Favipiravir|Antiviral medication used to treat influenza
223838814|NCT05417997|DRUG|Enoxaparin|Anticoagulant medication
223838815|NCT05417997|DRUG|Lansoprazole|Treat stomach ulcers, a damaged esophagus, gastroesophageal reflux disease (GERD), and high levels of stomach acid.
223838816|NCT05417997|DRUG|Paracetamol|Analgesic to treat minor aches and pains, and fever reducer.
223838817|NCT05417997|DRUG|Ceftriaxone/ Clarithromycin|Inhibits the production of pneumolysin
223838818|NCT05417997|DRUG|Methylprednisolone|Treat inflammation, severe allergies, flares of chronic illnesses
223838819|NCT02333851|DRUG|Mixtard 30:70 Novonordisk® twice daily|Premixed insulin twice daily before breakfast and before dinner
223838820|NCT02333851|DRUG|Lantus® once daily and Apidra® before meals|Injection of Lantus® insulin once daily and rapid insulin Apidra® before breakfast, lunch and dinner
223838821|NCT04737590|DEVICE|Bioactive glass|Comparison of bioactive glass to allogenic bone in pediatric bone cysts
223838822|NCT02106767|DRUG|Rosuvastatin|Rosuvastatin 20mg po x1
223838823|NCT02106767|DRUG|Rosuvastatin plus rifampin|Rifampin 600mg IV infused over 30 minutes followed by rosuvastatin 20mg PO x1
223838824|NCT06712498|PROCEDURE|External Oblique Intercostal Plane Block|After endotracheal intubation, a 22-gauge 100 mm long block needle will be inserted at the T6-T7 level under USG guidance and bilateral EOIB will be applied with 20 cc of 0.25% Bupivacaine on each side under the external oblique intercostal muscle (total 40ml bilaterally).
223838825|NCT06712498|DRUG|control group|No intervention
223838826|NCT01732575|BEHAVIORAL|Enrichment with meaning-generating activities|Gaps in the rehabilitation are identified by staff and researchers in dialogue. Staff gets relevant education. An intervention is tailored by staff and researchers to bridge the gaps. Consumers have a say and the intervention is revised accordingly. The intervention is implemented and continues for 14 months.
223838827|NCT00549497|DRUG|GW870086X|
223838828|NCT00893217|DRUG|Betaseron (Interferon beta-1b, BAY86-5046)|250 mcg
223838829|NCT00893217|DRUG|Betaseron (Interferon beta-1b, BAY86-5046)|500 mcg
223838830|NCT04103047|OTHER|SAD|The patients who have an SAD inserted as part of their normal Anaesthetic plan will be consented prior to their Anaesthetic and then have a questionnaire to fill out post operatively.
223838831|NCT04027361|DRUG|Amphetamine Extended Release (ER) Tablet 20 mg|A single 20 mg dose of amphetamine ER Tablet, orally administered
223838832|NCT00069719|DRUG|Glaucoma therapy|
223838833|NCT00099918|DRUG|vildagliptin|
223838834|NCT02814760|OTHER|training of emergency professionals to acute stroke management|"The training program aiming at improving the timeliness of care of acute stroke patients in ED was designed for triage ED nurses and ED physicians and it was based on 3 sub-objectives:~* Improving knowledge and skills of triage nurses to recognize patients with stroke symptoms~* Improving knowledge and skills of ED physicians to recognize stroke symptoms, to realize a good quality neurological examination and be able to measure the NIHSS (National Institute of Health Stroke Score), to have a better understanding of the physiopathology of ischemic stroke and thrombolysis, and to have a better understanding of the consequences of wasted time for patients Developing, together with other hospital professionals involved in acute stroke management, a clinical pathway adapted to the local characteristics an organization (ED organization optimization, management steps, connections between ED, radiology unit and stroke unit, thrombolysis organization)."
223838835|NCT04252937|DRUG|Adrecizumab|HAM8101 (Adrecizumab) is a humanized IgG1 monoclonal antibody (mAb).
223838836|NCT01411280|DRUG|methylphenidate|Ritalin 10mg, Ritalin 20mg
223838837|NCT00414414|DRUG|Prednisone|
223838838|NCT00414414|DRUG|placebo|placebo
223838839|NCT04609540|DRUG|Trastuzumab|Dual anti-HER2 therapy
223838840|NCT01174550|PROCEDURE|Coronary Angiography|Use of standard equipment for usual-care testing
223838841|NCT01174550|PROCEDURE|Stress Echocardiogram|Use of standard equipment for usual-care testing
223838842|NCT01174550|PROCEDURE|Nuclear Stress Test|Use of standard equipment for usual-care testing
223838843|NCT01174550|PROCEDURE|Exercise Electrocardiogram|Use of standard equipment for usual-care testing
223838844|NCT00083564|DRUG|STR(TM) (Skeletal Targeted Radiotherapy, Holmium-166-DOTMP)|
223838845|NCT04509284|OTHER|Training|The experimental group will perform a supervised progressive resistance training program, with five exercises for the upper- and lower body (box squat, bench press, trap bar deadlift, bench pull and lat pulldown), 2x/week for a 12 week period. The program will utilize a flexible progression system through three distinct training phases; 1) 2-4 sets of 10-12 repetitions, 2) 2-4 sets of 6-8 repetitions, 3) 2-4 sets of 2-4 repetitions. Number of sets are adjusted within session according to daily readiness while load is adjusted within and between sessions according to number of reps performed. A 3-5min rest period is provided throughout the program.
223838846|NCT04509284|OTHER|Control|The control group will be instructed to continue their everyday lifestyle with no specific instruction regarding exercise and/or diet. However, they will be encouraged not to engage in new forms of exercise or physical activity throughout the study period.
223838847|NCT06268925|OTHER|Exercises|number of exercises will be guided to do through zoom
223838848|NCT00846209|OTHER|Enhanced drug labeling|use of clear concise text and icons on drug warning labels
223838849|NCT03115775|DIETARY_SUPPLEMENT|Conjugated linoleic acid|Intervention will last up to 8 weeks. Subjects will receive conjugated linoleic acid (4000 mg Tonalin FFA 80) daily.
223838850|NCT03115775|DIETARY_SUPPLEMENT|Vitamin D|Intervention will last up to 8 weeks. Subjects will receive vitamin D3 (2000 IU) daily.
223838851|NCT03115775|DIETARY_SUPPLEMENT|Conjugated linoleic acid and Vitamin D|Intervention will last up to 8 weeks. Subjects will receive conjugated linoleic acid (4000 mg Tonalin FFA 80) and vitamin D3 (2000 IU) daily.
223838852|NCT03115775|OTHER|Corn oil (placebo)|Intervention will last up to 8 weeks. Subjects will receive corn oil (4000 mg) daily.
223838853|NCT02821312|DRUG|DA-8010|"Part A will comprise a single-dose, sequential-group study incorporating a food effect evaluation. Total 70 subjects will be studied in 7 groups (Groups A1 to A7); 60 male and 10 female. Each group will consist of 10 subjects of the same sex and 8 subject for DA-8010.~Part B will comprise a multiple-dose, sequential-group study. Total forty subjects (30 male and 10 female) will be studied in 4 groups (Groups B1 to B4), with each group consisting of 10 subjects of the same sex and 8 subject for DA-8010."
223838854|NCT02821312|DRUG|Placebo|"Part A will comprise a single-dose, sequential-group study incorporating a food effect evaluation. Total 70 subjects will be studied in 7 groups (Groups A1 to A7); 60 male and 10 female. Each group will consist of 10 subjects of the same sex and 2 subject for DA-8010.~Part B will comprise a multiple-dose, sequential-group study. Total forty subjects (30 male and 10 female) will be studied in 4 groups (Groups B1 to B4), with each group consisting of 10 subjects of the same sex and 2 subject for DA-8010."
223838855|NCT01536262|DRUG|Tiotropium + Olodaterol|Tiotropium and Olodaterol FDC once daily inhalation
223838856|NCT01536262|DEVICE|Respimat|Respimat inhaler
223838857|NCT01536262|DRUG|Tiotropium + Olodaterol|Tiotropium and Olodaterol FDC once daily inhalation
223838858|NCT01536262|DRUG|Olodaterol|Olodaterol once daily inhalation
223838859|NCT01536262|DEVICE|Respimat|Respimat inhaler
223838860|NCT01536262|DEVICE|Respimat|Respimat inhaler
223838861|NCT00412516|BIOLOGICAL|Live attenuated SA 14-14-2 vaccine|Live attenuated SA 14-14-2 vaccine coadministered with live measles vaccine (experimental Group)
223838862|NCT03572413|PROCEDURE|Low pressure pneumoperitoneum|Lowering intra-abdominal pressure during laparoscopic surgery
223838863|NCT03572413|DRUG|Rocuronium bromide|Deep (PTC 1-2) versus moderate (TOF count 1-2) neuromuscular block
223838864|NCT03673202|DIAGNOSTIC_TEST|Cx bladder Monitor test|Cxbladder Monitor is a non-invasive UC detection test measuring five messenger RNA (mRNA) biomarkers present at elevated levels in patients presenting with urothelial carcinoma and also two clinical variables (whether the previous tumor was primary or recurrent and the time since the previous tumor was resected).
223838865|NCT05080595|OTHER|Transportation assistance (Lyft rides)|Lyft rides will be provided to patients for any transplant-related medical visits
223838866|NCT01013675|BIOLOGICAL|Influenza Vaccine|surface antigen, inactivated, prepared in cell cultures
223838867|NCT01013675|BIOLOGICAL|Influenza Vaccine|surface antigen, inactivated, prepared in egg (influvac ®)
223838868|NCT05036694|DEVICE|FUJILAM KIT|Urine based test to detect LAM
223838869|NCT06783673|PROCEDURE|Upper GIT endoscopy|upper GIT endoscopy of suspected cases and multiple biopsies will be taken for histopathological examination
223838870|NCT05835050|DIAGNOSTIC_TEST|serum interleukin 10 level|b. Serum levels of IL-10 were measured using a quantitative enzyme-linked immunosorbent assay (ELISA)
223838871|NCT04061161|DRUG|Tiotropium Bromide|Participants will be double-blind randomized for Tiotropium or Placebo treatment for 6 weeks
223838872|NCT00000568|BEHAVIORAL|smoking cessation|
223838873|NCT00000568|DRUG|ipratropium|
223838874|NCT05588882|PROCEDURE|Wavefront-guided LASIK|Topography-guided utilizes topography mapping to perform the ablation
223838875|NCT05588882|PROCEDURE|Wavefront-guided|Wavefront-guided utilizes aberrometry to perform the ablation
223838876|NCT03504605|OTHER|Online self-compassion intervention|Parents are asked to write in an online text box about a parenting event in which they felt shame. They are then given a validated set of instructions asking them to reflect on the event and write self-compassionate responses.
223838877|NCT02087033|DIETARY_SUPPLEMENT|ritmonutra|2 tablets a day by mouth for 4 weeks
223838878|NCT02087033|DIETARY_SUPPLEMENT|placebo|sugar pill manufactured to simulated ritmonutra: 2 tablets a day for 4 weeks
223838879|NCT05257837|BEHAVIORAL|Gun handling behavior|Children will play in an observed room for 20 minutes. Aside from a selection of toys, two real handguns will be placed in a drawer. The handguns have been modified so they cannot fire. Inside the magazine, the handgun contains no bullets. Instead, it contains a sensor that counts the number of times the trigger is pulled with sufficient force to discharge the gun. This allows us to distinguish reliably the children who pull the trigger from those who handle the gun but do not pull the trigger
223838880|NCT05257837|OTHER|Debriefing|Children and their parents will be debriefed on the actual purpose of the study, including the role of the safety video and how the movie clips were edited.
223838881|NCT01355120|DRUG|Ipilimumab|Ipilimumab monotherapy 3mg/kg by four infusion every 3 weeks
223838882|NCT00164593|BEHAVIORAL|Youth Empowerment Solutions for Peaceful Communities|YES is a multi-faceted program that (1) engages 7th and 8th graders in a youth development program, (2) enhances neighborhood organizations' ability to include youth in their activities, and (3) connects the youth participants and adults in neighborhood organizations (e.g., crime watches, block groups, neighborhood associations) to carry out neighborhood improvement activities (e.g., community gardens, parks cleanup).
223838883|NCT06437405|DIETARY_SUPPLEMENT|Vinegar liquid|one pill daily
223838884|NCT06437405|DIETARY_SUPPLEMENT|vinegar pill|One pill daily
223838885|NCT01781611|DRUG|extended release dipyridamole 200mg/aspirin 25mg|one tablet twice daily for 24 weeks
223838886|NCT01781611|DRUG|81mg aspirin|half a tablet twice daily for 24 weeks
223838887|NCT01625338|DRUG|SOF|SOF 400 mg tablet administered orally once daily
223838888|NCT01625338|DRUG|RBV|RBV tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
223838889|NCT01625338|DRUG|Peg-IFN|Peg-IFN 180 μg administered once weekly by subcutaneous injection
223838890|NCT04565314|DIETARY_SUPPLEMENT|Plumpy'Mum|Mothers will consume Plumpy'Mum (one packet daily) from enrollment (child age 0-3 months) for 3 months.
223838891|NCT02945202|DEVICE|Biometry|All patients undergo all three examinations (biometry, refraction and corneal topography) 6 months after surgery
223838892|NCT02945202|DEVICE|Refraction|All patients undergo all three examinations (biometry, refraction and corneal topography) 6 months after surgery
223838893|NCT02945202|DEVICE|Corneal Topography|All patients undergo all three examinations (biometry, refraction and corneal topography) 6 months after surgery
223838894|NCT02046642|BEHAVIORAL|Maternal rest in left lateral position|After initial amniotic fluid index measurements, the participating pregnant women were instructed to turn their left sides and rest in that position for 15 minutes before a second amniotic fluid index measurement
223838895|NCT02046642|BEHAVIORAL|Maternal rest in right lateral position|After initial amniotic fluid index measurements, the participating pregnant women were instructed to turn their right sides and rest in that position for 15 minutes before a second amniotic fluid index measurement
223838896|NCT00426374|PROCEDURE|echocardiography and blood test|
223838897|NCT05420987|DIETARY_SUPPLEMENT|Jing Si herbal tea liquid packet|Jing Si herbal tea includes eight Taiwan native-grown herbs: such as mugwort leaves, fish needle grass, Ophiopogon japonicus, platycodon, perilla leaves, chrysanthemum, and licorice
223838898|NCT05148767|DRUG|Neoadjuvant chemoradiotherapy based on irinotecan|"Patients with locally advanced rectal cancer treated with irinotecan-based chemoradiotherapy were enrolled in this study. The dose of irinotecan is determined by the genotype of UGT1A1.Concurrent Chemoradiotherapy:~Radiation: 50Gy/25Fx; Capecitabine: 625mg/m2 bid Monday-Friday per week; Irinotecan: 80mg/m2 (UGT1A1\*28 and \*6: 6/6+GG) or 65mg/m2 (UGT1A1\*28 and \*6 ：6/7+GG or 6/6+GA) or 50mg/m2 （UGT1A1\*28 and \*6 ：7/7+GG or 6/6+AA or 6/7+GA）."
223838899|NCT01241578|BEHAVIORAL|Lifestyle Counseling|Participants receive instructions for making healthy changes to their diet and physical activity habits.
223838900|NCT01330121|OTHER|Pharmacist Counseling|"Pharmacist Counseling includes but is not limited to:~Reviewing and explaining their medications (dosing, side effects, route) Reviewing symptoms and complications of hyper and hypoglycemia Defining glycemic \& non-glycemic goal levels Explaining the importance of compliance with medications \& appointments Educating on the basics of nutrition and physical activity"
223838901|NCT02744274|OTHER|Verum acupuncture|"Patients will lay supine. The acupuncture physicians will disinfect the selected acupuncture points with alcohol and then needle them (30 gauze, 1.5-inch, Yuguang, Taiwan) with a plastic device is fixed needle body, so that the patient achieves a de qi sensation, which is often described as a pressure or achiness feeling. The acupuncture point will be bilateral Quchi, Waiguan, hegu, baxie, Zusanli, Yanglingquan, Sanyinjiao, Taichong, bafeng. Acupuncture needles will be left in place for approximately 30 minutes, and every 10 minutes twisting stainless steel needle to get a de qi."
223838902|NCT00031447|DRUG|Acyclovir|Oral suspension 300 mg/m\^2/dose, 3 times per day (TID), for 6 months.
223838903|NCT00031447|DRUG|Placebo|Placebo identical to oral acyclovir suspension in appearance and taste.
223838904|NCT01636362|DEVICE|Mepitel Ag|Mepitel Ag is an antimicrobial, meshed, non-adherent wound contact layer allowing passage of exudate and providing fixation and protection of tissues.
223838905|NCT04990687|DEVICE|gammaCore™|"Implantable VNS (iVNS), the electrical stimulation of the nervous system to modulate or modify function, has been FDA approved in the United States since the late 1990s. Implantable VNS therapy has been approved for use in epilepsy and depression.~When treating major depression with implanted VNS, the widely held belief is that chronic stimulation is required for therapeutic effect. In trials of implantable VNS in major depression, more patients respond at 12 months than at 3 months. Once depressed patients respond to VNS, the effects have been demonstrated to continue for up to five years with continued stimulation. This finding suggests that VNS gradually changes brain function through neuroplasticity."
223838906|NCT04457271|BEHAVIORAL|Goal Management Training (GMT)|GMT is a structured, short-term cognitive remediation program with an emphasis on mindfulness and practice in planning and completion of goal-oriented behaviours. The main objective of GMT is to help participants regain executive control in order to better define goals and monitor performance in achieving them. Sessions include instructional material, interactive tasks, discussion of patients' real-life deficits, and homework assignments. Mindfulness meditation is also incorporated for the purpose of developing the skill of bringing one's mind to the present to monitor ongoing behaviour, goal states, and the relationship between them, and for the development of attentional control. The program incorporates real-life examples to illustrate goal attainment failures and successes, as well as in-session practice of complex tasks that mimic real-life tasks - typically a challenge for individuals with executive function deficits (e.g., planning and set-shifting tasks).
223838907|NCT02947711|DRUG|E2027|2 x 50 mg capsules, once daily on Day 1 and Day 12
223838908|NCT02947711|DRUG|Diltiazem ER|1 x 300 mg capsule, once daily on Days 7 through 24
223838909|NCT04561414|DEVICE|LED light source system for endoscope|The prospective, multi-center, single-blind, parallel, randomized controlled superiority trial design is adopted to evaluate the safety and effectiveness of the LED light source system for endoscope during ureter transillumination. The trial will be carried out in 5 centers, with the competitive grouping mode adopted. This trial will be carried out in the General Surgery Department and the Gynecology Department. Totally 120 subjects with rectal cancer, endometriosis, cervical cancer, adenomyosis and pelvic adhesion requiring operation (60 subjects for each of the test group and control group) are involved. The test group use LED light source system for endoscope.
223838910|NCT04561414|DEVICE|Ureteral stent (Cook Ireland Ltd.)|The prospective, multi-center, single-blind, parallel, randomized controlled superiority trial design is adopted to evaluate the safety and effectiveness of the LED light source system for endoscope during ureter transillumination. The trial will be carried out in 5 centers, with the competitive grouping mode adopted. This trial will be carried out in the General Surgery Department and the Gynecology Department. Totally 120 subjects with rectal cancer, endometriosis, cervical cancer, adenomyosis and pelvic adhesion requiring operation (60 subjects for each of the test group and control group) are involved. The test group use Ureteral stent (Cook Ireland Ltd.).
223838911|NCT03569969|PROCEDURE|device: Tympanoplasty with Membrane Amniotic|amniotic membrane Tympanoplasty
223838912|NCT03569969|PROCEDURE|Tympanoplasty With Autologous Fascia|Autologous Temporalis fascia Tympanoplasty
223838913|NCT02623556|BIOLOGICAL|ESAT6-CFP10 (10ug/ml) in left arm and TB-PPD in right arm|All subjects including TB subjects and non-TB subjects with lung disease inject ESAT6-CFP10 (10ug/ml) in left arm and TB-PPD in right arm respectively. Two drug must use at the same participant and in different arms.
223838914|NCT02623556|BIOLOGICAL|ESAT6-CFP10 (10ug/ml) in right arm and TB-PPD in left arm|All subjects including TB subjects and non-TB subjects with lung disease inject ESAT6-CFP10 (10ug/ml) in right arm and TB-PPD in left arm respectively. Two drug must use at the same participant and in different arms.
223838915|NCT00058851|PROCEDURE|Manual lymph drainage|
223838916|NCT00058851|PROCEDURE|Combined physiotherapy|
223838917|NCT00058851|PROCEDURE|Compression bandaging|
223838918|NCT05722171|BIOLOGICAL|gdT cell injection targeting B7-H3 chimeric antigen receptor|The subjects, who sign the informed consent forms and been screened by inclusion/exclusion criteria, will be assigned into 1E8, 2E8 and 4E8 CAR-gdT groups in order of sequence. And the subjects will be administered once.
223838919|NCT04979390|DRUG|SHR-1316|SHR-1316 administrated intravenously (IV) at protocol defined dose levels
223838920|NCT03259347|BEHAVIORAL|Group-based Therapy|Young women with body dissatisfaction will be randomized to one of two conditions: 1) an educational-support group condition; or 2) a counter-attitudinal therapy condition. We will test if a brief dissonance-based eating disorder prevention program produces intervention effects when delivered to participants with sub-threshold and threshold eating disorders.
223838921|NCT05878743|BEHAVIORAL|Safety Planning a recovery-orientated mental health risk management intervention|Developing the skills to manage risks associated with mental health difficulties in ways which increase personal recovery for individuals.
223838922|NCT02697721|BEHAVIORAL|Powerful Tools for Caregivers|Powerful Tools for Caregivers is a 6-week psychoeducational program. Each week the caregivers will attend a 90-minute workshop in a group setting. These sessions will be co-led by two trained and certified leaders who follow the scripted program. In addition to providing education about caregiving and the importance of self-care, the classes will help caregivers develop self-care tools to manage personal stress and improve communication skills.
223838923|NCT02697721|OTHER|Control with delayed intervention|Control with delayed intervention
223838924|NCT05571800|OTHER|Mango|120g of fresh Mango
223838925|NCT05571800|OTHER|Placebo|200g isocaloric Granola Bar
223838926|NCT00320866|DEVICE|syringe driver|
223838927|NCT00440674|DEVICE|CoStar Paclitaxel-eluting coronary stent system|
223838928|NCT00238199|DIETARY_SUPPLEMENT|calcitriol|
223838929|NCT00238199|DRUG|docetaxel|
223838930|NCT01356030|PROCEDURE|ERCP|Endoscopic retrograde cholangiopancreatography (ERCP) is usually clinically indicated to place a stent (a plastic or metal tube) in the bile duct. The ERCP procedure is an endoscopic exam during which a small catheter or wire is placed into the bile duct from the point at which it connects to the small intestine. During such a procedure a stent can then be placed to help drain the bile across the site of blockage, and thereby treat your jaundice.
223838931|NCT01356030|PROCEDURE|EUS FNA|Endoscopic ultrasound (EUS) is a procedure in which a flexible tube with a tiny camera and ultrasound probe at the tip is placed through the mouth, down the esophagus, and into the stomach and duodenum (first part of the small intestine where bile flows from the bile duct into the intestine). This allows the doctor performing the EUS to get a much closer view of your pancreas and bile duct. If a suspicious mass is seen, a small sample of the mass (biopsy) is taken using fine needle aspiration (FNA). FNA involves the use of a thin hollow needle to extract cells for diagnostic purposes and is considered safer and less invasive than surgical biopsies.
223838932|NCT03403569|DRUG|Triptolide Wilfordii|In addition to appropriate ART, Triptolide Wilfordii will be given to patients in the experimental group at a dosage of 20mg three times a day per os for 12 months.
223838933|NCT03403569|DRUG|Placebo Oral Tablet|In addition to appropriate ART, placebo oral tablets will be given to patients in the experimental group at a dosage of 2 pills three times a day per os for 12 months.
223838934|NCT05368506|DRUG|Wee1 Inhibitor ZN-c3|Given PO
223838935|NCT03302910|OTHER|Short Stay Unit|Subjects will be treated for acute heart failure in the SSU and observed for improvement then, if appropriate, discharged. If not appropriate for discharge they will be admitted to inpatient.
223838936|NCT03302910|OTHER|Standard of Care|Subjects who come to the ER with acute heart failure who are randomized to inpatient stay.
223838937|NCT00552474|DEVICE|Libra Deep Brain Stimulation System|Active DBS Therapy
223838938|NCT00552474|DEVICE|Libra Deep Brain Stimulation System|Implanted system but no stimulation
223838939|NCT01477749|BIOLOGICAL|sipuleucel-T|Each dose of sipuleucel-T contains a minimum of 50 million autologous CD54+ cells activated with PAP-GM-CSF. The recommended course of therapy for sipuleucel-T is 3 complete doses, given at approximately 2-week intervals.
223838940|NCT03076658|RADIATION|EOS imaging|The EOS imaging system will be utilized to obtain full-body radiographs in frontal and sagittal projections obtained in the upright standing position. Measurements will include a coronal plumb-line, sagittal vertebral axis (SVA), external auditory meatus plumb-line, cervical lordosis, thoracic kyphosis, lumbar lordosis, hip flexion/extension, knee flexion/extension, ankle flexion/extension, T1 tilt, T1 spino-pelvic instance, acetabular index, pelvic tilt (PT), pelvic incidence (PI), and sacral slope (SS).
223838941|NCT03044093|DRUG|Mifepristone|The group that will get in addition to Misoprostol also Mifepristone
223838942|NCT03044093|DRUG|Placebo|The group that will only get Misoprostol
223838943|NCT03044093|DRUG|Misoprostol|Both groups will get think drug
223838944|NCT00311428|BIOLOGICAL|Influenza|
223838945|NCT02029703|DEVICE|Synvisc-One Injection|
223838946|NCT02029703|OTHER|Sham Injection|
223838947|NCT06073964|BEHAVIORAL|Trauma Resilience & Understanding Self-help Therapy|A self-help psychosocial therapeutic intervention requiring one to undergo a basic training in its community-based utilization.
223838948|NCT05645042|BEHAVIORAL|Transcendental Meditation (TM)|During the first week, each participant randomized to undergo TM will meet with a TM instructor on four consecutive days for 60 minutes, for an introductory training. Next, participants will meet for twelve 60-minute sessions over the course of three months and then once monthly for booster sessions for 6 months. All sessions will be recorded and reviewed for adherence to the TM protocol.
223838949|NCT05645042|BEHAVIORAL|Present Centered Therapy (PCT)|PCT treatments will be delivered by trained clinicians at master's or doctoral-level. Study therapists will be supervised by a a licensed psychologist. Participants assigned to this treatment will meet with a PCT therapist once a week for twelve 60-minute sessions over the course of 3 months and then monthly for months four through nine. Sessions will focus on current life problems as manifestations of PTSD. All sessions will be recorded and reviewed for adherence to the treatment protocol.
223838950|NCT03566589|DIETARY_SUPPLEMENT|Lactobacillus plantarum PS128|daily ingestion of 60 billion colony forming unit (CFU) of Lactobacillus plantarum PS128 (30 billion CFU/capsule)
223838951|NCT03839563|BEHAVIORAL|Exercise|Each session will last 60 min, consisting of 10 min of warm-up, 45 min of exercise, and a 5-min cool-down.
223838952|NCT00839982|DRUG|clofarabine|Given PO
223838953|NCT00839982|DRUG|cytarabine|Given SC
223838954|NCT03847168|DRUG|KN026|Patient will be intravenously administrated with one dose of KN026 every week or every other week.
223838955|NCT04252703|PROCEDURE|Percutaneous coronary intervention (PCI)|Invasive cardiac catheterization, balloon angioplasty and intracoronary stenting.
223838956|NCT02075983|BIOLOGICAL|GTU®-multiHIV B clade|The investigational HIV-1 vaccine GTU®-MultiHIV B clade encodes for a MultiHIV antigen (synthetic fusion protein built up by full-length polypeptides of Rev, Nef, Tat, p17 and p24 with more than 20 Th and CTL epitopes of protease, reverse transcriptase (RT) and gp160 regions of the HAN2 HIV-1 B clade.
223838957|NCT04267653|DRUG|Lactoferrin Bovine|treatment for 30 days
223838958|NCT04267653|DRUG|Ferrous Sulfate|treatment for 30 days
223838959|NCT01612364|PROCEDURE|thoracic sympathetic block|Thoracic sympathetic block is sympathetic block of upper limb described by Leriche e Fontaine em 1925. The block is performed under radioscopic view, positioning the needle lateral the body of thoracic vertebra T3, where infuse anesthetic solution. The theoretical advantage over the stellate ganglion is its greater specificity and efficiency. Solution block: 5ml ropivacaine 0,75% + 5ml de triamcinolone 2%
223838960|NCT04032457|DEVICE|Phase A - olifilcon B with Tangible Coatings|Daily disposable silicone hydrogel contact lens
223838961|NCT04032457|DEVICE|Phase B - etafilcon A with Tangible Coatings|Daily disposable hydrogel contact lens
223838962|NCT00724061|BIOLOGICAL|Pegylated interferon α-2b|PEG-IFN-α-2b will be administered subcutaneously once a week. The starting dose of PEG-IFN-α-2b will be 1.5μg/kg. Each patient will undergo dose escalation to 3, 4.5, 6, 7.5, and up to 9μg/kg every 2 weeks or to maximum tolerated dose will be allowed. If no dose limiting toxicity (DLT) is observed, the maximum dose reached will be expanded. Once this dose has been given weekly for 2 weeks with no DLT, therapy will continue at this dose for up to 1 year depending on response.
223838963|NCT00724061|OTHER|Psoralens with ultraviolet light A|Oral psoralen (8-methoxypsoralen, 0.6-1.0 mg/kg) will be taken 1.5 to 2 hours prior to UVA treatment. The initial UVA dosage will be approximately 0.5 to 1.5 J/cm2, and will be increased in increments as determined by skin type and tolerability. PUVA therapy will be given 2-3 times per week until complete remission (CR) is achieved. Afterwards, additional maintenance therapy will be given with a gradual reduction from once a week to every 4-6 weeks up to 1 year after CR was achieved.
223838964|NCT00724061|OTHER|Narrowband-ultraviolet light B|The initial NB-UVB dose will be 70% of the patient's MED and approximately 0.2 J/cm2 and will be increased by 15% of each subsequent treatment as determined by skin type and/or tolerability. Therapy will be given 3 times per week until complete remission (CR) is achieved. Additional maintenance therapy will be administered while gradually reducing NB-UVB from thrice weekly to once a week. All patients will continue maintenance NB-UVB therapy until 1 year after they have achieved CR.
223838965|NCT00000816|DRUG|Sulfamethoxazole-Trimethoprim|
223838966|NCT02328456|OTHER|SMS and free eye drops|The SMS reminder message will sent to the SMS associated with free eye drops group patients 1 week and 1 day before there appointment to remind them the exact time and address of the revisit appointment.The eye drops will be offered free to the the SMS associated with free eye drops group patients when they revisit on time.
223838967|NCT01342653|OTHER|Intraperitoneal and systemic chemotherapy plus maximum cytoreduction plus HIPEC|see Design
223838968|NCT00513903|BEHAVIORAL|Minimal intervention|Minimal intervention patients will be seen by a clinical pharmacist during the hospitalization period to improve continuity of pharmacy care following hospital discharge.
223838969|NCT00513903|BEHAVIORAL|Enhanced Intervention|Enhanced intervention patients will be visited in the hospital and will also be called by the clinical pharmacist following discharge to follow-up on any problems that might have developed after discharge.
223838970|NCT02034084|PROCEDURE|left radial approach|Coronary diagnostic procedures performed through left radial approach
223838971|NCT02034084|PROCEDURE|Right radial approach|coronary diagnostic procedures performed through right radial approach
223838972|NCT02783482|BIOLOGICAL|GC5107|GC5107 20g/200mL, intravenously, dose of 300 - 900 mg/kg (of body weight) every 21 or 28 days for 12 months, a follow-up (3 or 4 weeks)
223838973|NCT05648955|DIETARY_SUPPLEMENT|an enriched high protein and high energy oral nutrition supplement (ONS)|NA (see intervention name)
223838974|NCT01536782|PROCEDURE|Bolus|"The patients will be randomized into 3 different groups: Bolus, Gravity, and Pump. The randomization process will be based on age and estimated caloric needs (i.e if we have three 60-year-old patients whose estimated kcals needs are ≤ 1900kcals/day, then each patient will be randomized to either of the groups).~Each patient from each group will be receiving tube feeding education to their by RD. For consistency reasons, the same type of tube feeding formula (1.5 kcal/ml, no fiber) will be used. Patients' weight, tube feeding tolerance, and amount of estimated calories and protein met will be monitored weekly."
223838975|NCT01536782|PROCEDURE|Gravity|"The patients will be randomized into 3 different groups: Bolus, Gravity, and Pump. The randomization process will be based on age and estimated caloric needs (i.e if we have three 60-year-old patients whose estimated kcals needs are ≤ 1900kcals/day, then each patient will be randomized to either of the groups).~Each patient from each group will be receiving tube feeding education to their by RD. For consistency reasons, the same type of tube feeding formula (1.5 kcal/ml, no fiber) will be used. Patients' weight, tube feeding tolerance, and amount of estimated calories and protein met will be monitored weekly."
223838976|NCT01536782|DEVICE|Pump|"The patients will be randomized into 3 different groups: Bolus, Gravity, and Pump. The randomization process will be based on age and estimated caloric needs (i.e if we have three 60-year-old patients whose estimated kcals needs are ≤ 1900kcals/day, then each patient will be randomized to either of the groups).~Each patient from each group will be receiving tube feeding education to their by RD. For consistency reasons, the same type of tube feeding formula (1.5 kcal/ml, no fiber) will be used. Patients' weight, tube feeding tolerance, and amount of estimated calories and protein met will be monitored weekly."
223838977|NCT01601743|BEHAVIORAL|Sitting|Sitting for the same period of time and duration (30 minutes per session, 3 times per week, over 4 consecutive weeks).
223838978|NCT01601743|BEHAVIORAL|Running|Exercise (running) for 30 minutes per session, 3 times per week, over 4 consecutive weeks.
223838979|NCT01601743|BEHAVIORAL|Walking|Exercise (walking) for 30 minutes per session, 3 times per week, over 4 consecutive weeks.
223838980|NCT05847764|DRUG|RC48+Tislelizumab+carboplatin|RC48+PD-1/PD-L1 inhibitor+chemo in treatment-naive patients harboring HER2 alterations
223838981|NCT05847764|DRUG|RC48+Furmonertinib, 1L|RC48+Furmonertinib in treatment-naive patients harboring EGFR mutations as well as HER2 alterations
223838982|NCT05847764|DRUG|RC48+Furmonertinib, 2L+|RC48+Furmonertinib in patients who failed at least one line of standard treatment and harboring HER2 alterations
223838983|NCT05374083|PROCEDURE|Alveolar ridge preservation using autogenous demineralized dentin block graft|Atraumatic extraction of non restorable tooth, then the extracted tooth will be prepared and demineralized by hydrochloric acid (HCL) acid and inserted as demineralized dentin block graft in the socket
223838984|NCT05374083|PROCEDURE|Alveolar ridge preservation using particulate deproteinized bovine bone graft|Atraumatic extraction of non restorable tooth, then the socket will be packed by particulate deproteinized bovine bone
223838985|NCT00953160|DEVICE|Cutera Radio Frequency Device|Up to three treatments, one pass, dosage range of 15-60 kJ.
223838986|NCT03793855|BEHAVIORAL|Nutritional Strategy|Counseling based on dietary goals and mindfulness techniques.
223838987|NCT03793855|BEHAVIORAL|Dietary Prescription|Dietary prescription according to guidelines.
223838988|NCT04387890|DIAGNOSTIC_TEST|Serologic SARS-CoV-2 screening|Quantitative Indirect Chemiluminescence Immunoassay (CLIA) to access SARS-CoV-2 specific IgM and IgG serum antibody level every 2 weeks during follow up
223838989|NCT04798703|DRUG|ONCOFID-P-B™ (PACLITAXEL-HYALURONIC ACID)|12 weekly intravesical instillations of ONCOFID-P-B™ (intensive treatment phase) followed by maintenance phase of the study, during which ONCOFID-P-B™ is furtherly administered once a month for 12 months in patients who achieved a complete response (CR) after the 12 weekly instillations.
223838990|NCT01686269|PROCEDURE|blood collecting|
223838991|NCT05168644|DRUG|Niclosamide Inhalation Powder|Investigational drug will be supplied as capsules, each capsule contains 0.25 mg or 1 mg of Niclosamide Inhalation Powder. The capsules will be administered with the provided breath actuated Plastiape RS00 Model 8 Dry Powder Inhaler device.
223838992|NCT05168644|DRUG|Placebo|Placebo will be supplied as capsules, each capsule will contain no active ingredient. The capsules will be administered with the provided breath actuated Plastiape RS00 Model 8 Dry Powder Inhaler device.
223838993|NCT00425503|DRUG|PS-341 (bortezomib)|PS-341 is a dipeptidyl boronic acid inhibitor with high specificity for the proteasome developed by Millennium Pharmaceuticals Inc. to treat human malignancies. It is the first member of this class of anti-tumor agents to come to human trials. Patients will receive PS-341 (1.6mg/m2/dose) by intravenous push weekly for 4 consecutive weeks followed by a 24-72 hour rest. This schedule consists of one treatment cycle. Upon the completion of 4 weeks of PS-341 followed by a 24-72 hour rest period, radical prostatectomy will be performed.
223838994|NCT00479947|DRUG|Probiotics (Natural product)|
223838995|NCT00479947|DRUG|Probiotics (L. rhamnosus GR-1 and L. reuteri RC-14)|
223838996|NCT02785601|DRUG|Trazodone Hydrochloride prolonged-release tablets|strength 75mg, 150 mg. Oral administration with 200ml water
223838997|NCT02118714|DRUG|Atrasentan|Atrasentan
223838998|NCT02544737|DRUG|Apatinib|Patients with metastatic lesions of esophageal cancer after been treated with surgery or definitive chemoradiotherapy receiving Apatinib (850mg) daily over 4 weeks.
223838999|NCT00963703|DRUG|Rituximab|Rituximab 1000 mg Intravenously day 1 and day 15
223839000|NCT02954575|DRUG|Wilate|
223839001|NCT00229619|DRUG|Rituximab|Rituximab (Rituxan) 375mg/m2 intravenous infusion. The infusion will be once every week for a total of 4 doses.
223839002|NCT05466903|DIETARY_SUPPLEMENT|Early diet opening|Effects of early dietary recovery after colon polypectomy and colonoscopic mucosal resection on postoperative hemorrhage in patients
223839003|NCT04681677|RADIATION|Radiation: Intra-operative Radiation Therapy - IORT|Single fraction, Intra-operative Radiation Therapy at the time of surgical resection of recurrent GBM followed by Bevacizumab 28-56 days after surgery.
223839004|NCT04681677|DRUG|Bevacizumab|Bevacizumab
223839005|NCT03337880|OTHER|instrumental delivery|the birth was assisted with an extractor.
223839006|NCT03537053|BEHAVIORAL|A plan to Move a Little and Often|"The intervention content is reported using the behaviour change technique (BCT) Taxonomy v1 (Michie, et al. 2013). The video will contain the BCT: information about health consequences. The booklet will consist of BCTs: self-monitoring of behaviour, goal setting behaviour, action planning, commitment, social support (practical), self-talk, and mental rehearsal of successful performance. Lastly, usage of the Facebook group will include BCTs: commitment, and social support unspecified, practical and emotional.~Mental rehearsal, goal setting behaviour and action planning will be delivered through mental simulation exercises (Taylor, et al. 1998). BCTs self-monitoring of behaviour, goal setting behaviour, and commitment will be delivered using implementation intentions (Gollwitzer 1993)."
223839007|NCT04945343|PROCEDURE|Growing Rods|Growing Rods(GR), are implants used to correct pediatric scoliosis deformity. They attempt to allow the growth of the spine and thorax while controlling curve progression to preserve normal lung volume.
223839008|NCT00131560|GENETIC|VRX496-Modified Autologous T cells|Genetic: Anti-HIV antisense
223839009|NCT01080963|DRUG|Daptomycin|one infusion of 350 mg intraoperatively after disconnection from the heart-lung machine as an add-on to standard antibiotic prophylaxis
223839010|NCT01080963|DRUG|Cefuroxime|1500 mg intravenous 30min preoperatively during anesthesia and 1500 mg intravenous intraoperatively after disconnection from the heart-lung machine
223839011|NCT02796443|PROCEDURE|Laparoscopic cholecystectomy (LC)|Removal of the gallbladder via a minimally invasive approach
223839012|NCT02500927|DRUG|ASP8273 Capsules|oral
223839013|NCT02500927|DRUG|ASP8273 Capsules A|oral
223839014|NCT03952455|PROCEDURE|Bilateral surgical implantation of DBS system to Nucleus Accumbens|We plan to use the SceneRay 1242 (SceneRay, SuZhou, China) electrode with a diameter of 1.27 mm and 4 contacts. The SceneRay 1242 electrode combined with the SceneRay 1181 implantable pulse generator has the advantage of adaptive coverage area for the Ventral Capsule/Ventral Striatum, enabling simultaneous implantation in the nucleus accumbens (NAc; 2 ventral contacts) and the anterior limb of the internal capsule (ALIC; 2 dorsal contacts) with independently programmed parameters such as frequency, amplitude, and voltage; and remote and wireless programing, which allows for convenient and prompt adjustments in emergency situations. The contact length is 3.0 mm and the spacings between the ventral and dorsal contacts are 2 mm, 4 mm, and 4 mm, respectively, spanning a total length of 22.5 mm (3 + 2 + 3 + 4 + 3 + 4 + 3 mm, with 0.5 mm projecting from the electrode tip).
223839015|NCT00795418|BIOLOGICAL|Placebo|Placebo comparator
223839016|NCT00795418|BIOLOGICAL|CAD106|
223839017|NCT03553862|BEHAVIORAL|collaborative care|The intervention arm will receive collaborative care from a team of healthcare professionals that consists of pharmacist, physicians, nurses and dietitians. Patients in the intervention group will also receive clinical interventions carried out by the pharmacist.nurses and dietitians as well as a pharmacist.
223839018|NCT05079880|DRUG|300 mg of caffeine citrate infusion|At the end of the surgery, the study drug was given intravenously over ten minutes than the sevoflurane infusion was stopped corresponding to the start of the recovery period
223839019|NCT05079880|DRUG|Placebo|At the end of the surgery, the placebo was given intravenously over ten minutes than the sevoflurane infusion was stopped corresponding to the start of the recovery period
223839020|NCT05081375|DRUG|Enoxaparin Injectable Product|Not holding prophylaxis dose prior to surgical procedure
223839021|NCT05081375|DRUG|Sodium chloride|Holding prophylaxis dose of Enoxaparin replacing with placebo
223839022|NCT02400307|DRUG|Bictegravir|75 mg tablet administered orally
223839023|NCT00444717|DRUG|pitavastatin|Pitavastatin (2mg/day) was administered for 12 weeks
223839024|NCT03093311|OTHER|NIRS based protocol|Each desaturation episode will be managed according to a standardized protocol - correction of extreme head position will be followed by optimisation of mean arterial pressure (MAP), arterial hemoglobin oxygen saturation, end tidal carbon dioxide concentration and a level of hemoglobine concentration.
223839025|NCT06022874|OTHER|Phoilex Releaf Gel|"Patients will be given the Releaf Gel to apply to the affected areas daily. They will be examined at the following time points: Immediately after application, 1 week, 2 weeks, and 4 weeks.~The instructions given to the patient shall be to apply one pump per every affected area, wash hands before applying to affected area, apply twice a day (morning, and evening), apply on clean skin, and application after showering is advised.~The number of pumps of Phoilex Releaf gel will be documented within a chart provided to the patient. It is suggested that not more than 25 lesions compassing an area greater than 50 cm² in total be treated during the course of this study.~The maximum dose would be 240 mL of Phoilex Releaf gel in 30 days. The minimum dose would be 0.5 mL (one pump) of the Phoilex Releaf gel in 30 days. The maximum daily dose of CBD per day 46 mg per application, equivalent to 92 mg per day."
223839026|NCT00792129|DEVICE|The Atavi System|"The primary device in the Atavi system is the Flex Posture retractor and accessories such as dilators and an Expander Instrument.~The Atavi System includes instruments used to access the spine by dilation of the overlying tissues, as well as a retracting device that is used to maintain the access. Once the retractor is in place, the visualization components of the system may be used."
223839027|NCT03904082|PROCEDURE|Erector Spinae Plane block ( Group ı)|ESP Block will perform preoperative to all patients in ESP block group. Patients in all groups will provide with intravenous patient- controlled analgesia device containing morphine for postoperative analgesia.
223839028|NCT03904082|PROCEDURE|Serratus Anterior Plane block ( Group ıı)|SAP Block will perform preoperative to all patients in SAP block group. Patients in all groups will provide with intravenous patient- controlled analgesia device containing morphine for postoperative analgesia.
223839029|NCT03904082|PROCEDURE|Control Group (GROUPIII)|Control group will receive no intervetion. Patients in all groups will provide with intravenous patient- controlled analgesia device containing morphine for postoperative analgesia.
223839030|NCT00816140|DRUG|Cravit based triple therapy|"Levofloxacin based triple therapy~LALa regimen: levofloxacin 750mg (levofloxacin500 1.5 tablets) once daily, amoxicillin 1000mg twice daily, lansoprazole 30mg twice daily for 7 days"
223839031|NCT00816140|DRUG|Klaricid based triple therapy|"Clarithromycin based triple therapy~CALa regimen: clarithromycin 500mg twice daily, amoxicillin 1000mg twice daily, and lansoprazole 30mg twice daily for 7 days"
223839032|NCT00876122|DRUG|GDC-0941|Escalating oral dose
223839033|NCT06305507|OTHER|Focussed laser therapy|"Others: Spot laser therapy~Other names:~Spot laser therapy Low Level Laser Therapy (LLLT) - Local Spot~The intervention involves the precise and focused application of low-power laser on specific areas related to plantar fasciitis. The local point technique is characterized by directing the laser directly to the painful point, seeking optimal stimulation in the affected region. This approach allows for targeted delivery of treatment to the area where pain is experienced, with the goal of maximizing the effectiveness of the therapy in reducing the symptoms associated with plantar fasciitis."
223839034|NCT06305507|OTHER|Shower laser therapy|"Laser Therapy Sweeping~The intervention involves constantly moving the low-power laser over the areas affected by plantar fasciitis in a sweeping pattern. The sweeping technique seeks to cover a greater extent of the painful area during each treatment session. This approach differs by providing broader stimulation across the affected area, exploring the possibility of additional benefits compared to the local spot technique."
223839035|NCT00401817|DRUG|Bevacizumab|15 mg/kg on day 1 of each of 6 cycles
223839036|NCT00401817|DRUG|Rituximab|"Rituximab will be administered prior to CHOP on day 3 of every cycle for a total of 6 cycles.~The dose to be administered is:~Rituximab: 375 mg/m2"
223839037|NCT00401817|DRUG|CHOP|Standard CHOP chemotherapy will be administered at full dose every 21 days for a total of 6 cycles. The doses to be used are: Cyclophosphamide: 750 mg/m2 IV on day 3 Doxorubicin: 50 mg/m2 IV on day 3 Vincristine: 1.4 mg/m2 IV (not to exceed 2.0 mg total) on day 3 Prednisone: 100 mg PO days 3 - 7
223839038|NCT03729206|DIAGNOSTIC_TEST|intravital microscopy|intravital microscopy with sidestream dark-field imaging
223839039|NCT02015663|DRUG|Tobramycin Inhalation Powder|Tobramycin Inhalation Powder 112 mg (four 28-mg capsules) taken via inhaler once or twice a day, depending on study arm
223839040|NCT01226173|DEVICE|Bio-Rad Platelia Dengue NS1 Ag test|The purpose of the study is to screen blood donors for the presence of dengue NS1 antigen at the ARC in Puerto Rico region using the Bio-Rad Platelia Dengue NS1 Ag test.
223839041|NCT04584606|DIAGNOSTIC_TEST|Lab workup (on admission and regularly during follow up).|"Complete blood count with differential leucocytic count. Absolute lymphocytic and neutrophilic count. Liver functions: Aspartate transaminase and Alanine transaminase . Renal functions: Blood urea nitrogen, serum Creatinine. HbA1C. C-reactive protein (quantitative). Serum ferritin level. D - dimer level (quantitative). Coagulation profile (Prothrombin time/ Partial thromboplastin time/ International normalized ratio).~Troponin level. Arterial blood gases when needed."
223839042|NCT01761786|GENETIC|CYP2C19 genotyping|CYP2C19 genotyping will be performed in the intervention group. In patients with \*1/\*1 genotype (Extensive Metabolizer) clopidogrel will be prescribed. All patients who are carrier of a loss-to-function (\*2 or \*3) gene allel and all patients randomized to the control group will be prescribed prasugrel or ticagrelor, according to local protocol.
223839043|NCT01305057|OTHER|Pyridoxine tri-isopalmitate|2% dosage, oil-in-water emulsion, twice a day, 28 days
223839044|NCT00006085|DRUG|CP-609,754|
223839045|NCT02787538|BEHAVIORAL|US-ANSWER-2 decision aid|US-ANSWER-2 will consist of: 1) an Information Module that presents effectiveness and side effects of each treatment option, and 2) an interactive Value Clarification Module that guides patients to consider what matter to them the most, and the pros and cons of each treatment option. Within the Information Module, the decision support information (i.e., the benefits and harms of treatment options) will be presented in narrated text, graphics, and a series of animated patient stories demonstrating attributes required for effective communication with doctors and significant others.
223839046|NCT02787538|BEHAVIORAL|Control group (Online medication guide)|Standard online medication guide.
223839047|NCT02145793|BEHAVIORAL|ADHD Group Curriculum|Study specific ADHD Group curriculum was designed and implemented for the study. Parent curriculum included the following topics: What is ADHD, medications, educational advocacy, how to prevent behavioral issues and how to defuse common behavioral challenges and manage stress. Child curriculum included the following topics: what is ADHD, social skills and friendships, handling school and organization skills, understanding feelings and managing negative emotions
223839048|NCT00479674|DRUG|Abraxane|100 mg/m2 IV over 30 min days 1,8,15. Cycles Repeated Every 28 days until documented evidence of disease progression by RECIST criteria, intolerable toxicity, or death..
223839049|NCT00479674|DRUG|Bevacizumab|10 mg/kg IV days 1,15 Cycles Repeated Every 28 days until documented evidence of disease progression by RECIST criteria,intolerable toxicity, or death.
223839050|NCT00479674|DRUG|Carboplatin|area under curve (AUC)=2 IV over 15 min days 1,8,15. Cycles Repeated Every 28 days until documented evidence of disease progression by RECIST criteria, intolerable toxicity, or death.
223839051|NCT00643500|DRUG|Levetiracetam|
223839052|NCT01054911|DRUG|Sunitinib|All patients will receive sunitinib 37.5 mg p.o. daily for up to 12 weeks to be taken orally.
223839053|NCT01054911|PROCEDURE|Surgery|Following sunitinib therapy, patients will be evaluated for surgery. It is anticipated that the quality of response will allow for complete resection of residual tumor. Surgical resection, if eligible, will occur around week 14-16.
223839054|NCT04531683|OTHER|electroacupuncture|same as described in experimental arm.
223839055|NCT04531683|OTHER|sham electroacupuncture|same as described in sham comparator.
223839056|NCT04531683|BEHAVIORAL|life style counselling|life style counselling to patients with mixed urinary incontinence contains advice on daily drinking, caffeine intake, diet, constipation, exercise, heavy lifting, lung disease, urinary track infection and etc.
223839057|NCT02071095|DRUG|Arm A: Poly-ICLC|Poly-ICLC (Hiltonol®, Oncovir) Administration - On days 1 and 2, patients randomized to this arm will be injected subcutaneously in the arm with 1.4 mg of Poly-ICLC (Hiltonol®, Oncovir). Each subject will receive a total of 2 SC doses of Poly-ICLC. The volume of each injection is 0.7ml. The investigators who are blinded will not be present at the time of injection by the study nurse.
223839058|NCT02071095|DRUG|Arm B: Normal Saline|Normal Saline - On days 1 and 2, patients randomized to this arm will be injected subcutaneously in the arm with normal saline obtained from the Rockefeller University Pharmacy. Each subject will receive a total of 2 SC doses of normal saline. The volume of each injection is 0.7ml. The investigators who are blinded will not be present at the time of injection by the study nurse.
223839059|NCT00146640|DRUG|MR Prednisone|Participants will receive tablets containing MR prednisone (to achieve the appropriate dose of 3-10 milligrams \[mg\] prednisone per day) at bed time.
223839060|NCT00146640|DRUG|IR Prednisone|Participants will receive tablets containing IR prednisone (to achieve the appropriate dose of 3-10 mg prednisone per day) in the morning.
223839061|NCT00146640|DRUG|Placebo - MR Prednisone|Participants will receive placebo matching to MR prednisone tablet at bed time.
223839062|NCT00146640|DRUG|Placebo - IR Prednisone|Participants will receive placebo matching to IR prednisone tablet in the morning.
223839063|NCT00060021|PROCEDURE|acupuncture therapy|
223839064|NCT00060021|PROCEDURE|management of therapy complications|
223839065|NCT00060021|PROCEDURE|pain therapy|
223839066|NCT04018443|DIAGNOSTIC_TEST|common carotid artery diameter measurement|measurement of common carotid artery diameter will be carried out two times: the initial measurement (pre-infusion) which is followed by infusion of crystalloid solution (Ringer lactate) 30 ml/min till reaching a total infusion volume of 7 ml/kg body weight then another ultrasound measurement will be taken (prost-infusion). Between these sequential measurements, the patient position will not be changed. The percentage increase in CCA diameter will be calculated using the formula: \[(dia-mpost/dia-mpre) × 100\] - 100 \[11\].
223839067|NCT03983902|PROCEDURE|Delayed cord clamping|Delayed cord clamping will occur for up to 2 minutes.
223839068|NCT03983902|PROCEDURE|Umbilical cord milking|Umbilical cord milking will occur milking of the 30 cm of the cord from placental site to baby, at a speed of 5 cm/second, 3 times in preterm newborns, 4 times in term newborns.
223839069|NCT03983902|PROCEDURE|Immediate cord clamping|Immediate cord clamping will occur in 20 seconds after birth.
223839070|NCT01739556|DRUG|Antiplatelet Regimen Modification (aspirin or ticagrelor)|
223839071|NCT01882894|DEVICE|Custom PFO|PFO made out of thermoplastic material molded to the patient's foot
223839072|NCT01882894|OTHER|Faux orthosis|Foam cut out
223839073|NCT01056211|PROCEDURE|laser treatment|Starlux 300 Lux 1540nm Fractional laser hand piece
223839074|NCT01056211|PROCEDURE|treatment without laser|Starlux 300 Lux 1540nm Fractional laser hand piece
223839075|NCT01056211|PROCEDURE|laser treatment|Starlux 300 Lux 1540nm Fractional laser hand piece
223839076|NCT01403844|OTHER|Carotenoid Depletion|Depletion of carotenoids using a restricted food list
223839077|NCT01403844|OTHER|Carotenoid Repletion|Carotenoid repletion with provided diet based on dietary guidelines.
223839078|NCT01403844|OTHER|Carotenoid Depletion|Carotenoid depletion using a restricted food list.
223839079|NCT01403844|OTHER|Natural Repletion|Resumption of usual personal diet regimen. No restrictions.
223839080|NCT02682017|OTHER|Pork meat from pigs feed with a standard feed.|4 week intervention with 700g (raw weight) of pork meat (3x pork burgers (125g raw weight each) + pork mince (325 g raw weight) per week.
223839081|NCT02682017|OTHER|Pork meat from pigs fed a feed with a Laminarin/fucoidan mix|4 week intervention with 700g (raw weight) of pork meat (3x pork burgers (125g raw weight each) + pork mince (325 g raw weight) per week from pigs fed animal feed supplemented (5.37 kg/tonne of feed) with spray-dried laminarin and fucoidan (seaweed).
223839082|NCT01989715|OTHER|analyzing the position of the body, muscle activity|
223839083|NCT03131141|DRUG|BC-3781|Lefamulin (BC-3781) is a potent, semi-synthetic antibacterial belonging to a novel class for systemic human use known as the pleuromutilins
223839084|NCT02839681|DRUG|Anetumab Ravtansine|Administered intravenously (IV) every 3 weeks
223839085|NCT02839681|DEVICE|Blood test|Research blood test for eligibility
223839086|NCT01656759|DRUG|Evicel Fibrin Spray|10cc syringe dose, once at the end of TKA
223839087|NCT00125775|BIOLOGICAL|Engerix-B|Engerix-B at 0, 1, 6 months
223839088|NCT02687919|OTHER|Modified Paleo diet|Nine cups of vegetables and some fruits, meat protein including organ meat, and complete abstinence from products containing gluten (wheat, barley, rye, etc.), dairy, potatoes, and legumes (beans, lentils, peanuts, soy, etc.)
223839089|NCT03848312|BEHAVIORAL|Cognitive Training|Participants will be completing a total of 45 computerized sessions.
223839090|NCT03848312|BEHAVIORAL|Computerized Cognitive Stimulation|Participants will be completing a total of 45 computerized cognitive stimulation sessions.
223839091|NCT00217100|DIETARY_SUPPLEMENT|Multivitamin|1 tablet a day
223839092|NCT00217100|DIETARY_SUPPLEMENT|Placebo|1 tablet a day
223839093|NCT03327675|OTHER|68Ga-PSMA (HBED-CC) PET|68Ga-PSMA PET/MR
223839094|NCT02667691|DIETARY_SUPPLEMENT|SODB Dimpless|Subjects are supplemented with SODB, daily over 3 Months. Each volunteer was seen for the 4 visits: - visit of pre-inclusion, - visit V1, so-called inclusion visit, - visit V2 at 1,5 months and - visit V3 at 3 months
223839095|NCT02667691|DIETARY_SUPPLEMENT|Placebo|Subjects are supplemented with placebo, daily over 3 Months. Each volunteer was seen for the 4 visits: - visit of pre-inclusion, - visit V1, so-called inclusion visit, - visit V2 at 1,5 months and - visit V3 at 3 months
223839096|NCT02667691|OTHER|caloric restriction|Caloric recommendation reduced by 20%
223839097|NCT05099887|BIOLOGICAL|Procenta conformable barrier|Wound care dressing biologic allograft
223839098|NCT05463211|DEVICE|Trexo Plus Pediatric Exoskeleton|Wearable pediatric robotic walker for the lower extremities
223839099|NCT05040061|BEHAVIORAL|SkillJoy Intervention|The savoring treatment consisted of an ecological momentary intervention (EMI) for learning and practicing savoring skills-SkillJoy. SkillJoy prompted participants to attend to positive aspects of the present moment, plan and engage in enjoyable activities, record and reflect on positive experiences, note events that turned out well, and look forward to positive events.
223839100|NCT05040061|BEHAVIORAL|Active Self-Monitoring Control Intervention|The active self-monitoring control EMI prompted participants to notice and write current thoughts and feelings, plan the day's major activities, remember and write about their daily events, and anticipate upcoming important events.
223839101|NCT02165124|DEVICE|Artificial Embolization Device|Embosphere Microspheres
223839102|NCT01488110|DEVICE|In-house prototype invented by Jan-Erik Juto|30 minutes treatment with an active nasal probe.
223839103|NCT01488110|DEVICE|In-house prototype invented by Jan-Erik Juto|30 minutes treatment with an inactive nasal probe.
223839104|NCT01693146|DEVICE|Nasal oxygen insufflation with a TNI® 20 oxy device|Nasal insufflation at a constant high flow of 15 L/min with oxygen addition starting at 0.5 L/min
223839105|NCT01693146|DEVICE|Nasal insufflation of oxygen|Nasal insufflation of oxygen starting at at flow of 0.5 L/min.
223839106|NCT00768599|DRUG|Econazole Nitrate Cream 1%|Topical cream, applied once daily for 4 weeks.
223839107|NCT00768599|DRUG|Econazole Nitrate Foam 1%|Topical foam, applied once daily for 4 weeks.
223839108|NCT00768599|DRUG|Vehicle Foam|Topical foam, applied once daily for 4 weeks.
223839109|NCT02874846|DRUG|Netarsudil ophthalmic solution 0.02%|Once daily in both eyes (OU) in the evening (PM) for 7 days
223839110|NCT02874846|OTHER|Netarsudil Ophthalmic Solution Vehicle|Once daily in both eyes (OU) in the evening (PM) for 7 days
223839111|NCT00803140|PROCEDURE|Cautery vs Active Control Arm (Scalpel)|"Interventions: The cautery used will be the standard operating room monopolar cautery used at our institution. The cautery will be used on a cut setting of 20 with a blend setting of zero (pure cut). A standard protected needle tip cautery will be used.~A #15 blade carbon steel scalpel blade will be used on ½ of the incision; a cautery device with the above-mentioned settings will be used on the other ½ of the wound. The patient will be randomly assigned to receive the cautery incision on the left or right side. The same surgeon will make all of the skin incisions and perform the skin closures in order to provide as much standardization as possible.~The closure will be standardized."
223839112|NCT05678153|DIAGNOSTIC_TEST|Nordic Orofacial Test-Screen (NOT-S)|screening tool to detect orofacial dysfunction
223839113|NCT00305890|BEHAVIORAL|Lifestyle Behavioral Weight Management Program|The lifestyle behavioral weight management program will focus on lifestyle, exercise, attitudes, relationships, and nutrition. Participants will attend 12 weekly group sessions, followed by 6 every-other-week group sessions.
223839114|NCT00305890|BEHAVIORAL|Pain-Coping Skills Training|The pain-coping skills training will focus on minimizing maladaptive over-reactions and enhancing adaptive strategies to control and decrease pain. Participants will attend 12 weekly group sessions, followed by 6 every-other-week group sessions.
223839115|NCT00305890|OTHER|Standard Care|Standard care will include routine medical care.
223839116|NCT02093585|DRUG|abacavir (600 mg QD)|
223839117|NCT02093585|DRUG|tenofovir (245 mg QD)|
223839118|NCT01845636|DRUG|Donepezil|Donepezil 5mg will be given for 4 weeks and if tolerated, the dose will be increased to 10 mg per day. The dose range of 5 to 10 mg of donepezil per day will be continued for the study duration, and this is the recommended dose for donepezil in the treatment of mild to moderate Alzheimer's disease.
223839119|NCT01845636|DRUG|Atropine|A single acute dose of 1 mg of atropine nasal spray is administered to the nostril. The dose chosen reflects clinical doses typically used by Ear, Nose, and Throat (ENT) physicians.
223839120|NCT06171048|BIOLOGICAL|CM310|CM310 injection
223839121|NCT06012838|BEHAVIORAL|Cause classification of OHCA protocol|training program with cause classification of OHCA protocol
223839122|NCT03233165|PROCEDURE|Er:YAG laser|"Ablation of the lesions Device: Er:YAG laser (LightWalker AT, Fotona, Slovenia, 2013) with a non-contact X-Runner digitally controled hand-piece.~Settings for the Er:YAG laser were as follows: pulse mode was Quantum Square Pulse (QSP), pulse energy of 120mJ, frequency of 20Hz and water sprey level was set to10ml per minute."
223839123|NCT03233165|PROCEDURE|Er,Cr:YSGG laser|Ablation of the lesions Device: Er,Cr:YSGG laser(WaterLase iPlus, Biolase LTD, USA) using contact mode. Settings were subsequent: power 50W, frequency 50Hz and concentration ratio of air and water was 2:4.
223839124|NCT04322487|DIAGNOSTIC_TEST|Lung ultrasound|A proposal of a standardized approach in order to optimize the use of lung ultrasound in COVID-19 patients. We focus on equipment, procedure, classification and data-sharing.
223839125|NCT05122754|DRUG|B/F/TAF|Bictegravir/emtricitabine/tenofovir alafenamide once daily, 1 tablet at a time, with or without food for 48 weeks.
223839126|NCT05122754|DRUG|TDF-based triple ART regimen switching to B/F/TAF|Tenofovir disoproxil fumarate was administered once daily, one tablet at a time, with or without food. After Week 24, control subjects were also switched to bictegravir/emtricitabine/tenofovir alafenamide once daily, one tablet at a time, with or without food for the later 24 weeks.
223839127|NCT00209729|DRUG|Taxotere|X mg/m2, IV (in the vein) on day 1 and 15 of each 28 day cycle.
223839128|NCT00209729|DRUG|TS-1|Day 1-14, P.O. everyday
223839129|NCT00131911|DRUG|sorafenib tosylate|400 mg given orally
223839130|NCT00329303|DRUG|Certolizumab Pegol (Cimzia®)|"* Pharmaceutical Form: Solution for injection in pre-filled syringe~* Route of Administration: Subcutaneous use~* Dose and Administration details :~  2 x 1 mL Certolizumab Pegol at Week 0, followed by~* 1 x 1 mL Certolizumab Pegol plus 1 x 1 mL Placebo (for blinding reasons) in the Certolizumab Pegol 200 mg arm at Weeks 2, 4, 6, 8 and 10~* 2 x 1 mL Certolizumab Pegol in the Certolizumab Pegol 400 mg arm at Weeks 2, 4, 6, 8 and 10"
223839131|NCT00747279|OTHER|Carbohydrate restrictive strategy|Patients will receive intravenous hydration with a glucose free solution (Ringer III) and enteral nutritional formula containing 33.3% carbohydrates, 16.7% proteins and 50% lipids. These patients will receive regular insulin subcutaneously four times daily, aiming to maintain blood glucose levels at least below 180 mg/dl, and in stable patients, ideally below 150 mg/dl.
223839132|NCT00747279|DRUG|Intensive insulin therapy|Continuous intravenous regular insulin infusion will be adjusted to maintain glycemic levels at least below 150 mg/dl, and, in stable patients and ideally, between 80 and 120 mg/dl. Patients will be submitted to capillary glycemic measurements every 2 hours. The insulin dose is adjusted according to an algorithm run by nurses and overseen by physicians. These patients will receive glucosaline (5% glucose + 0.9 NaCl) hydration and enteral nutrition with a formula containing 45% carbohydrates, 17% proteins and 38% lipids.
223839133|NCT01367587|DRUG|IV Methylnaltrexone|
223839134|NCT05706662|PROCEDURE|inguinal hernia repair with mesh|inguinal hernia repair with mesh
223839135|NCT03230487|DRUG|BI 1015550|Part 1 - single rising dose. Part 2 multiple rising dose
223839136|NCT03230487|DRUG|Placebo|Part 1 - single rising dose. Part 2 multiple rising dose
223839137|NCT05415059|DEVICE|Covatech Stoma bag material|Strips of Covatech Stoma bag used to asses adhesion of 3M material to be used in LEAFix device
223839138|NCT02485795|OTHER|Observational|This study will evaluate the impact of genetic testing information on medical regimen plans and whether this information results in benefits to patient care.
223839139|NCT04055480|DEVICE|Closed-loop using standard rapid-acting insulin|Closed-loop using standard rapid-acting insulin
223839140|NCT04055480|DEVICE|Closed-loop using faster insulin aspart|Closed-loop using faster insulin aspart
223839141|NCT00162539|OTHER|echography|Correlation of neonatal thyroid volume with maternal iodine deficiency
223839142|NCT05549024|DRUG|68Ga-RM26-RGD|Intravenous injection of 68Ga-RM26-RGD with a dosage of approximately 1.8-2.2 MBq (0.05-0.06 mCi)/ kg.
223839143|NCT05549024|DRUG|18F-FDG|18F-FDG injection
223839144|NCT05549024|DRUG|68Ga-RM26|Intravenous injection of 68Ga-RM26-RGD with a dosage of approximately 1.8-2.2 MBq (0.05-0.06 mCi)/ kg.
223839145|NCT05549024|DRUG|68Ga-RGD|Intravenous injection of 68Ga-RGD with a dosage of approximately 1.8-2.2 MBq (0.05-0.06 mCi)/ kg.
223839146|NCT02295982|PROCEDURE|Hand assisted laparoscopic nephrectomy|patients with renal cancer will undergo hans assisted laparoscopic nephrectomy
223839147|NCT03985722|DRUG|Olaratumab and Trabectedin|"Dose escalation levels:~LEVEL -1: Olaratumab 15 mg/Kg D1 and D8 + Trabectedin 0.9 mg/m2 D1 This is a security level in case level 0 causes DLT.~LEVEL 0\*: Olaratumab 15 mg/Kg D1 and D8 + Trabectedin 1.1 mg/m2 D1. \* Dose starting level is 0.~LEVEL 1: Olaratumab 15 mg/Kg D1 and D8 + Trabectedin 1.3 mg/m2 D1.~LEVEL 2: Olaratumab 15 mg/Kg D1 and D8 + Trabectedin 1.5 mg/m2 D1.~LEVEL 3\*\*: Olaratumab 20 mg/kg C1D1 and C1D8 (induction) + Trabectedin 1.5 mg/m2 D1 and Olaratumab 15 mg/kg D1 and D8 (maintenance) + Trabectedin 1.5 mg/m2 D1~\*\*In LEVEL 3, Olaratumab dose of 20 mg/kg will be considered only for the first 2 doses (as induction doses, cycle 1 days 1 and 8). Then, the maintenance dose will be 15 mg/m2 for the rest of cycles."
223839148|NCT04992442|DRUG|TAK-935 Oral Tablet|TAK-935 tablet
223839149|NCT04992442|DRUG|[14C]TAK-935 IV Infusion|\[14C\]TAK-935 IV infusion
223839150|NCT04992442|DRUG|[14C]TAK-935 Oral Solution|\[14C\]TAK-935 oral solution
223839151|NCT02114827|BEHAVIORAL|Video|23-minute video
223839152|NCT02114827|BEHAVIORAL|FAQ Sheet|
223839153|NCT01697787|DRUG|Amodiaquine-Artesunate|If necessary, the study drug will be crushed, dissolved in water and squirted into the mouth using a spoonful. Administration of the treatments will be directly observed. After drug administration, patients will be kept for at least 30 minutes in the clinic. A dose will be repeated in full if vomiting occurs within 30 minutes of administration and halved if vomiting is between 30 minutes and 1 hour post dosing.
223839154|NCT01697787|DRUG|Artemether-lumefantrine|If necessary, the study drug will be crushed, dissolved in water and squirted into the mouth using a spoonful. Administration of the treatments will be directly observed. After drug administration, patients will be kept for at least 30 minutes in the clinic. A dose will be repeated in full if vomiting occurs within 30 minutes of administration and halved if vomiting is between 30 minutes and 1 hour post dosing.
223839155|NCT01359410|DEVICE|Mesh reinforced staple line (SEAMGUARD)|Reinforce the pancreatic transaction with SEAMGUARD®
223839156|NCT01359410|DEVICE|Stapled without mesh reinforcement (PER-STRIPS DRY)|Stapled without mesh reinforcement (PERI-STRIPS DRY®)
223839157|NCT04142125|DRUG|Rivaroxaban 2.5 Mg Oral Tablet bid|Pts will receive rivaroxaban + aspirin
223839158|NCT04142125|DRUG|Acetylsalicyclic acid 81 mg tablet qd|Pts will receive ASA
223839159|NCT03695289|BEHAVIORAL|iOTA SMI|Participants randomized to the iOTA SMI arm will undergo an assessment of individual behavior risks, will participate in collaborative goal-setting with a health coach, and will use an interactive text system that will provide ongoing support and self-monitoring of behavior change goals.
223839160|NCT03695289|BEHAVIORAL|Health Education Control|Participants randomized to the Health Education Control arm will receive monthly counseling on energy balance, physical activity and nutrition.
223839161|NCT02848495|GENETIC|Non-Interventional|
223839162|NCT00630162|GENETIC|amoeba|
223839163|NCT04389255|OTHER|Star Excursion Balance Test|The Star Excursion Balance Test (SEBT) is a dynamic test that requires strength, flexibility, and proprioception. It is a measure of dynamic balance that provides a significant challenge to athletes and physically active individuals. The test can be used to assess physical performance, but can also be used to screen deficits in dynamic postural control due to musculoskeletal injuries (e.g. chronic ankle instability), to identify athletes at greater risk for lower extremity injury, as well as during the rehabilitation of orthopeadic injuries in healthy active adults.\[
223839164|NCT04389255|DEVICE|Balance Master device|The Balance Master (Neurocom International, Inc Clackamas,) device is a computerized posturography device. The device consists of a fixed support surface consisting of a force table and individuals, a variety of ground elements and a computer screen that will provide visual feedback and conduct test protocols. Posturography tests a person's ability to integrate visual, vestibular and somatosensory inputs and suppress inappropriate sensory information. Thus, it can quantitatively score the person's balance and examine balance problems in detail with the tests it contains. There are various protocols that evaluate balance differently in Balance Master (BMc). Limits of Stability Test (LOS) and Modified Clinical Test of Sensory Interaction in Balance (mCTSIB) were used in the BMc.
223839165|NCT06184477|OTHER|PEDIATRIC TONSILLECTOMY; SURGICAL EXPERIENCE AND PROLONGED HOSPITALIZATION|we aim to compare hospitalization times of pediatric patients that operated by expert surgeon or young surgeon
223839166|NCT02883543|DRUG|icotinib|Icotinib is orally administered three times per day.
223839167|NCT02883543|DRUG|Chemotherapy|"Chemotherapy is given by intravenous administration. Three regimens are available in this study.~Regimen 1: etoposide 75mg/m2 d1-5 + cisplatin 75 mg/m2 day1/ day1-2.~Regimen 2: docetaxel 75mg/m2 d1 + cisplatin 75 mg/m2 day1/ day1-2.~Regimen 3: pemetrexed 500mg/m2 d1 + cisplatin 75 mg/m2 day1/ day1-2"
223839168|NCT02883543|RADIATION|Radiotherapy|5Gy/75.00Gy, 10f/2w for peripheral lung cancer, and 2.4Gy/59.52Gy, 20f/4w for central lung cancer.
223839169|NCT04776447|DRUG|Carboplatin|"Structure: The cis-diamino (cyclobutane-1, 1 dicarboxylate) plating. Stability: 24 hours at ambient temperature in 5% glucose, glucosamine or physiologic saline. It is recommended not to dilute with chlorinated solutions for this could affect the carboplatin.~Route of administration: Intravenous infusion.~Guidelines of Carboplatin administration: According to the standard of each center.~Other Name: ATC code: L01XA02"
223839170|NCT04776447|DRUG|Placlitaxel|"Structure: A diterpene whose composition is: 5b, 20-epoxy-1, 2a, 4,7b, 10b, 13a-hexahidroxytax-11-en 9 one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)- N-benzoyl-3-phenylisoserine.~Stability: Concentrations of 0.3-1.2 mg/ml in 5% dextrose or normal saline have demonstrated chemical and physical stability for more than 27 hours at ambient temperature (25ºC approximately). The intact vial must be stored between 15º and 25ºC.~Guidelines of Paclitaxel administration: Paclitaxel must be administered by infusion over 3 hours in dextrose (D5W) or normal saline (NS). The concentration must not exceed 1.2 mg/ml."
223839171|NCT04776447|DRUG|Atezolizumab|"Atezolizumab is a humanized immunoglobulin (IgG1) monoclonal antibody that is produced in Chinese hamster ovary (CHO) cells. Atezolizumab targets programmed death-ligand 1 (PD-L1) on tumor-infiltrating immune cells (ICs) or tumor cells (TCs) and prevents interaction with the programmed death-1 (PD-1) receptor and B7.1 (CD80), both of which function as inhibitory receptors expressed on T cells and other immune cells.~Patients will receive 1200 mg of atezolizumab administered by IV infusion every 21 days (+/- 3 days) in a monitored setting where there is immediate access to trained personnel and adequate equipment/medicine to manage potentially serious reactions."
223839172|NCT03552978|BEHAVIORAL|Tech-Facilitated IC Intervention|The Integrated Care (IC) treatment protocol for smoking cessation is a PTSD-informed intervention that has been adapted to be delivered over video or telephone and to incorporate technological components, including the Stay Quit Coach (SQC) smart phone application (app) which is a public domain, no-cost mobile app designed to complement the IC protocol with evidence-based tools to support smoking cessation. and the coVita Bedfont® Scientific Ltd iCO® Smokerlyzer® device and app which is a mobile carbon monoxide (CO) monitor that provides CO readings in order to self-monitor progress in quitting. The coVita mobile app is compatible with iOS \&Android and used with the iCO® Smokerlyzer® to display CO readings. Content of sessions is consistent with that delivered in the IC treatment protocol for veteran smokers with post-traumatic stress disorder (PTSD).
223839173|NCT03552978|BEHAVIORAL|VA Quitline|The SFVAMC's standard of care referral service, known as the VA Quitline which involves weekly telephone sessions through the VA's proactive telephone Quitline, available to all veterans for up to 8 weeks.
223839174|NCT04702022|DIAGNOSTIC_TEST|18FDG PET / CT|The PET/CT procedure was performed using cross-calibrated Philips Gemini TF Big Bore or TF 16 PET/CT systems (Philips Medical Systems, Cleveland, OH) at 201 18 minutes following intravenous injection of a mean dose of 3.2 0.2 MBq/kg of body weight of 18 F-FDG. A low-dose helical CT (5-mm slice thickness, 120-kV tube voltage, and 40-mAs tube current-time product) centered to the renal transplant was performed, followed by PET scanning with two bed positions, each lasting 240 seconds. Images were reconstructed using iterative list mode time-of-flight algorithms. Corrections for attenuation, dead time and random and scatter events will be applied.
223839175|NCT06318663|OTHER|Survivor Mom Companion|Weekly intervention sessions will follow the survivor Moms' Companion manualized modules. One module each week. The module centers on reinforcement of information introduced in each previous module, then emotional support, and referrals to additional services or specialists as needed. Participants in each session will practice applying knowledge and skills using the module's vignettes. Process guides prompt inquiry about in vivo management of post-traumatic stress disorder reactions and emotional and interpersonal responses to events since the last session. Each module may require 45 minutes of self-study before each session and 45 minutes of in-session time spent with the interventionist.
223839176|NCT06136312|DEVICE|Multi4|TURBT procedure performed with the Multi4 instrument in local anesthesia
223839177|NCT03175575|BEHAVIORAL|Access to a community garden in deprived neighborhoods|
223839178|NCT03473756|DRUG|Rogaratinib (BAY1163877)|Part A:Rogaratinib will be administered orally until disease progression, unacceptable toxicity or consent withdrawal. The starting dose of 800 mg b.i.d. will be confirmed using a dose selection design.
223839179|NCT03473756|DRUG|Atezolizumab|Part A: A fixed dose of 1200 mg atezolizumab will be administered through intravenous (i.v.) infusion on Day 1 of each 21-day cycle until disease progression, unacceptable toxicity or consent withdrawal.
223839180|NCT03514264|PROCEDURE|Gutta Percha and AHPLUS cement (group A)|"First intervention: endodontic instrumentation and introduction of intact medication that will remain inside the tooth for 4 weeks.~Second intervention: removal of intracanal medication and canal filling with cement AHPLUS and guttapercha"
223839181|NCT03514264|PROCEDURE|PBS CIMMO cement (group B)|Single intervention: endodontic instrumentation and obturation with cement PBS CIMMO
223839182|NCT02148718|BIOLOGICAL|adalimumab|Adalimumab pre-filled syringe, administered by subcutaneous injection
223839183|NCT04827290|BEHAVIORAL|Low-AGE diet|Low-AGE diet during 24 months
223839184|NCT04827290|BEHAVIORAL|High-AGE diet|High-AGE diet during 24 months
223839185|NCT05683522|OTHER|Sub-omohyoidal Plane Block|The ultrasound guided sub-omohyoidal plane block will be performed. Patients in this group will be given 15 mL of local anesthetic into the interfascial plane under the omohyoid muscle. This block will be performed preoperatively.
223839186|NCT05683522|OTHER|Cervical Plexus Block|A cervical plexus block will be applied by applying 10 mL of local anesthetic under ultrasound guidance. This block will be done before the surgery.
223839187|NCT05683522|OTHER|Costoclavicular Block|Costoclavicular brachial plexus block will be applied by administering 20 mL of local anesthetic under ultrasound guidance. This block will be performed preoperatively.
223839188|NCT04129632|BEHAVIORAL|IEPF Wellness Tool|A daily 5 minute mindfulness exercise over 28 days
223839189|NCT00884819|DRUG|Fenofibrate|fenofibrate 200 mg daily for 6-months
223839190|NCT00884819|OTHER|Placebo|Placebo match for 6 months
223839191|NCT03276702|PROCEDURE|Re-biopsy|For those participants who agree, a biopsy of their tumor to obtain tissue for genetic analysis will be done at the time of relapse or disease progression.
223839192|NCT03276702|OTHER|Questionnaire|Parents or patients will be asked to complete a questionnaire to assess the impact and perception of an optional/research only biopsy. A second questionnaire will be administered approximately 4-8 weeks after biopsy to assess decisional regret.
223839193|NCT05211830|DRUG|SXR1096 cream|Skin cream to be applied twice a day to a predefined area of the skin
223839194|NCT05211830|DRUG|Placebo cream|Skin cream to be applied twice a day to a predefined area of the skin
223839195|NCT02242461|DRUG|Rhodiola placebo capsules|Corn starch
223839196|NCT02242461|DRUG|Rhodiola Crenulata|Rhodiola Crenulata
223839197|NCT01577732|BIOLOGICAL|Infanrix-IPV+Hib™|Single dose administered intramuscularly (IM) into the anterolateral side of the right thigh.
223839198|NCT01226264|PROCEDURE|Diffusion weighted MRI (DW- MRI)|"An MRI examination (including diffusion-weighted sequences) belongs to the standard protocol for patients with cervical uterine cancer. The additional burden is therefore restricted to an extra MRI scan during and/or early after therapy.~MRI is a technique based on magnetic fields and do not require the use of ionizing radiation. Because of the strong magnetic field, a few precautions should be taken. This means that all metal and magnetized objects must be removed from the patient before entering the MRI room. Patients with a pacemaker, a cardiac defibrillator or other implanted conductor/prosthesis are for this reason not eligible for the study.~During the examination, an intravenous and vaginal contrast medium will be administered. In most cases, patients do not experience any discomfort and the use of these contrast agents is part of the clinical routine."
223839199|NCT01164787|DRUG|Trandolapril|Trandolapril 4 mg Tablets of Dr. Reddy's Laboratories Limited
223839200|NCT01164787|DRUG|Mavik|Mavik® 4 mg Tablets of Abbott Laboratories, USA.
223839201|NCT05445687|BEHAVIORAL|Narrative language intervention program|"Narrative language targets improving narrative macrostructure and microstructure.~The program will include 24 illustrated story sequences with a minimum of 5 sequences representing the main story elements: characters and setting; problems; internal response; actions; and consequence. Story icons will be designed to represent the main 5 elements to accompany storytelling and act as visual prompts.~Each story will reflect specific content with several target vocabulary words and complex morphosyntax. Each story will be followed by comprehension questions to facilitate understanding and answering question about stories.~The following procedure will be implemented with each story: Modeling, answering comprehension questions, retelling with icons and colored illustrations, retelling with icons only, and retelling without icons. This procedure is adapted from story champs intervention program"
223839202|NCT05445687|BEHAVIORAL|Conventional language intervention|Language rehabilitation targets improving semantics, syntax, pragmatics and phonology.
223839203|NCT01305824|DRUG|PRT-201|PRT-201 10 micrograms administered at the time of AVF creation.
223839204|NCT01305824|DRUG|Placebo|Placebo administered at the time of AVF creation.
223839205|NCT01305824|DRUG|PRT-201|PRT-201 30 micrograms administered at the time of AVF creation.
223839206|NCT05763459|DRUG|ABBV-CLS-7262|Drug: ABBV-CLS-7262 Drug: Digoxin Drug: Rosuvastatin
223839207|NCT04298684|DRUG|METFORMIN|"After inclusion, a central randomization will allow subjects to benefit from either metformin (group 1) or sitagliptin (group 2). A follow-up schedule will be given to the included patient for future visits. thyroid ultrasonography to analyze the TN evolution in the 2 groups.~In arm 1, the subjects will receive metformin at the initial dose of 500mg x 2 / day, which will be increased weekly to 500mgx3 / day and then 1gx2 / day in order to obtain the minimum effective dose on glycemic control. In case of intolerance, the tolerated and effective dose will be taken back provided an effective glycemic control.~A classic follow-up will be done every 3 months. Thyroid US and measure of HOMA-IR index will be done every 6 months for 2 years. If the goal of HbA1c will not achieved, a treatment with glicazide will be introduced."
223839208|NCT04298684|DRUG|Sitagliptin|"After inclusion, a central randomization will allow subjects to benefit from either metformin (group 1) or sitagliptin (group 2). A follow-up schedule will be given to the included patient for future visits. thyroid ultrasonography to analyze the TN evolution in the 2 groups.~In arm 2, sitagliptin will be prescribed at 100mg / day. A classic follow-up will be done every 3 months. Thyroid US and measure of HOMA-IR index will be done every 6 months for 2 years. If the goal of HbA1c will not achieved, a treatment with glicazide will be introduced."
223839209|NCT04751864|DEVICE|Cranial Electrotherapy Stimulator (CES) Device|Fisher Wallace Cranial Electrotherapy Stimulator (CES) Device
223839210|NCT06433466|OTHER|Videos featuring influencers promoting e-cigarettes alongside healthy lifestyle activities|Young adults were randomly shown 10 videos, featuring influencers promoting e-cigarettes alongside healthy lifestyle activities (experimental group), or a healthy lifestyle activity alone (control).
223839211|NCT03888365|DRUG|Treprostinil|Treprostinil treatment will be at the discretion of the participant's physician, and determined on an individual basis.
223839212|NCT03888365|DRUG|Non-Treprostinil PAH Medications|Non-treprostinil treatment will be at the discretion of the participant's physician, and determined on an individual basis.
223839213|NCT06498674|DIAGNOSTIC_TEST|Supplementary Pathological Examination|For the same thyroid nodule, if there is discordance between the interpretations of AI-assisted ultrasound and traditional two-dimensional ultrasound, supplementary fine needle aspiration biopsy or intraoperative biopsy will be performed to clarify the nature of the nodule.
223839214|NCT06498674|OTHER|No Need for Supplementary Pathological Examination|For the same thyroid nodule, if there is discordance between the interpretations of AI-assisted ultrasound and traditional two-dimensional ultrasound, there is no need for supplementary fine needle aspiration biopsy or intraoperative biopsy.
223839215|NCT02192359|BIOLOGICAL|Carboxylesterase-expressing Allogeneic Neural Stem Cells|Given intracranially
223839216|NCT02192359|DRUG|Irinotecan|Given IV
223839217|NCT02192359|DRUG|Irinotecan Hydrochloride|Given IV
223839218|NCT02192359|OTHER|Laboratory Biomarker Analysis|Correlative studies
223839219|NCT02192359|OTHER|Pharmacological Study|Correlative studies
223839220|NCT00315224|BEHAVIORAL|heart-rate controlled 12 week exercise program|
223839221|NCT04951479|DEVICE|Gel-Bead embolization|OptiSphere is FDA approved for the embolization of hypervascular tumors. The product is crosslinked with glutaraldehyde, which improves the mechanical strength of the spheres and provides controlled degradation after implant. The spherical shape provides smooth embolic delivery and even, predictable distribution. In this study the Optispheres will be used for Geniculate artery embolization (GAE) which is a minimally-invasive procedure that has historically been performed for treatment of patients with recurrent knee hemarthrosis. Embolization is a procedure in which material is used to block small blood vessels. Angiogenesis, or growth of new vessels, has been implicated in the initiation and maintenance of joint inflammation. GAE has been applied to patients with moderate osteoarthritis-related pain refractory to maximal medical management with preliminary studies demonstrating a reduction in patient pain.
223839222|NCT03954496|DEVICE|transcranial direct current stimulation|This is a non-invasive form of stimulation which delivers safe, low levels of electrical current to the brain through the scalp.
223839223|NCT03954496|BEHAVIORAL|Intensive upper extremity motor training|This training is administered one-on-one with an occupational therapist. Activities will be focused on skills the participant wants to regain.
223839224|NCT04341155|DRUG|Dexamethasone|Patients in experimental arms will receive i.v. dexamethasone 20 mg (4 ampules = 20mL) for 7 days
223839225|NCT04341155|DRUG|Placebo|Patients in placebo arms will receive 20 mL normal saline intravenously for 7 days
223839226|NCT00277589|DRUG|Levothyroxin-Na|1 tablet 30 minutes before breakfast
223839227|NCT00277589|DRUG|Levothyroxine-Na + iodide|1 tablet 30 minutes before breakfast
223839228|NCT00277589|DRUG|Iodide|1 tablet 30 minutes before breakfast
223839229|NCT00277589|DRUG|Placebo|1 tablet 30 minutes before breakfast
223839230|NCT00161096|DRUG|pantoprazole 20 mg (drug)|
223839231|NCT00063674|BEHAVIORAL|Nutrition Education|
223839232|NCT00063674|BEHAVIORAL|After-school dance class|
223839233|NCT02175160|OTHER|Braking and functionality|
223839234|NCT00519987|DRUG|intranasal ketamine|intranasal ketamine
223839235|NCT05012254|DRUG|Ipilimumab|"Patients will receive Ipilimumab 1mg/Kg administered by IV infusion every 42 days (Q6W) until disease progression, unacceptable toxicity, loss of clinical benefit as judged by the investigator or up to a maximum of 2 years of treatment.~Structure: is a fully human monoclonal antibody with two heavy chains and two kappa light chains linked together by way of disulfide bonds. The molecular weight is approximately 148 kDa and it exists in solution at a physiologic pH of 7.0.~Route of administration: Intravenous infusion."
223839236|NCT05012254|DRUG|Nivolumab|"Patients will receive Nivolumab 360 mg administered by IV infusion every 21 days (Q3W) until disease progression, unacceptable toxicity, loss of clinical benefit as judged by the investigator or up to a maximum of 2 years of treatment.~Structure: Nivolumab is a soluble protein consisting of 4 polypeptide chains, which include 2 identical heavy chains and 2 identical light chains.~Route of administration: Intravenous infusion."
223839237|NCT05012254|DRUG|Carboplatin|"Patients will receive Carboplatin AUC 5 or 6 administered by IV infusion every 21 days (Q3W), for 2 cycles.~Structure: The cis-diamino (cyclobutane-1, 1 dicarboxylate) platin. Stability: 24 hours at ambient temperature in 5% glucose, glucosa or physiologic saline. It is recommended not to dilute with chlorinated solutions since this could affect the carboplatin.~Route of administration: Intravenous infusion. Guidelines of Carboplatin administration: According to the standard of each center."
223839238|NCT05012254|DRUG|Cisplatin|"Patients will receive Cisplatin 75mg/m2 administered by IV infusion every 21 days (Q3W), for 2 cycles.~Structure: (CAS No. 15663-27-1, MF-Cl2H6N2Pt; NCF-119875), cisplatinum, also called cis-diamminedichloroplatinum(II), is a metallic (platinum) coordination compound with a square planar geometry. It is a white or deep yellow to yellow-orange crystalline powder at room temperature.~Stability: Do not store above 25°C. Do not refrigerate or freeze. Keep container in the outer carton to protect from light. Following dilution in 0.9% sodium chloride injection, chemical and physical in-use stability has been demonstrated for up to 14 days at 20°C.~Route of administration: Intravenous infusion. Guidelines of Cisplatin administration: According to the standard of each center."
223839239|NCT05012254|DRUG|Paclitaxel|"Patients will receive Paclitaxel 200mg/m2 administered by IV infusion every 21 days (Q3W), for 2 cycles.~Structure: A diterpene whose composition is: 5b, 20-epoxy-1, 2a, 4,7b, 10b, 13a-hexahidroxytax-11-en 9 one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)- N-benzoyl-3-phenylisoserine.~Stability: Concentrations of 0.3-1.2 mg/ml in 5% dextrose or normal saline have demonstrated chemical and physical stability for more that 27 hours at ambient temperature (25ºC approximately). The intact vial must be stored between 15º and 25ºC.~Guidelines of Paclitaxel administration: Paclitaxel must be administered by infusion over 3 hours in dextrose (D5W) or normal saline (NS). The concentration must not exceed 1.2 mg/ml."
223839240|NCT05012254|DRUG|Pemetrexed|"Patients will receive Pemetrexed 500mg/m2 administered by IV infusion every 21 days (Q3W), for 2 cycles.~Structure: Pemetrexed disodium (ALIMTA®, pemetrexed) is a novel pyrrol \[2,3 d\]-pyrimidine based folic acid analogue.~Route of administration: Intravenous infusion. Guidelines of Pemetrexed administration: According to the standard of each center"
223839241|NCT05942079|OTHER|REİKİ|Reiki is applied as an alternative and complementary treatment method.
223839242|NCT01433393|DRUG|TAK-875|
223839243|NCT01433393|DRUG|TAK-875|
223839244|NCT01433393|DRUG|Placebo|
223839245|NCT01305928|OTHER|Warm Hand-off|"Warm Hand-Off~Staff brief intervention and warm hand-off (5 min):~* Assess withdrawal, need for medication change~* Describe warm hand-off process~* Provide 2-page flyer~* Perform call, leave room~* Notify patients' nurse patient is talking to quitline~Quitline session (20 min):~* Collect minimum data set~* Explore thoughts/feelings toward quitting~* Provide medication education~* Build plan to stay quit~* Schedule next call~Staff check-back (5 min):~* Ask patient how session went~* Ask if patient requests cessation medication script on discharge"
223839246|NCT01305928|OTHER|Fax|"Fax~Staff standard in-patient session: (30 minutes):~* Assess withdrawal, need for medication change~* Conduct assessment of smoking history, interest in quitting~* Explore relevance, risks, rewards, and roadblocks (4Rs) related to smoking and quitting~* Provide 2-page flyer~* Provide medication education~* Build plan to stay quit~* Describe fax-referral process~* Ask if patient requests cessation medication script on discharge"
223839247|NCT01758874|PROCEDURE|phlebotomy|repeated phlebotomy for 4 weeks
223839248|NCT02600182|DEVICE|Bilevel Positive Airway Pressure|Bilevel positive airway pressure twice per day during the hospital stay.
223839249|NCT05925738|DIAGNOSTIC_TEST|PET/CT-based Deep Learning Signature|Deep Learning Signature Based on PET-CT for Predicting the Aggressive Histological Pattern in Resected Non-small Cell Lung Cancer
223839250|NCT02506621|DEVICE|R test|
223839251|NCT02506621|DEVICE|Nuubo|
223839252|NCT02506621|DEVICE|TECHNOMED pocket ECG|
223839253|NCT02506621|DEVICE|ZIO xt patch|
223839254|NCT02506621|DEVICE|MoMe|
223839255|NCT05502224|OTHER|Ergospirometry|Maximum aerobic capacity (VO2 max), Maximum load, Ventilatory threshold and the patient's RQ
223839256|NCT02908854|OTHER|Adding spices and herbs to school lunch vegetables|Direct measurement of school lunch vegetable intake among students both before and after spices and herbs are added.
223839257|NCT00324012|DRUG|cisplatin, taxotere|cisplatin 75 mg/m2 Taxotere 75 mg/m2
223839258|NCT03358212|DRUG|Denosumab|Denosumab 120mg was administrated to patients by subcutaneous injection every four weeks, with loading doses on Day 8 and Day 15 of the first cycle.Patients were instructed to take calcium supplements orally every day and avoid any oral operation during treatment
223839259|NCT02492061|BEHAVIORAL|Demand creation for couples' HCT|The demand creation for couples' HCT intervention aims at improving uptake of couples' HCT among married couples in Rakai, southwestern Uganda
223839260|NCT03881540|OTHER|tDNA-MI group|tDNA care with structured low calorie meal plan of 1200-1500 kcal/day with conventional foods + 1-2 serving of diabetes specific meal replacements and motivational interviewing counseling. .
223839261|NCT03881540|OTHER|tDNA-CC group|tDNA care with structured low calorie meal plan of 1200-1500 kcal/day with conventional foods + 1-2 serving of diabetes specific meal replacements+ 150 min/week of moderate intensity exercise + and conventional counselling.
223839262|NCT03881540|OTHER|UC group|Meal plan of 1200-1500 kcal/day using conventional foods + 150 min/week of moderate intensity exercise + and conventional counselling
223839263|NCT02688920|PROCEDURE|EUS and OCT imaging|Intraluminal imaging using endoscopic ultrasound and endoscopic optical coherence tomography
223839264|NCT06396962|OTHER|WANG DAORONG|surgery
223839265|NCT00510796|BEHAVIORAL|Interview|Interview regarding perception of pain and the benefits and barriers to the combined screening.
223839266|NCT03713645|DRUG|Tacrolimus Extended Release Oral Tablet [Envarsus] 0.13mg/kg/day initiated within post-operative day 3 after kidney transplant|Study drug (tacrolimus extended-release) initiated at 0.13/mg/kg/day for all patients
223839267|NCT03826433|BIOLOGICAL|Peripheral iv|6\*10\^7 cells
223839268|NCT02514564|BEHAVIORAL|Exercise|Patients included in the study will be enrolled in a cardiac rehabilitation program, in an independent manner of the study protocols.
223839269|NCT03439371|OTHER|HLA-mismatched micro-transplantation after induction chemotherapy|HLA-mismatched micro-transplantation after induction chemotherapy
223839270|NCT05893563|OTHER|Standard Post-Operative Clinic Visit|In clinic, the joint will be assessed (ROM, stability testing), standard X-rays will be taken of the joint, and patient reported outcomes (questionnaires) will be completed by patient (WOMAC, UCLA, VR12, EQ5D, Oxford Hip).
223839271|NCT05893563|OTHER|Study-Specific Outcomes|Patients will complete additional questionnaires (SF12 and HHS), will undergo RSA and CT imaging for implant stability analysis, and will provide a stool sample for gut microbiome analysis.
223839272|NCT06332950|DRUG|Adebrelimab, Irinotecan Liposome (II)|"Adebrelimab:1200 mg, IV, D1, Q3W~Irinotecan Liposome (II): RP2D, IV, D1, Q3W~Escalating doses to determine recommended phase 2 dose (RP2D) of Irinotecan Liposome (II).~Participants will receive Adebrelimab (1200 mg, IV, D1, Q3W) plus the RP2D of Irinotecan Liposome (II)."
223839273|NCT06332950|DRUG|Adebrelimab, Irinotecan Liposome (II), Famitinib|"Adebrelimab:1200 mg, IV, D1, Q3W~Irinotecan Liposome (II): RP2D, IV, D1, Q3W~Famitinib: RP2D, QO, QD~Escalating doses to determine recommended phase 2 dose (RP2D) of Famitinib.~Participants will receive Adebrelimab (1200 mg, IV, D1, Q3W) plus the RP2D of Irinotecan Liposome (II) and Famitinib."
223839274|NCT02023216|DEVICE|Pacifier|The effect of NNS on GER features will be evaluated in preterm infants suffering from GER symptoms, for which a 24-hour pH-MII monitoring has been scheduled. During the monitoring period each infant will receive 8 meals: 4 meals will be followed by NNS, applied by pacifier, while the other 4 not. The sequence of NNS application will be consecutively alternated in study participants. At least 2 hours of NNS are required for the validity of each post-prandial evaluation; measures to fix the pacifier will be strictly forbidden. In the subgroup of babies with recurrent desaturations a simultaneous non-invasive 6-hour PSG monitoring comprehensive of 2 meals (one followed by NNS, the other not), will be performed to evaluate the effect of NNS on apneas, bradycardias and hypoxic episodes.
223839275|NCT01082146|DRUG|Lurasidone|40 mg suspension, PO, for 7 days
223839276|NCT00871793|OTHER|Occupational therapy|Participants in this arm will receive six sessions of occupational therapy in a 5 week period.
223839277|NCT03975387|DRUG|ASTX295|ASTX295 orally for 28-day cycle continuous or on an intermittent dosing schedule.
223839278|NCT03276663|OTHER|Formula feeding regimen|The feeding regimen consists of an existing commercial starter formula followed by a new follow-up formula
223839279|NCT01831414|OTHER|Water immersion at cervical level|balneotherapy session of spinal cord patients with a Water immersion at cervical level
223839280|NCT01831414|OTHER|Water immersion at xyphoid level|balneotherapy session of spinal cord patients with a Water immersion at xyphoid level
223839281|NCT04178200|DRUG|Lidocaine 2% Injectable Solution 0.75 ml|0.75 ml of Lidocaine will be added to the anesthetic solution.
223839282|NCT04178200|DRUG|Bupivacaine Hcl 0.5% Inj 0.75 ml|0.75 ml of Bupivacaine will be added to the anesthetic solution.
223839283|NCT04178200|DRUG|Lidocaine 2% Injectable Solution 1.5 ml|1.5 ml of Lidocaine will be added to the anesthetic solution.
223839284|NCT04178200|DRUG|Bupivacaine Hcl 0.5% Inj 1.5 ml|1.5 ml of Bupivacaine will be added to the anesthetic solution.
223839285|NCT02641951|OTHER|Stellate ganglionic block|Ultrasound guided stellate ganglionic block
223839286|NCT02641951|OTHER|Pecs II block|Ultrasound guided Pecs II block
223839287|NCT06487767|OTHER|Surgery|Surgery for operable cervical cancer
223839288|NCT03877263|DIAGNOSTIC_TEST|Endocervical swab for detection of STI|After we collect the samples, they will be evaluated using the Hologic APTIMA Chlamydia trachomatis and Neisseria gonorrhoeae assays.
223839289|NCT03877263|DIAGNOSTIC_TEST|Vaginal swab for detection of STI|"After we collect the samples, they will be evaluated using the Hologic APTIMA Chlamydia trachomatis and Neisseria gonorrhoeae assays.~We will then compare the results from a vaginal vs. endocervical specimens within and between the groups"
223839290|NCT06077669|DRUG|Methylphenidate|Single oral dose of methylphenidate (5mg or 10 mg)
223839291|NCT06077669|DRUG|Placebo|oral placebo
223839292|NCT03781713|OTHER|KDIGO|Interventions to prevent renal replacement therapy
223839293|NCT03781713|OTHER|Delta SOFA|interventions to improve SOFA score
223839294|NCT03781713|COMBINATION_PRODUCT|Hypoglycemia|Interventions to prevent new episodes of hypoglycemia in the next 24 hours
223839295|NCT03781713|DRUG|Drug interaction risk D or X|Intervention in the therapeutic plan in order to avoid adverse drug reactions.
223839296|NCT03781713|DRUG|Antimicrobial stewardship|Optimization of anticrobial therapy based on Gram stain, MALDI TOF, MIC and antimicrobial susceptibility
223839297|NCT03532893|OTHER|No intervention|This is a multi-center,observational, prospective, cohort study. A total of 10,000 subjects aged 40～75 without history of lung disease will be recruited and followed for 3 years. So there is no intervention in this study.
224264651|NCT04306952|BEHAVIORAL|Extended MBI|"The extended MBI consists of four weekly group sessions followed by four group sessions every other week over the course of 12 weeks. Each group session will be two hours. The group sessions will be identical to the standard package except for the timing (every other week) of the last four sessions. In addition to the group sessions, the MBI provider will offer office hours in between the bi-weekly group sessions, where participants will be able to schedule individual sessions with the MBI provider to discuss questions and troubleshoot their mindfulness practice. In addition, participants will receive an all-day meditation retreat, similar to the other conditions. The rationale for testing the extended MBI is to optimize acceptability and uptake based on the investigator's preliminary data by allowing for a slower, extended pace of learning mindfulness practices with an opportunity to have individual discussions with the instructor (16 hours of contact + individual office hours)."
223839298|NCT03331627|DRUG|STR001-IT and STR001-ER|STR001-IT intrataympanic injection and STR001-ER tablet
223839299|NCT04425993|DRUG|Isosorbide Dinitrate 5 MG|All patients without contraindications should receive sublingual isosorbide dinitrate tablet within 5 minutes before ERCP.
223839300|NCT04425993|DRUG|Indomethacin 100 MG|All patients without contraindications should receive rectal indomethacin within 30 min before ERCP.
224264652|NCT01001403|DRUG|Nafamostat|0.2 mg/kg as bolus 1 minute before reperfusion
224264653|NCT01001403|DRUG|Normal saline|10 ml of normal saline
224264654|NCT06431321|BEHAVIORAL|Tabudira Parenting Intervention for Early Childhood Development|2 session programme delivered weekly over 2 weeks using group-based delivery aimed at reducing child maltreatment, improving parenting behaviours and parent's mental health.
224264655|NCT06431321|OTHER|Nutritional guide for younger children|2 session programme delivered weekly over 2 weeks aimed at providing parents with nutritional education to help provide maximum nutrition to the growing child
224264656|NCT05315063|OTHER|Eccentric Training|Once achieved, this flexed hip position will be held for 5 seconds. This procedure will be repeated 6 times with no rest between repetitions
224264657|NCT05315063|OTHER|Muscle Energy Technique (PIR)|"The participant will be asked to resist the movement with no more than 25% of strength. The contraction will be held for 7-10 seconds followed by complete relaxation of the limb.~On exhalation, the knee joint will be straightened (extended) towards its new barrier and through that barrier a stretch was applied and maintained for 30 seconds.3 repetitions of this process will be done"
224264658|NCT04142918|OTHER|Immunostaining|Immunostaining of oral mucosa/gingiva samples
224264659|NCT02537457|DRUG|Rivaroxaban (BAY 59-7939)|Rivaroxaban granule15mg for one day
224264660|NCT02537457|DRUG|Rivaroxaban (Xarelto, BAY 59-7939)|Rivaroxaban tablet15mg for one day
224264661|NCT05374057|OTHER|Chiropractic spinal manipulative therapy (CSMT)|See study arm.
224264662|NCT05374057|OTHER|CSMT sham manipulation|See study arm.
223839301|NCT04425993|DRUG|Sublingual Placebo|All patients without contraindications should receive sublingual placebo within 5 minutes before ERCP.
223839302|NCT04425993|DRUG|Rectal placebo|All patients without contraindications should receive rectal placebo within 30 min before ERCP.
223839303|NCT02635282|DRUG|intranasal ketamine|
223839304|NCT02635282|DRUG|intranasal fentanyl|
223839305|NCT02635282|DRUG|intranasal midazolam|
223839306|NCT00000582|DRUG|factor ix|
223839307|NCT06476340|OTHER|No intervention|None, questionnaires/CBCT/3D photography/physical examination
223839308|NCT03491124|OTHER|Auricular Acupuncture|Up to five small ASP needles placed in each ear until pain is reduced to 1/10.
223839309|NCT03491124|OTHER|Sham Treatment|Laser pointer pointed at the ear, but not turned on.
223839310|NCT05919667|DIETARY_SUPPLEMENT|Dairy and plant-based dairy beverages and solids|Crossover design: participants received all treatment arms in a randomized order
223839311|NCT04789200|DRUG|NX9 Oral Contrast Agent|Distension and marking of the bowel lumen will be compared between the 1st and 2nd scan. Ability to see IV contrast enhancement will be assessed on the 3rd scan in relationship to the 2nd scan.
223839312|NCT05397808|OTHER|Pilates Training|The group that received pilates training.
223839313|NCT05397808|OTHER|breathing and relaxation exercises|The group who received breathing and relaxation exercises with a home program.
223839314|NCT01656928|BEHAVIORAL|preschool-based nutritional intervention|6-month intervention administered once weekly by a nutrition expert consisting of joint meal preparation and activities for children and parents such as tasting and preparing nutritious, fresh foods.
223839315|NCT04278430|DEVICE|transcranial direct current stimulation|"The tDCS stimulator (ActivaDose II tDCS Device; IOMED Inc., Salt Lake City, USA) is a standardized instrument used and tested in children. Two tDCS electrodes of dimensions 3 x 3 were used for the brain stimulation. The electrodes were inserted into a wet saline sponge."
223839316|NCT04278430|DEVICE|Sham tDCS|Five children with LSIH were randomly allocated to this group. All participants received sham tDCS for 3 weeks on alternate days and completed 10 treatment sessions. The sham tDCS followed preparatory procedures similar to that used for the experimental group, except that the device was disconnected after the initial increase of the current. Children usually started the activity without noticing that the device was disconnected. The children were assessed at baseline, during the 5th and 10th sessions, and during a follow-up that was scheduled for 4 months later.
223839317|NCT04927039|DRUG|5ml of inhaled normal saline|After the initiation of OLV, 5ml of normal saline is inhaled for 20 minutes using ultrasonic nebulizer, which is connected to the inspiratory limb of the ventilator system. Arterial blood gas analysis is performed 20 minutes after the completion of drug inhalation.
223839318|NCT04927039|DRUG|20μg (2ml) of inhaled iloprost (Ventavis®) and 3ml of inhaled normal saline|After the initiation of OLV, mixture of iloprost 2ml and normal saline 3ml is inhaled for 20 minutes using ultrasonic nebulizer, which is connected to the inspiratory limb of the ventilator system. Arterial blood gas analysis is performed 20 minutes after the completion of drug inhalation.
223839319|NCT02150265|BEHAVIORAL|SMART manual cognitive behavioral therapy|
223839320|NCT06488768|OTHER|Radial nerve block|Ultrasound-guided Radial nerve block. Conducted with 10 mL of Lidocaine 2%. Ultrasound image are stored for documentation.
223839321|NCT01213173|DRUG|Succinate Metoprolol (Betaloc ZOK®)|treatment with 47.5mg for two weeks, if tolerated and without Systolic blood pressure\<100mmHg and heart rate \<45 bpm according to 12-lead Electrocardiogram at Week 3, the dosage will be titrated to 95mg and last for another 6 weeks
223839322|NCT01213173|DRUG|Succinate Metoprolol (Betaloc ZOK®)|Treatment with 95mg for two weeks, and if tolerated and without bradycardia symptoms presented, Systolic blood pressure\<100mmHg and heart rate \<45 bpm according to 12-lead Electrocardiogram at Week 3，the dosage will be force titrated to 190mg and last for another 6 weeks
223839323|NCT05125692|PROCEDURE|vaginal surgical repair of isthmocele|after preoperative identification of the borders of the isthmocele using transvaginal ultrasound measurements, the isthmocele is repaired via vaginal approach
223839324|NCT03162965|OTHER|Oraquick HIV Self Test|This is an oral swab in home HIV test.
223839325|NCT03162965|OTHER|Clinic Based HIV Counseling and Testing (HCT)|Receiving Counseling and Testing for HIV at the clinic.
223839326|NCT01186861|DRUG|OSI-906|Tablet administered with food and with up to 200 mL of water
223839327|NCT01186861|DRUG|erlotinib|Tablet administered at least 2 hours after food with up to 200 mL of water
223839328|NCT01186861|DRUG|placebo|Tablet administered at least 2 hours after food with up to 200 mL of water
223839329|NCT06655012|DRUG|Salmeterol|Participants are administered 200 µg salmeterol (8 puffs) from a MDI device
223839330|NCT06655012|DRUG|Placebo|Participants are administered placebo (8 puffs) from a MDI device
223839331|NCT00852137|DRUG|PEP005 (ingenol mebutate) Gel, 0.05%|PEP005 (ingenol mebutate) Gel 0.05% once daily for 2 consecutive days
224264663|NCT05374057|DRUG|Ibuprofen|See study arm.
224264664|NCT05374057|DRUG|Placebo medication|See study arm.
224264665|NCT06516172|OTHER|Comprehensive disease-specific rehabilitation|"Participation in (a) inpatient rehabilitation, (b) outpatient centre-based, (c) outpatient digitally-enhanced centre- and home-based, or (d) outpatient home-based digital/tele rehabilitation.~Duration is 3 weeks for inpatient and 12 weeks for outpatient programmes."
223839332|NCT00852137|DRUG|Vehicle Gel|Vehicle Gel once daily for 2 consecutive days
223839333|NCT03253770|DEVICE|SIMMAX2|Digital cognitive aid or paper cognitive aid during the management of a cardiac arrest in the recovery room or in the delivery room.
223839334|NCT02353832|DEVICE|Injectable Rectal Spacer (SpaceOAR, Duraseal or equivalent)|Injectable Rectal Spacer (SpaceOAR, Duraseal or equivalent PEG based product
223839335|NCT06555133|COMBINATION_PRODUCT|yttrium-90 radioembolization|yttrium-90 radioembolization in combination with capecitabine and atezolizumab for the treatment of unresectable colorectal cancer liver metastases in individuals who have been treated with two or more lines of systemic therapy.
223839336|NCT04880161|BIOLOGICAL|Ampion|Inhaled Ampion
223839337|NCT04880161|OTHER|Placebo|Inhaled Placebo
223839338|NCT04788030|OTHER|Nerve reconstruction|Nerve bridging with muscle-in-vein conduits
224264666|NCT00326872|DRUG|Cediranib Maleate|
223839339|NCT02881190|DRUG|RC48-ADC|
223839340|NCT05151042|PROCEDURE|wafer-less approach|"Using the software, 3D digitized bony mandible will be virtually osteotomized and repositioned to the new postoperative position. CAD/CAM generated preoperative wafer will be placed on the lower arch dentition, the guide has an extension to guide medial, vertical, oblique cuts as well as screw holes for reference landmarks for proximal segment \& tooth bearing segment. Drilling of all the reference landmarks on the proximal segment and locating medial, vertical, oblique cuts.~Removal of guide, then BSSO is performed. The final wafer is placed, the guiding hole on the proximal segment will then be realigned with the previously drilled screw holes, fixation using mono cortical screws then drilling screw holes for plate fixation.~Fixation of the osteotomy using 2.0 mm pre-bent mini plates."
223839341|NCT05151042|PROCEDURE|Computer Guided orthognathic surgery using occlusal wafers|"Using the software, 3D digitized bony mandible will be virtually osteotomized and repositioned to the new postoperative position.~dental casts will be scanned dental casts are superimposed to the CT cuts into the virtual software environment to produce final wafer CAD/CAM repositioning guide. the generated preoperative wafer will be placed on the lower arch dentition, the guide has an extension to guide medial, vertical, oblique cuts as well as screw holes for reference landmarks for proximal segment \& tooth bearing segment.~Drilling of all the reference landmarks on the proximal segment and locating medial, vertical, oblique cuts. Removal of guide, then BSSO is performed.~The final wafer is placed, the guiding hole on the proximal segment will then be realigned with the previously drilled screw holes, fixation using mono cortical screws then drilling screw holes for plate fixation.~Fixation of the osteotomy using 2.0 mm pre-bent mini plates."
223839342|NCT01244139|DRUG|BIIB033|IV infusion of 0.3, 1, 3, 10, 30, 60 or 100 mg/kg
223839343|NCT01244139|DRUG|Placebo|IV infusion dummy drug
223839344|NCT04419532|DRUG|DS-1055a|"Administered as an intravenous infusion on Day 1 of every 21-day cycle following low dose administration(s) in priming dose period.~Infusion duration: 180 minutes for the first infusion, and if no infusion-related reaction, 120 minutes for subsequent infusions"
223839345|NCT00723333|PROCEDURE|Reduced Intensity Conditioning (RIC) Allogenic Transplant|Reduced Intensity Conditioning (RIC) Regimen Allogenic Stem Cell Transplant
223839346|NCT06824246|BEHAVIORAL|Water conservation education|The programme of training for participants will be based on the Health Belief Model, and will consist of two sessions on individuals' water footprints and water consumption habits. Support for the sessions will be provided by brochures and videos that have been prepared for this purpose. Women will be given brochures and a list of things to do to save water. They will also be informed that their monthly water bill will be monitored during the process.
223839347|NCT06824246|BEHAVIORAL|Monitoring water bill|Participants in the control group will be informed that their water bills will be monitored for water savings.
223839348|NCT05151562|BEHAVIORAL|Virtual Music Therapy|Each study participant will receive two 30-minute live synchronous virtual music therapy sessions per week for a period of 8 weeks to be delivered by a board-certified music therapist (using Zoom as a primary platform). These individualized therapeutic encounters will use music that is personally meaningful and familiar to the participant and the participant's loved ones to facilitate reminiscence. Decision-making processes made by the music therapist will reflect a flexible session structure and series of intervention choices contingent on each participant's cultural identity, expressive and receptive communication, fine and gross motor ability, affect, orientation to time and place, and personal preferences on any given day.
223839349|NCT03194074|DRUG|Propofol|In propofol/remifentanil group, propofol at a rate 75\~150 µg/kg/min and remifentanil at 0.1-0.3 µg/kg/min are maintained throughout surgery.
223839350|NCT03194074|DRUG|Desflurane|In desflurane/remifentanil group, desflurane at end tidal concentration at 0.7\~1.0 minimum alveolar concentration (MAC) and remifentanil 0.1-0.3 ug/kg/min are used.
223839351|NCT00250172|DRUG|[C-11](R)-rolipram|
223839352|NCT01813032|PROCEDURE|Forearm Vascular Study|Forearm venous occlusion plethysmography to measure forearm blood flow during intra-arterial infusion of the vasodilators Verapamil (10-100 µg/min), bradykinin (100-1000 pmol/min), sodium nitroprusside (2-8 µg/min) and Acetylcholine (5-20 µg/min).
223839353|NCT01813032|PROCEDURE|Badimon Chamber|Ex-vivo assessment of thrombus formation using the Badimon Chamber
223839354|NCT05591469|DEVICE|IR Camera|the respiration parameters are measured using an IR camera.
223839355|NCT05591469|DEVICE|Electrical Impedance Tomography|the respiration parameters are measured using an electrical impedance tomograhy.
223839356|NCT06991283|DEVICE|transcutaneous vagus nerve stimulation|The stimulation times are fixed between 07:00-09:00 in the morning and 19:00-21:00 in the evening, with an interval of 12 hours between the two sessions. The device is set with a pulse width of 200 microseconds and a pulse frequency of 20 hertz. The stimulation intensity is individually adjusted to above the perception threshold and below the discomfort level of 1 milliampere.
223839357|NCT06991283|DEVICE|Sham (no implant)|Vagus nerve stimulation is delivered through a transcutaneous electrical nerve stimulation device by attaching an ear clip to the tragus. But no stimulation will be delivered. The sham stimulation will be performed twice daily, each session lasting for half an hour. The stimulation times are fixed between 07:00-09:00 in the morning and 19:00-21:00 in the evening, with an interval of 12 hours between the two sessions.
223839358|NCT06991231|PROCEDURE|Total knee arthroplasty (TKA)|Administered as part of patient standard of care.
223839359|NCT06991231|DEVICE|Cryoablation|Cryoablation will be administered on the leg of the knee indicated for surgery.
223839360|NCT06991218|PROCEDURE|cardiac surgery|Adult patients (age ≥18 years) who underwent cardiac surgery with cardiopulmonary bypass were included.
223839361|NCT05259553|OTHER|Blood samples|"Peripheral blood sampling will be performed at different time points of the study, for a total volume of 20-40 mL:~* Sampling before MM treatment,~* Sampling during MM treatment (at 3 months post-initiation if no autograft or before autograft),~* Only for Patients treated with Apixaban or Eliquis®, 2 additional samplings during MM treatment for pharmacokinetics analysis."
223839362|NCT05218980|DIETARY_SUPPLEMENT|Olives|Organic olives (provided by Sakellaropoulos Organic Farms; Sparta, Greece)
223839363|NCT06674265|BIOLOGICAL|Allogenic NK cells infusion|Natural Killer (NK) cells are extracted from a healthy donor through apheresis and processed in a clean room using the CLINIMACS device. After quality assessment, these cells are stored at -198°C until needed. When required, the cells are thawed, washed, and evaluated for viability and sterility before being administered to the patient at a dosage of 5 × 10\^6 cells per kilogram of body weight. Two further injections may be considered based on the patient's response and confirmed improvement via MRI MIBG. Injections are scheduled seven to ten days after each chemotherapy course according to the standard treatment protocol.
223839364|NCT06918639|PROCEDURE|Pulpotomy|VPT: Partial pulpotomy: 2 mm of pulp tissue is removed with a high speed 014 diamond round bur different from the one used to remove carious tissue. In those cases in which access to the pulp tissue induces a painful sensation due to failure of the anaesthetic technique, intrapulpal anaesthesia shall be used, and this parameter shall be recorded.Cotton wool impregnated with 2.5% stabilised sodium hypochlorite shall be held over the pulp exposure to achieve haemostasis. If it is not possible to control bleeding, proceed to a complete pulpotomy procedure. If in this case it is impossible to achieve haemostasis, the possibility of performing a TPV is ruled out and the RCT is excluded from the study. Once haemostasis has been achieved, BiodentineXp is applied according to the manufacturer's instructions and a material thickness of 2-3 mm is ensured. Full pulpotomy: The same anterior procedure .Complete removal of the tissue from the pulp chamber. Maximum haemostasis time: 10 minutes
223839365|NCT06625281|PROCEDURE|Epleys Maneuver|"* The patient begins in an upright sitting posture, with the legs fully extended and the head rotated 45 degrees towards the affected side.~* The patient is then quickly and passively forced down backwards by the therapist performing the treatment into a supine position with the head held approximately in a 30-degree neck extension~* The therapist observes the patient's eyes for primary stage nystagmus. The patient remains in this position for 1-2 minutes.~* The patient's head is then turned 90 degrees to the opposite direction so that the unaffected ear faces the ground, for 1-2 minutes.~* Keeping the head and neck in a fixed position relative to the body, the individual rolls onto their shoulder, rotating the head another 90 degrees in the direction they are facing. The patient is now looking downwards at a 45-degree angle.~* The eyes should be immediately observed by the therapist for secondary stage nystagmus. The patient remains in this position for 1-2 minutes."
223839366|NCT06625281|PROCEDURE|Semont-plus maneuver|"* The Semont-plus maneuver includes the upright position with turning of the head by 45° toward the non-affected side.~* Then movement of the body by 150° toward the affected side, which moves the otoconia further in the direction in which they should move and since the clot is beyond the vertex, the movement of body by 240° moves the clot into the direction of the vestibulum."
223839367|NCT06625281|PROCEDURE|Brandt-Daroff exercises|"* Patient sits on the edge of bed. and lies down onto the side that causes dizziness to increase. Look towards the ceiling. Stay in this position for 2 minutes.~* Sits upright and then wait for 30 seconds.~* Moves rapidly to the opposite side for 2 minutes."
223839368|NCT06625359|DRUG|Thiotepa in conditioning before transplantation|"For patients with ECOG PS 0 or 1 For patients with ECOG PS 0 or 1 and age \&lt; 60 years old, conditioning regimen before autologous stem cell transplantation consists of thiotepa, bulsulfan, and cyclophosphamide from day -9. Beginning on day -9 and through day -7, each patient was treated with thiotepa (200mg/m m2 IV per day). On days -6 to -4, patients received bulsulfan (2.7mg/kg IV over 3 hours per day every). Bulsulfan-related seizure prophylaxis was given with levetriacetam (1500mg loading on day -6, 500mg twice daily on days -5 to -3). On days -3 and -2, cyclophosphamide (60mg/kg IV per day) was given given.~Patients with ECOG PS 2 or age ≥ 60 years old received bulsulfan (3.2mg/kg IV over 3 hours per day for 2 days) resulting in 8 days regimen."
223839369|NCT06624813|PROCEDURE|Robot-assisted partial prostatectomy|Focal therapy with surgery for single lobe prostate cancer, partial robot-assisted partial prostatectomy
223839370|NCT03008720|DEVICE|Transcranial direct current stimulation (tDCS)|
223839371|NCT03008720|DEVICE|Functional electrical stimulation (FES)|
223839372|NCT03008720|DEVICE|Sham stimulation|
223839373|NCT06687681|BIOLOGICAL|NK cell therapy|Active NK cell injection through lumbar puncture in patient with Astrocytoma IDH-mutant, Oligodendroglioma IDHmutant, Glioblastoma IDH-wild type, Diffuse midline glioma, Diffuse hemispheric glioma, Diffuse pediatrictype high-grade glioma IDH-wild type
223839374|NCT06624826|DEVICE|Emmetropic modality|PureSee IOL, emmetropic modality
223839375|NCT06624826|DEVICE|Monovision modality|PureSee IOL, monovision modality
223839376|NCT06697990|DRUG|Iruplinalib|60 mg of Iruplinalib, once daily for 7 days, followed by 180 mg of Iruplinalib, once daily in a 28-days cycle.
223839377|NCT06897215|DEVICE|Hyaluronic acid hydrogel|Assigned to the Experimental Cohort once OM grade 2.0 presents, Gelclair is a hyaluronic acid hydrogel that acts as a protective film in the management of OM. This product is used internationally and has been recently approved by Health Canada as a Class 2 Medical Device with an indication to manage the symptoms of OM caused by radiotherapy and chemotherapy.
223839378|NCT05182892|OTHER|Change of stimulation amplitudes in dopaminergic OFF drug state|Change of stimulation amplitudes during experiment in dopaminergic OFF drug state.
223839379|NCT05091684|DRUG|Fibrinogen Concentrate Human|Refractory transfused patients who present grade ≥ 2 hemorrhagic symptoms will receive a single injection of fibrinogen concentrate (1.5g) followed by platelet transfusion within 2 hours. Blood sampling will be done at different time points to measure clot viscoelasticity: at baseline, after fibrinogen injection, after platelet transfusion and the day after transfusion or before the next platelet transfusion if \< 24 hours.
223839380|NCT06910514|COMBINATION_PRODUCT|Mucopolysaccharide saline solution 0.9%|Injectable solution designed for submucosal elevation in endoscopic mucosal resection. Administered via submucosal injection prior to polyp resection, adding 1% indigo carmine before administration.
223839381|NCT06910514|COMBINATION_PRODUCT|Saline solution 0.9%|Control injectable solution composed of saline 0.9 %. Administered via submucosal injection prior to polyp resection, adding 1% indigo carmine before administration.
223839382|NCT06911515|OTHER|peripheral venous blood samples, these will be performed in order to measure the biological markers in the serum|peripheral venous blood samples, these will be performed in order to measure the biological markers in the serum
223839383|NCT06908278|BEHAVIORAL|Suture Simulation Training for Episiotomy Repair|"This intervention involves training participants to perform episiotomy repairs using a suture simulator. Participants will practice suturing techniques in a controlled, safe environment to improve their self-efficacy in performing the procedure. The training includes both theoretical learning and hands-on practice. The goal is to enhance the participants' confidence and competence in performing episiotomies.~(This description outlines the nature of the intervention and the learning objectives.)"
223839384|NCT06917820|PROCEDURE|Interscalene brachial plexus block|Ultrasound-guided peripheral nerve block that includes injection of local anesthetics between the C5 and C6 nerve roots and between C6 and C7 nerve roots.
223839385|NCT06917820|PROCEDURE|Clavipectoral fascia plane block|Ultrasound-guided peripheral nerve block that includes injection of local anesthetics between the periosteum of clavicle and the surrounding clavipectoral fascia.
223839386|NCT06919120|DRUG|Simethicone is mixed into the final packet of compound polyethylene glycol electrolyte powder|The patients added one bottle of simethicone when taking the final packet of compound polyethylene glycol electrolyte powder.
223839387|NCT06919120|DRUG|Take simethicone separately|Take one bottle of simethicone orally after finishing the last sip of compound polyethylene glycol electrolyte solution.
223839388|NCT06918535|OTHER|Progressive Muscle Relaxation Technique|Progressive Muscle Relaxation (PMR) is a relaxation technique that involves systematically tensing and then relaxing different muscle groups in the body to reduce physical tension and stress. Developed by Edmund Jacobson in the 1930s, PMR aims to promote deep relaxation by increasing awareness of muscle tension and learning to release it. The technique is typically performed in a quiet environment, starting from the feet and progressing upward or vice versa. It is commonly used for stress management, pain relief, anxiety reduction, and improving overall well-being.
224264667|NCT01902394|OTHER|Whole grains|Following completion of the baseline period (a 2-week run-in phase), participants in the WG group will receive a diet providing 100% of energy requirements in a diet rich in whole grains and the RG group will be provided with 100% of energy requirements in a diet rich in refined grains but otherwise similar to the WG diet for 6 weeks.
224264668|NCT01902394|OTHER|Refined grains|Following completion of the baseline period (a 2-week run-in phase), participants in the WG group will receive a diet providing 100% of energy requirements in a diet rich in whole grains and the RG group will be provided with 100% of energy requirements in a diet rich in refined grains but otherwise similar to the WG diet for 6 weeks.
224264669|NCT02436200|DEVICE|Neuromuscular Electrical Stimulation|Revitive IX neuromuscular electrical stimulation device will be given to all participants as per protocol.
224264670|NCT02471807|DEVICE|Edwards FORMA Tricuspid Transcatheter Repair System|
224264671|NCT00957021|DEVICE|Triathlon® PS Total Knee System|Triathlon® PS Total Knee system
224264672|NCT02000388|DRUG|Ketorolac Tromethamine|
224264673|NCT02000388|OTHER|Standard of Care|
224264674|NCT00961376|BIOLOGICAL|PBMC re-infusion|Autologous PBMC re-infusion
224264675|NCT00961376|BIOLOGICAL|CD25 depletion|Autologous, CD25-depleted PBMC re-infusion
224264676|NCT03031795|DRUG|Ketorolac|Oral Tablet
224264677|NCT03031795|DRUG|Placebo|Oral Tablet
223839389|NCT06918535|OTHER|Muscle Energy Technique|Muscle Energy Technique (MET) is a manual therapy approach that uses the patient's voluntary muscle contractions against a controlled resistance provided by the therapist to improve musculoskeletal function. It is commonly used to lengthen shortened muscles, improve joint mobility, and reduce pain. MET works by engaging the target muscles in an isometric or isotonic contraction, followed by a relaxation phase, allowing for a greater stretch or repositioning of the joint. It is frequently used in physiotherapy for conditions such as muscle tightness, joint restrictions, and postural imbalances.
223839390|NCT06918418|DRUG|Salbutamol (Ventolin®)|Children were given 0.5% salbutamol aerosol solution (0.15 mg/kg weight, up to a maximum of 5 mg) in 5mL of normal saline solution for 7 min every 20 min for 2 h, and then every 30 min for two more hours. Aerosol were generated by nebulizer powered by compressed-air (5 L/min) with Y-connection with oxygen (3 L/min) and delivered via a face mask.
223839391|NCT06918418|DRUG|salbutamol + ipratropium bromide nebules|In addition to Salbutamol nebulization, children received ipratropium bromide nebulization. Ipratropium bromide solution (250 mcg in children \<20 kg weight or 500 mcg in children \>=20 kg) every 20 min for the first 2 hours then every 30 min for 2 hours more will be given in between the salbutamol nebulization. Aerosol were generated by nebulizer powered by compressed-air (5 L/min) with Y-connection with oxygen (3 L/min) and delivered via a face mask.
223839392|NCT06918028|OTHER|With fundus diseases|With fundus diseases
223839393|NCT06918028|OTHER|Without fundus diseases|Without fundus diseases
223839394|NCT05904106|DRUG|Venetoclax plus Azacitidine|"Induction cycle 1:~100 mg venetoclax p.o. on day 1; 200 mg venetoclax p.o. on day 2; 400 mg venetoclax p.o. on days 3-28; 75 mg/m\^2 azacitidine s.c. on days 1-7~Induction cycles 2-3:~400 mg venetoclax p.o. on days 1-28; 75 mg/m\^2 azacitidine s.c. on days 1-7~Postremission cycles 1-9:~400 mg venetoclax p.o. on days 1-28; 75 mg/m\^2 azacitidine s.c. on days 1-7"
223839395|NCT05904106|DRUG|standard of care chemotherapy plus gemtuzumab ozogamicin|"Induction cycle 1:~200 mg/m\^2 cytarabine cont inf i.v. on days 1-7; 60 mg/m\^2 daunorubicin i.v. on days 3-5; 3 mg/m\^2 (max 1 vial) gemtuzumab ozogamicin i.v. on days 1+4+7~Induction cycle 2 (patients not in remission, moderate or non-responders):~3000/1000 mg/m\^2 cytarabine i.v. BID on days 1-3; 10 mg/m\^2 mitoxantrone i.v. on days 3-5~Postremission cycles 1-3:~3000/1000 mg/m\^2 cytarabine i.v. BID on days 1-3"
223839396|NCT04267146|DRUG|Nivolumab|"Solution for intravenous injection 10 mg/ml. Initial dose : 3 mg/kg Nivolumab will be given at 3 mg/kg/injection every two weeks from the first day of radiotherapy to the last day of chemotherapy.~One de-escalation dose : 1 mg/kg"
223839397|NCT04267146|DRUG|Temozolomide|Capsules: 5, 20, 100, 140, 180 and 250 mg orally. Temozolomide will be given at 75mg/m2/day from the day of start of radiotherapy to the last day of radiotherapy, then, after one month rest at 200mg/m2/day for five consecutive days for 12 cycles (28 days cycle).
223839398|NCT04267146|RADIATION|Radiotherapy|Total dose of 54 Gray(Gy) units delivered in 30 daily fractions of 1.8 Gy over 6 weeks during the chemoradiation period.
223839399|NCT03923673|PROCEDURE|Pericardiotomy|The minimally invasive procedure that creates a small opening in the sac that surrounds the heart.
223839400|NCT03735810|DRUG|LBS-008|LBS-008 oral capsules
223839401|NCT03735810|DRUG|Placebos|Oral capsules
223839402|NCT05902403|OTHER|invasive mechanical ventilation|Invasive mechanical ventilation for patients admitted to the ICU
223839403|NCT03179540|PROCEDURE|Non-operative management|Patients who are eligible and provide informed consent to participate in the trial will undergo non-operative management (i.e., active surveillance for 24 months) according to the schedule outlined in the study protocol.
223839404|NCT03325621|BIOLOGICAL|PRS-080#022-DP|Biological/Vaccine: PRS-080#022-DP Hepcidin antagonism to mobilize iron and to treat anemia
223839405|NCT03325621|BIOLOGICAL|PRS-080-Placebo#001|Placebo Comparator
223839406|NCT03299374|OTHER|Pilates Intervention|Intervention based on Pilates principles
223839407|NCT03299374|OTHER|Fall prevention intervention|Intervention based on principles to prevent falls
223839408|NCT00777803|DRUG|NT 201 (IncobotulinumtoxinA (Xeomin®/Bocouture®))|NT201, also known as IncobotulinumtoxinA (Xeomin®/Bocouture®), active ingredient: Clostridium botulinum neurotoxin type A free from complexing proteins, powder for solution for injection dose, 24 units; one injection session of solution, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl). Of the 0.6 mL total injection volume, an aliquot of 0.15 mL was administered in the procerus muscle, aliquots of 0.125 mL were administered in the medial part of the both corrugator muscles and aliquots of 0.1 mL were administered in the middle part of both corrugator muscles.
223839409|NCT00777803|DRUG|OnabotulinumtoxinA (Vistabel®)|OnabotulinumtoxinA (Vistabel®), active ingredient: Clostridium botulinum neurotoxin type A, powder for solution for injection dose, 24 units; one injection session of solution, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl). Of the 0.6 mL total injection volume, an aliquot of 0.15 mL was administered in the procerus muscle, aliquots of 0.125 mL were administered in the medial part of the both corrugator muscles and aliquots of 0.1 mL were administered in the middle part of both corrugator muscles.
223839410|NCT06224595|DRUG|CS32582 capsule|Participants receive CS32582 orally single or multiple doses
223839411|NCT06224595|DRUG|Placebo capsule|Participants receive placebo matching CS32582 orally single or multiple doses
223839412|NCT01268059|DRUG|Carboplatin|Carboplatin (carboplatin area under the plasma concentration-time curve \[AUC\] of 6 milligram per milliliter into minute \[mg/mL\*min\] administered as an intravenous (IV) infusion once every 21 days on Day 1, for a total of 6 doses (cycles) until unacceptable toxicity, disease progression, or other reasons for participant withdrawal.
223839413|NCT01268059|DRUG|Paclitaxel|Paclitaxel 200 milligram per square meter (mg/m\^2) administered as an intravenous (IV) infusion once every 21 days on Day 1, for a total of 6 doses (cycles) until unacceptable toxicity, disease progression, or other reasons for participant withdrawal.
223839414|NCT01268059|DRUG|MEDI-575|MEDI-575 at a dose of 25 milligram per kilogram (mg/kg) administered as an IV infusion once every 21 days on Day 1 for a total of 6 cycles until unacceptable toxicity, disease progression, initiation of alternative anticancer therapy, or other reasons for participant withdrawal. MEDI-575 alone continued in those participants who achieved stable disease or better at the completion of carboplatin/paclitaxel therapy and did not demonstrate toxicity to MEDI-575.
223839415|NCT02783105|OTHER|Musical intervention|
223839416|NCT02783105|OTHER|Control|Patients wear headphones twice a day during 30 minutes, starting at the onset of desedation (Day 0) until day 21, but no music is provided (blank playlist): Sham
223839417|NCT03850444|BIOLOGICAL|pembrolizumab|
223839418|NCT03850444|DRUG|carboplatin|
223839419|NCT03850444|DRUG|paclitaxel|
223839420|NCT03850444|DRUG|pemetrexed|
223839421|NCT03114943|BIOLOGICAL|NBP608|Preparation of the Oka/SK strain of live, attenuated varicella virus
223839422|NCT03114943|BIOLOGICAL|Varivax|Preparation of the Oka/Merck strain of live, attenuated varicella virus
223839423|NCT05154344|DRUG|Capmatinib|Available through expanded access
223839424|NCT03645603|DRUG|Dexmedetomidine|intravenous infusion
223839425|NCT03645603|DRUG|Placebo|intravenous infusion of physiological saline solution to mimic dexmedetomidine infusion
223839426|NCT05628662|DEVICE|Automated Insulin Delivery System (SAFE-AP)|Each subject will undergo a 32-hour in-hospital study, including 4 meals (60 grams of carbohydrates each, except 50 grams for breakfast), one overnight period and 2 unannounced aerobic exercise sessions. Each exercise session consists of three 15-minute sets on a cycle ergometer at 70% of maximum heart rate with 5 minutes of rest between sets.
223839427|NCT01598987|DRUG|Introduction of everolimus with reduced cyclosporine or tacrolimus dose, the earliest 1 month and the latest 6 months after liver transplantation.|Immunosuppression after liver transplantation. Pediatric transplant recipients received a starting dose of 0.8 mg/m\^2/dose in combination wit Cyclosporine A or 2.0 mg/m\^2/dose in combination with tacrolimus, twice-daily. Thereafter, doses were adjusted to achieve everolimus C-0h blood trough level between 3 to 8 ng/ml.
223839428|NCT00006221|DRUG|ixabepilone|
223839429|NCT01144117|DRUG|Erythropoietin|Erythropoietin 48000 IU given I.V. in 17 courses
223839430|NCT04497311|DIAGNOSTIC_TEST|Thoraxic computed tomography|Diagnostic lung CT.
223839431|NCT02107274|DRUG|Azithromycin|Azithromycin (C38H72N2O12 MW 749) is a 15-membered azalide, a subclass of macrolide antibiotics
223839432|NCT02107274|DRUG|Placebo for Azithromycin|In Part One of the study participants will be randomised to receive 12 weeks of either placebo or azithromycin in a 1:1 ratio in a double-blinded fashion. After 12 weeks, in Part Two of the study, all participants will receive placebo in a double-blinded fashion for an additional 12 weeks.
223839433|NCT02293707|BIOLOGICAL|GX301|"GX301 therapy consists of four human telomerase reverse transcriptase (hTERT) peptides and two adjuvants.~Peptides are hTERT (540-548) Acetate, hTERT (611-626) Acetate, hTERT (672-686) Acetate and hTERT (766-780) Acetate. Adjuvants are Montanide ISA 51 VG and imiquimod 5% cream (Aldara).~Each GX301 administration will consist of four intradermal injections - one injection for each hTERT peptide - given at the same time and followed by topical application of imiquimod. Each intradermal injection will consist of a fixed hTERT peptide dose, 500 µg, reconstituted as a solution and mixed with Montanide ISA 51 VG."
223839434|NCT05878353|PROCEDURE|Decontamination of the pocket with local doxycycline|Gentle debridement will be performed under local anesthesia (mepivacain 2% 1:1000) for a time of 5 minutes by mean of ultrasonic devices by the same experienced clinician. Great attention will be made to avoid marginal and interproximal soft tissue damage. Local doxycycline was administered according to the manufacturer's instruction. Briefly, the plastic needle of the syringe will be inserted into the sulcus and the product will be progressively released in the periodontal pocket up to the gingival margin. The syringe will be then removed and a cotton pellet used to compact the gel into the sulcus. Patients will be then instructed not to floss or use interdental brushes in that area for the following 10 days.
223839435|NCT05878353|PROCEDURE|Decontamination of the pocket with mechanical instrumentation|Gentle debridement will be performed under local anesthesia (mepivacain 2% 1:1000) for a time of 5 minutes by mean of ultrasonic devices by the same experienced clinician. Great attention will be made to avoid marginal and interproximal soft tissue damage.
223839436|NCT00703482|DRUG|Fenofibrate/CoQ10|Fenofibrate pbo/CoQ10 placebo
223839437|NCT00703482|DRUG|Fenofibrate/CoQ10|Fenofibrate pbo/CoQ10 200 mg
223839438|NCT00703482|DRUG|Fenofibrate/CoQ10|Fenofibrate 160mg/CoQ10 placebo
223839439|NCT00703482|DRUG|Fenofibrate/CoQ10|Fenofibrate 80/CoQ10 100 mg
223839440|NCT00703482|DRUG|Fenofibrate/CoQ10|Fenofibrate 160mg/CoQ10 100 mg
223839441|NCT00703482|DRUG|Fenofibrate/CoQ10|Fenofibrate 80 /CoQ10 200 mg
223839442|NCT00703482|DRUG|Fenofibrate/CoQ10|Fenofibrate 160mg/CoQ10 200 mg
223839443|NCT03097211|DRUG|Placebo|Placebo capsules. Orally, with 240 mL of potable water.
223839444|NCT03097211|DRUG|BIA 6-512|The investigational products consisted of capsules containing BIA 6-512 25 mg, 50 mg, 75 mg, 100 mg. Orally, with 240 mL of potable water.
223839445|NCT03097211|DRUG|Madopar® 250|Levodopa/benserazide immediate release tablets 200mg/50mg. Orally, with 240 mL of potable water.
223839446|NCT03097211|DRUG|Nebicapone|Nebicapone 150 mg tablets. Orally, with 240 mL of potable water.
223839447|NCT05899049|BIOLOGICAL|Pembrolizumab|Pembrolizumab 400 mg administered Q6W via IV infusion
223839448|NCT05899049|DRUG|Belzutifan|Belzutifan 120 mg administered QD via oral tablet
223839449|NCT05899049|BIOLOGICAL|Pembrolizumab/Quavonlimab|Pembrolizumab/quavonlimab is a co-formulated product composed of pembrolizumab 400 mg in combination with quavonlimab 25 mg, administered Q6W via IV infusion
223839450|NCT05899049|DRUG|Lenvatinib|Lenvatinib 20 mg administered QD via oral capsule
223839451|NCT01178242|PROCEDURE|Salivary Gland and Labial Mucous Membrane Transplantation|"Minor salivary glands (SG) will be obtain en block from the same donor site, at the inferior or superior labial mucous membrane, above the orbicularis oris muscle to correct lubrication. The thin split thickness graft of mucous membrane will be suture to the sclera with absorbable sutures"
223839452|NCT02763098|DRUG|Remi 0.1|Intravenous (IV) administration of 0.5 mg Atropine prior to the induction, the patients randomly (by lot) received one of the three different doses (0.1 µg/kg/min) of remifentanil infusion for two minutes.After 2-minute remifentanil infusion, 0.5 mg/kg propofol was administered via IV route increasing the dose by 10 mg every 10 seconds; 0.5 mg/kg rocuronium was administered via IV route at the time of loss of eyelash reflex and consciousness. Two minutes later, intubation was performed. After recording the baseline values of heart rate, systolic arterial pressure, mean arterial pressure and diastolic arterial pressure, which were planned to be investigated, and administering atropine, a total of six measurements at one-minute intervals were performed until the time of intubation.
223839453|NCT02763098|DRUG|Remi 0.2|.Intravenous (IV) administration of 0.5 mg Atropine prior to the induction, the patients randomly (by lot) received one of the three different doses (0.2 µg/kg/min) of remifentanil infusion for two minutes.After 2-minute remifentanil infusion, 0.5 mg/kg propofol was administered via IV route increasing the dose by 10 mg every 10 seconds; 0.5 mg/kg rocuronium was administered via IV route at the time of loss of eyelash reflex and consciousness. Two minutes later, intubation was performed. After recording the baseline values of heart rate, systolic arterial pressure, mean arterial pressure and diastolic arterial pressure, which were planned to be investigated, and administering atropine, a total of six measurements at one-minute intervals were performed until the time of intubation.
223839454|NCT02763098|DRUG|Remi 0.3|Intravenous (IV) administration of 0.5 mg Atropine prior to the induction, the patients randomly (by lot) received one of the three different doses (0.3 µg/kg/min) of remifentanil infusion for two minutes.After 2-minute remifentanil infusion, 0.5 mg/kg propofol was administered via IV route increasing the dose by 10 mg every 10 seconds; 0.5 mg/kg rocuronium was administered via IV route at the time of loss of eyelash reflex and consciousness. Two minutes later, intubation was performed. After recording the baseline values of heart rate, systolic arterial pressure, mean arterial pressure and diastolic arterial pressure, which were planned to be investigated, and administering atropine, a total of six measurements at one-minute intervals were performed until the time of intubation.
223839455|NCT02298374|OTHER|Homecare reablement|
223839456|NCT02298374|OTHER|usual care|
223839457|NCT03412838|PROCEDURE|graft surgery|A graft surgery using bone allogenic blocks that are screwed over the atrophic sites of the maxilla to obtain bone augmentation to support dental implants
223839458|NCT03940469|DRUG|Saline|2 ml normal saline
223839459|NCT03940469|DRUG|Dexamethasone Injection|8 mg dexamethasone
223839460|NCT03940469|DRUG|Dexmedetomidine Hydrochloride|100 microgram dexmedetomidine
223839461|NCT00767715|DRUG|olanzapine|physician determined dose, oral, daily, 5 months
223839462|NCT00767715|DRUG|haloperidol|physician determined dose, oral, parenteral (\<= 3 days), daily, 5 months
223839463|NCT00767715|DRUG|zuclopentixol|physician determined dose, oral, parenteral (\<= 3 days), daily, 5 months
223839464|NCT02941146|DEVICE|The ZELTIQ System|The CoolSculpting System will be used to perform the treatments with the CoolAdvantage family of applicators.
223839465|NCT05838612|OTHER|Heat acclimation|Participants will complete a 7-day passive heat acclimation protocol consisting of immersion in warm water (\~40°C) for 1 hour over 7 consecutive days.
223839466|NCT01660295|DRUG|Certoparin 3,000 IU Once Daily|Certoparin 3,000 IU subcutaneous injection once daily
223839467|NCT01660295|DRUG|Certoparin 3,000 IU Twice a Day|Certoparin 3,000 IU subcutaneous injection twice a day
223839468|NCT01660295|DRUG|Certoparin 8,000 IU Once Daily|Certoparin 8,000 IU subcutaneous injection once daily
223839469|NCT01660295|DRUG|Certoparin 8,000 IU Twice a Day|Certoparin 8,000 IU subcutaneous injection twice a day
223839470|NCT01972087|BEHAVIORAL|Telephone simulation training|The intervention consists of four 20-minute telephone simulation training sessions over a 4 month period (one session each month). Each 20-minute training session will include 3 simulated 9-1-1 calls, performed by a standardized caller (trained actor) and feedback will be provided right away by a trained observer who takes notes during the simulation calls and discusses the teaching points after the session. In total, the 9-1-1 dispatchers will receive 12 different simulated calls.
223839471|NCT02394886|BIOLOGICAL|ALLO-ASC-DFU|
223839475|NCT03281265|OTHER|standard treatment|
223839476|NCT01036087|DRUG|Panitumumab|2.5 mg/kg IV on Day 1 of Week 1 over 60 minutes, followed by 2.5 mg/kg weekly Weeks 2-12.
223839477|NCT01036087|DRUG|Nab-paclitaxel|100 mg/m2 IV over 30 min on Day 1 of Weeks 2-13 over 30 minutes.
223839478|NCT01036087|DRUG|Carboplatin|AUC 2 IV over 30 min on Day 1 of Weeks 2-13 after completion of Abraxane through separate IV line.
223839479|NCT01036087|DRUG|5-Fluorouracil|500 mg/m2 IV every 3 weeks, starting on Day 1 of Week 14 (4 cycles, each 3 weeks long, over 12 weeks).
223839480|NCT01036087|DRUG|Epirubicin|100 mg/m2 IV over 30 min every 3 weeks starting on Day 1 of Week 14 (4 cycles, each 3 weeks long, over 12 weeks).
223839481|NCT01036087|DRUG|Cyclophosphamide|500 mg/m2 IV every 3 weeks starting on Day 1 of Week 14 (4 cycles, each 3 weeks long, over 12 weeks).
223839482|NCT00134810|BIOLOGICAL|Botulinum toxin type A|
223839483|NCT00406809|DRUG|ABT-263|"Oral solution~Phase 1 dosing was under two different schedules: 14 days on drug, 7 days off or 21 days continuous dosing.~Oral solution and tablets~Phase 2a dosing under 21 day continuous dosing.~\- 150 mg lead-in dose for 7-14 days followed by a 325 mg continuous once daily dose."
223839484|NCT02595307|BEHAVIORAL|Pamphlet|Written pamphlet outlining the risks of surgery as discussed in consultation.
223839485|NCT05151133|BIOLOGICAL|Low dose UCMSCs|Receive one course of treatment with a single injection : 0.5×10\^6 cells/kg, with a total volume of 100 ml UCMSCs;
223839486|NCT05151133|BIOLOGICAL|Moderate dose UCMSCs|Receive one course of treatment with a single injection : 1.0×10\^6 cells/kg, with a total volume of 100 ml UCMSCs;
223839487|NCT05151133|BIOLOGICAL|High dose UCMSCs|Receive one course of treatment with a single injection : 2.0×10\^6 cells/kg, with a total volume of 100 ml UCMSCs;
223839488|NCT00512408|DRUG|testosterone|
223839489|NCT04376476|BIOLOGICAL|Blood sample|blood samples will be taken as below: Group E1: At day 0 Group E2: At day 0, day 7, day 14 Group E3: At day 0
223839490|NCT04376476|BIOLOGICAL|Low or upper respiratory tract sample|"Low or upper respiratory tract sample will be collected in order to take virology measurements:~Group E1: At day 0 Group E2: At day 0, day 7, day 14 Group E3: At day 0"
223839491|NCT04376476|BIOLOGICAL|Stool collection or fecal swab|"The stool collection or fecal swab will be collected in order to take virology measurements:~Group E1: / Group E2: At day 0, day 7, day 14 Group E3: At day 0"
223839492|NCT04376476|OTHER|phone call|phone calls will be performed to collect data regarding patients' symptoms at: Group E1: Day 14 Group E3: Day 14
223839493|NCT06356181|DEVICE|Respiratory Maximus Training Device|Those in the intervention group will wear the respiratory training device for 3 days per week of high-intensity functional training over 6-weeks.
223839494|NCT06356181|DEVICE|No Respiratory Training Device|Those in the control group will train for 3 days per week of high-intensity functional training over 6-weeks.
223839495|NCT03961256|DRUG|Exenatide SR|Exenatide SR 2 mg subcutaneous (SQ) weekly
223839496|NCT05310721|BEHAVIORAL|Early time-restricted eating|Participants will eat ad libitum within an 8-hour early eating window starting not later than 10am. No calorie-containing food or beverage intake will be allowed outside the 8-hour eating window. Participants will also receive standard recommendations on healthy lifestyle based on Mediterranean dietary pattern and physical activity recommendations for weight loss and health promotion
223839497|NCT05310721|BEHAVIORAL|Late time-restricted eating|Participants will eat ad libitum within an 8-hour late eating window starting not earlier than 1pm. No calorie-containing food or beverage intake will be allowed outside the 8-hour eating window. Participants will also receive standard recommendations on healthy lifestyle based on Mediterranean dietary pattern and physical activity recommendations for weight loss and health promotion
223839498|NCT05310721|BEHAVIORAL|Self-selected time-restricted eating|Participants will self-selected an 8-hour eating window to eat ad libitum. No calorie-containing food or beverage intake will be allowed outside the 8-hour eating window. Participants will also receive standard recommendations on healthy lifestyle based on Mediterranean dietary pattern and physical activity recommendations for weight loss and health promotion
223839499|NCT02708641|DRUG|pembrolizumab|200 mg IV given every three weeks
223839500|NCT01501916|DIETARY_SUPPLEMENT|Vitamin D3|daily dosage of 50 µg Vitamin D3 for 8 weeks
223839501|NCT01501916|DIETARY_SUPPLEMENT|Placebo|daily intake of placebo
223839502|NCT04591184|BIOLOGICAL|Covigenix VAX-001 placebo|Placebo vaccine
223839503|NCT04591184|BIOLOGICAL|Covigenix VAX-001|Active Covigenix VAX-001
223839504|NCT02347449|OTHER|Questionnaires, Oncotype Dx Assay|"1. Physician pre-assay questionnaire~2. Patient pre-assay questionnaire~3. Oncotype DX® Assay~4. Physician post- assay questionnaire~5. Patient post-assay questionnaire"
223839505|NCT01021878|OTHER|icodextrin|glucose sparing dialysis solution
223839506|NCT01021878|OTHER|Dianeal|glucose based dialysis solution
223839507|NCT02213679|DIETARY_SUPPLEMENT|Guanidinoacetic acid|Dietary supplement
223839508|NCT02213679|OTHER|Placebo|Placebo
223839509|NCT05175443|OTHER|Exercise|Participants will be trained, by a physical therapist, to perform a set of four daily exercises requiring 1 sets of 2 minutes for each exercise totaling 8 minutes of targeted exercise per day for 8 weeks of the intervention. These exercises will be progressed or modified every 2-4 weeks to assure the participant is receiving maximal benefit for their exercise intervention.
223839510|NCT00345462|BIOLOGICAL|Trivalent virosomal influenza vaccine|
223839511|NCT01532050|DEVICE|Mandibular Advancement Device ( MAD)|
223839512|NCT06390553|DEVICE|Task-Oriented Virtual Reality Application with Crowd Simulation|Patients will be treated 4 days a week for 8 weeks in accordance with their assigned group.
223839513|NCT06390553|PROCEDURE|Conventional Parkinson Rehabilitation|Patients will be treated 4 days a week for 8 weeks in accordance with their assigned group.
223839514|NCT04442672|PROCEDURE|acute compartment syndrome model of health volunteer|the acute compartment syndrome model of health volunteer is induced by pressurizing the calves by the cuff, and the cuff is inflated and pressurized to a pressure value of 20, 30, 40, 50, 60, 70, 80 mmHg. the pressure inside the cuff was up to 10 s during pressurization and maintained stable for 1 min, measured and the above indicators were recorded within 3 min.
223839515|NCT04442672|PROCEDURE|sham|surrounding the cuff but not inflate it.
223839516|NCT02424344|DRUG|Aclidinium/Formoterol|Aclidinium bromide/Formoterol fumarate FDC 400/12μg dry powder for oral inhalation twice daily via Genuair inhaler
223839517|NCT02424344|DRUG|Placebo|Dose-matched placebo dry powder for oral inhalation twice daily via Genuair inhaler
223839518|NCT03128203|DRUG|Oxytocin|Oxytocin, intranasally administrated
223839519|NCT03128203|DRUG|Placebos|Saline, intranasally administrated
223839520|NCT02008058|BEHAVIORAL|Survey|Patients will report pain and analgesic use through the automated telephone system, for 7 days in a row, once every 6 weeks. Data from diagnostic tests (CT Abdomen/Pelvis, Bone Scan, PSA, and circulating tumor cells) conducted during the study period will be collected from medical records by local personnel and entered into the secure online database quarterly, but no specific tests or schedules will be required in this observational study. Patients will remain on study for up to 26 months (slightly longer than the expected median survival in this population based on data from docetaxel, abiraterone, and MDV3100 pivotal phase 3 trials).
223839521|NCT04040543|DIETARY_SUPPLEMENT|lipid-based nutrient supplement containing adherence markers|The supplement will be provided once daily for 10 days
223839522|NCT04040543|DIETARY_SUPPLEMENT|lipid-based nutrient supplement containing or not containing adherence markers|The product containing adherence markers will be provided once daily every other day (5 days total); the product not containing adherence markers will be provided on the intervening days for a total of 10 days.
223839523|NCT04040543|DIETARY_SUPPLEMENT|lipid-based nutrient supplement not containing adherence markers|The supplement will be provided once daily for 10 days
223839524|NCT02488772|DEVICE|Sleep mask|
223839525|NCT02488772|OTHER|Standard of care|Standard of care as decided by treating emergency physician
223839526|NCT02488772|DEVICE|Ear Plugs|
223839527|NCT05661526|OTHER|Bloodpoly board game|Blood transfusion training given by Bloodpoly board game
223839528|NCT05661526|OTHER|Text-to-speech group|Blood transfusion training given by text-to-speech
223839529|NCT01421043|DRUG|triazolam liquid oral drops|0.25 mg single dose oral drops
223839530|NCT01421043|DRUG|triazolam tablets|0.25 mg single oral dose
223839531|NCT00593164|DEVICE|Cooling with ThermoSuit with Magnesium Sulfate Infusion|Cooling with LRS ThermoSuit within 15 minutes of intravenous Magnesium Sulfate infusion (30 mg/kg, added to 100 ml normal NaCl solution, given over 15 min).
223839532|NCT00593164|DEVICE|Cooling with ThermoSuit with Normal Saline Infusion|Cooling with LRS ThermoSuit within 15 minutes of normal saline infusion (100 ml of normal NaCl solution, given over 15 min).
223839533|NCT03152565|DRUG|Avelumab|"Autologous Dendritic Cells vaccine: A dose of ADC at days 1, 14, 28, 42 and 56 (total of 5 doses), and thereafter every 6 months until disease progression (maximum of 6 additional doses) or unacceptable toxicity.~Avelumab will be administered intravenously at a dose of 10 mg per kilogram of body weight, every 14 days until disease progression or unacceptable toxicity."
223839534|NCT02920398|DRUG|turoctocog alfa pegol|Administered as intravenous injections at a dose of 50 U/kg. Patients will receive each product in a randomised cross-over design for comparison of the pharmacokinetics between turoctocog alfa pegol from the pivotal process and turoctocog alfa pegol from the commercial process.
223839535|NCT00730418|DRUG|Doxazosin|Treatment with doxazosin 4mg daily for 24 mos
223839536|NCT00730418|DRUG|Doxazosin|Treatment with doxazosin 8mg daily for 24 mos
223839537|NCT00003802|DRUG|pyrazoloacridine|
223839538|NCT04721509|DEVICE|Experimental : Smartphone-based telemedicine with the app 'Songaree diabetes'|Experimental group: outpatient clinic and offline education every 12 weeks plus telemedicine and education with smartphone app 'Songaree diabetes' every 2 weeks for 24 weeks
223839539|NCT06450184|DRUG|Pimavanserin 34 mg|1 capsule of Pimavanserin Capsule 34mg
223839540|NCT06450184|DRUG|NUPLAZID 34 MG Oral Capsule|1 capsule of Pimavanserin Capsule 34mg
223839541|NCT01460381|DRUG|LY2216684|
223839542|NCT01460381|DRUG|Quinidine|
223839543|NCT01445639|DRUG|Dexmedetomidine|Intravenous infusion at rate of 0.4μg/kg/h, during the first 24 hours postoperatively
223839544|NCT01445639|DRUG|Normal saline|as placebo
223839545|NCT06102343|DEVICE|Alma Harmony|Acne scars treatment using non-ablative ER:Glass 1540 nm laser module.
223839546|NCT00378872|DRUG|IV Tranexamic acid 10mg/kg pt body weight|
223839547|NCT00378872|DRUG|Quixil topical sealant|
223839548|NCT06036030|DRUG|Dihydroartemisinin|dihidroartemisinin dose of 2-4 mg/Kg Body weight taken for 3 days
223839549|NCT06036030|DRUG|Piperaquine|piperaquine at a dose of 16-32 mg/Kg body weight taken for 3 days
223839550|NCT06036030|DRUG|Primaquine|Primaquine dose 0.25 mg/kg body weight given to uncomplicated Plasmodium falciparum patients on the first day only
223839551|NCT06036030|OTHER|Momordica Charantia Extract|Momordica charantia extract capsules at a dose of 325 mg were given to patients for 3 days
223839552|NCT03738657|OTHER|Olfactory screening|Therefore prior to gustatory testing, patients will be screened and assessed as having either normal or abnormal olfactory function using the Sniffin' Sticks (Burghart; Wedel, Germany). The test consists of 12 odour pens which represent every-day odours (peppermint, fish, coffee, banana, orange, rose, lemon, pineapple, cinnamon, cloves, leather and liquorice). Patients are presented with an odour and select the perceived smell using a multiple-forced-choice method.
223839553|NCT03738657|OTHER|Quantative Gustatory Testing using Taste Strips|"Following screening for olfactory function, whole mouth gustatory function will be assessed using validated taste strips (Burghart; Wedel, Germany). Filter paper test strips are impregnated at one end with 2cm2 of either sweet, sour, salty or bitter taste solutions in four concentrations. In a pseudo-randomised sequence, individual strips will be placed on the tongue and patients will be asked to close their mouth in order to assess whole mouth function. Through a forced-choice procedure patients will be asked to identify the taste stimuli. Scores for individual taste qualities will range from 0-4 and an overall taste score will range from 0-16.~Patients will rinse their mouth with tap water prior the application of each taste strip."
223839554|NCT01824446|DRUG|Radiolabeled SPD602 (FBS0701, SSP-004184)|A single oral dose of 3g of radio-labelled SSP-004184 on Day 1
223839555|NCT00335543|DRUG|cisplatin|
223839556|NCT00335543|DRUG|gemcitabine hydrochloride|
223839557|NCT00335543|PROCEDURE|adjuvant therapy|
223839558|NCT00335543|PROCEDURE|conventional surgery|
223839559|NCT00335543|PROCEDURE|neoadjuvant therapy|
223839560|NCT00335543|RADIATION|radiation therapy|
224264678|NCT04025021|DIETARY_SUPPLEMENT|Targeted Fortification|The TPN and SMOF lipids will be optimized to provide a goal of 4 g/kg/day of protein, and 100-130kcal/kg/day. At 100 ml/kg/day of enteral feeds additional liquid protein and/or microlipids will be added to the breast milk to provide goal of 4 g/kg/day of protein and 100-130 kcal/kg/day. This will be determined by analysis of the milk and reported composition. They will continue targeted fortification for 4 weeks after achieving full feeds of 150 ml/kg/day.
224264679|NCT04025021|DEVICE|The Miris Human Milk Analyzer|The Miris human milk analyzer is a mid infrared that reports the amount of energy absorbed at each wavelength. The amount of fat (grams), lactose (grams), total protein (grams), true protein (grams), and energy (kcal) per 100 ml will be reported.
224264680|NCT03354338|DRUG|Amoxicillin|Intensive Periodontal treatment; Pre-medication with 2 gr of oral Amoxicillin 1 hour before treatment
224264681|NCT03354338|OTHER|Placebo|Intensive Periodontal treatment; Pre-medication with 2 gr of Placebo 1 hour before treatment
224264682|NCT02075333|DIETARY_SUPPLEMENT|Ingestion of solution|Participants will ingest the solution
224264683|NCT02075333|DIETARY_SUPPLEMENT|Rinising of solution|Participants rinse the solution in the oral cavity
224264684|NCT06076109|OTHER|Prone position|Patients who require supplemental oxygen through a non-invasive device (nasal cannulas or reservoir mask) in the prone position.
224264685|NCT06076109|OTHER|Standard treatment|Patients who require supplemental oxygen through a non-invasive device (nasal cannulas or reservoir mask) in the supine position with the head of the bed between 30-60º.
224264686|NCT05240417|PROCEDURE|"Pontic-shield technique"|A 1mm thick fragment of the vestibular aspect of the root will remain after extraction (partial extraction)
224264687|NCT05240417|PROCEDURE|Alveolar ridge preservation|Particulate deproteinized bovine bone and porcine collagen membrane will be placed after tooth extraction
224264688|NCT06426290|BEHAVIORAL|post-surgery psychological evaluation|"Following questionnaires will be done :~Patient Health Questionnaire (PHQ-9) Generalized Anxiety Disorder (GAD-7) Three Factor Eating Questionnaire (TFEQ-R21) Quality of life for obesity and dietetic questionnaire (EQVOD) Body Esteem Scale (BES) Figure Rating Scale (auto-questionnaire)"
224264689|NCT04212845|DRUG|Bupivacaine;Dexamethasone Solution for Injection|8 mg Dexamethasone and %0.25 bupivacaine
224264690|NCT04212845|DEVICE|Fluoroscopy|Fluoroscopy-guided transforaminal injection
224264691|NCT04212845|DEVICE|Ultrasound|Ultrasound-guided erector spinae plane block
224264692|NCT01986647|BEHAVIORAL|On the Move exercise - exercise leader|exercise physiologists
223839561|NCT05037656|BEHAVIORAL|School-based curriculum|Participants will be randomized, at the school level, to receive either the e-cigarette/tobacco/areca nut use prevention curriculum or the standard of care (i.e., control). The curriculum will be implemented using 5 intensive in-class lessons over the span of 6 weeks. All sessions of the curriculum follow the same basic format: a) an introduction and/or review of the past lesson, b) a cultural wall activity, c) a video, d) 1-2 interactive activities, and e) a wrap-up activity. Lessons are designed such as to help improve knowledge about drugs and correct cognitive misperceptions and to train on skills to resist normative social influence. Participants will complete identical survey questionnaires for assessments at 3 time-points: pretest (baseline, before implementing the intervention), immediate posttest (following the end of the intervention), and six-month follow-up. The surveys will be administered in the classroom, during regular school hours.
223839562|NCT05476822|DIAGNOSTIC_TEST|Obtain antibody titers|Obtain blood samples for antibody titers at the time of enrollment, at three months, six months and nine months post vaccine booster (+/- ten days).
223839563|NCT06439953|DEVICE|Chlorhexidine gluconate solution|Evaluating the prophylactic use of Irrisept irrigation alone
223839564|NCT06439953|DRUG|Vancomycin|Evaluating the use of versus vancomycin-saline irrigation with or without topical vancomycin
223839565|NCT05663892|DRUG|Biktarvy 50/200/25 Tab|As the HIV ART, the combination of B/F/TAF, known as Biktarvy®, which is a widely available Single Tablet Regimen (STR) approved by Health Canada is the drug under investigation. Participants in groups 1 and 2 will either have to already be taking B/F/TAF or will be required to switch to it at baseline and they will self-administer B/F/TAF once daily in the morning, with or without food. Participants taking their dosage at night will be required to switch to a morning dose at the screening visit.
223839566|NCT05663892|DRUG|Estradiol Tablets|"Oral 17(beta)-estradiol as the estrogen and an anti-androgen (pharmaceutical \[e.g., spironolactone, cyproterone, finasteride, leuprolide, bicalutamide, dutasteride\] and/or surgical \[orchiectomy\] and/or medical \[hypogonadism\]).Doses of estradiol range from 1 mg to a maximum of 6 mg per day.~Participants must take 2 mg until the Month 2 Visit. Trans women participants in both groups 1 and 3 must divide their dose to twice a day (BID) if they are taking \> 2 mg per day and take 2 mg in the morning and the rest of the dosing in the evening. Participants who are only taking 2mg of estradiol once daily at night must switch their dosing to the morning. Participants who either crush or take the oral estradiol sublingually must switch to swallowing the tablet orally from the day after the screening visit until the Month 2 visit, otherwise the estradiol concentrations will be markedly higher."
223839567|NCT05992233|DEVICE|Dual wavelength low level laser|Application of double wavelength low level laser to the related area after tooth extraction.
223839568|NCT05992233|DEVICE|Placebo|Only red light applied.
223839569|NCT04018781|OTHER|medication reconciliation|"During hospitalization, the hospital pharmacist will carry out a pharmaceutical analysis for all patients included in the study, each time the prescription is changed and within a maximum of 24 hours (working days).~If necessary, in consultation with the doctor in charge of the patient, the pharmacist may also propose a pharmaceutical interview to the patient at any time during his hospitalisation (e.g. proposal for the de-prescription of benzodiazepines, Proton Pump Inhibitors, etc., according to the recommendations in force)."
223839570|NCT05144386|BIOLOGICAL|EBT-101|EBT-101 is a HIV-1-specific clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 gene editing system delivered by adenovirus-associated virus vector serotype 9 (AAV9) for intravenous (IV) administration
223839571|NCT03947957|DIAGNOSTIC_TEST|collection of expectoration, stools and blood|collection of expectoration, stools and blood
223839572|NCT01426620|DIETARY_SUPPLEMENT|Blueberry powder|The intervention consists of 2-3 packages (15 grams per package) of lyophilized blueberry powder, taken daily after mixing with natural yogurt, milk, water, or juice in combination with set dosage of docetaxel (35 milligrams per meter squared) administered intravenously every week for 4 cycles, 21-day cycles.
224264693|NCT01986647|BEHAVIORAL|Standard program - exercise leader|This is an impairment-based exercise program focusing on flexibility, strength and endurance and is taught by research staff who are PTs, PTAs, or exercise physiologists
224264694|NCT01986647|BEHAVIORAL|On the Move exercise - staff activity personnel|this is a group exercise program focusing on the timing and coordination of walking. The program is taught by a person from the facility that the research team trained.
224264695|NCT01986647|BEHAVIORAL|Standard program - staff activity personnel|This is an impairment-based exercise program focusing on flexibility, strength and endurance and is taught by a member of the facility that the research staff trained.
224264696|NCT02905435|DEVICE|Biodegradable Temporizing Matrix|The Biodegradable Temporizing Matrix (BTM) (also known as NovoSorb BTM) comprises a completely synthetic, sterile, integrating dermal component (porous biodegradable polyurethane foam) and a temporary epidermal barrier component (a non-biodegradable polyurethane sealing membrane). These layers are adhered with a biodegradable polyurethane bonding layer. BTM will be implanted and fixed into position to close a debrided burn wound. After a period of integration, the sealing membrane is removed and a split skin graft is applied.
224264697|NCT01885819|BIOLOGICAL|Autologous stromal vascular fraction cells|
224264698|NCT01442051|PROCEDURE|Acute Normovolemic Hemodilution|A predetermined volume of whole blood will be removed from these patients based on an established protocol. Crystalloid and colloid will then be infused to replace intravascular volume based on this protocol. Patients will be closely monitored intraoperatively with serum arterial hemoglobin (HgB) levels drawn hourly. Patients will be transfused with autologous blood if HgB \< 7.0 g/dL. If the volume of autologous blood has not been transfused within eight hours or by the completion of the procedure, the remainder will be transfused at that time. If the volume of autologous blood has been transfused and the patients require additional blood transfusions (HgB \<7g.dL), allogenic blood will be transfused thereafter. These transfusion triggers are based on common intraoperative practice patterns. Patients may also be transfused intraoperatively at any time for a HgB ≥ 7.0 g/dL based on the judgment of the attending anesthesiologist or surgeon but the reason will be recorded.
224264699|NCT03459339|DEVICE|Tethered Capsule Endomicroscopy (TCE)|Tethered Capsule Endomicroscopy will be used to detect Barrett's Esophagus
224264700|NCT00595153|DRUG|Pulmicort|inhaled powder of inhaled corticosteroid, 1 puff (180mcg) twice a day for 8-10 weeks
223839573|NCT04351750|OTHER|general exercise|The participants will receive training sessions twice a week for 8 weeks. General exercise includes aerobic exercise (stationary bike) and resistance training (thera-band, sandbags, dumbbell and swiss ball), and the intensity and progression of both aerobic and resistance exercises will be provided as recommended by the ACSM, and the exercise will individualized based on participant's HRR, 1 RM weight and Borg Scale of Perceived Exertion Scale (Borg RPE scale). An oximeter will be utilized to monitor the heart rate and SPO2 of the participants to ensure safety during the training session.
223839574|NCT04351750|OTHER|pelvic floor muscle training|Participants will do pelvic floor muscle training in different positions. Each session includes three sets of eight to twelve maximum voluntary contractions of pelvic floor muscle, with holding the contraction for 6 to 8 seconds, and if possible, to do three fast contractions at the end of each set.
223839575|NCT03623412|DIAGNOSTIC_TEST|75g oral glucose tolerance test|Women with one abnormal value in the OGTT during pregnancy (minor degree of glucose intolerance) will be offered a post-partum 75g GTT (Glucose Tolerance Test), similar to that offered to women with GDM
223839576|NCT03623412|DIAGNOSTIC_TEST|75g GTT|post-partum GTT
223839577|NCT05836662|OTHER|CrashCourse Concussion Education in Virtual Reality|The TeachAids concussion education, including CrashCourse and Brain Fly-Through, will be shown in 3D (via a Virtual Reality headset). These educations are the exact same content as the 2D versions viewed on a laptop, but the modality (via a VR headset) is different.
223839578|NCT01462201|DEVICE|Non Invasive Ultrasound|Each treatment session is estimated to take approximately 60 minutes and will be performed on a bi-weekly basis.
223839579|NCT05767164|PROCEDURE|cervical single open-door surgery|The patients were operated by the cervical single open-door surgery, which were used with the Centerpiece titanium plate to internal fixation.
223839580|NCT03701100|DEVICE|tDCS|tDCS
223839581|NCT05942404|PROCEDURE|mechanical bowel preparation|mechanical bowel preparation before surgery
223839582|NCT01333943|PROCEDURE|Study Group: Experimental|The study group will receive the saphenous nerve block, at the level of the adductor canal. The block will be under ultrasound guidance. The local anesthetic will be 15 ml of 0.5% bupivicaine. The study group will also receive a combined spinal epidural, with 2.5 ml of 0.5% bupivacaine as the spinal agent. Additional drugs include anti-emetics, specifically Ondansetron (4 mg).
223839583|NCT01333943|PROCEDURE|Control Group|The control group will receive the femoral nerve block. The block will be under ultrasound guidance. The local anesthetic will be 30 ml of 0.25% bupivicaine. The control group will also receive a combined spinal epidural, with 2.5 ml of 0.5% bupivacaine as the spinal agent. Additional drugs include anti-emetics, specifically Ondansetron (4 mg).
223839584|NCT03626974|BIOLOGICAL|Venipuncture|Venipuncture for blood collection
223839585|NCT03626974|DEVICE|Diffuser spreading odor|Diffuser will place under a Hood with an air-flow
223839586|NCT01353235|DRUG|Prednisolone|Patients assigned to corticotherapy arm, will receive oral prednisolone 1mg/kg/j as an add on therapy for a maximum of 10 days.
223839587|NCT01353235|DRUG|usual care|no drug administered
223839588|NCT03109717|DRUG|Monoamine Oxidase Inhibitor (MAOI)|Monoamine Oxidase Inhibitor
223839589|NCT04502667|DRUG|Cholecalciferol|1000U or 2000U every 24 hours orally
223839590|NCT05178394|DEVICE|Weightlifting belts and wrist straps|"The participants wore a weightlifting belt (Heavywear Nylon Contour Belt H9, North Carolina, USA) for the with weightlifting belt conditions and/or put on a pair of wrist straps (Versa Gripps Professional Series, Versa Gripps, Maine, USA) for the with wrist strap conditions. The steps involved in completing a conventional deadlift have been detailed in Holmes."
223839591|NCT05247840|DIAGNOSTIC_TEST|uroflowmetry|Uroflowmetry will be performed using a uroflow-cystometer (UroDoc Frytech) which determines Qmax, Qave and TQmax. Voided volume (in mL), voiding time (in sec), average and maximum urinary flow rate (Qave and Qmax in mL/sec), and time to maximum urinary flow (TQmax in sec) will be measured; urine flow acceleration (Qacc in mL/sec2) will be calculated. Qmax and Qave are defined according to the International Children's Continence Society. Voided volume will be measured by the uroflow-cystometer device; boys void in a standing, girls in a sitting position. Postvoid bladder diameter (mm) will be measured by ultrasonography and converted to bladder residual volume (mL). The device will be calibrated according to the prescribed instructions for use by a skilled technician. The examinations will take approximately 10 minutes.
223839592|NCT05247840|DIAGNOSTIC_TEST|Cardiovascular autonomic dysfunction test proposed by Ewing et al.|CAD will be assessed by five reproducible and standardized cardiovascular reflex tests described by Ewing et al. Three of the five tests assess parasympathetic function: heart rate response to deep breathing, to standing, and the Valsalva maneuver. Two tests evaluate sympathetic function which are blood pressure responses from lying to standing and at sustained handgrip. Each of these five tests is assigned a score of 0 for normal, 0.5 for borderline, and 1 for abnormal results. The sum of these 5 scores - which is the Ewing score - is used to assess severity of CAD. Patients having Ewing score ≥ 2 form the CAD + group, and patients who have less than 2 form the CAD - group.
223839593|NCT05247840|DIAGNOSTIC_TEST|peripheral nerve conduction test|Peripheral neuropathy will be evaluated by nerve conduction test. The device measures motor conduction in the lower extremities. It operates at two dedicated frequencies in order to perform a thick myelin sheath cordless fibre (5Hz) and thin myelinated nerve fibre (2000Hz) examination. The device will be calibrated according to the prescribed instructions for use by a skilled technician.
223839594|NCT01421771|DRUG|Antihypertensive Agents|"Study formulary consists of ACE/ARB, Beta Adrenergic Blocker, Calcium Channel Blocker, vasodilators, peripheral alpha antagonist and central alpha agonist.~ACE I or ARB is first line, the order of addition of subsequent medications is per the discretion of the investigator"
223839595|NCT01421771|OTHER|Dry weight Challenge|Reduce the estimated dry weight of the patient's progressively over 2 -week intervals until the dry weight challenge is no longer tolerated or the patient is at BP goal
224264701|NCT06204367|DIAGNOSTIC_TEST|Lung Ultrasonografisi|It is aimed to compare the agreement between lung ultrasonography and clinical score in the diagnosis and follow-up of newborn babies who are followed up in the neonatal intensive care unit due to bronchiolitis caused by frequently encountered RSV and other viral factors.
224264702|NCT01808716|DEVICE|Low-level laser therapy (808nm) and exercise|Use of low-level laser therapy(LLLT)or placebo-LLLT applied on biceps brachii for muscle damage recovery
224264703|NCT04737239|OTHER|Corticosteroid injections for CTS treatment|Treatment of carpel tunnel syndrome with corticosteroid injections for EMG mild and EMG negative patients
223839596|NCT01421771|DIETARY_SUPPLEMENT|Extend dialysis treatment time and re-challenge estimated dry weight|Extend dialysis treatment time and re-challenge estimated dry weight
223839597|NCT02091063|DRUG|ACY-1215|All patients will take the oral ACY-1215 160mg for 28 consecutive days on a 28-day treatment cycle. Each dose will be administered at least 1 hour after ingestion of food and followed by at least 4 ounces of water. Patients will be instructed not to ingest food or other oral medication for at least 2 hours after each ACY-1215 dose.
223839598|NCT06629129|DRUG|Latanoprost (0.005%)|MEAN OCULAR PERFUSION PRESSURE WAS MEASURED AND CORRELATED TO THE IOP AND OPTIC NERVE PERFUSION IN RESPONSE TO LATANOPROST TREATMENT
223839599|NCT02863159|DEVICE|Tecnis Multifocal 1-Piece IOL|+2.75D (ZKB00), +3.25D (ZKB00), +4.00D (ZMB00)
223839600|NCT03367364|BEHAVIORAL|Patient education bundle (PEB),|A charge nurse will intervene in real-time via an EHR-triggered alert when there is documentation that a dose of VTE prophylaxis medication is not given for any reason. The charge nurse will speak to the bedside nurse and one of them will provide the patient with the education bundle including one-on-one personalized discussion, supplemented by a 2-page paper handout and patient education video.
223839601|NCT03367364|BEHAVIORAL|Nurse feedback and coaching (NFC)|Nurse leadership (i.e. managers, directors) will provide data to all nurses on their personal clinical effectiveness with the proportion of doses of VTE prophylaxis administered. The data will have comparisons to their nurse peers on the same floor. Coaching for nurses will include one-on-one conversations with bedside nurses with lower performance than their peers.
223839602|NCT03259971|DIETARY_SUPPLEMENT|Probiotic-Lactobacillus plantarum PS128|Probiotic supplement of Lactobacillus plantarum PS128 , 1 tablet , twice a day , 12 hrs apart, lasting 2 months for Tic disorders and 4 months for Rett syndrome
223839603|NCT03259971|DIETARY_SUPPLEMENT|Placebo|placebo , 1 tablet , twice a day , 12 hrs apart, lasting 2 months for Tic disorders and 4 months for Rett syndrome
223839604|NCT04751513|OTHER|auricular acupressure|Pressure on auricular point of Shenmen (TF4), Sympathesis (AH6a), Subcortex (AT4), Endocrine (CO18), finger (SF1), and toe (AH2) of the ear.
223839605|NCT04953156|DRUG|Nitroglycerin|data will be retrieved from intraoperative medical records for the period from May 2020 to May 2021 for patients meeting the eligibility criteria who developed uncontrolled elevation of their blood pressure and received nitroglycerine infusion
223839606|NCT04953156|DRUG|Dexmedetomidine|All patients who develop uncontrolled elevation of their blood pressure and meeting the eligibility criteria from July 2021 to July 2022 will receive dexmedetomidine bolus of 1mic/kg over 20 minutes and then continuous infusion of 0.2-0.7 mic/kg/hour adjusted according to each patient hemodynamic response.
223839607|NCT00252785|DRUG|Budesonide/Formoterol|
223839608|NCT00252785|DRUG|Budesonide|
223839609|NCT00252785|DRUG|Theophylline|
223839610|NCT05169021|DRUG|Amlodipine folic acid 5.8mg+intensive antihypertensive therapy|"Amlodipine folic acid tablet 5.8mg, taken daily, in the morning after waking.~To achieve target blood pressure(SBP\<130mmHg), this study will provide, if needed, concurrent antihypertensive medications. Patients will be asked to discontinue all prior concurrent medications. Recommended treatment options are described below:~1. Add candesartan 4mg;~2. Add indapamide 2.5mg;~3. Increase dose of candesartan to 8mg;~4. Increase dose of amlodipine to 7.5mg-10mg."
223839611|NCT05169021|DRUG|Amlodipine folic acid 5.8mg+standard antihypertensive therapy|"Amlodipine folic acid tablet 5.8mg, taken daily, in the morning after waking.~To achieve target blood pressure (SBP:130-140mmHg), this study will provide, if needed, concurrent antihypertensive medications. Patients will be asked to discontinue all prior concurrent medications. Recommended treatment options are described below:~1. Add candesartan 4mg;~2. Add indapamide 2.5mg;~3. Increase dose of candesartan to 8mg;~4. Increase dose of amlodipine to 7.5mg-10mg."
223839612|NCT05169021|DRUG|Amlodipine+intensive antihypertensive therapy|"Amlodipine tablet 5.8mg, taken daily, in the morning after waking.~To achieve target blood pressure (SBP: 130-140 mmHg), this study will provide, if needed, concurrent antihypertensive medications. Patients will be asked to discontinue all prior concurrent medications. Recommended treatment options are described below:~1. Add candesartan 4mg;~2. Add indapamide 2.5mg;~3. Increase dose of candesartan to 8mg;~4. Increase dose of amlodipine to 7.5mg-10mg."
223839613|NCT05169021|DRUG|Amlodipine+standard antihypertensive therapy|"Amlodipine tablet 5.8mg, taken daily, in the morning after waking.~To achieve target blood pressure (SBP: 130-140 mmHg), this study will provide, if needed, concurrent antihypertensive medications. Patients will be asked to discontinue all prior concurrent medications. Recommended treatment options are described below:~1. Add candesartan 4mg;~2. Add indapamide 2.5mg;~3. Increase dose of candesartan to 8mg;~4. Increase dose of amlodipine to 7.5mg-10mg."
223839614|NCT05557019|DEVICE|Booster Balloon Catheter|The Booster balloon therapy (i.e. partial occlusion of the CS lumen with a subsequent backward pressure elevation without obstructing the CS blood flow) will start immediately after a successful PCI of the culprit coronary lesion in the LAD, with TIMI-II flow restoration. The Booster balloon therapy will then be continued for up to 90 min, but not less than 60 min.
223839615|NCT01391156|DRUG|3%Minoxidil lotion|3% Minoxidil lotion apply two times a day
223839616|NCT01391156|DRUG|3% Minoxidil with 0.1% Finasteride lotion|3% Minoxidil with 0.1% Finasteride lotion apply two times a day.
223839617|NCT06103461|PROCEDURE|Autologous fat grafting|Autologous fat grafted at contour defects with pigmentary changes
223839618|NCT01102478|DRUG|losartan potassium / hydrochlorothiazide|100 mg / 25 mg tablet
223839619|NCT05337969|DRUG|Metformin and Vildagliptin 850/50 mg|50 mg Vildagliptin + 850 mg Metformin as single-dose per study period
223839620|NCT02408562|OTHER|i.c.v. infusion of sNN0031 by an Implanted infusion system|I.c.v. infusion during 2 12d cycles separated by 3 mo. 6 mo follow-up after 2nd cycle.
223839621|NCT02408562|OTHER|i.c.v. infusion of aCSF by an Implanted infusion system|I.c.v. infusion during 2 12d cycles separated by 3 mo. 6 mo follow-up after 2nd cycle.
224264704|NCT05604209|BIOLOGICAL|ChAdOx1.HIVconsv62|Administered intramuscularly (IM) at Day 0
224264705|NCT05604209|BIOLOGICAL|ChAdOx1.tHIVconsv1|Administered intramuscularly (IM) at Day 0
224264706|NCT05604209|BIOLOGICAL|MVA.tHIVconsv4|Administered intramuscularly (IM) at Day 28
224264707|NCT05604209|BIOLOGICAL|MVA.tHIVconsv3|Administered intramuscularly (IM) at Day 28
224264708|NCT05604209|OTHER|Placebo|Administered at intramuscularly (IM) Day 0 and Day 28
224264709|NCT02082327|DRUG|IV migalastat HCl|
224264710|NCT02082327|DRUG|IV placebo|
224264711|NCT02082327|DRUG|oral migalastat HCl|
223839622|NCT05186090|BEHAVIORAL|24-week resistance exercise program|This group will perform a 24-week resistance exercise program. Participants will engage in 180 minutes/week of resistance exercise (3 supervised sessions peer week, 60 min/session). The training will consist of a combination of upper and lower body exercises using elastic bands and participants' body weight as the primary resistance. Exercise load and intensity will be based on the number of repetitions (i.e.,10-12 repetitions), resistance of the elastic bands, in ascending order with seven intensities, and also on the exercises' difficulty (i.e., three levels). The prescribed targeted intensity will reach 70-80% of the participants' maximum rating perceived exertion (i.e., 7-8 RPE).The progression (horizontal) will be standardized according to the execution time and RPE, and individualized according to execution speed and band resistance. Heart rate will be monitored in all sessions. Further, intrinsic motivation before and after session and sleep quality will be registered.
223839623|NCT03234621|OTHER|ventilator setting during one-lung ventilation|providing various tidal volumes according to the groups with constant PEEP
223839624|NCT03344289|DIAGNOSTIC_TEST|Colonoscopy|Participants will be randomized towards colonoscopy withdrawal with either LCI or HD-WLE
223839625|NCT03789552|DRUG|T89 capsule|T89 capsules (75mg)
223839626|NCT03789552|DRUG|Placebo capsule|Placebo capsules (0mg)
223839627|NCT04135144|OTHER|Group 1 (printed materials)|Exercises were given at least 3 times a week for 10 weeks and 1 set per day for a total of 6 weeks. individuals; normal joint movement exercises; neck flexion, lateral flexion, rotation, extension and retraction movements, isometric exercises; neck flexion, extension, lateral flexion and rotation movements and stretching exercises; neck lateral flexion, neck rotation and flexion movements were given.
223839628|NCT04135144|OTHER|Group 2 (video phone reminder)|Exercises were given at least 3 times a week for 10 weeks and 1 set per day for a total of 6 weeks. individuals; normal joint movement exercises; neck flexion, lateral flexion, rotation, extension and retraction movements, isometric exercises; neck flexion, extension, lateral flexion and rotation movements and stretching exercises; neck lateral flexion, neck rotation and flexion movements were given.
223839629|NCT02360345|DRUG|ONX-0801|
223839630|NCT05493722|OTHER|PS and OS stimulation order 1|PS, OS, OS
223839631|NCT05493722|OTHER|PS and OS stimulation order 2|OS, PS, OS
223839632|NCT05493722|OTHER|PS and OS stimulation order 3|OS, OS, PS
223839633|NCT05974826|BEHAVIORAL|the SI! Program for Secondary Schools (NCT03504059)|The SI! Program is implemented from 1st to 4th grade of Secondary Schools. A total of 12 hours of classroom intervention per academic year, organized through three educational units, and with active and participative methodologies, and complementary intervention in the family setting, at school and on teachers.
223839634|NCT05974826|BEHAVIORAL|the Fifty-Fifty Program (NCT02367963)|"1. Training stage: the focus is on improving individual health, through workshops (given in person by experts), and on the challenges of changing habits supervised and supported by the SHE Foundation~2. Peer-to-peer support group sessions: It is designed to make the subjects participate actively in their healthcare. Along the sessions subjects propose assumable health goals. Participants will be able to view videos with key messages from the workshops to continue the sustainability of the changes made, and the development of new ones. Peer-to-peer support group sessions have two phases: a) leaders will receive support from the Foundation; b) participants will become agents of change with the people around them, and also in their municipality with specific actions to promote health. The role of Foundation's will only be to monitor and resolve possible doubts."
224264712|NCT05812625|OTHER|Myokinetic stretching technique|Myokinetic stretching technique (MST) is a form of myofascial release, which involves active or passive stretching and movement as well as muscle energy techniques until a desirable release from the taut band is achieved.
224264713|NCT05812625|OTHER|Post Isometric Relaxation|Post Isometric Relaxation (PIR) is the effect of the decrease in muscle tone in a single or group of muscles, after a brief period of submaximal isometric contraction of the same muscle.
224264714|NCT00827840|DRUG|Paliperidone ER|3mg to 12mg of Paliperidone ER once a day
224264715|NCT00827840|DRUG|Risperidone|1 to 6 mg of risperidone once or twice a day
224264716|NCT06042296|OTHER|Expression of CD44, E-cadherin and PCNA|The investigators use primary antibodies against CD44 (1:50 dilution) and E-cadherin (1:200 dilution), and a human monoclonal antibody against PCNA (1:100 dilution) for antigen retrieval. Histopathological and immunohistochemical staining findings will be reported using a Nikon light microscope and an image analysis system (Nikon Instruments Europe BV)
224264717|NCT02986256|BEHAVIORAL|Taking pictures|Photograph of foot ulcer with transmission to referring nurse 1 time per week
224264718|NCT02986256|BEHAVIORAL|Visit at home|Home visit by the referring nurse every 15 days
224264719|NCT00112437|DRUG|Odanacatib|Odanacatib 3 mg, once weekly for 24 months
224264720|NCT00112437|DRUG|Odanacatib|Odanacatib 10 mg, once weekly for 24 months
224264721|NCT00112437|DRUG|Odanacatib|Odanacatib 25 mg, once weekly for 24 months
224264722|NCT00112437|DRUG|Odanacatib|Odanacatib 50 mg, once weekly for 24 months
224264723|NCT00112437|DIETARY_SUPPLEMENT|Vitamin D3|Vitamin D3, two 2800 IU weekly throughout the study
224264724|NCT00112437|DIETARY_SUPPLEMENT|Calcium Carbonate|Participants who have a calcium intake less than 1000 mg/day will receive daily calcium supplements providing 500 mg of elemental calcium.
224264725|NCT00112437|DRUG|Placebo|Placebo to Odanacatib 3 mg, 10 mg, 25 mg, or 50 once weekly for 24 months
224264726|NCT04783337|DIAGNOSTIC_TEST|HR-pQCT (high resolution computertomograph)|In addition to determining the bone density, a quantitative bone structure analysis with measurement of the number of thickness and distribution of the trabeculae can also be carried out. In addition, the finite element analysis (FEA) allows strength models of the examined bone to be created from the data of the hr-pqCTs. In this way, the osseous consolidation of the fracture can not only be observed, but also tested for resilience with the help of mathematical models.
224264727|NCT04783337|DIAGNOSTIC_TEST|Blood withdrawal|Bone remodeling blood marker: S-CTX (Crosslaps), S-TRA5b ( tartrate-resistant acid phosphatase), S-PINP (Procollagen type 1 amino-terminal propeptide), BALP, Calcium, parathyroid hormone, 25-OH-Vitamin D3 (HPLC)
224264728|NCT00531128|BEHAVIORAL|High/Low Sitosterol|
224264729|NCT02011828|DRUG|Ergocalciferol|50,000 IU/week
224264730|NCT02011828|DRUG|Placebo|Placebo tablet
224264731|NCT02440997|OTHER|aromatherapy|
224264732|NCT02440997|OTHER|foot bath|
223839635|NCT06534463|OTHER|All treatment regimen selections and usage will be determined by the physician based on clinical practice and/or the respective drug labels in China.|The dosage and duration of any drug in this study will be determined by the physician based on local clinical practice and local drug labels. The drugs in this study include, but are not limited to, Obinutuzumab, Rituximab, Bruton tyrosine kinase inhibitors, and Lenalidomide. In this non-interventional study, all treatment drug usage will be determined by the physician based on clinical practice and/or the respective drug labels in China.
223839636|NCT01551589|RADIATION|Involved Field Irradiation(IFI)|Involved Field Irradiation(IFI):only irradiate positive lymph node by CT or PET-CT Radiation: IMRT IMRT is administered with chemotherapy from week 1 to week 8PTV-GTV（primary tumor）：66-70Gy/33\~35F，once a day, 5 times per week PTV-CTV（Clinical target,primary tumor extended 3cm in Axial）：50-56Gy/33\~35f，once a day, 5 times per week PTV-GTVnd（positive node）：66-70Gy/33\~35F，once a day, 5 times per week.
223839637|NCT01551589|DRUG|docetaxel and cisplatin|Drug: docetaxel and cisplatin.Consists of docetaxel 60-80mg/m2 day 1 and cisplatin 25mg/m2 days 1 to 3, repeat every 3 weeks, for 2 cycles.
223839638|NCT01551589|RADIATION|Elective Nodal Irradiation (ENI)|The CTVn of ENI included the involved lymph node regions and clinically uninvolved lymph nodal stations according to the location of primary tumor. Lymph node station numbers 1/2/4/5/7, 2/4/5/7 and 4/5/7/16/17were included for upper, middle and lower thoracic ESCC in the ENI arm respectively.
223839639|NCT00635843|DEVICE|MAVERICK™ Disc|The MAVERICK™ disc is a spinal arthroplasty system and is intended to replace a damaged disc in the lumbar spine. It is a permanent implant used to maintain motion at the treated level and is inserted using an anterior surgical approach.
223839640|NCT00635843|DEVICE|LT-CAGE® Lumbar Tapered Fusion Device and INFUSE® Bone Graft|The control is the treatment with LT-CAGE® Lumbar Tapered Fusion Device and INFUSE® Bone Graft. It is commercially available for anterior lumbar spine interbody fusion procedures.
223839641|NCT03554187|DEVICE|Ultrasonic periodontal Debridement, with appropriate device|Dental procedure that includes therapeutic interventions such as scaling to remove calculus and all soft deposits, root planing to eliminate subgingival calculus and smooth the tooth surface, and root débridement to eliminate subgingival biofilm and lightly mineralized deposits.
223839642|NCT03554187|BIOLOGICAL|Analyzes of periodontopathogenic bacteria|Collection of plaque, to analyze the bacteria in the pocket
223839643|NCT03554187|GENETIC|IL1B test|susceptibility to periodontal disease (scratch swab onto the tongue) (no invasive)
223839644|NCT03554187|BIOLOGICAL|Salivary Sampling|Salivette to chew. To analyse salivary microbiota
223839645|NCT03554187|DEVICE|Halitosis measure|With appropriate device : halimeter
223839646|NCT03327506|DRUG|Alprazolam 0.5 mg|alprazolam 0,5 mg the eve and the morning of the surgery versus a preoperative hypnosis session
223839647|NCT05329389|DEVICE|StoneMD|StoneMD - is an app from App Store (for iOS) or Google Play (for Android).
223839648|NCT05329389|BEHAVIORAL|Schools of Patients|"The Schools for Patients with Urolithiasis is an online course for patients with urinary stone disease."
223839649|NCT05329389|BEHAVIORAL|Standard recommendation|Only fluid balance recommendations given at the day of discharge.
223839650|NCT01800344|DEVICE|LMA|
223839651|NCT01800344|DEVICE|Ultra|Ultra
223839652|NCT01511536|DRUG|Cabazitaxel XRP6258|Pharmaceutical form:solution Route of administration: injection
223839653|NCT01511536|DRUG|Abiraterone acetate|Pharmaceutical form:tablets Route of administration: oral
223839654|NCT01511536|DRUG|Prednisone 5 mg|Route of administration: oral
223839655|NCT00928460|PROCEDURE|Removal of preoperative electrocardiogram|A new preanesthesia evaluation strategy without routine ECG. Initially, all patients in the participating centers are assessed following the regular strategy (with routine ECG). The new strategy (without routine ECG) is rolled out to the participating hospitals sequentially. At the end of the trial all participating centers will use the new preoperative strategy.
223839656|NCT02357758|DRUG|Antibiotic Prophylaxis|Approved clinical dosage or antibiotics
223839657|NCT00688506|DEVICE|combined sono-electro-magnetic therapy (Sonodyn Medico Star)|twice a day for 10 minutes during 12 weeks
223839658|NCT00688506|DEVICE|placebo therapy (Placebo Sonodyn Medico Star)|twice a day for 10 minutes during 12 weeks
223839659|NCT01062984|PROCEDURE|Continuous Venovenous Hemofiltration (CVVH)|The NxStage system will be used for CVVH using the NxStage Cartridge Express dialyzer (polyethersulfone membrane). The blood flow rate will be set at 250 cc/min, and decreased at the discretion of the primary nephrologist's assessment of filter pressures and alarms. Replacement fluid will be delivered pre-filter for CVVH; the target effluent flow rate will be 35ml/kg/hr plus desired ultrafiltration (fluid removal). A maximum of 4.5 L/hr effluent will be prescribed to obese or hypercatabolic patients.
223839660|NCT01062984|PROCEDURE|Continuous Venovenous Hemodialysis (CVVHD)|The NxStage system will be used for CVVH and CVVHD using the NxStage Cartridge Express dialyzer (polyethersulfone membrane). The blood flow rate will be set at 250 cc/min, and decreased at the discretion of the primary nephrologist's assessment of filter pressures and alarms. Replacement fluid dialysate will be infused countercurrent to blood flow the target effluent flow rate will be 35ml/kg/hr plus desired ultrafiltration (fluid removal). A maximum of 4.5 L/hr effluent will be prescribed to obese or hypercatabolic patients.
223839661|NCT03696979|OTHER|Myofascial induction therapy|Myofascial induction therapy is a therapy concept focused on optimizing function and balance within the fascial system. The approach aims at global recovery, local correction and painless body use.
223839662|NCT03696979|OTHER|Therapeutic pain education|Therapeutic pain education is a training intervention that aims to reduce pain and disability by helping patients better understand the biological processes that support pain states. The neurobiology of pain and pain processed by the nervous system is explained to the patient in detail. Changes the patient's olab viewpoint to pain. For example, the patient believes that the cause of pain is caused by tissue damage. The patient who receives pain training understands that the cause of pain is the hypersensitive central nervous system. As a result, the patient's fear avoidance behavior decreases and he starts to move more easily. Because the sensitivity of the central nervous system will be alleviated, the perceived pain will decrease.
223839663|NCT06486935|DEVICE|IoT sensors|The proposed assistive Activities of Daily Living (ADL) monitoring system consists of ambient infrared sensors embedded seamlessly into the living environment, and a visualization app. Multimodality sensors with wireless data transmission capability will be installed at different locations (e.g. bedroom, kitchen, toilet, bathroom, living room, etc.) to monitor and detect the activities performed by individual elderly, such as cooking, sleeping, going to the bathroom, going out of the apartment or potential wandering, bathroom falls, etc. In addition, a micro-bend fiber optic pressure sensor mat will be placed unobtrusively below the bed mattress to measure the elderly's heart and respiratory rates during sleep. This mat helps provide information on the quality of sleep and sleep-wake rhythms of the elderly with sleep disorders. The collected data will then be transferred through a secured gateway with Raspberry Pi to a dedicated server for data processing and analysis.
223839664|NCT06486935|OTHER|Traditional/Manual elderly monitoring|Traditional elderly care without the use of IoT sensors.
223839665|NCT02688036|RADIATION|hypofractionated concurrent chemoradiotherapy|For patients with Limited Disease Small Cell Lung Cancer, 45Gy/15F of radiotherapy with concurrent chemotherapy will be used in experimental arm.
223839666|NCT02688036|RADIATION|conventionally fractionated concurrent chemoradiotherapy|For patients with Limited Disease Small Cell Lung Cancer, 60Gy/30F of radiotherapy with concurrent chemotherapy will be used in the control arm.
223839667|NCT02318225|DRUG|Misoprostol|"Misoprostol (400µg) will be administered vaginally 12 hours before office hysteroscopy. A rigid 2.9 mm hysteroscope with 30° forward oblique lens will be used in the procedure. The uterine cavity will be distended by warm saline at a pressure between 60-80 mmHg. All the procedures will be performed during the proliferative phase using the vaginoscopic approach as described by Betocchi and Selvaggi in 1997 . All the procedures will be diagnostic.~Pain intensity will be assessed by visual analogue scale during the examination and 30 minutes after the procedure. A visual analogue scale ranging from 0 to 10 will be used (zero indicates no pain and 10 indicates the worst possible experienced pain)."
223839668|NCT02318225|DRUG|Placebo|"Placebo will be administered vaginally 12 hours before office hysteroscopy. A rigid 2.9 mm hysteroscope with 30° forward oblique lens will be used in the procedure. The uterine cavity will be distended by warm saline at a pressure between 60-80 mmHg. All the procedures will be performed during the proliferative phase using the vaginoscopic approach as described by Betocchi and Selvaggi in 1997 . All the procedures will be diagnostic.~Pain intensity will be assessed by visual analogue scale during the examination and 30 minutes after the procedure. A visual analogue scale ranging from 0 to 10 will be used (zero indicates no pain and 10 indicates the worst possible experienced pain)."
223839669|NCT05701943|BEHAVIORAL|Home-Based|During the home-based intervention, aerobic training was performed using body weight exercises such as jumping jacks, standing box, side shift with floor touch, high knees, half burpee, and hook box (Borrega-Mouquinho et al., 2021).
223839670|NCT05701943|BEHAVIORAL|Gym-Based|During the gym-based intervention, aerobic training was performed on cycle ergometers (Star Trac Spinner Blade ION 7220, Vancouver, WA).
223839671|NCT00671593|BIOLOGICAL|House Dust Mite|"Dermatophagoides pteronyssinus: nebulized inhaled dosing is every 10 minutes per protocol limits at the following Allergen Concentration , (5 breaths of duration 0.8 seconds using a dosimeter) 0.0 AU, 0.3 AU/ml,~1 AU/ml, 3 AU/ml, 10 AU/ml, 30 AU/ml, 100 AU/ml, 300 AU/ml, 1000 AU/ml, 3000 AU/ml"
223839672|NCT00671593|BIOLOGICAL|Diluent|Greer lab allergen extract diluent (0.5% sodium chloride, 0.25% sodium bicarbonate, 50% glycerin (v/v), and 0.4% phenol)nebulized inhaled dosing is every 10 minutes per protocol limits at the following Diluent Concentration, (5 breaths of duration 0.8 seconds using a dosimeter)
223839673|NCT03681821|BEHAVIORAL|Transtheoretical Model (TTM)-based Intervention|Patients in the intervention group had access to conventional care, in addition to receiving the follow-up TTM-based intervention sessions. The intervention was provided by trained nurses, including one researcher and one ET nurse. Sessions were held in the meeting room in the unit four times: at baseline (T0), 2 days before discharge (T1), and at 1-month (T2) and 3-months (T3) after discharge, according to the assessment of their current stage of change delivered by filling the Stages of Change Subscale. Each face-to-face group contact lasted about 1 hour, depending on the complexity of the patients' problems.
223839674|NCT06438393|DIAGNOSTIC_TEST|CT coronary angiography and non-contrast CT|"A CTCA is an X-ray computed tomography of the coronary arteries that allows visualization of coronary plaques with high temporal and spatial resolution, however, it implies the use of iodine contrast and exposition to clinically significant ionizing radiation.~Non-contrast ECG-gated CT (calcium score - CCS image). A non-contrast cardiac CT for CCS can be performed very quickly with significantly lower radiation (\~6 times lower) than CTCA and without the need for contrast."
223839675|NCT05969106|DEVICE|Tandem Control-IQ|AID-system
223839676|NCT00765362|DEVICE|Encore Mobile-Bearing Knee|Used for primary total knee replacement
223839677|NCT03351361|DRUG|Nivolumab + Ipilimumab|Nivolumab dosed intravenously over 30 minutes at 240 mg every 2 weeks combined with Ipilimumab dosed intravenously over 30 minutes at 1 mg/kg every 6 weeks until disease progression, unacceptable toxicity, or other reasons specified in the protocol.
223839678|NCT03351361|DRUG|Chemotherapy|Doublet of chemotherapy according to standard of care carboplatin (AUC 5) with a dose that will be capped to 700 mg and pemetrexed (500 mg/m²) over 4 to 6 hours every three weeks (restricted to non-squamous histology) or carboplatin (AUC 6) with a dose that will be capped to 700 mg and paclitaxel (90 mg/m²) D1 D8 D15 over 4 to 6 hours every 4 weeks, with a maximum of 4 cycles of carboplatin based doublet, and the possibility to use maintenance with pemetrexed.
223839679|NCT05564182|DEVICE|High intensity laser therapy|HILT will be applied to the patients five times a week for a period of three weeks and one session per day for a total of 15 sessions by a physical therapy technician who is experienced in using a laser device (BTL-6000 high intensity laser 12 W, Stevenage, Hertfordshire, England). It will be used in the rotator cuff muscles area in two stages, Phase I and Phase II. For analgesic effect in phase I. Phase II will also be applied for the biostimulation effect.
224264733|NCT03541252|DRUG|AFL-assisted cisplatin+5-FU|Patients will receive AFL-assisted cisplatin+5-FU as a treatment for their BCC. In brief, treatment areas consisting of tumors and a 5 mm margin will undergo CO2 laser exposure followed by 60 min topical application of a marketed and commercially available IV cisplatin solution (0.1%) After removal of cisplatin, a commercially distributed 5-FU cream (5%) will be applied to the treatment area at a dose of 0.125 ml per cm2 and left under occlusion. After skin evaluations on Day 1 and 5 after treatment, the same 5-FU dose will be applied, again left under occlusion. In total, 5-FU will remain on the skin for 7 days after AFL treatment whereafter it will be washed off. An additional repeat AFL-cisplatin+5-FU treatment on Day 30 will be offered if tumors persist, based on clinical evaluation and imaging on Day 30.
223839680|NCT05564182|OTHER|Therapeutic Exercise|Therapeutic Exercise As therapeutic exercise program; A multidisciplinary stroke rehabilitation program will be implemented in the presence of a specialist physiotherapist. In addition, a therapeutic exercise program including passive, actively supported and active ROM exercises, stretching, strengthening and mobilization exercises will be applied to all patients by physiotherapists according to the level of pain and limitation.It was planned to implement a total of 15 sessions 5 days a week for 3 weeks, for approximately 30 minutes.
223839681|NCT03337347|DEVICE|CTC/DTC count|The presence of CTCs/DTCs in the peripheral blood and/or bone marrow may identify colorectal cancer patients with high risk of disease recurrence who may benefit from adjuvant therapy.
223839682|NCT03941938|PROCEDURE|Cyanoacrylate reinforcement|Anastomosis Reinforcement with with nebulization of 1cc of glue on the anastomosis line
223839683|NCT03941938|PROCEDURE|No reinforcement|Nothing applied on the anastomosis line
223839684|NCT00557505|DRUG|PF-03732010|IV infusion. Escalating dose levels, starting at 0.5 mg/kg to Maximum Tolerated Dose. Cycle length of 4 weeks for first cycle, and 2 weekly for subsequently cycles was originally explored, yet based on emerging PK data the Cycle 1 duration is 2 weeks and then weekly. Number of Cycles: Until Progression or unacceptable toxicity develops.
223839685|NCT05608720|BEHAVIORAL|Information Booklet|Information Booklet prior to the dental visit
223839686|NCT04873713|DEVICE|Magnetic Tape® aplicación|Magnetic tape® is applied without creating any tension over low back
223839687|NCT04873713|DEVICE|Kinesiology Tape|Kinesiology Tape is applied without creating any tension over low back
223839688|NCT02782429|DRUG|Ketamine|
223839689|NCT02782429|OTHER|Saline|
223839690|NCT02332317|BEHAVIORAL|Palliative rehabilitation|12-week individually customized, specialized palliative rehabilitation program
223839691|NCT03457194|BIOLOGICAL|Quadrivalent Influenza Vaccine|Inactivated quadrivalent influenza vaccine that is used for active immunisation against influenza A, B virus strains (contained in vaccine). Single dose administration by intramuscular injection to all enrolled pregnant women as part of routine antenatal care.
223839692|NCT03457194|BIOLOGICAL|DTP Vaccine (Multiple Actives)|Pertussis vaccine acellular combined with diphtheria and tetanus toxoids. Single dose administration by intramuscular injection, to all enrolled pregnant women who are 28 weeks or greater gestation at time of enrolment, as part of routine antenatal care.
223839693|NCT03914339|PROCEDURE|Periodontal and orthodontic treatment|Eighteen periodontally compromised patients who give be given both periodontal and orthodontic treatment
223839694|NCT03914339|PROCEDURE|periodontal treatment|Eighteen periodontally compromised patients who give be given periodontal treatment alone.
223839695|NCT06270511|DRUG|S-337395|Administered as an oral suspension.
223839696|NCT06270511|DRUG|Placebo|Administered as an oral suspension.
223839697|NCT04710693|DIAGNOSTIC_TEST|CAD polyp-detection system|Software will be used during the procedure to aid the detection of polyps during the procedure.
223839698|NCT03244137|OTHER|Pulmonary rehabilitation|See group description.
223839699|NCT01800409|DEVICE|AFES|During the stimulation sessions electrical stimulation will be applied for 40 minutes per day, 5 days per week for a total of 8 weeks
223839700|NCT00099424|BEHAVIORAL|High-intensity exercise training|
223839701|NCT01418092|DRUG|ALKS 37|Capsules for oral administration
223839702|NCT01418092|DRUG|Placebo|Capsules for oral administration
223839703|NCT00518752|PROCEDURE|Standard Oral Care|Patients in this arm will receive standard oral care with manual brushes and routine oral hygiene products twice a day
223839704|NCT00518752|PROCEDURE|Comprehensive Oral Care|Patients will receive a comprehensive oral care protocol using mechanical brushes and oral care products formulated for patients with a dry mouth twice a day
223839705|NCT02786979|DRUG|Beraprost|Oral
223839706|NCT02786979|DRUG|Aspirin|Oral
223839707|NCT04850144|DRUG|Tiotropium Bromide Monohydrate|Tiotropium Easyhaler 10 µg/dose Product variant D
223839708|NCT04850144|DRUG|Tiotropium Bromide Monohydrate|Tiotropium Easyhaler 10 µg/dose Product variant E
223839709|NCT04850144|DRUG|Tiotropium Bromide Monohydrate|Tiotropium Easyhaler 10 µg/dose Product variant F
223839710|NCT04850144|DRUG|Tiotropium Bromide Monohydrate|Tiotropium Easyhaler 10 µg/dose Product variant G
223839711|NCT04850144|DRUG|Tiotropium Bromide Monohydrate|Tiotropium Easyhaler 10 µg/dose Product variant H
223839712|NCT04850144|DRUG|Tiotropium Bromide Monohydrate|Spiriva 18 µg/capsule inhaled via Handihaler
224264734|NCT02577458|DRUG|CM082|CM082 tablets taken orally once a day on 28-day cycles
224264735|NCT02577458|DRUG|Everolimus|Everolimus tablets taken orally once a day on 28-day cycles
224264736|NCT00207662|DRUG|infliximab or placebo|
224264737|NCT04371224|DRUG|Irinotecan Liposomal Injection [Onivyde]|both arm
224264738|NCT04371224|DRUG|Capecitabine|NaliCap
224264739|NCT04371224|DRUG|5-fluorouracil|NAPOLI
224264740|NCT04371224|DRUG|Leucovorin|NAPOLI
224264741|NCT04584749|DRUG|Lidocaine Iv|"2% lidocaine or 0.9% physiological saline will be used as placebo, and it will be administered as a bolus during anesthetic induction equivalent to 1.5 mg / kg of lidocaine. After induction, an intravenous infusion will be started at 0.1 ml / kg / h of the study preparation, equivalent to 2mg / kg / h of lidocaine.~20 ml syringe for induction and two 50 ml syringes for anesthetic maintenance containing 2% Lidocaine ."
224264742|NCT04979143|PROCEDURE|Surgical Approach|The surgical laser used will be randomized. All lasers used during this trial are all FDA approved devices and used per routine clinical care.
224264743|NCT00227370|DRUG|valganciclovir|valgan 900mg QD x 9 months post lung transplant
224264744|NCT00227370|OTHER|Placebo|
224264745|NCT03846193|BIOLOGICAL|GT005|GT005 is a recombinant, non-replicating AAV2 expressing human complement factor I (CFI). GT005 was administered as a single time subretinal injection into the study eye of subjects allocated to one of the two GT005 doses.
224264746|NCT03846193|DEVICE|GT005 / Device: Orbit™ Subretinal Delivery System|"GT005 is a recombinant, non-replicating AAV2 expressing human complement factor I (CFI).~A single dose of GT005 was administered with subretinal injection via suprachoroidal cannulation approach.~Device: Orbit™ Subretinal Delivery System"
224264747|NCT04693429|DRUG|Bepotastine Besilate|Bepotastine Besilate 1.5% QID (quater in die) for 7 days
223839713|NCT04850144|DRUG|Tiotropium Easyhaler with oral activated charcoal|The charcoal suspension will be administered orally with Tiotropium Easyhaler 10 µg/dose Product variant F
223839714|NCT01244763|DRUG|Roxadustat|Oral capsule
223839715|NCT06090435|BEHAVIORAL|Therapeutic exercise plus motor imagery|Therapeutic exercise programme (aerobic exercise and strengthening exercise) to which is added a motor imagery intervention (which consists of imagining the same movements but not performing them for real).
223839716|NCT06090435|BEHAVIORAL|Therapeutic exercise plus action observation|Therapeutic exercise programme (aerobic exercise and strengthening exercise) to which is added an action observation intervention (which consists of observing the same movements but not performing them for real).
223839717|NCT06090435|BEHAVIORAL|Therapeutic exercise|Therapeutic exercise programme (aerobic exercise and strengthening exercise) to which is added a sham action observation intervention (which consists of observing planets in space).
223839718|NCT00519779|DIETARY_SUPPLEMENT|omega-3 supplementation|2.5 g/day omega-3
223839719|NCT00519779|DIETARY_SUPPLEMENT|Oral omega-3 fish oil placebo|to match experimental dosage
223839720|NCT05908448|DEVICE|13 CGM (continuous glucose monitor)|The I3 CGM consists of three main components: a Sensor Pack (Applicator-Sensor assembly), a Transmitter Pack (with Bluetooth Low Energy (BLE)) and a mobile application (I3 CGM App). The user can view their glucose data on the I3 CGM App running on a compatible mobile device.
223839721|NCT03330119|DRUG|Alternate Management|With the alternate management protocol, the pre-operative order set is the same, with the addition of a single preoperative dose of acetaminophen 1 g IV x1, gabapentin 600 mg PO x1, and ondansetron 8 mg IV x1. Post-operatively, patients receive the same ketorolac 30mg x 9 doses every 6 hours, as well as acetaminophen 975 mg every 6 hours, both given standing. These two are timed so the patient is receiving one of the two medications every 3 hours during their inpatient stay. After 9 doses of ketorolac, the patient receives 600mg of ibuprofen PO, also given standing, instead of the ketorolac. If the patient requires narcotics, they may receive them on an as needed basis. IV fluids are running at 80 cc/ hour. Patients are encouraged to ambulate, including the evening of the surgery, have their foley catheter removed 12 hours post-operatively, and can have a regular diet immediately.
223839722|NCT03330119|DRUG|Control|The regular Lankenau cesarean section order set includes routine vital signs, labs, IV fluids, and fetal heart monitoring. Post standard cesarean section orders include IV fluids running at 125 cc/ hour, along with routine post-partum care. In terms of pain control, most patients receive 9 doses of 30mg of IV ketorolac every 6 hours, along with hydromorphone, oxycodone/acetaminophen, or a hydromorphone PCA, per patient or attending request.
223839723|NCT05284422|PROCEDURE|Traditional Peripheral venous catheter insertion|Insertion of a short catheter in a peripheral vein with the help of visualization palpation
223839724|NCT05284422|PROCEDURE|Ultrasound-guided insertion of a peripheral venous catheter|Insertion of a short catheter in a peripheral vein with the help of an ultrasound device
223839725|NCT06429566|DRUG|GB001 recombinant peptide spray low dose group、high dose group|Administrated oral spray. Each subject will take oral GB001 recombinant peptide spray 4 times a day, 4 sprays each time, no more than 29 times，The dosage of the group is 0.108mg/spray for low dose group and 0.216mg/spray for high dose group.
223839726|NCT06429566|DRUG|GB001 recombinant peptide spray placebo|Administrated oral spray.Each subject will take oral GB001 recombinant peptide spray placebo 4 times a day, 4 sprays each time, no more than 29 times
223839727|NCT03748264|OTHER|Standard of Care|In the standard of care or the control condition, participants will receive the sites therapy initiation standard of care for setting up and educating the participants on their Obstructive Sleep Apnea, mask, and device information. This group will use a wireless modem that is attached to the PAP device and uploads adherence and other therapy information daily to a secured database (Encore Anywhere). With this method, therapy information is not directly available to the participant but will continuously be available to site staff personnel.
223839728|NCT03748264|DEVICE|DreamMapper Application|The DreamMapper application condition will receive the site's therapy initiation standard of care and will also download the DreamMapper application on their iPhone or Android smart phone. Therapy information and educational material will be available continuously to the participant with DreamMapper through the application. Study personnel will have access to adherence and therapy information continuously.
223839729|NCT03748264|DEVICE|DreamMapper Application with Therapist Assist|The DreamMapper with Therapist Assist will review the Therapist Assist automated educational material on Obstructive Sleep Apnea, their Philips Respironics mask and DreamMapper. These participants will download the DreamMapper application onto their iPhone or Android smart phone. Therapy information and educational material will be available continuously to the participant with DreamMapper. Study personnel will have access to adherence and therapy information continuously.
223839730|NCT03818997|DRUG|DKN-01|Patient will receive DKN-01 300 mg IV every 2 weeks
223839731|NCT03818997|DRUG|Atezolizumab|Patient will receive Atezolizumab 840 mg IV every 2 weeks until PD
223839732|NCT03818997|DRUG|Paclitaxel|Patient will receive Paclitaxel 80 mg/m2 IV on day 1, 8 and 15 of a 28 day cycle until PD
223839733|NCT05506644|OTHER|HRV-Biofeedback/Mind-Body Therapy|A 7-week protocol using real-time feedback on heart rate variability
223839734|NCT02383550|OTHER|Observational Cognitive assessments|Observational
223839735|NCT04135495|DRUG|ELX-02|ELX-02 is a small molecule, new chemical entity being developed for the treatment of genetic diseases caused by nonsense mutations. ELX-02 is a eukaroyotic ribosomal selective glycoside (ERSG)
223839736|NCT04135495|DRUG|Ivacaftor|CFTR potentiator
223839737|NCT05256043|DIAGNOSTIC_TEST|Diabetes Diagnosis|HbA1c \> 6.5%
223839738|NCT00060827|DEVICE|Head Impact Recording Technology (HIRT)|
223839739|NCT00310713|BIOLOGICAL|Meningococcal C conjugate vaccine|Group 1: Meningococcal C conjugate vaccine dose boost on Visit 6 (day 0), blood sample on Visit 7 (day 3 post immunization) Group 2: Meningococcal C conjugate vaccine dose boost on Visit 6 (day 0), blood sample on Visit 7 (day 5 post immunization) Group 3: Meningococcal C conjugate vaccine dose boost on Visit 6 (day 0), blood sample on Visit 7 (day 7 post immunization) Group 4: Meningococcal C conjugate vaccine dose boost on Visit 6 (day 0), blood sample on Visit 7 (day 9 post immunization) Group 5: Meningococcal C conjugate vaccine dose boost on Visit 6 (day 0), blood sample on Visit 7 (day 10 post immunization)
223839740|NCT00457080|DEVICE|Alaris ETCO2 monitor - cont. resp. rate, & apnea events|
223839741|NCT04902170|PROCEDURE|25 gauge pars plana vitrectomy|25 gauge pars plana vitrectomy
223839742|NCT06303830|DIETARY_SUPPLEMENT|Sodium nitrate|Sodium Nitrate
223839743|NCT05677867|DRUG|Formulation A (PF-07081532 20 mg plus 60 mg)|Formulation A: administered as a 20 mg immediate release tablet and a 60 mg immediate release tablet
223839744|NCT05677867|DRUG|Formulation B (PF-07081532 80 mg)|Formulation B: administered as a 80 mg immediate release tablet
223839745|NCT02628522|OTHER|ADRCs therapy|Patients with chronic anal fissures will receive one treatment of local injections of fat enriched with adipose derived regenerative cells starting from December 2014.
223839746|NCT02628522|DEVICE|Celution|Adipose derived regenerative cell isolation
223839747|NCT02628522|DEVICE|Tulip cannulas|Lipoaspiration
223839748|NCT02628522|OTHER|20mL Lidocaine 2% and Epinephrine 1:100 000|Infiltration prior to liposuction
223839749|NCT05382455|OTHER|Delphi Questionnaire|"An invitation email, including a link to the survey, will be sent to the panel of experts in Ai in healthcare.~The Delphi questionnaire will be administered via Welphi.com. In the first survey, panel members will outline the AI reporting standards in systematic reviews and objectively identify critical aspects of reporting methodology and results.~In subsequent surveys, the expert panel will evaluate the modified criteria using a 1 to 5-point Likert scale with space provided for suggested edits and comments. Multiple rounds will be conducted until consensus is reached. After each round of Likert responses, the study team will calculate the agreement and distribution of responses. Likert responses will be dichotomized with positive values indicating agreement and neutral or negative values indicating disagreement.~For the questions that do not reach a consensus of more than 80% in the first round or need further explanation, additional rounds of the survey may be performed."
223839750|NCT02476643|OTHER|Integrative Therapy|This group receives an integrative therapy at the Department of Internal and Integrative Medicine, i.e. a combination of conventional diagnostic and therapeutic interventions with specific naturopathic, and complementary medicine approaches, and physical therapy.
223839751|NCT01275053|DRUG|leptin|0.01mg/kg
223839752|NCT03393910|DIAGNOSTIC_TEST|Experimental Pelvic Exam|"The pelvic exam will be completed in the following order: external, speculum, bimanual exam in the standard group. In the Experimental group the pelvic exam will be done with external xam, bimanual exam then speculum exam."
223839753|NCT04558099|BEHAVIORAL|MBSR|Described previously
223839754|NCT02818608|DEVICE|Functional Electrical Stimulation (FES)|Functional Electrical Stimulation (FES) + Sham Transcranial direct brain stimulation (tDCS)
223839755|NCT02818608|DEVICE|Combination of Transcranial direct brain stimulation (tDCS) and FES|Real Functional Electrical Stimulation (FES) + Real Transcranial direct brain stimulation (tDCS)
223839756|NCT05180812|DEVICE|ExoNet Tuned to Gravity Support|This study's primary goal is to test the safety, feasibility, and efficacy of the ExoNET device developed in the Robotics Lab at the Shirley Ryan AbilityLab. We want to observe if individuals using the ExoNET tuned to gravity support will notice a reduction in bicep muscle activity, leading to an improvement in functional outcome measures in stroke patients.
223839757|NCT01615861|PROCEDURE|IOL implantation|Micro-incision phacoemulsification cataract surgery (C-MICS) and IOL implantation with 1.8mm cartridge tip insertion technique.
223839758|NCT01615861|DEVICE|IOL Implantation|Micro-incision phacoemulsification cataract surgery (B-MICS) and IOL implantation with 1.4mm wound-assist insertion technique.
223839759|NCT02600858|BEHAVIORAL|Upper limb feeding training|"Participants will spoon two raw kidney beans at a time from a center proximal start cup to three distal target cups positioned 16 cm away at 45°, 90° and 135° around the start cup as fast as possible using their non-dominant hand. Spooning two beans between the start cup and a target cup is considered one repetition; each trial will consist of 15 repetitions. Participants will perform 50 trials per day for 3 consecutive days."
223839760|NCT06392516|DRUG|Ketoacid|250 ml ketoacid two hours before the hemodialysis session ended
223839761|NCT02724787|BEHAVIORAL|Manage Emotions to Reduce Aggression (MERA)|MERA is a 3-session group treatment that teaches Veterans the purpose of emotions, how trauma and combat can increase emotions, and how to better regulate them. The skills use cognitive-behavioral and mindfulness techniques to help Veteran better regulate their emotions. These skills are commonly used in clinical practice, but have not been delivered in 3 sessions.
223839762|NCT04081298|BEHAVIORAL|Health Education|Attend nutrition and PA classes, and cooking sessions
223839763|NCT04081298|OTHER|Physical Activity|Participate in physical activities
223839764|NCT04081298|OTHER|Health Promotion and Education: Text Messages|Receive motivational text messages
223839765|NCT04081298|OTHER|Health Promotion and Education: Web Site|Given access to nutrition website
223839766|NCT04081298|OTHER|Quality-of-Life Assessment|Ancillary studies
223839767|NCT04081298|OTHER|Questionnaire Administration|Ancillary studies
223839768|NCT03285451|DIAGNOSTIC_TEST|submental ultrasonography|Submental ultrasound, the noninvasive and convenient tool, has been widely applied to measure the tongue base thickness in patients with obstructive sleep apnea, so as to predict the severity and relationship with upper airway collapse.
223839769|NCT01537354|DRUG|Curosurf®|Initial dose is 2.5ml/kg (200 mg/kg phospholipid) administered via endotracheal tube. Subsequent doses if needed are 1.25 mL/kg (100 mg/kg phospholipids).
223839770|NCT01537354|DRUG|Survanta®|Initial dose is 4 mL/kg (100 mg/kg phospholipids) administered via endotracheal tube. Subsequent doses if needed are 4 mL/kg (100 mg/kg phospholipids).
223839771|NCT01242943|DRUG|131I-L19SIP Radioimmunotherapy (RIT)|"Dosimetric evaluation with 131I-L19SIP will be performed to assess eligibility for Radioimmunotherapy.~Phase I: Patients eligible for Radioimmunotherapy will receive escalating doses of therapeutic 131I-L19SIP administration (intravenously) at the following dosages (expressed in mCi/m2): 111, 139 and 167."
223839772|NCT01150851|OTHER|caloric restriction|10 to 15% reduction in total daily calories (300 to 500 kcal reduction) from the usual daily energy consumption for 4 months duration
223839773|NCT01150851|OTHER|aerobic exercise|supervised physical activity for a maximum of 30-45 minutes, 3 times per week for 4 months duration
223839774|NCT03497182|DEVICE|Breath sample collection|Subject exhales into breath collection container.
223839775|NCT00282321|BEHAVIORAL|High Protein diet|
223839776|NCT00282321|BEHAVIORAL|High carbohydrate diet|
223839777|NCT04232748|DRUG|first line systemic treatment for colorectal cancer|systemic chemotherapy (capecitabine or fluorouracil, oxaliplatin or irinotecan, with or without biological agents including cetuximab, bevacizumab, or panitumumab.
223839778|NCT05471193|DIAGNOSTIC_TEST|Machine Learning Prediction|Machine Learning Prediction
223839779|NCT04368195|PROCEDURE|Erector spinae block|Erector Spinae Plane Block (ESPB) - first recently described for the treatment of thoracic neuropathic pain, is a peri-paravertebral regional anesthesia technique that has since been reported as an effective technique for prevention of postoperative pain in various surgeries (10-12). In ESPB, local anesthetic is reported to be administered in to the interfascial plane between the transverse process of the vertebra and the erector spinae muscles, spreading to multiple paravertebral spaces.
223839780|NCT01980979|DRUG|Remodulin|Subcutaneous (SQ) remodulin will be initiated at 1.25 ng/kg/min, and increased by 2-6 ng/kg/min weekly to a target dose of 40 ng/kg/min. If the initial infusion rate cannot be tolerated it will be reduced to 0.625 ng/kg/min. If subjects cannot tolerate the SQ therapy, we will attempt to switch to IV therapy.
223839781|NCT01138319|GENETIC|DNA analysis|
223839782|NCT01138319|GENETIC|mutation analysis|
223839783|NCT01138319|GENETIC|polymerase chain reaction|
223839784|NCT01138319|OTHER|laboratory biomarker analysis|
223839785|NCT03150680|GENETIC|SNPs associated with CAD, SNPs associated with pharmacological response to clopidogrel and statins|Genotyping will be carried out by Next-Generation Sequencing (NGS)
223839786|NCT04555629|OTHER|Advanced Cognitive Stimulation Therapy Hong Kong|A modified version of Cognitive Stimulation Therapy for people with moderate to severe dementia translated and culturally adapted for the Hong Kong Chinese population.
223839787|NCT05562843|BIOLOGICAL|Autologous Cellular Therapy with PRP-PC|In this study, cells will be harvested from the patient from the peripheral blood, isolated and concentrated using centrifugation, then returned to the patient same day via the peripheral circulation.
223839788|NCT02059161|DRUG|MK-1293|MK-1293 dosed subcutaneously once daily at bedtime for 52 weeks. Initial dose will be determined based on the participant's previous insulin therapy. Thereafter, the dose will be titrated to the suggested target for fasting fingerstick glucose levels. MK-1293 dosing once daily at times other than bedtime will be permitted for participants with a previously established dosing time.
223839789|NCT02059161|DRUG|Lantus™|Lantus™ dosed subcutaneously once daily at bedtime for 52 weeks. Initial dose will be determined based on the participant's previous insulin therapy. Thereafter, the dose will be titrated to the suggested target for fasting fingerstick glucose levels. Lantus™ dosing once daily at times other than bedtime will be permitted for participants with a previously established dosing time.
223839790|NCT02059161|DRUG|Prandial Insulin|Participants will continue their prandial insulin during the study.
223839791|NCT00324532|DRUG|ProBactrix|
223839792|NCT00980707|DRUG|Inhaled corticosteroid (fluticasone)|inhaled fluticasone 220 ug/bid
223839793|NCT00905060|BIOLOGICAL|HSPPC-96|Autologous tumor-derived heat shock protein peptide-complex (HSPPC-96) administered at 25 μg per dose injected intradermally once weekly for 4 consecutive weeks and monthly following standard treatment with radiation and temozolomide.
223839794|NCT00905060|DRUG|Temozolomide|Maintenance temozolomide treatment is given 2 weeks after administration of the fourth vaccine at an initial dose of 150 mg per square meter (mg/m2) for 5 consecutive days in a 28-day cycle. The dose was increased to 200 mg/m2 for 5 days in subsequent cycles.
223839795|NCT00905060|PROCEDURE|Standard Surgical Resection|Patients will undergo standard surgical resection of intracranial tumor
223839796|NCT02319447|BEHAVIORAL|Additional education|"Our Intervention includes a 60-90 minute educational seminar, entitled Destination: Transplant, featuring live speakers, delivered to small groups of Black kidney transplant candidates and their family and friends. Topics include: 1) basic facts about Chronic Kidney Disease (CKD), transplant, and the waiting list; 2) the experience of receiving a LDKT transplant (by a Black LDKT recipient); 3) the experience of serving as a living kidney donor (by a Black living kidney donor); and 4) strategies to increase the chances of getting a transplant sooner. Participants receive monthly mailed, written information for 9 months and a follow-up phone call from a transplant educator, 3 months after attending the seminar."
223839797|NCT00280449|BEHAVIORAL|strengths-based case managed proactive service model|
223839798|NCT01356238|OTHER|MRC media|Culture media
223839799|NCT01356238|OTHER|Sydney IVF media|Culture media
223839800|NCT01306708|DRUG|amitriptyline|Nerve suprascapular blockade with local anaesthetic agent (novabupivacaine 0.25%, 10 ml, once per week) + oral tricyclic antidepressant (amitriptyline 25 mg, twice per day, for 14 days);
223839801|NCT01451060|DRUG|Metaraminol|It will be used a dose of 0.5 mg to any fall in blood pressure of the fetus until birth
223839802|NCT01451060|DRUG|Ephedrine|It will be used at any one dose de1mg fall in blood pressure of the fetus until birth
223839803|NCT03293485|DRUG|Imipenem+Cilastatin/Relebactam|Imipenem+Cilastatin/Relebactam 200/100 mg to 500/250 mg, depending on renal function, 30-minute IV infusion once every 6 hours
223839804|NCT03790293|DRUG|Rituximab|Patient was enrolled into the RITUXIMAB 3 study in the arm Rituximab in association with low corticosteroids'therapy
223839805|NCT03790293|DRUG|corticosteroids'therapy|Patient was enrolled into the RITUXIMAB 3 study in the arm Patient was enrolled into the RITUXIMAB 3 study in the arm standard corticosteroid
223839806|NCT01364961|DIETARY_SUPPLEMENT|Resveratrol capsules|2 x 75 mg resveratrol each day, for 4 weeks
223839807|NCT01325987|DIETARY_SUPPLEMENT|Vitamin D2|Subjects with vitamin D deficiency (serum 25(OH)D \<20ng/ml) will receive an 8 week of vitamin D treatment (50,000 IU oral vitamin D2/once per week) vs. placebo. All subjects will continue their existing hypoglycemic regimen.
223839808|NCT01325987|OTHER|Sugar pill|"1. group: vitamin D2 50000 IU weekly once for 8 weeks~2. nd group: placebo weekly once for 8 weeks"
223839809|NCT01228383|BIOLOGICAL|Rabies virus-specific monoclonal antibodies|CL184 20 IU/kg intramuscularly on Day 0.
223839810|NCT01228383|BIOLOGICAL|human polyclonal rabies immune globulin (HRIG)|HRIG 20 IU/kg intramuscularly on Day 0.
223839811|NCT01228383|BIOLOGICAL|Placebo|Placebo intramuscularly on Day 0.
223839812|NCT01228383|BIOLOGICAL|Human diploid cell vaccine (HDCV)|Rabies vaccine (HDCV) given on Days 0, 3, 7, 14, and 28.
223839813|NCT01228383|BIOLOGICAL|Purified verocell rabies vaccine (PVRV)|Rabies vaccine (PVRV) given on Days 0, 3, 7, 14, and 28.
223839814|NCT05050487|PROCEDURE|PENG block|"The PENG block is performed under US guid¬ance, . The pa¬tient is placed in the supine position a curvilinear low-fre¬quency ultrasound probe (2-5 MHz) is initially placed in a transverse plane over the AIIS and then aligned with the pubic ramus by rotating the probe approximately 30-45 degrees . .~The needle, usually a 22-G80-mm echogenic device, is inserted from lateral to medial with an in-plane approach to place the tip in the plane between the psoas tendon anteriorly and the pu¬bic ramus posteriorly .~After needle insertion and following negative aspiration, the local anesthetic is injected . The volume used of 20 ml of(L-bupivacaine; concentration 0,25% ) . This fascial plane appeared to continue in the hip pericapsular plane."
223839815|NCT05050487|PROCEDURE|lumbar erector spinae plane block|"The lumbar erector spinae block is performed under US guid¬ance, after adequate skin disinfection The patient is placed in the lateral decubitus position according to the selected site of surgical intervention.~The 4th lumbar vertebral level will determined The convex USG transducer was placed at the mid-vertebral line in the sagittal plane. The transducer was shifted from the midline, 3.5-4 cm laterally to the side of the surgery to visualize the erector spinae muscle and transverse process . 0.5-1 ml of the prepared LA solution (20 ml bupivacaine 0.25%). All LA was administered to this location between the transverse process and the erector spinae muscle."
223839816|NCT03180411|BEHAVIORAL|Interview|"Cognitive Testing Phase Group: Participants take part in one-on-one interview with research staff and asked questions about participant's health and the disease. The interview may take from 45-60 minutes to complete.~Pilot Testing Phase Group: After Cognitive Testing Phase interview, participants have a second one-on-one interview. The interview will last from 45-60 minutes."
223839817|NCT03180411|BEHAVIORAL|Questionnaire|Participant completes a questionnaire about the disease, what participant understands about it, and the treatment plan recommended. Participant asked to give participant's opinion about colorectal cancer follow-up materials. The questionnaire will take 35-45 minutes.
223839818|NCT02821390|DRUG|Nepafenac Eye Drops|One drop instilled to the eye's cul de sac prior to the intravitreal injection.
223839819|NCT02821390|DRUG|Placebo (Artificial Tears)|One drop instilled to the eye's cul de sac prior to the intravitreal injection
223839820|NCT03127592|DRUG|Fixed Dose Combination|Fixed Dose Combination of Etodolac 400 mg + Cyclobenzaprine 10 mg
223839821|NCT03127592|DRUG|Etodolac|Individual drug
223839822|NCT03127592|DRUG|Cyclobenzaprine|Individual drug
223839823|NCT05728983|OTHER|Sleep levels|Sleep levels are what the experimenter prescribes to participants in the study.
223839824|NCT01840761|DRUG|herbal drug|
223839825|NCT01840761|DRUG|placebo|
223839826|NCT02633319|BEHAVIORAL|Skilful Parenting|Skilful Parenting is a 2-week group-based parenting intervention delivered by Investing in Children and Our Societies to caregivers who are members of farmer groups in participating villages. It reinforces positive parenting practices, empowering parents to address the challenges that they face in bringing up their children. The intervention helps create parent peer groups to share ideas, support, information, and resources in the community. The intervention involves weekly sessions with farmer groups, awareness raising amongst local authorities and communities, and the establishment of parent peer groups. Topics consist of the following issues related to parenting: roles and responsibilities; family relations; communication; values; positive discipline; child protection; and family budgeting.
223839827|NCT02633319|OTHER|Agrics|Agrics provides smallholder farmers, organized in farmer groups, with access to farm inputs on a credit basis, and agricultural extension and advisory services to improve farming techniques and improve market connections. These services include an intensive intervention during planting season and then ongoing support after the initial 3-month intervention.
223839828|NCT02958228|BEHAVIORAL|Positive Mental Imagery Training (PMIT)|
223839829|NCT02958228|BEHAVIORAL|Cognitive Control Training (CCT)|
223839830|NCT02958228|OTHER|Treatment as Usual|
223839831|NCT02511561|DRUG|OTO-201 (ciprofloxacin)|
223839832|NCT03040193|DRUG|Lignocaine Nebulization|4% Lignocaine delivered via Nebulization
223839833|NCT03040193|DRUG|Saline Nebulization|Normal Saline Delivered via Nebulization
223839834|NCT03404869|DRUG|ORL-1M - D-mannose|Oral ORL-1M
223839835|NCT03511183|DRUG|XELIRI + bevacizumab|Irinotecan，200mg/㎡,d1;Capecitabine, 1000mg/㎡ bid1-14;Bevacizumab,7.5mg/kg ,d1; every 21 days as a cycle
223839836|NCT03511183|DRUG|XELOX + bevacizumab|Oxaliplatin ,130mg/㎡,d1;Capecitabine, 1000mg/㎡ bid1-14;Bevacizumab,7.5mg/kg ,d1; every 21 days as a cycle
223839837|NCT04184024|OTHER|Massage|"Soft tissue massage known as Swedish massage technique was applied to the neck area for 20 minutes. This massage was carried out 3 days a week for 4 weeks (12 sessions) by the supervisor physiotherapist."
223839838|NCT04184024|OTHER|Kinesio tape|Patients were taped according to the Kenzo Kase's Kinesio Taping Method by an experienced physical therapist. The application was carried out in a relaxed sitting position. Y banding with extensor muscles on the back of the neck with muscle technique, I banding with the upper trapezius with muscle technique and I banding with ligament technique to the middle region of the neck were performed.
223839839|NCT04184024|OTHER|Neck stabilization exercise|Neck stabilization exercise was performed in stages with gradual progression according to the stages of motor learning and sensory-motor integration, namely, static, dynamic, and functional. The program started with postural training and then the cervical bracing technique with the activation of deep neck flexors for NSE was performed. The patients were asked to maintain a neutral spine during the exercises and throughout the day as much as possible. The difficulty and variety of exercises were increased weekly. It was carried out 3 days a week for 4 weeks (12 sessions) by the supervisor physiotherapist.
223839840|NCT01723826|DRUG|Crenezumab|Participants will receive intravenous infusion of crenezumab every 4 weeks for 144 weeks.
223839841|NCT05455944|DRUG|Pregabalin 150mg|Two capsules of pregabalin is administered orally to patients
223839842|NCT05455944|DRUG|Placebo|Two identical placebo capsules is administered orally to patients
223839843|NCT02086799|DRUG|IV thyroxin|Patients will receive treatment with intra-venous thyroxine 100mcg once on admission and additional 100mcg after 12 hours.
223839844|NCT02086799|DRUG|Placebo|Patients will receive treatment with normal saline 100ml once on admission and additional 100ml after 12 hours
223839845|NCT01798082|OTHER|Pelvic organ prolapse decision aid|
223839846|NCT02460744|RADIATION|Hypofractionation|Radiation dose of 34Gy in 10 fractions over 2 weeks.
223839847|NCT05018962|DEVICE|Cutting balloon followed by paclitaxel coated balloon|Cutting balloon followed by paclitaxel coated balloon
223839848|NCT03405181|OTHER|Training with additional weight|The infants will be positioned in a reclined position. A bracelet with an additional weight (20% of the total mass of the upper limb) will be placed on both wrists. The training will happen 2x/week, during 4 weeks (8 sessions). An object will be used to stimulate the reaching behavior, which will be displayed by the examiner (positioned in front of the infant), and presented in the midline at shoulder height, considering the distance from the arm's length of the infant to the height of the wrist. The physiotherapist will draw the attention of the infant to the object, moving it momentarily so that the infant perceives it and reaches it. After reaching, the object will be carefully removed and resubmitted in order to elicit a new movement. The interval between each presentation will be of approximately 5 seconds. At least 10 movements will be stimulated. If the infant does not achieve the 10 reaches within the maximum interval of 15 minutes, the session will be terminated.
223839849|NCT03405181|OTHER|Training without additional weight|The infants will be positioned in a reclined position. A bracelet without the additional weight will be placed on both wrists. The training will happen 2x/week, during 4 weeks (8 sessions). An object will be used to stimulate the reaching behavior, which will be displayed by the examiner (positioned in front of the infant), and presented in the midline at shoulder height, considering the distance from the arm's length of the infant to the height of the wrist. The physiotherapist will draw the attention of the infant to the object, moving it momentarily so that the infant perceives it and reaches the object. After reaching, the object will be carefully removed (or picked up) and resubmitted in order to elicit a new movement. The interval between each presentation of the object will be of approximately 5 seconds. At least 10 movements will be stimulated. If the infant does not achieve the 10 reaches within the maximum interval of 15 minutes, the session will be terminated.
223839850|NCT03939221|BEHAVIORAL|Infrared Lamp and Acupressure|Measure the ankle and wrist acupoints skin conductance to evaluate the basic condition of terminal hospice patients. Then investigators use the infrared lamp and acupressure(tender points, PC6 and ST36 for one minutes) for our patient for the cold limbs, pain control and constipation problems.
223839851|NCT00739193|DRUG|amiodarone|
223839852|NCT00000390|DRUG|Imipramine hydrochloride|
223839853|NCT05281393|BEHAVIORAL|PrEPresent|PrEP2Prevent is being done in several phases (parts) to develop and pilot test a PrEP activation, navigation and support intervention for young men who have sex with men (YMSM), trans youth and non-binary youth in Los Angeles. It targets an intervention for these young people where they need it most - on PrEP uptake. PrEP stands for pre-exposure prophylaxis.
223839854|NCT03295006|DEVICE|TheraSphere|Patients who had received TheraSphere
223839855|NCT01852955|DRUG|IV acetaminophen|Administration of IV acetaminophen 1000 mg over 15 minutes at the start of surgical closure
223839856|NCT01852955|DRUG|Placebo|Administration of placebo (sterile normal saline)group-same volume of saline solution administered in the same fashion as the acetaminophen
223839857|NCT01729897|DRUG|Etomidate|
223839858|NCT01729897|DRUG|Fentanyl|
223839859|NCT01729897|DRUG|Propofol|
223839860|NCT02408549|DRUG|Lacosamide Tablet|"* Active substance: Lacosamide~* Pharmaceutical form: Tablet~* Concentration: 50 mg and 100 mg~* Route of Administration: Oral administration"
223839861|NCT02408549|DRUG|Lacosamide Oral Solution|"* Active substance: Lacosamide~* Pharmaceutical form: Oral solution~* Concentration: 10 mg/ml~* Route of Administration: Oral administration"
223839862|NCT03550729|BEHAVIORAL|Endurance training|Endurance training 3 times per week during 3 months using interval training above 70% of load peak reached in the incremental exercise test. The duration of the sessions will be adapted individually to each patient (approximately 60 minutes).
223839863|NCT01043536|RADIATION|radiotherapy|patients will receive from 6 to 7 weeks 5 days a week radiations. The dose of radiation will depend on the level they will be included.
223839864|NCT01043536|DRUG|temozolomide|patient will receive whatever the level 7 days a week, temozolomide at the dose of 75mg/m2 during radiotherapy period. They will then follow one month after the end the radiochemotherapy an adjuvant treatment corresponding to a 5 days treatments of temozolomide at the dose of 200mg/m2 every 28 days.
223839865|NCT04919681|OTHER|Stretch exercises|The intervention comprises of six weeks daily bi-lateral static stretching of the knee flexors. Stretches are performed seated on the ground. The participant sits upright on the floor with one leg straight. The sole of the other foot should be placed on the inside of the outstretched leg. The participant leans slightly forward, trying to touch their toes while maintaining full knee extension. Stretching is performed to the point of discomfort, and each stretch is held for 30-seconds for three repetitions.
223839866|NCT04994574|DRUG|tiotropium/olodaterol|From Visit 2(Baseline), test subjects will be use tiotropium/olodaterol inhaler once a day for 4 weeks. After that, visit the hospital at 4 weeks to receive examination and terminate participation.
223839867|NCT00191048|DRUG|Atomoxetine|
223839868|NCT01699893|OTHER|unique arm|blood, nasal swab, skin biopsy, stool samples
223839869|NCT02013687|BIOLOGICAL|Pfs25 VLP- FhCMB|
223839870|NCT01272011|OTHER|Intermittent Hypoxia|Individuals received exposure to intermittent hypoxia for 10 days, and placebo for 1-2 days.
223839871|NCT01272011|OTHER|Locomotor Training|Individuals received 10 days of locomotor training, intense walking training on a treadmill with body weight support. Manual assistance was provided at the legs to optimize stepping patterns.
223839872|NCT01627340|BIOLOGICAL|Engerix™-B vaccine|3 doses administered intramuscularly (IM) in the deltoid region of the non-dominant arm.
223839873|NCT03513211|DRUG|SUBA-itraconazole|150mg PO BD
223839874|NCT03513211|DRUG|Hydroxychloroquine|Escalating doses in Rolling 6 Phase I
223839875|NCT04859049|PROCEDURE|infromedial single injection|"Group 1: We used a 25G/ 1 length needle to inject 3ml of lidocaine: bupivacaine (1:1) with 30 IU hyaluronic acid, 0.5ml below the inferior punctum in the lower lid medial margin."
223839876|NCT04859049|PROCEDURE|medial canthus injection|": We used a 25G/ 1 length needle to inject 3ml of lidocaine: bupivacaine (1:1) with 30 IU hyaluronic acid classical medial canthal injection"
223839877|NCT01657032|DIETARY_SUPPLEMENT|Smectite|Eligible children received smectite (3g) once a day till diarrhea stop with LGG (ATCC 53103) at a daily dosage of 6×10 9 colony forming units (CFU) in one dose for 7 days.
223839878|NCT01657032|DIETARY_SUPPLEMENT|Placebo|Eligible children received placebo: glucose (3g) once a day till diarrhea stop with LGG (ATCC 53103) at a daily dosage of 6×10 9 colony forming units (CFU) in one dose for 7 days.
223839879|NCT01657032|DIETARY_SUPPLEMENT|Lactobacillus GG|All children received LGG (ATCC 53103), dose 6×10 9 colony forming units (CFU), once a day for 7 days with placebo or smectite
223839880|NCT01694875|DEVICE|APTIMA HPV Assay|In Vitro Diagnostics Assay
223839881|NCT03178305|BEHAVIORAL|Do CHANGE|"Besides the behavior change programme (Do Something Different)~1. All patients will receive: Fitbit, Beddit, Care-portal, Do CHANGE app (including dietary habits picture taking), CookiT (smart spatula that monitors cooking behavior)~2. patients with heart failure will, in addition to the above mentioned, be offered a weight scale, blood pressure monitor, and FluiT (smart cup to measure fluid intake).~3. Patients with hypertension will also be offered a bloodpressure monitor.~Data from these devices will be gathered and visible for patients (in patient portal) and for their health care provider (health care provider portal). In case of negative results the patient will be contacted by their health care provider (usually the cardiologist).~Once every week the patients will be contacted to discuss their progress and will be given feedback about their dietary intake."
223839882|NCT03633903|BEHAVIORAL|Mindfulness|Mindfulness based stress reduction adapted for teens is a mindfulness intervention designed to aid adolescents in understanding stress, better coping with stress, and promoting resilience
223839883|NCT05968482|DRUG|Diclofenac Sodium Gel|Topical application on both knees
223839884|NCT06337539|DRUG|SSRI|"Outpatients with a diagnosis of major depression in the Psychiatry Outpatient Clinics will be evaluated for recruitment.~* Recruitment visit: It will be carried out by one of the psychiatrists participating in the study. The patient will be informed about the study and written consent will be requested. Subsequently, the inclusion and exclusion criteria will be reviewed, and all demographic and clinical variables will be collected.~* Baseline visit: One of the psychiatrists will interview the patient and apply the semi-structured clinical interview and the psychopathological evaluation questionnaires. In addition, a blood draw will be performed for serum collection, spectral cytometric analysis of lymphocyte subpopulations and obtaining peripheral blood mononuclear cells (PBMCs).~* Follow-up visit after 3 months of treatment: Clinical variables will be collected and the same procedures will be performed as during the baseline visit. Not in the control group."
223839885|NCT03062150|DRUG|Placebo|Placebo
224264748|NCT05114512|OTHER|RAPTOR protocol: hybrid in-person + telehealth physical therapy services|All participants will receive the RAPTOR intervention, which includes 2 in-person physical therapy visits and 8 telerehabilitation visits. Participants will attend an initial in-person PT evaluation to meet their provider, receive a hands-on assessment of their impairments and functional limitations, and receive instruction in an initial home exercise program. The remainder of their visits will be completed remotely, using a telerehabilitation platform. At the conclusion of care, the patient will return to the clinic for a follow-up assessment and training on their final home exercise program.
224264749|NCT06276556|DRUG|ABP-671|"Participants who were randomized to any of the ABP-671 treatment groups in Part 1 or Part 2 of Study ABP-671-301 will continue to receive the same dose level and dosing regimen during the Treatment Period of this Extension Study.~Participants who were randomized to receive placebo in Part 1 or Part 2 of Study ABP-671-301 will receive ABP-671 during the Treatment Period of the Extension Study."
224264750|NCT06276556|DRUG|Allopurinol|Participants who were randomized to receive allopurinol in Part 1 of Study ABP-671-301 will continue to receive allopurinol during the Treatment Period of the Extension Study.
224264751|NCT04778501|DEVICE|IOL implantation experimental|Mono- or bilateral implantation of toric intraocular lenses PODEYE TORIC. If only one eye qualifies for toric lens implantation due to small amount of pre-existing corneal astigmatism, one eye will be implanted with PODEYE TORIC and the contralateral eye will be receive an implantation with the monofocal parent lens PODEYE (PhysIOL sa/nv, Liège, Belgium).
224264752|NCT01476969|DEVICE|Remote ischemic postconditioning|the treatment group consisted of three 4-minute cycles left lower limb ischemia,induced by inflating a blood pressure cuff on the lower limb to 600 mmHg with an intervening 4 minutes of reperfusion ,during which time the cuff was deflate;the control group consisted of placing an uninflated cuff on the left lower limb for 24 minutes.The postconditioning protocol was applied after the aortic cross-clamping.
224264753|NCT02337322|DRUG|Dolutegravir|
224264754|NCT02337322|DRUG|Darunavir/r|
224264755|NCT03517319|DRUG|Normal Saline 0.9% 1.2 ml|
224264756|NCT03517319|DRUG|Clostridium Botulinum Toxin Type A (Nabota, DWP 450) 15 U|
224264757|NCT03517319|DRUG|Clostridium Botulinum Toxin Type A (Nabota, DWP 450) 30 U|
224264758|NCT03517319|DRUG|Clostridium Botulinum Toxin Type A (Nabota, DWP 450) 50 U|
224264759|NCT03517319|DRUG|Clostridium Botulinum Toxin Type A (Nabota, DWP 450) 70 U|
224264760|NCT07135102|DRUG|225Ac-PSMA-XT|Patients will receive 225Ac-PSMA-XT administration at an interval of 6 weeks between each dose.
224264761|NCT05278520|PROCEDURE|Total hip arthroplasty|Hip joint replacement surgery. Elective for RA and OA cases.
224264762|NCT02612298|DRUG|Arotinolol Hydrochloride|Arotinolol Hydrochloride, oral, 5-15mg, bid for 12 weeks.
224264763|NCT02612298|DRUG|Metoprolol succinate sustained-release tablet|Metoprolol succinate sustained-release tablet,oral, 23.75-71.25mg, qd for 12 weeks.
224264764|NCT04013841|OTHER|Oral-agents/Enema|"1. Oral-agents for mechanical bowel preparation prior to left-side colorectal resection~2. Enema for mechanical bowel preparation prior to left-side colorectal resection"
224264765|NCT06628232|OTHER|pacifier with breast milk|swaddling in the mother\&#39;s lap together with giving a pacifier dipped in breast milk
224264766|NCT06628232|OTHER|heel heating|swaddling in the mother\&#39;s lap together with local dry heat application
224264767|NCT06628232|OTHER|interventions combined|swaddling in the mother\&#39;s lap together with giving a pacifier dipped in breast milk and heel heating
224264768|NCT06628232|OTHER|Control|swaddling the baby in the mother\&#39;s lap
224264769|NCT07032389|COMBINATION_PRODUCT|Polypill|The polypill is an inert capsule designed to combine multiple individual medications into a convenient, once-daily pill. In this case it will include DAPT and a statin.
224264770|NCT00003885|DRUG|arsenic trioxide|
224264771|NCT05404789|OTHER|Centrifugation|Subjects will participate in up to seven different centrifuge profiles over a single day of training (approximately 8 hours). Exposures are design to simulate a spaceflight profile using acceleration anticipated for commercial spaceflights.
224264772|NCT06725160|BEHAVIORAL|Parent Coaching|Three sessions of parent coaching of child positive affect will be administered based on modules from PCIT-ED.
224264773|NCT06725160|BEHAVIORAL|Active Control|General parent support and psychoeducation based on components of standard PCIT.
223839886|NCT03062150|DRUG|Fludrocortisone|Fludrocortisone
223839887|NCT03062150|DRUG|D-Cycloserine|D-Cycloserine
223839888|NCT01398761|OTHER|Signout tool|Electronic signout tool
223839889|NCT01018043|OTHER|Adult Cancer Patients|Tracking anemia management in Adult Cancer Patients
223839890|NCT02046538|DRUG|Leucovorin|400 mg/m2 IV over two hours (or administered concurrently with oxaliplatin or irinotecan, depending on the assigned regimen)
223839891|NCT02046538|DRUG|Oxaliplatin|85 mg/m2 IV over two hours
223839892|NCT02046538|DRUG|5-FU|400 mg/m2 IV bolus, then 2400 mg/m2 continuous IV infusion over 46-48 hours
223839893|NCT02046538|DRUG|Irinotecan|180 mg/m2 IV over 90 minutes
223839894|NCT06278389|DRUG|ACC017 tablets|ACC017 tablets 5 mg, 20 mg, 40 mg, 80 mg, 120 mg, and 160 mg (tentative) with matching placebo
223839895|NCT06278389|DRUG|Emtricitabine and Tenofovir Alafenamide Fumarate Tablets|Participants received a single oral dose of ACC017 tablets with emtricitabine and tenofovir alafenamide fumarate tablets under the fasting condition.
223839896|NCT00189280|DRUG|Imiquimod|cream 5%, 5 days out of seven, for 6 weeks
223839897|NCT03302533|PROCEDURE|Total elbow arthroplasty|Implantation of a total elbow arthroplasty after distal humerus fracture
223839898|NCT05653180|DRUG|IBI310|2mg/kg IV,3 weeks later, 1mg/kg IV Q6W
223839899|NCT05653180|DRUG|sintilimab|200mg IV Q3W
223839900|NCT02848235|OTHER|Standard of Care + EMMA|Mother Mentors will provide enhanced care, above that of the standard of care, to include clinic visit exit discussions, visit reminder messages, and patient follow-up in the event that a clinic visit is missed.
223839901|NCT05767138|BEHAVIORAL|HPV Vaccine Acceptance Survey|
223839902|NCT00431743|DRUG|Hydroxyethylstarch 130/0,4|
223839903|NCT00431743|DRUG|Lactated Ringer's solution|
223839904|NCT04887961|DRUG|PLD and Trabectedin rechallenge|Platinum partially sensitive patients i.e. patients who recur with a platinum free interval between 6 and 12 months, who have previously received pegylated liposomal doxorubicin and are suitable for rechallenge with pegylated liposomal doxorubicin (PLD) with the combination of trabectedin (Yondelis®) and relapsed ovarian cancer fully platinum sensitive patients not able to receive or not willing to receive other platinum treatments
223839905|NCT02685592|DRUG|5-aminolevulinic acid nanoemulsion|A 1 millimeter thick layer of 5-aminolevulinic acid nanoemulsion light sensitizing gel is applied on the skin and let to absorb 3 hours before illumination.
223839906|NCT05312619|OTHER|Cross sectional survey|A cross-sectional descriptive survey of the Burden of Lyme disease for individual with a history of Lyme disease who contract COVID-19 or are vaccinated against COVID-19
223839907|NCT02314455|OTHER|D-xylose|There will be four patient groups analyzed. Ten patients each, 10 with active eosinophilic esophagitis defined by consensus guidelines, 20 patients in histologic remission (10 by steroids and 10 by diet) and 10 control volunteers will be studied. Patients who have consented to the trial will be scheduled at the Clinical Research Unit (CRU) Patients will report to Charlton 7 the CRU, having their height, weight, blood pressure and temperature recorded. Subjects can choose to either have a saline lock IV placed or have their bloods drawn 3 separate times. They will receive 25 grams of D-xylose orally. The D-xylose will be mixed in 10 cc of water with 2 teaspoons of honey. D-xylose serum levels will be drawn at 5 and 10 and 60 minutes.
223839908|NCT03059160|DRUG|Tridecanoic Acid|3 times daily oral doze of the drug for 20 weeks with 4 weeks of baseline and 4 weeks of washout
223839909|NCT02839083|OTHER|Thoracic Paravertebral group|Thoracic paravertebral block is performed using bupivacaine 0.25% in a total volume of 30 ml
223839910|NCT02839083|OTHER|Pecs II group|Ultrasound guided ipsilateral Pecs II block is performed using bupivacaine 0.25% in a total volume of 30 ml
223839911|NCT02202590|DEVICE|SECM Capsule|Imaging of the esophagus using the SECM capsule and system
223839912|NCT05269511|DRUG|Chinese herbal medicine is in the form of granules (9 g/sachet), which is comprised of ten medicinal herbs.|Oral administration, twice per day.
223839913|NCT04086173|DIETARY_SUPPLEMENT|Probiotics|Probiotics will be administered at night and will consist of 4 capsules
223839914|NCT04086173|OTHER|Placebo|Placebo
223839915|NCT04305236|DRUG|Abemaciclib|Given PO
223839916|NCT04305236|DRUG|Fulvestrant|Given Intramuscularly
223839917|NCT04542447|DRUG|Nuvastatic|Polymolecular botanical standardized extract Orthosiphon stamineus/Orthosiphon aristatas as an immunomodulator adjuvant therapy
223839918|NCT01047943|DRUG|Topical application of STA-21 ointment for treatment of psoriasis|
223839919|NCT00813007|BEHAVIORAL|Questionnaires|5 Questionnaires at differing times before and after surgery.
223839920|NCT04724174|PROCEDURE|pancreaticogastrostomy|Pancreaticogastrostomy technique was performed according to the precise description of Addeo et al.
223839921|NCT04724174|PROCEDURE|pancreaticojejunostomy|Pancreaticojejunostomy technique was performed using the 5/0 polypropylene interrupted monofilament suture in a one-layered duct-to-mucosa end-to-side anastomosis (Cattell-Warren anastomosis).
223839922|NCT02885532|OTHER|University of California, San Diego Brief Assessment of Capacity to Consent Tool|Non-pregnant, English speaking patients older than 18 with evidence of acute alcohol intoxication were considered eligible for participation. Patients were asked to complete the 10 question tool on arrival to the emergency department. Patie
223839923|NCT04377997|DRUG|Enoxaparin|Given the established link between endothelial dysfunction and thrombosis in patients with cardiovascular disease9, 10 and the association between coagulopathy and adverse outcomes in patients with sepsis11, the association between increased coagulation activity, end-organ injury, and mortality risk may represent a modifiable risk factor among COVID-19 patients with critical illness. Therefore, we propose to conduct a randomized, open-label trial of therapeutic anticoagulation in COVID-19 patients with an elevated D-dimer to evaluate the efficacy. Most patients will receive low molecular weight heparin however, unfractionated heparin (UFH) will be administered for those with morbid obesity or moderate to severe renal dysfunction.
223839924|NCT00680693|BEHAVIORAL|Mindfulness training|8 weekly 2-hour classes
223839925|NCT00680693|BEHAVIORAL|Psycho-educational support group for women with IBS|8 weekly 2-hour meetings
223839926|NCT03894943|DIAGNOSTIC_TEST|PET/CT scan|Patient receive a PET/CT scan of their cerebrum and lumbar spine prior to surgery, 4-6 weeks after surgery and 6 months after surgery
223839927|NCT03894943|DIAGNOSTIC_TEST|Quantitative Sensory Testing|Patients undergo a battery of quantitative sensory tests prior to surgery, 4-6 weeks after surgery and 6 months after surgery
223839928|NCT04273685|BEHAVIORAL|Cognitive remediation training, social recovery therapy|10 weeks cognitive remediation training plus social recovery therapy. One hour face to face contact time with intervention therapist per week. At-home cognitive remediation training completion.
223839929|NCT04273685|OTHER|treatment as usual|10 weeks Treatment as usual non directive counselling One hour face to face contact time with intervention therapist per week.
223839930|NCT03905382|OTHER|Qualitative|Focus group and 1:1 telephone interviews
223839931|NCT01580527|PROCEDURE|Total parenteral nutrition|Total parenteral nutrition in postoperative of pancreaticoduodenectomy
223839932|NCT01580527|PROCEDURE|Enteral nutrition|Early enteral nutrition in postoperative of pancreaticoduodenectomy
223839933|NCT05911074|DIAGNOSTIC_TEST|The Abbott Panbio™ COVID-19 Ag Rapid Test|This is the intervention or medical device(s) intended to be used with a study participant according to the study protocol.
223839934|NCT05711329|OTHER|Accuracy|We will validate the accuracy of the method proposed by the SFAR to detect OSA patients via videoconference (in comparison with the results of the PSG).
223839935|NCT01634711|DEVICE|L-C Ligament|The L-C Ligament is a bioresorbable, three-dimensional (3-D) braided scaffold made from poly L-lactic acid (PLLA) fiber. One device is used to replace the ACL. The L-C Ligament is an interventional device. The L-C Ligament is comprised of three regions: (1) The femoral tunnel attachment site, (2) The ligament region (intra-articular zone), and (3) The tibial tunnel attachment site. For several months after surgery, the L-C Ligament replaces the function of the ACL. During this time, ligament tissue regenerates within and around the L-C Ligament, which is slowly absorbed and replaced by the ACL.
223839936|NCT04422821|DEVICE|Flash Glucose Monitoring|Flash Glucose Monitoring FreeStyle Libre™ (Abbott Diabetes Care, Alameda, CA) sensor placed subcutaneously that will be applied for 14 days, then removed and changed for the second sensor for the next 14 days.
223839937|NCT04422821|DEVICE|Self-Monitoring of Blood Glucose|Self-Monitoring of Blood Glucose with a standard glucose meter (iXell®; Genexo sp; Warsaw, Poland) performed through a skin-puncturing 4 times a day for 28 days.
224264774|NCT03317067|DRUG|Dexmedetomidine|The 4D trial is an investigator-initiated, prospective, multicenter, randomized, double-blinded, two-arm trial, randomizing 300 non-intubated ICU patients with diagnosis of agitated delirium to receive dexmedetomidine or placebo as a cure
224264775|NCT03317067|OTHER|Placebo|The 4D trial is an investigator-initiated, prospective, multicenter, randomized, double-blinded, two-arm trial, randomizing 300 non-intubated ICU patients with diagnosis of agitated delirium to receive dexmedetomidine or placebo as a cure
224264776|NCT07128485|OTHER|Fentanyl test strips|Fentanyl test strips (FTS) are small strips of paper that can detect the presence of fentanyl in illicit drugs.
224264777|NCT07128485|BEHAVIORAL|Fentanyl test strip education|Developed in the R61 phase, the educational intervention will provide participants with knowledge about how to correctly use fentanyl strips.
224264778|NCT07128602|DEVICE|active transcranial direct current stimulation (tDCS)|20 minutes of anodal tDCS over the primary motor cortex contralateral to the participants surgical limb during a quadriceps torque matching task
224264779|NCT07128602|DEVICE|sham transcranial direct current stimulation (tDCS)|Participants receive sham tDCS in which the device only delivers current during the first and last 30 seconds while participants perform a quadriceps torque matching task
224264780|NCT02588339|DRUG|Panobinostat|Panobinostat (PANO) will begin 5 days (Day -5) before transplant day (Day 0). All participants will take PANO by mouth once a day, three times a week (48 hours apart), every week for 26 weeks (approximately 6 months). PANO will be provided by Novartis as 5-mg pink gelatin capsules.
224264781|NCT02588339|DRUG|Sirolimus|Sirolimus will be given the day before transplant and continued daily for at least one year. SIR will be administered starting on day -1 and thereafter. Dosing will be adjusted to maintain therapeutic targets per Moffitt institutional standards.
224264782|NCT02588339|DRUG|Tacrolimus|Tacrolimus as an infusion or as a pill will begin 3 days before transplant (day -3) and following Moffitt institutional guidelines for dosing. Tacrolimus will be given for at least 50 days and participants will remain on Tacrolimus for as long as it is necessary per standard of care.
224264783|NCT03922490|DEVICE|Lipogems Device PLUS debridement|Lipogems is the name of the technology used to obtain stem cells from the abdomen, which will then be injected into the knee after knee arthroscopy.
224264784|NCT03922490|PROCEDURE|Debridement only|Patients will undergo knee arthroscopy as a standard treatment for their condition but will not receive the fat-derived stem cell treatment nor will undergo any additional procedures.
223839938|NCT02916472|BEHAVIORAL|CyberCycling|All exercise training will be performed under the supervision of a qualified exercise trainer certified in Advanced Cardiac Life Support. Participants in the exercise groups will be asked to perform aerobic exercise on a stationary bike ('cybercycle') 3 days per week for 12 weeks. Exercise intensity and duration will be based on a progressive program and adapted, as needed, based on the participants' tolerability. Heart rate will be monitored throughout the exercise session and Rating of Perceived Exertion (RPE) monitored at least every 10 minutes. The target heart rate (THR) zone will be determined using the Karvonen formula.
223839939|NCT02916472|BEHAVIORAL|Stretching|Participants randomized to the control condition will receive a progressive resistance training program with TheraBands™ and a stretching program to complete at home 2 days/week for 12 weeks. The resistance band program will include upper body and lower body exercises. Participants will be provided with two different colored resistance bands (lighter colored - easier resistance; darker colored - harder resistance). Participants will start by completing 1-2 sets, 2 days/week with the easier/lighter band for the first 4 weeks, progress to 2-3 sets, 2 days/week with the easier band for the next 4 weeks; and, then, progress to 1-2 sets with the darker/harder band for the last 4 weeks. In addition, all participants in the 'control' condition will be advised to conduct upper body and lower body stretches 2 days/week. All resistance band exercises and stretches will be demonstrated to the participant by the exercise physiologist before the 12 week program begins.
223839940|NCT02916472|BEHAVIORAL|Resistance Bands|"Participants randomized to the control condition will receive a progressive resistance training program with TheraBands™ and a stretching program to complete at home 2 days/week for 12 weeks.~The resistance band program will include upper body and lower body exercises and will be provided with two different colored resistance bands (one lighter colored for easier resistance; one darker colored for a harder resistance). Participants will start by completing 1-2 sets, 2 days/week with the easier/lighter band for the first 4 weeks, progress to 2-3 sets, 2 days/week with the easier band for the next 4 weeks; and, then, progress to 1-2 sets with the darker/harder band for the last 4 weeks. In addition, all participants in the 'control' condition will be advised to conduct upper body and lower body stretches 2 days/week. All resistance band exercises and stretches will be demonstrated to the participants by the exercise physiologist before the 12 week program begins."
223839941|NCT00005864|DRUG|chloroquinoxaline sulfonamide|
223839942|NCT01773538|DRUG|Lactulose and rifaximin|3 months treatment. lactulose 25 Ml x3 per day. Rifaximin (550 mg) x 2 per day.
223839943|NCT01773538|DIETARY_SUPPLEMENT|Branched Chain amino acids|30 grams of branched chain amino acids (Bramino) per day is given to the patients in the antiHE treatment arm along with lactulose and rifaximin.
223839944|NCT01773538|OTHER|Placebo|Patients in the placebo-arm receives both placebo-Bramino, placebo-lactulose and placebo-rifaximin.
223839945|NCT03082209|DRUG|ABBV-621|Intravenous (IV)
223839946|NCT03082209|DRUG|Venetoclax|tablet, oral
223839947|NCT03082209|DRUG|Bevacizumab|IV infusion
223839948|NCT03082209|DRUG|FOLFIRI|IV infusion
223839949|NCT05530954|OTHER|Mineral trioxide aggregate (MTA)|Materials for Vital Pulp Capping
223839950|NCT05530954|OTHER|Hard setting Calcium Hydroxide (Dycal)|Materials for Vital Pulp Capping
223839951|NCT06009783|OTHER|ChatGPT Language Model|ChatGPT Language Model - ability to converse with the model and ask questions regarding vasectomies
223839952|NCT00761774|DRUG|Brivaracetam|Subjects will begin at a recommended dose of Brivaracetam 100 mg/day. Subjects will continue treatment at a dose up to a maximum of 200 mg/day with a twice per day administration. Up- and down-titration steps may be performed in steps of a maximum of 50 mg/day on a weekly basis. Full down-titration should include a one week step on 20 mg/day. The study medication will come in 10 mg and 25 mg tablet strengths.
223839953|NCT01925170|DEVICE|Molecular Breast Imaging|Molecular breast imaging is a new nuclear medicine technique for imaging the breast. It uses small field of view semiconductor-based gamma cameras that use Cadmium Zinc Telluride detectors. These have superior spatial and energy resolution to conventional sodium iodide detectors.
223839954|NCT01925170|DEVICE|Conventional Mammography|Mammography is the process of using low-energy X-rays (usually around 30 kVp) to examine the human breast and is used as a diagnostic and a screening tool.
223839955|NCT01925170|DRUG|Technetium (99mTc) sestamibi|Technetium (99mTc) sestamibi is a pharmaceutical agent used in nuclear medicine imaging. The drug is a coordination complex consisting of the radioisotope technetium-99m bound to six methoxyisobutylisonitrile (MIBI) ligands.
223839956|NCT05539404|PROCEDURE|Endovascular treatment in addition of best medical treatment.|Endovascular treatment (EVT) of acute ischemic stroke (AIS) related to an anterior large cerebral vessel occlusion (LVO)
223839957|NCT03165383|DRUG|Bupivacaine (Transversus Abdominis Plane Block)|Intervention - At the end of surgery Ultrasound guided Transversus Abdominis Plane block was given with 20 ml 0.25 % bupivacaine bolus and repeated every 8 hourly up to 24 hours.
223839958|NCT03165383|DRUG|Intravenous Patient Controlled Analgesia (PCA) Morphine|PCA Intravenous Morphine 1 milligram bolus on demand was given as rescue analgesia up to 24 hours.
223839959|NCT02186938|DEVICE|FloTrac|
223839960|NCT04900883|OTHER|survey|anonymous survey
223839961|NCT01077024|OTHER|Smoking-cessation treatment|Smoking cessation treatment includes four components: 1. brief weekly individual smoking-cessation counseling study weeks 1-10; 2. extended-release (XL) bupropion (300 mg/day)study weeks 1-10; 3. nicotine inhaler (6-16 cartridges per day ad libitum)during the post-quit treatment phase; 4. prize-based contingency management during the post-quit treatment phase.
223839962|NCT03042442|DIAGNOSTIC_TEST|Point-of care biomarkers|Point-of care biomarkers(Activin,Midkine) assessed by WB and IHC
223839963|NCT03042442|OTHER|Clinical, venous blood samples, pancreatic tissue|Clinical evaluation, venous blood samples and pancreatic tissue needed for determining point-of-care biomarkers.
223839964|NCT03042442|OTHER|Follow-up|Participants will be assessed (by telephone) over a period of 2 years
223839965|NCT03379233|COMBINATION_PRODUCT|Concept2 inhaler|Fixed combination of Indacaterol maleate (QAB149) and glycopyrronium bromide (NVA237), 110/50 μg, capsule added to Concept2 inhaler
223839966|NCT03379233|COMBINATION_PRODUCT|Concept2 inhaler with patient application|Fixed combination of Indacaterol maleate (QAB149) and glycopyrronium bromide (NVA237), 110/50 μg, capsule added to Concept2 inhaler with application used for monitoring
223839967|NCT04755868|DRUG|Talazoparib|The Arm A (Experimental arm) Maintenance therapy with talazoparib (1mg once daily) (once daily 1.0 mg oral administration), 103patients
223839968|NCT04755868|DRUG|Placebo|The Arm B (Control arm) Maintenance therapy with placebo (once daily 1.0 mg oral administration), 103patients
223839969|NCT04651231|PROCEDURE|releasable sutures in punch trabeculectomy|punch trabeculectomy,scleral flap suturing
223839970|NCT01238029|DRUG|Lapatinib and Capecitabine and Vinorelbine|Dose finding Study Lapatinib: 1000-1250 oral, once daily, days 1-21 Capecitabine: 1000 mg/sqm oral, bid, days 1-14 Vinorelbine 10-22,5 mg/sqm, i.v. Day 1 + 8
223839971|NCT01603121|DRUG|Lisofylline|Lisofylline single dose of 9 mg/kg continuous intravenous infusion over a 10 hour period, and lisofylline single dose of 12 mg/kg continuous subcutaneous infusion over a 10 hour period during the alternate period 1 week apart.
223839972|NCT04500743|DRUG|Dienogest|Group B (n=67) who had daily oral Dienogest 2 mg/d for 3 months before starting standard long protocol for IVF
223839973|NCT04500743|DRUG|leuprorelin acetate|Group A (n=67) who had monthly depot GnRHa for 3 months before ovarian stimulation in IVF treatment (Ultra-long protocol)
223839974|NCT02932111|PROCEDURE|osteopathic session|3 osteopathic manipulative sessions. An six-week double-blind treatment period lasting from week 2 (Visit V1) until week 6, Visit 3.
223839975|NCT02932111|PROCEDURE|Placebo manipulative session|3 osteopathic manipulative sessions. An six-week double-blind treatment period lasting from week 2 (Visit V1) until week 6, Visit 3.
223839976|NCT01340833|DRUG|GSK2118436|Two capsules each containing 75 mg GSK2118436, followed by a single IV dose of 50 ug (no more than 7.4 kBq or 200 nCi) \[14C\]GSK2118436, starting 1.75 hours after the oral dose
223839977|NCT05170542|DRUG|Camrelizumab+S-1|Camrelizumab: intravenous drip, fixed dose 200 mg, D1, repeated once every 3 weeks.
223839978|NCT00628628|DRUG|As Needed Rasburicase|.15 mg/kg IV Over 30 Minutes On Day 1. Day 2-5, once daily as needed.
223839979|NCT00628628|DRUG|Fixed Dose Rasburicase|.15 mg/kg IV Over 30 Minutes Daily
223839980|NCT02742909|DRUG|rhBNP|rhBNP was administered as a continuous infusion for 24 hours before or after placebo
223839981|NCT02742909|DRUG|placebo|normal saline as a placebo was administered as a continuous infusion for 24 hours
223839982|NCT01218685|BIOLOGICAL|Split inactivated A/California/7/2009 (H1N1) (NYMC X-179A) VIRUS|1 full dose of 15 micrograms, IM, for volunteers 9 years of age or older; children 6 months to 2 years of age, half of the dose,IM, with 21 days interval; children 3 years old up to 8 years old, 1 full dose, IM, twice, with 21 days interval.
223839983|NCT04344990|PROCEDURE|Epidural analgesia - Group E|Postoperative analgesia with continuous epidural infusion (control group) with Ropivacaine 0.2% + clonidine 150μg with PCA pump (2ml/h and bolus dosage 0,5ml per 15min)
223839984|NCT04344990|PROCEDURE|Femoral blockade - Group F|Postoperative analgesia with continuous femoral nerve blockade infusion with Ropivacaine 0.2% + clonidine 150μg with PCA pump (2ml/h and bolus dosage 0,5ml per 15min) .
223839985|NCT04344990|PROCEDURE|Intraarticular infusion - Group I|Postoperative analgesia with continuous intraarticular infusion with Ropivacaine 0.2% + clonidine 150μg with PCA pump (2ml/h and bolus dosage 0,5ml per 15min)
223839986|NCT01539941|BEHAVIORAL|Medication integration protocol|MIP is a 5 session protocol. The first session consists of pretreatment assessment activities using measures administered during routine clinical intake. The following sessions, MIP Sessions 1-4, are meant to be delivered sequentially, commencing sometime after session 2 or 3 of treatment, that is, after completion of initial treatment contracting and engagement interventions that will usually be focused on ASU-related referral problems for this population. The proposed pilot work will shed light on the optimal timing for MIP Sessions 1-4.
223839987|NCT02300311|DRUG|nonivamide + nicoboxil (Finalgon cream)|2 cm cream line for a skin area approximately 20 x 20 cm2 up to 3 times in a 24 hour period
223839988|NCT02300311|DRUG|placebo matching nonivamide + nicoboxil (Finalgon cream)|2 cm cream line for a skin area of approximately 20 x 20 cm2 up to 3 times in a 24h period
223839989|NCT00419003|DRUG|Lamotrigine|anticonvulsant medication
223839990|NCT00419003|DRUG|Ketamine|subanesthetic dose of NMDAR antagonist
223839991|NCT00419003|DRUG|Riluzole|glutamate release inhibitor
223839992|NCT05250479|BEHAVIORAL|Mindfulness education|44 primiparous pregnant women will receive mindfulness education
223839993|NCT02531438|DRUG|Omadacycline|Injection for IV; Oral tablets
223839994|NCT02531438|DRUG|Moxifloxacin|IV solution; Oral tablets
223839995|NCT03259698|DRUG|nPEP|Participants will receive Bictegravir/emtricitabine/tenofovir alafenamide 50/200/25mg (Biktarvy®) one tablet once daily as study drug to complete a 28 day course of PEP.
223839996|NCT03259698|BEHAVIORAL|Text Messaging Support|"Text messaging support service ('WelTel'): community-based counselors will provides standardized weekly 'check-in' messages during the participants 12-week course of nPEP follow-up. Participants in the text-message arm will also have the option of receiving generic non-specific automated text reminders of their upcoming appointments in the form of Don't forget about tomorrow."
223839997|NCT03259698|OTHER|Nurse-Led nPEP|nPEP follow-up is provided by nurse-led care at a local sexual health clinic instead of a hospital-based ID physician.
223839998|NCT00772928|BIOLOGICAL|Pentacel™: HCPDT-IPV//PRP-T Vaccine and Prevnar®|0.5 mL, Intramuscular
223839999|NCT00772928|BIOLOGICAL|Pentacel™: HCPDT-IPV//PRP-T Vaccine and Prevnar®|0.5 mL, Intramuscular
223840000|NCT03730298|DIETARY_SUPPLEMENT|American Ginseng|cpr
223840001|NCT03730298|OTHER|Placebo|cpr
223840002|NCT06425705|DRUG|Silymarin|140 mg of silymarin administered orally three times daily, alongside their standard treatment with renin-angiotensin system inhibitors.
223840003|NCT06425705|DRUG|Placebo|placebo capsule three times a day alongside their standard treatment with renin-angiotensin system inhibitors.
223840004|NCT04917692|DRUG|Empagliflozin|2.5 mg daily
223840005|NCT02843022|BEHAVIORAL|standardized electronic messages|supportive and educational short messages
223840006|NCT02843022|BEHAVIORAL|nurse phone call if requested|"If participant responds yes to an offer for a phone call, a nurse calls them within a week of this response"
223840007|NCT02843022|BEHAVIORAL|Staff nurse phone follow-up|Usual care: hospital nurse or lactation consultant calls patient within 2-3 weeks prior to discharge. Message left if patient is not reached.
223840008|NCT00325559|PROCEDURE|Normoinsulinemic eu- or hyperglycemic clamp|
223840009|NCT04288466|DIETARY_SUPPLEMENT|maltodextrin|maltodextrin solution 450ml
223840010|NCT01233102|DRUG|Conserved Therapy|Conserved Therapy
223840011|NCT01233102|PROCEDURE|Hepatic artery infusion or Intravenous infusion|Patients with liver cirrhosis will be randomly divided into three groups. Umbilical cord MSCs will be infused to patients using interventional method via hepatic artery for one group. The catheter will be inserted to proper hepatic artery. After the catheter placement confirmed by angiography, umbilical cord MSCs will be infused slowly in 20-30 minutes. Umbilical cord MSCs will be infused intravenously slowly for 30-60 minutes in the intravenous infusion group. The control group will receive conserved therapy.
223840012|NCT00801242|DRUG|Degarelix 240 mg / 80 mg|For each treatment cycle, a starting dose of 240 mg of degarelix was administered on Day 0 as two 120 mg subcutaneous (s.c.) injections in the abdominal region. Thereafter, 6 doses of 80 mg degarelix were administered 28 days apart via single s.c. injections.
223840013|NCT02781064|DRUG|Atorvastatin 20mg|Atorvastatin and matching placebo to be taken in a randomised order for 12 months
223840014|NCT02781064|DRUG|Placebo|Atorvastatin and matching placebo to be taken in a randomised order for 12 months
223840015|NCT04734041|BEHAVIORAL|Anti-inflammatory (Mediterranean-style) diet|Prescription of an anti-inflammatory diet, which encourages increasing whole fruits, vegetables, and grains, as well as balancing macronutrients (proteins, carbohydrates, and fat) for every meal.
223840016|NCT04734041|BEHAVIORAL|Behavioral and psychosocial support|Capture a complete and detailed medical history and background. Discuss familial and social support, provide psychosocial support, assess the patient's current self-management strategies for self-care, and assess the patient's current self-management strategies for mental health. Recommendations will be made in accordance with the needs of the participant.
223840017|NCT04042662|OTHER|no intervention|no intervention
223840018|NCT02381899|DRUG|Bendamustine and Rituximab|Patients receive bendamustine and rituximab. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.
223840019|NCT02015195|OTHER|Acetic Acid (5%)|
223840020|NCT02015195|OTHER|Sodium Bicarbonate Slurry (50%)|
223840021|NCT02015195|OTHER|Papain Slurry (70%)|
223840022|NCT02015195|OTHER|Ammonia (10%)|
223840023|NCT02015195|DRUG|Lidocaine (4%)|
223840024|NCT02015195|OTHER|Isopropyl Alcohol (70%)|
223840025|NCT02015195|OTHER|Hot Tap Water (40 degrees Celsius)|
223840026|NCT02015195|OTHER|No treatment|
223840027|NCT03660072|OTHER|Non-Interventional|Non-Interventional
223840028|NCT01318811|DRUG|Dilute unfractionated heparin|Patients in the dilute heparin arm will receive a systemic loading dose of heparin of 15 units per kilogram of weight by rapid intravenous bolus. Then a maintenance rate of heparin of 7.5 U/Kg per hour will be started. Heparin will be delivered as a solution of 2 units/mL and the infusion will be prepared with 2,000 units of heparin in 1,000 mL of 0.9% NaCl and delivered intravenously proximal to the dialysis filter.
223840029|NCT01318811|DRUG|Standard concentration unfractionated heparin|Patients in the standard heparin arm will receive a systemic loading dose of heparin of 15 units per kilogram of weight by rapid intravenous bolus. Then a maintenance rate of heparin of 7.5 U/Kg per hour will be started and delivered in a standard concentration intravenously proximal to the dialysis filter via a syringe. The concentration of heparin used will be 1,000 units of heparin per 1 mL of 0.9% NaCl.
223840030|NCT00811187|DRUG|Lidocaine paracervical block|5cc 1% lidocaine injection in each paracervical region
223840031|NCT00811187|DRUG|Normal Saline|5cc Normal Saline injection in each paracervical region
223840032|NCT03618303|DIAGNOSTIC_TEST|PET-MRI scan|Patients will undergo combined Positron Emission Tomography and Magnetic Resonance Imaging prior to a planned invasive angiogram (performed as standard of care). During the angiogram procedure, an additional imaging test (optical coherence tomography) will be performed.
223840033|NCT02877953|BEHAVIORAL|the prevention of complications post-TIPS|Continuous nursing through telephone follow-up, family visits, and WeChat guided patients to prevent gastrointestinal bleeding, infection and constipation ,intake quality low-protein diet, recognize minimal encephalopathy, monitor blood ammonia, return visit regularly, deal with adverse drug reactions of anticoagulant.
223840034|NCT04326985|BIOLOGICAL|Autologous Mesenchymal Stem Cells Treatment (MSCs)|The MSCs treatment group patients will receive an intra-articular injection of a mesenchymal stem cell (MSCs) suspension in the affected knee.
223840035|NCT04326985|DRUG|Hyaluronic acid (HA)|The HA group patient will be given a single intra-articular injection of hyaluronic acid sodium salt, Synvisc-One (TRB Chemedica Ltd.)
223840036|NCT05585762|OTHER|Ketone ester|75 mL chocolate flavored beverage containing 25 g of ketone ester. Half a bottle (12.5 g/day) will be consumed for the first 7 days and a complete bottle (25 g/day) will be consumed for the remaining 77 days.
223840037|NCT05585762|OTHER|Non-ketone placebo|75 mL chocolate flavored beverage containing 25 g of non-ketogenic fat. Half a bottle (12.5 g/day) will be consumed for the first 7 days and a complete bottle (25 g/day) will be consumed for the remaining 77 days.
223840038|NCT00526305|DRUG|Vincristine|1,5 mg/m2 i.v., days 1 and 8
223840039|NCT00526305|DRUG|Daunorubicin|60 mg/m2, i.v., days 1 and 8
223840040|NCT00526305|DRUG|Prednisone|60 mg/m2 day, i.v. or oral, days 1 to 14
223840041|NCT00526305|DRUG|L-Asparaginase|10.000 UI/m2, i.v., days 5-7 and 11-13. Total: 6 doses.
223840042|NCT00526305|DRUG|Mitoxantrone|12 mg/m2 i.v days 15, 16 and 17
223840043|NCT00526305|DRUG|Cytosine Arabinoside|1.500 mg/m2 /12 hours, days 16, 17 and 18 (total: 6 doses) If slow response to treatment: 3.000 mg/m2/12 hours, days 18, 19, 20 and 21 (8 doses)
223840044|NCT00526305|DRUG|Hydrocortisone|10 mg ,15 mg or 20 mg depending of age
223840045|NCT00526305|DRUG|Mercaptopurine|50 mg/m2, oral, days 1 to 7, 28-35 and 56-63 in consolidation
223840046|NCT00526305|DRUG|Cyclophosphamide|600 mg/m2 day, i.v., days 1 to 15 in consolidation
223840047|NCT00526305|DRUG|Dexamethasone|10 mg/m2 day, oral or i.v. days 1-14 5 mg/m2 day, oral. or i.v., days 15-21
223840048|NCT04179994|OTHER|Miswak extract-containing toothpaste|Miswak extract-containing toothpaste will be applied to the tooth diagnosed with DH
223840049|NCT04179994|OTHER|Potassium nitrates-containing toothpaste|Potassium nitrates-containing toothpaste will be applied to the tooth diagnosed with DH
223840050|NCT04179994|OTHER|Placebo|A toothpaste containing the same ingredients of the test toothpaste except for the active ingredient
223840051|NCT05590910|OTHER|Music|Fifteen minutes of classical music will be played overhead in the classroom. The students will be instructed not to use other electronic devices such as ear buds or phones during this time.
223840052|NCT04427722|DEVICE|MPS-Flex Total Knee Joint Prostheses|Patients who have received MPS-Flex Total Knee Joint Prostheses for their primary TKA and meet the Patient Selection Criteria outlined in the study protocol.
223840053|NCT03232190|OTHER|Web Application|Parents receive a web application that offers information and support until the age of 2.
223840054|NCT00994279|BEHAVIORAL|Yoga|Yoga sessions
223840055|NCT00994279|BEHAVIORAL|Education|Educational Wellness Group
223840056|NCT04317170|OTHER|Music|Participants will be played Frederic Chopin's piano sonatas through a headphone device prior to and during injection of local anesthesia during their routine standard of care dermatologic procedure
223840057|NCT01791426|DEVICE|Artelac Rebalance|Instill 1 drop of the Artelac Rebalance eye drops in each eye 3 to 5 times per day for 90(± 10) day treatment.
223840058|NCT01791426|DEVICE|Vismed|Instill 1 drop of the Vismed eye drops in each eye 3 to 5 times per day for 90(± 10) day treatment.
223840059|NCT00812630|DRUG|MENT or placebo|A dose of 1600µg/d of MENT will be delivered daily using a gel formulation containing 8.0 mg of MENT per 1.0 mL (delivering 800µg/d). Two mLs of gel will be applied daily for four weeks in the pilot study (by 6 men) and for 12 weeks in the main trial (by 62 men).
223840060|NCT01606189|DRUG|GW-1000-02|Contains delta-9-tetrahydrocannabinol (THC) (25 mg/ml) and cannabidiol (CBD) (25mg/ml) as extract of Cannabis sativa L, with peppermint oil, 0.05% (v/v), in ethanol:propylene glycol (50:50) excipient. Each actuation delivered 100 μl (THC 2.5 mg and CBD 2.5 mg). The maximum daily exposure was set at 48 actuations per day.
223840061|NCT01606189|DRUG|GW-2000-02|Contains THC (25 mg/ml) as extract of Cannabis sativa L, with peppermint oil, 0.05% (v/v), in ethanol:propylene glycol (50:50) excipient. Each actuation delivered 100 μl (THC 2.5 mg). The maximum daily exposure was set at 48 actuations per day.
223840062|NCT01606189|DRUG|Placebo|Contains peppermint oil, 0.05% (v/v), quinoline yellow, 0.005% (w/v), sunset yellow, 0.0025% (w/v), in ethanol:propylene glycol (50:50) excipient. Each actuation delivered 100 μl. The maximum daily exposure was set at 48 actuations per day.
223840063|NCT03110679|BIOLOGICAL|injection of autologous bone marrow concentrate|
223840064|NCT03110679|BIOLOGICAL|injection of hyaluronic acid.|
223840065|NCT00162942|DEVICE|Adacolumn|"Ten apheresis sessions:~One hour of Adacolumn Apheresis System procedure per visit. Patient had two procedures per week for the first two weeks followed by one apheresis session per weeks for two weeks (Weeks 1-4). then a week break occurs for rest followed by one apheresis session per week for 4 weeks (weeks 6-9)."
223840066|NCT00162942|DEVICE|Sham|Sham, ten apheresis sessions within 9 weeks
223840067|NCT01513356|DRUG|BKM120|BKM120 will be administered on a continuous once daily dosing schedule at a dose of 100 mg (p.o.)until progression of disease or unacceptable toxicity or a maximum of 4 weeks.
223840068|NCT04730180|DEVICE|Transcranial Magnetic Simulation|Brain stimulation treatment will be performed using FDA-cleared TMS coils according to their intended use of treatment of medication resistant depression by targeting the dorsolateral prefrontal cortex.
223840069|NCT04730180|DEVICE|Mixed reality neuronavigation|Targeting of the dorsolateral prefrontal cortex will be performed with the help of a mixed reality neuronavigation system.
223840070|NCT02162732|DEVICE|Guided Therapy|A total of 200 neuroblastoma, brain tumor, and rare tumor patients will be treated. Guided therapy will allow the use of any therapeutic combination (up to 4 agents) provided it includes medications contained in the study report. All patients will be followed for survival, disease response, progression and safety. All patients will be treated according to the discretion of the treating oncologist and study committee (minimum 3 oncologists and one pharmacist). Extent of disease will be measured and assessed for changes throughout the course of the study and at 6-8 week intervals (every 2 cycles).
223840071|NCT00287638|DEVICE|CPAP|Continuous positive pressure device with a time clock
223840072|NCT00287638|DEVICE|placebo|no CPAP
223840073|NCT00410384|DRUG|Placebo|Placebo IV plus standard therapy; placebo administered on Days 0, 14, 28, and every 28 days thereafter through 72 weeks.
223840074|NCT00410384|DRUG|Belimumab 1 mg/kg|Belimumab 1 mg/kg IV plus standard therapy; belimumab 1 mg/kg administered on Days 0, 14, 28, and every 28 days thereafter through 72 weeks.
223840075|NCT00410384|DRUG|Belimumab 10 mg/kg|Belimumab 10 mg/kg IV plus standard therapy; belimumab 10 mg/kg administered on Days 0, 14, 28, and every 28 days thereafter through 72 weeks.
223840076|NCT01649102|DEVICE|Tunneled Cuffed Catheter (Palindroom, Hemoglide Bard)|"A tunneled cuffed catheter is inserted, randomization between:~* Palindroom~* Hemoglide Bard"
223840077|NCT01167023|DRUG|Prasugrel|Administered orally, once daily for 30 days.
223840078|NCT01167023|DRUG|Placebo|Administered orally, once daily for 30 days.
223840079|NCT03496961|BEHAVIORAL|Yan Nian Jiu Zhuan Fa|Yan Nian Jiu Zhuan Fa are the kneading methods while cognitive behavior education is the psychological education
223840080|NCT00080002|DRUG|Pegamotecan|
223840081|NCT03186937|DIETARY_SUPPLEMENT|hominex-2|Hominex-2 is a methionine-free amino acid modified medical supplement
223840082|NCT00429702|DRUG|Decadron®|Given IV
223840083|NCT00429702|DRUG|Benadryl®|Given IV
223840084|NCT00429702|DRUG|Ativan®|Given IV
223840085|NCT00429702|DRUG|ondansetron hydrochloride|Given IV
223840086|NCT00108784|BEHAVIORAL|Reduced-energy-density diet|
223840087|NCT04121273|BIOLOGICAL|CAR-T cell immunotherapy|"Patients enrolled will recieve three different doses of the CAR-T cell every two weeks as follows:~Dose 1: 1x10\^7/m2~Dose 2: 3x10\^7/m2~Dose 3: 1x10\^8/m2~The cell numbers are calculated according to CAR-positive T cells."
223840088|NCT01111890|DRUG|Azarga (brinzolamide 1% / timolol 0.5%)|Dosed twice daily at 9:00 AM and 9:00 PM for 12 weeks
223840089|NCT01111890|DRUG|Cosopt (dorzolamide 2% / timolol 0.5%)|Dosed twice daily at 9:00 AM and 9:00 PM for 12 weeks
223840090|NCT05168969|OTHER|Questionnaire|The families and health care providers will be invited to fill in a questionnaire related to hyperekplexia (clinical, pharmacological, and genetic data).
223840091|NCT04502927|PROCEDURE|Passive extension mobilization of the hand and wrist joints|"The physiotherapist will proceed with the passive mobilization of the spastic hand of the stroke patient or the dominant hand for healthy volunteers.~Two mobilizations will be performed for each participant, i.e. one for each type of medial or lateral grip. The order of mobilization will be determined by randomization."
223840092|NCT01253200|DEVICE|Blazer® Open-Irrigated Ablation Catheter|Blazer® Open-Irrigated Ablation Catheter
223840093|NCT01253200|DEVICE|Control Catheter|Open-irrigated radiofrequency ablation catheters that have received FDA market approval for the treatment of type 1 atrial flutter
223840094|NCT05651880|DRUG|Baricitinib 4 MG|4 mg per day for 6 months (For patients with creatinine clearance between 30 and 60 mL/min at baseline or during the study, the dosage of baricitinib will be 2 mg daily)
223840095|NCT02049437|DRUG|tocilizumab|"Subjects will be randomized 1:1 to one of the following arms:~ARM A: TCZ, 4 mg/Kg by IV infusion over 60 minutes (not to exceed 400 mg) once at study entry, followed by TCZ, 8 mg/Kg by IV infusion over 60 minutes (not to exceed 800 mg) at weeks 4 and 8, and THEN placebo by IV infusion at weeks 20, 24, and 28.~ARM B: Placebo by IV infusion at study entry followed by placebo by IV infusion at weeks 4 and 8, and THEN TCZ, 4 mg/Kg (not to exceed 400 mg) by IV infusion over 60 minutes once at week 20, followed by TCZ, 8 mg/Kg (not to exceed 800 mg) by IV infusion over 60 minutes at weeks 24 and 28."
223840096|NCT02049437|DRUG|Placebo|"Subjects will be randomized 1:1 to one of the following arms:~ARM A: TCZ, 4 mg/Kg by IV infusion over 60 minutes (not to exceed 400 mg) once at study entry, followed by TCZ, 8 mg/Kg by IV infusion over 60 minutes (not to exceed 800 mg) at weeks 4 aned 8, and THEN placebo by IV infusion at weeks 20, 24, and 28.~ARM B: Placebo by IV infusion at study entry followed by placebo by IV infusion at weeks 4 and 8, and THEN TCZ, 4 mg/Kg (not to exceed 400 mg) by IV infusion over 60 minutes once at week 20, followed by TCZ, 8 mg/Kg (not to exceed 800 mg) by IV infusion over 60 minutes at weeks 24 and 28."
223840097|NCT04392258|DIAGNOSTIC_TEST|TSH determination|Determination of serum concentration of thyrotropin (TSH)
223840098|NCT04392258|DIAGNOSTIC_TEST|FT4 determination|Determination of serum free thyroxine (FT4) concentration
223840099|NCT04392258|DIAGNOSTIC_TEST|FT3 determination|Determination of serum free triiodothyronine (FT3) concentration
223840100|NCT04392258|DIAGNOSTIC_TEST|SPINA-GT|Calculation of thyroid's secretory capacity (SPINA-GT)
223840101|NCT04392258|DIAGNOSTIC_TEST|SPINA-GD|Calculation of total deiodinase activity (SPINA-GD)
223840102|NCT06221774|DRUG|TT-00420 + Toripalimab|TT-00420 tablets in combination with Toripalimab injection
223840103|NCT05987150|RADIATION|Variation in anisotropy of the Spinal Cord using diffusion tensor imaging|All examinations were performed on a 3.0-T MRI machine with a 12-channel spine special coil (Ingenia CX, Philips Healthcare, Best, the Netherlands). The multi-sequence MRI protocol included conventional T1-weighted (sag \& tra), T2-weighted (sag \& tra), and DTI sequence.
223840104|NCT04121208|DRUG|JNJ-40346527|Active study drug
223840105|NCT04121208|OTHER|Placebo|Non-active study drug
223840106|NCT06492538|PROCEDURE|various types of angle interventions|procedures include laser peripheral iridotomy (LPI) to relieve pupillary tissue and deepen peripheral anterior chamber depth, Argon laser peripheral iridoplasty (ALPIp) to stimulate iris contraction and widen the angle, and mechanical separation of adhered angle tissues using instruments like goniosynechialysis hooks or iris repositor. Ab interno goniotomy using instruments like retina hooks, trabeculectomy hooks, or cannulas are used to incise trabecular meshwork and Schlemm's canal walls to enhance aqueous humor outflow.
223840107|NCT02217995|BEHAVIORAL|Mindfulness-Based Cognitive Therapy (MBCT)|"MBCT teaches patients to become more aware of, and to relate differently to, their thoughts, feelings, and bodily sensations. Through MBCT, patients will learn skills that allow them to disengage from habitual (automatic) dysfunctional cognitive routines, such as obsessional thinking. As an example, patients are encouraged to relate to thoughts and feelings as passing events in the mind, rather than to identify with them or treat them as accurate representations of reality. The MBCT protocol for OCD patients is adapted from Segal et al.'s original MBCT manual for depression (Segal, Williams \& Teasdale, 2002)."
223840108|NCT01096095|DRUG|Placebo|Powdered placebo in sachets containing each 3g. At the start of the study, the dose will be 15g/day (five sachets).
223840109|NCT01096095|DRUG|Sodium Phenylbutyrate|Powdered sodium phenylbutyrate in sachets containing each 3g. At the start of the study, the dose will be 15g/day (five sachets) and may be reduced in case of mild adverse events.
223840110|NCT00705640|BIOLOGICAL|incomplete Freund's adjuvant|Given subcutaneously and intradermally
223840111|NCT00705640|BIOLOGICAL|multi-epitope melanoma peptide vaccine|Given subcutaneously and intradermally
223840112|NCT00705640|BIOLOGICAL|tetanus toxoid helper peptide|Given subcutaneously and intradermally
223840113|NCT00705640|PROCEDURE|biopsy|Patients undergo surgical biopsy at replicate vaccine site
223840114|NCT01649726|PROCEDURE|Apnea test - control|
223840115|NCT01649726|PROCEDURE|Apnea test - CPAP|
223840116|NCT00625274|DRUG|Esomeprazole|40mg Oral
223840117|NCT00625274|DRUG|Lansoprazole|30mg Oral
223840118|NCT00625274|DRUG|Pantoprazole|40mg Oral
223840119|NCT04970238|DRUG|Levosimendan|Test drug: drug preparation method: 5ml (12.5mg) levosimendan injection was mixed with 500ml 5% glucose injection, the initial loading dose was 6 µg / kg for 10 minutes, followed by continuous infusion of 0.1 µg/ kg / min for 24 hours.
223840120|NCT04970238|OTHER|placebo|Control drug: 5% glucose injection, intravenous injection method is the same as the experimental group pump dose, the initial load dose of treatment is 6 µg / kg for 10 minutes, followed by continuous infusion of 0.1 µg / kg / min for 24 hours.
223840121|NCT01505075|RADIATION|Hypofractionated radiation|40 Gy in 5 fractions to prostate, 30 Gy in 5 fractions to seminal vesicles; total treatment duration 29 days
223840122|NCT01506921|DRUG|Racemic ketamine|0.6 mg/kg
223840123|NCT01506921|DRUG|S-ketamine|0.3 mg/kg
223840124|NCT04700319|DRUG|CD19/CD20 CAR-T cell infusion|CD19/CD20 CAR-T,Infusion,iv,0.2×10\^6-5×10\^6γδT /kg,once
223840125|NCT04462913|OTHER|no intervention|This is an observation study, with no intervention
223840126|NCT03459495|DEVICE|therapeutic ultrasound|Patients in the ultrasound group will be administered to the posterior neck region for 5 minutes in pulsed mode (pulse rate 1: 1) at 1 MHz, 1.5 W / cm2. The treatment will be done 5 days a week for a total of 10 days
223840127|NCT03459495|DEVICE|placebo ultrasound|When the ultrasonic device is in the closed position, the ultrasonic probe will be applied for 5 minutes in the posterior neck region of the patients. The treatment will be done 5 days a week for a total of 10 days.
223840128|NCT00393627|BEHAVIORAL|Sleep Education Program|The Sleep Education Program (SEP) is conducted by a licensed MS- or PhD-level mental health professional experienced in working with persons with dementia and their caregivers. The therapist meets with the AFH owner/operator and staff for four weekly sessions at the AFH. The SEP content includes information about the causes of sleep problems in dementia, and provides staff with assistance in developing customized resident behavioral sleep plans focused on environmental (light and noise), dietary (eliminating caffeine and excessive nighttime fluids), and sleep scheduling (reducing afternoon/ evening napping; consistent, appropriate bed and rising times) factors that are commonly associated with resident nighttime awakenings. A written manual is used.
223840129|NCT04187534|OTHER|Albumin Fluid Resuscitation Optimization Intervention|Multi-faceted quality improvement intervention to optimize appropriateness of albumin use for fluid resuscitation
223840130|NCT04187534|OTHER|Usual Practice|Albumin fluid resuscitation according to usual practice
223840131|NCT03838159|DRUG|Paclitaxel|"Paclitaxel must be administered by infusion over 3 hours in dextrose (D5W) or normal saline (NS). The concentration must not exceed 1.2 mg/ml.~The infusions must be mixed as soon as possible before the start of each infusion since the stability of paclitaxel beyond 24 hours is not known.~In-line filtration is obligatory since a small number of fibers within the acceptable limits of the USP Particulate Matter Test for LVP have been reported. Cellulose acetate filters of 0.22-micron pore size (such as IVEX II) can be used. The solution that shows excessive particulate matter must be rejected."
223840132|NCT03838159|DRUG|Carboplatin|Carboplatin must be administered at the end of the Paclitaxel infusion
223840133|NCT03838159|DRUG|Nivolumab|"Nivolumab is a soluble protein consisting of 4 polypeptide chains, which include 2 identical heavy chains and 2 identical light chains.~The administration of nivolumab infusion must be completed within 24 hours of preparation."
223840134|NCT03175991|DIAGNOSTIC_TEST|ultrasonography|"A morphologic evaluation will be performed according to International Ovarian Tumor Analysis Group recommendations for the following parameters:~Bilaterality , wall thickness, septations , papillary projections, solid areas, and echogenicity. The presence of ascites also will be recorded. Pattern recognition analysis will be used for ovarian masses highly suggestive of some diseases , then color Doppler will be activated to identify vascular color signals within the lesion."
223840135|NCT04338529|DRUG|Binosto 70Mg Effervescent Tablet|As discussed in group descriptions
223840136|NCT05569005|OTHER|THS use|Subjects who are not willing to quit smoking during the study duration will switch from cigarettes to using THS
223840137|NCT05569005|OTHER|Cigarette|Subjects who are not willing to quit smoking during the study duration will continue smoking their own preferred brand of commercially available cigarettes.
223840138|NCT05569005|OTHER|Smoking Abstinence|Subjects who are willing to quit smoking may be prescribed an NRT to support them in remaining abstinent from use of any tobacco and nicotine containing products during the study. (Behavioral support will be provided to subjects to aid with abstinence.)
223840139|NCT02065011|DRUG|Blood draw for the laboratory assessment|
223840140|NCT06494072|DRUG|Ampicillin for Injection|Ampicillin is an intravenous antibiotic commonly used in the initial treatment of children hospitalized with community-acquired pneumonia.
223840141|NCT06494072|DRUG|Ceftriaxone for Injection|Ceftriaxone is an intravenous antibiotic commonly used in the initial treatment of children hospitalized with community-acquired pneumonia.
223840142|NCT06494072|DRUG|Amoxicillin|Amoxicillin is an oral antibiotic commonly used in the treatment of children hospitalized with community-acquired pneumonia to complete the antibiotic course after discharge.
223840143|NCT06494072|DRUG|Ampicillin / Sulbactam Injection|Ampicillin/Sulbactam is an intravenous antibiotic commonly used in the initial treatment of children hospitalized with community-acquired pneumonia.
223840144|NCT06494072|DRUG|Amoxicillin-clavulanate|Amoxicillin-clavulanate is an oral antibiotic commonly used in the treatment of children hospitalized with community-acquired pneumonia to complete the antibiotic course after discharge.
223840145|NCT06494072|DRUG|Clindamycin|Clindamycin is an antibiotic that can be given intravenously or orally that is sometimes used in the treatment of children hospitalized or discharged with community-acquired pneumonia.
223840146|NCT06494072|DRUG|Cefprozil|Cefprozil is an oral antibiotic sometimes used in the treatment of children hospitalized with community-acquired pneumonia to complete the antibiotic course after discharge.
223840147|NCT06494072|DRUG|Levofloxacin|Levofloxacin is an antibiotic that can be given intravenously or orally that is sometimes used in the treatment of children hospitalized or discharged with community-acquired pneumonia.
223840148|NCT04712565|DEVICE|Astra Tech Implant System Profile EV|dental implant with a sloped neck configuration
223840149|NCT04712565|DEVICE|Astra Tech Implant System EV|dental implant with a conventional neck configuration
223840150|NCT04529538|BIOLOGICAL|Novel Oral Polio Vaccine Type 1 (nOPV1)|Each 0.1 mL (2 drops) dose of vaccine contains approximately 10\^6.5 CCID50.
223840151|NCT04529538|BIOLOGICAL|Novel Oral Polio Vaccine Type 3 (nOPV3)|Each 0.1 mL (2 drops) dose of vaccine contains approximately 10\^6.5 CCID50.
223840152|NCT04529538|BIOLOGICAL|Sabin Monovalent Oral Polio Vaccine Type 1 (mOPV1)|The Sabin mOPV1 control vaccine contains ≥ 10\^6.0 CCID50 per 0.1 mL (2 drops) dose.
223840153|NCT04529538|BIOLOGICAL|Sabin Monovalent Oral Polio Vaccine Type 3 (mOPV3)|the Sabin mOPV3 control vaccine contains ≥ 10\^5.8 CCID50 per 0.1 mL (2 drops) dose.
223840154|NCT05317143|OTHER|Evaluation of prostate cancer margins|Evaluation of prostate cancer margins
223840155|NCT06391034|DRUG|hyperpolarized pyruvate +/-urea (13C/15N)|Given IV
223840156|NCT06391034|RADIATION|Non-investigational Stereotactic body radiotherapy (SBRT)|Stereotactic body radiotherapy given outside of this study
223840157|NCT06391034|PROCEDURE|Radiotherapy (RT)|Radiation therapy given outside of this study
223840158|NCT06391034|PROCEDURE|Multi-parametric magnetic resonance imaging (mpMRI)|Imaging scan
223840159|NCT06391034|BIOLOGICAL|Non-interventional hormone therapy|Therapy given outside of this study as part of standard of care
223840160|NCT06391034|PROCEDURE|Prostate Biopsy|Biopsies may be taken from Trans-rectal ultrasound (TRUS) -visible lesion at the urologist's discretion
223840161|NCT06119087|DEVICE|Mechanical insufflation|"Mechanical insufflation (MI) is a chest physiotherapy exercise that will be performed using a type of mechanical insufflator-exsufflator (MI-E) known as the BiWaze Cough device. The device connects to a tube that can interface with a patient using either a facemask or mouthpiece.~Mechanical insufflation is a chest physiotherapy exercise that passively inflates the chest with positive pressure that is delivered in coordination with the patient's own inspiratory timing until maximal inflation capacity (MIC), determined by the patient or maximal chest rise on visual inspection. At MIC, the patient passively exhales, which completes one cycle. Prior literature has used a dose of 5 sets of 5 cycles once or twice daily. The maneuver is usually performed with assistance of a caregiver to hold the mask or mouthpiece in place."
223840162|NCT06397885|DEVICE|Milli Vaginal Dilator|Patient-controlled vaginal dilator that provides therapy through distention of the vaginal tissue under electromechanical expansion
223840163|NCT03431805|DRUG|Tranexamic Acid Injectable Solution|After the routine and prophylactic administration of a uterotonic , the intervention will be the IV administration of a 10-ml blinded ampoule of the study drug (either TXA or placebo according to the randomisation sequence) to the woman within 3 minutes after birth, slowly (over 30-60 seconds), once the cord has been clamped.
223840164|NCT03431805|DRUG|Sodium Chloride 0.9%|After a routine and prophylactic administration of a uterotonic , the intervention will be the IV administration of a 10-ml blinded ampoule of the study drug (either TXA or placebo according to the randomisation sequence) to the patient within 3 minutes afterbirth), slowly (over 30-60 seconds), once the cord has been clamped.
223840165|NCT02498379|DRUG|Cu[64]-25%CANF-Comb|Intravenous injection of 4-8 mCi of Cu\[64\]-25%CANF-Comb with PET-CT scans performed 1-4 hours, 5-10 hours, and 22-26 hours or 46-50 hours after injection.
223840166|NCT00461214|OTHER|Participation in laparoscopic training curriculum|General Surgery Training Outcome
223840167|NCT04293809|DRUG|Exparel Injectable Product|bupivacaine liposome injectable suspension
223840168|NCT04293809|DRUG|Bupivacaine Hydrochloride|1.3%, 13.3 mg/mL
223840169|NCT00159510|DRUG|Methylene blue|Injection bolus of 2 mg/kg PBW and infusion of 0.2 mg/kg/hr
223840170|NCT00159510|DRUG|Nitric oxide|An inhalation of NO via ETT at 10 ppm, partially weaned by 72 hrs of therapy
223840171|NCT00159510|DRUG|Methylene blue & nitric oxide|See the dosage in the previous arms
223840172|NCT02303743|DEVICE|Smart Phone Application|Bowel preparation was evaluated using the Harefield Cleansing Scale (HCS). The scale was the primary outcome measure
223840173|NCT02303743|DEVICE|Written instructions with visual aids|written instructions with visual aids explaining the procedure and when to begin self-administration of the bowel solution (control group).
223840174|NCT02899598|BIOLOGICAL|Extra blood draw samples|NEVER STARTED
223840175|NCT02899598|BIOLOGICAL|extra amniotic fluid samples|NEVER STARTED
224264785|NCT02794584|DRUG|sufentanil anesthesia|Anaesthesia is maintained by inhaled isoflurane in concentrations 0.7-0.8 % end-tidal with additional sufentanil injected during surgery, as required. During extracorporal circulation patients receive isoflurane via a vaporizer incorporated in the extracorporeal gas supply in the same concentrations.
224264786|NCT02794584|PROCEDURE|Hybrid closure|Hybrid closure of ventricular septal defects through the delivery system without cardiopulmonary bypass by transthoracic minimally invasive small incision.
224264787|NCT02794584|PROCEDURE|Control|Surgical closure of ventricular septal defects with cardiopulmonary bypass by routine open thoracotomy.
224264788|NCT04935554|OTHER|Person centred care|physical activity, nutrition, motivation, health competence, psychosocial.
224264789|NCT03705117|BIOLOGICAL|V565|Capsules for oral administration
224264790|NCT01215903|DIETARY_SUPPLEMENT|Fish gelatin and omega-3 polyunsaturated fatty acid|
224264791|NCT01215903|DIETARY_SUPPLEMENT|Omega-3 polyunsaturated fatty acid|
224264792|NCT03263793|BEHAVIORAL|Choral (group) singing therapy sessions|Choral (group) singing therapy sessions will be conducted once weekly and daily home practice exercises will be assigned. All vocal exercises are based on principles that have been successful in other intensive Parkinson Disease vocal exercise programs.
224264793|NCT04472858|DRUG|Donafenib|dose escalation: Donafenib 100 mg QD/100 mg BID/200 mg BID (p.o.). dose expansion: Patients will be assigned to specific tumor types and treated at the recommended dose for dose escalation.The recommended dose for dose escalation will be determined by the dose escalation study.
224264794|NCT04472858|DRUG|CS1001|CS1001 will be administrated by intravenous (i.v.) infusion once every 28 days
224264795|NCT02225106|DRUG|Methylphenidate|Subjects will be treated with oral methylphenidate, using a forced titration up to a dose of 30 mg given twice daily for 4 weeks. At that point, the neuropsychologic tests are repeated.
224264796|NCT05124522|BEHAVIORAL|MSPA eClass|An 8-week MS-HAPA Internet-based intervention
224264797|NCT03197818|DRUG|CHF 5993 100/6/12.5 µg|Fixed combination of extrafine beclometasone dipropionate 100 µg plus formoterol fumarate 6 µg plus glycopyrronium bromide 12.5 µg / metered dose
224264798|NCT03197818|DRUG|160 µg budesonide + 4.5 µg formoterol fumarate|Fixed combination of budesonide 160 µg plus formoterol fumarate 4.5 µg
224264799|NCT02623647|RADIATION|stereotactic body radiotherapy SBRT|40 Gy in 3 fractions to the prostate gland delivered with stereotactic body radiotherapy
224264800|NCT03501511|BEHAVIORAL|IDF modules|Patients in this arm will receive Pre-Ramadan education using IDF module for 4 weeks prior to Ramadan fasting
224264801|NCT03501511|BEHAVIORAL|Conversational Maps|Patients in this arm will receive Pre-Ramadan Education using Ramadan Fasting Diabetes conversation map for 4 weeks prior to Ramadan fasting
223840176|NCT03513198|DIAGNOSTIC_TEST|Endoscopic ultrasound (including fine needle aspiration)|"EUS will be performed before (including EUS-FNA for confirmation of diagnosis) and 2 months after the first course of treatment.~* Protocol of EUS with EUS-FNA should include linear EUS instruments with complete examinations of the pancreas.~* Tumor characteristics (echogenicity, echostructure, size) will be described as well as presence/absence of power Doppler signals.~* EUS-FNA will be performed in all pancreatic masses with at least four passes."
223840177|NCT03513198|OTHER|Contrast-enhanced endoscopic ultrasound (CE-EUS)|"CE-EUS will be performed during usual EUS examination before and 2 months after the first course of chemotherapy.~* The starting point of the timer will be considered the moment of intravenous contrast injection (Sonovue 4.8 mL).~* The whole movie (T0-T120s) will be recorded in a DICOM format on the embedded HDD of the ultrasound system, for later analysis.~* All post-processing and computer analysis of digital movies will be performed within the coordinating IT Center using Vue-Box"
223840178|NCT03513198|OTHER|Endoscopic ultrasound elastography (EG-EUS)|"EUS-EG will be performed during usual EUS examinations, before and 2-months after the first course of chemotherapy, with two movies of 10 seconds recorded on the embedded HDD~* The region of interest for EUS-EG will be preferably larger than the focal mass. If the focal mass is larger than 3 cm, part of the mass will be included in the ROI, as well as the surrounding structures. Very large ROI for the elastography calculations will be avoided~* The following pre-settings will be used in all centers: elastography color map 1, frame rejection 2, noise rejection 2, persistence 3, dynamic rage 4, smoothing 2, blend 50%.~* SR and SH will be measured; with three measurements made and recorded on the embedded HDD."
223840179|NCT03513198|DIAGNOSTIC_TEST|Contrast-enhanced computed tomography (CT)|"* Contrast-enhanced computed tomography will be obtained before treatment to assess the local extension of the tumor, and presence of lymph nodes and distant metastases.~* A template will be used to report the imaging results.~* The template includes morphologic, arterial, venous, and extrapancreatic evaluations.~* Contrast-enhanced computed tomography will be performed 2 months after the first course of chemotherapy, using the same template, in order to evaluate the tumor response. Tumor response will be assessed according to the Response Evaluation Criteria in Solid Tumors (RECIST)."
223840180|NCT02355405|DEVICE|lung ultrasound|lung ultrasound investigations were performed right before and after the surgical procedure.
223840181|NCT02355405|RADIATION|thoracic computed tomography|thoracic CT were performed within one hour after the LUS investigation
223840182|NCT05080621|DRUG|Ripretinib|50 mg tablets
223840183|NCT05080621|DRUG|binimetinib|15 mg tablets
223840184|NCT00235495|BIOLOGICAL|Albumin|human albumin, 25%, 2.0g/kg intravenously (or equivalent volume of saline control), infused over 2 h, commencing within 5 hours of stroke onset
223840185|NCT00235495|DRUG|Saline|equivalent volume of isotonic saline control
223840186|NCT02810808|PROCEDURE|1+PRN|PRN intravitreal injections of Ranibizumab 0.5mg guided by BCVA stabilization after the injection of the same does at the first month.
223840187|NCT02810808|PROCEDURE|3+PRN|PRN intravitreal injections of Ranibizumab 0.5mg guided by BCVA stabilization after the first three monthly intravitreal injections of the same does.
223840188|NCT02810808|DRUG|Ranibizumab|Ranibizumab - a recombinant, humanized monoclonal antibody Fab that neutralizes all active forms of VEGF-A was recently approved by the Food and Drug Administration for the treatment of all angiographic subtypes of subfoveal neovascular age-related macular degeneration
223840189|NCT01739387|DEVICE|Flutiform® pMDI and Breath Actuated Inhaler (BAI)|Both devices contain placebo
223840190|NCT00248521|DRUG|alvespimycin hydrochloride|
223840191|NCT05350995|OTHER|No intervention|No intervention
223840192|NCT00374387|DRUG|Nuvaring|
223840193|NCT00374387|DRUG|low-dose combination pill|
223840194|NCT00374387|DRUG|minipill|
223840195|NCT00330213|BEHAVIORAL|red wine and cognac consumption|
223840196|NCT06492941|DRUG|Docetaxel for Injection (Albumin bound)|Docetaxel for Injection (Albumin bound), by intravenous infusion, every 3 weeks.
223840197|NCT06492941|DRUG|Placebo|Placebo was human blood albumin without the active ingredient docetaxel
223840198|NCT06492941|DRUG|Best supportive care|Best supportive care includes, but is not limited to, pain control, nutritional support, and psychological care.
223840199|NCT05623969|DIAGNOSTIC_TEST|Holter ,Echo , Speckle tracking echocardiography|A 24-h ambulatory Holter Echocardiography Speckle tracking echocardiography (STE)
223840200|NCT05756842|DIETARY_SUPPLEMENT|Honey-based gel supplementation|70 g/day of a honey-based gel divided into 2 equal doses of 35 gr (in the morning and evening) for a total duration of 14 days
223840201|NCT04216160|OTHER|ACN cream (YUN)|Application of the facial cream ACN (YUN) twice a day, for 8 weeks +/- 2 days. Assessment before product use (T0), after 2, 4 and 8 weeks +/- 2 days of product use (T2w, T4w and T8w, respectively) and after 4 weeks +/- 2 days without product use (T12w).
223840202|NCT04216160|OTHER|Placebo cream (YUN)|Application of the facial placebo cream twice a day, for 8 weeks +/- 2 days. Assessment before product use (T0), after 2, 4 and 8 weeks +/- 2 days of product use (T2w, T4w and T8w, respectively) and after 4 weeks +/- 2 days without product use (T12w).
223840203|NCT03577145|DIETARY_SUPPLEMENT|Tomato, onion & lovage soup with inulin|Source of polyphenols and non digestible carbohydrate
223840204|NCT03577145|DIETARY_SUPPLEMENT|Tomato, onion & lovage soup|Source of polyphenols
223840205|NCT03577145|DIETARY_SUPPLEMENT|Inulin|Source of non digestible carbohydrate
223840206|NCT05194007|DRUG|Frondanol|Frondanol capsule (1000 mg) will be administered orally (Twice daily) in the double blind settings
223840207|NCT05194007|DRUG|Placebo|Placebo (corn starch) capsule will be administered orally (Twice daily) in the double blind settings
223840208|NCT02219594|DEVICE|CT image for patient with suspected in-stent restenosis|"Gemstone CT or 320-detector row spiral CT was assigned randomly to patient who was suspected in-stent restenosis.About after 10 days,they would accept the check of OCT which wold be the gold standard of in-stent restenosis."
223840209|NCT05567952|DRUG|nirmatrelvir|Participants will receive 2 tablets of nirmatrelvir every 12 hours
223840210|NCT05567952|DRUG|ritonavir|Participants will receive 1 capsule of ritonavir every 12 hours
223840211|NCT05567952|DRUG|placebo for nirmatrelvir|Participants will receive 2 tablets of placebo for nirmatrelvir every 12 hours. A placebo does not have any medicine in it but looks just like the medicine being studied.
223840212|NCT01759992|DEVICE|Threshold® Inspiratory Muscle Trainer (treatment).|Interval-based program consisting of seven cycles of 2-minutes work and 1-minute rest. The sessions will take place 3 times per week over a eight-week period for a total of 24 sessions. All participants were familiarized with the breathing exercises over a two-week familiarization period at the beginning of the protocol. The load will be adjusted at ≥ 50% of baseline MIP.
223840213|NCT04680910|DRUG|Propofol|Targeted propofol infusion in TRD patients will induce sedation with maximal expression of EEG slow waves and minimal burst suppression.
223840214|NCT04680910|DIAGNOSTIC_TEST|Electroencephalography (EEG)|EEG will be recorded during propofol infusion and during overnight sleep. Sleep EEG data will be acquired for a minimum of one night prior to the first sedation session, providing a baseline measure. Additional overnight sleep recordings will be performed on day of sedation and subsequent nights.
223840215|NCT04680910|DIAGNOSTIC_TEST|Slow-Wave Activity|Duration of slow waves during sedation will be evaluated using automated approaches. SWA during sedation will be calculated as the total power in the 0.5-4 Hz frequency band/total time in minutes. SWA during N2/N3 sleep will be calculated as the total power in the 0.5-4 Hz frequency band/total time in minutes in the N2 and N3 sleep stages. Delta sleep ratio will be computed from the SWA measured during the first and second N2/N3 cycles.
223840216|NCT04707794|DRUG|Sevoflurane|Sevoflurane delivery will will be titrated to maintain anaesthesia depth of 50 (BIS score) using bispectral (BIS) index monitioring
223840217|NCT04707794|DRUG|Desflurane|Desflurane delivery will be titrated to maintain anaesthesia depth of 50 (BIS score) using bispectral (BIS) index monitioring
223840218|NCT05139160|DIETARY_SUPPLEMENT|Protein quality|the present investigation aims to study a novel protein based protein isolate blend with and without leucine an compared with whey protein isolate to determine its impact aminoacidemia and muscle protein synthesis healthy adults.
223840219|NCT06158347|DEVICE|hyperbaric oxygen chamber|Hyperbaric oxygen therapy allows patients to breathe 100% oxygen through an O2 Fresh M50 (HBOT Medical, Wonju, South Korea) chamber. Upon entering the chamber, oxygen is supplied by gradually increasing the barometric pressure from normal pressure to 1.5 atmospheres absolute (ATA).
223840220|NCT03549806|DIAGNOSTIC_TEST|No Intervention. Test is computer algorithm.|Diagnostic algorithms (test) will be run on already acquired clinical data. No study intervention in operator-prescribed clinical ablation. Predictive accuracy of test for study outcome will then be determined in follow-up
223840221|NCT03282019|DEVICE|High-flow nasal cannula therapy|Subjects will receive nocturnal high-flow nasal cannula therapy with the myAIRVO2®, in addition to their current Home oxygen therapy (HOT). The myAIRVO2® is used for at least 4 hours per day with flow rates in the range 30-40 L/min. The investigator can adjust the nocturnal oxygen flow rates to keep SpO2 88-92% stably. If the subjects report discomfort, the investigator can adjust the flow rates in the range at least 20 L/min.
223840222|NCT03282019|DEVICE|Home oxygen therapy (HOT)|All subjects will continue their current Home oxygen therapy (HOT) which kept original usage conditions at the time of enrollment throughout the entire duration of the study regardless of treatment arm assignment.
223840223|NCT06542705|DEVICE|Arthrex Internal Brace|The Arthrex Internal Brace method for ACL reconstruction consists of suture tape used to reinforce the ACL during surgery. This suture tape is secured in place with bioabsorbable anchors that gradually degrade within the body over time.
223840224|NCT06542705|PROCEDURE|ACL Reconstruction|All patients will undergo ACL reconstruction (ACLR) with or without an internal brace. ACLR technique will be standardized to standard anteromedial (AM) portal femoral drilling to ensure consistency between surgeons.
223840225|NCT05468567|DIAGNOSTIC_TEST|SPHERE protocol : Spatial hearing performances test|Participants will be instructed to localize a sound emitted in their environment using a virtual reality setup (SPHEAR protocol).
223840226|NCT05468567|DIAGNOSTIC_TEST|French Matrix Test : audiology test of speech in noise perception|Intelligibility threshold is the signal-to-noise ratio (in decibels) for which the subject can repeat 50% of the words heard in a dichotic listening.
223840227|NCT05468567|BEHAVIORAL|SSQ15 questionnaire of life : (The Speech, Spatial and Other Qualities of Hearing Scale)|The SSQ questionnaire is a clinical subjective scale that allows evaluating of hearing performances in daily life. The questionnaire is divided into 3 main items (A: speech; B: spatial hearing; C: other qualities of hearing) comprising questions with rating scores out of ten.
223840228|NCT06042127|PROCEDURE|POEM-F|POEM-F would be performed as described in the arms section
223840229|NCT06042127|PROCEDURE|Conventional POEM|Anterior POEM performed as described in the arms section
223840230|NCT04230694|DEVICE|Dexcom Generation 6 CGM (Dexcom Gen6) device|Standing orders for blood sugars less than 100 will allow for administration of glucose replacement in the intervention group based on Dexcom Gen6 readings.
223840231|NCT02697799|BEHAVIORAL|High-level recruitment strategy consent form|Patients will be exposed to pre-consent messaging and a consent form that includes supplemental information describing a high-level recruitment strategy
223840232|NCT02697799|BEHAVIORAL|Mid-level recruitment strategy consent form|Patients will be exposed to pre-consent messaging and a consent form that includes supplemental information describing a mid-level recruitment strategy
223840233|NCT05931198|OTHER|Modified illusion of the rubber (syncrhone)|The residual limb of the patient will be hide for the patient. The prothesis and the other hand of the patient will be visible. The investigators are going to touch the residual limb and the prothesis at the same time (synchrone) during at least 2 min. The investigators will ask to the patient to point where they felt the touching spot on a tray with measurement grid and to asnwer to the pre-prepared questionnaire.
223840234|NCT05931198|OTHER|Modified illusion of the rubber (asynchrone)|The residual limb of the patient will be hide for the patient. The prothesis and the other hand of the patient will be visible. The investigators are going to touch the residual limb and the prothesis not at the same time (asynchrone) during at least 2 min. The investigators will ask to the patient to point where they felt the touching spot on a tray with measurement grid and to asnwer to the pre-prepared questionnaire.
223840235|NCT04569708|OTHER|Auditory stimulation|Quiet auditory stimulation timed with sleep physiology
223840236|NCT05610410|OTHER|Laser speckle contrast analysis|Peripheral endothelial function assessment using Laser speckle contrast analysis and Peripheral reactive hyperemia assessment using EndoPAT
223840237|NCT02193633|DRUG|AZD2014 3 on/4 off & weekly paclitaxel|AZD2014 3 days on, 4 days off + weekly paclitaxel
223840238|NCT02193633|DRUG|AZD2014 2 on/5 off & weekly paclitaxel|AZD2014 2 days on, 5 Days off + weekly paclitaxel
223840239|NCT03337503|DRUG|THC and CDB in a 1 to 1 ratio|capsule containing cannabis oil
223840240|NCT03337503|DRUG|Experimental: THC and CBD in a 1 to 2 ratio|capsule containing cannabis oil
223840241|NCT03337503|DRUG|High CBD with trace THC oil|capsule containing cannabis oil
223840242|NCT03337503|OTHER|placebo|carrier oil capsule
223840243|NCT01005771|DRUG|GF-001001-00|GF-001001-00 2%, 1% and 0.25% twice daily for 7 days
223840244|NCT01005771|DRUG|Placebo|Matching placebo
223840245|NCT03672760|DEVICE|CardioBreathApp|Respiratory exercises performed with CardioBreathApp prescription and voice and visual guidance
223840246|NCT03672760|DEVICE|IMT PowerBreath|Inspiratory Muscle Training (IMT) performed with 30% load based on Maximal Inspiratory Pressure
223840247|NCT03672760|DEVICE|IMT PowerBreath Placebo|Inspiratory Muscle Training (IMT) without load
223840248|NCT04494321|DRUG|Budesonide|Inhaled corticosteroid
223840249|NCT04494321|DRUG|Formoterol|Long Acting Beta Agonist (LABA)
223840250|NCT03685188|DRUG|Oxycodone Hydrochloride|Subjects will receive patient' controlled intravenous analgesia in analgesic pump with 0.4 mg/ml of oxycodone for postoperative analgesia.
223840251|NCT03685188|DRUG|Sufentanil Citrate|Subjects will receive patient' controlled intravenous analgesia in analgesic pump with 2 μg/ml of sufentanil for postoperative analgesia.
223840252|NCT03425136|OTHER|Systems Analysis and Improvement Approach (SAIA)|Five-step systems analysis and iterative improvement cycles applied by district maternal and child health supervisors to subordinate health facilities providing prevention of mother-to-child HIV transmission services at the facility level.
223840253|NCT03869034|COMBINATION_PRODUCT|HAIC+PD1|Sintilimab ( 200mg Q3W iv D1)+FOLFOX-HAIC（oxaliplatin, 130 mg/m2 and leucovorin, 200 mg/m2, and fluorouracil, 400 mg/m2, bolus and 2400 mg/m2 over 46 hours Q3W D2 D3), maximally 8 cycles Multi-disciplinary consultation was organized to decide the chance of surgery and subsequent treatment per 2 treatment cycles. Patients who achieved partial response (PR) or minor response (MR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 and were assessed as eligible for R0 resection go on to undergo surgical resection. After recovery from operation , sintilimab monotherapy was given per three weeks for maximally 16 doses. Patients who were ineligible for resection would continue to receive the combination therapy.
223840254|NCT03869034|DRUG|HAIC|FOLFOX-HAIC: oxaliplatin, 130 mg/m2 and leucovorin, 200 mg/m2, and fluorouracil, 400 mg/m2, bolus and 2400 mg/m2 over 46 hours Q3W D2 D3, for maximally 8 cycles, and the safety parameters are reviewed before the start of each course of HAIC treatment. Patients who achieve partial response (PR) or minor response (MR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 and are assessed as eligible for R0 resection go on to undergo surgical resection. No other anti-tumor therapies are allowed before PD or postoperative relapse is confirmed.
223840255|NCT00421421|DRUG|Dutasteride|
223840256|NCT05202236|DRUG|pemigatinib|The patients will receive 13.5 mg (1 pill/time) of pemigatinib once a day (QD) orally following a 2-week administration/1-week interruption regimen, with 21 days as a cycle. They should take pemigatinib at regular times of the day to avoid the effects of inconsistent timing on plasma concentrations.
223840257|NCT01672983|DRUG|ABT-450/ritonavir, ABT-267|ABT-450 (tablet) dosed with ritonavir (capsule), and ABT-267 (tablet)
223840258|NCT03768661|PROCEDURE|Single-incision Laparoscopic cholecystectomy|laparoscopic cholecystectomy performed through a single device located at a unique umbilical incision
223840259|NCT03768661|PROCEDURE|Laparoscopic Cholecystectomy|laparoscopic cholecystectomy performed using three-trocars standard technique
223840260|NCT05247879|DIETARY_SUPPLEMENT|Glucose containing Oral Rehydration Solution (ORS)|Oral rehydration solution
223840261|NCT05247879|DIETARY_SUPPLEMENT|Sugar free - amino acid and electrolyte ORS|Glucose free oral rehydration solution
223840262|NCT06532552|DRUG|VACl|Azacitidine:75mg/m2 Subcutaneous daily for 7 days Venetoclax: orally once daily (100 mg d1, 200mg d2, 400mg d3-28) Cladribine: 5mg/m2 IV over approximately 1 to 2 hours, daily on days 1-3.
223840263|NCT06532552|DRUG|VACh|Azacitidine: 75mg/m2 Subcutaneous daily for 7 days Venetoclax: orally once daily (100mg d1, 200mg d2, 400mg d3-28) Chidamide: 10mg orally daily for 12 days
223840264|NCT06532552|DRUG|VACl Alternating With VACh|"VACl:~Azacitidine:75mg/m2 Subcutaneous daily for 7 days Venetoclax: orally once daily (100 mg d1, 200mg d2, 400mg d3-28) Cladribine: 5mg/m2 IV over approximately 1 to 2 hours, daily on days 1-3.~VACh:~Azacitidine: 75mg/m2 Subcutaneous daily for 7 days Venetoclax: orally once daily (100mg d1, 200mg d2, 400mg d3-28) Chidamide: 10mg orally daily for 12 days"
223840265|NCT06532552|DRUG|VA|Azacitidine: 75mg/m2 Subcutaneous (SC) daily for 7 days Venetoclax: orally once daily (100mg d1, 200mg d2, 400mg d3-28).
223840266|NCT03410485|DEVICE|BIS index/NoL index|"Remifentanil i.v. infusion will be run between 0.03 and 0.15 mcg/kg/min and boluses (0.4mcg/kg) will be given to keep a NoL index between 10-20.~Once intubated, the maintenance of anesthesia will be achieved with: desflurane set at 1 MAC to start, then adapted to the BIS between 45-55."
223840267|NCT03410485|DEVICE|Variation of baseline mean arterial pressure|"Remifentanil i.v. infusion will be run between 0.03 and 0.15 mcg/kg/min and boluses (0.4mcg/kg) will be given to keep a baseline mean arterial pressure between 10% of variation.~Once intubated, the maintenance of anesthesia will be achieved with: desflurane set at 1 MAC to start, then ajusted to 0.8 MAC."
223840268|NCT05829941|BEHAVIORAL|Smartwatch app to deliver binge-eating CBT strategies|Participants will receive a smartwatch with a pre-loaded app that will alert the participant to relevant binge-eating strategies based on their previous detected behavior.
223840269|NCT05829941|BEHAVIORAL|Reminder control condition|Participants will receive a smartwatch that vibrates randomly, and will be instructed the vibration is a cue not to binge eat.
223840270|NCT00611637|BIOLOGICAL|CMV pp65 Specific T Cells|Donor derived CMV pp65 specific T cells (1 x 105 CD3+ cells/kg (maximum 1 x 107 CD3+ cells) will be infused into recipient over 10 minutes.
223840271|NCT03177564|PROCEDURE|Protective ventilation 1|Low tidal volume, high inspired oygen fraction (FiO2) and recruitment maneuver.
223840272|NCT03177564|PROCEDURE|Protective ventilation 2|Low tidal volume, PEEP, moderate inspired oygen fraction (FiO2) and recruitment maneuver.
223840273|NCT03177564|PROCEDURE|Driving Pressure Limited Ventilation|Positive end expiratory pressure is adjusted to minimize driving pressure, plateau pressure minus end expiratory pressure from 3 to 10 cmH2O during one-lung ventilation and a FiO2 of 60%
223840274|NCT03049982|DEVICE|Auto-titrating mandibular positioner test|Participants will undergo a theragnostic test using the auto-titrating mandibular positioner to determine if they are eligible candidates to use oral appliance therapy for their obstructive sleep apnea. The device works by moving the lower jaw forward in response to respiratory events while the participant sleeps. All participants will undergo the same test.
223840275|NCT02522052|OTHER|Blue mussel diet|5 meals a week containing blue mussels
223840276|NCT02522052|OTHER|Meat/Control diet|5 meals a week containing meat
223840277|NCT03516149|OTHER|Foam Rolling Exercise|Foam rolling exercise will be performed actively. Participants will use a foam roller for exercise. They will position the foam roller on the chair. Afterwards, they will use their body weights to rub the elbow area (biceps brachii muscle) with this foam. There will be 2 sets and each set will be 1 minute. Single set contains 10 repetitions in 1 minute with 30 seconds resting period between sets
223840278|NCT03610217|OTHER|Interstitial lung disease induction algorithm|Patients failing first line mycophenolic acid (MFA) will be randomized to MFA plus rituximab or intravenous cyclophosphamide. If they fail the second line they will be crossed over to the other option.
223840279|NCT03610217|OTHER|Pulmonary arterial hypertension algorithm|Patients diagnosed with pulmonary arterial hypertension secondary to systemic sclerosis will be randomized to receive anticoagulation (warfarin, rivaroxaban or apixaban)
223840280|NCT03610217|OTHER|Raynaud's phenomenon algorithm|"Patients with mild Raynaud's phenomenon not responding to the first line treatment (nifedipine), will be randomized to receive losartan or nifedipine plus atorvastatin or nifedipine plus losartan. If they fail the second line they will be crossed over to the other options randomly.~Patients with severe Raynaud's phenomenon not responding to the first line treatment (nifedipine) or failing the previous mild Raynaud's algorithm, will be randomized to receive nifedipine plus sildenafil or nifedipine plus intravenous iloprost. If they fail the second line they will be crossed over to the other option."
223840281|NCT03610217|OTHER|Digital ulcer algorithm|"Patients with active digital ulcers not healing after 3 months or developing new ones with nifedipine will be randomized to nifedipine plus sildenafil or nifedipine plus intravenous iloprost. If they fail the second line they will be crossed over to the other option.~Patients who develop new digital ulcers under treatment with nifedipine will be randomized to nifedipine plus atorvastatin plus standard of care or nifedipine plus standard of care. If they fail the second line they will be crossed over to the other option."
223840282|NCT03610217|OTHER|Inflammatory arthritis algorithm|Patients with inflammatory arthritis failing methotrexate and/or prednisone and/or hydroxychloroquine and/or sulfasalazine will be randomized to receive intravenous rituximab or subcutaneous tocilizumab. If they fail the second line they will be crossed over to the other option.
223840283|NCT03610217|OTHER|Gastroesophageal reflux algorithm|Patients with gastroesophageal reflux failing standard doses of proton pump inhibitors (PPI) will be randomized to receive double doses of PPI or standard dose of PPI plus ranitidine or double doses of PPI plus domperidone or double doses of PPI plus prucalopride/erythromycin. If they fail the second line they will be crossed over to the other options randomly.
223840284|NCT03610217|OTHER|Bacterial overgrowth algorithm|Patients with bacterial overgrowth will be randomized to receive erythromycin or metronidazole or amoxicillin. If they fail the second line they will be crossed over to the other options randomly.
223840285|NCT03610217|OTHER|Constipation algorithm|Patients with constipation will be randomized to receive bisacodyl or magnesium sulphate or polyethylene glycol or senna.If they fail the second line they will be crossed over to the other options randomly.
223840286|NCT03610217|OTHER|Skin involvement algorithm|"Patients with skin involvement and modified Rodnan skin score \<32 will be randomized to receive methotrexate or mycophenolic acid or methotrexate plus mycophenolic acid. If they fail the second line they will be crossed over to the other option.~Patients with skin involvement and modified Rodnan skin score \>32 will be randomized to receive methotrexate plus mycophenolic acid or intravenous cyclophosphamide. If they fail the second line they will be crossed over to the other option."
223840287|NCT03610217|OTHER|Pain algorithm|Patients with pain failing first line treatment with acetaminophen or celecoxib or ibuprofen will be randomized to receive pregabalin or duloxetine. Patients with skin involvement and modified Rodnan skin score \<32 will be randomized to receive methotrexate or mycophenolic acid or methotrexate plus mycophenolic acid. If they fail the second line they will be crossed over to the other option. In case they fail the second line they will be treated with medical marijuana.
223840288|NCT05160025|OTHER|Virtual reality bicycling|This is a single arm study in which all participants will execute the same three bicycling tasks over one session. Exercise intensity and enjoyment are measured while participants bicycle in a virtual reality environment (wearing virtual reality goggles) in three different conditions lasting approximately 8 minutes each.
223840289|NCT05516342|BEHAVIORAL|LEAD IT! Programming|LEAD IT! is an intervention that enables persons with dementia to lead activities for their peers. The activities take place on tablets.
223840290|NCT04643743|DEVICE|Endarterectomy|Endarterectomy is a surgical procedure to remove the atheromatous plaque material, or blockage, in the lining of an artery constricted by the buildup of deposits. It is carried out by separating the plaque from the arterial wall.
223840291|NCT01929993|PROCEDURE|SWETZ|Straight wire excision of transformation zone is an electrosurgical conization method, which uses a straight wire electrode as a knife to remove the dysplastic epithelium of the cervix.
223840292|NCT01929993|PROCEDURE|LLETZ cone|LLETZ cone is a electrosurgical conization method, which is performed with a large loop electrode of 20 mm depth. The loop is applied to the cervix outside the lateral margin of the transformation zone and brought slowly to the controlateral transformation zone margin.
223840293|NCT01852162|DRUG|Dabigatran|Dabigatran 150mg
223840294|NCT01852162|DRUG|Placebo|Matching placebo tablets
223840295|NCT03224338|DRUG|Dolutegravir 50 mg|Dolutegravir will be used in combination with 2 nucleoside reverse transcriptase inhibitors (NRTIs). The NRTIs used in combination with DTG will be abacavir (ABC) plus lamivudine (3TC) or tenofovir (TDF) plus emtricitabine (FTC), which is in line with the current standard of care. The combination ABC/3TC/DTG will be preferential except in case of hepatitis B co-infection or in case the subject has a positive HLA-B\*5701 allele screening assessment.
223840296|NCT03679702|DEVICE|Viveve System|Radiofrequency device utilized in general surgical procedures for electrocoagulation and hemostasis.
223840297|NCT04176614|OTHER|cereal-legume snack|cereal-legume biscuit
223840298|NCT04176614|OTHER|cereal snack|cereal biscuit
223840299|NCT06055777|DRUG|SZEY-2108 for injetion|Part1（Single-dose intravenous infusion dose-escalation trial）:100mg，200mg，500mg, 1000mg, 2000mg，4000mg and the dose of last cohort to be determined. Single intravenous doses on D1；Part 2（Multi-dose intravenous infusion dose-escalation trial）：1000mg at Q8h，2000mg at Q8h, and one dose level of 1000mg, 1500mg or 2000mg at Q6h. Multiple intravenous doses of SZEY-2108 at Q8h or Q6h on D1\~D7 and on the morning of D8.
223840300|NCT06055777|DRUG|Placebo|Part1（Single-dose intravenous infusion dose-escalation trial）:250mL/500mL，Single intravenous doses on D1；Part 2（Multi-dose intravenous infusion dose-escalation trial）：250mL,Multiple intravenous doses of placebo at Q8h or Q6h on D1\~D7 and on the morning of D8.
223840301|NCT01427387|DRUG|ASP0456|oral
223840302|NCT01427387|DRUG|Placebo|oral
223840303|NCT00002563|PROCEDURE|psychosocial assessment and care|Evaluate psychosocial function at prestudy, 6 months after starting treatment on S9133, and annually at 1-7 years after starting treatment on S9133.
223840304|NCT00002563|PROCEDURE|quality-of-life assessment|Evaluate quality of life at prestudy, 6 months after starting treatment on S9133, and annually at 1-7 years after starting treatment on S9133.
223840305|NCT03904719|DRUG|CM082 plus JS001|CM082: 150mg once a day orally (taken within half an hour after breakfast) JS001: An intravenous infusion of a solution having a concentration of 1-3mg/ml was prepared with 0.9% physiological saline, and administered once every three weeks. Using an inline filter (0.2 or 0.22 μm), the drug was diluted with physiological saline and intravenously administered within 60 minutes.
223840306|NCT01866475|DEVICE|EZ-IO|To have an EZ-IO placed up to 48 hours
223840307|NCT02991885|BIOLOGICAL|HAL-MPE1|Weekly subcutaneous administrations of HAL-MPE1
223840308|NCT02991885|DRUG|HAL-MPE1 placebo|Weekly subcutaneous administrations of HAL-MPE1 placebo
223840309|NCT02115854|OTHER|labial biopsy|
223840310|NCT03871933|OTHER|Measurement of lung function, electrocardiography, echocardiography and autonomic function|Measurement of lung function, electrocardiography, echocardiography and autonomic function
223840311|NCT04333836|DEVICE|Removable Clear Aligners|"1. Plaster dental models will be poured from the rubber base impression.~2. Digital dental models will be created through scanning of plaster dental models.~3. Planning of the aligners will be done on 3 shape clear aligner studio®.~4. Aligners will be fabricated on 3d printed models using vacuum formers.~5. Anchorage reinforcement for posterior segments by using buccal miniscrews.~6. Patient will receive the first aligner and will be instructed to wear it full time (except during eating and brushing) for 2 weeks.~7. Patient will receive the following aligner after 2 weeks.~8. Follow up visits every 2 weeks until complete canine retraction."
223840312|NCT03647319|DEVICE|High-frequency rTMS on left DLPFC+anodal tDCS on right DLPFC|10Hz rTMS over the left DLPFC and anodal tDCS over the right DLPFC are simultaneously stimulated.
223840313|NCT03647319|DEVICE|High-frequency rTMS on left DLPFC+cathodal tDCS on right DLPFC|10Hz rTMS over the left DLPFC and cathodal tDCS over the right DLPFC are simultaneously stimulated.
223840314|NCT03647319|DEVICE|High-frequency rTMS on left DLPFC+sham tDCS on right DLPFC|10Hz rTMS over the left DLPFC and sham tDCS (no stimulation) over the right DLPFC are simultaneously stimulated.
223840315|NCT02466126|BEHAVIORAL|bCBT|"The bCBT intervention uses 6 active-treatment sessions, each lasting 30 to 40 minutes, and telephone booster sessions to solidify changes. All participants receive an initial (core) session. In this session, participants work with their study clinician to set goals that are not restricted to emotional health (e.g., depression) but may also address physical health concerns (e.g., diet, exercise, managing a chronic condition). Following the core session, clinicians provide participants with a series of module choices, from which they select skills that match their most pressing needs. Each module focuses on a CBT technique (e.g., behavioral activation, changing thoughts), introduced and customized to the patient's immediate goals, regardless of the focus (physical or mental health)."
223840316|NCT00244361|DRUG|rituximab|
223840317|NCT06522672|DIETARY_SUPPLEMENT|My Happy Flo|The intervention aims to alleviate period symptoms including heavy flows, prolonged periods, cramps, mood disturbances, energy levels, cycle regulation, and fatigue. Blood tests for Vitamin D and Iron levels will be conducted at Baseline and after the third menstrual cycle. Participants will complete validated questionnaires assessing period symptoms after each menstrual cycle.
223840318|NCT03081208|DRUG|Nolasiban 900mg|Nolasiban dispersible tablets for single oral administration
223840319|NCT03081208|DRUG|Placebo|Placebo dispersible tablets for single oral administration
223840320|NCT03660943|DRUG|Placebo|Receiving Placebo Injection
223840321|NCT03660943|DRUG|CNTX-4975-05|Receiving CNTX-4975-05 Injection
223840322|NCT03329833|BEHAVIORAL|Motivational Interviewing|Motivational interviewing will consist of weekly phone calls for two months, bi-weekly phone calls for two months, and monthly phone calls for two months.
223840323|NCT03329833|BEHAVIORAL|Web-based application|Web-based application participants will be asked to log activity at least on a daily basis.
223840324|NCT06216028|BIOLOGICAL|Autologous Bone Marrow Aspirate Concentrate|Range of between 18.7 X 104 cells/mL and 21.8 X 106 cells/mL total nucleated cells (TNC)
223840325|NCT04096365|DEVICE|Subcostal Temporary Extracardiac Pacing Lead|The StealthTrac Lead is designed to facilitate extracardiac temporary ventricular pacing and sensing. The distal end of the StealthTrac Lead is designed to reside within the connective tissue of the anterior mediastinum outside the pericardium. The StealthTrac Lead is delivered using the MACH I Delivery Tool, which is designed to facilitate insertion of the StealthTrac Lead through a small skin incision parallel to the sternum, without the need for fluoroscopic guidance.
223840326|NCT04019522|OTHER|Acute Intermittent Hypoxia (AIH)|An oxygen monitor will continuously measure and record the fraction of inspired oxygen delivered to the subject. Inspired fraction of oxygen (FiO2) of the gas mixture will be individually adjusted using the valve settings to reach the targeted SpO2. The gas mixtures administered during the four sessions will be 21% O2 (target SpO2 = 95%), 17% O2 (target SpO2 = 92%), 13% O2 (target SpO2 = 87%) and 9% O2 (target SpO2 = 82%).
223840327|NCT04577820|DRUG|garetosmab|Repeated doses administered intravenously (IV) every four weeks (Q4W)
223840328|NCT01452672|RADIATION|Radiotherapy|RT 40 Gy in 15 fractions
223840329|NCT01452672|RADIATION|Irradiation of the chest-wall and supraclavicular fossa|RT 40Gy in 15 fractions
223840330|NCT00839202|OTHER|FVIII immuno-assay|There is no intervention. This is a study of the differences in assays.
223840331|NCT02522520|BEHAVIORAL|Pedometer intervention|12 weeks physical activity intervention (supervised/non-supervised)
223840332|NCT02522520|BEHAVIORAL|Pedometer + hospital based intervention|12 weeks physical activity intervention (supervised/non-supervised)
223840333|NCT02522520|DEVICE|Omron Walking Style pro. 20|
223840334|NCT05192512|DRUG|TQB2928 injection|TQB2928 injection is a CD47 Blocker.
223840335|NCT04650347|PROCEDURE|visualized internal urethrotomy|incision of a urethral stricture to treat urinary obstruction using Quanta Holmium device or Sache cold knife, 18 Fr silicon catheter was kept for 7 days following the prodecure.
223840336|NCT00864565|DRUG|Fentanyl 25 μg/h transdermal system, single application|A: Experimental Subjects received Corium International, Inc formulated products
223840337|NCT00864565|DRUG|Duragesic 25 μg/h transdermal system single application|B: Active comparator Subjects received Jassen Pharmaceutica Products, L.P. formulated products
223840338|NCT05310084|BIOLOGICAL|BNT162b2|Intramuscular injection
223840339|NCT05310084|OTHER|Placebo|Saline intramuscular injection
223840340|NCT05310084|BIOLOGICAL|Seasonal Inactivated Influenza Vaccine|SIIV intramuscular injection
223840341|NCT04921995|DRUG|Tislelizumab|"1. Chemotherapy (including but not limited to following):~   GP regimen: gemcitabine 1000mg/m2 d1, d8 + cisplatin 25 mg/m2 d1-3, every 3 weeks for 4-6 cycles; GX regimen: gemcitabine 800mg/m2 d1 + capecitabine 750 mg/m2 d1-14, every 3 weeks for 4-6 cycles.~   Capecitabine: 750 mg/m2 d1-14, every 3 weeks until unacceptable toxicities or patient's withdraw.~2. anti-PD-1 antibody: Tislelizumab concurrently with chemotherapy: 200mg, every 3 weeks for 12 weeks. Tislelizumab in maintenance period: 200mg every 3 weeks or 400mg every 6 weeks, until one year or disease progression, or in the case of intolerable toxicities."
223840342|NCT04727710|BEHAVIORAL|Mindfulness-based Intervention|A self-directed, web-based mindfulness training. Investigators recommend one module a week for 6 weeks. Each module is approximately 1 hour long and consists of didactic components as well as meditation and mindfulness exercises.
223840343|NCT04727710|BEHAVIORAL|Usual Care|Standard pre-operative survivorship seminar, offered monthly to all patients at Michigan Medicine about to undergo prostatectomy and their partners is aimed at promoting realistic expectations of prostatectomy outcomes, typical side effects, rehabilitation and emotional adjustment.
223840344|NCT02705911|OTHER|Isometric handgrip exercise|Participants have to perform 4 x 2 minute contractions with alternating hands, separated with 1 minute rest period using a ZonaHealth device;
223840345|NCT02705911|OTHER|Aerobic endurance training|To perform 150 minutes extra/week at moderate aerobic intensity
223840346|NCT05373901|DRUG|Dinutuximab Beta|Dinutuximab beta was administered intravenously at a dosage of 10 milligrams/ meters squared (mg/m2) per day for 10 consecutive days
223840347|NCT05373901|DRUG|13-cis-Retinoic Acid|13-cis-Retinoic Acid was administered orally at a daily total dose of 160 mg/m2, divided into approximately two equal doses given twice daily for 14 days following the conclusion of dinutuximab beta infusion.
223840348|NCT04440228|BEHAVIORAL|TeamSTEPPS|"TeamSTEPPS is an evidence-based approach for teams that can be adapted for school mental health.~Team Strategies and Tools to Enhance Performance and Patient Safety (TeamSTEPPS), has been widely disseminated in health care settings with promising outcomes. TeamSTEPPS is designed to build competencies in the areas of leadership, situation monitoring, mutual support, and communication and has been associated with improvements in teamwork and communication as well as patient outcomes, such as decreased seclusion in psychiatric hospitals."
223840349|NCT04129762|OTHER|Diet without NCS|"A standard diet in terms of macronutrients will be calculated.~* 55% Carbohydrates~* 20% protein~* 25% Lipids The energy calculation will be done with the Harris Benedict formula and a diet with equivalents will be made and then a menu distributed in 5 meals, lasting 7 days.~The menu will not contain products with NCS."
223840350|NCT04129762|OTHER|Diet with NCS|"A standard diet in terms of macronutrients will be calculated.~* 55% Carbohydrates~* 20% protein~* 25% Lipids The energy calculation will be done with the Harris Benedict formula and a diet with equivalents will be made and then a menu distributed in 5 meals, lasting 7 days.~The menu will contain products with NCS."
223840351|NCT05475223|DIAGNOSTIC_TEST|End Tidal Carbon Monoxide Value|A noninvasive ETCO value will be obtained by inserting a soft silicon cannula placed in the baby's nostril for a few minutes to measure exhaled end tidal carbon monoxide; a value corrected for ambient ETCO value will be recorded.
223840352|NCT03251144|DRUG|Switch to E/C/FTC/TAF daily|"If the participant is on an antiretroviral regimen other than Elvitegravir (ELV)/cobicistat CO)/emtricitabine (FTC)/tenofovir (TDF)\] (E/C/FTC/TDF) then the participant will be asked to switch to E/C/FTC/TDF for up to 6 months. This will allow for future switch (after these 6 months) from E/C/FTC/TDF 1 tablet once daily to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/FTC/TAF) 1 tablet once daily for a period of 12 months.~b) If the participant is on E/C/FTC/TDF 1 tablet once daily then the participant will be asked to switch from /C/FTC/TDF 1 tablet once daily to /C/FTC/TAF 1 tablet once daily for a period of 12 months."
223840353|NCT02892409|DRUG|Clarithromycin|Clarithromycin tablets
223840354|NCT02892409|DRUG|Amoxicillin|Amoxicillin capsules
223840355|NCT02892409|DRUG|Tripotassium bismuth dicitrate|Tripotassium bismuth dicitrate tablets
223840356|NCT02892409|DRUG|Lansoprazole|Lansoprazole capsules
223840357|NCT02892409|DRUG|TAK-438|TAK-438 tablets
223840358|NCT01049750|OTHER|type 2 diabetic patients|males; type 2 diabetic patients
223840359|NCT05737563|DRUG|PD-1 Inhibitors|Teripulimab 240mg, injection or Carrelizumab 200mg, injection, every 3 weeks.
223840360|NCT05737563|DRUG|Irinotecan|Irinotecan: 200mg/m2, injection (For patients who are confirmed to be homozygous for UGT1A1\*6 or UGT1A1\*28 or UGT1A1\*6 and UGT1A1\*28 at the same time, the starting dose of CPT-11 is 150 mg/m2).
223840361|NCT05737563|DRUG|Capecitabine tablets|Capecitabine: 1600 mg/m2/d, oral, 2 weeks on and 1 week off.
223840362|NCT03700255|PROCEDURE|PickUpSimTM simulation training program|"The residents will take part in simulation sessions of 30 minutes duration. There will be 4 training sessions with seven simulation scenarios available. During the sessions, the following data will be collected for each scenario success or failure, reason for failure, time needed for completion, and oocyte retrieval rate. All scenarios will be repeated in the same conditions in the second week and data collected again. In the following 15 days, residents will start performing OPU, under direct supervision from senior physicians. For each patient, the resident will puncture one ovary. During the retrieval, the operator will specify the number of follicles punctured for each collected tube. The identity of the operator and the number of follicles punctured (per tube and in total) are noted on a separate sheet entitled the retrieval sheet. After the first month, residents will start performing all the OPUs, including both ovaries, supervised by the senior physicians."
223840363|NCT03356743|DEVICE|Spectrum Analysis|The ultrasound probe will be placed on the lung surface in several different directions to obtain the cross section with maximum diameter. Three spectral parameters including midband-fit (dB), intercept (dB), and slope (dB/MHz) will be calculated and compared between the tumor and the lung.
223840364|NCT00868205|DIETARY_SUPPLEMENT|Coffee consumption|3 or 5 cups of coffee daily for eight weeks
223840365|NCT02331940|DRUG|tiotropium|Comparison of the effect of tiotropium delivered by the Respimat Soft Mist Inhaler versus the HandiHaler on sleeping oxygen saturation and sleep quality in patients with COPD.
223840366|NCT02331940|DEVICE|Handihaler|Inhalation via the HandiHaler once daily
223840367|NCT02331940|DEVICE|Respimat|Inhalation via the Respimat once daily
223840368|NCT05372003|DRUG|Dupilumab|dupilumab injections will be prescribed and managed by dermatology as standard of care
223840369|NCT05372003|OTHER|Photo therapy|light therapy will be prescribed and managed by dermatology as standard of care
223840370|NCT02123966|DRUG|Sirolimus|
223840371|NCT01974921|DEVICE|ALAIR Catheter. Radiofrequency system.|Radiofrequency with Alair Catheter trhough flexible bronchoscopy in three different sessions (right lower lobe, left lower lobe, both upper lobes).
223840372|NCT02810743|DRUG|ddAC-CP-Olaparib|ddAC-CP-Olaparib
223840373|NCT02810743|DRUG|ddAC-mini CTC|ddAC - mini CTC
223840374|NCT03904628|DRUG|TG02 capsules oral administration, BIW in every 28d|TG02 capsules150mg oral administration, BIW in every 28d
223840375|NCT03904628|DRUG|TG02 capsules oral administration, BIW in every 28d|TG02 capsules 200mg oral administration, BIW in every 28d
223840376|NCT03904628|DRUG|TG02 capsules oral administration, BIW in every 28d|TG02 capsules 250mg oral administration, BIW in every 28d
223840377|NCT04974502|PROCEDURE|Nonsurgical periodontal treatment|Oral hygiene instructions, scaling and root planning.
223840378|NCT06148259|OTHER|International prostate symptom score|Questionnaire of 8 questions to be administered to all patients about prostate symptoms
223840379|NCT06148259|DIAGNOSTIC_TEST|Assessment of prostate volume|Measurements using ultrasound
223840380|NCT06148259|OTHER|Pittsburgh sleep quality Index|Questionnaire to assess quality of sleep
223840381|NCT06148259|DIAGNOSTIC_TEST|Glycated hemoglobin|Measures control of diabetes
223840382|NCT03654989|DRUG|Treprostinil iontophoresis|We will administer treprostinil at increasing doses by a iontophoresis.
224264802|NCT05387109|DRUG|penpulimab combined with anlotinib|penpulimab: fixed dose of 200 mg, administered on the first day of each cycle, repeated every 3 weeks; Anlotinib: 12 mg, administered on days 1-14, orally once a day, about half an hour before breakfast (the daily dose should be as much as possible), taken with warm water, and repeated every 3 weeks
224264803|NCT01418573|OTHER|Palaeolithic meal 1|Based on estimated ratios for protein, fat and carbohydrates that are typical of Hunter-Gatherers and does not contain ingredients that were not available in pre-neolithic times
224264804|NCT01418573|OTHER|Palaeolithic meal 2|Based on WHO dietary guidelines for protein, fat and carbohydrate but does not contain ingredients that were not available in pre neolithic times
224264805|NCT01418573|OTHER|Reference meal|Based on WHO dietary guidelines for protein, fat and carbohydrate.
224264806|NCT04733456|BEHAVIORAL|Quality of life questionnaires|Mayo Clinic Score (UC) or HBI score (CD), short IBDQ73, \*EQ5D-5L, \*GAD-774, \*PHQ-975, \*PROMIS (Gastrointestinal Belly Pain), Multidimensional Assessment of Interoceptive Awareness (MAIA)77, \*Pain Catastrophizing Scale, Pittsburg Sleep Quality Index (PSQI) and Fatigue Severity Scale (FSS) at baseline and 16 weeks after the start of anti-TNF therapy
224264807|NCT04733456|DEVICE|NIRS|A TechEn NIRSOptix continuous-wave fNIRS system will be used to record changes in cerebral oxygenation, at a sampling rate of 25 Hz
224264808|NCT04733456|OTHER|Stool Collection|For assessment of the known biomarker fecal calprotectin, in addition to fecal bacterial and fungal microbiome
224264809|NCT04733456|OTHER|Blood and urine collection|for inflammatory markers and metabolomic \[IMC\] analysis
224264810|NCT02604641|DIETARY_SUPPLEMENT|Placebo group|Subjects will take 5 mL of placebo syrup (0 mg CoQ10/day) once per day for 12 weeks.
224264811|NCT02604641|DIETARY_SUPPLEMENT|Quvital LD group|Subjects will take 5 mL of LD syrup (50 mg CoQ10/day) once per day for 12 weeks.
224264812|NCT02604641|DIETARY_SUPPLEMENT|Quvital HD group|Subjects will take 5 mL of LD syrup (150 mg CoQ10/day) once per day for 12 weeks.
224264813|NCT01074424|GENETIC|proteomic profiling|
224264814|NCT01074424|OTHER|laboratory biomarker analysis|
224264815|NCT00197249|BIOLOGICAL|Combined Vi polysaccharide typhoid vaccine and hepatitis A vaccine- Hepatyrix|
224264816|NCT03187821|PROCEDURE|Laser peripheral iridotomy|location of laser peripheral iridotomy
224264817|NCT02305134|DRUG|Tipepidine Hibenzate|
224264818|NCT02305134|DRUG|Placebo|
224264819|NCT04946708|OTHER|Exercise program (virtual/remote)|Intervention (8 weeks): using the participants' initial assessment and personal characteristics, the therapist will provide personalized recommendations (e.g. maximum heart rate, minimum SpO2), explain the educational materials, and instruct patients on safety precautions. All participants (and immediate caregiver if necessary) will receive training in: 1) basic device management (join a zoom meeting, watch a YouTube video), 2) use of the portable spirometer and its associated app, 3) use of finger pulse oximeter and 4) recording of the values in a dairy.
224264820|NCT01379313|PROCEDURE|conventional I:E ratio|conventional I:E ratio of 1:2 is applied.
224264821|NCT01379313|PROCEDURE|1:1 ratio|I:E ratio of 1:1 is applied.
224264822|NCT01379313|PROCEDURE|2:1 group|Inverse I:E ratio of 2:1 is applied.
224264823|NCT01379313|PROCEDURE|external PEEP|external positive end-expiratory pressure of 5 cmH2O is applied.
224264824|NCT00365053|DRUG|belinostat|Given IV
224264825|NCT00365053|OTHER|laboratory biomarker analysis|Correlative studies
224264826|NCT03590119|DRUG|Lutetium Lu 177-DOTATATE|Intra-arterial infusion of Lu-177-DOTATATE
224264827|NCT05538858|PROCEDURE|Mechanical Ventilation|Positive pressure mechanical ventilation
224264828|NCT04534985|BEHAVIORAL|Dietary|Dietary intake behavioral intervention via time restricted feeding and normal healthy eating recommendations vs. normal healthy eating recommendations without restricted
224264829|NCT01569113|DRUG|Ulipristal Acetate (UPA) + ethinylestradiol/levonorgestrel (Microgynon)|UPA: 30 mg, 1 tablet, single intake Microgynon 30mcg/150mcg, 1 tablet per day, 21-day intake
224264830|NCT01569113|DRUG|placebo + ethinylestradiol/levonorgestrel|placebo: 1 tablet, single intake Microgynon 30mcg/150mcg, 1 tablet per day, 21-day intake
224264831|NCT01866124|OTHER|Cash transfer|Recipient of transfers Mothers are the primary recipient of the CT. Cash is transferred using mobile phone credits that can be cashed at specific cash points provided by a telecom company.
224264832|NCT03420092|DRUG|Form 1 of AZD5718 tablets|The participants will be dosed with Form 1 of AZD5718 following an overnight fast of at least 10 hours.
224264833|NCT03420092|DRUG|Form 2 of AZD5718 tablets|The participants will be dosed with Form 2 of AZD5718 following an overnight fast of at least 10 hours.
224264834|NCT03420092|DRUG|Form 3 of AZD5718 tablets|The participants will be dosed with Form 3 of AZD5718 following an overnight fast of at least 10 hours.
224264835|NCT03420092|DRUG|Form 4 of AZD5718 tablets|The participants will be dosed with Form 4 of AZD5718 following an overnight fast of at least 10 hours.
224264836|NCT03420092|DRUG|Form 5 of AZD5718 tablets|The participants will be dosed with Form 5 of AZD5718 following an overnight fast of at least 10 hours.
224264837|NCT03420092|DRUG|Selected form (Form 2 - 5) of AZD5718 tablets|The participant will be administered with selected form (one of Form 2-5) of AZD5718 tablets 30 minutes after start of the meal.
223840383|NCT03654989|DEVICE|Remodulin® placebo iontophoresis|"Placebo iontophoresis will be performed using Remodulin® placebo (United Therapeutics) delivered with Axion GmbH electrodes connected to a PeriIont generator (Perimed).~* Part 1: 1 administration/day, on separate days, with 72h between two doses. The intensity will be set at 120 µA during 60 minutes, i.e. a total current of 17.3 mC/cm².~* Part 2: 1 administration/day for 10 days. The intensity will be set at 120 µA during 60 minutes, i.e. a total current of 17.3 mC/cm²."
223840384|NCT03941301|DEVICE|Light therapy|Participants will be exposed to bright treatment light or red light 30 minutes every day for 4 weeks.
223840385|NCT05470062|DEVICE|arch support insoles (FootDisc)|The FootDisc insole is designed with curEVA for shock absorption and motion reduction, poron for secondary heel and metatarsal protection, and dynamic arch support for returning energy for propulsion
223840386|NCT02022514|OTHER|Mononuclear cells from autologous bone marrow|Mononuclear bone marrow cells autologous intracoronary
223840387|NCT02022514|DRUG|Conventional medical treatment|
223840388|NCT04365413|DEVICE|MSOT Device|The MSOT Device will be used to take images of the tumor and/or lymph nodes of patients with solid tumors before and after surgery to measure the margins of the tumor and/or positive lymph node.
223840389|NCT04365413|PROCEDURE|Temperature Measurement|The temperature of the skin will be measured prior to and after MSOT imaging.
223840390|NCT04525300|DRUG|Liraglutide|Randomization was performed with the use of a computer-generated system provided by the sponsor. Eligible patients were randomly assigned, in a 2:1 ratio, to receive once-daily subcutaneous injections of liraglutide, starting at a dose of 0.6 mg with weekly 0.6-mg increments to 3.0 mg, or placebo; both groups received counseling on lifestyle modification
223840391|NCT04525300|DRUG|placebo|Randomization was performed with the use of a computer-generated system provided by the sponsor. Eligible patients were randomly assigned, in a 2:1 ratio, to receive once-daily subcutaneous injections of liraglutide, starting at a dose of 0.6 mg with weekly 0.6-mg increments to 3.0 mg, or placebo; both groups received counseling on lifestyle modification
223840392|NCT06580834|DEVICE|Cergenx Wave|Short EEG recording using EEG amplifier with cloud based algorithm to assess brain injury.
223840393|NCT03046303|PROCEDURE|ERAS|optimized pain control, restricted I.V. fluids, early initiation of post-operative oral feeding and enforced mobilization
223840394|NCT02037061|DRUG|Bupivacaine|Intraoperatively the patient will receive 10ml of bupivacaine injected into the sacrospinous ligament.
223840395|NCT02037061|OTHER|Normal Saline|
223840396|NCT03019458|DIETARY_SUPPLEMENT|MINGO|6 20oz sachets will be taken daily by intervention group
223840397|NCT04099953|DIAGNOSTIC_TEST|Hand grip, joint range of motion , functional level of the upper extremity, physical activity levels|Hand grip force with Jamar Hand Dynamometer, joint range of motion with Baseline Digital Goniometer, functional level of the upper extremity with the Shoulder-Arm and Hand Problems Questionnaire(DASH), physical activity levels with International Physical Activity Questionnaire Short Form(IPAQ-short form) and physical functions with Human Activity Profile (HAP) were evaluated.
223840398|NCT06352190|DRUG|[14C] SY-5007|Carbon-14 labeled SY-5007
223840399|NCT06459362|DIAGNOSTIC_TEST|Serum cystatin C|Diagnostic test for detection of acute kidney injury
223840400|NCT05675774|DIAGNOSTIC_TEST|Dual Energy CT|Patients with acute stroke who receive intervention will undergo dual-energy CT in lieu of single-energy CT at 24 hours post-intervention.
223840401|NCT02548793|OTHER|Education: CPR Training via Mobile App|Using a mobile app to train users on chest-compression only CPR. Subjects will be encouraged to share the app with family and friends.
223840402|NCT02548793|OTHER|Education: CPR Training using the CPR Anytime VSI Kit|Subjects will be trained using the American Heart Association's Family and Friends CPR Anytime Kit. Subjects will undergo training in-hospital and will be encouraged to take the kit home to share with their family members and friends.
223840403|NCT04638699|OTHER|OptiScreen training|Special psycho-oncological training for nursing staff to acquire basic knowledge about the experience of mental stress as well as diagnostics of psychosocial stress
223840404|NCT05466708|DRUG|Esketamine combined with dexmedetomidine|"Esketamine, injection, 50mg/ bottle, source: hospital pharmacy, production unit: Jiangsu Hengrui Pharmaceutical Co., LTD., validity: 2 years, storage condition: airtight shading, room temperature.~Dexmedetomidine, injection, 0.2mg/ bottle, source: Hospital Pharmacy, manufacturer: Jiangsu Hengrui Pharmaceutical Co., LTD., expiration date: 18 months, storage condition: airtight shading, room temperature."
223840405|NCT05466708|DRUG|Dexmedetomidine|Dexmedetomidine, injection, 0.2mg/ bottle, source: Hospital Pharmacy, manufacturer: Jiangsu Hengrui Pharmaceutical Co., LTD., expiration date: 18 months, storage condition: airtight shading, room temperature.
223840406|NCT01446029|DEVICE|Video Telemonitoring Device with Clinical Care Modules|Telemonitoring of vital signs; videoconferencing, remote titration of diabetes, blood pressure, and lipid medications using evidence based treatment algorithm, and cooperative goal setting using education modules to enhance lifestyle changes
223840407|NCT05731375|DIAGNOSTIC_TEST|31-MRS at 7 Tesla (T)|31-MRS imaging at 7T to evaluate mitochondrial function in skeletal and cardiac muscles.
223840408|NCT02044198|BIOLOGICAL|FMP2.1/AS01B|50 µg FMP2.1 in 0.5 mL of the adjuvant AS01B (containing 50 mcg MPL + 50 mcg QS21) is administered via intramuscular (IM) injection in the deltoid region of the non-dominant arm
223840409|NCT00862511|DEVICE|Coated Total Knee Arthroplasty|Implantation of a coated Total Knee Arthroplasty
223840410|NCT00862511|DEVICE|Standard Total Knee Arthroplasty|Implantation of a Standard Total Knee Arthroplasty
223840411|NCT02402972|DRUG|FUDR +oxaliplatin|IPC: one dose of fluorodeoxyuridine (FUDR) 1000 mg and oxaliplatin 100 mg were administered as a bolus into the regional vein
223840412|NCT02402972|DRUG|oxaliplatin+Leucovorin+5-FU|Adjuvant chemotherapy (AC): All patients received mFOLFOX6 adjuvant chemotherapy: oxaliplatin+Leucovorin+5-FU
223840413|NCT00021398|DRUG|fluorouracil|
223840414|NCT00021398|DRUG|leucovorin calcium|
223840415|NCT00021398|PROCEDURE|conventional surgery|
223840416|NCT00021398|RADIATION|radiation therapy|
223840417|NCT05267015|PROCEDURE|Gingival coverage using coronally advanced flap and a connective tissue graft|A coronally advanced flap is applied for recession coverage in the maxilla in a split-mouth randomized trial using a subepithelial connective tissue graft
223840418|NCT05267015|PROCEDURE|Gingival coverage using coronally advanced flap and platelet rich fibrin membranes|A coronally advanced flap is applied for recession coverage in the maxilla in a split-mouth randomized trial using platelet rich fibrin membranes
223840419|NCT04313387|DIAGNOSTIC_TEST|Corneal tomography multivariate index derived from a support vector machine (CTMVI).|MATHEMATICAL ALGORITHM: To build the equation extracted from SVM, 58 variables were used, some of them were extracted from the spreadsheet.. After the construction of these 58 feature vectors (FV), an SVM-derived index was created, which was called the corneal tomography multivariate index derived from a support vector machine (CTMVI). Considering that each patient represents a point on a cartesian plane with 58 dimensions (each coordinate representing one of the 58 FV), the role of SVM is to find the hyperplane that best separates the CG, KCG, and VAE-NT G subjects. A hyperplane is algebraically described by a linear equation; in this case, there are 59 coefficients, 58 of which are related to the FV and one independent coefficient representing the bias (which is a possible parallel dislocation of a given hyperplane).
223840420|NCT04082455|RADIATION|carbon ion radiotherapy|carbon ion radiotherapy
223840421|NCT00376480|BIOLOGICAL|anti-thymocyte globulin|
223840422|NCT00376480|BIOLOGICAL|peripheral blood lymphocyte therapy|
223840423|NCT00376480|DRUG|fludarabine phosphate|
223840424|NCT00376480|DRUG|methylprednisolone|
223840425|NCT00376480|DRUG|thiotepa|
223840426|NCT00376480|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
223840427|NCT00376480|PROCEDURE|in vitro-treated peripheral blood stem cell transplantation|
223840428|NCT00376480|RADIATION|total-body irradiation|
223840429|NCT01561079|DRUG|Buprenorphine|Daily sublingual buprenorphine treatment of pregnant, opioid dependent women from up to 34 weeks gestation through one month of infant age.
223840430|NCT06113029|DIAGNOSTIC_TEST|The Hamilton Rating Scale for Anxiety|The scale consists of 14 items, each defined by a series of symptoms, and measures both psychic anxiety (mental agitation and psychological distress) and somatic anxiety (physical complaints related to anxiety).
223840431|NCT06113029|DIAGNOSTIC_TEST|The Beck Depression inventory|one of the most widely used instruments for measuring the severity of depression
223840432|NCT06113029|DIAGNOSTIC_TEST|Rand SF-36 Questionnaire|The SF-36 measures eight scales: physical functioning (PF), role physical (RP), bodily pain (BP), general health (GH), vitality (VT), social functioning (SF), role emotional (RE), and mental health (MH). Component analyses showed that there are two distinct concepts measured by the SF-36: a physical dimension, represented by the Physical Component Summary (PCS), and a mental dimension, represented by the Mental Component Summary (MCS). All scales do contribute in different proportions to the scoring of both PCS and MCS measures
223840433|NCT03969602|BEHAVIORAL|Cognitive-behavioral Therapy|The biopsychosocial approach of CBT focuses on the complex interaction between psychological, social and biological factors. The biopsychosocial model assumes that health problems are hardly ever limited to just one domain of human experience but by multiple domains of human experience. CBT helps patients understand thoughts and feelings that influence behaviors. It consists of a cognitive aspect and a behavioral aspect. The cognitive aspect is based on Becks cognitive model: the way that individuals perceive a situation is more closely connected to their reaction than the situation itself. A person's cognition has impact on their mood and emotions, their bodily reactions and their behavior. The second part of cognitive behavior therapy focuses on the actual behaviors that are contributing to the problem. The goal of CBT is to identify maladaptive thoughts and change them into more realistic and constructive thoughts to modify feelings and behavior and thereby the experience of pain.
223840434|NCT03969602|OTHER|Biomedical and surgery-specific education|Biomedical and surgery-specific education preoperatively and an exercise manual postoperatively.
223840435|NCT03215225|PROCEDURE|Root canal orthograde treatment|
223840436|NCT04768062|DRUG|Viltolarsen|Received during weekly intravenous infusions
223840437|NCT02467374|BEHAVIORAL|Behavior Therapy|"BT for OCD focuses primarily on exposure with response prevention (ERP). ERP involves gradual exposure to anxiety-provoking situations (things or situations that frighten or disturb some people), and will help to prevent compulsions (repetitive behaviors)."
223840438|NCT01212705|DEVICE|Adaptive servoventilation|Background expiratory positive airway pressure with some inspiratory pressure support when needed
223840439|NCT02781155|OTHER|Moxibustion|Participants are taught to self administer moxibustion to acupuncture point Zusanli St-36 daily throughout the course of their chemotherapy
223840440|NCT01930617|PROCEDURE|Burr hole surgery with various drainage techniques|"Surgical technique~1. Continuous irrigation and drainage~2. Passive subdural drain~3. Active subgaleal drain"
223840441|NCT00917189|BEHAVIORAL|Challenging Our Minds Program|A computerized cognitive intervention that provides training in attention, memory, and executive function
223840442|NCT01971307|OTHER|SGE-PsyScan|
223840443|NCT05408650|OTHER|Aromatherapy Massage|"The PI will dilute pure lavender essential oil (Lavandula angustifolia) with almond oil at a dilution rate of 2.5% and apply it to the hands and feet of the patient.~* The massage technique including effleurage, petrissage, friction and lymphatic drainage on hands and feet will be adapted from Salvo, (2015) and Youssef and Hassan, (2017).~* The massage will be applied to the patient's hands and feet while the patient in semi-fowler's position."
223840444|NCT01349855|DRUG|Insulin glargine HOE901|Pharmaceutical form:solution for injection: new formulation and marketed formulation Route of administration: subcutaneous
223840445|NCT05315804|OTHER|MINSD and amelogenins|After local anesthesia, MINSD will be performed using an ultrasonic scaler with fine tips and micro-curette; then, amelogenins in gel will be applied to the intraosseous periodontal pockets using a sterile syringe with plasticized needle.
223840446|NCT05315804|OTHER|MINSD|Only subgingival mechanical debridement (MINSD) will be performed with an ultrasonic scaler with fine tips and micro-curette.
223840447|NCT00227747|DRUG|capecitabine|
223840448|NCT00227747|DRUG|oxaliplatin|
223840449|NCT00227747|PROCEDURE|conventional surgery|
223840450|NCT00227747|PROCEDURE|neoadjuvant therapy|
223840451|NCT00227747|RADIATION|radiation therapy|
223840452|NCT04860700|DRUG|anlotinib hydrochloride|Patients receive anlotinib hydrochloride 12mg orally once daily on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
223840453|NCT01819415|DIETARY_SUPPLEMENT|Anti-VEGF plus AREDS-2|Omega-3 metabolites supplementation
223840454|NCT01819415|DIETARY_SUPPLEMENT|Anti-VEGF plus AREDS-1|Patients receiving intravitreal anti-VEGF and AREDS-1 supplementation plus Lutein, without Omega-3.
223840455|NCT01214564|DRUG|PEP005 (ingenol mebutate) Gel|0.05%
223840456|NCT03394664|BEHAVIORAL|Feeding Study|Food provision throughout the study: 1) Run-In Phase (VLC diet, weight loss); 2) Residential Phase (3 different test diets, weight-loss maintenance).
223840457|NCT00268411|DRUG|gemcitabine hydrochloride|
223840458|NCT00268411|DRUG|oxaliplatin|
223840459|NCT03765697|DRUG|Lidocaine 5% medicated plaster|Topical application at the site of skin affected by painful PHN for up to 12 hours per day (plaster-free interval at least 12 hours).
223840460|NCT02644538|DRUG|PegIFN alfa-2a|chronic hepatitis B patients who treated with nucleot(s)ides (including lamivudine, adefovir, entecavir, tenofovir) arrived HBV DNA \<1000copies/ml, and HBsAg\<3000IU/ml, then change the treatment to original nucleot(s)ides add on PegIFN alfa-2a, the combined treatment is for 48 weeks, and follow up for 24 weeks
223840461|NCT05004779|PROCEDURE|human stem cell conditioned media was applied after non-ablative laser therapy|After laser treatment on hypertrophic scars, human stem cell media was applied to one side
223840462|NCT05004779|PROCEDURE|normal saline was applied after non ablative laser therapy|physiological saline was applied to the other side.
223840463|NCT02647918|DRUG|Sotagliflozin|Single dose
223840464|NCT02647918|DRUG|Sotagliflozin|2 single doses
223840465|NCT01605331|DRUG|sustained-release recombinant human GH (SR-rhGH)|
223840466|NCT06556030|DRUG|Botulinum Toxin A|Botulinum Toxin
223840467|NCT06556030|OTHER|CONTROL|Saline Solution
223840468|NCT04521205|DRUG|fecal microbiota capsule|a capsule full of fecal microbiota extracting from the health
223840469|NCT04982380|DRUG|Bifidobacterium, Lactobacillus, Enterococcus and Bacillus Cereus Tablets, Live|Patients will be instructed to continue current antidiabetic treatment, which should be kept unchanged throughout the trial, and start treatment with Bifidobacterium, Lactobacillus, Enterococcus and Bacillus Cereus Tablets, Live (Siliankang) 3 tablets p.o. tid for 12 weeks.
223840470|NCT04982380|DRUG|Siliankang simulating tablets|Patients will be instructed to continue current antidiabetic treatment, which should be kept unchanged throughout the trial, and start treatment with Siliankang simulative tablets 3 tablets p.o. tid for 12 weeks.
223840471|NCT05205941|DRUG|MMV688533|Not exceeding 200mg
223840472|NCT05248360|DEVICE|Hydrogen-oxygen mixed gas(H2-O2) inhalation|H2-O2 inhalation, 900ml/min, 2h/d \* 4 weeks (≥5 days/week)
223840473|NCT05248360|DEVICE|Air inhalation|Air inhalation, 900ml/min, 2h/d \* 4 weeks (≥5 days/week)
223840474|NCT04138628|DRUG|Atezolizumab|The study drug will be given according to current recommendations as systemic treatment every third week for 12 months or until progression. Treatment will be initiated within 28 days of detection of ctDNA.
223840475|NCT03454243|DRUG|RXDX-106|Patients will receive continuous daily oral doses of RXDX-106 in 21 day cycles. To determine the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D), study drug will be administered in an escalated fashion starting at dose of 10 mg/day and will proceed at the dose levels prespecified by the dose escalation schema. Once daily dosing for RXDX-106 will initially be tested. However, other dosing schedules (eg, every other day, weight based, etc) may be tested based on safety and PK data to optimize drug exposure.
223840476|NCT04089176|DRUG|Carbetocin|carbetocin 100 mcg + RLS solution 10 ml injected directly into the vein over 2 min
223840477|NCT04089176|DRUG|oxytocin|oxytocin 20 IU diluted in 1000 ml of RLS solution administered intravenously at rate 120 ml/hr x 8 hr
223840478|NCT00039208|DRUG|fluorouracil|
223840479|NCT00039208|DRUG|irinotecan hydrochloride|
223840480|NCT00039208|DRUG|leucovorin calcium|
223840481|NCT00039208|DRUG|oxaliplatin|
223840482|NCT00664521|BIOLOGICAL|Rituximab|Rituximab will be administered as an intravenous infusion at a dose of 1000 mg at Weeks 1 and 3.
223840483|NCT00664521|DRUG|Atacicept|Atacicept will be administered at a dose of 150 mg subcutaneously once a week from Week 7 to 32.
223840484|NCT00664521|DRUG|Placebo matched to atacicept|Placebo matched to atacicept will be administered subcutaneously once a week from Week 7 to 32.
223840485|NCT05362526|DEVICE|HFOT using AIRVO2|The AIRVO 2 is for the treatment of spontaneously breathing patients who would benefit from receiving high flow warmed and humidified respiratory gases. The subjects in this group will receive HFOT at a flow rate of 60-30L liters per minute, maximum concentration of 40%, which will be titrated by bedside nurse to maintain an oxygen saturation of 92% or greater (unless there is a history of COPD and then the clinician can recommend \>88%)
223840486|NCT05362526|DEVICE|COT|Subjects will be placed on aerosolized trach mask with cool humidification, and titrated to keep oxygen saturation \>92% (unless there is a history of COPD and then the clinician can recommend \>88%)
223840487|NCT03667326|DRUG|Aspirin tablet|Low dose aspirin, 81mg tablets, PO
223840488|NCT03667326|DRUG|Placebo oral capsule|Placebo oral capsule, PO
223840489|NCT03558113|DIAGNOSTIC_TEST|light induced fluorescence intraoral camera|intraoral oral light induced fluorescence diagnostic camera
223840490|NCT00125983|DRUG|Lopinavir/ritonavir|
223840491|NCT00125983|DRUG|Ortho Novum 1/35|
223840492|NCT00125983|DRUG|Ortho Evra|
223840493|NCT03835520|DRUG|Immunotherapeutic Agent|Immunotherapy will be administered according to standard of care and reimbursement modalities in Belgium.
223840494|NCT03835520|DRUG|Molecular Target|Targeted agents will be administered according to standard of care and reimbursement modalities in Belgium. Targeted agents will be administered according to manufacturer's instructions.
223840495|NCT02459964|DRUG|Fentanyl Nasal Spray|Fentanyl nasal spray 100 mcg delivered at time 0 (defined as the time when intranasal Fentanyl spray is administered) with a rescue dose allowed at time 0.5 hour (h)
223840496|NCT02459964|DRUG|Hydromorphone Hydrochloride|Hydromorphone hydrochloride 1.5 mg pushed intravenously (IV) at time 0 (defined as the time of completion of opioid IV push) with a rescue dose allowed at time 0.5 hour (h).
223840497|NCT02459964|BEHAVIORAL|Phone Call|Study nurse to call patient 24 hours after participation to ask about side effects since taking part in the study. The phone call should last about 5 minutes.
223840498|NCT01409226|DEVICE|3.0-T MRI|Participants undergo MRI prior to biopsy.
223840499|NCT01409226|PROCEDURE|biopsy|Participants undergo breast biopsy after 3.0-T MRI.
223840500|NCT01960361|DEVICE|ICE dental implant|ICE- Implant Classical Esthetic implant
223840501|NCT05883579|PROCEDURE|percutaneous coronary intervention|doing percutaneous revascularization of chronic coronary total occlusion.
223840502|NCT04559308|DRUG|Metformin|first-line anti-diabetic drug
223840503|NCT04559308|DRUG|Chemotherapy|First line neoadjuvant chemotherapy protocol
223840504|NCT00423644|DRUG|Darinaparson|420 mg/m2 of Darinaparsin given twice weekly for three weeks, followed by one week of rest for up to six months
223840505|NCT00367237|DRUG|Infliximab + methotrexate (IFX + MTX)|Infliximab 5 mg/kg infusion at Weeks 0, 2, 6, 14 and oral methotrexate 15 mg/week for 16 weeks. Methotrexate dose can be increased to 20 mg/week at week 6.
223840506|NCT00367237|DRUG|Methotrexate (MTX)|Oral methotrexate 15 mg/week for 15 weeks. Dose can be increased to 20 mg/week at Week 6.
223840507|NCT02785055|PROCEDURE|Thoracic Epidural Placement|Thoracic Epidural Placement
223840508|NCT02785055|DRUG|Bupivacaine 0.05%|Delivery of epidural solution containing both bupivacaine 0.05%/hydromorphone0.01mg/mL solution
223840509|NCT02785055|DRUG|Hydromorphone 0.01mg/mL|Delivery of epidural solution containing both bupivacaine 0.05%/hydromorphone0.01mg/mL solution
223840510|NCT06493084|DRUG|LAE102 intravenous administration|A single dose of LAE102 administered intravenously
223840511|NCT06493084|DRUG|placebo intravenous administration|A single dose of placebo administered intravenously
223840512|NCT06493084|DRUG|LAE102 subcutaneous administration|Single dose of LAE102 administered subcutaneously
223840513|NCT06493084|DRUG|placebo subcutaneous administration|single dose of placebo administered subcutaneously
223840514|NCT06493084|DRUG|LAE102 multiple subcutaneous administration|Multiple dose of LAE102 administered subcutaneously
223840515|NCT06493084|DRUG|Placebo multiple subcutaneous administration|Multiple dose of placebo administered subcutaneously
223840516|NCT05318014|DIETARY_SUPPLEMENT|Intervention group|dietitian regular nutrition education which was following a low protein diet and supply one serving per day of 6 % low protein formula (200mL,2kcal/ml) for 24 weeks
223840517|NCT05318014|OTHER|Regular nutrition education|dietitian regular nutrition educataion which was following a low protein diet
223840518|NCT06131073|OTHER|speed endurance production (SEP) training along with conventional training.|this include speed endurance training for 3 days in a week for 8 weeks.
223840519|NCT06131073|OTHER|conventional training|this include conventional training for 3 days in a week for 8 weeks.
223840520|NCT04010175|BEHAVIORAL|Control - Cognitive training in a practitioner's office one time per week|Participant will perform 1-hour cognitive computer based training one time per week in a practitioner's office during 4 months (16 weeks of training = 16 hours of training). This training will include 10 short tasks of increasing difficulty. Performance of these tasks involve cognitive functions such as: executive functions, reasoning, auditive, visual and visuo-spatial memory, speed of processing, short-term memory and working memory. Thus the training aims to exercise all these cognitive functions.
223840521|NCT04010175|BEHAVIORAL|Experimental group 1 - Cognitive training in a practitioner's office one time per week and cognitive distance training one time per week|Participant will perform 1-hour cognitive computer based training one time per week in a practitioner's office and one time per week cognitive distance training in her/his place of residence, during 4 months (16 weeks of training = 32 hours of training).
223840522|NCT04010175|BEHAVIORAL|Experimental group 2 - Cognitive training in a practitioner's office one time per week and cognitive distance training four times per week|Participant will perform 1-hour cognitive computer based training one time per week in a practitioner's office and four times per week cognitive distance training in her/his place of residence during 4 months (16 weeks of training = 80 hours of training).
223840523|NCT02162940|OTHER|Visual analogue score|Visual analogue score vas used to evaluate pain.
223840524|NCT02162940|OTHER|The SF 36 test|The SF 36 test (SHORT FORM 36) was used to evaluate quality of life.
223840525|NCT03826602|DRUG|Tucatinib|150mg administered orally twice daily
223840526|NCT03826602|DRUG|Metformin|850mg administered orally
223840527|NCT03826602|DRUG|Iohexol|1500 mg administered intravenously (IV)
223840528|NCT00221130|PROCEDURE|surgical operation of cell transplantation|
223840529|NCT02718443|DRUG|VXM01|Oral immunotherapy targeting VEGFR2
223840530|NCT00550732|DRUG|Posaconazole|Posaconazole oral suspension was administered as 400 mg twice daily (bis in die, BID) with food or 200 mg four times daily (quater in die, QID) without food for a minimum of 1 month.
223840531|NCT03455413|DEVICE|Swisstom BB2 EIT device|Swisstom BB2 EIT device and NeoSensor Belts will be used to assess lung aeration, ventilation distribution and strech during invasive ventilation in perioperative care.
223840532|NCT05326373|DRUG|Stannous fluoride|brush twice daily with stannous fluoride toothpaste for 8 weeks
223840533|NCT00183573|BEHAVIORAL|Brief Motivational Intervention|15-20 minute, motivational one-on-one counseling
223840534|NCT00183573|BEHAVIORAL|Brief Informational Intervention|15 minute informational DVD on safer sex
223840535|NCT00183573|BEHAVIORAL|Intensive Informational Intervention|4-hour, information-only intensive group workshop
223840536|NCT00183573|BEHAVIORAL|Intensive Info-Motivation-Behavioral Skills Intervention|4-hour, intensive group workshop with emphasis on motivation and skills
223840537|NCT00415155|DRUG|LY2181308|"Phase 1: 250mg, IV, loading dose days 1-3 cycle 1 then weekly for six 28 day cycle. (dose escalation)~Phase 2: phase 1 recommended dose, maximum 750mg dose, IV, loading dose days 1-3 cycle 1 then weekly for six 28 day cycle."
223840538|NCT06021990|DRUG|Clopidogrel Bisulfate 75Mg Tab|Severe COPD patients who meet eligibility criteria will be given Clopidogrel Bisulfate 75 mg Tablet daily, along with standard of care treatment till the completion of the study duration or any side effects that warrants stoppage of the drug
223840539|NCT04689698|DIAGNOSTIC_TEST|Thomayer test|Testing of the ankle in sagittal line and Thomayer test before and after flossing of sole.
223840540|NCT00866216|DRUG|Azithromycin Monohydrate 600mg Tablets Geneva Pharmaceuticals|
223840541|NCT00866216|DRUG|Zithromax (Azithromycin Dihydrate) 600mg Tablets Pfizer Inc.|
223840542|NCT01841840|OTHER|Low-Frequency Passive Vibration|10 minute session of passive vibration set to a frequency of 25Hz and a high amplitude exposed to the legs
223840543|NCT01841840|OTHER|High-Frequency Pasive Vibration|10 minute session of passive vibration set to a frequency of 40Hz and a low amplitude exposed to the legs
223840544|NCT01207934|DIETARY_SUPPLEMENT|placebo|saline placebo
223840545|NCT01207934|DRUG|low-dose leptin|30mg per day of recombinant methionyl human (r-met hu) leptin for fourteen days
223840546|NCT01207934|DRUG|high-dose leptin|80mg per day of recombinant methionyl human (r-met hu) leptin for fourteen days
223840547|NCT01276535|DEVICE|Erchonia MLS + Erchonia THL|"The Erchonia® MLS is administered weekly for 6 continuous weeks at the test site by the study investigator.~The Erchonia THL is administered twice daily for 6 continuous weeks (42 days) at home by the subject.~Administration of the MLS and the THL occur simultaneously over the 6-week administration phase.~The intent is to evaluate the effectiveness of Erchonia MLS \& Erchonia THL when administered together, and not to compare Erchonia MLS vs. Erchonia THL"
223840548|NCT01966536|PROCEDURE|CD133+ cells transplantation into ovarian artery of one ovary|
223840549|NCT01960205|DRUG|Saxagliptin|5mg a day for 6 months
223840550|NCT01960205|DRUG|saxagliptin|2.5 mg a day for 6 months
223840551|NCT01960205|DRUG|metformin|500mg three times a day for 6 months
223840552|NCT01960205|OTHER|lifestyle intervention|lifestyle intervention for 6 months
223840553|NCT00707863|DRUG|Escitalopram|10 mg of Escitalopram by mouth once a day for 8 weeks
223840554|NCT05255263|OTHER|PIEB|Programmed Intermittent Epidural Bolus with Patient-Controlled Epidural Analgesia
223840555|NCT05255263|OTHER|CEI|Continuous Epidural Infusion with Patient-Controlled Epidural Analgesia
223840556|NCT02800928|DRUG|CERC-501|CERC-501
223840557|NCT02800928|DRUG|Placebo|Placebo
223840558|NCT04027335|DEVICE|leva|Vaginal device used for pelvic floor muscle exercises
223840559|NCT01853163|PROCEDURE|Gadolinium analysis in bone and tissue samples|Gadolinium analysis in bone and tissue samples from patients undergoing an orthopaedic surgical procedure who had received GBCAs in the past.
223840560|NCT03231449|OTHER|observation of current care|The study FEVRIER (survey of hospitalizations in cardiology units in sub-Saharan Africa) aims to establish a description of sub-Saharan standard of care, in order to get a cross sectional analysis (globally and per country) and a longitudinal analysis (evolution during 5 years).
223840561|NCT03897166|DEVICE|Trimodality|Positron Emission Tomography coupled with Computed tomography and immediately followed by Magnetic Resonance Imaging
223840562|NCT00861978|DRUG|St. John's Wort extract|Coated tablets (batch no. 02080277) containing 300 mg of St. John's Wort extract LI 160 (drug-extract ratio 3-6:1; extraction solvent: 80% Methanol in water; batch no. 02019073) administered orally twice daily (morning and evening) with some liquid for 8 weeks
223840563|NCT00861978|DRUG|Placebo|Coated placebo tablets (batch no. 01010177) that were identical in shape, size, taste and color were administered orally twice daily (morning and evening) with some liquid for 8 weeks.
223840564|NCT01969162|PROCEDURE|Tear Sample Collection|Tear sample collection as per protocol. No investigational drug is administered in this study.
223840565|NCT04289285|DRUG|IBI306 450mg SC Q4W|Subjects will receive IBI306 450mg every 4 weeks subcutaneously.
223840566|NCT04289285|DRUG|Placebo SC Q4W|Subjects will receive placebo every 4 weeks subcutaneously.
223840567|NCT04289285|DRUG|IBI306 600mg SC Q6W|Subjects will receive IBI306 600mg every 6 weeks subcutaneously.
223840568|NCT04289285|OTHER|Placebo SC Q6W|Subjects will receive placebo every 6 weeks subcutaneously.
223840569|NCT03114046|BEHAVIORAL|Lower extremity Constraint-induced movement therapy(LE-CIMT)|"Both phases (A and B) will last 10 weekdays, and during baseline and treatment phases, the data will be collected on 5 different odd days. Considering the long period of data collection. During the baseline phase, no assessment will be administered on even days. The treatment will be delivered daily, along 10 weekdays, 3.5 hours per day. The motor training will be delivered during 3 hours and 30 minutes will be allocated to the administration of the TP.~Both caregivers and participants will be individually interviewed before and after treatment."
223840570|NCT03505359|OTHER|partial knee immobilization protocol|12 weeks rehabilitation protocol including exercises to improve range of motion, gait, balance, muscle strength with a 0-60 degrees articulated knee brace in the first 6 weeks in the experimental group.
223840571|NCT03505359|OTHER|standard ACL reconstruction rehabilitation protocol|12 weeks rehabilitation protocol including exercises to improve range of motion, gait, balance, muscle strength.
223840572|NCT04237454|DEVICE|Thermal Imaging Camera|To develop a non-ionising radiation-based method of excluding fractures in children with suspected physical abuse
223840573|NCT00799461|OTHER|internet-based intervention|Delayed access to online educational information and resources for managing long term complications of hematopoietic cell transplantation
223840574|NCT00799461|OTHER|questionnaire administration|Completion of questions in an online format
223840575|NCT00799461|PROCEDURE|psychosocial assessment and care|Assessment and care of psychosocial aspects
223840576|NCT00799461|PROCEDURE|assessment of therapy complications|Evaluation of complications of treatment
223840577|NCT00799461|PROCEDURE|management of therapy complications|Managing therapy complications
223840578|NCT00799461|PROCEDURE|fatigue assessment and management|Assessing and managing fatigue
223840579|NCT00799461|OTHER|counseling intervention|Counseling provided via telephone
223840580|NCT03172793|DRUG|Telavancin Injection|Receive 3 doses of telavancin as described in arm/groups, followed by collection of blood for pharmacokinetic analyses.
223840581|NCT04792983|OTHER|No intervention|This is an observational study with no interventions.
223840582|NCT01336335|DEVICE|CPAP|CPAP
223840583|NCT01817543|DEVICE|AutoloGel|Autologel is a platelet-rich plasma gel used in the treatment of non-healing wounds
223840584|NCT02106221|OTHER|Intervention|Will receive payments based on achievement in meeting goals based on specified high value elements as well as effort.
223840585|NCT02106221|OTHER|Control|Will receive payments based on achievement in meeting goals.
223840586|NCT03084952|DRUG|18-Methoxycoronaridine|Drug under evaluation for leishmaniasis treatment
223840587|NCT03084952|DRUG|Glucantime|Leishmaniasis standard drug in Brazil
223840588|NCT00933062|DRUG|SRT2104|2.0 g of SRT2104 will be supplied in hard gelatin capsules each containing 250 mg SRT2104. SRT2104 will be administered within 30 minutes following the start of consumption of a standardized non-high-fat meal (approximately 650 kcal with approximately 30% of calories derived from fat). The eight capsules of SRT2104 will be orally-administered with approximately 200 mL water.
223840589|NCT00933062|DRUG|Placebo|Placebo will be supplied in hard gelatine capsules containing an appropriate amount of placebo. Placebo will be administered within 30 minutes following the start of consumption of a standardized non-high-fat meal (approximately 650 kcal with approximately 30% of calories derived from fat). The eight capsules of placebo will be orally-administered with approximately 200 mL water.
223840590|NCT04004208|DRUG|Eylea (Aflibercept, BAY86-5321)|Solution in a sterile glass vial, Dose A, IVT injection.
223840591|NCT04004208|PROCEDURE|Laser photocoagulation|Transpupillary conventional laser ablative therapy
223840592|NCT04463615|DRUG|Leflunomide|Given PO
223840593|NCT03941782|DRUG|Alpelisib|As a single agent, alpelisib will be administered at a starting dose of 350 mg orally once daily on a continuous dosing schedule and can be adjusted for toxicity per the recommendations in this protocol. No pretreatment will be given prior to the medication.
223840594|NCT04394819|OTHER|electromyography-triggered electrical stimulation|All treatments were planned as 2 sessions per week, for a total of 10 sessions for 5 weeks. For EMG-trigger-ES application, dual-channel Nu-Tek® brand, Maxi plus 2 Model EMG-trigger-BF-ES Device in our clinic was planned to be used. With EMG-triggered-ES application, while the patient is in a sitting position, shoulder adduction, and the elbow is 90 degrees of flexion and pronation, the patient will extend to the ball of 5 cm in diameter, which is placed as far as the distance between the acromion and the 3rd toe, and then the finger-wrist active extension will be stimulated and then It was planned to apply the ball to be grasped. One of the two 5x5 cm superficial square electrodes of the device was planned to be placed on the extensor carpi radialis and extensor digitorum Communis and the other 2 cm distal.
223840595|NCT05010382|PROCEDURE|Implant placement surgery|Under local anaesthesia, full-thickness mucoperiosteal flaps were elevated, the alveolar ridge measured, and a proper implant dimension (3.75 mm and 4.25 mm diameter; 8 mm, 10 mm and 11.5 mm length) and position selected. After site preparation, each patient was randomly allocated to the test or the control group. Patients in the test group received a modified implant design with the coronal third presenting a machined surface (hybrid surface (HS) group), while in the control group the same implant design with a titanium rough surface up to the implant shoulder was used (rough surface (RS) group). Implants were placed 1 mm sub-crestally. In the case of dehiscence or fenestrations around the implant, the patient was excluded from the study. Once inserted, healing abutments (ranging between 3 -5 mm) were placed, and flaps sutured around the abutments to allow for a transmucosal healing.
223840596|NCT02055911|DRUG|Ranibizumab|monthly ranibizumab (0,5 mg injected intravitreally in a standard fashion) until maximum visual acuity (VA) is achieved and remains stable for three consecutive months (for a minimum of 3 initial injections).
223840597|NCT03738579|DEVICE|Next Science Group|TorrentX Wound Wash will be used for irrigation and then BlastX Wound Gel will be applied to the wound after debridement/irrigation during in-clinic visits. BlastX Wound Gel will be re-applied again during mid-week dressing change. Dressing used will be plain foam dressing from control group arm.
223840598|NCT03738579|DEVICE|Control Group|Foam Dressing will be used in conjunction with standard of care for chronic wound management, such as debridement and irrigation.
223840599|NCT03738579|DEVICE|Antibacterial Control Group|Foam Dressing AG will be used in conjunction with standard of care for chronic wound management, such as debridement and irrigation.
223840600|NCT06164353|BIOLOGICAL|Partially demineralized dentin graft covered with a collagen membrane|The stored tooth will undergo grinding using the tooth transformer device. The produced particulate dentin graft will be of a particle size 400-800 µm. Afterwards, these particles will undergo partial demineralization by immersion in in 2% HNO3 for 10 minutes. Then, it will be washed twice using phosphate buffered saline. The exposed implant threads will be covered by partially demineralized autogenous dentin graft in the test group
223840601|NCT05720000|DEVICE|Photobiomodulation|Patient will receive the application of the low-power 660 nm Newskin MMO red LED in the immediate postoperative period. The application will be made punctually over the entire length of the wire, which measures 5 cm, totaling 10 application points with 1 cm of distance between them. The LED application will be repeated twice a week, with a minimum interval of 48 hours, totaling 9 laser applications over 30 days.
223840602|NCT05720000|PROCEDURE|PDO thread|The participant's face will be cleaned with a 0.2% chlorhexidine solution. 0.1 ml of injectable anesthetic (2% lidocaine hydrochloride without vasoconstrictor, XYlestesin) will be administered in the skin layer at the point of incision in the glabellar region with a 30-gauge needle. A subincision will be made with a 21-gauge cannula in the glabellar ridge and then an injectable thread will be applied in the deep dermal layer below the glabellar ridge in the same direction as it.
223840603|NCT01637558|DRUG|8 hourly LPV/r during TB treatment|8 hourly LPV/r during TB treatment
223840604|NCT01637558|DRUG|Nevirapine|
223840605|NCT01637558|DRUG|Lopinavir/Ritonavir|
223840606|NCT03656900|DEVICE|rTMS BA9/BA46|10 sessions of low-frequency repeated transcranial magnetic stimulation over two weeks on cortical area 9, then 4 weeks wash-out, then 10 sessions of low-frequency repeated transcranial magnetic stimulation repeated low frequency over two weeks on cortical area 46.
223840607|NCT03656900|DEVICE|rTMS BA46/BA9|10 sessions of low-frequency repeated transcranial magnetic stimulation over two weeks on cortical area 46, then 4 weeks wash-out, then 10 sessions of low-frequency repeated transcranial magnetic stimulation repeated low frequency over two weeks on cortical area 9.
223840608|NCT03656900|RADIATION|brain MRI|T1 weighted full-head high-resolution MRI with 1 mm seam cuts and sagittal orientation.
223840609|NCT03656900|OTHER|Medical evaluation|complete evaluation with 6 scales (HDRS, MADRS, Beck, CGI, COVI, UKU)
223840610|NCT03656900|OTHER|Psychological assessment|Subjective Life Profile Assessment (SLPA) and Helping Alliance Assessment
223840611|NCT03022266|BEHAVIORAL|Financial Incentive and Mobile Phone App|Subjects receiving the Financial Incentive and Mobile Phone App will each participate in a 90-day adherence promotion program. When users first log in to the app, the screen will display an incentive of $150 that participants have earned by enrolling in the program. Participants will be told that each missed medication check-in will result in a $2 deduction from the account before it is paid out. Each $50 portion (minus any penalties) of the $150 incentive will be paid out in 30-day installments by remotely crediting a previously distributed debit card. Adherence will be measured simultaneously by app photos and CleverCap(R) electronic monitoring (EM) devices filled with a 90-day supply of aspirin. Claims data will be analyzed for a 90 day period to account for any hospital admissions.
223840612|NCT01341080|DRUG|Varenicline|Varenicline 1mg twice daily for eight weeks after a one week dose escalation period.
223840613|NCT01341080|DRUG|Sugar pill|1mg twice daily for eight weeks after a one week dose escalation phase.
223840614|NCT00766857|DRUG|exenatide|Exenatide 5 mcg BID for 4 weeks, subsequently increased to 10 mcg BID for the remainder of the study (total of 26 weeks).
223840615|NCT00766857|DRUG|Insulin glargine|Insulin glargine will be initiated at 10 IU QD, titrated according to fasting blood glucose concentrations based on general protocol-defined guidance.
223840616|NCT04830514|OTHER|Recommended Dietary Allowance of Protein|0.8 g/kg/day protein intake
223840617|NCT04830514|OTHER|Habitual protein intake|1.0 g/kg/day protein intake
223840618|NCT04830514|OTHER|Optimal Protein Intake|1.5 g/kg/day protein intake
223840619|NCT05198453|BIOLOGICAL|vaccination|patients who received COVID-19 vaccine
223840620|NCT02926300|BIOLOGICAL|stem cells|IV infusion
223840621|NCT01924481|DIETARY_SUPPLEMENT|High Caffeine|
223840622|NCT01924481|DIETARY_SUPPLEMENT|Low caffeine|
223840623|NCT01924481|DIETARY_SUPPLEMENT|High theobromine|
223840624|NCT01924481|DIETARY_SUPPLEMENT|low theobromine|
223840625|NCT01924481|DIETARY_SUPPLEMENT|No theobromine|
223840626|NCT05067959|BIOLOGICAL|Covid-19 vaccine|blood tests and questioners before 1st vaccine, 3 weeks before 2nd vaccine, 4 weeks after 2nd vaccine, 6 months after 1st vaccine, and 12 months after 2nd vaccine
223840627|NCT00201253|OTHER|Bronchoalveolar lavages and venipunctures only|
223840628|NCT03990025|DIAGNOSTIC_TEST|Linked Color Imaging|Linked Color Imaging (LCI) is a form of image enhanced endoscopy that uses a laser endoscopic system that acquires images by simultaneously using narrow-band wavelength light and white light in an appropriate balance. This enhances slight color differences in the red region of the mucosa.
223840629|NCT03990025|DIAGNOSTIC_TEST|White Light Imaging|White Light Imaging (WLI) uses conventional white light that encompasses all bandwidths of light to illuminate areas of interest to obtain endoscopic images.
223840630|NCT05592652|OTHER|Survey|Survey including demographic, clinical and psychopathological questions
223840631|NCT00145262|PROCEDURE|Autologous Bone Marrow Mononuclear Cell Implantation|
223840632|NCT03318120|BEHAVIORAL|Progressive Resistance Training|Participants will perform required resistance training exercises at regular intervals for a period of up to 3 years. They will be tested at a baseline visit, then every 6 months for a total of at least 5 visits. During these visits, they will be asked to complete the following: questionnaires about quality of life and depression, tests to measure strength and motor function, tests to measure cognition, an orientation session to learn a precision griping task, structural and functional MRI scans of the brain, measurement of brain waves using a non-invasive technique called electroencephalography (EEG) and muscle activity using electromyography (EMG), measurement of brain function with TMS, pregnancy test (if applicable).
223840633|NCT03035240|BEHAVIORAL|Financial Education|Participants randomized to financial education will undergo a year long financial education. This involves 9 weeks of weekly classes followed by one on one coaching for a year.
223840634|NCT03486743|BEHAVIORAL|Educational video on LARC|Participants will watch a short educational video on long acting reversible contraceptive or LARC
223840635|NCT02527850|DEVICE|B-cure laser|
223840636|NCT01445756|DRUG|Lidocaine|During the procedure (placement of the IUD), 1ml of gel will be applied to the anterior lip of the cervix. After 1 minute of waiting, a tenaculum will be placed to steady the cervix. The catheter will be introduced into the cervical canal, past the external os and 1-1.5ml of gel will be placed into the canal. After another minute, the IUD will be placed in the standard fashion.
223840637|NCT01445756|DRUG|Placebo|Placebo; no topical lidocaine administered
223840638|NCT01378897|DEVICE|MedSignals®pillbox,Omron pedometer,VitalSignals®weight scale|Participants will use three home monitoring devices (i.e., weight scale, pedometer, pillbox) for two months. In addition, participants will receive weekly phone calls from the study's bariatric dietician during weeks 1-4 of the study and then receive biweekly calls during the second month. The structured phone calls (approximately 10-15 minutes each call) will focus on discussing the patient's adherence data, discussing any barriers to adherence, and providing tailored patient education.
223840639|NCT03743012|OTHER|Integrated cardiac rehabilitation|Participants enrolled to the integrated cardiac rehabilitation arm will participate in individually tailored rehabilitation sessions that will involve aerobic activity focused on exertion at the participant's aerobic threshold (AT) over a duration of three months.
223840640|NCT03743012|OTHER|Usual Care|Participants randomized to the usual care arm will be instructed on the benefits of exercise and continue with usual care. Participant activity will be tracked monthly using pedometers for three months of follow up.
223840641|NCT05510401|OTHER|SECURIDRAP® SELFIA®|Use of SECURIDRAP® SELFIA® for 15 night
223840642|NCT03434535|DEVICE|Technology Intervention|A combination of existing technology and a new app developed by InHealth Measurement Corp to (1) remotely monitor a participant's activity level and weight and (2) remotely provide updates to the participants regarding their progress towards the goals established in the Prostate Cancer Foundation Health and Wellness guidelines.
223840643|NCT02945293|OTHER|Oxycodone|This study is interventional. Participants are given a single, one time administration of medication 10mg of oxycodone and observed
223840644|NCT00570661|DRUG|ITF2357|ITF2357 orally administered at the cumulative daily dose of 1.5 mg/kg, achieved by administration of different dose strengths identifiable by different colours.
223840645|NCT01734382|DRUG|Tocilizumab|Participants will receive tocilizumab IV infusions of 12 mg/kg (for participants \< 30 kg) or 8 mg/kg (for participants \>/=30 kg) Q2W/Q3W/Q4W.
223840646|NCT01932138|OTHER|Enhanced CHW intervention|"The CHW employed in this study are a health worker cadre that already exists in the Tanzanian public-sector health system, so-called home-base carers (or HBC). The HBC in this study are supervised by another existing cadre, so-called community-based health care workers (or CBHC). The CBHC are clinic-based and are charged to organize community outreach activities in the Tanzanian public-sector health systems. The CBHC (1-2 per clinic) are also active in the control arm; in this intervention arm, there role is changed: they are actively supervising a large number of CHW. Per street (or mtaa), 1-2 CHW are assigned to carry out the enhanced CHW intervention."
223840647|NCT01932138|OTHER|Standard of care|The standard of care in the Tanzanian health care system does not include any CHW intervention to enhance ANC and PMTCT uptake and retention. The only community-based intervention are PMTCT follow-up organized by a health worker cadre who works out of ANC and primary care clinics (so-called CBHC).
223840648|NCT04664335|OTHER|questionnaire|if no Reply to questionnaire, telephone interview
223840649|NCT01823120|OTHER|Supportive and interactive text messages|
223840650|NCT01663675|GENETIC|karyotype|
223840651|NCT04672746|BEHAVIORAL|Brief MI interaction via instant communication|Telephone peer counselling+referral to treatment if required+The interaction communication using brief motivational interviewing via the chatting function of instant messaging apps (e.g., WhatsApp, WeChat). The intervention will last for 6 month with a frequency of at least twice a week.
223840652|NCT04672746|BEHAVIORAL|General health information|"Telephone peer counselling+referral to treatment if required+general health information via SMS, such as do physical exercise for at least 30 min per week will keep you healthy for 6 month with a frequency of least twice a week."
223840653|NCT06201013|BEHAVIORAL|urotherapy|Participants were asked to undergo a 30-min session every 6 weeks at follow-up, including (1) education about the disease to dispel doubts about it and to understand the benefits of curing the dysfunction in order for the child to have a better therapeutic outcome, (2) urination at regular intervals and the establishment of good urination habits, (3) dietary instructions to avoid constipation, (4) accurate recording of symptoms of OAB, and (5) communication with the research team every 2 weeks.
223840654|NCT06201013|DRUG|Solifenacin Succinate|In addition to urotherapy, take Solifenacin succinate 5mg once daily, maximum dose 10 mg/day
223840655|NCT06201013|DRUG|Vitamin D3|In addition to urologic therapy, vitamin D drops containing 400 IU of vitamin D3 per capsule, 1,200 iu per oral dose, twice daily, for a total of 2,400 iu/d; serum vitamin D levels need to be rechecked at every 6-week follow-up visit
223840656|NCT00925028|DRUG|Warfarin|Patients of group A will have the task of managing their own warfarin therapy using the provided nomograms. In the second office visit patients will be told to which group they were randomized and if they are in group A they will then be instructed on how to use the warfarin adjustment nomograms provided. After four months the groups will switch to the alternate management strategy. Patients in both groups will use warfarin tablets of two dosage strengths, 1 mg and 5 mg. All INR testing will be done at the community laboratory and results will be made available to the patient for dosage adjustment, as well as the physician. The physician's office will be available for appointments and phone calls from study subjects to discuss and support the process at any time.
223840657|NCT00925028|DRUG|Warfarin|Patients of group B will continue to be managed by their physician. This time those in group B will be instructed on how to use the nomograms during an office visit. Patients in both groups will use warfarin tablets of two dosage strengths, 1 mg and 5 mg. All INR testing will be done at the community laboratory and results will be made available to the patient for dosage adjustment, as well as the physician. The physician's office will be available for appointments and phone calls from study subjects to discuss and support the process at any time.
223840658|NCT02710006|PROCEDURE|Sonohysterography|Sonohysterography, also known as saline infusion sonography, is a special, minimally invasive ultrasound technique. Sonohysterography is a technique in which fluid is injected through the cervix into the uterus, and ultrasound is used to. It provides pictures of the inside of a woman's uterus. Three-dimensional sonohysterography is based on volumetric scanning of uterus and its cavity during saline infusion.
223840659|NCT03248440|DRUG|SUN-131 1.5% TDS|SUN-131 1.5% TDS will be worn for 14 days
223840660|NCT03248440|DRUG|Placebo TDS|No active substance; Placebo TDS will be worn each day for 14 days
223840661|NCT04737174|DRUG|ES-481|28-day screening period followed by 4-week dose escalation period followed by 16-week treatment period followed by 4-week dose washout period
223840662|NCT01052662|DRUG|Memantine|30mg/day Memantine orally everyday for 12 weeks
223840663|NCT01052662|DRUG|Memantine|15 mg/day Memantine orally everyday for 12 weeks
223840664|NCT01052662|DRUG|Placebo|Placebo orally everyday for 12 weeks
223840665|NCT01148043|DRUG|Hydroxychloroquine|200 mg capsule, 2 capsules QD for 24 weeks.
223840666|NCT01148043|DRUG|cellulose|capsule, 2 capsules QD for 24 weeks
223840667|NCT00436787|DRUG|Fondaparinux Sodium|
223840668|NCT04849728|DRUG|IVA337|A total of 1000 patients will be randomised to receive lanifibranor (800 mg/day) or lanifibranor (1200 mg/day), or matching placebo, employing a 1:1:1 randomisation scheme, respectively, without interruption between Part A and Part B.
223840669|NCT04849728|DRUG|Placebo|A total of 1000 patients will be randomised to receive lanifibranor (800 mg/day) or lanifibranor (1200 mg/day), or matching placebo, employing a 1:1:1 randomisation scheme, respectively, without interruption between Part A and Part B.
223840670|NCT00725582|DRUG|IMA-026|
223840671|NCT00725582|OTHER|Placebo|
223840672|NCT00087490|DRUG|linezolid|
223840673|NCT00087490|DRUG|vancomycin|
223840674|NCT02034435|OTHER|Low Salt diet plus Placebo tablet|
223840675|NCT02034435|OTHER|Low Sodium diet plus Salt tablet|
223840676|NCT02034435|DRUG|Epleronone|50mg daily
223840677|NCT02034435|DRUG|Amlodipine|5mg daily
223840678|NCT03208556|BIOLOGICAL|iPD1 CD19 eCAR T cells|"iPD1 CD19 eCAR T cells are administrated in a 3-day split-dose regimen （d0, 30%; d1, 30%; d2, 40%）.~CAR T cell dose escalation: 1×10\^5 /kg，1×10\^6 /kg，3×10\^6 /kg，and 6×10\^6 CAR T cells/kg"
223840679|NCT03208556|DRUG|Fludarabine and cyclophosphamide|Fludarabine 25 mg/m2 d1-3; cyclophosphamide 250 mg/m2 d1-3. Lymphodepletion chemotherapy is completed 1 to 4 days before CAR T cell infusion
223840680|NCT05495451|BEHAVIORAL|Moderate-carbohydrate Mediterranean diet, Personalized exercice prescription and training, Intermittent fasting|Multidisciplinary program will provide the teaching and supervision necessary to integrate the new knowledge and commitment to these lifestyle changes.
223840681|NCT01192087|DRUG|Cetuximab|cetuximab initial dose (7 days prior to RT treatment start): 400 mg/m² body surface cetuximab weekly doses (from RT treatment start throughout radiation treatment): 250 mg/m² body surface
223840682|NCT01166087|DRUG|Fluoxetine Hydrochloride|Fluoxetine Hydrocloride Delayed-Release Capsules, 90 mg of Dr. Reddy's Laboratories.
223840683|NCT00374621|DRUG|Misoprostol with or without isosorbide mononitrate|Misoprostol 50 micrograms orally then 100 micrograms every 4 hours for up to four doses until modified Bishop score of 8 or higher was observed vs. the same misoprostol dosing plus isosorbide mononitrate 40 mg vaginally every 6 hours up to two doses total until a modified Bishop sore of at least 8 was observed
223840684|NCT05635266|DIAGNOSTIC_TEST|Specimen sample|The study may require a tissue collection and/or a participant survey for participation. Most tissue collected will come from a blood draw; up to 100mL for the health condition group, 60mL for the exceptive condition group, and up to 180mL for the control group (if determined safe for the participant). Participant surveys may involve participant reported outcomes (PROs) or custom participant surveys.
223840685|NCT00740519|DRUG|insulin detemir|Start dose and frequency to be prescribed by the physician as a result of a normal clinical evaluation.
223840686|NCT03918018|DEVICE|BORA Band SpO2 Validation Study|"Qualified healthy volunteers will be enrolled into the study. Subjects will recline for the study. Reference sensor(s) will be placed on each subject to evaluate the SpO2 accuracy and performance. Shield material may be used between any adjacent finger sensors to prevent optical crosstalk.~Simultaneous data collection will be set up for device under test and the control pulse oximeter. The data from the test device will be collected by the sponsor or trained Clinimark Study staff. Data will be collected for 1 second intervals data analysis. The SpO2 accuracy of the test devices will be evaluated over the oxygen saturation range between 70-100%.~The investigational device will only be placed on the wrist. The control pulse oximeter may be alternated through fingers between subjects."
223840687|NCT02235610|PROCEDURE|EVLP Group|"EVLP technique (Lund Protocol): open left atrium, Steen solution mixed with red blood cells and perfusion 100% of the donor predicted cardiac output.~Lungs with good and stable function during EVLP will be transplanted into recipients as per current clinical practice."
223840688|NCT03950908|OTHER|Single bite biopsy technique|During biopsy collection one specimen will be retrieved during a single passage of the biopsy forceps.
223840689|NCT03950908|OTHER|Double bite biopsy technique|During biopsy collection two specimens will be retrieved during a single passage of the biopsy forceps.
223840690|NCT00910884|OTHER|laboratory biomarker analysis|No supplements are given
223840691|NCT00910884|PROCEDURE|therapeutic dietary intervention|Given orally daily for 12 months
223840692|NCT00630539|DRUG|Placebo|1 tablet per day, orally, in the morning, with food for 12 weeks - from Visit 2 (Randomization, Day 1) to Visit 4 (End of therapy, Week 12).
223840693|NCT00630539|DRUG|Ospemifene 5 mg|1 tablet of ospemifene 5 mg (QD), orally, in the morning, with food for 12 weeks - from Visit 2 (Randomization, Day 1) to Visit 4 (End of therapy, Week 12).
223840694|NCT00630539|DRUG|Ospemifene 15 mg|1 tablet of ospemifene 15 mg (QD), orally, in the morning, with food for 12 weeks - from Visit 2 (Randomization, Day 1) to Visit 4 (End of therapy, Week 12).
223840695|NCT00630539|DRUG|Ospemifene 30 mg|1 tablet of ospemifene 30 mg (QD), orally, in the morning, with food for 12 weeks - from Visit 2 (Randomization, Day 1) to Visit 4 (End of therapy, Week 12).
223840696|NCT01700530|DRUG|Statin|Statins (40mg/day)for 12 weeks
223840697|NCT01700530|OTHER|Exercise only|12 weeks of exercise training (5 days a week for 45-50 min a session)
223840698|NCT01700530|OTHER|Statins + Exercise|Statins (40mg/day of simvastatin) plus exercise training (5 days/wk for 45-50 min a session) for 12 weeks
223840699|NCT01253980|DRUG|Amoxicillin|Amoxicillin syrup 20-30mg/kg 8 hourly for 5 days
223840700|NCT01253980|DRUG|Placebo|"Placebo suspension made of water, dextrose and glycerine with a similar taste and appearance to the active comparator.~Dose 20-30mg/kg 8 hourly for 5 days"
223840701|NCT02420587|DRUG|AMG 208|Dose of AMG 208 is 400 mg by mouth daily given in 6 weeks cycles.
223840702|NCT02420587|BEHAVIORAL|Questionnaire|Questionnaire completion about pain at baseline, Day 22 of Cycle 1, Day 1 of Cycle 2, Day 22 of Cycle 2, every 6 weeks, and at end of study visit.
223840703|NCT01023178|DRUG|17beta Estradiol|Oral pill given daily at increasing doses every 6 months for 18 months.
223840704|NCT01023178|DRUG|Conjugated estrogens|Oral pill, started at a low dose taken daily, dose increased every 6 months for 18 months
223840705|NCT01023178|DRUG|17Beta Estradiol - transdermal|Transdermal estrogen patch, started at low dose with increasing doses eery 6 months for 18 months
223840706|NCT01023178|DRUG|Progesterone, micronized|Given starting at 18 months
223840707|NCT03050281|OTHER|Simulation/Cadaver lab|The primary focus of this study is to determine whether the use of a comprehensive, combined, and simplified approach of using cadavers and simulation laboratories to train third-year medical students will have a beneficial effect on student performance in the OB-GYN and surgical clerkships.
223840708|NCT03050281|OTHER|Lectures|Standard Anatomy lectures were offered.
223840709|NCT03862521|OTHER|Low carbohydrate diet|Low carbohydrate diet
223840710|NCT03862521|OTHER|Very low carbohydrate diet|Very low carbohydrate diet
223840711|NCT05297123|DRUG|All-trans retinoic acid|All-trans retinoic acid (ATRA) 20mg 3 times a day for 8 weeks.
223840712|NCT05297123|DRUG|Arsenic Trioxide|ATO 0.15mg/kg/d for 8 weeks (If the total daily amount is greater than 10mg, only 10mg/d can be given)
223840713|NCT05297123|DRUG|Realgar-Indigo naturalis formula|60 mg/kg/d for 8 weeks
223840714|NCT03547505|PROCEDURE|R-Pilot®|Glide path preparation using R-Pilot® in reciprocating manner.
223840715|NCT03547505|PROCEDURE|ProGlider®|Glide path preparation using ProGlider® in a rotating manner.
223840716|NCT03547505|PROCEDURE|Manual preparation|Glide path preparation using manual K-files numbered from 08 to 15.
223840717|NCT02116387|OTHER|Routine Physical Therapy|Patients randomized to this arm will participate in a classic physical therapy program (15 weeks, a total of 15 sessions).
223840718|NCT02116387|DEVICE|I-Moove Physical Therapy|Patients randomized to this arm will participate in a physical therapy program using the I-Moove device (15 weeks, a total of 15 sessions).
223840719|NCT02519556|DRUG|Probiatop|Dilute one sachet in 100ml of water and take it in every morning, once a day for 6 months.
223840720|NCT02519556|DRUG|Placebo|1 sachet, once a day for 6 months. Dilute one sachet in 100ml of water and take it in every morning.
223840721|NCT03985579|OTHER|Kinesiology taping application|Application of elastic cotton strip with an acrylic adhesive that is used with the intent of treating pain and disability from athletic injuries and a variety of other physical disorders
223840722|NCT05953753|BEHAVIORAL|Food system and demand generation|The project is focused on improving egg consumption through enhanced availability, accessibility, and improved demand. To achieve this goal, the project intervention mix will work through three pathways: access, enabling environment, and demand. The access pathway aims to sustain availability and consumption of eggs by school children (age 6-9 years) from BoP households through interventions targeted at the Poultry Association of Nigeria (PAN) and state lead egg aggregators for the HGSFP. The enabling environment pathway focuses on the broader institutional, governance, and political factors to support accessibility, availability, improved consumption, and increased consumer demand for eggs. The demand pathway will be addressed by mass media and interpersonal communication to increase the willingness and motivation of parents/caregivers in BoP households to support and sustain egg consumption by pre-school children in Kaduna State.
223840723|NCT06493929|OTHER|Chest ultrasound|to assess diaphragmatic excursion (DE(. M-mode was used to record the movement of the diaphragm during tidal breathing when the sampling line and diaphragm were as vertical as possible (not \< 70°). The data was measured from the first respiratory cycle at 0 min after SBT.
223840724|NCT06493929|OTHER|Calculation of Mechanical Power on the first day of intubation and before First trial of weaning:|"Total respiratory rate (RR). Positive end-expiratory pressure (PEEP) (the external or applied PEEP) recorded, not the total PEEP, or intrinsic PEEP. The plateau pressure (Pplat) was measured during an inspiratory pause on the ventilator. Peak inspiratory pressure (Ppeak) should be obtained while the patient is relaxed, not coughing or moving in bed. MP was calculated according to Gattinoni's simplified mechanical power equation as follows (3,8):~MP(J/min)=0.098×VT×RR×(Ppeak-0.5×ΔP)."
223840725|NCT05877560|DEVICE|Anodal-Transcranial Direct Current Stimulation|Non-invasive brain stimulation will involve the use of anodal transcranial direct current stimulation to apply a 2 milliamp current over the left frontal eye field for approximately 20 minutes with a ramp up to the maximum programmed current and ramp down of 20 seconds.
223840726|NCT05877560|BEHAVIORAL|Office-Based Vergence/Accommodative Therapy|Office-based vergence accommodative therapy involves weekly in-office appointments with the therapist lasting approximately 60 minutes per visit during which time in-office procedures will be performed, and home therapy procedures will be demonstrated. Participants will be prescribed 15 minutes of home reinforcement therapy procedures to be completed 5 days per week. Therapy will consist of two phases adapted from the Convergence Insufficiency Treatment Trial (CITT). Therapy procedures will include gross convergence, accommodation. non-computer based vergence, and computer-based vergence.
223840727|NCT05877560|DEVICE|Sham Transcranial Direct Current Stimulation|Sham transcranial direct current stimulation will be applied over the left frontal eye field with the current ramping up for 20 seconds before ramping down for 20 seconds. The 2 milliamp current stimulation will occur for only a few seconds at the start and at the end of the 20 minutes.
223840728|NCT06774248|BEHAVIORAL|Youth Opioid Recovery Support (YORS)|"The Youth Opioid Recovery Support (YORS) model is an innovative wrap-around approach that attempts to address barriers to medication adherence in this vulnerable young adult population. The YORS intervention primary components are (as detailed below):~1. Low barrier access to MOUD, including home delivery, ride-share app transportation and mobile van delivery and low barrier access to MOUD in general~2. Engagement of families in collaborative treatment planning and monitoring with a focus on medication adherence~3. Assertive continuing care: actively tracking and communicating with youth and families by text and social media to promote engagement and adherence~4. Contingency management: to provide incentives for medication adherence"
223840729|NCT02633943|OTHER|Safety and efficacy assessments|"Genetic: No interventional drug product utilized in this follow-up study~Participants received a single IV infusion of LentiGlobin BB305 Drug Product in the parent studies. Vector copy number (VCN) measurement, safety evaluations, disease-specific assessments, and assessments to monitor for long-term effects of autologous transplant are conducted in this study."
223840730|NCT05913778|DEVICE|Enhanced external counterpulsation|Enhanced external counterpulsation (EECP) is a noninvasive therapy for the treatment of patients with coronary artery disease.The systolic deflation/diastolic inflation sequence of EECP leads to systolic unloading and diastolic augmentation, resulting in increased blood flow in a pulsatile manner in coronary artery and in others organ arteries.
223840731|NCT04883346|DRUG|Liraglutide|Liraglutide by subcutaneous injection administered daily. Dose will be initiated at 0.6mg per day and increased to a maximum of 3.0 mg per day as tolerated.
223840732|NCT04707716|OTHER|conometric concept Acuris system|implant crown retention type using friction only
223840733|NCT04707716|OTHER|screw retention|screw retained implant crown
223840734|NCT04707716|OTHER|cementation|cement retained implant crown
223840735|NCT05190549|PROCEDURE|CAV regimen bridging to HSCT|The enrolled patients will be firstly given CAV bridging regimen (cladribine 5mg/m2/ day for 5 days, cytarabine 20mg q12h for 10 days, and began at 100 mg on day 1 and increased stepwise over 3 days to reach the target dose of 400 mg (100 mg, 200 mg, and 400 mg) on days 1-21. Conditioning regimen for allo-HSCT may be administrated after completion of the CAV regimen, with or without consolidation therapy.
223840736|NCT04002479|DEVICE|Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)|An intratumoral insertion of radioactive sources \[Ra-224 containing stainless-steel 316LVM tubes- (Alpha DaRT seeds)\]. The seeds release by recoil into the tumor short-lived alpha-emitting atoms.
223840737|NCT06458543|DRUG|Longidaza|Bovhyaluronidase azoximer, vaginal suppositories 3000 IU, 1 suppository vaginally every other day, course of 10 days
223840738|NCT06458543|DRUG|Metronidazole 500 mg|Metronidazole, tablets 500 mg, 1 tablet 2 times a day, orally, course 7 days
223840739|NCT04599478|DRUG|Naltrexone and Bupropion medication|NB medication will be taken daily in pill form.
223840740|NCT04599478|BEHAVIORAL|Behavioral Weight Loss|Behavioral Weight Loss (BWL) counseling includes weekly sessions.
223840741|NCT04599478|OTHER|Placebo|Placebo will be inactive and taken daily in pill form.
223840742|NCT00204035|BEHAVIORAL|Evaluation (behavior)|TEACH is a precollege enrichment program for highschool students to encourage and promote these students towards careers in clinical research. To accomplish this, instruments designed to evaluate the knowledge, attitudes, and behaviors are administered during their participation in the TEACH program.
223840743|NCT05257590|DRUG|Nivolumab Injection [Opdivo]|Nivolumab will be administered at 240 mg, IV, Q2 weeks with an option for 480 mg, IV, Q4 weeks starting with Cycle 3 if judged to be reasonable by the investigator based on the safety and tolerability.
223840744|NCT05257590|DRUG|CVM-1118|CVM-1118 will be administered 200 mg, PO, BID with an option to increase the starting dose to 300 mg, PO, BID for the subsequent subjects following assessment of safety data from the initial 10 subjects.
223840745|NCT05930756|PROCEDURE|Radiofrequency ablation|Genicular radiofrequency ablation uses thermal energy to percutaneously create lesions in neural tissues of the genicular nerves that innervate the anterior knee capsule and disrupt the conduction of pain signals.
223840746|NCT06379893|DRUG|Voltaren Gel 1% (diclofenac sodium) (US only)|Participants in the US will use Volatren Gel containing 1% diclofenac sodium.
223840747|NCT06379893|DRUG|Voltaren Gel 1.16% (diclofenac diethylammonium) (EU only)|Participants in the EU will use Volatren Gel containing 1.16% diclofenac diethylammonium.
223840748|NCT06379893|DRUG|Voltaren Gel 2.32% (diclofenac diethylammonium) (EU only)|Participants in the EU will use Volatren Gel containing 2.32% diclofenac diethylammonium.
223840749|NCT02223182|BIOLOGICAL|Viaskin Milk 150 mcg|Subjects epicutaneously administered daily (up to 24 hours application per day) with a patch containing 150 mcg cow's milk proteins.
223840750|NCT02223182|BIOLOGICAL|Viaskin Milk 300 mcg|Subjects epicutaneously administered daily (up to 24 hours application per day) with a patch containing 300 mcg cow's milk proteins.
223840751|NCT02223182|BIOLOGICAL|Viaskin Milk 500 mcg|Subjects epicutaneously administered daily (up to 24 hours application per day) with a patch containing 500 mcg cow's milk proteins.
223840752|NCT02223182|BIOLOGICAL|Viaskin Placebo|Subjects epicutaneously administered daily (up to 24 hours application per day) with a patch containing a matching placebo formulation.
223840753|NCT00924989|DRUG|OSI-906|Administered orally
223840754|NCT00924989|OTHER|Placebo|Matching placebo administered orally
223840755|NCT05039450|DRUG|EFX|Investigational drug, Efruxifermin
223840756|NCT05039450|DRUG|Placebo|Placebo
223840757|NCT00180947|DRUG|Vinorelbine, cyclofosfamide|
223840758|NCT05653310|DRUG|Tradipitant|Tradipitant Capsule
223840759|NCT05653310|DRUG|Placebo|Placebo Capsule
223840760|NCT06301399|DRUG|Rituximab+PD-1 or PD-L1 inhibitors+targeted therapy|Rituximab: Dissolve 375mg/m2 in 0.9% sodium chloride injection, dilute to a concentration of 1 mg/mL of rituximab, intravenous infusion every 3 weeks until tumor progression or intolerable toxic reactions occur. The recommended initial infusion rate is 50mg/h; After the initial 60 minutes, an increase of 50mg/h can be made every 30 minutes until the maximum speed is 400mg/h. The starting rate of rituximab infusion in the future can be 100mg/h, increasing by 100mg/h every 30 minutes until the maximum rate is 400mg/h.
223840761|NCT05649332|DEVICE|Argogen (silver zeolite powder)|The medical device will be self-administered by each patient twice daily without interruption for the duration of the study (4 weeks) or until complete healing. Application is carried out by spraying at short intervals, lightly pressing the dispenser button and directing the spray onto the area to be treated.
223840762|NCT06499207|DIAGNOSTIC_TEST|Photon-counting detector computed tomography (PCD-CT)|Patients undergoing follow-up coronary angiography with IVI after percutaneous coronary intervention (PCI) as part of routine clinical practice will additionally receive coronary computed tomography angiography (CCTA) with PCD as part of this study.
223840763|NCT03909139|BIOLOGICAL|BMAC|A bone marrow biopsy needle will be inserted through an arthroscopy portal and directed to the acetabuloplasty site. Bone marrow is aspirated then centrifuged. From the centrifuged sample, the buffy coat layer (layer of cells, found between the red blood cells and the plasma layers) is removed. The buffy coat layer contains mesenchymal stromal cells. This is called BMAC or Bone Marrow Aspirate Concentrate. The BMAC will be injected into the intra-articular space.
223840764|NCT03069469|DRUG|Vimseltinib|Colony-stimulating factor 1 receptor (CSF1R) inhibitor
223840765|NCT05804396|DEVICE|Relivion®|Active stimulation device
223840766|NCT03714022|DRUG|Abatacept|Participants will receive abatacept at a single dose 750 mg as IV infusion.
223840767|NCT00367393|DRUG|Pimecrolimus cream 1%|Pimecrolimus cream 1% bid, as needed
223840768|NCT02005003|BEHAVIORAL|Inhibitory task|Participants perform a binary decision on each presented stimuli. Of the two possible outcomes, participants are instructed to make a motor response (go) for one type, and are to withhold a response (no-go) for the other type. Reaction time and accuracy are measured for each event
223840769|NCT02005003|PROCEDURE|Blood samples|Hormone levels will be analyzed from blood samples obtained before and after a caloric preload given at each visit
223840770|NCT02005003|BIOLOGICAL|Feces collection|Feces samples will be collected on the morning of each visit, before and after each 2-week intervention period, as well as after each 2-week washout period following each intervention period.
223840771|NCT02005003|PROCEDURE|Caloric preload|A caloric preload will be given to participants, following which blood will be taken at 65 minutes later (specified in Blood sampling) following the ingestion of the caloric preload.
223840772|NCT02005003|BEHAVIORAL|Food selection task|Participants are given the opportunity to write and use a computer program to specify amount and type of food would ideally like to consume
223840773|NCT02005003|BEHAVIORAL|Memory task|Participants perform short memory tasks on each visit
223840774|NCT02005003|BEHAVIORAL|Food consumption task|Participants are given a selection of food items to consume on each visit
223840775|NCT05121675|BEHAVIORAL|Neuroflow app: Mental health and wellbeing resources for adults|"The NeuroFlow app delivers resources on resilience training, mindfulness-based strategies and cognitive behavioral therapy to adults looking to support their mental health and wellbeing. The specific journey (i.e., content such as activities, videos, trackers, and journaling) is tailored to individuals based on depression and anxiety screeners administered upon signing up to the app."
223840776|NCT00165867|DRUG|E7070|
223840777|NCT04625478|OTHER|Patients having had an osteo-articular infection with Stahylococcus|Immunostaining targeting staphylococci and components will be performed on tissue samples collected from patients with osteo-articular infection
223840778|NCT00197301|BIOLOGICAL|Vaccination|
223840779|NCT00859417|PROCEDURE|Traditional surgery|Traditional surgical method without prosthesis (correction of the anterior prolapse through vaginal tract with the use of autologous tissue).
223840780|NCT00859417|DEVICE|Perigee® prosthesis|Surgical method with Perigee® prosthesis
223840781|NCT03864133|DRUG|Omidria|Phenylephrine and Ketorolac infusion of 1%/0.3% during cataract surgery.
223840782|NCT00927628|PROCEDURE|Vitrectomy|Patients underwent vitrectomy with or without internal limiting membrane (ILM) peeling for an idiopathic full-thickness macular holes. Simultaneous phacoemulsification with intraocular lens implantation was performed on all phakic patients who were \>40-years-of-age.
223840783|NCT02668432|DRUG|Amiodarone|Patients will receive a 150 mg IV bolus amiodarone dose, followed by a 1 mg/min continuous infusion for six hours, then 0.5 mg/min. Conversion to PO amiodarone will be based on patient hemodynamic stability and physician/pharmacist discretion. The total loading dose will be calculated based on all IV and PO amiodarone administered within 7 days from initiation of amiodarone. All doses will be compared in total PO equivalents (accounting for 50% bioavailability of PO vs IV amiodarone). Randomization may be overridden by the attending or fellow physician if the patient's severity of illness warrants. Discontinuation of amiodarone in the full-load group will be at the discretion of the physician/pharmacists, after the pre-determined randomization loading dose has been provided.
223840784|NCT04391075|PROCEDURE|Pudendal nerve block|Pudendal nerve block provided during last fase of delivery
223840785|NCT04447820|DRUG|K-877-ER (Dose A)|Dose A Oral Administration
223840786|NCT04447820|DRUG|K-877-ER (Dose B)|Dose B Oral Administration
223840787|NCT04447820|DRUG|K-877-IR|K-877-IR Oral Administration
223840788|NCT06410911|PROCEDURE|Subcostal Transversus Abdominis Plane block in patients undergoing open cholecystectomy surgery.|"Subcostal Transversus Abdominis Plain block will be performed under ultrasound guidance using a 5-10 MHz linear transducer. The needle will be inserted perpendicular to the skin 2 fingers below the costal~margin, just lateral to the rectus abdominis muscle. After confirming the needle tip's location within the TAP, 20 mL of 0.25% bupivacaine will be injected on both sides in patients undergoing open cholicystectomy surgery."
223840789|NCT06410911|PROCEDURE|Erector Spinae Block in patients undergoing open cholecystectomy|Ultrasound-guided Erector Spinae block using 20 mL of 0.25% bupivacaine will be injected bilaterally at the T7- T8 vertebral level in patients undergoing open cholecystectomy The probe will be advanced 3 cm to the right lateral direction and rotated 90 degrees, and the transverse processes will be determined . Next, 5 mL of 2% lidocaine will be administered to the predicted needle entry point. A 22-gauge, peripheral nerve block needle will cephalocaudally advanced by the in-plane technique. The needle tip will be continuously advanced toward the transverse process to 1-2 mm before contact with the transverse process. After negative aspiration, 20 ml of 0.25% bupivacaine will be injected with intermittent negative aspirations into the fascia of the erector spinae muscle.
223840790|NCT06410911|DRUG|Sbcostal transversus Abdominis block and erector spinae block for both groups|Each patients group will recieve a type of block by injecting 20 ml of 0.25% bupivacaine on each side in patients undergoing open cholecystectomy
223840791|NCT04850742|PROCEDURE|Cryopreserved aorta|After resection of the tracheal or bronchial lesion with standard surgical techniques, the airway gap is reconstructed with a segment of human cryopreserved (-80 celsius degree) aortic allograft, which was not matched by the ABO and leukocyte antigen systems. The anastomosis is performed with standard technique for airway anastomosis. An Ultraflex covered tracheobronchial stent is inserted to prevent collapse for the aortic graft.
223840792|NCT03753880|DEVICE|HEMOPATCH Sealing Hemostat|Hemopatch sealing hemostat used after LR to cover the resection surface
223840793|NCT00183924|DRUG|Estramustine|
223840794|NCT00183924|DRUG|Docetaxel|
223840795|NCT00183924|DRUG|Carboplatin|
223840796|NCT02838004|DEVICE|IOL MINI WELL READY|IOL MINI WELL READY
223840797|NCT02789163|DEVICE|Ultrasound|breast ultrasound; hand held and automated volume breast scanner
223840798|NCT03289455|BIOLOGICAL|AUTO3 (CD19/22 CAR T cells|Following preconditioning with chemotherapy (cyclophosphamide and fludarabine) patients will be treated with 1 to 5.0 x 10⁶/kg CD19/CD22 Chimeric Antigen Receptor (CAR) positive T cells as a single or split dose.
223840799|NCT06094140|DRUG|Durvalumab|"Durvalumab will be supplied by AstraZeneca as a 500 mg vial concentrate for solution for infusion. The solution contains 50 mg/mL durvalumab, 26 mM histidine/histidine-hydrochloride, 275 mM trehalose dihydrate, and 0.02% weight/volume (w/v) polysorbate 80; it has a pH of 6.0 and density of 1.054 g/mL. The label-claim volume is 10 mL.~Durvalumab is a sterile, clear to opalescent, colorless to slightly yellow solution, free from visible particles.~Investigational product vials are stored at 2°C to 8°C (36°F to 46°F) and must not be frozen. Investigational product must be kept in original packaging until use to prevent prolonged light exposure."
223840800|NCT06094140|DRUG|Oxaliplatin|85mg/m2 intravenously on day 1
223840801|NCT06094140|DRUG|Irinotecan|150mg/m2 intravenously on day 1
223840802|NCT06094140|DRUG|Calcium folinate (leucovorin)|50mg as an intravenous bolus
223840803|NCT06094140|DRUG|Fluorouracil|2400mg/m2 by continuous infusion via pump over 46 hours starting on day 1
223840804|NCT06094140|DRUG|Pegylated G-CSF|6mg by subcutaneous injection to be given on day 3 of each cycle.
223840805|NCT03157011|OTHER|Global symptom score (GSS) questionary|systematic research of digestive symptoms in patients with SGSp with Global symptom score (GSS) questionary, which allowed to grades severity of 10 digestive symptoms (absent, mild, moderate, or severe), asthenia and fever.
223840806|NCT01067495|BEHAVIORAL|Cardiac rehabilitation|Participants will participate in a 6-month cardiac rehabilitation exercise program. This program will include aerobic and resistance training, and education sessions on risk factor management.
223840807|NCT00114959|DRUG|Homoharringtonine|"Participants are administered homoharringtonine (omacetaxine) 2.5 mg/m\^2 by continuous 24-hour intravenous (IV) infusion daily on Days 1-5 of each 4 week treatment cycle. Participants who do not achieve a meaningful hematologic or cytogenetic response by the end of the fourth cycle are discontinued from the study. Otherwise, participants may continue additional cycles of this combined treatment for a maximum of 12 cycles.~Participants who achieved a molecular or cytogenetic response, or a complete hematologic remission (CHR), could undergo subsequent cycles with a maintenance schedule of homoharringtonine 2.5 mg/m\^2 by continuous 24-hour IV infusion daily for 2 days every 4 weeks. Dose escalations in subsequent cycles were allowed by one day at a time if the participant was unable to maintain CHR in the maintenance schedule."
223840808|NCT00114959|DRUG|Imatinib Mesylate|Taken by mouth with a daily dose of 400 mg for participants in the chronic phase of chronic myeloid leukemia (CML) or 600 mg for participants in the accelerated or blast phase of CML. For the first cycle of therapy only, imatinib was started on Day 4 of homoharringtonine treatment.
223840809|NCT04069910|OTHER|Quality-of-Life Assessment|Ancillary studies
223840810|NCT04069910|OTHER|Questionnaire Administration|Ancillary studies
223840811|NCT04069910|RADIATION|Stereotactic Radiosurgery|Undergo SRS/SRT
223840812|NCT04069910|PROCEDURE|Therapeutic Conventional Surgery|Undergo standard of care surgery
223840813|NCT04931173|OTHER|IVA+OA versus IVA+MBP+OA|Non-inferiority RCT comparing IVA+OA+MBP vs IVA+OA to reduce surgical site infection following colon surgery
223840814|NCT06229886|OTHER|Application of positive-end-expiratory pressure|Application of PEEP on mechanically ventilated pediatric patients. Point-of-care-ultrasound performed after each PEEP application.
223840815|NCT03572764|DRUG|CPX-351|-CPX-351 will be provided by Jazz Pharmaceuticals
223840816|NCT03572764|PROCEDURE|Research skin biopsy|"-And/or buccal swab~* Pre-treatment~* Post-induction (no earlier than Day 28 and no later than Day 56 from last induction)"
223840817|NCT03572764|PROCEDURE|Research blood draw|"* Pre-treatment~* Post-induction (no earlier than Day 28 and no later than Day 56 from last induction)~* Post-consolidation 1 (if applicable)~* Post-consolidation 2 (if applicable)~* Post-transplant Day 30 (if applicable)~* Post-transplant Day 100 (if applicable)"
223840818|NCT03572764|PROCEDURE|Research bone marrow aspirate|"* Pre-treatment~* Post-induction (no earlier than Day 28 and no later than Day 56 from last induction)~* Post-consolidation 1 (if applicable)~* Post-consolidation 2 (if applicable)~* Post-transplant Day 30 (if applicable)~* Post-transplant Day 100 (if applicable)"
223840819|NCT05051540|DEVICE|Sigvaris Compreflex Inelastic Compression Wrap|Compreflex compression system using wraps to apply compression of 30-40 mmHg.
223840820|NCT00081029|PROCEDURE|management of therapy complications|
223840821|NCT00081029|RADIATION|radiation therapy|
223840822|NCT05115656|BEHAVIORAL|Online group 1|The intervention is specifically tailored to meet particular cognitive standard and satisfy the needs of brain injury patients. For 2-3 hours weekly, participants will be immersed in mental exercises designed to help them overcome various challenges.
223840823|NCT05115656|BEHAVIORAL|Online group 2|The intervention is specifically tailored to meet particular cognitive standard and satisfy the needs of brain injury patients. For 2-3 hours weekly, participants will be immersed in mental exercises designed to help them overcome various challenges.
223840824|NCT05355597|DRUG|Exparel Injectable Product|Both drugs have same desired effect. Will be injected intra-operatively while subjects are under anesthesia to alleviate significant post-operative pain.
223840825|NCT05355597|DRUG|Multi-Drug Cocktail (Ropivicaine, Epinephrine, Ketolorac, Clonidine)|Same desired effect as Exparel but different mechanism of action. Will be injected intra-operatively while subjects are under anesthesia to alleviate significant post-operative pain.
223840826|NCT02719197|DRUG|AC-083|Hard gelatin capsules for oral administration formulated at a strengths of 1, 10 and 100 mg
223840827|NCT02719197|DRUG|Placebo|Placebo capsules matching AC-083 capsules
223840828|NCT04725968|PROCEDURE|Urgent major general surgery|All geriatric patients (75 years and over) going under urgent major general surgery during 2018 in our centre
223840829|NCT03931005|OTHER|Collaboration Decision Support Guide|Electronic toolkit intended to help organizational leaders select partners and negotiate partnerships for implementation. This will contain: 1) a brief summary of collaboration approaches associated with implementation, 2) detailed descriptions of collaboration strategies, 3) a decision analysis tool that guides the selection of collaborative strategies given the community context, and 4) sample contract or agreement language that specifies the nature of the partnership and expectations.
223840830|NCT01402258|BEHAVIORAL|Tailored Internet-administrated CBT-Treatment|This intervention contains 6-8 text-based self-help modules in which 4 modules are fixed (the first three and the last) and the rest are prescribed following the diagnostic telephone interview. These modules contain material on panic disorder, social phobia, stress management, assertiveness training, concentration, relaxation among other things.
223840831|NCT03656458|OTHER|Warm Up|10 low jumps 5 Illiopoase Stretches 5 L/L Abductor Stretches 10 Trunk rotations 10 Should Circumduction Clock wise/Counter clockwise 10 Cervical Rotations Clockwise/Counter Clockwise
223840832|NCT03656458|OTHER|Conventional Balance Training|"Internal Protuberances:~1. Looking up/Looking down/looking over the shoulder (Rt. /Lt.) 10 Reps Each~2. Looking behind over the shoulder (Rt. /Lt.)10 Reps~3. Looking Up with overhead Upper Limb Flexion. 5 Reps~4. Reaching out of Base of support (Rt. /Lt. / midline Cross) 10 Reps Each~5. Side to Side weight Shifting 10 Reps~6. Standing on toes/Heels 10 Reps each~External Protuberance:~1. Tuck forward/ Backward/ Sideways(Rt. /Lt.) 10 reps Each~2. Bosu Ball Training"
223840833|NCT03656458|OTHER|Biodex Balance Training|Biodex Balance Training Using Biodex Balance System SD
223840834|NCT05274776|DEVICE|EOS calculator|For this study the EOS calculator was developed as a mobile application (by everywhereIM), including CE marking. It is concerned a medical device for health care professionals.
223840835|NCT00615433|DRUG|Lurasidone|120mg/day
223840836|NCT00615433|DRUG|Olanzapine|15mg/day
223840837|NCT00615433|DRUG|Placebo comparator|Placebor Comparator
223840838|NCT00615433|DRUG|Lurasidone 40 mg tablets|Lurasidone 40 mg tablets
223840839|NCT00866710|OTHER|Exercise-based behavioral therapy|Participants will be taught pelvic floor muscle exercises as well as urge suppression strategies to overcome the urge to void. In the first 20 participants, computer-assisted biofeedback will also be utilized to help participants identify the pelvic floor muscles and contract and relax these muscles while keeping the abdominal muscles relaxed
223840840|NCT04770818|DEVICE|Modified Brostrum procedure with Internal Brace Augmentation|Open, anatomic repair of the anterior talofibular and calcaneofibular ligaments for lateral ankle stability with InternalBrace augmentation.
223840841|NCT04770818|DEVICE|Modified Brostrum procedure|Open, anatomic repair of the anterior talofibular and calcaneofibular ligaments for lateral ankle stability
223840842|NCT06161649|BEHAVIORAL|accepting the operation process of automated intelligent education software system|"1. Execute registration and qualification review~2. Automated smart education interaction"
223840843|NCT04360226|OTHER|Non-interventional|Non-interventional, subjects will only have routine testing (blood biomarkers, spirometry, peak inspiratory flow measurements) and be asked to complete questionnaires.
223840844|NCT00102193|DEVICE|Adacolumn Apheresis System|
223840845|NCT04130906|DEVICE|Intermittent Theta Burst Stimulation|iTBS will be delivered to the left dorsolateral prefrontal cortex (DLPFC) at 80% of resting motor threshold using standard stimulation parameters; triplet-bursts will be delivered at high frequency (50 Hz) with an inter-burst interval of 200 ms. Each TBS train will last 2 seconds and consists of 10 triplet-bursts (30 pulses). Each iTBS session will involve 10 TBS trains repeated every 10 seconds for 190 seconds, with a total number of 600 pulses delivered during each session.
223840846|NCT04130906|DEVICE|Sham Intermittent Theta Burst Stimulation|Sham stimulation will be delivered left dorsolateral prefrontal cortex (DLPFC) using the same parameters as real iTBS however, a sham coil will be used. The sham coil makes the same noise and creates a similar sensation on the scalp as the real coil but does not produce a magnetic field.
223840847|NCT01007552|DRUG|Gemcitabine, Capecitabine and Bevacizumab|Bevacizumab 15 mg/ kg every 3 weeks, starting day 1; Capecitabine 650 mg/m2 bid x 14 days starting day 1, Gemcitabine 1000 mg/m2 days 1 and 8, cycles to be repeated every 21 days.
223840848|NCT04361630|DRUG|FGF 2|Following a standard surgical protocol, rhFGF-2 impregnated membranes will be placed in sites with gingival recession.
223840849|NCT02451423|DRUG|Atezolizumab|1200 mg Given IV
223840850|NCT01448174|DRUG|Atorvastatin|"Atorvastatin (10 - 80 mg/day) will be administered orally in the one evening dose in the case of strict indications for such a treatment. Before starting atorvastatin, serum lipid profile will be examined two times, and when both results are abnormal the treatment is started. Duration of administration:~* atorvastatin 12 weeks, 6 weeks washout, placebo 12 weeks or~* placebo 12 weeks,6 weeks washout,atorvastatin 12 weeks."
223840851|NCT00816660|BIOLOGICAL|Recombinant von Willebrand factor : recombinant FVIII (rVWF:rFVIII)|Single dose, dose escalation, various cohorts
223840852|NCT00816660|BIOLOGICAL|Marketed plasma-derived VWF/FVIII concentrate|Cross-over: recombinant FVIII (rVWF:rFVIII) and marketed plasma-derived VWF/FVIII concentrate
223840853|NCT06376318|DRUG|Inotrope|Vasopressors: Norepinephrine, vasopressin Inotropes: Epinephrine, Dobutamine, Milrinone
223840854|NCT06376318|DEVICE|Mechanical circulatory support|Intra-aortic balloon pump Extracorporeal membrane oxygenation (ECMO)
223840855|NCT06376318|DRUG|anti-bodies|Anti-Dipeptidyl peptidase 3 (DPP3), Anti-Bioactive adrenomedullin (bio-ADM)
223840856|NCT02818075|OTHER|Mobile Phone Based Peer Support|Adolescents allocated to the experimental group will have access to all standard prenatal and postpartum community supports. In addition, mobile phone-based peer support (MPPS), which consists of support provided by a peer mentor via mobile phone (with both voice calling and Short Message Service text message capabilities) will be provided during pregnancy and for 12 weeks postpartum. Peer support is defined as a specific type of social support (informational, appraisal, and emotional support) that is provided by a peer mentor who possesses experiential knowledge of adolescent motherhood and is of similar age to the participant.
223840857|NCT02818075|OTHER|Usual Care|Participants allocated to the usual care group will not receive the peer support intervention but will have access to all standard community prenatal and postpartum support services such as 1) the Canada Prenatal Nutrition Program; 2) postpartum home visits / telephone support from a public health nurse; 3) postpartum appointments with midwives, obstetrician, family physician, and / or pediatricians, and 4) prenatal and postpartum support as needed from psychiatrists, psychologists, social workers, breastfeeding clinics, and community resources.
223840858|NCT01493830|GENETIC|fluorescence in situ hybridization|
223840859|NCT01493830|GENETIC|gene expression analysis|
223840860|NCT01493830|GENETIC|microarray analysis|
223840861|NCT01493830|GENETIC|mutation analysis|
223840862|NCT01493830|GENETIC|protein analysis|
223840863|NCT01493830|OTHER|immunohistochemistry staining method|
223840864|NCT01493830|OTHER|laboratory biomarker analysis|
223840865|NCT01493830|OTHER|microscopy|
223840866|NCT05794282|PROCEDURE|the robot assisted total hip arthroplasty|the robot assisted total hip arthroplasty
223840867|NCT05794282|PROCEDURE|the conventional total hip arthroplasty|the conventional total hip arthroplasty
223840868|NCT05249764|OTHER|Supervised Home Based Exercise Training|Exercise program was prepared based on WHO, American College of Sports Medicine (ACSM), Geriatrics Physiotherapists Association and Otago exercise program for the exercise group. The older adults are given individual supervised exercise training in their own homes for eight weeks, 3 days a week and 45 minutes a day, by a physiotherapist according to social distance rules. This exercise training consists of a program that includes strengthening, flexibility, aerobic and balance exercises. Each exercise is started with eight repetitions and each week will be increased by two repetitions. In case of fatigue, a rest is given. Brochures are also be prepared for the exercises. Before each session, individuals performed warm-up exercises for 5 minutes. At the end of the session, individuals performed cooling exercises.
223840869|NCT05249764|OTHER|Unsupervised stretching and breathing exercises|Individuals in the control group are performing stretching exercises for proximal extremity muscles for 15 minutes 3 times a week for eight weeks. The participants also perform breathing exercises for 5 minutes a day.
223840870|NCT02941185|DRUG|Devit-3 Oral Drop|
223840871|NCT04845438|DIAGNOSTIC_TEST|fibrogastroscopy, biopsy of the gastric mucosa, microscopy biopsy materials, using Bile Reflux Index|fibrogastroscopy, biopsy of the gastric mucosa, microscopy biopsy materials, using Bile Reflux Index
223840872|NCT00752570|DRUG|AMG 386|AMG 386 (10 mg/kg QW) will be administered until subject develops disease progression, clinical progression, unacceptable toxicity, or withdraws consent.
223840873|NCT00752570|DRUG|AMG 386 Placebo|AMG 386 placebo QW will be administered until subject develops disease progression, clinical progression, unacceptable toxicity, or withdraws consent.
223840874|NCT00752570|DRUG|FOLFIRI|"Administration of FOLFIRI chemotherapy will commence on day 1 of each dosing week following the administration of AMG 386.~FOLFIRI Q2W regimen: irinotecan 180 mg/m2 IV over 90 (+-15) minutes on Day 1, leucovorin 400 mg/m2 IV over 2 hrs on Day 1, 5 FU 400mg/m2 IV bolus, followed by 2400 mg/m2 continuous IV infusion over 46 hrs +- 2 hours.~FOLFIRI will be administered until disease progression, FOLFIRI intolerability, death, or study withdrawal by the subject, investigator, or sponsor, whichever occurs earliest."
223840875|NCT03202875|DRUG|SAR341402|"Pharmaceutical form: solution~Route of administration: subcutaneous"
223840876|NCT03202875|DRUG|Insulin Aspart|"Pharmaceutical form: solution~Route of administration: subcutaneous"
223840877|NCT03202875|DRUG|Insulin Aspart|"Pharmaceutical form: solution~Route of administration: subcutaneous"
223840878|NCT01125774|DRUG|Telcagepant|Telcagepant 140 mg film coated tablet for oral administration
223840879|NCT01125774|DRUG|Placebo|Placebo to match telcagepant 140 mg film coated tablet for oral administration
223840880|NCT00971516|PROCEDURE|Implant placement|dental implant placement
223840881|NCT00971516|PROCEDURE|Implants surgery|dental implant surgery
223840882|NCT03271619|OTHER|Surface current measurement|Measurement of surface current between electrodes placed on the chest wall during defibrillation
223840883|NCT04855487|BEHAVIORAL|Nurse-patient dyadic storytelling intervention|During the 5-week online intervention, adolescents/young adults with cancer will create their stories following the guiding questions and online meetings with nursing research staff. The target audience of their stories will be their primary nurses. This online dyadic storytelling intervention is designed to promote in-depth self-reflection and meaningful and therapeutic relationships within bedside nurses. The intervention is designed following the Story Theory and Pennebaker's Expressive Writing paradigm.
223840884|NCT05698654|BEHAVIORAL|Fasting-mimicking diet (FMD)|"The subjects will be instructed to follow their usual diet plan, except for 5 days when they eat the foods in the FMD box.The fasting-mimicking diet consists of a blend of 100% plant based nutrients generally regarded as safe. The formulation of these products is based on studies carried out at the Longevity Institute of the University of Southern California and his collaborators over several decades of studies.~This food plan provides for the replacement of the normal diet with the organic plant products contained in the fasting-mimicking diet for five consecutive days."
224264838|NCT06660121|PROCEDURE|Electrochemotherapy with bleomycin|Electrochemotherapy (ECT) with bleomycin is a localized treatment approach used for managing desmoid fibromatosis, a benign but locally aggressive tumor. This technique combines electrical pulses with the administration of bleomycin, a chemotherapeutic agent, to enhance drug uptake into tumor cells. The electrical pulses create temporary pores in the cell membranes, allowing bleomycin to enter more effectively, leading to increased cytotoxicity. ECT is typically performed on patients who have not responded to conventional therapies or for whom surgery is not feasible. ECT can lead to significant tumor shrinkage and improvement in symptoms, making it a promising option in the multidisciplinary management of desmoid fibromatosis.
223840885|NCT05698654|BEHAVIORAL|Longevity Diet (LD) + Fasting-mimicking Diet (FMD)|"The subjects will be instructed to follow their longevity diet plan, except for 5 days when they eat the foods in the FMD box, based on the following guidelines:~vegan based diet with the addition of low mercuryfish 2-3 times a week; protein content should be 0.7-0.8 grams per kilogram of ideal weight per day (most of the protein coming from whole cereals,vegetables, legumes and tree nuts only part from fish); monounsaturated and polyunsaturated fats are predominant and very low amounts of saturated and trans-fats are allowed; complex Carbohydrates from vegetables, whole grains and legumes; addition of vitamins, minerals and Omega3 fats; food selected between the traditional food consumed by ancestry; time-restricted feeding: all food must be consumed within 12 hours each day. for those who are overweight or are nearly overweight (BMI \>25 kg/m2), either lunch or dinner will be substituted with a low calorie, low sugar snack (approximately 100 kcal: salad, nuts, fruit, etc.)."
223840886|NCT04578028|DRUG|ONO-2808|Investigational drug
223840887|NCT04578028|DRUG|Placebo|Placebo drug
223840888|NCT01055106|DRUG|GW05|vaginal gel once daily regimen A
223840889|NCT01055106|DRUG|GW05|vaginal gel once daily regimen B
223840890|NCT01055106|DRUG|GW05|vaginal gel once daily regimen C
223840891|NCT01055106|DRUG|Metronidazole|vaginal gel 0.75% once daily for 5 days
223840892|NCT03886675|OTHER|CO2 flushing|As above
223840893|NCT03886675|OTHER|Saline flushing|As above
223840894|NCT01134211|DEVICE|nelfilcon A|Commercially marketed, single-vision, soft contact lens for daily disposable wear
223840895|NCT01134211|DEVICE|filcon II 3|Commercially marketed, single-vision, soft contact lens for daily disposable wear
223840896|NCT01258218|DEVICE|Implantation of an Accent MRI device|Implantation of an Accent MRI device
223840897|NCT01807078|DRUG|Ezetimibe|10 mg p.d. of ezetimibe
223840898|NCT01807078|DIETARY_SUPPLEMENT|Nutraceuticals|1 capsule/day containing monacolin K 10 mg, policosanol 10 mg, and phytosterols 300 mg
223840899|NCT02521519|OTHER|Medial branch block in one side|MBB: Using sterile conditions, 25G needles will be placed in the desired position. In its final position for the L3 and L4 vertebrae the needle tip should reside at the junction of the superior articular process and the transverse process. At the L5-S1 level the needle tip should reach the junction between the sacral ala and the superior articular process of S1. Following a negative aspiration 0.5ml of injectate will be injected into each site.
223840900|NCT02521519|OTHER|paravertebral deep intramuscular (PDI) injection|injections will target the deep para-spinal muscles between the spinous process and inter-pedicular line of the L3-5 vertebrae. Under fluoroscopic guidance, a 25-gauge needle will be advanced, directed towards the lamina at the mid-distance between inter-pedicular line and the spinous process of the L3, L4 and L5 vertebrae, until touching the bone. A straight forceps will be attached to the junction of the skin and the needle; the needle will then be withdrawn by 1.4cm, to reside inside the muscle bulk. A five ml syringe diameter will be used to point 1.4 cm withdrawal. Following a negative blood aspiration, each level will be injected with 0.5 ml of the injectate.
223840901|NCT03580720|OTHER|Inspiratory threshold loading protocol|Subjects will be instrumented with catheters that measure electrical activity of the diaphragm and transdiaphragmatic pressure. Subjects will perform a stepwise inspiratory threshold loading protocol to induce a wide range of diaphragm activity.
223840902|NCT06083675|DRUG|Semaglutide|Administered as oral tablets.
223840903|NCT06083675|DRUG|Empagliflozin|Administered as oral tablets.
223840904|NCT06083675|DRUG|Metformin|Administered as oral tablets.
223840905|NCT05573919|DEVICE|VivAer Stylus|This device will be used to complete its corresponding procedure, which involves reshaping a patient's nasal sidewall tissue through the delivery of radiofrequency heating.
223840906|NCT00403988|DRUG|Oxaliplatin|
223840907|NCT00403988|DRUG|vinorelbine|
223840908|NCT00429793|DRUG|temsirolimus|Given IV
223840909|NCT01339494|DIETARY_SUPPLEMENT|Arginine and citrulline supplementations|Arginine or citrulline will be given orally at dose of 10 grams per meter square body surface area per day divided every 4 hours.
223840910|NCT05375565|OTHER|weight bearing exercises|"* Standing knee raise 10 rep x 2sets~* Standing knee bend 10 rep x 2sets~* Standing hip extension 10 rep x 2sets~* Shallow squats 5 rep x 2 sets After 4 week gradually restricting the use of assistive device when patient become able to walk and stand for 10 mins then add stair climbing and descending with a step height not higher than 7 inch.~The session will be around 45 to 60 minutes on each patient with 2 sessions per week on alternate days to observe the long term effects."
223840911|NCT05375565|OTHER|non weight bearing exercises|"* Seated knee flexion 10 rep x 2sets~* Seated knee extension 10 rep x2sets~* Use of stationary bicycle 10 mins~* Side lying leg lift 10 rep x2sets~* Straight leg raise 10 rep x 2sets The session will be around 45 to 60 minutes on each patient with 2 sessions per week on alternate days to observe the long term effects."
223840912|NCT03748537|DRUG|Hydrocortisone|After resuscitation, hypoperfusion in the sepsis patients will be treated by fluid resuscitation and vasopressor. Some groups of patients may be not responsive to this treatment (MAP \<65 mmHg), administration of steroids to this group will be blindly randomized (treatment and control group). During resuscitation of septic shock patients with fluid resuscitation and vasopressors, some may not respond to treatment (MAP \< 65 mmHg). Patients who have shock refractory to fluid resuscitation and norepinephrine therapy for more than 0.5 mcg/kg/min will be blindly randomized to receive steroid (treatment group) or placebo (control group). Blood samples will be obtained to determine mitochondrial functioning before, at day 1 and day 7 after administration of study medications in both groups.
223840913|NCT01620411|OTHER|Comprehensive Medical Management|Standard of care for failed back surgery syndrome sustained while on active duty, primarily focused on physical therapy, medication including: opioid analgesics, muscle relaxants, non-opioid analgesics, etc.
223840914|NCT01620411|PROCEDURE|Spinal Cord Stimulator|This arm combines comprehensive medical management (as above) with the trial and possible eventual permenant placement of a spinal cord stimulator, a common pain management procedure.
223840915|NCT00465712|PROCEDURE|transabdominal amnioinfusion|transabdominal amnioinfusion performed 4 to 24 hours before the second trial of external cephalic version
223840916|NCT00903773|DRUG|telaprevir|
223840917|NCT02784652|DRUG|Zoledronic acid|Zoledronic acid: every 4 weeks, 6 times, 4.0 mg iv
223840918|NCT02784652|RADIATION|Radiotherapy|Radiotherapy: 5 days/ week, 3 Gy \* 10-13 fractions or 4 Gy \* 5 fractions,
223840919|NCT05943483|OTHER|CCMQ questionnaire|Test subjects were required to fill out our modified CCMQ (Constitution in Chinese Medicine Questionnaire) Questionnaire.
223840920|NCT05027750|BEHAVIORAL|Application of The Theory of Planned Behaviour For Weight Control|The training to be imparted to the participants was applied online in groups of 5-6 people via the Google Meet program. Obesity training consisting of a total of five sessions. Each session lasted for approximately 30 minutes. After the training given to intervention group, the women will be followed-up for 6 months. The women in the intervention group will be given counseling service by the researchers, and their status will be evaluated every month.
223840921|NCT01355783|DRUG|E7777|Treatment in both arms is for 6 cycles at 21 days/cycle.
223840922|NCT02733107|DRUG|Apatinib|Apatinib, 250mg daily, po, continue until disease progression
223840923|NCT02733107|DRUG|Etoposide|Etoposide, 50mg daily, po, day 1 to day 20, repeat Q 4 weeks until disease progression
223840924|NCT00097370|DRUG|mepolizumab|Study Drug
223840925|NCT03013361|DRUG|Bupivacaine|Post operative pain control
223840926|NCT03013361|DRUG|Ropivacaine|Post operative pain control
223840927|NCT03013361|OTHER|Normal Saline|Acts as comparator
223840928|NCT04595695|BEHAVIORAL|Transparent mask|A transparent mask worn by the surgeons in customary fashion will be used.
223840929|NCT04595695|BEHAVIORAL|Typical surgical covered mask|A standard covered surgical mask worn by the surgeons in in customary fashion will be used.
223840930|NCT02419755|DRUG|Bortezomib|Bortezomib will be given as a 1 mg/mL solution intravenous (IV) push over 3 to 5 seconds. For subcutaneous (SQ) administration, bortezomib will be mixed at 2.5 mg/ml.
223840931|NCT02419755|DRUG|Vorinostat|Vorinostat should be taken orally (PO) with food.
223840932|NCT02419755|DRUG|Mitoxantrone|Given by intravenous (IV) injection.
223840933|NCT02419755|DRUG|Cytarabine|Given by intravenous (IV) injection.
223840934|NCT02419755|DRUG|Methotrexate|Methotrexate will be given intrathecally (IT) along with hydrocortisone and cytarabine.
223840935|NCT02419755|DRUG|Hydrocortisone|Hydrocortisone will be given intrathecally (IT) along with methotrexate and cytarabine.
223840936|NCT02419755|DRUG|Peg-L-Asparaginase|Given by intravenous (IV) or intramuscular (IM) injection.
223840937|NCT02419755|DRUG|Erwinia L-Asparaginase|To be used in case of allergy or intolerance to PEG-Asparaginase. Given by intravenous (IV) or intramuscular (IM) injection.
223840938|NCT02419755|DRUG|Dexamethasone|Given orally (PO) or intravenously (IV).
223840939|NCT02419755|DRUG|Mercaptopurine|Given orally (PO).
223840940|NCT02419755|DRUG|Doxorubicin|Given intravenously (IV).
223840941|NCT02337361|BEHAVIORAL|Electronic SBI|"Bilingual (English and Spanish) e-SBI with four key components:~1\) Beverage-specific drink size assessment; 2) Individualized feedback on the woman's drink sizes and on discrepancies between her drink size and the standard size for each beverage; 3) A personalized plan for reducing consumption which includes goal setting; and 4) an analysis of high risk situations for drinking alcohol, and suggested coping strategies."
223840942|NCT03354299|DIETARY_SUPPLEMENT|coconut milk|50 cc of coconut milk supplementation plus 25 gram sugar (pudding) was given to cirrhosis patients as late night snack
223840943|NCT01300793|DRUG|Velcade (bortezomib), rituximab, ifosfamide, carboplatin, etoposide|Rituximab, 375 mg/m2, IV on day 1 Etoposide, 100 mg/m2, IV on days 2 to 4 Carboplatin, AUC 5 (using the Calvert Formula), IV on day 3 Ifosfamide, 5 g/m2 with Mesna 5 g/m2, CIV over 24 hours beginning D. 3 Bortezomib,1.0mg/m2 starting cohort. Based upon a satisfactory safety profile, additional pts. will be enrolled into the 1.3, 1.5 and 1.7mg/m2 cohorts given IVP over 3 sec. d. 1, 4, 8 \& 11 q. 28 days.
223840944|NCT01031043|DRUG|Bethanechol|Taking part in this research study is voluntary. Patient may choose not to take part in this research study or may withdraw consent at any time. Their choice will not at any time affect the commitment of the health care providers to administer care. If the patient decides not to participate or withdraw from the study there will be no penalty or loss of benefits to which they are otherwise entitled.
223840945|NCT02203097|PROCEDURE|Partial pressure of CO2 at the end of an exhaled breath|Three previously defined EtCO2 levels (partial pressure of CO2 at the end of an exhaled breath) were adjusted during anesthesia.
223840946|NCT02203097|DRUG|Propofol|Propofol is administered to all patients via target-controlled infusion (TCI) to reach 4 mcg/ml constant plasma concentration according to the Schneider model during the course of the narcosis.
223840947|NCT02472561|OTHER|Fitbit Physical Activity Monitor|Physical Activity: The study team will provide an individualized goal of total number of steps to attain daily and will be monitored using a Fitbit activity tracker. The total daily step goal will be reviewed by study staff and modified at weeks 4 and 8.
223840948|NCT02472561|OTHER|mHealth Glucometer|Blood Glucose: The participant will monitor their fasting blood glucose once per week by using an mHealth Glucometer and mobile app.
223840949|NCT02472561|OTHER|mHealth Blood Pressure|Blood Pressure: The participant will monitor their blood pressure once per week by using an mHealth Blood Pressure cuff and mobile app.
223840950|NCT03432039|BEHAVIORAL|Psychoeducation|This intervention has three phases occurring the same time as the Psychoeducation intervention. Phase I provides verbal and written information about the paediatric acute care unit services and policies. Phase II consists of: (a) verbal and written information about the general paediatric unit and its policies, and (b) a parent-child activity having ''control'' activities like reading a story not related to hospital stay. Phase III of the control program consists of a telephone call 2-3 days after discharge during which time mothers were informed that they should contact their primary healthcare providers if their children were having any problems or unusual symptoms. They also were asked to comment on their children's hospital stays during this telephone call.
223840951|NCT03432039|BEHAVIORAL|Behavioral|This is an educational-behavioural intervention that educates the parent about the children's likely emotional and behavioural problems that may result from ICU admission. Phase I will be delivered within 6 to 16 hours of admission to the hospital where caregivers are provided with information about the child's likely emotional reactions during admission in hospital. Phase II will be delivered within 2 to 16 hours of transfer to the general ward and will consist of: (a) verbal and written information to reinforce information provided in Phase I and (b) a parent-child skills building activities. Phase III of the COPE intervention program will occur 2 to 3 days after hospital discharge and will consist of a telephone call during which a 5 minute script will be read that reinforces young children's typical post-discharge emotions and behaviours and parenting behaviours which would continue to facilitate positive coping outcomes in their children.
223840952|NCT01091285|DEVICE|Foley Catheter|Foley Catheter 16-19 H
223840953|NCT01091285|DEVICE|Double Balloon Catheter|Double Balloon Catheter for 16-19H
223840954|NCT04022642|OTHER|High-Intensity Interval Training|"The program will be applied in the first 10-15 minutes of each PE class, twice a week, including a brief warm-up, ranged from 14 to 20 intervals, adopting a 2:1 work to rest ratio (ie, 30-s work, followed by 30-s rest)~A cut-point of \>=90% of maximal heart rate was used as our criterion for satisfactory compliance to high-intensity exercise~In order to estimate effort, fatigue and training load, a subjective effort scale will be used throughout each session. The heart rate will be monitored throughout the session in real time through Bluetooth technology.~Actigraph accelerometers (wGT3X-BT), randomly distributed by the students in each session, will be used to characterize the intensity of the sessions."
223840955|NCT00553111|OTHER|educational video|educational video
223840956|NCT01553786|DRUG|Lenalidomide|Lenalidomide
223840957|NCT03608020|DRUG|BMX-001|Manganese butoxyethyl pyridyl porphyrin
223840958|NCT03608020|RADIATION|Whole Brain Radiation Therapy|Whole Brain Radiation Therapy per standard of care.
223840959|NCT02427646|DRUG|BoNT-A|A serotype of botulinum toxins that has specificity for cleavage of SYNAPTOSOMAL-ASSOCIATED PROTEIN 25 (SNAP-25). BoNT-A's pharmacological action is to inhibit the release of acetylcholine from the neuromuscular junction. BoNT-A peripherally applied using optimal parameters by intramuscular injections to treat tremor in the most bothersome upper extremity every 16 weeks over 96 weeks. The study will be extended for those participants who benefited and will receive treatment every 12 weeks over 96 weeks. BoNT-A dose will range from 50-300 U per arm.
223840960|NCT00831246|OTHER|chewing gum - Extra Winterfresh|Patients are given standard post-op care with clear liquid diet as tolerated plus chewing gum q8 for 30minute chewing intervals.
223840961|NCT00831246|OTHER|Standard Post-Op Care|Patients are given standard post-op care with clear liquid diet as tolerated.
223840962|NCT01932944|DEVICE|No treatment|
223840963|NCT03754738|DEVICE|Balloon guide catheter|Use a balloon guide catheter in the mechanical thrombectomy
223840964|NCT03754738|DEVICE|Non-balloon guide catheter|Use a non-balloon guide catheter in the mechanical thrombectomy
223840965|NCT04136028|DRUG|Kineret|Kineret at a dose of 8 mg/kg per day subcutaneously daily, every day at the same time
223840966|NCT00989170|BEHAVIORAL|Family Program for the Prevention of Weight Gain|The Family Workbook is a step-by-step instruction guide for families to use throughout the 6-month period, detailing healthy lifestyle. All handouts, instructions, activities, and a timeline of the program are laid out for families in this workbook.
223840967|NCT00989170|BEHAVIORAL|Control Group|This group will not be provided the workbook and it is hypothesized those in the control group will gain excess weight.
223840968|NCT00052559|BIOLOGICAL|bevacizumab|Given IV
223840969|NCT00052559|DRUG|fluorouracil|Given IV
223840970|NCT00052559|RADIATION|external beam radiation therapy|Undergo external beam radiation therapy
223840971|NCT00052559|PROCEDURE|therapeutic conventional surgery|Undergo surgery
223840972|NCT00052559|OTHER|laboratory biomarker analysis|Correlative studies
223840973|NCT02288858|DIETARY_SUPPLEMENT|Viviscal Oral Supplement Tablets|Tablet (512 mg)
223840974|NCT03946657|DRUG|Inhalational anesthetic|Oxygen/air (fraction of inspired oxygen (FiO2) of 0.40), inspiratory fresh gas flow of 2 L/min), sevoflurane (1 minimum alveolar concentration \[MAC\]) and remifentanil IV infusion (0.1-0.25 mcg/kg of LBW/min) were used.Neuromuscular blockade was performed during the operation by rocuronium infusion (0.3-0.7 mg/kg of LBW/h), ensuring that PTC was zero.
223840975|NCT03946657|DRUG|Intravenous anesthetic|Propofol infusion (4-8 mg/kg of total body weight/h), oxygen/air (FiO2 of 0.40; inspiratory fresh gas flow of 2 L/min) and remifentanil IV infusion (0.1-0.25 μg/kg of LBW/min) were used.Neuromuscular blockade was performed during the operation by rocuronium infusion (0.3-0.7 mg/kg of LBW/h), ensuring that PTC was zero.
223840976|NCT05823779|OTHER|Blood draw|We will be drawing blood for verify HIV status, HSV 1 or 2 antibodies, CD4 and HIV-PCR
223840977|NCT01040663|OTHER|Dietary intervention|Subjects will be randomly assigned to receive 1 of 3 diets for 4 weeks.
223840978|NCT01641861|DEVICE|Papacarie®|Papacarie® is chemo-mechanical method for caries removal
223840979|NCT01641861|PROCEDURE|Conventional method|caries removal by using rotary instrument.
223840980|NCT05263453|DRUG|HL-085|HL-085 capsule 12mg administered orally twice daily in a 21-day treatment cycle
223840981|NCT05263453|DRUG|Vemurafenib|Vemurafenib tablet 720mg administered orally twice daily in a 21-day treatment cycle
223840982|NCT06089876|BEHAVIORAL|STRAVA mobile application|The adolescents in the intervention group will use the STRAVA mobile application for a period of 10 weeks. To do so, they will follow the instructions provided by the researchers on the frequency of use, the distance to be covered and how to record it.
223840983|NCT04858789|BEHAVIORAL|Culturally Adapted Cognitive Behavioral Intervention (CA-CBI)|CA-CBI is an intervention based on Culturally Adapted Cognitive Behavioral Therapy (CA-CBT) which was developed by Devon Hinton. This transdiagnostic intervention has a structured manual which can be culturally adapted and it will be used to decrease psychological distress and increase well-being by targeting cognitive and behavioral changes.
223840984|NCT05335135|OTHER|TriageGO-MDW Clinical Decision Support|TriageGO-MDW is non-device clinical decision support that provides patient-level clinical risk estimates based on clinical data derived from the electronic health record
223840985|NCT05335135|OTHER|Usual Care|Clinical care without decision support provided by TriageGo-MDW
223840986|NCT03174964|DRUG|IVIg|Patients will take a dose of 400mg/kg of IVIg 2 days before ET.
223840987|NCT04125017|DEVICE|ICSI with laser pulse|Using laser pulse before ICSI
223840988|NCT04125017|DEVICE|ICSI with micro needle technique|Using micro needle technique before ICSI
223840989|NCT06031662|DEVICE|Intermittent Theta-Burst Stimulation|Accelerated course of left dlPFC iTBS, consisting of 600 pulses/session, 50 minutes intersession interval, 8 session/day for 5 days) at 90% resting MT
223840990|NCT06031662|DEVICE|Sham Intermittent Theta-Burst Stimulation|Magventure Active/Placebo B70 coil specifically designed for randomized clinical trials with TMS. This system uses electrodes placed on the scalp to provide stimulation mimicking the active treatment condition
223840991|NCT01101542|BIOLOGICAL|Cervarix.|Subjects will receive three doses of the Cervarix vaccine administered intramuscularly according to a 0, 1, 6 month vaccination schedule in routine clinical practice settings.
223840992|NCT01101542|OTHER|Data collection|All adverse events will be recorded by all subjects or the subject's parents/guardians using diary cards.
223840993|NCT05162768|DRUG|Elamipretide|60 mg of elamipretide administered as once daily 0.75 mL subcutaneous injections for 48 weeks
223840994|NCT05162768|DRUG|Placebo|Placebo administered as once daily 0.75 mL subcutaneous injections for 48 weeks
223840995|NCT05002361|DRUG|Dexamethasone|24 mg intravenous Dexamethasone (6 ml)
223840996|NCT05002361|DRUG|Isotonic saline|6 ml of isotonic saline
223840997|NCT04803084|OTHER|Tempus assay|Blood collection
223840998|NCT04803084|OTHER|Advanced pathology 1|Tissue procurement (from diagnostic biopsy)
223840999|NCT04803084|OTHER|Advanced pathology 2|Tissue procurement (from research biopsy)
223841000|NCT04606888|DEVICE|Transcutaneous electrical acupoint stimulation|According to the traditional Chinese medicine 15,three acupuncture points were selected as the target points: bilateral Neiguan ,Yintang and bilateral Zusanli.. A transcutaneous electrical stimulator was used to provide an altered frequency 2/100 Hz,disperse-dense waves,and adjusted intensity which was less than 10mA.
223841001|NCT03230929|DEVICE|BIS-PLE|Anesthesiologist attaches the sensors of BIS and PLEM 100 on the forehead of the patient, and adheres the neuromuscular monitoring device on the medial side of the wrist and the ipsilateral thumb to continuously monitor the state of consciousness and muscle relaxation before, during and after surgery. Reversal of muscle relaxant could be performed by intravenous injection of sugammadex 4 mg/ kg in the case of deep neuromuscular relaxation, and 2 mg / kg in the case of shallow muscle relaxation degree under neuromuscular monitoring. After then, they monitor and record the values of BIS, PLEM 100, and neuromuscular monitoring in 1 minute increments for 5 minutes.
223841002|NCT05168865|DRUG|Letrozole 2.5mg|Letrozole 5 mg starting on day 3 of spontaneous menstrual period or after progesterone withdrawal bleeding for five consecutive days.
223841003|NCT02173353|DEVICE|Ultrasound|Ultrasound to be done just before standard radiation therapy treatment
223841004|NCT05459818|DEVICE|Viabahn implanted|An individual patient data analysis obtained from databases used in prospective studies that published results of patients treated with the latest generation heparin-bonded Viabahn in the femoropopliteal artery.
223841005|NCT06663579|OTHER|Fathers who practicing kangaroo care|The study group (n=28) It consists of fathers of babies practicing Kangaroo Care with both their mothers and fathers in the neonatal intensive care unit.
223841006|NCT05230550|DRUG|Somapacitan|Sogroya® therapy in participants with AGHD (only severe case) under normal clinical practice conditions
223841007|NCT06613659|DRUG|traditional Chinese medicine (TCM)|Taking the use of traditional Chinese medicine syndrome differentiation treatment as the exposure factor, the continuous use of traditional Chinese medicine for 3-5 days was defined as mild exposure, continuous use of traditional Chinese medicine for 6-10 days as moderate exposure, and continuous use of traditional Chinese medicine for more than 10 days as severe exposure. The exposed group used TCM syndrome differentiation therapy combined with conventional western medicine treatment (integrative medicine treatment cohort), and the non exposed group used conventional western medicine treatment without standardized TCM syndrome differentiation treatment (Western medicine treatment cohort). The treatment plan was formulated by the clinician, and the researcher did not intervene.
223841008|NCT06613659|DRUG|non traditional Chinese medicine (non-TCM)|Taking the use of traditional Chinese medicine syndrome differentiation treatment as the exposure factor, the continuous use of traditional Chinese medicine for 3-5 days was defined as mild exposure, continuous use of traditional Chinese medicine for 6-10 days as moderate exposure, and continuous use of traditional Chinese medicine for more than 10 days as severe exposure. The exposed group used TCM syndrome differentiation therapy combined with conventional western medicine treatment (integrative medicine treatment cohort), and the non exposed group used conventional western medicine treatment without standardized TCM syndrome differentiation treatment (Western medicine treatment cohort). The treatment plan was formulated by the clinician, and the researcher did not intervene.
223841009|NCT00901485|DEVICE|AutoVPAP|Automatically titrated non-invasive ventilator, with target gross alveolar ventilation and back up respiratory rate determined by learn function. Nocturnal use for one month in patient's home.
223841010|NCT00901485|DEVICE|VPAPIIIST-A|Standard non-invasive ventilator with pressure and respiratory rate settings determined by healthcare professional. Nocturnal use for one month in the patient's home.
223841011|NCT06918262|DIAGNOSTIC_TEST|local treatment|Tumour somatic mutations were identified by 1021 panel sequencing of tumour tissues from cancer patients, and up to 20 mutations were selected as follow-up monitoring loci based on the tumour somatic variants of the patients, and a personalised panel was designed and customised.Post-operative blood from patients was analysed for recurrence risk stratification and drug indications using a combination of personalised panel and a cancer-specific core panel (\~5 kb) stacked on top of each other. The postoperative blood of patients was subjected to cfDNA targeted capture and ultra-high depth NGS sequencing (\&gt;100,000×) to analyse the status of the surveillance loci in the peripheral blood for recurrence risk stratification and medication advice.
223841012|NCT06696196|DEVICE|smart watches(wearable devices)|Participants will be asked to wear two smart watches simultaneously. The first smart watch is a dedicated prototype for validating algorithm developed by MediaTek. The second smart watch is Basis Peak. These watches are going to acquire PPG, body movements, skin temperature, and skin conductance.
223841013|NCT06697470|DEVICE|Ultrasound and Bioelectrical Impedance Analysis for Muscle Thickness and Fluid Balance Assessment Translation|This intervention involves the use of ultrasound and bioelectrical impedance analysis (BIA) to monitor changes in muscle thickness and assess fluid balance in critically ill patients. Measurements will be taken daily during the patients' ICU stay, with a focus on rectus femoris, tibialis anterior, and biceps brachii muscles, as well as total body fluid compartments. The study aims to explore correlations between muscle thickness variations, fluid balance, and patient outcomes.
223841014|NCT06744439|DRUG|BR1015|One tablet administered alone
223841015|NCT06744439|DRUG|BR1015-2|One tablet administered alone
223841016|NCT06744439|DRUG|BR1015-3|One tablet administered alone
223841017|NCT06919822|DEVICE|Personalized SCAN Electrical Stimulation|"* Stage 1: iTBS Intervention (14 days) and Washout Period (3-6 months)~  * All enrolled participants undergo:~    * Baseline clinical assessments~   * Structural and functional MRI with pBFS mapping~   * Resting motor threshold determination~ * Daily iTBS sessions targeting individualized SCAN coordinates:~    * Treatment duration: 14 consecutive days~   * Post-intervention evaluation at Day 14-21~ * Mandatory observation window:~    * No neuromodulation therapies permitted~   * Stable PD medication regimen maintained~   * Monthly safety monitoring~* Stage 2: Surgical Intervention and Follow-up (12 months)~  * Surgical Procedure:~    * Epidural electrode implantation~   * 7-day externalized stimulation testing~   * Pulse generator internalization~ * Chronic Stimulation Stage:~    * Parameter optimization visits~   * Scheduled follow-ups at Months 1, 3, 6, 9, 12"
223841018|NCT06918587|DEVICE|TPI-120 with On body injector|6mg Subcutaneous injection
223841019|NCT06918587|DRUG|Fylntera|6mg subcutaneous
223841020|NCT02239653|BEHAVIORAL|Physician communication|
223841021|NCT04722224|OTHER|Home-based pulmonary rehabilitation|The reabilitAR program includes the self-management educational program Living Well with COPD. The exercise training will include endurance, resistance/strength, flexibility and balance training.
223841022|NCT01907399|OTHER|Blood samples|
223841023|NCT03511989|DEVICE|Bone borne distractor|Bone borne distraction device
223841024|NCT03511989|DEVICE|Tooth borne distractor|Tooth borne distraction device
223841025|NCT03511989|PROCEDURE|Segmental LF1 Osteotomy group 1|
223841026|NCT03511989|PROCEDURE|Segmental LF1 Osteotomy group 2|
223841027|NCT03511989|PROCEDURE|Segmental LF1 Osteotomy group 3|
223841028|NCT06120751|BIOLOGICAL|TTVA|Intramuscular injection, 1 dose of 0.5ml inoculated on Day 0
223841029|NCT06120751|BIOLOGICAL|TT|Intramuscular injection, 1 dose of 0.5ml inoculated on Day 0
223841030|NCT00432159|DEVICE|Cervical TDR|Cervical total disc replacement using a DISCOVER Artificial Cervical Disc.
223841031|NCT00432159|DEVICE|ACDF with plate|Anterior cervical discectomy followed by insertion of allograft spacer and placement of an anterior plate.
223841032|NCT00002374|DRUG|Ritonavir|
223841033|NCT00002374|DRUG|Nelfinavir mesylate|
223841034|NCT00002374|DRUG|Saquinavir|
223841035|NCT00002374|DRUG|Stavudine|
223841036|NCT06242496|OTHER|Retrospective follow-up|Data collection
223841037|NCT03437434|OTHER|Visual Acuity|Ocular Examination
223841038|NCT03952065|DRUG|PD1/PDL1/CTLA4 inhibitors|Infusion of PD1/PDL1/CTLA4 inhibitors through peripheral vein or neck artery/intra-tumor.
223841039|NCT06507969|OTHER|The Effect of Body Composition on Respiratory Parameters, Functional Capacity and Sleep in Healthy Young Adults|Sociodemographic information of all participants will be obtained within the scope of the evaluations. Body composition parameters will be measured with Tanita DC360 Body Analysis Scale. In pulmonary function test, Forced vital capacity (FVC), Forced expiratory volume in 1st second (FEV1), Tiffeneau ratio (FEV1/FVC), peak expiratory flow rate (PEF) values will be evaluated with COSMED Pony FX (COSMED; Italy) spirometer. Respiratory muscle endurance will be assessed by Maximum Minute Ventilation will be determined. Pittsburg Sleep Quality, a reliable questionnaire that assesses sleep quality The index will be filled in by the participants. 6 Minutes to assess functional capacity A walking test will be performed and the distance travelled by individuals will be recorded
223841040|NCT00347659|DRUG|BLVR System|Treatment is administered in a single treatment session.
223841041|NCT01965080|DRUG|Exemestane|One tablet Exemestane 25 mg daily
223841042|NCT01256476|DRUG|pitavastatin|pitavastatin 4 mg once daily (QD)
223841043|NCT01256476|DRUG|pravastatin|Pravastatin 40 mg once daily (QD)
223841044|NCT02153385|OTHER|Yoga|Yoga program was 60 min per session, twice per week for 8 weeks. Led by an experienced yoga instructor.
223841045|NCT05226481|OTHER|Trauma-focused cognitive behavioral therapy (TF-CBT)|Trauma-focused cognitive-behavioral therapy (TF-CBT) is an evidence-based method for the treatment of posttraumatic stress among youth.
223841046|NCT04727775|DRUG|Favipiravir|Antiviral drugs
223841047|NCT04727775|DRUG|Remdesivir|Antiviral drugs
223841048|NCT05104762|DEVICE|plasmapheresis device|Group 1: 54 patients of Guillian Barrie syndrome undergo plasma exchange (5 sessions)
223841049|NCT05104762|DRUG|Intravenous immunoglobulin|group 2: 27 patients undergo intravenous injection of immunoglobulin for 5 consecutive days of IVIG 0.4gm/kg/day.
223841050|NCT00163215|DRUG|Somatropin|Adapted dosage based on IGF 1 level and weight Form: liquid; Dosage and Frequency: from 0.0033mg/kg/day to 0.0067 mg/kg/day; Duration: 3 years
223841051|NCT02272023|BEHAVIORAL|Intensive Motivational Interviewing|Weekly individual therapy sessions over 9 weeks (Intensive MI condition) consisting of supportive and directive interventions. The control condition consists on a single session of MI and nutritional education.
223841052|NCT02272023|BEHAVIORAL|Single session of Motivational Interviewing|
223841053|NCT02985697|DRUG|Dexmedetomidine|The intervention being tested is intranasal dexmedetomidine
223841054|NCT02985697|DRUG|Midazolam Hydrochloride|Oral midazolam is being used as the Active Comparator. It will also be used in conjunction with IN dexmedetomidine in some experimental groups.
223841055|NCT02985697|DRUG|Nitrous Oxide|Nitrous oxide to be administered in conjunction with other interventions, per study design.
223841056|NCT05177081|DEVICE|Preemptive management using home BIA monitoring system|Patients check their body composition and fluid using Home BIA system. Investigators analyze patients' body congestion status and send patient's edema status and direction of extra-diuretics usage to enrolled patients every one week.
223841057|NCT04729543|BIOLOGICAL|Adoptive therapy with autologous MC2 TCR T cells|Adoptive therapy with autologous MC2 TCR T cells combined with AZA/VP
223841058|NCT05406986|OTHER|care bundle application|The patients in the experimental group will be given care according to the current care bundle for 14 days
223841059|NCT02651103|DEVICE|NIRS|Cerebral oxygenation monitor which is standard of care for this surgery.
223841060|NCT05305040|BIOLOGICAL|Posoleucel (ALVR105)|Administered as 2-4 milliliter infusion, visually identical to placebo
223841061|NCT05305040|BIOLOGICAL|Placebo|Administered as 2-4 milliliter infusion, visually identical to Posoleucel (ALVR105)
223841062|NCT00184561|DRUG|biphasic insulin aspart|
223841063|NCT06305988|DEVICE|Transcranial direct current stimulation|The anode patch is placed in Fz, and the cathode patch is placed on right cheek, powered by direct current with a current of 1.5mA. Subjects in the placebo comparator group will receive sham tDCS for 1 week, which mimics the tDCS intervention in terms of electrode placement and session frequency. However, the device will deliver a 0mA current, ensuring no actual stimulation occurs. The anode patch is placed at Fz, and the cathode patch is positioned on the right cheek, to maintain the blinding of the intervention.
223841064|NCT03679130|BEHAVIORAL|Structured supervised exercise training|EXE contains three weekly one-hour exercise sessions at moderate intensity, more specifically one water exercise session and two land exercise sessions. The training will be supervised, held in teams, and both water and land exercise sessions will consist of a combination of aerobic and resistance training.
223841065|NCT03679130|BEHAVIORAL|Motivational counseling supported by health technology|MOT contains four individual and three group counseling sessions taking place from randomization until GA week 33+6 and aim to motivate the participants to increase their physical activity level at moderate intensity. During individual sessions, feedback on physical activity performance will be provided based on activity data acquired from the activity tracker and further, MOT-participants will receive weekly SMS-reminders about physical activity.
223841066|NCT03412942|DEVICE|FISH SP|The device will be used to close the femoral artery after angiogram and/or endovascular procedure.
223841067|NCT05976490|BEHAVIORAL|Information and Support Intervention|Information guide and four one-on-one coaching sessions
223841068|NCT05976490|OTHER|Usual supportive care|Referral to cancer center supportive care services (e.g., social work) upon request from the patient, caregiver, or clinician
223841069|NCT02944903|OTHER|Audit|Questionnair
223841070|NCT01033643|DRUG|MK-3614|Participants were administered 0.25 mg tablet, orally for a total daily dose according to randomization.
223841071|NCT01033643|DRUG|Placebo for MK-3614|Participants were administered dose matched placebo tablets according to randomization.
223841072|NCT00262444|PROCEDURE|Different turning frequencies|
223841073|NCT06395363|PROCEDURE|fixation method|The fixation methods were either involved trans-articular fixation through the acromioclavicular joint, supplemented with an additional cerclage wire tension band for enhanced stability. Or, creating a tunnel in the sub-acromial space posterior to the acromioclavicular joint and inserting the hook into this tunnel.
223841074|NCT01430702|DEVICE|Computerized medication delivery unit (Electronic Medication Management Assistant (EMMA)|The patient's prescriptions and refills are packaged in standard-sized blister cards and loaded into EMMA units. The EMMMA identifies each medication automatically - no patient input is required. When activated by the patient, the medications are selected from the blister cards and released into the delivery tray. The EMMA will remain in the patient's home for a period of 30-days immediately following hospitalization. After 30 days, the EMMA MDU will become available for the next eligible patient. This maximizes the number of patients that can benefit from the MDU, while addressing the transition period when medication-reconciliation problems are most common.
223841075|NCT02823743|DRUG|Aspirin|Daily medication
223841076|NCT02823743|DRUG|Placebo|Daily intake
223841077|NCT06633796|DEVICE|AMADEO|304 / 5.000 The rehabilitation treatment includes 10 sessions of combined treatment of paraffin therapy, functional occupational therapy and polyarticular mobilization of the fingers with a robotic arm (Amadeo). The sessions will be scheduled 2 times a week for 5 consecutive weeks.
223841078|NCT06633796|PROCEDURE|Standard of care|The rehabilitation treatment includes 10 sessions of combined treatment of paraffin therapy and occupational therapy for functional purposes. The sessions will be scheduled 2 times a week for 5 consecutive weeks.
223841079|NCT02442414|DRUG|KBP-5209|Single oral dose beginning at 20 mg with daily dosing for 28 day cycles.
223841080|NCT05879640|BEHAVIORAL|Sleep education|Participants receive a handout about age appropriate sleep goals and tips for improving sleep. The handout also contains links to educational videos about sleep hygiene and the importance of sleep to healing after illness. The handout is reviewed with a clinician at bedside prior to hospital discharge.
223841081|NCT00465361|PROCEDURE|performance feedback with an educational module|individual performance feedback with an educational module
223841082|NCT06755710|BEHAVIORAL|Introductory PTSD module|The Introductory PTSD module consist of four session focusing on motivation
223841083|NCT06755710|BEHAVIORAL|Shared Decision Making|A patient-centred shared decision making session where one of four standardised treatments can be chosen
223841084|NCT06755710|BEHAVIORAL|Treatment as Usual|Treatment as usual
223841085|NCT06755710|BEHAVIORAL|Standardised treatments|One of four treatments Treatment as ususal Sessions with psychologists Sessions with nurses Sessions with medical doctors
223841086|NCT04430517|DRUG|Nicotinamide riboside|Participants will take 4 pills every day, each containing 250 mg NR (NIAGEN® by Chromadex; www.chromadex.com), via the oral route, for 12 weeks.
223841087|NCT06796049|BEHAVIORAL|Information pamphlet + social norm driver|"The information pamphlet is given to participants at the end of the visit. The pamphlet contains an easy-to-read description of FIT screening adapted from the NYC department of health C5 Colorectal cancer (CRC) screening coalition pamphlet and lead-time CRC screening messaging tool, instructions on how to complete the test and the importance of FIT screening.~The information pamphlet will also contain a social norm driver that displays the sub-par screening rate the clinic compared to a collective New York State screening rate and a national screening rate goal set by the CDC."
223841088|NCT06796049|BEHAVIORAL|Information pamphlet|The information pamphlet is given to participants at the end of the visit. The pamphlet contains an easy-to-read description of FIT screening adapted from the NYC department of health C5 CRC screening coalition pamphlet and lead-time CRC screening messaging tool, instructions on how to complete the test and the importance of FIT screening.
223841089|NCT03927365|DEVICE|Inhalation from a salt particle inhaler with or without content|Inhalation from inhaler with (active) or without (placebo) content
223841090|NCT05825820|BEHAVIORAL|Enhanced Outreach Intervention (EOI) plus Care as Usual|"The EOI will contain four main components: safety planning, caring contacts, care engagement, and risk assessment.~A phone call (or text messaging) from Samaritans staff will be conducted every week of the 12 week intervention. Conversations will use a standardized phone script to (a) conduct a risk assessment, (b) develop and review a list of coping skills to use if you have suicidal thoughts, and (c) discuss participants' plans for receiving mental health care. Samaritans staff will also send a caring text message or email at least once per week.~Participants will also receive standard care that hospitals give for individuals who present to the ED with suicidal thoughts."
223841091|NCT01289704|OTHER|TreSPE|"1. treadmill: 5'warm up, 20'aerobic exercise (gradually incremented to 30', from session to session, if possible), 5'warm down, controlling hearth rate, blood pressure and SaO2.~2. Respiratory Physiotherapy: positive Expiratory Pressure (PEP) bottle for 10' (in various postures), and postural training, for the other 10'.~3. Stretching for 20', of the triceps surae, tibialis posterior, extensor and flexors digitorum longus and brevis, both at the bed and in a static position.~4. Proprioceptive and postural kinesitherapy according to the Perfetti method.~5. Balance Exercising consists of exercises carried on by basculating bars with improving difficulties in the instruments utilized and in the tasks with therapist supervision and near a handbar preventing falls."
223841092|NCT01289704|OTHER|SPE|"1. Respiratory Physiotherapy for 20', consisting of Positive Expiratory Pressure (PEP) bottle for 10' (in various postures), and postural training according to the Mèzières technique, for the other 10'.~2. Stretching for 20', of the triceps surae, tibialis posterior, extensor and flexors longus and brevis, both at the bed and in a static position.~3. Proprioceptive and postural kinesitherapy according to the neurocognitive method.~4. Balance Exercising consists of exercises carried on by moving bars with improving difficulties in the instruments utilized and in the tasks with therapist supervision and near a handlebar preventing falls."
223841093|NCT01189253|DRUG|doxorubicin hydrochloride|
223841094|NCT01189253|DRUG|trabectedin|
223841095|NCT01189253|OTHER|laboratory biomarker analysis|
223841096|NCT01189253|PROCEDURE|quality-of-life assessment|
223841097|NCT04502719|DIAGNOSTIC_TEST|Nutritional screening.|Nutritional screening with the RFH-NPT and LDUST questionnaires.
223841098|NCT02174211|DRUG|Ranibizumab|Intravitreal injection of ranibizumab
223841099|NCT02174211|DRUG|Aflibercept|Intravitreal injection of aflibercept
223841100|NCT01561690|DRUG|ARRY-502, CRTh2 antagonist; oral|multiple dose, single schedule
223841101|NCT01561690|DRUG|Placebo; oral|matching placebo
223841102|NCT03232177|DRUG|Anagre Cap.|from 0.5mg twice a day to maximally increase total10mg in 8 weeks and maintain maximal tolerable dose to 104 weeks
223841103|NCT03350321|DRUG|Molidustat (BAY85-3934)|Starting dose of molidustat once daily (OD) will be titrated based on the subject's Hb (Hemoglobin) response
223841104|NCT03350321|DRUG|Darbepoetin alfa|Starting dose of darbepoetin alfa once every 2 weeks will be titrated based on the subject's Hb (Hemoglobin) response
223841105|NCT02652130|BIOLOGICAL|Remestemcel-L|No intervention was given in Study MSB-GVHD002 (NCT02652130). It was a safety follow-up trial of remestemcel-L-treated participants from Study MSB-GVHD001.
223841106|NCT00121940|BEHAVIORAL|Guided Care|"Specially trained registered nurse (Guided Care Nurse) based in a primary care practice collaborates with two primary care physicians to provide seven services for 40-60 high-risk patients: comprehensive assessment and care planning; best practices for chronic conditions; self-management; healthy lifestyles; coordinating care; educating and supporting unpaid caregivers; and accessing community resources."
223841107|NCT05000450|GENETIC|ALLO-605|ALLO-605 is an anti-BCMA, TRAC/CD52 allogeneic edited, intracellular cytokine signaling containing, CAR T cell product
223841108|NCT05000450|BIOLOGICAL|ALLO-647|ALLO-647 is a monoclonal antibody that recognizes a CD52 antigen
223841109|NCT05000450|DRUG|Fludarabine|Chemotherapy for lymphodepletion
223841110|NCT05000450|DRUG|Cyclophosphamide|Chemotherapy for lymphodepletion
223841111|NCT05708417|BEHAVIORAL|Lifestyle Intervention|"The intervention in SDOI has the predominantly focus on each individual reflection and realisation and is built upon ACT' six core processes: 1) Acceptance, 2) Cognitive defusion 3) Being present, 4) Self as context, 5) Values, and 6) Committed action.~The program is based on up to 13 times attendance within the 12 months intervention period."
223841112|NCT05708417|OTHER|Placebo|No lifestyle intervention within the study, only test/datacollection
223841113|NCT06022809|BEHAVIORAL|Dada Kwa Dada (individual-level)|Dada Kwa Dada (DKD) intervention is an adapted version of Sister to Sister (S2S) intervention (a brief, health profession-led, individual-level intervention proven to increase condom use and decrease STIs among African American women). Intervention is a 1hr to 1.5hrs session and offered in English or French.
223841114|NCT06022809|BEHAVIORAL|DADA (group-level)|DADA intervention is an adapted version of Sisters Informing Sisters about Topics on AIDS (SISTA) intervention (a peer-led, group-level intervention proven to increase condom use and decrease STIs among African American women). This is a 6hrs intervention implemented in two three-hour sessions and offered in English or French.
223841115|NCT00203138|DRUG|rasagiline mesylate|
223841116|NCT00353054|DRUG|Caltrate® 600 + D|
223841117|NCT00353054|BEHAVIORAL|Weight loss intervention|
223841118|NCT03174093|BEHAVIORAL|MATCh AFib application|The application comprehends five steps: (1) An educational video about how AF can cause stroke; (2) A calculator of risk scores (CHA2DS2-VASc, HAS-BLED and SAMe-TT2R2); (3) A screen with pictograms to allow better understanding of the scores by patients and to demonstrate how much each anticoagulant can decrease stroke risk or increase bleeding risk; (4) A summary about types of medications available, and (5) An output formulary in which the physician can register patient's contact to continue receiving information about atrial fibrillation and anticoagulation through SMS. Physicians can save patient's history of INR tests and previous doses of anticoagulation prescribed and also use a calculator to adjust the dose.
223841119|NCT06297980|OTHER|Personalized modifications to treatment to address menstrual cycle effects on glycemia|The study physician will examine glucose patterns measured using continuous glucose monitoring over a 3 month observational period to identify hypo- or hyperglycemia related to menstrual cycle phase or exercise, and will provide changes to insulin basal or bolus rates, carbohydrate ratios, post-exercise food intake or use of sleep mode on automated insulin delivery systems.
223841120|NCT05708820|BEHAVIORAL|Online education programme|Online group will follow the education programme through videos that they can view at any time and a live session to answer questions.
223841121|NCT05708820|BEHAVIORAL|Standard education programme|Face-to-face educacion programme in a group session
223841122|NCT03665506|DRUG|Trifluridin/Tipiracil|QoL assessment
223841123|NCT01269398|DEVICE|GO-LIF and SpineAssist SYSTEMS|
223841124|NCT02274246|DRUG|gadobutrol|Gadobutrol administration in healthy volunteers
223841125|NCT03809884|BEHAVIORAL|Dietary Counselling|Individually tailored strategy to increase potassium in the diet.
223841126|NCT03809884|DRUG|Potassium Citrate|Dosing of 50 to 100 mmol of potassium citrate per day (as 25 to 50 ml of the liquid solution).
223841127|NCT03664661|DRUG|BCMA nanobody CAR-T cells|"step 1: Collect 50-100ml of peripheral blood for culture of BCMA nanobody CAR- T cells. step 2. After 72 hours, pretreated with FC regimen, details as follow Cyclophosphamide 600-800mg/m2 for 2 days Fludarabine 25-30mg/m2 for 3 days. step 3: After another 48 hours transfusion the cells back to the patients the numbers of infused CAR T cells are 5x106 /kg for the first 3 patients, 1.5x107 /kg for the second 3 patients and 4.5x107 /kg for the third 3 patients.~After finishing this, another 6 patients will be enrolled for observation of efficacy."
223841128|NCT02891369|OTHER|No intervention. Descriptive study|
223841129|NCT04975581|BIOLOGICAL|Allograft Patch|Rotator Cuff repair with Allograft Patch (Graftjacket Now)
223841130|NCT02728219|PROCEDURE|TACE|In this study we prospectively select some early diagnosed recurrent HCC patients after radical resection with AFP conversion, then they will be treated with transcatheter arterial chemoembolization (TACE)
223841131|NCT02728219|PROCEDURE|Hepatectomy|Repeat Hepatectomy after postoperation recurrence
223841132|NCT02664220|DRUG|Povidone-iodine irrigation|"Povidone-iodine (PVI) is an antiseptic solution consisting of polyvinylpyrrolidone with water, iodide, and 1% available iodine. It has bactericidal ability against a large array of pathogens, including those pathogens which commonly cause postoperative IAA in children with perforated appendicitis.~1% PVI will be used. Once the appendix has been removed and hemostasis ensured, the surgeon will perform the irrigation with 10cc/kg (minimum 100ml and maximum 1000ml) of 1% PVI. After completing the irrigation, the surgeon will suction out all intra-abdominal fluid into a suction canister."
223841133|NCT02664220|PROCEDURE|No irrigation|Patients allocated to the control group will not undergo intra-abdominal irrigation.
223841134|NCT05154916|OTHER|Virtual Reality Based Relaxation Program|Virtual Reality Based Relaxation Program
223841135|NCT00108524|BEHAVIORAL|Low carbohydrate ketogenic diet|A low-carb diet limits carbohydrates - such as grains, starchy vegetables and fruit - and emphasizes dietary protein and fat.
223841136|NCT00108524|DRUG|Orlistat|In addition to the low fat diet, Orlistat is taken 3 times daily.
223841137|NCT00108524|BEHAVIORAL|Low-fat diet|Participants receive counseling on a low fat diet over 48 weeks aimed at reducing fat and calorie intake
223841138|NCT04222244|OTHER|No intervention will be administered. We are only performing tests and measures.|No intervention will be administered. We are only performing tests and measures.
223841139|NCT04166968|DEVICE|Anodal transcranial direct current stimulation (A-tDCS)|Anodal tDCS will be performed for 20 minutes over the affected hemisphere with an intensity set to 2 mA
223841140|NCT04166968|DEVICE|Cathodal transcranial direct current stimulation (C-tDCS)|Cathodal tDCS will be performed for 20 minutes over the unaffected hemisphere with an intensity set to 2 mA
223841141|NCT04166968|DEVICE|Sham stimulation (sham-tDCS)|placebo stimulation
223841142|NCT04166968|BEHAVIORAL|Neuromotor training|conventional neuromotor treatment
223841143|NCT03132714|PROCEDURE|Full-mouth ultrasonic debridement|Full-mouth ultrasonic debridement will be performed in order to treat diseased sites
223841144|NCT03132714|DRUG|Amoxicillin 500mg|Administration of Amoxicillin 500mg tid for 7 days
223841145|NCT03132714|DRUG|Metronidazole 400mg|Administration of Metronidazole 400mg tid for 7 days.
223841146|NCT03132714|DRUG|Clarithromycin 500mg|Administration of Clarithromycin 500mg bid for 7 days
223841147|NCT03132714|PROCEDURE|Single application of PDT|Single application of photodynamic therapy (PDT) at day 0.
223841148|NCT03132714|PROCEDURE|Repeated application of PDT|Repeated application of photodynamic therapy (PDT) at 0, 1, 2, 7 and 14 days post-operatively.
223841149|NCT01896011|BIOLOGICAL|Teriparatide 20 mcg|Teriparatide 20 mcg injection pen
223841150|NCT01896011|OTHER|Placebo|Placebo 20 mcg injection pen
223841151|NCT05748795|PROCEDURE|bronchoscopy brochoalveolar lavage|"* 2%lidocaine gel will be used to anaesthesize nasal mucosa.6ml lidocaine 2%diluted in 5cc normal saline lidocaine spray solution will be used for anaesthesizing the vocal cords and mucosa of the bronchial tree(13).~* Intravenous midazolam (0.01-0.1mg\\kg) will be given to achieve conscious sedation in selected cases(13).~* Flexible Bronchoscopy will be done under continuous monitoring for O2 saturation, heart rate, blood pressure and respiratory rate.~* The bronchoscope will be introduced into the nasal cavity and advanced to the level of the vocal cords. Lidocaine will be instilled through the bronchoscope to the vocal cords and tracheobronchial tree.~* Using sterile bronchoscope in the lobar bronchus of tumor location,100 mL of sterile normal saline in fractionated doses will be injected and then BAL will be removed by suction to be collected in sterile side-way bottles."
223841152|NCT04838821|BIOLOGICAL|Anti SARS-CoV-2 equine hyperimmune serum|All participants in the treatment groups will receive a single intravenous infusion on day 1 containing the specified dose according to their assigned group 12mg/kg, 30 mg/kg or 56mg/kg. Total volume of the infusion is 180ml, to be administered during a time period of at least 1 hour. Study participants will be followed during their hospitalization until they are discharged and on Study Day 28.
223841153|NCT04838821|BIOLOGICAL|placebo|All participants in the placebo group will receive a single intravenous infusion on day 1 containing a specified volume of a saline IV solution preparation. Total volume of the infusion is 180ml, to be administered during a time period of at least 1 hour. Study participants will be followed during their hospitalization until they are discharged and on Study Day 28.
223841154|NCT02307123|PROCEDURE|Intubation|HEMS physician prehospital intubation
223841155|NCT00917254|DRUG|YM150|oral
223841156|NCT00917254|DRUG|Placebo|oral
223841157|NCT00917254|DRUG|Enoxaparin|injection
223841158|NCT02651558|DEVICE|Experimental: OBPM 2015-MD-0022 - CHEST|"At the onset of general anesthesia:~1. continuous measurements of radial arterial blood pressure values (arterial catheter, via a commercial PHILIPS IntelliVue MP50 monitor)~2. continuous estimates of optical blood pressure values at the chest (optical blood pressure system, via Swissmedic approved OBPM measuring device 2015-MD-0022 developed by CSEM)~will be recorded."
223841159|NCT02651558|DEVICE|Experimental: OBPM 2015-MD-0022 - CHEST & FINGER|"At the onset of general anesthesia:~1. continuous measurements of radial arterial blood pressure values (arterial catheter, via a commercial PHILIPS IntelliVue MP50 monitor)~2. continuous estimates of optical blood pressure values at the chest (optical blood pressure system, via Swissmedic approved OBPM measuring device 2015-MD-0022 developed by CSEM)~3. continuous estimates of optical blood pressure values at the fingertip (optical blood pressure system, via Swissmedic approved OBPM measuring device 2015-MD-0022 developed by CSEM)~will be recorded."
223841160|NCT02651558|DEVICE|Experimental: OBPM 2015-MD-0022 - FINGER|"At the onset of general anesthesia:~1. continuous measurements of radial arterial blood pressure values (arterial catheter, via a commercial PHILIPS IntelliVue MP50 monitor)~2. continuous estimates of optical blood pressure values at the fingertip (optical blood pressure system, via Swissmedic approved OBPM measuring device 2015-MD-0022 developed by CSEM)~will be recorded."
223841161|NCT04215744|BEHAVIORAL|Ice water immersion|Ice water immersion of the left hands
223841162|NCT00237367|DRUG|rabeprazole and pantoprazole|
223841163|NCT00751790|DRUG|triptorelin embonate (INN)|Triptorelin embonate 22.5 mg 6 month formulation to be injected every 24 weeks
223841164|NCT02536690|DRUG|Propofol|Propofol bolus dose administration according to the predetermined dose by biased coined design up-and-down study.
223841165|NCT02536690|DRUG|Remifentanil|Remifentanil 0.25 mcg/kg/min infusion for 5 min before propofol administration.
223841166|NCT02536690|DRUG|Midazolam|Remifentanil 0.25 mcg/kg/min infusion for 5 min before propofol administration followed by midazolam 0.03 mg/kg administration 1 min after remifentanil infusion start.
223841167|NCT05181306|PROCEDURE|Robotic-assisted Total Gastrectomy with D2 Lymphadenectomy|Robotic-assisted total gastrectomy with D2 lymph node dissection will be performed with curative treated intent according to the patients' or their legal representatives'willing to choose robotic-assisted total gastrectomy and excluding T4b、bulky lymph nodes or distant metastasis case by diagnostic laparoscopy. The alimentary canal reconstruction method is selected as esophageal jejunal R-Y anastomosis. Whether to reinforce the anastomotic manually is decided by the surgeon's experience. The reconstruction can be carried out by extracorporeal or intracorporeal anastomosis.
223841168|NCT05181306|PROCEDURE|Laparoscopic-assisted Total Gastrectomy with D2 Lymphadenectomy|Laparoscopic-assisted total gastrectomy with D2 lymph node dissection will be performed with curative treated intent according to the patients' or their legal representatives'willing to choose laparoscopic-assisted total gastrectomy and excluding T4b、bulky lymph nodes or distant metastasis case by diagnostic laparoscopy. The alimentary canal reconstruction method is selected as esophageal jejunal R-Y anastomosis. Whether to reinforce the anastomotic manually is decided by the surgeon's experience. The reconstruction can be carried out by extracorporeal or intracorporeal anastomosis.
223841169|NCT01192490|DRUG|Lidocaine|5cc of 2% Lidocaine gel will be placed on the cervix and intra-cervically prior to placement of a Mirena
223841170|NCT01192490|DRUG|Lubricant|KY Gel will be placed on the cervix and intra-cervically prior to placement of the Mirena
223841171|NCT06056154|DEVICE|LIO ASQELIO TM monofocal QLIO130C|Intraocular lens (IOL) implant. All patients will have been treated as per standard clinical practice.
223841172|NCT04961216|BEHAVIORAL|OPTIMISE|Self-regulation intervention
223841173|NCT02490930|DRUG|Fingolimod|Oral fingolimod will be given 1 week prior to the initiation of concurrent radiation and temozolomide and will be discontinued immediately upon completion of the six weeks of therapy.
223841174|NCT04488172|DIETARY_SUPPLEMENT|Multi-vitamin supplementation|Vitamin B6:100 mg/day Vitamin B9: 5 mg/day Vitamin D: 1000 IU/day Vitamin E: 400 IU/day Co-Q10: 100 mg/day
223841175|NCT01553162|GENETIC|DNA analysis|
223841176|NCT01553162|GENETIC|RNA analysis|
223841177|NCT01553162|GENETIC|gene expression analysis|
223841178|NCT01553162|OTHER|laboratory biomarker analysis|
223841179|NCT02099032|OTHER|3g milk polar lipid fortified cheese consumption|Women will have to consume daily 100g of a 3g milk polar lipid fortified cheese product instead of usual cheese products during four weeks.
223841180|NCT02099032|OTHER|5g milk polar lipid fortified cheese consumption|Women will have to consume daily 100g of a 5 g milk polar lipid fortified cheese product instead of usual cheese products during four weeks.
223841181|NCT02099032|OTHER|Unfortified cheese product consumption|Women will have to consume daily 100g of a unfortified cheese product instead of usual cheese products during four weeks
223841182|NCT04428086|DRUG|Apatinib in arm1|Apatinib will be administered at a dose of 250 mg once daily from Day 4 to Day 9.
223841183|NCT04428086|DRUG|Rosuvastatin|Rosuvastatin will be administered as a single oral 10 milligram (mg) dose on Day 1 and Day 7.
223841184|NCT04428086|DRUG|Apatinib in arm2|Apatinib will be administered at a dose of 250 mg once daily from Day 3 to Day 7.
223841185|NCT04428086|DRUG|Metformin|Metformin will be administered as a single oral 500 mg on Day 1 and Day 6.
223841186|NCT03415490|OTHER|Folded technique of self-adherent wrap|Wrapping a piece of self-adherent wrap around the patient's head starting with the opened end on the forehead above the affected eye.The bandage is then firmly but not tightly wrapped around the head twice. Then, after the second circuit, the bandage is brought on the cheek and up over the eye to the forehead, where it was passed between the eyebrows but not wrapped around the head. Instead, the bandage is folded and then first passed back on the cheek of the affected side then back to the forehead a total of four times. Finally, the bandage is wrapped completely around the head once
223841187|NCT03415490|OTHER|Classic technique of self-adherent wrap|Wrapping a piece of self-adherent wrap around the patient's head starting with the opened end on the forehead above the affected eye.The bandage is then firmly but not tightly wrapped around the head twice. After the second circuit, the bandage was brought below the ear, up over the eye and around the head of the non-affected side and then wrapped around the head in the same manner four times. The bandage is then brought around the head once.
223841188|NCT02219828|DRUG|Anakinra|2mg/Kg daily sc up to 100mgday as maximum dose
223841189|NCT02219828|DRUG|Placebo|Placebo
223841190|NCT00004287|GENETIC|H5.001CBCFTR|
223841191|NCT03560141|DEVICE|LID011121 contact lens|Investigational silicone hydrogel contact lens
223841192|NCT03560141|DEVICE|Comfilcon A contact lens|Commercially available silicone hydrogel contact lens
223841193|NCT00455468|PROCEDURE|Day-care treatment vs. hospital care|
223841194|NCT05108389|DIAGNOSTIC_TEST|Viscoelastic haemostasis monitor output|Observational
223841195|NCT00482105|OTHER|EGIR Tape|Tape stripping is a non-invasive method that allows the recovery of cells
223841196|NCT03164733|OTHER|incubation|standardized wear particles are co-incubated with isolated patient cells (monocytes)
223841197|NCT06077019|DRUG|Vilanterol and Fluticasone Furoate|Participants inhale 25 µg vilanterol + fluticasone furoate daily
223841198|NCT06077019|DRUG|Indacaterol and Mometasone Furoate|Participants inhale 125 µg indacaterol + mometasone furoate daily
223841199|NCT06077019|DRUG|Placebo|Participants inhale placebo daily
223841200|NCT00238043|DRUG|Biogeneric Epoetin|
223841201|NCT03997942|OTHER|Effect of exercise|Once the data are available, we hope to have information about which of the exercise practices included in the rehabilitation program of acute upper extremity burn patients is more effective.
223841202|NCT00181779|DRUG|aripiprazole (Abilify)|
223841203|NCT03406234|OTHER|No intervention.|Cross-sectional observation without interventions.
223841204|NCT02147860|DEVICE|Diabetes Assistant (DiAs) with USS Virginia|DiAs is the central component of our system. It is a standard cell phone running on an Android operating system. The cell phone has been changed to prevent from (1) using it as a phone or browser, (2) changing the volume (3) accidentally shutting it off. The cell phone runs an algorithm and is connected to work with the insulin pump and continuous glucose monitor to help keep the blood sugar in a desired range and help avoid hypoglycemia during the night.
223841205|NCT02147860|OTHER|Sensor Augmented Pump Therapy|Subjects randomized to this placebo group will wear a continuous glucose monitoring system (CGM) to measure sensor glucose and a physiological monitor to measure heart rate and 3-axis accelerometer for 24-72 hours.
223841206|NCT03250780|PROCEDURE|indigo-carmine 0.2% using a spray catheter|
223841207|NCT03250780|PROCEDURE|0.03% using a foot pump|
223841208|NCT06014567|PROCEDURE|Magnetic Resonance Imaging|"1. A single (≤45 minutes) brain MRI will include T1w and T2w imaging to assess the morphology and structure of the brain, as well as inflammatory processes. Diffusion-weighted imaging will be used to gain information about internal brain connectivity related to brain functions. MRI, MR angiography (MRA) and fMRI pulse sequences will also be acquired to detect vascular pathologies and brain lesions. T2w morphological images of the whole spine will also be obtained.~2. A single (≤45 minutes) MR imaging investigation to include cardiovascular, abdominal, and musculoskeletal regions. MRI will be performed to assess the structure and function of these body regions and organs, including functional imaging of the heart. These investigations will include T1w and T2w imaging to assess morphology and structure, mapping studies of T1, T2 and T2\*, perfusion imaging and cine imaging to assess the heart dynamically."
223841209|NCT04317768|BEHAVIORAL|Basic oral health education and motivation|Subjects will receive verbal oral hygiene instructions using a model to demonstrate only once at the beginning of the study, no further motivation or educational seminars will be done.
223841210|NCT04317768|BEHAVIORAL|Intensive oral health education and motivation|Subjects will be educated and motivated by an intensive program consisting of verbal instructions, PowerPoint lectures, posters and live demonstrations about oral hygiene instructions and teaching the proper way to brush the teeth. These will be reinforced by the investigator at intervals of 1 week, 1 month, 3 months, 6 months and 1 year.
223841211|NCT01591395|PROCEDURE|laparoscopic total extraperitoneal hernia repair (single port vs. multiport)|comparison of single port laparoscopic TEP and multiport laparoscopic TEP repair for adult inguinal hernia
223841212|NCT05439265|OTHER|Electronic medical record order panel and resident involvement|Prior to 2014, there was no formal process for evaluation of patients with HIT. In November of 2014, an EMR tool was created in an effort to improve heparin allergy documentation and HIT management. This EMR tool prompts the medical team to perform the 4T score, displays the appropriate HIT labs, alternative anticoagulation strategies, instructs the nurse to apply an allergy bracelet, and notifies the pharmacy resident through the order verification queue. The pharmacy resident then performs an independent 4T score, discontinues all heparin products, documents the heparin allergy in the medical record, and assesses the need for alternative anticoagulation.
223841213|NCT05265988|DRUG|Cabozantinib|Cabozantinib at initial dosage of 40 mg per day and continuation of androgen deprivation therapy
223841214|NCT02398838|DRUG|Home administration of 200 mg mifepristone|Home administration of 200 mg mifepristone.
223841215|NCT02398838|DRUG|Home or clinic administration of 400 mcg buccal misoprostol|Home or clinic administration of 400 mcg buccal misoprostol
223841216|NCT03770377|DEVICE|Intermittent Perturbation to Continuous Perturbation|Manipulate the Movement Planning Period (MPP), by interrupting sensory predictions by removing e-stim during the inter-trial interval (Intermittent Perturbation), followed by a washout/de-adaptation period.
223841217|NCT03770377|DEVICE|Continuous Perturbation to Intermittent Perturbation|Manipulate the Movement Planning Period (MPP), by keep sensory input about the perturbation constant by maintaining e-stim during the inter-trial interval.
223841218|NCT05144815|OTHER|IPC + Exercise protocol|"The intervention consists of two parts: IPC and endurance training protocol.~IPC: participants will be placed in a supine position and a pneumatic compression cuff (Riester Komprimeter, Jungingen Germany) (96 centimetres long x 13 centimetres wide) will be placed on the proximal part of each lower extremity. Occlusion will then be performed by inflating the cuff to 220 mmHg for 5 minutes, followed by reperfusion to 0 mmHg for 5 minutes. Each session will consist of 3 sets of 5 minutes of ischaemia followed by 5 minutes of reperfusion.~Endurance training protocol: walking 20 min at moderate intensity (i.e. 64- 76 % HRmax, 12-13 Borg Scale) in a circuit designed in an open field, 3 times a week, for 6 weeks."
223841219|NCT05144815|OTHER|Sham IPC + Exercise protocol|"The intervention consists of two parts: sham IPC and endurance training protocol.~Sham IPC: the pressure cuff will be inflated by only 10 mmHg, so that it will act as a placebo.~Endurance training protocol: walking 20 min at moderate intensity (i.e. 64- 76 % HRmax, 12-13 Borg Scale) in a circuit designed in an open field, 3 times a week, for 6 weeks."
223841220|NCT04928989|OTHER|convergence dialogue meeting|Digital counceling with convergence dialogue tripartite meeting. will be conducted in accordance with work dialogue for return to work. Workplace dialogue among employee with neck problems, an expert in the work environment, and the immediate manager. The purpose of the conversations is, in open dialogue, to reach a common understanding of the situation and identify possible interventions to maintain or improve the employee´s work ability.
223841221|NCT00537862|DRUG|Enteric-Coated Mycophenolate Sodium (EC-MPS)|
223841222|NCT00157053|DRUG|Antihemophilic factor, recombinant, manufactured protein-free|
223841223|NCT03836664|DRUG|Timolol|Timolol is a clear solution supplied in a plastic ophthalmic dispenser.
223841224|NCT03836664|DRUG|Placebo|Placebo is normal saline solution that will be supplied in container matched to Timolol container.
223841225|NCT01822158|OTHER|Vaginal Delivery Debrief Checklist|Participating team members will utilize Vaginal Delivery Debrief checklist
223841226|NCT04901728|BEHAVIORAL|Cultural Domain Analysis|80 and up to a maximum of 120 participants
223841227|NCT04901728|BEHAVIORAL|Focus Group Discussion|At least 18 and up to a maximum of 60 participants
223841228|NCT04901728|BEHAVIORAL|In-depth interview|At least 18 and up to a maximum of 36 participants
223841229|NCT03717545|OTHER|second allogeneic stem cell transplantation|"1. Change another donor~2. conditioning regimen: FLU/CY/anti-CD25 moAb"
223841230|NCT00568347|DRUG|fluticasone 100mcg/ salmeterol 50mcg|inhaled fluticasone 100mcg/salmeterol 50mcg bid X 3 months
223841231|NCT00568347|DRUG|fluticasone 250/salmeterol 50|inhaled fluticasone 250/salmeterol 50 X 3 months to evaluate effect on lung function and exhaled nitric oxide
223841232|NCT00568347|DRUG|salmeterol|salmeterol 50 mcg by dry powder inhaler disk bid to evaluated effect on lung function and exhaled nitric oxide
223841233|NCT00568347|DRUG|Salmeterol|salmeterol 50mcg bid X 3months
223841234|NCT00568347|DRUG|salmeterol and fluticasone propionate|salmeterol 50mcg/fluticasone 250mcg by DPI bid
223841235|NCT05971641|OTHER|progressive relaxation exercise|Patients who undergo total knee replacement surgery in the experimental group will be taught progressive relaxation exercises. The exercise will last for 30 minutes and will be applied twice a day. Patients will wear a smart wristband. Patient Information Form, Numeric Rating Scale, Richard Campbell Sleep Quality Survey, and Postoperative Recovery Index Scale will be administered. The scales will be filled out for 5 days and will take approximately 10-15 minutes.
223841236|NCT01427907|DRUG|Calcium acetate oral solution (COS)|Each subject will undergo two separate treatment periods. Subjects will ingest either COS or sevelamer for 28 days (Treatment Period 1) and then switch to the other binder for 28 days (Treatment Period 2).
223841237|NCT01427907|DRUG|Sevelamer carbonate|Each subject will undergo two separate treatment periods. Subjects will ingest either COS or sevelamer for 28 days (Treatment Period 1) and then switch to the other binder for 28 days (Treatment Period 2).
223841238|NCT03676556|DRUG|Lidocaine|Two sterile gauzes will be dampen with the content of the syringe (20ml lidocaine 0.5%) and apply on the wound. After 7-15minutes of waiting to the effect, the wound treatment will start.
223841239|NCT03676556|DRUG|Saline Solution|Two sterile gauzes will be dampen with the content of the syringe (20ml saline serum) and apply on the wound. After 7-15minutes of waiting to the effect, the wound treatment will start.
223841240|NCT02377219|OTHER|hormonal and blood analysis|
223841241|NCT00502281|DRUG|highly purified urinary FSH|
223841242|NCT00502281|BEHAVIORAL|timed intercourses, intrauterine insemination|
223841243|NCT03628079|DRUG|ReposMBZ|Capsules 50mg, 100mg, 200mg
223841244|NCT04361747|BEHAVIORAL|nursing counseling|The counseling intervention was designed to facilitate self-awareness, reduce self-blame, clarify doubts, listen to patient concerns, promote forward thinking, and encourage life planning.
223841245|NCT01442168|DRUG|Sevuparin sodium + atovaquone/proquanil|Sevuparin 4 times per day and malanil according to label
223841246|NCT01442168|DRUG|atovaquone/proquanil|malanil according to label
223841247|NCT00684502|DRUG|AZD2066|Oral solution administered orally once per day on day 1, and then day 3 through to day 12. Specific dose depends on dose panel.
223841248|NCT00684502|DRUG|Placebo|Administered orally as a solution once per day on day 1, and then day 3 through to day 12.
223841249|NCT04880213|DRUG|M5049|Participants will receive single oral dose of film-coated tablet M5049 at low dose on Day 1 under fasted condition.
223841250|NCT04880213|DRUG|M5049|Participants will receive single oral dose of film-coated tablet M5049 at medium dose on Day 1 under fasted condition.
223841251|NCT04880213|DRUG|M5049|Participants will receive single oral dose of film-coated tablet M5049 at high dose on Day 1 under fasted condition.
223841252|NCT00815321|BIOLOGICAL|Autologous CIK cell infusion|4 CIK cells will be infused into patients at regular 3-weekly intervals for 4 infusions. The target cell dose per infusion is 1x10e10 CD3 cells. For patients with uncontrolled accelerated or blastic transformation undergoing chemotherapy, this will be given at the nadir of lymphopenia following chemotherapy. For other patients this will be given without interruption of the ongoing treatment with Imatinib or other kinase inhibitor.
223841253|NCT01663337|BEHAVIORAL|Cognitive Processing Therapy (CPT)|CPT is a highly structured course of therapy that focuses primarily on the cognitive restructuring of trauma related beliefs.
223841254|NCT01663337|BEHAVIORAL|Relapse Prevention (RP)|RP utilizes high-risk situation assessment/avoidance, drink refusal skills, assertiveness training,cognitive restructuring as well as other approaches to address issues of alcohol use/dependance.
223841255|NCT05580146|DIETARY_SUPPLEMENT|Zynamite® 15% 150mg|leaves of the mango food plant
223841256|NCT05580146|DIETARY_SUPPLEMENT|Zynamite® 15% 300mg|leaves of the mango food plant
223841257|NCT05580146|DIETARY_SUPPLEMENT|Zynamite® 15% 600mg|leaves of the mango food plant
223841258|NCT05580146|DIETARY_SUPPLEMENT|Placebo|Sunflower oil matched for appearance
223841259|NCT04036240|OTHER|Finger feeding|After discharge, subjects will be given HMF supplementation by finger feeding method using finger feeder
223841260|NCT04864561|BIOLOGICAL|VLA2001|whole virus inactivated SARS-CoV-2 vaccine adjuvanted with cytosine phospho-guanine (CpG) 1018 in combination with aluminium hydroxide 2 vaccinations 28 days apart
223841261|NCT04864561|BIOLOGICAL|AZD1222|2 vaccinations 28 days apart AZD1222 is a recombinant, replication-defective chimpanzee adenovirus expressing the SARS-CoV-2 S surface glycoprotein.
223841262|NCT04864561|BIOLOGICAL|VLA2001 - adolescent part|whole virus inactivated SARS-CoV-2 vaccine adjuvanted with cytosine phospho-guanine (CpG) 1018 in combination with aluminium hydroxid 2 vaccinations 28 days apart and with a booster vaccination on day 208. Placebo group will receive VLA2001 on day 208 and following second vaccination 28 days later.
223841263|NCT04864561|BIOLOGICAL|Placebo|2 vaccinations 28 days apart with placebo (PBS buffer based on Dulbecco's PBS media formulation without Calcium and Magnesium )
223841264|NCT01571921|DIETARY_SUPPLEMENT|Gamma-Delta Tocotrienol and Tocotrienol Rich Fraction|Single oral TRF or Gamma-Delta Tocotrienol dosage
223841265|NCT02392338|PROCEDURE|Hybrid procedure|Eletrophysiologic study via femoral vein approach to confirm pulmonary vein isolation lesion and box lesions in left atrium
223841266|NCT05892575|BEHAVIORAL|improving quality of life, coping with urinary incontinence and kegel exercise training|Face-to-face training will be given to the elderly in the experimental group for a total of 5 weeks, once a week day (60 minutes). In the 4th week, reminder messages will be started over the phone. The 4th week kegel exercise chart and nutrition list will be given. In the 5th week, kegel exercise dance will be watched. Sending reminder messages from the phone will continue for 3 months.
223841267|NCT02388555|PROCEDURE|Posterior osteotomy correction|The DLS patients underwent osteotomy including pedicle subtraction osteotomy (PSO) or Smith-Petersen osteotomy (SPO)
223841268|NCT03690856|OTHER|inflammatory, neuropsychological and neuroimaging assessment|"Acts add by research:~pregnancy test; Centralized: IL1, IL6, TNF~Neuropsychologic tests at M6 and M24:~Edinburgh Ladder Lateral Test, Direct and Inverse Verbal Empan, Matrices (WAIS IV), Similarities (WAIS IV), Vertebral fluences, STROOP test, TMT test (Delis Kaplan), WCST test, CPT III, WAIS IV (code)"
223841269|NCT02485743|OTHER|Active Diet Products|A range of Active Diet Products that will be provided as part of a weight maintenance diet which contain active ingredients aimed at increasing satiety (such as inulin, β-glucan, protein, and mycoprotein). All ingredients are accepted food ingredients approved for human consumption in Europe.
223841270|NCT02485743|OTHER|Placebo Diet Products|A range of Placebo Diet Products matching those provided in the Active Diet which will be provided as part of a weight maintenance diet but do not contain additional ingredients aimed at improving satiety (food matrices will be the same - e.g. shakes, cheeses etc but without active ingredients).
223841271|NCT03813056|DRUG|Glanatec|Rho kinase Inhibitor
223841272|NCT03813056|DRUG|Optive, Ophthalmic Solution|artificial tears (placebo)
223841273|NCT03813056|PROCEDURE|Descemet Membrane Endothelial Keratoplasty|Partial thickness corneal transplant that replaces only the diseased corneal endothelium and descemet membrane of the recipient.
223841274|NCT04268563|DRUG|placebo|Oral rehydration solution
223841275|NCT04268563|DRUG|metformin|metformin tablet
223841276|NCT04268563|DRUG|Sitagliptin|Sitagliptin tablet
223841277|NCT04268563|DRUG|Sitagliptin/metformin|Sitagliptin/metformin tablet
223841278|NCT02783157|DEVICE|Transcutaneous Low-Level Vagal Nerve Stimulation (LLVNS)|Low-level vagal nerve stimulation will be delivered via a clip applied to the ear throughout the surgical procedure. The voltage used will be individualized to each patient, based upon the voltage necessary to slow the sinus rate during testing.
223841279|NCT02783157|DEVICE|Sham LLVNS|A clip will be applied to the ear, but no stimulation will be delivered throughout the procedure.
223841280|NCT00239161|DRUG|Levofloxacin|
223841281|NCT01575470|BIOLOGICAL|autologous bone marrow mononuclear cells|bone marrow harvest (5ml/kg of body weight) performed within 36 hours of injury, followed by single intravenous infusion of bone marrow mononuclear cells.
223841282|NCT01065272|DRUG|Dexamethasone|"0.5 ml Salbutamol in 2 ml normal saline is given at 0,30,60,120,180 minutes and then every 2 hourly till discharge.~1mg/kg of oral Dexamethasone with cherry flavour is also given in the first day, then 0.6 mg/kg/day for 4 days"
223841283|NCT01065272|DRUG|Placebo|"0.5 ml Salbutamol in 2 ml normal saline is given at 0,30,60,120,180 minutes and then every 2 hourly till discharge.~1mg/kg of oral Placebo is also given in the first day, then 0.6 mg/kg/day for 4 days"
223841284|NCT03317353|DEVICE|Vestibular rehabil.: CDP|Vestibular rehabilitation, ten sessions
223841285|NCT03317353|DEVICE|Vestibular rehabil.: optokinetic stimuli|Vestibular rehabilitation, ten sessions
223841286|NCT03317353|OTHER|Vestibular rehabil.: home exercises|Exercises performed twice a day for two weeks. Approximate duration of each session: 15 minutes
223841287|NCT02873676|BEHAVIORAL|nutritional intervention|The intervention is made up of nutrition supplements and dietary pattern modification, which includes whey 30g/d(plus three times every week),vitamin D 1000IU, omega-3 fatty acid (DHA1200mg and EPA 800mg)
223841288|NCT02873676|BEHAVIORAL|resistance training program|The training program involve warm-up exercise, muscle strength training and relaxing
223841289|NCT02873676|BEHAVIORAL|lifestyle modification project|Lifestyle modification project is made up of multi-dimensional intensive nutritional intervention and resistance training
223841290|NCT02873676|BEHAVIORAL|control|The intervention involve dietary pattern modification and protein intake standardization
223841291|NCT05930899|OTHER|Genetics|TOmAS is a biobank and all patients will be genotyped
223841292|NCT04617600|DRUG|MTA|Survival rate using MTA in cariously exposed vital primary molars
223841293|NCT04617600|DRUG|TheraCal PT|Survival rate using TheraCal PT in cariously exposed vital primary molars
223841294|NCT02179918|DRUG|PF-05082566|Starting dose of 0.45 mg/kg q3wks IV, dose escalation
223841295|NCT02179918|DRUG|MK-3475|2 mg/kg q3wks, IV
223841296|NCT03429387|DIAGNOSTIC_TEST|FDG-PET/CT|FDG-PET performed with low dose CT
223841297|NCT03429387|DIAGNOSTIC_TEST|Conventional CT|HRCT and CT of sinuses +/- other regions as per clinician's discretion
223841298|NCT04814940|OTHER|MENOPUR Cohort|"Non-interventional~All directions for medication usage were solely at the discretion of the investigator in accordance with their usual routine clinical practice and are assumed to be consistent with the national prescribing information of the medicinal product in the country in which the study take place."
223841299|NCT05602116|DRUG|Adipose tissue derived mesenchymal stromal/stem cells (Cell2Cure®)|"The Investigational Product is a C2C\_ASC cell product (Cell2Cure®, Cell2Cure Aps, Denmark).~C2C\_ASC is an advanced therapy investigational medicinal product (ATIMP) manufactured from abdominal adipose tissue derived mesenchymal stromal cells (ASC) from healthy donors. C2C\_ASC is aseptically procured and manufactured according to tissue law and GMP by Cell2Cure ApS or Cardiology Stem Cell Center, Rigshospitalet, Copenhagen, Denmark, using manual isolation of cells from abdominal fat tissue, xeno-free cell expansion in automated closed bioreactor systems and cryopreservation of the final product.~The active substance is the in vitro expanded ASCs. The final product, C2C\_ASC, is provided as a cryopreserved suspension of 50 million ASCs per ml with a total volume of 1,3 ml per vial. The excipient is CryoStor10 (Biolife Solutions), holding 10% DMSO."
223841300|NCT02774252|DRUG|BAY987521|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation number - Y49-103)
223841301|NCT04118699|DRUG|Rifaximin oral tablet|Patients with chronic idiopathic intestinal pseudo-obstruction (CIIPO) or patients with chronic intestinal pseudo-obstruction (CIPO), secondary to systemic scleroderma, are administered investigational product (rifaximin) for 4 weeks
223841302|NCT04118699|DRUG|Placebo oral tablet|Patients with chronic idiopathic intestinal pseudo-obstruction (CIIPO) or patients with chronic intestinal pseudo-obstruction (CIPO), secondary to systemic scleroderma, are administered placebo for 4 weeks
223841303|NCT06183918|DRUG|Tranexamic acid|"1. Group: Gauze soaked with 1000 mg TXA-topical~2. Group: Gauze soaked with 500 mg TXA + 5 cc saline -topical The prepared anterior nasal packing and medication administration were performed. Pressure was applied to both sides of the nose wings during the application for 10 minutes. It was checked whether the bleeding continued at the 5th and 10th minutes after anterior nasal packing and medication administration."
223841304|NCT06183918|OTHER|Saline|3\. Group: Gauze soaked with 10 cc of saline-topical. The prepared anterior nasal packing and medication administration were performed. Pressure was applied to both sides of the nose wings during the application for 10 minutes. It was checked whether the bleeding continued at the 5th and 10th minutes after anterior nasal packing and medication administration.
223841305|NCT06563531|PROCEDURE|Pharmacological thromboprophylaxis and elastic compression|Patients benefit from thromboembolism prevention through pharmacological thromboprophylaxis and elastic restraint after total hip or knee arthroplasty.
223841306|NCT06563531|PROCEDURE|Pharmacological thromboprophylaxis without elastic compression|Patients benefit from thromboembolism prevention through pharmacological thromboprophylaxis only after total hip or knee arthroplasty.
223841307|NCT00276250|DRUG|Efalizumab|Efalizumab was a medication approved for use in psoriasis which was being explored to determine efficacy with immunosuppression following organ transplantation. Efalizumab was administered subcutaneously on a weekly basis. Upon efalizumab being withdrawn from the US market, the protocol was amended to alter the immunosuppressive regimen to abatacept for the study participants.
223841308|NCT00276250|DRUG|Abatacept|Abatacept is drug used to treat autoimmune diseases. Abatacept is administered intravenously, monthly, in weight-based doses and is given for as long as transplanted islets are functioning.
223841309|NCT00276250|DRUG|Belatacept|Belatacept is a medication to provide extended graft survival while limiting the toxicity generated by standard immune suppressing regimens. Belatacept is administered intravenously. The protocol for this study was amended to substitute belatacept for abatacept for all newly enrolling participants (current participants remained on abatacept).
223841310|NCT03189134|DRUG|Fluorescite|Dilute fluorescite will be applied to cardiac tissue prior to imaging
223841311|NCT03189134|DEVICE|Cellvizio 100 Series System with Confocal Miniprobes|Microscopy system will image cardiac tissue.
223841312|NCT06018194|DEVICE|ElucidVivo|Plaque morphology characterization on coronary CTA for predicting fractional flow reserve (FFRct)
223841313|NCT06023550|OTHER|Treatment with surgery and/or conservative measures|Patients will be treated according to established clinical practice with surgery and/or conservative measures.
223841314|NCT02678052|DRUG|Vedolizumab|Vedolizumab exposure
223841315|NCT02678052|BIOLOGICAL|Other Biological Agent|Other Biological Agent exposure
223841316|NCT05793892|DRUG|Lidocaine tetracaine cream|The test drug and the control drug will be uniformly spread over the treatment area using a tongue platula to form a thin layer of approximately 1 mm,right then left . The drug remained in the treatment area for 30 minutes (± 2 minutes) .
223841317|NCT04337489|DEVICE|SensiumVitals wearable sensor|A waterproof, light, wearable sensor measuring vital signs (heart rate, respiratory rate, temperature) continuously.
223841318|NCT01615627|DRUG|HypotonicTreprostinil Solution|Hypotonic Treprostinil Solution
223841319|NCT01615627|DRUG|Eutonic Treprostinil Solution|Eutonic Treprostinil Solution
223841320|NCT04890132|BEHAVIORAL|VOR precision training|Subjects are rotated in yaw using a pseudo-random sum of sines motion (0.5 - 2.0 Hz), view a monitor 1 m away, and are instructed to move their avatar through a maze using a joystick. The size of the maze becomes smaller in real-time when they are successful so that the patient is at the limit of their acuity. This task requires patients to optimize dynamic visual acuity to threshold-level images while rotating. We predict that VOR precision will gradually improve during training and that after training VOR precision will be better than the pre-training data. The sham task is as above but the acuity required to see the maze will set at a much larger level so baseline visual precision will be adequate to perform the task easily.
223841321|NCT04866342|DEVICE|Servo control (closed-loop automatic control of the inspiratory fraction of oxygen (FiO2)) - IntellO2 OAM|"FiO2 adjustments will be made by the IntellO2 Oxygen Assist Module (OAM) for Precision Flow (IntellO2, Vapotherm, USA). By means of a modified closed-loop algorithm, the devise uses MasimoSET or Nellcor pulse oximetry to target a user-set SpO2 value.~Manual adjustments of the inspired oxygen fraction can additionally be made as per standard care."
223841322|NCT06339112|OTHER|Playing with toy nebulizer|The child who needs to take inhaler medication is taken to the observation room. Before starting the procedure, the toy nebulizer is introduced to the child. The toy nebulizer is shown to the child as an example and allowed to play, thus reducing the level of fear. Inhaler medication is given through a mask for 10 minutes. Vital signs (pulse) before and after the application. , blood pressure, SPo2, respiration), the Child Fear Scale will be evaluated by the researcher and the parent and recorded in the intervention follow-up form by the researcher.
223841323|NCT06339112|OTHER|Cartoon|"Approximately 10 minutes for the child. Inhaler medication will be given with a mask that lasts. 2-3 minutes before starting drug treatment, the child will be allowed to watch cartoons according to his age group and will be encouraged to do so throughout the procedure.~Vital signs (pulse, blood pressure, SPo2, respiration) before and after the application, the Child Fear Scale will be evaluated by the researcher and the parent and recorded in the intervention follow-up form by the researcher."
223841324|NCT03711838|DIETARY_SUPPLEMENT|N-Acetylcysteine|N-Acetylcysteine in a powder form diluted in a 250 ml drink containing 248 ml water and 2 ml of natural, non-caloric, flavoring-sweetener containing sucralose.
223841325|NCT03711838|DIETARY_SUPPLEMENT|Placebo|Placebo consisted of 248 ml water and 2 ml of natural, non-caloric, flavoring-sweetener containing sucralose.
223841326|NCT02817490|OTHER|patient education program|"The PREDUSED patient education program aims to make the patient actor of his pathology by providing him a box of therapeutic tools in order to: improve his knowledge of the disease, improve the management of pain, fatigue and episodes of instability; learn to communicate about the disease; set realistic goals.~The program includes theoretical information, practical cases, and discussions between participants and professionals.~It is the first patient education program in France for the patients with hypermobility type Ehlers-Danlos Syndrome. It is proposed two times a year. Six patients can participate at each session."
223841327|NCT06042985|DRUG|The absorption effect between calcium citrate and calcium carbonate|Elemental Calcium citrate supplementation will significantly improve patients' absorption after BMS in all cases.
223841328|NCT06510517|OTHER|Calculation of Mechanical Power.|"Total respiratory rate (RR). Positive end-expiratory pressure (PEEP) (the external or applied PEEP) recorded, not the total PEEP, or intrinsic PEEP. The plateau pressure (Pplat) was measured during an inspiratory pause on the ventilator. Peak inspiratory pressure (Ppeak) should be obtained while the patient is relaxed, not coughing or moving in bed. MP was calculated according to Gattinoni's simplified mechanical power equation as follows (3,8):~MP(J/min)=0.098×VT×RR×(Ppeak-0.5×ΔP)."
223841329|NCT06510517|OTHER|Measurement Diaphragmatic Excursion after first SBT|Chest ultrasound to assess diaphragmatic excursion (DE(. M-mode was used to record the movement of the diaphragm during tidal breathing when the sampling line and diaphragm were as vertical as possible (not \< 70°). The data was measured from the first respiratory cycle at 0 min after SBT. The DE at 0 min, 5 min, and 30 min of SBT was respectively named as DE0, DE5, and DE30. The variation of right DE between each time point was named as ΔDE30-5 and ΔDE30-0. (7)
223841330|NCT05465421|OTHER|bone marrow aspiration from maxillary tuberosity and BMMNCs separation to be seeded on PRF and used for socket preservation|"Local anaesthesia will be administered by infiltration or nerve block to achieve the necessary anaesthesia to allow extraction of the indicated tooth Extraction will be done as atraumatically as possible removing any pathosis found that may interfere with bone formation A trapezoidal flap will be created above the extraction socket to allow closure of the surgical site.~BMMNC will be seeded on platelet rich fibrin and inserted in the socket The flap will be closed by interrupted sutures using 5-0 sutures. implant placement 3 months later"
223841331|NCT01719146|OTHER|Specimen collection|At the beginning of each midweek hemodialysis session, a blood specimen (4 mL) will be drawn from the study subject. Out of this specimen a 1 mL serum sample will be frozen and stored. A 3 mL blood sample will be shipped overnight to WNERTA for laboratory testing.
223841332|NCT00974103|OTHER|exercise advise|Exercises
223841333|NCT00974103|OTHER|chiropractic treatment and exercises|Manipulation, mobilisation, soft tissue work, ergonomic and exercise advise. Maximum 12 treatments
223841334|NCT00972543|BIOLOGICAL|Efalizumab (Raptiva)|"Double-blind phase 0.7mg/kg subcutaneously (sc), followed by 1mg/kg/wk sc for 12 weeks.~Open label extension 0.7mg/kg sc Raptiva followed by 1mg/kg/wk sc for a further 12 weeks."
223841335|NCT00972543|BIOLOGICAL|Placebo|Double-blind phase sc Placebo for 12 weeks. Open label extension 0.7mg/kg sc Raptiva followed by 1mg/kg/wk sc for a further 12 weeks.
223841336|NCT03413605|BEHAVIORAL|A Multilevel CBPR Intervention|The intervention will be implemented through a group-based education workshop. The education session is a curriculum-based group education; each group will be having about 15-20 participants. All group education sessions will take place at collaborating Viet community partners sites, and delivered in Vietnamese language, with offering of refreshment. We will allow 5-7 minutes for participants to get to know each other and to get comfortable talking to the group. Education will have two major topics--- (a) CDC's standard Clinical Preventive Services Guidelines for adults 50+ (CPS). (b) culturally tailored CRC information discussion.
223841337|NCT01888562|DRUG|Ponatinib|Ponatinib 45 mg daily for 4 weeks (4 weeks equal one cycle)
223841338|NCT02981225|DIETARY_SUPPLEMENT|Phytostandard® Rhodiola-Saffron|
223841339|NCT06140667|DEVICE|LarysealTM Pro|The LarysealTM Pro is the new generation mask for safe and effective airway management, as it could reduce the risk of aspiration by the integrated suction catheter port to allow effective removal of fluids and gastric contents. So that, it could be a promising airway device as its symmetrical cuff and tube contoured to match the oropharyngeal anatomy for quick and easy first time insertion success. It could be applied in both routine and advanced airway management for patients with a higher risk of a difficult airway, unexpected intubation difficulties, beside to airway control during anesthesia. It was presented in the clinical market in sizes 3, 4 and 5 (according to the body weight; size 3: 30-50Kg, size 4: 50-70 Kg, and size 5:70-100Kg) that can accept larger tracheal tube up to 7.5 and 8mm inner diameter respectively with maximum suction catheter size of 16 Fr.
223841340|NCT06140667|DEVICE|Ambu Aura Gain|The AuraGain is Ambu ꞌs 3rd generation disposable laryngeal mask, satisfying 3 fundamental airway management needs by integrating gastric access channel for managing gastric content and intubation capability using standard ET-tubes in an anatomically curved single-use device that facilitates rapid establishment of a safe airway through integrated bite absorption area that could prevent airway occlusion. Other characters include pilot balloon that identifies mask size and provides tactile indication of degree of inflation, navigation marks for guiding flexible scope and is made of phthalate-free material. Its thin and soft cuff is designed to deliver high seal pressure up to 40 cmH2O. It was presented in the clinical market in sizes 3, 4, 5 and 6 (according to the body weight; size 3: 30-50 kg, size 4: 50-70 kg, size 5: 70-100 kg, and size 6: \>100 kg) with maximum suction catheter size of 16 Fr.
223841341|NCT02954718|OTHER|activity training|
223841342|NCT04533217|PROCEDURE|Vertebroplasty|Injection of cement into vertebral lesion(s)
223841343|NCT04537949|BIOLOGICAL|BNT162b3|Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection (Prime/Boost (P/B) regimen).
223841344|NCT03381014|DRUG|Chemotherapy, Cancer, Anthracyclines|follow up cardio-toxicity .... by speckle tracking echo and cardiac troponin
224076043|NCT07142863|DRUG|Envafolimab and neoadjuvant chemotherapy|"\* PD-L1 inhibitor envafolimab Paediatric (\<18 years): 2.5 mg/kg (maximum 200 mg) by subcutaneous injection on Day 1 of every week (q1w).~Adult (≥18 years): 200 mg flat dose by subcutaneous injection on Day 1 of every week (q1w).~* Neoadjuvant chemotherapy--MAP regimen (paediatric patients) Doxorubicin 75 mg/m² intravenously on Days 1-2, administered in weeks 1 and 6 of each 6-week cycle.~Cisplatin 120 mg/m² intravenously on Days 1-3, administered in weeks 1 and 6 of each 6-week cycle.~Methotrexate 8-12 g/m² intravenously on Day 1 of weeks 3 and 4 of each 6-week cycle.~* Neoadjuvant chemotherapy--DIA regimen (adult patients) Doxorubicin 75 mg/m² intravenously on Days 1-2, administered in weeks 1 and 6 of each 6-week cycle.~Cisplatin 120 mg/m² intravenously on Days 1-3, administered in weeks 1 and 6 of each 6-week cycle.~Ifosfamide 12-15 g/m² total dose intravenously on Days 1-5 of week 3 of each 6-week cycle."
223841345|NCT04560907|PROCEDURE|Aquablation|"By means of a high-pressure saline stream, parenchymal tissue of the prostate is removed endoscopically through a heat-free mechanism called hydrodissection. The intervention is supported by live ultrasound guidance and the required depth as well as the angle of the resection is planned out prior to the resection. The bladder is accessed using a 24-Fr hand-piece, which accommodates the scope. The handpiece is supported by an articulating arm attached to the operation table. Once placed in the optimal position, the system automatically adjusts the alignment as necessary.~Hemostasis is consecutively achieved through diathermy and post procedure, a threeway catheter is inserted and bladder irrigation is initiated."
223841346|NCT04560907|PROCEDURE|HoLEP|This is done endoscopically under general anesthesia the three lobes of the prostate that are cored out intact with the laser are pushed into the bladder before being morcellated by a special instrument inserted through the telescopic camera. A catheter is placed into the bladder to drain the urine while the raw surface heals, then left in place for around 24 hours before being removed on the day of discharge from hospital. Sterile saline fluid is also irrigated into the bladder through the catheter to dilute any blood in the urine and prevent clots from forming.
223841347|NCT01882062|DRUG|Triheptanoin 1g/kg/day|
223841348|NCT04003974|DRUG|Losmapimod oral tablet|Losmapimod will be administered with food when possible.
223841349|NCT04003974|DRUG|Placebo oral tablet|Placebo will be administered with food when possible
223841350|NCT04296942|BIOLOGICAL|Brachyury-TRICOM|Every three weeks, until cycle 9, then every 12 weeks: \*Recombinant MVA-Bavarian Nordic (BN)-Brachyury recommended phase 2 dose (R2PD): 4 injections of vaccines with 1 given subcutaneous (SC) in each extremity on Day 1 of Cycles 1 and 2. Each injection of MVA-BN-Brachyury consists of 2.0 x 10\^8 infectious units (Inf.U). \*Recombinant fowlpox virus (FPV)-BN-Brachyury: 1 injection given SC in one extremity on Day 1 of Cycles 3 and beyond. Each injection of FPV-BN-Brachyury consists of 1.0 x 10\^9 Inf.U.
223841351|NCT04296942|DRUG|Entinostat|5mg by mouth weekly (RP2D) administered by patient on Days 1, 8 and 15 of each cycle.
223841352|NCT04296942|BIOLOGICAL|M7824|1800mg via intravenous (IV) infusion every (q)3 weeks on Day 1 of each cycle.
223841353|NCT04296942|BIOLOGICAL|Ado-trastuzumab emtansine|3.6mg/kg via intravenous (IV) infusion every (q)3 weeks on Day 1 of each cycle.
223841354|NCT01680120|PROCEDURE|Continuous spinal anaesthesia|"Standard monitoring including continuous electrocardiogram, noninvasive automated arterial blood pressure and pulse oximetry will be applied.~Subarachnoid puncture will be performed with a 18-gauge Tuohy needle at the L4-5 or L3-4 interspace using a midline approach. Three cm of a 22-gauge catheter will be introduced cephalad through the needle. The initial dose is arbitrarily chosen as 1 ml of 0.5 % isobaric bupivacaine on the basis of clinical experience, the local anaesthetic will be injected through the catheter over 5-10 s. After completion of injection the patients remain in the lateral position for 5 min and then will be returned to the supine position.~Successive injections of 0.2 ml of 0.5 % isobaric bupivacaine will be performed every 15 min until a satisfactory sensory level is obtained (T12)."
223841355|NCT02920593|DRUG|Vitamin D3|Vitamin D prophylaxis
223841356|NCT00840320|DRUG|1278863|15mg, 25mg, 50mg, 150mg
223841357|NCT00840320|DRUG|Placebo|matching placebo
223841358|NCT00335153|DRUG|Levodopa-carbidopa intestinal gel|Infusion should be kept within a range of 0.5-10 mL/hour (10-200 mg levodopa/hour) and is usually 2-6 mL/hour (40-120 mg levodopa/hour).
223841359|NCT00335153|DEVICE|CADD-Legacy® 1400 ambulatory infusion pump|
223841360|NCT00335153|DEVICE|PEG tube|percutaneous endoscopic gastrostomy tube
223841361|NCT00335153|DEVICE|J-tube|jejunal tube
223841362|NCT05913323|DEVICE|Rapid Expiratory Occlusion Monitor (REOM)|Device for which Health Canada approval (ITA Authorization) has been obtained for use in the present study.
223841363|NCT05913323|DIAGNOSTIC_TEST|Standard oscillometry|tremoflo device-100, Thorasys Thoracic Medical Systems Inc., Montreal, Canada
223841364|NCT05913323|DIAGNOSTIC_TEST|Standard pulmonary function test|Standard-of-care respiratory test.
223841365|NCT06421974|PROCEDURE|DaVinci si or xi system|In this study, subjects were randomly divided into an experimental group (robot-assisted radical resection of right colon cancer group, referred to as robotic surgery group) and a control group (laparoscopic radical resection of right colon cancer group, referred to as laparoscopic surgery group).
223841366|NCT06421974|PROCEDURE|laparoscopic radical resection|In this study, subjects were randomly divided into an experimental group (robot-assisted radical resection of right colon cancer group, referred to as robotic surgery group) and a control group (laparoscopic radical resection of right colon cancer group, referred to as laparoscopic surgery group).
223841367|NCT04164160|OTHER|integrated-care-model benefiting group|Patients will be called for the ﬁrst interview of the study by the healthcare professional. Their data will be automatically entered in the Salut + Social app, they will be asked to respond to the study questionnaires (ad hoc questionnaire for sociodemographic data, EuroQol-5D, Zarit questionnaire and Morisky-Green test) and will take part in the future actions to be planned for them. Patients will receive an appointment to attend their PCC at 6, 9, and 12 months after their incorporation into the program. In those follow-up, the same questionnaires will be provided together with the IEXPAC questionnaire, which evaluates the experience of the chronic patient with the new care model.
223841368|NCT04038099|DRUG|Water-Based Vaginal Lubricant|5cc water based jelly applied intraurethral
223841369|NCT04038099|DRUG|lidocaine topical|5cc 2% lidocaine jelly applied intraurethral
224076044|NCT06942351|OTHER|Walnuts|Daily consumption of 1.5 ounces of plain walnuts for 12 weeks
224076045|NCT06942351|OTHER|Crackers|Daily consumption of non-whole grain crackers for 12 weeks (caloric equivalent to 1.5 ounces of plain walnuts)
224076046|NCT06942286|DIAGNOSTIC_TEST|HPV Self-Collection|Participants will perform HPV self-collection.
223841370|NCT00166660|BEHAVIORAL|NIDCAP (Newborn Individualized Developmental Care)|The NIDCAP model aims to create a relationship-based developmentally supportive care environment for the preterm infant and family. The theory proposes that care implementation that takes into account the infants' thresholds of disorganization is most supportive of long term outcome. Specifically, the intervention consisted of weekly neurobehavioral observations and reports of the experimental group infants' behavior with suggestions for parents and staff in ways to support each infant's development. The developmental specialists formally observed each infant's behavior weekly throughout the hospitalization, starting with the phase of the infant's initial stabilization, and then every seven days throughout hospital discharge and to 2wCA.
223841371|NCT03992911|DRUG|Simmtecan, 5-FU and l-LV|Simmtecan was administered intravenously at 80 mg per square meter on day1 with LV 400 mg per square meter administered as a 2-hour infusion, and 5-FU 2400 mg per square meter as a 46-hour infusion on day1 every 2 weeks in one course.
223841372|NCT03992911|DRUG|Toripalimab|Toripalimab was administered intravenously at 240 mg on day 1 every 2 weeks in one course.
223841373|NCT03992911|DRUG|Etoposide, Cisplatin|Etoposide was administered intravenously at 100 mg per square meter on day 1,2,3 with Cisplatin at 80 mg per square meter on day 1 every 3 weeks in one course.
223841374|NCT03992911|DRUG|Etoposide, Carboplatin|Etoposide was administered intravenously at 100 mg per square meter on day 1,2,3 and Carboplatin with AUC 5mg/mL/min on day 1 every 3 weeks in one course.
223841375|NCT03688542|OTHER|Quality Circle Deprescribing Module|The Quality Circle Deprescribing Module consist of a discussion bringing together nurses, physicians and responsible pharmacist to create a local deprescribing consensus for frequently used drug classes, as well as implementation strategies for the consensus..
223841376|NCT03264196|PROCEDURE|Open Reduction and Internal Fixation|Surgical treatment of fracture
223841377|NCT01113463|DRUG|TPI 287|Starting dose of 160 mg/m\^2 as a 60-minute (± 10 minutes) IV infusion once every 3 weeks, (i.e., 1 cycle = 21 days).
223841378|NCT00033956|DRUG|M40403|
223841379|NCT01349751|DRUG|isobaric levobupivacaine|0.42% either isobaric levobupivacaine 3 ml spinal injection once
223841380|NCT01349751|DRUG|hyperbaric levobupivacaine|0.42% hyperbaric levobupivacaine 3 ml spinal injection once
223841381|NCT00533247|DRUG|Celecoxib|
223841382|NCT02478359|BEHAVIORAL|Physical Activity Coaching (Walk On!)|The 12-month Walk On! intervention included a baseline in-person assessment, collaborative monitoring of steps using two types of activity sensors, semi-automated step goal recommendations using an interactive voice response system or web application, ongoing individualized reinforcement from a physical activity coach, and peer/family support.
223841383|NCT05489861|BEHAVIORAL|M-AM|To examine the effects of affirmation and infant massage taught to their parents on their infants' sleep quality and parent-infant attachment.
223841384|NCT05489861|BEHAVIORAL|F-AM|To examine the effects of affirmation and infant massage taught to their parents on their infants' sleep quality and parent-infant attachment.
223841385|NCT00996086|DEVICE|CRT device implant|CRT device-recipients
223841386|NCT03891680|DRUG|Botox Injectable Product|Intra articular Botox injection
223841387|NCT03891680|DEVICE|Radiofrequancy|Genicular nerves radiofrequancy
223841388|NCT05224687|OTHER|Retroactive review of patient data of those receiving a dose of daptomycin|A retrospective analysis will be conducted using patient data of those receiving a dose of daptomycin at MCMC, Methodist Dallas Medical Center, Methodist Richardson Medical Center, or Methodist Mansfield Medical Center.
223841389|NCT03794778|DRUG|pegylated liposomal doxorubicin|PLD 30 mg/m2, i.v.,d1; once every 21days
223841390|NCT03794778|DRUG|paclitaxel|paclitaxel 175 mg/m2, i.v.,d1; once every 21days
223841391|NCT03794778|DRUG|Carboplatin|carboplatin AUC 5, i.v.,d1; once every 21days,
223841392|NCT01800149|PROCEDURE|Ridge Augmentation|After tooth extraction, the sockets will be filled with bovine bone mineral and covered with a porcine collagen membrane
223841393|NCT01237678|DRUG|IMGN901|Phase 2 regimen is IMGN901, Carboplatin, and Etoposide. IMGN901 to be given on days 1 and 8 every 21 days.
223841394|NCT01237678|DRUG|Carboplatin and Etoposide|Patients assigned to Arm 2 were to receive carboplatin at the same AUC as utilized in Arm 1
223841395|NCT06413615|DRUG|FDA022-BB05|Monoclonal antibody-drug conjugate for injection
223841396|NCT04315038|PROCEDURE|spinal anesthesia|Plan to enroll 200 health volunteers and 40 neurodegenerative diseases patients with received spinal anesthesia. Blood will be collected at time point of pre-anesthesia 10 minutes and CSF samples will be collected at time point during spinal anesthesia induction. Blood will be collected, drawn into EDTA-coated tube.
223841397|NCT05513521|OTHER|High-velocity interval training|For the velocity training protocol, the 11 exercises will be completed at 40% of their 1RM. In the first three weeks of training, the loading volume will be increased gradually. During week one participants will complete one set of each exercise. Week two will consist of two sets, and weeks 3-12, three sets. Keiser pneumatic resistance machines are interfaced with a laboratory computer, which allows the transfer and analysis of data including force, velocity, and power.
223841398|NCT05513521|OTHER|Resistance training|For the load training protocol, the 11 exercises will be completed at 79% of their 1RM. In the first three weeks of training, the loading volume will be increased gradually. During week one participants will complete one set of each exercise. Week two will consist of two sets, and weeks 3-12, three sets. Keiser pneumatic resistance machines are interfaced with a laboratory computer, which allows the transfer and analysis of data including force, velocity, and power.
223841399|NCT02830789|DIETARY_SUPPLEMENT|Calcium Carbonate|
223841400|NCT02830789|DIETARY_SUPPLEMENT|Calcium Citrate|
223841401|NCT02830789|DIETARY_SUPPLEMENT|Placebo|Tablet manufactured to mimic a calcium carbonate tablet
223841402|NCT02830789|PROCEDURE|Roux-en-Y gastric bypass|Roux-en-Y gastric bypass surgery at least 12 months before study inclusion
223841403|NCT02184884|DEVICE|MACE after OPCAB|
223841404|NCT02184884|DEVICE|without MACE after OPCAB|
223841405|NCT01455740|BEHAVIORAL|Provider Visit Incentive (PVI)|"All participants received the standard of care (SOC), which included not only medical care but also a wide range of social services. In addition, participants in the PVI arm received financial incentives designed to motivate health-improving behaviors. After the initial study enrollment visit, participants in the PVI arm received a $30 payment each time they showed up as scheduled for one of their next four HIV primary care visits.~Participants in the PVI arm were also asked to return for a sixth, unanticipated study visit approximately three months after the last of the four study visits to which the incentive scheme applied. To reduce attrition, participants were offered $100 for showing up to the fifth and sixth study visits."
223841406|NCT01455740|BEHAVIORAL|Incentive Choice (IC)|"All participants received the SOC. In addition, participants in the IC arm received financial incentives designed to motivate health-improving behaviors. At the initial study enrollment visit, participants in the IC arm chose between either the incentive scheme assigned to the PVI arm or an incentive scheme that tied payments to clinic attendance and ART medication adherence. Participants who selected the 2nd option received a $30 payment at each of their next 4 HIV primary care visits if the (i) showed up as scheduled and (ii) presented a dose-recording pill bottle cap indicating that they correctly took at least 90% of doses of a sentinal medication since the previous study visit.~Participants in the IC arm were also asked to return for a 6th, unanticipated study visit approximately three months after the last of the 4 study visits to which the incentive scheme applied. To reduce attrition, participants were offered $100 for showing up to the 5th and 6th study visits."
223841407|NCT03789903|DIAGNOSTIC_TEST|amniotic fluid lactate|AF lactate
223841408|NCT02069587|DIETARY_SUPPLEMENT|pomegranate|
223841409|NCT02336893|BEHAVIORAL|Training|The final training was provided to a group of 34 residents --from internal medicine, anesthesiology, gynecology, and intensive care-- in charge of giving information to the patient's family members in the ICU. They were trained in the semi-structured interview PACIENTE (Present oneself and greet, Attend and listen, Call diagnosis, Inform treatment, Expose prognosis, Name introductory phrases to bad news, Take time to provide empathetic comfort, Explain an action plan involving the family) conjointly while participating in simulated difficult clinical cases with family members-actors. Four training programs were performed from February to September 2014.
223841410|NCT05146011|PROCEDURE|Gatsric balloon insertion|Insertion of Gastric balloon prior to laparoscopic gastric bypass surgery
223841411|NCT05122403|PROCEDURE|MRgFUS central lateral thalamotomy|MRgFUS central lateral thalamotomy is a minimally invasive and effective procedure for medication-refractory neuropathic pain patients.
223841412|NCT04487028|PROCEDURE|Fiberoptic Endoscopic Evaluation of Swallowing|This procedure involves inserting a flexible laryngoscope that contains a light source and video camera on the end through the open passage of the nose towards the back of the throat in order to visualize the swallowing mechanism.
223841413|NCT04889781|DRUG|Dexamethasone injection|Compare the effect of dexamethasone injection on reducing post-op pain after impacted third molar Surgery
223841414|NCT04889781|PROCEDURE|Piezosurgery|Compare the effect of Piezosurgery device use on reducing post-op pain after impacted third molar Surgery
223841415|NCT04889781|PROCEDURE|Conventional Rotatory instruments|Surgical extraction using conventional rotatory instruments to perform osteotomy
223841416|NCT05397015|OTHER|No intervention will be done|No intervention will be done
223841417|NCT06479473|RADIATION|Radiotherapy to all residual lesions|Patients assigned to chemoimmunotherapy with radiotherapy group would first receive PET-CT and cranial contrasted MRI to ascertain residual lesions. All residual lesions would be irradiated in a hypofractionated manner.
224076047|NCT07144007|DRUG|Dexmedetomidine|In rhinoplasty, 10 minute infusion of 0,5 mcg/kg dexmedetomidine will be administered after nasal packing
223841418|NCT06479473|DRUG|Chemoimmunotherapy|atients assigned to chemoimmunotherapy group would receive 4 to 6 cycles of chemoimmunotherapy followed by consolidative immunotherapy
223841419|NCT05960279|DEVICE|MD100|"The MD100 (Medfield Diagnostics, Gothenburg, Sweden) consists of 8 antennas and measurement electronics integrated into a single device; rechargeable ion batteries power the instrument. The radiation transmitted from the device equals approximately 1% of the radiation emitted from a mobile phone. The device is non-invasive and small enough that it can be moved around with ease.~The system transmits microwaves with an output of 0.2 milliWatts (mW) for less than 90 seconds. The power absorbed by the body is 100mW/kg which is a factor of 200 less than what is established by the existing safety standard for microwaves. A mobile phone output, by comparison, can be up to 250mW.~The patient's head is placed in the instrument during measurement while the patient is supine. The procedure takes, on average, 5 minutes to perform."
223841420|NCT02842879|OTHER|Outpatient Foley cervix priming|Outpatient setting for cervix priming with Foley catheter
223841421|NCT05508516|DRUG|Shugan Dingtong decoction|Patients will accept Shugan Dingtong decoction 150ml (twice, per day) for 12 weeks.
223841422|NCT05508516|DRUG|Duloxetine Hydrochloride|Patients will accept duloxetine hydrochloride 20mg (twice, per day) for 12 weeks.
223841423|NCT03023332|BEHAVIORAL|Resourcefulness Training|A cognitive-behavioral intervention delivered through iPad technology that consists of teaching and reinforcing personal (self-help) and social (help-seeking) resourcefulness skills.
224076048|NCT07144007|DRUG|Propofol|In rhinoplasty, 0,5 mg/kg propofol IV bolus will be administered after nasal packing
224076049|NCT06947083|DRUG|Elranatamab|Maintenance therapy
223841424|NCT03023332|BEHAVIORAL|Biofeedback training|"Use of a heart-rate variability (HRV) tracking device to enable one to learn to alter physiology to improve health. Devices are used to measure physiological activity, e.g., breathing and heart function, and provide rapid, accurate feedback to the user, thereby enabling desired physiological changes that can endure over time without continued use of the device and continue to influence behavior."
223841425|NCT03023332|BEHAVIORAL|Bipolar Education|An educational program designed to teach family caregivers of about the types, causes, symptoms, episodes, warning signs, and treatments for individuals with bipolar disorder, as well as available resources for assisting a family member with bipolar disorder. The content to be presented within an audiovisual format using iPad technology follows the recommendations and guidelines developed through research and by the Depression and Bipolar Support Alliance and the National Institute of Mental Health.
223841426|NCT02447679|DRUG|thalidomine|thalidomine (400mg/day) for 1 year to prevent HCC recurrence
223841427|NCT02447679|DRUG|tegafur-uracil|tegafur-uracil (2 tablelet twice a day) for 1 year to prevent HCC recurrence
223841428|NCT00170235|OTHER|Prehabilitation|Exercise class pre-surgery
223841429|NCT00170235|OTHER|Usual care|Exercise booklet, physiotherapy if needed
223841430|NCT06450535|PROCEDURE|Autogenous onlay bone block harvesting from retromolar bone in anterior maxilla|"Surgical protocol ( retromolar bone harvesting) After injecting local anesthesia a crestal incision is done, from a point on the occlusal surface along the external oblique ridge and extending anteriorly and inferiorly through the buccal mucosa, parallel to the gingival margin of the mandibular molars.~The subperiosteal dissection extend to expose the ascending ramus and the retromolar region With the aid of surgical carbide burs, two proximal vertical cuts penetrating the cortex of the external oblique ridge.~The depth of penetration of the posterior cut did not exceed 2.5 mm to avoid injury to the inferior alveolar nerve.~By using microsaw , an inferior cut of 3.2 mm in depth joining the anterior and posterior vertical cuts was done.~Small perforations of 3-4 mm in depth were performed on the superior aspect of the external oblique ridge using 1 mm drill bur.~Finally, the block was sheared off using a chisel."
223841431|NCT06450535|PROCEDURE|Autogenous cortical shell technique from retromolar bone in anterior maxilla|"The harvested cortical plate was then split longitudinally in two parts using a microsaw, and thinned with the bone scraper to achieve a plate of 1 mm thickness.~The plate was fixed at a distance from the residual ridge with 2 screws. Autogenous bone particles, collected with the bone scraper, were tightly packed into the gap between the plate and the recipient site."
223841432|NCT01818700|DRUG|Buprenorphine|8weeks treatment with Norspan®(Buprenorphine)
223841433|NCT02567474|BEHAVIORAL|5 A model|self management program based on 5A model
223841434|NCT02412761|DRUG|Lisinopril|Initial dose: 0.1 mg/kg/dose orally, once daily (maximum initial dose 10 mg/dose). Maximum final dose: 40 mg/dose or 0.6 mg/kg/dose.
223841435|NCT02412761|DRUG|Amlodipine|Initial dose: 0.1 mg/kg/dose orally, once daily (maximum initial dose 5 mg/dose). Maximum final dose: 10 mg/dose
223841436|NCT02412761|DRUG|Hydrochlorothiazide|Initial dose: 1 mg/kg/dose orally, once daily (maximum initial dose 25 mg/dose). Maximum final dose: 50 mg/dose or 3 mg/kg/dose
223841437|NCT04974320|BIOLOGICAL|blood biomarkers|All patients were obtained blood biomarkers: troponin, ST2, copeptin
223841438|NCT04751175|DRUG|Ketamine|Ketamine, being a non-competitive antagonist of NMDA receptors, could represent a good option as an opioid treatment enhancer for acute postoperative pain and avoid chronic pain, by reducing the '' wind-up '' phenomenon of central sensitization
223841439|NCT04751175|DRUG|Dexamethasone|"A meta-analysis published in September 2011 affirms that the administration of dexamethasone at a dose of 0.1 mg / kg is an effective complement to multimodal analgesia strategies to reduce postoperative pain and opioid consumption after surgery.~Preoperative administration of the drug produces a more consistent analgesic effect than intraoperative administration"
223841440|NCT04751175|DRUG|Physiologic saline|placebo
223841441|NCT00003650|DRUG|asparaginase|
223841442|NCT00003650|DRUG|cyclophosphamide|
223841443|NCT00003650|DRUG|cytarabine|
223841444|NCT00003650|DRUG|daunorubicin hydrochloride|
223841445|NCT00003650|DRUG|dexamethasone|
223841446|NCT00003650|DRUG|etoposide|
223841447|NCT00003650|DRUG|mercaptopurine|
223841448|NCT00003650|DRUG|methotrexate|
223841449|NCT00003650|DRUG|methylprednisolone|
223841450|NCT00003650|DRUG|mitoxantrone hydrochloride|
223841451|NCT00003650|DRUG|prednisone|
223841452|NCT00003650|DRUG|vincristine sulfate|
223841453|NCT00003650|RADIATION|radiation therapy|
223841454|NCT05715450|PROCEDURE|Falciformopexy for Treatment Perforated Peptic Ulcer|use the falciform ligament on perforated peptic ulcer
223841455|NCT02058342|BEHAVIORAL|Active Play at Home|The Active Play at Home (APAH) curriculum includes age-appropriate goal-oriented physical activities that combine playground and video games using the Nintendo Wii™ with exercises targeting: muscular strength and endurance, aerobic endurance, flexibility, balance, agility, and motor coordination. APAH was designed for children ages 8-11 without disability and ages 8-15 years with PWS. The playground games and interactive console-based games are to be performed twice weekly each. The activity is progressed from 25 to 45 minutes of moderate to vigorous physical activity throughout the 24 weeks period. Parents and children are trained to use the curriculum hands-on at baseline.
223841456|NCT00004108|DRUG|exatecan mesylate|
223841457|NCT02237378|RADIATION|FDG PET scan|Following an overnight fast, subjects will be positioned in the Discovery 660 PET/VCT scanner. Following a scout scan to confirm patient positioning, low dose xray CT scan is performed for photon attenuation. A 20 minute dynamic PET scan is started simultaneously with 3 MBq/kg of N-13 ammonia to measure myocardial perfusion. Following N-13 decay,a 60 minute dynamic PET scan with 3 MBq/kg F-18- FDG to measure myocardial glucose uptake. Blood sampling for glucose and insulin will occur at pre specified time points throughout the scan.
223841458|NCT05531903|DEVICE|Description of Slow pathway signals to facilitate ablation|3D endocardial mapping in order to identify slow pathway signals and abolish or modificate them after radiofrequency ablation
223841459|NCT02553941|DRUG|Azacitidine|Given intravenous or subcutaneous
223841460|NCT02553941|DRUG|Ibrutinib|Given by mouth once daily
223841461|NCT05992155|DRUG|TAK-279|TAK-279 capsules.
223841462|NCT01333761|DEVICE|Cardiox FDS|The Cardiox Shunt Detection system consists of a sensor placed in contact with the outer ear, similar to a finger probe used to detect oxygen levels in blood. Through an intravenous line, ICG (indocyanine green) at a dosage of 10 mg (2 mL of 5 mg/mL ICG solution) per test, is administered into the right or left antecubital fossa. The presence of ICG in the veins within the outer ear are detected, and the results are displayed on a monitor. All patients will also be evaluated with TCD and TEE for the presence of RTLS.
223841463|NCT04186169|PROCEDURE|Catheter ablation|Catheter ablation
223841464|NCT01657682|DRUG|Crenolanib besylate|"Crenolanib besylate, 100 mg TID, taken orally at least 30 minutes pre- or post- meal. Patients will complete a daily diary to record the date, time and amount (number of tablets) of crenolanib taken and eating schedule.~Concurrent hydroxyurea (maximum 5g total daily dose x 14 days) is permitted during the first 28 days of study therapy."
223841465|NCT01719861|DRUG|Desipramine HCL|Desipramine is a tricyclic antidepressant (TCA). All patients will start off with a 25 mg dose by mouth nightly (QHS), increasing weekly for 6 weeks. The target dose level at 6 weeks is 450 mg (maximum dosage) or the maximum tolerated dose (MTD) for each subject.
223841466|NCT02651402|BEHAVIORAL|FRIENDS for Life|Friends for Life (FRIENDS): FRIENDS, a GCBT program, is an effective program for the prevention and treatment of anxiety disorders in children evidenced by a meta-analysis on school-based interventions for at-risk and clinically anxious youth. FRIENDS was developed based on the view that anxiety is a tripartite construct involving physiological, cognitive, and behavioral components. Core Intervention components: Experts in CBT for childhood anxiety disorders have identified 5 essential components: psychoeducation, somatic management skills training, cognitive restructuring, exposure methods, and contingency management. The FRIENDS protocol consists of 10 weekly sessions and two booster sessions. We included the booster sessions in the regular protocol for a total of 12 sessions.
223841467|NCT02651402|BEHAVIORAL|Adapted FRIENDS|Adapted Friends (aFRIENDS): We conducted planned adaptations to the FRIENDS protocol based on our collective experience with the protocol and qualitative data (focus group and interviews). We followed procedures developed by Lee and colleagues, including surveying service providers and trainers regarding the appropriateness of FRIENDS for the target population. Changes were made to the language (idioms, metaphors, words), cultural fit (cultural values), methods (session length, number of sessions), activities (in-session practices), which resulted in additions and substitutions in these areas while maintaining the 5 essential components of the treatment. aFRIENDS is a briefer (8-session) and more engaging and culturally-sensitive protocol than FRIENDS.
223841468|NCT02651402|BEHAVIORAL|Train-the-Trainer|Train the Trainer (TT): agency supervisors are trained to conduct effective supervision (one initial training and 2 booster sessions), and then go on to train intervention therapists.
223841469|NCT02651402|BEHAVIORAL|Train-the-Trainer Plus|Train the Trainer Plus (TT+): a modified train-the-trainer approach by which supervisors receive training plus extended on-going consultation on conducting effective supervision with intervention therapists.
223841470|NCT06277128|DRUG|WS016 3g|Acute treatment phase: WS016, oral, 3g , three times a day for 48 hours; Maintenance treatment phase: WS016, oral, 3g, once daily for 12 days.
223841471|NCT06277128|DRUG|WS016 6g|Acute treatment phase: WS016, oral, 6g , three times a day for 48 hours; Maintenance treatment phase: WS016, oral, 6g, once daily for 12 days.
223841472|NCT06277128|DRUG|WS016 12g|Acute treatment phase: WS016, oral, 12g , three times a day for 48 hours; Maintenance treatment phase: WS016, oral, 12g, once daily for 12 days.
223841473|NCT06277128|DRUG|Matching Placebo|Acute treatment phase: Matching Placebo, oral, three times a day for 48 hours; Maintenance treatment phase: Matching Placebo, oral, once daily for 12 days.
223841474|NCT01386216|DEVICE|Magellan®|Autologous Bone Marrow Cell Concentrate Prepared Using the Magellan System to be injected into the ischemic muscle tissue at 0.5 cc/injection for a total of 12-20 cc.
223841475|NCT04569214|DRUG|PAZ320|Treatment arm B - 2 tablets of PAZ320 and 2 tablets of placebo, total of 4 tablets Treatment arm C - 4 tablets of PAZ320
223841476|NCT04569214|OTHER|Placebo|Treatment arm A - 4 tablets of placebo Treatment arm B - 2 tablets of PAZ320 and 2 tablets of placebo, total of 4 tablets
223841477|NCT05880693|DRUG|Dexmedetomidine|Group 1 received dexmedetomidine
223841478|NCT05880693|DRUG|Magnesium sulfate|the group 2 received magnesium sulfate
223841479|NCT03943186|DEVICE|Ectoin Lozenges Honey Lemon|application of Ectoin Lozenges (EHT02) in accordance with the instructions for use
223841480|NCT03943186|DEVICE|Hyaluronic Acid/Icelandic moss Lozenges|application of the lozenges in accordance with the instructions for use
223841481|NCT06488066|OTHER|Data collection|Collection of clinical data from groups of patients already implanted with the light adjustable lens (LAL) and have completed light treatments.
223841482|NCT02250144|DEVICE|Foot orthoses|
223841483|NCT05300880|OTHER|Training program|A multi-component intervention based on health coaching. The strategies of this program consisted in five 16-hour sessions using case studies to find out whether nurses were able to empower chronic cardiac patients and debriefing and a 4-hour booster session seven months later.
223841484|NCT04569279|DRUG|Rivaroxaban|Rivaroxaban (Rovaltro®) is a novel oral anticoagulant that acts selectively, reversibly, and potently on activated Factor X (Factor Xa) inhibiting a critical point on the coagulation cascade. Rivaroxaban has excellent bioavailability, rapid onset of peak anticoagulation effect, and predictable pharmacokinetic and pharmacodynamic properties making routine laboratory monitoring and dose adjustments almost unnecessary (11). Rivaroxaban is an extensively studied drug and has received approvals for anticoagulation in several preventive and therapeutic indications (11). Now medical literature has some solid evidence that Rivaroxaban is comparable with other anticoagulants in terms of efficacy. Several studies imply that Rivaroxaban may have a lower risk of major bleeding (11). Several reports and small case-series (12,13) suggest that rivaroxaban may be beneficial as Warfarin in the treatment of cerebral venous thrombosis (CVT) with less or no major complications.
223841485|NCT04569279|DRUG|Warfarin|Warfarin (Orfarin®) is the most popular vitamin K antagonist and is considered the standard of care in many venous and arterial anticoagulation indications with extensive clinical experience regarding its use. This inexpensive and effective drug has a narrow therapeutic window that is affected by diet changing and many drug interactions, making frequent monitoring with prothrombin time (PT)/international normalized ratio (INR) highly important.(14)
223841486|NCT01616719|DEVICE|DTRAX Graft|DTRAX Graft is an allograft implant inserted to support spinal fusion.
223841487|NCT00310362|BEHAVIORAL|Use of Interactive Voice Response (IVR) system to improve adherence to GI appointments and prep procedures|Interactive voice response system (IVR) calls patients 7 or 3 days prior to their appointment. Information available in the IVR system is based on the same template nurses use in usual care and includes an appointment reminder, preparation instructions, basic information about the procedure, and answers to commonly asked questions.
223841488|NCT00715286|OTHER|timing of surgery|Surgery is followed by chemotherapy
223841489|NCT00715286|OTHER|timing of surgery|Chemotherapy is followed by surgery
223841490|NCT05365867|BEHAVIORAL|iCAN Group|See description in iCAN study arm.
223841491|NCT03453385|BEHAVIORAL|Electronic Cigarette|An e-cigarette and four weeks of e-liquid provided to participants.
223841492|NCT00419068|DRUG|Cholecalciferol|
223841493|NCT00419068|DRUG|Migliol Placebo Oil|
223841494|NCT04308616|OTHER|Blood samples|Blood samples
223841495|NCT02055859|RADIATION|Radiosurgery|
223841496|NCT03912103|OTHER|Interdisciplinary Deprescribing and Medication Optimization Intervention|as current
223841497|NCT05561855|BEHAVIORAL|lifestyle intervention|"During the 3-month lifestyle intervention period, the participants need to complete the weight monitoring, behavioral goal recording, diet and exercise recording, online course learning by using the WeChat official account module of Weight Loss and Glucose Control.They will receive corresponding feedback and integral rewards every week, and receive monthly follow-ups to complete health education, goal review, motivational interview as well as collecting medication changes and blood glucose monitoring data."
223841498|NCT04284748|OTHER|Plyometric exercise with blood flow restriction|"Blood flow restriction training is an exercise protocol based on the method of limiting blood flow with external pressure by pneumatic tourniquet from the proximal of the muscle to be strengthened. Blood flow restriction (Occlusion) during pliometric exercises for 8 weeks, a pneumatic tourniquet (Kaatsu Master) proximal to the thigh will be applied to each patient within a safe pressure range. The pressure to be applied to the patient will be calculated with the following formula described in the literature.~Pressure = 0.5 x (systolic blood pressure) + 2 x (thigh circumference) + 5 Application will be done for a maximum of 15 minutes, then rest for 10-15 minutes and other exercises will continue.~Plyometric training with blood flow restriction. Jump in functional squat system (30+15+15+15= 75 rep) Lunge jump (30 rep) Side jump (30 rep) Box jump (15 rep) Exercises to be added after 4 weeks; Square jump (15 rep) One leg hop (15 rep)"
223841499|NCT04284748|OTHER|Plyometric exercise|Plyometric training Jump in functional squat system (30+15+15+15= 75 rep) Lunge jump (30 rep) Side jump (30 rep) Box jump (15 rep) Exercises to be added after 4 weeks; Square jump (15 rep) One leg hop (15 rep)
223841500|NCT04284748|OTHER|Routine physiotherapy program|Anterior and lateral plan exercise (3x10 rep) Open kinetic quadriceps and hamstring strengthening exercise (3x10 rep) Lunge exercises on different ground (3x10 rep) Single leg squat exercise on different ground (3x10 rep) Anterior and lateral walking exercise in a squatting position with an exercise band (40 step) Balance and proprioceptive exercises
223841501|NCT06336746|DEVICE|Esophageal Doppler|Esophageal Doppler: measuring cardiac performance. INVOS: measuring regional saturation of the brain.
223841502|NCT02117115|RADIATION|Dynamic contrast-enhanced computed tomography|CT scan performed between Day +7 and Day +14.
223841503|NCT02117115|DRUG|Ioversol|To optimize visualization of bowel mucosal, patient will be given 1350 ml, or as much as can be tolerated, of negative oral contrast to distend the small bowel one hour prior to scanning. A weight-based volume of Optiray-350 will be injected at a rate of 4 cc/sec followed by 50 cc of saline flush also at 4 cc/sec.
223841504|NCT01716832|BEHAVIORAL|Mindfulness Walking|Mindful walking in a small group twice a week for 60 minutes within 4 weeks.
223841505|NCT04863105|DRUG|Abiraterone acetate tablets(Zecke ®250 mg);Abiraterone acetate tablets(250 mg)|"Subjects were allocated to one of three groups randomly and equally with a 7-day washout interval between the two periods.Abiraterone acetate tablets(Zecke ® 250 mg,Batch number:VYCB manufactured by Patheon Inc.)and Abiraterone acetate tablets(250 mg,Batch number:17F0023DD9 manufactured by Qilu Pharmaceutical Co., Ltd) were used in this study."
223841506|NCT01126021|BEHAVIORAL|Financial incentives|Participants are eligible for incentives if they participate in at least 30 games per day.
223841507|NCT01126021|BEHAVIORAL|No incentives|Participants will be given training and access to the software to participate in mental exercises but will not be given financial incentives for participation.
223841508|NCT04455724|DEVICE|Negative pressure incisional wound therapy|A vacuum-style dressing system that is sealed in place over a surgical wound, applying constant negative pressure to the healing tissues.
223841509|NCT04455724|DEVICE|Standard sterile dressing|A standard, sterile island dressing
223841510|NCT06422026|DIETARY_SUPPLEMENT|APCP I|Each subject takes one active bottle per day for 24 weeks. Each bottle contains APCP 3 g.
223841511|NCT06422026|DIETARY_SUPPLEMENT|APCP II|Each subject takes one active bottle per day for 24 weeks. Each bottle contains APCP 4 g.
223841512|NCT06422026|DIETARY_SUPPLEMENT|Placebo|Each subject takes one active bottle per day for 24 weeks.
223841513|NCT06224075|BEHAVIORAL|Task-specific training|"Participants in the intervention group will receive the treatment established for the control group and nursing care based on task-specific training. The intervention was designed with the aim of improving inhaler management in COPD patients. The content of the tasks will be adapted to the different types of devices present in the patient's therapeutic regimen, mainly pressurized cartridge and dry powder devices.~In order to carry out the intervention, several tasks related to education, assessment and/or training will be established with the aim of improving the ability to use the prescribed inhalers. The tasks have been classified into 3 blocks: technique execution, device cleaning and medication administration."
223841514|NCT06224075|OTHER|Usual care|All patients will receive standard treatment during their hospital stay (medical and pharmacological care). This treatment will include steroids, antibiotics, inhaled bronchodilators and oxygen therapy. In addition, during hospitalization they may receive diuretics, anticoagulants and cardiovascular treatments if necessary.
223841515|NCT02656940|DIETARY_SUPPLEMENT|Group 1 - diet rich in n-3 and n-6 PUFA|In order to achieve the desired intake of unsaturated FA, the group received individual portions of vegetable oils in the form of sachets, which were consumed for lunch and dinner, besides gelatin capsules, for 60 days.
223841516|NCT02656940|DIETARY_SUPPLEMENT|Group 2 - diet rich in MUFA|In order to achieve the desired intake of unsaturated FA, the group received individual portions of vegetable oils in the form of sachets, which were consumed for lunch and dinner, besides gelatin capsules, for 60 days.
223841517|NCT02656940|DIETARY_SUPPLEMENT|Group 3 - Placebo group|Placebo group was instructed to keep their eating habits and consuming placebo for 60 days.
223841518|NCT04833855|BIOLOGICAL|Tezepelumab Dose 1|Subcutaneous injection.
223841519|NCT04833855|BIOLOGICAL|Tezepelumab Dose 2|Subcutaneous injection.
223841520|NCT04833855|BIOLOGICAL|Omalizumab|Subcutaneous injection.
223841521|NCT04833855|BIOLOGICAL|Placebo|Subcutaneous injection.
223841522|NCT04654351|DRUG|TAK-667|TAK-667 single SC administration
223841523|NCT03364816|PROCEDURE|TDR|total artificial disc replacement
223841524|NCT02109679|DRUG|metformin|multiple doses metformin given as tablet
223841525|NCT02109679|DRUG|BI 187004|multiple doses BI 187004 given as tablets
223841526|NCT02109679|DRUG|BI 187004|multiple doses BI 187004 given as tablets
223841527|NCT02109679|DRUG|metformin|multiple doses metformin given as tablet
223841528|NCT05073081|OTHER|Prehab for LSS|The 8-week prehabilitation program will be delivered online by physiotherapists, chiropractors, and kinesiologists through synchronous and asynchronous exercise sessions, along with online educational sessions.
223841529|NCT05073081|OTHER|Usual Care|Participants in the control group will receive usual care as per surgeons' current practice.
223841530|NCT03306615|DRUG|Hyaluronidase|HYLENEX recombinant, diluted with 0.9% Sodium Chloride Injection
223841531|NCT03306615|DRUG|Placebo|0.9% Sodium Chloride Injection
223841532|NCT03682536|DRUG|Luspatercept|Specified dose on specified days
223841533|NCT03682536|DRUG|Epoetin alfa|Specified dose on specified days
223841534|NCT04385342|DRUG|FSH|Controlled ovarian stimulation by FSH followed by HMG versus FSH plus HMG
223841535|NCT04385342|DRUG|HP-hMG|Controlled ovarian stimulation by FSH followed by HMG versus FSH plus HMG
223841536|NCT05786313|PROCEDURE|Centerpiece titanium plate|All indexes were collected from the patients with Centerpiece titanium plate for internal fixation.
223841537|NCT05115955|DRUG|DS group|In DS group, subjects will receive intramuscular single dose of NALDEBAIN® at least 12 hours before surgery.
223841538|NCT05115955|DRUG|Control group|In Control group, subjects will receive intramuscular 2 ml sesame oil at least 12 hours before surgery.
223841539|NCT01269853|DRUG|Bevacizumab|"Experimental portion of this proposal:~This trial will have two experimental arms that will be open labeled and non-randomized.~ARM 1 (If the patient has multifocal disease or leptomeningeal disease)~Day 0: Intraarterial Bevacizumab single dose (15mg/kg) after Mannitol to open the blood brain barrier Day 28: Intravenous Bevacizumab (10mg/kg) every two weeks thereafter until disease progression on MRI scan.~If progression occurs, repeat Intraarterial Bevacizumab single dose (15mg/kg) to area of progression and wait 28 days and then restart Intravenous Bevacizumab (10mg/kg) every two weeks thereafter until progression on MRI scan.~Repeat Cycle"
223841540|NCT01269853|DRUG|Bevacizumab|"ARM 2 (If the patient has no multifocal disease or leptomeningeal disease)~Day 0: Intraarterial Bevacizumab single dose (15mg/kg) after Mannitol to open the blood brain barrier Day 28: No biweekly IV Bevacizumab treatment~If MRI shows progression then repeat Intraarterial Bevacizumab single dose (15mg/kg) to area of progression Repeat Cycle"
223841541|NCT03903835|DRUG|Enzalutamide Oral Capsule|Detailed conditions for the use of the study treatments including dose and dosages are described in accordance with the marketing authorization in the SmPC (Summary of Product Characteristics).
223841542|NCT03903835|DRUG|Abiraterone Oral Tablet|Detailed conditions for the use of the study treatment including dose and dosages are described in accordance with the marketing authorisation in the SmPC.
223841543|NCT03903835|DRUG|Carboplatin|Carboplatin will be administered every 3rd week with an AUC (area under curve) = 5 with a dose calculated according to the Carboplatin AUC Dose calculation (Calvert formula):Dose (mg) = TargetAUC (mg/ml x min) x \[GFR ml/min + 25\].
223841544|NCT03903835|DRUG|Cabazitaxel 60 mg Solution for Injection|Detailed conditions for the use of the study treatment including dose and dosages are described in accordance with the marketing authorisation in the SmPC.
223841545|NCT03903835|DRUG|Docetaxel Injectable Solution|Detailed conditions for the use of the study treatment including dose and dosages are described in accordance with the marketing authorisation in the SmPC.
223841546|NCT03903835|DRUG|Radium Chloride Ra-223|Detailed conditions for the use of the study treatment including dose and dosages are described in accordance with the marketing authorisation in the SmPC.
223841547|NCT03903835|DRUG|Niraparib plus Abiraterone acetate plus Prednisone|Niraparib and Abiraterone acetate will be provided by Janssen and will be provided either as a fixed dose combination or as single agents. Detailed use of the study treatment including dose and dosages are described in the Investigator's brochures and SmPC.
223841548|NCT03903835|DRUG|Capivasertib plus Docetaxel|Capivasertib is provided by AstraZeneca and will be given in combination with Docetaxel. All subjects will be given up to ten 21-day docetaxel cycles. All subjects will receive Capivasertib, which will be administered as tablets taken twice a day orally, on a 4 days on/3 days off continuous schedule, commencing cycle one, day 2, until disease progression.
223841549|NCT03903835|DRUG|Apalutamide|Detailed conditions for the use of the study treatments including dose and dosages are described in accordance with the marketing authorization in the SmPC (Summary of Product Characteristics).
223841550|NCT03903835|DRUG|Darolutamide|Detailed conditions for the use of the study treatments including dose and dosages are described in accordance with the marketing authorization in the SmPC (Summary of Product Characteristics).
223841551|NCT06629025|DIAGNOSTIC_TEST|High-resolution impedance manometry|High-resolution impedance manometry (HRIM) can calculate the bolus motion parameters and the ratio of complete esophageal transit
223841552|NCT05370768|BEHAVIORAL|Parenting Mindfully Intervention|Includes meditation and using meditation and mindfulness in everyday life and in parenting interactions.
223841553|NCT04952987|DRUG|Diquafosol|Diquafosol (Diquas) is a P2Y2 receptor agonist which improves mucin and tear secretion
223841554|NCT05144802|PROCEDURE|acute hypoxia|Participants will be exposed to a 3-hour acute hypoxia
223841555|NCT02057380|DRUG|linsitinib|oral
223841556|NCT02057380|DRUG|erlotinib|oral
223841557|NCT02057380|DRUG|paclitaxel|Intravenous (IV) infusion
223841558|NCT02057380|DRUG|Bortezomib|Subcutaneous or IV
223841559|NCT02057380|DRUG|Dexamethasone|IV, Oral
223841560|NCT03852615|DIAGNOSTIC_TEST|Pre operation Blood sample for AMH|Blood sample for Anti Mullarian Hormone (AMH) analysis will be taken during preparation for surgery, while inserting vein line and taking the customary blood samples.
223841561|NCT03852615|DIAGNOSTIC_TEST|3 month post operation blood sample for AMH|Additional blood sampling that will include a single tube containing 3 cc of blood for analysis of AMH will be taken three month from operation.
223841562|NCT06345872|BEHAVIORAL|CBT-I|Includes 8 weekly sessions of CBT-I and 2 bi-monthly boosters. Each session is to be completed individually by the participant in a single sitting (less than 45 mins). Each session should be completed in 7 days with next session released only after prior one completed.
223841563|NCT06345872|BEHAVIORAL|Treatment as usual|Includes 8 weekly sessions of standard treatment and 2 bi-monthly boosters. Each session is to be completed individually by the participant in a single sitting (less than 45 mins). Each session should be completed in 7 days with next session released only after prior one completed.
223841564|NCT06345872|OTHER|Tapered Withdrawal|Individualized gradual tapered withdrawal following CDC guidelines, additional check-ins and motivational interviewing with a therapist.
223841565|NCT01912326|DEVICE|Pacemaker Implantation|Implantation of a dual chamber pacemaker
223841566|NCT04607252|DRUG|Metformin plus Megestrol acetate|metformin 1500mg, per day, oral; megestrol acetate 160mg per day, oral
223841567|NCT04607252|DRUG|Megestrol Acetate|megestrol acetate 160mg per day, oral
223841568|NCT03008122|OTHER|Placebo|Placebo
223841569|NCT03008122|BIOLOGICAL|Zika Virus Purified Inactivated Vaccine (ZPIV)|Zika Virus Purified Inactivated Vaccine with aluminum hydroxide adjuvant.
223841570|NCT04872062|DEVICE|NIV cards|Reading the data available on the NIV cards
223841571|NCT04872062|OTHER|Medical file|Using the data available in the medical file including clinical data, blood gas results, nocturnal oximetry results
223841572|NCT02338609|DRUG|Everolimus|At the discretion of the investigator, pediatric patients could be treated with commercially available everolimus, as per local product information / standard of care. Treatment duration and dose modifications were at the investigator's discretion, as per the local product information.
223841573|NCT02655653|DRUG|Epsilon-aminocaproic acid administered|Following anesthetic induction, Epsilon-aminocaproic acid was administered as a bolus loading dose of 150 mg/ kg followed by a maintenance infusion of 15 mg/ kg /hr. Maintenance infusion of both drugs was discontinued when the patient arrived in the cardiac surgical intensive care unit. In addition to routine blood sampling ( standard of care in our hospital), patients had thromboelastogram(TEG) and D-dimer levels drawn at the following time points: post incision but prior to initial antifibrinolytic load, immediately following the antifibrinolytic loading dose, and post-protamine reversal of heparin.
223841574|NCT02655653|DRUG|Tranexamic Acid administered|Following anesthetic induction, Tranexamic Acid was administered as a bolus dose of 30 mg /kg followed by a 16 mg/ kg/hour maintenance infusion. Maintenance infusion of both drugs was discontinued when the patient arrived in the cardiac surgical intensive care unit. In addition to routine blood sampling ( standard of care in our hospital), patients had thromboelastogram(TEG) and D-dimer levels drawn at the following time points: post incision but prior to initial antifibrinolytic load, immediately following the antifibrinolytic loading dose, and post-protamine reversal of heparin.
223841575|NCT04460079|DRUG|Peg-filgrastim|PegaGen® was injected as a single subcutaneous dose after completion of cytotoxic chemotherapy
223841576|NCT05138536|PROCEDURE|Pan-Computer Tomography|trauma centers use the pan-computed tomography (CT) scan (head, neck, chest, and abdomen/pelvis) for the evaluation of blunt trauma.
223841577|NCT05349136|OTHER|Synchronous telerehabilitation group|This group will receive Action Observation Treatment with a synchronous telerehabilitation method. Children in this group will be applied Action Observation Treatment 5 days a week for 3 weeks, for a total of 15 sessions under the supervision of a physiotherapist via videoconferencing.
223841578|NCT05349136|OTHER|Asynchronous telerehabilitation group|This group will receive Action Observation Treatment with an asynchronous telerehabilitation method. Children in this group will be applied Action Observation Treatment 5 days a week for 3 weeks, for a total of 15 sessions under parental supervision.
223841579|NCT05604235|OTHER|Therapeutic upper limb strength exercise treatment|A treatment with therapeutic strength exercises, twice a week, for two months, with a total of 10 exercises, with 20 repetitions each, aimed at improving the strength of the trapezius and sternocleidomastoid muscles mainly, as well as improving mobility in flexion, abduction and rotation of the affected upper limb. It will take approximately 30 minutes.
223841580|NCT05604235|OTHER|Treatment with passive and active mobilization of the upper limb.|A treatment with passive kinesitherapy, where the physiotherapist will perform the movements of flexion, abduction and rotation of the shoulder, without the patient's intervention; active kinesitherapy, where the patient will perform specifically prescribed movements, without weight, to improve the articular and muscular balance of the scapulo-humeral complex and neurodynamics, where mobilizations of the accessory spinal nerve will be performed through therapeutic exercise and manual neurodynamic therapy. This treatment will be carried out once a week for two months in 30-minute sessions.
223841581|NCT05970731|DRUG|Beclomethasone|84 mcg of Beclomethasone administered topically on an intranasal microsponge, placed in the olfactory cleft using a nasal endoscope, on day 1 and repeated on day 14.
223841582|NCT05970731|OTHER|Placebo|Placebo (0.9% sodium chloride) administered topically on an intranasal microsponge, placed in the olfactory cleft using a nasal endoscope, on day 1 and repeated on day 14.
223841583|NCT05970731|DEVICE|Microsponge|Drug delivery using chitosan-based biocompatible microsponge
223841584|NCT04940546|DRUG|Sintilimab|Mode of administration: Intravenously
223841585|NCT04940546|DRUG|Oxaliplatin|Mode of administration: Intravenously
223841586|NCT04940546|DRUG|Capecitabine|Mode of administration: Orally
223841587|NCT04940546|DRUG|Bevacizumab|Mode of administration: Intravenously
223841588|NCT06442189|DIETARY_SUPPLEMENT|Mediterranean Diet|The aim was to evaluate the effects of the application of a Mediterranean diet on the reproductive and metabolic parameters in the 3rd month of patients with a body mass index of 25 and more who were treated in our clinic due to a diagnosis of PCOS.
223841589|NCT04685733|DEVICE|Non-invasive hemodynamic measurements|Non-invasive hemodynamic measurements
223841590|NCT06352268|PROCEDURE|Pallidal, subthalamic or thalamic lesioning|Radiofrequency, ultrasound guided or other lesioning procedures of the Globus pallidus interna, subthalamic nucleus or Vim nucleus of the thalamus for the management of Movement disorders
223841591|NCT04616118|OTHER|Phone Visit|Participants randomized to this arm will receive usual care via telephone only
223841592|NCT04616118|OTHER|Video Visit|Participants randomized to this arm will receive usual care via video call
223841593|NCT01907152|OTHER|Protein enriched yoghurt drink and bread|
223841594|NCT03157102|DEVICE|HFNC|"Oxygen therapy will be delivered through high flow nasal cannulas. Aerosol treatments will be administered through a vibrating mesh nebulizer directly connected to the circuit (aerogen®). The airvo® system (Fisher \& Peykel Healthcare, Auckland, New Zealand) will be used as the high flow cannula system in the study. Cannula size will be tailored to the child according to the manufacturer's recommendations. The gas flow will be adjusted according to the child's weight in a predefined chart. FiO2 will be adjusted to allow for a SpO2 \>92%.~All the patients, regardless of their treatment failure status, will be evaluated at H2, H6, H12 and H24 to monitor their evolution (evaluation of the standard parameters, consciousness, PRAM (Pediatric Respiratory Assessment Measure) score, pain assessment by the FLACC (Face Legs Activity Cry Consolability) score). ."
223841595|NCT03157102|DEVICE|Standard Oxygen Treatment|"Children will receive supplemental oxygen as commonly delivered through a non-rebreather face mask or low flow nasal cannula (standard oxygen treatment) and beta2 agonist aerosol via vibrating mesh nebulizer (aerogen®) according to the procedures usually used in the unit and according to the GINA (Global Initiative for Asthma) protocol. This group is the standard treatment group and is therefore the control group.~All the patients, regardless of their treatment failure status, will be evaluated at H2, H6, H12 and H24 to monitor their evolution (evaluation of the standard parameters, consciousness, PRAM score, pain assessment by the FLACC score). The use of adjuvant therapies (magnesium sulfate, salbutamol IVSE, and ipratropium bromide) will remain at the discretion of the physician in charge of the child and will be evaluated as a secondary criterion."
223841596|NCT06157775|DIAGNOSTIC_TEST|Shear-wave elastography|Shear-wave elastography using a manual ultrasound with a 9L-Probe in B-mode.
223841597|NCT01766583|DRUG|CC-292 + lenalidomide|CC-292 + lenalidomide
223841598|NCT02234310|BIOLOGICAL|rFIXFc|Adjustments to the dose and interval of rFIXFc was made in this study based on investigator discretion using available pharmacokinetic (PK) data, subsequent FIX trough and peak levels, level of physical activity, and bleeding pattern, in accordance with local standards of care for a prophylactic regimen. There was an option to start study dosing as episodic treatment (on-demand).
223841599|NCT06077825|OTHER|postoperative rehabilitation|30 patients took postoperative rehabilitation after total hip arthroplasty surgery, 3 times a week, for 6 weeks. They took conventional rehabilitation (hip range of motion exercises, progressive strengthening exercises for hip and knee muscles, balance and proprioceptive exercises and gait training).
223841600|NCT05051787|BIOLOGICAL|Blood and milk samples|"2 types of samples will be taken over the same time slots in breastfeeding mothers treated with amoxicillin for at least 2 days:~* 3 breast milk collections of about 20 ml each made using an electric breast pump provided to the participant.~* 3 blood samples of approximately 5 ml each."
223841601|NCT02490384|PROCEDURE|Physical exam indicated cerclage|Cervical cerclage
223841602|NCT06162819|DRUG|Amitriptyline|Amitriptyline will be used for prophylaxis of migraine, also used as antidepressant
223841603|NCT06162819|DRUG|Flunarizine 5mg|Flunarizine will be used for prophylaxis of migraine,
223841604|NCT00931138|DRUG|chemotherapy (Aracytine + Daunorubicin)|Aracytine : 200 mg/m2 d1-d7 Daunorubicin : 80 mg/m2 d1-d3
223841605|NCT00931138|DRUG|chemotherapy (Aracytine + Daunorubicin)|Aracytine : 200 mg/m2 d1-d7 Idarubicin :12 mg/m2 d1-d3
223841606|NCT00931138|DRUG|chemotherapy (Aracytine + Daunorubicin)|Aracytine : 200 mg/m2 d1-d7 Idarubicin : 12 mg/m2 d1-d4
223841607|NCT05256303|OTHER|Home Hospital care|Patients receive hospital-level care in their home
223841608|NCT05256303|OTHER|Traditional Hospital care|Patients receive hospital-level care in the hospital.
223841609|NCT03298815|BIOLOGICAL|Amniotic Fluid Eye Drops (AFED)|One drop (0.25 mL) in one eye twice daily for up to 3 months
223841610|NCT03298815|OTHER|Saline Solution|One drop (0.25 mL) in the other eye twice daily for up to 3 months
223841611|NCT03251378|DRUG|Fruquintinib (HMPL-013)|Fruquintinib is a small molecule tyrosine kinase inhibitor (TKI) that targets VEGFR-1, -2, and -3, with a novel chemical structure which belongs to the quinazoline class.
223841612|NCT03083743|BIOLOGICAL|Recombinant human Apo-2 ligand for Injection|150μg/kg/d IV (in the vein), on day 1 to 7 of each 21 day cycle
223841613|NCT03083743|BIOLOGICAL|Placebo|150μg/kg/d IV (in the vein), on day 1 to 7 of each 21 day cycle
223841614|NCT05765110|OTHER|Dopaminergic OFF drug state|Experiment will be performed without dopaminergic medication
223841615|NCT05765110|OTHER|DBS OFF state|Turning off the stimulation during experiment
223841616|NCT05765110|OTHER|Dopaminergic ON drug state|Experiment will be performed with dopaminergic medication
223841617|NCT05765110|OTHER|DBS ON state|Experiment will be performed with stimulation (ON condition)
223841618|NCT06851156|DEVICE|tTIS|CM-pf tTIS
223841619|NCT06160921|OTHER|Standard therapy|Individualized blood pressure reduction program
223841620|NCT04060680|DEVICE|Defibrillation using the Extravascular ICD|VT/VF induction attempted for defibrillation testing, as well as requisite electrical testing.
223841621|NCT06662448|DEVICE|SAVIR Alpha Synch mobile (SASm)|The SAVIR Alpha Synch mobile is a device first used in office and then intended to be used for the home therapy of the visual system with non-invasive electrical stimulation.
223841622|NCT00935792|DRUG|alemtuzumab|Given subcutaneously
223841623|NCT00935792|DRUG|everolimus|Given orally
223841624|NCT02322775|BIOLOGICAL|Benralizumab|Benralizumab administered subcutaneously every 4 weeks
223841625|NCT02322775|BIOLOGICAL|Placebo|Placebo administered subcutaneously every 4 weeks
223841626|NCT02956967|OTHER|Overall satisfaction questionnaires of home use of Nivestim|
223841627|NCT01273532|DRUG|tapentadol (CG5503) ER 100-mg TRF|100mg TRF single oral dose
223841628|NCT01273532|DRUG|tapentadol (CG5503) ER 50-mg TRF|100 mg TRF single oral dose
223841629|NCT02076867|BEHAVIORAL|Intensive Short-Term Dynamic Psychotherapy|The ISTDP model is an emotion focused brief format of psychotherapy that helps the patients identify and address emotional factors that culminate into exacerbation and perpetuation of somatic symptoms. Treatment will be provided according to manualized recommendations. The emphasis is on awareness of emotions and how they affect the person's behavioral patterns and somatic presentation. The research protocol calls for the treatment duration to be initially agreed at 8 weeks and then reviewed. Treatment should be delivered as a maximum 20-session time-limited format. The first session is an extended 2-3 hour appointment; then sessions are planned to occur on a weekly basis lasting 60 minutes in duration. Treatment progress is reviewed, specifically at sessions 4 and 8 to clarify the goal and objectives of further sessions. Patients are informed of the maximum treatment length. Termination in fewer sessions is based upon agreement between therapist and patient.
223841630|NCT02076867|BEHAVIORAL|Medical Care As Usual (MCAU)|This Medical Care As Usual (MCAU) was selected to control for both the role of emergency department care and family doctors care, as well as the passage of time and the natural emergence and reduction in symptoms before further intervention. Participants allocated to this group are advised that care will continue to be provided to them by the ED and they will be contacted with an appointment to see a therapist in 8 weeks should they so wish. They are advised to contact their family physician for routine care where necessary
223841631|NCT05553158|DEVICE|Compression pants|Similar to compression stockings for the legs which are designed to apply pressure to improve venous return in the legs, compression pants have been designed to apply pressure to pelvic veins to improve the symptoms of Pelvic Congestion Syndrome.
223841632|NCT05553158|DEVICE|Embolization coils|Embolization coils are used to block the veins they are positioned in. This is a standard treatment offered to patients at The Whiteley Clinic.
223841633|NCT00870025|BIOLOGICAL|human chorionic gonadotropin|200 IU, sc, every 5 days, 4 doses
223841634|NCT00870025|BIOLOGICAL|placebo|diluent, every 5 days, s.c., 4 doses
223841635|NCT05581797|OTHER|Psilocybin-assisted psychotherapy|8 sessions of interpersonal therapy and 2 doses of psilocybin
223841636|NCT05802550|OTHER|Ocular Surface Disease Index|Questionnaire on ocular surface disorders
223841637|NCT05802550|OTHER|Interferometry|Non-contact examination measuring NIBUT (non-invasive break-up time), meibography and tear meniscus measurement
223841638|NCT05802550|OTHER|Oxford score|Investigation and quantification of superficial corneal punctate keratitis using the Oxford score
223841639|NCT05802550|OTHER|Conjunctival collection|Two conjunctival prints: one for metabolomic and one for lipidomic
223841640|NCT05802550|OTHER|Aqueous humor collection|Collection of 0.1 mL of aqueous humor immediately after making the accessory corneal incision at the beginning of the cataract surgery.
223841641|NCT05802550|OTHER|Quantification of Tyndall and flare|Quantification of Tyndall and flare (from 1 to 4 crosses) in anterior chamber
223841642|NCT00796536|BEHAVIORAL|Group cognitive behavioral therapy|Each CBT session will last for 90 minutes and will teach participants specific skills to better cope with chronic pain. These skills will include breathing exercises, distraction, and relaxation techniques.
223841643|NCT00796536|BEHAVIORAL|Pain education|Patients will receive mailed educational materials to their homes on a weekly basis. Weekly materials will contain information about the nature of chronic back pain, treatment options, exercises and stretching techniques for maintaining strength and flexibility, and proper protection for a healthy back. Pain education is the standard of care for most outpatient clinics.
223841644|NCT06306430|DEVICE|STANDARDTM F TB LAM FIA|STANDARDTM F TB LAM Ag FIA is a fluorescent immunoassay for the qualitative detection of specific antigen from mycobacterial lipoarabinomannan (LAM) in urine specimen. STANDARDTM F TB LAM Ag FIA should be used with the STANDARD F Analyzers manufactured by SD BIOSENSOR.
223841645|NCT04739423|DRUG|clenbuterol (CST-103), nadolol (CST-107), matching placebo|clenbuterol (CST-103) and matching placebo orange capsules; nadolol (CST-107) and matching placebo white capsules
223841646|NCT02538679|OTHER|Placebo|The usual intraoperative and postoperative pain control; NO TAP block performed
223841647|NCT02538679|DRUG|US TAP Bupivacaine/Epinephrine|Ultrasound guided bupivacaine 0.25% with epinephrine 1:400k will be injected to the transversus abdominis plane.
223841648|NCT02538679|DRUG|Lap TAP Bupivacaine/Epinephrine|Laparoscopic guided bupivacaine 0.25% with epinephrine 1:400k will be injected to the transversus abdominis plane.
223841649|NCT02006303|PROCEDURE|Green light PVP|The green light laser has a wavelength of 532 nm which is strongly absorbed by red tissues and hemoglobin; this renders a blood rich organ such as the prostate gland to be an excellent target. The procedure uses the technology of high-powered laser light combined with fiber optics to vaporize the overgrowth of prostate cells quickly and accurately. As the surgeon directs the laser at the prostate, the intense pulses of light emitted from the fiber are absorbed by the blood. Within moments, the temperature of the blood becomes so great it causes the nearby cells to vaporize. Once the procedure is completed, patients have immediate post-operative symptom relief and dramatic improvements in symptoms, urinary flow rates, and bladder emptying.
223841650|NCT02006303|PROCEDURE|Prostatic artery embolization|Prostatic artery embolization consists of gaining access into the patients arterial system via a common femoral artery puncture using a small needle and sheath. Once the access is established, a micro-catheter is navigated through the arterial system using X-ray guidance into the arteries feeding the prostate. There, small polyvynil alcohol plastic beads are injected to block the blood flow to the prostate. By doing so, the prostate undergoes an ischemic injury and there is reduction in gland size and relief of obstructive symtpoms.
223841651|NCT01691443|PROCEDURE|pressure sensor and wrist shaker, not marked CE, developped by Texisense|
223841652|NCT02556723|DRUG|Intravitreal injections of ziv-aflibercept|All subjects will receive intravitreal injections of ziv-aflibercept under sterile conditions at baseline, 4 weeks, 8 weeks, 12 weeks, 16 weeks, and 20 weeks. No topical or systemic antibiotics will be prescribed (pre- injection or postinjection).
223841653|NCT00294996|DRUG|Myocet|
223841654|NCT00881010|BEHAVIORAL|Telephone Intervention|Automated Telephone Interactive Voice Response (IVR) system taking approximately 5 minutes, 2 times week for 10 weeks, to rate pain and symptoms.
223841655|NCT00881010|BEHAVIORAL|Questionnaires|Surveys approximately 1 hour each at 2 regularly scheduled clinic visits to rate pain and symptoms. Regardless of group, all symptoms are to be reported.
223841656|NCT02209207|DEVICE|Treadmill|
223841657|NCT02209207|OTHER|walking training|
223841658|NCT01682707|PROCEDURE|laryngoscopy|tracheal intubation with two different techniques, track light and laryngoscopy.
223841659|NCT01682707|PROCEDURE|track light|
223841660|NCT04482855|DEVICE|Low-level laser|Low-level laser therapy
223841661|NCT05157204|PROCEDURE|measurment of interleukin-6 at exhaled condensate|the breath condensate samples were collected using a specially designed condensing chamber ( Ecoscreen; Jaeger, Hoechberg, Germany) to measure the interleukin-6 at exhaled condensate of 60 participants
223841662|NCT00899002|GENETIC|comparative genomic hybridization|
223841663|NCT00899002|GENETIC|molecular genetic technique|
223841664|NCT00899002|GENETIC|mutation analysis|
223841665|NCT00899002|GENETIC|polymerase chain reaction|Not noted
223841666|NCT00899002|GENETIC|proteomic profiling|
223841667|NCT00899002|OTHER|immunohistochemistry staining method|not noted
223841668|NCT00899002|OTHER|laboratory biomarker analysis|not noted
223841669|NCT00899002|OTHER|mass spectrometry|not noted
223841670|NCT00899002|OTHER|medical chart review|not noted
223841671|NCT00236028|DRUG|Infliximab|
223841672|NCT01373853|PROCEDURE|Lens Fragmentation by means of a femtosecondlaser|In Group A the anterior capsulotomy and a pre-fragmentation of the ocular lens will be performed by means of femtosecond laser surgery.
223841673|NCT01373853|PROCEDURE|Manual Phacoemulsification|Group B acts as a control group where the capsulotomy and lens fragmentation are performed manually
223841674|NCT05976594|DIAGNOSTIC_TEST|serology and virology detection of hepatitis E virus|Serum will be tested for HEV serology and virology, including HEV-IgM, HEV-IgG, HEV-antigen, and HEV-RNA for HEV species A (HEV-A) and HEV species C (HEV-C)，and further HEV genotyping for those positive for HEV-RNA.
223841675|NCT05781490|DRUG|Lumentin® 44 Powder for oral foam|Lumentin® 44 is a foam for oral use.
223841676|NCT01521143|BIOLOGICAL|Cvac|Injections were done at 4 anatomical sites, 1 injection in each of the upper portions of both arms and both thighs.
223841677|NCT01521143|BIOLOGICAL|Placebo|"Injections were done at 4 anatomical sites, 1 injection in each of the upper portions of both arms and both thighs.~Placebo consisted of the Cvac formulation buffer (5% HSA, 10% DMSO) with 0.9% simethicone provided in 1 mL vials that had been cryopreserved and stored at the manufacturing facility."
223841678|NCT01593735|DRUG|MK-2748|MK-2748 tablets, orally, once daily for 7 days, dose level dependent on Panel assignment
223841679|NCT01593735|DRUG|Placebo|Placebo tablets, orally, once daily for 7 days
223841680|NCT02851043|DEVICE|pneuRIP (breathing with resistance)|subjects are given a resistance element to breath through
223841681|NCT02851043|DEVICE|Respitrace system (Carefusion) (breathing without resistance)|subjects are asked to breath normally
223841682|NCT01714089|DRUG|RNS60 125 ml|
223841683|NCT01714089|DRUG|RNS60 250 ml|
223841684|NCT01714089|DRUG|Interferon beta 1a|
223841685|NCT01140659|PROCEDURE|Video-assisted sympathectomy|All participants were randomized into two groups of 20 patients (G3 and G4) and underwent video-assisted sympathectomy, being followed for 12 months. During this period, the subjects completed a questionnaire about quality of life and carried out the measurements of sweat by VapoMeter.
223841686|NCT05395572|DEVICE|Kinesio® Tape|In order to increase the activity of underactive muscles, the tape is applied from origin to insertion with a 15-25% tension. The Kinesio® Tape mechanical muscle correction will be performed with one Y-strip of Kinesio® Tape over the bilateral cervical multifidus and semispinalis cervicis muscles, while also including portions of other cervical extensor muscles (the semispinalis capitis, splenius cervicis, levator scapulae, upper trapezius, longus coli, and splenius capitis).
223841687|NCT05029856|BIOLOGICAL|SII B.1.351|"Intramuscular (deltoid) injections of 3 μg SII B.1.351 and 50 μg Matrix-M1 Adjuvant,~1 or 2 doses:1 on Day 0 and ± 1 on Day 21."
223841688|NCT05029856|BIOLOGICAL|SII B.1.351|"Intramuscular (deltoid) injections of 5 μg SII B.1.351 and 50 μg Matrix-M1 Adjuvant,~1 or 2 doses:1 on Day 0 and ± 1 on Day 21."
223841689|NCT05029856|BIOLOGICAL|SII Bivalent|Intramuscular (deltoid) injections of 6 μg SII Bivalent and 50 μg Matrix-M1 Adjuvant, 2 doses: 1 on Day 0 and 1 on Day 21.
223841690|NCT05029856|BIOLOGICAL|SII Bivalent|Intramuscular (deltoid) injections of 10 μg SII Bivalent and 50 μg Matrix-M1 Adjuvant, 2 doses: 1 on Day 0 and 1 on Day 21.
223841691|NCT05029856|BIOLOGICAL|SII B.1.617.2|"Intramuscular (deltoid) injections of 5 μg SII B.1.617.2 and 50 μg Matrix-M1 Adjuvant,~1 or 2 doses:1 on Day 0 and ± 1 on Day 21."
223841692|NCT03212365|DRUG|Fixed dose|Participants will receive 40 mg enoxaparin twice daily
223841693|NCT03212365|DRUG|Variable dose|Participants will receive 0.5mg/kg enoxaparin twice daily
223841694|NCT02507219|DRUG|Ibuprofen|On the day of sessions 2-4, subjects will receive either placebo, 200 mg of ibuprofen or 600 mg of ibuprofen after signing the consent form for this study in a randomized, double-blind, counter balanced order. Each study session will occur 1-2 weeks following the previous session. Ibuprofen will be capsuled, and identical placebo capsules will be produced.
223841695|NCT06481930|DIAGNOSTIC_TEST|Detection of Cervical Lesions by Fluorescence Photoelectric Image|The enrolled patients underwent fluorescence photoelectric cervical lesion image detection, followed by colposcopy and biopsy to obtain histopathological results. The results of fluorescence photoelectric image detection were compared with histopathological results, and at the same time compared with HPV and TCT results at the time of enrollment.
223841696|NCT02036060|DRUG|docetaxel 75 mg/m2 + prednisone 10 mg/d + abiraterone 1000 mg/d|Docetaxel 75 mg/m2 + prednisone 10 mg/d + abiraterone 1000 mg/d in 21 day cycles.
223841697|NCT02036060|DRUG|docetaxel 75 mg/m2 + prednisone 10 mg/d|Docetaxel 75 mg/m2 plus prednisone 10 mg/d in 21 day cycles.
223841698|NCT02434952|DRUG|Dihydroartemisinin piperaquine (DHA PP)|
223841699|NCT02434952|DRUG|Primaquine|
223841700|NCT04921605|DEVICE|DragonFly transcatheter mitral valve clamping system|To conduct edge-to-edge repair with Dragonfly System under the guidance of transesophageal echocardiography.
223841701|NCT05162118|DRUG|Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell)) in combination with Nivolumab|Intratumoral injection of VG161 on day 1 only or day 1 through 3, in combination of Nivolumab intravenous injection only, Once every 2 weeks, 3 mg/kg each time.
223841702|NCT03853590|PROCEDURE|Roux-en-Y gastric bypass|Creation of a small pouch from the stomach and connection of the newly created pouch directly to the small intestine so that swallowed food bypasses most of the stomach and the first section of the small intestine.
223841703|NCT03853590|PROCEDURE|Laparoscopic adjustable gastric banding|Placement of a soft silicone ring with an expandable balloon in the center, around the top part of the stomach to create a two-compartment stomach, with a much smaller top part above the band. The subject will eat enough food only to fill the top part of the stomach decreasing caloric consumption.
223841704|NCT02656043|DRUG|XPF-005|Comparison of active treatment XPF-005 topical gel against Placebo (XPF-005 Vehicle Gel) applied to face for acne vulgaris.
223841705|NCT02656043|DRUG|Placebo|
223841706|NCT01443143|OTHER|Portion-controlled diet|During this diet period, participants will consume portion-controlled products from the Nutrisystem-D program for three entrees and one (women) or two (men) snacks per day. These pre-packaged portion-controlled items will be supplemented with grocery additions (fruits, vegetables, and low-fat dairy items) to provide approximately 1300 (women) to 1500 (men) calories per day. The Nutrisystem-D program (i.e., provided foods plus grocery additions) provides approximately 53% of calories from carbohydrate, 22% of calories from fat (6% from saturated fat and 0% from trans fat), and 25% of calories from protein. Women and men on the program consume approximately 1800 and 2000 mg/d, respectively, of sodium, and 31 and 35 g/d, respectively, of fiber.
223841707|NCT01443143|DIETARY_SUPPLEMENT|Usual Diet|"During the usual diet period, participants will not be given any specific instructions about what they should or should not consume. Instead, they will be told to Eat how you would normally eat if you were not in this study."
223841708|NCT01648218|DRUG|Neutral protamine hagedorn (NPH) insulin|
223841709|NCT01648218|DRUG|Regular human insulin or Insulin Aspart|
223841710|NCT01648218|DRUG|Insulin glargine|
223841711|NCT00005982|DRUG|nelarabine|Given IV
223841712|NCT00005982|OTHER|pharmacological study|Correlative studies
223841713|NCT00649129|DRUG|Oxybutynin Chloride ER Tablets 10 mg|2x10mg, single dose fasting
223841714|NCT00649129|DRUG|Ditropan XL® Tablets 10 mg|2x10mg, single dose fasting
223841715|NCT03050294|BEHAVIORAL|Phone calls|Phone calls twice daily
223841716|NCT03050294|DRUG|Desoximetasone 0.25% spray|Desoximetasone 0.25% spray applied twice daily
223841717|NCT00177879|BEHAVIORAL|website comparison|
223841718|NCT04948073|OTHER|Dynamic neuromuscular stabilization approach|The experimental group will follow a DNS exercise protocol based on previous procedure for a whole period of 6 weeks (three 50-min sessions per week) in addition the conventional treatment.
223841719|NCT04948073|OTHER|Conventional treatment|Patients from both groups will receive a conventional 6-week treatment programme (18 treatment sessions, three a week, for 30-40min duration).
223841720|NCT04843319|DRUG|VERU-100|GnRH antagonist
223841721|NCT00819234|DRUG|Placebo|placebo pramlintide and placebo metreleptin twice daily
223841722|NCT00819234|DRUG|Pramlintide and Metreleptin|Subcutaneous injection, twice daily
223841723|NCT01149603|DEVICE|HeartMate II Ventricular Assist Device|The HeartMate II Left Ventricular Assist Device has been approved by the FDA for use in bridge-to-transplant therapy and destination therapy for patients with endstage heart failure.
223841724|NCT03176745|DIAGNOSTIC_TEST|multiple breath washout|determination of lung clearance index using SF6 multiple breath washout
223841725|NCT05392426|DEVICE|Left Ventricular Global Longitudinal Strain|Left Ventricular Global Longitudinal Strain is collected from Speckle tracking imaging (STI) technique of echocardiography. This index is tested before and after the surgery.
223841726|NCT05392426|DEVICE|EF CO SV EDV ESV|Ejection fraction、cardiac output、stroke volume、end diastolic volume、end systolic volume. These indexes are collected before and after the surgery, using traditional echocardiography.
223841727|NCT01156415|DRUG|AGO178|
223841728|NCT01156415|DRUG|AGO178|
223841729|NCT00333515|DRUG|Human Butyrylcholinesterase (HuBChE) derived from human plasma|Administration via IV infusion at a rate of 50 mg/min (2 mL/min)
223841730|NCT00333515|DRUG|Placebo: Normal saline|Administration via IV infusion at a rate of 50 mg/min (2 mL/min)
223841731|NCT00232076|DRUG|ciclosporin|
223841732|NCT05395143|DRUG|Zinc sulfate|Zinc sulfate tablet 30mg once daily orally for 8 weeks along with Atorvastatin.
223841733|NCT05395143|DRUG|Placebo|Placebo tablet 30mg once daily orally for 8 weeks along with Atorvastatin.
223841734|NCT04912557|OTHER|postoperative pain assess|numerical pain scale and Metameric levels of cold insensitivity
223841735|NCT05174065|DRUG|Apremilast|Oral tablets
223841736|NCT05174065|DRUG|Placebo|Oral tablets
223841737|NCT03982940|DEVICE|BGP+ Stent Graft System as bridging stent|BGP+ Stent Graft System as bridging stent
223841738|NCT06357741|DRUG|Denosumab|Desumumab, 60mg single injection
223841739|NCT05314283|DEVICE|DV3395 C1|Participants will be exposed to and swallow DV3395 C1 once. The participants will stay at the clinic research center for up to 6 days .
223841740|NCT00216320|DEVICE|WalkAide|Arm 1 - Subjects wear WalkAide for 6 weeks then cross over to AFO wear for 6 weeks
223841741|NCT00216320|DEVICE|AFO|Arm 2 - Subjects wear AFO for 6 weeks then cross over to WalkAide wear for 6 weeks
223841742|NCT00216320|DEVICE|AFO|Arm 3 - Subjects wear AFO for entire 12 weeks with no crossover
223841743|NCT06218134|BIOLOGICAL|human Wharton's jelly-derived mesenchymal stem cells|human Wharton's jelly-derived mesenchymal stem cells(product name: EN001)
223841744|NCT02710058|BEHAVIORAL|one-time qualitative assessment|The study involves a one-time qualitative assessment to explore key cultural influences on AMBER breast cancer survivors' health behavior. We will focus on self-efficacy in healthcare, coping with breast cancer, social networks of support, and culturally-sensitive support groups. The study investigator will administer questions from the structured interview guide, estimated to take 90 minutes.
223841745|NCT00593320|RADIATION|Stereotactic Radiosurgery|
223841746|NCT05922163|DEVICE|Evidence-based VR simulation|Evidence-based VR simulation videos on BTs for nursing students were developed, including 1) animated blood formation physiology and side effects of BT and 2) 360° BT nursing practice.
223841747|NCT04912141|DRUG|conestat alfa or placebo|"Conestat alfa will be dosed by body weight at 50 U/kg (maximum 4200 U) or 100 U/kg (maximum 8400 U).~Placebo will consist of normal saline (NaCl 0.9%). The interventions will be given to the patients by IV-line."
223841748|NCT01342887|DRUG|cyclosporine|Given IV
223841749|NCT01342887|DRUG|pravastatin sodium|Given PO
223841750|NCT01342887|DRUG|mitoxantrone hydrochloride|Given IV
223841751|NCT01342887|DRUG|etoposide|Given IV
223841752|NCT01342887|PROCEDURE|bone marrow aspiration|Correlative studies
223841753|NCT01015014|DRUG|AN3365|LP, 600 mg vial; reconstituted in Normal Saline
223841754|NCT01015014|DRUG|Placebo|0.9% sodium chloride for injection
223841755|NCT02221323|DRUG|Insulin LISPRO|
223841756|NCT01049061|DRUG|MORAb-003|MORAb-003 is intravenously administered to patients with solid tumor once a week for 4 weeks as 1 cycle in order to investigate dose-limiting toxicity and estimate maximum tolerated dose
223841757|NCT03470285|PROCEDURE|Multiparametric MR imaging (mpMRI)|The main objective of the study is to assess the diagnostic accuracy of mpMRI in small renal tumors. The study characteristics will comply with recommended methods (Quadas, Stard). The population to be included will be representative of patients who would benefit from mpMRI if it is demonstrated to be accurate. In this project, the MR protocol will used the conventional MR sequences either on 1.5 or 3T systems and do not require development. Each center may use their own protocol as long as it includes the mandatory sequences.
223841758|NCT03074110|DEVICE|Isocapnic hyperventilation|Mechanical hyperventilation to enhance elimination of inahalation anesthetics. Administration of a precalculated flow of CO2 according to gender and weight into the inspiratory limb of the breathing circuit in order to avoid hypocapnia.
223841759|NCT05827822|DEVICE|Sober Time ACT|Mental health assessment (regular assessment and reporting feedback), daily clock-in (reporting alcohol use and providing encouragement and reinforcement), mental knowledge base (Tips for the Day based on cognitive behavioral techniques, popular alcohol withdrawal courses, alcohol health education manuals) and self-assistance tools (mindfulness meditation training and emergency help buttons)
223841760|NCT02100618|PROCEDURE|Blood sampling|Blood samples will be collected from all subjects at Year 6.5
223841761|NCT00209274|DEVICE|Percutaneous mitral valve repair using MitraClip implant|MitraClip Implant
223841762|NCT00209274|PROCEDURE|Mitral valve repair or replacement surgery|Repair or replacement of mitral valve
223841763|NCT04997967|DRUG|Ketamine/Propofol|The level of sedation was assessed at 1-3 min intervals, and the infusion rate was adjusted accordingly to achieve a Ramsay Sedation Scale (RSS) score of 5. Any movement of the patient was treated by increasing infusion rate and the infusion was discontinued at the end of the procedure. The total propofol consumed was calculated and the recovery time was recorded and calculated as the time from discontinuation of infusion of the study drug till achievement of RSS score of 3. Then patients were discharged to post-anesthesia care unit (PACU) after attaining an Aldrete Recovery Scale Score of 9- 10 \[19\]. Time taken to achieve this score was also recorded.
223841764|NCT04997967|DRUG|Propofol|Sedation was initially started by bolus dose of 0.5 mg/kg propofol IV over 3 minutes then, infusion was started at the rate of 50 µg /kg/min till RSS score of 5.
223841765|NCT02753530|DRUG|Arimoclomol|2 capsules (2 x 124 mg arimoclomol base; equivalent to 2 x 200 mg arimoclomol citrate) taken 3 times daily during breakfast, early afternoon, and at bedtime
223841766|NCT02753530|OTHER|Placebo|2 matched placebo capsules taken 3 times daily during breakfast, early afternoon, and at bedtime
223841767|NCT02517333|OTHER|EPIC Club|Weekly exercise gym sessions (1-2 times weekly) for 45-60 mins each session. Participants will start with a warm-up of 30 mins cardiovascular training either doing cycling, treadmill running or cross-training. The remainder of the session consists of strength/resistance and weight-training involving leg press, leg extensor, pull downs, kettle bells, dumbbells. Gym sessions aim to involve bursts of high-intensity and monitoring of heart rate (potentially with wrist activity monitors with heart rate monitoring and accelerometers) to identify level of physical activity intensity. Participants will also have the opportunity to engage in 'Have a go' sports days run by the Oxfordshire Sports Partnership.
223841768|NCT05229874|DRUG|carbon nanoparticles|Endoscopic injection
223841769|NCT05229874|DRUG|Indocyanine green|Endoscopic injection
223841770|NCT01797796|DRUG|PF-06305591|150 mg PF 06305591 will be administered to subjects as a 100 mL extemporaneous prepared oral solution once.
223841771|NCT01797796|OTHER|Capsaicin challenge|110 mg capsaicin cream (Axsain®) will be applied topically at each visit.
223841772|NCT01797796|DRUG|Placebo|Placebo will be administered to subjects as a 100 mL extemporaneous prepared oral solution once.
223841773|NCT01797796|OTHER|Capsaicin challenge|110 mg capsaicin cream (Axsain®) will be applied topically at each visit.
223841774|NCT06145022|BEHAVIORAL|lifestyle modification|The group intervention is carried out once a week for 10 weeks for a total of 60 hours with elements of mindfulness-based stress reduction (MBSR) and mind / body medicine. In this project, this program will be adapted to the specific needs of irritable bowel syndrome patients.
223841775|NCT06145022|BEHAVIORAL|waitlist control group|Participants in this group receive a one-time education unit within the scope of 1,5 hours on the influence of lifestyle factors on the disease, also self-help materials for independent training offered. Following the follow-up measure also this group is given the opportunity to participate in the multimodal stress reduction- and lifestyle modification program.
223841776|NCT02344303|DRUG|TRV130|
223841777|NCT02344303|DRUG|Moxifloxacin|
223841778|NCT02344303|DRUG|Placebo|
223841779|NCT03323151|DRUG|Ixazomib|Ixazomib 3 mg by mouth on days 1, 8 and 15 by mouth days 1-28 of a 28 day cycle. Dose may be escalated (Ixazomib 4 mg) dependent on dose-limiting toxicities. Note: Ixazomib dose will not be de-escalated but remain at 3 mg.
223841780|NCT03323151|DRUG|Ixazomib|Ixazomib 4 mg by mouth on days 1, 8 and 15 of a 28 day cycle until progression or unacceptable toxicity.
223841781|NCT03323151|DRUG|Ibrutinib|Ibrutinib 560 mg by mouth days 1-28 of a 28 day cycle. Dose may be de-escalated (Ibrutinib 420 mg) or escalated (Ibrutinib 560 mg) dependent on dose-limiting toxicities.
223841782|NCT03323151|DRUG|Ibrutinib|Ibrutinib 560 mg by mouth days 1-28 of a 28 day cycle until progression or unacceptable toxicity.
224076050|NCT07143942|BEHAVIORAL|Kinesio Taping|"KT-EDF+I Taping method: flex the knee 60° and apply two mesh Kinesio tape strips with natural tension to the painful area of the patellar tendon. Use a jellyfish-shaped Kinesio tape strip with natural tension to the center of the knee joint, aligning the center hole with the treatment area. Apply a thin KT strip clockwise around the tape strip. Then, stretch the center of an I-type tape strip to 50%-75% tension and apply it horizontally to the painful area of the patellar tendon, covering 1/3 to 1/2 the width of the inferior pole of the patella. Secure the ends without tension., and a Y-shaped muscle tape to apply to the gluteus medius (from the muscle origin to the insertion point).~After KT taping, patients were instructed to maintain the taping for 5 days before replacing it. KT-EDF+I taping intervention was continued for 8 weeks."
223841783|NCT00002735|DRUG|Induction chemotherapy|Cisplatin and 5-Fluorouracil
223841784|NCT00002735|DRUG|cisplatin|Cisplatin 100 mg/m2 IV infusion over 90 minutes Day 1 every 21 days for 2 cycles.
223841785|NCT00002735|DRUG|fluorouracil|5-Fluorouracil 1,000 mg/m2/day continuous IV infusion over 24 hours Days 1 through 5 every 21 days for 2 cycles.
223841786|NCT00002735|RADIATION|low-LET cobalt-60 gamma ray therapy|180 cGy per day, Days 1-5, every week for eight weeks
223841787|NCT02346487|DRUG|LPV/RTV pellets and AZT/3TC or ABC/3TC|"Drug: LPV/r pellets 40/10 mg: orally taken twice a day. Dosage according to patient's weight:~* Between 3 and 5.9kg: 2 capsules twice a day~* Between 6 and 9.9kg: 3 capsules twice a day~* Between 10 and 13.9kg: 4 capsules twice a day~* Between 14 and 19.9kg: 5 capsules twice a day~* Between 20 and 24.9kg: 6 capsules twice a day~Drug: NRTIs (AZT/3TC 60/30mg tablet or ABC/3TC 60/30mg tablet). Dosage according to patient's weight:~* Between 3 and 5.9kg: 1 tablet twice a day~* Between 6 and 9.9kg: 1.5 tablets twice a day~* Between 10 and 13.9kg: 2 tablets twice a day~* Between 14 and 19.9kg: 2.5 tablets twice a day~* Between 20 and 24.9kg: 3 tablets twice a day"
223841788|NCT01667120|DRUG|Ketorolac|Ketorolac 0.5mg/kg IV q8h x 72h.
223841789|NCT01667120|DRUG|placebo|0.9% normal saline 1ml/kg
223841790|NCT05185700|BEHAVIORAL|post covid 19 symtoms|observation
223841791|NCT02663258|DRUG|Pembrolizumab|
223841792|NCT04248075|DEVICE|Electroencephalogram|Electroencephalogram is performed before, during, and 1 day after surgery in elderly patients undergoing spinal anesthesia.
223841793|NCT02914106|OTHER|Observational Study|Patients were diagnosed for AIS by a certified neurologist at the Emergency Room of the Central Military Hospital. Neurological, cognitive and functional status were determined by NIHSS score, Photo test, Pfeiffer mental status score and by modified Rankin score respectively. A sample of venous blood was withdrawn in the early morning (07 to 09 AM) after assessment of neurological and cognitive status.
223841794|NCT04187703|DRUG|5-azacytidine|5-azacytidine 50 mg/m\^2 Day 1 every week ± G-CSF \~5 µg/kg (300µg vs 480µg)
223841795|NCT04187703|DRUG|Decitabine|Decitabine 5 mg/m\^2 Day 4 every week ± G-CSF \~5 µg/kg (300µg vs 480µg)
223841796|NCT05823337|DIETARY_SUPPLEMENT|selenium+ diet|Selenium functions as an active site component of an antioxidant enzyme, glutathione peroxidase, and helps scavenge free radicals.
223841797|NCT05823337|DIETARY_SUPPLEMENT|only diet|diet suitable for pregnancy
223841798|NCT00324714|DRUG|risedronate sodium|
223841799|NCT00324714|OTHER|diagnostic laboratory biomarker analysis|
223841800|NCT06748911|DEVICE|NaviCam Detachable String Capsule|Subjects will swallow the NaviCam capsule with 20 ml water while positioned in the upright position. Once the capsule reaches the gastric cardia, the string will slowly be pulled up to systematically inspect the Z-line and upper, middle, and lower thirds of the esophagus guided by real-time viewing and by moving the capsule solely with the tether. Images will be captured at a rate of 2 frames per second.
223841801|NCT06919549|PROCEDURE|mini anchor|arthroscopic repair of triangular fibrocartilage complex tears using mini anchor
223841802|NCT06918769|DIAGNOSTIC_TEST|Sysmex UF-5000 system|Provide real time bacterial count in urine samples and Gram-staining results. High bacterial count suggests likelihood of active UTI and indicated for antibiotics treatment; while low bacterial count suggests UTI not likely.
223841803|NCT06918769|DRUG|Empirical antibiotics|Empirical antibiotics per local guideline/ investigator's discretion for urinary tract infection
223841804|NCT06917898|DRUG|Spinal Anesthesia with Bupivacaine and Fentanyl|25 mcg Fentanyl 12.5 mg Bupivacaine
223841805|NCT06917898|DRUG|Spinal Anesthesia with Bupivacaine and Midazolam|2 Mg Midazolam 12.5 mg Bupivacaine
223841806|NCT06919484|OTHER|RCexp|patients received different RCexp
223841807|NCT06919978|BEHAVIORAL|The Position to Prevent Pleural Irritation (PPPI)|The Position to Prevent Pleural Irritation (PPPI) was administered once before sleep on the first night of the day the participant arrived at the clinic.
223841808|NCT02861495|DEVICE|Humeral Compression/Distraction (CD) Nail|Surgical fixation of humeral shaft fractures with Humeral Compression/Distraction (CD) Nail implant
223841809|NCT06360601|DRUG|Labetalol Injection|Labetalol intravenous infusion 20ml/hr
223841810|NCT06360601|DRUG|HydrALAZINE Injection|Hydralazine intravenous infusion 5mg/hr
223841811|NCT02993029|DRUG|99Tc-MDP|99Tc-MDP 15mg in 100ml normal saline intravenously dripped every twice a week for 5 weeks, every 1weeks for 10 weeks, every 2weeks for 10 weeks, every 1 month for 6 months.
223841812|NCT02993029|DRUG|Celecoxib|Celecoxib capsule 200mg qd by mouth.
223841813|NCT06028841|BIOLOGICAL|VLA1553|Single intramuscular vaccination on Day 1 with VLA1553, a lyophilized live-attenuated Chikungunya vaccine candidate 1x10E4 TCID50 per dose
223841814|NCT00823589|OTHER|Blood test and clinical test|Blood test and clinical test
223841815|NCT02794116|PROCEDURE|Conventional Sealants|It is a preventive treatment for caries lesions. The procedure following operative sequence: prophylaxis; absolute isolation; application of 37.5% phosphoric acid for 30 s in enamel; extensive washing; drying with cotton and air jet for 5 s; sealing with resin sealant application (Fluroshield, NY, USA), according to manufacturer guidelines; removal absolute isolation; examination of occlusal contact and final polishing.
223841816|NCT02794116|PROCEDURE|Resin Sealants|It is a resin sealants to preventive treatment for caries lesions. The procedure following operative sequence: prophylaxis; absolute isolation; application of 37.5% phosphoric acid for 30 s in enamel; extensive washing; drying with cotton and air jet for 5 s; sealing with resin sealant application (Fluroshield, NY, USA), according to manufacturer guidelines; removal absolute isolation; examination of occlusal contact and final polishing.
223841817|NCT00378521|DRUG|MQX-503|
223841818|NCT04071080|DRUG|fluorescein sodium|Fluorescein sodium in 500mL Gatorade
223841819|NCT04071080|DRUG|Placebo|500mL Gatorade
223841820|NCT01620827|OTHER|Hospital Landline Phone Calls|Follow-up phone calls are made from the hospital landline phones in a research office
223841821|NCT01620827|OTHER|Private Cell Phone Calls|Follow-up phone calls are made from the private cell phones of research assistants
223841822|NCT03556826|BEHAVIORAL|Social Value Learning Training|For each child, two faces will be assigned the high-value (HV) status and the other two the low-value (LV) status. Value status will be randomized between the faces and children and all four faces will have the same probability of being assigned HV or LV across all participants. A gaze fixation on a HV face will always activate a dynamic display and the face will smile brightly. A gaze fixation on a LV face will always result in no change to its display.
223841823|NCT04330443|PROCEDURE|Surfactant therapy|To study if lung ultrasound allows an earlier surfactant therapy (within the first 2 hours of life) compare to FiO2 and Chest X Ray
223841824|NCT00535197|BIOLOGICAL|Infusion of autologous CD34+ stem cells into middle cerebral artery|intra-arterial infusion into ipsilateral MCA, via trans-femoral approach
223841825|NCT04925050|DRUG|VB0004|Each study part (A,B and C) will be completed sequentially or with partial overlapping. Safety and PK data through at least day 8 from a subsequent cohort will be reviewed by the SMC prior to dosing the fed period of FE cohort. Safety data will be assessed by SMC after completing each cohorts in MAD healthy volunteers and MAD mild Hypertension patients.
223841826|NCT04925050|OTHER|Matching Placebo for VB0004|Matching Placebo
223841827|NCT06114329|DRUG|AL01211|AL01211 is a novel, proprietary, selective GCS inhibitor with high potency against GCS with limited off target activity.
223841828|NCT04902742|PROCEDURE|Fluoroscopy-guided ganglion impar block|Fluoroscopy guidance is used for correct visualization of injection site, and so obtained more successful results. Patients are placed in the prone position. Injection site is cleaned thrice with povidone iodine %10 solution and covered with sterile drapes. Being most commonly used technic, transsacrococcygeal technique, a 22-gauge, 1.5-inch spinal needle is advanced through the sacrococcygeal disk and positioned carefully anterior to the sacrococcygeal junction. Injection of contrast results in a classical comma sign. A mixture of steroid and local anesthetic is given.
223841829|NCT04902742|PROCEDURE|Fluoroscopy-guided caudal epidural steroid injection|Fluoroscopy guidance is used for correct visualization of injection site, and so obtained more successful results. Patients are placed in the prone position. Injection site is cleaned thrice with povidone iodine %10 solution and covered with sterile drapes. An 18-gauge epidural needle (Tuohy) is advanced at an angle of 45° to the skin until a 'give-way' sensation is felt and position of the needle is confirmed by lateral and anteroposterior fluoroscopic images. Then 5 ml of iohexol solution is injected through it to confirm the position. A properly placed needle would produce a classical 'inverted fern tree' appearance in anteroposterior view after dye injection or a 'filling defect'. The needle is introduced up to S3 level for proper spread of the drug. A mixture of steroid and local anesthetics is given.
223841830|NCT01913756|DIETARY_SUPPLEMENT|Gamalost (Norwegian traditional cheese)|
223841831|NCT01913756|DIETARY_SUPPLEMENT|Gouda-type cheese|
223841832|NCT06256302|PROCEDURE|Transverses Abdominis Plane Block|Transverses abdominis plane block will be provided randomly using prospective double-blinding.
223841833|NCT06256302|PROCEDURE|Local wound infiltration|Local wound infiltration will be provided randomly using prospective double-blinding.
223841834|NCT03739879|DEVICE|Inspiratory Muscle Trainer Philips Respironics|Subjects exercised using inspiratory muscle trainer (Philips Respironic®) for 8 weeks. Training dose with IMT was determined by inspiratory muscle strength result and adjusted in every evaluation visit. The subject was expected to do exercise twice daily for 15 minutes each session with 30-70% intensity from determined MIP score. Exercise is monitored and noted in a logbook.
223841835|NCT00001538|BIOLOGICAL|APL 400-003|
223841836|NCT00115180|OTHER|No intervention|No intervention
223841837|NCT06477939|DRUG|Administration of L-TC|"Administration of L-TC (300 mg) as an IV perfusion, before each radiotion session~Radiotherapy : delivered at 40.5 Gy in 15 fractions of 2.7 Gy - One fraction a day 5 fractions per week~\+ Temozolomide delivered at a dose of 75 mg per square meter per day, given 7 days per week from the first day of radiotherapy until the last day of radiotherapy, but for no longer than 25 days."
223841838|NCT06477939|OTHER|Radiotherapy plus Temozolomide|"Radiotherapy : delivered at 40.5 Gy in 15 fractions of 2.7 Gy - One fraction a day 5 fractions per week~\+ Temozolomide delivered at a dose of 75 mg per square meter per day, given 7 days per week from the first day of radiotherapy until the last day of radiotherapy, but for no longer than 25 days."
223841839|NCT04859556|DEVICE|Alcon 25Gauge, 10,000 cuts per minute Ultravit cutter|a proprietary Vitrector from Alcon for the use on the Constellation system
223841840|NCT04859556|DEVICE|Alcon 25Gauge, 5,000 cuts per minute Ultravit cutter|a proprietary Vitrector from Alcon for the use on the Constellation system
223841841|NCT02600429|DRUG|RGN-259|A preservative-free, sterile eye drop solution containing Tβ4 for direct instillation into affected eye(s), five times a day for 4 weeks.
223841842|NCT02600429|DRUG|Placebo|It is composed of the same excipients as RGN-259 but does not contain Tβ4
223841843|NCT06309043|DRUG|recombinant anti-EGFR human/murine chimeric monoclonal antibody injection|a single dose，250 mg/m2
223841844|NCT04730336|DEVICE|Tixel|Peri-Orbital fractional treatment on the Eye-Lid to assess the effect on Dry Eye symptoms
223841845|NCT05484024|DRUG|Sintilimab|PD-1 inhibitor
223841846|NCT05484024|RADIATION|Short-course radiotherapy|Pelvic radiation
223841847|NCT05484024|COMBINATION_PRODUCT|CAPOX/mFOLFOX|chemotherapy regimen
223841848|NCT00003195|BIOLOGICAL|recombinant interferon alfa|
223841849|NCT00003195|DRUG|busulfan|
223841850|NCT00003195|PROCEDURE|allogeneic bone marrow transplantation|
223841851|NCT00003195|PROCEDURE|peripheral blood stem cell transplantation|
223841852|NCT00003195|RADIATION|radiation therapy|
223841853|NCT00231179|BEHAVIORAL|Home visiting professional support model|Home visits and telephone calls keyed to well child visits.
223841854|NCT00231179|OTHER|Control|The control group received an information booklet on child/family services upon enrollment and transportation for the follow-up evaluations. They were called every 4 months to maintain contact information
223841855|NCT05245656|DRUG|RB/RBAC alternating|"Patients assigned to the RB alternating with RBAC arm will receive six cycles of alternating RB (odd cycles) or RBAC (even cycles)~RB (1st, 3rd, and 5th cycles)~* Rituximab 375mg/m2, IV, D1~* Bendamustine 90mg/m2, IV, D1-2~RBAC (2nd, 4th, and 6th cycles)~* Rituximab 375mg/m2, IV, D1~* Bendamustine 70mg/m2, IV, D2-3~* Cytarabine 500mg/m2, IV, D2-4"
223841856|NCT05245656|DRUG|RB|"Every 4 weeks for 6 cycles~* Rituximab 375mg/m2, IV, D1~* Bendamustine 90mg/m2, IV, D1-2"
223841857|NCT00142064|BEHAVIORAL|observed levels of pain|
223841858|NCT03427229|BIOLOGICAL|Single-infusion FMT|Patients will receive a single fecal infusion by colonoscopy
223841859|NCT03427229|DRUG|Vancomycin (before randomization)|Vancomycin is administered in all patients for 3 days before randomization. Then vancomycin is stopped and patients are randomized to single-infusion FMT or multiple-infusion FMT.
223841860|NCT03427229|BIOLOGICAL|multiple-infusion FMT|Patients will receive multiple fecal infusions by colonoscopy
223841861|NCT05629598|BIOLOGICAL|Recombinant human erythropoietin injection|The dose of PEG-EPO (CHO cells) is converted according to the average weekly dose of short-acting EPO before randomization (4 weeks before randomization) multiplied by the corresponding conversion coefficient (low conversion coefficient is 0.004, High conversion coefficient is 0.008).
223841862|NCT05629598|BIOLOGICAL|Human erythropoietin injection|Refer to the product instructions
223841863|NCT00920374|BIOLOGICAL|Fluarix™/Influsplit SSW®|single intramuscular dose on Day 0
223841864|NCT02401529|DRUG|IV dexamethasone|0.15 mg/kg
223841865|NCT02401529|DRUG|Oral prednisolone|0.25mg/kg/day for 7 days then tapering for next 7 days
223841866|NCT02401529|DRUG|Paracetamol|acetaminophen 15 mg/kg/dose every 6 hours
223841867|NCT02401529|DRUG|IV saline|IV saline
223841868|NCT01414036|OTHER|Enhanced Traditional Care control|Educational brochure, list of hospital and community resources
223841869|NCT01414036|BEHAVIORAL|Patient navigation|Patients will receive up to 4 hours of patient navigation, in person or over the phone, over a 3-month period.
223841870|NCT02583074|PROCEDURE|Stimulation|After surgery, patients in 'Neurostimulation Group' will receive subthalamic nucleus stimulation for 3 months.
223841871|NCT02583074|PROCEDURE|Sham-stimulation|After surgery, patients in 'sham-stimulation Group' will receive subthalamic nucleus sham-stimulation for 3 months.
223841872|NCT04438811|OTHER|delivery of the spinal anesthetic by a trained medical officer|The delivery of spinal anesthesia by the trained medical officers in 3 rural Indian hospitals will be compared to those delivered by consultant anesthetists in the same hospitals in a non-inferiority analysis.
223841873|NCT04438811|OTHER|delivery of spinal anesthetic by a consultant anesthetist|The delivery of spinal anesthesia by the trained medical officers in 3 rural Indian hospitals will be compared to those delivered by consultant anesthetists in the same hospitals in a non-inferiority analysis.
223841874|NCT02491411|DRUG|Dexamethasone|Given PO
223841875|NCT02491411|DRUG|Enzalutamide|Given PO
223841876|NCT02491411|OTHER|Laboratory Biomarker Analysis|Correlative studies
223841877|NCT02491411|OTHER|Quality-of-Life Assessment|Ancillary studies
223841878|NCT01884974|OTHER|myeloproliferative disease|Echocardiogram, demographic data, St George respiratory questioner
223841879|NCT04034238|DRUG|LMB-100|Arms 1 and 2: Administered intravenous (IV) as an approximate 30-minute infusion of each 21-day cycle on days 4, 6 and 8 until disease progression, intolerance or withdrawal from study.
223841880|NCT04034238|DRUG|Tofacitinib|Arms 1 and 2: Administered orally twice daily on days 1-10 of each cycle until disease progression, intolerance or withdrawal from study.
223841881|NCT04034238|DEVICE|Mesothelin Expression|Test for mesothelin expression in tumor tissues for study eligibility
223841882|NCT03863717|OTHER|Arm Endurance Exercise Training|Pulmonary Rehabilitation Program including Upper Limb Endurance Exercise Training with arm cycle ergometer
223841883|NCT03863717|OTHER|Control|Pulmonary Rehabilitation Program without Upper Limb Endurance Exercise Training
223841884|NCT01039090|DRUG|Continuous Apomorphine infusion|Continuous Apomorphine infusion during 6 months
223841885|NCT01039090|DRUG|Usual dopaminergic per os treatment|No specific change in the dopaminergic per os treatment
223841886|NCT03968887|OTHER|plasma oxidized low-density lipoprotein levels|Detection of plasma oxidized low-density lipoprotein levels
223841887|NCT03688295|OTHER|No antibiotics|Patients will not receive antiobitherapy post surgery for CAA
223841888|NCT03688295|DRUG|Antibiotics|Patients will receive antiobitherapy post surgery for CAA
223841889|NCT05727995|DEVICE|PICO7|"The use of PICO is contraindicated in the presence of:~* Patients with malignancy in the wound bed or margins of the wound~* Previously confirmed and untreated osteomyelitis~* Nonenteric and unexplored fistulas~* Necrotic tissue with eschar present~* Exposed arteries, veins, nerves or organs~* Exposed anastomotic sites~* Emergency airway aspiration~* Pleural, mediastinal or chest tube drainage~* Surgical suction."
223841890|NCT05727995|OTHER|usual care dressing|usual care dressing
223841891|NCT01182870|DRUG|choleclaciferol|800-6000 IU cholecalciferol per day
223841892|NCT03294265|BEHAVIORAL|Peer support sessions|"Stages of mourning and motivation Patients introduce themselves, share their experience and mention a strategy on moving on to the next stage Reminder of metabolic control goals Leaders write on the board metabolic variables and ask everybody the goal values. Patients share their results and mention plans to improve them Self-care activities Leaders ask who owns a glucometer, how regularly they use it, its importance and consequences of not doing so.~Simplified meal plan Everyone brings a snack. Leaders ask if each snack is appropriate, how everyone carries out their meal plan, barriers and possible strategies Activities to increase physical activity Everyone compares who achieves 10 thousand steps/day and who doesn't, then mention benefits of exercise"
223841893|NCT03294265|BEHAVIORAL|Reminders|"Creation of a group on WhatsApp to send leaders and patients a weekly reminder on the different areas of self-care, such as foot care, self-monitoring, adherence to meal plan, medication and exercise.~This intervention will be applied to both groups."
223841894|NCT05274789|DRUG|Dexmedetomidine|Patients in the experimental group were given a loading dose of 0.6 μg/kg of dexmedetomidine intravenously after 10 minutes of intubation, followed by a continuous infusion at a rate of 0.4 μg/kg/h until 30 min before the end of the surgery.
223841895|NCT05274789|OTHER|Saline|Patients in the experimental group were given a loading dose of 0.6 μg/kg of saline intravenously after 10 minutes of intubation, followed by a continuous infusion at a rate of 0.4 μg/kg/h until 30 min before the end of the surgery.
223841896|NCT01031693|DEVICE|Transcranial Magnetic Stimulation|daily sessions for 5 days
223841897|NCT01955382|DRUG|Actidose Aqua|Actidose Aqua (oAC) (Paddock Laboratories is sold over the counter in the United States in bottles containing 25 g/120 mL (NDC # 0574-0121-04) or 50 g/240 mL (NDC # 0574-0121-08). oAC is stable at room temperature.
223841898|NCT01955382|DRUG|Artesunate|Artesunate (AS) obtained from Guilin Pharma (Shanghai), the only pharmaceutical company GMP pre-qualified by the WHO. The product artesunate for injection + 5% sodium carbonate inj + 0.9% sodium chloride inj will be delivered in vials of 30 mg and 60- mg vials, respectively, and will be dosed at 2.4 mg/kg as recommended for SM treatment by the WHO
223841899|NCT01955382|DRUG|Amodiaquine|Amodiaquine obtained from Pfizer (Dakar), is provided as 200-mg tablets or syrup (50 10 mg/mL), and will be provided as age-based doses per the manufacturer's directions.
223841900|NCT06212921|DIAGNOSTIC_TEST|Sequential blood samples|Sequential blood samples for diagnostic tests is the only intervention in thei study
223841901|NCT02029053|DEVICE|Vaginal Lubrication Ring for Vaginal Dryness|"Participants will be asked to complete 4 study visits and one final follow-up phone call. Each study visit will include a brief vaginal exam where vaginal fluid levels and pH levels are checked and questionnaires are completed. Daily diaries will be completed at home and returned to the study staff at subsequent visits.~Participants will self-insert the Intravaginal ring on the 1st study visit. The 2nd study visit will occur 3-4 days later.~The 3rd study visit will occur approximately 7 days after the 1st visit. Participants will remove the device and self-insert a new intravaginal ring.~The 4th study visit will occur approximately 14 days after the first visit. Participants will remove the intravaginal ring and undergo a final vaginal exam.~Participants will be called approximately 7 days after the last visit and will be asked about their current vaginal dryness symptoms and how they felt about the device during the study."
223841902|NCT02953275|DRUG|vedolizumab|standard of care
223841903|NCT02953275|DRUG|Pentoxifylline|added to vedolizumab
223841904|NCT02953275|DRUG|placebo|added to vedolizumab
223841905|NCT03296579|DEVICE|BiPAP|The patient's breathing is assisted by cycling between high and low pressures at a pre-set rate.
223841906|NCT03296579|DEVICE|CPAP|The patient breathes against a constant pressure delivered by face mask.
223841907|NCT03296579|DRUG|Ipratropium|Nebulized q6h
223841908|NCT03296579|DRUG|Magnesium Sulfate|50mg/kg IV, 4 doses q6h
223841909|NCT03296579|DRUG|Aminophylline|6mg/kg IV (if no progress)
223841910|NCT03296579|DRUG|Standard steroid dose, hourly salbutamol, oxygen as needed|Standard common therapies for all three arms.
223841911|NCT03936062|DRUG|Sitagliptin|Sitagliptin dispensing claim is used as the exposure
223841912|NCT03936062|DRUG|Sulfonylurea|2nd generation sulfonylurea dispensing claim is used as the reference
223841913|NCT00691158|DRUG|Pramlintide (Amylin)|4.7 mls of Amylin 15mcg/ml IV bolus.
223841914|NCT00691158|DRUG|Placebo (Normal Saline)|4.7 mls normal saline IV bolus x1
223841915|NCT00691158|DRUG|2 Metreleptin|Receive .06mg/kg of metreleptin IV bolus x1
223841916|NCT00691158|DRUG|Leptin plus Pramlintide|receive leptin IV bolus x1 and pramlintide bolus at Timepoint +0 and +30 minutes.
223841917|NCT05266196|DRUG|Seclidemstat|Treatment assigned as per parent protocol
223841918|NCT05972083|DRUG|Analgesia management; group S and C|Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. If the NRS score is ≥ 4, 0.5 mg kg-1 iv meperidine will be administered as a rescue analgesic. Postoperative patient evaluation will be performed by an anesthesiologist blinded to the procedure.
223841919|NCT03324685|DRUG|BIIB074|BIIB074 is administered as specified in the treatment arm.
223841920|NCT03324685|DRUG|OC (ethinyl estradiol and levonorgestrel)|OC is administered as specified in the treatment arm.
223841921|NCT00575978|DRUG|Hydralazine|Dose Level 1: 150 mg/d 50 mg PO TID Dose Level 2: 200 mg/d 50 mg PO QID Dose Level 3: 225 mg/d 75 mg PO TID
223841922|NCT05376605|OTHER|assessment|Evaluations of the patients will be made with scales, questionnaires and physical tests.
223841923|NCT06189716|DEVICE|High flow oxygen through nasal cannula|High flow oxygen through nasal cannula and measurement of oxygen and carbon dioxide fraction in the hypopharynx of healthy volunteers in different physiological conditions.
223841924|NCT03243760|DRUG|CCI15106 7.5 mg capsule|Orange capsule containing a white to off-white powder, 21.4 mg of CCI15106: Trehalose:Trileucine 35/55/10 weight by weight (w/w)
223841925|NCT03243760|DRUG|Placebo|Orange capsule containing a white to off-white powder, 21.4 mg of Trehalose:Trileucine 85/15 w/w
223841926|NCT03243760|DRUG|Placebo-2|Orange capsule containing a white to off-white powder, 21.4 mg of lactose. Placebo-2 to be used if unexpected safety signals are observed with the use of matching placebo.
223841927|NCT05219045|OTHER|Ohio RETAIN|RETAIN projects include a combination of medical provider services, stay-at-work/return-to-work (SAW/RTW) coordination services, and other SAW/RTW services. The evaluation compares the treatment group that is eligible to receive the full set of RETAIN intervention activities and an active comparator that is not.
223841928|NCT02065245|BIOLOGICAL|Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs)|Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs) administered by peripheral intravenous infusion
223841929|NCT02065245|BIOLOGICAL|Placebo|Placebo administered by peripheral intravenous infusion.
223841930|NCT02065245|BIOLOGICAL|Penicillin/Streptomycin-Free Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs)|Penicillin/Streptomycin-Free Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs) administered by peripheral intravenous infusion.
223841931|NCT05597098|DRUG|Cantharidin|0.1% cantharidin solution in acetone from 0.7% stock solution of cantharone is prepared and applied immediately. 10 μl of cantharidin per disc.
223841932|NCT01419847|DRUG|Ciclopirox|
223841933|NCT01419847|DRUG|Placebo|
223841934|NCT00764179|OTHER|milk enriched in proteins (2.15 g/100ml)|"Neonates will drink the hyperproteinic milk until they reach the 25th of Sempé and Pedron curve (milk to be taken at least until 40 weeks of amenorrhoea or at maximum until 4 months of corrected age)"
223841935|NCT00764179|OTHER|milk with normal protein concentration (1.45g/100ml)|"Neonates will drink the normoproteinic milk until they reach the 25th of Sempé and Pedron curve (milk to be taken at least until 40 weeks of amenorrhoea or at maximum until 4 months of corrected age)"
223841936|NCT01518257|BIOLOGICAL|botulinum toxin Type A|A single 200U (2 mL) dose of botulinum toxin Type A injected into the intra-articular space of the study knee on Day 1.
223841937|NCT01518257|DRUG|Normal Saline|A single 2 mL dose of Normal Saline (placebo) injected into the intra-articular space of the study knee on Day 1.
223841938|NCT03185429|BIOLOGICAL|Tumor Specific Antigen-loaded Dendritic Cells|Subjects will be given subcutaneous injection of 5.0x10\^6-1.0x10\^7 TSA-DC on week 1,3,5,11,17,23,35,47.
223841939|NCT03185429|DRUG|Cyclophosphamide|300 mg/m2 by vein before the first cell infusion.
223841940|NCT00924664|BIOLOGICAL|Tanezumab 20 mg|Tanezumab 20 mg administered IV every 8 weeks for 3 administrations followed by SC administration every 8 weeks for 4 administrations over a period of 64 weeks
223841941|NCT00924664|BIOLOGICAL|Tanezumab 10 mg|Tanezumab 10 mg administered IV every 8 weeks for 3 administrations followed by SC administration every 8 weeks for 4 administrations over a period of 64 weeks
223841942|NCT01304706|DRUG|Fluocinolone Acetonide|0.2 μg/day
223841943|NCT05895656|OTHER|7 Tesla MRI|Performing an additional 7 Tesla MRI examination as part of the initial treatment pathway.
223841944|NCT03134456|DRUG|Pembrolizumab Injection|Pembrolizumab according to the dosage and administration in Product Information of Keytruda in Korea (2mg/kg) until it is changed to 200mg flat dose.
223841945|NCT02949817|DEVICE|digital rehabilitation system with wearable multi-IMU(inertial measurement unit) sensors (Rapael kids)|1.The Rapael kids, a video-game based rehabilitation therapy system using IMU sensors as a game interface, newly-developed in Korea will be used on upper limb function of children with pediatric brain injury patients. 20 of All 40 children will receive the conventional occupational therapy and additional video-game based rehabilitation therapy, 30 minutes daily 5 times per week, for 4 weeks.
223841946|NCT02949817|OTHER|Conventional OT group|2\. Conventional OT group will recieve the conventional occupational therapy and one more conventional occupational therapy additionally. The additional occupational therapy training will be performed 30 minutes daily 5 times per week, for 4 weeks.
223841947|NCT03940261|OTHER|High Intensity Interval Training|Participants will complete exercise training 3x/week for 10 weeks. Exercise will consist of 10, 1-minute cycling intervals at 90% of peak power output, each separated by 1-min at 10% peak power output.
223841948|NCT03940261|OTHER|Continuous Moderate Intensity Training|Participants will complete exercise training 3x/week for 10 weeks. Exercise will consist of 30-50 minutes of cycling at 60% peak power output.
223841949|NCT03139175|DEVICE|balance assessment with Biodex balance system|All subjects of three groups will be assessed with the evaluation device( balance system).
223841950|NCT06080711|OTHER|AI assistance|Participants will be informed of the diagnostic probabilities for each of ten differential diagnoses according to the AI tool
223841951|NCT03293862|DEVICE|prophylactic polypropilene mesh|Placement of onlay polypropilene prophylactic mesh after midline fascial closure.
223841952|NCT03293862|PROCEDURE|Midline Fascial Closure|midline fascial closure using uninterrupted PDS 0 suture
223841953|NCT03293862|DEVICE|vacuum drainage system|Placement of a subcutaneous vacuum drainage system
223841954|NCT01739517|DRUG|Omegaven Therapy|After baseline labs, which have been collected no earlier than seven days prior to the initiation of therapy are obtained, therapy with Omegaven will be initiated at a starting dose of 0.5 g/kg/day infused over 12 hours. If tolerated, the dose will be increased to 1 g/kg/day, the goal dose. Omegaven will be infused intravenously through either a central or peripheral catheter in conjunction with parenteral nutrition.
223841955|NCT01400100|DRUG|Intraarterial application of Octreotide|500 µg / 5 ml Octreotide is given as a single bolus injection in the gastroduodenal artery intraoperatively.
223841956|NCT01400100|DRUG|sterile NaCl (sodium chloride) 0,9% solution|a single intraarterial shot of 5 ml saline solution in the gastroduodenal artery
223841957|NCT04478175|OTHER|multidisciplinary assessment and intervention|early multidisciplinary assessment and intervention in addition to usual patient care
223841958|NCT01394770|DRUG|Aliskiren|Aliskiren 150 mg for 1 month with forced uptitration to 300 mg compared in parallel group with amlodipine 5 mg with forced uptitration to 10 mg
223841959|NCT03766919|DEVICE|Implant of the INVICTA lead|The implant or the attempt to implant an INVICTA lead
223841960|NCT00029523|DRUG|Intrathecal (injected into the spinal fluid) DepoCyt|
223841961|NCT00029523|DRUG|Intrathecal methotrexate|
223841962|NCT00029523|DRUG|Intrathecal cytarabine (also known as ara-C)|
223841963|NCT04639154|PROCEDURE|Erector spinea plane block|ESPPB will be performed at the T5 and T8 levels of the spine using an in-plane approach. A real-time ultrasound machine will be used to evaluate block performance. A high frequency linear ultrasound probe will be placed longitudinally at a distance of 3 cm from the midline. After identifying the erector spinae muscle and transverse processes, we will insert a 22 G, 100-mm needle after standard skin disinfection. It will be inserted in a caudal-to-cephalad direction using a sterile probe cover until the tip lay in the interfacial plane deep into the erector spinae muscle. This plane will be opened following hydrolocalization with normal saline then 30 mL of 0.25% bupivacaine will be injected slowly, with or without adjuvants, and aspirate every 5 ml to ensure block performance.
223841964|NCT02379364|DEVICE|Diacutaneous Fibrolysis|Diacutaneous Fibrolysis is a non invasive physiotherapeutic technique applied by means a set of metallic hooks having the advantage of allowing a deeper and more precise application, which could not be achieved manually
223841965|NCT03141164|OTHER|computerized training|Computerized training
223841966|NCT04609293|COMBINATION_PRODUCT|camrelizumab+apatinib+hyperfractionated radiotherapy|Immunotherapy, anti-angiogenesis targeted therapy combined with hyperfractionated radiotherapy
223841967|NCT05599360|DRUG|Vyxeos|Vyxeos (daunorubicin and cytarabine) liposome for injection
223841968|NCT05599360|DRUG|Mylotarg|Gemtuzumab ozogamicin is an antibody-drug conjugate (ADC) composed of the CD33-directed monoclonal antibody (hP67.6; recombinant humanized immunoglobulin \[Ig\] G4, kappa antibody produced by mammalian cell culture in non-secreting 0 (NS0) cells) that is covalently linked to the cytotoxic agent N-acetyl gamma calicheamicin. Gemtuzumab ozogamicin consists of conjugated and unconjugated gemtuzumab. The conjugated molecules differ in the number of activated calicheamicin derivative moieties attached to gemtuzumab. The number of conjugated calicheamicin derivatives per gemtuzumab molecule ranges from predominantly zero to 6, with an average of 2 to 3 moles of calicheamicin derivative per mole of gemtuzumab.
223841969|NCT02339727|DIETARY_SUPPLEMENT|Preterm infants formula|The group 1 of children will receive a preterm infants formula supplemented with DHA and ARA with a relationship omega 6/omega 3 = 2/1 during the first 3 months of life. And group 2 will receive other Preterm infants formula very similar, but with a ratio of DHA and AA=1/1 also during the first 3 months of life.
223841970|NCT03882489|DRUG|Isobaric 2-chloroprocaine|The doses of isobaric 2-chloroprocaine will be administrated intrathecally and will be adjusted according to the observed responses in the previous subjects.
223841971|NCT00550472|DIETARY_SUPPLEMENT|probiotics|Lactobacillus paracasei Lpc-37, Lactobacillus acidophilus 74-2 Bifidobacterium animalis subsp. lactis DGCC 420
223841972|NCT04907448|OTHER|Physical Therapy|"The IsoK-ST group received their usual physical therapy program for 45 minutes, three times a week for eight successive weeks, which comprised advanced balance training, weight-bearing exercises, gait training, postural and flexibility exercises, and strength training exercises.~Additionally, the IsoK-ST group received an IsoK-ST program, thrice/week for eight successive weeks.~The control group received the usual physical rehabilitation program only for 45 minutes, three times a week for eight successive weeks."
223841973|NCT04356066|DIAGNOSTIC_TEST|serum cxcl10 by ELISA|serum sample
223841974|NCT03158948|DRUG|Nangibotide 0.3 mg/kg|Formulated LR12 peptide
223841975|NCT03158948|DRUG|Placebo|placebo
223841976|NCT03158948|DRUG|Nangibotide 1 mg/kg|Formulated LR12 peptide
223841977|NCT03158948|DRUG|Nangibotide 3 mg/kg|Formulated LR12 peptide
223841978|NCT02391909|BIOLOGICAL|Vivotif|
223841979|NCT00288769|DRUG|daily sublingual tablets Vitamin B12 1000 mcg versus placebo|
223841980|NCT02338037|PROCEDURE|Therapeutic Conventional Surgery|Undergo tumor resection
223841981|NCT02338037|PROCEDURE|Biopsy|Undergo biopsy
223841982|NCT02338037|DRUG|Eribulin Mesylate|Given IV
223841983|NCT02338037|PROCEDURE|Microdialysis|Undergo intracerebral microdialysis
223841984|NCT02338037|OTHER|Pharmacological Study|Correlative studies
223841985|NCT05978661|DRUG|FKC288|Administration of FKC288 Four dose groups of 0.1×10\^6 CAR-T/kg, 0.3×10\^6 CAR-T/kg, 1.0×10\^6 CAR-T/kg, and 3.0×10\^6 CAR-T/kg FKC288 are designed in this study. 3 to 6 subjects are expected to be enrolled in each dose group according to observed DLT.
223841986|NCT06705530|BIOLOGICAL|Hem101|CAR-T lymphocytes specific to CD19 B-cell antigen
223841987|NCT01876043|DRUG|plitidepsin|"Patients received plitidepsin as an i.v. 3-h infusion of 5 mg/m2/day on days 1 and 15 every 4 weeks. Patients discontinued plitidepsin if one of the following occurred: consent withdrawal, unacceptable toxicity, disease progression (RECIST v1.1), intercurrent illness or investigator's decision.~Single-arm phase II clinical trial based on a two-stage optimal Simon's design with 37 evaluable patients (first stage: 17 patients) used to distinguish a favorable true non-progression rate of 40% from a null rate of 20% (90% power and 10% type I error).~* Stage 1(17 participants): if \<=3 non-progressions at 3 months, the study was stopped early. Otherwise, the second group of 20 participants was recruited.~* Stage 2 (37 participants): if \>= 11 non-progressions, Aplidin was considered promising."
223841988|NCT00713934|BIOLOGICAL|CD133|portal vein infusion of CD133+ cells
223841989|NCT00713934|BIOLOGICAL|BM-MNC|portal vein infusion of BM-MNC
223841990|NCT01730417|DRUG|no carrier added metaiodobenzylguanidine|Sequential imaging was performed to determine radiation dosimetry of high specific activity 123I-mIBG
223841991|NCT00079937|DRUG|Omalizumab|The omalizumab dose administered, based on the patient's body weight and total serum IgE level at Screening, and the number of injections and injection volume was determined from the dosing tables in the protocol. Omalizumab 75 to 375 mg was administered subcutaneous (SC) every 2 or 4 weeks depending on the dose.
223841992|NCT00079937|DRUG|Placebo|Placebo was administered subcutaneous (SC) every 2 or 4 weeks depending on the dosing schedule in the protocol.
223841993|NCT00079937|DRUG|Fluticasone|Patients entered the study using their current formulation of any inhaled steroid (proprietary drug and device) ≥ 200 μg/day equivalent of fluticasone administered with a dry-powder inhaler.
223841994|NCT04965883|PROCEDURE|Excision and Grafting|reconstruction of deep burn by grafting
223841995|NCT04965883|PROCEDURE|dressing then delayed grafting|multiple dressing and delayed grafting
223841996|NCT01616563|BEHAVIORAL|Dietary Intervention|Nutrition assessment, review of the basic principles of dietary intervention for metabolic syndrome with an emphasis on the clinical risk factors identified for each individual, joint goal setting to determine what dietary changes are feasible, considering intention and barriers to dietary behaviour change.
223841997|NCT01616563|BEHAVIORAL|Exercise Prescription and Fitness Program|Exercise tests (aerobic fitness, muscular and flexibility tests) recommended by the Canadian Society of Exercise Physiology (CSEP), followed by an individualized exercise plan including fitness assessments.
223841998|NCT02206685|DRUG|Methadone|The treatment group will receive 0.2 mg/kg methadone diluted to a 20 ml infusion over 10 minutes
223841999|NCT02206685|DRUG|Normal Saline|the control group will receive a 20 ml normal saline placebo infusion over 10 minutes
223842000|NCT04448743|OTHER|Blood sample|20 Ml blood sample
223842001|NCT01392755|DRUG|danoprevir|oral doses of danoprevir
223842002|NCT01392755|DRUG|omeprazole|oral doses of omeprazole
223842003|NCT01392755|DRUG|ranitidine|oral dose of ranitidine
223842004|NCT01392755|DRUG|ritonavir|oral doses of ritonavir
223842005|NCT02582203|DRUG|Ceftaroline|
223842006|NCT02582203|DRUG|Vancomycin|
223842007|NCT02054247|DEVICE|ultrasound|a frequency of 1 megahertz and with an intensity of 1 W/cm2, 5 days a week for a total of 15 sessions
223842008|NCT02054247|DEVICE|pulsed ultrasound|a frequency of 1 megahertz and with an intensity of 1 W/cm2 and a pulsed mode duty cycle of 1:4, 5 days a week for a total of 15 sessions
223842009|NCT02054247|DEVICE|placebo ultrasound|same ultrasound device as described above seemed to be working but without delivering any output, 5 days a week for a total of 15 sessions
223842010|NCT01195675|DRUG|BI 10773 (low)|single oral dose
223842011|NCT01195675|DRUG|Moxifloxacin|single oral dose
223842012|NCT01195675|DRUG|BI 10773 Placebo|2 times single dose
223842013|NCT01195675|DRUG|BI 10773 (high)|single oral dose
223842014|NCT01106287|DRUG|MK-0941|A single 60, 80, 100, 120 or 140 mg oral dose of MK-0941 will be administered in each period
223842015|NCT01106287|DRUG|Comparator: Placebo|a single oral placebo will be administered in the designated period (Periods 1-5)
223842016|NCT04669613|OTHER|CUDI|Analysis of the CEUS data by means of Contrast ultrasound dispersion imaging
223842017|NCT03299387|DRUG|Nitrofurantoin|Participants will receive oral Nitrofurantoin 100 mg twice daily for 7 days
223842018|NCT03299387|DRUG|Gentamicin|Participants will receive intravesical via catheter Gentamicin solution 25 mg in 50cc for 3 days
223842019|NCT00072475|DRUG|vatalanib|Pts registered before 1/15/05 1250 mg/day PO After 1/15/05: Start w/ 750 mg/day PO; escalate q 4 wks in absence of Grade 2 or \> tox (1st increase=1000mg/day; 2nd increase 1250 mg/day)
223842020|NCT03545490|DIETARY_SUPPLEMENT|Early nutritional intervention|Early nutritional intervention (Ensure) was given two weeks before radiotherapy. Ensure 3 times per day, Mixing 55.8 g or 6 spoons of Ensure with 190 mL of warm water.
223842021|NCT05727956|PROCEDURE|Aneurysmectomy|Complete aneurysmectomy with end-to-end anastomosis for the true aneurysm or partial aneurysmectomy with a direct repair.
223842022|NCT04591899|DEVICE|CAD/CAM splints|"Each of the maxillary and mandibular cast will scanned alone and then both scanned together in the centric relation using FREEDOM HD scanner1.~The CAD/ CAM splint will be designed using Exocad software; the design will be the same as the conventional one. The surveying will be done by the software and the under-cuts blocked.~The splints will be printed using Dent2 3D printer and then cured using Dentcure. The CAD/CAM splints material will be hard resin from PhotoCentric 3D."
223842023|NCT04730947|DRUG|Dapagliflozin|10 mg orally once a day
223842024|NCT04730947|DRUG|Placebo|Taken orally once a day, the placebo looks identical to the study drug but it contains no active ingredient
223842025|NCT03093610|PROCEDURE|Traditional|Removal of the chest tube after air leakage has ceased and fluid drainage is 200ml/24h or less.
223842026|NCT03093610|PROCEDURE|Test|Removal of the chest tube after air leakage has ceased and fluid drainage is 5ml/kg/24h or less.
223842027|NCT03060187|OTHER|KU Score|Exam with a max score of 10 and min score of 0. Designed as a preoperative assessment of the patient's airway.
223842028|NCT03916614|BEHAVIORAL|Screening Tool for Relief of Trauma (START)|The Screening and Tool for Awareness and Relief of Trauma (START) was developed for patients that come from communities with sustained and persistent trauma. It consists of six screening questions adapted from the validated Primary Care PTSD Screen,\[30\] with input from focus groups, surveys and in-depth interviews with victims of violence. The full START intervention requires 30-45 minutes of structured conversation at the end of which the participant leaves with a better understanding of trauma symptoms as well as on-the-spot instruction on a set of techniques designed to alleviate the symptoms of PTSD. Based on the results of their screening, the participant will be offered up to four techniques to alleviate their symptoms
223842029|NCT03916614|BEHAVIORAL|standard of care|Screening for PTSD and referral for outpatient services if warranted as well as usual care from Violence Prevention and Outreach Program (VPOP) staff.
223842030|NCT06300398|DRUG|IAMA-6|IAMA-6 liquid suspension
223842031|NCT06300398|DRUG|Placebo|Placebo-to-match IAMA-6 liquid suspension
223842032|NCT01461356|PROCEDURE|Minimally invasive total knee replacement|A cemented tricompartmental total knee replacement will be performed using a minimally invasive surgical approach.
223842033|NCT01461356|PROCEDURE|Standard approach total knee replacement|A cemented tricompartmental total knee replacement will be performed using a traditional medial parapatellar surgical approach.
223842034|NCT05916885|OTHER|short-intensity modified CIMT and conventional therapy|an experimental group receiving short-intensity modified CIMT and conventional therapy
223842035|NCT05916885|OTHER|conventional therapy alone|a control group receiving conventional therapy alone.
223842036|NCT05883800|RADIATION|On-couch adaptive radiotherapy|A new treatment plan, guided by volumetric images, is created at each treatment session
223842037|NCT04559932|OTHER|Tracheostomy Training Course|A standardized competency-based education tracheostomy module has been developed by the investigator group in collaboration with Respiratory Medicine, Complex Care, Respiratory Therapy, Nursing Education, Family Advisory Network and the Learning Institute at SickKids. Instructional methods for the full module are based on principles of adult learning and evidence from the procedure education literature and include the use of interactive, small-group teaching, hands-on simulation-based learning stations with relevant equipment as well as a formal assessment of knowledge and skills using simulation. Pre-learning packages are sent to course attendees at the time of registration to facilitate higher level discussions on the day of the course. While investigators have rigorously developed the curriculum and evaluation measures, the course outcomes remain unknown.
223842038|NCT05623280|DRUG|Indocyanine green|Injection around the areola with 2-4 points Indocyanine green with 2ml of 1.25mg/mL
223842039|NCT06487026|DEVICE|ArcBlate Focused Ultrasound Ablation System|MR-guided High Intensity Focused Ultrasound (MRgHIFU)
223842040|NCT01189955|PROCEDURE|HS total thyroidectomy|In the HS group, using the new harmonic scalpel device Focus (Ethicon Endo Surgery, Cincinnati, OH, USA) was used for cutting and coagulation . For closure of and division of superior and inferior arteries and veins we set the instrument at a power 2 i.e. more coagulation. And when smaller vessels like capsule veins we set it to the level 5 i.e. more cutting The superior artery and vein was divided close to the gland to avoid damage to superior laryngeal nerve. And control of any bleeding from the bed using the active blade of harmonic. Finally we insert drain.
223842041|NCT01189955|PROCEDURE|conventional total thyroidectomy|A prophylactic antibiotic in the form of a third-generation cephalosporin was administered 2 hours before the operation. The operation was performed with the patient in the supine position under general anesthesia with endotracheal intubation. A Kocher incision, was made at the lower neck crease two finger above suprasternal notch. In the conventional group, mono- and bipolar coagulation, as well as ligatures, were allowed.
223842042|NCT00940017|DRUG|anidulafungin and voriconazole|Subjects will be admitted to the clinical research unit on Day 0. Subjects will receive anidulafungin intravenously in a loading dose of 200 mg on Day 1, followed by maintenance doses of 100 mg Q24h on Day 2 and Day 3. Simultaneously, using a separate intravenous access, subjects will receive voriconazole in a loading dose of 6 mg/kg Q12h on Day 1, followed by a maintenance dose of 4 mg/kg Q12h on Day 2, and a 4 mg/kg morning dose on Day 3.
223842043|NCT01450943|DEVICE|SECONDARY dressing gauze and tape|SECONDARY dressing gauze and tape
223842044|NCT01450943|PROCEDURE|debridement, irrigation|debridement, irrigation
223842045|NCT01450943|DEVICE|Dermagraft|Dermagraft per company protocol
223842046|NCT01450943|DEVICE|Oasis|Oasis per company protocol
223842047|NCT05153174|DRUG|Sulforaphane|This is an over-the counter nutritional supplement. Participants will be given the extra strength tablets.
223842048|NCT04018729|DEVICE|Zephyr Endobronchial Valve|Endoscopic lung volume reduction therapy.
223842049|NCT04018729|BIOLOGICAL|Marrow-derived mesenchymal stromal cell|Mesenchymal stem cells have anti-inflammatory, anti-fibrotic, microbicide and repair potential.
223842050|NCT00903045|DRUG|Propiverine hydrochloride|Propiverine hydrochloride 20mg twice a day
223842051|NCT00903045|DRUG|Placebo|Identical placebo twice a day
223842052|NCT02201030|BIOLOGICAL|NBP606|A single intramuscular injection into the thigh
223842053|NCT02201030|BIOLOGICAL|Prevnar13|A single intramuscular injection into the thigh
223842054|NCT06376890|DIETARY_SUPPLEMENT|Red chili peppers|2.4 grams/day of powdered red chili pepper
223842055|NCT06376890|DIETARY_SUPPLEMENT|Green Chili Pepper|2.4 grams/day of powdered green chili peppers
223842056|NCT06376890|DIETARY_SUPPLEMENT|Placebo|2.4 grams of a metabolically equivalent placebo
223842057|NCT05665855|DIETARY_SUPPLEMENT|Ketone monoester|A commercial liquid ketone monoester supplement.
223842058|NCT05665855|OTHER|Placebo|A liquid placebo that is taste-matched to the ketone monoester supplement.
223842059|NCT05507697|BIOLOGICAL|HUC-MSCs|5 × 10\^6 cells/mL, 1 mL per injection, each injection point is 2 cm apart ,1.0-1.5 cm deep, total amount of injection is estimated based on the surface area of the patient's lower limb
223842060|NCT05507697|BIOLOGICAL|Lipoic Acid|Lipoic Acid Injection，600 mg/d for 15 consecutive days
223842061|NCT01618331|BEHAVIORAL|Regular exercise|Duration: 3 session each week, in 12 week. Intensity: 70 % of VO2max. Type: cycle-ergometer exercise.
223842062|NCT01618331|DIETARY_SUPPLEMENT|Protein-carbohydrate supplementation|Dosage: 45g powder mixed in 0.5 L water After each exercise session, 3 times each week, in 12 weeks.
223842063|NCT00175240|BEHAVIORAL|Evidence summaries endorsed by local opinion leaders|
223842064|NCT01747161|DRUG|Botulin toxin|50 I.E. Botulin toxin. Injections in 6 spots of the vestibulum vaginae (3 sessions (every 6 weeks))
223842065|NCT01747161|DRUG|physiological water|3 mL physiological water. Injections in 6 spots of the vestibulum vaginae (3 sessions (every 6 weeks))
223842066|NCT00304811|DRUG|Vancomycin|
223842067|NCT00304811|DRUG|Vancomycin plus Gentamicin|
223842068|NCT00304811|DRUG|Vancomycin plus Rifampin|
223842069|NCT00304811|DRUG|Vancomycin plus Gentamicin plus Rifampin|
223842070|NCT02023944|OTHER|Memory and Aging Course|This is a 12-week course that will provide participants with an understanding of what normal and pathological aging processes look like. It will also provide participants with methods to maintain healthy lifestyles as they continue to grow older.
223842071|NCT03397160|BEHAVIORAL|Decision Support Intervention (DSI)|"A question list (QL) that includes areas of patient concern are created by the health coach for use by the patient and the urologist at their first consultation visit where they discuss the extent of their cancer and consider treatment options. The coach uses the Prostate Cancer SCOPED model to complete a Prostate Cancer SCOPED Model Form. The SCOPED model uses concepts such as the situation, choices (treatment), objectives (personal goals and priorities), people (involved in supporting a treatment decision), evaluation and decisions (clarifying which choice is best and next steps)."
223842072|NCT05400980|DEVICE|Urocross implant|Urocross implant inserted via delivery catheter
223842073|NCT05400980|DIAGNOSTIC_TEST|Sham-control|Cystoscopy
224076051|NCT07143942|BEHAVIORAL|Kinesio Taping|"KT-I taping method: bend the knee joint 30°, use an I-shaped muscle tape to apply horizontally to the painful area of the patellar tendon (from the middle to the sides) with 50%-75% tension, and then use a Y-shaped muscle tape to apply to the gluteus medius (from the muscle origin to the insertion point).~After KT taping, patients were instructed to maintain the taping for 5 days before replacing it. KT-I taping intervention was continued for 8 weeks."
223842074|NCT05241795|OTHER|Knee then Ankle rehabilitation protocol|"Patients will start with knee exercise program that includes~* Partial Squats: The exercise will be performed as 3 sets of 10 repetitions each day.~* Toe Raises: The exercise will be performed as 3 sets of 10 repetitions each day.~* Stationary bike will be used (10-15 minutes /day) when the patients can bend their knees at least 100 degrees, as cycling is considered as an excellent conditioning and building exercise for the quadriceps muscles. As the patient's ability to pedal the bike with the operative leg improved, the therapist will increase the resistance.~* Hamstring exercises: After 6 weeks, the hamstring muscles will be exercised by the patient pulling the heel back producing a hamstring contraction.~Then, Patients will start ankle exercises program that includes:~* Standing calf raises~* Foot lift~* Ankle eversion exercises~* Ankle Plantarflexion exercises"
223842075|NCT05241795|OTHER|Ankle then Knee rehabilitation protocol|"Patients will start ankle exercises program that includes:~* Standing calf raises~* Foot lift~* Ankle eversion exercises~* Ankle Plantarflexion exercises~Then, Patients will start with knee exercise program that includes~* Partial Squats: The exercise will be performed as 3 sets of 10 repetitions each day.~* Toe Raises: The exercise will be performed as 3 sets of 10 repetitions each day.~* Stationary bike will be used (10-15 minutes /day) when the patients can bend their knees at least 100 degrees, as cycling is considered as an excellent conditioning and building exercise for the quadriceps muscles. As the patient's ability to pedal the bike with the operative leg improved, the therapist will increase the resistance.~* Hamstring exercises: After 6 weeks, the hamstring muscles will be exercised by the patient pulling the heel back producing a hamstring contraction."
223842076|NCT01456663|DRUG|AFQ056|
223842077|NCT04484064|BEHAVIORAL|Adherence program|This program combines adherence evaluation using an electronic monitor (MEMS®) and feedback with repeated medication adherence interviews with the pharmacist.
223842078|NCT03596424|DRUG|Ketamine Hydrochloride|Intraoperative bolus and infusion (see arm description)
223842079|NCT03596424|DRUG|Dexmedetomidine Hydrochloride|Intraoperative bolus and infusion (see arm description)
223842080|NCT03596424|COMBINATION_PRODUCT|dexmedetomidine Hydrochloride and Ketamine Hydrochloride|Intraoperative bolus and infusion (see arm description)
223842081|NCT05406791|OTHER|VIRA App|Support from coach and using the VIRA app
223842082|NCT05406791|OTHER|Mood Education App|Support from mood education app
223842083|NCT03674593|PROCEDURE|Mitral valve chordae prosthesis|"The method consists of five stages:~1. Measure the required length of the chords~2. Forming loops~3. Fixation of the loop group to the papillary muscles~4. Fixation of chordal loops to the free edge of the valve~5. Annuloplasty with a support ring and a hydraulic test to confirm the absence of prolapse"
223842084|NCT03674593|PROCEDURE|Mitral valve chordae translocation|"The method consists essentially of three stages:~1. Selection of the secondary chord.~2. Fixation of secondary chords to the free edge of the valve.~3. Annuloplasty support ring and hydraulic test to confirm the absence of prolapse."
223842085|NCT03844516|OTHER|Peak oxygen uptake test with pacing|Peak oxygen uptake test with paced heart rate
223842086|NCT03844516|OTHER|Peak oxygen uptake test without pacing|Peak oxygen uptake test without paced heart rate
223842087|NCT04359056|OTHER|Clinical pharmacy activities along the care pathways|"PICC line implantation: Optimize the logistics circuit of the PICC line by rationalizing orders through the evaluation of potential losses.~Ensure the due traceability of the implanted medical device. Discharge order : Analysis, optimization and pharmaceutical interventions if necessary Discharge Pharmaceutical Interview : Discussion with the patient, Information about the PICC line maintenance and associated therapies, Information about the prescribed drugs.~Call to the community pharmacist to transfer the patient's prescription. Follow-up calls for 3 months after discharge~* Patients: Two calls the first week after implantation, then one call per month for a maximum of 3 months, Clinical data collection :Pharmaceutical advices if necessary~* Liberal nurses: same frequency, Clinical data collection, Pharmaceutical advices if necessary~* Community pharmacist: one call per month, information relevant to the patient's follow-up will be collected."
223842088|NCT06527105|DEVICE|Eye masks and ear plugs|Eye masks and ear plugs given during sleeping time in Icu After cardiac surgery
223842089|NCT04506671|PROCEDURE|Renal biopsy|Renal biopsy will be performed prior to the cryoablation on the basis of the center and according to the current protocols
223842090|NCT04506671|PROCEDURE|Cryoablation|Cryoablation under CT guidance will be performed on the basis of the center and according to the current protocols
223842091|NCT04506671|PROCEDURE|Partial nephrectomy|Partial nephrectomy will be performed on the basis of the center and according to the current protocols
223842092|NCT01414530|DRUG|oral contraceptive|ethinyl estradiol 0.03mg/levonorgestrel 0.15mg daily for 8 weeks
223842093|NCT01414530|DRUG|NSAID|ibuprofen 200mg/arginine 185mg twice per day for 8 weeks
223842094|NCT02751099|OTHER|transplanted patients|bone biopsy, echocardiogram, blood samples
223842095|NCT04290429|DRUG|Teduglutide|Treatment of patients with SR-GI-GVHD with teduglutide
223842096|NCT01789203|DRUG|Ciprofloxacin|Patients will be randomized 2:1 active comparator, Cipro, to placebo comparator.
223842097|NCT01789203|DRUG|placebo|Patients will be randomized 2:1 placebo comparator to active comparator, Cipro.
223842098|NCT05835024|DEVICE|Acorai Sensor Data Collection (ASDC) system 1.0 - Phase 1|"A supervised session that includes 10 minutes of patient information entry, 5 minutes of sensor recording time and 10 minutes of margin for setting up the system and patient, thus a total evaluation duration of approximately 25 minutes prior to the Right Heart Catheterization.~No follow-up period for the subjects will be required for this clinical investigation. Patients will be followed as per standard of care, at the hospital.~A single follow-up observational data collection will be conducted at 90 days, to collect the number of unplanned hospitalizations since the procedure visit. This does not involve active patient participation."
223842099|NCT05835024|DEVICE|Acorai Sensor Data Collection (ASDC) system 1.0 - Phase 2|"A supervised session that includes 10 minutes of patient information entry, 5 minutes of sensor recording time and 10 minutes of margin for setting up the system and patient, thus a total evaluation duration of approximately 25 minutes prior to the Right Heart Catheterization.~No follow-up period for the subjects will be required for this clinical investigation. Patients will be followed as per standard of care, at the hospital."
223842100|NCT02144324|DEVICE|Tandem Appliance|We are going to use a modified version of the Tandem Appliance
223842101|NCT05640921|BEHAVIORAL|Gi-CBT|Gi-CBT designed to cover relevant aspects of tackling trauma, and the CBT component will involve addressing negative thoughts, building more positive ones and building resilience.
223842102|NCT05640921|OTHER|Media Orientation|The MO sessions will embed media content to create awareness of the government's approaches to reintegration.
223842103|NCT03861728|DEVICE|0.01% Hypochlorous acid|Randomized to treatment 0.01% Hypochlorous acid four times a day to the affected eye for 2 weeks. (Avenova is a FDA approved device)
223842104|NCT03861728|OTHER|Placebo|Placebo to be used four times a day to the affected eye for 2 weeks
223842105|NCT02711982|PROCEDURE|Optic canal and optic nerve sheath decompression|within 5 days from trauma
223842106|NCT02711982|DRUG|methylprednisolone|within 5 days from trauma
223842107|NCT00354029|DRUG|S (+) Ketamine|0,35 mg/kg bolus after induction of anaesthesia; 5 ug/kg/min. continuous until the end of surgery
223842108|NCT00354029|DRUG|Placebo|isotonic saline
223842109|NCT00826280|DRUG|regadenoson|IV
223842110|NCT00826280|DRUG|overencapsulated caffeine|oral
223842111|NCT00826280|RADIATION|technetium|IV
223842112|NCT00826280|DRUG|placebo|oral
223842113|NCT03831438|DRUG|AVID200|Intravenous infusion of AVID200 Q2 weeks for 3 doses
223842114|NCT03201757|DRUG|ALKS 3831|Olanzapine + samidorphan, daily oral dosing
223842117|NCT05811208|DEVICE|automated pupillometry|Automated pupillometry every 6 hours
223842118|NCT05811208|DIAGNOSTIC_TEST|questionnaire|"CAM ICU questionnaire will be used for delirium screening the incidence of pain will be assessed using 3 valid scales. The Visual Analogue Scale (VAS), the Behavioral Pain Scale (BPS) and the Critical Care Observational Tool (CPOT) will be used.~questionnaires will be done the same time as pupillometry"
223842119|NCT05098600|OTHER|Exposure of interest|Common autoimmune and atopic conditions consist of atopic dermatitis, allergic rhinitis, asthma, Crohn's disease, ulcerative colitis, Celiac disease, Pernicious anaemia, Type 1 diabetes, Autoimmune thyroiditis (Hashimoto's thyroiditis, Grave's disease, atrophic, unspecified), rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, polymyalgia rheumatica, Systemic lupus erythematosus, Sjogren syndrome, psoriasis, vitiligo, Multiple sclerosis
223842120|NCT01424163|DRUG|Single dose reduced|Treatment 1 (Part A)
223842121|NCT01424163|DRUG|Single dose standard|Treatment 2 (Part A)
223842122|NCT01424163|DRUG|Multiple Dose|Treatment 3 (Part A)
223842123|NCT01424163|DRUG|Multiple Dose|Part B
223842124|NCT06418373|BEHAVIORAL|Get Ready with My Heart Program|"In the intervention group, adolescent CHD patients undergo a comprehensive assessment by cardiology and cardiothoracic experts to determine their suitability for transitional care management. Based on the Get Ready with My Heart Program, a personalized transition plan is developed, offering courses and resources that enhance self-management skills such as medication management, symptom monitoring, and health record maintenance. Throughout the transition period, regular support and follow-ups are provided to ensure that both patients and their families are adequately supported. The program includes regular assessments of transition readiness and quality of life changes to understand the intervention's impact and make necessary adjustments. Additionally, feedback is actively collected from patients and their families to continuously improve and refine the program."
223842125|NCT06418373|BEHAVIORAL|Conventional intervention|Adolescent CHD patients and their caregivers receive comprehensive health education and medical management. Upon admission, a detailed assessment of each patient's medical history and physical examination is conducted. A treatment and perioperative care plan is then tailored, including medication management with anticoagulants and antiarrhythmics, and surgery-related health guidance. Regular cardiac monitoring and follow-up assessments ensure treatment effectiveness and health status updates. Post-discharge, patients receive lifestyle management advice through remote consultations, focusing on diet and physical activity. Additionally, training on recognizing and managing emergencies is provided, equipping patients and caregivers to handle potential crises effectively. This holistic approach aims to improve both immediate and long-term health outcomes for adolescent CHD patients.
223842126|NCT05349877|BEHAVIORAL|Expressive writing|Write, continuously for 20 minutes, about deepest emotions and thoughts concerning experiences of minority stress, exploring a particular event and how it has affected the participant.
223842127|NCT05349877|BEHAVIORAL|Self-affirmation|Write, continuously for 20 minutes, about values the participant think is important to overcome experiences of minority stress.
223842128|NCT05349877|BEHAVIORAL|Placebo|Write, continuously for 20 minutes, about their daily routine, without expressing feelings and deep thoughts about it.
223842129|NCT03205020|DIAGNOSTIC_TEST|serum amyloid a test|"* Women who are diagnosed with preterm labor (28-36 weeks) will be enrolled in this study. Serum samples will be collected from all women before any intervention. All women will be sampled once at the time of admission.~* Venous blood sample (5 c.c) will be taken from each participant for examination of serum amyloid A.~* The collected blood will be centrifuging and serum will be stored to measure the level of amyloid A by (ELISA) technique in clinical pathology department- Ain shams University"
223842130|NCT05578924|OTHER|" women group "|women aged more than 18 years old
223842131|NCT04656002|DRUG|Vactosertib|Take Baektoseotip (TEW-7197) twice a day for 5 days and take a break for 2 days (5D on/2D off). With this method, progression up to the 28th day is taken as one cycle. Take it with or without food every twelve hours
223842132|NCT02297503|DRUG|Azzalure|Glabellar lines
223842133|NCT02297503|DEVICE|Restylane/Emervel filler|Facial tissue augmentation
223842134|NCT02297503|DEVICE|Restylane Skinbooster|Facial skin rejuvenation
223842135|NCT00809432|DEVICE|Face mask (Dust Respirator)|Subjects to wear a simple face mask for 24 hours prior to the study day and the 24 hours of the study day. They will be instructed to wear the mask as much as possible when indoors and at all times when outdoors.
223842136|NCT00809432|OTHER|No Face mask|Subjects will not wear a face mask to reduce their personal exposure to air pollution
223842137|NCT00351221|DRUG|rhIGF-1/rhIGFBP-3|
223842138|NCT00950053|PROCEDURE|Achilles decompression & debridement|Surgical intervention
223842139|NCT00950053|PROCEDURE|Achilles decompression and debridement with FHL transfer|surgical intervention
223842140|NCT02021461|DRUG|ESL Banana taste|oral suspension with Banana flavor at a concentration of 50 mg/mL and was administered in 2.5 mL doses.
223842141|NCT02021461|DRUG|ESL Grape taste|oral suspension with Grape flavor at a concentration of 50 mg/mL and was administered in 2.5 mL doses.
223842142|NCT02021461|DRUG|ESL Tutti-Frutti taste|oral suspension with Tutti-Frutti flavor at a concentration of 50 mg/mL and was administered in 2.5 mL doses.
223842143|NCT03514589|DRUG|nasal Tetracosactide|Bioavailability of nasal synacthen compared to IV comparator
223842144|NCT03514589|DRUG|IV tetracosactide|Bioavailability of nasal synacthen compared to IV comparator
223842145|NCT00105885|PROCEDURE|telephone care|Patients randomized to receive telephone care will be scheduled to see their provider at twice the recommended clinical visit interval, and two ten-minute telephone contacts will be scheduled at a specific time at standard 0.67 and 1.3 times the multiple of the recommended interval.
223842146|NCT00740662|PROCEDURE|Distal gastric bypass|Distal gastric bypass
223842147|NCT04547803|OTHER|Standard of Care|Outpatient appointments and activities including radiologic procedures for discharging patients as standard of practice
223842148|NCT04547803|OTHER|Video Visit|15-20 minute Video visit with an advanced practice provider (nurse practitioner or physician assistant) approximately 2-5 days after discharge.
223842149|NCT01426815|DRUG|Placebo|The prefilled syringe with placebo will be administrated subcutaneously every 4 weeks during a study period of 24 weeks.
223842150|NCT01426815|DRUG|Golimumab|The prefilled syringe with golimumab 50mg (Simponi ®) will be administrated subcutaneously every 4 weeks during a study period of 48 weeks.
223842151|NCT06283602|DIAGNOSTIC_TEST|oral health status|the dentists examined the dried teeth with a probe and mount mirror in a dental unit.
223842152|NCT04255875|BIOLOGICAL|Placebo|Participants will receive matching placebo
223842153|NCT04255875|BIOLOGICAL|PF-07209326|Participants will receive SC or IV single ascending doses
223842154|NCT04255875|BIOLOGICAL|PF-07209326|SCD participants will receive a multiple dose of subcutaneous PF-07209326
223842155|NCT03029338|BIOLOGICAL|CD19 CAR T cells|CD19 CAR T cells was transduced with a lentiviral vector to express anti-CD19 scFv TCRζ:4-1BB.
223842156|NCT02788656|DEVICE|Implantable Hemodynamic Monitor|The CardioMEMS device is an implantable pulmonary artery pressure monitor that is FDA-approved for use in patients with symptomatic heart failure and previous heart failure hospitalization. Patients eligible for this study are those with an already implanted CardioMEMS device.
223842157|NCT02788656|DRUG|Angiotensin-Converting Enzyme Inhibitor|Conventional, guideline-directed therapy for heart failure and reduced ejection fraction
223842158|NCT02788656|DRUG|Angiotensin II Type 1 Receptor Blocker|Conventional, guideline-directed therapy for heart failure and reduced ejection fraction in ACE-inhibitor intolerant patients
223842159|NCT02788656|DRUG|sacubitril/valsartan|Angiotensin-neprilysin inhibitor that is now FDA-approved and guideline-directed therapy for patients with symptomatic heart failure and reduced ejection fraction despite treatment with an ACE-inhibitor/Angiotensin-Receptor Blocker
223842160|NCT02263885|DEVICE|ExAblate Transcranial System|Transcranial MRgFUS
223842161|NCT04446975|OTHER|BPA|At the time of writing the prescription an automatic notification will appear on the care provider's screen that identifies a suggested post-discharge opioid dose within the electronic prescription pad. If approved by the provider, opioid-only prescriptions will be written as suggested. Final dosing decisions and drug choices will remain at the discretion of the treating provider.
223842162|NCT02695043|BEHAVIORAL|RRTBIMS|TBI patients discharged from Bellevue inpatient rehabilitation and enrolled in the Rusk Rehabilitation Traumatic Brain Injury Model System (RRTBIMS)
223842163|NCT02695043|BEHAVIORAL|Multimedia Multicultural Educational Program for TBI (MMEPT)|
223842164|NCT04818879|OTHER|Vojta|"The subject will be placed on a stretcher with the torso uncovered. Once the adhesive electrodes have been placed in the different recording areas on the anterior part of the trunk, a recording of the activity at rest will begin, two minutes of stimulation (digital pressure), one minute of rest, two minutes of stimulation in the contralateral side and, finally, one minute of rest.~The therapy consists of the application of a stimulating pressure in the pectoral area in the pattern of the locomotion complex of reflex rolling in its first phase. For this, the subject will be placed in a supine position aligned with respect to the axial axis, with the arms along the body, the lower extremities in extension, and the head extended with a rotation of approximately 30º towards one side of the stimulation. The manual stimulation pressure will be exerted in the space between the 6th-7th or the 7th-8th rib under the mammillary line, with a force of about 2 kg."
223842165|NCT04818879|OTHER|Control|"The subject will be placed on a stretcher with the torso uncovered. Once the adhesive electrodes have been placed in the different recording areas on the anterior part of the trunk, a recording of the activity at rest will begin, two minutes of stimulation (digital pressure), one minute of rest, two minutes of stimulation in the contralateral side and, finally, one minute of rest.~The control group will receive an application in an area with low receptor density located on the thigh, with a force of about 2 kg."
223842166|NCT00864058|DRUG|Gabapentin 400 mg capsules|A: Experimental Subjects received Actavis formulated products under fasting conditions
223842167|NCT00864058|DRUG|NEURONTIN® 400 mg capsules|B: Active comparator Subjects received Parke-Davis's marketed product
223842168|NCT01724203|DIETARY_SUPPLEMENT|Lactobacillus rhamnosus|
223842169|NCT01724203|DIETARY_SUPPLEMENT|Bifidobacterium animalis subsp. lactis|
223842170|NCT01724203|DIETARY_SUPPLEMENT|Placebo|
223842171|NCT05355922|OTHER|Electrical electrostimulation of the quadriceps muscle|Exercises associated with electrical electrostimulation of the quadriceps muscle of patients with knee osteoarthritis
223842172|NCT05355922|OTHER|Electrical electrostimulation of the quadriceps muscle (placebo)|Exercises associated with electrical electrostimulation (placebo) of the quadriceps muscle of patients with knee osteoarthritis
223842173|NCT03659487|PROCEDURE|Nissen|Laparoscopic total (Nissen) fundoplication
223842174|NCT03659487|PROCEDURE|Toupét|Laparoscopic posterior 270 degrees partial fundoplication
223842175|NCT00230451|PROCEDURE|Radiation|
223842176|NCT00230451|DRUG|Paclitaxel|
223842177|NCT00230451|DRUG|Cisplatin|
223842178|NCT00230451|DRUG|5-Fluorouracil|
223842179|NCT01813955|DRUG|Papaverine or placebo|Papaverine delayed release (depot capsule, 300 mg, orally, one single dosage per subject) or placebo
223842180|NCT06497985|DRUG|Tucidinostat|30mg orally BIW
223842181|NCT06497985|DRUG|Sintilimab|200 mg intravenously (IV) Q3W
223842182|NCT06497985|DRUG|Bevacizumab|7.5mg/kg intravenously (IV) Q3W
223842183|NCT06497985|DRUG|Fruquintinib|5mg orally QD
223842184|NCT05113589|DEVICE|PBM TREATMENT|Participants randomized to this treatment will receive a whole body PBM treatment using a NovoTHOR® whole body light bed. For each treatment session, participants will lie supine in the treatment bed for 20 minutes, with no or minimal attire (underwear). Treatment sessions will be three times weekly for a period of 4 weeks, totalling 12 treatment sessions
223842185|NCT05113589|DEVICE|PLACEBO PBM|The placebo feature of the whole body PBM bed provides controls that select active or placebo (sham) treatments in a way undetectable by participant, operator or observers, such that no-one is aware whether the participant is receiving an active or placebo treatment. There is a switch box that randomises participants to active or placebo; no other randomisation is necessary.
223842186|NCT00051415|BEHAVIORAL|Flaxseed-supplemented diet|
223842187|NCT02725203|BEHAVIORAL|Activate|The Activate intervention consists of four nurse-led consultations in a thee-month period. In the consultations patients receive structured and comprehensive support in achieving an improved level of physical activity. The Behavior Change Wheel was used to develop the Activate intervention, and led to a selection of 17 behavior change techniques, which are integrated in the Activate intervention
223842188|NCT00821925|PROCEDURE|bone densitometry|All patients do a bone densitometry after the inclusion.
223842189|NCT01444066|PROCEDURE|Dilation of the esophagus|Esophagus will be dilated with a Savory dilator.
223842190|NCT04816682|DRUG|Silymarin|Silymarine tablets will be provided irrespective of meal by a registered nurse T.I.D
223842191|NCT04550156|PROCEDURE|Colorectal Bundle|"1. Preoperative optimization of the nutritional status: Perform nutritional risk screening (NRS), measure albumin or prealbumin preoperatively and initiate nutritional support~2. Preoperative showering with an antiseptic agent~3. Administer preoperative antibiotic prophylaxis~4. Hair removal in the operative field with clippers~5. Peri-, intra-, and postoperative warming to maintain body temperature~6. Peri- and intraoperative glucose control~7. Usage of a wound protection device~8. Change of gloves and instruments after anastomosis~9. Anastomosis only with experienced senior surgeon present in theatre for any elective and emergency procedures"
223842192|NCT03683355|RADIATION|18F-FDG PET/CT|18F-FDG PET/CT and blood cultures will be performed at 3-month follow-up after TAVR Patients with positive 18F-FDG PET/CT (moderate or intense radiolabeled tracer uptake) will be scheduled for a second 18F-FDG PET/CT at 6-month follow-up.
223842193|NCT00249223|DRUG|Risperidone Long acting injectable|
223842194|NCT03881657|BEHAVIORAL|Reverse Colocated Integrated Care|A reverse colocated integrated care model is one where primary care and preventive services are embedded within a behavioral health service setting.
223842195|NCT03881657|BEHAVIORAL|Usual Care|Behavioral health services without primary care or integrated care services
223842196|NCT05009446|PROCEDURE|endoscopic surgery|endoscopic surgery or endoscope-assisted surgery open surgery
223842197|NCT05009446|RADIATION|intensity-modulated radiation therapy or volume of rotating intensity-modulated radiotherapy or Proton or heavy ion radiation therapy|radiotherapy was administrated before surgery
223842198|NCT05009446|DRUG|Chemotherapy drug|Chemotherapy was administrated before surgery. Chemotherapy may also be administrated after surgery in selected cases.
223842199|NCT02455687|DRUG|Hi-dose iv MgSO4|
223842200|NCT02455687|DRUG|Nebulized budesonide|
223842201|NCT02455687|DRUG|Std-dose iv MgSO4|
223842202|NCT02455687|DRUG|Nebulized normal saline|
223842203|NCT00112723|DRUG|alvocidib|Given IV
223842204|NCT05121155|DEVICE|ICP wave morphology comparison between a non-invasive (Brain4care) and a invasive method|We prospectively collected data of adults admitted to an intensive care unit (ICU) with subarachnoid hemorrhage (SAH), intracerebral hemorrhage (ICH) or ischemic stroke (IS) in whom invasive ICP monitoring placed. Measures had been simultaneously collected from the following non-invasive indices: optic nerve sheath diameter (ONSD), pulsatility index (PI) using transcranial Doppler (TCD), a 5-point visual scale designed for Computed Tomography (CT) and two parameters (time-to-peak \[TTP\] and P2/P1 ratio) of a non-invasive ICP wave morphology monitor (Brain4care\[B4c\]). Intracranial hypertension was defined as an invasively measured ICP \> 20 mmHg for at least five minutes
223842205|NCT06055907|DIAGNOSTIC_TEST|Serum anti-Xa activity|4 hours after third dose of dalteparin, serum anti-Xa activity is measured
223842206|NCT00002556|DRUG|vincristine sulfate|Given IV
223842207|NCT00002556|DRUG|carmustine|Given IV
223842208|NCT00002556|DRUG|melphalan|Given PO
223842209|NCT00002556|DRUG|cyclophosphamide|Given IV
223842210|NCT00002556|DRUG|prednisone|Given PO
223842211|NCT00002556|BIOLOGICAL|recombinant interferon alfa-2b|Given SC
223842212|NCT00002556|OTHER|laboratory biomarker analysis|Correlative studies
223842213|NCT01530074|PROCEDURE|Temporary blocking of mandibular nerve|IM. Lidocaine 2% 7.2ML
223842214|NCT05692843|DRUG|Cyclosporin A|"Once the patient is included in the clinical trial their therapeutic management will be carried out according to usual clinical practice, but additional procedures will be performed:~1. The frequency of follow-up visits will be increased in order to collect data related to clinical efficacy, safety and quality of life;~2. Biological samples will be obtained (blood and urine) for biochemical, kinetic, pharmacogenetic and immunological biomarker analysis to identify variables associated to CsA treatment."
223842215|NCT05692843|OTHER|Follow-up of Cyclospoin treatment already started|"If the patient is receiving cyclosporine therapy, a blood sample for pharmacogenetic analysis will be obtained at screening; also, at discretion of the treating physician, biological samples will be obtained (blood and urine) in this visit and in the follow-up visits to assess biochemical and kinetic variables. Clinical data (scales) will be collected from clinical records from treatment start until study inclusion and prospectively after study inclusion.~If the patient received cyclosporine previously but is no longer under CsA therapy, a blood sample will be extracted at screening for pharmacogenetic analysis. Clinical data (scales) will be collected from clinical records."
223842216|NCT05764317|DRUG|Amlodipine 5 mg + atorvastatin 10 mg + perindopril arginine 5 mg|a triple fixed combination of atorvastatin, perindopril and amlodipinedose combinations, was in a 3-month in accordance to the instruction for medical use approved in the Russian Federation
223842217|NCT05764317|DRUG|Amlodipine 5 mg + atorvastatin 20 mg + perindopril arginine 5 mg|a triple fixed combination of atorvastatin, perindopril and amlodipinedose combinations, was in a 3-month in accordance to the instruction for medical use approved in the Russian Federation
223842218|NCT05764317|DRUG|Amlodipine 5 mg + atorvastatin 20 mg + perindopril arginine 10 mg|a triple fixed combination of atorvastatin, perindopril and amlodipinedose combinations, was in a 3-month in accordance to the instruction for medical use approved in the Russian Federation
223842219|NCT05095155|GENETIC|SNP analysis of the DNA|SNP analysis of the DNA obtained from peripheral blood sample
223842220|NCT06629623|OTHER|No intervention|No intervention
223842221|NCT01363947|DRUG|DNIB0600A|Several dose levels will be evaluated for DNIB0600A administered via IV infusion on Day 1 of each 21-day cycle until disease progression.
223842222|NCT00355667|DRUG|furosemide|Patients with chronic heart failure receive furosemide and other standard treatment/
223842223|NCT00355667|DRUG|azosemide|Patients with chronic heart failure receive azosemide and other standard treatment.
223842224|NCT02205879|DRUG|Pregabalin|
223842225|NCT02205879|DRUG|Placebo|
223842226|NCT03047603|DIAGNOSTIC_TEST|PIVKA-II|Serum samples are tested for tumor markers including PIVKA-II,AFP,AFP-L3% and biochemical tests.
223842227|NCT03074981|DEVICE|Combined TopClosure & Vcare Alpha|"Combined TopClosure \& Vcare Alpha Treatment. The investigators will debride the wound if necessary. Wound biopsies will be taken to determine the existing pathogens and direct the antibiotic treatment.~Wound measurements will be taken. Afterwards the wound will be approximated by the TopClosure device and the patient will be connected to a Negative Wound pressure device Vcare Alpha.~The investigators will change dressings according to schedule. If the wound is clean the investigators will change dressings every 3-5 days, If the wound is infected the investigators will change dressings every 2-4 days, If the investigators encounter a severe infected wound with a lot of pus the investigators will change dressings every 1-3 days, The investigators will determine the time to heal when the wound is clean and there is no further need for Negative Pressure Wound Treatment (ROI-NPT) up to 10 weeks."
223842228|NCT02677246|DRUG|Denosumab|"Denosumab, one sub-cutaneous infusion, given within 2 weeks after engraftment defined as neutrophils \> 0,5x10(9)/L and chimerism ≥ 10% of donor origin.~Before starting Denosumab several requirements have to be met: 1) Calcemia and Phosphatemia in the normal ranges, 2) adequate Calcium and Vitamin D intakes according to age.~Biological activity of Denosumab measured by CTX blood level, expected to last for 4 to 6 months after one infusion.~Possibility of subsequent infusions at the same dose level, every 5 to 6 months, for patient remaining on corticotherapy, provided no DLT occurred and provided CTX blood level decreased under the required threshold, after the previous infusions of Denosumab"
223842229|NCT01403987|BEHAVIORAL|Residency Program Teaching|The residency program provides education surrounding the management of ascites to all house-staff in the training program. This consists of lectures, case-based or bedside discussions, and board review. All arms will receive the standard teaching provided by the residency program.
223842230|NCT01403987|BEHAVIORAL|Lecture|During resident rotations on inpatient wards there are typically several dedicated, one-hour discussions facilitated by the team's supervising attending, addressing a variety of internal medicine topics. In place of or in addition to one of these discussions, a gastroenterology fellow will meet with the team for one hour to discuss a standardized case of a patient with ascites and the management issues. At this time they will review the consensus guidelines for management, and be provided with a pocket card with key points.
223842231|NCT01403987|OTHER|Pocket Card Reference|A 4x6 inch laminated card will be administered to both intervention arms at the beginning of the study. The card will contain a brief summary of AASLD guidelines, indications for and contraindications to paracentesis, and key studies to order for fluid analysis. The organization of residency rotations is such that members of one randomization group do not typically work with members of other groups, however in the event that there is crossover, they will be free to share information as they see fit in order to optimize patient care.
223842232|NCT01403987|BEHAVIORAL|Pager|"The intensive education arm will be given a pager number at their initial meeting that they can use to call for personal assistance with performing paracentesis. Since a paracentesis is frequently referred to by housestaff as a tap, the pager number will correlate with the letters, TAPS, or #8277. The goal of the pager is to provide supervision and individual teaching so that the care provider can become proficient in the procedure."
223842233|NCT02083640|DRUG|Palbociclib Formulation Reference|125 mg single dose of palbociclib formulation with 16 micrometer API particle size and dissolution level 1, which is representative of the intended commercial hard gelatin capsule.
223842234|NCT02083640|DRUG|Palbociclib Formulation Test|125 mg single dose of palbociclib formulation with 41 micrometer API particle size and dissolution level 1
223842235|NCT02083640|DRUG|Palbociclib Formulation Test|125 mg single dose of palbociclib formulation with 16 micrometer API particle size and dissolution level 2
223842236|NCT00825474|OTHER|operation;TACE plus PEI|Under normal rules, the operation group open abdomen to perform operation through subtotal incision while the patient has been general anesthesia with trachea cannula. The operation range on hepatic tissue of un-tumor tissue around tumor should maintain at least 1cm. As for the micro-create treatment combination group, taking TACE all through arteria cruralies super-elect arteria hepatica and injecting MITO、FUDR、iodipin. By B transonogram guiding to nyxis liver biopsy,and perform per cutem absolute alcohol injection treatment.
223842237|NCT00180440|DEVICE|ICD|all models of Guidant/Bsc ICD's
223842238|NCT04937075|OTHER|No intervention|No intervention
223842239|NCT06391203|PROCEDURE|Long-term Drainage|After drilling or puncture, the drainage catheter is indwelling continuously and keeps to drainage for 7 days. Keep incision sterility, record the daily fluid drainage flow, and perform biochemical and bacterial culture identification tests for CSF regularly. Removing drainage catheter when the allocated time is reached. If there is still unabsorbed effusion after the allocated time is reached, the catheter placement time is extended and the relevant information is recorded.
223842240|NCT06391203|PROCEDURE|Short-term Drainage|After drilling or puncture, the drainage catheter is indwelling continuously and keeps to drainage for 2 days. Keep incision sterility, record the daily fluid drainage flow, and perform biochemical and bacterial culture identification tests for CSF regularly. Removing drainage catheter when the allocated time is reached. If there is still unabsorbed effusion after the allocated time is reached, the catheter placement time is extended and the relevant information is recorded.
223842241|NCT01614756|BIOLOGICAL|BMS-981164|
223842242|NCT01614756|BIOLOGICAL|Placebo matching with BMS-981164|
223842243|NCT00361309|DRUG|SU011248|Patients will receive SU011248 37.5 mg/day for 4 weeks continuously followed by 2 weeks of rest per cycle (each cycle = 6 weeks).
223842244|NCT00800124|PROCEDURE|cemented Landos prosthesis vs. uncemented Landos prosthesis|randomization between the cemented and non-cemented prosthesis.
223842245|NCT00220935|DEVICE|Orthotrac Pneumatic Vest|
223842246|NCT05638659|BEHAVIORAL|Computerized dual-task balance and home program|Portable force plate with aluminum top plate for measuring ground reaction forces, moments and the center of pressure in biomechanics. Through software to collect data from the force plates, converts the trials into useful information and plots the results. The force plates and charge amplifiers are fully remote controlled by software thus making the system extremely flexible and easy to use.
223842247|NCT05638659|BEHAVIORAL|Medical consultation and traditional balance training|Participants were assigned to read the health education flier and were assessed directly.
223842248|NCT00020189|DRUG|acetylsalicylic acid|
223842249|NCT00020189|DRUG|alvocidib|
223842250|NCT00020189|DRUG|clopidogrel bisulfate|
223842251|NCT04571073|PROCEDURE|Fascial Distortion Model|"Using physical exam and manual manipulation skills informed by the FDM, he identified and treated locations of presumed fascial distortion about the plantar area of the foot; distortions could include any of the six reported fascial anomalies in the FDM: continuum distortions, trigger bands, herniated trigger points, folding distortions, cylinder distortions, and tectonic fixations. Each distortion is associated with a recommended reparative manipulation. The purported mechanism of action is that the distortion-specific manipulation restores normal fascial homogeneity."
224076052|NCT07143942|BEHAVIORAL|exercise therapy|"Phase 1 aims to control load and reduce pain. This includes quadriceps isometric exercises, double-legged squats with the knees bent 90 degrees against a wall, Spanish squats, vastus medialis exercises, single-leg hip bridges with the affected leg supported, and stretches for the quadriceps, hamstrings, and calf triceps.~Phase 2 aims to gradually increase load and strengthen the training. This includes eccentric and progressive loading exercises. This includes single-leg squats on a 25° incline, lunges, vastus medialis exercises, step-ups, and gluteus resistance exercises.~Phase 3 aims to strengthen function and gradually return to sports. Energy-conserving exercises such as jumping, box jumps, and interval running are performed, gradually increasing jump height, running distance, and speed. After completing all of these exercises and experiencing no knee discomfort for 24 hours, specific exercises can be gradually introduced."
224076053|NCT07135583|OTHER|Active Comparator: Single Intervention 1|Acute intermittent hypercapnic-hypoxia (15 episodes of 1.5 minute O2= 9%, CO2=4% and balance N2, interspaced with 1.5 min room air
223842252|NCT04313348|BEHAVIORAL|eMobilize-Uganda application|"Arm 1 is the Control arm. Participants will receive no SMS reminders nor social supporter notifications. Arm 2, Scheduled SMS arm: Will receive an mHealth intervention targeted to the study participant (such as health information on an eMobilize-Uganda CommCare application or messaging and SMS reminders, or a voice call if at high risk). A weekly SMS reminder on the impending ANC appointment and expected date of delivery will be sent to participants. The content of the SMS reminders will be customized at enrolment. Arm 3 social support engagement arm: Will receive an mhealth intervention targeted to the participant plus an intervention targeted to engage the social supporter. Study participants will receive health information through the eMobilize-Uganda CommCare application or messaging + weekly SMS reminders + weekly SMS notifications to the 2 pre-identified social supporters. Notifications will bear upcoming ANC visit and delivery due date for all the study follow-up period."
223842253|NCT01278693|DRUG|L-carnitine|500 mg,twice daily, 16 weeks
223842254|NCT01278693|DRUG|placebo|500 mg,twice daily, 16 weeks.
223842255|NCT04962100|OTHER|Analysis of capacitation-associated tyrosine phosphorylation in human sperm by flow cytometry|"After the assessment of the macroscopic and microscopic characteristics of the sample, we will wash the sample and process it using three layers of density gradients.~In the case of samples for diagnostic analysis, the remaining volume will be incubated in at 37ºC, and 0.1-0.2 ml aliquots will be taken from the end of the processing at t0 (just before introducing the sample in the incubator), at t1 (after one hour of incubation) and at t3 (after 3 hours of incubation). Additionally, a sample will be taken after washing, prior to processing the sample with the density gradients. In the case of samples processed for insemination, an additional aliquot will be taken at the exact moment in which the insemination is carried out and the elapsed incubation time will be noted.~The evaluation of the capacitation will be carried out by analyzing the state of phosphorylation of tyrosines by flow cytometry."
223842256|NCT00305760|DRUG|Cetuximab|Cetuximab will be administered at an initial dose of 400 mg/m2, followed by weekly doses of 250 mg/m2 for a total of 6 cycles that last 3 weeks each.
223842257|NCT00305760|BIOLOGICAL|Pancreatic tumor vaccine|Vaccine will be administered one day after cyclophosphamide (day 1) every three weeks for 6 cycles.
223842258|NCT00305760|DRUG|Cyclophosphamide|Cyclophosphamide 250 mg/m2 will be administered one day prior to vaccination (day 0) every three weeks for 6 cycles.
223842259|NCT00180674|DRUG|Warfarin|
223842260|NCT02194218|DRUG|Nevirapine, low dose|50 mg
223842261|NCT02194218|DRUG|Nevirapine, high dose|100 mg
223842262|NCT05428579|PROCEDURE|Retroperitoneal Liposarcoma resection|Retroperitoneal Liposarcoma resection
223842263|NCT03706963|OTHER|Phone Call|-phone call 7 days (+/- 2 days) into preoperative period
223842264|NCT00649662|DRUG|Ciprofloxacin Extended-Release Tablets 1000 mg|1000mg, single dose fasting
223842265|NCT00649662|DRUG|Cipro® XR Tablets 1000 mg|1000mg, single dose fasting
223842266|NCT03950401|PROCEDURE|Monocryl|subcuticular Monocryl wound closure
223842267|NCT03950401|PROCEDURE|Nylon|wound closure using nylon suture on the skin
223842268|NCT01899560|PROCEDURE|Measure lung and chest wall elastance with esophageal catheter|"Patients will be in supine position with 30-45° head of bed elevation. The cuff of the endotracheal tube will be transiently overinflated to 60 cmH2O to ensure there will be no air leaks. NMBA (cisatracurium) will be administrated \[9\]. The fraction of inspired oxygen (FiO2) will be adjusted for continuously monitored oxygen saturation (SpO2) between 90 to 94%. Patients will be ventilated in pressure control with 15 cmH2O of driving pressure.~A low flow pressure/volume curve from 0 to 40 cmH2O will be performed."
223842269|NCT01899560|OTHER|non-invasive method for measuring the lung elastance|by measuring volume recruited during a change of pressure (∆PEEP/∆EELV)
223842270|NCT03089372|DEVICE|ARIES-ED device|The Dornier Aries-ED device will be used for the purpose of the study. LI-ESWT will be applied to the penile shaft 3 areas, and the 2 crura (two sites).
223842271|NCT02438774|BEHAVIORAL|post-harvest intervention package|The intervention group received post-harvest intervention package. The package is composed of 5 components, namely 1) hand sorting, 2) drying surface, 3) proper drying, 4) application of insecticide, 5) dehulling . The intervention will last for 7 months.
223842272|NCT02438774|BEHAVIORAL|Routine agriculture extension services|This group continued to receive routine agriculture education on good practices for handling crops; an agricultural extension service offered to farmers regularly by village agriculture extension officer at village level. The extension services provided includes the provision of farmers with knowledge, information, experiences and technologies needed to increase and sustain productivity and avoiding crop spoilage during storage for improved wellbeing and livelihoods
223842273|NCT01472627|PROCEDURE|Blood draws|Blood draws
223842274|NCT01831492|DEVICE|zeolite + dolomite|Given for 12 weeks, after a 4 weeks wash- out of all supplements/drugs
223842275|NCT01831492|DEVICE|cellulose|given for 14 weeks
223842276|NCT03391167|PROCEDURE|Ultrasound guided erector spinae plane block|A high-frequency linear ultrasound transducer will be placed in a longitudinal parasagittal orientation 3 cm lateral to T9 spinous process. The erector spinae muscles will be identified superficial to the tip of T9 transverse process. The patient's skin will be anesthetized with 2% lidocaine. A 17-gauge 8-cm needle will be inserted using an in-plane superior-to-inferior approach to place the tip into the fascial plane on the deep (anterior) aspect of erector spinae muscle. The location of the needle tip will be confirmed by visible fluid spread lifting erector spinae muscle off the bony shadow of the transverse process. A total of 30 mL of 0.375% bupivacaine will be injected (maximum of 3mg/kg).
224076054|NCT07135583|OTHER|Active Comparator: Single Intervention 2|An open-loop continuous tSCS stimulation \[30 min duration, low frequency (30 Hz), tolerable intensity (\~10-15 mA), 400 µsec pulse width, biphasic symmetric waveform\] will be delivered using 2 channels: Channel 1- C4-C5 spine; Channel 2- T4 spine; returning electrodes at ASIS.
223842277|NCT03391167|OTHER|Standard Pain Followup and Monitorization|Numeric Rating Scale (NRS) pain score will be recorded from 20th minute in recovery room followed by 1.-3.-6.-12.-18.-24.hours. Intravenous meperidine administration at 0.5 mg / kg rescue analgesia was determined in patients with a NSR score of 6 and over in the postoperative collection room. It is planned that the patient will continue to follow the hourly NRS score in ward. Intramuscular diclofenac will be administered in this period if NRS 6 and if it is over, intravenous 0.5 mg / kg meperidine will be administered if NRS score is 6 or more after 2 hours. Salvage analgesic needs and times will be noted in detail, and the use of rescue analgesics, as well as NRS scores at designated hours, will be kept in a statistical evaluation.
223842278|NCT00618670|BEHAVIORAL|Walking Exercise|Three times per week for 3 months
223842279|NCT00618670|BEHAVIORAL|Control--Resistance Training|Three times per week for 3 months
223842280|NCT03250312|OTHER|The Osteopathic Manipulation|The types of OMT techniques used will include muscle energy, articular, or high velocity-low amplitude (HVLA) as indicated by the physical findings and will be at the discretion of the treating physician. Additional techniques such as still, counter strain, facilitated positional release, balanced ligamentous tension, and cranial techniques may also be used at the discretion of the treating physician. The treatment will conclude with 2 minutes of pedal lymphatic pumping
223842281|NCT04349111|RADIATION|Intra-operative Radiation Therapy - IORT|Single dose of 20 Gy
223842282|NCT02223689|PROCEDURE|Skin Affix|
223842283|NCT06309303|OTHER|Clinical evaluation|Evaluation of clinical manifestation, laboratory ad imaging testing results, disease course, treatment and outcome
223842284|NCT05215652|OTHER|adherence monitoring package (AMoPac)|"AMoPac is a tool that consists of~* an electronic monitoring device,~* data management and data analysis,~* feedback on patient's performance,~* clinical-pharmaceutical evaluation of medication adherence,~* transmission of an adherence report."
223842285|NCT02705326|DEVICE|Opti-Speech|Uses visual feedback of the tongue's motion to guide speech sound production
223842286|NCT00372528|DRUG|pregabalin (LYRICA)|150 mg up to a maximum of 600 mg per day bid or tid as required
223842287|NCT05808647|BEHAVIORAL|5-day controlled metabolic dietary intake|Over 5-days, all food will be provided from the metabolic kitchen and participants will be instructed to eat all of the food provided each day and only the food provided each day.
223842288|NCT05101109|DRUG|ABL501|ABL501 will be administered biweekly of every 28-day cycle in the dose-escalation. The dosing interval to be used in the dose-expansion part will be re-evaluated based on the emerging safety and PK data from the dose-escalation part of the study.
223842289|NCT00688961|DRUG|Aspirin|generic aspirin
223842290|NCT00688961|DRUG|omega-3 acid ethyl esters|4, 1 g capsules q.d.
223842291|NCT04560582|PROCEDURE|Blood Draw|Participants will have blood drawn for analysis at baseline and every 4 weeks for a total of 7 blood draws over 24 weeks.
223842292|NCT03195582|DRUG|Corsodyl|following local anesthesia buccal and lingual flaps will be raised minimally, the cover screw will be removed from the implant. In the test group, Corsodyl gel 1% CLOROHEXIDINE will be applied on the implant and the healing abutment.
223842293|NCT00347867|DRUG|Viagra administration in IUGR/PET pregnancies|
223842294|NCT06108492|DRUG|SHR-2005|"In dose Escalation: Four dose levels are preset. The administration cycle included 6 times of induction perfusion period and 15 times of maintenance perfusion period.~In indication Expansion: Indications will be selected to evaluate preliminary efficacy."
223842295|NCT06028256|DRUG|Norepinephrine Hydrochloride|"Both arms of patients will receive standard anesthesia and surgical management. Radial artery cannulation and invasive blood pressure monitoring will be perform.~Norepinephrine will be pumped at a rate of 10 ml/h for 5 minutes before anesthesia induction to skin incision."
223842296|NCT06028256|DRUG|Placebo|Normal saline will be pumped at a rate of 10 ml/h for 5 minutes before anesthesia induction to skin incision.
223842297|NCT02240680|DRUG|placebo|placebo matching linagliptin 5 mg
223842298|NCT02240680|DRUG|linagliptin|5 mg once a day
223842299|NCT05700708|DIAGNOSTIC_TEST|Echocardiographic assessment|POC-Echocardiography to assess dynamic changes in cardiac output to assess therapeutic responses with albumin, midodrine, diuretics and domiciliary albumin
223842300|NCT06429371|OTHER|Quantitative Sensory Testing|Participants will undergo heat pain threshold, cold pain threshold, pressure pain threshold, temporal summation, and conditioned pain modulation to characterize pain sensitivity.
223842301|NCT06429371|OTHER|Pain-Related Psychological Factors|Participants will complete psychological questionnaires to characterize these factors.
223842302|NCT05575843|OTHER|Neurostatus-SMARTCARE|The Neurostatus-EDSS is assessed by HCPs while the examination is video-recorded. HCPs underwent extended training. For details of the examination refer to the second section of the detailed description.
223842303|NCT05575843|OTHER|Standard Neurostatus-EDSS|The Neurostatus-EDSS is assessed by neurologists while the examination is video-recorded. Neurologists underwent standard training.
223842304|NCT04924582|OTHER|Capacity Coaching|Capacity Coaching focuses on developing the capacity within patients to adapt, endure, and function optimally in their lives along with illness and treatment.
223842305|NCT04448327|DEVICE|active tVNS|non-painful electrical stimulation of the auricle for 30 minutes during a functional magnetic resonance imaging session
223842306|NCT04448327|DEVICE|Sham tVNS|Sham stimulation of the auricle for 30 minutes during a functional magnetic resonance imaging session
223842307|NCT03668782|PROCEDURE|Umbilical cord milking|The babies were held at the level of the placenta, while the umbilical cord was milked or cut and clamped.
223842308|NCT02034721|DIETARY_SUPPLEMENT|Protein supplement|24 g protein before, 12 g during, and 24 g after eccentric exercise
223842309|NCT02034721|DIETARY_SUPPLEMENT|Placebo|Placebo
223842310|NCT02809638|OTHER|ultrasound elastography|
223842311|NCT01235429|BEHAVIORAL|Partners in Care|Participants will be offered 12 group diabetes self-management educational lessons delivered by trained community health workers.
223842312|NCT01235429|BEHAVIORAL|Partners in Care|Diabetes self-management education
223842313|NCT06059053|DEVICE|Semibranch CMD branched aortic stentgraft|bEVAR with a custom made abdominal aortic multibranch, which incorporates the semibranch design
223842314|NCT00562965|DRUG|inotuzumab ozogamicin|IV administration, 1.8mg/m² on day 2 of each cycle every 28 days, for up to 8 cycles.
223842315|NCT00562965|DRUG|rituximab|IV administration, 375 mg/m² on day 1 of each cycle every 28 days, for up to 8 cycles.
223842316|NCT00562965|DRUG|rituximab|intravenous rituximab at a dose of 375 mg/m2 on day 1
223842317|NCT00562965|DRUG|cyclophosphamide|intravenous cyclophosphamide at a dose of 750 mg/m2 on day 1
223842318|NCT00562965|DRUG|vincristine|intravenous vincristine at a dose of 1.4 mg/m2 (not to exceed 2 mg) on day 1
223842319|NCT00562965|DRUG|prednisone/prednisolone|oral prednisone/prednisolone at a dose of 40 mg/m2 on days 1 through 5
223842320|NCT00562965|DRUG|mitoxantrone|mitoxantrone 10 mg/m2 intravenous on day 2
223842321|NCT00562965|DRUG|fludarabine|fludarabine 25 mg/m2 intravenous on days 2 through 4
223842322|NCT00562965|DRUG|dexamethasone|oral dexamethasone 20 mg/day on days 1-5
223842323|NCT05275270|OTHER|oxytocin gel|The active oxytocin gel (A) consisted of oxytocin dissolved in a gel-based on hypromellose with a pH of 3.8. 1 ml of gel contained 600 IU of oxytocin
223842324|NCT05275270|OTHER|placebo gel|The placebo gel (B) consisted of the gel alone
223842325|NCT06201065|PROCEDURE|Hepatic arterial infusion chemotherapy|administration of oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries
223842326|NCT06201065|DRUG|Lenvatinib|12 mg (or 8 mg) once daily (QD) oral dosing
223842327|NCT06201065|DRUG|Toripalimab|240 mg iv.drip Q3W
223842328|NCT06201065|DRUG|oxaliplatin , fluorouracil, and leucovorin|FOLFOX-HAIC
223842329|NCT00847093|DRUG|LMX4|One inch every six hours
223842330|NCT00847093|DRUG|LMX4 Placebo|One inch every six hours
223842331|NCT02402179|OTHER|Tryptophan|Tryptophan will be supplied at 13.2, 26.4, 39.7, or 52.9% of requirement; sourced from crystalline amino acid and white cornmeal maize.
223842332|NCT01911221|BIOLOGICAL|rMenB+OMV NZ|Recombinant MenB with Outer Member Vesicle (OMV) from the New Zealand strain
223842333|NCT06036979|PROCEDURE|Paravertebral plane block|With the patients are placed in the sitting position, counting down from C7 spinous process, a high frequency linear ultrasound probe is placed on the spinous process in the parasagittal plane at T5 level and then is slided laterally 2-3 cm to make the transverse processes clearly visualized . Under aseptic conditions, a 22-gauge block needle (50mm, B.Braun, Germany) is inserted using in-plane technique toward the paravertebral space, immediately above the pleura and below the superior costotransverse ligament. The position of the needle is confirmed by the descent of the pleura when injecting 2 to 3 ml of saline solution for hydrolocalization. Then 0.3ml/kg of bupivacaine 0.25% is injected under ultrasound guidance. Block success is defined as reduced sensitivity to cold and pinprick stimuli as compared with the contralateral side 20 minutes after local anesthetic injection.
223842334|NCT06036979|PROCEDURE|Erector spinae plane block|With the patients are placed in the sitting position, counting down from C7 spinous process, a high frequency linear ultrasound probe is placed on the spinous process in the parasagittal plane at T5 level and then is slided laterally 2-3 cm to make the tips of the transverse processes clearly visualized . The following muscles seen from superficial to deep layer are trapezius, rhomboid major and erector spinae muscles. Under aseptic conditions, a 22-gauge block needle (50mm, B.Braun, Germany) is inserted using in-plane technique to reach the interfascial plane between the transverse process and the erector spinae muscle. Following confirmation of the accurate position of the needle tip with 3-5 ml normal saline solution, 0.3ml/kg of bupivacaine 0.25% is injected under ultrasound guidance. Block success is defined as reduced sensitivity to cold and pinprick stimuli as compared with the contralateral side 20 minutes after local anesthetic injection.
223842335|NCT06036979|DRUG|Intravenous morphine, ketorlac and paracetamol|• In the control group only we add 10mg intravenous morphine, 30 mg intravenous ketorlac and 1 gm intravenous paracetamol for analgesia.
223842336|NCT00525057|DRUG|Dalteparin|Given SC
223842337|NCT05071573|OTHER|Optimised electronic patient records|Viral load champions trained in the monitoring of patient on antiretroviral therapy to aid prompt identification of virological failure and institution of appropriate clinical management
223842338|NCT03007342|DRUG|Amoxicillin/Clavulanate Potassium 875 mg-125 mg oral tablet|
223842339|NCT03007342|DRUG|Placebo|
223842340|NCT05556005|DRUG|Trimetazidine Dihydrochloride|Trimetazidine Dihydrochloride 35 mg modified release tablet used twice daily
223842341|NCT05556005|DRUG|Placebo|Starch tablets used twice daily
223842342|NCT03464396|OTHER|Bedside Physiology study|A 90-minute recording in conjunction with the respiratory evaluations using standard recording equipment that includes a conventional pulse oximeter, an EEG, an airflow sampling catheter near the nose, and respiratory inductance plethysmography (RIP) bands. Standard clinical bedside monitoring will continue during the respiratory evaluations.
223842343|NCT03464396|OTHER|Carotid Body Function Test|Infants without nasal cannula will have a nasal cannula placed in their nares. After a 15-minute baseline period and during quiet sleep, the infant will then be exposed to 30 seconds of 100% oxygen (O2) by increasing FiO2. This test will be repeated 3 times, with at least 3 minutes between tests to allow for return of oxygen saturation (SpO2) to baseline values. If oxygen saturations increase to 99% for 15 seconds or the infant is apneic for greater than 5 seconds following initiation of 100% oxygen (O2), the test will be stopped and FiO2 brought back to baseline. Infants in the NICU will be monitored continuously with heart rate, respiratory rate, and SpO2% for 12 hours after Carotid Body Function Test according to NICU standards. Infants discharge who return for Carotid Body Function Test at 40 and 52 weeks PMA will be monitored continuously for 1 hour after the test is finished.
223842344|NCT03464396|OTHER|Room Air Challenge|Infants receiving nasal cannula high flow support 3 liters per minute (LPM) or less with or without supplemental O2 at 36 weeks PMA will be eligible. After a 15-minute quiet sleep period, infants' FiO2 will be weaned, in 0.20 decrements for 5 min intervals. Flow then decreased in 10 min intervals, initially in 1 Liter Per Minute (LPM) decrement until nasal cannula flow is 1LPM, and then decreased by 50% decrements to 0.125 LPM then off. If the infant is weaned to room air alone for 15 minutes, not meeting failure criteria, he/she has passed the RAC. Failure of the RAC is defined as occurring when SpO2% falls below 80%, even briefly, or remains less than 90% for 5 consecutive minutes any time during the test, bradycardia (Heart rate \[HR\] \< 80 bpmx 10 sec) or persistent apnea despite stimulation. Infant is returned to the level of support provided before the RAC begun if meets any failure criteria.
223842345|NCT03464396|OTHER|Hypoxia Challenge Test|"A physician investigator will review 30 minutes of continuous recording made 24 hours prior to test scheduled to identify infants that are at high risk for significant oxygen desaturations during Hypoxemia Challenge.~If subject passes the screening test, the hypoxic challenge will be performed. For the hypoxemia test, a nasal cannula will be placed prior to a 15 minute period of quiet sleep recorded to confirm antecedent stability of ventilatory pattern and SpO2%. During the 15 minutes of quiet sleep, the infant is required to maintain a SpO2 of \> 92% in order to undergo the HCT. After the 15-minute baseline recording, HCT will begin using FiO2 = 0.18 for 5 minutes, unless failure criteria is met: SpO2% \< 80% even briefly, or SpO2% 80% to 85% for 15 seconds. If infant does not meet failure criteria, infant will be given FiO2 0.15 for 10 minutes. If an infant meets even a single criterion for failure, Hypoxic mixture will be stopped."
223842346|NCT03464396|OTHER|Effects of Nasal Cannula Flow|"Infants will have nasal catheter in place (NeoTech Premature RAM Cannula). A 15-minute baseline recording of physiologic study parameters prior to initiation. Tested in three groups of infants.~1. 28 and 32 weeks PMA flow rates increased after a 15-minute baseline period to 3LPM, or by 1LPM to a max of 5LPM for 15 minutes. Infant on Bubble CPAP will be increased 1cm H2O to max 8 cm H2O for 15 minutes.~2. Infant's that fail the RAC or HCT at 36 weeks with periodic breathing, high flow at 3LPM will be started for 2 minutes or until periodic breathing stops. Infants on Bubble CPAP will not undergo the RAC or HCT. Their pressure is increased by 1cm H20 to max of 8 cm H2O for 15 minutes.~3. Infant on RA at 40 and 52 weeks PMA with periodic breathing lasting longer than 1 minute during the 15-minute baseline period, flow at 3LPM will be started for 2 minutes or until periodic breathing stops."
223842347|NCT03464396|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|A non-sedating MRI scan will be performed on 3 subsets of infants at 37-40 weeks Post Menstrual Age (PMA), or when infant is within one week of discharge from the NICU. Standard images as well as research images will be obtained. The research images use the same MRI scanner and collection techniques as standard clinical imaging, but provide a more detailed examination of brain anatomy and injury. Collection of these sequences using our standard non-sedated acquisition practices for infants is well tolerated. Infants will be placed in scanner by registered nurse accompanied by radiology technician to assure infants' comfort during scan. Infant will remain on cardio-respiratory monitor during MRI via a pulse oximetry probe. It will take no longer than one hour to complete MRI scan including transportation to radiology unit.
223842348|NCT03464396|DIAGNOSTIC_TEST|Echocardiogram|An echocardiogram (referred to as an ultrasound of the heart on the consent form) will be performed to assess cardiac structure and function. Echocardiograms are performed routinely in premature newborns in the NICU. The Echocardiogram will be performed at the infant bedside and will be coordinated with bedside nurse. The infant will remain on a cardio-respiratory monitor during the echocardiogram for approximately 15 minutes.
223842349|NCT03464396|OTHER|Blood Sample|Infants that have echocardiograms will have a blood sample collected near the time the echocardiogram is obtained, 3-blood samples total. The blood sample will only be collected with parental permission on an opt-in or out-basis and collected only with routine clinical labs.
223842350|NCT00563654|DRUG|Alfuzosin GITS (Xatral XL)|
223842351|NCT02298543|OTHER|coronary spasm|
223842352|NCT04795141|DRUG|ABY-035|ABY-035 Solution for injection
223842353|NCT04795141|DRUG|Placebo|Normal Saline for injection
223842354|NCT03505645|PROCEDURE|Periarticular infiltration|"The injection will consist of the same drugs for all patients: 150mg levobupivacaine 0.25%, 10mg morphine; and 30mg ketorolac made up to a volume of 150ml with saline.~The difference between treatment groups is how the multimodal injection is administered: either by periarticular infiltration around the knee, or by simple intra-articular injection after the knee joint capsule has been closed.~Treatment group 1: Periarticular infiltration~Intra-operatively after bone cuts have been made and prior to implant cementation, the multimodal injection will be infiltrated around the knee at 6 specific sites:~1. Medial femoral condyle periosteum~2. Medial gutter~3. Lateral femoral condyle periosteum~4. Lateral gutter~5. Posteromedial capsule~6. Posterolateral capsule"
223842355|NCT03505645|PROCEDURE|Intra-articular infiltration|"The injection will consist of the same drugs for all patients: 150mg levobupivacaine 0.25%, 10mg morphine; and 30mg ketorolac made up to a volume of 150ml with saline.~The difference between treatment groups is how the multimodal injection is administered: either by periarticular infiltration around the knee, or by simple intra-articular injection after the knee joint capsule has been closed.~After implant cementation and watertight joint capsular closure, the multimodal injection will be injected intra-articularly through the closed capsule."
223842356|NCT01894958|DRUG|NNZ-2566|Glycyl-L-2-Methylpropyl-L-Glutamic Acid (NNZ-2566) supplied as a lyophilized powder (2g in 50mL vials or 3g in 30mL bottles) for reconstitution with strawberry flavored solution 0.5% v/v in Water for Injection.
223842357|NCT01894958|DRUG|Placebo|Strawberry flavored solution
223842358|NCT01026415|DRUG|brentuximab vedotin|1.8 mg/kg IV every 21 days
223842359|NCT01026415|DRUG|rifampin|600 mg/day PO
223842360|NCT01026415|DRUG|midazolam|1 mg IV
223842361|NCT01026415|DRUG|ketoconazole|400 mg/day PO
223842362|NCT01026415|DRUG|brentuximab vedotin|1.2 mg/kg IV every 21 days
223842363|NCT04651738|DIAGNOSTIC_TEST|DNA methylation testing|Methylation testing of host DNA, namely, BHLHE22, CELF4, HAND2, and ZNF177
223842364|NCT01447355|DRUG|cholecalciferol|Given PO
223842365|NCT06080217|DEVICE|study group|"The patients were lying in the lithotomy position with the stretched lower extremities. Probes are placed on the lower part of the abdomen in the area of the bladder (active probe) and on the lumbar spine (passive probe). A capacitive probe in the free treatment / power control program was used, where high frequency electricity was released to the bladder for 20 minutes with a frequency of 1.0 MHz and energy to maximum 410 C. Initialy, maximum energy of 75% and a frequency of 0.8 MHz was applied, which was reduced depending on the heat that was pleasant for the patient. Then, the power was reduced to 50% and increased the frequency to 1.0 MHz, which also meant moderate energy absorption. The procedure with this energy was continued until the end, and the patients absorbed 18-19 kJ of energy in average."
223842366|NCT06080217|DEVICE|placebo (sham control)|"The patients were lying in the lithotomy position with the stretched lower extremities. Probes are placed on the lower part of the abdomen in the area of the bladder (active probe) and on the lumbar spine (passive probe). A capacitive probe in the free treatment / power control program was used, but without any energy transferred through the probe,"
223842367|NCT00942240|DRUG|ACU-4429|administered orally once a day for 14 days
223842368|NCT00942240|DRUG|matching placebo tablet|administered orally once a day for 14 days
223842369|NCT06039891|DRUG|Nimotuzumab、Tislelizumab|Subjects will receive Nimotuzumab 400 mg/time, intravenous injection, qw; Tislelizumab 200 mg/time, q3w until disease progression, intolerable toxicity, or 24 months of medication
223842370|NCT03782948|DEVICE|Standard gait training on BART without pelvic perturbations|The Balance Assisted Robot on Treadmill (BART) enables various types of gait training on treadmill with visual feedback. It interfaces to the pelvis of the walking subject in an actuated and admittance-controlled manner, thus providing transparent haptic interaction with negligible power transfer.
223842371|NCT03782948|DEVICE|Robotised gait training with BART with pelvic perturbations|In addition to the standard gait training, the BART will deliver perturbations in the forward/backward and left/right direction.
223842372|NCT04701502|DIETARY_SUPPLEMENT|Viusid|"Patients received daily doses of 30 ml of Viusid every 8 hours plus standard care for COVID-19. Viusid is administered orally.~Treatment duration: 21 days"
223842373|NCT04701502|DIETARY_SUPPLEMENT|Asbrip|"Patients received daily doses of 10 ml of Asbrip every 8 hours plus standard care for COVID-19. Asbrip is administered orally.~Treatment duration: 21 days"
223842374|NCT04701502|DRUG|Standard Care|Standard care for COVID-19
223842375|NCT00965484|DEVICE|New Genotropin Pen|Subjects will use the genotropin pen for 2 months. After 2 months patients and caregiver will be asked to fill out a questionnaire to assess perception of the genotropin pen
223842376|NCT02288715|OTHER|no interventions|
223842377|NCT00315211|DRUG|Intravenous Topotecan|Topotecan 3 mg/m2 IV over 30 minutes on Days 1 and 8 every 21 days
223842378|NCT00315211|DRUG|Intravenous Docetaxel|Docetaxel 30 mg/m2 IV over 60 minutes on Days 1 \& 8 of a 21 day cycle
223842379|NCT00848211|OTHER|Placebo|Subcutaneous injection on Day 0, Day 28, and Day 84
223842380|NCT00848211|BIOLOGICAL|TUTI-16 (0.03mg)|Subcutaneous injection on Day 0, Day 28, and Day 84
223842381|NCT00848211|BIOLOGICAL|TUTI-16 (0.1mg)|Subcutaneous injection on Day 0, Day 28, and Day 84
223842382|NCT00848211|BIOLOGICAL|TUTI-16 (0.6mg)|Subcutaneous injection on Day 0, Day 28, and Day 84
223842383|NCT01124617|DRUG|Tapentadol|Tapentadol hydrochloride extended-release(ER) will be administered as oral tablet at dose ranging from 25 milligram (mg) to 250 mg twice daily for 12 weeks.
223842384|NCT01124617|DRUG|Placebo|Matching Placebo will be administered as oral tablet at dose ranging from 25 mg to 250 mg twice daily for 12 weeks.
223842385|NCT00646867|DEVICE|Tetrix|Twice daily topical application
223842386|NCT00646867|DEVICE|Placebo|Twice daily topical application
223842387|NCT00945477|DRUG|Pazopanib (GW786034)|Pazopanib 800 mg daily x 12 weeks
223842388|NCT00669695|DRUG|Atorvastatin treatment|Atorvastatin treatment: tablets of 40 mg Atorvastatin will be administered orally, respecting the dosage of 40 mg/day, for 6 months.
223842389|NCT00669695|OTHER|CPAP device|This device consists in a nasal continuous positive airway pressure (CPAP). It will be applied 3 months after the beginning of drug treatment and for 3 months.
223842390|NCT00669695|OTHER|sham CPAP treatment|This device consists in a sham CPAP. It will be applied 3 months after the beginning of drug treatment and for 3 months.
223842391|NCT02013232|DRUG|Aripiprazole|
223842392|NCT02724267|BIOLOGICAL|131I-chTNT-1/B|29.6 MBq/kg,intravenous administration in 1 hour，1-3 course of treatment
223842393|NCT03675204|OTHER|No intervention|No intervention
223842394|NCT01210053|DRUG|malate Given orally|Patients receive oral sunitinib malate 25 mg daily in the absence of disease progression or unacceptable toxicity.
223842395|NCT00619151|DEVICE|Top Hat|Implant of CarboMedics Top Hat mechanical valve.
223842396|NCT00619151|DEVICE|Regent|Implant of the St. Jude Medical Regent mechanical valve
223842397|NCT06042998|PROCEDURE|Robotic radical gastrectomy|Laparoscopic gastrectomy
223842398|NCT06187870|OTHER|Collection of biological data|Biological samples will be collected from the patient at the time of their access to the Hospital
223842399|NCT02461511|OTHER|Therapeutic Education|participation in a therapeutic education program on diabetes
223842400|NCT04358471|BIOLOGICAL|Intravitreal AAVCAGsCD59|AAVCAGsCD59 is administered as an intravitreal injection in the enrolled eye
223842401|NCT04358471|OTHER|Intravitreal Sham Injection|Sham injection mimics a real injection in the enrolled eye
223842402|NCT05328440|DRUG|Pyrotinib Maleate|once a day, 125mg each time, taking for 3 weeks, stopping for 1 week, 4 weeks as a cycle. It is recommended to take medicine at about the same time every day, take it with warm water, and fast at least 1 hour before and after taking medicine
223842403|NCT05328440|DRUG|Dalpiciclib Isethionate Tablets|400mg once a day, oral administration within 30 minutes after breakfast, continuous administration for 28 days as a cycle
223842404|NCT05328440|DRUG|Inetetamab|the initial dose is 8mg / kg and the subsequent dose is 6mg / kg. It is administered intravenously for 21 days.
223842405|NCT05328440|DRUG|Fulvestrant|fluvestrant is administered intravenously on the 1/15 day of the first cycle, and then on the first day of each cycle, 500mg / time, intravenously
223842406|NCT02825043|DEVICE|High-Flow Nasal Cannula|This is a humidified oxygen delivery system.
223842407|NCT06215729|BEHAVIORAL|routine rehabilitation treatment|The routine rehabilitation treatment included intervention for risk factors (such as blood pressure, blood lipids, and blood glucose control, restriction of smoking and alcohol, exercise, etc.) Besides, the patients with stable vital signs were scheduled for specialized rehabilitation training upon enrollment, and targeted rehabilitation programs were selected, conducted by experienced rehabilitation therapists.
223842408|NCT06215729|BEHAVIORAL|conventional cognitive training|including Memory training, attention training, and executive function training were conducted 2-5 times per week, lasting for 30-60 minutes each session, based on the patient's condition.
223842409|NCT06215729|BEHAVIORAL|Computer-assisted Cognitive Function Training|Based on the patient's cognitive impairment assessment results, the training content includes Attention game training, Executive function program training, Logical reasoning training, Agility training, Memory training. The training is conducted seven days a week, once a day, for a duration of 30-45 minutes per session
223842410|NCT05482568|DRUG|SHR-A1811 & Pyrotinib/SHR-A1811 & SHR-1316|"Drug: SHR-A1811 \& Pyrotinib~SHR-A1811： intravenous Pyrotinib：oral~Drug: SHR-A1811 \& SHR-1316~SHR-A1811： intravenous SHR-1316： intravenous"
223842411|NCT05805540|PROCEDURE|Cold-water immersion|Subjects were immersed, in a sitting position where legs were always covered, in cold water at 11ºC in periods of 2 minutes submerged and 2 minutes out of the water at room temperature (25ºC), repeating this process 5 times
223842412|NCT05805540|PROCEDURE|Protein-carbohydrates supplementation|Subjects consumed a mixed carbohydrate and protein beverage, composed of 0.3gr/kg of maltodextrin and 0.2gr/kg of neutral whey protein in 0.5 litres of water. Subject sat for 25 minutes until all recovery methods were completed.
223842413|NCT05805540|PROCEDURE|Active recovery|Subjects was carried out using a bicycle ergometer. The subjects pedaled for 25 minutes at 50% of the maximum heart rate (HRmax)
223842414|NCT05805540|PROCEDURE|Placebo|Subjects drank a water-based drink and sweetener. Subject sat for 25 minutes until all recovery methods were completed.
223842415|NCT02444143|DRUG|tacrolimus extended release|
223842416|NCT06088901|PROCEDURE|Autologous Blood Patch|2 ml/kg of whole blood (max 100 ml) is obtained via venipuncture. This blood is then injected via the chest tube which will then be clamped for 180 minutes, before being returned to suction. During this period of clamping, the patient will be rotated from side to side intermittently to help the blood move around the extrapleural space.
223842417|NCT03582137|DRUG|Cannabidiol|Subjects randomized to this arm will receive Cannabidiol Cannabis extract oral solution
223842418|NCT03582137|OTHER|Placebo|Subjects randomized to this arm will receive Placebo
223842419|NCT05391204|OTHER|Functional Tests|Various physical exercices of inferior members
223842420|NCT02402764|DRUG|Selinexor|Participants will receive selinexor twice weekly on Monday/Wednesday, Tuesday/Thursday or Wednesday/Friday of Weeks 1, 2 and 3 of each 4-week cycle. Selinexor will not be taken during Week 4. One cycle is defined as 28 days or 6 doses. The starting dose for this trial is 60 mg (flat dose as long as their dose-based body surface area (BSA) analysis does not exceed 70 mg/m\^2).
223842421|NCT01982760|DRUG|DDAVP|Patients Receiving DDAVP prior to operation
223842422|NCT05569655|DRUG|Tolvaptan|Within 12 hours of admission, subjects were randomly assigned to two groups using the central randomization method. For subjects in group A, tolvaptan (15 mg/d) is added to standard therapy (furosemide:20-40mg/d). The treatment lasts for a total of seven days to assess the efficacy and safety of tolvaptan in the treatment of PAH-induced right heart failure.
223842423|NCT05569655|DRUG|Furosemide|Within 12 hours of admission, traditional standard therapy (furosemide:20-40mg/d) is used for all subjects in our clinical trial. The treatment lasts for a total of seven days.
223842424|NCT00483262|DRUG|CCI-779|Given by injection once a week for 5 weeks (5 weeks equals one cycle) for up to 8 cycles
223842425|NCT00483262|DRUG|Bortezomib|Given by injection once a week for 4 weeks (a cycle equals 5 weeks) for up to 8 cycles
223842426|NCT00377598|DRUG|TAK-583|TAK-583 5 mg, tablets, orally, once daily for up to 8 weeks
223842427|NCT00377598|DRUG|TAK-583|TAK-583 25 mg, tablets, orally, once daily for up to 8 weeks
223842428|NCT00377598|DRUG|TAK-583|TAK-583 50 mg, tablets, orally, once daily for up to 8 weeks
223842429|NCT00377598|DRUG|TAK-583|TAK-583 100 mg, tablets, orally, once daily for up to 8 weeks
223842430|NCT00377598|DRUG|Placebo|TAK-583 placebo-matching tablets, orally, once daily for up to 8 weeks
223842431|NCT03123640|OTHER|Medication reconciliation and medication review|Pharmacist performed medication reconciliation and medication review
223842432|NCT03704298|DRUG|Cyclophosphamide|Administered according to package insert
223842433|NCT03704298|DRUG|Fludarabine|Administered according to package insert
223842434|NCT03704298|BIOLOGICAL|Axicabtagene Ciloleucel|A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells administered intravenously
223842435|NCT03704298|BIOLOGICAL|Utomilumab|Administered as an IV infusion
223842436|NCT02726555|DRUG|Red yeast rice and atorvastatin|Participants will receive 2 capsules of 300mg red yeast rice and 2 capsules of 10mg atorvastatin for 24 weeks.
223842437|NCT02726555|DRUG|Atorvastatin alone|Participants will receive 2 capsules of placebo and 2 capsules of 10mg atorvastatin for 24 weeks.
223842438|NCT04554498|DEVICE|1) high flux hemodiafiltration thrice -weekly during a 24 month follow-up|"1. the comparison of the effects of the two membranes on the serum levels of albumin, B2M, CRP, myoglobin, light chains, retinol binding protein, homocysteine, p-cresol, indoxyl sulfate, BPA, alpha-1-microglobulin (A1M), FGF23 (fibroblast growth factor 23), and inflammatory cytokines;~2. the evaluation of the changes induced by the two filters on lymphocyte subsets, monocyte activation and senescence, and apoptosis rate;~3. the definition of the impact of the two membranes on the accumulation of AGEs as an index of metabolic and oxidative stress, determined by a non-invasive method based on the measurement of skin autofluorescence through a dedicated device (AGE Reader, DiagnOptics Technologies BV, Groningen, Netherlands)."
223842439|NCT05895773|DRUG|Povidone-Iodine|Povidone Iodine 0.5% plus glycyrrhizin acid 2.5 mg/ml as a nasal and an oropharyngeal spray (mint flavored) will be applied 4 times per day.
223842440|NCT05895773|DRUG|Saline spray|Normal saline 0.9% as a nasal and oropharyngeal spray (Mint flavored) will be applied 4 times per day.
223842441|NCT03766828|PROCEDURE|inside-out-access technique with inside-out access device (Surfacer (R))|inside-out-access technique with (Surfacer (R)) with a new CE certified device (Surfacer (R), Bluegrass Vascular)
223842442|NCT03766828|PROCEDURE|access technique including Sharp recanalization|access technique with Sharp recanalization via interventional radiology
223842443|NCT04007809|OTHER|Glucagon|Every patients will undergo stimulated C peptide test. Glucagon will be administered using intravenous route (0,03 mg/kg, max 1mg).
223842444|NCT05789355|DIETARY_SUPPLEMENT|NUV001|Daily supplementation with NUV001 at 1000 mg (4 tablets of 250 mg each) for 90 days with a prolonged follow-up of 1 month (30 days) after stopping the supplementation
223842445|NCT02453529|DRUG|WCK 4873|Oral tablets
223842446|NCT05084300|OTHER|Pain Neuroscience Education|A total of 10 PNE sessions (Neuroscience pain education) will be carried out, two each week in addition medical treatment similar to control group (Usual care). The NPE sessions will be conducted by an experienced NPE certified physical therapist in 35 minute face-to-face group sessions. In NPE, the patient is taught about the physiology of pain, central sensitization, representation of the different body regions in the brain, pain-related changes in body perception, and the psychosocial dimensions of pain.
223842447|NCT05084300|OTHER|Usual care|The control group (Usual care) is treated with usual treatment, managment or medication for fibromyalgia, anxiolytics, antidepressants, analgesics. Depending on the medical needs and criteria of patients´s primary care physician.
223842448|NCT00918190|DRUG|Placebo|Saline
223842449|NCT00918190|DRUG|Ondansetron, Dexamethasone|Use of ondansetron and dexamethasone as combined antiemetics
223842450|NCT00918190|DRUG|Midazolam, dexamethasone|use of midazolam and dexamethasone as combined antiemetic
223842451|NCT01607970|DRUG|Oxytocin|Oxytocin: 24 IU; 3 puffs per nostril, each with 4 IU OXT
223842452|NCT02303574|DRUG|AZD7986, oral solution, 1 to 50 mg/mL|Starting dose in single ascending dose part: 5 mg
223842453|NCT02303574|DRUG|Placebo, oral solution|Matching placebo
223842454|NCT04875260|OTHER|Critical Care|Critical care in the intensive care units
223842455|NCT01873677|DRUG|M518101|
223842456|NCT01873677|DRUG|Vehicle|
223842457|NCT05943587|OTHER|culture-sensitive PNE4kids|Culturally adapted PNE4kids used by physiotherapists worldwide in chronic pain rehabilitation.
223842458|NCT05943587|OTHER|standard education|Standard education used by physiotherapists worldwide in chronic pain rehabilitation.
223842459|NCT04002089|DRUG|Exparel Injectable Product|bupivacaine liposome injectable suspension
223842460|NCT04002089|DRUG|Bupivacaine|1.3%, 13.3 mg/mL
223842461|NCT00859014|BIOLOGICAL|Autologous Bone Marrow Mononuclear Cells|Harvest of bone marrow from ischemic stroke patients, isolation of bone marrow mono-nuclear cells, and peripheral IV infusion of autologous bone marrow mono-nuclear cells
223842462|NCT02731404|PROCEDURE|HFJV ventilation|The investigators used the Perkins tonometer for monitoring intra-ocular pressure. Evaluation of intra-ocular pressure was done before induction of anesthesia, end of induction, during surgery and at the end of surgery.
223842463|NCT02731404|PROCEDURE|IPPV ventilation|The investigators used the Perkins tonometer for monitoring intra-ocular pressure. Evaluation of intra-ocular pressure was done before induction of anesthesia, end of induction, during surgery and at the end of surgery.
223842464|NCT05030376|DIETARY_SUPPLEMENT|intraileal infusion|intraileal glucose or intraileal saline infusion
223842465|NCT01863966|OTHER|hot water drinking therapy|Drink 200ml hot water 3min before and after a meal. Swallow food with hot water and drink 200ml hot water before sleep
223842466|NCT01863966|PROCEDURE|Pneumatic dilation|Patients who are unsatisfied with hot water drinking therapy are to receive standard pneumatic dilation under endoscope
223842467|NCT03431519|PROCEDURE|VP|Percutaneous Injection of Strontium Containing Hydroxyapatite versus Polymethacrylate plus Short Segment Pedicle Screw Fixation
223842468|NCT04796935|DEVICE|Tactile Imaging (VerTouch)|VerTouch device used to identify and mark, or begin placement of a needle at an insertion site. After the device is taken off the back, the procedure will continue in the usual manner.
223842469|NCT04796935|OTHER|Control (palpation)|Control, palpation used to identify and mark an insertion site.
223842470|NCT00599677|OTHER|acupuncture|Subjects are treated five days a week continuously, and for four weeks.They are treated 30min every time.
223842471|NCT00599677|DRUG|Itopride|Each pill weighs 50mg, once a pill, three times a day. The pills are taken half an hour before meals, and be taken 4 weeks continuously.
223842472|NCT02854891|OTHER|autorefractometer, A-scan ultrasound|A measurement of refraction will be made by the Autorefractometer. A measurement of the eyes' biometer data will be made by A-scan ultrasound.
223842473|NCT02888795|DRUG|hypertonic dextrose prolotherapy|five intra-articular injection at 2-weeks intervals in weeks 0, 2, 4, 6, 8.
223842474|NCT00783718|DRUG|vedolizumab|Vedolizumab for intravenous infusion
223842475|NCT00783718|OTHER|Placebo|Placebo intravenous infusion
223842476|NCT01575145|BEHAVIORAL|Quitline facilitation intervention|brief quitline facilitation intervention
223842477|NCT01575145|BEHAVIORAL|Brief stop-smoking intervention|brief review of tips to help maintain smoking abstinence, using brochure
223842478|NCT00602901|OTHER|HVLA-SM|High-velocity low amplitude spinal manipulation (HVLA-SM)
223842479|NCT00602901|OTHER|LVVA-SM|Low-velocity variable amplitude spinal manipulation (LVVA-SM)
223842480|NCT00602901|DRUG|Usual medical care|Celebrex: po, 200mg, qd, six weeks; Aleve: po, 220mg, bid, six weeks; Bextra: po, 10mg, qd, six weeks; Naproxen: po, 500mg, bid, six weeks.
223842481|NCT06394336|OTHER|Muscle strengthening|Strengthening exercises for the intrinsic muscles of the foot and hips
223842482|NCT06394336|DRUG|Standard treatment (oral analgesic/anti-inflammatory drug)|oral analgesic/anti-inflammatory drug. Education.
223842483|NCT01632865|DEVICE|stenting|Apollo stent (MicroPort Medical, China),Neuroform stent (Stryker/Boston Scientific, USA) or Wingspan stent (Stryker/Boston Scientific, USA), et al.
223842484|NCT05868499|BIOLOGICAL|EXG34217|Single infusion
223842485|NCT02482909|PROCEDURE|Hepatic resection|Anatomical surgical resection of the liver including the tumor
223842486|NCT02482909|PROCEDURE|Radiofrequency ablation|Percutaneous ablation using radiofrequency under the imaging guidance
223842487|NCT02668835|DEVICE|Non intervention-Monitoring device|Fox Insight self-monitoring android app and smartwatch Participants will be asked to wear a smartwatch with accelerometers, during day and night, for a period of 2 weeks. Additionally, a self-monitoring app on a smartphone is used, where the participant reports when they take any medication and performs a focused attention task to encourage resting tremor.
223842488|NCT02668835|GENETIC|Non intervention-Genetic testing|
223842489|NCT00315965|DRUG|Nitric oxide, Carbon monoxide, Helium|
223842490|NCT02135783|PROCEDURE|Decompressive Craniectomy|A portion of frontal,temporal, and parietal bone was removed by craniectomy and the size of decompression was about 10x12 cm2.Intracerebral hematoma was evacuated by transcortical approach with the aid of a surgical microscope.
223842491|NCT02135783|PROCEDURE|non-Decompressive Craniectomy|a simple hematoma removal by osteoplastic craniotomy group (HR) or Intracerebral hematoma was evacuated by transcortical approach with the aid of a surgical neuroendoscopyand the size of decompression was about 3x2.5 cm2.
223842492|NCT02007447|DRUG|OCYTOCINA - SPRAY NASAL|The initial sample is divided into two groups (A and B): group A receive oxytocin intranasal for 8 weeks 24UI twice a day (3 applications per nostril 4UI 12/12 hours); group B will receive placebo for 8 weeks
223842493|NCT05254730|DEVICE|macro-micro tetrodes for intracranial recording|novel design of tetrode micro electrodes within the standard macro intracranial electrodes used clinically for identification of the epileptogenic zone
223842494|NCT01783457|OTHER|Control|Usual treatment: pharmacological treatment + regular sessions with their psychiatrist.
223842495|NCT01783457|OTHER|Individual psychoeducation|"Usual treatment + individual psychoeducational programme, consisting of 14 sessions of 60 minutes every other week for six months, focused on improving patient awareness of their condition, adherence to treatment, identification of prodromes, early intervention in potential relapses, anxiety management techniques, social skills, healthy lifestyle habits and problem solving.~Programme of sessions available upon request."
223842496|NCT00000989|DRUG|Zidovudine|
223842497|NCT00000989|DRUG|Sargramostim|
223842498|NCT00000989|DRUG|Ganciclovir|
223842499|NCT00696293|DRUG|Duloxetine|Duloxetine up to 120 mg/day + Clinical Management
223842500|NCT01687192|BIOLOGICAL|HPV prophylactic vaccine Gardasil|3 injections: at Inclusion visit then 2 and 6 months after.
223842501|NCT00651677|PROCEDURE|HAL proctectomy|Hand-assisted laparoscopic proctectomy
223842502|NCT00651677|PROCEDURE|"straight laparoscopic proctectomy"|"straight laparoscopic proctectomy"
223842503|NCT00651677|PROCEDURE|Hand-assisted laparoscopic proctectomy|hand-assisted laparoscopic proctectomy
223842504|NCT00651677|PROCEDURE|SL Proctectomy|Straight laparoscopic proctectomy
223842505|NCT00586274|PROCEDURE|CD34 selected haploidentical PBSCT|Infusion of CD34 selected haploidentical PBSCT
223842506|NCT00586274|DRUG|Fludarabine|day -8 through day -4 Fludarabine 30 mg/m\^2
223842507|NCT00586274|BIOLOGICAL|T cell infusion|"At least 30 days after the stem cell infusion, patients will be dosed with T cells. This study will begin with a dose of T cells known not to cause GvHD even in haploidentical recipients, even when the T cells administered have not first been allodepleted. Dose escalation will follow a traditional up and down method, but as results become available they will be used to determine subsequent dose levels by the continual reassessment method. Initially, 2 patients will be entered beginning at dose level 1. Each and every patient will receive up to three additional injections of T cells at the same dose, at monthly intervals, provided there is no evidence of grade 2 or higher GVHD, until total T cell numbers are \> 1000/ul.~Dose level -1 (1 x 10\^3 T cells/Kg); Dose level 1 (1 x 10\^4 T cells/Kg); Dose level 2 (1 x 10\^5 T cells/Kg); Dose level 3 (1 x 10\^6 T cells/Kg); Dose level 4 (5 x 10\^6 T cells/Kg)"
223842508|NCT00586274|BIOLOGICAL|Campath 1h|10 mg iv over 4 hours day-8 through day-6
223842509|NCT00586274|BIOLOGICAL|anti-CD45|anti-CD45 400 ug/kg over 6 hours day -5 through day -2
223842510|NCT02133274|BEHAVIORAL|Brief Psychosocial Intervention|Five weekly sessions of a Brief Psychosocial Intervention based of Behavioral Cognitive Therapy designed specifically for the present study.
223842511|NCT02133274|OTHER|Early Palliative Care|Early integration of Palliative Care into the standard oncologic care. Patients starting first line chemotherapy will receive immediately evaluation by the board-certified palliative care physicians.
223842512|NCT01759121|RADIATION|T-PRP|532nm-short pulse panretinal photocoagulation with PASCAL function
223842513|NCT01759121|RADIATION|S-PRP|532nm-partially subthreshold short pulse panretinal photocoagulation with PASCAL endpoint management function
223842514|NCT02374502|BEHAVIORAL|Brief Intervention|'Brief Intervention' is the term used to mean verbal advice, discussion, negotiation or encouragement, with or without written or other support or follow-up. 'Brief Interventions' provide a structured way to deliver advice and involve the provision of formal help and follow-up. They aim to equip people with tools to change attitudes and handle underlying problems.
223842515|NCT00647140|OTHER|18F-L-DOPA PET|PET performed 30 minutes after IV injection of 4 MBq/kg of 18F-DOPA
223842516|NCT01027871|DRUG|LY2605541|subcutaneous injection of LY2605541 every morning with dose titration based on blood glucose measures for 12 weeks
223842517|NCT01027871|DRUG|insulin glargine|subcutaneous injection of insulin glargine every morning with dose titration based on blood glucose measures for 12 weeks
223842518|NCT00140881|DRUG|MK0476; montelukast sodium|
223842519|NCT00140881|DRUG|Comparator: placebo|
223842520|NCT05407194|DIETARY_SUPPLEMENT|Collagen + vitamin C|Participants take the supplement (or placebo) every day for 24 weeks. On three days per week they perform tendon loading exercises.
223842521|NCT04268264|PROCEDURE|Incremental haemodialysis|twice weekly haemodilysis at the start, gradually building up to full dose dialysis over a period of 15 weeks
223842522|NCT04268264|PROCEDURE|Conventional haemodialysis|three times weekly 4-hour long haemodialysis sessions from the start
223842523|NCT06234397|DRUG|BH3120|BH3120 will be administered as an IV infusion over 90 minutes on Day 1 of every 3-week treatment cycle
223842524|NCT06234397|DRUG|pembrolizumab|Fixed dose of pembrolizumab will be administered as an IV infusion over 30 minutes on Day 1 of every 3-week treatment cycle
223842525|NCT05873803|BIOLOGICAL|GR1802 injection|150mg/1ml. 2 ml every two weeks Route of administration: Subcutaneous
223842526|NCT05873803|BIOLOGICAL|placebo|0mg/1ml. 2 ml every two weeks Route of administration: Subcutaneous
223842527|NCT02405390|PROCEDURE|Video Laryngoscopy|Head motion will be measured by using Polhemus Patriot™ electromagnetic tracking system
223842528|NCT02405390|PROCEDURE|Direct Laryngoscopy|Time for intubation will be measured from the laryngoscope entering the mouth to the endotracheal tube passing through the vocal cords
223842529|NCT02405390|DEVICE|Storz C-Mac® laryngoscope|
223842530|NCT05773898|OTHER|other|The interviewers will collect data from relatives using questionnaires and evaluation grids based on an identification form, a Life Trajectory questionnaire, an anthropological evaluation grid, a retrospective psychiatric diagnosis questionnaire (SCID), a socio-demographic questionnaire, a questionnaire on suicide risks and a questionnaire on emotional state.
223842531|NCT05994235|DRUG|Mosunetuzumab|"Mosunetuzumab will be administered in weekly dose increments (step-up dosing) during Cycle 1 and then on Day 1 of each cycle. Mosunetuzumab will be given in 28-day cycles for up to 12 cycles. Mosunetuzumab will be administered SC at the dose of 5 mg on Day 1, 45 mg on Day 8, and 45 mg on Day 15 in Cycle 1. Beginning with Cycle 2, it will be administered SC at the dose of 45 mg on Day 1. Each cycle lasts 4 weeks."
223842532|NCT05994235|DRUG|Tazemetostat Pill|Oral tazemetostat will be administered by mouth twice daily at standard dosing (800 mg twice daily) beginning at the same time as mosunetuzumab initiation until disease progression, unacceptable toxicity, or consent is withdrawn. Patients will remain on tazemetostat for up to twelve 28-day cycles from initiation of mosunetuzumab.
223842533|NCT06087692|OTHER|Exercise|-based game therapy applied in addition to aerobic exercise
223842534|NCT04869657|BEHAVIORAL|Coaches with Children's Hospital of Philadelphia (CHOP) Research Consultant Support|Coaches employed by the school district will support the implementation of three evidence-based practices, while themselves being remotely supported by CHOP research consultants.
223842535|NCT04869657|BEHAVIORAL|Coaches without CHOP Research Consultant Support|Coaches employed by the school district will support the implementation of three evidence-based practices without any additional support from CHOP research consultants.
223842536|NCT05877547|DRUG|Efinopegdutide|Subcutaneous (SC) injection in dose-escalation regimens potentially including doses of 2 mg, 4 mg, 7 mg, and 10 mg
223842537|NCT05877547|DRUG|Semaglutide|SC injection in a dose-escalation regimen of 0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, and 2.4 mg
223842538|NCT05877547|DRUG|Placebo|SC injection of matching placebo
223842539|NCT04536025|OTHER|Qualitative focus group interviews|Prosthetists and/or expert working group members will participate in qualitative focus group interviews up to 120 minutes in length.
223842540|NCT04536025|OTHER|Qualitative semi-structured interviews|People with lower limb amputation and/or expert working group members will participate in qualitative individual, semi-structured interviews approximately 60 minutes in length.
223842541|NCT04159896|DRUG|Pan-VEGFR/TIE2 Tyrosine Kinase Inhibitor CEP-11981|Given PO
223842542|NCT04159896|BIOLOGICAL|Nivolumab|Given IV
223842543|NCT02156791|BIOLOGICAL|gpASIT+TM|
223842544|NCT02877537|DRUG|Salbutamol|bronchodilation obtained with 2 inhalations of salbutamol (100 µg per dose) with inhalation chamber
223842545|NCT02877537|PROCEDURE|Forced oscillation technique|before and after bronchodilation
223842546|NCT02877537|PROCEDURE|Plethysmography|
223842547|NCT02413788|OTHER|aerobic exercise|aerobic training 40 minutes on a treadmill (60-80% of maximum heart rate)
223842548|NCT02413788|OTHER|combined exercise|aerobic training 40 minutes on a treadmill (60-80% of maximum heart rate); resisted training in equipment and free weights for 10 minutes with a set of 10 repetitions in quadriceps, triceps and biceps of the arms and legs
223842549|NCT02413788|DEVICE|treadmill|
223842550|NCT05055375|OTHER|questionnaire survey|We will conduct a questionnaire survey of outpatients.
223842551|NCT02084082|DRUG|Linagliptin/Metformin ER FDC|1x Linagliptin/Metformin FDC tablet
223842552|NCT02084082|DRUG|Linagliptin|1x Linagliptin tablet
223842553|NCT02084082|DRUG|Metformin ER|2x Metformin ER tablets
223842554|NCT05266261|DRUG|Ibandronate Oral Tablet|150 mg of ibandronate + 24,000 IU of cholecalciferol
223842555|NCT04285502|PROCEDURE|SURGICAL DRAIN|A surgical drain is a tube used to remove blood, abscess and any type of fluid at the site of the place it is inserted
223842556|NCT02887651|RADIATION|Cavity boost radiation|Cavity boost radiation therapy with 10 x 3 Gy for patients suffering from complete resected cerebral metastases
223842557|NCT05209399|PROCEDURE|Ultrasound guided injection|All intraarticular hip injections will be performed under real-time ultrasound guidance using a GE LOGIQ P9 ultrasound machine with a C1-5-RS 1-5 MHz curvilinear transducer (GE Healthcare, Chicago, IL, USA). For the procedure, patients will be placed in a supine position. The curvilinear transducer and ultrasound machine will be used to visualize the anterior aspect of the hip joint in a sagittal oblique plane. Sterile technique will be used to perform the procedure.
223842558|NCT05860543|DIAGNOSTIC_TEST|C2i-WGS-MRD Test|The C2i-WGS-MRD Test (hereinafter referred to as C2i-Test), a personalized molecular circulating tumor DNA (ctDNA) test, is an in vitro qualitative test that uses next generation sequencing (NGS) based whole-genome sequencing (WGS) data for detecting molecular residual disease (MRD) in patients diagnosed with muscle-invasive bladder cancer (MIBC) and histopathologically classified as stage II-IIIA
223842559|NCT05705167|DRUG|Plitidepsin|IV infusion over 60-minutes
223842560|NCT06340880|OTHER|Serratus anterior plane block|ultrasound guided SAPB vs anatomical landmark guided SAPB
223842561|NCT05675696|OTHER|Esophageal Catheter|Newly designed external monitor that will capture esophageal pressure from a proprietary nasogastric tube combined with simultaneous pressure, flow, and volume measurements from the ventilator tubing.
223842562|NCT05499585|OTHER|Whole Dairy|2 1/2 servings of whole dairy per day
223842563|NCT04736056|BEHAVIORAL|Mindfulness-Based Therapy for Insomnia with Cognitive-Behavioral Symptom Coping Skills|Mindfulness-based sleep strategies and cognitive-behavioral symptom coping skills.
223842564|NCT05806554|DEVICE|Continuous glucose monitoring device|Continuous glucose monitoring device
223842565|NCT03163511|COMBINATION_PRODUCT|VC-02 Combination Product|PEC-01 cells loaded into a Delivery Device
223842566|NCT06624189|OTHER|Auto-pended bot liver ultrasound order|This alert prompt providers at the time of encounter to place appropriate imaging orders for hepatocellular carcinoma (HCC) screening in patients with cirrhosis.
223842567|NCT04238455|PROCEDURE|Sham serratus anterior plane block|The serratus anterior plane block will be performed by the anesthesiology team just prior to emergence from general anesthesia.
223842568|NCT04238455|PROCEDURE|Serratus anterior plane block|The serratus anterior plane block will be performed by the anesthesiology team just prior to emergence from general anesthesia.
223842569|NCT06648096|DRUG|Afatinib|Afatinib starting at 20 mg (weeks 1-2), escalating to 30 mg after two weeks (weeks 3-4) and escalating to 40 mg after one month (week 5 - thereafter) if no hematologic or other relevant toxicities are observed (CTCAE V5.0 \< grade 2)
223842570|NCT03959098|DRUG|Herbal medicine|Herbal medicine will be administered in water-based decoction (120ml) and dried powder (2g) form (Ostericum koreanum,Eucommia ulmoides, canthopanax sessiliflorus, Achyranthes japonica, Psoralea corylifolia, aposhnikovia divaricata, Cibotium barometz, Lycium chinense, Boschniakia rossica, Cuscuta chinensis, Glycinemax, Atractylodes japonica) at the physician's discretion.
223842571|NCT03959098|PROCEDURE|Chuna manual medicine|Chuna is a Korean manual therapy directed at the spine and joints that incorporates various spinal manual medicine techniques for joint mobilization involving highvelocity, low amplitude thrusts to joints slightly beyond the passive range of motion and gentle force to joints within the passive range of movement. Chuna manual medicine will be administered to the pelvic, lumbar, thoracic, and cervical vertebrae at the physician's discretion.
223842572|NCT03959098|PROCEDURE|Bee venom pharmacopuncture|Bee venom pharmacopuncture will be administered only after confirming a negative response to hypersensitivity skin test. Diluted bee venom saline:bee venom ratio, 10,000:1) filtered for allergens will usually be injected at 4-5 acupoints proximal to the dysfunctional site at the physician's discretion. Each acupuncture point will be injected to a total of 0.5-1 cc using disposable injection needles (CPL, 1 cc, 26G x 1.5 syringe, hinchang medical co., Korea).
223842573|NCT03959098|PROCEDURE|Pharmacopuncture|Pharmacopuncture consisting of select herbal ingredients will be dministered at Hyeopcheok (Huatuo Jiaji, EX B2), Ah-shi points and local acupuncture points using disposable injection needles (CPL, 1 cc, 26G x 1.5 syringe, Shinchang medical co., Korea) at the physician's discretion.
223842574|NCT03959098|PROCEDURE|Acupuncture|Acupuncture treatment will be administered using mainly proximal acupuncture points and Ah-shi points.
223842575|NCT03959098|PROCEDURE|Electroacupuncture|Electroacupuncture treatment will be administered using mainly proximal acupuncture points and Ah-shi points.
223842576|NCT03959098|PROCEDURE|Cupping|Cupping treatment will be administered at 1-2 points using mainly proximal acupuncture points and Ah-shi points.
223842577|NCT03959098|PROCEDURE|Other intervention(s)|Patients will be allowed any other additional intervention(s) as deemed necessary regardless of type or dose, and patterns of use will be investigated and recorded as a pragmatic clinical study.
223842578|NCT03437668|DRUG|WSE|WSE tablets
223842579|NCT03437668|DRUG|Placebo Oral Tablet|Placebo tablet
223842580|NCT02099539|BIOLOGICAL|N-803|Intravenous infusion for cohort 1, 2, 3 and 4; subcutaneous injection for cohort 5, 6 and 7; two 6-week treatment cycles: ALT-803 on Day 1, 8, 15, 22; stable or benefitting patients may receive up to two additional 6-week cycles
223842581|NCT05515874|DRUG|Feraheme|"Ferumoxytol contains iron and is used for the treatment of anemia, so it may affect any iron supplementation prescribed by a physician. Iron is metabolized in the liver, so impaired liver function could interfere with the metabolism of ferumoxytol.~Patients will receive up to a total maximum ferumoxytol dose of 4 mg/kg (71.6 µmol Fe/kg) of body weight, diluted in 200 mL of 0.9% normal saline, at a rate of 10 ml/minute for 20 minutes, The injection rate and maximum dosage are well within the safety thresholds regarding the FDA recommendation of ferumoxytol use."
223842582|NCT05787652|BEHAVIORAL|ARTEMIS mobile app|Access to a self-regulation based mobile application.
223842583|NCT05812794|DEVICE|Transcranial Direct Current Stimulation (tDCS)|"Participants will come for 5 sequential days of 2 hour long occupational therapy sessions augmented by tDCS for the first 20 minutes of the session. At arrival, the stimulation safety sheet will be completed by the occupational therapist.The saline soaked electrodes will be placed on the study subjects head and connected to the Soterix 1x1 Limited Total Energy (LTE) enabled tDCS device. Current output through the device will be sham stimulation on day 1 , followed by steady increases to a maximum of 1milliampere (mA) in patients aged 5-12 years old, and 1.5 mA in patients aged 13-19 years old, per the study design flow sheet at the end of this protocol. Blood pressure, pulse rate, and peg-board scores will be recorded as indicated on the stimulation safety sheet during each session.A repeat assessment will be done by the occupational therapist one week post therapy completion.There will be a repeat assessment visit 3 months post intervention."
223842584|NCT06101927|DRUG|Whole body study and SPECT with [99mTc]Tc-BQ0413|One single intravenous injection of \[99mTc\]Tc-BQ0413, followed by gamma camera imaging after 2, 4, 6 and 24 hours.
223842585|NCT00250419|BIOLOGICAL|V930|
223842586|NCT01692262|DRUG|Intermittent dosing of AZD5363|Intermittent dosing of AZD5363: oral solid formulation, twice daily (480 mg bid 4 days on and 3 days off). Recruitment suspended and will not be re-opened.
223842587|NCT01692262|DRUG|Intermittent dosing of AZD5363|Intermittent dosing of AZD5363: oral solid formulation, twice daily (480 mg bid 4 days on and 3 days off). Treatment to begin on Day 1 and to continue to study withdrawal. Recruitment complete.
223842588|NCT01692262|DRUG|Intermittent dosing of AZD5363|Intermittent dosing of AZD5363: oral solid formulation, twice daily (480 mg bid 4 days on and 3 days off). Treatment to begin on Day 1 and to continue until study drug withdrawal. This part of the study will not be conducted.
223842589|NCT05299086|DRUG|Intranasal Drug (INCS = Fluticasone furoate nasal spray, Placebo = Normal saline nasal spray)|The investigators want to compare the efficacy of intranasal corticosteroid between daily versus as needed use in children with perennial allergic rhinitis which had not been studied before.
223842590|NCT02679651|OTHER|Ultrasound of the foot|An ultrasound will be used to determine the thickness of the fat pad
223842591|NCT02679651|OTHER|Pedobarograph Measurements|This non-invasive device measures the force and pressure of the foot while standing and walking.
223842592|NCT02679651|OTHER|Manchester Foot Pain and Disability Index|This is a patient completed questionnaire that assesses level of function from the past month specific to foot pain.
223842593|NCT04289987|BIOLOGICAL|CVI-HBV-002|Investigational Product
223842594|NCT04289987|BIOLOGICAL|Normal Saline(placebo)|Investigational Product
223842595|NCT04996069|DEVICE|Crest Whitening Emulsions|Subjects with Xerostomia will be asked to apply the study intervention product to their teeth up to 4 times per day for 1 week to investigate if the study intervention product increases saliva production in this dry mouth populaiton.
223842596|NCT04456738|BEHAVIORAL|Parent Training|16 weeks of of parent training led by a trained group facilitator
223842597|NCT00995358|BIOLOGICAL|peptide|Each of three peptides (1mg) mixed with IFA (1ml) were injected every week at five round.
223842598|NCT05711238|OTHER|Robotic rehabilitation|In robot-assisted therapy, the therapist selects different programs with personalized environments to train patients to strengthen limb muscles that have previously had difficulty with movements or are relatively weak. Active (individual finger movement, memory, motility, apple tree, target board, recycling bins, balloons, firefighter), auxiliary, and passive (cpm, cpm plus) treatment options are available in the system.
223842599|NCT05711238|OTHER|Conventional rehabilitation|Conventional therapy group In the pediatric rehabilitation of the children's hands on the affected side, an exercise program consisting of 40 minutes of hand finger joint range of motion exercises (passive, active assistive), strengthening exercises, and coarse and fine dexterity exercises was planned, accompanied by a physiotherapist experienced for at least 5 years.
223842600|NCT05413564|OTHER|optimized self-exclusion procedure by extending the suspension of commercial solicitations for a total of 9 months|optimized self-exclusion procedure A
223842601|NCT00135746|DRUG|nicotine transdermal system|
223842602|NCT01435408|OTHER|Conventional primary PCI|Conventional primary PCI in STEMI with implantation of DES.
223842603|NCT01435408|OTHER|Ischemic postconditioning.|Primary PCI in STEMI with implantation of DES. Following re-opening of the culprit artery mechanical postconditioning with 4 cycles of 30/30 sec. reperfusion/re-occlusion i performed.
223842604|NCT01435408|OTHER|Deferred stenting in primary PCI.|In STEMI re-opening of the artery with guidewire/thrombectomy/small size balloon inflation DES stenting is postponed for 48 hours.
223842605|NCT06224270|BIOLOGICAL|Adjuvanted Recombinant Zoster Vaccine (RZV)|The RZV vaccine is indicated for prevention of herpes zoster (HZ) in adults aged 18 years and older who are or will be at increased risk of HZ. Patients with IBD on immunosuppressive therapy are at increased risk for HZ.
223842606|NCT05988489|BEHAVIORAL|Dynamic Deconstructive Psychotherapy (DDP)|DDP treatment with an assigned therapist for up to 12 months
223842607|NCT05988489|BEHAVIORAL|Brief Intervention and Contact (BIC)|BIC treatment with an assigned therapist for up to 12 months
223842608|NCT04666454|DRUG|Adenosine|Adenosine infusion 70 µg/kg/min for 3 hours.
223842609|NCT04666454|DRUG|Dipyridamole 200 mg|200 mg b.i.d
223842610|NCT04666454|DRUG|Apixaban 5 mg Oral Tablet|5mg b.i.d
223842611|NCT04666454|OTHER|Care as recommended by the Taskforce on Takotsubo Syndrome of the Heart Failure Association of the European Society of Cardiology for takotsubo syndrome|This treatment will vary depending on local routines and the degree of adherence to the recommendations.
223842612|NCT03621553|DRUG|Ergocalciferol|Vitamin D2 50,000 units
223842613|NCT03621553|DRUG|Placebo|Sugar pill manufactured to mimic ergocalciferol 50,000 units
223842614|NCT03621553|DRUG|Calcium Citrate with Vitamin D2|To meet the recommended minimum daily dietary requirements
223842615|NCT01266044|PROCEDURE|Acupuncture - Group 1|Acupuncture at 14 points. The needles will remain in place for 20 minutes with each treatment.
223842616|NCT01266044|PROCEDURE|Acupuncture - Group 2|Acupuncture needles placed at different points from Group 1. The needles will remain in place for 20 minutes with each treatment.
223842617|NCT01266044|OTHER|Standard Care|Standard oral care recommendations. Participants in all groups will receive the same recommendations.
223842618|NCT01266044|OTHER|Questionnaire|Baseline assessments will be completed within 7 days prior to starting radiotherapy, and patients will then complete the same assessments again at week 4 and 7 of radiotherapy and 3, 6, and 12 months after the end of radiotherapy.
223842619|NCT05737550|DEVICE|Previct Drugs|Previct Drugs is a new non CE-marked eHealth system intended to be used for future monitoring and treatment of patients with substance use disorder (SUD). Previct Drugs consists of an application (app) to be installed on a smartphone, a web-based careportal to be accessed from a computer by the healthcare professional for administration and access of registered data, and a database for storage, handling, and analysis of reported data. Previct Drugs is intended to be used by healthcare professionals and patients within treatment of SUD.
223842620|NCT00125151|DRUG|C1 inhibitor concentrate (C1-esteraseremmer-N)|
223842621|NCT04465890|DRUG|ASC22|200mg/1ml/1bottle
223842622|NCT04465890|DRUG|sodium chloride|90mg/10ml/1 bottle
223842623|NCT03395587|BIOLOGICAL|Autologous, tumor lysate-loaded, mature dendritic cells (DC)|Advanced therapy medicinal product (ATMP) produced at the University Hospital Düsseldorf according to Good Manufacturing Practice (GMP) with production permission according §13 AMG (German Drug Law) of the local authorities (Bezirks¬regierung Düsseldorf)
223842624|NCT03395587|DRUG|standard therapy|temozolomide, fractionated radiochemotherapy
223842625|NCT04091672|PROCEDURE|Control Intervention (Conventional Autograft)|Meshed split-thickness skin graft, with standardized wound dressings (Telfa™ Clear and Xeroform™)
223842626|NCT04091672|DEVICE|Investigational Intervention (RECELL + more widely meshed autograft)|More widely meshed split-thickness skin graft, Spray-on Skin™ Cells prepared using RECELL, and standardized wound dressings (Telfa™ Clear and Xeroform™)
223842627|NCT03416218|BEHAVIORAL|Prognosis|Prognosis will be a single-player 2D, digital simulation game and supporting multimedia website. Players are situated as a major official of Hexacago, and tasks them with managing the city's finances, education levels, and health concerns to lower rates of teenage pregnancy and sexually transmitted infections. In the game Prognosis, player dispatches professionals from a variety of fields to different neighborhoods around the city, observing the effects of their resource allocation decisions across multiple systems over many in-game months. The supporting multimedia website will house curriculum and learning tools to support the learning objectives of Prognosis.
223842628|NCT04709731|DRUG|Ponatinib 15mg QD|Ponatinib 15 mg tablet, taken orally once daily
223842629|NCT04709731|DRUG|Ponatinib 30mg QD|Ponatinib 30 mg tablet, taken orally once daily
223842630|NCT06403644|DEVICE|NovoTHOR XL Photobiomodulation Full Body Light Bed|Low powered full-body photobiomodulation light bed therapy will be administered via the NovoTHOR XL light therapy bed which emits an average irradiance of \~30 mW/cm\^2.
223842631|NCT06403644|DEVICE|ARRC LED Photobiomodulation Full Body Light Bed|High powered full-body photobiomodulation light bed therapy will be administered via the ARRC LED light therapy bed which emits an average irradiance of \~75 mW/cm\^2.
223842632|NCT03037060|OTHER|[11C]-(+)-PHNO PET scan|PET scan
223842633|NCT03037060|OTHER|Alcohol Self-Administration|Session for assessing motivation for consuming alcohol.
223842634|NCT03037060|OTHER|Craving Task|Cue exposure paradigm
223842635|NCT03037060|OTHER|MRI scan|MRI scan scan to analyze the PET data will be administered.
223842636|NCT03037060|OTHER|Neuropsychological Assessment|Cognitive questionnaires administered over course of study.
223842637|NCT04941417|DRUG|PD-1 inhibitor|Two to three cycles of neoadjuvant chemotherapy in combination with PD-(L)1 inhibitor will be administered before surgery, followed by another one to two cycles of neoadjuvant chemotherapy in combination with PD-(L)1 inhibitor and PD-(L)1 inhibitor monotherapy for up to 1 year.
223842638|NCT05296629|DRUG|DFD-29|DFD-29 (40 mg) extended release capsules
223842639|NCT05296629|DRUG|Doxycycline|Doxycycline 40 mg capsules
223842640|NCT05296629|DRUG|Placebo|Placebo capsules
223842641|NCT01796665|DRUG|Clindamycin Phosphate and Benzoyl Peroxide Topical Gel 1.2%/2.5%|
223842642|NCT01796665|DRUG|Acanya Gel|
223842643|NCT01796665|DRUG|Placebo of Clindamycin Phosphate and Benzoyl Peroxide Topical Gel 1.2%/2.5% product|
223842644|NCT05603962|BEHAVIORAL|Visual training|Visual training is the main type of management for CI patients clinically; however, the existing training protocol required patients to make several visits to the clinic for visual training, which might increase the burden for patients and result in higher failures in training. Therefore, this study will use a simple training method by utilizing prisms for CI patients to train at home, then compare visual symptoms and binocular vision after the training.
223842645|NCT02268396|DRUG|Glycopyrronium and Formoterol Fumarate Metered-dose Inhaler|GFF MDI administered as 2 inhalations BID
223842646|NCT04840147|DEVICE|JointRep®|JointRep® is a medical device based on a thermogel polymer (Chitosan) for the treatment of chondral lesions, which consists of an injectable aqueous composition that forms a solid and sticky hydrogel in situ within cartilage defect(s). JointRep® is composed of an injectable thermo-gelling aqueous composition. It is used in conjunction with a Bone Marrow Stimulation type of procedure like Microfracture.
223842647|NCT04840147|PROCEDURE|Microfracture|Microfracture is a bone marrow stimulation type of procedure where after debridement of the damaged chondral tissue within the lesion, obtention of stable vertical margins and curettage of the entire calcified layer, multiple holes are created with a variety of instruments (awls, picks, microdills, nanofracture) to establish a communication with the subchondral bone to create a blood clot to elicit the natural healing process
223842648|NCT04529057|PROCEDURE|Rapid Maxillary Expansion Treatment|The patients were treated with KBME, Hyrax and MIDME maxillary expansion appliances, respectively. All expansion appliances containing a Hyrax expansion screw positioned parallel to the second premolars and were used to correct the posterior crossbite. In the MIDME group, two mini-screws with a diameter of 1.6 mm and a length of 10 mm are located on the right and left sides between the roots of the 2nd premolar and 1st molar teeth with 60-70° angle. KBME and Hyrax expansion appliances were cemented with glass ionomer cement and MIDME was cemented with using the light-cured composite. Same protocol was applied to all patients during RME treatment. Expansion screws in all groups were activated by two turns a day.
223842649|NCT03720015|BEHAVIORAL|Physical exercise|Physical exercise controlled program supervised by an accredited exercise specialist
223842650|NCT03720015|DIETARY_SUPPLEMENT|Nutritional management|Nutritional management controlled by a PhD clinical and sport nutrition specialist
223842651|NCT02342912|BEHAVIORAL|Social Media Treatments|Each of the three intervention groups offers information that has been shown to be important for college students to have a healthy body weight. All three groups provide information on topics that we know are related to having a healthy body weight, like managing stress, keeping track of how you spend your time, and increasing self-awareness of certain health behaviors. Two of the three programs are focused on weight loss for a healthy body. The third group focuses on having a healthy mind, body and having energy during college.
223842652|NCT02836145|OTHER|Differentiation of hiPSCs to skeletal muscle progenitors|
223842653|NCT01579656|DIETARY_SUPPLEMENT|Salba|25g of ground Salba baked into a bran muffin matched for total available carbohydrate (50g), total dietary fibre (15g), and calories (494.5 kcal) with the addition of flour, inulin or canola oil. One of five muffins (Salba, Poppy, Sesame, Flax, Bran) will be administered at each visit.
223842654|NCT01579656|DIETARY_SUPPLEMENT|Poppy|25g of ground Poppy Seeds baked into a bran muffin matched for total available carbohydrate (50g), total dietary fibre (15g), and calories (494.5 kcal) with the addition of flour, inulin or canola oil. One of five muffins (Salba, Poppy, Sesame, Flax, Bran) will be administered at each visit.
223842655|NCT01579656|DIETARY_SUPPLEMENT|Flaxseed|25g of ground Flaxseed baked into a bran muffin matched for total available carbohydrate (50g), total dietary fibre (15g), and calories (494.5 kcal) with the addition of flour, inulin or canola oil. One of five muffins (Salba, Poppy, Sesame, Flax, Bran) will be administered at each visit.
223842656|NCT01579656|DIETARY_SUPPLEMENT|Sesame|25g of ground Sesame Seeds baked into a bran muffin matched for total available carbohydrate (50g), total dietary fibre (15g), and calories (494.5 kcal) with the addition of flour, inulin or canola oil. One of five muffins (Salba, Poppy, Sesame, Flax, Bran) will be administered at each visit.
223842657|NCT01579656|DIETARY_SUPPLEMENT|Wheat Bran|Bran muffin matched for total available carbohydrate (50g), total dietary fibre (15g), and calories (494.5 kcal). One of five muffins (Salba, Poppy, Sesame, Flax, Bran) will be administered at each visit.
223842658|NCT05202379|DRUG|CC-42344|CC-42344 capsules
223842659|NCT05202379|DRUG|Placebo|Placebo capsules
223842660|NCT05915130|BEHAVIORAL|Gait training|They will negotiate (natural or virtual) obstacles such as avoiding a rock or crossing over a tree root, thus improving their gait adaptability capacities.
223842661|NCT06401850|OTHER|Education Group|The intervention provided to the training group focuses on improving skills to cope with polycystic ovary syndrome. This intervention includes topics such as encouraging healthy lifestyle habits, raising awareness about nutrition and exercise, teaching stress management techniques, and offering strategies to support hormonal balance. It provides participants with the tools they need to understand and manage symptoms that impact their lives. It also provides a supportive environment, encouraging participants to share their experiences with each other and receive support. This intervention aims to improve individuals' overall quality of life while strengthening their ability to manage their own health and well-being.
223842662|NCT06401850|OTHER|Control Group|No intervention was made to the control group. This group did not receive additional training or support to cope with polycystic ovary syndrome. In this way, the effects of the control group on lifestyle, symptom management and overall quality of life were evaluated in comparison with the training group. This approach focuses on determining the direct effects of the intervention, while allowing to observe the natural course of the control group, and the results help to provide a clear assessment of the effectiveness of the intervention.
223842663|NCT04240119|OTHER|According to current clinical care standards|Enrolled subjects may be treated with medical management or surgically using indirect revascularization surgery.
223842664|NCT00003372|DRUG|topotecan hydrochloride|
223842665|NCT04602364|OTHER|Noninterventional|Not applicable; Noninterventional study
223842666|NCT05311475|DRUG|Mometasone|Mometasone furoate nasal spray (50 mcg per actuation)
223842667|NCT05311475|DRUG|Azelastine|Azelastine hydrochloride nasal spray (140 mcg per actuation)
223842668|NCT05311475|DRUG|Placebo|Placebo nasal spray
223842669|NCT02028910|DRUG|Ondansetron|"The treatment is administered orally in a single dose of 2.5 ml = 2 mg per 5 kg weight of the child, not to exceed the maximum dose of 10mg. A second dose, the same dose is given back if the child vomits within 15 minutes after the first administration.~The bottle contains at least 2 doses of up to 10 mg for a second dose can be given back in case of vomiting within 15 minutes after the first dose in children weighing more than 25 kg.~The dosage should be adjusted according to the weight of the child"
223842670|NCT05924893|DRUG|Naltrexone Hydrochloride|naltrexone film
223842671|NCT05924893|DRUG|Carboxy methyl cellulose|Carboxy methyl cellulose drops
223842672|NCT03746275|DRUG|Rivaroxaban (BAY59-7939, Xarelto)|2.5 mg twice daily
223842673|NCT03746275|DRUG|Acetylsalicylic acid|75 - 100 mg once daily according to local label
223842674|NCT00408668|BIOLOGICAL|PEV3A|
223842675|NCT00408668|BIOLOGICAL|FP9 ME-TRAP|
223842676|NCT00408668|BIOLOGICAL|MVA ME-TRAP|
223842677|NCT00323089|PROCEDURE|microcoil insertion and excision|The objective of this study is to determine if subcentimetre pulmonary nodules can be accurately and safely excised by endoscopic stapling devices after they have been localized using CT and marked with a microcoil device.
223842678|NCT03939520|DRUG|pirfenidone and nintedanib|The experimental group will receive pirfenidone 2403 mg per day (at least 1602 mg) in combination with nintedanib 300 mg per day (at least 200 mg) during 24 weeks.
223842679|NCT03939520|DRUG|pirfenidone or nintedanib|The second intervention group will switch from one monotherapy during 24 weeks: with pirfenidone 2403 mg per day (at least 1602 mg) or nintedanib 300 mg per day (at least 200 mg) to the other monotherapy (nintedanib in patients who received pirfenidone as first line therapy before inclusion and conversely).
223842680|NCT03939520|DRUG|pirfenidone or nintedanib|The control group will keep on the same monotherapy during 24 weeks: with pirfenidone 2403 mg per day (at least 1602 mg) or nintedanib 300 mg per day (at least 200 mg) to the other monotherapy (nintedanib in patients who received pirfenidone as first line therapy before inclusion and conversely).
223842681|NCT01939158|BIOLOGICAL|Meningococcal vaccine GSK134612|1 or 2 doses administered intramuscularly in the left anterolateral thigh or deltoid region
223842682|NCT01939158|BIOLOGICAL|Prevenar 13™|1 dose administered intramuscularly in the right anterolateral thigh or deltoid region
223842683|NCT04417556|DIAGNOSTIC_TEST|Sleep measurement|Sleep measurement with polysomnography, actigraphy, and Thai-version Richards Campbell Sleep Questionnaire.
223842684|NCT05373290|OTHER|there is no intervention in the study|there is no intervention in the study
223842685|NCT00069862|DRUG|Deferitrin (GT56-252)|
223842686|NCT00069862|DRUG|desferoxamine (DFO)|
223842687|NCT02272699|DRUG|Nimotuzumab|Nimotuzumab 200mg per week for 6 weeks.
223842688|NCT02272699|DRUG|Paclitaxel|Paclitaxel 175mg per square metre on day 1, repeated every 3 weeks for 2 cycles.
223842689|NCT02272699|DRUG|Cisplatin|Cisplatin 30mg per square metre on day 1 and day 2, repeated every 3 weeks for 2 cycles.
223842690|NCT02272699|RADIATION|Radiation|IMRT of primary tumor and local lymph nodes with 95% PTV of 41.4 Gy/23f. Nimotuzumab 200mg per week for 6 weeks.
223842691|NCT02272699|PROCEDURE|Surgery|Esophagectomy
223842692|NCT00449423|DRUG|acipimox|
223842693|NCT00286689|DRUG|Growth Hormone|
223842694|NCT00286689|PROCEDURE|Whole body Protein turnover|
223842695|NCT00286689|PROCEDURE|DEXA scan|
223842696|NCT04638777|DEVICE|rTMS with H-coil|Real repetitive transcranial magnetic stimulation with H-coil over M1 and PFC
223842697|NCT04638777|DEVICE|rTMS with H-coil|Real repetitive transcranial magnetic stimulation with H-coil over M1 and sham repetitive transcranial magnetic stimulation with H-coil over PFC
223842698|NCT04638777|DEVICE|rTMS with H-coil|Sham repetitive transcranial magnetic stimulation with H-coil over M1 and PFC
223842699|NCT04073355|BEHAVIORAL|Physical Activity|Smartphone-delivered physical activity intervention
223842700|NCT05427357|OTHER|Non-selective closed kinetic chain exercises (NSKCE) and selective closed kinetic chain exercises (SCKCE)|"Non-selective closed kinetic chain double-leg semi-squat exercise In this exercise, the standing patient leans his or her back against the wall and slides down the wall until the knees are about 45 degrees flexed. Daily program was determined as 5 sessions and 10 repeats. The knee stayed at flexion position for 10 seconds in each repeat, which aimed the contraction of quadriceps muscle. There is a relaxation period for 5 seconds between each repeat.~Selective closed kinetic chain double-leg semi-squat exercise with hip adduction In this exercise, the standing patient leans his or her back against the wall, forces the knees for adduction by squeezing the pillow placed between the knees and slides down the wall until the knees are about 45 degrees flexed. Daily program was determined as 5 sessions and 10 repeats."
223842701|NCT04580654|BIOLOGICAL|CSL312|Fully human immunoglobulin G4/lambda recombinant monoclonal antibody against Factor XIIa
223842702|NCT02688972|OTHER|cold water immersion|The volunteers stayed immerged up to the iliac crest, in the water with water. The temperature utilized was 10 degree C and the time was 10 minutes
223842703|NCT02688972|OTHER|Control group|The volunteers stayed in rest about 10 minutes
223842704|NCT02074566|OTHER|Cryoballoon ablation|PVI using cryoballoon
223842705|NCT02824289|BEHAVIORAL|Sun Safe Workplaces Program|The intervention began by sending a Program Announcement Packet and requesting the first face-to-face meeting. At the first meeting, intervention staff covered: 1) Introduction to SSW; 2) Sun Safety Practices in the Workplace; 3) Sun Safety Policy for Outdoor Workers; 4) Sun Safety Policy Adoption; 5) Sun Safety Policy Reinforcement and Maintenance. They presented the SSW Website and a Sun Safety Tool Box. Following the first meeting, the manager scheduled Sun Safety Training by intervention staff with various employee groups. Workplace Sun Safety Materials were sent in four sets (twice a year over two years) for distribution to employees. Research staff made monthly Follow-up Contacts with managers.
223842706|NCT02824289|BEHAVIORAL|Attention Control|Research staff sent printed materials on occupational sun safety to local government organizations twice. These included posters with personal protection messages and skin cancer rates, risk assessment brochures, worksite guides, total skin self-examination CD-Rom, the American Academy of Dermatology SPOT bookmark, and a sun safety tip card from the Occupational Safety and Health Administration (OSHA). Staff made presentations on general sun safety topics (not policy) at state professional conferences.
223842707|NCT05640817|DRUG|Pentoxifylline 400 mg SR tablets|a nonspecific phosphodiesterase inhibitor, was first considered in the treatment of peripheral vascular diseases
223842708|NCT05640817|DRUG|cisplatin with standard hydration with normal saline|chemotherapy
223842709|NCT01293461|DRUG|CBX129801|Subcutaneous injection
223842710|NCT01293461|DRUG|Placebo|Subcutaneous injection
223842711|NCT05448261|BEHAVIORAL|Emotion-centered problem-solving intervention (EPi)|"The EPi is built upon the model of relational/problem-solving model of stress and is aimed at supporting caregivers in (1) revisiting stressful caregiving and associated problem from a psychological distanced perspective; (2) adopting problem orientation toward one's experience in the present moments with curiosity, openness and acceptance; and (3) applying the problem-solving skills learned for the enhancement of their psychosocial wellbeing in the stressful caregiving context. To reduce the incongruence between caregivers and stroke survivors in problem-solving, we will adopt a shared problem, shared action plan approach for the family caregivers and stroke survivors."
223842712|NCT05448261|OTHER|stroke education|Information is related to stroke and recurrent stroke and strategies for assisting stroke survivors in day-to-day activities.
223842713|NCT06500286|DRUG|Marciane|Group A caudal block 0.25% bupivacaine was administered at a dose of 0.2 ml/k
223842714|NCT06500286|DRUG|Marcaine|Dorsal penil block 0.25% bupivacaine was administered at a dose of 0.2 ml/k
223842715|NCT04878042|DEVICE|Hydrogen peroxide|Mouth wash and nasal spray 3 times a day for 3 days
223842716|NCT04878042|DEVICE|Placebo|Mouth wash and nasal spray 3 times a day for 3 days
223842717|NCT03893591|DIAGNOSTIC_TEST|Anti Xa levels|one Blood sample
223842718|NCT01131247|DRUG|ofatumumab + bendamustine|Loading dose of ofatumumab at 300mg IV with subsequent doses at 100mg IV on D1 of all cycles (maximum of 6 cycles) in combination with bendamustine 90mg/m2 on day 2 of all cycles. Neulasta 6mg SQ will also be given on day 8 of cycle 1 only.
223842719|NCT04291521|DRUG|Ketamine|Administering ketamine as an induction medication for intubating adult trauma patients within 24 hours of hospital admission.
223842720|NCT04291521|DRUG|Etomidate|Administering etomidate as an induction medication for intubating adult trauma patients within 24 hours of hospital admission.
223842721|NCT04291521|DRUG|Propofol|Administering propofol as an induction medication for intubating adult trauma patients within 24 hours of hospital admission.
223842722|NCT01345292|DEVICE|Mouthwash|Rinse with 10 ml of the assigned mouthwash for 60 seconds after you brush in your usual manner twice daily for one minute using at least a one-inch strip of the assigned toothpaste
223842723|NCT01345292|DRUG|Potassium nitrate toothpaste|Brush in your usual manner twice daily for at least one minute using at least a one-inch strip of the assigned toothpaste
223842724|NCT01345292|DRUG|Sodium fluoride toothpaste|Brush in your usual manner twice daily for at least one minute using at least a one-inch strip of the assigned toothpaste
223842725|NCT00279474|BEHAVIORAL|cognitive-behavior groups|
223842726|NCT03756389|DRUG|BMX-010|Safety and efficacy of BMX-010 in topical treatment of rosacea.
223842727|NCT00984178|OTHER|Granulocite Colony Stimulating Factor treatment (G-CSF)|G-CSF will be administered at a dose of 10 mcg/kg/day. The administration begins at the first 24 hours post-reperfusion, remaining for 5 days
223842728|NCT00984178|OTHER|Bone marrow mononuclear cells|Bone marrow mononuclear cells will be isolated with a Ficoll technique from 50 cc of bone marrow aspiration
223842729|NCT01386086|DRUG|aripiprazole|The starting dose of aripiprazole will be 2 mg and the dose adjusted to a maximum of 15 daily
223842730|NCT01359137|BEHAVIORAL|Probation as usual|Routine probation with do deferred jail condition.
223842731|NCT01359137|BEHAVIORAL|Deferred Jail|Discretionary deferred jail in response to violations of probation conditions.
223842732|NCT01359137|BEHAVIORAL|Arizona's SAFE|Swift Accountable Fair Enforcement (SAFE) uses non-discretionary brief jail sanctions for probation violations.
223842733|NCT03742843|COMBINATION_PRODUCT|A multi-omics analysis|A multi-omics analysis including whole exome sequencing, transcriptomics and metabolomics for eutopic and ectopic endometrium
223842734|NCT00189020|BIOLOGICAL|PCV7|PCV7 at age 2 and 4 months
223842735|NCT00189020|BIOLOGICAL|PCV7|PCV7 at age 2, 4 and 11 months
223842736|NCT04511663|COMBINATION_PRODUCT|Assertive community treatment|The intervention team consisted of psychiatrists, nurses, clinical psychologists, social workers, rehabilitation teachers. The specific services provided by the team include individual service plan. Each patient got a comprehensive evaluation within one month to establish treatment goals and individual intervention plan, rehabilitation training, family intervention peer support group, individual psychological counseling and crisis intervention.
223842737|NCT04511663|COMBINATION_PRODUCT|Basic public health services.|The control group received regular medical follow-up including symptom and medication evaluation, social function evaluation and physical examination after hospital discharge. The frequency was once a quarter.
223842738|NCT01385280|BIOLOGICAL|therapeutic estradiol|Given orally (PO)
223842739|NCT01385280|DRUG|exemestane|Given PO
223842740|NCT01385280|OTHER|laboratory biomarker analysis|Correlative studies
223842741|NCT01385280|OTHER|enzyme-linked immunosorbent assay|Correlative studies
223842742|NCT04358861|PROCEDURE|Nonsurgical Root canal therapy|After administration of LA and rubber dam isolation, acess cavity was prepared using carbide burs. Working length was determined using root ZX apex locator and was verified radiographically. Canal preparation was done with protaper gold rotary instruments. 5ml of 5.25% NaOCl was used as irrigant. After instrumentation , the canals were irrigated with 5.0 ml of 17% EDTA for 1minute followed by irrigation with 5.0 ml of 5.25% NaOCl. Canals were dried with absorbent paper points, filled with calcium hydroxide paste and access cavity was restored with IRM.At the recall appointment ; after one week,paste removal, copious irrigation was done with 5.25% NaOCl and canals were dried with paper points. Canals were obturated with Gutta-Percha and ZOE based sealer.
223842743|NCT04358861|DEVICE|Dental operating microscope|Dental operating microscope; a high magnification and illumination device was used in experimental group for performing nonsurgical root canal therapy.
223842744|NCT06199687|OTHER|Use of Virtual Reality|Use of Virtual Reality after After Thyroid-Parathyroid Surgery
223842745|NCT00668174|BEHAVIORAL|Exercise|Moderate intensity exercise, 5 days per week, 45 min per session, 50-70% max HR, divided into a 3-month individualized and 9-month maintenance period.
223842746|NCT03303105|DRUG|TEV-48125|TEV-48125 will be administered subcutaneously once every 4 weeks.
223842747|NCT03303105|DRUG|TEV-48125|TEV-48125 will be administered subcutaneously once every 12 weeks.
223842748|NCT05428436|DRUG|BI 1015550 ICF|BI 1015550 intended Commercial Formulation (iCF)
223842749|NCT05428436|DRUG|BI 1015550 TF2|BI 1015550 trial formulation 2 (TF2)
223842750|NCT05240859|DRUG|Geleli|Adalimumab Biosimilar
223842751|NCT02828930|DRUG|Idasanutlin|Idasanutlin 300 mg tablet orally on Day 1; 400 mg tablet orally on Day 11 and Day 19. Participants, who are eligible to enter in optional treatment extension phase, will continue treatment with idasanutlin 200 mg tablet orally once daily for 5 days of 28-day cycle.
223842752|NCT02828930|DRUG|Placebo|Placebo matching to idasanutlin aqueous dispersion will be administered orally on Day 11.
223842753|NCT02828930|DRUG|[13C]-radiolabeled Idasanutlin|\[13C\]-radiolabeled idasanutlin 100 mcg will be administered as IV infusion over 15-minute on Day 1.
223842754|NCT02828930|DRUG|[14C]-radiolabeled Idasanutlin|\[14C\]-radiolabeled idasanutlin 100 mg capsule (2, 50 mg capsules containing approximately 100 microcurie of radioactivity) will be administered orally on Day 1.
223842755|NCT06355817|DEVICE|Vibration|Vibration Assist Device, held to the forehead
223842756|NCT06355817|OTHER|Tapping|Tapping on the forehead
223842757|NCT06076759|DRUG|Intrathecal morphine or dexmedetomidine|Intrathecal injection
223842758|NCT02627625|DRUG|Tiotropium|4 inhalations
223842759|NCT01785420|DRUG|Trastuzumab|A single dose of Trastuzumab (Herceptin, Hoffman La Roche) at 8 mg/Kg as a 90 minute infusion in 250 ml of normal saline, in the window period of 14 days (both days inclusive) prior to the planned date of surgery.
223842760|NCT01785420|DRUG|Placebo|A 90 minute intravenous infusion of saline as placebo
223842761|NCT03014102|DRUG|Recombinant Human Thrombopoietin|Recombinant human Thrombopoietin is a full length glycosylated molecule identical to endogenous Thrombopoietin.
223842762|NCT04822298|DRUG|AMG 160|AMG 160 administered as an intravenous (IV) infusion
223842763|NCT00453089|DRUG|VG101|
223842764|NCT03321760|RADIATION|Stereotactic Ablative Radiation Therapy (SABR)|SABR will be delivered to the primary disease and hilar (N1) node over 5 fractions.Reductions may be made to the hilar (N1) node according to a 3+3 design during the run-in period.
223842765|NCT01893320|DRUG|Vosaroxin|"Phase I Starting Dose: 90 mg/m2 by vein on Days 1 and 4 of each cycle.~Phase II Starting Dose: 70 mg/m2 by vein on Days 1 and 4 of each cycle, or maximum tolerated dose from Phase I."
223842766|NCT01893320|DRUG|Decitabine|Phase I and II: 20 mg/m2 by vein daily for 5 consecutive days (Days 1 to 5).
223842767|NCT05946876|DRUG|XH-S003 (A)|IP: XH-S003 IP: XH-S003 Dose: 25 mg, 100 mg Dose Formulation: Capsule Route of Administration: Oral
223842768|NCT05946876|OTHER|Placebo (B)|Dose: 25 mg, 100 mg Dose Formulation: Capsule Route of Administration: Oral
223842769|NCT00001061|DRUG|Sevirumab|
223842770|NCT00001061|DRUG|Foscarnet sodium|
223842771|NCT00001061|DRUG|Ganciclovir|
223842772|NCT03666429|DEVICE|Bulb suction|Parents will use the bulb suction on their child in the emergency room then complete a 7 point likert survey.
223842773|NCT03666429|DEVICE|NoseFrida|Parents will use the NoseFrida in the emergency department and complete a 7 point likert survey.
223842774|NCT04920214|DIAGNOSTIC_TEST|SonoVue|CEUS examination was performed and corresponding image information of liver lesions was obtained.
223842775|NCT06298630|OTHER|Assessments|Safety and efficacy assessments
223842776|NCT06629870|DEVICE|virtual reality|patients who received distraction using virtual reality glasses
223842777|NCT06629870|OTHER|control group|no any anxiety-reducing application
223842778|NCT06629870|OTHER|hypnotherapy|patients receiving hypnotherapy
223842779|NCT06629870|OTHER|mindfulness|patients who underwent mindfulness-based meditation
223842780|NCT02208323|DEVICE|Bubble CPAP|Respiratory assistance
223842781|NCT00951561|DEVICE|Vipon|The Vipon is a tampon with a small motor unit within, which produces vibratory stimulation, used during menstruation to provide pain relief for women with dysmenorrhea.
223842782|NCT00951561|DRUG|Ibuprofen|400 mg daily
223842783|NCT02092987|OTHER|Social work support|All study participants were provided access to social support services at Riverstone Senior Life services
223842784|NCT02092987|OTHER|Educational material|All participants received educational material about dementia and caregiving in addition to information about resources for persons with dementia and their caregivers, including resources at the Alzheimer's Association such as support groups, and clinical and service resources available citywide.
223842785|NCT02092987|BEHAVIORAL|NYU caregiver counseling intervention|"The first component consists of 2 individual and 4 family counseling sessions. These sessions last between 1 and 1.5 hours. The second component of the intervention is participation in a caregiver support group . The third component of the treatment is ad hoc counseling. New psychiatric and behavioral problems of patients, which are generally more stressful than the need for assistance with activities of daily living or physical limitations, often precipitate ad hoc calls from caregivers."
223842786|NCT02092987|BEHAVIORAL|REACH OUT counseling intervention|All aspects of the REACH OUT Intervention involve problem solving techniques and the development of written action plans. The goal of this intervention is to engage the caregiver in joint problem-solving with the objective of creating a written action plan targeting specific caregiving problems. The basic steps of problem solving are: 1.Define the problem. 2. Set goals 3. Brainstorm with caregiver and List possible solutions on a pad of paper, 4. Select solutions, 5. Develop an action plan based on these solutions, 6. Implement the action plan, track progress, and make adjustments as needed
223842787|NCT03432221|DRUG|Desvenlafaxine|Patients included in the study will receive antidepressant treatment with desvenlafaxine. The switch from SSRI to desvenlafaxine will coincide with the baseline visit (Visit 0). The dose of desvenlafaxine will be established based on clinical judgment. As the approach will be naturalistic, the inclusion in this study will not influence the clinical choice, hence changes in the pharmacological strategy will be permitted.
223842788|NCT00852475|DIETARY_SUPPLEMENT|MUFA MOVE! (Monounsaturated fatty enriched diet)|MUFA MOVE!diet and exercise program
223842789|NCT00852475|DIETARY_SUPPLEMENT|PUFA MOVE! (Polyunsaturated fatty acid enriched diet)|PUFA MOVE! diet and exercise program
223842790|NCT02538640|OTHER|High-SDS biscuit|Consumption of the high-SDS product (50g) alone with a glass of water
223842791|NCT02538640|OTHER|Low-SDS extruded cereals|Consumption of the low-SDS product (42g) alone with a glass of water
223842792|NCT05515094|BEHAVIORAL|Empowerment Counseling Intervention|The intervention entails case managers conducting first-line support (i.e., a brief psychosocial support session), and a safety and health assessment, adapted from current case management content and the Safe and Sound intervention.
223842793|NCT01979978|OTHER|Healthy Buddies Curriculum|"Each week, intermediate students will receive a 45-minute healthy-living lesson plan from their classroom teacher. Later that week, intermediate students will serve as peer mentors (Buddies), teaching a 30-minute lesson to their younger students. The Physical activity (i.e.Go Move!) component of the lesson plans includes 30-minutes of structured aerobic fitness sessions, called fitness loops, with the student pairs twice weekly. The dietary (Go Fuel!) component includes lessons about distinguishing nutritious and from unhealthy (nutrient poor-energy rich) foods and beverages. The body image (Go Feel Good!) component, the students are taught to value classmates based on individual traits rather than peer influence."
223842794|NCT05876936|DEVICE|contact lens sensor (CLS) SENSIMED Triggerfish®|contact lens sensor CLS placing and fitting evaluation, 24h recording
223842795|NCT00515086|DRUG|Everolimus|Tablets taken once a day with a full glass of water.
223842796|NCT00515086|PROCEDURE|Surgery|Salvage surgical resection
223842797|NCT03810482|DEVICE|Pedometer|A pedometer will be worn by the patient at home for days 1 to 14 and 60 to 74.
223842798|NCT03810482|OTHER|6 minute walking test|Performed according to current recommendations during routine visits (baseline and \~90 days for the purposes of this study).
223842799|NCT02028884|DRUG|Satralizumab|Satralizumab will be administered subcutaneously (SC) at Weeks 0, 2, and 4, and thereafter once every 4 weeks (Q4W).
223842800|NCT02028884|DRUG|Placebo|Placebo will be administered subcutaneously (SC) at Weeks 0, 2, and 4, and thereafter once every 4 weeks (Q4W).
223842801|NCT02028884|DRUG|Baseline Treatment|As specified in the protocol, one of the following drugs at a stable dose is required as monotherapy for baseline treatment during the double-blind period: azathioprine (AZA); mycophenolate mofetil (MMF); or oral corticosteroids (CS). For participants aged 12 to 17 years at the time of informed consent, baseline treatment with AZA or MMF in combination with oral CS is also permitted. Change or termination of baseline treatment is only permitted during the open-label extension period.
223842802|NCT02373813|DRUG|etanercept pre-filled syringe subcutaneous injection|etanercept for injection in pre-filled syringes
223842803|NCT02373813|DRUG|Oral methotrexate|"During the open-label run-in period, methotrexate will be provided as 2.5 mg tablets.~During the double-blind treatment period, methotrexate will be provided as 2.5 mg capsules."
223842804|NCT02373813|DRUG|Placebo for etanercept subcutaneous injection|etanercept placebo for injection in pre-filled syringes
223842805|NCT02373813|DRUG|Placebo for methotrexate|methotrexate placebo capsules
223842806|NCT02373813|DIETARY_SUPPLEMENT|Folic acid (non-investigational product)|Folic acid 5 to 7 mg per week as per investigator judgment or according to local standard of care.
223842807|NCT00589212|DEVICE|GliaSite Radiation Therapy System|GliaSite RTS is designed to deliver intracavitary radiation therapy for brain tumors. Following surgical resection, the balloon catheter is inflated to fill the cavity and Iotrex radiotherapy solution infused. It is a single applicator system that provides a uniform and conformal dose to the resection cavity.
223842808|NCT04577248|DEVICE|edge-to-edge valve repair|edge-to-edge valve repair
223842809|NCT03279198|BEHAVIORAL|TIWeb|Intervention: TIWeb program is interactive and tailored to the participant's individual beliefs and demographics. Individuals receiving the TIWeb will be given information that allows them to call and receive an FOBT kit in the mail or schedule an appropriate CRC test and/or mammogram.
223842810|NCT03279198|BEHAVIORAL|CSC|Intervention: CSC - a telephone counseling call during which the participant is given the opportunity to complete CRC screening (FOBT or a colonoscopy) and/or mammography screening.The CSC included tailored counseling as well as the ability to schedule BC and CRC screening tests.
223842811|NCT03279198|BEHAVIORAL|UC|Intervention: The usual care group received usual care that varies dependent upon the practice setting.
223842812|NCT03279198|BEHAVIORAL|TIWeb+CSC|Intervention: TIWeb + CSC ((Tailored web intervetion+Cancer screening) group receive a mailed TIWeb, which is followed in four weeks by a CSC with the same opportunity to receive FOBT kits or schedule a colonoscopy and/or mammogram. The nurse counselor, knowing the participant is a good candidate for screening tests, will be trained to schedule CRC or BC screening appointments or to mail FOBT kits to individuals in the intervention groups even if they have not had a recent clinic visit.
223842813|NCT02693626|BEHAVIORAL|intensive cessation message|Mobile phone-based text message （three to five messages per day） interventions ('Happy Quit') for smoking cessation for 12 weeks with 24 week follow up.
223842814|NCT02693626|BEHAVIORAL|Not intensive cessation message|Mobile phone-based text message （three to five messages per week） interventions ('Happy Quit') for smoking cessation for 12 weeks with 24 week follow up.
223842815|NCT00185484|DRUG|YAZ (DRSP 3 mg/EE 0.02 mg, BAY86-5300)|Oral administration of YAZ (0.02mg ethinyl estradiol-ß-cyclodextrin clathrate and 3mg drospirenone, 24 day hormone tablets followed by 4 days of placebo tablets for 13 cycles
223842816|NCT00274989|DRUG|Bendamustine|"First-Line Therapy: Bendamustine i.v. 90 mg/m² day 1-2, q4wks, cycle 1 to 6~2nd to 4th -Line Therapy: Bendamustine i.v. 70 mg/m² day 1-2 q4wks, cycle 1 to 6"
223842817|NCT00274989|BIOLOGICAL|Rituximab|"First-Line Therapy: Rituximab i.v. 375 mg/m² day 0, q4wks, cycle 1; Rituximab i.v. 500 mg/m² day 1, q4wks, cycle 2-6~2nd to 4th -Line Therapy: Rituximab i.v. 375 mg/m² day 0, q4wks, cycle 1; Rituximab i.v. 500 mg/m² day 1, q4wks, cycle 2-6"
223842818|NCT00618280|DRUG|nicotine nasal spray|0,5 mg nicotine nasal spray or placebo (pepperspray)
223842819|NCT06249789|PROCEDURE|Spinal Anesthesia|Participants in this arm will receive single-shot spinal anesthesia with 12-15 mg of either 0.05% or 0.75% bupivacaine (iso or hyperbaric) once before surgery. Additionally, they will undergo an ultrasound-guided nerve block called the Fascia Iliaca Compartment Block (FICB ) in combination with spinal anesthesia.
223842820|NCT06249789|PROCEDURE|General Anesthesia|Participants in this group will be given a combination of general anesthesia and a nerve block. General anesthesia involves the use of a sedative called propofol, along with devices to ensure that the airway remains open during the procedure. Additionally, they will undergo an ultrasound-guided nerve block known as the Fascia Iliaca Compartment Block (FICB) in combination with spinal anesthesia.
223842821|NCT04931680|OTHER|Data collection|During the follow-up consultation, six weeks after inclusion (S6), data will be collected using a standardized digital questionnaire, including clinical features, economic, social and cultural characteristics, housing conditions and therapeutic details (type of environmental decontamination and treatment received). Data will then be compared between patients with therapeutic success or failure. A urine test strip will also be used during the S6 consultation to screen for proteinuria. The prevalence of post-streptococcal glomerulonephritis will be extrapolated from that of proteinuria.
223842822|NCT01969890|DRUG|G-CSF administration|Zarzio - 5 microg/kg bis in die for 6 days
223842823|NCT02547805|DRUG|ALLN-177|ALLN-177 7,500 units (5 capsules) PO TID with meals
223842824|NCT02547805|DRUG|Placebo|Placebo 5 capsules PO TID with meals
223842825|NCT05176353|OTHER|VAP diagnostic stewardship bundle|Multifaceted VAP diagnostic stewardship bundle targeting the respiratory culture testing workflow through a custom order set within the institutional electronic medical record. Interventions will be made at the three levels of the diagnostic testing pathway (ordering, collection and reporting of test results). Full details available in detailed study description.
223842826|NCT01071694|DRUG|Interferon beta 1-b (Betaferon/Betaseron, BAY86-5046)|Patients receiving Betaferon according to routine clinical practice
223842827|NCT05557422|DIAGNOSTIC_TEST|BD OneFlow LST, and B-CLPD T1 to T4 Assays|a panel of fluorochrome-conjugated antibodies for qualitative flow-cytometric immunophenotyping of mature lymphocyte populations on the BD FACSLyric™ flow cytometer with BD FACSuite™ Clinical application.
223842828|NCT03783455|PROCEDURE|Non arthroscopic joint lavage|Instillation of 4 litters of cold physiological serum
223842829|NCT03783455|PROCEDURE|Non arthroscopic joint lavage plus corticosteroid|Instillation of 4 litters of cold physiological serum followed by intraarticular injection of triamcinolone
223842830|NCT03783455|PROCEDURE|Non arthroscopic joint lavage plus hyaluronic acid|Instillation of 4 litters of cold physiological serum followed by intraarticular injection of hyaluronic acid
223842831|NCT03783455|PROCEDURE|Intraarticular injection of corticosteroid|Intraarticular injection containing 40 mg of triamcinolone acetonide.
223842832|NCT03783455|PROCEDURE|Intraarticular injection of hyaluronic acid|Intraarticular injection containing 4 mL of a bioengineered hyaluronic acid.
223842833|NCT00135967|DRUG|mycophenolate mofetil orally 1000 mg twice a day (BID)|
223842834|NCT00135967|DRUG|prednisone 0,5 mg/kg orally on alternate days|
223842835|NCT00135967|DRUG|intravenous (i.v.) methylprednisolone 1000 mg, total 9|
223842836|NCT05153954|OTHER|Quantitative Indocyanine Green Fluorescence Angiography|Quantitative analyse of ICG around the proximal/oral part of the anastomosis pre-formation of the primary anasomosis
223842837|NCT02403674|DRUG|Doravirine, Tenofovir, Lamivudine|One doravirine, tenofovir, lamivudine tablet taken q.d. by mouth.
223842838|NCT02403674|DRUG|ATRIPLA™|One ATRIPLA™ tablet taken q.d. by mouth
223842839|NCT02403674|DRUG|Placebo|Placebo tablets matched to ATRIPLA® or Doravirine, Tenofovir, Lamivudine.
223842840|NCT04202575|PROCEDURE|Tube clamping|Clamping of the tube between the additional and standard venous reservoir
223842841|NCT06400056|DRUG|Terbinafine|FDA approved
223842842|NCT03037190|OTHER|withdrawal of gluten from the diet|Gluten free diet the same recommendations as for patients with diabetes and known celiac disease
223842843|NCT02906306|BEHAVIORAL|Individual Occupational Therapy|45 minutes 3 times per week 6 months in nursing homes (A and B)
223842844|NCT02906306|BEHAVIORAL|Group Occupational Therapy|45 minutes 3 times per week 6 months in nursing homes (A and B)
223842845|NCT02256787|DRUG|BILB 1941 ZW - single rising dose part|
223842846|NCT02256787|DRUG|Placebo|
223842847|NCT02256787|DRUG|BILB 1941 ZW - solution|
223842848|NCT02256787|DRUG|BILB 1941 ZW - tablet|
223842849|NCT02256787|OTHER|standardized breakfast|
223842850|NCT06191536|OTHER|Pilates|
223842851|NCT06191536|OTHER|Pelvic floor exercises|
223842852|NCT03387917|DRUG|TLD-1|TLD-1 is a new liposomal formulation of the anthracycline doxorubicin.
223842853|NCT03387917|DRUG|Caelyx|Caelyx is a liposomal formulation of the anthracycline doxorubicin
223842854|NCT03043066|PROCEDURE|Scaling and root planing|subjects underwent full mouth supragingival and subgingival scaling
223842855|NCT03043066|DRUG|scaling and root planing along with antibiotic intervention|subjects underwent full mouth supragingival and subgingival scaling along with antibiotic intervention of amoxicillin of 500 mg and metronidazole of 400 mg thrice daily for 7 days
223842856|NCT05950906|DRUG|PDM608|PDM608 subcutaneous at single or multiple dose(s) assigned by cohort
223842857|NCT05950906|DRUG|Placebo|Placebo subcutaneous at single or multiple dose(s) to match PDM608 administration.
223842858|NCT01440244|PROCEDURE|Cervical mediastinoscopy|minimally invasive technique to perform pleural evaluation, pleural biopsy and pleurodesis
223842859|NCT01254305|DRUG|Levomilnacipran ER|Drug: Levomilnacipran ER (40 -120 mg/day) Study drug is to be given orally, in capsule form, once daily for 8 weeks
223842860|NCT01254305|DRUG|Paroxetine, Sertraline, Citalopram or Fluoxetine.|Paroxetine (20, 40, or 60 mg/day) to be given orally, in capsule form, once daily for 8 weeks, or Sertraline (50, 100, or 150 mg/day) to be given orally, in capsule form, once daily for 8 weeks, or Citalopram (20, 40, or 60 mg/day) to be given orally, in capsule form, once daily for 8 weeks or Fluoxetine (20, 40, or 60 mg/day) to be given orally, in capsule form, once daily for 8 weeks
223842861|NCT01254305|DRUG|Placebo|Matching placebo capsules, oral administration, once daily dosing
223842862|NCT00004225|BIOLOGICAL|Ad5CMV-p53 gene|
223842863|NCT00004225|RADIATION|radiation therapy|
223842864|NCT03273803|DIAGNOSTIC_TEST|Heart sound recording using smartphone application|Heart sound recording and analysis using android smartphones (Samsung Galaxy S5, Galaxy S6, and LG G3)
223842865|NCT04786886|OTHER|VIrtual Reality Visual Field Exam|Virtual reality visual field exam will be administered using the virtual reality headset. Exams can take up to 20 minutes.
223842866|NCT05481034|DEVICE|SMA bolus option|SMA comprises the selection of predefined carbohydrate quantities for meal insulin dosing. Meal carbohydrate contents will be set on an individual basis at the baseline visit.
223842867|NCT05481034|DEVICE|Exactly estimated carbohydrate content bolus option|The carbohydrate content of meals is estimated in grams of carbohydrates prior to a meal bolus
223842868|NCT01725867|OTHER|PT program|manual myofascial release for craniomandibular system for 30\~40 minutes chin-in exercise within 10 minutes and as home exercise self-care education twice per week for 8 weeks
223842869|NCT01725867|DEVICE|oral appliance|custom-made oral appliance: wear every night for 8 weeks, occasional drop is allowed self-care education
223842870|NCT01387646|BEHAVIORAL|Project IMAGE|Participants in the intervention arm will be interviewed at baseline, given a targeted physical exam including a STI/HIV screen, pap smear and contraception counseling and enrolled in the intervention. The intervention will include 2 workshops, 5 support groups sessions and 2 individual counseling sessions. They will be interviewed and examined again after completing the intervention, to establish a post-intervention baseline.
223842871|NCT04669080|BEHAVIORAL|Health care provider cost navigation training|Health care providers and asthma educators in a pediatric asthma clinic will receive an online training about the importance of cost of care conversations, how to start cost of care conversations with families, how to refer families to cost navigation resources, and how to lead asthma specialty care teams in cost navigation.
223842872|NCT05711628|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo ASCT
223842873|NCT05711628|DRUG|Bendamustine|Given IV
223842874|NCT05711628|DRUG|Brentuximab Vedotin|Given IV
223842875|NCT05711628|DRUG|Carboplatin|Given IV
223842876|NCT05711628|PROCEDURE|Computed Tomography|Undergo PET/CT and CT
223842877|NCT05711628|DRUG|Etoposide|Given IV
223842878|NCT05711628|DRUG|Gemcitabine|Given IV
223842879|NCT05711628|DRUG|Ifosfamide|Given IV
223842880|NCT05711628|DRUG|Pegylated Liposomal Doxorubicin Hydrochloride|Given IV
223842881|NCT05711628|BIOLOGICAL|Pembrolizumab|Given IV
223842882|NCT05711628|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
223842883|NCT05711628|RADIATION|Radiation Therapy|Undergo RT
223842884|NCT05711628|OTHER|Transplant Conditioning|Receive standard preparative chemotherapy regimen
223842885|NCT05711628|DRUG|Vinorelbine|Given IV
223842886|NCT03803917|PROCEDURE|Injection with freshly collected autologous adipose tissue|
223842887|NCT01174992|BIOLOGICAL|Evicel|EVICEL is a human plasma derived fibrin sealant
223842888|NCT01174992|OTHER|Sutures only|Standard of care
223842889|NCT03442920|OTHER|Exercise|This group made exercise for 12 week/3 times a week.
223842890|NCT01161160|BIOLOGICAL|GSK Biologicals' GSK2340274A (two different formulations)|Intramuscular injection
223842891|NCT01161160|BIOLOGICAL|GSK Biologicals' - GSK2340272A|Intramuscular injection
223842892|NCT03738241|BIOLOGICAL|A/H7N9|Monovalent split 2017 A/H7N9 Inactivated Influenza Virus Vaccine containing the Hemagglutinin (HA) and Neuraminidase (NA) from low pathogenic avian influenza A/Hong Kong/125/2017 (H7N9) and the PB2, PB1, PA, NP, M and NS from A/Puerto Rico/8/1934 (H1N1). The HA content of the 2017 A/H7N9 vaccine formulations were determined by Single Radial Immunodiffusion (SRID) assay to be approximately two times higher (14.45 mcg of HA per 0.5 mL dose) than the targeted HA content on the label (7.5 mcg of HA per 0.5 mL dose).
223842893|NCT03738241|DRUG|AS03|AS03 oil-in-water emulsion-based adjuvant system containing DL-alpha-tocopherol, squalene, polysorbate 80, and a buffer.
223842894|NCT03738241|OTHER|Phosphate Buffered Saline (PBS) diluent|0.006M PBS diluent for Influenza Virus Vaccine.
223842895|NCT04430374|OTHER|No interverntion|No intervention will be done, registry only
223842896|NCT04222647|DRUG|WO533|Intravaginal application
223842897|NCT01238796|DRUG|telavancin|Intravenous
223842898|NCT05032235|DRUG|Fluzoparib|Normal Renal Function:A single oral dose of Fluzoparib will be administered.
223842899|NCT05032235|DRUG|Fluzoparib|Mild Renal Impairment:A single oral dose of Fluzoparib will be administered.
223842900|NCT05032235|DRUG|Fluzoparib|Moderate Renal Impairment:A single oral dose of Fluzoparib will be administered.
223842901|NCT03871881|OTHER|Magnetic Resonance Imaging|Magnetic Resonance Imaging (MRI) of the brain's macro- and microstructures. Furthermore, brain regional interactions and activity is examined with quantitative functional-MRI (fMRI)
223842902|NCT03871881|OTHER|Neuropsychological assessment|A special designed neuropsychological test battery of validated tests to assess function of cognitive domains
223842903|NCT04155099|BIOLOGICAL|RBX7455|RBX7455 is a preparation of live intestinal microorganisms (active drug) purified from stool donations obtained from healthy, screened donors, mixed with preservative, lyophilized, and put into capsules. The capsules are taken orally (i.e., by mouth). After ingestion, these freeze-dried microorganisms can reconstitute and proliferate in the gut.
223842904|NCT04155099|BIOLOGICAL|Placebo|Capsule with cellulose filler
223842905|NCT00554164|DRUG|(R-)CHOP protocol|Patients with a persistently positive interim-PET scan assigned to arm B1 will receive another six cycles of the (R-)CHOP regimen (rituximab, cyclophosphamide, doxorubicine, vincristine, prednisone).
223842906|NCT00554164|DRUG|B-ALL protocol|Patients with a persistently positive interim-PET scan assigned to arm B2 will receive six blocks of the B-ALL protocol (rituximab, methotrexate, ifosfamide, etoposide, cytarabine, vincristine, cyclophosphamide, doxorubicine, vindesine, dexamethasone).
223842907|NCT00554164|DRUG|(R-)CHOP protocol|Patients with a negative interim-PET scan assigned to arm A1 will receive another four cycles of the (R-)CHOP regimen (rituximab, cyclophosphamide, doxorubicine, vincristine, prednisone). Arm A1 was closed when the number of patients required for the randomisation between arms A1 and A2 was reached.
223842908|NCT00554164|DRUG|(R-)CHOP protocol|Patients with a negative interim-PET scan assigned to arm A2 will receive another four cycles of the (R-)CHOP regimen (rituximab, cyclophosphamide, doxorubicine, vincristine, prednisone) plus two additional doses rituximab. Since the number of patients required for the randomisation between arms A1 and A2 has been reached, all patients with a negative interim-PET scan are treated according to arm A2.
223842909|NCT03625011|DRUG|Gabapentin|This double blinded randomized control trial will enroll 50 children age 3-18 years, undergoing T/As. Patients will be receiving either one gabapentin dose (15mg/kg up to 600mg) or placebo preoperatively. Both control and test group will receive the standard narcotic regimen intraoperatively.
223842910|NCT01188122|DEVICE|AnapnoGuard 100|Respiratory guard system during mechanical ventilation
223842911|NCT03169361|DRUG|Ixazomib|Ixazomib capsules
223842912|NCT00670995|BEHAVIORAL|Interactive Tobacco Education|Increase perceived behavioral control (self-efficacy) Decrease willingness to use tobacco Decrease intentions to use tobacco
223842913|NCT05551962|PROCEDURE|Soft tissue augmentation with CTG|"1. Incision the mucosa at the alveolar ridge, mucosal-periosteal flap elevation~2. Placement of the Astra Tech dental implant (Dentsply, Germany)~3. Sampling of free connective tissue graft from the maxilla tuber area~4. Fixation of the graft to the vestibular flap~5. Suturing the wound tightly"
223842914|NCT05551962|PROCEDURE|Soft tissue augmentation with CM|"1. Incision the mucosa at the alveolar ridge, mucosal-periosteal flap elevation~2. Placement of the Astra Tech dental implant (Dentsply, Germany)~3. Modeling of sterile collagen matrix according to the shape of the recipient bed~4. Fixation of the collagen matrix to the vestibular flap~5. Suturing the wound tightly"
223842915|NCT03464253|DEVICE|Performance of the transcranial Doppler (TCD)|Within 24 hour before the operation, TCD is performed using Siemens Acuson X300 machine with ultrasound frequency is 1 - 5 MHz probe to measure Mean Velocity and Pulsatility Index in the right middle cerebral artery.postoperatively, TCD study is performed twice at 24h and 48h after spinal anesthesia. For 5 days postoperatively, the Patients are assessed clinically for the occurrence of headache. Patients who developed PDPH will be identified and their pre and post puncture measurements will be compared with the corresponding measurements of PDPH free patients.
223842916|NCT01631903|DRUG|telepristone acetate 12 mg|12 mg, vaginal capsule, once daily for 4 months
223842917|NCT01631903|DRUG|telepristone acetate 3 mg|3 mg, vaginal capsule, once daily for 3 months
223842918|NCT01631903|DRUG|telepristone acetate 6 mg|6 mg, vaginal capsule, once daily for 3 months
223842919|NCT01631903|DRUG|telepristone acetate 12 mg|12 mg, vaginal capsule, once daily, for 3 months
223842920|NCT01631903|DRUG|telepristone acetate 24 mg|24 mg, vaginal capsule, once daily for 4 months
223842921|NCT02594696|OTHER|Proactive Psychiatry Consultation (PPC)|"* The psychiatrist conducts a tailored, cancer-specific assessment to optimize psychiatric symptoms and collaborates with the oncologist to develop and modify the cancer treatment plan.~* The case manager, a social worker, engages with the patient to promote self-management, identify and address barriers to care, and bridge communication with oncology and mental health.~* The psychiatrist and case manager proactively monitor symptoms and the process of cancer care, remain in regular contact with the patient and communicate with the oncology team at least every 4 weeks~* The psychiatrist and case manager are available for consultation across care settings (outpatient, inpatient, home).~* Recommendations are documented in the medical record and communicated directly to the oncology team"
223842922|NCT00088465|DRUG|Intramuscular olanzapine depot|45-405 milligram (mg), intramuscular injection, on a 2-, 3-, or 4-week interval.
223842923|NCT03845764|DIAGNOSTIC_TEST|Rapid on-site evaluation|Specimens obtained with endoscopic sampling procedures are stained with a rapid method (i.e., Diff Qui) and submitted to on-site cytologic review
223842924|NCT03337750|BEHAVIORAL|Web-PE Therapy|Ten 60-minute psychotherapy sessions over 8 weeks, focused on gradually confronting distressing trauma-related memories and reminders. Web-PE is an internet-based version of prolonged exposure (PE) for posttraumatic stress disorder (PTSD).
223842925|NCT06104540|OTHER|Experimental I liquid vaseline groups|Patients in the liquid vaseline group will apply liquid vaseline twice a day for 3 months. Depending on the size of the burn area, 5-10 ml of liquid petroleum jelly will be applied to the burn area by massaging for 5 minutes twice a day, and each application will be recorded in the application follow-up form. Patients will be visited on the 15th day, first month, second month, and third month after the application begins.
223842926|NCT06104540|OTHER|Experimental II extra virgin olive oil groups|Patients in the extra virgin olive oil group will apply extra virgin olive oil twice a day for 3 months. Depending on the size of the burn area, 5-10 ml of liquid petroleum jelly will be applied to the burn area by massaging for 5 minutes twice a day, and each application will be recorded in the application follow-up form. Patients will be visited on the 15th day, first month, second month, and third month after the application begins.
223842927|NCT06104540|OTHER|Control Croup|No intervention will be made other than the recommendations of the institution's physicians and nurses.
223842928|NCT05979194|BEHAVIORAL|Labor Care Guide|Identifying information and labor characteristics at admission, supportive care, care of the baby, care of the woman, labor progress, medication, and shared decision-making
223842929|NCT00495469|DRUG|GSK189075|GSK189075 is available as a white, capsule-shaped tablet dosage form containing 50mg, 125mg, 250mg or 500mg of GSK189075 per tablet
223842930|NCT00495469|DRUG|Placebo|Available as Placebo matching tablet to GSK189075
223842931|NCT03405298|BEHAVIORAL|Educational Material|Educational material is in the form of a brochure
223842932|NCT03405298|BEHAVIORAL|Supplemental Collaborative Care|Supplemental care management consist of meeting with a behavioral health care manager over five sessions in-person or via phone call; the care manager will review patient information with the consulting psychiatrist, who can then make recommendations back to the primary care provider
223842933|NCT06476899|DRUG|orelabrutinib|orelabrutinib tablets
223842934|NCT06476899|DRUG|FCR/BR|FCR/BR
223842935|NCT06476899|DRUG|BTK inhibitor|BTK inhibitor choose by physican
223842936|NCT04302675|BEHAVIORAL|Prevention, Maternal Immunization|"This intervention will be focused on behavior change, both through providers gaining context, knowledge, confidence, and skills in talking to pregnant mothers about vaccination during pregnancy, but also with patients having increased knowledge about immunization issues, and decreased anxiety about getting vaccinated.~There is only one intervention arm in this study, and this study is looking at prevention in a pre-post feasibility study."
223842937|NCT02303119|DRUG|Rituximab IV|intra-venous, 375 mg/m²
223842938|NCT02303119|DRUG|Rituximab SC|sub-cutaneous, 1400 mg
223842939|NCT02062905|DRUG|Dexamethasone|
223842940|NCT02062905|OTHER|Placebo Vehicle|
223842941|NCT04610203|DIETARY_SUPPLEMENT|25 g Nutralys Pea Protein|To determine the glycaemic response, insulinaemic response, GIP response and GLP-1 response to 50g Glucose +25g Nutralys S85 Plus
223842942|NCT04610203|DIETARY_SUPPLEMENT|50 g Nutralys S85 Plus.|To determine the glycaemic response, insulinaemic response, GIP response and GLP-1 response to 50g Glucose+50 g Nutralys S85 Plus .
223842943|NCT04610203|DIETARY_SUPPLEMENT|50 g Glucose|To determine the glycaemic response, insulinaemic response, GIP response and GLP-1 response to 50g Glucose
223842944|NCT00448864|DRUG|Ecallantide|
223842945|NCT00448864|DRUG|Placebo|
223842946|NCT00410995|DRUG|Naproxen|
223842947|NCT01757080|OTHER|Cardiorespiratory performance assessment with ergospirometry test|
223842948|NCT01757080|OTHER|Biochemical analysis|
223842949|NCT03578562|OTHER|Targeted training intervention|An 8-week progressive homebased training intervention with supervised booster-sessions
223842950|NCT04189328|PROCEDURE|dental implant placement using magnifying loupes and microsurgical instruments|microsurgical dental implant placement employin splt finger technique by Misch
223842951|NCT04189328|PROCEDURE|macrosurgical dental implant placement|macrosurgical placement of single dental implants
223842952|NCT01491529|DRUG|AFQ056|"AFQ056 will be supplied as oral modified release tablets in 25 mg, 50 mg, 100 mg, 150 mg, and 200 mg.~Patients will be randomized in two groups by amantadine status.~* Group 1: Patients are not permitted to take amantadine within 2 weeks prior to the BL1 visit.~* Group 2: Patients must be on a stable and well tolerated dose of amantadine for at least 4 weeks prior to BL1 and must maintain the stable dose of amantadine during the remainder of the study.)"
223842953|NCT01491529|DRUG|Placebo|Placebo for AFQ056 will be supplied as oral tablets.
223842954|NCT04069390|DEVICE|CARDIOSKIN - Short record|A short record (max 2H15) is performed with Cardioskin
223842955|NCT04069390|DEVICE|Cardioskin - long record|A long record (max 8H) is performed with Cardioskin
223842956|NCT04069390|DEVICE|Neuronaute - long record|A long record (max 8H) is performed with Neuronaute
223842957|NCT04069390|DEVICE|Neuronaute -short record|A short record (max 2H15) is performed with Neuronaute
223842958|NCT02616354|DRUG|Imipenem|Patients in group I received a dose of imipenem/cilastatin 1g each every 8 hours or 0.5g every 6 hours optimized two-step infusion therapy (rapid first-step infusion in 30 min and slow second-step infusion above 1.5 hours)
223842959|NCT04679584|OTHER|Observation of different courses of SARS-CoV-2 infection in different phases (acute vs. post-acute) and settings|Oberservatory Cohorts focusing (I) on subjects after SARS-CoV-2 infection that are recruited from the general population (POP), and on subjects with acute SARS-CoV-2 infections recruited (II) in university hospital high-care settings or (III) general health care
223842960|NCT00892229|DRUG|Misoprostol (given buccally)|400 microgram misoprostol given buccally three hours before dilation and curettage (PHARMACIA CORPORATION - Istanbul, serial number 022-00, a tablet contains 200 micrograms)
223842961|NCT00892229|DRUG|Misoprostol (given vaginally)|400 microgram misoprostol (MISOPROSTOL - PHARMACIA CORPORATION - Istanbul, serial number 022-00, a tablet contains 200 micrograms)
223842962|NCT06296251|OTHER|Placebo treatment|Microcrystaline cellulose (MCC)
223842963|NCT06296251|DIETARY_SUPPLEMENT|Plant derived phenolics|Dietary supplement containing plant derived phenolics
223842964|NCT05900999|BEHAVIORAL|Feasibility of idle time exercise|The experiments in this proposal will assess the utility and subjective patient experience performing idle time exercise intervention designed to reduce learned non-use of the hemiparetic arm in the days, and weeks immediately following stroke. Exercise will be cued by wearable technology that provides vibrotactile cues similar to those provided by FitBit devices. Participants will be asked to perform simple exercises after receiving a vibration cue. In the first four sessions they will tap the more-involved wrist; in the second four sessions they will passively move the more-involved elbow through a range of motion; in the final four sessions they will actively move the more-involved elbow through a range of motion. Accelerometers in the wearable devices will monitor motion of the wrist during the exercise sessions. We will interview the participants two months later regarding how well they use the more-involved arm to perform daily activities.
223842965|NCT03312803|PROCEDURE|Mini autogenous skin graft|mini-autogenous skin grafts and skin homograft versus autogenous skin grafts for covering post burn wounds in children.
223842966|NCT04282902|DRUG|pirfenidone|Pirfenidone is administered orally 3 times a day, 2 tablets each time, for a period of 4 weeks or longer
223842967|NCT04056156|BEHAVIORAL|HIV-screening advice|To increase GP's HIV-testing behavior a targeted HIV-testing advice is spread to participants through an electronic mail
223842968|NCT04056156|BEHAVIORAL|HIV-testing advice plus group-level training|To increase specific HIV-testing behavior among GPs a targeted HIV-testing advice is spread to participants through an electronic mail and an additional face-to-face group-level training is provided.
223842969|NCT02114008|OTHER|Endoscopic examinations|Patients underwent two endoscopic examinations within two weeks. RGV was measured by aspiration of gastric contentes into a graduated cylinder after traditional fasting (at least 8 hours before the test) and after abbreviated fasting (3 hours with 200ml of water containing 25g of 12.5% maltodextrin). All patients received both oral and written information about the protocol at the outpatient clinic.
223842970|NCT04454567|DRUG|ABI-H0731|Participants will receive ABI-H0731 tablets orally once daily
223842971|NCT04454567|DRUG|Placebo|Participants will receive placebo to ABI-H0731 tablets orally once daily
223842972|NCT04454567|DRUG|NrtI|Entecavir (ETV), tenofovir alafenamide (TAF), or tenofovir disoproxil fumarate (TDF) SOC according to the respective package insert
223842973|NCT03815916|DRUG|Gold Nanocrystals|CNM-Au8 is a dark red/purple-colored liquid formulation consisting of a stable suspension of faceted clean surfaced elemental gold nanocrystals in buffered deionized water with a concentration of up to 0.5 mg/mL of gold. The formulation is buffered by sodium bicarbonate present at a concentration of 0.546 mg/mL. There are no other excipients. The drug product is formulated to be taken orally and will be provided in single dose HDPE containers. The study doses vary by the concentration of gold nanocrystals per milliliter in a volume of 60 mL.
223842974|NCT03197311|OTHER|Mobile app|A customized mobile application will be developed and downloaded to subjects; smartphones to monitor postoperative analgesic consumption, and disposal; pain control and patient satisfaction. The mobile app will provide notifications for medications and select education links on the prescribed analgesics. Subjects will receive reminders to take medications as directed. Subjects will be able to monitor and report their pain during the first week after surgery.
223842975|NCT01600703|DRUG|Sitagliptin|Sitagliptin, 100mg, oral, single dose
223842976|NCT01600703|DRUG|Placebo|Placebo, oral, single dose
223842977|NCT02275936|DRUG|N91115|S Nitrosoglutathione Reductase Inhibitor
223842978|NCT04637464|OTHER|Early termination of empirical antibiotics|Termination of empirical antibiotics for febrile neutropenia based on clinical parameters, regardless of neutrophile count.
223842979|NCT04261920|DRUG|Huangqi Guizhi Wuwu decoction|"The experimental group took Huangqi Guizhi Wuwu decoction twice a day, infused with warm water. Consistently used during patients receiving XELOX5 adjuvant chemotherapy for at least 12 weeks (every 3 week is a cycle, 4 cycles).~The control group took placebo twice a day, infused with warm water. Consistently used during patients receiving XELOX5 adjuvant chemotherapy for at least 12 weeks (every 3 week is a cycle, 4 cycles)."
223842980|NCT04927052|DEVICE|Revanesse Shape + with Lidocaine|Revanesse Shape + with Lidocaine. Participants had 1 cheek treated with Revanesse Shape + with Lidocaine
223842981|NCT04927052|DEVICE|Juvederm Voluma with Lidocaine.|Juvederm Voluma with Lidocaine. Participants had 1 cheek treated with Juvederm Voluma with Lidocaine
223842982|NCT03318744|DRUG|Aspirin|Aspirin is one of the most widely used antithrombotic agents to prevent recurrent ischemic stroke for patients with prior symptomatic ischemic stroke.
223842983|NCT03318744|DRUG|Placebo Oral Tablet|Placebo resembling aspirin tablet will be be given to participants in control arm.
223842984|NCT03450876|OTHER|Non-Interventional|Non-Interventional
223842985|NCT04602962|PROCEDURE|fertility preservation, several methods|fertility preservation using assisted reproductive techniques or not
223842986|NCT03238482|DRUG|salmeterol-fluticasone|Seretide Diskus 50/250 µg/dose
223842987|NCT03238482|DRUG|salmeterol-fluticasone|Salmeterol/fluticasone Easyhaler 50/250 µg/dose, product E
223842988|NCT03238482|DRUG|salmeterol-fluticasone|Salmeterol/fluticasone Easyhaler 50/250 µg/dose, product F
223842989|NCT03238482|DRUG|salmeterol-fluticasone|Salmeterol/fluticasone Easyhaler 50/250 µg/dose, product G
223842990|NCT04294082|BEHAVIORAL|Mindfulness based intervention|"A four session, 120 mins per session mindfulness based course delivered weekly oer the course of four weeks. The mindfulness sessions are based on the model delineated by Kabat-Zinn (1992) and will encompass:~* an introduction to mindfulness~* body-scan exercises~* sitting meditation~* mindful movement exercises~* individual and group reflections~* homework exercises"
223842991|NCT04925180|DRUG|Cyproterone Acetate (Androcur, BAY94-8367)|As prescribed by the treating physician
223842992|NCT01805856|DRUG|PIPC piperacillin sodium|
223842993|NCT01805856|DRUG|CEZ, cefazolin sodium|
223842994|NCT05091762|BEHAVIORAL|exercise|Upper limb resistance training with blood flow obstruction
223842995|NCT00182416|DEVICE|pacemaker|
223842996|NCT04162366|DRUG|Aprocitentan 25 mg|Tablet, oral use once daily
223842997|NCT04162366|DRUG|Placebo|Matching placebo tablet, oral use once daily
223842998|NCT01779882|DRUG|Busulfan-Cyclophosphamide as Conditioning Regimen before Allogeneic Hematopoietic Stem Cell Transplantation|Test the hypothesis, that the order of application of Busulfan (BU) and Cyclophosphamide (CY) has an impact on toxicity after allogeneic Hematopoietic stem cell transplantation (HSCT) and that CY-BU reduces liver toxicity compared to BU-CY.
223842999|NCT01779882|DRUG|Cyclophosphamide-Busulfan as Conditioning Regimen before Allogeneic Hematopoietic Stem Cell Transplantation|Test the hypothesis, that the order of application of Busulfan (BU) and Cyclophosphamide (CY) has an impact on toxicity after allogeneic Hematopoietic stem cell transplantation (HSCT) and that CY-BU reduces liver toxicity compared to BU-CY.
223843000|NCT01175707|DRUG|Daptomycin|
223843001|NCT01175707|DRUG|Vancomycin|
223843002|NCT06480656|PROCEDURE|Rehabilitation with eccentric cycling exercise|Instead of normal cycling, patients will exercise on the eccentric bike.
223843003|NCT06480656|PROCEDURE|normal rehabilitation|Normal rehabilitation will be conducted
223843004|NCT03320109|OTHER|Vitamin D|
223843005|NCT00186680|PROCEDURE|high dose chemo then auto hematopoietic cell transplant|
223843006|NCT02461238|OTHER|Vouchers|The vouchers sent to families can be used in supermarkets for fresh, frozen or canned fruits and vegetables, excluding potatoes. The amount of the vouchers takes into account family composition, calculated to correspond to a serving per day per person.
223843007|NCT02461238|OTHER|Nutrition education|Nutrition education workshops taught by a dietician
223843008|NCT05877404|OTHER|Surveys|Survey on practice patterns surrounding tumor genetic testing in endometrial cancer.
223843009|NCT01178515|OTHER|Modification of the content of fat in milk|Comparison of three levels of fat content in cow´s milk
223843010|NCT01178515|OTHER|Modification of the content of cows milk|Comparison of three levels of fat content in cows' milk
223843011|NCT01178515|OTHER|Modification of the fat content of cows´ milk|Comparison of three levels of fat content in cow´milk
223843012|NCT00003743|BIOLOGICAL|aldesleukin|
223843013|NCT03465111|DRUG|ACTH (adrenocorticotropic hormone) gel|The dose of H.P. Acthar Gel is 80 Units administered subcutaneously
223843014|NCT03677726|BEHAVIORAL|Mindfulness Based Therapy for Insomnia|The mindfulness-based intervention consists of eight 2-hour sessions covering various mindfulness techniques (e.g. mindfulness of breath, body and movement, senses and informal practice, and empathy and compassion) that pertain to people with sleep problems and insomnia. Participants will be provided handouts for the information covered during these talks and discussions.
223843015|NCT03677726|OTHER|Sleep Hygiene Education Exercise Program|The Sleep Hygiene Education and Exercise Program has known relationships with good sleep quality. It will comprise 8 weekly 2-hour sessions. Each session will introduce a concept related to sleep and sleep hygiene. The facilitator will provide the theory and rationale behind the concept, and encourage participants to share and discuss their experiences related to the concept. The session will end with the participants evaluating how to implement the specific concept in their daily lives, and its potential implications for their sleep. Participants will be provided with a manual that outlines the concept and how they intend to apply it to their daily lives.
223843016|NCT00041262|DRUG|cisplatin|
223843017|NCT00041262|DRUG|epirubicin hydrochloride|
223843018|NCT00041262|DRUG|fluorouracil|
223843019|NCT00041262|PROCEDURE|conventional surgery|
223843020|NCT00041262|PROCEDURE|neoadjuvant therapy|
223843021|NCT04668183|PROCEDURE|Pudendal nerve block group|A 22 Gauge 50 mm insulated needle was then introduced in the anterior-posterior direction at the middle of the ultrasound probe's superior edge with an out-of-plane approach and using an inclination of 15° in the sagittal plane. The needle tip's position was identified by direct visualization using the movement of adjacent anatomical structures.
223843022|NCT04668183|PROCEDURE|Dorsal penile nerve block group|Half of the total 0.2 ml/kg dose of 0.25% bupivacaine was administered while observing its distribution with US. The same procedure was then repeated on the other side of the penis.
223843023|NCT01885364|DRUG|Normal saline|intravenous injection with normal saline before injection of propofol
223843024|NCT01885364|DRUG|Esmolol|intravenous injection with remifentanil 0.5 mg/kg before injection of propofol
223843025|NCT01885364|DRUG|Remifentanil|intravenous injection with remifentanil 0.35 ug/kg before injection of propofol
223843026|NCT01885364|DRUG|propofol|intravenous injection after pretreatment
223843027|NCT01779921|DRUG|activated recombinant human factor VII|Treatment of bleeding episodes and treatment during surgery and prophylaxis as per discretion of the investigator.
223843028|NCT01779921|DRUG|Fresh frozen plasma (Source unspecified)|Treatment of bleeding episodes and treatment during surgery and prophylaxis as per discretion of the investigator.
223843029|NCT01779921|DRUG|Plasma-derived FVII (LFB)|Treatment of bleeding episodes and treatment during surgery and prophylaxis as per discretion of the investigator.
223843030|NCT01779921|DRUG|Prothrombin Complex conc. (PCC)|Treatment of bleeding episodes and treatment during surgery and prophylaxis as per discretion of the investigator.
223843031|NCT01779921|DRUG|Plasma-derived FVII conc. (pdFVII Baxter)|Treatment of bleeding episodes and treatment during surgery and prophylaxis as per discretion of the investigator.
223843032|NCT01779921|DRUG|Plasma-derived FVII conc. (pdFVII PFL)|Treatment of bleeding episodes and treatment during surgery and prophylaxis as per discretion of the investigator.
223843033|NCT03230955|BEHAVIORAL|Psychological and psycho-educational support by phone|The intervention is based on cognitive-behavioural therapy (CBT). The intervention, in order to achieve behavioural changes, will include components based in Bandura's social learning theory and social cognitive theory (Bandura, 1986) and the transtheorical model of change (Prochaska, 1992). It has been shown that expectations and self-efficacy are behavioural predictors and that they are an effective framework for the assistance to quit smoking. This theory allows evaluating patient motivation phase and adapting the interventions according to each phase (Fiore, 2011)
223843034|NCT03230955|OTHER|Brief counselling session|Brief counselling session
223843035|NCT04643730|OTHER|Acupressure methods|Acupressure on the KI3 and St36 points applied to the babies in the acupressure group for a total of 7 minutes before the heel prick
223843036|NCT04643730|OTHER|Foot Reflexology Methods|Foot reflexology was applied to the babies in the foot reflexology group for a total of 7 minutes before the heel prick
223843037|NCT04643730|OTHER|Control Grup|No pre-application was made to the babies in the control group as a routine procedure.
223843038|NCT01203241|PROCEDURE|Pulmonary vein encircling|Pulmonary vein encircling by performing continuous radiofrequency lesions surrounding each ipsilateral pulmonary vein antrum
223843039|NCT01203241|PROCEDURE|Pulmonary vein encircling plus roof ablation|Pulmonary vein encircling by performing continuous radiofrequency lesions surrounding each ipsilateral pulmonary vein antrum plus creation of a radiofrequency line joining contralateral superior pulmonary veins throughout the left atrial roof.
223843040|NCT02988375|BEHAVIORAL|dCBTI|
223843041|NCT02988375|BEHAVIORAL|Sleep Education|
223843042|NCT04871087|DEVICE|Green Light|"The Allay Lamp is a consumer product currently available and widely used in the US. It emits low intensity (1-10lux)narrow band (20nm) green light (peak wavelength 520nm) that is marketed as non-irritating to users. In that context, it is not a medical device and does not require a 510(k). However, we believe that light likely also has benefits for sleep. To better understand its effects,we are planning to conduct the proposed study. In that context, the Allay Lamp would be considered an investigational medical device because it has not been cleared or approved by FDA for the intended purpose of treating sleep. No FDA submission should be necessary for this study using 21 C.F.R. 812.3, because the Allay Lamp is a non-significant risk (NSR) device:~It is not an implant It is not intended for use in supporting or sustaining human life The Allay Lamp provides a very low risk light-based therapy. The light provides no more risk than any other table lamp available on the market today."
223843043|NCT04943835|OTHER|Observational - No intervention|
223843044|NCT01147549|DRUG|[C14]AZD9668|Oral Solution 60 mg Single Dose
223843045|NCT05258617|DEVICE|LLLT Photobiomodulation|Treatment with red LED light using UltraSlim device.
223843046|NCT03791528|OTHER|Kinesio-taping treatment group|In treatment group; Kinesio-taping 3 times at 5-day intervals, one of the fan-shaped cut bands, 2-3 inches above the SIJ, and the other below 2-3 inches below the SIJ, and crossed each other by 90 degrees. evaluated at baseline, the twentieth minute after application and on the 15th day by physical examination of the sacroiliac joint, visual analog scale, Modified Oswestry Low Back Pain Disability Questionnaire.
223843047|NCT04922099|DEVICE|glycemic gap|"Measurements of HbA1c-based adjusted glycemic gap:~The estimated chronic average glucose levels (eAG) over the past 3 months will calculate from the equation AG = 28.7 × HbA1c - 46.7 Glycemic gap was calculated as the ADAG level subtracted from the admission glucose level."
223843048|NCT06272955|DEVICE|Spinal Cord Stimulator (SCS)|"Patients are already implanted with device from the H-49023 study.~The SCS implantation technique consists of inserting epidural leads-containing multiple stimulating electrodes (8). Two leads will be implanted percutaneously into the epidural space.~The implantable pulse generator (IPG) is a neurostimulation system designed to deliver low-intensity electrical impulses. The system is intended to be used with leads and extensions that are compatible with the system. This neurostimulation system is indicated (FDA approved) as an aid in the management of chronic, intractable pain of the trunk and/or limbs. The intended use in this study is considered experimental."
223843049|NCT02797483|OTHER|Test Fat Blue|Each subject received a palm olein-based run in diet for 2 weeks, followed by random assignment Test Fat Blue which incorporated into daily snacks (\~50g of test fats, 2 experimental cupcakes (\~15g test fat each) for breakfast and 4 pieces experimental cookies (\~5g test fat each) for afternoon tea together with a palm olein-based background diet for 16 weeks.
223843050|NCT02797483|OTHER|Test Fat Green|Each subject received a palm olein-based run in diet for 2 weeks, followed by random assignment Test Fat Green which incorporated into daily snacks (\~50g of test fats, 2 experimental cupcakes (\~15g test fat each) for breakfast and 4 pieces experimental cookies (\~5g test fat each) for afternoon tea together with a palm olein-based background diet for 16 weeks.
223843051|NCT02797483|OTHER|Test Fat Red|Each subject received a palm olein-based run in diet for 2 weeks, followed by random assignment Test Fat Red which incorporated into daily snacks (\~50g of test fats, 2 experimental cupcakes (\~15g test fat each) for breakfast and 4 pieces experimental cookies (\~5g test fat each) for afternoon tea together with a palm olein-based background diet for 16 weeks.
223843052|NCT00309816|DRUG|sildenafil|
223843053|NCT03606460|DRUG|Ocrelizumab Dose 1|300 mg infusion administered to ocrelizumab-naive participants per approved protocol (over approximately 2.5 hours or longer) as per standard of care followed by a second 300 mg shorter infusion over approximately 1.5 hours.
223843054|NCT03606460|DRUG|Ocrelizumab Dose 2 and Dose 3|600 mg infusion of ocrelizumab administered at a shorter rate (i.e. over the course of approximately 2 hours) at Week 24 and at Week 48
223843055|NCT06401928|DEVICE|transcranial direct current stimulation|Patients will receive 10 sessions of either 1.5 mA electrical stimulation for 20 minutes each day over 10 consecutive days.
223843056|NCT06401928|DEVICE|transcranial direct current stimulation combined with cognitive training|Patients will receive 10 sessions of 20 minutes of 1.5 mA electrical stimulation on 10 consecutive days. Each session is followed by 30 minutes cognitive training in which patients conduct several computerized cognitive tests.
223843057|NCT06401928|DEVICE|transcranial direct current stimulation|Patients will receive 10 sessions of sham (placebo) electrical stimulation for 20 minutes each day over 10 consecutive days.
223843058|NCT04170023|DRUG|ALXN2050|Oral FD inhibitor
223843059|NCT03963479|COMBINATION_PRODUCT|Magnesium and Vitamin B6|Magnesium and Vitamin B6 will be given to the enrolled patients for 3 months
223843060|NCT01307852|DEVICE|Plastic Scintillation Detectors|Radiation detectors attached to rectal balloon for each CT scan done during each radiation treatment. Treatment delivery Monday through Friday for 7 weeks.
223843061|NCT02613780|PROCEDURE|Crosslinking|corneal collagen crosslinking with riboflavin
223843062|NCT02613780|PROCEDURE|Photorefractive keratectomy|
223843063|NCT02613780|DEVICE|iDesign® Advanced WaveScan Studio|Used to map wavefront aberration in planning photorefractive keratectomy
223843064|NCT03818308|DRUG|Sofosbuvir and Velpatasvir|All subjects will receive one film-coated tablet of sofosbuvir/velpatasvir (400/100 mg) orally once daily for 8 weeks.
223843065|NCT01153854|DRUG|Racecadotril|oral racecadotril (1.5mg./Kg./t.i.d. doe 5 days) in double blind assigned.
223843066|NCT01153854|DRUG|Placebo groups|Placebo with feature color, appearance and tase similar to racecadotril t.i.d. for 5 days
223843067|NCT04402671|OTHER|non-cross-linked porcine skin collagen membrane|non-cross-linked porcine skin collagen membrane used is Bioguide, Geistlisch Pharma AG, Wolhusen, Switzerland.
223843068|NCT04402671|OTHER|glutaraldehyde cross-linked bovine collagen membrane|glutaraldehyde cross-linked bovine collagen membrane GCLM used is RTM Collagen®, Osteogenics Biomedical, Lubbock, TX, USA.
223843069|NCT05225454|OTHER||
223843070|NCT04426487|DRUG|Progesterone|Intramusculer progesterone
223843071|NCT06275880|OTHER|Intra-articular infiltration of PVP Collagen|Intra-articular collagen injection plus physiotherapy program
223843072|NCT06275880|OTHER|Rehabilitation|Patients who received conservative treatment through rehabilitation with a home program for one month
223843073|NCT04514042|PROCEDURE|Peroral endoscopic myotomy|Patients will be hospitalized for 24 hours before procedure or at the day of procedure (depending on preference of each center). Procedures will be performed always using carbon dioxide insufflation and whenever possible under general anesthesia with endotracheal intubation by anesthesiologist recommendations. The procedure will begin after general endoscopic evaluation of the Zenker's diverticulum and esophagus. An incision of the bridge between the Zenker's diverticulum and the esophagus will be done using procedure as peroral endoscopic myotomy. All the procedures will be documented with photographs or videorecordings.
223843074|NCT04514042|PROCEDURE|Flexible endoscopic septotomy|Patients will be hospitalized for 24 hours before procedure or at the day of procedure (depending on preference of each center). Procedures will be performed always using carbon dioxide insufflation and whenever possible under general anesthesia with endotracheal intubation by anesthesiologist recommendations. The procedure will begin after general endoscopic evaluation of the Zenker's diverticulum and esophagus. An incision of the bridge between the Zenker's diverticulum and the esophagus will be done using procedure as flexible endoscopy septotomy. All the procedures will be documented with photographs or videorecordings.
223843075|NCT05864768|DIETARY_SUPPLEMENT|Vegan/vegetarian diet|"At baseline, following the compilation of a periodontal chart in which pocket probing depth (PPD) and FMPS and FMBS were recorded, patients with pathological probing depths \>3mm associated with periodontitis were excluded. Healthy patients underwent a prophylaxis session and oral hygiene instructions with brushing and flossing. A mouthwash based on chlorhexifdine 0.20% to be used twice a day was prescribed.~At 15 days from the baseline (T0) the periodontal chart was compiled again and the parameters relating to PD, FMP, FMBS and the Eastman Interdental Bleeding Index (EIBI) were collected. Patients with FMBS and FMPS values \>20% were excluded.~From time T0 all patients were asked to suspend the interdental hygiene maneuvers by interrupting the use of dental floss and abandoning the use of mouthwash. All patients were recalled weekly, for a total of 4 times (T1, T2, T3, T4) in which parameters related to FMBS, FMPS and EIBI were recorded."
223843076|NCT05864768|DIETARY_SUPPLEMENT|Omnivorous diet|"At baseline, following the compilation of a periodontal chart in which pocket probing depth (PPD) and FMPS and FMBS were recorded, patients with pathological probing depths \>3mm associated with periodontitis were excluded. Healthy patients underwent a prophylaxis session and oral hygiene instructions with brushing and flossing. A mouthwash based on chlorhexifdine 0.20% to be used twice a day was prescribed.~At 15 days from the baseline (T0) the periodontal chart was compiled again and the parameters relating to PD, FMP, FMBS and the Eastman Interdental Bleeding Index (EIBI) were collected. Patients with FMBS and FMPS values \>20% were excluded.~From time T0 all patients were asked to suspend the interdental hygiene maneuvers by interrupting the use of dental floss and abandoning the use of mouthwash. All patients were recalled weekly, for a total of 4 times (T1, T2, T3, T4) in which parameters related to FMBS, FMPS and EIBI were recorded."
223843077|NCT01668342|BEHAVIORAL|SMS assessments & feedback|Daily symptom assessments tied to tailored feedback
223843078|NCT04994262|OTHER|Menthol Lozenge|"In the study, Oka Menthol, a herbal lozenge produced by Otacı, will be used. Its formula contains: menthol 0.26%, eucalyptol 0.065%, thymol 0.0002%, camphor 0.0002%, anise oil, thyme oil, coltsfoot, marshmallow flower, bovine tail flower extracts, glucose and sucrose.~Medical properties: Otacı Oka Menthol Pastil shows antibacterial and fungicidal properties with eucalyptol in its composition. Menthol is effective against local anesthetic, local antitussive and irritation. It also plays a mild analgesic role with camphor in its content. It has an antibacterial and antifungal effect with thymol, a phenolic antiseptic. Otaco Oka Menthol Pastilles also contain extracts of coltsfoot, cow's tail flower and marshmallow flower which are anti-irritant and expectorant."
223843079|NCT04404140|DRUG|Ipatasertib|Ipatasertib will be administered at a dose of 400 mg, as per the dosing schedule described above.
223843080|NCT04404140|DRUG|Atezolizumab|Atezolizumab will be administered at a fixed dose of 1200 mg, as per the dosing schedule described above.
223843081|NCT04404140|DRUG|Docetaxel|Docetaxel will be administered at a dose of 75 mg/m\^2, as per the dosing schedule described above.
223843082|NCT00519363|DRUG|atorvastatin|atorvastatin 40mg, given orally daily for 3 months.
223843083|NCT02372448|OTHER|ALK analysis on CTCs detected by ISET|
223843084|NCT01289405|DEVICE|Continuous Positive Airway Pressure (CPAP)|mechanical splint to open airway during sleep, considered the gold standard treatment for patients with obstructive sleep apnea
223843085|NCT03513861|OTHER|FASTER Assessment tool|The FASTER assessment tool consists of monitoring mental status, respiratory distress and capillary refill time by parents of children admitted to the hospital with febrile illness. Parents in the intervention group are asked to monitor their child hourly with the FASTER tool and signal severity of illness to the healthcare team via color coded flag system. Number of healthcare provider - patient reassessments will be compared in intervention and control group.
223843086|NCT04987710|DEVICE|intracranial rescue stenting|use of intracranial rescue stenting as re-perfusion technique after failed thrombectomy
223843087|NCT04124991|DRUG|Durvalumab|Radioembolization with Yttrium-90 Microspheres
223843088|NCT04124991|RADIATION|Radioembolization|Radioembolization with Yttrium-90 Microspheres
223843089|NCT04626921|DRUG|CNM-Au8|30 mg of CNM-Au8
223843090|NCT01220440|DRUG|Methylphenidate|Methylphenidate:10mg x 3 for one week
223843091|NCT01220440|DRUG|Placebo|Placebo: 1 pill x 2 for one week, 2 pills x 2 for one week.
223843092|NCT01220440|DRUG|Dextroamphetamine|Dextroamphetamine: 5mg x 2 for one week, 10mg x 2 for one week
223843093|NCT04890665|BEHAVIORAL|Online psychological intervention for healthcare workers|"The intervention is based on Cognitive Behavioral Therapy, Mindfulness, Behavioral Activation Therapy, Acceptance and Commitment Therapy and Positive Psychology, aimed at the Psychoeducation regarding the manifestations of anxiety, depression, burnout, fatigue compassion, posttraumatic stress disorder, and affectations in sleep quality and perception of life quality in healthcare workers.~And 3 complementary modules that according to the scientific literature could affect the mental health of healthcare workers related to how to deliver bad health news, Psychological first aid and how beliefs could influence physical and emotional self-care in the face of the COVID-19 pandemic."
223843094|NCT05078021|DIAGNOSTIC_TEST|Bronchoscopy|Bronchoscopy will be performed in all groups with endobronchial biopsies, brushings and bronchial washing performed.
223843095|NCT00977028|DRUG|Tumescent Local Anesthesia (lidocaine, epinephrine)|Tumescent solution of lidocaine (up to 1 gm per liter) and epinephrine (up to 1 mg per liter)with subcutaneous infiltration of up to 45 mg per kilogram
223843096|NCT00977028|PROCEDURE|Liposuction|Subcutaneous infiltration of tumescent local anesthesia (large volumes of dilute lidocaine and epinephrine) on at least two different occasions, followed by sequential serum samples every two hours for HPLC determination of serum lidocaine concentration and peak serum lidocaine concentration, initially without subsequent liposuction and finally on the last occasion with liposuction
223843097|NCT04311073|DRUG|Tranexamic Acid|IV Tranexamic acid in 50 ml will be given 15 minutes prior to initial surgical incision in the placebo group.
223843098|NCT04311073|DRUG|Placebos|IV normal saline 50 ml will be given 15 minutes prior to initial surgical incision in the placebo group.
223843099|NCT02015533|DRUG|CR8020|CR8020 50 mg/kg solution will be administered as a single 2-hour intravenous infusion.
223843100|NCT02015533|DRUG|Placebo|Placebo will be administered as a single 2-hour intravenous infusion.
223843101|NCT03923608|DIAGNOSTIC_TEST|Maximal muscle strength Test|1RM test performed in 5 different tools (Elastic Band, Pulley, halter, digital dynamometer and isokinetic dynamometer)
223843102|NCT03923608|DIAGNOSTIC_TEST|Exhaustion test|Test performed until individual exhaustion in 5 different tools (Elastic Band, Pulley, halter and isokinetic dynamometer)
223843103|NCT00755755|DRUG|PGL4001 (ulipristal) and iron|tablets
223843104|NCT00755755|DRUG|PGL4001 matching placebo and iron|tablets
223843105|NCT00755755|DRUG|PGL4001 (ulipristal) and iron|Tablets
223843106|NCT02947763|DRUG|mixture of metronidazole, ciprofloxacin, and minocycline|placement of intracanal medication
223843107|NCT03637595|PROCEDURE|Acupuncture|3 sessions of acupuncture will be the reference therapy against which the energy medicine intervention is being compared.
223843108|NCT03637595|PROCEDURE|Enery Medicine Intervention|3 sessions performed by Energy Medicine practitioner, who will perform an assessment followed by the intervention.
223843109|NCT03637595|PROCEDURE|Sham Energy Medicine|a non-energy trained confederate to be determined from the clinical research coordinators and non traditional volunteers enrolled administering assessments and providing therapeutic company.
223843110|NCT04108338|OTHER|Trial setting|Study results from clinical trials usually have been found not work efficiently in clinical practice. This outcome disparity may be caused by different pragmatic features of medical environment, also known as study setting such as trial setting and real-world setting, in which biases inherent to clinical trial design restrict its applicability even though all confounding factors are avoided.
223843111|NCT04458389|DRUG|TY101|"Dose escalation: TY101 0.3mg/kg or 1mg/kg or 3mg/kg or 10mg/kg 200mg Intravenous Q3W, 2 years depending on response.~Dose expansion: Subjects received TY101 injection for a maximum of 2 years until progressive disease, intolerant toxicity, death, or withdrawal from the study occurred."
223843112|NCT00592748|RADIATION|Charged Particle Radiation Therapy|Radiation doses will be determined by planning CT
223843113|NCT00083174|DRUG|exemestane|one 25 mg tablet daily in am
223843114|NCT03605875|BEHAVIORAL|Web-App|Cambian IT Health solutions from Surrey BC developed the infrastructure
223843115|NCT03605875|BEHAVIORAL|Paper|Contains similar questions to the Web-App tool
223843116|NCT00056368|DRUG|Anidulafungin|
223843117|NCT00056368|DRUG|Fluconazole|
223843118|NCT00938561|DRUG|Inulin|
223843119|NCT03791177|OTHER|Music Therapy|"Patients in the study group were exposed to flute music therapy (Sufi musical recital - Huseyni mode) at low tempo (60-80 rhythm / min) with weak beats and calm rhythms during the UDS.~This audition involves both vocal and instrumental music performed by a reed flute called 'Ney'. A competent lecturer who was specialized in music suggested all the musical compositions during the therapy"
223843120|NCT05212948|DRUG|S-268019-b|Solution for IM injection
223843121|NCT05212948|DRUG|Placebo|Saline solution for IM injection
223843122|NCT03753087|DRUG|Empagliflozin|10 mg tablet
223843123|NCT03753087|OTHER|Standard care|Standard care with no SGLT-2 inhibitors
223843124|NCT03697226|DRUG|Topical ABI-1968|Multiple Doses of Topical ABI-1968 Cream with 4 once weekly doses administered in up to 5 Cohorts
223843125|NCT00220103|DRUG|epirubicin, capecitabine, cisplatin|
223843126|NCT00220103|PROCEDURE|Surgical resection|
223843127|NCT00889564|DEVICE|HeRO Vascular Access Device|Long-term subcutaneous vascular access device for hemodialysis
223843128|NCT01055782|DEVICE|Endoguide|Use of endoguide to facilitate completion of endoscopy
223843129|NCT04135924|OTHER|Rehabilitation|physical exercise and respiratory muscle training
223843130|NCT00626600|DRUG|Oxycodone Hydrochloride|
223843131|NCT04541225|DRUG|NUV-422|NUV-422 is an investigational drug for oral dosing.
223843132|NCT05630339|DIETARY_SUPPLEMENT|Magnesium chloride|Each 650 mg capsule contains 340 mg of magnesium chloride, which must be ingested twice a day with aliments.
224264839|NCT02088931|BIOLOGICAL|Treg infusion|At the time of Treg infusion (day 0), maintenance immunosuppression will remain unchanged which consists of TAC, MPA and steroids. On follow-up biopsy 2 weeks after Treg infusion, the inflammatory load will be assessed by computer assisted image analysis looking at the number of infiltrating cells per square mm as well as the percentage of renal cortex infiltrated with lymphocytes. If the inflammatory load has decreased by ≥50% and infused Tregs are observed in the allograft, everolimus will be started at 1.5 mg bid and the dose of tacrolimus will be decreased by 50%. After 2 weeks, tacrolimus will be discontinued. These patients will remain on everolimus, mycophenolic acid and prednisone through the end of the study and the follow-up period. If on the 2-week follow-up biopsy, there is no decrease in the inflammatory load or there is a decrease \<50%, no change will be made to the maintenance immunosuppressive regimen consisting of TAC, MPA and prednisone.
224264840|NCT06618339|BEHAVIORAL|Mindfulness-based intervention|8 Session Mindfulness-based intervention
224264841|NCT05098223|BEHAVIORAL|Intervention to remove price promotions on unhealthy foods when online shopping|Removal of price promotions on unhealthy foods
223843133|NCT05630339|DIETARY_SUPPLEMENT|Vitamin D|Each tablet contains 4000 IU of vitamin D, and must be ingested a pill per night.
223843134|NCT05630339|DIETARY_SUPPLEMENT|Inert placebo|Instead of dietary supplements, sodium bicarbonate as inert placebo will be administered twice a day in 650 mg capsules.
223843135|NCT06102785|DRUG|Fruquintinib, TAS102|Fruquintinib combined with TAS102
223843136|NCT02953548|DRUG|GWP42003-P|Clear, colorless to yellow solution containing cannabidiol dissolved in the excipients sesame oil and anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring.
223843137|NCT00578227|BIOLOGICAL|Cervarix™|Three doses of vaccine administered intramuscularly with the second and third dose given one month and six months after the first dose
223843138|NCT00578227|BIOLOGICAL|Twinrix ™ Paediatric|Three doses of vaccine administered intramuscularly with the second and third dose given one month and six months after the first dose
223843139|NCT00696904|DRUG|ABT-333|Capsule, see arms for intervention description
223843140|NCT00696904|DRUG|Placebo|Capsule, see arms for intervention description
223843141|NCT01899209|PROCEDURE|STARR|
223843142|NCT01899209|PROCEDURE|Laparoscopic Ventral Rectopexy|
223843143|NCT00430378|PROCEDURE|Acupuncture|Acupuncture for 20 minutes before the radiation therapy session, 3 days a week for 7 weeks.
223843144|NCT00430378|OTHER|Standard Care|No Acupuncture.
223843145|NCT00555347|DRUG|Armodafinil|Dosage 150-250 mg
223843146|NCT00555347|DRUG|Placebo|Placebo
223843147|NCT00565318|DRUG|Benfotiamine|3x 300 mg film coated tablet daily (900 mg per day). Duration: 12 weeks.
223843148|NCT00565318|DRUG|Placebo|3x 1 film coated tablet daily. Duration: 12 weeks.
223843149|NCT06193330|PROCEDURE|antibiotic-coated plate|A plate for fixing long bone fractures is coated with antibiotics cement prepared in theatre
223843150|NCT06193330|PROCEDURE|external fixator|external fixators are applied to participants with severe long bone fractures
223843151|NCT00318513|DRUG|Bevacizumab|
223843152|NCT00577629|DRUG|cyclophosphamide|1.5g/m2 IV over 1 hour on days 1-4 of induction for a total dose of 6.0g/m2
223843153|NCT00577629|DRUG|etoposide|300mg/m2 IV over 1 hour every 12 on days 1-3 of induction for a total dose of 1.8 g/m2.
223843154|NCT00577629|DRUG|rituximab|375mg/m2 each week x 4 weeks of induction, beginning on day 1
223843155|NCT00577629|DRUG|cytarabine|3g/m2 IV over 1 hour every 12 during consolidation for a total of 8 doses
223843156|NCT00577629|DRUG|doxorubicin|45mg/m2/day IV over 30 minutes on days 1, 2, 3 during consolidation
223843157|NCT00577629|DRUG|tositumomab|450mg unlabeled tositumomab over 1 hour, followed by 5 millicurie (mCi) Iodine I-131 labeled tositumomab over 20 minutes on day 0. Therapeutic dose of labeled tositumomab will be administered on day 15.
223843158|NCT04878380|DEVICE|Fitbit|A consumer sleep tracker will be used to monitor sleep patterns throughout the study
223843159|NCT04878380|BEHAVIORAL|Sleep education tips|Sleep tips will be provided before the intervention phase
223843160|NCT04878380|BEHAVIORAL|Goal-setting|During the intervention phase, the Goal-Setting group will be additionally rewarded for achieving sleep goals, i.e. 30 mins longer than their habitual sleep duration and sleeping before midnight.
223843161|NCT00364598|DRUG|Anginera, a human tissue replacement therapy|
223843162|NCT01664234|OTHER|laryngoscopy with oxygen|Patients will be randomly assigned to laryngoscopy with or without simultaneous insufflation of oxygen at 4 L/minute. Oxygen will be provided by a flowmeter connected via rigid tubing to the track-mounted endotracheal tube on the AirTraq.
223843163|NCT01664234|OTHER|laryngoscopy without oxygen|Patients will be randomly assigned to laryngoscopy without simultaneous insufflation of oxygen at 4 L/minute.
223843164|NCT00244257|BIOLOGICAL|GMA161|0.1 mg/kg, IV infusion on Day 0 and monitored for 7 days with collection of blood samples
223843165|NCT00244257|BIOLOGICAL|GMA161|0.3 mg/kg, IV infusion on Day 0 and monitored for 7 days with collection of blood samples
223843166|NCT00244257|BIOLOGICAL|GMA161|0.6 mg/kg, IV infusion on Day 0 and monitored for 7 days with collection of blood samples
223843167|NCT00244257|BIOLOGICAL|GMA161|1.0 mg/kg, IV infusion on Day 0 and monitored for 7 days with collection of blood samples
223843168|NCT00244257|BIOLOGICAL|GMA161|3.0 mg/kg, IV infusion on Day 0 and monitored for 7 days with collection of blood samples
223843169|NCT00116740|DRUG|APD356|
223843170|NCT06466668|DIAGNOSTIC_TEST|Sleep study|All subjects will undergo a polysomnography at home
223843171|NCT06466668|DIAGNOSTIC_TEST|stress-related biomarkers and microbiome composition will be assessed using saliva samples|stress and stress-related inflammatory biomarkers will be tested using saliva sample
223843172|NCT06466668|DIAGNOSTIC_TEST|Audiological tests|Pure tone audiometry, Uncomfortable Loudness Levels, Distortion-Product Otoacoustic Emissions, tablet test for hyperacusis, tablet test for hearing screening
223843173|NCT01414166|DRUG|ERN/LRPT|ERN/LRPT combination tablets (each containing 1 g of extended release niacin and 20 mg of laropiprant), orally, one tablet once per day for 4 weeks, then 2 tablets once per day for 12 weeks
223843174|NCT01414166|DRUG|placebo|ERN/LRPT-matched placebo, orally, one tablet once per day for 4 weeks, then 2 tablets once per day for 12 weeks
223843175|NCT04096313|DIAGNOSTIC_TEST|HbA1c, Lipids, UACR|compare diagnostic tests to reference methods
223843176|NCT06356207|DIAGNOSTIC_TEST|Tilt Table Test|The main goal of the study is to evaluate the time elapsed between the T-LOC during Video Tilt Table Testing and the asystole at the ECG using a national registry and to assess its predictive value in patients undergoing invasive treatment. The hypothesis is that a vasodepressive component could lessen the effect of pacing in a patient, leading to cerebral hypoperfusion and syncope despite maintaining a stable rhythm.
223843177|NCT03033914|DRUG|doxorubicin|Doxorubicin: 25 mg/m\^2 will be administered by IV infusion on Days 1 and 15 of each 28-day cycle
223843178|NCT03033914|DRUG|Bleomycin|Bleomycin: 10 units/m\^2 will be administered by IV infusion on Days 1 and 15 of each 28-day cycle
223843179|NCT03033914|DRUG|vinblastine|Vinblastine: 6 mg/m\^2 will be administered by IV infusion on Days 1 and 15 of each 28-day cycle
223843180|NCT03033914|DRUG|dacarbazine|Dacarbazine (DTIC): 375 mg/m\^2 will be administered by IV infusion on Days 1 and 15 of each 28-day cycle.
223843181|NCT03033914|DRUG|Nivolumab|nivolumab 240mg q14 days
223843182|NCT03213470|OTHER|magnetic resonance imaging|
223843183|NCT02374333|BIOLOGICAL|huCART19|
223843184|NCT03177187|DRUG|AZD5069|10mg and 40mg plain, beige, film-coated tablets packaged in bottles
223843185|NCT03177187|DRUG|Enzalutamide 40 MG|Enzalutamide is presented in 40mg white to off white capsules or tablets. The capsules/tablets are provided in a cardboard wallet incorporating a PVC/PCTFE/aluminium blister which holds 28 soft capsules/tablets. Each carton contains 4 wallets (112 soft capsules/tablets). Or tablets in bottles (120 per bottle).
223843186|NCT05429021|DRUG|IMM-BCP-01|Single dose of IMM-BCP-01
223843187|NCT05429021|DRUG|Placebo|Placebo matching single dose of IMM-BCP-01
223843188|NCT05489224|BIOLOGICAL|CT-P47|CT-P47, 8 mg/kg (not exceeding 800 mg/dose) by intravenous (IV) infusion every 4 weeks (Q4W)
223843189|NCT05489224|BIOLOGICAL|EU-approved RoActemra|EU-approved RoActemra, 8 mg/kg (not exceeding 800 mg/dose) by IV infusion Q4W
223843190|NCT02130492|RADIATION|FDG|The intervention arm consists of treatment with increasing doses of \[18F\]-Fluorodeoxyglucose.
223843191|NCT04651348|DRUG|Recombinant Humanized Monoclonal Antibody MIL95|"PART A :The patients confirming to the eligibility criteria will be assigned to the 4 dose groups (0.1mg/kg, 0.3mg/kg, 0.8mg/kg, 1.0mg/kg, respectively) based on the sequence of inclusion. Each patient will receive an intravenous infusion of MIL95 every week on Day 1 for a maximum of Twelve weeks.~PART B:One recommended dose as a priming dose will be selected from 4 dose groups(0.1mg/kg、0.3mg/kg、0.8mg/kg、1.0mg/kg) based on results of PART A. Each patient will receive a priming dose of MIL95 on Day 1 Cycle 1.The patients will be assigned to the 5 maintenance dose groups (3mg/kg, 10mg/kg, 20mg/kg, 30mg/kg, 45mg/kg, respectively) based on the sequence of inclusion. The maintenance dose was given on Day 8,15,22 Cycle 1 and on Day 1,8,15,22 Cycle 2+. Each cycle was 28 days."
223843192|NCT06148753|OTHER|Manuka Health Eternal Renewal Regenerating Face Serum with Royal Jelly and Bee Venom|Face serum containing manuka honey, royal bee jelly, and bee venom.
223843193|NCT06511934|DEVICE|BrainGate Neural Interface System|Placement of the BrainGate2 sensor(s) into arm-hand motor-related cortex.
223843194|NCT02977156|BIOLOGICAL|Pexa-Vec|IT Injections will be performed by a radiologist using imaging-guidance, ultrasound or computed tomography (CT). The dose to be injected could be divided between 1 to 5 tumor lesions.
223843195|NCT02977156|DRUG|Ipilimumab|IT Injections will be performed by a radiologist using imaging-guidance, ultrasound or computed tomography (CT). The dose to be injected could be divided between 1 to 5 tumor lesions.
223843196|NCT00522184|PROCEDURE|intra-articular injection of etanercept|
223843197|NCT00522184|PROCEDURE|intra-articular injection of steroid|
223843198|NCT01799954|BIOLOGICAL|DNA-HIV-PT123|4 mg of DNA encoding clade C ZM96 Gag and gp140, CN54 Pol-Nef, administered intramuscularly (IM)
223843199|NCT01799954|BIOLOGICAL|NYVAC-HIV-PT1|(along with NYVAC-HIV-PT4); ≥ 5x106 PFU encoding clade C ZM96 gp140 and ZM96 Gag and CN54 Pol-Nef, administered IM
223843200|NCT01799954|BIOLOGICAL|NYVAC-HIV-PT4|(along with NYVAC-HIV-PT1); ≥ 5x106 PFU encoding clade C ZM96 gp140 and ZM96 Gag and CN54 Pol-Nef, administered IM
223843201|NCT01799954|BIOLOGICAL|AIDSVAX® B/E|300mcg of subtype B (MN) HIV gp120 glycoprotein and 300mcg of subtype E (A244) HIV gp120 glycoprotein absorbed onto 600mcg of aluminum hydroxide gel adjuvant, administered IM.
223843202|NCT01799954|BIOLOGICAL|Placebo for DNA/NYVAC|Sodium Chloride for injection, 0.9% administered IM
223843203|NCT01799954|BIOLOGICAL|Placebo for AIDSVAX(R) B/E|600 mcg of aluminum hydroxide adjuvant, administered IM
223843204|NCT04842968|OTHER|Methylene blue injection|Methylene blue solution is injected ex vivo in the main supplying artery trunk of the freshly removed colorectal specimen. (50 mg in 30 ml saline)
223843205|NCT03168880|DRUG|Paclitaxel + Carboplatin|Platinum based chemotherapy against the standard taxane based chemotherapy in the neo- adjuvant setting
223843206|NCT03168880|DRUG|Paclitaxel only|
223843207|NCT04348370|BIOLOGICAL|BCG Vaccine|BCG vaccine will be administered by research nurses. Participants and investigators will be blinded.
223843208|NCT04348370|BIOLOGICAL|Placebo Vaccine|Placebo vaccine will be administered by research nurses. Participants and investigators will be blinded.
223843209|NCT04231110|BIOLOGICAL|Fecal microbiota transplantation|Use of fecal microbiota transplantation enemas once weekly in patients who are initiating vedolizumab treatment
223843210|NCT03921905|DIAGNOSTIC_TEST|ABI measurement|ABI measurement wil be done with an automatic device to diagnose PAD in patients with CAD
223843211|NCT05002478|OTHER|Prone positioning|Turn patient in prone position after surfactant administration.
223843212|NCT06099015|DEVICE|Cera™ Vascular Plug System|The Cera™ Vascular Plug System is composed of Cera™ Vascular Plug and its accessory Introducer Kit. The Cera™ Vascular Plug is a self-expandable, cylindrical Ni-Ti wire mesh device.
223843213|NCT03886181|DEVICE|Device: Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)|An intratumoral insertion of a seed(s), loaded with Radium-224, securely fixed in the seeds. The seeds release by recoil into the tumor short-lived alpha-emitting atoms.
223843214|NCT05221398|DRUG|Immune Checkpoint Inhibitors Based Adjuvant therapy|Patients in this group will recieve immune checkpoint inhibitors based adjuvant therapy
223843215|NCT05221398|OTHER|Active surveillance|Patients in this group only receive active surveillance
223843216|NCT00203775|DRUG|risperidone|
223843217|NCT03194776|DRUG|LLG783|LLG783 concentrate solution for infusion/injection suitable for i.v. administration as well as s.c. administration.
223843218|NCT03194776|DRUG|Placebo|Placebo to LLG783 concentrate solution for infusion/injection suitable for i.v. administration as well as s.c. administration.
223843219|NCT04473859|DRUG|FSR Peptide 20μM|Administered immediately after punch-biopsy and 24 hours after punch biopsy.
223843220|NCT04473859|DRUG|FSR Peptide 50μM|Administered immediately after punch-biopsy and 24 hours after punch biopsy.
223843221|NCT04473859|DRUG|FSR Peptide 100μM|Administered immediately after punch-biopsy and 24 hours after punch biopsy.
223843222|NCT04473859|DRUG|FSR Peptide 200μM|Administered immediately after punch-biopsy and 24 hours after punch biopsy.
223843223|NCT04473859|DRUG|Placebo|Administered immediately after punch-biopsy and 24 hours after punch biopsy.
223843224|NCT06214806|BEHAVIORAL|Grocery Vouchers|Participants will be given vouchers to buy groceries each month for five months.
223843225|NCT00958529|DIETARY_SUPPLEMENT|Inulin Fiber Supplement|Orange juice fortified with 0, 5g, and 10g of 2 inulin products
223843226|NCT01984125|OTHER|Point-of-Care Prompt|
223843227|NCT04838093|DIAGNOSTIC_TEST|PCR|"Nasal or pharyngeal respiratory swabs were routinely taken of each patient admitted at our departments and repeated regularly at 48 h intervals during the inpatient stay.~In the HCP cohort testing for SARS-CoV-2 RNA was performed, on a weekly basis, at the Department of Laboratory Medicine, Medical University of Vienna, Austria, using real-time polymerase chain reaction (RT-PCR). Comparability of the results of all test methods used was confirmed by participation in international quality control ring trials."
223843228|NCT01659138|DRUG|SAR339658|"Pharmaceutical form:solution for infusion~Route of administration: intravenous"
223843229|NCT01659138|OTHER|Placebo|"Pharmaceutical form: solution for infusion~Route of administration: intravenous"
223843230|NCT05617235|DEVICE|Kinesiology taping|"On the postoperative 0th day, kinesiology taping was applied to the patients in the study group whose hemodynamic status was stable after extubation by an expert physiotherapist. Investigators applied kinesiology taping as described below:~1. In order to stimulate the facilitation of the diaphragmatic function~2. Taping was applied to the latissimus dorsi and serratus anterior muscles, which were cut during the thoracotomy.~3. In addition, kinesiology taping can be performed on the trigger pain point of the patient .~After 3-4 days, the tape was renewed. Thus, taping was done twice for each patient. The bands were removed at 1 week postoperatively."
223843231|NCT00764868|DRUG|Lisdexamfetamine Dimesylate (LDX)|optimal dose of 30, 50 or 70 mg once daily
223843232|NCT05571930|PROCEDURE|Secondary TEVAR after initial FET procedure|Under general anesthesia, via percutaneous femoral access, the investigators implant a TEVAR in the endovascular part of a FET. This secondary connexion is indicated in case distal thoracic aortic involvement such as aneurysm or dissection.
223843233|NCT05716633|DIAGNOSTIC_TEST|MRI|Serial MRI scans will be performed starting at day 15 from date of pain. Subsequent scans will be performed at 5 days interval till the clinically significant encapsulation (for all the collections in an individual patient) is seen.
223843234|NCT03557255|DRUG|Levosimendan|Preoperative 24 hours infusion of levosimendan for chronic heart failure patients prior to major abdominal cancer surgeries.
223843235|NCT03557255|DRUG|Saline|Preoperative 24 hours infusion of normal saline for chronic heart failure patients prior to major abdominal cancer surgeries.
223843236|NCT02963597|DEVICE|AirSense™ 10 AutoSet|The AirSense 10 AutoSet is a device that provide non-invasive ventilatory support to treat patients with sleep disordered breathing. The device is intended for home and hospital use. The treatment pressure required by the patient may vary due to changes in sleep state, body position and airway resistance. In AutoSet mode, the device provides only that amount of pressure required to maintain upper airway patency. The AirSense 10 AutoSet provides a minimum and maximum pressure within the range of 4-20 cm of water.
223843237|NCT02963597|OTHER|Standard Medical Therapy|Standard medical therapy according to current guidelines.
223843238|NCT00308061|BIOLOGICAL|FMP1/AS02A|FMP1 antigen contained 62.5 ug of lyophilized protein with 3.1 percent lactose as cryoprotectant. It's reconstituted in approx. 600 uL AS02A adjuvant manufactured by GSK. AS02A contains 50 ug MPL and 50ug QS21, 250uL of SB62 (oil/water emulsion) in phosphate buffered saline (PBS) per volume of 0.5 mL. All AS02A vials contained 0.65 to 0.75 mL of liquid.
223843239|NCT00308061|BIOLOGICAL|Imovax Rabies Vaccine|Sterile, stable, freeze-dried suspension of rabies virus prepared from the strain PM-1503-3M, obtained from the Wistar Inst. in Philadelphia. Each 1 mL dose of vaccine contained 100 mg of human albumin, \<150g of neomycin sulfate, and \>2.5 IU of rabies antigen.
223843240|NCT06148714|DIETARY_SUPPLEMENT|Provitalize Natural Menopause Probiotic|Supplement containing a Probiotic blend of Bifidobacterium breve, Lactobacillus Gasseri, and Bifidobacterium animalis subsp. Lactis.
223843241|NCT06148714|OTHER|Placebo|Placebo comparator containing Pure hydroxypropyl methylcellulose (HPmC) with food dye.
223843242|NCT06038071|OTHER|nutrition, IYCF, WASH education|nutrition, IYCF, WASH education
223843243|NCT06038071|OTHER|scheduled anthropometric screening|anthropometric screening by health care workers at 1, 3, and 6 months
223843244|NCT06038071|OTHER|family MUAC|family MUAC training for the primary caregiver present at the time of recovery
223843245|NCT05040243|OTHER|Yanqing Zhitong Ointment Acupoint application|Yanqing Zhitong Ointment is a traditional external preparation of experiential prescription, which is an extract made by water extraction and concentration of Qingfengteng, Corydalis yanhusuo, Interleukin, Kansui, Asarum, etc. Clinical studies in the past ten years have preliminarily shown that it has the effects of warming meridians, promoting blood circulation, dredging collaterals and relieving pain, and has a definite effect.
223843246|NCT05040243|OTHER|placebo acupoint application|"The control group was combined with placebo acupoint application on the basis of conventional acupuncture treatment.~Placebo patch: colored and drug-free patch (composition: petrolatum, food coloring) Acupuncture, application of acupuncture points and treatment course were the same as those in the treatment group."
223843247|NCT05736770|OTHER|Respiratory rehabilitation and out of bed mobilization|The Respiratory rehabilitation and out of bed mobilization group will perform following exercises: pre operative out of bed mobilization, active cycle breathing techniques, forced expiratory technique and volume based incentive spirometery
223843248|NCT05736770|OTHER|conventional treatment|The conventional exercise program group will perform :Flow based Incentive spirometery, Chest percussion if needed
223843249|NCT00595283|BEHAVIORAL|Parent Child Interaction Therapy-Emotion Development (PCIT-ED)|PCIT-ED includes fourteen 1-hour therapy sessions over 14 weeks. Sessions will focus on positive parent-child interactions skills, ways to manage emotions, and relaxation techniques.
223843250|NCT00595283|BEHAVIORAL|Developmental Education Parenting Intervention (DEPI)|DEPI includes 14 weekly, 1-hour education sessions covering a range of child development and parenting topics. Classes are in a small group format and will emphasize emotional and social development.
223843251|NCT05470660|PROCEDURE|Root coverage using coronally advanced flap combined with micro-needling|modified coronally advanced flap will be performed in sites of recession defects, then micro-needling will be performed after 1 month from the coronally advanced flap procedure to ensure the initial flap healing.
223843252|NCT05470660|PROCEDURE|coronally advanced flap combined with Alloderm|modified coronally advanced flap will be performed in sites of recession defects in Association with alloderm to cover the exposed root and 3 mm of connective tissue mesial and distal to it.
223843253|NCT03810885|OTHER|Bread with reduced salt content|Bread with gradually lowered salt content
223843254|NCT03810885|BEHAVIORAL|Dietary advice|Participants will receive information on how to lower salt and increase potassium intake
223843255|NCT03810885|OTHER|Bread with standard salt content|Bread with normal salt content
223843256|NCT05612529|DEVICE|US , Echocardiography|"* Carotid ultrasonography: Parameters will be measured by single blinded independent examiner using an ultrasound device. Baseline carotid FTc, ΔVpeak, will be measured.~* Echocardiography: Stroke Volume will be measured by transthoracic echocardiography.~* Renal and splenic Doppler resistivity index.~* Inferior vena cava collapsibility and distensibility indices.~* Central venous pressure estimation by central venous catheter, and central - Lung ultrasound for detection of lung congestion~* Lung ultrasound for detection of lung congestion."
223843257|NCT06089187|PROCEDURE|Endotracheal intubation using an endotracheal tube with cuff inflated with air|After endotracheal intubation, the endotracheal tube cuff is inflated with air
223843258|NCT06089187|PROCEDURE|Endotracheal intubation using an endotracheal tube with cuff inflated with saline|After endotracheal intubation, the endotracheal tube cuff is inflated with saline
224264842|NCT06507176|PROCEDURE|flexible ureteroscopic lithotripsy|This group of patients underwent flexible ureteroscopic lithotripsy.
224264843|NCT06507176|PROCEDURE|percutaneous nephrolithotomy|This group of patients underwent percutaneous nephrolithotomy.
224264844|NCT05293106|BIOLOGICAL|Platelet Transfusion|All platelet transfusions will be given as 10mL/kg as is considered standard of care.
224264845|NCT03991273|OTHER|Y-M2M©|The Y-M2M© group will receive classes that will be delivered onsite at a YMCA facility. Movement-to-Music (M2M©) is an instructor-guided exercise program that is coupled with music to enhance strength, cardiorespiratory capacity, range of motion, and balance.
224264846|NCT03991273|OTHER|B-M2M©|The B-M2M© group will receive the same onsite M2M© classes as the Y-M2M© group, but they will also be provided with the option of performing home-based M2M© that will be delivered via videoconferencing.
224264847|NCT02891863|DEVICE|LEVER Acute Study System|The LEVER Acute Study System is an acute pacing and shock delivery system intended for investigational use only. The LEVER Acute Study System is intended for acute conversion testing of monomorphic ventricular tachycardia by one of three different VT conversion methods.
224264848|NCT01771263|DEVICE|iControl-RP|
224264849|NCT00599079|DRUG|Azithromycin|Azithromycin Daily Dosage dependent on clinical factos such as age, weight and patient specific health descriptors
224264850|NCT01307124|DRUG|kaletra|"The study participants will receive Lopinavir/ritonavir heat-stable tablet (100/25 mg or 200/50 mg) q 12 hour plus NRTIs. The other NRTIs is depend on physician discretion.~Arm 1:LPV/r Standard dose Arm 2:Low dose BW 25-35 kg 300/75 mg 200/50 mg BW \>35-50 kg 400/100 mg 300/75 mg"
224264851|NCT03253510|OTHER|Poly-amide|New denture base material that exhibit high flexibility, physical strength, heat and chemical resistance and the exceedingly rare allergy response
224264852|NCT03253510|OTHER|Poly-methyl methacrylate|Gold standard denture base material
224264853|NCT00445796|DRUG|Artesunate|
224264854|NCT00445796|DRUG|Amodiaquine|
223843259|NCT05136742|OTHER|aerobic exercise and diet program|It is an interventional study in which 60 women estimated to enrol according to random allocation and assigned into two groups equal. The study group will receive aerobic exercises in addition to diet recommendations while the control group will receive diet recommendations. the aerobic exercises in form of treadmill training intensity of exercises high intensity, target heart rate (THR) will be60-70% of heart maximum (HR MAX)time of session 40 min initial 10 min warm up exercise on treadmill in low intensity and active phase20- 30 min intensity will increase until patient reach to THR then intensity decrease until session will be ended by cooling down phase for 10 min . The volunteers will perform exercises 3 times per week for 12 weeks .insulin resistance will be measured by HOMA -IR index and sex hormones (estridol ,testosterone. sex hormone binding globin ) pre and post intervention and use zung self-rating depression scale to assess depression
223843260|NCT05136742|OTHER|diet program|balanced restricted diet
223843261|NCT05981456|OTHER|patient safety competency|Investigation of the effect of patient safety education given with the flipped education model and traditional education model on the competence levels of the students.
223843262|NCT05981456|OTHER|satisfaction with the training method|Investigation of the effect of patient safety education given with the flipped education model and traditional education model on the satisfaction levels of the students from the education methods.
223843263|NCT01077661|DRUG|Nebivolol|patients administrated Nebivolol according to the prescribing information
223843264|NCT00771628|DEVICE|Flex-It Stylet|Patients will be intubated using the GlideScope with an ETT fitted with a Flex-It stylet.
223843265|NCT00771628|DEVICE|Standard malleable stylet|Patients will be intubated using the GlideScope with an ETT fitted with a standard malleable stylet.
223843266|NCT04438785|DEVICE|The intervention consists of myofunctional therapy (MT) using the AirwayGym app.|Intervention. Patient newly diagnosed with severe OSAHS should perform muscle upper airway exercises using the App AirwayGym 20 minutes a day during 90 days.
223843267|NCT05564988|OTHER|Preconditionning|"Remote ischemic conditioning will be induced using a Tourniquet cuff applied to the patient's non-dominant arm. The device used will be an Ulrich Kariba machine. A strip of absorbent cotton will be applied to the arm and the tension cuff will be placed over it in a standard way. The systolic pressure and the application time will be set manually.~Ischemia will be obtained after inflating the cuff to a pressure of 200 mmHg (or a pressure at least 50 mmHg above the patient's systolic pressure). After a five-minute period, the cuff will be deflated and the arm allowed to reperfuse for five minutes. These maneuvers will be repeated until 3 cycles of ischemia- reperfusion have been completed once a day. Patients will experiment with this procedure for at least 5 days."
223843268|NCT03701464|PROCEDURE|Endoscopic naso-gallbladder drainage|Using ERCP technique insert a naso-gallbladder drainage tube through common bile duct and cystic duct.
223843269|NCT03701464|PROCEDURE|Percutaneous gallbladder drainage|Percutaneous transhepatic technique insert drainage tube into gallbladder
223843270|NCT00765089|PROCEDURE|Isolation of pulmonary veins with Bipolar radiofrequency ablation|
223843271|NCT01498874|DRUG|Placebo|Sterile solution administered subcutaneously on Day 0, Day 28, and Day 56
223843272|NCT01498874|DRUG|gevokizumab|Sterile solution administered subcutaneously on Day 0, Day 28, and Day 56
223843273|NCT01498874|DRUG|gevokizumab|Sterile solution administered subcutaneously on Day 0, Day 28, and Day 56
223843274|NCT04011033|BIOLOGICAL|iNKT cells|5×10\^8-10\^9/m2 iNKT cells will be infused to patients at 1st, 3rd, 5th, 7th, 9th, 11th week after first TAE/TACE therapy.
223843275|NCT04011033|DRUG|Human recombinated Interleukin-2|IL-2 will be given at a dose of 25,000 IU/kg/day for 5-14 days after iNKT cells infusion.
223843276|NCT04011033|PROCEDURE|TAE/TACE|TAE/TACE will be conducted to all patients at 0th week and 4th week.
223843277|NCT01823341|DEVICE|Pump suspension algorithm|The study laptop will communicate to the pump causing a suspension based on output from the algorithm which predicts hypoglycemia.
224264855|NCT05126485|DEVICE|Haptic Biofeedback from SageMotion Biofeedback System|"Haptic biofeedback units (vibrating motors) will be placed on individual body segments. The haptic biofeedback system will be configured to provide vibratory stimuli when a target minimum hip extension angle is reached during the loading response. The minimum threshold will be determined by the therapist based on the patient's current ability. Specifically, the system will target a 10-20% increase in extension angle from their current level, as identified by the therapist. A vibration stimulus will be first applied each time this minimum angle is achieved, and will continually increase in intensity in proportion to the degree with which the patient exceeds this minimum value. The stimuli will stop being applied when the extension angle drops back below the threshold. These intensity-modulated stimuli have been selected to encourage the patient to exceed the minimum threshold rather than stop extending when the stimulus is first applied"
223843278|NCT01230034|DRUG|Ramipril|pill, 5 and 10 mg/day, od, 24 weeks
223843279|NCT01230034|DRUG|Imidapril|pill, 10 and 20 mg/day, od, 24 weeks
223843280|NCT00217711|DRUG|Capecitabine|capecitabine
223843281|NCT00217711|DRUG|irinotecan hydrochloride|irinotecan hydrochloride
223843282|NCT00217711|DRUG|oxaliplatin|oxaliplatin
223843283|NCT04327596|PROCEDURE|RF ablation of AF using CARTO 3 and a Thermocool ST SF ablation catheter|Ablation of AF is standard of care in the management of patients with paroxysmal or persistent AF. The most common triggers initiating AF arise from pulmonary veins (PV) and successful electrical isolation of PV's can significantly reduce the burden of AF. Therefore, the main objective in patients undergoing ablation of AF is to achieve PV isolation.
223843284|NCT01548391|DRUG|HX-1171|20mg, 200mg, 500mg
223843285|NCT06251908|OTHER|Rewritalize|"REWR is conceptualised as a hybrid between an art group and a group therapy intervention. It is structured as a progressive participatory art group program led by a conductor-tandem: the primary conductor, a professional writer with extensive teaching experience, is supplemented by a co-conductor with clinical expertise who participates in the group activities together with the other participants. The conductor-tandem secure high artistic standards while also ensuring psychological safety. A close collaboration between the two is necessary and both participate in a 30-hour preparatory course and are supervised during the course of the intervention.~The writing course consists in 15 sessions of 3 hours per session. At each session participants are introduced to literary texts that work as prompts for the writing exercises, which last 5-15 min. After each text is read out loud, the participants engage in a reflective discussion about the text."
223843286|NCT06251908|OTHER|Standard mental health care|"F-ACT is a community-based treatment model that provides multidisciplinary, flexible, and assertive outpatient treatment to patients with severe mental illness. OPUS is a nationally implemented 2-year-long early intervention for people with first-episode psychosis. OPUS is a multidisciplinary assertive community treatment model and offer psychoeducation, social skills training, relapse prevention and family involvement, including possibility for treatment participation in psychoeducational multifamily groups.~In F-ACT and OPUS a primary staff member is in regular contact with the patient and responsible for coordinating the treatment elements. The treatment is individual and contingent upon patients' needs."
223843287|NCT03347838|DRUG|Nivolumab|Nivolumab is a human monoclonal antibody that blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2.
223843288|NCT06576908|DEVICE|HyperSight Imaging|Subjects receive both HyperSight imaging and conventional imaging, on their first day of radiation treatment, on their second day of treatment, and on their last day of treatment.
223843289|NCT06839274|OTHER|transvaginal Ultrasound|The only additional measure will be the measurement of the follicle volumes on the day of trigger and before oocyte pick up procedure. This will be performed at the same time as the pre Oocyte pick up ultrasound prior to the patient admission to the recovery room for preparation. The ultrasound that will be used already has a pre build program that calculates the follicular volume automatically and hence not extending the ultrasound time.
223843290|NCT02027935|BIOLOGICAL|Aldesleukin|Given SC
223843291|NCT02027935|BIOLOGICAL|Autologous CD8+ Melanoma Specific T Cells|Given IV
223843292|NCT02027935|DRUG|Cyclophosphamide|Given IV
223843293|NCT02027935|BIOLOGICAL|Ipilimumab|Given IV
223843294|NCT02027935|OTHER|Laboratory Biomarker Analysis|Correlative studies
223843295|NCT06576193|BEHAVIORAL|Safe Dates for Young Parents (SDYP)|"SDYP is a healthy relationship and intimate partner violence (IPV) prevention program, adapted from Safe Dates (Foshee et al., 1998; Foshee et al., 1996) designed for teens, that focuses on pregnant or parenting females. The program consists of ten group-based sessions (50 minutes each) led by a trained facilitator which include interactive discussions, analysis of scenarios, games, role-plays, brainstorming, and a poster contest and theatrical play."
223843296|NCT05546099|BEHAVIORAL|Self-management of BP medications|Patients will be educated on how to manage their home BP based on a pre-determined protocol. They will then monitor home BP and adjust meds accordingly and under the guidance of the clinical pharmacist.
223843297|NCT05546099|BEHAVIORAL|Self-monitoring of home BP|Patients will be educated on how to monitor home BP and will be educated to contact their primary care provider/CKD provider if the BP is above the goal.
223843298|NCT04057833|DRUG|E-CEL UVEC|Local implantation of E-CEL UVEC cells at the supraspinatus tendon repair site
223843299|NCT00689104|DRUG|Mirabegron|Tablets
223843300|NCT00689104|DRUG|Tolterodine|Capsules
223843301|NCT00689104|DRUG|Placebo to Mirabegron|Matching mirabegron placebo tablets.
223843302|NCT00689104|DRUG|Placebo to Tolterodine|Matching tolterodine placebo capsules.
223843303|NCT05620472|DRUG|Diagnostic Test: whole body study and SPECT with [99mTc]Tc(CO)3-(HE)3-Ec1|One single intravenous injection of \[99mTc\]Tc(CO)3-(HE)3-Ec1, followed by gamma camera imaging after 2, 4, 6 and 24 hours.
223843304|NCT05130138|OTHER|Pharmaceutical intervention|Patients with pharmacokinetic and/or pharmacodynamics interactions will be proposed to participate to educational sessions to discuss about treatments taken and modifications possibilities.
223843305|NCT06226870|PROCEDURE|root canal tretment|traditional therapy
223843306|NCT06226870|PROCEDURE|biodentin VPT|Alternative therapy
223843307|NCT06226870|PROCEDURE|PRF|Alternative therapy
223843308|NCT04474600|DRUG|Propofol|The induction and maintenance of anesthesia was performed by total intravenous anesthesia using propofol. In both groups, remifentanil is continuously infused throughout the surgery.
223843309|NCT04474600|DRUG|Desflurane|The induction and maintenance of anesthesia was performed by inhalation anesthesia using desflurane. In both groups, remifentanil is continuously infused throughout the surgery.
223843310|NCT00184119|PROCEDURE|Psychiatric Intensive Care Unit|
223843311|NCT00184119|PROCEDURE|Care in whole acute unit|psychiatric acute care as usual
223843312|NCT04873817|DEVICE|IonicRF Generator and compatible accessories|Participants will receive IonicRF lesion generator, along with any country-specific market-released accessory (i.e. electrode, cannula, grounding pad, and adaptor cable) compatible with the IonicRF Generator
223843313|NCT00924560|DRUG|91-day Levonorgestrel Oral Contraceptive|"Levonorgestrel/ethinyl estradiol 0.15/0.03 mg and ethinyl estradiol 0.01 mg tablet.~Take 1 tablet daily"
223843314|NCT00924560|DRUG|28-day Levonorgestrel Oral Contraceptive|Levonorgestrel/ethinyl estradiol 0.10/0.02 mg tablet and placebo. Take 1 tablet daily
223843315|NCT01925781|DRUG|Nicotine polacrilex|2 mg and 4 mg gum will be used according to the FDA approved product labelling
223843316|NCT01925781|OTHER|STAM 1100mAh CE4 eGo Clearomizer|
223843317|NCT01307280|BEHAVIORAL|RCT1|the bookHEALTH manual and eHEALTH tools, the basic Internet component of the intervention
223843318|NCT01307280|BEHAVIORAL|RCT2|bookHEALTH and an interactive version of eHEALTH that provided tailored computerized feedback whenever participants submitted weekly assessments
223843319|NCT01307280|BEHAVIORAL|RCT3|bookHEALTH, the interactive version of eHEALTH, and telephonic coaching support provided by trained health lifestyle coaches every 2 weeks alternating between a telephone call (typically 15 to 20 minutes) and a personalized e-mail. The coaches used motivational interviewing, helped participants solve problems, and reinforced their successes.
223843320|NCT01579019|DRUG|RO5024048|1500 mg po bid, 24 or 26 weeks
223843321|NCT01579019|DRUG|RO5024048|1000 mg po bid, 24 or 26 weeks
223843322|NCT01579019|DRUG|danoprevir|100 mg po bid, Weeks 1 to 24 or Weeks 3 to 26
223843323|NCT01579019|DRUG|peginterferon alfa-2a [Pegasys]|180 mcg sc qw, 24 or 26 weeks
223843324|NCT01579019|DRUG|ribavirin [Copegus]|1000 mg or 1200 mg po daily, 24 or 26 weeks
223843325|NCT01579019|DRUG|ritonavir|100 mg po bid, Weeks 1 to 24 or Weeks 3 to 26
223843326|NCT03606096|BIOLOGICAL|Boostrix IPV infant acellular Pertussis|mother is randomized to receive Boostrix ® Polio (GSK) and infant acellular pertussis
223843327|NCT03606096|BIOLOGICAL|Boostrix IPV infant whole Pertussis|mother is randomized to receive Boostrix ® Polio (GSK) and infant whole Pertussis
223843328|NCT03606096|BIOLOGICAL|TT infant acellular Pertussis|mother is randomised to receive Tetanus Toxoid and infant acellular Pertussis
223843329|NCT03606096|BIOLOGICAL|TT infant whole Pertussis|mother is randomised to receive Tetanus Toxoid and infant whole Pertussis
223843330|NCT01114620|BIOLOGICAL|Arepanrix™|Intramuscular administration, one dose
223843331|NCT04635501|DEVICE|ABS 5.6.7|Patients whose access site will be closed with the ABS 5.6.7
223843332|NCT00734513|BEHAVIORAL|Partner-assisted emotional disclosure|Patients and partners in the partner-assisted emotional disclosure condition will attend four weekly face-to-face sessions with a therapist. The first session will last 75 minutes and will focus on training in skills to facilitate the patient's disclosure. The subsequent 3 sessions will last 45 minutes each. In these sessions, the therapist will briefly review the strategies and provide feedback from the previous session and the patient will spend 30 minutes talking about their cancer-related concerns to the partner.
223843333|NCT00734513|BEHAVIORAL|Cancer Education|The cancer education protocol consists of four weekly face-to-face sessions for education about living with GI cancer. The cancer education sessions will be delivered to patients and their partners and use a presentation and discussion format. Handouts and discussion sessions will center on the following topics: Orientation to Duke Cancer Care and the treatment team; suggestions for communicating with health care providers; resources for health information, psychosocial support, and financial concerns; evaluating health information on the internet; the impact of cancer on different domains of quality of life; and suggestions for maintaining quality of life.
223843334|NCT00000316|DRUG|Cocaine|
224264856|NCT01711632|DRUG|Vemurafenib|Patients will receive vemurafenib at a dose of 960mg orally b.i.d. continuously in cycles of 4 weeks (28 days) as outpatient. A bone marrow aspirate and/or biopsy will be performed after the first cycle for research purposes only. After the completion of the third cycle, a repeat bone marrow aspirate and/or biopsy will be performed for assessment of response and evaluation of MRD. Following the third cycle assessments, patients who achieve complete response (CR) with detectable MRD or partial response (PR) may continue with vemurafenib for up to 3 additional cycles at the treating physician's discretion (Cycles 4-6). Patients who achieve CR without MRD will be observed as part of post-treatment followup, and may be re-treated with vemurafenib after relapse (as per below). Patients who achieve no response (NR) after the initial 3 cycles of vemurafenib will be removed from the study. They will be followed every 3 months as part of posttreatment followup for a total of 12 months.
224264857|NCT03325387|DRUG|LY3305677|Administered SC
224264858|NCT03325387|DRUG|Placebo|Administered SC
224264859|NCT05163847|BIOLOGICAL|Cam2020 M2SR H3N2 influenza vaccine|Administered intranasally on Day 1
224264860|NCT05163847|BIOLOGICAL|Fluzone HD IIV|Administered intramuscularly on Day 1
224264861|NCT05163847|OTHER|IN Placebo|Administered intranasally on Day 1
224264862|NCT05163847|OTHER|IM Placebo|Administered intramuscularly on Day 1
224264863|NCT03679598|DRUG|Alvelestat (MPH966)|Alvelestat was developed as treatment for lung diseases like Chronic Obstructive Pulmonary Disease. Alevelestat works by blocking certain proteins in the body that are responsible for inflammation and damage to the lungs that can lead to COPD symptoms.
224264864|NCT03679598|OTHER|Placebo|Placebo is a pill or tablet that does not contain any study drug.
224264865|NCT03877939|DIAGNOSTIC_TEST|Blood samples collection for analysis|"Blood samples:~Blood samples will be collected for the determination of the levels of various biomarkers (Kisspeptins and miRNAs), which are molecules that regulate the expression of proteins and can serve as markers for predicting pregnancy viability. Additionally, after biochemical or week 10 of clinical pregnancy confirmation, blood samples will be collected for KIR and HLA-C typing, Oral glucose tolerance test (OGTT) and analysis of the levels of miRNAs related with insulin resistance, miR-424-5p and miR-15b.~Uterine biopsy (only in patients with BP):~Uterine biopsy samples will be collected also after biochemical pregnancy confirmation for the determination of the levels of miRNAs related with insulin resistance, miR-424-5p and miR-15b."
224264866|NCT00881634|DRUG|Cetirizine HCl/Pseudoephedrine HCl 5 mg/120 mg Tablets (Sandoz, USA)|
224264867|NCT00881634|DRUG|Zyrtec-D 12 Hour 5 mg/120 mg Extended Release Tablets (Pfizer, USA)|
224264868|NCT02365363|OTHER|Control|Non pulse ingredient bagel
224264869|NCT02365363|OTHER|Pea flour|Pulse ingredient bagel
224264870|NCT02365363|OTHER|Pea fibre|Pulse ingredient bagel
223843335|NCT06397287|OTHER|Observation of patients undergoing sugery|All patients undergoing urological surgery or treatment receive standardized questionnaires on quality of life, satisfaction, pain and physical recovery. Indication-specific, individual pathways are set up,
223843336|NCT02696226|DRUG|SAVR Warfarin|Warfarin treatment for 12 weeks with a target INR of 2-3 Warfarin treatment to begin on postoperative day 1-3 according to the patient's clinical status When warfarin treatment is discontinued, patients will be treated according to standard of care (aspirin 81 mg/day) indefinitely
223843337|NCT02696226|DRUG|SAVR Aspirin|Aspirin (81 mg/day) to begin within 1-3 postoperative days according to the patient's clinical status and continue indefinitely per standard of care.
223843338|NCT02696226|DRUG|TAVR Warfarin and clopidogrel|Begin Warfarin and clopidogrel (75 mg/day) treatment within 1-3 days postop for 12 weeks with a target INR of 2-3 When warfarin is discontinued, begin aspirin (81 mg/day) and continue aspirin/clopidogrel for 12 weeks At 24 weeks, study treatment will end and patients will be treated according to standard of care (aspirin 81 mg/day) indefinitely
223843339|NCT02696226|DRUG|TAVR Aspirin and clopidogrel|Aspirin (81 mg/day) and clopidogrel (75 mg/day) in periprocedural period and continue for 24 weeks At 24 weeks, study treatment will end and patients will be treated according to standard of care (aspirin 81 mg/day) indefinitely
223843340|NCT03564054|PROCEDURE|Photodynamic Therapy|Participants on this arm will be treated with photodynamic therapy. PDT is a two-stage process. The first stage of PDT is the intravenous injection of porfimer sodium (Photofrin) administered as a single slow intravenous injection over 3 to 5 minutes. The second stage involves the application of laser light to the tumor by bronchoscopy.
223843341|NCT03564054|PROCEDURE|Argon Plasma Coagulation|"Participants on this arm will be treated with argon plasma coagulation. A flexible probe housing a wire delivers high-frequency, high-voltage electric current to a monopolar tungsten electrode present at the tip of the probe. Argon gas flows through the probe, and is charged or ionized to produce plasma as it flows around the tungsten electrode. Electric current flows through the plasma to the nearest tissue, and heat is produced as it passes through the tissue. Increased resistance created by coagulated tissue impairs the flow of electric current, and keeps the ablation depth to 1 to 2 mm."
223843342|NCT04477850|DRUG|Luspatercept|Specified dose on specified days
223843343|NCT00415740|DRUG|ELC200 (carbidopa+levodopa+entacapone)|
223843344|NCT03658629|BIOLOGICAL|NanoFlu (Quad-NIV)|2018-2019 Investigational Quadrivalent Seasonal Influenza Vaccine
223843345|NCT03658629|OTHER|Matrix-M Adjuvant|Adjuvant
223843346|NCT03658629|OTHER|Placebo|Placebo
223843347|NCT03658629|BIOLOGICAL|Fluzone HD|2018-2019 Licensed Trivalent Seasonal Influenza Vaccine
223843348|NCT03658629|BIOLOGICAL|Flublok Quadrivalent|2018-2019 Licensed Quadrivalent Seasonal Influenza Vaccine
223843349|NCT03658629|BIOLOGICAL|Influenza Vaccine|2018-19 Licensed Seasonal Influenza Vaccine
223843350|NCT02909101|DEVICE|Active Cognitive Training (ACT)|Cognitive training games
223843351|NCT02909101|DEVICE|Control Training (CON)|Cognitive training games
223843352|NCT02005614|PROCEDURE|Gamma Knife Radiosurgery|"Treatment will be administered on an outpatient basis. No other treatment, investigational or commercial agents or therapies other than those described below may be administered with the intent to treat the patient's brain metastases.~Gamma knife radiosurgery is a one day out-patient procedure. Time from initiation of treatment (premedication and placement of a stereotactic frame) until end of treatment (completion of radiation delivery and removal of stereotactic frame) ranges from 3 to 16 hours."
223843353|NCT06270420|DEVICE|Technological Motor Rehabilitation|Patients will undergo to motor treatment in the HoSmartAI room using one of the technological devices (i.e. OAK, VRRS Evo by Khymeia Group, Padova, Italy; AMADEO, PABLO by Tyromotion GmbH, Gratz, Austria), for the upper limb and lower limb motor recovery, balance and manual dexterity recovery. The duration of the treatment will be 15 sessions, 1 hour each, with daily frequency, 5 days a week, for a total of 3 weeks.
223843354|NCT06827912|PROCEDURE|Interscalene Nerve Block|After sterile conditions are provided with the patient in the supine position, the brachial plexus will be identified in the supraclavicular fossa above the clavicle with ultrasonography. The transducer will be directed cephalad and 20 cc 0.5% bupivacaine will be applied to the interscalene space with a 50 mm block needle from the point where the C 5-6-7 nerve roots give the impression of a rosary bead between the anterior and medial scalene muscles.
223843355|NCT06827912|PROCEDURE|Shoulder Anterior Capsule Block|In pericapsular nerve block application, the patient will be placed in a supine position and the arm will be externally rotated and abducted to 45 degrees. After sterile conditions are provided, the humerus head, the tendon of the subscapularis muscle and the deltoid muscle above it will be identified with ultrasonography. 15 cc of 0.5% bupivacaine will be injected into the interfascial space between the deltoid muscle and the subscapularis muscle with a 22gauge 50 mm block needle. Then, the block needle will be directed deep into the subscapularis muscle and another 5 cc of 0.5% bupivacaine will be injected under the subscapularis muscle.
223843356|NCT04245046|DRUG|Candesartan, Amlodipine, Atorvastatin|compare the pharmacokinetic of candesartan cilexetil, atorvastatin as atorvastatin calcium trihydrate, amlodipine as amlodipine besilate from reference products given as a multiple dose
224264871|NCT02365363|OTHER|Pea flour and pea fibre|Pulse ingredient bagel
224264872|NCT02365363|OTHER|Pea flour and pea protein|Pulse ingredient bagel
224264873|NCT02365363|OTHER|Pea flour + pea fibre + pea protein|Pulse ingredient bagel
224264874|NCT01701063|DRUG|Telaprevir|100- and 250-mg chewable tablets or 375-mg film-coated tablets for oral administration
224264875|NCT01701063|DRUG|Peginterferon alfa-2b|50 μg/0.5 mL, 80 μg/0.5 mL, 120 μg/0.5 mL, or 150 μg/0.5 mL for subcutaneous (SC) injection
224264876|NCT01701063|DRUG|Ribavirin|200-mg capsules or 40-mg/mL solution for oral administration
224264877|NCT05387408|BEHAVIORAL|Best Practice Health and Employment Opioid-related Policies|The intervention will include information to promote policies and programs to prevent opioid abuse and aid recovery such as drug testing for opioids, health and employee assistance programs, job accommodations, and education to deliver training to prevent opioid use, and prevent stigma.
224264878|NCT01773408|DRUG|RO5503781 MBP|Participants will receive RO5503781 tablets daily (current formulation) containing microprecipitated bulk powder (MBP) at a starting dose of 400 milligrams (mg).
223843357|NCT03242044|PROCEDURE|Congenital diaphragmatic hernia resuscitation with an intact umbilical cord|10 infants with left or right sided congenital diaphragmatic hernia will be intubated and ventilation initiated while still attached to the placental circulation through the umbilical cord. In addition, at the same time, a nasogastric tube will be placed in the stomach to drain entrained air and secretions. After 5 minutes of resuscitation with the umbilical cord intact, the umbilical cord will be cut, infants separated from the placenta and resuscitation performed per routine neonatal resuscitation protocols. Feasibility, the optimal approach and maternal and infant tolerance to the procedure will be assessed as part of the study.
223843358|NCT03439696|PROCEDURE|Thoracoscopic surgery|Video-assisted thoracoscopic surgery for pulmonary or mediastinal lesions.
223843359|NCT01095718|BEHAVIORAL|Errorless Learning|"Errorless learning refers to the use of feedforward instruction before actions to prevent learners from making mistakes. The therapist presents steps with the following instruction and the visual cues e.g., Here are steps that you need to do to make some coffee, please repeat them.~The therapist gives cues before the completion of each step. At each step the patient receives verbal and visual cues. Then cue cards are hidden, and the therapist asks immediately to give the answer about the step involved.~The therapist allows the participant to try finding the solution, if the answer or action is not immediately given, the participant receives a cue, and moves to the next step.~During cueing the patient will mostly receive verbal and visual cues and if necessary physical help."
223843360|NCT01095718|BEHAVIORAL|Modeling|"The therapist gives the same tailored baseline information for each task. The therapist issue specific information for each step. Using tailored mastery modeling, the therapist shows the steps in front of the patient. There is a special emphasis on adjusting the modeling just above the patient's abilities.~The therapist does the steps, at the same time he/she uses verbal cues during the performance.~Then the therapist asks immediately to the patient to do the steps."
223843361|NCT01095718|BEHAVIORAL|Trial and Error|"The therapist gives the same tailored baseline information for each task. The therapist issue specific information for each step. Using tailored mastery modeling, the therapist shows the steps in front of the patient. There is a special emphasis on adjusting the modeling just above the patient's abilities.~The therapist does the steps, at the same time he/she uses verbal cues during the performance.~Then the therapist asks immediately to the patient to do the steps."
223843362|NCT05886075|DRUG|Recombinant oncolytic herpes simplex virus type 1 (R130)|R130, a modified herpes simplex virus-Ⅰ (HSV-1) containing the gene coding for anti-CD3 scFv/CD86/PD1/HSV2-US11
223843363|NCT03073005|OTHER|Simulation-based Mastery Learning (SBML)|The SBML training group will first 1) watch the VAD video, then 2) participate in a SBML intervention using the simulator for a) driveline exit site sterile dressing changes; b) performing controller self-tests; c) changing power sources; d) troubleshooting emergent VAD-related malfunction; and e) recognizing specific signs and symptoms requiring immediate contact with the VAD team.
223843364|NCT03024242|DEVICE|Tight vaginoscope|
223843365|NCT01992198|DRUG|cefoperazone + metronidazole|"1.Clinical parameters (2 of 3):~1)temperature\<37.8℃ or 2)HR \<100bpm or 3)SpO2 \>95% 2.Laboratory parameters (3 of 3):~1)CRP or 2)PCT reduction 70% compared to zenith for 2 consecutive samples 3)WBC \<12×10E9/L for 2 consecutive samples 3.Image parameter (1 of 1): liquid collection developed \<30% compared to that of 72h"
223843366|NCT01992198|PROCEDURE|oral care by chlorhexidine gluconate|oral care by 0.2% chlorhexidine gluconate twice daily
223843367|NCT01992198|PROCEDURE|enteral nutrition|
223843368|NCT01992198|DRUG|Somatostatin|
223843369|NCT01992198|DRUG|Meropenem|"All patients in cefo-group do not meet 1 of 3 laboratory parameter or image parameter or 2 of 3 clinical parameters.~1.Clinical parameters (2 of 3):~1)temperature\<37.8℃ or 2)HR \<100bpm or 3)SpO2 \>95% 2.Laboratory parameters (3 of 3):~1)CRP or 2)PCT reduction 70% compared to zenith for 2 consecutive samples 3)WBC \<12×10E9/L for 2 consecutive samples 3.Image parameter (1 of 1): liquid collection developed \<30% compared to that of 72h"
223843370|NCT04374617|DIAGNOSTIC_TEST|Duplex ultrasound and Computed Tomography Angiography|All venous thromboembolisms suspected will diagnosed with ultrasound and CT-angiography
223843371|NCT02380521|DRUG|Exenatide once weekly (BYDUREON™)|"Exenatide is considered investigational medicinal product (IMP) and will be prescribed to enrolled patients in accordance with local requirements.~Exenatide will be available at a fixed dose of 2 mg and supplied as a kit. Exenatide should be injected subcutaneously (SC) in the thigh, upper arm (deltoid region) or abdomen. The injection site does not have to be consistent throughout the study. Injection can be done at any time of the day irrespective of meals. It is recommended that the time of injection is consistent throughout the study. Subjects will be instructed to perform an air shot before the first injection.~Subjects will follow a fixed dose of 2 mg"
223843372|NCT04757558|DEVICE|C-MAC video-stylet|Patients will be randomly assigned two group 40 patients each, C-MAC-VS group (VS group) (Karl Storz GmbHand Co.KG, Germany), and control group (C group). This will be done using a closed envelope technique using a computer-generated block randomization method.
223843373|NCT04757558|DEVICE|Macintosh laryngoscope|Patients will be randomly assigned two group 40 patients each, C-MAC-VS group (VS group) (Karl Storz GmbHand Co.KG, Germany), and control group (C group). This will be done using a closed envelope technique using a computer-generated block randomization method.
223843374|NCT05104411|OTHER|Rehabilitative intervention|Active rehabilitation programs were done for all patients. Participants were asked to attend exercise program at PT room or bedside. Exercise program was offered once or twice daily on weekdays, by trained kinesiologists. In PT programs, most patients performed strengthening exercise of lower extremities, balance training, sit-up training, sit-to-stand training and gait training for about 30 minutes. Each program was individualized to participants' current physical function. In bedside programs, patients also underwent strengthening exercise and balance training without gait training for about 10 minutes. The duration of exercise program at PT room depends on the patient's condition(upto 1 month).
223843375|NCT05104931|DRUG|Nanoformed Piroxicam IR Tablet|Orally delivered Nanoformed Piroxicam
223843376|NCT05104931|DRUG|Felden (piroxicam) Tablets|orally delivered Felden (reference) tablets
223843377|NCT05104931|DRUG|Brexidol (piroxicam) Tablets|orally delivered Brexidol (reference) tablets
223843378|NCT01290094|DRUG|ibandronate [Bonviva/Boniva]|3 mg intravenously every 3 months
223843379|NCT04563052|BEHAVIORAL|Educational Program on Air Pollution as a Health Risk Reduction Strategy|A power point presentation about the health impact of exposure to fine particulate matter (PM2.5) on health. Pm2.5 is found outdoors and indoors. Information will be reviewed about steps to take for the participants to locate the information using a smart phone and steps to take to decrease exposure to prevent illness such as heart disease or strokes.
223843380|NCT00219401|BIOLOGICAL|Pneumococcal 7 valent conjugate vaccine (Prevenar®)|Accelerated PCV vaccinaton.
223843381|NCT03766594|DRUG|Sildenafil Citrate|Respatio(R) 25mg tablets four times daily for 24 days preconceptionally starting first day of previous period
223843382|NCT03766594|DRUG|Folic Acid|Folic acid(R) 0.5mg tablets once daily for 3 months preconceptionally
223843383|NCT03766594|DRUG|Placebo Oral Tablet|Placebo tablet apparently identical to Respatio(R) 25mg tablets, taken four times daily for 24 days preconceptionally starting first day of previous period
223843384|NCT05781529|PROCEDURE|Alveolar ridge augmentation with injectable platelets rich fibrin|Injectable platelets rich fibrin is added to xenograft for alveolar ridge augmentation in order to preserve bone and decrease bone resorption
223843385|NCT05781529|PROCEDURE|Alveolar ridge augmentation with hyaluronic acid|Hyaluronic is added to xenograft for alveolar ridge augmentation in order to preserve bone and decrease bone resorption
223843386|NCT05781529|PROCEDURE|Alveolar ridge augmentation with xenograft|Xenograft is added alone as a active compatator
223843387|NCT01630499|BEHAVIORAL|Tailored Lifestyle Intervention (TLI)|The intervention is a nutrition, physical activity, and behavioral weight management program that is tailored to the specific needs of breast cancer survivors.
223843388|NCT01630499|BEHAVIORAL|Commercial Weight Loss Program (CWLP)|This intervention is a generic, widely-available weight management program.
223843389|NCT02729792|DEVICE|rTMS|intermittent theta burst stimulation (iTBS)
223843390|NCT03186807|DIAGNOSTIC_TEST|ultrasonographic scan of fetal brain|"1. Routine measurement of BPD, HC, OFD, cisterna magna, cerebellum, lateral ventricle(1).~   specific measurements as follow:~2. Parietoccipital fissures will be measured from the most external border of cortex to the luminar line.~3. Lateral fissure depths will be measured from the most external border of the insular cortex to the interface confirmed between the subarachnoid space and the skull.~4. Cingulate fissures will be measured in the mid-coronal plane tracing a perpendicular line from the median longitudinal fissure to the apex of the cingulate fissures.~6\. Calcarine fissures will be measured in the coronal transcerebellar plane as tracing a perpendicular line from the median longitudinal fissure to the apex of the calcarine fissures."
224264879|NCT01773408|DRUG|RO5503781 SDP|Participants will receive RO5503781 tablets daily (new optimized formulation) containing spray-dried powder (SDP) at recommended dose(s) for development from Phase 1b to Phase 3.
224264880|NCT01773408|DRUG|Idarubicin|Idarubicin will be administered as per standard clinical practice.
224264881|NCT01773408|DRUG|Daunorubicin|Daunorubicin will be administered as per standard clinical practice.
224264882|NCT01773408|DRUG|Cytarabine|Parts 2 and 4: Participants will receive cytarabine 1000 milligrams per meter squared (mg/m\^2) intravenous (IV) infusion daily. Part 3: Participants will receive cytarabine 100-200 mg/m\^2 IV infusion daily.
224264883|NCT01154712|DEVICE|Real Deep TMS|Stimulation parameters : Dorso lateral prefrontal cortex,1HZ,600 pulses per session,15 sessions
224264884|NCT01154712|DEVICE|Sham Deep TMS|Stimulation parameters : Dorso lateral prefrontal cortex,1HZ,600 pulses per session,15 sessions
224264885|NCT06559917|OTHER|life review|"After consenting, they will complete the first questionnaire before receiving the Happiness Ledger intervention via social media. Family members will have one week to organize photos, after which patients will share the meaning of the photos. This process will be recorded by the researcher and will last approximately 40 to 60 minutes. The researcher will then create a three-minute video using the photos, and the participating family members will assist in uploading the photos to the family LINE group as feedback to the subjects. The second questionnaire will then be completed."
223843391|NCT06231082|PROCEDURE|Group one - percutaneous (P)|Percutaneous procedure will be performed under standard conditions, under transabdominal ultrasound guidance. After choosing the optimum needle trajectory, the skin site will be marked, standard skin sterilization with iodine and surgical draping of the site will be performed. Local anesthesia of the site with gradual lidocaine solution infiltration of the skin and underlying planes will be performed. Under ultrasound guidance, with collaboration of the patient for the respiratory movements, one or two passages with a 16G needle will be performed (BARD Max Core 16G, Becton Dickinson, USA). Specimens will be collected in formalin and send to pathology for processing.
223843392|NCT06231082|PROCEDURE|Group two - EUS FNB (E)|"EUS guided liver FNB will be performed under deep sedation with propofol under anesthesiology monitoring. A 19G gauge Franseen needle (Acquire 19G, Boston Scientific, USA) will be used with the wet suction technique. Before inserting into the operating channel, the stylet will be removed, and the needle will be primed with heparin (500UI/5ml). After liver puncture, the 20ml aspiration syringe will be attached. Three needle actuations will be performed, one or two passes in the left liver lobe. At the end of the 3rd actuation, the syringe aspiration will be stopped, the needle will be left in place in the liver parenchyma for 2 to 3 minutes. The liver needle path will be examined with Doppler ultrasound to look for possible bleeding. If present, about 25% of the needle content will be pushed in the liver path, as previously described - the blood patch technique."
223843393|NCT05661760|BEHAVIORAL|interdisciplinary multimodal pain treatment|A combination of physical and psychosocial treatment methods is employed, including Emotional Awareness and Expression Therapy (EAET), Pain Neuroscience Education (PNE), Acceptance and Commitment Therapy (ACT), graded activity, exposure in vivo, and experiential learning through physical training.
223843394|NCT01484106|OTHER|Fluid Resuscitation|"In the Treatment group, this information will be used in a specific 4-hour treatment algorithm to guide fluid administration that is summarized in Figure 1. The information provided by the NICOM in response to the fluid bolus will be used to assess whether the subject is fluid responsive (FR)."
223843395|NCT01484106|OTHER|Standard of Care|Standard of Care
223843396|NCT06033131|DRUG|Metformin ER|Metformin ER, one gram three times daily taken orally. Once the participants have been recruited, they will start by taking one 500 mg tablet three times a day. If well tolerated it will be increased day two to a maximum of two tablets three times a day. Treatment will continue until delivery. If there are side effects that are not tolerable, the dose will be decreased and the participant will remain blinded. Each participant will keep a treatment diary and number of tablets taken will be documented by the participant or hospital staff. The study will not alter or interfere with treatment or care routinely given for preterm preeclampsia.
223843397|NCT06033131|DRUG|Placebo|Placebo, two tablets three times daily taken orally. Once the participants have been recruited, they will start by taking one tablet three times a day. If well tolerated it will be increased day two to a maximum of two tablets three times a day. Treatment will continue until delivery. If there are side effects that are not tolerable, the dose will be decreased and the participant will remain blinded. Each participant will keep a treatment diary and number of tablets taken will be documented by the participant or hospital staff. The study will not alter or interfere with treatment or care routinely given for preterm preeclampsia.
223843398|NCT04601376|BEHAVIORAL|Mobile Monitoring Tool|a text-messaged based outcomes collection system
223843399|NCT05791877|DEVICE|pneuRIP|Respiratory sensor to measure pulmonary function
223843400|NCT04890145|DEVICE|RW-Precision-Coupler|Implantation of the RW-Precision-Coupler together with FMT-VORP 503
223843401|NCT03230006|BEHAVIORAL|Unified Protocol for Transdiagnostic Treatment of Emotional Disorders|The UP will be conducted in a standardized fashion over 16 sessions, in a minimum of 16- and a maximum of 21-weeks, following the published therapist guide with minor refinements for application in the proposed comorbid population.
223843402|NCT03230006|BEHAVIORAL|Take Control|TC will be conducted over 12 sessions, in a minimum of 12- and a maximum of 16-weeks. Therapists will review material from TC and offer general advice on implementation of the alcohol reduction skills in daily life.
223843403|NCT05203731|BEHAVIORAL|Exercise|Moderate intensity exercise (typically a brisk walk or light run) will occur for 20 minutes after the emotional learning procedures on Day 1.
223843404|NCT05203731|BEHAVIORAL|Sitting|Sitting will occur for 20 minutes after the emotional learning procedures on Day 1.
223843405|NCT04949399|DRUG|OnabotulinumtoxinA|Injection
223843406|NCT04949399|DRUG|Placebo|Saline Injection
223843407|NCT04778488|DEVICE|Near-Infrared-Spectroscopy (NIRS)|Placement of 2 NIRS optodes on the patients' forehead, measurement of NIRS during cardiac arrest and up to 72h post return of spontaneous circulation
223843408|NCT00271414|DRUG|Duragesic® (fentanyl) Transdermal Therapeutic System (TTS)|
223843409|NCT04210193|DRUG|ALK Alutard 5-grasses|0.1 mL of 10 000 SQ-U/mL (1000 SQ-U) as an intralymphatic injection
223843410|NCT04210193|DRUG|ALK Diluent|0.1 mL of ALK Diluent as an intralymphatic injection
223843411|NCT00814489|BIOLOGICAL|GSK2231395A|Two doses will be administered intramuscularly; one dose at Month 0 and the second dose a Month 2. Two different formulations of this vaccine will be tested.
223843412|NCT00814489|BIOLOGICAL|Engerix-B|Two doses will be administered intramuscularly; one dose at Month 0 and the second dose a Month 2.
223843413|NCT03773055|DRUG|NPC-06|Patients will receive once a day for 7 days.
223843414|NCT06920095|OTHER|Progressive muscle relaxation exercises|A total of 18 sessions of progressive relaxation were performed, 3 days a week for 6 weeks.
223843415|NCT06508723|PROCEDURE|Dental implant placement|The same routine implant placement protocol will be applied to both study groups with different surfaces and will be placed in the bone. After local anesthesia, a full-thickness flap will be raised. The implant socket will be created according to the protocol recommended by the company and all implants will be placed in the socket with a torque force of 35 N and the implants will be placed. Once bleeding control is achieved, the flap will be closed primarily. Healing caps will be installed after 3 months. After waiting for wound healing, prosthetic restoration will be performed.
223843416|NCT04827017|OTHER|follow up|follow up population
223843417|NCT02182882|DRUG|GINSANA|
223843418|NCT02182882|DRUG|Placebo|
223843419|NCT02077738|DEVICE|HFCWO (Hill-Rom Vest™ Airway Clearance System)|study subjects in the HFCWO group received HFCWO for 15 min twice a day for 5 days after extubation
223843420|NCT05404113|OTHER|sustained natural apophyseal glide|Mulligan's C1-C2 self-SNAG+ strengthening exercises for anterior and posterior neck muscles (extension, flexion, rotation, lateral flexion) Frequency: 2-3 times/week for 3 weeks Intensity: moderate intensity (pain free) Time: 20 minutes/session Type: Mobilization with movement SNAG Conventional PT including strengthening exercises neck muscles 10 repetitions, 1 set Resisted neck flexion, extension, lateral flexion, rotation Frequency: 2-3 times/week for 3 weeks Intensity: moderate-high intensity (depending on pain tolerance) Time: 10 minutes/session Type: Strengthening Exercise
223843421|NCT05404113|OTHER|deep friction massage|Cyriax deep friction massage+ strengthening exercises for anterior and posterior neck muscles (extension, flexion, rotation, lateral flexion) Frequency: 2-3 times/week for 3 weeks Intensity: moderate-high intensity (depending on pain tolerance) Time: 20 minutes/session Type: Deep soft tissue massage Conventional PT including strengthening exercises neck muscles 10 repetitions, 1 set Resisted neck flexion, extension, lateral flexion, rotation Frequency: 2-3 times/week for 3 weeks Intensity: moderate-high intensity (depending on pain tolerance) Time: 10 minutes/session Type: Strengthening Exercise
223843422|NCT05626283|DRUG|transforaminal epidural injection.|transforaminal epidural steroid injection.
223843423|NCT05626283|OTHER|micro RNA-155 serum level|Estimation of miR-155 expression level:
223843424|NCT02401399|DIETARY_SUPPLEMENT|Regular diet|The patients receive regular diet 900 Kcal/day during 15 days before surgery
223843425|NCT02401399|DIETARY_SUPPLEMENT|High protein formula|The patients receive high protein formula during 15 days before surgery
223843426|NCT02401399|DIETARY_SUPPLEMENT|Immunonutrition|The patients receive Immunonutrition formula during 15 days before surgery
223843427|NCT02395185|OTHER|Milk bottle administration|Patients are given a bottle of milk during the casting process.
223843428|NCT02395185|OTHER|Water bottle administration|Patients are given a bottle of water during the casting process.
223843429|NCT02395185|OTHER|Sucrose bottle administration|Patients are given a bottle of sucrose during the casting process.
223843430|NCT05213403|DIAGNOSTIC_TEST|Evaluation with new scoring system|"Evaluate whether patients who have received surgery in line with the developed scoring system have a better aesthetic and oncological outcomes"
223843431|NCT01095224|BIOLOGICAL|rAd35 Env A|1 x 10\^10 particle units (PU) administered as 1 mL intramuscularly (IM) in deltoid
223843432|NCT01095224|BIOLOGICAL|rAd5 Env A|1 x 10\^10 PU administered as 1 mL IM in deltoid
223843433|NCT01095224|BIOLOGICAL|rAd5 Env B|1 x 10\^10 PU administered as 1 mL IM in deltoid
223843434|NCT03446508|DEVICE|Active frontal|1\) active HD-tDCS will be administered
223843435|NCT03446508|DEVICE|Active parietal|2\) active HD-tDCS will be administered
223843436|NCT03446508|DEVICE|Sham|3\) sham HD-tDCS - no current
223843437|NCT05491161|OTHER|Longitudinal study|Longitudinal study following infant development from birth to 1 year of age
223843438|NCT06500949|PROCEDURE|Vagus Nerve Pulmonary Branch Block|Following thoracotomy, the thoracic surgeon, under direct thoracoscopic guidance, used forceps to elevate the apex of the lung, thus exposing the main trunk of the pulmonary branches of the vagus nerve. The injection needle was then advanced from a lateral-to-medial direction, and 2.5 ml of 0.375% ropivacaine was administered in close proximity to the targeted vagal branch.
223843439|NCT06500949|PROCEDURE|Vagus Nerve Pulmonary Branch Injection|Following thoracotomy, the thoracic surgeon, under direct thoracoscopic guidance, used forceps to elevate the apex of the lung, thus exposing the main trunk of the pulmonary branches of the vagus nerve. The injection needle was then advanced from a lateral-to-medial direction, and 2.5 ml of normal saline was administered in close proximity to the targeted vagal branch.
223843440|NCT00563277|PROCEDURE|combined pterygium and cataract operation|
223843441|NCT00563277|PROCEDURE|pterygium excision followed by cataract operation|
223843442|NCT05395208|BEHAVIORAL|Therapeutic touch group accompanied by white noise|During the intravenous catheter intervention, approximately 15-20 minutes of white noise was applied with therapeutic touch.
223843443|NCT04364945|DRUG|dexmedetomidine|administration of dexmedetomidine 1 mcg/kg/hr
223843444|NCT04364945|DRUG|remifentanil|administration of remifentanil 0.1-0.2 mcg/kg/min
223843445|NCT04364945|DRUG|Sevoflurane|Anesthesia is maintained using sevoflurane.
223843446|NCT06713161|DIAGNOSTIC_TEST|NIR-II Probe(i.e ICG-POL6326) incubation solution|After the tissues were incubated with the optimal concentration of the NIR-II probe for the appropriate time, the tissues were washed with the eluate, and then the fluorescence intensity of different tissues was detected to evaluate whether the tissues had cancer tissue invasion.
223843447|NCT02683824|DIAGNOSTIC_TEST|Computed Tomography|Undergo CT scan
223843448|NCT02683824|OTHER|Laboratory Biomarker Analysis|Correlative studies
223843449|NCT02683824|DIAGNOSTIC_TEST|PET/MRI scan|Undergo PET/MRI scan
223843450|NCT02683824|DRUG|[18F]FP-R01-MG-F2|radioactive tracer
223843451|NCT06231628|PROCEDURE|Percutaneous cementoplasty|"Percutaneous image guided cementoplasty will be performed as follows:~Low-viscosity radiopaque bone cement will be quickly mixed and transferred to 1-ml syringes to reduce injection resistance. Injection will be initiated 2-4 min after mixing. When the resistance to cement injection becomes high in the beginning, the cement will be pushed in with a stylet, and it will go well afterward. As much bone cement as possible will be injected while avoiding leakage into the hip joint, sciatic notch, or veins under fluoroscopic monitoring. When significant cement leakage occurred at the initial stage, cement injection will be performed via another route or will be stopped and resumed when the cement viscosity increased. The cement will begin to harden after 8 min, and the operator, therefore, will aim to complete the delivery of the injection within 10 min. The injection needles must be removed before the cement hardens completely"
223843452|NCT03952481|DRUG|Lifitegrast 5% Ophthalmic Solution|Participants will received lifitegrast 5% ophthalmic solution twice a day in each eye for approximately 4 weeks.
223843453|NCT05125861|PROCEDURE|remote ischemic conditioning|Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min re-perfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 200 mmHg. All patients underwent dynamic cerebral autoregulation on days 1-2 and 7-10 after onset, and intravenous blood was collected by a nurse and stored in the laboratory 0-6 hours after thrombolysis and 24 hours after thrombolysis.
223843454|NCT05125861|PROCEDURE|sham remote ischemic conditioning|Sham remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min re-perfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 60 mmHg. All patients underwent dynamic cerebral autoregulation on days 1-2 and 7-10 after onset, and intravenous blood was collected by a nurse and stored in the laboratory 0-6 hours after thrombolysis and 24 hours after thrombolysis.
223843455|NCT03573362|DEVICE|ViziShot FLEX 19G needle|EBUS-TBNA using the ViziShot FLEX 19G needle
223843456|NCT03573362|DEVICE|Vizishot 22G needle (standard)|EBUS-TBNA using the Vizishot 22G needle (standard)
223843457|NCT02813499|OTHER|CARE Rule|Evaluation of the clinical suspicion of myocardial infarction, calculation of CARE rule and troponin assay performed by the practitioner.
223843458|NCT00093795|DRUG|Cyclophosphamide|"Group 1: cyclophosphamide 500 mg/m2 IV every 21 days for 6 cycles~Group 2 and Group 3: cyclophosphamide 600 mg/m2 IV every 14 days for 4 cycles"
223843459|NCT00093795|DRUG|Docetaxel|75 mg/m2 IV every 21 days for 6 cycles
223843460|NCT00093795|DRUG|Gemcitabine|2000 mg/m2 IV every 14 days for 4 cycles
223843461|NCT00093795|DRUG|Paclitaxel|175 mg/m2 IV every 14 days for 4 cycles
223843462|NCT00093795|DRUG|Doxorubicin|"Group 1: 50 mg/m2 IV every 21 days for 6 cycles~Group 2 and Group 3: 60 mg/m2 IV every 14 days for 4 cycles"
223843463|NCT03597308|DRUG|5mg of Oxycodone every 6 hours as needed for pain|5mg of Oxycodone every 6 hours as needed for pain
223843464|NCT03597308|DRUG|600mg of Ibuprofen every 6 hours as needed for pain|600mg of Ibuprofen every 6 hours as needed for pain
223843465|NCT03597308|DRUG|500mg of Acetaminophen every 6 hours as needed for pain|500mg of Acetaminophen every 6 hours as needed for pain
223843466|NCT00031343|DRUG|highly active antiretroviral therapy (HAART)|
223843467|NCT06052982|PROCEDURE|Drainage|At the end of the knee arthroplasty, a drain is placed or not at the surgical site depending on randomization result
223843468|NCT02689375|DEVICE|Senza Spinal Cord Stimulation system|Suitable participants will be booked to have spinal cord stimulator trial leads implanted and an external programmable High Frequency battery trial box as a day case
223843469|NCT01439425|BEHAVIORAL|Weight Loss|The low-calorie diet was designed to achieve a loss of 5-10% of initial body weight. The caloric restriction was 500 kcal below the resting energy expenditure, as evaluated by the Harris-Benedict equation. Intervention group patients received a balanced diet scheme, based on a caloric intake reduction related to BMI and sex (range: 1200-1500 kcal/d for women, 1300-1600 kcal/d for men).
223843470|NCT00031291|DRUG|Anthrax Immune Globulin|
223843471|NCT04940390|DRUG|Dihydroergotamine|Dihydroergotamine is a semi-synthetic derivative of ergotamine tartrate.
223843472|NCT04940390|DRUG|Placebo|Placebo for STS101
223843473|NCT04764019|DIAGNOSTIC_TEST|High resolution intestinal manometry|Evaluation of intestinal manometry by the use a high resolution intestinal manometry catheter with 34 closely spaced sensors.
223843474|NCT00961805|BEHAVIORAL|Dance|Belly dance classes twice a week for 16 weeks. Each class had a maximum of eight students. The classes were administered by a physiotherapist with eight years of experience in belly dance. Classes began with a warm-up exercise, followed by the predetermined movements for the day, choreography and a cool-down exercise. The participants received a compact disc with music and an exercise book with the history and movements proposed for the program. Beginning in the fourth week, a set sequence of movements in the form of choreography was established for memorization and training at home.
223843475|NCT00961805|OTHER|Control Group|The control group did not receive any intervention. They attended all assessments and remained on the waiting lis (after the end of the study was offered to this group the same treatment in the intervention group).
223843476|NCT03089346|DIAGNOSTIC_TEST|Magnetic Resonance Imaging (MRI) with Ultrashort Echo Time (UTE)|Magnetic Resonance Imaging (MRI) with Ultrashort Echo Time (UTE) pulse sequences on a 1.5T magnet (Avanto dot, Siemens) with 3D reconstruction of the bronchial tree using Neko-MR software in asthma in order to assess bronchial thickness.
223843477|NCT03089346|DIAGNOSTIC_TEST|Computed tomography (CT)|Computed tomography (CT) on a Definition 64 (Siemens) with 3D reconstruction of the bronchial tree using Neko-3D software in asthma in order to assess bronchial thickness.
223843478|NCT02949271|OTHER|Programmed Intermittent Epidural Bolus|
223843479|NCT02949271|OTHER|Continuous Epidural Infusion|
223843480|NCT02949271|DRUG|Ropivacaine|
223843481|NCT02949271|DRUG|Fentanyl|
223843482|NCT04094012|DRUG|isoniazid and rifapentine|This prospective multicenter randomized control trial (RCT) will be conducted on LTBI cases (see 2. Study population) to compare the risk of SDRs under conventional 3HP regimen (Arm 1: 3HP) and a new regimen consisting of daily RPT (10 mg/kg) plus INH (5 mg/kg) for 1 month (Arm 2: 1HP)
223843483|NCT02817633|DRUG|TSR-022|TSR-022 will be administered.
223843484|NCT02817633|DRUG|Nivolumab|Nivolumab will be administered.
223843485|NCT02817633|DRUG|TSR-042|TSR-042 will be administered.
223843486|NCT02817633|DRUG|TSR-033|TSR-033 will be administered.
223843487|NCT02817633|DRUG|Docetaxel|Docetaxel will be administered.
223843488|NCT02817633|DRUG|Pemetrexed|Pemetrexed will be administered.
223843489|NCT02817633|DRUG|Cisplatin|Cisplatin will be administered.
223843490|NCT02817633|DRUG|Carboplatin|Carboplatin will be administered.
223843491|NCT00082485|DRUG|Baclofen|Dose escalation 10-60mg (week 1) 60 mg (weeks 2-7) Dose taper (week 8)
223843492|NCT00082485|OTHER|Placebo|Placebo
223843493|NCT05119933|DRUG|YL-15293|After a screening period of approximately 28 days, eligible patients will receive oral YL-15293 once daily until documented disease progression, unacceptable AEs, intercurrent illness prevents further administrations of study treatment, investigator's decision to withdraw the patient, the patient withdraws consent, pregnancy of the patient, or for administrative reasons (see Section 7.1). Following the end of treatment, patients will continue to be followed for safety for 30 days. Patients who permanently discontinue study treatment for reasons other than disease progression will have post-treatment follow-up for disease assessment until start of new anticancer treatment, patient withdraws consent, is lost to follow-up, death, or until the Sponsor stops the study, whichever comes first.
223843494|NCT02161510|DRUG|MK-2248|MK-2248 in once-daily oral doses of 200-≤800 mg for 7 days
223843495|NCT05458102|DRUG|Vesatolimod|Administered orally
223843496|NCT05458102|DRUG|Cobicistat|Administered orally
223843497|NCT05458102|DRUG|Voriconazole|Administered orally
223843498|NCT05458102|DRUG|Rifabutin|Administered orally
223843499|NCT03881254|OTHER|Human Autologous Homologous Skin Construct|Application of a autologous human derived skin polar units
223843500|NCT03881254|OTHER|Additional Outer Dressing Applicaiton|Application of Moisture retentive dressing, and a multi-layer compression dressing
223843501|NCT03881254|OTHER|Offloading|Patient will be offloaded in a diabetic camboot after treatment, or total contact cast if patient cannot be fit with diabetic offloading boot
223843502|NCT03881254|OTHER|Fibracol Wound Dressing|Application of Collagen Alginate Dressing
223843503|NCT03610477|DIETARY_SUPPLEMENT|Medium chain triglycerides|Gel capsules, each containing 1 gram
223843504|NCT03610477|DIETARY_SUPPLEMENT|Long chain triglycerides|Gel capsules, each containing 1 gram
223843505|NCT04616365|PROCEDURE|Semi-Elective Lung Transplantation|When suitable donor lungs become available for a consented recipient, the transplant procedure (anesthesia starting time) will be allowed to begin earliest at 6am with the lungs being preserved at 10°C cold static preservation upon organ arrival to our hospital using a specific incubator, regardless of when donor cross clamp occurs. The maximum time allowed between donor cross clamp and recipient anesthesia initiation will be 12h.
223843506|NCT00515840|OTHER|Physiotherapist|Physiotherapist administered breathing retraining programme
223843507|NCT02562014|OTHER|Glucose|75g glucose
223843508|NCT02562014|OTHER|Inulin|75g glucose plus 24g inulin
223843509|NCT02562014|OTHER|Resistant Starch|75g glucose plus 28.2g resistant starch
223843510|NCT03837925|DRUG|Atorvastatin 40mg Tablet|Patient participation for 6 weeks of treatment
223843511|NCT03837925|DRUG|Placebo comparator|Patient participation for 6 weeks of treatment
223843512|NCT03860246|DIAGNOSTIC_TEST|Portable ECG monitor|Recording of ECG rhythm on a portable monitor (Kardia Mobile)
223843513|NCT06629974|BEHAVIORAL|Parental empowerment program|"The empowerment program consisted of two parts: the empowerment training program for parents and motivational interviews.~The empowerment training program was prepared to enable parents to carry out the care process more effectively in areas where parents have difficulties caring for their children with autism. Within the scope of the empowerment training program, parents were trained on the importance of play and communication, problems and management in the field of nutrition, sleep problems and management, safety and protection from accidents, and problems and management in the field of self-care.~Ten days after the empowerment training program, two face-to-face motivational interviews were conducted with each participant in the intervention group. Each participant had a one-week break between the first and second motivational interviews. Each motivational interview session lasted approximately 25-30 minutes."
223843514|NCT01576510|BEHAVIORAL|Prolonged Exposure (PE)|Prolonged Exposure (PE) therapy consists of ten 90-minute sessions. Elements of PE include imaginal and in vivo exposure to trauma reminders; breathing retraining; cognitive restructuring; and PTSD psychoeducation. The therapist helps the patient cognitively restructure his/her experience of the traumatic event. Each week the narrative is elaborated, becoming more detailed and exhaustive, until the patient habituates to it, extinguishing the anxiety it formerly aroused.
223843515|NCT03434743|OTHER|Rehabilitative|Non-nutritive sucking on emptied breast
223843516|NCT03434743|OTHER|Active Comparator|Non-nutritive sucking on pacifier
223843517|NCT00723294|PROCEDURE|cryosurgery|
223843518|NCT00723294|PROCEDURE|therapeutic conventional surgery|
223843519|NCT02714803|BEHAVIORAL|"Connective tissue massage and Conservative applications"|Connective tissue massage and conservative aplications were applied 5 days per week for a total of 10 sessions for 2 weeks.
223843520|NCT02714803|BEHAVIORAL|"Classic massage group and Conservative applications"|Classic massage and conservative aplications were applied 5 days per week for a total of 10 sessions for 2 weeks.
223843521|NCT02714803|BEHAVIORAL|"Sham massage group and Conservative applications"|Sham massage and conservative aplications were applied 5 days per week for a total of 10 sessions for 2 weeks.
223843522|NCT06281717|DEVICE|Fetal Endotracheal Occlusion (FETO)|The FETO insertion procedure will be performed between gestational age 27 weeks 0 days and 29 weeks and 6 days. The Goldballoon Detachable Balloon (GOLDBAL2) will be inserted in the airway of the fetus using the Delivery Microcatheter (BALTACCI-BDPE100). The fetal tracheal balloon will be removed between 34 weeks 0 days and 34 weeks 6 days gestation or earlier as indicated.
223843523|NCT02877199|OTHER|Triple therapy|Cohort of patients who received triple therapy combining pegylated-interferon/ribavirin + first generation protease inhibitor boceprevir or telaprevir as part of routine clinical practice
223843524|NCT04874610|DRUG|Methylprednisolone|Administration of methylprednisolone Prescribed per Standard of care
223843525|NCT01530009|DRUG|Amoxicillin|A liquid preparation of amoxicillin will be administered via a nasoduodenal catheter as a one time dose of 20 mg/kg.
223843526|NCT01530009|OTHER|Placebo|A liquid placebo will be administered via nasoduodenal catheter to patients based on random assignment.
223843527|NCT00273455|DRUG|bimatoprost 0.03%|
223843528|NCT00273455|DRUG|dorzolamide 2%/timolol maleate 0.5% fixed combination|
223843529|NCT00273455|DRUG|placebo|
223843530|NCT06492577|OTHER|Pulmonary rehabilitation protocol|In the initial phase (days 1-7), aerobic exercise sessions will be 20-30 minutes, strength training will include 1-2 sets at 50% of 1RM, and breathing exercises will last 10 minutes daily. In the progressive phase (days 8-14), aerobic exercise sessions will increase to 30-40 minutes, strength training to 2-3 sets at 60% of 1RM, and breathing exercises to 10-15 minutes daily. In the advanced phase (days 15-21), aerobic exercise sessions will be 40-45 minutes, strength training will be 2-3 sets at 70% of 1RM, and breathing exercises will continue for 10-15 minutes daily.
223843531|NCT06492577|OTHER|Progressive muscle relaxation protocol|Participants in this arm will undergo a 21-day progressive muscle relaxation (PMR) program aimed at reducing anxiety and improving sleep quality in patients with long-term COVID-19 symptoms. Each daily session lasts 20 minutes and involves systematic muscle tensing and relaxation, starting from the feet and progressing to the head, combined with slow, deep breathing. During the initial phase (days 1-7), the focus is on introducing PMR techniques and targeting different muscle groups. In the progressive phase (days 8-14), full-body PMR sessions enhance relaxation and breathing techniques. The advanced phase (days 15-21) maximizes relaxation and incorporates visualization techniques.
223843532|NCT06628505|OTHER|Speech in Noise Training|The active controls will receive frequency discrimination training that uses the same visual landscape and basic task of controlling the wisp based on judgments about acoustic cues. The task requires participants to avoid obstacles by swiping upward or downward on the touchscreen to indicate whether a test frequency associated with the obstacle was higher or lower, respectively, than a target sound presented slightly before the test sound.
223843533|NCT06628505|OTHER|Spatial Hearing Training Group|"Stimulus presentation and response measurement (Aim 2): Acoustic stimuli will be presented with a 360° speaker array that are fixed in place behind an opaque, nearly sound transparent, acoustic fabric curtain to avoid visual influences. Manual responses will be collected using a keyboard. Custom Matlab scripts control all relevant variables with millisecond precision. A webcam monitors the participant (not recorded) for the sole purpose of making sure the participant is always facing straight ahead.~Sound localization task and training: Participants will judge the location of a target white noise sound (1000 ms, 70 dB SLP, 10-10,000 Hz) by moving an auditory pointer that appears 2 seconds after the offset of the target sound.~The training group are given feedback about how their perceived location related to the actual sound location."
223843534|NCT06628505|OTHER|Spatial Hearing Control Group|"Stimulus presentation and response measurement (Aim 2): Acoustic stimuli will be presented with a 360° speaker array that are fixed in place behind an opaque, nearly sound transparent, acoustic fabric curtain to avoid visual influences. Manual responses will be collected using a keyboard. Custom Matlab scripts control all relevant variables with millisecond precision. A webcam monitors the participant (not recorded) for the sole purpose of making sure the participant is always facing straight ahead.~Sound localization task and training: Participants will judge the location of a target white noise sound (1000 ms, 70 dB SLP, 10-10,000 Hz) by moving an auditory pointer that appears 2 seconds after the offset of the target sound.~The training group are NOT given feedback about how their perceived location related to the actual sound location."
223843535|NCT06572462|DRUG|individualized ATG dosing strategy|Investigators quantified active ATG exposure in 106 haploidentical peripheral blood stem cell transplantation (haplo-PBSCT) recipients, who received a conventional fixed dose of 10 mg/kg ATG during conditioning, the optimal concentration range of active ATG-AUC was determined through the application of machine learning methods, was found to be 100-148.5 × 10\^3 UE·d/L. This concentration range was associated with a reduction in CMV/EBV reactivation, without an increase in acute GVHD or malignant disease relapse. Mathematical function was then exploited to determine the total targeted ATG dose on -3days to -2days based on concentrations of active ATG on -5daysto -4days. Based on this function, investigators established a dosing strategy that aimed to maintain the active ATG-AUC within the optimal range.
223843536|NCT04950751|BIOLOGICAL|candidate vaccine, SCB-2020S|a recombinant SARS-Co-2 trimeric S-protein (from B.1.351 variant) subunit vaccine for COVID-19
223843537|NCT02141347|DRUG|Tremelimumab|Tremelimumab administered intravenously
223843538|NCT02141347|DRUG|MEDI4736|MEDI4736 administered intravenously.
223843539|NCT05986487|DEVICE|CPAP or usual practice|CPAP (continuous positive airway pressure) is a machine that uses mild air pressure to keep breathing airways open while you sleep.
223843540|NCT05986487|DEVICE|Monitoring and intervention in follow-up|Each participating center can incorporate monitoring and intervention in the follow-up of patients into their work dynamics. Through the use of mobile applications, you can monitor the variables of: weight, diet, lifestyle, exercise and sleep. This intervention will help the patient to improve in different aspects of their health.
223843541|NCT06508346|BIOLOGICAL|anti-CD19-CAR-T cells|Intravenous injection
223843542|NCT05967442|DRUG|Magnesium Sulfate|Magnesium Sulfate 2gm in 50ml D5W over 20 minutes
223843543|NCT05967442|DRUG|Metoclopramide 10mg|Metoclopramide 10mg in 50ml D5W over 20 minutes
223843544|NCT05967442|DRUG|Prochlorperazine (Compazine) Injection|Prochlorperazine 10mg in 50ml D5W over 20 minutes
223843545|NCT06540287|OTHER|Observational|No intervention
223843546|NCT06313684|OTHER|Comprehensive Initial Assessment|"Initial Assessment includes all those necessary to prescribe exercise training, as well as dietary and adherence promotion interventions.~* Functional capacity with 6MWT~* Assessment of skeletal muscle strength, flexibility, and balance.~* Assessment of function~* Assessment of dietary habits~* Assessment of self-efficacy and barriers to CR adherence.~* Screening for depression."
223843547|NCT06313684|OTHER|Continuous evaluation|Evaluations during the course of the program will be carried out to inform the progression through the CR stages, the intensity of training and education needs.
223843548|NCT06313684|OTHER|Interval Exercise|"High-intensity interval training prescribed by physical therapist:~* According to an adapted Wisloff protocol.~* Borg scale to monitor intensity.~* Training 3 times per week."
223843549|NCT06313684|BEHAVIORAL|Psychosocial support|"Based on social-cognitive theory, with self-efficacy as a focus:~* Face-to-face sessions in the first stage of the program: Education, self-monitoring and motivational interview.~* Face-to-face session in the second stage of the program: promoting behavior changes by self-control and self-monitoring~* Regular communication with patients will be supported by the use of mobile devices during the third and fourth stages of program."
223843550|NCT06313684|OTHER|Diet management|A dietary plan supported by a nutritionist will be made together with the patient.
223843551|NCT06313684|OTHER|Resistance exercise|"Resistance exercises:~* With TheraBand.~* Intensity according to the perceived exertion scale~* Twice a week."
223843552|NCT06313684|OTHER|Continuous exercise|"Moderate-intensity continuous exercise prescribed by physical therapist :~* The intensity will be moderate, as tolerated~* Borg scale to monitor intensity.~* Frequency of training of 1 to 3 times per week, until completed 20 sessions in 10-12 weeks."
223843553|NCT06313684|OTHER|Initial Assessment|"Includes all those necessary to plan exercise training, as usual:~* Functional capacity with 6MWT.~* Assessment of skeletal muscle strength."
223843554|NCT05121207|DEVICE|Terahertz scanning|Short scans using Terahertz device
223843555|NCT05797311|OTHER|Proprioceptive Neuromuscular Facilitation (PNF)|Proprioceptive Neuromuscular Facilitation (PNF) techniques are a therapeutic exercise approach developed based on functional activities in daily life. At the stage of regaining movement and function, it creates models similar to functional activities.
223843556|NCT05797311|OTHER|Shoulder Stabilization Exercises|Scapular stabilization exercise and stabilization exercise for the shoulder joints
224264886|NCT03657550|DRUG|Levamlodipine, Amlodipine|In Part 1, this group of subjects were treated with a single dose of 5 mg levamlodipine maleate tablets (Test Product), then crossed over to receive a single dose of 10 mg Amlodipine Besylate Tablet NORVASC® (Reference Product) under fasted conditions. After a wash-out period for 14-days, all subjects were rolled over to Part 2 where they received a single dose of 5 mg levamlodipine maleate tablets under a high-fat/high-calorie meal to assess food effect.
223843557|NCT04184102|BEHAVIORAL|education|The intervention group received pre-surgery education and training on therapeutic exercises in addition to the routine hospital care. The educational material was developed by the principal investigator (PI) and included a power point and a booklet with instructions on the exercises as well as information about the surgery and what to expect after the surgery. The educational material was based on previous research and adopted to our population after consultation with a panel of experts including two nurses and three physicians. Eligible women were approached while waiting for their appointment with their surgeon. If they showed interest in participating they signed a consent form. The PI explained the study and what is involved in participating including the weekly phone calls for women in the intervention group. Participants were told that they will visited at home by the PI to assess their ROM and to fill out a questionnaire.
223843558|NCT02272465|OTHER|No intervention|Observational study
223843559|NCT06321172|DEVICE|FES Bike|Six months of FES-cycling trainings twice a week is performed for each pilot. Each session includes at most 30 minutes of stimulation. At the beginning of the training period, a conditioning phase is performed until the pilot reaches pedalling autonomy. This period is also used to define the stimulation parameters (minimum and maximum values of current intensity and pulse width), reference cadence and gear, specific for the ability of each pilot. Then the training period starts and is performed indoor, setting the resistance of the smart trainer at 10% for all the participants. The sessions are organized as follows: a 3-minute warmup followed by four sets of 6 minutes of pedalling and a 3-minute cool down.
223843560|NCT04609150|OTHER|Bone marrow fat quantification by MRI|Bone marrow fat quantification by MRI at the moment of the diagnosis of vertebral fracture before treatment by vertebroplasty
223843561|NCT02703532|BEHAVIORAL|CARE-CITE Education Program|"CARE-CITE is an online educational program developed to provide information that may help caregivers understand more about constraint-induced movement therapy (CIMT) and their potential roles in helping the stoke survivor gain as much benefit as possible from CIMT.~If participants do not have access to a computer or tablet, they will be loaned an electronic tablet for the 2-3 week period of the study to access the information.~Participants will be asked to review six educational modules over a period of 2-3 weeks while the stroke survivor receives CIMT.~Participants will attend three in home evaluation visits; one at the beginning of the stroke survivors therapy sessions, one at the end of his/her therapy visit series, and a third evaluation one month later in which they will be asked to complete questionnaires. Evaluation visits will take approximately 1 ½ hours to complete."
223843562|NCT02703532|BEHAVIORAL|Traditional Education|Investigators will explain constraint-induced movement therapy (CIMT) to caregivers and stroke survivors during the first home therapy session for the stroke survivor and provide traditional educational information about CIMT during therapy sessions as needed.
223843563|NCT02703532|BEHAVIORAL|Constraint-Induced Movement Therapy (CIMT)|"Constraint-Induced Movement Therapy (CIMT) is one type of therapy that helps stroke survivors gain more use of their weaker arm.This therapy involves wearing a soft mitt (like a sock or oven mitt) on the stronger arm to remind the stroke survivor to use their weaker arm for daily activities and also intensive practice of tasks with the supervision of a therapist.~Participants will attend three in home evaluation visits; one at the beginning of your therapy sessions, one at the end of your therapy visit series and a third evaluation one month later. These evaluation sessions will involve an evaluation of arm function and answering three questionnaires about how well the weaker arm works and how the stroke has affected daily activities. The interview questions and assessment will take approximately 1 ½ hours to complete."
223843564|NCT03980756|DRUG|AD-206 20mg|1 tablet administered before the breakfast during 7 days
223843565|NCT03980756|DRUG|Esomeprazole 20mg|1 tablet administered before the breakfast during 7 days
223843566|NCT03980756|DRUG|AD-206 40mg|1 tablet administered before the breakfast during 7 days
223843567|NCT03980756|DRUG|Esomeprazole 40mg|1 tablet administered before the breakfast during 7 days
223843568|NCT01637493|DRUG|Pegfilgrastim|Single SC injection of the appropriate dose of drug ranging from 30 mcg/kg to 200 mcg/kg at postchemotherapy 48hr in cycle 2, followed by two doses SC injection of the appropriate dose of drug ranging from 15 mcg/kg to 100 mcg/kg at postchemotherapy 48hr in cycle 3.
223843569|NCT01637493|DRUG|Pegfilgrastim|Single SC injection of the appropriate dose of drug ranging from 30 mcg/kg to 200 mcg/kg at postchemotherapy 48hr in cycle 2, followed by two doses SC injection of the appropriate dose of drug ranging from 15 mcg/kg to 100 mcg/kg at postchemotherapy 48hr in cycle 3.
223843570|NCT01637493|DRUG|Pegfilgrastim|Single SC injection of the appropriate dose of drug ranging from 30 mcg/kg to 200 mcg/kg at postchemotherapy 48hr in cycle 2, followed by two doses SC injection of the appropriate dose of drug ranging from 15 mcg/kg to 100 mcg/kg at postchemotherapy 48hr in cycle 3.
223843571|NCT01637493|DRUG|Pegfilgrastim|Single SC injection of the appropriate dose of drug ranging from 30 mcg/kg to 200 mcg/kg at postchemotherapy 48hr in cycle 2, followed by two doses SC injection of the appropriate dose of drug ranging from 15 mcg/kg to 100 mcg/kg at postchemotherapy 48hr in cycle 3.
223843572|NCT00632762|DRUG|mantadix|dose greater or equal to 200 mg/day and progressively increasing doses (100mg every 3 days until the pre-study dose is reached).
223843573|NCT05886738|OTHER|Fasting|Obese and lean groups will fast for 48 hours, followed by a 3-hour refeeding period.
223843574|NCT02440906|BEHAVIORAL|Patient-Directed Wellness Account|The intervention group (n=629) continue to receive usual care and receive a financial incentive to use in meeting their health goals.
223843575|NCT02440906|BEHAVIORAL|Health Navigator|The intervention group (n=629) will work with a health navigator on a monthly basis to develop and refine patient-centered health goals. Motivational interviewing techniques are used to establish the wellness goals.
223843576|NCT02213900|DRUG|Haloperidol|0.5mg IV Push immediately after surgery and Q8H following for a total of 4 days
223843577|NCT02213900|DRUG|Placebo|
223843578|NCT00652574|DRUG|Dasatinib|70 mg by mouth twice daily x 28 days, for up to 2 years after surgery.
223843579|NCT01608893|DRUG|Carvedilol|6.25 po bid titrated to 25 mg bid as tolerated over a 1 month period
223843580|NCT01608893|DRUG|Metoprolol|titrated to 50 mg po bid as tolerated over a 1 month period
223843581|NCT04870164|DRUG|Ensovibep|The study will start with a low-dose cohort and after a safety review escalate to the higher dose cohorts. 3 IV infusion, 2 IV bolus, 4 subcutaneous and 4 intramuscular cohorts are planned. Subjects receive one or two administration(s) on day 1, depending on the cohort.
223843582|NCT04870164|DRUG|Placebo|One administration at day 1 by infusion.
223843583|NCT06051162|DEVICE|BP management with HPI guidance|The hemodynamic condition of the HPI group will be managed by HPI guidance which is derived by arterial pressure waveform information, including Eadyn, SVV, dP/dt.
223843584|NCT02511704|DRUG|Nicotine|Multiple dose nicotine
223843585|NCT02511704|DRUG|Nicotine|Multiple dose nicotine
223843586|NCT04230161|OTHER|Standard long-lasting insecticidal net|Yahe LN (Yamei Industry) contains a pyrethroid insecticide.
223843587|NCT04230161|OTHER|Chlorfenapyr insecticide treated net|Interceptor G2® (BASF) is an ITN containing two active ingredients: Alpha-cypermethrin, a pyrethroid insecticide, and chlorfenapyr, a pyrrole insecticide.
223843588|NCT04230161|OTHER|Indoor residual spraying|Fludora Fusion (Bayer Vector Control) is a spray containing two active ingredients: clothianidin, a neonicotinoid insecticide, and deltamethrin, a pyrethroid insecticide.
223843589|NCT01593878|OTHER|TV|test taken with TV on
223843590|NCT02271594|BEHAVIORAL|Intensive Training on Best Insulin Injection Technique|The intervention consists of instructing patients in whom LH is detected and who are currently injecting into it to move injections to non-LH areas; reducing insulin doses initially by 10-20% to avoid hypoglycaemia and then titrating to target control; instructing these patients to correctly rotate sites (leaving 1 cm between injection punctures and allowing used sites to heal for 2-4 weeks before injecting in them again); instructing these patients to forego needle reuse; and instructing these patients to switch to 4 mmx32G needles. A battery of tools (described below) will be used to deliver and reinforce this training, including frequent contact by phone or other electronic means after the initial training.
223843591|NCT02271594|BEHAVIORAL|Standard education on injection technique|Usual and customary education and training normally provided injecting patients at the center
223843592|NCT01685580|DEVICE|Manufacturer (VPAP ST)|non-invasive ventilation in two pressure levels 7 days before surgery
223843593|NCT02942901|PROCEDURE|PET-CT|
223843594|NCT02633891|BEHAVIORAL|Balance exercise|tailored balance exercise program
223843595|NCT02633891|BEHAVIORAL|Standard care|general health education and fall prevention classes
223843596|NCT06323330|OTHER|Speech rehabilitation|Melodic Intonation Therapy- Indian Adaptation module which will be developed in the pilot phase
223843597|NCT00224796|DEVICE|V.A.C. ® System|
223843598|NCT05550974|DEVICE|Minimally Invasive Surgery|gynecological, urologic, thoracic, plastic and reconstructive and ENT etc. endoscopic and laparoscopic surgical procedures
223843599|NCT05243992|OTHER|CTS-PAD device imaging|Participants in the CTS-PAD Study will undergo a conventional ABI (cABI) evaluation, followed by the non-contact imaging evaluation with the CTS-PAD device. The supplemental CTS-PAD testing will add approximately ten (10) minutes to the overall evaluation time.
223843600|NCT05090423|OTHER|balance training alone|"The subjects will warm up to stretch the lower extremity for 5 minutes.~The physical therapist will instruct the patient how to use the foot tripod within 5 minutes. And then, giving him or her balance training.~At the first, the patient double legs stand on the ground to throw and catch a ball for 30 seconds, and then one leg stand on the ground to throw and catch a ball for 30 seconds. When finished, the patient can take 1 minutes rest.~Second, the patient will finish the prescribed the task stand on different materials, which included the exercise mat, dynair, bosu and foam roller."
224264887|NCT03657550|DRUG|Amlodipine, Levamlodipine|In Part 1, this group of subjects were treated with a single dose of 10 mg Amlodipine Besylate Tablet NORVASC® (Reference Product), and then crossed over to receive a single dose of 5 mg levamlodipine maleate tablets (Test Product) under fasted conditions. After a wash-out period for 14-days, all subjects were rolled over to Part 2 where they received a single dose of 5 mg levamlodipine maleate tablets under a high-fat/high-calorie meal to assess food effect.
224264888|NCT05571449|PROCEDURE|Open reduction and internal fixation|Internal fixation of the fracture
224264889|NCT05571449|PROCEDURE|Standard osteosynthesis planning|Plain radiograph and CT images are used
224264890|NCT05571449|PROCEDURE|3-D model osteosynthesis planning|A 3D plastic model made from CT images is used
224264891|NCT00171015|DRUG|valsartan plus hydrochlorothiazide|
224264892|NCT05963750|OTHER|virtual reality|virtual reality
224264893|NCT01503658|DRUG|Clopidogrel+Aspirin|Clopidogrel 75 mg, Aspirin 100 mg
224264894|NCT05006131|OTHER|Screening for pancreatic cancer|Screening for pancreatic cancer using EUS or MRI
224264895|NCT03957226|DEVICE|e-OPRA (electronic-Osseoanchored Prosthese for the Rehabilitation of Amputees)|The e-OPRA is an implant system that provides an alternative to traditional socket prostheses by establishing a direct, load-bearing link between the patient's skeleton and a prosthesis for transhumeral amputees. The anchorage element of the system is implanted directly into the bone while the electrodes that provide control signals for the prosthesis are implanted into muscle grafts on the transhumeral amputation.
224264896|NCT01787565|OTHER|painPREMIER cohort|Low back pain patients prospectively recruited during the study period and managed with painPREMIER.
224264897|NCT01787565|OTHER|Control cohort|A matched group of low back pain patients not managed with painPREMIER.
224264898|NCT00243425|PROCEDURE|Standard Quality Improvement|
224264899|NCT00243425|PROCEDURE|Patient-centered Intervention|
224264900|NCT06396286|PROCEDURE|single rod|surgical correction of severe adolescent idiopathic scoliosis with screws and a single rod.
224264901|NCT02024230|DRUG|Rivaroxaban or Warfarin|a multi-center, prospective, non-randomized, open-label, physician-initiated interventional allocation study either rivaroxaban or warfarin
224264902|NCT01078350|PROCEDURE|tumor tissue aspiration|
224264903|NCT01078350|PROCEDURE|phlebotomy|
224264904|NCT03810586|DEVICE|Non-invasive measurement of blood pressure|Comparing non-invasive measurement of blood pressure using the PPG-based BB-613 device to a blood pressure manomtry holter device (HUGECARE NIBP Monitor)
224264905|NCT01919112|DEVICE|tDCS|Anodal tDCS will be administered with swallowing exercises
224264906|NCT05795621|BIOLOGICAL|IBI311|10 mg/kg on Day 1 followed by 20 mg/kg q3W for the remaining 7 infusions for phase II/III.
224264907|NCT05795621|BIOLOGICAL|placebo|4 does of placebo for phase II; 8 does of placebo for phase III.
224264908|NCT02095379|OTHER|oligosecretary|not abvailable
224264909|NCT03915600|OTHER|Quinoa|Personalized diet added with quinoa
224264910|NCT03915600|OTHER|Flaxseed|personalized diet added with flaxseed
224264911|NCT03915600|OTHER|Quinoa and Flaxseed|personalized diet added with quinoa and flaxseed
223843601|NCT05090423|OTHER|balance training and neurodynamic intervention for the common peroneal nerve|"The physical therapist will give the patient neurodynamic intervention for the common peroneal nerve, which is performed slider the nerve 2 seconds.~The slider technique is repeated 30 seconds for 4 times, each time can be take a rest 1 minutes.~The physical therapist will instruct the patient how to use the foot tripod within 5 minutes. And then, giving him or her balance training.~At the first, the patient double legs stand on the ground to throw and catch a ball for 30 seconds, and then one leg stand on the ground to throw and catch a ball for 30 seconds. When finished, the patient can take 1 minutes rest.~Second, the patient will finish the prescribed the task stand on different materials, which included the exercise mat, dynair, bosu and foam roller."
223843602|NCT06458738|DEVICE|Printable denture base material|The newly developed printable denture base material will be used for the production of dentures.
223843603|NCT04196985|DIAGNOSTIC_TEST|PET/MRI|each patient will perform PET/CT and PET/MRI scans in two different days within the interval of less than 2 weeks receiving two different FDG injections. Administered FDG activity for each PET scan will be 4 MBq/Kg up to a maximum of 400 MBq.
223843604|NCT04196985|DIAGNOSTIC_TEST|PET/CT|each patient will perform PET/CT and PET/MRI scans in two different days within the interval of less than 2 weeks receiving two different FDG injections. Administered FDG activity for each PET scan will be 4 MBq/Kg up to a maximum of 400 MBq.
223843605|NCT01497444|DRUG|hypoxia-activated prodrug TH-302|
223843606|NCT01497444|DRUG|sorafenib tosylate|
223843607|NCT05985291|COMBINATION_PRODUCT|SCS in combination with CMM|Subjects receiving BurstDR spinal cord dorsal column stimulation in combination with conservative medical management for the treatment of painful diabetic neuropathy as part of regular medical care.
223843608|NCT02142439|BEHAVIORAL|Strength training|Three times per week with strength training
223843609|NCT03790397|DRUG|Osimertinib|Patients treated with Osimertinib within the Special Use medication Program (SUMP).
223843610|NCT02107001|PROCEDURE|Lung ultrasound|Lung ultrasonography performed and interpreted by a physician (Pulmonologist or Emergency Physician) possessing specific knowledge in the procedure and a training of at least 100 thoracic ultrasonographies in accordance to a prespecified protocol.
223843611|NCT06469892|OTHER|Detect the expression level of miR-185 in salivary and plasma exosomes.|"Participants were instructed to refrain from eating, drinking, brushing their teeth, rinsing their mouth, or taking medications for one hour before saliva collection. They were then asked to bend over, lower their head, open their mouth, and allow saliva to flow naturally without chewing or spitting. Using a specialized container, 2 mL of unstimulated saliva was collected.~Participants fasted overnight before blood collection. Researchers used plasma tubes containing anticoagulant (EDTA) to obtain venous blood (4-5 mL) from the participants\&#39; upper arm. Subsequently, the blood was gently inverted to ensure optimal contact with the anticoagulant before centrifugation at 2000 rpm and 4°C for 10 minutes. Following centrifugation, the supernatant was extracted."
223843612|NCT02435901|DRUG|alemtuzumab (Campath IH)|Alemtuzumab (Campath IH) is given daily over first 4 days, Day -20 to Day -17
223843613|NCT02435901|DRUG|Fludarabine|Fludarabine 35/m2 is given daily over 4 days on Day -7 to Day -4.
223843614|NCT02435901|DRUG|Melphalan|Melphalan 70mg/m2 is given daily over 2 days on Day -3 to Day -2.
223843615|NCT02435901|DRUG|Cyclosporine|Immunosuppressant to prevent graft vs host disease is given on Day -1 prior to stem cell infusion
223843616|NCT02435901|DRUG|Mycophenolate mofetil|Immunosuppressant to prevent graft vs host disease is given on Day -1.
223843617|NCT02435901|DRUG|Tacrolimus|Immunosuppressant to prevent graft vs host disease is given Day -1 prior to stem cell infusion
223843618|NCT02435901|BIOLOGICAL|Hematopoietic Stem Cell Transplantation|Human Leukocyte Antigen (HLA) matched or mismatched; related or unrelated hematopoietic stem cells to be transplanted on Day 0.
223843619|NCT01323660|DRUG|GSK573719/GW642444 125/25|125mcg/ 25mcg QID (Once daily , inhaled)
223843620|NCT01323660|DRUG|GSK573719/GW642444 62.5/25|62.5mcg/25mcg QID
223843621|NCT01323660|DRUG|GSK573719 125|125mcg QID
223843622|NCT01323660|DRUG|GSK573719 62.5|62.5mcg QID
223843623|NCT01323660|DRUG|GW642444 25|25mcg QID
223843624|NCT01323660|DEVICE|placebo|Comparator QID
223843625|NCT00350532|DRUG|clonidine|Patients will receive intrathecal clonidine (or clonidine injected into cerebrospinal fluid)
223843626|NCT00350532|DRUG|clonidine|Patients will receive intrathecal clonidine (or clonidine injected into cerebrospinal fluid)
223843627|NCT05287932|BEHAVIORAL|Brief physical activity intervention|See arm/group descriptions
223843628|NCT05379127|OTHER|Patient-empowered follow up|"The patient-empowered follow-up protocol consists of patient-reported outcome measures (PROMs), self-assessment tools and clinical assessment including physical examination. Radiographs will only be taken when progression of the scoliosis (curve progression) or postoperative complications are suspected based on test results and based on the criteria of so called 'sense of alarm'.~Note: Sense of alarm ('niet pluis') is based on any deterioration on the above-mentioned PROMs, self-assessment tool, and clinician-based measurement instruments, which is a signal for the treating physician to consider when a radiograph is appropriate. Sense of alarm is described as any other concern by the orthopaedic surgeon, parent or child which warrants a radiograph. For both the Bunnell Scoliometer (clinical assessment tool) and the Scolioscoop (patient self-assessment tool) a threshold of ≥4° is used."
223843629|NCT05379127|OTHER|Standard follow-up|Routine radiographs are taken at each follow up visit during standard care (to detect possible curve progression or rule out postoperative complications).
223843630|NCT01598025|RADIATION|total-body irradiation (TBI)|
223843631|NCT01598025|DRUG|thiotepa|
223843632|NCT01598025|DRUG|fludarabine phosphate|
223843633|NCT01598025|DRUG|melphalan|
223843634|NCT01598025|BIOLOGICAL|anti-thymocyte globulin|
223843635|NCT01598025|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
223843636|NCT01598025|BIOLOGICAL|peripheral blood stem cell transplantation|
223843637|NCT01598025|OTHER|laboratory biomarker analysis|
223843638|NCT02474615|PROCEDURE|ENDODONTIC SURGERY|ENDODONTIC SURGERY
223843639|NCT00223054|DRUG|tacrolimus|retrospective analyze of drug levels in comparison to polymorphism
223843640|NCT00223054|DRUG|sirolimus|retrospective of drug blood trough levels in comparison to polymorphism of enzymes of drug metabolism
223843641|NCT00223054|DRUG|everolimus|retrospective of drug blood trough levels in comparison to polymorphism of enzymes of drug metabolism
223843642|NCT00223054|DRUG|cyclosporin A|retrospective of drug blood trough levels in comparison to polymorphism of enzymes of drug metabolism
223843643|NCT00270114|DRUG|epoetin alfa|
223843644|NCT06192706|DEVICE|Foldax Tria Aortic Valve|Aortic Valve Replacement
223843645|NCT06489171|PROCEDURE|Received laparoscopic-assisted vaginal radical trachelectomy|"The LAVRT procedure began with laparoscopic pelvic lymphadenectomy, and all lymph nodes were removed for frozen pathological analysis. The laparoscopic-assisted vaginal radical trachelectomy procedure was continued only if the nodes were negative. The pararectal pouch was revealed, and the uterine arteries were divided from their origin to the internal iliac artery. The ureters were freed from the posterior leaf of the broad ligament down to the level where they entered the ureteral tunnel and then displaced laterally. The uterosacral ligaments, cardinal ligaments, and parametrial portions were then divided and dissected. The section of the procedure was performed laparoscopically. The vaginal epithelium was circumferentially incised approximately 3 cm distal to the endocervix. Frozen section analysis confirmed no cancer involvement at the endocervical or vaginal margin. The vaginal mucosa was sutured to the cervical stump to form a new cervical os."
223843646|NCT03700606|PROCEDURE|High flow nasal cannula|8 liters per minute of blended oxygen through Fisher Paykel Optiflow Jr 2 nasal prongs.
223843647|NCT03700606|PROCEDURE|Nasal CPAP|Nasal continuous positive airway pressure of 5-7 cm/H20 delivered using Ventilator or bubble cpap device through short nasal prongs or a nasal face mask.
223843648|NCT00278564|BIOLOGICAL|Hematopoietic stem cell transplantation|Autologous hematopoietic stem cell transplantation
223843649|NCT00278564|DRUG|Cyclophosphamide|
223843650|NCT00278564|DRUG|Mesna|
223843651|NCT00278564|DRUG|ATG(rabbit)|
223843652|NCT00278564|DRUG|Methylprednisolone|
223843653|NCT00278564|DRUG|G-CSF|
223843654|NCT00278564|DRUG|Rituxan|
223843655|NCT02143674|OTHER|Muscle stretching and Strength Training|"Each step of stretching on specific muscles was repeated three times by keeping the posture for 30 seconds, (Arnold and Kokkonen, 2007; Toraman A, Yildirim. 2010; Dai, Ware, Giuliani, 2012; Duque et al., 2013; Granacher et al., 2013). The Pectoral, Quadriceps, Paraspinal, Abdominal and Ischial tibial and sural triceps muscles were elongated.~Strength Training Muscle strengthening was performed using weights and dumbbells. The training load individually determined through the test of strength with 10 repetitions maximum. The load was reevaluated four weeks of training. The Abdominal, Paraspinal, Quadriceps and Posterior thigh muscles (hamstrings) were submitted to the intervention protocol."
223843656|NCT02143674|OTHER|Educated about physical exercises|
223843657|NCT05323929|PROCEDURE|ESD|Endoscopic Submucosal Dissection for early gastric cancer
223843658|NCT00970411|DRUG|KRN951|Orally once daily administration
223843659|NCT01246648|PROCEDURE|Biopsy|dental extraction and gingival epithelial biopsy
223843660|NCT01246648|PROCEDURE|biopsy|dental extraction and gingival epithelial biopsy
223843661|NCT01246648|PROCEDURE|Biopsy|dental extraction and gingival epithelial biopsy
223843662|NCT06263985|DEVICE|Axis Dermis biologic mesh repair for pelvic organ prolapse|Subjects with pelvic organ prolapse will undergo a pelvic organ prolapse repair with the use of Axis Dermis biologic mesh.
223843663|NCT00914017|DRUG|Atorvastatin|Atorvastatin, 40 mg daily for 1 year
223843664|NCT00914017|DRUG|Placebo|sugar pill daily for 1 year
223843665|NCT01616290|DRUG|PRT-201|0.03, 1, or 3 mg single adventitial administration
223843666|NCT02286440|OTHER|AssureRx GeneSight genotyping results|
223843667|NCT02286440|OTHER|Treatment as usual|
223843668|NCT00051311|PROCEDURE|Stem cell transplantation|Recipients will receive donor stem cells 3 days after conditioning therapy is completed.
223843669|NCT00051311|DRUG|Fludarabine|Recipients will receive induction therapy with fludarabine, cyclophosphamide, etoposide, doxorubicin, vincristine, and prednisone. One cycle is 5 days on drug therapy followed by a 16 day rest period.
223843670|NCT00051311|DRUG|Cyclophosphamide|Recipients will receive induction therapy with fludarabine, cyclophosphamide, etoposide, doxorubicin, vincristine, and prednisone. One cycle is 5 days on drug therapy followed by a 16 day rest period.
223843671|NCT00051311|DRUG|Etoposide|Recipients will receive induction therapy with fludarabine, cyclophosphamide, etoposide, doxorubicin, vincristine, and prednisone. One cycle is 5 days on drug therapy followed by a 16 day rest period.
223843672|NCT00051311|DRUG|Doxorubicin|Recipients will receive induction therapy with fludarabine, cyclophosphamide, etoposide, doxorubicin, vincristine, and prednisone. One cycle is 5 days on drug therapy followed by a 16 day rest period.
223843673|NCT00051311|DRUG|Vincristine|Recipients will receive induction therapy with fludarabine, cyclophosphamide, etoposide, doxorubicin, vincristine, and prednisone. One cycle is 5 days on drug therapy followed by a 16 day rest period.
223843674|NCT00051311|DRUG|Prednisone|Recipients will receive induction therapy with fludarabine, cyclophosphamide, etoposide, doxorubicin, vincristine, and prednisone. One cycle is 5 days on drug therapy followed by a 16 day rest period.
223843675|NCT00051311|DRUG|Methotrexate|Recipients will receive 4 doses of methotrexate by vein after the transplant to help prevent graft-versus-host disease (GVHD)..
223843676|NCT00051311|DRUG|Cyclosporine|Recipients will receive cyclosporine by vein or by mouth for about 6 months after the transplant to help prevent graft-versus-host disease (GVHD).
223843677|NCT00051311|PROCEDURE|Apheresis|Donors will undergo apheresis to collect stem cells for a stem cell transplant for the recipient.
223843678|NCT04318964|BIOLOGICAL|TAEST16001 cells|"The patients in the dose increasing part and the expanding part received the intravenous reinfusion of TAEST16001 cells on the 5th day (i.e. the interval was 4 days) after the lymphocyte elimination chemotherapy: If the dose level of reinfusion was 1 and 2, the planned total amount of TAEST16001cells (calculated by TCR-T positive cells) was given a single reinfusion on the 1st day of the study. If the dose level of reinfusion was 3 and 4,then the total amount of TAEST16001cells (calculated by TCR-T positive cells) was planned to be reinjected in 60% and 40% proportion on the first and second day of the study.~After the first reinfusion of TAEST16001 cells, the patients will be given a small dose of IL-2 subcutaneously (study day 1 to day 14), 500000 U / time. The first injection will be carried out within 30 minutes after the cell reinfusion, twice a day (interval 10-12 hours), for 14 days."
223843679|NCT01132911|DRUG|Vorinostat (SAHA)|
224264912|NCT04263506|OTHER|Vignette with emphasis on supervisor's opinion|A vignette describing a dilemma situation for a researcher (e.g. adding an honorary author) with or without the description of supervisor's advice that does not oppose to detrimental research practice (i.e. the supervisor is fine with whatever the PhD student decides in the dilemma).
223843680|NCT01132911|DRUG|Velcade (PS-341, Bortezomib)|
223843681|NCT05646069|DEVICE|Storz Flex-XC1 Disposable Flexible Ureteroscope|Patients will receive flexible ureteroscopy with the Storz Flex-XC1 disposable flexible ureteroscope.
223843682|NCT05646069|DEVICE|Storz Flexible Digital Ureteroscope|Patients will receive flexible ureteroscopy with the Storz flexible Digital ureteroscope.
223843683|NCT02721758|BEHAVIORAL|Brief Motivational Intervention|
223843684|NCT03002987|BEHAVIORAL|Active Pregnancy policy|Education (3 hours) of leaders in how to implement Active pregnancy policy at their departments/work places
223843685|NCT05142228|DRUG|Erenumab-Aooe|Administered once every 4weeks/28 days at visit 1, visit 2 and visit 3 for a total of 3 cycles.
223843686|NCT05142228|OTHER|Placebo|Administered once every 4weeks/28 days at visit 1, visit 2 and visit 3 for a total of 3 cycles.
223843687|NCT00098943|BIOLOGICAL|CNGRC peptide-TNF alpha conjugate|
223843688|NCT04880343|DIETARY_SUPPLEMENT|Group (A)|Group that will take a daily dose of the commercial dietary supplement provided by the sponsor, composed of mannose, cran-max and vitamin D for 6 months
223843689|NCT04880343|DIETARY_SUPPLEMENT|Group (B)|Group that will take a daily dose of the commercial dietary supplement provided by the sponsor, composed of mannose, cran-max and vitamin D for 3 months
223843690|NCT04884698|DEVICE|Stimit Activator|"The Stimit Activator Device is composed of three components.~1. A magnetic stimulator generating current pulses~2. A novel Stimit coil design optimized for phrenic nerve stimulation~3. A coil positioning device for quick, easy and reproducible coil positioning"
223843691|NCT05049629|DEVICE|Lacrimera|A new preservative-free formulation of eye drops consists of a novel biopolymer, chitosan-N-acetylcysteine (C-NAC; Lacrimera®, Croma-Pharma GmbH, Leobendorf, Austria), which electrostatically binds to the mucine layer of the tear film forming a glycocalyx-like structure.
223843692|NCT05049629|DEVICE|Hylo-Vision|Preservative-free, Hyaluronic-acid containing eyedrops (Hylo-Vision® sine)
223843693|NCT04878172|DEVICE|TempSure Firm|The TempSure firm will be used on the abdomen for non-invasive lipolysis.
223843694|NCT02256969|DRUG|Blephamide|
223843695|NCT02256969|DRUG|GenTeal PM Night-Time|
223843696|NCT02256969|PROCEDURE|Meibomian Gland Probing|For anesthesia, topical 3.5% lidocaine hydrochloride jelly (Akron) was applied directly with sterile cotton-tipped applicator to the lid margin for 3 times every 10 minutes before the procedure. If necessary, 2% lidocaine was injected into the lid margin during the procedure to provide additional comfort. After obtaining adequate anesthesia, the solid stainless steel probes (Maskin® Meibomian Gland Intraductal Probes, Rhein Medical Inc.) were used to probe all the meibomian glands of upper lids of both eyes at the slit lamp. All patients were initially be probed with a 1-mm probe followed by a 2-mm probe for all glands.
223843697|NCT02256969|PROCEDURE|Sham Meibomian Gland Probing|For anesthesia, topical 3.5% lidocaine hydrochloride jelly (Akron) was applied directly with sterile cotton-tipped applicator to the lid margin for 3 times every 10 minutes before the procedure. If necessary, 2% lidocaine was injected into the lid margin during the procedure to provide additional comfort. The patient's lid margin was touched with the probes without actual probing of the meibomian gland orifices.
223843698|NCT02333773|PROCEDURE|Irreversible electroporation (IRE)|Irreversible Electroportion For Unresectable Portal venous tumor emboli guide with ultrasound or/and CT.
223843699|NCT04516811|BIOLOGICAL|COVID-19 convalescent plasma (CCP) plus standard of care (SOC)|A single unit of approximately 200-250 mL of CCP that contains anti-SARS-CoV-2 collected by plasmapheresis from a volunteer who recovered from COVID19 with SOC as determined by local practice and guidelines.
223843700|NCT04516811|BIOLOGICAL|Standard of care (SOC) plus placebo|A single unit of 200 mL normal saline with SOC as determined by local practice and guidelines
223843701|NCT01902901|GENETIC|Whole Genome Sequencing|Participants will receive Whole Genome Sequencing
223843702|NCT01902901|GENETIC|Carrier status testing|Carrier status testing
223843703|NCT00372567|DRUG|sunitinib malate|37.5 mg daily
223843704|NCT00372567|DRUG|imatinib mesylate|800mg daily
223843705|NCT00083421|DRUG|ONO-2506PO|
223843706|NCT02920944|DEVICE|EUS-FNB with 20 gauge ProCore needle|EUS-FNB with 20-gauge (Echotip ProCore; Cook Endoscopy Inc, Limerick, Ireland)
223843707|NCT02920944|DEVICE|EUS-FNB with 22 gauge ProCore needle|EUS-FNB with 22-gauge (Echotip ProCore; Cook Endoscopy Inc, Limerick, Ireland)
223843708|NCT05238779|OTHER|Standard of care including palliative care|Usual care includes laboratory evaluations, imaging, and certain procedures and medications. In some cases of patients undergoing transplant evaluation, usual care will also include multiple visits with members of the liver transplant team. A palliative care consult will also be part of standard of care. The primary goal of the palliative care consult is not to arrange hospice (though that can be done in appropriate situations) but to identify and try to address the impacts of the disease and its symptoms on patient's life.
223843709|NCT01079598|DEVICE|RF Ablation (ClosureRFS Stylet)|Bipolar energy radiofrequency ablation with RFS stylet
223843710|NCT04882462|DRUG|Nimotuzumab|Nimotuzumab, 400mg, intravenously every 3 weeks, for at least 18 weeks
223843711|NCT04882462|DRUG|Sintilimab|Sintilimab, 200mg, intravenously every 3 weeks, for at least 18 weeks;
223843712|NCT04882462|DRUG|Chemotherapy drug|Chemotherapy drugs were selected by the investigator, every 3 weeks, for 18 weeks
223843713|NCT06202937|BEHAVIORAL|Mother Baby Yoga|Fragile Baby Perception Syndrome, Maternal Attachment, Depression-Anxiety-Stress Level
223843714|NCT06202937|OTHER|No intervention:control|the control group received the usual care
223843715|NCT00660166|BIOLOGICAL|NK-Cell Infusion|The infusion of natural killer (NK) cells will be performed in the Infusion Center at New England Medical Center. The NK cells will be given to the subject intravenously (into a vein). In addition, a balanced salt solution will be infused beginning about two hours prior to and continuing for two hours after the infusion of NK cells to keep the fluid level in the body well balanced. The subject will also receive Benadryl by injection 15-30 minutes prior to infusion to counteract and prevent any unwanted allergic side effects. The subject will be observed for any side effects during this time. If the subject feels well, he/she can go home. However, there may be a requirement to keep him/her overnight.
223843716|NCT02396030|DRUG|Magnesium sulfate 50% - 1g/h|Patients will receive after the loading dose os magnesium sulfate, the maintenance dose of 1g/hour of intravenous of magnesium sulfate for 24 hours after loading dose
223843717|NCT02396030|DRUG|Magnesium sulfate 50% - 2g/h|Patients will receive after the loading dose os magnesium sulfate, the maintenance dose of 1g/hour of intravenous of magnesium sulfate for 24 hours after loading dose
223843718|NCT00303303|BIOLOGICAL|Crotaline Polyvalent Immune Fab (ovine) (active initial and maintenance therapy)|Crotaline Polyvalent Immune Fab (Ovine), 4 vials initially; Second 4-vial dose two hours later if needed to achieve initial control of the envenomation syndrome; active maintenance therapy with 2 vials administered 6, 12, and 18 hours after initial control is achieved.
223843719|NCT00303303|BIOLOGICAL|Crotaline Immune Fab (ovine) (active initial therapy; placebo maintenance therapy)|Crotaline Polyvalent Immune Fab (Ovine), 4 vials initially; Second 4-vial dose two hours later if needed to achieve initial control of the envenomation syndrome; placebo maintenance therapy administered 6, 12, and 18 hours after initial control is achieved.
223843720|NCT00303303|BIOLOGICAL|Placebo|Placebo therapy in place of initial and maintenance antivenom therapy. Note that open-label rescue therapy is mandated if the envenomation syndrome becomes severe, or if progression of envenomation signs/symptoms has not spontaneously halted by 6 hours.
223843721|NCT03261635|DRUG|Ranibizumab Injection|patients received monthly 0.5 mg ranibizumab intravitreal injections for 3 months, after which monthly injections were administered pro re nata
223843722|NCT03261635|DRUG|Indomethacin|patients self-administered one drop of indomethacin 0.5% eye drops three times a day for 12 months
223843723|NCT02981134|PROCEDURE|Computed tomographic scan|after 1year of BVS implantation, computed tomographic scan will be performed
223843724|NCT05675631|OTHER|Suspension training|This group will perform training using suspension devices.
223843725|NCT05675631|OTHER|Strength training|This group will perform training using weights and elastic bands.
223843726|NCT04599452|BIOLOGICAL|Allogeneic NK cell regimen group|"10 patients with recurrent refractory elderly AML were treated with allogeneic NK cell regimen.~Allogeneic NK cell regimen ×3 cycle; Cyclophosphamide 300mg/m2.d d1to 3; G-CSF 150ug bid d4-11; Azacitidine 75mg/m2 d5-11; Allogeneic NK cell 10-30×10\^6/kg d13，d15."
223843727|NCT00301379|OTHER|Observation data collection study.|This is a data collection study where the main purpose is to collect information about the treatments patients receive for their unresectable cholangiocarcinoma.
223843728|NCT02832765|RADIATION|A|Intensity modulated radiotherapy (IMRT) 30Gy in 10 fractions of the involved spinal bone metastases
223843729|NCT02832765|RADIATION|B|Intensity modulated radiotherapy (IMRT) 30Gy in 10 fractions with an SIB with 40 Gy in 10 fractions to the metastasis of the involved spinal bone metastases
223843730|NCT02832765|RADIATION|C|Intensity modulated radiotherapy (IMRT) 20Gy in 5 fractions of the involved spinal bone metastases
223843731|NCT02832765|RADIATION|D|Intensity modulated radiotherapy (IMRT) 20Gy in 5 fractions with an SIB with 30 Gy in 5 fractions to the metastasis of the involved spinal bone metastases
223843732|NCT01330355|DRUG|Besivance|Besifloxacin hydrochloride 0.6% ophthalmic suspension, one drop instilled into infected eye, three times daily (TID) for 7 days
223843733|NCT01330355|DRUG|Gatifloxacin|Gatifloxacin 0.3% ophthalmic solution one drop instilled into infected eye, TID for 7 days
223843734|NCT00402883|DRUG|Bevacizumab|15mg/kg week 1, 4, 16, 19, 22, 25, 28, 31, 34, 37, 40, 43, 46, and 49.
223843735|NCT00402883|DRUG|Pemetrexed|500mg/m2 week 1, 4, 16, 19 and 22.
223843736|NCT00402883|PROCEDURE|Radiotherapy|1.8 Gy single daily fractions(Monday-Friday), to total dose 61.2 Gy (7 weeks)
223843737|NCT00402883|OTHER|Folic Acid|350 to 1,000 ug or equivalent supplementation administered orally beginning 1 to 2 weeks before the first dose of pemetrexed and continued daily until the patient discontinues study therapy.
223843738|NCT00402883|OTHER|vitamin B12|1,000ug administered by intramuscular injection 1 to 2 weeks before the first dose of study therapy and repeated every 9 weeks until the patient discontinues therapy.
223843739|NCT00402883|DRUG|carboplatin|AUC=5 administered intravenously weeks 1 and 4.
223843740|NCT02858934|RADIATION|Tomotherapy|"Dose prescription:~Whole breast irradiation: 25 Gy in 5 daily fractions of 5 Gy Boost: 30 Gy in 5 daily fractions of 6 Gy The boost will be delivered as a simultaneous integrated boost (SIB).~Target volumes:~Clinical target volume (CTV) breast: defined by the soft tissue of the breast down to the pectoralis fascia, but excluding the skin and the underlying muscle, ribs, lung and heart.~Gross tumor volume (GTV) boost: includes all gross tumor volume, as visible on computer tomography, mammography and/or magnetic resonance imaging (MRI). MRI imaging is preferentially performed in treatment position.~CTV boost: includes the primary tumor, with a margin of 1.0 cm in all directions to encompass potential microscopic disease extension. The CTV boost excludes the skin, pectoralis muscle, ribs, lung and heart.~Planning target volume (PTV): CTV plus a margin of 5 mm in all directions, but limited at 5 mm below the skin surface."
223843741|NCT05826548|BEHAVIORAL|Telerehabilitation group|Patients will undergo the experimental intervention for 1 hour/day, for 5 days, for 4 weeks.
223843742|NCT05826548|BEHAVIORAL|Conventioanl treatment group|Patients will undergo the control intervention for 1 hour/day, for 5 days, for 4 weeks.
223843743|NCT06396845|PROCEDURE|robotic surgery|robotic surgery
223843744|NCT06396845|PROCEDURE|laparoscopic surgery|laparoscopic surgery
223843745|NCT00824785|DRUG|epirubicin, oxaliplatin, capecitabine (EOX)|epirubicin 50mg/m(2) IV on day 1 oxaliplatin 130mg/m(2) IV on day 1 with hydration capecitabine 1250mg/m(2)/day PO in two divided doses continuously from days 1-21
223843746|NCT00824785|DRUG|EOX + panitumumab|epirubicin 50mg/m(2) IV on day 1 oxaliplatin 100mg/m(2) IV on day 1 with hydration capecitabine 1000mg/m(2)/day PO in two divided doses continuously from days 1-21 panitumumab -9 mg/kg every 21 days
223843747|NCT03566680|DEVICE|Orthokeratology|Orthokeratology is a type of contact lens that is worn over night to reduce refractive error, so patients do not need to wear vision correction during the day.
224264913|NCT02043132|DRUG|Tranexamic Acid|Patients randomized to TXA receive an infusion of the standard dose of Tranexamic acid (10 mg/kg) within 60 minutes prior to surgery and at wound closure. The pharmacy uses the randomization list in sequential order to determine whether that patient will receive Tranexamic acid or placebo and will provide two unlabeled IV bags (patient receives two doses) of the appropriate solution.
224264914|NCT02043132|DRUG|Placebo|Patients randomized to placebo receive an infusion of 10 mg/kg of normal saline within 60 minutes prior to surgery and at wound closure. The pharmacy uses the randomization list in sequential order to determine whether that patient will receive Tranexamic acid or placebo and will provide two unlabeled IV bags (patient receives two doses) of the appropriate solution.
224264915|NCT04467151|DRUG|anti-SARS-CoV-2 plasma|Administration of anti-SARS-CoV-2 convalescent plasma
224264916|NCT04467151|OTHER|Placebo|Administration of placebo (albumin 5%)
224264917|NCT05571462|OTHER|Activity monitor group|No intervention will be applied. All included patients will be monitored with body-worn physical activity monitors during two periods.
224264918|NCT03659994|DIETARY_SUPPLEMENT|Multivitamin|Vitabeard
224264919|NCT03659994|DIETARY_SUPPLEMENT|Placebo|Placebo
223843748|NCT06204185|DRUG|Metformin|Locally delivered Metformin gel in the treatment of periodontitis patients
223843749|NCT06204185|DRUG|Placebo|Placebo gel consist of drug without the active component.
223843750|NCT00451698|DRUG|acyanotic erythropoietin|Single dose IV push
223843751|NCT00451698|DRUG|acyanotic placebo|Single dose IV push
223843752|NCT01209676|DRUG|IMCgp100 injection|a monoclonal T cell receptor anti-CD3scFv fusion protein
223843753|NCT06530667|DEVICE|broadband collaborative pulse ablation|Via CT guided, patients with malignant pulmonary nodules would be treated by broadband collaborative pulse ablation
223843754|NCT05401916|DRUG|Tramadol|Patients will be received tramadol with intravenous patient controlled analgesia (IV PCA) device during postoperative 24 hours. The PCA solution will be prepared with 500 mg tramadol in 100 mL of saline (5 mg/ml). The PCA device was adjusted as infusion: 2 ml/h, bolus: 2 ml, lockout period: 15 min.
223843755|NCT05401916|DRUG|Paracetamol|1 g paracetamol will be administered 30 minutes before the end of surgery. All administrations will be applied through IV infusion over 30 minutes. Patients will be received tramadol with intravenous patient controlled analgesia (IV PCA) device during postoperative 24 hours. The PCA solution will be prepared with 500 mg tramadol in 100 mL of saline (5 mg/ml). The PCA device was adjusted as infusion: 2 ml/h, bolus: 2 ml, lockout period: 15 min.
223843756|NCT05401916|DRUG|Ibuprofen|800 mg ibuprofen (diluted with 250 ml saline) will be administered 30 minutes before the end of surgery. All administrations will be applied through IV infusion over 30 minutes. Patients will be received tramadol with intravenous patient controlled analgesia (IV PCA) device during postoperative 24 hours. The PCA solution will be prepared with 500 mg tramadol in 100 mL of saline (5 mg/ml). The PCA device was adjusted as infusion: 2 ml/h, bolus: 2 ml, lockout period: 15 min.
223843757|NCT06132321|BEHAVIORAL|Quality of life questionnaires|Detecting by mean of questionnaires quality of life, urinary function, pain, sexual function and lymphedema status before and after surgery for vulvar cancer, associated or not to vulvar reconstruction
223843758|NCT06068166|COMBINATION_PRODUCT|TEA plus GDMT|Thoracic epidural anesthesia (TEA), the infusion of anesthetic agents (eg, lidocaine or ropivacaine) into the epidural space, is used to achieve sympathetic block at the T1 to T4 levels in thoracic and abdominal surgical procedures. Since 1995, Professor Liu Fengqi has pioneered the use of TEA to treat end-stage HFrEF and achieved surprising results. TEA could reduce the enlarged heart cavity, halt and reverse cardiac remodeling, and improve cardiac systolic and diastolic function. Currently, thousands of HFrEF patients have received TEA procedure. All the patients received maximally tolerated guideline-directed medical therapy (GDMT).
223843759|NCT06068166|DRUG|GDMT|All the patients received maximally tolerated guideline-directed medical therapy (GDMT) alone.
223843760|NCT04437108|PROCEDURE|Li-SWT (suprapubic approach)|The patient will be asked to lie in flat dorsal position. A commercially used gel for sonography will be applied to the suprapubic region. The applicator will be placed on suprapubic region with two fingers apart from the symphysis pubis tilting to 45°. Shock waves will be directed to 3 different sites; the midline (over the bladder dome) and 3 cm right and left to the midline (over bilateral bladder walls). The patient will receive 3000 shocks (1000 shocks per site) with energy flux density of 0.12 mJ/mm² and frequency of 4 Hz.
223843761|NCT04437108|PROCEDURE|Li-SWT (perineal approach)|The patient will be asked to lie in lithotomy position. A commercially used gel for sonography will be applied to the perineum. The applicator will be placed on perineal region. Shock waves will be directed to 3 different sites: the midline and 2 cm above and below the midline. The patient will receive 3000 shocks (1000 shocks per site) with energy flux density of 0.12 mJ/mm² and frequency of 4 Hz.
223843762|NCT04437108|PROCEDURE|Li-SWT (combined approach)|The patient will receive 3000 shocks; 1500 shocks through suprapubic approach (500 shocks per site) and another 1500 shocks through perineal approach (500 shocks per site) with energy flux density of 0.12 mJ/mm² and frequency of 4 Hz.
223843763|NCT04437108|PROCEDURE|Sham treatment|The same technique of Li-SWT will be used but the applicator of the shock wave device will be turned off.
223843764|NCT04437108|DRUG|Solifenacin|The patients will be treated by antimuscarinics (solifenacin) which are considered as the conventional treatment of storage symptoms after prostatectomy.
223843765|NCT04950543|BEHAVIORAL|Meditation|An online survey will be offered to participants who have enrolled in a 21-day meditation online course. The survey will be conducted using mobile website technology before and after the online course and additionally after 3 and 6 months.
223843766|NCT03458897|DIAGNOSTIC_TEST|serial functional magnetic resonance imaging (MRI)|All subjects with sickle cell disease undergoing bone marrow transplantation will undergo up to 4 functional MRI scans.
223843767|NCT00582790|DRUG|IL2|Interleukin-2 will be given at a starting dose of 7 MU/m2/day by subcutaneous injection days 1-5, on weeks 1 through 3, in four week (28 days) cycles.
223843768|NCT00582790|DRUG|Zoledronic acid|Zoledronic acid will be given on day 1 intravenously over 15 or 30 minutes starting at 400mcg. If no significant increase in gamma delta-T cell augmentation is seen, the dose of zoledronic acid will be increased in the subsequent cycle up to a maximum dose of 3mg.
223843769|NCT02699801|DRUG|propofol|propofol for post-sternal closure sedation
223843770|NCT02699801|DRUG|Dexmedetomidine|dexmedetomidine for post-sternal closure sedation
224264920|NCT02956525|DRUG|Dexibuprofen|Dexibuprofen 200 mg
224264921|NCT00635648|DRUG|caspofungin acetate|Intravenous (IV) caspofungin acetate 50 mg/day. Participants with esophageal candidiasis will be treated for at least 7 days and for at least 72 hours after symptoms resolve for a maximum of 28 days; participants with invasive candidiasis will have a 70 mg loading dose on study day 1 and will be treated for at least 14 days after the last positive culture of Candida from the blood or other normally sterile body site for a maximum of 60 days; these participants should also have improvement in clinical and radiographic signs of disease for at least 48 hours before completion of the study therapy.
224264922|NCT00012974|BEHAVIORAL|GTelephone-administered Cognitive-Behavioral Therapy (T-CBT)|
224264923|NCT00012974|PROCEDURE|Provider education, computer reminders, nurse case management|
224264924|NCT03720444|OTHER|MDT (mechanical diagnosis and therapy) method|The intervention consists of a first session to carry out an assessment, followed by 4 reassessment sessions
224264925|NCT04194801|DRUG|Phase Ib: Fisogatinib (BLU-554) 400mg in combination with Sugemalimab (CS1001) 1200mg|Phase Ib: participants received 400 mg Fisogatinib (BLU-554) once daily (QD), in combination with 1200mg fixed dose Sugemalimab (CS1001) once every 3 weeks (Q3W). Every 21 days (3 weeks) will be considered as one cycle.
223843771|NCT03301922|BEHAVIORAL|Metacognitive therapy and work-focused interventions|Metacognitive therapy and work-focused interventions, up to maximum 12 sessions, with weekly session of 45-60 minute duration. The metacognitive treatment program is based on Wells' manual. The work-focused intervention is based on Lagerveld and Blonk. The interventions are run in parallel.
223843772|NCT03301922|OTHER|Waiting list|Waiting list
223843773|NCT01941264|OTHER|community based screening and treatment|Already described in intervention arm description.
223843774|NCT00480441|DRUG|Dronabinol|10mg capsules taken 4 times daily for 2 weeks and then tapered over 1 week
223843775|NCT00480441|BEHAVIORAL|BRENDA therapy|weekly therapy sessions for 6 weeks
223843776|NCT00480441|DRUG|Placebo|4 capsules daily for 2 weeks followed by a 1 week taper
223843777|NCT02374957|DRUG|Cilostazol|100 mg twice daily for 90 days
223843778|NCT05039918|BEHAVIORAL|Affective touch|Gentle stroking at CT-optimal speed
223843779|NCT01495195|DRUG|High-dose donepezil|Donepezil titrated to 22.5 mg daily
223843780|NCT01495195|DRUG|Low-dose donepezil|Donepezil titrated to 10 mg daily
223843781|NCT01495195|DRUG|Selegiline|Transdermal selegiline, 6 mg daily
223843782|NCT01495195|DRUG|Placebo|microcrystalline cellulose
223843783|NCT01687270|DRUG|Sofosbuvir|Sofosbuvir 400 mg tablet administered orally once daily
223843784|NCT01687270|DRUG|RBV|Ribavirin (RBV) 200-mg tablet(s) administered orally in a divided daily dose starting at 400 mg, subsequently adjusted (range: 200 to 1200 mg in a divided daily dose) based upon a number of factors including hemoglobin value, creatinine clearance, and weight.
223843785|NCT05094115|BEHAVIORAL|Psychological Flexibility Training (PFT)|"A 2-day workshop lasting approximately 8 hours per day. Day 1: an overview of the training and to describe the posture or stance that prepares one to respond to challenging situations in a psychologically flexible manner.~Day 2: identifies common coping strategies that typically fail or even backfire over the long term and to practice skills that promote psychological flexibility. Experiential exercises will be integrated throughout the training.~Following the PFT, 4 optional, monthly, one-hour booster sessions to supply refresher information.~* An experiential exercise to highlight one or more process/concept that was introduced during the 2-day training.~* Questions from the attendees about applying the concepts in their lives.~* Comments and questions from the booster session facilitators to encourage application of the concepts."
223843786|NCT05349084|DIAGNOSTIC_TEST|PET-cCTA-cFFR|patients presenting with stable angina and a moderate pretest likelihood for CAD who are already scheduled to undergo ICA for the clinical indication of angina will be recruited to undergo PET-cCTA-cFFR
223843787|NCT03307746|DRUG|Varlilumab|"Rituximab is a so-called direct-targeting mAb, which binds to the CD20 molecule on the surface of normal and malignant B cells. The mAb then engages immune effectors cells, such as macrophages, through Fc:Fc gamma receptor interaction, leading to tumour cell killing by antibody directed cellular cytotoxicity and/or phagocytosis (ADCC/ADCP).~Varlilumab (1F5, CDX-1127) is a recombinant and fully human IgG1kappa mAb that binds to human CD27 with high affinity (62). As far as we are aware, it is the only anti-CD27 mAb in clinical development. Once bound, varlilumab blocks CD70 binding to CD27."
223843788|NCT00165360|DRUG|Temozolomide|Given once daily for 49 days followed by 28 days with no drug for a maximum of a year and a half
223843789|NCT01719120|BEHAVIORAL|Cognitive-Behavioral Therapy|CBT for insomnia aims at changing dysfunctional cognitive beliefs and maladaptive behaviors contributed to the maintenance of insomnia. It involves 4 main components including behavioral, cognitive, educational, and relaxation treatments.
223843790|NCT04643249|DRUG|KL1333|Tablet
223843791|NCT04643249|DRUG|Flurbiprofen|Tablet
223843792|NCT04643249|DRUG|Dextromethorphan|Syrap
223843793|NCT04643249|DRUG|Bupropion|Tablet
223843794|NCT04643249|DRUG|Midazolam injection|solution for injection
223843795|NCT04643249|DRUG|Omeprazole|Capsule
223843796|NCT04643249|DRUG|Caffeine|Tablet or capsule
223843797|NCT04643249|DRUG|Repaglinide|Tablet
223843798|NCT02865434|DRUG|Tc99m-tilmanocept|Tilmanocept is a radiotracer that accumulates in macrophages by binding to a mannose binding receptor that resides on the surface.
223843799|NCT02865434|PROCEDURE|SPECT Imaging (60 Minutes post-injection)|Subjects enrolled in Groups 1-9 will receive whole body planar SPECT imaging with 3D SPECT or SPECT/CT for targeted joints of interest 60 Minutes post-injection.
223843800|NCT02865434|PROCEDURE|SPECT Imaging (180 Minutes post-injection)|Subjects enrolled in Groups 1-9 will receive whole body planar SPECT imaging with 3D SPECT or SPECT/CT for targeted joints of interest 180 Minutes post-injection.
223843801|NCT02865434|PROCEDURE|Whole body planar SPECT imaging (15 Minutes post-injection)|Subjects enrolled in Groups 10-11 will receive a whole body planar SPECT scan performed 15 minutes post-injection for dosimetry.
223843802|NCT02865434|PROCEDURE|Whole body planar SPECT imaging (60 Minutes post-injection)|Subjects enrolled in Groups 10-11 will receive a whole body planar SPECT scan performed 60 minutes post-injection for dosimetry.
223843803|NCT02865434|PROCEDURE|Whole body planar SPECT imaging (180 Minutes post-injection)|Subjects enrolled in Groups 10-11 will receive a whole body planar SPECT scan performed 180 minutes post-injection for dosimetry.
223843804|NCT02865434|PROCEDURE|Whole body planar SPECT imaging (18-20 Hours post-injection)|Subjects enrolled in Groups 10-11 will receive a whole body planar SPECT scan performed 18-20 Hours post-injection for dosimetry.
223843805|NCT02865434|PROCEDURE|Blood Collection for PK Testing (15 Mins Before Injection)|Blood will be collected for subjects enrolled in Groups 10-11 for the purpose of PK analysis within 15 minutes prior to administration of Tc 99m tilmanocept
223843806|NCT02865434|PROCEDURE|Blood Collection for PK Testing (after injection)|Blood will be collected for subjects enrolled in Groups 10-11 for the purpose of PK analysis immediately following administration of Tc 99m tilmanocept (00:00)
223843807|NCT02865434|PROCEDURE|Blood Collection for PK Testing (15 minutes post injection)|Blood will be collected for subjects enrolled in Groups 10-11 for the purpose of PK analysis at 15 ± 5 minutes post injection of Tc 99m tilmanocept
223843808|NCT02865434|PROCEDURE|Blood Collection for PK Testing (60 minutes post injection)|Blood will be collected for subjects enrolled in Groups 10-11 for the purpose of PK analysis at 60 ± 15 minutes post injection of Tc 99m tilmanocept
223843809|NCT02865434|PROCEDURE|Blood Collection for PK Testing (180 minutes post injection)|Blood will be collected for subjects enrolled in Groups 10-11 for the purpose of PK analysis at 180 ± 15 minutes post injection of Tc 99m tilmanocept
223843810|NCT02865434|PROCEDURE|Blood Collection for PK Testing (18-20 hours post injection)|Blood will be collected for subjects enrolled in Groups 10-11 for the purpose of PK analysis at 18-20 hours post injection of Tc 99m tilmanocept
223843811|NCT02865434|PROCEDURE|Planar Image with both Hands in Field of View|Subjects in Groups 1-9 and Groups 10 and 11 will receive planar imaging with both hands in the field of view at 60 and 180 minutes post-injection.
223843812|NCT05407363|PROCEDURE|ABB and ATG with simultaneous implant placement|Ridge augmentation using ABB and ATG as a graft material with simultaneous implant placement
223843813|NCT05407363|PROCEDURE|XBB and ATG with simultaneous implant placement|Ridge augmentation using XBB and ATG as a graft material with simultaneous implant placement
223843814|NCT05407363|PROCEDURE|ABB and ABG with simultaneous implant placement|Ridge augmentation using ABB and ABG as a graft material with simultaneous implant placement
223843815|NCT02689271|OTHER|MRI|VERDICT diffusion-weighted microstructure imaging sequence
223843816|NCT03887962|DEVICE|Virtual Environment Biofeedback|Treadmill walking. Modified available technology for gait capture. Tailored software for virtual environment rendering and immersive qualities
223843817|NCT03887962|DEVICE|Treadmill walking with no Virtual Environment Biofeedback|Treadmill walking. Flat screen / no virtual environment to act as attentional control.
223843818|NCT00067145|BEHAVIORAL|Face-to-face maintenance program|
223843819|NCT00067145|BEHAVIORAL|Internet maintenance program|
223843820|NCT00508976|DRUG|Injected bupivacaine post-operatively|Patients will receive 30 ml of 0.9% normal saline divided equally and injected prior to port site incision, then 10ml of 0.9% normal saline streamed via port directed at operative field, then 10ml of 0.9% normal saline aerosolized into the coelomic cavity prior to deflation, and our current standard of care, which is 30ml of 0.5% bupivacaine, divided equally between the five port-sites, injected at the end of the operation.
223843821|NCT00508976|DRUG|Streamed bupivacaine versus streamed normal saline|Patients will receive 30ml of 0.9% normal saline divided equally and injected prior to port site incisions, then 10ml of 0.5% bupivacaine streamed via port directed at operative field, then 10ml of 0.9% normal saline aerosolized into the coelomic cavity prior to deflation and our current standard of care, which is 30ml of 0.5% bupivacaine, divided equally between the five port-sites, injected at the end of the operation.
223843822|NCT00508976|DRUG|Aerosolized bupivacaine versus aerosolized saline|Patients will receive 30 ml of 0.9% normal saline divided equally and injected prior to port site incision, then 10ml of 0.9% normal saline streamed via port directed at operative field, then 10ml of 0.5% bupivacaine aerosolized into coelomic cavity prior to deflation and our current standard of care, which is 30ml of 0.5% bupivacaine, divided equally between the five port-sites, injected at the end of the operation.
223843823|NCT00508976|DRUG|Injected lidocaine pre-incision vs saline pre-incision|Patients will receive 30ml of 1% lidocaine divided equally and injected prior to port site incisions, then 10ml of 0.9% normal saline streamed via port directed at operative field, then 10ml of 0.9% normal saline aerosolized into the coelomic cavity prior to deflation and our current standard of care, which is 30ml of 0.5% bupivacaine, divided equally between the five port-sites, injected at the end of the operation.
223843824|NCT03670381|OTHER|Psychiatric diagnosis|
223843825|NCT01004263|DRUG|rizatriptan benzoate|Single dose of 5 mg or 10 mg orally disintegrating tablet at onset of migraine attack
223843826|NCT06143020|PROCEDURE|Erector spinae plane block|In the ESPB group, the patients were placed in the lateral decubitus position. The ultrasound probe was located in longitudinal orientation at the level of the T4 spinous process and then placed 3 cm laterally from the midline to the side involved in the surgery. The ultrasound landmarks, T4 transverse process, and the overlying trapezius, rhomboideus, and erector spinae muscles, were identified. Under aseptic conditions, an 80-mm 21-gauge block needle was inserted in-plane at an angle of 30-40° in the cranial-to-caudal direction until the tip contacted the T4 transverse process.After the hydrodissection with 2-3 mL of isotonic saline solution confirmed the correct needle tip position, the intermixture was injected in the interfascial plane between rhomboideus major and erector spinae muscle. Local anesthetic spread in a fascial longitudinal pattern deep to the erector spinae muscle was visualized using ultrasound guidance.
223843827|NCT02861261|DRUG|1. Berberine hydrochloride tablets ; 2. ProMetS probiotics powder|"1. 0.6g (6 pills) of Berberine tablets administered twice a day orally before meal ;~2. 4g (2 strips) of ProMetS probiotics powder administered orally every night"
223843828|NCT02861261|DRUG|1. Berberine placebo tablets ; 2. ProMetS probiotics powder|"1. 6 pills of Berberine placebo tablets administered twice a day orally before meal;~2. 4g (2 strips) of ProMetS probiotics powder administered orally every night"
223843829|NCT02861261|DRUG|1. Berberine hydrochloride tablets; 2. Probiotics placebo powder|"1. 0.6g (6 pills) of Berberine tablets administered twice a day orally before meal;~2. 2 strips of probiotics placebo powder administered orally every night"
223843830|NCT02861261|DRUG|1. Berberine placebo tablets; 2. Probiotics placebo powder|"1. 6 pills of Berberine placebo tablets administered twice a day orally before meal;~2. 2 strips of probiotics placebo powder administered orally every night"
223843831|NCT04679883|DRUG|5% GLH8NDE|5% GLH8NDE as eye drops
223843832|NCT04679883|DRUG|Placebo|Placebo as eye drops
223843833|NCT06043804|OTHER|Doppler ultrasound measurement of changes in uterine artery blood flow|Doppler ultrasound measurement of changes in uterine artery blood flow
223843834|NCT00936013|DRUG|oseltamivir|75mg p.o Bid for 5 days
223843835|NCT00936013|DRUG|oseltamivir and chinese medicinal herbs|oseltamivir: 75mg p.o bid for 5 days chinese medicinal herbs:200ml p.o qid for 5 days
223843836|NCT02444442|DEVICE|Renal Denervation|Deliberate disruption of the renal nerves via radio frequency energy delivery to renal arteries.
223843837|NCT02444442|OTHER|Sham control|Arterial access only. No delivery of radio frequency energy to renal arteries.
223843838|NCT05791721|DRUG|Etoricoxib 90 Mg Oral Tablet|Intervention will be applied one hour before surgical extraction of impacted mandibular third molar
223843839|NCT05791721|DRUG|Dexamethasone 4mg|Intervention will be applied one hour before surgical extraction of impacted mandibular third molar
223843840|NCT03500705|DEVICE|Mirror Therapy|Mirror Therapy involved the patient sitting on a chair at a table with a standard mirror placed on the table in the mid-sagittal plane between both arms, with the reflective side of the mirror facing the non-affected arm. The patient is instructed to observe the reflection of the non-affected arm during the sessions. The patient was not given any instruction on the use of the affected arm.
223843841|NCT03500705|OTHER|Cross-Education of Strengthening.|Cross-education of strengthening involves training one side of the body with the intention of producing strengthening gains on both sides of the body. In this case the strengthening was done on the non-affected arm of each stroke patient.
223843842|NCT02810561|OTHER|No Intervention|No intervention was completed with this study.
223843843|NCT03528135|BEHAVIORAL|Project PRIDE|See arms section.
223843844|NCT02635061|DRUG|ACY-241|Specified dose on specified days
223843845|NCT02635061|DRUG|Nivolumab|Specified dose on specified days
223843846|NCT03247062|OTHER|Quality improvement - sleep bundle|implementation of a sleep bundle
223843847|NCT04534855|DRUG|Treprilimab|Treprilimab 240mg Q3W until progression or unacceptable toxicity
223843848|NCT02150044|DEVICE|Acclarent Tympanostomy Tube Delivery System (TTDS).|tympanostomy tube delivery system
223843849|NCT03756194|DEVICE|Socially-assistive Pepper robot with a CARESSES cultural competence solution|"Week 1. On the first day, training will be provided to the participants enabling them to familiarise themselves with the robot's functionalities. The robot will be culturally aware i.e., it will be aware of the participants' cultural background prior to the testing commencing. As such, it will pre-load the appropriate CKB and apply this during its time with the participants. During the next two sessions, the robot will interact and provide culturally-competent assistance, however, it will not learn and adjust to the participants' individual cultural values and preferences.~Week 2. The participants will again utilize the robot for three days, but it now will learn from the responses it receives from them, consequently interacting in a culture-specific personalised way."
223843850|NCT03756194|DEVICE|Socially-assistive control Pepper robot with an alternative CARESSES solution|"Week 1. On the first day, training will be provided to the participants enabling them to familiarise themselves with the robot's functionalities. During the next two sessions, the CARESSES control robot will not be culturally aware: it will pre-load a generic and more limited CKB that is not tailored for anyone's cultural profile. It will also not learn and adjust to the participants' values and preferences.~Week 2. Participants will again utilize the robot for three days, but the CARESSES control robot will now be configured to be able to learn and adapt to the individual's particular profile. This robot's learning will not include propagation: improving its cultural knowledge base in one area will not also automatically lead to knowledge improvements in other related areas. This robot will possess the same full suite of functions as the CARESSES robot although will be less likely to offer these in a culturally appropriate way."
223843851|NCT05366387|DEVICE|intrapulmonary percussive ventilation|Intrapulmonary percussive ventilation is a non invasive ventilation technique where small boli or air are delivered, at adjustable frequency and pressure, to the upper airways though a mouthpiece. IPV is currently used in the clinic to aid with airway clearance in neuromuscular and airway diseases.
223843852|NCT05366387|RADIATION|delivery of 99mTc-DTPA aerosol|A 99mTc-DTPA aerosol (500 MBq+/-20%, 3 ml volume) is generated with a jet nebuliser (MMAD 4 µm). The aerosol is inhaled by the study subject and lung deposition is imaged by SPECT
223843853|NCT00958009|DEVICE|Rebidose®|The device is a ready to use single use auto injector containing Rebif® 44 mcg in a 0.5 mL prefilled syringe for sc injection
223843854|NCT01581853|DRUG|Lopinavir/ritonavir 800 mg / 200mg|Lopinavir/ritonavir 800 mg / 200mg will be change from its approved posology (2 times daily)to once daily in patients with undetectable viral load and in stable treatment with Lopinavir/ritonavir 800 mg / 200mg in monotherapy for at least 6 months
223843855|NCT01223859|PROCEDURE|Interstitial soft palate surgery|Soft palate RF surgery in local anaesthesia
223843856|NCT06294951|DIAGNOSTIC_TEST|fMRI|The fMRI is acquired using a Siemens 3.0T MRI scanner. BOLD functional images are scanned using an echo planar imaging (EPI) sequence. The scanning parameters are: TR=2s, matrix size of 64\*64, number of layers=30, layer thickness=3.75\*3.75\*4.5mm, and bottom-up interval scanning. A total of 540 whole brain functional images are acquired.
223843857|NCT00353145|DRUG|Gemcitabine (Gemox)|1000 mg/m\^2, infused at 10 mg/m\^2/min on Day 1 repeated every 14 days (one cycle).
223843858|NCT00353145|DRUG|Oxaliplatin|100 mg/m\^2 by vein infused on Day 2 over two hours, repeated every 14 days (one cycle).
223843859|NCT00353145|BEHAVIORAL|Questionnaire|Quality of Life Surveys
223843860|NCT04166461|OTHER|Not application, observational study|Not application, observational study
223843861|NCT05420662|PROCEDURE|Manipulation of vagina during abdominal hysterectomy operation|The manipulator applied vaginally prevents unnecessary vaginal length loss by ensuring that the vaginal cuff is cut from the top point.
223843862|NCT05420662|PROCEDURE|Classical conventional abdominal hysterectomy operation|Classical conventional abdominal hysterectomy operation without any manipulation from the vagina.
223843863|NCT00527085|DRUG|AMG 073|30 mg QD orally 50 mg QD orally 70 mg QD orally 90 mg QD orally 120 mg QD orally 180 mg QD orally
223843864|NCT00527085|DRUG|Placebo|30 mg QD orally 50 mg QD orally 70 mg QD orally 90 mg QD orally 120 mg QD orally 180 mg QD orally
223843865|NCT00558753|DRUG|pregabalin|PO pregabalin 300 mg 2 hours prior to surgery, and 150 mg twice a day for 10 postoperative days. Pregabalin will be tapered to 75 mg twice daily between days 11 to 12 and then to 50 mg twice daily between days 13 to 14 post operatively and then stopped.
224264926|NCT04194801|DRUG|Phase Ib: Fisogatinib (BLU-554) 600mg in combination with Sugemalimab (CS1001) 1200mg|Phase Ib: participants received 600 mg Fisogatinib (BLU-554) QD, in combination with 1200mg fixed dose Sugemalimab (CS1001) Q3W. Every 21 days (3 weeks) will be considered as one cycle.
224264927|NCT04194801|DRUG|Phase II: Fisogatinib (BLU-554) 600mg in combination with Sugemalimab (CS1001) 1200mg|Phase II: participants received 600 mg Fisogatinib (BLU-554) QD, in combination with 1200mg fixed dose Sugemalimab (CS1001) Q3W. Every 21 days (3 weeks) will be considered as one cycle.
224264928|NCT01942239|DEVICE|real time continuous glucose monitoring|
224264929|NCT03827395|BIOLOGICAL|HEV 239|Hepatitis E vaccine against HEV genotypes 1 and 4. The HEV 239 vaccine is a 26 kDa recombinant polypeptide corresponding to amino acid residues 368-606 of the capsid protein of a genotype 1 HEV strain. The vaccine is expressed in Escherichia coli (E. coli) and vaccine doses contain 30 µg of the purified antigen in 0.5 mL buffered saline adsorbed to 0.8 mg aluminium hydroxide.
224264930|NCT03827395|OTHER|Placebo|0.9% Sodium Chloride Injection, USP (Normal Saline) is a sterile, nonpyrogenic, isotonic solution of sodium chloride and water for injection (WFI). Each mL contains sodium chloride 9 mg and may contain HCl or NaOH for pH adjustment (pH 5.3 \[4.5 - 7.0\]).
224264931|NCT04267692|OTHER|HaRTC|HaRT-C participants will attend 8, virtual, adapted, low-barrier, weekly, closed-group Talking Circles-- named Harm Reduction Treatment Circles or HaRTC -- lasting approximately 2 hours each. During the HaRTC, the circle keeper will present the day's harm reduction topic, smudge the space, and allow participants to open themselves up to the circle. Topics presented by the Circle Keeper focus on harm-reduction and improving overall quality of health. Abstinence from alcohol use is not a requirement. We will not limit participants' access to treatment or services in either arm.
224264932|NCT01923740|DEVICE|XIENCE V EECSS|Subjects receiving XIENCE V
224264933|NCT01923740|DEVICE|Absorb BVS System|Subjects receiving Absorb BVS System
224264934|NCT00005040|DRUG|arsenic trioxide|
224264935|NCT05324033|RADIATION|multiparametric MRI on the bladder|comparison between mpMRI and histopathology
224264936|NCT05324033|PROCEDURE|diagnostic cystoscopy +/- TURBT|conventional way of diagnosis
223843866|NCT00558753|DRUG|Placebo|Placebo for Given 2 hours prior to surgery, and twice a day for 14 postoperative days.
223843867|NCT04058314|DEVICE|Gemini IV|Eyes randomized to receive the Gemini IV device will receive the study device in conjunction with an approved monofocal or toric IOL post cataract extraction
223843868|NCT04058314|DEVICE|Control Eye|Control eyes will receive an approved monofocal or toric IOL post cataract extraction
223843869|NCT04056104|DIAGNOSTIC_TEST|SpO2 and PIx Measurement|Right upper and any lower extremity oxygen saturation (SpO2) and perfusion index (PIx) will be measured
223843870|NCT05649579|DRUG|Dupilumab|Duplimab was administered according to the guidelines of the atopic dermatitis treatment regimen, which involved the first dose of 600 mg followed by 300 mg every two weeks. Because of comorbidities or the side effects of corticosteroid, some patients used dupilumab in the initial course of treatment, while others added dupilumab when the traditional drugs proved ineffective. The discontinuation was a joint decision between treating dermatologists and patients. Concomitant medicine was decided by clinicians, depending on the assessing of disease status and patients' choices, and reduced according to international guidelines.
223843871|NCT03599115|BEHAVIORAL|Inhibitory Control Training|Computerized go/no-go task where individuals make responses to certain items (go trials) and withhold responses from certain items (no-go trials, in this case, trials surrounded by a black box). Intervention is designed to target and improve inhibitory control cognitive mechanisms in general (generic arm) or towards high-calorie foods specifically (food arm).
223843872|NCT04805151|OTHER|No intervention|No intervention
223843873|NCT00686621|DRUG|Posaconazole|Posaconazole oral suspension 400 mg twice daily with meal or nutritional supplement. Alternatively, if meal or nutritional supplement is not tolerated, posaconazole should be administered at a dose of 200 mg four times a day.
223843874|NCT02353611|OTHER|6% hydrogen peroxide|
223843875|NCT02353611|OTHER|35% hydrogen peroxide|conventional peroxide whitening compound acted like control
223843876|NCT01293162|DRUG|Armolipid Prev|Ortosiphon 300 mg/die, CoQ10 15 mg/die, Berberine 500 mg/die, red yeast 60 mg/die, policosanol 10 mg/die, Folic acid 200 mg/die
223843877|NCT03351829|GENETIC|Gene-modified autologous stem cells|1 infusion for 5x10\^6\~1x10\^7 gene-modified cells; or more infusions depending on the circumstances
223843878|NCT01605136|DRUG|Afamelanotide|One 16mg subcutaneous implant every 2 months for 6 months.
223843879|NCT01605136|DRUG|Placebo|One placebo subcutaneous implant every 2 months for 6 months
223843880|NCT01072929|DRUG|Armodafinil|Doses of either 150mg/day or 200 mg/day in tablet form taken orally, once daily in the morning.
223843881|NCT01072929|DRUG|Placebo|Matching Placebo, also in tablet form taken orally, once daily in the morning.
223843882|NCT00800371|PROCEDURE|intra-articular steroid injection|Steroid injection into otherwise noncontrollable arthritis.
223843883|NCT00019318|DRUG|romidepsin|
223843884|NCT01101906|DRUG|OSI-906|OSI-906 administered orally
223843885|NCT01101906|DRUG|Placebo|Matching placebo administered orally
223843886|NCT06640894|OTHER|MegaPower training|See arm/group descriptions
223843887|NCT06640894|OTHER|Usual Care|See arm/group descriptions
223843888|NCT05935267|PROCEDURE|thoracic irrigation|We will start this study using 20% as the approximate national intervention rate, based on current literature, with the goal of detecting a 50% reduction in the experimental arm (i.e. 10% secondary intervention rate after thoracic irrigation). Therefore, we will plan to enroll 108 patients in the irrigation cohort and 324 patients in the control cohort. An interim analysis will be conducted once 54 patients have been enrolled in the irrigation cohort. The secondary intervention rate in the irrigation cohort and the standard cohort will be determined, and any adjustments to sample size will be made at that time.
223843889|NCT05328505|RADIATION|Image-guided Radiotherapy|de-escalation radiotherapy to elective volumes + simultaneous integrated boost to PSMA avid lesions delivered in 20 fractions +/- ADT (clinical decision). The elective prostate bed and pelvic lymph node regions will receive 45 Gy. The PSMA-avid lymph node(s) will receive an SIB to 55-60 Gy and/or the PSMA-avid lesion in the prostate bed will receive an SIB to 60 Gy. Pelvic nodal treatment and ADT use will be left to the discretion of the treating physician.
223843890|NCT06015646|BEHAVIORAL|Personalized lifestyle coaching and educational handout|Participants will receive a one-page educational handout on strategies to minimize fatigue at the beginning of the study. Participants will also receive a 30-minute focused, personalized lifestyle coaching within a week of the initial overnight shift. The lifestyle coach will be in close contact during the night shifts.
223843891|NCT06015646|BEHAVIORAL|Handout|Participants will receive a one-page educational handout on strategies to minimize fatigue at the beginning of the study
223843892|NCT04824131|DRUG|Oral cabotegravir (CAB)|30 mg tablets
223843893|NCT04824131|DRUG|CAB LA|Administered as one 3 mL (600 mg) IM injection in the gluteal muscle at two time points 4 weeks apart and every 8 weeks thereafter
223843894|NCT04824131|DRUG|Oral tenofovir disoproxil fumarate/emtricitabine (TDF/FTC)|300 mg/200 mg fixed-dose combination tablets
224264937|NCT06562647|DRUG|SY001|PBMC-derived anti-mesothelin Cheimeric Antigen Receptor macrophages
224264938|NCT00294047|BIOLOGICAL|Cervarix|Subjects were planned to receive three doses of the study vaccine administered intramuscularly according to a 0, 1, 6 month vaccination schedule.
224264939|NCT00294047|BIOLOGICAL|Placebo control|Subjects were planned to receive three doses of the control vaccine administered intramuscularly according to a 0, 1, 6 month vaccination schedule.
224264940|NCT01689077|OTHER|Therapeutic hypothermia|Mild therapeutic hypothermia with a target temperature of 33 degrees Centigrade for 24 or 48 hours
224264941|NCT04418297|DRUG|CT-G20|oral tablet
224264942|NCT04418297|DRUG|Placebo|oral tablet
224264943|NCT00080392|DRUG|DNA Plasmid Vector|
224264944|NCT00080392|DRUG|EW-A-401 DNA Plasmid Vector|
224264945|NCT03110991|BEHAVIORAL|Multicomponent Cognitive Behavioral Intervention administered via a smartphone App (CCIA)|Multicomponent Cognitive Behavioral Intervention administered via a smartphone App (CCIA)
224264946|NCT03110991|BEHAVIORAL|Multicomponent Cognitive Behavioral Intervention administered via a smartphone App+ telephone contact via conference call (CCIA+CC)|Multicomponent Cognitive Behavioral Intervention administered via a smartphone App+ telephone contact via conference call (CCIA+CC)
224264947|NCT00538031|DRUG|cyclophosphamide|Given orally
224264948|NCT00538031|DRUG|celecoxib|Given orally
223843895|NCT05895630|BEHAVIORAL|Interactive physical exercise|Interactive remote sessions of physical exercise in groups of 10 patients. The sessions are categorized by level 1, 2 or 3 and the allocation to this level is decided according to a decision tree taking into account the mobility profile (balance and cardiomuscular health). The intervention will last 12 weeks. The sessions will be delivered 3 times per week (Monday, Wednesday, Friday) offering a total of approximately 180 min/week.
223843896|NCT05895630|BEHAVIORAL|Video physical exercise|Individual remote sessions of physical exercise based on pre-recorded videos. The video sessions are categorized by level 1, 2 or 3 and the allocation to this level is decided according to a decision tree taking into account the mobility profile (balance and cardiomuscular health). The videos will be delivered 3 times per week (Monday, Wednesday, Friday) offering a total of approximately 180 min/week.
223843897|NCT06577857|DEVICE|Inferonasal Minimally Invasive Micro Sclerostomy|The Inferonasal MIMS® procedure uses the proprietary MIMS® device, which creates a sclerostomy in the inferonasal quadrant of the eye.
223843898|NCT06522867|OTHER|Intraocular pressure measure|The intraocular pressure of the subjects using either the Goldmann applanation tonometer, Icare or Accupen. The order of the measure is randomized.
223843899|NCT03549988|OTHER|Fecal Calprotectin (FC) measurements with IBDocTM|"Each IBDocTM kit measure one fecal calprotectin value. The IBDoc® is an in-vitro diagnostic immunoassay analyzed by a downloadable smartphone application (CalApp®). A patient is able to process their stool at home using a test cassette.~The IBDocTM test results are displayed in a light signal system as three titre categories; normal \<100 µg/g (green), 100-300 µg/g (yellow), \>300 µg/g (high). Patients' results will be sent directly to the central research coordinator through the IBDoc® Web Portal. If the FC is \>250 µg/g a second FC will be performed within 2 weeks. If this result is \<250 µg/g patients will continue to monitor their FC every 2 months. If the second result is \>250 µg/g, the attending physician will review the patient either by telephone or in the office within 7 days."
223843900|NCT04887285|DEVICE|Virtual reality|Subjects in the virtual reality group will be offered a variety of immersive environments to choose from (mountains, beach, rainforest and temperate forest) in addition to local anesthetic.
223843901|NCT04887285|DRUG|Intravenous sedation|Sedation will be administered using low-dose midazolam and/ or fentanyl. We will use a wide range of dosing (1-5 mg for midazolam, up to 150 mcg for fentanyl) to maximize generalizability and account for widespread variability in clinical circumstances, medical practice and patient response (personalized medicine). Sedation will be titrated to effect by a board-certified or eligible anesthesiologist so that patients remain responsive to verbal stimuli.
223843902|NCT04887285|OTHER|Standard care|Patients will receive superficial local anesthetic with 1% lidocaine. Local anesthetic will be administered by the physician performing the procedure titrated to patient comfort.
223843903|NCT04640571|DRUG|pravastatin and chenodeoxycholic acid, after metformin and placebo|single oral dose of pravastatin 80 mg and chenodeoxycholic acid 250 mg
223843904|NCT04640571|DRUG|valacyclovir, chenodeoxycholic acid, and enalaprilat, after polysorbate 80 and placebo|single oral dose of valacyclovir 500 mg, chenodeoxycholic acid 250 mg, and enalaprilat 20 mg
223843905|NCT04515797|DRUG|Glecaprevir and Pibrentasvir|4 weeks of treatment starting within 24 hrs of kidney transplant
223843906|NCT06298032|DRUG|Olamkicept Part A|"Intravenous infusion. Single dose.~Part A consists of 3 different doses~* 1200 mg~* 1800 mg~* 2400 mg"
223843907|NCT06298032|DRUG|Olamkicept Part B|"Intravenous infusion. Multiple doses.~Part B consists of 3 different doses.~* 1200 mg~* 1800 mg~* 2400 mg"
223843908|NCT06298032|DRUG|Placebo|Intravenous infusion
223843909|NCT06431022|BEHAVIORAL|webSTAIR|WebSTAIR is a self-paced, brief skills-focused treatment for PTSD that focused on improving one's ability to manage emotions and relationships.
223843910|NCT06431022|BEHAVIORAL|CHW coaching|CHWs will provide webSTAIR coaching, which includes motivational, problem solving, and cognitive-behavioral strategies to enhance skills practice and engagement.
223843911|NCT06268301|DRUG|Budesonide|Budesonide oral suspension
223843912|NCT05408455|OTHER|EMST150 (Expiratory muscle training)|Respiratory exercise device (Expiratory muscle trainer) developed for the expiratory muscles, and resistant expiratory muscle training were applied. Threshold loading was applied to the cases at approximately 30% of the respiratory muscle strength values measured in the 1st week. In respiratory muscle training, the pressure value was increased according to the tolerance of the patient and training was given at a pressure value between 50-75%. The subjects were asked to do 10 vigorous expirations at the adjusted pressure value by doing normal inspiration for expiratory muscle training in a comfortable sitting position. This program was applied in 3 sets in the same way for approximately 30 minutes. It was continued 3 days a week for 8 weeks
223843913|NCT05408455|OTHER|Sham EMST150 (Expiratory muscle training)|The subjects were asked to perform normal inspiration and then exhale 10 times for expiratory muscle training without threshold loading. This program was applied in 3 sets in the same way for approximately 30 minutes. It will continue 3 days a week for 8 weeks
223843914|NCT06068153|DRUG|Sotorasib|Sotorasib is administered at a dose of 960 mg (8x 120 mg) orally, once daily until progression or unacceptable toxicity.
224264949|NCT03444792|PROCEDURE|mechanical dilatation of the cervix|"the surgeon will perform the cervical dilatation by inserting the double-gloved index ﬁnger into the cervical canal of the patients after the extraction of placenta and membranes. The outer glove will be removed after this procedure.~\- If failed the surgeon will use artery forceps to dilate cervix"
224264950|NCT01862601|DEVICE|JetTouch Needle-free injection system|Needle-free injection system believed to provide consistent and reliable delivery of material to the bladder wall.
224264951|NCT02063139|DRUG|Flutiform 50/5 ug (2 puffs bid) pMDI|
224264952|NCT02063139|DRUG|Fluticasone 50 ug (2puffs bid) pMDI|
224264953|NCT02063139|DRUG|Beclometasone Autohaler 50 ug (2 puffs bid)|
224264954|NCT06404866|BEHAVIORAL|eMotion|Participants will complete one lesson per week. The weekly education is targeted to women and contains personalized content via a variety of diverse lesson narratives. Each week participants listen to scripted sessions they can complete on their own time regarding each of the weekly topics (lasting about 30 minutes). At the end of the week, they then meet individually with a study team member virtually to discuss the same subject.
224264955|NCT02393144|DEVICE|Transperineal ultrasonography, General Electric Healthcare Voluson Ultrasound System|Assessment of cervical dilatation, angle of progression and head position via transperineal ultrasonography
223843915|NCT06068153|DRUG|Lenvatinib|Lenvatinib is administered at a dose of 20 mg orally (2x 10 mg), once daily until progression or unacceptable toxicity.
223843916|NCT03934905|DRUG|sulforaphane|The participants will be dosed, based on weight, in a double-blind fashion with identical appearing placebo or sulforaphane caplets in a daily dose for 12 weeks of: two caplets for individuals \<100 lb., four caplets for individuals 100-200 lb. and eight caplets for individuals \>200 lb. Avmacol or placebo will be prescribed by Dr. Awasthi and will be dispensed by local pharmacy or study coordinators at TTUHSC/UMC Lubbock. We will be doing pill counts to make sure that volunteers have used as directed. We will measure the Sulforaphane level in plasma by well-established method.
223843917|NCT03934905|DRUG|Placebo Oral Tablet|The participants will be dosed, based on weight, in a double-blind fashion with identical appearing placebo or sulforaphane caplets in a daily dose for 12 weeks of: two caplets for individuals \<100 lb., four caplets for individuals 100-200 lb. and eight caplets for individuals \>200 lb. Avmacol or placebo will be prescribed by Dr. Awasthi and will be dispensed by local pharmacy or study coordinators at TTUHSC/UMC Lubbock. We will be doing pill counts to make sure that volunteers have used as directed. We will measure the Sulforaphane level in plasma by well-established method.
223843918|NCT05633771|OTHER|Hyrimoz|There is no treatment allocation. Patients administered Hyrimoz by prescription that have started as routine medical treatment will be enrolled.
223843919|NCT00525694|OTHER|Glucose tolerance test|10 ounces glucose tolerance test solution
223843920|NCT00525694|OTHER|glucose tolerance test solution|75 grams glucose load
223843921|NCT00525694|OTHER|Diet Coke|10 ounces of Diet Coke
223843922|NCT00525694|OTHER|Coke Zero|10 ounces of Coke Zero
223843923|NCT01827280|DRUG|Vildagliptin|Vildagliptin 50mg/pill will be administered at 10 AM and at 6 PM also for 30 days.
223843924|NCT02028975|OTHER|Measure the threshold of detection for linoleic acid|
223843925|NCT02028975|OTHER|Oral stimulation tests|
223843926|NCT02028975|OTHER|Venous blood samples|
223843927|NCT02028975|OTHER|Samples for genetic studies (ancillary study)|
223843928|NCT04349579|DRUG|Rifamycine|Local anesthesia was obtained using 2 ml articaine hydrochloride 40 mg/ml with epinephrine 0.01 mg/ml . The horizontal incision was made with no. 15 scalpel blade and a full thickness mucoperiosteal flap was raised. In all surgical procedures, bone removal and/or tooth sectioning were performed under sterile saline irrigation. Following the extraction, granulation tissues were removed, and bleeding was controlled. Finally, extraction socket was irrigated with the solution which contains 250 mg rifamycine and the mucoperiosteal flap was repositioned by 3.0 silk sutures.
223843929|NCT04349579|DRUG|Saline Solution|Local anesthesia was obtained using 2 ml articaine hydrochloride 40 mg/ml with epinephrine 0.01 mg/ml . The horizontal incision was made with no. 15 scalpel blade and a full thickness mucoperiosteal flap was raised. In all surgical procedures, bone removal and/or tooth sectioning were performed under sterile saline irrigation. Following the extraction, granulation tissues were removed, and post extraction cavity was irrigated with saline solution. After the bleeding was controlled, the mucoperiosteal flap was repositioned by 3.0 silk sutures.
223843930|NCT02635659|OTHER|Encapsulated nutrients|
223843931|NCT02635659|OTHER|Placebo|
223843932|NCT02783950|OTHER|Decipher Prostate Cancer Classifier|The Decipher test (GenomeDx Biosciences, San Diego, CA) is a genomic test that predicts high grade disease, the probability of metastasis and prostate cancer-specific mortality for men with prostate cancer.
223843933|NCT06370351|COMBINATION_PRODUCT|SENS-501 administration|Administration of SENS-501 with a dedicated administration system
223843934|NCT01723774|DRUG|PD0332991|
223843935|NCT01723774|DRUG|Anastrozole|
223843936|NCT01723774|DRUG|Goserelin|
223843937|NCT01723774|PROCEDURE|Surgery (standard of care)|-Breast and axillary lymph node surgery
223843938|NCT01723774|PROCEDURE|Tumor biopsy|
223843939|NCT06515184|DRUG|PharmaNord Bio-Quinone Active CoQ10 Gold 100mg|"Each participant receives one softgel three times a day. Arm 1 receives one 100mg softgel and two placebo softgels per day.~Because of the presence of the IND, the dropdown menu does not allow us to choose dietary supplement. The option drug was chosen as the closest permissible option."
223843940|NCT06515184|DRUG|PharmaNord Placebo|"Each participant receives one softgel three times a day. Arm 3 receives three placebo softgels per day. Supplement is taken orally in divided doses, with the last softgel not close to bedtime.~Because of the presence of the IND, the dropdown menu does not allow us to choose dietary supplement. The option drug was chosen as the closest permissible option."
223843941|NCT06515184|DRUG|PharmaNord Bio-Quinone Active CoQ10 Gold 100mg|"Each participant receives one softgel three times a day. Arm 2 receives three 100mg softgels per day. Supplement is taken orally in divided doses, with the last softgel not close to bedtime.~Because of the presence of the IND, the dropdown menu does not allow us to choose dietary supplement. The option drug was chosen as the closest permissible option."
223843942|NCT04672408|DEVICE|His bundle pacing|Pacing with capture of the His bundle
223843943|NCT04672408|DEVICE|Right ventricular pacing|Pacing from the right ventricular lead (septal or apical)
223843944|NCT02399995|BEHAVIORAL|HRQoL questionnaires.|"Questionnaires/Forms to be completed preoperatively in clinic with assistance from research study administrator:~* Baseline sociodemographic and clinical variable data sheet (RSA)~* EORTC QLQ-C30, QLQ-LMC21, EuroQoL EQ-5D-5L/VAS~* Baseline disease status and treatment assessment questionnaire Questionnaires/Forms to be completed at first postoperative clinic visit:~* EORTC QLQ-C30, QLQ-LMC21, EuroQoL EQ-5D-5L/VAS~Questionnaires/Forms to be mailed to patients at ± 2 month window at the following time points 6,12,18,24, and 36 months following hepatectomy:~* EORTC QLQ-C30, QLQ-LMC21, EuroQoL EQ-5D-5L/VAS~* Post surgical follow up disease status and treatment assessment questionnaire~* At 8 weeks following the mailing of the initial questionnaire package if no response has been received, research personnel will attempt to contact participants by phone."
223843945|NCT00739453|DRUG|OSI-906|administered orally
223843946|NCT00739453|DRUG|erlotinib|administered orally
223843947|NCT05417698|OTHER|Exercise Only (Ex only)|Unsupervised, home-based, equipment-free high-intensity interval training of 20 minutes exercise performed 3 times a week, for a duration of 8-weeks. Participants will perform exercises to their own suitability in a progressive manner throughout the 8-weeks. Exercises will be exerted at least ≥80% of predicted heart rate maximum (HRmax; 220-age) during the high-intensity intervals, as well as at least 17 out of 20 Rate of Perceived Exertion on the Borg Scale.
224264956|NCT02393144|DEVICE|Cardiotocography, Bionet FC1400 Fetal Monitor|Assessment of strength of uterine contractions (Montevideo units) and fetal heart rate (beat per minute) with electronic monitors.
224264957|NCT02393144|OTHER|Amniotomy|Artificial rupture of membranes to assess meconium staining and induce labor speed.
224264958|NCT02393144|DRUG|Analgesics, Opioid, Meperidine|Administration of meperidine for labor analgesia.
224264959|NCT02393144|DRUG|Labor augmentation, Oxytocin|Oxytocin infusion for augmentation of labor.
224264960|NCT02393144|DRUG|Labor induction, Oxytocin|Oxytocin infusion for induction of labor.
224264961|NCT02393144|DRUG|Cervical ripening, labor induction, Dinoprostone|Administration of dinoprostone pessary for cervical ripening and labor induction.
223843948|NCT05417698|OTHER|Exercise and Mediterranean Diet (Ex + MedDiet)|"Participants in Ex+MedDiet arm adhere to a non-caloric restrictive Mediterranean diet throughout the 8-weeks comprising of a diet encompassing a focus on minimally processed food, incorporating a wide variety of fruits, vegetables, legumes and wholegrains, whilst utilising olive oil as the main source of fat. They will be encouraged to eat more oily and white fish, with moderate consumption of nuts, poultry and dairy products, and low consumption of red/processed meat and alcohol.~Participants will also perform unsupervised, home-based, equipment-free high-intensity interval training of 20 minutes exercise performed 3 times a week, for a duration of 8-weeks. Participants will perform exercises to their own suitability in a progressive manner throughout the 8-weeks. Exercises will be exerted at least ≥80% of predicted heart rate maximum (HRmax; 220-age) during the high-intensity intervals, as well as at least 17 out of 20 Rate of Perceived Exertion on the Borg Scale."
223843949|NCT06302062|DRUG|Tumor Associated Lymph node T cell|At least one lymph sample is resected from each participant, then it is separated and cultured ex vivo to expand the population of Tumor Associated Lymph node T cells (FIT003 TAL-T). After lymphodepletion, patients are infused with FIT003 TAL-T.
223843950|NCT06302062|DRUG|cyclophosphamide|A one-day intravenous injection of cyclophosphamide was administered two days prior to the initial cell transfusion.
223843951|NCT06302062|DRUG|IL-2|The IL-2 treatment will be continued for 5 days.
223843952|NCT06302062|DRUG|Serplulimab Injection|In group B, Serplulimab Injection was injected before and after cell transfusion. If two cell transfusions were performed,Serplulimab Injection were given again .
223843953|NCT04058392|BIOLOGICAL|Camu Camu Capsules|Camu Camu powder encapsulated (500mg each). 2 capsules per day will be used for this study
223843954|NCT06351267|OTHER|Core Stability Exercises|Core stability exercises will be used to strengthen the core muscles, which includes sets of exercises like pelvic tilts, wall squatting, bridging, bird dog and heel walking which targets core muscles.
223843955|NCT06351267|OTHER|Back Strengthening exercises|Back strengthening exercises will be used to strengthen the back muscles which include sets of exercises that target back muscles like cat-cow exercise, child pose, heel sits, and kegels.
223843956|NCT03663712|BIOLOGICAL|Talimogene Laherparepvec|TVEC is an oncolytic, genetically modified virus designed to reproduce in tumor tissue and stimulate your immune system to attack the tumor cells
223843957|NCT05768555|OTHER|Whole body vibration intervention at 40 Hz|Whole body vibration intervention will be performed with the Power Plate Pro 5 device (Power Plate International, London, UK). Whole body vibration training will be performed at a frequency of 40 Hz. Individuals will perform; static squat, dynamic toe raise, static abduction and dynamic squat exercises in both hips on a vibrating platform. All exercises will consist of 45 seconds of vibration and 15 seconds of rest. Each exercise will be repeated three times. Total intervention time will be 15 minutes.
223843958|NCT05768555|OTHER|Whole body vibration intervention at 25 Hz|Whole body vibration intervention will be performed with the Power Plate Pro 5 device (Power Plate International, London, UK). Whole body vibration training will be performed at a frequency of 25 Hz. Individuals will perform; static squat, dynamic toe raise, static abduction and dynamic squat exercises in both hips on a vibrating platform. All exercises will consist of 45 seconds of vibration and 15 seconds of rest. Each exercise will be repeated three times. Total intervention time will be 15 minutes.
223843959|NCT05768555|OTHER|Whole body vibration intervention at 0 Hz|Whole body vibration intervention will be performed with the Power Plate Pro 5 device (Power Plate International, London, UK). Whole body vibration training will be performed at a frequency of 0 Hz. Individuals will perform; static squat, dynamic toe raise, static abduction and dynamic squat exercises in both hips on a vibrating platform. All exercises will consist of 45 seconds of vibration and 15 seconds of rest. Each exercise will be repeated three times. Total intervention time will be 15 minutes.
223843960|NCT05842343|OTHER|Stool sample|Purification by affinity of the IgA coated bacteria from a fecal solution. Genomic analysis of the bacteria for diversity and richness
223843961|NCT05842343|OTHER|Food intake evaluation|Measure (by survey) of food group intake for : lipids /proteins / fibers / carbohydrates
223843962|NCT04319094|BEHAVIORAL|PEERS|Peer mentors deliver depression care that include social support and coping skills, focused on goal setting and small behavioral changes.
223843963|NCT04319094|OTHER|Social interaction|Study staff will provide a combination of 8 social interaction visits and phone calls to the participants randomized to this condition.
223843964|NCT05112315|DEVICE|Predigraft|The Subject randomized to the Predigraft will benefit from Predigraft, a remote monitoring software that issues an alert to the investigator when the allograft survival prediction calculated by the iBox algorithm is decreasing. This follow-up is on top of the site's standard of care.
223843965|NCT05914324|DEVICE|Phefumla device|The Phefumla device uses the Motorola Moto G Power mobile phone. The device utilizes an Android 10 operating system and has 64 gigabyte memory with 4 gigabyte random access memory (RAM). The battery is a 5000 milliampere lithium polymer rechargeable battery, which should last at least 24 hours with minimal phone use. Data can be stored on the device and integration with information systems is planned. The reflectance sensor works on a variety of body parts including the finger, toe, and forehead.
223843966|NCT05914324|DEVICE|LB-01 device|The LB-01 probe uses transmissive oximetry with the light-emitting diode (LED) and photodetector (PD) positioned opposed to one another when placed on body tissues like fingers, and is used with the Acare pulse oximeter device. The LB-01 probe is an elongated clip sensor with an offset optics location near the hinge, permitting stable positioning on the child's big toe. By incorporating softer hollow silicone pads this design grasps the foot while placing the optics over the toe, to minimize movement artifact, an important issue for child measurements. The soft pads allow comfortable use across the smaller foot of neonates, and the design remains similar enough to a conventional finger sensor that it can be used on adult fingers as well.
223843967|NCT03969277|OTHER|Graded Motor Imagery|"The first stage of GMI includes laterality reconstruction. Patients will view and determine if the various images of body parts to image portrays the right or left side. The second stage targets activation of the primary motor cortex by imagine moving the involved body part. The final stage involves that the patient watches the unaffected body part moving in a mirror to trick the brain into thinking the affected body part is actually moving in a pain-free way. This will be applied for 6 weeks."
223843968|NCT03969277|OTHER|Standard Rehabilitation|Shoulder, elbow and wrist AROM exercises. Elbow flexion and extension, and wrist flexion and extension stretching exercises. Elbow and wrist strengthening exercises. Grip strengthening exercises. This will be applied for 6 weeks.
223843969|NCT03969277|OTHER|Home Exercise Program|Proprioception exercises for the elbow. Scapulothoracic strengthening exercises. This will be applied for 6 weeks.
223843970|NCT03969277|OTHER|Cold Application|Cold application around the elbow joint for 15 minutes in every session.
223843971|NCT00202397|DRUG|Riluzole|capsule-shaped 50 mg tablets bid for 8 weeks
223843972|NCT00202397|OTHER|placebo|capsule-shaped tablet bid for 8 weeks
223843973|NCT03057132|DEVICE|Cavilon Advanced Skin Protectant|Cavilon Advanced Skin Protectant
223843974|NCT06408246|DRUG|Guanfacine|Guanfacine immediate release is an established and safe FDA-approved treatment that acts directly by stimulating α2A adrenoceptors.
223843975|NCT06408246|DRUG|Sertraline|Sertraline is a well-tolerated FDA-approved antidepressant that is among the most widely prescribed medications for depression.
223843976|NCT05493371|DRUG|Empagliflozin 10 MG|10 mg once daily empagliflozin oral tablets for 12 weeks
223843977|NCT05211531|OTHER|Measuring number of post-operative steps|Measuring the number of post-operative steps that inpatients take.
223843978|NCT01016353|DEVICE|NPWT|ABThera Open Abdomen Negative Pressure Therapy System
223843979|NCT01016353|DEVICE|BVPT|Barker's Vacuum Packing Technique
223843980|NCT05018273|BIOLOGICAL|VB10.NEO|The personalized vaccine VB10.NEO vaccine is given in combination with the PD-L1 inhibitor atezolizumab.
223843981|NCT02518932|DRUG|Last 5 amino acids of GLP-1|To examine insulinomimetic properties of LVKGR
223843982|NCT02518932|DRUG|placebo saline|
223843983|NCT06010485|OTHER|Serial Casting|A short leg cast is applied to the serial casting group by an orthopedic specialist once every three days for three weeks.
223843984|NCT06010485|OTHER|Exercise|Stretching exercises, strengthening exercises, balance exercises, proprioception exercises, and heel walking exercises are applied to the physical therapy group for 3 weeks with a physiotherapist for 3 sessions a week.
223843985|NCT06330831|OTHER|Intensive, Group Based Constraint Induced Therapy (CIMT)|See arm description. Children who were in study 2 received two consecutive episodes of the intensive, group based CIMT intervention (episode 1 during the first summer, episode 2 during the following summer).
223843986|NCT02487446|DRUG|QVA149|QVA149 capsules for inhalation, delivered via QVA149 single dose dry powder inhaler (SDDPI)
223843987|NCT02487446|DRUG|Umeclidinium/vilanterol|Umeclidinium/vilanterol for inhalation, delivered via ELLIPTA® inhaler
223843988|NCT02487446|DRUG|Placebo (umeclidinium/vilanterol)|Matching Placebo to umeclidinium/vilanterol for inhalation, delivered via ELLIPTA® inhaler
223843989|NCT02487446|DRUG|Placebo (QVA149)|Matching Placebo to QVA149 capsules for inhalation, delivered via QVA149 SDDPI
224264962|NCT03431636|OTHER|immersion|cold water immersion
224264963|NCT03431636|OTHER|ice pack|ice packs through the body
224264964|NCT03431636|OTHER|rest|seated rest
224264965|NCT01891773|BEHAVIORAL|Inhaled steroids in school.|Morning dose of inhaled steroids given in school by school nurse instead of at home.
224264966|NCT03418753|DIAGNOSTIC_TEST|EyeBOX for ICP|non-invasive ICP Score algorithm using eye-tracking data from the EyeBOX(TM) device, which tracks the movement of the pupils over time
224264967|NCT04562935|OTHER|admission to pediatric intensive care with mechanical ventilation|admission to pediatric intensive care with mechanical ventilation
224264968|NCT05582967|OTHER|Completion of focused Electronic Case Report Form|All patients will have a focussed Electronic Case Report Form completed collecting information around Presenting complaint, Past Medical History, Family History, Physical Examination findings, and Investigations.
224264969|NCT00241020|DRUG|Octreotide|
224264970|NCT04029545|DEVICE|PN40082|1.0 mL pre-filled syringes with 25 mg/mL of stabilized hyaluronic acid and lidocaine 0.3% w/w.
224264971|NCT02458664|GENETIC|Genetic analysis on tumor kept in tumor bank|
224264972|NCT05372250|OTHER|Measurement of the diaphragmatic excursion according to the position of the body by ultrasound|Measurement of the diaphragmatic excursion according to the position of the body by ultrasound
224264973|NCT01802112|DIETARY_SUPPLEMENT|Resistant maltodextrins|15 grams of Resistant maltodextrins per day dissolved in water during 21 days
224264974|NCT01802112|OTHER|placebo|15gr placebo
224264975|NCT02722187|PROCEDURE|subinguinal microscopic varicocelectomy|
224264976|NCT02722187|PROCEDURE|laparoscopic varicocelectomy|
223843990|NCT02911272|DEVICE|2-hour action line on WHO modified partograph|observations and findings in a woman in labour are recorded on this device (WHO modified partograph) in a graphic format in which the action line is located 2-hour from the alert line
223843991|NCT02911272|DRUG|Oxytocin|Oxytocin augmentation of slow labour progress at the respective action line location on the WHO modified partograph
223843992|NCT02911272|PROCEDURE|Forewater amniotomy|Forewater amniotomy at the vaginal examination confirming active phase labour
223843993|NCT02911272|DEVICE|4-hour action line on WHO modified partograph|observations and findings in a woman in labour are recorded on this device (WHO modified partograph) in a graphic format in which the action line is located 4-hour from the alert line
223843994|NCT02509403|DRUG|Essential oils infused Perineal Hygiene wipe|Each participant will be asked to complete a treatment period of one month's duration. At the start of the study, the participants will be asked to fill-out a baseline questionnaire and will be given a month's supply of the perineal hygiene towel with instructions about its use. At day 15, 30 and 45 follow-ups will be conducted.
223843995|NCT05547802|BIOLOGICAL|BBIBP-CorV and/or BNT162b2 vaccine|Booster immunization was carried out at least 4 months after the first two doses of basic immunization.
223843996|NCT03109106|DEVICE|PCT Arm|PCT-guided antibiotic therapy per study protocol
223843997|NCT01822821|DRUG|IV Acetaminophen|Patients will receive up to four doses of IV Acetaminophen (1000mg)every six hours after surgery along with standard PCA (patient controlled) opioids.
223843998|NCT01822821|DRUG|Placebo|Patients will receive up to four doses placebo every six hours after surgery along with standard PCA (patient controlled) opioids.
223843999|NCT05780047|DIAGNOSTIC_TEST|Mail-in Urine Test for EDCs|Million Marker provides a mail-in urine test for Bisphenol A (BPA) and phthalates. Users take a comprehensive exposure survey (via the MM app), send back their samples, view their personalized reports with tailored product recommendations, make changes to reduce their exposures, and retest to monitor their progress. Participants will also fill out surveys to assess changes in their environmental health literacy, readiness to change, and analyses of lifestyle behaviors and product use.
223844000|NCT05147987|DEVICE|Hands free wearable breast pump|Use of a supplementary breast pump which can be discreetly worn and is hands free
223844001|NCT00014690|DRUG|plevitrexed|
223844002|NCT00014690|DRUG|topotecan hydrochloride|
223844003|NCT02907697|BEHAVIORAL|Life Steps-Drug Use|
223844004|NCT02907697|BEHAVIORAL|General Health Education|
223844005|NCT00185367|DRUG|EV/DNG (Qlaira, BAY86-5027, SH T00658K)|7 cycles each consisting of 28 days (no tablet-free intervals); Day 1-2: 3.0 mg EV; Day 3-7: 2.0 mg EV + 2.0 mg DNG; Day 8-24: 2.0 mg EV + 3.0 mg DNG; Day 25-26: 1.0 mg EV; Day 27-28: placebo;In addition SH D 593 B (Miranova) matching placebo
223844006|NCT00185367|DRUG|SH D 593 B (Miranova)|7 cycles each consisting of 28 days (no tablet-free intervals); Day 1-21: 0.02 mg EE + 0.10 mg LNG; Day 22-28: placebo; In addition EV/DNG (Qlaira, BAY86-5027, SH T00658K) matching placebo
223844007|NCT00894751|DRUG|dexmedetomidine|dexmedetomidine general anesthesia for MRI
223844008|NCT00894751|DRUG|propofol|propofol general anesthesia for MRI
223844009|NCT05039424|PROCEDURE|Endoscopic per-oral pyloromyotomy (POP)|Per-oral pyloromyotomy (POP), alternatively knows as gastric per-oral endoscopic myotomy (G-POEM), accomplishes longitudinal division of the pylorus using an endoscope. This procedure involves utilizing endoscopic electrosurgical knife to make an incision in the gastric mucosa and develop a submucosal tunnel to visualize the pyloric ring. The pyloric ring is divided longitudinally, and the mucosotomy incision is sealed with endoscopic clips.
223844010|NCT05039424|PROCEDURE|Diagnostic esophagogastroduodenoscopy (EGD) without pyloric disruption|While under general anesthesia, a standard gastroscope is introduced and a diagnostic upper endoscopy is performed. The operator talks through the procedure steps as if completing POP. The gastroscope is withdrawn and the patient is extubated.
223844011|NCT04568096|COMBINATION_PRODUCT|Aerosolized All-Trans Retinoic acid plus oral Tamoxifen|After randomization and standard treatment The infected patients will receive Aerosolized All-Trans Retinoic Acid in gradual in 2 divided doses increases from 0.2 mg/kg/day to 4 mg/kg/day as inhaled All-Trans Retinoic Acid therapy plus tamoxifen 20mg orally once daily. for 14 days
223844012|NCT04568096|OTHER|Standard treatment|Standard treatment is according to the protocol of treatment of 2019-nCoV infection
223844013|NCT06065774|PROCEDURE|The Laterally Closed Tunnel Technique with SCTG|"Local anesthesia using 4% articane with 1:100.000 epinephrine was applied.•~Then specially designed tunneling instruments \[devmed\] were used through the sulcular incision to create a pouch.~A microsurgical blade was used at the inner surface of the pouch till sufficient tissue release was achieved.~Tissue forceps was used to approximate the mesial and distal margin of the gingiva at the pouch margin.~After harvesting the graft, it was placed at the prepared pouch after root surface biomodification using EDTA gel 24% for 2 minutes and copious rinsing with saline solution.~SCTG was pulled using single or mattress sutures and the graft was fixed mesial and distal at the inner part of the pouch using resorbable suture material \[Vicryl suture\], then the graft was sutured around the neck of the CEJ by sling suture 6/0 polypropylene."
224264977|NCT00691782|OTHER|Survey of exercise practices|detailed questionnaire regarding the subject's race, income level; type(s), frequency, intensity, and amount of exercise; attitudes about exercise; hair style; hair care practices; attitudes about hair; hair and scalp health; and attitudes about exercise with regards to hair
224264978|NCT03482180|DRUG|KI1106 4g, QD|KI1106 4 Capsules
224264979|NCT03482180|DRUG|Atorvastatin Calcium 20mg, QD|Atorvastatin Calcium 20mg
224264980|NCT01715922|DRUG|Fluconazole|Induction treatment for 2 weeks: Fluconazole (1600mg/j) Consolidation treatment for 8 weeks: fluconazole (800 mg/j)
224264981|NCT01715922|DRUG|Flucytosine|Flucytosine (100 mg/kg/j) for 2 weeks
224264982|NCT01715922|PROCEDURE|lumbar punctures|lumbar punctures to control intracranial pressure
223844014|NCT06065774|DRUG|The Laterally Closed Tunnel Technique with collagen matrix mucograft|"Local anesthesia using 4% articane with 1:100.000 epinephrine was applied.•~Then specially designed tunneling instruments \[devmed\] were used through the sulcular incision to create a pouch.~A microsurgical blade was used at the inner surface of the pouch till sufficient tissue release was achieved.~Tissue forceps was used to approximate the mesial and distal margin of the gingiva at the pouch margin.~After harvesting the graft, it was placed at the prepared pouch after root surface biomodification using EDTA gel 24% for 2 minutes and copious rinsing with saline solution.~collagen matrix was pulled using single or mattress sutures and the graft was fixed mesial and distal at the inner part of the pouch using resorbable suture material \[Vicryl suture\], then the graft was sutured around the neck of the CEJ by sling suture 6/0 polypropylene."
223844015|NCT06065774|PROCEDURE|Modified Coronally Advanced Tunnel Technique with SCTG.|"Supraperiosteal incisions was extended to the mucosal level beyond the MGJ to allow sufficient tissue mobility and release.~The tunnel was extended in all directions around the recession defect to create a sufficient pouch for connective tissue graft stabilization.~The interdental papilla tunneling adjacent to the defect was a critical step for technique success.~Then perfect root planning was performed at the denuded root surface to remove the necrotic cementum at the accessible recession defect.~Subsequently palatal anesthesia was given to harvest palatal SCTG using deepitheliailized free gingival graft (FGG) technique.~SCTG was pulled using single or mattress sutures and the graft was fixed mesial and distal at the inner part of the pouch using resorbable suture material \[Vicryl suture\], then the graft was sutured around the neck of the CEJ by sling suture 6/0 polypropylene."
223844016|NCT06065774|DRUG|Modified Coronally Advanced Tunnel Technique with collagen matrix mucograft|"Supraperiosteal incisions was extended to the mucosal level beyond the MGJ to allow sufficient tissue mobility and release.~The tunnel was extended in all directions around the recession defect to create a sufficient pouch for connective tissue graft stabilization.~The interdental papilla tunneling adjacent to the defect was a critical step for technique success.~Then perfect root planning was performed at the denuded root surface to remove the necrotic cementum at the accessible recession defect.~Subsequently palatal anesthesia was given to harvest palatal SCTG using deepitheliailized free gingival graft (FGG) technique.~collagen matrix was pulled using single or mattress sutures and the graft was fixed mesial and distal at the inner part of the pouch using resorbable suture material \[Vicryl suture\], then the graft was sutured around the neck of the CEJ by sling suture 6/0 polypropylene."
223844017|NCT05421273|DEVICE|Spinal cord stimulation using passive recharge burst stimulation|Passive recharge burst is marked by a recharge pattern that passively compensates for charge differences.
223844018|NCT05421273|DEVICE|Spinal cord stimulation using active recharge burst stimulation|Active recharge burst is characterized by negative pulses that directly compensate for charge differences.
223844019|NCT01667315|DRUG|Bupivacaine 0,375%|Positive or negative block results in a 1-mL reduction or increase in volume, respectively.
223844020|NCT00153335|BEHAVIORAL|patient-provider interaction|
223844021|NCT02249871|DRUG|semaglutide|All subjects will be treated for 10 consecutive days including dose escalation, with 5 days on 5 mg oral semaglutide followed by 5 days on 10 mg oral semaglutide.
223844022|NCT02249871|DRUG|Omeprazole|Will be given daily with oral semaglutide.
223844023|NCT03590743|DRUG|Apixaban|Active anticoagulation with apixaban 10 mg twice daily for 7 days followed by 5 mg twice daily to complete a total of 3 months treatment.
223844024|NCT03590743|OTHER|Placebo|apixaban matching placebo 2 tablets twice daily for 7 days followed by one tablet twice daily to complete a total of 3 months.
223844025|NCT04223921|OTHER|Comparison of patient's medicines|"Comparison of patient's medicines:~* between patient's discharge from hospital and one month after this discharge (acute geriatric care unit)~* between patient's admission and discharge from hospital (acute geriatric care unit"
223844026|NCT00671684|PROCEDURE|Endoscopic Mucosal Resection (EMR)|EMR is a common procedure in gastroenterology. The technique involves placing a band around a piece of mucosa in the GI tract. The band and the tissue are then removed using a cautery snare. The technique can be used to obtain tissue for diagnostic purposes or to remove lesions for therapeutic purposes.
223844027|NCT00530179|PROCEDURE|Autologous Blood Stem Transplantation|2 CYCLES OF R-CHOP + R-DICEP/R-BEAM FOLLOWED BY AUTOLOGOUS BLOOD STEM CELL TRANSPLANTATION
223844028|NCT00530179|DRUG|R-CHOP|6 - 21 DAY Cycles of R-CHOP
223844029|NCT01046747|PROCEDURE|Placement of external fixation pins|The fractures will be treated according to standard of care. If the external fixation is to be used as a staging procedure, then this will be removed and an internal fixation procedure will be performed. The pin sites will be checked daily according to standard of care. All individuals involved in the examination of the pin sites will receive a standardized training in the grading of pin tract infection and loosening. Each pin site will be graded individually by three persons to evaluate internal accuracy of our grading. Pin tract infections will be first graded as yes or no, and then graded according to the Modified Joglekar Classification (Grade 0-4, Grade 0: no erythema, no drainage; Grade 1: erythema, no drainage OR no erythema with serous drainage; Grade 2: erythema, serous drainage; Grade 3: erythema, purulent drainage; Grade 4: gross pin loosening). Pin loosening will be evaluated at the time of pin removal and graded as either yes or no.
223844030|NCT00604786|DRUG|omalizumab|Dosing is based on IgE level and weight given every 2 or 4 weeks
223844031|NCT00604786|DRUG|placebo|Dosing is based on IgE level and weight given every 2 or 4 weeks
223844032|NCT03174795|DRUG|RO7079901|Participants will receive RO7079901 2000 milligrams (mg) IV treatment, three times a day (TID) for up to 14 days.
223844033|NCT03174795|DRUG|Meropenem|Participants will receive meropenem 2000 mg IV treatment TID for up to 14 days.
223844034|NCT00001416|DRUG|CEREDASE™|
223844035|NCT01221181|DRUG|Eculizumab|Dosage/Frequency: 900 mg IV once a week for 4 weeks, 1200 mg IV week 5, then 1200 mg IV every 2 weeks through week 53.
223844036|NCT00253903|DRUG|eplivanserin (SR46349)|oral administration
223844037|NCT00253903|DRUG|placebo|oral administration
223844038|NCT02698436|DEVICE|Acne Mask|The light therapy device contains a combination of red and blue light-emitting diodes. The device is applied once daily, in the evening for a duration of 10 minutes
223844039|NCT02698436|DRUG|2.5% Benzoyl Peroxide Treatment|The BPO treatment is applied twice daily, once in the morning and once in the evening
223844040|NCT01233635|OTHER|no drug|none, no drug
223844041|NCT01233635|DRUG|start cozaar|start cozaar
223844042|NCT01233635|DRUG|continue cozaar|continue cozaar
223844043|NCT06008535|PROCEDURE|Open inguinal hernia repair|Lichtenstein hernioplasty or open inguinal hernia repair with self-gripping mesh
223844044|NCT03732586|DIETARY_SUPPLEMENT|Omega 5 fatty acid supplement|Patients will be randomized to receive traditional treatment (prednisone 40 mg per day) plus omega 5 fatty acid ( 2 capsules of 0.64g per day) for 28 days.
223844045|NCT03732586|OTHER|PLACEBO|Patients will be randomized to receive the traditional treatment (prednisone 40 mg per day) plus placebo (2 capsules of placebo with identical appereance and size like omega 5 supplement) for 28 days.
223844046|NCT01020565|DRUG|Entecavir|Tablet, P.O., 0.1 OR 0.5 mg, once daily, 52 weeks
223844047|NCT02081365|BEHAVIORAL|Computerized Dental Anxiety Treatment|The Computerized Dental Anxiety Treatment Program consists of treatment modules that are be delivered through a computer. The modules use Cognitive Behavioral Therapy (CBT) to assist the participant in preparing a personal plan for managing his/her dental anxiety. The program incorporates a range of CBT techniques, including cognitive restructuring, exposure, and motivational interviewing.
223844048|NCT01283217|DRUG|DS|Docetaxel with S-1. S-1: Orally, within 30 minutes after ingestion of food. Docetaxel and Cisplatin: IV infusion.
223844049|NCT01283217|DRUG|SP|S-1 with cisplatin. S-1 : Orally, within 30 minutes after ingestion of food. Docetaxel and Cisplatin: IV infusion.
223844050|NCT00001084|DRUG|Indinavir sulfate|
223844051|NCT00001084|DRUG|Lamivudine|
223844052|NCT00001084|DRUG|Stavudine|
223844053|NCT00001084|DRUG|Zidovudine|
223844054|NCT01394991|DRUG|Epoetin alfa 450 IU/kg once a week|450 IU/kg once a week by subcutaneous injection preferably in the abdomen for up to 4 weeks after the last dose of chemotherapy for a maximum of 26 weeks.
223844055|NCT01394991|DRUG|Epoetin alfa 150 IU/kg 3 times a week|150 IU/kg 3 times a week by subcutaneous injection preferably in the abdomen for up to 4 weeks after the last dose of chemotherapy for a maximum of 26 weeks.
223844056|NCT01394991|DRUG|Epoetin alfa 450 IU/kg once a week (QW)|450 IU/kg once a week (QW) by subcutaneous injection preferably in the abdomen for up to 4 weeks after the last dose of chemotherapy for a maximum of 26 weeks
223844057|NCT01394991|DRUG|Epoetin alfa 150 IU/kg 3 times a week (TIW)|150 IU/kg 3 times a week (TIW) by subcutaneous injection preferably in the abdomen for up to 4 weeks after the last dose of chemotherapy for a maximum of 26 weeks.
223844058|NCT02621788|BEHAVIORAL|Stress Management and Resiliency Training for Residents (SMART-R)|The SMART-R is a mind-body Educational Program for residents that is aimed at reducing the impact of stress and enhancing coping strategies through skill building exercises. The intervention consists of 3, 2 hour sessions over the course of 12 months.
223844059|NCT04435886|DIETARY_SUPPLEMENT|Probiotic|Probiotic mixture with maltodextrin as a carrier.
223844060|NCT04435886|DIETARY_SUPPLEMENT|Placebo|Placebo comparator with maltodextrin as a carrier.
223844061|NCT00489073|DRUG|duloxetine|
223844062|NCT00489073|DRUG|placebo|
223844063|NCT02850328|OTHER|examination of muscle function and MVC in weightlessness|"MVC tested during three different tasks: (1) leg press, (2) plantarflexion and (3) grip strength.~parameters of muscle function that can be easily implemented in parabolic flight:~* Rate of force development~* Electromyographic activity~* Ultrasound measure: fascicle length and pennation angle of the gastrocnemius medialis muscle~* Superimposed twitch torque (M-waves at rest and V-waves in MVC conditions)~* Maximum voluntary activation capacity (%VA): %VA = (1-\[torque superimposed twitch/torque resting twitch\])\*100%."
223844064|NCT04345211|OTHER|Group1, walking group|The walking group includes a weekly walking goal of 75 minutes.
223844065|NCT04345211|OTHER|Group 2, Walking plus manual therapy|Walking plus self-administered thorax manual therapy
223844066|NCT04345211|OTHER|Group 3; Walking plus exercises with Theraband|Walking plus thorax exercises with Theraband
223844067|NCT01081353|DRUG|Acetylsalicylic Acid (Aspirin BAY1019036)|One tablet of new formula Aspirin under fasting conditions
223844068|NCT01081353|DRUG|Alka Seltzer Extra Strength|One effervescent tablet under fasting conditions
223844069|NCT01081353|DRUG|Aspirin Migraine|One effervescent tablet under fasting conditions
223844070|NCT01081353|DRUG|Aspirin Aspro|One effervescent tablet under fasting conditions
223844071|NCT02230579|DRUG|MMV390048 5mg|"Supplied as powder in bottle formulation for reconstitution pre-dose"
223844072|NCT02230579|DRUG|MMV390048 20mg|"Supplied as powder in bottle formulation for reconstitution pre-dose."
223844073|NCT02230579|DRUG|MMV390048 40mg|"Supplied as powder in bottle formulation for reconstitution pre-dose"
223844074|NCT02230579|DRUG|MMV390048 80mg|"Supplied as powder in bottle formulation for reconstitution pre-dose"
223844075|NCT02230579|DRUG|MMV390048 120mg|"Supplied as powder in bottle formulation for reconstitution pre-dose"
223844076|NCT02230579|DRUG|Placebo to match MMV390048|"Supplied as powder in bottle formulation for reconstitution pre-dose"
223844077|NCT04279028|BEHAVIORAL|Adapted CBT|"ACBT is derived from traditional CBT principles, but eliminates the text-heavy requirements. Traditional CBT incorporates the use of complex worksheets and a lengthy workbook, whereas ACBT replaces these skill learning activities with simpler, straightforward exercises that are practiced in session along with the therapist. This real world practice eliminates the need for reading and writing as part of CBT while simultaneously recapitulating how the patient would actually implement CBT procedures. In session exercises will mirror that of standard CBT practices. For example, they could include lessons in goal setting, distinguishing situations, moods, and thoughts, and experiments to test underlying assumptions. Participants will be assigned paper-free homework assignments."
223844078|NCT04279028|BEHAVIORAL|Standard CBT|CBT involves the therapist and client working to identify and change negative beliefs and thoughts, replacing them with more accurate and balanced thoughts. CBT for Depression will be conducted according to standard manuals and incorporate the use of a common workbook used within CBT sessions. As per standard practice, participants will be assigned worksheets from their workbook used both in session and as homework assignments.
223844079|NCT04750408|DEVICE|Standard oxygen|COT describes the application of low-flow oxygen in any way (Hudson mask, nasal prongs,...).
223844080|NCT04750408|DEVICE|Nasal high-flow|F is combination of room air supplemented with oxygen can be better patients. This gas mixture will be provided to the patient with a specialized nasal prong.
223844081|NCT06407479|OTHER|proprioceptive neuromuscular facilitation technique group|Proprioceptive Neuromuscular Facilitation Technique group; In addition to the exercises applied to the participants and the control group, combined isotonic contractions and dynamic stabilization will be used as facilitation techniques, and hold-relax technique will be used as an inhibition technique.
223844082|NCT06407479|OTHER|eccentric muscle training technique application group|Eccentric Muscle Training Technique: Participants will receive eccentric muscle training in addition to the exercises given to the control group. Before the application, 5-minute warm-up exercises will be given to the neck area. Eccentric muscle training will be applied to the muscles of the participants in the cervical region. Eccentric exercise will be strengthened in the cervical region muscles in the direction of movement in each plane, that is, flexion / extension and lateral flexion. The movements will first be explained and demonstrated to the patient.
223844083|NCT06407479|OTHER|Control|No intervention will be made.
223844084|NCT00062868|BIOLOGICAL|LMP1/2 CTLs (ALCI - Group A)|"Each patient will receive 2 injections, 14 days apart, according to the following dosing schedules:~Dose Level One~Day 0: 2 x 10\^7 cells/m2; Day 14: 2 x 10\^7 cells/m2~Dose Level Two~Day 0: 2x10\^7 cells/m2; Day 14: 1x10\^8 cells/m2~Dose Level Three~Day 0: 1x10\^8 cells/m2; Day 14: 2x10\^8 cells/m2"
223844085|NCT00062868|BIOLOGICAL|LMP1/2 CTLs (ALCI - Group B)|"Each patient will receive 2 injections, 14 days apart, according to the following dosing schedules:~Dose Level One~Day 0: 2x10\^7 cells/m2; Day 14: 2x10\^7 cells/m2~Dose Level Two~Day 0: 2x10\^7 cells/m2; Day 14: 1x10\^8 cells/m2~Dose Level Three~Day 0: 1x10\^8 cells/m2; Day 14: 2x10\^8 cells/m2"
223844086|NCT00062868|BIOLOGICAL|LMP1/2 CTLs (ALCI - Group C)|"Each patient will receive 2 injections, 14 days apart, according to the following dosing schedules:~Dose Level One~Day 0: 2x10\^7 cells/m2; Day 14: 2x10\^7 cells/m2~Dose Level Two~Day 0: 2x10\^7 cells/m2; Day 14: 1x10\^8 cells/m2~Dose Level Three~Day 0: 1x10\^8 cells/m2; Day 14: 2x10\^8 cells/m2"
223844087|NCT00062868|BIOLOGICAL|LMP2 CTLs (ALSCER - Group A)|"Each patient will receive 2 injections, 14 days apart, according to the following dosing schedules:~Dose Level One~Day 0: 2 x 10\^7 cells/m2; Day 14: 2 x 10\^7 cells/m2~Dose Level Two~Day 0: 2x10\^7 cells/m2; Day 14: 1x10\^8 cells/m2~Dose Level Three~Day 0: 1x10\^8 cells/m2; Day 14: 2x10\^8 cells/m2"
223844088|NCT00062868|BIOLOGICAL|LMP2 CTLs (ALSCER - Group B)|"Each patient will receive 2 injections, 14 days apart, according to the following dosing schedules:~Dose Level One~Day 0: 2x10\^7 cells/m2; Day 14: 2x10\^7 cells/m2~Dose Level Two~Day 0: 2x10\^7 cells/m2; Day 14: 1x10\^8 cells/m2~Dose Level Three~Day 0: 1x10\^8 cells/m2; Day 14: 2x10\^8 cells/m2"
223844089|NCT00062868|BIOLOGICAL|LMP2 CTLs (ALSCER - Group C)|"Each patient will receive 2 injections, 14 days apart, according to the following dosing schedules:~Dose Level One~Day 0: 2x10\^7 cells/m2; Day 14: 2x10\^7 cells/m2~Dose Level Two~Day 0: 2x10\^7 cells/m2; Day 14: 1x10\^8 cells/m2~Dose Level Three~Day 0: 1x10\^8 cells/m2; Day 14: 2x10\^8 cells/m2"
223844090|NCT00062868|BIOLOGICAL|LMP1/2 CTLs (ALCI - Expansion - Group A)|"Each patient will receive 2 injections, 14 days apart, according to the following dosing schedules:~Dose Level One~Day 0: 2 x 10\^7 cells/m2; Day 14: 2 x 10\^7 cells/m2"
223844091|NCT00062868|BIOLOGICAL|LMP1/2 CTLs (ALCI - Expansion Group B)|"Each patient will receive 2 injections, 14 days apart, according to the following dosing schedules:~Dose Level One~Day 0: 2x10\^7 cells/m2; Day 14: 2x10\^7 cells/m2"
223844092|NCT00062868|BIOLOGICAL|LMP1/2 CTLs (ALCI - Expansion Group C)|"Each patient will receive 2 injections, 14 days apart, according to the following dosing schedules:~Dose Level One~Day 0: 2x10\^7 cells/m2; Day 14: 2x10\^7 cells/m2"
223844093|NCT04141163|DRUG|Metformin|Metformin, 1,1 dimethylbiguanide, or systematic (IUPAC) name N,N-dimethylimidodicarbonimidic diamide, is an oral anti-diabetic medicine approved in the US by the FDA in 1994. It is marketed alone under the names metformin (generic), Glucophage XR, Riomet, Fortamet, Glumetza, Obimet, Gluformin, Dianben, Diabex, and Diaformin and in combination with other drugs under the names Actoplus Met, Metaglip, Glucovance, Janumet, Kombiglyze XR, and PrandiMet
223844094|NCT04141163|DRUG|Placebo oral tablet|No therapeutic effect
223844095|NCT01734811|BIOLOGICAL|Biological vaccine|daily spray (2 puff of 100 µL) for six months
223844096|NCT00002915|DRUG|penclomedine|
223844097|NCT04560361|OTHER|Electroacupuncture treatment|Continue the electroacupuncture treatment as described above for 30 minutes.
223844098|NCT04560361|OTHER|Sham electroacupuncture treatment|Continue the sham electroacupuncture treatment as described above for 30 minutes.
223844099|NCT01324882|DEVICE|Colonoscopy with Olympus Technically Improved Colonoscope|The standard colonoscopy will be performed using the Olympus Technically Improved Colonoscope.
223844100|NCT01324882|DEVICE|Control with standard colonoscope Olympus CF-H180|Standard colonoscopy using the adult scope, Olympus CF-H180.
223844101|NCT06075888|DIAGNOSTIC_TEST|Metagenomic diagnosis (mNGS, DISQVER)|Blood sample taken for metagenomic sequencing at inclusion visit.
223844102|NCT06478771|DEVICE|Essix retainer|A clear plastic removable retainer.
223844103|NCT06478771|DEVICE|Lingual retainer|A fixed retainer placed on the lingual side of the teeth.
223844104|NCT00725010|DRUG|Temozolomide|Temozolomide will be administered orally at 75 mg/m\^2 with radiotherapy during the concomitant treatment phase. After four weeks, temozolomide will be administered at 150 mg/m\^2 to 200 mg/m\^2 from Day 1 to Day 5 of six therapy cycles during the monotherapy phase.
223844105|NCT00725010|RADIATION|Radiotherapy|Radiotherapy will consist of fractionated focal irradiation at a dose of 2 Gy per fraction given Monday through Friday for a total dose of 60 Gy, administered with temozolomide during the concomitant treatment phase.
223844106|NCT02239185|PROCEDURE|Hernial sac ligation in continuity|Laparoscopic closure of hernia sac at internal inguinal ring in continuity using 3 - 0 non-absorbable purse-string suture. The spermatic vessels and vas deferens are well visualized and protected during the suture. In all cases, hydro dissection can be done by injection of saline to separate the peritoneum from cord structures. Two 3-mm.needle holders are used for intracorporeal insertion of purse string suture around the opened IIR with intracorporeal knot tying. The stitches included the peritoneum and the underlying muscular tissue lateral to the spermatic cord. The procedure is modified in children with a dilated internal ring.
223844107|NCT02239185|PROCEDURE|Hernial sac disconnection|Circumferential incision on the peritoneum at IIR will be started to separate hernia sac from the peritoneum. Initial disconnection of the vas and vessels will be done and then the peritoneum posterior to the internal ring will be divided and then the anterior disconnection will be carried out. Saline can be injected to separate the peritoneum from cord structures (hydro dissection). Care is taken not to damage the vas and vessels by handling them. Then the proximal part of the sac will be sutured using non-absorbable 3-0 prolene on round body needle.
223844108|NCT02619708|BEHAVIORAL|Immersive Preoperative Experience|The video will include a simulated patient encounter (with actors not real patients) showcasing the preoperative experience of the patient, including getting checked in, meeting the nurses, surgeons, and the anesthesiologists. The technology used will allow the immersion of the patient in the preoperative environment. Patients will be able to look around and explore the spaces they will visit on the day of their operation.
223844109|NCT06443671|DRUG|CapeOX|"Receiving CapeOX treatment for up to four cycles before surgery:~Capecitabine: 1000mg/m2, BID, PO, D1-14, Q3W; Oxaliplatin: 130 mg/m2, intravenous drip for 0-2 hours, D1, Q3W."
223844110|NCT06443671|DRUG|Fruquintinib and Tislelizumab combined with mCapeOX|"Receiving Fruquintinib plus Tislelizumab combined with mCapeOX treatment for up to four cycles before surgery:~Fruquintinib: 3mg/d, QD, PO, Use for 2 weeks, stop for 1 week, Q3W; Tislelizumab: 200mg, D1, Intravenous infusion, Q3W; Capecitabine: 825mg/m2, BID, PO, D1-14, Q3W; Oxaliplatin: 100 mg/m2, intravenous drip for 0-2 hours, D1, Q3W."
223844111|NCT02970747|DRUG|Carfilzomib|In accordance with SmPC.
223844112|NCT05541419|DRUG|Budesonide Nasal|The patient performed a lavage once daily with 2mg dilute budesonide. The maximum clinical treatment consists of intramuscular injection of Dispropan® in intramuscular injectable suspension and busonid in nasal spray, two sprays of 50mcg in each nostril.
223844113|NCT05541419|DRUG|Placebos|Composed of 1% glycerin diluted in water. The maximum clinical treatment consists of intramuscular injection of Dispropan® in intramuscular injectable suspension and busonid in nasal spray, two sprays of 50mcg in each nostril.
223844114|NCT03116451|BEHAVIORAL|Foot Health Promoting Program|An electronic intervention for 8 weeks consisting of foot self-care guidance targeted to nurses.
223844115|NCT03780205|OTHER|Prescription glasses for bilateral amblyopia|Correction of refractive error with prescription glasses both eyes
223844116|NCT03780205|OTHER|Prescription glasses for unilateral amblyopia|Correction of asymmetric refractive errors with lenses
223844117|NCT06021119|DRUG|Dipeptidyl peptidase-4 inhibitors|Dipeptidyl peptidase-4 inhibitors with Iftar meal
223844118|NCT05420532|OTHER|Exergaming|A video game-based physical activity training applied using a commercial game console.
223844119|NCT05929456|DRUG|Cetuximab-IRDye800|patients will receive a single IV injection of Cetuximab-IRDye800CW 2-4 days prior to surgert. The IMP (Investigational medicinal product)/tracer will be used for fluorescence guided surgery.
223844120|NCT00202826|PROCEDURE|Video Assisted Thorascopic Surgery Thoracostomy Tube Placement & Drainage|
223844121|NCT02414828|BIOLOGICAL|Placebo|This is the identical buffer solution in which AERAS-402 is formulated. The placebo (1.0 mL volume) was administered by intramuscular (IM) injection to the deltoid area on Study Day 0 for groups 1 and 2 and Study Day 0 and 42 for group 3.
223844122|NCT02414828|BIOLOGICAL|AERAS-402 3 x 10^8 vp|AERAS-402 was administered by single intramuscular (IM) injection to the deltoid area on Study Day 0
223844123|NCT02414828|BIOLOGICAL|AERAS-402 3 x 10^9 vp|AERAS-402 was administered by single intramuscular (IM) injection to the deltoid area on Study Day 0
223844124|NCT02414828|BIOLOGICAL|AERAS-402 3 x 10^10 vp|AERAS-402 was administered by intramuscular (IM) injection to the deltoid area on Study Days 0 and 42.
223844125|NCT02669719|BIOLOGICAL|chemotherapy followed dendritic cells|Pemetrexed and carboplatin would be administered on day 1 of each 3-week cycle.Patients will start with dendritic cells treatment on Day 15 of pemetrexed and carboplatin chemotherapy from Cycle 3 provided that both leukapheresis and the production of dendritic cells are successful.
223844126|NCT02669719|DRUG|pemetrexed and carboplatin|Chemotherapy with 4-6 cycles of pemetrexed and carboplatin as first-line induction chemotherapy followed by pemetrexed as maintenance therapy.
223844127|NCT01423357|OTHER|Condom distribution and peer education|Condom distribution and condom demonstrations by youth peer educators at least twice a week
223844128|NCT03635177|PROCEDURE|Remote ischemic conditioning|Four weeks of daily ischemic conditioning and four weeks of sham ischemic conditioning in a cross over design
223844129|NCT04680936|DRUG|Dextrose 5% in water|low dose dextrose solution
223844130|NCT04680936|DRUG|Dextrose 15 % in Water|high dose dextrose solution
223844131|NCT04680936|DRUG|Isotonic sodium chloride solution|isotonic saline solution
223844132|NCT00875147|DRUG|bevacizumab|Neoadjuvant chemotherapy with bevacizumab
223844133|NCT03916380|DIETARY_SUPPLEMENT|Grapefruit Juice|Single 8 ounce administration of oral grapefruit juice
223844134|NCT01938417|DRUG|tobramycin|
223844135|NCT03429309|DRUG|Propofol|Anesthesia was induced by intravenous infusion of propofol via the syringe pump at a rate of 30 mg/kg/h.
223844136|NCT02817373|OTHER|Ultrasound scan performed through a vaginal probe|5-8 minute scan recording : endometrial thickness, endometrial pattern, endometrial -myometrial junction appearance, subendometrial wave contractions (presence and number), endometrial surface area
223844137|NCT06325943|DRUG|Rituximab|Patients will receive two doses of rituximab 1 g at two-week interval and one dose of rituximab 1 g at month 6
223844138|NCT06325943|OTHER|Placebo|Patients will receive two doses of placebo at two-week interval and one dose of placebo at month 6
223844139|NCT00048854|DRUG|Sertraline|Patients who meet study criteria will be given 50 mg per day of sertraline to be taken an estimated 2 weeks before menstruation.
223844140|NCT00048854|OTHER|Treatment as usual (TAU)|At the TAU baseline visit, patients will be told of their diagnosis of PMS/PMDD. Those patients who decide to seek treatment outside of the study protocol or do not wish to seek treatment will be asked to participate in the TAU part of this protocol. Patients in TAU will be contacted monthly to obtain monthly information about how they have been feeling (blinded ratings) using the study measures.
223844141|NCT06067100|DRUG|Indacaterol and Mometasonefluroate (low dose)|Participants are administered 125 µg indacaterol + mometasonefluroate
223844142|NCT06067100|DRUG|Placebo|Participants are administered placebo
223844143|NCT06067100|DRUG|Indacaterol and Mometasonefluroate (high dose)|Participants are administered 500 µg indacaterol + mometasonefluroate
223844144|NCT05593458|DRUG|Oxaliplatin by arterial infusion plus S-1|3 cycles oxaliplatin by arterial infusion plus S-1 every 21 days as neoadjuvant chemotherapy.
223844145|NCT05593458|DRUG|SOX neoadjuvant|3 cycles of SOX neoadjuvant chemotherapy every 21 days.
223844146|NCT05593458|DRUG|Sintilimab neoadjuvant|3 cycles of neoadjuvant immunotherapy every 21 days.
223844147|NCT05593458|PROCEDURE|gastrectomy plus D2 lymph node dissection|All patients, whose lesions are resectable and medically operable after 3 cycles neoadjuvant chemotherapy, will receive gastrectomy plus D2 lymph node dissection.
223844148|NCT05593458|DRUG|SOX adjuvant, Sequential S-1|"3 cycles of SOX adjuvant chemotherapy every 21 days after surgery in both groups.~Sequential S-1 chemotherapy every 21 days till 1 year postoperation."
223844149|NCT05593458|DRUG|Sintilimab adjuvant|3 cycles of adjuvant immunotherapy every 21 days.
223844150|NCT00674947|DRUG|BIIB015|IV infusion once every 3 weeks until disease progression or unacceptable toxicity
223844151|NCT01974687|DRUG|Uprifosbuvir|Uprifosbuvir 5 mg, 25 mg, or 50 mg capsule, or 150 mg tablet, administered by mouth.
223844152|NCT01974687|DRUG|Placebo|Matching placebo to uprifosbuvir capsule administered by mouth.
223844153|NCT01974687|DRUG|Itraconazole|Itraconazole is supplied as 10 mg/mL oral solution or 100 mg capsules administered by mouth.
223844154|NCT00124605|DRUG|pamidronate disodium|Given IV
223844155|NCT00124605|DRUG|arsenic trioxide|Given IV
223844156|NCT00124605|OTHER|laboratory biomarker analysis|Correlative studies
223844157|NCT00124605|OTHER|pharmacological study|Correlative studies
223844158|NCT03412981|OTHER|pregnant mothers|we will be collecting data on a cohort of pregnant mothers
223844159|NCT04453787|OTHER|Arch support orthoses with forefoot medial wedge|The degree of forefoot wedge will be 3 degree. If needed, it could be adjusted. The subjects need to wear the orthoses for at least 30 hour per week during the experiment.
223844160|NCT04453787|OTHER|Arch support orthoses|The arch support of the orthoses could be adjusted depends on the evaluation of subject. The subjects need to wear the orthoses for at least 30 hour per week during the experiment.
223844161|NCT04453787|OTHER|Flat insole|The flat insole used as a placebo intervention. The shape of this insole is flat, and made by soft EVA. It only provide shock absorbtion without any support. The subjects need to wear the orthoses for at least 30 hour per week during the experiment.
223844162|NCT00005305|OTHER|No interventions - observational study|
223844163|NCT03591965|DRUG|ATG-008|Approximately 20 subjects will receive oral ATG-008 at an initial dose of 45 mg/QD and another 20 subjects will receive oral ATG-008 at an initial dose of 20mg/BID for 28 days each cycle.
223844164|NCT03031639|PROCEDURE|Endoscopic approach thyroidectomy|Thyroid surgery using endoscopy.
223844165|NCT02748239|BEHAVIORAL|MEDIAS 2 CT|The MEDIAS 2 CT is a education program for the initiation of a conventional insulin therapy in type 2 diabetic patients. The program consists of 6 lessons and is conducted in group settings (4-8 participants).
223844166|NCT02748239|BEHAVIORAL|Current CT program|The Current CT program is currently used for the initiation of conventional insulin therapy in type 2 diabetic patients. The program consists of 6 lessons and is conducted in group settings (4-8 participants).
223844167|NCT06117475|PROCEDURE|Posterior corpectomy|Removal of posterior portion of vertebrae by posterior approach
223844168|NCT05696808|DIETARY_SUPPLEMENT|IHPD|The intervention is planned as a supervised dietary supplementation, with a goal of restricting the calorie intake to 25 Kcal/Kg BW/day, with a protein intake of 1 gm/Kg BW/day i.e., around 15 % of total calories from protein, 35% from fats and 50% from carbohydrates. Major portion of the carbohydrates is vegetables, fruits and then cereals (high fiber cereals), more amount of tomato and amla at least 200 gm in a day, protein requirements are met by mainly legumes like chick pea black - (kala chana) and moong sprouts besides dals. Lean meats and egg whites would be allowed as the non-vegetarian source. Milk products used are only milk and buttermilk, curd (excluding paneer). Major source of oil would be mustard oil only.
223844169|NCT05696808|DIETARY_SUPPLEMENT|Western Diet|The intervention is planned with a goal of restricting the calorie intake to 40 Kcal/Kg BW/day, around 10-15 % of total calories from protein, 30-35% from fats and 55-60% from carbohydrates. Major portion of the carbohydrates is Western fast food comprising of pizza and burger, French fries, sweets, muffins, cakes, chocolates, sugar sweetened beverages.
223844170|NCT06556004|BIOLOGICAL|TRIMELVAX|The safety of this immunotherapeutic compound will be tested in patients with advanced melanoma and will secondarily evaluate the induced immune response.
223844171|NCT05644405|DIAGNOSTIC_TEST|FloTrac Vigileo|A dedicated transducer (FloTrac TM, Edwards Lifesciences, LLC, Irvine, CA, USA) was connected to the radial arterial line on one side and to the Vigileo System (Vigileo TM Edwards Lifesciences, LLC, Irvine, CA, USA) on the other side
223844172|NCT03896230|DRUG|Ketamine Injectable Product|Three different doses of ketamine will be administered.
223844173|NCT05476211|DEVICE|BTL-785F|Radiofrequency
223844174|NCT00972985|DRUG|modafinil|oral tablet, 100 mg, single acute dose
223844175|NCT00972985|DRUG|methylphenidate|oral tablet, 20 mg, single acute dose
223844176|NCT00972985|DRUG|lorazepam|oral tablet, 1 mg, single, acute dose
223844177|NCT00972985|DRUG|placebo|oral tablet, single acute dose
223844178|NCT02613897|DRUG|Saxagliptin|Saxagliptin (Onglyza™) is approved by the US FDA as an adjunct to diet and exercise to improve glycemic control in adults with T2DM. The 5 mg dose will be used for this study as it is the dose that is routinely used in the clinic. In addition, this dose is used in the pivotal studies in the saxagliptin/dapagliflozin clinical program.
223844179|NCT02613897|DRUG|Dapagliflozin|Dapagliflozin (Farxiga) is approved by the FDA as an adjunct to diet and exercise to improve glycemic control in adults with T2DM. Dapagliflozin (Farxiga) is also approved in the EU as an adjunct to diet and exercise to improve glycemic control in patients with T2DM for whom metformin use is considered inappropriate due to intolerance, and in combination with other glucose-lowering medicinal products when these, in combination with diet and exercise do not provide adequate glycemic control. The 10 mg dose was chosen for this study because it has been extensively studied in Phase 3 trials and has demonstrated a favorable benefit-risk profile. In addition, this dose is the most commonly used dose in most countries.
223844180|NCT02613897|DRUG|Placebo|Placebo
223844181|NCT01712685|DRUG|18F-VM4-037|Drug being tested for use in cancer imaging studies. It may help tumor tissue show up more clearly during scans.
223844182|NCT01712685|PROCEDURE|PET/CT|
223844183|NCT01866917|DRUG|Ropivacaine 0.5% 20cc injectate bilaterally|
223844184|NCT01866917|DRUG|Placebo|
223844185|NCT00232934|DRUG|Thalidomide|
223844186|NCT06423599|DRUG|Semaglutide Injectable Product|Weight loss using Semaglutide
223844187|NCT06423599|DIETARY_SUPPLEMENT|Calorie-restricted diet|Weight loss by calorie-restricted diet program followed by a weight loss maintenance follow-up program
223844188|NCT06657547|OTHER|Normal conditions|Participants are administered salmeterol, after which they perform various performance tests in normal conditions. Following the administration of salmeterol, urine samples are collected over the next 24 hours at intervals of 0.5, 1, 2, 4, 8, and 24 hours after administration.
223844189|NCT06657547|OTHER|Heated conditions|Participants are administered salmeterol, after which they perform various performance tests in heated conditions. Following the administration of salmeterol, urine samples are collected over the next 24 hours at intervals of 0.5, 1, 2, 4, 8, and 24 hours after administration.
223844190|NCT06657547|DRUG|Salmeterol inhalation and urine samples|After the experimental day under normal conditions, all participants are administered 200 µg of salmeterol daily (8 puffs from the MDI device) during a 6-day intervention period. Two hours after inhalation, the participants collect spot urine samples at home
223844191|NCT06811532|OTHER|Blood perfusion analysis using SPY-Q software|Use of the SPY-Q analysis software during surgery to calculate bone profusion scores on several areas of the scapular tip flap (endosteum of scapula bone segments and latissimus dorsi muscle component).
223844192|NCT02773251|DRUG|hyaluronic acid-carboxymethylcellulose|
223844193|NCT06193161|BEHAVIORAL|Therapist-supported internet delivered prolonged exposure|Therapist-supported internet delivered prolonged exposure for eight weeks.
223844194|NCT03406442|PROCEDURE|Transpterygoid approaches|All patients will be operated by transpterygoid approaches which is classified into 5 major types.Type A involves thinning of the pterygoid process to access to Pterygopalatine fossa. Type B involves the removal of the medial and anterior aspect of the base of the pterygoid process to access the lateral recess of sphenoid sinus. Type C involves removing the base of the pterygoid plates to reach the petrous apex, Meckel's cave, or cavernous sinus. Type D requires removal of the pterygoid plates to access the infratemporal fossa. Type E requires the removal of the medial pterygoid plate or the entire pterygoid process, and the medial third of the Eustachian tube to acessof the lateral nasopharynx
223844195|NCT01194505|OTHER|Sciatic, femoral, obturator nerve blocks|Ultrasound guided blocks with ropivacaine
223844196|NCT01194505|OTHER|Sciatic nerve block, posterior lumbar plexus block|Ultrasound and neurostimulator nerve blocks with ropivacaine
223844197|NCT06667856|OTHER|Asynchronous exercise group|Application of foot core training combined with lower extremity exercises using asynchronous telerehabilitation method.
223844198|NCT06667856|OTHER|Synchronous exercise group|Application of foot core training combined with lower extremity exercises using synchronous telerehabilitation method.
223844199|NCT06611137|COMBINATION_PRODUCT|SBRT+Toripalimab Plus Docetaxel and Cisplatin|All participants will receive SBRT (18Gy/3 fractions, QOD ) to gross tumor and metastatic lymph nodes, followed by neoadjuvant chemoimmunotherapy of Toripalimab (240mg) Plus Docetaxel (75mg/m2, q3w) and Cisplatin (75mg/m2, q3w) for 3 cycles. If tumor has complete or partial response at 2 weeks after the last course of neoadjuvant chemotherapy, participants will then receive intensity modulated radiotherapy (54Gy/27 fractions). If tumor is stable or progressive, participants will receive radical resection with or without postoperative intensity modulated radiotherapy when necessary.
223844200|NCT06610370|OTHER|Group 1|95 children with spastic cerebral palsy were included. Gross Motor Function Measure-88 (GMFM-88) and Gross Motor Function Classification System (GMFCS) were applied to the cases before and after the Selective Dorsal Rhizotomy (SDR) surgery.
223844201|NCT05707182|DRUG|18F-rhPSMA-7.3|18F-rhPSMA-7.3 PET/MR
223844202|NCT04428164|OTHER|The Richards-Campbell Sleep Questionnaire (R-CSQ)|"Tool developed to assess patient satisfaction and comfort in the hospital setting.~The R-CSQ is a scale used to measure different aspects of sleep quality. This scale allows the patient to rate their quality and amount of sleep on a scale of 0-100. The R-CSQ allows the patient to rate six different components of their sleep, including sleep depth, sleep latency, awakenings, returning to sleep, sleep quality, and noise."
223844203|NCT04428164|OTHER|Revised American Pain Society Outcome Questionnaire (APS-POQ-R)|The APS-POQ-R can be utilized to measure perceived levels of pain in patients. The APS-POQ-R scale is a validated scale that is used in the hospital setting with reliable and consistent results. This scale measures five aspects of a patient's perception and experiences with pain and a sixth aspect including nonpharmacological interventions.
223844204|NCT06611761|PROCEDURE|Shoulder arthroscopy|Shoulder arthroscopy in procedures that cause intense postoperative pain
223844205|NCT05641467|OTHER|virtual reality glasses|OculusQuest 2 128GB brand virtual reality glasses will be used in our research. OculusQuest 2 128GB is the original all-in-one gaming system for virtual reality. It can only be used as desired with the VR headset and controllers. It adapts to its environment. In this way, it can be played standing and sitting in small and large areas. When glasses will be used on another pregnant women within the scope of COVID-19 measures, disinfection will be provided with 'DiverseyOxivir Plus (hydrogen peroxide)' surface disinfectant. Before the episiotomy repair, the video glasses will be opened, the video will be adjusted to suit the woman. In order for the repair method to be the same for all women, It will be planned to use absorbable, synthetic, braided, sterile surgical thread produced from 1-0 polyglactin.
223844206|NCT06426771|BEHAVIORAL|Dietary Inflammatory Index|The aim of this study was to compare the dietary habits of patients with PCOS and an AMH value of \>3.32 ng/ml, of patients with low ovarian reserve without PCOS and an AMH value of less than 1.2 ng/ml and of patients with normal AMH values (between 1.2-3.32 ng/ml) according to Dietary Nutrient Density according to Dietary Inflammatory Index, Dietary Phytochemical Index and Nutrient Rich Food Index.
223844207|NCT06426771|DIAGNOSTIC_TEST|hormone profile|In the routine practice of the PCOS clinic, about 7 ml of blood is taken in a vacuum gel tube for hormonal and biochemical analysis by medical staff. The blood samples are centrifuged by the researchers at 1000xg for 20 minutes. In the next step, the supernatant part is separated and transferred to 3 mL Ependorfs. These samples are used to determine the levels of anti-Müllerian hormone (AMH), oestradiol, LH and FSH, which are routinely determined at the PCOS clinic.
223844208|NCT06697652|PROCEDURE|adrenalectomy|adrenalectomy
223844209|NCT06608888|DIAGNOSTIC_TEST|MRI|"Multimodal MRI technology is a method that combines various magnetic resonance imaging techniques, providing more comprehensive images and information about human tissues and organs. These different imaging techniques include, but are not limited to:~Structural MRI (sMRI): Provides information about the types of brain tissues, such as gray matter, white matter, and cerebrospinal fluid.~Functional MRI (fMRI): Dynamically measures the hemodynamic response related to brain neural activity, commonly used to study brain functional activities.~Diffusion Tensor Imaging (DTI): Offers information on the structural connections between brain regions, which can be used to study the neural fiber pathways of the brain"
223844210|NCT06614283|BEHAVIORAL|Diabetes self management @ click|A mobile application tailored for patients with Type 2 diabetes, aiming to enhance their self-management practices will be used for the intervention arm. The app includes features such as medication tracking, appointment scheduling, patient data storage, advice for treatment and follow-ups, health education and promotion, and real-time health monitoring.
223844211|NCT06614803|DEVICE|Transcutaneous vagus nerve stimulation combined slow breathing|The stimulation parameters were set to a burst pulse wave with a frequency of 20Hz, 200μs,5s ON-5s OFF,and a burst frequency of 2000Hz. Electrodes were attached to the tragus and cymba conchae of the left ear,the screen of the device displays slow breathing guidance video at 0.1Hz, while the device delivered stimulation during the 5 seconds of exhalation.
223844212|NCT06614803|DEVICE|Transcutaneous vagus nerve stimulation|Without slow breathing guidance video on the stimulation device,the stimulation parameters were set to a burst pulse wave with a frequency of 20Hz, 200μs,5s ON-5s OFF,and a burst frequency of 2000Hz. Electrodes were attached to the tragus and cymba conchae of the left ear
223844213|NCT06613386|OTHER|The information-based discharge preparation service (IBDPS)|"The main modules of the IBDPS platform include:~* Establishing information records for infants and parents.~* Collaboratively identifying existing or potential caregiving challenges.~* Assessing parents' emotional and psychological states, providing support and intervention.~* Collaboratively establishing caregiving objectives with parents.~* Collaboratively formulating and executing caregiving plans.~* Assessing parental support resources, offering analysis, assistance, and necessary referrals.~* Conducting outcome assessments."
223844214|NCT03035071|PROCEDURE|minimally invasive esophagectomy|In the MIE group the laparoscopic procedure was performed for gastric tube formation. The patient was placed in supine position with legs apart. The surgeon stands between the legs using a five-trocar technique. Laparoscopy will be followed by an anterolateral thoracotomy in the fourth intercostal space.
223844215|NCT03035071|PROCEDURE|open esophagectomy|in the open group the gastric mobilization and gastric tube formation will be perfumed with an open surgical approach. Laparotomy will be performed, followed by an anterolateral thoracotomy in the fourth intercostal space.
223844216|NCT06613503|DEVICE|AI-supporter|rticipants in the experimental group will use the AI-supporter, an intelligent excretion management robot. This device utilizes AI-driven visual recognition technology to automatically detect urine and feces, followed by a cleaning and drying process. When the AI-supporter detects excretion, it activates an automated sequence that washes, dries, and sanitizes the perineal area without requiring the caregiver to remove the diaper. The AI-supporter also records relevant data, such as the time, frequency, and weight of excretion, for further analysis. This intervention is designed to reduce the incidence of urinary tract infections (UTIs) and incontinence-associated dermatitis (IAD), as well as lessen the workload for caregivers
223844217|NCT06614153|DRUG|HRG2010(I)|HRG2010(I)
223844218|NCT06614153|DRUG|HRG2010(II)|HRG2010(II)
223844219|NCT06614153|DRUG|Sustained-release Carbidopa/Levodopa|Sustained-release Carbidopa/Levodopa
223844220|NCT06613646|PROCEDURE|Ultrasound-guided injection of the subacromial bursa and pectoralis minor|"Patients will first receive an ultrasound-guided injection of the subacromial bursa. After the subacromial bursa injection, patients will be monitored for 1 hour, after which the level of relief in their complaints will be assessed using the Numeric Rating Scale (NRS), and passive range of motion will be measured.~Following the subacromial bursa injection, patients will receive an ultrasound-guided injection of the pectoralis minor muscle. After the pectoralis minor muscle injection, patients will again be monitored for 1 hour, after which the level of relief in their complaints will be assessed using the NRS, and passive range of motion will be measured."
223844221|NCT06613646|DRUG|Lidocaine (drug)|5 mL of 2% lidocaine will be used as a local anesthetic for the subacromial bursa injection, and 4 mL of 2% lidocaine will be used for the pectoralis minor muscle injection.
223844222|NCT05504343|DEVICE|"Intensity SL Intraocular Lens"|Cataract surgery and intraocular lens implantation
223844223|NCT06006130|DEVICE|Active Repetitive Transcranial Magnetic Stimulation (rTMS)|rTMS is a non-invasive, non-painful procedure used to relieve chronic pain and promote short-term changes. The abductor pollicis brevis (APB) muscle of the left motor cortex will be targeted using neuronavigation software. 1500 pulses will be delivered at 10 Hz stimulation. Stimulation will be delivered at 80% of the resting motor threshold obtained from the right APB muscle. The delivery of rTMS requires 11 minutes in total.
223844224|NCT06006130|DEVICE|Sham Repetitive Transcranial Magnetic Stimulation (rTMS)|A sham coil will be utilized for the sham rTMS condition. It is important to note that from the participant perspective, the sham stimulation will feel and sound identical to active. The location and all other parameters of Sham rTMS will be identical to Active rTMS.
223844225|NCT06615141|DEVICE|Oculus Quest 3|Oculus quest 3 is a standalone virtual reality headset developed by Meta. It offers precise motion tracking and offers an innovative intervention for stroke rehabilitation, enhancing upper limb motor function throug task - specific exercises.
223844226|NCT06615141|DEVICE|Neofect Smartboard and Tyromotion Myro|"Neofect Smart Board provides non-immersive VR rehabilitation through gamified, task specific exercises to improve upper limb mobility in an interactive way.~Tyromotion Myro uses non-immersive VR therapy combining sensor-based feedback and interactive games to enhance fine motor skills."
223844227|NCT06401993|PROCEDURE|"The dao qi tong luo group"|"The dao qi tong luo group will accept acpuncture. Acupuncture will be performed at acupoints including TE17 (Yifeng), SI19 (Tinggong), GB2 (Tinghui), TE5 (Waiguan), TE3 (Zhongzhu) and etc. Among them, the dao qi tong luo group will make patients feel qi."
223844228|NCT06401993|PROCEDURE|The acupuncture group|The acupuncture group will accept acpuncture. Acupuncture will be performed at acupoints including TE17 (Yifeng), SI19 (Tinggong), GB2 (Tinghui), TE5 (Waiguan), TE3 (Zhongzhu) and etc. The acupuncture group will not feel qi.
223844229|NCT06697535|DRUG|JYP0061|Administered orally with a dose reduction over time as specified in Arm descriptions. Tablets are taken within a specific time frame after meals.
223844230|NCT06697535|DRUG|Intravenous Glucocorticoids|Administered intravenously with a gradually decreasing dose over time, as specified in the Standard Dose Glucocorticoids arm.
223844231|NCT06697535|DRUG|Oral Glucocorticoids|Administered orally with a tapered dosing schedule, as specified in the Standard Dose Glucocorticoids arm, with adjustments based on participant response.
223844232|NCT04811651|BIOLOGICAL|Umbilical Cord-derived Mesenchymal Stem Cells|umbilical cord derived mesenchymal stem cells were intravenously injected in a single dose of one hundred million.
223844233|NCT04811651|DRUG|Placebo|intravenous placebo solution with the same appearance as the treatment group.
223844234|NCT06740357|OTHER|Tumor response monitoring program|three steps of tumor response evaluation (STEP 1 at 2 months, STEP 2 at 4 months, STEP 3 at 6 months after completion of neoadjuvant treatment): STEP 1: digital rectal examination, pelvic MRI, rectoscopy, TAP scan STEP 2: DRE, pelvic MRI, rectoscopy STEP 3: DRE, pelvic MRI, rectoscopy, TAP or PET scan
223844235|NCT06740357|OTHER|Standard evaluation of tumor response|Assessment at 2 months (+/- 7 days) after neoadjuvant treatment: digital rectal exam, pelvic MRI, rectoscopy, TAP scan
223844236|NCT06740357|OTHER|Shared decision-making|At each stage of the monitoring program and depending on the clinical and oncological results, the decision to preserve the rectum will be discussed with the patient according to a shared-decision program.
223844237|NCT06740357|OTHER|Decision-making according to national recommendations|The decision to preserve the rectum is based on assessment at 2 months after completion of neoadjuvant treatment (standard of care since the GRECCAR2 trial).
223844238|NCT06740357|OTHER|Follow-up|Every 3 months for 2 years, then every 6 months for the third year
223844239|NCT05846087|BEHAVIORAL|sleep retraining therapy|Sleep retraining therapy improves sleep efficiency (total sleep time/total time in bed) by reducing the amount of time spent in bed awake. The digitally designed version which SleepFix delivers uses an algorithm which requires the users current sleep times and ideal wake-up time to determine when one should get into bed to fall asleep and when one should get out of bed.
223844240|NCT05846087|OTHER|sleep health education modules|educational modules about sleep and insomnia; its causes; and its impact on various aspects of life. This information is arranged into three modules which will be provided to participants over three weeks.
223844241|NCT04754061|DRUG|Psilocybin|"Phase 1 (week 1): all enrolled participants will take a single 1mg oral dose of psilocybin once per day on Monday and Thursday. If no adverse events are reported at any point during the week (Mon-Fri), the participant will continue to Phase 2 for week 2.~Phase 2: The participant will take a single 1mg oral dose of psilocybin once per day for 5 consecutive days (Monday to Friday). If no adverse events are reported at any point during the week (Mon-Fri), the participant will continue to Phase 3 for week 3.~Phase 3: The participant will take two 1mg oral doses (2mg total) of psilocybin once per day for 5 consecutive days (Monday to Friday). If no adverse events are reported at any point during the week (Mon-Fri), the participant will continue to Phase 4 for week 4.~Phase 4 (maximum allowable dose): The participant will take three 1mg oral doses (3mg total) of psilocybin once per day for 5 consecutive days (Monday to Friday)."
223844242|NCT06166511|PROCEDURE|Laparoscopic liver resection|Using Laparoscopy in liver resection
223844243|NCT01201564|PROCEDURE|intraperitoneal onlay mesh repair|The IPOM technique provides mesh positioning directly into the abdominal cavity onto the defect under laparoscopic control while in sublay position the mesh is placed directly behind des rectus muscle after small incision close to the belly button.
223844244|NCT01201564|PROCEDURE|sublay mesh repair|The IPOM technique provides mesh positioning directly into the abdominal cavity onto the defect under laparoscopic control while in sublay position the mesh is placed directly behind des rectus muscle after small incision close to the belly button.
223844245|NCT06818071|BEHAVIORAL|Points and Leaderboards|"Participants will have the opportunity to gain points if they meet their self-set daily step goal throughout the experiment period.~Participants will also compete with others in their own respective groups on a leaderboard in regards to each day's daily step count."
223844246|NCT06818071|BEHAVIORAL|Social Aspects|Participants will be randomly assigned into groups of three to compete with other groups based on their daily step count. Each day, one participant will be randomly selected to represent the group against their opponent. If they walked more than their randomly selected opponent, the participant's group will receive a positive, encouraging message congratulating them for winning that day. If they did not walk more than their randomly selected opponent, they will receive a motivational message to encourage them to walk more.
223844247|NCT06818071|BEHAVIORAL|Health Messages|Experiment participants will receive messages that encourage healthy behaviors. These include topics such as: nutrition, sleep, physical activity, and decreased consumption/use of unhealthy products (tobacco, alcohol, etc.).
223844248|NCT06818071|BEHAVIORAL|Pikmin Bloom|Participants will play the mobile game Pikmin Bloom, which encourages users to increase their daily step count and allows them to utilize various gamified elements to do so. The game has many gamified elements included, such as personalization and avatar, social aspects, competition, collaboration, progression, and many more.
223844249|NCT06760533|DRUG|Psilocybin 25 mg|Psilocybin 25 mg (active treatment) administered during the psychotherapy treatment session.
223844250|NCT06760533|BEHAVIORAL|Psychotherapy Treatment Session|The psychotherapy treatment sessions will be conducted by two therapists, who will be both present for all the sessions during three phases of treatment: Preparation, Medication Administration, and Integration.
223844251|NCT06760533|DRUG|Niacin 100 mg|Niacin 100 mg (placebo) administered during the psychotherapy treatment session.
223844252|NCT06829238|DRUG|Metformin|Participants will receive Metformin ER (500mg increasing to 1000mg) or placebo for 16 weeks to assess immune restoration and inflammatory response.
223844253|NCT06829238|DRUG|Placebo|Participants will receive placebo for 16 weeks and assess immune restoration and inflammatory response.
223844254|NCT06829238|BIOLOGICAL|Jynneos|All participants will take a Jynneos (MPOX) vaccine.
223844255|NCT06829238|BIOLOGICAL|Capvaxvie|All participants will take a Capvaxvie (PCV21, pneumococcal) vaccine.
223844256|NCT06766981|PROCEDURE|Infiltration with Articain 4%|The experimental group of patients that are diagnosed for tooth extraction of mandibular 1st. molar will undergo extraction using an infiltration technique for local anaesthesia. In contrast to the conventional group that will receive Inferior alveolar nerve block
223844257|NCT06766981|PROCEDURE|Inferior Alveolar Nerve Block|This group will receive a conventional inferior alveolar nerve block (IANB) technique with 2% lidocaine with epinephrine (1:80,000) for tooth extraction.
223844258|NCT06891703|OTHER|[18F]ACI-15916|\[18F\]ACI-15916 is an intravenously administered radioactive imaging agent being studied as a potential positron emitting radiopharmaceutical for in vivo imaging of α-synuclein deposits.
223844259|NCT06779149|BEHAVIORAL|Cognitive Behavioral Treatment for Insomnia (CBT-I)|Participants in this treatment group will receive CBT-I. CBT-I sessions will occur weekly for the first 4 sessions and biweekly for the last 2 sessions (treatment phase is thus 8 weeks). : Graduate level students in clinical psychology will serve as therapists for this project.
223844260|NCT06779149|DRUG|Lemborexant|Participants assigned to this group will be prescribed 5 to 10 mg of lemborexant to be taken at bedtime in 5 mg capsules. Lemborexant (Dayvigo) is a Dual Orexin Receptor Antagonist approved by Health Canada for the treatment of adult with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance. Pharmacy staff will package medications for each participant in a generic bottle labeled with the participant's ID code and treatment dates (identical for the lemborexant and placebo arms). Six consultation visits will be conducted during the 8-week treatment phase to monitor treatment response and drug side effects. The starting dose will be 5 mg with titration to 10 mg if needed (i.e., based on clinical response and tolerability) following the first week.
223844261|NCT06779149|DRUG|Placebo|Participants assigned to this group will be prescribed 5 to 10 mg of placebo to be taken at bedtime in 5 mg capsules identical to lemborexant. Pharmacy staff will package medications for each participant in a generic bottle labeled with the participant's ID code and treatment dates (identical for the lemborexant and placebo arms). Six consultation visits will be conducted during the 8-week treatment phase to monitor treatment response and drug side effects. The starting dose will be 5 mg with titration to 10 mg if needed (i.e., based on clinical response and tolerability) following the first week.
223844262|NCT03253653|DEVICE|Differential effects of waterpipe smoking practices on toxicity of waterpipe tobacco smoke|In a repeated measures design, 50 adult male and female exclusive WP tobacco smokers will smoke WP tobacco weekly over a 3-week study period with 3 WP smoking practices as follows: 1) using room temperature water in the WP jar, 2) adding ice cubes to the water in the WP jar, and 3) using a charcoal-free electronic WP head to heat the tobacco. Six Spot first morning urine samples will be provided by participants. Two urine samples per each of the 3 smoking sessions. Urine samples will be provided on the day of the WP tobacco smoking session and the following day. Physiological measures will be taken at Baseline during the office visit and before and after each of the 3 WP tobacco smoking sessions.
223844263|NCT05700214|DRUG|Ropivacaine injection|30ml of 0.35% ropivacaine
223844264|NCT05700214|DRUG|Lidocaine IV|Before induction bolus of 1% lidocaine 1,5mg/kg IBW i.v., continuous infusion of 1% lidocaine intraoperatively rate 1 mg/kg IBW i.v.
223844265|NCT06846034|OTHER|Hypoxia administration study group|Acute 2-hour hypoxia (14.5%FiO2 corresponding to 3000m altitude)
223844266|NCT06846034|COMBINATION_PRODUCT|Renal clairance study|"Assessment of renal clearance by measuring Glomerular Filtration Rate (GFR) after two agents infusion:~* Aminohippurate Sodium (or or para-aminohippuric acid \[PAH\]) Inj 20% Diagnostic agent used to measure effective renal plasma flow (ERPF)~* Iohexol Inj 300 MG/ML Diagnostic agent used to measure glomerular filtration rate (GFR)"
223844267|NCT06750965|DIAGNOSTIC_TEST|Serum M protein screening|Using highly sensitivity test to screen serum M protein of all participants.
223844268|NCT06780293|OTHER|Laser acupuncture (LA)|The RJ-Laser acupuncture device (Reimers \& Janssen GmbH, Waldkirch, Germany) is used with a laser wavelength of 810 nm (infrared). The Bahr frequency B3 is set at 2398 Hz, with an energy output of 400 mW, operating in intermittent pulse mode. Each acupoint is irradiated for 15 seconds. A total of 8 bilateral acupoints are treated per session, with a total treatment time of approximately 120 seconds.
223844269|NCT06780293|DIAGNOSTIC_TEST|Numerical Rating Scale (NRS)|LA+LA group of SJS-DES, Sham+LA group of SJS-DES, LA+LA group of Non-SJS-DES, Sham+LA group of Non-SJS-DES and Waiting list will take the Numerical Rating Scale (NRS).
223844270|NCT06780293|DIAGNOSTIC_TEST|Schirmer's test|LA+LA group of SJS-DES, Sham+LA group of SJS-DES, LA+LA group of Non-SJS-DES, Sham+LA group of Non-SJS-DES and Waiting list will take the Schirmer's test.
223844271|NCT06780293|DIAGNOSTIC_TEST|Ocular Surface Disease Index (OSDI)|LA+LA group of SJS-DES, Sham+LA group of SJS-DES, LA+LA group of Non-SJS-DES, Sham+LA group of Non-SJS-DES and Waiting list will take the OSDI test.
223844272|NCT06780293|DIAGNOSTIC_TEST|EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI)|LA+LA group of SJS-DES, Sham+LA group of SJS-DES, LA+LA group of Non-SJS-DES, Sham+LA group of Non-SJS-DES and Waiting list will take the ESSPRI.
223844273|NCT06780293|DIAGNOSTIC_TEST|Traditional Chinese Medicine (TCM) tongue diagnosis|LA+LA group of SJS-DES, Sham+LA group of SJS-DES, LA+LA group of Non-SJS-DES, Sham+LA group of Non-SJS-DES and Waiting list will take the Traditional Chinese Medicine (TCM) tongue diagnosis.
223844274|NCT06780293|DIAGNOSTIC_TEST|Traditional Chinese Medicine (TCM) pulse diagnosis|LA+LA group of SJS-DES, Sham+LA group of SJS-DES, LA+LA group of Non-SJS-DES, Sham+LA group of Non-SJS-DES and Waiting list will take the Traditional Chinese Medicine (TCM) pulse diagnosis.
223844275|NCT06780293|DIAGNOSTIC_TEST|Traditional Chinese Medicine (TCM) constitution questionnaire|LA+LA group of SJS-DES, Sham+LA group of SJS-DES, LA+LA group of Non-SJS-DES, Sham+LA group of Non-SJS-DES and Waiting list will take the Traditional Chinese Medicine (TCM) constitution questionnaire.
223844276|NCT06780293|DIAGNOSTIC_TEST|Traditional Chinese Medicine (TCM) heart rate variability analysis|LA+LA group of SJS-DES, Sham+LA group of SJS-DES, LA+LA group of Non-SJS-DES, Sham+LA group of Non-SJS-DES and Waiting list will take the Traditional Chinese Medicine (TCM) heart rate variability analysis.
223844277|NCT06780293|DIAGNOSTIC_TEST|nailfold microcirculation assessment|LA+LA group of SJS-DES, Sham+LA group of SJS-DES, LA+LA group of Non-SJS-DES, Sham+LA group of Non-SJS-DES and Waiting list will take the nailfold microcirculation assessment.
223844278|NCT06780293|DIAGNOSTIC_TEST|iris examination|LA+LA group of SJS-DES, Sham+LA group of SJS-DES, LA+LA group of Non-SJS-DES, Sham+LA group of Non-SJS-DES and Waiting list will take the iris examination.
223844279|NCT06780293|OTHER|Sham Laser Acupuncture|"The RJ-Laser acupuncture device (Reimers \& Janssen GmbH, Waldkirch, Germany) is used with a laser wavelength of 810 nm (infrared). The Bahr frequency B3 is set at 2398 Hz, with an energy output of 400 mW, operating in intermittent pulse mode. Each acupoint is irradiated for 15 seconds. A total of 8 bilateral acupoints are treated per session, with a total treatment time of approximately 120 seconds.~The sham laser acupuncture procedure follows the same process as the true laser acupuncture protocol, including the positioning, cleaning of acupoints, and wearing of protective goggles. However, no laser emission is delivered during the treatment. This ensures a consistent experience for the patient while maintaining the blinding integrity of the study."
223844280|NCT06621563|DRUG|HS-20117 combined HS-20093|HS-20117 + HS-20093
223844281|NCT06621563|DRUG|HS-20117 combined Platinum-containing chemotherapy|HS-20117 + cisplatin/carboplatin + pemetrexed
223844282|NCT06621563|DRUG|HS-20117 combined HS-20093 and 5-FU|HS-20117 + HS-20093 + 5-FU
223844283|NCT06621563|DRUG|HS-20117+CAPEOX|CAPOEX: Oxaliplatin+Capecitabine
223844284|NCT06621563|DRUG|HS-20117+FOLFIRI|FOLFIRI=Irinotecan+Leucovorin Calcium+5-FU
223844285|NCT06621563|DRUG|HS-20117+mFOLFOX6|mFOLFOX6=Oxaliplatin+Leucovorin Calcium+5-FU
223844286|NCT06907030|OTHER|No intervention|No intervention
223844287|NCT06906094|PROCEDURE|Selective meniscectomy|involves the partial removal of the damaged meniscus.
223844288|NCT06913114|DIAGNOSTIC_TEST|Lafayette|The Lafayette handheld dynamometer data correlates with the measurements taken using the 10-Meter Walk Test (10MWT) or not.
223844289|NCT06913114|DIAGNOSTIC_TEST|Lafayette|Lafayette handheld dynamometer.
223844290|NCT06918080|DRUG|Ursodeoxycholic Acid 250 Mg Oral Capsule|Daily doses of Ursodeoxycholic acid (UCD) Ursofalk) in a dose of 20 mg/Kg/day in two divided doses depending on their body weight for 12 weeks will be assigned to arm(1)
223844291|NCT06918080|DIETARY_SUPPLEMENT|Omega -3 fatty acids|Supplementation of omega 3, the dose of omega-3 fatty acids will be determined by baseline weight (\<40 kg-450 mg/day, 40-60 kg-900 mg/day, \>60 kg-1300 mg/day) will be assigned to children in arm (1). Side effect such as gastrointestinal upset and allergy will be monitored, compliance will be monitored by weekly phone call
223844292|NCT06918080|BEHAVIORAL|Physical exercise|Patients assigned to arm (1) will participate in a 12-week exercise program for 30-45 min/day for 3 days/week. in the first two weeks and for 60 min/day for 4-5 days/week in the following weeks
223844293|NCT06918080|BEHAVIORAL|Mediterrenean diet|"Patients in arm (1) will follow Mediterranean Diet (MD) for 12 weeks, this diet is characterized by a high intake of vegetables, fruit, whole cereals, legumes, nuts, and fish and a low intake of red meat and homemade desserts. The main added fat is extra virgin olive oil, with 35-40% kcal from fat (\<10% from saturated fat), 40-44% kcal from carbohydrate, and 20% kcal from protein.( Plaz et al., 2019) Patient caloric intake will be calculated according to the Recommended Daily Allowance (RDA) for age.~Compliance to the MD will be assessed in all patients using the KIDMED index at 4 ,8 and 12 weeks.Those who prove to be non-compliant will be excluded from the study."
223844294|NCT06918080|BEHAVIORAL|Diet according to NASPGHAN guidelines|Patients in arm (2) will receive lifestyle modification according to NASPGHAN Clinical Guidelines for the treatment of NAFLD in Children. Patients will follow healthy and well-balanced diet. Patient caloric intake will be calculated according to the Recommended Daily Allowance (RDA) for age, with avoidance of sugar-sweetened beverages, moderate- to high-intensity exercise daily will be encouraged, and screen time will be limited to less than 2 hours.
223844295|NCT06919510|DRUG|lvonescimab|lvonescimab, DS1, D1,q3w, intravenous infusion
223844296|NCT06919510|DRUG|CAPOX (oxaliplatin/capecitabine)|Oxaliplatin 130 mg / m2, D1, intravenous infusion, q3w, Capecitabine 1000 mg / m2,twice a day, oral,1-14 days, then rest for 7 days, q3w.
223844297|NCT06919510|RADIATION|radiotherapy|5\* 5Gy, once a day, 5Gy each time, for 5 days
223844298|NCT06919510|PROCEDURE|Surgery or watch&wait|The surgical method is selected by the investigator. Watch and Wait (only for patients with clinical complete response after neoadjuvant therapy)
223844299|NCT06918444|DEVICE|WARIFA app with AI|"Participants will be given access to the WARIFA app on their mobile phones during the study.~This app will collect activity data as well as questionnaires and diaries. Using this data and artificial intelligence, it will provide participants with personalised information and recommendations about their lifestyle and risk of chronic non-communicable diseases."
223844300|NCT06918444|DEVICE|WARIFA app without AI|"Participants will be given access to the WARIFA app on their cell phones during the study.~This app will collect activity data, as well as through questionnaires and diaries. With this data, it will give information and general recommendations to the participants related to their lifestyle habits and risks of chronic non-communicable diseases, following the WHO guidelines. This version will not use artificial intelligence or personalized messages."
223844301|NCT06919406|BEHAVIORAL|Mindfulness Intervention for emotional distress(MIED）|MIED is an eight-week program developed based on MBSR and the Unified Protocol for Transdiagnostic Treatment of Emotional Disorders. MIED consists of weekly group sessions with daily interactive materials delivered via a WeChat-based mini-program. The group sessions, conducted online, provide structured content and interactive discussions aligned with the weekly themes, for example including psychoeducation on mindfulness, emotions, and emotional distress. Mini Program and lasted for 49 days. Each day, participants received different materials including (a) an audio recording of mindfulness meditation guidance; (b) learning materials in text or audio; and (c) assignments (for example, informal mindfulness practice, emotion journal, and challenging tasks).
223844302|NCT06918600|OTHER|Virtual Reality-Supported Early Mobilization Program|"The intervention involves the use of a virtual reality (VR)-supported mobilization program specifically designed for patients recovering from open-heart surgery. Participants wear a VR headset that delivers guided sessions comprising:~Breathing Exercises: Deep breathing and coughing techniques to support respiratory function and prevent complications.~Lower Limb Exercises: Interactive movements aimed at improving circulation and preventing venous stasis.~Mobilization Strategies: Gradual and guided steps to assist patients in transitioning from bed to ambulation, tailored to their recovery stage.~This intervention is unique because it integrates an immersive and engaging digital environment to promote physical activity, reduce anxiety, and enhance motivation during the critical early postoperative phase. Unlike standard rehabilitation practices, the VR program provides real-time feedback and visual cues to ensure correct execution of movements."
223844303|NCT06918288|DEVICE|High flow nasal canula|All patients assigned to the HFNC group will receive HFNC immediately after extubation. Researchers will need to choose the suitable size nasal catheter. The initial airflow will be set to 50 L/min and adjusted according to patient tolerance with an absolute humidity setting to 44 mgH2O/L and the temperature setting to 37 °C.The patient's respiratory rate will be maintained below 30 beats/min or the baseline level before extubation with a SpO2 at 88-92%. HFNC failure is defined as escalation to NIV or invasive mechanical ventilation due to respiratory failure.
223844304|NCT06918288|DEVICE|Non-invasive positive pressure mechanical ventilation|All patients assigned to the control group will receive NIV immediately after extubation. Researchers will use a standard oronasal mask to connect the patient to the ventilator. The patients will be on Spontaneous/Timed (S/T) mode, with the initial end-expiratory pressure setting to 4 cmH2O. The pressure level will gradually increase to ensure that the patients can trigger the ventilator with each inhalation. The initial inspiratory pressure will be set at 8 cmH2O and adjusted according to the tidal volume with 6-8 ml/kg and tolerance of patients. The pres- sure level and the fraction of inspiration oxygen will be adjusted in order to maintain the respiratory rate ≤ 30/ min or the baseline level before extubation, a partial pressure of carbon dioxide (PaCO2) at 45-60 mmHg or the last PaCO2 level recorded before extubation, and a pulse oxygen saturation at 88-92%. NIV treatment failure is defined as a return to invasive mechanical ventilation.
223844305|NCT06919679|DRUG|BrECADD|Brentuximab Vedotin Etoposide Cyclophosphamide Doxorubicin Dacarbacine Dexamethasone
223844306|NCT06919302|BEHAVIORAL|Digital Heart Health Program|The digital heart health program will include the web-based app, which will deliver the intervention through interactive features (dashboard, goal setting, gamification, nudges, etc.) and will be supported by a 16-session synchronous online behaviour change program and provision of key study foods.
223844307|NCT06920511|DEVICE|Cognitve rehabilitation with virtual reality and robotic arm|The intervention consists of a cognitive rehabilitation program using the PRoBio platform, a bio-cooperative robotic system integrating virtual reality and real-time multisensory feedback. The PRoBio platform includes a robotic arm (TIAGo), a virtual reality interface (VRRS), and sensors to monitor biomechanical, cognitive, and emotional parameters during training.
223844308|NCT06918405|DRUG|Tirzepatide|"All the included patients in both the diabetic and nondiabetic groups will receive the same intervention of tirzepatide at a dose of 15 mg administered subcutaneously once a week in addition to lifestyle modification.~Initially, tirzepatide will be started with a dose of 2.5 mg once weekly subcutaneous injection for the first 4 weeks. After the stabilization period of the drug, the dose will be increased to 5 mg after 4 weeks, 7.5 mg after 8 weeks, 10 mg after 12 weeks, 12.5 mg after 16 weeks and finally 15 mg after 20 weeks."
223844309|NCT06918301|DIAGNOSTIC_TEST|Measurement of cardiac performance|Measurement of cardiac performance by different devices
223844310|NCT06919029|DEVICE|Advanced Hybrid Closed Loop from onset of type 1 diabetes in children|The objective of this study is to evaluate glycemic control of users of the AHCL system MiniMed 780G with GS4 calibration-free sensor in children and adolescents with newly diagnosed T1D implemented directly upon T1D diagnosis in combination with continuous glucose monitoring system (CGMS) compared with those treated with MDI retrieved from historical data- in a single- arm open-label prospective observational study, assessed at 3 months. After the initial study period there will be a 3month extension phase of the study.
223844311|NCT06914206|DRUG|esketamine group|in addition to receiving the combination of PRF of DRG and standardized drug treatment, patients will also undergo a single intravenous infusion of esketamine.
223844312|NCT06914206|DRUG|PRF group|In the control group, patients will receive PRF+standardized drug treatment. Pulsed radiofrequency (PRF) will be performed on DRG by an designated physician in each participating center. They will be treated with PRF (PMG-230, Baylis Medical Inc.) using a 21-gauge sterilized radiofrequency needle (a 10-cm trocar with a 5-mm active tip, PMF-21-100-5, Baylis Medical Inc.), which are carefully inserted until the needle tip reaches the upper edge of the intervertebral foramen. The parameters of PRF treatment will be set at 42 ℃, 2 Hz with 20 milliseconds current. The standardized drug treatment will include antiviral therapy, anticonvulsant treatment, three-step analgesic therapy
223844313|NCT06917833|OTHER|compare infant hypoxic events in both groups|early neonatal resuscitation will be done by the pediatrician according to the guidelines, APGAR score of the baby will be calculated,, any hypoxic events will be traced and any need of respiratory support for the baby or NICU admission, as well as weight of the baby, mode of delivery and any birth traumas will be recorded.all this will be compared between two groups.
223844314|NCT06934148|BEHAVIORAL|Blocked Trials|Each search task will be presented in a block of trials.
223844315|NCT06934148|BEHAVIORAL|Mixed trials|All tasks will be randomly mixed in a single block of 400 trials
223844316|NCT00929305|DEVICE|Erchonia PL2000|The Erchonia PL2000 Laser emits 1 mW of red (635nm wavelength) light via an electric diode energy source. It is a hand-held device that uses rechargeable batteries or a separate power adapter.
223844317|NCT00929305|DEVICE|Placebo laser|Inactive laser light
223844318|NCT00188409|PROCEDURE|CT scan|
223844319|NCT03624595|DRUG|Dexmedetomidine|Dexmedetomidine infusion is administered from 16:00 to 08:00 during the night of surgery in the intensive care unit; and will repeated for a maximum of 5 consecutive nights. For patients with mechanical ventilation, the infusion rate is 0.2-0.7 ug/kg/h; for those without mechanical ventilation, the infusion rate is 0.05-0.2 ug/kg/h. The target depth of sedation is Richmond Agitation-Sedation Scale (RASS) -1.
223844320|NCT03624595|DRUG|Placebo|Placebo (normal saline) infusion is administered in the same rate for the same duration as in the dexmedetomidine group. The conventional sedation is provided when necessary with propofol and/or midazolam by intravenous infusion/injection. The target depth of sedation depth is RASS -1.
223844321|NCT04406779|DEVICE|thyroid USG was perform, blood samples were taken for the meausurement of thyroid hormone and autoantibodies|thyroid USG was perform, blood samples were taken for the meausurement of thyroid hormone and autoantibodies
223844322|NCT04610684|DRUG|Carboplatin|Carboplatin 5-6 mg/mL/min AUC will be delivered over 30 - 60 minutes intravenously on Day 1 of each 21 day Cycle after completion of atezolizumab. For 4 cycles.
223844323|NCT04610684|DRUG|Etoposide|Etoposide 80-100 mg/m2 will be delivered over 60 minutes intravenously on Days 1-3 of each 21 day Cycle after completion of carboplatin (Day 1 only). For 4 cycles.
223844324|NCT04610684|DRUG|Atezolizumab|Atezolizumab 1200 mg will be delivered over 60 (± 15) minutes intravenously on Day 1 of each 21 day Cycle for 4 cycles then continue as monotherapy maintenance with the same schedule.
223844325|NCT05079217|BIOLOGICAL|High-dosage SARS-CoV-2 vaccine|SARS-CoV-2 Inactivated Vaccine 1200SU inactivated virus in 0.5 mL of aluminium hydroxide solution per injection
223844326|NCT05079217|BIOLOGICAL|Medium-dosage SARS-CoV-2 vaccine|SARS-CoV-2 Inactivated Vaccine 600SU inactivated virus in 0.5 mL of aluminium hydroxide solution per injection
223844327|NCT03478579|OTHER|observational|No intervention, it is observational study
223844328|NCT02190838|DRUG|Metformin|per os 850 mg BID
223844329|NCT02190838|DRUG|Melatonin|per os 3 mg daily
223844330|NCT02190838|DRUG|Dacarbazine|IV 1 hour 1000 mg/m\^2 once in 28 days
223844331|NCT02998827|DRUG|Thalidomide|
223844332|NCT02998827|DRUG|infliximab, azathioprine|other treatment include infliximab, azathioprine
223844333|NCT02998827|OTHER|enteral nutrition|
223844334|NCT03494699|BEHAVIORAL|Multidisciplinary prevention|group cognitive training (every month) App-based Cognitive Training at Home (using smartphone application) physical activity/body weight/smoking \& alcohol cessation monitoring and feedback
223844335|NCT02655692|DRUG|Ketamine|FDA approved anesthetic medication with rapid acting antidepressant effects.
223844336|NCT02655692|DRUG|Placebo/Saline|This is a saline placebo/non-active solution.
223844337|NCT03768245|BEHAVIORAL|Health Education and Physical activity program|Its objective is to empower children on healthy lifestyle, addressing four main topics: nutrition (i.e. healthy food, hydration), adequate quantities of food, physical activity, and self-monitoring. The program is implemented in the classroom through workshops planned and conducted by psychologists and nutritionists. A total of 12 workshops are planned, to be conducted once a week, and lasting 50 minutes each. The Physical activity program objective is to develop an active scholar environment, and consists of a moderate-vigorous activity, five days a week. The activities are divided into two types: (a) in the school backyard for 60 minutes, three times a week, and (b) in the classroom two days a week, for 15 minutes three times a day, adding up to 45 minutes daily.
223844338|NCT03768245|DIETARY_SUPPLEMENT|Nutrition Program|Its objective is to maintain lean mass, decrease fat mass and ensure mineral vitamins and fatty acids intake, maintain proper growth under National Specific Action Program: Food and Activity4. From total energy, a fat intake of 25-35%, carbohydrate intake of 45-65%, protein intake of 10-30%, and total calories are adjusted according to age. The Nutrition program consists of three meals: breakfast, a snack for a mid-morning playtime, and lunch at school. Food is prepared daily following sanitary and quality standards of Mexican official regulation. Breakfast is served 40 minutes before starting class time, lunch is served 40 minutes before leaving school.
223844339|NCT02721511|DRUG|Furosemide Injection Solution 8mg/mL|Furosemide Injection Solution, 8 mg/mL, (total dose =80 mg) administered subcutaneously as 30 mg over the first hour and then as 12.5 mg per hour over the subsequent 4 hours by means of the B. Braun Perfusor® Space Infusion Pump System.
223844340|NCT01084161|DRUG|N1539|5 mg IV once per day
223844341|NCT01084161|DRUG|N1539|7.5 mg IV once per day
223844342|NCT01084161|DRUG|N1539|15 mg IV once per day
223844343|NCT01084161|DRUG|N1539|30 mg IV once per day
223844344|NCT01084161|DRUG|placebo|IV placebo once per day
223844345|NCT01084161|DRUG|Morphine|morphine 10-15 mg IV once per day
223844346|NCT01084161|DRUG|N1539|60 mg IV once per day
223844347|NCT01217580|DRUG|0.5% ropivacaine|20ml each side of the hip of 0.5% ropivacaine into the transverse abdominis plane after patient is brought to the recovery area after elective cesarean delivery
223844348|NCT01217580|DRUG|0.9% sodium chloride|20ml each side of the hip of 0.9% sodium chloride into the transverse abdominis plane after patient is brought to the recovery area after elective cesarean delivery
223844349|NCT02728245|DRUG|Dienogest|Dienogest 2mg po qd
223844350|NCT02728245|DRUG|Placebo drug|Placebo 1 table po qd
223844351|NCT02728245|PROCEDURE|Surgery|conservative surgery without intent to oophorectomy
223844352|NCT03959709|PROCEDURE|immediate acellular dermal matrix-assisted implant-based breast reconstruction with prepectoral implant placement.|On the day of surgery, after the completion of the mastectomy, the vascularity of the mastectomy flaps will be evaluated, and debridement is performed where necessary. A temporary implant sizer is placed in the pocket to assess the position and shape of the prepectoral pocket. The pocket is adjusted where necessary. A sheet of ADM (DermAcell) is then selected. The DermAcell will be prepared as per the manufacture's instructions and fenestrated using size 11 blade. The DermACELL piece will be trimmed to the appropriate shape and sutured to the superior medial and lateral edges of the pectoralis major muscle. The inferior edge will be sutured to the fascia at the level of the inframammary fold. Two closed suction drains will be placed (one below the mastectomy skin flap, and one below DermACELL). The implant will be inserted to the pre-pectoral pocket and several anchor sutures will be used to secure the superior-medial edge of DermACELL to mastectomy flap.
223844353|NCT03959709|PROCEDURE|Immediate acellular dermal matrix-assisted implant-based breast reconstruction with subpectoral implant placement|On the day of surgery, after the completion of the mastectomy, the vascularity of the mastectomy flaps will be evaluated, and debridement is performed where necessary. The reconstructive operative procedure will then proceeded with (1) elevation of the pectoralis major muscle with release of inferior attachments; (2) placement of implant subpectorally; (3) placement and suturing of DermACELL to constitute the inferolateral breast pocket; (4) placement of two closed suction drains (one superiorly between the pectoralis major and skin, and one inferiorly between the DermACELL and skin); (5) removal of sizer and placement of permanent to the pocket and (6) suture the inferior edge of DermACELL to the inferior edge of the pectoral major muscle. The skin will be closed and the dressing will be applied as standard protocol.
223844354|NCT00038792|DRUG|Recombinant Human Keratinocyte Growth Factor|
223844355|NCT00312078|DIETARY_SUPPLEMENT|Yogurt Supplementation|
223844356|NCT01251614|BIOLOGICAL|Adalimumab|Adalimumab by subcutaneous injection every other week (eow)
223844357|NCT01251614|DRUG|Methotrexate|Methotrexate 0.1 mg/kg at Week 0 and up to 0.4 mg/kg per week (maximum dose of 25 mg/week) orally.
223844358|NCT01251614|BIOLOGICAL|Placebo to Adalimumab|A single subcutaneous loading dose at Week 0 followed by eow dosing beginning at Week 1.
223844359|NCT01251614|DRUG|Placebo to Methotrexate|Orally once a week
223844360|NCT02387203|DRUG|PrevPac (Prevacid, Amoxicillin, Clarithromycin)|30mg Prevacid, 1g amoxicillin, 500mg clarithromycin administered together for oral use, twice daily for 14 days preoperatively and twice daily for 14 days at least 4 weeks postoperatively
223844361|NCT02153788|DRUG|Temazepam|Temazepam 15 mg orally at bedtime
223844362|NCT02153788|DRUG|Placebo|
223844363|NCT05247853|PROCEDURE|Blood collection|Blood collection at enrollment visit
223844364|NCT05247853|PROCEDURE|Oral, cervicovaginal and anal specimen collection|Oral, cervicovaginal and anal specimen collection at enrollment and follow-up visits
223844365|NCT05247853|PROCEDURE|Anoscopy & Biopsy of Acetowhite Lesions|Used for management in follow-up visits of persistent anal HPV16/18+ in WLWH
223844366|NCT05247853|PROCEDURE|Colposcopy & Biopsy of Acetowhite Lesions|Used for management in follow-up visits of persistent type-specific high-risk HPV cervicovaginal HPV
223844367|NCT05247853|PROCEDURE|Ablative Treatment|Use for management in follow-up visits of persistent cervicovaginal HPV 16/18+ in WLWH, as identified in colposcopy and biopsy
223844368|NCT05247853|PROCEDURE|LEEP (Loop Electrosurgical Excision Procedure)|Use for management in follow-up visits of persistent cervicovaginal HPV 16/18+ in WLWH, as identified in colposcopy and biopsy that ablation ineligible
223844369|NCT05322161|BEHAVIORAL|yoga classes|"There will be 6 total yoga classes (one introduced per week for a 6 week period). Each yoga session will be divided into three components, which will vary in duration based on a curriculum designed specifically with the post-partum state of mothers in mind:~1. Yoga postures (Asana) = low impact gentle postures meant to be done individually~2. Breathing techniques (Pranayama) = deliberate modifications of breath such as rapid diaphragmatic breathing, slow/deep breathing, alternate nostril breathing, breath holding~3. Meditation (Dhyana) = guided meditation"
223844370|NCT01032850|DRUG|Sorafenib & Capecitabine|Intervention: Sorafenib twice a day by mouth (400mg), Capecitabine twice a day by mouth (850mg). One cycle of treatment will consist of capecitabine on days 1-7 and 15-22 while sorafenib will be given daily continuously. Cycles will be repeated every 28 days.
223844371|NCT03426514|PROCEDURE|Three-port Laparoscopic Surgery|Patients undergo three-port laparoscopic surgery. The surgery will be completed by a surgeon and a camera-person without another assistant. The surgeon will adjust surgical position to expose the operative field with the help of gravity. All the orther operative procedures are the same as conventional laparoscopic surgery.
223844372|NCT03426514|PROCEDURE|Conventional Laparoscopic Surgery|Patients undergo conventional laparoscopic surgery（4 or more ports）.The surgery will be routinely completed by a surgeon，a camera-person and another assistant to provide counter-traction.
223844373|NCT00530374|DIETARY_SUPPLEMENT|Oral Iron Supplement|Iron Sprinkles are provided as a powder in a single-dose sachet to be taken once daily for 60 days
223844374|NCT00530374|DIETARY_SUPPLEMENT|Placebo|Placebo Sprinkles are provided as a powder in a single-dose sachet to be taken once daily for 60 days
223844375|NCT03044769|PROCEDURE|Malformations resection|Resection of the malformation lung sections with a healthy adjacent part
223844376|NCT02487290|DEVICE|Aneufix ACP-T5|The ACP-T5 is injected via translumbar approach into the aneurysm sac near the entrance/exit of bloodvessel. ACP-T5 will cure and block the endoleak.
223844377|NCT05955599|OTHER|ACL Injury Prevention Training|Supervised ACL injury prevention training twice a week (2 x 15 minutes) over an 8-week period.
223844378|NCT05955599|OTHER|Control - Shoulder Injury Prevention Training|Supervised shoulder injury prevention training twice a week (2 x 15 minutes) over an 8-week period.
223844379|NCT02746900|PROCEDURE|Cervical cerclage|McDonald cervical cerclage
223844380|NCT01684046|DEVICE|Opti-Free® PureMoist® MPDS|
223844381|NCT01684046|DEVICE|RevitaLens MPDS|
223844382|NCT01684046|DEVICE|Habitual Contact Lenses|Silicone hydrogel contact lenses per participant's habitual brand, prescription, and replacement schedule worn on a daily wear basis for at least 8 hours a day, 5 days a week for the duration of the study. During the washout period, the contact lenses were worn on a daily disposable basis.
223844383|NCT04074551|DRUG|HCP1701|HCP1701
223844384|NCT04074551|DRUG|Losartan|Losartan
223844385|NCT04074551|DRUG|Amlodipine|Amlodipine
223844386|NCT04074551|DRUG|Rosuvastatin and Ezetimibe|Rosuvastatin and Ezetimibe
223844387|NCT03521323|DRUG|Umbilical Cord Mesenchymal Stem Cells|Intrathecal Transplantation of Umbilical Cord Mesenchymal Stem Cells
223844388|NCT03521323|DRUG|Placebos|Placebos: Saline，Sham operation
223844389|NCT05336123|BEHAVIORAL|Hatha Yoga|Weekly hatha yoga classes lasting 10 weeks.
223844390|NCT05336123|BEHAVIORAL|Health Education|Weekly health education classes lasting 10 weeks.
223844391|NCT04902586|DEVICE|TTFields|The TTFields, consisting of low-intensity, 200 kHz frequency, alternating electric fields, was delivered (≥ 18 hours/d) via 4 transducer arrays on the shaved scalp and connected to a portable device.
223844392|NCT06063330|COMBINATION_PRODUCT|RQ-001|"Drug product RQ-001 is the fully assembled device consisting of the vial containing RQ-01 and the actuator. Drug Product RQ-001 has been developed with an Aptar Bidose liquid nasal spray unit device (BDSI V3) capable of intranasally delivering a 200 uL total volume of drug product (specifically, 100 uL per nare, which delivers a 200 uL of total volume). The combination product comprises the drug constituent (RQ-01) and the assembly of commercially available, off-the-shelf device components.~Study staff will be responsible for assembling the drug product RQ-001 and subjects will self-administer under the supervision of study staff in the clinic."
223844393|NCT06063330|OTHER|Placebo|Matching placebo will be manufactured just as RQ-01 drug substance, with the active ingredient addition step omitted. Placebo will appear similar to RQ-01 drug substance as a clear to hazy, colorless to yellowish liquid. Matching placebo will be administered the same way as RQ-01
223844394|NCT05482386|OTHER|Statin discontinuation|Statin therapy will be stopped. Additional lipid-lowering medication lowering LDL cholesterol will also be stopped.
223844395|NCT04531540|DRUG|Butenafine HCl 1% (BAY1896425)|Approximately 0.2 g of cream containing butenafine HCl 1% were applied to the upper back skin.
223844396|NCT02688621|BEHAVIORAL|Internet Only|18 month behavioral weight loss intervention delivered online
223844397|NCT02688621|BEHAVIORAL|Internet + Incentives|18 month behavioral weight loss intervention delivered online with the possibility of earning incentives for losing weight and performing weight loss behaviors including monitoring food intake, exercising, and daily weighing
223844398|NCT02512146|PROCEDURE|colonoscopy|Patients will undergo colonoscopy and participants will get biopsies from the colon.
223844399|NCT04582357|BEHAVIORAL|Physical activity program|The physical activity program is a suite of several exercises which intend to improve muscular mass of targeted muscles.
223844400|NCT01501630|DEVICE|performance of PET/CT and whole-body MRI|For PET/CT radiopharmaceuticals, both registered in France:Fluoride (18F)FLUOROCHOLINE (18F)No contrast agent scheduled for MRI in the study RadiopharmaceuticalsSingle use, 2-4 MBq/kg body weight, IV infusion
223844401|NCT06504875|DRUG|Tislelizumab|Tislelizumab 200mg ivd D1
223844402|NCT06504875|DRUG|Interleukin-2|Interleukin 2 100IU HD,QOD d1-d14
223844403|NCT06504875|DRUG|Capecitabine|Capecitabine: 1000mg/m2 bid po, d1-d14
223844404|NCT06504875|DRUG|Oxaliplatin|Oxaliplatin 130mg/m2 ivd, d1
223844405|NCT05698940|PROCEDURE|Infundibultomy|Infundibultomy on one side of patient
223844406|NCT03239210|DRUG|Ondansetron|5-HT3 (serotonin receptor type 3) antagonist commonly used to treat nausea and vomiting
223844407|NCT03239210|DRUG|Placebo|placebo equivalent
223844408|NCT05634213|DRUG|normal saline|Once the patient is placed on cardiopulmonary bypass, the product will be injected into the left atrial wall using a 27 gauge needle as 4 injections of 200 μL each. Two will be placed in the atrial appendage. The remaining 2 injections will be placed equidistant on the anterior atrial free wall. Each injection will be performed just under the surface of the atrial epicardium over 30 seconds. The needle will stay in place for 10 seconds after the injection to limit back flow from the site of injection.
223844409|NCT00629512|DRUG|Esomeprazole|20mg oral daily
223844410|NCT00629512|DRUG|Esomeprazole|40mg oral daily
223844411|NCT00629512|DRUG|Placebo|
223844412|NCT06502015|DIAGNOSTIC_TEST|biomaker levels|this study will discover and validate novel biomarkers (including blood, feces, bone marrow and lymph nodes etc al) of various neurological autoimmune diseases
223844413|NCT00476203|BEHAVIORAL|Yoga|Instructor-led yoga classes 1/time per week + 4 days of home practice
223844414|NCT00476203|OTHER|Delayed yoga classes|Delayed yoga classes (after 6 months) offered \[wait list control group\]
223844415|NCT01575860|DRUG|Lenalidomide|Lenalidomide, 10mg, oral tablets, daily
223844416|NCT00188929|PROCEDURE|PET Scan with [18F]Fluoro-2-deoxyglucose (FDG)|
223844417|NCT04648306|DEVICE|Prophylactic Impella support for a non-emergent PCI|Impella percutaneous mechanical circulatory support is placed via the femoral or axillary artery prior to a non-emergent PCI in patients at high risk for periprocedural complications including hemodynamic collapse.
223844418|NCT03311854|DRUG|Emapalumab|Emapalumab was administered at an initial dose of 6 mg/kg by intravenous infusion. Emapalumab treatment continued at a dose of 3 mg/kg, every 3 days until study day 15, and then twice-a-week for an additional 2 weeks, i.e., until study day 28. The emapalumab regimen could be adapted (the frequency between infusions shortened, the dose increased, or the treatment prolonged beyond 4 weeks) upon assessment of a favourable benefit-risk profile. There was a 4-week off-drug follow-up period (up to Week 8).
223844419|NCT06200038|OTHER|Mulligan Reverse Natural Apophysial Glide Technique (RNAGS)|"Mulligan mobilization techniques was applied to the upper thoracic segments with the RNAGS technique. The application was performed with one hand (thumb in extension, other fingers flexed) that was used to perform the pushing maneuver on the transverse processes, while the other arm was used to gently grasp the head of the patient and recline the neck against the body for stabilization.~Conventional TENS was applied to the neck area with 2 channels and 4 electrodes for 20 min (current passage time: 50-100 microseconds, frequency: 0-120 Hz). Ultrasonography was performed for 8 minutes with an intensity of 1.5 w/cm2 and a frequency of 1 MHz. Stretching exercises were applied to the upper part of the trapezius and levator scapula muscles for 15-30 seconds for 10 repetitions by a physiotherapist."
223844420|NCT06200038|OTHER|Conventional physical therapy and sham manual therapy|"A sham Mulligan RNAGS technique with low pressure compression was applied to thoracic region.~Conventional TENS was applied to the neck area with 2 channels and 4 electrodes for 20 min (current passage time: 50-100 microseconds, frequency: 0-120 Hz). Ultrasonography was performed for 8 minutes with an intensity of 1.5 w/cm2 and a frequency of 1 MHz. Stretching exercises were applied to the upper part of the trapezius and levator scapula muscles for 15-30 seconds for 10 repetitions by a physiotherapist."
223844421|NCT06200038|OTHER|Conventional physical therapy|Conventional TENS was applied to the neck area with 2 channels and 4 electrodes for 20 min (current passage time: 50-100 microseconds, frequency: 0-120 Hz). Ultrasonography was performed for 8 minutes with an intensity of 1.5 w/cm2 and a frequency of 1 MHz. Stretching exercises were applied to the upper part of the trapezius and levator scapula muscles for 15-30 seconds for 10 repetitions by a physiotherapist
223844422|NCT06085196|BEHAVIORAL|Mindful walking activity|Participate in 24 sessions of outdoor mindful walking on a local walking trail over three months
223844423|NCT01408680|DIETARY_SUPPLEMENT|Coenzyme Q10|Wafer taken daily by mouth for duration of study, containing Coenzyme Q10 at 600 mg.
223844424|NCT01408680|DIETARY_SUPPLEMENT|Coenzyme Q10|Wafer taken daily by mouth for duration of study, containing Coenzyme Q10 at 1200 mg.
223844425|NCT01408680|DIETARY_SUPPLEMENT|Placebo|Wafer taken daily by mouth for duration of study, containing inactive ingredients. Wafer is indistinguishable from those wafers containing CoQ10.
223844426|NCT00081809|DRUG|autologous human tumor-derived HSPPC-96|
223844427|NCT04286022|OTHER|Speed Loss 20% Strength Training|Strength training based on the control of speed loss in execution.
223844428|NCT04286022|OTHER|Reduced Rest Time Strength Training|Strength training based on a protocol that includes reduced rest times between sets.
223844429|NCT05939622|OTHER|Structural and functional MRI|MRI using a Siemens MAGNETOM Prisma 3T scanner before and after a course of therapy, using resting state fMRI and with cognitive paradigm.
223844430|NCT05939622|DRUG|Ethyl methyl hydroxypyridine succinate + Meldonium|Ethyl methyl hydroxypyridine succinate 100.0 mg/mL, meldonium dihydrate - 100.0 mg/mL (Solution for intravenous and intramuscular administration)
223844431|NCT05939622|DRUG|Placebo|Placebo was used in the same way
223844432|NCT04658719|DEVICE|Camstent Coated Catheter|The patented 'M4D coating' is applied to inner and outer surfaces using a 'dip/dry' process before sterilisation, creating a safe, inert, and long-lasting finish. The coating reduces friction of the catheter surface, enhancing patient comfort on insertion and withdrawal. It also incorporates the materials which virtually preclude biofilm formation. The coating doesn't elute antibacterial agents or toxins, avoiding the build-up of dead bacteria on the device surface and retaining effectiveness throughout extended use (NB. Effectiveness is not lost because of leaching away of an active antimicrobial agent). Finally, the absence of anti-bacterial moieties means that the healthy microbial flora is not disturbed.
223844433|NCT04658719|DEVICE|Standard Care|Uncoated Foley Catheter
223844434|NCT02985333|DRUG|Paclitaxel|Paclitaxel 170 mg/m(2) IV over 3 h d1
223844435|NCT02985333|DRUG|Cyclophosphamide|Cyclophosphamide 200mgmg/m(2) IV d1,3,5
223844436|NCT02985333|DRUG|Dexamethasone|Dexamethasone 20mg iv d1-4
223844437|NCT06140160|PROCEDURE|Doppler ultrasound|To carry out an additional measurement using Doppler ultrasound (non-invasive examination). Doppler ultrasound measurements of the diameter and length of the perforating artery using a high-frequency Doppler ultrasound probe following a Doppler ultrasound of the supra-aortic trunks.
223844438|NCT01094743|DEVICE|galyfilcon A prototype lens|Silicone hydrogel contact lens
223844439|NCT01094743|DEVICE|lotrafilcon B lens|Silicon Hydrogel contact lens
223844440|NCT02851511|BEHAVIORAL|Cognitive Training|Cognitive Training employs an eight component, PositScience BrainHQ suite via its researcher portal.
223844441|NCT02851511|DEVICE|tDCS (active stimulation)|A Soterix Clinical Trials Direct Current Stimulator will apply 20 minutes of 2.0mA direct current through two biocarbon rubber electrodes encased in saline soaked 5cm x 7cm sponges (8cc of 0.9% saline solution per sponge) placed over the frontal cortices at F3 and F4 (10-20 system).
223844442|NCT02851511|DEVICE|tDCS (sham stimulation)|Sham stimulation is performed with the same device and all procedures will be identical except for the duration of stimulation. Participants will receive 30 seconds of 2 mA of direct current stimulation at the beginning of the session. Participants habituate to the sensation of tDCS within 30-60 seconds of stimulation. This procedure provides the same sensation of tDCS without the full duration of stimulation, making it a highly effective sham procedure.
223844443|NCT02851511|BEHAVIORAL|Educational Training|Educational training involves watching educational videos produced by the National Geographic Channel, which cover a range of topics such as history, nature, and wildlife. Participants will be asked to complete questions on the content of the videos to ensure sustained attention.
223844444|NCT02687386|DRUG|Mitoxantrone packaged EDV (EnGeneIC Delivery Vehicle)|EnGeneIC Delivery Vehicles (EDVs) are nanocells which can be loaded with anti-cancer drugs (mitoxantrone in this study) and targeted to tumor cells. These bacterially-derived nanocells are coated in bispecific antibodies (BsAb) that recognize oncogenic receptors on the tumor cell surface. Once bound to the tumour cell, the targeted and drug-loaded EDVs are endocytosed and release their toxic payload to destroy the tumor cell.
223844445|NCT03909464|DEVICE|Neurosensory testing with Pressure-Specified Sensory Device|Patients will have neurosensory function of hands and feet tested with the non-invasive Pressure-Specified Sensory Device.
223844446|NCT05487469|DRUG|Thymosin Alpha1|Thymosin alpha 1, 1.6mg injection hypodermic (I.H), every 12 hours for 5 days at least during the ICU admission. The administration will be terminated any day during the treatment when the patient is deemed as qualified for ICU discharge or dead
223844447|NCT05487469|OTHER|Blank Control|the Control group did not receive Thymosin alpha 1 or any placebo.
223844448|NCT00004136|PROCEDURE|Radiofrequency Ablation|Tumors heated to target temperature by electrodes for maximum of 20 minutes
223844449|NCT04494373|DRUG|HS-20090|A human IgG2 monoclonal antibody with affinity and specificity for human RANKL
223844450|NCT04494373|DRUG|Xgeva®|A human IgG2 monoclonal antibody with affinity and specificity for human RANKL
223844451|NCT06206681|PROCEDURE|Ultra-pulsed Carbon Dioxide Laser|Excision of eyelid lesion
223844452|NCT01359098|DRUG|Ciprodex Otic Suspension|4 gtt b.i.d. for 7 days.
223844453|NCT01359098|DRUG|Ciprodexa Otic Foam|0.3% Ciprofloxacin, 0.1% Dexamethasone Otic Foam, 1 actuation, q.d. for 7 days
223844454|NCT06142240|OTHER|exercise programe|"The components of the exercise programe will be: muscle strength training and continuous-variable aerobic training or HIIT with loads between 70-90% of maximum heart rate. The aerobic training will last about 30 minutes and will then be completed with muscle training of the upper and lower limbs with loads determined according to the perception of effort (loads around 50-70%). The sessions will be monitored with pulse oximetry (heart rate and oxygen saturation), perception of fatigue and sensation of suffocation (Borg scale). The intensity of each component of the programme will be individualised according to the conditions of each subject.~Adherence to the programme will be recorded as successful when participation in the sessions is greater than 80% of the total number of sessions."
223844455|NCT02095600|RADIATION|Radiosurgical thalamotomy|
223844456|NCT06009380|OTHER|Physiotherapy and Rehabilitation|The control group will receive the usual post-operative care of stretching lower extremity strengthening balance exercises and activities of daily living recommendations. In addition to the program given to the control group, the dual task program will be given progressively to the study group.
223844457|NCT02487719|DRUG|Iron sulfate and Iron polymaltose for prevention of iron deficiency anemia|
223844458|NCT01326585|DRUG|Dexamethasone Sodium Phosphate Injection|8mg (2cc of 4mg/mL solution), IV solution, 1-time dose during surgery
223844459|NCT01326585|DRUG|Saline Injection|2cc of 0.9% normal saline, IV injection, 1-time dose during surgery
223844460|NCT06382545|PROCEDURE|Fanta (Pepsi gold) (FPG)|endodontic treatment of posterior teeth with Fanta (Pepsi gold) (FPG)
223844461|NCT06382545|PROCEDURE|M3-pro+ Gold (assorted) (MPG)|endodontic treatment of posterior teeth with M3-pro+ Gold (assorted) (MPG) rotary files.
223844462|NCT06335758|DEVICE|Use of ReX to dispense and monitor solid oral medication therapy.|ReX Remote Digital Nurse comprising hand-held dispenser, disposable drug cartridge and web application (ReX Treatment Manager).
223844463|NCT00003377|DRUG|cisplatin|
223844464|NCT00003377|DRUG|paclitaxel|
223844465|NCT00003377|RADIATION|brachytherapy|
223844466|NCT00003377|RADIATION|radiation therapy|
223844467|NCT03675711|DEVICE|Midline|Patient will receive a Midline catheter within 48h after disappearance of indication for CVC
223844468|NCT03675711|DEVICE|PVC|Patient will receive a standard PVC within 48h after disappearance of indication for CVC
223844469|NCT03928561|DEVICE|Active intense Pure Air XL air cleaner|Cat allergen is nebulized in the EEC. When the concentration is stable, air cleaners are switched on. The number of air cleaners placed in the EEC is defined according to the volume of the EEC and the air renewal. Patients are exposed to cat allergen in the presence of active air cleaners in the EEC
223844470|NCT03928561|DEVICE|Placebo Intense Pure Air XL air cleaner|Cat allergen is nebulized in the EEC. When the concentration is stable, placebo air cleaners are switched on. The placebo effect is obtained thanks to the removal of air cleaners filters prior to the exposure. The number of placebo air cleaners placed in the EEC is defined according to the volume of the EEC and the air renewal. Patients are exposed to cat allergen in the presence of placebo air cleaners in the EEC.
223844471|NCT02759003|PROCEDURE|Nightime NIV initiation|In-hospital vs home
223844472|NCT03671538|DRUG|Anlotinib|Anlotinib 12mg qd on day 1 to 14 of a 21-day cycle
223844473|NCT03671538|DRUG|pemetrexed|pemetrexed 500mg/m2 on day 1 of a 21-day cycle ;
223844474|NCT03671538|DRUG|Cisplatin|Cisplatin 75mg/m2 on day 1 of a 21-day cycle ;
223844475|NCT03951376|BEHAVIORAL|UPRIGHT intervention|The UPRIGHT intervention design consists of two different phases consecutively implemented in two school years: intensive phase and follow-up phase. During the intensive phase, all stakeholders are trained in the UPRIGHT WELL-BEING FOR US programme (18 skills). The follow-up phase (WELL-BEING FOR ALL) intends not only to maintain the effect of the intensive training in youths, but also to boost the positive mental health atmosphere created in the whole school. To do so, different collective activities will be organized at school level such as celebration of thematic days, activities with the community, and outdoor/indoor activities.
223844476|NCT02050789|BEHAVIORAL|flexible duty hours|If a hospital is assigned to the intervention arm, all categorical and preliminary general surgery residents in that general surgery program will switch to the flexible duty hours while at an enrolled hospital.
223844477|NCT00350181|DRUG|Sirolimus|Immunosuppressant beginning day -3 with 12 mg oral loading dose, 4 mg/day orally for adults
223844478|NCT00350181|DRUG|MMF|Immunosuppressant given through IV on day 0 at 15 mg/kg twice daily ≥ 2hr after the completion for the donor cell infusion
223844479|NCT00350181|DRUG|BCNU|15 mg/kg, IV
223844480|NCT00350181|DRUG|VP-16|60 mg/kg, IV
223844481|NCT00350181|DRUG|CY|For subjects aged 18-60 with lymphoma 100 mg/kg, IV For subjects aged with AML, ALL or CML 18-50 60 mg/kg, IV For subjects aged 51-60 with MDS, AML or ALL or patients age 18-60 with MDS, secondary AML or non-CML myeloproliferative disease 45 mg/kg
223844482|NCT00350181|DRUG|FTBI|1320 cGy delivered in 11 120 cGy fractions over 4 day
223844483|NCT00350181|DRUG|BU|BU 1 mg/kg every 6hr x 4 doses, IV
223844484|NCT00972712|DRUG|Bortezomib and Tipifarnib|"Dose level -1: Bortezomib (0.7 mg/m²; days 1,4,8,11); Tipifarnib (100 mg po BID)~Dose level 1: Bortezomib (1.0 mg/m²; days 1,4,8,11); Tipifarnib (100 mg po BID)~Dose level 2: Bortezomib (1.0 mg/m²; days 1,4,8,11); Tipifarnib (200 mg po BID)~Dose level 3: Bortezomib (1.0 mg/m²; days 1,4,8,11); Tipifarnib (300 mg po BID)~Dose level 4: Bortezomib (1.0 mg/m²; days 1,4,8,11); Tipifarnib (400 mg po BID)~Schema B~Dose level 1: Bortezomib (1.3 mg/m²; Days 1,4,8,11); Tipifarnib (300 mg po BID)~Dose level 2: Bortezomib (1.3 mg/m²; Days 1,4,8,11); Tipifarnib (400 mg po BID)"
223844485|NCT02856529|OTHER|Training|The Basic Infection Control Skills License program (BICSL) includes meningitis and influenza vaccination as well as fit test to verify the correctly fitting of the respirator. Also, the license program includes training on hand hygiene and the use of personal protective equipment (PPE). To get the license, each participants must get the vaccination and attend one to one training session with a program trainer 34.
223844486|NCT02856529|OTHER|General session|A general session about the basic of infection control was conducted for this group. The lecture performed in the same way of the regular training fulfill.
223844487|NCT02584790|DEVICE|Laryngoscope with NBI system|All post-radiotherapy 8 weeks NPC patient will routinely undergo laryngoscope examination (WL system) and NP biopsy will be taken at the same time to determine if there is any residual NPC. In this study, laryngoscope with NBI system will be used. NBI system will be turn on during the post radiotherapy 8 week laryngoscope examination in additional to routine WL system
223844488|NCT01468415|DRUG|phenol|1 cc of 8% phenol dissolved in water or 20cc of 8o mg Methylprednisolone diluted in 0.25% marcaine.
223844489|NCT02949310|DRUG|Nefopam|
223844490|NCT02949310|DRUG|Normal Saline|
223844491|NCT00336921|DRUG|Alfuzosin|Once daily
223844492|NCT00336921|DRUG|Placebo|Once daily
223844493|NCT02862054|PROCEDURE|splenectomy|
223844494|NCT05072990|DRUG|Chinese herb medicine|Patients took 200 ml Chinese herb decoction twice a day before breakfast and dinner.
223844495|NCT00657774|DRUG|FlutiForm 250/10 ug|SKP FlutiForm 250/10ug is a HFA pMDI that delivers 125ug of Fluticasone propionate per actuation and 5ug of Formoterol fumarate per actuation. Patients will take 2 actuations BID for 6 weeks.
223844496|NCT00657774|DRUG|FlutiForm 100/10 ug|SKP FlutiForm 100/10ug is a HFA pMDI that delivers 50ug of Fluticasone propionate per actuation and 5ug of Formoterol fumarate per actuation. Patients will take 2 actuations BID for 6 weeks.
223844497|NCT00657774|DRUG|Oral Prednisone 10mg|2 x 5 mg oral prednisone tablets, over encapsulated, once a day for one week.
223844498|NCT00657774|DRUG|Placebo|2 x 5 mg placebo tablets, over encapsulated, once a day for six weeks. SKP FlutiForm placebo HFA pMDI. Two actuations BID for six weeks.
223844499|NCT01417000|BIOLOGICAL|GVAX Pancreas|
223844500|NCT01417000|BIOLOGICAL|CRS-207|
223844501|NCT01417000|DRUG|Cyclophosphamide|
223844502|NCT04837950|PROCEDURE|Diaphragmatic traction-suture|Measurement of pleural cavity volume before pulling the diaphragmatic traction-suture Measurement of pleural cavity volume after pulling the diaphragmatic traction-suture
223844503|NCT00890474|PROCEDURE|Moxibustion of the BL67 acupoint|Moxibustion sessions every day (every other day in hospital, self-administration at home the other day) during a maximum of 14 days. Stopped if cephalic version.
223844504|NCT00699933|OTHER|CT-guided percutaneous drainage technique|Evaluation of different diagnostics and evaluation of outcome of patients who received percutaneous CT-guided drainage for necrotic debridement and analyze the further outcome
223844505|NCT05004480|DEVICE|Treadmill|Electronic treadmill, Hammer T-2000 Treadmill, 2,5 HP - 140 Kilograms
223844506|NCT03487874|PROCEDURE|Conventional interscalene block|Under ultrasound guidance, the 5th to 7th cervical nerve roots are blocked.
223844507|NCT03487874|PROCEDURE|Interscalene block with C8 root block|Under ultrasound guidance, the 5th to 8th cervical nerve roots are blocked.
223844508|NCT03487874|DRUG|0.75% ropivacaine|Placement of 25 to 30 ml of 0.75% ropivacaine around the cervical nerve roots
223844509|NCT05165069|DRUG|Mecobalamin 5 MG Disintegrating Oral Tablet|Mecobalamin 0.5mg / time, 3 times / day,was taken continuously for 6 months
223844510|NCT05165069|DRUG|placebo|placebo 0.5mg / time, 3 times / day,was taken continuously for 6 months
223844511|NCT05078385|DRUG|AGLE-102|AGLE-102, bone marrow mesenchymal stem cell derived extracellular vesicles (EVs)
223844512|NCT01160991|PROCEDURE|Glucose clamp technique|euglycemic hyperinsulinemic clamp with target blood glucose of 90 mg/dl (5 mmol/l), followed by hyperglycemic clamp, target blood glucose of 180 mg/dl (10 mmol/l) for measurement of insulin sensitivity and insulin secretion
223844513|NCT01160991|DRUG|Amisulpride|Single dose of amisulpride 200 mg p.o. given at 8:00 a.m.
223844514|NCT01160991|DRUG|Olanzapine|Single dose of olanzapine 10 mg p.o. given at 8:00 a.m.
223844515|NCT01160991|DRUG|Placebo|Placebo capsules are given at 8:00 a.m.
223844516|NCT03096119|OTHER|home blood pressure measurement|We ask participants to measure their home blood pressure 7 days or more.
223844517|NCT00009958|BIOLOGICAL|recombinant fowlpox-CEA(6D)/TRICOM vaccine|Given SC
223844518|NCT00009958|BIOLOGICAL|recombinant vaccinia-CEA(6D)-TRICOM vaccine|Given intradermally
223844519|NCT00009958|BIOLOGICAL|sargramostim|Given SC
223844520|NCT00009958|OTHER|laboratory biomarker analysis|Correlative studies
223844521|NCT02847585|DIETARY_SUPPLEMENT|Water-soluble Ubiquinol|10 mg/kg BW/d, by oral drops
223844522|NCT02846818|PROCEDURE|Microdialysis|Extracerebral MD catheters were positioned in a retrograde direction in the internal jugular vein.
223844523|NCT03068286|BEHAVIORAL|Space in Diabetes|The SilverCloud interventions comprise of 8 modules of evidence-based CBT which have been tailored. Psychoeducational content in the diabetes programme focusses on the impact that mood can have on self-management and self-care when living with diabetes.
223844524|NCT03068286|BEHAVIORAL|Space in COPD|The SilverCloud interventions comprise of 8 modules of evidence-based CBT which have been tailored.Additional content on panic has been included in the COPD programme. Symptoms of COPD and anxiety can be closely linked, and this content provides CBT-based strategies for dealing with symptoms of panic and anxiety.
223844525|NCT03068286|BEHAVIORAL|Space in Chronic Pain|"The SilverCloud interventions comprise of 8 modules of evidence-based CBT which have been tailored. A module on health anxiety, titled Anxiety and your Health, has been added to the chronic pain programme. This module provides psychoeducational content on health anxiety, the unhelpful behaviours that accompany it and how these can negatively impact on the experience of pain."
223844526|NCT03748771|DEVICE|ApneaLink Air|"The ApneaLink Air device is indicated for use by Health Care Professionals (HCP), where it may aid in the diagnosis of sleep disordered breathing for adult patients.~ApneaLink Air records the following data: patient respiratory nasal airflow, snoring, blood oxygen saturation, pulse and respiratory effort during sleep. The device uses these recordings to produce a report for the HCP that may aid in the diagnosis of sleep disordered breathing or for further clinical investigation. The device is intended for home and hospital use under the direction of a HCP."
223844527|NCT00821236|DEVICE|Excimer Laser|WaveLight ALLEGRETTO WAVE™ wavefront guided or optimized excimer laser treatment
223844528|NCT00821236|DEVICE|AMO/VISX CustomVue™|Excimer Laser
223844529|NCT00821236|DEVICE|LADARVision 4000 excimer laser|Excimer Laser
223844530|NCT01855308|PROCEDURE|Single site robotic chole|Cholecystectomy
223844531|NCT01855308|DEVICE|da Vinci Si Surgical System|minimally invasive robotic surgical system designed to facilitate complex procedures
223844532|NCT04415840|DIAGNOSTIC_TEST|acetic acid test|using acetic acid to unmask dysplastic lesions on the cervix uteri
223844533|NCT04415840|DIAGNOSTIC_TEST|Lugol's solution test|using Lugol's solution after acetic acid test to unmask dysplastic lesions on the cervix uteri
223844534|NCT05434442|OTHER|simulation model training|"Tracheal aspiration training of caregivers assigned to the simulation training group will be given to the same standard by researcher. It will be shown in practice on the tracheostomy care simulator."
223844535|NCT05434442|OTHER|mobile app training|"An animation-based mobile application will be installed on the phones of the caregivers assigned to the mobile application group and will be introduced and made available to their use by the researcher."
223844536|NCT05434442|OTHER|control group|Clinical routine training will be given to caregivers in this group.
223844537|NCT00693030|DEVICE|sirolimus drug eluting coronary stent Cypher™ (Cordis Corp, Johnson & Johnson Co)|comparison of multiple drug eluting stents
223844538|NCT00693030|DEVICE|paclitaxel polymer drug eluting stent Taxus Libertè™ (Boston Scientific, Natick MS)|comparison of multiple drug eluting coronary stents
223844539|NCT00693030|DEVICE|zotarolimus drug eluting coronary stent Endeavor™ (Medtronic, Santa Rosa, CA)|comparison of multiple drug eluting coronary stents
223844540|NCT00693030|DEVICE|Libertè bare metal coronary stent Libertè™ BMS(Boston Scientific, Natick, MS)|comparison of DES in overlap vs BMS in overlap
223844541|NCT00789061|DRUG|Proton pump inhibitor|One dosage/day/year
223844542|NCT06170060|OTHER|Laparoscopic Sleeve Gastrectomy|Laparoscopic sleeve gastrectomy (LSG) is a surgical procedure widely used in the treatment of obesity. It's a bariatric procedure, meaning its primary aim is to induce weight loss, and it has gained popularity due to its effectiveness and relatively low complication rates compared to other bariatric surgeries.
223844543|NCT01928940|DRUG|dabrafenib|150 mg twice daily
223844544|NCT01928940|DRUG|trametinib|2 mg once daily
223844545|NCT06107621|BEHAVIORAL|iCBT for Gambling Disorder and psychiatric comorbidities|The iCBT, is based on the gambling pathways model. As a clinical conceptualization, the treatment build on loss of control, but also include additional interventions (e.g., emotion regulation and impulse control) targeting the etiological co-morbidity factors in the pathways model for emotionally vulnerable and impulsive gamblers (pathways subtypes 2 and 3).
223844546|NCT06456931|BEHAVIORAL|Traditional Buddhist mindfulness|Details are provided in the arm/group descriptions.
223844547|NCT06456931|BEHAVIORAL|secular mindfulness based cognitive therapy|Details are provided in the arm/group descriptions.
223844548|NCT03063307|PROCEDURE|Atraumatic Restorative Treatment|
223844549|NCT03063307|OTHER|Silver Diamine Fluoride|
223844550|NCT02954055|DRUG|Paclitaxel|Arm A
223844551|NCT02954055|DRUG|Cyclophosphamide|Arm B
223844552|NCT02954055|DRUG|Capecitabine|Arm B
223844553|NCT02954055|DRUG|Vinorelbine|Arm B
223844554|NCT02408965|DRUG|Methergine|0.2 mg of methylergonovine maleate
223844555|NCT02408965|OTHER|placebo|saline placebo to maintain blinding
223844556|NCT02248142|DRUG|Pramipexole|
223844557|NCT03956199|PROCEDURE|pulpotomy|removal of the pulp from pulp chamber
223844558|NCT03956199|PROCEDURE|Root canal treatment|Removal of at the entire content of the root canal system and root canal obturation
224264983|NCT01756807|DEVICE|The COMBO Stent|The COMBO Stent is developed basing on the GENOUS stent platform, and in addition, it also delivers a drug called sirolimus to the treated coronary blood vessel. The stent's original CD34 antibody coating is designed to promote healing of the coronary artery by catching circulating endothelial progenitor cells as they pass through the stent. These cells are naturally flowing in the circulation and are responsible for endothelial healing. This is intended to help the blood vessel wall heal over the stent more quickly and restore normal tissue function in the stented area. The combination of these two technologies in this new COMBO stent is expected to produce even better clinical results, which have been investigated in the previous REMEDEE Study.
223844559|NCT05972239|OTHER|Standard pulmonary rehabilitation program|Educational interventions, 3 individual sessions of 10-20 minutes and 1 weekly group meeting of 45-60 minutes on nutrition and on the emotional management of the disease. Supervised and incremental aerobic training, lasting at least 30 minutes, 5/6 days a week for a total of 12-14 sessions. The initial workload will be set between 50-70% of the maximum load (watts) determined starting from the 6MWT using the Hill equation and will be increased to reach a perception of moderate-intense fatigue and/or dyspnea. Supervised strength training of the lower limbs and upper limbs, lasting 30 minutes, 5/6 times a week for a total of 12-14 sessions. The workload will be calibrated to allow the execution of 12 consecutive repetitions and will be progressively increased by 0.5 kg in order to cause a moderate/intense fatigue and/or dyspnea. Group exercises aimed at improving flexibility of the trunk, lower and upper limbs, lasting at least 30 minutes, 5/6 days a week, for a total of 12-14 sessions.
223844560|NCT05972239|OTHER|Balance training added on standard pulmonary rehabilitation|Educational interventions, 3 individual sessions of 10-20 minutes and 1 weekly group meeting of 45-60 minutes on nutrition and on the emotional management of the disease. Supervised and incremental aerobic training, lasting at least 30 minutes, 5/6 days a week for a total of 12-14 sessions. The initial workload will be set between 50-70% of the maximum load determined from the 6MWT (Hill equation) and will be increased based on dyspnea. Supervised strength training of the lower limbs and upper limbs, lasting 30 minutes, 5/6 times a week for a total of 12-14 sessions. The workload will be progressively increased. Supervised balance training sessions lasting 30 minutes, 5/6 times a week for a total of 12-14 sessions. The sequence of the exercises will be personalized according to the result of the Berg Balance Scale and modified according to the progress.
223844561|NCT01313598|DRUG|GLPG0187|continuous IV infusion
223844562|NCT06219603|OTHER|survey|questions around socio-demographic information, including age, sex, marital status, residency, education level, and employment status. After that, specific questions were asked to measure the level of knowledge and awareness about rheumatic diseases
223844563|NCT06340243|RADIATION|radiotherapy|radiotherapy
223844564|NCT03968237|DRUG|Buprenorphine/Naloxone|Controlled substances
223844565|NCT00607516|PROCEDURE|Cemented primary bipolar hemiarthroplasty of the hip|Cemented primary bipolar hemiarthroplasty of the hip
223844566|NCT00607516|PROCEDURE|Uncemented primary bipolar hemiarthroplasty of the hip|Uncemented primary bipolar hemiarthroplasty of the hip
223844567|NCT03018145|DEVICE|Wagon|
223844568|NCT03018145|DEVICE|Standard stretcher car|
223844569|NCT06180798|PROCEDURE|cold snare endoscopic mucosal resection (C-EMR)|"All procedures will be performed by experienced endoscopists (\>3 years of experience/\>1000 polypectomies) with the patient in the left lateral position under propofol sedation.~The polyp size will be assessed by boston biopsy forceps (open jaws -7mm) or boston jumbo biopsy forceps (open jaws 10mm) or submucosal injection needle (Olympus (4mm)). A standard snare will be used .~submucosal injection of saline mixed with methylene blue will be used (no epinephrine) followed by resection using snare without using electrocautery in C-EMR group.After polypectomy, the area is inspected for residual polyp using NBI and if present, will be resected using biopsy forceps.~Bleeding will be assessed for 2 mins to decide upon requirement of immediate hemostatic methods in the form of clipping or electrocoagulation."
223844570|NCT06180798|PROCEDURE|Hot snare endoscopic mucosal resection (H-EMR)|"All procedures will be performed by experienced endoscopists (\>3 years of experience/\>1000 polypectomies) with the patient in the left lateral position under propofol sedation.~The polyp size will be assessed by boston biopsy forceps (open jaws -7mm) or boston jumbo biopsy forceps (open jaws 10mm) or submucosal injection needle (Olympus (4mm)). A standard snare will be used.submucosal injection of saline mixed with methylene blue will be used.Using ERBE electrosurgical unit - EndoCut Q mode (effect interval duration) and forced coagulation mode in H-EMR group.~After polypectomy, the area is inspected for residual polyp using NBI and if present, will be resected using biopsy forceps."
223844571|NCT02729324|DRUG|Medical Radiation Protectants (FORRAD®)|Medical Radiation Protectants (FORRAD®) is prescribed at the beginning of radiotherapy for free. Patients are asked to start topical application of Medical Radiation Protectants (FORRAD®) on irradiated skin at the onset of radiotherapy, three times a day (30 minutes before radiotherapy, after radiotherapy, and before bedtime), until completion of their radiotherapy. All patients will receive conventional health education and medical care for prevention and treatment of radiation dermatitis. When grade 2 or higher radiation dermatitis is developed, patients can continue using Medical Radiation Protectants (FORRAD®). When grade 3 or higher radiation dermatitis happened, other interventions, such as prophylactic or therapeutic antibacterial therapy, will be used, and radiotherapy should be interrupted, until moist desquamation is cured.
223844572|NCT02729324|DRUG|Trolamine (Biafine)|Trolamine (Biafine) is prescribed at the beginning of radiotherapy. Patients are asked to start topical application of trolamine (Biafine) on irradiated skin at the onset of radiotherapy, three times a day, until completion of their radiotherapy. All patients will receive conventional health education and medical care for prevention and treatment of radiation dermatitis. No other prophylactic creams, lotions, or gels are allowed. When grade 2 or higher radiation dermatitis is developed, patients cannot use trolamine any more, and they will receive other conventional medical care for treatment of radiation dermatitis in the investigators institution. When grade 3 or higher radiation dermatitis happened, other interventions, such as prophylactic or therapeutic antibacterial therapy, will be used, and radiotherapy should be interrupted, until moist desquamation is cured.
223844573|NCT04795102|COMBINATION_PRODUCT|immediate implant placement with ATBG and L-PRF|immediate implant placement using ATBG as a graft material, with L-PRF
223844574|NCT04795102|COMBINATION_PRODUCT|immediate implant placement with ATBG|immediate implant placement using ATBG as a graft material without L-PRF
223844575|NCT02350361|DRUG|Recombinant human endostatin|Recombinant human endostatin 7.5mg/m2
223844576|NCT02350361|DRUG|Placebo|Placebo
223844577|NCT02096003|DRUG|Intrathecal morphine|0.25mg intrathecal morphine is the standard opioid medication the investigators use for analgesia for cesarean sections. It is the control arm.
223844578|NCT02096003|DRUG|Intrathecal hydromorphone|50mcg intrathecal hydromorphone will be added to 1.5mg 0.75% bupivicaine for single shot spinal anesthesia.
223844579|NCT01636440|DEVICE|Conditioned Pain Modulation|Measure of the conditioned pain modulation with the nociceptive withdrawal reflex and ice water stimulation
223844580|NCT01636440|DEVICE|Conditioned Pain Modulation|Suprathreshold electrical stimulation with 1.5 times the mean electrical pain detection threshold
223844581|NCT02467153|OTHER|RET|"RET: A supervised group exercise programme with a maximum of n=10-12 participants per group to be attended 3 times per week for 6 months.~The RET programme includes elements of current established programmes for falls prevention/ core stability (i.e., OTAGO, PEPPI) and will tailored to a range of abilities within the target group.~Vitamin D3 supplementation: vitamin D3 given orally as tablets at a dosage of 800 IU/day for 6 months."
223844582|NCT02467153|DIETARY_SUPPLEMENT|Placebo|Placebo given orally as tablets; 1 tablet per day for 6 months.
223844583|NCT02467153|DIETARY_SUPPLEMENT|Vitamin D3|Placebo given orally as tablets; 800 IU as 1 tablet per day for 6 months.
223844584|NCT02078830|DEVICE|3M™ Tegaderm™ CHG I.V. Securement Dressing|Chlorhexidine gluconate (CHG) has been dissolved into a soft gel pad (3x4 cm) to provide a reservoir for consistent and continuous antimicrobial action over time. The gel pad is active on contact without requiring additional moisture. CHG migrates under the catheter to provide continuous circumferential antimicrobial protection at the insertion site. Soft and conformable, the gel pad moulds around the catheter and hub.
223844585|NCT02078830|DEVICE|Placebo Comparator: 3M™ Tegaderm™ I.V. Advanced Dressing|Placebo Dressing with the same shape like the CHG-Dressing without CHG.
223844586|NCT01511250|BIOLOGICAL|TDV|TDV 0.5 mL, injection, subcutaneously, once on Day 0 (first dose) and Day 90 (second dose). TDV comprised of 4 recombinant, live attenuated dengue virus strains: TDV-1, TDV-2, TDV-3 and TDV-4 containing 2\*10\^4 PFU, 5\*10\^4 PFU, 1\*10\^5 PFU, and 3\*10\^5 PFU respectively, total virus per dose: 4.7\*10\^5 PFU.
223844587|NCT01511250|BIOLOGICAL|Placebo|TDV placebo-matching 0.5 mL injection, subcutaneously, once on Day 0 (first dose) and Day 90 (second dose).
223844588|NCT04990882|OTHER|Interpretation of FAPI-PET/CT scans|Each observer's Group will be asked to review FAPI-PET/CT scans of patients with representative cancer types.
223844589|NCT00980278|PROCEDURE|Sinus lift augmentation and dental implant|transalveolar sinus augmentation will be performed. After 4 months, dental implants will be delivered only if primary stability can be achieved.
223844590|NCT00980278|BIOLOGICAL|Aastrom BRCs|sinus augmentation, BRC application, dental implant
223844591|NCT00142766|BEHAVIORAL|Nurse Implemented Goal-Directed Comfort Algorithm|See description
223844592|NCT06107920|DRUG|Neoadjuvant chemotherapy|Diverting stoma- neoadjuvant chemotherapy - colectomy - +/- adjuvant chemotherapy
223844593|NCT03610633|DRUG|Oxytocin|The neuropeptide oxytocin (OT) increases social approach, trust, and reduces anxiety to social stress.
223844594|NCT03610633|DRUG|Placebo|Saline solution.
223844595|NCT03795701|DRUG|Saxenda®|Receiving escalating dose of Saxenda® for the first 4 weeks (0.6mg, 1.2mg, 1.8mg, 2.4 mg) and receiving full-dose (3.0 mg) for 12 weeks.
223844596|NCT03795701|OTHER|Placebo|Receiving equivalent volumes of the pre-filled solutions from pen-injector as Liraglutide 3.0 group .
223844597|NCT04668144|DRUG|Cangrelor|Cangrelor will be used at the FDA recommended dose using a 30 μg/kg bolus followed by 4 μg/kg/min infusion. The total infusion will last 2 hours.
223844598|NCT04668144|DRUG|Prasugrel|Prasugrel will be used in line with FDA recommendations using a 60mg LD followed by a 10mg daily maintenance dose started 24 hours after LD administration
223844599|NCT03243656|DRUG|Eltrombopag|An oral thrombopoietin receptor agonist
223844600|NCT00611065|DEVICE|magnetic resonance imaging|MR contrast agent (0.1 mmol/kg)
223844601|NCT04241796|DEVICE|Multi-Cancer Early Detection Test|Blood collection and multi-cancer early detection testing with return of results.
223844602|NCT04616482|BEHAVIORAL|Digital therapeutic carbohydrate restriction (TCR) program|A 12-week, personalized, online program to teach and coach patients about therapeutic carbohydrate restriction as for obesity and/or T2D (or risk of T2D). The program is intended to enhance the usual clinical care provided for patients.
223844603|NCT01619254|BEHAVIORAL|Hand washing with soap and hand finger nail clipping|Assess the impact of hand washing with soap and nail clipping on child health
223844604|NCT04015986|DIETARY_SUPPLEMENT|Microbiota Directed Complementary Food-2|MDCF prototype with four complimentary food ingredients without powdered milk (rationale: lead with evidence from the recently completed pre-POC clinical trial of promoting growth promoting microbiota and positive effects on growth
223844605|NCT04015986|DIETARY_SUPPLEMENT|Ready to Use Supplementary Food|Rice-lentil based RUSF (rationale: reference standard of care for post-SAM, MAM; based on knowledge of its effects on child growth and the gut microbiota)
223844606|NCT02148809|RADIATION|1mL of I-131 Human Serum Albumin is injected prior to the measurements|
223844607|NCT06188260|DRUG|Systane COMPLETE Lubricant Eye Drops|Active Ingredients: Propylene Glycol 0.6% Purpose: Lubricant
223844608|NCT00916006|DRUG|PEP005 Gel|0.015%, three day treatment
223844609|NCT00916006|DRUG|Vehicle gel|Vehicle gel, three day treatment
223844610|NCT00723320|DRUG|Atorvastatin|atorvastatin 10mg/d
223844611|NCT00723320|BEHAVIORAL|Aggressive lifestyle intervention|aggressive lifestyle intervention
223844612|NCT01253915|DRUG|Nasal Carbon Dioxide|10 sec/nostril up to 4 times to treat one migraine
223844613|NCT01253915|DRUG|Placebo|10 sec/nostril up to 4 times to treat a migraine
223844614|NCT01051778|DRUG|enoxaparin 40mg plus low dose aspirin|Enoxaparin 40mg/day by subcutaneous injection ( Clexane 40 mg, Aventis international, Sanofi-aventis France ) is started when the serum pregnancy test become positive. Enoxaparin is stopped 2 days before planned induction of labor or cesarean section and twice-daily unfractionated heparin (UFH) is initiated. The evening UFH dose is cancelled before planned caesarean section . The patients are asked to stop enoxaparin or UFH with the beginning of labor pains . Low dose aspirin (75 mg/day)(Aspocid Paediatric ,Chemical Industries Development (CID)) is started before conception and continued until 36 weeks gestation.
223844615|NCT01051778|DRUG|Heparin calcium5,000 U twice daily plus low dose aspirin|Heparin Calcium 5,000 U twice daily (Cal-Heparine, Amoun Pharmaceutical Co, Egypt) by subcutaneous injection is started when the serum pregnancy test become positive. The evening UFH dose is cancelled before planned caesarean section . The patients are asked to stop UFH with the beginning of labor pains . Low dose aspirin (75 mg/day)(Aspocid Paediatric ,Chemical Industries Development (CID))is started before conception and continued until 36 weeks gestation .
223844616|NCT04293991|DEVICE|High Flow Nasal Cannula|Evaluate the use of HFNC in prevention of intubation in immunocompromised patients adimitted to icu.
223844617|NCT04293991|DEVICE|Non Invasive Ventilation|Evaluate the use of HFNC in prevention of intubation in immunocompromised patient admitted to icu.
223844618|NCT01366196|DRUG|Pregabalin 150 mg|Patients will receive two 75 mg capsules of pregabalin 1 hour before surgery. They continue to take 2 capsules of 75 mg (total 150 mg) until POD 14.
223844619|NCT01366196|DRUG|Placebo|Patients will first receive two capsules of the placebo drug (with no active ingredients per dose) one hour before surgery. Patients will continue taking two capsules per day until POD 14.
223844620|NCT02871765|OTHER|Patient education related Warfarin|Patient education related Warfarin: each subject in the experimental group was taught individually according to investigator's brochure in the outpatient department (OPD) by researchers. Three months later, participants received a follow-up phone call in order to clarify any questions related to the brochure. The contents of the brochure consisted of: the purpose of taking Warfarin, side effects, adjustments to daily diet, and precautions (i.e. how to take medication safely, interaction between foods and medicine, prevention and checking of signs and symptoms of bleeding). The control group received the brochure after pretest and routine care only in the OPD. All participants completed posttest at 6-month follow-up.
223844621|NCT02929108|BEHAVIORAL|Facebook|Participants will be enrolled in a Secret Facebook group for social support and education
223844622|NCT02929108|BEHAVIORAL|ACCESS|"Intervention will have two components.~1. Participants will be enrolled in a Secret Facebook group for social support and education~2. Participants will use web conferencing technology to participate in their interdisciplinary team meeting"
223844623|NCT06053593|DEVICE|Testing of self collected urine|Each PWD will test their self-collected urine.
223844624|NCT06053593|DEVICE|Labeling Evaluation|Each PWD will complete a labeling evaluation.
223844625|NCT06053593|DEVICE|Urine Control testing|Each PWD will test four urine control solutions.
223844626|NCT01763736|BEHAVIORAL|Music|playlist per patient preference
223844627|NCT04308447|DEVICE|AbleLite|The AbleLite device is a passively powered orthotic device designed to support and assist the arms of patients with neuromuscular weakness for activities of daily living.
223844628|NCT06108141|BEHAVIORAL|Resident Education And Counseling on Household Firearm Safety|An intervention that includes a self-directed online curriculum and virtual reality simulations, designed to teach firearm screening and counseling among clinicians.
223844629|NCT06108141|BEHAVIORAL|Modified American Academy of Pediatrics Safer|An intervention that includes a self-directed online curriculum.
223844630|NCT00052962|PROCEDURE|Cytoreductive surgery|"Patients will undergo a laparotomy, surgical incision in the abdomen to assess the peritoneal cavity with cytoreductive surgery or tumor debulking, to reduce tumor size.~Drug: Post operative chemotherapy: systemic oxaliplatin 85 mg/m\^2 on day 1 only, leucovorin 200 mg/M\^2/day on day 1, 2, 15, and 16, and infusional 5-flurouracil (5-FU) 800 mg/m\^2 on day 8, every other week of every four weeks (two weeks per month) starting 4 to 6 weeks after operation and continuing for four cycles { 16 weeks total}."
223844631|NCT00052962|PROCEDURE|Continuous hyperthermic peritoneal perfusion (HIPEC/CHPP)|"Patients will undergo a laparotomy, surgical incision in the abdomen to assess the peritoneal cavity with cytoreductive surgery or tumor debulking, to reduce tumor size.~Followed by continuous hyperthermic peritoneal perfusion (HIPEC) with 250 mg/m\^2 cisplatin. Post operative dwell chemotherapy given once between post op day 7 and 12: 5-fluororacil (5-FU) 800 mg/m\^2 and paclitaxel 125 mg/m\^2.~Drug: Post operative chemotherapy: systemic oxaliplatin 85 mg/m\^2 on day 1 only, leucovorin 200 mg/M\^2/day on day 1, 2, 15, and 16, and infusional 5-flurouracil (5-FU) 800 mg/m\^2 on day 8, every other week of every four weeks (two weeks per month) starting 4 to 6 weeks after operation and continuing for four cycles { 16 weeks total}."
223844632|NCT03148938|OTHER|Digital Assessment on mobile|"The digital assessment is composed on 4 tests:~* walking test~* coordination test~* attention test~* vision test"
223844633|NCT02915809|BIOLOGICAL|GC3110B vaccine|0.5mL, Intramuscular
223844634|NCT02915809|BIOLOGICAL|GCFLU Quadrivalent Inj. vaccine|0.5mL, Intramuscular
223844635|NCT02240875|BIOLOGICAL|cAd3-EBO Z at 1 x 10^10 vp|Low dose cAd3-EBO Z
223844636|NCT02240875|BIOLOGICAL|cAd3-EBO Z at 2.5 x 10^10 vp|Medium dose cAd3-EBO Z
223844637|NCT02240875|BIOLOGICAL|cAd3-EBO Z at 5 x 10^10 vp|High dose cAd3-EBO Z
223844638|NCT02240875|BIOLOGICAL|4.4x10^8 TCID50s MVA-BN® Filo|High dose MVA-BN® Filo
223844639|NCT02240875|BIOLOGICAL|2.2x10^8 TCID50s MVA-BN® Filo|Low dose MVA-BN® Filo
223844640|NCT02240875|BIOLOGICAL|4.4 x 10^7 TCID50s MVA-BN® Filo|Very low dose MVA-BN® Filo
223844641|NCT05227313|DIETARY_SUPPLEMENT|Eefooton oral solution|Eefooton is extracted from Rhodiola, Huang Qi, American Ginseng, Dang Ginseng, and Ligustrum lucidum by biotechnology. It has immunomodulatory effects, anti-oxidation and anti-inflammatory effects, and regulates calcium metabolism.
223844642|NCT05227313|DIETARY_SUPPLEMENT|Placebo oral solution|oral solution matched placebo
223844643|NCT02483299|DRUG|Metformin|
223844644|NCT02483299|DRUG|Glucophage tablets and Victoza|
223844645|NCT03627962|OTHER|gaze-directed oculomotor training|"Device: Tobii PCEye~Protocol: Visual span was calculated by the distance between human-computer and dpi of fonts. Pointer speed was programmed 120pixels (5 degrees)/1sec for image drift of reading.~Dosage: 1) gaze-access required 20 to 10 degrees per fixation to activate text-to-speech (TTS) read-aloud function; about 30 repetitions of saccade and fixation.~2\) gaze-directed OMT limited to 10-5 degrees. Chinese characters recognition in multiple choice format, about 60 repetitions.~Target behavior - gaze-directed access by Tobii PCEye: reading from left to right (=horizontal mouse mover); read-aloud function by gaze dwell \> 500ms. To enhance purposeful and repetitive eye movement.~Frequency: 2 session/wk x 8 wks~Duration: 30 min/session"
223844646|NCT00912587|DRUG|ghrelin|0.1 microgram/kg/min, intravenous for 60 minutes
223844647|NCT00550108|OTHER|Ethanol lavage|Ethanol lavage of pancreatic cysts.
223844648|NCT00138632|DRUG|PTK787|Visudyne® + PTK787, 500 mg/day
223844649|NCT00138632|DRUG|PTK787|Visudyne® + PTK787 1000 mg/day
223844650|NCT00138632|DRUG|Placebo|Visudyne® + Placebo
223844651|NCT05068713|OTHER|Usual Care + High Target of Mean Arterial Pressure|Targeting the weaning of vasopressors to a mean arterial pressure of 85-90mmHg in the first 24h after liver trasnplant.
223844652|NCT05068713|OTHER|Usual Care|Targeting the weaning of vasopressors to a mean arterial pressure of 65-70mmHg in the first 24h after liver trasnplant.
223844653|NCT05248035|OTHER|Adult patient hospitalized in ICU|acquisition of dynamic parameters in addition to pupillary diameter, such as . pupillary diameter, variation of the pupillary diameter, pupillary constriction speed, pupillary dilatation speed, photomotor reflex latency, NPi and symmetry of pupillary responses after a standardized light stimulus
223844654|NCT01102322|BEHAVIORAL|Quality|Factors associated with the use of lung protective ventilation strategy (LPV) in ALI/ARDS patients in ICU
223844655|NCT06518837|DRUG|Tirzepatide|The intervention aims to assess the feasibility, safety, and efficacy of tirzepatide for weight loss in patients with early-stage hormone receptor-positive, HER2-negative breast cancer, potentially improving treatment outcomes and overall health.
223844656|NCT04971694|OTHER|No interventions or procedures|This is a retrospective observational study and data will be collected from the subject's existing medical record. No interventions or procedures will be required for this study.
223844657|NCT03703479|OTHER|autologous blood clot made from the patient own clot without any additive|advanced Platelet-rich fibrin clot is made from venous blood withdrawn from the patient
223844658|NCT02453724|DEVICE|Observation for safety|The investigators will perform the routine lung exam used in emergency department evaluations for shortness of breath in patients scheduled for computed tomography. The investigators will observe if there are any parenchymal changes noted on the chest tomography scan.
223844659|NCT00857142|DRUG|oxymorphone hydrochloride|
223844660|NCT00857142|DRUG|Opana|
223844661|NCT05794373|PROCEDURE|Standard physiotherapy for low back pain in a municipality setting|Patients (N=100) referred to a municipality-based rehabilitation for low back pain are included. The physiotherapists choose the rehabilitation strategy based on what they consider relevant for the patients. After the first 100 patients have been discharged from municipality care, the physiotherapists will participate in an educational intervention (12 sessions) focusing on the management of low back pain within a multidimensional framework. In the educational intervention, the participants will learn how to identify the presence of unhelpful thoughts and emotions and how to address these as part of the intervention. The course will thus be a mix of theoretical and practical teaching, including case supervision and feedback. Following the educational intervention, an additional 100 patients referred to the rehabilitation program will be included. The intervention is aimed at the physiotherapists where the patients will receive the best available care, before or after the intervention.
223844662|NCT02744508|DRUG|palonosetron|
223844663|NCT02744508|DRUG|palonosetron with dexamethasone|
223844664|NCT06020417|DEVICE|O-ARM (Medtronic, Inc, Louisville, CO)|scanner that allows imaging of screws intraoperatively
223844665|NCT06020417|PROCEDURE|Conventional corrective surgery for arthrodesis|Conventional procedure without neuronavigation guide
223844666|NCT06112704|DRUG|HS-20093|Intravenous (IV) infusion of HS-20093 Q3W; Participants will receive continuous treatment until the end of the study in the absence of unacceptable toxicities and confirmed disease progression.
223844667|NCT04519450|DEVICE|Mindray TE7 ultrasound machine|The study was performed using a Mindray TE7 ultrasound machine with the depth of the linear probe at 70 mm and gain of 90 dB; settings remained unchanged during the study. Measurements of the right m. sternocleidomastoideus, the right m. trapezius, and the right upper leg were taken, with the final value being the average of three measurements for each. The probe was set at the musculoskeletal ultrasound setting.
223844668|NCT06228703|DEVICE|High-flow nasal cannula device with flow setting at 40 L/min or higher|Eligible participants will use the high-flow nasal cannula device (Airvo3 or HFT 750) with flow set at 40 L/min or higher
223844669|NCT05113927|DEVICE|Selene|SELENE imaging of all margins, with record of each margin assessment and an opportunity to excise tissue from the lumpectomy cavity post-imaging. The new margin will be imaged with SELENE and the surgeon will record the assessment and may take additional tissue (up to a maximum of six total shaves, including up to two shaves in each orientation) or record why no further tissue may be taken.
223844670|NCT05380739|BEHAVIORAL|Working Memory Training|A 10-session working memory (WM) training program
223844671|NCT06645249|DRUG|Amiodarone (Antiarrhythmic drug)|Comparing 2 regimes of amiodarone pre-electrical cardioversion witn ECG monitoring
223844672|NCT06268860|DRUG|Rocatinlimab vial injection|Vial solution for SC injection administered on Day 1
223844673|NCT06268860|COMBINATION_PRODUCT|Rocatinlimab prefilled syringe|Prefilled syringe solution for SC injection administered on Day 1
223844674|NCT06640751|BEHAVIORAL|Health behavior intervention|The program is a group-based intervention provided by a healthcare team consisting of researchers, cardiologists, family doctors, community healthcare workers, psychologists, and health education specialists. The intervention is structured around three modules-predisposing, enabling, and reinforcing factors-that provide a framework for educational interventions aimed at promoting healthy behaviors in hypertensive patients.
223844675|NCT06644014|BEHAVIORAL|Exercise|"Participant will communicate with a chatbot-like proprietary AI to receive exercise instructions. The AI will provide personalized advice according to the user's needs, aiming for 2-3 hours of steady-state zone 2 -effort aerobic exercise. Instructions will also be tailored to the user's exercise preferences and limitations (for example, suggest cycling, if running is not convenient)."
223844676|NCT06644014|BEHAVIORAL|Exercise|Supervised HIIT -cycling twice a week. Intensities for cycling intervals will are based on the participants fitness-level determined at first visit. Intensity will gradually increase over the 12-week period
223844677|NCT06644014|DEVICE|Smart Ring|Participants will only receive an Oura Ring, but will not change anything about their normal physical activity.
223844678|NCT06247098|PROCEDURE|Sinus Lift augmentation|Randomised Sinus Lift augmentation either with Xenograft - Autogenous ratio 1:4 (test) or Xenograft alone (Control)
223844679|NCT06247098|DEVICE|Cone-beam computed tomography systems (CBCT)|An research only use of CBCT at visit 2 to review healing status.
223844680|NCT04805346|DEVICE|autoRIC®|With the patient sitting upright in bed or a chair, the remote ischemic conditioning intervention will consist of 4 automatic cycles of upper arm blood pressure cuff inflation to 200 mm Hg for 5 minutes to induce transient, noninjurious, limb ischemia, followed by cuff deflation for 5 minutes, for a total of 35 minutes (autoRIC®, Cellaegis Devices, Mississauga, ON, Canada).17 The remote ischemic preconditioning cycles will be performed by trained research personnel prior to each cycle of chemotherapy (total treatments variable based on chemotherapy protocol
223844681|NCT04872959|OTHER|HealthReveal|"In the Intervention arm, for each study visit, the site will receive a pre-visit assessment of GDMT accompanied by recommended adjustment(s) using information extracted weekly from the sites' EHR.~The recommended adjustment(s) will be conveyed using proprietary software from HealthReveal, with a suggested follow up plan. All reminders regarding dosing targets are based on the 2020 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment.~Additionally, during visits at baseline, 3 months, and 6 months, the KCCQ-23 will be completed.~In the Usual Care arm, during visits at baseline, 3 months, and 6 months, the KCCQ-23 will be completed."
223844682|NCT02513914|DEVICE|Dural Venous Sinus Stenting|See Dural Venous Sinus Stenting arm.
223844683|NCT02513914|DEVICE|Cerebrospinal Fluid Shunting|See Cerebrospinal Fluid Shunting arm.
223844684|NCT06030089|OTHER|Pharmacokinetic sampling|4 blood withdrawals ( before treatment, Day 5, Day 9 and relapse or 12 months after start of treatment) for the plasma dosage of VEN and inhibition of its Bcl-2
223844685|NCT06030089|OTHER|Vital status determination|Survival situation 12 months after start of treament
223844686|NCT06030089|OTHER|Toxicity assessments|Toxicity events
223844687|NCT06030089|DRUG|Venetoclax and azacitidine combination|Response to treatment
223844688|NCT05861089|DIAGNOSTIC_TEST|end-tidal CO2 measurement|Measurements will take place day before surgery, under resting conditions (while sitting in a quiet room with no disruptions) using the Capnography monitor from Nonin Medical (breath by breath data will be recorded and analyzed). Patients will be allowed to get used to the nasal cannula for the first two minutes. Mean end-tidal CO2 value will then be calculated from the following two minutes of spontaneous breathing.
223844689|NCT03643965|DRUG|Nefecon|Nefecon 16 mg for daily administration by mouth for 9 months.
223844690|NCT03643965|DRUG|Placebo oral capsule|Placebo capsules for daily administration by mouth for 9 months.
223844691|NCT05676996|OTHER|attachment-based support|attachment-based support application; It includes video-based trainings on attachment via mobile application and breastfeeding and skin-to-skin contact support for mothers on postpartum day 0.
223844692|NCT06178315|PROCEDURE|EUS-guided celiac plexus block|Under EUS-guidance, celiac plexus block will be performed with injection of bupivacaine and triamcinolone into the area of celiac plexus.
223844693|NCT06178315|PROCEDURE|Sham procedure|Celiac plexus will not be performed in this arm.
223844694|NCT05683301|DRUG|Amlodipine + Perindopril|Single pill combination of dual antihypertensive agent
223844695|NCT05683301|DRUG|Perindopril + Indapamide|Single pill combination of dual antihypertensive agent
223844696|NCT05683301|DRUG|Amlodipine + Indapamide|Single pill combination of dual antihypertensive agent
223844697|NCT03593759|DRUG|Prednisone or Prednisolone|Oral prednisone/prednisolone tablet
223844698|NCT03593759|DRUG|Methotrexate|Oral, subcutaneous, or intramuscular methotrexate
223844699|NCT06570551|DEVICE|i3 CGM(continuous glucose monitor)|The i3 CGM consists of a Sensor Pack (including probe, iCGM-S3), a Transmitter Pack (iCGM-t3), and an application (iCGM-APP (released version: V02)).application (i3 CGM App). The user can view their glucose data on the i3 CGM App running on a compatible mobile device.
223844700|NCT06220474|DEVICE|The Thermage FLX System|The Thermage FLX System is tested for its therapeutic efficacy and safety on treating refractory Meibomian Gland Dysfunction
223844701|NCT06220474|DEVICE|Sham treatment|Sham treatment acts as a control to test the therapeutic efficacy and safety of The Thermage FLX System
223844702|NCT01688102|DIETARY_SUPPLEMENT|Oral Vitamin D3|50,000 units orally, each week x8 weeks; supplemental doses of 50,000 units orally, each month thereafter as needed
223844703|NCT01688102|RADIATION|Ultraviolet Light|16 treatments, 2-3 times weekly over 8 weeks; initial dose 45-75 seconds, whole-body exposure except face and groin, increasing by 10% as tolerated, to a maximum of 4.5 minutes
223844704|NCT00170911|DRUG|AAE581|
223844705|NCT00610883|DRUG|LSA4, Cyclophosphamide, Methotrexate, Daunomycin, L-asparaginase, BCNU|LSA4 intervention includes three phases: induction, consolidation and maintenance
223844706|NCT04625855|DRUG|TBPM-PI-HBr|TBPM-PI-HBr (3 x 200 mg tablets) once
223844707|NCT04269070|BEHAVIORAL|Standing condition|Participants will be asked to stand an additional 6 minutes per hour above their median standing time from the observed time in the usual behavior condition.
223844708|NCT04269070|BEHAVIORAL|Light physical activity (LPA) condition|Participants will be asked to perform 6 additional minutes per hour above their median LPA time from the observed time in the usual behavior condition.
223844709|NCT04269070|BEHAVIORAL|Usual behavior condition|Participants will be asked to perform their normal work activities in their normal work environment for one week. There will be no modifications to their work environment or instructions given of what activities to partake in. This period will be used to understand their normal standing and LPA behaviors to determine the personalized changes to their standing and LPA behaviors in the other conditions.
223844710|NCT03674840|PROCEDURE|angle kappa based SBL-3 implantation|SBL-3 implantation based on kappa angle guided by Callisto Eye System(Carl Zeiss Meditec, Germany) intraoperatively.
223844711|NCT03674840|PROCEDURE|0 to 180 degree SBL-3 implantation|SBL-3 implantation in the direction of 0 to 180 degree guided by Callisto Eye System(Carl Zeiss Meditec, Germany) intraoperatively.
223844712|NCT01037543|DRUG|HM10460A or placebo or Neulasta|Single SC injection of the appropriate dose of drug ranging from 1.1 mcg/kg to 270 mcg/kg.
223844713|NCT04119245|DEVICE|I-gel supraglottic airway device|After induction of general anesthesia, we will measure the Oropharyngeal leak airway pressure during controlled ventilation in supine and in positions after insertion of I-gel.
223844714|NCT00832780|RADIATION|Stereotactic Body Radiation|A total of 60 Gy using 12 Gy per fraction over 5 fractions to be given within 10 calendar days. Each fraction of 12 Gy will be divided into 2 fractions of 6 Gy given in one day within 6 hours. Dose will be prescribed to the isodose line which covers at least 90% of the planning target volume. Dose homogeneity +/- 5%.
223844715|NCT02862782|DRUG|hCG (Ovitrelle 250 mcg mcg - Merck Serono)|
223844716|NCT02862782|DRUG|hCG (Ovitrelle 250 mcg mcg - Merck Serono) + GnRH agonist (Decapeptyl 0.2mg - Ferring Gmgh)|
223844717|NCT02396940|DEVICE|3D HD laparoscopy|Olympus 3D laparoscopy ENDOEYE FLEX in high definition with the use of passive, polarizing glasses.
223844718|NCT02396940|DEVICE|2D HD laparoscopy|Placebo
223844719|NCT04968782|OTHER|Patients with acute appendicitis|No intervention, single survey
223844720|NCT06028048|BEHAVIORAL|PLACES|"The PLACES intervention is based on eight IPS principles, ensuring competitive employment, client choice, service integration, personalized benefits counseling, rapid job search, systematic development, and individualized support.~Coaches: Certified IPS coaches receive training from Phrenos IPS knowledge center and Re-turn. Ongoing support includes video lectures, clarifications with researchers, and biannual collective sessions. Coaches, regionally specialized, implement interventions autonomously.~Intervention Phases:~1. Intake and Assessment: Participants meet IPS coaches within three days to discuss goals, procedures, and responsibilities, continuing until objectives are met.~2. Acquisition and Application: Coaches assist job search and placement, aiming for employment within 30 days.~3. Placement and Support: Coaches offer personalized support, adapting to needs, scheduling meetings based on preferences.~The intervention ends at 12 months or when goals are achieved."
223844721|NCT03421444|OTHER|No intervention|No intervention
223844722|NCT02938650|DRUG|Nitrosomonas eutropha|Subjects will get nitrosomonas eutropha to apply for one week. There is only one arm to this study. Subjects will apply the medication twice a day for one week.
223844723|NCT01683695|DRUG|AMG 557|AMG 557 will be administered as subcutaneous injections in the anterior abdomen of the subjects.
223844724|NCT01683695|DRUG|Matching Placebo|Placebo will be administered as subcutaneous injections in the anterior abdomen of the subjects.
223844725|NCT01149135|DEVICE|Blue enriched light with a low intensity|30 minutes in the morning, 750 lux
223844726|NCT01149135|DEVICE|standard light treatment|standard light treatment, 30 minutes, 10 000 lux
223844727|NCT03141658|DRUG|TS-134|Multiple dose titrations from 10 mg to 20 mg once daily for 6 days
223844728|NCT03141658|DRUG|TS-134|Multiple dose titrations from 10 mg to 60 mg once daily for 6 days
223844729|NCT03141658|DRUG|Placebo|Multiple doses of placebo once daily for 6 days
223844730|NCT03141658|OTHER|Ketamine|0.23 mg/kg bolus over one minute on Screening (baseline) and Day 6
223844731|NCT06494423|BEHAVIORAL|Work Support (WorkS)|The WorkS intervention entails two structured visits with a research team member initiated 6-months post-HSCT, which is the earliest point at which most HSCT survivors can safely consider returning to work. The sessions are focused on 1) identifying challenges of navigating work and illness; 2) linking survivors with psychological, rehabilitative, governmental, and community resources that can promote recovery and well-being; and 3) communicating with employers regarding the necessary work modifications to achieve mutual goals.
223844732|NCT03569813|BEHAVIORAL|PrEP@Home System|"The PrEP@Home system includes a home care kit mailed quarterly to participants. The kit has components for self-collection of urine, rectal and pharyngeal swabs, microtube blood collection, and materials for return shipping. Biological tests routinely performed at PrEP follow-up (FU) visits will be done on the specimens. At months 6 and 12, the kit will include materials to assess for protective levels of emtricitabine triphosphate (FTC-TP).~The system includes a study app through which participants may track the mailing of home testing kits, access quarterly surveys, and communicate with study clinicians. The surveys will include domains that physicians assess at PrEP care quarterly FU visits (sexual risk, illicit substance use, PrEP adherence, side effects).~Study Clinicians will review Lab and survey results and if the results show no contraindications for PrEP continuation, the clinician may renew a participant's PrEP prescription. Telemedicine visits will be scheduled as needed."
223844733|NCT03569813|OTHER|Standard of Care|Control participants will receive clinic-based PrEP follow-up. After the baseline assessment, control participants will receive active linkage to standard, clinic-based PrEP care for their next PrEP care follow-up visit. Participants will also download the control version of the study app, which will contain only research elements pertinent to their participation in the control arm of the study including quarterly surveys. At months 6 and 12, control arm participants will be sent materials for DBS self-collection and return shipping to allow for measurement of the study outcome, emtricitabine triphosphate (FTC-TP).
223844734|NCT00480805|DRUG|MK0954A, losartan potassium (+) hydrochlorothiazide (HYZAAR) / Duration of Treatment : 8 Weeks|
223844735|NCT00480805|DRUG|Comparator : ramipril /Duration of Treatment : 8 Weeks|
223844736|NCT06174896|PROCEDURE|Group 1|The LMA Proseal will be inserted directly by hand, without the use of any laryngoscope, as recommended in the instruction manual. The cuff will be gently guided along the hard palate where it is pushed into the hypopharynx and increased resistance is felt, and the cuff will be placed towards the hypopharynx.
223844737|NCT06174896|PROCEDURE|Group 2|Appropriately sized laryngoscope blade will be used and after the location of the epiglottis is determined, the tongue and epiglottis will be lifted forward. Then, LMA Proseal will be placed at the point where resistance is felt at a level where the proximal edge of the mask can be seen.
223844738|NCT06174896|PROCEDURE|Group 3|After the video laryngoscope is placed with an appropriately sized blade, the location of the epiglottis and vocal cords will be determined and the LMA Proseal will be placed at the point where slight resistance is encountered after the epiglottis is lifted. proximal aspect of LMA
223844739|NCT06646926|OTHER|Body tempering|Participant will be positioned prone on the Body Tempering Ab Mat with their feet hanging off the end of the mat. The body tempering intervention will be applied by the same investigator for all trials. The body tempering device will be applied dynamically to each participant for 4 minutes, with the device placed on both participants' lower extremities at the same time. First, the examiner will set a timer for two minutes and begin rolling one 80-pound body tempering device along the participant's gastrocnemius-soleus complex at a rate of 30 beats per minute, traveling from the Achilles tendon (medial malleolus) to the inferior aspect of the popliteal fossa, indicated by fibular head. The participant will then take thirty seconds to transition to a supine position and receive tempering with an 80-pound tempering device along their middle to distal quadriceps, set a timer for 2 minutes.
223844740|NCT06646926|OTHER|Foam rolling self-myofascial release|Participants will be instructed via standardized script to perform self-myofascial release (SMR) on their gastrocnemius-soleus complex and quadriceps muscles. The first SMR sequence will be performed by having the participant place the foam roller behind both calves, beginning the roll at the medial malleolus and ending at the inferior aspect of the popliteal fossa, indicated by the fibular head. The participant will perform this for two minutes, rolling at a tempo of 30 beats per minute. Next, the participant will take thirty seconds to transition to a prone position, placing the foam roller just distal to the hip crease, just inferior to the AIIS, and rolling inferiorly to the area just proximal to the most superior aspect of the patella. This self-release sequence will be performed for two minutes at a tempo of 30 beats per minute. The total time should be four minutes, matching the total time of the experimental intervention group.
223844741|NCT06570785|DEVICE|Intra-Operative Positioning System (IOPS)|This medical device provides surgeons with 3D visualization for increased surgical precision while reducing the use of contrast dye and radiation exposure for patients and healthcare professionals alike. IOPS provides 3D electromagnetic navigation of interventional devices as an adjunct to fluoroscopy. During the intervention, the IOPS devices can be visualized with on-screen image guidance. The console is operated by a technician under a physician's instruction. The IOPS guidewires and catheters can be used together or combined with off-the-shelf 0.035-inch catheters and guidewires, as needed.
223844742|NCT06570785|DEVICE|Conventional group|This group will be treated using standardised materials (wires, catheters) during EVAR.
223844743|NCT03184545|DEVICE|EMS|The EMS device Flex MT Plus (Electrostim Medical Services Inc. Tampa, FL) is a neuromuscular stimulator. It is approved by the FDA. The Electrical muscle stimulation (EMS) applied to vastus medialis obliquus (VMO) muscle for 20 minutes, 3 times daily and it would be 5 times a week for 12 weeks at 40 Hz. The pulse duration will be 0.26ms, at 5 seconds on and 10 seconds off.
223844744|NCT03184545|OTHER|Physical therapy|Standard physical therapy exercises
223844745|NCT01767909|DRUG|Insulin (Humulin® R U-100)|20 IU bid taken twice daily (approximately 30 minutes after breakfast and dinner) for a total of 40 IU daily, which will be administered intranasally. The device used to administer insulin releases a metered dose into a chamber covering the participant's nose. The insulin is then inhaled by breathing evenly over a specified period.
223844746|NCT01767909|DRUG|Placebo|Placebo taken twice daily (approximately 30 minutes after breakfast and dinner), which will be administered intranasally. The device used to administer placebo releases a metered dose into a chamber covering the participant's nose. The placebo is then inhaled by breathing evenly over a specified period.
223844747|NCT05129800|OTHER|Platelet-rich plasma|"PRP preparation involved, withdrawal 8-10ml from each patient into a tube containg either 3,8 % sodium citrate and either enoxaparin gel or thixotropic cell-separation gel. The tubes were centrifuged at either 3900 rpm for 10 minutes or at 1500g for 5 minutes, resulting in four layers: a cell-rich layer at the bottom of the tube covered by the separating gel, a PRP layer on top of the gel, and a platelet-poor plasma (PPP) layer at the top. The tube was gently agitated in order to mix the PPP with the PRP. The solution, cca 4-5ml, was withdrawn with a needle and injected to the scalp-frontoparietal region using either a syringe and a 4mm needle or an injector. According to the protocol of our hospital, the injections to the scalp were spaced 0.5-1cm apart.~PRP was applied once every month for 3 months. Macroscopic and digital phototrichographic photos were taken before the beginning of treatment, 1 month after the last injection, and 3 months after the end of treatmert."
223844748|NCT05129800|OTHER|Mesotherapy|"For mesotherapy, usually around 5ml of saline solution was withdrawn using a needle and released to the selected ampule containing adipose tissue stem-cell conditioned media and mixture of recombinant growth factors, in a powder form. We used preparations from two different companies, differing in the combination and concentration of ingredients. After the injection of normal saline, the ampule was gently agitated in order to disperse the powder and injected to the scalp-frontoparietal region using either a syringe and a 4mm needle or a gun injector. The injections were spaced 0.5-1cm apart.~Mesotherapy was repeated every 1-2 weeks for 6-7 times according to the protocol recommended for each preparation. Macroscopic and phototrichographic photos were taken before the beginning of treatment, a month after the last injection and 3 months after the end of treatment."
223844749|NCT06583837|DRUG|Orelabrutinib|Orelabrutinib was administrated for 12 weeks
223844750|NCT06583837|RADIATION|response-adapted radiation|response-adapted ultra-low dose 4Gy radiation
223844751|NCT03669042|DEVICE|PhotoFix|PhotoFix Patch Implantation
223844752|NCT05407220|DRUG|HCP1904-1|take it once per period
223844753|NCT05407220|DRUG|HCP1904-3|take it once per period
223844754|NCT05869838|DEVICE|Colonoscopy|Screening or surveillance colonoscopy
223844755|NCT06233630|DRUG|Control Test - spinal anesthesia|No peripheral nerve block Only spinal anesthesia
223844756|NCT06233630|DRUG|Ropivacaine 0.2% Injectable Solution ESPB|ultrasound guided erector spinae plane block (ESPB) - L2 level, unilateral
223844757|NCT06233630|DRUG|Ropivacaine 0.2% Injectable Solution iPACK+ACB|ultrasound guided iPACK block + Adductor Canal Block
223844758|NCT06095206|DRUG|GenSci094|On the morning of day 1 pre-meal, a single SC injection of 150 μg GenSci094 was administered in the abdominal wall.
223844759|NCT06505265|DRUG|Povorcitinib|Oral; Tablet
223844760|NCT04956692|BIOLOGICAL|Pembrolizumab SC|SC injection
223844761|NCT04956692|BIOLOGICAL|Pembrolizumab IV|IV injection
223844762|NCT04956692|DRUG|Paclitaxel|IV injection
223844763|NCT04956692|DRUG|Nab-Paclitaxel|IV infusion
223844764|NCT04956692|DRUG|Carboplatin|IV infusion
223844765|NCT04956692|DRUG|Cisplatin|IV infusion
223844766|NCT04956692|DRUG|Pemetrexed|IV infusion
223844767|NCT04639947|DEVICE|EyeCheck|EyeCheck is a newly developed device to provide intraocular pressure (IOP) measurements of the eyes.
223844768|NCT04639947|DEVICE|Traditional Tonometer (Goldmann and Tonopen)|Standard of care intraocular pressures will be taken using the Goldmann and Tonopen to compare to the EyeCheck.
223844769|NCT06339983|OTHER|Manual Scar Mobilization Therapy:|In this therapy, deep pressure on some point of the area of the scar will be given which will be perpendicular to the skin and will be followed by skin rolling
223844770|NCT06339983|OTHER|Myofascial Cupping Therapy:|A disposable plastic cup (5cm) will be positioned at THE selected area of the cesarean scar. Then, negative pressure will be applied using a mechanical vacuum pump, the cup will be gently slid around the selected area rhythmically to get a massage-like effect
223844771|NCT06536036|DRUG|SIM0270|Use according to the prescribed protocol
223844772|NCT03541603|DRUG|Levosimendan|A sterile 2.5 mg/mL concentrate solution that is diluted in 5% Dextrose or 0.9 Normal Saline to achieve a 50 microgram/min solution for infusion
223844773|NCT03541603|DRUG|Matching Placebo|A sterile 2.5mg/mL concentrate solution that is diluted in 5% Dextrose or 0.9 Normal Saline to achieve a 50 microgram/min solution for infusion
223844774|NCT05305911|DRUG|SGLT-2 inhibitors|SGLT2 inhibitor once daily for six months
223844775|NCT05305911|DRUG|Placebo|Placebo once daily for six months
223844776|NCT05183555|DRUG|68Ga-DOTATOC PET/CT|68Ga-DOTATOC PET/CT will be recorded the following day of 18F-FDG PET/CT if patient signed the consent
223844777|NCT05837026|BEHAVIORAL|Enhanced Outreach Intervention (EOI) plus Care as Usual (CAU)|"The EOI will contain four main components: safety planning, caring contacts, care engagement, and risk assessment.~Outreach (via phone or text messaging) from Samaritans staff will be conducted every week of the 12 week intervention. Conversations will use a standardized phone script to (a) conduct a risk assessment, (b) develop and review a list of coping skills to use if the participant has suicidal thoughts, and (c) discuss plans for receiving mental health care. Samaritans staff will also send a caring text message or email at least once per week.~Participants will also receive standard care that hospitals provide to patients who present with suicidal thoughts."
223844778|NCT05837026|OTHER|Care as Usual (CAU)|Participants will receive standard care that hospitals provide to patients who present with suicidal thoughts.
223844779|NCT06054828|BEHAVIORAL|mHELP@ICU|"The 14-day mHELP@ICU consists of the following three components:~1. Cognitive engagement twice daily: Participants will receive orienting communication, plus one of the following training on attention, memory, or function execution.~2. Physical activity once daily: Participants will receive a passive range of motion(ROM) and/or anti-gravity ROM exercise if tolerated.~3. Feeding monitor daily: The exact feeding data will be abstracted from medical records."
223844780|NCT02735252|OTHER|Systemic therapy|Systemic therapy is selected by the physician and is not restricted by the study. Molecular testing will be performed on tissue and blood to identify patterns and relationships with clinical outcomes in each group.
223844781|NCT02735252|DEVICE|StrataNGS|CLIA-approved assay that is being performed as part of standard of care genomic profiling of patients tumor biopsies. The product currently covers about 90 cancer genes and is able to pick up all the known mutations and other types of genetic alterations across them, he added
223844782|NCT02691065|DRUG|Integrase Inhibitor|Raltegravir
223844783|NCT05478863|DRUG|Oral Placebo|Placebo will be orally self-administered by study participants.
223844784|NCT05478863|DRUG|Oral THC|THC will be orally self-administered by study participants.
223844785|NCT05478863|DRUG|Oral CBD|CBD will be orally self-administered by study participants.
223844786|NCT05478863|DRUG|Oral Caffeine|Caffeine will be orally self-administered by study participants.
223844787|NCT06148766|OTHER|Manuka Health Eternal Renewal Regenerating Face Cream with Royal Jelly and Bee Venom|Face cream containing manuka honey, royal bee jelly, and bee venom.
223844788|NCT06321159|OTHER|mobile application|mobile application for diet, exercises and medication adherence
223844789|NCT04863898|BEHAVIORAL|Drug-use stigma reduction intervention for HIV care and treatment clinic staff|We will adapt the HP+ health facility HIV stigma-reduction intervention to focus on drug stigma in HIV CTCs. The intervention will address key stigma drivers, including fear, awareness of stigma, and stigmatizing attitudes and beliefs, through a participatory training approach that involves all levels of staff and is grounded in social cognitive theory principles. The approach seeks to reduce stigma through fostering empathy, interpersonal interactions (contact strategies) and building efficacy for stigma reduction through awareness, skills, and knowledge building. The intervention consists of five-2.5 hour participatory training sessions.
223844790|NCT03093363|OTHER|Pharmacist's intervention|"Pharmacist's intervention with asthmatic patients:~* Detailed questionnaire on asthma and treatments (atopy, comorbidities, smoking status, asthma control, adverse effects of treatments, etc.)~* Explanation of asthma and inflammation~* Explanation of triggers and how to avoid it~* Explanation of asthma treatments~* Explanation of the inhalation technique with a physical demonstration~* Emphasis on treatment adherence~* Assessment of comorbidities and their treatment~* Emphasis on influenza vaccination"
223844791|NCT03093363|OTHER|Questionnaires for control group|\- Detailed questionnaire on asthma and treatments (atopy, comorbidities, smoking status, asthma control, adverse effects of treatments, etc.)
223844792|NCT03166592|DEVICE|Magnetic resonance imaging with contrast|injection of gadolinium contrast then acquisition of images with magnetic resonance imaging then spectroscopy
223844793|NCT05634889|RADIATION|De-escalation|No regional radiotherapy. Radiotherapy is given to the remaining breast after breast conserving surgery. Chest wall radiotherapy after mastectomy only in case of wide spread multifocality.
223844794|NCT00614744|PROCEDURE|Hypothermia|Induced Whole-body hypothermia (with a target esophageal temperature of 33.5°C) for 96 hours
223844795|NCT00614744|PROCEDURE|Normothermic Control|Normothermic Control group (with esophageal temperature at or near 37.0°C) for 96 hours
223844796|NCT01839825|DEVICE|QuietCare|
223844797|NCT03302806|OTHER|Non interventional Study|
223844798|NCT00877851|BEHAVIORAL|Computer-based Program|The intervention group will receive an initial training session which will include a demonstration of the layout and main features of the computer-based program and some instructions on how to navigate around the different sections of the program. As a minimum level of use, participants will be asked to use the self-monitoring and goal setting aspects of the computer-based program on at least a weekly basis.
223844799|NCT04021056|OTHER|No intervention|
223844800|NCT01258387|DRUG|Glial growth factor 2/ Neuregulin 1β3|
223844801|NCT01258387|OTHER|Placebo|
223844802|NCT02121704|DEVICE|Magnetic Endoscope Imaging (Scope Guide)|
223844803|NCT00770211|DRUG|IncobotulinumtoxinA (Xeomin) (20 Units)|The treatment will be administered only once at day 0 at five injection sites in the glabellar area. The total dose of 20 Units IncobotulinumtoxinA (Xeomin) is reconstituted in a total injection volume of 0.5 mL that is to be injected to the five sites in equal aliquots of 0.1 mL.
223844804|NCT00770211|DRUG|Placebo|The treatment will be administered only once at day 0 at five injection sites in the glabellar area. Volume of Placebo equivalent to IncobotulinumtoxinA (Xeomin).
223844805|NCT00168181|PROCEDURE|Submandibular gland Transfer|
223844806|NCT00168181|DRUG|Salagen|
223844807|NCT05705050|DRUG|Aminophylline group|Patients will receive 4 mg/kg aminophylline diluted in 100 ml normal saline over 20 minutes after induction of anesthesia and positioning of patients in lithotomy position.
223844808|NCT05705050|OTHER|Control group|Patients will receive 100 ml normal saline over 20 minutes after induction and lithotomy positioning.
223844809|NCT06528132|BEHAVIORAL|Mindfulness-based intervention (MBI) (enhanced with peer supporters)|Mindfulness-based intervention combines mindfulness meditation with cognitive behavioural therapy (CBT) elements to reduce or prevent recurrent major depressive disorders. On-site support and regular follow-up by peer supporters.
223844810|NCT06528132|BEHAVIORAL|Experimental: social worker-led MBI (without peer supporters)|Mindfulness-based intervention combines mindfulness meditation with cognitive behavioural therapy (CBT) elements to reduce or prevent recurrent major depressive disorders.
223844811|NCT03362619|BIOLOGICAL|CC-EIEs|2 to 4 infusions, once a week, for 1x10\^5\~1x10\^7 CTLs/kg via IV, abdominal cavity or intratumoral injection each time
223844812|NCT01939938|DEVICE|Nasal and Oronasal PAP Mask|Subjects will be imaged via MRI wearing a nasal and oronasal PAP mask at 5, 10 and 15 cm H20.
223844813|NCT05764512|OTHER|Endorphin massage|"With the anterior surface of the fingertips of the hand, a V will be drawn slowly, starting from the sacral region and towards the ribs. The same process will be continued from the sacral region until the 7th cervical vertebra.~From the 7th cervical vertebra, the front surface of the fingertips will be descended first to the shoulders and then to the dorsal region of the upper and forearms in turn.~Starting from the dorsal region of the forearm, the first stage of the massage will end by descending to the upper arm, shoulders, 7th cervical vertebra, spine and sacral region with the back of the thumbs. These massage steps will be repeated until 20 minutes are completed.~Endorphin massage will be applied every 2 hours."
223844814|NCT05993208|DIAGNOSTIC_TEST|optical coherence tomography,multifocal electroretinogram. VA measurment|retinal photography
223844815|NCT02453646|DEVICE|NexSite HD Patients|Measurement of CRBSI rate and other device related adverse events in patients with NexSite HD Catheter.
223844816|NCT00165152|PROCEDURE|Genetic Counseling|Two visits with a specially trained genetic counselor or nurse in conjunction with a medical oncologist and/or a medical specialist will be done in which information will be given either about genetic counseling or enhanced informed consent. These visits will be audio-taped to monitor how the project staff is covering the important information about testing.
223844817|NCT00165152|PROCEDURE|Informed Consent Counseling|Two visits with a specially trained genetic counselor or nurse in conjunction with a medical oncologist and/or a medical specialist will be done in which information will be given either about genetic counseling or enhanced informed consent. These visits will be audio-taped to monitor how the project staff is covering the important information about testing.
223844818|NCT03005288|DRUG|BYM338 10 mg/kg|intravenous infusion every four weeks
223844819|NCT03005288|OTHER|Placebo|intravenous infusion every four weeks
223844820|NCT06346145|PROCEDURE|Bariatric surgery|Type of surgery assigned by surgeon in consultation with patient
223844821|NCT06346145|PROCEDURE|Standard care|Standard care can consist of dietary intervention, physiotherapy or drug treatment in accordance to the care given in the region of Sweden where the patient resides.
223844822|NCT03605186|OTHER|Chamomile oral cryotherapy|The infusion of chamomile will be prepared in the clinic with 400 mL of distilled water and 10 g of chamomile flowers (Chamomile classic infusion, Royal Herbs). Patients are asked to swish the chamomile ice cubes around their oral cavities starting 5 minutes before chemotherapy infusion, continuing 30 minutes throughout the session and for additional 35 minutes after completion of intravenous chemotherapy session.
223844823|NCT03605186|OTHER|Oral cryotherapy|The plain icecubes will be prepared in the clinic with 400 mL of distilled water. Patients are asked to swish the ice cubes around their oral cavities starting 5 minutes before chemotherapy infusion, continuing 30 minutes throughout the session and for additional 35 minutes after completion of intravenous chemotherapy session.
223844824|NCT04692714|DEVICE|Knee prosthesis implementation with additional cement|During surgery, a TRIATHLON prosthesis will be implemented with the MAKO robot with additional cement.
223844825|NCT04692714|DEVICE|Knee prosthesis implementation without additional cement|During surgery, a TRIATHLON prosthesis will be implemented with the MAKO robot without additional cement.
223844826|NCT06203262|DEVICE|FieldForce™ Ablation System Ventricular Tachycardia|Catheter ablation is a minimally invasive procedure. The physician advances multiple catheters into the heart that are used to diagnose and localize abnormal cardiac tissue involved in the initiation and maintenance of ventricular tachycardia and/or PVCs. Once the abnormal tissue is identified a specialized catheter is advanced to the target and energy is applied to destroy the abnormal tissue. The intervention will be identical to the conventional procedure except that an investigational ablation catheter will be used to deliver energy.
223844827|NCT06203262|DEVICE|FieldForce™ Ablation System Premature Ventricular Contractions|Catheter ablation is a minimally invasive procedure. The physician advances multiple catheters into the heart that are used to diagnose and localize abnormal cardiac tissue involved in the initiation and maintenance of ventricular tachycardia and/or PVCs. Once the abnormal tissue is identified a specialized catheter is advanced to the target and energy is applied to destroy the abnormal tissue. The intervention will be identical to the conventional procedure except that an investigational ablation catheter will be used to deliver energy.
223844828|NCT05047094|DEVICE|Diffusing Alpha Radiation Emitters Therapy (DaRT)|An intratumoral insertion of a seed(s), loaded with Radium-224, securely fixed in the seeds. The seeds release by recoil into the tumor short-lived alpha-emitting atoms.
223844829|NCT05047094|DRUG|Pembrolizumab|200 mg administered as an intravenous infusion over 30 minutes every 3 weeks
223844830|NCT06252662|DRUG|Dexmedetomidine|block duration extension additive
223844831|NCT06252662|DRUG|Liposomal bupivacaine|Control arm, comparison for block duration with dexmedetomidine
223844832|NCT03282175|OTHER|Exercise|Exercise session consisted of general warm-up of 10 min, followed by 35-40 min of resistance exercises (chair squats, band seated: biceps curl, seated row, knee extension, leg press and hip abduction; standing behind the chair: knee flexion, and calf rise), and general cool down of 10 min.
223844833|NCT03282175|OTHER|Training|Each training session consisted of general warm-up of 10 min, followed by 35-40 min of resistance exercises (chair squats, band seated: biceps curl, seated row, knee extension, leg press and hip abduction; standing behind the chair: knee flexion, and calf rise), and general cool down of 10 min.
223844834|NCT03282175|OTHER|Control group|The control group did not receive any treatment.
223844835|NCT00591357|DRUG|loperamide|4 mg PO initially and 2 mg after each water stoll not to exceed 10 mg qd
223844836|NCT00591357|DRUG|placebo|4 mg PO initially and 2 mg after each water stoll not to exceed 10 mg qd
223844837|NCT03789643|DRUG|JTT-251|Active drug tablets containing JTT-251
223844838|NCT03789643|DRUG|Placebo|Placebo tablets matching in appearance to the active drug tablets
223844839|NCT04447781|BIOLOGICAL|INO-4800|\- Manufacturer: Inovio Pharmaceuticals Inc.
223844840|NCT04447781|DEVICE|CELLECTRA® 2000|\- Manufacturer: Inovio Pharmaceuticals Inc.
223844841|NCT04447781|OTHER|Saline-sodium citrate (SSC) buffer|\- Manufacturer: Inovio Pharmaceuticals Inc.
223844842|NCT00530192|OTHER|Treatment based on Molecular Profiling|Treatment with commercially available treatments (per package insert instructions)
223844843|NCT02403531|DRUG|Docetaxel|Include brand names, serial numbers and code names to improve search results on the ClinicalTrials.gov web site.
223844844|NCT02403531|DRUG|Cisplatin|Include brand names, serial numbers and code names to improve search results on the ClinicalTrials.gov web site.
223844845|NCT02403531|RADIATION|Radiotherapy|definitive radiotherapy
223844846|NCT00415974|BEHAVIORAL|Physician Counseling|Physician-patient visits will occur in the primary care setting and are scheduled at study onset (beginning of step 1) and at the end of the first year. An extra physician visit will occur for patients who do not progress from step 1 after two attempts. At study entry, physicians will discuss the purpose and importance of the intervention and encourage participation. Physicians will underline the value of attending all study visits and complying with study protocol and instructions. Subsequent physician visits will focus on weight loss progress and overcoming barriers.
223844847|NCT00415974|BEHAVIORAL|Health Educator|Health education sessions are held with teens and parents at the primary care setting. These include information on nutrition, physical activity, and weight loss. Behavioral approaches are used to enhance the home environment, food preparation, and planned physical activity to elicit weight loss, including discovery of perceived and actual barriers to modification of eating and physical activity behaviors. The Health Educator focuses on problem-solving and tailored selection of behavior change skills to help participants overcome difficulties. In addition to reviewing the assessment and generating solutions to barriers, sample meal plans (including strategies for restricting calories) and pedometers will be distributed at the initial health educator visit. Pedometers are encouraged to monitor progress with physical activity goals. An initial binder is distributed to teen and parent participants at the initial session and subsequent materials are added with each visit.
223844848|NCT00415974|BEHAVIORAL|Phone Counseling|Brief counseling calls will occur between PACE-PC participants and assigned counselors during all steps. In general, these calls occur on a bi-weekly to monthly basis in steps 1 and 2, and monthly in step 3. Such calls are intended to encourage continued goal attainment and progression and to promote healthy eating and physical activity behaviors. Counselors will review progress since the last clinical interaction (e.g., health educator visit, phone call, or physician visit) and help adolescents set new goals that are appropriate and attainable. Data from pedometers may be discussed during these sessions as an interim assessment of progress on physical activity behaviors between formal study measurement visits. After speaking with the adolescent, the counselor will talk with the parent (when feasible) to reinforce parental involvement and emphasize the importance of the healthy changes in the home environment to encourage goal attainment.
223844849|NCT00415974|BEHAVIORAL|Health promotion materials on physical activity and nutrition|PACE-PC adolescents and their families will receive information regarding healthy eating and physical activity behaviors on a weekly basis via mail. These behavioral-based materials will educate participants and their families on healthy behaviors that are necessary for successful weight management. Topics will coincide with the intervention goals and include supplemental information to enhance quality of life and improve body image. Topics will include realistic goal-setting and attainment, how to handle holidays and celebrations, eating fast food, grocery shopping and food preparation, and relapse prevention, etc.. Topics will include specific strategies related to the adolescent's readiness to change to reflect processes that are most appropriate. Content from these materials will be addressed by the phone counselors to ensure that participants received and understood intervention messages.
223844850|NCT05419674|DRUG|Vonoprazan|Potassium-competitive acid blocker
223844851|NCT05419674|DRUG|Rabeprazole|Proton pump inhibitor
223844852|NCT05419674|DRUG|Amoxicillin|Antibiotic for H. pylori eradication
223844853|NCT05419674|DRUG|Clarithromycin|Antibiotic for H. pylori eradication
223844854|NCT05419674|DRUG|Colloidal bismuth pectin|Gastric mucosal protective drug with anti-H. pylori effect
223844855|NCT04123860|OTHER|ultrasonic hydrodynamic maxillary sinus lift buccal pad fat|ultrasonic hydrodynamic maxillary sinus lift and buccal fat pad as grafting material followed by immediate implant
223844856|NCT04123860|OTHER|ultrasonic hydrodynamic maxillary sinus lift platelet rich fibrin|ultrasonic hydrodynamic maxillary sinus lift and platelet rich fibrin as grafting material followed by immediate implant
223844857|NCT03607903|BIOLOGICAL|Adalimumab ID|Adalimumab intradermal using MicronJet600 microneedle from NanoPass
223844858|NCT03607903|BIOLOGICAL|Adalimumab SC|Adalimumab subcutaneous using regular needle
223844859|NCT03607903|OTHER|Saline ID|Saline intradermal using MicronJet600 microneedle from NanoPass
223844860|NCT03607903|OTHER|Saline SC|Saline subcutaneous using regular needle
223844861|NCT02250495|DEVICE|Sympara Therapeutic System|Sympara Therapeutic System as a non-invasive, fully reversible alternative for the treatment of hypertension
223844862|NCT00019890|DRUG|dendritic cell-gp100-MART-1 antigen vaccine|
223844863|NCT00019890|DRUG|sargramostim|
223844864|NCT04355676|DRUG|Selinexor|20 mg selinexor oral tablet.
223844865|NCT02846662|BEHAVIORAL|CONEMO|The study intervention has two components: the smartphone application CONEMO and primary care nurses monitoring patients' adherence to the intervention. CONEMO is a 6-week low-intensity behavior activation program delivered in 18 sessions that include messages related to the treatment goals, motivating them to do certain activities, helping to select and plan activities and messages related to psychological skills that facilitate the incorporation of activities in everyday life and to tackle obstacles that hinder patients to be more active. Primary care nurses are responsible for training participants to use the CONEMO app, monitoring patients' adherence to CONEMO, calling patients when they are non-adherent, and giving technical support when necessary.
223844866|NCT02355704|DRUG|Atorvastatin|Patients were assigned to two groups, one of them received oral atorvastatin (study group) and the other, homologated placebo (control group) for 4 weeks before a kidney transplantation. Previous surgical procedure controls were performed
223844867|NCT02355704|DRUG|Placebo|Patients were assigned to two groups, one of them received oral atorvastatin (study group) and the other, homologated placebo (control group) for 4 weeks before a kidney transplantation. Previous surgical procedure were performed
223844868|NCT04774185|DEVICE|New hearing aid loudspeaker|The new hearing aid loudspeaker will be fitted to the participants individual ear anatomy and hearing loss.
223844869|NCT04774185|DEVICE|Standard hearing aid loudspeaker|The standard hearing aid loudspeaker will be fitted to the participants individual ear anatomy and hearing loss.
223844870|NCT04884984|BIOLOGICAL|anti-CLL1 CART|Split intravenous infusion of anti-CLL1 CAR T cells \[dose escalating infusion of (5-20)x10\^6 anti-CLL1 CAR T cells/kg\].
223844871|NCT00158080|PROCEDURE|hemofiltration|
223844872|NCT04346303|OTHER|Short-term Interactive Video Games|"1. Collect basic information through a structured questionnaire, which includes basic information, disease status, life style and other related information.~2. Three data collections were performed, namely the baseline period (T0) and the pre-program (T1) two weeks later. Three weeks of intervention activities were provided twice a week, followed by a post-test ( post-program, T2).~3. After a total of six times mentioned above, each 60 minutes of interactive video game intervention, the patient completed the activity feedback form, reflecting the feelings and feedback of participating in the activity."
223844873|NCT02006043|DRUG|Erlotinib 150mg|
223844874|NCT03004599|DEVICE|SYM-SV-002 Aortic Bioprosthesis and SYM-DS-002 Transfemoral Delivery System|Transcatheter Aortic Valve Implantation via Transfemoral Approach
223844875|NCT01429714|DEVICE|Individually tailored duration of elastic compression therapy|Individually tailored duration of elastic compression therapy,based on signs and symptoms according to the Villalta scale, following an initial therapeutic period of 6 months
223844876|NCT01429714|DEVICE|Elastic compression therapy with a standard duration of 24 months|Elastic compression therapy with a standard duration of 24 months
223844877|NCT05597683|PROCEDURE|Arm I (QL block and multimodal analgesia), Arm II (multimodal analgesia without regional block)|"Arm I (QL block and multimodal analgesia): Bilateral transmuscular QL block will be done. Postoperative multimodal analgesia including administration of acetaminophen, NSAIDs,nefopam, and rescue opioids~Arm II (multimodal analgesia without regional block): No block will be done. Postoperative multimodal analgesia including administration of acetaminophen, NSAIDs, nefopam, and rescue opioids"
223844878|NCT06026787|DRUG|Dapagliflozin 10mg Tab|Dapagliflozin 10 mg will be added to the standard of care regimen of primary nephrotic syndrome patients
223844879|NCT01397487|PROCEDURE|Blastomere biopsy|The blastomere biopsy will be done after 72 hours of embryo culture. An inverted microscope Olympus IX70 with a heated stage will be used to perform the biopsy. The micromanipulation for the blastomere extraction will be made with a micropipette MBB-FP-M-30 (Humagen).
223844880|NCT04632966|BIOLOGICAL|Biological: PTP-001|allogeneic placental tissue particulate
223844881|NCT02841722|PROCEDURE|ERIBULIN + G-CSF (Granulocyte-Colony Stimulating Factor)|8 additional blood samples
223844882|NCT01047072|DRUG|fludarabine phosphate|Given IV
223844883|NCT01047072|RADIATION|total-body irradiation|Undergo total-body irradiation
223844884|NCT01047072|DRUG|tacrolimus|Given orally
223844885|NCT01047072|DRUG|mycophenolate mofetil|Given orally
223844886|NCT01047072|BIOLOGICAL|rituximab|Given IV
223844887|NCT01047072|DRUG|cyclophosphamide|Given orally
223844888|NCT01047072|PROCEDURE|nonmyeloablative allogeneic hematopoietic stem cell transplantation|Undergo transplantation
223844889|NCT01047072|PROCEDURE|peripheral blood stem cell transplantation|Undergo transplantation
223844890|NCT01862211|OTHER|blood sampling|A blood sampling will be performed for the genetic analysis and the measurement of serum IL-8.
223844891|NCT00665561|DRUG|Maraviroc along with an optimized background antiretroviral drug regimen|Maraviroc prescribed per approved local label.
223844892|NCT00665561|DRUG|Optimized background antiretroviral drug regimen without maraviroc|Optimized background antiretroviral therapy prescribed per approved local label and treatment guidelines.
223844893|NCT04780438|DRUG|Dapagliflozin|Patients rendomized in this arm will receive dapagliflozin at a target dose of 10mg once daily.
223844894|NCT04780438|DRUG|Placebo|Patients rendomized in this arm will receive placebo.
223844895|NCT02851199|DEVICE|Electroencephalography|Electroencephalograph recording following hyperventilation in different participant's body postures
223844896|NCT05678595|DEVICE|high-intensity laser therapy|HILT: A hot laser derived from a Nd: YAG laser has 12 W (watt) and 1064 nm characteristics. The device will administered to the hand wrist area in two steps in the HILT group: phase I and phase II. The application will made utilizing continuous circular movements in both phases I and II. The first five sessions consisted of a 100-second intermittent phase analgesic effect at 8 W and 8 J/cm2 for a total energy of 200 J. The following five sessions consisted of a continuous 11 minutes 6 second bio stimulating effect with a dosage of 3 W 80 J/cm2. Over the course of two weeks, ten treatment sessions of HILT will be given.
223844897|NCT05678595|DEVICE|sham high-intensity laser therapy|HILT is administered as a placebo for two weeks, 5 sessions a week, for a total of 10 sessions.
223844898|NCT03980405|DIETARY_SUPPLEMENT|Group 1- Control Diet|Oral 5ASA+ Low Residue Diet for 6 weeks and Oral 5ASA+ Free Diet for 6 more weeks
223844899|NCT03980405|DIETARY_SUPPLEMENT|Group 2- UCD Diet|Oral 5ASA+ UC Diet for 6 weeks and Oral 5ASA+ UC Diet Stage 2 for 6 more weeks
223844900|NCT06385470|BEHAVIORAL|Dynamic Temporal and Tactile Cueing treatment|"DTTC is a motor-based treatment designed for children with CAS who may have limited verbal output. It applies the principles of motor learning and focuses on speech movement gestures in the context of functional words and phrases.~The participants will receive two versions of the DTTC treatment (i.e., DTTC in English \[DTTC-E\] and DTTC in Cantonese \[DTTC-C\]), where probe data will be collected before, during, between and after the treatment intervention."
223844901|NCT03824236|BIOLOGICAL|RTS,S/AS01E (SB257049)|Subjects from the P-Fx and NP-Fx groups will receive one Fx booster dose of RTS,S/AS01E at Day 1.
223844902|NCT05391802|DEVICE|Transcatheter mitral valve repair|Transcatheter mitral valve repair (TMVr) is a minimally invasive procedure. Doctors place a thin tube (calleda catheter) into a large vein to reach your heart. A clip is then placed onto the center of your mitral valve. The valve continues to open and close, allowing blood to flow through while reducing MR.
223844903|NCT04688021|DRUG|Cytarabine|4 mg/m2/day administered IV day -10 through -9.
223844904|NCT04688021|DRUG|Busulfan|3.2 mg/kg/day administered IV day -8 through -6.
223844905|NCT04688021|DRUG|Cyclophosphamide|1.8 g/m2/day administered IV day -5 through -4.
223844906|NCT04688021|DRUG|Me-CCNU|250mg/m2 once administered orally on day -3.
223844907|NCT04688021|DRUG|Rabbit antithymocyte globulin|1.5mg/kg/day administered IV day -5 through -2.
223844908|NCT04688021|DRUG|Tocilizumab|8mg/kg administered IV on day -1.
223844909|NCT04688021|PROCEDURE|Allogeneic HSCT|Day 0
223844910|NCT04688021|DRUG|Cyclosporin A|2.5 mg/kg/day administered intravenously from day -7, target: 200-300ng/mL. Usually tapered during the second month, and ended in complete withdrawal during the ninth month after transplantation.
223844911|NCT04688021|DRUG|Mycophenolate Mofetil|500 mg/day administered intravenously from day -9, ended in complete withdrawal on day +100.
223844912|NCT04688021|DRUG|MTX|15 mg/m2 administered intravenously on day +1, 10mg/m2 on day +3, +6, and +9.
223844913|NCT01416909|OTHER|Laxative Treatment|Participants will be taken off any laxative preparation they may already be on. Patients will be put on laxative treatment based on the Constipation Treatment Protocol.
223844914|NCT01416909|OTHER|Standard of Care|Participants will receive their usual care at Moffitt while participating in weekly assessments. After participation in the study is complete, participants will be offered the same protocol that is given to patients in the treatment groups.
223844915|NCT01416909|OTHER|Assessment Questionnaires|Constipation Assessment Scale (CAS), Laxative Interview (based on Laxative Diary completed by patients), Memorial Symptom Assessment Scale (MSAS), Functional Assessment of Cancer Therapy-General (FACT-G).
223844916|NCT01786343|DRUG|Decitabine|20 mg/m2 by vein daily for either 5 or 10 days.
223844917|NCT03530020|OTHER|monolithic zirconia crowns|full anatomical monolithic crowns
223844918|NCT03530020|OTHER|lithium silicate crowns|lithium silicate glass ceramics are highly resistance to chipping
223844919|NCT00906880|DRUG|Nifurtimox-Eflronithine Combination Treatment (NECT)|co-administration of nifurtimox (10 days, 15 mg/kg/day, p.o. TID) and eflornithine (7 days, 400 mg/kg/day, i.v. BID)
223844920|NCT06093529|DIAGNOSTIC_TEST|complete blood count, CD3+ , CD4+ , CD8+, CD16+, CD56+, IFN-γ.|"1. Full history~2. Thorough clinical examinations~3. Laboratory investigations will include:~   1. complete blood count with focus on platelet count, platelet distribution width and mean platelet volume. Platelet count will be confirmed by direct blood film and blood smear.~  2. Measurements of CD3+, CD4+, CD8+ and natural killer cells (CD16+, CD56+) will be conducted using flow cytometry.~  3. Serum IFN-γ levels will be determined using an ELISA kit.~4. Response to the treatment will be assessed according to The International Working Group criteria which defines Response as platelet count ≥ 30 x 10⁹/L and \>2-fold increase in platelet count from baseline and absence of bleeding, measured on 2 occasions greater than 7 days apart. No response is characterized by a platelet count \<30 x 10⁹/L or a less than 2-fold increase in platelet count from baseline, or the presence of bleeding."
223844921|NCT00701311|DRUG|CC-10004|CC-10004 20 mg per day
223844922|NCT01702038|DRUG|Rituximab|1000 mg administered intravenously
223844923|NCT01076218|DEVICE|FreeStyle Navigator Continuous Glucose Monitoring System Version 1.5|This is not an interventional study. Subjects must maintain their own diabetes treatment regimen throughout the study duration.
223844924|NCT01024205|DRUG|sunitinib malate|
223844925|NCT01024205|OTHER|laboratory biomarker analysis|
223844926|NCT01024205|PROCEDURE|adjuvant therapy|
223844927|NCT01024205|PROCEDURE|neoadjuvant therapy|
223844928|NCT01024205|PROCEDURE|therapeutic conventional surgery|
223844929|NCT04435730|DIAGNOSTIC_TEST|serum level of Mac 2 binding protein|"Serum levels of Mac 2 binding protein will be measured for all the study subjects using Enzyme-Linked Immuno sorbent Assay (ELISA).~2 ml of venous blood will be collected from patients and controls under complete aseptic conditions in a plain tube. Sample will be allowed to clot for 15-30 min at room temperature and then centrifuged at 2500 rpm for 10-15 min. Serum will be separated and stored at -20 C or lower till time of assessment."
223844930|NCT04435730|DEVICE|musculoskeletal ultrasound|MSUS examination will be performed for patients of all groups and control group.Gray scale (GSUS) and power Doppler (PDUS) at joints levels and entheses will be performed with the same transducer of My Lab Seven Crystalline esaote machine.
223844931|NCT00710723|PROCEDURE|vitrification|Vitrification using Hemi-straw carrier system.
223844932|NCT03418779|DRUG|The Yi-Qi-Qing-Jie herbal compound|The compounds are blends of individual herbal extracts from YQF (consisting of Astragalus membranaceus, Saposhnikovia divaricata (turcz.) Schischk, Flos lonicerae, Angelica sinensis, Dioscorea nipponica, Hedyotis diffusa Willd, rhubarb, Spatholobus suberectus, with the effect of reinforcing Qi and activating blood, clearing away heat and poison, dissolving dampness and downbearing turbid) dissolved in 150 ml boiled water and taken orally twice a day for the duration of the treatment and follow-up phases.
223844933|NCT03418779|DRUG|Immunosuppressants|Immunosuppression therapy comprises oral prednisolone (0.5-0.8 mg/kg/day; exact dose decided by the investigator, maximum dose not exceeding 60 mg/day) for 8 weeks, then tapered by 5-10 mg/day every 4 weeks, with a total treatment period of 24-32 weeks. Participants with persistent proteinuria ≥ 1 g/day after 8 weeks of corticosteroid monotherapy will receive 0.8-1.0 g of intravenous cyclophosphamide (CTX) every 4 weeks, total dose of not exceeding 8 g (exact dose decided by the site investigator). If severe CTX-related adverse events occur, such as alanine transaminase (ALT) exceeding the upper limit of two times, infections requiring hospitalization, granulocytes \< 3.0 × 109/L and platelets \< 50.0 × 109/L, CTX will stop being administered, symptoms will be treated, and adverse events recorded. Also, the frequency of detection will be increased to once every 2 weeks and the affected participant will be withdrawn if persistent infection or myelosuppression occurs.
223844934|NCT03418779|OTHER|Optimized Supportive Care|"The optimized supportive care included:~1. Lifestyle: low-salt, restricted protein dietary with sufficient calorie supply, smoking cessation, moderate alcohol consumption and keeping a healthy weight~2. The use of renin-angiotensin system blockade: lowering blood pressure to a target below 135/85 mmHg, during which treatment was adjusted to ensure that patients were receiving the maximum labelled or tolerated dose of RAS blockade~3. Patients with Diabetes Mellitus received insulin or oral hypoglycemic agents to achieve HbA1c≤ 7.0%~4. Received uricosuric agents or xanthine oxidase inhibitors as necessary to achieve serum uric acid \<6 mg/dL in female, \<7 mg/dL in male"
223844935|NCT03418779|OTHER|Yi-Qi-Qing-Jie herbal compound placebo|Patients will receive Yi-Qi-Qing-Jie herbal compound placebo instead for the duration of the treatment and follow-up phases. The major component of the placebo is malt dextrin which looks, smells and tastes like YQF compound, and it comes in packaging with a similar appearance to YQF compound; it is also dissolved in 150 ml boiled water and taken orally twice a day.
223844936|NCT04767646|PROCEDURE|Intensive rehabilitation program with CPNB|"The patient will have an intensive rehabilitation program (two 30-minute kinesitherapy sessions every day and 30-minute occupational therapy sessions 5 days a week) with the CPNB.~The patient will have follow-up consultation at 1 month, 3 month, 6 month and 1 year after the beggining of the intensive rehabilitation program"
223844937|NCT04677465|DEVICE|RheOx Bronchial Rheoplasty|bronchial rheoplasty is a staged procedure wherein pulsed electric fields are delivered to the right lung in the first treatment visit, and then the left lung is treated approximately 1 month later.
223844938|NCT04677465|DEVICE|Sham Procedure|staged sham procedure wherein bronchoscopy is performed, the catheter is inserted into the right lung, but energy is not delivered; then the same steps are performed in the left lung approximately 1 month later (no energy is delivered to the patient)
223844939|NCT00670540|OTHER|procedure of Deep Vein Thrombosis (DVT) and PE (Pulmonary Embolism) diagnosis|patients with a clinical suspicion of Venous ThromboEmbolism (VTE = Deep Vein Thrombosis or Pulmonary Embolism) were eligible
223844940|NCT00236821|DRUG|levofloxacin|
223844941|NCT03882463|DEVICE|Continuous glucose monitoring with the stop insulin pump function|"Children with type 1 diabetes using insulin pump and continuous glucose monitoring without the stop insulin pump functionare then using the predictive system for stopping before hypoglycaemia medtronic Minimed with SmartGuard technology."
223844942|NCT01140347|BIOLOGICAL|Placebo|8 mg/kg IV every 2 weeks
223844943|NCT01140347|BIOLOGICAL|Ramucirumab DP (IMC-1121B)|8 milligrams/kilogram (mg/kg) intravenous (IV) every 2 weeks
223844944|NCT01140347|OTHER|BSC|Palliative and supportive care for disease-related symptoms and toxicity associated with treatment as deemed medically necessary and appropriate in the opinion of the investigator.
223844945|NCT00761254|DRUG|Domperidone|Initially, 10mg of oral Domperidone will be administered 2-4 times a day as needed. This dosage may be increased or decreased depending on how the subject responds to the drug.
223844946|NCT01515319|DRUG|Y242|Single ascending dose: subcutaneous injection of 2, 7.5, 15, 30, 60 and 90 mg Y242 (Part A); Multiple ascending dose: Y242 single subcutaneous dose, administered once a week for 5 weeks (Part B)
223844947|NCT01515319|DRUG|0.9% saline|Identical volume to that of Y242
223844948|NCT06659887|DEVICE|nasal cannula|After induction, bag-mask ventilation with 100% oxygen and flow rates of 6 L/ min will be carried out until the expired oxygen concentration will be \>90%, saturation of oxygen was 100%, and end tidal carbon dioxide was 30-40 mmHg. Once this will be reached, bag-mask ventilation will be stopped and apneic oxygenation will be initiated for 3 minutes
223844949|NCT05573113|DIAGNOSTIC_TEST|Bowel Ultrasound|Bowel Ultrasound
223844950|NCT05573113|DIAGNOSTIC_TEST|Abdominal radiograph|Abdominal radiograph
223844951|NCT00759824|DRUG|Adriamycin, cyclophosphamide, vindesine, valproic acid|Adriamycin 45 mg/m² day 1 IV Cyclophosphamide 1 g/m² day 1 IV Vindesine 3 mg/m² day 1 IV Valproic acid 20-30 mg/kg/day from day -7 until the end of treatment, orally
223844952|NCT01449929|DRUG|dolutegravir 50 mg OAD|1 x 50 mg tablet OAD
223844953|NCT01449929|DRUG|darunavir 800mg OAD|2 x 400mg tablets OAD
223844954|NCT01449929|DRUG|ritonavir 100mg OAD|1 x 100mg tablet OAD
223844955|NCT06615583|DEVICE|Surgical device|The C-REX device consists of an invasive surgical part, including two anastomotic rings, and surgical instruments for assisting the placement of the anastomotic ring to intestine. The rings are loosen from the inside of the intestinal wall and expelled with faeces per rectum once the anastomosis is healed in approximately ten days.
223844956|NCT06615596|BEHAVIORAL|discontinue anticoagulation therapy|Participants in the discontinuation arm will cease anticoagulation therapy following randomization. Smart wearable devices will monitor for AF recurrence, and patients will be followed for 24 months, with primary endpoints including thromboembolic and bleeding events.
223844957|NCT06615596|DRUG|Anticoagulant drugs|Participants in the continuation arm will receive oral anticoagulant drugs such as dabigatran, rivaroxaban, apixaban, warfarin, etc. tailored to their specific risk profiles. The discontinuation arm will cease anticoagulation therapy following randomization. Smart wearable devices will monitor for AF recurrence, and patients will be followed for 24 months, with primary endpoints including thromboembolic and bleeding events.
223844958|NCT06615596|PROCEDURE|Catheter Ablation|Catheter ablation is a medical procedure used to treat atrial fibrillation (AF) by targeting and destroying small areas of heart tissue that cause irregular heartbeats. Using a specialized catheter, radiofrequency energy, cryotherapy, or pulsed field ablation (PFA) is applied to isolate the pulmonary veins or ablate other specific heart areas. The goal is to restore normal heart rhythm by electrically isolating problematic areas responsible for AF. This FDA-regulated procedure is minimally invasive and requires follow-up monitoring for AF recurrence and other potential complications. No specific ablation technique is mandated, allowing flexibility for operators to choose based on their expertise and center practices. The ablation strategy may include pulmonary vein isolation or additional procedures based on the type of AF. This approach distinguishes the study by providing real-world applicability, reflecting the diversity of ablation methods used in clinical practice.
223844959|NCT06613607|OTHER|Core Strengthening|"Strengthening protocol will comprise of following three phases:~Warm up phase Following exercise would be performed in warm up; Scissor skier, Criss cross crunches, , Hip circles, Bent over twist.~Strengthening:~Abdominal bracing Bracing with heel slides Bracing with leg lifts Bracing with bridging Quadruped alternate arm and leg lifts with bracing Side support with knees flexed Cool down phase: Following exercise would be performed for cood down: Child's pose, Cat cow stretch, Lower back stretch, Obliques stretch"
223844960|NCT01703533|DRUG|NNZ-2566|Glycyl-L-2-Methylpropyl-L-Glutamic Acid (NNZ-2566) supplied as a lyophilized powder (2g in 50mL vials) for reconstitution with strawberry flavored solution 0.5% v/v in Water for Injection.
223844961|NCT01703533|DRUG|Placebo|Strawberry flavored solution and Water for Injection
223844962|NCT06668480|PROCEDURE|Conventional Physical Therapy|It will comprise of hot pack for 10 minutes, TENs at 80-100 Hz over trapezius for 10 minutes.Strengthening of deep neck flexors
223844963|NCT06668480|PROCEDURE|Strengthening Exercise|Strengthening exercises of lower fibers of trapezius
223844964|NCT06668480|PROCEDURE|SNAG'S|Sustained natural apophysial glides will consist of frequency: 4 sets of 3-5 repetition per session for 2 weeks
223844965|NCT06118710|DRUG|Dexamethasone|Dexamethasone prior to paclitaxel infusion according to local care standards.
223844966|NCT06118710|DRUG|H1 Antihistaminics|Clemastine or Cetirizine prior to paclitaxel infusion according to local care standards
223844967|NCT06602752|BEHAVIORAL|Food system and demand generation|The Vegetables for All project will create FFZs in low-income urban and peri-urban areas. FFZs are the last mile/point of purchase for delivering a variety of fresh, safe, and accessible vegetables to BoP households. The program will link vendors and farmers through market facilitators, support the uptake of digital solutions for vendors to access vegetables, and support district governments to improve market infrastructure. To encourage BoP parents of children 3-9 years to buy and consume more vegetables, the program will include a demand generation component.
223844968|NCT01871285|DRUG|Buprenorphine|
223844969|NCT01871285|DRUG|Placebo film|Matching placebo buccal film
223844970|NCT01871285|DRUG|Oxycodone|Oxycodone extended-release (ER) or immediate-release (IR) 5, 10, 15, 20, and 30 mg over-encapsulated oral tablets
223844971|NCT01871285|DRUG|Morphine sulfate|Morphine sulfate 15, 30, and 60 mg ER or 15 and 30 mg IR over-encapsulated oral tablets
223844972|NCT01871285|DRUG|Placebo capsule|Oral placebo capsules matching the over-encapsulated morphine sulfate and oxycodone tablets
223844973|NCT04313530|DEVICE|Repetitive Transcranial Magnetic Stimulation|Transcranial magnetic stimulation (TMS) is a non-invasive method that uses electromagnetic induction to produce electric currents in the cortex that are strong enough to depolarise neurons sufficiently to trigger action potentials. It is an outpatient based procedure that when used in conjunction with a neuro-navigation system, specific cortical areas can be targeted for greater accuracy and efficacy. In clinical studies, TMS is delivered as trains of pulses (repetitive TMS, rTMS) to prolong its effects. While the exact mechanism of TMS treatment fatigue is unknown, it is thought to regulate the activity of the complex cortical and subcortical networks connectivity changes involved in the processing of fatigue signals.
223844974|NCT04831164|OTHER|NA (not an interventional study)|(not an interventional study)
223844975|NCT01959880|DEVICE|The Contour Profile Gel (CPG) breast implants|"The CPG mammary prosthesis is a silicone elastomer mammary device with a textured surface. The Siltex® (textured) shell consists of a smooth shell bonded to an additional layer of silicone that has a textured pattern imprinted into its surface. The Siltex® shell is textured to provide a disruptive surface for collagen interface. The CPG implant contains a gel that is a more cohesive silicone gel than that used in other Mentor gel implants. The gel is made from the same materials as Mentor's standard gel. The contour shape of the CPG is designed to provide inferior projection with reduced superior fullness. The CPG mammary prosthesis contains raised orientation marks on the anterior and posterior of the implant which may help the physician ensure proper placement.~The Contour Profile Gel is available in sizes 125cc - 690cc and 4 styles with various projection and height options in this study."
223844976|NCT02359968|DRUG|FOLFOX|radiochemotherapy before surgery
223844977|NCT02359968|DRUG|CarboP-pacliT|radiochemotherapy before surgery
223844978|NCT06615687|PROCEDURE|Inverted T shape Free Gingival Graft|"the preparation of the recipient site commenced by making a horizontal incision at the mucogingival junction (MGJ) as well as two vertical incisions extending to the adjacent teeth and about 3-4 mm beyond the MGJ. A sharp split-thickness flap will be reflected, and the surfaces between these incisions will be de-epithelialized. Also, all the surfaces of the interdental papilla up to the lingual side will be de-epithelized using a 15c blade and microsurgical scissor .(Harvesting of the palatal donor site will be designed 2 mm away from the gingival margin using a template in the form of an inverted T-shape, taking into consideration the position of the greater palatine blood vessels at 5 mm. 2 mm is required for the width of the interproximal extension with 3 mm length to obtain an even thickness of 1-1.5 mm .~Placement of the graft : The Inverted T FGG will be inserted between the teeth to cover interproximal tissue defect and sutured lingually into the lingual marginal gingiva"
223844979|NCT06615687|PROCEDURE|Free Gingival Graft|"Preparation of the recipient site :Following an intrasulcular incision, 2 mm-long horizontal incisions at the level of the CEJ will be performed bilaterally. From these, vertical releasing incisions will be placed in a diverging manner, extending well into the alveolar mucosa, a thin partial thickness flap will be subsequently raised then excised. The dimension of the resulting site will be measured to obtain a rectangular foil template .~Harvesting of the Graft :Using the foil template, graft dimensions will be outlined in the palate adjacent to the premolars and first molar. A partial thickness graft consisting of epithelium and a thin layer of underlying connective tissue will be harvested (intended total thickness of graft: 1.5 mm), maintaining a distance of ≥2 mm to the maxillary teeth."
223844980|NCT06614088|DIAGNOSTIC_TEST|serum calprotectin|A blood sample is collected at time of admission to detect serum level of calprotectin
223844981|NCT06613620|OTHER|Standard Treatment|"All participants will receive 4 weeks of intervention with a frequency of 3 times/week i.e. 10minutes of hot pack followed by post facilitation stretching and strengthening protocol.~The exercise protocol will be taught to the patient by an experienced physiotherapist and supervised on the subsequent sessions. The protocol will be gradually progressed as per the patient's tolerance."
223844982|NCT06613620|OTHER|Visual and auditory feedback on SEMG biofeedback unit|Patients will receive SEMG biofeedback assisted post facilitation stretching and strengthening. Patients will receive 50-80%of their maximum voluntary contraction as per the biofeedback and gradually the contraction time will be increased.
223844983|NCT06613620|OTHER|Electrical muscle stimulation|Electrical muscle stimulation will be provided in addition to visual and auditory feedback by the SEMG biofeedback unit to the weak muscles until the patients achieve the desired level of contractions.
223844984|NCT06615414|OTHER|participants are not assigned an intervention as part of the study|participants are not assigned an intervention as part of the study
223844985|NCT05468658|OTHER|Designing the birthing unit according to the philosophy of Feng Shui|"1. The cabinets will be painted using salmon and pastel green.~2. It is planned to make designs specific to the philosophy of Feng Shui on the doors and walls of the birthing unit.~3. Live nature videos and sounds will be projected onto the wall.~4. Fabric curtains will be replaced with curtains designed according to the philosophy of Feng Shui.~5. Natural plants will be placed.~6. Lighting will be used.~7. Bed linen will be designed according to the Feng Shui.~8. Wooden bell will be used.~9. Turtle, elephant and Wu Lou objects will be placed.~10. The Bagua mirror will be placed.~11. Crystals will be placed.~12. Natural stones will be placed.~13. The fountain will be placed in the east compass direction of the unit.~14. Straw bamboo separator will be used."
223844986|NCT06918860|OTHER|Analysis|Analysis and review of imaging and clinical data
223844987|NCT06917937|OTHER|Exercise Program|Our exercise program in our study; (i) foot intrinsic muscle strengthening exercise (with a load of 3 kg), (ii) plantar fascia stretching with finger extension, (iii) standing gastrocnemius muscle stretching, (iv) sitting achilles tendon stretching, (v) plantar fascia and gastrocnemius stretch on the step, (vi) cold massage exercise in the arch of the foot. We stated that the group to which exercise was added should do the exercises regularly for 6 weeks, in the specified number and time.
223844988|NCT06917937|OTHER|Corticosteroid injection|"The orthopedic physician administered the corticosteroid injection as a mixture of 1 ml of arthropane (5 mg of triamcinolone hexacetonide) and 4 ml of citanest. Before the application, the physician cleaned the area to be treated with 10% povidone iodine. He made a single dose injection by entering the painful point determined by palpation around the calcaneal spur and plantar fascia from the percutaneous foot-heel lateral. The patients were in the prone position with the ankle in a neutral position.~After the application, he covered the area with a sterile cloth and said to remove it after 3 hours. He stated that patients could apply ice to the injected area if necessary for pain control, and advised patients to avoid all jogging and other high-impact activities on the day of injection. No additional treatments, including NSAIDs, orthoses, and night splints, were allowed during the study period."
223844989|NCT06919042|DEVICE|Pulsed Acoustic Cellular Expression therapy|The therapy involves the delivery of targeted acoustic energy that initiates cellular mechanotransduction pathways, inducing beneficial biological responses such as enhanced angiogenesis, modulation of fibroblast proliferation and differentiation, and reorganization of aberrant extracellular matrix components.
223844990|NCT06303778|OTHER|Stand Down mobile app|The Stand Down mobile app is a smartphone-based stand-alone intervention designed to help persons manage drinking and alcohol-related problems on their own. The app is based on principles of motivational enhancement and cognitive-behavioral therapies and comprises 7 modules organized around 4 goals: (i) Enhance awareness of drinking patterns (assessment and personalized feedback), (ii) Establish and monitor progress towards drinking goal - i.e., moderation or abstinence, (iii) Manage cravings and other problems using in-the-moment tools, and (iv) Connect users with other types of support.
223844991|NCT06303778|OTHER|Standard Care|Participants assigned to the standard care condition will receive standard MAUD care delivered by their CPSs and will not receive access to SD-App. Three medications, naltrexone, disulfiram, and acamprosate, have been approved by the Federal Drug Administration and topiramate has been recommended by the VA/DoD clinical practice guidelines for SUD. MAUD includes these four medications. All medication decisions will be between the CPS and the Veteran and not influenced by study participation.
223844992|NCT06613555|OTHER|Retinal imaging|"the retinal imaging work-up includes:~* OCT-angiography~* Retinophotography~* Adaptive optics~performed at inclusion, at 6 months and then once a year for 10 years for patients Only performed at inclusion for controls"
223844993|NCT06613555|BIOLOGICAL|Biological check-up|"it is performed at inclusion and then once a year for 10 years for patients~Only performed at inclusion for controls"
223844994|NCT06614075|BEHAVIORAL|Questionnaire and anthropometric measurement|Questionnaire including sociodemographic characteristics, lifestyle habits, body weight, height, dietary assessment and diabetes risk; Anthropometric measurement including waist circumference
223844995|NCT06615648|BEHAVIORAL|PMT|7-minute PMT intervention video
223844996|NCT06615648|BEHAVIORAL|Non-contact Control|6-minute alternative video
223844997|NCT06613776|DRUG|Amoxicillin|4 capsules of amoxicillin 500mg, 2 grams in total, one hour before surgery
223844998|NCT06613776|DRUG|Placebo|4 empty capsules of amoxicillin 500mg (placebo), one hour before surgery
223844999|NCT06612606|OTHER|observational study|This was an observational study with no intervention.
223845000|NCT06613581|OTHER|Home-based follow-up|Follow-up after surgery for colorectal carcinoma, performed from home, within the bounds of the Dutch National guidelines
223845001|NCT01919619|BIOLOGICAL|Ipilimumab|Given IV
223845002|NCT01919619|DRUG|Lenalidomide|Given PO
223845003|NCT06671327|DRUG|Preemptive Dexmedetomidine injection|The DEX group was continuously pumped at 1.5 μg /(kg·h) for 15 minutes before induction, and after induction continue infusion 15min.
223845004|NCT06671327|DRUG|Sodium Chloride 0.9% Inj|The Placebo group was infused with equal amounts of isochronous normal saline.
223845005|NCT06682624|DEVICE|MRI|Magnetic Resonance Imaging in recognition of pediatric neurodegenerative disease patterns
223845006|NCT06685276|DRUG|Fruquintinib|Fruquintinib: 5mg qd, po, 2 weeks on/1 week off, q3w, or 3mg qd, po, q3w.
223845007|NCT06685276|DRUG|Sintilimab|Sintilimab: 200mg, iv, d1, q3w.
223845008|NCT06685276|DRUG|Chidamide|Chidamide: 30mg/m2, po, biw.
223845009|NCT04854486|OTHER|GSE and Xylitol|Participants are given the experimental treatment to be used for 7 days.
223845010|NCT04854486|DRUG|Control Placebo|Saline
223845011|NCT06693024|DRUG|neratinib|neratinib 240mg qd for 1 year
223845012|NCT06682117|DRUG|DC Vaccine|"Patients will receive Neo-DC vaccine infusion either by dose 1 (1×10\^7 cells/time) or dose 2 (5×10\^7 cells/time) every 7 days, four cell infusions are one treatment cycle.~The dose limited toxity observation time is within 28 days after the first Neo-DC vaccine infusion.~If the efficacy is evaluated as clinical benefit (CR/PR/SD) or immune unconfirmed progress ( iUPD), treatment cycle can be continued until the completion of four Neo-DC vaccine administrations or disease progression (iCPD by iRECIST) or start new anti-tumor treatment or stop treatment by other reasons."
223845013|NCT06628466|DRUG|Nuberol Forte|Quality of Life study
223845014|NCT06137755|BIOLOGICAL|CVI-VZV-001|Investigational Product
223845015|NCT06137755|BIOLOGICAL|Shingrix|Investigational Product
223845016|NCT04207255|DRUG|Opaganib|500mg of Opaganib orally twice a day continuously.
223845017|NCT04207255|DRUG|Abiraterone|IV as directed by SOC
223845018|NCT04207255|DRUG|Enzalutamide|IV as directed by SOC
223845019|NCT04207255|DRUG|Opaganib|250mg of Opaganib orally twice a day continuously.
223845020|NCT06697561|BEHAVIORAL|patient education program|"The intervention for the experimental group was an evidence-based educational program for hand dysfunction in patients with systemic sclerosis, which included a health education manual and multimedia videos developed through evidence translation. Additionally, individual education and consultation were provided."
223845021|NCT06697886|DRUG|Antiwei Granules|During the 3-day treatment period, participants will receive 9 sacks of Antiwei granules. Oral administration, 1 sack (6g) per time, 3 times daily.
223845022|NCT06697886|DRUG|Antiwei Granules Placebo|During the 3-day treatment period, participants will receive 9 sacks of Antiwei granules. Oral administration, 1 sack (6g) per time, 3 times daily.
223845023|NCT06696235|DEVICE|Early initiation of continuous renal replacement therapy|Patients will be randomized to either the standard initiation of the CRRT group or the accelerated initiation of the CRRT group with a 1:1 ratio.
223845024|NCT06696235|DEVICE|Standard initiation of continuous renal replacement therapy|Patients will be randomized to either the standard initiation of the CRRT group or the accelerated initiation of the CRRT group with a 1:1 ratio.
223845025|NCT04323735|DRUG|Culturelle 10 Billion CFU Capsule|"LGG® (Culturelle Probiotic with Lactobacillus RhamnosusGG, shown to produce the largest amount of antibacterial substances against pathogenic bacteria) will be used. For the LGG® instillation, participants will be instructed to mix the contents of 1 LGG capsule into 45 cc sterile 0.9% saline. After mixing, participants will draw up the 45cc liquid LGG mixture into a 60cc syringe and instill via the indwelling catheter (the catheter will not be changed as this would represent 2 interventions). Participants will be instructed the plug their catheter for 1 hour. Participants will receive 2 or 4 LGG capsules (depending on randomization group) and will repeat this process the following day (Low dose) or twice daily for a total of four doses (High dose) according to randomization group."
223845026|NCT06697275|DEVICE|Hypnotic Virtual reality|Hypnotic Virtual reality mask Deepsen® with age-appropriate software Birdy®
223845027|NCT06697275|DEVICE|Interactive virtual reality|Interactive virtual reality mask Deepsen® with age-appropriate software Birdy®
223845028|NCT06697275|OTHER|Standard method|Use of local anesthesic cream + Nurse and/or parents distraction +/- anxioloytic gas
223845029|NCT06698224|DEVICE|Spinal cord transcutaneous stimulation|Physical therapy combined with spinal cord transcutaneous stimulation will increase activity in the paralyzed or weak arm and hand muscles in individuals with spinal cord injury. Transcutaneous spinal cord stimulation is a non-invasive stimulation strategy and are known to facilitate recovery of lost function post spinal cord injury.
223845030|NCT06698224|DEVICE|Paired spinal cord and peripheral nerve stimulation|Physical therapy combined with paired spinal cord-peripheral nerve stimulation will increase activity in the paralyzed or weak arm and hand muscles in individuals with spinal cord injury. Transcutaneous spinal cord and peripheral nerve stimulation are both non-invasive stimulation strategy and are known to facilitate recovery of lost function post spinal cord injury.
223845031|NCT06697795|DEVICE|Virtual Reality-Assisted Hypnotherapy|Virtual Reality-Assisted Hypnotherapy utilizes HypnoVR software delivered through VR glasses to provide a relaxing virtual environment. The intervention is integrated into a standard physical therapy program, with participants receiving 20-minute VR-assisted hypnotherapy sessions during each of the 15 supervised physical therapy sessions over a 3-week period. This approach aims to improve pain management, quality of life, and adherence to treatment in patients with chronic neck pain.
223845032|NCT06697795|OTHER|Standard Physical Therapy|Participants in the control group will undergo a standard physical therapy program focused on the cervical region, consisting of 15 sessions over 3 weeks. Each session will be supervised by physiotherapists in a clinical setting and will include traditional physical therapy techniques such as therapeutic exercises
223845033|NCT06696495|DIAGNOSTIC_TEST|Measurement of the size and width of the foot|Assessment of the height of the plantar arch using a podoscope, and application of functional scales such as the AOFAS (Ankle and Foot Outcome Score), the FPI (Foot Posture Index) and the FFI (Foot Function Index). In addition, the distribution of plantar pressure and the centre of pressure (COP)
223845034|NCT06697080|DRUG|Human umbilical cord mesenchymal stem cells|Human umbilical cord mesenchymal stem cells
223845035|NCT06697067|PROCEDURE|modified smead jones|interrupted suture technique
223845036|NCT06697067|PROCEDURE|conventional comtinuous suture techniques|continuous suture technique
223845037|NCT06713772|DEVICE|Dermabond Mini, 0.36ml, Ethicon Johnson and Johnson, Somerville, New Jersey, USA|Dermabond Mini, 0.36ml, Ethicon Johnson and Johnson, Somerville, New Jersey, USA
223845038|NCT06713772|DEVICE|Steri-StripsTM (3M, St. Paul, Minnesota, USA|Steri-StripsTM (3M, St. Paul, Minnesota, USA
223845039|NCT06713772|DEVICE|Monosyn, B.Braun, 118 Pfieffewiesen, Melsungen, Germany|Monosyn, B.Braun, 118 Pfieffewiesen, Melsungen, Germany
223845040|NCT06698081|OTHER|Video Multimedia|The second group will be informed of the Standard Informed Consent Form, Verbal Information, and Multimedia. In addition to the standard consent process, we planned to show a 6-minute video multimedia presentation containing information about undescended testis and orchiopexy.
223845041|NCT06696391|OTHER|Venous Excess Ultrasound (VEXUS)-Guided Management|"Expert operators will perform VEXUS within 6 hours of randomization and repeat the assessment every 24 hours for 3 days, or until ICU discharge or death. After each assessment, investigators will grade the severity of venous congestion using a modified version of the VEXUS score and provide updated management recommendations.~Patients without congestion will receive standard fluid management. For mild congestion, investigators will implement fluid restriction (e.g., minimizing maintenance fluids) while maintaining nutrition and blood product administration as clinically indicated. For moderate to severe congestion, investigators will 1. target negative fluid balance (-1 to -2L/24h) through fluid restriction and diuretics, 2. perform cardiac ultrasound to guide inotrope administration and optimize RV physiology, and 3. optimize PEEP for ventilated patients.~All patients will receive the standard of care based on Surviving Sepsis Campaign guidelines."
223845042|NCT06710977|DRUG|Safety of intracameral levofloxacin in cataract surgery|Intracameral levofloxacin (0.1ml/0.5mg)
223845043|NCT06710977|DRUG|Use of intracameral cefazolin in cataract surgery|Intracameral cefazolin (0.1ml/1mg)
223845044|NCT06696872|OTHER|core exercises|The core muscle strength training program were lasted for 8 weeks and comprised of 3 training sessions per week, with a total of 24 sessions. Each session were lasted for 30 to 45 minutes, starting with a brief warm-up exercise program consisting of low-intensity core strength exercises to prepare the neuromuscular system for the training loads and ending with a cool-down program
223845045|NCT06696872|OTHER|Proprioceptive Neuromuscular Facilitation|The hold-relax proprioceptive neuromuscular facilitation stretching protocol consisted of passively moving the dominant leg into a position where the subjects felt mild discomfort and holding that position for 30 seconds. Subjects were then asked to isometrically contract the stretched muscle for 10 seconds; this were followed by muscle relaxation in the same posi¬tion for 30 seconds, before being stretched to a new point of mild discomfort. The leg were then released
223845046|NCT06696755|DRUG|Icalcaprant|Oral Capsules
223845047|NCT06696755|DRUG|Placebo for Icalcaprant|Oral Capsules
223845048|NCT06711367|BEHAVIORAL|tell show do behavior management technique|tell show do behavior management technique about the the diagnosis and procedures of dental restoration
223845049|NCT06711367|BEHAVIORAL|a costume-designed storybook|a costume-designed storybook explaining the diagnosis and procedures of dental restoration
223845050|NCT06712472|DRUG|Olaparib (300 mg BID)|Olaparib 300mg Bid during one year.
223845051|NCT04000893|OTHER|Resistance exercise session|Acute isometric exercise session performed with handgrip Jamar about 20 minutes monitored.
223845052|NCT06918210|PROCEDURE|Indocyanine Green|Visualization of the bile ducts with ICG
223845053|NCT06918210|PROCEDURE|Cholangiography|Visualization of the bile ducts with intraoperative cholangiography
223845054|NCT05591703|BEHAVIORAL|Clinical Outcomes and Questionnaires|Clinical patient-reported outcomes will be administered remotely at specified timepoints. No treatment or intervention will be administered in this protocol.
223845055|NCT06908564|DEVICE|Experimental: Interactive balance rehabilitation based on serious games.|The intervention of the Experimental Group consists of 30 minutes (16 sessions, 4 days/week, for 4 weeks) of balance rehabilitation exercises using non-immersive virtual reality through the OAK device (Khymeia Group, Italy). The system includes exercises that require the patient to reach visual targets by shifting their Center of Pressure (COP). The exercises are categorized based on the direction of COP displacement and can be performed with increasing difficulty, as determined by the physiotherapist during the rehabilitation process.
223845056|NCT06908564|OTHER|Active Comparator: conventional balance rehabilitation without the use of technological devices.|"Intervention of the Control Group (CG) consists of 30 minutes (4 days/week, for 4 weeks) of conventional balance rehabilitation treatments without the use of technological devices. The motor exercises will focus on the rehabilitation of balance, the trunk, and the lower limbs and will be carried out with a physiotherapist who will tailor the treatment according to the patient's characteristics and needs. Primary attention will be given to recovering trunk control and seated posture. This phase will focus on restoring and maintaining muscle trophism in the anterior and posterior kinetic chains of the thigh and lower leg, as well as the hip's range of motion, through isometric exercises and gentle joint mobilizations while adhering to anti-dislocation guidelines.~The process will continue with the reacquisition of the upright stance, emphasizing proprioceptive, coordination, and balance abilities. Once the upright position is stabilized, gait re-education will be introduced."
223845057|NCT06325670|BEHAVIORAL|BED treatment|A 12 session cognitive behavioural intervention in groups for Danish adults with type 2 diabetes and Binge Eating Disorder.
223845058|NCT06325670|OTHER|Waitlist|A waitlist control group that receives regular type 2 diabetes treatment while waiting to receive the BED treatment intervention.
223845059|NCT06913738|BEHAVIORAL|GPM-Extended|GPM-extended is a dimensional adaptation of Good Psychiatric Management (GPM) that retains its core principles-validation, real-life focus, alliance building-while enhancing flexibility and personalization. It emphasizes diagnostic clarity, treatment prioritization, and individualized psychoeducation based on three key personality dilemmas: fear of abandonment, self-esteem dysregulation, and control dependency. These dilemmas guide the focus of therapy and case management. Treatment goals are collaboratively set and regularly reassessed to align with the patient's evolving needs. The intervention includes weekly individual therapy and tailored group programs, with clinical strategies adapted to each dominant dilemma.
223845060|NCT06913738|BEHAVIORAL|Classic GPM|The classic GPM group follows the validated and manualized version of Good Psychiatric Management (GPM) for BPD. It emphasizes symptom stabilization through weekly individual therapy and pragmatic case management every 3 weeks. Unlike GPM-extended, it uses a uniform therapeutic framework rather than tailoring treatment to individual personality dilemmas,.The intervention includes weekly individual therapy and standardized group programs, with clinical strategies applied uniformly across patients, centered on interpersonal hypersensitivity and building stable life roles.
223845061|NCT06914453|DEVICE|Air Q-3 Supraglottic Airway Device|Oropharyngeal leak pressure and other performance characteristics including time to insertion, first-pass success rate, ease of orogastric tube (OGT) insertion, laryngeal alignment using a fiberoptic scope, and incidence of postoperative sore throat.
223845062|NCT06914453|DEVICE|Ambu AuraGain Supraglottic Airway Device|Oropharyngeal Leak Pressure and other performance characteristics including time to insertion, first-pass success rate, ease of orogastric tube (OGT) insertion, laryngeal alignment using a fiberoptic scope, and incidence of postoperative sore throat.
223845063|NCT05968079|DEVICE|Masimo W1™ and Apple Watch Series 8|Noninvasive wearable health monitoring device
223845064|NCT05031936|PROCEDURE|cervical spinal injection with 0.2% ropivacaine|spinal injections performed in cervical pillar area to relieve chronic neck pain
223845065|NCT06920394|OTHER|Survey using a questionnaire.|In the present study, no intervention will be carried out, and only the patients recruited will complete the questionnaires set out below.
223845066|NCT06918730|PROCEDURE|U-POEM|Water immersion for luminal distension of the GI tract as opposed to carbon dioxide insufflation
223845067|NCT06918730|PROCEDURE|CO2-POEM|POEM is routinely performed under carbon dioxide insufflation (CO2-POEM) as this gas is more rapidly absorbed than air.
223845068|NCT06920082|OTHER|Progressive muscle relaxation exercises|A total of 18 sessions of progressive relaxation were performed, 3 days a week for 6 weeks.
223845069|NCT06918912|DRUG|Loncastuximab Tesirine (Anti-CD19 Antibody-Drug Conjugate)|Loncastuximab Tesirine is an antibody-drug conjugate specifically targeting CD19, a protein found on the surface of B-cells. It is designed to deliver a cytotoxic pyrrolobenzodiazepine dimer directly to CD19-expressing malignant B-cells. Unlike traditional chemotherapies, Loncastuximab Tesirine combines the precision of an anti-CD19 monoclonal antibody with a potent chemotherapy agent, offering targeted therapy for relapsed or refractory Diffuse Large B-Cell Lymphoma (DLBCL) and High-Grade B-Cell Lymphoma (HGBCL) after failure of CAR-T therapy. It is administered intravenously every 3 weeks, with an initial higher dose of 150 μg/kg followed by a reduced dose of 75 μg/kg for up to 8 cycles, distinguishing it from other treatments by its specific targeting mechanism and dosage regimen tailored to this patient population.
223845070|NCT06919289|DRUG|Infiltration of papaverine|The study was randomized and double blinded. For randomization, the first extremity had either an infiltration of 0.5 cc of papaverine HCL (30mg/ml) for a 15mg perineural infiltration, or .5 cc of 1% lidocaine without epinephrine determined by a coin toss application.
223845071|NCT06919289|DRUG|Lidocaine infiltration|The study was randomized and double blinded. For randomization, the first extremity had either an infiltration of 0.5 cc of papaverine HCL (30mg/ml) for a 15mg perineural infiltration, or .5 cc of 1% lidocaine without epinephrine determined by a coin toss application.
223845072|NCT06918782|DRUG|Osimertinib plus platinum doublet chemotherapy|Based on the FLAURA2 study (which was not subdivided into ctDNA clearance subgroups), it is hypothesized that adding systemic chemotherapy to osimertinib will prolong PFS and OS and increase objective response rate even among the poor prognostic subgroup with failed ctDNA clearance after initial osimertinib monotherapy. By incorporating systemic chemotherapy (pemetrexed/carboplatin) to first-line osimertinib treatment among the poor prognostic group of metastatic EGFR-mutant lung adenocarcinoma with failure of plasma ctDNA EGFR mutant clearance despite initial osimertinib treatment.
223845073|NCT06919250|OTHER|Patients with systemic lupus erythematosus|Population: Patients with systemic lupus erythematosus. Intervention: Identification of the degree of physical activity of patients with systemic lupus erythematosus.
223845074|NCT06920264|DRUG|Tranexamic acid|A total of 150 participants will be enrolled and randomized 1:1 to receive either a standard dose of TXA (1000 mg) or an equivalent volume of placebo (normal saline, NS) at the time of surgery. .
223845075|NCT06920264|OTHER|placebo|saline
223845076|NCT06920316|DEVICE|Gro Health digital application|The Gro Health digital application is a personalised treatment platform proven to support sustainable weight loss. It is non-MHRA regulated as MASLD is within the device's UKCA/CE UKNI/CE marked indication. Gro Health reports 7% weight loss at 52 weeks in patients with Type 2 Diabetes Mellitus. We can set up the application so patients follow a Mediterranean diet. Over 1000 recipes of different cuisines will be available, along with weekly diet plans and shopping lists. Based on the patient's body mass index, daily calories and macronutrient targets will be calculated in line with the Mediterranean diet. Aerobic exercise can be tracked by daily step count linked by compatible smartwatches and smartphones. Physical activity can also be logged manually. Gro Health provides educational videos on aerobic and resistance exercise, along with 'follow along' videos of exercises for patients. These videos range from ones for beginners to those who have more experience with exercise.
223845077|NCT06918496|DEVICE|Surgical placement of a prosthetic or biologic graft (patch), or an allograft for cardiac and (cardio)vascular repair.|"Suture line bleeding in cardiac and vascular reconstruction poses significant risks, including morbidity, mortality, and complications related to blood loss and transfusion. Advances in surgical techniques have improved hemostasis but may not suffice, especially in patients on anticoagulant or antiplatelet medications or those using synthetic graft materials.~Surgical adhesives are valuable adjuncts to standard hemostatic techniques, aiming to prevent postoperative bleeding and its associated complications. NE'X Glue R-eco, a novel surgical adhesive, utilizes recombinant human serum albumin (rHSA) and glutaraldehyde (GA) for suture line sealing. It is similar to BioGlue®, which uses bovine serum albumin (BSA) and GA, and has proven safety and benefits.~Distinguishing Features of NE'X Glue R-eco:~Composition: Uses rHSA expressed in plants, offering improved biocompatibility and reduced risk of allergic reactions.~Bonding Strength: Demonstrates high bonding strength in tests, comparab"
223845078|NCT06919263|BEHAVIORAL|Influencer marketing|Participants viewed survey-imbedded promotional images featuring influencers
223845079|NCT06918249|OTHER|No intervention|
223845080|NCT06914557|DEVICE|Scrambler Therapy|Scrambler therapy will be administered by the staff of the Supportive Oncology and Palliative Care team who have been trained in Scrambler therapy and have extensive experience providing it to patients with neuropathic cancer-related pain. Patients who meet the study criteria will be treated daily, Monday through Friday, for up to 10 sessions. The treatment may be terminated sooner if a patient experiences complete pain relief or if it is ineffective after five sessions. Patients will be closely monitored during the treatment. The treatment is non-painful and not associated with any significant adverse effects.
223845081|NCT06914557|OTHER|Questionnaire and Physical Exam|15-minute-long questionnaires evaluating Pain and degree of pain.
223845082|NCT06919848|DRUG|TORIPALIMAB INJECTION(JS001 )|Toripalimab will be administered by IV, 240 mg on day 1 of each 21 day cycle until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
223845083|NCT06919848|DRUG|Lenvatinib|Lenvatinib will be administered (bodyweight ≥ 60 kg, 12 mg; \< 60 kg, 8 mg) orally daily until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
223845084|NCT06919848|DRUG|H101|H101 will be percutaneously injected into tumor on day 1 of every 21-day cycle. Lenvatinib plus Toripalizumab will be administered 1-3 days after H101 injection.
223845085|NCT06919848|DRUG|FOLFOX|FOLFOX chemotherapy was administered intravenously every 2 weeks for a maximum of 12 cycles (oxaliplatin 85 mg/m², leucovorin, 400 mg/m2, fluorouracil 400 mg/m² \[bolus\], and fluorouracil 2400 mg/m² as a 46-h continuous intravenous infusion
223845086|NCT06918626|PROCEDURE|ELC + Spyglass cholangiography|Study group (Spyglass Discover). Patients will undergo ELC surgery as soon as the ACC diagnosis has been confirmed. During surgery, intra-operative cholangiograpy (IOC) will be performed in order to exclude the presence of CBDS and in case of confirmation or still suspicion of CBDS, the exploration of the common bile duct and its eventual clearance via Spyglass Discover is carried out during ELC.
223845087|NCT06918626|PROCEDURE|ERCP + Early Laparoscopic cholecystectomy (ELC) in two stage procedures|Control group (ELC sequential treatment after possible clearance of CBDS via ERCP). Following the diagnosis of ACC, patients with CBDS high/intermediate risk are introduced either directly, in case of high risk, or after performing second-level diagnostics (MNR cholangiography or endoscopic ultrasound), in the case of intermediate risk, to the ERCP with the aim of eliminating CBDS preoperatively and then the ELC will be performed.
223845088|NCT06918756|OTHER|Questionnaires|Completion of new questionnaire in addition to other patient reported outcome measures that measure cough severity and cough-related quality of life.
223845089|NCT06918756|OTHER|Focus group interviews|Semi-structured focus group interviews for patients with refractory chronic cough
223845090|NCT06918756|OTHER|Objective cough measures|Cough monitoring and cough sensitivity testing.
223845091|NCT06917859|DRUG|Methylprednisolone group|In this study patients will be given a single intra-venous dose of methylprednisolone (2 mg/kg) after the induction of anesthesia, and before the initiation of CPB.
223845092|NCT06918678|DEVICE|Tai Chi intervention|The Tai Chi program was delivered virtually via Zoom by a certified Tai Chi instructor for 12 weeks. Tai Chi forms employed in the class was adapted from an evident-based fall prevention program - Tai Ji Quan: Moving for Better Balance. This program is a research-based Tai Chi balance training regimen. The program composed of core adapted Tai Chi movements and various therapeutic movements as well as breathing exercises
223845093|NCT06918678|OTHER|Usual care condiition|In the usual care condition, the investigators requested that participants maintain their regular activities during their time in the usual care condition. The participants were encouraged to refrain from Tai Chi, but not prohibited from engaging in Tai Chi, in the usual care period.
223845094|NCT06036381|DIAGNOSTIC_TEST|Radiomic analysis of imaging - MRI, PET, CT|Radiomic analysis of imaging will be undertaken as a standard of care to develop computational algorithms for patients treated in our institution.
223845095|NCT04308551|DRUG|Indobufen|Indobufen Tablets
223845096|NCT04308551|DRUG|Aspirin|Aspirin Tablets
223845097|NCT04286555|OTHER|DASH4D diet|"DASH stands for Dietary Approaches to Stop Hypertension. The DASH diet is a healthy dieter that lowers blood pressure. The DASH diet emphasizes fruits, vegetables, and low-fat dairy products; includes whole grains, poultry, fish, and nuts; and is reduced in red meat, sweets, and sugar-containing beverages. The DASH4D dietary pattern is a version of the DASH diet that is lower in carbohydrate."
223845098|NCT04286555|OTHER|comparison diet|The comparison dietary pattern is based on a typical American diet, with macronutrient distributions generally at the average of typical US intake, and micronutrient targets generally near the 25th percentile of usual US intake (with the exception of sodium).
223845099|NCT04286555|OTHER|higher sodium|3700 mg/day sodium (at the 2000 kilocalorie level)
223845100|NCT04286555|OTHER|lower sodium|1500 mg/day sodium (at the 2000 kilocalorie level)
223845101|NCT06914180|DRUG|esketamine group|In the esketamine group, in addition to receiving PRF treatment+pregabalin for rescue analgesia, patients will also undergo a single intravenous infusion of esketamine. A total of 0.5 mg/kg of esketamine will be diluted in 50 mL of normal saline. The infusion will commence with an intravenous injection of 10 mg of esketamine over 1 minute, followed by a maintenance dose of 8 mg/h. The infusion rate will be adjusted based on the patients' tolerance levels.
223845102|NCT06914180|DRUG|control group|In the control group, patients will receive PRF+pregabaline treatment. Pulsed radiofrequency (PRF) will be performed on GG by a designated physician in each participating center. PRF treatment (PMG-230, Baylis Medical Inc.) targeting to GG will be applied for 900 seconds. The parameters of PRF treatment will be set at 42 ℃, 2 Hz with 20 milliseconds current. Regarding pregabalin, the dosage is titrated based on patients'pain intensity and tolerance. This process fully accounts for individual patient differences to optimize treatment outcomes.
223845103|NCT06914193|DRUG|esketamine+PRF treatment group|In the esketamine group, in addition to receiving PRF treatment+pregabalin, patients will also undergo a single intravenous infusion of esketamine.
223845104|NCT06914193|DRUG|PRF treatment group|In the control group, patients will receive PRF treatment. PRF will be performed on DRG by an designated physician in each participating center. The patients will be treated with PRF (PMG-230, Baylis Medical Inc.) using a 21-gauge sterilized radiofrequency needle (a 10-cm trocar with a 5-mm active tip, PMF-21-100-5, Baylis Medical Inc.), which will be carefully inserted until the needle tip reached the upper edge of the intervertebral foramen under the guidance of three-dimensional (3D) CT. PRF treatment (PMG-230, Baylis Medical Inc.) targeting to DRG will be applied for 900 seconds. The parameters of PRF treatment will be set at 42 ℃, 2 Hz with 20 milliseconds current. Regarding pregabalin, the dosage is titrated based on patients'pain intensity and tolerance. This process fully accounts for individual patient differences to optimize treatment outcomes.
223845105|NCT06913335|PROCEDURE|laparoscopic ovarian cystectomy using hemostatic sealant|"* A small incision will be made on the ovarian surface using laparoscopic scissors.~* Nontraumatic grasping forceps will be used to dissect the cyst capsule away from the soft tissue of the ovary.~* The cyst will be removed intact to avoid spillage of its contents. If rupture occurs, the peritoneal cavity will be irrigated thoroughly.~* After the removal of the cyst, the ovarian bed should be inspected for bleeding, and if there is minimal bleeding, using of electrocautery should be avoided to minimize thermal damage to the ovary.~* The hemostatic sealant as Surgicel original, Surgicel Fibrillar (ETHICON, USA) which is an absorbable hemostat (oxidized regenerated cellulose) will be applied directly to the bleeding surface 1:5sheets of hemostat will be used."
223845106|NCT06913335|PROCEDURE|laparoscopic ovarian cystectomy using electrosurgical energy|"A small incision will be made on the ovarian surface using laparoscopic scissors.~* Nontraumatic grasping forceps will be used to dissect the cyst capsule away from the soft tissue of the ovary.~* The cyst will be removed intact to avoid spillage of its contents. If rupture occurs, the peritoneal cavity will be irrigated thoroughly.~* After the removal of the cyst, the ovarian bed should be inspected for bleeding, and if there is minimal bleeding, using of electrocautery should be avoided to minimize thermal damage to the ovary In the electrosurgical energy using group the hemostasis method will be different and will be achieved using electrosurgical energy.~* After the cyst removal and cyst bed examination, any bleeding will be carefully coagulated using bipolar electrosurgical energy~* Minimal energy will be applied for short durations to reduce collateral thermal"
223845107|NCT06920563|OTHER|Video|Those in the intervention arm will watch a short educational video.
223845108|NCT06920563|OTHER|Text Reminder|Those in the intervention group will receive regular text message reminders to check their blood pressures
223845109|NCT06920563|OTHER|Blood pressure threshold|Those in the intervention group will have a lower blood pressure threshold to titrate their BP medications towards
223845110|NCT06918743|DRUG|RSS0393 ointment|RSS0393 ointment 0.01%
223845111|NCT06918743|DRUG|RSS0393 ointment|RSS0393 ointment 0.03%
223845112|NCT06918743|DRUG|RSS0393 ointment placebo|RSS0393 ointment placebo
223845113|NCT06918314|DEVICE|Blood Flow Restriction Kaatsu Training Device|"The Blood Flow Restriction (BFR) intervention uses a pneumatic cuff to partially restrict arterial and fully restrict venous blood flow, creating a hypoxic environment that enhances muscle activation and strength at low exercise intensities. In this study, BFR will be applied intermittently during low-intensity treadmill walking with controlled pressure adjustments.~The Moxy Muscle Oxygen Monitor is a non-invasive NIRS device that measures muscle oxygen saturation (SmO₂) and total hemoglobin (THb). Placed on the quadriceps femoris muscle, it will track oxygenation changes before, during, and after BFR exercise, helping assess muscle metabolism and performance adaptations."
223845114|NCT06919211|PROCEDURE|Perfluorocarbon Liquid vs. Posterior Retinotomy during Pars-plana Vitrectomy for The Surgical Repair of Rhegmatogenous Retinal Detachment|This study compares outcomes of perfluorocarbon liquid (PFCL) versus posterior retinotomy (PR) during Pars plana vitrectomy (PPV) for Rhegmatogenous retinal detachment (RRD), focusing on anatomical success, visual acuity, intraocular pressure (IOP), and complications
223845115|NCT06919367|OTHER|age estimation using orthopantomography|Dental age estimation will be performed with 3 different methods based on orthopantomographic images obtained during routine examinations of patients.
223845116|NCT06918145|PROCEDURE|Lymphaticovenous Anastomosis|The basic principle of LVA surgery is to anastomose the deep cervical lymphatic vessels of the brain with adjacent small veins, effectively enabling the direct reflow of accumulated Aβ and tau proteins in the brain's lymphatic circulation into the venous system, thereby improving the symptoms of Alzheimer's Disease (AD).
223845117|NCT06920121|OTHER|Virtual reality glasses|Virtual reality glasses Beginning 2-3 minute before the start of the procedure, the patients will be watched (5 minutes) with an android mobile phone inserted into the Cardboard Super Flex Binoculars Glasses, with a music background, licensed product.
223845118|NCT06920121|OTHER|Stress ball|Patients will be instructed to continue squeezing and relaxing the stress ball (squeezing and relaxing once, counting from one to three) for 5 minutes before and throughout the AVF cannulation procedure. Patients will be instructed to focus their attention on the stress ball and focus on squeezing the stress ball.
223845119|NCT06919731|OTHER|whole blood flow cytometry analisys|Evaluation of platelet prothrombotic potential through a flow-cytometry analysis of platelet activation marker expression, including P-selectin, aGPIIbIIIa and TF, as well as platelet-leukocyte aggregate formation.
223845120|NCT06920355|OTHER|Produce Prescription|Each month, participants will receive a fixed amount of funds on the PRx card. Participants will be able to use these funds to purchase fruits, vegetables, beans, nuts, nut butters, seeds, plant-based oils, seafood, and yogurts from participating grocery stores. These funds will be provided through an electronic PRx benefit card that is activated after the initial baseline in-person visit is completed. The card will be reloaded monthly for a period of 6 months.
223845121|NCT06920355|BEHAVIORAL|Nutrition Education|Participating pharmacies/grocery chains will have Registered Dietitians (RD/RDN) on staff who can provide participants with nutrition education programs, coaching, and/or nudges.
223845122|NCT06933693|BEHAVIORAL|Mixed trials|All tasks will be randomly mixed in a single block of 400 trials.
223845123|NCT06933693|BEHAVIORAL|Blocked Trials|Each search task will be presented in a block of trials.
223845124|NCT06934213|BEHAVIORAL|Choice|The observer gets to make a choice about the sequence of trials they see
223845125|NCT06934213|BEHAVIORAL|Mixed trials|The search tasks are either intermixed. Otherwise trials are run in blocks
223845126|NCT04834024|DRUG|Recombinant Humanized Monoclonal Antibody MIL62, lenalinomide|The patients confirming to the eligibility criteria will receive MIL62 from cycle 1 to cycle 30 and lenalidomide from cycle 1 to cycle 18, unless either rapid disease progression or unacceptable toxicity was observed.
223845127|NCT04834024|DRUG|lenalinomide|The patients confirming to the eligibility criteria will receive lenalidomide for 18 cycles, unless either rapid disease progression or unacceptable toxicity was observed.
223845128|NCT05640128|OTHER|Aldosterone in HPLC-MS/MS|Aldosterone in HPLC-MS/MS
223845129|NCT06297564|OTHER|Progesterone primed endometrial protocol|The cases were received soft progesterone capsules (brand name: Utrogestan, 100 mg, Laboratories Besins International, France) 100 mg and 150 IU of human menopausal gonadotropin (hMG) concomitantly from the menstrual cycle (MC) day 3 until the trigger day.
223845130|NCT06297564|OTHER|Gonadotropin-releasing hormone antagonist protocol|The cases were received the gonadotropin-releasing hormone antagonist (GnRH-ant) protocol consisting of HMG 150 IU's daily injection from MC 3 until the trigger day. GnRH-ant (Cetrotide, 0.25 mg, MerckSerono) was started when at least one of the following criteria were met: LH \>10 IU/L, the presence of at least one follicle with mean diameter \>14 mm, or serum E2 level \>600 pg/mL.
223845131|NCT06393634|DRUG|Testosterone injection|A single injection of testosterone
223845132|NCT06393634|DRUG|Testosterone gel|A daily dose of testosterone gel
223845133|NCT06393634|DRUG|Testosterone Oral|A twice-daily pill of testosterone pill to swallow
223845134|NCT04216225|OTHER|pre-hospital tourniquet placement|patients with extremity injuries presenting with or without pre-hospital tourniquet placement.
223845135|NCT05432479|DIETARY_SUPPLEMENT|Probiotic|Single strain probiotic in a form of a sachets with a daily dose of 1.0E+9 Colony Forming Unit (CFU) per day for 4 weeks
223845136|NCT05432479|DIETARY_SUPPLEMENT|Placebo|Placebo
223845137|NCT04060784|PROCEDURE|Immediate implant placement and provisionalization|Failing tooth will be extracted and immediate placed endosseous implant
223845138|NCT00662909|DRUG|Mirabegron|Oral
223845139|NCT00662909|DRUG|Placebo|Oral
223845140|NCT03709784|DRUG|Observational study to examine safety, tolerability, and effectiveness of SPINRAZA® prescribed as part of standard of care|This is an observational study of adult patients with SMA to examine the safety, tolerability, and effectiveness of SPINRAZA® (nusinersen) for up to 30 months.
223845141|NCT03709784|OTHER|One time survey|One time survey
223845142|NCT03802773|PROCEDURE|CB transplantation|Myeloablative conditioning with post-transplant cyclophosphamide in patients receiving a matched CB transplant for hematological malignancies.
223845143|NCT06163222|BEHAVIORAL|Additional message with behavioural science-informed content and associated web pages|Behavioural science-informed messages sent 14-days prior to outpatient appointment which include links to re-designed web pages
223845144|NCT06163222|OTHER|Usual communication strategy|Usual communications sent from outpatient services to remind participants about their appointments
223845145|NCT03764345|DRUG|Sofosbovir/Lepipasvir (200/45mg) tablet (Heterosofir)|Patients receive oral daily dose of Sofosbovir/Ledipasvir (200/45mg) daily for 8 weeks
223845146|NCT04376164|RADIATION|low level laser therapy|mandibular anterior teeth were irradiated by gallium aluminum arsenide semiconductor laser with 635 nm wavelength, 6.5J/cm2energy density, for 10 seconds at 10 points (0.2 J/point) on facial and lingual aspects. This protocol was started immediately after first wire insertion and then at days 3,7,14 of the first month and repeated for additional 2 months
223845147|NCT00690456|DRUG|Rimonabant|Tablet, oral administration
223845148|NCT00690456|DRUG|Placebo (for Rimonabant)|Tablet, oral administration
223845149|NCT00690456|DRUG|Metformin|Metformin continued at stable dose as background therapy
223845150|NCT00948844|DEVICE|Hybrid (3-d accelerometers, and gyroscopes)|A 3 D accelerometer worn on the lower back or leg
223845151|NCT04978363|DEVICE|BOOT|A walking boot is a common type of brace/boot that restricts ankle and foot movement.
223845152|NCT04978363|DEVICE|HFC|The Hands Free Crutch (HFC) by iWalkFree, Inc. is a novel, ambulatory assistive device that prevents foot and ankle loading while also allowing free use of the arms and hands.
223845153|NCT04978363|DEVICE|SAC|Standard axillary crutches (SAC) are ambulatory assistive devices, commonly used for lower extremity injuries or surgeries.
223845154|NCT04978363|DEVICE|HFC+BOOT|The Hands Free Crutch (HFC) by iWalkFree, Inc. is a novel, ambulatory assistive device that prevents foot and ankle loading while also allowing free use of the arms and hands. A walking boot is a common type of brace/boot that restricts ankle and foot movement.
223845155|NCT04978363|DEVICE|SAC+BOOT|Standard axillary crutches (SAC) are ambulatory assistive devices, commonly used for lower extremity injuries or surgeries. A walking boot is a common type of brace/boot that restricts ankle and foot movement.
223845156|NCT00418847|DRUG|miglustat|Target dose of 320 mg/m\^2/day (divided in 3 doses) will be based on the Body Surface Area (BSA). For children with a BSA \> 1.3, 200 mg TID will be administered. For children with a BSA of 0.8-1.3, 100 mg TID will be administered.
223845157|NCT04094064|DEVICE|Continuous Glucose Monitor|Use of a continuous glucose monitor during study period.
223845158|NCT02111343|OTHER|Computer-based auditory training (CBAT)|"There are 3 listening games (i.e. Doggy, Who-Is-Right, Story-in-noise) that target on speech-in-noise training and 1 listening game (i.e. TATP) that aims to train dichotic listening.~Patient was required to undergo the training for 30 minutes per day, 5 sessions per week, for a duration of 12 weeks. Parents were advised to keep a journal to record child's training hour of the day."
223845159|NCT05777057|DIAGNOSTIC_TEST|Diagnodent|using DIAGNDENT depends on the principle that when 655nm wavelength of Diode laser is irradiated on dental surface, intraoral bacteria metabolites will absorb it and then metabolites emit a red fluorescence. The dental surface will reflect this fluorescence and gives number between 0 and 99 on the screen of the DIAGNdent.
223845160|NCT05520827|DRUG|BI 1584862|BI 1584862
223845161|NCT05520827|DRUG|Placebo|Placebo
223845162|NCT00536666|DRUG|Iron oligosaccharide|
223845163|NCT03371108|BIOLOGICAL|Gan & Lee Insulin Glargine Injection|Route of administration: subcutaneous injection
223845164|NCT03371108|BIOLOGICAL|Lantus®|Route of administration: subcutaneous injection
223845165|NCT04108910|DIAGNOSTIC_TEST|Guidance UTI|
223845166|NCT02563600|BEHAVIORAL|Pre-letter telephone call.|A brief 2-10 min telephone call made to the patient prior to receipt of appointment invitation letter.
223845167|NCT02563600|BEHAVIORAL|Post-letter telephone call|A brief 2-10 min telephone call made to the patient after receipt of appointment invitation letter.
223845168|NCT02714829|DEVICE|Inject BMP|Injection of ExcelOS-inject(beta-TCP) containing rhBMP-2.
223845169|NCT02714829|DEVICE|ExcelOS-inject|Injection of ExcelOS-inject(beta-TCP) without rhBMP-2.
223845170|NCT05190185|BIOLOGICAL|TAA06 injection|The subjects, who sign the informed consent forms and been screened by inclusion/exclusion criteria, will be treated with 1×106\~1×108 CAR-T/kg. And the subjects will be administered once.
223845171|NCT04416139|BIOLOGICAL|Infusion IV of Mesenchymal Stem cells|Mesenchymal Stem cells from bank will be applied IV, at dose 1 million xKg in a single dose
223845172|NCT05978609|DRUG|Candonilimab|Candonilimab 10mg/kg, Ivgtt，Q3W，Every 21 days is a cycle, administered on the first day of each cycle, and used continuously；
223845173|NCT05978609|DRUG|Cisplatin|Cisplatin，25mg/m2，Ivgtt，Dosing on days 1 and 8，Every 21 days is a cycle, administered on the first day of each cycle, and used continuously；
223845174|NCT05978609|DRUG|Gemcitabine|gemcitabine 1000mg/m2，Ivgtt，Dosing on days 1 and 8，Every 21 days is a cycle, administered on the first day of each cycle, and used continuously；
223845175|NCT00521716|DEVICE|Intracapsular Femoral Fracture Fixation|The WaisFix100i combines a new and unique Internal Triangular Cage nail fixator and three lag screws.
223845176|NCT00521716|DEVICE|WaisFix100i for Intracapsular Femoral Fracture Fixation|The WaisFix100i combines a new and unique Internal Triangular Cage nail fixator and three lag screws.
223845177|NCT05626543|BEHAVIORAL|Cognitive behavior therapy (CBT) and Mindfulness-based stress reduction (MBSR) programs|Cognitive behavior therapy (CBT) and Mindfulness-based stress reduction (MBSR) programs will be used combinedly. CBT will be constructed based on the CBT model of Beck, (2021) and mindfulness practice will be implemented based on the MBSR program developed by Williams et. al. (2011).
223845178|NCT05805059|DEVICE|Control Contact Lens (stenfilcon A)|one week wear
223845179|NCT05805059|DEVICE|Test Contact Lens (senofilcon A)|one week of wear
223845180|NCT06219785|DEVICE|Low-Intensity Shockwave therapy (LiSWT)|Participants will receive once-a-week LiSWT treatments of 0.2 mJ/ mm² over the lateral penile shaft (distal, mid, and proximal penile shaft), 500 impulses in each area, for a total of 1500 shocks along the penis once a week for six weeks, with a total of 6 treatments once a week.
223845181|NCT05882032|DRUG|LY3502970|Administered orally.
223845182|NCT03892850|BEHAVIORAL|Nurse prescription|Pharmacological nurse prescription. Subjects are individuals who request a same day consultation for minor acute pathologies and meet the selection criteria
223845183|NCT03892850|BEHAVIORAL|Medical prescription|Pharmacological medical prescription. Subjects are individuals who request a same day consultation for minor acute pathologies and meet the selection criteria
223845184|NCT04188288|DEVICE|Experimental feedback|Participants provided with feedback of target brain activation patterns (for example, in the form of a line graph) and will be instructed to try to make the line go up or down.
223845185|NCT04188288|DEVICE|Control feedback|Participants provided with control type of feedback (for example, in the form of a line graph) and will be instructed to try to make the line go up or down.
223845186|NCT04188288|DEVICE|fMRI|fMRI will be used to assess brain activity
223845187|NCT02790606|DEVICE|Covera(TM) Vascular Covered Stent|Treatment of stenoses with primary percutaneous transluminal angioplasty (PTA) and placement of the Covera Vascular Covered Stent.
223845188|NCT02735915|BIOLOGICAL|Herpes Zoster Vaccine GSK1437173A|Intramuscular injection
223845189|NCT05356403|DRUG|Difelikefalin 1 mg Oral Tablet|Difelikefalin 1 mg medication taken orally 1 time/day
223845190|NCT05356403|DRUG|Placebo Oral Tablet|Placebo tablet taken orally 1 time/day
223845191|NCT05328973|OTHER|ELEQUIL|patch placed on skin
223845192|NCT06331962|OTHER|remote home-based exercise therapy group|"Location and Frequency: Four times per week at the individual's ownhome. Exercise Duration: Eight weeks (subject to adjustments based onactual progress), with a total exercise time of 40 minutes each session.~Exercise Components: Cardiovascular endurance exercise, resistancetraining, sensory exercises.~Note: The participant will receive a customized exercise plan based ontheir capabilities, including guidelines and exercise instructions (exercisenames, required equipment, movement sequences, repetitions,precautions)."
223845193|NCT06331962|OTHER|supervised exercise therapy group|"Exercise Location and Frequency: Physiotherapy Center (twice a week)and individual's home (twice a week).~Exercise Duration: Eight weeks (subject to adjustments based on actualprogress), with a total exercise time of 40 minutes each session.~Exercise Components: Cardiovascular endurance exercise, resistancetraining, sensory training exercises. The home-based exercise trainingcontent is partially the same as the remote home-based exercise group."
223845194|NCT06331962|OTHER|regular care group|Perform regular care for eight consecutive weeks. After the trackingperiod ends (8 weeks), provide home-based education on resistanceexercises, cardiovascular endurance exercises, and sensory trainingexercises.
223845195|NCT03203161|PROCEDURE|bariatric surgery|Roux-and-Y Gastric Bypass or Sleeve gastrectomy
223845196|NCT02680769|DIETARY_SUPPLEMENT|300 mg of citrate Mg|This group will take an oral supplementation of 300 mg of citrate magnesium
223845197|NCT02680769|OTHER|Placebo|This group will take a placebo
223845198|NCT00227981|BEHAVIORAL|Interpersonal Psychotherapy|
223845199|NCT00227981|DRUG|Fluoxetine|
223845200|NCT06630923|DRUG|Human albumin|Experimental intervention (Group A): Continuous slow IV infusion of Human Albumin, based on diuresis-adjusted dosing, not later than 30 minutes after randomisation and not later than 2 hours after admission. Concomitant continuous slow IV infusion of diuretics (furosemide) based on body weight- and diuresis-adjusted dosing. Control intervention (Group B): Continuous slow IV infusion of diuretics (furosemide), based on body weight - and diuresis-adjusted dosing. Experimental intervention (Human Albumin) is off-label treatment for patients with acute decompensation of CHF in Greece. Control intervention (IV diuretic therapy) is on-label treatment for acute decompensation CHF in Greece.
223845201|NCT01218828|OTHER|LVEDP -Based hydration strategy|
223845202|NCT01218828|OTHER|Standard hydration|
223845203|NCT02728271|BIOLOGICAL|HPC cell infusion|"Administration of total lymphatic irradiation, antithymocyte globulins, and high dose cyclophosphamide, followed by the infusion of autologous stem cells.~Patients will not receive any cyclosporin A, rituximab, or azathioprine post transplant."
223845204|NCT03422978|DRUG|Dexmedetomidine|Single dose dexmedetomidine administered over 60 seconds post-induction.
223845205|NCT03422978|DRUG|Normal saline|Single dose normal saline administered over 60 seconds post-induction.
223845206|NCT02098902|BEHAVIORAL|Smart Moms Intervention|Reduction in child sugar-sweetened beverage consumption and maternal caloric beverage consumption, in addition to self-selected 100-calorie dietary and physical activity changes made by the mother to promote modest weight loss. Content will be delivered via one in-person group meeting, weekly online lessons, and weekly text messages. Mothers will self-monitor their weight and their own and their child's beverage consumption via text message every 2-3 days.
223845207|NCT01525433|BEHAVIORAL|DVD|Participants will received a mailed DVD containing culturally appropriate information about the importance of cervical cancer screening
223845208|NCT01525433|BEHAVIORAL|Promotora|Participants will receive a home visit from a lay community health educator ('Promotora') and will be shown a DVD containing culturally appropriate information to educate participants about the importance of cervical cancer screening
223845209|NCT00486733|DEVICE|DermaGold|The first four follow-up study assessment and data collection points will coincide with scheduled operative interventions on the wound guided by clinical situation and the treating physician's judgment (approximately every 3-4 days). Subsequent follow-up study assessment and data collection points will occur on study days 28 ± 3, 42 ± 3, 60 ± 3, and 90 ± 3.
223845210|NCT00946114|DRUG|sildenafil|tablets, 20mg, TID, 112 weeks at the maximum
223845211|NCT00946114|DRUG|sildenafil|tablets, 20mg x 4 (80mg), TID, approximately 70 weeks
223845212|NCT04833192|DIAGNOSTIC_TEST|experimental group|DHEAS.24h-UFC,ACTH and cortisol are measured in the experimental group
223845213|NCT06163521|OTHER|Education|A training consisting of 8 sessions of 40 minutes each will be applied to the children. One session will be done every week. The training will consist of activities including information, discussion and role-playing about children with special needs. The training topics consist of; Children with Special Needs Empathy Differences, Respect for Differences Contact Activity Awareness Benevolence Social Acceptance and Behaviour What can we do?
223845214|NCT00517478|PROCEDURE|Blood Sample|
223845215|NCT00316784|DRUG|IDEA-033 (and rescue medication)|
223845216|NCT02304822|DRUG|Multiple-dose of Ciprofloxacin prophylaxis|Multiple-dose prophylactic antibiotic of 200mg intravenous ciprofloxacin, 30 minutes before surgery and within 12 hours after surgery additionally
223845217|NCT02304822|DRUG|Single-dose of Ciprofloxacin prophylaxis|Single-dose prophylactic antibiotic of 200mg intravenous ciprofloxacin, 30 minutes before surgery only.
223845218|NCT02304822|DRUG|Zero-dose of Ciprofloxacin prophylaxis|Zero-dose of ciprofloxacin prophylaxis with none intravenous ciprofloxacin either preoperatively or postoperatively
223845219|NCT01841827|DRUG|Cilostazol|
223845220|NCT01841827|DRUG|Placebo|
223845221|NCT01387490|BEHAVIORAL|Individualized Scheduled Telephone Support (ISTS)|ISTS is a telephone intervention that provides injury-related education, training in problem solving, and focused behavioral strategies for problems (e.g., anxiety, depression) that commonly co-occur with Mild Traumatic Brain Injury (MTBI). ISTS also includes access to usual care and web-based and printed educational material. The 12 phone calls included in ISTS will be administered over a 6-month period.
223845222|NCT01387490|OTHER|Usual Care (UC)|UC is the usual care provided to service members attending the Traumatic Brain Injury (TBI) Clinics at Madigan Army Medical Center and Womack Army Medical Center, plus web-based education and 12 mailings of educational materials over a 6-month period.
223845223|NCT03728738|PROCEDURE|Head of Bed Positioning|The head of bed (HOB) position will be selected through computerized randomization, and will include either zero degree positioning or thirty degree HOB elevation
223845224|NCT05302843|DRUG|BPI-28592|Characterize the pharmacokinetics (PK)，safety，antitumor activity of BPI-28592
223845225|NCT02024308|DRUG|Fludarabine|50 mg/m2, IV (in the vein) in combination with cytarabine 1.4mg/m2/d for 5 days with each cycle of 28 days. Number of cycles: 4
223845226|NCT02024308|DRUG|Cytarabine|2000mg/m2/12h, IV (in the vein) for 3 days with each cycle of 28 days. Number of cycles: 4
223845227|NCT01447914|DRUG|Tivantinib|Given at a dose of 360 mg oral (PO) twice daily continuously for each day of every 4-week treatment cycle, which will be taken as three tablets of 120 mg each.
223845228|NCT01447914|OTHER|Diagnostic laboratory biomarker analysis|Correlative studies
223845229|NCT01447914|OTHER|Questionnaire administration|Ancillary studies
223845230|NCT01447914|PROCEDURE|Quality-of-life assessment|Ancillary studies
223845231|NCT02888613|PROCEDURE|mini laparotomy|The patient will be positioned supine. After induction of general anesthesia, a median umbilical incision will be performed. The average length of the incision of the laparotomy will be 10 cm (8-12 cm). The small intestine will be then mobilized medially and held by an orthostatic retractor. Arterial dissection and control as well as bypasses will be performed according to the conventional technique. In case of occlusive disease of the iliac arteries, femoral site will be selected to achieve the distal anastomoses of the bifurcated prosthetic graft.
223845232|NCT02888613|PROCEDURE|mini lumbotomy|"After induction of general anesthesia, the patient will be positioned in right lateral decubitus at 45° of the table plane. The incision will be performed from the tip of the eleventh rib with a slightly sloping path to the outer edge of the rectus muscle. The average length of the incision of the laparotomy will be 10 cm (8-12 cm).~Abdominal aorta will be approached retroperitoneally. Arterial dissection and control as well as bypasses will be performed according to the conventional retroperitoneal technique. In case of occlusive disease of the iliac arteries, femoral site will be selected to achieve the distal anastomoses of the bifurcated prosthetic graft."
223845233|NCT01483287|DIETARY_SUPPLEMENT|Alpha-Galactosidase|"The study is conducted during a total of two days at two different occasions. Visit 1: The patients will be served breakfast and lunch at the gastro unit and dinner will be enclosed when the patient leave for home. At each meal (breakfast, lunch, and dinner) the participants will ingest three capsules with a total content of 1200 GaIU alpha-galactosidase-randomized to be either the enzyme (α-Galactosidase) or a non-active substance (placebo). Visit 2: The procedure from visit 1 will recur after at least two weeks has passed - except that the content of the capsules will be opposite from the first visit.~No other food or beverage are ingested from 1800 hours the evening before the intervention day until breakfast the day after intervention (no exact time)."
223845234|NCT06629415|DRUG|Indocyanine Green|"injecting 7.5 mg (3 ml of a 25 mg/10 ml solution) intravenously in the pre-operative holding area at least 20 minutes before surgery.~Before dissecting the adhesions surrounding the hepatoduodenal ligament, fluorescence cholangiography (FC) is carried out to determine the anatomy of the extrahepatic bile ducts by converting the full-color images to fluorescence images using filter switches on the camera head and/or light source in the laparoscopic imaging system (Fig. 1). The \&amp;#34;critical view of safety\&amp;#34; is then reached by dissecting Calot\&amp;#39;s triangle and using FC to verify whether the accessory bile ducts are present or absent throughout the procedures. It is necessary to acquire fluorescence image"
223845235|NCT06629415|DRUG|Indocyanine Green Drug|1.25 mg of ICG powder was dissolved in 3 cm of saline, and the concentration was roughly 0.04 mg after each 1 cm of saline was diluted by 9 cm of saline. In order to prevent dye leakage that might result in false FC results, a veress needle was inserted through the abdominal wall and into the gall bladder fundus through the liver bed. The puncture site was then cauterized.
223845236|NCT06461741|DEVICE|Integrated Dual-task EMG Biofeedback Training (EMG-BF)|"The intervention is an exercise training that is facilitated by feedback derived from electrical muscle activity measured through electromyography (EMG). An EMG Biofeedback software uses a machine learning algorithm to identify the desired movements and reinforce them by displaying feedback on a computer monitor in the form of videogame control. The EMG acquisition hardware must have at least 4 sensor channels and a sampling rate of \>1KHz. Other than these specifications, any generic EMG amplifier can be used. The effect of the device is therefore primarily defined by the software. An in-depth description of the software and hardware systems is published in the cites study, An EMG-Based Biofeedback System for Tailored Interventions Involving Distributed Muscles. In this trail is the Explore+ ExG amplifier which is sold by Mentalab."
223845237|NCT06461741|BEHAVIORAL|Traditional Balance Exercise Training (BAL-EX)|This intervention is a time-matched active comparator for the EMG-BF intervention. A sequence of seven traditional, balance exercises, taking 1-3 minutes each, is repeated for a total of 30 minutes on each of 18 sessions in the 6-week intervention period. The exercises are ones that challenge the coordination and strength of postural muscles in the presence of various vestibular stimuli. The specific exercises are described in the Arm description.
223845238|NCT04746859|OTHER|Prevention Visit|Patients will have a one-on-one, approximately one-hour long visit with a specially trained Prevention Practitioner. During this visit, they will discuss the patient's health history, their risks for developing chronic diseases, including cancer, and possible steps they can take to reduce those risks. The Prevention Practitioner will also assist the patient to develop and articulate specific goals the patient would like to work on to reduce their risk of chronic diseases.
223845239|NCT04746859|BEHAVIORAL|Peer health coaching|Patients will be invited to register with the software platform used to facilitate peer health coaching. Once they have registered, they will be matched to a peer health coach who will connect with the patient to initiate the process. The coach will work collaboratively with the patient to help her follow through on a step-wise, personalized plan to achieve health goals that were developed with their prevention practitioner. The coach's approach will be informed by principles of brief action planning and motivational interviewing. Coaches will also provide social support, help to navigate to relevant information and community resources, and advise about options for self-monitoring. Coaching will occur over 12-16 sessions via phone calls, text messages, video calls and/or in-person meetings as desired/convenient and in accordance with local public health guidelines.
223845240|NCT03588975|BIOLOGICAL|MACI|autologous cultured chondrocytes on porcine collagen membrane
223845241|NCT03588975|PROCEDURE|microfracture|Arthroscopic microfracture treatment
223845242|NCT05036772|DEVICE|Virtual reality|The experimental arm will have the possibility to use a distracting virutel environment for the duration of hysterosalpingography.
223845243|NCT01764386|DRUG|NB|Naltrexone SR 32 mg/Bupropion SR 360 mg (NB) in combination tablets (daily dosage)
223845244|NCT01764386|BEHAVIORAL|CLI|The Comprehensive Lifestyle Intervention (CLI) program includes telephone counseling, internet education, goal setting, and online tracking tools.
223845245|NCT01764386|BEHAVIORAL|Usual Care|Usual Care is a self-directed lifestyle intervention program
223845246|NCT03377036|DIAGNOSTIC_TEST|DBT+s2D|Digital breast tomosynthesis plus synthesized 2D mammograms
223845247|NCT03377036|DIAGNOSTIC_TEST|2D-FFDM|2D full-field digital mammography
223845248|NCT05232136|BIOLOGICAL|OH2 injection|OH2: Oncolytic Type 2 Herpes Simplex Virus
223845249|NCT01496196|DRUG|tranexamic acid|500 mg/5 ml 3-4 times a day
223845250|NCT01496196|DRUG|tranexamic acid|500 mg/5 ml 3-4 times a day
223845251|NCT03076801|BEHAVIORAL|Choral Singing|In addition to usual medical care, participants in the intervention group will participate in weekly 60-90 minute singing sessions led by professional musicians over a 12-week period. Sessions will begin with a 5-minute physical warm-up of gentle stretching and a 5-minute vocal warm-up. Music will be selected from a variety of genres and eras. Attendance will be taken weekly.
223845252|NCT00498186|DRUG|Rotigotine|"Rotigotine transdermal patches once daily:~2.5cm2 (0.5mg/24 hours) 5cm2 (1mg/24 hours) 10cm2 (2mg/24 hours) 15cm2 (3mg/24 hours) 20cm2 (4mg/24 hours)"
223845253|NCT05406492|OTHER|Residual blood|Residual blood samples(1\~2 cc) at each sampling time are collected from all subjects while using ECMO for drug concentration assays(LC-MS/MS etc.).
223845254|NCT05846711|DIAGNOSTIC_TEST|BPPV diagnostic|Supine Roll Test and Dix-Hallpike Test
223845255|NCT05846711|DEVICE|TRV chair|Mechanical rotational chair
223845256|NCT05846711|DEVICE|VNG goggles|Goggles for video nystagmography
223845257|NCT05846711|DEVICE|IMU sensor|A sensor that measures triaxial acceleration and triaxial angular velocity.
223845258|NCT05846711|PROCEDURE|Manual BPPV diagnostics|Bedside BPPV diagnostics
223845259|NCT03929302|DEVICE|MyTAP oral appliance plus mouth shield|The midline traction oral appliance (MyTAP, AMI Inc., Dallas, Texas) is currently marketed as a medical device to treat snoring and obstructive sleep apnea and is FDA cleared will be used in all the three arms.
223845260|NCT04113837|DIETARY_SUPPLEMENT|food range|"The food range is comprised of:~sausages (1100 g per week) eggs (3 eggs per week), 100 g mushrooms per day, one bread per week, bread rolls, 100 ml ice cream per week, 3x 70 g pasta per week"
223845261|NCT02757885|PROCEDURE|Bone Marrow Transplant (BMT)|Participants will receive a bone marrow infusion from a human leukocyte antigen (HLA) mismatched donor through a central venous catheter.
223845262|NCT02757885|DRUG|Hydroxyurea|Hydroxyurea is part of the bone marrow transplant preparative regimen. Hydroxyurea will be administered at a dose of 30 mg/kg orally as a single daily dose for 90 days (from day -100 to day-10). Hydroxyurea dosing will be based on adjusted body weight in participants weighing \>125% ideal body weight.
223845263|NCT02757885|DRUG|Thiotepa|Thiotepa is part of the bone marrow transplant preparative regimen. Thiotepa will be administered at a dose of 10mg/kg intravenously (IV) over 2 hours or per institutional guidelines on day -7. Thiotepa dosing will be based on adjusted body weight in patients weighing \>125% ideal body weight.
223845264|NCT02757885|DRUG|Fludarabine monophosphate|Fludarabine is part of the bone marrow transplant preparative regimen. Fludarabine 30 mg/m2/day will be administered from day -7 to day -3 (for a total of 150 mg/m2 over 5 consecutive days) and administered intravenously (IV) over a minimum of 30 minutes. In participants weighing \> 125% ideal body weight, fludarabine will be dose based upon adjusted body weight.
223845265|NCT02757885|DRUG|Cyclophosphamide|"Cyclophosphamide is part of the bone marrow transplant preparative regimen. Cyclophosphamide will be administered on days -6 and -5 prior to bone marrow infusion at a dose of 14.5 mg/kg intravenously (IV) infused over 1-2 hours.~Post bone marrow infusion cyclophosphamide will be infused on days +3 (between 60 and 72 hours post marrow infusion) and +4 (approximately 24 hours after day +3 dose) at a dose of 50 mg/kg IV infused over 1-2 hours.~For participants weighing more than 125% of their ideal body weight, dosing will be based on adjusted ideal body weight."
223845266|NCT02757885|OTHER|Rabbit Anti-thymocyte Globulin|Rabbit anti-thymocyte globulin (ATG) is part of the bone marrow transplant preparative regimen. It is an infusion of rabbit-derived antibodies against human T cells used for prevention of acute rejection in organ transplantation. Rabbit ATG will be administered on day -9 at 0.5 mg/kg and on days -8 and -7 at 2 mg/kg (for a total dose 4.5 mg/kg).
223845267|NCT02757885|RADIATION|Total Body Irradiation|Participants will receive 200 cGy of TBI in a single fraction.
223845268|NCT05928182|BEHAVIORAL|El Faro Treatment Intervention|"Pre - Measures: complete Child Behavior Checklist (CBCL), ADHD module of the MINI International Neuropsychiatric Interview for Children and Adolescents (MINI) administered by study team, ADHD Rating Scale (ADHD-RS; parent and teacher ratings), ADHD Functional Impartment Scale (ADHD-FX), Parenting Sense of Competence (PSOC), demographic information, and medical history. \[All rating scales are parent-report unless noted otherwise\]~Treatment: Complete an 8-week adapted El Faro treatment intervention with homework tasks.~Post-Measures: CBCL, ADHD-RS (parent and teacher ratings), ADHD-FX, and PSOC. We will also acceptability and feasibility via measuring session attendance (rated by the therapist each session), homework completion (rated by the therapist each session), 7 treatment acceptability questions. \[All rating scales are parent-report unless noted otherwise and administered at post-treatment visit unless noted otherwise\]."
223845269|NCT05998590|DIETARY_SUPPLEMENT|High protein supplement|The participants received a 60g protein bolus each evening prior to sleep from week 3 to week 12 of training.
223845270|NCT05998590|DIETARY_SUPPLEMENT|Moderate protein supplement|The participants received a 20g protein bolus each evening prior to sleep from week 3 to week 12 of training.
223845271|NCT05998590|DIETARY_SUPPLEMENT|Carbohydrate placebo|The participants received an isocaloric carbohydrate bolus each evening prior to sleep from week 3 to week 12 of training.
223845272|NCT05998590|OTHER|Control: No supplementation|The participants did not receive any supplementation but instead acted as a control group doing BT only
223845273|NCT06218186|DEVICE|Medical Device: Wesper Lab Home Sleep Test|Wesper Lab is a medical device that is used for the diagnosis of sleep apnea. Wesper lab is composed of two flexible biosensors that adhere to the abdomen and thorax with medical grade adhesive. A FDA approved pulse oximeter is worn on a finger.
223845274|NCT05387928|DRUG|KL340399 injection|KL340399 injection is a STING-activating. The strength of KL340399 is 0.2 mg/vial，0.2 mg/vial.
223845275|NCT02197871|DIETARY_SUPPLEMENT|enteral nutrition emulsion|The patient should drink the oral nutritional supplements according to the estimated energy intake and make a record everyday.The patients will be followed up regularly.
223845276|NCT00291707|DRUG|Cetuximab|The initial dose of cetuximab is 400 mg/m2 intravenously administered over 120 minutes, followed by weekly infusions at 250 mg/m2 IV over 60 minutes. The infusion rate of cetuximab must never exceed 5 mL/min.
223845277|NCT00291707|DRUG|Pemetrexed|• Pemetrexed 350-500 mg/m2 IV over 10 minutes (see dose escalation design. Dose will be decreased to 200 mg/m2, if the first dose level of 350 mg/m2 is not tolerable) on days 1 and 22, (and 43 if \>6000 cGy to be delivered)
223845278|NCT00291707|PROCEDURE|radiation therapy|• Radiation therapy standard fractionation 2 Gy/day without planned interruptions beginning on day 1. Radiation will be given M-F for 6-7 consecutives weeks
223845279|NCT04501224|DRUG|Tenofovir alafenamide fumarate|Patients would take tenofovir alafenamide fumarate, 25mg，once per day
223845280|NCT04501224|DRUG|Entecavir or Tenofovir disoproxil fumarate|Patients would take entecavir 0.5 mg once per day, or tenofovir disoproxil fumarate 300 mg once per day
223845281|NCT02458846|OTHER|Crowded HOTV Acuity Test|This is one of the most sensitive tests of acuity for vision screening of young children. The child is asked to recognize a letter (H,O,T,V) that is surrounded by bars to induce the crowding effects typical of amblyopia. Children were tested monocularly and was required to achieve at least 20/32 in each eye to pass. Children already wearing glasses were tested with their glasses on.
223845282|NCT02458846|OTHER|Preschool Randot Stereoacuity Test|"This is a reliable screening test for stereo depth perception for young children. Children wear polarized stereoglasses and are asked to identify or match shapes that are hiding in the snow, which cannot be perceived if the child has abnormal binocular vision. Children were required to achieve at least 60 arcseconds of disparity to pass. Children already wearing glasses were tested with their glasses worn under the stereo glasses."
223845283|NCT02458846|DEVICE|Plusoptix Autorefractor|Autorefractors are electronic devices that measure refractive errors by focusing a light onto the child's eyes and recording how their reflections from the retina return to the camera. The Plusoptix has been shown to have high sensitivity and specificity in previous research. AAPOS (2013) guidelines were used to determine the referral criteria.
223845284|NCT02458846|OTHER|Comprehensive Eye Exam|Children who did not pass all three screening tests were referred for full cycloplegic optometry exams, with a parent/guardian present. Optometrists assessed visual history, monocular visual acuity (near \& far), strabismus, binocular function, abnormalities of the anterior segment, and cycloplegic refraction. If the optometrist prescribed glasses, frames were chosen at the time of the exam and the glasses were dispensed either at school (with an optician) or at the optometrist's office.
223845285|NCT00512824|DIETARY_SUPPLEMENT|low calcium milk of 180 ml|twice daily for 24 weeks
223845286|NCT00512824|DIETARY_SUPPLEMENT|regular milk of 180 ml|twice daily for 24 weeks
223845287|NCT00512824|DIETARY_SUPPLEMENT|regular milk of 180 ml + probiotics|twice daily for 24 weeks
223845288|NCT00512824|DIETARY_SUPPLEMENT|regular milk of 180 ml + probiotics|twice daily for 24 weeks
223845289|NCT01436409|OTHER|echography|echography during labor
223845290|NCT00886613|BIOLOGICAL|V212|Two doses of 0.65 mL V212 subcutaneous injection administered at Day 1 and Day 31
223845291|NCT00886613|BIOLOGICAL|Comparator: Zostavax™|Two doses of 0.65 mL Zostavax™ subcutaneous injection administered at Day 1 and Day 31
223845292|NCT00886613|BIOLOGICAL|Comparator: Placebo|Two doses of 0.65 mL subcutaneous injection of placebo administered at Day 1 and Day 31
223845293|NCT00886613|OTHER|VZV Skin Test|Three intradermal injections of the 0.1 ml varicella antigen (VZV Skin Test reagent) were administered, once at baseline before the first vaccination, a second time before the second vaccination, and a third time approximately 14 days after the second vaccination.
223845294|NCT00886613|OTHER|Saline|One intradermal injection of the 0.1 ml saline was administered at the time of the baseline VZV skin test prior to the first vaccination. Saline and VZV skin test reagents were administered on opposite arms.
223845295|NCT06479460|DIAGNOSTIC_TEST|ctDNA-MRD|This study is an observational non intervention study that only tests peripheral blood samples from different treatment nodes of the subjects, without interfering with the normal clinical diagnosis and treatment process of the patients.
223845296|NCT01515956|DRUG|BMN 110|Patients will receive intravenous (IV) infusions of study drug at a dose of 2.0 mg/kg/wk over a period of approximately 4 hours every week for up to 208 weeks.
223845297|NCT04704960|OTHER|Diagnostic Test: liquid biopsy|detection of tumor DNA alteration in cf-DNA
224264984|NCT03928405|OTHER|Exercises with Nintendo Wii virtual reality device|In the first session, each Nintendo Wii components were introduced to each individual. The selected games and how they were played were taught to each individual by the physiotherapist and practically taught. The games were played with the help of physiotherapists in the first session so that individuals could transfer the correct weight on the Nintendo Wii balance board and to use the game console's control. The patient was supported with verbal and physical feedback when the patient played incorrectly during the games in the next sessions. Games that require serious balance and coordination were considered as a difficult activity for the patient and were not used in this study. The difficulty of the games was set to the simplest level for each patient. As the patients were successful the games' difficulty level was upgraded. The difficulty of the games has been increased according to the classification determined by the Nintendo Wii device.
224264985|NCT00779519|DRUG|TTP435|
224264986|NCT00779519|DRUG|Placebo|
223845298|NCT03783533|BEHAVIORAL|Behavioral Activation|Intervention: Behavioral Activation (BA) therapy is based on a functional analytic model of depression that highlights the need for increased positive reinforcement (rewards) and decreased anhedonia, or diminished motivation to seek rewards, to maintain normal mood. BA is significantly more effective than Cognitive Behavioral Therapy and comparable to antidepressant medication in reducing depressive symptoms among depressed adults (Dimidjian et al., 2006). McCauley (senior mentor) et al. (2016) adapted BA for adolescents to target anhedonia, effective problem solving and avoidant behaviors with peers, family, and school. McCauley's findings and others show BA is a promising intervention for adolescent MDD (Chu et al., 2009; Cuijpers et al.,, 2007; McCauley et al., 2015; Ritschel et al., 2011). BA focuses on targeting ideographically identified avoidant behaviors and rewarding experiences that affect mood.
223845299|NCT01492309|DEVICE|Active Transcranial Magnetic Simulation|Subjects will be given active TMS 5 days per week for 4 weeks for a total of 20 sessions. Each session will last approximately 10 minutes.
223845300|NCT01492309|DEVICE|Sham Transcranial Magnetic Stimulation|Subjects will be given sham TMS 5 days per week for 4 weeks for a total of 20 sessions. The sham coil contains a shielding mechanism which diverts the magnetic field away from the patient. The sham treatment will last approximately 10 minutes.
223845301|NCT01169519|DRUG|Sildenafil by injection|Sildenafil 0.125mg/kg injection over 20min
223845302|NCT01169519|DRUG|Sildenafil by injection|Sildenafil 0.25mg/kg injection over 20min
223845303|NCT01169519|DRUG|Sildenafil by injection|Sildenafil 0.35mg/kg by injection over 20min
223845304|NCT01169519|DRUG|Sildenafil by injection|Sildenafil 0.45mg/kg by injection over 20min
223845305|NCT03539159|OTHER|Allogeneic conventional sized serum eye drops|allogeneic serum conventional sized drops (40-50 µL, administrated using the Meise applicator) applied six times a day (when appropriate, lowering the dose to 3-4 times a day is allowed) for a period of one month
223845306|NCT03539159|OTHER|Allogeneic micro sized serum eye drops|Allogeneic serum micro eye drops (5-10 µL, administrated using the mu-Drop applicator) applied six times a day (when appropriate, lowering the dose to 3-4 times a day is allowed) for a period of one month
223845307|NCT05553561|PROCEDURE|IPRL device|Intense pulsed light therapy (IPL) is a non-coherent large wavelength high-intensity light in the range of 500-1200nm. It has been used by many investigators for the treatment of evaporative dry eye safely and effectively.
223845308|NCT05553561|PROCEDURE|pharmacological therapy & Eyelid hygiene|traditional methods of MGD treatment as Eyelid hygiene, topical preservative free lubricant, topical \& systemic antibiotics \& anti-inflammatory agent
223845309|NCT03107702|DIAGNOSTIC_TEST|melatonin|the relationship between melatonin level and analgesia requirement.
223845310|NCT03988062|DEVICE|TrelliX Embolic Coil System|Embolic coil with shape memory polymer
223845311|NCT01343173|DRUG|Imatinib stop|To stop imatinib after inclusion.
223845312|NCT04151121|BEHAVIORAL|MBCT (Mindfulness Based Cognitive Therapy)|MBCT is recognized behavior therapy for patients with recurrent depression. The program will be adapted for patients with chest pain.
223845313|NCT05506709|DEVICE|Seawater nasal spray|Subjects will use the nasal spray (moderately hypertonic solution based on 100% natural sea water rich of marine trace elements with added manganese and calcium) at least once and up to 6 times as necessary per day during the 14-day test period. Each application is composed of two irrigating sprays per nostril for a total of 4 sprays per application.
223845314|NCT03298464|BIOLOGICAL|NGM313|Subcutaneous injection
223845315|NCT03298464|DRUG|Pioglitazone|White to off-white round tablet
223845316|NCT00073970|DRUG|celecoxib|400mg, given twice daily
223845317|NCT03681691|DRUG|Estradiol patch|transdermal 17β-estradiol patch
223845318|NCT00748969|DRUG|Somatropin (DNA origin)|The study starting dose of Nutropin AQ® will be 0.48 mg/kg/week divided into daily SC injections. Nutropin AQ® will be administered by either the subject or, if unable to demonstrate competency in this, then by the guardian. To decrease the risk of increased intracranial hypertension, the dose in the first month of treatment will be decreased by 50% (0.24 mg/kg/week), and then increased to 0.48 mg/kg/week if tolerated well after 1 month.
223845319|NCT00387062|DEVICE|Computer-based Cognitive Training|
223845320|NCT06426082|BEHAVIORAL|Thermoneutral condition|Participants will be exposed 2 hours/day at 32ºC for 5 days/week
223845321|NCT06426082|BEHAVIORAL|Cold condition|Participants will be exposed 2 hours/day at 18ºC for 5 days/week
223845322|NCT06426082|BEHAVIORAL|Aerobic exercise condition|Participants will perform aerobic exercise training 5 days/week at 65% heart rate reserve for 60 minutes each training session
223845323|NCT06426082|DRUG|Salbutamol|Participants will take salbutamol 12 mg/day. 7 days week
223845324|NCT01912001|OTHER|Telephone follow-up|
223845325|NCT01912001|OTHER|Sympton Assessment|
223845326|NCT04679363|OTHER|Active release technique|ART will be performed on upper trapezius and sternocleidomastoid, starting from 5 repetitions in 1st and 2nd week and progressing to 10 repetitions in 3rd week. ART will be performed in supine position with a pillow under knees. After the shortened area of the targeted muscle is identified, soft tissue mobilization with active movement and passive overpressure will be applied. The active movement in technique will be from shortened position of muscle to lengthened position.
223845327|NCT04679363|OTHER|Post isometric relaxation|PIR will be performed on upper trapezius and sternocleidomastoid muscles, starting from 5 repetitions in 1st and 2nd week and progressing to 10 repetitions in 3rd week. The patient will be instructed to move the ear towards the shoulder of the affected side, against the resistance of the therapist's hands with minimum force (only 20% of their total force). The patient will be instructed to perform isometric contraction of the affected side along with inhalation and position for 10 seconds. Then the patient will exhale completely and relax. During this relaxation phase head and neck are taken further away from ipsilateral shoulder and ipsilateral shoulder is pushed downward until next restriction is met.
223845328|NCT03983343|DEVICE|exofin®|Perineal skin will be closed by adhesive glue - exofin® (Octyl-2-cyanoacrylate).
223845329|NCT05163756|DRUG|DW1903|q.d. PO, DW1903 + Placebo of DW1903-R1
224264987|NCT06476093|DRUG|Anlotinib hydrochloride|Anlotinib#12mg#PO#Q3W#d1-14# SRT#depends
223845330|NCT05163756|DRUG|DW1903-R1|q.d. PO, Placebo of DW1903 + DW1903-R1
223845331|NCT03613129|DRUG|CT38|Infusion
223845332|NCT06027112|OTHER|musculoskeletal injuries|This research will be conducted to identify the factors that increase the risk of musculoskeletal injuries in university students,
223845333|NCT01153750|DRUG|Glivec|
223845334|NCT02334306|BIOLOGICAL|AMG 557/MEDI5872|Participants will receive a fixed SC dose of 210 mg MEDI5872 (AMG 557/MEDI5872) QW for 3 weeks (Days 1 to 15) and then Q2W for 9 weeks (Days 29 to 85) in double-blind period of the study. In open-label period, all participants from double-blind period will receive a fixed SC dose of 210 mg MEDI5872 from Day 99 to Day 183 (QW from Days 99 to 113 for participants from Placebo arm and on Days 99 and 113 for participants from MEDI5872 210 mg arm; and Q2W from Days 127 to 183 for participants from both arms).
223845335|NCT02334306|OTHER|Placebo|The SC dose of placebo every week for 3 weeks (Days 1 to 15) and then every 2 weeks for 9 weeks (Days 29 to 85) in double-blind period of the study. In open-label period, an additional dose of blinded placebo will be administered on Day 106 for participants who will receive MEDI5872 210mg in double-blinded period.
223845336|NCT00280033|BIOLOGICAL|Aluminum hydroxide|Provided in vials that contain 0.8 mL volume per vial.
223845337|NCT00280033|BIOLOGICAL|Inactivated Influenza A/H5N1 Vaccine (Chiron)|Monovalent subvirion H5N1 vaccine (HA of A/Vietnam/1203/04) provided in unit-dose vials containing 60 mcg/mL A/H5N1 HA as determined by single radial immunodiffusion. It may be formulated with MF59 or aluminum hydroxide. Dosages: 7.5 mcg, 15 mcg, 30 mcg, or 45 mcg.
223845338|NCT00280033|BIOLOGICAL|MF-59|Proprietary experimental adjuvant. Provided in vials that contain 0.7 mL volume per vial.
223845339|NCT00280033|DRUG|Placebo|Saline placebo.
223845340|NCT00465985|DRUG|ACZ885|
223845341|NCT00465985|DRUG|Placebo|
223845342|NCT00285558|BEHAVIORAL|CBT with peer-enhanced activities|
223845343|NCT00285558|BEHAVIORAL|CBT with supervised aerobic exercise|
223845344|NCT04417712|DEVICE|KONAR-MF™ VSD Occluder|All patients will be implanted with a KONAR-MF™ VSD Occluder in accordance with the instructions for use (IFU).
223845345|NCT01385865|DIETARY_SUPPLEMENT|Mulberry leaf extract|18 tablets/day (6 tablets/serving x 3servings/day, mulberry leaf extract 336mg/1 tablet (800mg), 1-Deoxynojirimycin 4.3mg/1 g mulberry leaf extract), Duration: 4 weeks
223845346|NCT01385865|DIETARY_SUPPLEMENT|Placebo|18 tablets/day (6 tablets/serving x 3servings/day, lactose 511mg/1 tablet (650mg)), Duration: 4 weeks
223845347|NCT05939557|PROCEDURE|Jones technique|is a gentle soft tissue manipulation consisting of a passive procedure that positions the body in a position of comfort to release tissue that compresses or shortens the body structure (muscle contraction and joint dysfunction)
223845348|NCT05939557|DEVICE|Kinesiotape|KT has an S-shaped glue, which lifts the skin, thus improving blood and lymphatic circulation, with the intention of relieving pain and improving musculoskeletal diseases especially in sports
223845349|NCT06103240|OTHER|Lacticaseibacillus rhamnosus LRa05|Bacterial count:100 billion CFUs Take one sachet per day for 4 weeks.
223845350|NCT03302156|DRUG|PSMA-based 18F-DCFPyL PET tracer|PSMA-based 18F-DCFPyL PET tracer that will be used to determine the presence or absence of cancer
223845351|NCT03532178|DRUG|"Group A. Muscle relaxant #1: rocuronium + sugammadex; Muscle relaxant #2: succinylcholine +saline"|"The participants will be randomized to start with Muscle relaxant #1 in the first study treatment, and will switch to Muscle relaxant #2 in the second study treatment period."
224264988|NCT01749553|OTHER|Sleeper Stretch|Posterior shoulder stretch technique
224264989|NCT06451653|BEHAVIORAL|Men in Maternity Health (MiM) Intervention|The six-month MiM education program focused on maternal health education for male partners of pregnant women in the intervention area. Assigned midwives offered two-hour-long, face-to-face health education and discussion sessions at five selected health centres every second and fourth Sunday, respectively, to accommodate participants' work schedules. Attendance consistently remained high at 80% of participants every month, with home visits for absentees to provide health education.
224264990|NCT03277963|DEVICE|Pain perception tests (mechanical : VON FREY ELECTRONIQUE or electrical stimulus : PAIN MATCHER®)|From a basal level causing no particular sensation, the mechanical or electrical stimulus is applied with a constant increasing rate of progression.
224264991|NCT00924638|DEVICE|Reveal® XT Insertable Cardiac Monitor|The Insertable Cardiac Monitor is implanted under the skin in the region of the thorax. It continuously monitors the heart's electrical activity for up to three years. ECG data are stored when the device detects a cardiac arrhythmia.
224264992|NCT00051779|DRUG|CAL|
224264993|NCT05314257|DRUG|Granisetron Hydrochloride|IV granisetron 1mg
224264994|NCT05314257|OTHER|0.9% normal saline|IV 5ml of 0.9% normal saline
224264995|NCT05248230|BIOLOGICAL|4D-710|4D-710 is an adeno-associated virus (AAV) gene therapy comprised of an AAV capsid variant (4D-A101) carrying a transgene cassette encoding human cystic fibrosis transmembrane conductance regulator with a deletion in the regulatory domain (CFTRΔR).
224264996|NCT04218435|DRUG|Sacubitril / Valsartan Oral Tablet|"Sacubitril/Valsartan is indicated to reduce the risk of cardiovascular death and hospitalization for heart failure in patients with chronic heart failure (NYHA Class II-IV) and reduced ejection fraction.~Sacubitril/Valsartan is usually administered in conjunction with another heart failure therapies, in place of an ACE inhibitor or other ARB."
224264997|NCT00847535|BIOLOGICAL|autologous muscle cell injection|Injection of autologous muscle cells
224264998|NCT04603703|OTHER|HVLAT Manipulation|"Ultrasound for 10 mins/1 set/ (3 days/ week), Moist hot pack for 10 mins/1 set/ (3 days/ week), Piriformis stretching for 7 sec hold/ 7 repititions/ 1 set/ (3 days/ week), Myofascial release of lumbosacral paraspinal muscles for 3 mins/ 1 set/ (3 days/ week), Gluteal muscles strengthening for 10 sec hold/ 5 reps/ 1 set/ (3 days/ week), Sciatic Neurodynamics with 10 oscillations/ 3 sets/(3 days/ week), HVLAT manipulation/ 1 rep/ 1set/ (3 days/ week),~A total of 2 weeks (6 sessions, 3 sessions/ week) were given each consisting of 30 mins."
224264999|NCT04603703|OTHER|Conventional Physical Therapy|"Ultrasound for 10 mins/1 set/ (3 days/ week), Moist hot pack for 10 mins/1 set/ (3 days/ week), Piriformis stretching for 7 sec hold/ 7 repititions/ 1 set/ (3 days/ week), Myofascial release of lumbosacral paraspinal muscles for 3 mins/ 1 set/ (3 days/ week), Gluteal muscles strengthening for 10 sec hold/ 5 reps/ 1 set/ (3 days/ week), Sciatic Neurodynamics with 10 oscillations/ 3 sets/(3 days/ week),~A total of 2 weeks (6 sessions, 3 sessions/ week) were given each consisting of 30 mins."
224265000|NCT04237415|PROCEDURE|EMG biofeedback training|
223845352|NCT03532178|DRUG|"Group B. Muscle relaxant #2: succinylcholine +saline; Muscle relaxant #1: rocuronium + sugammadex;"|"The participants will be randomized to start with Muscle relaxant #2 in the first study treatment, and will switch to Muscle relaxant #1 in the second study treatment period."
223845353|NCT01701154|OTHER|respiratory muscle strength training|
223845354|NCT03180190|DRUG|Hydroxychloroquine Oral Tablet|"slit lamp and fundus examination using both direct and indirect ophthalmoscope Screening for HCQ ocular toxicity by~* Perimetry using Octopus perimeter and utilizing 24-2 test strategy,~* Electroretinography (ERG) under scotopic and photopic conditions and Spectral domain optical coherence tomography (SD-OCT)"
223845355|NCT03206931|DRUG|Selitrectinib (BAY2731954)|Selitrectinib is administered as capsules or liquid formulation.
223845356|NCT04399707|DEVICE|Transcutaneous electrical nerve stimulation (TENS) unit|Patients will be randomized to active TENS unit, placebo TENS unit, or no TENS unit
223845357|NCT04399707|DEVICE|Placebo transcutaneous electrical nerve stimulation (TENS) unit|Patients will be randomized to active TENS unit, placebo TENS unit, or no TENS unit
223845358|NCT05392764|DRUG|Empagliflozin 10 MG|once-daily oral empagliflozin 10 mg
223845359|NCT05392764|DRUG|Placebo|Placebo matching empagliflozin 10 mg
223845360|NCT04077684|DRUG|Interleukin-2|IL2 (0.2 MIU, 0.5 MIU or 1 MIU) : placebo = 1:1:1:1
223845361|NCT00233792|DEVICE|sirolimus coated Bx VELOCITY stent - fast release|
223845362|NCT00233792|DEVICE|sirolimus coated Bx VELOCITY stent - slow release|
223845363|NCT02636413|DRUG|gaxilose|After gaxilose administration, urine collection, cuantification (firstly from 0 to 4 hours, and total urine from 0 to 5 hours), and xilose cuantification afterwards.
223845364|NCT02636413|DIETARY_SUPPLEMENT|lactose|After lactose administration, expired hydrogen measurement at pre-specified intervals.
223845365|NCT04031417|OTHER|Hypoxia|
223845366|NCT04031417|OTHER|Low Humidity|
223845367|NCT00552734|DEVICE|Insulin Guidance Software|At baseline a healthcare provider reviewed the features of the software on the PDA and loaded a subject specific insulin dosing algorithm into the software based on the physician's recommendations. The program advised basal, bolus and correction insulin dosages based on individual patients' prescriptions in addition to being alerted for SMBG testing. Subjects in the experimental group were also asked to input their blood glucose values into the PDA via the touch screen. Subjects then received a recommended insulin dose based on their prescription which was programmed by the healthcare provider. The patients were asked to either agree with the recommended insulin dose or disagree, and manually enter the insulin dose they took for a given event.
223845368|NCT02543450|OTHER|Cardiovascular and task-oriented training|
223845369|NCT02543450|OTHER|Upper limb strength training program|
223845370|NCT02824367|BEHAVIORAL|Completion of scales evaluation|Patient complete scores to perfectionism scales (Frost Multidimensional Perfectionism Scales (FMPS), Hewitt Multidimensional Perfectionism Scale (HMPS), scores to depression scale (Beck Depression Inventory (BDI)) and anxiety scale (State Trait Anxiety Inventory (STAI))
223845371|NCT02771418|DRUG|Propofol|Intravenous induction and maintenance of general anesthesia with propofol is a routine practice for this intervention
223845372|NCT02771418|DRUG|Sevoflurane|Volatile induction and maintenance of general anesthesia with sevoflurane is a generally acceptable clinical approach for this intervention
223845373|NCT02771418|PROCEDURE|Elective carotid endarterectomy|
223845374|NCT01121783|OTHER|Lactisole|A pre-infusion of lactisole solution (0.25mg/ml) is administered as a bolus (1ml/kg bodyweight)via intragastric tube. After 15 minutes a 1M glucose solution is administered as a bolus via intragastric tube.
223845375|NCT01121783|DIETARY_SUPPLEMENT|Lactisole|A pre-infusion of lactisole solution (0.25mg/ml)is administered as a bolus (1ml/kg body weight) via intragastric tube. After 15 minutes tap water will be administered as a bolus via the intragastric tube.
223845376|NCT01121783|DIETARY_SUPPLEMENT|Lactisole|A pre-infusion of tap water(is administered as a bolus (1ml/kg bodyweight)via intragastric tube. After 15 minutes a 1M glucose solution is administered as a bolus via intragastric tube.
223845377|NCT01121783|DIETARY_SUPPLEMENT|Lactisole|A pre-infusion of tap water is administered as a bolus (1ml/kg bodyweight)via intragastric tube. After 15 minutes tap water is administered as a bolus via intragastric tube.
223845378|NCT00628940|RADIATION|PET images with 18F-fluoromethylcholine|sequential PET images with 18F-fluoromethylcholine
223845379|NCT06351280|OTHER|Standardised Physiotherapy Plan|"Single session of coached deep breathing and coughing exercises. 10 supervised slow flow deep breaths to total lung capacity with a 3-5 second end inspiratory hold completed with 2 end inspiratory sniffs. 2-3 supported coughs or huffs. Repeated for another set. Patients instructed to perform independently hourly. Assisted ambulation according to the following protocol:~* Stage 1 of 2 minutes.~* Stage 2 of 0-1 minute.~* Stage 3 of 1 - 3 minutes.~* Stage 4 of 3 - 6 minutes.~* Stage 5 of 6 - 10 minutes.~* Stage 6 of 10 - 15 minutes.~* Stage 7 \> 15 minutes. Total session time is the accumulative work time."
223845380|NCT02390557|OTHER|Survey|PDQS survey reports only
223845381|NCT02390557|OTHER|YESHealth|Arm 3: YESHealth and PDQS survey reports to providers
223845382|NCT01376141|DRUG|Sumatriptan|
223845383|NCT00440986|PROCEDURE|Eritrocytoapheresis|
223845384|NCT02192034|BEHAVIORAL|Navigation|
223845385|NCT01612754|BEHAVIORAL|Noise reduction work place rules|"Information conferences for all theatre staff (100%)on the detrimal effects of high noise levels in the operating theatre. Issue of workplace rules on handouts and poster on theatre doors: Ban of all mobile phones from theatre. Only conversations about the ongoing case are allowed. No restocking etc. during an operation and no work in this operating room concerning other patients (e.g. later on the list). Turnig of of unnecessary suckers, warming devices etc. . No in and out during the procedure.~Technical: Sound Ears (TM, Sound Ear A.S. Copenhagen, Denmark) taped to all 4 Walls. Optical Telephones."
223845386|NCT01612754|BEHAVIORAL|Presence of an examiner in the concerned theatre|Research Clerk present in theatre, writes on note pad.
223845387|NCT03278028|DRUG|A-101 Topical Solution|A-101 Topical Solution
223845388|NCT03278028|DRUG|A-101 Vehicle Solution|A-101 Vehicle Solution
223845389|NCT02414230|DRUG|Drug: F 18 T807|Participants will receive a single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807. For those who cannot tolerate the full exam, participants will receive single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807.
223845390|NCT02114840|PROCEDURE|Pronator quadratus preservation after volar plate fixation in wrist fractures|Pronator quadratus preservation after volar plate fixation in wrist fractures
223845391|NCT02114840|PROCEDURE|Pronator quadratus repair after volar plate fixation in wrist fractures|Pronator quadratus repair after volar plate fixation in wrist fractures
223845392|NCT02114840|PROCEDURE|Pronator quadratus nonrepair after volar plate fixation in wrist fractures|Pronator quadratus nonrepair after volar plate fixation in wrist fractures
223845393|NCT00247156|PROCEDURE|Acupressure treatments and NAET treatments|
223845394|NCT04900155|DRUG|Atorvastatin 80mg|Initially, hypolipidemic treatment with atorvastatin at a dose of 80 mg / day is prescribed from the first 24-96 hours of myocardial infarction in addition to standard therapy for the disease.
223845395|NCT04900155|DRUG|Atorvastatin-Ezetimibe|In the absence of reaching the target level of LDL-C ≤1.4 mmol / L and ≥50% of the initial level after 4-6 weeks from the onset of myocardial infarction, patients additionally receive ezetimibe at a dose of 10 mg 1 time / day.
223845396|NCT01004328|OTHER|Intervention 1: Electronic medical record (EMR)-based transitional care intervention|Electronic delivery of enhanced discharge information to the ambulatory physician with plans for follow-up appointment, notice of any new medications, and recommendations for laboratory monitoring
223845397|NCT05482919|BEHAVIORAL|Baseline Survey|The baseline survey, initial PHQ-9 and GAD-7, could be collected prior to surgery after consent, or on the day of surgery, for participants who are undergoing elective surgery or urgent procedures and did not attend pre-operative clinic. Demographic information such as race and ethnicity, pain medications and pain history and baseline self-reported health information will be collected. It will take about 15 minutes to complete.
223845398|NCT05482919|BEHAVIORAL|Post Operative Surveys|Post operative surveys will be collected at one week, two weeks, one month, then monthly up to 6 months after surgery with total of 7 post-op surveys. Refer to Table 1 for visit windows. The study survey could be collected by phone, REDCap texting or email per the subject's preference. Survey content will also include: daily average and maximum self-reported pain scores on a 0-10 Numeric Rating Scale (NRS) pain scale, average hours of sleep, anxiety and depression screens using the PHQ-9 and GAD-7 questionnaires (Months 1, 3, and 5), pain location and quality, percentage of day spent in pain, satisfaction with recovery using a five-point Likert scale, and type, quantity and timing of any medications used for pain (including opioid alternatives).
223845399|NCT05482919|BEHAVIORAL|Qualitative Interviews|Using sampling to identify adolescents who exhibit higher pain scores or prolonged opioid use compared to peers after completion of the first three surveys (pre-operative, Week 1, Week 2), the study will also select a representative sample of adolescents who are recovering as anticipated. Examples of delayed recovery include a higher proportion of moderate to severe pain scores, dissatisfaction with recovery and prolonged opioid use compared to peers. As a balancing measure, the upper limit of adolescents who are perceived to exhibit delayed recovery that are approached for interviews will be capped at a 3:1 ratio compared to those who are recovering as anticipated, and Investigators will prioritize an equal demographic distribution among the two groups. Interviews will take place over the phone or through a CHOP approved vendor at 1 and 3 months after surgery; audio will be recorded with participant consent.
223845400|NCT00973141|DRUG|JNJ-42160443|Type=exact number, unit=mg, number=1, form=solution for injection, route=Subcutaneous use. One injection of 1 mg of JNJ-42160443 every 4 weeks for up to 104 weeks (JNJ-42160443 at a concentration of 10 mg/mL was provided for use in this study).
223845401|NCT00973141|DRUG|JNJ-42160443|Type=exact number, unit=mg, number=10, form=solution for injection, route=Subcutaneous use. One injection of 10 mg of JNJ-42160443 every 8 weeks for up to 104 weeks (JNJ-42160443 at a concentration of 10 mg/mL was provided for use in this study).
223845402|NCT00973141|DRUG|JNJ-42160443|Type=exact number, unit=mg, number=3, form=solution for injection, route=Subcutaneous use. One injection of 3 mg of JNJ-42160443 every 8 weeks for up to 104 weeks (JNJ-42160443 at a concentration of 10 mg/mL was provided for use in this study).
223845403|NCT00973141|DRUG|Placebo|Form=solution for injection, route=Subcutaneous injection. One injection of matching placebo every 4 or 8 weeks for up to 104 weeks.
223845404|NCT00973141|DRUG|JNJ-42160443|Type=exact number, unit=mg, number=3, form=solution for injection, route=Subcutaneous use. One injection of 3 mg of JNJ-42160443 every 4 weeks for up to 104 weeks (JNJ-42160443 at a concentration of 10 mg/mL was provided for use in this study).
223845405|NCT00973141|DRUG|JNJ-42160443|Type=exact number, unit=mg, number=6, form=solution for injection, route=Subcutaneous use. One injection of 6 mg of JNJ-42160443 every 8 weeks for up to 104 weeks (JNJ-42160443 at a concentration of 10 mg/mL was provided for use in this study).
223845406|NCT00067639|DRUG|Pegfilgrastim (Neulasta)|12 mg single injection of pegfilgrastim under the skin prior to apheresis.
223845407|NCT00067639|PROCEDURE|Apheresis|Collection of stem cells, repeated daily until target stem cell dose reached, maximum of 5 procedures.
223845408|NCT04521192|DRUG|Fluzoparib|the first period: test preparation; the second period: reference preparation
223845409|NCT04521192|DRUG|Fluzoparib|the first period: reference preparation the second period: test preparation
223845410|NCT03578640|DRUG|Elbasvir, Grazoprevir 50-100Mg Oral Tablet|Daily, fixed-dose combination of Elbasvir 50 mg and Grazoprevir 100 mg given in a single oral tablet for 8 weeks.
223845411|NCT04096157|DRUG|Isavuconazonium sulfate IV|Intravenous (IV) via nasogastric (NG) tube
223845412|NCT04096157|DRUG|Isavuconazonium sulfate capsules|Oral
223845413|NCT05657067|BEHAVIORAL|Emotionally Focused Family Therapy (EFFT)|The rationale behind EFFT is that mental health problems in children and adolescents often originate and/or are exacerbated by negative interaction patterns rooted in insecure attachment bonds within families. Therefore, the main treatment goal of EFFT is the development of secure attachment between parents and their children.
223845414|NCT03801772|DEVICE|Metronome|Pacing aquatic exercises to the beats per minute of a metronome. The metronome will be adjusted to each patient's pain free exertion level. Patients will start with 10-20 repetitions of the exercises depending on their physical ability. The repetitions will be progressed as the patient's strength and endurance improve and noted in the chart and the flow sheet. The metronome will be synchronized during their second aquatic therapy treatment. The beats per minute (BPM) will be increased on the metronome during the series of treatments until the patient can no longer maintain proper technique with the exercises. The exercises will continue at this BPM during future visits. The patient will be instructed to keep pace with the beat of the metronome for the duration of the exercise.
223845415|NCT01554254|DRUG|TXA127|300mcg/kg/day, subcutaneous injection for up to 28 days
223845416|NCT04644861|OTHER|Program of adapted physical activity|3 workouts of one hour every week during 4 months. Program will be conducted by adapted physical activity teachers and sports doctor.
223845417|NCT05718297|DRUG|Brigatinib|"Brigatinib is administered for 3 years or until progression of disease, or unacceptable toxicities or withdrawal of consent, whatever occurs first. After the treatment period of 3 years, patient's ongoing treatment will be managed according to local standard and best clinical practice.~Brigatinib should be taken approximately at the same time each day. It may be taken with or without food. Patients shall be instructed to swallow the tablets whole and not crush or chew them."
223845418|NCT05718297|DRUG|Durvalumab|Patients in the control arm will be observational, or, as per investigators choice, patients may receive durvalumab, administered within the label in the respective country.
223845419|NCT01328587|DRUG|Eltrombopag|Eltrombopag will be administered for 16 to 20 weeks at a starting dose of 150mg/day (East Asian ancestry 75mg /day). The dose will decreased and increased (maximum dose 300mg/day) based on safety and response.
223845420|NCT00463151|DRUG|rebamipide|0, 60, 150, 300mg of rebamipide per day for 6 weeks into colon
223845421|NCT01570777|PROCEDURE|renal denervation and optimized medication regimen|Patients are treated with the renal denervation plus a standardized optimal antihypertensive treatment which is adapted every month starting two month after randomization on the basis of home BP monitoring results at follow-up visits.
223845422|NCT01570777|PROCEDURE|optimized medication regimen|Patients are treated with a standardized optimal antihypertensive treatment which is adapted every month starting two month after randomization on the basis of home BP monitoring results at follow-up visits.
223845423|NCT05173571|COMBINATION_PRODUCT|Comprehensive patient support program (educational, physiotherapy, nutritional, emotional)|Identification of patient needs and non-pharmacological holistic approach, including education, emotion and nutrition (nurse) and optimization of physical activity (respiratory physiotherapist)
223845424|NCT03417973|DEVICE|dorsal root ganglion neuromodulation|stimulation for neuromodulation of the dorsal root ganglion
223845425|NCT01221077|DRUG|OSI-906|As of 01 March 2013, OSI-906 is no longer being administered
223845426|NCT01221077|DRUG|Erlotinib|Erlotinib administered orally
223845427|NCT01221077|DRUG|Placebo|As of 01 March 2013, the matching placebo is no longer being administered
223845428|NCT02425683|DRUG|Regorafenib|120 mg or 160 mg by mouth each day for first 21 days of each 28-day cycle, for maximum of 6 cycles
223845429|NCT02453230|BEHAVIORAL|Lights on|Determine if ambient room light stimulation changes the amount of time required to perform the fetal biophysical profile.
223845430|NCT00293462|BIOLOGICAL|sargramostim|
223845431|NCT00293462|OTHER|oral salt and soda mouthwash|Patients receive oral salt and soda mouthwash, holding it and swallowing it in intervals over 1 hour once daily.
223845432|NCT00688688|DRUG|Mirabegron|Tablets
223845433|NCT00688688|DRUG|Tolterodine|Extended release capsules
223845434|NCT00688688|DRUG|Placebo to Mirabegron|Matching mirabegron placebo tablets.
223845435|NCT00688688|DRUG|Placebo to Tolterodine|Matching tolterodine placebo capsules.
223845436|NCT06290232|DEVICE|Fetoscopic Laser Photocoagulation|Pregnant patients diagnosed with type II vasa previa will undergo fetoscopic laser photocoagulation of the involved fetal vessels. FLP will be performed laparoscopically using a fetoscope (tiny telescope) and a laser device inside of the womb. This procedure will be completed at 30w0d to 32w6d gestational age.
223845437|NCT06146738|BEHAVIORAL|Palliative Care|Best supportive care without surgical intervention
223845438|NCT06146738|PROCEDURE|Tumor biopsy|Tumor biopsy
223845439|NCT06146738|PROCEDURE|Tumor resection|Maximal safe resection of the tumor
223845440|NCT01950260|DRUG|Levothyroxine|Early initiation of levothyroxine after radioactive iodine (to start at 4 weeks).
223845441|NCT01950260|OTHER|Placebo|Placebo to start at 4 weeks after RAI
223845442|NCT03283553|OTHER|Checklist, MyChart, OpenNotes|1\) Patient-family agenda-setting checklist, 2) Facilitated proxy registration for MyChart, and 3) Education on access to doctor's electronic visit notes.
223845443|NCT03283553|OTHER|Usual Care|Routine medical oncology care
223845444|NCT04132284|BEHAVIORAL|DBT-Based Parenting Intervention|The intervention will consist of 8-10 individual parent sessions, to be completed within one week after the teen completes the IOP program. Sessions will be 1 hour in length and will be offered weekly. Therapists may see parents more than once a week if needed, as long as the total number of sessions does not exceed 10. Sessions will follow the standard agenda used for DBT skills training: 1) mindfulness practice, 2) homework review, 3) teaching of a new skill; 4) practice of the new skill; and 5) assignment of new homework (Linehan, 1993). The intervention will utilize the Middle Path module of the DBT Skills Manual for Adolescents (Rathus \& Miller, 2015), which was created by the developers of DBT for adolescents and includes both instructions for therapists and handouts for clients.
223845445|NCT04132284|BEHAVIORAL|Treatment as Usual|No parenting intervention provided beyond standard practices in DBT IOP program.
223845446|NCT02460887|DRUG|Gemcitabine|Experimental arm: Patients receive gemcitabine (1000 mg/m² d1,8) and cisplatin (80mg/m² d1) every 3 weeks for 2 cycles before IMRT.
223845447|NCT02460887|DRUG|cisplatin|Experimental arm: Patients receive gemcitabine (1000 mg/m² d1,8) and cisplatin (80mg/m² d1) every 3 weeks for 2 cycles before IMRT.
223845448|NCT02460887|DRUG|cisplatin|Active Comparator arm: Patients receive weekly cisplatin 40 mg/m² up to 7cycles during IMRT.
223845449|NCT02460887|RADIATION|Intensity-modulated Radiotherapy|Intensity modulated-radiotherapy (IMRT) is given as 2.0-2.33 Gy per fraction with five daily fractions per week for 6-7 weeks to a total dose of 66 Gy or greater to the primary tumor.
223845450|NCT00574678|OTHER|Tear collection|"A tear sample (\~75 microliters in a tuberculin syringe with the needle removed) will be taken at time of the initial clinic visit. After collection, the tears will be put directly on ice and taken to the lab. If it is not possible to obtain natural tears, an eye wash method using sterile saline will be employed and the fluid collected using the aforementioned technique. The SELDI-MS process will be conducted on the specimen immediately. The remainder of the tear specimen will be stored in a -80ºC freezer until completely analyzed."
223845451|NCT03686683|BIOLOGICAL|sipuleucel-T|Sipuleucel-T is an autologous cell product consisting of antigen presenting cells (APCs) loaded with recombinant fusion protein composed PAP linked to GM-CSF (PA2024), a recombinant fusion protein composed of prostatic acid phosphatase (PAP), linked to granulocyte-macrophage colony-stimulating factor (GM-CSF).
223845452|NCT04704102|BEHAVIORAL|Muscle energy technique (MET)|A manual therapy technique that uses the gentle muscle contractions of the patient to relax and lengthen muscles and normalize joint motion.
223845453|NCT04704102|BEHAVIORAL|Strain-counterstrain (SCS)|"It's also called the positional release technique, a manual therapy technique that passively positions the hypertonic (spasmed) muscles and dysfunctional joints in positions of shortened or comfort."
223845454|NCT04704102|BEHAVIORAL|sham SCS|SCS intervention that position with opposite site limb and direction, and with modified method as consider the easiness of a practitioner to press the tender points
223845455|NCT03639441|PROCEDURE|dry needling|Dry needling, also known as myofascial trigger point dry needling, is an well-proved technique in alternative medicine similar to acupuncture. It involves the use of either solid filiform needles or hollow-core hypodermic needles for therapy of muscle pain, including pain related to myofascial pain syndrome. Dry needling is sometimes also known as intramuscular stimulation (IMS).
223845456|NCT03639441|PROCEDURE|Transcutaneous electrical nerve stimulation|"Transcutaneous electrical nerve stimulation (TENS or TNS) is the use of electric current produced by a device to stimulate the nerves for therapeutic purposes.~TENS, by definition, covers the complete range of transcutaneously applied currents used for nerve excitation although the term is often used with a more restrictive intent, namely to describe the kind of pulses produced by portable stimulators used to treat pain. The unit is usually connected to the skin using two or more electrodes. A typical battery operated TENS unit is able to modulate pulse width, frequency and intensity. Generally TENS is applied at high frequency (\>50 Hz) with an intensity below motor contraction (sensory intensity) or low frequency (\<10 Hz) with an intensity that produces motor contraction."
223845457|NCT04304469|OTHER|surveys|delivery of the survey at a domestic violence consultation
223845458|NCT04304469|OTHER|follow-up|follow-up of women 6 months after their consultation
223845459|NCT03255941|DRUG|DMPA|The safety and effectiveness of provision of injectable contraception will be compared between providers' screening and counseling for eligibility to use DMPA.
223845460|NCT03255941|DRUG|Sayana Press|The safety and effectiveness of provision of injectable contraception will be compared between providers' screening and counseling for eligibility to use Sayana Press
223845461|NCT05876910|BEHAVIORAL|Speech Production Tasks|View visual cues and undergo speech production for 30 minutes. Electrical stimulation of speech related brain regions in the middle of speech production.
223845462|NCT05323721|DRUG|Sulfadoxine pyrimethamine and amodiaquine|This is where children 3-59 months will receive SPAQ for SMC
223845463|NCT05323721|DRUG|dihydroartemisinin-piperaquine|This is where children 3-59 months will receive DP for SMC
223845464|NCT00372060|DRUG|sitagliptin phosphate|Sitagliptin (MK0431) 50 or 100 mg once daily for 52 weeks
223845465|NCT00372060|DRUG|Comparator: sitagliptin phosphate (MK0431)|Sitagliptin (MK0431) 50 or 100 mg once daily for 40 weeks
223845466|NCT00372060|DRUG|Comparator: pioglitazone|pioglitazone once daily for 52 weeks
223845467|NCT00372060|DRUG|Comparator: placebo (unspecified)|Placebo once daily for 12 weeks
223845468|NCT00961493|BEHAVIORAL|Acceptance based behavioral therapy|16 individual psychotherapy sessions focused on psychoeducation about anxiety, anxious responding, the function of emotions, mindfulness, and problems with efforts to constrict one's emotional experience; training in mindfulness skills; practice applying mindfulness skills in daily life, including acceptance of, rather than efforts to control, internal experience; and identification of values in areas of life and practice engaging in chosen actions.
223845469|NCT00961493|BEHAVIORAL|Applied relaxation|16 sessions of individual psychotherapy focused on psychoeducation about anxiety and anxious responding; training in multiple forms of relaxation; early cue detection; and practice applying relaxation in daily life.
223845470|NCT02476630|DEVICE|StO2 measurement|All participants will have a measurement of the tissue oxygen concentration (StO2) level after applying the noninvasive probe to the thenar eminence. This measurement is done at the same time as a blood gas from the central venous catheter is obtained. The StO2 measurement is documented once for the subject in the study.
223845471|NCT02476630|OTHER|Blood Gases|All participants will have a measurement of the tissue oxygen concentration (StO2) level after applying the noninvasive probe to the thenar eminence. This measurement is done at the same time as a blood gas from the central venous catheter is obtained. The StO2 measurement is documented once for the subject in the study.
223845472|NCT01579578|DRUG|AZD8931|40 mg, oral dose twice daily
223845473|NCT01579578|DRUG|Placebo|Placebo, oral dose twice daily
223845474|NCT01579578|DRUG|Paclitaxel|IV once weekly for 3 weeks followed by a week off.
223845475|NCT00984074|PROCEDURE|blood-oxygen-level-dependent functional magnetic resonance imaging|
223845476|NCT00984074|PROCEDURE|diffusion tensor imaging|
223845477|NCT00984074|PROCEDURE|dynamic contrast-enhanced magnetic resonance imaging|
223845478|NCT00984074|PROCEDURE|functional magnetic resonance imaging|
223845479|NCT00984074|RADIATION|intensity-modulated radiation therapy|
223845480|NCT00984074|RADIATION|radiation therapy treatment planning/simulation|
223845481|NCT02703727|BEHAVIORAL|Extended polymedication check|"Behavioral: Medication review~Patients on oral anticoagulants and polypharmacy will receive extended polymedication check to identify Pharmaceutical Care Issues, Adherence Issues, Drug related problems and Knowledge Gaps~The PMC has been implemented in 2010 as a new cognitive service provided by any community pharmacist to patient with polypharmacy (n\>3 drugs) on long term conditions (\> 3 months) and is reimbursed by swiss health insurance. The semi-structured interview contains questions about knowledge on oral anticoagulation therapy. This extended PMC follows a structured predefined protocol.~As an outcome, pharmacist may install a compliance support e.g. weekly filled pill organizer."
223845482|NCT00285688|PROCEDURE|gastroscopic examination|gastroscopic examination for tissue biopsy and real time PCR for gene study
223845483|NCT02201563|DRUG|Minocycline|Oral minocycline (100mg twice a day) for 3 months
223845484|NCT00037999|PROCEDURE|Testosterone supplement|
223845485|NCT03394963|BEHAVIORAL|Food-based dietary guidelines for healthier diet|Develop and validate food-based dietary guideline and a healthy eating index
223845486|NCT05377099|DIAGNOSTIC_TEST|CORVIS|Measurement of the DA ratio, IR and SSI before and after for patients under gone LASIK, femto LASIK and PRK using the CORVIS device.
223845487|NCT03640013|PROCEDURE|Hall Technique PMC|Hall Technique primary fitted crowns to restore carious primary molars
223845488|NCT04108689|BEHAVIORAL|I-ACT|An internet-based behavioral psychotherapy intervention to enhance athletic performance in elite ice hockey players.
223845489|NCT00249483|DRUG|Venlafaxine|Venlafaxiine 300mg/day
223845490|NCT00249483|DRUG|Placebo|Placebo
223845491|NCT05927961|DIAGNOSTIC_TEST|histopathology|There is a clear boundary between adrenal adenoma and surrounding normal tissue. There is no clear boundary between adrenal hyperplasia and surrounding normal tissues.
223845492|NCT01235325|DIETARY_SUPPLEMENT|phylloquinone (vitamin K1)|1000 mcg phylloquinone (vitamin K1) once daily for 12 months
223845493|NCT01235325|DIETARY_SUPPLEMENT|placebo|placebo oil capsule
223845494|NCT03464643|OTHER|embryo culture|Single embryo culture means only one embryo is cultured in one drop, and the group culture refers to culture of 2-5 embryos in one drop. The main advantage of group culture may be secreting some paracrine cytokines by embryos and benefit each other; and the possible disadvantage of group culture is that embryo secreting of some harmful substances which accumulated to a certain extent will damage the developmental potential of embryos. The advantages and disadvantages of single embryo culture are contrary to group culture.
223845495|NCT05159882|DRUG|THR-1442 and Dapagliflozin placebo|THR-1442 tablets 20mg and Dapagliflozin tablets placebo
223845496|NCT05159882|DRUG|Dapagliflozin 10mg and THR1442 placebo|Dapagliflozin tablets 10mg and THR-1442 tablets placebo
223845497|NCT03423264|DRUG|Gabapentin|"Gabapentin taken as follows:~Day 1 (evening): 600 mg Day 2 (morning): 600 mg Day 2 (evening): 600 mg Day 3 (morning): 600 mg Day 3 (evening): 900 mg Day 4 (morning): 900 mg Day 4 (evening): 900 mg Day 5 (morning): 900 mg Day 5 (noon): 900 mg Day 5 (evening): 900 mg"
223845498|NCT01893528|DRUG|REGN2009|
223845499|NCT01893528|OTHER|placebo|
223845500|NCT02803840|RADIATION|Low-dose radiotherapy|2 x 2 Gy on symptomatic sites only
223845501|NCT01988519|PROCEDURE|Closed gravity drain|passive tube drains (PFM Medical, Köln, Germany)
223845502|NCT01988519|PROCEDURE|closed suction drain|BLAKE Silicon drains (Ethicon, USA)
223845503|NCT02271282|DRUG|Toremifene|
223845504|NCT02271282|DRUG|Placebo|
223845505|NCT02271282|DRUG|GHRH/Ghrelin combined Injection|
223845506|NCT01120171|DRUG|Cyclophosphamide|"Cyclophosphamide (IV) 600 mg/m2 on day 1. Treatment repeats every 21 days. Primary prophylaxis with pegfilgrastim (6 mg) administered 24 hours after chemotherapy.~Therapy will continue until maximum response,or unacceptable toxicity."
223845507|NCT01120171|DRUG|Liposomal-encapsulated doxorubicin|"Liposomal-encapsulated doxorubicin (IV) 50 mg/m2 on day 1. Treatment repeats every 21 days.~Primary prophylaxis with pegfilgrastim (6 mg) administered 24 hours after chemotherapy.~Therapy will continue until maximum response or unacceptable toxicity."
223845508|NCT00657111|DRUG|CS-8958 formulated as dry powder|CS-8958, formulated as a dry-powder and will be administered from capsules containing 5 mg CS-8958 and lactose to 25 mg (placebo) inserted into a FlowCaps inhaler device.
223845509|NCT00657111|OTHER|Placebo|placebo capsules containing 25 mg lactose
223845510|NCT05352529|DEVICE|The MapHabit system|"The MapHabit System (MHS) is a commercially available visual mapping software application that utilize visual, audio, and text media to create step-by-step visual guides to assist individuals and their caregivers in structuring and accomplishing activities of daily living (ADLs). The goal of the application is to develop and facilitate habits and routines using structured visual and auditory stimuli that can be customized by the user and can include educational and lesson-based material in addition to ADLs. The application was made available to families through compatible smartphones and tablets.~The MHS is a general wellness product and there is no regulatory oversight of the MapHabit System mapping functionality. This functionality is not a regulated medical device."
223845511|NCT05352529|DEVICE|Dementia educational videos|Investigators collected publicly available educational videos regarding dementia-related caregiving and support. The videos were made available to participants through compatible tablets.
223845512|NCT05504694|DRUG|Ofatumumab|"The enrolled patients will receive ofatumumab (20 mg/0.4 ml) subcutaneously administered at baseline, Day 7, Day 14 and monthly thereafter. Patients will receive ofatumumab therapy for a total of 48 weeks.~The first 4 infusions will be administered at study center site; subsequent infusions will be given in the patient's home with a nurse online interview to administer the infusion."
223845513|NCT06475170|PROCEDURE|proximal gastrectomy combined with 'λ+α' double-tract anastomosis|"1. The lymphadenectomy is performed according to the Japanese Gastric Cancer Treatment Guidelines~2. Transection of the esophagus is performed using a linear stapler 2cm away from the proximal end of the tumor.~3. The jejunum is dissected 30 cm from the flexor ligament and the distal jejunum is lifted in an anterior colonic direction to the esophageal dissection.~4. Esophagojejunal anastomosis at 16 cm from the distal jejunal stump；~5. Residual gastrojejunostomy at 8 cm from the distal jejunal stump；"
223845514|NCT06305273|OTHER|Head position for face mask ventilation during induction supine|Participant to be ventilated starting 2 minutes after induction of general anesthesia via a face mask while in supine position. Participants will be crossed over to the head elevated position after the first measurement is obtained.
223845515|NCT06305273|OTHER|Head position for face mask ventilation during induction head elevated|Participant to be ventilated starting 2 minutes after induction of general anesthesia via a face mask while in head elevated position. Participants will be crossed over to the supine position after the first measurement is obtained.
223845516|NCT01528709|DRUG|Atorvastatin 80 mg daily|Atorvastatin 80 mg daily for 1 year
223845517|NCT01528709|DRUG|Atorvastatin 10 mg daily|Atorvastatin 10 mg daily for 1 year
223845518|NCT01034111|DRUG|Sitagliptin phosphate|Sitagliptin 100 mg tablet by mouth once daily for 4 weeks.
223845519|NCT01034111|DRUG|Metformin|Stable dose of metformin tablet(s) by mouth (at least 1000 mg/day) for 4 weeks.
223845520|NCT00386594|DRUG|852A|
223845521|NCT03682354|DRUG|Intercostal Nerve Block with PCIA|Intercostal nerve block consists in the injection of Ropivacaine (4 ml,0.5%) in related intercostal spaces. Patient-controlled intravenous analgesia regimen is conducted with sufentanil.
223845522|NCT03682354|DRUG|Erector Spinae Plane Block (ESPB)|Erector Spinae Plane Block consists in the injection of Ropivacaine (20ml, 0.5%), in the anatomical plane between the Erector Spinae muscles and transverse process, laterally to the spinous process of T5 . The catheter was inserted and secured in place under ecographic guidance, and a patient-controlled regional anesthesia regimen was conducted with 0.2% ropivacaine.
223845523|NCT04163471|DEVICE|Radial artery mechanical compression for hemostasis|Transradial hemostasis following arterial catheterization procedures
223845524|NCT01314495|DRUG|Abatacept|Abatacept will be administrated as a 30 minute intravenous infusion.
223845525|NCT01314495|DRUG|Inactive infusion|Placebo will be administered as a 30 minute intravenous infusion.
223845526|NCT02726178|DRUG|Advil® Pediatric drops for infants|Study the effect of inhibition of prostaglandins with ibuprofen vs placebo administration on cardio respiratory events in preterms infants
223845527|NCT02726178|DRUG|Placebo|Study the effect of inhibition of prostaglandins with ibuprofen vs placebo administration on cardio respiratory events in preterms infants
223845528|NCT03254069|DEVICE|Stainless Steel Crowns|SSCs were placed on children's primary molars, and bite force was registered prior to the study, and periodically after the study.
223845529|NCT05841160|DRUG|Ecopipam Hydrochloride|oral tablets
223845530|NCT05841160|DRUG|Moxifloxacin|oral tablet
223845531|NCT05841160|DRUG|Placebo|oral tablet
223845532|NCT04778384|BEHAVIORAL|Micro-training to promote self-management in pain therapy|Micro-training according to the checklist \& targeted discussion / dismantling of patient-related barriers based on the answers in the second part of the questionnaire (BQII Barriers Questionnaire) In this discussion, the nurses give their opinion on any patient-related barriers that become apparent after completing the second part of the questionnaire. This is not done according to a fixed template, but with the specialist knowledge and everyday experience of the nurse.
223845533|NCT04778384|OTHER|Sham intervention|An unstructured conversation is carried out. Patient questions are answered correctly, but there is no training, rather patient information.
223845534|NCT01068054|DRUG|tacrolimus|0.1% ointment,apply bid, 8 weeks
223845535|NCT01068054|DRUG|cyclosporins|2% eyclosporine eye drops apply 1 drop to each eye QID
223845536|NCT05124899|DRUG|CAP UnScented|Sunscreen lip balm.
223845537|NCT05124899|DRUG|CAP Herbal Mint|Sunscreen lip balm.
223845538|NCT05124899|DRUG|CAP Mountain Berry|Sunscreen lip balm.
223845539|NCT05124899|DRUG|SPF Standard Sunscreen|SPF Standard (7 percent \[%\] Padimate-O and 3% Oxybenzone)
223845540|NCT00438971|DRUG|Duloxetine|Treatment will be initiated at 30mg/day in the first week (week 0), and then increased to 60mg/day at week 1, with the option to increase to 90mg at week 4, and 120mg at week 6.
223845541|NCT05426291|OTHER|BIOMARKER LEVELS IS IT POSSIBLE TO PREDICT ACUTE RENAL DAMAGE IN THE PREOP PERIOD?|In open heart surgery, it will be followed whether acute kidney injury will develop by looking at the biomarkers in the preoperative period.
223845542|NCT01833975|BIOLOGICAL|Transplantation of Autologous stem cell [MNCs] .|Intra thecal transplantation of Autologous stem cell \[MNCs\],100millions per dose in 3 divided doses at interval of 10 days.
223845543|NCT05712811|DRUG|CRYOTHERAPY|Group A had their warts treated once every two weeks for a total of twelve weeks, with liquid nitrogen using cryoget method for 10 to 15 seconds on each lesion (depending on size, until a narrow white rim of around 1 mm developed around it).
223845544|NCT05712811|DRUG|Tricholoracetic acid|Group B were treated with liquid TCA 90% by an applicator every two weeks for a total of twelve weeks. After 20 minutes, patients were instructed to remove the solution by washing their warts with water or regular saline.
223845545|NCT02481882|DEVICE|Magnetic Resonance Imaging|All scanning will be performed using a 7 Tesla Philips Achieva scanner with multi-transit capability (Philips Medical Systems, Best, The Netherlands). The volunteers will be scanned with a 32-channel receive coil.
223845546|NCT02481882|DRUG|Prohance (Gadoteridol)|A gadolinium based liquid administered intravenously in order to quantify blood flow in the brain using an MR scanner.
223845547|NCT01677039|DRUG|Test formulation administered with water|single dose of 20 mg of test formulation with 240 mL of water
223845548|NCT01677039|DRUG|Test formulation administered with 20% ethanol|single dose of 20 mg of test formulation with 240 mL of 20% ethanol in water
223845549|NCT01677039|DRUG|Test formulation administered with 40% ethanol|single dose of 20 mg of test formulation with 240 mL of 40% ethanol
223845550|NCT05080920|DIETARY_SUPPLEMENT|Rosmalip®|Nutritional Supplement+Usual Care
223845551|NCT05080920|OTHER|Placebo|Placebo+Usual Care
223845552|NCT02688361|DRUG|Fluimucil® 2% solution|Participants will be orally administered with 10ml of 2% oral solution of Fluimucil® (reference).
223845553|NCT02688361|DRUG|Acetylcysteine 2% solution|Participants will be orally administered with 10ml of 2% oral solution of Acetylcysteine (test)
223845554|NCT04438551|BEHAVIORAL|Standard dietary counseling|Subjects will be given a low sodium diet handout with counseling, complete a validated questionnaire on low sodium foods, and complete a 24-hr urine collection.
223845555|NCT04438551|BEHAVIORAL|Mobile app|Subjects will be given a low sodium diet handout with counseling, complete a validated questionnaire on low sodium foods, and complete a 24-hr urine collection. Subjects will be given a mobile app to build grocery lists where the sodium level will be recorded and tracked in the app.
223845556|NCT01278537|BEHAVIORAL|Information|Booklet, motivational interviewing, brief advice
223845557|NCT00716573|DRUG|everolimus|0,75 mg bid, 24 months
223845558|NCT05535036|DRUG|Dexamethasone 4mg|all patients had standard non-invasive monitoring including an electrocardiogram, non invasive blood pressure and pulse oxymetry. An 18-gauge intravenous cannula was inserted into the nondominant arm or hand and 500 ml of a saline solution (0.9 %) was infused. The prevention of postoperative nausea and vomiting (PONV) was assured to all patients by administering 4 mg of IV Ondansetron. Spinal anesthesia was performed according to our department protocol: L4-L5 or L3-L4 intervertebral space puncture using a 25 gauges needle, with injection of 0.5% hyperbaric Bupivacaine mixture (dose depending on patient height) associated with 2.5 ug Sufentanil and 100 ug Morphine. Before surgical incision, patients received either an intravenous injection of 8 mg (2 ml) Dexamethasone (DG) or 2 ml of a Saline solution (PG).
223845559|NCT05535036|DRUG|Placebo|patients received 2ml of intravenous saline solution
223845560|NCT00002569|DRUG|lomustine|
223845561|NCT00002569|DRUG|procarbazine hydrochloride|
223845562|NCT00002569|DRUG|vincristine sulfate|
223845563|NCT00002569|RADIATION|radiation therapy|
223845564|NCT03869242|DEVICE|NovoTTF-200A|newly diagnosed GBM patients treated with NovoTTF-200A concomitant to RT and TMZ.
223845565|NCT04635436|OTHER|Split-belt treadmill walking.|"The intervention will consist of split-belt treadmill walking. During the test session, participants will walk on a split-belt treadmill mounted on force sensors with the belts running at the same or at different velocities. They will walk freely without any support. The test sequence will be the following:~1. Baseline phase. 3 minutes walking at increasing speed, speed will be increased of 0.1 m s-1 every 30 s. A brief pause of around 1 minute will follow.~2. Habituation phase. 30 seconds walking at 0.2 m s-1.~3. Adaptation phase. The velocity of the belt under the non-affected lower limb will be increased to 0.6 m s-1, while the other belt will maintain its velocity of 0.2 m s-1 for 6 minutes.~4. Post-adaptation phase. Belts' velocities will be restored at 0.2 m s-1 for 6 minutes.~Participants will be informed before the changes in belts' velocities with a verbal warning.~Participants will repeat the same protocol with the affected lower limb on the fast belt after one week."
223845566|NCT04850365|PROCEDURE|Hysteropexy|"Abdominal Sacral cervicopexy:~The approach involves suspending the cervix to the anterior longitudinal ligament on the sacrum using permanent sutures or polypropylene mesh.~Vaginal Sacrospinous cervicopexy:~This transvaginal extraperitoneal technique involves suspending the sacrospinous ligament to the cervix using either a dissolvable or permanent suture. The suspension is performed in a unilateral fashion."
223845567|NCT03906474|BIOLOGICAL|Blood-stage controlled human P. falciparum malaria infection|Volunteers will be challenged with malaria by administering a small amount of P. falciparum infected blood intravenously.
223845568|NCT05883319|OTHER|manuel therapy|approaches will be applied for 3 days / week for 6 weeks.
223845569|NCT05883319|OTHER|exercises|approaches will be applied for 3 days / week for 6 weeks.
223845570|NCT03155191|BIOLOGICAL|TBI-1501|"Phase-I portion:~Cyclophosphamide is administered for conditioning medication of TBI1501, that is CD19-CAR-T cells, (cohort -1: 3×10\^5 cells/kg, cohort 1: 1×10\^6 cells/kg, cohort 2: 3×10\^6 cells/kg).~Phase-II portion:~Recommended dose of Phase-II part will be administered. Cyclophosphamide will be administered as conditioning. The end of study will be Week 52 after administration of TBI-1501."
223845571|NCT01495780|BEHAVIORAL|Remote Health Monitoring|1 year of remote health monitoring of symptoms, medication use, breathing tests, physical activity, and healthcare utilization.
223845572|NCT05410535|DRUG|Patients who continued UDCA 300mg medication|patients who continued UDCA 300mg prescription for the prevention of gallstone after PEGASUS-d trial
223845573|NCT05410535|OTHER|Patients who discontinued UDCA 300mg prescription|patients who discontinued UDCA 300mg prescription for the prevention of gallstone after PEGASUS-d trial
223845574|NCT02987829|DRUG|TRC253|TRC253 is a high-affinity, small molecule antagonist of the androgen receptor (AR) with inhibitory activity against wild type AR and specific mutated variants of AR. TRC253 blocks AR nuclear translocation as well as AR binding to DNA and is an antagonist of transcription for wild type AR and mutated AR. TRC253 is orally active and does not have agonist activity towards either the wild type or mutated ARs. TRC253 treatment in the Hershberger assay results in complete inhibition of androgen sensitive organ development. TRC253 is efficacious in an LNCaP xenograft model driven by F876L (also known as F877L) mutant AR.
223845575|NCT00647348|DRUG|Simvastatin|80mg simvastatin oral once daily for 24 months
223845576|NCT00647348|DRUG|Placebo|Oral placebo tablet once daily for 24 months
223845577|NCT02117869|OTHER|Low furanocoumarin hybrid grapefruit juice|3 consecutive daily doses of 200ml low furanocoumarin grapefruit juice plus midazolam 5mg orally on the third day.
223845578|NCT02117869|OTHER|Regular grapefruit juice|3 consecutive daily doses of 200ml regular grapefruit juice plus midazolam 5mg orally on the third day.
223845579|NCT02117869|OTHER|Water (control)|3 consecutive daily doses of 200ml water plus midazolam 5mg orally on the third day.
223845580|NCT02554175|DRUG|Propofol|Propofol was administered to achieve target propofol Ce
223845581|NCT00714233|DRUG|Metformin|Metformin 425mg. capsules, 2 capsules BID x 24 weeks
223845582|NCT00714233|DRUG|Oral Contraceptive Pills (Yasmin)|Yasmin oral contraceptive tabs; 1 tab daily x 24 weeks
223845583|NCT00714233|BEHAVIORAL|Lifestyle Modification|weekly classes x 24 weeks for training in diet, exercise and behavior modification skills
223845584|NCT00714233|DRUG|placebo|placebo to the active metformin arm. 2 capsules BID x 24 weeks.
223845585|NCT03967561|OTHER|Progressive water-based aerobic training|The intervention will comprise walking/running in shallow pool with progression in the training variables. The training will have 12 weeks of duration with 3 weekly sessions (of 50 minutes each).
223845586|NCT03967561|OTHER|Non-progressive aerobic training|The intervention will comprise walking/running in shallow pool without progression in the training variables. The training will have 12 weeks of duration with 3 weekly sessions (of 50 minutes each).
223845587|NCT00264680|DRUG|lamotrigine|
223845588|NCT00264680|DRUG|valproic acid|
223845589|NCT01743651|DRUG|arbaclofen|40 mg/day as 20 mg arbaclofen ER administered orally 2 times per day
223845590|NCT01743651|DRUG|baclofen|80 mg/day as 20 mg baclofen administered orally 4 times per day
223845591|NCT01743651|DRUG|Placebo|arbaclofen image matched placebo tablets administered orally 2 times/day or baclofen image matched placebo capsules administered orally 4 times/day
223845592|NCT02849262|DRUG|Omiganan (CLS001) topical gel|
223845593|NCT02849262|DRUG|Vehicle topical gel|
223845594|NCT02284464|DRUG|Prednisone withdrawal|Withdrawal of steroids
223845595|NCT02284464|DRUG|Prednisone continuation|Continuation of steroids
223845596|NCT04788017|DRUG|Ziresovir|"Planned treatments are:~* Cohort 1: 300 mg of ziresovir~* Cohort 2: up to 600 mg of ziresovir~* Cohort 3: up to 900 mg of ziresovir"
223845597|NCT04788017|OTHER|Placebo|"Planned treatments are:~* Cohort 1: 300 mg of placebo~* Cohort 2: up to 600 mg of placebo~* Cohort 3: up to 900 mg of placebo"
223845598|NCT02741843|BEHAVIORAL|Patient Education|
223845599|NCT00462553|DRUG|sunitinib malate|Given orally
223845600|NCT00462553|DRUG|gemcitabine hydrochloride|Given IV
223845601|NCT02743663|PROCEDURE|Bronchodilator response|Bronchodilator (Salbutamol - dose dependent on participant prescription) to wheezing subjects. 15 minutes after bronchodilator, spirometry and FOT repeated.
223845602|NCT02743663|PROCEDURE|Allergy Skin Test|Child will be tested for allergies to 17 different allergens, and positive (histamine) and negative (glycerin) controls, for a total of 19 allergens.
223845603|NCT02743663|PROCEDURE|Multiple-Breath Washout|Facemask in children 3-5 yrs, Wash-in phase: medical air inhaled during tidal breathing until steady state. Bias flow switched to 100% oxygen. Wash-out phase: patient breathes in 100% oxygen until nitrogen levels reach \~2%. Each test in duplicate and average is calculated.
223845604|NCT02743663|PROCEDURE|Forced Oscillation Technique|Sterile mouthpiece attached to FOT device. Patient is tested seated with noseclips and mouthpiece. FOT device produces oscillations at different frequencies (from that flow into lungs. Device measures resistance and reactance in lungs.
223845605|NCT02743663|PROCEDURE|Spirometry|Forced exhale manoeuvre completed by participant into flow meter, measuring forced exhale volumes and speed.
223845606|NCT02743663|DRUG|salbutamol|Given during bronchodilator response.
223845607|NCT02743663|PROCEDURE|Nasal Brush|Nasal brush of 1 inferior turbinate to collect epithelial cells. Collected on either nare, choice dependent on how clear the nare is (i.e. no mucous, no nasal mucosal edema, no major structural impediments).
223845608|NCT02743663|PROCEDURE|Blood sample|8mLs of venous blood collected using a butterfly needle of appropriate gauge. Blood sample used to collect CBC values, total IgE, serum, DNA, plasma, and whole blood.
223845609|NCT02743663|PROCEDURE|Basophil activation test|Collect basophils from whole blood sample, and expose cells to food allergens in flow cytometry machine to measure allergic response, if any.
223845610|NCT02743663|PROCEDURE|Nasal swab|Gentle swabbing of both nasal openings to collect mucous sample for analysis of microbial contents (i.e. bacteria, virus, fungi).
223845611|NCT01653743|DRUG|MSJ-0011|Subjects who underwent ovarian stimulation with follitropin alfa according to a low-dose step-up protocol for maximum of 28 days will receive a single dose of 250 microgram (mcg) MSJ-0011 (choriogonadotropin alfa \[recombinant human Chorionic Gonadotropin, r-hCG\]) subcutaneously (SC) within 32 hours after the last dose of follitropin alfa administration unless dominant follicle reached a mean diameter of greater than or equal to (\>=) 18 millimeter (mm); not more than 3 follicles each with a mean diameter of \>=16 mm and serum Estradiol (E2) level within an acceptable range for the number of follicle present, and not more than 2,000 picogram per milliliter (pg/mL).
223845612|NCT01653743|DRUG|urinary hCG (u-hCG)|Subjects who underwent ovarian stimulation with follitropin alfa according to a low-dose step-up protocol for maximum of 28 days will receive a single dose of 5,000 IU u-hCG intramuscularly dose within 32 hours after the last dose of follitropin alfa administration unless dominant follicle reached a mean diameter of \>=18 mm; not more than 3 follicles each with a mean diameter of \>=16 mm and serum E2 level within an acceptable range for the number of follicle present, and not more than 2,000 pg/mL.
223845613|NCT01653743|DRUG|Follitropin alpha|Low-dose step-up protocol involves starting dose of follitropin alfa as 75 International Units (IU) subcutaneously per day ,increments by 37.5 IU every 7 days (Day 8, 15, 28) will be done if no ovarian response will be observed for maximum of 28 days.
223845614|NCT05769374|DEVICE|cooperative versus competitive AVG play|The duration of the study was 8 weeks and the frequency was 60 minutes three times a week. In the first two weeks, three games, Golf, Just Dance and Tennis, will be selected to experiment on easy and normal difficulty respectively. In the three weeks from week 3 to Week 5, Bowling, Shape Boxing and Table tennis will be selected for the experiment with easy, normal and difficult difficulties respectively. In the last three weeks, Rowing, Family ski and Baseball will be selected to carry out experiments with easy, ordinary and difficult difficulty respectively.Additionally,participants in control group did not participate in any AVG intervention and maintained their daily physical activity behaviors
223845615|NCT04807179|DEVICE|Experimental: RF Device Arm|Non-invasive radiofrequency Alexandrite laser
223845616|NCT06118619|DRUG|Interferon-Gamma|received by microbiological synthesis; specific antiviral activity on cells is 2x10\*7 Units per mg of protein
223845617|NCT04889118|BIOLOGICAL|Pembrolizumab|IV infusion
223845618|NCT04889118|DRUG|Lenvatinib|Oral capsule
223845619|NCT04889118|DRUG|Placebo for lenvatinib|Oral capsule
223845620|NCT00372970|DRUG|Botulinum toxin A|200 U given by injection into the pylorus.
223845621|NCT00372970|DRUG|Placebo|saline injection into pylorus.
223845622|NCT05761067|PROCEDURE|Percutaneous Coronary Intervention (PCI)|Alternative treatment
223845623|NCT00562393|OTHER|Nutritional|Overfeeding high fat diet for 28 days
223845624|NCT05087238|BEHAVIORAL|CBT|Cognitive Behavior Therapy for PVC-specific anxiety education, in-vivo exposure, interoceptive exposure, behavioral activation, relapse prevention
223845625|NCT02817503|DRUG|Standard BP control|Enalapril-folic acid will be used as an initial therapy. Other drugs, including CCB (amlodipine preferred), diuretics (hydrochlorothiazide preferred), and β-blockers, are allowed, in order to achieve the SBP target.
223845626|NCT02817503|DRUG|Moderate BP control|Enalapril-folic acid will be used as an initial therapy. Other drugs, including CCB (amlodipine preferred), diuretics (hydrochlorothiazide preferred), and β-blockers, are allowed, in order to achieve the SBP target.
224265001|NCT01463579|OTHER|Exercise Programme|"Patients will complete three exercise sessions per week (2 supervised and 1 unsupervised) for 6 weeks. They will receive a written exercise manual which facilitates completion of their exercise programme. The exercise programme will consist of a warm-up, an exercise circuit, a period of aerobic exercise, and a cool down. The programme will be tailored to each patient's ability and needs.~At the end of the 6 weeks patients will receive a short consultation to set goals relating to continuing exercise at home."
223845627|NCT02817503|DRUG|Intensive BP control|Enalapril-folic acid will be used as an initial therapy. Other drugs, including CCB (amlodipine preferred), diuretics (hydrochlorothiazide preferred), and β-blockers, are allowed, in order to achieve the SBP target.
223845628|NCT05053308|DRUG|Intravenous Infusion|IV PCA(fentanyl) Fentanyl bolus = MME \* 15%
223845629|NCT05053308|DRUG|Sublingual Tablet|subligual fentanyl(Narco®) Fentanyl 100mcg/200mcg/300mcg according to the around-the-clock opioid requirement.
223845630|NCT00828620|OTHER|Imaging study|PET-CT
223845631|NCT05127395|OTHER|To assess the clinical impact of dosing acyclovir based on IBW or adjBW for HSV encephalitis to definitively guide safe and effective therapy.|The study center utilize Epic ® electronic health record (Verona, Wisconsin; www.epic.com) for which all data will be extracted from. Each study center will obtain individual IRB approval prior to data collection. SSM - St. Clare will serve as the lead center for the study with all other centers sending collected and de-identified data to this central site for analysis.
223845632|NCT04846062|BEHAVIORAL|nutrition behavior intervention|Iodized salt utilization and iron dietary intake behavior
223845633|NCT02899637|DEVICE|Active high-frequency Transcranial Magnetic Stimulation|Active intervention, 5Hz on the lower limbs area of the motor cortex, during one week
223845634|NCT02899637|DEVICE|Sham high-frequency Transcranial Magnetic Stimulation|Sham intervention, 5Hz on the lower limbs area of the motor cortex, during one week
223845635|NCT01631708|PROCEDURE|Erythrocytapheresis|"To achieve a blinded randomised trial, apheresis treatment will be used. Those in arm 1 will have erythrocytapheresis reducing iron levels and those in arm 2 will have plasmapheresis and their iron levels will not be reduced.~An apheresis machine will be used to remove red blood cells only from the erythrocytapheresis group. Subjects will have third weekly treatments until SF levels are reduced to \~100 ug/L in accordance with current guidelines."
223845636|NCT01631708|PROCEDURE|Plasmapheresis|An apheresis machine will be used to remove blood plasma only from the plasmapheresis group. Those in arm 2 will have the approximate number of episodes of apheresis that would be required to reduce their SF to normal had they been randomised to the true treatment arm. Those in the sham arm will be offered to have venesection at their choice of venue or to have their SF normalised by erythrocytapheresis after the initial blinded part of the study. This will be done because it will not be known for some time if there is benefit from normalisation of SF and therefore leaving people with elevated SF that may be harmful.
223845637|NCT03768544|BEHAVIORAL|Self-help guided by a lay provider|Self-help based on the principles of cognitive-behavioral therapy and guided by a lay provider. Treatment lasts 15 weeks, is based on a participant's manual, and consists of relaxation, differentiation of the main types of worries, learning to tolerate uncertainty, questioning false beliefs about worries, problem solving, cognitive exposure, and planning pleasant activities. Weekly telephone sessions with the lay provider serve to provide support.
223845638|NCT03768544|BEHAVIORAL|Waiting list where participants wait for delayed treatment|Participants have a 15-week wait period during which they receive a 15-minute telephone call from the local professional research assistant on three occasions separated by four-week intervals. The purpose of these calls is to encourage the participant to persevere until the start of treatment and to identify potential negative effects that could be associated with the waiting period. Participants receive self-help guided by a lay provider after the waiting period.
223845639|NCT05238597|DRUG|A197 Ophthalmic Solution|A197 Ophthalmic Solution
223845640|NCT05238597|DRUG|A197 Vehicle Control|A197 Vehicle Control
223845641|NCT05238597|DRUG|Active Comparator|Active Comparator
223845642|NCT01438437|PROCEDURE|PAI|Under local anaesthesia, taking proper aseptic precautions, 40% acetic acid (total dose not exceeding 3 times the diameter of the mass, (not more than 2ml in one sitting), will be injected into the mass through the percutaneous route
223845643|NCT01438437|PROCEDURE|RFA|Under aseptic conditions and local anesthesia, the needle electrode would be introduced percutaneously into the tumor under ultrasound guidance.
223845644|NCT05906329|RADIATION|Low-dose radiotherapy combined with conventional fractionated radiotherapy|Select the primary lesion, the largest metastatic lesion, or the lesion causing symptoms, and perform routine segmentation (1.8-2Gy/f, 40Gy-60Gy). For the remaining lesions, at least one easily assessable and measurable lesion should be selected as the observation lesion. Unselected lesions (≤ 10) should be given 1.6Gy/f, 1f/w, 4-6 times in total.
223845645|NCT05284058|OTHER|Cardiac Magnetic Resonance Imaging (MRI)|Patients will undergo 2 MRI exams: 1 MRI before surgical intervention (maximum 21 days before) and 1 MRI three months after surgery (+/- 14 days), with intravenous administration of gadolinium.
223845646|NCT05357196|DRUG|PT-112|"Drug: PT-112, The MTD(Maximum Tolerated Dose ) and RP2D of PT-112 when used in combination with gemcitabine will be determined during dose escalation.~Drug: Gemcitabine, Gemcitabine will be administered at a fixed dose of 1000 mg."
223845647|NCT02527889|OTHER|Exercise training|8-week resistive exercise training
223845648|NCT04582045|DEVICE|silver impregnated dressing|comparison of Mepilex versus our standard techniques
223845649|NCT00257816|DRUG|Topotecan|"(First stage of accrual, 6 patients)-2 mg/m2 IV on days 1, 8, 15, 22, 29 and once during parametrial boost (6 cycles)~If none or 1 of the 6 patients in the first Stage of accrual finish the prescribed therapy in over 8 weeks, then the second Stage of accrual (an additional 6 patients) will increase the Topotecan dose to 3 mg/m2 on days 1, 8, 15, 22, 29 and once during parametrical boost (6 cycles). If 2 or 3 of the patients in the first stage of accrual finish the prescribed therapy in over 8 weeks, the dose of the Topotecan will remain the same in the second Phase of accrual. If 4 or more of the patients in the first stage of accrual finish the prescribed therapy in over 8 weeks, there will be no second phase of accrual."
223845650|NCT00257816|DRUG|Cisplatin|40 mg/m2 IV (Maximum total dose of 70 mg) on days 1, 8, 15, 22, 29 and once during parametrial boost (6 cycles)
223845651|NCT03917212|OTHER|No intervention|No intervention, observational study with metabolic characterisation
223845652|NCT01827228|OTHER|Assays|May vary across sites
223845653|NCT01827228|OTHER|HIV medical care|This will be expedited and assisted via community outreach for Recents and Acutes
223845654|NCT01827228|OTHER|Social network and venue tracing|This is described in Arms 1 and 2
223845655|NCT01827228|OTHER|Community alerts|When we find recently or acutely infected participants, we will issue community alerts as described in Arm descriptions
223845656|NCT01827228|OTHER|Community education|Throughout the study we will educate affected communities about recent and acute HIV infection and about the importance of avoiding stigma
223845657|NCT01827228|BEHAVIORAL|HIV counseling|As part of HIV testing, we will provide participants with standard counseling
223845658|NCT04208737|PROCEDURE|recruitment maneuver|30 cmH2O pressure 15 seconds
223845659|NCT05765032|DRUG|SHR-A1921；|Drug: SHR-A1921 administered as an IV infusion Drug: Adebrelimab administered as an IV infusion Drug: Carboplatin administered as an IV infusion Drug: Cisplatin administered as an IV infusion Drug: Bevacizumab administered as an IV infusion
223845660|NCT02723357|BEHAVIORAL|Financial Coaching|Enrollment in one-to-one financial coaching intervention to support savings, income, and credit while reducing debt using available tools in the community development field.
223845661|NCT02723357|BEHAVIORAL|Access to Social Service Referrals|Access to referrals for common social needs.
223845662|NCT03738358|DIETARY_SUPPLEMENT|Trehalose|80 mL pouch/day for 12 weeks, containing trehalose 5 g, water 74.92 g and scent additive 0.08 g
223845663|NCT03738358|OTHER|Placebo|80 mL pouch/day for 12 weeks, containing water 79.92 g and scent additive 0.08 g
223845664|NCT01853358|BIOLOGICAL|NK Cell infusion|"* level 1: 1 x 10e6 NK cells /kg;~* level 2: 5 x 10e6 NK cells /kg;~* level 3: \> 5.10e6 and ≤ 5.10e7 cellules NK/kg"
223845665|NCT02745769|DRUG|Ramucirumab|Administered IV
223845666|NCT02745769|DRUG|Merestinib|Administered orally
223845667|NCT02745769|DRUG|Abemaciclib|Administered orally
223845668|NCT00257777|PROCEDURE|Myocardial protection techniques|
223845669|NCT00602160|DRUG|FAHF-2 (TM)|"We propose to test 10 tablets administered orally three times daily (t.i.d.) for 6 months in the Phase II study. The subjects will be randomized to 1 of 2 groups; FAHF-2 or Placebo group.~Both groups will undergo physician supervised Double-blinded placebo controlled food challenges, once during screening before starting treatment and again after 6 months of therapy."
223845670|NCT05009485|DEVICE|Current Health platform|A remote patient monitoring system which includes a small footprint device and tablet, combined with an AI-powered, cloud-based system driving advanced real-time and predictive analytics related to a patient's clinical condition. The wearable records heart rate, respiratory rate, oxygen saturation, skin temperature and step count.
223845671|NCT01582243|DRUG|Vildagliptin|Vildagliptin 50 mg plus metformin 500 mg as Single Pill combination (SPC)
223845672|NCT04088994|OTHER|AOT Pathological Model Experimental Group|The children will participate in a rehabilitation intervention based on the observation of unimanual and bimanual actions performed by a model with the same degree of motor impairment, but an improvement on the participant's current abilities.
223845673|NCT04088994|OTHER|AOT Healthy Model Control Group|The children assigned to the healthy group will participate in a rehabilitative protocol based on the AOT observing unimanual and bimanual actions performed by a healthy model
223845674|NCT01154686|BEHAVIORAL|Cogmed|The Cogmed Working Memory Training Program will be used as the experimental program because of preliminary evidence indicating its effectiveness in enhancing WM and reducing behavioural symptoms of inattention/hyperactivity in children. This software-based training program was designed to improve WM abilities, particularly in children with ADHD or severe attention problems. Training is implemented with a software program (RoboMemo©). It includes a set of auditory verbal and visual-spatial WM tasks presented via computer. All tasks involve: maintenance of simultaneous mental representations of multiple stimuli, unique sequencing of stimulus order in each trial and progressive adaptation of difficulty level as a function of individual performance.
223845675|NCT01805323|DRUG|Dexamethasone Intravitreal Implant|Dexamethasone Intravitreal Implant (OZURDEX®) previously administered according to general clinical practice.
223845676|NCT02143531|DRUG|4 mg of Ondansetron IV|
223845677|NCT02143531|DRUG|1mg of Haloperidol IV|
223845678|NCT05587140|DEVICE|Acupuncture like TENS|Frequency: 4 Hz, pulse duration: 200 μs, intensity: 3/10 painful sensation with muscle contraction , time: 30 minutes
223845679|NCT05587140|DEVICE|Conventional TENS|Frequency: 100 Hz, pulse duration: 200 μs, intensity: strong but comfortable tingling sensation , time: 30 minutes
223845680|NCT05587140|DEVICE|Sham TENS|Frequency: 4 Hz, pulse duration: 200 μs, intensity: tingling sensation, time: turn on the electricity for 15 seconds, then turn off the machine for 30 minutes
223845681|NCT04484688|DRUG|perindopril-bisoprolol|outpatients with permanent atrial fibrillation and with preserved ejection fraction
223845682|NCT06096129|PROCEDURE|Spy PTC|Percutaneous transhepatic cholangioscopy with SpyGlass DS system
223845683|NCT03351309|BEHAVIORAL|Telephone-based Cognitive Behavioral Therapy (CBT)|Four session telephone CBT protocol.
223845684|NCT00255021|BIOLOGICAL|Diphtheria, Tetanus, Polio, Acellular Pertussis and Hib Vac|0.5 mL, IM
223845685|NCT00119587|DRUG|darbepoetin alfa|
223845686|NCT05945082|OTHER|biopsy|biopsy of a colorectal cancer site
223845687|NCT02309840|BEHAVIORAL|choice architecture|"1. Place vegetables at the beginning of the lunch line.~2. Place fruits in attractive bowls or trays lined with appealing fabric, and place other fruit options next to the cash registers.~3. Promote fruits and vegetables with prominently displayed signage and images.~4. Place white milk selection in front of sugar-sweetened milk (e.g. chocolate milk) or at eye-level."
223845688|NCT02309840|OTHER|Chef-enhanced meals|meals prepared by a professional chef with enhanced palatability
223845689|NCT05823987|DRUG|H101|a modified human recombinant type 5 adenovirus with genetic modifications
223845690|NCT05823987|DRUG|Tislelizumab|a PD-1 immune check inhibitor
223845691|NCT05823987|DRUG|Lenvatinib|Lenvatinib capsules
223845692|NCT03354533|DRUG|L-fucose|Oral ORL-1F
223845693|NCT02493790|OTHER|Cognitive and motor performances|
223845694|NCT06137313|OTHER|questionnaire|completion of a questionnaire
223845695|NCT02803294|PROCEDURE|transcatheter aortic valve replacement|
223845696|NCT02836678|BIOLOGICAL|Ridge splitting, immediate implant, Nanobone with PRF.|"* Dental implant (is a surgical component that interfaces with the bone of the jaw or skull to support a dental prosthesis).~* Alloplast bone graft material (Nanobone)~* PRF platelet rich fibrin. (second-generation Platelet rich plasma where autologous platelets and leucocytes are present in a complex fibrin matrix to accelerate the healing of soft and hard tissue)."
223845697|NCT02836678|BIOLOGICAL|Ridge splitting, immediate implantand PRF.|"* Dental implant (is a surgical component that interfaces with the bone of the jaw or skull to support a dental prosthesis).~* PRF platelet rich fibrin. (second-generation Platelet rich plasma where autologous platelets and leucocytes are present in a complex fibrin matrix to accelerate the healing of soft and hard tissue)."
223845698|NCT03098264|PROCEDURE|Simultaneous surgery|Simultaneous surgery in complicated hepatolithiasis
223845699|NCT03098264|PROCEDURE|staged surgery|staged surgery in complicated hepatolithiasis
223845700|NCT05603026|DEVICE|Self-expanding valve (Medtronic Evolut FX)|Bioprothesis Medtronic Evolut FX supra-annular self-expanding valve
223845701|NCT05603026|DEVICE|Balloon-expanding valve (Edwards Sapien 3 Ultra)|Bioprosthesis Edwards Sapien 3 Ultra valve
223845702|NCT01757509|OTHER|Intervention group|"Participants will attend eight weeks of set dancing classes. Each class will be one and a half hours. Family members or volunteers will partner each participant with Parkinson's disease. The class will be led by a Chartered Physiotherapist who is also a set dancing teacher. Set dancing steps and sets will be thought and progressed in line with the participants' abilities. Frequent rests will be taken during the class.~Participants will be given a home exercise programme which will involve mental rehearsal, listening to music, watching dance DVD's and practicing dance material in the seated position to reduce the risk of falling."
223845703|NCT04690283|DRUG|Mimetic granules of Yiqi-Wenjing prescriptions|The intervention relates to a multiple granules, which contains 2.5% concentrated Huangqi-Guizhi-Wuwu decoction (a classical traditional Chinese prescription consists of astragalus membranaceus, cassia twig, radix paeoniae alba, ginger and jujube), 2.5% concentrated Danggui-Sini decoction (a classical traditional Chinese prescription consists of angelica sinensis, cassia twig, radix paeoniae alba, asarum, tetrapanax papyriferus, jujube and honey-fried licorice root), bitter principle, food colouring and starch.
223845704|NCT04690283|DRUG|Huangqi-Guizhi-Wuwu granules|The intervention relates to a traditional Chinese prescription granules, which contains astragalus membranaceus, cassia twig, radix paeoniae alba, ginger and jujube.
223845705|NCT04690283|DRUG|Danggui-Sini granules|The intervention relates to a traditional Chinese prescription granules, which contains angelica sinensis, cassia twig, radix paeoniae alba, asarum, tetrapanax papyriferus, jujube and honey-fried licorice root.
223845706|NCT02994550|DRUG|FSH/LH|
223845707|NCT05077631|DRUG|ACD856|Single oral doses of ACD856 administered in a fasted state in escalation schedule of dose 1, dose 2, dose 3, dose 4, dose 5, dose 6 and dose 7. The escalation schedule may be adapted based on evaluation by internal Safety Review Committee.
223845708|NCT05077631|DRUG|Placebo|Placebo oral solution
223845709|NCT05077631|DRUG|ACD856 (fed cohort)|Single oral dose of ACD856 in fed state of either dose 4 or dose 5.
223845710|NCT02967666|RADIATION|FDG ligand|
223845711|NCT02967666|RADIATION|DOTANOC ligand|
223845712|NCT02896608|DEVICE|measure of neuronal excitability|
223845713|NCT05057754|BEHAVIORAL|Cooling|Participants' dominant hand and wrist will be immersed in cool water (20°C) for five minutes. The cool water will be kept to around 20°C (19 - 21°C) by frequently checking the temperature and corrected when it rises to 20.5°C
223845714|NCT05057754|BEHAVIORAL|Heating|A heat pack wrapped in a towel will be applied to participants' dominant hand for five minutes.
223845715|NCT05057754|BEHAVIORAL|Exercising|Participants will be asked to participate in moderate-intensity physical activities to induce an increase in blood pressure. The physical activity will be two sets of 30 jumping jacks, followed by 15 squats. Participants are allowed to rest for 20 seconds between the two sets.
224265002|NCT01463579|OTHER|Standard Care|Following ICU admission patients are discharged to hospital wards to the care of a consultant, and the patients are no longer under the care of the ICU team. They are provided with appropriate medical and nursing care, and with referral to other disciplines as necessary. One mobile and able to return home to a carer or another facility they are discharged from hospital. There is usually no support to address potential problems specific to critical illness for patients after ICU discharge.
224265003|NCT04560231|DRUG|Remdesivir|200 mg I/v Remdesivir will be given to moderate disease patients of COVID-19. It will be loading dose then 100 mg I/V dose will be given for 5 days. Customized decision for Remdesivir dosage will be made by attending infectious diseases physician, comfort with usage, bacterial co-infection and duration of Ventilation and dose will be extended up to 10 days according to clinical condition of the patients.
223845716|NCT05057754|BEHAVIORAL|Typing|All participants will be asked to perform a typing task with a standard wired keyboard. All subjects will be asked to type for five minutes.
223845717|NCT05057754|BEHAVIORAL|Using a mouse|"Participants will be asked to draw as many lower-case alphabet characters from a to z as possible using a standardized scroll mouse for five minutes in the Windows Microsoft Paint software."
223845718|NCT05057754|BEHAVIORAL|Cooking|Participants will be asked to participate in a cooking trial following a prespecified cooking recipe of Rice Krispy Treat. he participant will be asked to follow the procedures as follows: (1) cut and put wax paper in the pan; (2) cut butter into 4 pieces; (3) place butter in a pot over a portable stove and stir until the butter is completely melted; (4) add four oz of marshmallows and stir until melted; (5) add cereal and the rest of marshmallows and stir until all ingredients are combined (6) transfer the ingredients to the pan and use a silicone spatula to pat the ingredients evenly into pan.
224265004|NCT03835468|DIETARY_SUPPLEMENT|Galacto-oligosaccharides|GOS is a form of prebiotic, which enhance the growth of beneficial gut bacteria
223845719|NCT02215798|DRUG|Cymbalta|
223845720|NCT00508885|DRUG|Niacinamide|Niacinamide 250 mg twice daily titrated up to 750 mg twice daily
223845721|NCT00508885|DRUG|Placebo|Placebo
223845722|NCT00253214|DRUG|galantamine hydrobromide|
223845723|NCT02723656|BEHAVIORAL|Online Referral NYS Quitline|Care coordinator will make an online referral to the NYS Quitline.
223845724|NCT02723656|BEHAVIORAL|Tobacco cessation counseling and coordination of cessation medications|Care coordinator will obtain verbal consent to transfer the patient to the NYS Quitline via 3-way call (warm transfer). The care coordinator will also assist the patient in obtaining NRT from a regular care provider, then call the patient every three months for 12 months to assess current smoking and offer to help smokers obtain additional cessation counseling and medications.
223845725|NCT03668067|DEVICE|2WIN photoscreener|conventional infrared off-axis photoscreener
223845726|NCT02397889|DRUG|Ketamine|This arm will receive 0.5mg/kg repeated dose ketamine (6 intravenous infusions, 3 per week for 2 weeks).
223845727|NCT02397889|DRUG|Midazolam|This arm will receive 0.045mg/kg repeated dose intravenous midazolam (6 intravenous infusions, 3 per week for 2 weeks).
223845728|NCT04768790|OTHER|multidisciplinary program|multimodal exercises to improve, through gradual exposure, cervical mobility, postural control and strengthening of the cervical muscles; stabilization techniques for the deep neck muscles; task-oriented exercises maintaining the activation of the deep spinal muscle. Under the supervision of a psychologist, the subjects will also be involved in cognitive-behavioral therapy aimed at modifying the fear of movement (kinesiophobia) and the maladaptive behavior of the disease. Ergonomic consultancy.
223845729|NCT04768790|OTHER|General program|exercises for muscle strengthening, regional stretching and spinal mobilization. Ergonomic consultancy.
223845730|NCT01125202|BEHAVIORAL|SCT-based behavioral intervention|Intervention group continues to receive routine dialysis care. The intervention duration is 16 weeks. Intervention contacts are 2x/week for weeks 0-8, weekly for weeks 9-12, and every other week for weeks 13-16. Personal digital assistant dietary records are use to provide targeted counseling and engaged the participant in problem solving around dietary issues.
223845731|NCT01125202|BEHAVIORAL|Attention Control|Attention control participants continue to receive routine dialysis care. Attention control participants view 5 computerized educational programs PowerPoint slides) that summarize the various elements of the HD diet. The 5 modules evenly over the 4-month study period.
223845732|NCT03270930|PROCEDURE|Emergency laparotomy|All patients in study underwent emergency laparotomy within 24 hours of presentation after adequate resuscitation of minimum 1 hour.
223845733|NCT02747264|DEVICE|eRAPID|eRAPID is an online system for patients to self-report symptoms and AE during and after cancer treatments. eRAPID allows AE reporting from home or hospital and enables patient reported data to be integrated into existing EPR to allow for the reports to be used in routine care. In addition the system is capable of generating alerts for severe AE to the relevant clinical team and providing patient advice on managing mild and moderate AE.
223845734|NCT06044961|RADIATION|CT scan|All pre-operative CT scan collected
223845735|NCT01112072|DRUG|Riboflavin|Corneal epithelium removed followed by riboflavin drop administration every 2 minutes for 30 minutes followed by UV light exposure with additional riboflavin administration every 2 minutes for 30 minutes. Subjects will be randomized to receive Intacs placement either immediately before CXL or 3 months before CXL.
223845736|NCT01101919|DRUG|CP-690,550|Days 1 and 6 dose of 10 mg once daily Days 2-5 doses of 10 mg twice daily
223845737|NCT04942470|OTHER|Aloe vera and propolis applied|Suitable of sterile pads containing aloe vera and propolis to the area with pressure sores
223845738|NCT05298670|DRUG|MetFORMIN 1000 Mg Oral Tablet|Antidiabetic agent used to treat type 2 diabetes, and to prevent type 2 diabetes.
223845739|NCT05298670|DRUG|Interferon beta-1a|Disease Modifying Therapies (DMTs)
223845740|NCT00000988|DRUG|Stavudine|
223845741|NCT03332966|DIAGNOSTIC_TEST|Psychiatric questionnaires|"Participants will fill in the following questionnaires as part of routine intake assessments:~Generalised Anxiety Disorder Assessment (GAD-7); Mini-Social Phobia Inventory; Beck Depression Inventory 21A; Pittsburgh Sleep Quality Index; Insomnia Severity Index; Youth Experiences and Health Questionnaire; Adolescent Dissociative Experiences Scale (abbr.); Adolescent Peer Relations Instrument (APRI-B + cyberbullying, abbr.); Adolescent Trauma and Dissociation Scale (abbr.); Alcohol Use Disorders Identification Test; Alcohol, Smoking and Substance Involvement Screening Test - Lite (extended); Nicotine Questionnaire incl. Heavy Smoking Index; Internet Addiction Test (abbr.); European School Survey Project on Alcohol and Other Drugs 2015 Social Media Use and Computer Gaming; McMaster Family Assessment Device - General Functioning positive items; Multidimensional Scale of Perceived Social Support; Brief Resilience Scale; The Short Warwick-Edinburgh Mental Well-Being Scale"
223845742|NCT03332966|DIAGNOSTIC_TEST|Semi-structured psychiatric interview|Kiddie Schedule for Affective Disorders and Schizophrenia, version K-SADS-PL 2013.
223845743|NCT02775617|DRUG|Ivermectin|Participants will be offered treatment for both yaws and scabies either in parallel or in sequence. Ivermectin will be offered as a a single dose 200μg/kg on Day 1 and Day 8.
224265005|NCT03835468|DIETARY_SUPPLEMENT|Maltodextrin|sugar based placebo
224265006|NCT01252953|DRUG|Anacetrapib|tablet, 100mg daily
224265007|NCT01252953|DRUG|Placebo anacetrapib|tablet, 1 tablet daily
224265008|NCT03954431|DIAGNOSTIC_TEST|Dedicated breast CT(BCT)|The breast CT device will take multiple pictures of the subject's uncompressed breast and creates a 3-D image of the breast.
224265009|NCT01057368|BEHAVIORAL|Day of intensive meditation practice|Long-term meditators practice for \~6 hours of meditation at each time point
224265010|NCT01057368|BEHAVIORAL|Mindfulness Based Stress Reduction (MBSR)|8-week class designed to enhance well-being through training in mindfulness meditation
224265011|NCT01057368|BEHAVIORAL|Health Enhancement Program (HEP)|8-week class designed to enhance well-being through training in physical activity, functional movement, music therapy, and nutrition
224265012|NCT05073380|BEHAVIORAL|Intervention Group - PRO-ECO Intervention|The PRO-ECO intervention will be tailored to individual sites. Through collection of focus group and baseline data, the intervention will be further refined to provide site-specific adjustments, such as specific materials in the built environment design modification or targeted training. Identified features of effective interventions outlined in the literature have informed the development of the intervention foundation and potential tailoring.
223845744|NCT02775617|DRUG|Azithromycin|Participants will be offered treatment for both yaws and scabies either in parallel or in sequence. Azithromycin will be offered as single dose of 30mg/kg, max 2G.
223845745|NCT02775617|DRUG|Permethrin|Participants will be offered treatment for both yaws and scabies either in parallel or in sequence. Individuals with a contra-indication to ivermectin will be offered Permethrin instead.
223845746|NCT04547543|OTHER|Videoconsultation|Patient randomized on video-consultation group will have a video-consultation with the investigator within 3 months after the randomization. During this consultation, the investigator performs a clinical interrogation in order to collect anthropometric parameters: (sex, age, weight, height, body mass index (BMI)), blood pressure (by blood pressure monitor at home), the level of physical activity (by Actimetry over 7 days), smoking status and alcohol status
223845747|NCT00875641|OTHER|Health Insurance Database|Review of two health insurance databases in the US to determine the safety outcomes among infants who have received Rotarix or IPV vaccination.
223845748|NCT04656470|DRUG|Dexmedetomidine|Patients will be delivered dexmedetomidine anesthesia to gain greater understanding of its analgesic effects.
223845749|NCT06008067|RADIATION|tricuspid annular plane systolic excursion (TAPSE)|Echocardiography
223845750|NCT04055896|OTHER|Medication Reduction|Systematic approach to reduction in polypharmacy
223845751|NCT04198961|OTHER|opioid prescribing|Individualized taper and safety recommendations will be communicated to prescribers via an electronic medical record encrypted message.
223845752|NCT01857453|DRUG|carboplatine|carboplatine + etoposide based chemotherapy followed by radiation therapy with 24 Gy on the in toto neuro axis and 54 Gy on the post operative bed
223845753|NCT01857453|DRUG|Etoposide|carboplatine + etoposide based chemotherapy followed by radiation therapy with 24 Gy on the in toto neuro axis and 54 Gy on the post operative bed
223845754|NCT01857453|RADIATION|radiation therapy|carboplatine + etoposide based chemotherapy followed by radiation therapy with 24 Gy on the in toto neuro axis and 54 Gy on the post operative bed
223845755|NCT02931162|OTHER|Herb-partitioned moxibustion|Patients receive herb-partition moxibustion 3 times a week, once a day for 30 minutes, for a total of 12 weeks.
223845756|NCT02931162|OTHER|Sham herb-partitioned moxibustion|Patients receive sham herb-partition moxibustion 3 times a week, once a day for 30 minutes, for a total of 12 weeks.
223845757|NCT01441778|DRUG|NSS nasal irrigation salt|nasal irrigation twice daily for 4 weeks period
223845758|NCT01441778|DRUG|BHS nasal irrigation salt|nasal irrigation twice daily for 4 weeks period
223845759|NCT05356026|OTHER|Online postpartum follow-up|The women in the experimental group were administered three follow-ups (education/consultancy) in line with the timing and content in the T.R. Ministry of Health Postpartum Care Management Guide (2014). The follow-ups were performed using the Zoom® program, which enabled video talk.
223845760|NCT03404609|DEVICE|MagPro X100 by MagVenture|Participants received 5 consecutive days of accelerated cTBSmod to the right frontal pole. Each cTBSmod session was comprised of 1800 pulses, delivered in a continuous train of 600 bursts. Each burst contained 3 pulses at 30 Hz, repeated at 6 Hz. Ten sessions were applied per day (18,000 pulses/day, hourly) (90,000 total pulses) using a Magventure Magpro X100. Stimulation was delivered at 90% resting motor threshold (depth corrected). Localite Neuronavigation System was used to position the TMS coil over the individualized stimulation target.
223845761|NCT02800161|DRUG|Trehalose|Trehalose 70g/die
223845762|NCT02800161|DRUG|Maltose|Maltose 70g/die
223845763|NCT02507310|OTHER|thermostat|ambient temperature as modified by thermostat
223845764|NCT00240643|DRUG|SB424323|
223845765|NCT04827225|BEHAVIORAL|questionnaires|Questionnaires (EPDS, HADS, PPQ, MIBS, etc.) will have to be completed by the parents at different stages of their child's development (38 weeks of amenorrhea, 3 months and 24 months).
223845766|NCT05905289|OTHER|observational study|no intervention as it is an observational study
223845767|NCT04706247|OTHER|thoracic combined spinal epidural anesthesia|A combined spinal-epidural anesthesia set will be used for the block. Using the loss of resistance to saline technique, an 18 G Tuohy needle will be advanced to the T2-3 vertebral interspace with the mid-line approach. After confirming the epidural space, a 26 G pencil point spinal needle will be inserted slowly through the Tuohy needle to puncture the dura. After free flow of cerebrospinal fluid will be observed, local anesthetic wil be injected into the subarachnoid space over 15 secs. Then, an epidural catheter will be inserted into the epidural space.
223845768|NCT06183047|DIAGNOSTIC_TEST|early release of chromogranin A (CgA) in patients with neuroendocrine tumours (NET) treated with peptide receptor radionuclide therapy (PRRT).|early release of chromogranin A (CgA) in patients with neuroendocrine tumours (NET) treated with peptide receptor radionuclide therapy (PRRT).
223845769|NCT03931603|OTHER|MRI|MRI protocol associating sagittal and axial (+/- coronal) sequences in T2 + / - turbo spin T1 weighting with fat saturation.
223845770|NCT04612595|OTHER|serum urea nitrogen to creatinine ratio|According to sex and CKD stage , patients are divided into four groups,then evaluate whether the different mean sUCR and ΔsUCR can influent the survival of DKD patients.
223845771|NCT00618358|DEVICE|Vascular Sealant System|The Vascular Sealant System is intended for use in vascular reconstructions to achieve adjunctive hemostasis by mechanically sealing areas of leakage.
223845772|NCT00618358|OTHER|Gelfoam/Thrombin|
224265013|NCT05073380|BEHAVIORAL|Wait List Group - Normal Daily Practice|ELCCs that are randomly assigned to the waitlist group will participate in their normal daily practice, including standard curriculum and outdoor play time. Once post-data collection is complete, wait list sites will be given the PRO-ECO intervention.
223845773|NCT01454362|DRUG|Nicotine|Inhalation of nicotine.
223845774|NCT02955862|OTHER|Vietnam Cryptococcal Retention in Care Study (CRICS)|"Drug: Fluconazole HIV-infected patients with CD4 ≤100 cells/μL who present for HIV care at outpatient clinics (OPCs) in Vietnam where CrAg screening is offered will be recruited into the study. Study participants will be screened for cryptococcal antigen using the Lateral Flow Assay (LFA). Those who are CrAg-positive, but have no features of central nervous system (CNS) disease, will be treated with high-dose fluconazole.~Other Names:~• Fluconazole"
223845775|NCT00447915|DRUG|ibandronic acid 0.5mg|0.5mg(i.v.)/month for 35 months
223845776|NCT00447915|DRUG|RIS placebo|0 mg(p.o.)/day for 36 months
223845777|NCT00447915|DRUG|1.0mg ibandronic acid|1.0mg(i.v.)/month for 35 months
223845778|NCT00447915|DRUG|ibandronic acid placebo|0mg(i.v.)/month for 35 months
223845779|NCT00447915|DRUG|2.5mg RIS|2.5 mg(p.o.)/day for 36 months
223845780|NCT00447915|DIETARY_SUPPLEMENT|Calcium and Vitamine D3|Calcium 305 mg and Vitamine D3 200IU(p.o.)/day for 36 months
223845781|NCT04500821|DEVICE|Activator LFD-2100|LipiFlow treatment with the Activators LFD-2100 will be performed on both eyes with MGD
223845782|NCT05717985|PROCEDURE|modified combined approach|A thin layer of epithelium will be excised from the harvested graft. This epithelium will be replaced at the donor site and sutured.
223845783|NCT05717985|PROCEDURE|de-epithelized gingival graft|Only dressing material will be placed at the donor site after graft harvesting
223845784|NCT06371482|DRUG|Durvalumab|Durvalumab is an immunoglobulin G (IgG) 1-κsubtype monoclonal antibody (mAb) that blocks the interaction of PD-L1 with PD-1 in T cells and CD80 (B7.1) in immune cells (ics). Durvalumab is developed by Astrazeneca /MedImmune for the treatment of cancer. Durvalumab is designed to reduce the cytotoxicity of antibody-dependent cells and complement dependent cytotoxicity. In vitro studies have demonstrated that Durvalumab can antagonize the inhibition of PD-L1 in human primary T cells, causing them to resume proliferation and release interferon gamma (IFNγ). To date, more than 1,800 patients have been treated with valiuzumab as a single agent or in combination with other cancer agents as part of ongoing studies. Durvalumab: 10mg/Kg, intravenously, starting at week 7 every 3 weeks for at least 1 year, or until progression, intolerance, or spontaneous withdrawal of the patient.
223845785|NCT06371482|DRUG|Chemotherapy drug of EP regimen|"Etoposide: 80-100mg/m², intravenous infusion, given at week 1, 4, 7, 10, 13, 16, a total of 6 cycles.~Carboplatin: AUC=5-6, intravenous infusion, given at weeks 1, 4, 7, 10, 13, 16, a total of 6 weeks. Or cisplatin: 75-80mg/m2 intravenously, given at weeks 1, 4, 7, 10, 13, 16 for a total of 6 weeks."
223845786|NCT06371482|RADIATION|radiotherapy|Radiotherapy: Total dose of 60Gy/30 times, each time 2.0Gy, 5 times a week from week 7 to week 12 of radiotherapy.
223845787|NCT02609555|PROCEDURE|TEM perineal rectopexy|perineal rectopexy using polyprolene mesh assisted by TEM technique and special proctoscope postanal repair in two layers to narrow the postanal space anal cerclage with absorbable sutures
223845788|NCT02267980|DRUG|Sevoflurane|Inhalation anesthetic agent
223845789|NCT02267980|DRUG|Ketamine|Intravenous anesthetic agent
223845790|NCT02267980|DRUG|Saline|Isotonic solution for placebo group
223845791|NCT06121570|PROCEDURE|Sentinel Lymph Node Biopsy (SLNB)|A sample of the participant's tumor-draining lymph nodes will be collected and sent to the biotherapy center for LNL isolation and expansion.
223845792|NCT06121570|DRUG|Doxorubicin|Doxorubicin will be administered at 60 mg/m\^2 IV on Day 1 of Cycles 1-2 of the neoadjuvant chemotherapy of the study.
223845793|NCT06121570|DRUG|Epirubicin|Epirubicin will be administered at 100 mg/m\^2 IV on Day 1 of Cycles 1-2 of the neoadjuvant chemotherapy of the study.
223845794|NCT06121570|DRUG|Cyclophosphamide|Cyclophosphamide will be administered at 600 mg/m\^2 IV on Day 1 of Cycles 1-2 of the neoadjuvant chemotherapy of the study.
223845795|NCT06121570|DRUG|Cyclophosphamide|Cyclophosphamide will be administered at 500 mg/m\^2 IV daily for three days. Cyclophosphamide will be initiated five days prior to the anticipated LNL transfer, and the precise timing will depend on the rate of in vitro LNL growth.
223845796|NCT06121570|DRUG|Fludarabine|Fludarabine will be administered at 30 mg/m\^2 IV daily for three days. Fludarabine will be initiated five days prior to the anticipated LNL transfer, and the precise timing will depend on the rate of in vitro LNL growth.
223845797|NCT06121570|BIOLOGICAL|Tumor-draining lymph node-derived lymphocyte (LNL)|Participants receive single infusion of LNL at the recommended phase 2 dose (RP2D).
223845798|NCT06121570|BIOLOGICAL|Interleukin-2|Eight to twelve hours after completing the LNL infusion, all participants will receive intermediate-dose decrescendo IL-2 IV.
223845799|NCT06121570|DRUG|Nab-paclitaxel|Nab-paclitaxel will be administered at 260 mg/m\^2 IV on Day 1 of Cycles 3-6 of the neoadjuvant chemotherapy of the study.
223845800|NCT00797225|DRUG|Leuprorelin Acetate Depot|Leuprorelin acetate depot injection 3.75 mg administered as an intramuscular injection
223845801|NCT00797225|DRUG|Elagolix|Elagolix tablets administered orally
223845802|NCT00797225|DRUG|Placebo to Elagolix|Placebo tablet administered orally
223845803|NCT00797225|DRUG|Placebo to Leuprorelin Acetate|Saline solution administered as an intramuscular injection
223845804|NCT04921761|PROCEDURE|Conventional epidural|In this group, a 20-gauge multi-orifice catheter was threaded through the cephalic-directed tip of the epidural needle 5 cm into the epidural space.
223845805|NCT04921761|PROCEDURE|Dural puncture epidural|In this group, the dura was punctured by 25G Whitacre needle. After confirmation of CSF flow, the needle was removed and the epidural catheter was threaded.
223845806|NCT03054220|DRUG|Dextromethorphan 5 MG|
223845807|NCT03054220|DRUG|Tramadol 10 mg|
223845808|NCT03054220|DRUG|Duloxetine 60mg|
223845809|NCT03054220|DRUG|Paroxetine 20 mg|
223845810|NCT00498537|DRUG|spironolactone|
224265014|NCT03595462|OTHER|Snack|"Hummus and Pretzels- The study participants will be provided with a hummus and pretzels snack to consume every day for a week. The energy content of the hummus and pretzels will be \~240 kcal. The hummus and pretzels contain 6 g protein, 27 g carbohydrates, 0 g sugar, 4 g fiber, and 12 g fat.~Granola Bars- The study participants will be provided with two granola bars to consume every day for a week. The energy content of the two granola bars will be \~240 kcal. The two granola bars contain 4 g protein, 38 g carbohydrates, 16 g sugar, 2 g fiber, and 9 g fat."
224265015|NCT03595462|OTHER|No Snack|The study participants will not be provided with any snack and will be told to consume nothing from 2-4pm for a week.
224265016|NCT05620862|DRUG|Mitoxantrone Hydrochloride Liposome|In phase Ia, mitoxantrone hydrochloride liposome will be administered by an intravenous infusion at three doses of 16 mg/m2, 20 mg/m2 and 24 mg/m2 . In phase Ib, mitoxantrone hydrochloride liposome will be administered by an intravenous infusion of 24mg/m2. Up to 6 cycles (21 days per cycle)
224265017|NCT05620862|DRUG|Irinotecan|50mg/ m2，d1-5, 21 days per cycle
224265018|NCT05620862|DRUG|Vincristine|Vincristine 1.5mg/ m2，d1 , 21 days per cycle
224265019|NCT03367260|OTHER|Preference Elicitation|Survey of patient preferences for treatment
224265020|NCT00018460|DRUG|Vitamin B|
223845811|NCT00534755|OTHER|Breast Cancer database|prospective breast cancer database
223845812|NCT02905513|BEHAVIORAL|Contraceptive app instant messages|
223845813|NCT02905513|OTHER|Mobile phone app|
223845814|NCT04307979|DIETARY_SUPPLEMENT|High-fat coffee|A high fat coffee that consists of 29 grams of added fat from grass fed ghee, and MCT oil.
223845815|NCT04307979|DIETARY_SUPPLEMENT|Black coffee|A regular black coffee with no added caloric content.
223845816|NCT01363479|DRUG|Oral palonosetron|
223845817|NCT01363479|DRUG|I.V. palonosetron|
223845818|NCT01363479|DRUG|Dexamethasone|
223845819|NCT02922972|DEVICE|Autologous Platelet Rich Plasma obtained with RegenKit®-BCT|After complete resection of the keloid scar, the first injection was administered before closure into the lesion resection bed and edges. Three additional injections were administered with a one-month interval.
223845820|NCT06416280|OTHER|Assessment of the TRiP(cast) score|"In patients presenting to the emergency department with trauma to a lower limb, the TRiP(cast) score is assessed in accordance with the recommendations. If the patient does not object. The attending physician will then be asked to fill in his implicit assessment of the risk of venous thromboembolism on a paper CRF and then to complete his assessment of the TRiP(cast) score. He will then be free to decide whether or not to anticoagulate the patient.~At the same time, a doctor not involved in the patient's care will assess the TRiP(cast) score and record it on a paper CRF. The second doctor's assessment will be independent and will have no impact on the patient's management.~The CRFs will then be analysed and stored. Data will be anonymised during data collection and each patient will be assigned an anonymity number."
223845821|NCT05478122|DEVICE|Trachospray for awake videolaryngoscopy|Subjects will be asked to inhale 4 ml lidocaine 4% via the Trachospray device
223845822|NCT06459661|OTHER|Diet|Intake of unrefined, intact plant foods
223845823|NCT00363285|BIOLOGICAL|gonadotrophin releasing hormone|
223845824|NCT00363285|DRUG|cyproterone acetate|
223845825|NCT00363285|PROCEDURE|quality-of-life assessment|
223845826|NCT00246298|DRUG|epoetin alfa|
223845827|NCT00250224|DEVICE|Radiotherapy stent|
223845828|NCT03084861|DRUG|Cord Blood Eye Drops|Eye drops plasma from cord blood diluted v/v with Plasmalyte®, without antimicrobial preservatives
223845829|NCT03084861|DRUG|Conventional treatment|"1. Artificial tears: Lubristil ®~2. Therapeutic Contact lens: Air Optix Night\&Day"
223845830|NCT01352507|DRUG|Tadalafil|Administered Orally
223845831|NCT01352507|DRUG|Sildenafil|Administered Orally
223845832|NCT04231461|PROCEDURE|Cardiac Surgery|Routine or urgent cardiac surgery
223845833|NCT01119703|BIOLOGICAL|Tetanus & Diphtheria booster vaccine (Td)|Tetanus \& Diphtheria booster vaccine (Td), single intramuscular dose
223845834|NCT01119703|BIOLOGICAL|TwinrixTM [Hepatitis A Inactivated & Hepatitis B (Recombinant) Vaccine]|TwinrixTM \[Hepatitis A Inactivated \& Hepatitis B (Recombinant) Vaccine\], intramuscular, two doses of standard three dose regimen (opposite arms)
223845835|NCT01119703|BIOLOGICAL|Dukoral® Traveler's Diarrhea Vaccine (WC/rBS)|Dukoral® Traveler's Diarrhea Vaccine, recombinant Cholera toxin B subunit (WC/rBS), standard two oral doses per treatment regimen
223845836|NCT00409864|PROCEDURE|Endoscopic biliary stenting, Percutaneous biliary stenting|percutaneous 10 F stent, endoscopic 10 F stent insertion
223845837|NCT00279058|PROCEDURE|Immunotherapy treatment for melanoma|
223845838|NCT02673008|BIOLOGICAL|donor lymphocyte infusion|DLI was administered at a median dose of 1.0 (range 0.7-1.4) ×10\*8 mononuclear cells/kg.
223845839|NCT03178201|DRUG|TGR-1202|Treatment will be self-administered on an outpatient basis. Patients will take TGR-1202 800 mg, oral, one tablet daily on a continuous basis. Each cycle lasts 28 days.
223845840|NCT01802203|DEVICE|truFreeze Spray Cryotherapy|spray cryotherapy
223845841|NCT04069546|DEVICE|remote ischemic conditioning|RIC is a physical strategy performed by an electric device with cuffs placed on the unilateral arm and inflated to 180 mmHg for 5-min followed by deflation for 5-min, the procedures are performed repeatedly for 5 times.
223845842|NCT05854628|PROCEDURE|skin biopsy|Skin biopsies will be obtained at different time points.
223845843|NCT05912751|OTHER|Exercise Then Foam Roll|Participants in AB will perform the experimental (exercise) intervention first and the control (foam rolling) intervention second.
223845844|NCT05912751|OTHER|Foam Roll Then Exercise|Participants in BA will perform the control (foam rolling) intervention first and the experimental (exercise) intervention second.
223845845|NCT02396992|OTHER|Minimal-Massive Intervention|The intervention will consist in basic recommendations based on the evaluations done at admission and discharge: a) diet adaptation (solids and fluids) based on dysphagia clinical evaluation (V-VST) to avoid efficacy or safety alterations; b) nutritional supplements in case of malnutrition (MNA-sf; bioimpedance and blood analysis) to improve nutritional status;and c) oral health and hygiene recommendations (toothbrushing and antiseptic mouthwashes to decline bacterial colonization).
223845846|NCT03677947|BEHAVIORAL|Exposure and response prevention|ERP is a treatment developed to help people confront their fears based on the rationale that exposure to feared objects, activities, or situations in a safe environment helps reduce fear and decrease avoidance. During the treatment, participants will engage in these exposures to feared stimuli within and between sessions according to hierarchies developed during the initial evaluation sessions, and refrain from engaging in compulsive behaviour until their anxiety subsides (i.e. ritual prevention). Exercises will consist of both exposure in vivo (i.e. exposure in real life situations) and/or imaginal exposure according to recommendations.
223845847|NCT03677947|OTHER|Inference-based cognitive therapy|The treatment primarily targets the dysfunctional reasoning that gives rise to obsessional doubts and overvalued ideas. IBCT does not include exposure in vivo, but instead, aims to bring resolution to the initial obsessional doubt or overvalued idea by showing the participant that the obsession is the result of incorrect reasoning.
223845848|NCT06324955|BEHAVIORAL|Standard/common language during induction|The anesthesiologist taking care of the patient will use scripted common/standard language during the induction.
224265021|NCT00380679|BIOLOGICAL|Influenza vaccination|
224265022|NCT00380679|BIOLOGICAL|Pneumococcal polysaccharide vaccination|
224265023|NCT00064090|DRUG|cytarabine|
224265024|NCT00064090|DRUG|triapine|
224265025|NCT01007994|DRUG|New Medication: Enalapril, Isradipine, Propranolol|"Enalapril will be added in the evening at 8 pm. If the subject is already on an ACEI or there is a contraindication to starting an ACEI the subject will be started on isradipine instead. If the subject is already on an ACEI and calcium channel blocker at baseline, propranolol will then be the new medication added.~Dosing will be as follows:~ACEI: Enalapril \< 40 kg starting dose 2.5 mg titrate to 5 mg \> 40 kg starting dose 5 mg titrate to 10mg Calcium Channel Blocker: Isradipine \< 40 kg 2.5 mg \> 40 kg starting dose 2.5 mg titrate to 5 mg Beta Blocker: Propranolol \<40 kg starting dose 10 mg titrate to 20 mg \>40 kg starting dose 20 mg titrate to 40 mg"
223845849|NCT06324955|BEHAVIORAL|Positive language during induction|The anesthesiologist taking care of the patient will use scripted positive language during the induction.
223845850|NCT06631599|OTHER|Physical training|The intervention consisted of physical exercise according to various protocols
223845851|NCT06632093|PROCEDURE|hepatic artery infusion chemotherapy|Hepatic arterial infusion chemotherapy including FOLFOX and RALOX
223845852|NCT06632093|DRUG|Lenvatinib + PD-1 monoclonal antibody|PD-1 inhibitors including Camrelizumab, Sintilimab, Tislelizumab
223845853|NCT06630507|BEHAVIORAL|Educational module|1 hour pre-recorded educational module created by Dr. Sharma.
224265026|NCT06441591|DRUG|Vinpocetine|Vinca derivative of apovincamine, phosphodiestrase 1 inhibitor, sodium-gated voltage channel
224265027|NCT06441591|DRUG|Standard Therapy|Anti-hypertensive and anti-diabetic medications according to the the institution's protocol
224265028|NCT06441591|OTHER|Placebo|Starch-filled capsules, matching those of the intervention
224265029|NCT02516189|OTHER|Strength training program|"Strength Training program applied twice a week for sixteen weeks. Each training exercises has a total time of 50 minutes. Warm-up: 5 minutes of stretching. Training: Leg press; Leg Curl; Vertical traction; Chest press; Abdominal crunch; Lower back. Gametherapy.~Relaxation: 5 minutes of stretching."
224265030|NCT01710748|DEVICE|Polymer-Based Everolimus-Eluting Stent|Polymer-Based Everolimus-Eluting Stent
224265031|NCT01710748|DEVICE|Polymer-Free Amphilimus-Eluting Stent|Reservoir-Based Polymer-Free Amphilimus-Eluting Stent
224265032|NCT06627348|DEVICE|Hilotherm ChemoCare|Hilotherapy
224265033|NCT00283764|DRUG|Xalatan|
224265034|NCT01519830|DRUG|Iron carboxymaltose (Ferinject)|Intravenous iron
224265035|NCT01519830|DRUG|Placebo|0.9% NaCl solution
224265036|NCT02235922|OTHER|Dual task training|The dual task training consisted of individuals subjected to a multicomponent exercise program associated to cognitive tasks.
224265037|NCT02235922|OTHER|Conventional training|The conventional training consisted of individuals subjected to a multicomponent exercise program.
224265038|NCT04967469|DRUG|Calcitriol|end-stage renal failure patients who is hyperparathyroid with ESRD take calcidol preoperative Parathyroidectomy
224265039|NCT04967469|DRUG|Alfacalcidol 0.5 MCG Oral Capsule|end-stage renal failure patients who is hyperparathyroid with ESRD take alfacalcidol preoperative Parathyroidectomy
224265040|NCT00966485|DRUG|80 mg ASA dosing|
224265041|NCT00966485|DRUG|500 mg ASA dosing|
224265042|NCT03198663|BEHAVIORAL|POSSE|Popular-opinion leader
224265043|NCT00958724|DRUG|Neratinib|
224265044|NCT00958724|DRUG|Vinorelbine|
224265045|NCT06628141|OTHER|Nutritional support tool|Nutritional support tool
223845854|NCT04685343|BEHAVIORAL|Quantitative Sensory Testing|Quantitative sensory testing (QST) consisting of 4 pain induction and sensory sensitivity tasks (i.e., pressure applied to the thumbnail, arms, shoulders, and lower abdomen, a cold water task, and one video-watching task).
223845855|NCT04685343|OTHER|fMRI|Functional magnetic resonance imaging (fMRI) session consisting of structural and functional brain scans.
223845856|NCT02862418|OTHER|UTE MRI|One MRI with UTE settings will be acquired.
223845857|NCT03686384|DRUG|SVT-15652|1 vial twice daily
223845858|NCT03686384|DRUG|Placebo|1 vial twice daily
223845859|NCT05939947|DRUG|ALE.F02|Continuous intravenous (IV) infusion administered once every second week to a total of 3 doses.
223845860|NCT05939947|DRUG|Placebo|Continuous intravenous (IV) infusion administered once every second week to a total of 3 doses.
223845861|NCT05876585|DRUG|Ondansetron 8 mg ampoule|Study drug
223845862|NCT05876585|DRUG|Metoclopramide 10 mg ampoule|Comparator drug
223845863|NCT04761393|PROCEDURE|Hyperpolarized 129Xe (Xenon) diffusion-weighted MRI|Participants will inhale a one litre gas mixture containing hyperpolarized 129Xe mixed with nitrogen (N2) or helium (4He) from a one litre dose bag. Breath-hold will be up to 16 seconds
223845864|NCT02098031|OTHER|Improving nutrition knowledge among mothers|
223845865|NCT02820051|DEVICE|Transcutaneous CO2 monitor|Measurement and surveillance of transcutaneous CO2 pressure (PtcCO2) to determine PtcCO2 behavior for each sedation group.
223845866|NCT02820051|DRUG|Midazolam|The initial dose was 0.05 mg/kg. Additional doses of 2 mg of midazolam were allowed to reach a score level of three to four in the Observer´s assessment of alertness/ sedation scale.
223845867|NCT02820051|DRUG|Propofol|The initial dose was 0.1 mg /kg. Additional doses of 10 mg of propofol were allowed to reach a score level of three to four in the Observer´s assessment of alertness/ sedation scale.
223845868|NCT02820051|DRUG|Nalbuphine|The starting dose was 2 mg with additional doses of 1 mg if it was necessary.
223845869|NCT02820051|DRUG|Lidocaine|Lidocaine spray was applied to the nasal mucosa and pharynx for bronchoscope nostril insertion, and only in the pharynx for bronchoscope oral insertion. Topical lidocaine was applied using the spray-as-you-go technique, at a maximum dose of 7 mg/kg.
223845870|NCT01222247|DRUG|Betamethasone|The active study drug, betamethasone. 3 mg per ml betamethasone sodium phosphate 3 mg per milliliter betamethasone acetate The first dose of study drug medication will be administered at randomization as 2 ml injection; the next dose of 2 ml will be administered 24 hours later.
223845871|NCT01222247|DRUG|Placebo|Similar course of identical appearing placebo: 2 mL IM injections, 24 hours apart.
223845872|NCT05446389|DEVICE|Pacifier Activated Lullaby ®|Pacifier Activated Lullaby (PAL®) is a medical device that encourages and reinforces the development of non-nutritive sucking (NNS) of premature infants. This is accomplished by giving positive feedback in the form of music/mother's voice as an auditory input in direct response to effective sucking.
223845873|NCT06222619|PROCEDURE|Potal vein embilization|Portal vein of involved bile duct is embolized to increase the volume of remnant liver.
223845874|NCT06546696|BEHAVIORAL|Competency Based Approaches to Community Health (COACH)|COACH is a multi-level intervention, consisting of 1) developmentally appropriate health curriculum for children; 2) family-based content that both targets parent weight loss and leverages a shared parent-child experience to improve family health behaviors; 3) community-level intervention to improve access and quality of family-based programming at local Parks and Rec centers.
223845875|NCT04939428|DRUG|Molnupiravir|Four molnupiravir 200 mg capsules taken by mouth.
223845876|NCT04939428|DRUG|Placebo|Placebo capsule matched to molnupiravir 200 mg capsules taken by mouth.
223845877|NCT05938868|DEVICE|Low intensity pulsed ultrasound (LIPUS)|LIPUS will be delivered intra-orally using a probe applied on the buccal aspect of the implant site. The probe is in contact with the buccal attached gingiva with a thin film of intra oral gel intervening between them, acting as a transmitting medium. It will be applied twice a week for 20 minutes each session that commenced after surgery on the second day and continued for 10 weeks. The intensity of ultrasound therapy used was 30 mW/cm2 with a frequency of 1.5 MHz and temporal average power of 20 Mw
223845878|NCT05938868|DEVICE|low level diode laser therapy|The patients will be irradiated with low level diode laser therapy (GaAs) (Chattanooga, model 27841, USA) .Patient will be irradiated with low level diode laser therapy with parameters: wavelength 850 nm and power of 200 mw in continuous mode will be applied in six points in non-contact method 10 mm away from the peri-implant soft tissue after suturing. The laser irradiations will be administered at six sites that included mesiobuccally, distobuccal, midbuccal, midlingual, mesial, and distal areas around implant for a duration of 10 seconds for each site. The total energy delivered was 6 J per session. And is based on a previous study by Gulati et al., 2020
223845879|NCT05938868|OTHER|Standard Care|Patients in all three groups will receive the standard care which includes: (1) Extra-oral ice packs during the first 2 days every two hour; (2) maintain daily routine oral hygiene after surgery; (3) Patients will be instructed to eat a soft diet for one weeks; (4) Broad spectrum oral antibiotics in a dose of one capsule every twelve hours for a week; (5) Non-steroidal anti-inflammatory drugs at a dose of one tablet every 8 hours for four days; (6) Warm chlorhexidine gluconate solution as a mouthwash for a period of 2 weeks to enhance plaque control.
223845880|NCT06204666|DIETARY_SUPPLEMENT|High Dose Hemp Fiber Bar|High dose hemp fiber bar with other ingredients
223845881|NCT06204666|DIETARY_SUPPLEMENT|Low Dose Hemp Fiber Bar|Low dose hemp fiber bar with other ingredients
223845882|NCT06204666|DIETARY_SUPPLEMENT|Placebo|Placebo bar with other ingredients
223845883|NCT05302791|DEVICE|Muscle Cooling|Cooling wrap will be set to 10°C
223845884|NCT05302791|OTHER|Resistance Exercise|Resistance Machines (Leg Press and Knee extension). 12 rep Max
223845885|NCT06401005|DRUG|Cadonilimab (AK104)|8Gy\*3 SBRT to irradiate the primary lesion (without axillary lymph node metastasis) or 6Gy\*3 SBRT irradiation to irradiate the primary lesion and axillary lymph node metastasis will be administered at first. And then the first cycle of chemotherapy+AK104 given within 24 hours of the end of SBRT. The total eight cycles of preoperative chemotherapy combined with immunotherapy were administered. Surgical resection was performed within 4-6 weeks after the completion of the eighth cycle of chemotherapy combined with immunotherapy. The chemotherapy regimen consisted of: Four cycles of doxorubicin 50mg/m2 (Q3W) + cyclophosphamide 600mg/m2 (Q3W) were administered, followed by four cycles of sequential albumin paclitaxel (125 mg/m2, d1, d8) and carboplatin (AUC=6, d1, Q3W) for 4 cycles. Postoperative completion of 9 cycles of immunotherapy was continued ± the need for postoperative adjuvant radiotherapy was confirmed based on the patient's preoperative status.
223845886|NCT06362837|BEHAVIORAL|Education intervention on nutrition, gender equity, WASH, sexual and reproductive health rights|Educational training on nutrition, gender equity, WASH, sexual and reproductive health rights will take place in communities (including schools) for women, men, and adolescents
223845887|NCT06362837|DIETARY_SUPPLEMENT|school-based iron-folic acid supplement program|The program will help support and promote the school-based programs of weekly iron and folic acid supplementation for adolescent girls, in countries where it is allowed.
223845888|NCT06362837|BEHAVIORAL|Health service training on equitable access to nutrition, health, and sexual and reproductive services|Training and support activities to make gender-equitable nutrition, health, and sexual and reproductive services in the health facilities
223845889|NCT06362837|DIETARY_SUPPLEMENT|bio-fortified crops|The program promotes and distributes bio-fortified crops, including orange-fleshed sweet potatoes, rice, beans, and corn
223845890|NCT05801042|DIETARY_SUPPLEMENT|Maltodextrin|Placebo product
223845891|NCT05801042|DIETARY_SUPPLEMENT|Encapsulated Lactocaseibacillus rhamnosus|Probiotic product
223845892|NCT05801042|DIETARY_SUPPLEMENT|Non-encapsulated Lactocaseibacillus rhamnosus|Probiotic product
223845893|NCT05821907|BEHAVIORAL|data collection group|The scale development process generally consists of three stages as item production, theoretical analysis and psychometric analysis. The researcher provides theoretical support to the item pool during item production. In the theoretical analysis stage, the content validity of the new scale is evaluated and the first item pool is ensured to reflect the desired structure. In the final stage of the psychometric analysis, the researcher evaluates whether the new scale establishes validity and reliability.
223845894|NCT02696785|DRUG|Ixekizumab|Administered SC
223845895|NCT02696785|DRUG|Placebo|Administered SC
223845896|NCT02696785|DRUG|Adalimumab|Administered SC
223845897|NCT05683262|PROCEDURE|Ultrasound-guided sacrococcygeal and/or intercoccygeal joint injection|Ultrasound guidance is used for correct visualization of injection site, and so obtained more successful results. Patients are placed in the prone position with a pillow under the abdomen to flatten the lumbar curvature. Lower extremities should be internally rotated while feet are inverted to help flatten the gluteal region. Injection site is cleaned thrice with povidone iodine %10 solution and covered with sterile drapes. Ultrasonography gel was applied on the probe and the probe was wrapped with a transparent thin sheath and cleaned with povidone iodine. Sterile gel is applied on the skin. The sacrococcygeal ligament, the sacrococcygeal and intercoccygeal joints were visualized. The sacrococcygeal and/or intercoccygeal joints were entered using the in-plane technique with a 23 gauge 6 cm long needle. When it was seen that the needle tip was inside the joint, 3 cc of 2% lidocaine + 1 cc betamethasone solution was injected.
223845898|NCT05683262|PROCEDURE|Ultrasound-guided coccygeal nerve block|Patients are placed in the prone position with a pillow under the abdomen. Lower extremities are internally rotated while feet are inverted. Injection site and the probe are cleaned thrice with povidone iodine %10 solution. Sterile gel is applied. The prob was placed on coccygeal cornu and the coccygeal nerve was visualized superomedial to the CC in the subcutaneous tissue layer. Hydrodissection was made by administering 5 ml of 5% dextrose + 1 ml of 2% lidocaine via an in-plane approach with a 23 gauge 6 cm long needle, targeting the short axes of the bilateral coccygeal nerves.
223845899|NCT05683262|PROCEDURE|Ultrasound-guided sacrococcygeal and/or intercoccygeal joint injection after coccygeal nerve block|After the coccygeal nerve block, when the pain with palpation of the coccygeal region was reduced by at least 50%, the sacrococcygeal ligament, sacrococcygeal and intercoccygeal joints were visualized.The sacrococcygeal and/or intercoccygeal joints were entered using the in-plane technique with a 23 gauge 6 cm long needle. When the needle tip was inside the joint, 3 cc of 2% lidocaine + 1 cc betamethasone solution was injected.
223845900|NCT02155582|DRUG|Copanlisib (BAY80-6946)|0.8 mg/kg body weight and 0.4 mg/kg (not to exceed 65 mg) for the non-diabetic patients;45 mg and 60 mg for the diabetic patients; Intravenous (IV) infusion over 1 hour. Dosing of copanlisib will be on Days 1, 8, and 15 of each 28 day treatment cycle.
223845901|NCT01011790|BEHAVIORAL|Healing Rhythms™ Meditation Program|The Healing Rhythms™ meditation program was chosen as the intervention for this study because it has a long history of use in the consumer market, it provides a dual-mode biofeedback which allows users to visually see their progress, and it provides an attractive and engaging user interface which is enjoyable to use. This is a critical factor as the research cited documents the importance of adherence in achieving optimal outcomes.
223845902|NCT03328520|BEHAVIORAL|WILD 5 Wellness Intervention|"Behaviors in 6 areas of wellness: Sleep, Social Connectedness, Exercise, Nutrition, Mindfulness and HERO (Happiness, Enthusiasm, Resilience, Optimism)"
223845903|NCT05282342|DIAGNOSTIC_TEST|Diagnostic tests|No intervention will be carried out. Participants of the whole groups will be underwent the same tests.
223845904|NCT03662893|BEHAVIORAL|behavioural therapy with written checklist form to complete|Behavioural therapy for overactive bladder such as advice on fluid balance, bladder retraining, urgency suppression or normal voiding techniques, pelvic floor muscle training, caffeine reduction, dietary changes, weight loss and other life style changes
223845905|NCT03662893|DRUG|Antimuscarinic drugs used in overactive bladder|Antimuscarinic drugs (Tolterodine, solifenacin, propiverine, darifenacin,fesoterodine)
223845906|NCT03662893|BEHAVIORAL|behavioural therapy with written guideline|behavioural therapy with written guideline,which are the same as those in the checklist
223845907|NCT03328559|DIAGNOSTIC_TEST|ISET® - Isolation by Size of Tumor cells|early stage bronchial cancer patient will have a blood collection
223845908|NCT03328559|DIAGNOSTIC_TEST|ISET® - Isolation by Size of Tumor cells|advanced stage bronchial cancer patient will have a blood collection
223845909|NCT04871373|BEHAVIORAL|Motivational interviewing|A periodontist was trained and evaluated by two expert psychologists in MI, who also supervised the interviewer to ensure that the intervention was properly applied. The periodontist conducted sessions of motivational interviewing monthly to the participants of the experimental group.
223845910|NCT04871373|BEHAVIORAL|Oral Hygiene Instructions|A periodontist delivered OHI to all the participants of both studied groups. Also, every single patient received a G.U.M. kit with special orthodontic hygiene tools.
223845911|NCT01988987|OTHER|Inpatient Postpartum GTT|Women with gestational diabetes will undergo a 75 gram, 2 hour, oral glucose tolerance test 2-4 days postpartum prior to hospital discharge, in addition to undergoing the standard of care, outpatient glucose tolerance test performed 6-12 weeks postpartum
223845912|NCT03888911|DIETARY_SUPPLEMENT|High dose IQP-LU-104 (5120mg)|1 sachet to be taken 2 times daily orally, together with 2 main meals
223845913|NCT03888911|DIETARY_SUPPLEMENT|Low dose IQP-LU-104 (2560mg)|1 sachet to be taken 2 times daily orally, together with 2 main meals
223845914|NCT03888911|DIETARY_SUPPLEMENT|Placebo|1 sachet to be taken 2 times daily orally, together with 2 main meals
223845915|NCT05457361|DRUG|VEN combined with azacitidine plus homoharringtonine|VEN begins at 100 mg on day 1 and increases stepwise over 3 days to reach the target dose of 400 mg (100 mg, 200 mg, 400 mg); dosing is continued at 400 mg per day from day 4 through day 14; azacitidine (75 mg/m²) is administered subcutaneously on days 1-7, and HHT (1 mg/m²) on days 1-7.
223845916|NCT05457361|DRUG|VEN combined with azacitidine|The use of VEN is just the same as it dose in VAH regimen except lasting for 28 days. The use of azacitidine is exactly the same as VAH group does.
223845917|NCT02919085|PROCEDURE|Early ambulation|Procedure to accelerate the ability of a patient to walk or move about by reducing the time to ambulation. It is characterized by a shorter period of hospitalization or recumbency than is normally practiced.
223845918|NCT03620929|DRUG|Estradiol Valerate|In all cases hormone therapy will be started from the day of operation, consisting of estradiol valerate at a dose of 4mg/d for 21 days, with the addition of dydrogesterone at a dose of 10 mg/d for the last 7 days of the estrogen therapy. After the withdrawal bleed, the hormone therapy will be repeated for another cycle. Second-look hysteroscopy will be carried out in the early proliferative phase, 4 weeks after the initial operation; a third-look hysteroscopy will be carried out 8 weeks after the initial operation. After assessment of the extent and severity of any reformed adhesion, hysteroscopic adhesiolysis will be carried out at the time of the second-look or third-look procedure, if adhesion had recurred.
223845919|NCT05946746|DIETARY_SUPPLEMENT|PeptiStrong|PeptiStrong is a protein hydrolysate derived from Vicia faba. It is a free-flowing powder, pale yellow in colour. For the purposes of the trial, PeptiStrong will be encapsulated in size '00' hydroxypropyl methylcellulose capsules.
223845920|NCT05946746|DIETARY_SUPPLEMENT|Placebo SMCC silicated micro-crystalline cellulose|Placebo - SMCC silicated microcrystalline cellulose (INCI name: MCC, cellulose gel), For the purposes of the trial, SMCC will be encapsulated in size '00' hydropropyl methylcellulose.
223845921|NCT05425797|OTHER|In-Person Prevention Practitioner Visit|BETTER Intervention visit with PP which will take place in-person at the PP's office.
223845922|NCT05425797|OTHER|Video-Call Prevention Practitioner Visit|BETTER Intervention visit with PP which will take place virtually via a secure video system.
223845923|NCT05425797|OTHER|Phone Prevention Practitioner Visit|BETTER Intervention visit with PP which will take place via telephone.
223845924|NCT02320253|BEHAVIORAL|In Person Group (IP)|The goals of the diabetes lifestyle intervention program are weight loss of 5-10% of initial body weight and increased activity levels to 175 minutes/week of moderate intensity physical activity. Dietitians will deliver the adapted Look AHEAD lifestyle intervention via in-person groups combined with 2-3 individual sessions per year. The program curriculum focuses on nutrition, activity, and behavioral topics and incorporates the use of meal replacements for the first 4-16 weeks to enhance weight loss success.
223845925|NCT02320253|BEHAVIORAL|Telephone Conference Call Group (TCC)|The goals of the diabetes lifestyle intervention program are weight loss of 5-10% of initial body weight and increased activity levels to 175 minutes/week of moderate intensity physical activity. Dietitians will deliver the adapted Look AHEAD lifestyle intervention via telephone conference call groups combined with 2-3 individual sessions per year. The program curriculum focuses on nutrition, activity, and behavioral topics and incorporates the use of meal replacements for the first 4-16 weeks to enhance weight loss success. Dietitians will deliver the adapted Look AHEAD lifestyle intervention.
223845926|NCT02320253|BEHAVIORAL|Medical Nutrition Therapy (MNT)|Participants are referred to meet with a registered dietitian for individual medical nutrition therapy sessions up to 3-4 times per year.
223845927|NCT06134505|PROCEDURE|Use of Barrier cream group 1 in the healing of diaper dermatitis|"In this study, the infant's first-degree diaper dermatitis was determined by the doctor or midwife using the Uncomplicated Diaper Dermatitis Severity Rating Scale in Infants. After first-degree diaper dermatitis was detected in the babies and their written consent was obtained, the parents of the babies were informed about the research before application and the parent-baby identification information form was filled out. Families were provided with education based on the ABCDE model. Mothers were informed that Barrier cream 1 would be used at each diaper change. Baby dermatitis was monitored face to face by the researcher on the 1st, 3rd and 5th days, and the scores were recorded on the observation form. Follow-up of those with a diaper dermatitis score of 0 was discontinued because full recovery was achieved."
223845928|NCT06134505|PROCEDURE|Use of Barrier cream 2 in the healing of diaper dermatitis|"In this study, the infant's first-degree diaper dermatitis was determined by the doctor or midwife using the Uncomplicated Diaper Dermatitis Severity Rating Scale in Infants. After first-degree diaper dermatitis was detected in the babies and their written consent was obtained, the parents of the babies were informed about the research before application and the parent-baby identification information form was filled out. Families were provided with education based on the ABCDE model. Mothers were informed that barrier cream 2 would be used at each diaper change. Baby dermatitis was monitored face to face by the researcher on the 1st, 3rd and 5th days, and the scores were recorded on the observation form. Follow-up of those with a diaper dermatitis score of 0 was discontinued because full recovery was achieved."
223845929|NCT06134505|PROCEDURE|Use of olive oil in the healing of diaper dermatitis|"In this study, the infant's first-degree diaper dermatitis was determined by the doctor or midwife using the Uncomplicated Diaper Dermatitis Severity Rating Scale in Infants. After first-degree diaper dermatitis was detected in the babies and their written consent was obtained, the parents of the babies were informed about the research before application and the parent-baby identification information form was filled out. Families were provided with education based on the ABCDE model. Mothers were informed that olive oil would be used at each diaper change. Baby dermatitis was monitored face to face by the researcher on the 1st, 3rd and 5th days, and the scores were recorded on the observation form. Follow-up of those with a diaper dermatitis score of 0 was discontinued because full recovery was achieved."
223845930|NCT05717075|BEHAVIORAL|Parents Round|The intervention carried out in this study is called Family Round. The Family Round is an additional medical round, aiming to involve parents in the discussion. The basic attitude of the healthcare staff is to make decisions collaboratively with parents or other family members based on the parents' observations of their infant and parents' opinions. As our daily medical round is carried out in the morning between 8 and 10 a.m. and we offer no accommodation for parents in the NICU, the Family Round will be carried out separately in the afternoon. One neonatologist who is in charge of the infant or taking care of the infant on that day will be a facilitator and proceed with the Parent Round according to the protocol. Other healthcare staff are also encouraged to participate, although the number of participants is limited.
223845931|NCT00603538|DRUG|CP-751,871 + carboplatin + paclitaxel|Chemotherapy (carboplatin and paclitaxel) and CP-751,871 (6, 10 or 20mg/kg) will be administered by intravenous infusion every three weeks.
223845932|NCT05975996|DRUG|Cyclophosphamide added to standard immunosuppressive therapy with herombopag|Severe aplastic anemia patients will receive a daily dose of Anti-lymphocyte globulin (25mg/kg) for the initial five days at the beginning of the treatment. Cyclosporine will be administered daily at a dosage of 3-5mg/kg. Herombopag will be administered daily at a dosage of 15mg starting from the first day of treatment and continuing for a duration of six months. The moderate-dose cyclophosphamide (20mg/kg) will be administered on days 29-30 and days 43-44.
223845933|NCT05064761|DEVICE|Sculptra new dilution|Treatment to improve appearance of cellulite.
223845934|NCT05654649|DRUG|0.9%sodium chloride|Patients received 5 ml of IV normal saline as a placebo just before spinal anesthesia
223845935|NCT05654649|DRUG|Dexamethasone|Patients received IV dexamethasone 8 mg in 5ml normal saline 0,9%, just before spinal anesthesia.
223845936|NCT02460029|OTHER|Ventral hernia|Visualization of the mesh surface and the confirmation with MRI scan at 1 month and 13 months after standardized retromusculare incisional hernia repair with the visible CICAT mesh (Dynamesh®).
223845937|NCT00741273|DRUG|Proellex|Proellex 25 mg capsule, single dose
223845938|NCT02393261|OTHER|2500ml Huaren peritoneal dialysate|use 2-3 bags of 2500ml Huaren dialysate in the daytime and keep 1 bag of 2500ml Huaren dialysate in the night
223845939|NCT02393261|OTHER|2000ml peritoneal dialysate|use 3-4 bags of normal 2000ml dialysate in the daytime and keep 1 bag of 2000ml dialysate in the night
223845940|NCT01091181|PROCEDURE|hysterotomy at cesarean|incision to open the uterus at cesarean.
223845941|NCT01033396|DRUG|PF-03654764|PF-03654764 single dose 5 mg
223845942|NCT01033396|DRUG|Allegra|Fexofenadine single dose 60 mg
223845943|NCT01033396|DRUG|PF-03654764|PF-03654764 single dose 5 mg
223845944|NCT01033396|DRUG|Allegra-D|Fexofenadine 60 mg combined with pseudoephedrine 120 mg single dose
223845945|NCT01033396|DRUG|Placebo|Placebo single dose
223845946|NCT00565682|DRUG|etoricoxib 120 mg|etoricoxib 120 mg, tablet, orally, OD
223845947|NCT06919146|BEHAVIORAL|Physical Activity|EG participated in AGPAP (4:00 pm-5:00 pm) twice a week, every Wednesday and Friday, for a total of 60 minutes, for 12 weeks. EG and CG did not participate in any additional physical activity programs after-school.
223845948|NCT06920329|DRUG|Peginterferon α-2b based injection|Peginterferon α-2b injection, 180 μg administered subcutaneously in the abdomen or thigh once weekly, with regular follow-up for HBV recurrence. Patients will be followed up every 12 weeks.
223845949|NCT06918652|PROCEDURE|Transmural ultrasound-guided gallbladder drainage|TUGD will be performed using the bi-flanged LAMSs mounted on an electrocautery-enhanced delivery system (Hot-AXIOS™) by an experienced endoscopist defined as \> 10 LAMS positioning per year. The diameter and length of the stent and the modality of placing the stent (under complete EUS view or with endoscopic or fluoroscopic guidance) will be chosen at the discretion of the endoscopist performing the procedure
223845950|NCT06918652|PROCEDURE|Laparoscopic cholecystectomy|LC will be performed by the four-trocar technique with transection of the cystic duct and cystic artery after reaching the critical view of safety. ELC will be performed by a surgeon trained and experienced in laparoscopic surgery defined as \> 5 laparoscopic procedures for ACC on a yearly basis
223845951|NCT06918184|BEHAVIORAL|Specific Exercise Therapy|The exercise protocol includes mobilisation and stretching with 40-minute sessions twice weekly for 8 weeks post-initiation, transitioning to a home-based maintenance phase for 4 months. All sessions will be supervised by certified physiotherapists.
223845952|NCT06920277|DEVICE|Ultrasound scans|10 seconds scanning for one block region
223845953|NCT04259970|DRUG|Initiation of CFTR Modulator|Inhaled contrast for MRI occurring at each 4 visits.
223845954|NCT04541901|OTHER|Massage|12 minutes of effleurage and petrissage on the upper limbs
223845955|NCT04541901|OTHER|Cold water immersion|12 minutes of cold water immersion at the shoulder level with water temperature between 11 to 15°C
223845956|NCT04191161|DEVICE|Wearing the rigid brace|Custom braces are made from 4mm thick polyethylene with Velcro® fastening. They are Computer Aided Designed and are made by the same manufacturer (LAGARRIGUE). A thermal sensor chip will placed in the brace to assess observance.
223845957|NCT06329804|OTHER|Isometric Handgrip Exercise Training (IHGT)|Each IHGT session will consist of 4 x 2-minute contractions at 30% maximal voluntary contraction, with 2-minutes of rest in between, performed with the dominant hand. Training will be performed using an electronic hand dynamometer (Camry EH101, Zhongshan Camry Electronic Co. Ltd, Guangdong).
223845958|NCT01565538|DRUG|Erlotinib|150 mg Given orally
223845959|NCT01565538|DRUG|Pemetrexed|500mg/m2 Given IV
223845960|NCT05263141|PROCEDURE|retro-auricular single-site endoscopic thyroidectomy|The strap muscles and the sternocleidomastoid muscle were separated. Upper parathyroid and lower parathyroid glands were identified and preserved. The recurrent laryngeal nerve (RLN) was identified，A lobe of thyroid specimen and central lymph nodes were dissected.
223845961|NCT05263141|PROCEDURE|traditional open surgery thyroidectomy|The strap muscles were separated in the midline to expose the thyroid gland. Upper parathyroid and lower parathyroid glands were identified and preserved. The recurrent laryngeal nerve (RLN) was identified， a lobe of thyroid specimen and central lymph nodes were dissected.
223845962|NCT04074954|PROCEDURE|Cataract surgery|Patients will receive cataract surgery
223845963|NCT05512260|DEVICE|Individual decision aid (iDA)|A web-based iDA (accessible online with various content), will be developed towards individuals approached to cancer screening, although public and accessible to all who are interested in cancer and screening. DAs in screening usually include information on the disease, screening, screening tests, benefits and harms and some value clarification exercise (e.g., interactive questions) aiming at shedding light on the individual´s values and preferences, knowledge and lifestyle.
223845964|NCT00361998|DRUG|NITROFURANTOIN MACROCRYSTALS|
223845965|NCT00699738|BEHAVIORAL|Breastfeeding|Breastfeeding
223845966|NCT00699738|BEHAVIORAL|Bottlefeeding|Bottlefeeding
223845967|NCT02253186|DEVICE|Auto-Adjustable MOBIDERM Armsleeve|
223845968|NCT04181801|PROCEDURE|Subtotal cholecystectomy|a surgical procedure in which more than the top half of the gallbladder is removed
223845969|NCT00017277|BIOLOGICAL|epoetin alfa|
223845970|NCT00017277|RADIATION|radiation therapy|
223845971|NCT01334541|BEHAVIORAL|SAFE VET|"All SAFE VET EDs provide a standardized intervention that is specifically adapted for use in the ED to mitigate suicide risk. Given that the SAFE VET intervention was developed for use in a busy ED setting, the length of the intervention is approximately 45 minutes. The SAFE VET intervention is administered by a clinical provider who has been specifically trained and consists of:~1. Risk Assessment~2. Safety Planning Intervention: Developed by Stanley and Brown (2008), Safety Planning Intervention consists of a hierarchically-arranged list of coping strategies identified for use during a subsequent suicidal crisis.~3. Clinical Follow-Up Protocol"
223845972|NCT04672460|DRUG|TALZENNA capsule|Current commercial talazoparib formulation 1 mg once daily given under fasting condition
223845973|NCT04672460|DRUG|Talazoparib soft gel capsule|Proposed talazoparib soft gel capsule formulation 1 mg once daily under fasting condition
223845974|NCT04672460|DRUG|Talazoparib soft gel capsule|Proposed talazoparib soft gel capsule formulation 1 mg once daily under fed condition
223845975|NCT03575962|DRUG|GSK3640254 bis-hydrochloride salt capsule|Administered orally (as single dose) on morning of Day 1, as 2 capsules of 100 mg following a moderate calorie and fat meal during Period 1 and Period 2, at the specified sequence, as per study.
223845976|NCT03575962|DRUG|GSK3640254 Mesylate Salt Capsule|Administered orally (as single dose) on morning of Day 1, as 2 capsules of , 100 mg following a moderate calorie and fat meal during Period 1 and Period 2, at the specified sequence, as per study.
223845977|NCT00059917|DRUG|polyglutamate camptothecin|
223845978|NCT03286725|BEHAVIORAL|Physical Education (PE) Programme|"A programme of activities for PE lessons has been developed by Oxford Brookes University (in collaboration with Oxfordshire Sport and Physical Activity) to try to optimise the benefit of PE for brain function. Staff from Oxford Brookes University will train PE teachers to deliver this programme.~The Intervention involves roughly 20 minutes of prescribed activities per week, to be delivered within school PE lessons."
223845979|NCT00049517|BIOLOGICAL|sargramostim|Given IV or as an injection
223845980|NCT00049517|DRUG|busulfan|Given IV
223845981|NCT00049517|DRUG|cyclophosphamide|Given IV
223845982|NCT00049517|DRUG|cytarabine|Given as a continuous infusion
223845983|NCT00049517|DRUG|gemtuzumab ozogamicin (GO)|Given IV
223845984|NCT00049517|DRUG|Daunorubicin|Given intravenously daily for 3 days at a dose of either 45 or 90 mg/m2.
223845985|NCT00049517|PROCEDURE|Autologous HCT|Autologous hematopoietic cell transplantation
223845986|NCT00049517|PROCEDURE|Allogeneic HCT|Allogeneic hematopoietic cell transplantation
223845987|NCT01663610|BEHAVIORAL|VardagsSMART|VardagsSMART Internet-based course with therapist support during 6 weeks
223845988|NCT06454292|DRUG|Oliceridine Fumarate|After subjects were enrolled, the original sedative and analgesic drugs were discontinued, and a starting dose of 6ug/kg/h of oliceridine fumarate was continuously pumped, and the time of oliceridine fumarate initiation was recorded as T0. Subjects were assessed for sedation using the RASS score, and for analgesia using the CPOT score. Waiting for the original sedative-analgesic drug to elute until CPOT ≥ 3 and RASS \> 0. Adjust the infusion rate of oliceridine fumarate according to the CPOT score (recommended to be adjusted by 2ug/kg/h, the range of adjustment is 2-20 ug /kg/h, and the maximum infusion rate is not more than 20 ug /kg/h) until the analgesic score of the subject is CPOT\<3. The interval between two trial drug rate adjustments should be ≧5 min, and a CPOT score should be performed before each drug adjustment.
223845989|NCT06454292|DRUG|Remifentanil|After subjects were enrolled, the original sedative and analgesic drugs were discontinued, and remifentanil was continuously pumped at a starting dose of 1.5ug/kg/h. The time of remifentanil initiation was recorded as T0. Subjects were assessed for sedation using the RASS score and analgesia using the CPOT score. We waited for the original sedative-analgesic drugs to elute until CPOT ≥ 3 and RASS \> 0. The infusion rate of remifentanil was adjusted according to the CPOT score (1.5ug/kg/h is recommended, the range of adjustment is 1.5\~12μg/kg/h, and the maximum infusion rate is not more than 12μg/kg/h) until the subject's analgesic score of CPOT\<3, and the interval between the two experimental rate adjustments of the drug should be ≧5min, and the CPOT score should be performed before each adjustment of the drug. The CPOT score should be performed before each drug adjustment.
223845990|NCT05218603|DRUG|Bortezomib|Maintenance: Administration as per routine clinical practice.
223845991|NCT05218603|DRUG|Daratumumab|Maintenance: Administration as per routine clinical practice.
223845992|NCT05709548|DRUG|Indocyanine green|Subjects with a diagnosis of acute cholecystitis who undergo urgent laparoscopic cholecystectomy with the preoperative administration of indocyanine green (between 1-2 hours prior to surgery).
223845993|NCT00318968|DRUG|Esomeprazole|
223845994|NCT00049114|DRUG|doxorubicin hydrochloride|
223845995|NCT00049114|DRUG|cyclophosphamide|Given IV
223845996|NCT00049114|DRUG|tipifarnib|Given orally
223845997|NCT00049114|BIOLOGICAL|filgrastim|Given subcutaneously
223845998|NCT00049114|PROCEDURE|therapeutic conventional surgery|Undergo complete resection
223845999|NCT00049114|OTHER|laboratory biomarker analysis|Correlative studies
223846000|NCT03614130|DEVICE|LID011121 contact lens|Investigational silicone hydrogel contact lens
223846001|NCT03614130|DEVICE|Comfilcon A contact lens|Commercially available silicone hydrogel contact lens
223846002|NCT00421915|DRUG|Enbrel (etanercept)|
223846003|NCT02836665|PROCEDURE|Telemedicine for dermatological emergency patients|"Study-related photographs of the skin lesion made by a tablet and anamnesis data are uploaded to the hospital information system medico. Those data can directly be processed by the dermatological investigator in charge who enters his diagnosis and his therapy proposal without being on site."
223846004|NCT05668091|DRUG|Nirmatrelvir|Two 150 mg tablets taken by mouth every 12 hours.
223846005|NCT05668091|DRUG|Ritonavir|One 100 mg capsule taken by mouth every 12 hours.
223846006|NCT05668091|DRUG|Placebo|Two tablets containing placebo matching nirmatrelvir taken by mouth every 12 hours.
223846007|NCT04042467|BEHAVIORAL|Greenlight Plus|Families randomized to the Greenlight Plus arm will receive a HIT intervention starting at the newborn clinic visit. During the newborn visit, these families will receive basic instructions on how to access the Greenlight technology platform, which includes the iOTA text-messaging application and a website (usable on desktop or mobile platform). Families will receive text messages and goal-setting over the first 2 years of the child's life.
223846008|NCT04042467|BEHAVIORAL|Greenlight|All residents and families seen in the participating clinics will receive the basic Greenlight materials.
223846009|NCT05905458|DRUG|HRS9950 tablets|HRS9950 tablets, oral, once a week, low dose
223846010|NCT05905458|DRUG|HRS9950 tablets|HRS9950 tablets, oral, once a week, high dose
223846011|NCT05905458|DRUG|HRS9950 placebo tablets|HRS9950 placebo tablets, oral, once a week.
223846012|NCT06629948|DEVICE|x ray|whole spine x ray posterioanterior and lateral views
223846013|NCT06629948|DIAGNOSTIC_TEST|the cranio-cervical flexion test|measure of deep neck flexors muscles endurance
223846014|NCT06172595|DIAGNOSTIC_TEST|FET PET|There is only one study visit during which study subjects will undergo a 18F-FET PET/CT in SGH. Following that, they will be followed up as per their routine clinical care. Data collection timepoints will be at 30 days, 4 months, 8 months and 1 year.
223846015|NCT01895140|DEVICE|Renal denervation device|
223846016|NCT03273530|OTHER|Integrated Supported Employment|vocational assessment followed by job placement and on-going work-related social skills revision and reinforcement
223846017|NCT03299491|OTHER|MWA intervention|The MWA intervention will involve upgrading existing maternity waiting areas to ensure that essential supplies and services are available to create a comfortable environment for women to temporarily reside in and have easy access to skilled obstetric services.
223846018|NCT03299491|OTHER|IEC intervention|"Community and religious leaders will each attend one-day workshops designed using participatory, adult learning methods to help participants better understand the importance of maternal health care services, identify barriers to accessing care and to strategize how to promote utilization of services. Half-day workshops will conducted in subsequent years to build on shared experiences.~Health extension workers will attend 3-day workshops to identify enablers and barriers to implementation of the safe motherhood components of the health extension program and strategize on how to engage community and religious leaders to support access to maternal health care services in their communities.~Half-day workshops will conducted in subsequent years for each of the participant groups to build on shared experiences."
223846019|NCT06278857|DRUG|Dostarlimab-Gxly 50 MG/1 ML Intravenous Solution [JEMPERLI]|The dosing regimen follows standard clinical care protocol comprising of 4 cycles every 3-weeks, a rest period of 34 weeks followed by 3 cycles every 6 weekly for a total of 7 cycles.
223846020|NCT03176030|DIETARY_SUPPLEMENT|Fortified Foods|The intervention under study is the provision of between-meal fortified foods (enhanced with protein, energy, and micronutrients) and meal supplementation where meals are poorly consumed. Foods will include both savory and sweet foods with different flavors. Foods will be matched as closely as possible in protein and energy and are calculated to provide typically 210 kcal and 5g protein per item. The volume / weight of the foods are standardized to be of relatively small portion size, such as 100 ml for ice-creams, 40 g for cakes and biscuits, and 100 ml for soup. Some of the products will be supplemented with micronutrients particularly needed by older adults, such as Vitamins (C, D, folic acid, B2, B6) and calcium at one third of the Dietary Reference Values (DRV) per portion. The aim is to achieve a daily consumption of two additional fortified food items.
223846021|NCT02764307|DEVICE|Constant jet nebulizer|A constant jet nebulizer (Neb-easy, Galemed Corp., Taiwan) was tested with salbutamol sulfate powered by compressed gas flow at 6 L/min.
223846022|NCT02764307|DEVICE|Breath enhanced nebulizer|A breath enhanced nebulizer (Pari LC plus, Pari Inc., Germany) was tested with salbutamol sulfate powered by compressed gas flow at 6 L/min.
223846023|NCT02764307|DEVICE|Manual-actuated nebulizer|A manual-actuated nebulizer (A-T Neb, Atlantean Corporation, Taiwan) was tested with salbutamol sulfate powered by compressed gas flow at 6 L/min.
223846024|NCT02764307|DEVICE|Breath-actuated nebulizer|A breath-actuated nebulizer (AeroElipes, Trudell Medical Inc, Canada) was tested with salbutamol sulfate powered by compressed gas flow at 6 L/min.
223846025|NCT01211665|DRUG|Methylprednisolone|In intravenous form (for a daily dose of 1 g/day on treatment days).
223846026|NCT01211665|DRUG|Prednisolone|Oral prednisolone used as a taper, with suggested dosages starting at 80 mg and tapering to 5 mg.
223846027|NCT01551836|DRUG|Paracetamol formulation 1|formulation 1
223846028|NCT01551836|DRUG|Paracetamol formulation 2|Formulation 2
223846029|NCT02685293|DRUG|GFF MDI (PT003)|Glycopyrronium and Formoterol Fumarate Inhalation Aerosol; PT003, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (GFF MDI)
223846030|NCT02685293|DRUG|Placebo MDI|Placebo Metered Dose Inhaler (MDI) for Glycopyrronium and Formoterol Fumarate Inhalation Aerosol
223846031|NCT04093128|OTHER|herbal tea intervention|herbal tea intervention for 7 weeks
223846032|NCT05039736|DRUG|Cabozantinib|Given by PO
223846033|NCT05039736|DRUG|Nivolumab|Given by IV
223846034|NCT00672152|BIOLOGICAL|WT1 derived peptides|"WT1 derived peptides consisting of 0.3mg (cohort 1) or 1mg (cohort 2) of each of the following peptides mixed with 1ml Montanide ISA 51 and 100mcg GM-CSF in a total volume of 2ml:~* WT peptide #1: HLA-A2 restricted: RMFPNAPYL~* WT peptide #2: HLA-A24 restricted: CMTWNQMNL~* WT peptide #3: HLA-DR15 restricted: QARMFPNAPYLPSCL~* WT peptide #4: HLA-DRw53 restricted: LKGVAAGSSSSVKWT~Immunization with the peptide pools will be given as 200 microliter intradermal and 1.8ml subcutaneously in opposite thighs."
223846035|NCT01390857|DRUG|Valaciclovir|
223846036|NCT05247216|DRUG|Hemay007 800 mg QD group|daily oral administrtion of Hemay007 800 mg QD for 12 weeks, 4 tablets of 200mg Hemay007 and 2 tablets of placebo.
223846037|NCT05247216|DRUG|Hemay007 1200 mg QD group|daily oral administrtion of Hemay007 1200 mg QD for 12 weeks, 6 tablets of 200mg Hemay007.
223846038|NCT05247216|DRUG|Hemay007 600 mg QD group|daily oral administrtion of Hemay007 600 mg QD for 12 weeks, 3 tablets of 200mg Hemay007 and 3 tablets of placebo.
223846039|NCT05247216|DRUG|Hemay007 placebo group|daily oral administrtion of placebo for 12 weeks 6 tablets of placebo.
223846040|NCT01123161|DEVICE|hypothermia and anti-shivering treatment|Hypothermia is induced using the Celsius Control™ System. Shivering is treated with buspirone, meperidine and surface warming
223846041|NCT01123161|DRUG|Group1: IV t-PA and normothermia|Group 1 will t-PA as standard of care and normothermia
223846042|NCT05165914|DRUG|Intravenous midazolam before emergence from general anesthesia|Intravenous administration of 0.03 mg/kg midazolam just before emergence from anesthesia.
223846043|NCT05165914|DRUG|Intravenous normal saline before emergence from general anesthesia|Intravenous administration of normal saline just before emergence from anesthesia.
223846044|NCT05091164|PROCEDURE|Drug induce sleep endoscopy of upper aerodigestive tract under hypnosis|Drug induce sleep endoscopy of upper aerodigestive tract under hypnosis.
223846045|NCT04551417|PROCEDURE|Free graft urethroplasty|Free graft urethroplasty will be performed either with ventral or dorsal onlay of the graft.
223846046|NCT05343884|RADIATION|Myocardial perfusion imaging|Myocardial perfusion imaging
223846047|NCT05879666|BEHAVIORAL|Online educational phthalate course|This is an online course focused on phthalates for reproductive health professionals. It consists of videos from patient, scientist, and OBGYN perspectives describing how phthalates relate to reproductive health. There is also an interactive module and worksheet to facilitate conversations about phthalates with pregnant individuals.
223846048|NCT04267094|DEVICE|Iterative reconstruction at reduced radiation dose|Evaluating Agatston coronary calcium score using reduced dose acquisitions reconstructed using iterative reconstruction
223846049|NCT01565161|BEHAVIORAL|Home-Based Health Coaching|"The 6-month intervention arm consists of 3 components:~1. In-home coaching visits with a health educator trained in motivational interviewing to encourage behavior change. In addition to 4 monthly in-home coaching visits, participants receive 4 monthly coaching phone calls to supplement the in-person visits.~2. Use of mobile technology to deliver health information by text message - participants receive messages twice weekly for 16 weeks and then weekly for 8 weeks of the program. Those without a phone capable of receiving text messages receive postcards by mail.~3. Printed materials, including educational handouts, newsletters, and activities highlighting target behaviors, sent monthly for 4 months."
223846050|NCT01565161|BEHAVIORAL|Mailed materials|"We designed materials for our control group focusing on Developmental milestones during early childhood to provide information that participants would find relevant and helpful for parenting, but that would also not influence intervention behaviors, such as TV viewing or household routines related to sleeping, eating, or television viewing.~Participants received 4 monthly mailing packages, each focusing thematically on one of four milestone domains: motor, language, cognitive and social/emotional. Educational materials were adapted from the Center for Disease Control's Positive Parenting Tips for Healthy Child Development, and the mailing included child-appropriate incentives to reinforce the concepts presented in the educational materials."
223846051|NCT01641276|DEVICE|Low intensity amplitude-moduled electromagnetic fields|Patients in each arm will be exposed to 30 min of amplitude-moduled low intensity electromagnetic fields only one time.
223846052|NCT02963220|BEHAVIORAL|CBT-AR|20-30 sessions of cognitive behavioral therapy for avoidant/restrictive food intake disorder (CBT-AR), held once per week in an outpatient setting
223846053|NCT03737175|PROCEDURE|Carotid Artery Stenting|Carotid Artery Stenting
223846054|NCT03737175|PROCEDURE|Carotid Endarterectomy|Carotid Endarterectomy
223846055|NCT02462655|OTHER|Pre-lipid apheresis|Blood samples will be taken just before the start of the lipid apheresis treatment.
223846056|NCT02462655|OTHER|Post-lipid apheresis|Blood samples will be taken following the lipid apheresis treatment.
223846057|NCT00403884|PROCEDURE|Selective RPE laser treatment|interventional SRT laser treatment
223846058|NCT02933320|BIOLOGICAL|BI-1206 single agent dose escalation phase|BI-1206 single agent dose escalation phase to determine the MTD or maximum administered dose (MAD) and recommended Phase II dose (RP2D) for evaluation of BI-1206.
223846059|NCT02933320|BIOLOGICAL|Combination of BI-1206 with rituximab escalation phase|An investigation of combination treatment of BI-1206 with rituximab.
223846060|NCT02933320|BIOLOGICAL|BI-1206 single agent expansion phase|BI-1206 single agent expansion phase at the RP2D.
223846061|NCT02933320|BIOLOGICAL|Combination of BI-1206 with rituximab expansion phase|BI-1206 in combination with rituximab at the RP2D.
223846062|NCT05455346|DIAGNOSTIC_TEST|Ultrasound imaging|"Ultrasound B-mode images will be unilaterally collected from the biceps femoris muscle of the dominant limb for each participant using a commercial ultrasound system and linear array transducer. Standardized image locations will correspond to 33%, 50%, and 67% of the thigh length from the ischial tuberosity.~Three repeat longitudinal extended-field-of-view images of the entire biceps femoris muscle will be collected for offline analysis for fascicle length, muscle thickness, and pennation angle. Transverse extended-field-of-view images will be captured at the proximal, mid-belly, and distal locations to determine regional anatomical cross-sectional area of the biceps femoris long head muscle.~To determine changes in tissue stiffness via ultrasound shear wave speed, the same transducer will be placed in the same locations in a longitudinal view. Shear wave maps will be generated by the ultrasound system and shear wave speed measures extracted from the middle of the map."
223846063|NCT05455346|OTHER|Hamstring Eccentric Strength Testing|"Prior to each test, participants will perform a standardized 5-minute general warm-up followed by a task-specific warm-up including 3 sets of submaximal trials. Load increases (5-20%) will be added for each RDL 3-repetition maximum trial attempt until the participant cannot complete 3 repetitions through the full range of motion using proper technique. A 3-minute rest will be administered between all warm-up and testing sets to allow for full recovery.~Participants will kneel on a commercial device used to assess maximum eccentric knee flexor strength via uniaxial load cells with their ankles secured into fixed hooks. Participants will slowly lower their torso to the ground with arms crossed across their chest and without bending at the hips or spine. The maximal test will consist of 1 set of 3 maximal repetitions. If participants can control lower themselves to the ground, then they will hold barbell plates (5-10 lb increments) across their chest while performing the NHE."
223846064|NCT05455346|OTHER|Maximal 60 m Sprint|Following a standardized warm-up, inertial measurement units (IMUs) will be placed on the sternum, sacrum, and bilaterally on the thighs, legs, and foot. Each participant will perform a total of 3 maximal 60 m sprints from a standing position with 1.5-3 min rest in between each trial to minimize the effects of fatigue.
223846065|NCT05455346|OTHER|Romanian Deadlift|The RDL intervention will be performed twice per week for 6 weeks. Participants will hinge at the hips lowering the bar to just below their patella before reversing the movement. The RDL will be performed with a 6 second eccentric component and returning to the start position with a maximal concentric hip extension.
223846066|NCT05455346|OTHER|Nordic hamstring exercise|The NHE will be performed twice per week for 6 weeks. Participants will be instructed to maintain their ankles in a dorsiflexed position, lower themselves as close to the ground as possible at a constant and controlled speed while maintaining a neutral position of the hips and trunk, and to cross their arms in front of their chest.
223846067|NCT01642940|DRUG|Prasugrel|Prasugrel 10mg/day
223846068|NCT01642940|DRUG|Ticagrelor|Ticagrelor 90mg twice a day
223846069|NCT06631365|DEVICE|PrEPsmart mobile app|"The PrEPsmart mobile app is an innovative and comprehensive app to support sexual minority men (SMM) using on-demand pre-exposure prophylaxis (PrEP) or daily PrEP. The PrEPsmart app consists of the following components:~1. PrEP 211 dosing/sex diary and reminders~2. Feedback on PrEP protection levels~3. Quick tips~4. Bi-directional secure messaging"
223846070|NCT06631365|DRUG|Truvada|Combination medication used in Human immunodeficiency virus (HIV) prevention, it blocks virus pathways to infection.
223846071|NCT06631963|BEHAVIORAL|Emotional Awareness and Expression Therapy|Emotional Awareness and Expression Therapy (EAET) is a form of psychotherapy designed to help individuals identify, process, and express emotions that may be linked to physical symptoms or chronic pain. It emphasizes the role of unresolved emotional experiences, such as trauma or interpersonal conflicts, in contributing to physical distress. Through EAET, patients learn to connect their emotions to their physical symptoms, express those emotions in a healthier way, and ultimately reduce both emotional and physical suffering. This therapy has been shown to be effective in treating conditions such as chronic pain, irritable bowel syndrome, and fibromyalgia.
223846072|NCT06629467|BEHAVIORAL|Cognitive-behavioral therapy for smoking cessation|Treatment components will include psychoeducation on the consequences of tobacco use and the benefits of quitting; therapeutic commitment; self-monitoring of cigarette smoking; brief advice on healthy eating behaviors and sleep hygiene, physiological feedback (based on CO levels), training in self-control strategies, stimulus control, management of craving with alternative activities, diaphragmatic breathing, weekly personalized physical activity objectives, and relapse prevention strategies. The protocol consists of a nicotine fading procedure, which consists of a weekly reduction in nicotine intake of 30% (based on both tobacco brands and the number of cigarettes) from the first to the fifth session.
223846073|NCT06629467|BEHAVIORAL|Personalized PA plan|The treatment provider will fix an objective (e.g. go for brisk walking for 30 minutes 3 times this week) for each participant every week according to his/her current PA level, time availability, likes, and fitness level.
223846074|NCT06629467|DEVICE|Fitbit Versa 3|Wearable activity tracker with the functionalities of a watch function, including time, date, calendar, and weather (connection to the internet is required). Physical activity monitoring (steps per day, active minutes per day, plants climbed, heart rate monitoring, time, intensity, caloric expenditure, and exercise type of exercise session), sleep monitoring (sleep time, sleep phases time, sleep quality), stress levels managing and guided breathing application are the main health-related functionalities.
223846075|NCT03349190|DRUG|ULIPRISTAL ACETATE|Ulipristal Acetate (Esmya) administrated for fibroids indication before surgery and IVF/ICSI procedure(retrospective study)
223846076|NCT06630481|DRUG|neoadjuvant therapy|Neoadjuvant chemotherapy, neoadjuvant radiotherapy, or both.
223846077|NCT03874975|DRUG|oral vitamin D|vitamin D and UVB versus UVB alone in psoriatic patients and evaluate patients by PASI score before and after treatment and measure serum vitamin D before and after treatment
223846078|NCT05507463|DRUG|KBP-7072|KBP-7072
223846079|NCT05507463|DRUG|Placebo|Placebo
223846080|NCT01760681|DEVICE|H- Coil DTMS|20 daily deep rTMS treatments
223846081|NCT01760681|DEVICE|Sham|
223846082|NCT05818813|DEVICE|Renal denervation|Renal denervation (ReCor Medical)
223846083|NCT06497634|PROCEDURE|25 PP|Spinal anesthesia will be performed in sitting position, with 25 G pencil point needle (Whitacre -Egemen®) midline through the L4-5 or L5-S1 interspace, parallel to the dural fibers. Upon clear cerebrospinal fluid (CSF) detection, the needle apertures will be turned towards the cephalad direction, and 3 ml (15 mg) of 0.5% hyperbaric bupivacaine (Marcaine Heavy ®) will be injected into the intrathecal space.
223846084|NCT06497634|PROCEDURE|25 Q|Spinal anesthesia will be performed in sitting position, with 25 G sharp edge needle (Quincke -Egemen®) midline through the L4-5 or L5-S1 interspace, parallel to the dural fibers. Upon clear cerebrospinal fluid (CSF) detection, the needle apertures will be turned towards the cephalad direction, and 3 ml (15 mg) of 0.5% hyperbaric bupivacaine (Marcaine Heavy ®) will be injected into the intrathecal space.
223846085|NCT06497634|PROCEDURE|27 Q|Spinal anesthesia will be performed in sitting position, with 27 G sharp edge needle (Quincke -Egemen®) midline through the L4-5 or L5-S1 interspace, parallel to the dural fibers. Upon clear cerebrospinal fluid (CSF) detection, the needle apertures will be turned towards the cephalad direction, and 3 ml (15 mg) of 0.5% hyperbaric bupivacaine (Marcaine Heavy ®) will be injected into the intrathecal space.
223846086|NCT06497634|OTHER|Optic Nerve Sheath Measurement|Sonographic measurement of ONSD (EsaoteMyLabFive, Cenova, Italy) for all patients will be performed by a single experienced anesthesiologist. After a thin gel layer apply to the upper eyelid, the patient in the supine position and with the eyes closed, using a 6-13 MHz linear probe, optic sheath nerve measurement will be done 3 mm behind the optic globe, with a total of three measurements of which the final value will be recorded.The measurement will be repeated five times using US guidance at the following time points: T0 (pre-anesthesia), T1 (5 minutes after spinal block), T2 (15 minutes after spinal block, T3 (tourniquet opening), and T4 (24 hours after spinal block ) respectively.
223846087|NCT03647475|COMBINATION_PRODUCT|Device: Medtronic Resolute Onyx Zotarolimus-Eluting Coronary Stent System Treatment Followed by one-month DAPT|To evaluate the clinical safety of the Resolute Onyx stent with use of one-month DAPT in subjects deemed at high risk for bleeding and/or medically unsuitable for more than one-month DAPT treatment.
223846088|NCT04767230|OTHER|Dietary Intervention|A heart-healthy diet + daily consumption of 30 grams of flaxseed + 25 mL/day of refined olive oil in adjunct to medical treatment for 3 months
223846089|NCT02741011|OTHER|Radiological examination|During the period of two years, mentally handicapped patients were enrolled in this study. First a radiological examination was performed under sedation anesthesia and then an oral examination was performed when patient underwent general anesthesia for dental treatments. Oral and radiological examinations were compared with each other and also with treatment results to define the necessity of the radiological examination of mentally handicapped patients.
223846090|NCT06268210|DRUG|Lazertinib+Pemetrexed+Carboplatin|Lazertinib: 240 mg once daily (pre-/post-surgery for 3 years) Pemetrexed: 500 mg/m2 every 3 weeks (neoadjuvant therapy for 3 cycles) Carboplatin: AUC5 every 3 weeks (neoadjuvant therapy for 3 cycles)
223846091|NCT06268210|DRUG|Lazertinib|Lazertinib will be administered at a dosage of 240 mg once daily, both before and after surgery, for a duration of 3 years.
223846092|NCT01079455|DRUG|Corticosterone|Hyaluronic acid 40 mg / 2 ml Corticosteroids 80 mg / 2 ml Bupivacaine 0.125% / 2 ml
223846093|NCT02821598|OTHER|Upper Limb pattern with flexion - abduction - external rotation|"The PNF pattern will be applied three times. Participants will be in supine position under a stretcher, with arms folded and lower limbs in neutral position. In order to induce irradiation for the contralateral lower limb, the left foot sole will be kept in contact with the wall. For EMG recording, the participant will be positioned at the end of the PNF pattern and then the isometric contraction will be solicited. The command used was: do not let me move you."
223846094|NCT02821598|OTHER|Lower Limb pattern with flexion - adduction - external rotation with knee flexion|"The PNF pattern will be applied three times. Participants will be in supine position under a stretcher, with arms folded and lower limbs in neutral position. In order to induce irradiation for the contralateral lower limb, the left foot sole will be kept in contact with the wall. For EMG recording, the participant will be positioned at the end of the PNF pattern and then the isometric contraction will be solicited. The command used was: do not let me move you."
223846095|NCT02821598|OTHER|Lower Limb pattern with flexion - abduction - internal rotation with knee flexion|"The PNF pattern will be applied three times. Participants will be in supine position under a stretcher, with arms folded and lower limbs in neutral position. In order to induce irradiation for the contralateral lower limb, the left foot sole will be kept in contact with the wall. For EMG recording, the participant will be positioned at the end of the PNF pattern and then the isometric contraction will be solicited. The command used was: do not let me move you."
223846096|NCT02821598|OTHER|Lifting to the right|"The PNF pattern will be applied three times. Participants will be in supine position under a stretcher, with arms folded and lower limbs in neutral position. In order to induce irradiation for the contralateral lower limb, the left foot sole will be kept in contact with the wall. For EMG recording, the participant will be positioned at the end of the PNF pattern and then the isometric contraction will be solicited. The command used was: do not let me move you."
223846097|NCT02821598|OTHER|Sit to Stand|"Subjects will be sitting on a chair without armrests with ankles positioned at approximately 10 degrees of dorsiflexion. Knees will be kept at approximately 100 degrees of flexion. During the task, the participant will be instructed to stand from the sitting position while keeping their arms crossed over the chest. The examiner will give the command ready - set - go. The task will be performed three times."
223846098|NCT04575805|BEHAVIORAL|Internet-delivered Combined Cognitive Bias Modification (iCBM-C)|The iCBM-C is online CBM intervention which is the combination of iCBM-I and iCBM-A interventions for obsessive-compulsive symptoms delivered in eight sessions, twice per week for 4 weeks. The presentation order of the two intervention components will be counterbalanced to allow exploration of any order effects. Thereby, half of the participants in iCBM-C group will complete the iCBM-A task followed by iCBM-I, while the other half will complete the iCBM-I task followed by iCBM-A during each session.
223846099|NCT04575805|BEHAVIORAL|Internet-delivered Cognitive Bias Modification-Interpretation (iCBM-I)|The iCBM-I is online CBM intervention for obsessive-compulsive symptoms comprised of delivery of OCD related scenarios taking place over eight sessions, twice per week for 4 weeks.
223846100|NCT04575805|BEHAVIORAL|Internet-delivered Cognitive Bias Modification-Attention (iCBM-A)|The iCBM-A is online CBM intervention for obsessive-compulsive symptoms comprised of delivery of the modified dot-probe task taking place over eight sessions, twice per week for 4 weeks.
223846101|NCT02741479|OTHER|Airplane Test|"The airplane test requires the subject to bend forward, bringing the upper body and one leg horizontal, making a T position with the body with the arms out to the sides while in single-leg stance; they then bend the supporting leg, bringing the finger tips towards the floor, followed by straightening the supporting leg and bringing the arms back out to the sides. This motion is repeated five times on each leg per trial. The airplane will be performed to a metronome to standardize performance time"
223846102|NCT04106440|BEHAVIORAL|Application Use|Use applications after initial diagnosis to share information with study team.
223846103|NCT01827410|PROCEDURE|Ventral hernia repair|
223846104|NCT05205993|DRUG|Intrauterine infusion|A total of 10 intrauterine infusions of 3ml of ciprofloxacin at a concentration of 200 mg/100 ml
223846105|NCT05205993|DRUG|Oral administration|per os antibiotic administration as the standard line of strategy for treating CE of doxycycline at a dosage of 100mg twice a day and metronidazole of 500mg twice a day for a total of 30 days
223846106|NCT03574909|DRUG|Aspirin|Tromalyt® 150mg prolong release capsule for oral ingestion. The capsule contains 150mg of anti-platelet agent acetylsalicylic acid, maize starch and Sucrose 20:80. The capsule also contains Copovidone (Kollidon VA-64), Eudragit L, Ethylcellulose and Triacetin. The capsule is made with gelatin, erythrosine, quinoline yellow, titanium dioxide.
223846107|NCT03574909|DRUG|Placebos|Size 0 hard gelatin capsules containing 99% of microcrystalline cellulose and 1% of magnesium stearate (Sanitatis®). The capsules contain 198mg microcrystalline cellulose and 2mg of magnesium stearate
223846108|NCT03089619|DRUG|Human-Spongiosa|after tooth extraction, the dental alveolus is filled with the bone substitute material (Human-Spongiosa) and covered with a membrane (mucoderm®)
223846109|NCT03089619|DEVICE|collacone®|after tooth extraction, the dental alveolus is filled with the bone substitute material (collacone®) and covered with a membrane (mucoderm®)
223846110|NCT05414565|DEVICE|Vivity IOL|Commercially available extended vision IOL
223846111|NCT05414565|DEVICE|Aspheric monofocal IOL|Commercially available aspheric IOL
223846112|NCT02470624|OTHER|treatment following current guideline|
223846113|NCT05518513|DRUG|Bupivacain|adductor canal block with 0.25% bupivacaine
223846114|NCT04541186|DRUG|Pegozafermin|Subcutaneous injection
223846115|NCT04541186|DRUG|Placebo|Matching placebo
223846116|NCT06445231|DIAGNOSTIC_TEST|Implementation of echocardiography in nursing homes|An ultrasound will be carried out in the EHPAD, the result of which will be interpreted by a cardiologist then sent to the establishment and the attending physician with instructions to follow.
223846117|NCT00094250|BEHAVIORAL|Resistance and Aerobic Training|
223846118|NCT00045695|DRUG|bortezomib|PS-341 bolus intravenous injection twice weekly\* for 2 out of every 3 weeks
223846119|NCT01245777|DRUG|ferric carboxymaltose|20 women with Restless Legs Syndrome (RLS) and iron deficiency and/ or anaemia in the third trimester of pregnancy will receive intravenous Ferric carboxymaltose in one or two single doses.
223846120|NCT04370236|DRUG|INB03|Patients will receive up to two once per week subcutaneous injections of 1mg/kg INB03
223846121|NCT04370236|DRUG|Placebo|Patients will receive up to two once per week subcutaneous injections of Placebo
223846122|NCT02893540|DRUG|Capecitabine|we are going to compare two maintenance treatment models with capecitabine in this study
223846123|NCT04543344|DRUG|Recifercept|recifercept powder for solution for injection
223846124|NCT04543344|OTHER|Placebo|solution for injection
223846125|NCT01719289|BEHAVIORAL|PROGRAVIDA|Women in the intervention group receive a program based on psycho-education and problem solving techniques, delivered by a nurse assistant at the women's homes. The program comprises 8 sessions, 6 during pregnancy and 2 after delivery. Intensity of depressive symptoms is assessed using the PHQ-9, at the beginning of the sessions. Women with severe depression are referred to the family doctor and are assessed for the need of antidepressant medication.
223846126|NCT02224833|BEHAVIORAL|Pharmacist intervention|"Systematic review of treatments:~Identification of reasons for PPI.~* Determination of recommended pharmacotherapeutic alternatives.~* Issue recommendations for therapeutic appropriateness to the doctor (via registration on the EHR and verbal communication if deemed appropriate); that will be of 4 types: Add medicine, discontinue medicine, adjust dosage, replace medicine.~After the medical visit (the next day) New treatment review for: Checking acceptance or rejection of the recommendations issued, review potential new prescriptions made without pharmacist recommending, and whether these new drugs lead to PIP."
223846127|NCT05954169|DRUG|SHR4640|SHR4640 single-dose
223846128|NCT05331495|DEVICE|Intraoperative Hemoperfusion|During the operation, the hemoperfusion device and the membrane oxygenator of the extracorporeal circulation device were operated in parallel.
223846129|NCT00691028|DRUG|TA-650 3 mg/kg|3 mg/kg of TA-650 will be intravenously infused over a period of more than 2 hours at weeks 0, 2 and 6. Then 3 mg/kg of TA-650 will be intravenously infused over a period of more than 2 hours at weeks 14, 22, 30, 38 and 46.
223846130|NCT00691028|DRUG|TA-650 6 mg/kg|3 mg/kg of TA-650 will be intravenously infused over a period of more than 2 hours at weeks 0, 2 and 6 weeks. Then 6 mg/kg of TA-650 will be intravenously infused over a period of more than 2 hours at weeks 14, 22, 30, 38 and 46.
223846131|NCT00691028|DRUG|TA-650 10 mg/kg|3 mg/kg of TA-650 will be intravenously infused over a period of more than 2 hours at weeks 0, 2 and 6. Then 10 mg/kg of TA-650 will be intravenously infused over a period of more than 2 hours at weeks 14, 22, 30, 38 and 46.
223846132|NCT02349113|DRUG|Estrogens (Climara)|Treatment with estrogens: Estradiol dermal patch 0.1mg/d transdermally
223846133|NCT03085017|DEVICE|BoneSeal|BoneSeal® is an absorbable synthetic bone hemostats that also contains of PLA, PEG and hydroxyapatite which supports bone re-growth. Product code MTJ. FDA number K142348.
223846134|NCT03085017|DEVICE|Ostene|OSTENE is a synthetic, biodissolvable implant material that, provides immediate bone hemostasis, can be used on all bleeding bone surfaces, is completely biocompatible and water-soluble polymer, is a mechanical barrier that does not act biochemically.
223846135|NCT00058058|PROCEDURE|MRI|Breast contralateral to the breast diagnosed with cancer was scanned prior to initiation of chemotherapy and within 90 days of a negative mammogram of the study breast. A recent (within 90 days) negative or benign mammogram (defined by final BI RADS category 1 or 2) and negative or benign clinical breast exam of the study breast were required for entry into the study.
223846136|NCT01528124|DRUG|LY3025876|Given as a subcutaneous injection
223846137|NCT01528124|DRUG|Placebo|Given as a subcutaneous injection
223846138|NCT06300840|DEVICE|BalanceBelt|The vibrotactile belt (i.e., Elitac BalanceBelt®) supports patients with severe balance disorders by substituting the missing balance information with vibrations (haptic feedback).
223846139|NCT00233129|BEHAVIORAL|Top Down|Six months
223846140|NCT00233129|OTHER|cognitive rehabilitation day treatment program|six months
223846141|NCT03382743|DRUG|Endocervical Lidocaine spray|5 sprays of endocervical Lidocaine spray (10%) is used 3 minutes before office hysteroscopy
223846142|NCT06141746|DEVICE|Lung ultrasound|Early detection of fluid accumulation in alveolar, interstitial and intracellular compartments of the lung due to intravascular absorption of irrigation fluid of PNL guided by lung ultrasound by detection of sonographic B lines.
223846143|NCT06340789|DRUG|Sodium Benzoate 2gram/day|the add-on sodium benzoate with conventional pharmacological treatment
223846144|NCT06340789|DRUG|Placebo|the add-on placebo with conventional pharmacological treatment
223846145|NCT02874261|DEVICE|Whole Body Periodic Acceleration|oscillating bed that the subject will lie on 3 days a week for 45 minutes at 140 cycles per minute.
223846146|NCT02375321|BEHAVIORAL|CPAP and Psychological support|Six sessions of psychological support with cognitive behavioural orientation lasting 1 hour every two weeks for 3 months
223846147|NCT06042114|BEHAVIORAL|Surah Inshirah|Patients in the experimental group will be listened to the Surah al-Inshirah after surgery and its effect on pain and anxiety levels will be evaluated.
223846148|NCT00360126|DRUG|lamotrigine|
223846149|NCT05337072|DIAGNOSTIC_TEST|Microbiome study|Investigation of the vaginal and endometrial microbiome
223846150|NCT03049696|BEHAVIORAL|ENCOURAGEING START|16-week physical activity and behaviour modification/education program. CMBS approved bariatric surgery patients participate in structured, supervised physical activity sessions (2 per week) and behaviour modification-education classes during weeks 1 through 8. During weeks 9 through 16, patients will be given access to attend drop in physical activity sessions or can opt to complete physical activity at home.
223846151|NCT02596906|DEVICE|tDCS|Prior to the reasoning training, participants will undergo tDCS. Participants will receive 20 minutes of tDCS using 2mA or less targeting the inferior frontal gyrus prior to each of their 8 reasoning training sessions for a total of 160 total combined minutes. This time does not include set up time which should take no more than 5 minutes. A brief engaging film is shown to participants during the 20 minute session.
223846152|NCT02596906|DEVICE|Sham tDCS|For the sham tDCS group, the device will be turned off after 30s. The only reported sensations from tDCS is an itching or a tingling when the device turns on but disappears quickly. Thus, those receiving sham tDCS will be unaware that the device has turned off, and will experience an initial tingling similar to that received in the tDCS group.
223846153|NCT04647162|PROCEDURE|hematoma evacuation by craniotomy|The intervention method of hematoma evacuation is under craniotomy.
223846154|NCT04647162|PROCEDURE|hematoma evacuation by stereotactic puncture|The intervention method of hematoma evacuation is under stereotactic puncture.
223846155|NCT04647162|PROCEDURE|hematoma evacuation by neuroendoscopy|The intervention method of hematoma evacuation is under neuroendoscopy.
223846156|NCT04647162|OTHER|life support|The treatments in medical group includes life support, nutrition support, and rehabilitation therapy。
223846157|NCT03255018|BIOLOGICAL|Pembrolizumab|Administered intravenously (IV) at a fixed dose of 200 mg every 3 weeks until disease progression or unacceptable toxicity; treatment may continue indefinitely if clinical benefit with options for treatment interruption if responding disease and re-treatment upon relapse.
223846158|NCT04835584|DRUG|KRT-232|KRT-232 is an experimental MDM2 inhibitor anticancer drug taken by mouth.
223846159|NCT04835584|DRUG|Dasatinib|Dasatinib is a Tyrosine Kinase Inhibitor anticancer drug taken by mouth.
223846160|NCT04835584|DRUG|Nilotinib|Nilotinib is an Tyrosine Kinase Inhibitor anticancer drug taken by mouth.
223846161|NCT01105494|DRUG|epoetin beta [NeoRecormon]|As prescribed by physician
223846162|NCT03379415|DEVICE|Footwear|Different types of footwear will be tested to see if these can be used to help slow the progression of osteoarthritis in meniscectomy patients or even stop it from occurring.
223846163|NCT03379415|PROCEDURE|Gait analysis|Gait analysis will be done during several different tasks wear the footwear
223846164|NCT03601143|OTHER|Blood samples prior to a new line of AR-targeted therapy|Blood will be drawn at baseline prior to a new line of AR-targeted therapy.
223846165|NCT00450892|DRUG|docetaxel+lapatinib|3 cycles of docetaxel (100 mg/m²) + lapatinib (1000 mg/d) followed by 3 cycles of FEC
223846166|NCT00450892|DRUG|docetaxel + trastuzumab|3 cycles of docetaxel (100 mg/m²) + trastuzumab weekly schedule followed by 3 cycles of FEC 100
223846167|NCT00450892|DRUG|docetaxel + trastuzumab + lapatinib|"3 cycles of docetaxel (100 mg/m²) + trastuzumab weekly schedule~+lapatinib (1000 mg/d) followed by 3 cycles of FEC 100"
223846168|NCT05262972|OTHER|Conservatory treatment|Personalized plantar orthosis
223846169|NCT05262972|OTHER|Innovate treatment|Personalized plantar orthosis + percutaneous electrolysis
223846170|NCT03381430|DRUG|Gefitinib|Gefitinib 250 mg/day oral daily
223846171|NCT04986540|DRUG|SHR-1906；Placebo|"Drug: SHR-1906 IV, single dose~Drug: Placebo IV, single dose"
223846172|NCT01495507|PROCEDURE|MPFL- Reconstruction|
223846173|NCT00790062|DRUG|Oxytocin|See arms
223846174|NCT03504449|OTHER|neoadjuvant chemoradiotherapy|
223846175|NCT02365896|PROCEDURE|TLDG or LADG|
223846176|NCT00874796|DRUG|GS-9450|Taken as one capsule by mouth once daily
223846177|NCT00874796|DRUG|Placebo|Taken as one placebo capsule (matching in appearance to GS-9450 capsules) by mouth once daily
223846178|NCT00886808|DRUG|iCo-007 Intravitreal Injection|single dose iCo-007 Intravitreal Injection
223846179|NCT02157714|DRUG|PRX002|
223846180|NCT02157714|OTHER|Placebo|
223846181|NCT01711918|DRUG|Domperidone|oral tablet; dose is 10mg per tablet given up to 3 times daily.
223846182|NCT05886751|OTHER|Black Doctor Screening Video|Participants will view an online video with a Black doctor speaking about prostate cancer screening.
223846183|NCT05886751|OTHER|White Doctor Screening Video|Participants will view an online video with a White doctor speaking about prostate cancer screening.
223846184|NCT05886751|OTHER|Black Patient Screening Video|Participants will view an online video with a Black patient speaking about prostate cancer screening.
223846185|NCT05886751|OTHER|White Patient Screening Video|Participants will view an online video with a White patient speaking about prostate cancer screening.
223846186|NCT05886751|OTHER|Black Doctor Clinical Trials Video|Participants will view an online video with a Black doctor speaking about prostate cancer clinical trials.
223846187|NCT05886751|OTHER|White Doctor Clinical Trials Video|Participants will view an online video with a White doctor speaking about prostate cancer clinical trials.
223846188|NCT05886751|OTHER|Black Patient Clinical Trials Video|Participants will view an online video with a Black patient speaking about prostate cancer clinical trials.
223846189|NCT05886751|OTHER|White Patient Clinical Trials Video|Participants will view an online video with a White patient speaking about prostate cancer clinical trials.
223846190|NCT01227642|OTHER|An ultrasound-based technique to identify prostate cancer|The technique uses current ultrasound equipment already in use for prostate brachytherapy guidance.By extracting and processing the radiofrequency signal obtained from the ultrasound transducer in ways not done to create the standard B-mode ultrasound image, areas of cancer can be identified and displayed overlying the standard B-mode ultrasound image. Comparing the results with this technique to the results of prostate biopsies demonstrates a high degree of accuracy with the area under the receiver-operator characteristic curve of 0.87, a result superior to any other imaging methods.
223846191|NCT01227642|OTHER|pre-implant transrectal ultrasound images and planning|an ultrasound-based technique to identify cancer-containing areas within the prostate.
223846192|NCT01227642|OTHER|ultrasound-based cancer-specific images|ultrasound-based cancer-specific images of the prostate prior to the brachytherapy and use them to direct the dosimetry planning
223846193|NCT06564831|OTHER|SLAM + SOC|Weekly Treatment visits for 12 weeks begin at day 0. SLAM applications with SOC until ulcer closure, or a maximum of 12 weeks, whichever occurs first.
223846194|NCT06564831|OTHER|SOC|Beginning at the screening visit, participants will receive weekly treatment with standard of care (cleaning, debridement, ulcer moisture balance, and offloading) until ulcer closure, or a maximum of 12 weeks, whichever occurs first.
223846195|NCT04124068|OTHER|Hydrogen peroxide teeth whitening gel|Hydrogen peroxide teeth whitening gel with concentrations ranging between 6% - 30%
223846196|NCT04124068|DEVICE|GLO Brilliant Teeth Whitening Device|Intra-oral mouthpiece connected to a battery in order to generate light and heat to effect the whitening treatment.
223846197|NCT04124068|DEVICE|GLO Lit Teeth Whitening Device|Intra-oral mouthpiece connected to a battery in order to generate light and heat to effect the whitening treatment.
223846198|NCT04124068|DEVICE|GLO Science Professional Teeth Whitening Device|Intra-oral mouthpiece connected to a battery in order to generate light and heat to effect the whitening treatment.
223846199|NCT02111148|PROCEDURE|Urea and creatinine|the vagina will be washed with 5ml saline, urea and creatinine will be detected biochemically in the vaginal wash.
223846200|NCT02111148|PROCEDURE|Nitrazine|Nitrazine detection in vaginal wash
223846201|NCT02111148|DRUG|5ml saline|the vagina will be washed with 5ml saline and vaginal wash will be collected.
223846202|NCT05054400|DRUG|F18 Fluciclovine|Given by IV
223846203|NCT05054400|OTHER|Standard of Care|Standard of care
223846204|NCT01360840|DRUG|EMD 525797|Subjects will be administered with EMD 525797 at a dose of 1500 milligram (mg) (diluted with 0.9 percent \[%\] sodium chloride) as a 1-hour intravenous infusion every 3 Weeks until disease progression or unacceptable toxicity, whichever comes first, unless the subject stopped the trial treatment for other reasons.
223846205|NCT01360840|DRUG|EMD 525797|Subjects will be administered with EMD 525797 at a dose of 750 mg (diluted with 0.9% sodium chloride) as a 1-hour intravenous infusion every 3 Weeks until disease progression or unacceptable toxicity, whichever comes first, unless the subject stopped the trial treatment for other reasons.
223846206|NCT01360840|OTHER|Placebo|Subjects will be administered with placebo (as 0.9% sodium chloride) as a 1-hour intravenous infusion every 3 Weeks until disease progression or unacceptable toxicity, whichever comes first, unless the subject stopped the trial treatment for other reasons.
223846207|NCT01360840|OTHER|Standard of Care (SoC)|All the subjects followed the SoC consisting of the continued treatment with luteinizing-hormone releasing hormone agonists (or antagonists).
223846210|NCT04201015|DEVICE|Heart rate optimisation using force frequency data|Programming heart rate rise according to the force frequency relationship
223846211|NCT00959803|DRUG|PF-04447943|3 mg solution, oral single dose.
223846212|NCT00959803|DRUG|PF-04447943|10 mg solution, oral single dose.
223846213|NCT00959803|DRUG|PF-04447943|25 mg solution, oral single dose.
223846214|NCT00959803|DRUG|Placebo|Solution, oral single dose.
223846215|NCT00959803|DRUG|PF-04447943|25 mg solution, oral twice daily for 7 days.
223846216|NCT00959803|DRUG|Placebo|Solution, oral twice daily for 7 days.
223846217|NCT02300779|DIETARY_SUPPLEMENT|Low-residue diet|"Subjects will be instructed by members of the research team to follow a low-residue diet for 4 days.~Bowel cleansing will begin at 9:00 pm on the evening before the colonoscopy is scheduled. Participants will take 8 sachets of the investigational product and take their contents diluted in 2 liters of water. Eight other sachets, also diluted in 2 liters of water will be taken 4 to 5 hours before the procedure.~Fasting will be required from 2 hours after the bowel cleansing is complete. Their usual treatment for diabetes (whether insulin or an oral agent) will be adjusted."
223846218|NCT02300779|DIETARY_SUPPLEMENT|Usual care|"Subjects will be instructed by members of the research team to follow a low-residue diet for 3 days followed by a liquid-only diet for an additional day.~Bowel cleansing will begin at 9:00 pm on the evening before the colonoscopy is scheduled. Participants will take 8 sachets of the investigational product and take their contents diluted in 2 liters of water. Eight other sachets, also diluted in 2 liters of water will be taken 4 to 5 hours before the procedure.~Fasting will be required from 2 hours after the bowel cleansing is complete. No modifications in their usual treatment will be made."
223846219|NCT06026358|DRUG|Tirbanibulin|subjects receive 2,5 mgTirbanibulin in 250 mg ointment with daily administration of one single sachet on the left hand and 250mg ointment placebo on the right hand for 5 d in a single-blinded manner.
223846220|NCT03471468|PROCEDURE|kinetics of microparticles under chemotherapy|Blood samples done before chemotherapy and 6 hours later for each of six chemotherapies required by the protocol.
223846221|NCT04007003|BEHAVIORAL|training in optimal insulin injection technique|the training will be delivered in person as well as through online training modules via the BD and Me(TM) platform
223846222|NCT05204784|PROCEDURE|Rheopheresis treatment|After obtaining venous access, anticoagulated blood is pumped through a plasmafilter. The plasma is then run through the Rheofilter and large plasma proteins are removed. Finally, cells are reinfused, and blood is returned to the patient.
223846223|NCT05204784|DRUG|Intravenous Infusion|Standard of care treatment consists of intravenous iloprost infusions at a dose of 0.5-2 ng/kg/min administered over at least 6 hours as per local standard
223846224|NCT02442544|DIETARY_SUPPLEMENT|Prebiotic|1:1 oligofructose: inulin 8 g orally /day
223846225|NCT02442544|DIETARY_SUPPLEMENT|Placebo|maltodextrin 3.3g orally/day
223846226|NCT00930189|DRUG|intravitreal injection of ranibizumab|
223846227|NCT00930189|DRUG|intravitreal injection of triamcinolone|
223846228|NCT00930189|PROCEDURE|photodynamic therapy|
223846229|NCT00207649|BEHAVIORAL|Shared decision-making for PSA screening tool|Interventions to Improve Shared Decision-Making: Prostate Cancer Screening is a prospective study of educational interventions to improve shared decision-making of physicians and their patients about prostate cancer screening. Physicians will be randomized by practice site to receive standard informational brochures (control group) or a novel web-based interactive curriculum that provides education about prostate cancer screening, including potential benefits and harms, fundamentals of effective patient counsel, and shared decision-making. In addition, patients at intervention sites will be randomized to receive either the brochure or a patient-oriented interactive curriculum covering content similar to that contained in the physician tool. Physicians in all groups will also see one unannounced standardized patient (SP) trained to portray a patient interested in discussing PSA.
223846230|NCT03199885|DRUG|Atezolizumab|Given IV
223846231|NCT03199885|PROCEDURE|Biopsy|Undergo biopsy
223846232|NCT03199885|PROCEDURE|Bone Scan|Undergo bone scan
223846233|NCT03199885|PROCEDURE|Computed Tomography|Undergo CT scan
223846234|NCT03199885|DRUG|Docetaxel|Given IV
223846235|NCT03199885|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223846236|NCT03199885|DRUG|Paclitaxel|Given IV
223846237|NCT03199885|BIOLOGICAL|Pertuzumab|Given IV
223846238|NCT03199885|OTHER|Placebo Administration|Given IV
223846239|NCT03199885|OTHER|Quality-of-Life Assessment|Ancillary studies
223846240|NCT03199885|BIOLOGICAL|Trastuzumab|Given IV
223846241|NCT06209359|DRUG|Ammonium Chloride|Participants will be randomized to receive either ammonium chloride or placebo. Participants will receive randomized drug in combination with IV bumetanide, bendroflumethiazide, and amiloride. Following a washout period, participants will be crossed over to the alternate drug.
223846242|NCT06209359|DRUG|Placebo|Participants will be randomized to receive either ammonium chloride or placebo. Participants will receive randomized drug in combination with IV bumetanide, bendroflumethiazide, and amiloride. Following a washout period, participants will be crossed over to the alternate drug.
223846243|NCT06356272|OTHER|Non-Interventional Study|Non-interventional study
223846244|NCT04680702|DIAGNOSTIC_TEST|Sims Score|Evaluation Of siMS Score As Amarker Of Metabolic Syndrome In Children With Simple Obesity
223846245|NCT00802490|DEVICE|Brain-Computer Interface System|Newly-developed video games employing neurofeedback strategy to be played twice a week, 1 hour per session for a period of ten weeks.
223846246|NCT00802490|DEVICE|Brain-Computer Interface System|Newly-developed video games employing neurofeedback strategy to be played once for 1 hour.
223846247|NCT02311192|DEVICE|Ultrasonography B-scan|The patient's eye will be anesthetized. The ultrasound probe will then be used to obtain images by keeping the probe in light contact with the eye.
223846248|NCT03229889|DRUG|Cialis 5Mg Tablet|Cialis is a PDE-5 inhibitor that has been shown to relax smooth muscle. Patients will be asked to 1 pill for 7 days prior to surgery.
223846249|NCT03229889|DRUG|Flomax 0.4Mg Capsule|Tamsulosin is an alpha-blocker that has been shown to relax smooth muscle in the genitourinary system. Patients will be asked to 1 pill for 7 days prior to surgery.
223846250|NCT03229889|COMBINATION_PRODUCT|Cialis + Flomax|Cialis is a PDE-5 inhibitor that has been shown to relax smooth muscle. Tamsulosin is an alpha-blocker that has been shown to relax smooth muscle in the genitourinary system. A combination of these two drugs may increase the relaxation effects in the ureter. Patients will be asked to 1 of each pill for 7 days prior to surgery.
223846251|NCT03229889|DRUG|Placebo|This is plant cell based pill that contains no active ingredient. Patients will be asked to 1 pill for 7 days prior to surgery.
223846252|NCT05023720|OTHER|nonintervention|
223846253|NCT05650294|DIETARY_SUPPLEMENT|PL+ omega 3 fatty acids|PL+ omega 3 fatty acids is a food supplement that combines krill oil and FO EE. The dose will be around 1250 mg EPA+DHA.
223846254|NCT05650294|DIETARY_SUPPLEMENT|FO EE fatty acids|A conventional fish oil food supplement containing EPA and DHA in the EE form. The dose will be 1250 mg EPA+DHA.
223846255|NCT01351038|DRUG|Epirubicine, Oxaliplatin, Capecitabine, Panitumumab|3 cycles (repeated q 21d) Epirubicine 50mg/m² i.v. d1 Oxaliplatin 100mg/m² i.v. d1 Panitumumab 9mg/kg i.v. d1 Capecitabine 500mg/m² bid d1-21
223846256|NCT03405415|DEVICE|Blood glucose monitoring system and continuous interstitial glucose monitoring system|"At enrolment, participants are provided with BGM (Blood Glucose Monitoring) and CGM (Continuous Glucose Monitoring) systems. They will use the systems throughout the study. Participants will visit the study site three times. During the first visit, a standardized oral glucose tolerance test will be performed to ensure that participants do not have diabetes mellitus and to obtain glucose concentration data from people without diabetes mellitus during a glucose challenge. On another two days, participants will visit the study site for standardized breakfast and lunch meals to provide glucose concentration data under standardized conditions.~Outside of the study site visits, participants are asked to eat similar meals on two days to obtain glucose concentration data under repeated conditions that represent daily life.~During the study, participants are asked to document meals, physical activity and addition comments to provide context to the recorded glucose concentration data."
223846257|NCT01373047|BIOLOGICAL|anti-CEA 2nd generation designer T cells|Three infusions of gene-modified T cells over the course of 6 weeks into the hepatic artery via a percutaneous approach.
223846258|NCT02700685|DIETARY_SUPPLEMENT|Pycnogenol|Dietary supplement, standardised extract of French maritime Pine bark. This group receives a nutritional supplement for a period of 10 weeks.
223846259|NCT02700685|DRUG|Methylphenidate|Standard pharmaceutical treatment for ADHD, slow release.
223846260|NCT02700685|OTHER|Placebo|Placebo treatment (identical capsules containing excipients only)
223846261|NCT05421845|BEHAVIORAL|mobile-based combining with hospital-based lifestyle interventions|The same as that stated in arm descriptions.
223846262|NCT00252993|DRUG|DDP225|
223846263|NCT01145144|DRUG|dehydroepiandrosterone crystalline fine powder|
223846264|NCT01883765|BEHAVIORAL|Neurofeedback active|
223846265|NCT01883765|BEHAVIORAL|Neurofeedback sham|
223846266|NCT01883765|BEHAVIORAL|Metacognitive Training|
223846267|NCT03122964|DIAGNOSTIC_TEST|AssureMDx|combined panel of methylation and mutation markers for the detection of bladder cancer
223846268|NCT04038281|OTHER|Sensory tests|Fat, bitter taste sensitivity and food preference measurement
223846269|NCT05102903|DRUG|BR1016A|All subjects who have been fasting for at least 10 hours prior to administration will take 1 tablet of study drug or comparator orally with 150 mL of water at room temperature at around 8 a.m. on the administration day of each period.
223846270|NCT05102903|DRUG|BR1016B|All subjects who have been fasting for at least 10 hours prior to administration will take 1 tablet of study drug or comparator orally with 150 mL of water at room temperature at around 8 a.m. on the administration day of each period.
223846271|NCT00746928|OTHER|Chronic Intermittent Hypoxia|Chronic Intermittent Hypoxia mimicking the CIH undergone by patients suffering from Sleep Apnea Syndrome, is applied to Healthy subject during 8 hours a day (nights) for a 14 days period. The cycle of intermittent Hypoxia is 30 drop in SaO2 per hours with a 10% decrease in SaO2.
223846272|NCT01813422|BIOLOGICAL|Evolocumab|Administered by subcutaneous injection
223846273|NCT01813422|DRUG|Placebo|Administered by subcutaneous injection
223846274|NCT06231485|BEHAVIORAL|STEPS2|One of the two health education curricula as described in arm/group descriptions.
223846275|NCT06231485|BEHAVIORAL|STYH|One of the two health education curricula as described in arm/group descriptions.
223846276|NCT06528977|OTHER|Western Diet|Consumption of 10 days of a diet high in added sugars (25% of total caloric intake)
223846277|NCT02212886|DRUG|GA Depot 80 mg|Recruitment completed
223846278|NCT02212886|DRUG|GA Depot 40 mg|Recruitment completed
223846279|NCT02734368|DRUG|Hyperpolarized Helium-3|
223846280|NCT00816582|PROCEDURE|Diagnostic Imaging: 18F-FDG PET/CT Scan - Baseline|A18F-FDG PET/CT scan performed at baseline, prior to starting the fulvestrant treatment, to identify the sites involved by the subject's cancer.
223846281|NCT00816582|PROCEDURE|Diagnostic Imaging: 18F-FES PET/CT - Baseline|A 18F-FES PET/CT scan performed at baseline, prior to starting the fulvestrant treatment, to determine the hormone receptor content of the sites involved by the breast cancer.
223846282|NCT00816582|PROCEDURE|Diagnostic Imaging: 18F-FES PET/CT - 3 month follow-up|A 18F-FES PET/CT scan performed after three (3) monthly injections of fulvestrant to determine whether estrogen uptake is blocked by fulvestrant.
223846283|NCT02742051|DRUG|Everolimus|Neoadjuvant endocrine therapy
223846284|NCT02742051|DRUG|Letrozole|Neoadjuvant endocrine therapy
223846285|NCT02742051|DRUG|Fluorouracil|Neoadjuvant chemotherapy
223846286|NCT02742051|DRUG|Epirubicin|Neoadjuvant chemotherapy
223846287|NCT02742051|DRUG|Cyclophosphamide|Neoadjuvant chemotherapy
223846288|NCT01781910|DIETARY_SUPPLEMENT|Branched Chain Amino Acid drink supplement|
223846289|NCT01781910|DIETARY_SUPPLEMENT|Placebo|
223846290|NCT02312440|DRUG|0.9% sodium chloride|The normal saline solution will be prepared under sterile conditions. In the operation room the sterile bag containing the solution will be given to the scrub nurse. The contents (60 ml) will be emptied in a sterile surgical bowl and the nurse will ask the surgeon to apply the solution before wound closure.The dosage and applying route can also be looked up in doctor's order sheet.
223846291|NCT02312440|DRUG|tranexamic acid|The Tranexamic Acid solution will be prepared under sterile conditions. In the operation room the sterile bag containing the solution will be given to the scrub nurse. The contents (60 ml) will be emptied in a sterile surgical bowl and the nurse will ask the surgeon to apply the solution before wound closure.The dosage and applying route can also be looked up in doctor's order sheet.
223846292|NCT02312440|DRUG|tranexamic acid|"The Tranexamic Acid solution will be prepared under sterile conditions. In the operation room the sterile bag containing the solution will be given to the circuit nurse and the circuit nurse will ask the anesthetist to apply the solution intravenously before tourniquet deflation. The dosage and applying route can also be looked up in doctor's order sheet.~60 Milliliters（ml） by irrigation for 3 minutes before wound closure."
223846293|NCT00487721|DRUG|Silibin-Phytosome|Subjects will take Silibin-Phytosome for 2-10 weeks. The dose of Silibin-Phytosome is 13 grams daily, in three divided doses. Patients will be asked to mix 1 level teaspoon and 1 heaping ¼ teaspoon of Silybin-Phytosome powder into 6 tablespoons of applesauce for each dose.
223846294|NCT00547261|DRUG|SSR97225|every 3 weeks
223846295|NCT00004870|BIOLOGICAL|oblimersen sodium|
223846296|NCT00004870|DRUG|irinotecan hydrochloride|
223846297|NCT01800955|DEVICE|resistive capacitive diathermy treatment (resistive capacitive diathermy, Hcr 902, Unibell)|The resistive capacitive diathermy is a medical device supplying low (448 KHz) radiofrequencies with maximum output power of 200 W. It is used to reduce pain and inflammation and allowing healing processes. diathermy treatment is administered for a thirty minutes session, three times per week for a total of ten sessions.
223846298|NCT01800955|OTHER|sham placebo resistive capacitive diathermy treatment|"The sham treatment is administered with the diathermy device set on on but not active (not supplying energy) and the treatment session has the same modalities, frequency and duration of experimental diathermy group"
223846299|NCT04173845|DRUG|Tianqi Pingchan Granule|Tianqi Pingchan Granule are given twice a day
223846300|NCT04173845|DRUG|Tianqi Pingchan Granule Placebo|Tianqi Pingchan Granule Placebo
223846301|NCT05092932|OTHER|Normal Foot Force|LoadSol Insoles will be inserted into the participants shoes. The device measures the pressure distribution on the bottom of the foot. Participants will then be asked to walk normally, use crutches, use a walker, and use a wheeled knee scooter. The pressure placed throughout the foot will be analyzed and compared under different conditions. This testing will take approximately 10 minutes.
223846302|NCT04623723|OTHER|PS (DS-016A, EMS® Piezon, Switzerland) scaler tips. )|Supragingival scaling with a portable ultrasonic scaler device (EMS®) with Piezon, Switzerland using PS (DS-016A, EMS® Piezon, Switzerland) scaler tips
223846303|NCT04623723|OTHER|Conventional (FS-407, EMS® Piezon, Switzerland)|Supragingival scaling with a portable ultrasonic scaler device (EMS®) with Piezon, Switzerland using Conventional (FS-407, EMS® Piezon, Switzerland)
223846304|NCT00438906|PROCEDURE|Biopsy, Fine Needle Aspiration (FNA)|If a pancreatic lesion of concern is identified, a small needle is inserted in the lesion in the pancreas and cells of the lesion are aspirated. Diagnosis of the lesion can typically occur with FNA.
223846305|NCT00438906|DRUG|Secretin (human synthetic) - ChiRhoClin|Secretin is a synthetic human hormone that encourages the pancreas to create fluid. This will allow pancreatic juice to be collected via gentle suction in the duodenum where the pancreatic juice naturally flows.
223846306|NCT02923128|DRUG|Dexmedetomidine|Dexmedetomidine 3 ug/kg is diluted to 150ml with 0.9% saline,continuous micro-pump infusion for 72 hours with 2ml/h speed.
223846307|NCT02923128|DRUG|Sufentanyl|Sufentanyl 3 ug/kg is diluted to 150ml with 0.9% saline,continuous micro-pump infusion for 72 hours with 2ml/h speed.
223846308|NCT02923128|DRUG|Saline|Saline is used to dilute other drugs
223846309|NCT06001684|BIOLOGICAL|IBR854 Cell Injection|The minimum initial dose is 3.0×10\^9 cells and then escalate to 5.0×10\^9 cells and 7.0×10\^9 cells. Every 21 days is one cycle, and intravenous infusion is performed on day 1 and day 8 of each cycle.
223846310|NCT04517994|BEHAVIORAL|Active Treatment|See arm description.
223846311|NCT04517994|BEHAVIORAL|Supportive Treatment|See arm description.
223846312|NCT01763047|DEVICE|etafilcon A|To be worn in a daily wear modality for a minimum of 6 hours per day.
223846313|NCT01763047|DEVICE|lotrafilcon B|Lenses will be worn in a reuseable modality; cleaned and disinfected each night.
223846314|NCT01112735|BIOLOGICAL|FS VH S/D 4 s-apr (= two-component fibrin sealant, double virus inactivated, made from pooled human plasma)|Dosage form: spray (aerosolized sealant), Dosage frequency: once (1 layer). ARTISS will be applied onto the fascia or the wound bed.
223846315|NCT01112735|PROCEDURE|Standard of care|Standard of care
223846316|NCT00205894|DEVICE|bion microstimulator|
223846317|NCT05647356|DRUG|Bicalutamide 50 mg|Bicalutamide at a dose of 50mg once daily for 28 days.
223846318|NCT00438425|DIETARY_SUPPLEMENT|Dietary Portfolio - Intensive|Dietitians advised participants to consume the following therapeutic diet components (\<7% of energy saturated fat, \<200 mg/d cholesterol) plus the combination of viscous fibers, soy protein, plant sterols and nuts. The portfolio diet plan will include foods which contribute 9.8 g/1000 kcal viscous fiber as B-glucan (oats, barley, oat bran breads and soups) and psylliium (cereal), 0.94 g plant sterol/1000 kcal diet (in sterol margarine), 22.5 g soy protein/1000 kcal (soy burgers, dogs, links, other meat analogues, milks, yogurts and cheese) and 22.5 g nuts/1000 kcal as part of a low fat vegetarian diet. Participants received 7 visits during a 6-month period with the study dietitian.
223846319|NCT00438425|DIETARY_SUPPLEMENT|Dietary Portfolio - Routine|Dietitians advised participants to consume the following therapeutic diet components (\<7% of energy saturated fat, \<200 mg/d cholesterol) plus the combination of viscous fibers, soy protein, plant sterols and nuts. The portfolio diet plan will include foods which contribute 9.8 g/1000 kcal viscous fiber as B-glucan (oats, barley, oat bran breads and soups) and psylliium (cereal), 0.94 g plant sterol/1000 kcal diet (in sterol margarine), 22.5 g soy protein/1000 kcal (soy burgers, dogs, links, other meat analogues, milks, yogurts and cheese) and 22.5 g nuts/1000 kcal as part of a low fat vegetarian diet. Participants received 2 visits during a 6-month period with the study dietitian.
223846320|NCT00438425|DIETARY_SUPPLEMENT|Control (low saturated fat therapeutic diet)|Dietitians advised participants to consume the following therapeutic diet components (\<7% of energy saturated fat, \<200 mg/d cholesterol) with a focus on low-fat dairy and whole grain cereals together with fruit and vegetables as part of a low fat vegetarian diet, and avoidance of the specific portfolio components.
223846321|NCT00846781|DRUG|Denufosol tetrasodium Inhalation Solution|60 mg by oral inhalation three times daily
223846322|NCT02550054|DRUG|Epo|Epo is administered 1000 U/kg, iv in 48 hours after premature birth, and at 48 hours interval for 3 doses per week. After 6 doses, subcutaneously 400 U/Kg per injection and 3 doses per week until at corrected age of 34 weeks.
223846323|NCT02550054|DRUG|Normal saline|Normal saline is administered 5ml, iv at 3 to 6 hours after premature birth, and at 48 hours interval for 3 doses per week. After 6 doses, Subcutaneously 3 doses per week until at corrected age of 34 weeks.
223846324|NCT03381391|BEHAVIORAL|Personalized Feedback Intervention|The current intervention included personalized feedback regarding their alcohol consumption, alcohol-related consequences, gender-specific normative drinking comparisons, personal risk factors (e.g., dependence symptoms, family history of alcoholism), and alcohol expectancies. The intervention also included didactic material related to alcohol (e.g., effects at different BAC levels, tolerance) and drinking moderation strategies. The feedback was presented graphically in a feedback report with the individual's information.
223846325|NCT05161702|OTHER|MAG-SPM treatment on isolated PBMC cells|Cells are isolated form the participant's blood donation (4x 10mL k2EDTA tubes per participant) and maintained in culture with LPS, a pro-inflammatory and pro-proliferative agent. Then, PBMC are separated in two, one half treated with MAG-SPM and the other half remains with LPS only. Proliferative activities are measured and compared in both cell dish.
223846326|NCT05161702|OTHER|Isolated PBMC cells without treatment.|Cells are isolated form the participant's blood donation (4x 10mL k2EDTA tubes per participant) and maintained in culture with LPS, a pro-inflammatory and pro-proliferative agent. Then, PBMC are separated in two, one half treated with MAG-SPM and the other half remains with LPS only. Proliferative activities are measured and compared in both cell dish.
223846327|NCT01121874|PROCEDURE|Ligament reconstruction with suture fixation system|CMC arthroplasty consisting of reconstruction of the palmar oblique ligament using a suture fixation system
223846328|NCT01121874|PROCEDURE|Ligament Reconstruction with Tendon Interposition (LRTI)|commonly performed CMC arthroplasty technique, consisting of a trapeziectomy, followed by palmar oblique ligament reconstruction using a harvested flexor tendon from the wrist.
223846329|NCT01121874|PROCEDURE|Ligament reconstruction with suture fixation system|CMC arthroplasty consisting of reconstruction of the palmar oblique ligament using a suture fixation system, with a decreased period of immobilization from 6 weeks to 2 weeks.
223846330|NCT03529864|OTHER|Exercise Therapy|
223846331|NCT03127345|DRUG|Omegaven|Intravenous omega 3 fatty acid administration
223846332|NCT03127345|DRUG|Intralipid|Standard of care
223846333|NCT00263679|BIOLOGICAL|Prophylaxis: Diphtheria, tetanus and pertussis|
223846334|NCT05536284|DRUG|Bisoprolol Fumarate Tablets|Antihypertensive drug used for acute coronary syndrome patients
223846335|NCT06339905|PROCEDURE|Sonic Activation with EndoActivator|sonic activation
223846336|NCT06339905|PROCEDURE|Control Needle Irrigation|control group
223846337|NCT03999944|DEVICE|positive airway pressure system|Positive Airway Pressure System
223846338|NCT00884611|DEVICE|Predictive Low Glucose Suspend Algorithm ON|The algorithm uses a Kalman filter-based model to predict whether the sensor glucose level will fall below 80 mg/dL within a given time period and suspends the insulin pump if this event is predicted.
223846339|NCT00884611|DEVICE|Predictive Low Glucose Suspend Algorithm OFF|
223846340|NCT00479180|BIOLOGICAL|Vascugel|One time implant on the day of surgery
223846341|NCT00479180|BIOLOGICAL|Placebo Comparator|One time implant on the day of surgery
223846342|NCT06280729|OTHER|AI-Analyis|The study will investigate classification (ie logistic regression, decision tree, random forest, support vector machine, K nearest neighbour, naive bayes) ML models and treatment effect estimation ML models (T-learner, X-learner..).
223846343|NCT04749693|DEVICE|DBLG1 System|Use of DBLG1 System in real life condition
223846344|NCT02763553|DIETARY_SUPPLEMENT|Ketogenic Feed|A low-carbohydrate, high-fat feed designed to induce a ketotic state.
223846345|NCT02763553|DIETARY_SUPPLEMENT|Standard Feed|Standard enteral feed used in critical care patients requiring nutrition via a nasogastric tube
223846346|NCT02980380|OTHER|Non-invasive brain computer interface|"The hemodynamic change in the motor cortex of the CLIS patient will be recorded across many sessions spread over more than a year and will be used to train a classifier to predict the yes and no answering pattern of the CLIS patient. For patient who can still open their eyes but cannot use any other means of communication will control an EEG based BCI for communication."
223846347|NCT03061344|BIOLOGICAL|DVIU treated with liquid buccal mucosal graft|DVIU treated with liquid buccal mucosal graft; internal urethrotomy for urethral stricture followed by injection of morcellated buccal mucosal graft mixed with fibrin glue (Tisseel, Baxter)
223846348|NCT02095158|DRUG|Oxymetazoline HCL Cream 1.0%|Oxymetazoline HCL Cream 1.0% applied to the face once daily for 52 weeks.
223846349|NCT04866056|DRUG|Jaktinib|Jaktinib PO BID
223846350|NCT04866056|DRUG|azacitidine|Azacytidine SC
223846351|NCT04161222|OTHER|Experimental group|Experimental group will perform a typical warm-up of competitive football, added to a specific activation of gluteus medius and core.
223846352|NCT04161222|OTHER|Control group|Control group will perform a typical warm-up of competitive football
223846353|NCT03095209|DRUG|Carboplatin|chemo regimen will carboplatin-paclitaxel managed by the treating medical oncologist. Patients are planned to receive surgery at approximately 6 to 9 weeks (maximum 12 weeks post-CRT) after finishing CRT with surgical aspects determined by the treating surgical oncologist.
223846354|NCT03095209|DRUG|Paclitaxel|chemo regimen will carboplatin-paclitaxel managed by the treating medical oncologist. Patients are planned to receive surgery at approximately 6 to 9 weeks (maximum 12 weeks post-CRT) after finishing CRT with surgical aspects determined by the treating surgical oncologist.
223846355|NCT03095209|RADIATION|Radiation Therapy|The total radiation dose will be 50.4 Gy in daily fraction of 1.8 Gy for esophageal cancer and 60 Gy in daily fraction of 2 Gy for non-small cell lung cancer.
223846356|NCT00598013|DRUG|Pioglitazone|The pioglitazone treatment group received 30mg pioglitazone at 2 weeks after renal transplantation for 12 months.
223846357|NCT00870259|DIETARY_SUPPLEMENT|Optifast VLCD|Meal replacement, three times daily for 8 weeks
223846358|NCT02887378|DEVICE|hot clamps|reusable hot biopsy forceps
223846359|NCT02887378|DEVICE|normal clamps|
223846360|NCT01270789|DRUG|Liraglutide|Liraglutide administered as once daily sc injection
223846361|NCT01270789|DRUG|placebo|placebo administered as once daily sc injection
223846362|NCT01567059|DRUG|tosedostat|Given PO
223846363|NCT01567059|DRUG|cytarabine|Given IV
223846364|NCT01567059|DRUG|decitabine|Given IV
223846365|NCT03693755|PROCEDURE|In-plane Group|Placement of femoral nerve catheter under ultrasound control
223846366|NCT03693755|PROCEDURE|Out-of-plane Group|Placement of femoral nerve catheter under ultrasound control
223846367|NCT01594060|DRUG|Insulin, regular - act rapid|4 shots of regular insulin: 3 before meals and one at bedtime.
223846368|NCT01594060|DRUG|Insulin glulisine, Insulin glargine|1 shot glargine at bedtime 3 shots glulisine before meals
223846369|NCT02282527|BIOLOGICAL|Liquid Alpha₁-PI|Liquid Alpha₁-PI, 60 mg/kg, 8 weekly intravenous infusions
223846370|NCT02282527|BIOLOGICAL|Prolastin-C|Prolastin-C, 60 mg/kg, 8 weekly intravenous infusions
223846371|NCT04216303|DIAGNOSTIC_TEST|hemoglobin A1c|The hemoglobin A1c test (A1c) screens for, helps diagnose, and monitors diabetes and prediabetes.
223846372|NCT02759198|DRUG|YH23537|Drug: YH23537 750mg Drug: YH23537 1500mg Drug: YH23537 3000mg
223846373|NCT02759198|DRUG|Celecoxib|Drug: Celecoxib 200mg
223846374|NCT02759198|DRUG|YH23537 placebo|Drug: YH23537 750mg placebo Drug: YH23537 1500mg placebo Drug: YH23537 3000mg placebo
223846375|NCT00941031|DRUG|AIN457|
223846376|NCT00941031|DRUG|AIN457A|"Induction with monthly injections - Monthly: secukinumab (AIN457) 150 mg s.c. administered at weeks 1, 5, 9"
223846377|NCT00941031|DRUG|AIN457A|"Early loading induction - Early: secukinumab (AIN457) 150 mg s.c. administered at weeks 1, 2, 3, 5"
223846378|NCT00941031|DRUG|Placebo|"Placebo - Placebo: Placebo administered at weeks 1, 2, 3, 5, 9"
223846379|NCT01872611|DRUG|Nepafenac Ophthalmic Suspension, 0.3%|
223846380|NCT01872611|OTHER|Vehicle|Inactive ingredients used as placebo comparator
223846381|NCT01872611|DRUG|Prednisolone acetate|1 drop instilled in the operative eye 4 times daily beginning post-operatively on the day of surgery for the first 2 weeks, followed by 2 times daily for the next 2 weeks
223846382|NCT03645356|DEVICE|Fixed Appliances|Using an MBT-prescription of metallic brackets, patients will be treated in the conventional way
223846383|NCT03645356|DEVICE|Clear Aligners|Using a sequence of clear aligners, patients will be give an aligner every two weeks until the completion of treatment
223846384|NCT00276328|DRUG|Diosmectite (Smecta®)|
223846385|NCT04159948|DIETARY_SUPPLEMENT|Carbohydrate drink|"This is a commercially available pre-op carbohydrate drink used in enhanced recovery programmes."
223846386|NCT05989737|BEHAVIORAL|Acceptance-Enhanced Behavior Therapy|8-module intervention delivering acceptance-enhanced behavior therapy through a fully automated website. This intervention was adapted from the Acceptance-enhanced behavior therapy workbook (Woods \& Twohig, 2008).
223846387|NCT01090609|DEVICE|Stent implantation|Stent implantation
223846388|NCT00623922|BEHAVIORAL|Patient education with individual nurse consultations|3 group meetings followed by 1-2 individual nurse consultations.
223846389|NCT04750629|DEVICE|POC CoviDx™ Rapid Antigen Test|All patients will have a nasal swab for CoviDx™ Rapid Antigen testing
223846390|NCT03124108|DRUG|Elafibranor 80 mg|Two coated tablets daily for 12 weeks
223846391|NCT03124108|DRUG|Elafibranor 120 mg|Two coated tablets daily for 12 weeks
223846392|NCT03124108|DRUG|Placebo|Two coated tablets daily for 12 weeks
223846393|NCT05191251|DIAGNOSTIC_TEST|HEMSTOP questionnaire|A HEMSTOP questionnaire is obtained during the anesthesia consultation.
223846394|NCT06226987|DIAGNOSTIC_TEST|68Ga-DOTATATE PET/MRI|PET/MRI scanning
223846395|NCT00631917|DRUG|Aliskiren|Aliskiren 300 mg once a day
223846396|NCT00631917|DRUG|Ramipril|Ramipril 10 mg once a day
223846397|NCT00631917|OTHER|Placebo to Ramipril|Placebo capsules to match ramipril.
223846398|NCT00631917|OTHER|Placebo to Aliskiren|Placebo tablets to match aliskiren.
223846399|NCT01954940|DEVICE|Whole Body Vibration Therapy|
223846400|NCT03433261|DIETARY_SUPPLEMENT|Ketogenic Diet|Eat a ketogenic diet (low carbohydrate, high fat diet) for 72 hrs prior to the experiment and consume a dietary ketone supplement 60 minutes before the experiment.
223846401|NCT00145535|DEVICE|SOLX Titanium Sapphire Laser (TiSaLT)|Spot laser treatment, \~50 spots over 180°
223846402|NCT00145535|DEVICE|Argon Laser Trabeculoplasty (ALT)|Spot laser treatment, \~50 spots over 180°
223846403|NCT01167036|DEVICE|FascialEdge instrument|Stroking massage to patient tolerance over the muscle
223846404|NCT01167036|OTHER|Placebo electric point stimulation|Detuned electric point stimulation over the involved muscle
223846405|NCT06183710|BEHAVIORAL|Contingency management|Psychosocial intervention
223846406|NCT06389318|DRUG|buccal midazolam +oral placebo syrup|Children received oral chloral hydrate (Chloral Hydrate mixture, concentration at 0.5gm/5ml, 250 ml bottle, prepared at abo Elreesh pharmacy, Elmoneerah , Egypt) at 50 mg /kg, intranasal dexmedetomidine at 2 μg/kg and buccal normal saline. Dexmedetomidine used was preservative-free dexmedetomidine (Precedex, 2ml ampoule,100 ug /ml, Hospira, Inc, Rocky Mount, USA) in a concentration of 100 μg/mL. Undiluted drug was withdrawn into a 1 mL tuberculin syringe.
223846407|NCT06389318|DRUG|oral chloral hydrate,intranasal dexmedetomidine and buccal normal saline|Children received oral chloral hydrate (Chloral Hydrate mixture, concentration at 0.5gm/5ml, 250 ml bottle, prepared at abo Elreesh pharmacy, Elmoneerah , Egypt) at 50 mg /kg, intranasal dexmedetomidine at 2 μg/kg and buccal normal saline. Dexmedetomidine used was preservative-free dexmedetomidine (Precedex, 2ml ampoule,100 ug /ml, Hospira, Inc, Rocky Mount, USA) in a concentration of 100 μg/mL. Undiluted drug was withdrawn into a 1 mL tuberculin syringe.
223846408|NCT05481294|OTHER|Transpersonal Supportive Coaching|Coaching is given for four months (two times a month) with a 45-minute duration per coaching by a professional coach
223846409|NCT05481294|OTHER|Standard Support|Standard support is given for four months using a support system provided by Peer Support Foundation
223846410|NCT05650333|DRUG|Ritlecitinib 20 mg|orally administered, Ritlecitinib 20 mg once daily (QD)
223846411|NCT04795089|PROCEDURE|Shunt surgery|Patients are evaluated before and after shunt surgery which is a standard intervention in the clinical practice. HI do not undergo intervention.
223846412|NCT04963621|BEHAVIORAL|Child-Adolescent Emotion and Stress Intervention Program|Intervention programs include Emotion and Stress Intervention for children with emotional and stress problems
223846413|NCT02271607|DEVICE|moxibustion|The treatment schedule is three times per week for four weeks. Indirect moxa pillars and indirect-container moxibustion will be used.
223846414|NCT06200636|DEVICE|Use of the PELSA System for dISF extraction|Dermal interstitial fluid will be extracted using the investigational device, for further analysis.
223846415|NCT02616263|OTHER|Foot exercise|
223846416|NCT02616263|OTHER|Shoulder exercise|
223846417|NCT05882318|DEVICE|eCoin Peripheral Neurostimulator System|The eCoin device is a leadless, coin-sized tibial neurostimulator for treatment of urgency urinary incontinence. It emits a dome-shaped electrical field to deliver low-duty cycle stimulation to the tibial nerve. The device is to be implanted under local anesthetic in the lower leg, and once activated delivers automatic 30-minute treatment sessions without the need for patient management.
223846418|NCT05390645|DRUG|MFA-370|MFA-370 is a treatment with a combination of two approved pharmaceuticals
223846419|NCT06058637|DEVICE|Eye screening|Nurse-assisted eye-screening will take place with the Easee app, which is implemented on the tablet or laptop of the community nurse. The nurse's smartphone will function as a remote control by which he/she submits input to a computer screen that displays the test. If the participant can do the test by him or herself, the nurse will merely supervise to ensure correct application. Standard audio instructions guide the nurse and participant through the test. The test will start with triage questions, which are used to set up a correct referral. During the test, both eyes are tested consecutively, covering one eye at a time. The participant will wear his/her spectacles, if present. The participant is presented a sequence of optotypes (i.e. tumbling-E and triangle-circle optotypes) that the participant must correctly identify, in addition to various grate sizes, both near and at a distance. The Amsler grid test is performed to detect any macular problems.
223846420|NCT05913739|OTHER|Oxygen Therapy|Nocturnal oxygen therapy minimum 6 hours
223846421|NCT06306274|DRUG|Tacrolimus|Tacrolimus (0,1%) ointment
223846422|NCT06306274|DRUG|Placebo|Placebo ointment
223846423|NCT01851109|BEHAVIORAL|genetic counseling|"The genetic counseling sessions are conducted by a licensed genetic counselor, certified by the American Board of Genetic Counseling and the American Board of Medical Genetics. This clinical counseling session may include, but is not limited to the following:~1. A review of medical and family history information to determine which genetic test (BRCA, HNPCC, p53, etc.), if any, is appropriate;~2. Discuss how the results - positive or negative - affect cancer risk~3. Discuss how cancer risk might be managed (surveillance, prophylactic surgery, oral contraceptives, etc.);~4. Discuss how the test is conducted and what the results might be (positive, negative, uncertain);~5. Discuss the disadvantages of genetic testing (cost, insurance coverage, worry about insurance discrimination, uncertain results, etc.) and the psychological and emotional issues surrounding testing, etc."
223846424|NCT05000190|DIETARY_SUPPLEMENT|Active capsule|1 capsule daily for 28 days
223846425|NCT05000190|OTHER|Placebo capsule|1 capsule daily for 28 days
223846426|NCT03374046|PROCEDURE|Apneic Oxygenation|Supplemental oxygen will be provided via nasal cannula during intubation attempt
223846427|NCT03298113|DEVICE|Cavilon Advanced Skin Protectant|Applicator contains a polymeric-cyanoacrylate solution intended to cover and protect intact or damaged skin. Upon application to skin, the liquid dries rapidly to form a primary long-lasting waterproof, highly durable film barrier.
223846428|NCT03298113|DEVICE|IAD Hospital Standard Care|Devices such as local skin protectants will be used according to the hospital IAD care regime and under consideration of the respective manufacturers' instructions for use.
223846429|NCT05653570|DIAGNOSTIC_TEST|Electrical stimulation|Electrical stimulation will be used to confirm needle and catheter placement within the interfascial plane between the erector spinae muscle and thoracic transverse process.
223846430|NCT05653570|DIAGNOSTIC_TEST|Ultrasound|Ultrasound guidance will be used to visualize needle and catheter placement within the interfascial plane between the erector spinae muscle and thoracic transverse process.
223846431|NCT02939183|DRUG|Immediate Release (IR) Formulation|Immediate Release (IR) Formulation
223846432|NCT02939183|DRUG|Gastro-Retentive (GR) Formulation|Gastro-Retentive (GR) Formulation
223846433|NCT02939183|DRUG|Dexamethasone|Dexamethasone
223846434|NCT02939183|DRUG|Pomalidomide|Pomalidomide
223846435|NCT05096117|DRUG|ASP8062|ASP8062 is a novel compound with positive allosteric modulator (PAM) activity on the γ-aminobutyric acid type B (GABAB) receptor, 25 mg, 1 x per day for 6 weeks
223846436|NCT05096117|DRUG|Placebo|1 x per day for 6 weeks
223846437|NCT06291701|DIAGNOSTIC_TEST|Assessment of scapular endurance|For the assessment of scapular endurance, participants will be instructed to bend their arms and elbows while keeping a wooden rod placed between their elbows, pull a spring dynamometer placed between thei
223846438|NCT06291701|DIAGNOSTIC_TEST|Prone Bridge Test|"For the Prone Bridge Test, participants will be instructed to lie face down with their hands and feet shoulder-width apart and then raise their bodies off the ground by lifting themselves up on their hands, forearms, and toes. A stopwa"
223846439|NCT06291701|DIAGNOSTIC_TEST|Side Bridge Test|"For the Side Bridge Test, participants will be asked to lie on their right side, supporting themselves on their forearm and elbow, and lift themselves off the ground. A stopwatch will be started, and the test will be terminated if there is any deviation from the position. The elapsed time will be recorded in seconds. The test will then be repeated on the left side."
223846440|NCT06291701|DIAGNOSTIC_TEST|Closed Kinetic Chain Upper Extremity Stability Test|For the Closed Kinetic Chain Upper Extremity Stability Test, participants will be asked to assume a push-up position on a flat surface with their hands placed on two parallel lines drawn 90 cm apart. They will then be instructed to touch one hand to the other hand's side as many times as possible within 15 seconds. The test will be repeated three times, and the average of the scores will be calculated.
223846441|NCT06291701|DIAGNOSTIC_TEST|Seated Medicine Ball Throw Test|"For the Seated Medicine Ball Throw Test, participants will be asked to sit on the ground with their back, shoulders, and head against the wall. Holding a 2 kg medicine ball with both hands, they will start with their elbows bent and arms at their sides, then extend their elbows to throw the ball forward as far as possible. The distance between the wall and the point where the ball lands will be recorded. The test will be performed three times, and the average will be calculated."
223846442|NCT04486638|BIOLOGICAL|Dengue Tetravalent Vaccine, Live|Pharmaceutical form: Powder and solvent for suspension for injection Route of administration: Subcutaneous
223846443|NCT06008678|DEVICE|RXiBreeze PAP System, Model RXiBreeze 20A|The RXiBreeze PAP System is a prescription-only positive airway pressure (PAP) ventilator used to treat obstructive sleep apnea (OSA). It is a microprocessor-controlled device that provides mechanical ventilation to a subject.
223846444|NCT06122935|DEVICE|Aurora Xi New Nomogram Software 2.0|Plasma collection with a proprietary plasma collection volume nomogram provides a more individualized approach to determining the volume of plasma collected from each donor.
223846445|NCT06122935|DEVICE|Aurora Xi Currently Approved Software 1.3|Plasma collection using the currently marketed Optimized Nomogram (software version 1.3) for the Aurora Xi Plasmapheresis System
223846446|NCT05896306|OTHER|No intervention|No intervention
223846447|NCT05962125|OTHER|periodic alveolar recruitment maneuvers|A stepwise increment of tidal volume was used for each ARM.
223846448|NCT05962125|OTHER|positive end-expiratory pressure|a PEEP of 6 to 8 cm H2O
223846449|NCT03099785|DRUG|Rifamycin SV 600mg t.i.d.|Morning: one 600 mg tablet Afternoon: one 600 mg tablet Evening: one 600 mg tablet
223846450|NCT03099785|DRUG|Rifamycin SV b.i.d. + Placebo|Morning. one 600 mg tablet Afternoon: one matching placebo tablet Evening: one 600 mg tablet
223846451|NCT03099785|DRUG|Placebo t.i.d.|Morning. one matching placebo tablet Afternoon: one matching placebo tablet Evening: one matching placebo tablet
223846452|NCT04178005|DRUG|Cladribine|All study participants will receive treatment with cladribine 10 mg tablets at the recommended cumulative dose of 3.5 mg/kg, divided into 2 yearly treatment courses (1.75 mg/kg per treatment course). This regimen corresponds to the recommended dosage as per the USPI
223846453|NCT04001114|COMBINATION_PRODUCT|Sampling Research Cigarettes|Participants sample two research cigarettes, which differ in typical tobacco smoke constituents such as tar, nicotine, carbon monoxide, etc. In the Cigarette Discrimination Session, participants sample both types of cigarettes repeatedly, guess their identity (A or B) with regard to reference cigarettes, and rate their subjective effects. In the Ad Libitum Smoking Session, participants can smoke one of these cigarette types as much or as little as they like for eight hours.
223846454|NCT04425148|DEVICE|Transcranial Alternating Current Stimulation (tACS)|tACS is a noninvasive way of stimulating the brain externally using weak electric currents. Electrodes are placed into a cap that you wear on your head. A weak electrical current travels back and forth through the electrodes to your head.
223846455|NCT04425148|DEVICE|Sham Transcranial Alternating Current Stimulation (sham tACS)|Sham (placebo) simulation of transcranial alternating current stimulation without receiving any real stimulation.
223846456|NCT06041997|BEHAVIORAL|Smartphone restriction|The patients will then be advised to cut down the usage by one-third in terms of usage hours. The compliance will be checked at the time of outcome assessment.
223846457|NCT01733134|DRUG|Tolvaptan|Tolvaptan 30 mg. tablet for subjects enrolled prior to first 8 hours of coming to an emergency department. Repeated daily up to 5th day.
223846458|NCT01733134|DRUG|placebo|Patient in the placebo group will receive tolvaptan in addition to standard therapy
223846459|NCT01464294|DEVICE|Milled ceramic restorations|Restoration of back teeth with milled ceramic crowns or onlays
223846460|NCT01464294|DEVICE|Milled nano-composite restorations|Restoration of back teeth with milled crowns or onlays
223846461|NCT05087732|DEVICE|STYLAGE® M Lidocaïne|Up to 2 mL will be injected at Day 0 on a nasolabial fold and, if required, up to 1 mL could be injected 14 days after on the same nasolabial fold (touch-up).
223846462|NCT05087732|DEVICE|STYLAGE® M|Up to 2 mL will be injected at Day 0 on a nasolabial fold and, if required, up to 1 mL could be injected 14 days after on the same nasolabial fold (touch-up).
223846463|NCT03486197|OTHER|Laboratory Biomarker Analysis|Correlative studies
223846464|NCT03486197|BIOLOGICAL|Pembrolizumab|Given IV
223846465|NCT03486197|RADIATION|Radiation Therapy|Undergo neutron radiation therapy
223846466|NCT05990881|DRUG|Botulinum toxin|Patients in this group will receive an injection of Botulinum toxin.
223846467|NCT05990881|DRUG|Standard-of-care corticosteroid injections|Patients in this group will receive an injection of corticosteroid injections, which are considered standard of care.
223846468|NCT03941574|DRUG|HLX10|HLX10 developed by our company is sterile intravenous injection, with specification of 100 mg/10 mL/bottle. The main ingredient is 10.0 mg/mL of recombinant humanized anti-PD-1 monoclonal antibody. The excipients include 0.95 mg/mL citric acid (citric acid monohydrate), 4.56 mg/mL sodium citrate (sodium citrate dihydrate), 3.0 mg/mL sodium chloride, 30.0 mg/mL mannitol and 0.20 mg/mL polysorbate 80 (tween 80), with pH of 5.5.
223846469|NCT02451280|PROCEDURE|Unilateral Hybrid Intervention|For the unilateral RT training, participants will practice with their affected arms following a unilateral training protocol of BMT for 45 minutes (Yang, et al., 2012). For the UAT training, participants will receive training of the affected UL in functional tasks with behavioral shaping for 45 minutes (Lin, Wu, et al., 2009).
223846470|NCT02451280|PROCEDURE|Bilateral Hybrid Intervention|For the bilateral RT training, patients will focus on training involving both arms using the BMT robot for 45 minutes. During the 45 minutes BAT training, participants will receive training in tasks focusing on bilateral symmetric or alternating movements of both ULs.
223846471|NCT02451280|PROCEDURE|Robot-Assisted Training|The RT intervention will be matched in duration and intensity with the hybrid interventions. Participants in the RT group will practice on the BMT with bilateral protocols for 90 minutes. The tasks will be tailored according to the level
223846472|NCT00320476|DRUG|Velcade|
223846473|NCT00317538|DRUG|infliximab, etanercept|
223846474|NCT01861782|OTHER|Dead Sea Solar and Water Treatment|
223846475|NCT01861782|OTHER|Sulfur Pool & Medicinal Mud|
223846476|NCT06167382|OTHER|Questionnare|Demographic Survey Form,the Physical Activity Readiness Questionnaire for Everyone (PAR-Q+),Goniometric Measurements, Digital Dynamometer Measurements, Hand Grip Measurements, Hand Reaction Measurements, Dexterity and Function Measurements, Jamar Handheld Dynomometer Measurement, Pinchmeter Measurement, Purdue Pegbord Test, Minnesota Manuel Skill Test, Nelson Hand Reaction Test, Modified Borg Scale
223846477|NCT06167382|OTHER|Device: Arm Ergometer|Participants will sign a consent form approved by the ethics comittee. Before data collection height, weight, daily computer usage time, dominant hand, body mass index, heart rate, blood pressure and saturation values be recored. Before arm ergometer exercise, the muscle strength, hand grip strength, joint range of motion, dexterity and reaction speed will be evaluated. The dexterity and reaction speed will be done with Minnesota Manuel Skill Test, Purdue Pegbord Test and Nelson Hand Reaction Test.Participants will be training at least 24 hours apart at 60%, 70%, and 80% of exercise intensity maximum heart rate on arm ergometer. The tests will repeat at the same time with a maximum deviation of 1 hour on 3 different days. At the end of arm ergometer exercise, the necessary evaluations will be made again and the participants will be rest for 15 minutes. 15 minutes after the participants rested, the necessary evaluations will be made again.
223846478|NCT02800811|DRUG|FR104|GMP FR104 is provided to the site in extractable volume vials containing FR104. Appropriate Dilutions in Ringer's lactate solution is made on site.
223846479|NCT02800811|DRUG|Placebo|The placebo injection contains the vehicle. For placebo dosing, vehicle is administered in accordance with the volume of study drug administered.
223846480|NCT01537250|DRUG|Levofloxacin 500 mg placebol|oral form,,once adily,7\~10 days
223846481|NCT01537250|DRUG|Levofloxacin 500 mg placebol|oral form,,once adily,7\~10 days
223846482|NCT01537250|DRUG|Nemonoxacin 3 tablets|oral form,once daily,7\~10 days
223846483|NCT03424239|DRUG|Zoledronic Acid|5mg zoledronic acid
223846484|NCT03424239|DIETARY_SUPPLEMENT|Calcium citrate + vitamin D|Chewable 500mg calcium citrate with 500 International Units (IU) Vitamin D3
223846485|NCT03424239|DIETARY_SUPPLEMENT|Vitamin D3|1000IU Vitamin D3 gummy
223846486|NCT02618629|DRUG|14C-Z-215|Single oral dose of 20mg Z-215 and 14C-Z-215 solution
223846487|NCT04890756|OTHER|observational|"The reliability was determined (n=100) by filling out the mBQ, two times, one week apart (test-retest).~For validation (n=45), the scores between the modified Baecke Questionnaire and the International Physical Activity Questionnaire were compared and the correlation between the modified Baecke Questionnaire and VO2max(via Astrand-Rhyming Cycle Ergometer Test) and between mBQ and interview (via METS) were assessed."
223846488|NCT02496988|DRUG|Temozolomide|Capsules supplied in 5-mg, 20-mg, 100-mg, 140-mg, 180-mg, and 250-mg strengths; dosed at 200 mg/m2/day for 5 consecutive days, repeated every 28 days
223846489|NCT02496988|BIOLOGICAL|CIK|The patients received autologous cytokine-induced killer cells transfusion one week after Temozolomide treat
223846490|NCT00003957|BIOLOGICAL|filgrastim|
223846491|NCT00003957|BIOLOGICAL|recombinant human stem cell factor|
223846492|NCT00003957|DRUG|cyclophosphamide|
223846493|NCT00003957|DRUG|cytarabine|
223846494|NCT00003957|DRUG|etoposide|
223846495|NCT00003957|DRUG|melphalan|
223846496|NCT00003957|DRUG|mitoxantrone hydrochloride|
223846497|NCT00003957|DRUG|paclitaxel|
223846498|NCT00003957|PROCEDURE|peripheral blood stem cell transplantation|
223846499|NCT01364220|DRUG|Rosuvastatin|Rosuvastatin 20mg tablet, once daily, for 14 days
223846500|NCT01364220|OTHER|Placebo tablet|Placebo tablet, once daily, for 14 days
223846501|NCT00318656|DRUG|rosiglitazone-metformin fixed dose combination|
223846502|NCT00318656|DRUG|metformin + glimepiride|
223846503|NCT02301234|DRUG|Placebo|Placebo will be administered once every 4 weeks with or without adjunctive therapy for 16 weeks by subcutaneous (SC) injection (injection under the skin) into the thigh or abdomen.
223846504|NCT02301234|DRUG|Fulranumab 1 mg|Fulranumab will be administered once every 4 weeks with or without adjunctive therapy for up to 16 weeks by SC injection into the thigh or abdomen.
223846505|NCT02301234|DRUG|Fulranumab 3 mg|Fulranumab will be administered once every 4 weeks with or without adjunctive therapy for up to 16 weeks by SC injection into the thigh or abdomen.
223846506|NCT02301234|DRUG|Celecoxib 100 mg|Double-blind capsules taken twice daily for up to 16 weeks.
223846507|NCT02301234|DRUG|Celecoxib 100 mg Matching Placebo|Double-blind capsules taken twice daily for up to 16 weeks.
223846508|NCT05498311|RADIATION|Intraoperative Radiotherapy (IORT)|The Intrabeam Photon Radiosurgery System will deliver 20 Gy in the act of breast surgery
223846509|NCT05498311|PROCEDURE|Breast conservative surgery|Breast conservative surgery with the aim of resecting breast tumour and with or without oncoplastic surgery
223846510|NCT05498311|RADIATION|External Beam Hypofractionated Radiotherapy (EBRT)|A External Beam Hypofractionated Radiotherapy will be administered after surgery. y. The dose per fraction will be 2.67 Gy per session. EBRT will be performed daily from Monday to Friday for fifteen fractions.
223846511|NCT03356015|DRUG|4L Polyethylene Glycol|4L group received double-dose PEG at 19:00 in the evening before the day of colonoscopy at a rate of 250 mL every 15 minutes.
223846512|NCT03356015|DRUG|3L Polyethylene Glycol|3L group were instructed to drink 1L PEG at 19:00 in the evening before the day of colonoscopy at a rate of 250 mL every 15 minutes
223846513|NCT02641210|PROCEDURE|Periodontal Treatment|Periodontal Treatment using Gracey curettes and ultrasonic device.
223846514|NCT02641210|DRUG|Albendazole|All participants took Albendazole 400 mg before the intervention.
223846515|NCT03276364|DIAGNOSTIC_TEST|Ultrasound|Point-of-care ultrasound examination by pulmonary and critical care fellow
223846516|NCT03905135|DRUG|rhIL-15|Interleukin-15 (IL-15) will be administered by continuous intravenous infusion in a dose-escalation fashion with a starting dose level of 1 mcg/kg/day, a second dose level of 2 mcg/kg/day, a third dose level at 3 mcg/kg/day, and a fourth dose level at 4 mcg/kg/day on days 1-5 of each of six cycles.
223846517|NCT03905135|DRUG|rhIL-15|Interleukin-15 (IL-15) will be administered by continuous intravenous infusion at the maximum tolerated dose (MTD) or maximum administered dose (MAD) on days 1-5 of each of six cycles
223846518|NCT03905135|BIOLOGICAL|Avelumab|Avelumab (intravenous (IV) over 1 hour) will be administered at a dose of 10 mg/kg on days 8 and 22 of each of six cycles.
223846519|NCT01740557|BIOLOGICAL|Aldesleukin|Given IV
223846520|NCT01740557|BIOLOGICAL|CXCR2-transduced Autologous Tumor Infiltrating Lymphocytes|Given IV
223846521|NCT01740557|DRUG|Cyclophosphamide|Given IV
223846522|NCT01740557|DRUG|Fludarabine Phosphate|Given IV
223846523|NCT01740557|OTHER|Laboratory Biomarker Analysis|Correlative studies
223846524|NCT01740557|BIOLOGICAL|NGFR-transduced Autologous T Lymphocytes|Given IV
223846525|NCT01740557|OTHER|Quality-of-Life Assessment|Ancillary studies
223846526|NCT01102296|BIOLOGICAL|Hepatitis A vaccine|2 or 3 doses of hepatitis A vaccine to HIV-infected male homosexuals and 2 doses of hepatitis A vaccine to HIV-uninfected male homosexuals.
223846527|NCT02138513|BEHAVIORAL|Mindfulness Based Cognitive Therapy|This MBCT protocol consists of 8 weekly sessions of 2,5 hours each and a silent day of 6 hours of meditation practice. Similar to group MBCT, in the online MBCT group, participants will be asked to practice at home for 45 minutes, 6 days a week. They will receive files with meditation and yoga exercises to support this.
223846528|NCT03724474|BEHAVIORAL|Be SMART|The behavioral intervention will examine 12-week changes in sleep metrics and physical activity, compared to baseline measures, between subjects randomly assigned to a treatment (Be SMART) and an active control (Fitbit Only) condition (n=30, respectively).
223846529|NCT03533855|DIAGNOSTIC_TEST|CS plus FRFSE|"we perform a classic Fast Relaxation Fast Spin Echo (FRFSE) 3D MRI and add compressed sensing sequence"
223846530|NCT00490555|DRUG|Testosterone gel|Testosterone gel 10 g
223846531|NCT00490555|DRUG|Dutasteride|dutasteride 0.5 mg orally
223846532|NCT00490555|DRUG|Depo-Medroxyprogesterone (DMPA)|300 mg DMPA injection on Day 0 IM (into the muscle)
223846533|NCT00490555|OTHER|Placebo Testosterone gel|Place gel applied daily for 12 weeks
223846534|NCT00490555|OTHER|Placebo dutasteride|placebo pill for 12 weeks
223846535|NCT00490555|OTHER|Placebo DMPA|placebo DMPA injection Once
223846536|NCT05577962|DRUG|T group|OFA scheme (group T) was given dexamethasone 8mg for anti-inflammatory and antiemetic before operation, flurbiprofen axetil 50mg for preemptive analgesia, and dexmedetomidine was infused under ECG monitoring at an initial rate of 0.5 μ G/kg (more than 10min), then changed to 0.2ug/kg/h, and stopped infusion 20 minutes before operation closure. Before induction, lidocaine (1mg/kg), esketamine (0.5mg/kg), propofol (1-2mg/kg) and rocuronium (0.6mg/kg) were infused slowly, and endotracheal intubation was carried out when the anesthetic was fully effective and the BIS value was about 40. After successful intubation, an experienced anesthesiologist guided by ultrasound performed bilateral superficial cervical plexus block with 0.5% ropivacaine and injected 3-4ml at two points respectively; During the operation, sevoflurane (MAC1.0 - 1.4) was used to maintain the depth of anesthesia
223846537|NCT03313089|BEHAVIORAL|"Papas más nutritivas (PSAN)"|"Activities of the project Papas más nutritivas"
223846538|NCT03782038|DEVICE|MCD|Micro coring skin removal with automated coring device
223846539|NCT06061484|DIETARY_SUPPLEMENT|ready-to-use therapeutic food (RUTF)|Standard formulation meeting UNICEF specifications: https://www.unicef.org/supply/sites/unicef.org.supply/files/2023-04/U239977-RUTF-Novel-Specification.pdf
223846540|NCT06061484|DRUG|Amoxicillin|Standard weight-based dosing per Ehtiopian national guidelines
223846541|NCT00671463|PROCEDURE|Pancreatic duct stenting|In the treatment arm, patients will have a pancreatic duct stent placed prior to having their distal pancreatectomy.
223846542|NCT02806895|DRUG|JZP-110|
223846543|NCT02806895|DRUG|Placebo|
223846544|NCT02540941|OTHER|non|
223846545|NCT00568503|DRUG|QAX028|
223846546|NCT00568503|DRUG|Placebo|
223846547|NCT00568503|DRUG|Tiotropium bromide|
223846548|NCT00568503|DRUG|QAX028|
223846549|NCT00568503|DRUG|QAX028|
223846550|NCT02949648|DEVICE|Electronic cigarette|Electronic cigarettes are devices that do not burn or use tobacco leaves but instead vaporize a solution the user then inhales. The device contains an electronic vaporization system, rechargeable batteries, electronic controls and cartridges of the liquid is vaporized.
223846551|NCT02042443|DRUG|Capecitabine|Given PO
223846552|NCT02042443|DRUG|Fluorouracil|Given IV
223846553|NCT02042443|OTHER|Laboratory Biomarker Analysis|Correlative studies
223846554|NCT02042443|DRUG|Leucovorin Calcium|Given IV
223846555|NCT02042443|DRUG|Trametinib|Given PO
223846556|NCT04071522|OTHER|no intervention|no intervention
223846557|NCT01890161|DRUG|AXP1275|AXP1275 50 mg (2 × 25-mg capsules)
223846558|NCT01890161|DRUG|AXP1275 matching placebo|AXP1275 matching placebo (2 capsules)
223846559|NCT03222284|DEVICE|Cornerstones4Care Powered by Glooko App|Cornerstones4Care Powered by Glooko App is an iOS or Android smartphone application designed to support diabetes management by offering people with diabetes easily accessible, personalized tools for self-monitoring and education. C4C allows people with diabetes to monitor personal health metrics and blood glucose levels, with the aim to achieve participant behavior changes that may contribute to lower hospitalizations, diabetes-related complications and overall healthcare costs.
223846560|NCT03000712|BIOLOGICAL|Autologous Adipose Tissue derived MSCs 1x10^8cells/3ml|biological : Autologous Adipose Tissue derived MSCs 1x10\^8cells/3ml drug: saline solution
223846561|NCT02897284|BEHAVIORAL|Mindfulness 8 weeks|8 sessions of mindfulness
223846562|NCT02897284|BEHAVIORAL|Mindfulness 2 weeks|2 sessions of mindfulness
223846563|NCT00272285|DRUG|Ramosetron|IV, concomitant administration with dexamethasone
223846564|NCT00272285|DRUG|Granisetron|IV, concomitant administration with dexamethasone
223846565|NCT05350436|BEHAVIORAL|Balance Conditions|"Balance Conditions: (\~ 5 minutes in total)~* Balance Condition 1 (Feet 20cm apart)~* Balance Condition 2 (Feet together)~* Balance Condition 3 (Tandem stance)~Initial measurements of balance conditions serve two purposes: it generates a postural control baseline for us without the attribution of singing conditions, furthermore it allows us to separately measure long-term singing experience's effect on postural control, by assessing tasks differing in difficulty level. Balance conditions will be randomised to prevent a learning effect."
223846566|NCT05350436|BEHAVIORAL|Singing|"Singing Conditions: (\~ 15 minutes)~* Warmup - including jaw and breathing exercises~* Singing Condition 1 (Spoken Happy Birthday - Traditional Tempo)~* Singing Condition 2 (Sung Happy Birthday - Traditional Tempo~* Singing Condition 3 (Spoken Happy Birthday - Fast Tempo)~* Singing Condition 4 (Sung Happy Birthday - Fast Tempo)~* Singing Condition 5 (Spoken Happy Birthday - Slow Tempo)~* Singing Condition 6 (Sung Happy Birthday - Slow Tempo)~Link to singing instructional video:~https://www.dropbox.com/s/tro58i6vx6i6w3a/Singing%20Balance%20Exercise%20Video.mp4?dl=0~Time stamps for the video:~* Warmup (including jaw exercises and breathing exercises) - beginning at 2:55 until 6:06~* Happy Birthday protocol - beginning at 15:26 until 20:21"
223846567|NCT03106376|OTHER|16% O2 gas in breathed air|"Inspiratory gas mixtures: Hypoxic inspiratory gas will be obtained by adding nitrogen (N2) to normobaric, normoxic air with medical N2 tanks.~Delivery of gas mixture: The gas mixture will be delivered by standard tight facemask."
223846568|NCT03106376|OTHER|26% O2 gas in breathed air|"Inspiratory gas mixtures: Hyperoxic inspiratory gas will be obtained by adding oxygen (O2) to normobaric, normoxic air with medical O2 tanks.~Delivery of gas mixture: The gas mixture will be delivered by standard tight facemask."
223846569|NCT02112929|DRUG|Hyperpolarized xenon|Inhalation of up to one litre of polarized xenon gas, up to four inhalations per day are permitted.
223846570|NCT00205530|BEHAVIORAL|Brain Injury Family Intervention (BIFI)|The Brain Injury Family Intervention (BIFI) was developed over the last decade based upon considerable clinical experience and research review. The BIFI is a structured approach to helping families address their most common and salient issues, concerns, and challenges. The BIFI is implemented in five 90-minute sessions.
223846571|NCT04357418|OTHER|it is a survey|this interview can be carried out face to face or remotely.
223846572|NCT02735187|DEVICE|Blue light treatment|Phototherapy of localized psoriasis vulgaris plaque with a wearable device emitting blue light at 453nm.
223846573|NCT02735187|DRUG|Vitamin D|Treatment of contralateral localized psoriasis vulgaris plaque with Vitamin D creme (Daivonex)
223846574|NCT03595943|DIETARY_SUPPLEMENT|Low glycemic index, pulse-based diet|Diet that includes pulses (i.e. meals that contain chickpeas, lentils, beans, or peas)
223846575|NCT03595943|DIETARY_SUPPLEMENT|Moderate glycemic index hospital diet|Diet that is derived from a regular hospital menu for patients
223846576|NCT03661554|BIOLOGICAL|BCMA CAR-T Cells|The Chinese name of CAR-T cells is chimeric antigen receptor T cells. It is through gene transfection technology, so that patients with T lymphocytes can carry B cell-specific antigens, so that T lymphocytes can selectively kill B lymphocyte-derived tumor cells.
223846577|NCT03049436|OTHER|Program of adapted physical activity|
223846578|NCT01105572|DEVICE|Intel Health Guide|An Internet-connected device with member-customized protocols and response algorithms. Participants interact with the Intel HealthGuide device, receiving immediate feedback, and also transmitting blood pressure, weights and responses to questions to a site monitored by their nurse case manager.
223846579|NCT01105572|OTHER|Case Management|Specialized Medicare Case Managers review and coordinate services for members with multiple and complex needs with identified gaps in their care Medicare Case Management staff strives to enhance the member's quality of life, support continuity of care, facilitate provision of services in the appropriate setting and manage cost and resource allocation to promote quality, cost-effective outcomes. Specially trained Medicare Case Managers collaborate with the member, family, caregiver, member authorized representative, treating practitioner, health care provider, community services and other Aetna programs to coordinate care, with a focus on member education and maximizing quality outcomes.
223846580|NCT01007149|DRUG|omalizumab|Omalizumab was supplied in 5mL vials with solution for subcutaneous injection.
223846581|NCT01007149|DRUG|Placebo|Placebo was supplied in vials with solution for subcutaneous injection.
223846582|NCT00431795|DRUG|Pegylated liposomal doxorubicin (Caelyx)|Pegylated liposomal Doxorubicin (Caelyx) at the dose of 50mg/m\^2 IV every 4 weeks for 6 consecutive cycles
223846583|NCT00431795|DRUG|Epirubicin|Epirubicin (Farmorubicin) at the dose of 90mg/m\^2 IV every 3 weeks for 6 consecutive cycles
223846584|NCT02784704|DRUG|Eravacycline|
223846585|NCT02784704|DRUG|Meropenem|
223846586|NCT02784704|DRUG|Placebo|
223846587|NCT01403792|DRUG|P2G12|A single intravaginal administration of 1ml P2G12/placebo.
223846588|NCT01913340|DRUG|Erythropoietin|1000 U/kg/dose IV x 5 doses
223846589|NCT01913340|DRUG|Normal saline|placebo: NS IV x 5 doses
223846590|NCT05398120|BEHAVIORAL|Skills Group|Adolescents and young adults with a CHR syndrome ages 13-18 will complete feasibility and outcome measures while participating in a weekly skills group for 6 months.
223846591|NCT00793806|DEVICE|Diffuse Optical Spectroscopy|Diffuse Optical Spectroscopy measurements will be compared to a variety of laboratory parameters routinely measured in Chronic Inflammation and Oxidative Stress in Chronic Kidney Disease
223846592|NCT01235585|DRUG|Placebo|Oral doses, once a day for 52 weeks
223846593|NCT01235585|DRUG|bitopertin [RO4917838]|Oral dose level 1, once a day for 52 weeks
223846594|NCT01235585|DRUG|bitopertin [RO4917838]|Oral dose level 2, once a day for 52 weeks
223846595|NCT05010304|DRUG|Amoxicillin|Two-dose amoxicillin challenge
223846596|NCT05750745|DRUG|Sensodyne Sensitivity & Gum|Sensodyne Sensitivity \& Gum toothpaste is containing 0.454% w/w SnF2.
223846597|NCT05750745|DRUG|Crest Cavity Protection Fresh Lime|Crest Cavity Protection Fresh Lime is containing 1150 parts per million (ppm) fluoride as Sodium fluoride (NaF).
223846598|NCT05750745|DRUG|Sensodyne Repair and Protect|Sensodyne Repair and Protect toothpaste is containing 5.0% w/w calcium sodium phosphosilicate (CSPS).
223846599|NCT05060471|DRUG|Toripalimab|Four cycles of neoadjuvant PD-1 antibody toripalimab combined with docetaxol and cisplatin, followed by radiotherapy and two cycles of concurrent toripalimab.
223846600|NCT04423731|DRUG|Folfirinox|Neoadjuvant chemotherapy is given according to different regimens, preferably FOLFIRINOX according to the recommendations in the national Norwegian guidelines. The choice of chemotherapy regimen is decided by the treating oncologist.
223846601|NCT03889899|DEVICE|Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)|An intratumoral insertion of a seed(s), loaded with Radium-224, securely fixed in the seeds. The seeds release by recoil into the tumor short-lived alpha-emitting atoms.
223846602|NCT03848481|DRUG|CBDV Compound|CBDV is obtained from the Cannabis sativa L. plant and contains a negligible quantity (less than 0.2%) of THC
223846603|NCT03848481|DRUG|Placebo|Placebo oral solution contains matching excipients.
223846604|NCT06141668|OTHER|Neurostimulation|Electrical stimulation
223846605|NCT05825417|DRUG|Selexipag|If Arm A - Up-titration to maximum tolerated dose followed by de-escalation If Arm B - Up-titration to maximum tolerated dose followed by observation, modification or transition at discretion of responsible care team where necessary.
223846606|NCT05825417|DRUG|Riociguat|If Arm A - Up-titration to maximum tolerated dose followed by de-escalation If Arm B - Up-titration to maximum tolerated dose followed by observation, modification or transition at discretion of responsible care team where necessary.
223846607|NCT05825417|DEVICE|CardioMEMS pulmonary artery pressure monitor|Implantation and remote monitoring established with patient initiated daily readings
223846608|NCT05825417|DEVICE|Confirm Rx|Implantation and remote monitoring established with automated daily readings / downloads
223846609|NCT02389426|DEVICE|TCD baseline|"Measurement of cerebral circulation parameters with transcranial doppler baseline.~This examination will be performed in patients with multiple sclerosis and in healthy controls."
223846610|NCT02389426|DEVICE|TCD after bosentan administration|"Measurement of cerebral circulation parameters with transcranial doppler after administration of one tablet tracleer (Bosentan) 62,5 mg per oral.~This examination will only be performed in patients with multiple sclerosis."
223846611|NCT02389426|DEVICE|NIRS baseline|"Measurement of frontal lobe oxygen saturation with near-infrared spectroscopy baseline.~This examination will be performed in patients with multiple sclerosis and in healthy controls."
223846612|NCT02389426|DEVICE|NIRS after bosentan administration|"Measurement of frontal lobe oxygen saturation with near-infrared spectroscopy after administration of one tablet tracleer (Bosentan) 62,5 mg per oral.~This examination will only be performed in patients with multiple sclerosis."
223846613|NCT06544928|DEVICE|RESP Biosensor|The RESP Biosensor will be placed on the patient for periodic recording of auscultory sound.
223846614|NCT03968991|DIAGNOSTIC_TEST|VISIODOL® (Diagnostic tool)|Tool for assessing pain in the blind subject (with congenital or acquired deficiency)
223846615|NCT04544540|OTHER|Units of transfusion|Participants will either receive 1-unit or 2-unit red blood cell outpatient transfusions
223846616|NCT03109015|DRUG|Sunitinib|Patients randomized to sunitinib schedule 4/2 will receive sunitinib at 50 mg daily for 4 weeks on, followed by 2 weeks off, per standard of care. Cardiopulmonary Exercise Testing (CPET) will be performed at baseline, 4 weeks and 12 weeks.
223846617|NCT03109015|DRUG|Sunitinib|Patients randomized to sunitinib schedule 2/1 will receive sunitinib 50 mg daily for 2 weeks on, followed by 1 week off. Cardiopulmonary Exercise Testing (CPET) will be performed at baseline, 5 weeks and 12 weeks.
223846618|NCT05803824|OTHER|exercise therapy program|"patients will receive Baduanjin Qigong exercise plus selected exercise. the subjects will recive Baduanjin exercise 3 times each week, 30- 60 minutes each time for 12 weeks.~The whole set of Baduanjin exercise consists of 9 postures: (1) ready position, (2) holding the hands high with palms up. (3) posing like an archer shooting on left and right sides, (4) holding one arm aloft . (5) looking backwards to prevent sickness and strain, (6) swinging the head and lowering the body t. (7) moving the hands down the back and legs and touching the feet . (8) thrusting the fists and making the eyes glare . and (9) raising and lowering the heels .~Selected Exercise Program: Patients will receive~* balance exercises is composed of three phases, including warm-up, balance training and cool down.~* Resisted Exercises were given according to the standardized Oxford technique of progressive resistance exercises"
223846619|NCT06197880|OTHER|Anterior teeth retraction|En masse retraction of the upper and lower anterior segments using maximum anchorage
223846620|NCT03796494|PROCEDURE|Straight abutment|This is the classic abutment, straight and anti-rotational for dental implants which have been tested before
223846621|NCT03796494|PROCEDURE|Slim abutment|This is the new concept of the prostheses abutment, slim and anti-rotational to improve the width of biologic space
223846622|NCT02994706|PROCEDURE|Home Monitoring|Participants selected to receive home monitoring, in addition to routine CF care, will be given a digital lung function monitor (spirometer) and a modified mobile phone.
223846623|NCT02994706|OTHER|Clinical Care|Participants selected for this arm will continue to receive routine clinical care.
223846624|NCT00219921|DRUG|Intrathecal morphine at surgery, 0.1mg and placebo|
223846625|NCT00219921|DRUG|Patient Controlled Analgesia with iv morphine and placebo|
223846626|NCT00219921|DRUG|intrathecal morphine AND patient controlled analgesia with iv morphine|
223846627|NCT04493437|DEVICE|Telerehabilitation|Blood pressure (iHealth Neo), weight (iHealth Lina), step counters(Fitbit Inspire \& Charge 3), sleep sensor (Emfit QS), tablet (iPad Air 2), and ECG recorder (AliveCor KardiaMobile).
223846628|NCT04958187|DRUG|ANG-3777|Arm assigned to this intervention will receive 2 mg/kg, IV
223846629|NCT05983692|DEVICE|Magnesium based wire|Mg wire will be used as a braiding suture to braid tendon graft, which is a standard preparation of graft and is not related to fixation of the tendon graft
223846630|NCT04488874|DRUG|Sodium Lactate|"Sodium lactate is administered at 2.5mL/kg during the first surgical incision. Neurosurgeon will evaluate the brain relaxation using a validated scale once the dura is open. A stage 1(perfectly relaxed) or 2((acceptably relaxed) is considered satisfactory.~Sodium Lactate and Mannitol 20% are used at an equimolar dose"
223846631|NCT04488874|DRUG|Mannitol 20% Infusion|Mannitol 20% is administered intravenously at a dose of 5mL/kg, so 1g/kg, during the first surgical incision. Neurosurgeon will evaluate the brain relaxation using a validated scale once the dura is open. A stage 1(perfectly relaxed) or 2((acceptably relaxed) is considered satisfactory.
223846632|NCT00783692|DRUG|vedolizumab|Vedolizumab for intravenous infusion
223846633|NCT00783692|OTHER|Placebo|Placebo intravenous infusion
223846634|NCT03750656|DRUG|Hyoscyamine|Patients will be randomized to receive hyoscyamine for lower urinary tract symptoms are placement of ureteral stent
223846635|NCT03750656|DRUG|Tamsulosin|Patients will be randomized to receive tamsulosin for lower urinary tract symptoms are placement of ureteral stent
223846636|NCT01536353|DRUG|AGSAV301|tablet, q.d.
223846637|NCT01536353|DRUG|Exforge 10/160|Tablet, q.d.
223846638|NCT04569578|OTHER|Policy|"The intervention will include:~i. Formalized physical activity policies implemented in preschools including the following:~1. A minimum of 3 hours of total daily outdoor time scheduled both in the morning and in the afternoon~2. At least 10 minutes teacher-led active play per day~3. A minimum of 1 weekly outdoor excursion~4. Meet the children outdoors when they arrive at preschool and/or picked up by their parents~5. Only use screen tablets and computers for educational teaching purposes~6. Communicating to, and encouraging, the parents to actively transport their children to and from preschools~ii. A study website with an activity bank also serving as a platform for inter-professional education that preschool teachers can share and communicate about engaging activities and experience~iii. Weekly follow-up and feedback by web-based questionnaires"
223846639|NCT03237221|DRUG|Treat patient according to Global Initiative for Asthma (GINA) guideline|Treat patient according to Global Initiative for Asthma (GINA) guideline
223846640|NCT00198874|BEHAVIORAL|Integrated Family and Cognitive-Behavioral Therapy|The family therapy component of IFCBT includes engagement, active treatment, and maintenance phases. The cognitive program focuses on harmful effects of drugs and strategies to better manage drug abuse risks. The cognitive-behavioral program introduces youths to problem-solving behavior change principles and study skills to promote school achievement.
223846641|NCT00198874|OTHER|Education|Drug education curriculum was delivered to participants assigned to this condition.
223846642|NCT03986606|BIOLOGICAL|PSB205|PSB205 is a bi-functional product that has been engineered to contain two unique monoclonal antibodies.
223846643|NCT02283645|DRUG|3 % minoxidil lotion|
223846644|NCT02283645|DRUG|Placebo|
223846645|NCT01258361|PROCEDURE|echocardiography|Echocardiography is performed for all patients
223846646|NCT05688371|DRUG|standard dose morphine|Receiving 0.05 mg morphine/kg as a bolus.
223846647|NCT05688371|DRUG|low dose morphine plus dexmedetomidine|Receiving 0.02 mg morphine/kg as a bolus dose + 0.2 microgram/kg dexmedetomidine
223846648|NCT04150835|DRUG|Xingnaojing injection|Xingnaojing injection (20 ml)+0.9% diluted sodium chloride injection 250ml, IV (in the vein), every 12 hours for 10 days.
223846649|NCT04150835|DRUG|Xingnaojing placebo injection|Xingnaojing placebo injection (20 ml)+0.9% diluted sodium chloride injection 250ml, IV (in the vein), every 12 hours for 10 days.
223846650|NCT04150835|OTHER|Standard care|Guidelines-based standard care for acute ischemic stroke.
223846651|NCT01650337|OTHER|Smartphone Application|Smartphone application to help monitor caloric intake and expenditure
223846652|NCT05251285|PROCEDURE|Nipple-Sparing Mastectomy|Nipple-Sparing Mastectomy using da Vinci X/Xi Surgical System
223846653|NCT00002620|DRUG|carmustine|
223846654|NCT00002620|DRUG|chemotherapy|
223846655|NCT00002620|DRUG|mitolactol|
223846656|NCT00002620|RADIATION|low-LET cobalt-60 gamma ray therapy|
223846657|NCT00002620|RADIATION|low-LET photon therapy|
223846658|NCT01231282|OTHER|diffusion-weighted MRI|MRI scan without contrast administration and without radiation exposure
223846659|NCT05892913|DRUG|Slow dose preemptive Atropine|it will planned to administer 0.4 mg/4mL diluted atropine in 20 seconds(10mcg/kg), as a slow bolus as bradycardia would expected (10% reduction in peak heart rate after spinal anesthesia)
223846660|NCT05892913|DRUG|Ephedrine|For sympathetic blockade (SBP\<90) developed in patients in the ephedrine group, a bolus dose of 5 mg/mL ephedrine was used and repeated if necessary.
223846661|NCT03071497|DIAGNOSTIC_TEST|Non-invasive analysis of Zinc protoporphyrin|In patients fitting the inclusion criteria Zinc protoporphyrin will be measured non-invasively as proxy for iron deficiency. Results will be compared to ZnPP reference values measured via HPLC and with spectroscopical measurements performed on whole blood as well as with blood values (HB, MCH, MCV, ferritin, CRP, transferrin saturation, soluble transferrin receptor) assessed during clinical routine.
223846662|NCT00768066|BIOLOGICAL|Autologous human mesenchymal cells (hMSCs)|Participants will receive 40 million cells/mL delivered in either a dose of 0.25 mL per injection for a total of 1 x 108 (100 million) hMSCs x 10 injections or a dose of 0.5 mL per injection for a total of 2 x 108 (200 million) x 10 injections. The injections will be administered transendocardially during cardiac catheterization using the Biocardia Helical Infusion Catheter.
223846663|NCT00768066|BIOLOGICAL|Autologous human bone marrow cells (hBMCs)|Participants will receive 40 million cells/mL delivered in either a dose of 0.25 mL per injection for a total of 1 x 108 (100 million) hBMCs x 10 injections or a dose of 0.5 mL per injection for a total of 2 x 108 (200 million) x 10 injections. The injections will be administered transendocardially during cardiac catheterization using the Biocardia Helical Infusion Catheter.
223846664|NCT00768066|BIOLOGICAL|Placebo|Participants will receive 0.5 mL injections of phosphate-buffered saline (PBS) and 1% human serum albumin (HAS) x 10 injections. The injections will be administered transendocardially during cardiac catheterization using the Biocardia Helical Infusion Catheter.
223846665|NCT04631549|DRUG|SHR3680|SHR3680, PO, single dose
223846666|NCT00548964|DRUG|Lithium|600-900mg of Li carbonate
223846667|NCT00548964|DRUG|Ketamine|0.5mg/kg of ketamine
223846668|NCT04831775|BEHAVIORAL|Memory, Attention, and Problem Solving Skills for Diabetes|The intervention is composed of 4 small-group webinar classes and home-based individual online cognitive skills practice and will be held over 8 weeks. The classes will be taught by a GRA. Classes 1 \& 2 will focus on common cognitive problems in T2DM and strategies to improve cognitive skills. Classes 3 \& 4 focus on lifestyle changes to support cognitive functioning and DM-SM skills. Each online class will follow the same format: (1) introduction/revisiting content from the previous class; (2) review of progress on computer exercises; (3) practicing cognitive strategies in class; and (4) a weekly topic. The GRA will also prescribe exercises for the following weeks.
223846669|NCT04831775|BEHAVIORAL|Brain Games|The computer-training component uses a model for cognitive training that adapts to the user through an integrated hierarchical structure. The BrainHQ website houses the interactive program that runs on standard web browsers. Participants will only need a computer, smart phone, or tablet with Internet access to securely log onto the website. Each participant will be registered by the project staff using anonymous ID numbers that will allow unlimited access during the study. The website stores each session completed, and participants can start subsequent sessions wherever they stopped the last time logged on.
223846670|NCT04838210|BEHAVIORAL|EleVATE Group Care|10-session (2 hours per session) group prenatal care model following the prenatal visit schedule recommended by ACOG. In addition to pregnancy and infant-care related content, the EleVATE GC curriculum includes behavioral health strategies that can be used to manage depression and labor pain and navigate the daily frustrations and stress of life. Groups are facilitated by an obstetric clinician.
223846671|NCT04838210|BEHAVIORAL|Individual Prenatal Care|The dominant model of prenatal care in the United States, consisting of one-on-one encounters between a patient and obstetric clinician. Patients are seen for 10-15 mins every 4 weeks until 28 weeks gestation, every 2 weeks until 37 weeks or more by provider discretion), and weekly until delivery. Visits focus on routine screening tests and prenatal care.
223846672|NCT03015740|OTHER|Laboratory Biomarker Analysis|Correlative studies
223846673|NCT03015740|BIOLOGICAL|Nivolumab|Given IV
223846674|NCT03015740|OTHER|Quality-of-Life Assessment|Ancillary studies
223846675|NCT03015740|OTHER|Questionnaire Administration|Ancillary studies
223846676|NCT03015740|DRUG|Sitravatinib|Given PO
223846677|NCT06614244|PROCEDURE|Oral immunotherapy (OIT)|OIT in DOPA group will be implemented as follows. Both the first micro-dose of the offending food and the subsequent micro-increments will be administered at home. Any interruptions and resumptions of OIT, due to intercurrent events (e.g. infections), will be managed via email with or without medical visit via video call. Patients will be provided with ondansetron (sublingual film) and instructions for its use. An explanatory letter will also be provided in case of need for emergency room access.
223846678|NCT06614244|DIETARY_SUPPLEMENT|Culprit food elimination diet|The Diet group consists of a population of children affected by acute persistent FPIES subjected to the traditional measure, i.e. the elimination diet of the incriminated food.
223846679|NCT01273090|DRUG|imetelstat sodium|
223846680|NCT01273090|OTHER|laboratory biomarker analysis|
223846681|NCT01273090|OTHER|pharmacological study|
223846682|NCT06688708|DEVICE|Using vibrating foot orthosis with tactile stimulation|Stimulating tactile sensation by using vibrating foot orthosis in conjunction with a random 0-100 Hz square wave pulse stimulus and pseudorandom white noise via a stochastic resonance approach.
223846683|NCT06688708|DEVICE|Using vibrating foot orthosis without tactile stimulation|Stimulating tactile sensation by using vibrating foot orthosis with only vibration 100 Hz freqency.
223846684|NCT04895345|DRUG|TQB2450|TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.
223846685|NCT04895345|RADIATION|Intensity modulated radiotherapy|Intensity-modulated conformal radiotherapy (IMRT) is a kind of three dimensional conformal radiotherapy, which requires the dose intensity in the radiation field to be adjusted according to certain requirements.
223846686|NCT02449044|DRUG|Tolvaptan|Once Daily
223846687|NCT04086758|DRUG|zolbetuximab|Zolbetuximab will be administered as a 2-hour intravenous infusion
223846688|NCT06629285|PROCEDURE|Continuous compression cryotherapy|Using continuous compression cryotherapy around knee after anterior cruciate ligament reconstruction for 3 postoperative days
223846689|NCT06629285|PROCEDURE|Conventional ice treatment|Using icepack around knee after anterior cruciate ligament reconstruction for 3 postoperative days
223846690|NCT06628479|OTHER|interleukin, enzyme, hormone|Relaxin, MMP-2 and IL-6 values from vaginal washing fluid, peritoneal washing fluid and serum samples
223846691|NCT06631794|BEHAVIORAL|A short talk about the importance of HPV vaccination|"Investigator plan to set up a short talk to 3rd grade classes in addition to the usual sexual health training. The issue of HPV vaccination will be systematically addressed for 10 minutes to encourage catch-up vaccination.~The usual training include different themes such us : definition of sexual health, anatomy, sexually transmitted infections contraception/condoms, menstrual cycles, voluntary interruption of pregnancy, consent, sexual abuse/violence/harassment, pornography, anti-discrimination....~A 45-minute talk will include 2 or 3 topics from the above list. A ten minutes of talk will be added to the usual training to explain the HPV vaccination (a topic not usually addressed in sexual health training), covering the following elements: definition of HPV infection"
223846692|NCT06629194|DIAGNOSTIC_TEST|interferon gamma releasing assay (IGRA)|All patients who suspected CD or TB will be tested for interferon-gamma releasing assay. An interferon-gamma release assay is a blood test that measures the body\&#39;s immune response to Mycobacterium tuberculosis, the bacteria that causes tuberculosis.
223846693|NCT06631573|OTHER|fixed all-on-four prosthesis reinforced with PEEK framework.|Prosthetic rehabilitation of mandibular edentulous arches with fixed all-on-four prosthesis reinforced with PEEK framework.
223846694|NCT06631573|OTHER|Fixed all-on-four prosthesis reinforced with Co-Cr framework|Prosthetic rehabilitation of mandibular edentulous arches with fixed all-on-four prosthesis reinforced with Co-Cr framework
223846695|NCT06631196|PROCEDURE|Jacobson's PMRT|each child in the intervention group will perform five sessions of Jacobson's PMRT. Each session lasted for 15-20 minutes under the supervision of the researcher.
223846696|NCT06629337|GENETIC|H1 receptor blockade: 540 mg (Allegra), H2 receptor blockade: 40 mg (Pepcid AC)|Subjects ingested fexofenadine (540 mg, tablet) at least 50 minutes before and famotidine (40 mg, tablet) 1 hour 50 minutes before the onset of each protocol because these dose of oral fexofenadine and famotidine reaches its peak concentration at around 1 h and 2 h, respectively
223846697|NCT06630182|OTHER|Bortner self-questionnaire|14 items
223846698|NCT06630182|OTHER|Self-questionnaire BFI-10|10 items
223846699|NCT06629428|DRUG|Ublituximab|The participants will receive 48 weeks of treatment with ublituximab.
223846700|NCT06629883|BEHAVIORAL|REPS w/BANDS|This theory-informed, one-arm proof-of-concept study provided participants (n=10) with an SHVD, exercise equipment (exercise bands, stability ball), and 2 supervised RE sessions per week for 12 weeks via the SHVD's video feature and incorporated strategies from self-determination theory to meet the psychological needs of autonomy, competence, and relatedness. Participants were randomly paired with a buddy.
223846701|NCT06696625|DEVICE|Transcutaneous Auricular Vagus Nerve Stimulation|"taVNS device (Elmmedicare, EC100, Shenzhen, China) was used to apply stimulation for patients.~Stimulation parameters comprised an electrical current of 1 mA at a frequency of 20 Hz, with a waveform width of 1 ms. Repurposed off-the-shelf devices were utilized for this purpose, with the stimulator generating single square-wave pulses lasting 1 ms each. Enhancing conductivity was achieved by wiping the ear with tap water. The electrodes were placed on the cymba conchae and concha around the affected ear, which is the region of rich vagus nerve branch distribution."
223846702|NCT06696625|DRUG|0.1% sodium hyaluronate eye drop|Participants received 0.1% sodium hyaluronate eye drop (HYLO COMOD® eye drops, Ursapharm, Ltd., Germany).
223846703|NCT06696248|DRUG|Carvedilol and alverine|On the basis of maintaining unchanged routine hepatoprotective and symptomatic supportive treatments and the original dose of carvedilol, participants will be administered with compound alverine citrate capsules (Le Jian Su; specification: each capsule contains alverine citrate 60 mg and simeticone 300 mg; manufactured by Laboratoires MAYOLY SPINDLER), at a dosage of 180 mg/day (1 capsule orally, 3 times a day), for a continuous period of 24 weeks.
223846704|NCT06698016|DRUG|Nemtabrutinib|Oral administration
223846705|NCT06698016|DRUG|Efavirenz|Oral administration
223846706|NCT06697639|BEHAVIORAL|Rehabilitation Group|In addition to routine postpartum care, small-sized WAFF air cushions will be issued during the hospitalization period to guide patients in performing the WAFF pelvic-abdominal mechanical rehabilitation exercises. Patients will also be instructed to join the experimental group's WeChat group. After discharge, researchers will upload WAFF pelvic-abdominal mechanical rehabilitation instructional videos. Patients are required to complete their rehabilitation exercises twice daily, each session lasting 10-15 minutes. Patients need to upload their exercise videos twice a week, and researchers will provide motion guidance based on the video content until the patient's postpartum follow-up examination. The abdominal rectus muscle, pelvic floor muscle function, and adherence to rehabilitation exercises will be assessed for patients in both groups at 6-8 weeks and 6 months postpartum.
223846707|NCT06696976|OTHER|Telerehabilitation|"A qualified physiotherapist himself used the digital platform Zoom (Zoom Video Communications or WhatsApp video communication) to deliver synchronic online sessions (60 min each), sending each participant a link by email, half an hour before the weekly meetings. The patients were also invited to present themselves in comfortable gymnastic clothing and with tools useful for the motor program: a chair, a stick, a bottle full of water (or small weights if the patient had them), and a mat.~Nerve gliding exercises: These 5 Nerve gliding exercises will perform 3 times a week requiring 10 minutes to complete.~Balance exercises: Balance exercise include 10 exercises and take 20 minutes of completion, 2minute for each exercise.~Resistance training using Thera Band will performed with the presence of the researcher as an instructor.The main upper-extremity movements consisted of chest press, shoulder press etc and in lower extremity such as leg press ,back thgh press etc. in patient."
223846708|NCT06696976|OTHER|Clinical rehabilitation|"A qualified physiotherapist himself used the digital platform Zoom (Zoom Video Communications or WhatsApp video communication) to deliver synchronic online sessions (60 min each), sending each participant a link by email, half an hour before the weekly meetings. The patients were also invited to present themselves in comfortable gymnastic clothing and with tools useful for the motor program: a chair, a stick, a bottle full of water (or small weights if the patient had them), and a mat.~Nerve gliding exercises: These 5 Nerve gliding exercises will perform 3 times a week requiring 10 minutes to complete.~Balance exercises: Balance exercise include 10 exercises and take 20 minutes of completion, 2minute for each exercise.~Resistance training using Thera Band will performed with the presence of the researcher as an instructor.The main upper-extremity movements consisted of chest press, shoulder press etc and in lower extremity such as leg press ,back thgh press etc. in patient."
223846709|NCT06698029|OTHER|VIM Targeting|Targeting with the use of VIMRS-LAT-1.0
223846710|NCT06696859|DRUG|Antibiotics|Bacterial culture (sputum ,blood and pleural fluid) Antibiotics sensitivity tests
223846711|NCT06698315|OTHER|Observation|Medical Records Chart Review
223846712|NCT06697288|OTHER|Tested product group|Apply the test product per zone at least twice a day on the face, neck (neck \& nape), décolleté and back of the hand in the morning and at midday whatever the weather conditions and the activities of the day
223846713|NCT06697288|OTHER|Control group|Maintain their normal routine of using cosmetics (cleansers and moisturizers) and normal sun protection habits (if applicable)
223846714|NCT06696937|OTHER|Tai chi|Tai chi is a practice that involves a series of slow gentle movements and physical postures, a meditative state of mind, and controlled breathing. Tai chi originated as an ancient martial art in China. Over the years, it has become more focused on health promotion and rehabilitation.
223846715|NCT06696937|OTHER|full body vibrator|Advocates say that as little as 15 minutes a day of whole-body vibration three times a week may aid weight loss, burn fat, improve flexibility, enhance blood flow, reduce muscle soreness after exercise, build strength and decrease the stress hormone cortisol.
223846716|NCT06696144|DIAGNOSTIC_TEST|Skin swabs for multi drug resistant bacteria|Swabs from personal items or skin will be obtained from stuff and analyzed to detect CVE or VRE bacteria using Automated Susceptibility Testing
223846717|NCT06697665|BIOLOGICAL|LM103|Patients were treated with PD-1, cyclophosphamide and fludarabine, LM103 and IL-2 treatment.
223846718|NCT06697548|OTHER|Pain Neuroscience Education|Participants will watch and discuss a short (5-minute) standardized pain neuroscience education video with their treating provider. The video explains and illustrates how chronic pain is different than acute pain in that it concerns nervous system hypersensitivity more than local tissue damage. Pain neuroscience education principles from the video will then be used to throughout all interventions to coach the participants through graded exposure of activities that may have previously been painful or provoked anxiety.
223846719|NCT06697548|OTHER|Lumbopelvic and Hip Therapeutic Exercise|These motor control exercises will focus on proprioception, coordination, and sensorimotor control training and include progressive exercises that focus on transversus abdominis, lumbar multifidus, diaphragmatic, pelvic floor muscles, and deep hip stabilizers. Exercises will progress from more stabilized (e.g., pelvic tilt, cat and cow) to less stabilized and more dynamic and functional (e.g., forward bending, eccentric squat) to mimic the demands of work duty. Exercise will be trained and progressed during the clinical visits and be performed daily at home.
223846720|NCT06697548|OTHER|Extrapelvic Manual Therapy|Thrust and non-thrust manual therapy will be applied to the lumbar facet, sacroiliac, and hip joints based upon the clinical exam in a semi-standardized manner
223846721|NCT06697548|OTHER|Extrapelvic Dry Needling|Dry needling treatment to muscles of the lumbopelvic and upper thigh regions in a semi-standardized manner based upon a palpatory examination. The palpatory examination will include the erector spinae, lumbar multifidi, gluteus medius/minimus, piriformis, illiacus, and hip adductor muscles.
223846722|NCT06697548|OTHER|Deep Paced Diaphragmatic Breathing Training|The breathing intervention will start with education describing the link between the diaphragm and the pelvic floor to include awareness of any breath holding patterns and finding positions that facilitate expansion of the ribs, abdominals, and pelvic floor muscles with inhalation. Then progressive training will be given to encourage deep breathing at a pace of approximately 6 breaths per minute.
223846723|NCT06697548|OTHER|Chronic Pelvic Pain Education|During the first visit, participants will receive and briefly discuss the 2023 standardized patient educational handout created by the International Pelvic Pain Society with their treating provider. The educational handout describes chronic pelvic pain etiology, typical symptoms, examination, and treatments.
223846724|NCT06697548|OTHER|Intravaginal and intrarectal pelvic floor physical therapy|Superficial vulvar, perineal and intravaginal manual therapy and biofeedback utilizing commonly used techniques in previous research selected based on identified impairments from the pelvic floor examination will be performed.
223846725|NCT06697249|OTHER|Analysis of postoperative CT scans checking for the feasibility of transcatheter valve-in-root implantation|CT scans of patients after biological root replacement and root repair were assessed with the 3mensio Software (Aortic valve package, 3mensio 10.1, Pie Medical Imaging. Before carrying out the measurements, markers for alignment of the aortic root and ascending aorta were placed manually. The annular area was measured for both groups. In patients after biological root replacement the area of the annulus was defined as the ring of the initial aortic valve prosthesis. Coronary buttons were measured at their lowest and highest point to define partial or full position below the valve level and the general button size. For assessment of the annular-to-coronary distance, the lower edge of the coronary button was chosen. VTC was assessed after root replacement in patients who had at least one coronary partially under the level of the valve. For this measurement a virtually inserted valve was placed in the bioprosthetic frame.
223846726|NCT06632262|DRUG|ABSK061 + ABSK043|Participants with fibroblast growth factor receptor (FGFR) mutations and FGFR gene fusions will receive a dose of ABSK061 + ABSK043 oral capsule until disease progression, intolerable toxicity, withdrawal of consent, decision by the investigator to discontinue treatment, or end of data collection timepoint if there is clinical benefit in the opinion of the investigator, has been achieved.
223846727|NCT06632262|DRUG|ABSK061+ABSK043 in combination with CAPOX|Participants with HER2-Gastric/Gastroesophageal Junction Cancer and fibroblast growth factor receptor 2( FGFR2 ) amplification and overexpression will receive a dose of ABSK061 + ABSK043 oral capsule in combination with CAPOX until disease progression, intolerable toxicity, withdrawal of consent, decision by the investigator to discontinue treatment, or end of data collection timepoint if there is clinical benefit in the opinion of the investigator, has been achieved.
223846728|NCT03853798|DRUG|AG-348|Participants will receive 5, 20, or 50 mg twice a day for up to 192 weeks (not including dose taper) unless the dose is modified for reasons related to safety.
223846729|NCT00147043|PROCEDURE|Leukapheresis|
223846730|NCT00147043|PROCEDURE|Infusion of stem cells via image guided scan|
223846731|NCT04601779|BEHAVIORAL|VIPP-PUF|The VIPP-PUF Intervention is developed as an add-on to the existing PUF-program to address infants with major cognitive and regulatory vulnerabilities identified at age 9-10 months and adapted to the settings of community health nurses. The intervention (VIPP-PUF) will be created from an evidence-based method, the Video-based Intervention to Promote Positive Parenting (VIPP), to comprise six therapeutic sessions delivered by the community health nurse during home visits over a three months period. The VIPP -PUF builds on teaching the health nurses to promote parents' sensitivity to meet infants' cognitive and regulatory vulnerabilities, while taking in account the particular needs of families of psycho-social disadvantage.
223846732|NCT06696885|OTHER|Mobile based video games and task based training|The experimental group received a mobile-based applications for 20 minutes and tasks-based training for 20 minutes per day (a total of 40 minutes), 6 days a week for 17 weeks. The time between each game was divided accordingly to work on improving hand function. The games and tasks were divided into three broad categories, Easy, Moderate, Difficult. Each category is applied for 6 weeks
223846733|NCT06698185|DEVICE|Materna Prep Device|Materna Prep Device
223846734|NCT06698185|DEVICE|Sham Control|Sham Control
223846735|NCT06697613|PROCEDURE|Hyperthermic intraperitoneal chemotherapy|Patients diagnosed with FIGO Stage 3 or stage 4 ovarian cancer received hyperthermic intraperitoneal chemotherapy with cisplatin following cytoreductive surgery including primary debulking surgery, interval debulking surgery and secondary debulking surgery.
223846736|NCT05118932|BEHAVIORAL|Mindful Movement Intervention|"There are five components that together make-up the Mindful Movement Intervention: Biomechanical Warm-ups, Yoga postures, modified Tai Chi sequence, Imaginative Play, and Reflection. During the year, participants will learn a Simplified Form of a classic Tai Chi sequence. Yoga movements will be used to prepare participants for the nuanced movements of Tai Chi practice, with both Yoga and Tai Chi providing a physical framework in which participants can track their own progress and begin to understand how to better regulate their attention, behavior and emotional responses. Imaginative Play and Reflection Activities are used to stimulate a deeper curiosity in participants about the everyday use and employment of mindfulness practice and to engage participants."
223846737|NCT06711653|DIAGNOSTIC_TEST|Vestibular evoke myogenic potential|routine Vestibular test
223846738|NCT06697119|OTHER|Fecal Microbial Transplantation|Fecal suspension is delivered to duodenal 3rd portion via esophagogastroduodenoscopy
223846739|NCT06713018|PROCEDURE|Three cannulated compression screws by navigation system|Patients with femoral neck fractures treated with three cannulated compression screws assisted by a navigation system
223846740|NCT06713018|PROCEDURE|Traditional three cannulated compression screws|Patients with femoral neck fractures treated with traditional three cannulated compression screws
223846741|NCT06711978|DRUG|Mirogabalin|Participants will receive Mirogabalin at a dose of twice daily for 4 weeks to manage CIPN pain.
223846742|NCT06711978|DRUG|Duloxetine|Participants will receive Duloxetine at a dose of once daily for 4 weeks to manage CIPN pain.
223846743|NCT06711289|DIAGNOSTIC_TEST|Carotid ultrasound measurement|Pulsed-wave Doppler acquisition of the carotid artery. One acquisition will be made with the slow-speed setting (33 mm/s) and one with the medium-speed setting (66 mm/s).
223846744|NCT06711289|DIAGNOSTIC_TEST|Vital sign measurement|Measurement of noninvasive blood pressure, at different time points before and after the induction of spinal anesthesia.
223846745|NCT06711289|DRUG|Spinal anesthesia|Following the standard of care, the patients received spinal anesthesia. The type and dosage of the local anesthetic were at the discretion of the treating anesthesiologist.
223846746|NCT06713291|PROCEDURE|Sliding compression locking plate|The patients with femoral neck fracture were treated with three cannulated compression screws or sliding compression locking plate.
223846747|NCT06713291|PROCEDURE|Three cannulated compression screws|The patients with femoral neck fracture were treated with three cannulated compression screws.
223846748|NCT05108051|DRUG|ZSP1273|ZSP1273 tablets 600mg administered orally once daily
223846749|NCT05108051|DRUG|Oseltamivir|Oseltamivir 75mg administered orally twice daily
223846750|NCT04794621|DEVICE|Electroceutical Dressing Technology-EDThi|Use of EDThi for 3 weeks post enrollment
223846751|NCT04794621|DEVICE|Adding EDTlo (Procellera®) for 3 weeks after use of EDThi|Use of EDTlo (Procellera®) for additional 3 weeks
223846752|NCT03717259|PROCEDURE|Open nephrectomy|The surgical technique for open nephrectomy consists of placing the donor in the lateral decubitus position and making an incision with or without rib resection that allows retroperitoneal access.
223846753|NCT03717259|PROCEDURE|Hand-assisted laparoscopic nephrectomy|The hand-assisted technique begins with the incision for the introduction port of the hand, the renal artery and vein are divided using endoscopic staples and the graft is manually removed.
223846754|NCT03717259|PROCEDURE|Laparoscopic nephrectomy|In the pure laparoscopic technique the patient is placed in the same position of lateral decubitus and after introducing the trocars in the abdomen, the colon is mobilized and the renal capsule is divided, the kidney is removed after performing the cut of the renal artery and vein through a suprapubic incision.
223846755|NCT06805058|OTHER|comedy therapy|Patients will be shown 10-minute Turkish comedy films prepared by the researchers
223846756|NCT06744426|DRUG|BR1015|One tablet administered alone
223846757|NCT06744426|DRUG|BR1015-2|One tablet administered alone
223846758|NCT06744426|DRUG|BR1015-3|One tablet administered alone
223846759|NCT06824402|DEVICE|Forceps Biopsy|10-12 transbronchial lung biopsies will be obtained using standard of care biopsy forceps: Olympus disposable EndoJaw (FB-211), Olympus, USA
223846760|NCT06824402|DEVICE|Cryoprobe Biopsy|3 transbronchial lung biopsies of two separate lobes will be obtained using a flexible cryoprobe: single-use, ø 1.1 mm (Erbe Elektromedizin GmbH, 20402-401) used with ERBECRYO 2 (Erbe Elektromedizin GmbH, 10402-000
223846761|NCT06917976|BEHAVIORAL|to compare the effect of environment and attitude of dentist in children visiting specialized pediatric dental clinic and general dental clinic .|the investigators will measure salivary cortisol and salivary alpha amylase and using children fear dental survey schedule - dental subscale
223846762|NCT06920212|PROCEDURE|FMT capsule|Fecal microbiota transplantation (FMT) is a method for treating imbalances in the intestinal microbiota. Its basic principle involves extracting a portion of feces from a healthy individual that contains a diverse population of beneficial bacteria, processing it, and transplanting it into the digestive system of the recipient to restore a balanced intestinal microbiota.
223846763|NCT06919276|OTHER|Vaping Device Labeling|"Participants will view one vape image (experimental stimulus) and are randomized to a label presented and the color/flavor of the vaping device presented.~The label conditions are:~1. plain (i.e., no labeling on device)~2. contains THC~3. contains 80% THC~4. contains 80% THC - HIGH POTENCY~5. contains nicotine~6. contains 5% nicotine~7. contains 5% nicotine - HIGH STRENGTH The color/flavor conditions are: mint/mint, white/original, blue/blueberry."
223846764|NCT06919237|OTHER|HIIT Intervention|Over the first 4 weeks, participants will perform 4 bouts of 2 min of high-intensity exercise at 80-90% heart rate reserve (HRR), during the next 4 weeks, participants will perform 6 bouts of 2 min of high-intensity exercise at 80-90%HRR, while in the last 4 weeks participants will perform 6 bouts of 2 min of high-intensity exercise at 90%HRR). Exercise bouts will be interspersed by 2 min of active recovery at 50-60% HRR.
223846765|NCT06919237|OTHER|MICT Intervention|Over the first 4 weeks participants in MICT will perform continuous exercise at 50-60% HRR (2x10'), during the next 4 weeks participants will perform continuous exercise at 50-60% HRR (2x12'), while in the last 4 weeks participants will perform continuous exercise at 60-70% HRR (2x15').
223846766|NCT06919237|OTHER|HRV-Guided Intervention|"Following a 10-day initial characterization period, where the HRV is measured with plethysmography continually during the night, with Whoop (https://www.whoop.com) device, the individual HRV profile is defined, still, participants will use the Whoop during all intervention to allow the updating of HRV profile. Then, considering the daily individual autonomic regulation, following a decision-making schema modiﬁed from Kiviniemi et al., (2007) \[21\], exercise intensity will be defined for the training session, i.e., if LnRMSSD7day-roll-avg remained inside the smallest worthwhile change (SWC) (SWC = 0.5 × standard deviation), high intensity or moderate-intensity training sessions is prescribed, if LnRMSSD7day-roll-avg fell outside SWC, low intensity or rest is prescribed, leading to different workloads from the predefined training programs."
223846767|NCT05396547|DEVICE|Treated with Ledinbio device|Treated with Ledinbio device
223846768|NCT05096299|DEVICE|OCS Heart|Transplanted with OCS preserved heart.
223846769|NCT06478654|PROCEDURE|Bilateral Modified Pectoral Nerve Block (PECS II).|"The procedure will be done bilateral with the patient lying in the supine position and the ipsilateral arm will be abducted and externally rotated, and the elbow flexed 90°.~The block will be managed by in-plane technique. After confirming the location of the needle with 2-3 mL of saline, 10 mL of 0.25% bupivacaine will be injected. Then, the needle will be advanced to the interfascial plane between the pectoralis minor and serratus anterior muscle, and 20 mL of 0.25% bupivacaine will be administered with the same procedure. The Block will be repeated on the other side using similar technique taking into consideration the toxic dose of bupivacaine"
223846770|NCT06478654|PROCEDURE|Bilateral Thoracic Erector spinae plane block (ESPB).|Under all aseptic precautions and sonar guided, ESP block will be managed at T4 or T5 bilateral using a high-frequency linear ultrasound probeWe will inject 20ml of bupivacaine 0.25% into interfacial plane below to erector spinae, a manifest linear pattern will be visualized uplifting the muscle. The Block will be repeated on the other side using similar technique taking into consideration the toxic dose of bupivacaine.
223846771|NCT01169805|DRUG|Ondansetron|Ondansetron/single injection/4 mg/IV
223846772|NCT01169805|DRUG|Ramosetron|Ramosetron HCl/single injection/0.3mg/IV
223846773|NCT01169805|DRUG|Palonosetron|Palonosetron HCl/single injection/0.075mg/IV
223846774|NCT01169805|DRUG|Normal saline inj|normal saline injection 2ml
223846775|NCT05601466|DRUG|QN-023a|NK cell therapy
223846776|NCT05601466|DRUG|Cyclophosphamid|Lympho-conditioning Agent
223846777|NCT05601466|DRUG|Fludarabine|Lympho-conditioning Agent
223846778|NCT05601466|DRUG|Cytarabine|Lympho-conditioning Agent
223846779|NCT05763004|DRUG|IOS-1002|monotherapy
223846780|NCT05763004|DRUG|IOS-1002 + KEYTRUDA® (pembrolizumab)|combination therapy
223846781|NCT04504903|BEHAVIORAL|Cognitive Behavioral Therapy For Work Success (CBTw)|Veterans will go to 12 weekly group sessions and will learn healthy thinking about work, positive behavioral coping related to work, and will form a work success plan based on their work goals.
223846782|NCT04504903|BEHAVIORAL|Psychoeducation|Veterans will go to 12 weekly group sessions and will learn more information about their mental health conditions. Psychoeducation modules are from the Illness Management and Recovery program.
223846783|NCT03992638|PROCEDURE|leucocyte and platelet-rich fibrin (L-PRF) in combination with CAF|Completing root coverage by coronally advanced flap technique in combination with L-PRF.
223846784|NCT03992638|PROCEDURE|CAF|Completing root coverage by coronally advanced flap technique alone
223846785|NCT01471262|PROCEDURE|Right hepatectomy|Right liver resection
223846786|NCT01471262|PROCEDURE|Extended right hepatectomy|Right hepatectomy involving 5 or more segments
223846787|NCT00359619|BIOLOGICAL|CervarixTM|Subjects were administered three doses of HPV vaccine
223846788|NCT00359619|BIOLOGICAL|HPV investigational vaccine GSK568893A, different formulations|Subjects were administered three doses of HPV investigational vaccine
223846789|NCT04774406|DRUG|olaparib, rucaparib, niraparib, talazoparib, veliparib, pamiparib, fluzoparib|All patients treated at least with 1 PARPi (alone or in combination)
223846790|NCT00716079|OTHER|Blood pressure management policies|The trial is an assessment of BP lowering management strategies, using routinely available drugs. There is some flexibility in the use of particular BP lowering agents to achieve BP targets.
223846791|NCT01260974|DRUG|Caspofungin|50mg/dd for 21dd, starting within 24h from Liver Transplantation.
223846792|NCT00117611|DRUG|Anti-IgE antibody omalizumab or placebo|given subcutaneously oce or twice monthly depending on dose
223846793|NCT05759221|PROCEDURE|Bronchoscopy with airway biopsy|Forceps biopsy of peripheral airways under direct endoscopic visualisation.
223846794|NCT06518005|DRUG|Imlifidase|Imlifidase: single administration (dose is confidential), Lyophilized powder for concentrate for solution for infusion
223846795|NCT06518005|DRUG|GNT0003|GNT0003: single administration 5E+12 VG/kg, Sterile concentrate for solution for infusion
223846796|NCT00878384|DRUG|Medication to control ventricular rate in AF|Standard pharmacologic rate control. Current therapy will be adjusted to achieve rate-control targets of \<80bpm and \<110bpm on exercise (6 minute walk). Where necessary, additional medication will be given as per standard practice (digoxin or beta-blocker). Typical does: Digoxin 62.5-250mcg o.d. ; Bisoprolol 1.25-20mg o.d.; Carvedilol 3.125-50mg b.d. ; Nebivolol 1.25-10mg o.d.
223846797|NCT00878384|PROCEDURE|Catheter Ablation for Persistent Atrial Fibrillation|Radiofrequency catheter ablation, which may include pulmonary vein isolation, atrial substrate modification, and/or linear ablation.
223846798|NCT06710561|DRUG|SPN01 for Injection|After each subject was randomly assigned, different doses of SPN01 for Injection (0.02 mg/kg, 0.06 mg/kg, 0.12 mg/kg) were administered intravenously in a single dose.
223846799|NCT06710561|OTHER|Placebo|After each subject was randomly assigned, a single intravenous injection of 0.9% sodium chloride was administered
223846800|NCT06710561|DRUG|SPN01 for Injection|Colorectal cancer subjects will receive intravenous injection of SPN01 0.06 mg/kg for a single dose.
223846801|NCT03919617|DRUG|REMD-477|4-Week, open-label, once weekly subcutaneous injection with 70mg REMD-477.
223846802|NCT05406934|BIOLOGICAL|Infliximab|obseravation with investigation
223846803|NCT02807753|OTHER|Ankle and Knee Ultrasound Joint Assessment|Ultrasound Examination of the ankles and knees
223846804|NCT02807753|OTHER|Ankle and Knee Magnetic Resonance Imaging|Ankle and Knee Magnetic Resonance Imaging
223846805|NCT00256308|DRUG|Oxaliplatin|70mg/m2 IV over 120 min once a week during radiation
223846806|NCT00256308|PROCEDURE|Radiation|200 cGy/day - Megavoltage equipment with energy of Cobalt 60 or higher - Daily from Monday to Friday
223846807|NCT01419717|DRUG|Denosumab|Administered by subcutaneous injection every 4 weeks (Q4W)
223846808|NCT02857283|OTHER|Ozone|Participants will be exposed to a concentration of ozone for 6.5 hours at a concentration that varies 0.06 to 0.08
223846809|NCT02857283|OTHER|Filtered Air|Participants will be exposed to filtered clean air
223846810|NCT02857283|DEVICE|Health and Exposure Tracker (HET)|Ozone and heart rate tracker
223846811|NCT04885595|PROCEDURE|Forceps biopsy and cryobiopsy|Once the nodule is visualized by radial EBUS, the position of the probe in relation to the lesion is noted. Routinely, forceps biopsy and cryobiopsy are used serially in each patient within the same session.
223846812|NCT03698136|OTHER|Stimulation of denervated muscles|The study investigates the effect of electrical stimulation on denervated muscles in the forearm and hand regarding muscle structure and thickness. The study will be performed on tetraplegics who have either paralysed the wrist extensor, the short thumb spreader or the muscle between the thumb and index finger.The study lasts 12 weeks and consists of an ultrasound examination at the beginning and end of the study and an intermediate stimulation phase.The stimulation takes place either during an inpatient stay or at home for 12 weeks, 5 times a week 33 minutes.
223846813|NCT04740255|DEVICE|Straberi Epistamp|The patient's entire face will be treated. The following settings will be used as a treatment protocol. Needle length between .02- 1.55 mm
223846814|NCT01626274|DEVICE|LAVIMO in- ear sensor system|Long term vital signs parameters like heart rate, heart rate variability, breathing and oxygen saturation are measured via in- ear sensor system during 1 polysomnographic night
223846815|NCT05949372|OTHER|Giving a biological breastfeeding position|The mother is half-sitting, in the most comfortable position where she can make eye contact with her baby. The baby's head is placed on the mother's chest with her legs on the mother's stomach. With this position, gravity fixes the baby's whole body to that of its mother.
223846816|NCT05949372|OTHER|Giving a football ( armpit) position|The mother sits upright, leaning back, and the baby's bottom and the right or left side of the mother is supported by pillows from whichever side she will breastfeed. The baby's head is placed on the breast that is breastfed and the feet are laid flat so that they pass under the armpit of the breastfed side. While the mother's hand on the breastfeeding side holds the baby's head, the other hand directs the breast towards the baby and breastfeeding is initiated.
223846817|NCT02018666|DEVICE|NAVA endotracheal tube|
223846818|NCT00114803|DRUG|Calcitonin nasal spray (salmon)|
223846819|NCT00587288|BIOLOGICAL|Reslizumab|
223846820|NCT00587288|OTHER|Saline|
223846821|NCT04444180|DIAGNOSTIC_TEST|Virtual hand illusion (VHI)|Using VHI, the two basic self-representation of sense of ownership and sense of agency of the subjects will be observed.
223846822|NCT04107519|BEHAVIORAL|Goal-Directed Resilience Training|This pilot study seeks to test the efficacy of a resilience skills training intervention for former football players who experience chronic pain. Between 20 to 48 eligible and consented participants from the Atlanta area will be identified (with a goal of 40 completing the study). They will undergo a pre-training test session and will then be randomized to either the Immediate GRIT (ImT) training intervention or the Delayed Training (DeT) control. The immediate (ImT) group will be trained for 4 weeks with 2 biweekly sessions. At the end of GRIT training they will be post-tested. The delayed (DeT) group wait during these 4 weeks and do not receive training. At the end of the 4-week waiting period, they will also be post-tested. At this point, they will be offered GRIT training for 4 weeks with 2 biweekly sessions. At the end of their training, they will be given a second post-testing. This process will then be repeated for two additional groups of 5-12 lmT and 5-12 DeT participants.
223846823|NCT01207908|DRUG|IGF-1|IGF-1 will be administered once daily by subcutaneous injection every morning with breakfast. Duration 6 months.
223846824|NCT06306859|BEHAVIORAL|Using m-health for monitoring and education provision|The intervention group will be given access to m-health. The m-health aims to monitor patient's status i.e blood pressure, heart rate, fluid intake, dietary intake. In addition, there will be education provided through the m-health. The education will be on fluid and diet adherence
223846825|NCT06306859|OTHER|Standard care|The comparator group will be given standard and routine care
223846826|NCT05080192|DRUG|Fenofibrate|145 mg/d of Tricor (administered as part of the parent FERMIN trial) for 10 days, or renal corrected dose equivalent (depending on renal function)
223846827|NCT05080192|DRUG|Placebo|Matching placebo (once/day) for 10 days
223846828|NCT05074498|DRUG|TB006|intravenous infusion
223846829|NCT05074498|DRUG|Placebo|intravenous infusion
223846830|NCT04944693|OTHER|Different ATS values.|"Observational, different ATS values were measured on MRI images and were regarded as interventions for different cohorts."
223846831|NCT00161447|DRUG|Acyline|Acyline 300 mcg/kg SQ every 2 weeks for 12 weeks
223846832|NCT00161447|DRUG|Testosterone Gel|Testosterone Gel (10 g daily
223846833|NCT00161447|DRUG|Depo-Medroxyprogesterone|DMPA (injected into muscle) Day 0 \& month 3
223846834|NCT01240356|DEVICE|2-MHz transcranial Doppler ultrasound|2-hours of hands-free ultrasound will be insonated continuously. A brain MRI with gadolinium will be performed before and after the ultrasound.
223846835|NCT01240356|DEVICE|2-MHz transcranial Doppler ultrasound insonation|2-hours of hands-free ultrasound delivered to in the intracranial vessels.
223846836|NCT00287573|DEVICE|TAXUS Express2|Paclitaxel-Eluting Coronary Stent System
223846837|NCT00287573|PROCEDURE|Brachytherapy (beta source)|Brachytherapy (beta source)
223846838|NCT02756104|OTHER|phenotyping Tcells|Collecting blood for analyses of the T cells phenotypes
223846839|NCT02756104|OTHER|Supplementation in vitamin D|Supplementation in vitamin D for the patients who are deficient on vitamin D
223846840|NCT06306846|RADIATION|SBRT+immunochemotherpy|SBRT radiotherapy，followed with PD-1 monoclonal antibody and TP chemotherapy
223846841|NCT06306846|DRUG|Immunochemotherapy|PD-1 monoclonal antibody and TP chemotheapy
223846842|NCT06306846|DRUG|cetuximab+immunochemotharpy|PD-1 monoclonal antibody and TP chemotheapy combined with cetuximab
223846843|NCT01106703|DIETARY_SUPPLEMENT|PG102, a water soluble extract from Actinidia arguta|PG102 two tables(Actinidia arguta extract:Microcrystalline cellulose(1:1)mixed powder 1120mg) twice a day for 8weeks
223846844|NCT01106703|OTHER|placebo|placebo two tables(equivalent dose of Microcrystalline cellulose) twice a day for 8weeks
223846845|NCT00578435|PROCEDURE|Busulfan, Cyclophosphamide, BMD|Busulfan 0.8 or 1 mg/Kg/day Days 8-6 Cyclophosphamide 50 mg/Kg/day Days 2-5 BMT Day 0
223846846|NCT04911686|DEVICE|rod distraction|Our study entails the application of a simple method for correction of FKFD in younger children using a simple cast distraction technique. This conservative method aims at avoiding the complications of surgery in children while achieving a reasonable amount of correction.
223846847|NCT06479564|OTHER|free weight training and machine training|20 participants will be in control group who will only perform free weight and machine training
223846848|NCT06479564|OTHER|Aerobic Exercises|20 participants will be in experimental group giving them aerobic exercise training protocol along with free weight and machine training
223846849|NCT04599114|BEHAVIORAL|VIRTUES|VIRTUES is a digital health platform that offers 2 way communication between clinicians and patients to address symptoms stemming from atrial fibrillation.
223846850|NCT04844099|DRUG|Dihydroartemisinin Piperaquine|Administered as dihydroartemisinin (20mg) and piperaquine (160 mg)
223846851|NCT01249300|OTHER|No intervention|No intervention
223846852|NCT00027612|DRUG|carmustine|IV
223846853|NCT00027612|DRUG|irinotecan hydrochloride|IV
223846854|NCT00027612|RADIATION|radiation therapy|
223846855|NCT04859777|DRUG|MPT-0118|MPT-0118 is an inhibitor of MALT1 protease
223846856|NCT04859777|DRUG|MPT-0118 + pembrolizumab|MPT-0118 is an inhibitor of MALT1 protease; pembrolizumab is a PD-1 inhibitor
223846857|NCT03960255|OTHER|Normal standard care|Both groups will receive standardized treatment and care for diabetic foot ulcers
223846858|NCT04751747|PROCEDURE|Computed Tomography|Undergo CT simulation
223846859|NCT04751747|OTHER|Contrast Agent|Given IV
223846860|NCT01554592|DRUG|Withdrawal of statin therapy|Participants currently received statin therapy will have their statin stopped for 12 weeks.
223846861|NCT01554592|DRUG|Statin therapy|Participants will continue on stable statin therapy.
223846862|NCT04701060|DRUG|Camrelizumab:200mg， iv，d1 q2w;apatinib:250mg,po，qd，q2w|preoperative：Camrelizumab ：200mg， iv，d1 q2w；apatinib：250mg,po，qd，q2w；four cycles， operation postoperation 4-8weeks，Camrelizumab ：200mg， iv，d1 q2w；apatinib：250mg,po，qd，q2w；Up to one year
223846863|NCT06277622|DEVICE|PFUN|perform preoperative preparation, intraoperative operation and internal fixation implantation according to the instructions provided in the product packaging.
223846864|NCT06277622|DEVICE|PFNA|perform preoperative preparation, intraoperative operation and internal fixation implantation according to the instructions provided in the product packaging.
223846865|NCT03470987|PROCEDURE|Phase I Periodontal therapy|Oral hygiene instuction, scaling and root planning
223846866|NCT03470987|DIETARY_SUPPLEMENT|Metabolic control|Calorie restricted diet
223846867|NCT05224362|DEVICE|A repeated measures acute study using using elastic resistance bands in older adults to challenge stability.|A repeated measures acute study using using elastic resistance bands in older adults to challenge stability. Exercises with an elastic resistance band anchored from the ground and placed at the hip and chest region will be trialled. Bertec force plate analysis will be performed to assess the acute effects on balance and stability. A semi- structured interview will identify the impact and practicalities of the intervention. The information will be used in the development of an evaluation process with key consideration of the planning phase of the intervention. Questions with verbal cues to provide perceptions of the exercise selection such as likes/ dislikes, safety, confidence, difficulty, enjoyment and band placement will be asked to determine the acceptability, accessibility, appropriateness and usability of the protocol and build insights into the participant preferences.
223846868|NCT03631563|DRUG|Immunosuppressive Agent|ATG-Fresenius versus ATG
223846869|NCT02967016|BEHAVIORAL|Actigraph|following delivery a ActiGraph will be offered to patients to track their steps
223846870|NCT06145256|DEVICE|MRI brain, MSCT brain, Transcranial Ultrasound|MRI, MSCT and transcranial Ultrasound are an important diagnostic modalities in the assessment of severity and outcome of HIE
223846871|NCT03423394|BEHAVIORAL|Motivational Enhancement Therapy|The MET intervention will consist of three 45-90 minute telephone delivered sessions that will be staggered to occur 1 week, 1 month, and 2 months after the baseline assessment. The first MET session intervention will involve a counselor using motivational interviewing (MI) strategies to establish an empathic therapeutic relationship and focus learning about the PTSD symptoms the participant is experiencing and exploring ambivalence about seeking treatment services. MET sessions 2 and 3 will focus on identifying and responding to risk factors for dropping out of treatment (increases in ambivalence, avoidance behavior, concerns about stigma, life chaos), identifying and responding to barriers to participant's active engagement in treatment, and facilitating enrollment in alternate therapeutic resources if necessary.
223846872|NCT03423394|BEHAVIORAL|Treatment as Usual|TAU will include a written referral list comprised of PTSD resources including information on in-person treatments, self-help, web-based and bibliotherapy options. At the completion of the study, participants in the TAU condition will be offered the MET intervention.
223846873|NCT06411145|DRUG|OXERVATE® 0.002%|Cenegermin-bkbj (20 mcg/mL) is an ophthalmic solution contained in a multiple-dose vial. The topical drops are administered 6 times/day for a 8-week course.
223846874|NCT02770040|DRUG|Infliximab|INFLIXIMAB (REMICADE) in the form of a freeze-dried compound is conditioned in 100mg vials. Treatment will first be reconstituted in 250ml isotonic saline solution and infused
223846875|NCT03972293|BEHAVIORAL|Intern Health Study behavioral change mobile notification|The study's mobile app will be used to deliver intervention notifications. The intervention notifications appear on the participant's phone lock screen. The notifications have 3 categories: mood notifications, activity notifications, sleep notifications. Mood notifications aim to increase the participant's mood. Activity notifications aim to increase the participant's physical activity. Sleep notifications aim to increase the participant's sleep duration. To increase the category of interest, the notifications use two types of messages: life insights and tips. Life insights provide participants information on their historical data (for a given category) in order to help them self-monitor. Tips are non-data based notifications which provide general advice for improving the category of interest.
223846876|NCT03972293|BEHAVIORAL|Intern Health Study mobile app|The Intern Health Study mobile app is able to conduct a daily mood survey. It also aggregates and visualizes historical data on intern mood, activity, and sleep.
223846877|NCT04550650|OTHER|Training groupe|Using virtual training
223846878|NCT04550650|OTHER|PNF|PNF technique was used
223846879|NCT04550650|OTHER|Spinning grp|They only worked with spinning bikes.
223846880|NCT04550650|OTHER|Balance|Balance development was done
223846881|NCT04004702|DRUG|Levetiracetam|Levetiracetam 500mg twice a day
223846882|NCT01576315|DRUG|Itraconazole/voriconazole|The two treatments will be administered orally for 6 months One doage of treatment permitted based on plasma levels will be performed after two weeks of treatment.
223846883|NCT04675411|DEVICE|Smart care|Home based nursing intervention with smart assisted technology
223846884|NCT04675411|DEVICE|usual care|Routine hospital care with only in-hospital rehabilitation
223846885|NCT01459315|DRUG|dolutegravir|Subjects will take a GSK1349572 (dolutegravir) 50mg tablet by mouth once daily for 8 days. GSK1349572 concentrations will be measured in blood plasma, seminal fluid, rectal fluid, and rectal tissue over 24 hours after a single dose and over two 24 hour periods once steady state is reached. Blood plasma will be collected pre-dose and 1, 2, 3, 4, 5, 6, 8, 12, 18, and 24 hours after dosing. Each subject will also provide a total of 9 seminal and rectal fluid samples and have 2 rectal tissue biopsies performed pre-dose or at 1, 3, 6, 12, 18, or 24 hours after receiving single or multiple doses.
223846886|NCT04029740|BEHAVIORAL|CBT- both internet and face to face|There are a few common psychotherapies for treating PD, with Cognitive Behavioral Therapy (CBT) as the most common. The most known type of CBT for treating PD consists of two major strategies: cognitive restructuring, and interoceptive and structured exposure to bodily sensations that have become associated with panic attacks (D H Barlow, 1997). The ICBT therapy is based on Barlow and Craske's (2007) protocol for treating PD with elaborations (Huppert \& Baker-Morissette, 2003). It includes six modules containing psychoeducation, cognitive restructuring, exposures, acceptance, and consolidation of gains and relapse prevention. The online modules include reading passages, worksheets, videos, and homework assignments. After completing each module, participants practice related skills and complete homework assignments. The treatment is up to 16 weeks long; participants are encouraged to complete the treatment within this time period, and reminders are sent to monitor their progress.
223846887|NCT04029740|OTHER|No intervention|Healthy controls will not receive any intervention.
223846888|NCT03712293|DEVICE|BBB Disruption with Chemotherapy Arm|The ExAblate BBB disruption of targets associated with enhancing post-resection MRI imaging procedure will be performed with ExAblate 4000 type 2.0 system and will coincide with on one of three first days of each planned TMZ adjuvant therapy cycle as one procedure per cycle.
223846889|NCT01218503|BEHAVIORAL|CHOICES - obese|Standard group behavioral weight loss treatment
223846890|NCT04759339|DRUG|AG-920|AG-920 is a sterile, isotonic, non-preserved aqueous solution containing the active ingredient Articaine HCl 8%
223846891|NCT04045366|OTHER|Sample collection|Plasma and BAL sample collection
223846892|NCT06184789|DIAGNOSTIC_TEST|Echocardiographic assessment|Echocardiographic and hemodynamics assessment of Mitraclip results
223846893|NCT02723851|DEVICE|Corsens|Recording and calculating Peak Endocardial Acceleration (PEA) Myocardial Contractility Index \[MCI\] and isovolumetric contraction (IVCT). Measurements will not affect the treatment provided to the patients.
223846894|NCT00306683|DRUG|DIAZOXIDE|
223846895|NCT03155204|DRUG|tiotropium pMDI|inhalation
223846896|NCT05137951|DEVICE|Rebee sensor|Rebee is a wearable motion sensor package of sensor with its own mobile application, which measures range of joint movement in different planes easily which the patient able to wear the sensor and move easily to measure ROM and record the measurement at the application software Digital goniometer Goniometry has been described as a tool to measure angle. It gives the physician a useful method to diagnose musculoskeletal function in terms of ROM, monitor the progress of an intervention, record the data for future follow-up, and meet statutory and legal requirements for impairment rating and disability determinations where applicable
223846897|NCT06634537|DEVICE|Active Comparator: insoles hard, soft and barefoot|"Primary Outcome Measure:~1\. Stabilometry The measurements were conducted University. To assess participants' balance, the anthropometric position of the protocol proposed by the International Society for the Advancement of Cineatropometry (ISAK) was assigned: participants placed their mi Frankfort; the upper limbs remained relaxed throughout the body, with palms facing forward and thumbs separated from the rest of the toes, and were barefoot with feet externally rotated f 30 degrees and with a heel distance of 4cm.~The children were wearing sports costumes to contribute their free movement. For stabilometry data collection will use an inertial measurement instrument called Gyko® It is a state-of-the-art device that allows to measure an objective assessment of acceleration, angular velocity and with an acquisition frequency of 100Hz \[Time Frame: pre intervention, 3 months post intervention, 6 months post intervention\]"
223846898|NCT02886988|DRUG|Botulinum toxin type A|50 units of botulinum toxin diluted in 1 ml of normal saline will be administered. 0.1mlof BTA will be injected with a 30G needle.
223846899|NCT02886988|DRUG|normal saline|0.1mlof normal saline will be injected with a 30G needle.
223846900|NCT02579512|OTHER|Extra-corporeal ECG signal analysis|The NIA algorithm is similar to the traditional 12-lead ECG equipment. By analyzing patient data, NIA algorithm provides more detailed results compared to traditional 12-lead ECG. Patients with suspected coronary artery disease are conventionally diagnosed and treated by cardiac catheterization. However, cardiac catheterization is invasive procedure. Unless clinical diagnosis is evident before cardiac catheterization, a treadmill exercise test, a nuclear medicine myocardial perfusion test, or a multi-direction coronary CT angiogram is usually performed to increase the accuracy of diagnosis. But these examinations are not accessible to all patients, and are time-consuming and costly.
223846901|NCT00398502|DRUG|MOA-728|
223846902|NCT04879134|DRUG|Apomorphine Injectable Solution|"Patients will receive the treatment while they are in an OFF period, without the effect of any antiparkinsonian medication. For this study, the initial dose of apomorphine or placebo will be 2 mg. We selected an initial standardized dose based on the pharmacological characteristics of apomorphine. Assessments will be completed 30 and 60 minutes after the initial dose. At 60 minutes from the first dose, a 3 mg dose will be administered, and again, assessments will be completed after 30 and 60 minutes. The total given dosage will be 5 mg. Blood pressure and pulse will be checked every 20 minutes after injections.~Other Names:~Movapo"
223846903|NCT04879134|DRUG|Placebo|"0.9% saline placebo injection~Other Names:~• Saline"
223846904|NCT03797235|PROCEDURE|Dominant Arm|The volume of local anesthetic used for the block of the ulnar and median nerve will be 5 times the estimated 95% effective dose (ED 95 ) of LA needed to block the nerve relative to the nerve cross-sectional area. The ED 95 for the ulnar nerve has been elucidated to be 0,11ml/mm2. The same ED 95 will be used for the median nerve.
223846905|NCT03797235|PROCEDURE|Non-dominant arm|The volume of local anesthetic used for the block of the ulnar and median nerve will be 5 times the estimated 95% effective dose (ED 95 ) of LA needed to block the nerve relative to the nerve cross-sectional area. The ED 95 for the ulnar nerve has been elucidated to be 0,11ml/mm2. The same ED 95 will be used for the median nerve.
223846906|NCT00731107|PROCEDURE|laparoscopic surgery|XCEL bladeless trocar laparoscopic entry
223846907|NCT00731107|PROCEDURE|laparoscopic surgery|Veress Needle laparoscopic entry
223846908|NCT00450502|DRUG|Batracylin|
223846909|NCT06098027|DRUG|[14C]CS0159|Single oral administration of 4mg \[14C\]CS0159
223846910|NCT04248764|OTHER|Foam roller application|Following the fatigue protocol, foam roller application will be applied to the quadriceps femoris muscle for five minutes in the prone position.
223846911|NCT04248764|OTHER|Massage application|Following the fatigue protocol, sports massage will be applied to the quadriceps femoris muscle for five minutes.
223846912|NCT01450878|DRUG|beta-epoietin|100 000UI beta-epoietin injection one hour before organ retrieval
223846913|NCT03401788|DRUG|Belzutifan|120 mg once daily (three 40 mg oral tablets once daily).
223846914|NCT06527027|OTHER|Lymph node assessment according to RECIST 1.1 in CT|RECIST 1.1 classifies lymph nodes as healthy when they have a short axis dimension (SAD) of \<10 mm; Nodes with a SAD dimension \>=10 mm are considered to be involved in the cancer process.
223846915|NCT06527027|OTHER|Lymph node assessment according to Node-RADS in CT|Node-RADS classifies lymph nodes taking into account parameters such as: size, degree of homogeneity, boundaries and shape of the node. Depending on the degree of change in a given parameter, an appropriate number of points are awarded in each category, and the sum of the points determines the final classification of the node into one of five categories of probability of being affected by a cancer process: 1-very low, 2-low, 3-medium, 4 -high, 5-very high.
223846916|NCT06527027|OTHER|Lymph node assessment according to LN-RADS in CT|"LN-RADS (Lymph Node Reporting and Data System) categorizes nodes according to a scale that reflects the radiological and clinical forms of the nodes and the level of probability of a malignant process:~LN-RADS 1 - normal lymph node LN-RADS 2 - enlarged and fatty lymph node, not suspected from an oncological point of view LN-RADS 3 - lymph node with features suggesting reactive changes. LN-RADS 4a - lymph node with slight oncological suspicion LN-RADS 4b - lymph node with strong oncological suspicion LN-RADS 5 - definitely cancerous node"
223846917|NCT06527027|OTHER|Lymph node assessment according to RECIST 1.1 in MRI|RECIST 1.1 classifies lymph nodes as healthy when they have a short axis dimension (SAD) of \<10 mm; Nodes with a SAD dimension \>=10 mm are considered to be involved in the cancer process.
223846918|NCT06527027|OTHER|Lymph node assessment according to Node-RADS in MRI|Node-RADS classifies lymph nodes taking into account parameters such as: size, degree of homogeneity, boundaries and shape of the node. Depending on the degree of change in a given parameter, an appropriate number of points are awarded in each category, and the sum of the points determines the final classification of the node into one of five categories of probability of being affected by a cancer process: 1-very low, 2-low, 3-medium, 4 -high, 5-very high.
223846919|NCT06527027|OTHER|Lymph node assessment according to LN-RADS in MRI|"LN-RADS (Lymph Node Reporting and Data System) categorizes nodes according to a scale that reflects the radiological and clinical forms of the nodes and the level of probability of a malignant process:~LN-RADS 1 - normal lymph node LN-RADS 2 - enlarged and fatty lymph node, not suspected from an oncological point of view LN-RADS 3 - lymph node with features suggesting reactive changes. LN-RADS 4a - lymph node with slight oncological suspicion LN-RADS 4b - lymph node with strong oncological suspicion LN-RADS 5 - definitely cancerous node"
223846920|NCT06631859|OTHER|Cosmetic products containing 0% Assam tea|Cosmetic products containing 0% Assam tea
223846921|NCT06631859|OTHER|Cosmetic products containing 2.5% Assam tea|Cosmetic products containing 2.5% Assam tea
223846922|NCT01996644|DRUG|Placebo vs Setraline|Placebo
223846923|NCT01996644|DRUG|Setraline|250mg DCS
223846924|NCT04760444|BEHAVIORAL|Peer Leader Diabetes Self-Management Support|While the effectiveness of peer-led interventions delivering diabetes-related education and support for short-term clinical, psychosocial, and behavioral improvements is well-established, older Black men in particular are less likely to participate and are at a higher risk of drop-out from these studies. This intervention aims to determine if using older Black men as peer leaders to other older Black men will improve retention rates for this population.
223846925|NCT04760444|BEHAVIORAL|Virtual Diabetes Self-Management Education|Participants will attend 10 hours of virtual group diabetes self-management education classes led by a certified diabetes care and education specialist through the online HIPPA compliant Zoom, Med platform.
223846926|NCT06429410|DIETARY_SUPPLEMENT|fortified formula milk powder|Fortified formula milk powder supplemented with whey protein, calcium, vitamin D, colostrum basic protein, β-hydroxy-β-methylbutyrate, and sodium hyaluronate per day orally for 24 weeks.
223846927|NCT06429410|DIETARY_SUPPLEMENT|formula milk powder|Formula milk powder supplemented with whey protein, calcium, vitamin D, colostrum basic protein, and sodium hyaluronate per day orally for 24 weeks.
223846928|NCT06429410|DIETARY_SUPPLEMENT|regular milk powder|Regular milk powder does not contain and additional supplementation, and the color, flavor, shape, taste, and weight are same with the formula milk powder.
223846929|NCT02404454|PROCEDURE|Hysteroscopic metroplasty|
223846930|NCT02404454|DEVICE|Autocross-linked acid hyaluronic gel|Patients received adhesion barrier with 5 ml of autocross-linked acid hyaluronic gel
223846931|NCT02404454|PROCEDURE|Office second look hysteroscopy|Second-look hysteroscopy after three months
223846932|NCT00362193|BEHAVIORAL|Telephonic diabetes care|
223846933|NCT04471467|PROCEDURE|Fixed tracheal tube|Tracheal tube fixation is determined by the surgeon according to the needs of the operation and is an independent process. Our research simply installed a monitoring device between the tube and the nose. The tube fixation takes place whether the observation of pressures is agreed to or not, as per standard protocol.
223846934|NCT04664777|DEVICE|Masimo Model RDS7A|Masimo monitoring platform equipped with Radical-7 Pulse CO-Oximeter fingertip probe for measurement non-invazive hemoglobin level (SpHb) an perfusion index (PI)
223846935|NCT02510534|DRUG|Menopur 150 international units|Menopur 150 international units given x 1 dose
223846936|NCT02510534|DRUG|Endometrin 100 mg|Endometrin 100mg twice daily x 14 days
223846937|NCT04205032|DEVICE|Test of the different devices integrated in cardiospace II|"The different devices included in CARDIOSPACE II will be tested~* Electrocardiogram~* Vascular Doppler~* LaserDoppler and iontophoresis~* Brachial blood pressure~* Continuous blood pressure recorded at the finger level~* Ultrasound~* Ambulatory Electrocardiogram / SAO2 (arterial oxygen saturation)"
223846938|NCT01954043|DRUG|Dabrafenib 150 mg twice a day (BID)|Dabrafenib dosed at 150mg twice a day from Day 1 to the morning of Day 29
223846939|NCT01954043|DRUG|Rabeprazole 40 mg once daily (OD)|Rabeprazole dosed at 40mg each morning on Days 16 to 19
223846940|NCT01954043|DRUG|Rifampin 600 mg OD|Rifampin dosed at 600mg each morning on Days 20 to 29
223846941|NCT01244984|DRUG|Fluticasone Furoate/GW642444 Inhalation Powder|Fluticasone Furoate/GW642444 inhalation powder inhaled orally once daily for 52 weeks
223846942|NCT01244984|DRUG|Fluticasone Furoate Inhalation Powder|Fluticasone Furoate inhalation powder inhaled orally once daily for 52 weeks
223846943|NCT04442659|DIAGNOSTIC_TEST|pre hospital triage tool|EMS workers fill in an application containing 10-13 vclinical items
223846944|NCT02286661|PROCEDURE|Casting (long arm)|Casting using plaster of paris after closed reduction of distal radius fracture
223846945|NCT02286661|PROCEDURE|Casting (short arm)|
223846946|NCT05157334|DEVICE|Non-invasive auricular electrical transcutaneous vagus nerve stimulation|"A NEMOS ® stimulator (Cerbomed, Erlangen, Germany) is used for transcutaneous auricular vagus nerve stimulation. This is a handheld battery driven stimulator which stimulates conca in the outer ear. It stimulates in a serie of small electrical impulses with a pulse width at 250 us and a frequency at 25 Hz for 30 minutes in a cycle for 30 seconds on and 30 seconds off to avoid habituation. It is previously indicated that a stimulation intensity at 0,5 mA, 1 mA or 1,5 mA does not cause a significant chance in HRV, thus 0,5 mA is used in this study."
223846947|NCT05157334|OTHER|Deep breathing|The participant is first verbally introduced to the breathing exercises, and then to the visually cue (animation), which the participant have to follow throughout the session.
223846948|NCT01262495|OTHER|cryopreservation|cryopreservation of testicular tissue
223846949|NCT05293301|DEVICE|Use of Periodontal Endoscope (Perioscopy®) to enhance visualization while performing teeth deep cleaning|Deep cleaning or scaling and root planing (SRP) using a Periodontal Endoscope or Perioscopy® for enhanced visualization, on teeth in one half of the mouth
223846950|NCT05293301|DEVICE|Use of traditional loupes to enhance magnification to enhance visualization while performing teeth deep cleaning|Deep cleaning or scaling and root planing (SRP) using tradional loupes for enhanced visualization on teeth, in the other half of the mouth
223846951|NCT03660605|OTHER|Rhythmic Auditory Stimulation|Participants will complete 6 weeks of walking training (3x/week). During each session, participants will walk on a treadmill for up to 20 minutes (stepping to a metronome at 85% of typical cadence) followed by overground walking for up to 15 minutes (stepping to a metronome at 115% of typical cadence).
223846952|NCT05014724|DRUG|Rozanolixizumab|Rozanolixizumab is dosed weekly. Patients should continue to receive the dose they were receiving in the CIDP04 (NCT04051944) trial.
223846953|NCT04721392|OTHER|Mental fatigue (Stroop task)|"A modified Stroop task of approximately 60 min will be used in order to induce mental fatigue (MF). This will be based on their performance during the max test that was conducted during the familiarization session. In this task, which will be partitioned in 4 blocks of 468 stimuli, four colored words (rood, blauw, groen and geel) will be presented one at a time on a computer screen. The participants will be required to indicate the color of the word, ignoring the meaning of the word itself."
223846954|NCT04721392|OTHER|Control (documentary)|In the control task subjects will have to watch a documentary of 60 min on the same computer screen as the one used for the experimental trial. In order to avoid under- and over-arousal the subjects will have the opportunity to choose between several documentaries as proposed by the research team.
223846955|NCT00427973|DRUG|cediranib maleate|Given orally
223846956|NCT00427973|OTHER|laboratory biomarker analysis|Peripheral blood was obtained from all patients enrolled for studies of early changes in circulating proangiogenic and proinflammatory molecules and cells. Blood samples were collected in EDTA-containing tubes before and after cediranib therapy on days 1 and 14 of cycle 1. Circulating VEGF, placental growth factor (PlGF), sVEGFR1, basic fibroblast growth factor (bFGF), interleukin (IL)-6, IL-8, transforming growth factor a ((TNF-a), gamma interferon (IFN-g) were measured using multiplex ELISA plates from Meso-Scale Discovery. Hepatocyte growth factor (HGF), insulin-like growth factor 1 (IGF-1), sVEGFR2, angiopoietin 2 (Ang-2), sTie2, soluble c-KIT, carbon anhydrase 9 (CAIX), and stromal cell-derived factor-1a (SDF1a) were measured using ELISA kits from R\&D Systems.
223846957|NCT00427973|PROCEDURE|computed tomography|computed tomography (CT) every 8 weeks to evaluate response and progression.
223846958|NCT00427973|PROCEDURE|dynamic contrast-enhanced magnetic resonance imaging|Magnetic resonance imaging (MRI) every 8 weeks to evaluate response and progression.
223846959|NCT00427973|OTHER|pharmacological study|Blood samples to characterize the steady-state PK of cediranib were drawn from a peripheral vein shortly before patients received the dose on days 8 and 15 of cycle 1 and at the following times relative to dosing on day 1 of cycle 2: 5 min and 1, 2, 4, 6, 8, and 24 hours, with the last sample collected before taking the next daily dose.
223846960|NCT02708459|DEVICE|surgically inserted Transversus abdominus plane catheter|at end of surgery, a surgeon will insert catheter in Transversus abdominus plane (TAP) between internal oblique muscle and Transversus abdominus muscle
223846961|NCT02708459|DRUG|Intravenous morphine|Boluses of intravenous morphine (2 mg) will be given to patients if Visual analogue scale (VAS) more than 3
223846962|NCT02708459|DRUG|Bupevecaine|
223846963|NCT02708459|DRUG|Dexmedetomedine|
223846964|NCT01287338|DRUG|Olopatadine|low dose
223846965|NCT01287338|DRUG|Olopatadine|high dose
223846966|NCT04698291|PROCEDURE|Blood Donation|The blood donation will take place at the Gene \& Health clinical assessment centre facilities. A trained member from Gene \& Health program will be responsible for taking the blood samples.
223846967|NCT06161883|OTHER|Soffritto|The intervention trial was a single-center, prospective, controlled, randomized two-arm longitudinal crossover trial lasting 16 weeks. This duration encompassed a 2-week run-in period, a 6-week intervention period (either in the soffito or control group), a 2-week wash-out period, and another 6-week intervention period (soffritto or control group).
223846968|NCT05396495|DEVICE|NeurolyserXR|Using the NeurolyserXR to non-invasively ablate the posterior sacral branches enervating the sacroiliac joint
223846969|NCT06233955|DEVICE|Low Level laser therapy|is a non-invasive light source treatment that generates a single wavelength of light. It emits no heat, sound, or vibration. It is also called photobiology or bio-stimulation
223846970|NCT06233955|OTHER|Maitland mobilization technique|is a process of examination; assessment and treatment of musculoskeletal disorders by manipulative physiotherapy where a chain of oscillatory joint mobilization grades based on the pathological limit of tissue are used
223846971|NCT01868867|BEHAVIORAL|Intervention|On line tutorial followed by text messaging during treatment and iPad for patient education
223846972|NCT00743405|DRUG|GSK1034702|Oral or liquid
223846973|NCT00743405|DRUG|Placebo|To match GSK1034702
223846974|NCT03297749|OTHER|Observational study (no intervention)|No interventions
223846975|NCT05939726|OTHER|Moisturising cream with vitamin E concentrate|The vitamin E moisturising cream contains 3% w/w of palm-oil-derived vitamin E concentrate, consisting of the following isomers: alpha-tocopherol, alpha-tocotrienol, beta-tocotrienol, gamma-tocotrienol, and delta-tocotrienol. This formula provides a total of 1.2g tocotrienols per 100g product.
223846976|NCT05939726|OTHER|Moisturising cream without vitamin E concentrate|This moisturising cream is a similar moisturising cream but without the addition of the vitamin E concentrate
223846977|NCT05939726|OTHER|Urea cream|Urea cream (10%w/w) is used as the standard of care for PPE.
223846978|NCT02072226|DRUG|Alteplase|Single dose of alteplase will be administered at 0.9 milligrams per kilogram (mg/kg) IV (maximal dose of 90 mg).
223846979|NCT02072226|DRUG|Alteplase Placebo|Single dose of alteplase placebo will be administered as IV injection.
223846980|NCT02072226|DRUG|Aspirin|Single dose of aspirin will be administered at 325 mg orally.
223846981|NCT02072226|DRUG|Aspirin Placebo|Single dose of aspirin placebo will be administered orally.
223846982|NCT06492356|DEVICE|Tripolar radiofrequency therapy|Twenty patients underwent weekly TriPollar RF treatment, using a new RF technology with three or more electrodes. Glycerin was applied to the treatment area before and after each session, with the procedure lasting 15 minutes. The technology uses a sequence of electrical modulation to prevent overheating and requires no active cooling of the electrodes or skin.
223846983|NCT06492356|DRUG|medical treatment|Twenty patients will receive medical treatment by dermatologist.
223846984|NCT01335789|DRUG|Oxytocin|40 IUs
223846985|NCT01335789|DRUG|Saline|40 IUs
223846986|NCT04378582|OTHER|risk factors|This is an observational study, so there are no interventions. Investigators will collect data about demographics, comorbidities, and other risk factors such as severity of disease at admission, need for advanced life support, need for invasive mechanical ventilation and ventilator parameters on day1 of mechanical ventilation or ICU admission as potentially association with survival
223846987|NCT00119743|BIOLOGICAL|undecavalent pneumococcal-protein D conjugate vaccine|
223846988|NCT04157842|PROCEDURE|total hip replacement with subtrochanteral osteotomy|applying subtrochanteral osteotomy during the operation to release the tension of vessels and nerve
223846989|NCT04157842|PROCEDURE|total hip replacement with no osteotomy|just total hip replacement
223846990|NCT03720340|DRUG|Recombinant Human Interleukin-11|Recombinant Human Interleukin-11 was administed through respiratory tract.
223846991|NCT03720340|DRUG|Saline|saline was administed through respiratory tract
223846992|NCT03559361|DIETARY_SUPPLEMENT|EPA-rich|6 months omega 3 supplementation
223846993|NCT03559361|DIETARY_SUPPLEMENT|DHA-rich|6 months omega 3 supplementation
223846994|NCT03559361|DIETARY_SUPPLEMENT|Olive oil Placebo|6 months placebo supplementation
223846995|NCT05951595|DRUG|Artemether-Lumefantrine-Amodiaquine (ALAQ)|A new fixed-dose combination containing artemether, lumefantrine and amodiaquine (ALAQ) will be used in the trial. Each paediatric (dispersible) tablet will contain 20 mg artemether, 120 mg lumefantrine, 40 mg amodiaquine. Adult (hard) tablets will contain either 50 mg or 60 mg of artemether, 300 or 360 mg of lumefantrine and 100 or 120 mg of amodiaquine. The treatments will be administered in 6 doses over 3 days at H0, H8, H24, H36, H48 and H60. The target dosing will be in line with the ranges recommended by the WHO (total dose of 5-24 mg/kg of artemether, 29-144 mg/ kg of lumefantrine, 22.5-45 mg/kg of amodiaquine).
223846996|NCT05951595|DRUG|Artemether-Lumefantrine (AL)|A fixed-dose combination of AL will be used in the trial. Each paediatric (dispersible) or adult (non-dispersible) tablet will contain 20 mg artemether, 120 mg lumefantrine and will be administered in 6 doses over 3 days at H0, H8, H24, H36, H48 and H60. The target dosing will be in line with the ranges recommended by the WHO (total dose of 5-24 mg/kg of artemether, 29-144 mg/ kg of lumefantrine).
223846997|NCT05951595|DRUG|Artesunate-Amodiaquine (ASAQ)|ASAQ will also be administered as a fixed dose combination. The tablets will contain 25 mg of artesunate and 67.5 mg of amodiaquine in the paediatric formulation and 100 mg artesunate, 270 mg amodiaquine in the adult formulation. The dosing will be administered once a day for 3 days at H0, H24 and H48 according to the schedule currently recommended by the WHO.
223846998|NCT04222387|DEVICE|OCT-B scan|OCT-B scan (Optical coherence tomography)
223846999|NCT02850627|DRUG|Tongguan capsule|eligible participants were randomized to receive Tongguan capsule ( 1.5 g/day for six months immediately after PCI)
223847000|NCT02850627|DRUG|placebo capsule|eligible participants were randomized to receive placebo capsule ( 1.5 g/day for six months immediately after PCI)
223847001|NCT03220139|OTHER|fat intake|Observational study on fat intake and mortality
223847002|NCT01214902|DEVICE|Constraint induced movement therapy (CIMT)|soft mitten worn on the non hemiplegic hand
223847003|NCT01214902|BEHAVIORAL|play|play which encourages the use of the hemiplegic hand
223847004|NCT02387346|DEVICE|Magstim Rapid 2 Repetitive Transcranial Magnetic Stimulation|
223847005|NCT02387346|DEVICE|Magstim Rapid 2 Sham Stimulation|
223847006|NCT04472871|DEVICE|Left atrial appendage closure|The left atrial appendage (LAA) is a small, ear-shaped sac in the muscle wall of the left atrium (top left chamber of the heart). It is unclear what function, if any, the LAA performs. In patients with heart failure and atrial fibrillation, reduced left atrial appendage (LAA) emptying velocities leads to LAA thrombus formation therefor a higher rate of stroke and embolism are observed even on oral anticoagulants. FDA approved devices for left atrial appendage closure will be used under guidance of angiography and trans-esophageal echo with highly efficient and trained personnel.
223847007|NCT06328946|BEHAVIORAL|Basic treatment|including intracranial pressure reduction, anti-infection therapy, blood pressure and blood glucose control
223847008|NCT06328946|DEVICE|Intermittent Oro-esophageal Tube Feeding|The observation group was given enteral nutritional support with Intermittent Oro-esophageal Tube Feeding according to the following procedure: Before each feeding, inside and outside of the tube was cleaned with water. During feeding, the patient should maintain a semi-reclining or sitting position with mouth opened, and the tube was inserted slowly and smoothly into the upper part of the esophagus by medical staffs while the appropriate depth of intubation was checked with the calibration markings on the tube wall. The distance from the incisors to the head part of the tube should be between 22-25 cm. However, the specific depth should be evaluated based on patients' feedback and adjusted accordingly. After insertion, the tail part of the tube should be put into a container full of water and the absence of continuous bubbles indicated a successful intubation. Then, the feeding was to be conducted three times per day with 50 ml per minute and 400-600ml for each feeding.
223847009|NCT06328946|DEVICE|Nasogastric Tube Feeding|The control group was given enteral nutritional support with Nasogastric Tube Feeding according to the relevant guidelines. Within 4 hours after admission, the placement of the feeding tube was conducted by professional medical staffs and after intubation, the tube was secured to the patient\&#39;s cheek with medical tape. The feeding was conducted once every 3-4 hours, with 200-300ml each time. The total feeding volume was determined based on daily requirements. The feeding content was formulated by the nutritionists based on the patient\&#39;s condition and relevant guidelines to reach the energy demand as 20-25 kcal/kg/day and protein supplementation of 1.2-2.0 g/kg/day for both two groups. For patients with limited tube feeding compliance, we made appropriate adjustments to ensure that they were not at risk of severe malnutrition as much as possible.
223847010|NCT05695573|DIAGNOSTIC_TEST|ACR, fasting, postprandial blood glucose ,HbA1c, creatinine, cystatin-C, BUN, Na, K , lipid profile|Use the ACR to divide diabetic patients to 3groups not normoalbuminuria, microalbuminuria, macroalbuminuria to evaluate the urinary uromodulin level and its exosomal umod mRNA as a potential biomarker of Diabetic nephropathy diagnosis
223847011|NCT01995370|DRUG|aspirin|Aspirin (81mg or 100mg) will be orally administered once daily.The treatment period will begin with the first visit of the first subject and end one year after the first visit of the last subject.
223847012|NCT01995370|DRUG|clopidogrel|Clopidogrel (50mg or 75mg) will be orally administered once daily.The treatment period will begin with the first visit of the first subject and end one year after the first visit of the last subject.
223847013|NCT01995370|DRUG|cilostazol|Cilostazol (100mg twice daily) will be orally administered. The treatment period will begin with the first visit of the first subject and end one year after the first visit of the last subject.
223847014|NCT06240039|OTHER|Evaluating the acute effect of an amino acid infusion with and without a concomitant infusion of the somatostatin analogue octreotide to eliminate endogenous production of glucagon|"The experimental days consist of four study days:~1. Assessment of liver fat and visceral fat by magnetic resonance imaging (MRI; 6-point Dixon) (study day A)~2. Somatostatin infusion (4 hours) plus amino acid infusion (45 minutes) (study day B)~3. Saline infusion (4 hours) plus amino acid infusion (45 minutes) (study day C)~4. Somatostatin infusion (4 hours) plus saline infusion (45 minutes) (study day D)~The subjects will participate in the experimental days (study day B to D) in randomized order on three different days. For study day B to D, at timepoint t = -75, subjects will receive either; a 240-minute intravenous infusion of a somatostatin analogue (at 200 ng/kg/min (infusion rate will not exceed 1000 µg/hour) or saline. After 75 minutes (timepoint t = 0), the subjects will receive a 45-minute intravenous infusion of amino acids or saline at 3.885 ml/kg/hour.~In total, blood will be sampled 11 times over a period of 6 hours and 15 minutes."
223847015|NCT03422510|DRUG|CXA-10|CXA-10 (10-nitro-9(E)-octadec-9-enoic acid) is a specific isomer of nitro-oleic acid (OA-NO2)
223847016|NCT03450109|DRUG|LY01005|One gluteal IM injection
223847017|NCT03450109|DRUG|Zoladex|One Subcutaneous injection in the abdominal wall
223847018|NCT05334082|OTHER|FIFA 11+|15 progressive exercise drills for training preparation (warm-up)
223847019|NCT01695343|BIOLOGICAL|KB001-A|
223847020|NCT01695343|DRUG|Placebo Comparator|
223847021|NCT03888820|DRUG|Biofreeze|Biofreeze is a topical analgesic that uses the cooling effect of menthol, a natural pain reliever, to soothe minor muscle and joint pain. The product will be applied immediately after walking. The participant will wait 15 minutes prior to walking again.
223847022|NCT03888820|DRUG|Placebo|The placebo is the Biofreeze product with all active ingredients removed. The product will be applied immediately after walking. The participant will wait 15 minutes prior to walking again.
223847023|NCT01364519|DRUG|Fluticasone Propionate|Dry powder for inhalation, Single Dose, 500mcg
223847024|NCT01364519|DRUG|Placebo for Fluticasone Propionate|Dry powder for inhalation, Single Dose, placebo
223847025|NCT00197457|PROCEDURE|serum pepsinogen|
223847026|NCT00197457|PROCEDURE|urea breath test|
223847027|NCT02157402|BEHAVIORAL|Social marketing activities and pop-up events to promote healthy lifestyles|
223847028|NCT05114044|OTHER|Core stability training|The core stability training were performed 5 days a week for 15 min over a period of 3 weeks. The conventional therapy were performed 5 days a week for 30 min (remaining time of each session) over a period of 3 weeks. Duration of each session was 45 min.
223847029|NCT05114044|OTHER|Conventional therapy|The conventional therapy were performed 5 days a week for 45 min over a period of 3 weeks. Duration of each session was 45 min
223847030|NCT03241498|OTHER|Medicines optimisation|
223847031|NCT04660084|DIAGNOSTIC_TEST|Ultra-rapid molecular point-of-care testing|"Ultra-rapid molecular testing (UR-MT) comprises automated detection using the new BioFire® FilmArray® Pneumonia plus platform (Biomérieux). The total turn-around time is \<2 hrs.~The UR-MT is combined with standard of care, comprising:~Microbiological processing per current standard of care entails culture of respiratory tract samples according to national protocols to detect respiratory bacteria, identified using biochemical methods and/or matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF MS). Respiratory viruses are identified using real-time PCR (for metapneumovirus, rhinovirus, influenza A, influenza B, parainfluenza 1-3, RSV and SARS-CoV-2). The total turn-around time is up to 48 hrs."
223847032|NCT02831114|OTHER|Acupuncture|Acupuncture uses tiny needles to promote blood flow, nervous system signaling, and brings the body back into homeostasis which the state of optimum functioning. Treatment for taxane induced peripheral neuropathy will consist of traditional acupuncture and will use points located in the foot (SP 3, ST 41, LR 3, K 3, GB 41), knee (SP 9, ST 36, K 10, GB 34), and arm (LI 11). Participants will continue to take their conventional therapy. Each acupuncture treatment will take place at Oriental Medicine Associates with trained acupuncturist, William Hendry. Each session should last about 30 minutes.
223847033|NCT03465007|DRUG|Hydrocortisone|we will give IV Hydrocortisone 100 mg prior to HD to the patients who developed intra-dialytic hypotension and monitor their BP response during the HD treatments.
223847034|NCT03465007|DRUG|Normal saline|we will give IV normal saline 100 mg prior to HD to the patients who developed intra-dialytic hypotension and monitor their BP response during the HD
223847035|NCT01005992|PROCEDURE|Fractional laser treatment|A complete treatment will consist in four laser sessions with a second-generation erbium-doped 1,550-nm fractional photothermolysis laser (Fraxel SR laser, Reliant Technologies Inc at 1-month intervals. Treatment will be delivered with a 15-mm tip and concomitant air-cooling system (Zimmer MedizinSystems, Irvine, CA). Fluence and treatment level will be registered on every session and will be adjusted according to patient tolerance.
223847036|NCT01005992|PROCEDURE|Standard scar management|The standard treated scar arm consists of a similar lesion in an equivalent location in the same patient or the half of a lesion that is suitable to be divided (size at least 4% body surface area). This arm will be managed only with standard burn treatment modalities.
223847037|NCT05186545|DRUG|surufatinib + fulvestrant + chidamide|surufatinib: 250 mg/d, QD PO; Fulvestrant: 500mg, im, Q4W; Chidamide 30mg, PO, BIW; Q4W
223847038|NCT04101123|OTHER|Non-Interventional|Non-Interventional
223847039|NCT00021112|DRUG|cisplatin|
223847040|NCT00021112|DRUG|etoposide|
223847041|NCT00021112|PROCEDURE|conventional surgery|
223847042|NCT00021112|RADIATION|radiation therapy|
223847043|NCT04927598|DEVICE|plasmapheresis|patients of Gullian Barrie syndrome undergo plasmapharesis
223847044|NCT03570255|DEVICE|RD SET Neo SpO2|All subjects are enrolled in the experimental group and receive the RD SET Neo SpO2 sensor.
223847045|NCT05753137|OTHER|Acupuncture|The treatment will take place once a week, over six weeks. The needles will placed in the body for 20 minutes. A total of 12 Needles(6 acupoints, bilaterally) will be used in each session.Participants in the treatment group will undergo acupuncture targeting ophthalmology-related acupuncture points, aiming to elicit the 'De Qi' sensation.
223847046|NCT05753137|OTHER|Acupuncture placebo|A total of 12 Needles(6 acupoints, bilaterally) will be used in each session. Acupuncture points are different from the experimental group.The control group will receive minimum acupuncture stimulation targeting non-ophthalmic acupuncture points without the intention of achieving the 'De Qi' sensation.
223847047|NCT04550416|OTHER|ProMark Information and Test Results|Participants in the intervention arm will receive information (both print and webinar format) about ProMark in between Round 1 and Round 2 data collection, as well as appropriate ProMark test results for each of the vignette-based simulated patients that they care for in the second round of data collection.
223847048|NCT05461924|OTHER|questionnaire survey|questionnaire survey the long term outcomes of long-segment HSCR and compared with rectosigmoid HSCR
223847049|NCT00140166|DRUG|niacinamide|
223847050|NCT00140166|DRUG|pyridoxine|
223847051|NCT00140166|DRUG|ascorbate|
223847052|NCT01124162|DRUG|Losartan|100 mg Tablet
223847053|NCT01124162|DRUG|Cozaar®|100 mg Tablet
223847054|NCT02022462|BEHAVIORAL|Health Navigation|"Experimental: Immediate peer health navigator intervention vs. waitlist control.~The immediate peer health navigator intervention group will receive assistance for 6 months and then followed up with after an additional 6 months. Participants will receive training in how to self-manage their physical health and healthcare. The intervention is individualized and the number of contacts by the navigator will be determined by their need level. The waitlist control group will complete a baseline assessment and then wait for 6 months before receiving the peer health navigator intervention. They will complete a follow-up assessment after 6 months of the intervention."
223847055|NCT05980468|OTHER|music therapy|Music intervention sessions will be applied to each participant for 5 weeks, 3 days a week, 20 minutes per session.
223847056|NCT04586192|OTHER|Common Elements Toolbox- Adult version (COMET-A)|COMET includes four different modules that teach participants exercises designed to improve mental health and well-being. Participants are asked to complete exercises focused on behavioral activation, cognitive restructuring, gratitude and self-compassion. At the end of the intervention, participants are sent templates that they can you to complete the exercises on, and are encouraged to continue practicing their exercises in their daily life.
223847057|NCT04586192|OTHER|Self-awareness Control|A control condition in which participants learn about self-awareness through writing about memories, writing a short argumentative essay, and noticing objects in their surroundings.
223847058|NCT00707590|DRUG|BMS-767778 or Placebo|
223847059|NCT04451889|DEVICE|miniprobe Alveoflex|Alveoflex uses 488nm laser, generating real time moving images with an optical area of 600μm at a video frame rate of 12 images per second and a focus depth of 50μm
223847060|NCT04371926|DRUG|Hydroxychloroquine Sulfate|"Patients will receive hydroxychloroquine sulfate 400 mg twice daily on the day of enrollment, then 200 mg twice daily for the next 4 days for a 5 day total course.~Staff will receive HCQ sulfate 400mg/week for 4 weeks"
223847061|NCT02680756|DRUG|Ferric Maltol|
223847062|NCT02680756|DRUG|Ferric Carboxy Maltose|
223847063|NCT03907007|DEVICE|Percutaneous electrical nerve stimulation|Stimulation and medication at the same instant
223847064|NCT03907007|DEVICE|Percutaneous electrical nerve stimulation|Stimulation is given without administering medication
223847065|NCT02560103|OTHER|Transmeridian travel across multiple time zones|
223847066|NCT04744597|BEHAVIORAL|Real execution of Fitts's law tasks|Children will be training Fitts's law tasks of different difficulties. Once each task will be solved, they will receive a new, more demanding task
223847067|NCT04744597|BEHAVIORAL|Motor imagery of Fitts's law tasks|Children will be training Fitts's law tasks of different difficulties, same as RE group but the exception of doing it mentally - motor imagery of Fitts's law tasks with eyes open.
223847068|NCT04744597|BEHAVIORAL|Skip counting|Children in SCg will silently count (one number per second) in the same working blocks as both experimental groups with a task of saying the number they reached during each block - control condition to keep them mentally active at very low mental engagement.
223847069|NCT02210702|DRUG|Ethinyl Estradiol 35mcg/Norethindrone 1mg|
223847070|NCT02210702|DRUG|Ethinyl Estradiol 20mcg/Norethindrone 1mg|
223847071|NCT01702896|DRUG|Interleukin-2|Interleukin-2
223847072|NCT00779571|BEHAVIORAL|Crispbread|8 week low calorie diet
223847073|NCT04281264|BEHAVIORAL|Passive Hypoxia|During 30 minutes of session, the participants will perform an intellectual activity while they will be exposed to normobaric hypoxic conditions in a hypoxic chamber (CAT 310, Lousiville, Colorado). They will inspire oxygen fraction (FiO2) set to 16.1% (0.16)
223847074|NCT04281264|BEHAVIORAL|Normoxia Circuit Training with Elastic Bands|"Each training sessions will consist of a circuit training with elastic bands, where different muscle groups will be involved (pectoral, shoulders, back, arms, thighs, legs and abdominals). Duration of the session will be about 30 minutes, which will include 10 minutes warm-up consisting of slight movements, and 5 minutes of static stretching for the muscles at the end of the sessions. Main section of the sessions will be a circuit that will be composed by 3 sets of 12-15 repetitions of nine different exercises.~Subjects will inspire FiO2 of 21.0% (0.21)"
223847075|NCT04281264|BEHAVIORAL|Hypoxia Circuit Training with Elastic Bands|"Each training sessions will consist of a circuit training with elastic bands, where different muscle groups will be involved (pectoral, shoulders, back, arms, thighs, legs and abdominals). Duration of the session will be about 30 minutes, which will include 10 minutes warm-up consisting of slight movements, and 5 minutes of static stretching for the muscles at the end of the sessions. Main section of the sessions will be a circuit that will be composed by 3 sets of 12-15 repetitions of nine different exercises.~Subjects will inspire FiO2 of 21.0% (0.21)"
223847076|NCT04281264|BEHAVIORAL|Normoxia Vibration|"The subjects will perform dynamic and static vibration exercise provide by a commercially available device (Galileo 2000, Novotec GmbH, Pforzheim, Alemania). The duration of the WBV session will be about 30 minutes, which will include 10 minutes warm-up consisting of slight movements, and 5 minutes of static stretching for the muscles.~Repetitions of 30 seconds with a frequency of 18.5 Hz will be performed. The rest interval will be 60 seconds between 4 repetitions during weeks 1-12 and 45 seconds between 5 repetitions during weeks 12-24. The vertical amplitude of WBV was set at 2.5 mm. Four stance will be performed on platform.~Subjects will inspire FiO2 of 21.0% (0.21)"
223847077|NCT04281264|BEHAVIORAL|Hypoxia Vibration|"The subjects will perform dynamic and static vibration exercise provide by a commercially available device (Galileo 2000, Novotec GmbH, Pforzheim, Alemania). The duration of the WBV session will be about 30 minutes, which will include 10 minutes warm-up consisting of slight movements, and 5 minutes of static stretching for the muscles.~Repetitions of 30 seconds with a frequency of 18.5 Hz will be performed. The rest interval will be 60 seconds between 4 repetitions during weeks 1-12 and 45 seconds between 5 repetitions during weeks 12-24. The vertical amplitude of WBV was set at 2.5 mm. Four stance will be performance on the platform.~Participants will inspire a fraction of inspired oxygen (FiO2) of 16.1% (0.16)"
223847078|NCT02805387|DIETARY_SUPPLEMENT|Treatment|Bicarbonate was ingested
223847079|NCT00364442|DRUG|fluticasone propionate/salmeterol|investigational drug
223847080|NCT01516892|BIOLOGICAL|onabotulinumtoxinA|Participants received 155 U of onabotulinumtoxinA approximately every 12 weeks for 108 weeks. OnabotulinumtoxinA was administered as 31 intramuscular injections in 7 head/neck muscle areas.
223847081|NCT00447434|DRUG|Natto extract (Nattokinase)|
223847082|NCT04290585|OTHER|Questionnaire Administration|Ancillary studies
223847083|NCT04290585|BEHAVIORAL|Telephone-Based Intervention|Receive text message reminders
223847084|NCT00580437|PROCEDURE|Dobutamine Stress Echocardiogram|stress echocardiograms involving the use of intravenous Optison or Definity contrast agents to improve endocardial definition
223847085|NCT00088673|DRUG|3APS|
223847086|NCT04475224|DRUG|KP-100IT|Intrathecal injection of 0.6 mg HGF starting at 72 hours since the injury and repeating weekly 5 times
223847087|NCT01145456|DRUG|gamma-secretase/Notch signalling pathway inhibitor RO4929097|Given orally
223847088|NCT01145456|DRUG|gemcitabine hydrochloride|Given IV
223847089|NCT01145456|OTHER|pharmacological study|Correlative studies
223847090|NCT01145456|OTHER|laboratory biomarker analysis|Correlative studies
223847091|NCT05390476|DRUG|Capecitabine|500mg orally three times a day (continuously)
223847092|NCT05390476|DRUG|Tucidinostat|20mg each time, orally 30 minutes after dinner, 3 weeks for a cycle, administered on day 1, day 4, day 8, day 11, day 15,and day 18 of each cycle (twice a week, at least 3 days between each administration)
223847093|NCT05125367|PROCEDURE|coronary stent implantation|coronary stent implantation using everolimus-eluting balloon expandable stents
223847094|NCT05125367|PROCEDURE|bypass grafting|coronary artery bypass graft
223847095|NCT01600911|OTHER|Low phytochemical diet(LPD), high phytochemical diet(HPD)|LPD is a basal diet which low in soy,vegetable and fruit and other plant food to approach low phytochemical. HPD is the diet which add two serving test vegetable in the lunch of LPD.
223847096|NCT01141933|OTHER|Cognitive-existential intervention|Over the past 2 years we developed a 12-week cognitive-existential intervention consisting of 12 modules. The first three modules essentially involve cognitive and behavioral techniques proposing reinforcement of the use of active behavioral (e.g., relaxation, activation) and emotional (cognitive reframing) strategies. This content comes from classical cognitive-behavioral techniques. The next 3 modules, inspired by empirically-tested interventions further explore emotional strategies. The last six modules specifically address the existential dimension. They are adapted from logotherapy techniques, which are also empirically-based, and have been adapted to a French-Canadian culture by our team. They aim to improve meaning-based and emotional coping strategies.
223847097|NCT01141933|OTHER|Usual care|This group receive the usual treatment only.
223847098|NCT02135458|OTHER|Telemonitoring|
223847099|NCT02135458|OTHER|Conventional care|
223847100|NCT04278820|DRUG|TQA3526|Tablet(s) administered orally once daily
223847101|NCT04278820|DRUG|Placebo to match TQA3526|Tablet(s) administered orally once daily
223847102|NCT02323386|DEVICE|Primary Total Knee Arthroplasty (ATTUNE Knee System)|"The patient will undergo primary Total Knee ArthroplastY use ATTUNE Knee System. During surgery a navigation system will be used to record preoperative joint kinematics under different tests. During the test the 6 degrees of freedom (DOF) of the joint will be computed and shown to the surgeon; these are the femoral rotation and translation pattern against flexion ranges. Navigation system will be also used to monitor the implant positioning and possible surgical bias. Dynamic RSA will be used to analyze the in vivo kinematics of the prosthesis at 6 months follow-up.~The above mentioned motion tests will be performed 3 times. The first 2 will be executed to gain comfort with the experimental set-up with no X-ray exposure. During the last data is collected."
223847103|NCT00608348|PROCEDURE|Hyperinsulinemic glucose clamp procedures|2 hours of either euglycemic or hypoglycemic glucose clamping
223847104|NCT00608348|PROCEDURE|moderate exercise|90 minutes of moderate exercise with either hyperinsulinemia or euinsulinemia
223847105|NCT05580796|DRUG|KSH01 injection|TCR-T cell injection
223847106|NCT05392738|DEVICE|I-Stent implantation|I-Stent implantation
223847107|NCT00465751|DRUG|chenodeoxycholic acid|chenodeoxycholic acid 500 mg capsules tid po
223847108|NCT00465751|DRUG|placebo capsules|placebo capsules containing mannitol tid po
223847109|NCT00147355|DRUG|ondansetron, ibuprofen, paracetamol|ondansetron 4mg bid + Ibuprofen 200mg qds + paracetamol 1g qds days 1-6 inclusive of rIL-2 dosing cycle
223847110|NCT00147355|DRUG|Ondansetron, ibuprofen, paracetamol|Ondansetron 4mg bid + codeine phosphate 15mg tds + Ibuprofen 200mg qds + paracetamol 1g qds days 1-6 inclusive of rIL-2 dosing cycle
223847111|NCT00147355|DRUG|metoclopramide, ibuprofen, paracetamol|metoclopramide 10mg qds + Ibuprofen 200mg qds + paracetamol 1g qds days 1-6 inclusive of rIL-2 dosing cycle
223847112|NCT00147355|DRUG|Metoclopramide, codeine phosphate, ibuprofen, paracetamol|metoclopramide 10mg qds + codeine phosphate 15mg tds + Ibuprofen 200mg qds + paracetamol 1g qds days 1-6 inclusive of rIL-2 dosing cycle
223847113|NCT04238000|DEVICE|repetitive transcranial magnetic stimulation|Cerebellar repetitive theta Burst stimulation will be performed as detailed in the Real arm description
223847114|NCT04381494|DEVICE|Multiparametric Mobile Technology|Using a spirometer, an armband, and a tablet to collect data.
223847115|NCT03136263|DRUG|Oxytocin nasal spray|Single-dose intranasal oxytocin (24 IU; Syntocinon® nasal spray, Victoria Pharmacy, Zürich, Switzerland)
223847116|NCT03136263|DRUG|Placebo nasal spray|Single-dose intranasal placebo (inactive ingredients of Syntocinon® nasal spray, Victoria Pharmacy, Zürich, Switzerland)
223847117|NCT04310579|DRUG|Oxycodone and Midazolam|"In one period subjects receive oxycodone 10-15 mg immediate release (IR) and placebo IV 1x per day.~In a second period (randomized cross-over), subjects receive midazolam 0.0375-0.075 mg/kg IV and oral placebo tablet 1x per day.~In a third period (randomized cross-over), subjects receive oxycodone 10-15 mg IR tablet and 0.0375-0.075 mg/kg midazolam IV 1x per day.~In a fourth period (randomized cross-over), subjects receive oral placebo tablet and placebo IV 1x per day."
223847118|NCT04310579|DRUG|Oxycodone, Paroxetine, and Quetiapine|"In one period, subjects receive: oxycodone 10-15 mg IR tablet 1x per day and oral placebo 3x per day on Days 1 and 5; and oral placebo 3x per day on Days 2-4.~In a second period (randomized cross-over), subjects receive: oxycodone 10-15 mg IR tablet 1x per day, paroxetine 40 mg tablet 1x per day, and oral placebo 1x per day on Days 1 and 5; and paroxetine 40 mg tablet 1x per day and oral placebo 2x per day on Days 2-4.~In a third period (randomized cross-over), subjects receive: oxycodone 10-15 mg IR tablet 1x per day, quetiapine 50 mg tablet 2x per day, and oral placebo 1x per day on Day 1; quetiapine 100 mg (2x50 mg tablets) 2x per day and oral placebo 1x per day on Day 2; quetiapine 150 mg (3x50 mg tablets) 2x per day and oral placebo 1x per day on Day 3; quetiapine 200 mg (4x50 mg tablets) 2x per day and oral placebo 1x per day on Day 4; and quetiapine 200 mg (4x50 mg tablets) 1x per day and oral placebo 1x per day on Day 5."
223847119|NCT04037735|DEVICE|ATTUNE S+ Knee Prosthesis by DePuy|Total Knee Replacement (TKR) Surgery with ATTUNE S+ Knee Prosthesis by DePuy
223847120|NCT04037735|DEVICE|PFC Sigma Knee Prosthesis by DePuy|Total Knee Replacement Surgery with PFC Sigma Knee Prosthesis by DePuy
223847121|NCT06421090|DEVICE|Transauricular Vagal Nerve Stimulation|Transauricular vagal nerve stimulation，Intervention group25Hz，Control group1Hz
223847122|NCT05584046|OTHER|CDAM|Novel drugs such as Traditional Chinese Medicine (TCM) formula that can suppress inflammation may augment tissue healing and reduce activity-related pain in patients suffering from plantar fasciitis. Our team has experiences of using TCM for the treatment of plantar fasciitis. Based on our previous experience, our group has developed a new proprietary topical TCM herbal formula, CDAM, containing Carthami Flos , Dipsaci Radix , Aconiti Lateralis Radix Praeparata and Herba Menthae for the treatment of plantar fasciitis.
223847123|NCT00387491|DRUG|MOA-728|
223847124|NCT04147416|DRUG|HSK3486 0.1-0.2 /0.3 mg / kg group|Administered with HSK3486 at a loading dose of 0.1-0.2 mg/kg via intravenous pump. Then HSK3486 shall be administered immediately at an initial maintenance dose of 0.3 mg/kg/h respectively.
223847125|NCT04147416|DRUG|Propofol 0.5-1.0/1.5 mg/kg group|Administered with Propofol at a loading dose of 0.5-1.0mg/kg via intravenous pump. Then Propofol shall be administered immediately at an initial maintenance dose of 1.5 mg/kg/h respectively.
223847126|NCT03635112|DRUG|Placebo|Placebo will be taken daily by mouth (orally) for up to 12 weeks in the morning before eating.
223847127|NCT03635112|DRUG|TD-1473|TD-1473, at Dose A or Dose B depending upon arm, will be taken daily by mouth (orally) for up to 12 weeks in the morning before eating. An additional 48 weeks either at Dose A or Dose B, depending on arm, may be administered if subjects finish the 12 week induction period.
223847128|NCT05579080|DEVICE|noninvasive ventilation|The medical records whose patients used some type of non-invasive ventilatory device and devices that promote oxygen supplementation will be analyzed.
223847129|NCT00456274|PROCEDURE|Frequent baseline blood sampling|3 ml of blood sampled every 10 minutes for a total of 8-12 hours
223847130|NCT03086512|DEVICE|Acutrak 2® - 7.5 Screw|"The Acumed Acutrak 2® - 7.5 is a fully-threaded headless screw fixation, composed of 17 unique screw size options. The Acutrak 2® - 7.5 is available in sizes from 40 mm to 120 mm and is inserted using a 4.0 mm hex driver over a .094 guide wire. The Acutrak 2 Part Number is 30-0XXX and 30-0XXX-S."
223847131|NCT03086512|DEVICE|Synthes® 7.3 Cannulated Screw|The Synthes® 7.3 mm Cannulated screws are available in three thread options: 16 mm, 32 mm or fully threaded. This study will use the partially threaded options. The screws can be placed by small diameter guide wires. They are composed of 316L stainless steel or titanium alloy (Ti-6Al-7Nb).
223847132|NCT05165030|GENETIC|Blood Sample|clinical-radiological evaluation, genetic analysis by whole exome sequencing and constitution of a bio-collection
223847133|NCT00507208|DEVICE|Dynasplint Trismus System|The Dynasplint System will be used for 6 months.
223847134|NCT00507208|OTHER|Tongue Depressors|Tongue depressors to be used for 3 months at which time mouth opening will be measured. If there is no change then the patient will crossover to the Dynasplint Trismus System for another 3 months.
223847135|NCT00225719|DRUG|rHDL|
223847136|NCT03837769|DEVICE|Aktiia OBPM PulseWatch wrist device|The optical signals at the wrist are recorded non-invasively. The BP measurements are further determined from these optical signals and are compared to the reference BP readings.
223847137|NCT06097429|DIAGNOSTIC_TEST|blood sample for platelet aggregation|evaluate platelet aggregation using light-transmission aggregometry and adenosine diphosphate (ADP)
223847138|NCT01221142|DEVICE|"Cincinnati Sub-Zero, Blanketrol III"|
223847139|NCT02128789|OTHER|Elder Tree website|Elder Tree is a private, secure information, support and communication website developed for this study.
223847140|NCT02881125|DRUG|Nortriptyline Hydrochloride|Given PO
223847141|NCT02881125|DRUG|Paclitaxel|Given IV
223847142|NCT02082405|DRUG|bortezomib|Given SC or IV
223847143|NCT02082405|DRUG|cyclophosphamide|Given PO
223847144|NCT02082405|DRUG|dexamethasone|Given PO
223847145|NCT02082405|OTHER|laboratory biomarker analysis|Optional correlative studies
223847146|NCT02082405|OTHER|quality-of-life assessment|Ancillary studies
223847147|NCT02375581|DRUG|Icotinib|125mg, Po, TID during RT
223847148|NCT02375581|RADIATION|Thoracic radiotherapy|involved-Field irradiaton without elective nodal irradiation
223847149|NCT01520350|DRUG|Low dose Adjunctive Aripiprazole|low-dose 2-5mg/d for 8 weeks
223847150|NCT01520350|DRUG|placebo|Placebo
223847151|NCT03142646|BIOLOGICAL|IM19 CAR-T|All patients will be treated with fludarabine and cyclophosphamide for 3 days,then,CAR-T cells expressing CD19 CAR will be infused 24-96 hours later.
223847152|NCT00363116|DRUG|Daclizumab|daclizumab 1 mg/kg/dose every 14 days for 5 doses
223847153|NCT01023919|DEVICE|Device: Polymer-based sirolimus-eluting stent(Cypher stent ) and Polymer-free paclitaxel-eluting stent (YinYi stent)|Cypher stent or YinYi stent randomly implanted in coronary artery disease
223847154|NCT00698191|BIOLOGICAL|Allogeneic MSC (AlloMSC)|"Intervention:~Cyclophosphamide will be administered intravenously at at total dose of 0.8-1.8g 24 hours before transplantation.~Allogeneic bone marrow derived mesenchymal stem cells (matched family donors)will be infused intravenously at 106 cells/kg body weight"
223847155|NCT02446223|DRUG|Inggenol Mebutate 0.015%|
223847156|NCT03199417|DRUG|Multiprofen|A multimodal topical cream treatment with Ketoprofen, Baclofen, Amitryptiline, and lidocaine in a carrier gel.
223847157|NCT03199417|OTHER|Placebo|An identically packaged placebo cream
223847158|NCT02715063|BEHAVIORAL|High Intensity Interval|Exercise will be performed at three sessions per week. All sessions will be supervised by a trained health or exercise professional.
223847159|NCT02715063|BEHAVIORAL|Resistance training|Exercise will be performed at three sessions per week. All sessions will be supervised by a trained health or exercise professional.
223847160|NCT02715063|BEHAVIORAL|Plus: High Intensity Interval + Resistance Training|Exercise will be performed at three sessions per week. All sessions will be supervised by a trained health or exercise professional.
223847161|NCT02715063|OTHER|Usual clinical care|Dietary restriction (1300-1500kcal) 50-52% carbohydrates, 33-35% fat, 15-20% protein
223847162|NCT03138473|DIAGNOSTIC_TEST|Residual SYNTAX Score|"The baseline SYNTAX score and the residual SYNTAX score (rSS) are calculated by summing up the individual scores for each lesion with a diameter stenosis ≥50% in vessels with a diameter ≥ 1.5 mm in the angiography obtained before and after the procedure. The SYNTAX algorithm of scoring is fully described elsewhere.~The modified Age, Creatinine, and Ejection Fraction (ACEF) score is calculated based on the age, creatinine clearance (CrCl) and left ventricular ejection fraction (LVEF), using the formula age/LVEF +1 point for every 10 ml/min/1.73 m2 reduction of CrCl below 60 ml/min/1.73 m2 (1 point for CrCl between 59 and 50, 2 points for CrCl between 49 and 40 and 3 points for CrCl between 39 and 30 ml/min/1.73 m2). The CrCl is calculated via the Cockroft-Gault equation using age, gender weight and serum creatinine before PCI. The baseline SYNTAX score was then multiplied by the modified ACEF score to obtain the baseline clinical SYNTAX score."
223847163|NCT03138473|DIAGNOSTIC_TEST|SYNTAX Revascularization Index|The SYNTAX Revascularization Index (SRI), representing the proportion of CAD burden treated by PCI, was calculated using the following formula: SRI= (1-\[rSS/bSS\]) ×100.
223847164|NCT06581926|OTHER|Behavioral assessment|nutrition knowledge reward-related eating body awareness
223847165|NCT05550480|DEVICE|Continuous glucose monitoring|Continuous glucose monitoring for 50 days
223847166|NCT03923101|DIAGNOSTIC_TEST|Topographic, tomographic and biomechanical analysis.|"The study is based upon data obtained during routine medical follow-ups using~1. the Pentacam high resolution (Oculus, Wetzlar, Germany)~2. the Corvis ST (Oculus, Wetzlar, Germany)~3. the Anterior-Segment Optical Coherence Tomograph (AS-OCT) Casia 2 (Tomey, Nagoya, Japan)~4. the Ocular Response Analyzer (Reichert Technologies, New York, USA)."
223847167|NCT03006341|DRUG|Dabigatran etexilate|observed upto 12 months
223847168|NCT03006341|DRUG|Warfarin|Observed upto 12 months
223847169|NCT05309486|OTHER|Online and Face-to-face Pilates trainings|Key elements of Pilates, including breathing, focusing, rib cage position, shoulder position, and head and neck positions, will be taught in both groups on the first day. Individuals will be asked to maintain the smoothness of these critical elements throughout the exercises. Different imagery techniques will be used in the exercises, and the exercises will be combined with breathing exercises. The intensity of the exercises will be increased by using different positions and elastic bands (Theraband Elastic Band Hygienic Corporation, Akron, Ohio). Band Resistances will be increased in biweekly periods. Stretching and posture exercises will be used during the cool-down period. The subjects in pilates group will be informed about the side effects such as shortness of breath, dizziness, headache, and muscle pain. Participants will be asked to stop the exercise in case of any side effects.
223847170|NCT02575235|DRUG|Cetylpyridinium Chloride (CPC)|Two study groups take CPC of 1.5mg and 4.5mg daily for four weeks.
223847171|NCT02575235|DRUG|placebo|Control group takes the placebo for the same period.
223847172|NCT01989637|DIETARY_SUPPLEMENT|Strawberry Meal|High-fat meal (50 g total fat) with 40 g freeze dried strawberry powder
223847173|NCT01989637|DIETARY_SUPPLEMENT|Control Meal|High-fat meal (50 g total fat) with a matched placebo powder containing no strawberry bioactives
223847174|NCT03255642|DRUG|Melatonin 2mg|4 weeks of 2mg prolonged release melatonin (Circadin)
223847175|NCT03255642|DRUG|ClonazePAM 0.5 MG|4 weeks of 0.5mg clonazepam (Rivotril)
223847176|NCT00180518|DEVICE|Over-the-wire & Rapid Exchange ACCULINK (tm) Carotid Stent & ACCUNET (tm) embolic protection system|"Two rapid exchange devices will be evaluated: the RX ACCUNET Embolic Protection System (RX ACCUNET) and the RX ACCULINK Carotid Stent System (RX ACCULINK).~The RX ACCUNET Embolic Protection System is intended to facilitate the placement of diagnostic and therapeutic devices during interventional procedures and to capture embolic material that may be present during carotid artery interventional procedures.~The RX ACCULINK™ Carotid Stent System is intended for the treatment of carotid artery stenosis in the internal carotid artery (ICA), with or without involvement of the contiguous common carotid artery (CCA), in asymptomatic patients and symptomatic patients."
223847177|NCT03956173|OTHER|Hypoglycemic combined with either normo or hyperglycemic clamp.|Twenty-four patients with type 1 diabetes has been recruited for a cross-over study including two experimental days, a combined hypo- and hyperglyemic clamp and a combined hypo- and euglycemic clamp, respectively. Patients will be randomised 1:1 to start with either the combined hypo- and hyperglycemic or the hypo- and euglycemic clamp. The hypo- and hyperglycemic or the hypo- and euglycemic clamp are estimated to last 255 minutes. The two clamp days will be separated by at least 30 days.
223847178|NCT02148406|BEHAVIORAL|Yoga Skills Training (YST)|Undergo YST
223847179|NCT02148406|OTHER|questionnaire administration|Ancillary studies
223847180|NCT02148406|OTHER|fatigue and depressive symptom assessment and management|Ancillary studies
223847181|NCT02148406|OTHER|psychological stress assessment|Ancillary studies
223847182|NCT02148406|OTHER|laboratory biomarker analysis|Correlative studies
223847183|NCT02148406|OTHER|Attention Control|
223847184|NCT03349684|DRUG|Acarbose|Uptitrated in the treatment phase from 50 mg per day for 1 week, followed by 100 mg per day for another week, and 150 mg per day for the rest 14 weeks, oral, with the first mouthful of main meal
223847185|NCT03349684|DRUG|Metformin|500 mg 3 times daily, oral, with the first mouthful of main meal
223847186|NCT03349684|DRUG|Placebo|Acarbose matching placebo, oral
223847187|NCT00343798|DRUG|cyclophosphamide|Given IV
223847188|NCT00343798|DRUG|fludarabine phosphate|Given IV
223847189|NCT00343798|DRUG|cyclosporine|Given IV
223847190|NCT00343798|DRUG|mycophenolate mofetil|Given IV or PO
223847191|NCT00343798|OTHER|ex-vivo umbilical cord blood expansion|Undergo double-unit umbilical cord blood transplantation
223847192|NCT00343798|PROCEDURE|double-unit umbilical cord blood transplantation|Undergo double-unit umbilical cord blood transplantation
223847193|NCT00343798|PROCEDURE|biopsy|Optional correlative studies
223847194|NCT00343798|OTHER|immunologic technique|Correlative studies
223847195|NCT00343798|OTHER|diagnostic laboratory biomarker analysis|Correlative studies
223847196|NCT03881358|DEVICE|ortho-k lenses and thinner spectacles|Conventinally designed (Emerald) ortho-k lenses (target for -4.00D) and thinner specs during day time
223847197|NCT03881358|DEVICE|newly designed ortho-k lenses|Newly designed (Topaz) ortho-k lenses for high myopia (target for full correction)
223847198|NCT04087044|DEVICE|Computerized Rotational Head Impulse Test ( crHIT)-Vertical|"1. Oculo-Motility and Positional Testing,~2. Caloric Testing"
223847199|NCT06554964|PROCEDURE|performing chromotubation during the laparoscopy in order to assess the tubal patency of the remaining fallopian tube|Performing chromotubation )injection of blue dye to the fallopian tube via cevical catheter) during the laparoscopy in order to assess the tubal patency of the remaining fallopian tube
223847200|NCT05304390|BEHAVIORAL|Patient Navigation|Receive patient navigation intervention
223847201|NCT05304390|OTHER|Questionnaire Administration|Ancillary studies
223847202|NCT05304390|BEHAVIORAL|Smoking Cessation Intervention|Receive an intervention for smoking cessation
223847203|NCT05304390|PROCEDURE|Carbon Monoxide Measurement|Undergo carbon monoxide measurement
223847204|NCT02243007|DRUG|FOLFIRINOX|
223847205|NCT02243007|DRUG|Gemcitabine/nab-Paclitaxel|
223847206|NCT02243007|RADIATION|Radiation therapy|
223847207|NCT02243007|DRUG|Capecitabine|
223847208|NCT01187303|DRUG|Ofatumumab|300 mg/m2 d1 week 1 1000mg/m2 d1 week 2-8
223847209|NCT02950545|DEVICE|Placebo Lenses|AcuVue Oasys Bandage Lenses with no prescription
223847210|NCT02950545|DEVICE|Spherical Lenses|1-DAY ACUVUE® MOIST contact lenses
223847211|NCT02950545|DEVICE|Toric Lenses|1-DAY ACUVUE® MOIST for ASTIGMATISM contact lenses
223847212|NCT06405074|DEVICE|low intensity focused ultrasound (LIFU)|"Low-intensity focused ultrasound (LIFU) provides an energy source with millimeter resolution that can be focused anywhere in the brain safely and effectively for non-invasive and transient neuromodulation. LIFU is an important advance and of great significance for brain-mapping efforts, diagnostics, and therapies in neuroscience and particularly promising for addiction therapy as it provides unprecedented non-surgical access to the brain regardless of depth.~Much lower intensities of focused ultrasound (LIFU) are used so that tissue damage does not occur, but neural activity can be modulated. LIFU utilizes acoustic energy at much lower levels to affect tissue by mechanical effects."
223847213|NCT03101592|OTHER|Three-month ART dispensing|Patients enrolled in the three-month ART dispensing arm will receive a 90-day supply of ART from their provider for the duration of the study.
223847214|NCT03101592|OTHER|Six-month ART dispensing|Patients enrolled in the six-month ART dispensing arm will receive a 180-day supply of ART from their provider for the duration of the study.
223847215|NCT00003543|BIOLOGICAL|monoclonal antibody A33|
223847216|NCT00003543|DRUG|carmustine|
223847217|NCT00003543|DRUG|fluorouracil|
223847218|NCT00003543|DRUG|streptozocin|
223847219|NCT00003543|DRUG|vincristine sulfate|
223847220|NCT06047262|DRUG|Dapansutrile|Patients receive investigational product.
223847221|NCT06047262|DRUG|Placebo|Patients receive placebo.
223847222|NCT04741971|DIETARY_SUPPLEMENT|Probiotics group|Will give Probiotics with Vitamin D3 one drop per day for 90 days
223847223|NCT04741971|DIETARY_SUPPLEMENT|Non-probiotics group|Will give Vitamin D3 five drops per day for 90 days
223847224|NCT06179095|OTHER|Virtual reality|Participants will view a specific relaxing and distracting scenario using virtual reality (VR) for approximately 7-8 minutes from one minute before the procedure until the end of the procedure. Assessment will be performed with STAI just before the intrauterine device insertion procedure, and again with STAI after the procedure.
223847225|NCT04555330|DEVICE|Physical activity measurement|"To assess physical activity two small tri-axial accelerometers embedded in medical Band-Aids will be used. The accelerometers are discretely worn on the lateral aspect of the thigh.~The accelerometers sample accelerations continuously during hospitalisation and are connected wirelessly to a tablet that via an inbuilt algorithm classify the recordings as bedridden (lying down), sitting, standing, and walking."
223847226|NCT04555330|DEVICE|Visual Feedback|The tablet will be placed on the patients bedside table and provides feedback on the amount of physical activity and motivational imagesand texts that will be visible for the patients, the health care staff and visitors.
223847227|NCT05766163|DEVICE|DaVinci RARP|Assisted-robotic radical prostatectomy.
223847228|NCT05766163|DEVICE|Hugo RARP|Assisted-robotic radical prostatectomy.
223847229|NCT05766163|DEVICE|Versius RARP|Assisted-robotic radical prostatectomy.
223847230|NCT00413491|PROCEDURE|MR mammography|MR mammography
223847231|NCT00413491|PROCEDURE|MR|MR
223847232|NCT01728389|PROCEDURE|Intrabone transplantation|Direct intrabone transplantation procedure of peripheral blood haematopoietic stem cells form HLA-matched sibling donors in patients with myeloid and lymphoid malignancies.
223847233|NCT03355053|DRUG|Dexmedetomidine|"Dex (Precedex, Dexmedetomidine HCl Injection) is produced by Pfizer Inc, NY, Ny (formerly Hospira). Dex is a white or almost white powder that is freely soluble in water and has a pKa of 7.1. Its partition coefficient in-octanol: water at pH 7.4 is 2.89. Dex is supplied as a clear, colorless, isotonic solution with a pH of 4.5 to 7.0. Each mL contains 118 mcg of dexmedetomidine hydrochloride equivalent to 100 mcg (0.1mg) of dexmedetomidine and 9 mg of sodium chloride in water. The solution is preservative-free and contains no additives or chemical stabilizers. The MGH Pharmacy currently obtains Dex from the supplier as a solution in 50 mL clear-glass bottles, as a clear liquid, at a concentration of 4mcg/mL."
223847234|NCT03355053|DRUG|Placebo|"From the package insert: 0.9% Sodium Chloride Injection, USP is sterile and nonpyrogenic. It is produced by Pfizer Inc, NY, Ny (formerly Hospira). It is a parenteral solution containing sodium chloride in water for injection intended for intravenous administration. Each 100 mL of 0.9% Sodium Chloride Injection, USP contains 900 mg sodium chloride in water for injection. Electrolytes per 1000 mL: sodium (Na+ ) 154 mEq; chloride (Cl- ) 154 mEq. The osmolarity is 308 mOsmol/L (calc.). The pH is 5.6 (4.5 to 7.0). This solution contains no bacteriostat, antimicrobial agent or added buffer and is intended only as a single-dose injection. When smaller doses are required, the unused portion should be discarded. 0.9% Sodium Chloride Injection, USP is a parenteral fluid and electrolyte replenisher. Sodium Chloride, USP is chemically designated NaCl, a white crystalline powder freely soluble in water. Water for Injection, USP is chemically designated H2O."
223847235|NCT01770860|DEVICE|6660|At each daily visit, designated study personnel will replace the specific test product on the assigned wound site.
223847236|NCT01770860|DEVICE|4314|At each daily visit, designated study personnel will replace the specific test product on the assigned wound site.
223847237|NCT01770860|DEVICE|8336|At each daily visit, designated study personnel will replace the specific test product on the assigned wound site.
223847238|NCT01770860|DEVICE|4840|At each daily visit, designated study personnel will replace the specific test product on the assigned wound site.
223847239|NCT01351610|BIOLOGICAL|PTA + Infusion of MSC_Apceth|percutaneous transluminal angioplasty followed by infusion of MSC\_Apceth
223847240|NCT01351610|PROCEDURE|PTA|percutaneous transluminal angioplasty only
223847241|NCT02694679|BEHAVIORAL|CBNH|The household-level intervention package targets health behaviors surrounding neonatal and maternal health, and diarrhea and respiratory illness prevention and management.
223847242|NCT02276131|DEVICE|Vigilant Diabetes Management Application|Human factors and usability assessment of the device in the hands of diabetes subjects and caregivers
223847243|NCT03461887|BEHAVIORAL|Exercise|"Home-based exercise training program that requires only minimal equipment, and is individually adaptable to the participant's exercise level (6 times per week; 15-20 min; 38 exercise cards and one interactive training agenda booklet). After randomization, a health care professional (HOMEX coach) will visit the intervention group participants at their home to set up the training location, to instruct the exercises and to establish individualized goals. Follow-up visits are planned after 3 and 8-9 weeks. Regular telephone calls will be conducted by the same HOMEX coach to motivate the patients, to discuss training progress and concrete benefits and barriers, and to adapt goals and the training program. Additional intervention elements are that a relative or friend is involved as a sparring partner to support the participant. The general practitioner is informed about the participation of his/her patient in the intervention."
223847244|NCT03936829|DRUG|Cyclophosphamide|Admitted to the hospital every 4 weeks. Cyclophosphamide was intravenously instilled (500mg mg/m2 of BSA) after contraindications are excluded. ECG monitoring will be taken during the medication. A total of 6 treatments will be performed.
223847245|NCT04471987|DRUG|IL12-L19L19|"Part I - The dose escalation is designed with an initial accelerated phase followed by a standard 3+3 design. Cohorts contain one patient until first instance of moderate toxicity or a DLT in the DLT observation period (28 days). With the second occurrence of moderate toxicity or occurrence of a DLT the accelerated phase will be terminated and the dose escalation will continue with a 3+3 dose escalation. Initiation of the study treatment for an individual subject will occur not less than 7 days after initiation of the study treatment for the previous patient. Not more than 2 patients are to be treated simultaneously within their DLT observation period (i.e., Day 1 to Day 28).~Part II - Dose expansion: Once the dose escalation is completed, additional 40 patients will be enrolled at the RD to better understand the safety profile and to explore early signs of efficacy in different disease indications."
223847246|NCT04471987|DRUG|IL12-L19L19|Patients initially receive 8 consecutive administrations of IL12-L19L19 every week. At the end of this eight weeks treatment window, a tumor assessment is performed and those patients who achieve a clinical benefit (SD, PR, CR) may continue treatment with IL12-L19L19 as a biweekly maintenance therapy until disease progression, unacceptable toxicity, withdrawal of consent, at the discretion of the investigator or up to 1 year from study treatment start.
223847247|NCT02341534|DEVICE|BioMonitor|Patients will be implanted with the BioMonitor + Home Monitoring feature
223847248|NCT04100954|DEVICE|Reinforced prosthesis|Implementation of a reinforced prosthesis during a medical consultation or under local anesthesia, after removal of the former prosthesis, in case of intraprothetic leakage.
223847249|NCT04100954|DEVICE|Standard prosthesis|Implementation of a standard prosthesis during a medical consultation or under local anesthesia, after removal of the former prosthesis, in case of intraprothetic leakage.
223847250|NCT03398356|DRUG|Metformin|"for group A: 12 weeks metformin treatment in a final dose 3 x 500 mg~for group B: 3 weeks metformin treatment in a dose 3 x 500 mg, next: 3 weeks metformin treatment in a final dose 3 x 1000mg, next: 3 weeks metformin treatment in a dose 3 x 500 mg."
223847251|NCT06344455|BEHAVIORAL|School Retention and Completion Incentive Savings via Modified Iowa Gambling Task A|Participants will engage in a modified version of the Iowa Gambling Task with visual stimuli that are aligned with the Pé-de-Meia program's requirements. Advantageous cards will display images that are congruent with the program's criteria, while disadvantageous cards will feature images that are contrary to the Pé-de-Meia program's requirements.
223847252|NCT06344455|BEHAVIORAL|Iowa Gambling Task|The participants will play the unmodified Iowa Gambling Task.
223847253|NCT06344455|BEHAVIORAL|School Retention and Completion Incentive Savings via Modified Iowa Gambling Task B|"The participants will play the modified IGT (Iowa Gambling Task). For the disadvantageous cards, images that align with the requirements of the Pé-de-Meia program will be presented, while for the advantageous cards, images that contradict the criteria of the Pé-de-Meia program will be shown."
223847254|NCT05237193|DIAGNOSTIC_TEST|The level of CIN|The extracted DNA from bile will be analyzed by UCAD to determine the level of CIN. And the patient will be followed for up to 2 years.
223847255|NCT01048151|BIOLOGICAL|TNFerade™ Biologic|AdGVEGR.TNF.11D
223847256|NCT03091712|DEVICE|Glooko Mobile Insulin Dosing System(MIDS)|Mobile Insulin Dosing System (MIDS) for all long acting insulin degludec titration management
223847257|NCT04643353|DEVICE|Non-ablative vaginal Erbium YAG laser treatment|Laser therapy is performed using a 2940 nm VEL (SP Spectro, Fotona, Slovenia) with SMOOTH mode setting, which enables non-ablative, thermal-only operation. The parameters are selected based on extensive preclinical and clinical studies.
223847258|NCT04643353|OTHER|PFE|PFE will be prescribed as it is already implemented in clinical practice (i.e. up to 2x 9 sessions with a pelvic floor physiotherapist of choice). Type of physiotherapy, number of completed sessions and duration of therapy will be recorded.
223847259|NCT04034121|DEVICE|DESolve Cx drug eluting coronary scaffold system|percutaneous coronary intervention
223847260|NCT00740285|DRUG|Lidocaine 2% without vessel constrictor|"* first 5 days: 20ml lidocaine 2% without vessel constrictor + physiological solution 0,9% 500ml intravenously during 4 hours~* next 5 days: 30ml lidocaine 2% without vessel constrictor + physiological solution 0,9% 500ml intravenously during 4 hours total: 10 days"
223847261|NCT00740285|OTHER|Placebo - physiological solution 0,9%|first 5 days: 20ml of physiological solution 0,9% 500ml + physiological solution 0,9% 500ml intravenously during 4 hours next 5 days: 30ml of physiological solution 0,9% 500ml + physiological solution 0,9% 500ml intravenously during 4 hours total: 10 days
223847262|NCT01522339|DEVICE|GE OPTIMA MR430s with HDX/GE Electronics|MRI scan(s) for no longer than 60 minutes
223847263|NCT01738711|BEHAVIORAL|Cognitive behavioural therapy|Patient receive 2-6 sessions depending on individual need. first session is 1 hour duration with additional sessions approximately 30 minutes.
223847264|NCT02369523|DRUG|Exparel|Mixture of 50 mL of 0.25% Bupivacaine with epinephrine, 40 mL of sterile saline and 20 mL of Exparel®.
223847265|NCT02369523|DRUG|Ropivacaine cocktail (PIC)|400 mg Ropivacaine, 5 mg morphine, and 0.4 mg epinephrine in 100 cc solution
223847266|NCT02369523|DRUG|Bupivacaine|"Continuous Femoral Nerve Block- 0.25% Bupivacaine at a rate of 5 ml/hour for 48 Hours.~Sciatic nerve block - 0.125% bupivacaine"
223847267|NCT06310564|RADIATION|SABR|"A biological effective dose (BED) ≥125 Gy10 should be administered when constraints to the organs at risk (OARs) are respected \[10\]; if not possible, a BED schedule no lower than 100 Gy10 should be administered. In compliance with these instructions, treatment schedules, total dose and fractionation will be prescribed according to the clinical practice of each participating Center. The constraints for the organs at risk will be respected according to the available data.~In any case, biological effective dose (BED) ≥125 Gy10 should be administered when constraints to the organs at risk (OARs) are respected; if not possible, a BED schedule no lower than 100 Gy10 should be administered.~SABR will be administered before systemic treatment start, or before starting the second systemic treatment cycle at the latest."
223847268|NCT03432533|DRUG|romosozumab HCP administration with PFS|210 mg romosozumab SC QM by HCP administration with 2 PFS
223847269|NCT03432533|DEVICE|romosozumab self-administration with AI/Pen|210 mg romosozumab SC QM by self-administration with 2 AI/Pens
223847270|NCT02362633|DEVICE|real tDCS|For active tDCS, a 2 mA current will be delivered for 20 minutes with 20 second up and down ramp times. The anodal electrode will be placed on the right DLPFC (F4; 10-20 EEG system), and the cathode electrode will be placed on the left DLPFC (F4;10-20 EEG system), which is known to be related to cognitive function. The electrodes used for tDCS are saline-soaked sponges (25 cm2).
223847271|NCT02362633|DEVICE|sham tDCS|Sham tDCS will be delivered for 20 minutes. The anodal electrode will be placed on the right DLPFC (F4; 10-20 EEG system), and the cathode electrode will be placed on the left DLPFC (F4;10-20 EEG system), which is known to be related to cognitive function. The electrodes used for tDCS are saline-soaked sponges (25 cm2).
223847272|NCT01648283|DRUG|IV racemic methadone HCl|IV racemic Methadone HC1 6 mg
223847273|NCT01648283|DRUG|Oral racemic methadone HCl|oral d5-methadone HCl 11 mg
223847274|NCT04170426|BIOLOGICAL|autologous adipose derived stem cells|Culture expanded mesenchymal stem cells isolated from patient's own abdominal fat tissue
223847275|NCT01942083|DRUG|OPB-111077|
223847276|NCT00226200|DRUG|Omalizumab|
223847277|NCT05543096|DEVICE|Adroit Guiding Catheter, Cordis Transradial Access Devices, Cordis Diagnostic Catheters, Cordis Guidewires|Observation
223847278|NCT06526728|DRUG|Hyperbaric oxygen|Participants will be subjected to seven once-daily sessions of hyperbaric oxygen therapy. Each session will last 115-120 minutes whereby the chambre will be pressurized to 2.4 ATA during which participants will breathe 100% (pure) oxygen.
223847279|NCT03983161|DRUG|Fedratinib|Fedratinib
223847280|NCT04880070|DEVICE|Shockwave Treatment|Self-controlled, single-arm group using the Shockwave device.
223847281|NCT02113111|BEHAVIORAL|Fasting|Fasting therapy was adapted from Buchinger, including a fasting period of 7 days. After 2 prefasting days with 800kcal per day from vegetables and rice/potatoes, fasting starts with the ingestion of an oral laxative. During fasting patients receive small quantities of juice and herbal teas, and a vegetable broth for lunch, altogether no more than 350kcal per day. At the end, fasting is broken by an apple or cooked potato, and for the following 3 days nutrition returns to normocaloric diet.
223847282|NCT01257165|DRUG|Zopiclone|Zopiclone pill 5 or 10 mg, given orally as a single dose.
223847283|NCT01257165|DRUG|Ethanol|50 mg per 70 kg body weight, given orally as a single dose
223847284|NCT01257165|DRUG|Placebo pill|Placebo pill identical to zopiclone pill, given orally as a single dose
223847285|NCT01257165|DRUG|Placebo drink|Placebo drink, given orally as a single dose
223847286|NCT05531825|DEVICE|A device for detecting arteriovenous fistula vascular function|An innovative design based on PVDF piezoelectric membrane by combining all kinds of technologies including NB-iot/4G transmission mode to realize real-time monitoring and feedback of the health status of arteriovenous fistula vessels
223847287|NCT03907605|OTHER|anti- mullerian hormone|All patients belong to the same group. The blood samples will be collected at the time of surgery and 3 months after surgery from the patients who need uterine artery ligation for PPH. The blood samples will be centrifuged within 2 hours after being obtained and assessed on the same day. AMH concentrations will be measured with an enzymatically amplified two-sided immunoassay
223847288|NCT04512742|OTHER|biting by Phlebotomus duboscqi infected with Leishmania major|The first six subjects will be exposed to biting by Phlebotomus duboscqi infected by Leishmania major and assess the 'take rate', that is the number of subjects developing parasitologically confirmed cutaneous leishmaniasis (PCCL) lesions. If 6/6 subjects develop PCCL lesions no further recruitment will take place; if only \< 6 subjects develop PCCL lesions, then an adaptive design will be followed.
223847289|NCT03867864|DEVICE|Necklace with essential oil for the first 4 weeks|The necklaces contain essential oil.
223847290|NCT03867864|DEVICE|Necklace without essential oil for the first 4 weeks|The necklaces do not contain essential oil.
223847291|NCT03867864|OTHER|Washout|Washout (do not wear the necklace) for one week for two groups, then two groups cross-over.
223847292|NCT03867864|DEVICE|Necklace with essential oil for last 4 weeks|The necklaces contain essential oil.
223847293|NCT03867864|DEVICE|Necklace without essential oil for last 4 weeks|The necklaces do not contain essential oil.
223847294|NCT00138164|BIOLOGICAL|denileukin diftitox|
223847295|NCT05995171|OTHER|Questionnaire|Quality of life questionnaires will be used specifically for this research: Pediatric Quality of Life Invertory and EA-QoL
223847296|NCT05736367|DRUG|U-13C-glucose|Discover new insights into the glucose, TCA cycle, amino acid, and lipid metabolic dependencies of HR+/Her2- breast cancer, via liquid chromatography-mass spectrometry (LC-MS) and nuclear magnetic resonance (NMR) spectroscopy analysis of in vivo U-13C-glucose-labeled biopsy of tumor and benign adjacent tissue
223847297|NCT06555432|DRUG|LIVTENCITY|LIVTENCITY tablet.
223847298|NCT01446003|DRUG|MK-8457|10 x 10-mg capsule BID for 10 days
223847299|NCT01446003|DRUG|Placebo for MK-8457|10 x 10-mg capsule BID for 10 days
223847300|NCT02185664|PROCEDURE|landmark technique|The apex of the imaginary triangle formed between the two heads of sternocleidomastoid and clavicle was used as the point of needle entry, just lateral to the pulsation of the internal carotid artery and directed towards the ipsilateral nipple at an angle of 45 degrees.
223847301|NCT02185664|DEVICE|Static Ultrasound technique|Static ultrasound guided internal jugular vein cannulation was performed by using the transthoracic echocardiography probe supplied with the transesophageal echocardiography machine in the cardiothoracic surgery operation theatre. The internal jugular vein was located and marked using this method prior to puncture.
223847302|NCT06100029|DRUG|Lavender|The lavender aroma (L. angustifolia ssp. Angustifolia) is provided by Pranarom International, Ghislenghien, Belgium. Lavender aroma will be contained in a 10 ml glass bottle with a drop stopper and place the bottle within 20 cm of the patient's pillow so that the aroma can reach the patient. The entire course of treatment lasts 5 days.
223847303|NCT06100029|BEHAVIORAL|A2F bundle|A: assess, prevent, and manage pain; B: both spontaneous awakening and breathing trials; C: choice of analgesia and sedation; D: delirium assessment, prevention, and management; E: early mobility and exercise; and F: family engagement/empowerment
223847304|NCT03688854|DIETARY_SUPPLEMENT|SCFA mixture|Intracolonic administration
223847305|NCT00518375|DRUG|Rapamune® (Sirolimus)|
223847306|NCT00518375|DRUG|Neoral® (Cyclosporine)|
223847307|NCT00518375|DRUG|Corticosteroids|Left up to local practice but steroids are typically used perioperatively
223847308|NCT06585540|DRUG|Amisulpride IV Prevention|Patients in this arm will receive Amisulpride 5mg IV as a preventative dose after the induction of anesthesia
223847309|NCT06585540|DRUG|Amisulpride IV Treatment|Patients in this arm will receive Amisulpride 10mg IV for first-line treatment of Post-Operative Nausea and Vomiting in the post-anesthesia care unit.
223847310|NCT06585540|DRUG|Placebo Preventative|Patients in this arm will receive placebo (Normal Saline) while under general anesthesia
223847311|NCT06585540|DRUG|Placebo Treatment|Patients in this Arm will receive placebo as first line treatment of Post-Operative Nausea and Vomiting in the Post Anesthesia Care Unit
223847312|NCT06030687|OTHER|Ad libitum data collection|Food purchase, prep, eat and toss data
223847313|NCT05159908|DRUG|NBI-921352|Tablets for oral administration
223847314|NCT05159908|DRUG|Placebo|Matching placebo tablets for oral administration
223847315|NCT03230591|OTHER|Echocardiography|LV vortex flow in Echocardiography
223847316|NCT03001986|BIOLOGICAL|inactivated EV71 vaccine (KMB-17 cells)|Receiving 2 doses of the EV71 inactivated vaccine at an interval of 1 month.
223847317|NCT04455048|OTHER|Cervicothoracic thrust manipulation|The patient will be positioned in a supine position with arms crossed over over the trunk and holding the shoulders. The therapist will place a stabilizing hand over transverse process of T1 in pistol grip and contacted patients elbow with sternum and patient will be asked do a hip bridge while taking a deep breath than exhale. Thrust manipulation will be applied at the end of exhale.
223847318|NCT04455048|OTHER|Cervicothoracic thrust manipulation sham|The patient will be positioned in a supine position with arms crossed over over the trunk and holding the shoulders. The therapist will place a stabilizing hand over transverse process of T1 in pistol grip and contacted patients elbow with sternum and patient will be asked do a hip bridge while taking a deep breath than exhale. A soft compression will be applied at the end of exhale without a thrust.
223847319|NCT05984641|DEVICE|CONAN® Proctological Cream|The active treatment samples used for the duration of the study were allocated at the site involved and consisted in 30 g tubes with an endorectal applicator, identified by the batch number, expiry date and information on the study on dedicated labels. The treatment of patients randomized to Group A consisted in applying the local treatment (1 application 3 times/day) for 30 days. Instrutction to an healthy diet including an adequate fibre intake and general advice for facilitating evacuation using stool softeners.
223847320|NCT01205750|OTHER|Glucose clamp|450 min hyperinsulinemic euglycemic glucose clamp, 0,5 mU / kg lean body mass / min
223847321|NCT02477826|DRUG|Nivolumab|
223847322|NCT02477826|DRUG|Ipilimumab|
223847323|NCT02477826|DRUG|Carboplatin|
223847324|NCT02477826|DRUG|Cisplatin|
223847325|NCT02477826|DRUG|Gemcitabine|
223847326|NCT02477826|DRUG|Pemetrexed|
223847327|NCT02477826|DRUG|Paclitaxel|
223847328|NCT00597883|PROCEDURE|Carotid endarterectomy|(non-experimental) carotid endarterectomy (CEA) for treatment of carotid artery stenosis
223847329|NCT00597883|OTHER|Neurological and neuropsychological evaluations|Clinical examinations consisting of a neurological and neuropsychological evaluation
223847330|NCT05550337|DRUG|Trifarotene 0.005 % Topical Cream|Cream
223847331|NCT05550337|DRUG|AKLIEF®|Cream
223847332|NCT05550337|DRUG|Placebo|Cream
223847333|NCT05950113|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow biopsy and aspiration
223847334|NCT05950113|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy and aspiration
223847335|NCT05950113|PROCEDURE|Computed Tomography|Undergo PET/CT
223847336|NCT05950113|DRUG|Cyclophosphamide|Receive IV
223847337|NCT05950113|PROCEDURE|Echocardiography|Undergo ECHO
223847338|NCT05950113|DRUG|Fludarabine|Receive IV
223847339|NCT05950113|OTHER|Fludeoxyglucose F-18|Receive IV
223847340|NCT05950113|OTHER|Immunotherapy|Receive CART-BCMA/CS1 cells IV
223847341|NCT05950113|PROCEDURE|Leukapheresis|Undergo leukapheresis
223847342|NCT05950113|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223847343|NCT05950113|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
223847344|NCT06006091|DRUG|Letrozole|Different endothelial preparations according to groups, see arm descriptions for details
223847345|NCT06576895|OTHER|No intervention|No intervention
223847346|NCT04989439|OTHER|Electrical impedance tomography and ultrasonography of the lung|Both EIT and LUS are non-invasive methods and do not pose any additional risk for the patient. The LuMon System with pediatric EIT belts (LuMon Belt, Sentec, Landquart, Switzerland) will be used. The belt will be placed on the thorax circumference of the infant and connected to the LuMonConnector (Sentec, Landquart, Switzerland). Small electrical currents (3 mA, 198 kHz) will be repetitively injected in rotation through adjacent electrode pairs, and voltage changes will be measured by all passive electrodes pairs (scan rate 48 Hz). Changes in lung electrical impedance will be continuously recorded for 5 minutes. EIT data will be analyzed off-line using Matlab (Mathworks, Natick, Massachusetts, USA). The regional tidal volume distribution, the homogeneity of tidal ventilation distribution, regional respiratory system compliance, and alveolar overdistension and collapse will be assessed. LUS will be performed by experienced users, with a 10 MHz linear transducer.
223847347|NCT04783415|DRUG|Acalabrutinib|Given PO
223847348|NCT04783415|BIOLOGICAL|Ublituximab|Given IV
223847349|NCT04783415|DRUG|Umbralisib|Given PO
223847350|NCT06506240|OTHER|Acupuncture|Treatment will be administered by licensed practitioners with over five years of experience, in separate rooms to prevent patient interaction. The selected acupuncture points include LI11 (Quchi), SP10 (Xuehai), ST36 (Zusanli), SP6 (Sanyinjiao), LR3 (Taichong), LI4 (Hegu), ST25 (Tianshu), CV4 (Guanyuan), GV20 (Baihui), and superior GV29 (superior Yintang). Patients will receive acupuncture or sham acupuncture three times weekly for 6 weeks.
223847351|NCT03115346|OTHER|Decision aid|Decision aid for repair type for aortic abdominal aneurysms
223847352|NCT05457244|DEVICE|single-port robotic surgery|Colorectal surgery using the da Vinci SP System will be performed via the umbilicus, McBurney's site or the reverse McBurney's site depending on the sites of lesion. All of these patients will undergo a standard minimally invasive resection in the same fashion as would be carried out with multiport laparoscopic or robotic surgery.
223847353|NCT05117034|DRUG|Morphine|Intraoperative intravenous administration of 0.08 mg/kg morphine at dura closure.
223847354|NCT05117034|DRUG|Nacl 0.9%|Intraoperative intravenous administration of 0.08 ml/kg NaCl 0.9% at dura closure.
223847355|NCT05506345|BEHAVIORAL|Creative Drama Workshop|"* The host introduces the theme and stressor scene of this workshop~  * Nursing students group discussion~    * Nursing student group performance practice ④Nursing group formal performance ⑤Nursing student group discussion ⑥The representative of the nursing student group made a speech ⑦ The host summarizes the positive coping methods of nursing students in stressor events"
223847356|NCT04816526|BIOLOGICAL|Descartes 08|Car T-cells
223847357|NCT01737268|DRUG|FK949E|Oral tablet
223847358|NCT03743922|DRUG|Calciferol|calciferol capsule
223847359|NCT03743922|DRUG|Placebo|placebo capsule
223847360|NCT04160585|OTHER|There is no intervention.|There is no intervention.
223847361|NCT06419946|DRUG|Temozolomide|In the experimental treatment arm: a combination of Temozolomide and Lomustine, taken together, two separate pills
223847362|NCT06419946|DRUG|Lomustine|In the experimental treatment arm: a combination of Temozolomide and Lomustine, taken together, two separate pills
223847363|NCT03788291|DRUG|Acalabrutinib|100 mg by mouth twice a day starting on day 8 of cycle 1
223847364|NCT03788291|DRUG|Rituximab|Administered 2 times weekly for 6 cycles. Initial dose day 1: 50 mg IV, then 50 mg SQ thereafter.
223847365|NCT03869853|BEHAVIORAL|Entrepreneurial stimulation and integrated education|one month cycle of stimulation of business with integrated education on nutrition, health, and gender empowerment
223847366|NCT03869853|BEHAVIORAL|control|no intervention
223847367|NCT05588791|DIAGNOSTIC_TEST|whole-body computed tomography|whole-body computed tomography prescription in the emergency department : an identification tool for low risk patients
223847368|NCT06118736|PROCEDURE|Temporary Medial Hemi-epiphysiodesis of the proximal femur|Temporary Medial Hemi-epiphysiodesis of the proximal femur
223847369|NCT05503420|DEVICE|Masticatory muscle training exerciser|In addition to the normal stroke rehabilitation training, the participants will be instructed on an active range of motion (AROM) exercise to improve coordination of the masticatory muscles. This part will be performed with a 5-second hold at the end of the range of motion for each motion, with 10 repetitions performed for each motion. In addition, each participant will be provided with a device, a U-shaped apparatus covered by silicon and having 3 small springs inside to provide resistance during chewing to be placed inside the mouth for carrying out a chewing exercise. The participant will be instructed to perform a chewing exercise using the device for around 10 minutes each time, twice a day, and 7 days per week. The exercise includes isotonic and isometric muscle training.
223847370|NCT00461565|DRUG|Sildenafil|A1) Two dosis of 200 mg Sildenafil orally. Patients receive either A1) or A2) in cross over design with either B1) or B2).
223847371|NCT00461565|DRUG|Placebo|A2) Matching Placebo orally. Patients receive either A1) or A2) in cross over design with either B1) or B2).
223847372|NCT00461565|DRUG|Vardenafil (Levitra, BAY38-9456)|B1) At least 15 dosis of 20 mg Levitra orally. Patients receive either A1) or A2) in cross over design with either B1) or B2).
223847373|NCT00461565|DRUG|Placebo|B2) Matching Placebo orally. Patients receive either A1) or A2) in cross over design with either B1) or B2).
223847374|NCT01155999|DRUG|T1225|one drop twice daily (morning and evening) in each eye from Day 0 to Day 2
223847375|NCT01155999|DRUG|Tobramycin|1 to 2 drops every two hours while awake on Days 0-1, up to 8×/day, then 1 to 2 drops 4 times daily on Days 2-6
223847376|NCT04636697|DRUG|Intramuscular injection|Subjects will receive two doses of placebo given 21 days apart into the deltoid region of the alternating arm (each arm will be injected once)
223847377|NCT04636697|BIOLOGICAL|Intramuscular vaccine|Subjects will receive two doses of 3.75 µg of CoVLP adjuvanted with AS03 adjuvant given 21 days apart into the deltoid region of the alternating arm (each arm will be injected once)
223847378|NCT05900453|OTHER|Clinical decision support (CDS) tool|"The web-based clinical decision support (CDS) tool uses patient information (e.g., age, sex, BMI, perioperative status) to create personalized predictions of recovery following knee replacement. The CDS tool predicts range of motion, physical function, and pain recovery. Clinicians can use these predictions to (1) inform patients of their expected prognosis, (2) monitor patients' recovery against their predicted recovery, and (3) tailor treatments according to individual patients' needs.~Clinicians were provided with basic training for how to use the CDS tool, and were given examples of how to integrate it into clinical care. However, the CDS tool did not dictate any treatment decisions; clinicians were free to use the CDS tool at their discretion to inform decision making."
223847379|NCT00609141|BIOLOGICAL|cixutumumab|Given IV
223847380|NCT00609141|OTHER|pharmacological study|Correlative studies
223847381|NCT00609141|OTHER|laboratory biomarker analysis|Correlative studies
223847382|NCT04271384|COMBINATION_PRODUCT|nivolumab|Combined neoadjuvant therapy consisting of nivolumab + SABR
223847383|NCT03310229|RADIATION|plain chest x-ray|the participants will be subjected to plain chest x-ray with other tools to help diagnose pulmonary hypertension in haemodialysis patients
223847384|NCT01442974|DRUG|Gemcitabine plus nab-paclitaxel|Gemcitabine 1000mg/mq on d1,8,15 over 28 days of cycle nab-paclitaxel 125mg/mq on d1,8,15 over 28 days cycle Treatment will be administered for two cycles
223847385|NCT01668979|DEVICE|new system to detect Near Falls|We will invite healthy older adults with a history of falls to try the new system and assess whether the new system can induce, detect and quantify Near Fall episodes
223847386|NCT02269436|DRUG|sNN0029 infusion solution|4 µg/day, continuous i.c.v administration
223847387|NCT02659644|DRUG|Oral L-citrulline|There will be a total of 16 patients divided into 4 equal cohorts. The first 4 cohorts will be started on a 7 day oral regimen of twice daily L-citrulline. They will return to clinic on day #7 to evaluate nitric oxide metabolite levels and pharmacokinetic (PK) profile of citrulline. After PK analysis, the next cohort of patients will be given a higher or lower dose based on their weight and also based safety and tolerability. Of note, a PK analysis will be performed for each 4 patient cohort prior to starting citrulline for the subsequent cohort. Assessment for adverse events will be done at specified times throughout the study duration via both phone and clinic encounters.
223847388|NCT02555007|DRUG|Vinorelbine|
223847389|NCT00943423|RADIATION|Involved Field Radiotherapy|IFRT 30Gy delivered in daily fractions of 1.8 - 2.0Gy
223847390|NCT00943423|OTHER|No further treatment|
223847391|NCT03341806|DRUG|Avelumab|Avelumab will be administered intravenously every 2 weeks at a dose of 10 mg/kg for 2 cycles
223847392|NCT03341806|COMBINATION_PRODUCT|MRI-guided LITT therapy|(Part B) prior to receiving Avelumab 10 mg/kg every 2 weeks + LITT
223847393|NCT04218643|OTHER|Ultrasound-guided technique|IV inserted via ultrasound guidance
223847394|NCT04218643|OTHER|Standard technique|IV inserted via standard technique
223847395|NCT01576237|OTHER|blood donation|blood donation with preparative hemapheresis
223847396|NCT02765243|BIOLOGICAL|Anti-GD2 CART|Anti-GD2 4th Generation Chimeric Antigen Receptor-modified T Cells
223847397|NCT04973618|BIOLOGICAL|APVO436|"APVO436~Dosage: APVO436 will be administered at a fixed dosage of 18 mcg after a weekly ramp up during Cycle 1 (Step-up dosing: C1D15: 6 mcg over 22 hours, C1D22: 12 mcg over 8 hours, C2D1: 18 mcg over 6 hours, C2D8: 18 mcg over 4 hours), totaling 18 µg in Cycle 1 and 72 µg/cycle for Cycles 2-4 for a total of 234 µg for the projected 4-cycle treatment course.~Dosage Form: IV Solutions for Intravenous Administration~Frequency: Weekly"
223847398|NCT02266329|DRUG|prazosin hydrochloride|Prazosin as oral capsules titrated to the maximum dose or the maximum tolerated dose based on a dosing algorithm. The maximum dose to be used in this trial is 5mg in the morning and 20 mg at bedtime.
223847399|NCT02266329|DRUG|placebo|Oral capsules of placebo identical in appearance to prazosin capsules titrated in the same manner as prazosin.
223847400|NCT04742244|DIETARY_SUPPLEMENT|Lvemon verbena extract|Each capsule contained 200 mg of lemon verbena extract 2 capsules/day, 14 days
223847401|NCT04742244|DIETARY_SUPPLEMENT|maltodextrin|Each capsule contained 0 mg of lemon verbena extract 2 capsules/day, 14 days
223847402|NCT01051011|DRUG|insulin glargine|initial dose 10 international units (IU) sc daily, titrated according to the mean FPG, 24 (-52) weeks
223847403|NCT01051011|DRUG|metformin|as prescribed
223847404|NCT01051011|DRUG|taspoglutide|10mg sc weekly, 24 (-52) weeks
223847405|NCT01051011|DRUG|taspoglutide|10mg sc weekly the 1st 4 weeks followed by 20mg sc weekly, 24 (-52) weeks
223847406|NCT02662738|DIETARY_SUPPLEMENT|Natural fruit extract|
223847407|NCT02662738|OTHER|Placebo|
223847408|NCT02662738|OTHER|Glucose solution|
223847409|NCT03499600|BEHAVIORAL|Clinical Assessment and CFI|CA and CFI families will participate in the Cultural Formulation Interview prior to their standard intake.
223847410|NCT03499600|BEHAVIORAL|Clinical Assessment|CA families will participate their standard intake procedures.
223847411|NCT02912039|DEVICE|TetraGraph|A sequence of 3 sets of Train of four (TOF) stimuli delivered (every 20 sec) at the pre-determined current amplitude (for instance, 40 mA, then 30 mA, then 50 mA, then 20 mA).
223847412|NCT02912039|DEVICE|TOF Watch|A sequence of 3 sets of TOF stimuli delivered (every 20 sec) at the pre-determined current amplitude (for instance, 40 mA, then 30 mA, then 50 mA, then 20 mA).
223847413|NCT05014620|OTHER|Semi-directive interview|semi-structured exploratory interview
223847414|NCT03727360|OTHER|Exercise Training|Supervised exercise conducted four days per week for six months.
223847415|NCT03727360|OTHER|Flexibility Control|Supervised exercise conducted four days per week for six months.
223847416|NCT05477862|BEHAVIORAL|Clinically Designed Improvisatory Music|Clinically Designed Improvisatory Music (CDIM) is a form of improvised music based on calm-inducing sound parameters which brought relief to our cohort of neurology patients.
223847417|NCT05910931|DRUG|ICG angiography|"* A first injection with the patient asleep before starting the intervention to visualize the vascular anatomy of each patient and assess the pedicles and incisions.~* A second bolus after breast resection to assess the viability of skin flaps and glandular pedicles.~* A third injection to obtain an angiography after implant placement and wound closure.~For angiography, the SPY System with the SPY-Q software will be used."
223847418|NCT01133613|DRUG|Bone morphogenetic protein 7|Single intraarticular injection of BMP-7 or placebo on Day 1
223847419|NCT01137292|DRUG|voriconazole (VFEND®)|The use and dosage recommendations for voriconazole (VFEND®) will take place on the basis of the Summary of Product Characteristics (SmPC) and will be adjusted solely according to medical and therapeutic necessity. The formulation and dose will be managed by the treating physician according to the SmPC, disease and clinical situation. According to the SmPC, in the adults the treatment should be started with the loading dose of 6 mg/kg of voriconazole iv. every 12 hours (during the first 24 hrs) followed by the maintenance dose of 4 mg/kg BID. For peroral formulations, the initial dose should be depending on the weight of the patient 400 mg or 200 mg BID during the first 24 hrs, followed by the maintenance dose of 200 mg or 100 mg of voriconazole BID respectively For paediatric population (\<12 years of age), there is no initial dose necessary. Depending on the formulation, the daily dosage should be in children 7 mg/kg iv. BID or 200 mg of voriconazole orally BID.
223847420|NCT03236233|DRUG|PC786 - Single doses|Safety and tolerability of single doses
223847421|NCT03236233|DRUG|Placebo - Single doses|Safety and tolerability of single doses
223847422|NCT03236233|DRUG|PC786 - Repeat doses|Safety and tolerability of repeat doses
223847423|NCT03236233|DRUG|Placebo - Repeat doses|Safety and tolerability of repeat doses
223847424|NCT04549051|DEVICE|Tenex|Local anesthetic plus Tenex into the coracohumeral ligament for adhesive capsulitis
223847425|NCT04549051|DRUG|Local anesthetic|Only local anesthetic into the coracohumeral ligament for adhesive capsulitis
223847426|NCT03661970|OTHER|Cognate Speech Synthesizer sound percepts|The cognate speech synthesizer will generate an acoustic output, as well as a visual display of the acoustic signals. The outputs on the monitor and the synthesizer will be recorded.
223847427|NCT04837495|PROCEDURE|right stellate ganglion block|The skin should be anaesthetised with lidocaine 2%. Using a lateral approach and in-plane imaging, a blunt regional anaesthesia needle should be advanced deep to the carotid sheath towards the longus colli muscle. Following careful aspiration, inject 10 ml lidocaine 2% that will result in expansion of the fascia of the longus colli. Confirmation of the SGB success can be detected by warming of left upper limb and left Horner's syndrome.
223847428|NCT04122924|OTHER|Abdominal muscle training|The intervention starts 6-12 months postpartum and will last for three months with weekly follow-up through an exercise app. Before commencing the home-based program, women in the intervention group will have an individual session in how to perform the program with a physiotherapist. The intervention consists of a 10 min 5 days a week exercise program, including the following exercises; headlift, crunch and twisted crunch. General principles for strength training are followed: 3 sets of 8-12 contractions close to maximum. The participants will be provided with a smartphone app (Athlete Monitoring) to be reminded to exercise and to register adherence.
223847429|NCT04244591|DRUG|methylprednisolone therapy|Methylprednisolone 40 mg q12h for 5 days
223847430|NCT04244591|OTHER|Standard care|Standard care
223847431|NCT02014558|DRUG|Gilteritinib|Participants received gilteritinib oral tablets (10 mg, 40 mg or 100 mg, depending on the dose) once daily without food allowed for at least 2 hours before and 1 hour after dosing starting from day -2 and day of cycle 1, for continuous 28-day cycles.
223847432|NCT02014558|DRUG|Voriconazole|Participants received 200 mg voriconazole tablets daily every 12 hours starting from day 16 of cycle 1 through day 1 of cycle 2.
223847433|NCT02014558|DRUG|Midazolam|Participants received a single oral dose of 2 mg of midazolam syrup on day -1 and day 15 of cycle 1.
223847434|NCT02014558|DRUG|Cephalexin|Participants received a single oral dose of 500 mg cephalexin tablet or capsule on day -1 and day 15 of cycle 1.
223847435|NCT00186810|DRUG|Busulfan, Cyclophosphamide, Horse ATG|Transplant recipients received a myeloablative conditioning regimen of cyclophosphamide, Anti-Thymocyte Globulin (horse), and Busulfan. Cyclosporine and methotrexate were administered for GVHD prophylaxis.
223847436|NCT00186810|PROCEDURE|Allogeneic stem cell transplant|Allogeneic stem cell transplant Matched sibling donor transplant Cord blood transplant
223847437|NCT04703699|DEVICE|Myval Transcatheter Heart Valve Series|Myval™ THV is a newer-generation balloon-expandable THV characterized by a nickel-cobalt alloy frame composed of a single element - hexagon arranged in a hybrid honeycomb fashion.
223847438|NCT02894307|DRUG|Rivaroxaban|In patients with mechanical valves and unstable INR
223847439|NCT01472536|BEHAVIORAL|Sequestration|Students will be sequestered within their residence hall room for 3 days following influenza like illness symptoms.
223847440|NCT03861455|DRUG|Dupilumab|patient receive dupilumab 300 mg every 2 weeks after a 600 mg-loading dose of dupilumab on day 0
223847441|NCT03861455|DRUG|placebo|patient receive placebo
223847442|NCT04580407|BIOLOGICAL|TAK-672|B-Domain Deleted Recombinant Porcine Factor VIII
223847443|NCT04868396|PROCEDURE|Tumor biopsy|Tumor material will be derived from 'left-over' tumor tissue that is not needed for standardised diagnostics (immune histochemistry and molecular testing).
223847444|NCT04007887|OTHER|Adult education program|A 10-hour program embodying major adult education principles, designed to achieve cognitive involvement of patients in their treatment
223847445|NCT03181724|BEHAVIORAL|Decision Aid|"Cohort I will be managed with a decision aid (henceforth DA), and Cohort II will be managed without one. The patients in Cohort I will receive the DA, which they can complete in a separate room and take home. The decision aids include information on the disease/condition, treatment options, benefits, risks, scientific uncertainties, and probabilities of potential outcomes tailored to the patient's health risks factors. Additionally, it includes values clarifications such as describing outcomes in functional terms, asking patients to consider which benefits and risks matter most to them, and guidance in the steps of decision making and discussing their decision with family/friends. It is interactive and dynamic, helping patients clarify their preferences and come to a decision that feels best to them."
223847446|NCT06483022|BEHAVIORAL|BELIEVE IPE Training|The IPC training will be delivered to health team members who provide intrapartum and/or postpartum maternity care at each facility. Individuals with roles as maternity care providers, nurses, lactation consultants or doulas whose primary inpatient clinical assignment is maternity care will be included in the training. The training will consist of a pre-session module (about 60 minutes), a 90-minute interprofessional collaboration session, delivered using virtual reality head-sets, and post-session modules (about 60 minutes). The pre- and post-session modules will be delivered through an online learning platform.
223847447|NCT06483022|OTHER|Usual Care|Prior to implementation of the IPC training, birthing people at the facilities will receive treatment-as-usual
223847448|NCT04307550|DRUG|Isopropyl alcohol|10 inhalations of an isopropyl alcohol pad
223847449|NCT04307550|OTHER|Placebo|10 inhalations of a sterile saline pad
223847450|NCT03902340|DEVICE|ActiTENS|ActiTENS is a rechargeable box, weighing 64g attached by Velcro to an adhesive support, which can be positioned on the skin at any position chosen by the patient. The patient will use the programme (P4) prescribed by his doctor and will regulate the intensity of stimulation using an application downloaded to his smartphone which will communicate with the box via Bluetooth.
223847451|NCT03902340|DRUG|Level 2 Analgesic Treatments|"There are 4 level 2 oral analgesic treatments indicated for chronic nociceptive pain of moderate to severe intensity (between 4 and 7 on a simple numerical scale of 11 points) (12):~* Tramadol immediate release formulation (IR, one intake every 6 hours) or prolonged release formulation (PR, one intake every 12 hours); maximum posology 400mg/24h.~* Dihydrocodeine: 60mg every 12 hours; maximum posology 120mg/24h.~* Combination of paracetamol and codeine in a fixed combination every 6 hours; maximum posology of codeine: 300mg/24h.~* Combination of paracetamol and tramadol in a fixed combination; maximum posology of tramadol: 8 tablets/24h ie 300mg/24h."
223847452|NCT05267834|PROCEDURE|Conization and/or Hysterectomy|Women undergoing cervical conization or simple/modified/radical hysterectomy with or without pelvic lymphadenectomy
223847453|NCT01924234|DRUG|Morphine|
223847454|NCT01924234|DRUG|Remifentanil|
223847455|NCT02068885|BEHAVIORAL|Feeding study|Food provision throughout the study to all 3 dietary arms, with the following phases: 1) Weight loss; 2) Weight maintenance; 3) Ad libitum
223847456|NCT06132776|DEVICE|HiToP 191 PNP|High tone therapy
223847457|NCT06132776|DEVICE|Placebo device|Placebo therapy
223847458|NCT03316443|DEVICE|Glidescope|"The patient will be intubated by suitable sized tube (in males 8 mm and in females 7.5 mm internal diameter).~For endotracheal intubation with glidescope, size 3 blade will be used in all of the cases. Glidoscope will be advanced gently in the oral cavity (in the midline) and walked down the tongue. The scope will be further advanced into the vallecula and gentle lifting force will be applied for visualization of the glottis. Endotracheal tube will be loaded on specific rigid stylet with 60 degree bent and will be advanced into the trachea by the same operator.~Systolic, diastolic, mean arterial blood pressure and heart rate will be recorded at the following time points: T1: before anesthesia, T2: after induction and immediately before intubation, T3: immediate after completion of intubation, T4: after 1 minute of intubation, T5: after 2 minutes of intubation, T6: after 3 minutes of intubation, T7: after 5 minutes of intubation, T8: after 10 minutes of intubation."
223847459|NCT03316443|DEVICE|Macintosh|The patient will be intubated by suitable sized tube (in males 8 mm and in females 7.5 mm internal diameter). In Macintosh group we will use a blade size 3 at first. The laryngoscope will be advanced in patient mouth displacing the tongue laterally till the laryngoscope reach the vallecula and then gentle lifting will be applied till visualization of the laryngeal inlet then the tube will be advanced.Systolic, diastolic, mean arterial blood pressure and heart rate will be recorded at the following time points: T1: before anesthesia, T2: after induction and immediately before intubation, T3: immediate after completion of intubation, T4: after 1 minute of intubation, T5: after 2 minutes of intubation, T6: after 3 minutes of intubation, T7: after 5 minutes of intubation, T8: after 10 minutes of intubation.Maximal arterial blood pressure and heart rate changes will be recorded
223847460|NCT03921528|BIOLOGICAL|SRK-015|SRK-015 is a fully human anti-proMyostatin monoclonal antibody (mAb) of the immunoglobulin G4 (IgG4)/lambda isotype that binds to human pro/latent myostatin with high affinity. SRK-015 will be administered every 4 weeks by intravenous infusion.
223847461|NCT04928157|DEVICE|Positive Airway Pressure (PAP)|A device used with a nose or face mask which delivers airflow/pressure into the airway, holding the airway open and keeping it from collapsing. Device will be used for 8 weeks.
223847462|NCT00828919|DRUG|axitinib|BID oral tablets. dose of axitinib (AG 013736) will be the same as they were taking in the previous trial
223847463|NCT00828919|DRUG|crizotinib|BID oral Capsules. Dose of crizotinib will be the same taken in previous axitinib trial.
223847464|NCT04124822|DRUG|Piroxicam 20 mg|Piroxicm is from oxicam family of anti inflammatory drug that inhibits prostaglandin synthesis and effectively lower pain threshold levels
223847465|NCT04124822|DRUG|prednisolone 20 mg|prednisolone is from steroid family of anti inflammatory drug that inhibit arachidonic acid and effectively lowers the pain
223847466|NCT01245413|DEVICE|SenSura|Adhesive to stoma bag
223847467|NCT01245413|DEVICE|Athena|Adhesive to stoma bag
223847468|NCT06169436|PROCEDURE|Nephroureterectomy|Removal of cancer mass by urether and kidney complete resection.
223847469|NCT06713187|BIOLOGICAL|interleukin 23|assessment of interleukin 23 in Sera of patients using ELIZA
223847470|NCT05567159|DRUG|Donanemab|Administered IV.
223847471|NCT05959655|DEVICE|Glean Urodynamics System|Wireless, catheter-free urodynamics system
223847472|NCT04909008|OTHER|Exercise Training|10 weeks of supervised exercise training, 3 sessions per week at the cardiac rehab clinic at Mayo Clinic Florida.
223847473|NCT06603402|RADIATION|low-dose involved-field radiotherapy combined with immunochemotherapy|low-dose involved-field radiotherapy combined with immunochemotherapy
223847474|NCT03719677|BEHAVIORAL|Habit development intervention|Lifestyle behavior change intervention targeting physical activity and dietary habit development as well as improving physical and social functioning
223847475|NCT00442663|DEVICE|Transcervical Foley Catheter|
223847476|NCT00442663|DEVICE|Transcervical Foley Catheter with an EASI|
223847477|NCT06605677|OTHER|Questionnaire|An online questionnaire will be sent through e-mail to participants. It is divided into 4 sections: demography and general information 9 questions, knowledge 10 questions, attitude 10 questions and practice 10 questions. No previous similar studies were conducted in the United Arab Emirates (UAE) or internationally based on a search in PubMed and Cochrane library. Hence a validated questionnaire is lacking. Therefore, the questionnaire for this study is designed based on questions encountered daily by colleagues during the consultation, and it can serve the purpose of this study. Consent will be obtained and signed electronically by participants before starting the questionnaire. Participation involves minimal risk. Responses will be anonymous and confidential. Participants' involvement is voluntary, and they can withdraw at any time without any consequences. The time to complete the questionnaire is around 10-15 minutes. Each response will be saved using a unique identifier number.
223847478|NCT00179608|DRUG|CC-5013|
223847479|NCT05348824|DIETARY_SUPPLEMENT|Moringa oleifera leaf|Leaf extract preparation
223847480|NCT05348824|DRUG|Sodium hypochlorite|2.5% sodium hypochlorite (household bleaching agent)
223847481|NCT03314337|DEVICE|Pancreatic stent: PSOF COOK®|After removing the distal pancreas, PSOF COOK will be place in the main pancreatic duct
223847482|NCT00117754|DRUG|Terbinafine hydrochloride|
223847483|NCT05035264|DEVICE|Laryngeal mask insertion|Laryngeal mask insertion in neutral position
223847484|NCT05035264|DEVICE|Laryngeal mask insertion|Laryngeal mask insertion in sniffing position
223847485|NCT05035264|DEVICE|Laryngeal mask insertion|Laryngeal mask insertion in beyond sniffing position
223847486|NCT01374490|DRUG|Crofelemer|Crofelemer will be administered orally as 1 tablet(125 mg)BID for a total daily dose of 250mg crofelemer.
223847487|NCT06650696|BEHAVIORAL|PCE promotion|The intervention requires parents to complete a weekly parent-child interaction task online designed to foster positive childhood experiences. Parents will engage in structured activities with their children and document the interactions. Each week, they are expected to upload a report.
223847488|NCT06650696|BEHAVIORAL|Psychoeducation|Psychoeducation includes sessions for both parents and adolescents, covering key topics such as stress, emotional distress, and mental disorders. The content provides foundational knowledge to help participants understand and manage these challenges.
223847489|NCT06650696|BEHAVIORAL|Emotiaonl skill enhancement|This intervention combines online material with practical, emotion-focused activities. Participants will receive training online on emotional awareness and emotion regulation strategies, along with completing weekly writing assignments. These assignments focus on recent negative events and the emotions associated with them, encouraging emotional expression and processing.
223847490|NCT01423903|DRUG|OPB-51602|A cycle will consist of 28 days of OPB-51602 be taken by study subjects daily by mouth for every day of each 28 day cycle.
223847491|NCT06601907|BEHAVIORAL|alivis|alivis is an interactive online program for independent use by users with Borderline Personality Disorder. It focuses on recognized treatment elements from Dialectical Behavior Therapy, Schema Therapy, Acceptance and Commitment Therapy, and Mindfulness Self-Compassion Therapy.
223847492|NCT06607965|DIETARY_SUPPLEMENT|Whey Protein and Carbohydrates|"Experimental Group:~6 hours before surgery, patients orally consumed 250 ml of a full-nutrition liquid (220 ml homogenized diet, 50 g; containing 31.4 g carbohydrates, 8 g protein, and 215 kcal).~2 hours before surgery, patients orally consumed 200 ml of a clear liquid (50 g enzymatically hydrolyzed rice powder + 0.5 g low-sodium salt; containing 47.7 g carbohydrates, 6.5 g whey protein, and 193 kcal).~After surgery, once there were no symptoms such as dizziness or vomiting, patients could start consuming clear liquids (containing 47.7 g carbohydrates, 6.5 g protein, and 221 kcal) orally every 30 minutes, 4 times on the day of surgery.~Starting from the first day after surgery, patients consumed 200 ml of fat-free nutritional liquid (50 g enzymatically hydrolyzed rice powder + 7.5 g isolated whey protein + 0.5 g low-sodium salt; 223 kcal) per serving, 4 to 6 times per day as needed."
223847493|NCT06608121|OTHER|Upper limb isokinetic forces measurements|The trial is a single-center prospective interventional study. Patients aged 18 to 85 years hospitalized in a French rehabilitation center for stroke, multiple sclerosis or traumatic tetraplegia and presenting a motor deficit ≤3/5 at the shoulder and elbow will be included. MVF measurements will be performed using an isokinetic ergometer during a single session. Concentric and eccentric MVF, as well as the forces generated during passive motion, will be measured in shoulder external-internal rotation and in elbow flexion-extension, in the seated position. The demographic, anthropometric and medical data required for the study will be extracted from medical records. Patients' residual muscle strength will be described and modeled. Explanatory factors for model quality will be determined.
223847494|NCT06601387|PROCEDURE|choledochoduodonostomy|surgical drainage procedures
223847495|NCT06601387|PROCEDURE|hepaticojejunostomy|surgical intervention
223847496|NCT03466840|PROCEDURE|The coronally advanced lingual flap|": A full-thickness crestal incision is performed from the distal surface of the more distal tooth to retromolar pad and finishing with releasing incision. On the lingual side, a full-thickness muco-periosteal flap was elevated until reaching mylohyoid line. Then using a blunt instrument, it was localized a connective tissue band continuing with the epimysium of the mylohyoid muscle. It is inserted into the inner part of the lingual flap about 5mm from the crest in an apical direction. The blunt instrument is inserted below the connective band, and with gentle traction in the coronal direction, this muscular insertion was detached from the lingual flap. Using a periodontal probe, the amount of advancement is measured."
223847497|NCT03466840|PROCEDURE|Modified periosteal releasing Incision|"A full-thickness muco-periosteal flap is reflected on the buccal side. Near the base of muco-periosteal flap, the periosteum is incised less than 0.5mm in depth, creating two segments, coronal segment and apical segment, of the periosteal flap. The flap is pulled with a pair of periodontal forceps laterally. Subsequently, the lateral stretching of the coronal segment of the flap is performed by applying pressure using the blunt face of scalpel blade, or a blunt instrument, with sweeping motion. This motion helps stretching the flap over the submucosa, thereby permitting the flap to be mobile.Using a periodontal probe the amount of advancement is measured."
223847498|NCT06070597|DRUG|Iclepertin|Iclepertin
223847499|NCT06070597|DRUG|Iclepertin Placebo|Placebo to Iclepertin
223847500|NCT06070597|DRUG|Moxifloxacin|Moxifloxacin
223847501|NCT06070597|DRUG|Moxifloxacin Placebo|Placebo Moxifloxacin
223847502|NCT01953510|BIOLOGICAL|PCV10|PCV10 includes serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F and protein D is the main carrier protein
223847503|NCT01953510|BIOLOGICAL|PCV13|PCV13 includes serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F, individually linked to non-toxic diphtheria CRM197 carrier protein
224265046|NCT04444063|PROCEDURE|Non-Incised Papilla Surgical Approach|"Horizontal or oblique incision is done on the buccal mucosa as far as possible from the marginal keratinized tissue and the inter dental papilla The horizontal/oblique incision is extended mesio-distally enough to allow proper visualization of the defect A full thickness flap is elevated apico- coronally to expose the coronal limit of the defect Scaling and root planning are done using mini-curettes and power driven ultrasonic tips with care trying to maintain fibers attached to the cementum Granulation tissue is removed with mini-curettes detached from the bony walls and removed from the base of the papilla carefully with microblades and microscissors .~1ry soft tissue closure will be performed by horizontal mattress suture 2mm from the edges of the incision as a first line of closure and then simple interrupted suture as a second line of closure using (5-0, 6-0) polypropylene suture."
224265047|NCT00408616|BIOLOGICAL|Grazax-R|Grass tablet, 75.000 SQ per day for one year
224265048|NCT00408616|BIOLOGICAL|Grazax Placebo|Grazax Placebo, 0 SQ tablet per day for one year
224265049|NCT01026402|DRUG|AZD2014|Dose escalation phase: a single dose taken orally (solution or tablet) of AZD2014 on single dose day 1 (visit 2), followed by once or twice daily continuous dosing after a washout period (48 hours - 7 days) at visit 4, until discontinuation or withdrawal or Single or multiple doses taken orally (solution or tablet) of AZD2014 taken intermittently until discontinuation or withdrawal. Expansion phase: twice daily dosing from day 1 until discontinuation or withdrawal or a single dose taken orally of AZD2014 on single dose day 1 (visit 2), followed by a single dose on second single dose day 1 (visit 3) after a washout period (48 hours - 7 days) followed by once or twice daily continuous dosing after a washout period (48 hours - 7 days) at visit 4, until discontinuation or withdrawal or single or multiple doses taken orally (solution or tablet) of AZD2014 taken intermittently until discontinuation or withdrawal.
223847504|NCT03067051|DRUG|Verteporfin|In the last decade a clinical interest of developing new methods for minimally invasive treatments of organ-confined prostatic malignancies has been pursued. In this study the drug verteporfin for injection (VFI) is to be used with the SpectraCure P18 System (Interstitial multiple diode lasers and IDOSE® Software).
223847505|NCT03067051|DEVICE|SpectraCure P18 System|Interstitial Photodynamic therapy is provided with the the SpectraCure P18 system
223847506|NCT06610357|OTHER|Group 1|42 diparetic children with cerebral palsy were included in the study. The Modified Ashworth Scale (MAS), the Children's Functional Independence Measure (WeeFIM)-Mobility section and the Gross Motor Function Measure-88 (GMFM-88) were applied before and after SDR surgery.
223847507|NCT00117377|DRUG|Pimecrolimus|Pimecrolimus cream 1 % bid
224265050|NCT05604014|BEHAVIORAL|My Health Coach|My Health Coach is a self-directed mobile health intervention for adults with FASD. It is grounded in self-determination theory and integrates well-established behavior change strategies. It has a cloud-based infrastructure and uses a just-in-time adaptive intervention design and a simple and engaging chatbot interface. It provides adults just the right type and amount of support, when they are most receptive.
223847508|NCT00117377|DRUG|Placebo|Placebo application bid
223847509|NCT05402579|GENETIC|Genomic analysis|Genetic samples will be collected using a DNA saliva collection kit (Oragene: OG-510) and will be sent for genome-wide genotyping to The Centre for Applied Genomics in The Hospital for Sick Children (SickKids)
223847510|NCT05286541|PROCEDURE|Lateralized buccal cortex with xenograft|the buccal cortex of the deficient ridge was separated and lateralized then fixed at the desired distance
223847511|NCT05286541|PROCEDURE|Lateralized buccal cortex with autogenous particulate|lateralized buccal cortex with autogenous particulate
223847512|NCT06615167|DEVICE|ALZGUARD|A digital therapeutic(DTx) application that uses artifical intelligence to analyze cognitive function and provide a diagnosis of dementia.
223847513|NCT06614140|BIOLOGICAL|Personalized Neoantigen Peptide Vaccine with Poly-ICLC and Checkpoint Inhibitors|"This intervention involves a personalized neoantigen peptide vaccine composed of peptides containing tumor-specific mutations, such as SNVs, indels, and frameshift mutations. Neoantigens are selected based on criteria that enhance expression and immunogenicity.~The vaccine is administered alongside Poly-ICLC, a TLR3 agonist, to enhance immune activation. After the initial vaccine doses, checkpoint inhibitors (e.g., anti-PD-1 or anti-PD-L1) are introduced once neoantigen-specific T-cell responses are detected, preventing immune exhaustion and sustaining a strong immune response.~During the follow-up phase, both checkpoint inhibitors and Poly-ICLC are continued to maintain immune activity and ensure a lasting anti-tumor effect."
223847514|NCT06615440|DRUG|Alpha blocker|prazosin will be given to all children with systemic manifestations (orally or by nasogastric tube) at a dose of 30 μg/kg/dose;first repeat dose at 3 h followed by every 6 h till recovery. All patients will be monitored for clinical improvement with vital signs
223847515|NCT06615180|BEHAVIORAL|Transcultural Nursing Course (new curriculum)|"Multinational Collaboration: Developed with input from institutions across five countries, ensuring a broad, international perspective on transcultural nursing.~Comprehensive Theoretical Framework: Integrates multiple cultural competence models (Purnell, Campinha-Bacote, Papadopoulos) with Leininger's Culture Care Theory, offering a thorough approach.~Extensive Practical Training: Includes 17 hours of hands-on experience, featuring hospital visits and interactions with healthcare professionals.~Interactive Learning Methods: Combines role-playing, reflective essays, and cultural activities (e.g., traditional clothing, dances) for dynamic, multimodal education.~Peer Education: Incorporates peer education and evaluation, enhancing collaborative learning and critical thinking.~Standardized Materials: Educational materials and teaching methods are standardized across institutions to ensure consistency and quality in instruction."
223847516|NCT06613594|OTHER|Conventional physical therapy|Patients will receive hot pack, Broom stick ROM exercises, Codman and strengthening exercises. A total of 10 sessions, 5 sessions per week for 2 consecutive weeks.
223847517|NCT06613594|OTHER|Kaltenborn traction mobilization|kaltenborn direction non specific traction mobilization for (1 minute), 3 sets of 10 reps with 1 minute rest in between will be given.
223847518|NCT06613594|OTHER|Kaltenborn translatoric glides|Kaltenborn direction specific linear tranlatoric glides, rhtymic 5reps of each glide, such anterior glide for extension and external rotation, caudal glide for abduction,post glide for flexion and internal roation,these3 sets of painless glides will performed with 10 reps,rest of 1 minutes between these sets.
223847519|NCT06615362|PROCEDURE|preparation of dentin membrane from hopeless tooth for Guided Bone Regeneration in Immediate Implant|tooth extraction , preparation of dentin membrane ,immediate implantation ,Xenogeneic bone graft material, application of dentin derived barrier membrane
223847520|NCT06615362|PROCEDURE|Collagen Membrane for Guided Bone Regeneration in Immediate Implant|like group one but with application of collagen membrane
223847521|NCT06615193|DRUG|HDM2005|HDM2005 will be administered via IV infusion.
223847522|NCT06614452|DEVICE|EUS-FNB|"Endoscopic ultrasound will be performed using a curvilinear array echoendoscope. FNB with 22G or 25G end-cutting needles will be performed. The size of the needles will be based on the personal choice of the endoscopist. Likewise, the sampling technique, whether using the slow-pull, the dry suction, or the wet suction, will be based on the physician's choice. Three passes will be performed as per current guidelines. Specimens will be collected in 3 vials to allow for analysis according to needle pass; one for the first pass, one for the second pass, and one for the third and any eventual subsequent passes.~The rapid-on site cytological evaluation (ROSE) will not be available in this study."
223847523|NCT06613997|DRUG|Albendazole 400mg|Albendazole 400mg per days for 21 consecutive days
223847524|NCT06613997|DRUG|Placebo|Placebo for 21 consecutive days
224265051|NCT05159921|OTHER|Access to an automated conversational agent (SurgInfoBot)|See above under arm/group descriptions.
224265052|NCT00840203|DRUG|Rowasa® 4 gm/60 mL Rectal Enema|1 x 4 gm/60 mL, single-dose
224265053|NCT00840203|DRUG|Mesalamine 4 gm/60 mL Rectal Enema|1 x 4 gm/60 mL, single-dose
224265054|NCT02959879|DRUG|FOLFOX neoadjuvant chemotherapy|4 cycles of FOLFOX neoadjuvant chemotherapy are administrated to patient
224265055|NCT02959879|DRUG|FOLFIRINOX neoadjuvant chemotherapy|4 cycles of FOLFIRINOX neoadjuvant chemotherapy are administrated to patient
224265056|NCT02959879|PROCEDURE|curative surgery for resectable pancreatic duct adenocarcinoma|curative surgery for resectable pancreatic duct adenocarcinoma
224265057|NCT02959879|DRUG|Standard adjuvant chemotherapy|12 cycles of standard adjuvant chemotherapy are administrated
224265058|NCT02959879|DRUG|adjuvant chemotherapy|8 cycles of standard adjuvant chemotherapy are administrated
224265059|NCT02121184|DRUG|Routine oxytocin|per regular oxytocin protocols
224265060|NCT02121184|DRUG|Half-dose oxytocin|The dose of oxytocin currently being administered will be halved and not increased until after 60 minutes initiation of labor analgesia
224265061|NCT02042859|DEVICE|Endoscopic Bipolar RadioFrequency Probe used to remove tumors in bile duct to manage Pancreatic Cancer|
224265062|NCT05657587|DEVICE|SPRINT PNS|Each subject will have 2 leads placed for 60 days. The Sprint system delivers mild electrical stimulation to the shoulder. The Sprint system includes up to two leads (small wires) that are placed through your skin in your shoulder. The leads attach to devices worn on your body that delivers stimulation (stimulators).
224265063|NCT04056338|OTHER|No intervention|No intervention.
224265064|NCT02943343|OTHER|No intervention|
224265065|NCT06433232|PROCEDURE|ROOT CANAL TREATMENT|ROOT CANAL TREATMENT
224265066|NCT04882254|PROCEDURE|Normothermic machine perfusion|Additional 2h of normothermic machine perfusion of the donor kidney with a red cell based perfusate.
224265067|NCT04892615|DEVICE|drainage tube was removed on 5th days after surgery.|drainage tube was removed on 5th days after surgery.
224265068|NCT04892615|DEVICE|drainage tube was removed on 7th days after surgery.|drainage tube was removed on 7th days after surgery.
224265069|NCT01438593|PROCEDURE|Intercerebral implantation of allogenic CD34+ stem cell|Each patient will receive brain implant of approximately 5 million allogenic Umbilical cord blood CD34+ Stem Cell
224265070|NCT03393754|BIOLOGICAL|Hepatitis B Vaccination|Prophylactic Hepatitis B Vaccination
224265071|NCT03721653|DRUG|Bevacizumab|5 mg/kg iv over 30 minutes day 1
224265072|NCT03721653|DRUG|Irinotecan|165 mg/sqm iv over 60 minutes day 1
223847525|NCT06614530|DEVICE|Chilipad Docker Pro|The Chilipad Dock Pro is an advanced sleep system designed to optimize sleep by dynamically adjusting the bed\&#39;s surface temperature. It consists of a mesh mattress pad and a Dock Pro control unit that circulates water through the pad, allowing users to customize the temperature between 55°F and 115°F. The system offers both single and dual control, making it ideal for individual or shared use. Equipped with AI-driven features, the Dock Pro can monitor sleep patterns and environmental factors to make real-time adjustments, ensuring optimal sleep conditions throughout the night. This intelligent temperature management system is enhanced when paired with the optional Sleepme Tracker, creating a personalized sleep experience.
223847526|NCT06616506|DEVICE|newly-invented AI model|Apply newly-invented AI models to assist in determining surgical plans and outcome prediction.
223847527|NCT05039203|DEVICE|Indwelling urinary catheter|Removal of indwelling urinary catheter
223847528|NCT06614556|OTHER|Resistance Training|Participants in the training groups performed bilateral hand grip resistance training three times per week for four weeks using a specialized hand-grip kit provided to them. Participants were provided with pictures and instructions for each exercise upon completion of the initial testing (PRE) session. They were asked to perform 12 training sessions (approximately 30-45 mins) over the 4 weeks according to their schedule. Each participant was asked to keep a training log to assist with accountability. Those assigned to the control groups were asked to maintain their normal daily activities throughout the four weeks.
223847529|NCT06614816|BIOLOGICAL|Oka strain varicella attenuated live vaccine|lyophilized powder, subcutaneous injection
223847530|NCT05531370|OTHER|Breathing Retraining|"Conforming the real-world setting, all participants will continue standard asthma care, i.e., acute and planned visits at GP or pulmonologist.~BR aims to normalize the inhaled volume, nasal inhalation, exhalation to the resting position of the chest (functional residual capacity, FRC), use of the diaphragm muscle, and to move lower parts of the chest in a frequency of 12-16 per minute. This pattern is initially trained in rest (e.g., side lying or sitting), then during physical activity (e.g., walking). Uncontrolled coughing, frequent yawning or sighing is handled by a suppression technique. Relaxation technique is introduced as a separate activity but to be combined with the breathing pattern method to be used in both resting and as possible during physical activity."
223847531|NCT04918108|BIOLOGICAL|inflammatory response|laboratory data (leukocyte, neutrophils, monocyte, lymphocytes, platelet, fibrinogen, D-dimer, neutrophils-lymphocyte ratio, platelet-lymphocyte ratio, lymphocyte-monocyte ratio)
223847532|NCT06453109|DEVICE|low intensity focused ultrasound (LIFU)|"Low-intensity focused ultrasound (LIFU) provides an energy source with millimeter resolution that can be focused anywhere in the brain safely and effectively for non-invasive and transient neuromodulation. LIFU is an important advance and of great significance for brain-mapping efforts, diagnostics, and therapies in neuroscience and particularly promising for addiction therapy as it provides unprecedented non-surgical access to the brain regardless of depth.~Much lower intensities of focused ultrasound (LIFU) are used so that tissue damage does not occur, but neural activity can be modulated. LIFU utilizes acoustic energy at much lower levels to affect tissue by mechanical effects."
223847533|NCT06697366|DRUG|Irinotecan liposome injection Ⅱ|56.6 mg/m2，Q3W
223847534|NCT06697366|DRUG|Sintilimab|200mg，Q3W
223847535|NCT06698211|DRUG|Posaconazole tablet|Posaconazole tablet will be given at a dose of 300mg q12h on day 1 and 300mg qd from day 2 for patients who receive HSCT as the primary prophylaxis of IFD, after which the Posaconazole plasma concentration on day 5 will be examined. Once patients developed GI GVHD, first line therapy and second line treatment will be reviewed according to the condition, besides which the Posaconazole plasma concentration would be detected again on the first, third and fifth day after onset of GI GVHD symptoms to monitor the impact of GI GVHD on the Posaconazole plasma concentration.
223847536|NCT06711224|BEHAVIORAL|Digital intervention for adolscents with ADHD|The aim of the digital intervention is to promote coping of ADHD. The intervention has a duration of 6 weeks and will be delivered as a mobile app including weekly phone calls from a therapist. The intervention includes text, interactive exercises, animations, and coping skills. The themes of the intervention includes psychoeducation on ADHD, healthy habits (sleep, exercise, food), social skills, and emotion regulation. The adolescents have the possibility to choose some of the themes they want to work on during the intervention.
223847537|NCT05397106|DEVICE|CODMAN CERTAS Plus Programmable Valve|Patients will undergo implantation of the CODMAN CERTAS Plus Programmable Valve according to the device label.
223847538|NCT02501811|BIOLOGICAL|Mesenchymal Stem Cells (MSC)|15 transendocardial injections of 0.4ml MSCs administered to the left ventricle via NOGA Myostar injection catheter (single procedure)
223847539|NCT02501811|BIOLOGICAL|c-kit+ cells|15 transendocardial injections of 0.4ml c-kit+ cells administered to the left ventricle via NOGA Myostar injection catheter (single procedure)
223847540|NCT02501811|BIOLOGICAL|Placebo (Plasmalyte A)|15 transendocardial injections of 0.4ml placebo administered to the left ventricle via NOGA Myostar injection catheter (single procedure)
223847541|NCT06211257|OTHER|Dematerialized Personalized Care Plan (ePCP)|Post-treatment support with standard support combined with dematerialized support
223847542|NCT04377633|PROCEDURE|Oral handover|Anesthesia handover during surgery will be performed as usual, i.e., oral exchange of pertinent clinical information.
223847543|NCT04377633|PROCEDURE|Checklist handover|Anesthesia handover during surgery will be performed according to a structured handover checklist.
223847544|NCT05927480|BEHAVIORAL|Audio distraction|Music on an mp3 player will be provided to the patient for them to listen to while having the traction pin placed.
223847545|NCT01489176|DRUG|Regadenoson; Optison|A one-time intravenous bolus of Regadenoson 400 mcg; continuous intravenous infusion of Optison of 2-4 mL/minute.
223847546|NCT05881785|BIOLOGICAL|GR1501 low dose|3×low dose GR1501 every 2 weeks,then low dose GR1501 monthly
223847547|NCT05881785|BIOLOGICAL|GR1501 high dose|3×high dose GR1501 every 2 weeks,then high dose GR1501 monthly
223847548|NCT05881785|BIOLOGICAL|placebo|"* Core treatment period:placebo~* Maintenance treatment period: GR1501 injection"
223847549|NCT02624778|BIOLOGICAL|LY3002813|Administered IV
223847550|NCT02624778|DRUG|Placebo|Administered IV
223847551|NCT05541497|DRUG|Varenicline Tartrate|Days 1-3: 0.5mg study pill once per day, Days 4-7: 0.5mg study pill twice per day, Weeks 2-8: 1mg study pill twice per day
223847552|NCT05541497|DRUG|Placebo|Days 1-3: 0.5mg pill once per day, Days 4-7: 0.5mg pill twice per day, Weeks 2-8: 1mg pill twice per day
223847553|NCT06026189|DIAGNOSTIC_TEST|urine-first strategy|Only patients with an abnormal urine test result undergo a diagnostic workup, i.e. cystoscopy and upper-tract imaging.
223847554|NCT00982254|DRUG|Oral insulin|oral insulin capsule formulation (150 U insulin/200 mg 4-CNAB in one capsule); single dose administration of 300 U insulin (in two capsules) and of 150 U insulin (one capsule) on two separate dosing days.
223847555|NCT00982254|DRUG|regular human insulin|subcutaneous injection of 15 U regular human insulin; single dose administration on one separate dosing visit.
223847556|NCT03618095|DEVICE|LOTUS Edge Valve System|TAVR with the LOTUS Edge Valve System
223847557|NCT05300555|DRUG|Rivaroxaban 20 MG Oral Tablet|After randomization, the patient will start medication (rivaroxaban 20mg per day or 15mg per day if eGFR between 30 and 50ml/min/1,73m²) within 24 hours. The medication will be prescribed up to 30 days after hospital discharge and if there is no clinical, electrocardiographic and Holter evidence of AF, the medication will be discontinued
223847558|NCT05300555|DRUG|Warfarin|After randomization, the patient will start medication within 24 hours. Bridge with heparin or enoxaparin is recommended. The INR target is between 2,0 and 3,0. The medication will be prescribed up to 30 days after hospital discharge and if there is no clinical, electrocardiographic and Holter evidence of AF, the medication will be discontinued
223847559|NCT04587479|DRUG|JAB-8263|Variable dose, orally Q2D with 28 days each cycle
223847560|NCT05094284|DEVICE|BioFreedom Ultra|this is a registry only
223847561|NCT01171924|DRUG|CUDC-101|CUDC-101 administered as a 1 hour intravenous infusion at the maximum tolerated dose of 275 mg/m2 consecutively for 5 days on each 14 day cycle.
223847562|NCT01171924|DRUG|CUDC-101|CUDC-101 administered as a 1 hour intravenous infusion at the maximum tolerated dose of 275 mg/m2 on Monday, Wednesday, Friday for three consecutive weeks of each 28 day cycle.
223847563|NCT01286415|BEHAVIORAL|Group Cognitive Processing Therapy-Cognitive Only|Cognitive Processing Therapy (CPT) is an evidence-based form of Cognitive Behavioral Therapy (CBT) used to treat PTSD. CPT is a 12-session manualized program that focuses on challenging beliefs and assumptions related to the trauma, oneself, and the world. Sessions will be conducted twice weekly for six weeks; each session is 90 minutes.
223847564|NCT01286415|BEHAVIORAL|Group Present Centered Therapy|Present Centered Therapy (PCT) is a supportive group intervention typically used within the Department of Veterans Affairs (VA) healthcare systems to address problems of veterans with PTSD (Rosen, et al., 2004). PCT focuses on problem-solving current difficulties that may be related to past traumatic events, but does not address specific memories or cognitions about the trauma. Sessions will be conducted twice weekly for 6 weeks; sessions are 90 minutes.
223847565|NCT01537133|DRUG|fluticasone|Dry Powder Inhaler: 250 mcg/puff, one puff, twice a day
223847566|NCT01537133|DRUG|Placebo|Dry Powder Inhaler: Placebo
224265073|NCT03721653|DRUG|Oxaliplatin|85 mg/sqm iv over 2 hours day 1
224265074|NCT03721653|DRUG|L-Leucovorin|200 mg/sqm iv over 2 hours day 1
224265075|NCT03721653|DRUG|5-fluorouracil|3200 mg/sqm 48 h-continuous infusion
224265076|NCT03721653|DRUG|Atezolizumab|840 mg iv over 30 minutes (60 minutes at the first infusion) day 1
224265077|NCT03349567|BEHAVIORAL|Audit-and-feedback|We will monitor the antimicrobial-prescribing of providers in the experimental arm. Our study team will meet with providers in the experimental arm to provide guidance on optimal antimicrobial-prescribing. We will provide personalized feedback to providers in the experimental arm once every quarter.
224265078|NCT01193387|DRUG|insulin degludec|Each subject will be allocated to 2 single doses of trial product on 2 separate visits: One injection with formulation 1 and and one injection with formulation 2). Injected subcutaneously (under the skin).
224265079|NCT01193387|DRUG|insulin degludec|Each subject will be allocated to 2 single doses of trial product on 2 separate visits: One injection with formulation 1 and and one injection with formulation 2). Injected subcutaneously (under the skin).
224265080|NCT04961996|DRUG|Giredestrant|Giredestrant 30 milligrams (mg) will be administered orally once a day (QD) on Days 1-28 of each 28-day cycle for 5 years or until disease recurrence or unacceptable toxicity (whichever occurs first).
224265081|NCT04961996|DRUG|Endocrine Therapy of Physician's Choice|The endocrine therapy of physician's choice (TPC) is limited to tamoxifen or one of the specified third generation aromatase inhibitors: letrozole, anastrozole, or exemestane. Participants will receive TPC daily on Days 1-28 of each 28-day cycle for 5 years or until disease recurrence or unacceptable toxicity (whichever occurs first). Continuing TPC after 5 years is at the discretion of the investigator and per local standard of care. Dose administration of TPC should be performed in accordance with the local prescribing information for the respective product.
224265082|NCT04961996|DRUG|LHRH Agonist|A luteinizing hormone-releasing hormone (LHRH) agonist will be administered to male participants and premenopausal/perimenopausal participants according to local prescribing information. The investigator may determine and supply the appropriate LHRH agonist locally approved for use in breast cancer.
224265083|NCT04961996|DRUG|Abemaciclib|Abemaciclib 150 mg will be administered orally (PO) twice a day (BID) on Days 1-28 during each 28-day cycle for 2 years or until disease recurrence or unacceptable toxicity (whichever occurs first).
224265084|NCT03066544|DRUG|Bupivacaine|Nerve blocks with bupivacaine will be performed at initial visit
224265085|NCT03066544|DRUG|Naratriptan Pill|one pill will be administered twice each day for 5 days
223847567|NCT00610753|BEHAVIORAL|Family Behavior Therapy|This treatment is usually delivered in two phases: In the first phase there is an initial investigation of family behavior around feeding using a family meal followed by family therapy focused on enhancing feeding of the anorexic child in order to promote weight gain. In the second phase, once weight gain is well established the adolescent is given greater autonomy over feeding and in later sessions over other issues.
223847568|NCT00610753|BEHAVIORAL|Systems Family Therapy|This therapy is applied in three phases. 1. In the first 2 or 3-sessions the treatment is explained to the family and an initial examination of family issues begins. 2. In the second phase family interactions and psychological processes are explored with clarification for family members. 3. In the third phase knowledge of family patterns is refined aiming for behavior change.
223847569|NCT00606866|DRUG|placebo|Placebo for four weeks
223847570|NCT00606866|DRUG|Sorafenib|Sorafenib 200 mg twice daily
223847571|NCT00606866|DRUG|Sorafenib|Sorafenib, 400 mg twice daily
223847572|NCT02324114|DEVICE|Hsp90|Detect plasma Hsp90α concentration
223847573|NCT04513028|DIETARY_SUPPLEMENT|Beta-Glucan|500mg (1 capsule) by mouth twice a day for 21 days.
223847574|NCT04702503|DRUG|WP1220|Topical administration 2x daily for 84 consecutive days
223847575|NCT05169281|OTHER|Medication Disposal Packet|The disposal packet (DisposeRx Inc.) contains a powder that sequesters unused opioids in a polymer gel. The kits reached patients four days following their surgery based on prior data to leverage availability bias, or a tendency to think or act on things that are most present in one's mind, and provided patients with a disposal technique when they were likely to be finished with their opioids. The process of mailing the disposal packet is simple, low cost (\~$1.50/ mailed packet) and scalable.
223847576|NCT06550193|DEVICE|Ultrasound-guided procedure using AR/VR technology|Participants will receive the intervention, which involves utilizing AR/VR technology during ultrasound-guided procedures (e.g., regional anesthesia, line placement). All participants will receive standard pre- and post-block or line care as they normally would for the ultrasound-guided procedure.
223847577|NCT00531479|DRUG|voriconazole|"First week: Voriconazole 6 mg/kg IV bid for the first 24 hours, followed by 4 mg/kg IV BID plus anidulafungin placebo IV qd.~Second week: Voriconazole 4 mg/kg IV bid or 300 mg PO bid plus anidulafungin placebo IV qd.~Third and fourth weeks: Voriconazole 4 mg/kg IV bid OR 300 mg PO bid plus anidulafungin placebo IV qd,~OR~Voriconazole 4 mg/kg IV bid or 300 mg PO bid monotherapy.~Fifth and sixth weeks: Voriconazole 4 mg/kg IV bid or 300 mg PO bid monotherapy."
223847578|NCT00531479|DRUG|anidulafungin|"First week: Voriconazole 6 mg/kg IV bid for the first 24 hours, followed by 4 mg/kg IV bid plus anidulafungin 200 mg IV on day 1, followed by 100 mg IV qd thereafter.~Second week: Voriconazole 4 mg/kg IV bid or 300 mg PO bid plus anidulafungin 100 mg IV qd.~Third and fourth weeks: Voriconazole 4 mg/kg IV bid OR 300 mg PO bid plus anidulafungin 100 mg IV qd,~OR~Voriconazole 4 mg/kg IV bid or 300 mg PO bid monotherapy.~Fifth and sixth weeks: Voriconazole 4 mg/kg IV bid or 300 mg PO bid monotherapy."
223847579|NCT00531479|DRUG|voriconazole|"First week: Voriconazole 6 mg/kg IV bid for the first 24 hours, followed by 4 mg/kg IV bid plus anidulafungin 200 mg IV on day 1, followed by 100 mg IV qd thereafter.~Second week: Voriconazole 4 mg/kg IV bid or 300 mg PO bid plus anidulafungin 100 mg IV qd.~Third and fourth weeks: Voriconazole 4 mg/kg IV bid OR 300 mg PO bid plus anidulafungin 100 mg IV qd,~OR~Voriconazole 4 mg/kg IV bid or 300 mg PO bid monotherapy.~Fifth and sixth weeks: Voriconazole 4 mg/kg IV bid or 300 mg PO bid monotherapy."
223847580|NCT01898676|DRUG|Divalproex Sodium Extended-release 250mg|Two tablets of Divalproex Sodium Extended-Release 250mg will be given to the subject in two treatment periods
223847581|NCT01898676|DRUG|DEPAKOTE 250mg|Two tablets of DEPAKOTE 250mg will be given to the subject in two treatment periods.
223847582|NCT03910543|DRUG|Tofacitinib 5 mg twice daily|Tofacitinib will be administered at a dose of 5 mg twice daily
223847583|NCT04442984|DRUG|Irinotecan|d1 Irinotecan 180mg/m² every two weeks
223847584|NCT04442984|DRUG|Oxaliplatin|d1 Oxaliplatin 85 mg/m² every two weeks
223847585|NCT04442984|DRUG|5-FU|d1-2 5-FU 2200 mg/m² every two weeks
223847586|NCT04442984|DRUG|5-FU|d1 5-FU 250 mg/m² every two weeks
223847587|NCT04442984|DRUG|Leucovorin|d1 Leucovorin 400 mg every two weeks
223847588|NCT04442984|DRUG|5-FU|d1 5-FU 400 mg/m² every two weeks
223847589|NCT04442984|DRUG|5-FU|d1-2 5-FU 2400 mg/m² every two weeks
223847590|NCT03742219|BEHAVIORAL|Lifestyle Modification|"1. Community awareness: a) individuals will be made aware of their own chronic lifestyle diseases and risk factors b) communities will be made aware of their aggregated data concerning chronic lifestyle related diseases and risk factors.~2. Education for individuals and communities on the meaning of the lifestyle diseases and risk factors. a) individual and small group sessions explaining diseases and lifestyle measures that are helpful, b) community level education to tentatively include i) shopping guides and recipes, ii) urban gardening projects, iii) puppet shows and other community presentations, iv) literature and posters."
223847591|NCT05642000|BEHAVIORAL|SASEA HUB|SASEA HUB website, an intervention tool to increase COVID-19 testing
223847592|NCT03193346|BIOLOGICAL|botulinum toxin Type A|Botulinum toxin Type A (BOTOX®) 155U to 195U IM injections in head/neck areas.
223847593|NCT03193346|DRUG|placebo (sodium chloride 0.9 mg)|Placebo matching BOTOX® \[Sodium chloride 0.9 mg\] IM injections in head/neck areas.
223847594|NCT02008864|DRUG|Senna|(7.5 mg of sennosoides A and B) Senna tablet/ 2 times per day
223847595|NCT02008864|DRUG|Placebo|Placebo tablet/ 2 times per day
223847596|NCT00535977|DIETARY_SUPPLEMENT|Broccoli|400g ITC-enriched broccoli per week for 12 months
223847597|NCT00535977|DIETARY_SUPPLEMENT|Peas|400g frozen garden peas per week for 12 months
223847598|NCT05060614|PROCEDURE|Hip fracture surgery|Hip fracture surgery
223847599|NCT06631612|DRUG|ferric hydroxide polymaltose complex|participants will receive oral iron supplementation according to body weight every other day
223847600|NCT06631612|DRUG|ferric hydroxide polymaltose complex|participants will receive oral iron supplementation dose according to body weight daily
223847601|NCT06631612|DRUG|Albendazole.|both arms will receive Albendazole 400mg once at the beginning f the study to be repeated after 1 week
223847602|NCT06630403|OTHER|Demographic Data|Demographic data (age, height, weight, BMI) will be collected verbally through an assessment form.
223847603|NCT06630403|OTHER|Disease History|The number of exacerbations in the last 1 year, hospitalization and medications used will be questioned.
223847604|NCT06630403|OTHER|Pulmonary Function Test|Pulmonary Function Test will be performed with a spirometer.
223847605|NCT06630403|OTHER|Reaction Time|Reaction time will be evaluated with the Nelson Hand-Foot Reaction Test.
223847606|NCT06630403|OTHER|Functional Capacity|Functional capacity will be evaluated with 6 minute walk test
223847607|NCT06630403|OTHER|Dyspnea Perception|Dalhousie Dyspnea and Perceived Exertion Scale will be used to determine the level of dyspnea
223847608|NCT06630403|OTHER|Quality of Life|"Quality of life will be assessed with the Quality of Life Scale for Children\&#34;"
223847609|NCT06630403|OTHER|Fear of movement|Fear of movement will be evaluated with Tampa Kinesiophobia Scale
223847610|NCT06630403|OTHER|Ability of Motor Imagery|Motor Imagery ability will be assessed by Movement Imagery Questionnaire-3 and Vividness of Movement Imagery
223847611|NCT06630403|OTHER|Cognitive Functions|Cognitive functions will be assessed with Trail Making Test and Stroop Test
223847612|NCT00713739|DRUG|Alfuzosin|Patients who present to NMCSD with symptomatic ureteral stones visible on CT and KUB, and who are medically stable will be offered enrollment. The patients will be randomly assigned to one of 4 groups. Outpatient treatment groups will be randomized 1:1:1:1 and include; Group 1 - Alfuzosin 10 mg daily, Group 2 - Nifedipine 30 mg daily, Group 3 - Doxazosin 4 mg daily, or Group 4 - Prazosin 1 mg BID. The treatment regimens consist of daily medication until the stone passes or 21 days, whatever is shorter. Patients will also receive oral pain medication as needed.
223847613|NCT00713739|DRUG|nifedipine|Patients who present to NMCSD with symptomatic ureteral stones visible on CT and KUB, and who are medically stable will be offered enrollment. The patients will be randomly assigned to one of 4 groups. Outpatient treatment groups will be randomized 1:1:1:1 and include; Group 1 - Alfuzosin 10 mg daily, Group 2 - Nifedipine 30 mg daily, Group 3 - Doxazosin 4 mg daily, or Group 4 - Prazosin 1 mg BID. The treatment regimens consist of daily medication until the stone passes or 21 days, whatever is shorter. Patients will also receive oral pain medication as needed.
223847614|NCT00713739|DRUG|doxazosin|Patients who present to NMCSD with symptomatic ureteral stones visible on CT and KUB, and who are medically stable will be offered enrollment. The patients will be randomly assigned to one of 4 groups. Outpatient treatment groups will be randomized 1:1:1:1 and include; Group 1 - Alfuzosin 10 mg daily, Group 2 - Nifedipine 30 mg daily, Group 3 - Doxazosin 4 mg daily, or Group 4 - Prazosin 1 mg BID. The treatment regimens consist of daily medication until the stone passes or 21 days, whatever is shorter. Patients will also receive oral pain medication as needed.
223847615|NCT00713739|DRUG|prazosin|Patients who present to NMCSD with symptomatic ureteral stones visible on CT and KUB, and who are medically stable will be offered enrollment. The patients will be randomly assigned to one of 4 groups. Outpatient treatment groups will be randomized 1:1:1:1 and include; Group 1 - Alfuzosin 10 mg daily, Group 2 - Nifedipine 30 mg daily, Group 3 - Doxazosin 4 mg daily, or Group 4 - Prazosin 1 mg BID. The treatment regimens consist of daily medication until the stone passes or 21 days, whatever is shorter. Patients will also receive oral pain medication as needed.
223847616|NCT02653079|OTHER|Blood Draw and Questionaire|The study is observational. The treatment-plan of the underlying disease remained unchanged. Blood draw from patients at several time points during and after low dose radiation therapy.
223847617|NCT02222415|DIETARY_SUPPLEMENT|Exercise + Protein drink|
223847618|NCT00432653|DRUG|rituximab|
223847619|NCT06313723|OTHER|Prenatal education management delivered via podcast|Pregnant women assigned to the intervention group (52) will be listened to podcasts on a Samsung Galaxy J7 Prime brand phone while undergoing a 20-minute NST procedure
223847620|NCT01711047|PROCEDURE|Radiofrequency catheter Ablation|In this arm, catheter ablation would be performed in the left atrium and would include pulmonary vein isolation and linear ablations (roof and mitral isthmus lines)
223847621|NCT01711047|PROCEDURE|Radiofrequency catheter ablation|In this arm, catheter ablation would be performed in the left atrium, including pulmonary vein isolation, linear ablations (roof and mitral isthmus lines) and Complex Fractionated Atrial Electrograms (CFAE) ablation.
223847622|NCT00887640|DRUG|Temsirolimus|dosage form: IV dosage, frequency and duration: 25mg weekly until clinical progression
223847623|NCT00887640|DRUG|Diphenhydramine|Dosage form: IV or PO Dosage, frequency and duration: 25-50mg, 30 minutes prior to Temsirolimus infusion
223847624|NCT00208104|BEHAVIORAL|Motivational Interviewing|Trained nurses will interview the group using motivational interview counseling techniques. All sessions will be conducted with the aid of an adapted version of a standardized structured adherence counseling script. This script was specifically developed for use in medication adherence studies of HIV positive patients and has been provided for this trial.
223847625|NCT05809076|DEVICE|real tACS|tACS is a non-invasive method to induce brain modulation. It will be applied at a frequency of 40 Hz (gamma-tACS) with a peak-to-peak intensity of 2 mA. During the real tACS condition, the alternating current will be administered for 20 minutes.
223847626|NCT05809076|DEVICE|sham tACS|In the sham tACS condition, the current will be delivered only for the first 30 seconds and then stopped, in order to simulate the same somatosensory sensations as real tACS, but without inducing modulation.
223847627|NCT05908799|DRUG|Pembrolizumab + Pemetrexed-Platinum|Medication records in EHR database used to define exposure group
223847628|NCT05908799|DRUG|Pemetrexed-Platinum|Medication records in EHR database used to define comparator group
223847629|NCT06067178|BEHAVIORAL|Health Dialogue Intervention|"1. Lifestyle assessment: All participants fill out a questionnaire to assess behavioral risk factors for CVD and undergo blood tests for cholesterol and blood glucose.~2. Lifestyle health dialogue: When presenting in person at the primary care center, blood pressure, BMI, and waist-hip ratio will be measured. The results from the questionnaire, blood tests, blood pressure, and body measurements will be summarized using a visual tool, in which risk factors are graded into risk levels to estimate CVD risk. The visual tool will then be used in the health dialogue to discuss risk factors. The health dialogue is conducted by a licensed healthcare professional who has been trained in the methodology. The dialogue will be conducted in a person-centered manner and will aim to motivate and support lifestyle behavior changes when needed. If necessary, medical treatment will be provided according to existing guidelines."
223847630|NCT06067178|OTHER|Opportunistic Screening|"1. Risk factor assessment: Opportunistic screening entails screening for risk factors (blood pressure, BMI, blood tests for cholesterol and blood glucose, and smoking) among patients visiting the primary care center for another reason. Screening is conducted by a healthcare professional at which the patient has an appointment.~2. Detected risk factors for CVD are treated according to the existing care programs and guidelines at the primary care center, which should always include lifestyle advice as the first intervention and medication if hypertension is established. In this intervention, there is a more limited assessment of behavioral risk factors; that is, patients are asked about smoking, but assessment of diet, physical activity, or alcohol consumption is not included in the opportunistic screening."
223847631|NCT00328523|DRUG|MK-0653, ezetimibe|
223847632|NCT00328523|DRUG|Duration of Treatment: 3 months|
223847633|NCT04618458|BEHAVIORAL|Power to Prevent|Lifestyle diabetes prevention intervention based on the National Diabetes Prevention Program and tailored for African American families. The intervention will be delivered using telehealth and small group videoconferencing.
223847634|NCT00202358|DRUG|atenolol|
223847635|NCT00202358|DRUG|placebo|
223847636|NCT06037187|DIAGNOSTIC_TEST|Blood Draw|Standard coagulation assays (aPTT, INR, ACT), viscoelastic coagulation profiles (rotational thromboelastometry (ROTEM)/thromboelastography (TEG), tPA-challenged ROTEM/TEG), and molecular profiling
223847637|NCT01287052|DRUG|Nitrous Oxide|Once consent is obtained, the research assistant will notify the charge RN and MD of the patient's study participation. The patient will then be placed in a treatment room and nitrous oxide will be administered per the existing protocol. Each participant will be given nitrous oxide until he/she reports a pain score of zero or up to fifteen minutes. Study subjects will be asked to rate their pain on a scale of 0-10 before the treatment and after the treatment, the time duration of administering nitrous oxide will be recorded. In addition, the pain scores at 30, 60, 90, and 120 minutes post baseline measurement will be collected in order to evaluate the sustained effect of nitrous oxide in treating acute migraine pain. Someone from the study will also make a follow-up phone call 24 - 48 hours to see if pain relief persisted.
223847638|NCT04653350|OTHER|High Intensity Exercises|Supervised High intensity Progressive Resistance Training, High intensity weightbearing/Impact exercises and High challenging Balance Training will be given. 2 times/week for 40-50minutes session progressively over the duration of 8 months.
223847639|NCT04653350|OTHER|General Exercises|Supervised general fitness exercises including general body stretches, treadmill walking, mild to moderate intensity progressive resistance training \& balance exercises will be given. 2 times/week for 40-50minutes session progressively over the duration of 8 months
223847640|NCT01606384|DRUG|VASOPRESSIN V1B RECEPTOR ANTAGONIST (SSR149415)|Pharmaceutical form: Capsule Route of administration: oral
223847641|NCT01606384|DRUG|Placebo|Pharmaceutical form: Capsule Route of administration: Oral
223847642|NCT00697892|DRUG|lopinavir/ritonavir|Two tablets of lopinavir 200mg / ritonavir 50mg orally twice daily with food for 26 days
223847643|NCT00697892|DRUG|efavirenz|One 600mg tablet orally once daily before bedtime on an empty stomach for 26 days
223847644|NCT00697892|DRUG|artemether/lumefantrine|4 tablets of artemether 20mg/lumefantrine 120mg twice daily with food. 2 three-day courses will be administered (with washout in between) during the duration of the trial.
223847645|NCT02007083|PROCEDURE|Bilateral laminotomy (BL)|
223847646|NCT02007083|PROCEDURE|Unilateral laminotomy with crossover (UL)|
223847647|NCT02007083|PROCEDURE|Spinous Process Osteotomy (SPO)|
223847648|NCT02039700|DRUG|Lesinurad 400 mg|
223847649|NCT02039700|DRUG|[14C]lesinurad (100 μg per 10 mL)|
223847650|NCT06080958|DEVICE|NPWT|the NPWT dressing applied to fasciocutaneous flap
223847651|NCT06080958|OTHER|Conventional dressing|Conventional dressing ( topical care ) applied to fasciocutaneous flap
223847652|NCT01809379|DRUG|chemotherapy with doxorubicin and cisplatin|intraperitoneal chemotherapy applied as an aerosol and under pressure
223847653|NCT04792099|PROCEDURE|Continuous positive airway pressure|After study entry, CPAP will be provided via mask or binasal prongs in order to have a relatively uniform CPAP delivery system among infants in the treatment group. Bubble CPAP will be preferred over other modes of CPAP delivery. A PEEP of 5 will be used for uniformity.
223847654|NCT04792099|PROCEDURE|Nasal Cannula|After study entry, flow will be set to 0.5 L/kg with 1L maximum while on NC during the study period to reduce the risk of inadvertent PEEP with higher flows. Initial FiO2 can be titrated to achieve target saturations, and may be increased up to 100% while on NC.
223847655|NCT02037243|BEHAVIORAL|Standard Public Health Intervention with Water Treatment|Compound level meeting
223847656|NCT02037243|BEHAVIORAL|Standard Public Health Intervention with Water Treatment & Hand Washing|Compound level meeting
223847657|NCT02037243|BEHAVIORAL|Disgust and Shame Based Intervention with Water Treatment|Compound level meeting
223847658|NCT02037243|BEHAVIORAL|Disgust and Shame Based Intervention with Water Treatment & Hand Washing|Compound level meeting
223847659|NCT02055482|DRUG|Molidustat (BAY85-3934)|BAY85-3934 will be titrated at the scheduled dose control visits to maintain the Hb in the target range of 10.0 to 12.0 g/dL. Available doses include 15, 25, 50, 75, 100, and 150 mg/day OD. Treatment will be for minimum of 6 months to up to a maximum of 36 months.
223847660|NCT02055482|BIOLOGICAL|Darbepoetin|Darbepoetin will be administered according to the local label and titrated at the scheduled dose by intravenous injection. Treatment will be for a minimum of 6 months to up to a maximum of 36 months.
223847661|NCT03645174|DEVICE|Using long tube|Fiberoptic-guided intubation through LMA, using long tube
223847662|NCT03645174|DEVICE|Aintree catheter|Fiberoptic-guided intubation through LMA, using Aintree catheter
223847663|NCT06368180|DEVICE|Robotic assisted gait training|is a robotic treadmill training system that uses body weight support to suspend patients by attaching their legs to robotic legs that help them walk
223847664|NCT06368180|DEVICE|Body weight supported treadmill training|The Biodex Unweighting System was used to support the child's body weight, by an adjustable harness placed, over the treadmill.
223847665|NCT00782041|DRUG|Oxaliplatin|85 mg/m²
223847666|NCT00782041|DRUG|5-FluoroUracil|2,000 mg/m²
223847667|NCT00782041|DRUG|Folinic acid|20 mg/m²
223847668|NCT06268028|BEHAVIORAL|Training|Discharge training
223847669|NCT03392662|DEVICE|Hemopatch|Patients received product at the discretion of their surgeon.
223847670|NCT02501629|DRUG|Reslizumab|Reslizumab 110 mg was administered by qualified study personnel as subcutaneous injections in the upper arm(s) once every 4 weeks for a total of 6 doses. Drug was supplied in pre-filled syringes.
223847671|NCT02501629|DRUG|Placebo|Placebo was administered by qualified study personnel as subcutaneous injections in the upper arm(s) once every 4 weeks for a total of 6 doses. Drug was supplied in pre-filled syringes.
223847672|NCT02501629|DRUG|Non-Oral Corticosteroid (non-OCS) Asthma Medication|Participants continue using their non-OCS background asthma medications without change during the study's treatment period.
223847673|NCT02501629|DRUG|Oral Corticosteroid (OCS)|After screening and prior to study start, the participant's OCS dose was adjusted to determine the minimal effective OCS requirement.
223847674|NCT03007459|OTHER|Psychological health|Observing and measuring baseline, and changes in, psychological health through a fitness contest preparation period
223847675|NCT03007459|OTHER|Physiological health|Observing and measuring baseline, and changes in, physiological health through a fitness contest preparation period
224265086|NCT03066544|DRUG|Dexamethasone|one tablet will be administered twice each day for 3 days
224265087|NCT03066544|DRUG|Ketorolac|ketorolac will be administered intramuscularly (IM) or intravenously (IV) at initial visit
224265088|NCT04411680|DRUG|Sargramostim|Sargramostim is a glycosylated, yeast-derived recombinant human granulocyte-macrophage colony stimulating factor (rhu-GM-CSF). Dosage for inhaled sargramostim: 125 mcg twice a day. Dosage for intravenous sargramostim: 125mcg/m2/day given over a 4 hour period.
224265089|NCT04411680|DRUG|Standard of care|Standard of care for COVID-19
224265090|NCT05294276|OTHER|no intervention related|no intervention related
224265091|NCT05595980|DIETARY_SUPPLEMENT|Probiotic|Participants will consume 1 capsule containing 2 billion CFU of a Bacillus strain spore preparation once daily for 56 days
224265092|NCT05595980|DIETARY_SUPPLEMENT|Placebo|Participants will consume 1 capsule containing maltodextrin once daily for 56 days
224265093|NCT01728480|DRUG|entolimod|Given SC
224265094|NCT01728480|RADIATION|intensity-modulated radiation therapy|Undergo IMRT
223847676|NCT02004613|DRUG|Dexmedetomidine|Dexmedetomidine
224265095|NCT01728480|DRUG|cisplatin|Given IV
224265096|NCT01728480|OTHER|pharmacological study|Correlative studies
224265097|NCT01728480|OTHER|laboratory biomarker analysis|Correlative studies
224265098|NCT06430294|OTHER|Spinal mobilisation|Application of a force on pediatric manikins.
224265099|NCT00690027|PROCEDURE|Emergency portacaval shunt|
224265100|NCT00690027|PROCEDURE|Emergency and long-term endoscopic sclerotherapy|
223847677|NCT02004613|DRUG|Placebo|Normal saline administration matching dexmedetomidine rate of infusion
223847678|NCT00868231|DRUG|Aclidinium bromide 400 μg bid|Aclidinium bromide 400 μg twice-daily via inhalation by the Eklira Genuair® inhaler: 1 puff in the morning and evening for 15 days.
223847679|NCT00868231|DRUG|Tiotropium 18 μg once-daily|Tiotropium 18 μg once-daily via inhalation by Handihaler® dry powder inhaler: 1 puff in the morning for 15 days.
223847680|NCT00868231|DRUG|Placebo|Inhaled placebo: 1 puff in the morning (placebo to tiotropium) or in the morning and evening (placebo to aclidnium) for 15 days.
223847681|NCT00004209|DRUG|cisplatin|
223847682|NCT00004209|DRUG|mitomycin C|
223847683|NCT00004209|DRUG|vinblastine sulfate|
223847684|NCT00971009|BEHAVIORAL|OPPC service|Access to a practice-integrated nurse administered online patient-provider communication (OPPC) service including access to asking questions to social counselors
223847685|NCT00971009|BEHAVIORAL|WebChoice IHCA|The additional features of WebChoice allows patients to monitor their symptoms and health problems from home; provides them with individually tailored, just-in-time information and support to manage their symptoms and illness-related problems between treatments and during rehabilitation; and a forum, or e-group community, for group discussion with other cancer patients.
223847686|NCT02359838|OTHER|Baseline Geriatric Screening/Assessment|All patients receive baseline geriatric screening/assessment by a research assistant to determine frailty status.
223847687|NCT02359838|OTHER|Geriatrician Co-Management|A board-certified geriatrician embedded in the oncology clinic will co-manage patients randomized to this arm.
223847688|NCT03451643|PROCEDURE|ENDOSCOPIC PLACEMENT OF EXPANDABLE STENT|PLACEMENT OF AN ENDOSCOPIC SELF EXPANDABLE METAL STENT
223847689|NCT05245487|DIAGNOSTIC_TEST|DNA repair gene mutation analysis|Prospective monitoring of patients with next-generation sequencing for blood mutations
223847690|NCT05709457|BEHAVIORAL|Cash transfer in prior study|Women were offered a cash transfer conditional on attending prenatal and postnatal visits and delivering in a facility
223847691|NCT02135809|DEVICE|WallFlex Pancreatic Stent|Temporary placement of the WallFlex Pancreatic Stent for treatment of refractory pancreatic duct strictures in patients with painful chronic pancreatitis. Stent will be removed after 3-6 months indwell.
223847692|NCT04691544|BIOLOGICAL|Fecal microbiota transplantation (FMT)|Delivered by enema
223847693|NCT04661670|DEVICE|occlusal stabilization splints|an intraoral appliance that has flat surface to allow bilateral posterior contacts in coincidence with physiologic condylar seating and to produce smooth anterior guidance in excursions
223847694|NCT06480409|OTHER|VR Mindfulness and Stress Reduction Program|"Intervention Procedure:~Duration and Frequency: Participants will engage in 15-minute VR relaxation sessions, held five times a week over a period of one month.~VR Content: The VR sessions will feature high-quality 360° videos with therapeutic audio, including guided relaxation, calming music, and nature sounds.~Physiological Monitoring: Throughout the sessions, participants' physiological responses will be monitored using Polar H-10 sensors to measure heart rate variability (HRV), providing data on autonomic nervous system activity.~Psychological Assessment: Participants will complete the Perceived Stress Scale (PSS-10) before and after the intervention to evaluate changes in stress levels.~Cybersickness Monitoring: The occurrence of any adverse effects, such as cybersickness, will be monitored and recorded."
223847695|NCT04651179|OTHER|observation|not applicable, observational study
223847696|NCT02335021|DIETARY_SUPPLEMENT|Sucralose|2 packets per 12 fl oz
223847697|NCT02335021|DIETARY_SUPPLEMENT|Sucrose|equisweet to sucralose
223847698|NCT02335021|DIETARY_SUPPLEMENT|Sucralose + maltodextrin|sucralose plus equicaloric (to sucrose) maltodextrin
223847699|NCT02335021|DIETARY_SUPPLEMENT|Sucralose + Sucrose|half the amount of sucralose plus equicaloric sucrose
223847700|NCT04107337|OTHER|Vocal work session with straw exercises|"* Voice assessment: A questionnaire on the subject's voice biography will be sent to the subject at the moment of inclusion.~* Vocal exercises during 10 minutes : (1 minute) Checking the posture ; (1 minute) Control of the management of breath in the straw ; (1 minute) Phonation in the straw ; (2 minutes) Make a siren in the straw ; (4 minutes) Vocalizations in the straw on the arpeggio of Rossini.~This working session will be preceded and followed by the same 10-minutes voice assessment focusing on aerodynamic parameters."
223847701|NCT04107337|OTHER|Vocal work session with open mouth exercises|"* Voice assessment: A questionnaire on the subject's voice biography will be sent to the subject at the moment of inclusion.~* Vocal exercises during 10 minutes : (1 minute) Checking the posture ; (1 minute) Control of the management of breath on a \[f\] with open mouth ; (1 minute) Phonation on the vowel \[a\] with open mouth ; (2 minutes) Make a siren on the vowel \[a\] with open mouth ; (4 minutes) Vocalizations on the vowel \[a\] on the arpeggio of Rossini with open mouth.~This working session will be preceded and followed by the same 10-minutes voice assessment focusing on aerodynamic parameters."
223847702|NCT03463811|DIAGNOSTIC_TEST|Lactate concentration in vaginal fluid|Lactate concentration in vaginal fluid
223847703|NCT04053829|DEVICE|HOLOBalance|"The HOLOBalance tele-rehabilitation system will be used to deliver an evidence based, multi-sensory balance rehabilitation programme to participants, and will deliver a series of exercises prescribed by an expert balance physiotherapist following an initial balance assessment.~The HOLOBalance system will use a head mounted augmented reality display to deliver exercises and games to participants and will record task performance via a combination of body worn sensors and a depth camera. The HOLOBalance tele-rehabilitation system will provide feedback to the supervising clinical team regarding task performance, participant usage and user feedback. The system will have daily presence in the users' home with users expected to complete their prescribed rehabilitation on a daily basis, which mirrors the prescribed exercise routines often provided by balance physiotherapists."
223847704|NCT04053829|OTHER|OTAGO Home Exercise Programme|The OTAGO is a systematic, progressive strength and balance training programme and is supported by a comprehensive workbook that provides written and pictorial instructions for each exercise. It is well-established and widely used in clinical practice in the UK, and has been shown to reduce falls rate in older adults by 35-40%. It is well tolerated in older adults in community settings with good adherence rates.The OTAGO has also been used as the standard intervention in previous investigations of MSR interventions in older adults. To match intervention and control interventions, participants in the OTAGO group will be asked to complete the OTAGO programme every day for the duration of the 8 week programme.
223847705|NCT02931149|DRUG|Platelet-rich plasma|Submucosal injection with PRP was performed prior to endoscopic resection
223847706|NCT00810303|DRUG|Ezetrol (ezetimibe) multiple dose|administration of 1 tablet/day Ezetrol (10 mg ezetimibe) on study day 6-15 and a pharmakokinetic on study day 15 (0-24 h blood sampling, 0-24 h urine sampling and 5 d feces sampling (study day 11-15))
223847707|NCT00810303|DRUG|Ezetrol (ezetimibe) multiple dose and Sustiva (efavirenz) single dose|administration of 1 tablet/day Ezetrol(R) (10 mg ezetimibe) on study day 16-20 and 2 capsules Sustiva(R) (2x200 mg efavirenz) on study day 16 with a pharmakokinetic (0-120 h blood sampling, urine sampling (24 h intervals) and feces sampling on study days 16-20)
223847708|NCT00810303|DRUG|Ezetrol (ezetimibe) and Sustiva (efavirenz) multiple dose|administration of 1 tablet/day Ezetrol(R) (10 mg ezetimibe) and 2 capsules/day Sustiva(R) (2x200 mg efavirenz) on study day 21-30 and with a pharmakokinetic (0-120 h blood sampling, urine sampling (24 h intervals) on study day 30 and feces sampling on study day 26-30)
223847709|NCT00810303|DRUG|Sustiva (efavirenz) single dose|administration of 2 capsules Sustiva(R) (2x200 mg efavirenz) on study day 1 with a pharmakokinetic (0-120 h blood sampling, urine sampling (24 h intervals) and feces sampling on study days 1-5)
223847710|NCT06059313|OTHER|Submission of the NEO-PI-3 questionnaire|The questionnaire contains 240 statements. For each statement, the patient chooses the answer that best corresponds to their choice (FD: strongly disagree - D: disagree - N: neutral - A: agree - FA: strongly agree).
223847711|NCT06059313|OTHER|Submission of the Interpersonal Reactivity Index questionnaire (IRI)|The test assesses two cognitive and two affective components of empathy that influence each other and affect attitudes and behaviors toward others.
223847712|NCT05693662|BEHAVIORAL|Session 1|"* Ensuring group interaction, allowing parents to meet each other,~* Providing information in line with the Awareness-Based Self-Compassion Training Booklet for Parents of Children with Autism Spectrum Disorder prepared as training material,"
223847713|NCT05693662|BEHAVIORAL|Session 2|"* Making explanations about the contents of the training sessions to be held with parents,~* Teaching proper breathing techniques,~* Visual demonstration and application of relaxation techniques"
223847714|NCT05693662|BEHAVIORAL|Session 3|"* Breathing break with kindness application,~* Thinking and evaluating how threat, impulse and soothing systems develop in individuals' own lives,~* Safe place application,~* Applying kindness meditation,"
223847715|NCT05693662|BEHAVIORAL|Session 4|"* Breathing break with kindness application,~* The practice of establishing a compassionate relationship with resistance,~* Kindness meditation: a do-gooder application,~* A hand on the heart application,~* A compassionate companion application,"
223847716|NCT05693662|BEHAVIORAL|Session 5|"* Breathing break with kindness application,~* The practice of establishing a compassionate relationship with desire,~* Guided meditation to discover the inner pattern practice,~* Kindness meditation: a good friend application,"
223847717|NCT05693662|BEHAVIORAL|Session 6|"* Pretending practice regarding parents' awareness,~* An expanded version of the practices carried out in previous sessions to raise awareness, the internalizing compassion practice,~* Kindness meditation: a neutral person, kindness towards your body and walking with kindness practices, which are based on mindfulness practices and increase body awareness and mindful movement,"
223847718|NCT05693662|BEHAVIORAL|Session 7|"* A compassionate letter application, which is carried out by asking parents to think about a situation they have encountered recently or some time ago that still causes distress,~* Kindness meditation: the 'difficult' person, compassion and breathing: yourself and compassionate breathing: others practices,~* Researching how parents can cope with difficulties and implementing a compassionate breath break without words,"
223847719|NCT05693662|BEHAVIORAL|Session 8|"* Revisiting the good application to enable parents to experience the five senses in a pleasant way,~* Practices of self-forgiveness, asking for forgiveness, forgiving others, gratitude, which can be a way of mending the cracks in parents' relationships with themselves and others,~* Expanding the practice into kindness meditation: groups and all beings,"
223847720|NCT05693662|BEHAVIORAL|Session 9|"* The practice of allowing parents to choose a day in their lives for a few minutes to pause mindfully,~* A breather for wise and compassionate action practice,~* Calmness meditation application,~* Sharing the joy meditation application,"
223847721|NCT05693662|BEHAVIORAL|Session 10|"* Evaluating the entire education by telling parents about the practices they can use where help is needed to develop compassion towards self-healing skills,~* River of Life application, which evaluates awareness in depth,~* Saying goodbye."
223847722|NCT00010881|DRUG|antioxidants|
223847723|NCT00010881|BEHAVIORAL|stress reduction|
223847724|NCT02731521|DEVICE|3 Tesla Scanning|Approximately 120 brain tumor patients 50 patients with non-glioma disease, and 5 healthy volunteers will be scanned at either 3 Tesla or 7 Tesla.
223847725|NCT02731521|DEVICE|7 Tesla Scanning|Approximately 120 brain tumor patients 50 patients with non-glioma disease, and 5 healthy volunteers will be scanned at either 3 Tesla or 7 Tesla.
223847726|NCT05137912|BIOLOGICAL|Immunotherapy|"Patients within this intervention group will be histologically confirmed to have resectable non small cell lung cancer with stage II-IIIA.~Patients may receive single agent immunotherapy or immunotherapy combined with chemotherapy."
223847727|NCT03583437|BEHAVIORAL|Exercise|Moderate Intensity Exercise (50 % af VO2max) for 90 minutes
223847728|NCT03002844|DRUG|EGFR-TK Inhibitor|EGFR-TKI (gefitinib 250mg per day)
223847729|NCT03002844|DRUG|EGFR-TKI|EGFR-TKI (gefitinib 250mg per day)
223847730|NCT03002844|DRUG|EGFR-TKI and Chemotherapy|pemetrexed 500mg per kg q3w/gemcitabine 1000mg per kg q3w and carboplatin AUC=5 q3w
223847731|NCT05773612|OTHER|Rock Steady Boxing Class|Rock Steady Boxing is a non-contact fitness program designed specifically for people with Parkinson's Disease.
223847732|NCT05101330|DEVICE|Bilingual prescription medication labels|The bilingual PML contains English and Chinese medication-related instructions for participants.
223847733|NCT03281343|BEHAVIORAL|Motivational Interviewing & Patient Navigator|The specific content, structure, and implementation approach for MI-NAV will be guided by IDIs conducted during Phase 1 and Phase 2. Our initial plan is to deliver MI-NAV in two waves. The first wave will be aimed at promoting uptake of PrEP at the prison, through the use of motivational interviewing. The second wave will be aimed at linking at-risk women to community-based PrEP care upon release from incarceration, by utilizing a patient navigator approach.
223847734|NCT03281343|BEHAVIORAL|Standard of Care (SOC)|SOC will consist of a pamphlet regarding PrEP during incarceration, an offer of PrEP while incarcerated, and referral to community-based PrEP care upon release.
223847735|NCT03364959|OTHER|Corticosteroids inhalation|Flixotide inhalation followed by Qvar inhalation through a nasal filter and a mouth filter located in a partitioned face mask and delivered to an infant with asthma via a Tipshaler® holding chamber
223847736|NCT03364959|OTHER|Corticosteroids inhalation|Qvar inhalation followed by Flixotide inhalation through a nasal filter and a mouth filter located in a partitioned face mask and delivered to an infant with asthma via a Tipshaler® holding chamber
223847737|NCT04865562|DRUG|testosterone propionate|1mg/0.1mL solution, to be administered intranasally
223847738|NCT04865562|DRUG|0.5% cholorbutanol, saline|125 mg 0.5% cholorbutanol, 50mg saline
223847739|NCT02060279|OTHER|Lifestyle intervention and carotenoid supplements|2 week intervention partial hospitalization program followed by 8 bi-monthly sessions of a lifestyle intervention group run by a psychologist or health coach (research assistant). The entire intervention will last approximately 6 months. Children will participate in all aspects of the intervention including: dietary groups, life coaching, art and music therapy, school based learning, group therapy, physical activity, cooking, preparing meals, family therapy sessions, and yoga. The participants randomized to this study arm will also take Jarrow Formulas CaroteneAll® (5000 IU) supplement while at the intervention site for 2 weeks and then will continue to take the supplements for up to 6 months until their participation in the study is complete. Two capsules of supplement will be consumed daily with a meal with 6 oz. of water.
223847740|NCT02060279|OTHER|Lifestyle intervention and placebo|2 week intervention partial hospitalization program followed by 8 bi-monthly sessions of a lifestyle intervention group run by a psychologist or health coach (research assistant). The entire intervention will last approximately 6 months. Children will participate in all aspects of the intervention including: dietary groups, life coaching, art and music therapy, school based learning, group therapy, physical activity, cooking, preparing meals, family therapy sessions, and yoga. The participants randomized to this study arm will also take a gel-cap placebo while at the intervention site for 2 weeks and then will continue to take the placebo for up to 6 months until their participation in the study is complete. Two capsules of placebo will be consumed daily with a meal with 6 oz. of water.
223847741|NCT04582175|PROCEDURE|angioplasty|angioplasty of all non-culprit lesions
223847742|NCT03506490|OTHER|Aerobic exercises|The training session lasted 45 minutes and was composed of running exercises.
223847743|NCT01134809|PROCEDURE|Major abdominal surgery|All adult patients having major abdominal surgery
223847744|NCT03587194|DRUG|Otezla|Otezla 30mg BID
223847745|NCT00073957|BIOLOGICAL|rituximab|
223847746|NCT00073957|DRUG|cytarabine|to be used for CNS prophylaxis
223847747|NCT00073957|DRUG|liposomal cytarabine|to be used as CNS prophylaxis
223847748|NCT00073957|RADIATION|yttrium Y 90 ibritumomab tiuxetan|
223847749|NCT00407940|DEVICE|Lower extremity Atherectomy and Cryoplasty|
223847750|NCT02823496|OTHER|Sunscreen Lotion , BAY 987521|50 μl/ cm2 of the test article is applied directly to two sites on the skin and covered with the appropriate patch. 24 hours later, the patches are removed. The test sites are lightly wiped with a dry cloth/tissue and 3μl/cm2 of test article is reapplied directly to the skin of the test site designated for irradiation, and lightly spread over the test site. 48 hours later the procedure is repeated to the same test sites. This process is repeated twice weekly for a total of six exposures. Formulation A: Y49-103, Formulation B: Y71-150.
223847751|NCT02823496|OTHER|Untreated skin|One site is patched without treatment as control
223847752|NCT00601640|DRUG|Diclofenac Na gel|Given topically twice daily on days 1-90
223847753|NCT00601640|DRUG|Eflornithine HCL ointment|Given topically twice daily on days 1-90
224265101|NCT01166529|PROCEDURE|EUS-guided Celiac Plexus Neurolysis|All patients will receive anesthesia. The linear echo-endoscope will be advanced into the proximal stomach. It will be noted whether the tumor is seen in the celiac axis, if there is flow in the celiac artery, and if the celiac ganglia are seen. The celiac ganglia will be injected directly with 10cc of 0.25% bupivicaine followed by 10cc of 98% dehydrated alcohol. If the celiac ganglia cannot be identified, the posterior and anterior aspects of celiac artery take-off will be injected in a similar manner (twice the volume). Flow in the celiac axis will be confirmed. All injections will be performed with a standard EUS injection needle made especially for CPN . Prior to injection, aspiration will be performed through the needle to ensure that no blood is aspirated.
224265102|NCT05661591|DRUG|SHR2554 Tablets|SHR2554 Tablets+ Fluconazole Capsules
224265103|NCT05661591|DRUG|Fluconazole Capsules|SHR2554 Tablets+ Fluconazole Capsules
224265104|NCT06556329|OTHER|Robot (Intervention)|The research team will bring a socially assistive, artificially-enhanced robot during intravenous insertion procedures.
224265105|NCT00748566|DRUG|Ziprasidone HCL (oral)|Ziprasidone Hydrochloride 20 to 80 mg administered orally twice a day (40 to 160 mg total daily dose) for up to 1 year.
224265106|NCT03018990|OTHER|Ethanol|1 milliliter per kilogram body weight adjusted for elevated body mass index
224265107|NCT02349672|PROCEDURE|blood sample|Blood will be collected to test for concentrations of UCH-L1 and GFAP.
224265108|NCT04471116|DIETARY_SUPPLEMENT|OMNi-BiOTiC® FLORA plus+|OMNi-BiOTiC® FLORA plus + is a dietary supplement for the treatment of a disturbed vaginal flora (dysbiosis). The product combines probiotic bacterial strains with a special fiber mixture. The product contains the following strains: Lactobacillus crispatus LBV88, Lactobacillus rhamnosus LBV96, Lactobacillus gasseri LBV150N and Lactobacillus jensenii LBV116
224265109|NCT02182596|DRUG|Mylotarg|Dose level study
224265110|NCT05001958|BEHAVIORAL|Action observation|Participants will view a video of a task performed by a non-disabled actor and then the participants perform the task from the video with their weaker arm \& hand.
224265111|NCT06077786|DRUG|Lu AG06474|Oral solution
224265112|NCT06077786|DRUG|Placebo to Lu AG06474|Oral solution
224265113|NCT06077786|DRUG|Ibuprofen|Capsule
223847754|NCT05304520|DRUG|Natalizumab|Administered as specified in the treatment arm.
223847755|NCT00423774|BEHAVIORAL|Problem-Solving Education|
223847756|NCT02992665|DRUG|Ca Ionophore A23187|Sibling oocytes are to be randomized to artificially activated using Calcium ionophore in cases with severely compromized semen parameters
223847757|NCT02992665|OTHER|Placebo|Placebo is used to control Ca ionophore group
223847758|NCT00530777|DRUG|valacyclovir|500 mg oral valacyclovir twice daily from 34 weeks gestation to 1 year postpartum
223847759|NCT00530777|DRUG|placebo|oral placebo twice daily from 34 weeks gestation to 1 year postpartum
223847760|NCT04066998|OTHER|Tears sampling|Tears sampling
223847761|NCT04066998|OTHER|Lashes sampling|Lashes sampling
223847762|NCT06426654|DRUG|sintiliman plus LDRT|"All patients will start with one cycle of neoadjuvant therapy of sintilimab: sintilimab 200 mg, iv drip, d1, q3w.~LDRT will be performed in the target area. After radiotherapy, patients will receive another three cycles of sintilimab.~Radical D2 gastric cancer resection will be performed 4-6 weeks after the last administration of sintilimab.~The adjuvant therapy will start in 4-6 weeks after the surgery, and we recommend adjuvant treatment with sintilimab for up to 10 cycles."
223847763|NCT02359058|DRUG|Ramucirumab|Administered IV
223847764|NCT02359058|DRUG|Capecitabine|Administered orally
223847765|NCT02359058|DRUG|Cisplatin|Administered IV
223847766|NCT02359058|DRUG|S-1|Administered orally
223847767|NCT02359058|DRUG|Oxaliplatin|Administered IV
223847768|NCT05192824|DEVICE|Orthokeratology lens|The intervention was according to the design of different optical zone and peripheral reverse curve
223847769|NCT03163992|DRUG|Pembrolizumab|Pembrolizumab (MK-3475) 200 mg every 3 weeks (Q3W)
223847770|NCT04830254|DEVICE|Transcutaneous Electrical Nerve Stimulation(TENS) device|The Patients in group (A) received low-frequency TENS (frequency 4 Hz, pulse duration 200 μs,burst mode) was be applied through 2 output channels surface electrodes with an E2 TENS device, for 45 min per session, supramaximal stimulation to sympathetic ganglions in T12, L1, and L2, which innervate the lower extremity . For 45 min per session, three times per week, and for 12 weeks.
223847771|NCT02926742|DEVICE|EkoSonic Endovascular System|Ultrasound catheter-directed thrombolysis.
223847772|NCT05660850|DRUG|GDC-6599|GDC-6599 will be administered Days 1- 14 and on Days 29-42 as film-coated tablets
223847773|NCT05660850|OTHER|GDC-6599-matching placebo|GDC-6599-matching placebo will be administered Days 1- 14 and on Days 29- 42. as film-coated tablets
223847774|NCT05660850|DIAGNOSTIC_TEST|Mannitol|Mannitol challenge tests will be performed during screening and at least 2.5 hours following study drug administration at Study Visits 2, 4, 5 and 7
223847775|NCT03829280|BEHAVIORAL|Cognitive Adaptation Training|Psychosocial treatment using environmental supports to bypass cognitive and motivational problems and improve adaptive behavior
223847776|NCT03829280|BEHAVIORAL|Community Treatment|Medication follow-up and case management as provided in usual community care in the setting
223847777|NCT01104103|DEVICE|BOA(R)-Constricting IV Band|Device applied in accordance with manufacturer's instructions
223847778|NCT01104103|DEVICE|Standard elastic constricting band|Standard therapy
223847779|NCT05207787|DRUG|HS-10365|Single or multiple dose(s) of HS-10365 daily or twice every day. Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and/or unequivocal disease progression.
223847780|NCT02060097|DIETARY_SUPPLEMENT|Cocoa flavanol beverage|
223847781|NCT02060097|DIETARY_SUPPLEMENT|Placebo beverage|
223847782|NCT03267147|OTHER|no intervention is given|no intervention is given
223847783|NCT02833454|PROCEDURE|direct insertion anterior cruciate ligament reconstruction|ACL reconstruction based on direct insertion of ACL.
223847784|NCT02833454|PROCEDURE|single bundle anterior cruciate ligament reconstruction|anterior cruciate ligament reconstruction using single bundle technique
223847785|NCT02833454|PROCEDURE|double bundle anterior cruciate ligament reconstruction|anterior cruciate ligament reconstruction using double bundle technique
223847786|NCT03771235|BEHAVIORAL|Mindfulness-based Intervention for Tics|Psychological intervention that focuses on cultivating awareness of urges to tic and developing a different relationship to those urges through meditation and other mindfulness practices.
223847787|NCT03771235|BEHAVIORAL|Tic Information and Coping Strategies|Psychological Intervention that focuses on learning more about tics, practicing a range of strategies for coping with tics (e.g., relaxation, effective communication), and discussing challenges commonly experienced by individuals with tics.
223847788|NCT03365856|OTHER|observational study|as clinical practice
223847789|NCT00577447|DIETARY_SUPPLEMENT|docosahexaenoic acid (DHA)|Capsule containing 200mg of DHA
223847790|NCT00577447|DIETARY_SUPPLEMENT|Placebo|Placebo capsule containing corn and soybean oil
223847791|NCT03382821|PROCEDURE|Transforaminal ESI with dexamethasone|Catheter-targeted ESI via interlaminar access at the C7-T1 level with dexamethasone sodium phosphate 1.5 mL (10 mg/mL) and 1 ml 1% lidocaine (total volume 2.5 mL).
223847792|NCT03382821|PROCEDURE|Transforaminal catheter-targeted ESI with triamcinolone|Catheter-targeted ESI via interlaminar access at the C7-T1 level with triamcinolone acetonide 2 mL (40mg/mL) and 1 ml 1% lidocaine (total volume 3 mL).
223847793|NCT03382821|DRUG|Dexamethasone Sodium Phosphate 10 MG/ML|Transforaminal ESI with dexamethasone 1.5 mL of dexamethasone sodium phosphate in group #1
223847794|NCT03382821|DRUG|Lidocaine|1 mL of 1% lidocaine as diluent for the steroid in both group #1 and group #2
223847795|NCT03382821|DRUG|Triamcinolone Acetonide 40mg/mL|Transforaminal catheter-targeted ESI with triamcinolone acetonide 2 mL in group #2
223847796|NCT04296240|DRUG|Oxaliplatin and capecitabine|Patients receive 5-Fu and oxaliplatin based neoadjuvant chemotherapy for 3 months
223847797|NCT04296240|PROCEDURE|Total Mesorectal Excision|Patient receive total mesorectal excision after neoadjuvant chemotherapy
223847798|NCT00578695|DRUG|lixivaptan|Oral Capsule
223847799|NCT00578695|DRUG|Placebo|Oral Capsule
223847800|NCT04438915|BEHAVIORAL|Effect of Obesity on incidence of Postoperative cognitive in Gynecological Day- Day- case surgery|The effect of obesity on the incidence of postoperative cognitive dysfunction in Gynecological day-case surgery
223847801|NCT00282438|BIOLOGICAL|Autologous hematopoietic stem cell transplantation|Autologous hematopoietic stem cells will be injected after conditioning
224265114|NCT06077786|DRUG|Pregabalin|Capsule
223847802|NCT00282438|BIOLOGICAL|Allogeneic stem cell transplantation|Allogeneic stem cells will be injected after conditioning
223847803|NCT03247348|BEHAVIORAL|ReSeT-FM intervention|The ReSeT-FM intervention focuses on behavior changes strategies aimed at reducing sedentary time and includes: education, goal setting, self-monitoring of behavior and behavioral prompts to move via an activity tracker and phone app, and feedback on behavior via weekly meetings with study coaches.
223847804|NCT04596761|DEVICE|RF-utilizing powered toothbrush|RF-utilizing Powered toothbrush
223847805|NCT04596761|DEVICE|Control placebo with no RF|Placebo control, toothbrush with no RF
223847806|NCT01447797|DRUG|HCP0912 / Irbesartan and Atorvastatin|Irbesartan and Atorvastatin combination tablet / coadministration of Irbesartan and Atorvastatin
223847807|NCT02793609|OTHER|Intervention is to let patient to go home.|Intervention is to let patient to go home.
223847808|NCT02793609|OTHER|Intervention is to observe women in the ward.|Intervention is to observe women in the ward.
223847809|NCT00471211|DRUG|PBT2|
223847810|NCT03864484|DEVICE|iPad Application + Usual Rehabilitation|The experimental group receives usual rehabilitation. In addition, the experimental group will watch movies using the iPad application for 3 minutes, once daily for 5 weeks.
223847811|NCT03864484|BEHAVIORAL|Usual rehabilitation|The control group receives usual rehabilitation.
223847812|NCT02831400|BEHAVIORAL|Walking test|Walking test to increase cardiac output, maximum 12 minutes
223847813|NCT02831400|BEHAVIORAL|Standard Meal|After the walking test, volunteers eat a standard warm meal
223847814|NCT05831280|BEHAVIORAL|Laughter Yoga|"* Warm-up exercises (5 minutes),~* Deep breathing exercises (5 minutes),~* Childlike playfulness (5 minutes),~* Laughter exercises (15 minutes)."
223847815|NCT02778308|DRUG|Gemcitabine + Cisplatin|Day 1 and day 8 Gemcitabine Day 1 cisplatin
223847816|NCT04155853|PROCEDURE|Interposition Arthroplasty|A typical Wagner incision will be used at the thenar skin one centimeter distal to the radial styloid. The interval between the abductor pollicis longus and the extensor pollicis brevis will be developed, while protecting the dorsal sensory branches of the radial nerve. A longitudinal capsulotomy will be performed and after identifying the carpometacarpal and scaphotrapeziotrapezoid joints, the trapezium will be excised. Then, the empty space will be filled with a roll of fascia lata and fixed with a K-wire. The 1.4 millimeter K-wire will be introduced two centimeters distally to the metacarpal base and into the body of the trapezium. In case of scaphotrapeziotrapezoid joint arthritis, debridement and osteophyte excision of the scaphotrapezoid joint will be performed. In the end of the procedure, the capsule and the skin will be sutured, and a thumb spica will be placed to all patients.
223847817|NCT04155853|PROCEDURE|Hematoma and Distraction Arthroplasty|A typical Wagner incision will be used at the thenar skin one centimeter distal to the radial styloid. The interval between the abductor pollicis longus and the extensor pollicis brevis will be developed, while protecting the dorsal sensory branches of the radial nerve. A longitudinal capsulotomy will be performed and after identifying the carpometacarpal and scaphotrapeziotrapezoid joints, the trapezium will be excised. Then, the empty space will be stabilized with a K-wire without interposition of any material. The 1.4 millimeter K-wire will be introduced two centimeters distally to the metacarpal base and into the body of the trapezium. In case of scaphotrapeziotrapezoid joint arthritis, debridement and osteophyte excision of the scaphotrapezoid joint will be performed. In the end of the procedure, the capsule and the skin will be sutured, and a thumb spica will be placed to all patients.
223847818|NCT04818320|DRUG|Favipiravir|Day 1: 1800mg BD, day 2-5: 800mg BD
223847819|NCT01572077|RADIATION|FTHA, FDG PET imaging.|Subjects will undergo PET scans on 2 different days using 2 separate tracers, FTHA(fluoro-6-this-hepadecanoic acid) and FDG(fluoro-2- deoxy-glucose).
223847820|NCT06366893|DIETARY_SUPPLEMENT|DHA/AA emulsion supplement for preterm infant|Enteral supplementation of DHA/AA emulsion
223847821|NCT04390464|DRUG|Ravulizumab|Ravulizumab (Ultomiris, Alexion Pharmaceuticals) is a monoclonal antibody that binds to terminal complement protein C5 and prevents the complement-mediated destruction of cells. It is administered by intravenous infusion. Ravulizumab has a marketing authorisation in the UK for treating Paroxysmal Nocturnal Haemoglobinuria in adults.
223847822|NCT04390464|DRUG|Baricitinib|Baricitinib is administered orally once daily. It is licensed for treatment of rheumatoid arthritis, it is a relatively fast acting disease modifying anti-rheumatic drug and has the potential to be scaled up for use for a pandemic.
223847823|NCT04390464|OTHER|Standard of care|Regular standard of care for COVID-19 patients
223847824|NCT05249179|OTHER|Pacifier|Preterm infants in Groups 2 and 3 will suck a pacifier 3 times a day (09:00, 12:00, 15:00) for 3 minutes before feeding and then they will be fed with the O/G feeding tube.
223847825|NCT05249179|OTHER|Oral stimulation|Infants in groups 1 and 3 will receive a prefeeding oral stimulation program once a day, 15 to 30 minutes before a tube feeding. Oral stimulation programs will be delivered by trained nurses or pediatric physical therapies. Nurses will be trained to deliver the stimulation program to the infants, by a member from the pediatric physical therapies medical staff, before the beginning of the study. Based on Backman's principles, the pre-feeding oral stimulation program consisted of a 12-minute stimulation program that included stroking the cheeks, lips, gums, and tongue.
223847826|NCT00006265|DRUG|ara-C|3 g/sq m IV infusion over 3 hours Days 1-5
223847827|NCT00006265|BIOLOGICAL|gemtuzumab ozogamicin|9 mg/sq m IV infusion over 2 hrs D 1 (Cohort I); D 7 (Cohorts II, IA, \& IV); \& D 14 (Cohort IV) 4.5 mg/sq m IV infusion over 2 hrs D 8 (Cohort I) \& D 14 (Cohort II)
223847828|NCT02419521|DEVICE|Resolute Onyx Stent - 2.25 mm - 4.0 mm|
223847829|NCT03881631|BEHAVIORAL|Mindfulness Based Stress Reduction Program|Group-based intervention
223847830|NCT03881631|BEHAVIORAL|Living Well Program|Group-based intervention
224265115|NCT06077786|DRUG|Placebo|Capsule
224265116|NCT04090021|DRUG|Esomeprazole 40mg|Use in a drug combination for H. pylori eradication
224265117|NCT04090021|DRUG|Clarithromycin 500mg|Use in a drug combination for H. pylori eradication
224265118|NCT04090021|DRUG|Metronidazole 500 mg|Use in a drug combination for H. pylori eradication
224265119|NCT04090021|DRUG|Amoxicillin 1000 MG|Use in a drug combination for H. pylori eradication
224265120|NCT04090021|DRUG|Levofloxacin 500mg|Use in a drug combination for H. pylori eradication
224265121|NCT04090021|DRUG|Rifabutin 150 MG|Use in a drug combination for H. pylori eradication
224265122|NCT00841659|DRUG|Paroxetine HCl|40 mg Film-Coated Tablet
223847831|NCT04888455|DIAGNOSTIC_TEST|Quantitative sensory testing (QST)|Demographic data, pain characteristics, health status, emotional well-being, personality and lifestyle are assessed by questionnaires. Additionally, all patients underwent a clinical neurological examination and quantitative sensory testing (QST) according to the German Research Network on Neuropathic Pain (DFNS).
223847832|NCT03214887|BIOLOGICAL|RV-P1501|Gel-like product with BMMNCs in each ml of hyaluronan (HA) solution
223847833|NCT00587132|DRUG|Synthetic Human Secretin|0.2mcg/kg one time dose.
223847834|NCT04651244|DIAGNOSTIC_TEST|MRI|Gold standard for identifying inflammatory changes in patients with acute pyelonephritis
223847835|NCT04651244|DIAGNOSTIC_TEST|Ultrasound performed by a radiologist|US performed by a radiologist including standard grayscale evaluation of the kidneys, Doppler US and contrast enhanced US (CEUS).
223847836|NCT04651244|DIAGNOSTIC_TEST|Point of care ultrasound|Point of care US by a study assistant with basic ultrasound skills and training to access the presence or absence of hydronephrosis. If hydronephrosis is present it will be graded into one of four categories.
223847837|NCT06418906|OTHER|Self-reported questionnaires|After participants agree to participate in this study, they will first fill out the set of questionnaires once. After two weeks, the research team will send them reminders to fill out the same set of questionnaires again.
223847838|NCT01380119|BIOLOGICAL|V7|experimental arm
223847839|NCT01380119|OTHER|placebo|placebo pill
224265123|NCT00841659|DRUG|Paxil®|40 mg Film-Coated Tablet
224265124|NCT01988636|BIOLOGICAL|PfSPZ Vaccine|Aseptic, purified, vialed, cryopreserved, radiation attenuated NF54 p.falciparum sporozoites produced by Sanaria, Inc.
224265125|NCT01988636|DRUG|Placebo|Placebo
224265126|NCT04272437|DRUG|Concentrated herbal extract granules TRA|Concentrated herbal extract granules Subjects in the TRA group orally ingested one package of granules (5 g/package) two times daily with warm water after lunch and dinner for 6 consecutive weeks.
224265127|NCT04272437|DRUG|Placebo|Subjects in the placebo group orally ingested one package of granules (5 g/package) two times daily with warm water after lunch and dinner for 6 consecutive weeks.
224265128|NCT03444883|DRUG|Ilaprazole|10mgx2 tablet once daily for weeks
224265129|NCT06562998|DRUG|Pentoxifylline|Pentoxifylline 400mg twice daily plus paclitaxel based regimens for 12weeks.
224265130|NCT03993145|BEHAVIORAL|Web-based lifestyle intervention|Lifestyle intervention program including educational modules on diet and physical activity with visual and audio. Phone conversation with the clinical dietician at week 1, week 3, week 6, week 12 and month 6 (completion of the study).
224265131|NCT04010045|DEVICE|Endovascular Treatment of PAD|PAD endovascular treatment using the DABRA Laser System + other FDA cleared/ approved devices for the treatment of PAD.
224265132|NCT01159145|DRUG|D961H|Oral, capsule
224265133|NCT01159145|DRUG|Omeprazole|Oral, tablet
224265134|NCT06560437|OTHER|Chinese Jingjin Manual Therapy|Chinese Jingjin therapy is a form of manual therapy that utilizes the principles of Chinese Jingjin Theory (also known as Chinese Sinew Channel Theory) to alleviate nodular lesions in sinew channels caused by Jingjin injuries and to realign skeletal joints. Chinese Jingjin manual therapy is divided into three major parts: fascia manipulation, bone setting manipulation, and finishing techniques. The operation takes about 30 minutes, and there is one treatment every other day, three treatments per week, and five consecutive weeks of treatment.
224265135|NCT02725580|GENETIC|AT-GTX-501|CLN6 Gene delivered by Self-Complementary AAV9
224265136|NCT00834405|DRUG|ARAVA® 20 mg tablets|1 x 20 mg, single-dose non-fasting
224265137|NCT00834405|DRUG|Leflunomide 20 mg Tablets|1 x 20 mg, single-dose non-fasting
224265138|NCT00264134|DRUG|Docetaxel|
224265139|NCT00264134|DRUG|Irinotecan|
224265140|NCT00264134|DRUG|Carboplatin|
224265141|NCT06346535|DIAGNOSTIC_TEST|Cognitive Testing|Digital Cognitive Testing performed at home.
224265142|NCT06227858|DIETARY_SUPPLEMENT|Safr'Inside supplement (Activ'Inside, SAS)|Dietary supplementation will be taken in addition to habitual diet of the patients
224265143|NCT06227858|OTHER|Plcebo|Placebo capsule (matched to the experimental intervention in terms of colours and taste, without the active compounds saffron)
224265144|NCT01512628|DRUG|Pentaspan, voluven, volulyte|Different colloids are administered during operation for replacement of blood loss before the transfusion of blood.
224265145|NCT00674128|DEVICE|Cyanoacrylate tissue adhesive (Dermabond)|Skin closure will be performed with cyanoacrylate tissue adhesive.
224265146|NCT00674128|DEVICE|Polyglactin 910 suture (Vicryl)|Skin closure will be performed with polyglactin 910 suture.
224265147|NCT03147053|DRUG|Jiedu Tongluo granules|Patients in this group were administered the Jiedu Tongluo granules, 3.9mg/bag, 2 times/day for 8 weeks.
224265148|NCT03147053|DRUG|Placebo|Patients in this group were administered the placebo, 3.9mg/bag, 2 times/day for 8 weeks.
224265149|NCT03574805|DRUG|PRS-060|Study drug
224265150|NCT03574805|DRUG|Placebo|Inhalant designed to mimic PRS-060
224265151|NCT04285268|DRUG|Bortezomib|Given IV or SC
224265152|NCT04285268|BIOLOGICAL|Rituximab|Given IV
224265153|NCT04285268|DRUG|Venetoclax|Given PO
224265154|NCT03459235|OTHER|quality of life|Assessment of the impact of digestive sequelae (LARS score) and genitourinary sequelae (score IPSS, USP, FSFI et IIEF) in Patients With Rectal Cancer using validated questionnaires on quality of life (EORTC QLQ-C30 et QLQ-CR 29).
224265155|NCT01791751|DRUG|Clomifene Citrate|Clomiphene citrate 100 mg daily for 5 days
224265156|NCT05623592|DRUG|Methotrexate|17,5/15/10 mg Methotrexate subcutaneously
224265157|NCT05623592|DRUG|Sodium chloride|Sodium chloride subcutaneously
224265158|NCT03717701|DRUG|metformin|Patients will take metformin single dose of 1000 mg orally once a day
224265159|NCT03717701|DRUG|esomeprazole|Patients will take esomeprazole single dose of 40 mg orally once a day
224265160|NCT03717701|DRUG|Placebo|Patients will take inert tablets similar in appearance, color, and consistency
223847840|NCT00908674|DRUG|Cyproterone acetate (Androcur)|"The study drug will be administered either as monotherapy or in combination with other interventions (surgical castration or LHRH analogue treatment).~Daily dosage as monotherapy: 200-300 mg cyproterone acetate. Daily dosage following surgical castration: 100-200 mg cyproterone acetate. Daily dosage in combination with an LHRH-analogue: 100-200 mg cyproterone acetate.~Administration period: 12 months."
223847841|NCT04670575|PROCEDURE|Cataract Surgery with Implantation of Vivity Extended Range of Vision IOL|Patients with early stage glaucoma implanted with Vivity or Vivity Toric IOL
223847842|NCT01460992|PROCEDURE|Evia/Entovis pacemaker system under Magnetic Resonance Imaging (MRI) conditions|patients will undergo an MRI scan for 30 minutes.
223847843|NCT01784380|DRUG|Diane-35;metformin;Clomiphene citrate; Human menopausal gonadotropin|
223847844|NCT02782988|OTHER|olfactory tests, otoacoustic emissions (OAE)|Two series of olfactory tests will be performed : 1) the first one with simple odorants and 2) the second one with binary mixtures of odorants. These tests of nasal chemosensory performance are based on pen-like odor dispensing devices (Sniffin' Sticks, Burghardt, Wedel, Germany) and measure odor discrimination ability of young children in less than 15 min.
223847845|NCT02347917|DRUG|BBI608|480 mg orally twice daily (960 mg total daily dose)
223847846|NCT02347917|DRUG|Pemetrexed|500 mg/m2 I.V. infusion on Day 1 of each treatment cycle (except for cycle 1, in which Pemetrexed will be given on Day 3).
223847847|NCT02347917|DRUG|Cisplatin|75 mg/m2 I.V. infusion on Day 1 of each treatment cycle (except for Cycle 1, in which Cisplatin will be given on Day 3).
223847848|NCT03033732|DRUG|Methadone|Methadone is a synthetic analgesic drug used as a substitute drug in the treatment of opioid use disorder. Methadone is administered via strict daily witnessed ingestion.
223847849|NCT03033732|DRUG|Buprenorphine-Naloxone|Buprenorphine/Naloxone is an opioid agonist treatment used to treat opioid use disorder. Buprenorphine/Naloxone is administered via flexible take home dosing once the patient has reached stabilization as per physician discretion.
223847850|NCT03605329|OTHER|to explore the severity of NAC in case of OSAS|"After overnight polysomnography, cardiovascular autonomic neuropathy will be evaluated by different methods: study of HRV, cardiovascular autonomic reflex test (Ewing), measurements of urinary levels of catecholamines and measurements of sweat gland dysfunction using Sudoscan.~The severity of CAN will be evaluated in T1D patients with moderate to severe OSAS (apnea hypopnea index (IAH) ≥15 / hour) compared to T1D patients with IAH \<15 / hour."
223847851|NCT03542708|PROCEDURE|A-PRP|The cortex of selected ovary will be injected with autologous platelet rich plasma. Up to ten different sites will be injected under ultrasound guidance. The patient will be under IV sedation. Record of which ovary was injected will be kept in the online research database and not in the clinical chart.
223847852|NCT03771326|BIOLOGICAL|Kisspeptin-10|Kisspeptin-10 (metastin 45-54, Calbiochem, Darmstadt, Germany)
223847853|NCT03419780|BIOLOGICAL|Blood Transfusion|Patients are randomized to receive 1 or 2 units of packed red blood cells for initial transfusion.
223847854|NCT04315220|OTHER|Corestability training|"Level -1: Mat exercises~Abdominal muscle contraction,bridging,cat stretch,single limb circle and superman.:~Level- 2: Swiss Ball Exercises Abdominal contraction,bridging and squats."
223847855|NCT04315220|OTHER|No Intervention|No Intervention
223847856|NCT03680014|DIAGNOSTIC_TEST|CUSH|Machine learning assisted remote monitoring/ telehealth platform to predict and prevent falls
223847857|NCT03017456|BEHAVIORAL|Survivorship Care Plan|"SCP-Intervention: Patients in the SCP-Int arm will attend a one-time appointment with a trained oncology nurse while the patients in the UC arm will receive care according to the hospital standards for follow-up care. The intervention will be delivered during a regular follow-up appointment, face-to-face and will inform and educate patients on self-management and support as well as promote access to and coordination of post-treatment care. The appointment will focus on empowering the PC survivor to actively self-manage persistent treatment effects and to decrease their risk of late effects by providing effective health information, support, and self-management support. Nurses will integrate a number of active behavior change ingredients including the integration of motivational interviewing techniques which are effective in increasing healthy behaviors."
223847858|NCT03142789|DRUG|Initial bolus (Certa and standard catheter groups)|10 ml of ropivacaine 0,75% will be used to ensure correct position of the needle and to expand the adductor canal, followed by injection of another 10 ml of ropivacaine 0.75% via the catheter during real time US imaging to ensure correct placement of the catheter.
223847859|NCT03142789|DRUG|Initial bolus (Single bolus group)|20 ml of ropivacaine 0.75%
223847860|NCT03142789|DRUG|Intermittent boluses (Certa and standard catheter groups)|20 ml of ropivacaine 0.2% every 8 hour in the catheter
223847861|NCT03142789|DRUG|Intermittent boluses (Single bolus group)|0.1ml of ropivacaine 0.2% every 8 hour in the sham catheter
223847862|NCT05540990|DEVICE|Robot assisted gait training|15 sessions of robot-assisted gait training (two times per week with a maximum of 45 minute each).
223847863|NCT05540990|OTHER|Conventional physiotherapy|individually customized to the needs of the child and usually consists of 2-3 sessions of physiotherapy per week.
223847864|NCT05171933|BEHAVIORAL|Survey|This study is based on a survey made on COVID-19
223847865|NCT01008748|DRUG|Nicotine Replacement Therapy (NRT)|NRT for participants who smoke \>10 cigarettes/day will consist of 2 weeks of 21 mg nicotine patches, 1 week of 14 mg patches, and 1 week of 7 mg patches. Nicotine Patch therapy for participants who smoke 5-10 cigarettes/day will consist of 2 weeks of 14 mg patches and 2 weeks of 7 mg patches. Patch dispensation will occur at weekly treatment visits.
223847866|NCT01008748|BEHAVIORAL|Questionnaire|Computerized questionnaires at each of 5 visits and will take 1 1/2 hours to complete each time.
223847867|NCT01008748|BEHAVIORAL|Counseling|Each counseling session, whether face-to-face or over the phone, will last approximately 15 minutes. In-person counseling sessions occur at weeks -1, 0, and 3, with telephone counseling sessions occurring at weeks 0.5, 1, and 2. Counselors will conduct all sessions in Spanish.
223847868|NCT01008748|BEHAVIORAL|Self-Help Materials|Spanish-language self-help materials currently used by the NCI's Cancer Information Service.
223847869|NCT02616367|DRUG|liposomal bupivacaine Periarticular injection|Liposomal bupivacaine used for a periarticular injection in the knee
223847870|NCT02616367|DRUG|Ropivacaine Periarticular Injection|Periarticular Injection for the knee with ropivacaine
223847871|NCT06095310|BEHAVIORAL|New computer vision methods|Clinical interview: Hamilton scale using multi-modal sensors (cameras, audio, bracelet, fNIRS)
223847872|NCT01787994|GENETIC|Autologous CD4+ T cells genetically modified with a retroviral vector expressing the MazF endoribonuclease gene (MazF-T), given via intravenous infusion.|
223847873|NCT00514332|PROCEDURE|stent|stent placement for colorectal cancer obstruction
223847874|NCT03518983|DEVICE|Dornier Aries2 device|The Dornier Aries2 device and will be used for the purpose of the study. LI-ESWT will be applied to the penile shaft and the 2 crura(two sites).
223847875|NCT03518983|DEVICE|Dornier Aries2 device (sham probe)|The Dornier Aries2 device and will be used for the purpose of the study but the active probe will be replaced by an identical sham probe.
223847876|NCT06444009|DRUG|Ivonescimab combined with TP|Both interventions all drugs intravenous infusion, D1, once every 3 weeks, a total of 3 cycles.
223847877|NCT06444009|DRUG|Cadonilimab combined with TP|Both interventions all drugs intravenous infusion, D1, once every 3 weeks, a total of 3 cycles.
223847878|NCT06444009|DRUG|Penpulimab combined with TP|Both interventions all drugs intravenous infusion, D1, once every 3 weeks, a total of 3 cycles.
223847879|NCT00062062|DRUG|carboplatin|
223847880|NCT00062062|DRUG|gefitinib|
223847881|NCT00062062|DRUG|paclitaxel|
223847882|NCT02775435|BIOLOGICAL|Pembrolizumab|IV infusion
223847883|NCT02775435|DRUG|Paclitaxel|IV infusion
223847884|NCT02775435|DRUG|Nab-paclitaxel|IV infusion
223847885|NCT02775435|DRUG|Carboplatin|IV infusion Carboplatin dose should not to exceed 900 mg.
223847886|NCT02775435|DRUG|Saline placebo for pembrolizumab|IV infusion
223847887|NCT05811728|RADIATION|Low level laser therapy|The low-level laser applied will be a Diode laser\* emitting infrared radiation at a wavelength of 980 nm, in a continuous mode. On the experimental side, subjects will receive LLLT on days 0, 3, 7, 14, and every 2 weeks thereafter, till the termination of the study period (3 months).
223847888|NCT05811728|OTHER|without beam emission|The laser tip will be held passively on the control side without beam emission, providing a placebo effect.
223847889|NCT03681730|DEVICE|Virtual Reality|Participants wear a Virtual Reality headset that consists of a ASUS phone and a VOX+ Z3 3D Virtual Reality Headset. The phone runs the VR Roller Coaster app to produce the virtual environment.
223847890|NCT03059082|BEHAVIORAL|Recovery Navigator on an as needed basis up to 6 months|"This group will undergo contact with Recovery Navigator on an as needed basis up to 6 months and then have a 3 month and 6 month follow-up visit."
223847891|NCT03059082|BEHAVIORAL|Recovery Navigator prior to hospital discharge|This group will undergo one interaction with Recovery Navigator prior to hospital discharge and then have a 3 month and 6 month follow-up visit.
223847892|NCT03059082|OTHER|No interaction with Recovery Navigator|This group will not have any interaction with Recovery Navigator. They will have a 3 month and 6 month follow-up visit.
223847893|NCT03198546|BIOLOGICAL|GPC3 and/or TGFβ targeting CAR-T cells|Engineering GPC3 or/and TGFβ targeting CAR combined with/or without IL7/CCL19 and/or scfv against PD1/CTLA4/Tigit secreting vector into T cells with knockdown of PD1/HPK1, which are isolated from patients with advanced HCC, and then transfusing them back the patients.
223847894|NCT04056221|OTHER|Acupuncture|Acupuncture stimulation was done manually, using single-use acupuncture needles that will be inserted on the selected acupoints (R6, E6, E2, Ig4, VC24, TA23, B2) once a week,for 8 weeks, 20 minutes sessions with 12 weeks of follow up.
223847895|NCT04056221|OTHER|Sham acupuncture|The sham acupuncture consists of needles that achieves no skin penetration and are holden on the points by an adhesive pad.
223847896|NCT03840070|DEVICE|Potenfill|Maximum: 22ml
223847897|NCT02516176|BEHAVIORAL|treadmill training|Paretic leg step training while standing on a treadmill sideways and responding to treadmill being turned on suddenly.
224265161|NCT04987554|DIETARY_SUPPLEMENT|glycophosphopeptical AM3|3 g/day of AM3
224265162|NCT04987554|OTHER|Placebo|3 g/day of placebo
224265163|NCT00829452|DRUG|Ramipril 10 mg capsule|1 x 10 mg
224265164|NCT00829452|DRUG|Altace® 10 mg capsule|1 x 10 mg
224265165|NCT01425840|DRUG|Lidocaine|100 mg of the following formulations: Liposome-encapsulated 2,5% and 5% lidocaine gel, liposome placebo gel and 2.5% lidocaine and 2.5% prilocaine cream were applied once during 5 minutes.
224265166|NCT00991796|DRUG|CS-1008|CS-1008 powder for concentrate for solution for infusion. six cycles of combination therapy with 3 weeks equal to one cycle. 10 mg/kg
224265167|NCT00991796|DRUG|Placebo|Placebo
224265168|NCT00991796|DRUG|Paclitaxel|Paclitaxel concentrate for solution for infusion. once every 3 weeks for a maximum of 6 cycles. 175 mg/m2
224265169|NCT00991796|DRUG|Carboplatin|Carboplatin concentrate for solution for infusion. once every 3 weeks for a maximum of 6 cycles. 6 mg/m2
223847898|NCT06239662|BEHAVIORAL|Therapeutic Group|The first part of each meeting, lasting 45 minutes, will be held only with children and young people, while parents will wait in the waiting room. At the end of the first part, for each meeting, the children will be asked to make a commitment relating to the topics covered, which will be verified in the following meeting. Once the part with the patients has concluded, they will be accompanied to an adjacent environment where a pediatrician volunteer will be waiting for them and will offer fun and socialization activities. In the meantime, the parents will be seated and will address, together with the team staff, the same issues discussed with their children, again for a duration of approximately 45 minutes. Parents will also be invited to make a commitment similar to that required of children.
223847899|NCT06239662|BEHAVIORAL|Usual care|The dietician will meet individually each child together with parents. Dietician will provide nutritional advices.
223847900|NCT01513642|BEHAVIORAL|Breath Stacking|To perform the BS maneuver, a silicone mask containing a one-way valve was attached to the patient's face. Once the mask was adjusted to allow only inspiration (the expiratory branch remained occluded), the patient was asked to make successive inspiratory efforts during 20 seconds.
223847901|NCT05793099|OTHER|Effect of aqueous propolis gums in salivary and dental plaque pH in children|"The child will be given a 10% sucrose solution, and the salivary pH will be measured before and after giving sucrose solution (Baseline) and then the child will be given aqueous propolis gum to chew for 15 minutes to stimulate salivation. The saliva pH will be measured by taking a sample of the patient's saliva (3ml) while chewing the gum in the mouth in a disposable container and then saliva pH will be measured.~Dental plaque pH also will be measured before and after administration of a 10% sucrose solution (Baseline), and then 15 minutes after chewing aqueous propolis gum dental plaque will be collected using the plaque collection technique from the 6 buccal surfaces of teeth 16,21,26,36,41,46 using a sterile excavator. The sample will be mixed with 0.05 ml of distilled water until it dissolves and then dental plaque pH will be measured."
223847902|NCT05793099|OTHER|Effect of placebo gums in salivary and dental plaque pH in children|"The child will be given a 10% sucrose solution, and the salivary pH will be measured before and after giving sucrose solution (Baseline) and then the child will be given placebo gum to chew for 15 minutes to stimulate salivation. The saliva pH will be measured by taking a sample of the patient's saliva (3ml) while chewing the gum in the mouth in a disposable container and then saliva pH will be measured.~Dental plaque pH also will be measured before and after administration of a 10% sucrose solution (Baseline), and then 15 minutes after chewing placebo gum dental plaque will be collected using the plaque collection technique from the 6 buccal surfaces of teeth 16,21,26,36,41,46 using a sterile excavator. The sample will be mixed with 0.05 ml of distilled water until it dissolves and then dental plaque pH will be measured."
223847903|NCT00385658|DRUG|Fluvastatin extended release, fenofibrate|
223847904|NCT00385658|DRUG|Fixed combination simvastatin/ezetimibe|
223847905|NCT03452306|DRUG|Metformine|"First aIntervention Period:~Single administered dose of Metformin (750 mg tablet extended-release) in a fasting condition"
223847906|NCT03452306|DRUG|Glucophage® Long|"Second Intervention Period:~Single administered dose of Glucophage® (750 mg tablet extended-release) in a fasting condition"
223847907|NCT03452306|DRUG|Metformin|"Third Intervention Period:~Single administered dose of Metformin (750 mg tablet extended-release) in a fed condition"
223847908|NCT03452306|DRUG|Glucophage® Long|"Fourth Intervention Period:~Single administered dose of Metformin (750 mg tablet extended-release) in a fed condition"
223847909|NCT00064571|PROCEDURE|vocal fold medialization|
223847910|NCT00064571|PROCEDURE|vocal fold reinnervation|
223847911|NCT02634216|DIETARY_SUPPLEMENT|Capros|250 mg BID
223847912|NCT04766437|DRUG|Prasugrel 10mg|Once daily 10 mg prasugrel for 12 months preceded by a loading dose of 60 mg prasugrel at least 2 hours prior to percutaneous coronary intervention without concurrent aspirin therapy.
223847913|NCT04766437|DRUG|Ticagrelor 90mg|Twice daily 90 mg ticagrelor for 12 months preceded by a loading dose of 180 mg ticagrelor at least 2 hours prior to percutaneous coronary intervention without concurrent aspirin therapy.
223847914|NCT05200650|COMBINATION_PRODUCT|TumoCure|TumoCure is a polymer-based gel, loaded with Cisplatin in a dose of 100mg (10% w/w), injected to head and neck tumors locally in a single injection.
223847915|NCT03392337|DEVICE|Narrowband UVB phototherapy|Ultraviolet B phototherapy
223847916|NCT00956449|BIOLOGICAL|Seasonal Influenza Vaccine|1 dose of Influenza Vaccine Surface Antigen, Inactivated
223847917|NCT02952950|OTHER|Oralstimulation|The intervention group granted in total 1 hour instructions in a program of oral stimulation by one of two occupational therapists with experience in oral stimulation of preterm infants. The first guidance for parents has duration of approximately half an hour and then follow-up once or twice, depending on the needs of the family. To maintain consistent intervention over time is the program of oral stimulation written in a script, where the family also must record the following variables: date and time of oral stimulation. In occupational therapy the guidance and in the script examines the signs that the infant exhibits when it is ready / not ready for stimulation. The family also sees a movie where these signs and the program of oral stimulation review auditory and visual.
224265170|NCT05264896|DRUG|5-FU, Leucovorin, Oxaliplatin, Docetaxel|FLOT 4 cycles pre and post radical gastrectomy
224265171|NCT05264896|DRUG|XELOX|XELOX 8 cycles post radical gastrectomy
224265172|NCT00740896|BEHAVIORAL|Smoking|Active Comparator: Participants smoke 8 cigarettes in 4 hours.
224265173|NCT00740896|BEHAVIORAL|Smoking|Sham Comparator: Participants are not allowed to smoke for 4 hours.
224265174|NCT01296841|DEVICE|Collaborative Imaging|Hardware and software communication tools to provide clinical care from a distance.
224265175|NCT03168659|DEVICE|HeartLight|HeartLight Endoscopic Ablation System
224265176|NCT03168659|PROCEDURE|Ablation|Pulmonary vein isolation ablation
224265177|NCT06561308|DRUG|Pucotenlimab|Pucotenlimab is administered at 200mg, q3w，intravenous infusion
224265178|NCT06561308|DRUG|Carboplatin|AUC=4-6，q3w，intravenous infusion
224265179|NCT06561308|DRUG|Paclitaxel|175 mg/m2，q3w，intravenous infusion, administered over 30min.
223847918|NCT04392349|DEVICE|Haag-Streit EYESTAR 900|The EYESTAR 900 is a new device developed by HAAG-STREIT AG which utilises Optical Coherence Tomography (OCT) for quantitative measurements of the geometry of the eye. As a successor to the LENSTAR 900, it represents the most recent in a series of successful biometry devices.
223847919|NCT04392349|DEVICE|Tomey CASIA 2|The CASIA2 is a testing application for Cataract / Glaucoma / Cornea Surgery already established on the market. It is a representative device for measurement of anterior and posterior corneal curvature (anterior and posterior corneal topography) by optical coherence tomography, and for measurement of crystalline lens tilt by optical coherence tomography.
223847920|NCT04392349|DEVICE|Oculus PENTACAM HR|The Pentacam HR is a high-resolution rotating Scheimpflug camera system for anterior segment analysis already established on the market. It is used as representative device for advanced anterior segment analysis such as anterior and posterior corneal topography and corneal pachymetry.
223847921|NCT04392349|DEVICE|Zeiss ATLAS 9000|ATLAS is a corneal topography system used as representative device for measurement of anterior corneal curvature (anterior corneal topography).
223847922|NCT00994149|DRUG|Diazoxide|10mg/kg/d divide every 8 hours
223847923|NCT00994149|DRUG|Ora-plus|placebo, give every 8 hours.
223847924|NCT05468333|OTHER|Cigarette trial|Per NIH Program Official, this is not an ACT and thus full protocol info is not required at this time (and would be detrimental to the study if details were disclosed during recruitment).
223847925|NCT00005106|DRUG|Lamivudine/Zidovudine|
223847926|NCT00005106|DRUG|Abacavir sulfate|
223847927|NCT00005106|DRUG|Nelfinavir mesylate|
223847928|NCT00005106|DRUG|Lamivudine|
223847929|NCT00005106|DRUG|Stavudine|
223847930|NCT01738867|DRUG|GSK1521498|White HPMC capsule containing 10 mg of GSK1521498
223847931|NCT01738867|DRUG|Naltrexone (NTX)|Swedish orange gelatin capsule containing 25mg of NTX or 50mg of NTX
223847932|NCT01738867|DRUG|Placebo|Matching placebo capsules to GSK1521498 or NTX
223847933|NCT04793139|DRUG|Camrelizumab|Camrelizumab-treated advanced NSCLC Patients with advanced non-small cell lung cancer treated with camrelizumab. Dosage form, dosage, frequency and duration of camrelizumab is determined according to the investigator's actual clinical practice.
223847934|NCT03058783|DRUG|IDP-124 Lotion|IDP-124 Lotion, twice-daily application
223847935|NCT03058783|DRUG|IDP-124 Vehicle Lotion|IDP-124 Vehicle Lotion, twice-daily application
223847936|NCT03537651|DRUG|TEZ/IVA|Fixed-dose combination tablet for oral administration.
223847937|NCT03537651|DRUG|IVA|Tablet for oral administration.
223847938|NCT05553041|DRUG|18F-Fluciclovine PET-MRI|18F-Fluciclovine will be injected via IV prior to Positron emission tomography (PET)-Magnetic resonance imaging (MRI)
223847939|NCT04688411|BEHAVIORAL|MED-Go App|A novel multifunctional mobile app (MED-Go) to improve adherence to hydroxyurea in patients with sickle cell disease
223847940|NCT03610958|DEVICE|Epitomee Device|A non-surgical, non-pharmacologic, medical Device designed to enhance the feeling of satiety.
223847941|NCT04348331|DIAGNOSTIC_TEST|Dual echo MRI sequence|new MRI sequences for imaging of joints
223847942|NCT06029751|OTHER|No intervention|No intervention
223847943|NCT00029926|DRUG|2-deoxy-2 [F-18] fluoro-2-d-glucose|
223847944|NCT02403323|DRUG|Etrolizumab|105 mg etrolizumab subcutaneous administration once every 4 weeks
223847945|NCT05649878|DRUG|Evaluation of bioavailability of methylprednisolone succinate administered intravenously|Bioavailability of methylprednisolone in healthy subjects of both genders, when administered intravenously. The nominal doses were similar, volunteers were randomly assigned to receive a single dose of MEP by IV bolus of 1.5 mL. Venous blood samples were obtained via an indwelling catheter before administration and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 8, 12 and 24 h for DXM. Plasma was separated and frozen at -70 °C for further analysis.
223847946|NCT05649878|DRUG|Evaluation of bioavailability of methylprednisolone succinate administered intranasally|Bioavailability of methylprednisolone in healthy subjects of both genders, when administered intranasally. Volunteers were randomly assigned to receive a single dose of MEP intranasally by using a Mucosal Atomization Device (MAD Nasal). allowing direct pharmacokinetic comparison without dose normalization. Venous blood samples were obtained via an indwelling catheter before administration and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 8, 12 and 24 h for DXM. Plasma was separated and frozen at -70 °C for further analysis.
223847947|NCT00340613|DRUG|glargine insulin|
223847948|NCT02642419|DRUG|Rivaroxaban and single antiplatelet drug (aspirin, clopidogrel or prasugrel)|"* Rivaroxaban will be orally administered after a meal at a dose of 15 mg if the creatinine clearance (CLcr) is 50 mL/min or more and at a dose of 10 mg if the CLcr is 15-49 mL/min (regardless of time)~* Antiplatelet will be selected from aspirin or thienopyridine derivatives (clopidogrel or prasugrel)~  * Aspirin will be orally administered once a day at a dose of 81 mg or 100 mg~ * Clopidogrel will be orally administered once a day after a meal at a dose of 75 mg. The dose will be reduced to 50mg once a day depending on age, body weight or clinical findings.~ * Prasugrel will be orally administered once a day at a dose of 3.75 mg. If the body weight is 50kg or less a reduced dose(2.5 mg once a day) will be considered depending on the age, renal function or other bleeding and thrombotic risk."
223847949|NCT02642419|DRUG|Rivaroxaban|Rivaroxaban will be orally administered at a dose of 15 mg if the creatinine clearance (CLcr) is 50 mL/min or more and at a dose of 10 mg if the CLcr is 15-49 mL/min.
223847950|NCT05582057|BEHAVIORAL|Strengths to Grow: Preteen|An online, strength based parenting program for parents of preteens (aged 9-14).
223847951|NCT05121506|COMBINATION_PRODUCT|CBD and THC with GT4 technology|A single topical dose of CBD and THC will be administered with GT4 technology. The material will be provided in a single use pre-filled syringe.
224265180|NCT06561308|PROCEDURE|Surgery|Transabdominal hysterectomy + bilateral adnexectomy + pelvic lymph node dissection + pelvic-abdominal tumor resection +/- para-abdominal aortic lymph node dissection
224265181|NCT06089395|DRUG|Jiajian Guishen granules|This study was a stratified district group randomized, double-blind, double simulation, positive control clinical trial with JJGS granules + coenzyme Q10 simulant in the test group and JJGS granules simulant + coenzyme Q10 in the control group
223847952|NCT00223314|BEHAVIORAL|HIV, STD, Pregnancy Prevention Curriculum|The curriculum is designed to change students' knowledge, perceptions of norms, beliefs, self-efficacy, interpersonal skills (i.e., refusal skills), and high-risk behaviors related to HIV. The curriculum included use of facilitators for selected lessons such as role playing. Intervention strategies included demonstrations of skills by role playing, use of role model stories, and other experiential learning techniques. The curriculum was delivered during the school days by facilitators (project staff) who received intensive training prior to implementation and coaching and support during implementation.
223847953|NCT05764824|DIETARY_SUPPLEMENT|Blueberry powder|20 g per day of blueberry powder
223847954|NCT05764824|OTHER|Controlled and matched powder|20 g per day
223847955|NCT03582956|PROCEDURE|Euglycemic hyperinsulinemic clamp with tracer enhancement|To characterize the impact of adiposity on metabolism during puberty, adolescents will undergo the euglycemic hyperinsulinemic clamp study with tracer enhancement.
223847956|NCT03582956|PROCEDURE|Euglycemic hyperinsulinemic clamp with tracer enhancement|A comparison control group of 36 lean young adults with T1D will also be enrolled, since they will be unaffected by the adverse metabolic effects of puberty or obesity.
223847957|NCT00018525|PROCEDURE|Lung Volume Reduction Surgery|
223847961|NCT00197236|BIOLOGICAL|Havrix™|2 intramuscular injections, 6 months apart
223847962|NCT00197236|BIOLOGICAL|Infanrix™|1 intramuscular injection
223847963|NCT00197236|BIOLOGICAL|ActHIB™|1 intramuscular injection
223847964|NCT04034901|DEVICE|Monitoring of cardiorespiratory parameters with BORA Band|"The subjects will continuously wear a connected wrist-worn pulse oximeter which will remotely collect the following measurements :~* Activity~* Step count~* Heart rate~* Respiratory rate~* Skin temperature~* SpO2"
223847965|NCT03885596|DRUG|CA-008|Drug: CA-008 4.2 mg reconstituted in saline
223847966|NCT03885596|DRUG|Ketorolac|30 mg IV at the onset of anesthesia
223847967|NCT03885596|DRUG|Acetaminophen IV|1 g at the onset of anesthesia
223847968|NCT03885596|DRUG|Fentanyl|100 mcg IV fentanyl administered at the onset of anesthesia and additional 50 mcg near the end of surgery
223847969|NCT03885596|DRUG|Bupivacaine Hydrochloride|0.25% 30 mL (75 mg) prior to surgery
223847970|NCT03885596|DRUG|Lidocaine HCl|1.5% 12 mL at the end of surgery
223847971|NCT03885596|DRUG|Celecoxib|200 mg PO bid each day postoperative
223847972|NCT03885596|DRUG|Acetaminophen Oral|1 g postoperative
223847973|NCT03885596|DRUG|Lidocaine Hydrochloride|2% 15 mL at the end of surgery
223847974|NCT03885596|DRUG|Exparel|Bupivacaine liposome injection suspension
223847975|NCT03852433|DRUG|Bulevirtide|Administered via subcutaneous injections
223847976|NCT03852433|DRUG|Peginterferon Alfa-2a (PEG-IFN alfa)|Administered via subcutaneous injections
223847977|NCT06234280|DEVICE|Implantation of Eluvia stent|Implantation of Eluvia stent
223847978|NCT01076335|DRUG|Neoadjuvant Hormonal Therapy|Monthly or quarterly LHRH Agonist Depot injection (leuprolide or goserelin acetate) for one year.
223847979|NCT01076335|DRUG|Docetaxel|35 mg/m2 by vein (IV) on Day 1, 8, 15 and 22 every 6 weeks.
224265182|NCT06089395|DRUG|coenzyme Q10|This study was a stratified district group randomized, double-blind, double simulation, positive control clinical trial with JJGS granules + coenzyme Q10 simulant in the test group and JJGS granules simulant + coenzyme Q10 in the control group
224265183|NCT01412827|RADIATION|1/2 dose of 99mTc OR 201Tl tracers|"Rest: Imaging will occur 30 to 60 minutes after injection of tracer.~Stress: All patients will undergo a symptom-limited Bruce protocol treadmill exercise test. At peak stress, the radiotracer will be injected intravenously, and exercise will continue for an additional 60 s. The patients who are unable to achieve the targeted heart rate or exercise will be stressed pharmacologically. Dipyridamole (0.142 mg/kg/min) will be infused intravenously for 5 minutes, and 99mTc radiotracer will be injected at 2 min after infusion completion (7 min into the study). Aminophylline (100-200 mg) will be given intravenously 2 min after injection of the radiotracer."
224265184|NCT05032807|DRUG|Standard formulation|Cannabidiol 1000mg standard formulation, single dose, oral
224265185|NCT05032807|DRUG|Novel formulation|Cannabidiol 1000mg with lipid matrix, single dose, oral
223847980|NCT03092557|OTHER|Determination of local pleural strain|For each tidal volume, the local pleural strain will be determined over three consecutive respiratory cycles at four predetermined sites using lung ultrasonography.
223847981|NCT00731380|DRUG|ABI-007|Dose escalation beginning with ABI-007 75 mg/m2 day 1 + day 8, Cisplatin 100 mg/m2 day 1, 5-Fluorouracil (5-FU) 1000 mg/m2/d continuous infusion x 96 hours on day 1-4, for 3 weeks x 3 cycles. Followed by Concurrent weekly Carboplatin (AUC 1.5) with radiotherapy for 7 weeks. Carboplatin should be given on Monday or Tuesday of each week, if possible.
223847982|NCT02733250|BIOLOGICAL|Pembrolizumab|200mg IV Day 1 of each 21 cycles
223847983|NCT02733250|DRUG|Nab-Paclitaxel|100mg/m2 IV Day 1, 8 and 15 of every 21 day cycles
223847984|NCT01114919|BEHAVIORAL|Check Your Drinking (CYD)|"Internet based program of lower intensity as compared to the Alcohol Help Centre. It was designed to assesses drinking patterns, increase self-awareness of individual triggers, and set and achieve goals regarding abstinence."
223847985|NCT01114919|BEHAVIORAL|Alcohol Help Centre (AHC)|"Internet based program of higher intensity as compared to the Check Your Drinking intervention. It was designed to assesses drinking patterns, increase self-awareness of individual triggers, and set and achieve goals regarding abstinence."
223847986|NCT06067490|DRUG|RC1416(SAD)|RC1416(SAD),there are six doses(25mg-600mg) in this part. Each subjects will receive the drug once by subcutaneous injection.
223847987|NCT06067490|DRUG|Placebo(SAD)|Placebo(SAD), Each subjects will receive the placebo once by subcutaneous injection.
223847988|NCT06323668|PROCEDURE|Cardiac implantable electronic device extraction|The CIED removal will be done as soon as possible within 7 days.
223847989|NCT05832723|DEVICE|650 nm low-level red-light|Typically, children who uses the 650 nm low-level red-light will be recruited into this study. The use of any other myopia intervention is not restricted except for low concentrations of atropine. Because atropine will cause pupils dilated, the amount of light entering the eye can not be controlled, and red-light is a laser, to be safe, we need to take certain consideration of the amount of light-entering. Participants receive the 650 nm low-level red-light intervention not because they are enrolled in a study, they would receive the intervention in the same manner and intensity if they were not enrolled in the study.
223847990|NCT03461042|DRUG|Ramelteon 8mg|Ramelteon 8mg once daily before bedtime for 12 weeks since informed consent
223847991|NCT03461042|DRUG|Placebo|Placebo capsule once daily before bedtime for 12 weeks since informed consent
223847992|NCT00715806|DEVICE|Open MRI scanner.|Imaging in an Open MRI scanner.
223847993|NCT00715806|DEVICE|Closed MRI scanner.|Imaging in a short-bore closed MRI scanner.
223847994|NCT05037994|PROCEDURE|Ultrasound Guided Continuous Suprascapular Nerve Block With methyl prednisolone and marcaine|"The high frequency linear ultrasound transducer (Sonosite 6-13 MHz) in a transverse orientation will be placed over the scapular Spine.~Moving the transducer cephalad the suprascapular fossa will be identified. 18 gauge touhy needle will be inserted in plane after subcutaneous local anesthesia infiltration with 1 ml lidocaine 2% Real-time imaging will be used to direct injection of 2 ml lidocaine 2% to test perineural spread of injectate after confirmation of the position of tip of needle injection of 40mg methyl prednisolone diluted in 5 ml bupivacaine 0.5% will be done through the needle to anesthetize the nerve and create space for catheter insertion. After catheter insertion another 2 ml lidocaine 2% will be injected through the catheter to confirm position perineural in the scapular notch. Lastly Catheter will be fixed via skin tunnel and secured with skin sutures and adhesive tap."
223847995|NCT03749291|OTHER|Obemat2.0 therapy|"Lifestyle (diet \& physical activity) structured recommendations through a motivational interview.~Duration: 12(+3) months Description: 1 visit/month \& 3 Workshops in primary care centers Providers: pediatricians and nurses trained to perform motivational interview The interviews are structured as follows: First, checking the accomplishment of objectives to motivate the participant. Second, a specific topic per visit is explained to the participant. Third, a task related to the topic (i.e. to plan a weekly menu for the family) is given to be brought back at the next visit. 4th. Objectives about diet, weight \& physical activity are defined to be accomplished until the next visit."
223847996|NCT03749291|OTHER|Usual Clinical Practice|Lifestyle (diet and physical activity) Duration: 12 (+3) months Description: 1visit/month to the primary care centers. Providers: pediatricians \& nurses. Children assigned to the control group receive the usual treatment conducted in primary care centers based on the Clinical Practice Guidelines on the Prevention and Treatment of Child and Adolescent Obesity \[Spanish Ministry of Science and Innovation\], 2009). At visits, the family receive recommendations to carry out a balanced diet, to provide a moderate energy reduction from the previous intake. An increase in physical activity, both in terms of leisure activity, as sports is advised.
223847997|NCT05015478|DEVICE|Tailored Rhythmic Lighting Intervention|40 hertz (Hz) rhythmic lighting (RL) for a duration of 1 hour. The flicker frequency of the 40 Hz RL will be 40 Hz and the stimulation will be a square wave with a 50 % duty cycle (i.e., 12.5 milliseconds light- on and 12.5 milliseconds light-off). The RL will provide a 30 lux of red light on a vertical plane at the eye level.
223847998|NCT05015478|DEVICE|Placebo Rhythmic Lighting Intervention|Placebo rhythmic light (RL) for a duration of 1 hour. In the placebo RL condition, the duty cycle will be delivered at randomly varying frequencies of 20 Hz and 50 Hz, specifically avoiding the frequency of 40 Hz. The placebo RL conditions will provide a 30 lux of red light on a vertical plane at the eye level.
223847999|NCT03966716|DEVICE|Arthroplasty|Patients with an undisplaced femoral neck fracture receive a hemi or total hip arthroplasty depending on each hospital's routine for patient age and mobility.
223848000|NCT03966716|DEVICE|Internal Fixation|Patients with an undisplaced femoral neck fracture undergo a closed reduction and internal fixation with 2-3 screws or pins, or sliding hip screw device. Type of fixation depends on each hospital's routine.
223848001|NCT02341989|DRUG|Bleomycin Etoposide and Cisplatin|
223848002|NCT02341989|DRUG|Carboplatin|
223848003|NCT05278988|DRUG|PRS Regimen V|PRS Regimen V(bedaquiline, delamanid, clofazimine, pyrazinamide)
223848004|NCT05278988|DRUG|MDR-TB Treatment Regimen(WHO)|Treatment according to WHO MDR-TB treatment guidelines (2019)
224265186|NCT03810963|COMBINATION_PRODUCT|HIIT-FES Cycling combined with Nutritional Counseling|High intensity interval training functional electrical stimulation cycling for 30 minutes, three days per week for eight weeks, Nutritional counseling over the telephone for 30 minutes once per week for eight weeks.
223848005|NCT03276793|OTHER|MRI scan|Patients will undergo an MRI scan
223848006|NCT03276793|BEHAVIORAL|Behavioral testing|Patients will complete a series of cognitive tasks
223848007|NCT06466473|DRUG|Phenytoin (Ascoli)|Phenytoin 50mg chewable tablets
223848008|NCT06466473|DRUG|Phenytoin (Vega Baja)|Phenytoin 50mg chewable tablets
223848009|NCT05980793|PROCEDURE|PIP joint denervation|Surgical denervation of the PIP joint
223848010|NCT05980793|PROCEDURE|Patient education plus exercise|An education plus exercise program
223848011|NCT04081545|DRUG|Opioid Anesthetics|see arm/group description
223848012|NCT04081545|DRUG|Non Opioid Analgesics|see arm/group description
223848013|NCT03528629|DRUG|Zolbetuximab|Zolbetuximab will be administered as a 2-hour intravenous infusion.
223848014|NCT04087096|DRUG|Denosumab|Denosumab will be administered at postoperative months 1, 7, and 13
223848015|NCT04087096|DRUG|Placebo|Placebo will be administered at postoperative months 1, 7, and 13
223848016|NCT04087096|DRUG|Zoledronic Acid|Zoledronic Acid 5mg will be administered intravenously at postoperative month 19
223848017|NCT04436029|BIOLOGICAL|Descartes 11|Car T-cells
223848018|NCT02749331|DRUG|AdVince|Virus solution for infusion in intrahepatic artery
223848019|NCT00654238|DRUG|sorafenib|400mg PO BID daily
223848020|NCT00906490|DEVICE|Intravenous Blood Glucose monitoring system|Insertion of blood glucose monitoring sensor into peripheral vascular IV line.
223848021|NCT06168604|BEHAVIORAL|Pain Identification and Communication Toolkit|The Pain Identification and Communication Toolkit (PICT) is a multicomponent (6 module) intervention for family caregivers of persons with Alzheimer's disease and related dementias (ADRD). PICT consists of 4 weekly telephone sessions (30-60 minutes each) delivered by a trained interventionist
223848022|NCT06168604|BEHAVIORAL|Health Promotion Program|The attention control (AC) condition is referred to as the Health Promotion Program (HPP). The HPP will consist of 4 weekly telephone sessions (30-60 minutes each) but focus on caregiver health promotion topics, such as nutrition, exercise, and sleep.
223848023|NCT03664323|BIOLOGICAL|Evaluate the improvement in response from the end of anti-PD-1 monotherapy|Evaluate the improvement in response from the end of anti-PD-1 monotherapy to the first evaluation after introduction of CT alone (Group 1) or combined with anti-PD-1 (Group 2).
223848024|NCT03318913|OTHER|Placebo|5g of the sucralose administered as white plastic capsules
223848025|NCT03318913|OTHER|Fish protein hydrolysates|5g of the FPH dissolving in 100 mL of water
223848026|NCT05871242|DIETARY_SUPPLEMENT|Probiotic Lactobacillus crispatus M247|Patient who have received probiotic Lactobacillus crispatus M247
223848027|NCT01538446|DRUG|Modification of Prasugrel based on a biological assay|Monitoring with VerifyNow P2Y12, 2 weeks after initiation of 5 mg of maintenance dose of prasugrel, reduction of antiplatelet therapy if there is high on-treatment platelet inhibition (HPI) or increase in dosing if there is high on-treatment platelet reactivity (HPR) Device: VerifyNow point of care assay VerifyNow (ACCUMETRICS San Diego USA)
223848028|NCT01538446|DRUG|prasugrel / clopidogrel|fixed dose of prasugrel 5 mg
223848029|NCT01538446|DEVICE|Verify Now|Monitoring with VerifyNow P2Y12, 2 weeks after initiation of 5 mg of maintenance dose of prasugrel, reduction of antiplatelet therapy if there is high on-treatment platelet inhibition (HPI) or increase in dosing if there is high on-treatment platelet reactivity (HPR) Device: VerifyNow point of care assay VerifyNow (ACCUMETRICS San Diego USA)
223848030|NCT03031704|PROCEDURE|Endoscopic mucosectomy|Performing adenoma resection through standardized endoscopic mucosectomy of duodenal adenoma.
223848031|NCT02998489|OTHER|Fast milk advancement|30-40 cc/kg/d of human milk or formula milk until total enteral feeding has been achieved
223848032|NCT02998489|OTHER|Traditional milk advancement|20 cc/kg/d of human milk or formula milk until total enteral feeding has been achieved
223848033|NCT00142220|DRUG|Defined percentage of omega-3-fatty acids|
223848034|NCT03394248|DEVICE|Vector Mouthguard|The mouthguard will be used by athletes to measure the magnitude and number of impacts throughout one season.
223848035|NCT01248221|DRUG|[13C]-Spirulina platensis and 99mTc sulfur colloid|The subject will consume the test meal containing 13C-Spirulina and 99mTc sulfur colloid in no more than 10 minutes. Scintigraphic image acquisition will be obtained upon completion of the meal and at 15, 30, 45, 60, 90, 120, 150, 180, and 240 minute time points. Breath samples will be collected at baseline before the test meal is started and thereafter on the same time schedule as the scintigraphic procedure.
223848036|NCT02429609|DEVICE|Moorfields Acuity Chart|
223848037|NCT05922436|DRUG|QLG2071|intravenous injection
223848038|NCT05922436|DRUG|Cleviprex®|intravenous injection
223848039|NCT02521064|DIETARY_SUPPLEMENT|Exclusive Enteral Nutrition (EEN)|Patients will be treated with 8 weeks of Exclusive Enteral Nutrition (EEN). Patients will continue to receive usual medical care, and concurrent IBD treatments will be permitted.
223848040|NCT02521064|DRUG|Prednisone|Patients will be treated with 8 weeks of prednisone (corticosteroid). Patients will continue to receive usual medical care, and concurrent IBD treatments will be permitted.
223848041|NCT05165238|BEHAVIORAL|Impact of four week coaching program on dietary habits|A registered dietitian will provide dietary coaching via online groups to participants.
223848042|NCT03982420|PROCEDURE|Transcarotid Revascularization (TCAR)|Carotid revascularization treated with the FDA-cleared ENROUTE Transcarotid NPS in conjunction with the FDA-approved ENROUTE Transcarotid Stent
223848043|NCT01268566|DRUG|MEDI-575|MEDI-575 as an IV infusion.
223848044|NCT03537885|DIAGNOSTIC_TEST|Transcranial Direct Current Stimulation|Electrodes are placed on that head to deliver a non-invasive brain stimulation to the target area.
223848045|NCT03537885|DIAGNOSTIC_TEST|Transcranial Magnetic Stimulation|A coil is held tangential to the head in order to deliver a non-invasive brain stimulation to the target area.
223848046|NCT03537885|DIAGNOSTIC_TEST|Electroencephalography (EEG)|A cap is placed on the head with sensors to detect brain activity during the intervention.
223848047|NCT00928200|DRUG|Erwinase|"The dose of Erwinase will be assigned at study entry. The first dose of Erwinase wil be given between Days 3-5 and will continue on a M-W-F schedule for a total of 10 doses.~Erwinase will be administered as a 2-hour intravenous infusion."
223848048|NCT00928200|DRUG|Vincristine|1.5 mg/m2/dose IV push (maximum single dose 2 mg) on Days 1, 8, 15 and 22
223848049|NCT00928200|DRUG|Dexamethasone|10 mg/m2/day divided BID. Give by mouth days 1-14.
223848050|NCT00928200|DRUG|Doxorubicin|60 mg/m2/day IV over 15 minutes on day 1
223848051|NCT00928200|DRUG|Cytarabine|Given Intrathecally at the dose defined by age on day 1. 30 mg for age 1-1.99 50 mg for age 2-2.99 70 mg for age 3 and older
223848052|NCT00928200|DRUG|Methotrexate|Given Intrathecally to all patients who are CNS 1 or 2 at study entry. Dose defined by age. Given on day 15 8mg for age 1-1.99 10 mg for age 2-2.99 12 mg for age 3-8.99 15 mg for age 9 and older
223848053|NCT00928200|DRUG|Triple Intrathecal Therapy|Methotrexate, Cytarabine and Hydrocortisone given Intrathecally on day 8, 15 and 22 for patients who are CNS 3 at study entry. Doses determined by age.
223848054|NCT00928200|DRUG|Dexrazoxane|Due to the limited availability of Dexrazoxane (Zinecard®), treatment will be at the discretion of the treating physician. Dose should be 600 mg/m2 as a IV push immediately prior to anthracycline dose (the elapsed time from the beginning of the dexrazoxane dose to the end of the anthracycline infusion should be 30 minutes or less).
223848055|NCT01273558|DRUG|Canagliflozin|One 100 mg capsule taken orally (by mouth) on Days Days 1-8
223848056|NCT06217029|OTHER|physiotherapy and maxillary traction|"1. Mobility exercises~2. Ultrasound or electric stimulation~3. Application of equipment, such as braces, slings and taping~4. Registered massage therapy~5. Trigger point and myofascial release"
223848057|NCT06174480|OTHER|Cryostimulation|Cryostimulation (-50°C, forced ventilation for 3 minutes) during 20 sessions over 2 weeks.
223848058|NCT02138916|DRUG|Benralizumab Arm A|Benralizumab subcutaneously on study week 0 until study week 48 inclusive
223848059|NCT02138916|DRUG|Benralizumab Arm B|Benralizumab subcutaneously on study week 0 until study week 48 inclusive
223848060|NCT02138916|DRUG|Placebo|Placebo subcutaneously on study week 0 until study week 48 inclusive
224265187|NCT03810963|OTHER|Nutritional Counseling Only|Nutritional counseling over the telephone for 30 minutes once per week for eight weeks.
224265188|NCT05841654|DRUG|Azilsartan or antihypertensive drugs other than ACEI, ARB or ARNI|The patient's ECG information will be monitored through the ECG monitoring patch, and the time of the first atrial fibrillation event will be recorded. Monitoring whether the patient's blood pressure is controlled dynamically, using echocardiography to evaluate cardiac function, and using scales to assess the quality of life.
224265189|NCT04658225|PROCEDURE|0.12% chlorhexidine|the patients were randomly allocated into two groups of 15 individuals to rinse with antimicrobials twice a day for a period of four weeks. Group A, received 0.12% chlorhexidine antimicrobian in a vial previously identified as solution 1 and group B, received saline solution identified as solution 2.
223848061|NCT01348087|DRUG|AFQ056|The investigational drug, AFQ056, will be provided as hard gelatin capsules. Two different oral dosage strengths, identical in appearance, will be used.
223848062|NCT05717335|DRUG|TachoSil|Placement of TachoSil over the ventricular entry point in patients with periventricular lesions in order to avoid complications related to the ventricular entry.
223848063|NCT00555581|DRUG|Imatinib Mesylate|In initial phase, patients will be treated with Gleevec 400 mg daily for 12 months. In the extension phase, patients will be treated with Gleevec 400 mg daily for 27 months.
223848064|NCT05964257|DRUG|Botulinum toxin type A|Botulinum toxin type A(HU-014) will be administered intramuscularly to the bilateral masseter muscles on Visit 2.
223848065|NCT05964257|DRUG|normal Saline|Normal Saline will be administered intramuscularly to the bilateral masseter muscles on Visit 2.
223848066|NCT05805124|DIAGNOSTIC_TEST|Preop evaluation|"All preop evaluations prescribed in the preadmission clinic will be recorded, especially:~* renal function tests~* hematologic tests~* coagulation tests~* hepatic function tests~* ECG~* cardiac function tests~* pulmonary function tests~* endocrine function tests"
223848067|NCT03034733|DRUG|Dexamethasone|intravenous dexamethasone, two groups: 0,15 mg/kg, 0,25 mg/kg
223848068|NCT03034733|DRUG|Sodium Chloride, (24)NaCl 0,9%|intravenous placebo
223848069|NCT06440850|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223848070|NCT06440850|DRUG|Cobimetinib|Given PO
223848071|NCT06440850|PROCEDURE|Computed Tomography|Undergo CT scan
223848072|NCT06440850|PROCEDURE|Diagnostic Imaging|Undergo I-123 diagnostic scan
223848073|NCT06440850|PROCEDURE|I-131 Uptake Test|Undergo I-131 whole body scan
223848074|NCT06440850|RADIATION|Iodine I-131|Given PO
223848075|NCT06440850|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223848076|NCT06440850|PROCEDURE|Positron Emission Tomography|Undergo PET scan
223848077|NCT06440850|BIOLOGICAL|Recombinant Thyrotropin Alfa|Given IM
223848078|NCT06440850|PROCEDURE|Ultrasound Imaging|Undergo neck ultrasound
223848079|NCT06440850|DRUG|Vemurafenib|Given PO
223848080|NCT02387749|GENETIC|mesenchymal stem cells|collection of stem cells by bone marrow biopsy from iliac crest, then culture for 1 month , then IV transfusion on 2 sessions to the same patient
223848081|NCT00117988|DRUG|tanespimycin|
223848082|NCT02196051|OTHER|one bout of 45 minutes exercise|45 minutes of exercise on an elliptical exercise machine
223848083|NCT05592431|DEVICE|High Frequency Oscillatory Ventilation with Volume Guarantee (SLE6000;SLE)|ventilator settings will be recorded such as: inspiratory: expiratory ratio (I:E), fractionated inspired oxygen (FiO2), mean airway pressure (MAP), frequency (HZ), delta P and high-frequency tidal volume (VThf).
223848084|NCT05592431|DEVICE|High Frequency Oscillatory Ventilation (SLE6000;SLE)|ventilator settings will be recorded such as: inspiratory: expiratory ratio (I:E), fractionated inspired oxygen (FiO2), mean airway pressure (MAP), frequency (HZ), delta P
223848085|NCT03057561|DRUG|Cardiac MRI taken using contrast agent, Dotarem® (Gd-DOTA)|Gadolinium based contrast agent used in cardiac MRI scanning using 3.0 Tesla MRI
223848086|NCT03057561|DRUG|Cardiac MRI with contrast agent, Gadovist|Brand of Gd-DO3A-butrol; contrast agent used in cardiac MRI scanning using 3.0 Tesla MRI
223848087|NCT03929731|DIAGNOSTIC_TEST|Indocyanine Green Angiography|Intravenous injection of dye-indocyanine green
223848088|NCT05096884|DRUG|Metoprolol Succinate|The beta blocker metoprolol succinate will be initiated at a starting low dose of 25 mg daily for two weeks and will be escalated if well tolerated every 2 weeks to a maximum dose of 400 mg po daily.
223848089|NCT01420367|DRUG|metronidazole and cephalzolin|IV doses of metronidazole (12.5mg/kg up to 500mg) and cefazolin (25mg/kg up to 1g). One dose for study arm, two for comparative arm.
223848090|NCT04794179|DEVICE|Naida Link CROS|Individuals 18+ who already have Advanced Bionics CII/90K/Ultra cochlear implants will be given Naida Link CROS device to assess the effect the device has on speech understanding in challenging listening situations and on the quality of life in unilateral cochlear implant recipients and their frequent communication partners.
223848091|NCT02787967|DRUG|CHF 1535 35/4µg NEXThaler®|4 (four) inhalations (total dose: BDP/FF 140/16 µg)
223848092|NCT02787967|DRUG|free comb. beclomethasone DPI and formoterol DPI|2 (two) inhalations BDP 100 µg DPI + 4 (four) inhalations FF 6 µg DPI (total dose: BDP 200 µg + FF 24 µg
223848093|NCT05227469|BEHAVIORAL|myofunctional therapy|In order to confirm that the exercises are done for a sufficient time and are done correctly, the researcher will take video recordings from the participants and examine these recordings every other day. Respondents will be contacted when errors are detected.
223848094|NCT06383884|DRUG|Patritumab Deruxtecan|Patritumab deruxtecan will be administered as an IV infusion Q3W on Day 1 of each 21-day cycle as a fixed dose regimen of 5.6 mg/kg Q3W.
223848095|NCT05785897|DEVICE|Successful primary PCI, defined as primary PCI of the culprit lesion with ≥1 Abluminus NP polymer-free sirolimus-based nanocarrier eluting stent (Concept Medical Inc., India) implantation|"'All-comer' subjects with acute STEMI undergoing primary PCI according to current ESC guidelines will be eligible.~Eligible subjects will be pre-treated with DAPT consisting of aspirin (loading dose: 150-300 mg orally or 80-500 mg intravenously, maintenance dose: 75-100 mg daily orally) and a potent P2Y12 receptor inhibitor, either ticagrelor (loading dose: 180 mg orally, maintenance dose: 90 mg bd orally) or prasugrel (loading dose: 60 mg orally, maintenance dose: 10 mg od orally or 5 mg od orally if age \>75 years or weight \<60 kg) at the time of STEMI diagnosis, or at the very latest at the time of primary PCI.~Successful primary PCI, defined as primary PCI of the culprit lesion with ≥1 Abluminus NP polymer-free sirolimus-based nanocarrier eluting stent (Concept Medical Inc., India) implantation and final residual stenosis \<30% by visual estimation or 20% by QCA."
223848096|NCT04181775|DIAGNOSTIC_TEST|ADE-RED scoring tool|The ADE-RED scoring tool will reduce the incidence of future visits to the ED or future admissions by identifying patients who are at high risk for ADE-related readmissions.
223848097|NCT02636881|PROCEDURE|Autologous Chondrocyte Implantation|Implantation of the patients own cartilage cells in a chondral defect of the knee
223848098|NCT02636881|PROCEDURE|Arthroscopic Debridement|Arthroscopic diagnosis and debridement of the lesion, without cartilage therapy. Removal of lose bodies etc.
223848099|NCT06411665|DRUG|Oliceridine|Patient-controlled intravenous analgesia with oliceridine for up to 3 days after surgery.
223848100|NCT06411665|DRUG|Morphine|Patient-controlled intravenous analgesia with morphine for up to 3 days after surgery.
223848101|NCT06585020|DRUG|Arikayce|Treatment regimens containing three molecules, rifampicin, ethambutol, and clarithromycin with ARIKAYCE® during the 6 first months of treatment. After having confirmed the presence of all inclusion criteria and the absence of all exclusion criteria, and after having obtained the patient's free and informed consent, the patient will be included and randomized to one of the treatment regimens.
223848102|NCT06585020|DRUG|standard treatment|treatment regimens containing three molecules, rifampicin, ethambutol, and clarithromycin during the 6 first months of treatment. After having confirmed the presence of all inclusion criteria and the absence of all exclusion criteria, and after having obtained the patient's free and informed consent, the patient will be included and randomized to one of the treatment regimens.
223848103|NCT05433948|DIAGNOSTIC_TEST|Simultaneous EEG and CRT|"EEG is recorded with 32 electrodes and commercial recording equipment.10 min EEG is recorded in idle mode with eyes closed prior to continuous EEG recording during the CRT examination, see below.~The test is performed via a laptop using EKHO software. The software generates 150 sound stimuli of 90 dB, which the patient hears in sound-insulated headphones. Via a push button in the dominant hand, the patient must respond as quickly as possible as soon as sounds are perceived.~PSE test: Duration 20 min. Includes 5 tasks: Digit-symbol Test, Number Connecting Test A, Number Connecting Test B, Serial Dotting Test and Line Tracing Test. Exits in 4 versions, which are used in repeated tests to avoid the learning effect. Scores range from -18 t0 6 and less -4 is abnormal."
223848104|NCT01573143|DRUG|Rosuvastatin|Rosuvastatin (20 mg od) started not earlier than 8 days before surgery and continued until the 5th post-operative day included;
223848105|NCT01573143|DRUG|Placebo|Placebo started not earlier than 8 days before surgery and continued until the 5th post-operative day included.
224265190|NCT02353936|DRUG|BIBW2992|"International Nonproprietary Name (INN): BIBW 2992 Pharmacological dosage form: Film-coated tablet Supplier: Boehringer Ingelheim Pharma GmbH \& Co. KG Unit content: 40 mg, 30 mg, 20 mg film-coated tablet (BIBW 2992 content in film-coated tablet is related with equivalent free base BIBW 2992.) Daily dose: 40 mg Dosing period: To be successively administered once daily until a disease will develop, an unacceptable adverse event will occur, or another reason requiring discontinuation of the study will occur; For administration, study treatment consists of periods(each 4 weeks(28 days)).~Route of administration: Orally (Take by swallowing) Dosage: Once daily"
224265191|NCT06103097|OTHER|No interventions done (obervational)|Observational study
224265192|NCT04070898|PROCEDURE|Remove urinary catheter after surgery|Remove bladder catheter after surgery
224265193|NCT00366639|OTHER|Acute Decompensated Heart Failure|Treatment \& outcomes during hospital admission for Acute DHF
224265194|NCT03331458|BEHAVIORAL|exrecise intervention|Subjects will undergo pre-intervention measures, complete a daily physical activity diary, and post-intervention measures
224265195|NCT05854563|OTHER|Observational only, all subjects; measure DNA mutation and proteomic survey.|Observational only, all subjects; measure DNA mutation and proteomic survey.
224265196|NCT01457196|DIAGNOSTIC_TEST|Tumor Genetic Sequencing|This study will look at genetic material from a sample of the subjects tumor, look at certain changes in the genetic material, and see if these changes are related to the subjects cancer.
224265197|NCT06057558|BIOLOGICAL|Probiotic throat spray|Throat spray containing Lacticaseibacillus casei AMBR2
224265198|NCT00006516|BEHAVIORAL|Infant stimulation|
224265199|NCT02364986|DRUG|Rebif®|Rebif® 44µg (day 1, 3, 5 and 8) s.c.
224265200|NCT02364986|DRUG|Avonex|Avonex 30µg (day 1 and 8) i.m.
224265201|NCT04937439|OTHER|Traditional Physical Therapy program|"1. Facilitation of head control will be conducted.~2. Facilitation of trunk control will be applied~3. Facilitation of rolling~4. Facilitation of righting, protective and equilibrium reactions from supine, prone and sitting on a ball~5. Stretching exercises for the muscles liable to be tight~6. Facilitation of sitting"
224265202|NCT04937439|OTHER|Segmental trunk training A|Group (A) will wear an external segmental trunk support extended from the level of pelvis to a level just below the rib cage.
224265203|NCT04937439|OTHER|Segmental trunk training B|Group (B) will receive the same program given to (group A) while wearing an external segmental trunk support extended from the level of pelvis to a level just below the inferior angle of scapula.
224265204|NCT04937439|OTHER|Segmental trunk training C|Group (C) will receive the same program given to (group A and B) while wearing an external segmental trunk support extended from the level of last rib to the level of the inferior angle of scapula.
224265205|NCT02517424|DRUG|High THC/Low CBD Cannabis|Dried cannabis
224265206|NCT02517424|DRUG|High THC/High CBD Cannabis|Dried cannabis
224265207|NCT02517424|DRUG|Low THC/Low CBD Cannabis|Dried cannabis
224265208|NCT04677517|DEVICE|Modification of active microphone positioning|"Patient will pass the experimental tests described above with 3 different active microphone positions :~* on the cochlear implant processor;~* on the antenna~* in front of the external ear canal~Patient will pass the tests 1 week after each microphone position change, so that they can get used to the new position in their everyday life."
224265209|NCT04677517|BEHAVIORAL|SPHERE protocol|"Patient's 3D localization in noise will be assessed thnks to a 3D localization system called SPHERE based on virtual reality.~Data from spatial hearing perception will be recorded in three-dimensional space (azimuth, elevation, and depth). First, the pointing error will be computed separately for azimuth, elevation, and depth, in terms of constant error (absolute and signed) and variable error. Then, these separate errors will be combined into a cumulative error 3d-D (the 3d-D value), hence summarizing all three space dimensions, and taking into account absolute and variable error in one measure."
224265210|NCT04677517|BEHAVIORAL|French Matrix Test|This test assesses the intelligibility threshold defined as the noise level (in decibels) for which the subject can repeat 50% of the words heard (in dichotic listening), resulting in an Speech Recognition Threshold (SRT) value
224265211|NCT04677517|BEHAVIORAL|Quality of life questionnaire|The Speech, Spatial and Qualities of Hearing Scale short-form with 15 items (SSQ15) questionnaire is performed in order to evaluate auditory abilities of patients in different daily life situations.
224265212|NCT04677517|BEHAVIORAL|Likert scale|This subjective evaluation will be added to evaluate difficulties and self-confidence felt by participants during the SPHERE protocol and the French Matrix Test.
224265213|NCT02610881|DIETARY_SUPPLEMENT|Iron and Folic Acid (IFA)|1 mg of IFA syrup (containing 20 mg of elemental iron and 100 mcg of folic acid) will be taken twice per week for one month.
223848106|NCT06104865|BEHAVIORAL|Tinnitus Sound Therapy using (Resound Tinnitus relief) mobile application|Patient exposure to relieving sound(wind, rain, ocean waves, etc) of his own choice from the mobile phone application and using this effect with time to accommodate the brain to neglect the negative effects of tinnitus.
223848107|NCT05585112|DRUG|Lidocaine 2%|The child will be injected with lidocaine 2%,after that the treatment will be completed , Pain during injection and treatment will be assessed using the FLACC scale and pain after injection and treatment will be evaluated using the Wong-Baker faces pain rating scale
223848108|NCT05585112|DRUG|Articaine 4%|The child will be injected with 4% Articaine, after that the treatment will be completed , Pain during injection and treatment will be assessed using the FLACC scale and Wong-Baker faces pain rating scale
223848109|NCT02977143|PROCEDURE|Fluid loading of volulyte 300 ml|Administration of volulyte 300 ml and measurement of increase in cardiac index
223848110|NCT03050840|BEHAVIORAL|Way to Health|An online platform (Way to Health) will be used to test if self-monitoring plus gamification principles can increase steps per day and lower sugar sweetened beverage consumption per day, among obese children and adults, compared to self-monitoring alone.
223848111|NCT03563638|DIAGNOSTIC_TEST|75gOGTT|oral glucose tolerance test (OGTT) was conducted on all participants between the 24th and 28th gestation weeks.The diagnosis of GDM is made when any of the following plasma glucose values are met or exceeded: FPG≥5.1 mmol/L and/or 1h-PG ≥10.0 mmol/L and/or 2h-PG ≥8.5 mmol/ L.
223848112|NCT02125513|DRUG|carboplatin and paclitaxel followed by surgery|
223848113|NCT00444574|DRUG|Methylphenidate Transdermal System|The primary objective of this study was to evaluate, under controlled conditions, the safety and efficacy of MTS compared to placebo with reference to CONCERTA
223848114|NCT00444574|DRUG|Placebo|The primary objective of this study was to evaluate, under controlled conditions, the safety and efficacy of MTS compared to placebo with reference to CONCERTA
223848115|NCT00444574|DRUG|Concerta|The primary objective of this study was to evaluate, under controlled conditions, the safety and efficacy of MTS compared to placebo with reference to CONCERTA
223848116|NCT00818025|BEHAVIORAL|Pocket PATH (Personal Assistant for Tracking Health)|Participants in the intervention group will be trained to use a hand-held device with custom programs as a means of supporting, tracking, and interpreting discharge activities in addition to the standard paper-tracking methods.
223848117|NCT03310463|DRUG|ETX2514SUL|Single dose of up to 1000 mg ETX2514 and 1000 mg sulbactam given by concurrent 3-hr IV infusion
223848118|NCT00589862|DRUG|Plavix (Clopidogrel)|150 mg tablet of Plavix (Clopidogrel) per day for 12 months if resistance is identified
223848119|NCT04732039|OTHER|Measurement of peak oxygen uptake|Oxygen uptake measured on bike (pVO2) and during the conduction of specific daily life activities (ADL-VO2).
223848120|NCT04242394|PROCEDURE|ERCP|Routine ERCP procedures with gallbladder in situ patient
223848121|NCT02266420|PROCEDURE|Blood samples of 10 mL|Blood samples of 10 mL will be collected at initial visit; serum samples will then be stored at the end of the study (-80°C) and may be used for the purpose of further scientific research.
223848122|NCT05502380|DRUG|Standard antibiotic prophylaxis|One to three intravenous doses of cefuroxime 1.5 g intravenously; or 3g if obesity; or vancomycin 1 g or clindamycin 600 mg; if allergy. Continuation of eventual current therapeutic antibiotc regimens for any infection
223848123|NCT05214794|DRUG|nemolizumab|nemolizumab will be administered subcutaneous injection
223848124|NCT06404762|PROCEDURE|tSCTG+ CAF|In the tSCTG group, at the distal end of a second maxillary molar, an incision will be made using a double-bladed scalpel (SKU 10-130-05D; Hu-Friedy, Chicago, IL, USA) bucco-palatally, forming a 1,5 mm thick parallel line. Secondary incisions will be made to separate the graft using a 15c blade on the buccal and palatal sides. Later, the graft will be de-epithelialized extra-orally using a blade
223848125|NCT06404762|PROCEDURE|pSCTG+ CAF|In pSCTG group; the graft will be harvested through a single-incision approach at the lateral palatal mucosa
223848126|NCT06136806|DIAGNOSTIC_TEST|Ferumoxytol Enhanced Magnetic Resonance Angiography（ FE-MRA）；Coronary/Renal /Lower artery Arteriography|When the patient is suspected with multisite artery disease, FE-MRA and angiography will be performed according to the patient's clinical manifestation. For example, when the patient is suspected with coronary artery disease, coronary FE-MRA and angiography will be performed; when the patient is suspected with renal artery stenosis, renal artery FE-MRA and angiography will be performed; and when the patient is suspected with the lower extremity artery occlusion, the lower extremity artery FE-MRA and angiography will be performed.
223848127|NCT06136806|DIAGNOSTIC_TEST|Ferumoxytol Enhanced Magnetic Resonance Venography（ FE-MRV）, Computed Tomography Pulmonary Angiography, Ultrasound for Lower Extremity Deep Vein.|When the patient is suspected with venous thromboembolism, the lower extremity vein FE-MRV, pulmonary FE-MRA and ultrasound for lower extremity deep vein as well as computed tomography pulmonary angiography will be taken to ensure whether the patient with thrombus or not.
223848128|NCT01249742|BEHAVIORAL|Internet intervention|Our intervention, Sugarsquare, is a secured treatment environment only accessible by patients of the KDCN and members of the treatment team. Sugarsquare consists of two main sections. The first section is a semi-public setting on which adolescents can exchange experiences with their diabetes (care) through a forum and a real time chat-application. All patients and treatment team members can see all messages posted here. The second section consists of patients' individual pages with treatment overview and an application for private interaction with the treatment team. Patients can only access their own individual page; treatment team members can access pages of all patients. Sugarsquare is a secured webpage, accessible only through computers equipped with the right certificate (access device) and by using the appointed username-password combination.
223848129|NCT02221479|DRUG|plerixafor GZ316455|Pharmaceutical form:vial Route of administration: subcutaneous injection
223848130|NCT02221479|DRUG|Filgrastim|Pharmaceutical form:vial Route of administration: subcutaneous injection
224265214|NCT02610881|DIETARY_SUPPLEMENT|Micronutrient Powders (MNP)|"One sachet of micronutrient powder will be mixed into food to be taken once daily for a total of one month. One sachet of micronutrient powders includes the following:~Iron (Ferrous Fumarate) 12.5 mg Zinc (Zinc Gluconate) 5 mg Folic Acid 0.160 mg Vitamin-A (Vit-A Acetate) 0.30mg Vitamin-C (Ascorbic Acid) 30 mg Vitamin-B12 0.9 mcg Iodine 90 mcg Maltodextrin Base"
224265215|NCT02610881|BEHAVIORAL|Iron Plus Strategy Counseling|Mothers of participants will receive counseling on the benefits of regular iron intake, side effects associated with IFA administration, and the preservation of the IFA bottle and MNP sachets.
223848131|NCT01092624|DRUG|Solifenacin|There will be a two-week pessary run-in prior to randomization. If the subject completes the run-in period with no adverse reactions to the pessary, she will come in to the office for a randomization visit. She will be randomized to receive either 5 mg/day (one 5 mg tablet QD) of placebo or 5 mg/day (QD) of solifenacin for 12 weeks. At the end of week 6, patients will be assessed in the office. A standardized medication response questionnaire will be used to assess each subject's response to either the placebo or the solifenacin 5 mg. If the response is not adequate, the dose will be increased. Women whose symptoms have not improved since baseline will have their medication or placebo doses increased to 10 mg daily.
223848132|NCT01092624|DRUG|Placebo|There will be a two-week pessary run-in prior to randomization. If the subject completes the run-in period with no adverse reactions to the pessary, she will come in to the office for a randomization visit. She will be randomized to receive either 5 mg/day (one 5 mg tablet QD) of placebo or 5 mg/day (QD) of solifenacin for 12 weeks. At the end of week 6, patients will be assessed in the office. A standardized medication response questionnaire will be used to assess each subject's response to either the placebo or the solifenacin 5 mg. If the response is not adequate, the dose will be increased. Women whose symptoms have not improved since baseline will have their medication or placebo doses increased to 10 mg daily.
224265216|NCT06627881|OTHER|Continuous aerobic kayak training program|Sitting in a special chair on the Kayak Pro® Speed Stroke PRO ergometer. 5-minute warm-up and continuous training, for 30 minutes on the ergometer at a moderate to vigorous intensity, 5 days a week.
224265217|NCT06627881|OTHER|Aerobic Endurance Circuit Program|Sitting with feet flat on the floor and shoulder-width apart, in each session with a 5-minute warm-up, light intensity training with upper body strengthening, 5 days a week.
224265218|NCT06627881|OTHER|High intensity interval program with rope|Sitting with feet flat on the floor and shoulder-width apart, in each session with a 5-minute warm-up, vigorous intensity undulating rope training using the interval method, 5 days a week.
224265219|NCT02454595|BEHAVIORAL|Registry|Physician will complete a series of four questionnaires to capture the treatment decisions based upon standard clinical-pathological information and with the addition of the result of genomic testing (Prolaris test).
224265220|NCT05433220|OTHER|Best Practice Advisory using Electronic Health Record|Providers caring for patients randomized to the intervention arm will have a best practice alert appear for each of their eligible patients upon opening of the order entry screen in the patient's medical record. This alert informs the provider to the presence of HFrEF, notes the patient's current LVEF and current evidence-based medications, and gives access to an order set with recommended evidence- based, guideline-recommended, and FDA- approved therapies for patients with HFrEF. Providers will also have access to a link to best available guideline recommended information regarding treatment of heart failure to allow further education if desired by the provider. The alerts will also clearly state the expected monitoring and follow-up required for prescriptions of these medications.
224265221|NCT04596852|DEVICE|Assessment of the reliability of a protocol characterizing intersegmental hyper-resistance to passive stretch|"Passive solicitations of the main joints of the lower limb, of healthy children and children with cerebral palsy, are realized by two evaluators with a handheld dynamometer.~Repeated measures are performed to assess intra and inter-reliability."
224265222|NCT02888964|DRUG|Add-on therapy|Pioglitazone therapy
224265223|NCT03306238|PROCEDURE|Open approach to port insertion|This involves the peritoneum being cut down, followed by the insertion of a blunt trocar under direct visualisation, gas insufflation, and insertion of the laparoscope
224265224|NCT03306238|PROCEDURE|Closed approach to port insertion|This involves the insertion of a Veress needle (a needle equipped with a spring-loaded obturator) into the peritoneal cavity, followed by gas insufflation (act of blowing) and insertion of a trocar (a sharp, pointed instrument with a cannula used to enter the body cavity).
224265225|NCT02227238|DRUG|DTG|DTG is supplied as 50 mg tablets
224265226|NCT02227238|DRUG|LPV/RTV|LPV/RTV is supplied as the LPV/RTV oral tablet, which contains 200 mg of LPV and 50 mg of RTV
224265227|NCT02227238|DRUG|Two NRTIs|Investigators will choose a dual NRTI background regimen for each subject . In consultation with the medical monitor, 3TC may be added as a third NRTI to a dual-NRTI background regimen in subjects with chronic HBV infection and evidence of HIV resistance to 3TC
224265228|NCT04150549|BIOLOGICAL|Fecal Microbial Transplants|Healthy donor stool will be processed and placed into capsules.
224265229|NCT04150549|BIOLOGICAL|Fecal Microbial Transplants|Participants stool will be processed and placed into capsules.
224265230|NCT02375815|OTHER|Statin Choice Implementation|
224265231|NCT05172687|BEHAVIORAL|Overprescribing letter to attributed physician|Letter telling patient's attributed physician they were under review for high prescribing
224265232|NCT05172687|BEHAVIORAL|Placebo letter to attributed physician|Letter to patient's attributed physician about unrelated Medicare regulation
224265233|NCT02751437|DIETARY_SUPPLEMENT|Arginine|
224265234|NCT03601585|DEVICE|Comparison of dental biofilm removal.|Comparison of the use of 4 methods for dental biofilm removal
224265235|NCT03725345|BEHAVIORAL|MRI Scanner|Participants will enter the MRI scanner and complete a series of computer tasks that include noise blasts while undergoing brain scans that measure the structure and function of the brain
224265236|NCT01608906|DRUG|low dose intravenous heparin (LDIVH)|The LDIVH (experimental) group will receive a continuous heparin drip titrated to a prothrombin time (PTT) of 40-45. LDIVH subjects will have PTT tested within 24 hours prior to initiation of LDIVH. In addition, these subjects would continue to have a PTT tested every 6 hours until the PTT value falls between 40-45. All LDIVH subjects will have PTT values measured at least daily. This will continue until ICU discharge or a maximum of 28 days.
224265237|NCT01608906|DRUG|Heparin|5000 units given subcutaneously three times a day until ICU discharge or a maximum of 28 days
224265238|NCT03966911|DEVICE|Guardian™ Sensor (3) connected to a Guardian™ Connect Transmitter|Continuous Glucose Monitoring and frequent sample testing
224265239|NCT00327847|DRUG|Oral Vitamin D Supplementation|
224265240|NCT05635630|OTHER|ctDNA and adjuvant therapy|Patients of ctDNA positive group receive individual adjuvant chemotherapy. The ctDNA status are evaluated every 2 months.
223848133|NCT01092624|DEVICE|Ring pessary with support, Cooper Surgical, Trumbell, CT Ref # MXPRS03 non-latex|There will be a two-week pessary run-in prior to randomization. If the subject completes the run-in period with no adverse reactions to the pessary, she will come in to the office for a randomization visit. She will be randomized to receive either 5 mg/day (one 5 mg tablet QD) of placebo or 5 mg/day (QD) of solifenacin for 12 weeks. At the end of week 6, patients will be assessed in the office. A standardized medication response questionnaire will be used to assess each subject's response to either the placebo or the solifenacin 5 mg. If the response is not adequate, the dose will be increased. Women whose symptoms have not improved since baseline will have their medication or placebo doses increased to 10 mg daily.
223848134|NCT04942054|DRUG|Part 1|Dose escalation cohort
223848135|NCT04942054|DRUG|Part 2|Pharmacodyanamic (PD) dose exploration cohorts
223848136|NCT04942054|DRUG|Part 3|Dose expansion at dose(s) ≤ maximum tolerated dose (MTD) cohort
223848137|NCT00791531|DRUG|Methotrexate|Oral methotrexate 5mg once daily for 5 consecutive days
223848138|NCT03226730|BEHAVIORAL|Household Visits|Household visits will be conducted to build trust in the health system, educate regarding different forms of modern contraception, (how administered, how they work, availability), dispel related myths (i.e., those regarding infertility), promote the health advantages of birth spacing, and create related dialogue among adolescent wives and other household members present during these visits. The relais will provide and resupply oral contraceptive pills and condoms to interested participants and will accompany the married adolescent to the nearest health facility for other forms of contraception, if requested to do so. To complement the household visits to married female adolescents, male relais will conduct home visits to discuss healthy timing and spacing of pregnancy with husbands of adolescent females, provide education on different forms of contraception, and discuss concerns husbands may have regarding use of contraception.
224265241|NCT05635630|OTHER|ctDNA|Patients of ctDNA negative group are monitored by ctDNA every 3 months.
224265242|NCT02408653|DEVICE|EEG|
223848139|NCT03226730|BEHAVIORAL|Small Groups|In the wife-only groups, adolescent wives will be convened by trained adult female community members to learn and discuss a broad range of gender and health-related topics, with a focus on modern contraception, and cultivate self-efficacy, social support and life skills. The small groups will be led by trained female small group mentors who are trained peers and will follow a designated curriculum consisting of different topics each week developed by Pathfinder International and derived from Population Council/UNFPA's Safe Spaces curriculum. The husband groups will follow a curriculum adapted from Promundo's Program P6 and supplemented by the tools and activities developed by Pathfinder International. These groups of husbands will focus on fostering reflection and dialogue to contribute to more equitable gender norms, support for contraception use for HTSP, positive health seeking behavior for them and their families, and increased couples communication and joint SRH decision-making.
223848140|NCT01096056|BIOLOGICAL|Influenza vaccine GSK2186877A formulation 1|Intramuscular administration, 2 doses
223848141|NCT01096056|BIOLOGICAL|Influenza vaccine GSK2186877A formulation 2|Intramuscular administration, 1 dose
223848142|NCT01096056|BIOLOGICAL|Fluarix|Intramuscular administration, 1 dose
223848143|NCT03020355|PROCEDURE|Placental Blood Drainage|Immediately after vaginal delivery, after clamping and cutting the cord-the cord will unclamped and the blood will drained until the flow ceased.
223848144|NCT03020355|PROCEDURE|not Placental Blood Drainage|In the control group, the clamped cord will not released.
223848145|NCT02237079|DRUG|Bazedoxifene/Conjugated Estrogens (BZA/CE)|Daily tablet containing conjugated estrogens 0.45 mg and bazedoxifene 20 mg.
223848146|NCT02237079|DRUG|Placebo Oral Tablet|Daily placebo tablet
223848147|NCT01542619|BIOLOGICAL|rVIIa-FP|Recombinant VIIa-FP (rVIIa-FP) is a fusion protein linking coagulation factor VIIa with albumin and will be administered by intravenous infusion in escalating doses up to 1000 mcg/kg. Participants will receive pre-treatment with an oral anticoagulant starting 7 days prior to administration of study product and continuing for 7 days after study product has been administered.
223848148|NCT01542619|BIOLOGICAL|Placebo (0.9% normal saline)|Placebo will be administered by intravenous infusion. Participants will receive pre-treatment with an oral anticoagulant starting 7 days prior to administration of placebo and continuing for 7 days after placebo has been administered.
223848149|NCT06470776|BEHAVIORAL|Chatbot counselling|Access to a chatbot that provides smoking cessation counselling based on the 5A's (Ask, Advice, Assess, Assist, Arrange follow-up) and 5R's (Risk, Relevance, Rewards, Relevance, Roadblocks, Repetition) tobacco intervention models from baseline to 3-month post-baseline.
223848150|NCT06470776|BEHAVIORAL|Peer counselling|Usual treatment provided by the Youth Quitline, i.e., telephone counselling for smoking cessation based on the 5As and 5Rs models delivered by trained peer counsellors at baseline and 1 week, 1 month and 3 months post-baseline
223848151|NCT00362752|DRUG|Norfloxacin|400 mg po bid
223848152|NCT00362752|DRUG|Placebo|Placebo 400 mg po bid
223848153|NCT01289743|DRUG|Etanercept|Etanercept 25 mg subcutaneously twice a week
223848154|NCT03571243|OTHER|no intervention|observational study
223848155|NCT04380844|OTHER|Beprevent|10 will become part of the intervention group. At first, they are given a series of questionnaires, later (1 day later) we stay at their home to install the Beprevent device, which will remain in their home for a period of two weeks, to finish and once the device of your home, we will proceed to pass the same questionnaires as at the beginning of the test, in order to compare results.
223848156|NCT02828683|DEVICE|PCI in patients with ST-elevation myocardial infarction|Percutaneous coronary intervention in patients with ST segment elevation myocardial infarction (STEMI)
223848157|NCT02828683|DEVICE|PCI in patients with ST-elevation myocardial infarction|Percutaneous coronary intervention in patients with ST-segment elevatio myocardial infarction
223848158|NCT05536466|PROCEDURE|bariatric surgery|bariatric surgery
223848159|NCT00000821|DRUG|Aldesleukin|
223848160|NCT01368120|DEVICE|IV Clear™ Dressing|Polyurethane film, silicone adhesive dressing with chlorhexidine and silver
223848161|NCT01368120|DEVICE|Tegaderm CHG™|Polyurethane film, polyacrylate adhesive and a polyol hydrogel containing 2% w/w chlorhexidine gluconate
223848162|NCT01368120|DEVICE|Silicone Vehicle Control Dressing|Polyurethane film with silicone adhesive dressing, without antimicrobials
223848163|NCT01110174|DIAGNOSTIC_TEST|HD PET/CT|imaging
223848164|NCT01793272|OTHER|effect of pentoxifylline on ICSI outcome|semen processing with pentoxifylline prior to ICSI
223848165|NCT03781804|DRUG|OPN-375|OPN-375, BID
223848166|NCT04827459|BEHAVIORAL|Sleep Coach App|Participants will be encouraged to interact with the mobile app daily for as much time as they wish, or for as little as 5 - 10 minutes, over a 7-week period.
223848167|NCT02801929|DRUG|Coppertone (BAY987518)|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation Number - SR15-72\_V27-010).
223848168|NCT00002784|BIOLOGICAL|filgrastim|Filgrastim 10 mg/kg/d sc for 6 days after randomization.
223848169|NCT00002784|DRUG|CMF regimen|Cyclophosphamide 100 mg/m2 orally days 1 - 14, methotrexate 40 mg/m2 iv days 1 and 8, 5-fluorouracil 600 mg/m2 iv days 1 and 8. Repeat every 28 days.
223848170|NCT00002784|DRUG|cyclophosphamide|For high-dose EC arm: cyclophosphamide 4 gm/m2 iv as 4 divided doses. For standard chemotherapy arm: cyclophosphamide 600 mg/m2 iv day 1 of 21-day EC cycles, and cyclophosphamide 100 mg/m2 orally on days 1-14 of 28-day CMF cycles.
223848171|NCT00002784|DRUG|doxorubicin hydrochloride|Doxorubicin 60 mg/m2 iv on day 1 of 21-day cycles of AC.
223848172|NCT00002784|DRUG|epirubicin hydrochloride|Epirubicin 90 mg/m2 iv on day 1 of 21-day cycles of EC.
223848173|NCT00002784|DRUG|fluorouracil|5-fluorouracil 600 mg/m2 iv days 1 and 8 of 28-day cycles of CMF.
223848174|NCT00002784|DRUG|mesna|MESNA (7.2 gm/m2) on days 2 and 3 of 21-day cycles of dose-intensive EC.
223848175|NCT00002784|DRUG|methotrexate|Methotrexate 40 mg/m2 iv on days 1 and 8 of 28-day cycles of CMF.
223848176|NCT00002784|DRUG|tamoxifen citrate|Tamoxifen 20mg daily for 5 years or until relapse.
223848177|NCT00002784|PROCEDURE|peripheral blood stem cell transplantation|Peripheral blood progenitor cells (PBPC) infusion on day 5 of each 21-day cycle of dose-intensive EC.
223848178|NCT00002784|RADIATION|low-LET electron therapy|Radiation therapy to the conserved breast is mandatory, to be carried out according to the prospectively defined guidelines of each participating institution; either after all chemotherapy or integrated into CMF as agreed per institution. Radiotherapy to the chest wall following mastectomy is optional according to the prospectively defined guidelines of each participating institution.
223848179|NCT00002784|RADIATION|low-LET photon therapy|radiation therapy to the conserved breast is mandatory, to be carried out according to the prospectively defined guidelines of each participating institution; either after all chemotherapy or integrated into CMF as agreed per institution. Radiotherapy to the chest wall following mastectomy is optional according to the prospectively defined guidelines of each participating institution.
223848180|NCT04355130|DIETARY_SUPPLEMENT|Iron, vitamin B12 and acid folic supplementation|Vitamin and iron supplementation is administered one-two weeks before donation, and consist of iron supplementation (i.v. infusion of 20 mg/Kg ferric carboxymaltose in saline 100 ml), s.c. injection of 1 mg of vitamin B12 and acid folic 5 mg/die per os until day +15 post BM donation. BM collection is carried out by the transplant team and a maximal dose of 20-22 ml/Kg of the donor body weight is collected under general anesthesia (induction with fentanyl 1-3 mcg/Kg, Propofol 2-3 mg/Kg, rocuronium 0,6 mg/Kg and mantenaince with sevoflurane 0,8 MAC). Noninvasive cardiac output, blood pressure and hemoglobin monitoring are carried out during the entire procedure and in in the recovery room using the ClearSight™ system (Edwards Clinical) and the Radical Pulse co oxymeter (Masimo). After discharge from the hospital, donors will be revaluated on day + 7 after BM collection, and blood tests will be repeated in outpatient setting.
223848181|NCT00337818|BIOLOGICAL|Cervarix™|Three doses of vaccine according to a 0, 1, 6 month schedule (during the primary study)
223848182|NCT00725413|DRUG|etonogestrel implant (Implanon)|subdermal etonogestrel implant
223848183|NCT03994146|DRUG|Remifentanil|"Syringe containing 40 ml of Remifentanil 50 µg/ml for intravenous administration.~In order to maintain double blinding two identical syringes, prepared by pharmacy according to randomisation, will be simultaneously infused. One of the syringes will be abruptly stopped at the end of the operation whilst the other is tapered by stepwise decreases in infusion rate prior to the end of surgery."
223848184|NCT03994146|DRUG|Sodium Chloride 9mg/mL|"Syringe containing 40 ml of Sodium Chloride 9 mg/ml for intravenous administration.~In order to maintain double blinding two identical syringes, prepared by pharmacy according to randomisation, will be simultaneously infused. One of the syringes will be abruptly stopped at the end of the operation whilst the other is tapered by stepwise decreases in infusion rate prior to the end of surgery."
223848185|NCT04678830|DRUG|Placebos|Placebos
223848186|NCT04678830|DRUG|Leronlimab (700mg)|Leronlimab (PRO) 140 is a humanized IgG4, monoclonal antibody (mAb) to the C-C chemokine receptor type 5 (CCR5)
223848187|NCT00336232|DRUG|Vitamin K|phylloquinone (vitamin K1) 500 mcg daily in third month
223848188|NCT05590871|DEVICE|FlashPoint renal denervation system|Radio-frequency ablation of renal arterial sympathetic nerves
223848189|NCT05590871|OTHER|Sham|After a renal angiography according to standard procedures, subjects remain blinded and remain on the catheterization lab table for at least 20 minutes prior to introducer sheath removal.
223848190|NCT06629480|DRUG|Bictegravir|The aim of the study was to identify the incidence of MetS at 48 weeks for ATP III score in patients living with HIV (PLH) who started antiretroviral therapy (ART) with Dolutegravir based-regimen compared with Bictegravir based-regimen. A randomized open clinical trial was developed with men PLH who started ART randomized to BIC/FTC/TAF or DTG/3TC/ABC.
223848191|NCT02479867|DRUG|Cefadroxil|1 tablet from test vs 1 tablet from reference
223848192|NCT01190176|PROCEDURE|Gynaecological follow-up|Subjects will receive a gynaecological follow-up with cytology and oncogenic HPV DNA testing every 12 months, for up to a maximum of four years.
223848193|NCT01190176|BIOLOGICAL|Cervarix|Subjects received 3 doses of the HPV vaccine administered intramuscularly according to a 0, 1, 6 month vaccination schedule in the primary study HPV-015.
223848194|NCT01190176|BIOLOGICAL|Placebo control|Subjects received 3 doses of the control \[Al(OH)3\] administered intramuscularly according to a 0, 1, 6 month vaccination schedule in the primary study HPV-015.
223848195|NCT05694507|OTHER|Mental Well-being Chatbot|The chatbot contents are developed by Clinical psychologists and well-being promotion officers. Content includes relationships, stress, value, emotion, and positive psychology.
223848196|NCT05547659|DRUG|Pregabalin 150mg|Pregabalin 150mg preoperative in unimodal group Pregabalin 150mg preoperative in multi-modal group
223848197|NCT05547659|DRUG|Acetaminophen 1 G Oral Tablet|Acetaminophen 1 G Oral Tablet preoperative in multi-modal group
223848198|NCT05547659|DRUG|Celecoxib 400Mg Oral Capsule|Celecoxib 400Mg Oral Capsule preoperative in multi-modal group
223848199|NCT02189863|DEVICE|Lotrafilcon B MF|Multifocal contact lenses worn in both eyes
223848200|NCT02189863|DEVICE|Lotrafilcon B MV|Spherical contact lenses worn with 1 eye corrected for distance and 1 eye corrected for near
223848201|NCT02189863|DEVICE|Lotrafilcon B SVD|Spherical contact lenses worn with both eyes corrected for distance
223848202|NCT02189863|DEVICE|Comfilcon A MF|Multifocal contact lenses worn in both eyes
223848203|NCT02189863|DEVICE|Habitual contact lenses|Contact lenses worn in both eyes per subject's habitual prescription
223848204|NCT01743274|PROCEDURE|OCT|"Optical Coherence Tomography (OCT) is a recent imaging modality that yields cross-sectional images with a resolution 10 times greater than that of intravascular ultrasound (IVUS). OCT uses a near-infra-red light source to obtain images of the interior walls of the coronary arteries and is increasingly used to evaluate vulnerable atherosclerotic plaques and assess placement and response to stenting.~OCT images are acquired by automated pullback over 2 to 3 seconds of the light source that yields a helicoidal image of a longitudinal segment of 50 mm. Intravascular imaging is obtained by injecting contrast medium or saline solution."
223848205|NCT03697460|DRUG|INCB018424|INCB018424 PHOSPHATE CREAM 1.5%, topical application, twice daily on lesions of cutaneous LP.
223848206|NCT03184428|OTHER|Postoperative observation and survey|For postoperative Observation with a survey we ask the patients (or in case of no information the ophthalmologist) whether they had undergone a YAG-Laser-Capsulotomy after Cataract-Surgery or not.
223848207|NCT01819090|DEVICE|Elysee 150 ventilator|
223848208|NCT01819090|DEVICE|Elysee 150 ventilator with a ventilation switch control|
223848209|NCT03369951|DRUG|Minocycline|Minocycline is a semisynthetic derivative of tetracycline and is indicated for the treatment of infections due to susceptible isolates of designated microorganisms.
223848210|NCT02451293|DRUG|Melatonin (N-acetyl-5-methoxytryptamine)|
223848211|NCT02451293|DRUG|Placebo|
223848212|NCT05567666|DEVICE|Optilume Catheter System|Optilume Catheter System, which is a Dilation Drug Coated Balloon (DCB) Catheter
223848213|NCT03413774|PROCEDURE|vaginal swab|high vaginal and Endocrvical swabs for bacterial, protozoal and chlamydial infection- examined by PCR
223848214|NCT06081101|DRUG|Methylprednisolone Injection|Medication will be injected into SI joint under ultrasound guidance
223848215|NCT06081101|DRUG|Ketorolac Injection|Medication will be injected into SI joint under ultrasound guidance
223848216|NCT02178436|DRUG|gemcitabine hydrochloride|Given IV
223848217|NCT02178436|DRUG|Selinexor|Given IV
223848218|NCT02178436|OTHER|Pharmacological Study|Correlative studies
223848219|NCT02178436|OTHER|Laboratory Biomarker Analysis|Correlative studies
223848220|NCT02178436|DRUG|Nab paclitaxel|Given IV
223848221|NCT01807819|OTHER|Heart Failure|Patients will undergo echocardiogram and exercise testing. Two year phone follow-up.
223848222|NCT04004858|RADIATION|External beam radiation therapy|Patient will receive 60Gy in 20 fractions as per standard practice
223848223|NCT00365417|DRUG|Bevacizumab|15 mg/kg IV every 21 days x 4 cycles, then after clinical response assessment, 15 mg/kg IV every 21 days x 2 cycles, then following surgery, 15 mg/kg every 21 days x 10 cycles
223848224|NCT00365417|DRUG|Doxorubicin|60 mg/m\^2 IV every 21 days x 4 cycles
223848225|NCT00365417|DRUG|Cyclophosphamide|600 mg/m\^2 IV every 21 days x 4 cycles
223848226|NCT00365417|DRUG|Capecitabine|Following clinical response assessment, 650 mg/m\^2 twice a day (orally), days 1-14 every 21 days x 4 cycles
223848227|NCT00365417|DRUG|Docetaxel|Following clinical response assessment, 75 mg/m\^2 IV every 21 days x 4 cycles
223848228|NCT03272646|PROCEDURE|surgery|gastric resection or total gastrectomy
223848229|NCT03524820|DRUG|Cetuximab|Administration of drug
223848230|NCT02165423|BEHAVIORAL|myFAMI iPad application|
223848231|NCT03805958|PROCEDURE|realtime ultrasonography|Applying realtime ultrasound during the combined anesthesia
223848232|NCT03805958|PROCEDURE|prescan ultrasonography|Applying realtime ultrasound before the combined anesthesia
223848233|NCT05586217|OTHER|INCENTIVE SPIROMETRY|"* Sit up and hold the device.~* Then Place the mouthpiece spirometer in mouth and make a good seal over the mouthpiece with lips.~* Breathe out (exhale) normally.~* Breathe in (inhale) slowly. A piece in the incentive spirometer will rise as you breathe in. And try to get this piece to rise as high as you can.~* Usually, there is a marker placed by your doctor that tells you how big of a breath you should take.~A smaller piece in the spirometer looks like a ball or disk.~* Your goal should be to make sure this ball stays in the middle of the chamber while you breathe in.~* If you breathe in too fast, the ball will shoot to the top.~* If you breathe in too slowly, the ball will stay at the bottom. Hold your breath for 3 to 5 seconds. Then slowly exhale."
223848234|NCT05586217|OTHER|Active cycle of breathing|"Breathe in and out gently through your nose if you can. If you cannot, breathe through your mouth instead. If you breathe out through your mouth, it's best to use breathing control with 'pursed lips breathing'. keep your shoulders relaxed.~Try closing your eyes to help you to focus on your breathing and to relax. Breathing control should continue until the person feels ready to progress to the other stages in the cycle. Try to keep your chest and shoulders relaxed.~At the end of the breath in, hold the air in your lungs for 2-3 seconds before breathing out. Breathe out gently and relaxed. Repeat 3 - 5 times. Sit up straight with chin tilted slightly up and mouth open.~Take a slow deep breath to fill lungs about three quarters full. Hold breath for two or three seconds. Exhale forcefully, but slowly, in a continuous exhalation to move mucus from the smaller to the larger airways"
223848235|NCT03795974|BIOLOGICAL|MNC|Hematopoietic stem cells derived from allogenic umbilical cord
223848236|NCT03795974|BIOLOGICAL|MSC|Mesenchymal cells derived from allogenic umbilical cord
223848237|NCT03795974|PROCEDURE|Control|control group without injection and appearance simulating lumbar puncture without awareness of the patients and evaluators , but rehabilitation continued .
223848238|NCT03677375|DEVICE|INVSENSOR00026|Noninvasive pulse oximeter sensor
223848239|NCT04807660|OTHER|middle ear fluid sample|middle ear fluid sample for each enrrolled children
223848240|NCT02023203|PROCEDURE|Totally Extraperitoneal laparoscopic inguinal hernia repair|Laparoscopic hernioplasty
223848241|NCT01188317|DRUG|aleglitazar|repeated daily doses
223848242|NCT01188317|DRUG|placebo|repeated daily doses
223848243|NCT01188317|DRUG|ibuprofen|repeated daily doses
223848244|NCT06109532|OTHER|hyponatremia|hyponatremia at admission in dengue infected patients
223848245|NCT00258479|DRUG|ModafinilNicotine Replacement Therapy|A dose escalation design includes eight dose conditions across a 12-day study (nicotine low-high, modafinil low-high and 4 combinations). After day 1 placebo dose, placebo sessions occur in random order during low dose, high dose, and dose-combination testing. Modafinil and nicotine are tested alone with subjects exposed to low active doses prior to higher doses. Dose interactions will be determined with low doses tested in combination followed by low-high dose combinations then high-high dose combination. Doses are administered under double-blind, double dummy procedures. A nicotine patch (0, 7 or 14 mg doses) is applied at 7 am. Modafinil doses are prepared in size 00 opaque capsules. The modafinil dose (0, 100, 200 mg) is administered at 5 PM.
223848246|NCT00258479|DRUG|Modafinil|See Modafinil Intervention Description above.
223848247|NCT00445692|DRUG|Clarithromycin|Given Orally (PO)
223848248|NCT00445692|DRUG|Dexamethasone|Given PO
223848249|NCT00445692|DRUG|Lenalidomide|Given Orally (PO)
223848250|NCT01796977|DEVICE|OxyGenesys Dissolved Oxygen Dressing|
223848251|NCT01796977|DEVICE|Standard Gauze Dressing|
223848252|NCT01525979|BEHAVIORAL|Task-related unilateral arm training|The training tasks will involve daily activities with unilateral proximal or distal upper extremity movements for 5 days/week for 1.5 hours/day for 4 consecutive weeks.
223848253|NCT01525979|BEHAVIORAL|Task-related bilateral arm training|This intervention emphasizes UE movements (gross or fine motor tasks) involved in daily activities but focus on both UEs moving synchronously. The duration and intensity of treatment will also be 5 days/week for 1.5 hours/day for 4 consecutive weeks.
223848254|NCT01525979|BEHAVIORAL|Robot-assisted bilateral arm training|The Bi-Manu-Track used in this project (Reha-Stim Co., Berlin, Germany) enables the symmetric practice of 2 movement patterns: forearm pronation-supination and wrist flexion-extension. Each movement has 3 computer-controlled modes: (1) passive-passive, with both arms being moved by the machine with speed, range of motion, and resistance individually adjustable; (2) active-passive, with the unaffected arm driving the affected arm in a mirror-like fashion; and (3) active-active, with both arms actively moving against resistance.
223848255|NCT01525979|BEHAVIORAL|Robot-assisted unilateral arm training|The robot-assisted unilateral arm training group will use mode 1 and 3: (1) passive, affected arm being moved by the machine with speed and range of motion individually adjustable; and (2) active, with the affected arm actively moving. This training program will add an additional mode: active-resistance, with the affected arm/wrist actively moving against resistance.
223848256|NCT05008341|DRUG|Solriamfetol 150 mg Oral Tablet|Single-dose 150 mg tablet orally administered.
223848257|NCT04614077|OTHER|ex vivo organ bath testing, preservation of vein sections without contact to patient|1 piece of vein is separated during surgical bypass procedure, then randomized and put ex vivo in two solutions: saline and specific solution, then tested in the organ bath
223848258|NCT06434428|DRUG|dexmedetomidine (IV)|Administration of IV dexmedetomidine
223848259|NCT06434428|DRUG|dexmedetomidine (IN)|Administration of IN dexmedetomidine
223848260|NCT04038476|DIAGNOSTIC_TEST|Standard monitoring + transcutaneous CO2 monitoring|The transcutaneous CO2 Monitoring measures the CO2 partial pressure of the skin and in condition of good circulation these values approximate the arterial/venous CO2 partial pressure. The sensor is placed on the forehead. The physician adapts the sedation Management according to the transcutaneous CO2 monitoring.
223848261|NCT04038476|DIAGNOSTIC_TEST|Standard monitoring|The transcutaneous CO2-sensor is also positioned on the patients' forehead, but the transcutaneous CO2-monitoring is not available for the physician to adapt the sedative management.
223848262|NCT03883685|DIETARY_SUPPLEMENT|Probiotane|probiotics capsules of blended strains including Lactobacillus acidophilus, L. casei and L. rhamnosus
223848263|NCT03883685|DIETARY_SUPPLEMENT|Placebo|Placebo
223848264|NCT01821911|BIOLOGICAL|Zagreb2-1-1|Injection on day 0、7、21
223848265|NCT01821911|BIOLOGICAL|Essen|Injection on day 0、3、7、14、28
223848266|NCT01155245|DRUG|Forteo|Forteo pen
223848267|NCT04952272|COMBINATION_PRODUCT|CpG-ODN|CAR-T cells secreting scFv against OX40
223848268|NCT05792046|DEVICE|Visual field|test for detecting loss in visual function
223848269|NCT03331328|DEVICE|MonaLisa Touch|MonaLisa Touch is a fractional CO2 laser that has been specially designed with the DEKA pulse to stimulate vaginal tissue. It is delivered in a very precise manner and results in the synthesis of collagen and stratification of the vaginal epithelium with improvement of the vaginal pH and moisturization of the vaginal tissue due to increased blood flow and turgidity of the ground substance from the synthesis of the proteoglycans, hyaluronic acid and collagen.
223848270|NCT02928939|OTHER|drug-drug or drug-disease interaction|
223848271|NCT00880490|DRUG|Inhaled PT005|single dose, inhaled
223848272|NCT00880490|DRUG|Inhaled PT005|single dose, inhaled
223848273|NCT00880490|DRUG|Inhaled PT005|single dose, inhaled
223848274|NCT00880490|DRUG|Inhaled placebo|single dose, inhaled
223848275|NCT00880490|DRUG|Formoterol Fumarate 12 mcg (Foradil Aerolizer)|single dose, Formoterol Fumarate 12 mcg administered via the Aerolizer
223848276|NCT00607035|DRUG|Olmesartan medoxomil ＋Azelnidipine|The ARB plus CCB combination therapy group is administered olmesartan 20 mg/day and azelnidipine 16 mg/day for 6 months.
223848277|NCT00607035|DRUG|Olmesartan medoxomil + Hydrochlorothiazide|The ARB plus Diuretics combination therapy group is administered olmesartan medoxomil 20mg/day and hydrochlorothiazide 12.5mg/day for 6 months.
223848278|NCT02939001|DEVICE|iris recognition scanner|
223848279|NCT03425539|DRUG|Lucerastat|Hard gelatin capsules containing 250 mg of lucerastat and inactive excipients; 1000 mg (4 capsules) twice daily (b.i.d.); dose adjusted for renal function.
223848280|NCT03425539|DRUG|Placebo|Placebo capsules are identical in appearance to the lucerastat capsules, and contain inactive excipients; 4 capsules b.i.d.; dose adjusted for renal function.
223848281|NCT02040844|DRUG|Received Cat-PAD Treatment 1 in Study CP007 [NCT01620762]|
223848282|NCT02040844|DRUG|Received Cat-PAD Treatment 2 in Study CP007 [NCT01620762]|
223848283|NCT02040844|DRUG|Received Cat-PAD Treatment 3 in Study CP007 [NCT01620762]|
223848284|NCT03663101|DRUG|Lidocaine|0.5 mL (2.5 mg) of lidocaine per injection point will be injected subcutaneously (maximum 10 injection points).
223848285|NCT03663101|BIOLOGICAL|Botulinum toxin type A|0.2 mL of one of three different doses of Dysport per injection point will be injected intradermally (maximum 10 injection points).
223848286|NCT03663101|DRUG|Placebo|Part A - 0.5 mL of sodium chloride solution 0.9% (saline solution) per injection point will be injected subcutaneously (maximum 10 injection points).
223848287|NCT03663101|DRUG|Placebo|Part B - 0.2 mL of sodium chloride solution 0.9% (saline solution) per injection point will be injected intradermally (maximum 10 injection points, 2,0 mL maximum).
223848288|NCT05472649|BIOLOGICAL|Gene-Modified Cell Therapy|No investigational cell product will be administered
223848289|NCT05765591|OTHER|Balneotherapy and aquatic exercises|Information has already been included in arm/group descriptions
223848290|NCT01353638|DRUG|Dipeptiven (Alanyl-glutamine-dipeptide)|Two arms (A and B) and two treatment periods (1 and 2) are scheduled for this study. Each arm includes 14 patients. Schedule arm A: Treatment period 1 with one single peritoneal dialysis exchange (standard PD solution) with Alanyl-Glutamine-Dipeptide as add-on. 17,4 ml Dipeptiven (=3,48g N(2)-L Alanyl-L-Glutamin) will be dissolved at a final concentration of 0,174 %(= 8 mmol/l) in 2 liters of Dianeal®PD4 (at PH:5,5; Glucose-Concentration 3,86 %). After a wash out period (28 days + max 7 days), arm A undergoes treatment period 2, that is one single peritoneal dialysis exchange with standard PD solution without Alanyl-Glutamine-Dipeptide. Schedule Arm B: Treatment period 1 with one single peritoneal dialysis exchange with standard PD solution without Alanyl-Glutamine-Dipeptide followed by wash-out. Treatment period 2 for arm B includes one single peritoneal dialysis exchange with standard PD solution with Alanyl-Glutamine-Dipeptide as add-on. Dosages remain exactly the same.
223848291|NCT00609648|BEHAVIORAL|Computer Assisted Relaxation Learning|A self-paced computer program for reducing dental injection fear.
223848292|NCT00609648|BEHAVIORAL|Pamphlet|A pamphlet reassuring patients about dental injections.
223848293|NCT04784013|PROCEDURE|Conventional CLOSE-guided pulmonary vein isolation|Point-by-point RF delivery will be performed aiming for a contiguous circle enclosing the veins. RF will be delivered in a temperature and flow-controlled mode (QMODE, target temperature 45°C, low flow temperature 40°C, cut-off temperature 50°C) with a power of 35W(posterior)/50W(anterior) (irrigation flow at 4-15ml/min). RF will be delivered until an ablation index (AI) of ≥400 at the posterior wall/roof/south pole and ≥550 at the anterior wall.
223848294|NCT04784013|PROCEDURE|High power short duration pulmonary vein isolation|Point-by-point RF delivery will be performed aiming for a contiguous circle enclosing the veins. RF will be delivered in temperature-controlled mode (QMode+, target temperature 55°C, cut-off temperature 65°C) with a power of 90W (irrigation flow at 2-8ml/min). RF will be delivered for 4 sec at both the posterior and anterior wall.
223848295|NCT05579886|DEVICE|Control Lens|Daily disposable multifocal soft lens with 2 add design (2ADD) for 2 weeks
223848296|NCT05579886|DEVICE|Test Lens|Daily disposable multifocal soft lens with 3 add design (3ADD) for 2 weeks
223848297|NCT01560949|DRUG|Oxaliplatin|75 mg/m2 by vein on Day 1 of weeks 1, 3, 5, 7, 9 and 11 for 12 weeks.
223848298|NCT01560949|DRUG|Irinotecan|150 mg/m2 by vein on Day 1 of weeks 1, 3, 5, 7, 9 and 11 for 12 weeks.
223848299|NCT01560949|DRUG|5-FU|2000 mg/m2 by vein over 46 hour continuous infusion, on Days 1 - 2 during weeks 1, 3, 5, 7, 9 and 11 for 12 weeks.
223848300|NCT01560949|DRUG|Gemcitabine|350 mg/m2 by vein every week for 5 doses beginning Day 1 (days 1, 8, 15, 22, 29).
223848301|NCT01560949|RADIATION|Radiation Therapy|External beam radiation therapy delivered 5 days/week +/- 2 days over 5.5 weeks with 18-MeV photons. 3D conformal RT, a total dose of 50.4 Gy 1.8 Gy/fraction (28 fractions).
223848302|NCT04756050|DRUG|Bupivacaine HCl 0.5% Injectable Solution|20 ml of bupivacaine(Buvicaine HCl %0.5) and prilocaine(Priloc HCl %2) 1:1 mixture will be prepared in a way that there will be 5mcg adrenaline per ml.(9ml bupivacaine, 9ml prilocaine and 2ml saline with 50 mcg adrenaline per ml)
223848303|NCT04756050|DRUG|Prilocaine HCl % 2 injectable solution|20 ml of bupivacaine(Buvicaine HCl %0.5) and prilocaine(Priloc HCl %2) 1:1 mixture will be prepared in a way that there will be 5mcg adrenaline per ml.(9ml bupivacaine, 9ml prilocaine and 2ml saline with 50 mcg adrenaline per ml)
223848304|NCT04756050|DRUG|adrenaline amp 0.5mg|20 ml of bupivacaine(Buvicaine HCl %0.5) and prilocaine(Priloc HCl %2) 1:1 mixture will be prepared in a way that there will be 5mcg adrenaline per ml.(9ml bupivacaine, 9ml prilocaine and 2ml saline with 50 mcg adrenaline per ml)
223848305|NCT04756050|PROCEDURE|Ultrasound Guided Supraclavicular Block Corner pocket approach|The blocks will be performed by an experienced anesthesiologist with a USG guidance. Local anesthetic mixture will be given to the corner pocket - where the artery and the first rib intersect in the sonoanatomical image.
223848306|NCT04756050|PROCEDURE|Ultrasound Guided Supraclavicular Block Corner pocket + intracluster approach|The blocks will be performed by an experienced anesthesiologist with a USG guidance .10 ml of the local anesthetic mixture will be given to the described corner pack and the remaining 10 ml into the largest nerve cluster (Intracluster injection).
223848307|NCT04756050|PROCEDURE|Ultrasound Guided Supraclavicular Block multi approach|The blocks will be performed by an experienced anesthesiologist with a USG guidance Local anesthetic mixture will be administered by multi injection method between the nerve groups seen in the sonoanatomical image.
223848308|NCT04756050|PROCEDURE|diagraphma muscle evaluation with ultrasound|"All patients will be evaluated with USG in a head-up position facing the side to be operated before and 30 minutes after the block is performed.~The probe will be placed perpendicular to the chest wall, in the eighth or ninth intercostal space, between the anterior axillary and midaxillary lines, 0.5 to 2 cm below the costophrenic sinus."
223848309|NCT04865302|PROCEDURE|SSC|"Incubator phase I: After feeding the neonates will be brought in a prone position in the incubator and the NIRS sensor will be applied on the forehead for continuous cStO2 measurements throughout the study period. The neonate will rest in this position for 60 minutes.~SSC phase: The neonate will be brought on the mother's or father's chest (skin to skin) in a prone position and will stay in this position for 60 minutes.~Incubator phase II: The neonates will be brought back into the incubator for another 60 minutes in prone position. After 180 minutes the study period is over and the NIRS sensor will be removed."
223848310|NCT03032159|BEHAVIORAL|Text2Breathe Study Group|
223848311|NCT00681811|DRUG|HGT-1111|Patients currently dosed with 100 U/kg or 200 U/kg will continue this treatment. Patients dosed with 50 U/kg will be equally randomized to treatment on 100 U/kg or 200 U/kg. The dose will be adjusted every 6-week to account for changes in body weight.The infusion length will be dependent on the dose. Infusion of 100 U/kg will be diluted in 50 ml isotonic sodium chloride and infused over 30 minutes. Infusion of 200 U/kg will be administered in the same manner except for an infusion time of 60 minutes.
223848312|NCT01642264|BEHAVIORAL|WeBREATHe Training Program|The WeBREATHe Training Program is a web-based, interactive training program to teach pediatric respiratory therapists, nurses and nurse practitioners how to help their patients' parents to quit smoking.
223848313|NCT00137956|DEVICE|Emphasys Endobronchial Valve (EBV) Device and Procedure|
223848314|NCT00928109|BEHAVIORAL|CBCT|Cognitive Behavioral Couples Therapy - weekly manualized couples therapy
223848315|NCT00928109|BEHAVIORAL|Family Supportive Therapy|Couples meet once a week for an hour for a period of 20 weeks for couples therapy. Family Supportive Therapy is not manualized and is the standard form of care at the UNC Eating Disorders Program
223848316|NCT01365338|DRUG|Placebo|Administered as specified in the treatment arm
223848317|NCT01365338|DRUG|PF-04958242|Administered as specified in the treatment arm
223848318|NCT00747929|DRUG|S-2367 Placebo|four placebo tablets (total dose = 0 mg/day S-2367) administered orally once-a-day with morning meal while on a reduced calorie diet for a total of 54 weeks,
223848319|NCT00747929|DRUG|S-2367 800 mg|two 400 mg S-2367 tablets (total dose = 800 mg/day S-2367) administered orally once-a-day with morning meal while on a reduced calorie diet for a total of 54 weeks
223848320|NCT00747929|DRUG|S-2367 1600 mg|four 400 mg S-2367 tablets (total dose = 1600 mg/day S-2367) administered orally once-a-day with morning meal while on a reduced calorie diet for total of 54 weeks,
223848321|NCT00747929|OTHER|Reduced Calorie Diet|A diet with restricted calorie content
223848322|NCT01268761|DRUG|GnRH antagonist (Cetrorelix)|•GnRH antagonist (Cetrorelix 0.25) during 7 days beginning administration the second day of oocyte retrieval
223848323|NCT01268761|DRUG|Placebo (saline solution)|• Placebo (saline solution) 1 ampoule every 24 hours during 7 days beginning administration the second day of oocyte retrieval
223848324|NCT02530151|DRUG|Morphine with clonidine|see arm description
223848325|NCT02530151|OTHER|Normal saline|see arm description
223848326|NCT01562743|DRUG|SPM 962|Tansdermal patch
223848327|NCT05714670|DRUG|Curcumin Oral Capsule|Curcumin 1000 mg Oral Capsule beside the standard of care
223848328|NCT05674643|DIAGNOSTIC_TEST|Gastric Ultrasound Baseline Scans|The patient's abdomen will be scanned using the ultrasound device by an expert scanner and novice scanner for baseline assessment of the antral CSA and gastric volume using Perlas US qualitative grading assessment.
223848329|NCT05674643|DIAGNOSTIC_TEST|Acetaminophen Absorption Test (AAT)|"Prior to starting the AAT, a baseline plasma acetaminophen level (250 microliters) will be obtained from the intravenous catheter. The subject will then be given 12.5 mg/kg or max 650mg of single batch 32mg/mL acetaminophen followed by 6oz of water PO. Up to 3 additional small volume blood samples will be drawn for acetaminophen levels.~These additional blood samples (250 microliters each) will be obtained to measure acetaminophen plasma levels at the following goal intervals after acetaminophen administration.T1:10-20 mins, T2:35-45 mins, T3: 60mins. At the time of each lab draw gastric ultrasound will be assessed by the expert scanner to correlate gastric ultrasound with the acetaminophen absorption test as a gold-standard of gastric emptying."
223848330|NCT05674643|DIAGNOSTIC_TEST|Gastric Ultrasound Serial Scans|Cohort 1 will have multiple scans as part of assessing gastric emptying. These sequential scans after the baseline assessment will be done in line with the Acetaminophen Absorption Test timeline (T1:10-20 mins, T2:35-45 mins, T3: 60mins) and will be performed by an expert scanner only.
223848331|NCT02299921|OTHER|Characterize alcohol and drug use|Characterize alcohol and drug use in patients newly admitted to the medical ICU service, who are expected to stay in the ICU for greater than 48 hours. The investigators will collect blood, exhaled breath condensate, urine and hair samples over the first 10 days of hospitalization. A select subset of subjects will have bronchoalveolar lavage (BAL) obtained.
223848332|NCT06614322|DRUG|Pregabalin|300mg/day pregabalin capsule
223848333|NCT06614322|DRUG|Duloxetine|60mg/day duloxetine capsule
223848334|NCT06614322|OTHER|Placebo|Placebo capsule
223848335|NCT06615466|RADIATION|Partial Breast Irradiation|26Gy/5.2Gy/5f
223848336|NCT06615336|BEHAVIORAL|Intensive Sleep retraining|Intensive Sleep Retraining treatment consisted of 42 sleep onset trials over a 21-hour sleep deprivation period
223848337|NCT06615336|BEHAVIORAL|Total Sleep Deprivation|Total Sleep Deprivation treatment consisted of an equivalent 21-hour sleep deprivation period without sleep onset trials
223848338|NCT06614439|PROCEDURE|proximal gastrectomy|proximal gastrectomy
223848339|NCT06614439|PROCEDURE|total gastrectomy|total gastrectomy
223848340|NCT06271200|OTHER|Strategic lifestyle and drug interventions|"Participants in the Intensive Lifestyle Intervention (ILI) group will follow a program including:~1. time-restricted eating with a 16:8 pattern (eating within an 8-hour window, fasting for 16 hours),~2. walking over 10,000 steps daily, and~3. a daily calorie reduction of 500 kcal (with macronutrient distribution: 40-55% carbohydrates, 15-20% protein, 20-30% fat).~Participants in the Usual Lifestyle Intervention (ULI) group will maintain their habitual meal timing.~After the initial 24-week lifestyle program, ILI participants will be randomized (1:1) to receive either a GLP-1 receptor agonist (Rybelsus) or an SGLT-2 inhibitor (Forxiga) for 26 weeks, while continuing their lifestyle regimen. This phase will assess the impact of medication-with or without prior lifestyle intervention-on weight loss and liver fat. All participants will then be followed for an additional 52 weeks to evaluate long-term weight maintenance."
223848341|NCT06271200|OTHER|Control|"Participants in the ULI group will maintain their usual lifestyle without intervention during the first 24 weeks.~After the initial 24-week usual lifestyle intervention, participants in the ULI group will be randomly assigned in a 1:1 ratio to receive either Rybelsus (GLP-1 receptor agonist) or Forxiga (SGLT-2 inhibitor) for a duration of 26 weeks. This phase aims to assess the effects of these medications on weight reduction and liver fat content without prior intensive lifestyle intervention. All participants will be followed for an additional 52 weeks to evaluate the long-term sustainability of weight loss."
223848342|NCT05471232|GENETIC|Genomic sequencing and molecular diagnostic results, if any.|Genomic sequencing results may be used for diagnosis and treatment of participants.
223848343|NCT05471232|OTHER|EHR-Based Network Model|EHR-based network will be created to predict psychiatric outcomes in youth with IDDs
223848344|NCT06528782|OTHER|Pecha Kucha method|The Pecha Kucha method will be prepared in the form of a presentation consisting of 20 slides each shown for 20 seconds. The Pecha Kucha presentation lasts 6 minutes and 40 seconds, and most slides present only images. This method is planned to be used in breastfeeding education as it will be more memorable because it contains more visual, auditory and short information.
223848345|NCT06919393|OTHER|"Triple negative adul B-cell ALL"|"Samples will be studied with conventional techniques to classify and define properly the disease: morphology, immunophenotype, immunohistochemistry (IHC), conventional Cytogenetic Fluorescence in Situ Hybridization (FISH) will be used when appropriate.~● Isolation of Mononuclear cells~The following research methodologies will be applied:~* Next Generation Sequencing~* Flow cytometry analysis of 3C-up B-ALL top three markers~* Gene expression profile analysis~* Copy number Alterations analysis~* In vitro studies"
223848346|NCT06919107|OTHER|Survey of athletes|Data will be collected on the number of injuries (muscle and tendon), lower limb injuries in the last 3 athletic seasons, as well as age, sex, weekly training load with and without AFT, weekly training frequency, completion of a complementary toning program and foot size.
223848347|NCT06614569|DRUG|AXO-AAV-GM2|Participants who received AXO-AAV-GM2 will be tracked in long term follow up
223848348|NCT06614686|DRUG|U87 autologous CAR T-cell|Treatment with U87 chimeric antigen receptor T-cell infusion.
223848349|NCT05854992|DRUG|Acute migraine treatment with any prescribed triptans|Sumatriptan, treximet (sumatriptan/naproxen combination), zolmitriptan, naratriptan, rizatriptan, almotriptan, eletriptan, and frovatriptan. No restriction on dose, frequency, duration, or delivery routes.
223848350|NCT05854992|DRUG|Standard of care management of acute migraine without triptans|Any standard of care management without triptans
223848351|NCT05965362|OTHER|Observational; No Interventions were given.|Observational; No Interventions were given.
223848352|NCT06615323|BEHAVIORAL|Polyphonic Lullaby Group|After discharge, mothers will be asked to play the Dandini Dandini Dastana lullaby by vocal artist Mircan Kaya, which they downloaded from the YouTube application, and listen to it from a distance of one meter (away from the baby's head to minimize radioactive effects) and by switching the phone to airplane mode just before sleep. In the event of active sleep (signs of sleep transition such as slowing down muscle movements and closing eyes), the polyphonic lullaby volume will be gradually reduced. The polyphonic lullaby will be played at a volume level of 55 decibels for the first 5 minutes after falling asleep, then reduced to 25 decibels and then turned off. In order to reduce the effects of confounding factors, mothers in the polyphonic lullaby group who use another assistive method (breastfeeding/rocking to sleep) to put their babies to sleep will be excluded from the study.
223848353|NCT06615323|OTHER|Pish Pish Sound Group|After discharge, mothers will be asked to turn on the Piş Piş sound downloaded from the YouTube application and listen to it from a distance of one meter (away from the baby's head to minimize radioactive effects) and by turning the phone to airplane mode just before sleep. In case of active sleep (signs of sleep transition such as slowing down muscle movements and closing eyes), the piş piş sound will be gradually reduced. The polyphonic lullaby played will be at a volume level of 55 decibels for the first 5 minutes after falling asleep, then reduced to 25 decibels and then turned off. In order to reduce the effect of confounding factors, mothers in the piş piş sound group who use another assistive method (breastfeeding/rocking to sleep) to put their babies to sleep will be excluded from the scope of the research.
223848354|NCT01981161|PROCEDURE|biological samples and clinical data|
223848355|NCT06687460|OTHER|Brief electrical stimulation|During the nerve micro-reconstruction surgery, electrical stimulation is given to the distal end of the damaged nerve for 30 minutes.
223848356|NCT06687460|OTHER|no nerve electrical stimulation|only nerve microsurgical reconstruction, no nerve electrical stimulation
223848357|NCT05513235|OTHER|Digital personal health record|The digital personal health record is a mobile application ('app') entitled Caremap. The mobile app will be downloaded and accessible by parents/caregivers to help coordinate care.
223848358|NCT06711471|DRUG|trifluridine/tipiracil (TAS-102), bevacizumab plus camrelizumab|Patients enrolled in this study will receive trifluridine/tipiracil in combination with bevacizumab and camrelizumab, with a treatment cycle of 14 days, until disease progression, death, intolerable toxicity, or other criteria for discontinuation of study treatment as specified in the protocol (whichever occurs first).
223848359|NCT06713044|DEVICE|Murottal Therapy Intervention Name: Murottal (Islamic verse recitation)|To evaluate whether murottal recitations can reduce postoperative pain intensity and lower interleukin 6 levels, which are indicative of inflammation.
223848360|NCT06713044|DEVICE|Classical Music Therapy Intervention Name: Classical Music Listening|To evaluate the impact of classical music on reducing postoperative pain intensity and interleukin 6 levels in the body, thereby managing inflammation.
223848361|NCT06713044|OTHER|Standard Care (in control arm)|To serve as a control group no intervention
223848362|NCT06137469|DRUG|Acetaminophen/SHR20004|SHR20004 was administered by titration, with all subjects starting on Day 4 with an initial dose of 0.03 mg/d of SHR20004 or placebo, with the dose being increased by 0.03 mg/d per week. The dose was increased to 0.15 mg/d and then maintained for 5 days.
223848363|NCT06137469|DRUG|Acetaminophen/Placebo|Placebo was administered by titration, with all subjects starting on Day 4 with an initial dose of 0.03 mg/d of SHR20004 or placebo, with the dose being increased by 0.03 mg/d per week. The dose was increased to 0.15 mg/d and then maintained for 5 days.
223848364|NCT06712979|PROCEDURE|Adapted Lee Silverman Method|Exercise protocol with 6 steps that the voice professionals adapted from Lee Silverman Method
223848365|NCT06712979|DEVICE|Lung volume recruitment technique - LVRT|The adapted Lee Silverman Method will have a addiction of LVRT technique. Lung inflation begins, reaching an optimal inspiratory peak of 30 cmH2O. From this point, the sound /HA/ begins to be emitted until the most comfortable low sound, where the emission should be maintained for as long as possible, making sure that this time is not less than 12 seconds, trying to emit a high and comfortable vocal intensity. When performing the emissions, the mouth should be kept wide open with the tongue, jaw and neck relaxed, repeating 5 emissions in 3 series. Between series, the participant will be instructed to drink 50 ml of water exactly as in the previous emissions.
223848366|NCT06911827|DRUG|QLP2117|Specified dose on specified days
223848367|NCT06911827|DRUG|QL2107|Specified dose on specified days
223848368|NCT04571333|DEVICE|Mi2000 Totally Implantable Cochlear Implant|During the surgery visit, the Mi2000 Cochlear Implant will be implanted according to the general surgical guidelines and the Mi2000 specific surgical guidelines under general anaesthesia.
223848369|NCT02799706|DRUG|Degarelix|a GnRH antagonist will be given for a predefined duration of 18, 24, or 36 months as per institution policy
223848370|NCT02799706|DRUG|approved GnRH agonist|A non-steroidal anti-androgen (e. g. flutamide, bicalutamide) will be given orally one week before the first injection of the GnRH agonist and will be continued for no longer than 8 weeks to protect against flare.Dose may vary due to availability of different brand names and pharmaceutical forms The start of antiandrogen must be registered as day 1 of treatment in the GnRH agonist arm.
223848371|NCT02799706|RADIATION|Radiotherapy|.As the study investigates the effect of two drugs given concomitantly to radiotherapy, all patients will be treated with the same treatment technique and target dose. The preferred treatment technique is intensity modulated radiotherapy (IMRT)
223848372|NCT04990674|BEHAVIORAL|REMOTION|REMOTION is an internet-based program focusing on emotion regulation and aimed at reducing patient symptom severity and improving emotion regulation. It consists of six modules and the structure is based on the extended process model of emotion regulation by Gross (2015). The intervention is currently being studied in an outpatient psychotherapy setting (Bielinski et al., 2020).
223848373|NCT04990674|BEHAVIORAL|TAU|Treatment as usual (TAU), refers to standard treatment in an acute inpatient care setting at the Universitäre Psychiatrische Dienste Bern. This treatment includes different standard inpatient psychiatric care components (integrative psychiatric care).
223848374|NCT05798104|BEHAVIORAL|Collaborative nurse-pharmacist counseling|At the interventional appointment, study participants will first complete a modified Okere-Reiner pre-survey assessing patient perceptions of confidence and knowledge in their biologic therapy. Subsequently, a pharmacist will perform a refresher medication counseling, detailing indication, dosing, storage, and side effects. Upon completion of this counseling, an infusion nurse will then provide education demonstrating proper self-administration to the patient. The patient will then self-administer the medication with coaching and direct observation from the nurse. Afterwards, the patient will complete the Okere-Reiner post-survey to determine the effectiveness of the counseling session at improving perceived confidence and knowledge. Patients will complete both the pre-and post-surveys with direct entry to REDCap on an institution iPad during the study intervention visit.
223848375|NCT00867347|PROCEDURE|therapeutic conventional surgery|Patients undergo radical cystectomy
223848376|NCT00867347|RADIATION|radiation therapy|Patients undergo radiotherapy
223848377|NCT00797862|DRUG|Amlodipine|Amlodipine (5 mg and 10 mg) was provided as capsules taken orally once daily.
223848378|NCT00797862|DRUG|hydrochlorothiazide|Hydrochlorothiazide 12.5 mg capsules were taken orally once daily
223848379|NCT00797862|DRUG|Aliskiren|Aliskiren 150 mg and aliskiren 300 mg were provided as film-coated tablets, taken orally once daily.
223848380|NCT05753293|OTHER|breathing exercise|"Buteyko breathing technique developed to control hyperventilation and anxiety which leads to shortness of breath. It uses series of exercises to teach patients to breathe less deeply and less rapidly /Bhastrika Bellow Breathing is diaphragmatic breathing - deep breathing involving the diaphragm rather than the accessory muscles. Regulated pranayama exercises require inhalation, maintaining isometric contraction of respiratory muscles and forceful expiration. These techniques will strengthen respiratory muscles"
223848381|NCT01693094|BEHAVIORAL|Decision Aid|"Cohort I will be managed with a decision aid (henceforth DA), and Cohort II will be managed without one. The patients in Cohort I will receive the DA, which they can complete in a separate room and take home. The decision aids include information on the disease/condition, treatment options, benefits, risks, scientific uncertainties, and probabilities of potential outcomes tailored to the patient's health risks factors. Additionally, it includes values clarifications such as describing outcomes in functional terms, asking patients to consider which benefits and risks matter most to them, and guidance in the steps of decision making and discussing their decision with family/friends. It is interactive and dynamic, helping patients clarify their preferences and come to a decision that feels best to them."
223848382|NCT04167709|OTHER|Education in clinical competence in detecting signs of postpartum depression in immigrant mothers|Groupbased educational intervention aimed at nurses in the Child Health Services in strengthening clinical competence in detecting signs of postpartum depression in non-native-speaking immigrant mothers
223848383|NCT06628817|RADIATION|The Intensive Care Bundle with Mortality Reduction|a continuous automated medical quality monitoring and feedback system on the online platform, self-feedback and teamwork based on video conferencing, multidisciplinary online education, offline on-site supervision, and standardized intervention in the behavior of medical actors in the process of stroke treatment.
223848384|NCT03127358|DEVICE|AiCure|Smartphone App
223848385|NCT03127358|DEVICE|AiCure with gamification|Smartphone App with gaming.
223848386|NCT00409708|DRUG|Extended Release Methylphenidate (Ritalin LA ) plus Behavior Therapy|
223848387|NCT00409708|BEHAVIORAL|Behavior Therapy|
223848388|NCT00785772|DRUG|Gabapentin|100-200mg once a day
223848389|NCT00785772|DRUG|Gabapentin|200-500mg once a day
223848390|NCT00785772|DRUG|Gabapentin|400-1000mg (200-500 mg twice a day)
223848391|NCT04632368|BEHAVIORAL|Transcendental Meditation|TM, a mind-body intervention that can reduce sympathetic arousal and promote a state of relaxation and calm, will be offered to HCPs dealing with COVID-19 pandemic
223848392|NCT04477538|OTHER|Post-mastectomy breast reconstruction physical well-being survey|-The survey will ascertain: function status (BREAST Q - Physical Well Being Module and PROMIS upper extremity function), former interaction with physical or occupational therapy, amount of narcotics taken weekly due to chest/neck/breast pain, amount of Tylenol or similar anti-inflammatories taken weekly due to chest/neck/breast pain, and amount of muscle relaxants taken weekly due to chest/neck/breast pain.
223848393|NCT00328393|DRUG|Pioglitazone|45 mg 8 weeks
223848394|NCT00328393|DRUG|Placebo|Placebo
223848395|NCT01306669|BIOLOGICAL|Trivalent influenza vaccine|single dose of 0.5ml of Trivalent influenza vaccine for season will be administered into deltoid muscle of non-dominant arm
223848396|NCT01306669|BIOLOGICAL|Normal saline|Single dose of 0.5ml of normal saline will be administered into deltoid muscle of non-dominant arm
223848397|NCT03872297|DIETARY_SUPPLEMENT|Placebo supplement|"Consumption of a non active food complement during 3 months.~Tests performed :~* 2 blood tests :~* 2 body composition analysis via Dual-energy X-ray absorptiometry (DXA)~* 2 stool collections The first one of these analysis was performed at the beginning, second at the end of the study."
223848398|NCT03872297|DIETARY_SUPPLEMENT|Naticol supplement|"Consumption of the active food complement during 3 months containing Naticol.~Tests performed :~* 2 blood tests :~* 2 body composition analysis via Dual-energy X-ray absorptiometry (DXA)~* 2 stool collections The first one of these analysis was performed at the beginning, second at the end of the study."
223848399|NCT05270824|COMBINATION_PRODUCT|radical surgery after neoadjuvant immunotherapy|A total or distal gastrectomy with D2 lymph node dissection was done depending on the tumor location after neoadjuvant immunotherapy.
223848400|NCT05270824|COMBINATION_PRODUCT|radical surgery after neoadjuvant chemotherapy|A total or distal gastrectomy with D2 lymph node dissection was done depending on the tumor location after neoadjuvant immunotherapy.
224265243|NCT01158053|DEVICE|FFR and VH-IVUS|"* Stable Angina(SA), Unstable Angina(UA),Non ST-segment Elevation Myocardial Infarction(NSTEMI) or ST-segment Elevation Myocardial Infarction(STEMI) \>48hrs scheduled for cardiac catheterization ± PCI. All patient level inclusion and no exclusion criteria are met Signed Informed Consent~* No PCI or successful and uncomplicated PCI of all non study lesions. One or more study lesions identified.~All lesion level inclusion criteria and no exclusion criteria are met.~* FFR followed by VH-IVUS of study lesion(s)~* Any additional PCI based on routine clinical practice and FFR/IVUS data?~* If Yes: Final IVUS with VH imaging, Clinical follow-up at hospital discharge, 30 days, 6 months, and then yearly for 3 years~* If No: Clinical follow-up at hospital discharge, 30 days, 6 months, and then yearly for 3 years"
224265244|NCT01158053|DEVICE|IVUS and FFR|
224265245|NCT06414200|OTHER|multidisciplinary structured tailored made nutritional advice|The goal is a structured follow-up after discharge. Parents need to fill in questionnaires about eating behavior en feeding difficulties about their child. They also need to fill in a questionnaire about their stress. Together with their nutritional intake (3-days food diary) and growth a tailor-made nutritional plan is made. All the information I showed in a dashboard and discussed it with their dietitian. Who discusses this information in a multi-disciplinary team (pediatrician, psychologist and if needed a speech therapist).
224265246|NCT02086474|DRUG|Hyaluronan|Intra-articular injection
224265247|NCT02086474|DRUG|Bupivacaine|Extra-capsular injection
224265248|NCT06259630|DRUG|Nicotine|Participant receives oral dose of nicotine
224265249|NCT06259630|DRUG|Placebo oral capsule|Participant receives oral dose of placebo
224265250|NCT06179173|OTHER|HIIT-RCE|High-intensity interval training on semi-recumbent cycle ergometer
223848401|NCT03211598|PROCEDURE|TACE with Surefire|Subjects that consent to the study will receive their TACE procedure through the Surefire Infusion System
223848402|NCT04510337|DRUG|standard rocuronium dose|0.6 mg/kg rocuronium during induction of anesthesia
223848403|NCT04510337|DRUG|Magnesium sulfate|50 mg/kg magnesium sulphate added to 0.40 mg/kg rocuronium
223848404|NCT01474538|DRUG|Insulin Lispro|Insulin lispro (100 U/mL) administered by CSII pump
223848405|NCT01474538|DRUG|Insulin Aspart|Insulin aspart (100 U/mL) administered by CSII pump
223848406|NCT06282835|DRUG|Eravacycline Injection|Eravacycline at the recommended dose and administration method according to the instructions: 1 mg/kg intravenous administration, every 12 hours. The intravenous infusion duration is approximately 60 minutes. For patients with severe liver impairment (Child-Pugh class C), administer 1 mg/kg of this product every 12 hours on the first day, followed by 1 mg/kg every 24 hours starting from the second day.
223848407|NCT00009685|DRUG|VRC4302|
223848408|NCT04285996|PROCEDURE|PET Scan|
223848409|NCT03095911|OTHER|News items with spin|Interpretation of news items with spin
223848410|NCT03095911|OTHER|News items without spin|Interpretation of news items without spin
223848411|NCT01601314|DRUG|Magnesium Sulfate|"At the beginning of the neurosurgery, the subjects are going to receive one 4gr bolus in Sodium Chloride 100 mL, lasting 20 minutes, intravenously.~After that, a intravenously perfusion of Magnesium Sulfate 20 gr, in Sodium Chloride 1000 mL, lasting 24 hours, will be started."
223848412|NCT01601314|OTHER|Sodium Chloride|"At the beginning of the neurosurgery, the subjects are going to receive a bolus of Sodium Chloride 100 mL, lasting 20 minutes, intravenously.~After that, a intravenously perfusion of Sodium Chloride 1000 mL, lasting 24 hours, will be started."
223848413|NCT04372992|OTHER|Timing of stoma closure|Defining the best timing of stoma closure in relation to adjuvant therapy compliance
223848414|NCT01151254|DRUG|Isoflurane/sevoflurane|Volatile for sedation in the CVICU while intubated
223848415|NCT01151254|OTHER|Propofol|Propofol for sedation in the CVICU
223848416|NCT06435572|OTHER|Suction|Each patient will be evaluated as both the experimental and control group. In the study, open suction applied to the patient will be evaluated as control, and closed suction will be considered as the experimental group. The first suction of the same patient during the day will be done as open suction, and the second suction will be done as closed suction.
223848417|NCT02416674|PROCEDURE|abdominal wall transplantation|transfer of abdominal wall tissues from an organ donor to a pacient with a large abdominal wall defect.
223848418|NCT02416674|DRUG|Immunosuppressive Agents|Recipients of abdominal wall transplants will need to receive global immunosuppression with tacrolimus, mycophenolate mofetil and prednisone.
223848419|NCT01501929|DRUG|Metoprolol succinate|The subject will be started on metoprolol succinate (Toprol XL) 100-300mg daily, which he or she will continue for a period of 12 weeks. Following the 12-week treatment period, the procedures listed below will be performed. After completion of the study procedures, the medication will be discontinued.
223848420|NCT01501929|DRUG|Nebivolol|The subject will be started on nebivolol (Bystolic) 5-20mg daily, which he or she will continue for a period of 12 weeks. Following the 12-week treatment period, the procedures listed below will be performed. After completion of the study procedures, the medication will be discontinued.
224265251|NCT06179173|OTHER|Conventional physiotherapy|Conventional physiotherapy
224265252|NCT03166527|DRUG|Immune Globulin 10% Intravenous Solution|standard Immune lobulin 10% intravenous solution infusion at standard and high infusion rates.
224265253|NCT03498560|DEVICE|PSG|PSG data to be collected on the night before surgery to establish level of preexisting sleep disturbance.
224265254|NCT05204420|PROCEDURE|Gastric wide local excision for bleeding mass|Laparoscopic partial gastrectomy for gastric submucosal mass
224265255|NCT06431776|DRUG|Molgramostim|Molgramostim nebulizer solution will be administered once daily using a proprietary nebulizer optimized for the delivery of high molecular weight biologic compounds.
224265256|NCT02178891|DEVICE|extra short implant|
224265257|NCT02195544|DRUG|Synvisc®|
224265258|NCT02392689|OTHER|Procalcitonin|Procalcitonin guided antibiotic therapy
224265259|NCT01507662|BEHAVIORAL|Bone Mineral Density Result Letter and Bone Health Brochure|Letter mailed to patient to include - Date of DXA, T-score, impression, 10 year major fracture risk with visual depiction of risk, basic bone health guidelines, instructions to follow-up with their healthcare provider. The brochure will include information on osteoporosis, calcium, vitamin D, medicines, exercise, tobacco and alcohol cessation and where to find more information.
224265260|NCT04008680|OTHER|EQ-5D-5L survey internal consistency|To see how increasing the number of questionnaires affects the internal consistency of the EQ-5D-5L.
224265261|NCT05341180|DRUG|Polyethylene Glycol|Patients will be advised Anobliss (lidocaine with nifedipine) ointment for local application in the anal canal for one month for relief of pain and anal sphincter spasm. Polyethylene glycol syrup at a dose of 15-30 ml will be used for 2 weeks for relief of acute constipation. Patients will be assessed at 1 week and 1 month and evaluated for primary and secondary outcomes.
224265262|NCT05341180|DRUG|Isabgol + Lactulose|Patients will be advised Anobliss (lidocaine with nifedipine) ointment for local application in the anal canal for one month for relief of pain and anal sphincter spasm. Isabgol husk at a dose of 2 teaspoons in 200 ml of warm water before bedtime and 30 ml of syrup lactulose at bedtime will be used for 2 weeks for relief of acute constipation. Patients will be assessed at 1 week and 1 month and evaluated for primary and secondary outcomes.
224265263|NCT02666482|BEHAVIORAL|Stop Smoking SF Web App - baseline|Smoking cessation web app in Spanish and English. Accessible online at no charge.
224265264|NCT01627431|DRUG|Acetylsalicylic acid|100 mg once per day
224265265|NCT01627431|DRUG|Clopidogrel|75 mg once per day
224265266|NCT03587129|DRUG|Apatinib|An anti-tumor Targeted drug
223848421|NCT01501929|PROCEDURE|Non-invasive measurement of Cardiac Output (CO)|Cardiac Output (CO) will be measured non-invasively at rest and during exercise by thoracic electrical bioimpedance. Stroke volume will be derived from change in impedance/time measured during electrical systole. Cardiac output will be determined as the product of stroke volume and heart rate.
223848422|NCT01501929|PROCEDURE|Endothelial cell collection|We will collect endothelial cells from a superficial vein, usually in the arm. Following insertion of a peripheral intravenous (IV) catheter, we will collect cells from the inner lining of the vein using a thin, flexible J-tipped wire. The wire will be inserted through the IV into the vein and then removed, along with a sampling of endothelial cells. The cells collected will be processed and stained for several proteins involved in endothelial cell function, using immunofluorescent technique.
223848423|NCT01501929|PROCEDURE|Microvascular perfusion assessment using Definity|Using high-resolution ultrasound, we will measure skeletal muscle blood flow during infusion of a solution containing the octafluoropropane microbubble contrast agent, Definity. The solution will be a dilution of 1 vial of Definity to 30 cc of normal saline. The ultrasound probe will be placed over the forearm to obtain images while octafluoropropane microbubbles (Definity) are infused intravenously at the rate of 0.20 to 0.27 ml/min, not to exceed a maximum dose of 2 vials per study subject per day or visit. The microvascular perfusion assessment using Definity be performed at rest as well as during slow and fast handgrip exercises.
223848424|NCT03239925|RADIATION|Electromagnetic field of cell phone in ''on'' mode.|In experimental group, participants would hold a cell phone to their left ears in their left hands, in 'on' mode, for 15 min, and that they would thus be exposed to a 900-1800 MHz magnetic field (EMW) for 15 min.
223848425|NCT03239925|RADIATION|Electromagnetic field of cell phone in 'off' mode.|In control group, participants would hold a cell phone to their left ears in their left hands for 15 min in 'off' mode.
223848426|NCT02873884|BEHAVIORAL|Case-management|
223848427|NCT00354094|DRUG|[S,S]-Reboxetine|
223848428|NCT05507281|PROCEDURE|Ultrasound-guided Erector Spinae Plane Block|ultrasound-guided ipsilateral Erector Spinae Plane Block (20 ml (19ml bupivacaine 0.25% plus 1ml dexamethasone 4mg)).
223848429|NCT05507281|PROCEDURE|Retrolaminar Block|ultrasound-guided ipsilateral Retrolaminar Block (20 ml (19ml bupivacaine 0.25% plus 1ml dexamethasone 4mg)).
223848430|NCT05507281|PROCEDURE|Control|General anesthesia
223848431|NCT00931229|DRUG|entecavir|All eligible patients will receive rituximab-CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) chemotherapy according to current treatment guidelines. The primary endpoint of this study is the incidence of HBV reactivation, defined by a greater than 10-fold increase, compared with previous nadir levels, of HBV DNA during rituximab-CHOP chemotherapy and within 1 year after completion of the last course of rituximab-CHOP chemotherapy. Patients who have HBV reactivation during the study period will receive free entecavir treatment, one of the standard treatment for chronic hepatitis B, for 48 weeks.
224265267|NCT05121194|BEHAVIORAL|Cognitive Behaviour Therapy|Group-based cognitive behaviour therapy (CBT) is an evidence-based treatment that allows service providers to interact with high volumes of individuals who need mental health support. CBT is the most well-researched and well-recognized of all psychotherapies, and is often considered the gold-standard in psychotherapy treatment. While CBT has shown efficacy in the treatment of a range of mental and substance use disorders, it has also been shown to be useful in building resiliency, being used as a tool to better cope during stressful life situations even among individuals who do not have an existing mental illness. Furthermore, research suggests that gains achieved in mental health during CBT are maintained long after treatment completion.
224265268|NCT00197873|DIETARY_SUPPLEMENT|Lactobacillus Rhamnosus supplementation|Lactophilus supplementation is administered during chemotherapy.
224265269|NCT00197873|OTHER|Placebo administration.|Placebo is administered during chemotherapy.
224265270|NCT04541173|OTHER|Y-90 TARE|"This plan will involve treating the predominant liver lesions with segment Y-90 TARE using predetermined dosimetry, while keeping FLR equal or greater than 40% (FLR is estimated by excluding the liver volume of Y-90 infused distribution).~The maximal amount of Y-90 TARE treatment will be limited to only one lobe of the liver if segmental Y-90 TARE is not possible to treat the predominant lesion. Since segmental Y-90 TARE may result in less long term liver damage compared to lobal Y-90 TARE, segmental Y-90 TARE treatment is preferred to lobar Y-90 TARE if segmental Y-90 TARE treatment is able to treat all blood supply to the predominant lesion or lesion with vascular invasion to preserve liver function. For segmental treatment, a minimum tumor dose of 190 Gy should be used for glass microspheres and 120 Gy for resin microspheres. For lobar treatment, a minimum dose of 100 Gy should be used for resin microspheres."
224265271|NCT04541173|DRUG|Atezolizumab|Atezolizumab 1200 mg will be delivered as an IV infusion on Day 1 of each cycle (every 3 weeks). The initial dose will be delivered over 60 (± 15) minutes and if tolerated subsequent infusions may be given over 30 minutes.
224265272|NCT04541173|DRUG|Bevacizumab|Bevacizumab 15 mg/kg will be delivered as an IV infusion on Day 1 of each 3 week cycle.The initial dose will be delivered over 90 minutes (±15 minutes) and if tolerated subsequent infusions may be given over 60 minutes
223848432|NCT02851030|BEHAVIORAL|Move, Play, Learn!|Participants will attend a 4 hour workshop at the beginning of the intervention and the midpoint, covering project information, physical activity for young children, and distribution of project materials. Teachers will focus on one area of their child care day for 2 weeks each: indoor structured PA, outdoor structured PA, transitions between activities, and circle time. Participants will receive an email newsletter introducing the topic and will implement short (10 minutes) classroom activities. Teachers will also be educated about teacher PA practices, focusing on 1 behavior during each segment. Research staff will contact the teachers weekly to provide technical assistance, help teachers troubleshoot any issues that participants have with the activities, and provide encouragement.
223848433|NCT04813393|OTHER|Questionnaire Development|To evaluate psychometric the properties of the Compliance of Parents of Children with Cerebral Palsy to Home Program Assesment Questionnaire (CPHP-Q), a caregiver-report for adherence and frequency of home program implementation of parents of children with Cerebral Palsy.
223848434|NCT03120676|DRUG|Atezolizumab|All patients will receive atezolizumab 1200 mg via IV infusion on D1 of each 21-day cycle.
223848435|NCT00814853|DEVICE|NAVA (Extubation readiness testing failures)|Patients who fail the ERT will be place in the mode of ventilation NAVA.
223848436|NCT04585347|DRUG|ALZ-801 170 mg Fasting|
223848437|NCT04585347|DRUG|ALZ-801 205 mg Fasting|
223848438|NCT04585347|DRUG|ALZ-801 205 mg After Food|
223848439|NCT04585347|DRUG|ALZ-801 342 mg Fasting|
223848440|NCT00926393|DRUG|Quetiapine Immediate Release|Oral, 3 tablets daily: (2 x 25 mg + 1 x 50 mg) at one time each day
223848441|NCT00926393|DRUG|Quetiapine Extended Release|Oral, 3 tablets daily: (2 x 25 mg + 1 x 50 mg) at one time each day
223848442|NCT00738075|DEVICE|Auditory cue|When device recognizes automatically freezing episode it will generate auditory cue
223848443|NCT02271048|DEVICE|Remote ultrasonography interpretation using the smartphone|The reviewers interpreted the ultrasonography images on the smartphone transmitted from the ultrasound machine in real time
223848444|NCT00326027|DRUG|Pantoprazole|Efficacy of Pantoprazole
223848445|NCT03045692|DIAGNOSTIC_TEST|kidney function assessment by 4 hour creatinine clearance|4 hour creatinine clearance is used to decide colistin maintenance dosage.
223848446|NCT03045692|DIAGNOSTIC_TEST|kidney function assessment by creatinine based eGFR|creatinine based eGFR (which is not revised value with standardized body surface area, that is, 1.73m2) are used to decide colistin maintenance dosage.
223848447|NCT05496049|DEVICE|Triburter|Patients will have to repeat 50 ventilations (start with 20 repetitions in the first week, 30 in the second, 40 in the four week, and 50 in the last week) five days per day for four weeks. And they have to fill a calendar to ensurance the intervention.
223848448|NCT05496049|DEVICE|Incentive spirometry|They will repeat 10 ventilations per 5 five times a day. Both interventions will be performed for 4 weeks. They have to fill a calendar to ensurance the intervention.
223848449|NCT04163666|BEHAVIORAL|Mirror therapy|The intervention will take place at the home of the participant for 6 weeks (30 days), during 60-minute sessions, 30 of which will be for mirror therapy, while the remaining 30 minutes will be for task-oriented motor learning
223848450|NCT04163666|BEHAVIORAL|Cognitive therapeutic exercise|The intervention will take place at the home of the participant for 6 weeks (30 days), during 60-minute sessions, 30 of which will be for cognoscitive therapeutic exercise, while the remaining 30 minutes will be for task-oriented motor learning
223848451|NCT00174720|DRUG|Ciclesonide (XRP1526)|
223848452|NCT00353067|DRUG|veliflapon (DG-031)|
223848453|NCT03315403|DIAGNOSTIC_TEST|LytA targeted quantitative polymerase chain reaction (qPCR)|LytA qPCR and cultures will be performed on samples of the upper respiratory tract (nasopahrynx, oropharynx, saliva, sputum if available)
223848454|NCT02870543|DRUG|Phytolacca decandra|Treatment of bruxism
223848455|NCT02870543|DRUG|Melissa officinalis|Treatment of bruxism
223848456|NCT02870543|DRUG|Phyt.decandra + Melissa offic.|Treatment of bruxism
223848457|NCT06021574|DRUG|VDJ001|a novel recombinant humanized anti-interleukin-6 receptor monoclonal antibody
223848458|NCT06021574|DRUG|Placebo|Placebo
223848459|NCT05505929|DEVICE|Biofreedom Ultra|The BioFreedomTM Ultra CoCr DCS is a combination product consisting of two key components: the cobalt chromium stent platform coated abluminally with the active ingredient BA9TM (polymer and carrier free) and the delivery system.
223848460|NCT00716664|OTHER|A treatment series of gentle joint and muscle movements|Undertaken by a physiotherapist, weekly, for six weeks
223848461|NCT00716664|OTHER|Control group measurements|The control group are measured using the same outcome measures at the same time intervals, but receive no active intervention
223848462|NCT03152799|PROCEDURE|RIPC Remote Ischaemic Pre-Conditioning|intermittent limb ischaemia via a peripheral blood pressure cuff inflation and deflation
223848463|NCT03152799|OTHER|Sham Control|intermittent peripheral blood pressure cuff inflation and deflation which does not induce a protective cellular response
223848464|NCT00333541|BEHAVIORAL|Using internet/E-mail for follow-up|follow-up via email link to survey
223848465|NCT02793297|OTHER|refined wheat crisp bread|Refined wheat crisp bread (52 g) was served as part of a regular breakfast together with margarine (15 g), cheese (20 mg), coffee/tea (150 mL), and juice (150 mL). The amount of crisp bread was adjusted so that all arms provided a similar amount of available carbohydrate (35 g).
223848466|NCT02793297|OTHER|sourdough fermented rye crisp bread|Sourdough fermented rye crisp bread (59.4 g) was served as part of a regular breakfast together with margarine (15 g), cheese (20 mg), coffee/tea (150 mL), and juice (150 mL). The amount of crisp bread was adjusted so that all arms provided a similar amount of available carbohydrate (35 g).
223848467|NCT02793297|OTHER|unfermented rye crisp bread|Unfermented rye crisp bread (59.8 g) was served as part of a regular breakfast together with margarine (15 g), cheese (20 mg), coffee/tea (150 mL), and juice (150 mL). The amount of crisp bread was adjusted so that all arms provided a similar amount of available carbohydrate (35 g).
223848468|NCT02551354|DEVICE|Portable video pupillometer|Portable video pupillometer measures pupil diameter (PD) in patient during obstetrical labor
223848469|NCT06106659|DEVICE|Mini Midline|"The tube was placed in the upper arm in the test group and in the forearm in the control group. The veins were selected according to anatomical criteria (vein diameter and depth), and the puncture site was protected with a sterile cavity towel. The cannulation nurse wore sterile gloves and injected local anesthesia (1 mL of lidocaine) before venipuncture. Venipuncture was always performed using real-time ultrasound-guided visualization of the vein-guiding needle using an out-of-plane approach, and once the tip of the needle was visualized within the vein and the blood flowed back through the needle, a guidewire was introduced and the needle was removed. After the needle is removed, the cannula is advanced into the vein, the guidewire is removed, and the cannula is attached to an extension cord closed with a needleless connector."
223848470|NCT01935258|OTHER|Psychosomatic therapy|Psychosomatic therapy delivered by a psychosomatic therapist, consists of a combination of information and education delivery, relaxation therapy and mindfulness, cognitive approaches and activating therapy. This multi-component approach is captured into a protocol in which therapists are able to modify the treatment in order to deliver a tailor-made treatment for patients with MUS.
223848471|NCT01935258|OTHER|care as usual|usual care of the general practitioner
223848472|NCT03997006|DRUG|IV Aminophylline|IV Aminophylline (100 mg/8h)
223848473|NCT03997006|DRUG|IV Neostigmine Methylsulfate + Atropine Sulphate|IV Neostigmine/Atropine mixture (20 μg/kg Neostigmine + 10 μg/kg Atropine)/8h
223848474|NCT00415675|PROCEDURE|Motion CT Scans|A total of up to 12 scanning sessions used to understand how the tumor and other organs move while breathing.
223848475|NCT06630416|PROCEDURE|Biospecimen Collection|Undergo blood and urine sample collection
223848476|NCT06630416|PROCEDURE|Computed Tomography|Undergo CT
223848477|NCT06630416|DRUG|Pemetrexed|Given IV
223848478|NCT02611648|OTHER|Double HLD|Standard high level disinfectant (metricide ortho-phthalaldehyde) with an additional exposure time to disinfect
223848479|NCT02611648|OTHER|HLD/ETO|Standard high level disinfectant (metricide ortho-phthalaldehyde) followed by ethylene oxide
223848480|NCT06628492|DEVICE|stainless steel printed surgical guide|the patient will wear the stainless steel surgical guide for the insertion of one implant
223848481|NCT06628492|DEVICE|resin printed surgical guide|the patient will wear the resin surgical guide for insertion of adjacent another implant implant
223848482|NCT00192192|BIOLOGICAL|CAIV-T|
223848483|NCT04841486|OTHER|Data collection|evaluation of women's stress
223848484|NCT04488653|DIETARY_SUPPLEMENT|Oligopin®|French Maritime Pine Bark Extract - 100mg/day
223848485|NCT04488653|DIETARY_SUPPLEMENT|Placebo|Maltodextrin
223848486|NCT04185519|DEVICE|AI (model)|The process of the experiment (brief describe) This is a randomized, double-blind controlled trial to compare AI (model) with the physician on prescribing ESA dose to maintain hemoglobin near the therapeutic target, 11g/dl. A blind check by another physician for the prescriptions from both physician and AI (model) is arranged for safety purpose. Another physician will fail the prescription if the prescribed ESA dose, by his/her experience, will lead the participant's hemoglobin outside the range between 9 and 13 g/dl. Once the failed rate by AI is higher than the physician is 5%, , the study will be terminated. There will be three periods, namely ry 3 months.
223848487|NCT03361592|PROCEDURE|Spinal Manipulative Therapy|Lumbar (SMT) was performed using Diversified techniques, aiming to correct vertebral dysfunctional lumbar segments. Participants were asked to lay down prone on, to perform spinal motion palpation analysis was in order to evaluate the presence of dysfunction in vertebral segments of lumbar spine.
223848488|NCT03361592|PROCEDURE|SHAM|"The SHAM (pre-load positioning SMT) was performed with participant body positioning in the lateral position, as the SMT intervention. The doctor followed the participant through the same position of (SMT) intervention, using the maintenance of set-up position, but no manipulative thrust was delivered. The therapist applied minimal pressure and slid their hands across the skin to mimic the manipulative trust. The position was maintained 30 seconds on each side, and none of force or researcher body weight were putted in this procedure, only minimal pressure common to stabilize the set up position of (SMT)."
223848489|NCT05095623|OTHER|Natural History Observation|This is a natural history study.
223848490|NCT05349864|DRUG|PF-07284890 Treatment A|PF-07284890 tablet by mouth while fasting
223848491|NCT05349864|DRUG|PF-07284890 Treatment B|PF-07284890 tablet after low fat meal
223848492|NCT05349864|DRUG|PF-07284890 Treatment C|PF-07284890 tablet after high fat meal
223848493|NCT02333630|OTHER|AsthmaCare mobile health application|Personalized, interactive mobile health application designed to send daily medication reminders and assist with self management
223848494|NCT02333630|OTHER|Asthma education|A website with links to written asthma education and videos
223848495|NCT05963776|DEVICE|spirometry|pulmonary function tests using spirometry
223848496|NCT03613103|DEVICE|Video laryngoscopy|Intubation with videolaryngoscopy with highly curved blade
223848497|NCT03613103|DEVICE|Direct laryngoscopy|Intubation with direct laryngoscopy with macintosh blade
223848498|NCT04439513|DEVICE|Hemostasis|Compression device to achieve hemostasis.
223848499|NCT02416635|OTHER|Flow cytometry (FCM)|Use FCM to test PBMCs/CTCs from volunteers/patients.
223848500|NCT02416635|OTHER|RT-PCR|Use RT-PCR to test PBMCs/CTCs from volunteers/patients.
223848501|NCT03425292|DRUG|Temozolomide|concomitant and 5-day adjuvant temozolomide
223848502|NCT03425292|RADIATION|conformal brain radiation therapy|standard radiation therapy for newly diagnosed glioblastoma
223848503|NCT03425292|DRUG|Nivolumab|nivolumab 240 mg IV every 2 weeks for the first 28-day cycle, then option to modify to 480 mg IV every 4 weeks
223848504|NCT03425292|DRUG|Ipilimumab|ipilimumab 1 mg/kg IV every 6 weeks (or every 8 weeks when nivolumab is administered every 4 weeks) for a maximum of 4 doses
223848505|NCT03425292|DRUG|Bevacizumab|bevacizumab 5 mg/kg IV every 2 weeks (up to 10 mg/kg at treating physician's discretion)
224265273|NCT05366231|DRUG|Kesuting syrup|"Conventional treatment + Kesuting Syrup, take orally, 20 ml once, three times a day.Conventional treatment refer to Diagnosis and Treatment Protocol for COVID-19 (Trial Version 9 or later). Except for the test drugs, during the observation period, it is prohibited to use other Chinese and Western medicines for cough and phlegm elimination for treatment. If combined use is required, it shall be recorded truthfully."
224265274|NCT05366231|DRUG|LianHuaQingWen Granules|"Conventional treatment + LianHuaQingWen Granules, orally, 1 bag at a time, 3 times a day.Conventional treatment refer to Diagnosis and Treatment Protocol for COVID-19 (Trial Version 9 or later).Except for the test drugs, during the observation period, it is prohibited to use other Chinese and Western medicines for cough and phlegm elimination for treatment. If combined use is required, it shall be recorded truthfully."
224265275|NCT04805840|DEVICE|CoV-SCAN rapid COVID-19 antigen test|SARS-CoV-2 rapid antigen screening test
224265276|NCT03985657|DEVICE|CPAP|Continuous positive airway pressure (CPAP). Room air at pressures between 6-8 centimeters of water (cmH2O) delivered via heated humidified tubing and a nasal mask.
224265277|NCT05373576|BEHAVIORAL|TACHIDINO|"TACHIDINO is based on two principles a) selective stimulation of a cerebral hemisphere and specific reading strategies, and b) the training of selective visuospatial attention, as well as the perception of rapid movement and the visual characteristics of words even in the presence of so-called visual crowding or crowding, an automatic effect of our perceptual system that leads to obfuscation of the visual areas surrounding the object to be analyzed, to make its vision clearer (as suggested by the Magnocellular theory of dyslexia; Stein et al., 2019)."
224265278|NCT05423873|OTHER|Gentle Cleansing Lotion, Revision Skincare|Gentle cleansing lotion to be used by study participants twice daily
224265279|NCT00192257|BIOLOGICAL|CAIV-T and TIV|
224265280|NCT00028925|BIOLOGICAL|filgrastim|
224265281|NCT00028925|DRUG|carboplatin|
224265282|NCT00028925|DRUG|topotecan hydrochloride|
224265283|NCT00028925|RADIATION|WBRT|
224265284|NCT03449225|OTHER|Computer-Aided Genetic Education Module|Subjects will be provided with an electronic device to view Computer-Aided Genetic Education Module (CAGEM) software. This is an interactive software designed to provide subjects with tailored information regarding prenatal screening options for carrier status and aneuploidy.
224265285|NCT04348422|DIAGNOSTIC_TEST|COVID-19 RT-PCR|Nasoropharyngeal swabs for COVID-19 RT-PCR - initial screening/retest +every 10 days in 100 days followup period
224265286|NCT04348422|DIAGNOSTIC_TEST|COVID-19 Serology|Blood samples for COVID-19 serology - initial screening/retest +every 10 days in 100 days followup period Each sample will be examined by 4-6 serology kits.
224265287|NCT04348422|OTHER|Symptoms questionnare|Symptoms questionnaire which will be filled by participant on initial screening/retest visit + every 10 days in 100 days followup period
224265288|NCT01710722|DRUG|caffeine and ephedrine|Caffeine 200 mg tablets and ephedrine HCl 25 mg tablets three times a day with placebo leptin A-200 subcutaneously once daily.
224265289|NCT01710722|DRUG|Leptin A|Leptin A-200 20 mg subcutaneously once daily and placebo tablets of caffeine and ephedrine three times a day.
223848506|NCT03425292|DRUG|5-day Temozolomide|150 mg/m\^2 oral, once daily on Days 1-5 of each 28-day cycle (stepwise titration every cycle up to 200 mg/m\^2 permitted)
223848507|NCT03425292|DRUG|5-day Temozolomide|100 mg/m\^2 oral, once daily on Days 2-6 of each 6 week course (stepwise titration every cycle up to 200 mg/m\^2 permitted)
223848508|NCT03425292|DRUG|Lomustine|100 mg/m\^2 oral, on Day 1 of each 6 week course
223848509|NCT03425292|DRUG|Nivolumab monotherapy|nivolumab 300 mg IV every 2 weeks for the first 28-day cycle, then option to modify to 480 mg IV every 4 weeks
223848510|NCT03748732|PROCEDURE|sclerectomy|scleral flap
223848511|NCT00984282|DRUG|Sorafenib (Nexavar, BAY43-9006)|Sorafenib 400 mg will be administered orally, twice daily (approximately every 12 hours).
223848512|NCT00984282|DRUG|Placebo|Placebo (2 tablets) will be administered orally, twice daily (approximately every 12 hours).
223848513|NCT03013842|DEVICE|Raydiant Oximetry Sensor System|Administration of Fetal Oximetry Probe on 36 weeks or greater pregnant women
223848514|NCT02856711|BEHAVIORAL|Trauma-informed group|"The two interventions will be: 1) A viewing of All Babies Cry and a discussion of what it's like to be a new parent, 2) A Planning to Parent stress activity where parents discuss when they have felt overwhelmed, the coping mechanisms they used, and what can be done to manage those emotions in the future. The goal of this project is to gain insight from current participants in CenteringPregnancy group care around the ways that these interventions can better prepare parents to deal with the common stresses of parenthood."
223848515|NCT02223793|BEHAVIORAL|Information on high risk factor levels and lifestyle advice|This arm of high risk participants will be informed about their measured levels of the different cardiovascular risk factors. They will also receive information on how to lower their levels in 8 weeks
223848516|NCT02223793|BEHAVIORAL|No information on high risk factor levels but lifestyle advice|In this arm, participants will have delayed information on their risk factor levels, but they will receive general advices on how to lower levels in 8 weeks
223848517|NCT02223793|BEHAVIORAL|No information on high risk factor levels, nor lifestyle advice|In this arm, participants will have delayed information on both their risk factor levels and general information on how to lower risk factor levels.
223848518|NCT02950194|PROCEDURE|PPAWI|One-step procedure of a panniculectomy performed by a plastic surgeon together with a mesh augmentation of the abdominal wall by a general surgeon.
223848519|NCT06357572|DIAGNOSTIC_TEST|Thrombin generation assay (EnzySystem HemA version A - whole blood)|Whole blood obtained by venipuncture is immediately tested with the EnzySystem HemA version A), before and 0, 30, 120 and 240 minutes after administration of FEIBA.
223848520|NCT06357572|DIAGNOSTIC_TEST|Thrombin generation assay (Ceveron s100 (Technoclone) - fresh plasma)|Whole blood is centrifuged to obtain plasma. The fresh plasma is tested using the Ceveron s100.
223848521|NCT06357572|DIAGNOSTIC_TEST|Additional coagulation tests|"Plasma samples are frozen for later coagulation testing. The following tests are performed:~Factor VIII activity von Willebrand Factor antigen levels von Willebrand Factor ristocetin activity levels Prothrombin Fragment 1+2 levels ADAMTS13 activity FVIII antigen levels Nijmegen Hemostasis Assay"
224265290|NCT01710722|DRUG|caffeine, ephedrine, and leptin A|Caffeine 200 mg tablets and ephedrine HCl tablets 25 mg three times a day with leptin A-200 20 mg subcutaneously once daily.
224265291|NCT03505996|BIOLOGICAL|CS1001|Monoclonal antibody
224265292|NCT05325268|PROCEDURE|Osteosynthesis|Treatment of fracture with open reduction and osteosynthesis
224265293|NCT02195401|OTHER|Cleanroom|Cleanroom with air the quality of the pre-industrial age
224265294|NCT02230267|OTHER|High intensity exercise and balance training|
224265295|NCT02230267|OTHER|Usual care arm exercise|
224265296|NCT01395017|DRUG|dasatinib|GEM 1000 mg/m2 by intravenous \[IV\] infusion weekly for 3 weeks of a 4-week cycle plus dasatinib 100 mg (or matched placebo) by mouth once daily (QD). Subjects will continue to receive study treatment until disease progression, unacceptable toxicity, withdrawal of consent, or study termination.
224265297|NCT01395017|DRUG|Placebo|Matching Placebo
224265298|NCT03086434|OTHER|Culturally Tailored Intervention|School-based substance use prevention
224265299|NCT03086434|OTHER|Standard Substance Abuse Education|Class room program
224265300|NCT03985124|BEHAVIORAL|Tuning in to Kids for Teachers|This is an emotion-focused intervention for teachers giving them skills in emotion coaching children in their care and also understanding and managing their own emotions.
224265301|NCT05480423|BEHAVIORAL|Mindfulness-based intervention|1\. Psychoeducation video on mindfulness and mindful parenting. 2. Audio files of mindfulness exercises including mindfulness of breath, body scan, mindful stretching, mindfulness of soles of the feet, befriending exercises. 3. Informal mindfulness exercises by applying mindfulness in daily lives
224265302|NCT04604938|DRUG|Losartan|administration of losartan (50 mg) (oral)
224265303|NCT04604938|DRUG|Placebo oral tablet|administration of placebo (oral)
224265304|NCT06485518|BEHAVIORAL|The 5G RHS group receiving audio-video conferencing and effective data management for decision-making via augmented reality platform RealHealthcare System.|The 5G RHS group will receive audio-video conferencing and effective data management for decision-making via augmented reality platform. A total of 14 physicians from SRRSH will be participated in the study, offering remote consultations and instant guidance to the physician.
224265305|NCT01757379|DIETARY_SUPPLEMENT|13C-labeled Acetate|400 mg of sodium acetate 1-13C (2 colon delivery capsules with 200 mg)
224265306|NCT01757379|DIETARY_SUPPLEMENT|13C-labeled propionate|340 mg of sodium propionate 1-13C (2 colon delivery capsules with 170 mg)
224265307|NCT01757379|DIETARY_SUPPLEMENT|13C-labeled butyrate|990 mg sodium butyrate 1-13C (2 colon delivery capsules with 495 mg)
223848522|NCT00106431|DRUG|romidepsin (depsipeptide, FK228)|Study patients received romidepsin at a dose of 14 mg/m\^2 intravenously over 4 hours on Days 1, 8 and 15 of each 28-day cycle. The duration of study treatment was 6 cycles although patients who showed an objective response or stable disease could continue to receive therapy, at the discretion of the investigator, until disease progression or another withdrawal criterion was met.
223848523|NCT04518566|BEHAVIORAL|Nudges|Behavioral nudges will be delivered to patients' FitBit device through adaptive intervention platform via notification syncing. To ensure the delivered nudges are timely and personalized, predictive nudges will be developed based on patterns in patients' sociodemographic, clinical and baseline activity tracking. These nudges will be sent automatically to patients upon specific triggers. The nudges will also be assessed for its effectiveness in behavior change. For example, a predictive nudge to encourage patients to take a short walk after detecting long periods of sedentary time will be assessed for its effects by step counts data after delivery of nudge. An iterative approach will be used to generate an effective set of nudges and its most appropriate delivery times for specific activity patterns.
223848524|NCT05324631|DRUG|SHR0302|SHR0302, oral, once daily
223848525|NCT05324631|DRUG|SHR0302 placebo|SHR0302 placebo, oral, once daily
223848526|NCT04395755|BEHAVIORAL|Generalized Anxiety Disorder-7 (GAD-7)|The GAD-7 is useful in primary care and mental health settings as a screening tool and symptom severity measure for the four most common anxiety disorders.
223848527|NCT04395755|BEHAVIORAL|Patient Health Questionnaire-9 (PHQ-9)|The PHQ-9 is a multipurpose instrument for screening, diagnosing, monitoring and measuring the severity of depression.
223848528|NCT05312541|PROCEDURE|pre emptive local anaesthetic wound infiltration|Before skin incision by 15 min the surgeon will infiltrate the wound by syringe containing 20 ml mixture of (10 ml xylocaine 2%and 10 ml bupivacaine 0. 5%) in both groups
223848529|NCT00030381|DRUG|4'-iodo-4'-deoxydoxorubicin|Given IV
223848530|NCT00030381|OTHER|pharmacological study|Correlative studies
223848531|NCT02359435|DRUG|Reverse hybrid therapy|pantoprazole 40 mg b.d., amoxicillin 1 g b.d., clarithromycin 500 mg b.d. and metronidazole 500 mg b.d. for the first 7 days, followed by pantoprazole 40 mg b.d. and amoxicillin 1 g b.d. for another 5 days
223848532|NCT02359435|DRUG|Standard triple therapy|pantoprazole 40 mg b.d., clarithromycin 500 mg b.d., and amoxicillin 1 g b.d. for 12 days
223848533|NCT00523731|PROCEDURE|Angiogenic Cell Precursors (ACPs) or Vescell TM|
223848534|NCT00233740|DEVICE|OPTEASE Vena Cava Filter|
223848535|NCT06053788|DIAGNOSTIC_TEST|PocDoc|Point of care digital lipid test
223848536|NCT05759585|BEHAVIORAL|person-centered lifestyle intervention|Lifestyle intervention is a combined approach that encourages individuals to change their lifestyles by increasing participation in meaningful readings. This program aims to facilitate the individual's self-development of healthy routines and habits; It includes techniques such as patient education, occupational self-analysis, problem-solving, motivation generation, and implementation of behaviors to prevent and manage disease-related symptoms.
223848537|NCT00735800|BEHAVIORAL|Family Intervention:Telephone Tracking Support- Caregiver|Family-based problem solving treatment
223848538|NCT00735800|BEHAVIORAL|Telephone Support|Supportive telephone counseling about caregiving
223848539|NCT02287649|OTHER|blood sample|
223848540|NCT00623506|DRUG|Pregnenolone|"Placebo for two weeks (during placebo lead-in), then:~Pregnenolone 100 mg in divided doses (50 mg, PO, BID) Pregnenolone 300 mg in divided doses (150 mg, PO, BID) Pregnenolone 500 mg in divided doses (250 mg, PO, BID)"
223848541|NCT00623506|DRUG|Placebo|"Placebo for two weeks (placebo lead in), then:~Placebo equivalent to Pregnenolone arm: 100 mg in divided doses (50 mg, PO, BID) Placebo equivalent to Pregnenolone arm: 300 mg in divided doses (150 mg, PO, BID) Placebo equivalent to Pregnenolone arm: 500 mg in divided doses (250 mg, PO, BID)"
223848542|NCT01289119|DRUG|Alogliptin|Alogliptin tablets
223848543|NCT01289119|DRUG|Placebo to alogliptin|Alogliptin placebo-matching tablets.
223848544|NCT01289119|DRUG|Metformin|Stable metformin dose
223848545|NCT01289119|DRUG|Pioglitazone|Stable pioglitazone dose
223848546|NCT00165139|DRUG|Vincristine|Described under detailed description
223848547|NCT00165139|DRUG|Cyclophosphamide|Described under detailed description
223848548|NCT00165139|DRUG|Adriamycin|Described under detailed description
223848549|NCT00165139|DRUG|Etoposide (VP-16)|Described under detailed description
223848550|NCT00165139|DRUG|Cisplatin|Described under detailed description
223848551|NCT00165139|DRUG|Carboplatin|Described under detailed description
223848552|NCT00165139|DRUG|Melphalan|Described under detailed description
223848553|NCT00165139|DRUG|Ifosfamide|Described under detailed description
223848554|NCT00165139|DRUG|G-CSF (granulocyte-colony stimulating factor)|Described under detailed description
223848555|NCT00165139|DRUG|Mesna|Described under detailed description
223848556|NCT02414919|DRUG|Mirena (Levonorgestrel IUS, BAY86-5028)|Levonorgestrel-releasing intrauterine device 20 mcg/day
223848557|NCT02414919|DRUG|ParaGard|Copper T380A
223848558|NCT02414919|DRUG|Implanon/Nexplanon|Etonorgestrel contraceptive implant
223848559|NCT06491095|DIETARY_SUPPLEMENT|0 g Flax|175 g yogurt with no flax product
223848560|NCT06491095|DIETARY_SUPPLEMENT|40 g whole ground flaxseed|175 g yogurt with 40 g whole ground flaxseed
223848561|NCT06491095|DIETARY_SUPPLEMENT|40 g roasted then ground whole flaxseed|175 g yogurt with 40 g roasted then ground whole flaxseed
223848562|NCT06491095|DIETARY_SUPPLEMENT|40 g of whole intact flaxseeds|175 g yogurt with 40 g of whole intact flaxseeds
223848563|NCT06491095|DIETARY_SUPPLEMENT|28 g flax hulls|175 g yogurt with 28 g flax hulls
223848564|NCT05822271|PROCEDURE|Orthognathic Surgery|Type of surgery performed to correct skeletal malocclusions
223848565|NCT03675139|DRUG|Medroxyprogesterone Acetate|At a dosage of 10mg/day
223848566|NCT03675139|DRUG|Dydrogesterone 10 MG|At a dosage of 20 mg/day
223848567|NCT01704846|DRUG|BI 201335 NA 120 mg capsule|1capsule of BI 201335 NA 120 mg capsule
223848568|NCT01704846|DRUG|BI 201335 NA 120 mg capsule|1 capsule of BI 201335 NA 120 mg capsule
223848569|NCT01704846|DRUG|BI 201335 NA 40 mg capsule|3 capsules of BI 201335 NA 40 mg capsule
223848570|NCT01704846|DRUG|BI 201335 NA 40 mg capsule|3 capsules of BI 201335 NA 40 mg capsule
223848571|NCT02611414|DEVICE|anodal tDCS|tDCS anodal stimulation over M1 area applied for 20 minutes at five consecutive days.
223848572|NCT02611414|DEVICE|Sham tDCS|tDCS sham stimulation over M1 applied for 20 minutes (with current turned off at 30 seconds) at five consecutive days.
223848573|NCT01407601|DIETARY_SUPPLEMENT|daily supplementation of MK-7 over 6 weeks|once daily intake of MK-7 prior to dialysis over 6 weeks
223848574|NCT04579510|BIOLOGICAL|Novel monovalent oral poliovirus vaccine type 2 (nOPV2)|nOPV2 candidate 1 (S2/cre5/S15domV/rec1/hifi3) is a live-attenuated serotype-2 poliovirus that was derived from a modified Sabin type-2 infectious cDNA clone and propagated in Vero cells. To improve genetic stability, nucleotide sequence modifications were made in the major determinant for attenuation in the Sabin 5'-untranslated region. Additionally, two modifications in the polymerase 3D were made to further improve stability of the attenuation, and a key replication element from the 2C coding region was relocated to the 5'-untranslated region to inhibit recombination.
223848575|NCT04579510|BIOLOGICAL|Bivalent oral poliovirus vaccine (bOPV)|The live types 1 \& 3 oral polio vaccine (bOPV) is a bivalent vaccine containing suspension of types 1 \& 3 attenuated Polio viruses (Sabin strains).
223848576|NCT01756417|DRUG|Metformin|One 1,000 mg tablet of metformin taken orally (by mouth) on Day 1 and Day 8.
223848577|NCT01756417|DRUG|Canagliflozin (JNJ-28431754)|Four 25 mg tablets of canagliflozin (JNJ-28431754) taken orally on Days 4 through 8.
223848578|NCT04364880|DEVICE|TBS|Theta-burst stimulation (TBS) is a novel repetitive transcranial magnetic stimulation (rTMS)
223848579|NCT04364880|DEVICE|Sham|The sham-TBS coil produced a similar sound without a magnetic pulse.
223848580|NCT04311619|DRUG|[11C]UCB-J radiotracer|I.V. bolus administration of up to 15 mCi (equivalent to 0.3 rems) in the antecubital vein per injection
223848581|NCT04311619|DEVICE|PET-MR|Positron emission tomography and magnetic resonance imaging, with a scan duration of up to 120 minutes
223848582|NCT02321540|DRUG|Ibrutinib|"Part 1 Starting level of Ibrutinib: 560 mg by mouth daily in a 28 day cycle.~Part 2 Starting level of Ibrutinib: Maximum tolerated dose from Part 1 or 840 mg daily."
223848583|NCT00530335|DRUG|Atomoxetine|40 mg/day every day (QD), by mouth (PO), for 1 week; 80 mg/day every day, by mouth, for 1 week; 105 mg/day every day, by mouth, for 2 weeks; 120 mg/day every day, by mouth, for 4 weeks
223848584|NCT04097886|OTHER|Morning Exercise|moderate intensity exercise (70% VO2 max) each morning for 5 days
223848585|NCT04097886|OTHER|Evening Exercise|moderate intensity exercise (70% VO2 max) each evening for 5 days
223848586|NCT04577183|DEVICE|RD1 System|The RD1 is created by drawing the patient's blood with the use of citrate anticoagulant. The anticoagulant allows the clot to form later in a controlled fashion-citrate is a widely used anticoagulant. The blood is then placed in the clotting tray (within few minutes) and the coagulation is facilitated by adding calcium and kaolin (insoluble aluminum silicate). The forming clot assumes the shape of the tray containing it, and can then be applied to the wound, and then covered with primary and secondary dressings.
223848587|NCT00816335|PROCEDURE|PET/CT scan|For all patients undergoing a preoperative PET/CT scan on the day of surgery, at approximately 70 minutes post-injection of 18F-FDG, a diagnostic whole body PET/CT scan will be obtained on a Siemens Biograph 16 PET/CT scanner (Siemens, Knoxville, TN).
223848588|NCT00816335|DRUG|18F-FDG Injection|Patients undergoing a preoperative PET/CT scan the day of surgery, are required to have fasted for at least 4 hours prior to the anticipated preoperative PET/CT scan. Patients participating in this pilot study (whether they have had their preoperative PET/CT scan prior to the day of surgery or whether they are having their preoperative PET/CT scan on the day of surgery) will receive a preoperative IV injection into a peripheral vein of 15 mCi of 18FFDG at time interval of approximately 60 to 180 minutes prior to anticipated time of surgery.
223848589|NCT00816335|PROCEDURE|Preoperative 18F-FDG PET/CT Scan|Patients undergoing preoperative PET/CT scan day of surgery, at approximately 70 minutes post-injection of 18F-FDG, a diagnostic whole body PET/CT scan will be obtained. PET imaging will immediately be preceded by noncontrast transmission CT (for attenuation correction and anatomic correlation purposes) and will be obtained from the base of the skull to the mid thighs. Bed positions will be scanned for 3 minutes each, moving the patient through the scanner in a craniocaudal direction. Once the preoperative PET/CT scan is acquired, images will be reviewed by the nuclear medicine physician and the surgeon.
223848590|NCT00816335|DRUG|18F-FDG for patients with Bladder Cancer|Elimination of 18F-FDG by the urinary system and accumulation in the bladder impacts the differentiation between residual 18F-FDG in the bladder and activity in tumor and adjacent lymph nodes. For patients with bladder cancer, the urinary catheter routinely placed in the operating room will be inserted in the Ambulatory Surgery Unit (ASU) by the urologist on-service or the urology research nurse. A 3-way Foley catheter will be placed for continuous bladder irrigation with Normal Saline (0.9%) initiated in ASU and will continue for the duration of the imaging procedure at a standard rate of 10cc/minute. The urology research nurse will transport the patient to and from the PET/CT area and monitor the continuous bladder irrigation during the imaging session.
224265308|NCT01757379|DIETARY_SUPPLEMENT|Inulin|15 g of inulin dissolved in 200 ml of water
224265309|NCT02285049|OTHER|Urticaria Control Test|"* The patients get the 1st UAS28 form and four-week appointment to follow up.~* Collect completed UAS28 assessment, Patient's global assessment of disease severity (PatGA-LS) and Physician's global assessment of disease control (PhyGA-LS)~* Then patients fill the 1st UCT and DLQI questionnaire by themselves.~* The patients get the 2nd UAS28 form and four-week appointment to follow up.~* At the 2nd visit, collect completed UAS28 assessment. Assessment the severity of chronic urticaria symptoms by Patient's global assessment of disease severity (PatGA-LS) and Physician's global assessment of disease control (PhyGA-LS). The patients fill the UCT and DLQI and questionnaire by themselves."
224265310|NCT01782937|DRUG|KHK4827|140 mg (dosage may be increased to 210 mg in case of insufficient efficacy)
223848591|NCT00816335|PROCEDURE|Surgical Procedure|Previously determined operative procedure based on type of solid malignancy. Factors include extent and location of disease, physiologic status of patient intraoperatively, any technical considerations influenced by anatomic constraints, and a risk: benefit analysis of proposed procedure. The decision to proceed with resection on these factors, and will constantly re-evaluate during resection to ensure patient well-being, both short and long term, is foremost consideration. Evaluation of extent of disease during surgical exploration will include inspection and palpation of entire area being evaluated. Tissue that is highly suspicious for involvement with metastatic disease that alters the surgical decision making plan of resection will be biopsied or resected for histologic confirmation if feasible and safe. If patient is found to have resectable disease, deemed safe patient, surgeon will continue and proceed with definitive surgical resection with assistance of handheld gamma probe.
223848592|NCT00816335|PROCEDURE|Specimen PET/CT Scan|Resected surgical specimen will be placed on top of paraffin block. Digital photos of the specimen will be obtained for visual correlation of specimen placement on paraffin block. Two bed position 10 minute specimen PET/CT scan will be performed on surgical specimen. If remnant tissue is available, a second image maybe acquired via MRI. Images will be processed and reviewed for quality and presence or absence of hypermetabolic foci and correlated with anatomical information provided by CT and MRI imaging that were originally noted in the preoperative clinical PET/CT scan. During the time when the excised surgical specimens are transported to radiology for specimen PET/CT scanning, additional evaluation of these ex-vivo specimens with other tumor detection devices may be undertaken. Specimen will then be transported back to the operating room in order to be sent to and processed by surgical pathology for standard pathologic evaluation.
223848593|NCT04477798|DIAGNOSTIC_TEST|PCT-DIA/MS|PCT-DIA/MS will be validated to classify FNA biopsy specimens
223848594|NCT03374111|DRUG|Colla corii asini|15 g Colla corii asini granule daily for 8 weeks
223848595|NCT03374111|DRUG|a Simulate Agent of Colla corii asini granule|15 g a Simulate Agent of Colla corii asini granule daily for 8 weeks
223848596|NCT01205282|DRUG|Pioglitazone|A modified dose finding method will be used to determine safety and dose response among three dose levels (0.25mg/kg QD, 0.5mg/kg QD, and 0.75mg/kg QD). The dose has been based on the per weight maximum adult dose. Specifically, the FDA has approved 45mg as the maximum adult dose. For a 60kg adult, this is 0.75mg/kg. There will be 14 weeks of active treatment.
223848597|NCT01205282|DRUG|Placebo|There will be a 2 week period of placebo run-in.
223848598|NCT04440969|BEHAVIORAL|Multi-domain intervention|"Participants will undergo dual-task physical exercises and small group activities comprising of quizzes, puzzles and simulate daily living activities that have been gamified (Mindfun and MindGym, ProAge,Singapore). They will also play games on a touch screen device (computerised cognitive training) that aims to improve cognition in the domains of attention, memory, spatial ability, decision making and cognitive flexibility (Memorie, Neeuro, Singapore) while wearing the Senzeband, which emits low frequency signals on the forehead picked up by four individual sensors, allowing participant to play certain games without touching the device but by attention and focus (https://www.neeuro.com/senzeband).~Dietary guidance will be delivered via a dietary app (Glycoleap). Participants are expected to take photos of their meals daily and upload them onto the app. Certified dieticians will give advice and tips on their choice of food and how to make healthier choices through the app."
223848599|NCT05482854|OTHER|Analytical Treatment Interruption (ATI)|"Analytical Interruption of Treatment for 24-48 weeks~ART resumption and follow-up for 24 weeks if the participant meets at least one ART resumption criteria"
223848600|NCT02687646|DRUG|Adult Allogeneic Mesenchymal cells from adipose tissue.|"Study treatment consists of Mesenchymal Stem Cell (MSC) derived from donors adipose tissue and expanded in vitro in a specific medium with platelet lysate without addition of animal derived products.~Subjects will receive four sequential IV dose of Mesenchymal stem cells.~Sequential doses:~Day 1: 0.7-1 x 106 MSC / kg Day 4: 0.7-1 x 106 MSC / kg Day 11: 0.7-1 x 106 MSC / kg Day 18: 0.7-1 x 106 MSC / kg"
223848601|NCT03972423|OTHER|With or wiyhout a checklist|The evaluation of the impact of the use of this Checklist will be done in comparison with the standard transmission practice
223848602|NCT04857450|DRUG|Etomidate|Received Etomidate 0.2 mg/kg IV over 30 seconds, followed by Etomidate 0.05 mg/kg IV and repeated when needed.
223848603|NCT04857450|DRUG|Ketamine Hydrochloride|Received Ketamine 0.5 mg/kg IV over 30 seconds then Etomidate 0.1 mg/kg IV over 30 seconds, followed by 0.05 mg/kg IV and repeated when needed.
223848604|NCT02763020|OTHER|Fruit extracts high in polyphenols|
223848605|NCT02763020|OTHER|placebo|
224265311|NCT04074707|DIETARY_SUPPLEMENT|Labeled iron solution (60mg and 120mg Ferrous Fumarate)|3 doses of 60mg iron as ferrous fumarate are given on one consecutive day and one alternate day (e.g., days 1, 2, 4); 3 doses of 120mg iron as ferrous fumarate are given on one consecutive and one alternate day (e.g., days 20, 21, 23); 3 doses of 120mg iron as ferrous fumarate are given on one consecutive and one 3rd day (e.g., days 37, 38, 41). Iron doses are labeled with 4mg of a stable isotope in 200ml deionized water (57Fe, 58Fe or 54Fe). Participants will be randomly assigned to start with 60mg iron daily vs alternate day dosing, 120mg daily vs alternate day dosing or 120mg daily vs every-third day dosing.
224265312|NCT00643305|BEHAVIORAL|Skills Building with Motivational Interviewing|Based on the Stages of Change model, participants are provided with feedback related to their current HIV risk and Motivational Interviewing strategies are used to increase motivation to decrease HIV risk behaviors. Participants are also provided with information and training in skills critical for reducing HIV risk
224265313|NCT00643305|BEHAVIORAL|Skills Building|Participants are provided with information and training in skills critical for reducing HIV risk.
224265314|NCT05021276|DRUG|Ruxolitinib|Ruxolitinib and basiliximab are both second-line treatment for grade 3-4 steroid-resistant acute graft-versus-host disease.
224265315|NCT03677960|DRUG|Topical ABI-1968 cream|Multiple doses of Topical ABI-1968 Cream administered by the Investigator in the clinic up to Day 29
224265316|NCT01116791|PROCEDURE|Cytoreductive Surgery (CRS) plus Hyperthermic Intraoperative Peritoneal Chemotherapy with Cisplatin (HIPC)|"* CRS is defined as macroscopic tumour removal using surgical resection and/or local ablative therapy (LAT)~* HIPC is administered immediately after CRS"
224265317|NCT02002130|DRUG|Placebo GABA and Placebo GAD-alum|Maltodextrin as a placebo formulation for GABA Placebo GAD-alum injection
224265318|NCT02002130|DRUG|GABA and Placebo GAD-alum|Oral Active GABA with Placebo GAD-alum
224265319|NCT02002130|DRUG|Active Oral GABA and Active GAD-alum injection|Active Oral GABA and Active GAD-alum injection
223848606|NCT00710164|DRUG|XSCR capsule (Composed of Traditional Chinese Medicine Huangqi, Chuanxiong, Chishao, Danggui, Dilong, Taoren, Honghua.)|14 days of XSCR capsule
223848607|NCT00710164|DRUG|Placebo|14 days of Placebo
223848608|NCT05619887|DRUG|Fentanyl|Fentanyl, when administered into the intrathecal (spinal) space suppresses feedback from the muscles below the site of action, i.e., the legs. It does not affect resting cardiorespiratory responses. We are using this to test what role the muscle reflex plays during exercise.
223848609|NCT05619887|OTHER|Saline|An equal volume (as above) of saline will be administered into the intrathecal (spinal) space. This has no effect of cardiorespiratory responses at rest or during exercise; it is to control for the invasiveness of the procedure required to suppress muscle feedback in the experimental condition.
223848610|NCT01259687|DEVICE|Non-invasive cardiac output monitoring|During the surgery the continuous monitoring of blood pressure by peripheral artery catheter and cardiac output by NICOM (non-invasive cardiac output monitoring) will be applied. In case of intraoperative hemodynamic changes (hypertension, hypotension) the patient will be treated according to the standard care by Phenylephrine, Nitroglycerine or Colloid fluid boluses. Cardiac output will be measured by NICOM just before and after each treatment of hemodynamic events that described above. Simultaneous records of ECG, arterial and plethysmographic waveforms will be made just before and after each event. Systolic blood pressure and PuTT will be measured OFFLINE from the recorded waveforms
224265320|NCT01783392|PROCEDURE|Transcutaneous Electrical Nerve Stimulation|
224265321|NCT06471725|OTHER|combination of pilates exercises, Low-level laser therapy, and low-intensity ultrasound|The core and hip muscles will be targeted through a customized workout program consisting of exercises such as Breathing, Planks, Side- Planks, Weighted lunges, Glute Bridge, Clamshell, Half-Kneeling Hip Flexor Stretch, Swan dive, Roll down, Ab curls, and Shoulder bridge, Low-intensity Ultrasound , and low level laser therapy
224265322|NCT03294122|RADIATION|External beam radiotherapy for prostate cancer|Patients will receive radiotherapy for prostate cancer and possible adjuvant hormone therapies as foreseen by international guidelines. No modification of standard regimens is considered. PCa patients are treated with 78 Gy, 2Gy/fraction, in exclusive setting and with 70 Gy, 2Gr/fraction in the post-prostatectomy setting. Lymph node irradiation is performed (50 Gy, 2Gy/fraction) when indicated by risk class.
224265323|NCT03294122|RADIATION|External beam radiotherapy for head and neck cancer|Patients will receive radiotherapy for head and neck cancer and possible concomitant chemotherapies as foreseen by international guidelines. No modification of standard regimens is considered. In curative setting, HNCa patients are treated at a total dose of 70 Gy, 59.4 Gy and 56.1 Gy in 33 fractions to high risk Planning Target Volume (PTV), intermediate risk and low risk PTV, respectively. In high risk post-operative setting they are treated with 66 Gy (according to histopathological features), 60 Gy and 56.1 Gy to high, intermediate and low risk PTV, respectively; while, in intermediate risk post-operative case, intermediate and low risk PTV are irradiated with 60 Gy and 54 Gy, respectively. Chemotherapy will be platinum based (weekly or 3-weekly cisplatin).
224265324|NCT01004510|DRUG|zoledronic acid|Zoledronic acid (Zometa) 4mg IV every 4 weeks for 3 treatments with chemotherapy as selected by treating physician
224265325|NCT01063244|DEVICE|foley balloon only|place foley balloon only in cervix
224265326|NCT01063244|DEVICE|foley balloon with weight attached|foley balloon with 1000cc IV bag attached
224265327|NCT04306601|DEVICE|Low-Intensity Focused Ultrasound|Low-intensity focused ultrasound brain stimulation using focused ultrasound system (NS-US100; NEUROSONA Co. Ltd., Seoul, Korea)
224265328|NCT00001864|DRUG|Atropine|
224265329|NCT00001864|DEVICE|Patch|
224265330|NCT04482816|DEVICE|Physiological pacing|Pacing of the his bundle or the left bundle branch
224265331|NCT04482816|DEVICE|Right ventricular pacing|Conventional pacing; right ventricular pacing
224265332|NCT00473616|DRUG|AZD7762|intravenous infusion
224265333|NCT00473616|DRUG|Irinotecan|intravenous injection
223848611|NCT02492594|OTHER|Peripheral blood sampling|"Peripheral blood samples will be taken at 3-5 defined timepoints during febrile neutropenia:~* at the start of neutropenic fever~* after 24 hours~* after 48 hours~* before the start of antimycotic therapy, if pertinent~* at the end of antimycotic therapy, if pertinent"
223848612|NCT03871998|OTHER|Skin barrier protection in the first 2 months of life|Skin barrier protection in the first 2 months of life using a commercially available moisturiser from birth 2 months. Twice daily, whole-body application.
223848613|NCT04686643|DRUG|AGSAVI|S-amlodipine, Valsartan, Indapamide
223848614|NCT04686643|DRUG|AGLS|S-amlodipine, Valsartan
223848615|NCT04683497|OTHER|Contrast-enhanced Intraoperative Ultrasound|Intraoperative ultrasound with the administration of a contrast agent I.V.
223848616|NCT02999282|DEVICE|Anodal transcranial direct current stimulation|10 sessions of anodal transcranial direct current stimulation (5 days/week for 2 weeks)
223848617|NCT02999282|DEVICE|Sham transcranial direct current stimulation|10 sessions of sham transcranial direct current stimulation (5 days/week for 2 weeks)
223848618|NCT03218956|DIETARY_SUPPLEMENT|Dietary supplement: Protein intake|"Oral consumption of houly experimental meals. Includes 4 meals containing a mixture of free amino acids, carbohydrates from a flavored liquid, fat from corn oil and protein free cookies.~The last 4 meals will in addition contain labelled labelled 13C phenylalanine."
223848619|NCT00483912|DEVICE|Molecular adsorbent recirculating system|
223848620|NCT01721564|DRUG|Bosentan|62.5 mg Bosentan twice a day for 1 month 125 mg Bosentan twice a day for 5 months
223848621|NCT03661190|OTHER|Grammatical Reasoning|START measures the ability to determine the relationships among different shape combinations which are assigned to grammatical statements about them which can be either correct or incorrect. It is a measure of attention, working memory and executive control.
223848622|NCT03661190|OTHER|Card Pairs|A basic picture-matching task.
223848623|NCT04298840|DIETARY_SUPPLEMENT|Creatine Monohydrate Supplementation|Participants in the creatine monohydrate supplementation arm will consume 5 grams per day of creatine monohydrate.
223848624|NCT04298840|DIETARY_SUPPLEMENT|Placebo Supplementation|Participants in the placebo supplementation arm will consume 5 grams per day of maltodextrin placebo.
223848625|NCT02260739|OTHER|Blood samples|
223848626|NCT06196528|DEVICE|WristArt implant|implantation of the WristArt implant
223848627|NCT03841019|DEVICE|Magpro X100 + Option|In addition to treatment as usual (TAU), participants were supposed to receive twelve sessions of MST in four weeks (three sessions per week)
223848628|NCT03841019|DEVICE|ThymatronSystem Ⅳ Electroconvulsive System|In addition to treatment as usual (TAU), participants were supposed to receive twelve sessions of ECT in four weeks (three sessions per week)
223848629|NCT06343155|OTHER|Therapeutic Group|Pelvic tilt exercise:Participant will be supine position on the floor with your knees bent. Flatten your back against the floor by tightening your abdominal muscles and bending your pelvis up slightly. Lumbar flexion(single knee to chest): Participants will be supine position with knees bent and feet flat on the floor. The right knee will be brought closer to your chest and held with the hands. Lumbar flexion(double knee to chest) : Participants will be supine position with both legs flat on the floor. One hip and knee will be bent first to the chest, then the other to the chest. The knees will be grasped with the hands. Straight Leg Raise: Participants will be supine position with hips and legs comfortably on the floor. By contracting the quadriceps muscle the straight leg will be fixed. Inhaling slowly, the straight leg will be lifted six inches off the floor. Spine twist: Participants will turn their hips and knees to one side as much as possible in a supine position.
223848630|NCT06343155|OTHER|Rocabado's Group|Rest position of tongue: Making a 'clucking' sound positions the tongue against the hard palate in the correct resting position for appropriate nasal and diaphragmatic breathing. Once the activity is practiced, the patient is to attempt to maintain appropriate tongue / jaw resting position throughout normal activity. Shoulder retraction:Sitting up nice and tall, squeeze your shoulder blades back and together. Stabilized head posture:Place your hands behind your hand with fingers interlocked.Gently bring head forward with gentle overpressure from hands.Axial extension of the neck: Sitting up nice and bring your chin backward as if trying to make a double chin. Rotation control of temporomandibular joint: Place tongue at the roof of your mouth just behind your front teeth and place fist underneath chin. Gently open mouth into fist and hold for a few seconds. Rhythmic stabilization:Patients apply resistance to opening, closing, and lateral deviation with the jaw in a resting position.
223848631|NCT02988596|OTHER|Multidimensional Active Rehabilitation|Participants will be asked to complete activities aimed at: stabilization of symptoms, impairment reduction, activity integration, recovery acceleration and sport specific application during a 20 minute session at least 4 times a week. Activities will be selected by the supervising clinician with respect to the specific impairment presentation of each participant. Session logs will be completed by each clinician and will include the following information: initial symptom checklist, activity parameters, percentage of rest during the session, participants rating of perceived exertion, and final symptom checklist, session satisfaction rating, and session feedback.
224265334|NCT04775316|DEVICE|Leukomed T / Tplus skin sensitive treatment|Application of sterile wound dressing.
224265335|NCT04392596|DEVICE|Bone Mineral Density and Trabecular Bone score|"structural damage in the cervical and lumbar spine was scored according to the modified Stoke AS Spinal Score (mSASSS) which yielded a final summation score ranging from zero to 72.~BMD was measured using DXA (Lunar Prodigy densitometer, GE Healthcare, Madison, WI, USA).~BMD was measured at the lumbar spine (L1-L4) and the left hip (femoral neck and total proximal femur).~TBS was analyzed using DXA images over exactly the same region as the lumbar BMD assessment (L1-L4). Lumbar spine DXA images were reanalyzed using TBS iNight software version 2.1 (Med-I maps, Merignac, France). Patients were divided in 3 TBS groups according to guidelines for fracture risk \[22\]: any TBS \>1.31 was considered as normal; TBS values between 1.23 and 1.31 were consistent as partially degraded structure; and any TBS \<1.23 was considered as degraded structure."
224265336|NCT02028416|DRUG|ATG-fresenius|"we will create 2 arms as per randomization table. Both arms will receive ATG-Fresenius but with 2 different regimens.~the first arm will receive ATG-F @10mg/kg for 3 days and second arm will receive ATG-F same dose but for 5 days"
224265337|NCT03145987|DIETARY_SUPPLEMENT|Vitis vinifera extract|
224265338|NCT03145987|OTHER|Placebo|
223848632|NCT02988596|OTHER|Enhanced Graded Exertion|Participants will be asked to use their symptoms to guide their activity from the time of their injury until they are asymptomatic. Once they are asymptomatic they will begin the graded exertion (Zurich/Berlin Protocol). During this time clinicians will complete session logs that include the following information: initial symptom checklist, phase of graded return to play progression, activity parameters, percentage of rest during the session, participants rating of perceived exertion, and final symptom checklist, session satisfaction rating, and session feedback.
223848633|NCT05526508|DEVICE|Rebound exercise|Exercise training on the rebounder/ mini-trampoline with stability handles attached
223848634|NCT03615001|DEVICE|TDOC NXT|Assessing the Performance, Safety and Usability of our Next Generation T-DOC® NXT Catheter for Performing Urodynamic Studies
223848635|NCT00403208|PROCEDURE|Analgesia based sedation in ICU patients|
223848636|NCT06185400|DRUG|Disitamab Vedotin|RC48+third-generation EGFR TKIs (Almonertinib/Furmonertinib/Osimertinib) in treatment naive NSCLC
223848637|NCT06185400|DRUG|third-generation EGFR TKIs (Almonertinib/Furmonertinib/Osimertinib)|RC48+third-generation EGFR TKIs (Almonertinib/Furmonertinib/Osimertinib) after EGFR-TKIs progression
223848638|NCT06185400|DRUG|pyrotinib|RC48+pyrotinib after EGFR-TKIs progression
223848639|NCT05189587|DEVICE|transcranial electrical stimulation (TES)|Transcranial electrical stimulation (tES) is a noninvasive brain stimulation technique that passes an electrical current through the cortex of the brain to alter brain function. The electrical current is applied to an individual's scalp usually via two or more electrodes, and whilst a large amount of the current is conducted between electrodes through soft tissue and skull (Vöröslakos et al. 2018), a portion of the current penetrates the scalp and is conducted through the brain, where it can alter neuronal excitability. By altering the activity of brain regions involved with a behaviour of interest, investigators can observe the resulting behavioral changes and so establish a causal link between the two (Reed et al. 2018).
223848640|NCT06045637|BEHAVIORAL|Group included in a psychoeducational program based on the cognitive behavioral approach (experiment)|The 9-session cognitive behavioral approach-based psychoeducation program will last 5 weeks. Sessions; It will be carried out in the form of acquaintance, recognition of trauma and its effects, emotion and thought behavior analysis, cognitive errors, automatic thoughts and alternative thought generation, cognitive emotion regulation strategies, coping with negative emotions, instilling hope and termination session.
223848641|NCT05283369|DEVICE|Videogame therapy|The usual dose of conventional physical therapy, plus 300 minutes a week of in-home videogame therapy for 8 weeks.
223848642|NCT05283369|OTHER|Conventional therapy|The usual dose of physical and occupational therapy, for 8 weeks.
224265339|NCT04194333|PROCEDURE|Cone Beam CT with Embo Guide to creat 3D Overlay and CT Augmented Fluoroscopy to guide Electromagnetic Navigational Bronchoscopy instead of Standard Fluroscopic guidance using the C-Arm|Instead of the standard fluoroscopy using the C-arm, the intervention will undergo electromagnetic navigation guided bronchoscopy while using Cone Beam CT with Embo Guide to creat 3D Overlay and CT Augmented Fluoroscopy.
224265340|NCT01790685|DRUG|dexamethasone implant|
224265341|NCT04273295|OTHER|Abdominal massage|The patients lying in comfortable relaxed supine position and physiotherapist performed slow circular clockwise movements on the abdomen, throw tangential pushing, with digital pulp, slow and gradual pressure, with fingers inclination 45 degree. The pressure applied to the abdomen on each point for 1 min, beginning with the ascending colon, transverse colon, descending colon and sigmoid; this sequence was repeated approximately 15 min. The therapist teaches the parents this technique and asked them to apply at home 3 times / day for 15 min.
224265342|NCT01654419|DEVICE|Class II elastics and Sliding Jig|Class II elastics, 3/16 6 oz, used daily for 3 months 24 hours per day and sliding jig orthodontic device
224265343|NCT01654419|DEVICE|Class II elastic alone|Elastics Class II alone, used 24 hours per day for 3 months from the hook of the upper canine to the first lower molar hook
224265344|NCT04255433|DRUG|Tirzepatide|Administered SC
224265345|NCT04255433|DRUG|Dulaglutide|Administered SC
224265346|NCT01960296|DRUG|Clopidogrel|Continue home dose of clopidogrel into surgery
224265347|NCT01960296|DRUG|Discontinue Clopidogrel|Discontinue home dose of clopidogrel one week before surgery. Resume after surgery.
224265348|NCT02003391|DRUG|Beta-blocker monotherapy|Per participant's current prescribed therapy
224265349|NCT02003391|DRUG|Travoprost 0.004% / timolol 0.5% fixed combination ophthalmic solution|
224265350|NCT04894630|OTHER|antimicrobial treatment|Detailed history taking and all clinical findings were collected. Corneal scrapings were obtained from patients and subjected to staining and culture for bacterial and fungal pathogens; Bacterial and fungal growth were identified by standard laboratory procedures.
224265351|NCT02272803|DRUG|Lenalidomide|
224265352|NCT02272803|DRUG|Dexamethasone|
224265353|NCT02272803|BIOLOGICAL|Elotuzumab (BMS-901608)|
224265354|NCT06463119|OTHER|Collection of data in a registry|The aim of this observational project is to document the immunogenicity and reactogenicity of vaccines given to immunocompromised patients and collect it in a registry.
224265355|NCT00464763|DRUG|Dexmedetomidine|
224265356|NCT00464763|DRUG|Placebo|
224265357|NCT03051945|DRUG|Ketamine Hydrochloride|Study drug will be infused while the participant sits or lies in a comfortable position. The dose of ketamine used does not cause unconsciousness but may cause perceptual disturbances.
224265358|NCT03051945|OTHER|Normal saline|Placebo
224265359|NCT05787678|BIOLOGICAL|Dupilumab|600 mg (two 300 mg injections), followed by 300 mg monthly
224265360|NCT07113821|PROCEDURE|Biceps tenodesis alone|Biceps tenodesis in superior labrum anteroposterior lesion from type II to type IV
224265361|NCT07113821|PROCEDURE|Biceps tenodesis and labrum repair|Biceps tenodesis and labrum repair by anchors in superior labrum anteroposterior lesion from type II to type IV
224265362|NCT04363554|OTHER|Fluid intake|The participants will intake fluid
224265363|NCT04363554|OTHER|Thirsting|The participants will thirst
224265364|NCT01406353|PROCEDURE|Percutaneous Mitral Commissurotomy|Percutaneous mitral commissurotomy is performed by experienced interventional cardiologists using the Inoue balloon technique. During the procedure, conventional hemodynamic parameters are monitored. A successful immediate result is defined as a mitral valve area \> 1.5 square cm with less than moderate to severe mitral regurgitation.
223848643|NCT03988387|BEHAVIORAL|Peer Support (PS)|Participants randomized to the PS arm will be assigned a trained peer supporter. The peer supporters (PSr) will establish rapport and build trusting relationships with participants in order to increase self-efficacy and motivation to adhere to the daily PrEP regimen and to engage in HIV prevention behaviors, in general. The PSrs will assess for facilitators and barriers to PrEP adherence, conduct adherence counseling, and provide ongoing social and practical support (e.g. tailored appointment reminders, accompanying participants to medical appointments, and providing skills building for effective relationships with study site providers). PSrs will communicate with the participant on at least a weekly basis either in person or by phone and will track those who miss scheduled study visits. Participants will be encouraged to contact their PSrs in case of questions or concerns. For any clinical question, the peer supporter will direct the participant to the study nurse.
223848644|NCT03988387|BEHAVIORAL|Reminder and Resource Transfer (RRT)|"Participants who are randomized to the RRT arm will receive a discrete weekly SMS text (or voice message if participant is illiterate) to encourage healthy behaviors, study engagement and PrEP adherence. Messages will be a general message that the participant has selected and will not have any information identifying the participant as part of the study or describing the purpose of the study. An example text is Remember to look after yourself today, See you tomorrow. Participants will be requested to respond to the message with a brief answer. Participants will be advised that each answered text counts as a point toward resource transfer that can be redeemed at scheduled study visits in the form of a small gift, such as cosmetics, personal care items, accessories, or airtime.The value of the reward increases with points."
223848645|NCT03988387|DRUG|daily oral PrEP (emtricitabine 200 mg/tenofovir 300 mg) [FTC/TDF]|All participants will receive a one-month supply of daily oral PrEP (emtricitabine 200 mg/tenofovir 300 mg) \[FTC/TDF\] for the first month of enrollment.
223848646|NCT04285125|OTHER|cerebral MRI|Patients who agree to participate in the study will perform an MRI with ultra high resolution sequences added by the research MRI of control will be done at one year and two years
223848647|NCT04642261|DRUG|Empagliflozin 10 MG|Empagliflozin 10mg daily
223848648|NCT04642261|DRUG|Placebo pills|Identical in appearance to empagliflozin 10mg daily
223848649|NCT01551615|DRUG|Metformin 1000 mg|2 x 500 mg oral tablets
223848650|NCT01551615|DRUG|Vandetanib 800 mg|2 x 300 mg and 2 x 100 mg oral tablets
223848651|NCT02700867|DEVICE|NIO|Intraosseous access device NIO (Defibtech)
223848652|NCT02661035|DRUG|Allopurinol|300 mg/day (for peds -150 mg/m\^2/day), day -6 and continue through day 0 or longer if clinically indicated
223848653|NCT02661035|DRUG|Fludarabine|30 mg/m\^2 IV over 1 hour, day -6, -5, -4, -3 and -2
223848654|NCT02661035|DRUG|Cyclophosphamide|50 mg/kg IV over 2 hours, day -6
223848655|NCT02661035|DRUG|ATG|Only for patients with an unrelated donor (URD) and NO multi-agent chemotherapy 3 months prior to transplant. ATG will be administered IV every 12 hours for 6 doses on days -6, -5, and -4 according to institutional guidelines. Methylprednisolone 1 mg/kg IV administered immediately prior to each dose of ATG (6 doses).
223848656|NCT02661035|RADIATION|TBI|All patients who have had previous radiation therapy or TBI will be seen by Radiation Oncology prior to entrance on the protocol for approval for additional 200 cGy of TBI. TBI may be delivered by local guidelines provided the effective dose is equivalent to what is recommended in the TBI Guidelines. The dose of TBI will be 200 cGy given in a single fraction on day -1.
223848657|NCT02661035|DRUG|Tacrolimus|"All patients will receive tacrolimus therapy beginning on day -3. Initial dosing of tacrolimus will be 0.03 - 0.05 mg/kg/day IV; if the recipient body weight is \<40 kg, dosing will be 3 times daily, and if ≥ 40 kg, twice daily or per current institutional guidelines.~An attempt will be made to maintain a trough level of 5-10 ng/mL and subsequent dose modifications will be provided by the pharmacist.~Once the patient can tolerate oral medications and has a reasonable oral intake, tacrolimus will be converted to an oral form based on the current IV dose providing normal renal and hepatic function and no major drug interactions.~The timing of the tacrolimus taper will be at the discretion of the treating physician, but in general:~* Taper begins at day +100 +/- 10 days, if the patient is stably engrafted and has no active GVHD.~* Taper to zero by reducing dose by approximately 10% a week (rounded to nearest pill size), with a goal to discontinue by month 6 post-HCT."
223848658|NCT02661035|DRUG|MMF|"3 gram/day IV/PO for patients who are ≥ 40 kg divided in 2 or 3 doses. In obese patients (\>125% IBW) 15 mg/kg every 12 hours may be considered. Pediatric patient (\<40 kilograms) will receive MMF at the dose of 15 mg/kg/dose every 8 hours beginning day -3. MMF dosing will be monitored and altered as clinically appropriate based on institutional guidelines. Patients will be eligible for MMF dosing and pharmacokinetics studies.~MMF will stop at day +30 or 7 days after engraftment, whichever day is later, if no acute GVHD. (Definition of engraftment is 1st day of 3 consecutive days of absolute neutrophil count \[ANC) ≥ 0.5 x 109 /L\]). If no donor engraftment, MMF will continue as long as clinically indicated."
223848659|NCT02661035|BIOLOGICAL|Peripheral Blood Stem Cells|On day 0, patients will receive an allogeneic transplant using PBSC which are CD34+ selected as the donor graft. The graft will be infused over 15-60 minutes after premedication with acetaminophen 650 mg PO and diphenhydramine 25 mg PO/IV with doses adjusted for pediatric patients.
223848660|NCT02661035|BIOLOGICAL|Related or Unrelated Bone Marrow Cells|On day 0, a target dose of 3 x 10\^8 nucleated cells/kg recipient weight will be collected. The graft will be infused over 15-60 minutes after premedication with acetaminophen 650 mg PO and diphenhydramine 25 mg PO/IV with doses adjusted for pediatric patients.
223848661|NCT01176799|DRUG|Arm A|Doxorubicin 60mg/m2 day 1 Cyclophosphamide 600mg/m2 day1, every 3 weeks x 4 cycles
223848662|NCT01176799|DRUG|Arm B|Days -13 (or -7) to day 0 (total 7 or 14 days) - oral sunitinib daily Cycle 1: day 1 - Cycle 1 AC (60/600mg/m2); days 15-21 - oral sunitinib daily Cycle 2: day 1 - Cycle 2 AC (60/600mg/m2); days 15-21 - oral sunitinib daily Cycle 3: day 1 - Cycle 3 AC (60/600mg/m2); days 15-21 - oral sunitinib daily Cycle 4: day 1 - Cycle 4 AC (60/600mg/m2)
223848663|NCT00413868|PROCEDURE|LASIK|
223848664|NCT00413868|PROCEDURE|PRK|
223848665|NCT00413868|BEHAVIORAL|Small target contrast sensitivity and disability glare|
223848666|NCT03557385|DRUG|Iopamidol|"aFFR measurement with drug: Iopamidol (ISOVUE®-370). Subjects will receive an injector-based intracoronary bolus of contrast~* Rate of 4 mL/sec, volume of 10 cc (left coronary system)~* Rate of 3 mL/sec, volume of 6 cc (right coronary system)."
223848667|NCT03557385|DRUG|adenosine|FFR measurement with drug: adenosine. Intravenous adenosine will be administered at a rate of 140 μg/kg of body weight per minute x 2 minutes
223848668|NCT03557385|DEVICE|Navvus® Catheter|the NAVVUS RXi microcatheter will be used with a workhorse wire of the operator's choosing
223848669|NCT03557385|DEVICE|CVi® Contrast Delivery System|The CVi® Contrast Delivery System will be used to deliver the contrast medium
223848670|NCT05817331|OTHER|Carer Treatment Preference Myelodysplasia Questionnaire|Caregiver-reported outcome measure in MDS
223848671|NCT05817331|OTHER|Clinician Treatment Preference Myelodysplasia Questionnaire|Clinician-reported outcome measure in MDS
223848672|NCT05817331|OTHER|Patient Treatment Preference Myelodysplasia Questionnaire|Patient-reported outcome measure (PROM) in MDS
223848673|NCT02702024|PROCEDURE|Double uterine incision technique in uterus preserving surgery for placenta percreta|
223848674|NCT00857480|DRUG|NRL972|Single intravenous administration of 2 mg NRL972
223848675|NCT00857480|DRUG|NRL972|Pre-treatment and co-treatment with 1 g Cloxacillin t.i.d. for three days from the morning of D-3 until the morning of Day D01 0:30 hour before the intravenous administration of NRL972.
223848676|NCT00857480|DRUG|NRL972|Three week pre-treatment with daily doses of 500 mg b.i.d ursodeoxycholic acid from the morning of D-20 until the evening of Day D-1
223848677|NCT03761654|DIAGNOSTIC_TEST|Global Longitudinal Strain measure|Global Longitudinal Strain measure on day 1 of hospitalization
223848678|NCT00938340|DIETARY_SUPPLEMENT|"Walnut meat"|Separated, ground walnut de-fatted nut meat incorporated into inert food carrier
223848679|NCT00938340|DIETARY_SUPPLEMENT|Walnut Oil|Walnut oil extracted from nut meat and incorporated into inert food carrier
223848680|NCT00938340|DIETARY_SUPPLEMENT|Walnut Skins|Separated, ground walnut skins incorporated into inert food carrier
223848681|NCT00938340|DIETARY_SUPPLEMENT|Whole walnut|85g whole walnuts, ground, incorporated into inert food carrier
223848682|NCT00002937|DRUG|paclitaxel|
223848683|NCT00002937|DRUG|valspodar|
223848684|NCT02594215|DRUG|MK-7075 (miransertib)|MK-7075 or miransertib (formerly ARQ 092) is small molecule that effectively inhibits AKT. Proteus syndrome is caused by mosaic activating mutations in AKT1. This is a phase I study to determine a recommended dose for subsequent trials, which will determine the efficacy of miransertib in Proteus syndrome.
223848685|NCT02534896|DRUG|Treatment I|Sunpharma1505 and Placebo
223848686|NCT02534896|DRUG|Treatment II|Sunpharma1505 and Placebo
223848687|NCT02534896|DRUG|Treatment III|Reference1505 and Placebo
223848688|NCT01923857|DRUG|Androxal 25 mg|
223848689|NCT05779514|DRUG|Mirabegron|Health Volunteers ：Mirabegron p.o. 28 days 100mg qd./ Tumor patients ：Mirabegron p.o. 28 days 100 mg qd or 200 mg qd.
223848690|NCT02796092|DEVICE|Fibered platinum coils|
223848691|NCT02796092|DEVICE|Vascular plugs|
223848692|NCT03594331|DRUG|Low-dose PvP001|Low-dose PvP001
223848693|NCT03594331|DRUG|Medium-dose PvP001|Medium-dose PvP001
223848694|NCT03594331|DRUG|High-dose PvP001|High-dose PvP001
223848695|NCT03594331|DRUG|Placebo|100 mL liquid with no drug
223848696|NCT04288492|BEHAVIORAL|Respiratory biofeedback|Repeat the inspiration and exhalation breaths for a fixed period of time using a biofeedback device (ResCalm)
223848697|NCT00268606|BEHAVIORAL|cognitive-behavioral therapy|
223848698|NCT01180621|BIOLOGICAL|Fluviral|0.25 mL Fluviral for children up to and including 35 months of age 0.50 mL Fluviral for children 36-59 months of age
223848699|NCT00469300|DRUG|Iontophoretic delivery of acyclovir|
223848700|NCT01365403|DRUG|RO4917838|Single oral dose, Day 1 of study period 1 and Day 16 of study period 2
223848701|NCT01365403|DRUG|carbamazepine|multiple oral doses, Days 1-24 of study period 2
223848702|NCT02702921|DEVICE|Surgeon's 'standard of care' stapler|
223848703|NCT02702921|DEVICE|Ethicon Powered Vascular Stapler|
223848704|NCT05961670|DEVICE|Neer Infrared Spectroscopy|Premature infants will be studied with brain and lung NIRS before and after surfactant administration
223848705|NCT03751878|BEHAVIORAL|Evaluation of reporting inconsistencies|"1. The completed CONSORT checklist submitted by authors of manuscripts randomised to the intervention group will be assessed by the lead investigator (DB) as to whether it is consistent with the information that was actually reported in the manuscript. This evaluation will be focused on 8 core CONSORT items.~2. DB will produce a standardised report containing precise requests for authors in order to improve the completeness of reporting of the items where reporting inconsistencies were found. This report will consist of a brief introduction followed by a point by point description of the inconsistencies found together with precise requests related to the information missing and examples extracted from CONSORT. DB will upload this report to the submission on the managing system of the journal (Scholar One) to make it accessible to the handling editor of the manuscript.~3. This editor will include the report in the letter to authors alongside the standard peer review reports."
223848706|NCT03751878|BEHAVIORAL|Standard Peer Review.|Manuscripts will undergo the usual peer review process.
223848707|NCT01107626|DRUG|Paclitaxel|Given IV
223848708|NCT01107626|DRUG|Carboplatin|Given IV
223848709|NCT01107626|BIOLOGICAL|Bevacizumab|Given IV
223848710|NCT01107626|DRUG|Pemetrexed Disodium Heptahydrate|Given IV
223848711|NCT03992495|OTHER|Exercise|All participants will be exposed to aerobic/strengthening exercises
223848712|NCT00102414|DRUG|Gemcitabine|
223848713|NCT05975294|DRUG|amixture 0.125% bupivicaine with fentanyl|ultrasound guided continuous erector spinae plane block with abolus 0.3ml /kg of amixture 0.125% bupivicaine with fentanyl of 2 mic per ml then Infusion of 0.1 ml /kg/hr of the same mixture.
223848714|NCT05975294|DRUG|100 ml volume containing 80 mg of nalbuphine ,180 mg ketorolac, 24mg dexamethasone, 16 mg danset|PCA device of 100 ml volume containing 80 mg of nalbuphine ,180 mg ketorolac, 24mg dexamethasone, 16 mg danset and normal saline at a rate of 2 ml/h.
223848715|NCT05190913|OTHER|Instrumental perineal massage|In the active phase of labor, perineal massage will be performed with an instrument twice with an interval of one hour.
223848716|NCT05190913|OTHER|manual perineal massage|In the active phase of labor, manual perineal massage is performed twice an hour apart.
223848717|NCT04353037|DRUG|Group 1 HCQ|Enrolled participants randomized in Group 1 receive the HCQ drug
224265365|NCT02016274|OTHER|Sequential chemotherapy (paclitaxel 175mg/m2 d1; cisplatin 37.5mg/m2 d1,d2) and radiotherapy|Sequential paclitaxel/cisplatin chemotherapy and radiotherapy
223848718|NCT04353037|DRUG|Group 2 Placebo|Enrolled participants randomized in Group 2 will receive a placebo drug
223848719|NCT05830604|PROCEDURE|Occlusal Splint Treatment- Non Invasive treatment|Each patient in the study had temporomandibular disorder. The first-line routine treatment of this disease is an occlusal splint. This treatment was applied to each patient. Surgical intervention was not performed.
223848720|NCT03710564|BIOLOGICAL|Brolucizumab|6 mg/0.05mL solution for intravitreal injection
223848721|NCT03710564|BIOLOGICAL|Aflibercept|2 mg/0.05mL solution for intravitreal injection
223848722|NCT00241540|DRUG|Esomeprazole|
223848723|NCT02540135|OTHER|fluorescein|fluorescein and conventional neuro-navigation
223848724|NCT02540135|OTHER|intraoperative MRI|conventional neuro-navigation and iMRI
223848725|NCT01949909|BIOLOGICAL|CH-Alum50|intramuscular administration to Swiss volunteers of Alhydrogel and P27A antigen (50 microg)
223848726|NCT01949909|BIOLOGICAL|CH-GLA2.5/50|intramuscular administration to Swiss volunteers of GLA-SE (2.5microg) together with the P27A antigen (50 microg)
223848727|NCT01949909|BIOLOGICAL|TZ Ver|intramuscular administration of Rabies vaccine Verorub TM to in Phase IIb only to 8 Tanzanian volunteers in three injections
223848728|NCT01949909|BIOLOGICAL|TZ Alum 50|intramuscular administration to Tanzanian volunteers of Alhydrogel and P27A antigen (50 microg)
223848729|NCT01949909|BIOLOGICAL|TZ GLA 2.5/10|intramuscular administration to Tanzanian volunteers of GLA-SE (2.5 microg ) together with the P27A antigen (10 microg)
223848730|NCT01949909|BIOLOGICAL|TZ GLA5/50|intramuscular administration to Tanzanian volunteers of GLA-SE (5 microg) together with the P27A antigen (50 microg)
223848731|NCT01949909|BIOLOGICAL|TZ GLA2.5/50|intramuscular administration to Tanzanian volunteers of GLA-SE (2.5microg) together with the P27A antigen (50 microg)
223848732|NCT00533234|DEVICE|ExploR® Modular Radial Head|The ExploR® Modular Radial Head is a modular head and stem radial head/neck replacement.
223848733|NCT04667065|OTHER|Physical activity|Physical activity with the remotely guidance of physical activity teachers
223848734|NCT05082649|OTHER|Face to Face Exercise|Face to face (in clinic) progressive spinal stabilization exercises.
223848735|NCT05082649|OTHER|Telerehabilitation|Remotely (with video) progressive spinal stabilization exercises.
223848736|NCT01133132|BEHAVIORAL|Survivorship CHESS|Once the consent, baseline survey and one week accelerometer data is received by the UW research team subjects will be randomized to one of the two study conditions. Subjects will be notified of their randomization. Subjects randomized to the Survivorship CHESS condition will be offered training on the smartphone and the CHESS system. The project director (and site research coordinators) will provide training on the smartphone either in person or over the phone. Additionally, an online tutorial will be included in the Survivorship CHESS intervention for subjects to refer to as needed. Participants will then be asked to complete four surveys one baseline and then three follow up surveys.
223848737|NCT01133132|OTHER|Control|This person will receive usual care and a copy of the National Cancer Institute's Facing Forward booklet and the National Cancer Center Network cancer survivor toolbox.
223848738|NCT04009226|OTHER|Patient Registry|Participants who have volunteered to participate will complete various questionnaires relating to their condition.
223848739|NCT04572672|OTHER|Non-pharmacologic treatment; Pursed-Lip Breathing Combined with Number Counting|"Pursed-lip breathing and number counting one and two during inspiration, and then number counting, one, two, three, and four during exhalation. The nurse advised the patient to continue pursed-lip breathing with number counting for the first 15 minutes (min) of each hour to prevent the patient from being exhausted, total study time was 3 hours, or until the patient was discharged from the ER, or was withdrawn from the study."
223848740|NCT03617107|OTHER|reverse total shoulder arthroplasty|reverse total shoulder arthroplasty
223848741|NCT00003656|BIOLOGICAL|recombinant interferon alfa|
223848742|NCT00003656|DRUG|tretinoin liposome|
223848743|NCT03393520|DRUG|Placebo|oral capsules
223848744|NCT03393520|DRUG|AVP-786|oral capsules
223848745|NCT00630513|DRUG|Ertapenem|3 days regimen with Ertapenem (1 g/day i.v.)
223848746|NCT00630513|DRUG|Ampicillin-Sulbactam|3 days treatment with Ampicillin-Sulbactam (AS 3g x 3/ day i.v.)
223848747|NCT00939848|DRUG|gemcitabine|gemcitabine 1000 mg/m2 on days 1 and 8 of a 21-day cycle for 24 weeks in the absence of disease progression
223848748|NCT00939848|DRUG|cisplatin|cisplatin 25 mg/m2 on days 1 and 8 of a 21-day cycle for 24 weeks in the absence of disease progression
223848749|NCT00939848|DRUG|Placebo|20mg od (continuous dosing) until evidence of disease progression has been confirmed
223848750|NCT00939848|DRUG|cisplatin|cisplatin 25 mg/m2 on days 1 and 8 of a 21-day cycle for 24 weeks in the absence of disease progression
223848751|NCT00939848|DRUG|cediranib|cediranib 20mg oral daily (continuous dosing)until evidence of disease progression has been confirmed
223848752|NCT00939848|DRUG|gemcitabine|gemcitabine 1000 mg/m2 on days 1 and 8 of a 21-day cycle for 24 weeks in the absence of disease progression
223848753|NCT01073098|OTHER|Vascular occlusion test|Reperfusion slope after vascular occlusion test
223848754|NCT04892810|PROCEDURE|Percutaneous ablation|Hepatic Percutaneous Ablation with radiofrequency or microwave
223848755|NCT00151619|DRUG|Amlodipine|
223848756|NCT01904357|DRUG|Cefazolin 1 GM Injection|Subjects weighing ≥25 kg and \< 50 kg will receive the 1g dose.
223848757|NCT01904357|DRUG|Cefazolin 2 GM Injection|Subjects weighing ≥50 kg to ≤85 kg will receive the 2g dose.
223848758|NCT06048341|PROCEDURE|Sono-guided injection|After spinal anesthesia, patients will be injected around femoral nerve using ultrasonography.
223848759|NCT06048341|DRUG|Ropivacaine injection|After spinal anesthesia, patients will be injected 20ml ropivacaine around femoral nerve.
223848760|NCT06048341|DRUG|Saline injection|After spinal anesthesia, patients will be injected 20ml 0.9% saline around femoral nerve.
223848761|NCT06331754|OTHER|Technology-enabled blood pressure management|The intervention will consist of a technology-enabled remote hypertension management program.
223848762|NCT00106808|DRUG|Muraglitazar|
223848763|NCT00106808|DRUG|Pioglitazone|
223848764|NCT04144985|OTHER|Visual analog scale (VAS) of pain to evaluate the discomfort participants experience.|Eyelid retraction was performed with one of the three methods (eyelid speculum, unimanual eyelid retraction or cotton tipped applicator assisted eyelid retraction) and participants were then asked to rate their discomfort during the procedure with a visual analog scale (VAS) of pain.
223848765|NCT00188240|DRUG|Pegasys; Copegus.|
223848766|NCT02742142|OTHER|water as placebo|topical application of water as a placebo in the control arm
223848767|NCT02742142|DRUG|silver diammine fluoride|topical application of the SDF solution onto tooth root surfaces
223848768|NCT04548609|DEVICE|Transcranial Direct Current Stimulation|In tDCS, electrodes are applied on the scalp to transmit direct current at low current amplitudes.
223848769|NCT04422925|PROCEDURE|Living Donor Hepatectomy|On living donor hepatectomy (preoperative), the first following day of surgery, 3rd day, and 7th day, blood will be taken for the measurement of S100β, NSE, and GFAP levels in the postoperative period. The plasma of the blood taken will be separated and stored at -800C. Values will be measured by the ELISA method. During the hospitalization, the delirium status of the patients will be evaluated with the delirium evaluation scale (Delirium Rating Scale-Revised - 98 Turkish version). Functional and cognitive information and other results will be collected at each follow-up point.
224265366|NCT00707330|DRUG|Clarithromycin|Prolonged release tablet, 500 mg, 1 tablet a day for a week
223848770|NCT01941316|DRUG|Carfilzomib|20/36 \* mg/m\^2 stepped up dosing, IV infusion (over 30 min), on days 1, 2, 8, 9, 15 and 16 of each 28 day cycle. Number of cycles: 6, or until progression, or unacceptable toxicity, or treatment delay for any reason greater than 3 weeks.
223848771|NCT01941316|DRUG|Irinotecan|125 mg/m\^2, IV infusion (over 90 min), on days 1, 8, 15 of each 28 day cycle. Number of cycles: 6, or until progression, or unacceptable toxicity, or treatment delay for any reason greater than 3 weeks.
223848772|NCT01501214|DRUG|Atosiban|Patients in the atosiban group will receive intravenous atosiban 30 min before the transfer with a bolus dose of 6.75 mg, and the infusion will be continued with an infusion rate of 18 mg/h. After performing ET, the dose of atosiban will be reduced to 6 mg/h and the infusion will be continued for 2 hours (total administered dose: 37.5 mg). Those in the placebo group will receive normal saline only.
223848773|NCT01501214|DRUG|Normal saline|Normal saline given
223848774|NCT05082883|DIAGNOSTIC_TEST|Risk Assessment Cognitive Screening|Completion of a risk assessment cognitive screening app that includes working memory and voice-based tasks
223848775|NCT02637544|OTHER|acupuncture|classical acupuncture therapy
223848776|NCT00097253|BEHAVIORAL|Exposure to relaxant and stimulant odors|A yellow-tinted cotton ball containing 100 ml of the essential oil or distilled water was taped between the nose and upper lip on top of a piece of surgical tape; use of the barrier tape avoided percutaneous absorption . This method provided continuous and uniform exposure across subjects that would not have been possible with ambient room inhalation, and helped maintain experimenter blindness.
223848777|NCT05998668|OTHER|Genital hygiene training|In the first meeting with the women, 2 sessions of 45 minutes with a 10-minute break were held in the counselling rooms of the relevant family health centers. Two weeks after these sessions, a 45-minute session was held in order to reinforce the training with the same method.
223848778|NCT00841282|PROCEDURE|Colonoscopy for colorectal cancer screening|
223848779|NCT00841282|PROCEDURE|Water Infusion Colonoscopy|water infusion in lieu of air insufflation for screening colonoscopy
223848780|NCT00841282|PROCEDURE|Air insufflation colonoscopy|Conventional colonoscopy with air insufflation
223848781|NCT00372216|DRUG|Clopidogrel (Iscover/Plavix)|Pre-hospital loading-dose of 600 mg Clopidogrel as early as possible
223848782|NCT00690469|OTHER|Laboratory Biomarker Analysis|Correlative studies
224265367|NCT06561490|RADIATION|sonographic assesment of placental thickness and volume|sonographic assesment of placental thickness and volume
224265368|NCT04318808|PROCEDURE|Laser acupuncture|Laser acupuncture is a non-invasive therapy that involves stimulation of traditional acupoints with low-intensity, non-thermal laser irradiation.
224265369|NCT01670643|BEHAVIORAL|Video camera magnifier|reading with video camera magnifier
224265370|NCT02913287|DIETARY_SUPPLEMENT|Aquamin/Aquamin MG|Marine-based nutraceutical
224265371|NCT02913287|OTHER|Maltodextrin Placebo|Maltodextrin Placebo
224265372|NCT00675142|PROCEDURE|Intrauterine Insemination|Changing the time span between ovulation induction and IUI during fertility treatment.
224265373|NCT04116957|DEVICE|RTLS current tag|Validate location system performance against manual observation of nursing activity
224265374|NCT04116957|DEVICE|RTLS tag revised|Test a next-generation RTLS tag for healthcare process validation
224265375|NCT01165450|DRUG|Nexagon|There will be 3 groups of patients with persistent epithelial defects, treated in a dose-escalation fashion from 1µg to 3µg to 10 µg. Each group will consist of 18 patients randomized to Nexagon and 6 patients randomized to placebo only.
224265376|NCT01165450|DRUG|Vehicle only|There will be 3 groups of patients with persistent epithelial defects, treated in a dose-escalation fashion from 1µg to 3µg to 10 µg. Each group will consist of 18 patients randomized to Nexagon and 6 patients randomized to placebo only.
224265377|NCT03586219|BEHAVIORAL|Opioid-specific educational patient pamphlets|See prior description
224265378|NCT00357461|BIOLOGICAL|gp100:209-217(210M) peptide vaccine|
224265379|NCT00357461|BIOLOGICAL|gp100:280-288(288V) peptide vaccine|
224265380|NCT00357461|BIOLOGICAL|incomplete Freund's adjuvant|
224265381|NCT00357461|BIOLOGICAL|ipilimumab|
224265382|NCT01957280|DRUG|patritumab|
224265383|NCT04934098|DEVICE|Adjustable Compression Wrap|The material will be delivered, adapted, and oriented for the daily use of the adjustable compression wrap (Ready Wrap®). The wrap allows for easy use because it is the pre-molded system in inelastic material with self-adjusting compressible components according to the size and shape of the upper limb. Due to its compression properties, it can be used as a therapy to control lymphedema. The material composition is: 61% Nylon, 33% Polyurethane, 6% Elastane (Spandex)). The institutional protocol for the control of the lymphedema phase will be respected, in which the orthosis is used at home for the longest period possible, with the only removal for bathing and sleeping; in addition, skincare and therapeutic exercises for the upper limbs should be performed daily.
224265384|NCT04934098|DEVICE|Compression Bandage|Evaluation, skincare, compression bandaging, and guidance on therapeutic exercises for upper limbs. The material used for binding is tubular mesh, foam, elastic compression bandage. Therapy will be followed according to the institutional protocol for the lymphedema reduction phase, in which it will be reassessed twice a week for 30 days.
224265385|NCT05964049|DEVICE|active rTMS treatment|Participants will receive 5 sessions per day of 1800 pulses per session, lasting for 15 days. Individualized targets will be generated using the pBFS method.
224265386|NCT05964049|DEVICE|sham rTMS treatment|The parameters in the sham arms are the same as the active stimulation groups. Stimulation was delivered by the same device as the active group fitted with a sham coil.
224265387|NCT02865824|DRUG|Continue thienopyridine|Patients continue dual antiplatelet therapies before colonoscopy. The patients continue taking thienopyridine before colonoscopy
224265388|NCT02865824|DRUG|Discontinue thienopyridine|Patients who are taking dual antiplatelet therapies stop thienopyridine one week before they undergo colonoscopy
224265389|NCT00664053|DIETARY_SUPPLEMENT|DHEA|50mg daily for 6 months
224265390|NCT00664053|BEHAVIORAL|Yoga|2 sessions per week for 6 months
224265391|NCT00664053|DIETARY_SUPPLEMENT|Placebo|Placebo supplement every day for 6 months
224265392|NCT00664053|BEHAVIORAL|Aerobics|Walking/chair aerobics program 2 sessions per week for 6 months
224265393|NCT00879164|DRUG|bupivacaine hydrochloride|
224265394|NCT00879164|OTHER|questionnaire administration|
224265395|NCT00170469|BIOLOGICAL|AVA|
223848783|NCT00690469|OTHER|Questionnaire Administration|Ancillary studies
223848784|NCT01495637|DRUG|GM-CSF|GM-CSF is to be administered IV at one of four possible dosing regimens (three days at a dose of 30, 62, or 125 mcg/m2 per day, or an extended dosing regimen of 125 mcg/m2/day through post-trauma 6) if severe innate immune suppression is identified on post-trauma days 1, 2, or 3.
223848785|NCT04882722|OTHER|Questionnaire|Self-questionnaire reported before the first PPFR session and after the last session
223848786|NCT00533416|DRUG|ON 01910 Na|
223848787|NCT03699735|DEVICE|Bolero B90-SP|Behind the ear Hearing device fitted with an individual ear mold to compensate a Hearing loss
223848788|NCT04545606|BEHAVIORAL|In-Person CBT for insomnia in children with autism|"7 modules administered in-person~1. Sleep Hygiene \& Sleep Prescription~2. Bedtime Routine \& Parent Management~3. Cue Control \& Parent Management~4. Co-Sleeping \& Parents Fading out of Room~5. Circadian Education, Morning Routine, \& Relaxation~6. Cognitive Therapy Basics~7. Nighttime Fears, Anxiety, \& Nightmares"
223848789|NCT04545606|BEHAVIORAL|Remote CBT for insomnia in children with autism|"7 modules administered over telehealth/videoconferencing~1. Sleep Hygiene \& Sleep Prescription~2. Bedtime Routine \& Parent Management~3. Cue Control \& Parent Management~4. Co-Sleeping \& Parents Fading out of Room~5. Circadian Education, Morning Routine, \& Relaxation~6. Cognitive Therapy Basics~7. Nighttime Fears, Anxiety, \& Nightmares"
223848790|NCT04545606|BEHAVIORAL|Remote sleep hygiene and related education (SHARE) for insomnia in children with autism|"7 modules administered over telehealth/videoconferencing~1. Sleep Education~2. Sleep Architecture \& Parasomnias~3. Physical Activity \& Sleep~4. Nutrition, My Plate, \& Breathing during Sleep~5. Stress, Sleep, Dreams, \& Nightmares Connections~6. Mood, Self-Esteem, \& Sleep~7. Light \& Dark Cycle"
223848791|NCT01646502|BIOLOGICAL|Esp protein|
223848792|NCT01646502|OTHER|Standard wound care|
223848793|NCT02766504|DEVICE|airway ultrasound|airway assessment using ultrasound
223848794|NCT02196012|BEHAVIORAL|Intervention group|
223848795|NCT02196012|BEHAVIORAL|attention control condition|
223848796|NCT01428349|OTHER|Cognitive Remediation|Computer training on 3 tasks that targets the attention to context deficits associated with psychopathic offenders. Participants complete 6 training sessions, that include the tasks, feedback and real-world translational examples.
223848797|NCT01428349|OTHER|Cognitive Remediation|Computer training on 3 tasks that targets the affective cognitive control deficits associated with externalizing offenders. Participants complete 6 training sessions, that include the tasks, feedback and real-world translational examples.
223848798|NCT01219855|DRUG|Cohort 1 CTAP101 Capsules- 60µg|60µg of CTAP101 capsules given once daily for 42 days.
223848799|NCT01219855|DRUG|Cohort 1 CTAP101 Capsules - 90µg|90µg of CTAP101 capsules given once daily for 42 days.
223848800|NCT01219855|DRUG|Cohort 1 Matching Sugar Capsule|Placebo capsules given once daily for 42 days.
223848801|NCT01219855|DRUG|Cohort 2 CTAP101 Capsules - 30µg|30µg of CTAP101 capsules given once daily for 42 days.
223848802|NCT01219855|DRUG|Cohort 2 Matching Sugar Capsule|Placebo capsules given once daily for 42 days.
223848803|NCT04097899|OTHER|implementation of antimicrobial stewardship comprehensive care bundle program on ventilator associated pneumonia patients|"Construction of a comprehensive care bundle educational program. This program consisted of many elements: Antimicrobial stewardship programs, VAP bundles and infection control policy implementation and the investigators studied the impact of this program on:~* Antibiotics cost.~* Appropriates of antibiotic use (initiation, duration \& time of discontinuation).~* Rate of resistance~* Clinical outcome, infection rate \&length of stay."
223848804|NCT02960542|BEHAVIORAL|HELP Prevent Cancer Intervention|This Behavioral: Lifestyle Weigh Loss Intervention involves a dietary weight-loss program and an increase in caloric expenditure through moderate physical activity. The primary treatment objectives for the weight-loss component of the intervention will be to decrease caloric intake in a nutritionally sound manner so as to produce a weight-loss of .3 kg/week for a total weight loss of 5-7%. The primary objective for the physical activity component of the intervention will be to promote an increase in home-based energy expenditure to an eventual goal of 180 minutes/week.
223848805|NCT04088513|DRUG|Aspirin|This group will receive a 100 mg/day aspirin plus clopidogrel placebo for 90 days.
223848806|NCT04088513|DRUG|Clopidogrel|This group will receive a 75 mg/day clopidogrel plus aspirin placebo for 90 days.
223848807|NCT00590603|DRUG|Arsenic Trioxide, Ascorbic Acid and Bortezomib|"Phase I/Cohort I~Loading:~1. Arsenic Trioxide (ATO): 0.25 mg/kg IV over 1-2 hr qd x 5 days (Monday-Friday)~2. Ascorbic Acid: 1000 mg by IV infusion over 15 minutes after each infusion of arsenic trioxide qd x 5 days~Maintenance cycles (21 days)~1. ATO: 0.25 mg/kg IV over 1-2 hr once a week x 2 weeks every 3 weeks (one cycle) for a total of 6 cycles.~2. Ascorbic Acid 1000mg IV will be given within 30 minutes of completion of ATO.~3. Bortezomib 1 mg/m2 is administered intravenously in a 3-5 second bolus on days 1, 8 of a 21-day cycle. ATO is given at least one hour prior to Bortezomib. The first cycle will start on week 2, after loading dose week.~Phase I/Cohort 1 is followed by Cohort 2. Phase II uses maximum tolerated dose from Phase I."
223848808|NCT04808635|OTHER|no intervention, this is a cross sectional questionnaire based study.|no intervention, this is an observational cross sectional study
224265396|NCT00170469|BIOLOGICAL|rPA vaccine containing alhydrogel|
224265397|NCT01710696|DRUG|17-beta estradiol|5-15 mcg/kg daily for 2 years. Dose readjusted every 3 months. Administered orally
224265398|NCT01710696|DRUG|17-beta estradiol|0.2 mcg daily for 12 months, dose escalated to 0.5 mcg daily for 12 months. Administered orally
224265399|NCT01566435|DRUG|paclitaxel albumin-stabilized nanoparticle formulation|
224265400|NCT01566435|DRUG|Cisplatin|
224265401|NCT01566435|DRUG|Fluorouracil|
224265402|NCT01566435|RADIATION|Intensity modulated radiation therapy|
224265403|NCT01566435|DRUG|Cetuximab|
224265404|NCT01566435|PROCEDURE|Quality-of-life assessment|ACF baseline, IMRT baseline, Day 7, Week 12, months 6 and 12
223848809|NCT00883350|BEHAVIORAL|RIDE e-health application|The RIDE e-Health application utilizes the latest technology to obtain near real-time food intake, body weight, and exercise data from participants living in their natural environment. The application also provides personalized and timely feedback and treatment recommendations based on participants' data. The application relies on the Remote Food Photography Method (Martin, 2009), which was developed by our research team, to collect freeliving food intake data that is transmitted to the researchers in near realtime using a camera and Bluetooth-enabled cell phone. A scale is used to collect daily body weight data from participants and these data are automatically transmitted to the researchers via the same cell phone. The e-Health application collects exercise data from participants and these data are delivered to the researchers via the internet; personalized feedback and treatment recommendations are sent to the participant every 1 to 3 days via the cell phone.
223848810|NCT02191852|DRUG|Seresis®|
223848811|NCT03061955|BIOLOGICAL|influenza vaccination|administration of influenza vaccination
223848812|NCT03419208|OTHER|SPIN-HAND Program|The internet-based SPIN-HAND program consists of 4 modules (1) Thumb Flexibility and Strength (3 exercises); (2) Finger Bending (3 exercises); (3) Finger Extension (3 exercises); and (4) Wrist Flexibility and Strength (2 exercises). The program includes sections on developing a personalized program, goal-setting strategies and examples, progress tracking, sharing goals and progress with friends and family, and patient stories of experiences with hand disability and hand exercises. Instructional videos demonstrate and explain how to perform each exercise properly with pictures to illustrate common mistakes. Separate versions of each exercise are available for patients with mild/moderate and more severe hand involvement.
223848813|NCT06530875|BEHAVIORAL|training on hesitations regarding childhood vaccinations|Training will be given to expectant mothers on childhood vaccination hesitations
223848814|NCT04854993|DRUG|Sugammadex 6 mg/kg|i.v. injection of an increased (by 50%) dose of sugammadex to reverse dNMB
223848815|NCT04854993|DRUG|Sugammadex 4 mg/kg|i.v. injection of a standard dose of sugammadex to reverse dNMB
223848816|NCT06227286|DEVICE|EECP|EECP: 30-45 minutes/day, 5 days/week, 7 weeks, initiates with 0.030MPa.
223848817|NCT06227286|DEVICE|Sham-EECP|EECP: 30-45 minutes/day, 5 days/week, 7 weeks, constant to 75 mmHg.
223848818|NCT03360422|OTHER|Survey|Respondents meeting inclusion criteria will be informed they were selected for the longer survey and continue to the survey. Upon completion, the survey will generate a study identification (ID) that respondents will provide to study staff with additional contact information via phone, text or email to be compensated
223848819|NCT03360422|OTHER|Focus Group|After informed consent, participants will complete the web-based intervention component in development. Afterward, participants will be engaged by an experienced facilitator in a discussion of aspects of the intervention they liked and disliked and suggestions they have for enhancing its cultural appropriateness to young MSM.
223848820|NCT03360422|OTHER|Usability study|After informed consent, participants will utilize the mobile intervention in development for 30 days to establish usability, acceptability and correct any functionality issues.
223848821|NCT02732314|DRUG|Investigational OTC Cream|
223848822|NCT02732314|OTHER|Cosmetic Eczema Cream|
223848823|NCT02732314|DRUG|0.05% Desonide Cream|
223848824|NCT02732314|OTHER|Placebo Cream|
223848825|NCT05154799|BEHAVIORAL|Proprioception and tactile localization with manual or ocular response and/or free hand grasp|"In the first part of the study, the subject must designate a target in 2 ways: manual pointing or ocular saccadic response.~In the second part of the study the subject will have to reach and grasp a rectangular block of wood placed on the table at a distance of 35 cm. He will have to catch the wooden block, lift it a few centimeters and put it back on the table. Tool use and control phases: the subject grasps the wooden block with a tool or without the tool but with a weighted bracelet loading his wrist by the same amount as the tool."
223848826|NCT01835899|DRUG|Placebo|Placebo to BI 1015550
223848827|NCT01835899|DRUG|BI 1015550|medium dose 1 powder for oral solution
223848828|NCT01835899|DRUG|BI 1015550|medium dose 2 powder for oral solution
223848829|NCT01835899|DRUG|BI1015550|low dose 2 powder for oral solution
223848830|NCT01835899|DRUG|BI 1015550|low dose 1 powder for oral solution
223848831|NCT02664194|DEVICE|Proteus® Cooling System|Intravascular hypothermia as an adjunctive method to primary percutaneous coronary intervention, adjunct hypothermia methods and parameters, using Proteus® Cooling System.
223848832|NCT02664194|PROCEDURE|Primary Percutaneous Coronary Intervention|Primary percutaneous coronary intervention
223848833|NCT03444779|DEVICE|Tibial Tuberoplasty|Kyphoplasty ballon
223848834|NCT03444779|DEVICE|Open technique|Cutaneous incision with submeniscal arthrotomy under guidance of a fluoroscope.
223848835|NCT02993510|PROCEDURE|Microfracture|Microfracture is a well-established arthroscopic surgical technique for cartilage repair which involves several systematic steps, including debridement to a stable cartilage margin, careful removal of the calcified cartilage layer, and homogeneous placement of microfracture penetrations within the cartilage defect, with resultant complete defect fill by a well-anchored clot
223848836|NCT02993510|DEVICE|Chondro-Gide sutured|Implantation of Chondro-Gide membrane using atraumatic sutures following microfracture via mini-arthrotomy
223848837|NCT02993510|DEVICE|Chondro-Gide glued|Implantation of Chondro-Gide membrane using Fibrin glue following microfracture via mini-arthrotomy
223848838|NCT05598528|OTHER|Genomic profiles detection|The Paraffin-embedded tumor tissue at diagnosis is collected and assessed by Next- generation gene sequencing
223848839|NCT05598528|OTHER|circulating tumor DNA detection|The Plasma at diagnosis and at 1-month treatment are collected and assessed by Next-generation gene sequencing
223848840|NCT01521624|DRUG|Metformin|Metformin 1000 mg Daily in two divided doses plus advice for lifestyle modification
223848841|NCT04795544|PROCEDURE|Intracuff pressure measurement|Intracuff pressure is measured by a pressure manometer.
223848842|NCT04807517|DRUG|Buspirone|All participants in the study will receive open-label treatment with orally administered buspirone for the full duration of the 16-week trial. Buspirone has high affinity for serotonin 5-HT1A and 5-HT2 receptors and moderate affinity for dopamine D2 receptors. It is approved for the management of generalized anxiety disorder in adults.
223848843|NCT04077281|OTHER|Medication Coordinated care|"* Clinical Pharmacology \& Toxicology consult~* CPT team completes detailed circle of care communication~* Telemedicine followup by CPT team (approximately 48 hrs post-discharge \& 1 week to1 month post-discharge)"
223848844|NCT05889390|DEVICE|Oncotherm EHY-2030|Oncotherm EHY-2030 is a non-invasive electromagnetic devices with known anti-tumoral effects. It operates in a precision capacitive coupled impedance matched way, working on a radiofrequency of 13.56 MHz. mEHT exploits various biophysical differences of cancer cells. For example, energy absorption on the membrane rafts is different than those of healthy host cells, and damage-associated molecular patterns (DAMPS) will also occur leading to programmed or immunogenic tumor cell death. mEHT can enhance DNA fragmentation of tumor cells, increase the fraction of cells with low mitochondrial membrane potential, increase the concentration of intracellular Ca2+, increase the Fas, c-Jun N-terminal kinases and MAPK/ERK signaling pathways, increase the expression of pro-apoptotic Bcl-2 family proteins and can up-regulate the expression of genes associated with the molecular function of cell death (EGR1, JUN, and CDKN1A) and silencing others associated with cytoprotective functions.
223848845|NCT05889390|DRUG|Paclitaxel|weekly paclitaxel for 12 weeks
223848846|NCT05889390|DRUG|Carboplatin|added to weekly paclitaxel if patient has triple-negative breast cancer
223848847|NCT05889390|DRUG|Cyclophosphamide/Doxorubicin|according to the AC protocol
223848848|NCT05889390|PROCEDURE|Breast cancer removal surgery|Either breast-conserving surgery or total mastectomy after the neoadjuvant chemotherapy with or without mEHT (if feasible)
223848849|NCT05560399|DRUG|Iberdomide|Route of administration: oral pill. Schedule: Taken Once daily on days 1-21. Dose: will be tested at 1 mg, 1.3 mg, and 1.6mg. 1mg dose may be reduced to 0.75mg if not tolerated.
223848850|NCT05560399|DRUG|Elotuzumab|Route of administration: IV Dose: 10 mg/kg for cycles 1 and 2. 20 mg/kg for cycle 3 and beyond. Schedule: Days 1, 8, 15, and 22 for cycles 1 and 2. Then taken on Day 1 (every 28 days) of each cycle thereafter.
223848851|NCT05560399|DRUG|Dexamethasone|"Route of administration: Oral pill or IV Dose: 36 mg within 24 hrs of day 1 of each cycle and day 8, 15, and 22 of cycle 1 and 2.~40 mg on days 8, 15, 22 of cycle 3 and all subsequent cycles. (20 mg for \> 75 years old).~Schedule: On days that Elotuzumab is administered, Dexamethasone to be taken 28mg orally (for ≤75 years old) or 8mg orally (for \> 75 years old) between 3 and 24 hours before Elotuzumab plus 8 mg IV between 45 and 90 minutes before Elotuzumab for all patients.~On days that Elotuzumab is not administered but a dose of Dexamethasone is scheduled (Days 8, 15, and 22 of cycle 3 and all subsequent cycles), 40 mg orally for ≤75 years older and 20 mg for"
223848852|NCT03246581|DRUG|Tiotropium|inhalation
223848853|NCT06630962|OTHER|Financial Navigation Program|"A salaried financial navigator will be hired by the study sites. All responsibilities of the navigator will revolve around the structured financial navigation program. There is currently no research indicating that such a role has been incorporated at cancer centers in sub-Saharan Africa.~Through this program, the financial navigator will educate participants on financial literacy, insurance plans and payment options available through charities and financial assistance programs. In addition to providing financial counseling, the financial navigator will verify participant insurance documents, maintain records of financial agreements, and coordinate payments with insurance companies."
223848854|NCT06630702|DEVICE|SCS electrode stimulation 1|300Hz/300us
223848855|NCT06630702|DEVICE|SCS electrode stimulation 2|130Hz/300us
223848856|NCT06630702|DEVICE|SCS electrode stimulation 3|60Hz/300us
223848857|NCT06628544|BIOLOGICAL|BCG vaccination|BCG vaccination
223848858|NCT06628544|DRUG|Metformin is administered on the day 0|Metformin is administered on the day 0
223848859|NCT06628544|OTHER|Placebo|Placebo
223848860|NCT06628544|DRUG|Metformin is administered on the day 9|Metformin is administered on the day 9
223848861|NCT06628544|DRUG|Metformin is administered on the day 85|Metformin is administered on the day 85
223848862|NCT03480971|DRUG|Tempol|Investigational product is Tempol (4-hydroxy-2,2,6,6-tetramethylpiperidine-1-oxyl) oral solution. Tempol solution is an orange-colored, aqueous solution containing 7% Tempol along with xanthan gum, xylitol, aspartame, acesulfame potassium, sodium saccharin, alcohol, peppermint and wintergreen oils.
223848863|NCT03480971|DRUG|Placebo Solution|The placebo contains the same excipients as the active product plus FD\&C Yellow #6 for color matching.
223848864|NCT06250816|OTHER|The hospital gown with cartoon characters|The patient will be asked to choose one of the hospital gowns with cartoon characters they want to wear and put it on with parental assistance.
223848865|NCT03168438|DRUG|Letetresgene autoleucel|Letetresgene autoleucel (GSK3377794) as an IV infusion
223848866|NCT03168438|DRUG|Letetresgene autoleucel with pembrolizumab|Letetresgene autoleucel (GSK3377794) as an IV infusion, followed by pembrolizumab every 3 weeks
223848867|NCT03168438|DRUG|Fludarabine|Fludarabine will be used as lymphodepleting chemotherapy and will be administered via IV route.
223848868|NCT03168438|DRUG|Cyclophosphamide|Cyclophosphamide will be used as lymphodepleting chemotherapy and will be administered via IV route.
223848869|NCT03168438|DRUG|Pembrolizumab|Pembrolizumab is available as an IV infusion
223848870|NCT06629246|DRUG|Conventional heart failure treatment|Conventional heart failure treatment, which may include pharmacological therapies such as diuretics, ACE inhibitors/ARBs, beta-blockers, or aldosterone receptor antagonists, based on the clinical requirements of the condition.
224265405|NCT03999008|DRUG|Budesonide Oral|"The subjects will be included at time of the first dilation for an anastomotic stricture.~Basal physical exam and clinical evaluation (weight and height, dysphagia score, gastroesophageal reflux, feeding problems, respiratory symptoms, other symptoms).~Randomization will be conducted by centre. Because long gap esophageal atresia, high tension anastomosis and history of anastomotic leak are reported as risk factors for occurrence of anastomotic strictures, a stratification at randomization will be performed according to these criteria in each centre.~OVB or placebo will be given by the parents and started the day of the dilation at the first meal after recovering of the dilation and anesthesia.~Parents will be asked to bring the empty caps which will be counted for assessment of compliance."
224265406|NCT03999008|DRUG|Placebos|Apple Sauce 5 mL+ 1 mL saline
224265407|NCT06547177|OTHER|fruit juice|During labor, one group will follow the routine while the water group will only take water and fruit juice group will take water and fruit juice.
224265408|NCT03684928|DEVICE|Comfilcon A (test)|Daily wear contact lenses
224265409|NCT03684928|DEVICE|Senofilcon C (control)|Daily wear contact lenses
224265410|NCT05804786|DEVICE|Guided bronchoscopy|It is performed when a pulmonary lesion with a possibility of malignancy is found on chest CT and histological diagnosis and differentiation are required.
224265411|NCT00135850|GENETIC|VEGF-A165 plasmid|
223848871|NCT06629246|DRUG|Pogejiuxin decoction combined with conventional heart failure treatment|In addition to receiving standard heart failure treatment, patients are also administered Pogejiuxin Decoction.The formula of Pogejiuxin Decoction is as follows : Processed Aconite 60g (decocted initially for 1 hour), Dried Ginger 60g, Honey-fried Licorice 60g, Cornus officinalis 60g, Ginseng 30g (decocted separately), Raw Dragon Bone 30g (decocted initially for 1 hour), Raw Oyster Shell 30g (decocted initially for 1 hour), Living Magnetite 30g, for a total of 7 prescriptions. Usage: Uniformly decocted with a herbal medicine decoction machine to obtain the medicinal liquid, one prescription per day, taken twice daily in the morning and evening, each time 100ml, for a continuous treatment of 7 days.
223848872|NCT06629792|OTHER|Gentle Cleanser|The cleanser was instructed to be used twice daily over the course of 12 weeks
223848873|NCT06629792|OTHER|Facial Moisturizer|The Moisturizer was instructed to be applied to the global face twice daily over the course of 12 weeks.
223848874|NCT06629792|OTHER|sunscreen SPF 30|The Sunscreen was instructed to be applied once daily in the morning, with re-application with extended sun exposure per FDA guidelines over the course of 12 weeks.
223848875|NCT04903002|DRUG|24-IU oxytocin|Patients will self-administer a 2-week course of 24-IU intranasal oxytocin \[4-IU per puff (12-IU delivered to each nostril); Syntocinon, Novartis, Switzerland\], twice per day (once in the morning and once in the evening).
223848876|NCT04903002|DRUG|48-IU oxytocin|Patients will self-administer a 2-week course of 48-IU intranasal oxytocin \[4-IU per puff (24-IU delivered to each nostril); Syntocinon, Novartis, Switzerland\], twice per day (once in the morning and once in the evening).
223848877|NCT04903002|DRUG|Placebo|Patients will receive an intranasal placebo containing the same ingredients as the oxytocin nasal spray with the exception of active oxytocin. Administration schedule and procedure will be identical to that described in 24-IU oxytocin.
223848878|NCT06253325|DIAGNOSTIC_TEST|Measuring tissue oxygenation|Measuring oxygen content of arteries, capillaries and veins
223848879|NCT06253325|DIAGNOSTIC_TEST|Procalcitonin|Blood test
223848880|NCT06253325|DIAGNOSTIC_TEST|Mid-regional proadrenomedullin|Blood test looking at inflammation in the body
223848881|NCT06253325|DIAGNOSTIC_TEST|Hand-held video microscope|A handheld video microscope that looks at blood flow through the capillaries of the tongue
223848882|NCT05842850|BEHAVIORAL|Caloric restriction intervention|The intervention consist of 4-weeks limiting daily food intake to a window of 8 hours (8am to 4pm) and water-fasting for the remaining hours of the day. Participants (LBW NAFLD individuals only) will be instructed to eat a balanced diet according to the current dietary guidelines reduced by 20% calories to ensure energy deficit.
223848883|NCT05842850|OTHER|No intervention|No intervention
223848884|NCT06219213|OTHER|Glyceryl Eicosapentaenoate serum|Daily application of serum on both targeted skin areas for 14 consecutive days. Serum must be applied before the Cream on clean skin.
223848885|NCT06219213|OTHER|Glyceryl Eicosapentaenoate Cream A|Daily application of cream on both targeted skin areas for 14 consecutive days. Cream must be applied after the serum.
223848886|NCT06219213|OTHER|Glyceryl Eicosapentaenoate Cream B|Daily application of cream on both targeted skin areas for 14 consecutive days. Cream must be applied after the serum.
223848887|NCT06219213|OTHER|Glyceryl Eicosapentaenoate Cream C|Daily application of cream on both targeted skin areas for 14 consecutive days. Cream must be applied after the serum.
223848888|NCT05191797|DRUG|Bomedemstat|Given PO
223848889|NCT05191797|BIOLOGICAL|Atezolizumab|Given IV
223848890|NCT04398459|DRUG|Ibrutinib|Each recruited subject will accept Ibrutinib treatment.
223848891|NCT02911571|DEVICE|MMprofiler SKY92 gene signature|"MMprofiler is a gene expression assay system for detection of the presence (or absence) of the SKY92 high-risk gene signature to aid in the determination of the Multiple Myeloma patient's prognosis"
223848892|NCT06444347|DEVICE|Biosynthetic Mesh|The biosynthetic mesh group will undergo hiatal hernia repair with Phasix Mesh (Becton Dickinson, Franklin Lakes, NJ) reinforcement, secured with permanent suture.
224265412|NCT04632550|PROCEDURE|Circumferential pulmonary vein isolation(CPVI) group|"1. PVI(pulmonary vein isolation) will be performed using a radiofrequency catheter~2. Esophageal temperature will be monitored to prevent esophageal injury.~3. Evaluation of procedure time, radiofrequency ablation time~4. Evaluation of the complication after the procedure.~5. Rhythm follow-up will be performed after the procedure in accordance with the aforementioned study design."
223848893|NCT06444347|PROCEDURE|Hiatal Hernia Repair|The non-mesh group will undergo hiatal hernia repair with permanent suture only.
223848894|NCT05133167|PROCEDURE|Balloon Tamponade or B-Lynch|In group A, balloon tamponade (using Foley catheter 28 Fr) was used intra-operatively to prevent post-partum hemorrhage. Post-operative blood loss within first 24 hours was estimated by measuring the amount of blood collected in Foley balloon tamponade bag, in milliliters. In group B, B lynch suture was used intra-operatively to prevent post-partum hemorrhage. Post-operative blood loss within first 24 hours was estimated by the weight difference of the pads before and after patient use (1-gram weight difference = 1 ml blood volume lost). Mean blood loss within first 24 hours post procedure, was compared in both the groups for outcome measurement.
223848895|NCT01481935|OTHER|Enhanced cleaning of surfaces in ICU rooms|Using a paper towel pre-soaked with a commercially-available quaternary ammonium cleaning solution (Virex WetTask wipes, Kimberly-Clark, Irving, Texas), the following surfaces will be wiped clean by a study investigator if present: bed rail top bar, bed electronic control surfaces, moveable tray table top and control surfaces desktop and sides, IV poles, infusion pump control surfaces, nurse call button, patient telephone/remote control, sink console top, light switches and plates, supply cart top and drawer handles, ventilator control surfaces and desk, vital signs monitor control surfaces. Cleaning will occur once on the day of enrollment and follow-up.
223848896|NCT01481935|OTHER|Sham enhanced cleaning of surfaces in ICU rooms|While holding a paper towel pre-soaked with a commercially-available quaternary ammonium cleaning solution (Virex WetTask wipes, Kimberly-Clark, Irving, Texas), a study investigator will mime the action of wiping the following surfaces in the room clean if present: bed rail top bar, bed electronic control surfaces, moveable tray table top and control surfaces desktop and sides, IV poles, infusion pump control surfaces, nurse call button, patient telephone/remote control, sink console top, light switches and plates, supply cart top and drawer handles, ventilator control surfaces and desk, vital signs monitor control surfaces. The sham cleaning will occur once on the day of enrollment and follow-up.
223848897|NCT03563781|PROCEDURE|Sentinel node detection|Patients will receive injection of tracer in the ovarian ligaments to identify the lymphatic drainage of the affected ovary and ultimately the sentinel node. Afterwards, systematic lymphadenectomy will be accomplished according to current guidelines.
223848898|NCT04252820|DEVICE|WarmTouch total body blanket, Covidien Ltd, Mansfield, USA|Forced-air warming will be applied in the preanesthetic room
223848899|NCT00601965|DRUG|Escitalopram|20 mg daily oral escitalopram
223848900|NCT00601965|DRUG|Placebo|Placebo pill of daily oral escitalopram
223848901|NCT00601965|BEHAVIORAL|Cognitive behavioral therapy (CBT)|16 weekly 1-hour sessions
223848902|NCT06187974|OTHER|observation|observation
223848903|NCT03957980|OTHER|Occupational therapy|Child/caregiver dyads in this group will participate in telehealth-based intervention sessions in their home environment. Each child/caregiver dyad will participate in up to 9 interventions sessions. All intervention sessions will last 30-60 minutes. The intervention sessions will focus on task analysis, caregiver coaching, parent education and recommendations for task and home/environmental modifications to promote the child's functional vision.
223848904|NCT06265168|OTHER|Simulation|Physicians will participate in a simulated scenario of an adult comatose patient. The intervention will be presented as a learning situation where the physician interacts with a high-fidelity mannequin. The mannequin simulating the patient will manifest a Glasgow Coma Score of 3 (improving over time to a GCS of 4) and a range of physiological and pathological symptoms. Physicians will have access to emergency equipment, including intubation equipment, a defibrillator, and medications. A trained nurse will be present to assist with the simulation. After 20 minutes the patient will regain consciousness in order to avoid a frustrating experience for the physicians. After simulation termination, a senior physician will join the resident and ask him to report the current scenario and will stop the simulation. The entire scenario will be video-recorded.
223848905|NCT06566586|DRUG|TQB3702 tablets+Chemotherapy regimen|"TQB3702 tablets: Tyrosine kinase inhibitor；~Chemotherapy regimen：inhibiting tumor cell proliferation, suppressing DNA synthesis, inducing cell apoptosis, enhancing immune system function, and inhibiting angiogenesis；"
223848906|NCT06180382|DRUG|Adalimumab|Administration of adalimumab with optimisation either 80 mg every 14 days by subcutaneous injection, or the same dose of 40 mg every 7 days.
223848907|NCT06180382|DRUG|Vedolizumab|Strategy B: administration of vedolizumab 300mg by infusion at baseline, 14 days, 42 days and 60 days, followed by a dose of 108mg every fortnight by subcutaneous injection.
223848908|NCT03194061|RADIATION|Hypofractionated Radiotherapy|20 fractions of 275cGy 5 days/week
223848909|NCT03194061|DRUG|Weekly cisplatin|Concomitant weekly cisplatin 35mg/m2 x 4 weeks
223848910|NCT01605968|DEVICE|BCT Silver Bandage|Activated carbon fiber impregnated with silver particles
223848911|NCT01605968|DEVICE|Aquacel® Ag. Dressing|Antimicrobial primary dressing incorporating the unique gelling action of Hydrofiber® Technology with ionic silver for wounds that are infected or at risk of infection.
223848912|NCT00913432|DRUG|masitinib|3 mg/kg/day oral route
223848913|NCT00913432|DRUG|masitinib|masitinib 6 mg/kg/day oral route
223848914|NCT03297983|DRUG|M7583|Subject will receive either M7583 PiC or M7583 tablet formulation orally under fasted conditions in part 1 followed by M7583 tablet formulation under fed condition in part 2 of the study.
223848915|NCT02809911|DEVICE|Provant|
223848916|NCT02594176|DEVICE|FLEXISEQ®|applicable gel
223848917|NCT02594176|DEVICE|Placebo|applicable gel
223848918|NCT03563053|COMBINATION_PRODUCT|EryDex System|"EryDex System was a combination product that was used to load dexamethasone sodium phosphate (DSP) into autologous erythrocytes (EDS) creating the EDS-end product which was infused into the patients.~EryDex treatment consisted of a dose range correspondent to the ATTeST High Dose (obtained by loading 125 mg of DSP to the EryDex process and that, in the ATTeST, resulted in a mean of 17.4 ± 5.4 mg (mean ± standard deviation) of DSP infused to patients) administered via ex vivo encapsulation into EDS that were infused into the patient with A-T.~The dose of EryDex treatment was selected to allow collection of long-term safety data on the dose of erythrocyte encapsulated DSP that was considered more effective among the two different doses that were employed in the ATTeST study, based on the analysis of the ATTeST blinded, Phase 3 study data."
223848919|NCT03137316|DIAGNOSTIC_TEST|intact parathyroid hormone level|obtain intact parathyroid hormone level from patients records.
223848920|NCT01836458|DRUG|KAE609|Patients will receive KAE609 single dose at a different dose level in each cohort.
223848921|NCT01190670|DRUG|Tacrolimus|Oral and Intravenous
224265413|NCT04632550|PROCEDURE|Posterior box isolation(POBI) group|"1. PVI will be performed using a radiofrequency catheter~2. Additional POBI(Posterior box isolation) is performed according to the traditional method and experience of the practitioner.~3. Esophageal temperature will be monitored to prevent esophageal injury.~4. The bidirectional block of each lesion set is the target of the procedures. But, we remain the incomplete block if three times of linear ablation failed to achieve the bidirectional block for the safety purpose.~5. Evaluation of procedure time, radiofrequency ablation time~6. Evaluation of the complication after the procedure.~7. Rhythm follow-up will be performed after the procedure in accordance with the aforementioned study design."
223848922|NCT01190670|DRUG|ASP015K|Oral
223848923|NCT05441020|OTHER|Administration of patient questionnaire|Patients undergoing maintenance hemodialysis complete electronic questionnaires on a tablet computer during this study to assess patient reported outcomes.
223848924|NCT02141581|BIOLOGICAL|Fluzone® (IM)|This vaccine is given intramuscularly (IM)
223848925|NCT02141581|BIOLOGICAL|Fluzone® Intradermal (ID)|This vaccine is given intradermally (ID)
224265414|NCT04632550|PROCEDURE|POBI+Anterior linear ablation(AL) group|"1. PVI, POBI will be performed using a radiofrequency catheter~2. Additional AL(anterior linear) ablation is performed according to the traditional method and experience of the practitioner.~3. Esophageal temperature will be monitored to prevent esophageal injury.~4. The bidirectional block of each lesion set is the target of the procedures. But, we remain the incomplete block if three times of linear ablation failed to achieve the bidirectional block for the safety purpose.~5. Evaluation of procedure time, radiofrequency ablation time~6. Evaluation of the complication after the procedure.~7. Rhythm follow-up will be performed after the procedure in accordance with the aforementioned study design."
224265415|NCT05167474|OTHER|breast milk smell|yenidoğanlara fototerapi tedavisi esnasında anne sütü kokusu uygulanmıştır.
223848926|NCT02141581|BIOLOGICAL|2011-2012 FluMist®|This vaccine is given intranasally
223848927|NCT00126113|BEHAVIORAL|PPT-based Counseling|Counseling based on Performance-Perceptual Discrepancy (PPDIS) consisting of explanation of hearing tests plus recommendations based on PPDIS
223848928|NCT00126113|BEHAVIORAL|Standard Educational Counseling|Standard educational counseling consisting of explanation of hearing tests
223848929|NCT01061905|BEHAVIORAL|Calorie information|Posting of Calorie information for sugar-sweetened and zero-calorie beverages
223848930|NCT01061905|BEHAVIORAL|Exercise Equivalent only|Posting of only exercise equivalents (e.g. 45 minutes on a treadmill) for both sugar-sweetened and zero-calorie beverages, prominently on a poster.
223848931|NCT01061905|BEHAVIORAL|Calorie & Exercise equivalent information|Posting of both calorie and exercise equivalents information for both sugar-sweetened and zero-calorie beverages, prominently on a poster.
223848932|NCT03918135|DRUG|Paracetamol|"1000 mg of paracetamol (parol 10mg/ml Mefar, Turkey) intravenous (IV) was given 100 patients~Other Names:~* Perfalgan~* Paracerol"
223848933|NCT03918135|DRUG|Ibuprofen|"400mg of ibuprofen(intrafen 400mg/4ml Gen ilaç sanayi, Turkey) intravenous (IV) was given 100 patients~Other Names:~Dorifen"
223848934|NCT00524147|PROCEDURE|Pigtail drainage|
223848935|NCT04415268|BEHAVIORAL|Exercise|Surpervised exercise program: Includes a concurrent exercise intervention (strength training and aerobic training), 3 days a week, 60 minutes sessions.
223848936|NCT04415268|BEHAVIORAL|Unsupervised exercise|Unsupervised exercise program: The same exercise program learned during the supervised phase will be practiced at home.
223848937|NCT04415268|DRUG|CFTR Modulators|"Standard of care: Lumacaftor with Ivacaftor or Tezacaftor combined with Ivacaftor.~For children between 6 and 11 years of age, Lumacaftor 400 mg combined with Ivacaftor 500 mg in total per day, divided into 2 doses per day; for those over 11 years of age, Tezacaftor 100 mg combined with Ivacaftor 150 mg in the morning, adding a dose of Ivacaftor 150 mg at night.~https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-000833-37/ES"
223848938|NCT05437471|DRUG|GNRH Analoge, Duphaston, Letrozole|GNRH Analoge, Duphaston, Letrozole
223848939|NCT06217731|COMBINATION_PRODUCT|Laser+clonazepam|treated with the Helbo® Theralite Laser 3D Pocket Probe low power diode laser once a week for a month and Rivotril 0.25mg once every 24 hours for a month
223848940|NCT06217731|DEVICE|Laser Sham|INACTIVE Helbo® Theralite Laser 3D Pocket Probe low power diode laser once a week for a month
223848941|NCT06217731|DEVICE|Laser|Active Helbo® Theralite Laser 3D Pocket Probe low power diode laser once a week for a month
223848942|NCT06217731|DRUG|Clonazepam|Rivotril 0.25mg once every 24 hours for a month
223848943|NCT00616161|DRUG|Istaroxime|0.5 microgram/kg/min IV for 6 hours
223848944|NCT00616161|DRUG|Istaroxime|1.0 microgram/kg/min IV for 6 hours
223848945|NCT00616161|DRUG|Istaroxime|1.5 microgram/kg/min IV for 6 hours
223848946|NCT00616161|DRUG|Placebo|Placebo
223848947|NCT05687942|DEVICE|REBUILD|3.1.1. REBUILD is an investigational medical device provided as a sterile, single use set containing 10 suture Anchors and two non-implantable Carriers, with reusable stainless-steel instruments for deployment supplied separately.
223848948|NCT01750996|BEHAVIORAL|Strongest Families|Behavioural intervention
223848949|NCT03604861|OTHER|Not applicable - no defined intervention|Participants who received at least one injection of RBP-6000 or placebo and either withdrew from or completed the Phase III clinical program which included studies NCT02357901 (RB-US-13-0001) and NCT02510014 (RB-US-13-0003) were eligible for the RECOVER Study.
223848950|NCT00561574|DRUG|Esmirtazapine|One tablet daily
223848951|NCT00503074|BEHAVIORAL|TV modification|Parents receive a health behavior-change intervention consisting of 1 in-person visit from a case manager, followed by phone and e-mail contact at least monthly. The intervention is designed to promote healthy TV viewing, including viewing fewer commercials, by the target child aged 2-5 years old, and uses health behavior change theory and social cognitive theory.
223848952|NCT00503074|BEHAVIORAL|safety and injury prevention|Parents receive behavior-change counseling around toddler and preschooler safety and injury prevention.
223848953|NCT01085487|DRUG|Levonorgestrel (Mirena, BAY86-5028)|Women using Mirena for treatment of menorrhagia
223848954|NCT01085487|DRUG|Hormonal treatment|Hormonal treatment (including combined oral contraceptives or oral or injectable progestogens)
223848955|NCT01085487|DRUG|Antifibrinolytic treatment|Antifibrinolytic treatment (such as tranexamic acid)
223848956|NCT03971357|DRUG|Netarsudil|netarsudil opthalmic solution 0.02%
223848957|NCT03971357|DRUG|Placebo|Placebo eye drops
223848958|NCT05260840|OTHER|Evaluation study - provision of an online questionnaire|Evaluation study - provision of an online questionnaire
223848959|NCT05399979|PROCEDURE|Labor Neuraxial Analgesia|Labor Neuraxial Analgesia
223848960|NCT03055845|DRUG|STA363|STA363, containing 3 different doses of active ingredient, in a volume of 1.5 mL. Administered as intradiscal injection.
223848961|NCT03055845|DRUG|Placebo|Matching placebo solution with identical appearance to the test product, used as reference treatment. Administered as intradiscal injection.
223848962|NCT05196594|DIAGNOSTIC_TEST|collection of stools for genetic analysis|Intestinal microbiome analysis
223848963|NCT06103422|DIAGNOSTIC_TEST|Whole mouth taste tests|Patients who underwent Le Fort I osteotomy, Sagittal Split Ramus Osteotomy, and Bimaxillary Surgeries were asked to identify the quality of 4 basic taste modalities preoperatively and at postoperative 1st, 3rd, and 6th months by administering whole mouth taste tests. In the whole mouth taste test, one ml of the specific solution was drawn into the syringe and sprayed into the mouth of the patient circularly. After each administration, patients spat out the solutions and reported whether they perceived any taste and, if so, which taste it was.
223848964|NCT06103422|DIAGNOSTIC_TEST|Localized taste tests|Patients who underwent Le Fort I osteotomy, Sagittal Split Ramus Osteotomy, and Bimaxillary Surgeries were asked to identify the quality of 4 basic taste modalities preoperatively and at postoperative 1st, 3rd, and 6th months by administering localized taste tests. In the localized mouth taste test, the highest concentration solution of one of the four flavors was administered. In each application, 0.25 ml of solution was absorbed on a sterile cotton swab and applied on 6 test areas on the palate and tongue.
224265416|NCT05579548|DRUG|Pegvaliase|Pregnant women exposed to pegvaliase within 2 weeks prior to LMP.
223848965|NCT04314661|BIOLOGICAL|Arthroscopy with Mesenchymal Stem Cells + Secretome + Secretome|After Arthroscopy intervention, patient recieve 10 million Allogeneic Umbilical Cord Mesenchymal Stem Cells in 2 cc NaCl, two weeks afterward, patient receive 2 cc Secretome, and four weeks later, patient receive another 2 cc Secretome. All intervention will be done via Intra-articular.
223848966|NCT04314661|BIOLOGICAL|Arthroscopy with Secretome + Mesenchymal Stem Cells + Secretome|After Arthroscopy intervention, patient recieve 2 cc Secretome, two weeks afterward patient receive 10 million Allogeneic Umbilical Cord Mesenchymal Stem Cells in 2 cc NaCl, and four weeks later, patient receive another 2 cc Secretome. All intervention will be done via Intra-articular.
223848967|NCT04314661|BIOLOGICAL|Non Arthroscopy with Mesenchymal Stem Cells + Secretome + Secretome|Without Arthroscopy intervention, patient recieve 10 million Allogeneic Umbilical Cord Mesenchymal Stem Cells in 2 cc NaCl, two weeks afterward, patient receive 2 cc Secretome, and four weeks later, patient receive another 2 cc Secretome. All intervention will be done via Intra-articular.
223848968|NCT04314661|BIOLOGICAL|Non Arthroscopy with Secretome + Mesenchymal Stem Cells + Secretome|Without Arthroscopy intervention, patient recieve 2 cc Secretome, two weeks afterward patient receive 10 million Allogeneic Umbilical Cord Mesenchymal Stem Cells in 2 cc NaCl, and four weeks later, patient receive another 2 cc Secretome. All intervention will be done via Intra-articular.
223848969|NCT04287751|DEVICE|CheckMeO2 Oximeter|Simultaneous recording with a current standard oximeter (Minolta i300) and prolonged recording device. Comparison of data from first night and incidence of obstructive sleep apnoea identified from additional nights of recording identified.
223848970|NCT02376933|PROCEDURE|Vertebroplasty|Under imaging guidance, a fractured vertebral body is stabilized with injected bone cement.
223848971|NCT02376933|RADIATION|Radiotherapy|Radiotherapy of metastatic lesions to the spine.
223848972|NCT02064751|DEVICE|CRT with MultiPoint Pacing|
223848973|NCT02064751|PROCEDURE|Hemodynamic measurements for CRT device programming|
223848974|NCT04157166|DIAGNOSTIC_TEST|to record a whole body 3D of 25 minutes in camera VERITON-CT ™|The procedure of recording of 25 minutes in camera VERITON-CT ™ including the registration whole body 3D coupled to a scanner low dose (CT) will be added to conventional recording followed by complementary images SPECT/CT
223848975|NCT06168123|BEHAVIORAL|Quality of life questionnaires will be assessed in addition to standard care|Quality of life questionnaires will be assessed in addition to standard care
223848976|NCT03860077|DRUG|Very Low Nicotine Content Cigarettes|Very Low Nicotine Content Cigarettes
223848977|NCT03860077|DRUG|Normal Nicotine Content Cigarettes|Normal Nicotine Content Cigarettes
223848978|NCT02646046|BEHAVIORAL|Combi lone-CPR|When study participants meet the arrest victim (simulated), they start chest compression and call for help to EMS at the same time, then continue the chest compression and 2 breath alternatively until the EMS arrival
223848979|NCT02646046|BEHAVIORAL|Conventional lone-CPR|When study participants meet the arrest victim (simulated), they first call for help to EMS and then start chest compression and 2 breath alternatively until the EMS arrival
223848980|NCT01546571|BIOLOGICAL|POL-103A|POL-103A is administered intradermally, divided into 4 injections (0.2 mL each injection) into the volar surface of forearms and into the anterior upper thighs
223848981|NCT01546571|BIOLOGICAL|POL-103A without API|Placebo is administered intradermally, divided into 4 injections (0.2 mL each injection) into the volar surface of forearms and into the anterior upper thighs
223848982|NCT02924454|DRUG|metoprolol|One hundred and twenty ml, 0.5 mg metoprolol/ml (as metoprolol tartrate) is administered as an intravenous bolus injection followed by a continuous infusion. Infusion is halted if heart rate drops below 35 bpm or systolic blood pressure drops below 80 mm Hg, or the participant experiences subjective side effects. Infusion stops at T=30 minutes.
223848983|NCT02924454|DRUG|intravenous lipid emulsion|Intravenous lipid emulsion 20 % is administered as an intravenous bolus infusion (1.5 ml/kg) followed by continuous infusion (infusion rate: 0.25 ml/kg/min). Lipid emulsion infusion is stopped at T = 30 minutes.
223848984|NCT02924454|DRUG|Sodium chloride 0.9% solution - lipid emulsion dummy|Isotonic 0.9 % sodium chloride solution is administered as an intravenous bolus infusion (1.5 ml/kg), followed by continuous infusion (infusion rate: 0.25 ml/kg/min). Infusion is stopped at T = 30 minutes.
223848985|NCT02924454|DRUG|Sodium chloride 0.9% solution - metoprolol dummy|Saline solution is administered as an intravenous bolus injection followed by a continuous infusion to T=30 minutes.
223848986|NCT02793882|DRUG|18F-Fluorocholine PET/CT|
223848987|NCT02147990|DRUG|Rociletinib|Rociletinib will be administered to patients orally
223848988|NCT02831153|PROCEDURE|coronary angiography|Coronary angiography will be performed by transfemoral or transradial approach in all patients. In order to evaluate each coronary artery, at least four views from the left and two views from the right system will be taken.
223848989|NCT03693222|DRUG|Tramadol Hydrochloride|The Wong-Baker facial pain scale was used to assess pain (1: no pain, 10: worst possible pain). During monitoring patients with pain score ≥3 had intravenous 1 mg/kg tramadol hydrochloride administered, After 15 minutes following tramadol injection, cases with pain score continuing ≥3 were to be assessed as insufficient analgesia and had 0.1 mg/kg morphine hydrochloride planned for intravenous administration.
223848990|NCT03693222|DRUG|Morphine Sulfate|The Wong-Baker facial pain scale was used to assess pain (1: no pain, 10: worst possible pain). During monitoring patients with pain score ≥3 had intravenous 1 mg/kg tramadol hydrochloride administered, After 15 minutes following tramadol injection, cases with pain score continuing ≥3 were to be assessed as insufficient analgesia and had 0.1 mg/kg morphine hydrochloride planned for intravenous administration.
223848991|NCT00630864|DRUG|Fx-1006A|During Part 1, patients will receive Fx-1006A 20mg soft gelatin capsules once daily (at the same time each day) for two weeks. During Part 2, patients will receive Fx-1006A 20mg soft gelatin capsules once daily to complete a total of 12 months of dosing
223848992|NCT03034382|DRUG|Morphine|5 mg morphine in 5 ml volume are injected perineurally as adjuvants for 10 ml of lidocaine + epinephrine 1:400,000 in ultrasound guided interscalene block
223848993|NCT03034382|DRUG|Nalbuphine|5 mg nalbuphine in 5 ml volume are injected perineurally as adjuvants for 10 ml of lidocaine + epinephrine 1:400,000 in ultrasound guided interscalene block
223848994|NCT03034382|DRUG|Bupivacaine 0.5%|10 ml of 1% lidocaine +1:400,000 epinephrine and 5 ml of bupivacaine 0.5% injected perineurally in interscalene block
223848995|NCT03034382|DRUG|Lidocaine Hydrochloride 1% and epinephrine 1:400,000|10 ml of 1% lidocaine and 1:400,000 epinephrine were injected perineurally in interscalene block
223848996|NCT05991505|OTHER|Physical exercise|Multimodal exercises twice a week
223848997|NCT00124982|DRUG|Abatacept|IV solution, IV infusion, between 500mg and 1gram based on body weight, monthly, 6 months.
223848998|NCT00124982|DRUG|Non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)|During the study, subjects continued to receive 1 or more background non-biologic DMARDs (e.g. methotrexate, leflunomide) at the dose level(s) and regimen(s) administered at the time of abatacept treatment onset (Day 1).
223848999|NCT00124982|DRUG|Anti-Tumor Necrosing Factor (TNF) Therapy|Any of the anti-TNF therapies (Infliximab, Adalimumab, Etanercept, etc.)administered at the approved label dose for at least 3 months
223849000|NCT01237392|DEVICE|Contact ultrasonic debridement device|Cavitational ultrasound wound debridement device
223849001|NCT03638219|OTHER|Data collection about eligible patients presented to our department from 2015 to 2018. Then follow up till 2020.|Data collection, follow up and bioscore calculation at the end of study
223849002|NCT02942147|DEVICE|TENS|Group 2 patients were administered TENS therapy 30 minutes a day for 15 days at the outpatient physiotherapy unit of the Physiotherapy and Rehabilitation Department. The TENS therapy was applied in the form of conventional TENS subtype with 80-100 Hz frequency by placing four electrodes on the region where the pain was most intense.
223849003|NCT02942147|PROCEDURE|Conventional or Pulse Radiofrequency|In the radiofrequency method applied to Group 1 and Group 3 patients, the targeted facet joints were marked while the fluoroscope was in antero-posterior position. During this marking, the fluoroscope was directed towards cephal or caudal so that at whatever level the median ramus block was to be involved the endplate of that vertebra would become a straight line. The connection point of the superior articular protrusion was marked on the fluoroscope using the transverse process and the intervention was applied with a 22G, 10-cm radiofrequency cannula with 0.5 cm active tip in a way that bone contact was established through the tunneled vision technique. The intervention was completed after the radiofrequency procedure was applied at four levels.
223849004|NCT02228603|BEHAVIORAL|high-intensity exercise training|
223849005|NCT02228603|BEHAVIORAL|web-based follow-up program|
223849006|NCT02228603|BEHAVIORAL|usual care|
223849007|NCT04813211|PROCEDURE|mobile artificial cervical vertebrae replacement|"1. Position: The patient is in a supine position with the neck hyperextended, ensuring his/her neck and shoulders in a stable and neutral position before surgery and the cervical spine in a physiological curvature position.~2. Anesthesia: General anesthesia via oral tracheal intubation.~3. Surgical approach: Anterior cervical spine approach through the space between the visceral sheath and the vascular sheath.~4. Surgical method: Two intervertebral discs with adjacent lesions and part of the vertebral body between them will be removed. A curette is used to carefully strike off the annulus fibrosus and cartilage on the surface of the adjacent upper and lower endplates. Intraoperatively, the midlines of the segment and the vertebra to be replaced should be mapped out. When decompression, the midline for decompression should not be deviated from the planned midlines."
223849008|NCT04813211|PROCEDURE|anterior cervical corpectomy and fusion|"1. Position: The patient is in a supine position with the neck hyperextended.~2. Anesthesia: General anesthesia via oral tracheal intubation.~3. Surgical approach: Anterior cervical spine approach through the space between the visceral sheath and the vascular sheath.~4. Surgical method: Two intervertebral discs with adjacent lesions and part of the vertebrae between them will be removed. A curette will be used to carefully strike off the annulus fibrosus and cartilage on the surface of the adjacent upper and lower endplates. The removed vertebral bone will be trimmed into cancellous bone particles and filled in a cervical titanium cage with an appropriate size. The titanium cage will be implanted into the vertebral space, and fixed with adjacent vertebrae using anterior cervical titanium plates and screws."
223849009|NCT02393664|DRUG|propofol, bupivacaine|Nonintubated technique for thoracoscopic surgery using propofol infusion, intercostal and vagal blocks with bupivacaine infiltrations.
223849010|NCT02393664|DRUG|sevoflurane, rocuronium|Conventional intubated general anesthesia for thoracoscopic surgery using sevoflurane and rocuronium, and tracheal intubation with a double-lumen tube or a endobronchial blocker.
223849011|NCT02439255|OTHER|Laboratory Biomarker Analysis|Correlative studies
223849012|NCT02439255|DIETARY_SUPPLEMENT|Phytochemical|Given black raspberry (BRB) nectar per oral (PO)
223849013|NCT02439255|OTHER|Placebo|Given PO
223849014|NCT02439255|OTHER|Screening Questionnaire Administration|Ancillary studies
223849015|NCT03687385|DEVICE|high-flow nasal oxygenation (HFNO)|Experimental HFNO: O2 flow 40L/min, FiO2 40%
223849016|NCT03687385|DEVICE|low-flow nasal oxygenation (LFNO)|Active comparator LFNO: O2 flow 5L/min, FiO2 40%
223849017|NCT03411811|OTHER|Usual Care|Therapeutic ultrasound, myofascial release of extensor and flexor muscles of forearm and stabilization exercises for the wrist.
223849018|NCT03411811|PROCEDURE|Dextrose|Injection of 1 ml of 12.5% dextrose in 1% lidocaine at 0, 3 and 6 weeks in 5 locations: Origin of ulnar collateral ligament, insertion of ulnar collateral ligament on the triquetrum, insertion of the extensor carpi ulnaris on the base of the 5th metacarpal, triquetral hamate ligament and ulnotriquetral joint space.
223849019|NCT01853917|OTHER|questionaires and structured interviews|We will do questionaires on pregnant women before they have their baby and after they have their baby. We will do structured interviews after they have their baby
223849020|NCT01779375|DRUG|Metformin|
223849021|NCT01779375|DRUG|Glargine|
223849022|NCT06083714|OTHER|Scapular Stabilization Exercises|Home-based scapular stabilization exercises (Inferior Glide, Low Row, Scapular Clock, Wall Push Up, Wall Slide and Squat Robbery) will be performed once or twice a day, 3 sets x 20 repetitions, 3 days a week for 8 weeks.
223849023|NCT06083714|OTHER|Schroth Exercises|It will be implemented face to face, 3 days a week, each session lasting approximately 45 minutes and in 8-week programs.
223849024|NCT00254475|DRUG|simvastatin|
223849025|NCT00254475|DRUG|valsartan|
223849026|NCT00430677|DRUG|Corticosteroids (prednisone or prednisolone)|tablets, oral, 0.5-0.8 mg/kg, daily
223849027|NCT00430677|DRUG|Abatacept|intravenous solution, injectable, 30 mg/kg, every 28 days
223849028|NCT00430677|DRUG|Abatacept|intravenous solution, injectable, 10 mg/kg, every 28 days
223849029|NCT00430677|DRUG|Mycophenolate mofetil (MMF)|tablets, oral, 1.5 to 2 g, daily
223849030|NCT00430677|DRUG|Abatacept|intravenous solution, injectable, 10 mg/kg, every 28 days
223849031|NCT02770664|DRUG|Placebo|Placebo
223849032|NCT02770664|DRUG|LC28-0126 Dose A|LC28-0126 Dose A
223849033|NCT02770664|DRUG|LC28-0126 Dose B|LC28-0126 Dose B
223849034|NCT02770664|DRUG|LC28-0126 Dose C|LC28-0126 Dose C
223849035|NCT05058794|OTHER|Blood flow Restriction/Resistance Training|During each exercise, only blood flow in the involved leg was restricted using an aneroid sphygmomanometer. Prior to exercise the cuff was placed on the most proximal portion of the limb and limb occlusion pressure (LOP) was calculated in the body position that the Blood flow Restriction (BFR) stimulus would be applied. Blood Flow Restriction BFR pressure was set at 50% occlusion. Resistance applied for 1 minute (60 sec) with 30 % load of 1 repetition maximum. Subjects will receive treatment bilaterally. Participants will perform exercises 2 sets with 15 repetitions through 0 to 90 degrees.
223849036|NCT05058794|OTHER|Conventional Therapy Group|Resistance applied for 1 minute (60 sec) with 30 % load of 1 repetition maximum. Subjects will receive treatment bilaterally.participants will perform 2 sets with 15 repetitions in (0 to 90 degree.)
223849037|NCT04459832|PROCEDURE|stretch hamstring|Stretching of the hamstring muscles was performed by the primary researcher. A straight-leg-raising technique was used for this stretch because we believe that it is commonly used in the clinical setting for elderly people. All subjects were supine lying as flat as possible
223849038|NCT04535375|DIAGNOSTIC_TEST|Doppler Ultrasound of venous cerebral circulation|No additional ultrasound examinations, specifically for the purpose of this study, will be performed. Instead, with each routine ultrasound examination, additional images on top of the routine frames will be collected. Those images will document the velocity and flow in the internal cerebral veins bilaterally using the standard Color Doppler tech-nique. Taking these additional images will prolong the time of ultrasound examination only minimally (with a few minutes).
223849039|NCT01333514|DRUG|aspart|Subjects will received aspart insulin subcutaneously based on the amount of carbohydrates consumed based on the formula 0.1 units/kg X (grams of carbohydrate eaten/75 grams carbohydrate)
223849040|NCT01333514|DRUG|aspart- Insulin|0.1 units/kg of Aspart insulin will be given subcutaneously TID with meals if a subject eats 50% or more of their meal-tray
223849041|NCT05013164|DRUG|Folinic Acid|Folinic Acid was given at the dose of 2mg/kg per day in two divide doses( maximum 50 mg per day) given for 12 weeks
223849042|NCT02851147|DEVICE|SL-D301|Slit Lamp
223849043|NCT02851147|DEVICE|DC-4|Digital Camera Attachment
223849044|NCT02851147|DEVICE|SL-3G|Slit Lamp
223849045|NCT04733300|BEHAVIORAL|Mindfulness-Based College for Young Adults|"MB-College (MBC) is a 9-week, 9 session curriculum providing systematic and intensive training in mindfulness meditation practices, applied to health behaviors relevant to young adults (18-29). The curriculum, which is based on the manualized and standardized Mindfulness-Based Stress Reduction (MBSR) curriculum is designed to teach participants how to integrate and apply mindfulness in their everyday lives to the range of challenges arising from medical and psychological conditions and life stresses.~MBC will be administered live, online via a video conferencing platform to participants enrolled in the active arms of the study: (1) standard dose MBC and (2) low-dose MBC. Standard dose MBC meets once a week for 2.5 hours for 9 weeks, while low-dose MBC meets for 1.5 hours per week for 9 weeks. There is an all-day retreat that takes place around week six of the program that applies to both MBC programs."
223849046|NCT04733300|OTHER|Health Education for Young Adults|The health education control group will receive young adult-specific online health resources offered through www.youngwomenshealth.org and www.youngmenshealthsite.org. Both websites provide resources to improve mental and physical health, and include opportunities to ask health questions, and learn ways to improve mental and physical well-being.
223849047|NCT00836810|DRUG|Timed Release Tablet Prednisone|Dose: 7mg, taken at 10pm every night for 2 weeks in the form of oral tablets.
223849048|NCT00836810|DRUG|Prednisolone|Dose: 7mg, taken in the morning for 2 weeks in the form of oral tablets.
223849049|NCT00112112|BIOLOGICAL|FluMist|"The total volume of 0.5 mL was administered intranasally with a spray applicator (approximately 0.25 mL into each nostril). Each dose contained approximately 10 to 7th TCID 50 (median tissue culture infectious dose) of each of three influenza virus strains. During the 2005 enrollment period, the three 2004/2005 influenza virus strains were used: A/New Caledonia/20/99(H1N1), A/Wyoming/03/2003(H3N2), and B/Jilin/20/2003). During the 2006 and 2007 enrollment periods, the three 2005/2006 influenza virus strains were used: A/New Caledonia/20/99(H1N1), A/California/7/2004(H3N2), and B/Jiangsu/10/2003 (B/Shanghai/361/2002-like.~brief description of the arm. This element may not be necessary if the associated intervention descriptions contain sufficient information to describe the arm."
223849050|NCT00112112|BIOLOGICAL|Placebo|Placebo intranasal mist was composed of allantoic fluid stabilized with buffer containing sucrose, potassium phosphate, and monosodium glutamate. The total volume of 0.5 mL was administered intranasally with a spray applicator (approximately 0.25 mL into each nostril).
223849051|NCT06341374|BIOLOGICAL|Influvac Tetra|All participants will take influenza vaccine (Influvac Tetra, Abbott Biologicals, IL, USA) and the trained immune response will be evaluated.
223849052|NCT06054789|DRUG|68Ga-PSMA-33|Subjects will receive one injection of 68Ga-PSMA-33/PSMA-617 (3-7mCi ), a PET radiopharmaceutical selective for Prostate-Specific Membrane Antigen. 68Ga-PSMA-33/PSMA-617 injection will be followed by a 10 ml saline flush.
223849053|NCT00013650|DRUG|Cyclophosphamate|
223849054|NCT02216786|DRUG|AZD2014|Oral tablet
223849055|NCT02216786|DRUG|Everolimus|Oral tablet
223849056|NCT02216786|DRUG|Fulvestrant|Im injection
223849057|NCT04451733|PROCEDURE|Endotracheal intubation|Perform the endotracheal intubation during CPR
223849058|NCT02121574|DEVICE|Zero flux and ingestible thermometers|
223849059|NCT03102242|DRUG|Atezolizumab|Single arm phase II trial of induction immunotherapy with anti-PD-L1 for patients with unresectable stage III NSCLC and PS 0-1.
223849060|NCT02286856|BEHAVIORAL|diet intervention|The dietary intervention implies optimizing the diet based on individually calculated energy and protein requirements, while for remaining nutrients advise in line with recommended daily amounts (RDA) will be provided. This nutrients will be translated to food products and lifestyle advice is added. Individual diet counseling will be part of the intervention to improve compliance.
223849061|NCT02957292|DRUG|Levonorgestrel (13,5 mg) intrauterine device|
223849062|NCT02957292|DEVICE|Cooper (380mm2) intrauterine device|
223849063|NCT00895024|BEHAVIORAL|Phone Interview/Questionnaire|35-minute questionnaire over the phone.
223849064|NCT03357224|DRUG|Atezolizumab|Patients will receive atezolizumab 1200 mg IV Q3w for 1 year.
223849065|NCT00389519|DRUG|ramipril|once a day oral ramipril capsules given for 4 weeks
223849066|NCT00389519|DRUG|placebo|once a day oral placebo capsule for 4 weeks
224265417|NCT01023113|PROCEDURE|PASCAL laser|PRP will be completed in 2-3 sitting at 3 days interval with one spots apart and moderate intensity gray burns will be given between arcade to periphery
224265418|NCT01023113|PROCEDURE|Conventional laser|PRP will be completed in 2-3 sitting at 3 days interval with one spots apart and moderate intensity gray burns will be given between arcade to periphery
224265419|NCT04221113|PROCEDURE|physiotherapy|Two protocols have been described for physiotherapy of post extensor tendon injuries. one is immobilization till 3 weeks and than gradual increase in active motion of hand. The second protocol is early active motion. this would be done under senior physiotherapist.
224265420|NCT01222234|DRUG|Cholecalciferol - CKD|Cholecalciferol tablet 50,000 IU twice weekly for 8 weeks
224265421|NCT01222234|DEVICE|Calcitriol - CKD|Calcitriol 0.25 mcg once daily for 8 weeks
224265422|NCT01222234|DRUG|Cholecalciferol - non-CKD|Cholecalciferol tablet 50,000 IU twice weekly for 8 weeks
224265423|NCT04460716|PROCEDURE|Major noncardiac surgery|Vascular, thoracic, visceral, orthopedic, gynecologic, urologic, ENT, maxillo-facial, plastic and reconstructive surgery
224265424|NCT06562088|DRUG|HDM1002 and rifampicin|Administered orally
224265425|NCT06562088|DRUG|HDM1002 and itraconazole|Administered orally
224265426|NCT06687057|BEHAVIORAL|HRV Biofeedback Training|The intervention involves 5 training sessions lasting 45 minutes (specifically, 5-minute baseline and 5 HRV biofeedback trials lasting 5 minutes each) according to the protocol published by Lehrer et al. (2013). Physiological signals (ECG and respiratory rate) will be recorded during all sessions. During the training, participants will see on the screen a graph representing heart rate superimposed on a graph representing abdominal breathing. They will be asked to synchronize the two signals so that the changes in heart rate are in phase with the respiratory cycle in order to maximize the difference between the maximum and minimum heart rate within each respiratory cycle \[i.e., respiratory sinus arrhythmia (RSA), an index of vagal modulation on the heart\] (Lehrer et al., 2003; Lehrer et al., 2000).
224265427|NCT06687057|OTHER|Placebo Training|The Placebo procedure requires participants to attend 5 sessions lasting 45 minutes during which they perform a task. Physiological signals (ECG and respiration rate) will be recorded during all sessions. Participants will see on the screen a graph representing heart rate superimposed on a graph representing abdominal breathing but these will not directly reflect the subject's cardiorespiratory activity. Participants in the control group will be asked to synchronize the two signals so that the changes in heart rate are in phase with the respiratory cycle, but the feedback on the screen will not reflect that subject's RSA changes.
224265428|NCT05124600|DEVICE|SavvyHealth|Participants will use the new app, SavvyHealth, for 21 days.
224265429|NCT07026864|RADIATION|MR-guided Radiation Therapy|MR-guided Radiation Therapy
224265430|NCT06691243|DRUG|Semaglutide|The initial dose will be semaglutide 0.25mg which, if tolerated, will be escalated to 0.5mg. Escalation will continue to 1.0 mg and afterwards to 2.0 mg. The highest possible dose will be 2.0mg semaglutide.
224265431|NCT06691243|DRUG|Placebo|Patients randomized to placebo arm will receive placebo injection every week.
224265432|NCT06878989|BEHAVIORAL|Caloric restriction diet|Dietary intervention consisting on a meal plan designed to induce an 8-10% weight loss over a 12-16 week period.
224265433|NCT06878989|BEHAVIORAL|Weight maintenance diet|Dietary intervention consisting on a meal plan designed to maintain a stable body weight for up to 16 weeks.
224265434|NCT07138209|DRUG|QLS32015|QLS32015 will be administered subcutaneously.
224265435|NCT07138209|DRUG|Pomalidomide|Pomalidomide will be administered orally.
224265436|NCT07138209|DRUG|Selinexor|Selinexor will be administered orally.
224265437|NCT07138209|DRUG|Dexamethasone|Dexamethasone will be administered orally
224265438|NCT06555640|DRUG|DR10624 Injection|Drug: DR10624 injection
224265439|NCT06555640|DRUG|Placebo|Drug: placebo
224265440|NCT05829460|DRUG|Semaglutide|This medication is self-administered as a subcutaneous injection in the abdomen, thigh, or upper arm; injection site should be rotated when using the same body region.
224265441|NCT05829460|DRUG|Placebo|This medication is self-administered as a subcutaneous injection in the abdomen, thigh, or upper arm; injection site should be rotated when using the same body region.
224265442|NCT05829460|DRUG|LNG-IUD (Progestin)|Released via the levonorgestrel-releasing IUD.
224265443|NCT05829460|BEHAVIORAL|Telemedicine behavioral weight program|Optional to attend.
224265444|NCT01620840|DRUG|Lacosamide 10mg/ml|intravenous administration up to 10 days
224265445|NCT00531180|PROCEDURE|4D CT scans|Three 4D CT scans will be performed. After you are out of the CT scanner, ventilation images will be calculated from the 4D CT images and will be compared with the standard ventilation imaging method.
224265446|NCT00531180|PROCEDURE|Lung Function Imaging|Lung function imaging performed to provide information on how well the lungs work, how air moves into the lungs with breathing, and blood circulation into the lungs.
224265447|NCT03733145|DRUG|Angiotensin II|Participants in the ACE inhibitors, angiotensin-receptor blockers (ARBs), and Other Classes of Antihypertensive Agents who's systolic blood pressure (SBP) is less than 80% of the baseline reading is detected, will have Ang II initiated at 2 ng/kg/min through a peripheral IV. The infusion will be increased at the discretion of the clinical team based on the response of the patient until a SBP within 5% of the baseline SBP.
224265448|NCT03512483|BEHAVIORAL|Virtual Atrial Fibrillation Clinic|Participants in the intervention group will receive usual GP care plus the vAFC which consists of telehealth appointments with Nurse Practitioner/Cardiologist and access to an AF specific educational website. It is anticipated the vAFC, as with the onsite clinic, will include a maximum of four scheduled telehealth appointments: an initial appointment following randomization, at 4-6 weeks, 3 months, and 6 months.
223849067|NCT04692948|OTHER|Chimeric antigen receptor T cells (car-t)|Chimeric antigen receptor T cells (car-t) is one of the most effective therapies for malignant tumors (especially hematological tumors). Like other immunotherapies, the basic principle is to use the patient's own immune cells to clear cancer cells. Chimeric antigen receptor (car) is the core component of car-t, which endows T cells with the ability to recognize tumor antigens in an independent manner, which enables car modified T cells to recognize a wider range of targets than natural T cell surface receptors (TCR). The basic design of car includes a tumor associated antigen binding region (usually derived from scFv segment of monoclonal antibody antigen binding region), transmembrane region and intracellular signal region. The selection of target antigen is a key determinant for the specificity and effectiveness of car and the safety of genetically modified T cells.
223849068|NCT00733460|DRUG|BFPET|
223849069|NCT01994161|PROCEDURE|intracranial stenting|"all the participants in this group will be performed with intracranial stenting~\--------------------------------------------------------------------------------"
223849070|NCT02639429|DRUG|Vaginal Misoprostol|
223849071|NCT02639429|DEVICE|Foley Balloon + Vaginal Misoprostol|
223849072|NCT04566874|DEVICE|ALIF|Anterior Lumbar Interbody Fusion
223849073|NCT03920163|OTHER|Enhanced Recovery Measures|Perioperative measures
223849074|NCT02441075|OTHER|70% Ethanol|the study will use 70% ethanol lock in the CVLs. A 2ml 70% ethanol lock will be instilled into the white lumen of the CVL for 2 hours. At the end of 2 hours, the ethanol will be withdrawn; the CVL lumen flushed with normal saline, and the CVL would be available for normal use for that day.
223849075|NCT01311713|DRUG|CEP-9722|CEP-9722 will be administered per dose and schedule specified in the arm description.
223849076|NCT05616221|BIOLOGICAL|AP-PA02|Bacteriophage administered via inhalation
223849077|NCT05616221|OTHER|Placebo|Inactive Placebo administered via inhalation
223849078|NCT05843656|OTHER|Non-invasive brain stimulation|based on sleep-physiology (slow-wave and spindles)
223849079|NCT00946192|DRUG|Transdermal 17Beta-estradiol, progesterone|100 mcg/day 17Beta-estradiol; transdermal twice weekly application for 12 months (with cyclic micronized progesterone pills (Prometrium): 200 mg taken orally daily Day 1 to Day 12 each month) + Elemental calcium 1200 mg and Vit D 400 IU taken orally daily
223849080|NCT00946192|DRUG|Ethinyl Estradiol + Desogestrel|Oral ethinyl estradiol (0.03 mg) + desogestrel (0.15 mg) + Elemental calcium 1200 mg and Vit D 400 IU taken once daily
224265449|NCT07061821|OTHER|accelerated cardiac cine-MRI sequence|Addition of an accelerated cardiac cine-MRI sequence with deep learning-based image reconstruction to the standard cardiac MRI protocol, performed during the same session
224265450|NCT07075822|OTHER|20g of FiberSMART®|20g of FiberSMART® dissolved in 250g of water
224265451|NCT07075822|OTHER|20g of Dextose|20g of dextrose dissolved in 250g of water
224265452|NCT07075822|OTHER|Water Control|250g of water
224265453|NCT05309135|DRUG|HCEC-1|HCEC-1 = human cultured corneal endothelial cells and Rho kinase Y-27632 inhibitor
224265454|NCT06140355|BEHAVIORAL|Qigong|a Qigong introduction class and a 12-week remote Qigong intervention, with a 6-month follow-up
224265455|NCT06140355|BEHAVIORAL|Daily 2 min pain management survey|Completing one short survey (2 min) daily through your phone or computer (you will get a survey link through email or text), with a 6-month follow-up.
224265456|NCT05880082|DRUG|Tislelizumab|Tislelizumab 200mg, Q3W, 2-4 cycles Albumin paclitaxel 240 mg/m², adjusted according to the patient Carboplatin: AUC=5 Q3W, d1 or cisplatin: 20mg/m² iv, D1-3 Q3W or Nedaplatin: 70mg d1 Q3W
224265457|NCT06904378|DRUG|Ontegimod|Per assigned dose level.
224265458|NCT06904378|DRUG|Gemcitabine|The dose of gemcitabine is 1000 mg/m\^2.
224265459|NCT06904378|DRUG|Nab paclitaxel|The dose of nab-paclitaxel is 125 mg/m\^2.
224265460|NCT02287961|PROCEDURE|Standard proctologic examination|(with digital rectal examination and 2 anal swabs) at initial inclusion visit, M12 and M24 follow-up visits and if applicable M6 and M18 control visits
224265461|NCT02287961|PROCEDURE|High resolution anoscopy|at initial inclusion visit, Month 12 and Month 24 follow-up visits and if applicable Month 6 and Month 18 control visits
224265462|NCT02287961|PROCEDURE|Biopsy(ies) during High Resolution Anoscopy|only if lesion suggestive of AIN detected during High Resolution Anoscopy
224265463|NCT02287961|PROCEDURE|High Resolution Anoscopy biannually|Only if high-grade lesion (ASC-H, HSIL ou AIN2/3)
224265464|NCT06912295|DRUG|HL-1186|HL-1186 tablet for oral administration.
224265465|NCT06912295|DRUG|HL-1186 placebo|HL-1186 placebo tablet for oral administration.
224265466|NCT00025935|DRUG|Lithium|
224265467|NCT06495450|DEVICE|Omnidirectional Virtual Reality and Treadmill Training|Omni-VR forest scenario developed by our team involving real-life dual task walking and dynamic balance activities (ie. stepping over obstacles, and managing distractions) will be used for treatment group.
224265468|NCT06495450|BEHAVIORAL|Traditional Exercise|A traditional exercise program including strengthening and unidirectional treadmill activities for the same duration will be completed in control group.
224265469|NCT03031821|DRUG|Metformin|Metformin Duration: 18 months 850 mg PO OD x 30 days then 850 mg PO BID for duration
224265470|NCT03031821|DRUG|Placebo Oral Tablet|"Placebo Oral Tablet Duration 18 months~1 tablet (850 mg) PO OD x 30 days then 1 tablet PO BID for duration"
224265471|NCT07112040|BEHAVIORAL|Behavioral - ASSYST-VS Protocol|"The ASSYST-SV protocol consists of three sessions, each lasting approximately 90 minutes, ideally delivered once per week over a three-week period.~The intervention includes:~Session 1: Psychoeducation: Explanation of typical responses to sexual trauma, providing information about the recovery process, and establishing a strong therapeutic alliance between the client and therapist.~Sessions 1-3: Emotional self-regulation using trauma-sensitive yoga exercises adapted for survivors of sexual violence.~Sessions 2-3: Trauma desensitization using EMDR-informed techniques, including bilateral stimulation and self-applied tools such as the Butterfly Hug.~Safety procedures and closure are included in all sessions to ensure emotional containment and promote participant well-being.~The intervention is delivered by trained professionals in specialized support services for victims of gender-based violence."
224265472|NCT06912945|PROCEDURE|using diode laser 980nm wavelength in benign laryngeal lesions|using diode laser 980nm wavelength in treatment of benign laryngeal lesions
224265473|NCT06912945|PROCEDURE|using diode laser 450nm wavelength in benign laryngeal lesions|using diode laser 450nm wavelength in treatment of benign laryngeal lesions
223849081|NCT00946192|DIETARY_SUPPLEMENT|Sham Comparator|Elemental calcium 1200 mg and Vit D 400 IU taken orally daily
223849082|NCT00146978|PROCEDURE|intra-arterial treatment|
223849083|NCT03416751|BIOLOGICAL|Fecal Microbial Transplant|Fecal transplant from a donor in the OpenBiome Registry
223849084|NCT03416751|OTHER|Placebo|Placebo enemas
223849085|NCT03924245|DRUG|Entinostat|Given by mouth
223849086|NCT03924245|DRUG|Olaparib|Given by mouth
223849087|NCT04543513|OTHER|Real-time functional magnetic resonance neurofeedback (rtfMRI-nf)|Real-time functional magnetic resonance imaging neurofeedback (rtfMRI-nf) is a procedure using an MRI scanner that allows participants to observe their own neural activity in the moment. They are taught to self-regulate this activity during a task.
223849088|NCT04001504|BIOLOGICAL|Double Dose Quadrivalent Influenza Vaccine|Double Dose QIV (30µg Hemagglutinin)
223849089|NCT04001504|BIOLOGICAL|Standard Dose Quadrivalent Influenza Vaccine|Standard Dose QIV (15µg Hemagglutinin)
223849090|NCT04362319|DIAGNOSTIC_TEST|Questionnaire forms|Assessment of demographics, burnout, depression and self-perceived medical errors
223849091|NCT02990858|DRUG|PRO 140 SC injections|
223849092|NCT01080131|DRUG|Canakinumab 150 mg|Canakinumab 150 mg was supplied in 6 mL glass vials each containing nominally 150 mg canakinumab (plus 20% overfill).
223849093|NCT01080131|DRUG|Triamcinolone acetonide 40 mg|Triamcinolone acetonide 40 mg was supplied as a suspension.
223849094|NCT01080131|DRUG|Placebo to canakinumab|Placebo to canakinumab was supplied in 6 mL glass vials containing placebo powder as a lyophilized cake.
223849095|NCT01080131|DRUG|Placebo to triamcinolone acetonide|Placebo triamcinolone acetonide was supplied as a lipid emulsion similar in appearance to triamcinolone acetonide.
223849096|NCT02959151|DRUG|CAR-T cell|CAR-T cells are generated by T cells from the patients or a suitable donor transfected by CAR-lentivirus vectors. There are three options for CAR-targets: GPC3 for hepatocellular carcinoma;mesothelin for pancreatic cancer metastatic; CEA for colorectal cancer metastatic.
223849097|NCT03677206|DEVICE|Exposure to green LED light|Participants will be exposed to green LED strip lights in a dark room for 2 hours a day.
223849098|NCT03677206|DEVICE|Exposure to white LED light|Participants will be exposed to white LED strip lights in a dark room for 2 hours a day.
223849099|NCT03518541|PROCEDURE|Femoral Derotation Osteotomy (FDO)|Correction of malrotation of the femoral bone by osteotomy, derotation and osteosynthesis
223849100|NCT05553119|BEHAVIORAL|Home Rehabilitation Monitoring System|Established home-based pulmonary rehab system consists of three commercial devices (Garmin Vívofit™ activity monitor, Nonin 3150 WristOx2® Pulse Oximeter, Android tablet) and two software applications for telemonitored home pulmonary rehabilitation.
223849101|NCT05553119|BEHAVIORAL|Health coaching calls|Coaching calls based on motivational interviewing principles will occur weekly for twelve weeks following a standard protocol, lasting no more than 5-10 minutes.
223849102|NCT05139732|DIAGNOSTIC_TEST|Magnetic Resonance Imaging (MRI)|In order to investigate the metabolic profile, magnetic resonance spectroscopy (MRS) will be applied. Functional MRI (fMRI) allows to indirectly track cell activation measuring the blood-level dependent signal changes followed spontaneously (in resting state) or evoked by a task. Diffusion weighted imaging (DWI) is based on the differences in motion of the water molecules given by the underlying microarchitecture of the nervous tissue. Diffusion tensor imaging (DTI) allows visualisation of the nerve bundles and alterations thereof. Thus, microstructural alterations can be measured.
223849103|NCT05652608|BEHAVIORAL|Immune Strength|Multi-week wellness program provided by the Cleveland Clinic
223849104|NCT02572778|PROCEDURE|Local biopsy in the tumor|A tumor biopsy of 0.5 cm2 or more will be collected from every patient during surgery or endoscopy after informed consent and if there is enough material after review by the pathologist.
223849105|NCT02914067|OTHER|Neurocognitive testing|
223849106|NCT02914067|DEVICE|rsfcMRI|The imaging protocols will be a combined version of a standard of care (SOC) protocol with a research portion. The SOC portion of the pre-surgical scans includes a 3D T2-weighted (T2w) scans and 3D pre- and post-contrast T1-weighted (T1w) images, both at high resolution (1.0 mm3) for use in the intraoperative navigation system. This scan also includes a DTI portion for definition of fiber bundles of interest. The SOC portion of the post-surgical scans includes transverse FLAIR and post-contrast T1w images in all 3 planes. The research portion of the scan will be identical at all 3 time points and include 15 min of rsfcMRI during which the non-sedated subjects will be asked to stay still and awake while looking at a fixation cross
223849107|NCT01698671|DEVICE|InterGard Synergy Vascular Graft|
223849108|NCT03759171|OTHER|Guitars for Vets Intervention|This was an active intervention providing veterans with an acoustic guitar, guitar pick, tuning instruments, a music book, practice CDs, and individual and group sessions of music instruction during a 6-week intervention period. Six tailored 1-hour individual guitar instruction sessions were scheduled (1 session per week). In addition to the 6 tailored individual lessons, the intervention provided 3 group sessions. Veterans were given a guitar that they could keep upon completion of the program. The same instructor was assigned to a subject for the duration of the study, and group sessions were supervised by the Education Director of Guitars for Vets.
224265474|NCT06912945|PROCEDURE|using traditional cold instrumentations in benign laryngeal lesions|using traditional cold instrumentations in treatment of benign laryngeal lesions
223849109|NCT03526445|DRUG|Glucagon|Glucagon (4 ng/kg/min)
223849110|NCT03526445|DRUG|Saline|Placebo
223849111|NCT01634919|DEVICE|chronic hepatitis C|acoustic radiation force impulse ultrasonography
223849112|NCT04684342|DIAGNOSTIC_TEST|Routine Laboratory investigations|"1. Complete blood picture~2. Liver function test and prothrombine time \& concentration.~3. Blood urea and creatinine~4. Blood glucose, serum Na and K~5. CRP and ESR~6. Clinical specimens will be collected from patients according to the suspected site of infection (e.g. blood, urine, ascitic fluid, sputum or endo- tracheal aspirates) VITEK 2Compact inflammatory markers"
223849113|NCT06141239|PROCEDURE|Autologous Tooth Root|An autologous Tooth Root is made from one's own tooth root and covered in an extraction socket where bone graft is placed.
223849114|NCT06141239|DRUG|Vit.D3|Local administration of Vit.D3, through the effect of Vit.D3 to explore whether it can help to accelerate the healing of tooth extraction cavity and the clinical effectiveness of bone regeneration
223849115|NCT06141239|OTHER|bone graft|Selecting bone materials for alveolar ridge preservation according to treatment needs
223849116|NCT06664112|DEVICE|AIDA Analysis|The women will be followed until and after the birth, under intrapartum ultrasound monitoring, with all clinical, ultrasonographic and obstetric parameters, analyzed by AIDA method.
223849117|NCT06612554|DIETARY_SUPPLEMENT|zinc acetate|Participants in Control group. They will continue the SoC + 3 tablets of placebo and participants in Zinc supplementation group. Tablets will be separated 12h (just in case the ART is based in Integrase Inhibitors (INSTI)) during supplementation for 16 weeks with 3 tablets of zinc (83mg Zinc acetate/tablet).
223849118|NCT06612554|OTHER|Placebo|participants in Control group. They will continue the SoC + 3 tablets of placebo. 3 tablets separated 12h from ART during 16 weeks
223849119|NCT06613750|DRUG|Sitagliptin and Gliclazide|Participants in this arm will receive sitagliptin phosphate 100 mg once daily combined with gliclazide sustained-release tablets 30-120 mg once daily for 12 weeks
223849120|NCT06613750|DRUG|Metformin|Participants in this arm will receive metformin 500 mg to 2000 mg per day, divided into two doses, for 12 weeks
223849121|NCT06615271|PROCEDURE|Neurosurgery|Patients who have undergone neurosurgery form more than 3 hours.
223849122|NCT03250325|BIOLOGICAL|TBI-1301|Split dose of TBI-1301 is administered intravenously for 2 days following cyclophosphamide pre-treatment.
223849123|NCT03250325|DRUG|Cyclophosphamide|Cyclophosphamide (750mg/m2/day x 2 days Intravenous (IV)) is administered as pre-treatment medication of TBI-1301.
223849124|NCT06617065|DRUG|Addition of 1 mL of 50% dextrose solution to the usual local anesthetic solution of choice for each patient.|"The principal investigator will use a palpation-guided approach to select the injection sites. Injection solutions will be prepared by the assisting nurse. For each patient, 1 mL of a 50% dextrose solution (Pfizer Canada ULS, Kirkland, Québec) will be added to the usual local anesthetic solution of choice.~Solutions contain either 0.3% Ropivacaine, 1% Procaine, 0.5% Lidocaine, 0.25% Bupivacaine, or a mixture of 0.25% Bupivacaine and 2% Lidocaine in a 9:1 ratio."
223849125|NCT06920290|DEVICE|Visual Field Perimeter Optimized with Eye Gaze Capture and Artificial Intelligence|"1. Natural Eye Movement To the best of our knowledge, this is the first visual field perimeter software that allows users to move their eyes naturally during the test. Previous visual field tests required that patients maintain a central gaze throughout the test as test points flashed in the periphery of their vision; our test allows patients to look directly at these test points.~2. Simplified Data Capture To the best of our knowledge, this is the first visual field perimeter software that reliably eliminates the need for a hand-held clicker to register test points as the user sees them.~3. Attention Monitoring In previous tests, staring at a central spot could induce sleepiness and inattention; our test employs a software monitor that pauses the test, gives encouragement when appropriate, and allows the patient to regain focus. This allows for far greater accuracy in data reporting.~4. Artificial Intelligence (AI) Our test uses AI to optimize the test parameters."
223849126|NCT04155424|DRUG|Eculizumab|Following a weight-based weekly dose of eculizumab during an induction phase, participants will receive weight-based doses of eculizumab every 2 weeks during the Primary Treatment Period and Extension Treatment Period.
223849127|NCT06621329|COMBINATION_PRODUCT|Transnasal sphenopalatine ganglion block|Transnasal sphenopalatine ganglion blocks will be performed using the Tx360 device. Medications used during the procedure include 0.75% bupivacaine with or without 1 mg of preservative free dexamethasone.
223849128|NCT05322980|DIAGNOSTIC_TEST|Microcephaly|Those with a z score of birth head circumference \< -2 (primary microcephaly) are classified into the Microcephaly group.
223849129|NCT04209127|PROCEDURE|Microwave treatment via needle antenna|Microwave treatment via needle antenna, (Emprint Covidien microwave ablation system) either percutaneous or vaginally administrated
223849130|NCT04209127|PROCEDURE|Embolization of uterine artery or branches thereof (routine treatment where polyvinyl alcohol particles are released into the predefined bloodstream)|Embolization via percutaneous catheter
223849131|NCT06625762|OTHER|Nantes bariatric surgery cohort|The participants will be individuals living with obesity undergoing bariatric surgery
223849132|NCT06685107|OTHER|Standard of Care Analgesia|Analgesia as determined by the treating physician
223849133|NCT06685107|OTHER|Standard of Care Analgesia + Virtual Reality|Analgesia as determined by the treating physician and Virtual Reality experience that will use a geriatric-focused VR platform that has age appropriate VR content and will run for approximately 5-10 minutes
223849134|NCT05436054|DRUG|Picoprep|200 patients will be randomised to this arm
223849135|NCT05436054|DRUG|Plenvu|200 patients will be randomised to this arm
224265475|NCT06238843|DRUG|Irinotecan OR Paclitaxel or Trifluridine/tipiracil（ FTD/TPI）|"Drugs: Irinotecan Subjects in the control arm will receive irnotecan 150mg/m2 IV D1, D15, Q4W in 4-weeks cycles.~Drugs: Paclitaxel Subjects in the control arm will receive paclitaxel 80mg/m2 IV D1, D8, D15, Q4W in 4-week cycles, Drugs:FTD/TPI Subjects in the control arm will receive FTD/TPI 35 mg/m2 up to a maximum of 80 mg orally twice a day on Days 1 to 5 and Days 8 to 12, Q4W (applicable in US/EU/Japan and other regions where FTD/TPI is approved for GC treatment)."
224265476|NCT06238843|DRUG|IBI343|Subjects in the experimental arm will receive IBI343 6mg/kg intravenous infusion (IV) D1, Q3W in 3-week cycles .
224265477|NCT06921967|DEVICE|Rose K2|Corneal RGP lens with flexible parameters.
224265478|NCT06921967|DEVICE|Onefit MED|Scleral RGP lens with flexible parameters.
224265479|NCT07110207|BIOLOGICAL|Blood test|Metabolic measurements and measurements of hormones related to food intake
224265480|NCT07110207|OTHER|Interrogation of the subject|Collection of socio-demographic data, medical and family history, medication
224265481|NCT07110207|OTHER|Cognitive assessment|MMSE and MoCA cognitive tests
223849136|NCT06622499|DRUG|Ringer's Lactate|"On the first trial day healthy volunteers are randomized to receive 1 liter of Ringer's lactate either cold (10°C, 50°F), or at room temperature (22°C, 71.6°F) with 100 ml/min. After a minimum washout period of 24 hours, subjects are switched to receive infusion at the other aforementioned temperatures."
223849137|NCT02338622|DRUG|olaparib|olaparib BD
223849138|NCT02338622|DRUG|AZD5363|AZD5363 BD
223849139|NCT04861051|DRUG|Ketamine|Study participants will receive 0.5mg/kg of ketamine - one single infusion
223849140|NCT06627439|BEHAVIORAL|Comadres Saludables|Comadres Saludables is a web-based healthy living training for community health workers aimed at addressing obesity in Latinas. Comadres Saludables will combine both theory and evidence-based practices to provide participants with the self-efficacy, knowledge, and skills required to effectively implement an obesity intervention for Hispanic women. Participants (CHWs) will build their skillset through interactive quizzes, exercises, and video role-playing scenarios. Additionally, Comadres Saludables allows participants to utilize interactive mHealth tools to enhance implementation with Hispanic women. Participants will access the training for three months.
223849141|NCT06627439|BEHAVIORAL|Control|Participants will access the web-based HHS Promoting Healthy Choices and Community Changes that includes a variety of content via text, audio, and video. The information is designed to educate CHWs on how to implement health interventions for positive community change. They are asked to review it for three months.
223849142|NCT06627907|OTHER|fluid challenge|"The study protocol is started during a period of intraoperative hemodynamic stability, as previously defined (i.e. change in mean arterial pressure of less than 10% during 5 minutes \[32, 33\]). The study protocol is was the following: 1) a set of measurements was recorded (T0) at a baseline 2) (T1) after one minute the EEOT is then performed by stopping the mechanical ventilation for 30 seconds (T2 - end of the EEOT test); 3) (T3) a FC of overall 6 mL/Kg of crystalloid solution is infused over 10 minutes (T4 end of the FC). The attending anesthetist is allowed to interrupt the protocol at any stage for either hemodynamic instability or any other adverse effects requiring urgent treatment.~The protocol is entirely intraoperative and data collections ends after FC administration. No follow-up is needed.~The mentioned timepoints T0 - T1 - T2, corresponding to intrapeortive data recording points are also the endpoints of the study. At each specific timepoint, a marker is added to the M"
224265482|NCT07110207|OTHER|Nutritional assessment|Anthropometric data (weight, height, BMI, waist circumference, hip circumference, android/gynoid ratio, triceps skinfold thickness, brachial circumference), bioelectrical impedance analysis (body fat percentage, lean body mass, body water percentage and bone mass in kg)
224265483|NCT07110207|OTHER|Taste tests|Recording of PEGs in response to a sucrose solution (prepared beforehand)
224265484|NCT07110207|OTHER|Sucrose taste detection test|Triangular test
224265485|NCT06916221|BEHAVIORAL|Long Term Memory|Tablet computer game designed to stimulate environmental enrichment via an adaptive and immersive experience learning virtual neighborhoods and errands in order to complete assigned errands.
223849143|NCT06627907|DIAGNOSTIC_TEST|end-expiratory occlusion test|"The study protocol is started during a period of intraoperative hemodynamic stability, as previously defined (i.e. change in mean arterial pressure of less than 10% during 5 minutes \[32, 33\]). The study protocol is was the following: 1) a set of measurements was recorded (T0) at a baseline 2) (T1) after one minute the EEOT is then performed by stopping the mechanical ventilation for 30 seconds (T2 - end of the EEOT test); 3) (T3) a FC of overall 6 mL/Kg of crystalloid solution is infused over 10 minutes (T4 end of the FC). The attending anesthetist is allowed to interrupt the protocol at any stage for either hemodynamic instability or any other adverse effects requiring urgent treatment.~The protocol is entirely intraoperative and data collections ends after FC administration. No follow-up is needed.~The mentioned timepoints T0 - T1 - T2, corresponding to intrapeortive data recording points are also the endpoints of the study. At each specific timepoint, a marker is added to the M"
223849144|NCT06692985|OTHER|Clinical and epidemiological data|Collection of clinical and epidemiological data on day 0
223849145|NCT06692985|OTHER|Parasitological samples|Parasitological samples : smear for on-site analysis and swabs to be sent to the Cayenne Hospital for PCR at day 0
223849146|NCT06692985|OTHER|Assessment of clinical course and response to treatment|Follow-up visit with assessment of clinical course and response to treatment at M6
223849147|NCT06692985|OTHER|DLQI questionnaire|DLQI questionnaire at M6
223849148|NCT06693882|DEVICE|EYETRONIC Nextwave System|"Eyetronic Nextwave is a neurostimulation device that stimulates the optic nerve non-invasively using transcranial alternating current stimulation delivered through goggles in patients presenting with glaucoma.~Eyetronic is approved in Europe for the treatment of glaucoma to possibly delay progression of visual field (VF) loss for at least 12 months. The indication for use in Europe includes all patients suffering from neuropathies of the optic nerve resulting in loss of VF. Two studies conducted in Europe have demonstrated improvement in visual fields following 10-days of optic nerve stimulation treatment with this device. In the current study, the Eyetronic system will be used to treat only those individuals who have visual field loss from glaucoma."
223849149|NCT04159506|BEHAVIORAL|mindfulness, emotion didactics, interpersonal skills, experiential learning|mindfulness interventions involve body scanning, deep breathing, and muscle relaxation. Emotion didactics focus on emotion recognition and regulation. Interpersonal skill development looks at how to use emotion regulation to improve social functioning. Experiential learning means learning either through interactions with horses or via team-building activities.
224265486|NCT06916221|BEHAVIORAL|Worder|Tablet computer game designed to stimulate interest in solving word puzzles, much like the Boggle game.
224265487|NCT07116681|DRUG|Inhaled treprostinil|Inhaled treprostinil is an inhaled prostacyclin analog which triggers pulmonary arterial dilation. This is the only intervention in this trial.
224265488|NCT07114796|DIETARY_SUPPLEMENT|Standard Commercial Lactose-Free Formula|"COMMERCIAL LACTOSE FREE FORMULAS Intervention Type: Dietary Supplement or Nutritional Intervention~Name of Intervention: Standard Commercial Lactose-Free Formula~Description: A commercially available lactose-free formula (e.g., Isomil, Alfamino, or equivalent), used for feeding children during the stabilization phase of persistent diarrhea treatment.~Route: Oral/Nasogastric~Dosage: 130 ml/kg/day as per WHO schedule~Duration: 7 days"
224265489|NCT07114796|DIETARY_SUPPLEMENT|Rice based recipe method feeding formula|"Rice based recipe method feeding formula Intervention Type: Dietary Supplement or Nutritional Intervention~Name of Intervention: Rice-Based Lactose-Free Therapeutic Formula~Description: A locally prepared rice-based formula developed as an alternative to F-75, using puffed rice, sugar, oil, and micronutrient mix. It is lactose-free and used for feeding well-nourished children with persistent diarrhea.~Route: Oral/Nasogastric~Dosage: As per WHO feeding schedule - 130 ml/kg/day in 2-hourly feeds.~Duration: 7 days during the stabilization phase~For Arm: COMMERCIAL LACTOSE FREE FORMULAS Intervention Type: Dietary Supplement or Nutritional Intervention~Name of Intervention: Standard Commercial Lactose-Free Formula~Description: A commercially available lactose-free formula (e.g., Isomil, Alfamino, or equivalent), used for feeding children during the stabilization phase of persistent diarrhea treatment.~Route: Oral/Nasogastric~Dosage: 130 ml/kg/day as per WHO schedule~Duration:"
224265490|NCT06907017|DEVICE|LVAS|Implantation and use of the CorWave LVAS to evaluate the safety and effectiveness of the CorWave LVAD to treat advanced left ventricular heart failure.
224265491|NCT06923033|BEHAVIORAL|Smartphone App|Participants will download a study app that will allow them to track smoking urges and abstinence. Access to augmented reality will become available after 48 hours of self-reported abstinence.
224265492|NCT07121972|PROCEDURE|Magnetic resonance imaging (MRI)|Undergo Magnetic resonance (MR) imaging
224265493|NCT07121972|DEVICE|Artificial Intelligence (AI)|AI applied to MRI images
224265494|NCT07129980|DEVICE|ARGOS Biometer|The ARGOS biometer uses swept-source optical coherence tomography (SS-OCT) with a 1060 nm tunable laser to capture high-resolution B-scan images of the entire eye. This technology enables sum-of-segments (S-O-S) biometry, measuring each ocular component-corneal thickness, aqueous depth, lens thickness, and vitreous length-individually and summing these values to determine total axial length. SS-OCT provides deep tissue penetration while simultaneously capturing keratometry, white-to-white, and pupillometry data in a single scan. For keratometry measurements, the ARGOS uniquely employes SS-OCT-based telecentric keratometry, which involves projection of 16 infrared LEDs in a wider 3.0 mm ring pattern onto the cornea and calculates curvature from those reflections.
224265495|NCT07138976|OTHER|sampling tissue|EUS- and US- guided pancreatic biopsy
224265496|NCT07140367|PROCEDURE|Transarterial Microembolization|Identification of the hypervascularization of the knee. Selective and super-selective catheterization of pathological genicular arterial branches, through the use of micro-catheters. - Injection of embolizing material (Nexsphere-F - Kardia) - Control of technical success: the embolization will be followed by diagnostic arteriography that will evaluate the success of the procedure (occlusion of more than 90 percent of the pathologic vasculature).
224265497|NCT07139080|BEHAVIORAL|Mobile education|It consists of participants who will download the mobile patient education and breathing exercise reminder program and apply it for 10 weeks.
223849150|NCT02662192|OTHER|Exercise + health education+ auditory rehabilitation|comparison of 3/4 of an hour balance, resistance and strength training, 1 hour health education, 1 hour auditory rehabilitation
223849151|NCT02662192|OTHER|auditory rehabilitation alone|10 weeks of one hour per week of group auditory rehabilitation
223849152|NCT06631066|RADIATION|neoadjuvant chemoradiation|Neoadjuvant chemoradiation will be prescribed as: 4 cycles of Adriamycin and Cyclophosphamide followed by radiotherapy concurrently with taxanes/ taxanes and carboplatin. followed by surgery as indicated.
223849153|NCT06629532|OTHER|medical management, surgical interventions, and rehabilitative strategies|By leveraging a wide array of treatment data - including medical management, surgical interventions, and rehabilitative strategies - the RESEARCH registry intends to provide a granular view of current treatment landscapes and their direct impact on patient recovery and quality of life.
223849154|NCT06631261|OTHER|No intervention; Observational study|No intervention
223849155|NCT06698302|BEHAVIORAL|Questionnaires|Administer translated COMPAT-SF questionnaires to Spanish-speaking CP patients
223849156|NCT06696807|DRUG|glucocorticosteroids and/or intravenous immunoglobulin|methylprednisolone: 20-200mg/day intravenous immunoglobulin: 5-20 g/day
223849157|NCT06696742|DRUG|Clostridium Butyricum Tablets|Gemcitabine and Cisplatin combined with Clostridium Butyricum Tablets
223849158|NCT06696742|DRUG|Cisplatin|Gemcitabine and Cisplatin
223849159|NCT05336552|OTHER|Validated questionnaire : Social Phobia Inventory ( SPIN ) questionnaire|Social Phobia Inventory ( SPIN ) questionnaire which is consisted of 17 items. . The answers of each item ranged from 0 ( Not at all ) to 4 ( Extremely ). The total score will be calculated to determine the severity of the problem .
223849160|NCT06696664|DRUG|PEG-IFN-α|chronic hepatitis B (CHB) who were continuously treated with pegylated interferon (PEG-IFN - α) for more than 24 weeks
223849161|NCT06630572|DRUG|Rifaximin|Patients randomized to receive Rifaximin for 14 days
223849162|NCT06630572|DRUG|Placebo|Patients randomized to receive Placebo for 14 days
223849163|NCT00116870|DRUG|lovastatin|
223849164|NCT03315221|OTHER|Test product|HMF with added lipids - Intervention group
223849165|NCT03315221|OTHER|Control product|Commercially available HMF (without lipids) - control group
223849166|NCT06698159|DEVICE|Cryoablation with cryoballoon 28 mm|Pulmonary vein isolation using 28 mm balloon cryoablation
223849167|NCT06698159|DEVICE|Cryoablation with cryoballoon 31 mm|Pulmonary vein isolation using 31 mm balloon cryoablation
223849168|NCT06697210|DEVICE|• Dental Floss (Vitis®, Dentaid, Barcelona, Spain).|Dental Floss: A piece of dental floss approximately 40-50 cm in length was taken and placed between the index and middle fingers of each hand, leaving about 2-3 cm free in the middle. The floss was then inserted, embracing the mesial and distal surfaces, and moved up and down three times on each side
223849169|NCT06697210|DEVICE|• Superfloss (Oral B®, Procter & Gamble, USA)|Superfloss: The stiffened end was used to introduce the thread and the spongy-floss into the interproximal area on both the mesial and distal parts, and a gentle back-and-forth motion was applied to remove bacterial plaque. The spongy-floss was then pulled through to the regular floss section and gently slid under the gumline, followed by an up-and-down motion. These movements were repeated three times on each side.
223849170|NCT06697210|DEVICE|• Oral irrigator (Waterpick®, Water Pik, Inc., CO., USA)|Oral Irrigator: The finest tip was selected and placed in the mesiobuccal, distobuccal, mesiolingual, and distolingual interproximal spaces. The irrigator was activated at medium power (2/3), and the process was repeated three times on each side for five seconds.
223849171|NCT06697210|DEVICE|• Interproximal brushes (Interprox®, Vitis, Dentaid, Spain)|Interproximal Brush Group: According to the interproximal space, the appropriate size was selected for each case. The brush was then placed horizontally in the interproximal space mesially and distally, and a back-and-forth movement was performed three times on each side.
223849172|NCT06697860|DEVICE|Radial Shockwave Therapy|In Group A, Radial Shockwave Therapy (RST) was given to the plantar fascia for 5 minutes, with each session consisting of 5-10 shock wave pulses of varied intensity. Following that, stretching exercises for the plantar fascia and calf muscles were done for 30 minutes, with three sets of 30-second holds for each stretch. This therapy procedure was followed out in weekly sessions for 8 weeks, each lasting 40 minutes in total.
223849173|NCT06697860|DEVICE|Graston Instrument|Group B employed Graston Instrument-Assisted Soft Tissue Mobilization (IASTM) for 5-10 minutes to target and break down plantar fascia adhesions. The therapist used a specialized device to apply controlled, precise pressure to the fascia. Following that, stretching exercises for the plantar fascia and calf muscles were done for 30 minutes, with three sets of 30-second holds for each. The entire therapy procedure was carried out in weekly sessions for 8 weeks, each lasting 40 minutes in total..
224265498|NCT07139392|BIOLOGICAL|Albumin (5% serum-protein solution containing immunoglobulins)|"* Preoperative Phase:~  * Oral hygiene instruction~ * Phase I periodontal therapy~ * Initial photography and papillary height measurements using digital calipers or customized stents~* Surgical Technique:~  * Local anesthesia~ * Intrasulcular incision around target teeth~ * Papilla preservation flap~ * Harvesting CTG from the palate~ * Injection of liquid Bio-PRF at the papillary base (test group)~ * CTG positioned in the papilla region~ * Suturing with microsurgical technique~* Postoperative Protocol:~  * Analgesics (e.g., ibuprofen 400 mg)~ * Chlorhexidine 0.12% mouth rinse for 2 weeks~ * Suture removal at 10-14 days~ * Follow-up at 1 month, 3 months, and 6 months"
224265499|NCT07139392|BIOLOGICAL|connective tissue graft|Local anesthesia. Intrasulcular incision around target teeth. Papilla preservation flap. Harvesting CTG from the palate
223849174|NCT06697834|PROCEDURE|Histotripsy ultrasound session|The study will be performed with the MINDRAY DP-10 ultrasound device equipped with a linear probe and histotripsy functionality.
223849175|NCT06697834|OTHER|VAS questionnaire|Pain assessment with the EVA questionnaire
223849176|NCT06697834|OTHER|AOFAS questionnaire|AOFAS questionnaire at visit 1 and visit 4 (75 days after the first visit).
223849177|NCT06697769|OTHER|virtual reality|breastfeeding simulation with virtual reality glasses
223849178|NCT06696989|OTHER|Frenkel's exercises|In this group, participants will receive Frenkel's exercises, and the total treatment session will be 60 minutes of routine physical therapy, i.e., breathing, stretching, ROM's, and joint mobility, with rest intervals in between for 20 minutes. To begin the intervention, the investigator will perform Frenkel's exercises for 40 minutes in total, with rest intervals between each exercise, initially performing 5 repetitions and then gradually progressing to 10 and then 15 repetitions, respectively, after 2 weeks.
223849179|NCT06696989|OTHER|Core stability exercises|This group participants will receive core stability exercises, and the total treatment session will also be 60 minutes. The routine physical therapy includes breathing, stretching, joint rotations, ROM's, and frequent periods of rest in between the treatment sessions. To begin the intervention the investigator will perform core stability exercises for 40 minutes in total with rest intervals between each exercise and initially performing 5 repetitions and then gradually progressing to 10 and then 15 repetitions, respectively after 2 weeks.
223849180|NCT06698055|OTHER|Flywheel Resistance Exercise|FW is conducted in a leg extension machine (LegExx, Exxentric, Stockholm, Sweden) and leg press machine (YoYo™ Leg Press, nHANCE, Sweden).
223849181|NCT06698055|OTHER|Weight Stack Resistance Exercise|WS is conducted in a leg extension machine (Seated leg press, Nordic Gym, Bollnäs, Sweden) and a leg press machine (Seated leg extension, Nordic Gym, Bollnäs, Sweden)
223849182|NCT06705023|BIOLOGICAL|Uncultured, autologous, adipose-derived regenerative cells (UA-ADRCs)|Intracardial venous injection of fresh, uncultured, autologous, adipose-derived regenerative cells isolated from lipoaspirate at the point of care.
223849183|NCT06705023|OTHER|Continuation of patient's best guideline based medical treatment|Patients will receive continuation of their best guideline based medical treatment.
223849184|NCT06711562|DRUG|Anti-Infective Drugs|Anti-infective drugs are administered using the traditional clinical dosing regimen, with no interventions.
223849185|NCT06711159|DEVICE|continuous positive airway pressure|Initiation of treatment with continuous positive airway pressure for obstructive sleep apnea
223849186|NCT06697574|BEHAVIORAL|Hypnosis aimed at stress reduction and health of the oral mucosa|"* Induction.~* Hypnotic relaxation and escalating deepening of hypnotic trance.~* Suggestions for healing and wellness of the oral mucosa and for balanced and optimal performance of the immune system, tailoring metaphors and images based on interview with patients.~…the interior of the mouth is soft, healthy pink, intact and whole. It functions optimally as it should - enabling joyful eating and tasting, speaking with ease for any needed expression, any function of the mouth that needs to be used can be done so easily.~The immune system is very wise - it knows perfectly how to function in a balanced and harmonious way. Its wisdom enables it to act if the body needs defense and to standby and rest if it does not.~* Ego strengthening.~* Anchoring - using a predetermined mark selected by the patient.~* Dehypnotisation."
223849187|NCT06697574|BEHAVIORAL|Psychoeducation|A short explanation about the psycho-neuro-immune system and its part in oral lichen planus
223849188|NCT06714149|DIAGNOSTIC_TEST|Immunoreactivity testing|Blood samples will be collected and used to determine the intensity of the allergenicity of the subject toward different types of pollen. This will be done by the detection of sIgE antibodies to the pollen extracts and basophil activation testing (BAT) with pollen extracts.
223849189|NCT06714149|DIAGNOSTIC_TEST|Immunoreactivity testing (negative control)|Blood samples will be collected and used to determine the background activity of our immunoreactivity tests. The investigators will use samples from negative controls to demonstrate that non-allergic individuals do not react to our assays, confirming that our pollen extracts have no background reactivity. This will be done by the detection of sIgE antibodies to the pollen extracts and basophil activation testing (BAT) with pollen extracts.
223849190|NCT06706063|OTHER|Ultrasonography of muscles|The biceps brachii, flexor digitorum superficialis and profundus muscles and gastrocnemius muscles of the participants on the affected and unaffected sides will be evaluated ultrasonographically. Two researchers (with at least 5 years of experience in ultrasound imaging) blinded to the clinical evaluations of the patients and previous measurements will evaluate the same patients at two different times to test interobserver reproducibility. Muscle thickness, fascicle length and pennation angle will be recorded on B-mode imaging. In addition, elastographic evaluation will be performed on the same muscles and strain rate will be recorded.
223849191|NCT06712303|DEVICE|MRI ,ct|"Every patient will be subjected to~1\. MSCT examination: All patients will undergo MSCT (Siemens somatom 32 slice ,16 slice ,GE bright speed 16 slice ) Non contrast high-resolution CT of the temporal bone with the following parameters:{ 0.75-mm collimation, 130 kvp, 20 mA, topogram length 265}. Patients will be scanned in the supine position with craniocaudal direction. Scanning will be parallel to the orbito-meatal line from the lower margin of the external auditory meatus and extended upward to the arcuate eminence of the superior semicircular canal, as seen on the lateral topogram. Followed by image reconstruction in both the axial and coronal planes to evaluate the inner ear and its malformations, The initial data sets will be reconstructed at 0.6 mm slice thickness. The raw axial image data set can be reconstructed with a section thickness of as little as 0.3 mm to obtain high-quality coronal reformatted images. A 512 × 512 matrix is used, and all the images are reviewed wit"
223849192|NCT06713629|PROCEDURE|cardiac surgery via median sternotomy|For both groups, the same median sternotomy cardiac surgery procedure
223849193|NCT06713785|DRUG|Amlodipine|Amlodipine 1mg/ml Oral Solution
223849194|NCT06918457|DIAGNOSTIC_TEST|AI EEG analysis system|The first stage, physicians independently diagnose pediatric epilepsy with EEG; the second stage, Artificial intelligence EEG analysis system assisted physicians to diagnose pediatric epilepsy
223849195|NCT05859997|BIOLOGICAL|BRL-301|Single dose of Allogeneic Anti-CD19 CAR T cells will be infused
223849196|NCT04300933|BEHAVIORAL|Electroencephalogram-based neurofeedback|In this project, SCD participants will receive electroencephalogram-based neurofeedback therapy, once a day, for 5 days. Then, the investigators will compare their memory changes between baseline and post-therapy visits.
223849197|NCT04899284|OTHER|Early Intensive Bimanual Stimulation|Early intensive bimanual stimulation program for infants showing early signs of UCP, delivered by the family environment, in the child's familiar surroundings, under the guidance of a therapist, over a period of 2 months.
223849198|NCT05925712|DEVICE|AeroFit Seal-In Liner / Socket|Össur AeroFit® solution is a transfemoral breathable prosthetic interface, combining the AeroFit® Seal-In liner and AeroFit® Socket.
223849199|NCT05925712|DEVICE|Seal-In Silicone Liner|Seal-In Silicone Lineris transfemoral prosthetic interface used in combination with a prosthetic socket system.
223849200|NCT05471167|BIOLOGICAL|BCG|Exposure is defined as having received the BCG vaccine during the first year of life.
223849201|NCT01159158|DRUG|Nateglinide|Nateglinide Tablets 120 mg
223849202|NCT01348321|DRUG|Levamisole|Group 1: Azithromycin 500 mg per day, three days a week plus oral levamisole 150 mg per day, two days a week. Group 2: Azithromycin 500 mg per day, three days a week. The used medications were not revealed to their physician. A questionnaire was filled for every patient and photos were taken from lesions using a digital camera at first, second and final visit.
223849203|NCT04236713|OTHER|Dietary intervention 1|Limiting dietary exposure to ethylenediaminetetraacetic acid, erythorbate, propionate and related food additives; limiting eating out to a maximum of 2 days per week.
223849204|NCT04236713|OTHER|Dietary intervention 2|Limiting dietary exposure to nitrites, sulfites and related food additives; limiting eating out to a maximum of 2 days per week; limiting drinking wine to a maximum of 2 days per week.
223849205|NCT02485964|OTHER|Blood draw|One time blood draw at time of consent. Blood will be stored until all subjects have been enrolled and then the enzyme-linked immunospot (ELISPOT) assay will be done to measure the antigen-specific interferon secretion.
223849206|NCT01456780|DRUG|Loteprednol/tobramycin|Zylet (loteprednol/tobramycin) drops, 1 drop twice a day for 4 weeks.
223849207|NCT01456780|DRUG|Loteprednol|Eye drops, 1 drop twice a day for 4 weeks
223849208|NCT01456780|DRUG|B+L Advanced Eye Relief Lubricant Drop|Bausch + Lomb (B+L) Advanced Eye Relief Lubricant Drop (Artificial Tears), 1 drop twice a day for 4 weeks.
223849209|NCT03298932|PROCEDURE|Aortic valve surgery|Aortic valve surgery
223849210|NCT04413279|PROCEDURE|LipiFlow Thermal Pulsation|To manage patients with dry eye disease secondary to MGD
223849211|NCT04413279|DRUG|Dexamethasone Intracanalicular Insert, 0.4mg with LipiFlow Thermal Pulsation|to investigate the benefit of managing patients with DED secondary to MGD with a sustained release intracanalicular dexamethasone (0.4 mg) insert in addition to LipiFlow Thermal Pulsation
223849212|NCT02214667|BEHAVIORAL|Dual-diagnosis motivational interviewing (DDMI)|DDMI is an evidence-based adaptation to motivational interviewing. DDMI incorporates an integrated framework and accommodates cognitive impairments and disordered thinking associated with co-occurring substance use and mental disorders.
223849213|NCT02214667|BEHAVIORAL|Integrated group therapy (IGT)|IGT is an evidence-based practice for treating co-occurring disorders. IGT focuses on relapse prevention by reducing substance use and stabilizing psychiatric symptoms.
223849214|NCT02214667|BEHAVIORAL|Jail and community-based behavioral health services|Existing behavioral health service programs
223849215|NCT05409404|OTHER|Aerobic exercise + hot water immersion|Light to moderate intensity aerobic exercise for 30 minutes, followed by 30 minutes of hot water immersion at 40°C.
223849216|NCT05409404|OTHER|Aerobic exercise + thermoneutral water immersion|Light to moderate intensity aerobic exercise for 30 minutes, followed by 30 minutes of thermoneutral water immersion at 34°C.
223849217|NCT02337010|DEVICE|CeVOX|Central venous saturation was continuously monitored by using a CeVOX monitor (Pulsion Medical Systems, Munich, Germany). The CeVOX probe (PV2022-37; Pulsion Medical Systems, Munich, Germany) was inserted into the internal jugular central venous catheter as described in the user's manual.
223849218|NCT02337010|DEVICE|CVP|Central venous pressure was continuously monitored by using a central venous catheter. The probe was inserted into the internal jugular central vein as described in the user's manual.
223849219|NCT02337010|DRUG|Fluid bolus|If hypovolaemia was suspected fluid bolus was given in the form of 250 ml hydroxyethyl starch solution (HES, 6% hydroxyethyl starch 130/0.4 in 0.9% sodium chloride, Voluven, Fresenius Kabi, Germany) over 15 minutes.
223849220|NCT02337010|DRUG|Vasopressor|If hypotension was present it was treated with vasopressor as 10 mcg bolus or continuous infusion of norepinephrine (Arterenol® Sanofi, Germany).
223849221|NCT04355637|DRUG|Inhaled budesonide|adding budesonide to standard of care for pneumonia in COVID19 positive patients
223849222|NCT01759979|PROCEDURE|Laser and mechanical lithotripsy|Patients will undergo cholangioscopy guided laser treatment in addition to treatment with mechanical lithotripsy using basket and balloon techniques.
223849223|NCT01759979|PROCEDURE|Mechanical Lithotripsy|Patients in the mechanical lithotripsy arm will undergo treatment only with basket and balloons to facilitate stone removal but not laser lithotripsy.
223849224|NCT01369589|DRUG|P-552|P-552 will be administered as 10 mL mouth rinse to be swished in the mouth fro 30 seconds and then completely expectorated.
223849225|NCT01369589|DRUG|Placebo|Placebo will be administered as 10 mL mouth rinse to be swished in the mouth for 30 seconds and then completely expectorated.
223849226|NCT02329041|DEVICE|McGrath Series 5|one kind of videolaryngoscopes, which are widely used in airway management.
223849227|NCT02329041|DEVICE|Airtraq|another kind of videolaryngoscopes, which are also widely used in airway management.
223849228|NCT00315055|BIOLOGICAL|DTaP-IPV-HB-PRP~T vaccine|0.5 mL, Intramuscular (IM)
223849229|NCT00315055|BIOLOGICAL|DTaP-IPV//PRP~T combined|0.5 mL, IM
223849230|NCT00315055|BIOLOGICAL|Hepatitis B vaccine|0.5 mL, IM
223849231|NCT03946813|OTHER|Autologous PRP preparation|For each patient, autologous PRP preparation havs to be injected to both ovaries and ultrasound (US) guide
223849232|NCT05122312|DRUG|Olinanoseal|it contains nanometer particles of fluoroapatite and calcium fluoride - guarantees the resistance to cracks and abrasion. At the same time insoluble nano-fluoroapatites fill all enamel microcracks and closes open dentinal tubules.
223849233|NCT05122312|DRUG|Curodont D'senz|This agent contains p 11-4 peptide in addition to fluoride
223849234|NCT00932919|BEHAVIORAL|Thought field therapy|5 sessions with Thought field therapy
223849235|NCT00932919|BEHAVIORAL|Cognitive therapy|12 sessions of Cognitive therapy
223849236|NCT00932919|BEHAVIORAL|Wait list|3 months waiting, then randomized to either thought field therapy or cognitive therapy
223849237|NCT01168401|BIOLOGICAL|NoV GI.1/GII.4 Bivalent VLP Vaccine|"2 Doses 28 days apart Cohort A: 18-49 Years~Cohort A1: IM Norovirus Bivalent GI.1/GII.4 VLP Vaccine (5/5 mcg)~Cohort A2: IM Norovirus Bivalent GI.1/GII.4 VLP Vaccine (15/15 mcg)~Cohort A3: IM Norovirus Bivalent GI.1/GII.4 VLP Vaccine (50/50 mcg)~Cohort A4: IM Norovirus Bivalent GI.1/GII.4 VLP Vaccine (150/150 mcg)~Cohort B: 50-64 Years IM Norovirus Bivalent GI.1/GII.4 VLP Vaccine (50/50 mcg)~Cohort C: 65-85 Years IM Norovirus Bivalent GI.1/GII.4 VLP Vaccine (50/50 mcg)~Cohort D: 18-49 Years IM Norovirus Bivalent GI.1/GII.4 VLP Vaccine (50/50 mcg)"
223849238|NCT01168401|BIOLOGICAL|Saline|Two doses 28 days apart
223849239|NCT01260662|DRUG|Propofol|1 mg/kg IV bolus followed by 0.5 mg/kg every 3 minutes as need for sedation
223849240|NCT01260662|DRUG|1:1 Propofol/Ketamine|Propofol and ketamine mixed 1:1, given at 1 mg/kg IV bolus followed by 0.5 mg/kg every 3 minutes as need for sedation
223849241|NCT01260662|DRUG|4:1 Propofol/Ketamine|Propofol and ketamine mixed 4:1, given at 1 mg/kg IV bolus followed by 0.5 mg/kg every 3 minutes as need for sedation
223849242|NCT06235879|OTHER|Control Group (Interscalene brachial plexus block)|"Patients will receive ultrasound guided interscalene brachial plexus block after induction of general anesthesia.~Scanning with SonoSite M-Turbo C ® Ultrasound device with HFL - 38 X Linear probe (Japan) with high frequency (6 -13 MHz) will be started just below the level of the cricoid cartilage medial to the sternocleidomastoid muscle.~the transducer will be moved slightly laterally across the neck to identify the scalene muscles and the brachial plexus that is present between the anterior and middle scalene muscles at the level of the sixth cervical vertebra deep to the sternocleidomastoid muscle.~The needle will be then inserted in-plane toward the brachial plexus, in a lateral-to-medial direction.~After negative aspiration and assurance that high resistance to injection is absent, 0.25% bupivacaine hydrochloride will be injected in a 5-ml increment below the lower root, between the 3 roots, and above the upper root.(Total amount is 15 ml of 0.25% bupivacaine hydrochloride)."
223849243|NCT06235879|PROCEDURE|Pericapsular nerve group (PENG) block|"Patients will receive ultrasound guided Pericapsular nerve group (PENG) block after induction of general anesthesia.~Using SonoSite M-Turbo C ® Ultrasound device with HFL - 38 X Linear probe (Japan) with high frequency (6 -13 MHz) ,A linear ultrasound probe will be placed longitudinally between the coracoid and the humeral head.~After defining the humeral head, the tendon of the subscapular muscle and the deltoid muscle over it, a 50-mm needle will be inserted using the ''in plane'' technique. When the needle pass through the deltoid muscle and touched the subscapularis tendon, a bone-like hard tissue will be felt and the needle can't be advanced further.~The needle tip will be placed between the deltoid muscle and subscapularis tendon, after a careful aspiration, 15 ml of 0.25% bupivacaine hydrochloride will be injected."
223849244|NCT02518906|BEHAVIORAL|Adolescent Identity Treatment|"Integrative Approach for the treatment of adolescents with Personality Disorder.~Manual was published in 2013."
223849245|NCT02518906|BEHAVIORAL|DBT-A|Dialectic Behavioral Treatment for Adolescents is the most commonly used Approach for the Treatment of adolescents with Boderline Personality Disorder
223849246|NCT04461223|DIAGNOSTIC_TEST|contrast-enhanced cardiac magnetic resonance imaging(MAGNETOM Aera 1.5T)|CMR T1 mapping, T2mapping, T2\* mapping, LGE, ECV
223849247|NCT00000772|DRUG|Ribavirin|
223849248|NCT00000772|DRUG|Didanosine|
223849249|NCT02980679|DRUG|CTC|After injection of CTC, a whole body and thyroid scan will be performed.
223849250|NCT02980679|DRUG|G-PERT|After injection of G-PERT, a whole body and thyroid scan will be performed.
223849251|NCT03352388|DIETARY_SUPPLEMENT|Dairy- and berry-based snacks|High-protein dairy-based products and energy-enriched berry products for three months
223849252|NCT00672256|BEHAVIORAL|Smoking Abstinence|Smokers were scanned after having quitting smoking for 24 hours, and scanned after smoking as usual.
223849253|NCT06480422|OTHER|Segmental breathing technique|To begin an autogenic drainage sit in a relaxed seated position with neck extended slightly. Blow patient's nose and huff, cough to clear your upper airways to mucus. This technique has three phases. Moving mucus from small airways (Unsticking), Moving mucus from small airways to medium sized airways(Collecting), Moving mucus from medium sized airways to large airways(Evacuation) Take in a deep breath. Hold the breath for three seconds. With some gentle force exhale all the air out of your lungs. Repeat three times. Do not cough untill after the third breath. Repeat sessions 3 times in a week for 4 almost weeks. Repeat the cycle untill you have cleared your lungs as much as possible, 20 and 45 minutes.
223849254|NCT06480422|OTHER|autogenic drainage|"To begin an autogenic drainage sit in a relaxed seated position with neck extended slightly.Blow ptient's nose and huff, cough to clear your upper airways to mucus.This technique has three phases. Moving mucus from small airways (Unsticking), Moving mucus from small airways to medium sized airways(Collecting), Moving mucus from medium sized airways to large airways(Evacuation) Take in a deep breath.Hold the breath for three seconds.With some gentle force exhale all the air out of your lungs. Repeat three times.Do not cough untill after the third breath.~Repeat sessions 3 times in a week for 4 almost weeks. Repeat the cycle untill you have cleared your lungs as much as possible, which should take between 20 and 45 minutes."
223849255|NCT03016897|OTHER|Respirometer, Handgrip Meter, Skulpt Chisel, ActigraphyMeter|Respirometer, Handgrip Meter, Skulpt Chisel, ActigraphyMeter
223849256|NCT03106025|DEVICE|Ultrasound|Each participant will receive an ocular ultrasound which poses minimal to no harm to the participant and the ultrasound results compared to final diagnosis.
223849257|NCT03106025|OTHER|Ophthalmology Assessment|Number of subjects with retinal detachment per formal ophthalmology assessment. This assessment is a composite measurement which includes the following chief complain, primary impression, right visual acuity, left visual, acuity, ultrasound diagnosis, diagnosis changed, ophthalmology diagnosis.
223849258|NCT00248612|DRUG|Venlafaxine|Participants will be assigned to a 12-week treatment condition; all treatment conditions will begin with a 1-week placebo run-in, after which participants will begin a trial of venlafaxine. The treatments will conclude with a 2-week medication taper.
223849259|NCT00248612|BEHAVIORAL|CBT|CBT is Cognitive Behavioral Therapy. Participants will be assigned to a 12-week treatment condition; all treatment conditions will begin with a 1-week placebo run-in, after which participants will begin a trial. The treatments will conclude with a 2-week medication/placebo taper.
223849260|NCT00248612|OTHER|Progressive muscle relaxation therapy (PMR)|For patients with comorbid alcohol-use and anxiety disorders, CBT and pharmacotherapy will be contrasted with relaxation training and placebo medication; all treatment conditions will begin with a 1-week placebo run-in, after which participants will begin a trial of venlafaxine or placebo.
223849261|NCT00248612|OTHER|Placebo medication|For patients with comorbid alcohol-use and anxiety disorders, CBT and pharmacotherapy will be contrasted with relaxation training and placebo medication; all treatment conditions will begin with a 1-week placebo run-in, after which participants will begin a trial of venlafaxine or placebo.
223849262|NCT06211140|DEVICE|tACS|tACS in 4 weeks, once per weekday for 40 minutes each, 20 sessions. The treatment group will receive transcranial alternating current stimulation at a gamma frequency (77.5Hz) with a peak amplitude of 15mA.
223849263|NCT06211140|OTHER|Control|Without the tACS stimulation in this group.
223849264|NCT00395434|DRUG|Combretastatin A4 Phosphate (CA4P)|
223849265|NCT00395434|DRUG|Bevacizumab (Avastin)|
223849266|NCT04483882|DEVICE|Tactile Labels for Drug identity and dose frequency|The tactile labeling proposed in this protocol is rigid labeling. A ring-clip has an inner diameter of 12.5cm, an outer diameter of 16 cm, and a height of 1.5 cm. The ring is cut at 2 cm to form a semi-circle allowing it to be clipped onto the bottleneck. The ring clip fits most if not all prescription eye drop bottles. The individual protrusions with shapes at the end can be cut off by the pharmacist to match the frequency of administration prescribed.
223849267|NCT00272610|DRUG|0.4% Retinol Cream|
223849268|NCT03172403|DIAGNOSTIC_TEST|Height and weight|Height and weight will be measured to estimate cachexia degree at the time of anaesthetic consultation. (V1)
223849269|NCT03172403|DIAGNOSTIC_TEST|Blood samples|Blood samples will be collected for measuring myostatin on blood at the time of anaesthetic consultation, the day before resection surgery, follow-ups at 1, 3 and 6 months. (V1, V2, V3, V4, V6)
223849270|NCT03172403|DIAGNOSTIC_TEST|Skeletal muscle force|Skeletal muscle force will be determined from Computerized Tomography (CT)-scan at the time of anaesthetic, follow-ups at 1, 3 and 6 months. (V1, V3, V4, V6)
223849271|NCT03172403|DIAGNOSTIC_TEST|Skeletal muscle index|Skeletal muscle index will be determined from Computerized Tomography (CT)-scan at the time of anaesthetic, follow-ups at 1, 3 and 6 months. (V1, V3, V4, V6)
223849272|NCT03172403|DIAGNOSTIC_TEST|Muscle biopsy|Muscle biopsy will be performed during resection surgery under general anaesthesia. (V2)
223849273|NCT02634008|DRUG|Paritaprevir/ritonavir/ombitasvir|
223849274|NCT02634008|DRUG|Dasabuvir|
223849275|NCT02634008|DRUG|Ribavirin|
223849276|NCT02634008|DRUG|Glecaprevir/pibrentasvir|
223849277|NCT00533039|DRUG|Varespladib (A-002)|250mg tablets BID for 3-5 days pre-angioplasty and 5 days post-angioplasty.
223849278|NCT00533039|DRUG|placebo|250mg tablets BID 3-5 days pre-angioplasty and 5 days post-angioplasty.
223849279|NCT01720043|DRUG|Velcade|Single dose of Velcade (1.0-1.3 mg/m2 dose)
223849280|NCT03129035|PROCEDURE|Cesarean hystrectomy|Upper segment cesarean section followed by fetal extraction and cesarean hystrectomy started without any attempts of placental removal
223849281|NCT03129035|PROCEDURE|Internal iliac artery ligation|The retroperitoneal space was entered at the level of common iliac bifurcation and followed to the point of division into the external and internal iliac arteries. The ureter was retracted medially by gentle finger dissection, revealing the retroperitoneal anatomy. The fat and loose connective tissue around the IIA and vein were removed and a right-angle clamp was passed beneath the IIA from the lateral to the medial side approximately 4 cm distal to its origin. Using an absorbable suture, the IIA was ligated doubly in all cases . Pulsations of the external iliac and femoral arteries were identified after internal iliac ligation. The procedure was then repeated on the other side
223849282|NCT01688973|DRUG|Erlotinib Hydrochloride|150 mg (1 tablet) by mouth on days 1-28, once daily, until disease progression
223849283|NCT01688973|OTHER|Laboratory Biomarker Analysis|Correlative studies
223849284|NCT01688973|DRUG|Tivantinib|360 mg (3 tablets) by mouth, Twice daily (720 mg total daily dose) on days 1-28, until disease progression
223849285|NCT02090309|DRUG|Hydrocortisone|100 mg IV (in the vein) injection as a single bolus of hydrocortisone for the study group.
223849286|NCT02090309|DRUG|normal saline 0.9%|IV injection of 5 ml normal saline 0.9% as a single bolus.
223849287|NCT00762658|DRUG|AN2728 Ointment, 5%|
223849288|NCT00762658|DRUG|AN2728 Ointment, 2%|
223849289|NCT00762658|DRUG|AN2728 Ointment, 0.5%|
223849290|NCT00762658|DRUG|AN2728 Ointment Vehicle|
223849291|NCT00762658|DRUG|Betnesol®-V Creme, 0.1%|
223849292|NCT00762658|DRUG|Protopic® Ointment, 0.1 %|
223849293|NCT02212717|PROCEDURE|EUS-guided gallbladder drainage (EGBD)|The gallbladder would be identified by a linear echoendoscope (EUS) and a suitable puncture site in the stomach or the duodenum without intervening blood vessels would be located. The gallbladder would be punctured with a 19-gauge needle and a guidewire would be passed through the needle and looped in the gallbladder. The Hot AXIOS stent would then be inserted. A naso-gallbladder drain or a 5-7Fr double pigtail stents can be inserted into gallbladder if the effluent failed to clear after irrigation. This would be performed to improve drainage and avoid obstruction of the stent.
223849294|NCT02212717|PROCEDURE|Percutaneous cholecystostomy (PC)|Trained interventional radiologists in the respective hospitals would perform the procedure under local anesthesia. A transhepatic route would be used in all patients to decrease bile leakage. An 8.5 Fr pigtail drainage catheter would be placed between the 8th or 9th intercostal space under sonographic and fluoroscopic guidance. The pigtail catheter would be drained to a bedside bag.
223849295|NCT04660370|DRUG|CKD-348|QD, PO
223849296|NCT04660370|DRUG|CKD-828, D097, D337|QD, PO
223849297|NCT05015517|PROCEDURE|Erector spinae plain block|Patients will be placed in the lateral position.Ultrasonography will be performed by an experienced anesthetist.The 4th lumbar vertebral level will be determined using the conventional method (imaginary line between two iliac crests). The low frequency convex probe (2-5MHz) will then be placed at the mid-vertebral line in the sagittal plane. It will be shifted from the midline, 3.5-4 cm lateral to the side of the surgery to visualize the erector spinae muscle and transverse process. Using the out-plane technique a 22G/80-mm block needle will be advanced until it reaches the transverse process. After negative aspiration, 0.5-1 ml of the prepared local anaesthetic solution (20 ml bupivacaine 0.5%, 10 ml lidocaine 2%) and 10 ml normal saline will be administered for hydrodissection to confirm correct location. The needle will be repositioned by pulling back a few millimeters if resistance occurred when injecting local anesthesia
223849298|NCT05015517|PROCEDURE|Fascia Iliaca block|"Patients will be placed in supine position. Ultrasonography will be performed by an experienced anesthetist using ultrasound device equipped with a low frequency (2-5 MHz) convex probe and an echogenic 21 G/ 10 cm needle will be used.~The probe will be placed in the inguinal crease. Scan will be started laterally from the femoral artery and nerve in the inguinal crease to identify the Sartorius muscle. The muscle will then be traced until its origin at the anterior superior iliac spine is identified and the shadow of the bony of iliac crest \& iliacus muscle will be seen. Injection will be performed at the plane deep to the fascia iliaca and above the lateral part of the iliacus muscle. After negative aspiration, the prepared local anaesthetic solution (15 ml bupivacaine 0.5%, 15 ml normal saline) will be injected incrementally, aspirating every 5 ml."
223849299|NCT00182520|DRUG|Topiramate|25 mg - 400 mg/day x 12 weeks
223849300|NCT00182520|DRUG|placebo|25 - 400 mg/day x 12 weeks
223849301|NCT01054430|DRUG|avanafil|200 mg avanafil tablets QD
223849302|NCT04832646|PROCEDURE|atrial fibrillation ablation|persistent atrial fibrillation ablation with both AF and sinus rhythm map available
223849303|NCT02606292|PROCEDURE|Photoacoustic endoscopy|
223849304|NCT02606292|PROCEDURE|Endoscopic ultrasound (standard of care)|
223849305|NCT02606292|PROCEDURE|Endoscopic surgery (standard of care)|
223849306|NCT00123747|PROCEDURE|Positron Emission Tomography (PET) scan Imaging|
223849307|NCT06214468|COMBINATION_PRODUCT|Acetaminophen and Nicotinamide Riboside|Collection of urine at different time intervals following ingestion of Tylenol plus Nicotinamide Riboside
223849308|NCT06214468|DRUG|Acetaminophen|Collection of urine at different time intervals following ingestion of Tylenol only
223849309|NCT04697251|DIAGNOSTIC_TEST|FOT measurements in newborns and small infants|Measurements will be performed using the device TremoFlo N-100, at bedside, with the infant in the supine position during quiet natural sleep. After proper cleaning and decontamination, the face mask of the device will be preheated at 37oC (to avoid awakening) and will be placed on infant's face. The duration of each measurement will be predetermined at 10 s. At least 3 technically acceptable measurements will be performed per infant, with 30 s intervals between them. The validity of each measurement will be assessed according to the coherence function (automatically determined by the operating system of the device).
223849310|NCT02138331|BIOLOGICAL|MSC exosomes.|Exosomes: (Size) 40-100 nm, (markers) CD63, CD9, Alix, TSG 101, HSP 70 Microvesicles: (Size) 100-1000 nm, (markers) Annexin V, Flotillin-2, selectin, integrin, CD40 metalloproteinase
223849311|NCT00551772|DRUG|SB-742457|
223849312|NCT03789799|OTHER|TIAB: microcrystalline titanium dioxide with covalently linked monovalent silver ions|TIAGIN vaginal capsule, composition: TIAB (microcrystalline titanium dioxide with covalently linked monovalent silver ions), Sodium Hyaluronate, Aloe Barbadensis Extract
223849313|NCT03789799|OTHER|Placebo|Placebo vaginal capsule, composition: Sodium Hyaluronate, Aloe Barbadensis Extract
223849314|NCT05795829|DEVICE|disposable intravascular ultrasound ablation catheter and ultrasound ablation instrument|Disposable intravascular ultrasound ablation catheters (used with an ultrasound ablation instrument) can use ultrasound energy to block sympathetic activity in the renal arteries.
223849315|NCT04346524|OTHER|sampling of microbiome|women will sample from vagina, feces, and saliva during pregnancy
223849316|NCT02306564|DRUG|Cabergoline|given to patients at high risk for OHSS
223849317|NCT03771846|DRUG|irinotecan, oxaliplatin , fluorouracil, and leucovorin|administration of irinotecan, oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries
223849318|NCT03771846|DRUG|gemcitabine and oxaliplatin|administration of gemcitabine and oxaliplatin via vein
223849319|NCT05578352|OTHER|Add oral hyppoglycemia drug|Oral hypoglycemic drugs with insulin sensitization effect are added, reduce insulin dose according to blood glucose
223849320|NCT05578352|OTHER|Add GLP-1 receptor agonist|Add GLP-1 receptor agonist and reduce insulin dose according to blood glucose
223849321|NCT05578352|OTHER|Change insulin|Change premix insulin to long-acting insulin
223849322|NCT00504114|PROCEDURE|ACL Reconstruction Surgery|
223849323|NCT00504114|PROCEDURE|Cartilage Resurfacing Surgery|
223849324|NCT00504114|PROCEDURE|Total Knee Replacement|
223849325|NCT04594330|DRUG|virgin coconut oil (VCO)|15 mL of VCO twice a day for 14 days
223849326|NCT04594330|OTHER|placebo|15 mL of placebo twice a day for 14 days
223849327|NCT05014555|BIOLOGICAL|COVID-19 Vaccine|Three-dose mRNA COVID-19 vaccine per standard of care
223849328|NCT06138951|OTHER|Endurance exercise|On the trial day before commencing the indicator amino acid oxidation metabolic trial, participants will either rest, perform a 10km run on a treadmill, or perform a 20km run on a treadmill.
223849329|NCT05237219|PROCEDURE|Passive heating|Patients will perform baths in 38°C natural thermal mineral water a maximum of five times per week, over a 12-week period. This will result in a maximum of 60 visits. Each visit will take a maximum of 30 minutes with a physical check-up before and after the bath.
223849330|NCT05237219|PROCEDURE|Thermoneutral|Patients will perform baths in 30-32°C natural thermal mineral water a maximum of five times per week, over a 12-week period. This will result in a maximum of 60 visits. Each visit will take a maximum of 30 minutes with a physical check-up before and after the bath.
223849331|NCT05982353|DEVICE|PTFE application|Polytetrafluoroethylene membrane used over immediate implants intraoperatively. Healing and osseointegration with the exposed membrane is assessed at the end of followup
223849332|NCT05982353|DEVICE|Gelatin sponge|gelatin sponge used over immediate implants intraoperatively. Healing and osseointegration with the exposed membrane is assessed at the end of followup
223849333|NCT01282437|RADIATION|Prophylactic Cranial Irradiation|"* 18 fractions of 2Gy~* 12 fractions of 2.5Gy~* 10 fractions of 3 Gy"
223849334|NCT00706693|DIETARY_SUPPLEMENT|Ingestion of BD glucose tablets (TM)|Hypoglycemia (blood glucose is less than 4.0 mmol/L as measured by a glucose meter) will be treated with BD glucose tablets by giving 10g of glucose in children 10 and under. Children and teens over 10 will receive 15g of glucose.
223849335|NCT00706693|DIETARY_SUPPLEMENT|Ingestion of Skittles (TM)|Hypoglycemia (blood glucose is less than 4.0 mmol/L as measured by a glucose meter) will be treated with Skittle by giving 10g of sucrose in children 10 and under. Children and teens over 10 will receive 15g of sucrose.
223849336|NCT00706693|DIETARY_SUPPLEMENT|Ingestion of Fruit to Go (TM)|Hypoglycemia (blood glucose is less than 4.0 mmol/L as measured by a glucose meter) will be treated with Fruit to Go by giving 10g of fructose in children 10 and under. Children and teens over 10 will receive 15g of fructose.
223849337|NCT02485379|PROCEDURE|Prostate biopsy|"Systematic biopsies (SB) and targeted biopsies (TB) are performed in the same patients by two independent operators. In patients without abnormalities on mp-MRI, no targeted biopsies will be carried out and the detection of clinically significant cancer will be considered as negative for the TB strategy."
223849338|NCT01092806|DRUG|Tacrolimus|Two different formulations of the drug is compared. The dose is adjusted according to whole blood concentrations in accordance with center protocol. Switch between the two formulations are done by a 1:1 conversion of daily dose.
223849339|NCT03441360|DRUG|Eribulin mesylate|Intravenous infusion
223849340|NCT00269399|DRUG|Rifaximin (Xifaxan)|
223849341|NCT00269399|DRUG|Vancomycin|
223849342|NCT04861610|BEHAVIORAL|Brief mindfulness based program|An intervention promotes the acceptance and emotion regulation in caregiving for frail older adults
223849343|NCT04861610|BEHAVIORAL|Psychoeducation|An intervention promotes the coping and problem solving in caregiving for the frail older adults
223849344|NCT03639324|DRUG|Dose combination 1-1|100 mg QD of idelalisib + 100 mg QD of venetoclax
223849345|NCT03639324|DRUG|dose combination 1-2|100 mg QD of idelalisib + 200 mg QD of venetoclax
223849346|NCT03639324|DRUG|Dose combination 1-3|100 mg BID of idelalisib + 200 mg QD of venetoclax
223849347|NCT03639324|DRUG|dose combination 1-4|150 mg BID of idelalisib + 200 mg QD of venetoclax
223849348|NCT03639324|DRUG|Sub-Trial: Dose combination 2-1|100 mg BID of idelalisib + 100 mg QD of venetoclax
223849349|NCT03639324|DRUG|Sub-Trial: Dose combination 2-2|150 mg BID of idelalisib + 100 mg QD of venetoclax
223849350|NCT03396835|DEVICE|INVSENSOR00009|All subjects who are enrolled into the test group and participate in data collection receive both the INVSENSOR00009 and the control sensor simultaneously on the forehead.
223849351|NCT02906878|PROCEDURE|Platelets transfusion|Prophylactic platelet transfusion in thrombocytopenic patients for the placement of a central venous catheter
223849352|NCT02893228|PROCEDURE|Saline|At the location chosen for interscalene block the needle tip will be positioned anterior to the anterior scalene muscle. At this point 10ml of 0.9% saline will be injected.
223849353|NCT02893228|DRUG|Levobupivacaine|the needle tip will then be positioned between C5 and C6 nerve roots. At this location, 20 ml of 0.25% levobupivacaine will be injected in 5 ml increments with intermittent aspiration. The needle tip will not be repositioned unless the patient complaints of paraesthesia
223849354|NCT00198848|DRUG|Iron-folic acid supplement|
223849355|NCT01239563|DRUG|antithymocyte globulin|Thymoglobulin 1.5mg/kg, 4 doses Thymoglobulin 6mg/kg, single dose
223849356|NCT01239563|DRUG|Basiliximab|Intravenous 20mg, day 0\&4
223849357|NCT01570660|DRUG|Pioglitazone|12 weeks of pioglitazone treatment
223849358|NCT05753852|DRUG|Tauroursodeoxycholic Acid|Tauroursodeoxycholic acid (TUDCA) 250 mg capsules Doses: 4 capsules (1 g) twice daily 10-15 minutes after a meal Mode of administration: orally Duration: 18 months
223849359|NCT04315454|DRUG|Levobupivacaine|A group of patients will receive 20 ml of normal saline into the interfascial plane between rhomboids major \&erector spinae muscle bilaterally at level thoracic spine T7,10 ml each side, the other group of patients will receive 20 mg 0.25% Levobupivacaine bilaterally as above 10 mg each side.
223849360|NCT02052648|DRUG|Indoximod|
223849361|NCT02052648|DRUG|Temozolomide|
223849362|NCT02052648|DRUG|Bevacizumab|
223849363|NCT02052648|RADIATION|Stereotactic Radiation|
223849364|NCT00422019|DRUG|AMG 102 at 10 mg/kg|AMG 102 at 10 mg/kg IV (in the vein) every 2 weeks
223849365|NCT00422019|DRUG|AMG 102 at 20 mg/kg|AMG 102 at 20 mg/kg IV (in the vein) every 2 weeks
223849366|NCT03467724|DEVICE|Fractional Radiofrequency (FRF)|Fractional radiofrequency will be delivered to the area of the surgical scar.
223849367|NCT01325870|DEVICE|ACD-CPR|
223849368|NCT01325870|DEVICE|ITPR|standard CPR with use of the CirQlator intrathoracic pressure regulator (ITPR)
223849369|NCT01325870|PROCEDURE|S-CPR|standard manual CPR
223849370|NCT01325870|DEVICE|Impedance Threshold Device (ITD)|
223849371|NCT01385384|DEVICE|NeuRx RA/4 diaphragmatic pacemaker|"Patients will be implanted with 4 intramuscular electrodes, 2 in each hemi-diaphragm, using laparoscopic techniques.~The abdominal cavity is inflated with CO2 and 4 ports are inserted: one for optics, 2 for a probe containing a temporary electrode for mapping the diaphragm and the electrode insertion tool, and a smaller one for the output wires of the electrodes of the abdominal cavity. The intra-abdominal pressure variation during the stimulation test (mapping) will be measured externally by one of the ports.~Sites that provide the optimal response (greater region and magnitude) are noted.~Once the optimal site for electrode placement is identified two intramuscular electrodes are deployed in each hemi-diaphragm. The guide wires will come out of the peritoneum through the port placed in the xiphoid region. An additional electrode is placed subcutaneously in the upper abdomen. The instruments and ports are then removed and the incision sites closed."
223849372|NCT04124263|OTHER|Educational short message texts|Educational messages for patient engagement
223849373|NCT04124263|OTHER|Adherence short message texts|Reminder messages of medication use time
223849374|NCT00162071|DRUG|apadenoson|
223849375|NCT02071979|DEVICE|Autologous PRP Gel|Autologous PRP Gel is prepared using the Arteriocyte Magellan® System (510(k) approved), an Autologous Platelet Separator Instrument, which is a microprocessor-controlled centrifuge designed to be used in the clinical laboratory or intraoperatively at point of care for the safe and rapid preparation of platelet poor plasma and platelet concentrate (platelet rich plasma) from a small sample of blood. The Arteriocyte Magellan® automatically and quickly separates PRP from anticoagulated blood and dispenses it into a separate sterile syringe. The prepared PRP is then activated (by mixing with thrombin and calcium chloride) and sprayed directly on the area to be treated.
223849376|NCT02071979|DEVICE|Autologous PRP Injections|Autologous PRP Gel is prepared using the Arteriocyte Magellan® System (510(k) approved), an Autologous Platelet Separator Instrument, which is a microprocessor-controlled centrifuge designed to be used in the clinical laboratory or intraoperatively at point of care for the safe and rapid preparation of platelet poor plasma and platelet concentrate (platelet rich plasma) from a small sample of blood. The Arteriocyte Magellan® automatically and quickly separates PRP from anticoagulated blood and dispenses it into a separate sterile syringe. The prepared PRP is then drawn into multiple small syringes and injected directly into the wound bed or the skin surrounding it.
223849377|NCT02071979|DEVICE|Autologous PRP Gel plus PRP Injections|Autologous PRP Gel is prepared using the Arteriocyte Magellan® System (510(k) approved), an Autologous Platelet Separator Instrument, which is a microprocessor-controlled centrifuge designed to be used in the clinical laboratory or intraoperatively at point of care for the safe and rapid preparation of platelet poor plasma and PRP from a small sample of blood. The Arteriocyte Magellan® automatically and quickly separates PRP from anticoagulated blood and dispenses it into a separate sterile syringe. The prepared PRP is then divided into equal parts and half is drawn into multiple small syringes and injected directly into the skin surrounding the wound bed, half is activated (by mixing with thrombin and calcium chloride) and sprayed the wound bed.
223849378|NCT02071979|PROCEDURE|Standard Wound Care|Subjects in the control group will receive Standard Wound Care treatment for chronic wounds according to accepted medical practices.
223849379|NCT00882882|DRUG|Metformin HCL 500 mg Extended-Release Tablets, Geneva PTC|
223849380|NCT00882882|DRUG|Metformin HCL 500 mg Extended-Release Tablets, Geneva PTC|
223849381|NCT00882882|DRUG|GLUCOPHAGE XR 500 mg ER Tablets Bristol-Myers Squibb|
223849382|NCT00882882|DRUG|GLUCOPHAGE XR 500 mg ER Tablets Bristol-Myers Squibb|
223849383|NCT02236559|DEVICE|Noninvasive positive pressure ventilation (NIPPV)|"Patients will be fit with an oronasal mask using a fitting gauge that will be applied by a respiratory therapist or other clinician skilled in management of NIPPV. Initial pressures will be at low end of suggested range but can be increased as rapidly as necessary to alleviate respiratory distress. Targets should be to lower respiratory rate to the low 20s and achieve tidal volumes of 6-8 ml/kg ideal body weight. If patients find pressures uncomfortably high, they can be lowered as necessary by 1 to 2 cmH2O decrements to enhance tolerance. EPAP (PEEP) can also be adjusted upward as needed to reduce triggering effort (by counterbalancing auto-PEEP) or to improve oxygenation.~FIO2 will be 1.0 initially to assure adequate oxygenation, but should be adjusted promptly to maintain an FIO2 of no greater than 0.6 with an EPAP (PEEP) of not more than 10 cm H2O to maintain a PaO2 \> 88%."
223849384|NCT02236559|DEVICE|Vapotherm|Patients will be fit with a Vapotherm adult nasal cannula that will be applied by a respiratory therapist or other clinician skilled in management of HFT. Initial flow will be set to 35 L/min but can be decreased or increased as rapidly as necessary to alleviate respiratory distress and optimize patient comfort. Targets should be to lower respiratory rate to the low 20s and with a HFT flow rate between 20 to 35 L/min. Starting temperature will be between 35 to 37 C; if patients find the gas temperature to be uncomfortable, it can be lowered as necessary down to 33 C to enhance tolerance. FIO2 will be 1.0 initially to assure adequate oxygenation, but should be adjusted promptly to maintain an FIO2 of no greater than 0.6 to maintain a PaO2 \> 88%.
223849385|NCT01672840|DIETARY_SUPPLEMENT|5g Cocoa Consumption|Daily consumption of 10g Extra Dark cholocate and a beverage containing 2.5g of cocoa powder for 8 weeks
223849386|NCT01672840|DIETARY_SUPPLEMENT|10g Cocoa Consumption|Daily consumption of 20g Extra Dark cholocate and two beverage containing 2.5g of cocoa powder each for 8 weeks
223849387|NCT00343824|PROCEDURE|aquacel AG hydrofiber versus acticoat burn dressing|Aquacel AG hydrofiber versus acticoat burn dressing will be compared.
223849388|NCT02516644|BEHAVIORAL|Virtual Reality|12 sessions of 1 hour (30 min of virtual reality and 30 min of aerobic exercise with treadmill training): three times a week over four weeks
223849389|NCT02516644|BEHAVIORAL|Conventional Therapy|12 sessions of 1 hour of conventional physiotherapy: three times a week over four weeks
223849390|NCT04547348|DRUG|Denosumab Injection|Injections made subcutaneously per standard description
223849391|NCT03701230|OTHER|low temperature rota-flush solution|Patients with severe calcified lesions undergoing RA were performed with low temperature rota-flush solution. The investigators used thermal insulation equipment to keep rota-flush solution at 0～5℃. The EKG and blood pressure were monitored during the RA procedure. After RA, the investigators monitored levels of myocardial injury biomarkers for 3 days every 8 hours.
223849392|NCT00697814|DRUG|Clomiphene citrate|Clomiphene 50 mg/day for 12 weeks
223849393|NCT01379287|DRUG|Iso-Fludelone|Iso-fludelone will be administered IV over 6 hours (+/- 30 mins) on Day 1 of every 3 week cycle.
223849394|NCT00730002|PROCEDURE|Magnetic Resonance Angiography (MRA)|As part of the Magnetic Resonance(MR) scan, you will need to lie still on a padded MR table inside the MR machine for about 15 minutes at a time while MR studies are being performed on you. The total time for the clinical portion of the MR study is approximately 35-40 minutes and there will be an additional 30 minutes for the research related MR studies. The total time you will spend on the MR table for this research will seldom be more than one hour.
223849395|NCT00730002|PROCEDURE|Magnetic resonance imaging|MR spectroscopy
223849396|NCT00730002|PROCEDURE|MRA|MRA of the brain
223849397|NCT00730002|PROCEDURE|MRA|
223849398|NCT00730002|PROCEDURE|diffusion Imaging|MRA of the Brain
223849399|NCT00730002|PROCEDURE|perfusion imaging.|MRA of the brain
223849400|NCT04884399|DRUG|CMAB818|vascular endothelial growth factor (VEGF) inhibitor
223849401|NCT04884399|DRUG|Lucentis®|vascular endothelial growth factor (VEGF) inhibitor
223849402|NCT03355495|PROCEDURE|Colonoscopy - Position Change|Colonoscopy is the gold standard for detecting precancerous lesions. We are proposing that changing positions will provide better visualization for detecting such lesions. We will test our intervention of patients positioned in the Right Lateral Decubitus Position to the gold standard of Left Lateral Decubitus Positioning, hypothesizing better visualization in the right lateral decubitus position.
223849403|NCT00921076|BEHAVIORAL|Gait Analysis|A computerized motion analysis system to observe the effect of ankle arthroplasty versus ankle arthrodesis on the kinematic behaviour of the foot and ankle during gait.
223849404|NCT04300816|BEHAVIORAL|CBT for Uncertainty Tolerance|"Participants work one-on-one with an interventionist. Treatment sessions focus on understanding the difference between the controllable and uncontrollable aspects of MS, ability to tolerate not knowing exactly what the future will hold, setting personal goals for what accepting what MS will look like, and finding ways to live in conjunction with personal values despite the MS diagnosis."
223849405|NCT04300816|BEHAVIORAL|Traditional CBT|Participants work one-on-one with an interventionist. Treatment sessions focus on goal setting, positive activities, identifying and challenging unhelpful thoughts, and bolstering social support.
223849406|NCT05285514|DIAGNOSTIC_TEST|Comparison of macro- and microcirculatory parameters|"Microcirculation examination using sublingual videomicroscopy, tissue O2 saturation (StO2) by NIRS and transcutaneous CO2 pressure (tcpCO2) monitoring, in conjunction with macrocirculatory parameters measures including cardiac output, arterial pressure and pulsed O2 saturation, in order to establish the relationship between the macrocirculatory changes in blood pressure and cardiac output and the microcirculatory flow and capillary density during vasoactive agent use. . Participants receive interventions as part of routine medical care to restore Cerebral Perfusion pressure (CPP) to appropriate levels (60-70 mmHg)"
223849407|NCT01680276|BEHAVIORAL|PBS based staff training|"Please see published study protocol for more information:~http://www.biomedcentral.com/1471-244X/14/219"
223849408|NCT01680276|OTHER|Treatment as Usual|http://www.biomedcentral.com/1471-244X/14/219
223849409|NCT01149681|DRUG|APLIDIN (plitidepsin)|"Aplidin® (plitidepsin) lyophilized powder and solvent for concentrate for solution for infusion. (2 mg plitidepsin vial and 4 ml ampoule).~Plitidepsin will be administered at 5 mg/m2 intravenously diluted to a total volume of 250 ml in 0.9% saline or 5% dextrose solution on Day 1 and 15 every four weeks for a maximum period of 6 cycles."
223849410|NCT00757718|DEVICE|CPAP|One half of the subjects will be randomly assigned to wear continuous a positive airway pressure device on the second night of the study. Portable polysomnography will be repeated for this night and morning bloodwork for inflammatory markers will be repeated.
223849411|NCT00757718|DEVICE|Oral Appliance|Half of the subjects will be assigned to wear an oral appliance and nasal strip on the second night of the study. Repeat portable polysomnography will be performed and morning bloodwork will again be drawn for inflammatory markers.
223849412|NCT00957086|DRUG|Nimotuzumab|Administered by intravenous infusion at 200 mg absolute per dose, diluted in 250 ml of sodium chloride over 30 minutes. 8 weekly doses of study drug will be given, beginning on first week of radiotherapy.
223849413|NCT00957086|DRUG|Placebo|Administered by intravenous infusion at 200 mg absolute per dose, diluted in 250 ml of sodium chloride over 30 minutes. 8 weekly doses of study drug will be given, beginning on first week of radiotherapy.
223849414|NCT01225939|DRUG|AZD8329|tablet
223849415|NCT01225939|DRUG|AZD8329|Solution
223849416|NCT03015974|DRUG|Corticosteroid|
223849417|NCT03015974|DRUG|Cyclophosphamide|
223849418|NCT03015974|DRUG|Mycophenolate mofetil|
223849419|NCT03015974|DRUG|Dipyridamole|
223849420|NCT03015974|DRUG|ACE Inhibitor or Angiotensin receptor antagonist|
223849421|NCT00817635|DRUG|LCI699|LCI699 oral capsules
223849422|NCT00817635|DRUG|Eplerenone|Eplerenone oral capsules
223849423|NCT00817635|DRUG|LCI699-matching Placebo|LCI699-matching placebo oral capsules
223849424|NCT00817635|DRUG|Eplerenone-matching Placebo|Eplerenone-matching placebo oral capsules
223849425|NCT02404064|DRUG|cefamezin 1g IV|perioperative antibiotics (Cefamizin 1g IV; )
223849426|NCT02404064|DRUG|metronidazole 500 mg IV|perioperative antibiotics (metronidazole 500 mg IV )
223849427|NCT02404064|DRUG|Placebo|No perioperative antibiotics
223849428|NCT00000676|DRUG|Clotrimazole|
223849429|NCT00000676|DRUG|Fluconazole|
223849430|NCT06392932|DEVICE|QDOT Micro ablation catheter|QDOT Micro ablation catheter
223849431|NCT06392932|DEVICE|ST SF ablation catheter|ST SF ablation catheter
223849432|NCT05593822|PROCEDURE|primary percutaneous intervention|percutaneous catheterization through peripheral arteries to coronary arteries
223849433|NCT01320436|DIETARY_SUPPLEMENT|Curcumin|3 capsules (820 mg containig 500 mg curcumin each) twice daily.
223849434|NCT01320436|DRUG|5-aminosalicylic acid|The dosage of 5ASA medication will be the maximum dosage given in this group of patients according to clinical guidelines (4gr' per os + topical 1gr mesalamine
223849435|NCT03241654|PROCEDURE|flow trigger|The flow trigger will be adjust during the pressure assist ventilation.
223849436|NCT03150563|OTHER|Passive static stretch|Each experimental group will be submitted to 10 (ten) sessions, with three (3) weekly sessions of static passive stretching, with a 48 h interval between them. Each session will be performed 3 (three) maneuvers containing a duration of 30 seconds, this being the same rest time, performed in all experimental groups.
223849437|NCT02823548|DRUG|Droglican|Chondroitin Sulfate 1,200mg + Glucosamine Hydrochloride 1,500mg
223849438|NCT02823548|DRUG|Placebo|Placebo
223849439|NCT02002819|DRUG|levetiracetam|
223849440|NCT00134511|DRUG|Torcetrapib/atorvastatin|
223849441|NCT06347952|PROCEDURE|Use of Acoustic and color imaging doppler during surgery for breast cancer|The intervention (post pilot study) is to systematically record the effect of routine use of acoustic as well as color imaging doppler during mammoplasty for breast cancer (for both the therapeutic and symmetrising breast reduction).
223849442|NCT03856541|DRUG|SHR-A1403|SHR-A1403 is a humanized anti C-Met immunoglobulin G2 (IgG2) monoclonal antibody conjugated with microtubule inhibitor. SHR-A1403 is provided as the lyophilized powder,40 mg/vial.SHR-A1403 was given intravenously per 3 weeks at the day 1.Intravenous infusion over 30 min
223849443|NCT05622188|OTHER|Elevated ambient heat|Temporary exposure to increased ambient temperature +10°C (the effect of the intervention is fully and spontaneously reversible)
223849444|NCT05622188|OTHER|Elevated relative humidity|Temporary exposure to increased ambient relative humidity +40% (max. 90%) (the effect of the intervention is fully and spontaneously reversible)
223849445|NCT05622188|OTHER|Exertion|Temporary exertion on an ergometer (1W/kg body weight) (the effect of the intervention is fully and spontaneously reversible)
223849446|NCT02465086|OTHER|Training of linguistic recursion|Training of recursion comprehension will include cooperative dialogue and feedback on the sentences and small dialogues. The training conditions will be further divided into marking the change of the truth-value.
223849447|NCT03533036|DEVICE|applied VR headset|Virtual reality (VR) is a three-dimensional experience created by a headset fitted with a video display. The device, designed to be worn on the face, immerses the viewer in a virtual world and can create a visual distraction from the patient's present situation. We will use a commercially available VR device, comprised of a phone and headset. The phone is inserted into the headset to act as the visual display that can create three dimensional environments. The patient will then choose the virtual reality experience she prefers from the two relaxation programs available. The VR device will be introduced to the participant and fitted to her head prior to the procedure. The device is intended to be worn during the full length of the procedure until the conclusion of the D\&C, however the participant may decide to stop wearing the device and choose to end the VR experience at any time.
223849448|NCT05634317|BEHAVIORAL|Smartphone delivered Behavioral activation|"Outline:~Session 0 45-minute psychoeducation on caregiving and depression~Session 1 Review the present use of time and use the monitoring form~Session 2 Brain-storm pleasant events and schedule pleasant activities~Session 3 Review scheduling of events and discuss how to improve~Session 4 Review modifications and consolidate gains on scheduling~Session 5 Review present social support and explore new sources of support~Session 6 Examine communication skills and explore new options~Session 7 Review new communications and discuss how to improve~Session 8 Review modification and consolidate gains on support"
223849449|NCT05634317|BEHAVIORAL|Smartphone delivered Mindfulness|"Outline:~Session 0 45-minute psychoeducation on caregiving and depression~Session 1 The Raisin exercise (eating meditation) and12-min body scan~Session 2 Exercises on thoughts and feelings 12-min body scan~Session 3 Exercises focusing on unpleasant experiences, practicing seeing and hearing , sitting meditation, 3-min breathing space, and mindful stretching and breath meditation~Session 4 Practicing seeing and hearing, mindful communication, 3-min breathing space, and sitting meditation~Session 5 Mindful walking, 3-min breathing space, and sitting meditation~Session 6 Sitting meditation, exercises on thoughts and alternative viewpoints, and 3-min breathing space (responsive)~Session 7 Sitting meditation, activity and mood exercise, identifying habitual emotional reactions to difficulties, and 3-min breathing space (responsive)~Session 8 12-min body scan, exercise on looking forward, and exercise on preparing for the future"
223849450|NCT00699686|DRUG|Glargine|Daily bedtime subcutaneous insulin Glargine in individualized doses.
223849451|NCT00699686|DRUG|Detemir|Daily bedtime subcutaneous insulin Detemir in individualized doses.
223849452|NCT03697733|PROCEDURE|fractional curettage|Fractional curettage under TIVA by used oral Etoricoxib120 mg at 30 minutes before fractional curettage and then added intravenous Propofol 2 mg/kg when start the procedure or Intravenous Fentanyl 1 microgram/kg and Propofol 2 mg/kg when start the procedure
223849453|NCT04405713|PROCEDURE|from the onset of symptoms within the first 3 days|ELC within 3 days of onset of ACC
223849454|NCT04405713|PROCEDURE|: from the onset of symptoms within the 4-7 days|ELC 4-7days of onset of ACC
223849455|NCT04405713|PROCEDURE|from the onset of symptoms beyond 7 days|ELC after 7days of onset of ACC
223849456|NCT04662840|PROCEDURE|Geniculate artery embolization|Under fluoroscopic guidance and angiographic imaging, a microcatheter is used to select all the arteries feeding the affected knee and Embosphere (100-300um) particles are injected to obtaining pruning of the hypervascular tissues arteries.
223849457|NCT04662840|PROCEDURE|Geniculate nerve ablation|Under fluoroscopic guidance, a Cool-tip RFA ablation needle is advanced such that it touches the femur at the condylar convexity on each side and the tibia at the tibial plateau convexity on the medial side. The ablation is performed to obtain an approximate zone of ablation of 2cm.
223849458|NCT04662840|PROCEDURE|Skin infiltration of local anesthetic at groin and knee|Freezing of the skin will be performed at the groin (as prior to an arterial access for embolization procedure) and at three areas around the knee (as prior to insertion of the ablation needles for nerve ablation procedure).
223849459|NCT03275896|OTHER|Descemet Membrane Transplantation|The diseased host Descemet membrane will first be stripped, as per a standard Descemet Stripping Automated Endothelial Keratoplasty surgery. A cadaveric, acellular Descemet membrane graft will then be harvested and transplanted onto the host.
223849460|NCT03883438|PROCEDURE|Modified coronally advanced flap and acellular dermal matrix graft|Evaluation of the effectiveness of vertical incisions in the management of multiple gingival recessions (Miller Class I\&II ≥3 mm) treated with coronally advanced flap and acellular dermal matrix graft
223849461|NCT04969822|DEVICE|iDAScore®|A system that studies time lapse images obtained from the embryo culture system, Embryoscope, throughout the development to blastocyst. The system uses data acquired from a sequence of embryo images and has taught itself to identify the embryos with the highest likelihood of implanting and leading to fetal heart-beat detection.
223849462|NCT03121131|OTHER|Clinical Exam Findings|Findings found on clinical exam of a patient the radiologist will be reading CT scans of.
223849463|NCT03121131|OTHER|Inaccurate Clinical Exam Findings|Inaccurate findings are given to the radiologists
223849464|NCT03121131|OTHER|No clinical exam findings|No clinical exam findings are given to the radiologists
223849465|NCT05982600|DIAGNOSTIC_TEST|Single Assessor Teledermatological triage (TDT)|The skin lesion is assessed, diagnosed and triaged by one dermatologist assessors.
223849466|NCT05982600|DIAGNOSTIC_TEST|2 people Teledermatological triage (TDT)|The skin lesion is assessed, diagnosed and triaged by 2 dermatologist assessors. Worst case overrules.
223849467|NCT05982600|DIAGNOSTIC_TEST|3 people Teledermatological triage (TDT)|The skin lesion is assessed, diagnosed and triaged by 3 dermatologist assessors. Worst case and majority consensus assessments are calculated separately.
223849468|NCT05982600|DIAGNOSTIC_TEST|5 people Teledermatological triage (TDT)|The skin lesion is assessed, diagnosed and triaged by 5 dermatologist assessors. Worst case and majority consensus assessments are calculated separately.
223849469|NCT02661997|BEHAVIORAL|Tai Chi Intervention|All components of the program derive from the classical Yang Tai Chi 108 postures, which has been shown to be a moderate intensity exercise. Each Tai Chi session will last 60 minutes, twice a week for 12 weeks. In the first session, the Tai Chi instructors will explain exercise theory and procedures of Tai Chi. In subsequent sessions, subjects will practice Tai Chi under the instruction of one of the Tai Chi instructors. Every session will include the following components: (1) warm up and a review of Tai Chi principles; (2) meditation with Tai Chi movement; (3) breathing techniques; and (4) relaxation. The investigators will instruct patients to practice at least 30 minutes a day at home throughout the intervention period and will provide them with training materials for home practice.
223849470|NCT02661997|BEHAVIORAL|Wellness Intervention|The investigators will utilize a wellness education program for the control group because this approach has been successfully used in other Tai Chi studies from the investigators' team. Participants in the Wellness condition will also attend two 60-minute sessions per week for 12 weeks. The Wellness condition will correspond to the VA Whole Health Program to emphasize wellness across various domains (e.g., physical, emotional, and spiritual lives.) Each session will include a video clip as well as a brief mindfulness exercise that corresponds with the material being presented. The project coordinator for this study will provide the didactic lessons.
223849471|NCT00763282|BEHAVIORAL|Self Management (SM)|Self Management (SM) consists of: 1) on-site decisional support to promote provider adherence to ulcer management guidelines, 2) enhanced, interactive PrU education, 3) chronic disease self-management skill building via telephone based groups, 4) proactive care management using MI to support ongoing self-management activities, and 5) distance technology.
223849472|NCT00763282|BEHAVIORAL|Motivational Interviewing (MI)|Self Management and Motivational Interviewing (SM+MI) participants were assigned to both a self-management and motivational interview group. An education control intervention (ED) designed to be a credible intervention that is comparable to the SM will control for potential effects of natural history/time, treatment dosing, measurement processes, attention, the non-specific effects of therapeutic alliance, social support, and of receiving a manualized treatment with specific therapist procedures.
223849473|NCT00763282|BEHAVIORAL|Education (ED)|The ED intervention differs only in that subjects will not be instructed in any specific problem solving, self-monitoring, or SM techniques, with the exception of encouraging them to become informed consumers of SCI care.
223849474|NCT03284749|OTHER|Copper impregnated wound dressing|Copper impregnated wound dressing
223849475|NCT03284749|OTHER|Normal wound dressing|Normal wound dressing
223849476|NCT03284749|OTHER|Copper impregnated maternity pads|Copper impregnated maternity pads
223849477|NCT03284749|OTHER|Normal maternity pads|Normal maternity pads
223849478|NCT05693155|BEHAVIORAL|Voluntary self-exclusion from gambling ('Spelpaus')|Voluntary self-exclusion from gambling, using the government-based, official service 'Spelpaus' (literally 'play break')
223849479|NCT04370782|DRUG|Hydroxychloroquine|Hydroxychloroquine 400mg twice a day (BID) on day 1, followed by 200mg BID for days 2-5
223849480|NCT04370782|DRUG|Azithromycin|Azithromycin 500mg on day 1, followed by 250mg once daily for days 2-5
223849481|NCT04370782|DRUG|Zinc Sulfate|Zinc sulfate 220mg once daily for 5 days
223849482|NCT04370782|DRUG|Doxycycline|Doxycycline 200 mg once daily for 5 days
223849483|NCT06495411|OTHER|pranayama-|Pain of patients will be evaluated with the Visual analog scale at the 6th hour, 12th hour, 24th hour and at discharge.
223849484|NCT06495411|OTHER|deep breathing-|Pain of patients will be evaluated with the Visual analog scale at the 6th hour, 12th hour, 24th hour and at discharge.
223849485|NCT06495411|OTHER|control|Pain of patients will be evaluated with the Visual analog scale at the 6th hour, 12th hour, 24th hour and at discharge.
223849486|NCT05638230|DIAGNOSTIC_TEST|Left atrial reservoir strain|"LA strain measurements can be obtained by two dimensional (2D) speckle tracking echocardiography (STE). Longitudinal strain and strain rate curves are generated for each of six atrial segments, obtained from the apical four and two chamber views.~In the reservoir phase, as the LA fills and stretches, there is positive atrial strain that reaches its peak in systole at the end of LA filling, prior to opening of the mitral valve. Following this, passive LA emptying ensues with opening of the mitral valve resulting in decreased atrial strain with negative deflection of the strain curve up to a plateau period which is analogous to diastasis. LA reservoir strain (LARS), or peak atrial longitudinal strain or LA systolic strain, is measured at the end of the reservoir phase."
223849487|NCT00742274|DEVICE|Gore TAG Endoprosthesis|Implant Gore TAG device with Best Medical therapy per physician discretion
223849488|NCT00742274|OTHER|Best Medical Therapy|Best Medical therapy is regimen of antihypertensive medications used to maintain blood pressure below 125/80 mm/Hg throughout the entire follow-up period. Because BMT is assessed by blood pressure response to medication, specific medication regimens for each patient will differ. The typical regimen consists of 1 to 4 concomitant antihypertensive medications that may include angiotensin converting enzyme (ACE) inhibitors, alpha blockers, beta blockers, calcium channel blockers, diuretics, and/or vasodilators.
223849489|NCT00100984|DRUG|FUZEON [enfuvirtide]|
223849490|NCT03245060|BEHAVIORAL|Adapted Solution Focused Brief Therapy|Solution Focused Brief Therapy is an approach to building positive change in a person's life. It builds up a picture of a client's preferred future (or how a person would like their life to be); encourages a person to notice positive signs of change; and explores personal resources, skills and resilience. In the present project, the therapy has been adapted so that it works well with people who have a language disability.
223849491|NCT01912703|OTHER|Telephone interview|Subjects with incomplete data will be asked to complete a telephone interview
223849492|NCT00507637|DRUG|NT 201|Injection of up to 50 Units NT 201 (incobotulinumtoxinA/Xeomin®) per eye and injection visit (8 injections visits in total).
223849493|NCT05307991|DRUG|PrEP|HIV pre-exposure prophylaxis (or PrEP) will include the Malawi-approved PrEP regimen at time of study enrollment. At time of submission, the only Malawi-approved regimen includes Tenofovir/emtricitabine (TDF/FTC) containing 300 mg of TDF and 200 mg of FTC. If additional PrEP regimens become available in Malawi during the study recruitment or follow-up, participants will be able to choose from any regimen that they are eligible to receive per Malawi PrEP guidelines.
223849494|NCT05307991|DEVICE|STI testing|Urine specimens will be tested for Chlamydia trachomatis (Ct) and Neisseria gonorrhoeae (GC) using GeneXpert® (Cepheid, Sunnyvale, CA) Xpert® CT/GC platform and cartridge and syphilis RPR titer (BD Macro-VUE™, Becton, Dickinson and Company, Franklin Lakes, NJ \[FDA approved\]) with confirmatory Treponema pallidum particle agglutination (TP-PA) (Serodia Fujirebio Inc, Malvern, PA \[CE mark\]) if RPR is positive.
223849495|NCT05307991|BEHAVIORAL|Assisted partner notification|"Participants will be asked to provide the name and locator information for all sexual partners in the preceding 6 months. Participants will be asked to refer sexual partners to the clinic and will be provided with cards to distribute to partners. Each card will request that the recipient report to the STI clinic with the card and will contain a linking number that links them back to the index participant.~Sexual Partner Tracing: In accordance with the contract referral approach, if the named partners do not present to an STI clinic within 7-14 days, community outreach workers will contact the partners and counsel them to visit the clinic. Contact may be made through telephone, text message, or in person, as needed and will not disclose the name or identify of the index patient."
223849496|NCT05307991|DIAGNOSTIC_TEST|Acute HIV testing|Persons initiating or re-initiating PrEP will also be screened for acute HIV infection (AHI) using Abbott RealTime HIV-1 Assay (Abbott Laboratories, Chicago, IL) or Xpert® HIV-1 Viral Load (GeneXpert, Cepheid, Sunnyvale, CA).
223849497|NCT02364518|PROCEDURE|Snoreplasty|The procedure will be performed under local anesthesia in the examination chair. The subject's throat will be anesthetized with benzocaine spray followed by infiltration of the soft palate with 4-5 milliliters of 1% lidocaine with 1:100,000 epinephrine. The TranQuill suture will be inserted into the soft palate tissues using a predescribed pattern.
223849498|NCT02427737|BEHAVIORAL|Comfort Talk® Training|Personnel of MRI units is trained in advanced rapport skills, patient-centered and hypnoidal language, correct use of suggestions and skills of tension diffusion. This entails 16 hrs classroom work, additional on-site post-training support, and access to a post-training support web module resulting in at least 20 hrs training.
223849499|NCT06189742|BIOLOGICAL|Tezepelumab|Tezepelumab is a monoclonal antibody that blocks thymic stromal lymphopoietin (TSLP).
223849500|NCT02799056|DEVICE|Thoracic ultrasound|The ultrasound will be performed using the ultrasound system GE Logiq XP equipped with a linear probe of 10 MHz. The diaphragm is visualized as two parallel echogenic lines at the eighth intercostal space in the mid-axillary line. The images will be captured during the inspiratory and expiratory tidal volume to and during maximum inspiration and expiration. Each image will be frozen in B mode and the diaphragm thickness will be measured from the center line pleural half the peritoneal line. The fraction of diaphragmatic thickening it is calculated by the formula: diaphragmatic thickness at the end of inspiration - thickness to diaphragmatic at the end of exhalation / diaphragmatic thickness at the end of exhalation x 100. The number of areas with lines B also will be measured.
223849501|NCT03519321|DEVICE|MID-C|The MID-C system is being connected to the spine via standard unilateral posterior approach. Pedicle screws above and below the main curve are being used to attach the device to the selected vertebra.
223849502|NCT03047733|DEVICE|The XTRAC Excimer Laser System|Initial irradiation dose was 50 mJ/cm2 on face and 100 mJ/cm2 on trunk and extremities. If there had not been minimal asymptomatic erythema, energy level was escalated by 50 mJ/cm2.
223849503|NCT03047733|DRUG|Topical tacrolimus 0.1% ointment|Application of topical tacrolimus 0.1% ointment on the both lesions once daily.
223849504|NCT00297765|DRUG|Tacrolimus, Prograf®|
223849505|NCT02258295|DRUG|Intragel|Intragel has an average molecular weight of 800-1200 kDaltons.
223849506|NCT02258295|DRUG|Saline|Saline
223849507|NCT00852228|DRUG|IV cetuximab|Cetuximab is administered every two weeks at the dose of 500 mg/m² over 2h30 (150 minutes).
223849508|NCT00852228|DRUG|HAI chronomodulated chemotherapy|"Irinotecan (180 mg/m²) on day 2 as a 6 hour infusion, starting at 2:00, with a peak at 5:00~Oxaliplatin (85 mg/m²) in split daily doses for 3 days, starting on day 2. Daily sinusoidal infusion duration will last from 10:15 to 21:45, with peak delivery rate at 16:00.~5-Fluorouracil (2800 mg/m²) in split daily doses for 3 days, alternating with oxaliplatin infusions, starting on day 2. Daily sinusoidal infusions will last from 22:15 to 9:45 , with peak delivery at 4:00.~Treatments will be repeated every 2 weeks."
223849509|NCT00852228|DRUG|HAI conventional chemotherapy|"Irinotecan (180 mg/m²) on day 1 as a one hour infusion, then~Oxaliplatin (85 mg/m²) on day 1 as a two hour infusion, then~5-Fluorouracil (2800 mg/m²) as a 48 h infusion starting on day 2, after completion of oxaliplatin delivery.~Treatments will be repeated every 2 weeks."
223849510|NCT01281761|DRUG|cetuximab/irinotecan/simvastatin|D1 Cetuximab 500mg/m2 IV stepwise shortened infusion duration- \[C1D1 over 120min, C2D1 over 90min,subsequent dose over 60min\] D1 Irinotecan 150-180mg/m2 + Dextrose 5% 500ml IV \[over 90min\] D1-14 Simvastatin 80mg P.O(continuous, daily) every 2weeks
223849511|NCT02782182|DRUG|FOLFIRINOX (oxaliplatin, leucovorin, irinotecan)|FOLFIRINOX administered preoperatively and postoperatively
223849512|NCT02071511|PROCEDURE|Ablation of ventricular arrhythmias|control group: Ablation of ventricular arrhythmias
223849513|NCT02071511|PROCEDURE|Ablation of ventricular arrhythmias + renal denervation|Intervention group: Ablation of ventricular arrhythmias + renal denervation
223849514|NCT01674569|DRUG|X-82 oral|X-82 oral for 24 weeks or until unacceptable toxicity develops
223849515|NCT01674569|DRUG|ranibizumab (Lucentis)|Rescue treatment with intravitreal ranibizumab (Lucentis) as needed
223849516|NCT01894347|OTHER|TDM, Monitoring of Neuro-and Nephropathology|Therapeutic drug monitoring of serum levels and Monitoring of Neuro- and Nephropathology
223849517|NCT02327039|DRUG|Dapagliflozin|Sodium glucose cotransporter-2 inhibitor
223849518|NCT02327039|DRUG|Placebo|Tables of Dapagliflozin placebo
223849519|NCT00335556|DRUG|Doxorubicin Hydrochloride|Given IV
223849520|NCT00335556|DRUG|Irinotecan Hydrochloride|Given IV
223849521|NCT00335556|PROCEDURE|Conventional Surgery|Patients undergo resection
223849522|NCT00335556|DRUG|Cyclophosphamide|Given IV
223849523|NCT00335556|DRUG|Etoposide|Given IV
223849524|NCT00335556|DRUG|Carboplatin|Given IV
223849525|NCT00335556|BIOLOGICAL|Dactinomycin|Given IV
223849526|NCT00335556|DRUG|Vincristine Sulfate|Given IV
223849527|NCT00335556|RADIATION|Radiation Therapy|Undergo radiotherapy
223849528|NCT00335556|OTHER|Laboratory Biomarker Analysis|Correlative studies
223849529|NCT03244566|DIAGNOSTIC_TEST|positron emission tomography|patients who had esophagectomy with 3-field lymphadenectomy underwent examination of positron emission tomography prior to surgery within 2 weeks.
224265500|NCT07139496|DEVICE|Spinal Cord Stimulator|"After the implantation of the spinal cord stimulator, the study will begin with 3 phases:~For the first phase, SCS over lumbrosacral spinal cord will be activated for 3 months with appropriate stimulation of lower limb muscles for walking.~For the second phase, SCS over lumbrosacral spinal cord will be stopped. SCS over the injury site will be activated for 3 months with appropriate stimulation of lower limb muscles for walking.~For the third phase, SCS over both lumbrosacral spinal cord and injury site of spinal cord will be activated for another 3 months with appropriate stimulation of lower limb muscles for walking~During all the phrases, physiotherapy of individual muscle groups for walking will be arranged. Exoskeleton training will also be arranged for 4 to 5 hours per week."
224265501|NCT07140263|BEHAVIORAL|CARE MI|"The intervention consists of four sessions, each lasting between 60 and 90 minutes, ideally delivered on consecutive weeks. It integrates psychoeducation on trauma and moral injury, emotional regulation strategies, and incorporates elements from several evidence-based approaches. These include the EMDR-IGTP-OTS group protocol, acceptance and values-based work from ACT, and self-compassion-focused interventions.~In the Waiting List arm, CARE-MI will be delivered after the initial assessment period of the Experimental arm."
223849530|NCT01273701|BEHAVIORAL|Psychosocial intervention|"The treatment is one-year long and composed of 3 stages of psychosocial intervention. Subjects of TSTSU arms receive urine methamphetamine examinations at each visit, while subjects in OPD arm being tested at first/last visits and during stage changes.~-Stage 1, early intensive monitoring stage: The visit interval is 1 week. If the urine tests and self-report on methamphetamine use are negative for consecutive 4 visits, subjects can proceed to stage 2. (In OPD arm, the visit interval can be 2 weeks according to subjects' requirements.)~-Sage 2, late intensive monitoring stage: The visit interval is 2 week. If the urine tests and self-reports are straightly negative for 4 visits, subjects can proceed to stage 3. Whenever recent methamphetamine is detected, subjects should move back to stage 1.~-Stage 3, usual monitoring stage: The visit interval is 1 month until the end of treatment. Whenever recent methamphetamine is detected, subjects should move back to stage 1."
223849531|NCT01273701|BEHAVIORAL|Telephone reminding|Subjects in TSTSU-T group will receive addition telephone reminding one day before each visit. Each call will be no longer than five minutes. On the telephone, brief motivation enhancement may be conducted.
223849532|NCT03038256|DRUG|concurrent capecitabine-based long-term radiotherapy followed by 4 cycles XELOX and a delayed TME|"concurrent capecitabine-based long-term radiotherapy: capecitabine 825mg/m2,bid,d1-5, q week with Radiation treatment. Radiation treatment was given at 1·8 Gy per day, 5 days per week for 5-6 weeks, after a 45 Gy radiation dose in 25 fractions to the pelvis, a boost dose of 5·4 Gy in 3 fractions to the tumor bed or concurrent boosted.~XELOX:~Oxaliplatin: 130mg/m2,IV,d1; Capecitabine: 1000mg/m2,bid,d1-14; repeated every 3 weeks~Surgery Procedure:~Total Mesorectal Excision"
223849533|NCT03038256|DRUG|concurrent capecitabine-based long-term radiotherapy followed by a Regular TME and 6 Cycles XELOX|"concurrent capecitabine-based long-term radiotherapy: capecitabine 825mg/m2,bid,d1-5, q week with Radiation treatment. Radiation treatment was given at 1·8 Gy per day, 5 days per week for 5-6 weeks, after a 45 Gy radiation dose in 25 fractions to the pelvis, a boost dose of 5·4 Gy in 3 fractions to the tumor bed or concurrent boosted.~XELOX:~Oxaliplatin: 130mg/m2,IV,d1; Capecitabine: 1000mg/m2,bid,d1-14; repeated every 3 weeks~Surgery Procedure:~Total Mesorectal Excision"
223849534|NCT04379986|DEVICE|Senbiosys|The patients will undergo blood pressure estimation as per clinical routine and will simultaneously wear the device.
223849535|NCT06478043|DRUG|ivonescimab|20mg/kg, IV, D1, Q3W
223849536|NCT06478043|DRUG|irinotecan liposome|56.5mg/m\^2, IV, D1, Q2W
223849537|NCT00998816|DRUG|Pregabalin|pregabalin capsules (150mg,oral) will be administered 1 hour before lateral thoracotomy, 12 hours after the thoracotomy and then 12 h BID for 10 additional days.
223849538|NCT03431779|PROCEDURE|Adipose derived stem cell transplantation via lipofilling|Liposuction of 60cc abdominal fat with its adipose derived stem cells which will be reinjected (10-20 cc) in the vestibular area after centrifugation for 3 minutes at 1000 rpm and decantation of oil and red blood cells.
223849539|NCT03431779|PROCEDURE|Surgical excision|Excision of painful areas
223849540|NCT04358328|OTHER|Comprehensive geriatric assessment (CGA) and care|Comprehensive geriatric assessment and care including geriatric-, nursing-, physiotherapist-, and dietician assessments followed by appropriate interventions.
223849541|NCT04358328|OTHER|Standard care|Standard pre-, peri- and post operative care.
223849542|NCT03780309|BEHAVIORAL|Exercise Self-Monitoring|Participants engaged in exercise self-monitoring utilizing a traditional calendar recording method and heart rate monitor.
223849543|NCT03780309|BEHAVIORAL|Blood Pressure Self-Monitoring|Participants engaged in blood pressure self-monitoring by measuring blood pressure twice daily and before and after exercise.
223849544|NCT03288350|DRUG|mDCF + Avelumab|Patients will receive neoadjuvant therapy consisting of 4 cycles of avelumab added to the modified chemotherapy regimen of docetaxel, cisplatin, 5-fluorouracil (mDCF), followed by surgery and assessment of pathologic response. Then they will receive 4 cycles of adjuvant therapy of mDCF and avelumab.
223849545|NCT00478556|DRUG|Omnipaque|Oral CT contrast
223849546|NCT00478556|DRUG|Gastroview|Oral CT contrast
223849547|NCT02718469|BIOLOGICAL|Ebola Vaccine - low dose|2 x 0.5ml vaccine will be given as intramuscular injections on each of day 1 and day 28
223849548|NCT02718469|BIOLOGICAL|Ebola Vaccine - mid dose|2 x 0.5ml vaccine will be given as intramuscular injections on each of day 1 and day 28
223849549|NCT02718469|BIOLOGICAL|Ebola Vaccine - high dose|2 x 1.0ml vaccine will be given as intramuscular injections on each of day 1 and day 28
223849550|NCT02718469|BIOLOGICAL|Placebo|2 x 0.5ml or 2 x 1.0ml placebo will be given as intramuscular injections on each of day 1 and day 28 depending on cohort
223849551|NCT03771027|OTHER|The low FODMAP diet.|The low FODMAP group had reduced the intake of FODMAP. Children received 3 main meals and 2 snacks daily prepared by the catering company according to the Human Nutrition Recommendations for Polish Population. The dietary intervention lasted four weeks.
223849552|NCT03771027|OTHER|The diet based on NICE guidelines.|The control group based on NICE guidelines received diet contained products with different FODMAP content. Children received 3 main meals and 2 snacks daily prepared by the catering company according to the Human Nutrition Recommendations for Polish Population. The dietary intervention lasted four weeks.
223849553|NCT04238104|OTHER|no intervention|it's only observational study. No interventions.
223849554|NCT06368609|DIAGNOSTIC_TEST|IgG RDT|Sera will be thawed at room temperature; 15 µL of serum will be added to the sample pad of each dipstick, which will then be placed upright into a well containing 3 drops of buffer. The pads at the bottom of the dipstick shall then wick up the buffer to run up the nitrocellulose membrane towards the absorbent pad. The results can be read after 15-20 minutes. The presence of the control line will indicate proper execution of the test, with valid result. In case of absence of this line, the result will be considered invalid. Positive results will be defined as test with presence of both control and positive (including faint) lines; negative results will be defined as tests with presence of control line only.
223849555|NCT06368609|DIAGNOSTIC_TEST|IgG4 RDT|Sera will be thawed at room temperature; 15 µL of serum will be added to the sample pad of each dipstick, which will then be placed upright into a well containing 3 drops of buffer. The pads at the bottom of the dipstick shall then wick up the buffer to run up the nitrocellulose membrane towards the absorbent pad. The results can be read after 15-20 minutes. The presence of the control line will indicate proper execution of the test, with valid result. In case of absence of this line, the result will be considered invalid. Positive results will be defined as test with presence of both control and positive (including faint) lines; negative results will be defined as tests with presence of control line only.
223849556|NCT00854139|DRUG|Cyclophosphamide, anti-thymocyte globulin|"Cyclophosphamide 60 mg/kg IV on Day -5, -4 Anti-thymocyte globulin 20 mg/kg IV on Day -1, Day +1, +3, +5~Cyclosporine starting on Day -1 at 5 mg/kg daily I.V. and reduced to 3 mg/kg on Day +4, and adjusted to provide a trough whole blood concentration of 250-400 ng/mL. The route of administration will be changed to oral as soon as the patient is able to tolerate oral medications"
223849557|NCT00854139|PROCEDURE|Kidney transplant|On Day 0 the renal transplant is performed according to standard surgical techniques, preferably using an iliac fossa, extraperitoneal approach
223849558|NCT00854139|RADIATION|Thymic irradiation|Thymic irradiation 7 Gy on Day -1
223849559|NCT00854139|PROCEDURE|Bone marrow transplant from a related donor|• Donor bone marrow (\> 2 x 108 nucleated cells/kg of recipient body weight) is prepared for infusion according to the standard procedure at the medical center. A total of 15,000 Units of heparin is mixed with the marrow, which is infused at a rate of 300-500 cc/hr. The infusion begins in the operating room as soon as the vascular anastomosis of the renal allograft has been completed. Protamine, 25 mg, is administered I.V. after completion of the first half of the bone marrow infusion. If a partial thromboplastin time measured after completion of the marrow infusion is \> 60 seconds, the protamine treatment shall be repeated
223849560|NCT02722356|DRUG|Oxytocin|Oxytocin administered per oxytocin group or standard practice group (see above)
223849561|NCT05457842|DRUG|pudexacianinium chloride|Intradermal injection
223849562|NCT02380729|GENETIC|Gene Panel Sequencing|Enrichment for and panel sequencing of 2942 disease genes listed in the Online Mendelian Inheritance of Man (OMIM) database.
223849563|NCT02380729|GENETIC|Whole Genome Sequencing (WGS)|Whole Genome Sequencing of the index case and of both parents in the event that Gene Panel Sequencing did not identify a disease-causing mutation.
223849564|NCT05750095|BEHAVIORAL|Incredible Years Autism Spectrum and Language Delay Programme|Incredible Years Autism Spectrum and Language Delay Programme is a manualised group based intervention in 13 weekly 2-hour sessions. The programme targets parents of children aged 2-6 years, with autism spectrum disorder or language delay.
223849565|NCT05750095|BEHAVIORAL|First Aid for Parents|"First Aid for Parents is a program consisting of three full day work-shops targeting communication, interaction and daily living skills for parents of children with autism spectrum disorders"
223849566|NCT00100659|DRUG|Pegylated Interferon/ribavirin|
223849567|NCT05692258|OTHER|Acupuncture|"Acupuncture is a kind of therapy used to treat diseases, in which a needle (usually a millimeter needle) is inserted into a patient's skin or tissue at a certain Angle to stimulate a specific part of the body (acupoint).~Disposable sterile acupuncture filiform needle (0.30mm×25mm、0.30mm×40mm), Guizhou Andi Medical Equipment Co, LTD, Guizhou Food and Drug Supervision and Equipment Production Xu 20170011."
223849568|NCT00643708|PROCEDURE|ovarian interstitial laser treatment|Different dose of laser: group A, one point per ovary.
223849569|NCT00643708|PROCEDURE|ovarian interstitial laser treatment|Different dose of laser: group B, two points per ovary.
223849570|NCT00643708|PROCEDURE|ovarian interstitial laser treatment|Different dose of laser: group c, three points per ovary.
223849571|NCT00643708|PROCEDURE|ovarian interstitial laser treatment|Different dose of laser: group D, four-five points per ovary.
223849572|NCT00124956|DRUG|Doxorubicin|
223849573|NCT00390403|DRUG|R-(-)-gossypol acetic acid|
223849574|NCT00390403|DRUG|temozolomide|
223849575|NCT00390403|GENETIC|gene expression analysis|
223849576|NCT00390403|GENETIC|mutation analysis|
223849577|NCT00390403|GENETIC|protein expression analysis|
223849578|NCT00390403|OTHER|laboratory biomarker analysis|
223849579|NCT00390403|OTHER|pharmacological study|
223849580|NCT00390403|PROCEDURE|adjuvant therapy|
223849581|NCT00390403|RADIATION|radiation therapy|
223849582|NCT02718118|DEVICE|Dysport reconstituted at 1.5 mL (0.05 mL/injection)|Subjects treated for moderate to severe (GLSS = 2 or 3) glabellar lines at maximum frown.
223849583|NCT02718118|DEVICE|Dysport reconstituted at 2.5 mL (0.08 mL/injection)|Subjects treated for moderate to severe (GLSS = 2 or 3) glabellar lines at maximum frown.
223849584|NCT02180087|DRUG|Ketoprofen|
223849585|NCT05043818|OTHER||This study is an observational study and does not involve intervention.When the patient comes to the hospital or on the first to the second day of admission, the subject will be given a full scale check once（Screening related scales for anxiety and depression symptoms (PHQ9, SDS, HADS, HAMA, HAMD), inflammatory bowel disease quality of life scale (IBDQ), modified Mayo score for patients with ulcerative colitis/ simplified CDAI score for patients with Crohn's disease , Stool characteristics, degree of abdominal pain, gastrointestinal symptom scale (GSRS), etc.）. The stool sample will be collected once and 16S rRNA sequencing.
223849586|NCT05776576|BEHAVIORAL|Evaluation|Within the scope of the evaluation, first of all, physical activity levels of children and adolescents with physical disabilities, barriers that prevent them from participating in physical activity, and motivators that can increase their participation will be determined, accompanied by an interactive roundtable meeting. Afterwards, posture analyzes of children and adolescents with special needs with physical disabilities will be performed by physiotherapists.
223849587|NCT05776576|BEHAVIORAL|Education|"In the education part, interactive informative seminars titled Physical Activity in Individuals with Special Needs will be given and after the objective posture assessments, postural disorders of children and adolescents with special needs will be determined and accordingly, posture and ergonomics training will be given to the participants individually."
224265502|NCT07140263|BEHAVIORAL|TAU: Treatment as usual|During the waiting period, Waiting list group will receive usual institutional support.
224265503|NCT07140406|OTHER|conventional rehabilitation training|The rehabilitation training is designed based on the specific functional conditions of the patient's limbs. The specific training methods include proper limb positioning, exercise therapy such as passive movement, anti-spasticity training, scapular girdle muscle training, joint extension training, forearm pronation and supination training, occupational therapy, joint movement training, roller treatment, and fine motor skill training, etc. The treatment is conducted once a day and five times a week. The treatment lasts for 4 consecutive weeks.
224265504|NCT07140406|OTHER|conventional acupuncture|Conventional acupuncture treatment involves needling at acupoints on the upper limbs of patients to improve their upper limb function. The treatment is administered once a day, five times a week, for a continuous period of four weeks.
224265505|NCT07140406|OTHER|Acupuncture with the milli-needle fire-puncture on flexor muscle groups|The acupuncture points of the milli-needle fire-puncture device are located in the flexor muscle groups of the upper limbs, including the biceps brachii and the flexor muscle group of the forearm.
223849588|NCT05776576|OTHER|Experimentation|In the experimentation part, group exercises, dance therapy programs and technology-supported exercise educations with various technological equipment will be implemented in the company of physiotherapists, taking into account the posture assessments.
223849589|NCT04555044|DRUG|Clinolipid|Lipid injectable emulsion, USP 20%
223849590|NCT04555044|DRUG|Intralipid|Standard-of-Care Soybean Oil-Based Lipid Emulsion. 20% (lipid injectable emulsion, USP)
223849591|NCT00013026|BEHAVIORAL|CHF Self-management Education (Web-based Education)|
223849592|NCT05685758|OTHER|FTP-based therapeutic mobile-app|Participants are expected to play games within the mobile app and complete the available daily levels of 4 out of 5 games on at least 4 days per week for 8 weeks.
223849593|NCT01675830|DEVICE|Heat Retention Head Wrap|Applied to infant's heads during the rewarming phase of CBP surgery
223849594|NCT05402228|DIAGNOSTIC_TEST|temporomandbular joint disorders|no intervention
223849595|NCT04088188|DRUG|Cisplatin|Given IV
223849596|NCT04088188|DRUG|Gemcitabine|Given IV
223849597|NCT04088188|DRUG|Ivosidenib|Given PO
223849598|NCT04088188|DRUG|Pemigatinib|Given PO
223849599|NCT06510283|DRUG|Taitacept|Telitacicept will be subcutaneously injected at a dose of 240mg per week, lasting for at least 24 weeks.
223849600|NCT01949584|DEVICE|nasal continuous positive airway pressure less than or equal to 6 cm H2O|Low level continuous positive airway pressure delivered during sleep.
223849601|NCT02266810|DEVICE|PROPEL Mini Sinus Implant.|Placement of sinus implant following frontal sinus surgery
223849602|NCT02266810|PROCEDURE|Sinus Surgery alone|Sinus surgery only, without implant placement
223849603|NCT02266810|DEVICE|Propel Nova Sinus Implant|Placement of sinus implant following frontal sinus surgery
223849604|NCT05338242|DEVICE|Real-Time Exposure Feedback|Participants will receive real-time exposure monitors that continuously display real-time air concentration information and a color-coded designation for the current risk level.
223849605|NCT00445406|DRUG|bevacizumab + doxorubin hydrochloride liposme|Patients receive bevacizumab IV over 30-90 minutes and doxorubicin hydrochloride liposome IV over 30-90 minutes on days 1 and 15. Treatment repeats every 4 weeks for up to 6 courses
223849606|NCT00445406|DRUG|Bevacizumab|Patients then receive bevacizumab alone IV over 30-90 minutes on days 1 and 15. Courses with bevacizumab repeat every 4 weeks in the absence of disease progression or unacceptable toxicity
223849607|NCT04898322|DRUG|SY-005|2.5mg of SY-005 for each dose，doses to be given every 12 hours over a period of 5 days
223849608|NCT04898322|DRUG|SY-005|5mg of SY-005 for each dose，doses to be given every 12 hours over a period of 5 days
223849609|NCT04898322|DRUG|SY-005|10mg of SY-005 for each dose，doses to be given every 12 hours over a period of 5 days
223849610|NCT04898322|DRUG|Placebo|Placebo
223849611|NCT05046158|DEVICE|Transforming Powder Dressing|Altrazeal transforming powder dressing is methacrylate-based powder dressing made from the same materials used in the production of contact lenses. Upon hydration, the powder transforms into a moist, non-occlusive barrier that covers and protects the wound from exogenous bacteria while helping manage exudate through vapor transpiration.
223849612|NCT05046158|OTHER|Standard of care topical wound agents and dressings|Standard wound dressings such as gauze or foams. Moisture regulating topical agents may also be used to prepare the wound bed.
223849613|NCT00548119|BIOLOGICAL|NeoCart|autologous tissue implant
223849614|NCT00548119|PROCEDURE|microfracture|microfracture
223849615|NCT01269606|DRUG|insulin aspart|At the first treatment visit, a single dose of insulin aspart at 0.2 U/kg via IM (in the muscle) injection is administered. At the second treatment visit, a single dose of fast-acting insulin human at 0.2 IU/kg via IM (in the muscle) injection is administered. Subjects will resume their usual insulin treatment in the wash-out period of 4-28 days between treatment visits.
223849616|NCT01269606|DRUG|insulin human|At the first treatment visit, a single dose of fast-acting insulin human at 0.2 IU/kg via IM (in the muscle) injection is administered.At the second treatment visit, a single dose of insulin aspart at 0.2 U/kg via IM (in the muscle) injection is administered. Subjects will resume their usual insulin treatment in the wash-out period of 4-28 days between treatment periods.
223849617|NCT01269606|DRUG|insulin aspart|At the first treatment visit, insulin aspart is intravenously infused for 24 minutes, with rate of 1.25 mU/kg/min at constant phase. At the second treatment visit, fast-acting insulin human is intravenously infused for 24 minutes, with rate of 1.25 mIU/kg/min at constant phase. Subjects will resume their usual insulin treatment in the wash-out period of 4-28 days between treatment visits.
223849618|NCT01269606|DRUG|insulin human|At the first treatment visit, fast-acting insulin human is intravenously infused for 24 minutes, with rate of 1.25 mIU/kg/min at constant phase. At the second treatment visit, insulin aspart is intravenously infused for 24 minutes, with rate of 1.25 mU/kg/min at constant phase. Subjects will resume their usual insulin treatment in the wash-out period of 4-28 days between treatment periods.
223849619|NCT04904757|DEVICE|Contrast-enhanced spectral mammography (CESM)|CESM is a mammogram performed after the injection of IV contrast. CESM is used most often when additional information is needed after a standard mammogram. CESM has also been used to determine the extent of a known breast cancer, to screen patients at high risk for developing breast cancer due to a family history or positive cancer genes, and for women with dense breast tissue. Two images are taken almost at the same time during the exam, after the iodine based contrast injection is administered. The first image is comparable to a regular mammogram. The second image shows areas that take up the contrast (enhance) showing increased blood flow. Breast cancers often enhance with contrast due to a greater amount of blood vessels. Non-cancerous lesions can also have greater blood flow.
223849620|NCT00479141|BEHAVIORAL|HIV skills training|Eight 2-hour group skills training sessions will occur during Weeks 1 through 8 and booster sessions will occur every two months during Months 3 through 15
223849621|NCT00479141|BEHAVIORAL|Popular Opinion Leaders training|Two-hour training sessions about anti-stigma and anti-discrimination will occur for 4 weeks, followed by support meetings every 2 months during Months 2 through 13.
223849622|NCT01877616|OTHER|diagnostic test|Polysomnography
223849623|NCT01877616|OTHER|Diagnostic test|overnight polysomnography
223849624|NCT05603442|PROCEDURE|Thoracic intervertebral foramen block|The thoracic intervertebral foramen block is performed by placing the needle tip over and behind the transverse process of vertebra, via the thoracic intervertebral foramen.
223849625|NCT00988286|PROCEDURE|CEP, MEP, TMS|Patients and healthy volunteers will undergo cortical evoked potentials (CEP), motor evoked potentials (MEP) and transcranial evoked potentials (TMS).
223849626|NCT01724255|OTHER|questionnaire|
223849627|NCT01062880|BEHAVIORAL|self-guided internet modules|Patients are assigned at random to either unspecific (n= 1000) or individualized (n=1000) self guided internet modules.
223849628|NCT06096428|DEVICE|Pulsed-field ablation|Pulsed-field ablation will be done using pentaspline catheter (Farawave, Boston Scientific) and pulsed-field energy generator. The goal will be achieve of electrical isolation of pulmonary veins.
223849629|NCT06096428|DEVICE|Radiofrequency ablation|Pulmonary vein isolation will be done using radiofrequency catheter (Qdot, Biosense-Webster) and generator of radiofrequency energy (nGEN, Biosense-Webster).
223849630|NCT01771887|BEHAVIORAL|education program|education program in 6 hours and monitoring phone every 15 days
223849631|NCT05105152|BIOLOGICAL|SC-DARIC33|Infusion with SC-DARIC33 followed by intermittent oral rapamycin administration
223849632|NCT03802786|DRUG|Imeglimin|Single administration dose of imeglimin
223849633|NCT04590794|DIAGNOSTIC_TEST|Soluble Urokinase Plasminogen Activator Receptor|Participants will undergo sampling of peripheral venous blood, immediately after admission. Blood samples drawn from all patients and EDTA plasma will be stored at -80° C until later measurement. Plasma suPAR levels will be determined using the suPARnostic® ELISA assay (ViroGates, Denmark), which is based on a simplified double monoclonal antibody sandwich ELISA assay whereby samples and peroxidase-conjugated anti-suPAR are first mixed together and then incubated in anti-suPAR pre-coated micro wells. The recombinant suPAR standards of the kit are calibrated against healthy human blood donor samples. suPAR concentrations are determined as ng/mL plasma.
223849634|NCT03601507|DRUG|Alpelisib|Given PO
223849635|NCT03601507|OTHER|Laboratory Biomarker Analysis|Correlative studies
223849636|NCT03601507|OTHER|Pharmacodynamic Study|Correlative studies
223849637|NCT03601507|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
223849638|NCT00243334|OTHER|Integration of advanced clinical decision support with ambulatory computerized physician order entry|Actiobable Reminders related to medication monitoring, preventive care and chronic disease management, and test result follow-up are administered either during the visit or between visits.
223849639|NCT01043549|DEVICE|rTMS|Repetitive transcranial stimulation of the posterior parietal cortex
223849640|NCT01043549|DEVICE|Sham rTMS|Repetitive transcranial stimulation of the posterior parietal cortex
223849641|NCT03061513|DRUG|Ubiquinol|Ubiquinol caplets 600mg/day
223849642|NCT03061513|DIETARY_SUPPLEMENT|Placebo|placebo
223849643|NCT03478501|BEHAVIORAL|Decision Aid|This intervention is a tablet based Lethal Means Decision Aid with proposed use to augment lethal means counseling in emergency departments for patients at risk of suicide.
223849644|NCT02107014|DRUG|Low Dose Naltrexone|Naltrexone 4.5 mg p.o. nocte
223849645|NCT03761784|DRUG|S6G5T-3|Once a day topical cream
223849646|NCT03761784|DRUG|S6G5T-8|Once a day topical cream
223849647|NCT04245319|DRUG|Acitretin|The patients will receive the drug and the effect on repigmentation on vitiligo lesions will be observed
223849648|NCT04245319|OTHER|Narrow band ultraviolet B|Patients receive nbUVB session 3 times per week
223849649|NCT00104754|DRUG|liposomal SN-38|
223849650|NCT02992275|OTHER|Neuromuscular electrical stimulation (NMES)|Participants will receive NMES to the hip abductors while performing strength training 3 times per week for 24 weeks
223849651|NCT02992275|OTHER|Multi-Modality Balance Intervention (MMBI)|Participants will attend a group balance class that focuses on movement and obstacle negotiation 3 times per week for 24 weeks
223849652|NCT00478855|DRUG|Tazocin (Piperacillin/Tazobactem)|
223849653|NCT00586339|BIOLOGICAL|Cervarix|Intramuscular injection, 3 doses
223849654|NCT00586339|BIOLOGICAL|Placebo Control|Intramuscular injection, 3 doses
223849655|NCT04135209|DIAGNOSTIC_TEST|Optical coherence tomography angiography OCTA|Macular scanning using regular structural OCT as well as microvasculature analysis using OCTA
223849656|NCT03588845|OTHER|Treatment Protocol|Protocol treatment sites will be expected to see the patient within a pre-specified window of time. The doctors at that site will apply the treatment algorithm and will make decisions about response to treatment based on the algorithm and on specific patient answers to questionnaires. The treatment protocol will only be made available to IRBs, not to any site personnel before randomization. This was derived from a survey of rheumatologists in many countries and gastroenterologists, mostly in North America, who were asked multiple questions about how they would treat and follow up patients with suspected SIBO. Successful treatment is a response on GSS of no diarrhea plus a total GSS of \< 5.
223849657|NCT03588845|OTHER|Standard of Care|Physicians randomly assigned to standard of care will also be informed of their patients who met eligibility criteria. They will not be aware of the detailed treatment protocol but will be informed of which medications are in the protocol eg antibiotics, prokinetics etc. They will be free to contact the patients at their convenience and to treat them in any way they deem suitable, preferably using these medications but at doses and frequencies according to their own wishes.
223849658|NCT04428320|PROCEDURE|Pelvic floor injection|Injection of 10 cc of bupivacaine
223849659|NCT03697213|OTHER|Online study|20 hypothetical patient summaries
223849660|NCT03462199|DIETARY_SUPPLEMENT|Actazin (green kiwi powder) High Dose|Participants will consume 4 capsules (600 mg green kiwi powder) daily for 28-days
223849661|NCT03462199|DIETARY_SUPPLEMENT|Actazin (green kiwi powder) Low Dose|Participants will consume 4 capsules (150 mg green kiwi powder) daily for 28-days
223849662|NCT03462199|DIETARY_SUPPLEMENT|Control Formula (Actazin green kiwi powder + PreticX prebiotic)|Participants will consume 4 capsules (150 mg green kiwi powder + 250 mg PreticX prebiotic) daily for 28-days
223849663|NCT03462199|DIETARY_SUPPLEMENT|Livaux (gold kiwi powder) High Dose|Participants will consume 4 capsules (600 mg gold kiwi powder) daily for 28-days
223849664|NCT03462199|DIETARY_SUPPLEMENT|Livaux (gold kiwi powder) Low Dose|Participants will consume 4 capsules (150 mg gold kiwi powder) daily for 28-days
223849665|NCT03462199|DIETARY_SUPPLEMENT|Placebo (microcrystalline cellulose)|Participants will consume 4 capsules containing no active ingredients daily for 28-days
223849666|NCT01353092|DEVICE|Re5 Pulsating ElectroMagnetic Fields|"Re5 Treatment Helmet using Pulsating ElectroMagnetic Fields (PEMF):~30 minutes of active PEMF therapy in the morning and 30 minutes of active PEMF therapy in the afternoon"
223849667|NCT01353092|DEVICE|Re5 Pulsating ElectroMagnetic Fields (PEMF)|"Re5 Treatment Helmet using Pulsating ElectroMagnetic Fields (PEMF):~30 minutes of sham therapy and 30 minutes of active therapy (morning or afternoon)"
223849668|NCT02092844|BEHAVIORAL|CBT for Menopausal Insomnia (CBTMI)|Cognitive Behavioral Therapy for Menopausal Insomnia (CBTMI) includes education about sleep, sleep restriction, stimulus control, cognitive restructuring of sleep interfering thoughts, and relapse prevention; while also addressing women's beliefs about and reactions to hot flashes.
223849669|NCT00295867|DRUG|Zoledronic Acid|Zoledronic acid is a new, highly potent, heterocyclic nitrogen-containing third generation bisphosphonate that has demonstrated 40- to 850- fold greater potency than pamidronate in preclinical models of bone resorption. The mechanism of action of nitrogen-containing bisphosphonates such as pamidronate and zoledronic acid appears to involve inhibition of the mevalonate pathway
223849670|NCT05379868|PROCEDURE|Posterior column osteotomy|Apical full facet joint resection. Study intervention does not involve a device.
223849671|NCT05379868|PROCEDURE|No osteotomies|Standard treatment
223849672|NCT02734628|DRUG|Dexpanthenol (Bepanthen® Wund- und Heilsalbe, BAY81-2996)|30 g of 5% of the active ingredient dexpanthenol plus other ingredients as ointment
223849673|NCT02734628|DRUG|Placebo|Placebo to Bepanthen® ointment without active ingredient dexpanthenol
223849674|NCT06555523|OTHER|Ultrasound guided injection|The skin will be cleaned with a suitable antiseptic solution and a sterile, 25 G, 1.5 inch dental-tipped needle will be used. Patients will be injected with 5 ml 2% lidocaine + 5 ml 0.9% NaCl. The linear probe (PLT-704SBT, 7.5 MHz) of the ultrasound device will be kept parallel to the trapezoidal fibers on the marked trigger point and the dental-tipped needle will be directed to the targeted point in plane with real-time imaging
223849675|NCT06555523|OTHER|Blinded injection|The skin will be cleaned with a suitable antiseptic solution and a sterile, 25 G, 1.5 inch dental-tipped needle will be used. Patients will be injected with 5 ml 2% lidocaine + 5 ml 0.9% NaCl. The needle will be directed to the most sensitive point and advanced until it will be reached the trigger point.
223849676|NCT00143936|BEHAVIORAL|Low- Carbohydrate -Atkins Diet|Low Carbohydrate Diet
223849677|NCT00143936|BEHAVIORAL|Low Calorie Diet|Maintain a low calorie diet
223849678|NCT05875350|PROCEDURE|Intraligamental local anesthetic injection|The intraligamental technique was administered using ligajet intraligamentary jet injector (Micro Mega Company) containing Articaine hydrochloride 4% with adrenaline 1:200000 (ArtPharma Dent, inc, Egypt)
223849679|NCT05880732|DRUG|Magnesium Sulfate|Magnesium sulfate (MgSO4) is an N-Methyl D-Aspartate (NMDA) receptor antagonist that has been used for postoperative analgesia and reducing both the duration and intensity of pain by preventing central sensitization in response to peripheral painful stimulus4-9.
223849680|NCT05880732|DRUG|normal saline isotonic solution|only 250 ml of normal saline isotonic solution 30 minutes before induction,
223849681|NCT04851730|PROCEDURE|Orthopedic Physical Therapy Intervention|"First, a deep slow breathing protocol is intended to increase the expansion of the pelvic floor, utilizing the relationship between the diaphragm and the pelvic floor, resulting in a gentle stretching of the pelvic floor.~Next, abdominal soft tissue mobilization, or scar mobilization of the lumbopelvic abdominal area will take place.~Next, manual therapy to the thoracic or lumbar spine or the hips will be performed based on the impairments found in the orthopedic evaluation.~The participant will be given a home exercise program to support breath training, and manual therapy. During the initiation of the second visit each participant will watch a standardized pain education video on the tablet, Understanding pain in less than 5 minutes and what to do about it The above plan of care will be completed 2 times/week for 4 weeks for a total of 8 visits."
223849682|NCT04851730|DEVICE|Dry Needling|"Third, the investigator will dry needle appropriate muscles. Dry needling treatment technique will include insertion of a sterile, disposable, solid filament needle into the muscle belly in the area palpated as listed below. A 0.30 × 0.50mm, or specified size below, stainless steel Seirin J-type or Myotech needle will be used (Dommerholt 2011). Clean technique will be employed throughout the treatment procedure which includes hand washing, clean latex-free glove use, and skin-surface preparation with an alcohol swab ( Baima \& Isaac 2008). Each muscle will receive a maximal number of 2 insertions and each insertion consists of up to 5 seconds of a pistoning (in and out motion) technique in an attempt to elicit a local twitch response. Standard protocol for each muscle will be established prior to beginning data collection.~Details about the dry needling protocol can be found in Appendix L."
223849683|NCT00909935|DRUG|Dexmedetomidine|Initial 2 mcg/kg bolus administered over 10 minutes to achieve the Ramsey sedation score of 4 followed by an infusion of 1.5 mcg/kg/hr, which will run until patient is transferred to recovery area. Up to a further two boluses of 2 mcg/kg may be given to maintain an RSS of 4.
223849684|NCT01649635|DRUG|CABAZITAXEL (XRP6258)|Pharmaceutical form: solution Route of administration: intravenous
223849685|NCT01649635|DRUG|Prednisone|Pharmaceutical form: tablet Route of administration: oral
223849686|NCT01649635|DRUG|Ciprofloxacin|Pharmaceutical form: tablet Route of administration: oral
223849687|NCT01649635|DRUG|G-CSF (Granulocyte colony-stimulating factor)|Pharmaceutical form: solution Route of administration: subcutaneous
223849688|NCT03761966|OTHER|Pregnant women|
223849689|NCT04753463|OTHER|Survey|The on-line questionnaire which assess the subjective feelings of residents of pandemic impact on ophthalmology training programs
223849690|NCT03641950|DRUG|Botulinum toxin type A|Recommended initial dose to be intra-muscularly injected to the medial and contralateral pretarsal orbicularis oculi of the upper eyelid and the contralateral pretarsal orbicularis oculi of the lower eyelid is 1.25-2.5U (0.05ml \~ 0.1ml per site).
223849691|NCT01405235|DRUG|Paclitaxel|Paclitaxel 70 mg/m2/d i.v. on Days 1, 8, and 15 in combination with Topotecan 1.75 mg/m2/d i.v. on Days 1, 8, and 15, q 28 d
223849692|NCT01405235|DRUG|Cisplatin/Paclitaxel|Topotecan 0.75 mg/m2/d i.v. on Days 1- 3 in combination with Cisplatin 50 mg/m2 i.v. on Day 1, q 21 d
223849693|NCT00380705|DRUG|MK0476, Singulair, montelukast sodium / Duration of Treatment: 8 Weeks|
223849694|NCT06030427|BEHAVIORAL|Behavioral Dietary Intervention|Participate in weight management program
223849695|NCT06030427|OTHER|Educational Intervention|Receive patient education handouts
223849696|NCT06030427|OTHER|Health Promotion and Education|View behavioral educational PowerPoint presentation
223849697|NCT06030427|OTHER|Internet-Based Intervention|Complete virtual behavioral weight management with an integrated mindfulness component program
223849698|NCT06030427|OTHER|Interview|Ancillary studies
223849699|NCT06030427|OTHER|Medical Device Usage and Evaluation|Wear Fitbit
223849700|NCT06030427|BEHAVIORAL|Mindfulness Relaxation|Complete mindfulness components
223849701|NCT06030427|OTHER|Physical Performance Testing|Ancillary studies
223849702|NCT06030427|OTHER|Questionnaire Administration|Ancillary studies
223849703|NCT05455996|DRUG|MDMA|MDMA-assisted therapy
223849704|NCT05413928|BEHAVIORAL|Time Restrictive Eating- late|Eating window will be 10 hours or less, starting 3 hours after waking up. Same monitoring as Baseline phase.
223849705|NCT05413928|BEHAVIORAL|Time Restrictive Eating- early|Eating window will be 10 hours or less, starting 30 min after waking up. Same monitoring as Baseline phase.
223849706|NCT05413928|BEHAVIORAL|Time Restrictive Eating- early with early caloric intake|Same as TRE-early, but concentrating caloric intake early in the eating window Same monitoring as Baseline phase.
223849707|NCT05413928|OTHER|Macronutrient-controlled meals|Meals with a determined amount of protein, carbohydrates, and fat.
223849708|NCT06104657|OTHER|Non-Interventional Study|Non-interventional study
223849709|NCT06533254|OTHER|Predicting choice of dialysis|"Language data collected using survey 1, will be analyzed using Scaled Insights Behavioral AI solution to identify personality attributes and values. The resulting individual scores will be plotted on a graph and be used to identify specific personality clusters of patients.~Participants will respond to a survey that utilizes open and closed ended questions, asking broad questions about kidney failure and associated behaviors (e.g. diet, attitudes towards treatment). The open-ended questions will gather a natural language sample of 100-300 words whilst closed questions will capture data using Likert scale and multiple-choice responses.~The open-ended questions will gather a natural language sample of 100-300 words for analysis using Scaled Insights Behavioral AI approach. This language sample will be analyzed using Scaled Insights Behavioral AI system to identify personality attributes and values. Patients will also be asked their likelihood of selecting PD over HD."
223849710|NCT06533254|BEHAVIORAL|Behavioral nudges|"Patients with Chronic Kidney Disease, participants will be provided with their predicted personalized nudge to increase their likelihood of either maintaining their choice of peritoneal dialysis, or switching from hemodialysis to peritoneal dialysis.~Participants will respond to a survey that utilizes open and closed ended questions, asking broad questions about kidney failure and associated behaviors (e.g. diet, attitudes towards treatment). The open-ended questions will gather a natural language sample of 100-300 words whilst closed questions will capture data using Likert scale and multiple-choice responses."
223849711|NCT06150885|BIOLOGICAL|HLA-G-CAR.BiTE allogeneic γδ T cells|"Phase I is a multiple escalating dose, single arm, open-label and 3+3 design that implemented with five cohorts: low dose for single administration, low dose for twice administrations for 2 weeks, low, middle and high dose for 4 repeated administrations for 4 weeks.~Phase IIa is a single-arm, open-label and dose-expansion study and the effective dose of CAR-positive cells will be administered to 27 evaluable subjects with TNBC, NSCLC, CRC or GBM via intravenous infusion weekly for 4 weeks."
223849712|NCT01786746|BEHAVIORAL|cognitive behavioral therapy|cognitive behavioral therapy. 12 sessions.
223849713|NCT01786746|BEHAVIORAL|culturally adapted cognitive behavioral therapy|culturally adapted cognitive behavioral therapy for Chinese Americans. 12 sessions.
223849714|NCT01515358|DRUG|Placebo|Administered orally
223849715|NCT01515358|DRUG|LY3000328|Administered orally
223849716|NCT00658411|DRUG|deferoxamine|Given intravenously or subcutaneously over 8-12 hours daily for at least three weeks prior to transplantation date and continue until the day before the participant receives their donor's stem cells.
223849717|NCT03082885|DRUG|Thymosin-α1|1.6 mg s.c injection once per day for 7 days, then 1.6 mg s.c injection twice a week for 11 weeks.
223849718|NCT04548232|PROCEDURE|Laparoscopic sleeve gastrectomy|bariatric surgery
223849719|NCT02684084|DRUG|Ozurdex|OZURDEX® (DEX implant; Allergan Inc. Irvine, CA, USA) is a sustained-release biodegradable implant approved for treatment of Macular Edema secondary to central retinal vein occlusion as well as noninfectious uveitis affecting the posterior segment
223849720|NCT02684084|DRUG|Lucentis|LUCENTIS® (0.5 mg ranibizumab or RBZ, an anti-neovascular VEGF-A inhibitor, Novartis Pharmaceuticals Canada Inc.) was the first approved medical treatment for DME
223849721|NCT04305912|DEVICE|somofilcon A|Subjects will be randomized to wear somofilcon A daily disposable lenses.
223849722|NCT04305912|DEVICE|verofilcon A|Subjects will be randomized to wear verofilcon A daily disposable lenses.
223849723|NCT06548477|DRUG|Human albumin|Patients in intervention arm will also receive intermittent boluses of 20 percent human albumin (in addition to standard fluid therapy) that will be administered with dosage regimen of 1.25gm/kg of body weight per 24 hours. The maximum total calculated dose/volume of albumin for the patient will be infused @ 34 ml/hour (over 3 hours) and will be divided in 3 boluses, spaced at 8 hours intervals. During intervention period, duration of treatment (7-day study period) will cover the peak period of cerebral vasospasm from day 4th until 10th day. Albumin administration will be tailored according to the targeted values set for euvolemic fluid balance in each patient. Before randomization (within 72 hours post-ictus) and after day-10 (from day 11th-14th, patient will only receive standard fluid therapy.
223849724|NCT01649427|DRUG|Prograf|Prograf® capsules were supplied as capsules of 0.5 mg, 1 mg and 1.5 mg dose strengths.
223849725|NCT01649427|DRUG|Tacrolimus Hexal|"Tacrolimus Hexal® capsules were supplied to the investigators at dose strengths of 0.5 mg,~1 mg and 1.5 mg."
223849726|NCT03341026|OTHER|Metronom CGM device|Patient receives three Metronom CGM devices on day 1. On day 1, 4, 7 and 14, a hypo- or hyperglycaemic experiment will start according to allocation by randomizer.
223849727|NCT03341026|OTHER|Metronom CGM device|Patient receives three Metronom CGM devices on day 1. On day 1, 7, 10 and 14, a hypo- or hyperglycaemic experiment will start according to allocation by randomizer.
223849728|NCT02739568|DRUG|Pitolisant (BF2.649)|
223849729|NCT02739568|DRUG|Placebo|
223849730|NCT05630495|DEVICE|Picterus Jaundice Pro|Use Picterus Jaundice Pro, a smartphone app that is used to take photo of the newborns skin, where the Picterus calibration card is place.
223849731|NCT00740272|PROCEDURE|AF ablation + pacemaker implantation|regular pacemaker implantation and concomitant AF ablation procedure (PV isolation)
223849732|NCT00740272|PROCEDURE|Pacemaker implantation|regular pacemaker implantation
223849733|NCT02292667|PROCEDURE|TAP block|The aim of the Transversus Abdominis Plane (TAP) Block is to deposit local anesthetic in the plane between the internal oblique and the transversus abdominis muscles targeting the spinal nerves in this plane. The local anesthetic used in the ETAP study is Ropivacaine 0.375%. 2 ultrasound-guided injections of 10 ml will be performed on each side of the abdominal wall: 1 subcostal injection and 1 supra-iliac injection.
223849734|NCT02292667|DRUG|PCA with Chlorhydrate of Morphine|Doses of 1 mg of Chlorhydrate of Morphine will be delivered intravenously by the Patient Controlled Analgesia (PCA) pump. The PCA pump is a computerized pump which contains a syringe of 1 mg/ml of Chlorhydrate of Morphine as prescribed by the physician in charge of the patient, and connected directly to a patient's intravenous line. Doses of Chlorhydrate of Morphine can be self-administered by the patient as needed by the having the patient press a button.
223849735|NCT02292667|DRUG|Acetaminophen|1 g of Acetaminophen will be given intravenously each 6 h during 48 hours after the surgical procedure.
223849736|NCT01147770|DRUG|progesterone|duration
223849737|NCT00441675|PROCEDURE|Symptom Score|Symptom Score
223849738|NCT00441675|PROCEDURE|Symptom Score and PD20|Symptom Score and PD20
223849739|NCT06087068|DRUG|Thyroxine|The treatment goal after lobectomy was to control TSH within the normal reference range (0.4-5 mU/L)
223849740|NCT05837780|OTHER|Nasoalveolar molding device|comparison between using conventionally and digitally constructed nasoalveolar molding devices
223849741|NCT05066451|OTHER|%5 dextrose prolotherapy|"Patients in the study group will receive a total of 3 sessions of prolotherapy solution containing 5% dextrose at the beginning(0.) 3rd week and 6th week.~Prolotherapy was planned with the multiplanar injection technique (peppering technique) after palpating the most sensitive point on the lateral epicondyle and entering the lateral epicondyle from here and ensuring bone contact."
223849742|NCT05066451|OTHER|%15 dextrose prolotherapy|"Patients in the study group will receive a total of 3 sessions of prolotherapy solution containing 15% dextrose at the beginning(0.) 3rd week and 6th week.~Prolotherapy was planned with the multiplanar injection technique (peppering technique) after palpating the most sensitive point on the lateral epicondyle and entering the lateral epicondyle from here and ensuring bone contact."
223849743|NCT05822440|DRUG|PF-07817883|Single oral dose (period 1) or co-administered with itraconazole (period 2)
223849744|NCT05822440|DRUG|Itraconazole|Interacting drug which will be given for 7 days in period 2
223849745|NCT01609894|DIETARY_SUPPLEMENT|Individualized fortification of breast milk|"Lactose, fat and protein content will be measured prior to breast milk fortification.~Subsequently, breast milk for preterm infants will individually fortified adjusted by using data from milk analysis."
223849746|NCT01609894|DIETARY_SUPPLEMENT|Routine fortification of breast milk|Infants will be fed routine fortified breast milk.
223849747|NCT03603418|DRUG|Dexamethasone Sodium Phosphate|Dexamethasone is a synthetic glucocorticoid that is commonly used in human medical practice as potent anti-inflammatory, immunosuppressive and analgesic agent.
223849748|NCT03603418|OTHER|Distilled water|Distilled water
223849749|NCT05689216|BEHAVIORAL|Awake timed prone and repositioning|"Patients were instructed to adopt a timed prone and repositioning strategy with 4 sessions for four consecutive days.~Session 1, lying on the belly; Session 2, lying on the right side; Session 3, sitting up; Session 4, lying on the left side; then back to session 1 (30 minutes to two hours for each session). The daily duration of timed prone and repositioning is strongly recommended for 8-10 hours."
223849750|NCT05365386|DEVICE|Tixel C|This is a non-invasive thermo-mechanical treatment to the scalp and/or face using the Tixel technology.
223849751|NCT02525510|OTHER|Pump Eligible - Normothermia - Pump Both Kidneys|Normothermia and Machine Perfusion Deceased Donors will be kept normothermic (36.5-37.5 C) prior to organ recovery. Recovered kidneys will receive machine perfusion prior to implantation.OPO's protocol
223849752|NCT02525510|OTHER|Pump Eligible - Hypothermia and Pump Right Kidney|"Deceased Donors will be kept mildly hypothermic (34-35 C) for at least 12 hours prior to organ recovery. Right Kidney will receive machine perfusion prior to implantation and the Left Kidney will receive cold storage.~Recovered kidneys will be placed in University of Wisconsin for cold storage until reimplantation."
223849753|NCT02525510|OTHER|Pump Eligible - Hypothermia and Pump Left Kidney|Deceased Donors will be kept mildly hypothermic (34-35 C) for at least 12 hours prior to organ recovery. Left Kidney will receive machine perfusion prior to implantation and the Right Kidney will receive cold storage.
223849754|NCT02525510|OTHER|Not Pump Eligible - Normothermia|"Deceased Donors will be kept normothermic (36.5-37.5 C) prior to organ recovery.~Pulsatile Perfusion of kidney grafts based on the respective OPO's protocol"
223849755|NCT02525510|OTHER|Not Pump Eligible - Hypothermia|Deceased Donors will be kept mildly hypothermic (34-35 C) for at least 12 hours prior to organ recovery.
223849756|NCT02431663|DRUG|Ketamine|Intravenous administration in continuous
223849757|NCT05196737|BEHAVIORAL|Dry Needling|Dry needling is a procedure in which a thin, stainless steel needle is inserted into the skin to produce a muscle twitch response. It is intended to release a knot in a muscle and relieve pain.
223849758|NCT06550115|BEHAVIORAL|Time-restricted eating|Night shift workers will participate in 4 weeks of fasting during the biological nighttime while remaining awake during overnight work shifts.
223849759|NCT06550115|BEHAVIORAL|Control eating|Night shift workers will participate in 4 weeks of Control eating across the daytime and nighttime hours while remaining awake during overnight work shifts.
223849760|NCT05450783|OTHER|Biocollection|serum
223849761|NCT02735265|BEHAVIORAL|Virtual reality|12 training sessions (90 minutes a time, 2 times a week) IG:45 minute of Kinect for Xbox games and 45 minute of standard treatment.
223849762|NCT02735265|BEHAVIORAL|Standard treatment|CG: 90 minute of standard treatment. 12 training sessions (90 minutes a time, 2 times a week)
223849763|NCT04888585|DRUG|ABBV-154|Subcutaneous Injection
223849764|NCT04888585|DRUG|Placebo|Subcutaneous Injection
223849765|NCT04927975|DRUG|Upadacitinib|Oral tablets
223849766|NCT04927975|DRUG|Placebo|Oral tablets
223849767|NCT05365607|DEVICE|NightWare|A wearable digital therapeutic platform consisting of an Apple Watch and iPhone pre-provisioned with Nightware intervention app that will deliver a mild vibration to the watch after detecting individual having a nightmare based on Nightware proprietary algorithm, arousing the individual and disrupting nightmare without awakening.
223849768|NCT05365607|DEVICE|Sham NightWare|NightWare device will not deliver an intervention (i.e., no vibration)
223849769|NCT03548922|OTHER|Tanner stage|a scale of pubertal development in children, adolescents
223849770|NCT03548922|OTHER|Risser stage|a measure showing the growth left in the spine
223849771|NCT03548922|OTHER|Pressure of correction|an indirect parameter of the chest wall's flexibility. It is defined as the pressure applied to the patient, in the most protruding area of the chest, needed to accomplish a proper shape of the thorax.
223849772|NCT03548922|OTHER|Pectus carinatum protrusion|distance from the point of maximum protrusion to the estimated normal level of chest wall
223849773|NCT02882646|DEVICE|Bi-ADLER|Subjects will be asked to use the Bi-ADLER for 60 minutes. All subjects will be seated on the Bi-ADLER and asked to perform a battery of bimanual evaluation tasks (creating ovals, standard ADL tasks like pouring, reaching, drinking etc).
223849774|NCT03265704|OTHER|AGA - Control group|Data processing from Patient Medical Files
223849775|NCT03265704|OTHER|SGA - Control group|Data processing from Patient Medical Files
223849776|NCT03265704|OTHER|AGA-PIH Study group|Monitoring PIH-related changes in the newborn
223849777|NCT03265704|OTHER|SGA-PIH Study group|Monitoring PIH-related changes in the newborn
223849778|NCT03591289|DRUG|NMB with rocuronium bromide|Moderate versus deep neuromuscular block Not a device study
223849779|NCT03906747|OTHER|Interviews, questionnaire and focused group discussions|"To determine the effectiveness of the quality of care as perceived by relatives, we will perform a survey during the ED stay, with the next-of-kin to patients who was on the EOL pathway using a questionnaire developed for ED settings. The questionnaire will be administered by the research assistant face-to-face in the emergency department to assess the quality of care and the level of support provided to patients and their families in the last days of life.~We will also determine the level of staff's knowledge and perception of the EOL care using a locally-designed self-administered anonymous survey.~A focus group discussion (FGD) will be formed in each hospital to identify the gaps to the current EOL care by structured questionnaire. The group will also make recommendations to improve the quality of the EOL care. There will be separate FGD for: (i) healthcare professionals (ii) family members and (iii) general practitioners who will care for the patient if terminally discharged."
224265506|NCT07140406|OTHER|Acupuncture with the milli-needle fire-puncture on extensor muscle groups|The acupuncture points for the milli-needle fire-puncture device are located in the extensor muscle groups of the upper limbs, including the triceps brachii and the extensor muscles of the forearm.
224265507|NCT07140406|OTHER|Conventional needle puncture with a fire needle|The acupuncture points for milli-needle fire-puncture are commonly used ones on the upper limbs.
223849780|NCT03906747|OTHER|Review of medical records|"Electronic medical records will be reviewed to collect the following data:~1. Proportion of patients who fits criteria of EOL who died within 48 hours;~2. Proportion of patients on EOL pathway who have documentation that patient and/or family are given opportunities to discuss an individualised care plan;~3. Proportion of patients on EOL pathway who have documentation of an individualised care plan that is followed;~4. Proportion of patients on EOL pathway who have symptoms who are prescribed with medicines with individualised indications for use, dosage and route of administration"
223849781|NCT05042063|DEVICE|Hyfe Cough Tracker|"Hyfe Cough Tracker is a digital acoustic surveillance system that uses an artificial intelligence system to discriminate cough from non-cough sounds. Hyfe is an AI-enabled mobile app that records short snippets (\<0.5 seconds) of putative cough explosive sounds and then classifies them as cough or non-cough using a convolutional neural network (CNN) model. Briefly, the acoustic characteristics of recorded sounds are converted into an image file, which is then processed by an algorithm trained to identify graphical differences in images. This creates an adjustable prediction score, with values above it, resulting in a sound being classified as cough, and those below being classified as non-cough."
223849782|NCT05042063|DEVICE|Hyfe Air|Hyfe Air is a wearable device with an incorporated wireless lapel microphone. The device´s recordings can be run through the same cough-detection algorithm used by Hyfe Cough Tracker, while its results are directly stored in a remote database and are not displayed to participants.
223849783|NCT00420472|DRUG|mycophenolate mofetil [CellCept]|
223849784|NCT05167747|DIETARY_SUPPLEMENT|Dietary Supplement|"Dietary supplement formulated with magnesium, standardized extract of orthosiphon, standardized extract of hawthorn and standardized extract of hibiscus. Each tablet contains: 0.1 g magnesium, 0.25 g standardized extract of orthosiphon (Orthosiphon stamineus Benth), 0.16 standardized extract of hawthorn (Crataegus curvisepala Lind.) and 0.08 g standardized extract of hibiscus (Hibiscus sabdariffa L.).~Oral administration: 2 tablets/day at evening meal"
223849785|NCT05167747|OTHER|Placebo|Oral administration: 2 tablets/day at evening meal
223849786|NCT06329869|DRUG|Sacituzumab govitecan|Sacituzumab govitecan, 10 mg/kg intravenous infusion (the first infusion is to be administered over 3 hours; subsequent infusions may be administered over 1 to 2 hours if previous infusions were well tolerated) on day 1 and 8 of 21-day cycle.
223849787|NCT02484365|OTHER|No treatment|Attach adhesive probe on thumb or index finger
223849788|NCT04327037|BIOLOGICAL|Expanded Haploidentical Natural Killer cells|One dose (from 20x to \>100x 10\^6 /kg) of expanded haploidentical NK cells
223849789|NCT04327037|DRUG|IL-2|6 doses of IL-2 (1 × 10\^6 units/m2) from -1 day every other day.
223849790|NCT02708862|DEVICE|Preoxygenation|After 3 minutes of oxygen supplementation (preoxygenation), with each of the devices listed below, the exhaled oxygen content will be measured. All participants were enrolled in a single arm in which they underwent 4 interventions in series: 1) Simple mask at 60 L/min for 3 minutes 2) Non-rebreather at 60 L/min for 3 min 3) Non-rebreather at 15 L/min for 3 minutes 4) Bag valve mask at 15 L/min for 3 minutes
223849791|NCT05239702|BIOLOGICAL|CD7 CAR T-cells|Each subject receive CD7 CAR T-cells by intravenous infusion
223849792|NCT05492890|DEVICE|Dexcom G6|Continuous glucose monitoring
223849793|NCT02113163|DRUG|Metformin Eicosapentaenoate|
223849794|NCT02113163|DRUG|Metformin HCl and Vascepa|
223849795|NCT02758262|DEVICE|Noninvasive brain stimulation|
223849796|NCT03568162|DRUG|ISB 830 - Part 1 Group 1|Subcutaneous injection (SC) every 2 weeks
223849797|NCT03568162|DRUG|ISB 830 - Part 1 Group 2|Subcutaneous injection (SC) every 2 weeks
223849798|NCT03568162|DRUG|ISB 830 - Part 1 Group 3|Subcutaneous injection (SC) every 2 weeks
223849799|NCT03568162|DRUG|Placebo - Part 1 Group 4|Subcutaneous injection (SC) every 2 weeks
223849800|NCT03568162|DRUG|ISB 830 - Part 2 Group 5|Subcutaneous injection (SC) every 2 weeks
223849801|NCT03568162|DRUG|Placebo - Part 2 Group 6|Subcutaneous injection (SC) every 2 weeks
223849802|NCT04914312|DIETARY_SUPPLEMENT|Maqui berry/omeg-3 fatty acids|2 capsules BID per day containing a total of 600 mg of Maqui extract; 4 capsules per day supplying a total of 2000 mg EPA and 1000 mg DHA
223849803|NCT04914312|DIETARY_SUPPLEMENT|Placebos|4 olive oil soft gelatin capsules and inert two-piece capsules containing maltodextrin
223849804|NCT02471391|DRUG|ABT-199|
223849805|NCT02471391|DRUG|Ibrutinib|
223849806|NCT00925730|DRUG|Pimecrolimus|
223849807|NCT03717194|DRUG|Ertugliflozin|Ertugliflozin as add-on to Metformin and/or DPP4 inhibitors in patients with inadequately controlled type 2 diabetes
223849808|NCT03717194|DRUG|Placebo|Placebo as add-on to Metformin and/or DPP4 inhibitors in patients with inadequately controlled type 2 diabetes
223849809|NCT01668212|PROCEDURE|Doppler ultrasound|Doppler Ultrasound
223849810|NCT00333060|DRUG|OT-551 ophthalmic solution|
223849811|NCT06152029|DEVICE|Temporary PNS system|This system remains in place up to 60 days, then removed.
223849812|NCT06044948|DEVICE|Delefilcon A contact lenses|Daily disposable, silicone hydrogel spherical contact lenses
223849813|NCT04216433|PROCEDURE|endovascular surgery|"an innovative, less invasive procedure used to treat problems affecting the blood vessels, such as an aneurysm, which is a swelling or ballooning of the blood vessel. The surgery involves making a small incision near each hip to access the blood vessels."
223849814|NCT06519370|DRUG|FDA018-ADC|Subjects will receive FDA018-ADC 10 mg/kg of body weight via intravenous(IV) infusion on Day1 and 8 of a 21-day cycle in follow-up period until disease progression, unacceptable toxicity or death.
223849815|NCT06519370|DRUG|Eribulin|1.4mg/m\^2, IV (in the vein) on day 1 and Day 8 of each 21 day cycle
223849816|NCT06519370|DRUG|Capecitabine|1000 to 1250 mg/m\^2 will be administered in a 21-day cycle, with capecitabine administered orally twice daily for 2 weeks followed by 1-week rest
223849817|NCT06519370|DRUG|Gemcitabine|800 to 1200 mg/m\^2 will be administered IV on day 1 and Day 8 of each 21 day cycle
223849818|NCT06519370|DRUG|Vinorelbine|25 mg/m\^2, IV (in the vein) on day 1 and Day 8 of each 21 day cycle
223849819|NCT01013974|DRUG|GSK573719 250 μg|Strip 1 of the dry powder inhaler will contain GSK573719 250 μg micronized drug with lactose along with magnesium stearate. Strip 2 will contain lactose powder along with magnesium stearate. It will be available as dry off white powder for inhalation.
223849820|NCT01013974|DRUG|GSK573719 500 μg|Strip 1 of the dry powder inhaler will contain GSK573719 500 μg micronized drug with lactose along with magnesium stearate. Strip 2 will contain lactose powder along with magnesium stearate. It will be available as dry off white powder for inhalation.
223849821|NCT01013974|DRUG|GSK573719 1000 μg|Strips 1 and 2 of the dry powder inhaler will contain 500 μg each of GSK573719 micronized drug with lactose along with magnesium stearate. It will be available as dry off white powder for inhalation.
223849822|NCT01013974|DRUG|GSK573719 matching Placebo|Strip 1 and 2 of the dry powder inhaler will contain lactose powder along with magnesium stearate. It will be available as dry off white powder for inhalation.
223849823|NCT04530474|DRUG|Ivermectin Pill|Ivermecin as a one-time dose
223849824|NCT04530474|DRUG|Placebo|Inactive medication as a one time dose
223849825|NCT00399282|DRUG|Omega-3 and Vitamin E supplementation|
223849826|NCT03807505|PROCEDURE|Interscalene brachial plexus nerve block|An interscalene brachial plexus nerve block (single shot or catheter, depending on surgical procedure) will be placed under ultrasound guidance and all patients will receive 10cc 0.5% ropivacaine during block placement. Patients with a nerve catheter will receive a bolus of 5cc 0.5% ropivicaine postoperatively, on arrival to the recovery unit.
223849827|NCT03807505|PROCEDURE|Erector spinae plane block|An erector spinae plane block (single shot or catheter, depending on surgical procedure) will be placed under ultrasound guidance and all patients will receive 10cc 0.5% ropivacaine during block placement. Patients with a nerve catheter will receive a bolus of 5cc 0.5% ropivicaine postoperatively, on arrival to the recovery unit.
223849828|NCT04504084|OTHER|Decision aid|Patient Decision Aid is a tool that helps patient with ureteral stone become involved in decision making on choosing treatment for ureteral stone. Patient Decision Aid provides information about the options and outcomes, and by clarifying personal values.
223849829|NCT05143242|PROCEDURE|Hard tissue augmentation at the buccal aspect of single implants.|One or two releasing incisions are made. The periosteum is released and multiple bone perforations are made in the buccal bone prior to the application of deproteinized bovine derived xenograft. A Creos® membrane (Nobel Biocare, Gothenburg, Sweden) is used to cover the occlusal part of the alveolar crest and the xenograft particles. Finally, multiple single monofilament sutures are used for primary tension-free wound closure.
223849830|NCT05143242|PROCEDURE|Soft tissue augmentation at the buccal aspect of single implants.|A CTG is taken from the palate and transplanted to the buccal side between the alveolar bone and the buccal flap. The CTG is secured with single monofilament sutures.
223849831|NCT02081391|DRUG|Tapentadol oral solution 4 mg/mL|"Participants aged 6 months to less than 18 years old with a body weight below 20 kg received tapentadol oral solution 4 mg/mL by mouth every 4 hours for up to 72 hours.~Participants from birth to less than 6 months received tapentadol oral solution, diluted 4 fold."
223849832|NCT02081391|DRUG|Tapentadol oral solution 20 mg/mL|Participants aged from 6 months to less than 18 years with a body weight greater than or equal to 20 kg received tapentadol oral solution 20 mg/mL by mouth every 4 hours for up to 72 hours.
223849833|NCT02081391|OTHER|Placebo|Matching placebo oral solution was administered by mouth every 4 hours up to 72 hours.
223849834|NCT00339625|OTHER|low fat, high fiber, high fruit and vegetable eating plan|Participants were randomized to a low fat, high fiber, high fruit and vegetable (intervention arm) or their usual diet (control arm)
223849835|NCT05830695|DRUG|human treated dentin matrix|human treated dentin matrix is compared with mineral trioxide aggregate in apexogenesis
223849836|NCT05830695|DRUG|Mineral Trioxide Aggregate|mineral trioxide aggregate was used as control
223849837|NCT02659995|OTHER|No intervention|No interventions will be performed on these patients.
223849838|NCT05347537|OTHER|Mulligan mobilization|Mulligan Mobilization designed to reduce pain and improve the patient's range of motion. Mulligan's mobilization with movement at the frequency of 3 sets with 10 repetitions 3 times/ week without the clamshell exercise.
223849839|NCT05347537|OTHER|clamshell exercise|As a general exercise, the clamshell can help strengthen your medial glutes, bringing more power and stability to your hips. This group treated with mulligan's mobilization with movement and clamshell exercises.
223849840|NCT01084421|BEHAVIORAL|Computer-based parent-adolescent HIV communication|The parental intervention consists of a 60 minute computer-based program delivered in two sessions (one per week). The DVD ROM provides information about adolescent sexual risk and HIV prevention, strategies to support sexual specific communication and parent-adolescent communication in general. The computer based education program is provided in Spanish.
223849841|NCT01458275|DRUG|Ciclesonide nasal aerosol 37 mcg|ciclesonide nasal aerosol 37mcg - the dose is administered as 1 actuation per nostril to give a total dose of 37 mcg
223849842|NCT01458275|DRUG|ciclesonide nasal aerosol 74 mcg|ciclesonide nasal aerosol 74 mcg - the dose is administered as 1 actuation per nostril to give a total dose of 74 mcg
223849843|NCT01458275|DRUG|Placebo|Placebo - one actuation per nostril
223849844|NCT01339221|PROCEDURE|Stool samples|Stool samples collected and checked for the presence of rotavirus
223849845|NCT06097104|OTHER|electrolytes - serum blood samples|"CBC - Kidney function tests - liver function tests - ABG - levels of serum sodium, potassium, magnesium, phosphorus, ionized calcium and chloride, with maximum 5 mm blood sampling per day"
223849846|NCT00041795|DRUG|leteprinim potassium (Neotrofin)|
223849847|NCT04629144|DRUG|Belimumab|"Belimumab administered subcutaneously 200mg weekly from week 1 to week 24.~Both arms will have the same corticosteroid tapering scheme, with an initial dose of 30 mg/day. The following schedule of reduction of prednisone will apply to both groups as long as the disease is inactive:~* 30 mg/day week (W)0-W2,~* 20 mg/day W2-W4~* 15 mg/day W4-W6,~* 10 mg/day W6-W8,~* 5 mg/day W8-W10~Between W10-W12 the strategy for stopping glucocorticoids is left to the investigator's discretion.~Stopping glucocorticoid therapy at W12. At each step, the prednisone dose will be reduced only in the absence of signs of vasculitis activity."
223849848|NCT04629144|DRUG|Placebo|"Both arms will have the same corticosteroid tapering scheme, with an initial dose of 30 mg/day. The following schedule of reduction of prednisone will apply to both groups as long as the disease is inactive:~* 30 mg/day week (W)0-W2,~* 20 mg/day W2-W4~* 15 mg/day W4-W6,~* 10 mg/day W6-W8,~* 5 mg/day W8-W10~Between W10-W12 the strategy for stopping glucocorticoids is left to the investigator's discretion.~Stopping glucocorticoid therapy at W12. At each step, the prednisone dose will be reduced only in the absence of signs of vasculitis activity."
223849849|NCT02569229|OTHER|Diagnostics for glucose tolerance with 3 different methods.|"1. A 7-day course of subcutaneous continuous glucose monitoring system (CGMS).~2. An oral glucose tolerance test done within the 7 day period of CGMS.~3. Optionally a intravenous glucose tolerance test done within the 7 day period of CGMS."
223849850|NCT03251651|DRUG|Propofol|Propofol is infused continuously via the target-controlled infusion device (Orchestra®, Fresenius vial, Brezins, France), and the effect-site concentration is maintained within 0.5-2.0 μg/ml.
223849851|NCT03251651|DRUG|Dexmedetomidine|Dexmedetomidine is diluted with 0.9% saline to make a concentration of 4 μg/ml. As a loading dose, 1 μg/kg dexmedetomidine is administered over a 10-min period, which is then administered continuously at 0.1-0.5 μg/kg/h.
223849852|NCT03213041|DRUG|Carboplatin|Given IV
223849853|NCT03213041|OTHER|Laboratory Biomarker Analysis|Correlative studies
223849854|NCT03213041|BIOLOGICAL|Pembrolizumab|Given IV
223849855|NCT03087721|BEHAVIORAL|HIIT-LV|"Supervised endurance treadmill training as walking/running uphill, 3 times/week during 12 weeks starting at 85-90% of previously determined maximum oxygen consumption (VO2 max). Warm-up 3 min at 30% of VO2 max, 3 min cool-down. Progression in intensity every 3erd week."
223849856|NCT03087721|BEHAVIORAL|CAE|Supervised moderate intensity treadmill training, 3 times/week for 12 weeks starting at 70% of VO2 max. Warm-up 3 min at 30% of VO2 max, 3 min cool-down. Progression in intensity every 3erd week.
223849857|NCT01111591|DRUG|Cox2 inhibitor (Celecoxib)|From postoperative third day, administration will be started celecoxib 200mg bid for 6 months for administration group.
223849858|NCT02404246|BEHAVIORAL|Peer support program|
223849859|NCT02926937|DRUG|Sotagliflozin (SAR439954)|"Pharmaceutical form: tablet;~Route of administration: oral"
223849860|NCT02926937|DRUG|Placebo|"Pharmaceutical form: tablet;~Route of administration: oral"
223849861|NCT04035759|BEHAVIORAL|APPEAL|Three-session, individually administered program, with sessions spaced monthly. Optional weekly contacts with participants to support engagement in program exercises/activities.
223849862|NCT00350961|DRUG|Gemcitabine|
223849863|NCT00350961|DRUG|Oxaliplatin|
223849864|NCT00350961|DRUG|Capecitabine|
223849865|NCT01317017|DRUG|Actimmune|"* All subjects will receive one intradermal injections of 0.25ml of IFN-g (Actimmune TM 100 micrograms/0.5ml), in normal appearing skin of both normal volunteers and psoriasis patients.~* Blood will be taken at baseline and day 1. A skin biopsy (6mm punch) will be taken at the injection site 24 hours later.~* Patients will return at one to two weeks for suture removal.~* Clinical assessments done at every visit.~* Patients will also be evaluated at each visit for any adverse events."
223849866|NCT01559090|DRUG|MEDI-546|Stage I: 100 mg IV, single dose and multiple doses once every 4 wks for 48 wks Stage II: 300 mg IV, multiple doses once every 4 wks for 156 wks
223849867|NCT01559090|DRUG|MEDI-546|Stage I: 300 mg IV, single dose and multiple doses once every 4 wks for 48 wks Stage II: 300 mg IV, multiple doses once every 4 wks for 156 wks
223849868|NCT01559090|DRUG|MEDI-546|Stage I: 1000 mg IV, single dose and multiple doses once every 4 wks for 48 wks Stage II: 1000 mg IV, multiple doses once every 4 wks for 156 wks, the dose at Stage II was changed to 300 mg IV.
223849869|NCT05697965|DRUG|Vancomycin|applying 1 gm of vancomycin powder intracapsularly during primary total knee and hip arthroplasty to prevent periprosthetic joint infection
223849870|NCT05697965|PROCEDURE|Total knee or total hip arthroplasty|Primary total knee or total hip arthroplasty without using local vancomycin
223849871|NCT05518825|DIETARY_SUPPLEMENT|Fortimel/Nutridrink Compact Protein|Twice daily serving of the study product
223849872|NCT00425542|OTHER|Outpatient care (vs traditional inpatient care)|Patients randomized to the outpatient arm are discharged from the emergency department within 24 hours after randomization. Patients randomized to the inpatient arm are admitted to the hospital and are discharged based on the decision of the managing physician at the hospital.
223849873|NCT03571594|DRUG|ONO-5788|Investigational drug
223849874|NCT03571594|DRUG|ONO-5788 Placebo|Placebo Comparator
223849875|NCT03571594|DRUG|Octreotide|Active Comparator in Part D
223849876|NCT02653274|OTHER|Breakfast porridge|220 kcal breakfast porridge served with 240 mL glass of water
223849877|NCT04505124|BEHAVIORAL|FutureMe App|The FutureMe app provides visual and consequential feedback through a future-self avatar, meaning that the avatar changes its body shape and some additional characteristics based on the participants' activity and food purchasing behaviors. The app tracks participants physical activity behavior (steps) by means of their smartphone (integration to GoogleFit and AppleHealth) and motivates them to increase their step counts. The app also connects to participants' grocery loyalty cards to evaluate their food shopping behavior leveraging the Nutri-score concept. The app motivates participants to improve their food purchases through concrete shopping tips provided in-app.
223849878|NCT04505124|BEHAVIORAL|Conventional TrackingApp|The Control Conventional Tracking app provides numeric and factual feedback through conventional data-dashboards. The app tracks participants physical activity behavior (steps) by means of their smartphone (integration to GoogleFit and AppleHealth) and motivates them to increase their step counts. The app also connects to participants' grocery loyalty cards to evaluate their food shopping behavior leveraging the Nutri-score concept. The app motivates participants to improve their food purchases through concrete shopping tips provided in-app.
223849879|NCT00901056|DEVICE|Extracorporeal Shockwave Therapy|Energy Density - 0.02 - 0.15 mJ/mm2
224265508|NCT07139444|OTHER|One time Physical Therapy Evaluation|"A physical therapist will perform an evaluation which will consist of history taking and assessing the following: strength, endurance, range of motion, sitting/standing balance, sensory testing, and skin integrity. Following these assessments, the physical therapist will assess participant's functional mobility which involves assessing how you get out of bed, standing up, and walking. The physical therapist will also assess the participant on three tests which help determine your balance and assistance required with functional mobility. The tests that will be performed in no particular order are PASS, MSAS, AM-PAC 6-Clicks, OPS, MRS, and FCI. Data for the AM-PAC daily activity and applied cognition domains will be obtained from the patient's chart from the Occupational Therapy evaluation. Discharge destination information will be obtained from the PT evaluation and the discharge destinations will be acute/inpatient rehab, SAR, SNF, Home with or without home PT, and outpatient PT."
224265509|NCT07138989|DRUG|Valganciclovir Hydrochloride Tablets|Valganciclovir hydrochloride tablets will be administered at 900 mg twice daily from day 1 to day 14, followed by 450 mg twice daily from day 15 to day 20, for a total of 3 cycles.
224265510|NCT07138989|DRUG|gemcitabine, cisplatin, and PD-1 antibody|"Gemcitabine 1000 mg/m² will be administered intravenously on days 1 and 8; cisplatin 80 mg/m² intravenously on day 1; and PD-1 antibody intravenously on day 1. Each cycle is 21 days in duration, and treatment will be administered for a total of 4 to 6 cycles.~Following completion of the 4 to 6 cycles, patients will continue PD-1 antibody maintenance therapy (every 3 weeks) for up to two years or until disease progression, unacceptable toxicity, initiation of a new anticancer therapy, withdrawal of informed consent, or death."
223849880|NCT06254599|DRUG|SY-3505 Capsules|A third-generation ALK tyrosine kinase inhibitor
223849881|NCT06254599|DRUG|Crizotinib Capsules|An oral ALK tyrosine kinase inhibitor
223849882|NCT06232161|DEVICE|Red-light therapy device|Red-light therapy was performed with a low-intensity laser (LD-A, Jilin LD Optoelectronics Technology, Jilin, China) with an irradiance of 0.35 ± 0.02 mW/cm2, a wavelength of 650 nm ± 10 nm, and illumination of approximately 400 lux on average.
223849883|NCT06232161|DEVICE|Spectacles|Single focus spectacles, that is to say, wearing glasseses with minus power lens
223849884|NCT02513433|DRUG|Bupivacaine|Local anesthetic
223849885|NCT02513433|DRUG|Levobupivacaine|Local anesthetic
223849886|NCT02513433|DRUG|Ropivacaine|Local anesthetic
223849887|NCT02768805|BIOLOGICAL|15 µg/strain of Quadrivalent VLP Vaccine|Single dose of non-adjuvanted Quadrivalent VLP Vaccine
223849888|NCT02768805|BIOLOGICAL|30 µg/strain of Quadrivalent VLP Vaccine|Single dose of non-adjuvanted Quadrivalent VLP Vaccine
223849889|NCT02768805|BIOLOGICAL|15 µg/strain of the licensed quadrivalent vaccine|Single dose of the licensed quadrivalent vaccine
224265511|NCT07139678|OTHER|SUMAC|Participant will complete tasks given in SUMAC.
224265512|NCT07140185|BEHAVIORAL|Regular Weekly Physical Activity Program|Structured physical activity sessions three times per week, 50 minutes each, over 8 weeks. Includes aerobic exercises, supervised by trained instructors. Goal is to distribute the recommended weekly activity evenly.
223849890|NCT04463953|DRUG|Zanubrutinib,Ixazomib and Dexamethasone|Zanubrutinib, 160mg orally, twice a day; Ixazomib, 4 mg orally, day 1, 8, 15; Dexamethasone, 20mg orally, days 1, 8, 15；Ixazomib and dexamethasone every 4 weeks of a cycle, with induction of 6 cycles, and then maintain every 12 weeks, up to 6 cycles (96 cycles in total). Zanubrutinib is taken orally twice a day for up to 96 cycles, with a reduction in the last ID cycle. ZID regimen will continue 6 cycles after reaching the maximum response after introduction section.
223849891|NCT02622139|DEVICE|Multispectral Optoacoustic Tomography (MSOT)|MSOT for the evaluation of disease activity in IBD patients
223849892|NCT00264589|BEHAVIORAL|8 weeks individualized training program|no drugs added
223849893|NCT00974298|PROCEDURE|Total elbow replacement arthroplasty|Total elbow arthroplasty using pressfit technique in which no cement is used.
223849894|NCT04145102|OTHER|hesperidine|used for antibacterial and reminerlization assesment
223849895|NCT04145102|OTHER|propolis|used for antibacterial and reminerlization assesment
223849896|NCT04145102|OTHER|silver diamine fluoride|used for antibacterial and reminerlization assesment
223849897|NCT02723877|DRUG|PQR309|Dual phosphatidylinositol 3-kinase phosphoinositide 3-kinase/ mammalian target of rapamycin Inhibitor (= PI3K/mTOR Inhibitor)
223849898|NCT02723877|DRUG|Eribulin|non.taxane microtubule dynamics inhibitor
223849899|NCT01781702|DRUG|Pelubiprofen 30 mg|
223849900|NCT01781702|DRUG|Celebrex 200 mg|
223849901|NCT04705974|PROCEDURE|Fascia iliaca block|Fascia iliaca block will be performed under ultrasound guidenance.
223849902|NCT04705974|PROCEDURE|Femoral nerve block|Femoral nerve block will be performed under ultrasound guidenance.
223849903|NCT04705974|PROCEDURE|Pericapsular nerve group block (PENG block)|Pericapsular nerve group block (PENG block) will be performed under ultrasound guidenance.
223849904|NCT03031028|OTHER|ketogenic diet|Ketogenic Diet is a high fat, low carbohydrate diet.
223849905|NCT00056641|DRUG|tipranavir|
223849906|NCT00056641|DRUG|ritonavir|
223849907|NCT00056641|DRUG|saquinavir|
223849908|NCT00056641|DRUG|amprenavir|
223849909|NCT00056641|DRUG|lopinavir|
223849910|NCT04120337|DEVICE|RemovAid device + lidocaine patch|The RemovAid device incises the skin and grasps the implant for removal. A lidocaine patch will be used prior to incision.
223849911|NCT04120337|PROCEDURE|Standard technique + lidocaine injection|Using scalpel, tweezers, and forceps to remove a subdermal implant. A lidocaine injection will be used prior to incision.
223849912|NCT04120337|DEVICE|RemovAid device + lidocaine injection|The RemovAid device incises the skin and grasps the implant for removal. A lidocaine injection will be used prior to incision.
223849913|NCT02134275|BEHAVIORAL|Whole body vibration training|Each whole body vibration session will consist of a 20 min timed stand on the vibration platform where participants will stand with their knees in a slightly flexed position (120°) while the plate oscillates. The vibration frequency will be set at ranges between 20-40Hz and the amplitude set at 2mm displacement.
223849914|NCT02134275|BEHAVIORAL|Control group|Participants in this group will be asked to not make any significant changes to their lifestyle behaviors, such as diet and exercise, for the duration of the study.
223849915|NCT03008343|DEVICE|Irreversible Electroporation|One kind of electric ablation machine from Angiodynamic company (USA)
223849916|NCT03008343|BIOLOGICAL|Natural killer|Each treatment: 8-10 billion cells in all, transfuion in 3 times, i.v.
223849917|NCT05975320|DRUG|Warfarin|Patients receiving oral anticoagulants will be followed up for 6 months to detect occurrence of any major bleeding events include (spontaneous epistaxis , spontaneous bleeding per gums , hematemesis , bleeding per rectum , intracranial hemorrhage and internal hemorrhage ). Then, incidence of bleeding events using both (HAS-BLED) \& (ORBIT) SCORES will be calculated and compared for all cases .
223849918|NCT01234194|DRUG|rising remifentanil concentrations|remifentanil effect-compartment concentrations 0,1,2,3 ng/ml
223849919|NCT01234194|DRUG|falling remifentanil concentrations|remifentanil effect-compartment concentrations 3, 2, 1, 0 ng/ml
223849920|NCT06143761|DRUG|PD-1 inhibitor+carboplatin+albumin-bound paclitaxel|A comparative evaluation of patient prognosis between those who received neoadjuvant chemoimmunotherapy-surgery treatment and those who underwent surgery alone.
223849921|NCT01021644|BEHAVIORAL|aerobic exercise-training|3 times per week for 6 months
223849922|NCT01021644|BEHAVIORAL|stretch exercise|3 times per week for 6 months
223849923|NCT03356067|PROCEDURE|Gastric endoscopic peroral pyloromyotomy|"G-POEM is, in principle, adaptation of POEM (per-oral endoscopic myotomy) in the stomach. The procedure consists of:~1. Mucosal incision at the greater curvature 3-5 cm from the pylorus~2. Submucosal tunnelling~3. Finding pyloric sphincter~4. Myotomy (2-3 cm) of the pyloric muscle~5. Incision closure (endoclips or suture device)"
223849924|NCT03356067|PROCEDURE|Esophago-gastro-duodenoscopy|Standard endoscopic examination of the upper GI tract with flexible endoscope
224265513|NCT07140185|BEHAVIORAL|Weekend Warrior Physical Activity Program|Same total weekly activity as Arm 1, but concentrated in 2 weekend sessions of 75 minutes each. Includes aerobic exercises, supervised by the same trained instructors.
224265514|NCT07140471|PROCEDURE|Onlay Mesh Repair|Polypropylene mesh is placed over the anterior rectus sheath and fixed with Prolene sutures after hernia sac reduction.
224265515|NCT07140471|PROCEDURE|Sublay Mesh Repair|Polypropylene mesh placed in the retrorectus space and fixed with Prolene sutures after Rectus Sheath Dissection
224265516|NCT07139093|DEVICE|DBS-coupled tACS|tACS will be applied in a phase-coupled manner, so that tACS and DBS are synchronized
224265517|NCT07140588|PROCEDURE|Patients undergoing radical cystectomy will receive a novel NR-RC procedure using a genitofemoral nerve graft to enhance erectile function recovery.|Patients undergoing radical cystectomy will receive a novel NR-RC procedure using a genitofemoral nerve graft to enhance erectile function recovery.
224265518|NCT07138820|PROCEDURE|Parathyroidectomy|Imaging with 18-F-choline-PET-CT
224265519|NCT07139639|DRUG|Guanxinning Tablets|"Guanxinning Tablets~* Manufacturer: Zhengda Qingchunbao Pharmaceutical Co., Ltd.~* NMPA Approval No. Z20150028~* Administration: 4 tablets orally, three times daily for 6 months"
224265520|NCT07139639|DRUG|Matching Placebo for Guanxinning|"Matching Placebo for Guanxinning Tablets~* Manufacturer: Zhengda Qingchunbao Pharmaceutical Co., Ltd.~* Drug Product Certificate of Analysis Approval No.YF-R-C037A-2024104-A~* Administration: 4 tablets orally, three times daily for 6 months"
223849925|NCT05617339|BEHAVIORAL|I am (internet approach to migraine)|I AM has a biopsychosocial perspective. Modules 1-3 and 10 are mandatory and for those who are in need of shorter support and module 1-10 is for those who have more frequent and severe migraines and want a long time of support and treatment. The rationale of the treatment assumes that we do not know why we get migraines and instead focus on becoming as good as possible at managing the migraine attacks. The focus area of the treatments cognitive-behavioral interventions is, among other things, psychoeducation, what migraine is and what happens in the body during migraines and pain, interpretation of symptoms and information processing, training to stop through mindfulness and becoming aware of assumptions that guide behavior during pain management, management of grief, worry, guilt and feelings of shame based on self-compassion, challenging avoidances in a valued direction through ACT interventions and physiotherapist-led cardio training and exercises.
223849926|NCT02675855|OTHER|GrafixPRIME®|Human tissue, Wound cover, Application of a non-adherent dressing, a moisture retentive dressing, and a secondary dressing.
223849927|NCT02675855|PROCEDURE|Dressing Application|Wound cover, Application of a non-adherent dressing, a moisture retentive dressing, and a secondary dressing.
223849928|NCT02675855|DEVICE|Off-loading (walking boot)|Patients will be fitted for an off-loading device (walking boot) and agree to comply with use of the device during the course of the study
223849929|NCT04805645|OTHER|No intervention (Retrospective Cohort Observational)|No intervention as this study is a Retrospective Cohort Observational
223849930|NCT03455361|PROCEDURE|Stark Implant with low primary stability|
223849931|NCT00002589|BIOLOGICAL|aldesleukin|
223849932|NCT00002589|BIOLOGICAL|muromonab-CD3|
223849933|NCT00002589|BIOLOGICAL|therapeutic autologous lymphocytes|
223849934|NCT00002589|PROCEDURE|adjuvant therapy|
223849935|NCT05423080|DRUG|Bolus injection of remimazolam|Participants in this group are administered 0.2 mg/kg remimazolam via the bolus injection method for 20 seconds during anesthesia induction. If loss of consciousness (LOC) does not occur, the investigators will administer additional doses of 0.05 mg/kg repeatedly until LOC occurs.
223849936|NCT05423080|DRUG|Infusion of remimazolam|Participants in this group are administered remimazolam at a rate of 6 mg/kg/hr via the continuous infusion method during anesthesia induction. If loss of consciousness (LOC) does not occur, the investigators will escalate infusion dose to 12 mg/kg/hr until LOC occurs.
223849937|NCT00547976|DRUG|[C-11]PBR28|
223849938|NCT01585181|BIOLOGICAL|PXVX0200|Single dose; liquid suspension after reconstitution with buffer; 2x108 to 2x109 CFU in a liquid suspension
223849939|NCT01585181|BIOLOGICAL|Placebo|Approx 2 grams of lactose reconstituted in water
223849940|NCT00002179|DRUG|Indinavir sulfate|
223849941|NCT00002179|DRUG|Lamivudine|
223849942|NCT00002179|DRUG|Zidovudine|
223849943|NCT03722446|DEVICE|Arrow Catheter Kit.|The group will be randomized to receive this labor analgesia kit.
223849944|NCT03722446|DEVICE|B.Braun Catheter Kit|The group will be randomized to receive this labor analgesia kit.
223849945|NCT05126602|DIETARY_SUPPLEMENT|Vitamin D3 10000 IU|Tablet of 5000 IU of vitamin D3 given twice daily
223849946|NCT05126602|DIETARY_SUPPLEMENT|Vitamin D3 1000 IU|Tablet of 1000 IU of vitamin D3 given once daily
223849947|NCT01113229|DRUG|Misoprostol|two misoprostol tablets taken orally (400µg)
223849948|NCT04107649|BEHAVIORAL|Telephonic Active Coaching (Motivational Interviewing) + Financial Incentives|As part of TAC(MI)+FI, participants speak with a health coach at Brigham and Women's Hospital once a week via telephone for weeks 6-13 following surgery, and once every other week for weeks 14-31 after surgery. Participants in this arm can receive financial rewards for achieving weekly physical activity goals, as well as bonus rewards for achieving goals multiple weeks in a row. Over the course of this 6-month long TAC(MI)+FI intervention period, these participants are able to receive up to $680 for meeting physical activity goals, and up to $95 in bonus rewards.
223849949|NCT04107649|BEHAVIORAL|Wrist based activity tracker wear|Activity tracking data will be collected on a weekly basis. Participants who receive this intervention are eligible to be entered into a lottery to win one of two $25 rewards for every week they wear their wrist-based activity tracker \>10 hours for \>4/7 days a week, beginning 6-weeks after surgery.
223849950|NCT04107649|OTHER|Basic Study Activities|Basic study activities begin two-weeks before TKR and end approximately 24-months after TKR. Basic study activities include: two in-person visits at the local clinic site (2 weeks before TKR and 32-weeks after TKR), having check-in calls with study staff weekly from weeks 1-13 after surgery and every other week for weeks 14-31, completing 6 surveys, and wearing an ActiGraph activity tracker (waist-worn) for five one-week periods throughout the study (2-weeks before-TKR, 32-weeks post-TKR, one-year post-TKR, 18-months post-TKR, two-years post-TKR). All participants will be eligible to receive up to $235 for completing these activities over the course of two years.
223849951|NCT05803967|BEHAVIORAL|Baduanjin exercising|baduanjin will be applied 5 times per the week, under supervision, for 12 weeks,
223849952|NCT01577043|DRUG|Racecadotril|Racecadotril, 30 mg per sachet, dosage 1.5 mg./kg./day
223849953|NCT01577043|OTHER|Placebo|cornstarch powder diluted in distilled water, dosage 2.5 ml per dose
223849954|NCT05209542|PROCEDURE|Hysterosalpingo-Foam Ultrasonography|"* Initial 3-5 ml of foam contrast is to be introduced slowly into the endometrial cavity while the flow of contrast medium in each tube is evaluated using grayscale and power Doppler imaging~* Power Doppler is very helpful to confirm the direction of the flow as well as the acceleration during injection"
223849955|NCT05209542|PROCEDURE|Laparoscopy|• Standard laparoscopic evaluation with the dye test (methylene blue staining) is to be performed 1 day after ultrasound tests with 1 day of hospitalization under general anesthesia
223849956|NCT01571089|BEHAVIORAL|DBT-inspired anxiety treatment|In short, the treatment is 24 sessions consisting of skills-training strategies and exposure strategies. The idea is that the patient during the treatment will learn and practice the skills needed to handle exposures.
223849957|NCT02908464|DEVICE|Lumosity|A neurocognitive training program designed to enhance cognitive abilities
223849958|NCT01049139|BEHAVIORAL|1-sided messages|Supplemental information with 1-sided messages (emphasizes information content related to vaccine trial randomization and unproven efficacy of vaccine).
223849959|NCT01049139|BEHAVIORAL|2-sided messages|Supplemental information with 2-sided messages (acknowledges the beliefs that are at odds with the information content and seeks to neutralize those beliefs through counter-argument).
223849960|NCT01141140|BEHAVIORAL|Healthy|Favourable nutritional characteristics.
223849961|NCT01141140|BEHAVIORAL|Diet|Benefits of an ingredient/nutrient for weight management
223849962|NCT01141140|BEHAVIORAL|Unhealthy|Hedonic characteristics and less healthy ingredients.
223849963|NCT05464589|OTHER|Transcutaneous tibial nerve stimulation along with pelvic floor muscle srengthening|"Pelvic floor muscles strengthening:~Pelvic floor muscles training involves Kegel's exercises. Kegel exercises improve the function and tone of the pelvic floor. Kegel exercises represent the voluntary contraction and relaxation of the levator ani muscle (principally the pubococcygeus and puborectalis portions), which supports the vagina, bladder, and urethra. The slow contractions help with muscle strengthening.~Transcutaneous electrical stimulation of Tibial Nerve:~Transcutaneous Tibial nerve stimulation is a form of treatment technique that involves the use of electrical impulses to address urinary symptoms and target the lower urinary tract."
223849964|NCT05464589|OTHER|Pelvic floor muscles strengthening|"Pelvic floor muscles strengthening:~Pelvic floor muscles training involves Kegel's exercises. Kegel exercises improve the function and tone of the pelvic floor. Kegel exercises represent the voluntary contraction and relaxation of the levator ani muscle (principally the pubococcygeus and puborectalis portions), which supports the vagina, bladder, and urethra. The slow contractions help with muscle strengthening."
223849965|NCT02727621|DRUG|Dexmedetomidine|Anesthesia will be maintained with continuous infusion of dexmedetomidine 0.5-0.7 µg/kg/h in addition to sevoflurane supplementation as required, to maintain arterial blood pressure and heart rate within 20% of preoperative values. Muscle relaxation will be maintained with continuous rocuronium infusion 0.6 mg/kg/h.
223849966|NCT02727621|DRUG|propofol|Anesthesia will be maintained with continuous infusion of propofol 50-100 µg/kg/min in addition to sevoflurane supplementation as required, to maintain arterial blood pressure and heart rate within 20% of preoperative values. Muscle relaxation will be maintained with continuous rocuronium infusion 0.6 mg/kg/h.
223849967|NCT06244108|OTHER|Occupational therapy home program|"After evaluating the children, an occupational therapy home intervention program will be developed for each child. The program will be monitored through telephone and computer interviews, as well as video, photo, and audio recordings. The interventions in this study were selected based on successful occupational therapy home programs for children with disabilities. The program consists of five steps.~Step 1 is to establish collaborative relationships with parents. Step 2 is to determine the most appropriate goals for the child and their family. Step 3 involves selecting the most suitable therapeutic activities to achieve these goals. Step 4 is to educate and support parents in performing these therapeutic activities. Finally, Step 5 involves measuring the results and providing feedback."
223849968|NCT02214459|BEHAVIORAL|DASH Mobile mhealth enhanced coaching|Phone calls with a health coach that utilize the tracking data collected by the app and devices.
223849969|NCT00140673|BIOLOGICAL|Rotavirus|
223849970|NCT06058182|DIAGNOSTIC_TEST|blood draws|Pre-procedure, post-procedure (12-24 h), 6-month, and 12-month blood draws
223849971|NCT06250075|DIETARY_SUPPLEMENT|Formulation with probiotics|Lactobacillus acidophilus NCFM®, Lactobacillus paracasei Lpc-37 ™, Bifidobacterium lactis Bi-04™, Bifidobacterium lactis Bi-07™, Bifidobacterium bifidum Bb-02™)
223849972|NCT06250075|OTHER|Non-intervention for Clinical Outcomes -G5|only observation of clinical outcomes in the postoperative period
223849973|NCT04129424|DEVICE|Insulin pump (Microtech, Equil®)|Those patients of different types of diabetes mellitus were assigned to different groups, those groups were classified by the time to reach target blood glucose .
223849974|NCT00069459|DRUG|Extended-release Bupropion Hydrochloride|Bupropion hydrochloride will be available in dose strength of 150 and 300 milligram (mg). Subjects will receive one tablet of 150 mg bupropion hydrochloride from Day 1 to 7, from Day 8 to Week 27 will receive one tablet of 300 mg bupropion hydrochloride and from Week 28-29 one tablet of bupropion hydrochloride
223849975|NCT06146985|COMBINATION_PRODUCT|20 mg Famitinib & 1200 mg Adebrelimab|Famitinib is a novel multi-targeted tyrosine kinase inhibitor targeting VEGFR2, PDGFR, and c-kit. Adebrelizumab is a humanised immunoglobulin G4 (IgG4) monoclonal antibody that binds specifically to human PD-L1
223849976|NCT02017106|PROCEDURE|Endovenous Laser ablation and concomitant phlebectomies|
223849977|NCT02017106|PROCEDURE|Endovenous Laser ablation and sequential phlebectomies|
223849978|NCT04215913|OTHER|The investigators will extract total protein, DNA and RNA from PSC patients.|The investigators will extract total protein, DNA and RNA from PSC patients.
223849979|NCT00070954|DRUG|ginkgo biloba|EgB 761
223849980|NCT00070954|OTHER|matched placebo|Inactive look-alike placebo
223849981|NCT01710150|PROCEDURE|CTI ablation alone|
223849982|NCT01710150|PROCEDURE|CTI ablation and Pulmonary vein isolation (PVI)|
223849983|NCT02180113|DEVICE|Fibroscan® examination|Each patient undergo 1 LSM and at least 1 SSM (2 in more if the patient accept to participate at the ancillary study (intra and inter operator reproducibility of SSM).
223849984|NCT04018118|BIOLOGICAL|Biological sample|Additional blood samples for biobanking
223849985|NCT02840994|BIOLOGICAL|CV301|
223849986|NCT02840994|BIOLOGICAL|Pembrolizumab|
223849987|NCT02840994|BIOLOGICAL|Nivolumab|
223849988|NCT04720599|DIAGNOSTIC_TEST|ExoDx Prostate(IntelliScore)|The ExoDx Prostate test result supports the biopsy decision process by stratifying patients based on risk for high grade prostate cancer
223849989|NCT06486974|DRUG|NaF|Group 1 will be instructed to brush their teeth twice daily/2 minutes each time for the duration of this study
223849990|NCT06486974|DRUG|Na MFP|Group 2 will be instructed to brush their teeth twice daily/2 minutes each time for the duration of this study
223849991|NCT06611514|DRUG|Prasterone (DHEA)|Prasterone 6.5 mg vaginal tablets
223849992|NCT06611722|OTHER|Psychological and Functional Assessment|Assessment of Pain Sources: Patients are grouped based on intra-articular, extra-articular, or combined intra- and extra-articular hip pain.Psychological Assessment: Depression and anxiety are assessed using standardized questionnaires (e.g., BDI for depression, SAS for anxiety).Functional Assessment: Joint function and pain are evaluated using clinical and patient-reported outcome measures.
223849993|NCT06628882|PROCEDURE|Infraclavicular Block|types of anesthesia used in upper extremity surgeries
223849994|NCT06628882|PROCEDURE|Wide-Awake Local Anesthesia with No Tourniquet|types of anesthesia used in upper extremity surgeries
223849995|NCT06630052|OTHER|adductor canal clinical examination|clinical examination of the adductor canal in patients with knee pain not matching the radiological changes
223849996|NCT06697938|RADIATION|Preoperative SBRT for the Primary Lesion of Breast Cancer|SBRT for Primary Lesion of Breast Cancer, Radiation Dose: Primary Lesion ≤3 cm, GTV 24Gy/3F; Primary Lesion \>3 cm, GTV 30Gy/5F.
223849997|NCT06696339|DEVICE|PreemptiveAI SDK|Use the PreemptiveIAI SDK to measure heart rate.
223849998|NCT06698367|OTHER|Standard rehabilitation|Protocol based on the best available evidence and to be used in all participants in both groups. The standard rehabilitation protocol will consist of three postoperative phases: Mobilization (0 to 4 weeks), Strengthening (4 to 8 weeks) and Functional phase (8 to 12 weeks). Sessions will be held 3 times a week for 12 weeks. Each session will last 1 hour and will consist of different modalities of therapeutic exercise and cryotherapy.
223849999|NCT06698367|OTHER|Unilateral high-intensity strength exercise|Participants will be seated in an armchair with armrests and will perform 4 sets of 8 repetitions of an eccentric exercise for the pronosupinator muscles with a dumbbell with adjustable weights. The training will start with an intensity of 60% of 1RM, until reaching 80% 1RM.
223850000|NCT06698367|OTHER|Unilateral mobility exercises|Participants will be seated in an armchair with armrests and will perform 4 sets of 8 repetitions of an active mobility exercise for the pronation-supination muscles using a plastic rod.
223850001|NCT06697522|DRUG|Atropine Sulfate|low concentration atropine (0.01%)
223850002|NCT06697522|DRUG|Placebo|Blank comparator
223850003|NCT06696651|DEVICE|Electrical myostimulation|Electrical myostimulation in form of suit as in fig. Blue lines demonstrate areas of electrodes inside suit. twenty females will receive EMS session per week ( 20mins / week ) and following healthy diet for 6 weeks . 20 min = 1 min warm up, 6min upper body training, 6min lower body training, 6min core training, 1 min cooling down.
223850004|NCT06696651|DEVICE|Electronic cupping|Twenty females will undergo two weekly myofascial release sessions and a healthy diet for six weeks, using electronic cupping to ensure equal pressure on tender points.
223850005|NCT06696651|OTHER|healthy diet|The MedDiet diet focuses on high fat intake, primarily from extra-virgin olive oil, in vegetable dishes, and a high consumption of low-glycemic index carbohydrates like wholegrain cereals, legumes, nuts, fruits, and vegetables. Moderate to high fish consumption is also encouraged, with moderate to small amounts of poultry and dairy products. Red meat and meat products are limited or avoided.
223850006|NCT06701838|DIAGNOSTIC_TEST|11C-Methionine PET/CT|After a 3-month period of eucortisolaemia, patients will undergo a second MRI of the pituitary gland and 11C-methionine PET/CT scan with SUVmax ratio analysis of the presumed corticotroph pituitary adenoma.
223850007|NCT06703424|OTHER|Sit-cycling|Sit-cycling for 5 mins
223850008|NCT06703424|OTHER|Stand-twisting|Stand-twisting for 5 mins
223850009|NCT06712654|DRUG|AP306 75mg TID|receiving orally AP306 75mg (one tablet), three times a day
223850010|NCT06712654|DRUG|AP306 100mg TID|receiving orally AP306 100 mg (one tablet), three times a day.
223850011|NCT06712654|DRUG|AP306 125mg TID|receiving orally AP306 125 mg (one tablet), three times a day
223850012|NCT06712654|DRUG|AP306 125mg BID|receiving orally AP306 125 mg (one tablet), three times a day, among which one is a placebo tablet
223850013|NCT06712654|DRUG|AP306 150mg BID|receiving orally AP306 150 mg (one tablet), three times a day, among which one is a placebo tablet
223850014|NCT06712654|DRUG|Placebo TID|receiving orally one placebo tablet of AP306, three times a day
223850015|NCT06711679|DRUG|Low-dose ropivacaine|0.5 ml/Kg ropivacaine
223850016|NCT06711679|DRUG|Medium-dose of ropivacaine|1ml/Kg ropivacaine
223850017|NCT06711679|DRUG|High-dose ropivacaine|1.5 ml/Kg ropivacaine
223850018|NCT06707701|OTHER|acupuncture|Whether or not a patient has been treated with acupuncture will be one of the exposure factors of interest in the study
223850019|NCT06711419|PROCEDURE|f caudal neuroplasty using epidural catheter combined with Pulsed Radiofrequency (PRF) versus Pulsed Radiofrequency (PRF) alone|"Fluoroscopic guidance was used in all cases with a C-arm system. The patient was prone with a pillow under the lower abdomen. Anteroposterior (AP) images were taken to identify the target level. The C-arm was angled 15-30° to project the spinous process over the contralateral facet (scotty dog view). Skin was infiltrated with lidocaine, and a 22-gauge RF cannula was advanced under fluoroscopy. The tip was positioned in the dorsal-cranial quadrant of the intervertebral foramen on lateral images. PRF was applied with 4 cycles at 42°C for 8 minutes after sensory/motor testing. Injections of lidocaine and triamcinolone followed. In caudal neuroplasty, an epidural catheter was placed using the sacral hiatus as a guide. Fluoroscopy confirmed catheter position. Contrast was injected to confirm spread, and hyaluronidase and lidocaine were administered. Afterward, the catheter was removed."
223850020|NCT06707675|OTHER|Assessment|The patients' demographic information, weight and height measurements, occupational activities and desk work time, daily screen usage time, pain intensity (with VAS), cervical joint range of motion examination, pain threshold (with pressure algometer), functional status (with Neck Pain Disability Scale), sleep quality (with Pittsburgh Sleep Quality Scale), anxiety and depression symptoms (with Beck Depression Inventory), cognitive aspects of pain (with Pain Catastrophizing Scale) will be evaluated. The patients' chronotype preferences will be evaluated with Morningness Eveningness Questionnaire.
223850021|NCT06711432|DRUG|Norepinephrine or phenylephrine|Intraoperative use of norepinephrine or phenylephrine (norepinephrine 0.01-0.1ug/kg/min, or phenylephrine 0.15-1.1 ug/kg/min). The actual infusion speed depends on reaching the target MAP(\>=80mmHg).
223850022|NCT06711783|BEHAVIORAL|Family based therapy|Family based therapy following the Maudsley model
223850023|NCT06711081|DEVICE|low level laser device cryotherapy|using new device direct on the pulp tissue
223850024|NCT06712381|DRUG|Fluorouracil|Carac (fluorouracil) Cream, 0.5% is used by adults to treat skin conditions on the face and front part of the scalp called solar keratosis or actinic keratosis.
223850025|NCT06712381|PROCEDURE|Photodynamic therapy|Photodynamic therapy (PDT) is a procedure that uses a photosensitizing drug to apply light therapy selectively to target pre-skin cancer, acne and sun damage.
223850026|NCT06712381|PROCEDURE|Carac in combination with PDT|
223850027|NCT03614858|BIOLOGICAL|CART-19/22|Split intravenous infusion of CART-19/22 cells of (Dose escalating infusion of 1 - 20 x10\^6 CART-19/22 cells/kg).
223850028|NCT04219293|DEVICE|Microneedling w/ and w/o PRP|i. Split face comparison. Vertical line drawn midline nose extending upwards to hairline and downwards to jawline separating face into two equal treatment areas. The patients determined side of face will be treated with SkinPen Microneedling and PRP the other (nondetermined from randomization) will be treated with SkinPen Microneedling and glide. The patient side of face that will not use PRP will be treated first. The following settings will be used as treatment protocol. Topical anesthetic Benzocaine 20%, Lidocaine 10%, and Tetracaine 10% will be applied covering entire treatment area. The anesthetic will remain on skin for 30 minutes.
223850029|NCT03049111|BIOLOGICAL|Der f|Inhalation of Der f in mild asthmatics who are sensitive to Der f.
223850030|NCT05475470|PROCEDURE|finger-blade technique|laparoscopic access technique for group a
223850031|NCT05475470|PROCEDURE|Hasson's technique|laparoscopic access technique for group b
223850032|NCT05475470|PROCEDURE|veress needle technique|laparoscopic access technique for group c
223850033|NCT06549894|PROCEDURE|Performing endoscopic examinations|Performing endoscopic examinations in the conventional framework of patient follow-up. No patient data is collected. The physician performing the act is the subject of the study.
223850034|NCT01288638|OTHER|Pulse-based diet|The pulse based-diet will include meals prepared with dry peas, lentils, chickpeas, and beans. Two meals will be supplied daily for 16 weeks to those participants on the pulse-based diet program. Meals will contain approximately 90g dried peas, 225 g chickpeas or beans, or 150g lentils.
223850035|NCT01288638|OTHER|TLC diet|Grocery gift cards will be provided weekly for 16 weeks to those participants in the placebo group. Recipe booklet will be given to follow Therapeutic Lifestyle Changes (TLC) guidelines, recommended by National Cholesterol Education Program (NCEP) and will be based on lean-meats for the protein source. The recipes will exclude pulses.
223850036|NCT03832660|BEHAVIORAL|Lifestyle|A 4-month lifestyle intervention will consist of two integrated components i.e. physical activity and dietary supplementation with inorganic nitrate. The physical activity component aims to increase daily physical activity level by at least 2000 steps/day from baseline (e.g. walking for approximately 30 minutes), at least 5-7 days per week. The second component of the lifestyle intervention is a dietary supplementation with inorganic nitrate. A single dose of inorganic nitrate given in the form of concentrated nitrate-rich beetroot juice (NO3-, BEET IT Sport, James White Drinks Ltd., Ipswich, UK) containing 6 mmol of NO3- in 70 ml bottle.
223850037|NCT03832660|DRUG|Sacubitril/Valsartan|Angiotensin receptor neprilysin inhibitor Sacubitril / Valsartan: The treatment period begins on day 1 with initial dosing of sacubitril/valsartan, followed by uptitration every 2 to 4 weeks to the target dose of 97/103 mg twice daily. 3 doses of sacubitril/valsartan available throughout the study are 24/26 mg, 49/51 mg, and 97/103 mg, each taken by mouth twice daily. If the patient discontinues the study medication, the patient is advised to return to the clinic for an end-of-study visit. Patients undergo treatment for 4 months.
223850038|NCT03151421|BEHAVIORAL|Home air quality monitoring and feedback|Two-hundred smokers (50 in each country) will be recruited and offered low-cost, simple to operate particle counting instruments to measure and log SHS levels in their home for a period of 30 days. During this time near real-time, personalised feedback will be provided to, and discussed with, the smoker along with target-setting and exploration of suitable methods of behaviour-change. Feedback will be given via text message to mobile phones, emails and personal voicecalls. A final visit will gather data on changes made while a proportion of participants (10-20%) in each country will take part in a further qualitative interview by phone to gather data on their experience of the intervention.
223850039|NCT02909751|DRUG|Epirubicin 90 mg/m2 iv|Max. 3 months
223850040|NCT02909751|DRUG|Cyclophosphamide 600 mg/m2 iv|Max. 3 months
223850041|NCT02909751|DRUG|Docetaxel 100 mg/m2 iv OR paclitaxel 80 mg/m2 iv|Max. 3 months
223850042|NCT02909751|DRUG|Trastuzumab 8 mg/kg iv saturation, then 6 mg/kg iv (HER2 positive patients only)|Max. 3 months.
223850043|NCT02909751|DRUG|Pertuzumab 840 mg iv saturation, then 420 mg iv (selected HER2 positive patients only)|Max. 3 months
223850044|NCT02909751|DIETARY_SUPPLEMENT|Tocotrienol 300 mg x 3 daily|Max. 6 months
223850045|NCT01654705|DRUG|Pantoprazole|Pantoprazole 40mg Delayed release tablets (Test Product)
223850046|NCT01654705|DRUG|Pantoprazole|Protonix® Delayed Release 40 mg tablets (Reference product)
223850047|NCT03083522|DRUG|Ojeok-San|Usage: 3g, three times a day, each taken before or between meals Manufacturing company: HANPOONG PHARM \& FOODS Co. Ltd.
223850048|NCT03083522|DRUG|Placebo|Usage: 3g three times a day, each taken before or between meals Manufacturing company: HANPOONG PHARM \& FOODS Co. Ltd.
223850049|NCT02126397|PROCEDURE|polyps resection with Laser Diode|resection of endometrial polyps by hysteroscopy without anesthesia
223850050|NCT02126397|PROCEDURE|polyps resection with bipolar electrode|
223850051|NCT00004886|DRUG|docetaxel|
223850052|NCT00004886|DRUG|dofequidar fumarate|
223850053|NCT00660374|DRUG|insulin NPH|"Soft-treat-to-target dose titration scheme, injection s.c."
223850054|NCT00660374|DRUG|EX1000|"Soft-treat-to-target dose titration scheme, injection s.c."
223850055|NCT03079375|OTHER|basic intervention|medication review
223850056|NCT03079375|OTHER|extended intervention|medication review, medication interview before discharge and follow-up
223850057|NCT00266097|DRUG|erlotinib hydrochloride|Cohort (-1) = 50 mg daily Cohort 1 = 50mg daily Cohort 2= 75 mg daily Cohort 3 = 100mg daily Cohort 4 = 100mg daily Cohort 5 = 150mg daily
223850058|NCT00266097|DRUG|gemcitabine hydrochloride|Gemcitabine will be given at a dose of 100 mg/m2 for the first cohort and escalated to a fixed dose of 200 mg/m2 for the remaining 3 cohorts
223850059|NCT00266097|DRUG|oxaliplatin|Oxaliplatin will be given at 30 mg/m2 weekly for the first two cohorts and then will be dose-escalated to 45 mg/m2 and 60 mg/m2 for the next 2 in cohorts
223850060|NCT00266097|RADIATION|radiation therapy|5040 cGy, every week, up to 6 weeks
223850061|NCT00266097|DRUG|gemcitabine hydrochloride|Given weekly at a starting dose of 100mg/m2 in the first 3 cohorts and dose escalated to 200 mg/m2 for the remaining 2 cohorts
223850062|NCT00266097|DRUG|Oxaliplatin|The Part II dose of oxaliplatin will be determined by Part I of the study. The dose for Part II will be one dose level increase from the MTD determined in Part I.
223850063|NCT00004560|DEVICE|defibrillator|
223850064|NCT03818061|DRUG|Atezolizumab|Patients will receive the combination of Atezolizumab 1200 mg and Bevacizumab 15 mg/kg by IV infusion every 3 weeks.
223850065|NCT03818061|DRUG|Bevacizumab|Patients will receive the combination of Atezolizumab 1200 mg and Bevacizumab 15 mg/kg by IV infusion every 3 weeks.
223850066|NCT02321748|DRUG|Montelukast|
223850067|NCT02321748|DRUG|ASP2151|
223850068|NCT06413940|BEHAVIORAL|Myofunctional Therapy|Oropharyngeal and tongue exercises : strengthening upper airway muscle 20 minutes
223850069|NCT06413940|BEHAVIORAL|Inspiratory Muscle Training|Respiratory muscle strengthening:inspiratory muscle strengthening by resistive loading of 50% maximum inspiratory pressure.
223850070|NCT06413940|BEHAVIORAL|Aerobic Exercise|Exercise intensity :40%-60% HRmax , 3-5 days/week
223850071|NCT05044130|DIETARY_SUPPLEMENT|High-fat mixed-meal tolerance test (HF-MMTT)|The test meal consists of a standardized HF-MMTT (791 cal) with 197 g cream (38 % fat), 18 g sugar and 1 g vanilla sugar for taste (75 g fat, 25 g carbohydrate and 4 g protein)
223850072|NCT04045119|OTHER|Topical Moisturizer|The investigational product is a moisturizing facial cream for skin with imperfections that is applied topically and is manufactured by Avicanna Inc. This preparation contains widely used ingredients from mineral and botanical origin aimed at improving skin hydration and characteristics associated acne-prone skin. The moisturizer also contains 0.1% of hemp oil rich in essential fatty acids and antioxidants and 0.5% of cannabidiol with regulatory effect on the skin.
223850073|NCT00991276|DRUG|pregabalin|capsules; 300 mg once-per-day; 4 weeks of treatment
223850074|NCT00991276|DRUG|placebo|capsules; 0 mg once-per-day; 4 weeks of treatment
223850075|NCT00991276|DRUG|pramipexole|capsules; 0.5 mg once-per-day; 4 weeks of treatment
223850076|NCT04619459|OTHER|Kangaroo Mother Care (KMC)|Kangaroo mother care is a method of care of infants. The method involves infants being carried, usually by the mother, with skin-to-skin contact. Kangaroo mother care (KMC). early after delivery have better success at breastfeeding and achieve this success sooner. In this method The newborns' diapers were tied, their caps put on and then they were positioned on their mother's naked chest for KMC. The KMC session was continued for 3 hours.
223850077|NCT01268891|DRUG|Placebo|Once daily; tablet; orally; 18 weeks
223850078|NCT01268891|DRUG|Azilect®|1 mg daily; tablet; orally; 18 weeks
223850079|NCT02553382|DIETARY_SUPPLEMENT|Dietary, Herbal|Viscous fibre blend and Salba and American and Korean Red Ginseng capsules
223850080|NCT02553382|DIETARY_SUPPLEMENT|Positive Control|Oat bran blend and wheat bran capsules
223850081|NCT03962192|OTHER|Attitudinal measures|A collection of 3 distinct attitudinal instruments comprise this survey.
223850082|NCT03380975|DRUG|Montelukast 10mg|Montelukast is an orally active compound which binds with high affinity and selectivity to the CysLT1 receptor. Montelukast inhibits physiologic actions of LTD4 at the CysLT1 receptor without any agonist activity. As a result, bronchoconstriction is inhibited with decreased airway and blood eosinophil's leading to improved control over asthma and allergic rhinitis. Montelukast should be taken once daily in the evening
223850083|NCT04209881|OTHER|ovarian reserve for Ankylosing spondylitis and control groups|"Additional organ diseases due to the pathophysiology of the disease may be seen in women with ankylosing spondylitis. therefore, we established the first group of women with the diagnosis of ankylosing spondylitis.~Women Who Are Diagnosed With Ankylosing Spondylitis Will Form The Study Group. and health women will be control group.~Clinical And Laboratory Parameters Will Be Evaluated For Ovarian Capacity Of These Women.~Amh Will Be Looked For (Pmol / L). Antral Folukul Census In The Overin Folukular Stage Will Be Valued As Number. Fsh (Iu / L) And Estradiol (Pmol / L) Values Will Also Be Recorded."
223850084|NCT04311203|BEHAVIORAL|Mental Health First Aid|The intervention has 3 parts:1.Two-day MHFA training provided by MHFA England. A manualised programme designed to provide individuals with: an in-depth understanding of mental health and the factors that can affect wellbeing, practical skills to spot triggers and signs of mental health issues, confidence to step in, reassure and support a person in distress, enhanced interpersonal skills such as non-judgemental listening, knowledge to help someone recover their health by guiding them to further support - whether that's self-help resources, through their employer, the NHS, or a mix. 2.Raising awareness of the presence of MHFA in the organisation. 3.The application of MHFA to participants in the workplace using the manualised five-stage approach, ALGEE: Approach the person, assess and assist with any crisis; Listen and communicate non-judgementally; Give support and information; Encourage the person to get appropriate professional help and Encourage them to seek other forms of support.
223850085|NCT03353272|BEHAVIORAL|Patient Engagement Education and Restructuring of Cognitions|This protocol, informed by principles of CBT, involves three components: 1) engagement, 2) education and 3) cognitive restructuring and behavioral activation. A health coach who is responsible for engaging patients, educating them about pain modulatory mechanisms, and reinforcing cognitive and behavioral coping skills, will deliver the PEERC protocol.
223850086|NCT01552018|DRUG|Saxagliptin|Saxagliptin 5 mg, 1 tablet per day for 3 months
223850087|NCT01552018|DRUG|Placebo|Placebo, 1 tablet per day for 3 months.
223850088|NCT04672473|BIOLOGICAL|DC-CTL|DAC combined with Ag-CTL
223850089|NCT06417489|DRUG|Combination therapy|Henagliflozin Proline 10 mg qd+Regagliptin 100 mg qd+Metformin 500mg bid. The dose of metformin from the first to second week is 500mg bid, and the dose from the third to fourth week is 1000mg bid. If the maximum dose of metformin cannot be tolerated, the researcher shall increase the dosage according to the patient\&#39;s tolerance situation. The minimum dose is 1000mg/day.
223850090|NCT06417489|DRUG|Sequential treatment group|Metformin, the dose from the first to second week is 500mg bid, and the dose from the third to fourth week is 1000mg bid. If the maximum dose of metformin cannot be tolerated, the researcher shall increase the dosage according to the patient\&#39;s tolerance situation. The minimum dose is 1000mg/day. After the fourth week of treatment, blood glucose levels were measured. For those whose blood glucose levels did not meet the standard (fasting blood glucose (FPG)\&gt;7mmol/L, postprandial blood glucose (PPG)\&gt;10mmol/L), 10 mg qd of Henagliflozin Prolinewas sequentially added. If the blood glucose levels did not meet the standard after 4 weeks of treatment (FPG\&gt;7mmol/L, PPG\&gt;10mmol/L), 100 mg qd of Ruigeliflozin was added
223850091|NCT01976754|DRUG|Dexmedetomidine|Septic patients are randomly received 1 of 6 doses( 0.2,0.3,0.4,0.5,0.6,0.7μg/kg/h) dexmedetomidine.
223850092|NCT06548334|COMBINATION_PRODUCT|Advanced Physiotherapy|The physiotherapist used the regression techniques for 1 hour of session 2 times for 8 weeks. The caudal component involved the spinous process of the treated segment touching the therapist's hand and not applying force as though mobilising the segment at grade 2. These were applied if there is a suspected case of a posterolateral disc prolapse where the aim is to increase the diameter of the foramen and decrease the tension exerted on the nerve root. Applied posteroanterior was used to distract the anterior intervertebral end plate and to approximate the posterior end plates so as to pull back the protruded nuclear material by creating a negative pressure.
223850093|NCT06548334|OTHER|Conventional Physiotherapy Techniques|In traditional physiotherapy, the patient underwent two sessions per week for eight weeks. Each session lasted one hour and included 20minutes of TENS treatment. The flexibility exercises consisted of hamstring stretches and single and double knee-to-chest stretches. The strengthening exercises were partial sit-ups, quadruped lifts, and double leg hold; pelvic tilts were performed with 10-15 repetitions, each held for 20-30 seconds and repeated three times.
223850094|NCT01268345|DEVICE|blood glucose monitor|Blood glucose monitor is used to monitor the blood glucose level of the human-being
223850095|NCT01268345|DEVICE|blood glucose monitor|Blood glucose monitor is used to monitor the blood glucose level of the human-being.
223850096|NCT00664846|DRUG|Aspirin / Clopidogrel, Atorvastatin / Simvastatin|Standard Medical Management,including antiplatelet agents(Aspirin 75\~150mg/day or Clopidogrel 75mg/day),statins(Atorvastatin 20mg/day or Simvastatin 20mg/day),risk factor lowering agents (antihypertension agents:Amlodipine 5mg/day or Benazepril 10mg/day or Valsartan 80mg/day or Nifedipine 30mg/day or Indapamide 2.5mg/day,antidiabetic agents: Metformin 0.5 tid or Glipizide 5mg tid or Acarbose 50mg tid )if necessary,interactive education program (Online medical education program, health behavior guide) .
223850097|NCT00664846|DRUG|Asprin / Clopidogrel, Atorvastatin / Simvastatin|Antiplatelet agents(Aspirin 75\~150mg/day or Clopidogrel 75mg/day),statins(Atorvastatin 20mg/day or Simvastatin 20mg/day),risk factor lowering agents (antihypertension agents:Amlodipine 5mg/day or Benazepril 10mg/day or Valsartan 80mg/day or Nifedipine 30mg/day or Indapamide 2.5mg/day,antidiabetic agents: Metformin 0.5 tid or Glipizide 5mg tid or Acarbose 50mg tid )if necessary
223850098|NCT01301664|OTHER|total knee / hip replacement|Human cartilage tissues were harvested from osteoarthritic patient during total knee arthroplasty surgery.
223850099|NCT04069182|BEHAVIORAL|Behavioral Activation Therapy|Behavioral Activation Therapy (BAT) has its origins in Cognitive Behavioral Therapy. In BAT, the patient monitors his emotions and daily activities, as a behavioral element. It seeks to increase the number of pleasant activities and increase interactions with the environment. The BAT considers positive reinforcement as the main intervention strategy. The treatment focuses on helping patients to systematically increase contact with their life's reward sources and solve their problems through procedures that focus on activation and on processes that inhibit it such as escape, avoidance behaviors and ruminant thoughts. It is a brief treatment consisting of 10 to 12 sessions spaced weekly (one hour per session), the first sessions are an explanation of the treatment and depression. Subsequent sessions are based on a collaborative work where the therapist and the patient work together to find activities that are according to the needs of the patient.
223850100|NCT06375824|DRUG|Bufei Recipe|Bufei Recipe: Roasted Astragalus, Codonopsis pilosula, Walnut kernels, Sichuan Fritillaria, Angelica sinensis, Stir fried Purple Su Zi, Honey Baibu, Roasted Purple Aster, etc. Take 1 dose daily, 5 days a week.
223850101|NCT06375824|DRUG|Bufei Recipe placebo|The placebo was prepared using 5% of the drug, with color, odor, taste, appearance, and weight similar to the experimental group drug, and packaging consistent with the experimental group drug.
223850102|NCT02215044|DRUG|BI 2536, intravenous|
223850103|NCT02215044|DRUG|Gemcitabine, intravenous|
223850104|NCT03377855|OTHER|Default Prescribing Change|In the e-prescribing system, the default opioid dosage/duration is changed to the minimum recommended dosage from the CDC guidelines for short acting opioids.
223850105|NCT04658849|DRUG|Pioglitazone 30 Mg Oral Tablet|"Subjects will self-administer a 30 mg pioglitazone oral tablet daily for 6 months.~For patient taking a diabetic regimen of gemfibrozil, the dose will be 15 mg daily."
223850106|NCT04658849|DRUG|Pioglitazone placebo tablet|Subjects will self-administer an oral placebo tablet containing cellulose daily for 6 months.
223850107|NCT04622826|BIOLOGICAL|immune plasma|immune covid 19 plasma infusion
223850108|NCT04409210|BEHAVIORAL|Establishment of individual health records|Patients could upload self-test data (such as blood pressure, blood glucose, heart rate and weight) and medical institution examination data (such as blood lipids, ECG, echocardiography, etc.) through App. AND then the App can automatically generate health reports to reflect the dynamic changes of the data in the form of charts and whether the data is normal or not. It is convenient for patients to have a clear understanding of their health management, and if there are outliers, they can intervene in time.
223850109|NCT04409210|BEHAVIORAL|Cardiovascular risk assessment|The China-PAR risk prediction tool can be used to stratify the 10-years atherosclerotic cardiovascular disease (ASCVD) risk. Those with predicted risks of \<5%, 5-10%, and ≥10% could be classified into categories of low-, moderate-, and high-risk for ASCVD, respectively. It is a risk prediction tool for Chinese developed by the team of Professor Gu Dongfeng of Fuwai Hospital of the Chinese Academy of Medical Sciences. When patients are aware of their risk of cardio-cerebrovascular diseases, it is helpful for patients to take the initiative to manage their cardio-cerebrovascular health.
223850110|NCT04409210|BEHAVIORAL|Popularization of medical knowledge|Health education is divided into nine modules, such as introduction of cardio-cerebrovascular diseases, diet, exercise, sleep, psychology, medicine, cardiopulmonary resuscitation and cardiac self-rescue technology. The presentation of health education includes three modules: text, video and voice. Video and voice modules are more suitable for illiterates or people are inconvenient to read text. It mainly takes into account the fact that most of the high-risk population of cardio-cerebrovascular diseases are the elderly.
223850111|NCT04409210|BEHAVIORAL|Personalized Reminders|"1. Abnormal data reminder App can automatically judge whether the data is normal. If abnormal data is found, it will inform the patient in red font and remind the patient to consult the doctor in time. Patients can consult their family doctors directly online through App or go to the hospital.~2. Medication reminder After patients upload their own medication information, the App will automatically generate a medication alarm clock to remind patients to take the drugs.~3. Follow-up reminder According to the clinical diagnosis and conditions of patients, make personalized follow-up time. Family physicians could use the App to remind patients to fill in the follow-up form or go to the hospital."
223850112|NCT04409210|DRUG|Routine treatment|Family physicians conduct the corresponding treatment and management according to the diagnosis and conditions of the patients.
223850113|NCT00000871|BIOLOGICAL|MN rgp120/HIV-1 and GNE8 rgp120/HIV-1|
223850114|NCT00000871|BIOLOGICAL|MN rgp120/HIV-1 and A244 rgp120/HIV-1|
223850115|NCT00000871|BIOLOGICAL|ALVAC-HIV MN120TMG (vCP205)|
223850116|NCT00000871|BIOLOGICAL|rgp120/HIV-1 SF-2|
223850117|NCT04371536|DRUG|Ferrous Sulfate|Patients receive ferrous sulfate 3 mg/kg elemental iron once daily in liquid formulation.
223850118|NCT04371536|BEHAVIORAL|IRONCHILD|"Delivery of the intervention at each visit should take 15 minutes or less.~* Baseline visit (Session 1) content will be viewed~* At 1-month follow-up visit, additional (Session 2) content will be viewed~* At 3-month final visit, patients will view final (Session 3) content"
223850119|NCT01360190|DRUG|fluoxetine|fluoxetine 20 mg. daily
223850120|NCT03688828|DRUG|Saccharomyces boulardii|500mg bid
223850121|NCT03688828|DRUG|Esomeprazole|20mg bid
223850122|NCT03688828|DRUG|Amoxicillin|1.0g bid
223850123|NCT03688828|DRUG|Clarithromycin|0.5g bid
223850124|NCT03688828|DRUG|Bismuth potassium citrate|0.22g bid
223850125|NCT01769781|DRUG|anastrazole|combined treatment with aromatase inhibitor (anastrazole) plus GnRH analog (leuprolide acetate) for three months
223850126|NCT01769781|DRUG|GnRH analog alone|treatment for three months with GnRH analog (leuprolide acetate) alone
223850127|NCT04122807|PROCEDURE|Cardiac catheter ablation|Cryoablation
223850128|NCT03474562|DRUG|Duowell®|Telmisartan/Rosuvastatin 40/20mg (increased to Telmisartan 80mg if SBP \> 140mmHg or DBP \> 90mmHg at week 12)
223850129|NCT03474562|DRUG|Monorova® + Amlopin®|Rosuvastatin 20mg + Amlodipine 5mg (increased to Amlodipine 10mg if SBP \> 140mmHg or DBP \> 90mmHg at week 12)
223850130|NCT06080373|BEHAVIORAL|PROBECO|"Spanish participants in the active control group will undergo the PROBECO program, designed by the Spanish Penitentiary Agency for various violent crimes. It aims to eradicate criminal behavior, reduce recidivism, and teach social skills. It has four phases.~German participants will be placed in social therapeutic facilities for compulsory psychotherapy focused on relapse prevention."
223850131|NCT06080373|BEHAVIORAL|Formulation-based cognitive behavioral therapy|"The CBT program includes these core modules:~A. ADHD Psychoeducation: Provides information on ADHD characteristics, neurobiology, treatments, and their efficacy. Shared with a significant other if available.~B. Planning Skills and Distraction Management: Teaches time management, task prioritization, and distraction control techniques.~C. Cognitive Restructuring: Based on Ellis' Rational Behavioral Emotive Therapy, it helps participants identify and modify irrational thoughts for better emotional regulation.~D. Maintenance of Treatment Gains: Reviews progress, identifies risk factors, and develops action plans for post-treatment challenges."
223850132|NCT05560828|OTHER|Zio XT service|There will be no intervention. Standard of care at participating NHS organizations will not be affected.
223850133|NCT05836935|RADIATION|Multislice CT scan of the paranasal sinuses.|MSCT scan using GE Revolution Evo 128 multidetector elements scanner (GE Healthcare, Chicago, Illinois, United state) , Toshiba Alexion 16 detector elements scanner (Aplio 500, Toshiba Medical Systems, Otawara-shi, Tochigi 324-8550, Japan). Or Canon Aquilion Prime SP 160 -multidetector- row CT scanner (Canon Medical Systems, Tochigi, Japan) Thin slice Axial scans will be taken at 0.625-1.0 mm slice thickness, commencing from the hard palate till above the end of frontal sinuses, coronal and sagittal multiplanar reconstruction images will be obtained.
223850134|NCT05836935|RADIATION|MRI examination of the paranasal sinuses|MRI imaging using Philips Achieva 1.5T MRI device (Philips Achieva, Netherlands) or Siemens Magnetom Altea 1.5T MRI device (Siemens Healthineers, Germany) for suspected intracranial and orbital complications.
223850135|NCT05701462|DIAGNOSTIC_TEST|biopsy under sonographic gidance|pleural biopsy under sonographic guidance
223850136|NCT03155490|BEHAVIORAL|Leadership training|Subjects randomized to the experimental arm of the study will receive an additional 4 hours of simulation-based trauma team leadership training. This training is in addition to the baseline 2 hours of trauma leader training and orientation all subjects receive.
223850137|NCT04923139|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Dosage at the discretion of the treating physician
223850138|NCT00017004|RADIATION|External Beam Radiation Therapy|Undergo radiation
223850139|NCT00017004|DRUG|Cisplatin|Given IV
223850140|NCT00017004|RADIATION|Internal Radiation Therapy|Undergo radiation
223850141|NCT00017004|BIOLOGICAL|Epoetin Alfa|Given SC
223850142|NCT04542369|DRUG|Tislelizumab (BGB-A317) Plus Chemotherapy (Cisplatin/Carboplatin and Etoposide)|Inductive/neoadjuvant therapy: Tislelizumab + EP Maintenance/adjuvant therapy: Tislelizumab + EP
223850143|NCT00323752|PROCEDURE|rHuEpo|Subjects will be randomly assigned to either participate in the PAD program or receive the rHuEpo treatment. Subjects in the PAD group will donate 1 unit of blood at -14 and -7 days prior to surgery. A dose of 500 IU of rHuEpo will be administered subcutaneously to subjects in the rHuEpo group at -21, -14, and -7 days prior to surgery.
223850144|NCT00711646|DRUG|Sativex®|containing THC (27 mg/ml):CBD (25 mg/ml), in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring. Maximum permitted dose was eight actuations in any three hour period and 24 actuations (THC 65 mg: CBD 60 mg) in 24 hours
223850145|NCT00711646|DRUG|Placebo|containing peppermint oil, 0.05% (v/v), quinoline yellow, 0.005% (w/v), sunset yellow, 0.0025% (w/v), in ethanol:propylene glycol (50:50) excipient.
223850146|NCT01760291|DEVICE|WATCHMAN LAA Closure Technology|
223850147|NCT01802229|PROCEDURE|Prophylactic mesh placement|Placement of a Omega 3 mesh, fixed to the border of the fascia
223850148|NCT01802229|PROCEDURE|Fascial suture|The port-site hole is closed with simple suture of the fascia
223850149|NCT00186420|DRUG|Taxotere|
223850150|NCT04820582|OTHER|Delphi Questionnaire|Evaluation of a list of PROMs and CROMs specific for endometriosis (previously selected from a litterature review) on a Likert scale of 1 to 9 for their relevance and feasibility
223850151|NCT02321306|DRUG|LUM001|LUM001 administered orally once each day.
223850152|NCT00677248|DRUG|Ezetimibe and placebo|Placebo or three different doses of eprotirome added to ezetimibe treatment
223850153|NCT00677248|DRUG|Eprotirome and ezetimibe|Placebo or three different doses of eprotirome added to ezetimibe treatment
223850154|NCT02454205|DRUG|Linezolid|600mg Linezolid po daily, reduced to 300mg po daily if toxicity occurs.
223850155|NCT02454205|DRUG|Bedaquiline|400mg po daily for 2 weeks, followed by 200mg three times per week .
223850156|NCT02454205|DRUG|Levofloxacin|750mg (\<50kg) 1000mg (\>50kg)
223850157|NCT02454205|DRUG|Pyrazinamide|1000-1750mg (40-50kg) 1750-2000mg (51-70kg) 2000-2500mg (71-90kg)
223850158|NCT02454205|DRUG|Isoniazid|high dose Isoniazid 500mg (40-50kg) 750mg (51-70kg) 750-1000mg (71-90kg)
223850159|NCT02454205|DRUG|Ethionamide|15mg/kg (max 900mg)
223850160|NCT02454205|DRUG|Terizidone|750mg (40-70kg) 750-1000mg (71-90kg)
223850161|NCT02454205|DRUG|Moxifloxacin|400mg po daily.
223850162|NCT02454205|DRUG|Kanamycin|500-750mg (40-50kg) 1000mg (51-90kg) intramuscular daily during 6-8 month intensive phase.
223850163|NCT03721016|DRUG|MT10109L|MT10109Lwill be injected into either the Glabellar Lines (GL), Lateral Canthal Lines (LCL), or both.
223850164|NCT03721016|DRUG|Placebo|Placebo will be injected into either the Glabellar Lines (GL), Lateral Canthal Lines (LCL), or both.
223850165|NCT05585567|BIOLOGICAL|V-01/V-01-B5|Contains 10μg of V-01 and 10μg of V-01-B5
223850166|NCT05585567|BIOLOGICAL|V-01-351/V-01-B5|Contains 10μg of V-01-351 and 10μg of V-01-B5
223850167|NCT05585567|BIOLOGICAL|V-01|Contains 10μg of V-01
223850168|NCT03794804|DEVICE|ColdZyme|"ColdZyme® Mouth Spray, a CE -marked device with the following composition of the spray solution: glycerol, purified water, cod trypsin, ethanol (\<1 %), calcium chloride, trometamol and menthol.~ColdZyme is a non-sterile mouth spray packaged in a primary container consisting of a 20 ml semi-transparent plastic bottle, pump, actuator (spray nozzle) and an actuator terminal cap."
223850169|NCT03794804|DEVICE|ColdZyme Placebo|The placebo mouth spray solution has the following composition: ethanol (\<1 %), menthol and water. The placebo mouth spray is packaged in a primary container consisting of a 20 ml semitransparent plastic bottle, pump, actuator (spray nozzle) and an actuator terminal cap.
223850170|NCT03076736|BEHAVIORAL|Singing group + resource pack|SPA is a community-based, 10 weekly singing group. Each SPA session comprises 30 minutes of settling in/wrap-up and departure, and 60 minutes of group singing. Sessions will be led by a community music leader, co-facilitated by a person with aphasia, and involve the group singing from a songbook. Musical accompaniment will be provided by the facilitator(s). Small percussion instruments will be available for participants, enabling involvement of those with limited singing ability. Intervention content integrates the Information-Motivation-Behavioural (IMB) skills model of health behaviour change to support individuals in developing the social skills and confidence needed to improve psychosocial outcomes. Participants will also receive the resource pack.
223850171|NCT03076736|BEHAVIORAL|Resource pack|Resource pack with information on living with aphasia and local community activities.
223850172|NCT00365027|PROCEDURE|Delayed embryo transfer|
223850173|NCT02488317|OTHER|Decision Aid|Decision-making outcomes (e.g., self-efficacy) will be compared between patients who received and did not receive a decision aid. These arms were chosen because the current standard of care is for health care providers to discuss options with patients without using a decision aid.
223850174|NCT02762318|OTHER|Samples With DNA|"After consenting, all subjects have to undergo the following procedures:~Up to 25 ml of blood will be withdrawn. If for any reason, the blood sample cannot be obtained, a swab will be applied to the inside of the cheek to obtain saliva.~A questionnaire will be used to collect information about individual A routine physical exam will be performed. The subject's medical record will be reviewed To well document some of the specific phenotypes and conditions, physicians might take photographs of the affected body area.~For secondary subjects (relatives or family members), normal examination and routine lab tests/ imagining will be done if needed as per the related standard care."
223850175|NCT03155152|OTHER|DECT|The DECT program consists of a 4-week training intervention with three weekly sessions of high-intensity interval training, in which during each exercise bout the workload is imposed in a decremental fashion.
223850176|NCT03155152|OTHER|HIIT|The HIIT program consists of a 4-week training intervention with three weekly sessions of high-intensity interval training, in which during each exercise bout the workload is kept constant.
223850177|NCT03640273|DRUG|Prapchompoothaweep remedy|Take Prapchompoothaweep remedy capsule at 1,000 mg for 3 times a day before meals.
223850178|NCT03640273|DRUG|Loratadine 10 Mg|Take Loratadine 10 mg once a day before meals.
223850179|NCT00968240|DRUG|Super-Selective Intraarterial Intracranial Infusion of BEVACIZUMAB|"This phase I clinical research trial will test the hypothesis that Bevacizumab can be safely used by direct intracranial superselective intraarterial infusion up to a dose of 10mg/kg to ultimately enhance survival of patients with relapsed/refractory GBM/AA.~Day 0: Intraarterial Avastin single dose (starting at 2mg/kg and up to 10mg/kg) after Mannitol to open the blood brain barrier."
223850180|NCT02232178|DRUG|2 100mg Xaracoll implants|
223850181|NCT02232178|DRUG|3 100mg Xaracoll implants|
223850182|NCT02232178|DRUG|150mg Bupivacaine HCl injection|
223850183|NCT05097469|DEVICE|Carbon dioxide laser|3 consecutive sessions of carbon dioxide laser treatment
223850184|NCT05097469|DEVICE|Sham laser treatment|3 consecutive sessions of sham laser treatment
223850185|NCT01817036|DIETARY_SUPPLEMENT|Placebo|placebo
223850186|NCT01817036|DIETARY_SUPPLEMENT|Vitamin D|400 IU vitamin D per pill
223850187|NCT02184325|DRUG|Kiddi® Pharmaton Fizz, effervescent tablets|
223850188|NCT02184325|DRUG|Kiddi® Pharmaton Fizz, effervescent tablets: marketed formula|
223850189|NCT02184325|DRUG|Comparator product|active substances: Vitamin A, Vitamin B1, Vitamin B2, Vitamin B5, Vitamin B6, Vitamin B12, Vitamin C, Vitamin D, Vitamin E, Manganese, Copper, Calcium, Magnesium, Phosphorous, Iron, Zinc, Sodium, Molybden
223850190|NCT05001919|PROCEDURE|GTR|intrabony defects treated by surgery and bone graft +collagen membrane
223850191|NCT05001919|PROCEDURE|concentrated growth factor|intrabony defects treated by surgery and bone graft +concenrated growth factor membrane
223850192|NCT02454543|PROCEDURE|Radical prostatectomy|Study participants randomized in the intervention arm receive best systemic therapy in addition to radical prostatectomy with extended lymphadenectomy. It is not crucial whether the radical prostatectomy is performed open or robot-assisted.
223850193|NCT02454543|DRUG|Best systemic therapy|"For the antiandrogenic therapy a non-steroidal antiandrogen (e.g. flutamide, bicalutamide) or a gonadotropin-releasing hormone (GnRH) analogues (e.g. goserelin, leuprolide) are available.~The selection of best systemic therapy is up to the judgment of the treating urologist."
223850194|NCT00913913|BIOLOGICAL|DC vaccine|DC Vaccine therapy 10E7 intranodally every cycle
223850195|NCT00913913|DRUG|Bevacizumab|Bevacizumab 10mg/kg iv every 2 weeks
223850196|NCT00913913|BIOLOGICAL|IL-2|IL-2 18 MiU/m2 CI 5 days
223850197|NCT00913913|BIOLOGICAL|IFN|IFN 6 MiU subc TIW
223850198|NCT05739474|BIOLOGICAL|Influenza vaccine [inactivated]|solution for intramuscular injection, 1 dose (0.5 mL)
223850199|NCT05739474|BIOLOGICAL|Influenza vaccine [inactivated]|suspension for intramuscular and subcutaneous injection, 1 dose (0.5 mL)
223850200|NCT02753413|BIOLOGICAL|RSV vaccine GSK3003891A|Single dose administered intramuscularly at Day 0 in the deltoid region of the non-dominant arm.
223850201|NCT02753413|BIOLOGICAL|Boostrix|Single dose administered intramuscularly at Day 0 in the deltoid region of the non-dominant arm.
223850202|NCT06116162|DEVICE|SVF-gel Filling and CO2 fractional laser|"SVF-gel preparation and filling:The autologous fat graft was harvested from the lower abdomen or inner thigh of all subjects. Then the lipoaspirate was centrifuged at 1200g for 3 minutes to obtain Coleman fat in the middle layer. The Coleman fat was then transferred between two syringes until the Coleman fat converted into a uniform emulsion, and then processed by centrifugation at 2000g for 3 min. Finally, the remaining substance under the oil layer was SVF gel. We used a 22G sharp-tip injector to inject the SVF-gel into the dermis of acne scars, and the injected materials were diffusely distributed.~CO2 fractional laser treatment: After local anesthesia, Acupulse device (LUMENIS, US) was used to perform CO2 fractional laser. The laser was operated in DeepFX mode under the parameters of 20-25 MJ energy intensity, 5% coverage. Superficial mode under the parameters of 80-120 MJ energy intensity, 40-60% coverage."
223850203|NCT05652530|DRUG|Chimeric Antigen Receptor NK Cell Injection Targeting BCMA (BCMA CAR-NK)|This product is allogeneic NK cells which are cryopreserved after in vitro CAR genetic modification and scale-up manufacturing. Subjects are enrolled and treated with lymphocyte clearance chemotherapy (including pre-clearance evaluation), pre-infusion evaluation and BCMA CAR-NK cells infusion.
223850204|NCT05612659|PROCEDURE|Transcranial Electrical stimulation|Noninvasive electrical stimulation of lateral frontal cortex.
223850205|NCT05612659|PROCEDURE|Transcutaneous direct current stimulation|Noninvasive electrical stimulation of the T10 spinal column.
223850206|NCT02853474|BEHAVIORAL|Early Palliative Care visit|"A PC visit is a visit done by a PC physician. Any kind of visits done by other professionals IS NOT a PC visit.~Five PC visits are scheduled in this arm."
223850207|NCT02853474|OTHER|EORTC-QLQ-C30 questionnaire|The Quality of Life is assessed with the QLQ-C30 questionnaire at baseline, 12 and 24 weeks after inclusion, as well as every 8 weeks thereafter.
223850208|NCT02853474|OTHER|HADS score|The depression is assessed with the HADS scale (Hospital Anxiety and Depression Scale) at baseline, and then 12 and 24 weeks after inclusion.
223850209|NCT01020838|DRUG|Florbetaben (BAY94-9172)|Single intravenous injection 1-5ml, 300 MBq (+/- 20%)
223850210|NCT02470936|BEHAVIORAL|Lifestyle intervention|Patients will have access to the lifestyle website and an activity monitor (e.g., Fitbit), receive texts, and be provided with individualized lifestyle recommendations.
223850211|NCT02749045|RADIATION|SPECT imaging|myocardial perfusion imaging
223850212|NCT04340284|BIOLOGICAL|autologous adipose tissue derived stromal vascular fraction (SVF)|"liquid and solid portion of lipo-aspirate after non enzymatic processing yields SVF.~This isolation process yielded an abundant population of Adipose stromal cells(ASCs) which have multipotent differentiation potential. Immunophenotype is a CD14-, CD29+, CD31-, CD34low/+, CD45-, CD73+ and CD105+ ,~, the SVF represents the 50-70% in volume of a lipoaspirate specimen. The SVF hosts a heterogeneous cell population (110x103 cells/ml on average) comprising mainly CD105+ mesenchymal stem cells (MSC, 20%), plus a wide number of CD34+ hematopoietic cells (40%)."
223850213|NCT04484402|BIOLOGICAL|mesenchymal stem cells|Autologous adipose-derived mesenchymal stem cells mixed with sodium hyaluronate 1% solution
223850214|NCT04484402|BIOLOGICAL|limbal stem cells|Autologous adipose-derived limbal stem cells mixed with sodium hyaluronate 1% solution
223850215|NCT04484402|OTHER|standard treatment|Standard treatment according to the Clinical protocols
223850216|NCT01167426|DRUG|Glatiramer Acetate 20 mg/0.5 mL|20 mg/1.0 mL formulation of glatiramer acetate utilizing the autoject 2 for glass syringe.
223850217|NCT01167426|DRUG|Glatiramer acetate 20 mg/0.5 mL|20 mg/0.5 mL formulation of glatiramer acetate utilizing the autoject 2 20 mg/0.5 mL device.
223850218|NCT05086809|DEVICE|Device A|Participant wear Device A and evaluate the performance of the device.
223850219|NCT05086809|DEVICE|Device B|Participant wear Device B and evaluate the performance of the device.
223850220|NCT06554171|OTHER|Hippotherapy group|In addition to conventional physiotherapy, training will be given in the Hippotherapy Simulator for 15 minutes a day, 5 days a week for 4 weeks. The hippotherapy simulator serves a wide range of purposes from recreational use that mimics the movements of a real horse or can make similar movements, to fitness, exercise, sports, education and therapy and is suitable for use by individuals with cerebral palsy.
223850221|NCT06554171|OTHER|Control group|In addition to conventional physiotherapy, the control group will be allowed to sit in the Hippotherapy Simulature for 15 minutes a day, 5 days a week for 4 weeks. However, the simulator will be kept in closed position to prevent oscillations.
223850222|NCT01930019|DRUG|Intravenous administration of the induction agent of general anesthesia (etomidate or thiopental)|
223850223|NCT00518362|DRUG|TW|TW,120 mg/d
223850224|NCT06348186|OTHER|Guidebook|Folder that will be given to the participant to carry out 5 minutes of intervention daily
223850225|NCT06348186|OTHER|Guidebook and Myofascial Reorganization® (RMF).|The intervention will be carried out once a week for 30 minutes for 6 weeks. It will include passive, active-assisted moments (with and without load). In addition to a folder that will be given to the participant to carry out 5 minutes of intervention daily.
223850226|NCT02993471|DRUG|Drug Cocktail|Administered orally
223850227|NCT02993471|DRUG|Ixekizumab|Administered SC
223850228|NCT01363362|PROCEDURE|Selective Laser Trabeculoplasty|360° selective laser trabeculoplasty, 100 non-overlapping spots, energy 0,5-1,2 mJ
223850229|NCT02616861|DRUG|IW-1973|IW-1973 Tablet
223850230|NCT02616861|DRUG|Matching Placebo Tablet|Matching placebo tablet
223850231|NCT03426696|BEHAVIORAL|psychological condition|Graves ́ ophthalmopathy quality of life questionnaire, Symptom checklist 90(SLC-90), Hamilton anxiety scale(HAMA), Somatic self-rating scale(SSS), MATRICS Consensus Cognitive Battery (MCCB), Hamilton depression scale(HAMD)
223850232|NCT01908634|DIETARY_SUPPLEMENT|Milk-based Strawberry Beverage without meal|
223850233|NCT01908634|DIETARY_SUPPLEMENT|Water-Based Strawberry Beverage without meal|
223850234|NCT01908634|DIETARY_SUPPLEMENT|Milk-based strawberry Beverage with meal|
223850235|NCT01908634|DIETARY_SUPPLEMENT|Water-Based strawberry Beverage with meal|
223850236|NCT00722215|DRUG|BQ-123 (selective endothelin A receptor antagonist)|Single dose of BQ-123 given at a dose of 1000 nmol/min for 15 min intravenously.
223850237|NCT00722215|DRUG|0.9 % saline|Single 15ml 0.9% saline infused for 15 mins as placebo control
223850238|NCT00722215|DRUG|Nifedipine|Single dose of nifedipine 10 mg given orally as active control
223850239|NCT01524536|DRUG|prednisone|Glucocorticoids (GC) are considered the first- line therapy for hypereosinophilic syndrome.
223850240|NCT04176458|DEVICE|Methacetin Breath Test (MBT)|The hypothesis is that MBT CPDR 20 in the Fontan patient is abnormal as a result of alterations in liver perfusion, liver cell metabolic capability and transhepatic resistance secondary to hemodynamics unique to the Fontan as well as end-organ liver damage. Due to lack of robust biomarkers or other risk stratification schemes, we aim to determine whether there is prognostic value in hepatic MBT CPDR 20 in the Fontan patient.
223850241|NCT00853424|PROCEDURE|islet cell transplant|Human pancreases are retrieved from multiorgan donors and processed with intraductal collagenase perfusion, continuous digestion, and density gradient purification with impure tissue fractions cultured in vitro and then repurified to retrieve additional islets. Islets are implanted by ultrasound guided percutaneous portal embolization, to provide more than 12, 000 islet equivalents (IE) per kilogram of body weight (infusions from 1-3 donors per patient) Immunosuppression consists of antithymocyte globulin, basiliximab, mycophenolate mofetil and tacrolimus as described (Warnock et al Arch Surg 2005;140:735).
223850242|NCT00853424|OTHER|Medical therapy|subjects receive all recommended medical treatment for diabetes and diabetic eye disease
223850243|NCT04744779|BEHAVIORAL|Office-based accommodative/vergence therapy and home reinforcement|Office-based accommodative/vergence therapy (60 minutes per visit, one time per week, 16 weeks) and home reinforcement (15 minutes each time, five times per week, 16 weeks)
223850244|NCT05001828|DRUG|ADI-PEG 20|ADI-PEG 20 in combination with venetoclax and azacitidine
223850245|NCT04531488|PROCEDURE|Powered Mobility Training Simulator|Two groups of participants- 18 in each- were provided with either a simulator or powered wheelchair. Both groups were tested at baseline for powered mobility level. Both groups the practiced at home or school for 12 weeks, 4 times a week for at least 20 minutes. Both groups returned and underwent another evaluation to assess powered mobility level after 12 weeks of practice.
223850246|NCT04531488|OTHER|Training with Powered Wheel Chair|Training with Powered Wheel Chair
223850247|NCT03510091|BEHAVIORAL|Counseling|A video will be shown to parents of patients ages 9-18 that review HPV transmission, relation to cancer, role of immunization, myths, side effects, series timing and need for completion. All parents or legal guardians of patients will be given the option to proceed with HPV vaccination, decline, or discuss further with their provider
223850248|NCT00304980|DRUG|ARTEMETHER + LUMEFANTRINE VS. SULFADOXINE + PYRIMETHAMINE|
223850249|NCT03973424|BEHAVIORAL|Simple|Participants have three daily goals (weighing, dietary goal, activity goal), will self-monitor (weigh on Wi-Fi enabled scale, use a simplified form of tracking only high-calorie, high-fat foods in the study smartphone app, wear Fitbit activity tracker), will receive 4-5 tailored text messages each week, and will view weekly tailored feedback and lessons in smartphone app.
223850250|NCT03973424|BEHAVIORAL|Standard|Participants have three daily goals (weighing, dietary goal, activity goal), will self-monitor (weigh on Wi-Fi enabled scale, track calorie intake, wear Fitbit activity tracker), will receive 4-5 tailored text messages each week, and will view weekly tailored feedback and lessons in smartphone app.
223850251|NCT01570751|DRUG|insulin degludec|Cross-over trial, part 1: Individually adjusted IDeg administered subcutaneously (s.c., under the skin) once daily for 16 weeks in each treatment period.
223850252|NCT01570751|DRUG|insulin glargine|Cross-over trial, part 2: Individually adjusted IGlar administered subcutaneously (s.c., under the skin) once daily for the 16 week run-in period followed by 16 weeks in each treatment period.
223850253|NCT02013986|DRUG|etomidate|0.3mg/kg IV only once during induction of general anesthesia
223850254|NCT02013986|DRUG|midazolam|midazolam 0.1mg/kg IV only once before using of etomidate/propofol during induction of general anesthesia
223850255|NCT02013986|DRUG|propofol|2mg/kg IV only once during induction of general anesthesia
223850256|NCT05025124|DEVICE|Entia Liberty|Home monitoring system
223850257|NCT02321813|BEHAVIORAL|quality of life pathway|Quality of life measurement, diagnosis and tailored therapy (pain therapy, psychotherapy, social support, nutrition, stoma care, physiotherapy, fitness)
223850258|NCT02321813|OTHER|placebo control|Quality of life measurement
223850259|NCT00449657|DRUG|Taxol (paclitaxel)|paclitaxel 15mg/m2 Q am on Mon/Wed/Fri
223850260|NCT00449657|PROCEDURE|Radiotherapy|"Off cord thoracic radiotherapy 200cGy (total dose 1000cGy). Mon/Wed/Fri: radiotherapy is delivered at least 6 hrs after chemotherapy. Tue/Thurs: radiotherapy is delivered 24 hrs or less from the paclitaxel dose the day before.~Off-cord and off-esophagus concomitant boost radiotherapy 100 cGy (total dose 500 cGy)Mon/Wed/Fri of week 5"
223850261|NCT00449657|DRUG|Carboplatin|Carboplatin AUC 5mg/min/ml, prior to Gemcitabine on Wed of weeks 8 \& 9
223850262|NCT00449657|DRUG|Gemcitabine|Gemcitabine 1000 mg/m2 at a fixed dose rate of 10mg/m2/min on Wed during week 8 \& 9
223850263|NCT03487042|DRUG|Bimatoprost 0.03% ophthalmic solution|"Each patient will be subjected to the following:~One side will be treated by narrow band ultraviolet rays B sessions twice weekly for 3 months + topical bimatoprost 0.03% solution twice daily ( 1 drop for each 2 cm2 ) and the other side will be treated by topical bimatoprost 0.03% twice daily ( 1 drop for each 2 cm2 ) + narrow band ultraviolet rays B sessions twice weekly for 3 months + 10.600-nm fractional carbon dioxide laser sessions twice monthly for 3 months.~Patients' Evaluation:~The recruited patients will be subjected to:~A) Full history taking. B) General clinical examination. C) Dermatological examination of the skin lesions. D) Vitiligo area scoring index score will be calculated for each patient E) Clinical photographs will be taken at baseline, after each month during treatment and after the end of treatment by 3 months.~F) A skin biopsy from the treated lesions for histochemical examination. F) Dermoscopic evaluation of the treated sites every 2 weeks."
223850264|NCT03318536|DRUG|Granisetron Hydrochloride|Patients received Granisetron.
223850265|NCT03318536|DRUG|No Granisetron|Patients who did not receive Granisetron.
223850266|NCT01457560|BIOLOGICAL|DTPa-HBV-IPV/Hib (Infanrix hexa™)|Three doses administered intramuscularly
223850267|NCT01457560|BIOLOGICAL|OPV|One dose administered orally
223850268|NCT02740530|DEVICE|Magstim® Rapid 2 machine|See Arms description
223850269|NCT06169904|DRUG|Cisplatin injection|We observed the UC patients from Zhongshan Hospital receiving or not receiving adjuvant cisplatin-based chemotherapy after radical cystectomy.
223850270|NCT02000999|OTHER|brushing of bile duct strictures for cytology|
223850271|NCT01942967|OTHER|Echocardiography|"Measurement of:~* Left ventricular output (LVO).~* Right ventricular output (RVO).~* Assessment of the Mesenteric Artery Flow."
223850272|NCT01942967|OTHER|Near Infrared Spectroscopy Monitoring|Measurement of cerebral and mesenteric regional oxygen saturation(rSO2) trends and data while the baby on CPAP or TrPA modes of noninvasive ventilation.
223850273|NCT04097626|OTHER|nutrition education|The experimental group will receive nutrition education once during the study. It will occur at the beginning of the second week. This will consist of a 30-minute interactive lecture and a 15-minute question-and-answer session. The information covered will be basic nutrition principles for good health and to support regular exercise.
223850274|NCT04097626|OTHER|no nutrition education|This group will not receive nutrition education.
223850275|NCT01916889|OTHER|RACY test|
223850276|NCT04726046|DRUG|Cefotetan|Cefotetan (as Disodium) 1 GM Injection before surgery
223850277|NCT02480335|DRUG|bosentan|62.5 mg oral twice daily for 4 weeks, then 125 mg oral twice daily.
223850278|NCT02485626|PROCEDURE|2D tissue doppler echocardiography|
223850279|NCT06106087|OTHER|Mixed methods quality improvement intervention|Quality improvement training for frontline PCH staff
223850280|NCT00248391|BEHAVIORAL|upright feeding|
223850281|NCT02809300|BIOLOGICAL|blood collection|
223850282|NCT00221351|PROCEDURE|CRP point of care testing|
223850283|NCT03768856|RADIATION|Temporally Feathered Radiation Therapy (TFRT)|Up to 5 different plans are created and delivered on a daily basis Monday-Friday for 7 weeks. The treating physician designates up to 5 organs at risk (OARs) to be feathered based on the proximity to the target. The daily prescription dose delivered to the Planning Target Volumes (PTV) is not changed.
223850284|NCT01043471|OTHER|Chewing gum|Subjects were instructed to chew gum at least 6 times a day in an effort to reduce snacking.
223850285|NCT01043471|OTHER|Water|Subjects were instructed to drink 8 oz of water at least 6 times a day in an effort to reduce snacking.
223850286|NCT05949554|OTHER|Ketamine infusion|"Continuous measurement of burst suppression (BS) (%) and 95% spectral frequency front (SEF95) on frontal EEG Sedline® Masimo Corporation, USA).~EEG recording will start 10 minutes before the beginning of infusion until the total amount of 10 milligrams of Ketamine has been infused.~The duration varies depending on patient's weight.~Each patient will receive a dose of 0,5 mg/kg over a period of time of 2 or 4 hours."
223850287|NCT03172533|DRUG|ethinyl estradiol 0.03mg and dienogest 2 mg (combination)|approved oral contraceptive (Germany): Maxim
223850288|NCT03172533|DRUG|Placebo oral capsule|placebo
223850289|NCT00016913|DRUG|carboplatin|AUC=6 week one of each 4 week cycle
223850290|NCT00016913|DRUG|estramustine|2 tablets tid PO 5 of 7 days per week each 4 week cycle
223850291|NCT00016913|DRUG|paclitaxel|80 mg/sq m IV infusion over 1 hour weekly for ea 4 week cycle
223850292|NCT00016913|RADIATION|radiation therapy|77.4 Gy in 1.8 Gy fractions
223850293|NCT00016913|DRUG|leuprolide or goserelin acetate|7.5 mg IM injection once every 4 weeks for 6 months
223850294|NCT01971788|DEVICE|Optical Coherence Tomography of the infarct related artery|
223850295|NCT00588419|BEHAVIORAL|breast exam and questionaire|A physical examination of your breast(s), we will ask you to complete a short questionnaire that asks questions regarding sensations in your reconstructed breast(s) and another short questionnaire that asks questions regarding your medical and surgical history. The physical examination and the questionnaires will be completed in the outpatient clinic. This should take about 30 minutes to complete.
223850296|NCT00588666|DRUG|Bevacizumab|
223850297|NCT00588666|DRUG|Carboplatin|
223850298|NCT00588666|DRUG|Gemcitabine|
223850299|NCT05348226|DIAGNOSTIC_TEST|Additional Cardiac Magnetic Resonance Scan|Standard of care medical treatment with sacubitril/valsartan (Entresto). Additional Cardiac Magnetic Resonance Imaging (CMR) Scan after 4-6 months of treatment.
223850300|NCT00964314|OTHER|music|"Experimental Group one : Listening TCM five elements music therapy（TCMMT）based on conventional therapy in China.~Experimental Group two: Listening western music based on conventional therapy in China.~Control Group: no music therapy will be done."
223850301|NCT05721612|OTHER|Flapless transcrestal sinus lift approach with TPRF|Including 8 patients who will be treated by flapless transcrestal sinus floor elevation using the TPRF as a sole grafting material.
223850302|NCT05721612|OTHER|Flapless transcrestal sinus lift approach with PRF|Including 8 patients who will be treated by flapless transcrestal sinus floor elevation using the PRF as a sole grafting material.
223850303|NCT05522699|BEHAVIORAL|Cough suppressive therapy|"The cough suppressive therapy based on the treatment regime Physiotherapy, and speech and language therapy intervention for patients with refractory chronic cough (PSALTI) developed by S. Chamberlain et al (Thorax. 2017 Feb;72(2):129-136)."
223850304|NCT05522699|BEHAVIORAL|General healthy lifestyle instructions|The general healthy lifestyle instructions are based on the recommendations from the The Public Health Agency of Sweden.
223850305|NCT03804086|PROCEDURE|Advanced PRF (A-PRF) + nano-crystalline hydroxyapatite bone substitute combined with open flap debridement|"will treated with OFD +A- PRF+ nano-crystalline hydroxyapatite bone substitute,10 mL of blood will be drawn from only patient assigned to the intervention group by vein puncture of the antecubital vein and is collected in sterile glass test tube, without any anticoagulant.~* The blood will be quickly collected, and the tube will immediately centrifuge at 1500 rpm for14 min at room temperature.~* After centrifugation, the A-PRF clot will be removed from the tube using sterile tweezers and placed on sterile woven gauze. Membrane will prepared by compressing clots between two pieces of woven gauze."
223850306|NCT03804086|PROCEDURE|Open flap debridement|a periodontal access flap will be initiated by intrasulcular incisions on the buccal and lingual aspects. The incisions will be carried as far interproximally as possible to preserve the entire Interdental papillae and to achieve primary wound closure.
223850307|NCT06350045|COMBINATION_PRODUCT|PCNL|percutaneous nephrolithotomy
223850308|NCT03615248|DEVICE|BreatheSuite|"BreatheSuite (patent pending) is a device and mobile application developed by Mr. Brett Vokey, an engineering student at Memorial University of Newfoundland. BreatheSuite has been recognized by numerous provincial competitions, featured at the Eastern Health Innovation Showcase, and was recently selected as a finalist for the New York Health Innovation Challenge.~This device attaches to metered dose inhalers and it can determine if:~1. the dose was given,~2. the metered dose inhaler was properly shaken,~3. the metered dose inhaler is properly aligned,~4. the flow of medication is appropriate and~5. there is no accidental exhalation into the inhaler."
223850309|NCT01693419|DRUG|GES (Gemcitabine, Erlotinib, S-1)|"Treatment will be delivered as a 3-week cycle.~1. Gemcitabine 1000 mg/m² IV on day 1, 8~2. Erlotinib 100 mg/day PO on day 1~3. S-1 60 mg/m²/day PO on day 1-14"
223850310|NCT03102710|DEVICE|transcranial direct current stimulation (tDCS)|tCDS safely applies a weak electrical current to your scalp using two sponge electrodes that look like flat circular pads. The pads will be held in place on your head with a neoprene cap. The pads will be attached to a generator that will send a weak stimulus to your scalp. This current influences the way that your brain cells work. When the stimulus starts, you might feel a tingling sensation underneath the electrode pads. That sensation is not painful and goes away in seconds.
223850311|NCT03102710|OTHER|Lidocaine cream|Lidocaine cream will be applied on the arm to reduce pain sensitivity (analgesia).
223850312|NCT03102710|OTHER|Capsaicin cream|Capsaicin cream will be applied on the arm to increase pain sensitivity (hyperalgesia).
223850313|NCT03102710|OTHER|Control cream|A neutral cream will be applied on the arm as a control.
223850314|NCT00396058|DRUG|Methylphenidate|
223850315|NCT05074615|OTHER|Cranio-Cervical Flexion Training|"Participants of this group will receive conventional training along with Cranio-cervical flexion training:~* The pressure cuff is placed behind the neck just next to the occiput and inflated up to a baseline pressure of 20 mmHg. The patient is asked to perform Cranio-Cervical Flexion (CCF) to sequentially reach 5 pressure targets in 2 mmHg increments from a baseline of 20 mmHg to the final level of 30 mmHg. For each target level, the patient is instructed to maintain the contraction for 10 sec for 10 repetitions with brief rest periods between each contraction i.e., 3-5 seconds. Once a set of 10 repetitions of 10 sec is achieved at one target level, the exercise is progressed to train at the next target level up to the final target level at 30 mmHg.~Conventional therapy will be given along with home plan. Exercise protocol will consist of 30 minutes. Exercise will have total 3 sessions/week for 3 weeks."
223850316|NCT05074615|OTHER|Conventional Therapy|"Participants of this group will receive only conventional therapy and home plan will be given which includes;~* Hot pack placed on the posterior neck for 15 minutes.~* Transcutaneous electrical nerve stimulation (TENS) with a frequency of 80 Hz for 20 minutes with 10-30 mA intensity.~* Isometric exercises: Isometric neck flexion, extension, side bending exercises. 10 repetitions. Hold period is 10 seconds for each movement. Resistance would be provided manually by the therapist.~* Stretching exercises: Passive stretching for Sternocleidomastoid, Trapezius, Pectoralis Major. 10 reps and each stretch maintained for 10 seconds.~* Home Plan: Patients will be given a home plan of self-stretches and isometrics and instructions on how to perform and number of repetitions will be guided. Exercise protocol will consist of 25 minutes. Exercise will consist of total 3 sessions/week for 3 weeks"
223850317|NCT06582251|BEHAVIORAL|High-intensity functional training|Participants assigned to this group will undergo 8 weeks of high-intensity functional training.
223850318|NCT06582251|BEHAVIORAL|Traditional resistance training|Participants assigned to this group will undergo 8 weeks of traditional strength and hypertrophy training.
223850319|NCT06582251|BEHAVIORAL|Concurrent training|Participants assigned to this group will undergo 8 weeks of traditional strength and hypertrophy training followed by high-intensity interval aerobic training.
223850320|NCT01295918|DIETARY_SUPPLEMENT|L reuteri in children on antibiotics|Each patient will be assigned to receive either a probiotic supplement containing 1 x 10 8 CFU Lactobacillus reuteri DSM 17938 in the form of one chewable tablet once per day (BioGaia AB, Stockholm, Sweden) or placebo, identical in taste and appearance. The probiotic or placebo will be taken 2 hours after lunch each day, during the entire period of antibiotic treatment and for an additional 7 days.
223850321|NCT02862327|DRUG|intravenous dexamethasone|intravenous injection of dexamethasone
223850322|NCT02862327|DRUG|intravenous placebo|intravenous injection of placebo
223850323|NCT02862327|DRUG|perineural ropivacaine|brachial plexus block with perineural injection of Ropivacaine in the axillary fossa
223850324|NCT02862327|OTHER|ultrasound guidance|ultrasound guidance for brachial plexus block in the axillary fossa
223850325|NCT02118506|OTHER|Physical practice|"The control group underwent familiarization of gait phases using cards with gait phases and physical gait training.~Familiarization with gait cycle: Cards with pictures of an elderly person performing movements related to the adjustment of posture, gait initiation and gait phases were shown to the subjects. They should have organized them sequentially, showing that they learned gait phases. Then, they were submitted to a physical gait training. They underwent a single training session during 1 hour and 30 minutes and were reassessed 10 minutes and 1 day after the end of the session, in respect of the kinematic gait and mobility."
223850326|NCT02118506|OTHER|Mental and physical practice|"The experimental group underwent familiarization of gait phases using cards with gait phases, mental practice of gait and physical gait training.~Familiarization with gait cycle: Cards with pictures of an elderly person performing movements related to the adjustment of posture, gait initiation and gait phases were shown to the subjects. They should have organized them sequentially, showing that they learned gait phases.~Then, they were submitted to a mental training of gait. They imagined the gait steps per 400 repetitions. While imagining, they verbalized the gait phases.~Finally, they were submitted to a physical gait training. They executed 400 steps.~They underwent a single training session during 1 hour and 30 minutes and were reassessed 10 minutes and 1 day after the end of the session, in respect of the kinematic gait and mobility."
223850327|NCT04582877|DEVICE|FFR measurement|FFR is measured sequentially with the test article and the predicate device.
223850328|NCT04012853|DEVICE|transcranial direct current stimulation|Treatment group will receive 20 minutes of tDCS stimulation at 2.0 mA administered daily for five days per week and a total of 4 weeks. During the 20minute treatment session, both treatment and sham groups will complete mindfulness meditation via VA health system approved program (Mindfulness Coach).
223850329|NCT00897637|OTHER|laboratory biomarker analysis|Correlative studies
223850330|NCT04630652|DRUG|Risankizumab-Rzaa|Risankizumab at a dose of 150 mg with injections administered at baseline, week 4 and week 16 following FDA-approved dosage and time periods
223850331|NCT04630652|PROCEDURE|Punch biopsies of the skin at baseline visit|Two 6 mm punch biopsies of the skin at baseline visit
223850332|NCT04630652|PROCEDURE|Punch biopsies of the skin at week 28 visit|One 6 mm punch biopsy of the skin at week 28 visit
223850333|NCT03530553|OTHER|Hunt Motivational Scale|The Hunt Motivational Scale is a tool to help facilitate weight loss and motivate patients to track, plan, and practice healthy weight loss and weight maintenance practices.
223850334|NCT01501435|DRUG|CJ-30039|single dose
223850335|NCT01501435|DRUG|fenofibric acid|single dose
223850336|NCT04962334|DIETARY_SUPPLEMENT|Nutritional supplementation standardized formula.|Powder added to water, containing about 25% of recommended daily recommended intake (DRI) for calories, high protein (25% of calories) and multivitamin and mineral (25%-100% of DRI for recommended daily allowance (RDA) or adequate intake
223850337|NCT04962334|DIETARY_SUPPLEMENT|Placebo|Low caloric formula (powder added to water) without added vitamins and minerals
223850338|NCT03055767|DRUG|OnabotulinumtoxinA|The AB subject group will receive OnabotulinumtoxinA in the first treatment and saline placebo in the second.Both groups will then receive OnabotulinumtoxinA in the last two treatments. There will be one treatment at the beginning of each 12 week block, meaning 4 treatments over the 48 week study period total. Progress check-ups will occur every 6 weeks during the study. Randomization will be via selection of sealed envelope.
223850339|NCT03055767|OTHER|Placebo (Saline)|The BA subject group will receive saline and then Onabotulinumtoxin. A.Both groups will then receive OnabotulinumtoxinA in the last two treatments. There will be one treatment at the beginning of each 12 week block, meaning 4 treatments over the 48 week study period total. Progress check-ups will occur every 6 weeks during the study. Randomization will be via selection of sealed envelope.
223850340|NCT02759731|DRUG|Baricitinib|Cycle=28 days: Baricitinib: 1mg-4mg by mouth (PO) every day (QD)
223850341|NCT05555264|BEHAVIORAL|Self-Guided|Clients who select or are assigned the self-guided condition will be able to contact the Online Therapy Unit regarding any technical issues through the secure treatment platform; monitoring staff will respond by secure message to messages received however, no psychological intervention will be provided by monitoring staff as part of the ACCE treatment intervention. If there is a significant clinical issue requiring attention (e.g., a sudden increase in symptoms) monitoring staff will make a telephone call and crisis support will be provided if necessary.
223850342|NCT05555264|BEHAVIORAL|Therapist-Guided|Therapists will spend \~15 minutes/week communicating with each client who selects the therapist-guided condition, primarily using secure messages. Phone calls will only be made if there is a significant clinical issue requiring attention that the therapist does not feel can be addressed in a message (e.g., a question about the materials that cannot be easily addressed in a text format, a sudden increase in symptoms, increased suicide risk).
223850343|NCT02685280|DEVICE|Medtronic Restore Advanced 37713|Rechargeable neurostimulators are implanted when the non-rechargeable neurostimulators are end-of-life.
223850344|NCT00104611|DEVICE|Repetitive Transcranial Magnetic Stimulation|
223850345|NCT04638387|DIETARY_SUPPLEMENT|PB125|Nrf2 activator containing active ingredients carnosol, withaferin A, and luteolin.
223850346|NCT04638387|DIETARY_SUPPLEMENT|Placebo|Placebo comparator to P125
223850347|NCT06549517|BEHAVIORAL|Cognitive training|MTT24.5 consists in the learning of 40 new datas or knowledges, along 24.5 hours distributted on classes or sessions, during which an average of 3.5 new pieces of knowledge are taught and reinforced through training. Participants are trained using 4 techniques assigned to each new piece of information from a total of 100 available techniques. These techniques include the use of non-dominant skills, literacy in Braille for sighted individuals, and performing 5 actions simultaneously. Each technique is designed to aid in the memorization and learning of new knowledge
223850348|NCT00055432|DRUG|Gemzar and Alimta|
223850349|NCT00002111|DRUG|Saquinavir|
223850350|NCT03874455|DRUG|Tazemetostat|Tazemetostat (EPZ-6438) is a selective small molecule inhibitor of the histone-lysine methyltransferase EZH2 gene
223850351|NCT03460574|BEHAVIORAL|INFORMATION|After receiving expectation-disconfirming positive performance feedback, participants receive standardized information that stresses the relevance of this experience. In particular, participants are told that the performance test they worked on is highly relevant for both professional success and personal life satisfaction.
223850352|NCT03460574|BEHAVIORAL|SALIENCE|After receiving expectation-disconfirming positive performance feedback, partcipants in this condition are instructed to remember how well they performed on the performance test. Using a visual analogue scale, they were asked to specify how they performed relative to the other participants.
223850353|NCT03460574|BEHAVIORAL|ATTENTION|Before working on the performance test, participants are instructed to pay attention to the feedback they receive. In particular, they are asked to enter what would be a personally good result for them. It is supposed that this shift of attention increases the salience of the expectation-disconfirming feedback.
223850354|NCT03460574|BEHAVIORAL|CONTROL|This group does not receive any further intervention. Instead, participants of this group pass through the standard procedure of the EXPEC paradigm.
223850355|NCT06378879|DRUG|Propofol 100 MG in 10 ML Injection|Sedation induction time (minutes), total dose of propofol (mg), recovery time (minutes), any involuntary patient movement, quality of sedation (VAS) and adverse events
223850356|NCT04172844|DRUG|Azacitidine|75mg/m\^2 Days 1-7 given IV
223850357|NCT04172844|DRUG|Venetoclax|100 mg on cycle 1 day 1, 200 mg daily on cycle 1 day 2, 400 mg on cycle 1 day 3 and thereafter from cycle 1. Venetoclax is given for a minimum of 21 days and a maximum of 28 days. Administered orally.
223850358|NCT04172844|DRUG|Pevonedistat|The doses for the 3 + 3 design (dose escalation phase) are listed in the arm description. The dose-expansion phase will use the maximum-tolerated dose.
223850359|NCT00359957|BEHAVIORAL|Pediatric Obesity Intervention (STANDARD)|14 weekly behavioral intervention visits with parent and child; individual family sessions (25-30 minutes) and separate parent and child groups (40 minutes)
223850360|NCT00359957|BEHAVIORAL|Pediatric Obesity Intervention + High Activity (ADDED)|14 weekly behavioral intervention visits with parent and child; individual family sessions (25-30 minutes) and separate parent and child groups (40 minutes)
223850361|NCT00651885|DRUG|treprostinil dienthanolmine sustained release|UT-15C SR 1mg tablet
223850362|NCT00651885|DRUG|Placebo|Placebo
223850363|NCT02317705|DRUG|OTL38|
223850364|NCT02317705|DEVICE|Near infrared camera imaging system|Near infrared camera imaging system
223850365|NCT02317705|PROCEDURE|Laparotomy|primary surgical cytoreduction, interval debulking, or recurrent ovarian cancer surgery
223850366|NCT05288101|DIETARY_SUPPLEMENT|Proteinex and Enterex DBT Victus Laboratories|The supplement was provided five days per week. Three days a week, the supplement was given at the beginning of the HD session and the patients were instructed to consume it slowly during the next 3 hours. The remaining two days, the supplement was consumed at home and instructed to be consumed between meals. The ONS consisted of one can of polymeric formula (Enterex DBT, Victus Laboratories) and 5.6 g of a protein powder supplement (Proteinex, Victus Laboratories). The final mixture provided 240 kcal, 17 g protein, 8.1 g lipids, 25 g carbohydrates, 4 g dietary fiber, 201 mg sodium, 490 mg calcium, 356 mg phosphorus and 371 mg potassium
223850367|NCT05288101|PROCEDURE|Dry weight adjustment through BIVA|Those participants with post-dialysis vectors located within the 50 or 75% ellipses, were considered to be in dry weight, so they did not require any fluid removal adjustment. However, participants with vectors outside the 75% ellipse were considered overhydrated or dehydrated and dry weight was adjusted. In these patients, if the vectors fell outside the 75% ellipse but within the 95%, above or below the major axis, the established dry weight was adjusted by 0.5 Kg. If the vectors fell outside the 95% ellipse, the weight was adjusted by 1.0 Kg.
223850368|NCT00990756|DRUG|PF-03526299|dry powder for inhalation, 1.396 mg, BID for 14 days
223850369|NCT00990756|DRUG|PF-03526299|dry powder for inhalation, 4 mg, BID for 14 days
223850370|NCT02219490|DRUG|ABT-450/r/ABT-267|Tablet for oral use
223850371|NCT02219490|DRUG|ABT-333|Tablet for oral use
223850372|NCT02219490|DRUG|Ribavirin (RBV)|Ribavirin was provided as 200 mg tablets, and dosed based on weight,1000 to 1200 mg divided twice daily per local label. For example, for participants weighing \< 75 kg, RBV may have been taken orally as 2 tablets in the morning and 3 tablets in the evening which corresponds to a 1000 mg total daily dose. For participants weighing ≥ 75 kg, RBV may have been taken orally as 3 tablets in the morning and 3 tablets in the evening which corresponds to a 1200 mg total daily dose.
223850373|NCT00955461|PROCEDURE|RevLite laser treatment|Electro-optic Q-Switched Nd: YAG Laser treatment
223850374|NCT00955461|PROCEDURE|Fractionated Laser treatment|
223850375|NCT05290740|DRUG|Norepinephrine 5 mcg|norepinephrine bolus of 5 mcg for treatment of sever postspinal hypotension
223850376|NCT05290740|DRUG|Norepinephrine 10 mcg|norepinephrine bolus of 10 mcg for treatment of sever postspinal hypotension
223850377|NCT05893043|DRUG|GSBR-1290|Participants will receive GSBR-1290 oral capsules.
223850378|NCT05893043|OTHER|Placebo|Participants will receive matching placebo oral capsules.
223850379|NCT01014338|DRUG|Fosinopril|10mg od
223850380|NCT01014338|OTHER|lactose|placebo
223850381|NCT03898687|DEVICE|SLN Biopsy with Magtrace®/Sentimag®|Identification of SLN by means of Magtrace®/Sentimag® and SPIO-MRI
223850382|NCT04018417|DRUG|Amphotericin B|Drug concentration: 0.255 μg/mL
223850383|NCT04776486|DRUG|Iohexol|"Intravenous injection of 5 ml of iohexol (Omnipaque) to calculate the glomerular filtration rate (area under the curve).~Blood samples (2 ml) and urine (2 ml minimum) are to be collected for the determination of iohexol clearance at the following time points: pre-dose, 5 minutes, and 1, 2, 3, 4, 5, 6 hours post dose."
223850384|NCT00986271|PROCEDURE|EVLI was determinated by PiCCO plus system.|
223850385|NCT03383211|OTHER|RNAseq|Transcriptome profiling of peripheral blood using RNA sequencing technology
223850386|NCT05974943|OTHER|Problem Solving And Decision Making Education|"The Problem-Solving and Decision-Making Training Program, which was based on developing problem-solving and decision-making skills of nurse managers in the experimental group (n=30), was prepared. 2 faculty members and the researcher organized the training program consisting of four modules and 16 hours.~In the content of the Training Program; the definition of the concept of problem-solving and decision-making, the process of problem-solving and decision-making and decision-making models, the impact of decision-making on employee, patient and organizational outcomes, and the importance of managers' roles in decision-making, the importance of the role of nurse managers in decision making, the impact of managerial decisions on patient care outcomes, the impact of managerial decisions on nurse outcomes, the impact of administrative decisions on organizational results/performance, problem-solving, and decision-making techniques and case studies."
223850387|NCT04123002|OTHER|Miswak chewing sticks|Chewing stick are routinely used by this population
223850388|NCT01599325|DRUG|Azacitidine|Subcutaneous administration of azacitidine 75 mg/m\^2/day for 7 days every 28 days optimally for at least 6 cycles until disease progression, unacceptable toxicity, or treatment discontinuation for any other reason
223850389|NCT02934035|DRUG|Antidepressant|
223850390|NCT03879642|BEHAVIORAL|REDCHiP|10 week video-based telemedicine intervention to reduce hypoglycemia fear
223850391|NCT02155686|DEVICE|Biosensors|Device: Biometric sensors; Home automation; telecare
223850392|NCT02155686|DEVICE|Home automation|
223850393|NCT06099821|DRUG|KN046|KN046 is a recombinant humanized PD-L1/CTLA-4 bispecific single-domain antibody that blocks both PD-L1 interaction with PD-1 and CTLA-4 interaction with CD80/CD86.
223850394|NCT06099821|DRUG|Regorafenib|Regorafenib is a multi-target tyrosine kinase inhibitors and is one of the standard third-line therapy in mCRC
223850395|NCT06099821|DRUG|Apatinib|Apatinib is a novel, small molecule, selective vascular endothelial growth factor receptor-2 (VEGFR-2) tyrosine kinase inhibitor and is the second anti-angiogenic drug to be approved in China for the treatment of advanced or metastatic gastric cancer. It has been also reported to have anti-tumor efficacy in other kinds of digestive system cancers.
223850396|NCT06446674|PROCEDURE|mini monaka|mini monaka,perforated plugs
223850397|NCT02365298|DEVICE|etafilcon A|etafilcon A soft contact lens
223850398|NCT02365298|DEVICE|nelfilcon A|nelfilcon A
223850399|NCT01339702|OTHER|The National Prehospital TBI Management Guidelines|"In the post-implementation (after) cohort, implementation of the entire bundle of the TBI treatment guidelines with special emphasis on prevention and treatment of hypotension (IV crystalloids), prevention and treatment of hypoxia (pre-oxygenation with high-flow O2 via non-rebreather mask, bag-valve-mask, extraglottic airways/intubation when basic maneuvers have failed), and prevention of hyperventilation (in intubated patients) and prevention/treatment of hypoventilation (in all patients)."
223850400|NCT05767073|BEHAVIORAL|Lifestyle InterVEntion (LIVE)|"The lifestyle intervention Coaching on Lifestyle (CooL) (van Rinsum 2018)),formed the basis of LIVE and was adapted to specific dysfunctional elements in depressed patients regarding motivation and self-management.~The focus is on reducing depressive symptoms, enhancing the quality of life and possibly achieving weight loss.~The lifestyle intervention lasts six months, with 13 weekly 1.5 to 2 hour group sessions and five 45 to 60 -minute individual sessions with at least one person from the patient's support network of friends or family (preferably sharing the same household). All sessions end with individual homework exercises, and each session starts with a 10 to 15-minute positive psychology intervention (PPI) and 5 to 15 minutes of physical activity. These sessions are followed by two booster sessions after about two and six months. Groups consist of 4-8 people."
223850401|NCT04872712|PROCEDURE|Press needles|Manual acupuncture using press needles
223850402|NCT04872712|PROCEDURE|Filiform Needles|Manual acupuncture using filiform needles
223850403|NCT03545789|DRUG|[18F]MNI-958|Subjects will undergo PET imaging using \[18F\]MNI-958, a PET radioligand for imaging tau.
223850404|NCT03114722|DRUG|Citrate 4%|In patients randomised to the citrate arm, the PICC line will be locked with a total of 1.6ml of citrate 4% (0.8ml per lumen in a double-lumen PICC), between each use. Lines will also be flushed with 20ml of normal saline and locked with the locking agent twice a week, if the time elapsed between each use is more than one week. This is part of the standard local protocol. Patients will be followed for up to 6 months or until the catheter is removed, or until the study ends
223850405|NCT03114722|DRUG|Heparinised saline (10U/ml)|In patients randomised to the heparinised saline arm, the PICC line will be locked with 10U/ml heparinised saline between each use. Lines will also be flushed with 20ml of normal saline and locked with the locking agent twice a week, if the time elapsed between each use is more than one week. This is part of the standard local protocol. Patients will be followed for up to 6 months or until the catheter is removed, or until the study ends
223850406|NCT05753709|PROCEDURE|Hand sewn end-to-end anastomosis|Hand sewn end-to-end anastomosis (EE) Holding sutures were taken through a seromuscular bite with PDS (Polydiaxonone) 3-0 or Silk 2-0 RB (Round Bodied needle), one each at the mesenteric and antimesenteric ends of the stoma. A posterior layer of Lembert sutures was taken first. The first bite was taken at the anti-mesenteric end and a knot was applied. A Connell stitch was applied at the corner and then the posterior layer was closed using an inverting interlocking continuous stitch till the mesenteric end. Another Connell stitch was applied here to secure the corner and the suture was continued on to the anterior layer which was then closed in a similar manner using a continuous interlocking stitch. The final bite crossed the initial knot and the final knot was applied. An anterior layer of Lembert sutures was taken to reinforce the anastomotic line.
223850407|NCT05753709|PROCEDURE|Hand sewn side-to-side anastomosis|Hand sewn side-to-side anastomosis (HSSA) Each end of the stoma was closed using either a single layer of inverting interlocking continuous sutures with PDS 3-0 or Silk 2-0 RB, or a Linear Stapling device. The two closed stumps were then brought adjacent to each other in an anti-peristaltic arrangement. A posterior layer of Lembert sutures was applied using Silk 2-0 RB. The bowel wall was incised using electrocautery close to the suture line. The incision was lengthened up to a width of at least 5-6 cm. The posterior and anterior layer was now closed using the same technique as in HS using PDS 3-0. An anterior layer of Lembert sutures was applied. The mesenteric defect was then closed using a superficial interrupted layer of Silk 2-0 RB.
223850408|NCT05753709|PROCEDURE|Stapled side-to-side anastomosis|Stapled side-to-side anastomosis or Functional End-to-end anastomosis (SSSA/FEEA) The two limbs of a Linear Cutter SR55 are placed into the proximal and distal bowel loops of the stoma, facing as far away from the mesenteric border as possible and then fired. If both lumens are of similar size, traction sutures are applied with Silk 2-0 RB at the anterior and posterior termination ends of the staple line. The two ends are pulled away from each other, and a Linear Cutter SR75 is applied just below the edge of the bowel and fired. However, in case of an ileo-colostomy, after the first linear cutter SR55 is fired, the two suture lines are approximated in such a way that they do not get apposed but rather lie adjacent to each other. The lumen is then clamped in SR75 which is then fired.
223850409|NCT01878890|DRUG|Efavirenz 600mg|Efavirenz 600 mg (oral daily intake)
223850410|NCT01878890|DRUG|Efavirenz 1200 mg|Efavirenz 1200mg (oral daily intake)
223850411|NCT01878890|DRUG|Efavirenz 1800 mg|Efavirenz 1800mg (oral daily intake)
223850412|NCT01878890|DRUG|Efavirenz 2200 mg|Efavirenz 2200mg (oral daily intake)
223850413|NCT05015972|BIOLOGICAL|CTA30X UCAR-T injection|CTA30X UCAR-T injection is an allogeneic CAR-Ttargeted CD19 . A single infusion of CART cells will be administered intravenously.
223850414|NCT00542022|DRUG|MK0812 / Duration of Treatment: 12 Weeks|
223850415|NCT00542022|DRUG|Comparator: placebo (unspecified) / Duration of Treatment: 12 Weeks|
223850416|NCT02127476|DRUG|KHK6640|Single ascending dose and multiple ascending doses administration
223850417|NCT02127476|DRUG|Matching Placebo|Single ascending dose and multiple ascending doses administration
223850418|NCT01715909|DRUG|Oseltamivir|Participants will receive standard dose (30 to 75 milligrams \[mg\]) or triple standard dose (90 to 225 mg) of oseltamivir orally daily for up to maximum of 20 days. Standard dose of oseltamivir according to weight (except infants): 30 mg twice daily for \</= 15 kilograms (kg) body weight participants; 45 mg twice daily for 15 to 23 kg body weight participants; 60 mg twice daily for 23 to 40 kg body weight participants; and 75 mg twice daily for greater than (\>) 40 kg body weight participants. Standard dose for infants is 3 mg/kg.
223850419|NCT02648529|PROCEDURE|MRI|"Patients are investigated with the following sequences:~* High-resolution 3D T1-weighted anatomical MRI.~* DTI with 48 directions (to examine white matter)"
223850420|NCT02648529|PROCEDURE|functional MRI (fMRI)|"fMRI investigations will be focused on :~* language: investigation on possible atypical language networks in children with epilepsy. The fMRI task is a silent verb generation.~* Social cognition: investigations on social cognition skills~* Memory :~* Declarative memory: investigations on the pattern of activations in the brain associated with successful memory formation and changes from childhood to adolescence~* Working memory: A verbal and a spatial working memory task has been chosen, and is an adaptation of two published cross-sectional studies of working memory from Gabrieli and Sowell groups."
223850421|NCT02648529|BEHAVIORAL|neuropsychological assessment|Patients undergo a repeated annual neuropsychological assessment over the five years of their participation in the project.
223850422|NCT02506426|PROCEDURE|Endoscopic sinus surgery + Septoplasty|Opening of the paranasal sinuses along with correcting the nasal septum
223850423|NCT02506426|PROCEDURE|Septoplasty alone|Straightening of the nasal septum without opening the paranasal sinuses
223850424|NCT00415558|DEVICE|Microwave Ablation System|
223850425|NCT00312312|BIOLOGICAL|Specific immunotherapy|
223850426|NCT01886469|DRUG|HLD100-B|d-amphetamine sulfate capsules, 30 mg, CII (25% SR, 30% pH coat, slow release; formulation B)
223850427|NCT01886469|DRUG|HLD100-C|d-amphetamine sulfate capsules, 30 mg, CII (20% SR, 20% pH coat, fast release; formulation E) - this intervention may be deemed unnecessary based on results from Intervention 1.
223850428|NCT01886469|DRUG|HLD100-E|d-amphetamine sulfate capsules, 30 mg, CII (20% SR, 20% pH coat, medium release; formulation E) - this intervention may be deemed unnecessary based on results from Interventions 1 and 2.
223850429|NCT04636086|DRUG|Cholecalciferol|Vitamin D supplementation
223850430|NCT04636086|OTHER|Placebo|Placebo comparator
223850431|NCT01750957|DRUG|Placebo|orally daily, 12 weeks
223850432|NCT01750957|DRUG|RO4917523|Dose A orally daily, 12 weeks
223850433|NCT01750957|DRUG|RO4917523|Dose B orally daily, 12 weeks
223850434|NCT02974010|DRUG|NRX-101 Oral Capsule|Prospective Randomized Factorial Design Study as per arm/group descriptions
223850435|NCT02974010|DRUG|Lurasidone Oral Capsule|Prospective Randomized Factorial Design Study as per arm/group descriptions
223850436|NCT02974010|DRUG|Ketamine Intravenous Infusion|Randomized administration of Ketamine or Placebo in a 3 to 1 ratio
223850437|NCT02974010|DRUG|Saline Solution Intravenous Infusion|Randomized administration of Ketamine or Placebo in a 3 to 1 ratio
223850438|NCT04160689|BIOLOGICAL|implantology|placing of implant
223850439|NCT05062590|OTHER|Recommendations|Ressources recommendations and interventions curated to the needs of the EP such as refering them to a social activity for socially isolated EP
223850440|NCT00154713|BIOLOGICAL|CEA pulsed dendritic cells|
223850441|NCT02519296|BEHAVIORAL|Prolonged Exposure Therapy|8 sessions with prolonged exposure therapy and fMRI.
223850442|NCT02519296|BEHAVIORAL|Observation|fMRI.
223850443|NCT02519296|DEVICE|fMRI|Functional Magnetic Resonance Imaging of the brain
223850444|NCT06076343|BEHAVIORAL|DBT skills-training and Family Connections interventions|"DBT skills-training program includes four modules: 1. Mindufulness, 2. Distress Tolerance, 3. Emotion Regulation, 4. Interpersonal effectiveness.~FC program includes six modules: 1. Introduction, 2. Family Education, 3. Relationship Mindfulness Skills, 4. Family Environment Skills, 5. Validation Skills, 6. Problem Management Skills."
223850445|NCT02952755|DRUG|Co-administration of DWC20155/DWC20156|
223850446|NCT02952755|DRUG|DWC20162|
223850447|NCT02214108|OTHER|Nintendo Wii|Tennis, box and bowling on Nintendo Wii, 3 hours per week.
223850448|NCT01051882|BIOLOGICAL|MSC-NTF cells transplantation (IM)|In early ALS subjects: Autologous MSC-NTF cells will be transplanted under mild anesthesia, intramuscularly into patients' clinically unaffected (or only mildly affected) upper arm biceps and triceps muscles according to a pre-designed grid. Intramuscular injections will be by a 26 gauge needle to a 1.5cm depth (ensuring that injection is into muscle and not adipose tissue). The patients will be injected at 24 sites with a total of 24 million cells
223850449|NCT01051882|BIOLOGICAL|MSC-NTF cells transplantation (IT)|In progressive ALS subjects: Autologous MSC-NTF cells will be transplanted under mild anesthesia intrathecally(via a standard lumbar puncture)with a total of 60 million cells.
223850450|NCT04745702|COMBINATION_PRODUCT|Low Calorie Meals Rich in Plant Components|Twice a day reduced calorie frozen ready meals (rich in plant components) to substitute participants' two main meals/day consecutively for a period of 16 weeks.
223850451|NCT04745702|COMBINATION_PRODUCT|Low Calorie Balanced Meals|Twice a day reduced calorie frozen ready meals (balanced composition) to substitute participants' two main meals/day consecutively for a period of 16 weeks.
223850452|NCT06200402|DRUG|Antibiotic loaded|This is the intervention for the study group. It involves the use of bone cement mixed with antibiotics (typically gentamicin or similar) in the hip prosthesis surgery. The purpose of this intervention is to assess whether the antibiotic-loaded cement reduces the incidence of postoperative infections compared to standard cement
223850453|NCT06200402|OTHER|Placebo|Placebo
223850454|NCT00320489|DRUG|olanzapine|10 milligrams (mg), oral tablets, once daily for 4 weeks followed by 5-20 mg flexible dosing, oral tablets, once daily, for 100 weeks, for a total treatment duration of 104 weeks.
223850455|NCT00320489|DRUG|olanzapine pamoate depot|405 milligrams (mg), intramuscular injection, followed 4 weeks later by 150-405 mg flexible dosing, intramuscular injection, every 4 weeks thereafter for 96 weeks, for a total treatment duration of 104 weeks.
223850456|NCT03363256|BEHAVIORAL|TES-NAV|Internet-delivered psychosocial treatment grounded in the community reinforcement approach plus contingency management adapted for AI/AN
223850457|NCT03363256|BEHAVIORAL|TAU|Standard outpatient addiction treatment
223850458|NCT02577484|DEVICE|RXi System|"Provide hemodynamic information for the diagnosis and treatment of coronary and peripheral artery disease. The system is intended for use in catheterization and related cardiovascular specialty laboratories to compute and display fractional flow reserve or FFR.~Measurement of FFR requires simultaneously monitoring the blood pressures proximal and distal to a lesion. The RXi system includes a single use catheter (Navvus) with a pressure sensor for acquisition of the distal pressure. The proximal pressure is acquired by the guide catheter via an interface to the hospital hemodynamic monitor.~The Navvus catheter interfaces to the RXi system console which includes embedded software, a user interface touch screen and associated electronics."
223850459|NCT02577484|DEVICE|Pressure Wire|Provide hemodynamic information for the diagnosis and treatment of coronary and peripheral artery disease. The system is intended for use in catheterization and related cardiovascular specialty laboratories to compute and display fractional flow reserve or FFR.
223850460|NCT05818800|DEVICE|digital solution|randomised controlled trial where patients with hypertension will be randomised either to one of the two digital solutions
223850461|NCT05818800|OTHER|Standard Care|randomised controlled trial where patients with hypertension will be randomised r to standard care
223850462|NCT03244176|DRUG|Avelumab|"All participants will receive the following treatment:~Induction phase Avelumab at a dose of 10 mg/kg as a 1hour intravenous (IV) infusion once every 2 weeks for 2 cycles Plus Rituximab at a dose of 375mg/m2 as an IV infusion over at least 1 hour once every 2 weeks for 2 treatments~Then:~RCHOP - All participants will receive RCHOP chemotherapy treatment for 6 cycles. Each cycle will last for 21 days. Rituximab, cyclophosphamide, doxorubicin, and vincristine are given on the first day of each cycle by intravenous infusion. Prednisone is given orally from Day 1 until Day 5 of each cycle.~Then:~Maintenance phase - All participants will receive Avelumab at a dose of 10 mg/kg as a 1hour intravenous (IV) infusion once every 2 weeks for 6 cycles."
223850463|NCT00420589|DRUG|taranabant|taranabant 0.5 mg capsule, 1 mg capsule, 2 mg capsule once daily. Treatment for 52 weeks.
223850464|NCT00420589|DRUG|Comparator: placebo|Placebo capsules once daily. Treatment for 52 weeks
223850465|NCT03015831|DRUG|Colchicine|Colchicine will be given to open heart surgery patients
223850466|NCT03015831|DRUG|Placebo Oral Tablet|Placebo Oral Tablet will be given to open heart surgery patients according to randomization
223850467|NCT02537392|DIETARY_SUPPLEMENT|Vitamin B Complex and Folic Acid|Daily oral dose containing 2 mg vitamin B1, 2 mg vitamin B2, 2 mg vitamin B6, 2 μg vitamin B12, 2 mg calcium pantothenate, 15 mg nicotinamide and 0.4 mg folic acid.
223850468|NCT02537392|DIETARY_SUPPLEMENT|Iron and Folic Acid|Daily oral dose of 60 mg iron and 0.4 mg folic acid.
223850469|NCT02537392|DIETARY_SUPPLEMENT|Folic Acid|Daily oral dose of 0.4 mg folic acid.
223850470|NCT02096289|DRUG|Thioridazine|
223850471|NCT00803426|PROCEDURE|Sciatic nerve blockade for ankle/foot surgery|Injection of local anesthetic near the nerve to achieve anesthesia.
223850472|NCT03441984|DRUG|Treatment A|TRIUMEQ (Adult) administered as a, single dose, fixed dose combination (FDC) tablet - DTG 50 mg/ABC 600 mg/3TC 300 mg as 1 conventional tablet, orally as direct-to-mouth.
223850473|NCT03441984|DRUG|Treatment B|TRIUMEQ (Pediatric) administered as a, single dose, FDC tablet - DTG 5 mg/ABC 60 mg/ 3TC 30 mg, orally as 10 dispersible tablets
223850474|NCT03441984|DRUG|Treatment C|TRIUMEQ (Pediatric) administered as a, single dose, FDC tablet - DTG 5 mg/ABC 60 mg/3TC 30 mg, orally as direct-to-mouth.
223850475|NCT03441984|DRUG|Treatment D|"DTG and 3TC (Adult), administered as a, single dose, Single dose, 1 tablet DTG (50 mg) and~1 tablet 3TC (300 mg), orally as direct-to-mouth."
223850476|NCT03441984|DRUG|Treatment E|DTG and 3TC (Pediatric) administered as a, single dose, FDC tablet single dose, FDC tablet - DTG 5 mg/3TC 30 mg, orally as 10 dispersible tablets.
223850477|NCT03441984|DRUG|Treatment F|DTG and 3TC (Pediatric) administered as a, single dose, FDC tablet single dose, FDC tablet - DTG 5 mg/3TC 30 mg, orally as direct-to-mouth.
223850478|NCT05566847|OTHER|Physician Education|The physician education session delivered to primary care physicians in Arms 2 and 3 will provide an educational update from the regional clinical leader for diabetes regarding guidelines for diabetes treatment and addressing therapeutic inertia.
223850479|NCT05566847|OTHER|Accountable Population Manager outreach|Patients will be referred to an Accountable Population Manager (APM) for proactive outreach, including supporting medication adherence and educational and overall support for T2D management. An APM is a non-physician clinician (for example, a clinical pharmacist) supporting diabetes management.
223850480|NCT05805345|DEVICE|Delefilcon A toric soft contact lens|Commercially available silicone hydrogel contact lens
223850481|NCT05805345|DEVICE|Lehfilcon A toric soft contact lens|Commercially available silicone hydrogel contact lens
223850482|NCT05805345|DEVICE|Lotrafilcon B toric soft contact lens|Commercially available silicone hydrogel contact lens
223850483|NCT05805345|DEVICE|Verofilcon A toric soft contact lens|Commercially available silicone hydrogel contact lens
223850484|NCT02606734|DEVICE|Coronary Angiography|The DyeVert System will be used during coronary angiographic procedures which include: diagnostic only, diagnostic + PCI or PCI only cases.
223850485|NCT00624546|DRUG|Prevacid Solutabs|BID Prevacid Solutabs
223850486|NCT00624546|PROCEDURE|Antireflux surgery|Lap Nissen
223850487|NCT05450029|DRUG|Sintilimab|6 cycles of mFOLFOX6 (oxaliplatin 85 mg/m2, and folinic acid 400 mg/m2 followed by bolus 5-fluorouracil 400 mg/m2 and 5-fluorouracil 2400mg/m2 as a 46-hour continuous infusion on day 1) followed by long course chemoradiotherapy (50 Gy in 25 fractions) followed by surgery. Patients will receive sintilimab 3mg/kg every 2 weeks during chemoradiotherapy (2nd-6th cycle).
223850488|NCT05407519|DRUG|Tislelizumab + Sitravatinib|Drug: Tislelizumab Tislelizumab 200mg IV q3w Other Names: BGB-A317, Immunotherapy, Anti-PD-1 antibody Drug: Sitravatinib Sitravatinib 100mg PO qd Other Name: tyrosine kinase inhibitor, TKI
223850489|NCT00073138|DRUG|ABT-751|
223850490|NCT03807102|BIOLOGICAL|Tumor Vaccine|NeoAntigen Tumor Vaccine (5 injections for each 3 days and then 1 injection for each 3 months till recurrence or up to 2 years).
223850491|NCT04227990|DRUG|Plinabulin|Plinabulin (BPI-2358) is a synthetic, low molecular weight, new chemical entity that belongs to the diketopiperazine class of compounds. Plinabulin is intended for intravenous (IV) infusion and is diluted in D5W and administered for 30 minutes (± 5 minutes).
223850492|NCT04227990|DRUG|Pegfilgrastim|Pegfilgrastim is a long-acting granulocyte colony-stimulating factor that stimulates the growth of neutrophils, to reduce the incidence of fever and infection in patients with certain types of cancer who are receiving chemotherapy that affects the bone marrow.
223850493|NCT04227990|DRUG|Docetaxel, doxorubicin, and cyclophosphamide (TAC)|Docetaxel is a type of chemotherapy medicine called an taxane. Doxorubicin is a type of chemotherapy medicine called an anthracycline. Cyclophosphamide is a type of chemotherapy medicine called an alkylating agent.
223850494|NCT02540642|DIETARY_SUPPLEMENT|METHYLCOBALAMIN 500 micrograms|Tab Methycobalamin 500 ug will be given with other regular antidiabetic drugs
223850495|NCT05054062|DIAGNOSTIC_TEST|Sentinel node mapping using MRI|Sentinel lymph node mapping in melanoma patients using a magnetic tracer and MRI
223850496|NCT00370799|DRUG|Caudal epidural injection|group 1: Caudal epidural injection local anesthetics only
223850497|NCT00370799|DRUG|Caudal Epidural Injection with generic Celestone|Group 2. Caudal Epidural Injection local anesthetic with 6mg of non-particulate Celestone
223850498|NCT00370799|DRUG|Caudal Epidural Injection with Celestone|Group 3. Caudal Epidural Injection with local anesthetic with 6 mg of brand name Celestone
223850499|NCT00370799|DRUG|Caudal Epidural Injection with DepoMedrol|Group 4. local anesthetic with 40 mg of alcohol-free DepoMedrol
223850500|NCT05289830|DRUG|Escitalopram|Participants will receive Escitalopram 2 weeks: 10 mg/day (1 capsule) 8 weeks: 20 mg/day (2 capsules) 2 weeks: 10 mg/day (1 capsule)
223850501|NCT05289830|OTHER|Placebo|Participants will receive placebo supplements 2 weeks: 1 capsule 8 weeks: 2 capsules 2 weeks: 1 capsule
223850502|NCT02580448|DRUG|Seviteronel|Seviteronel given daily with evening meal in 28 day cycles
223850503|NCT06555224|DEVICE|Systane Hydration MDPF eye drops|Systane Hydration MDPF eye drops 4x daily for 3 months additional to routine medication after cataract surgery
223850504|NCT06556134|DRUG|Intravenous Iron Sucrose|Intravenous iron-hydroxide sucrose complex administered in a dose of 100 mg, diluted in 250 mL of normal saline, and infused weekly for a period of 3 months
223850505|NCT06556134|DRUG|Oral Iron|One oral capsule per day, containing 30 mg of pyrophosphate liposomal iron and 70 mg of ascorbic acid
223850506|NCT02498158|DEVICE|MRI scans|"20 subject (10 tolerant and 10 intolerant to heat) will undergo MRI scans (GE healthcare manufacturer) as follows:~1. anatomical scan according to standard protocol~2. functional scan according to the standard protocol of rest-state fMRI.~scans of 10 healthy subjects will be taken from existing scans at the imaging department."
223850507|NCT05130060|BIOLOGICAL|Colorectal Cancer Peptide Vaccine PolyPEPI1018|Given SC
223850508|NCT05130060|DRUG|Trifluridine and Tipiracil Hydrochloride|Given PO
223850509|NCT03643042|OTHER|Transfusion|Transfusion with Hb maintain between 80 and 100g/L or Hb maintain between 100 and 120g/L
223850510|NCT05893303|OTHER|1st Group|1st group is going to undergo scapula-oriented PNF techniques (diagonal) which are anterior elevation and posterior depression - posterior elevation and anterior depression with 20 repetitions with rhythmic initiation and repeated contractions facilitation techniques during all patterns. In addition to PNF techniques, gait training is going to be applied as standing with balance exercises (15 repetitions) as well as specific exercises for the stance and swing phases of the gait which are; stepping forward and sideways (15 repetitions), and gait education (walking 3 lapses within 2 meters parallel bar)
223850511|NCT05893303|OTHER|2nd Group|2nd group is going to undergo only gait training and balance exercises (15 repetitions) as well as specific exercises for the stance and swing phases of the gait which are; stepping forward and sideways (15 repetitions), and gait education (walking 3 lapses within 2 meters parallel bar)
223850512|NCT03350737|OTHER|Physical rehabilitation|Standard treadmill exercise session
223850513|NCT03350737|DRUG|Heparin|Heparin i.v.
223850514|NCT03350737|OTHER|Placebo|Sodium Chloride 0.9% i.v.
223850515|NCT03967925|DRUG|Belimumab|Sub-cutaneous injection
223850516|NCT03967925|DRUG|Rituximab|IV infusion 1g x 2
223850517|NCT03967925|DRUG|Prednisolone|20mg prednisolone tapering dose
223850518|NCT06313138|OTHER|The Individual and Family Enhancement Program|The program is a group-based intervention which will be developed by the researcher based on the Individual and Family Self-Management Theory (IFSMT) (self-management skills) and the principle of Medagogy (PITS model: Pathophysiology, Indications, Treatments, Specifies) to improve patients' and their families' understanding of disease-related information and self-management skills consisting of goal setting and action plan, self-monitoring, solving problems and decision-making, and emotional control.
223850519|NCT02050958|DRUG|OXP001|
223850520|NCT02050958|DRUG|Ibuprofen|
223850521|NCT00746330|DRUG|Mometasone furoate/formoterol fumarate (MFF)|Formoterol fumarate dihydrate / mometasone furoate combination product 10 μg / 100 μg delivered via Pressurized Metered Dose Inhaler (pMDI). One dose consisted of 2 puffs x 5 μg / 50 μg.
223850522|NCT00746330|DRUG|Formoterol fumarate 12 μg pMDI (F12M)|Formoterol fumarate dihydrate 12 μg delivered via Pressurized Metered Dose Inhaler (pMDI) (1 dose = 2 puffs x 6 μg).
223850523|NCT00746330|DRUG|Formoterol fumarate 12 μg DPI (F12D)|Formoterol fumarate dihydrate 12 μg delivered via Dry Powder Inhaler (DPI).
223850524|NCT00746330|DRUG|Placebo to F12D|Placebo to formoterol fumarate DPI delivered via DPI
223850525|NCT00746330|DRUG|Placebo to F12M/MFF|Placebo to formoterol fumarate pMDI and formoterol fumarate / mometasone furoate delivered via pMDI
223850526|NCT01981850|BIOLOGICAL|RO7490677|IV infusion
223850527|NCT01981850|DRUG|Ruxolitinib|IV infusion
223850528|NCT05723991|DRUG|Disitamab Vedotin and Gemcitabine|Disitamab Vedotin (RC48) 2.0mg/kg, once every two weeks, intravenous drip (60-90 min); Gemcitabine is 1000mg/m2, once every two weeks. After completing 3 cycles of neoadjuvant combined therapy, imaging evaluation was performed. If the tumor is T0, radical surgery for bladder cancer was performed; Otherwise, perform radical surgery for bladder cancer after completing 1-3 cycles of treatment (total cystectomy+standard/extended lymph node dissection)
223850529|NCT01461213|DRUG|rAAV2.REP1|Single subretinal injection of rAAV2.REP1 vector suspension containing 10e12 genome particles per ml. Dose 1 = dose containing approximately 10e10 rAAV2.REP1 genome particles. Dose 2 = dose containing approximately 10e11 rAAV2.REP1 genome particles.
223850530|NCT01958099|BEHAVIORAL|Education|
223850531|NCT00570869|OTHER|CPR Anytime|These participants will be consented, surveyed, asked to watch a 22-minute instructional Infant CPR DVD with an infant manikin.
223850532|NCT02524288|DRUG|ENG-E2 125 μg/300 μg vaginal ring|Up to 13 cycles of ENG-E2 125 μg/300 μg administered intravaginally, each cycle consisting of 21 days of vaginal ring use followed by 7 vaginal ring-free days.
223850533|NCT02558218|DRUG|Systane Ultra|Further to standard medication (tobradex quid for 20 days), participants were administered Systane Ultra quid for 2 months
223850534|NCT02558218|DRUG|tobradex quid (Standard)|Standard medication (tobradex quid for 20 days)
223850535|NCT00517933|DRUG|Sildenafil Citrate|Sildenafil citrate (20mg 3 times a day \[TID\] orally for 12 weeks followed by 20mg TID open-label sildenafil for an additional 12 weeks)
223850536|NCT00517933|OTHER|Placebo|Placebo (20mg TID orally for 12 weeks followed by 20mg open-label sildenafil for 12 weeks)
223850537|NCT00807430|DEVICE|Grindcare (Active)|Active treatment
223850538|NCT00807430|DEVICE|Grindcare (Placebo - the device is not activated)|Placebo treatment
223850539|NCT04868799|BIOLOGICAL|Mass spectrometry|Characterization of the proteomic and phosphoproteomic landscape using mass spectrometry
223850540|NCT05292599|OTHER|Experimental|CCFE will be performed with the patient in a supine position with both knees flexed at 45°. This exercise involves a craniocervical movement. The IFE will be performed with the patient in a supine position while the IEE will be performed in a prone position. Both exercises will activate cervical muscles. RFE and RRE will be performed with the patient in a sitting or standing position at the same time he resists with his hands on his head. ME the function of these exercises is to depress and stabilize the scapula.
223850541|NCT05292599|OTHER|Control|CCFE will be performed with the patient in a supine position with both knees flexed at 45°. This exercise involves a craniocervical movement. The IFE will be performed with the patient in a supine position while the IEE will be performed in a prone position. Both exercises will activate cervical muscles. RFE and RRE will be performed with the patient in a sitting or standing position at the same time he resists with his hands on his head. ME the function of these exercises is to depress and stabilize the scapula.
223850542|NCT01022489|DEVICE|Transcranial magnetic stimulation: rTMS|4 sessions of 13 minutes, with 2 sessions a day, at 20Hz frequency and at an intensity of 80% of rest motor threshold will be delivered
223850543|NCT01022489|DEVICE|Placebo (sham coil) treatment|Sham coil treatment
223850544|NCT05153135|DRUG|Ribociclib|Participants who initiated CDK4/6i therapy
223850545|NCT05153135|DRUG|Palbociclib|Participants who initiated CDK4/6i therapy
223850546|NCT05153135|DRUG|Abemaciclib|Participants who initiated CDK4/6i therapy
223850547|NCT06094205|DEVICE|BrainGate Neural Interface System|Placement of the BrainGate2 sensor(s) into the speech-related cortex
223850548|NCT06032234|OTHER|This is an observational study|This is an observational study
223850549|NCT06631495|OTHER|Observation|not available-observation study
223850550|NCT06628739|DRUG|Imatinib|The long-term maintenance dose of every patient was determined by the physician based on the guidelines and the patients' individual conditions such as adverse reactions.
223850551|NCT06631248|OTHER|Coordinative exercise protocol|During the eight-week period, all children in the structured coordinative exercise intervention group participated in 30-minute sessions twice a week on the same day and time. The purpose-oriented basic movement patterns created in the coordinative exercise content were organised in a play-oriented manner suitable for the preschool age range.
223850552|NCT06630715|DRUG|Upadacitinib 15 MG [Rinvoq]|15 mg/ day
223850553|NCT06631885|PROCEDURE|regenerative endodontic procedure using blood clot according to AAE|regenerative endodontic procedure using blood clot to replace the necrotic pulp tissues in immature teeth with a pulp like to tissue to complete root development. using AAE protocol
223850554|NCT06631885|PROCEDURE|regenerative endodontic procedure using photo activated nanochitosan 2%|regenerative endodontic procedure using blood clot to replace the necrotic pulp tissues in immature teeth with a pulp like to tissue to complete root development. using photosensitized nanochitosan for root canal disinfection
223850555|NCT06628973|BEHAVIORAL|Social prescribing|The intervention consists of SP, wherein patients identified as having significant SDOH-related vulnerabilities on the SPARK questionnaire or during an interview will have a consultation with a LW who will provide them with social prescriptions. LWs are individuals who LINK individuals with social needs to existing community supports and services within the community
223850556|NCT04713514|DRUG|OSE2101|subcutaneous injection on day 1, every 3 weeks for 7 doses then every 6 weeks up to week 48 and then every 12 weeks until intolerance, disease progression, or up to 2 years.
223850557|NCT04713514|DRUG|Pembrolizumab 25 MG/ML [Keytruda]|400 mg IV infusion on day 1 every 6 weeks until intolerance, disease progression, or up to 2 years.
223850558|NCT06384430|DIAGNOSTIC_TEST|Shoulder functional tests and ultrasound|On the day of the study, demographic data will be collected from patients with a clinical diagnosis of impingement and who agree to participate in the study, then DASH and Constant Murley scores will be calculated and subacromial bursa thickness, supraspinatus tendon thickness, acromiohumeral distance, supraspinatus tendon thickness/acromiohumeral distance ratio will be calculated on ultrasound.
223850559|NCT01277445|DIETARY_SUPPLEMENT|Prebiotic|Inulin-fructan 15mg/day for 28days
223850560|NCT01277445|DIETARY_SUPPLEMENT|Prebiotic|Daily consumption of 15g inulin-fructan for 28 days
223850561|NCT05926271|DRUG|Clopidogrel|See arm description earlier.
223850562|NCT03137966|DRUG|Deferoxamine|Deferoxamine (0.66mg/ml) will be applied locally as a gel (3 times a week) for a period of maximum three months or until intact skin.
223850563|NCT03137966|DRUG|Placebo|Placebo will be applied locally as a gel (3 times a week) for a period of maximum three months or until intact skin.
223850564|NCT06489249|DRUG|Placebo|Oral placebo tablet
223850565|NCT06489249|DRUG|Salsalate 750 MG Oral Tablet [DISALCID]|Oral salsalate tablet
223850566|NCT04005521|BEHAVIORAL|Preventive intervention|Preventive, structured exercise protocol
223850567|NCT04210024|OTHER|Diabetes Empowerment Education Program|Individuals identified as Community Health Workers will participate in the Diabetes Empowerment Education Program (DEEP™). DEEP, is an education curriculum designed to help people with pre-diabetes, diabetes, relatives and caregivers gain a better understanding of diabetes self-care. Classes last a total of six weeks, providing participants with eight unique learning modules. Health literacy will be assessed before and after participating in DEEP.
223850568|NCT00121199|BIOLOGICAL|rituximab|Given IV
223850569|NCT00121199|BIOLOGICAL|bevacizumab|Given IV
223850570|NCT00121199|DRUG|cyclophosphamide|Given IV
223850571|NCT00121199|DRUG|doxorubicin hydrochloride|Given IV
223850572|NCT00121199|DRUG|vincristine sulfate|Given IV
223850573|NCT00121199|DRUG|prednisone|Given PO
223850574|NCT00121199|OTHER|laboratory biomarker analysis|Correlative studies
223850575|NCT05926505|DRUG|Placebo|Placebo is injected subcutaneously once daily for 4 weeks. After the period of 4 weeks, patients allocated to arm 1 will be shifted to subcutaneous treatment with 100mg anakinra once daily for 4 weeks.
223850576|NCT05926505|DRUG|Anakinra 149 MG/ML Prefilled Syringe [Kineret]|Anakinra is injected subcutaneously as 100 mg once daily for 4 weeks. After the first period the patients will be randomized 1:1 to continue receiving subcutaneous treatment with 100mg anakinra once daily for 4 weeks or placebo once daily for 4 weeks.
223850577|NCT02518893|OTHER|Demographic Data|Demographic data will be collected from up to 50 service members who have participated in health research or who have previously declined research participation.
223850578|NCT02518893|OTHER|Interview|Up to 40 service members will participate in individual, in-depth, semi-structured interviews in person or via telephone.
223850579|NCT01250951|DRUG|Deferasirox|
223850580|NCT04749433|DRUG|[11C]CPPC Injection|A single dose of \[11C\]CPPC (370 megabecquerel (MBq) (X±1 mCi)) intravenously and subsequent positron emission tomography (PET) scan.
223850581|NCT06631352|OTHER|Hepatopancreatoduodenectomy|Pancreatoduodenectomy with liver resection
223850582|NCT06631456|OTHER|PRP injection|A total of 3 doses of intra-articular PRP were applied to the symptomatic knees of the patients under ultrasound guidance, once a week.
223850583|NCT06631456|OTHER|Ozone therapy|A total of 3 doses of intra-articular ozone therapy were applied to the symptomatic knees of the patients under ultrasound guidance, once a week.
223850584|NCT04917432|PROCEDURE|intravascular ultrasound (IVUS)|Intravascular imaging using a specialized catheter delivered through intra-arterial approach to reach the coronaries to guide CTO-PCI procedure and optimize the results after wire crossing.
223850585|NCT04917432|PROCEDURE|Conventional CTO PCI (non-IVUS guided)|Non-IVUS guided CTO PCI for wiring but may be used for results optimization after wire crossing
223850586|NCT02232763|DRUG|Losartan|12 weeks of losartan or placebo with crossover to the other
223850587|NCT02232763|DRUG|Placebo|12 weeks of losartan or placebo with crossover to the other
223850588|NCT02680093|OTHER|Cervical length in pregnant women.|"Pregnant Women beyond the date of birth. will be followed while coming to routine monitoring. physiological parameter of cervical length will be measured as the differential predictor to determine their due date. the cervical length will be measured as part of routine gynecologic examination to women who come for routine over due date follow up.~additional medical data will be collected from the patient medical record.- demographic data, and all the routine prenatal medical care the women will receive up to the delivery.and delivery out comes."
223850589|NCT05335681|BEHAVIORAL|WARM SHOWER APPLICATION|Experimental group; At least when the cervical opening is 4 cm (Latent phase) and 7 cm (Active phase) While the 20-minute hot shower (37 °C) intervention was performed, the control group only will receive standard care. hot shower; sacrum, lower abdomen and groin areas will be applied. Since possible complications may be encountered, pregnant women The researcher will be accompanied and sit safely in the chair. will be provided. VAS scale twice, before and after the intervention will be applied. Birth satisfaction scale before discharge will be applied.
223850590|NCT01103973|BEHAVIORAL|Mind/Body Program|Ten week group mind/body program
223850591|NCT01103973|BEHAVIORAL|Control|Spa gift certificates
223850592|NCT02540044|BEHAVIORAL|ANSWER-2 decision aid|ANSWER-2 will consist of: 1) an Information Module that presents effectiveness and side effects of each treatment option, and 2) an interactive Value Clarification Module that guides patients to consider what matter to them the most, and the pros and cons of each treatment option. Within the Information Module, the decision support information (i.e., the benefits and harms of treatment options) will be presented in narrated text, graphics, and a series of animated patient stories demonstrating attributes required for effective communication with doctors and significant others.
223850593|NCT02540044|BEHAVIORAL|Control Group (TAS Consumer Guide)|The Arthritis Society Consumer guide pdf.
224265521|NCT07138625|BIOLOGICAL|Nebulized normal saline|Eligible patients with moderate bronchiolitis who met the inclusion criteria were randomly assigned in a 1:1 ratio to either the hypertonic saline (3%) group or the normal saline (0.9%) group. Randomization was performed using a computer-generated random number sequence prepared by an independent statistician not involved in patient recruitment or treatment. Allocation concealment was ensured through the use of sequentially numbered, opaque, sealed envelopes, which were opened only after patient enrollment and completion of baseline assessments.
224265522|NCT07140055|DRUG|BLX-7006|BLX-7006 Single or Multiple doses administered orally as a tablet
224265523|NCT07140055|DRUG|Placebo|Participants will receive matching placebo of BLX-7006 for each of the oral cohorts.
223850594|NCT04109118|BEHAVIORAL|Distress Tolerance - Benzodiazepine Discontinuation (DT-BD)|Distress Tolerance - Benzodiazepine Discontinuation (DT-BD) is a psychosocial intervention. It is paired with a benzodiazepine taper. The aim of the psychosocial intervention is to improve individuals' ability to tolerate distress in order to assist benzodiazepine discontinuation in patients treated with OAT. There will be 5 sessions between therapist and participant prior to the start of the benzodiazepine taper. The taper for both the intervention and control conditions occurs over 9 weeks and involves weekly meetings with a benzodiazepine prescriber during which a gradual benzodiazepine dose reduction will take place. The DT-BD intervention combines elements of existing psychosocial interventions. Specifically, interoceptive exposure techniques will be paired with elements of acceptance and commitment therapy (ACT) and relapse prevention (RP).
223850595|NCT04109118|DRUG|BZD discontinuation protocol|All participants will undergo BZD discontinuation. Once the starting BZD dose is determined by prescription monitoring and/or self-report, we will maintain participants on this dose until the start of the BZD taper. Participants will see a study physician weekly to receive their BZD medication for the week until the taper is completed. BZD discontinuation in this study will consist of a gradual BZD taper in dose over 9 weeks. The taper will be flexible in that the study physician will utilize clinical judgement to lengthen the taper if necessary, depending on the severity of the participant's withdrawal symptoms. Anchor points will be set (33% reduction in dose after 2 weeks, 50% mid-treatment, 100% by week 8) to emphasize the time-limited nature of the taper.
223850596|NCT01830842|DRUG|Nicotine polacrilex|nonsmokers will be measured following nicotine administration
223850597|NCT01830842|DRUG|Placebo|nonsmokers will be measured following placebo administration
223850598|NCT01830842|OTHER|satiety|smokers will be measured in a smoking satiated condition
223850599|NCT01830842|OTHER|abstinence|smokers will be measured following 24-hours of smoking abstinence
223850600|NCT03235349|DRUG|Glecaprevir/Pibrentasvir|Coformulated tablet for oral administration
223850601|NCT04432974|DEVICE|Automatic closed-loop anesthesia|Total intravenous anesthesia performed with the ACTIVA automatic control system
223850602|NCT03553615|DRUG|Ivermectin Pill|oral anti-parasitic agent taken as a weekly dose for four weeks
223850603|NCT03618472|DRUG|Metformin Hydrochloride 850 MG|Regular strength metformin (850 mg/tab)
223850604|NCT03618472|DRUG|Placebo Oral Tablet|Starch based placebo manufatured to mimic Metformin 850 mg
223850606|NCT06460363|DEVICE|Transcranial alternating current stimulation (TACS)|Transcranial alternating sinusoidal current at frequency of 40 Hz applied for 60 min through a pair of saline-soaked surface sponge electrodes.
223850607|NCT06460363|DEVICE|Sham TACS|Sham treatment with few seconds of actual electrical current and same electrode configuration
223850608|NCT06000969|DEVICE|Lung Recruitment Conventional|the recruitment maneuver will be performed by manual inflation with a pressure of 30 cmH2O for 30 seconds.
223850609|NCT06000969|DEVICE|Lung Recruitment Ultrasound|the recruitment maneuver will be performed under the direct real-time guidance of ultrasound if atelectasis (defined as LUS of ≥ 2 for any of the 12 regions) is present. This will be done by manual inflation with a pressure of 10 cmH2O for 10 seconds, increased 10 cmH2O every 10 seconds until no collapsed areas are visible on the ultrasound, the maximum airway pressure will be limited to 40 cmH2O. This could be repeated if needed.
223850610|NCT05202080|OTHER|Opioid Counseling and Pain Coping Skills Video|The intervention will be in the form of a video of a PowerPoint presentation with instructions and exercises designed to coach patients about catastrophizing, coping skills, mindfulness and behavioral modification techniques, in addition to providing education regarding postoperative analgesia and opioid use.
223850611|NCT05761509|DRUG|Doravirine|The study treatments will used during 28 days according to the routine care of each investigator center.
223850612|NCT03834844|BEHAVIORAL|Meditation|Guided Meditation for 10-15 minutes daily for 6 days/week for 6 weeks
223850613|NCT03834844|OTHER|AF Education|6 weekly education modules on topics related to AF
223850614|NCT03834844|OTHER|Phone Calls|Weekly phone call to discuss patient concerns or questions
223850615|NCT05735847|PROCEDURE|Total Knee Arthroplasty (TKA)|The choice between TKA and UKA is based on the radiological presentation of the knee KOA on an x-ray. A surgery with TKA involves the replacement of both the medial and lateral compartments of the knee.
223850616|NCT05735847|PROCEDURE|Unicompartmental Knee Arthroplasty (UKA)|The choice between TKA and UKA is based on the radiological presentation of the knee KOA on an x-ray. A surgery with UKA involves the replacement of one compartment.
223850617|NCT05464108|DIAGNOSTIC_TEST|The diagnosis of Artificial Intelligence and endosopists|Endosopists and AI will assess the EGGIM score independently when the patients is eligible. In addition, they can not see the OLGIM score of the patients.
223850618|NCT04114396|DRUG|Anti-IL5 Antibody|Asthma group: Anti-IL5 treatment Control group: No biologic.
223850619|NCT04114396|PROCEDURE|Bronchoscopy|Optional for both arms
223850620|NCT02632916|DRUG|Zoledronic Acid|Intravenous zoledronic acid 0.025mg/kg at baseline, 6 months, 12 months and 18 months
223850621|NCT02632916|DRUG|Denosumab|Subcutaneous denosumab 1.0mg/kg at baseline, 6 months, 12 months and 18 months
223850622|NCT01870609|DRUG|defactinib (VS-6063)|
223850623|NCT01870609|DRUG|Placebo|Sugar pill manufactured to mimic defactinib tablet
223850624|NCT01639443|OTHER|Predictive no-show overbooking|"During intervention period, every Veteran scheduled for an endoscopy will be offered fast-track offer, which gives them a chance to get their endoscopy procedure done earlier than usual scheduling by overbooking their appointment in a predictive no-show slot."
223850625|NCT03400098|DRUG|Inotersen|Inotersen administered by subcutaneous (SC) injections in the abdomen, thigh, or upper arm
223850626|NCT04887272|OTHER|Supervised Exercise Training Protocol|EXT: Supervised EXT will include a progressive individualized program that combines aerobic and resistance protocols. Volume progression will begin with 3-days of supervised training sessions/wk and will increase by 1 session/wk to a maximum of 5-days/wk. Each EXT session will include 30 minutes of aerobic training (15 minutes cycling; 15 minutes treadmill walking/running/elliptical) and 30 minutes of resistance training (specifics below). Considering individual fatigue will be a concern, therefore similar to exercise training standards in COPD, the duration of rest periods may be extended (\~1-3 min) as needed, however, all exercise durations will be completed within a 1.5-hour time slot. On days that EXT and IMET interventions overlap, the training and IMET will be spread out over a 2-hour session as opposed to the 1.5-hour time slot.
223850627|NCT04887272|OTHER|Inspiratory Muscle and Exercise Training|Inspiratory Muscle Training (IMT): All IMT sessions will be performed similar to EXT, with the exception of having 2-3-sessions of at-home IMT training depending on where in the exercise progression the individual is (i.e., Week1 vs week 6). On the days that IMT and exercise training overlap, all training will be spread out over a 2-hour session with periods of IMT training occurring at the beginning, middle and end of the session. Each week will include a measure of Maximal Inspiratory Pressure (MIP) and a Test of Inspiratory Respiratory Endurance (TIRE). The intensity of the IMT will be 50% of the weekly MIP, thus progressive increases in IMT threshold intensity will remain at 50% of the weekly MIP. In contrast, the TIRE protocol will assess respiratory endurance based on the relative baseline intensity. Thus TIRE testing will begin at a MIP intensity of 50% (weeks 1-2), and then progressing to 65% (weeks 3-4), and 80% (weeks 5-6).
223850628|NCT00057382|DRUG|T138067 intravenous|
223850629|NCT00057382|DRUG|doxorubicin intravenous|
223850630|NCT04485741|DEVICE|RESP|The RESP device will be placed on the patient for periodic recording of auscultory sound.
223850631|NCT05803330|DRUG|Abandonment of intravenous volume expansion during preoperative preparation in patients with pheochromocytoma|Abandonment of intravenous volume expansion with alpha-blockers during preoperative preparation in patients with pheochromocytoma
223850632|NCT02842658|OTHER|A high-intensity interval exercise group|To avoid or reduce muscle soreness or cramps, adequate warm-up is suggested
223850633|NCT02842658|OTHER|An Attention-Control Group|Patients will be contacted weekly to access physical activity. To avoid or reduce muscle soreness or cramps, adequate warm-up is suggested
223850634|NCT05216237|DRUG|Sintilimab 200 mg, intravenously (IV) every 3 weeks(Q3W)|for 2-6 cycles followed by Sindilizumab plus Tegafur gimeracil oteracil potassium capsules.
223850635|NCT00964717|PROCEDURE|real chiropractic|real chiropractic manipulation
223850636|NCT00964717|PROCEDURE|Sham Chiropractic|Placebo stimulation using 'activator' thumper
223850637|NCT05586451|BEHAVIORAL|Traditional High Load Resistance Exercise (HLRE)|Participants will then perform 75% of tested 1RM for 3 sets of 12 repetitions at a pace of 1 repetition every 2 seconds on the dominant leg with one-minute rest between sets. After completing the HLRE protocol, participants will perform 2 post-exercise maximal voluntary contractions.
223850638|NCT05586451|BEHAVIORAL|Low Load Resistance Exercise with Blood Flow Restriction (LLBFR)|Participants will then perform 25% of tested 1RM for sets of 30, 15, 15, and 15 repetitions on the dominant leg at a pace of 1 repetition every 2 seconds with one-minute rest between sets. Participants will be fitted with an occlusion cuff on the proximal portion of the thigh. The limb occlusion pressure will be set at 60% blood flow occlusion and remain occluded throughout the exercise (Delfi Medical Innovations Personal Tourniquet System).
223850639|NCT05586451|BEHAVIORAL|Moderate Load Resistance Exercise with Blood Flow Restriction (MLBFR)|Participants will then perform 50% of tested 1RM for sets of 15, 8, 7, and 7 repetitions on the dominant leg at a pace of 1 repetition every 2 seconds with one-minute rest between sets. Participants will be fitted with an occlusion cuff on the proximal portion of the thigh. The limb occlusion pressure will be set at 60% blood flow occlusion and remain occluded throughout the exercise (Delfi Medical Innovations Personal Tourniquet System).
223850640|NCT01762371|OTHER|Khalifa Therapy|One hour of Khalifa's therapy which is specially applied pressure to the skin.
223850641|NCT02814825|OTHER|ViviGen|ViviGen Cellular Bone Matrix is a formulation of cryopreserved viable cortical cancellous bone matrix and demineralized bone. ViviGen is a Human Cells, Tissues, and Cellular and Tissue-based Product (HCT/P) as defined by the U.S. Food and Drug Administration in 21 CFR 127 1.3(d).
223850642|NCT05756998|DEVICE|Copper T380 IUD ( Paragard 380 A ,CooperSurgical, Inc. © 2022) (classic technique)|During CS , placement of CuT380 IUD at the top of the uterine fundus with ring forceps or manually; before closing the uterine incision, the strings were placed in the lower uterine segment. If the cervix was closed, dilatation from above with ring forceps or manually. Strings passed through the cervix with ring forceps, then checking that IUD remains at the fundus of the uterus prior to closing the uterine incision. The surgeon took a good care not to include IUD strings within the sutures. Six weeks postpartum; Patients will be questioned for any symptoms of complications or side effects. Pelvic examination (per speculum) and transvaginal ultrasound will be performed. Patient satisfaction will be assessed: pain using (VAS score), missed threads.
223850643|NCT05756998|DEVICE|Copper T380 IUD ( Paragard 380 A ,CooperSurgical, Inc. © 2022) ( New technique)|During CS, the plunger will be removed, the introducer remains in place and the arms of the IUD were released to be in a transverse position. The introducer will be inserted in the cervical canal through the uterine incision, threads might be shortened if needed or if couldn't be advanced into the cervical canal, The introducer containing the IUD will be then pushed upwards , towards the uterine fundus.The IUD will be placed at the uterine fundus and the IUD will be stabilized at its fundal position by grasping the fundus between the thumb anteriorly and the other fingers posteriorly. The uterine incision was closed while the introducer is in situ , then the introducer will be removed vaginally at the end of CS. Six weeks postpartum; Patients will be followed as in the classic technique group.
223850644|NCT05756998|PROCEDURE|cesarian section|Under general or spinal anathesia , the abdomen is opened in layers , the bladder is dissected downwards . The uterus is incised at its lower segment \& the fetus is extracted , followed by the placenta \& membranes . The CU T 380 IUD is inserted either by the classic technique or the standard technique . The uterus is closed in 2 layers by continous non - locked sutures .Proper hemostasis \& closure of the abdomen in layers .
223850645|NCT05899764|DRUG|Brivaracetam|"* Intravenous administration: 25 mg or 50 mg will be administered depending on its effects on epileptic activity during a hospital stay where simultaneous EEG and depth electrode recordings will be measuring epileptic activity.~* Oral administration: Subjects will take 25mg or 50mg twice a day for 12 months. The dosage will depend on its effects on epileptic activity. Brivaracetam levels will be measured on months 3, 6 and 12."
223850646|NCT02728986|DEVICE|Profore|Profore multilayer compression bandage + standard regimen for wound care according to investigator's choice
223850647|NCT02728986|DEVICE|Coban2|Coban2 compression system + standard regimen for wound care according to investigator's choice
223850648|NCT04714411|DRUG|Omadacycline|Omadacycline monotgherapy
223850649|NCT04784741|OTHER|Conventional static hamstring muscle stretching|Static stretching protocol had 10 repetitions in total with 15 seconds stretch time and 30 seconds relaxing time of hamstring muscle.
223850650|NCT04784741|DEVICE|Low amplitude whole body vibration therapy|"Given five sessions of low amplitude whole body vibration therapy for duration of 10 minutes, on alternative days, along with static stretching of hamstring muscles.~Static stretching protocol had 10 repetitions in total with 15 seconds stretch time and 30 seconds relaxing time of hamstring muscle."
223850651|NCT04784741|DEVICE|Biodex Balance System|Pre and post balance assessment by Biodex balance system
223850652|NCT04784741|PROCEDURE|Range of motion of hamstring muscle|Straight Leg Raising to check pre and post Range of Motion by using Goniometer
223850653|NCT01403675|PROCEDURE|Ovarian autotransplantation|There are two ways to transplant the thawed ovarian tissue back into a woman's body. It can be put back inside the abdomen, close to the natural location of the ovaries, or the tissue can be put under the skin of the abdomen. After you have had the transplant, your hormone function will be tested every month. Each month, you will have a blood draw to measure hormones and an ultrasound to see how the tissue is growing. These monthly visits will continue until you have normal hormone levels. If the transplant is successful, it is expected that your hormones would return to normal in 3 - 7 months. If your hormone levels return and stay regular for three months, then Dr. Kim will talk to you about trying to get pregnant. The method of getting pregnant will depend on the type of transplantation surgery you had and your current medical condition. You will have weekly blood tests and other tests to determine the best way to get pregnant.
223850654|NCT02611232|DRUG|Victoza®|Daily subcutaneous injections with increasing doses up to 1.8 mg per day. Duration of treatment 6 months. Duration of follow-up 24 months.
223850655|NCT02611232|DRUG|Placebo|Daily subcutaneous injections with increasing doses up to 1.8 mg per day. Duration of treatment 6 months. Duration of follow-up 24 months.
223850656|NCT00044928|DRUG|Piperacillin/Tazobactam|
223850657|NCT06494748|OTHER|Follow up Decision|"0: No need to follow up in Intensive Care Unit~1: Need to follow up in Intensive Care Unit"
223850658|NCT05756439|DRUG|Intravenous Sedatives with or Without Analgesia|Participants having dental surgery with conscious intravenous sedation
223850659|NCT05756439|DRUG|No IV sedation|Participants having dental surgery without conscious intravenous sedation
223850660|NCT01888718|DRUG|Fexofenadine Hydrochloride|Fexofenadine Hydrochloride Orally Disintegrating Tablets 30 mg
223850661|NCT04985383|DEVICE|AKST1210 S-15 at 250 mL/min|Procedure: Hemodialysis, AKST1210 column size 150mL and blood-flow rate at 250mL/min
223850662|NCT04985383|DEVICE|AKST1210 S-15 at 450 mL/min|Procedure: Hemodialysis, AKST1210 column size 150mL and blood-flow rate at 450mL/min
223850663|NCT04985383|DEVICE|AKST1210 S-25 at 250 mL/min|Procedure: Hemodialysis, AKST1210 column size 250mL and blood-flow rate at 250mL/min
223850664|NCT04985383|DEVICE|AKST1210 S-25 at 450 mL/min|Procedure: Hemodialysis, AKST1210 column size 250mL and blood-flow rate at 450mL/min
223850665|NCT04985383|DEVICE|AKST1210 S-35 at 250 mL/min|Procedure: Hemodialysis, AKST1210 column size 350mL and blood-flow rate at 250mL/min
223850666|NCT04985383|DEVICE|AKST1210 S-35 at 450 mL/min|Procedure: Hemodialysis, AKST1210 column size 350mL and blood-flow rate at 450mL/min
223850667|NCT03909581|PROCEDURE|Endoscopic coronary arterial bypass|is defined, for the purposes of this trial, as a planned off-pump minimally invasive (sternal-sparing), isolated LIMA-LAD revascularization (50 participants)
223850668|NCT03909581|PROCEDURE|Percutaneous Coronary Intervention|will be performed using standard techniques at the discretion of the operator (50 participants)
223850669|NCT02207361|DRUG|Paclitaxel, Carboplatin|Paclitaxel: 175mg/m2, IV, d1 Carboplatin: AUC 5, IV, d1 Every 21 days to 1 course of treatment.
223850670|NCT02207361|DRUG|Paclitaxel, Epirubicin|Paclitaxel: 175mg/m2, IV, d1 Epirubicin: 60-80mg/m2, IV, d1 Every 21 days to 1 course of treatment.
223850671|NCT05601843|DEVICE|Transcutaneous Electrical Nerve Stimulation (TENS)|TENS pads will be applied in a frame pattern around the area of maximal pain, as pointed out by the patient. The pads will be no more than 6 cm and no less than 3 cm away from the subjective area of maximal pain. The frequency of the TENS machine will be set to 100 Hz and the patient will be instructed on how to increase and decrease the amplitude based on their comfort. The patient will also be instructed on how to turn off the machine if they wish for any reason. Research assistants will be standing by during the intervention period to intervene if the patient requires assistance with the device.
223850672|NCT04145687|DRUG|Metformin|Metformin 500mg tid
223850673|NCT00006480|BIOLOGICAL|aldesleukin|
223850674|NCT00006480|BIOLOGICAL|therapeutic autologous lymphocytes|
223850675|NCT00006480|DRUG|chemotherapy|
223850676|NCT00006480|DRUG|ganciclovir|
223850677|NCT01729871|DRUG|rivaroxaban|rivaroxaban 20 mg orally, once-daily, administered preferably with the evening meal
223850678|NCT01729871|DRUG|uninterrupted vitamin K antagonist (VKA)|dose-adjusted vitamin K antagonist (VKA) to achieve a recommended International Normalized Ratio (INR) of 2.0 to 3.0
223850679|NCT03530280|DRUG|pregabalin (lyrica)|preoperative pregabalin and the postoperative sham block will perform.
223850680|NCT03530280|DRUG|Placebo oral tablet|The preoperative placebo oral tablet and the postoperative sham block will perform.
223850681|NCT03530280|DRUG|adductor canal block including bupivacaine|The preoperative placebo oral tablet and adductor channel block including 10 mL of 0.25% bupivacaine with 5 μg/mL epinephrine
223850682|NCT04228770|BEHAVIORAL|Meeting with pharmacist|Meeting with pharmacist to support drug management following their routine surgery.
223850683|NCT00515138|DRUG|Rituximab, Ifosfamide, Carboplatin, Etoposide, Bortezomib|Bortezomib starting at 1 mg/m(2), and escalating to 1.3, 1.5, 1.7. Bortezomib will be given on Days 1 (prior to rituximab) and 4, rituximab at 375 mg/m(2) on day 1, carboplatin AUC 5 and ifosfamide with mesna, each 5 mg/m(2), on day 3 and etoposide 100 mg/m(2)/day on days 2, 3, and 4 of a 21-day cycle. They will also receive filgrastim on days 6-13 or pegfilgrastim on day 6
223850684|NCT04094909|DRUG|Rh-endostatin|"Squamous NSCLC: Rh-endostatin+Pembrolizumab+carboplatin or cisplatin +\[nab\]-paclitaxel during the treatment. Rh-endostatin+Pembrolizumab during the maintenance period.~Non-squamous NSCLC: Rh-endostatin+Pembrolizumab+carboplatin or cisplatin +pemetrexed during the treatment. Rh-endostatin+Pembrolizumab + pemetrexed during the maintenance period."
223850685|NCT03199716|OTHER|Parent mentors|Parent mentors are to meet up with their assigned intervention group 4 times in 1 year and call the families monthly to document any diabetic complications
223850686|NCT00406289|PROCEDURE|18F-FDG-PET radiotherapy|
223850687|NCT03390556|OTHER|Nurse-delivered education|"The nurse will:~1. Give the caregiver and child an overview of asthma, and discuss asthma control, triggers, and medications.~2. Give caregivers information about asthma management written at or below 6th grade reading levels.~3. Provide colored medication labels to distinguish controller from rescue medications following the action plan color scheme (green for controller medications, red for rescue medications). Teach-back methods will be used to elicit understanding of correct indications of use.~4. Demonstrate MDI/spacer technique with teach-back.~5. Discuss age-appropriate caregiver and child responsibility for asthma management within the family, with an overview of transitioning responsibility.~6. Ask patients to make a 1 month follow-up appointment for asthma care."
224265524|NCT07138508|DRUG|Nicorandil 20mg|Oral nicorandil 20mg
224265525|NCT07139379|OTHER|task-oriented training|Motor training targeted to goals that are relevant to the functional needs of the patient
224265526|NCT07139379|OTHER|Virtual Reality Mirror Therapy|Virtual Reality Mirror Therapy using goggle
224265527|NCT07139379|OTHER|Virtual Reality-Based Generative Bimanual Cooperative Task-Oriented Mirror Therapy|Virtual Reality-Based Generative Bimanual Cooperative Task-Oriented Mirror Therapy using goggle
224265528|NCT07139808|DEVICE|GK5 CGKM|Wear for a consecutive 15 days
224265529|NCT07139184|DIAGNOSTIC_TEST|Diagnosis of Charcot foot disease|Diagnosis of Charcot foot disease will be obtained from the results of physical examination and according to x-ray examination of foot which was performed at the Radiology Department of Assiut University Hospital. The Eichenholtz classification system, developed by Sidney N. Eichenholtz in 1966, categorizes Charcot arthropathy (also known as Charcot foot) into three stages based on clinical and radiographic findings. These stages are development, coalescence, and reconstruction
224265530|NCT07139184|DIAGNOSTIC_TEST|Hematologic and biochemical parameters,|"Hematologic and biochemical parameters, including lymphocyte, monocyte, neutrophil, and platelet counts, as well as glucose, HbA1c, triglyceride (TG), HDL, and LDL levels, will be extracted from patient records.~NLR=absolute neutrophil count (109/L)/absolute lymphocyte count (109/L), PLR=platelet count (109/L)/absolute lymphocyte count (109/L), LMR=absolute lymphocyte count (109/L)/absolute monocyte count (109/L), GLR=glucose (mg/dL)/absolute lymphocyte ratio (109/L), TGR=triglyceride (mg/dL)/glucose ratio (mg/dL), THR=triglyceride (mg/dL)/HDL ratio (mg/dL), SIRI = absolute neutrophil count (109/L) × absolute monocyte count (109/L)/ absolute lymphocyte count (109/L), SII = platelet count (109/L) × absolute monocyte count (109/L)/absolute lymphocyte count (109/L), TyG index = fasting triglyceride (mg/dL) × fasting plasma glucose (mg/dL)/2, PIV =absolute neutrophil count (109/L) × platelet count (109/L) × absolute monocyte count (109/L)/absolute lymphocyte count (109/L)."
224265531|NCT07139184|DIAGNOSTIC_TEST|ELIZA Assay|For each patient, 2 ml of blood will be obtained. The serum levels of IL-10, TNF-α will be assessed by using (ELISA) kit obtained from (Biodiagnostic company, Egypt) according to the manufacturer protocol.
224265532|NCT07140302|PROCEDURE|deep brain stimulation|"Stereotactic implantation of DBS electrodes with chronic electrical stimulation of target nuclei for dystonia.~or Stereotactic radiofrequency ablation of dystonia-related target nuclei."
224265533|NCT07138859|DEVICE|Robot assisted radical right hemicolectomy (D3 lymph node dissection)|RRH (Robotic Right Hemicolectomy) group: Experimental group: Performing robotic radical right hemicolectomy (D3 lymph node dissection)
223850688|NCT03882515|OTHER|Myofascial Release|With the right hand in hand exerts caudal pressure in the superior fibers of the muscle, both sides by a minute and a half each. In the ventral decubitus, apply pressure and slip from T12 to the base of the skull nine times. Thumb in the individual's acromion and with the other to hold the pressure and slide in the direction of the other acromion three times. Hand at the base of the skull and with the contralateral tenar region perform pressure and slip in caudal direction on both sides by three times. Hand at the base of the skull and with the contralateral thumb exerting pressure and slip of C3 the distal insertion of the upper fibers on both sides. Thumbs at the base of the skull, exerting lateral traction of the fascia in opposite directions. Dorsal decubitus, thumbs above clavicles, perform detachment of fibers for one and a half minutes. Patient sitting, support the head of the metacarpals beside the spinous process from T1 to T12 and exert pressure and slip three times each.
223850689|NCT03882515|OTHER|Continuous Surface Slip Technique|"1. Individual in the ventral decubitus, position the entire palmar surface bilaterally in the spinous process of T1 in the caudal direction, performing superficial smoothing in a smooth and rhythmic movement up to T12.~2. Return of the hands from the caudal direction towards the cranial direction, bypassing the lateral borders of the trapezius muscle following the direction of the inferior, middle and superior fibers.~3. Continue surface smoothing with a smooth and rhythmic movement until the distal insertion of the trapezius upper fibers into the skull and resume step 1 slowly and continuously for 10 minutes."
223850690|NCT03882515|OTHER|Without intervention|Evaluation and re-evaluation without intervention
223850691|NCT03477682|OTHER|Early ambulation|Patients who are in the experimental arm will have a shorter duration of bedrest restriction following sartorius surgery (1 day) versus the standard group (5 days bedrest).
223850692|NCT05926791|OTHER|Cosmetic product|The educated group receives the cosmetic product SPF50+ according to the randomization list established at V1 and returns the products at V2
223850693|NCT01452490|DEVICE|Diode Laser Treatment|Laser treatment once every 6 weeks, for a total of 4 treatment sessions
223850694|NCT00809874|DIETARY_SUPPLEMENT|Casein|
223850695|NCT00809874|DIETARY_SUPPLEMENT|Whey Isolate|
223850696|NCT00809874|DIETARY_SUPPLEMENT|Whey Hydrolysate|
223850697|NCT00809874|DIETARY_SUPPLEMENT|Alphalact-Albumin|
223850698|NCT06369129|PROCEDURE|Orbital floor reconstruction with Patient Specific Zirconia Implant|Orbital floor reconstruction with Patient Specific Zirconia Implant will be done
223850699|NCT06369129|PROCEDURE|Orbital floor reconstruction with Patient Specific Titanium Implant|Orbital floor reconstruction with Patient Specific Titanium Implant will be done
223850700|NCT05005169|DIAGNOSTIC_TEST|SGB PCR|"This is a multi-center, randomized cluster and crossover study, and is open-label. The cluster is defined by the hospital center. Each center will therefore experiment with both strategies and the hospital centers will be randomized according to two arms:~* Arm n°1 : 1st period with SGB culture strategy and 2nd period with SGB PCR strategy.~* Arm n°2 : 1st period with SGB PCR Strategy and 2nd period with SGB culture Strategy Each inclusion period will last 6 weeks, with a 1-month wash-in period before each of the two inclusion periods of the study (training of the teams in intrapartum PCR detection). A wash-out period is not necessary in this study because the PCR machine will be removed from the centers when switching to the GBS culture strategy.~During these two periods, all patients meeting the inclusion and non-inclusion criteria will be included in the study after presentation of the study and oral consent."
223850701|NCT05005169|DIAGNOSTIC_TEST|SGB culture|"This is a multi-center, randomized cluster and crossover study, and is open-label. The cluster is defined by the hospital center. Each center will therefore experiment with both strategies and the hospital centers will be randomized according to two arms:~* Arm n°1 : 1st period with SGB culture strategy and 2nd period with SGB PCR strategy.~* Arm n°2 : 1st period with SGB PCR Strategy and 2nd period with SGB culture Strategy Each inclusion period will last 6 weeks, with a 1-month wash-in period before each of the two inclusion periods of the study (training of the teams in intrapartum PCR detection). A wash-out period is not necessary in this study because the PCR machine will be removed from the centers when switching to the GBS culture strategy.~During these two periods, all patients meeting the inclusion and non-inclusion criteria will be included in the study after presentation of the study and oral consent."
223850702|NCT04401722|PROCEDURE|PANCREATICODUDENECTOMY|dissection and removal of periampulary tumour with 3 reconstruction PJ, HJ, and GJ
223850703|NCT03486340|PROCEDURE|Cardiologic assessment|Aggressive ischemic risk factor management
223850704|NCT01066260|DIETARY_SUPPLEMENT|Probiotic formulation|Twice a day for 24 days
223850705|NCT01066260|OTHER|Placebo|Twice a day for 24 days
223850706|NCT00819910|DRUG|Rosiglitazone|Rosiglitazone 8mg daily for 12 weeks
223850707|NCT00819910|DRUG|Placebo (Rosiglitazone)|Placebo (Rosiglitazone) 8mg daily for 12 weeks
223850708|NCT00819910|DRUG|Placebo (Fenofibrate)|Placebo (Fenofibrate) 145 mg daily for 12 weeks
223850709|NCT00819910|DRUG|Fenofibrate|Fenofibrate 145 mg daily for 12 weeks
223850710|NCT00003891|DRUG|lurtotecan liposome|
223850711|NCT04449744|OTHER|MySafeRx Inspire Plus|The MySafeRx™ platform is a combination of several key components, including daily videoconferencing check-ins with motivational interviewing-based recovery coaching, text-messaging reminders, secure storage of buprenorphine/naloxone medication within a secure electronic pill dispenser, and a standardized protocol for supervising self-administration of medication via videoconferencing.
223850712|NCT04449744|OTHER|MySafeRx Inspire Flex|The MySafeRx™ platform is a combination of several key components, including daily videoconferencing check-ins with motivational interviewing-based recovery coaching, text-messaging reminders, secure storage of buprenorphine/naloxone medication within a secure electronic pill dispenser, and a standardized protocol for supervising self-administration of medication via videoconferencing. Based on clinical need, the participant may be assigned an electronic pill dispenser for the duration of the study by their clinical team.
223850713|NCT00836069|DRUG|No drug name provided by Sponsor; drug referenced as PD 0332334|Experimental study drug for generalized anxiety disorder, oral tablet, at a total daily dose of 450mg or 600mg, twice daily for 8 weeks and then 2 weeks of dose tapering.
223850714|NCT00836069|DRUG|Paroxetine|FDA Approved medication for generalized anxiety disorder, oral tablet, at 20mg, once daily for 8 weeks and then 2 weeks of dose tapering.
223850715|NCT00836069|DRUG|Placebo|inactive substance, oral tablet, once per day, for 10 weeks.
223850716|NCT02537899|DRUG|NeuroAiD|
223850717|NCT00903721|DRUG|mometasone furoate|"Metered-dose spray type suspension containing 50 μg mometasone furoate per spray. 2 sprays per nostril twice daily (total daily dose 200 μg)~Duration: up to 6 months"
223850718|NCT03229798|DRUG|Sumatriptan Succinate Oral Tablet|Sumatriptan succinate commercial Imitrex 100 mg tablet
223850719|NCT03229798|COMBINATION_PRODUCT|Transdermal delivery of sumatriptan succinate|Sumatriptan succinate transdermal drug delivery system
223850720|NCT00871429|OTHER|Lindi skin care products|"Subjects will then be instructed to apply all three products daily for 1 month.~The products include: Lindi Skin soothing balm (product A), Lindi Skin face serum (product B, and Lindi Skin face wash (product C)."
223850721|NCT05548530|PROCEDURE|Stereotactic intracranial hematoma puncture|Check the CT scan of the patient's brain, find out the largest hematoma level of the patient, measure the coordinates of the puncture center, locate and mark the skull surface according to the coordinates obtained from the measurement, select the puncture point under the stereotaxic instrument, and mainly avoid important blood vessels , nerves and functional areas. Use an electric drill to drill the puncture needle into the center of the hematoma, and slowly aspirate the hematoma from the side hole until the suction stops when there is resistance. The residual hematoma in CT and the location of the drainage tube were determined, and the position of the puncture needle was adjusted for the situation of brain CT. After the operation, according to the re-examination of cranial CT, urokinase was injected into the hematoma cavity through the drainage tube to dissolve the residual hematoma, and the operation process strictly followed aseptic operation.
223850722|NCT05548530|PROCEDURE|decompressive craniectomy|Prior to the procedure, all patients obtained endotracheal intubation under general anesthesia following the informed consent provided by their family members. Upon identifying the hematoma's location through CT imaging, the surgeon made a linear or horseshoe-shaped incision on the scalp and subsequently opened the dura mater after creating a bone flap. The hematoma was punctured using a brain needle, allowing for effective decompression. The cerebral cortex was incised along the cerebral gyri, facilitating the separation of brain tissue to eliminate residual hematoma. Once hemostasis was ensured within the operative area, a silicone drainage tube was inserted, and the cranial bone flap was restored to its original position. In cases of severe brain edema or cerebral herniation, bone flap decompression was performed.
223850723|NCT05548530|PROCEDURE|Neuroendoscopic|The patient's preoperative CT and MR imaging data were fused with a neuronavigation system to avoid important functional areas and select the closest point of the hematoma to the cortex as the location point. Routine craniotomy was performed with a 2\*3 cm bone window, the puncture direction was repositioned by neuronavigation, the sheath was placed at the center of the hematoma, the core was removed, the endoscope was gradually aspirated, and the bleeding was stopped with electrocoagulation if there was considerable active bleeding. A drainage tube was placed, the bone flap was reset after surgery, and the scalp was sutured.
223850724|NCT01912495|DRUG|Boceprevir|
223850725|NCT02304653|OTHER|Clinical descision making|Chage in diagnosis before and after the presentation of the reults of CRP and Leucocytes
223850726|NCT06285175|OTHER|Tele-REINVENT|Tele-REINVENT consists of EMG-biofeedback of the affected arm to control games on a computer screen.
223850727|NCT03323840|OTHER|Incentivized Care|Patients will receive a $10 gift card for every blood pressure measurement (up to 2 times/month)
223850728|NCT00898274|OTHER|immunoenzyme technique|Participants undergo blood sample collection. Samples are used to measure levels of antioxidant enzymes (i.e., glutathione, glutathione peroxidase, glutathione reductase, superoxide dismutase, and reduced glutathione) and biomarkers of oxidative stress and DNA damage in leukocytes (i.e., thiobarbituric acid reactive substances \[TBARS\] and 8-hydroxydeoxyguanosine). Samples are analyzed via antioxidant enzyme assay, TBARS assay, and enzyme-linked immunosorbent assay.
223850729|NCT00898274|OTHER|laboratory biomarker analysis|Participants undergo blood sample collection. Samples are used to measure levels of antioxidant enzymes (i.e., glutathione, glutathione peroxidase, glutathione reductase, superoxide dismutase, and reduced glutathione) and biomarkers of oxidative stress and DNA damage in leukocytes (i.e., thiobarbituric acid reactive substances \[TBARS\] and 8-hydroxydeoxyguanosine). Samples are analyzed via antioxidant enzyme assay, TBARS assay, and enzyme-linked immunosorbent assay.
223850730|NCT03722433|DRUG|Vigiis 101-LAB and sequential therapy|Vigiis 101-LAB is the probiotic containing Lactobacillus paracasei subsp. Paracasei, which is the isolate from Taiwanese by Prof. Pan. This strain is resistant to gastric acid and bile acid. Therefore, its survival rate in the gastrointestinal tract could be as high as 95%. Previous studies showed that Vigiis 101-LAB can modulate the gut microbiota, with 10% increase in Bifidobacterium species and 20% reduction in Clostridium difficile.
223850731|NCT03722433|DRUG|Placebo and sequential therapy|Placebo without Vigiis 101-LAB component
223850732|NCT05380232|BEHAVIORAL|Leisure-time physical activity|Self-reported leisure-time physical activity, categorized as; zero (reference), \>0-7.49 MET-hrs/week, 7.5-14.9 MET-hrs/week, or ≥15 MET-hrs/week.
223850733|NCT00196170|PROCEDURE|RF ablation of the cavo-tricuspid isthmus|8mm tip ablation catheter is used for the radiofrequency ablation of the cavo-tricuspid isthmus in typical atrial flutter
223850734|NCT00196170|PROCEDURE|cryo ablation of the cavo-tricuspid isthmus|Cryo 10mm tip ablation catheter is used for the cryo ablation of the cavo-tricuspid isthmus in typical atrial flutter
223850735|NCT00196170|PROCEDURE|irrigated tip radiofrequency ablation of the cavo-tricuspid isthmus|irrigated tip ablation catheter is used for the radiofrequency ablation of the cavo-tricuspid isthmus in typical atrial flutter
223850736|NCT00196170|PROCEDURE|cryo 6.5mm tip ablation of the cavotricuspid isthmus|cryo 6.5mm tip ablation catheter is used for the cryo ablation of the cavo-tricuspid isthmus in typical atrial flutter
223850737|NCT02109393|OTHER|MIRT|"It consists of a 4-weeks physical therapy which entails four daily sessions for five days. All treatments are performed in aerobic condition. The duration of each session, including recovery periods, is about one hour. The first session consists of a one-to-one session with physical therapist. The second session includes aerobic and repetitive exercises to improve balance and gait using different devices: a posturographic platform with visual cues, cycloergometer, treadmill-plus. The third is a session of occupational therapy. The last session includes one hour of speech therapy.~All patients undergo 20-minutes treadmill-plus training per day, 5 times a week, for 4 weeks."
223850738|NCT02109393|OTHER|MIRT+Lokomat|It consists of a 4-weeks physical therapy which entails four daily sessions for five days. All treatments are performed in aerobic condition. The duration of each session, including recovery periods, is about one hour. The first session consists of a one-to-one session with physical therapist. The second session includes aerobic and repetitive exercises to improve balance and gait using different devices: a posturographic platform with visual cues and cycloergometer. The third is a session of occupational therapy to improve autonomy in activities of daily life. The last session includes one hour of speech therapy. All patients undergo 20-minutes Lokomat® training per day in spite of treadmill-plus.
223850739|NCT05542680|DEVICE|cushion|In the intervention group, the special cushion for semi recumbent position was used
223850740|NCT00150566|DRUG|Lanthanum carbonate|
223850741|NCT04486729|OTHER|High PEEP with end inspiratory pause|Applying a PEEP value 10 cmH2O higher than the lower inflection point of the pressure-volume curve of the respiratory system with end inspiratory pause addition in volumen control ventilation
223850742|NCT04486729|OTHER|Low PEEP - FiO2 high|Applying a PEEP value equal to the lower inflection point of the pressure-volume curve of the respiratory system with a FiO2 necessary to achieve a SpO2 96-98%
223850743|NCT04486729|OTHER|High PEEP without end inspiratory pause|Applying a PEEP value 10 cmH2O higher than the lower inflection point of the pressure-volume curve of the respiratory system without end inspiratory pause addition in volumen control ventilation
223850744|NCT04486729|OTHER|Low PEEP - FiO2 low|Applying a PEEP value equal to the lower inflection point of the pressure-volume curve of the respiratory system with a FiO2 necessary to achieve a SpO2 88-92%
223850745|NCT02676297|DRUG|tiotropium|four inhalations
223850746|NCT04717882|DEVICE|CDSS-OPTIMED|The CDSS-OPTIMED is a software program that provides the physician with a personalized alert on whether to consider stopping or starting medication for a specific patient.
223850747|NCT03528954|DRUG|Propofol|Those who received intravenous propofol
223850748|NCT06556212|OTHER|Real-time feedback using smart swim goggles|Smart swim goggles (Form Athletica Inc.) with activity metrics (such as heart rate, swimming pace, and workout instructions) displayed in real-time during a swimming activity.
223850749|NCT00817050|DRUG|Mometasone Furoate Nasal Spray|One dose (2 sprays in each nostril) of Mometasone Furoate Nasal Spray
223850750|NCT00817050|DRUG|fluticasone nasal spray|One dose (2 sprays in each nostril) of fluticasone nasal spray
223850751|NCT06082076|DRUG|Dexmedetomidine|Patients will receive dexmedetomidine 0.5 mcg/kg diluted in 10 mL of NS given as IV infusion over 10 min before induction of spinal anesthesia
223850752|NCT06082076|DRUG|Ketamine|Patient will will receive ketamine 0.5 mg/kg diluted in 10 mL of NS given as IV infusion over 10 min before induction of spinal anesthesia
223850753|NCT06082076|DRUG|Meperidine|If the tested drug hasn't stopped shivering patient will receive 0.25 mg/kg meperidine
223850754|NCT03076450|DEVICE|Lung Ultrasound|Adjust PEEP real-time in term of LUS-RAS chang.
223850755|NCT03076450|DIAGNOSTIC_TEST|Maximum Oxygenation|Adjust PEEP real-time in term of PaO2+PaCO2≥400mmHg whether or not.
223850756|NCT05320913|PROCEDURE|Pericapsular nerve group(PENG) block combined with periarticular multimodal drug injection (PMDI)|periarticular local anesthetic infiltration with 120 mg of ropivacaine, epinephrine 0.2 mg and 30 mg of ketorolac diluted with normal saline to a total volume of 40 mL. + PENG block with ropivacaine 40 mg and epinephrine 0.1 mg with normal saline to a total volume of 20 mL
223850757|NCT05320913|PROCEDURE|isolated periarticular multimodal drug injection (PMDI)|periarticular local anesthetic infiltration with 150 mg of ropivacaine, epinephrine 0.3 mg and 30 mg of ketorolac diluted with normal saline to a total volume of 50 mL
223850758|NCT01391013|DRUG|Darunavir(DRV)|Oral administration of tablet DRV 800 mg (2 tablets of 400 mg) once daily at the same time, within 30 minutes after food for 48 weeks
223850759|NCT01391013|DRUG|Ritonavir|Oral administration of tablet ritonavir 100 mg once daily at the same time, within 30 minutes after food for 48 weeks
223850760|NCT01391013|DRUG|2 nucleoside reverse transcriptase inhibitors (NRTIs)|2 NRTIs will be administered as per the package inserts.
223850761|NCT01772719|DRUG|Simvastatin and zoledronic acid|"1. Simvastatin 80 mg PO daily starting two days before starting chemotherapy and stopping two days after chemotherapy.~2. Zoledronic acid 4 mg IV over 15 minutes on day 1 and then monthly."
223850762|NCT05268198|DRUG|APR002|Active Investigational Product
223850763|NCT05268198|DRUG|Placebo|Placebo
223850764|NCT04393896|BEHAVIORAL|WeChat-based integrative family intervention (WIFI)|The WIFI program will include three key components: psycho-education through WeChat Official Account publications, peer-support through a WeChat chat group, and professional support through WeChat private chat and video call
223850765|NCT00477412|DRUG|Bortezomib|Given IV
223850766|NCT00477412|DRUG|Cyclophosphamide|Given IV
223850767|NCT00477412|DRUG|Cytarabine|Given IV
223850768|NCT00477412|DRUG|Dexamethasone|Given PO or IV
223850769|NCT00477412|DRUG|Doxorubicin|Given IV
223850770|NCT00477412|DRUG|Methotrexate|Given IV
223850771|NCT00477412|BIOLOGICAL|Rituximab|Given IV
223850772|NCT00477412|DRUG|Vincristine|Given IV
223850773|NCT02315885|OTHER|Alcohol administration; Placebo administration|consumption of 3 alcohol doses (2 regular and one placebo) each within 2h on separate days
223850774|NCT04541641|PROCEDURE|New Reverse Drilling technique|a new technique of dental implant drilling that promote osseodensification by rotating the drills anti-clockwise rather than clockwise to promote bone condensation rather than bone cutting
223850775|NCT04541641|PROCEDURE|osteotome technique|a technique for dental implant placement by using the osteotome to condense the bone and create an osteotome rather than cutting the bone
223850776|NCT03146351|OTHER|Family based early intervention program (NDT-Bobath based)|Family based early intervention program is NDT - Bobath based home program. Physiotherapist teaches principles of the treatment to infants' family. Family applies the program at home.
223850777|NCT00731211|DRUG|Pazopanib|800 mg of pazopanib orally each day continuously
223850778|NCT01221337|OTHER|heparin free haemodialysis|"Comparison of two haemodialyzers VIE 2,1 versus EVODIAL 2,2 in a strategy of heparin-free haemodialysis (HFH)."
223850779|NCT02248454|DRUG|Lispro|Increasing insulin doses
223850780|NCT00089258|BIOLOGICAL|beta-glucan|
223850781|NCT00089258|BIOLOGICAL|monoclonal antibody 3F8|
223850782|NCT00089258|BIOLOGICAL|sargramostim|
223850783|NCT00089258|DRUG|isotretinoin|
223850784|NCT04729244|DRUG|CBD|Hemp Oil
223850785|NCT01943162|BEHAVIORAL|CPT|
223850786|NCT03429855|OTHER|trunk training|Bobath based trunk training
223850787|NCT03429855|OTHER|physiotherapy|conventional physiotherapy
223850788|NCT00237341|DRUG|fentanyl|
223850789|NCT01643291|PROCEDURE|Ultrasound|Ultrasound guidance for difficult lumbar punctures in the leukemic pediatric population.
223850790|NCT00618319|DRUG|BIIB021|Dose, schedule, and duration specified in protocol
223850791|NCT06092931|DRUG|DC-806|Oral tablets
223850792|NCT06092931|DRUG|Midazolam|Oral syrup
223850793|NCT06092931|DRUG|Repaglinide|Oral tablets
223850794|NCT06092931|DRUG|Digoxin|Oral tablets
223850795|NCT06092931|DRUG|Rosuvastatin|Oral tablets
223850796|NCT00001999|DRUG|Globulin, Immune|
223850797|NCT00001999|DRUG|Ganciclovir|
223850798|NCT00299702|DRUG|Abilify|10-30 mg once daily for 104 weeks
223850799|NCT00299702|DRUG|Risperidal Consta|25mg, 37.5mg, or 50mg every 2 weeks for 104 weeks
223850800|NCT00966199|DRUG|anti-hypertensive medication|8-12 weeks of anti-hypertensive treatment with 2 weekly titration using registered hypertensive medication
223850801|NCT00114933|DRUG|Stopping nucleosides and continuing lopinavir/ritonavir monotherapy|
223850802|NCT00751036|DRUG|Nilotinib|Nilotinib hard gel capsules were supplied to the Investigators at dose strengths of 200 mg. Nilotinib is a novel agent, which has been approved for the treatment of chronic phase and accelerated phase Philadelphia-chromosome-positive CML in adult patients resistant to or intolerant to prior therapy that included imatinib.
223850803|NCT00751036|DRUG|Imatinib|Imatinib tablets were supplied at 100 mg and/or 400 mg dose strength. Imatinib is an approved agent for GIST. Efficacy of imatinib at a dose of 400 mg bid has been established in the setting of disease progression after the use of the conventional dose (400 mg qd).
223850804|NCT05038969|DRUG|Stomopral|1 capsule contains 40 mg Esomeprazole
223850805|NCT05038969|DRUG|Nexium|1 capsule contains 40 mg Esomeprazole
223850806|NCT05460663|BEHAVIORAL|Stress Management and Resilience Training (SMART)|The Stress Management and Resilience Training (SMART) program was developed by Dr. Amit Sood. SMART focuses on improving the practices of gratitude, mindful presence, kindness, and developing a resilient mindset. The SMART program incorporates practices that focus on six individual factors that have been found to promote individual-level resilience: positive coping, positive affect, positive thinking, realism, behavioral control, and altruism. In this proposed study, SMART will be provided via either a two-hour, video teleconference (VTC) and in-person training or by completion of a self-paced, on-line version completed over a period of four to eight weeks.
223850807|NCT03150368|DRUG|ModraDoc006/r|Treatment with weekly ModraDoc006 (oral docetaxel) 10mg tablets in combination with ritonavir 100mg tablets
223850808|NCT05273801|DEVICE|Heart Rate Recording from Multiple Participants, No Visual Feedback|Heart rates are recorded from multiple participants during the group sessions. However during this intervention, it will not be cast to a TV for feedback to the participant or clinician.
223850809|NCT05273801|DEVICE|Visual Feedback of Multiple Participant Heart Rates|Visual feedback of HR is provided through a TV monitor. Multiple heart rates can be displayed and recorded simultaneously allowing for group encouragement, continuous monitoring and adjustment of all participants to ensure reaching appropriate target intensity.
223850810|NCT06654700|BIOLOGICAL|Recombinant Zoster Vaccine (CHO Cell)|0.5 mL per dose, containing a total of 50 µg recombinant varicella zoster virus glycoprotein E, adjuvanted with MA105. Intramuscular injection
223850811|NCT06622148|DRUG|Iron Sucrose injection (Test product, manufactured by Sichuan Huiyu Pharmaceutical Co., Ltd) and Iron Sucrose injection (Reference product, Venofer)|For the Group I, participants will receive a single intravenous injection of the Test Product (Iron sucrose injection, 100 mg iron/5 mL, manufactured by Sichuan Huiyu Pharmaceutical Co., Ltd). After a washout period, subjects will receive a single intravenous injection of the Reference Product (Iron sucrose injection, Venofer®, 100 mg iron/5 mL, held by AMERICAN REGENT, INC.) .
223850812|NCT06622148|DRUG|Iron Sucrose injection (Reference product, Venofer) and Iron Sucrose injection (Test product, manufactured by Sichuan Huiyu Pharmaceutical Co., Ltd)|For the Group II, participants will receive a single intravenous injection of the Reference Product (Iron sucrose injection, Venofer®, 100 mg iron/5 mL, held by AMERICAN REGENT, INC.) . After a washout period, subjects will receive a single intravenous injection of the Test Product (Iron sucrose injection, 100 mg iron/5 mL, manufactured by Sichuan Huiyu Pharmaceutical Co., Ltd).
223850813|NCT05592613|DEVICE|Next-generation Reader and ID-Cap System|The digital pill system (DPS) is comprised of an ingestible radiofrequency emitter, integrated into a standard gelatin capsule, which then over-encapsulates the study medication (PrEP or ART). On ingestion, the radiofrequency emitter is activated by chloride ions in the stomach, projecting a signal approximately three feet off the body. This radio signal is acquired by a wearable device (Reader) which stores and forwards data to a smartphone, enabling on-demand access to adherence data. The next-generation Reader is a wrist-borne device.
223850814|NCT05592613|DRUG|Truvada for pre-exposure prophylaxis (PrEP)|Participants will ingest one Truvada digital pill as PrEP per day, for 30 days total.
223850815|NCT05592613|DRUG|Biktarvy for antiretroviral therapy (ART)|Participants will ingest one Biktarvy digital pill as ART per day, for 30 days total.
223850816|NCT01867853|DEVICE|PLR|passive leg raising test was done before and at the end of SBT
223850817|NCT06711354|DRUG|Anti-CD20 Monoclonal Antibody|Injection of monoclonal anti-CD20 antibody as immunomodulatory treatment of multiple sclerosis
223850818|NCT06697457|OTHER|Craniocervical Flexion Exercise Group|"The patient will first be taught to contract the deep cervical flexors. Patients will be placed in a supine position (without a pillow) to ensure a neutral neck position. Patients will be asked to perform slow, controlled head and upper cervical flexion by bringing the chin closer to the chest (yes movement). The stabilizer will be inflated to 20 mmHg. Gradual training will be given to increase the pressure value by 2 mmHg between 20 and 30 mmHg. Each pressure value (22, 24, 26, 28 mmHg) will be held for 10 seconds and repeated 10 times. The exercise will be performed with 10 repetitions, 10 seconds of contraction and 5 seconds of relaxation. Exercise training will begin with 20 mmHg and once the patient can hold it for 10 seconds with 10 repetitions, the next level on the pressure stabilizer will be moved on.Treatments will be performed 3 days a week for 8 weeks."
223850819|NCT06697457|OTHER|Conventional Treatment Group|TENS will be applied with a TENS device at an intensity of 10-30 mA and a frequency of 80 Hz for 20 minutes. A pair of surface electrodes will be placed on the painful area of the neck. The intensity of TENS will be adjusted according to the patient's sensory thresholds so that the patient is not disturbed by a numb feeling. After TENS, continuous ultrasound will be applied to the cervical region to produce thermal effects. The intensity will be 1.5 W/cm² and the duration will be 5 minutes. Hotpack will be applied to the trapezius muscle for 10 minutes. Chin tuck exercise will be applied to the cervical region.Treatments will be performed 3 days a week for 8 weeks.
223850820|NCT06697457|OTHER|Dynamic Isometric Exercise Group|The exercises will be performed by the patient with an elastic band. The progression of the exercises will be performed using different colors of Thera-bands with different resistances. It will start with the red Thera-band with the lowest resistance and then move on to the green and then blue Thera-bands with increasing resistance. Cervical isometric exercises will be performed with elastic resistance bands, maintaining the chin tuck position, forward, backward, crosswise, right and left. There will be 10 repetitions for 10 seconds for each. Progression in Therabands will be according to the patient. When the patient does 10 repetitions for 10 seconds, the next Theraband will be used.Treatments will be performed 3 days a week for 8 weeks.
223850821|NCT06697457|OTHER|Static Isometric Exercise Group|The patient will perform isometric exercises with maximal effort against neck flexion, extension, lateral flexion and rotation with his/her hand in a sitting position. Each exercise will be performed for 10 seconds, with 15-second breaks in between, for 10 repetitions. Each patient will start with submaximal resistance to help them adapt to isometric exercises, and then progress will be checked until the patient reaches the maximum resistance that can be tolerated by each session. It will consist of cervical flexion, cervical extension, right lateral flexion, left lateral flexion, right rotation, left rotation exercises. Progress in the exercises will be according to the Rating of Perceived Exertion Borg (RPE) Scale according to the weeks.Treatments will be performed 3 days a week for 8 weeks.
223850822|NCT06714422|PROCEDURE|apple group|Doctors will bring apples during night shift
223850823|NCT06714422|PROCEDURE|no apple group|No apples during night shift
224265534|NCT07138859|DEVICE|Laparoscopic assisted radical right hemicolectomy (D3 lymph node dissection)|LRH (Laparoscopic Right Hemicolectomy) group: control group: underwent laparoscopic radical right hemicolectomy (D3 lymph node dissection)
224265535|NCT07140432|OTHER|Bone scintigraphy|A bone scintigraphy exam will be performed in addition of the already performed scanner in the current practice
224265536|NCT07139509|DRUG|allogeneic cord blood-derived, dual-targeting CD19/BCMA CAR-T cells|dosage form: UCAR-T cell injection Route of Administration: Single intravenous injection Participants will receive lymphodepletion with fludarabine (30 mg/m²/day) and cyclophosphamide (500 mg/m²/day) from Day -5 to -3, prior to UCAR-T cell infusion on Day 0.
223850824|NCT06711094|DRUG|Dalpiciclib|"Dalpiciclib: 125mg orally, with a treatment cycle every 28 days, with continuous administration for the first 3 weeks (days 1 to 21) and rest (no medication) for the second 1 week (days 22 to 28). It is recommended to take Dalpiciclib at about the same time every day.~Albumin-bound paclitaxel for injection: 125mg/m2, intravenous infusion for 30 minutes, D1, D8, every 28 days for a treatment cycle, at least ≥6 treatment courses.~Endocrine therapy: Endocrine therapy drugs are selected by the investigator"
223850825|NCT06712108|PROCEDURE|tranplant|double unit cord blood transplnat
223850826|NCT06714227|GENETIC|Molecular analysis of genomic DNA (exome sequencing) from peripheral blood sample|The first level of investigation will focus on genes already described in cases of pathogenic germline variants of prostate cancer and/or DNA repair system genes. The second level of investigation will consider variants in genes known to confer increased risk of cancer development, e.g., genes listed in the UK health system's solid tumor predisposition gene panel. Finally, pathogenic/probably pathogenic variants in the exome in genes attributable to increased risk will be evaluated on the basis of molecular pathway and findings in the scientific literature.
223850827|NCT02620072|DRUG|Oral Insulin|Total of 12 months treatment; dose escalation scheme: daily treatment with 7.5 mg or placebo for 3 months; increasing to daily treatment with 67.5 mg or placebo for the following 9 months of the treatment period. Follow-up will continue for 24 months after the last administration of treatment.
223850828|NCT02620072|OTHER|Placebo|Total of 12 months intervention period; daily administration of insulin or placebo capsules containing filling substance (microcrystalline cellulose). Follow-up will continue for 24 months after the last administration of treatment.
223850829|NCT05789472|BEHAVIORAL|Assessment|Executive functions and reaction times of all participants will be measured.
223850830|NCT02554240|DRUG|DA-5202 20mg|once a week, intra-articular injection, for 3 weeks
223850831|NCT02554240|DRUG|DA-5202 10mg|once a week, intra-articular injection, for 3 weeks
223850832|NCT02554240|DRUG|Na Hyaluronate 20mg|once a week, intra-articular injection, for 3 weeks
223850833|NCT01922570|DIETARY_SUPPLEMENT|nutrition|comparion of enteral versus enteral and supplemental parenteral nutrition
223850834|NCT02339779|PROCEDURE|autologous fat transfer|"Each procedure consists of the transfer of syringe-aspirated fat (form the abdomen, thighs, flanks) to the breast by injection in the subcutaneous planes.~Typically three separate procedures are needed for a complete breast reconstruction:~1. First session comprises of sub- and intrapectoral fat transfer during the primary mastectomy surgery, providing volume to the deep tissue planes.~2. Second session is preceeded by wearing an external pre-expansion device to prepare the recipient site for grafting. It aims to give the breast its shape and initial volume.~3. Third session is also preceded by external pre-expansion and aims to provide extra volume of the breast to achieve symmetry with the healthy breast."
223850835|NCT02339779|PROCEDURE|breast implant|"Implant-based reconstruction typically will occur as follows:~1. During the primary mastectomy surgery, a tissue expander will be implanted subpectorally.~2. The tissue expander will be gradually filled with sterile saline during outpatient clinic visits.~3. When the desired volume is achieved, a second operation will be planned, to exchange the tissue expanded with the definite breast implant.~(Note: in patients who are receiving encapsulectomy and implant exchange, the first 2 steps are skipped.)"
224265537|NCT07139288|BEHAVIORAL|therapeutic exercise program|Each subject completes four dynamic tasks, including ankle resistance exercises, resistance kinematic chain exercises, heel raise exercises, and BOSU ball exercises at 3 times per week for 4 weeks
224265538|NCT07139288|DEVICE|Extra corporeal shock wave therapy|"The extracorporeal shock waves will be delivered with 2,500 shockwave impulses (6 Hz), The intensity of extracorporeal shock waves is adjusted according to the patients' degree of tolerance to the pain. In the experimental group, the extracorporeal shockwave will apply to the anterior talofibular ligament, posterior talofibular ligament, calcaneofibular ligament, and tibialis anterior muscle.~twice per week for 4 weeks"
224265539|NCT07139288|DEVICE|photobiomodulation Therapy|Photobiomodulation therapy will be performed with a laser an 810 nm wavelength, 0 \~ 500 mW adjustable and continuous power output, and a 0.4 cm beam diameter was used. The subjects in the group C will be treated with the laser at a dose of 239 J/cm2 (power: 100 mW; intensity: 796 mW/cm2; irradiation time: 5 min/point, 20 min in total) at 3 times per week for 4 weeks
224265540|NCT07139756|DIAGNOSTIC_TEST|Lower body negative pressure|LBNP is a technique that redistributes blood from the upper body to the dependent regions of the legs, thus reducing central venous pressure and venous return and thereby activating the sympathetic nervous system (SNS). The subject is placed in a cylindrical airtight tank, which is sealed at the level of the iliac crests, and sub-atmospheric pressure is produced using a vacuum pump. It can be used to characterize the cardiovascular responses to orthostatic stress
224265541|NCT07140315|DRUG|[18F]DK222 radiotracer|\[18F\]DK222 is an investigational radiotracer used detect non-small cell lung cancer (NSCLC) or Urothelial Cancer (UC) tissue in the body when used with positron emission tomography/computed tomography. Participants will undergo a PET-CT scan after \[18F\]DK222 is injected into the participant's vein an intravenous line.
224265542|NCT07139405|DRUG|Metformin XR 1000mg|Arm 1: Metformin XR 1000mg Monotherapy (taken AM)
224265543|NCT07139405|DRUG|Valsartan 80mg Tablet|Arm 2: Valsartan 80mg (taken PM)
224265544|NCT07139405|DRUG|Valsartan 160mg tablet|Arm 3: Valsartan 160mg (taken PM)
224265545|NCT07139405|DRUG|Celecoxib (Celebrex®) 100mg|Arm 2: Celecoxib 100mg (taken AM)
224265546|NCT07139405|DRUG|Celecoxib (Celebrex®) 200mg|Arm 3: Celecoxib (taken AM)
224265547|NCT07139405|DRUG|Metformin XR 500 mg|Arm 2: Metformin 500mg (taken AM)
224265548|NCT07140198|PROCEDURE|Hyperbaric Oxygen Therapy|HBOT will be administered in five sessions (1 on Day 0, 2 on Day 1, 2 on Day 2), beginning immediately after the lipofilling. Each session consists of 100% oxygen inhalation at 2.5 ATA for 90 minutes. Postoperative MRI will be performed six months after each AFT session to assess the volume of retained graft.
224265549|NCT07140198|OTHER|Control|Patients in the control group will undergo standard follow-up after the lipofilling without HBOT.
223850836|NCT05266352|OTHER|Supervised exercise program|"A structured program consisting of range of motion, postural control, scapulothoracic strengthening, glenohumeral strengthening and dynamic stabilization exercises used in conservative treatment of rotator cuff tears will be performed for 8 weeks.~Patients will do the exercises under control of the physiotherapist in the clinic."
223850837|NCT05266352|DIAGNOSTIC_TEST|Home exercise program|"A structured program consisting of range of motion, postural control, scapulothoracic strengthening, glenohumeral strengthening and dynamic stabilization exercises used in conservative treatment of rotator cuff tears will be performed for 8 weeks.~Patients will do the exercises at home. Patients will visit the clinic every 2 weeks and progression of exercise program will be made."
223850838|NCT03947086|DEVICE|Transcranial Direct Current Stimulation (TDCS)- Active|A constant current stimulator (TCT Research Limited) will be used using electrodes of 5 × 5 cm2 embedded in saline (0.9 % NaCl) and application of 1.5 mA current for 20 minutes for 5 consecutive days. The cathode will be positioned in the right supra-orbital region, and while the anode will have the following provision in the left dorsolateral prefrontal cortex (F3).
223850839|NCT03947086|DEVICE|Transcranial Direct Current Stimulation (TDCS)- Sham|The protocol for participants receiving simulated current is identical, but the device ceases to emit current after 30 seconds of initiation of pacing.
223850840|NCT03947086|BEHAVIORAL|Cognitive Training|"Considering that the effects of TDCS are potentiated when applied during the execution of a task (online) (Miniussi, \& Ruzzoli, 2013), in the present study all participants received cognitive training, performed concomitantly with neurostimulation.~Cognitive training consists of two parts: standardized tasks directed to social cognition and activities that stimulate executive functions. The first part consists of tasks contained in a battery of social games (Gao \& Maurer, 2009; Dillon, Kannan, Dean, Spelke, \& Duflo, 2017). While the tasks directed to the executive domain are, namely: running mazes, assembling figures, completing parts of figures and the Super Lynx Memory Game. All participants, regardless of whether they underwent active or simulated stimulation, received cognitive training, respecting the ethical principles of ensuring therapeutic assistance to those involved."
223850841|NCT01162655|BEHAVIORAL|Cognitive-behavioral therapy for Insomnia (CBT)|6-week course of CBT delivered either using internet or telehealth
223850842|NCT02552550|PROCEDURE|Ability to swallow, speak and quality of life|This study will not change the patient's treatment. This will just be an evaluation, before any treatment, his ability to swallow, speak, then his quality of life, as in normal practice, after 3, 6 and 12 months after treatment.
223850843|NCT02707224|DRUG|DP-R208|Investigational product is prescribed to all of randomized subjects
223850844|NCT02707224|DRUG|Candesartan cilexetil|Investigational product is prescribed to all of randomized subjects
223850845|NCT02707224|DRUG|Rosuvastatin|Investigational product is prescribed to all of randomized subjects
223850846|NCT06100705|DRUG|Testosterone Cypionate|Testosterone Cypionate is an androgen and anabolic steroid medication which is used mainly in the treatment of low testosterone levels in men.
223850847|NCT06100705|DRUG|Sipuleucel-T|Sipuleucel-T is the first FDA-approved immunotherapy in treatment of mCRPC. It is a therapeutic cancer vaccine composed of activated autologous dendritic cells loaded with an engineered fusion protein of prostatic acid phosphatase and granulocyte-macrophage colony-stimulating factor, PAP-GMCSF, also called PA2024. This cellular product is prepared in three steps: (1) leukapheresis to isolate CD54+ dendritic cells, (2) the cells and harvested and cultured with PA2024 ex vivo, and (3) re-infusion of the activated DC into the original patient. The preparation and administration of this autologous cellular product are done every 2 weeks for a total of three infusions and is designed to elicit an immune response to prostatic acid phosphatase.
223850848|NCT04977856|BEHAVIORAL|Behavioral activation (BA)|The main goal of the BA is to increase engagement in values-based activities and decrease avoidant behaviors that serve to maintain depression. The adolescent will learn about depression, how behavioral activations works, monitor their own activities, plan and do more values-based activities and deal with obstacles to getting in touch with positive reinforcement, such as avoidance behaviors.
223850849|NCT04977856|OTHER|Regular care within primary or secondary mental health care for children|Regular care (supportive therapy, waitlist, psychological treatments, drugs, or a combination of different interventions)
223850850|NCT05779722|DEVICE|Vapor barrier|Vapor barrier
223850851|NCT00686023|PROCEDURE|internal fixation (DHS - richard nail)|internal fixation
223850852|NCT00686023|PROCEDURE|internal fixation (inflatable PFN by DISCOTEC)|internal fixation
223850853|NCT05526911|DRUG|TBAJ-876|"* Day 6 to Day 13: 200 mg TBAJ-876 oral suspension, fed~* Day 14 to Day 19: 165 mg TBAJ-876 oral suspension, fed~* Day 20 and Day 21: 200 mg TBAJ-876 oral suspension, fasting~* Day 22 to Day 24: 150 mg TBAJ-876 oral suspension, fed"
223850854|NCT05526911|DRUG|Midazolam|Day 1 and Day 20: Midazolam oral syrup: 2 mg, fasted
223850855|NCT05526911|DRUG|Digoxin|Day 2 and Day 21: Digoxin tablet: 0.25 mg, fasted
223850856|NCT05025449|DIAGNOSTIC_TEST|Focused Assessment with Sonography for Trauma (FAST)|The Focused Assessment with Sonography for Trauma (FAST) exam is widely used and accepted as part of Advanced Trauma Life Support (ATLS) protocol. After consent, a baseline FAST exam will be performed and documented. This FAST will be distinct from the initial ATLS resuscitation FAST in order to avoid any interference in the trauma evaluation. The investigator will use a phased array or curvilinear transducer to record video of their baseline FAST exam.
223850857|NCT05025449|DRUG|Bubble-Enhanced FAST (BEFAST)|Following the FAST exam and using the same machine, a BEFAST exam will be performed using a low mechanical index setting in contrast-specific imaging mode. A 2.4 mL IV dose of Lumason will be injected into the subject's IV, followed by saline flush. The contrast will be injected once for the right side of the body, and once for the left side of the body looking for disruptions in the normal enhancement pattern and evidence of active bleeding. To examine the right side of the body: the liver will be imaged first in arterial phase, followed by the right kidney, before returning to image the liver in venous phase. To examine the left side of the body: the pancreas will be imaged first, followed by the kidney and the spleen. The investigator will note evidence of solid organ injury, free fluid, or active extravasation on both sides of the body; lacerations will be graded by the American Association for the Surgery of Trauma (AAST) criteria.
223850858|NCT03804411|DRUG|Automatic system guided treatment|Addition of: 1A -vildagliptin 100 mg/day 2A - sitagliptin 100 mg/day, 3A- dapagliflozin 10 mg/day 4A- empagliflozin 10 mg/day 5A- liraglutide 1,2-1,8 mg/day 6A- exenatide 20 μg/day 7A - glimepiride 8A - gliclazide
223850859|NCT03804411|DRUG|Standard treatment|"Addition of:~1. B -vildagliptin 100 mg/day~2. B - sitagliptin 100 mg/day,~3. B- dapagliflozin 10 mg/day~4. B- empagliflozin 10 mg/day~5. B- liraglutide 1,2-1,8 mg/day~6. B- exenatide 20 μg/day~7. B - glimepiride~8. B - gliclazide"
223850860|NCT02518711|BEHAVIORAL|Behavioral Teacher Program|This program was based on the evidence-based Summer Treatment Program (MTA Cooperative Group, 1999), involving psycho-education for the teacher and universal and individual behavioral techniques that focused on classroom structure and contingency management
223850861|NCT02652234|DRUG|Endostar|Endostar, ih, QD，day 1 of cycle 1; Endostar, ih, QD，day 2-15 of cycle 3;
223850862|NCT02652234|DRUG|Chemotherapy|
223850863|NCT04903483|OTHER|bispectral index monitoring|intraoperative single-channel electroencephalography monitoring of the depth of anesthesia
223850864|NCT01353482|DRUG|Cisplatin|Cisplatin (75mg/m2 iv) wil be administered on day one of a 21 day cycle for up to 6 cycles
223850865|NCT01353482|DRUG|Pemetrexed|Patients will be given Pemetrexed (500mg/m2 iv) on day one of a 21 day cycle for up to 6 cycles
223850866|NCT01353482|DRUG|Vorinostat|The dose and frequency of vorinostat will be determined in the Phase I study. Vorinostat will be given concurrently with Cisplatin/Pemetrexed.
223850867|NCT01353482|DRUG|Placebo|Patients randomised into the placebo arm of the trial will receive Cisplatin and Pemetrexed as standard as well as placebo.
223850868|NCT03612115|DEVICE|Neuromuscular electrical stimulation|"Neuromuscular electrical stimulation to the bilateral deltoid and quadriceps femoris muscles with 50 Hz for 3 days/week, 8 weeks.~Device name: Four-channel Wireless Professional (DJO United Kingdom Ltd., Chattanooga, France)"
223850869|NCT00388011|DRUG|Intranasal Morphine (MNS075) 3.75 mg|Intranasal Morphine (MNS075) 3.75 mg
223850870|NCT00388011|DRUG|Intravenous Morphine 7.5 mg|Intravenous Morphine 7.5 mg
223850871|NCT00388011|DRUG|Intranasal morphine (MNS075) 7.5 mg|Intranasal morphine (MNS075) 7.5 mg
223850872|NCT00388011|DRUG|Intranasal morphine (MNS075) 15 mg|Intranasal morphine (MNS075) 15 mg
223850873|NCT00388011|DRUG|Intranasal morphine (MNS075) 30 mg|Intranasal morphine (MNS075) 30 mg
223850874|NCT00388011|DRUG|Intranasal placebo|Intranasal placebo
223850875|NCT02345200|PROCEDURE|bioelectrical impedance analysis|electrophysical measurement that allows to determine the exact composition of single body compartments by producing a magnetic field and detecting the potential difference through the body
223850876|NCT02345200|PROCEDURE|blood draw|blood samples are taken at 8 am in order to pay attention to the circadian rhythmicity to get a detailed hormonal status
223850877|NCT05502211|DRUG|Fentanyl|induction of anaesthesia using fentanyl
223850878|NCT05502211|DRUG|Lidocaine IV|induction of anesthesia using lidocaine
223850879|NCT01839903|OTHER|EDIS|Changes made to EDIS system to improve tracking and treatment of smoking in the ED
223850880|NCT01839903|OTHER|Care as usual|Care as usual in the ED will be tracked
223850881|NCT05088226|DRUG|Ruxolitinib combined with Chidamide.|"Drug: modified By/Cy conditioning regimen intensified by Ruxolitinib and Chidamide .~Day -15 # Ruxolitinib 70mg bid, Chidamide 30 mg once; Day -14 # Ruxolitinib 70mg bid; Day -13 # Ruxolitinib 70mg bid; Day -12 # Ruxolitinib 70mg bid, Chidamide 30 mg once; Day -11 # Ruxolitinib 70mg bid; Day-10# Cytarabine 4g/m2/day CI , Ruxolitinib 60mg bid; Day- 9# Cytarabine 4g/m2/day CI, Ruxolitinib 60mg bid; Day- 8 # Busulfan 0.8mg/ kg Q6h iv, Ruxolitinib 50mg bid, Chidamide 30 mg once; Day- 7# Busulfan 0.8mg/ kg Q6h iv, Ruxolitinib 50mg bid; Day-6# Busulfan 0.8mg/kg Q6h iv, Ruxolitinib 40mg bid; Day-5# Cyclophosphamide 1.8 g/m2/day CI, Ruxolitinib 30mg bid, Chidamide 30 mg once; Day-4# Cyclophosphamide 1.8 g/m2/day CI,Ruxolitinib 20mg bid; Day-3# Carmustine 250mg/m2/ day iv, Ruxolitinib 10mg bid; Day-2# Ruxolitinib 5mg bid, Chidamide 30 mg/day; Day-1# Ruxolitinib 5mg qd;"
223850882|NCT03238729|BEHAVIORAL|Heart Failure Education and Management App|Patients will be provided with an app on a smartphone that provides a daily checklist with items like reminders for logging weight and food, as well as educational components about heart failure and it's management.
223850883|NCT03238729|BEHAVIORAL|Heart Failure Literature|Patients will be provided standard literature about heart failure and the management of heart failure.
223850884|NCT05096806|OTHER|Acupuncture|Acupuncture is a non-pharmacological technique that consists in the stimulation of specific points located in the skin surface. Points are stimulated by piercing the skin with fine needles.
223850885|NCT05096806|DEVICE|TENS|TENS is a therapy that uses low voltage electrical current to provide pain relief. A TENS unit consists of a battery-powered device that delivers electrical impulses through electrodes placed on the surface of your skin. The electrodes are placed at or near nerves where the pain is located or at trigger points.
223850886|NCT00301509|DRUG|peginterferon and ribavirin|
223850887|NCT01953809|DRUG|GSK1322322|Oral tablets with unit dose strength of 500mg and dose level of 1500mg (3 x 500mg) for twice a day administration for 7 days in treatment phase
223850888|NCT01953809|DRUG|EE/NE|Oral contraceptive tablet containing 0.035mg EE and 1mg NE for once daily administration for 21 days in run-in phase and 21 days in treatment phase
223850889|NCT01953809|DRUG|GSK1322322 Placebo|GSK1322322 matching placebo tablets for twice a day administration (3 tablets each time) for 7 days in treatment period.
223850890|NCT01953809|DRUG|EE/NE Placebo|EE/NE matching placebo tablet for once daily administration for 7 days in run-in phase.
223850891|NCT03640455|DEVICE|Placebo|A tDCS (Low Current Transcranial Stimulation) device with two electrodes: active and reference, will be used. The tDCS will be applied next to the cortical representation zone of the primary motor cortex and left pre-motor for 30 minutes; placebo (dummy stimulation), according to the patient's randomization arm.
223850892|NCT03640455|DEVICE|Anodal|A tDCS (Low Current Transcranial Stimulation) device with two electrodes: active and reference, will be used. The tDCS will be applied next to the cortical representation zone of the primary motor cortex and left pre-motor for 30 minutes; intensity 2 mA, in anodal polarity, according to the patient's randomization arm.
223850893|NCT03640455|DEVICE|Cathodal|A tDCS (Low Current Transcranial Stimulation) device with two electrodes: active and reference, will be used. The tDCS will be applied next to the cortical representation zone of the primary motor cortex and left pre-motor for 30 minutes; intensity 2 mA, in cathodal polarity, according to the patient's randomization arm.
223850894|NCT00569946|DRUG|AG-013736|"AG-013736 5 mg BID will be administered orally on continuous schedule. Cycle length is 28 days. If the drug is well tolerated at 5 mg BID, the dose of AG-013736 may be titrated to 7 mg BID and then to a maximum of 10 mg BID.~Number of cycles: until progression or unacceptable toxicity develops."
223850895|NCT04276987|BIOLOGICAL|MSCs-derived exosomes|5 times aerosol inhalation of MSCs-derived exosomes (2.0\*10E8 nano vesicles/3 ml at Day 1, Day 2, Day 3, Day 4, Day 5).
223850896|NCT00639366|BIOLOGICAL|trastuzumab|
223850897|NCT00639366|DRUG|chemotherapy|
223850898|NCT00639366|RADIATION|radiation therapy|
223850899|NCT01367561|DRUG|Naloxone|
223850900|NCT01367561|DRUG|IV Methylnaltrexone (MNTX)|
223850901|NCT01367561|DRUG|Placebo|
223850902|NCT02165605|DRUG|HylaCare|cream
223850903|NCT02165605|DRUG|Placebo|placebo
223850904|NCT01549379|RADIATION|Dynamic Contrast Enhanced CT scan|The neck will be scanned using 120 kVp, 50 mAs, 8 x 5 mm slices at intervals of 2.8 - 3.0 s for 3 min. Contrast (e.g. Visipaque 320) at a dosage of 0.7 ml/kg is injected at 4 ml/s through an antecubital vein after a delay of 6 s from start of scanning.
223850905|NCT02089243|PROCEDURE|Vagus nerve stimulation therapy|The adjustments in device parameters were performed, individually, and solely at the discretion of the primary epileptologist with a formal protocol guiding changes.
223850906|NCT02089243|PROCEDURE|Resective surgery|The experienced neurosurgery are responsible for the selection of surgical techniques employed for medically refractory medial temporal lobe epilepsy that provide an effective treatment with significant preservation of neurological function and acceptable surgical risks.
223850907|NCT02072005|OTHER|mSMART smartphone application|This application is an interface that provides subjects with information and questionnaires related to their medication.
223850908|NCT01879904|PROCEDURE|Endoscopic submucosal dissection (ESD)|This study is suggest to patients with superficial medium or distal rectal tumors. The lesion was identified and demarcated using white-light endoscopy, magnifying endoscopy, and chromoendoscopy. Then, marking around the lesions was performed. Local injection was made using injection needle, and then mucosal incision was performed around the lesion using endo-knives. Submucosal dissection was performed using endo-knives. Hemostasis and vessel coagulation were practiced using primary hemostatic forceps during the procedure.
223850909|NCT00192153|BIOLOGICAL|CAIV-T or TIV|
223850910|NCT03556605|OTHER|OneTouch Reveal® Mobile APP system|Improved glycemic control in people with diabetes using the OneTouch Verio® Flex Blood Glucose Monitor and the OneTouch Reveal® Mobile APP system (intervention group) compared to subjects continuing to use their own Blood Glucose Monitor without connection to mobile diabetes apps (control group).
223850911|NCT03556605|OTHER|Current Blood Glucose Monitor|Subjects continue to use current Blood Glucose Monitor without connection to mobile diabetes apps.
223850912|NCT00762463|DRUG|Celecoxib|capsule, 200 mg QD, 6-12 weeks
223850913|NCT00762463|DRUG|Diclofenac SR|tablet, 75 mg QD,6-12 weeks
223850914|NCT06230562|BIOLOGICAL|Blood sample|The intervention is to take a blood sample every 6 months for 1 year which is not part of health routine care
223850915|NCT06230562|BIOLOGICAL|Blood sample|The intervention is to take a blood sample at baseline.
223850916|NCT00271765|DRUG|INO-1001|
223850917|NCT04413565|PROCEDURE|Simultaneous bilateral total knee arthroplasty|Two surgeon bilateral TKA group
223850918|NCT04413565|PROCEDURE|Sequenced bilateral TKA|Single surgeon bilateral TKA group
223850919|NCT01743729|DRUG|Lifitegrast|Lifitegrast Ophthalmic Solution 5.0%
223850920|NCT01743729|DRUG|Placebo|Placebo for Lifitegrast Ophthalmic Solution 5.0%
223850921|NCT00876044|DRUG|aflibercept (AVE0005)|Intravenous route
223850922|NCT00876044|DRUG|placebo|Intravenous route
223850923|NCT01306331|DRUG|Conceptrol|• Conceptrol® Vaginal Gel, which contains 100 mg (4% concentration) of nonoxynol-9 (N-9) in 2.5 mL volume of gel.
223850924|NCT01306331|DRUG|Amphora|• Amphora™ gel, which will be delivered in 5 mL doses, is a clear, water-based, petroleum-free gel.
223850925|NCT03136276|OTHER|IPS Empress CAD|standard etchable glass ceramics
223850926|NCT03136276|OTHER|polished Celtra Duo|new glass ceramic material
223850927|NCT06165926|DRUG|15% hypertonic dextrose|"The solution is prepared with 3 ml of 50% Dextrose, 1 ml of 2% xylocaine, and 6 ml of normal saline.~The ultrasound-guided injection of 15% hypertonic dextrose is performed at the first week. Subsequent ultrasound-guided shoulder joint injection treatment with hypertonic dextrose is performed at the fourth weeks. A total of 2 sessions of hypertonic dextrose injections are performed."
223850928|NCT06165926|DRUG|Normal saline|The solution is prepared with 1 ml of 2% xylocaine + 9 ml of normal saline. The ultrasound-guided injection of Normal saline(0.9%) is performed at the first week. Subsequent ultrasound-guided shoulder joint injection treatment with Normal saline is performed at the fourth weeks. A total of 2 sessions of Normal saline injections are performed.
223850929|NCT06165926|OTHER|physical therapy|Under the guidance and supervision of a physical therapist, the patient undergoes physical therapy sessions twice a week for a total duration of 8 weeks. Each session lasts approximately 30 minutes and includes joint activities, stretching, and muscle-strengthening exercises.
223850930|NCT03766438|BEHAVIORAL|Digital Storytelling Intervention|12-minute digital storytelling intervention in Spanish, with four individuals explaining their personal Type 2 Diabetes stories.
223850931|NCT03137914|BIOLOGICAL|Autologous chondrocyte transplantation|intraarticular injection into the TMJ (arthrocentesis) of autologous chondrocytes diluted in hyaluronic acid
223850932|NCT03137914|PROCEDURE|orthognathic surgery|Orthognathic surgery for correction of dentofacial deformity, performed before the cellular transplantation
223850933|NCT05821322|OTHER|Physical activity trial intervention|60 minutes aerobic ergocyle exercice at 60% VO2 Peak
223850934|NCT00535067|BEHAVIORAL|Questionnaire|Questionnaires taking 60 minutes total to complete.
223850935|NCT00001129|DEVICE|Electronic Medication Reminder System|
223850936|NCT00001129|BEHAVIORAL|Medication Manager|
223850937|NCT01703923|DRUG|FP01|
223850938|NCT01703923|DRUG|placebo|
223850939|NCT01101685|DRUG|Escitalopram|7 days dosing of 10mg per day
223850940|NCT01101685|DRUG|Placebo|7 days dosing at 10mg daily
223850941|NCT04048135|DRUG|Pegozafermin|Subcutaneous injection
223850942|NCT04048135|OTHER|Placebo|Subcutaneous injection
223850943|NCT00172185|DRUG|teduglutide 0.05 mg/kg/d|0.05 mg/kg/d subcutaneous injection
223850944|NCT00172185|DRUG|teduglutide 0.10 mg/kg/d|0.10 mg/kg/d subcutaneous injection
223850945|NCT06364839|OTHER||
223850946|NCT01677936|OTHER|Raisins|1 oz, 90 calorie packages of raisins will be administered to subjects in the raisin treatment arm
223850947|NCT01677936|OTHER|Snacks|100 calorie snack packs will be administered to the subjects in the snack group
223850948|NCT02633423|PROCEDURE|Use of PEEP before and after CPB|PEEP will be set in order to reach an airway pressure of 5 cmH2O
223850949|NCT02633423|PROCEDURE|No use of PEEP before and after CPB(ZEEP)|No PEEP will be used
223850950|NCT02633423|PROCEDURE|Ventilation with CPAP during CPB|A continuous Positive Airway Pressure (CPAP) will be applied during CPB
223850951|NCT02633423|PROCEDURE|No ventilation during CPB|No ventilation will be provided during CPB. Patients will be deconnected from ventilator. Lungs will completely collapse.
223850952|NCT06477926|DRUG|ABBV-668 IR|• Oral Capsule
223850953|NCT06477926|DRUG|ABBV-668 ER|• Oral Tablets
223850954|NCT05039723|DRUG|Radiesse, Xeomin, Belotero|Rejuvenation with Radiesse, Xeomin, Belotero
223850955|NCT03071185|PROCEDURE|femoral nerve block, common peroneal nerve block|For patients with fibular flaps harvested, femoral nerve block and common peroneal nerve with ropivacaine were administered. For patients with ALT flaps harvested, femoral nerve block with ropivacaine was administered.
223850956|NCT05040750|OTHER|laboratory investigation|observe the relation between cardiac markers and mortality rate in critically ill COVID 19 patients
223850957|NCT04257851|DRUG|Theophylline Anhydrous Oral Tablet|Theophylline tablet (150 mg/12h)
223850958|NCT04257851|DRUG|Sumatriptan Succinate Oral Tablet|Sumatriptan tablet (25 mg/12h)
223850959|NCT03879967|DEVICE|Allograft block graft|The graft used is a mineralized, cortico-cancellous, delipidized, lyophilized allogenic block.
223850960|NCT03755440|DRUG|PD-1 antibody (SHR-1210)|PD-1 antibody (SHR-1210), 200mg, ivdrip, every 2 weeks.
223850961|NCT05612243|OTHER|Consumption of a meal with yogurt enriched with probiotics immobilized on oat flakes and polyphenols|Participants will consume a meal including 200g of yogurt enriched with Lacticaseibacillus rhamnosus probiotics (3\*10\^9 cfu/g) immobilized on oat flakes (1g) and polyphenol-rich lyophilized extract (250mg) of Cistus Albidus (77,3 mg GAE/g), as well as two slices of white bread (80g) with butter (30g). Then blood biomarkers will be examined to determine the effect of functional yogurt on postprandial glycemia and lipemia
223850962|NCT05612243|OTHER|Consumption of a meal with yogurt enriched with probiotics immobilized on oat flakes|Participants will consume a meal including 200g of yogurt with Lacticaseibacillus rhamnosus probiotics (3\*10\^9 cfu/g) immobilized on oat flakes (1g), as well as two slices of white bread (80g) with butter (30g). Then blood biomarkers will be examined to determine the effect of probiotic-enriched yogurt on postprandial glycemia and lipemia.
223850963|NCT05612243|OTHER|Consumption of a meal with plain Yogurt with oat flakes|Participants will consume a meal including 200g of plain yogurt containing 1g of oat flakes, as a placebo, as well as two slices of white bread (80g) with butter (30g). Then blood biomarkers will be examined to determine the effect of probiotic-enriched yogurt on postprandial glycemia and lipemia.
223850964|NCT02059044|OTHER|ISTOP-ADE|Interactive Voice Response System + Pharmacist
223850965|NCT02496975|DRUG|Cyclosporine A|Participants will receive 2.5mg/kg load then 5mg/kg qd continuous infusion x 3 days (72hours)
223850966|NCT02496975|OTHER|Placebo|Participants will receive 2.5mg/kg load then 5mg/kg qd continuous infusion x 3 days (72hours)
223850967|NCT05582616|DEVICE|Transcranial Direct Current Stimulation|See treatment arm description
223850968|NCT05582616|DEVICE|Sham Transcranial Direct Current Stimulation|See sham comparator arm description
223850969|NCT04669249|BEHAVIORAL|PROCare|PROCare is a reward-based digital recovery management platform for individuals receiving medication treatment for opioid use disorder. Patients have the opportunity to earn both non-monetary and monetary incentives via smart debit card for a variety of clinically-indicated behaviors, including taking their medication (buprenorphine) as directed, attending clinic appointments and community-based mutual-help support group meetings, participating in routine outcomes monitoring surveys using validated measures, accessing the curated psychoeducation content library, and engaging in other recovery-oriented activities within the smartphone app.
223850970|NCT06631781|OTHER|GOLD-Cog+|6 weeks of combined cognitive intervention (GOLD-Cog+),which includes participation in 9, one hour long Cognitive-Orientation to Occupational Performance(CO-OP)-based group sessions and 24 individual and independent 30-minute computerized cognitive training (CCT) program using the Effectivate platform (Israeli-based CCT developed for older adults. Available in both Hebrew and English).
223850971|NCT06629727|OTHER|VR Group|the experimental group was shown a video through VRG during the lithotripsy procedure.
223850972|NCT06629727|OTHER|Control group|Patients received standard care during the procedure
223850973|NCT06628596|DIETARY_SUPPLEMENT|Paraxanthine 200mg and 300mg|Participants consumed 200 mg paraxanthine (PXN 200), 300 mg paraxanthine (PXN 300), or placebo (PLA) after an overnight fast. Supplements were ingested 30 minutes before a mixed meal in double-blind, randomized, placebo-controlled, crossover fashion.
223850974|NCT05120440|OTHER|Breakfast omission|Breakfast omission will consist of not eating breakfast on the morning of afternoon resistance training performance assessment.
223850975|NCT05120440|OTHER|Breakfast consumption|Breakfast consumption will consist of eating a standardized breakfast on the morning of afternoon resistance training performance assessment.
223850976|NCT02915055|DRUG|Ibuprofen 600 mg|Ibuprofen 600 mg to be taken every 8 hours (TID) as needed (PRN
223850977|NCT02915055|DRUG|standard oxycodone/acetaminophen|
223850978|NCT05070104|DRUG|CPI-613|250-1000mg/m2 -14 day cycle
223850979|NCT05070104|DRUG|modified FFX|Irinotecan: 150mg/m2 IV over 90 min-14 day cycle Leucovorin: 400mg/m2 IV over 2hrs with Irinotecan-14 day cycle Oxaliplatin: 85mg/m2 IV over 2hrs-14 day cycle 5FU: 2400mg/m2 IV over 46-48 hrs-14 day cycle
223850980|NCT05070104|DRUG|Bevacizumab|5mg/kg IV
223850981|NCT04275817|OTHER|Data collection|Telephone interview questionnaire, in-home face-to-face interview, and data from the Collection Site
223850982|NCT05914558|DIAGNOSTIC_TEST|Clinical appointment|One clinical interview and examination to confirm the diagnosis of trigeminal neuralgia and temporomandibular disorder.
223850983|NCT02909439|DRUG|Sugammadex|Sugammadex will be given for reversal of neuromuscular blockade.
223850984|NCT02909439|DRUG|Neostigmine|Neostigmine will be given for reversal of neuromuscular blockade.
223850985|NCT03347045|COMBINATION_PRODUCT|Trimodal Prehab & ERP|"1-hr daily exercise will be completed a total of 5d/week, of which 2 of these sessions are completed through a community fitness center. Following these sessions, the participant will consume a high-protein oral supplement.~Additionally, during the program, participants will be given the option of attending a stress-reduction group and will receive a take-home anxiety-reduction program. They will have access to a physiotherapist, kinesiologist, registered dietitian, and physician throughout the program.~The total length of this program is 8-weeks and is timed to occur in the waiting period between the consent for surgery and operation date."
223850986|NCT03347045|OTHER|No Prehab; ERP Alone|1-hr daily exercise with a self-completed home-exercise program. The participant will be given nutritional education material and a take-home anxiety-reduction program. They will be responsible for maintaining a journal of their activity.
223850987|NCT06431035|DIETARY_SUPPLEMENT|caffeine|The participants chewed either caffeine gum (5 mg/kg for 10 minutes per chew) or a placebo (10 minutes per chew, using regular gum).
223850988|NCT04338165|DRUG|Evolocumab 140 MG/ML [Repatha]|3 injections of evolocumab 140 milligrams performed within 30 minutes and self-administered (subcutaneously in the abdomen, thigh, or upper arm)
223850989|NCT04622527|OTHER|Random assigned paradigm viewing order|Participants experience the paradigm in a random order
223850990|NCT03908047|OTHER|magnetic resonance imaging|functional magnetic resonance imaging and diffusion tensor imaging after tibialis nerve stimulation
223850991|NCT00472147|PROCEDURE|shock efficacy|
223850992|NCT05085184|DRUG|administration of UI018|Test
223850993|NCT05085184|DRUG|co-administration of UIC201806 and UIC201602|Reference
223850994|NCT04164628|OTHER|Quality of life assessment|Quality of life will be assessed with Nottingham Health Profile
223850995|NCT05165290|DRUG|Latanoprost ophthalmic solution, 0.005%|Commercially available, FDA-approved generic latanoprost ophthalmic solution, 0.005% (LAT) without modification will be used as the active control
223850996|NCT05165290|DRUG|TC-002 latanoprost ophthalmic solution, 0.005%|TC-002 is formulated using the commercially available latanoprost drug substance; delivered drop to the eye is preservative-free.
223850997|NCT03491956|DEVICE|DFPP|Lipid levels,platelet function，and platelet RNA sequencing in hyperlipidemia patients before and after DFPP
223850998|NCT00666120|OTHER|Enfamil LIPIL with iron|cow's milk based infant formula
223850999|NCT00666120|OTHER|Good Start Supreme with DHA and ARA|partially hydrolzed cow's milk protein
223851000|NCT00349908|DEVICE|Cordis Neurovascular ENTERPRISE Self Expanding Stent System|Implantation of the device ENTERPRISE used to treat symptomatic stenosis in intracranial arteries.
223851001|NCT00349908|DEVICE|Cordis Neurovascular ENTERPRISE Self Expanding Stent System|Implantation of the device ENTERPRISE to treat wide-necked aneurysms
223851002|NCT05602857|OTHER|Balance Training|"The BT program has multiple difficulty levels, and each child will progress at an individual pace tailored to their balance skills. Training sessions will emphasize top-down control of balance and contain a combination of dynamic and static balance exercises. Children and their parents will receive written step-by-step instructions, with photos, verbal and/or video instructions on their private OneDrive folder.~To monitor compliance, whether the exercises were done properly, and evaluate a child's progress, the parent/guardian will film the sessions, and upload the video to OneDrive, so we can score the child's performance and provide them with a progress tracking chart.~Every child will be given the equipment needed to do the balance exercises: two wooden beams that will make a 12-foot balance beam, four small wooden cubes that will raise the balance beam 5 inches off the ground, a wobble board, a hopscotch mat, one roll of painter's tape, one measuring tape, a bell, a small book."
223851003|NCT05602857|OTHER|Music Training|"Children assigned to MT will be asked what kind of music and what performers they like best, and what songs they like most. After those open-ended questions, they will be asked about specific songs, guided somewhat by the child's previous answers, and will watch short excerpts from music videos to see which the child would like to listen to and watch during Week 1 of the MT program. This is all to guide the selection of music videos the child will enjoy and might give some thought to.~They will receive 10 music videos per week, through the child's private OneDrive folder, from which they can choose 4 to watch every session. Children will be instructed to not do anything else, but simply watch the videos or listen with their eyes closed.~To monitor compliance, and to check if the child was paying attention to the music videos or just having them play in the background while doing something else, the parent/guardian will film the MT sessions, and upload the video to OneDrive."
223851004|NCT03683472|BEHAVIORAL|Unwinding Anxiety Phone App|"The Unwinding Anxiety program focuses on teaching individuals 1) to understand how anxious worry is developed and perpetuated through reinforcement learning, 2) how to recognize these worry habit loops and 3) how to bring mindful awareness to moments of worry such that they can uncouple feelings of anxiety from reactive worry thinking and ride out habitual mind states that perpetuate and reinforce anxiety"
223851005|NCT04565249|DRUG|PLN-74809|PLN-74809
223851006|NCT04565249|DRUG|Placebo|Placebo
223851007|NCT04162509|OTHER|AR app|Participants will be exposed to nine different AR spider scenarios with a pre-defined length of 2 minutes for each level. Each level starts with a surface scan of the environment and the placement of the AR spider model(s) by tapping on the display. Through small text pop-ups the user is instructed to perform different tasks (e.g. looking at the spider model, approaching it, holding the hand under the model). They proceed to further levels according to a predefined exposure scheme based on SUDS for fear (scale 0=no fear to 10=maximum fear) and disgust (scale 0=no disgust to 10=maximum disgust) and the assurance of the task completed (yes/no). Users will repeat each level until their SUDS are 4 or below and have completed the task. Each exposure session is limited to approx. 30 minutes (controlled by the participants) irrespective of achieved level.
223851008|NCT01861678|PROCEDURE|High tie of IMA|Conventional technique
223851009|NCT01861678|PROCEDURE|Low tie of IMA|Technique for preserving left colic arterial perfusion
223851010|NCT04311229|DEVICE|Negative-Pressure Wound Therapy group|The wounds were initially evaluated for any necrotic findings and debrided if needed, and then washed with an antiseptic solution. 3-DWM was used to measure the pressure sores by taking pictures.The length and width of wounds were measured with disposable paper rulers. Wound depth was determined in centimeters with a sterile cotton-tip applicator by measuring against a ruler. The wound was closed using a Wound Care Kit that includes foam dressing, film drape, TRAC pad with tubing and a drainage canister. Foam material was placed inside the wound and was attached to the canister through tubing.The canister was attached to the Vacuum-Assisted Closure device, which is a portable device that applies intermittent or continuous negative pressure.The device was operated at 125 mmHg pressure for 5 minutes with and 2 minutes without active vacuum.Wound dressings were changed every 48 hours.Wound area was measured after all three rounds of treatment.
223851011|NCT04311229|OTHER|contol group|Wounds were finally covered with gauze dressing soaked with saline. Wounds were treated three times a day, and measurements were repeated every 48 hours. Every wound was measured a total of four times: one pre-treatment (baseline) and three post-treatment measurements.
223851012|NCT04157712|DRUG|ALZ-801 or matching placebo|
223851013|NCT04553302|OTHER|This study does not contain any intervention.|This study does not contain any intervention.
223851014|NCT04138771|DEVICE|An artificial intelligence system for postoperative management of cataract patients|This system can detect multiple postoperative complications of cataract patients and then provide a management strategy.
223851015|NCT00151996|DRUG|Methylphenidate + SPD503 (Guanfacine hydrochloride)|
223851016|NCT00151996|DRUG|Amphetamine + SPD503|
223851017|NCT01544140|DRUG|Midazolam|Oral syrup 7.5 mg, single dose
223851018|NCT01544140|DRUG|vandetanib|Oral tablets, 800 mg, single dose
223851019|NCT04319796|OTHER|Data set as defined by the ERN Research Workgroup of the European Commission|"The ERN-RND registry will be restricted to the minimum data set as defined by the ERN Research Workgroup of the European Commission. This includes the following data:~* Name of specialist center~* Pseudonym:~* Date of birth: For confidentiality reasons the ERN-RND registry will restrict this information to the Year of birth~* Sex~* Date of death: For confidentiality reasons the ERN-RND registry will restrict this information to the Year of death~* Age of onset~* Orphacode for specific rare disease: https://www.orpha.net/consor/cgi-bin/Disease\_Search.php?lng=DE~* Online Mendelian Inheritance in Man (OMIM) code as defined for genetic diseases: https://www.omim.org/~* Human Phenotype Ontology (HPO) terms for key features: https://hpo.jax.org/app/~* Agreement to be contacted for research purposes: Yes/No~* Biological samples (Yes / No)~* Link to a biobank (Link / No)~* Classification of disability (Disease group specific score)"
223851020|NCT05092906|OTHER|LP with complementary hypnoanalgesia|The lumbar puncture technique will be identical to that of the group standard of care. Hypnosis will be performed by a health professional trained in this practice, in addition to the standard analgesic management.
223851021|NCT05092906|OTHER|LP with standard of care|"The LP will be carried out according to the usual techniques without hypnosis.~Standard analgesic treatments will be used (except contraindications):~* EMLA (Lidocain+Prilocain) Cream/Patch~* Local anesthesia with lidocain chlorhydrate monohydrate 1% injectable~* Nitrous oxide"
223851022|NCT00496379|DRUG|ZK219477|Given intravenously over approximately 30 minutes once every 3 weeks
223851023|NCT00719017|PROCEDURE|Upper vaginectomy|Laparoscopic surgery with upper vaginectomy
223851024|NCT00719017|RADIATION|Post-operative brachytherapy|Laparoscopic surgery followed by brachytherapy
223851025|NCT00719017|PROCEDURE|Standard procedures|Laparoscopic surgery +/- brachytherapy +/- pelvic radiation
223851026|NCT02389192|DRUG|ZMAPP|ZMappTM, a combination of three mouse/human chimeric monoclonal antibodies (mAbs; c4G6, c2G4, and c13C6-FR1) directed against Ebola virus glycoprotein epitopes
223851027|NCT02074956|BIOLOGICAL|AERAS-404|AERAS-404 is comprised of the H4 antigen, a fusion protein of Mycobacterium tuberculosis antigens 85B and TB10.4; and IC31 adjuvant, a combination of a leucine-rich peptide and a synthetic oligonucleotide.
223851028|NCT02074956|BIOLOGICAL|Placebo|Sterile buffer containing 10 mmol Tris and 169 mmol of NaCl in 0.8 mL of aqueous solution. This is the identical buffer solution in which H4 and IC31 are formulated.
223851029|NCT05829174|BEHAVIORAL|Psychoeducation and cognitive modules|Psychoeducation and cognitive modules: what is procrastination, role of rewards, work environment, belief identification, cognitive restructuring, relapse prevention.
223851030|NCT05829174|BEHAVIORAL|Behavioral module: Starting on Time and Planning Realistically|Learning of realistic planning, and timely starting of work.
223851031|NCT05829174|BEHAVIORAL|Behavioral module: Working Time Restriction|Restriction of allowed time for work, and gradual increase of allowed time, if previous time windows where effectively used.
223851032|NCT05829174|BEHAVIORAL|Behavioral module: Pomodoro Time Management Technique|Working in 25 minutes time intervals
223851033|NCT02912195|DRUG|Intravenous lidocaine|Intravenous lidocaine drip over 10 minutes followed by intravenous lidocaine drip over 50 minutes
223851034|NCT02912195|DRUG|Intravenous morphine|Emergency department provider chooses appropriate dose of intravenous morphine
223851035|NCT02714127|OTHER|First-void urine collection|One time collection of ca. 20ml of first-void urine (i.e. the initial stream of the urine void) with the Colli-PeeTM device (Novosanis).
223851036|NCT02714127|OTHER|Cervicovaginal lavage fluid collection|During colposcopy, the cervicovaginal region is rinsed for 2 minutes with 50 ml acetic acid (5%). This fluid is not discarded like it is done usually, but the remaining lavage fluid (5% acetic acid containing cervicovaginal fluid) will be collected.
223851037|NCT01649791|DRUG|lenalidomide|Given orally
223851038|NCT01649791|OTHER|laboratory biomarker analysis|Correlative study
223851039|NCT01649791|PROCEDURE|lymph node biopsy|Correlative study
223851040|NCT01649791|PROCEDURE|bone marrow aspiration|Correlative study
223851041|NCT01649791|OTHER|pharmacological study|Correlative study
223851042|NCT01649791|OTHER|flow cytometry|Correlative study
223851043|NCT02295475|DRUG|Apixaban|
223851044|NCT02295475|DRUG|Warfarin|
223851045|NCT04257279|PROCEDURE|ExcelsiusGPS™|The ExcelsiusGPS™ is a Robotic Positioning System that includes a computer controlled robotic arm, hardware, and software that enables real time surgical navigation and robotic guidance using radiological patient images (pre-operative CT, intra-operative CT and fluoroscopy), using a dynamic reference base and positioning camera.
223851046|NCT05798208|DIAGNOSTIC_TEST|blood pressure measurement|Taking blood pressure with automated arm sphygmomanometer and pressure higher than 140/90 was considered abnormal
223851047|NCT01801930|DRUG|OCV-103 and OCV-104|0.3 mg of each
223851048|NCT01801930|DRUG|OCV-103 and OCV-104|1 mg of each
223851049|NCT01801930|DRUG|OCV-103 and OCV-104|3 mg of each
223851050|NCT01801930|DRUG|OCV-103 and OCV-104|6 mg of each
223851051|NCT02860923|DRUG|Exenatide|
223851052|NCT02860923|DRUG|Placebo|
223851053|NCT03937687|DRUG|Caffeine+TeaCrine+Dynamine|combination of caffeine, TeaCrine, and Dynamine
223851054|NCT03937687|DRUG|Placebo|Placebo
223851055|NCT03937687|DRUG|Caffeine|Caffeine
223851056|NCT02509780|OTHER|Vichy|Volunteers will be asked during 3 days to take their usual intake of fluids. For the following 7 days, they will take the usual intake of fluids plus 250 ml of Vichy water at 1 pm. For the following 7 days, they will take the usual intake of fluids plus 250 ml of Vichy water at 7 am and 7 pm. Ph and density measurement of urine will be made three times a day, at 7 am, 2 pm and 8 pm.
223851057|NCT03425604|PROCEDURE|Intrauterine insemination|
223851058|NCT05251688|OTHER|Cryoanalgesia|"On the first day of the study, the PI met the participants and assessed their level of consciousness using the Modified Glasgow Coma Scale to ensure that they were unconscious and reviewed the medical records to collect their sociodemographic data. After that, the participants received routine care before the arterial puncture. The PI assessed their pain scores during the puncture.~In the second meeting (on the same day or the following day), the PI prepared the ice packs by crushing small pieces of ice and wrapping them in smooth gauze to avoid skin damage and moisture in the puncture area. Before the arterial puncture, the ice pack was applied over the selected puncture site (radial, brachial, or femoral artery) for 5 minutes in addition to the routine care. After removing the ice pack, the nurse palpated the artery, wiped of the residue of ice vapor present on the skin, and took the arterial blood sample. During the puncture, the PI assessed the participants' pain scores."
223851059|NCT01487564|DRUG|Hydromorphone 16 mg|type= exact number, unit= mg, number= 16, format= tablet, route= oral use. One tablet of hydromorphone 16 mg.
223851060|NCT01188629|BEHAVIORAL|Safety Training|IT intervention focuses on safety in the home.
223851061|NCT01188629|BEHAVIORAL|Personal Health Partner and Counseling (PHP+C)|The PHP intervention will have three primary functional areas: 1) pre-visit assessment and counseling; 2) EHR data exchange with clinician review; and 3) post-visit follow-up, re-assessment, and counseling.
223851062|NCT05140564|BEHAVIORAL|STEADY intervention|STEADY is a novel Cognitive Behavioural Therapy (CBT) based intervention for eating disorders in type 1 diabetes.
223851063|NCT06386562|BEHAVIORAL|Family Check-up and Cognitive behavior therapy online: a Swedish internet-based parenting program|The internet-based parenting support program is based on social learning theory. A foundation is the Family Check-up program (FCU), which includes approaches from motivational interviewing (MI). The parenting support is also based on similar CBT-parenting strategies as in other evaluated face-to-face CBT-parenting support programs (e.g., Comet) as well as internet-based programs (e.g., iComet; ParentWeb).
223851064|NCT06386562|BEHAVIORAL|Family Check-up and Cognitive behavior therapy online: a Swedish internet-based parenting program with additional parental support|The internet-based parenting program includes the same contents and chat-function as in the other condition. The focus for the digital/phone meetings is to explore potential questions, problem-solve around potential challenges, and motivate parents to practice strategies and complete modules.
223851065|NCT01413113|DRUG|pazopanib hydrochloride|Given PO
223851066|NCT01413113|RADIATION|iodine I 131|Given IM
223851067|NCT06454773|DIETARY_SUPPLEMENT|NCT/NFT|extract from black pepper and hemp hull
223851068|NCT04371718|DRUG|JKB-122|JKB-122 is a TLR antagonist to immune modulate for autoimmune hepatitis
223851069|NCT04371718|OTHER|Placebo|A capsule has same component but active drug
223851070|NCT04157257|DRUG|TDF tablet|TDF tablet 300mg QD
223851071|NCT04157257|DRUG|Entecavir Tablet|Entecavir tablet 0.5mg QD
223851072|NCT04157257|DRUG|QL-007|QL-007 tablets 200mg BID
223851073|NCT00908947|DEVICE|PTA followed by placement of LifeStent® Vascular Stent|PTA followed by placement of LifeStent® Vascular Stent
223851074|NCT05381662|BIOLOGICAL|CD19 CAR-T cells and CD19 positive feeder T cells|Detailed Description: Patients were divided into two groups, group 1 and group 2, and each group was enrolled in 5 patients. Group 1 patients did not receive any pretreatment, and group 2 patients received pretreatment with cyclophosphamide and fludarabine prior to reinfusion. Then Patients were given Chimeric Antigen Receptor T-Cell ( CAR-T) and CD19-positive T cells.
223851075|NCT02786771|DEVICE|Spire|
223851076|NCT02786771|DEVICE|Muse headband|
223851077|NCT00553215|PROCEDURE|quality-of-life assessment|
223851078|NCT00553215|PROCEDURE|questionnaire administration|
223851079|NCT01835340|DEVICE|Drug: Propofol Anesthesia Patients will undergo propofol anesthesia.|
223851080|NCT01644773|DRUG|Crizotinib|"Starting dose level:~* Initial Treatment Plan: 130 mg/m\^2 per dose~* Modified Treatment Plan per Amendment 1.0: 165 mg/m\^2 per dose~The dose of a single agent will be increased by approximately 30% in each subsequent cohort until the MTD of this combination is reached.~The doses of each agent will not exceed their single-agent MTD already determined for children with recurrent solid tumors.~Cycle 1 (28 days): once a day for 28 days~Cycles 2-26 (28 days each): once a day"
223851081|NCT01644773|DRUG|Dasatinib|"Starting dose level: 50 mg/m\^2 per dose~The dose of a single agent will be increased by approximately 30% in each subsequent cohort until the MTD of this combination is reached.~The doses of each agent will not exceed their single-agent MTD already determined for children with recurrent solid tumors.~Cycle 1 (28 days): starting on day 3, once a day for 28 days~Cycles 2-26 (28 days each): once a day"
223851082|NCT00930813|DEVICE|Lutonix Catheter|Paclitaxel Coated Balloon Catheter
223851083|NCT00930813|DEVICE|Standard uncoated Balloon Angioplasty Catheter|plain, uncoated angioplasty balloon catheter
223851084|NCT01603719|DIETARY_SUPPLEMENT|new infant formula with prebiotics and beta-palmitate|experimental infant formula as sole source of nutrition over first 12 weeks of life
223851085|NCT02947568|OTHER|non-interventional study|
223851086|NCT04835038|DRUG|Sodium Bicarbonate Ringer's Injection|Intraoperative fluid therapy performed with BRS (Sodium Bicarbonate Ringer's Injection)
223851087|NCT04835038|DRUG|Sodium Lactated Ringer's Injection|Intraoperative fluid therapy performed with LRS (Sodium Lactated Ringer's Injection)
223851088|NCT03999554|BIOLOGICAL|LD Sing2016 M2SR H3N2 influenza vaccine|This group will receive a low dose of the Sing2016 M2SR H3N2 monovalent influenza vaccine administered intranasally.
223851089|NCT03999554|BIOLOGICAL|MD Sing2016 M2SR H3N2 influenza vaccine|This group will receive a medium dose of the Sing2016 M2SR H3N2 monovalent influenza vaccine administered intranasally.
223851090|NCT03999554|BIOLOGICAL|HD Sing2016 M2SR H3N2 influenza vaccine|This group will receive a high dose of the Sing2016 M2SR H3N2 monovalent influenza vaccine administered intranasally.
223851091|NCT03999554|BIOLOGICAL|LD Bris10 M2SR H3N2 influenza vaccine|This group will receive a low dose of the Bris10 M2SR H3N2 monovalent influenza vaccine administered intranasally.
223851092|NCT03999554|OTHER|Placebo|This group will receive saline placebo administered intranasally.
223851093|NCT06582563|DIAGNOSTIC_TEST|Whole Blood Clotting Time|Comparator
223851094|NCT05591079|DRUG|CS0159 (Linafexor)|Oral QD
223851095|NCT03780790|DRUG|Bupivacaine|% 0,25
223851096|NCT01101165|DRUG|Reformulated OXY (oxycodone HCl)|Reformulated OXY 40-mg tablet x 1 dose taken without food
223851097|NCT01101165|DRUG|Original OxyContin® (OXY) (oxycodone HCl)|Original OxyContin® (OXY) 40-mg tablet x 1 dose taken without food
223851098|NCT03655483|DRUG|GLS-010|Full-human anti-pd-1 monoclonal antibodies
223851099|NCT04517591|BEHAVIORAL|The Take a STAND for health|A 4-month parallel-group randomised controlled trial will be performed, in which patients post-bariatric surgery will be assessed at baseline pre-surgery (PRE-BAR), 3 months after surgery and pre-intervention (PRE-INT) and 4 months after intervention (POST). Moreover, a sub-sample of patients will perform a randomised crossover trial at baseline (PRE). Patients will complete three experimental sessions in a random manner, as follows: Prolonged sitting (SIT), in which participants engaged in prolonged sitting throughout an 5-h period and were instructed to minimize excessive movement; Exercise followed by prolonged sitting (EX), in which participants performed a 30-min moderate-to-vigorous exercise bout on a treadmill, subsequently, participants engaged in prolonged sitting as described for SIT; Light-intensity breaks (BR), in which participants completed a 3-min bout of light-intensity walking every 30 min of sitting throughout the experimental period.
223851100|NCT00273676|PROCEDURE|Conversion to oral antibiotic treatment after 3 days of intravenous antibiotic treatment|
223851101|NCT00800163|OTHER|ED Activation/Immediate Transfer|ED Physician Activation and Immediate Transfer Protocol - see Circulation. 2007;116:67-76
223851102|NCT00015457|DRUG|Amlodipine plus Botulinum toxin|
223851103|NCT02775981|DRUG|RX0041-002|
223851104|NCT04397198|DIAGNOSTIC_TEST|Speckle Tracking echocardiography|"Diagnostic tests:~Speckle Tracking echocardiography with analyzing the myocardial strain, myocardial velocities, 128-multislice CCTA with the evaluation of the Calcium Scoring (total and local) , identifying the coronary stenosis, evaluation of the plaque vulnerability degree, assess polar maps of the myocardium.~MRI for the evaluation of the percentage of myocardial scar, also the percentage of the viable myocardial tissue using contrast late enhancement sequences, measuring myocardial fibrosis using Q-mass software.~Diagnostic tests:~Laboratory assessment for the evaluation of the level of hs-CRP and myocardial necrosis biomarkers"
223851105|NCT04463264|DRUG|Nitazoxanide|NTX (500 mg every 6 hours for 14 days) orally with food (P.O.).
223851106|NCT04463264|DRUG|Placebo|Placebo (1 tablet every 6 hours for 14 days) orally with food (P.O.).
223851107|NCT04551157|OTHER|Video Viewing|Two patient information videos containing practical advice from staff about the recovery process, images of the wound throughout the healing process and ways to cope with the range of emotional responses that patients report following an open fracture.
223851108|NCT04669405|DEVICE|High intensity laser therapy|A prospective, randomized, controlled study was undertaken. A total of 44 patients who met inclusion criteria were randomly divided into two groups. HILT group (n=22) received 3 sessions of HILT per week for 3 weeks in addition to the multidisciplinary stroke rehabilitation and exercise program which performed 5 sessions per week for 3 weeks. Control group (n=22) received a multidisciplinary stroke rehabilitation and exercise program for HSP of 5 sessions per week for 3 weeks.
223851109|NCT04669405|OTHER|Therapeutic Exercise|A prospective, randomized, controlled study was undertaken. A total of 44 patients who met inclusion criteria were randomly divided into two groups. HILT group (n=22) received 3 sessions of HILT per week for 3 weeks in addition to the multidisciplinary stroke rehabilitation and exercise program which performed 5 sessions per week for 3 weeks. Control group (n=22) received a multidisciplinary stroke rehabilitation and exercise program for HSP of 5 sessions per week for 3 weeks.
223851110|NCT02665130|OTHER|Tai-chi plus Indacaterol|Participants perform Tai-chi exercise 5 days/week and take indacaterol 150ug/day for 24 weeks
223851111|NCT02665130|OTHER|Pulmonary rehabilitation plus Indacaterol|Participants perform conventional exercise 5 days/week and take indacaterol 150ug/day for 24 weeks
223851112|NCT06226974|OTHER|Static Stretching|"* Shoulder extension - shoulder extension with the hand resting on a door;~* Doorway stretch - horizontal abduction with the shoulder in 90º of abduction, the elbow in 90º of flexion and the forearm leaning against a door;~* Shoulder flexion - arms above the head against a wall;~* Cross-body stretch - maximal horizontal adduction of the arm, with the opposite hand holding the stretch;~* Overhead triceps - arm above the head and elbow flexed, with the other hand pulling the elbow;~* Internal Rotation 90° stretch - with the shoulder at 90º of flexion and the elbow at 90º of flexion, the opposite hand and forearm forces the internal rotation."
223851113|NCT00620581|DRUG|Paroxetine|Paroxetine 10mg and 20mg during the luteal phase of the menstrual cycle
223851114|NCT04363762|BEHAVIORAL|Internet-based multimodal pain program|A guided internet-based multimodal pain program for chronic TMD pain
223851115|NCT04363762|DEVICE|Occlusal splint|Occlusal splint, standard
223851116|NCT04127539|BEHAVIORAL|Strong & Steady exercise program|The community-based group exercise program S\&S, with strengthening and balance exercise as the main components. The participants will attend a once-weekly, one hour supervised session. The exercises that will be used can be found in the S\&S handbook which includes different difficulty levels. All instructors are volunteers and have completed the S\&S education. Each exercise session will consist of a warm-up (5-8 min.), endurance exercises (10-15 min.), strength exercises (15 min.), balance exercises (20 min.) and a cool down/stretching (5 min.). In addition to attending the group exercises, the participants will be taught and encouraged to do home exercises twice a week from hand out leaflets that can be found at www.sterkogstodig.no.
223851117|NCT03014687|DRUG|Placebo|PO BID placebo for 7 days. Postoperative days 1 through 7: patients will administer saline spray (e.g., Ocean nasal spray) to both nostrils four times daily. Postoperative days 8 through 30: patients will begin twice daily sinus irrigation rinse (e.g., Neti-pot) until day 30. After day 30, patients will perform sinus irrigation as needed. If a patient is unable to tolerate nasal rinses, saline spray can be used as an alternative.
223851118|NCT03014687|DRUG|Oral Antibiotics cefdinir or trimethoprim/sulfamethoxazole|Oral antibiotics (cefdinir \[Omnicef®\] 300 mg PO BID or trimethoprim/sulfamethoxazole \[Bactrim DS™\] PO BID for cephalosporin intolerant patients) for 7 days.Postoperative days 1 through 7: patients will administer saline spray (e.g., Ocean nasal spray) to both nostrils four times daily. Postoperative days 8 through 30: patients will begin twice daily sinus irrigation rinse (e.g., Neti-pot) until day 30. After day 30, patients will perform sinus irrigation as needed. If a patient is unable to tolerate nasal rinses, saline spray can be used as an alternative.
223851119|NCT05406180|BIOLOGICAL|VaxigripTetra inj.|Suspension for injection in a pre-filled syringe Injection intramuscular
223851120|NCT01188486|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|Standard of care diagnostic radiotherapy procedure
223851121|NCT01188486|RADIATION|Computed Tomography (CT)|For each participant, 3 chest CT scans will be obtained, 1 before and 2 after interstitial injection of the water-soluble contrast
223851122|NCT01188486|DEVICE|Cyberknife|Linear accelerator for producing high energy x-rays for radiation therapy.
223851123|NCT01188486|DEVICE|Trilogy|Linear accelerator for producing high energy x-rays for radiation therapy.
223851124|NCT01188486|DEVICE|True Beam|Linear accelerator for producing high energy x-rays for radiation therapy.
223851125|NCT01188486|DRUG|Iohexol|Aqueous solution of a nonionic, water-soluble radiographic contrast medium in prefilled cartridges with a molecular weight of 821.14 (iodine content 46.36%), available at 140, 180, 240, 300, and 350 mgI/mL.
223851126|NCT01188486|DRUG|Iodixanol|Aqueous solution of a nonionic, water-soluble, dimeric, isosmolar, radiographic contrast medium with a molecular weight of 1550.20 (iodine content 49.1%), available in 2 concentrations, (270 mgI/mL and 320 mgI/mL.
223851127|NCT01316978|DRUG|Ibuprofen|A single 2 x 100 mg dose of an experimental Ibuprofen Fast Melt Orodispersible Tablet administered orally, with a 7-day washout between visits
223851128|NCT01316978|DRUG|Ibuprofen|A single 200 mg Nurofen Meltlets Orodispersible Tablet administered orally, with a 7-day washout between visits
223851129|NCT01316978|DRUG|Ibuprofen|A single 2 x 100 mg dose of Junior Strength Motrin Chewable Tablet administered orally, with a 7-day washout between visits
223851130|NCT00331214|DRUG|Testosterone Transdermal System|testosterone patch (300 mcg/day), patch changed twice a week for six months
223851131|NCT00331214|DRUG|placebo patch|placebo patch replaced every 3-4 days for 6 months
223851132|NCT05203055|DRUG|Peginterferon alpha-2b|180μg/w
223851133|NCT05203055|DRUG|Nucleotide Analog|Etecavir 0.5mg qd or Tenofovir 300mg qd
223851134|NCT05203055|DRUG|pulse peginterferon alpha-2b|180μg/w for 8 consecutive weeks and cessation for 4 weeks
223851135|NCT00923676|DRUG|fenofibrate|pill 145 mg, 145 mg/day, for 12 months
223851136|NCT00923676|DRUG|Rosuvastatin|pills of 10 mg, 10 mg/day, 12 months
223851137|NCT00923676|DRUG|fenofibrate + rosuvastatin|fenofibrate 145 mg/day + rosuvastatin 10 mg/day for 12 months
223851138|NCT04322656|DEVICE|Lipiflow treatment|Patients will be treated on one eye with Lipiflow
223851139|NCT01244100|DRUG|PL2200 fasted|Fasted state
223851140|NCT01244100|DRUG|PL2200 fed|Fed state
223851141|NCT04054661|DIAGNOSTIC_TEST|SD Biosensor STANDARD G6PD Test|The SD Biosensor G6PD Analyzer is designed to measure the quantitative determination of total hemoglobin concentration and G6PD enzymatic activity in fresh human whole blood specimens based on reflectometry assays in a point-of-care setting. The test is intended to aid in the identification of people with G6PD deficiency. The test is currently not licensed for use in the US and is considered an investigational product.
223851142|NCT04054661|DIAGNOSTIC_TEST|Pointe Scientific Test Kit|The Pointe Scientific test kit will serve as the reference assay to assess G6PD activity. Its intended use is for the quantitative, kinetic determination of G6PD in blood at 340 nm.
223851143|NCT04054661|DIAGNOSTIC_TEST|HemoCue System|The HemoCue hemoglobin (Hb) 201+ system is designed for quantitative point-of-care whole blood hemoglobin determination in primary care using a specially designed analyzer, the HemoCue Hb 201+ Analyzer, and specially designed microcuvettes, the HemoCue Hb 201+Microcuvettes.
223851144|NCT04816890|DRUG|M1 Pram P037|Subcutaneous administration of M1 Pram P037 in combination with a basal insulin.
223851145|NCT04816890|DRUG|Insulin lispro|Subcutaneous administration of insulin lispro in combination with a basal insulin.
223851146|NCT03767114|DIAGNOSTIC_TEST|RT-PCR for ERAP1 detection|Reverse transcriptase -Polymerase Chain Reaction for ERAP1 detection
223851147|NCT03985709|OTHER|Probiotic product|Probiotic (Lactobacillus casei) once daily taken by 3 months.
223851148|NCT01588704|DRUG|Neoadjuvant Bevacizumab|Neoadjuvant Pemetrexed, Carboplatin and Bevacizumab followed by surgical resection
223851149|NCT03971747|BIOLOGICAL|AFP Specific T Cell Receptor T Cells|Autologous T cells transduced with lentivirus encoding AFP specific TCR gene
223851150|NCT00704756|BIOLOGICAL|PegIntron (peginterferon alfa-2b; SCH 54031)|PegIntron administered at 1.5 μg/kg body weight/week subcutaneously for up to 24 wks (Genotype \[G\] 2,3/low viral load G 1) or 48 weeks for (G 1,4,5)
223851151|NCT00704756|DRUG|Rebetol (ribavirin; SCH 18908)|Rebetol administered based on body weight 800-1200 mg/day (\<65 kg : 800 mg, 65 - 85 kg : 1000 mg, \>85 kg : 1200 mg) orally for up to 24 wks (Genotype \[G\] 2,3/low viral load G 1) or 48 weeks for (G 1,4,5)
223851152|NCT01002443|DRUG|Helicobacter pylori eradication|Omeprazole 20 mg or Rabeprazole 10 mg bid + clarithromycin 500 mg and amoxicillin 1,000 mg bid for 7 days
223851153|NCT01002443|DRUG|placebo|Omeprazole 20 mg or Rabeprazole 10 mg bid + two placebo (for antibiotics) for 7 days
223851154|NCT05295082|PROCEDURE|guided trephination-based drilling protocol|the implant site preparation in this group will be done by guided trephination protocol which uses the surgical guide to trephine the implant site then remove the guide and continue the drilling in a freehand manner
223851155|NCT05295082|PROCEDURE|guided Conventional drilling-based protocol|the implant site preparation in this group will be done by a guided conventional drilling protocol which uses the surgical guide to guide the sequential drills up to the final drill
223851156|NCT03404843|DRUG|Fasudil Hydrochloride|10 mg/mL vial of fasudil hydrochloride. 6 mL (60 mg) of fasudil hydrochloride are added to a 100 mL saline bag for delivery to subjects.
223851157|NCT03404843|OTHER|Saline|100 mL saline bag.
223851158|NCT00814281|OTHER|placebo|Placebo
223851159|NCT00814281|DRUG|Montelukast|10 mg ingested orally 1 hour prior to exercise testing
223851160|NCT00567164|DRUG|EE20/DRSP (BAY86-5300)|Combination tablet containing 0.02 mg ethinyl estradiol as betadex clathrate and 3.0 mg drospirenone
223851161|NCT00567164|DRUG|EE20/DRSP (BAY86-5300)|Combination tablet containing 0.02 mg ethinyl estradiol as betadex clathrate and 3.0 mg drospirenone
223851162|NCT00567164|DRUG|EE20/DRSP (YAZ, BAY86-5300)|Fixed package per cycle containing combination tablets containing 0.02 mg ethinyl estradiol as betadex clathrate and 3.0 mg drospirenone (24 per cycle) + tablets without active substance (4 per cycle)
223851163|NCT05158192|DRUG|Diosmin/Hesperidin (90/10) 500 mg Test Drug|Investigational Medicinal Product
223851164|NCT05158192|DRUG|Diosmin/Hesperidin (90/10) 500 mg Reference Product|Daflon (Trademark)
223851165|NCT02543216|DIETARY_SUPPLEMENT|Sunflower oil|Study diets were isocaloric following the habitual diet of the participants with a supplement of 30-50 ml (25-45 g) sunflower oil daily depending on body weight. Thus, approximately 16-28 g (6 E%) LA were provided daily on top of the average intake of approximately 10-12 g (4.5 E%).
223851166|NCT02302209|DRUG|Oxytocin|
223851167|NCT02302209|OTHER|Placebo Comparator|
223851168|NCT00346593|DEVICE|Silicone hydrogel contact lens|
223851169|NCT00586014|PROCEDURE|High-Dose Sequential Chemotherapy followed by ASCT|Patient will receive Cyclophosphamide(4 g/m2 over 2 hours) and blood progenitor cell collection (day -49). G-CSF (10 mcg/kg/d) will be administered SQ. A six hour leukapheresis will be performed,cells will undergo CD34+ cell selection, patients will receive high dose VP-16 (Etopophos)(day -28)(2 g/m2 over 4 hours)and G-CSF (5 mcg/kg/d) will be administered SQ two days following VP-16. The an IV of sulfamethoxazole-trimethoprim 1 ampule BID for 5 days (Day -5). BCNU 500 mg/m2 IV over 2 hours (Day -4). Melphalan (Day -2) will be administered IV (200 mg/m2 over 20 minutes). The frozen peripheral blood mononuclear cells will be transfused on Day 0. Day +1: G-CSF 5 mcg/kg/d SQ for 3 days.
223851170|NCT00710307|PROCEDURE|Blood sampling|Blood samples will be collected at visit 1 (day 1) and at visit 2 (day 14 to 45).
223851171|NCT00710307|GENETIC|Genetic analysis|The sample for genetic analyses may be taken at Visit 1. The blood sample volume will be 6 mL.
223851172|NCT00944801|DRUG|Pegylated Liposomal Doxorubicine|In the dose escalation phase of the study, PEG-Dox is raised in steps of 5 mg/m2 in a 3-by-3 design, starting with 5 mg/m2 (group 1) up to 20 mg/m2 (group 4). In the phase II part of the study, the targeted dose of 20 mg/m2 is administered up to a cumulative dose of 550 mg/m2 or until tumor progression.
223851173|NCT04056923|PROCEDURE|3D-printing guided|3D printed navigational template guided
223851174|NCT04056923|PROCEDURE|CT-guided|CT-guided
223851175|NCT04056923|DRUG|Indocyanine Green|The results are shown by comparison of different colors.
223851176|NCT04056923|DRUG|Methylene blue|The results are shown by comparison of different colors.
223851177|NCT04056923|PROCEDURE|Preoperative|Preoperative localization.
223851178|NCT04056923|PROCEDURE|Intraoperative|Intraoperative localization.
223851179|NCT00787956|BEHAVIORAL|Internet Chronic Disease Self-Management Program (ICDSMP)|
223851180|NCT05129982|DEVICE|whole body vibration|whole body vibration is a modality of physical therapy
223851181|NCT03877471|GENETIC|Cell therapy|Ovary injection with MSC-like cells through transvaginal ultrasound,3 injection points for each ovary.
223851182|NCT04059562|COMBINATION_PRODUCT|Combination of Lonsurf® and Irinotecan|"Trifluridine/Tipiracil (Lonsurf®) and Irinotecan~* Trifluridine/Tipiracil will be administered at a dose of 25 mg/m2 / dose twice daily on days 1-5 followed by a 9-days recovery period from day 6 trough day 14 of each 14-days treatment cycle.~* Irinotecan will be administered at the same time as Trifluridine/Tipiracil (Lonsurf®) on day 1 of each cycle at a dose of 180 mg/m2 / dose."
223851183|NCT06486818|PROCEDURE|Ablation of idiopathic monomorphic PVCs|3D carto ablation of idiopathic monomorphic PVCs
223851184|NCT05317962|DIAGNOSTIC_TEST|Transthoracic echocardiogram|Abbreviated transthoracic echocardiogram
223851185|NCT04164524|DRUG|Gentamycin|Gentamycin 160 mg spray applied over the mesh
223851186|NCT01468324|DRUG|AZD7451|Depending on dose level, AZD7451 will be given once daily for 28 day cycles.
223851187|NCT04138433|DEVICE|Real tDCS|Anodal tDCS 2 ma
223851188|NCT04138433|DEVICE|Sham tDCS|Sham tDCS 2 ma
223851189|NCT00996372|DRUG|flibanserin|patients will be randomized to flibanserin or placebo in a double-blind manner
223851190|NCT00996372|DRUG|placebo|patients will be randomized to flibanserin or placebo in a double-blind manner
223851191|NCT02280655|BIOLOGICAL|Storage-aged red blood cells (saRBCs) units|Packed RBCs units stored for greater than 21 days, with a mean storage duration of 29.6 ± 4.9 days (mean ± SD)
223851192|NCT02280655|BIOLOGICAL|Fresh red blood cells units|Packed RBCs units stored for less than 14 days, with a mean storage duration of 9.6 ± 3.9 days (mean ± SD)
223851193|NCT00927342|OTHER|Vivostat|Patients with an air leak at the end of thoracic surgery despite conventional measures(diathermy, suturing and/or stapling) will receive Vivostat sealant applied to the surface of the lung in an attempt to eliminate air leak
223851194|NCT00927342|OTHER|BioGlue|Patients with an air leak at the end of thoracic surgery despite conventional measures(diathermy, suturing and/or stapling) will receive Bioglue sealant applied to the surface of the lung in an attempt to eliminate air leak
223851195|NCT04940676|DRUG|Huzhangxiefei Decoction|Huzhangxiefei Decoction, 50ml, Oral Administered or Nasal Feeding 5 minutes after breakfast and dinner for 7 days
223851196|NCT04940676|DRUG|10% Huzhangxiefei Decoction|10% Huzhangxiefei Decoction, 50ml, Oral Administered or Nasal Feeding 5 minutes after breakfast and dinner for 7 days
223851197|NCT02430532|DRUG|dimethyl fumarate|capsule
223851198|NCT02430532|OTHER|Placebo|matched placebo capsule
223851199|NCT03995810|DIETARY_SUPPLEMENT|Carnosine, capsulle, 2 g/day, 8 weeks|We will administer supplemental carnosine (2 grams per day) for 8 weeks
223851200|NCT00271258|DRUG|SODIUM DIVALPROATE|
223851201|NCT01190150|DRUG|tranexamic acid|Either one or two modified-immediate release tranexamic acid tablets (0.65 g each) taken orally, administered with 240 mL of water, as a single dose, at approximately 8 AM.
224265550|NCT07139977|DRUG|Enfortumab Vedotin|Enfortumab vedotin is an ADC comprised of a fully human IgG1Κ antibody conjugated to the microtubule-disrupting agent MMAE via a protease-cleavable linker. Enfortumab vedotin is thought to induce anti-tumor activity by binding to the nectin-4 protein on the surface of cancer cells, leading to internalization, proteolytic cleavage of the linker, and intracellular release of MMAE that subsequently disrupts tubulin polymerization and leads to mitotic arrest and apoptosis of the tumor cell.
223851202|NCT04762342|OTHER|Power training|"First a brief warm up on a stationary bike and uni-lateral knee raises is completed.~Power training: Involves exercises performed with fast/explosive muscle contraction during the concentric phase, and slow/controlled (approximately 2-3 s) muscle contraction during the eccentric phase.~Functional- and balance exercises are included from week 9-24.~Progression:~Week 1-4: 3 sets of 12 repetitions at a load of 14 repetitions maximum (RM) with focus on introducing resistance exercise and familiarizing participants with exercises.~Week 5-8: 3 sets of 12 repetitions at a load of 14 RM the power training component.~Week 9-16: 3 sets of 10 repetitions at a load of 12 RM. Week 17-24: 3 sets of 8 repetitions at a load of 10 RM~Strengthening exercises:~* Bilateral leg-press~* Bilateral plantar flexion~* Bilateral knee extension~* Unilateral banded dorsal flexion~* Bilateral lying leg curl~* Back extension~* Shoulder press~* Seated row~* Chest press~* Lat pull-down"
223851203|NCT00082719|BIOLOGICAL|Recombinant Interferon Alfa|"In all arms, treatment begins at pre-operative visit and continues until cystoscopy.~Arm I: Low-dose interferon alfa subcutaneously (SC) twice daily. Arm II: Interferon alfa as in arm I at a higher dose. Arm III: Interferon alfa SC once daily. Arm IV: Interferon alfa as in arm III at a higher dose."
223851204|NCT00000746|BIOLOGICAL|rgp120/HIV-1 SF-2|
223851205|NCT00000746|BIOLOGICAL|Env 2-3|
223851206|NCT00000746|BIOLOGICAL|HIVAC-1e|
223851207|NCT00000746|BIOLOGICAL|gp160 Vaccine (MicroGeneSys)|
223851208|NCT01899222|DEVICE|Handheld fundus photography|diagnostic imaging with two types of retina camera
223851209|NCT02639962|RADIATION|Cardiac CT|Cardiac CT before the CAG, and follow up after 2 month and 12 month
223851210|NCT02962336|DRUG|Torrent's Olmesartan medoxomil, Amlodipine and Hydrochlorothiazide Tablets|Oral, crossover
223851211|NCT02962336|DRUG|Tribenzor Tablets of Daichi Sankyo Inc, USA|Oral, crossover
223851212|NCT02576418|OTHER|Partosure TTD test|PartoSure TTD test and CL will be performed on all patients and the test-to-spontaneous-delivery interval will be calculated.
223851213|NCT00832884|DRUG|Lacosamide|"0.7 mg/kg (up to maximum of 50 mg) x 5 subjects x 30 minutes; 1.4 mg/kg (up to a maximum of 100 mg) x 5 subjects x 30 minutes; 2.1 mg/kg (up to a maximum of 150 mg) x 5 subjects x 30 minutes; 2.9 mg/kg (up to a maximum of 200 mg) x 5 subjects x 30 minutes.~0.7 mg/kg (up to a maximum of 50 mg) x 5 subjects x 15 minutes; 1.4 mg/kg (up to a maximum of 100 mg) x 5 subjects x 15 minutes; 2.1 mg/kg (up to a maximum of 150 mg) x 5 subjects x 15 minutes; 2.9 mg/kg (up to a maximum of 200 mg) x 5 subjects x 15 minutes"
223851214|NCT05098340|GENETIC|Quantitative Real-time polymerase chain reaction|Quantitative Real-time polymerase chain reaction of circular RNA (circRNA).
223851215|NCT04017884|COMBINATION_PRODUCT|Remin Pro Forte|a combination of chemicals with natural products cream .
223851216|NCT04017884|COMBINATION_PRODUCT|Remin Pro|a combination of chemicals
223851217|NCT03192085|DIAGNOSTIC_TEST|SITA FAST VISUAL FIELD TEST|Diagnostic test for glaucoma
223851218|NCT03192085|DIAGNOSTIC_TEST|SITA STANDARD VISUAL FIELD TEST|Diagnostic test for glaucoma
223851219|NCT03735771|DRUG|Bupivacaine|0.25% bupivacaine plus fentanyl 8 mcg/ml
223851220|NCT05492474|PROCEDURE|Cranial Point of Care Ultrasound|Cranial ultrasound involves 2-dimensional B mode imaging of the brain parenchyma in the axial plane using a 1-2 MHz probe through the thin temporal bone. Upload of cPOCUS images will occur over DICOM® based Health Insurance Portability and Accountability Act (HIPAA) compliant platforms accessible via Cloud. Currently all handheld machines use Tricefy® or their own cloud based remote image access application.
223851221|NCT05464134|RADIATION|x-ray|plain radiographs of lower limb anteroposterior and lateral views , lumbar spine plain radiographs (anteroposterior, lateral, lateral in flexion and lateral in extension views )
223851222|NCT06079593|PROCEDURE|Gasless Macular hole surgery|Pars plana vitrectomy to treat full thickness macular hole, with internal limiting membrane flap and ophthalmic viscosurgical device covering
223851223|NCT06079593|PROCEDURE|Standard Macular hole surgery|Pars plana vitrectomy to treat full thickness macular hole, with internal limiting membrane peel, and C2F6 tamponade
223851224|NCT00679276|PROCEDURE|Prolift|surgical repair of vaginal prolapse
224265551|NCT07140536|OTHER|Environmental temperature|The office is day is spent in 19 or 23°C room temperature from 08:30AM to 04:30PM.
224265552|NCT07140536|BEHAVIORAL|Physical activity|From 08:30AM to 04:30PM, the office is day is spent either fully sedentary or interspersed with light walking on a treadmill (60 min at 10:00AM, 15 min at 01:00PM, 15 min at 02:00PM, 15 min at 03:00PM, 15 min at 04:00PM).
224265553|NCT07138547|DRUG|Eliglustat, CD30 target immunotherapy|"Eliglustat 63mg will be administered twice daily in the first 14 days and the following every other week.~CD30 target immunotherapy：Brentuximab Vedotin or CD30-targeting CAR-T Cell Therapy."
224265554|NCT07138898|DRUG|Methotrexate|Continue throughout perioperative period
224265555|NCT07138898|DRUG|Sulfasalazine|Continue throughout perioperative period
224265556|NCT07138898|DRUG|Hydroxychloroquine|Continue throughout perioperative period
224265557|NCT07138898|DRUG|Leflunomide|Continue throughout perioperative period
224265558|NCT07138898|DRUG|Azathioprine|Control group: Withhold the daily dose 1 week prior to surgery Intervention group: Withhold 2 days prior to surgery
224265559|NCT07138898|DRUG|Mycophenolate|Control group: Withhold the daily dose 1 week prior to surgery Intervention group: Withhold 2 days prior to surgery
224265560|NCT07138898|DRUG|Cyclosporine|Control group: Withhold the daily dose 1 week prior to surgery Intervention group: Withhold 2 days prior to surgery
224265561|NCT07138898|DRUG|Tacrolimus|Control group: Withhold the daily dose 1 week prior to surgery Intervention group: Withhold 2 days prior to surgery
224265562|NCT07138898|DRUG|Etanercept|Control group: Schedule surgery 2 weeks after last administered dose Intervention group: Schedule surgery 1 week after last administered dose
224265563|NCT07138898|DRUG|Adalimumab|Control group: Schedule surgery 3 weeks after last administered dose Intervention group: Schedule surgery 1 week after last administered dose
224265564|NCT07138898|DRUG|Golimumab|"Control group: Schedule surgery 5 weeks after last administered 4-week subcutaneous dose or 9 weeks after last administered 8-week intravenous dose.~Intervention group: Schedule surgery 2 weeks after last administered 4-week subcutaneous dose or 4 weeks after last administered 8-week intravenous dose."
224265565|NCT07138898|DRUG|Certolizumab|Control group: Schedule surgery 5 weeks after last administered dose. Intervention group: Schedule surgery 2 weeks after last administered dose.
223851225|NCT03588065|DIAGNOSTIC_TEST|FMS|"The evaluation of the risk of sports injury was obtained from the score in the Functional Movement Screen test suite.~The Functional Movement Screen (FMS) is a battery of tests that allows the integral assessment of the risk of injury, evaluating the basic patterns of movement and motor control through the performance of seven tests in which the combination of force is reflected muscle, flexibility, range of motion range, coordination, balance and proprioception"
223851226|NCT03588065|OTHER|TICS|The educational activities were directed to soccer players belonging to Equidad, Bogotá-Colombia. Computerized media were used within the reach of footballers, applied with professionals of physical activity sciences under blind study methodology, using the new tendencies of Information and Communication Technologies (ICT) in Health Education. The investigators counted on the advice of the group manager of knowledge of the secretary of the district of the city of Bogotá. In the educational intervention seven aspects were addressed, distributed in four weekly modules for a total of four months
223851227|NCT03588065|OTHER|CONFERENCE|The face-to-face educational intervention (conference) consisted of four educational sessions, distributed over four weeks during the sports transition period of the Equity sub-20 team. During these sessions, workshops (conferences) were held with the players following a face-to-face methodology . All these activities were concerted with the multidisciplinary team of the Equity football team and were carried out by the researcher at the University of La Sabana, a physiotherapist, who was studying the needs of the prevention of musculoskeletal injuries in football.
223851228|NCT03256344|BIOLOGICAL|Talimogene Laherparepvec|Virally based anti-cancer immunotherapy given by direct injection into tumors.
223851229|NCT03256344|BIOLOGICAL|Atezolizumab|A monoclonal antibody given by intravenous injection.
223851230|NCT04954430|DIAGNOSTIC_TEST|pupillometer|The dynamic changes of PLR were measured using the PLR-3000 pupillometer (NeurOptics, CA, USA), a hand-held portable device. Determination of PLR with automated pupillometry can be performed with a rubber cup covering the measured eye and the subject's hand covering the non-measured eye. A flash of visible white light with a duration of 0.8 sec and a pulse intensity of 50 µW is delivered to induce a pupillary reflex, and repeated video images at more than 30 frames/sec are stored for 6.65 sec. The device provided the examiner with maximum and minimum pupil size (Init and End), constriction percentage (%PLR), latency (LAT), constriction and dilation velocity (CV and DV), and T75.
223851231|NCT04490148|DEVICE|remote pulmonary function testing|Telemedicine delivery of pulmonary function testing in ALS, including Forced Vital Capacity (FVC) and Maximal Inspiratory Pressure (MIP)
223851232|NCT04490148|DEVICE|standard pulmonary function testing|Standard clinical delivery of pulmonary function testing in ALS, including Forced Vital Capacity (FVC) and Maximal Inspiratory Pressure (MIP)
223851233|NCT04490148|BEHAVIORAL|Nurse Respiratory Health Coaching (NRHC)|"Nurse Respiratory Health Coaching - The NRHC intervention follows the teamlet model described by Bennett et al. \[Bennett2010\], made up of the research coordinator who performs respiratory testing, and the nurse practitioner who coaches using the GROW (goals, realities, options, wrap-up) model."
223851234|NCT02199145|PROCEDURE|Blood and urine analysis|creatinine, albumin, blood electrolytes, proteinuria / creatinine in sample 1 assay Ac anti-PLA2R1 on 3 ELISA (human, rabbit and mouse)
223851235|NCT02834182|BEHAVIORAL|IRMf|
223851236|NCT02834182|BEHAVIORAL|Mini International Neuropsychiatric Interview|
223851237|NCT02834182|BEHAVIORAL|Positive And Negative Syndrom Scale|
223851238|NCT02834182|BEHAVIORAL|Young Mania Rating Scale|
223851239|NCT02834182|BEHAVIORAL|Hamilton Depression Scale|
223851240|NCT04461106|OTHER|Social Marketing Campaign|aims to raise awareness about the benefits of eggs - 'why eggs': increasing the value of eggs from a consumer perspective and encourage consumption of eggs by children (\<5yrs) and pregnant/lactating women
223851241|NCT04747106|BIOLOGICAL|plasma exchange|when ADP inhibition \>30%, plasma exchange, once or twice a week, 1000-1500ml plasma was exchanged for each time
223851242|NCT05001906|BEHAVIORAL|Exercise group|The exercise program comprises static and dynamic breathing exercises, muscle stretching exercises and muscle strength exercises, exercises to strengthen the abdominal wall muscles, exercises to strengthen the thigh muscles - quadriceps femoris (lat. musculus quadriceps femoris), to strengthen gluteal muscles, exercises to increase pelvic mobility, exercise to improve circulation, as well as pelvic floor muscle training with relaxation techniques.
223851243|NCT00691951|DRUG|budesonide and budesonide/formoterol|
223851244|NCT02885051|PROCEDURE|Recording of skin conductance and heart rate variability.|When a procedure of care will be prescribed, installation of the electrodes of measure of the cutaneous conductance on the foot and connection of the NIPE monitor to the cardio-respiratory monitor of the child used in routine. At this stage, beginning of the video recording.
223851245|NCT03255772|DIAGNOSTIC_TEST|Magnetocardiography|Study subjects will be placed within a magnetic shielding apparatus. Noninvasive sensors placed over the subject's torso will acquire magnetic field fluctuations generated by cardiac activity, which will then be analyzed for evidence of myocardial ischemia.
223851246|NCT01859312|DRUG|Hydrocortisone (Solucortef)|Continuous subcutaneous hydrocortisone infusion (CSHI) via Medtronic insulin pump (MMT-722NA). Total daily hydrocortisone dose was calculated based on the patient's estimated cortisol clearance. Rates were established to achieve peak and trough concentrations within the normal circadian cortisol range.
223851247|NCT01859312|DEVICE|Insulin pump (Medtronic)|Continuous subcutaneous hydrocortisone infusion (CSHI) via Medtronic insulin pump (MMT-722NA)
224265566|NCT07138898|DRUG|Infliximab|"Control group: Schedule surgery 9 weeks after last administered intravenous dose.~Intervention group: Schedule surgery 4 weeks after last administered dose."
224265567|NCT07138898|BIOLOGICAL|Rituximab|Control: Schedule 7 months after last administered dose. Intervention group: Schedule 3 months after last administered dose.
224265568|NCT07138898|BIOLOGICAL|Belimumab|"Control group: Schedule surgery 2 weeks after last administered subcutaneous weekly dose or 5 weeks after last administered 4-week intravenous dose.~Intervention group: Schedule surgery 1 week after last administered weekly dose or 2 weeks after last administered 4-week dose."
224265569|NCT07138898|BIOLOGICAL|Tocilizumab|"Control group: Schedule surgery 2 weeks after last administered subcutaneous weekly dose or 5 weeks after last administered 4-week intravenous dose.~Intervention group: Schedule surgery 1 week after last administered weekly dose or 2 weeks after last administered 4-week dose."
223851248|NCT06135831|OTHER|Functional olive paste|Homogenised olive pastes, enriched with mountain tea, were supplied by two ac-credited Greek olive oil and olive products companies, Arcadian Taste and GAEA. The fortified olive pastes, contained 7.5 g of extra virgin olive oil, 3.75 g of salt, 3.75 g of grated oregano, 3.75 g of grated pepper, 7.5 g of grated garlic, 6.25 g of orange juice, 65 g of Kala-mon olives without seeds and 3 g of mountain tea and weighted 100 gr per portion size, as well.
223851249|NCT06135831|OTHER|Calciovitmag (CDCaMg)|Vitamin C (1000 mg), vitamin D3 (500 mg), Calcium (Ca) (500 mg ) and Magnesium (Mg) (300 mg)/day
223851250|NCT06135831|OTHER|Phosporovitmag (PDCaMg)|Bisphosphonates (150 mg), vitamin D3 (500 mg), Ca (500 mg ) and Mg (300 mg)/daily
223851251|NCT06135831|OTHER|Control|Vitamin D3 (500 mg), Calcium (500 mg) and Magnesium (300 mg)/daily
223851252|NCT01597518|DRUG|Riluzole|100mg BID first 24 hours after the injury; 50mg BID 2--14 days following the injury
223851253|NCT01597518|DRUG|Placebo|Placebo 2x in first 24 hours; Placebo 2x day 2--14
223851254|NCT02648425|DRUG|ASLAN001|ASLAN001 400mg BID daily; ASLAN001 500mg BID daily; or ASLAN001 300mg BID daily
223851255|NCT02648425|DRUG|cisplatin + capecitabine|Cisplatin 80 mg/m2 IV infusion and capecitabine 1,000 mg/m2 orally BID for 14 days every 3 weeks
223851256|NCT02648425|DRUG|cisplatin + 5-fluorouracil (or+ Leucovorin)|"Cisplatin 80 mg/m2 IV infusion and 5-fluorouracil 800 mg/m2/day IV infusion for 5 days every 3 weeks;~Or~Cisplatin 35 mg/m2 24-hour infusion for day 1 and day 8, 5-fluorouracil 2,000 mg/m2 and Leucovorin 300mg/m2 24-hour infusion for day 1, day 8 and day 15 every 4 weeks."
223851257|NCT04312191|OTHER|Mantra Meditation|Mantra-based meditation will be taught using a standard one-word mantra (Om). Om is a non-English word that will help with focus as opposed to an English word which may cause distraction based on the word itself.
223851258|NCT02041676|PROCEDURE|Chest physiotherapy|
223851259|NCT02041676|PROCEDURE|Usual surveillance|Usual surveillance of the non invasive ventilation without chest physiotherapy.
223851260|NCT01879371|DRUG|Ibuprofen+caffeine FDC|oral dose
223851261|NCT01879371|DRUG|Ibuprofen (Nurofen Immedia®)|oral dose
223851262|NCT01879371|DRUG|Ibuprofen (Brufen®)|oral dose
223851263|NCT00866996|DRUG|Methylphenidate extended-release; Atomoxetine|
223851264|NCT05286424|PROCEDURE|fat grafting|Fat will be removed from abdomen or legs, processed and re-injected into grafting sites.
223851265|NCT05112250|DEVICE|Percutaneous Coronary Intervention|Intravascular lithotripsy (IVL)
223851266|NCT01496209|BIOLOGICAL|Endomyocardial injections of allogeneic Human CSps|NOGA electromechanical mapping and endomyocardial injections at 15 peri-infarct sites, via NOGA MYOSTAR catheter, of Allogeneic Human CSps.
223851267|NCT01496209|BIOLOGICAL|Endomyocardial injections of vehicle only.|NOGA electromechanical mapping and endomyocardial injections at 15 peri-infarct sites, via NOGA MYOSTAR catheter, of placebo.
223851268|NCT04406168|PROCEDURE|urinary diversion|follow up outcomes of urinary diversion
223851269|NCT01723670|DRUG|CHF 5074 1x|oral tablet, 1x, once a day for 24 months
223851270|NCT01723670|DRUG|CHF 5074 2x|oral tablet, 2x, once a day for 24 months
223851271|NCT01723670|DRUG|Placebo|oral tablet,once a day for 24 months
223851272|NCT02702674|DRUG|propranolol|propranolol 20 mg given before induction of labor
223851273|NCT02702674|DRUG|placebo|starch tablet containing no active drug material given before induction of labor
223851274|NCT02702674|DRUG|Oxytocin|intravenous infusion of oxytocin
223851275|NCT06317688|DIETARY_SUPPLEMENT|Extra-Virgin Coconut Oil|Active ingredients act as a destructor of bacteria, viruses and fungus
223851276|NCT03152149|DRUG|Tiotropium & olodaterol|Spiolto Respimat (Tiotropium 2.5 micrograms,olodaterol 2.5 micrograms) 2 puffs once daily for 6 months
223851277|NCT03152149|DRUG|fluticasone furoate & vilanterol|Relvar Ellipta (fluticasone furoate 92 micrograms, vilanterol 22 micrograms) 1 puff once per day for 6 months
223851278|NCT05994092|BEHAVIORAL|Voluntary Isocapnic Hyperpnea|The protocol of 3' of breathing with 20 breaths·min-1 frequency. The Isocapnic BreathWayBetter devices (Isocapnic Technologies Inc, Kelowna, Canada) with 6-liter bags were used. The protocol was performed in a seating position.
223851279|NCT04140058|DRUG|Ondansetron|ondansetron was administered 20 minutes prior to spinal anesthesia.
223851280|NCT04140058|DRUG|Normal saline|Placebo of 10 mL normal saline was administered.
223851281|NCT00578617|DRUG|Rate Control|Metoprolol 50-100mg
223851282|NCT00578617|DEVICE|Ablation Therapy|
223851283|NCT00578617|DRUG|Rate Control|Atenolol 50-100mg,
223851284|NCT00578617|DRUG|Rate control|Propranolol 40-80mg
223851285|NCT00578617|DRUG|Rate control|Acebutolol 200mg
223851286|NCT00578617|DRUG|Rate control|Carvedilol 6.25mg
223851287|NCT00578617|DRUG|Rate Control|Diltiazem 180-240mg
223851288|NCT00578617|DRUG|Rate Control|Verapamil 180-240mg
223851289|NCT00578617|DRUG|Rate Control|Digoxin 0.125mg
223851290|NCT00578617|DRUG|Rhythm Control|Propafenone 450mg
223851291|NCT00578617|DRUG|Rhythm control|Flecainide 200mg
223851292|NCT00578617|DRUG|Rhythm control|Sotalol 240mg
223851293|NCT00578617|DRUG|Rhythm control|Dofetilide 500mcg
223851294|NCT00578617|DRUG|Rhythm control|Amiodarone 200mg
223851295|NCT00578617|DRUG|Rhythm control|Quinidine 600-900mg
223851296|NCT01881919|DIETARY_SUPPLEMENT|Treatment|Address: Nature's Best, Century Place, Tunbridge Wells, Kent, TN2 3BE Phone:+44(0)1892 552030 Email:info@naturesbest.co.uk
223851297|NCT01881919|DIETARY_SUPPLEMENT|Control|Address: Fagron GmbH\&Co. KG, 22885 Barsbuttel, Germany Phone: +49(0)4067067680
223851298|NCT06266650|OTHER|Osteopathic Treatment Technique- Muscle Energy Treatment|Muscle Energy Treatment involves a patient actively using their muscles on request from a precisely controlled position, in a specific direction, against a distinctly executed counter force. During Muscle Energy Treatment, the physician positions the area of treatment into a position of resistance, which is the restrictive barrier. The physician then instructs the patient to use the targeted muscles for 3-5 seconds in the direction of ease while the physician provides a counterforce. The physician then tells the patient to stop contracting their muscles and evaluate the area for decreased tension, then repositions the patient into their new restrictive barrier. These steps are repeated three to five times and then the dysfunction is reevaluated.
223851299|NCT03014050|DEVICE|e-Tapper TT-R1|"The e-Tapper is a non-invasive, handheld electronic device designed to apply micro current stimulation to a person's hands at specified points representing various body parts, such as the head, leg, or foot. This is one form of Bio-Electro Stimulation Therapy known as the 11-point Hand Treatment System. The current delivered is less than one milliampere."
223851300|NCT02814305|BEHAVIORAL|Financial|Patient receives information on a program that may offer a financial benefit for disposing of unused opioid analgesics at a pharmacy
223851301|NCT02814305|BEHAVIORAL|Educational|Patient watches a video featuring narrative vignettes of patients who developed opioid dependence or abuse after using opioids postoperatively
223851302|NCT04034758|PROCEDURE|Standardized Quantitative multi-donor Intestinal Microbiota Capsule (SQIMC-md)|heterologous fecal microbiota transplantation (FMT) by Standardized Quantitative multi-donor Intestinal Microbiota Capsule (SQIMC-md)
223851303|NCT04034758|PROCEDURE|placebo capsule|Oral administration of 30 placebo capsule containing edible pigmented starch
223851304|NCT03585361|BEHAVIORAL|Health centers provide PPFP counseling and services|Providers trained on PPFP counseling skills and insertion technique for placing intrauterine devices (IUDs) immediately after birth with a refresher on insertion techniques for IUDs and implants. Training also included how to use tools to document PPFP services and referrals. Follow up supervision ensured skill mastery and retention.
223851305|NCT03585361|BEHAVIORAL|HEWs provide PPFP counseling and services|HEWs trained in PPFP counseling with a refresher on implant insertion skills. Training also included how to use tools to document PPFP services, method choice, and pregnancy risk at every contact during pregnancy and up to 12 months after birth. Follow up supervision ensured skill improvement and retention.
223851306|NCT03585361|BEHAVIORAL|Volunteers (Development Army) promote PPFP|HEWs orient volunteers on promoting PPFP and how to use a pictoral tool to remind women to access ANC, immunization, and PPFP services and to document women's method preferences and pregnancy risk at every contact during pregnancy and up to 12 months after birth.
223851307|NCT03585361|BEHAVIORAL|Health centers conduct data reviews|Health center staff document PPFP counseling, provision, and referrals in registers and use a facility dashboard to display and track aggregate PPFP data.
223851308|NCT03585361|BEHAVIORAL|HEWs and volunteers track PPFP|HEWs and volunteers track PPFP counseling, choice of method, receipt of methods, and pregnancy risk starting in pregnancy through 12 months postpartum. HEWs and volunteers meet and review data.
223851309|NCT01670019|DRUG|Asenapine 5-20 mg daily|5 mg QHS, or 5 mg BID, or 5 mg QAM and 10 mg QHS, or 10 mg BID
223851310|NCT01670019|DRUG|Placebo 1-4 tablets daily|One placebo tablet QHS, or one placebo tablet BID, or one placebo tablet QAM and two placebo tablets QHS, or two placebo tablets BID
223851311|NCT05495646|PROCEDURE|Central catheter insertion|The data will be obtained through the review of the medical records and the clinical follow-up of each patient to evaluate the technique of inserting the device, the possible risk factors of catheter-related infection, its clinical manifestations and the data microbiological.
223851312|NCT00580801|DRUG|Telaprevir|Telaprevir 750 milligram (mg) tablet will be administered three times a day orally for 2 weeks.
223851313|NCT00580801|DRUG|Pegylated-interferon-alfa-2a|Pegylated-interferon-alfa-2a (180 microgram \[mcg\] subcutaneous injection, once weekly) will be administered from Week 1 to Week 48 or 50.
223851314|NCT00580801|DRUG|Placebo|Matching placebo tablet to telaprevir was administered three times a day orally for 2 weeks.
223851315|NCT00580801|DRUG|Ribavirin|Ribavirin (1000-1200 mg as oral tablet daily) will be administered from Week 1 to Week 48 or 50.
223851316|NCT02905968|DEVICE|transanual tube placement|Transanual tube placement after anastomosis in low anterior resection for rectal cancer.
223851317|NCT04187157|DEVICE|Blue-light filtering intraocular lens|Bilateral implantation of blue light-blocking intraocular lens
223851318|NCT04187157|DEVICE|Conventional intraocular lens|Bilateral implantation of conventional intraocular lens
223851319|NCT00851942|DRUG|Synacthen (Tetracosactrin)|IV injection of 250 micrograms of Synacthen in 1ml
223851320|NCT01492387|OTHER|Discontinuation of antibiotic therapy|Patients randomized in the Individualized Arm will be treated according to clinical response: antibiotic therapy will be discontinued 48 hours after the day that the patient reaches clinical stability, with at least 5 days of total antibiotic treatment.
223851321|NCT00502593|BIOLOGICAL|Pandemic Influenza Vaccine (GSK1562902A)|2 doses, intramuscular injection on Days 0 and 21, 3 different formulations are tested.
223851322|NCT00502593|BIOLOGICAL|Fluarix™|2 doses, intramuscular injection on Days 0 and 21.
223851323|NCT06278064|OTHER|Gastric Cancer|Patients diagnosed with gastric cancer, including early stage gastric and advanced gastric cancer
223851324|NCT06278064|OTHER|Esophagus Cancer|Patients diagnosed with esophagus cancer, including early esophagus gastric and advanced esophagus cancer
223851325|NCT05575895|DIETARY_SUPPLEMENT|Ingestion of the energy drink (Red Bull®)|Ingestion of 250 ml of the energy drink (Red Bull®)
223851326|NCT05575895|DIETARY_SUPPLEMENT|Ingestion of mineral water|Ingestion of 250 ml of mineral water (Minalba®)
223851327|NCT00680472|DRUG|HKT-500 Ketoprofen Topical Patch|HKT-500 Ketoprofen Topical Patch
223851328|NCT00680472|OTHER|Placebo Patch|Treatment with Placebo Patch
223851329|NCT05629364|DRUG|KIO-101|Randomized, Controlled
223851330|NCT03244787|BEHAVIORAL|patient navigation|Current standard of care is for PNs to work with patients from health centers who are referred by providers. Intervention patients will appear on a PN list without any referral by providers. Control high risk patients will proceed normally and will be eligible to transfer to a PN list after the 6-month study period.
223851331|NCT02945267|DRUG|Nimotuzumab plus S1|Nimotuzumab Injection: 400 mg/w, Intravenous infusion, Infusion time ≥ 60 min, d1, once every two weeks;S1: 40 mg (Body surface area\<1.5 m2) or 60 mg (Body surface area\>1.5 m2) ,oral,d1-d14, every three weeks for a cycle
223851332|NCT02945267|DRUG|Placebo plus S1|Placebo: 400 mg/w, Intravenous infusion, Infusion time ≥ 60 min, d1, once every two weeks;S1: 40 mg (Body surface area\<1.5 m2) or 60 mg (Body surface area\>1.5 m2) ,oral,d1-d14, every three weeks for a cycle
223851333|NCT05045872|DRUG|domestic polysaccharide superparamagnetic iron oxide nanoparticle|Patients will receive contrast-enhanced renal magnetic resonance imaging with polysaccharide superparamagnetic iron oxide nanoparticle before renal angiography. Patients received intravenous polysaccharide superparamagnetic iron oxide nanoparticle before magnetic resonance imaging.
223851334|NCT00516711|DRUG|Sevoflurane|
223851335|NCT05222750|OTHER|Pre-COVID-19|Pre-COVID-19
223851336|NCT05222750|OTHER|COVID-19|COVID-19
223851337|NCT05222750|OTHER|COVID-19 vaccination roll-out|COVID-19 vaccination roll-out
223851338|NCT06166719|OTHER|No intervention|No intervention
223851339|NCT02578212|OTHER|Placebo|
223851340|NCT00820118|DRUG|Structured treatment interruption|"The preferentially recommended treatment of the study is atazanavir boosted with ritonavir, associated with a fixed combination of abacavir and lamivudine or emtricitabine + tenofovir~Usual dosage recommended :~* atazanavir : 300 mg/d~* ritonavir : 100 mg/d~* abacavir 600 mg and lamivudine 300 mg : once a day~* tenofovir 245 mg and emtricitabine 200 mg : once a day"
223851341|NCT05523258|BEHAVIORAL|Computerized cognition training|The researchers distribute tablet computers for the patients. The patients in this group receive cognitive function training under the guidance of a full-time cognitive function trainer. The training time is about 45-60 minutes every time, and the frequency is twice a day until the operation. After the operation, cognitive function training should be started as soon as possible when the patient meets the following conditions including Glasgow score ≥ 12, no mechanical ventilation and no sedative drugs. The training intensity is the same as that before operation, generally starting from the 2nd to 3rd day after operation and continuing to discharge or the 7th day after operation.
223851342|NCT05523258|BEHAVIORAL|Basic training based on tablet computer|The researchers distribute the same tablet computer to the patients. The patients in this group receive basic training under the guidance of a full-time cognitive function trainer. The training duration is the same as that of the test group.
223851343|NCT02121418|DRUG|Cytarabine|Given IV
223851344|NCT02121418|DRUG|Decitabine|Given IV
223851345|NCT02121418|OTHER|Laboratory Biomarker Analysis|Correlative studies
223851346|NCT06366594|BEHAVIORAL|Authentic leadership training program|37 first-line nurse managers received authentic leadership training program
223851347|NCT04856228|DIAGNOSTIC_TEST|diagnostic posterior interosseous nerve lidocaine injection|ultrasound guided posterior interosseous nerve and lateral epicondyle 1 ml 2% lidocaine injection
223851348|NCT05272124|OTHER|Hip Abductor Strengthening|"Elastic resisted training of Hip Abductors (5-10 seconds hold) 10 repetitions x 3 sets, 3 alternate days per week.~Elastic resisted training of Quadriceps (5-7 seconds hold) 10 repetitions x 3 sets, 3 alternate days per week.~Static Stretching of 5 seconds hold (Calf, Hamstrings, Gluteal muscles and Iliotibial band) 10 repetitions x 3 sets, 3 alternate days per week.~Patellar Mobilization in all four directions 10 repetitions x 3 sets, 3 alternate days per week.~Total 18 sessions were given in 06 weeks."
223851349|NCT05272124|OTHER|Traditional Physical Therapy|"Elastic resisted training of Quadriceps (5-7 seconds hold) 10 repetitions x 3 sets, 3 alternate days per week.~Static Stretching of 5 seconds hold (Calf, Hamstrings, Gluteal muscles and Iliotibial band) 10 repetitions x 3 sets, 3 alternate days per week.~Patellar Mobilization in all four directions 10 repetitions x 3 sets, 3 alternate days per week.~Total 18 sessions were given in 06 weeks."
223851350|NCT04087746|DRUG|Aflibercept|Intra-vitreal injection of AVEGF AFLIBERCEPT in group I
223851351|NCT04087746|DRUG|Ranibizumab|Intra-vitreal injection of AVEGF Ranibizumab in group 2
223851352|NCT03906630|DIAGNOSTIC_TEST|Telehealth clinical exam|This is a pseudo telehealth clinical exam for patients presenting with shoulder pain
223851353|NCT03906630|DIAGNOSTIC_TEST|Standard clinical exam|This is a standard in-person clinical exam for patients presenting with shoulder pain
223851354|NCT06582628|DRUG|Enzalutamide capsule|Enzalutamide capsules 160 mg orally daily
223851355|NCT06582628|DRUG|Enzalutamide capsule and Talazoparib capsule|Enzalutamide capsules 160 mg plus talazoparib capsules 0.5 mg, both orally daily
223851356|NCT03762330|BEHAVIORAL|COPD structured self-management plan.|Education plan , including knowledge of the disease, healthy life habits, correct use of inhalers, skills to control symptoms and strategies to face the disease and exacerbations
223851357|NCT03691961|OTHER|Hair sampling|After 4 months of treatment, a strand of hair from the vertex posterior region of the scalp about the width of a thin pencil and with a length equal to or greater than 3 cm will be cut.
223851358|NCT03691961|DIAGNOSTIC_TEST|Hair's drug concentrations|The hair's concentrations of budesonide/formoterol is analysed with mass spectrometry.
223851359|NCT02586454|PROCEDURE|Transmuscular quadratus lumborum block|
223851360|NCT02586454|DRUG|morphine|
223851361|NCT02586454|DRUG|ropivacaine|
223851362|NCT01913119|DRUG|Romidepsin|"Day 1, 8, and 15 of a 28-day cycle Romidepsin Treatment is repeated until documented disease progression or unacceptable toxicity.~Dose and administration: 4-hour infusion of 14 mg/m2"
223851363|NCT01923948|DRUG|Pregabalin|One 150 mg oral dose of Pregabalin given before surgery
223851364|NCT01923948|DRUG|Placebo (for Pregabalin)|One oral dose of placebo given before surgery
223851365|NCT02971306|DRUG|standard medical therapy|Standard medical therapy involves primary treatment with pentoxifylline at a dose of 400 mg three times a day and normal hospital nutrition (1800 to 2000 kcal per day). Diuretics, sodium restriction and albumin for treatment of ascites or fresh frozen plasma for coagulopathy or antibiotics for any focus of infection as spontaneous bacterial peritonitis (SBP), pneumonia, cellulitis, and urinary tract infection as indicated.
223851366|NCT02971306|DRUG|G-CSF|G-CSF- 5μg/Kg s.c every 12 hours for 5 consecutive days
223851367|NCT02971306|DRUG|n-Acetylcysteine|n-Acetylcysteine at 150, 50, and 100 mg/kg in 250, 500, and 1000 ml of 5% glucose solution over 30 minutes, 4 hours, and 16 hours, respectively; days 2 through 5: 100 mg/kg/day in 1000 ml of 5% glucose solution
223851368|NCT01664104|DRUG|Tocilizumab|Tocilizumab will be administered in routine clinical practice in accordance with local label. Study protocol does not specify/enforce any treatment regimen.
223851369|NCT03978533|BEHAVIORAL|Family Support Group|Family Support Groups will be piloted with families in community and clinical sites. Each pair of facilitators will pilot two groups of 6 families each. Each group is 4 sessions lasting 2 hours each. Each of the sessions incorporates didactic talks, family discussion, and separate breakout groups for adolescents and adults. Family Support intervention incorporates cognitive-behavioral theory of PM+ which underlies evidence-based techniques focused on stress management and behavioral activation. Family support intervention also incorporates resilience theory, which explains family protective processes that can ameliorate the negative consequences of hardships and challenges and enable healing and growth in families.
223851370|NCT00540813|DEVICE|drug eluting balloon|drug eluting balloon bifurcated coronary lesions single arm study
223851371|NCT00004192|BIOLOGICAL|filgrastim|
223851372|NCT00004192|BIOLOGICAL|pegfilgrastim|
223851373|NCT00004192|DRUG|cisplatin|
223851374|NCT00004192|DRUG|cytarabine|
223851375|NCT00004192|DRUG|etoposide|
223851376|NCT00004192|DRUG|methylprednisolone|
223851377|NCT03526081|OTHER|Chamomile Tea|Chamomile Tea in 300mL hot water
223851378|NCT03526081|OTHER|Parsley based drink|3.2 g dried parsley in 300mL hot water
223851379|NCT03526081|OTHER|Parsley Yogurt|3.2 g dried parsley in 100g plain yogurt
223851380|NCT03526081|OTHER|Apigenin|Apigenin capsule mixed with 300mL hot water
223851381|NCT03526081|OTHER|Parsley-based drink (II)|3.2 g dried parsley in 300mL hot water
223851382|NCT03875248|DEVICE|Blood pressure measurement|Measure optically the blood pressure through the use of a smartphone
223851383|NCT02939495|DRUG|Dapoxetine/Sildenafil 30/50 mg film coated tablet|1 tablet before sexual intercourse
223851384|NCT05837468|BEHAVIORAL|BETTERapp|The BETTER app offers a 'tailor-made' lifestyle programme including the option of personal coaching for a duration of 6 weeks. The BETTER app is an automated and digitised lifestyle programme based on the previously developed and evaluated BETTER programme.
223851385|NCT01025206|BIOLOGICAL|BI-505|Anti-ICAM-1 monoclonal antibody given as a i.v infusion every second week for four weeks,
223851386|NCT00002290|DRUG|Zidovudine|
223851387|NCT00002290|DRUG|Acyclovir|
223851388|NCT05739929|DRUG|Colchicine 0.5 MG Oral Tablet|0.5 mg colchicine tablets twice daily.
223851389|NCT05739929|DRUG|Placebo|Placebo tablets twice daily
223851390|NCT00683410|BIOLOGICAL|Pneumococcal Conjugate Vaccine, 7-valent (Prevenar)|
223851391|NCT03533556|DIETARY_SUPPLEMENT|L-theanine|Oral administration of 2.5 mg/kg body weight of L-theanine dissolved in 100 ml of water
223851392|NCT03533556|DIETARY_SUPPLEMENT|Caffeine|Oral administration of 2.0 mg/kg body weight of caffeine dissolved in 100 ml of water
223851393|NCT03533556|DIETARY_SUPPLEMENT|L-theanine-Caffeine Combination|Oral administration of a combination of 2.5 mg/kg body weight of L-theanine and 2.0 mg/kg body weight of caffeine dissolved in 100 ml of water
223851394|NCT03533556|OTHER|Placebo|Oral administration of 100 ml of water
224265570|NCT07138898|BIOLOGICAL|Anakinra|Control group: Schedule surgery 2 days after last administered daily dose. Experimental group: Schedule surgery 1 day after last administered daily dose.
224265571|NCT07138898|BIOLOGICAL|Canakinumab|Control group: Schedule surgery 5 weeks after last administered 4-week dose. Intervention group: Schedule surgery 2 weeks after last administered 4-week dose.
224265572|NCT07138898|BIOLOGICAL|Abatacept|"Control group: Schedule surgery 2 weeks after last administered weekly subcutaneous dose or 5 weeks after last administered monthly intravenous dose.~Intervention group: Schedule surgery 1 week after last administered weekly subcutaneous dose or 2 weeks after last administered monthly intravenous dose."
223851395|NCT05544578|BEHAVIORAL|Nurses Taking On Readiness Measures (N- TORM)|The intervention group will be educated about household emergency preparedness via a presentation and the Korean version of a New York City community-specific booklet called Ready New York: My Emergency Plan (NYC Emergency Management, 2022). The intervention will begin with instructing the participant to start the booklet during class 1 and completing it for homework. The class content will complement the booklet and the K-HEPI. The booklet includes preparedness recommendations, evacuation zone information, a disaster supply kit contents list, local utility company contact information, shelter locations, and special needs and priority utility restoration registry information. During class 2, study personnel will check for completion of the booklets, answer any questions that the participants may have about the evacuation and communication plans and disaster kits, and facilitate group discussion to foster social support from other community members.
223851396|NCT02866214|DRUG|Febuxostat|Film Coated Tablets of Donifoxate (Eva Pharma company ) 40mg administered thrice weekly post hemodialysis session
223851397|NCT02866214|DRUG|Placebo|"Film Coated Tablets (Placebo) to be administered thrice weekly post hemodialysis session.~same color, taste , size . Same all ingredients except Febuxostat (Active ingredient) ."
223851398|NCT00591838|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|
223851399|NCT06279819|DIETARY_SUPPLEMENT|gut microbiota-targeted dietary intervention|"The dietary intervention used the dietary intervention plan constructed in Phase 2, on the basis of which each study participant's individual dietary habits, food preferences and economic level were taken into account.~The dietary intervention was delivered by sending fresh ingredients. To ensure the freshness and quality of the ingredients, 2 dedicated researchers were jointly responsible for the procurement of fresh ingredients, which were purchased through regular channels on Monday, Wednesday and Friday mornings.~Ingredients will be delivered three times a week for a 12-week intervention period. The initial food items to be sent include: 90g of fish rich in omega-3 fatty acids; 300g of vegetables and/or legumes, and 200g of fruits; 30g of nuts; and a cup of probiotic yogurt.~Guided dietary follow-up was conducted through video viewing and WeChat or telephone follow-up. The researcher will provide cooking instruction or dietary pattern guidance by sending videos every two weeks."
223851400|NCT03586167|DEVICE|LID014341 contact lenses|Investigational monthly replacement silicone hydrogel contact lenses with water gradient coating
223851401|NCT03586167|DEVICE|Comfilcon A contact lenses|Silicone hydrogel contact lenses
223851402|NCT01607619|DIETARY_SUPPLEMENT|Anatabine|1mg anatabine in a mint-flavored mannitol lozenge
223851403|NCT02973243|DEVICE|Automatic RR Measurement|Different newly developed respiration rate sensors are applied at the bedside during the intervention phase which send data to the IntelliVue Guardian System.
223851404|NCT03237936|DRUG|1mg/mL ciclosporin|IKERVIS® (1mg/ml ciclosporin) eye drops administered once daily following 3 months of treatment
223851405|NCT04026191|DEVICE|OrthoVisc®-T (OVT)|Sodium hyaluronate supplied as a 2 mL (15mg/mL) unit dose in a 3 mL glass syringe.
223851406|NCT05818306|DRUG|BL-001|Live biological product BL-001
223851407|NCT05818306|DRUG|Placebo|Placebo
223851408|NCT00500500|DRUG|EGb 761® (Tanakan®)|
223851409|NCT00560014|DIETARY_SUPPLEMENT|Arginine and canola oil|Canola oil 1 tablespoon BID Arginine 9.0grams BID
223851410|NCT00560014|DIETARY_SUPPLEMENT|Coromega and Arginine|Arginine 9.0 grams BID Coromega dose based on weight
223851411|NCT03707678|DRUG|GSK2245035|GSK2245035 will be administered weekly once as a nasal spray solution with dosing strength of 10 ng per actuation. GSK2245035 will be available as a saline formulation, preserved with benzalkonium chloride and disodium edetate in an amber glass bottle fitted with a screw-fit atomizing pump.
223851412|NCT03707678|DRUG|Placebo|Placebo will be administered weekly once as a nasal spray solution. Placebo will be available as a saline formulation, preserved with benzalkonium chloride and disodium edetate in an amber glass bottle fitted with a screw-fit atomizing pump.
223851413|NCT03707678|DRUG|FP-DPI|FP will be administered using Diskus inhaler with dosing strengths of 500, 250, 100, 50 µg twice daily per actuation.
223851414|NCT03707678|DRUG|Albuterol/Salbutamol|Albuterol/Salbutamol MDI will be administered for symptom relief from screening to the end of the study.
223851415|NCT03707678|OTHER|eDairy|Subjects will record all the alerts indicative of worsening of asthma in eDairy.
223851416|NCT03707678|OTHER|ACQ-6|ACQ-6 will include six questions which enquire about the frequency and/or severity of symptoms. The response options for all these questions consist of a zero (no impairment/limitation) to six (total impairment/limitation) scale.
223851417|NCT02774538|OTHER|Agreement between oral and cervical HPV infection|"A total of 165 women will have a Pap test and an oral brushing performed on the day of inclusion. Risk factors for oral HPV infection will be defined using a self-administered survey summarizing the demographics and sexual behaviors.~A second oral brushing up to 18 months will be performed during a standard follow-up visit."
223851418|NCT04980261|PROCEDURE|ORIF + autograft|Patients will undergo a standard open reduction internal fixation (ORIF) procedure with autograft implantation (from the iliac crest).
223851419|NCT04980261|PROCEDURE|ORIF + FD BHA/Secretome|Patients will undergo an ORIF procedure and subsequently receive freeze-dried bovine hydroxyapatite/secretome composite implantation.
223851420|NCT01814644|BEHAVIORAL|TRIMM Intervention|Individuals in the TRIMM arm receive daily, individualized text-messages promoting positive lifestyle changes to support weight loss/management.
223851421|NCT01814644|BEHAVIORAL|Standard Care|Individual assessment, lifestyle counseling
223851422|NCT04299230|DEVICE|Cortium C3|
223851423|NCT03068611|BEHAVIORAL|Standard Web-based Smoking Cessation|A website and text messaging program that is publicly available through BecomeAnEX.com. Participants have access to the website whenever they wish.
223851424|NCT03068611|BEHAVIORAL|Alcohol-focused Web-Based Smoking Cessation|A website and text messaging program that is publicly available through BecomeAnEX.com. Participants have access to the website whenever they wish.
223851425|NCT06552494|OTHER|L-mHealth program|The intervention group receiving the L-mHealth program plus care as usual. Data will be collected at baseline (T0), 1 months (T1) and 3 months (T2) after the intervention.
223851426|NCT04163458|DRUG|MENOPUR solution for injection in pre-filled pen, 1200 IU/1.92 mL|Solution for injection in pre-filled pen, subcutaneous administration
223851427|NCT04163458|DRUG|MENOPUR powder and solvent for solution for injection, 75 IU|Solution for injection in vials (powder and diluent), subcutaneous administration
223851428|NCT04163458|OTHER|Placebo (for MENOPUR solution for injection in pre-filled pen)|Solution for injection in pre-filled pen, subcutaneous administration
223851429|NCT04163458|OTHER|Placebo (for MENOPUR powder and solvent for solution for injection)|Solution for injection in vials (powder and diluent); subcutaneous administration
223851430|NCT00812136|BEHAVIORAL|Using Parent Mentors to Improve Asthma Care for Urban Minority Children|
223851431|NCT01586299|DRUG|Ibuprofen|10 mg/kg every 8 hours until 24 hours after resolution of fever
223851432|NCT01586299|DRUG|Acetaminophen|15 mg/kg every 6 hours until 24 hours after resolution of fever
223851433|NCT05147506|DEVICE|CNRM DTx|A mobile application intervention adapted from the CBT for Depression and CBT for TBI manuals.
223851434|NCT05147506|OTHER|Psychoeducation Comparison|A mobile application that consists of psychoeducational material regarding depression and brain injury.
223851435|NCT00896948|GENETIC|Southern blotting|
223851436|NCT00896948|GENETIC|TdT-mediated dUTP nick end labeling assay|
223851437|NCT00896948|GENETIC|gene expression analysis|
223851438|NCT00896948|GENETIC|protein expression analysis|
223851439|NCT00896948|OTHER|flow cytometry|
223851440|NCT00896948|OTHER|fluorescent antibody technique|
223851441|NCT00896948|OTHER|immunoenzyme technique|
223851442|NCT00896948|OTHER|immunohistochemistry staining method|
223851443|NCT00896948|OTHER|immunologic technique|
223851444|NCT02144350|PROCEDURE|Hyperbaric oxygen|patients will be placed in a monoplane chamber and pressurized to 2.4 atmospheres with 100% oxygen for 90 minutes per session.
223851445|NCT02144350|PROCEDURE|Sham Hyperbaric Air|Patients will undergo a brief compression to 1.34 atmospheres with room air and then they will be brought back to 1.1 atmospheres to complete a 90 minute session.
223851446|NCT00542087|DRUG|MK0663, etoricoxib / Duration of Treatment: 6 Weeks|
223851447|NCT00542087|DRUG|Comparator: diclofenac sodium / Duration of Treatment: 6 Weeks|
223851448|NCT00624312|DRUG|Procrit|"10 days prior to surgery - injection of 60,000 IU of Procrit~Day of surgery - injection of 60,000 IU of Procrit"
223851449|NCT00624312|DRUG|Placebo|"10 days prior to surgery - injection with 60,000 IU of placebo~Day of surgery - injection with 60,000 IU of placebo"
223851450|NCT04617353|PROCEDURE|NO-based treatment of sterno-mediastinitis|"Preparation of a postoperative wound in case of infectious complications. A mandatory sampling material for culture and antibiotic sensitivity is collected before and after the air plasma flow treatment.~Direct effect of the air-plasma flow on the entire wound surface in sterilization mode with an exposure of 2-3 minutes for each surgical wound, until the level of bacterial contamination decreases to 10-5 and below.~The technique of using air-plasma flow when closing a wound after preventing infectious complications in it.~In the postoperative period, daily air-plasma flow treatment in sterilization mode along the suture line for 3 minutes. Penetrating drainage NO supply in the biological stimulation mode daily for 10 days, with an exposure of 1-2 minutes up to 10 days, with a volume of up to 2 liters per minute.~Collecting wound culture from the drainage containers on 1-3-7-12 days to detect pathogens and the bacterial number."
223851451|NCT04617353|PROCEDURE|Treatment of sterno-mediastinitis|patients who were treated for sterno-mediastinitis according to clinical guidelines, the main method of which is a permanent irrigation and aspiration flow drainage method, as well as a Vacuum Assisted Closure (VAC) system of dressings for vacuum drainage
223851452|NCT02129933|DRUG|Bevacizumab-IRDye800CW|"Intravenous administration of a microdose (4.5mg, subtherapeutic) of Bevacizumab-IRDye800CW 2 days prior to the fluorescence endoscopy procedure.~\* amendment June 2015: topical administration bevacizumab-800CW (100ug/ml)"
223851453|NCT02129933|DEVICE|Near infrared fluorescence endoscopy platform|A flexible fiber-bundle is attached with its proximal end to a camera which can detect near infrared fluorescent light. The distal end is inserted into the working channel of a clinical video endoscope to visualize the luminal wall. The fluorescent imaging will be performed prior and post the endoscopic resection (within the same endoscopic session)
223851454|NCT03250104|OTHER|Infection Control|The infection control bundle will include staff training, hand hygiene programs, disinfection measures, and contact isolation. Physicians will be discouraged to prescribe proton pump inhibitors (PPIs) where not explicitly needed. The intervention bundle will be defined based on current literature. For implementation, the investigator will adapt the bundle to specific local needs, discuss with the responsible department heads and ward staff, perform training and disseminate standards of care.
223851455|NCT03250104|OTHER|Antibiotic Stewardship|"Antibiotic stewards will develop local standards of procedure based on the provided training and guidelines. They will then train the responsible staff and disseminate guidelines as best suited for the local work environment, e.g. as pocket cards, posters, or electronically. Point-prevalence investigations and antibiotic visits will assure adherence to guidelines."
223851456|NCT00002932|DRUG|cisplatin|
223851457|NCT00002932|RADIATION|radiation therapy|
223851458|NCT00100100|DRUG|Modafinil|
223851459|NCT04243213|OTHER|Vibration Plate|Vibration at 15° tilt, which means the patients partly use their own body weight (resistive vibration exercise).
223851460|NCT04243213|OTHER|Tilt at 15°|To compare if a possible effect derives from the vibration or the tilting only, a second group was added who will only receive 10 min of 15° tilt without the vibration.
223851461|NCT04243213|OTHER|Standard hospital mobilization|early mobilization of patients 24h post surgery, done routinely, and physiotherapy this is done routinely in all patients
223851462|NCT02179281|DEVICE|Medtronic MiniMed™ 640G system|The MiniMed™ 640G system is indicated for the continuous delivery of insulin, for continuous or periodic monitoring of glucose levels in the fluid under the skin, with a feature for a prediction of low or high glucose episodes.
223851463|NCT02107378|BIOLOGICAL|DCVAC/OvCa|DCVAC/OvCa is the experimental therapy added on to Paclitaxel or topotecan or doxorubicin
223851464|NCT02107378|DRUG|Standard of Care (Paclitaxel or topotecan or doxorubicin)|Paclitaxel or topotecan or doxorubicin is Standard of Care First Line Chemotherapy
223851465|NCT01467700|DRUG|Ramelteon SL|Ramelteon SL tablets
223851466|NCT01467700|DRUG|Placebo|Ramelteon placebo-matching tablets
223851467|NCT03272113|BEHAVIORAL|SKIP-IT|A theory-based intervention using narrative, images and embedded behaviour change techniques, delivered via text-messaging.
223851468|NCT04136236|DIAGNOSTIC_TEST|The diagnosis of Artificial Intelligence and endoscopist|Suspected esophageal mucosal lesion is observed using pCLE, endoscopist and AI will make a diagnosis independently. In addition, the endoscopist can not see the diagnosis of AI. After a washout period, nonexpert endoscopists take the second assessment with AI assistance.
223851469|NCT02971930|BIOLOGICAL|BAY94-9027|Intravenous infusion of BAY94-9027
223851470|NCT03523962|DRUG|DuraPrep|The iodine-based treatment intervention is an antiseptic solution comprised of iodine povacrylex (0.7% free iodine) in 74% isopropyl alcohol. 3M™ DuraPrep™ \[3M Health Care, St Paul, MN\], will be the commercial product used.
223851471|NCT03523962|DRUG|ChloraPrep|The CHG intervention is an antiseptic solution comprised of 2% CHG in 70% isopropyl alcohol. ChloraPrep® \[CareFusion Inc., Leawood, KS, USA\] will be the product used.
223851472|NCT01293604|OTHER|Daily ingestion of whole grain barley and oats|Subjects will be randomly assigned to one of three treatments: 1) a control diet containing 0.7 daily servings of whole grain, 2) a diet containing at least 4 daily servings of whole grain barley or 3) a diet containing at least 4 servings of whole grain oats. After 6 weeks, risk factors of cardiovascular disease will be assessed after a 12 hr fast. During the seventh week, risk factors of cardiovascular disease will be assessed in the postprandial state.
223851473|NCT05372380|DRUG|BR1017-1|Administration to the F/F+AE group: BR1017-1 will be administered 1 tablet QD, five-day repeat dose
223851474|NCT05372380|DRUG|BR1017-2|Administration to the AE group: BR1017-2 will be administered 1 tablet QD, 9-day repeat dose Administration to the F+AE group: BR1017-2 will be administered 1 tablet once QD, 5-day repeat dose.
223851475|NCT02606409|DRUG|Dexmedetomidine|Dexmedetomidine sedation at a starting dose of 0.2-7.0 µg/kg/hour.
223851476|NCT02606409|DRUG|Propofol|Propofol sedation at a starting dose of 10-70 µg/kg/hour.
223851477|NCT05412030|BIOLOGICAL|AFX3772|AFX3772 administered intramuscularly 4 times within 12 months
223851478|NCT05412030|BIOLOGICAL|Prevnar 13|PCV13 administered intramuscularly 4 times within 12 months
223851479|NCT05412030|BIOLOGICAL|Prevnar 20|PCV 20 administered intramuscularly 4 times within 12 months
223851480|NCT03727854|DIETARY_SUPPLEMENT|Premeal protein enriched bar|Subjects in the intervention group will intake protein enriched bar 15 minutes before each meals (at least twice a day).
223851481|NCT03727854|BEHAVIORAL|Dietary modification|Subjects in this group will follow diabetes diet education.
223851482|NCT04951518|OTHER|VAN Stroke Scale|V.A.N Stroke Assessment measures unilateral weakness with visual deficits, aphasia, and neglect in possible stroke patients
223851483|NCT00384436|DRUG|escitalopram|
223851484|NCT03114904|OTHER|Variation of Jasinski score between H0 (stop of sedatives) and H6|To compare the effectiveness of a withdrawal management protocol with the usual management in cerebral patients (Subarachnoid haemorrhage (HSA), stroke and head trauma (CT))
223851485|NCT01425983|DIETARY_SUPPLEMENT|amino acid composition (asn01)|"Amino acid composition with micronutrients, once a day (in the evening, 2 hours after dinner) content of a sachet mixed with 200 ml water.~Duration: 12 weeks"
223851486|NCT01425983|OTHER|Placebo|"Placebo; once a day (in the evening, 2 hours after dinner) content of a sachet mixed with 200 ml water.~Placebo contains no amino acids and micronutrients and is identical in appearance and solution properties.~Duration: 12 weeks"
223851487|NCT00745446|PROCEDURE|Forearm Venous Occlusion Plethysmography|Forearm venous occlusion plethysmography with intra-arterial infusion of Acetylcholine (5-20mcg/min), bradykinin (30-300mcg/min), sodium nitroprusside (2-8mcg/min) and Verapamil (2-10 mcg/min) into non-dominant brachial artery
223851488|NCT06453356|DRUG|Zavegepant 10mg|intransal spray 10mg
223851489|NCT01205620|DEVICE|ITPR|• Upon incision of the pericardium the -9 mmHg ITPR device will be applied to the patient's endotracheal tube (in the ITPR randomized group).
223851490|NCT01205620|OTHER|No intervention|No intervention will be performed in the control group
224265573|NCT07138898|BIOLOGICAL|Secukinumab|"Control group: Schedule surgery 5 weeks after last administered subcutaneous dose.~Intervention group: Schedule surgery 2 weeks after last administered subcutaneous dose."
224265574|NCT07138898|BIOLOGICAL|Ixekizumab|Control group: Schedule surgery 5 weeks after last administered 4-week dose. Intervention group: Schedule surgery 2 weeks after last administered 4-week dose.
224265575|NCT07138898|BIOLOGICAL|Bimekizumab|Control group: Schedule surgery 9 weeks after last administered 8-week dose. Intervention group: Schedule surgery 4 weeks after last administered 8-week dose
224265576|NCT07138898|BIOLOGICAL|Ustekinumab|Control group: Schedule surgery 13 weeks after last administered 12-week dose. Intervention group: Schedule surgery 6 weeks after last administered 12-week dose.
224265577|NCT07138898|BIOLOGICAL|Guselkumab|Control group: Schedule surgery 9 weeks after last administered 8-week dose. Intervention group: Schedule surgery 4.5 weeks after last administered 8-week dose.
224265578|NCT07138898|BIOLOGICAL|Risankizumab|Control group: Schedule surgery 13 weeks after last administered 12-week dose. Intervention group: Schedule surgery 6-7 weeks after last administered 12-week dose.
224265579|NCT07138898|DRUG|Tofacitinib|Control group: Schedule surgery 4 days after last administered daily dose. Intervention group: Schedule surgery 2 days after last administered daily dose.
224265580|NCT07138898|DRUG|Upadacitinib|Control group: Withhold 4 days prior to surgery Intervention group: Withhold 2 days prior to surgery
224265581|NCT02293486|DIETARY_SUPPLEMENT|Pomegranate juice|Intake of 200 ml of pomegranate juice or pomegranate juice dilution during 21 days after exercise.
224265582|NCT07138612|BEHAVIORAL|Peer education group|Students will learn urinary catheterization through peer education.
224265583|NCT05735366|DRUG|SAIL66|SAIL66 as a IV infusion
224265584|NCT04725513|DEVICE|Shockwave Therapy|Participants will receive shockwave therapy once a week for three weeks
224265585|NCT04725513|DEVICE|Photobiomodulation Therapy|Participants will receive photobiomodulation therapy twice a week for three weeks
224265586|NCT04725513|OTHER|Physical Therapy|Participants will enroll in physical therapy and complete an at-home exercise protocol
224265587|NCT06791096|DIAGNOSTIC_TEST|AI-assisted auscultation|The study begins with non-blinded staff collecting medical histories and specialist physicians conducting face-to-face auscultations and assessments. Then, primary care doctors will conduct face-to-face auscultations and first assessments, and use AI-assisted stethoscopes to collect heart sounds following a set protocol. The AI model will analyze the data in real-time and provides an immediate diagnostic result, which is relayed back to the primary care physicians. Based on this, they will make a secondary assessment. All participants will undergo echocardiography.
224265588|NCT06791096|DIAGNOSTIC_TEST|Independent auscultation|It includes medical history collection by non-blinded independent personnel, face-to-face auscultation and evaluations conducted by specialist physicians and primary care doctors separately. All participants will undergo echocardiography.
224265589|NCT02324335|DRUG|Brilacidin|Oral Rinse used 3 times daily for 7 weeks
224265590|NCT02324335|OTHER|Placebo|
224265591|NCT02302716|DRUG|LY2963016|Administered SC
224265592|NCT02302716|DRUG|LANTUS®|Administered SC
224265593|NCT02302716|DRUG|Oral Antihyperglycemic Medication|Administered as per standard-of-care.
224265594|NCT06215196|DIETARY_SUPPLEMENT|Fiber Supplement Group|Semaglutide (2.4 mg weekly). Three daily packets of active fiber supplement (each containing 1g of glucomannan, 1g of inulin, and 3g of psyllium), taken 30 minutes before each main meal. The supplement is provided by S.Lab (Soloways), LLC.
224265595|NCT06215196|OTHER|placebo|Semaglutide (2.4 mg weekly). Three daily packets of placebo powder, taken 30 minutes before each main meal.
224265596|NCT03342235|PROCEDURE|Photorefractive Keratectomy (PRK)|Subjects randomized to refractive surgery will be referred to one of six study surgical centers (surgical centers are listed in Appendix B) to have photorefractive keratectomy (PRK) in the affected eye within 60 days after randomization.
224265597|NCT03342235|OTHER|Patching 2 hours per day|Patching prescribed 2 hours per day with continued refractive correction (with spectacles and/or contact lenses) as able.
224265598|NCT03342235|DEVICE|Excimer Laser System|Excimer Laser System for use in photorefractive keratectomy.
224265599|NCT00954603|DRUG|quetiapine|25-100 mg
224265600|NCT00954603|DRUG|haloperidol|0.5-2 mg
224265601|NCT01770002|PROCEDURE|Everted suture technique|
224265602|NCT01770002|PROCEDURE|Non-everted suture technique|
223851491|NCT05581160|DIAGNOSTIC_TEST|Assess the Performance of Metagenomic Sequencing in the Diagnosis of STI (NGS-IST)|"Proposal of the study to all eligible adult patients coming for pre-exposure prophylaxis (PrEP) consultations from the Infectious Diseases Department of Saint-Antoine and Tenon Hospitals (with delivery of a patient's information and signing an informed consent form).~During each visit (D0, M3, M6, M9, M12 and intermediate visits), patients will be asked to:~* Respond to a questionnaire on their history of taking antibiotics, STIs, their foreign travels, their consumption of tobacco, drugs, alcohol and their sexual practices.~* Perform the following additional samples at each visit, including the intermediate: rectal and throat swabs, urine sample and swab from the lesions in the case of ulceration presence due to STIs.~The diagnosis of STIs (NG and MG) will be carried out using 2 techniques: the reference technique and the Next-Generation-Sequencing (NGS) technique.~A serum sample will be collected during routine care. All samples will be stored after the analysis under -80° C."
223851492|NCT04478305|DRUG|Duavive 0.45Mg-20Mg Tablet|Duavee, marketed as Duavive in Canada.
223851493|NCT04813952|DRUG|Sevoflurane inhalant product|The sevoflurane dose differed in both groups in relation to the fresh gas flow. Since the fresh gas flow is less in group M, the concentration of sevoflurane consumed by the patient at the end of the case will be less.
223851494|NCT03241888|DRUG|Megestrol Acetate|At a dosage of 160 mg/day
223851495|NCT03241888|DEVICE|Levonorgestrel-releasing Intrauterine System(LNG-IUS)|Active ingredient: levonorgestrel 52mg. It is a hormone-releasing T-shaped intrauterine system.
223851496|NCT06630429|OTHER|Biospecimen Collection|Undergo collection of blood and stool samples
223851497|NCT06630754|OTHER|No Intervention: Observational Cohort|No intervention; observation cohort study
223851498|NCT06629402|DRUG|PF614|Experimental oxycodone prodrug
223851499|NCT06629402|DRUG|Placebo|Inactive medication
223851500|NCT06631703|OTHER|Group receiving Oral Colostrum Administiration|Description: Colostrum secreted in the first 3-5 days was oropharyngeal administered to the intervention group by withdrawing 0.2 ml of colostrum to be taken from the mother with the help of an insulin injector every three hours before each feeding meal in accordance with the literature.In the premature infants in the intervention group in which oropharyngeal colostrum was administered, the application was performed as follows: The oropharyngeal colostrum administration technique consists of slowly inserting a sterile 1 mL syringe without a needle with the tip of the syringe into the baby's mouth along the right buccal mucosa (0.1 mL) towards the oropharynx, then moving the syringe towards the inside of the cheeks and on the tongue, and repeating the same procedure on the left buccal mucosa (0.1 mL) without removing it (slow administration in approximately 1 minute). The routine feeding procedure was then continued
223851501|NCT06631625|DRUG|Lidocaine Intravenous Infusion|Patients will receive 1.5mg /kg lidocaine 2%; intravenously as a bolus dose then 1.5mg/kg/hr lidocaine infusion using a 50cc syringe pump intra-operatively.
223851502|NCT06631625|DRUG|Lidocaine and ketamine|Patients will receive same infusion regimen of lidocaine 2%; as in group L plus 0.35 mg/kg ketamine intravenously as a bolus dose, followed by intravenous infusion of 0.2 mg/kg/h using a 50cc syringe pump intra- operatively.
223851503|NCT06631625|DRUG|lidocaine and dexmedetomidine infusion|Patients will receive same infusion regimen of lidocaine 2%; as in group L plus 0.5 μg/kg dexmedetomidine intravenously as a bolus dose, followed by intravenous infusion of 0.4 μg/kg/h using a 50cc syringe pump intra-operatively.
223851504|NCT03578731|DEVICE|app|"The app is used to record the study parameters for a period of 90 days.~The following measures are used for data collection:~* Interview during regular consultation with doctor~* Web-App for gathering doctors data~* Consilium Smartphone App for gathering patient data During the course of care, the patient enters in a regular manner symptoms and treatment side effects in the Smartphone app. A continuous capture of the symptoms and treatment side effect is provided. If no entry is made within 3 days the patient is prompted to enter the data via a push message.~* Well-being through a patient rating on a visual analog scale~* Registration of symptoms and treatment side effects is done through the app~After completion of the study patients will be questioned according to:~• Usability and usefulness of the Smartphone app"
223851505|NCT05258006|PROCEDURE|Autogenous demineralized dentin nanoparticles|Effect of Autogenous demineralized dentin nanoparticles in bone gain in infrabony defect
223851506|NCT05169255|DRUG|Antibiotic administration|Individuals received either azithromycin or amoxicillin for 3 or 7 days
223851507|NCT06641778|OTHER|Fecal Microbiota Transplantation|Patients in the experimental group received conventional antibiotic therapy plus fecal microbiota transplantation, and the efficacy was compared with that in the control group
223851508|NCT04340245|OTHER|NA (Observational)|No interventions will be carried out. Comparisons will be made between patients whose cancer has progressed over the course of one year and patients whose cancer hasn't.
223851509|NCT02882503|DEVICE|endoscopic ultrasound - radiofrequency ablation (EUS-RFA)|Radiofrequency ablation will be applied with an innovative monopolar radiofrequency probe (1.2 mm Habib EUS-RFA catheter) placed through a 19 or 22 gauge fine needle aspiration (FNA) needle in patients with a tumor in the head of the pancreas.
223851510|NCT04811287|DEVICE|Carpal Tunnel Release with Platelet-Rich Plasma|CTR is performed with adjuvant PRP placed intra-operatively.
223851511|NCT04811287|PROCEDURE|Carpal Tunnel Release without Platelet-Rich Plasma|CTR is performed without adjuvant PRP placed intra-operatively.
223851512|NCT03396913|DEVICE|IPL|Intense pulsed light (IPL) is a non-invasive and non-laser light treatment that is FDA-approved for various conditions in dermatology. Subjects will receive a total of 4 IPL treatments over the course of the study, at intervals of 2 weeks. Each treatment will include applications of 10-15 IPL pulses in the malar region and close to the lower eyelids, followed by meibomian gland expression.
223851513|NCT03396913|DEVICE|Sham IPL|Sham intense pulsed light (IPL) will be implemented with an IPL device in which all light is blocked by a filter. Subjects will receive a total of 4 sham treatments over the course of the study, at intervals of 2 weeks. Each treatment will include applications of10-15 sham pulses in the malar region and close to the lower eyelids, followed by meibomian gland expression.
223851514|NCT03396913|PROCEDURE|MGX|Meibomian gland expression (MGX) will be implemented by squeezing the meibomian glands with the aid of two Q-tips positioned on either side of the meibomian glands, or with a meibomian gland expressor forceps
223851515|NCT00557843|DRUG|Bupivacaine|Wound perfusion with bupivacaine, plus patient controlled analgesia (PCA)
223851516|NCT00557843|DRUG|Saline|Wound perfusion with placebo solution (isotonic saline) plus patient controlled analgesia (PCA)
223851517|NCT06217354|DRUG|Carbetocin 100 Microgram/mL Solution for Injection|All patients will receive a bolus of carbetocin 100mcg IV over one minute after cord clamping. \[PabalVR, Ferring AG, Baar, Switzerland\]).then assess uterine contractility and postpartum bleeding measuring
223851518|NCT02694848|DRUG|Salvianolate injection|Traditional Chinese medicine injection，a kind of innovative drugs developed by Shanghai institute of materia medica, Chinese academy of sciences after 13 years of research and development.the content of magnesium acetate was 80%, and the other 20% were magnesium acetate.It has the function of promoting blood circulation,removing blood stasis and blood stasis,and is used for treating coronary heart disease with stable angina pectoris.
223851519|NCT02694848|DRUG|Aspirin|Molecular chemical formula: C9H8O4,molecular structure type: CH3COOC6H4COOH. It has the role of anti thrombosis In vivo, and it can inhibit the release of the platelet reaction, inhibit platelet aggregation, which is related to the reduction of TXA2 generation. Clinically itused to prevent the onset of cardiovascular and cerebrovascular diseases.
223851520|NCT05093712|OTHER|Educational Intervention|Watch educational video
223851521|NCT05093712|OTHER|Survey Administration|Complete surveys
223851522|NCT02454907|OTHER|Communication with the clinic|Over the course of the study, subjects will receive brief periodic communications on their cellular phone from the doctor's office.
223851523|NCT05767450|DIETARY_SUPPLEMENT|Probiotic Vivomixx®|The correct number of Vivomixx® sachets are given to parents with the indication to administer the dietary supplement as dissolved in drinking water or non-carbonated drinks.
223851524|NCT05767450|DIETARY_SUPPLEMENT|Placebo|The correct number of Placebo sachets are given to parents with the indication to administer the dietary supplement as dissolved in drinking water or non-carbonated drinks.
224265603|NCT03232541|OTHER|Standard care|A) Standard antiemetic treatment means receiving ordinary antiemetic medications. Within the group, the patients will be randomized to two communication types: 1) neutral communication or 2) strengthened positive communication regarding expected antiemetic effects of their treatment, using a standardized communication model.
223851525|NCT06437002|BEHAVIORAL|Mental Motor Chronometry (MMC) Task Hands and Feet and Whole Body|"The MMC will be used as a measure of MI and it is adapted for use in hands, feet, and the whole body as well as for online experimentation. The task is comprised of two conditions, MI, and motor execution, in which respectively participants will be asked to imagine and execute a movement sequence with both hands and feet and the whole body.~Hand movements: index and thumb opposition; thumb extension from the fist; middle finger crossed on the index finger; and extension of the index and the little fingers.~Foot movements: foot internal rotation, foot external rotation, foot dorsiflexion, and foot plantarflexion.~Whole-body movements: take a small bow, lift arms over the head and stand on the tips of the toes (stretch), extend hands forward and lower the backside (squats) and a small jump.~The types of movements required to be executed by participants are simple and do not require much energy. Therefore, people affected by AN and BN should be able to perform them without problems."
223851526|NCT00164489|BEHAVIORAL|Weight control and physical activity promotion|
223851527|NCT00813488|DRUG|Fentanyl Buccal Tablet|"FBT dose strengths = 200, 400, 600, or 800 mcg (1, 2, 3, or 4 tablets) taken prn (as needed) in the event of breakthrough pain.~The maximum dose of FBT permitted during the titration and double-blind periods in this study is 800 mcg (4 tablets).~For the subsequent 12-week open-label treatment period, patients will either continue with FBT treatment or begin treatment with an alternative short-acting opioid deemed appropriate for each patient by the clinician."
223851528|NCT00813488|DRUG|Immediate release oxycodone|"Immediate release oxycodone dosage strength: 15, 30, 45, and 60 mg doses (1, 2, 3 or 4 capsules) to be taken prn (as needed) for breakthrough pain.~The maximum single dose would be 60 mg (4 capsules)."
223851529|NCT04100356|OTHER|Exercise|Exercise program - indoor bicycle interval exercise, duration 60 min 3x week
223851530|NCT04100356|OTHER|Normal Diet|Normal diet recommended by the health authorities
223851531|NCT04100356|OTHER|LCHF Diet|LCHF Diet, a modified Atkins diet with high percentage of fat and very low percentage of karbohydrates
223851532|NCT02681276|PROCEDURE|Irrigation with 3% NaOCl|All the operators are informed to perform the endodontic treatment the way they normally do. The only variation during treatment was the concentration of the sodium hypochlorite solution for irrigation of the root canal.
223851533|NCT02681276|PROCEDURE|Irrigation with 0.5% NaOCl|All the operators are informed to perform the endodontic treatment the way they normally do. The only variation during treatment was the concentration of the sodium hypochlorite solution for irrigation of the root canal.
223851534|NCT01143077|DRUG|Lurasidone HCl|Lurasidone tablets, 40 mg/daily, 80 mg/daily, 120 mg/daily for 6 weeks
223851535|NCT04671628|BEHAVIORAL|Relaxing music|Participants will be asked to listen to relaxing music for 30 minutes each day. They will allowed to choose between several playlists based on their preference.
223851536|NCT01671475|DEVICE|microEEG (Bio-Signal microEEG)|"At the core, the Bio-Signal microEEG, is an FDA approved miniature, battery-operated, multi-channel, and portable system that records wideband bioelectric signals. The microEEG combines the characteristics of low noise and small size, due to a number of fundamental design characteristics. It records, amplifies, and digitizes the signals at a point very close to the electrodes. This allows the length of the wires between electrodes and the recorder's amplifiers to be very short, keeping them out of the way. Short wires also reduce any inconvenience signal artifacts or other problems that may be associated with the length of the wires. The microEEG's dimensions are about 2x2x1."
223851537|NCT00897767|OTHER|biologic sample preservation procedure|
223851538|NCT04681417|DRUG|Melphalan or Melphalan + Topotecan|IAC: 2-6 cycles every 1 month (number based on the local tumor evolution), performed using radio-guided catheterization and delivery at the ostium of the ophthalmic artery, in neuroradiology operating room, and under General Anesthesia (GA). IAC will be administered at the Fondation Rothschild Hospital in collaboration with the Interventional Neuroradiology team.
223851539|NCT04681417|DRUG|etoposide, carboplatin and vincristine or local ophthalmological treatment without IV chemotherapy|2 to 6 cycles of combined etoposide, carboplatin and vincristine or local ophthalmological treatment without IV chemotherapy : thermotherapy and/or cryotherapy and/or iodine-125 plaques and/or intravitreal chemotherapy injections
223851540|NCT04681417|DRUG|Carboplatin administered on Day 1|Chemothermotherapy : Intravenous injection by carboplatin
223851541|NCT04681417|DEVICE|Thermotherapy (local treatment)|Thermotherapy after carboplatin administered on Day 1
223851542|NCT04681417|DEVICE|Cryotherapy (local treatment)|Cryotherapy (local treatment)
223851543|NCT04681417|DEVICE|Iodine-125 plaques (local treatment)|Iodine-125 plaques (local treatment)
223851544|NCT04681417|DRUG|Intravitreal Melphalan chemotherapy injections (local treatment)|Intravitreal Melphalan chemotherapy injections (local treatment)
223851545|NCT05750511|DIAGNOSTIC_TEST|molecular tissue analysis|
223851546|NCT00635817|DRUG|Leuprolide acetate 11.25 mg|Two intramuscular injections of leuprolide acetate for depot suspension 11.25 mg administered 3 mo apart.
223851547|NCT00635817|DRUG|Leuprolide acetate 30 mg|Two intramuscular injections of leuprolide acetate for depot suspension 30 mg administered 3 mo apart.
223851548|NCT04179240|OTHER|audio and animated cartoon questionnaire|participants were asked to complete a questionnaire audio and animated cartoon on a platform
223851549|NCT03438487|BIOLOGICAL|Flucelvax Trivalent Influenza Vaccine|"Flucelvax is a cell culture seasonal trivalent influenza vaccine that contains the following influenza hemagglutinin antigens: 1) A/H1N1-like virus, 2) A/(H3N2)-like virus, 3) B/Yamagata lineage or B/Victoria lineage~Vaccine exposure in routine care (no vaccination per protocol)"
223851550|NCT03438487|BIOLOGICAL|Flucelvax Quadrivalent Influenza Vaccine|"Flucelvax Quadrivalent is a cell culture seasonal quadrivalent influenza vaccine that contains the following influenza hemagglutinin antigens: 1) A/H1N1-like virus, 2) A/(H3N2)-like virus, 3) B/Yamagata lineage, 4) B/Victoria lineage~Vaccine exposure in routine care (no vaccination per protocol)"
223851551|NCT02741167|PROCEDURE|CRS and HIPEC|During CRS, all visible peritoneal tumors are removed. Consequently micrometastasis are removed with hyperthermic intraperitoneal chemotherapy
223851552|NCT02841891|DEVICE|Sylys® Surgical Sealant|Standard Stapled Anastomosis Colectomy Procedure with the addition of Sylys® Surgical Sealant
223851553|NCT02841891|PROCEDURE|Stapled Anastomosis Colectomy Procedure|Standard Stapled Anastomosis Colectomy Procedure without the addition of Sylys® Surgical Sealant
223851554|NCT01130064|BIOLOGICAL|QAX576|every 3 weeks via intravenous infusion
223851555|NCT01130064|DRUG|Placebo|every 3 weeks via intravenous infusion
223851556|NCT02279342|DRUG|Febuxostat|The starting dose of the febuxostat will be 10mg /day. The dose will be increased to 20 mg/day at week 4 and finally titrated to 40 mg/day at week 8.
223851557|NCT01985399|BEHAVIORAL|Neuropsychological testing|Neuropsychological testing
223851558|NCT03702543|BEHAVIORAL|SymTrend, Inc.|Use of SymTrend and Apple Health apps with feedback and strategies provided.
223851559|NCT01066741|DRUG|Homeodent®|Two-minute mouthwash with 5 ml of solution diluted in 125 ml of water, 3 times per day after meals and tooth brushing.
223851560|NCT01066741|DRUG|1.4% Sodium Bicarbonate solution|Two-minute mouthwash with 125 ml of solution, 3 times per day after meals and tooth brushing
223851561|NCT00237107|PROCEDURE|Curretage|
223851562|NCT03231436|DRUG|Fixed dose of 12.5mg bupivacaine|Spinal anesthesia performed with 12,5mg of bupivacaine with 25mcg fentanyl for cesarean section
223851563|NCT03231436|DRUG|Height-adjusted dose of bupivacaine|Spinal anesthesia performed with height-adjusted dose of bupivacaine with 25mcg fentanyl for cesarean section
223851564|NCT01844544|OTHER|inspection of medical records|
223851565|NCT03121963|DRUG|Oxycodone|oxycodone tablet
223851566|NCT03121963|DRUG|Acetaminophen|acetaminophen tablet
223851567|NCT03121963|DRUG|Gabapentin|gabapentin tablet
223851568|NCT03121963|DRUG|Celecoxib|celecoxib tablet
223851569|NCT03121963|DRUG|Hydrocodone-Acetaminophen|hydrocodone 5 mg/acetaminophen 325 mg tablet
223851570|NCT00042588|DRUG|Recombinant Chimeric Monoclonal Antibody|
223851571|NCT03728036|BEHAVIORAL|conventional rehabilitation|The investigated cohort will be exposed to 'standard care' including conventional rehabilitation therapy.
223851572|NCT03545386|OTHER|Fecal microbiota transplantation|Stool from healthy donor administered via enema
223851573|NCT03545386|OTHER|Placebos|Saline with food coloring administered via enema
223851574|NCT02470104|DIETARY_SUPPLEMENT|Breastmilk|"* A registered dietician will supervise milk provision.~* If a nursing mother enrolls on the study, maternal and not donor milk will be given in the maximum volume possible with Prolacta supplementation if clinically indicated and recommended by the registered dietician."
223851575|NCT02549443|DIETARY_SUPPLEMENT|Amino acids|AA (Travasol Baxter, Deerfield IL) during and after surgery in an amount equivalent to 20% and 35% of the patient's energy expenditure (EE)
223851576|NCT03820986|BIOLOGICAL|Pembrolizumab|IV infusion
223851577|NCT03820986|DRUG|Lenvatinib|Oral capsule
223851578|NCT03820986|DRUG|Placebo for lenvatinib|Oral capsule
223851579|NCT02999217|DRUG|Iron isomaltoside|"Intravenous injection 1 g given postoperatively in the recovery ward.~Blood tests including red blood cell count, plasma ferritin, haemoglobin, haematocrit, mean corpuscular volume, mean haemoglobin concentration are made 1 day preoperatively, day 1, day 3 postoperatively, day of discharge and 1 month after discharge.~Reticulocyte count and reticulocyte haemoglobin concentration tests are made on the day of discharge and 1 month after discharge.~Count of total consumption of intravenous blood products. Count of total intravenous fluids. Clinical recovery and complications. Duration of hospital stay."
223851580|NCT02999217|DRUG|Saline|"Intravenous injection given postoperatively in the recovery ward.~Blood tests including red blood cell count, plasma ferritin, haemoglobin, haematocrit, mean corpuscular volume, mean haemoglobin concentration are made 1 day preoperatively, day 1, day 3 postoperatively, day of discharge and 1 month after discharge.~Reticulocyte count and reticulocyte haemoglobin concentration tests are made on the day of discharge and 1 month after discharge.~Count of total consumption of intravenous blood products. Count of total intravenous fluids. Clinical recovery and complications. Duration of hospital stay."
223851581|NCT03059992|DRUG|Ibrexafungerp|Experimental Study Drug
223851582|NCT05993403|OTHER|Intercultural Sensitivity Education Program|The training program consists of three sessions. In the Intercultural Sensitivity training for nurses, it was aimed to develop the level of intercultural sensitivity, and it was aimed to provide proficiency in providing services to raise awareness and knowledge about intercultural sensitivity.
223851583|NCT06659289|DEVICE|Efferon LPS|"Efferon LPS, a medical device, which is a single-use cartridge filled with a polymeric adsorbent that selectively adsorbs endotoxin via surface-immobilized ligand and excessive cytokines via its intrinsic porosity.~The hemoperfusion procedure is performed at the time of cardiopulmonary bypass during cardiac surgery. The therapy (Efferon LPS hemoperfusion) is performed once. The duration of the procedure is limited by the time ofcardiopulmonary bypass."
223851584|NCT02516774|DRUG|Adalimumab|
223851585|NCT02370732|OTHER|Alcohol|A weight based dose of alcohol will be administered during each study day.
223851586|NCT06611176|DRUG|Local levobupivacaine|submucosal injection of levobupivacaine during esophageal esad
223851587|NCT05279963|PROCEDURE|electroacupuncture|"The prespecified acupoints applied here will include bilateral Sanyinjiao(SP6), Shenshu(BL23), Ciliao(BL32), Zhongliao(BL33), Zhibian(BL54) .~Acupuncture treatment is carried out by acupuncturists who have been well trained. Acupuncture will be performed with disposable and sterile needles in the specification of 0.25 ×40 mm(diameter: 0.25mm; Suzhou Medical Products Factory Co., Ltd, China). Electroacupuncture procedures will be performed with electronic instruments (Hans-100A, Nanjing Jisheng Medical TechnologyCo., Ltd, China). Two paired of acupoints (i.e., two Shenshu(BL23) and two Ciliao(BL32), respectively) are connected to the EA apparatus. Alternating-frequency mode is selected and frequency is 2/100 Hz. EA intensity is determined in accordance with patients' endurance. EA will last for 30 min for each treatment. Patients will receive a total number of 12 EA sessions, with the frequency of 3 sessions per week for 4 weeks."
223851588|NCT05279963|DRUG|Amitriptyline|Participants in the medication group will be merely treated with oral administration of amitriptyline capsule. The dosage of amitriptyline is 25mg bid, for 4 weeks. Any changes in the medications of individual participants will be recorded on diary cards.
223851589|NCT05279963|PROCEDURE|sham electroacupuncture|"In the trunk region, the points are 5 cm away from respective acupoints. In the lower limb region, the point is 3 cm away from Sanyinjiao(SP6). All points will only receive shallow insertion.~Acupuncture will be performed with disposable and sterile needles in the specification of 0.25 ×40 mm(diameter: 0.25mm; Suzhou Medical Products Factory Co., Ltd, China).The needles are shallowly inserted to the subcutaneous area, and acupoints are connected to the EA apparatus without electricity. The frequency, intensity and duration of treatment will be the same as the electric needle group."
223851590|NCT06606613|PROCEDURE|Intraurethral injection|"Procedure: Intraurethral injection~Patients are positioned in the lithotomy position during the procedure. General and/or local anesthesia is administered depending on the investigator\&amp;amp;#39;s preference. An applicator developed for intraurethral injection will be used. This device comprises a holder that is placed into and fixates the urethra (i.e., it distends the urethral circumference, thus smoothing out the longitudinal folds), allowing the use of four syringes to inject cross-linked hyaluronic acid/dextranomer at approximately the 2, 4, 8, and 10 o'clock positions.~Drug: Cross-linked hyaluronic acid/dextranomer"
223851591|NCT06606613|PROCEDURE|Mid-urethral sling|"Procedure: Starting with the dorsal lithotomy position, a foley catheter is inserted to the urethra. Starting with 1-1.5 cm below the urethral meatus, a 1.5-2 cm vertical incision is made. Following the dissection of anterior vaginal mucosa, pubocervical fascia should be dissected sharply .~Dissection is continued laterally to the ischiopubic ramus. Starting downwards from the tendinous insertion of the adductor longus muscle at the level of clitoris, a 1cm incision is made close to the bone. The needle is placed in to the incision and passed medially through the obturator membrane. It has to be considered that the needle is passed very close to the bone in order not to damage the obturator vessel-nerve bundle. With the guidance of the opposite hand's index finger in the vaginal incision the tip of the needle has to be palpated afterwards passing with a 45-degree angle rotation. The next manoeuvre is passing the tip of the needle beside the urethra through the vaginal incision ."
223851592|NCT06613464|DIAGNOSTIC_TEST|diagnosis confirmation|The patients diagnoses will be confirmed though imaging methods like computed tomography chest x-ray and anamnesis
223851593|NCT06615089|OTHER|balance training|the elderly patients will receive balance training in the form of proprioceptive and vestibular training components. proprioceptive training include Standing static balance, lateral weight transfer, Lateral weight transfer near to chair, tandem closed eyes, walking on toes, Postural control using ball. Vestibular training in the form of Balance with head movement, seated lateral step in addition to Insoles inside the subjects' own regular shoes
223851594|NCT06615089|OTHER|orthotic prescription|the elderly patients will receive Insoles inside the subjects' own regular shoes
223851595|NCT06613919|DRUG|Anti-Tuberculosis Treatment|Standard, weight adjusted anti-TB therapy for six months
223851596|NCT06613919|DRUG|Anti-Tuberculosis Treatment|Standard, weight-adjusted anti-TB therapy for nine months
223851597|NCT06614023|PROCEDURE|coronary artery bypass grafting|surgical coronary revascularization
223851598|NCT00708097|DRUG|NaF|Fluoride
223851599|NCT00708097|DRUG|Placebo|Placebo
223851600|NCT00708097|DRUG|NaMFP|Fluoride
223851601|NCT06614621|DRUG|Adebrelimab +Etoposide+Platinum-based drugs|Adebrelimab：20mg/kg或1200mg ivgtt ，d1 ，Q3W Etoposide injection (E): 100mg/m2, ivgtt, d1,d2,d3,Q3W Platinum-based drugs：75mg/m2， ivgtt， d1,d2,d3,Q3W
223851602|NCT06614621|DRUG|Maintenance treatment period:|Adebrelimab：20mg/kg或1200mg，IV, Q3W； Apatinib Mesylate Tablets：250mg，P.O，qod
223851603|NCT06613932|PROCEDURE|pulpotomy|removal of the coronal pulp tissue and preservation of the radicular portion to ensure continuation of growth and vitality of tooth structure
223851604|NCT06615310|OTHER|ultrasonograpic evaluotion|The distance between the hyoid and thyroid cartilage, the volume of the geniohyoid, digastric anterior, sternohyoid and thyrohyoid muscles will be evaluated by ultrasound.
223851605|NCT06309342|OTHER|PREVFUNKTION|Functional profile and advice concerning cardiovascular fitness level, strength, mobility, balance and posture. Motivational interview and support in goalsetting to make lifestyle changes.
223851606|NCT06309342|OTHER|Control|Physical activity measured with accelerometers. Functional examination. Medical examination and advice concerning weight measures, blood pressure and standard blood tests.
223851607|NCT06613945|PROCEDURE|ERCP biliary drainage|bilateral metallic stents insertion will be attempted through ERCP to secure biliary drainage
223851608|NCT06613945|PROCEDURE|Combined ERCP and EUS-HGS biliary drainage|unilateral metallic stent will be inserted on right side by ERCP and a hepaticogastrostomy transmural stent will be inserted on left side by EUS to secure biliary drainage.
223851609|NCT05846165|DEVICE|Field-Cycling Imaging (FCI)|FCI scan
223851610|NCT06629909|DRUG|Secretome|3 ml Injection of secretome for 8 times two weeks apart
223851611|NCT05760755|BEHAVIORAL|Stick Together|The intervention consists of 12 online modules, completed flexibly during and immediately after primary cancer treatment. The intervention contains interviews with other couples, psychoeducational information, and interactive exercises on themes such as dyadic coping and communication, being diagnosed at a young age, fertility and children, and life after treatment.
223851612|NCT06697392|OTHER|ultrasound examination|The investigators intend to perform ultrasound examinations for the participants with CTS.
223851613|NCT06698094|BEHAVIORAL|Sustainable lifestyle|To encourage and nudge a sustainable lifestyle in an office context in order to improve public health and combat climate change.
223851614|NCT06698094|BEHAVIORAL|Healthy lifestyle|To encourage and nudge a healthy lifestyle in an office context, the participants in this arm will function as a control group receiving general recommendations based on NNR 2014 nutritional recommendations and WHO physical activity recommendations.
223851615|NCT06697054|DIAGNOSTIC_TEST|Sentinel node biopsy with either ICG or carbon dye injection to cervix|Either laparatomy or laparoscopy wil be performed to detect sentinel node stained with either ICG or carbon dye injected to cervix. A hemipelvis in which a sentinel is not found will be subjected to full lymphadenectomy.
223851616|NCT06696833|BIOLOGICAL|QH10304-BAL-01|dose escalation (3+3) : dose 1 (3 × 10\^8cells/kg) ,dose 2 (1 × 10\^9 cells/kg) ,dose 3 (3 × 10\^9cells/kg)
223851617|NCT06696833|DRUG|Fludarabine|Intravenous fludarabine 30mg/m2 on days-6 to -3,the infusion dose is adjusted according to the subject's condition
223851618|NCT06696833|DRUG|Cyclophosphamide|Intravenous cyclophosphamide 1000mg/m2 on days -5 to -3, the infusion dose is adjusted according to the subject's condition
223851619|NCT06697002|OTHER|lower trapezius strenghtening excercise|32 participants will be in control group who will perform strenghtening excerise of lower trapezius
223851620|NCT06697002|OTHER|scapular mobility exercise|32 participants will be in experimental group who will perform scapular mobility exercise
223851621|NCT03867617|OTHER|Regulatory T cells|Single infusion of expanded regulatory T cells.
223851622|NCT03867617|DRUG|Tocilizumab|Treatment during first month post-transplant.
223851623|NCT03867617|OTHER|Bone marrow|Infusion of donor bone marrow cells.
223851624|NCT03867617|PROCEDURE|Kidney transplant|Living donor kidney transplantation.
223851625|NCT03867617|OTHER|Immunosuppressive drug therapy|Immunosuppressive drug therapy.
223851626|NCT05974839|OTHER|Ocrelizumab|Non-interventional
223851627|NCT06696703|DRUG|Human urinary kininogenase(HUK)|Experimental group (HUK plus routine clinical treatment): administered within 48 hours of AIS onset, 0.15PNA unit was dissolved in 100ml sodium chloride injection by intravenous infusion for not less than 50 minutes, once a day.
223851628|NCT06696703|OTHER|Placebo|Placebo group (Normal sodium chloride injection plus routine clinical treatment): Normal sodium chloride administered within 48 hours of AIS onset, by intravenous infusion for not less than 50 minutes, once a day.
223851629|NCT06702839|OTHER|BETY (Cognitive Exercise Therapy Approach )|"Individuals with rheumatism were included in BETY sessions after the first session, which included functional gain with function-focused trunk stabilization exercises for their complaints and chronic pain management training based on neuroscience. BETY sessions included function-focused trunk stabilization exercises, chronic pain management, mood information management (dance therapy - authentic movement) as innovative. Individuals were included in a separate session of sexual information management and sleep education.~3 days a week for 3 months"
223851630|NCT06702839|OTHER|Home exercise program|Exercises have been shown and a brochure has been given The individuals in this group were mostly individuals from out of town who were given home exercise recommendations directed by a rheumatologist.
223851631|NCT06705413|OTHER|Aerobic exercise|a program consists of 10 minutes warming up, 30 minutes of aerobic exercises in the form of core strengthening exercises and stretching exercises and finally 10 minutes of cooling down. The participant will receive the aerobic program 4 sessions /week for three consecutive menstrual cycles.
223851632|NCT06705413|OTHER|Microbiome diet|The participants will receive Microbiome diet for three consecutive menstrual cycles. A three-phase diet (21-day phase, 28-day phase and maintenance phase) will be followed by the experimental group which contains some food restrictions and addition for certain food types which may improve gut health.
223851633|NCT06705439|DEVICE|Nelli|Nelli detects and registers activity that is indicative of seizure events. Nelli captures, stores, and processes video and audio recordings from each patient. Biomarker data is collected during periods of rest for the length of an examination period, which may span several days or months (when used inside and outside of a hospital setting, respectively), as prescribed by a treating physician.
223851634|NCT06629922|OTHER|No intervention|This is a observational study and the participants will not receive any intervention
223851635|NCT06480123|DRUG|Skin drug prepared with exome originated from stem cell|Skin drug prepared with exome originated from stem cell will be applied to patient with diabetic foot.
223851636|NCT00356317|BEHAVIORAL|Culturally informed therapy for schizophrenia (CIT-S)|This family therapy consists of 15 video-taped, therapy sessions, each lasting approximately 75 minutes. The 15-session treatment will be broken down into five segments (each lasting approximately three sessions) with the following goals: 1) Fortify a strong sense of family unity; 2) educate about schizophrenia; 3) foster adaptive use of cultural, spiritual and/or existential beliefs in conceptualizing and coming to terms with schizophrenia; 4) teach effective communication training techniques; and 5) and teach useful problem solving strategies.
223851637|NCT00356317|BEHAVIORAL|Psychoeducation treatment as usual|This family therapy consists of three weekly sessions focusing on education about schizophrenia.
223851638|NCT00324506|DRUG|Mycophenolate Mofetil (CellCept)|
223851639|NCT04178109|DRUG|Dexketoprofen/tramadol (27mg/75mg)|Postoperatively patients in Group A received the oral combination dexketoprofen/tramadol for the treatment of acute postoperative pain the first 72h
223851640|NCT04178109|DRUG|Tramadol hydrochloride|Patients in group B received IV tramadol 75mg every 8h
223851641|NCT04178109|DRUG|Paracetamol|Patients in group B received IV paracetamol 1g every 8h
223851642|NCT04178109|DRUG|Ropivacaine Hydrochloride 7.5 MG/ML|300mg ropivacaine as periarticular injection in a dilution of 100ml n/s 0,9% was done by the orthopedic surgeon in all patients
223851643|NCT04178109|DRUG|Levobupivacaine Hydrochloride|10-15mg levobupivacaine was done subarachnoidal for spinal anesthesia
223851644|NCT01434303|DRUG|Entinostat|Given PO
223851645|NCT01434303|OTHER|Laboratory Biomarker Analysis|Correlative studies
223851646|NCT01434303|DRUG|Lapatinib Ditosylate|Given PO
223851647|NCT01434303|BIOLOGICAL|Trastuzumab|Given IV
223851648|NCT01451814|BEHAVIORAL|Positive Psychotherapy for smoking cessation|6 sessions of individual behavioral smoking cessation counseling that incorporates techniques from Positive Psychotherapy to increase positive affect and reduce negative affect prior to and after quitting smoking. Intervention includes 8 weeks of transdermal nicotine patch.
223851649|NCT01451814|DRUG|Nicotine polacrilex|8 weeks of nicotine patch
223851650|NCT01451814|BEHAVIORAL|Relaxation training|Instructions in progressive muscle relaxation
223851651|NCT01451814|BEHAVIORAL|Behavioral smoking cessation treatment|Counseling on techniques to manage triggers and avoid smoking
223851652|NCT06127888|OTHER|Interviews|Semi-structured interviews
223851653|NCT06127888|OTHER|Surveys|Estructured survey
223851654|NCT06336486|DEVICE|intermittent pneumatic compression +pregabalin group|The investigators divided the patients into two equal groups , some of the patients were given an intermittent pneumatic compression program at a pressure of 35 mmhg for 30 min to the lower extremity for 10 days of extreme alternation in our clinic and pregabalin treatment was continued.
223851655|NCT06336486|OTHER|pregabalin group|only pregabalin treatment was continued.
223851656|NCT04260750|BEHAVIORAL|Internet-administered Cognitive behavioral therapy (ICBT)|"The intervention consists of fifteen modules, each having a specific focus on a problem (e.g. comorbid worry alongside the depression) or containing a specific strategy or element (e.g. behavioral activation).~The fifteen modules are:~Introduction/Psychoeducation about depression, Behavioral activation 1, Behavioral activation 2, Cognitive restructuring, Acceptance, Psychoeducation about emotions, Anxiety and exposure, Comorbid social anxiety, Comorbid worrying and generalized anxiety, Comorbid panic disorder, Sleep problems, Perfectionism, Stress management, Relaxation, and Relapse prevention.~The first and last module are assigned to all participants. The rest is picked either by the participants themselves or by the therapist conducting the intake interview."
223851657|NCT04106141|OTHER|6 weeks changing of archwire|changing the archwire after 6 weeks instead of 4 weeks
223851658|NCT04106141|OTHER|4 weeks changing of archwire|changing the archwire every 4 weeks
223851659|NCT06030908|PROCEDURE|Reconstruction of Achilles tendon insertion|knotless double-row anchor fixation of the achilles tendon insertion
223851660|NCT04120051|DIETARY_SUPPLEMENT|Fermented canola-seaweed|A daily sachet with 5 gram FCS-granulate for 6 weeks
223851661|NCT04120051|OTHER|Placebo|A daily sachet with 5 gram rye cereal for 6 weeks
223851662|NCT02599844|DRUG|Iodohippurate|An injection of non-radioactive iodohippurate (0.07 mL/kg) will be administered to determine renal plasma flow (RPF)
223851663|NCT02599844|PROCEDURE|24 hour ambulatory Blood Pressure|Ambulatory blood pressure (BP) monitoring will be performed using a commercially available device (TIBA Ambulo 2400) for 24 hours with measurements every 30 minutes while awake and every hour during sleep.
223851664|NCT02599844|PROCEDURE|Peripheral Arterial Tonometry|The peripheral arterial tonometry (PAT) device measures changes in the cutaneous circulation that correlate with flow-mediated dilatation.
223851665|NCT02599844|PROCEDURE|Pulse Wave Velocity|Carotid-femoral and carotid-radial pulse wave velocities (PWV), validated markers of individual cardiovascular risk, will be determined by applanation tonometry using SphygmoCorVx technology (AtCor Medical). PWV is an index of the overall stiffness of a vascular segment between measurement sites 59. Thus, while carotid-femoral PWV is an index of the overall stiffness of proximal (central) arteries, the overall stiffness of peripheral arteries contributes relatively more to carotid-radial PWV.
223851666|NCT02599844|DRUG|Gadolinium|Magnevist Gadolinium (GD)-diethylene-triamine-pentaacetic acid-bis-oleate (0.07 to 0.14 mL/kg) will be used to determine GFR.
223851667|NCT00608673|DRUG|Pimecrolimus 1% cream|a very thin coat of pimecrolimus 1% cream, twice daily topically to the facial lesions of discoid lupus erythematosus
223851668|NCT00608673|DRUG|betamethasone valerate 0.1% cream|A very thin coat of betamethasone valerate 0.1% cream, twice daily to facial lesions of discoid lupus erythematosus for 8 weeks.
223851669|NCT02356549|BEHAVIORAL|EMR Tailoring|Electronic Medical Records (EMR) data alone will be entered into the Michigan Tailoring System (MTS system) and their brochures will be prepared.
223851670|NCT02356549|BEHAVIORAL|Survey Tailoring|Survey that will use standardized, psycho-metrically sound measures to gather information about patients, including their levels of trust in medical research and preferences for information and decision involvement. The survey augmented by their EMR data will be used to develop a level of tailored messages.
223851671|NCT02356549|BEHAVIORAL|Physician Involvement|Prior to the consultation, physicians of patients will receive a summary of patients' tailored message brochure from the Research Assistant (RA) and included in the patient's notes. At the conclusion of the consultation, the RA will ask the oncologist whether or not a clinical trial was discussed and whether or not they read the patients brochure.
223851672|NCT06245200|OTHER|UNIPDES - Internet Based Intervention - GUIDED|The experimental group participants will receive the internet-based intervention consisting of six weeks. This intervention has cognitive, emotional and behavioral components. Users will be able to use content created with video, audio, animation and interactive forms on their electronic devices (PC; tabs or smartphones). Participants in this arm will receive weekly feedback from counselors through the web software used.
223851673|NCT06245200|OTHER|UNIPDES - Internet Based Intervention - UNGUIDED|The experimental group participants will receive the internet-based intervention consisting of six weeks. This intervention has cognitive, emotional and behavioral components. Users will be able to use content created with video, audio, animation and interactive forms on their electronic devices (PC; tabs or smartphones).
223851674|NCT04208243|BEHAVIORAL|Creative Arts Therapy|"The intervention will consist of approximately weekly CAT in the infusion center during cancer therapy. The interventionist is a Master's prepared, licensed dance/movement therapist who is experienced in music and art therapies as well. The CAT includes dance/movement such as playing with a parachute, simple yoga breathing and postures, and work with physioballs. The music includes singing, listening to music, and playing instruments. The art consists of drawing, finger painting, working with clay. The CAT may occur in individual sessions in private infusion rooms, or in groups in the middle of the infusion center. The CAT is not only a distraction, but also a therapeutic process addressing the stressors of cancer and its treatment. The dose of CAT will be recorded (number and type of sessions) and will be factored into the analysis."
223851675|NCT02955069|DRUG|PDR001|PDR001 was administered at a dose of 400 mg via intravenous infusion once every 4 weeks (Q4W). PDR001 was administered on Day 1 of every cycle. Each cycle was 28 days.
223851676|NCT05301400|DEVICE|Bti Unit|Comparison with or without the device
223851677|NCT04619654|PROCEDURE|Cataract surgery with implantation of trifocal IOL combined with trabecular scaffold|Cataract surgery with implantation of the PanOptix IOL combined with minimally invasive glaucoma surgery utilizing the Hydrus Microstent
223851678|NCT00009984|DRUG|fludarabine phosphate|Given IV
223851679|NCT00009984|DRUG|thalidomide|Given orally
223851680|NCT05582317|DRUG|Biodentine|Tricalcium silicate, dicalcium silicate, calcium carbonate and oxide filler, iron oxide shade and zirconium oxide
223851681|NCT05582317|DRUG|Simvastatin|3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor
223851682|NCT03178396|DIETARY_SUPPLEMENT|melatonin|controlled release, 9 mg taken 30 minutes before bedtime x 6 weeks
223851683|NCT06358066|DRUG|self assembling peptide p11-4 with fluoride|"Self-assembling peptide (P11-4) fluoride plus will be applied according to the manufacturer's instructions by pushing the two cylinders together and will left for 5 min till the tooth surface appears dry to insure its diffusion~The remineralizing process of the early enamel carious lesions will be assessed quantitatively using the laser fluorescence DIAGNOdent measuring and assessed qualitatively using ICDAS II scoring system at baseline 1, 3, 6 months post-treatment"
223851684|NCT06358066|DRUG|5% sodium fluoride varnish|Fluoride varnish will be applied under manufacturer instructions by applying thin layer of varnish with a brush in strokes The remineralizing process of the early enamel carious lesions will be assessed quantitatively using the laser fluorescence DIAGNOdent measuring and assessed qualitatively using ICDAS II scoring system at baseline 1, 3, 6 months post-treatment
223851685|NCT00036933|BIOLOGICAL|MUC-2-Globo H-KLH conjugate vaccine|
223851686|NCT00036933|BIOLOGICAL|QS21|
223851687|NCT00943605|DEVICE|Scalpel and Traditional Electrosurgery|The PEAK PlasmaBlade will be used for the entirety of the breast reduction, including the skin incision.
223851688|NCT00943605|DEVICE|PEAK PlasmaBlade|The entirety of the mastectomy will be performed with the PEAK PlasmaBlade, including the skin incision.
223851689|NCT05386446|DRUG|Interferon gamma human recombinant (IFN-G)|nasal form
223851690|NCT04103671|PROCEDURE|Prompt panretinal photocoagulation|Study eyes that receive panretinal photocoagulation (prompt PRP eyes at baseline) should have 1200 to1600 burns with a spot size on the retina of approximately 500 microns given over 1 to 3 sittings and completed within 4 weeks of initiation
223851691|NCT04103671|PROCEDURE|25G Pars-plana vitrectomy|Study eyes that receive standard 25G Pars-plana vitrectomy that remove all the vitreous, without laser or Silicone oil tamponade, but filled with perfusion fluid. Surgery should be completed within 4 weeks after randomization.
223851692|NCT03700658|DRUG|TV-46046|TV-46046 will be administered per dose and schedule specified in the arm.
223851693|NCT03700658|DRUG|Depo-subQ 104|Depo-subQ 104 will be administered per dose and schedule specified in the arm.
223851694|NCT03700658|DRUG|TV-46046 Placebo|TV-46046 Placebo will be administered per schedule specified in the arm.
223851695|NCT06502769|BEHAVIORAL|Therapeutic Exercise|A therapeutic exercise program will be carried out
223851696|NCT06502769|BEHAVIORAL|Pain Neurophysiology Education|A PNE program will be carried out
224076055|NCT07135583|BEHAVIORAL|Respiratory Resistance Exercise|Respiratory strength training will be conducted using a standard, spring-loaded threshold device while the participant is receiving either tSCS or Sham tSCS. Participants will complete one warm-up set at a pressure threshold approximately 40% of their pre-test outcomes (obtained on day 1 of the corresponding intervention block) for maximal inspiratory and expiratory pressure generation. Following the warm-up, participants will train at a pressure threshold approximately 70% of their pre-test outcomes and will complete three sets of 6-12 repetitions for both inspiratory and expiratory strength training. A training breath will consist of a \~1-2-second sustained effort through the device, separated by 5-10 seconds of quiet breathing. The order of the three sets each of inspiratory or expiratory training will alternate for each of the five daily sessions; the order on day 1 of training will be randomly determined.
223851697|NCT05150613|OTHER|No Mask|Participants fulfilling inclusion exclusion criteria will be asked to sign informed consent. Sealed envelope randomization method would determine order of testing (Group A; No mask, Group B; Surgical mask, Group C; N95 mask). For 6MWT, participants will be asked to walk on 30-meter unimpeded walkway as much as possible \& distance at end is recorded along with number of stops during test. For Bruce Protocol, participants will follow standard stage succession with an abrupt increase in speed \& inclination by end of each 3-minute cycle. The participants will be advised to perform test till exhaustion and level achieved will be recorded. The analyzed data will then be used to calculate VO2max and MET scores. Heart rate, SPO2, respiratory rate will be recorded at baseline, after 2 minutes and at test completion. BP will be recorded at baseline and at completion of test, while perceived discomfort scale \& post-exercise exhaustion scale will be assessed upon completion of exercise testing.
223851698|NCT05150613|OTHER|Surgical Mask|Participants fulfilling inclusion exclusion criteria will be asked to sign informed consent. Sealed envelope randomization method would determine order of testing (Group A; No mask, Group B; Surgical mask, Group C; N95 mask). For 6MWT, participants will be asked to walk on 30-meter unimpeded walkway as much as possible \& distance at end is recorded along with number of stops during test. For Bruce Protocol, participants will follow standard stage succession with an abrupt increase in speed \& inclination by end of each 3-minute cycle. The participants will be advised to perform test till exhaustion and level achieved will be recorded. The analyzed data will then be used to calculate VO2max and MET scores. Heart rate, SPO2, respiratory rate will be recorded at baseline, after 2 minutes and at test completion. BP will be recorded at baseline and at completion of test, while perceived discomfort scale \& post-exercise exhaustion scale will be assessed upon completion of exercise testing.
223851699|NCT05150613|OTHER|N95 Mask|Participants fulfilling inclusion exclusion criteria will be asked to sign informed consent. Sealed envelope randomization method would determine order of testing (Group A; No mask, Group B; Surgical mask, Group C; N95 mask). For 6MWT, participants will be asked to walk on 30-meter unimpeded walkway as much as possible \& distance at end is recorded along with number of stops during test. For Bruce Protocol, participants will follow standard stage succession with an abrupt increase in speed \& inclination by end of each 3-minute cycle. The participants will be advised to perform test till exhaustion and level achieved will be recorded. The analyzed data will then be used to calculate VO2max and MET scores. Heart rate, SPO2, respiratory rate will be recorded at baseline, after 2 minutes and at test completion. BP will be recorded at baseline and at completion of test, while perceived discomfort scale \& post-exercise exhaustion scale will be assessed upon completion of exercise testing.
223851700|NCT02298140|OTHER|SMS reminders|Text-message reminders about malaria case management will be prepared and distributed to all health workers seeing outpatients in the selected health facilities through their personal mobile phones and facility phones. These messages will reflect ACT recommendations from Tanzania's national guidelines for the diagnosis and treatment of malaria and training manuals. The intervention will run for three months, two text message a day will be send to all identified health workers during regular working hours (i.e. between 8 am to 3 pm), three times a week. To avoid health worker's fatigue of receiving these messages, the messages will also contain some non-malaria humorous, inspirational, motivational and educative contents.
223851701|NCT04148937|DRUG|LY3475070|Administered orally
223851702|NCT04148937|DRUG|Pembrolizumab|Administered IV
223851703|NCT03807557|OTHER|Robotic Constraint-induced movement therapy|"i.Robotic repetitive task-specific training followed by task-oriented practice: during each session, participants first receive 60 minutes of repetitive RT with the InMotion 3.0 robot (Interactive Motion Technologies Inc., Watertown, MA), followed by 30 minutes of functional practice using shaping technique.~ii.Restraint of the unaffected limb: Patients will wear a mitt to restrict the unaffected hand during training at clinic for 0.5 hours of functional practice each session, 3 sessions per week for 8 weeks.~iii. Transfer package: The transfer package aims at transferring the therapy gains to the participant's real world by use of a set of behavioral techniques. This is intended to have the participant responsible for adhering to the treatment requirements and encourage active engagement in the functional practice outside of the clinic setting. The participants will be given appropriated home assignment practicing daily activities outside of the clinic."
224076056|NCT07144579|BEHAVIORAL|Mozart music group|The experimental group was played Mozart - Sonata for Two Pianos in D, K. 448 on the clinic computer.
223851704|NCT03807557|OTHER|conventional UE rehabilitation training|focusing on UE training and including neuro-developmental techniques(Bobath, 1990), trunk-arm control (ie, practice UE tasks during standing), weight bearing by the affected arm, fine motor tasks practice, functional task practice, and practice on compensatory strategies for daily activities.
223851705|NCT03171896|OTHER|clown|A medical clown will be offerred to the parturient and will spend time with her during labor as long as she will want it
223851706|NCT03171896|OTHER|Sham|No clown will be present in the room during labor
223851707|NCT04232592|BIOLOGICAL|Inject a solution of stem cell preparation|The control group was injected with a solution of stem cell preparation
223851708|NCT04232592|BIOLOGICAL|Inject stem cells|Three dose groups were designed: low dose group, medium dose group and high dose group.
223851709|NCT02989012|DRUG|GanMaoKangNing Granules|3 times a day, 2 bags each time.
223851710|NCT02989012|DRUG|Analogous Oseltamivir Phosphate Capsules|2 times a day,1 capsule each time.
223851711|NCT02989012|DRUG|Oseltamivir Phosphate Capsules|2 times a day,1 capsule each time.
223851712|NCT02989012|DRUG|Analogous GanMaoKangNing Granules|3 times a day, 2 bags each time.
223851713|NCT05926050|DIETARY_SUPPLEMENT|Treatment (CopaPrime+ (USANA Health Sciences)|Participants received and consumed 2 treatment tablets immediately following baseline testing, and one hour prior to post-treatment testing. Each tablet contained extracts of Bacopa monnieri (150 mg), Coffea arabica (50 mg), and Panax quinquefolius L. (50 mg)
223851714|NCT05926050|OTHER|Placebo|Participants received and consumed 2 placebo tablets immediately following baseline testing, and one hour prior to post-treatment testing. Each tablet contained microcrystalline cellulose. The size, shape and appearance of the placebo tablet was identical to the treatment tablet.
223851715|NCT02033096|DRUG|Stannsoporfin|No intervention was administered during this observational study
223851716|NCT02033096|DRUG|Placebo Control|No intervention was administered during this observational study
223851717|NCT02033096|OTHER|Phototherapy (as needed)|No intervention was administered during this observational study
223851718|NCT06345612|BEHAVIORAL|hypoxia|eccentric training program conducted within normobaric hypoxic chamber
223851719|NCT06345612|BEHAVIORAL|normoxia|eccentric training program conducted within normoxic conditions
223851720|NCT06345612|DIETARY_SUPPLEMENT|creatine supplementation|5g of creatine per day
223851721|NCT06345612|DIETARY_SUPPLEMENT|no creatine supplementation|no creatine supplementation
223851722|NCT02492464|DIETARY_SUPPLEMENT|Red yeast rice|1 capsule to be taken before to sleep, each day, for 6 months
223851723|NCT02492464|DIETARY_SUPPLEMENT|Placebo|
223851724|NCT06364033|BIOLOGICAL|serologic response evaluation|Blood samples collection
223851725|NCT00338858|OTHER|walking and balance performance evaluation|
223851726|NCT00338858|PROCEDURE|muscle strength, walking and balance performance|HHD- muscle strength, Balance performance - TUG, FRT, Walking performance- gaiterite and 2 min walk test
223851727|NCT02931123|DRUG|lattulose and rifaximine|
223851728|NCT04262414|DEVICE|Functional Electrical Stimulation|"The device used was a prototype closed-loop FES system to improve standing balance by activating the ankle plantar flexors and dorsiflexors (i.e. A-FES system). As a closed-loop system, the body's position and velocity are continually monitored, and the level of stimulation adjusted accordingly on a moment-to-moment basis. This differs from currently available FES units, which do not monitor body movement and therefore, provide a constant level of stimulation unless manually adjusted by the user/PT. The control strategy used in the A-FES system mimics the physiological control system in able-bodied people, meaning it has the potential to re-educate normal movement patterns."
223851729|NCT00117871|DRUG|Resiquimod|
223851730|NCT05826834|DEVICE|ball-rolling (Myostorm ball)|the intervention group
223851731|NCT03182036|DEVICE|Portable pulsed oxygen|Hypoxemic patients will use portable pulsed oxygen at rest, and while performing a six-minute walk test.
223851732|NCT03093792|OTHER|Control|
223851733|NCT03093792|OTHER|American Heart Association plus exercise|
223851734|NCT03093792|OTHER|Curves Complete - I plus exercise|
224265604|NCT03232541|DEVICE|Sham acupuncture|"B) Sham acupuncture is administered bilaterally to a non-acupuncture point two body-inches proximal and one body-inch radial from PC6 using the telescopic Park Sham Device. The sham-needle is blunt and glides upward into its handle instead of penetrating. Marking tubes hold the needle in place. The therapist gives an illusion of manipulating the needle by turning it three times until it touches the skin, but no specific needle sensation (deqi) will occur. Within the group, the patients will be randomized to two communication types: 1) neutral communication or 2) strengthened positive communication regarding expected antiemetic effects of their treatment, using a standardized communication model."
223851735|NCT03093792|OTHER|Curves Complete - II plus exercise|
223851736|NCT04330950|OTHER|Neurocognitive tests|Preoperative: Battery of neurocognitive tests and questionnaires (MoCA, PHQ-9, Falls History, FIFE, STOPBANG, Nutritional Survey) Postoperative in PACU: NuDESC test Postoperative 30 days: 10 minute phone interview
223851737|NCT03069781|DRUG|17β-estradiol|1mg/day for 3-days and 3mg/day for 7-days of Estrance
223851738|NCT03069781|DRUG|Polycose|400 mg/day for 10-days of Polycose (Abbott Laboratories, St. Laurent, QC, Canada)
223851739|NCT00835016|BEHAVIORAL|Early psychosocial stimulation (LTP)|Learning through Play (LTP) groups will be conducted weekly for the first eight sessions and two fortnightly sessions. Parenting issues will be discussed with the mothers and play activities will be demonstrated with the children using LTP and home made materials.
223851740|NCT00519129|DEVICE|3D-imager|3D-imager vs fluoroscopy during coloscopy
223851741|NCT02785744|OTHER|Gaucher disease DNA mutation analysis|
223851742|NCT01568996|DRUG|broccoli sprout extract - sulforaphane (BSE-SFN)|50 µmol capsules, taken orally, once a day for 28 days
223851743|NCT01568996|DRUG|broccoli sprout extract - sulforaphane (BSE-SFN)|100 µmol capsules, taken orally, once a day for 28 days
223851744|NCT01568996|DRUG|broccoli sprout extract - sulforaphane (BSE-SFN)|200 µmol capsules, taken orally, once a day for 28 days
223851745|NCT00929591|DRUG|cyclophosphamide|
223851746|NCT00929591|DRUG|doxorubicin hydrochloride|
223851747|NCT00929591|DRUG|endocrine therapy|
223851748|NCT00929591|DRUG|endocrine-modulating drug therapy|
223851749|NCT00929591|DRUG|fluorouracil|
223851750|NCT00929591|DRUG|tamoxifen citrate|
223851751|NCT00929591|RADIATION|brachytherapy|
223851752|NCT00929591|RADIATION|low-LET electron therapy|
223851753|NCT00929591|RADIATION|low-LET photon therapy|
223851754|NCT00929591|RADIATION|radiation therapy|
223851755|NCT02467491|DEVICE|Jintronix|The participants will perform light exercises using the Jintronix software. Jintronix is an easy-to-use virtual physical activity platform designed for physical and occupational therapy. It combines common exercise movements, virtual games and motion sensing cameras to offer a fun and effective tool for physical activity.
223851756|NCT01735240|DRUG|AZD5069|AZD5069 15 mg (3x5 mg capsules) single administration
223851757|NCT01735240|DRUG|Ketoconazole|Ketoconazole 400 mg (2x200 mg tablets)
223851758|NCT03416465|BEHAVIORAL|medical questionnaire|The patient will complete a questionnaire of 10 questions before leaving hospital. This questionnaire concerns the care pathway for hospitalized patients.
223851759|NCT05880316|BEHAVIORAL|Intermittent Fasting|3:4 regime
223851760|NCT00145002|DRUG|VCAP-AMP-VECP with G-CSF and intrathecal prophylaxis|
223851761|NCT00145002|DRUG|biweekly-CHOP with G-CSF and intrathecal prophylaxis|
223851762|NCT04492631|DIETARY_SUPPLEMENT|Streptococcus salivarius DB-B5|Sachets containing Streptococcus salivarius DB-B5 will be dissolved in water and consumed by the participants (n=30) once daily for 4 weeks. The participants will consume 10 billion colony forming units (CFU) per day.
223851763|NCT04492631|OTHER|Placebo|Sachets containing a placebo (probiotic carrier) will be dissolved in water and consumed by the participants (n=30) once daily for 4 weeks.
223851764|NCT04117451|OTHER|Propolis|Investigating the impact of propolis mouthwash on oral and cardiovascular health
223851765|NCT02419261|DRUG|Analgesic nerve blockade (Ropivacaine)|Analgesic nerve blockade for Arthroscopic surgical repair of the anterior cruciate ligament
223851766|NCT02419261|PROCEDURE|Arthroscopic surgical repair of the anterior cruciate ligament|
223851767|NCT05395949|DRUG|conservative treatment|Prednisone 30 mg/day, supplemented with calcium and omeprazole, and Prednisone were slowly reduced to 10 mg/day after symptoms were relieved, and combined with 7.5 mg/week MTX therapy.
223851768|NCT01272648|BEHAVIORAL|RePCa A|"Intervention patients receives two consultations with a specialist oncology nurse three and six month after ended radiotherapy. The focus are on what is important for the patients at the specific time. The patient can bring his spouse.~Furthermore the patients have two physiotherapy consultations with guidance in pelvic floor exercises and an individual home-program of pelvic and functional training exercises"
223851769|NCT01842971|PROCEDURE|two stage hepatectomy|
223851770|NCT01137799|DRUG|JNJ-39393406|50mg nanosuspension (sort of liquid formulation) once daily (single dose)
223851771|NCT01137799|DRUG|placebo|Once daily (single dose)
223851772|NCT01137799|DRUG|JNJ-39393406|200mg nanosuspension (sort of liquid formulation) once daily (single dose)
223851773|NCT01137799|DRUG|JNJ-39393406|100mg nanosuspension (sort of liquid formulation) once daily (single dose)
223851774|NCT01137799|DRUG|JNJ-39393406|10mg nanosuspension (sort of liquid formulation) once daily (single dose)
223851775|NCT01137799|DRUG|JNJ-39393406|30mg nanosuspension (sort of liquid formulation) once daily (single dose)
223851776|NCT06411405|OTHER|Maternal medical history|See above; multiple factors to be collected broadly grouped into maternal medical, obstetric, and sociodemographic/lifestyle factors.
223851777|NCT03107611|DRUG|Pimecrolimus Cream, 1%|
223851778|NCT03107611|DRUG|Placebo Cream|
223851779|NCT03107611|DRUG|Pimecrolimus Cream, 1%|
223851780|NCT05903963|DRUG|Midazolam|midazolam infusion by 0.03-0.3mg/kg in increments of 1-2.5mg followed by Maintenance dose: 0.03-0.2mg/kg/hour for midazolam.
223851781|NCT05903963|DRUG|dexmedetomidine|dexmedetomidine infusion 1 µg/kg dexmedetomidine for 10 minutes followed by a continuous IV infusion at 0.2-0.3 µg/kg/hour .
223851782|NCT00361517|BEHAVIORAL|Galactomannan antigen monitoring, Aspergillus PCR|There will be blood draws twice weekly for monitoring GM antigen and once a week for Aspergillus PCR.
223851783|NCT00361517|OTHER|blood draws|Blood is drawn for monitoring of Galactomannan antigen in the blood
223851784|NCT00361517|OTHER|blood draws for GM monitoring|blood samples will be taken twice weekly for monitoring of GM antigen levels in the blood and once a week for Aspergillus PCR.
223851785|NCT00361517|DRUG|Amphotericin-B deoxycholate|1-1.5mg/kg, i.v, once a day
223851786|NCT00361517|OTHER|blood test|Blood will be tested twice a week for the presence of Galactomannan.
223851787|NCT00361517|OTHER|Blood test|Blood will be drawn twice a week and it will be tested for the presence of GM(a component of the cell wall of the mold Aspergillus which is released during growth)
223851788|NCT01720446|DRUG|semaglutide|Once weekly doses of 0.5 mg semaglutide after an initial dose escalation step of 0.25 mg as an add-on to the standard-of-care treatment. Administered subcutaneously (s.c., under the skin)
223851789|NCT01720446|DRUG|semaglutide|Once weekly doses of 1.0 mg semaglutide after an initial dose escalation step of 0.25 mg followed by 0.5 mg dose escalation as an add-on to the standard-of-care treatment. Administered subcutaneously (s.c., under the skin)
223851790|NCT01720446|DRUG|placebo|Once weekly doses volume-matched placebo, as an add-on to the standard-of-care treatment. Administered subcutaneously (s.c., under the skin).
223851791|NCT02496793|BEHAVIORAL|Peer-facilitated community support group|Support groups were composed of up to 20 women from community. Peer facilitator facilitated a total of 6 groups of a maximum of 20 women each. Women were exposed to 8 two hour sessions. Facilitators gave activities in support of MCH/PMTCT. Group met twice a month for four months. The support group meetings took place in the community at a convenient location for those attending (e.g. village meeting point, churches, schools or individual households). With local support through community leaders, the intervention involved trained peer facilitators working with pregnant and post-partum women to form ANC and PNC support groups through which they will present information on general maternal and child health and PMTCT specific topics using participatory learning and problem-solving approaches.
223851792|NCT02612584|DEVICE|Pinhole Soft Contact Lens apply for presbyopia|
223851793|NCT06390891|OTHER|Persons with pancreatic resection in a hospital with at least 50 pancreatic resections annually (observational),|Persons that have undergone a pancreatic resection at a hospital with at least 50 pancreatic resections annually (observational)
223851794|NCT06390891|OTHER|Persons with pancreatic resection in a hospital not performing at least 50 pancreatic resections annually (observational),|Persons that have undergone a pancreatic resection at a hospital with not at least 50 pancreatic resections annually (observational)
223851795|NCT04374708|DIAGNOSTIC_TEST|fMRI|fMRI: body morph test and neurocognitive testing
223851796|NCT03862833|DRUG|IL2|"Three IL2 levels will be tested:~Level 1: 2 millions UI/Infusion Level 2: 4 millions UI/Infusion Level 3: 6 millions UI/Infusion 4 weeks, 5 days per week from day + 15 post graft to day + 40"
223851797|NCT03862833|DRUG|Zoledronic Acid|4 mg at day +15 post graft
223851798|NCT02529696|DEVICE|Accelerometer|Measures patient movement
223851799|NCT02925052|DEVICE|Gastric Tube Guide|
223851800|NCT02925052|DEVICE|Conventional placement|
223851801|NCT05339971|OTHER|block perforation|The bone block used for lateral bone augmentation will be perforated several times.
223851802|NCT05679830|DRUG|Cannabidiol|Cannabidiol is a non-psychoactive cannabinoid obtained from the cannabis plant.
223851803|NCT03674190|PROCEDURE|Anterior Lumbar Interbody Fusion|Anterior Lumbar Fusion(ALIF)
223851804|NCT03674190|PROCEDURE|Total Disc Replacement|Total Disc Replacement
223851805|NCT04464421|BEHAVIORAL|Contingency Management (CM)|Participants were able to draw a gift card from a virtual fishbowl when their urine toxicology results are positive for buprenorphine metabolites. Gift card values were $25, $50, or $100.
223851806|NCT04464421|BEHAVIORAL|Brief Motivational Intervention + Substance Free Activities Session + Mindfulness-Based Adherence Promotion (BSM)|Participants had one-on-one sessions with a behavioral interventionist to discuss their goals regarding treatment, how to reach these goals, the importance of substance-free activities, and mindfulness skills.
223851807|NCT02245854|DEVICE|Exacto™|Cold snare polypectomy
223851808|NCT01393353|OTHER|Cognitive Training|
223851809|NCT01393353|OTHER|computer game|
223851810|NCT00076986|DRUG|IL13-PE38QQR|
223851811|NCT00076986|PROCEDURE|surgery and catheter placement (2 procedures)|
223851812|NCT00076986|DRUG|prolifespan 20 with carmustine implant (GLIADEL® Wafer)|
223851813|NCT00076986|PROCEDURE|surgery and wafer placement (1 procedure)|
223851814|NCT06450977|OTHER|MIND Diet|Daily meals designed to increase adherence to the Mediterranean-DASH Intervention for Neurodegenerative Delay (MIND) dietary pattern.
223851815|NCT06450977|OTHER|Control Diet|Daily meals designed to increase fruit, vegetable, and whole grain intake consistent with a healthy American diet.
223851816|NCT04922658|DRUG|Surufatinib|Surufatinib,300mg, qd, po, 21 days for a cycle; continuous administration until PD, death or intolerable toxicity.
223851817|NCT04922658|DRUG|Surufatinib Plus Vinorelbine|Surufatinib, 250mg, qd, po; Plus Vinorelbine, 20 mg, every 2 days; 21days for a cycle; continuous administration until PD, death or intolerable toxicity.
223851818|NCT01956669|DRUG|Pazopanib|Pazopanib was supplied as a series of aqueous film-coated tablets containing 200 mg (oval-shaped, white, packaged in bottles containing 34 tablets each), and 400 mg (oval-shaped, white, packaged in bottles containing 68 tablets each). Pazopanib Powder for Oral Suspension was a white to slightly colour powder supplied to the clinical sites in amber glass (United State Pharmacopeia (USP) Type III) bottles with child-resistant closures. Each bottle contains 5 g of pazopanib.
223851819|NCT02175212|DRUG|Short term androgen deprivation|"* Gosereline 3.6 mg 1 month plus 10.8 mg subcutaneously 3 months (total 4 months)~* Bicalutamide 50 mg tablet every day for 2 months"
223851820|NCT02175212|DRUG|Long term androgen deprivation|"* Gosereline 3.6 mg 1 month plus 10.8 mg subcutaneously 3 months (total 4 months)~* Bicalutamide 50 mg tablet every day for 2 months~* Gosereline 10.8 mg by subcutaneous injection every 3 moths for 2 years at the end of the radiotherapy"
223851821|NCT02175212|RADIATION|Short term androgen deprivation|Minimum dose of 76 Gy (range 76-82 Gy)
223851822|NCT02175212|RADIATION|Long term androgen deprivation|Minimum dose of 76 Gy (range 76-82 Gy)
223851823|NCT02874118|BEHAVIORAL|Fried scale for frailty assessement|
223851824|NCT02638415|PROCEDURE|HVPG-guided therapy|"Patients with an HVPG over 20mmHg will be suggested to receive transjugular intrahepatic portocaval shunt (TIPS) or surgical shunt operation.~Patients with an HVPG between 16 and 20mmHg can choose either endoscopic treatment or TIPS according their willingness and indication.~Patients with an HVPG below 16mmHg will be treated by endoscopy plus Carvedilol, until endoscopic treatment fails."
223851825|NCT02638415|OTHER|routine therapy|Patients start treatment without HVPG measurement and receive endoscopic therapy plus Carvedilol.
224265605|NCT03232541|DEVICE|Genuine acupuncture|C) Acupuncture will be administered bilaterally to the standard antiemetic point PC6 located two body-inches proximal of the wrist crease, between the tendons of palmaris longus and flexor carpi radialis. Sharp acupuncture needles will be inserted into a depth of a half body-inch. The needles will be manipulated three times (at the start, middle and end of the treatment session) by twirling and lifting until deqi occurres. Within the group, the patients will be randomized to two communication types: 1) neutral communication or 2) strengthened positive communication regarding expected antiemetic effects of their treatment, using a standardized communication model.
224265606|NCT04735887|OTHER|SADL-eM|The SADL-eM includes three elements essential to the intervention, namely: knowledge, skills, and advice. The manual includes 92 A5 pages with six detailed sections: an Introduction and five chapters: (1) Rehabilitation team, (2) Activities of Daily Living, (3) Assistive devices, (4) Home environment adaptation, and (5) Knowledge guide. The SADL-eM uses text and illustrative pictures that are carefully selected for contextual relevance. The manual is simple, easy, and suitable for people with a non-medical background.
224265607|NCT01139606|OTHER|Vibration resistance training|adding vibration to a standard resistance training with free-weights and checking the effect on muscle strength development and everyday functioning of upper limbs in untrained adults.
224265608|NCT02780063|OTHER|Lenstar Biometer|uses optical principles (laser interferometry) to measure axial length, measuring distance from the corneal apex to the retinal RPE. In addition to axial length, it also measures corneal thickness, anterior chamber depth, lens thickness, radii of curvature of flat and steep meridian, axis of flat meridian, white to white distance, and pupil diameter.
224265609|NCT04336332|COMBINATION_PRODUCT|Hydroxychloroquine Sulfate + Azithromycin|Given PO
224265610|NCT04336332|DRUG|Hydroxychloroquine Sulfate|Given PO
224265611|NCT01619956|DEVICE|SLA dental implants|Dental implant with surface modification.
223851826|NCT02638415|DRUG|Carvedilol|Patients in HVPG group with HVPG below 16mmHg and all patients in non-HVPG group will take Carvedilol 12.5mg/d if they have no contraindications.
223851827|NCT03931044|PROCEDURE|Image-Guided Robotic Gastrectomy|The near-infrared technology, integrated in the robotic camera, will be used to detect fluorescent lymphonodes.
223851828|NCT05616559|COMBINATION_PRODUCT|Treatment Package for First-Episode Depression|The outpatient 'treatment package' for first episode depression is a national uniform package designed by Mental Health Services in the Capital Region. The treatment package for first-episode depression is a program with manualized group CBT, psychoeducation of patients and relatives, and relapse prevention. Antidepressant medication and individual psychotherapy are available as needed.
223851829|NCT05060679|OTHER|Supportive therapy at the ICU|Non-septic ICU patients received adequate supportive treatment (fluid resuscitation, respiratory, anticoagulation, antimicrobial and vasopressor therapy along with sedation, ulcer prophylaxis and nutrition. Blood sampling for non-septic patients were the first (T1) and third (T3) postoperative morning at the ICU. Besides, 23 healthy outpatients were documented without sepsis or sepsis-related organ dysfuntion as a control group.
223851830|NCT05060679|OTHER|Sepsis therapy|Patients receiving sepsis therapy followed the international guidelines of the 2016 Surviving Sepsis Campaign (SSC) regarding respiratory, antimicrobial, anticoagulation, vasopressor and hydrocortisone therapy, along with adequate fluid resuscitation, sedation, ulcer prophylaxis and nutrition. Blood samples were collected at the ICU from this patient group at three time points (T1-3): T1: within 12 hours after admission; T2: second day morning; T3: third day morning of follow-up.
223851831|NCT05060679|OTHER|Sepsis-related organ dysfunction therapy|Patient management of sepsis and sepsis-related organ dysfunction followed the international guidelines of the 2016 Surviving Sepsis Campaign (SSC) regarding respiratory, antimicrobial, anticoagulation, vasopressor and hydrocortisone therapy, along with adequate fluid resuscitation, sedation, ulcer prophylaxis, nutrition and renal replacement therapy (if needed). In this patient group, blood sampling was performed at three time points (T1-3): T1: within 12 hours after admission; T2: second day morning; T3: third day morning of follow-up.
223851832|NCT02508896|BIOLOGICAL|AFFITOPE® AT04A+adjuvant|subcutaneous injection
223851833|NCT02508896|BIOLOGICAL|AFFITOPE® AT06A+adjuvant|subcutaneous injection
223851834|NCT02508896|BIOLOGICAL|Adjuvant without active component|subcutaneous injection
223851835|NCT02808442|BIOLOGICAL|UCART19|
223851836|NCT05593952|OTHER|Dual task|exercise with dual task + usual treatment
223851837|NCT05593952|OTHER|Single task|exercise without dual task + usual treatment.
223851838|NCT01072357|DRUG|Avastin® (bevacizumab)|One time subconjunctival injection of 0.1 mL (2.5 mg) bevacizumab followed by topical treatment with 1% solution bevacizumab four times a day for four weeks.
223851839|NCT01072357|DRUG|0.9% NaCl & Refresh Liquigel|One-time subconjunctival injection of 0.1mL 0.9% NaCl followed by topical treatment with Refresh Liquigel four times a day for four weeks
224076057|NCT07144579|BEHAVIORAL|preferred music group|The experimental group was made to listen to their preferred music in the clinic.
224076058|NCT07144722|OTHER|Exercise|What distinguishes this intervention from others is its hybrid delivery model, combining virtual more than in-person sessions to increase accessibility and adherence. Additionally, it incorporates specific inspiratory muscle training, which is often overlooked in standard prehabilitation programs, and emphasizes a personalized progression based on each participant's functional capacity and feedback. This tailored approach aims to optimize physical readiness before surgery while minimizing patient burden and travel requirements.
224076059|NCT07144631|DEVICE|Peroneal Nerve Stimulation (PNS) Device|The TOMAC™ system is a non-invasive, wearable peroneal nerve stimulator that delivers high-frequency electrical stimulation to the common peroneal nerves at the fibular head. It is FDA-cleared for the treatment of moderate-to-severe Restless Legs Syndrome (RLS) in adults but has not been studied in pregnancy. In this trial, pregnant participants will undergo an in-clinic titration session with uterine contraction and fetal monitoring at ≥28 weeks' gestation to determine comfortable therapeutic intensity. They will then use the device at home for 8 weeks, up to four 30-minute sessions daily, prioritizing periods of high symptom burden or before bedtime. Outcomes will assess feasibility, acceptability, adherence, symptom improvement, sleep quality, and maternal-fetal safety.
224076060|NCT07158944|BEHAVIORAL|More and Less|Dose: 10 group sessions + 6 individual booster sessions Frequency: 10 weekly group sessions (10 weeks) 6 booster sessions every 6th week
224076061|NCT07160478|OTHER|School Health Program|Health education interventions of approximately 60 minutes that include a conceptual presentation and a practical component.
224076062|NCT07166133|DEVICE|GORE® TAG® Thoracic Branch Endoprosthesis|Lesions in aortic arch in Zone 0 or Zone 1
224076063|NCT07169032|DEVICE|Er,Cr:YSGG laser irradiation|irradiation with a 2780 nm, 1.0 W Er,Cr:YSGG laser for 1 minute
224076064|NCT07169032|DRUG|Sham Laser irradiation|sham laser irradiation for 1 minute
224076065|NCT07169032|DRUG|Lidocaine|2% lidocaine gel
224076066|NCT07169032|DRUG|Vaseline|Vaseline
224076067|NCT07165158|DRUG|semaglutide combined with metformin|The initial dose of semaglutide is 0.25 mg once weekly. After 4 weeks, the dose is adjusted to 0.5 mg once weekly. After another 4 weeks, the dose is adjusted to 1 mg once weekly. During the same period, they will take metformin (500mg each time, three times a day) for treatment. The treatment course is 12 months.
224076068|NCT07169084|OTHER|Manual Therapy|Manual mobilization techniques applied to the cervical and upper thoracic regions, 3 sessions/week for 4 weeks.
224076069|NCT07169084|OTHER|Instrument-Assisted Soft Tissue Mobilization (IASTM)|Mobilization applied with instruments to cervical and upper thoracic muscles, 3 sessions/week for 4 weeks.
224076070|NCT07178600|DRUG|Ophthalmic administration of tropicamide/phenylephrine 8 mg/50 mg/mL.|Measurement of vital signs after ophthalmic administration of tropicamide/phenylephrine 8 mg/50 mg/mL
224076071|NCT03087955|DRUG|Acoziborole|Acoziborole 3 x 320 mg tablets (fasted state)
224076072|NCT04496739|BEHAVIORAL|Cancer Educational Materials|Receive educational materials about breast cancer risk and chemoprevention via RealRisk
224076073|NCT04496739|OTHER|Decision Aid|Given patient-centered decision support via an action plan
224076074|NCT04496739|OTHER|Decision Aid|Given decision support and action plans based on patient's interactions with RealRisks via the BNAV support tool
223851840|NCT00882635|DRUG|enoxaparin|"Enoxaparin 0.5 mg/kg IV bolus (Regardless of whether the investigator has chosen to initiate concomitant GP IIb/IIIa antagonist; provision for additional IV enoxaparin to be administered if elapsed time to PCI exceeds 2 hours (from original IV dose) - enoxaparin 0.25 mg/kg IV will be administered At the discretion of the treating physician, if sustained anticoagulation is required then enoxaparin subcutaneously will be administered - enoxaparin 1.0 mg/kg SQ q 12 hours.~Maintenance dose adjustment for renal insufficiency - creatinine clearance \< 30 ml/min, sc enoxaparin should be administered at 1.0 mg / kg / q24 hours. No adjustment of IV dose is required in case of renal insufficiency"
223851841|NCT00882635|DRUG|Unfractionated heparin|Unfractionated heparin 70 u/kg IV bolus (consistent with ASSENT 4 PCI) Baseline ACT will be draw at time of sheath insertion - With use of GP IIb/IIIa antagonist additional UFH will be administered to achieve an ACT of ≥200 - 250 seconds If IIb/IIIa is not utilized - additional UFH will be administered to achieve an ACT of ≥250-350 seconds At the discretion of the treating physician if sustained anticoagulation is required:UFH infusion 12/u/kg/hr IV infusion to commence
223851842|NCT00728637|BEHAVIORAL|Family Passport to Heart Health Program|Participants in this group received personalized heart disease risk factor screening at the baseline study visit. They were taught lifestyle approaches to risk reduction based upon national heart disease prevention guidelines, including the Adult Treatment Panel (ATP) III recommendations for improving blood cholesterol levels with a TLC diet. Participants had regular contact with study staff and will receive individualized feedback throughout the study.
223851843|NCT00728637|BEHAVIORAL|General Educational Materials|Participants in the control group received an educational brochure about heart health at the baseline study visit.
223851844|NCT00452465|BEHAVIORAL|ElderCare Plan|Nursing assessment and development of an appropriate care plan.
223851845|NCT00604006|DRUG|Spironolactone|25 mg tablets (placed in capsules for blinding) once daily.
223851846|NCT00604006|DRUG|Placebo|Placebo (lactose in capsules for blinding) once daily
223851847|NCT00223119|DEVICE|Absorbable Sutures|
223851848|NCT00315120|PROCEDURE|A. Active OMT and active UST|Active osteopathic manipulation (OMT) and active ultrasound physical therapy (UST)
223851849|NCT00315120|PROCEDURE|B. Sham OMT and active UST|Sham osteopathic manipulation (OMT) and active ultrasound physical therapy (UST)
223851850|NCT00315120|PROCEDURE|C. Active OMT and sham UST|Active osteopathic manipulation (OMT) and sham ultrasound physical therapy (UST)
223851851|NCT00315120|PROCEDURE|D. Sham OMT and sham UST|Sham osteopathic manipulation (OMT) and sham ultrasound physical therapy (UST)
223851852|NCT05126719|DRUG|MRG003|Administered intravenously
223851853|NCT05126719|DRUG|Capecitabine tablets|Administered peros
223851854|NCT05126719|DRUG|Docetaxel injection|Administered intravenously
223851855|NCT01424332|DRUG|Darexaban|oral
223851856|NCT01424332|DRUG|Acetyl Salicylic Acid (ASA)|oral
223851857|NCT05923762|BEHAVIORAL|OHRQoL|"Oral health-related quality of life will be measured by the Oral Impact on Daily Performance (OIDP)"
223851858|NCT02131324|DRUG|DFD06 Cream|
223851859|NCT02131324|DRUG|Clobetasol Propionate Cream 0.05%|
223851860|NCT00891618|OTHER|Acupuncture|3 acupuncture sessions per week for 4 weeks (Weeks 1-4), 1 week off (Week 5), then 2 per week for 4 more weeks (Weeks 6-10), total of 20 sessions. Each session lasts 20-30 minutes.
223851861|NCT03991949|OTHER|Experimental Infant Formula|Formula fed Ad libitum
223851862|NCT06553222|BIOLOGICAL|Putty bone - Tricalcium phosphate with Collagen gel|Minimally invasive debridement periodontal flap and Bone graft placement to augment the lost alveolar bone
223851863|NCT04753099|BEHAVIORAL|occupation-based coaching|"Occupation based coaching is an intervention proven to be an effective intervention in family-centered practice. OBC is a strength-based approach that emphases collaboration with clients in goals setting and attainment to increase overall health and quality of life. Clients are the central focus of the intervention and generate their own strategies to address goals as part of the coaching process. In their role as coach, the therapists employ techniques such as reflective questioning and comments to support clients in identifying existing routines and rituals that impact goal attainment and to increase knowledge and access to resources that can promote improved caregiver quality of life after a child's diagnoses with T1D. Occupation based coaching can be divided into the following steps: (1) setting goals, (2) exploring options, (3) planning action, (4) carrying out the plan, (5) checking performance, and (6) generalizing(Little et al., 2018, p.2)."
223851864|NCT00844571|OTHER|E-learning program|Participants are committed to accomplish the program in approximately 2 hours. Additionally to these mandatory hours, they were able to access the e-learning program at any time and place.
223851865|NCT01693614|DRUG|Buparlisib|100 mg hard gelatin capsules administered orally, once daily in cycles of 28 days
223851866|NCT05790408|DEVICE|Digital microscope integrated with intraoperative OCT (Zeiss Artevo 800, Carl Zeiss Meditec AG)|The Zeiss Artevo digital microscope integrated with iOCT (Zeiss Artevo 800, Carl Zeiss Meditec AG) is a commercially available, FDA approved device that can be utilized to visualize and evaluate the morphology of the trabeculectomy bleb during transconjunctival needle revision of trabeculectomy bleb.
223851867|NCT05790408|DEVICE|Spectralis Anterior-segment OCT (AS-OCT) (Heidelberg Engineering)|The Spectralis Anterior-segment OCT (AS-OCT) is a commercially available, FDA approved device that can be utilized to visualize and evaluate the morphology of the trabeculectomy bleb in the office.
223851868|NCT05655442|PROCEDURE|early APM|early APM within 3 and 6 month knee pain symptoms
223851869|NCT05655442|PROCEDURE|delayed APM|delayed APM within 6 and 12 month knee pain symptoms
223851870|NCT05479539|BEHAVIORAL|Action observation therapy|Participants will watch 12-minute video-clips followed by 8 minutes of motor imagery. Video-clips observation and imagination will be focused un shoulder tasks occuring on the three planes of motion.
223851871|NCT03812354|OTHER|THRIVE 4L/kg/min|High-flow nasal cannula therapy with 4L/kg/min with 100% oxygen via OptiFlow by Fisher\&Paykel, Auckland, New Zealand.
223851872|NCT03812354|OTHER|THRIVE 2L/kg/min|High-flow nasal cannula therapy with 2L/kg/min with 100% oxygen via OptiFlow by Fisher\&Paykel, Auckland, New Zealand.
223851873|NCT02650596|DRUG|GLP-1|Liraglutide were taken daily for 3 months
223851874|NCT02650596|DRUG|Placebo|Placebo were taken daily for 3 months
223851875|NCT05870241|OTHER|Ga-As Laser|Patient sits on a chair with back support and the two GA-AS laser ( 5 milli Watts \& 904 nm) probe will be applied one on the shoulder tip for 5 minutes and the other application another 5 minutes will be on the center of deltoid muscle. The main power of the laser switch will be turned on. The duration of the treatment will be 10 minutes.
223851876|NCT05870241|OTHER|Microcurrent Electrical Stimulation|The patient sits on a chair with back support and the two electrodes from Microcurrent 850 unit device will be applied one on the shoulder tip and the other electrode on the center of the deltoid muscle. A wet cloth was placed between the electrode and the patient's skin. An adhesive tape was used to hold the electrode over the treated areas. The main power switch will be turned on. The treatment duration will be for 10 minutes.
223851877|NCT05870241|OTHER|traditional therapy|the patients will receive traditional physical therapy in the form of manual lymphatic drainage , compression bandage, exercise to increase lymphatic drainage, skin care. and ROM exercises to improve shoulder mobility
223851878|NCT05609448|PROCEDURE|MRI-guided radioembolization|Catheter placement will be performed using fluoroscopy, after which patients are transferred to the MRI scanner, where holmium microspheres are administered based on MRI dosimetry. Thereby, patients get a personalized dose administration.
223851879|NCT06173570|DRUG|AZD0780|AZD0780 administered orally, once daily for 12 weeks
223851880|NCT06173570|DRUG|Placebo|Placebo administered orally, once daily for 12 weeks
223851881|NCT02918786|DEVICE|Nasal high-flow|After extubation, the patients will receive oxygen delivered through the nasal high-flow system (Optiflow™). The FiO2 will be adjusted in order to obtain a SpO2 between 92% and 98% in hypoxemic patients and between 88% and 95% in hypercapnic patients. Gas flow will be set until maximal level of 60 LPM.
223851882|NCT02918786|DEVICE|CPAP|After extubation, patients will receive CPAP at 5 cmH2O delivered by the variable generator WhisperFlow System. The FiO2 will be adjusted in order to obtain a SpO2 between 92% and 98% in hypoxemic patients and between 88% and 95% in hypercapnic patients.
223851883|NCT06060418|OTHER|aromtherapy|aromatherapy with essential oil is being used as a non-pharmacological nursing intervention within the health care setting. This approach aims to manage the patient's discomfort and alleviate the symptoms of postoperative nausea and vomiting. One of the most beneficial oils is Lavender Essential Oil (LEO), which is used to treat a variety of digestive issues.
223851884|NCT02161653|DRUG|Prednisone plus Metadoxine|
223851885|NCT02161653|DRUG|Pentoxifylline plus Metadoxine|
223851886|NCT06165185|OTHER|Water|Please see the associated arm description
223851887|NCT06165185|OTHER|Coffee|Please see the associated arm description
223851888|NCT06165185|OTHER|Control|Please see the associated arm description
223851889|NCT05061953|DEVICE|Eye-Tracking|Eye-tracking technology and algorithms used to successfully capture and track eye movements using an electronic tablet and the embedded camera of the device.
223851890|NCT00138606|DRUG|vildagliptin|
223851891|NCT00090298|DRUG|MK0653A, ezetimibe (+) simvastatin|
223851892|NCT00090298|DRUG|Comparator: Rosuvastatin|
223851893|NCT05691660|DRUG|TAS3731 Dose1|Oral administration,1 day,QD
223851894|NCT05691660|DRUG|TAS3731 Dose2|Oral administration,7 days,QD
223851895|NCT05691660|DRUG|TAS3731 Dose3|Oral administration,7 days,BID
223851896|NCT05691660|DRUG|Placebo|Oral administration, 1 day,QD
223851897|NCT05691660|DRUG|Placebo|Oral administration, 7 days,QD
223851898|NCT05691660|DRUG|Placebo|Oral administration, 7 days,BID
223851899|NCT00903019|BEHAVIORAL|Tele-Problem-Solving Therapy|Six sessions of tele-PST
223851900|NCT00903019|BEHAVIORAL|In-Person PST|Six sessions of in person PST
223851901|NCT00903019|BEHAVIORAL|Attention control|Six weekly telephone calls
223851902|NCT06432842|OTHER|Laser Treatment|In the study group, low-dose laser treatment was applied in addition to conventional treatment. Chattanoga Group Therapeutic Laser device was used for laser treatment. Laser treatment was applied to 8 sensitive points around the knee for 1 minute, for a total of 8 minutes. Laser treatment was applied continuously, with a wavelength of 830nm and a power of 6J.
223851903|NCT00328055|BEHAVIORAL|AD-Easy (Advance Directive-Easy)|
223851904|NCT00328055|BEHAVIORAL|AD-Standard (Advance Directive-Standard)|
223851905|NCT00530517|DEVICE|Intraject Sumatriptan|needle-free, single use, disposable, subcutaneous delivery system pre-filled with 6mg Sumatriptan
223851906|NCT00201695|DRUG|Doxil®|40 mg/m2 IV day 1
223851907|NCT00201695|DRUG|Vincristine|1.4 mg/m2 (maximum 2 mg) IV day 1
223851908|NCT00201695|DRUG|Dexamethasone|40 mg PO days 1-4
223851909|NCT00201695|DRUG|Arsenic Trioxide|0.25 mg/kg IV over 1-4 hours twice per week, week 1-4 of each cycle (i.e., days 1 and 4; 8 and 11; 15 and 18; 22 and 25)
223851910|NCT00562913|DRUG|Nexavar (Sorafenib, BAY43-9006)|Cyclophosphamide plus 400 mg BID sorafenib and doxorubicin
223851911|NCT00938535|BEHAVIORAL|Obesity Prevention|This arm includes an action plan, tailored print materials, telephone support calls, interactive self-monitoring, and a 12-month YMCA membership for the participant.
223851912|NCT01886014|DRUG|Oxytocin|
223851913|NCT01886014|OTHER|placebo|
223851914|NCT05677178|OTHER|observational|This study is an observational study without any intervention.
223851915|NCT06465680|BEHAVIORAL|Intern Health Study behavioral change mobile notification|The study's mobile app will be used to deliver push notifications. The notifications appear on the participant's phone lock screen. The notifications include 3 categories: mood notifications, activity notifications, sleep notifications. Mood notifications aim to increase the participant's mood. Activity notifications aim to increase the participant's physical activity. Sleep notifications aim to increase the participant's sleep duration. All notifications are categorized as one of five therapeutic approaches: 1) CBT-Behavioral, 2) CBT-Cognitive, 3) Distanced Self-Talk, 4) Mindfulness, 5) Motivational Interviewing.
223851916|NCT00420316|BIOLOGICAL|Rotarix (primary vaccination study)|GlaxoSmithKline Biologicals' oral live attenuated human rotavirus vaccine.
223851917|NCT00420316|BIOLOGICAL|Placebo (primary vaccination study)|Two liquid oral doses of placebo
223851918|NCT02145182|DRUG|Eculizumab|Eculizumab is a complement component 5 inhibitor.
223851919|NCT02145182|DRUG|Placebo|0.9% sodium chloride
223851920|NCT06327919|DIETARY_SUPPLEMENT|Probiotic supplement|multi-strain probiotics were used in this study. Each probiotic capsule contains Lactobacillus acidophilus, Bifidobacterium bifidum, Bifidobacterium lactis, Bifidobacterium longum, Lactobacillus reuteri, Lactobacillus rhamnosus, magnesium stearate and maltodextrin. 1.8 × 109 CFU / capsule. 2 capsules per day, for 12 weeks
223851921|NCT06327919|OTHER|Placebo supplement|The placebo capsule contains 300 mg of starch. 2 capsules per day, for 12 weeks
223851922|NCT03168191|DRUG|Nicotine|Participants will receive low dose nicotine (6 mg/ml) or high dose nicotine (12 mg/ml)
223851923|NCT03168191|OTHER|Experimental Flavor|Experimental fruit flavored e-cigarette for lab session
223851924|NCT03168191|OTHER|Menthol Flavor|Menthol flavored e-cigarette for lab session
223851925|NCT05419557|BEHAVIORAL|Virtual Family-Based Healthy Plate Club|IHPC provides produce boxes, nutrition and meal-preparation, education, and supportive counseling to address barriers related to obtaining produce and food. The intervention provides participants with a bi-weekly produce box for 12 weeks and helps families identify sustainable ways to obtain vegetables once the produce boxes end. The CHW will support families by coaching them on how to prepare these unfamiliar vegetables, give tips on finding sales at grocery stores, as well as by navigation to food assistance sites including food pantries. Parents will learn strategies to increase vegetable consumption by addressing perceived barriers - such as the child doesn't like vegetables. Curriculum will also include topics such as how to increase physical activity and reduce screen time.
223851926|NCT01196988|BIOLOGICAL|Influenza vaccine GSK2321138A|intramuscular injections
223851927|NCT01196988|BIOLOGICAL|FluarixTM|intramuscular injections
223851928|NCT01196988|BIOLOGICAL|Influenza vaccine GSK2604409A|intramuscular injections
223851929|NCT05036746|OTHER|No intervention|No intervention
223851930|NCT01337869|PROCEDURE|Bascom Cleft Lift|Patients are positioned prone. The skin incision is drawn on the natal cleft, marking out the area of skin to be excised. The skin from this side of the natal cleft is then elevated. The skin on the opposite side of the cleft then is undermined to a distance required to allow primary closure of the defect away from the midline without tension. The elevated skin island is excised. The sinuses remaining in the deeper tissues are curetted thoroughly. Hemostasis is maintained. A 12F low-suction drain is sited and fat of the natal cleft then is approximated by using an absorbable suture. The wound is closed with a 3-0 polypropylene suture.The drain remains in situ to time that drainage amount decreases below 20 ml/day. The suture is removed in the clinic 10 day after surgery.
223851931|NCT01337869|PROCEDURE|Limberg Flap|Patients are positioned prone. The area to be excised is mapped-out, and the flap is designed. The area to be excised is mapped on the skin in a rhomboid form. The skin incision is deepened to the presacral fascia. Tissue is removed en bloc. After removing the rhombic excision, the Limberg fascia cutaneous flap is prepared through the right or left-side gluteus maximus fascia. The flap is fully mobilized and transposed medially to fulfill the rhombic defect without any tension. Hemosthasis is accomplished. A 12F low-suction drain is sited and wound is closed in two layers: the subcutaneous tissue with absorbable suture and the skin with 3/0 polypropylene. drain remains in situ to time that drainage amount decreases below 20 ml/day. The suture is removed in the clinic 10 day after surgery.
223851932|NCT04846491|DRUG|Peginterferon alfa-2b injection|Peginterferon alfa-2b injection (high dose) will be weekly subcutaneous injected for 8 weeks and then stop for 4 weeks, 12 week a cycle, up to 12 cycles (144 weeks) at most. TDF will be taken orally during the whole treatment period. And then followed for 24 weeks after treatment.
223851933|NCT04846491|DRUG|Peginterferon alfa-2b injection|Peginterferon alfa-2b injection (low dose) will be weekly subcutaneous injected for 8 weeks and then stop for 4 weeks, 12 week a cycle, up to 12 cycles (144 weeks) at most. TDF will be taken orally during the whole treatment period. And then followed for 24 weeks after treatment.
223851934|NCT04846491|DRUG|TDF|Patients will take TDF orally for the first 48 weeks, and then one can choose to continue the single-TDF treatment up to 144 weeks, or may choose to change to receive peginterferon alfa-2b combined TDF therapy for the later 96 weeks, peginterferon alfa-2b will be weekly subcutaneous injected for 8 weeks and then stop for 4 weeks, 12 weeks a cycle. And then followed for 24 weeks after treatment.
223851935|NCT04846491|DRUG|Peginterferon alfa-2b injection|Peginterferon alfa-2b injection will be weekly subcutaneous injected for 8 weeks and then stop for 4 weeks, 12 week a cycle, up to 12 cycles (144 weeks) at most. TDF will be taken orally during the whole treatment period. And then followed for 24 weeks after treatment.
223851936|NCT01807858|DIETARY_SUPPLEMENT|Bifidobacterium lactis|5 billion active Bifidobacterium lactis
223851937|NCT01807858|DIETARY_SUPPLEMENT|Bifidobacterium lactis plus İnülin|5 billion Bifidobacterium lactis plus 900 mg İnülin per day will be given
223851938|NCT01807858|OTHER|Maltodextrin|Maltodextrin
223851939|NCT01807858|DIETARY_SUPPLEMENT|İnulin|900 mg inulin per day will be given
223851940|NCT05996757|PROCEDURE|Wet clothing removal|The participants in the intervention group will have their clothing removed prior to insulation.
223851941|NCT00601848|DRUG|chemotherapy|
223851942|NCT00601848|DRUG|porfimer sodium|
223851943|NCT00601848|OTHER|immunohistochemistry staining method|
223851944|NCT00601848|OTHER|laboratory biomarker analysis|
223851945|NCT00601848|PROCEDURE|spectroscopy|
223851946|NCT00601848|PROCEDURE|therapeutic conventional surgery|
223851947|NCT04502511|DIAGNOSTIC_TEST|Standard diagnosis test|Care as usual
223851948|NCT01703130|PROCEDURE|Dose of of ropivacaine 0.75% used in block procedure|
223851949|NCT06354738|PROCEDURE|total hysterectomy with bilateral salpingo-oophorectomy, lymph node staging and comprehensive peritoneal staging|"Surgical treatment will consist of total hysterectomy with bilateral salpingo-oophorectomy according to international guidelines.~In low- and intermediate-risk EC patients, staging will include a sentinel lymph node (SLN) procedure. In high intermediate-risk and high-risk EC patients, lymph node staging will involve SLN procedure and/or pelvic and para-aortic lymph node dissection (LND), depending on the local protocol.~The Study-related procedures include infracolic omentectomy or two separate omental representative biopsies, biopsies of all suspicious lesions as well as six peritoneal sites (bladder, pouch of Douglas, bilateral paracolic gutter and bilateral diaphragm).~Stage IV patients will be treated according to European guidelines. When feasible, full surgical intervention (i.e. debulking) is recommended. If this cannot be achieved, a radiologic and/or histologic confirmation of tumor spread beyond the uterus will be accepted."
223851950|NCT05416671|BEHAVIORAL|guided narrative technique-writing|The experimental group underwent the psychological intervention of guided narrative technique-writing with the theme of teacher criticism for 20 to 30 minutes once a day for three consecutive days.
223851951|NCT01863004|DRUG|Bortezomib|
223851952|NCT00335023|OTHER|Red blood cell transfusion|At least one unit of red blood cells will be administered. The target Hb value after transfusion is at least 8.7 g/dL.
223851953|NCT05571358|DEVICE|Virtual Reality (Nature Trek)|"At the end of each session, participants will experience an immersive virtual landscape displayed by Nature Trek VR software (httpp://naturetreksvr.com/). First, participants will be placed in a sit down position and guided for their breathing control during 5 minutes (meditation Lotus option). After that, they will be encouraged to freely move around a relaxing virtual environment during 15 minutes taking special attention to soothing sounds of nature. The themes environment will be selected based on the preferences of the participants.~At the beginning of the study, advice is given on general care, in physical activity and issues concerning drug intake. Patients are advised to refrain from any other specific training during the intervention period. Any deviations from the adherence and practice of the VRi are recorded daily, noting any adverse incidents."
223851954|NCT02104648|OTHER|Placebo RO4602522|Daily oral doses
223851955|NCT02104648|DRUG|RO4602522|Daily oral doses
223851956|NCT02104648|DRUG|RO4602522|Single, oral dose
223851957|NCT02104648|DRUG|moxifloxacin|400 mg oral dose given on Day 1 or 11
223851958|NCT02104648|OTHER|moxifloxacin placebo|Dose given orally on Days 1 and/or 11
223851959|NCT02274493|DEVICE|da Vinci® Robotic Surgical System|Da Vinci Robotic Surgical system to be used in procedures that harvest the latissimus dorsi muscle for reconstructive procedures
223851960|NCT02274493|PROCEDURE|LD muscle flap harvest procedure|Latissimus dorsi muscle flap harvest procedure using da Vinci® Robotic Surgical System for use in reconstructive surgery.
223851961|NCT02274493|PROCEDURE|Reconstructive surgery|Reconstructive surgery is considered to be standard of care.
223851962|NCT02274493|BEHAVIORAL|Questionnaires|Questionnaire about pain, as well as participant's shoulder, arm, and hand range of motion completed at baseline, and at follow up visits 3-6.
223851963|NCT00558363|DRUG|Avodart|0.5 mg administered orally once daily
223851964|NCT00558363|OTHER|placebo|Patients will be randomized at Visit 2 in 1:1 ratio to receive either 0.5 mg dutasteride or placebo
224265612|NCT01619956|PROCEDURE|Osteotome sinus floor elevation|"After locating the implant position by a round bur, the pilot drilling was performed to the depth approximately 1-2 mm away from the sinus floor boundary according to the depth taken from the pre-surgical radiograph. The cortical part of the implant bed was further widened to either 3.5mm for 4.1mm implants or 4.2mm for 4.8mm implants. Then the elevation of the maxillary sinus was achieved and developed using osteotome (Straumann Osteotome Kit, Straumann AG, Waldenburg, Switzerland) by light malleting to create a greenstick fracture on the compact bone of sinus floor and to increase diameters gradually till the final depth. The sinus membrane was tested again for any perforation by Valsalva manoeuvre."
224265613|NCT01619956|PROCEDURE|Bone grafting|the autogenous bone chips harvested during the drilling procedure was mixed up with Bio-Oss® in approximately 1: 4 ratio. And the mixture was placed into the 'socket' by osteotomes when elevating the sinus membrane until the final depth.
224265614|NCT00792207|OTHER|Virtual Coach software|The intervention being tested, the Virtual Coach, is an automated empathic computer agent which will run on patient's home computer and engage the patient in dialogues to deliver personalized feedback, education and coaching based on physiological data.
224265615|NCT00792207|OTHER|Activity monitor and website|The control group will use an activity monitor and a website to track activity levels.
224265616|NCT00557245|DRUG|Tenofovir Disoproxil Fumarate (TDF)|TDF 300 mg tablet, once daily + Placebo FTC/TDF orally, once daily.
224265617|NCT00557245|DRUG|Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF)|FTC/TDF - 200 mg tablet, once daily + Placebo TDF orally, once daily
224265618|NCT00557245|DRUG|Placebo|Placebo TDF \& Placebo FTC/TDF, 1 tablet each daily.
224265619|NCT03980301|DIAGNOSTIC_TEST|ultrasound|screening of pregnant women with hepatitis c virus received treatment in first trimester for congenital anomalies
224265620|NCT03627598|DEVICE|HFNC|patients will receive high flow warmed air with low inspired fraction of oxygen between non invasive ventilation sessions
224265621|NCT03627598|DEVICE|standard|patients will receive low flow oxygen therapy at 1 to 4 liters per minute
224265622|NCT01527838|BIOLOGICAL|Single FT1050 treated UCB unit|Ex-vivo CXCR4 upregulated hematopoietic progenitor cells, cord blood
224265623|NCT04569058|DEVICE|Transcranial Photobiomodulation|Transcranial Photobiomodulation--a noninvasive intervention in which near-infrared light (850 nanometer) is applied to forebrain.
224265624|NCT00851409|DRUG|Recombinant Human C1 Inhibitor|"50 IU/kg rhC1INH, IV injection over 4 to 5 minutes, once weekly over an 8-week treatment period."
223851965|NCT05534633|OTHER|Choice of STBBI test(s)|Participants may receive a point of care HIV test, and/or point of care HCV test, and/or dry blood spot test, which can test for HIV, HCV, and syphilis, at the participants' choice.
223851966|NCT03256812|DEVICE|ICT-based ECG monitoring|Continuous monitoring will begin from the time of participation in the trial in the ICT-based centralized monitoring group. 24-hr Holter monitoring will be implemented at the 3-, 6-, and 12-month follow-ups in this group, as in the Holter monitoring group. If heart rate drops below 40 beats/min or increases above 120 beats/min on ECG during ICT-based ECG home monitoring, the participant will be notified first through an alarm function.
223851967|NCT03256812|DEVICE|Holter monitoring|24-hr Holter monitoring will be implemented at the 3-, 6-, and 12-month follow-ups
223851968|NCT02434718|DRUG|Aducanumab|As described in the treatment arm
223851969|NCT02434718|DRUG|Placebo|IV administration of 0.9% sodium chloride
223851970|NCT01313182|DRUG|mupirocin calcium ointment, 2%|"Approximately one-half of the ointment from the single-use tube should be applied into 1 nostril and the other half into the other nostril twice daily (morning and evening) for 5 days.~After application, the nostrils should be closed by pressing together and releasing the sides of the nose repetitively for approximately 1 minute. This will spread the ointment throughout the nares."
223851971|NCT01313182|DRUG|3M Skin and Nasal Antiseptic|The solution is applied to for 30 seconds to each nostril twice for a total of 2 minutes. The solution is applied by rotating the applicator around the circumference of the nostril for 15 seconds and then rotating the applicator in the anterior nares for 15 seconds.
223851972|NCT01695317|DRUG|Acetyl-L-carnitine|Week 1: 500 mg x 3, Week 2-12: 500 mg x 6
223851973|NCT06555471|DRUG|Sintilimab|Sintilimab: 200mg iv q3w d1
223851974|NCT06555471|DRUG|S-1|po d1-d14，q3w； according to body surface area ：\<1.5m\^2 40mg/time；1.5\~1.8m\^2 50mg/time；\>1.8m2 60mg/time)
223851975|NCT06555471|DRUG|Capecitabine|1000mg/m2 Bid po d1-14，q3w，Reduce or discontinue depending on the condition of the subject.
223851976|NCT06555471|RADIATION|Extraperitoneal radiation therapy|once a day, five times a week, at a dose of 1.8-2 Gy/f, for a total of 45-50.4 Gy. Radiation therapy starts from the first cycle of Sintilimab Injection combined with chemotherapy
223851977|NCT03795740|DIAGNOSTIC_TEST|3-D CT scanning|For patients in Group 1,precisely analyzed CT scanning and/or pulmonary angiography will be done,and the patients in Group 1 will receive PEA procedure with the guide of precise 3-D imaging techniques
223851978|NCT01161719|BEHAVIORAL|parent training|Behavioral management skill training
223851979|NCT00606580|DRUG|WR 279,396 topical cream|WR 279,396 is a topical antibiotic cream containing 15% paromomycin and 0.5% gentamicin that will be applied to each lesion once a day and covered with a sterile gauze and tape dressing.
223851980|NCT00606580|DRUG|Paromomycin Alone topical cream|The antibiotic paromomycin 15% in the same topical cream used in arm 1 will be applied to lesions daily and covered with a protective sterile gauze and tape dressing.
223851981|NCT00606580|DRUG|Vehicle placebo cream|Applied daily to cutaneous leishmaniasis lesions, primarily ulcerative, and covered with a protective, sterile gauze and tape dressing.
223851982|NCT05145517|DEVICE|Open repair|Open repair of the aorta and peripheral arteries
223851983|NCT00434278|DRUG|Dornase alfa|2.5 mg inhalation dose twice daily for 14±2 days
223851984|NCT00434278|DRUG|placebo|2.5 mg inhalation dose twice daily for 14±2 days
223851985|NCT02565056|OTHER|Self help book + telephone support|Self-help book based upon principles of Acceptance and Commitment Therapy
223851986|NCT04837313|PROCEDURE|Fecal Microbiota Transplantation|Fecal Microbiota Transplantation
223851987|NCT00927823|DRUG|PF-04691502|Once daily continuous dosing. Dose escalation to Maximally tolerated dose (MTD) until progression or discontinuation.
223851988|NCT02430181|DRUG|lonafarnib|antiviral farnesyl transferase inhibitor
223851989|NCT02430181|DRUG|peginterferon alfa-2a|immunomodulator
223851990|NCT02430181|DRUG|ritonavir|CYP 3A4 inhibitor, lonafarnib booster
224076075|NCT04496739|OTHER|Interview|Participate in audio-recorded interview via telephone or video conference
224076076|NCT04496739|OTHER|Questionnaire Administration|Ancillary studies
224076077|NCT01061515|DRUG|Intraperitoneal Oxaliplatin|
224076078|NCT01061515|DRUG|Bevacizumab|
223851991|NCT06293547|DRUG|Silver Diamine Fluoride|Silber Diamine Fluoride, a colorless, odorless alkaline solution, effectively halts carious lesions in various populations, including children and elderly patients, or those averse to invasive treatments. Its high fluoride content facilitates remineralization, caries arrest, and prevention. SDF application is simple, non-invasive, cost-effective, and does not stain intact enamel, making it suitable for treating dentin hypersensitivity. Its ease of use is advantageous for children, patients with special needs, and the elderly. Particularly beneficial for high-risk patients with salivary dysfunction or multiple carious lesions, SDF offers potential in pediatric dentistry and community oral health by streamlining procedures, requiring rapid application without sharp instruments or anesthesia.
223851992|NCT01972139|DEVICE|Renal Denervation using the Symplicity Renal Denervation System|Subjects randomized to the renal denervation group underwent angiography and renal denervation.
223851993|NCT01972139|OTHER|Sham Renal Denervation|Prior to enrollment closure, subjects were treated with sham renal denervation. After enrollment closure, subjects previously enrolled were no longer eligible to cross-over.
223851994|NCT01972139|DEVICE|Renal Angiography|Subjects who met all criteria after the screening period did undergo a renal artery angiogram to evaluate renal artery anatomy. Only subjects with eligible renal artery anatomy were randomized.
224076079|NCT01061515|DRUG|Capecitabine|
223851995|NCT00578214|DRUG|Randomized Midazolam|Midazolam was prepared in a 2 mg/ml cherry flavored syrup. In the randomized arm, patients received a single-dose administration of 5 ml (10 mg) of the midazolam syrup.
223851996|NCT00578214|OTHER|Placebo|The placebo was prepared as a color- and texture-matched cherry flavored syrup without midazolam.
223851997|NCT00578214|DRUG|Local Anesthesia|Lidocaine 1% with 1:100,000 epinephrine
223851998|NCT00578214|DRUG|Prospective Midazolam|Midazolam was prepared in a 2 mg/ml cherry flavored syrup. Dosing in the prospective arm was based on weight (\>45 to 77 kg, 10 mg; \>77 to 100 kg, 15 mg; greater than or equal to 100 kg, 20 mg). In the prospective arm patients were given additional doses of midazolam as necessary (in 5 mg increments) to achieve and maintain the desired level of anxiolysis.
223851999|NCT02162238|DEVICE|LSF-filtering device|Device: LSF-filtering device LifeStraw Family is a water purification device that by means of hollow fibres removes solid particles (\<0.5 Nephelometric Turbidity units turbidity reduction), bacteria (\>Log 6 reduction), viruses (\>Log 4 reduction) and cysts (\>Log 3 reduction). Zinc enrichment is provided by a chamber housing a zinc releasing glass-plate that is placed annexed to the hollow fibre column. It is estimated that the LSF can provide about 5 mg of zinc/l of filtered water. By consuming daily a portion of 0.6 litres of enriched water, \>100% of the age-specific estimated physiologic requirement would be covered, assuming a fractional absorption of 40%.
223852000|NCT00238316|DRUG|letrozole|2.5 mg PO daily for 1 year
223852001|NCT00238316|OTHER|Placebo|2.5 mg PO daily for one 1 year
223852002|NCT04675463|DRUG|BGF Inhalation Aerosphere|Budesonide/Glycopyrronium/Formoterol: 160/7.2/4.8/ puff, twice daily with two puffs per time
223852003|NCT04675463|DRUG|GFF Inhalation Aerosphere|Glycopyrronium/Formoterol: 7.2/4.8 per puff, twice daily with two puffs per time
223852004|NCT03492632|OTHER|Hormone panel|Blood sampling on the 3rd day of menstrual cycle for the measurement of serum FSH,LH,PRL,E2 and AMH hormone levels.
223852005|NCT04002128|OTHER|Tracheal aspirates and nasal smears were taken in all the patients. Laparotomies were performed in all patients.|Nitrous oxyde and sevoflurane anesthesia may alter mucus transport in the early postoperative period. In colonized patients it may result in more respiratory complications.
223852006|NCT03976609|PROCEDURE|Maxillary Expansion|The patients with maxillary transverse deficiency were treated with Haas expander is a tooth and tissue-borne appliance with a jackscrew located at the anterior region of the arch with its arms bent posteriorly and soldered to the first permanent molar bands. Once activated, the appliances opens the palatal suture and increase the transverse dimension of the maxilla.
223852007|NCT00454662|DRUG|olmesartan medoxomil / amlodipine or azelnidipine|AT1 subtype angiotensin II receptor antagonist / calcium channel blocker : 5-40mg of olmesartan medoxomil / 2.5-5mg of amlodipine or 8-16mg of azelnidipine
223852008|NCT00454662|DRUG|olmesartan medoxomil / low dose thiazide type drug|AT1 subtype angiotensin II receptor antagonist / low dose diuretic : 5-40mg of olmesartan medoxomil / low dose thiazide type drug
223852009|NCT06140849|DIAGNOSTIC_TEST|artificial intelligence model|artificial intelligence model of anterior open bite diagnosis
223852010|NCT00504920|BEHAVIORAL|Questionnaire|Questionnaires (30 minutes each) + instruction on telephone survey system for measuring symptoms. Questionnaires 2 times a week while in the hospital or until able to use the telephone survey system.
223852011|NCT03369587|BEHAVIORAL|Handwriting Practice|Self-directed home handwriting practice daily for 6 weeks
223852012|NCT00392418|DRUG|Multiple micronutrient supplement (iron)|
223852013|NCT00077883|DRUG|TLK286, cisplatin|TLK286 administered once every 3 weeks (± 2 days) at two dose-ranging levels (750 mg/m²) and 1,000 mg/²) in combination with two dose levels of cisplatin (75 mg/m² and 100 mg/m²) of cisplatin once every 3 weeks (± 2 days).
223852014|NCT02709343|DRUG|Bone-marrow derived MSCs|Allogeneic ex vivo expanded, bone marrow-derived mesenchymal stromal cells
223852015|NCT02709343|DRUG|Placebo|Placebo product visually very similar to mesenchymal stromal cells
223852016|NCT01228851|OTHER|Balance Training|Group balance training sessions three times a week for 8 weeks
223852017|NCT00045916|PROCEDURE|High dosage electroconvulsive therapy|Participants will receive high dosage right unilateral ECT at six times the seizure threshold.
223852018|NCT00045916|DRUG|Nortriptyline|Participants will receive nortriptyline.
223852019|NCT00045916|DRUG|Venlafaxine|Participants will receive venlafaxine.
223852020|NCT00045916|DRUG|Lithium|Participants will receive lithium.
223852021|NCT00045916|PROCEDURE|Low dosage electroconvulsive therapy|Participants will receive low dosage bilateral ECT at one and a half times the seizure threshold.
223852022|NCT03658941|PROCEDURE|No dural tenting techniques|Not applying dural tenting sutures during closure of a craniotomy
223852023|NCT03658941|PROCEDURE|Dural tenting techniques|Applying at least 3 dural tenting sutures during closure of a craniotomy
223852024|NCT03736785|DRUG|LY3209590|Administered SC
223852025|NCT03736785|DRUG|Insulin Degludec|Administered SC
223852026|NCT02605434|DRUG|Accordion Pill™ Carbidopa/Levodopa|AP-CD/LD capsule containing 50 mg carbidopa with 400 mg or 500 mg levodopa administered orally twice or 3 times a day
223852027|NCT02605434|DRUG|Sinemet®|Sinemet® tables containing carbidopa and levodopa 25/100 mg will be administered orally at least 4 times a day according to patients need
223852028|NCT02605434|DRUG|Placebo -AP-CD/LD|Placebo for AP-CD/LD capsule
223852029|NCT02605434|DRUG|Placebo- Sinemet|Placebo for Sinemet tables
223852030|NCT01982643|DRUG|naltrexone plus bupropion|Participants will receive a monthly injection of extended-release depot naltrexone (XR-NTX; as Vivitrol®) plus once-daily bupropion extended-release tablets (BRP; as Wellbutrin XL®) for 8 weeks.
223852031|NCT01106729|DIETARY_SUPPLEMENT|Cyanidin 3 glucoside|Ingestion of 500mg of Cyanidin 3 glucoside (a naturally occurring plant pigment)
223852032|NCT01594502|DRUG|Dutasteride|0.5 mg daily
223852033|NCT01594502|DRUG|Placebo|Placebo Comparator
223852034|NCT01236989|PROCEDURE|anatomical liver resection|anatomical liver resection by means of IOUS-finger compression
223852035|NCT01236989|PROCEDURE|Non-anatomical liver resection|non-anatomical liver resection
223852036|NCT06398223|PROCEDURE|Carotid endarterectomy (CEA)|Carotid endarterectomy (CEA): Surgical procedure to remove the plaque buildup in the carotid artery.
223852037|NCT06398223|PROCEDURE|Carotid artery stenting|Carotid artery stenting: Treatment of the stenosis with a stent. The plaque in the artery wall is not removed but the narrowing is dilated.
223852038|NCT06161064|DRUG|Hyaluronic acid|hyaluronic acid is temporary material using for augmentation of vocal folds in patients with glottal insufficiency
223852039|NCT01744691|DRUG|Ibrutinib|All subjects will receive ibrutinib 420 mg (3 x 140-mg capsules) orally once daily.
223852040|NCT01539603|DEVICE|Drug eluting balloon + Bare metal stent|PCI using Sequent Please and then Coroflex Blue
223852041|NCT01539603|DEVICE|drug eluting stent (Zotarolimus-eluting stent)|conventional PCI using Endeavor Integrity
223852042|NCT02667730|DRUG|Acetaminophen|Acetaminophen 500 mg four times daily for 7 days
223852043|NCT02667730|DRUG|Naproxen|naproxen 500mg twice daily for 7 days
223852044|NCT02667730|DRUG|Celecoxib|celecoxib 100mg twice daily
223852045|NCT02667730|OTHER|physiotherapy only|physiotherapy only (no drug)
223852046|NCT02458534|OTHER|Mcgrath Mac videolaryngoscope|Participants perform three intubation attempts using Mcgrath Mac videolaryngoscope in the manikin with the normal airway and difficult airway settings.
223852047|NCT02458534|OTHER|C-MAC videolaryngoscope|Participants perform three intubation attempts using C-MAC videolaryngoscope in the manikin with the normal airway and difficult airway settings.
223852048|NCT02458534|OTHER|macintosh laryngoscope|Participants perform three intubation attempts using macintosh laryngoscope in the manikin with the normal airway and difficult airway settings.
223852049|NCT02086708|DEVICE|Shear Wave sonoelastography|Shear Wave Sonoelastography as a ultrasound technique to measure liver fibrosis is performed on patients scheduled for non-focal liver biopsy. Results are compared with pathological score of fibrosis from liver biopsy.
223852050|NCT03046290|PROCEDURE|circumcision|
224265625|NCT03432091|DRUG|melatonin|Ramelteon RMT (RMT, Rozerem®), a novel MT1 and MT2 agonist, has been approved for treatment of insomnia, and provides a strong phase shift signal to the circadian timing system. Melatonin receptor agonists have recently become available for treatment of sleep and psychiatric disorders
223852051|NCT03046290|DRUG|Lidocaine|
223852052|NCT03046290|DRUG|Ropivacaine|
223852053|NCT01895257|DEVICE|HAI-90Y radioembolization (SIR-spheres injection)|"Patients randomised to receive the combination of SIR-Spheres microspheres plus systemic chemotherapy LV5FU2 need to be assessed in order to determine their suitability for SIRT.~1. Hepatic Angiogram~2. Liver-Lung Break-Through Nuclear Scan"
223852054|NCT01895257|DRUG|systemic chemotherapy LV5FU2|"Systemic chemotherapy with modified LV5FU2 will be administered according to the following regimen.~Cycle 1 onwards:~Day 1 Hour 0: Leucovorin L (levoleucovorin) 200 mg/m2 (or folinic acid 400 mg/m²) in 250 ml glucose 5%, 2-hour IV infusion Hour + 2: 5-FU bolus 400 mg/m2, IV bolus Hour + 2: 5-FU continuous infusion 2400 mg/m2, 46-hour cont. IV infusion Day 14 End of cycle. To be repeated every 14 days until evidence of treatment failure."
223852055|NCT01168011|DRUG|rigosertib|Doses of rigosertib up to 700 mg twice a day or three times a day for 21 days of 21-day cycles. Treatment may continue until progression.
223852056|NCT02805244|DRUG|JTZ-951, 14C-JTZ-951|
223852057|NCT00012987|BEHAVIORAL|Quality Improvement|
223852058|NCT05060185|DEVICE|the Flow Diverter|Those who meet the inclusion criteria but do not meet the exclusion criteria will be enrolled through the electronic central registration system. The investigator log in to the central registration system, fill in the subject information and submit it who enroll in the study. The investigator complete the surgery and conduct relevant evaluation according to the protocol.
223852059|NCT04251351|DRUG|Paracetamol|Paracetamol 15 mg/kg/dose IV 6 hourly for 72 hours
223852060|NCT04251351|PROCEDURE|Mechanical antipyresis|"Mechanical antipyresis (i.e. loose clothing, tepid sponging, fanning and cooling blanket) if fever in the first 72 hours.~If a temperature \>38.5°C persists despite mechanical antipyresis, or if deemed necessary by the treating clinician, then paracetamol can be administered according to local practice (paracetamol IV 15 mg/kg as needed)."
223852061|NCT03278197|OTHER|Interviews|Interviews with patients, physicians and general practitioners (GPs) to define patients' decisional needs.
223852062|NCT03278197|OTHER|Treatmentchoice Decisional Tool|Patients and physicians navigate through Treatmentchoice Decisional Tool and think aloud while running the tool
223852063|NCT03278197|OTHER|Questionnaires|Patients and physicians fill out questionnaires on the usual care, Delphi study
223852064|NCT03278197|OTHER|Interviews with stakeholders|Interviews with stakeholders (patients, clinicians, nurses, GP's, patient organizations, insurance companies) to determine the barriers and facilitators to the implementation of shared decision making and the decision aid.
223852065|NCT04590989|OTHER|Personalized Nutrition Plan|"* Personalized breakfasts and dinners designed and cooked by Simplefeast, delivered twice a week (eaten 6 days per week) + access to Simplefeast's App for recipes of other meals not provided (i.e. lunches and Saturdays) which are designed to match the individual nutritional recommendations.~* Personalized behavioral change program via electronic push notifications by ONMI"
223852066|NCT04590989|OTHER|Non-Personalized Nutrition Plan|"* Standard meals of breakfasts and dinners designed and cooked by Simple feast, based on general dietary recommendations, and delivered to participants twice a week. In addition, they will also have access to Simple feast's recipe App for other meals not provided. The recipes presented are generic, not personalized.~* Subjects in the control group will also be enrolled in the behavioral program by ONMI, but the program will not be personalized nor based on the same behavior change methodology as in the PP group. In other words, the control group will get information more than is triggered to take actual action (i.e. general guidelines that is available from the National Health Service and World Health Organization)."
223852067|NCT02552277|BIOLOGICAL|PDA-002|PDA-002 cells administered intramuscular (IM) on study Days 1, 29, and 57.
223852068|NCT02552277|DRUG|Placebo|Subjects will receive placebo administered on study days 1, 29, and 57.
223852069|NCT04312568|DRUG|Fadanafil|Dose escalation for 8 groups: 12.5mg one dose, 25mg one dose, 50mg one dose, 100mg one dose, 200mg one dose, 300mg one dose, 400mg one dose, 500mg one dose
223852070|NCT04312568|DRUG|Placebo|Dose escalation for 8 groups: 12.5mg one dose, 25mg one dose, 50mg one dose, 100mg one dose, 200mg one dose, 300mg one dose, 400mg one dose, 500mg one dose
223852071|NCT04912362|DEVICE|YAG iridotomy|YAG iridotomy was performed one week before operation, and then CO2 Laser-Assisted Sclerectomy Surgery was performed
223852072|NCT01700790|DRUG|Lopinavir/ritonavir and ritonavir|Two tablets twice daily of Lopinavir/ritonavir 200 mg/50mg with 3 capsules of ritonavir 100 mg twice daily given with rifampin 600 mg daily
223852073|NCT00000456|DRUG|naltrexone (Revia)|
223852074|NCT00000456|BEHAVIORAL|cognitive behavior therapy|
223852075|NCT00000456|BEHAVIORAL|motivational enhancement therapy|
223852076|NCT01724788|DRUG|FUROSEMIDE|Pharmaceutical form: Solution Route of administration: Intravenous
223852077|NCT01724788|DRUG|FUROSEMIDE (HOE058)|Pharmaceutical form: Tablet Route of administration: Oral
223852078|NCT00198172|DRUG|Cisplatin plus Epirubicin|
223852079|NCT02701361|BEHAVIORAL|mobile mindfulness|Receives audiovisual mindfulness content via internet plus call depending on symptoms or request.
223852080|NCT02701361|BEHAVIORAL|standard mindfulness|Receives weekly calls from mindfulness expert for 4 weeks.
223852081|NCT02701361|BEHAVIORAL|education|Receives web-based content about critical illness topics. Also receives two calls from study team to describe materials and answer questions about materials.
223852082|NCT01034943|PROCEDURE|External fixation|Operation with external fixation and optional addition of k-wire
223852083|NCT01034943|PROCEDURE|Volar plate|Operation with a Synthes volar two column plate (TCP)
223852084|NCT00175435|BIOLOGICAL|Resiquimod gel|3 doses HPV vaccine 0.5 mL given IM with Topical Immune Modulator
223852085|NCT00175435|BIOLOGICAL|Resiquimod gel|3 doses HPV vaccine 0.5 mL given IM with Topical Immune Modulator.
223852086|NCT00175435|BIOLOGICAL|Resiquimod gel|3 doses HPV vaccine 0.5 mL given IM with Topical Immune Modulator.
223852087|NCT04591301|DRUG|HEC113995 PA•H2O tablets|Each dose of HEC113995 PA•H2O tablets will be administered with approximately 240 mL of water in the morning after fasting for at least 10 hours overnight.
223852088|NCT04591301|DRUG|Placebo tablets|Placebo tablets will be administered with approximately 240 mL of water in the morning after fasting for at least 10 hours overnight.
223852089|NCT04898803|OTHER|conventional DGVS training|see above
223852090|NCT04898803|OTHER|extended simulator training|see above
223852091|NCT03327155|DRUG|Tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC)|One tablet, containing 300mg of TDF and 200mg of FTC once daily with food.
223852092|NCT05138172|DEVICE|"Forced Air Heating Temperature control Twinwarm II"|"For this purpose, we will use a device that is already routinely used in all operation rommss at MHH, the so-called warm air device Twinwarm, Generation III. This device has a valid CE mark and will be used according to its purpose pre-, intra- and postoperative maintenance of the normothermic body temperature of the patient. The device will be used strictly according to the existing in-house SOP Heat Management of 04/2021 of the Department of Anesthesiology and Intensive Care Medicine of the MHH.~Convective air heating has been shown to be effective in many studies and can be used flexibly with a variety of different ceiling models."
223852093|NCT02426320|OTHER|Sedation Interruption Protocol|
223852094|NCT02426320|OTHER|Standard Sedation Protocol|
223852095|NCT04599582|DEVICE|Hip Arthroplasty|Patients are operated with hip replacement.
223852096|NCT04588480|BIOLOGICAL|BNT162b2|BNT162b2 (intramuscular injection)
223852097|NCT04588480|OTHER|Placebo|Placebo (intramuscular injection)
223852098|NCT05513690|PROCEDURE|Amnioinfusion at room temperature (intervention arm)|Routine amnioinfusion and intrauterine temperature probe sensor
223852099|NCT00137605|BIOLOGICAL|Pneumovax|
223852100|NCT00137605|BIOLOGICAL|Prevnar|
223852101|NCT01989442|DEVICE|binasal prongs|patients randomized to binasal prongs for NIV will use binasal prongs as an interface during continuous positive airway pressure support
223852102|NCT01989442|DEVICE|nasal mask|patients randomized to nasal mask for NIV will use nasal mask as an interface during continuous positive airway pressure support
223852103|NCT02197689|DEVICE|Personalized Medication Management Platform for SMS Reminder|The Personalized Medication Management Platform was developed by investigators that integrated with Hospital Information System (HIS) to collect the prescription information of patients and automatically send SMS to remind
223852104|NCT03828162|DRUG|Anticoagulants|
223852105|NCT05114109|DRUG|Isatuximab Injection|Isatuximab will be given intravenously at 10mg/kg at day 0, week (W)1, W2, W3, and W4 then every 2 weeks for a total of 12 infusions.
223852106|NCT05100329|DRUG|Mitoxantrone Hydrochloride Liposome injection|20 mg/m\^2, IV, on day 1 of every 3 weeks (q3w, a cycle)
223852107|NCT01611909|DRUG|p-menthane-3,8-diol oil|Apply topically to affected area twice daily
223852108|NCT03679962|BEHAVIORAL|Triple Chronotherapy|"Day 0: One night of total sleep deprivation. The first 24 hours are spent with 1:1 nursing care for provision of comfort measures to stimulate wakefulness and to encourage completion of the intervention.~Day 1-4: Sleep phase advancement Day 1: Sleep from 6 PM to 1 AM Day 2: Sleep from 8 PM to 3 AM Day 3: Sleep from 10 PM and 5 AM Day 4: Awaken at 5 AM; discharge following light therapy~On days 1-4 patients will receive bright light therapy at 7am to 7:30am using a 10,000 Verilux light box. At discharge patients will be given a light box, strongly advised to continue the maintenance sleep schedule and bright light therapy at 7am daily for 30 minutes. Patients will be scheduled for follow-up appointments at 1-week, 1-month and 2-month following discharge."
223852109|NCT03679962|BEHAVIORAL|Treatment as Usual|Normal inpatient care, including pharmacotherapy, psychotherapy, milieu therapy and social work interventions
223852110|NCT04258410|DRUG|Placebo oral soft chew|placebo identical to experimental drug contained in soft chew
223852111|NCT04258410|DRUG|Quercetin|experimental drug contained in soft chew
223852112|NCT01174316|DEVICE|AutoVPAP™|Automatically titrated non-invasive ventilator, with target gross alveolar ventilation, end expiratory positive pressure, and back up respiratory rate determined by the clinician based on height and weight. The NIV must be used for as many hours as possible over the 24 hour period but breaks for meals, physiotherapy and bathroom are allowed.
223852113|NCT01174316|DEVICE|VPAPIIIST-A™|Standard non-invasive ventilator, with inspiratory and expiratory positive pressure determined by the healthcare professional. The NIV must be used for as many hours as possible over the 24 hour period but breaks for meals, physiotherapy and bathroom are allowed.
223852114|NCT03653975|OTHER|no intervention|no intervention
223852115|NCT00317655|DRUG|Glucosamine sulphate|
223852116|NCT00317655|DRUG|Ginger|
223852117|NCT00317655|DRUG|Ginger-Avocado-Soya|
223852118|NCT00317655|DRUG|Ginger-ibuprofen|
223852119|NCT00702429|OTHER|Blood sampling|Analysis of the PNN, analysis of the monocytes
223852120|NCT00702429|OTHER|Blood sampling|Analysis of the PNN, analysis of the monocytes
223852121|NCT05730764|DIAGNOSTIC_TEST|Accurate prediction of fertilization disorders and clinical decision support systems assist doctors in decision-making|With the assistance of accurate prediction of fertilization disorders and clinical decision support systems, clinicians predict and judge the probability and key factors of fertilization disorders of patients, and formulate and implement personalized diagnosis and treatment plans based on the prediction results
223852122|NCT05730764|DIAGNOSTIC_TEST|Clinicians follow a routine protocol|Treatment is performed by the clinician according to the usual protocol.
223852123|NCT04469218|DEVICE|SafeBreak Vascular|SafeBreak Vascular is a breakaway connector that screws into peripheral IV lines using luer connectors on each end. The device is designed to separate when a harmful force is placed on an IV line. Upon separation, valves on each side of the device close. On the patient side of the device, the valve closes to prevent the loss of blood and on the IV pump side of the device, the valve closes to stop the flow of medication. The valve closing on the IV pump side of the line causes the pump's occlusion alarm to sound and notify nurses that the IV needs attention. The nurse is able to throw away the separated SafeBreak Vascular, install a new SafeBreak, and restart the patient's infusion without the negative cascade of events that can occur when a peripheral IV fails.
223852124|NCT04675255|PROCEDURE|Frequently sampled glucose tolerance testing|Frequently sampled glucose tolerance testing
223852125|NCT04675255|PROCEDURE|abdominal subcutaneous adipose tissue biopsy|abdominal subcutaneous adipose tissue biopsy
223852126|NCT04675255|PROCEDURE|MRI scan to assess intrahepatic triglyceride content|MRI scan to assess intrahepatic triglyceride content
223852127|NCT04564313|DRUG|Camrelizumab treatment|Camrelizumab (SHR-1210), 200mg, I.V., Q3W
223852128|NCT01738555|DRUG|amdoxovir 300 mg bid|2 x 150 mg capsules bid
223852129|NCT01738555|DRUG|amdoxovir 500 mg bid|2 x 250 mg capsules bid
223852130|NCT06057220|OTHER|No intervention sample collection only|No intervention
223852131|NCT02205931|OTHER|Ketogenic diet|The ketogenic diet is a high fat diet designed to mimic the effects on the body of starvation. The premise is the main energy intake is fat, which is utilised in the body and produces ketones.
223852132|NCT02205931|DRUG|Antiepileptic drug therapy|The control intervention will be drug therapy with the most appropriate further antiepileptic drug for a particular child, depending on their presenting seizures and syndrome and previous drugs used, and chosen by the expert clinician responsible for management of the patient's epilepsy.
223852133|NCT00119899|PROCEDURE|FDG-PET scan|
223852134|NCT06213051|DEVICE|• COPAN Self-collection FLOQSwabs® (COPAN, Italy)|COPAN swabs evaluated on Roche COBAS and Cepheid Xpert PCRs
223852135|NCT02900365|PROCEDURE|early cataract surgery & IOL implantation|first week cataract extraction and IOL implantation.
223852136|NCT02900365|PROCEDURE|late cataract surgery & IOL implantation|first month cataract extraction and IOL implantation.
223852137|NCT01624636|DRUG|Placebo|
223852138|NCT01624636|DRUG|LFG316|
223852139|NCT01624636|DRUG|LFG316|
223852140|NCT04782999|DIAGNOSTIC_TEST|Oral Glucose Tolerance Test|Standard test of glucose tolerance with ingestion of 75 g glucose followed by blood sampling.
223852141|NCT04782999|DIAGNOSTIC_TEST|Hyperglycemic clamp with infusion of saline, GLP-1 or GIP|"Blood glucose kept at 15 mmol/L via iv 20% glucose infusions.~Primed co-infusion of either:~* Saline~* GLP-1 (Prime dose 6 pmol/kg, infusion 1 pmol/kg/min)~* GIP (Prime dose 3 pmol/kg, infusion 1.5 pmol/kg/min)."
223852142|NCT00843193|DRUG|INTRAVENOUS GSK679586|GSK679586 will be provided as a clear or colorless to pale yellow liquid with the unit dose strength of 10mg/kg and will be infused over an hour. The infusion will be delivered by a programmable infusion pump
223852143|NCT00843193|DRUG|INTRAVENOUS PLACEBO|Clear or colorless 0.9% sodium chloride saline solution will be infused over an hour. The infusion will be delivered by a programmable infusion pump
223852144|NCT00843193|DRUG|FLUTICASONE PROPIONATE|Subjects will be supplied fluticasone propionate at Screening, Run-in and when needed during the study. Subjects will be up-titrated to 1000 μg/day and those who were already taking greater than equal to 1000 μg/day fluticasone propionate or equivalent prior to the study will remain on their pre-study dose.
223852145|NCT00921830|DRUG|ibuprofen|Each subject will receive single doses of (i) ibuprofen 50 mg suppository (ii) ibuprofen 200 mg suppository and (iii) ibuprofen 200 mg tablet in 3 separate dosing periods. Doses will be administered after an overnight fast.
223852146|NCT04035512|OTHER|Expressive writing|"The procedure for the writing group will be as follow:~on day 1 the researcher will call the participant at designed time and will provide a brief introduction to the writing task. Participant will be asked to go in a quiet place in their house where they would have no interruptions but can still be close to the phone. Next, participants were given standardized instructions. Then participants will ask to start writing immediately after hanging up the phone and to write for 20 minutes. The researcher will call the participants after 20 minutes. The procedure for the second and third writing days will be identical.~The above method was previously tested by Zakowski et al., 2004."
223852147|NCT00240916|BIOLOGICAL|Attenuvax (Measles Virus Live Vaccine, 0.5ml subcutaneous)|
223852148|NCT00240916|BIOLOGICAL|MMR-II (Measles-Mumps-Rubella Virus Live Vaccine, 0.5ml subcutaneous)|
223852149|NCT04511650|DRUG|Razuprotafib Subcutaneous Solution|Up to 3 daily dose levels of Razuprotafib Subcutaneous Solution will be evaluated. Doses will be administered subcutaneously three times daily (Q8H) for 7 days.
223852150|NCT04511650|DRUG|Placebo Subcutaneous Solution|Matched vehicle-controlled placebo solution will be administered subcutaneously three times daily (Q8H) for 7 days
223852151|NCT06022536|DRUG|SSS40|Subjects injected with SSS40
223852152|NCT06022536|DRUG|Placebo|Subjects injected with Placebo
223852153|NCT00946751|DRUG|Levetiracetam Tablets, 750 mg (Sandoz Inc.)|
223852154|NCT00946751|DRUG|Keppra (Levetiracetam) Tablets, 750 mg (UCB Pharma, Inc)|
223852155|NCT02561403|BEHAVIORAL|EVO multitask video game|Participants will play a multitasking game for 4 weeks
223852156|NCT02561403|BEHAVIORAL|EVO words video game|Participants will play a word puzzle game for 4 weeks
223852157|NCT00544440|DRUG|Abiraterone acetate|Abiraterone 1000 mg (4 x 250 mg tablets) taken orally once daily
223852158|NCT00544440|DRUG|Prednisone|Prednisone 5 mg tablet taken orally twice daily
223852159|NCT01134419|OTHER|Computerized handoff tool|Informatics tool to aid in transfer of patient care information
223852160|NCT01134419|OTHER|Team training|Teamwork training and revisions of handoff structure to optimize teamwork skills and verbal communications
223852161|NCT05703204|DRUG|QLF32101|The dose is given weekly and observed for 28 days(DLT observation period).Single agent treatment.
223852162|NCT05252624|DRUG|placebo|Placebo tablet manufactured to mimic henagliflozin 5 mg tablet
223852163|NCT05252624|DRUG|Henagliflozin 5Mg Tab|Single oral tablet
223852164|NCT01641172|PROCEDURE|Dexa scan|"the DEXA scan to measure bone and fat will be performed one time in the healthy controls and the patients participating in the cross sectional part of the study.~The patients in the longitudinal part of the study will have a DEXA scan at baseline, 1 month after the end of chemotherapy and after 1 year."
223852165|NCT01641172|PROCEDURE|audiogram|"the audiogram will be performed one time in the healthy controls and the patients participating in the cross sectional part of the study.~The patients in the longitudinal part of the study will have an audiogram at baseline, 1 month after the end of chemotherapy and after 1 year."
223852166|NCT01641172|PROCEDURE|measurement of heart rate variability and baroreflex sensitivity|"the measurements (continuous assessment of heart rate and blood pressure using an non-invasive Finapress device) during 30 minutes will be performed one time in the healthy controls and the patients participating in the cross sectional part of the study.~The patients in the longitudinal part of the study will have those measurements taken at baseline, 1 month after the end of chemotherapy and after 1 year."
223852167|NCT01641172|PROCEDURE|Glucose tolerance assessment|"Glucose tolerance will be assessed by drinking glucose water and measuring glucose at baseline and 2 hours later. It will be performed one time in the healthy controls and the patients participating in the cross sectional part of the study.~The patients in the longitudinal part of the study will have an assessment at baseline, 1 month after the end of chemotherapy and after 1 year."
223852168|NCT01641172|DIETARY_SUPPLEMENT|oral nutrition supplements|a set of 10 Oral Nutrition Supplements (ONS) will be offered combined with a questionnaire to measure appreciation and preference for these food products. All these tests and questionnaires will be performed longitudinally (before the first chemotherapy, on day 7 of the first course, before the second course, on day 7 of the second course, 1 month after start of the last course, 7 months after the start of chemotherapy, and 1 year after the start of chemotherapy) and cross-sectional (1, 3, 5 and 7 years after chemotherapy).
223852169|NCT01641172|BEHAVIORAL|Two day food records|Two day food records will be used to investigate the actual dietary intake before the first and second course, during (on day 5 and 6) first and second course, 1 month after start of the last course, 7 months after the start of chemotherapy, and 1 year after the start of chemotherapy.
223852170|NCT01641172|BEHAVIORAL|Food Frequency Questionnaire|A Food Frequency Questionnaire (FFQ) will be used to investigate the usual dietary intake before the start of the first course, before and after the second course, 1 month after start of the last course, seven months after the start of chemotherapy, and 1 year after the start of chemotherapy (longitudinal), and 1, 3, 5 and 7 years after chemotherapy (cross-sectional).
223852171|NCT04643405|DRUG|APG-1387 for Injection|APG1387 will be administered IV days 1， 8, 15 and 22 of a 28 day cycle.
223852172|NCT04643405|DRUG|Gemcitabine|Gemcitabine 1000 mg/m\^2 will be administered IV days 1, 8, and 15 of a 28 day cycle.
223852173|NCT04643405|DRUG|Nab paclitaxel|Nab-Paclitaxel 125mg/m\^2 will be administered IV days 1, 8, and 15 of a 28 day cycle.
223852174|NCT00983164|DIETARY_SUPPLEMENT|Antioxidant Supplementation|antioxidant supplementation (vitamin E 800 mg, C 500 mg and zinc 40 mg) for 24 weeks
223852175|NCT01129778|DRUG|Zegerid (proton pump inhibitor)|
223852176|NCT01129778|PROCEDURE|Bravo pH monitoring|
223852177|NCT05005065|DRUG|IN-C005 X mg|Oral capsule
223852178|NCT05005065|DRUG|IN-A001 Y mg|Oral tablet
223852179|NCT05005065|DRUG|IN-C005 Y mg|Oral capsule
223852180|NCT05005065|DRUG|IN-C005 Z mg|Oral capsule
223852181|NCT00889694|DRUG|Tripterygium|Tripterygium: 2 capsules per time, 3 times per day for 12 weeks.
223852182|NCT00889694|DRUG|Sulfasalazine|Sulfasalazine: 0.75 gram per time, 2 times per day for 12 weeks.
223852183|NCT00889694|DRUG|placebo|Placebo: 2 capsules per time, 3 times per day for 12 weeks.
223852184|NCT01081145|DRUG|Extended-release Guanfacine Hydrochloride|The test product will be provided as 1, 2, 3, and 4mg tablets. Subjects will be administered a once-daily dose between 1-7mg/day depending on age and weight.
223852185|NCT01081145|OTHER|Placebo|Matching placebo will be provided as 1, 2, 3, and 4mg tablets. Subjects will be administered a once-daily dose of placebo between 1-7mg/day depending on age and weight.
223852186|NCT00046995|DRUG|carboplatin|
223852187|NCT00046995|DRUG|fluorouracil|
223852188|NCT00046995|DRUG|leucovorin calcium|
223852189|NCT00046995|PROCEDURE|adjuvant therapy|
223852190|NCT06630468|OTHER|Task-oriented occupational therapy (TOOT)|The task-oriented occupational therapy intervention was applied to individuals in the TOOT group in the form of 30-minute sessions, 5 consecutive days a week, over 4 weeks.
223852191|NCT06630468|OTHER|Control group|Routine upper-extremity-based occupational therapy intervention was applied to individuals in the TOOT group in the form of 30-minute sessions, 5 consecutive days a week, over 4 weeks.
223852192|NCT06630988|OTHER|Failure rates|Describe the management failure rate for hand infections, including panariasis, phlegmons and arthritis.
223852193|NCT06631690|OTHER|Isokinetic and functional balance tests|Isokinetic and functional balance tests
223852194|NCT06629935|PROCEDURE|orthognathic surgery|Le Fort I surgery
224076080|NCT06776367|OTHER|Remote study participation and self-collection of specimens|Participants in Group B will complete all study procedures remotely and will not physically visit any clinical research site. This will include telehealth (videoconference) visits with study personnel, self-collection of specimens, shipping of specimens using pre-labeled packaging, and completion of electronic diaries for data collection.
224076081|NCT06776367|OTHER|Traditional clinical trial participation with clinician-collected specimens|Participants in Group A will attend study visits in person at a clinical research site and will have the majority of specimens collected by a clinician at the clinic. Group A participants will have some electronic diary usage.
223852195|NCT06631742|OTHER|Exergaming on Dividat Senso|"The active dance video game is played with the Dividat Senso (Dividat \| Senso: cognitive-motor training). It consists of a dance disc with four arrows (up, down, left, right), and the game is played on a large screen (which is connected to the PC). The screen indicates which arrow the person should step on, thus controlling the game through body movements. The games give the person feedback in the form of auditory, visual, and somatosensory stimuli."
223852196|NCT06631742|OTHER|Usual Care|Standardised care with meal service, individual activities (e.g. hiking group, walking group, exercise group, handicrafts, gardening group, singing, painting or lunch) and customized care and support as required.
223852197|NCT04674449|DIAGNOSTIC_TEST|Disclosure of IDP results|The results of the adjunctive IDP performed at time of invasive coronary angiography are made available to the catheter laboratory clinician, to aid in the diagnostic process.
223852198|NCT04674449|OTHER|IDP performed but results not disclosed|The results of the IDP performed at the time of invasive coronary angiography are concealed from the catheter laboratory clinician who will be blinded. The patient is managed according to standard of care.
223852199|NCT04936789|DEVICE|IMES|Surgical implantation of IMES
223852200|NCT01019616|DRUG|paclitaxel/anthracycline|standard chemotherapy regimen(containing paclitaxel or anthracycline) different from primary chemotherapy(containing anthracycline or paclitaxel)
223852201|NCT00574886|BIOLOGICAL|Id-KLH|Idiotype vaccine - .5mg recombinant idiotype immunoglobulin protein given subcutaneously for a total of five administrations over 6 months.
223852202|NCT00816829|DRUG|Placebo|Fenofibrate-matching placebo tablet
223852203|NCT00816829|DRUG|Fenofibrate|145 mg NanoCrystal tablet
223852204|NCT03394027|DRUG|ONC201|625 mg by mouth every 7 days; each cycle = 28 days. Patients will receive ONC201 as long as they derive clinical benefit or toxicity becomes impeditive.
223852205|NCT06583590|DRUG|Botulinum toxin A|Botulinum toxin (BoNT) is One of the most potent toxins known to humans produced by Clostridium botulinum that has been used to treat several striated and smooth muscle disorders. Because the pathophysiology and the reason for patients' lack of response to PDE5I is insufficient smooth muscle relaxation and veno-occlusive disorder (VOD) , BTX-A may prove to be a viable treatment for this patient population due to its availability to facilitate long-acting cavernosal smooth muscle relaxation by inhibition of the release of noradrenaline from the adrenergic neurons acting on the cavernosal smooth muscle. Thus, the dominant sympathetic basal tone of the cavernosal smooth muscle is essentially removed, facilitating the occurrence of an erection.
223852206|NCT06583590|DRUG|Tadalafil 5mg|Tadalafil is one of 5-phosphodiesterase inhibitors that used to treat male sexual function problems (impotence or erectile dysfunction-ED). In combination with sexual stimulation, tadalafil works by increasing blood flow to the penis to help a man get and keep an erection.Tadalafil is also used to treat the symptoms of an enlarged prostate (benign prostatic hyperplasia-BPH). It helps to relieve symptoms of BPH such as difficulty in beginning the flow of urine, weak stream, and the need to urinate often or urgently (including during the middle of the night). Tadalafil is thought to work by relaxing the smooth muscle in the prostate and bladder.
223852207|NCT05766098|GENETIC|Genotyping|Characterization of genetic profile of tumor tissues
223852208|NCT05557721|PROCEDURE|Topical lidocaine|Patients will receive topical anesthesia with tetracaine hydrochloride 1% three times, 5 minutes apart. Then, lidocaine gel 2% will be applied on the surface of the eye and refilled as needed for 10 minutes, as well as manipulated for a good coverage.
223852209|NCT05557721|PROCEDURE|MP-TLT|"Micro pulse transscleral laser treatment will be performed with the Iridex CycloG6 laser with the revised P3 probe, according to the recent consensus recommendations.~In brief, this includes MP-TLT with 2500 mW, 31.3% duty cycle, four 20 second sweeps per hemisphere, avoiding the 3 and 9 o'clock meridians and sectors with scleral thinning."
223852210|NCT05199025|DIAGNOSTIC_TEST|Biomarker|Perioperative biomarker analyses
223852211|NCT03879447|DRUG|Herbal medicine|Herbal medicine will be administered in water-based decoction (120ml) and dried powder (2g) form (Ostericum koreanum, Eucommia ulmoides, Acanthopanax sessiliflorus, Achyranthes japonica, Psoralea corylifolia, Saposhnikovia divaricata, Cibotium barometz, Lycium chinense, Boschniakia rossica, Cuscuta chinensis, Glycine max, Atractylodes japonica) at the physician's discretion.
223852212|NCT03879447|PROCEDURE|Chuna manual medicine|Chuna is a Korean manual therapy directed at the spine and joints that incorporates various spinal manual medicine techniques for joint mobilization involving high-velocity, low amplitude thrusts to joints slightly beyond the passive range of motion and gentle force to joints within the passive range of movement. Chuna manual medicine will be administered to the pelvic, lumbar, thoracic, and cervical vertebrae at the physician's discretion.
223852213|NCT03879447|PROCEDURE|Bee venom pharmacopuncture|Bee venom pharmacopuncture will be administered only after confirming a negative response to hypersensitivity skin test. Diluted bee venom (saline:bee venom ratio, 10,000:1) filtered for allergens will usually be injected at 4-5 acupoints proximal to the dysfunctional site at the physician's discretion. Each acupuncture point will be injected to a total of 0.5-1 cc using disposable injection needles (CPL, 1 cc, 26G x 1.5 syringe, Shinchang medical co., Korea).
223852214|NCT03879447|PROCEDURE|Pharmacopuncture|Pharmacopuncture consisting of select herbal ingredients will be administered at Hyeopcheok (Huatuo Jiaji, EX B2), Ah-shi points and local acupuncture points using disposable injection needles (CPL, 1 cc, 26G x 1.5 syringe, Shinchang medical co., Korea) at the physician's discretion.
223852215|NCT03879447|PROCEDURE|Acupuncture|Acupuncture treatment will be administered using mainly proximal acupuncture points and Ah-shi points.
223852216|NCT03879447|PROCEDURE|Electroacupuncture|Electroacupuncture treatment will be administered using mainly proximal acupuncture points and Ah-shi points.
223852217|NCT03879447|PROCEDURE|Cupping|Cupping treatment will be administered at 1-2 points using mainly proximal acupuncture points and Ah-shi points.
223852218|NCT03879447|PROCEDURE|Other intervention(s)|Patients will be allowed any other additional intervention(s) as deemed necessary regardless of type or dose, and patterns of use will be investigated and recorded as a pragmatic clinical study.
223852219|NCT05749029|BEHAVIORAL|Four Week Self-Compassion Course|"This is a four-week self-compassion course supplied by Balanced Minds. The owner of Balanced Minds is a Consultant to this study, who will be providing access to participants.~The self-help, self-compassion course is based on Compassionate Mind Training. This provides participants with opportunities to develop skills and attributes of compassion through a weekly 30-minute video on a specified topic, a 10-minute compassionate exercise that participants are encouraged to engage in daily for the week and a brief summary of the compassionate topic. The topics of the course are:~1. The Foundations of Self-Compassion~2. Developing your Compassionate Self~3. Deepening the Compassionate Relationship with Yourself~4. Self-compassion in Everyday Life."
223852220|NCT01766856|OTHER|Eustachian tube function testing|Eustachian tube function testing will consist of some or all of the following tests: Inflation/Deflation test, Forced Response test, Compliance test,Valsalva, Toynbee and Sniffing
223852221|NCT05391126|DRUG|Irinotecan|Usual dosing per package insert.
224265626|NCT05608486|DEVICE|aerSleep II|The aerSleep® II System includes a soft silicone collar, which is placed on the anterior neck. Integrated with the collar is a vacuum pump module (VPM), which cordlessly powers the generation of negative pressure within the collar's cavity. This negative pressure pulls the underlying tissues forward, maintaining airway patency.
224265627|NCT00229021|DRUG|doripenum|
223852222|NCT06555965|OTHER|Non-interventional study|There is no planned intervention in this study
223852223|NCT04427098|DRUG|Enoxaparin 40 Mg/0.4 mL Injectable Solution|Subcutaneous enoxaparin 40 mg once daily for 14 days.
223852224|NCT04427098|DRUG|Enoxaparin|Subcutaneous enoxaparin for 14 days: 60 mg once daily in case of body weight of 45 to 60 kg; 80 mg once daily in case of weight from 61 to 100 kg; 100 mg once daily in case of bodyweight \>100 kg
223852225|NCT06314594|PROCEDURE|Conventional treatment|Patients will randomly assigned to routine treatment group (control group) and individualized treatment model group (intervention group). All patients will observed and intervened for 4 months. Patients in the control treatment group will follow the treatment plan in the 2016SOSORT guidelines
223852226|NCT06314594|BEHAVIORAL|intervention treatment|"Patients will be input into the health management platform. The optimal treatment scheme will be then determined through data calculation and sent to individuals (or their families) or schools for implementation under the guidance of the platform. It is important to note that the specific treatment plan varied from person to person. Patients were observed and intervened for a period of 4 months.~1. Massage therapy~2. Posture guidance~3. Schroeder\&#39;s gymnastics therapy~4. Bioelectric stimulation therapy"
223852227|NCT06111508|DEVICE|Continuous Glucose Monitoring (CGM)-based titration algorithm implemented in DiAs|A Continuous Glucose Monitoring (CGM)-based once weekly titration algorithm of basal insulin as implemented in DiAs Cloud platform
223852228|NCT06310993|OTHER|Exercise|Exercise programme is the intervention for this study
223852229|NCT06141057|BIOLOGICAL|Matrix M with RH5.1|50 µg of Matrix-M adjuvant with RH5.1 at different doses on days 0 and 28.
223852230|NCT05887323|DEVICE|Implantation of the Tendril 2088 lead in the LBBA|Conduction system pacing is achieved by delivering a pacing stimulus to the Left Bundle Branch area of the heart with Abbott's Tendril 2088 lead.
223852231|NCT05893121|OTHER|Cardiac coherence session|A cardiac coherence session consists of an exercise of six breaths per minute during five minutes.
223852232|NCT05893121|OTHER|Information note about MRI|explanatory note about MRI examination
223852233|NCT01018511|DRUG|Placebo tamsulosin hydrochloride OCAS 0.4 mg|tablet
223852234|NCT01018511|DRUG|Placebo FDC tamsulosin hydrochloride/solifenacin succinate 0.4 mg/6 mg|tablet
223852235|NCT01018511|DRUG|Placebo FDC tamsulosin hydrochloride/solifenacin succinate 0.4 mg/9 mg|tablet
223852236|NCT01018511|DRUG|tamsulosin hydrochloride OCAS 0.4 mg|tablet
223852237|NCT01018511|DRUG|tamsulosin hydrochloride/solifenacin succinate fixed dose combination (0.4 mg/6 mg)|tablet
223852238|NCT01018511|DRUG|tamsulosin hydrochloride/solifenacin succinate fixed dose combination (0.4 mg/9 mg)|tablet
223852239|NCT01021930|DEVICE|Polymer-based sirolimus-eluting stent(Cypher stent ) and Polymer-free paclitaxel-eluting stent (YinYi stent)|Polymer-based sirolimus-eluting stent( Cypher, Cordis ) and Polymer-free paclitaxel-eluting stent (YinYi ),randomly implanted in two vessels of one patients
223852240|NCT05048355|DEVICE|Power Knee Mainstream Dynamic|Powered Microprocessor controlled prosthetic knee. The Power Knee Mainstream - Dynamic, was designed to provide powered swing dynamics to restore muscle activity and thereby attempting to mitigate this increase in metabolic cost that individuals living with TF amputation face.
223852241|NCT05048355|DEVICE|Passive microprocessor controlled knee|Any passive microprocessor controlled prosthetic knee on the market
223852242|NCT03918577|OTHER|Caloric Vestibular Stimulation|Cold water creates a convection current in the semicircular canal of the vestibular apparatus, leading to brief (\<3 min) and typically well tolerated sense of rotational movement. Similar stimulation is routinely used in standard vestibular diagnostic testing.
223852243|NCT06277817|OTHER|expiratory rib cage compression|Expiratory rib cage compression: The hands are placed on the lower third of the rib cage. During expiration, the end and sides of the patients' rib cage are gradually compressed with the hands.At the end of expiration, compression is released from the thorax to allow patients to take a free inspiration. After each compression, the patient is allowed to perform 3 breathing cycles.Expiratory rib cage compression is applied for 5 minutes.
223852244|NCT06277817|OTHER|percussion vibration|Percussion :Percussion is performed 3-5 times on each area from a height of approximately 10 cm with the domed hand. . It starts from the right and left lower lobes and goes up.Vibration:The hand is firmly/strongly placed on the application area. The arm and shoulder are stretched and the fingers are gently vibrated or shaken gently. While the patient is exhaling, vibration is performed 3-5 times in each area, starting from the right and left lower lobes.
223852245|NCT02900027|DRUG|APOC-III-L-Rx|Ascending single and multiple doses of IONIS-APOC-III-LRx by subcutaneous (SC) injection
223852246|NCT02900027|DRUG|Placebo Comparator|Sterile Normal Saline (0.9% NaCl) calculated volume to match active comparator
224265628|NCT06628115|DEVICE|cerament V or G|Cerament V or G implantation into forefoot or mid foot bone, and 7-10 days of oral antibiotics.
224265629|NCT00798603|BIOLOGICAL|bevacizumab|
224265630|NCT00798603|DRUG|carboplatin|
224265631|NCT00798603|DRUG|pemetrexed disodium|
224265632|NCT02435264|OTHER|Healthier Dining Program Intervention|The food environment at the intervention centers will be modified to increase the availability of healthier foods and low calorie meals.
224265633|NCT06209749|OTHER|Sensory-based intervention module|Consists of sensory-based activities (Set A-F) with six weeks of individual sessions and six weeks of group sessions
224265634|NCT05325515|DRUG|Conventional alendronate|Conventional alendronate 70mg weekly
224265635|NCT05325515|DRUG|Effervescent and buffered alendronate|Effervescent and buffered alendronate 70mg weekly
224265636|NCT01768260|DEVICE|Enhanced external counterpulsation|EECP is performed for 1 hours every day, for a total of 36 hours.
224265637|NCT01768260|DRUG|Aspirin|Standard drug therapy
224265638|NCT04796480|DIETARY_SUPPLEMENT|YOGURT|Group 1 was given yogurt
224265639|NCT04796480|DIETARY_SUPPLEMENT|LACTOSE FREE FORMULA MILK|Group 2 was given lactose free formula milk
224265640|NCT02225782|DRUG|Alteplase|Alteplase is a fibrinolytic drug widely used to restore hemodialysis catheter patency.
224265641|NCT05496920|DIAGNOSTIC_TEST|FD-PET/CT|Standard of care PET/CT with full dose (FD) of the radiopharmaceutical
224265642|NCT05496920|DIAGNOSTIC_TEST|LD-PET/CT|Additional low dose PET/CT performed within protocol defined time frame LD-PET/CT with additional ultra-low dose CT-less reconstruction
223852247|NCT06199401|PROCEDURE|Vascular Grafts Eversion and Built-in Technique(XJ-Procedure)|A 1.5-2cm wide bovine pericardial patch and graft ring will be placed inside and outside the aortic root and against the aortic wall, respectively, and continuously sutured near the commissure using 5-0 polypropylene. Then an eversion about 15mm of vascular graft will be intermittently sutured to full layers of aortic vascular with 2-0 pad polyester suture. Finally, the eversion and aortic wall will be continuously sutured together in one more turn.
223852248|NCT04523181|DRUG|Antroquinonol|double-blind for antroquinonol and Placebo with same out-look and same frequency.
223852249|NCT04523181|OTHER|Placebo|Capsule without active compound
224265643|NCT06056115|DRUG|Tislelizumab,Platinum|"1. Induction therapy stage:~   Tislelizumab plus platinum-containing drug chemotherapy was administered every 3 weeks and was expected to complete 6 cycles of treatment.~2. Maintenance treatment phase:~After completion of the induction therapy phase, patients whose antitumor response was confirmed as complete response, partial response, and disease stable according to RECIST v1.1 criteria were admitted to maintenance therapy ."
224265644|NCT05243251|DRUG|Olanzapine 5 MG|, Olanzapine (OLZ) is an atypical antipsychotic agent that blocks multiple neurotransmitters: dopamine at D1, D2, D3 and D4 brain receptors, serotonin at 5-HT2a , 5-HT2c, 5-HT3, and 5-HT6receptors, catecholamines at alpha 1 adrenergic receptors, acetylcholine at muscarinic receptors, and histamine at H1 receptors is suggested to have a valuable role in CAC
224265645|NCT05243251|DRUG|Placebo|Tablets containing 300 mg of microcrystalline cellulose. It will be identical to the active drug
224265646|NCT02464254|BEHAVIORAL|Physical activity plus positive affect|Subjects will be randomized to a physical activity goal and will receive the positive affect component.
224265647|NCT02464254|BEHAVIORAL|Physical activity plus education|Subjects will be randomized to a physical activity goal and will receive the educational component.
224265648|NCT01283503|DRUG|BKM120|
224265649|NCT04069936|BIOLOGICAL|MILs™ - NSCLC|To evaluate the safety of MILs™ - NSCLC alone in subjects with locally advanced and unresectable or metastatic NSCLC
224265650|NCT04069936|BIOLOGICAL|nivolumab|To evaluate the efficacy of MILs™ - NSCLC in combination with nivolumab in subjects with locally advanced and unresectable or metastatic NSCLC
224265651|NCT04069936|DRUG|tadalafil|To evaluate the efficacy of MILs™ - NSCLC in combination with nivolumab with or without tadalafil in subjects with locally advanced and unresectable or metastatic NSCLC
224265652|NCT05644106|DEVICE|personal sound amplification product, hearing aid|the device for hearing gain in sensorineural hearing loss
224265653|NCT01127087|DRUG|Oxazyme|"Oxazyme (registered trademark) is a non-systemic orally delivered drug composed of recombinant oxalate decarboxylase (OxDC). It is formulated to enzymatically degrade available dietary oxalate prior to its absorption.~Dosing: 1gm Oxazyme containing approximately 1600 Units OxDC in a sachet administered BID together with lunch and dinner. Subjects were instructed to open the oxazyme sachets and either sprinkle on food or add to a glass of water or fruit juice and consume the contents with a meal twice daily."
224265654|NCT01933282|DRUG|MESA chemotherapy|Methotrexate 2g/ m2，IV d1 etoposide 100mg/ m2，VD d2，d3，d4， dexamethasone 20mg/ m2，VD d2，d3，d4, d5 Polyehylene glycol-asparaginase muscular injection 2500IU/ m2, d5
224265655|NCT01933282|DRUG|MESA|Methotrexate etoposide dexamethasone Polyehylene glycol-asparaginase
224265656|NCT02316223|BEHAVIORAL|Supporting Asthma Management Behaviors in Aging Adults (SAMBA)|The SAMBA program will be led by an asthma care coach (ACC) and the home program by a community health worker (CHW). All interventions, including usual care, will include EMR-based asthma self-management and decision support tools for clinicians in all practice sites. The ACC and CHW will provide education, goal setting, and general self-management support with assigned patients and coordinate with PCPs through in-person and phone contacts over 12 months. Outcomes will be measured through interviews, EMR chart abstractions, and from the Statewide Planning and Research Cooperative System (SPARCS) dataset to identify all ED visits and hospitalizations to any New York State facility.
224265657|NCT02986555|DEVICE|Existing Biofeedback|Using relaxing assisted biofeedback approach
224265658|NCT02986555|DEVICE|Biofeedback accompanied with virtual reality|Using relaxation approach with existing biofeedback accompanied by virtual reality relaxation
224265659|NCT01929187|DRUG|Phytonail|
224265660|NCT01929187|DRUG|Loceryl|
224265661|NCT06043349|COMBINATION_PRODUCT|Platelet-Rich Plasma and Topical 5% Minoxidil|The intervention group will receive three PRP injections during three months in addition to the topical 5% minoxidil.
224265662|NCT06043349|DRUG|Topical 5% Minoxidil|The intervention group will receive topical 5% minoxidil as standard therapy for male androgenetic alopecia.
224265663|NCT04020458|PROCEDURE|dental intervention|"Dental intervention plan for Group 1 and 3 subjects with periodontitis only, i) Full mouth intraoral X-rays (FMX)~ii. Full periodontal exam, diagnosis, Oral hygiene instructions (OHI)~iii. RX: 7 days of p.o. metronidazole (250mg)/amoxicillin (500mg) T.I.D., combined with local chlorhexidine rinses (not for subjects with Kidney transplant).~iv. Single visit intensive scaling and root planning (SRP) (full mouth)~v. Re-evaluation after 4-6 weeks (referral for definitive treatment)~vi. Extraction of teeth deemed hopeless based on periodontal, endodontic or restorative considerations~vii. Caries control, sedative dressing (palliative), referral to endodontic dentist for root canal treatment (RCT)"
224265664|NCT06274762|OTHER|Training and BSE application on a model|A breast cancer awareness training designed according to the headings of sensitivity, seriousness, benefit, obstacle perception, health motivation and self-efficacy, which are the steps of the health belief model, followed by applied BSE on a model.
224265665|NCT04277793|BEHAVIORAL|Monitored self-guided problem solving|Problem Solving is a behavioral modification intervention focusing on the training of adaptive problem-solving skills in order to cope more effectively with everyday stressful events.
224265666|NCT05465863|BIOLOGICAL|SARS-CoV-2 mRNA BNT162b2 vaccine (Pfizer-BioNTech®)|When permitted by local guidelines, children and adolescents who were over 12 years old were notified of vaccine eligibility and encouraged to schedule an appointment
224265667|NCT02988258|GENETIC|CMV-TCR transduced donor-derived T cells|Dose escalation
224265668|NCT00000950|DRUG|Ethambutol hydrochloride|
224265669|NCT00000950|DRUG|Isoniazid|
224265670|NCT00000950|DRUG|Pyrazinamide|
224265671|NCT00000950|DRUG|Pyridoxine hydrochloride|
224265672|NCT00000950|DRUG|Rifampin|
223852250|NCT01688544|DRUG|Ilaprazole|Ilaprazole 10 mg for 7 days
223852251|NCT00919438|DEVICE|AVIVO™ Mobile Patient Management System|Non Invasive monitoring device
223852252|NCT01102361|PROCEDURE|Robotic Transperineal Biopsy|Saturation biopsy for previous negative patients
223852253|NCT01986374|DRUG|HCG is introduced|must have good blastocysts
223852254|NCT05684003|OTHER|Neuromuscular exercise based injury-prevention program|Neuromuscular exercise based injury-prevention program
223852255|NCT01751997|DRUG|Transplants from 8/8-matched Unrelated donors|"* Myeloablative conditioning~  1. Total body irradiation; 165 cGy, every 12 hours, 8 doses, days -7 to -4 (total 1320 cGy)~ 2. Cyclophosphamide; 60 mg/kg/day, IV for 30 minutes, days -3 to -2 (total 120 mg/kg)~ 3. Antithymocyte globulin (ATG); 1.25 mg/kg/day, IV for 6 hours, days -3 to -2, (total 2.5 mg/kg)~* Reduced-intensity conditioning; older patients (age \> 55 years) and/or patients with comorbidities~  1. Fludarabine; 30 mg/m\^2/day, IV for 1 hour, days -8 to -4 (total 150 mg/m\^2)~ 2. Busulfex; 3.2 mg/kg/day, IV for 3 hours, days -3 to -2 (total 6.4 mg/kg)~ 3. Total body irradiation; 200 cGy, every 12 hours 2 doses, days -1 (total 400 cGy)~ 4. ATG; 1.25 mg/kg/day, IV for 6 hours, days -3 to -2, (total 2.5 mg/kg)~* GVHD prophylaxis~  1. Tacrolimus; 0.03 mg/kg/day, IV for 24 hours from day -1 (0.12 mg/kg/day, PO, if tolerable)~ 2. Methotrexate; 5 mg/m\^2/day, IV push, days +1, +3, +6, +11"
223852256|NCT01751997|DRUG|Transplants from family-mismatched/haploidentical donors|"* Reduced-intensity conditioning~  1. Total body irradiation; 200 cGy, every 12 hours, 4 doses, days -9 to -8 (total 800 cGy)~ 2. Fludarabine; 30 mg/m\^2/day, IV for 1 hour, days -7 to -3 (total 150 mg/m\^2)~ 3. Busulfex; 3.2 mg/kg/day, IV for 3 hours, days -6 to -5 (total 6.4 mg/kg)~ 4. ATG; 1.25 mg/kg/day, IV for 6 hours, days -4 to -1 (total 5.0 mg/kg)~* GVHD prophylaxis~  1. Tacrolimus; 0.03 mg/kg/day, IV for 24 hours from day -1 (0.12 mg/kg/day, PO, if tolerable)~ 2. Methotrexate; 5 mg/m\^2/day, IV push, days +1, +3, +6, +11"
223852257|NCT02755922|BIOLOGICAL|Application of autologous mesenchymal stem cells|within the surgical procedure, mesenchymal stem cells, were applied on the fracture site. Imaging by X-ray and CT and imaging analysis was done after fracture repair, at week 4 and week 12
223852258|NCT01462019|DEVICE|Photobiomodulation|"the participants of this group will receive, in addition to guidance on the breast care and proper techniques for feeding, phototherapy applications through photobiomodulador a device developed specifically for the treatment of nipple injuries. The parameters for applications are: continuous mode of emission, power output 10 mW, wavelength infrared (scanning from 880 to 904 nm) fluence of 4 J / cm ² and total application time of 10 minutes.~The application of the device will be three times per week on alternate days for seven consecutive weeks, totaling 21 sessions."
223852259|NCT01686295|DEVICE|iRestore Hair Rejuvenation System|This study is to evaluate the effectiveness of the iRestore Hair Rejuvenation System when used as directed in promoting hair growth in men and women with androgenetic alopecia 3 times a week for 30 minutes on non-consecutive days
223852260|NCT01686295|DEVICE|sham device|This shame device will be a sham comparator to evaluate the effectiveness of the iRestore Hair rejuvenation System when used as directed in promoting hair growth in men and women with androgenetic alopecia 3 times a week for 30 minutes on non-consecutive days
223852261|NCT06176144|DRUG|Desflurane|Desflurane will be administered by inhalation for anesthesia maintenance. The concentration of inhaled desflurane will be adjusted to maintain the bispectral index (BIS) value between 40 and 60. Analgesia will be supplemented with remifentanil (administered by continuous infusion), and sufentanil (administered by intermittent injection).Towards the end of surgery, desflurane inhalational concentration will be decreased and sufentanil will be administered when necessary. Desflurane inhalation will be stopped at the end of surgery.
223852262|NCT06176144|DRUG|Sevoflurane|Sevoflurane will be administered by inhalation for anesthesia maintenance. The concentration of inhaled sevoflurane will be adjusted to maintain the bispectral index (BIS) value between 40 and 60. Analgesia will be supplemented with remifentanil (administered by continuous infusion), sufentanil (administered by intermittent injection).Towards the end of surgery, sevoflurane inhalational concentration will be decreased and sufentanil will be administered when necessary. Sevoflurane inhalation will be stopped at the end of surgery.
223852263|NCT01580943|DRUG|Chlorhexidine|Over a 72-h experimental non-brushing period, subjects abstained from all forms of mechanical oral hygiene and one group (test) used an 0.12% CHX mouthrinse with 0.05% CPC (Perioaid®), twice daily for 30 seconds and the other group (positive control) used a 0.2% CHX mouthrinse alcohol free (Corsodyl® Care), twice daily for 60 seconds. These regimens are suggested by the manufacturers in the instructions
223852264|NCT01580943|DRUG|Chlorhexidine|"All subjects received a questionnaire using a visual analogue scale designed to evaluate their taste to the mouthrinse, which they had used (What is your opinion concerning the taste of the mouth rinse?). Subjects marked a point on a 10 cm long uncalibrated line with the negative extreme response (0) on the left and the positive extreme (10) at the right end. Then, they were also asked about side effects in an open answer (Did you feel any side effects caused by mouth rinse?, If so, what are they?)."
223852265|NCT04550039|DEVICE|Body-weight-supported treadmill|Gait training performed on treadmill with overhead harness providing necessary body-weight-support with assistance from trained physical therapist
223852266|NCT04550039|DEVICE|Ekso Bionics EksoNR exoskeleton|Gait training performed overground in EksoNR exoskeleton with assistance from trained physical therapist
223852267|NCT04391309|BIOLOGICAL|anti-CD14|4 mg/kg on Day 1, 2 mg/kg on Days 2-4 administered intravenously (IV)
223852268|NCT04391309|OTHER|Placebo|Placebo administered intravenously on Days 1-4
223852269|NCT04391309|DRUG|remdesivir|Remdesivir administered intravenously for 5 days beginning with a 200 mg loading dose on Day 1, followed by 100 mg/day on Days 2-5.
223852270|NCT03514199|OTHER|Mediterranean-type diet|"Recommendations: ingest whole grains; three or more servings/day (various fresh fruits/vegetables); three or more servings/week of fish or seafood; white meat to red and processed meat (red meat to one serving or less/day); oilseed mix - 30g/day (nuts: 15g/day, almonds: 7.5g/day, hazelnuts: 7.5g/day); extra virgin olive oil (30ml/day: 2 soup spoons/day) as the main source of fat in the salads; two or more servings per week of sofrito; two servings/day of low-fat dairy products; limit to one serving/week the intake of fatty and cured cheeses; recommendation of 7 glasses per week of red wine (recommendation for habitual drinkers): 1 cup/day of 100ml for women and 1-2 cups/day of 150ml for men; limit to one serving/week the intake of chocolate with more than 50% cocoa."
224265673|NCT04483921|OTHER|Acute exercise|Participants will complete a morning exercise bout at 70% of their individual maximal aerobic capacity to burn 200 kilocalories above their basal metabolic rate.
223852271|NCT03514199|OTHER|Low fat diet|Recommendations: choose grilled, cooked, baked or soaked preparations; avoid frying (sweet or salty); avoid excess fat in the preparations and season the foods with herbs at will (marjoram, basil, oregano, onion, green seasoning, sweet pepper, sage, etc.); avoid frequent ingestion of sausages such as ham, turkey breast, among others; avoid eating fatty meats and strip the skin of poultry before preparation; avoid eating sweets and fatty foods; avoid ingesting bakery products, such as leafy, tart, savory pasta.
223852272|NCT01126840|BEHAVIORAL|Telephone Interview|The phone interview should take 30-45 minutes to complete.
223852273|NCT01126840|BEHAVIORAL|Questionnaire|Mailed questionnaire that contains questions about experiences living with colorectal cancer, take 45-60 minutes to complete.
223852274|NCT04682756|DIAGNOSTIC_TEST|The model of machine learning|Early diagnosis of NTEMI patients by machine learning model
223852275|NCT00322699|PROCEDURE|Whole bladder laser light treatment as an alternative to radical cystectomy|The drug,Photofrin,at the dose of 1.5 mg/kg is infused intravenously two days prior to performing whole bladder laser light (630 nm) treatment.
223852276|NCT00322699|DRUG|Photofrin|The drug,Photofrin,at the dose of 1.5 mg/kg is infused intravenously two days prior to performing whole bladder laser light (630 nm) treatment.
223852277|NCT03459183|DEVICE|Infrasound (85 dB; 6Hz) source|the infrasound source will emit inaudible 6Hz sound for 8 consecutive hours during participant's night sleep, local sound pressure (at participants head) will be calibrated at 85 dB
223852278|NCT03459183|DEVICE|Ultrasound (10dB below hearing threshold; 22.4 kHz) source|the ultrasound source will emit inaudible 22.4 kHz sound for 8 consecutive hours during night sleep
223852279|NCT03459183|DEVICE|Infrasound dummy source|the infrasound dummy source looks exactly like the according verum infrasound source but produces absolutely no sound
223852280|NCT03459183|DEVICE|Ultrasound dummy source|the ultrasound dummy source looks exactly like the according verum ultrasound source but produces absolutely no sound
223852281|NCT03025464|DEVICE|Obstructive Sleep Apnea Screening Device|Assessment of ability of device to detect apneas and hypopneas to screen for OSA
223852282|NCT04548622|DEVICE|Magstim Rapid 2 system triggering Magstim Super Rapid system|Week 1 treatment includes rTMS for 5 sessions to both the left and right Wernicke's area (BA22) synchronous with rTMS to opposite hemisphere middle temporal cortex (BA21). Week 2 treatment includes rTMS given for 5 sessions with positions reversed (e.g., if Wernicke's stimulation was on the left during Week 1, position of rTMS will switch to the right side during Week 2 and vice-versa). As in Week 1, active rTMS will also be given synchronously to the opposite hemisphere middle temporal cortex. Weeks 3 and 4 include 10 stimulation sessions to the configuration of sites producing greater improvement in comparing results of Week 1 and Week 2. rTMS for each stimulation session will be given at 1-Hertz (once per second) for 16 minutes without interruption.
223852283|NCT02908620|COMBINATION_PRODUCT|One spray CTY-5339-A|Metered spray bottle with ≈200 uL total spray volume. Contains the active ingredients: 14.0% Benzocaine (USP = 28 mg) and 2.0% Tetracaine Hydrochloride (USP = 4 mg). Administered in a single anesthetic spray.
223852284|NCT02908620|DRUG|One spray CTY-5339-CB|Metered spray bottle with ≈200 uL total spray volume. Contains the active ingredient: 14.0% Benzocaine (USP = 28 mg). Administered in a single anesthetic spray.
223852285|NCT02908620|COMBINATION_PRODUCT|Two sprays CTY-5339-A|Metered spray bottle with ≈400 uL total spray volume. Contains the active ingredients: 14.0% Benzocaine (USP = 56 mg total) and 2.0% Tetracaine Hydrochloride (USP = 8 mg total). Administered in two anesthetic sprays.
223852286|NCT02908620|DRUG|One spray CTY-5339-CB in combination with one spray CTY-5339-P (vehicle control: placebo)|A single spray of CTY-5339-CB in a metered spray bottle with ≈200 uL total spray volume, containing the active ingredient: 14.0% Benzocaine (USP = 28 mg). This was administered in combination with a single spray of CTY-5339-P (acting as vehicle control placebo with no active ingredient) in a metered spray bottle with ≈200 uL total spray volume. This combination was used to maintain double-blind conditions. The vehicle control was sprayed outside the circumscribed area to avoid dilution of active drug.
223852287|NCT02292394|BEHAVIORAL|Multicomponent Cognitive Behavioral Telephone Intervention|
223852288|NCT02292394|BEHAVIORAL|Telephone Intervention Pleasant Activities|
224076082|NCT06345937|BEHAVIORAL|Behavioural Experimental: guidelines-based physical activity|Through a combination of exercise trainer-led in-person and virtual sessions, as well as counselling for independent aerobic exercise, participants will be guided to achieve 150 weekly minutes of moderate-intensity aerobic activity and twice weekly whole-body muscle strengthening.
224265674|NCT01275664|PROCEDURE|Adjuvant Therapy|Ancillary studies
224265675|NCT01275664|DRUG|Aprepitant|Given IV and PO
224265676|NCT01275664|DRUG|Carboplatin|Given IP
224265677|NCT01275664|DRUG|Cisplatin|Given IP
224265678|NCT01275664|DRUG|Dexamethasone|Given PO
224265679|NCT01275664|DRUG|Granisetron Transdermal Patch|Apply one patch to upper arm
224265680|NCT01275664|PROCEDURE|Management of Therapy Complications|Ancillary studies
224265681|NCT01275664|OTHER|Questionnaire Administration|Ancillary studies
224265682|NCT06270745|DRUG|indocyanine green|Whether to use ICG to assess anastomotic perfusion during digestive system surgery
224265683|NCT06416241|DRUG|EYLEA 2 MG in 0.05 ML Injection|Intravitreal injection
224265684|NCT04487184|OTHER|Kinesiology taping|Recently, kinesiology tape is a common intervention in clinic and sport. The tension caused by tape elasticity and attachment techniques affects the effects that kinesiology tape produces, such as pain relief, circulation increase, proprioception enhancement, and muscle contraction improvement.
224265685|NCT04384224|OTHER|acupuncture|use disposable sterile steel needles to insert to the acupuncture point
224265686|NCT02260063|DRUG|Epinastine syrup|
224265687|NCT02260063|DRUG|Epinastine tablets|
224265688|NCT00529763|DRUG|Dasatinib|Tablets, Oral, 70 mg BID (AD CML) or 100 mg QD (Chronic CML), once or twice daily dependent on disease stage, until subjects meet discontinuation (DC) criteria for study
224265689|NCT03669250|DRUG|CVN058|CVN058 will be given at two doses, a low does and a high dose
224265690|NCT03669250|OTHER|Placebo comparator|inactive placebo
224265691|NCT03995849|DIAGNOSTIC_TEST|Cone Beam CT Scan|In this study, children will receive one CBCT scan before starting RT as part of standard approach. Then after RT, another CBCT scan will be used to measure movement between the beginning and end of RT.
224265692|NCT05786118|OTHER|No intervention|There is no intervention in this study
223852289|NCT05921409|DIETARY_SUPPLEMENT|Extra Virgin Olive oil-supplemented Mediterranean Diet Intervention|"This intervention (treatment) consist of taking Extra Virgin Olive Oil (treatment group made up of 103 patients and 22 healthy people) for 6 months, accompanied by Mediterranean diet-based menus. During this time, blood and stool samples were taken at different points: before the start of the intervention (T0), 3 months after the start (T1), at the end of the intervention in the sixth month (T2) and 6 months after leaving the study (TF). Hence, a total of 4 time points were taken for analysis: T0, T1, T2, TF. Additionally, and following these same time points, the physical and psychological health status of the participants will be evaluated using the SF-36 health questionnaire. Similarly, the course of the pathology in terms of the Fibromyalgia Impact Questionnaire (FIQ) score were recorded."
223852290|NCT05921409|DIETARY_SUPPLEMENT|Olive oil-supplemented Mediterranean Diet Intervention|"This intervention (treatment) consist of taking Olive Oil (placebo group made up of 103 patients and 22 healthy people) for 6 months, accompanied by Mediterranean diet-based menus. During this time, blood and stool samples were taken at different points: before the start of the intervention (T0), 3 months after the start (T1), at the end of the intervention in the sixth month (T2) and 6 months after leaving the study (TF). Hence, a total of 4 time points were taken for analysis: T0, T1, T2, TF. Additionally, and following these same time points, the physical and psychological health status of the participants will be evaluated using the SF-36 health questionnaire. Similarly, the course of the pathology in terms of the Fibromyalgia Impact Questionnaire (FIQ) score were recorded."
223852291|NCT00207129|DRUG|Ixabepilone|Solution, I.V. infusion, 40 mg/m2, Cycles 1-18: once per cycle (Day 1) cycles 2-18 (6-54 weeks) depending on response.
223852292|NCT00207129|DRUG|Capecitabine|Tablets, Oral, 1000 mg/m2, Cycle 1: Once (Day 1) Cycle 2: Twice daily (Days 1-5) Cycles 3-18: None, 2 cycles (6 weeks).
223852293|NCT02131740|OTHER|Eye rubbing|eye rubbing for 1 minute in horizontal direction clockwise, 5 second rest \& eye rubbing for a further 1 minute.
223852294|NCT02131740|OTHER|No eye rubbing|This eye will not be rubbed
223852295|NCT06488599|RADIATION|Peri-apical radiographs on the implants|Peri-apical radiographs on the implants supporting the prosthesis
223852296|NCT01756287|OTHER|Chinese ocular exercise|A kind of massage around the acupuncture points around the eye.
223852297|NCT00639613|PROCEDURE|Double-balloon enteroscopy|Double-balloon enteroscopy allows for the entire gastrointestinal tract to be visualized in real time. The technique involves the use of a balloon at the end of a special enteroscope camera and an overtube, which is also fitted with a balloon. The procedure is usually done with the use of conscious sedation. The enteroscope and overtube are inserted through the mouth and passed in conventional fashion (that is, as with gastroscopy) into the small bowel. Following this, the endoscope is advanced a small distance in front of the overtube and the balloon at the end is inflated. Using the assistance of friction at the interface of the enteroscope and intestinal wall, the small bowel is accordioned back to the overtube. The overtube balloon is then deployed, and the enteroscope balloon is deflated. The process is then continued until the entire small bowel is visualized. Double-balloon enteroscopy allows for the sampling or biopsying of small bowel mucosa.
223852298|NCT00639613|OTHER|Standard meal test|"Liquid meal consisting of 100 g Ny NAN dissolved in 300 ml water (ca. 5000 kJ) to be ingested over 5 minutes. Blood will be sampled for 4 hours following ingestion. Samples are centrifuges and plasma will be analysed for glucagon, GLP-1, GIP, insulin and C-peptide concentrations."
223852299|NCT02983214|DRUG|Clopidogrel|
223852300|NCT02983214|DRUG|Cilostazol|
223852301|NCT05584020|PROCEDURE|ACL Repair|Patients are undergoing arthroscopic anterior cruciate ligament repair. The native ACL is repaired using very strong sutures. This device is used to repair the native ACL and restore knee stability.
223852302|NCT05584020|PROCEDURE|ACL Reconstruction|Patients are undergoing arthroscopic anterior cruciate ligament reconstruction. The torn ligament is removed and replaced with a band of tissue that usually connects muscle to bone. The graft tendon is taken from another part of your knee or from a deceased donor.
223852303|NCT01201187|DRUG|YY-162|YY-162(Ginkgo extract 30mg+Ginseng extract 50mg) 1T/twice a day(bid) for 8weeks, po medication
223852304|NCT01201187|DRUG|Placebo|Placebo 1T/twice a day(bid) for 8weeks, po medication
223852305|NCT06007144|DEVICE|SPIRION Laryngeal Pacemaker System Implantation and follow-up|"Timeline of Visits~* Screening~* Baseline: Official baseline, assessment primary \& secondary objectives~* Implantation of device~* Activation \& fitting: Baseline active device; implanted device has just been activated; assessment of secondary objectives only~* 8 FU Visits over 2 years after activation; Includes~  * Baseline Switch Off: results of the visit preceding a 14-day switch-off of the device; assessment of secondary objectives only~ * Endpoints for~    * Pivotal phase: 12 months after activation; official endpoint for assessment of primary \& secondary objectives~   * Active post-pivotal phase: 24-month follow-up; endpoint for all secondary objectives~   * Switch Off: 2 Visits; assessment of secondary objectives only~ * Repeated checkpoints to assess device effects over 2 years: 5 visits; assessment of secondary objectives only~Device shall increase respiratory patency during inspiration, assessed by normalized PIF; other outcome measures are used to assess secondary objectives"
223852306|NCT01843465|OTHER|Maneuvers for documenting the disconnection|
223852307|NCT00953485|BIOLOGICAL|Allogeneic Mesenchymal Stem Cells (AlloMSC)|Allogeneic mesenchymal stem cells will be infused intravenously (single dose, 10\^6 cells/kg body weight).
223852308|NCT00885508|DRUG|Lenalidomide|"1. Induction treatment Lenalidomide 10 mg once daily PO during 3 weeks . in combination with classical 7+3 chemotherapy.~2. Consolidation treatment 6 monthly courses of : Lenalidomide 10 mg/ d during the first 2 weeks in combination with classical 5+1 consolidation chemotherapy~3. Maintenance treatment Lenalidomide 10 mg/d 2 weeks every month until relapse~In absence of toxicity, 20 additionnal patients will be included with lenalidomide dose of 25mg/J, then 20 other additionnals patients with Lenalidomide 50mg/J"
223852309|NCT01711307|PROCEDURE|operative|
223852310|NCT01711307|PROCEDURE|non-operative|casting within 48 hrs
223852311|NCT02466295|OTHER|Volume-controlled ventilation|I-gel will be inserted into the patient's mouth. After confirmation of adequate ventilation with the i-gel, the patient's lungs will be mechanically ventilated using the volume-controlled mode with tidal volume 8 ml/kg during surgery.
224265693|NCT04790643|OTHER|Exercise-based cardiac rehabilitation program (Stage 1)|In Stage 1 the volunteers will perform 24 sessions of exercise-based cardiac rehabilitation. The rehabilitation session is composed of the following activities: I. Initial rest (where the vital signs are evaluated); II. Warming-up (composed of 15 minutes of stretching and global exercises); III. Aerobic exercise (composed of 30 minutes of treadmill or cycle ergometer exercise, the intensity established varies from 40 to 70% of the heart rate reserve for those diagnosed with cardiovascular diseases and from 60 to 80% of the heart rate reserve for those with only cardiac risk factors); IV. Cooldown (composed of 5 minutes of slow walking).
224265694|NCT04790643|OTHER|Exercise-based cardiac rehabilitation program (Stage 2)|In Stage 2, the volunteers will perform 24 sessions of exercise-based cardiac rehabilitation. The rehabilitation session is composed of the following activities: I. Initial rest; II. Warming-up; III. Aerobic exercise (these three activities are the same as stage 1); IV. Resistance training (composed of 15 minutes of individualized resistance exercises); V. Cooldown.
223852312|NCT02466295|OTHER|Pressure-controlled ventilation|I-gel will be inserted into the patient's mouth. After confirmation of adequate ventilation with the i-gel, the patient's lungs will be mechanically ventilated using the pressure-controlled mode with tidal volume 8 ml/kg during surgery.
223852313|NCT00303849|DRUG|Carboplatin|Given IA
223852314|NCT00303849|DRUG|Etoposide|Given IV
223852315|NCT00303849|DRUG|Etoposide Phosphate|Given IV
224265695|NCT00469885|DRUG|Nicotine replacement|For reduction
224265696|NCT00469885|BEHAVIORAL|Motivational counseling|No drugs
224265697|NCT00828321|DRUG|Ramipril 10 mg capsule|1 x 10 mg
224265698|NCT00828321|DRUG|Altace® 10 mg capsule|1 x 10 mg
224265699|NCT04231643|DRUG|Dronabinol|one-time oral administration of 5 mg dronabinol
224265700|NCT04231643|DRUG|Epidiolex|one-time oral administration of 600 mg Epidiolex
224265701|NCT04231643|DRUG|Placebos|one-time oral administration of placebo
224265702|NCT01374646|BEHAVIORAL|JOIN Intervention|Behavioral group treatment for overweight and obese children and teens, that focuses on decreasing energy dense foods and sedentary behaviors.
224265703|NCT02131220|DRUG|Prourokinase|20mg intracoronary bolus infusion using selective catheter during PCI
224265704|NCT02131220|DRUG|Tirofiban|10ug/kg intracoronary bolus infusion using selective catheter during PCI
224265705|NCT02131220|DRUG|normal saline|intracoronary bolus infusion using selective catheter during PCI
224265706|NCT01208194|DRUG|MGN1703|solution, 60 mg, twice a week, until progression
224265707|NCT01208194|DRUG|Placebo|solution, 60 mg, twice a week, until progression
224265708|NCT03017729|BIOLOGICAL|Botulinum toxin type A|This is an observational study designed to reflect real world clinical practice in the use of abobotulinumtoxinA. AbobotulinumtoxinA injected doses, frequency of injections, number of injection sites and volume injected per site are in accordance with the current USPI and physician's clinical practice.
224265709|NCT04920695|DRUG|Nitric Oxide|Pulmonary vasodilator (gas).
224265710|NCT04920695|DRUG|Placebo|medical grade normoxic gas (FiO2 = 0.21)
224265711|NCT04879381|OTHER|Sputum samples|During consultation, one expectoration will be performed.
224265712|NCT03119896|OTHER|The Navigator Tool Intervention|The intervention consists of two parts; a training session on self-management of chronic conditions for the healthcare professionals, and a paper-based tool for the patients. Both parts aim to inform and prepare the two parties as to what self-management entails in order to facilitate a constrictive consultation.
224265713|NCT02658214|DRUG|paclitaxel + carboplatin|IV infusion
224265714|NCT02658214|DRUG|carboplatin + etoposide|IV infusion
224265715|NCT02658214|DRUG|gemcitabine + carboplatin|IV infusion
224265716|NCT02658214|DRUG|nab-paclitaxel (paclitaxel-albumin) + carboplatin|IV infusion
224265717|NCT02658214|DRUG|oxaliplatin + 5-fluorouracil (5FU) + leucovorin (calcium folinate/folinic acid)|IV infusion and bolus administration
224265718|NCT02658214|BIOLOGICAL|durvalumab|IV infusion
224265719|NCT02658214|BIOLOGICAL|tremelimumab|IV infusion
224265720|NCT02658214|DRUG|nab-paclitaxel (paclitaxel-albumin) + gemcitabine|IV infusion
224265721|NCT02658214|DRUG|cisplatin + 5-fluorouracil (5FU)|IV infusion
224265722|NCT06205264|OTHER|Strength training at high and low speeds.|"The training program will last for 8 weeks with a frequency of 3 sessions per week. Session duration will be 40-60 minutes, depending on the week within the developed schedule. To form the groups, participants will be randomly divided into two groups. On one hand, the explosive group will perform exercises in less time with faster movements, while the conventional group will execute the training with slower movements. The entire session will be designed and supervised by three exercise specialists. Each child must have a written informed consent completed by their parent/guardian.~Three days of strength training will be conducted following WHO recommendations, emphasizing multi-joint exercises."
223852316|NCT00303849|OTHER|Laboratory Biomarker Analysis|Correlative studies
223852317|NCT00303849|DRUG|Mannitol|Given IA
223852318|NCT00303849|DRUG|Melphalan|Given IA
223852319|NCT00303849|OTHER|Quality-of-Life Assessment|Ancillary studies
223852320|NCT00303849|DRUG|Sodium Thiosulfate|Given IV
223852321|NCT05623995|DRUG|PCSK9 inhibitor|Evolocumab per every two weeks, starting at day 1 and up to week 48, added to guideline recommended statin therapy..
223852322|NCT05623995|DRUG|Statin|Guideline recommended statin therapy.
223852323|NCT00881335|DEVICE|flutter mucus clearance device|five minutes every sessions, three sessions per day
223852324|NCT00967369|DRUG|Bortezomib|Given IV
223852325|NCT00967369|DRUG|Carboplatin|Given IV
223852326|NCT00967369|DRUG|Etoposide|Given IV
223852327|NCT00967369|DRUG|Ifosfamide|Given IV
223852328|NCT04989322|DRUG|Pembrolizumab|200 mg Q3W
223852329|NCT04989322|DRUG|Lenvatinib|8 mg daily
223852330|NCT04989322|DRUG|Pemetrexed|500 mg/m2 Q3W
223852331|NCT04989322|DRUG|Carboplatin|AUC5 Q3W
223852332|NCT01007708|DRUG|IDP-108|Topical application once a day for 48 weeks
223852333|NCT01007708|DRUG|Vehicle|Topical application once a day for 48 weeks
223852334|NCT01963026|OTHER|ToCUEST featuring a 'variable practice' approach.|Intervention Variable practice: The ToCUEST (Task-Oriented Client-centred Upper Extremity Skill Training) module \[17\] will be given to the participants, in which individual goals will be extracted using the COPM (Canadian Occupational Performance Measure). The training program will start with a task analysis and is based on principles of training physiology and motor learning, including variability practice, random practice, distribution based practice, feedback, whole learning. A detailed description of the ToCUEST module is given in Spooren et al. \[17\]. Intervention B will be called 'ToCUEST variability' in the present project.
223852335|NCT01963026|OTHER|ToCUEST featuring a 'constant practice' approach.|Intervention Constant practice: In order to evaluate the contribution of the component 'variability practice' in contrast with 'constant practice' the participants will be offered the modified ToCUEST ('ToCUEST constant') module in which the component 'variability practice' is replaced by 'constant practice'.
223852336|NCT03342924|OTHER|Flanker Test and physical fitness test|Socioeconomic status was determined using a trichotomous index. Inbody was used to assess body composition. To assess physical fitness, certain field tests were implemented using devices to quantify precise actions of physicality. Cognitive control was assessed using a computer-based Flanker Task.
223852337|NCT03719209|OTHER|HealthVoyager|HealthVoyager is a virtual reality application that allows providers to create customized representations for patients and share the results of endoscopic procedures via an interactive platform. The app can show both normal and abnormal endoscopic findings and anatomy. Families will also receive a web link so that they may access the procedure results via the app at home on their smartphone or tablet.
223852338|NCT03719209|OTHER|Standard Practice|Patients and families will receive handouts with printed images of their endoscopic findings, as per standard practice at Boston Children's Hospital.
223852339|NCT02793427|BIOLOGICAL|blood sample collection|
223852340|NCT02023372|OTHER|NuCel with Autograft|NuCel is a minimally manipulated allograft product derived from amniotic membrane along with cells from amniotic fluid. Local autograft is bone that comes from the patient's own vertebrae and surrounding bony structures.
223852341|NCT05909943|DRUG|Ruxolitinib|Treatment with ruxolitinib will be initiated in an initial dose regimen of 5-10 mg twice daily. Two months later, the dose of ruxolitinib will be increased to 10-15 mg twice daily.
223852342|NCT00296426|PROCEDURE|New technology - PAML|
223852343|NCT00005581|DRUG|cyclophosphamide|
223852344|NCT00005581|DRUG|epirubicin hydrochloride|
223852345|NCT00005581|DRUG|fluorouracil|
223852346|NCT00005581|DRUG|paclitaxel|
223852347|NCT04846101|OTHER|OMNISHADE|Anterior dental cavities (Class III, Class IV) will be restored with an omnishade composite material
223852348|NCT04846101|OTHER|MULTISHADE|Anterior dental cavities (Class III, Class IV) will be restored with conventional multishade composite material.
223852349|NCT04846101|DIAGNOSTIC_TEST|Instrumental Shade Analysis|Assessment will be performed by single operator using spectrophotometer (EASYSHADE) to detect color difference between tooth and restoration
224265723|NCT04130464|DRUG|Ropivacaine Infusion from ON-Q Pump|Infusion of 0.2% ropivacaine at 8 mL/hour for 72 hours
224265724|NCT04130464|DRUG|Ropivacaine + Ketorolac Infusion from ON-Q Pump|Infusion of 0.2% ropivacaine + 30 mg ketorolac at 8 mL/hour for 72 hours
224265725|NCT04130464|DRUG|Normal Saline Infusion from ON-Q Pump|Infusion of 0.9% normal saline at 8 mL/hour for 72 hours
224265726|NCT02509286|DRUG|5-Fluorouracil|2600 mg/m² (24 hours), d1 every two weeks;
224265727|NCT02509286|DRUG|Leucovorin|200 mg/m² in 250 ml NaCl 0.9%, d1 every two weeks;
224265728|NCT02509286|DRUG|Oxaliplatin|85 mg/m² in 500 ml G5% over 2h, d1 every two weeks;
223852350|NCT04846101|OTHER|Visual Shade Analysis|Visual assessment will be performed by two calibrated specialists to evaluate shade matching between the tooth and restoration
223852351|NCT04846101|OTHER|Patient satisfaction|Patient satisfaction of the final shade match will be assessed on a visual analogue scale
223852352|NCT02391662|DRUG|Nab-paclitaxel 125 mg/m2 weeks 1,2,3/4|Nab-paclitaxel 125 mg/m2 days 1,8 \& 15 in a 28 days cycle
223852353|NCT02391662|DRUG|Gemcitabine 1000 weeks 1,2,3/4|Gemcitabine 1000 days 1,8 \& 15 in a 28 days cycle
223852354|NCT06298188|DRUG|Risankizumab|Risankizumab
223852355|NCT02796976|OTHER|Training or control condition|Participants get a 12 week high intensity and walking-based interval training which is adapted to their individual physical fitness level or a general recommendation on physical activity according to European Guidelines.
223852356|NCT01300832|PROCEDURE|Duplex scan of lower extremities|Lower extremities will be duplex scanned pre and post-operatively
223852357|NCT03183024|BIOLOGICAL|benralizumab|open-label treatment
224265729|NCT02509286|DRUG|Docetaxel|50mg/m2 in 250 ml NaCl 0.9% over 1h, d1 every two weeks;
224265730|NCT02509286|DRUG|Carboplatin|Dose-dependant: 2mg/ml/min AUC in 500ml Glucose 5%, day 1, 8, 15, 22 and day 29.
224265731|NCT02509286|DRUG|Paclitaxel|50mg/m2 in 500ml NaCl 0.9% over 1 h, day 1, 8, 15, 22 and day 29;
224265732|NCT02509286|RADIATION|Neoadjuvant radiation|41.4Gy given in 23 fractions of 1.8Gy on days 1-5, days 8-12, days 15-19, days 22-26 and days 29-31.
223852358|NCT03183024|BIOLOGICAL|placebo|sterile water to mimic benralizumab
223852359|NCT02375516|BEHAVIORAL|Prevention Program|Youths in the intervention-arm will interact online with the initial intervention program between pretest and posttest measurement occasions and will interact with booster sessions subsequent to 1- and 2-year follow-up measurement occasions. Owing to the expense associated with developing a treatment-as-usual intervention for computer delivery in the control arm, youths assigned to the control arm will receive no intervention.
223852360|NCT05019781|OTHER|Therapeutic tape|Tape was applied to sternocleidomastoid, upper trapezius, deltoid, flexor palmaris longus muscles as suggested by Kase et al. (Kase, Wallis, Kase, \& Association, 2003). The tape was applied to the left side of the participants while sitting position because the violin is traditionally played by placing it on the left shoulder, balancing the neck using the left hand, and bowing with the right arm.
223852361|NCT05019781|OTHER|Placebo tape|The placebo tape was applied transverse to the muscle groups in two levels (a point of 10 cm above to wrist and elbow) with no tension when the participants were sitting position with the shoulder flexed at 90°, and the elbow flexed at 90°.
223852362|NCT00215306|DEVICE|CHARITÉ Artificial Disc|
223852363|NCT00215306|DEVICE|Anterior Interbody Fusion with BAK Cage|
223852364|NCT06340126|OTHER|Active release techniques|Active release techniques are soft tissue systems or movement-based techniques. It is used to treat muscles, nerves, fascia, ligaments, and tendons.
223852365|NCT06340126|OTHER|Relaxation exercises|Relaxation exercises include breathing exercises, pelvic floor exercises, and postural exercises. Exercises will be done in a sitting position
223852366|NCT03853733|RADIATION|rectal cancer radiotherapy|Conformal three-dimensional radiotherapy to deliver to the primary tumor and the enlarged pelvic nodes a total dose of 39Gy in 13 sessions of 3Gy in 17 days.
223852367|NCT06390488|OTHER|Transcutaneous medial plantar nerve stimulation (T-MPNS)|T-MPNS will be conducted unilaterally in the supine position using the electrotherapy device with surface electrodes. Two round self-adhesive electrodes will be positioned, with the negative electrode near the metatarsal-phalangeal joint of the great toe on the medial aspect of the foot and the positive electrode approximately 2 cm inferior-posterior to the medial malleolus (in front of the Medio-Malleolar-Calcaneal axis). Channel 1 will provide active stimulation, while channel 2 will remain inactive.
223852368|NCT06390488|OTHER|Sham Transcutaneous medial plantar nerve stimulation (T-MPNS)|Sham T-MPNS group will be stimulated using the same electrotherapy device, with patients positioned identically and electrodes placed in the same positions as in the T-MPNS group. The current characteristics (pulse frequency 20 Hz and pulse width 200 ms) will also remain consistent across both channels. The second channel of the stimulation device will be designated as the channel connected to the patient but without delivering stimulation.
223852369|NCT05824351|DEVICE|Tanzanian beeswax-pine resin|Thin ring of adhesive in the form of a Tanzanian beeswax-pine resin formula.
223852370|NCT05824351|DEVICE|Domestic beeswax-pine resin|Thin ring of adhesive in the form of a domestic beeswax-pine resin formula.
223852371|NCT05824351|DEVICE|Hollister's AdaptTM Barrier Rings|Thin ring of adhesive in the form of Hollister's AdaptTM Barrier Rings.
223852372|NCT04913649|DRUG|Ferric Derisomaltose 100 MG/ML|Postoperative treatment with a single dose IVI (ferric derisomaltose), with a dose of 20mg/kg in approximately 60 minutes.
223852373|NCT04913649|DRUG|Sodium chloride|Postoperative treatment with a single dose NaCl 0.9% in approximately 60 minutes.
223852374|NCT06466499|BEHAVIORAL|The intervention group|Is described in arm
223852375|NCT05390580|DEVICE|transcutaneous auricular vagal nerve stimulation|Stimulus of the auricular branch of the vagal nerve with the transcutaneous auricular vagal nerve stimulation.
223852376|NCT05390580|DEVICE|Sham transcutaneous vagal nerve stimulation|Patients assigned to the controls arm will have no electricity applied to the Auricular Branch of the Vagus Nerve. Stimulus will be provided to the lobule of the ear, which is not innervated by the Auricular Branch of the Vagus Nerve.
223852377|NCT05953350|DRUG|600mg bid dose of hydroxychloroquine combined with three predefined dose groups of palbociclib|hydroxychloroquine group of 600mg bid combined with three predefined dose groups of palbociclib: 100mg QD, 150mg QD, and 200mg QD, separately.
223852378|NCT05953350|DRUG|RP2D dose of 600mg bid of hydroxychloroquine combined with palbociclib was selected for phase II clinical trial.|After the exploration of 600mg bid dose of hydroxychloroquine combined with palbociclib, and the maximal tolerated dose (MTD) was determined, then RP2D dose of 600mg bid dose of hydroxychloroquine combined with palbociclib was selected for phase II clinical trial.
223852379|NCT00828945|DEVICE|Lipid Self Test|Self test for lipid levels, twice during study period
223852380|NCT05857293|DEVICE|Catheter-guided PDA stent implantation|PDA stent is the primary treatment for patients with duct-dependent pulmonary circulation. It serves as a temporary bridge for later surgical repair by keeping the duct patent to improve oxygen saturation
223852381|NCT06434857|PROCEDURE|Strength training in older adults with mild or non existent cognitive impairment|Strength training program applied to strength training group
223852382|NCT06434857|PROCEDURE|Multimodal excercise in older adults with mild or non existent cognitive impairment|Multimodal exercise program applied to multimodal exercise group
223852383|NCT00012467|DRUG|Itraconazole|
223852384|NCT00012467|DRUG|Flucytosine|
223852385|NCT00012467|DRUG|Fluconazole|
223852386|NCT00012467|DRUG|Amphotericin B|
223852387|NCT00012467|DRUG|Interferon gamma-1b|
224265733|NCT01360086|BIOLOGICAL|cetuximab|6 cycles of intravenous Cetuximab (500mg/m²),
224265734|NCT01360086|DRUG|cisplatin|Cisplatine (50mg/m²)
223852388|NCT01113515|DRUG|Esmolol hydrochloride|
223852389|NCT01113515|DRUG|Esmolol hydrochloride|
223852390|NCT01113515|DRUG|Esmolol hydrochloride|
223852391|NCT01113515|DRUG|Placebo gel|
223852392|NCT03319589|DIETARY_SUPPLEMENT|Supplement|locally prepared biscuit with low sugar content (less than 10% weight) designed to facilitate growth and cognitive development
223852393|NCT03578523|OTHER|3 Tesla multiparametric MR|Renal MRI Scan to assess blood flow, perfusion, oxygenation and microstructure (MR T1 relaxation time and diffusion). Each patient will have 3 renal MRI scans.
224265735|NCT01360086|DRUG|fluorouracil|LV5FU2s (folinic acid 400mg/m², 5FU bolus 400mg/m², and continuous infusion of 5FU 2400mg/m²) every 2 weeks
224265736|NCT01360086|DRUG|leucovorin calcium|
224265737|NCT01360086|PROCEDURE|adjuvant therapy|
223852394|NCT03578523|OTHER|renal histopathology scoring|Blinded fibrosis scoring of renal histopathology (If biopsy performed for clinical indication)
223852395|NCT03578523|BIOLOGICAL|Blood and urine sampling|"Blood and urine sampling around scan sessions; this will include routine patient care biochemistry and haematology panel,~urine protein and albumin measurements, stored plasma/serum/urine for subsequent analysis"
223852396|NCT03578523|BIOLOGICAL|Iohexol clearance test|Iohexol clearance to measure GFR within 1 week of the scan session
223852397|NCT02482233|BEHAVIORAL|ENDD (NJOY)|As described above.
223852398|NCT02482233|DRUG|NRT (NicoDerm CQ)|As described above.
223852399|NCT02482233|BEHAVIORAL|telephone counseling|Referral to the California Smokers' Helpline. California Smokers' Helpline will call the patient 4 times, or as agreed upon by the patient.
223852400|NCT02482233|BEHAVIORAL|brief advice|"Brief advice lasting less than 2 minutes will be delivered by the research assistant, investigator, or healthcare provider. The advice will be similar to the following statement (customized as needed to the patient): The most important advice I can give you is that quitting smoking is the number one thing you can do for your health and to prepare yourself for surgery. Quitting smoking before surgery may improve your chances of healing quickly. There's evidence that the longer you quit before your surgery, the fewer complications you'll have. I encourage you to make use of the resources that have been provided to you to help you quit and set your quit date for as soon as possible."
223852401|NCT02482233|BEHAVIORAL|brochure|"A brochure from the ASA (American Society of Anesthesiologists) about quitting smoking before surgery.~Available free from the ASA: http://ecommerce.asahq.org/publicationsAndServices/PatientBrochure\_%20For%20Posting.pdf"
223852402|NCT03917329|OTHER|ACT and PBS group workshop|Acceptance and Commitment Therapy and Positive Behaviour Support Group Workshop. Three sessions of approximately three hour duration. Groups will consist of 5-10 parents or 5-10 members of education staff. The group will include both didactic and experiential elements.
223852403|NCT06375356|BEHAVIORAL|Resistance Training|Strength exercises (3-4 sets each exercise) videos delivered electronically, participant self-tracks and self-progresses based on effort reported.
223852404|NCT04345523|OTHER|Blood and derivatives.|Administration of fresh plasma from donor immunized against COVID-19
223852405|NCT04345523|DRUG|Standard of Care|Standard of care for the treatment of COVID-19 in hospitalized patients
223852406|NCT03116282|BEHAVIORAL|E-alcohol therapy|Conversational therapy sessions provided via video conference by a professional alcohol therapist.
223852407|NCT03822351|DRUG|Durvalumab + Oleclumab|Durvalumab + Oleclumab
223852408|NCT03822351|DRUG|Durvalumab|Durvalumab
223852409|NCT03822351|DRUG|Durvalumab + Monalizumab|Durvalumab + Monalizumab
223852410|NCT05367674|BEHAVIORAL|Summer Harvest Adventure|Biobehavioral intervention focusing on nutrition and lifestyle behaviors.
223852411|NCT05367674|BEHAVIORAL|My Summer Plate (MSP)|My Summer Plate (MSP)
223852412|NCT06228742|OTHER|Unilateral leg immobilization|Participants will have one leg immobilized using a rigid knee brace. Participants will be expected to keep the knee brace on for 5 days and remain non-weight bearing on the immobilized leg. Participants will use crutches to remain non-weight bearing on the immobilized leg.
223852413|NCT06228742|OTHER|Contralateral active leg|One leg will remain non-immobilized and active during the study. Participants will use this leg to walk with crutches.
223852414|NCT02851810|BEHAVIORAL|oculomotor parameter recording|visual scanning behavior is assessed during visualization of emotional pictures
223852415|NCT02851810|BEHAVIORAL|attachment scale interview (ASI)|ASI is used to determine the attachment style of each participant
223852416|NCT02851810|BEHAVIORAL|psychophysiological recording|this consists of the measurement of the skin conductance reactivity (SCR) during the picture visualization
223852417|NCT02851810|BEHAVIORAL|psychometric assessment|self administered questionnaires are used to assess anxiety, depression and alexithymia.
223852418|NCT02851810|BEHAVIORAL|parent interview|an interview of the adolescent parent is performed in order to assess the confusion of the parent-child role and the interaction between the child and its parent.
223852419|NCT04272151|BIOLOGICAL|BCMA CAR-T cells|A single infusion of BCMA CAR-T cells will be administered intravenously.
223852420|NCT01227356|DRUG|imatinib and pegylated interferon|imatinib 400 mg p.o. daily pegylated interferon 50 ug s.c. weekly
223852421|NCT00369135|PROCEDURE|combined intervention|
223852422|NCT02157493|BEHAVIORAL|Arrowhead Business Group Curriculum|Arrowhead Business Group (ABG) is a culturally tailored entrepreneurship/life-skills intervention, which features instruction from American Indian paraprofessionals in an effort to decrease drug use, depressive symptoms, hopelessness and other high-risk behaviors among youth while improving their school performance and college/career aspirations.
223852423|NCT02157493|BEHAVIORAL|Recreational League Control Condition|The control condition will consist of a recreational sports league that will be led by local American Indian study staff who are experienced with Johns Hopkins camps and community-based Apache sports programs. Activities will be conducted on 3 Saturdays during the academic year to mixed gender groups of approximately 50 participants.
224265738|NCT01360086|PROCEDURE|neoadjuvant therapy|
224265739|NCT01360086|PROCEDURE|quality-of-life assessment|
224265740|NCT01360086|PROCEDURE|therapeutic conventional surgery|Surgery was planned 3-4 weeks after the end of neaodjuvant CT
224265741|NCT00754507|DRUG|colesevelam HCl tablets, and atorvastatin tablets|colesevelam HCl tablets,6 tablets/day; atorvastatin tablets, 1 tablets/day for 6 weeks
224265742|NCT00754507|DRUG|colesevelam HCl placebo tablets and atorvastatin tablets|colesevelam HCl placebo tablets, 6 tablets/day for 6 weeks atorvastatin tablets, 1 tablet/day for 6 weeks
224265743|NCT02483195|DRUG|5% Minoxidil|This will be a mixed combination of 5% Minoxidil and 200mg Spironolactone to be used once daily.
224265744|NCT02483195|DRUG|200mg Spironolactone|This will be a mixed combination of 5% Minoxidil and 200mg Spironolactone to be used once daily.
224265745|NCT02483195|DRUG|5mg Finasteride|This will be a mixed combination of 5mg Finasteride with placebo topical preparation to be used once daily.
224265746|NCT02483195|OTHER|Placebo|This will be a mixed combination of 5mg Finasteride with placebo topical preparation to be used once daily.
224265747|NCT05706415|DIAGNOSTIC_TEST|Clinicians will review the suggestions of a hypothetical AI|There is no intervention. Clinicians will review the suggestions of a hypothetical AI
223852424|NCT03274102|BIOLOGICAL|Concomitant administration of EV71 vaccine with EPI vaccines|"1. The investigated EV17 vaccine was manufactured by Sinovac Biotech Co., Ltd.； the recombinant hepatitis B vaccine was manufactured by Shenzhen Kangtai Biological Products Co., Ltd; the Group A meningococcal polysaccharide vaccine was manufactured by Wuhan Institute of Biological Products Co., Ltd.~2. The primary vaccination schedule of hepatitis B vaccine includes 3 doses with a schedule of 0,1,6 month, and subjects only receive 3rd vaccination in this study; the primary vaccination schedule of Group A meningococcal polysaccharide vaccine includes 2 doses with 3 months interval between doses, and subjects only receive 1st vaccination in this study"
223852425|NCT03274102|BIOLOGICAL|Single injection of EPI vaccine|"1. The recombinant hepatitis B vaccine was manufactured by Shenzhen Kangtai Biological Products Co., Ltd; the Group A meningococcal polysaccharide vaccine was manufactured by Wuhan Institute of Biological Products Co., Ltd.~2. The primary vaccination schedule of hepatitis B vaccine includes 3 doses with a schedule of 0,1,6 month, and subjects only receive 3rd vaccination in this study; the primary vaccination schedule of Group A meningococcal polysaccharide vaccine includes 2 doses with 3 months interval between doses, and subjects only receive 1st vaccination in this study"
223852426|NCT03274102|BIOLOGICAL|EV71 Vaccine only|The investigated EV17 vaccine was manufactured by Sinovac Biotech Co., Ltd.
223852427|NCT00462943|DRUG|Omacetaxine mepesuccinate|"Induction: 1.25mg/m\^2 subcutaneously twice daily for 14 consecutive days, every 28 days.~Maintenance: 1.25mg/m\^2 subcutaneously twice daily for 7 consecutive days, every 28 days.~Response targets during induction vary by chronic myeloid leukemia (CML) subclass (chronic, accelerated, or blast phase). Participants will complete at least one cycle (14 days treatment of a 28 day cycle) of induction therapy before changing to maintenance therapy. Participants not demonstrating evidence of clinical response after 6 induction cycles will be considered for removal from the study."
223852428|NCT05186454|DRUG|Morphine Sulfate|analgesia
223852429|NCT05186454|DRUG|Bupivacaine|Analgesia
223852430|NCT05186454|DRUG|dexamethasone, morphine, midazolam|1 ml containing 2 mg dexamethasone, 50 µg morphine, and 500 µg midazolam
223852431|NCT03166319|DIAGNOSTIC_TEST|MRI, including intracranial vessel wall imaging|MRI/MRA/intracranial high-resolution vessel wall imaging (HR-VWI)
223852432|NCT02929069|BEHAVIORAL|ESTEEM|ESTEEM is a 10-session intervention based on the Unified Protocol, an individually-delivered CBT intervention with efficacy for reducing stress-sensitive mental health disorders (e.g., depression, anxiety) by enhancing emotion regulation skills; reducing avoidance patterns; and improving motivation and self-efficacy for behavior change.
223852433|NCT02929069|BEHAVIORAL|CMHT|CMHT is the current standard of care for LGB individuals who seek mental, behavioral, or sexual health care is LGB-affirmative therapy.The practice of LGB-affirmative therapy is outlined across 21 guidelines published by the American Psychological Association.
223852434|NCT02929069|BEHAVIORAL|VCT|Voluntary Counselling and Testing (VCT).
223852435|NCT03042793|BIOLOGICAL|PD-L1 peptide vaccine|PD-L1 peptide given subcutaneously with Montanide ISA-51
223852436|NCT04742855|DIETARY_SUPPLEMENT|Probiotics|Study product is packaged as powders in a sachet. Participants and their parents will be instructed to dissolve the powder in water or milk, and to drink it in the morning and/or evening.
223852437|NCT04977960|DRUG|Potassium Canrenoate|potassium canrenoate for 7 days in addition to maximal medical treatment
223852438|NCT01845896|BEHAVIORAL|Training|
223852439|NCT01644162|DEVICE|iVAPS ventilation|3 months of ventilation on iVAPS mode
223852440|NCT04347499|OTHER|CaCBT based guided self help using Khushi aur Khatoon Manual|CaCBT based guided self help using the manual named Khushi Aur Khatoon in the intervention arm
223852441|NCT02631499|PROCEDURE|TACE|TACE is performed 4-6 weeks after hepatectomy. Epirubicin and lipiodol are used in TACE.
223852442|NCT02631499|DRUG|Epirubicin|Epirubicin is a chemotherapy drug used in TACE
223852443|NCT02631499|DRUG|lipiodol|lipiodol is a kind of embolization material used in TACE
223852444|NCT06182319|DRUG|Gastrografin|Administration of WSC (Gastrografin) 2 hours after placement of NGT.
223852445|NCT06182319|DRUG|Saline|Administration of Saline 2 hours after placement of NGT.
223852446|NCT06182319|PROCEDURE|SBO Treatment Without NG Tubes|Patients who decline to have NG tubes placed will be enrolled and followed with the same outcomes protocol as the other patients in the trial
223852447|NCT04164563|DEVICE|Even-Up|Orthotic shoe lift worn on contralateral foot to increase leg length
223852448|NCT01025869|DEVICE|Cinatra™ Corolimus Eluting Coronary Stent System|Stent implantation
223852449|NCT05092412|RADIATION|Low-dose radiotherapy|The LDRT deals with primary tumour in a 15 Gy of 5fractions over five days, starting from Day 1 in the first cycle.
223852450|NCT05092412|DRUG|Durvalumab|Durvalumab 1500 mg intravenous infusion, started to be used simultaneously with chemotherapy at week 0 and continued after chemotherapy.
223852451|NCT05092412|DRUG|Etoposide, and cisplatin/carboplatin|Starting from week 0, the dose of etoposide + carboplatin or cisplatin in the study will not exceed the dose for specific indications in the product instructions (etoposide \[80 to 100mg/m2\] via intravenous infusion and carboplatin \[ The area under the curve (AUC) is 5-6\] by intravenous infusion or cisplatin \[75-80 mg/m2\] by intravenous infusion), using up to 4 cycles. The choice of platinum drugs is at the discretion of the investigator.
223852452|NCT04757103|PROCEDURE|Resection of the retrorectal tumor|Surgical resection of the retrorectal mass
223852453|NCT02999581|DIETARY_SUPPLEMENT|C4 Extreme, C4 Extreme (without Advantra Z)|
223852454|NCT06650787|OTHER|Ultrasound was used to locate the end of the gastric tube|"1. Inform the family of the purpose and method of using bedside ultrasound to guide the placement of the gastric tube, and determine the position of the end of the tube.~2. The ultrasound machine was connected to the power supply and placed on the right side of the patient.~3. Select the appropriate type of gastric tube and measure the length of the indwelling gastric tube by nursing staff before inserting the tube.~4. Nurses who had been trained in ultrasound performed ultrasound judgment on the neck and abdomen of the children. Sonographers, intensive care physicians and nursing staff jointly judged the ultrasound images.~5. Conventional judgment method was used to determine the position of gastric tube~6. Bedside chest radiography, with results obtained by a radiologist.~7. Keep your child safe at all times."
224265748|NCT04132115|DRUG|Piperacillin/tazobactam|Therapeutic drug monitoring (TDM) of this antibiotic plasma concentration
224265749|NCT04132115|DRUG|Meropenem|Therapeutic drug monitoring (TDM) of this antibiotic plasma concentration
224265750|NCT04132115|DRUG|Daptomycin|Therapeutic drug monitoring (TDM) of this antibiotic plasma concentration
224265751|NCT04132115|DRUG|Ceftobiprole|Therapeutic drug monitoring (TDM) of this antibiotic plasma concentration
224265752|NCT04132115|DRUG|Linezolid|Therapeutic drug monitoring (TDM) of this antibiotic plasma concentration
224265753|NCT04132115|DRUG|Vancomycin|Therapeutic drug monitoring(TDM) of this antibiotic plasma concentration
224265754|NCT04132115|DRUG|Fluconazol|Therapeutic drug monitoring (TDM) of this antifungal plasma concentration
224265755|NCT04132115|DRUG|Acyclovir|Therapeutic drug monitoring (TDM) of this antiviral plasma concentration
224265756|NCT04132115|DRUG|Gentamicins|Therapeutic drug monitoring (TDM) of this antibiotic plasma concentration
224265757|NCT04132115|DRUG|Amikacin|Therapeutic drug monitoring (TDM) of this antibiotic plasma concentration
224265758|NCT04132115|DRUG|Ganciclovir|Therapeutic drug monitoring (TDM) of this antiviral plasma concentration
224265759|NCT02488057|DRUG|Liraglutide|Active comparator. See arm descriptions.
224265760|NCT02488057|BEHAVIORAL|Weight loss|Active comparator. See arm descriptions.
224265761|NCT03318757|DRUG|Bupivacaine Extended Release Liposome Injection|Bupivacaine Extended Release Liposome Injection (Exparel TM) 133 mg diluted in 10ml of normal saline (13.3 mg/ml) will be injected with a 25 gauge needle directly into the gingiva surrounding the surgical site at the conclusion of surgery.
224265762|NCT03318757|DRUG|Bupivacaine HCl|10ml of Bupivacaine HCl 0.5% will be injected with a 25 gauge needle directly into the gingiva surrounding the surgical site at the conclusion of surgery.
224265763|NCT05496192|DRUG|Nivolumab/rHuPH20|Specified dose on specified days
224265764|NCT05496192|DRUG|Nivolumab|Specified dose on specified days
224265765|NCT01907048|BEHAVIORAL|Rivaroxaban (Xarelto, BAY59-7939)|Survey to measure physician awareness and understanding of the key messages in the prescriber guide.
224265766|NCT01907048|BEHAVIORAL|Rivaroxaban (Xarelto, BAY59-7939)|Survey to measure patient awareness and understanding of the key messages in the patient card.
224265767|NCT01661517|BEHAVIORAL|Motivational interviewing and referral to treatment|
224265768|NCT01951209|DRUG|Rifaximin|550mg orally twice daily for 12 weeks
224265769|NCT01951209|DRUG|Placebo|Matched placebo
224265770|NCT04898998|DEVICE|Transcutaneous electrical nerve stimulation (TENS)|Surgical patients under general anesthesia were recruited from a medical center. Each patient was randomly assigned to the experimental group (TENS) or control group (routine care).
224265771|NCT04898998|OTHER|routine care|routine care
224265772|NCT00195754|DRUG|divalproex sodium|
224265773|NCT05503992|OTHER|Intervention package|The intervention package will include a mobile device configured with OpenSRP configured to facilitate clinical/service provision and stock management. The intervention also incorporates a training component on OpenSRP with accompanying follow-up supervisory visits for a limited period. Per the theory of changes, these activities will improve CHWs' knowledge and ability to use the platform for clinical care, dispensing, and workflow management, leading to an improved stock of commodities to meet preferred FP needs among last mile women.
224265774|NCT06160180|DRUG|Dexamethasone|Submucosal application
224265775|NCT04738968|DEVICE|Cochlear implant|A cochlear implant is standard care for profoundly deaf persons. It enables hearing through electrical stimulation of the auditory nerve.
224265776|NCT04921696|OTHER|RBC transfusion|RBC was transfused to the infants.
224265777|NCT04921696|OTHER|no-RBC transfusion|RBC was not transfused to the infants.
224265778|NCT03416049|DEVICE|PEMF therapy with a high-power PEMF device|The 20 participants assigned to a high-power PEMF device will treat each Venous Stasis Leg Ulcer (VSLU) area for 10 minutes twice a day.
224265779|NCT03416049|DEVICE|PEMF therapy with a medium PEMF power device|The 20 participants assigned to a medium-power PEMF device will treat each VSLU area for 15 minutes twice a day.
224265780|NCT03416049|DEVICE|PEMF therapy with a low-power PEMF device|The 20 participants assigned to a low-power PEMF device will treat each VSLU area for 30 minutes twice a day.
224265781|NCT03416049|DEVICE|PEMF therapy with the sham PEMF device|The 20 participants assigned to the sham PEMF device will treat each VSLU area for 15 minutes twice a day.
224265782|NCT02034513|DRUG|insulin degludec|Administered once daily, injected s.c. / subcutaneously (under the skin). Dose is individually adjusted.
224265783|NCT02034513|DRUG|insulin glargine|Administered once daily, injected s.c. / subcutaneously (under the skin). Dose is individually adjusted.
224265784|NCT02034513|DRUG|insulin aspart|Administered 2-4 times daily injected s.c. / subcutaneously (under the skin). Dose is individually adjusted.
224265785|NCT01969760|BEHAVIORAL|Healthy Families DC Program|A tailored family-based intervention for health promotion goal setting, substance use prevention, and promotion of physical activity
224265786|NCT00564031|DRUG|Femanest|2mg/day
224265787|NCT00564031|DRUG|gestapuran|5mg/day
224265788|NCT00564031|DRUG|placebo|daily
224265789|NCT00564031|DRUG|Femanest plus Gestapuran|combined daily
224265790|NCT00913276|DRUG|Propofol|
224265791|NCT00913276|DRUG|Sevoflurane|
224265792|NCT04089462|BEHAVIORAL|"Five sessions per period - Two sessions per period"|"Period 1: 5 exercise sessions on 5 consecutive days (4 min anaerobic exercise and 30 min aerobic exercise per session)~Period 2: 2 exercise sessions within a 5-day period (10 min anaerobic exercise and 75 min aerobic exercise per session)"
224265793|NCT04089462|BEHAVIORAL|"Two sessions per period - Five sessions per period"|"Period 1: 2 exercise sessions within a 5-day period (10 min anaerobic exercise and 75 min aerobic exercise per session)~Period 2: 5 exercise sessions on 5 consecutive days (4 min anaerobic exercise and 30 min aerobic exercise per session)"
224265794|NCT00481169|DRUG|Bazedoxifene Acetate (TSE-424)|
224265795|NCT05315791|PROCEDURE|different methods for maxillary sinus floor elevation|a: 0\~3mm+ground into pieces; b: 0\~3mm+replace the bone; c: 0\~3mm+turn inward to hold up the membrane; d: 3\~5mm+ground into pieces; e: 3\~5mm+replace the bone; f: 3\~5mm+turn inward to hold up the membrane
224265796|NCT02985749|DRUG|Intranasal Oxytocin|This study is examining the short-term efficacy and tolerability of intranasal oxytocin for the treatment of social impairment in youths and adults with high-functioning ASD (HF-ASD).
224265797|NCT03735706|RADIATION|Radiation dose reduction|The radiation dose is is different between groups
223852455|NCT06650787|OTHER|Conventional placing nasogastric tube group|"1. Choose the appropriate type of gastric tube, and measure the length of the indwelling gastric tube by the nursing staff before the tube insertion.~2. The gastric tube was inserted by the conventional blind insertion method.~3. The conventional judgment method was used to determine the position of the gastric tube.~4. Bedside chest radiography, with results obtained by a radiologist.~5. Keep your child safe at all times."
223852456|NCT05934773|DEVICE|KineAssist robotic treadmill|"A formal standardization procedure will be used. Prior to testing, the participant's weight, height, age, blood pressure, and resting heart rate will be recorded. Each session will take place over a 1 hour period. All of our participants will have 1 evaluation sessions prior to the training sessions (overground) and 1 evaluation sessions at the end of the training sessions (overground).~Each participant will have the training sessions up to 3 times each week. The total number of training sessions would be 12-16 sessions (based on duration of stay) of robotic treadmill training for, distributed equally over each specific training modality (Endurance x 4, Strength x 4, Speed x 4, and Dynamic Balance x 4)."
223852457|NCT02158065|OTHER|Coaching program|The coaching program consists of a (1) Step counter used as a coaching activity monitor to collect number of steps walked by the patients and (2) the Linkcare System, a mobile phone or tablet PC placed in the patient's home to collect data from the step counter. The system will set a daily activity goal for the patient based on achieved activity levels which will be measured by the step counter. Patients will also receive feedback, motivational and educational messages and direct calls from the coaching team at each institution.
223852458|NCT06191406|DIAGNOSTIC_TEST|6 minute walk test|Test for physical functions and cognitive functions
223852459|NCT06091436|DRUG|GenSci094|On the morning of day 2 or 3 of the menstrual cycle (Stimulation Day 1), a single SC injection of 150 μg or 100μg (0.5 mL) GenSci094 was administered in the abdominal wall.
223852460|NCT06091436|DRUG|Placebo RecFSH / follitropin alfa|powder-injection, but without the active ingedient, SC injection . Daily SC injections were started on Stimulation Day 1 and continued up to and including Stimulation Day 7.
223852461|NCT06091436|BIOLOGICAL|Biological: RecFSH / Follitropin alfa (Days 1 to 7)|Daily SC injections with 150IU or 225IU recFSH were started on Stimulation Day 1 and continued up to and including Stimulation Day 7.
223852462|NCT06091436|DRUG|Placebo GenSci094|Pre-filled syringe containing an identical solution when compared to GenSci094. On the morning of day 2 or 3 of the menstrual cycle (Stimulation Day 1), a single SC injection was administered in the abdominal wall.
223852463|NCT06091436|BIOLOGICAL|RecFSH / Follitropin alfa (Days 8 to hCG)|From Stimulation Day 8 onwards a daily SC dose 75IU～300 IU recFSH was administered up to and including the Day of hCG.
223852464|NCT06091436|DRUG|Ganirelix|On Stimulation Day 5 a daily SC injection of 0.25 mg was started, which continued up to and including the day of hCG
223852465|NCT06091436|BIOLOGICAL|hCG|When 3 follicles \>= 17 mm were observed by USS, a single dose of 10,000 IU/USP hCG was administered; or, for those at risk for Ovarian Hyperstimulation Syndrome (OHSS), a lower dose of 5,000 IU/USP
223852466|NCT06091436|DRUG|Progesterone|On the day of OPU, luteal phase support was started by administering micronized progesterone of at least 400 mg/day vaginally, and 40mg/d oral, which continued for at least 6 weeks, or up to menses.
224265798|NCT03735706|OTHER|Contrast media volume reduction|Contrast media volume is different between groups
224265799|NCT03735706|RADIATION|Unenhanced slice|One unenhanced slice at the level of the portal vein will be added to the protocol before administration of contrast media. It will only take a minute to perform this extra slice. The patient does not have to visit the department a second time and no (extra) contrast is needed for this slice.
224265800|NCT03735706|DIAGNOSTIC_TEST|Weight|A weighing scale is used to measure a patients body weight right before the scan.
224265801|NCT04097444|BIOLOGICAL|Bevacizumab|Given IV
224265802|NCT04097444|DRUG|5-fluorouracil|Given IV
224265803|NCT04097444|DRUG|Leucovorin calcium|Given IV
224265804|NCT04097444|DRUG|Irinotecan hydrochloride|Given IV
224265805|NCT04097444|DRUG|Oxaliplatin|Given IV
224265806|NCT04097444|DRUG|Capecitabine|Given PO
224265807|NCT03119662|DRUG|Visipaque|100 mL iodixanol (Visipaque Injection 320 mg I/mL), followed by a 10 mL saline flush to ensure delivery of the full dose of Visipaque.
224265808|NCT03119662|DRUG|Placebos|100 mL saline, followed by a 10 mL saline flush.
224265809|NCT00836862|OTHER|Biologic specimens|Banking of serum, DNA and tissue
224265810|NCT00510393|DEVICE|XIENCE V everolimus eluting coronary stent system|
224265811|NCT00510393|DEVICE|MULTILINK VISION coronary stent system|
224265812|NCT04544800|DEVICE|Use of Splint for UADT Visualization|The use of a splint to assist the patient and the surgeon with UADT procedures.
224265813|NCT01682187|DRUG|LY2157299|Administered orally
224265814|NCT01682187|DRUG|Lomustine|Administered orally
224265815|NCT00031954|DRUG|carboplatin|
224265816|NCT00031954|DRUG|gemcitabine hydrochloride|
224265817|NCT00031954|DRUG|paclitaxel|
224265818|NCT02465892|BEHAVIORAL|Pillars4Life|The Pillars4Life program will guide participants through activities that will help to identify stress and anxiety triggers, plan ways to cope with the stress of life and cancer, manage anxiety, deal with chronic pain, and balance competing priorities in life.
224265819|NCT05452213|DRUG|Ribociclib|"All patients will receive ribociclib in combination with standard endocrine therapy according to the current SmPC and local in-house standard.~Ribociclib will be administered once daily for 21 consecutive days followed by 7 days off treatment (28-day cycle). The daily dose is 600 mg/day.~Ribociclib and standard of care endocrine treatment will be prescribed and administered according to investigator's discretion."
224265820|NCT06482606|OTHER|Flickering Checkerboard Stimulation|This visual stimulation is a succession of alternating black and white squares on a small monitor in the scanner, the black and white checkerboard creates the effect of flickering lights.
224265821|NCT04581122|PROCEDURE|Lymphadenectomy|Patients with ground glass nodules smaller than 3cm and with more than 50%solid components would randomly assigned to selective lymphadenectomy group or systematic lymph node dissection group
224265822|NCT00347048|DRUG|tacrolimus|oral
224265823|NCT00347048|DRUG|Placebo|oral
224265824|NCT00660660|DRUG|Esomeprazole|Nexium 20 mg administered once daily as 22.3 mg of esomeprazole magnesium hydrate
224265825|NCT00660660|DRUG|Placebo|once daily
223852467|NCT06614972|DEVICE|Balloon-expandable drug-eluting stent|Balloon-expandable drug-eluting stent (BDES) is the device comprises of a balloon expandable sirolimus eluting stent and a delivery catheter that features a rapid exchange catheter design with a semi-compliant balloon located at its distal end.
223852468|NCT01960803|RADIATION|Intraoperative Electron Radiotherapy|Intraoperative Electron Radiotherapy (IOERT) is delivered after completion of the lumpectomy and sentinel node procedure.
223852469|NCT06700993|BEHAVIORAL|Treatment as Usual in Collaborative Care or Integrated Behavioral Health|Treatment as Usual will be whatever primary care and behavioral health services are standardly implemented for adolescents or young adults experiencing suicidality
223852470|NCT06700993|BEHAVIORAL|Connections model|The Connections model applies the Aeschi Model of suicide care to Collaborative Care or other Integrated Behavioral Health by centering the patient's clinical narrative, focusing treatment on the patient's unique drivers of suicide, and maximizing collaboration while maintaining the standards of suicide assessment and management expected by accrediting bodies.
223852471|NCT06712524|PROCEDURE|Breast-conserving plastic surgery|The commonly used breast conserving plastic surgery includes tennis racket, bat wing, V/J breast plasty, Grisotti and so on.
223852472|NCT06712524|PROCEDURE|Traditional breast surgery|Traditional breast surgery
223852473|NCT06714500|DEVICE|LuxValve PLlus|The LuX-Valve (Jenscare Biotechnology) is a radial force-independent orthotopic TTVR device. The feasibility and efficacy of this device have been reported by several studies (11-13). However, this valve was implanted through right atrial access, where a small incision of the right chest and right atrium is needed. The LuX-Valve Plus valve replacement system is the second-generation version of the LuX-Valve and can be implanted through the jugular vein.
223852474|NCT06713512|OTHER|No intervention|No Intervention
223852475|NCT06714175|BEHAVIORAL|Lower Limb Strength Training Program with Visual Feedback|This lower limb explosive strength training system integrates visual feedback games and is equipped with angle and force sensors to simultaneously output the power of the left and right legs, as well as maximum explosive force and pushing force. Users can immediately understand the balance of leg strength and make adjustments, making it particularly suitable for the elderly to improve lower limb strength or for rehabilitation training. The gamification of the system enhances the fun of training, while data quantification allows progress tracking, making the training more precise and effective. Additionally, after the game ends, data can be exported to Excel for further analysis to identify issues in the pushing process and optimize the training plan.
223852476|NCT06713850|DEVICE|Shockwave balloons|To evaluate the effectiveness and safety of the Shockwave intraperipheral shockwave catheter system in peripheral arterial angioplasty.
223852477|NCT06713473|OTHER|Rehumanized Intervention|"Participants will:~1\. be provided with a lay summary of an ostensible research article that used quantitative and qualitative data to capture the experiences of feeling less than human and mechanisms for reclaiming human identity. The summary will reveal general themes of humanness based on participant responses including body and soul awareness, agency, connection, and creativity.~1. write a 30-minute reflective essay on how did the rehumanization efforts described in the survey make people feel more human? where they will be encouraged to use examples from their own lives~2. asked to create videos based on the insights shared in the essays. The researchers will explain, We would like to record you reading your essay on camera. We believe it would be especially impactful for clinicians developing these interventions to hear directly from someone who has recently navigated similar experiences."
223852478|NCT06713473|OTHER|Control Intervention|"Participants will:~1\. be provided with a lay summary of an ostensible research article that used quantitative and qualitative data to capture the experiences of political attitudes and routes to political sophistication. The summary will reveal general themes of political sophistication based on participant responses including gathering information through diverse news outlets, analyzing policy and legislation, and participation in civic engagement~1. write a 30-minute reflective essay on how did the political efforts described in the survey refine political attitudes? where they will be encouraged to use examples from their own lives~2. asked to create videos based on the insights shared in the essays. The researchers will explain, We plan to take excerpts of what you write here and share it with future voters to aid in developing political attitudes."
223852479|NCT06713473|DIAGNOSTIC_TEST|Clinical Interview|Self-Injurious Thoughts and Behaviors Interview-Short Form (SITBI-SF). Participants will complete an in-person interview featuring 72-items about their history of self-injury and suicidal behaviors. This interview includes 6 yes/no style questions about suicidal thoughts, suicidal plans, suicidal gestures, suicidal attempts, nonsuicidal self-injury thoughts, and nonsuicidal self-injury. Each category that is endorsed, across the lifetime, has follow up questions surrounding times, duration, intensity, severity, type, and if medical attention was sought. This interview has sound psychometric properties.
223852480|NCT06713473|OTHER|Self-Report Measures|Depressive Symptom Index - Suicidality Subscale (DSI-SS). Patient Health Questionnaire-8 (PHQ-8). Interpersonal Needs Questionnaire (INQ). Self-Dehumanization Scale (SDS).
224076083|NCT06345937|BEHAVIORAL|Behavioural Experimental: guidelines-based physical activity and healthy eating|"Behavioural Experimental: guidelines-based physical activity:~Through a combination of exercise trainer-led in-person and virtual sessions, as well as counselling for independent aerobic exercise, participants will be guided to achieve 150 weekly minutes of moderate-intensity aerobic activity and twice weekly whole-body muscle strengthening.~Behavioural Experimental: guidelines-based healthy eating:~One-on-one phone/virtual counselling from a registered dietitian to change dietary habits to be in line with Canada's Food Guide."
224076084|NCT06345937|BEHAVIORAL|Behavioural: Stretching exercise|Twice weekly virtual instructor-led whole-body stretching.
224076085|NCT06362369|DRUG|Alintegimod|Alintegimod will be provided in bottles of 30 softgel capsules for oral administration
224076086|NCT06362369|DRUG|Ipilimumab|Ipilimumab (Yervoy) will be administered via IV
224076087|NCT06362369|DRUG|Nivolumab|Nivolumab (Opdivo) will be administered via IV
224076088|NCT04441905|OTHER|Placebo|One time 60-minute IV infusion of lyophilized placebo for SAR440894
224076089|NCT04441905|BIOLOGICAL|SAR440894|One time 60-minute IV infusion of SAR440894 monoclonal antibody (IgG1) directed against the E2 envelope protein of chikungunya virus
224265826|NCT02941939|OTHER|Hyperbaric chamber|
224265827|NCT02941939|OTHER|Ambient pressure|
224265828|NCT00566657|BIOLOGICAL|riferminogene pecaplasmid|"Formulation: 5 ml glass vials containing 2,5 ml riferminogene pecaplasmid~Route: intramuscular (IM) injection of 2.5 mL in the ischemic leg to be treated"
223852481|NCT06713473|OTHER|Blood Draw|Five milliliters of blood will be drawn before and after study interventions for the quantification of plasma oxytocin concentrations by certified phlebotomists. Samples will be collected into chilled EDTA tubes, inverted ten times to mix with anticoagulants, and centrifuged at 1600g for 15 minutes at 4˚C. Cleared plasma will be aliquoted into cryotubes and stored at -80˚C. Consistent with expert recommendations, oxytocin levels will be obtained from the samples diluted 1:4 (i.e., oxytocin can be discarded through plasma proteins when incorporating an extraction step before conducting the enzyme-linked immunosorbent assay \[ELISA\]). Second, to buffer against contrasting concerns, an aliquot of each sample will be analyzed for test-retest purposes. Oxytocin concentrations will be measured using a validated commercially available and sensitive ELISA neurophysin kit (Abcam).
223852482|NCT06714084|DRUG|Neoadjuvant Chemotherapy (NACT)|Two cycles of carbonilumab plus TP regimen neoadjuvant chemotherapy will be implemented to patients with advanced cervical cancer
223852483|NCT06714084|DRUG|maintenance therapy|one years of maintenance therapy with carbonilumab alone will be implemented to patients with advanced cervical cancer receiving standard concurrent chemoradiotherapy
223852484|NCT06713109|BEHAVIORAL|Motivational interview techniques|Motivational interviews will be conducted 4 times. As a result of these interviews, the breastfeeding problem or anxiety in the mother will be evaluated and the effectiveness of the interview will be solved.
223852485|NCT06712953|OTHER|the peer assessment group|Students in the peer assessment group were paired (by randomization, on their request) to have a teammate of the same sex before the extremity examination experience. In the following process, the students were asked to perform extremity examinations in line with the specified objectives. Students in the standardized patient group were asked to perform extremity examinations per the specified objectives in standardized patient.
223852486|NCT06711822|DEVICE|Shockplus-10|Patients with coronary artery calcification who are planned to undergo PCI and are deemed in need of ShockPulse-10 treatment by their physicians
223852487|NCT05267977|DRUG|Cephalosporin 1St Generation|
223852488|NCT05267977|DRUG|Aminoglycosides|
223852489|NCT02162446|DRUG|satoreotide trizoxetan|
223852490|NCT00982098|PROCEDURE|BioFeedback; Functional Electrical Stimulation; Pelvic Floor Muscle training exercises|After surgery: physical therapist's assisted pelvic floor muscle biofeedback (15 min/day for 10 days), followed by patient's instruction for pelvic floor muscle training and home based exercised pelvic floor muscle for 10 days. Then pelvic floor muscle biofeedback (15 min/day for 10 days) and functional electrical stimulation of pelvic floor (30 min/day for 10 days).
223852491|NCT03570957|DRUG|MT-2990|MT-2990 solution for injection in vial
223852492|NCT03570957|DRUG|Placebo|Placebo solution for injection in vial
223852493|NCT04844957|DRUG|Vitamin D|Clinical Study
223852494|NCT04844957|DEVICE|Full automatic chemiluminescence measuring instrument|Chemiluminescence immunoassay
223852495|NCT04358549|DRUG|Favipiravir|Favipiravir to be administered as an oral tablet or made into a slurry for subjects who cannot swallow tablets
223852496|NCT04358549|OTHER|Standard of Care|Standard of Care for individual study site as determined by each hospital's protocol
223852497|NCT03895034|DEVICE|Light Adjustable lens (LAL) and Light Delivery Device (LDD)|Eligible eyes will receive Light adjustable lens with Light delivery Device treatments
223852498|NCT05661162|DEVICE|CR 500™ SINGLE-DOSE GEL|CR 500™ SINGLE-DOSE GEL is a hydrogel to be applied to intact skin, useful to attenuate the physiological degeneration of cartilage typical of osteoarthritic processes. The presence of sodium hyaluronate facilitates the movement of joints and tendons for greater mobility and flexibility
223852499|NCT01926002|DRUG|Low-Dose MK-8351|Single administration of low-dose MK-8351.
223852500|NCT01926002|DRUG|High-Dose MK-8351|High-Dose MK-8351 administered as a single inhaled dose.
223852501|NCT01926002|DRUG|Placebo to MK-8351|Single-Dose Matching placebo to high-dose or low-dose MK-8351.
223852502|NCT03479034|OTHER|ScalaMed ePrescription application|Mobile phone application (Android and Apple) for storing electronic prescriptions
223852503|NCT05206890|DRUG|fluzoparib monotherapy or combination therapy|patients with epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer who underwent fluzoparib monotherapy or combination therapy
223852504|NCT03264742|OTHER|Ghrelin|The patients are assigned within the scope of the admission according to emergency to the treatment and clarification on the Stroke Unit of the KSW. There the patients are enclosed in the study and are examined according to the draught on the Stroke Unit within the scope of the complex treatment. The inclusion of the patients occurs after clarification and in the consent of the patients. In the morning after the admission day the decrease of the first blood test occurs within the scope of the blood sample as a matter of routine to be carried out for the Ghrelinbestimmung. Also 48 H occurs after the first withdrawal and 3 months after the stroke a blood sample to the regulation of Ghrelin.
223852505|NCT03923946|BEHAVIORAL|Compassion focused therapy|Compassionate Imagery intervention based on compassionate imagery exercises in The Compassionate Mind Workbook by Irons and Beaumont, 2017
223852506|NCT01118377|DRUG|Capecitabine|Capecitabine was supplied as film-coated tablets.
223852507|NCT01118377|RADIATION|Radiation therapy|Local irradiation using conformal, volume-based delivery techniques. The nominal energy of the X-rays was ≥ 4 MV.
223852508|NCT01553513|OTHER|[18F]-FDG positron emission computed tomography|"Patients will receive 20 mg furosemide and 20 mg butylscopolamine together with 370 MBq FDG. 120 minutes after the FDG application a ECG- and respiratory gated cardial PET acquisition will be performed, followed by a CT calcium scan, which will also be used for attenuation correction.~This will be followed by CT-angiography with the application of 80 ml contrast medium. Patients without betablocker and a heart rate of more than 70 / min will be treated with 50 - 100 mg metoprolol as long as there are no contraindications.~Subsequently, a 3D-mode whole body PET scan will be acquired followed by a low-dose CT transmission scan from the base of the scull to the iliac crest."
224076090|NCT06568315|DIETARY_SUPPLEMENT|Concurrent multiple micronutrient and calcium supplementation|Participants counseled to take United Nations International Multiple Micronutrient Antenatal Preparation (UNIMMAP) multiple micronutrient supplement providing 30 mg elemental iron and calcium supplement providing 500 mg elemental calcium as 1250 mg calcium carbonate together every morning from enrollment through the end of pregnancy
224265829|NCT00566657|BIOLOGICAL|Placebo (for riferminogene pecaplasmid)|"Formulation: 5 ml glass vials containing 2,5 ml placebo~Route: IM injection of 2.5 mL in the ischemic leg to be treated"
223852509|NCT01553513|PROCEDURE|Invasive coronary angiography|ICA is performed via the femoral artery in three projections (RAO 30°, RAO 15° and LAO 45°) and, if necessary, also in further projections. All angiograms are recorded digitally and assessed quantitatively by two experienced readers, who are blinded to the PET/CT results (Quant-Cor, QCA, Siemens Medical Systems, Forchheim, Germany or Digital Cardiac Imaging Systems, Philips, Eindhoven, Netherlands). The mean stenosis of the vessel is assessed in two projections and the percentage of stenosis is calculated for each single segment. Stenoses are localized by means of the AHA (American Heart Association) classification. Occlusions of the vessels are documented and revascularization is performed immediately in patients with acute coronary syndrome (STEMI, NSTEMI).
223852510|NCT01553513|PROCEDURE|Intravascular ultrasound and virtual histology|"During the procedure an intravascular ultrasound will be recorded in grayscale. Radiofrequency raw-data will be collected at the peak of the R-wave and a VH-IVUS data recorder is used to reconstruct a color-coded map. Acquired data will be evaluated with a dedicated software. The grayscale IVUS images will be analyzed frame by frame and used to measure the diameter of the vessel lumen, of the external elastic membrane (EEM) as well as plaque and media thickness (defined as EEM minus lumen). The plaque burden will be calculated.~A VH-IVUS analysis will be performed for each frame. Four plaque components will be color-coded: dense calcium white, the necrotic core red, fatty tissue light green and scar tissue dark green. color fractions are expressed as percentage of the plaque area and percentage of plaque volume.~Lesions will be classified: pathologic intima thickening, fibroatheroma with thin cap, fibroatheroma with thick cap, fibrotic plaque and fibro-calcified plaque."
223852511|NCT01553513|OTHER|Serum biomarkers|"A 20 ml blood sample will be obtained from each patient. The following biomarkers will be assessed: glucose level, HBA1C, cholesterol levels, LDL cholesterol, HDL cholesterol, triglycerides, fibrinogen, factor XIII, plasminogen, complement C3, TNF-alpha, IL-6, CRP, resistin, adiponectin, CD40, 5-lipoxygenase, MMP-9, MMP-1, osteopontin, osteoprotegerin, fetuin, FGF21.~ELISA and/or calorimetric assays will be used for the biochemical analyses of the serum markers."
223852512|NCT01255033|DEVICE|Monitoring of tissular oxygenation|"Equanox: cerebral oxygenation by spectroscopy, near-infrared through forehead and noninvasive devices~Inspectra: tissular oxygenation by spectroscopy, near-infrared through thenar and noninvasive device"
223852513|NCT01505101|BEHAVIORAL|Mindfulness-Oriented Recovery Enhancement|MORE is a multimodal, dual-process group intervention involving mindfulness training, cognitive restructuring, and positive emotion induction. MORE consists of eight, weekly, two-hour group sessions led by a trained therapist.
223852514|NCT01505101|BEHAVIORAL|Conventional Support Group (SG)|The control arm will participate in a time-matched, conventional SG led by a Master's level therapist, discussing topics pertinent to chronic pain and opioid misuse. The SG format is adapted from the support group detailed in the evidence-based, Matrix Intensive Outpatient Treatment manual. The SG consists of eight, weekly, two-hour sessions.
223852515|NCT05289466|RADIATION|Intraoperative Radiotherapy|Intraoperative Radiotherapy (Xoft, 20 Gy single dose)
223852516|NCT05289466|PROCEDURE|Oncoplastic partial mastectomy|Breast Conserving Therapy
223852517|NCT03837028|OTHER|FSFI|Sexual dysfunction was assessed via the self-administered Female Sexual Function Index Questionnaire which was adapted to the Turkish population. This is a 19-item questionnaire that covers six domains: desire; arousal, lubrication, orgasm, satisfaction, and pain. The full score is obtained by adding the six domain scores. FSFI scores range from 2.0 to 36.0, with higher scores indicating better sexual functioning.
223852518|NCT04771793|BEHAVIORAL|new physical restraint protocols|new physical restraint protocols
223852519|NCT01496521|DRUG|Aspirin|100mg qd for 6 months.
223852520|NCT01496521|DIETARY_SUPPLEMENT|Tea Polyphenols|300mg bid for 6 months.
223852521|NCT05990517|BIOLOGICAL|YD01-2022|Human islet cells were isolated and expanded in vitro to generate islets containing all types of pancreatic endocrine cells and possessing comparable function of human islets. These islet cells will be infused into the hepatic portal vein.
224265830|NCT04750681|DIETARY_SUPPLEMENT|Placebo|Subjects orally ingested, with water, one capsule per day (in the evening)
224265831|NCT04750681|DIETARY_SUPPLEMENT|Saffron|Subjects orally ingested, with water, one capsule per day (in the evening)
224265832|NCT01025141|DEVICE|Skeletal anchorage (MINISCREW)|Skeletal anchorage
224265833|NCT01025141|DEVICE|dental anchorage|dental anchorage (reference)
224265834|NCT05270499|DEVICE|Aveir VR Leadless Pacemaker System|This study will utilize real-world data from patients implanted with the Aveir VR Leadless Pacemaker System. No device intervention will be conducted in this study.
224265835|NCT01986725|BEHAVIORAL|standardized care (Intervention I)|During treatment and routine follow-up consultations, patients randomized to standard care will be provided with usual care and a predefined set of additional written information leaflets about supportive care options in the early treatment phase designed for the study.Usual care includes treatment during hospitalization by the gynecologist and the nurses according to the existing guidelines. At each follow-up visit, the gynecologist will conduct a physical examination. The follow-ups include also treatment of adverse effects of the therapy and rehabilitation.
224265836|NCT01986725|BEHAVIORAL|Standardized care + WOMAN-PRO II program (Intervention II)|This intervention is in addition to standard care. Nurse-led follow-up consultations with the WOMAN-PRO II program complementary to physician appointments have the goal to support women's self-management abilities in order to deal with occurring symptoms and related distress. Content of the WOMAN-PRO II program designed for this study is summarized in a handbook for professionals including patient clinical pathways and nurse interventions, supplemented by a patient booklet (paper based and electronic version) with tailored information according to patients' needs. The program includes five consultations with an approximate total duration of two hours.
224265837|NCT01026649|PROCEDURE|Central venous catheterization|Approach the internal jugular vein in a traditional one stage fashion during central venous catheterization
224265838|NCT01026649|PROCEDURE|Central venous catheterization|Approach the internal jugular vein in a 2 stage fashion during central venous catheterization
224265839|NCT03143049|DRUG|PCD|"For PCD, patients will be treated as follows: PO pomalidomide 4mg from D1-21, PO cyclophosphamide 400mg on D1, 8 and 15, and PO or IV dexamethasone 40mg D1, 8, 15 and 22 in a 28-day cycle.~Patients will be assessed every 28 days (+/- 10 days). Patients shall receive the treatment until disease progression, unacceptable toxicity as determined by treating physician, withdrawal of consent or mortality (whichever occurs first)."
224265840|NCT03143049|DRUG|PD|"For PD, Patients will be treated as follows: PO pomalidomide 4mg from D1-21 and PO or IV dexamethasone 40mg D1, 8, 15 and 22 in a 28-day cycle.~Patients will be assessed every 28 days (+/- 10 days). Patients shall receive the treatment until disease progression, unacceptable toxicity as determined by treating physician, withdrawal of consent or mortality (whichever occurs first)."
224265841|NCT04823936|OTHER|core stability training|core stability training program for 30 minutes including Supine abdominal draw in Abdominal draw in with double knee to chest Trunk twist while sitting on medical ball Lying supine on the medical ball and rotating the trunk to the sides Contracting abdominal muscles while lying in a supine position and pulling the limbs upward with arms and legs kept close Bringing up the arms and legs simultaneously in the prone position Bridging with head on medical ball hold this position for 3-5 s then slowly relaxes Bridging while shoulders and hands are on the floor and one leg is raised Lying supine on the medical ball and holding the abdomen in and bringing with one leg up
224265842|NCT04469400|DIETARY_SUPPLEMENT|Low fat diet intensive intervention|education and Compound protein solid beverage
224265843|NCT04469400|OTHER|Low-Carbon Water Diet Intensive Intervention|education and Nutrition bar
224265844|NCT02528045|PROCEDURE|Vitrectomy with scleral shortening|
224265845|NCT05341453|PROCEDURE|Individual physiotherapy (SMA-SOC)|Therapeutic procedures according to the recommended standard (SMA-SOC) will be used in the therapy. Elements of breathing gymnastics, vibration techniques, stretching, eccentric and concentric exercise procedures will be combined. Individual physiotherapy will be conducted on the basis of set goals from the kinesiological examination, it will be adapted to the individuality of the child - his cooperation, fatigue and sleep time.
224265846|NCT05341453|PROCEDURE|Hippotherapy|"HT by CP is an accredited form of hippotherapy, whose methodology is based on the clinical picture of cerebral palsy, but its procedures are applicable to a wider group of children with disabilities. Therefore, investigators anticipate it´s effect for children with SMA.~Based on a special type of examination, this method precisely determines the type / breed of the horse according to the biomechanics of the movement of its back in the step, the position of the child and the neurophysiological function of the back - differentiation or sensorimotor skills. Furthermore, according to the course of therapy, the physiotherapist determines the pace of the horse's step, its length, selects special manual contacts according to the current situation and adjusts the duration of therapy to the client's fatigue.~Therapy will be performed by therapists with professional competence to perform hippotherapy by children with CP."
224265847|NCT05341453|PROCEDURE|Therapeutic grooming|In order to influence the psychomotor development in a comprehensive way, the psychosocial activity of therapeutic grooming will also be included in the study. Its goal is to support children's communication, their interaction with the environment, the ability to establish contact with the horse and the overall emotional support of children with SMA. The purpose of this activity is to clean the horse, its possible guide, stroking and contact with the horse, work from the ground.
223852522|NCT04619914|DRUG|Clomid; Aventis pharma S.AE, Global Napi pharmaceuticals, Cairo, Egypt|CLOMID (clomiphene citrate tablets USP) is an orally administered, nonsteroidal, ovulatory stimulant designated chemically as 2-\[p-(2-chloro-1,2-diphenylvinyl)phenoxy\] triethylamine citrate (1:1)
223852523|NCT04619914|DRUG|letrozole (Femara; Novartis pharma AG, Basle, Switzerland)|Letrozole, or CGS 20267, is an oral non-steroidal type II aromatase inhibitor. It is a third generation aromatase inhibitor like exemestane and anastrozole, meaning it does not significantly affect cortisol, aldosterone, and thyroxine.
223852524|NCT05307614|DRUG|Moksi® 400mg Tablet|Single dose of Moxifloxacin 400 mg Tablet was administered after a 10-hour overnight fast.
223852525|NCT05307614|DRUG|Drug: Avelox® 400Mg Tablet|Single dose of Moxifloxacin 400 mg Tablet was administered after a 10-hour overnight fast.
223852526|NCT00157014|DRUG|Tacrolimus|Oral
223852527|NCT00157014|DRUG|Cyclosporine|Oral
223852528|NCT00157014|DRUG|Mycophenolate mofetil|Intravenous and Oral
223852529|NCT00157014|DRUG|Methylprednisolone|Intravenous
223852530|NCT00157014|DRUG|Prednisone|Oral
223852531|NCT05714735|RADIATION|Cerebral Venography|Cerebral Venography Observation by DSA examinations
223852532|NCT01362491|DRUG|Ibuprofen Sodium|Single-dose of ibuprofen sodium tablets (equal to 400 mg ibuprofen)
223852533|NCT01362491|DRUG|Standard Ibuprofen|Single-dose of standard ibuprofen tablets (400mg)
223852534|NCT01362491|DRUG|Placebo|Single-dose of placebo
223852535|NCT04710017|DRUG|Tranexamic acid|will be given Tranexamic acid at 500 mg four times daily (2 g/day) during the bleeding episodes for 5 days. The dose is 250 mg.
223852536|NCT04710017|DRUG|Medroxyprogesterone Acetate 150 MG/ML|will be given MPA at 150 mg once intramuscular injection
223852537|NCT04296513|DIAGNOSTIC_TEST|High-Definition white light endoscopy.|evaluation of the gastric mucosa with high-definition white light endoscopy (EG-29i10 gastroscope and EPKi7010 video processor). The endoscopy images will be seen on a 27inch, flat panel, high definition LCD monitor (Radiance™ ultraSC-WU27-G1520 model) by
223852538|NCT04296513|DIAGNOSTIC_TEST|High-definition magnification with digital chromoendoscopy.|Subject will be evaluated by upper endoscopy with the OE System (EPK-i7010 HD Video Processor and MagniView™ EG-2990Zi Video Gastroscope) with intravenous sedation in a standardized manner. This technique involves the use of a distal black rubber hood (OE-A58; Pentax) at the tip of the endoscope, to fix the distance between the tip of the endoscope and the gastric mucosa at 2 mm. The OE System will be used in mode 1 and mode 2 without optical magnification, to obtain an overview of the gastric body and identify any gross changes in the mucosa, then optical magnification will be implemented.
223852539|NCT02032719|BEHAVIORAL|smartphone-assisted health coaching|smartphone with software provides self monitoring of exercise, diet and stress reduction; provision of timely reminders; photo-journaling of meals; secure text messaging
223852540|NCT02032719|BEHAVIORAL|Lifestyle counseling|Lifestyle counseling
223852541|NCT02780245|DRUG|Tranexamic Acid|At 20 minutes preoperatively, TXA of 20 mg/kg was administered in Z Solution (500•0 ml normal saline containing a prophylactic antibiotic 1•0 g).
223852542|NCT02780245|PROCEDURE|Intraoperative Uterine Cooling|Intraoperatively immediately following delivery of the fetus the uterus was been externalized in the usual fashion, and the body of the uterus cephalad to the hysterotomy incision was been wrapped in sterile surgical towels saturated in sterile and iced normal saline. These towels came from a sterile cooling pot set to 30 degrees Fahrenheit. Iced saline-soaked towels was been kept in place for a minimum of 5 minutes and replaced at the discretion of the attending obstetrician until the hysterotomy is closed and the uterus is replaced into the patient's abdomen.
223852543|NCT01384240|DRUG|Proflavine Hemisulfate|3-ml of 0.01% proflavine(derived from dissolving 10 mg proflavine hemisulfate USP in 100 ml sterile water)
223852544|NCT04867902|BEHAVIORAL|Positive Psychology-Motivational Interviewing Intervention|Participants will receive a written treatment manual with detailed information about each topic. The intervention consists of 10 weekly phone sessions (30 minutes each). Each session includes a new psychological skill designed to increase positive emotions experienced during physical activity, a motivational skill designed to boost physical activity, and setting a physical activity goal for the next week using information from the Fitbit. A motivational interviewing approach will be used for all topics.
223852545|NCT02787161|DEVICE|Hemodiafiltration|High volume online HDF
223852546|NCT02787161|DEVICE|Hemodialysis|High-flux HD
223852547|NCT05583539|DIAGNOSTIC_TEST|Thromboelastography|Thromboelastography is a viscoelastic test that measures the dynamics of blood clotting on whole blood samples.
223852548|NCT00568659|PROCEDURE|specific elastance|The investigators study the specific lung elastance in ALI/ARDS patients in supine and prone position.
223852549|NCT03903081|DRUG|HEC110114 tablet|administered orally once daily
223852550|NCT03903081|DRUG|Placebo Oral Tablet|Placebo will be administered orally at a dose and frequency matched to HEC110114
223852551|NCT05051449|DRUG|Ketamine Hydrochloride|Ketamine will be administered by a nurse in a 2-week treatment phase, during which participants will receive six IV infusions of 0.5 mg/kg (over 40-50 minutes) ketamine three times per week. Infusion days for patients will be on Mondays, Wednesdays, and Fridays, +/- 1 day. Ketamine infusions will take place at the UMB General Clinical Research Center (GCRC). The GCRC nurse will deliver ketamine within a private exam room. The infusions will last 40-50 min, and the participant will be observed by the GCRC clinical staff for 2 hours post-infusion. Vital signs will be monitored throughout the treatment; specifically, blood pressure, pulse ox and heart rate will be checked prior to treatment, q20 minutes during infusion, and q30-60 minutes after infusion for up to three hours.
223852552|NCT05355116|DEVICE|Physiolab S1|A cryocompression device capable of circulating ice-water through a cuff at 6-12℃ with either a static pressure of 25mmHg or dynamic pressure of 25-50 mmHg or 25-75mmHg. The lowest temperature setting, and highest pressure setting will be used for this study.
223852553|NCT05355116|DEVICE|Breg Vpulse|A cryocompression device capable of circulating ice-water through a cuff at no lower than 5.5℃ with a dynamic peak pressure of 50 mmHg. The temperature of the ice-water, and the applied pressure, is not modifiable by the user.
224265848|NCT05141474|BIOLOGICAL|NEXTGEN-TIL|"NEXTGEN-TIL product is a cellular investigational product comprising a live cell suspension of autologous tumor-infiltrating lymphocytes derived from the patient's own tumor.~Each dose contains at least 5 x 10\^8 total viable lymphocytes, and a maximum of 1.11x10\^11. It will be administered IV on Day 0 (24h after the last dose of Fludarabine)."
224265849|NCT05141474|DRUG|Non-myeloablative Lymphodepletion (NMA-LD) Regimen|Patients will receive a NMA-LD chemotherapy based on Cyclophosphamide 60 mg/kg IV (once daily on Days -5 and -4) and Fludarabine 25 mg/m2 IV (once daily on Days -5 to -1).
223852554|NCT05355116|DEVICE|Aircast Cryo/Cuff|A cryocompression device capable of circulating ice-water through a cuff at an undefined, non-modifiable temperature with a static pressure that is also undefined and non-modifiable. The device will be applied as per the manufacturer's instructions, which will represent its maximum capability.
223852555|NCT05355116|DEVICE|GameReady|A cryocompression device capable of circulating ice-water through a cuff at 1-12℃ with a dynamic pressure of 5-15 mmHg, 5-50 mmHg, or 5-75 mmHg. The lowest temperature setting, and highest pressure setting will be used for this study.
223852556|NCT05355116|DEVICE|Physiolab Gel Therapy Wrap|A cryocompression cuff that applies an undefined, non-modifiable temperature with a static pressure that is also undefined and non-modifiable. The device will be applied as per the manufacturer's instructions, which will represent its maximum capability.
223852557|NCT06165731|BEHAVIORAL|Diaphragmatic Breathing Exercises|Mindful deep breathing cycle comprised of a 3-second inhale causing abdominal wall movement followed by a 5-second exhale, which will be completed for a total of 10 minutes of daily exercise
223852558|NCT06165731|BEHAVIORAL|Bladder Hygiene Education|Educational handout on bladder health and hygiene with recommendations endorsed by the International Urogynecologic Association
223852559|NCT06221332|OTHER|% 0.25 bupivakain 20cc|Pregnant women in group S will be given 0.25% bupivacaine, 10 cc on each side.
223852560|NCT06221332|OTHER|20 cc saline|Pregnant women in Group K will be given 10 cc of saline on both sides.
223852561|NCT02491736|DRUG|Ketoprofen|2.5% ketoprofen gel
223852562|NCT02491736|OTHER|Placebo|Placebo gel
223852563|NCT02931656|OTHER|Aquatic exercise|The aquatic exercise program will be under the professional guidance of a physiotherapist, with water at a temperature of around 26 to 28°C. The exercise sessions will be executed following the steps: 1) Heating (stretching and flexibility, static method, during 5'); 2) Aerobic exercise (running, displacements and combined movements of arms and legs, with 1minute interval, to 1minute activity and of during 20') 3) Spot exercises (strength / endurance of the upper and lower limbs and abdomen, using the resistance of water for 15') 4) Relaxation (slow walks for 5'). During the sessions of exercises the pregnant women will have heart rate monitored by the frequency meter (Polar Electro OY) to control the intensity of the exercises that will focus on the range of moderate intensity.
223852564|NCT01090024|DRUG|BI 671800|BI 671800
223852565|NCT01090024|DRUG|Placebo|Placebo matching BI 671800
223852566|NCT02305485|DEVICE|NeoVas BCS|Subjects receiving NeoVas BCS
223852567|NCT02305485|DEVICE|XIENCE PRIME EECSS|Subjects receiving XIENCE PRIME EECSS
223852568|NCT04886180|DEVICE|Oxiris membrane|Hemofiltration treatment with Oxiris membrane connected to the ECLS circuit for 24 hours.
223852569|NCT04886180|DEVICE|Prismaflex membrane|Treatment by hemofiltration with PrismaFlex ST150 membrane connected to the ECLS circuit for 24 hours.
223852570|NCT04886180|BIOLOGICAL|Blood tests|Blood tests before and just after membrane placement and at H6, H24, H48 and H72 after membrane placement
223852571|NCT01144949|DRUG|silodosin|one silodosin 8 mg capsule orally, once daily, with food for up to 4 weeks
223852572|NCT01144949|DRUG|placebo|one placebo capsule orally, once daily, with food for up to 4 weeks
223852573|NCT02008292|DRUG|Physostigmine|All subjects will receive physostigmine to induce elevated ACh levels in the brain.
223852574|NCT04213222|DRUG|Bevacizumab|bevacizumab combined with chemotherapy
223852575|NCT00003311|BIOLOGICAL|filgrastim|
223852576|NCT00003311|DRUG|cyclophosphamide|
223852577|NCT00003311|DRUG|cytarabine|
223852578|NCT00003311|DRUG|dexamethasone|
223852579|NCT00003311|DRUG|doxorubicin hydrochloride|
223852580|NCT00003311|DRUG|methotrexate|
223852581|NCT00003311|DRUG|vincristine sulfate|
223852582|NCT04166682|BEHAVIORAL|Home-based cardiac rehabilitation|cardiac rehabilitation done at home
223852583|NCT04166682|BEHAVIORAL|Routine care|Routine care and followup
223852584|NCT06421948|DRUG|Linperlisib and chidamide|A combination of linperlisib and chidamide will be administered for 6 cycles in patients responded to treatment.
223852585|NCT06421948|DRUG|cyclophosphamide, doxorubicin/epirubicin, vincristine, and prednisone|A combination of cyclophosphamide, doxorubicin/epirubicin, vincristine, and prednisone (CHOP) will be administered for 6 cycles in patients responded to treatment.
223852586|NCT00831597|DRUG|bendamustine|120 mg/m2 IV, Days 1, 2 of Cycles 1-6
223852587|NCT00831597|DRUG|rituximab|375 mg/m2 IV, Day 1 of Cycles 1-6
223852588|NCT03580967|DRUG|Vortioxetine|Oral pill to be taken daily for 8 weeks, 10 or 20 mg dosage. Participants who cannot tolerate this dose may be reduced to 5mg dose.
223852589|NCT01619943|OTHER|no intervention|clinical follow up
223852590|NCT01619943|OTHER|no intervention|no intervention
223852591|NCT00234143|BEHAVIORAL|Darbepoetin and Filgrastim|Aranesp and Neupogen G-CSF (Neupogen) 300 mcg s.c. twice a week, 3-4 days apart and EPO (Aranesp) 500 mcg s.c. once every 2 weeks until week 24, titrate depending of response
223852592|NCT00234143|DRUG|Darbepoetin|Aranesp EPO (Aranesp) 500 mcg s.c. once every 2 weeks until 24 weeks, titrate depending of response
223852593|NCT02195557|DRUG|Synvisc®|
223852594|NCT00567879|DRUG|Panobinostat|Participants received escalating doses of panobinostat until the maximum tolerated dose (MTD) was reached. The starting dose of panobinostat i.v. was 10mg/m\^2 at days 1 and 8 during a 21-day treatment cycle. The oral panobinostat starting dose was 20 mg twice weekly.
223852595|NCT00567879|DRUG|Trastuzumab|Fixed doses of trastuzumab were given in parallel with panobinostat. Trastuzumab i.v. was given weekly according to the instruction in the package insert.
223852596|NCT04836793|OTHER|Additional biological samples|Peripheral Blood Mononuclear Cell (PBMC) and plasma will be collected
223852597|NCT00602589|DRUG|Levofloxacin oral suspension; Levofloxacin oral solution; and Levofloxacin marketed tablet formulations|
223852598|NCT03552770|DRUG|Bevacizumab|pro-re-nata repeated single or combined intra-vitreous injection of bevacizumab
223852599|NCT00501241|DRUG|ATI-7505|Tablet,placebo, BID
223852600|NCT00501241|DRUG|ATI-7505|ATI-7505 20 mg BID for 4 weeks
223852601|NCT00501241|DRUG|ATI-7505|tablet, 40 mg, BID, $ weeks
223852602|NCT00501241|DRUG|ATI-7505|80 mg ATI-7505, BID for 4 weeks
223852603|NCT00501241|DRUG|ATI-7505|120 mg ATI-7505, BID, for 4 weeks
223852604|NCT02167646|PROCEDURE|Flap including bilateral nerve branches|Two nerve branches are attached with the flap for sensory coverage
223852605|NCT04411446|DRUG|Vitamin D|5 capsules of 100.000 UI Vitamin D orally given all at once. One dose.
223852606|NCT04411446|DRUG|Placebo|5 capsules of containing placebo orally given all at once. One dose.
223852607|NCT02716909|DEVICE|Cervical pessary|The cervical pessary is a silicone device that has been used to prevent SPTB Pessary will be placed between 18 and 23 6/7 weeks gestation, and will be removed during the 37th week of pregnancy (or earlier, if indicated)
223852608|NCT02943655|DRUG|combined contraceptive pills (microcept)|oral combined contraceptive once daily
223852609|NCT02943655|DRUG|medroxyprogesterone acetate (progest)|oral 5 mg medroxyprogesterone acetate daily
223852610|NCT02943655|DRUG|mefenamic acid (ponstan forte)|oral 500 mg mefenamic acid three times per day
223852611|NCT00470626|DEVICE|Celect Vena Cava Filter|Effective filtration of inferior vena cava blood to prevent thromboembolism.
223852612|NCT03645850|DEVICE|Vismed gel Multi 0.3% eye drops|Ophthalmic use. Vismed gel Multi 0.3% eye drops. One to two drops instilled in each eye from 4 to 6 times per day during 84 days of treatment.
223852613|NCT03645850|DEVICE|Vismed Multi 0.18% eye drops|Ophthalmic use. One to two drops instilled in each eye from 4 to 6 times per day during 84 days of treatment.
223852614|NCT00777556|DRUG|DR-104|One 1.5 mg tablet of levonorgestrel for emergency contraception within 72 hours following unprotected sexual intercourse.
223852615|NCT03833102|OTHER|biological analysis|ST types will be determined for all individualized bacterial strains. For all the bacterial strains, RNAs expression will be analyzed at three different growth phases: early exponential phase, mid exponential phase and early stationary phase. Expression of RNAIII and SprD will be evaluated by quantitative polymerase chain reaction.
223852616|NCT01768143|BEHAVIORAL|unexperienced endoscopy nurses|
223852617|NCT01768143|BEHAVIORAL|Experienced endoscopy nurses|
223852618|NCT04137874|DIAGNOSTIC_TEST|eSTROKE model|The eSTROKE model includes an electronic learning module, a full day course with practical teaching of National Institute of Health Stroke Scale and a mobile application which will be used for communication with in-hospital stroke physician
223852619|NCT04137874|OTHER|Control|Conventional prehospital care
223852620|NCT01499108|DRUG|liraglutide|Subcutaneous injection of liraglutide at doses of 0.6, 1.2, and 1.8 mg once daily during the 49 days duration of the study
223852621|NCT02104609|DRUG|Levonorgestrel 1.5mg by mouth once|Levonorgestrel 1.5mg by mouth given on menstrual cycle day 8
223852622|NCT02891629|DEVICE|EyeControl device|Use of device features including control of gestures, use of menus, activation of pre- defined modes and writing full sentences
223852623|NCT00633412|DRUG|Esomeprazole|20mg oral daily
223852624|NCT00633412|DRUG|Ranitidine|150mg oral twice daily
223852625|NCT00633412|DRUG|Esomeprazole|40mg oral tablet daily
223852626|NCT00207844|DRUG|Selenium as sodium selenite|
223852627|NCT01749787|DRUG|PRTX-100 at 1.5 mcg/kg|
223852628|NCT01749787|DRUG|PRTX-100 at 3.0 mcg/kg|
223852629|NCT01749787|DRUG|PRTX-100 at 6.0 mcg/kg|
223852630|NCT01749787|DRUG|PRTX-100 at 12.0 mcg/kg|
223852631|NCT01749787|DRUG|PRTX-100 at 240 mcg|
223852632|NCT01749787|DRUG|Placebo|Placebo administered via infusion once per week for 5 weeks
223852633|NCT01749787|DRUG|PRTX-100 at 420 mcg|
223852634|NCT01061229|DRUG|Homeopathic drug C12|Subjects in the intervention group are instructed to take five globules of the trial drug (potency C12), five times per day for a maximum of five days (5×5×5). The study medication is obtained from DHU (Germany), produced according to the Hahnemannian method. Subjects are asked to stop taking the medication, in agreement with their investigator, if they experience any of a predefined set of proving symptoms
223852635|NCT01061229|OTHER|Placebo|Placebo consists of pure sucrose globules (DHU, Germany) that are not potentiated nor impregnated with alcohol. The administration scheme is identical in the placebo control group to that of the intervention group.
223852636|NCT01194778|DIETARY_SUPPLEMENT|placebo|1 placebo sachet per day containing only sucrose during 12 weeks
223852637|NCT01194778|DIETARY_SUPPLEMENT|vitamin K1|15 µg vitamin K1 per day during 12 weeks
223852638|NCT01194778|DIETARY_SUPPLEMENT|vitamin K2|15 µg vitamin K2 per day during 12 weeks
223852639|NCT01194778|DIETARY_SUPPLEMENT|vitamin K2|30 µg vitamin K2 per day during 12 weeks
223852640|NCT01194778|DIETARY_SUPPLEMENT|vitamin K2|45 µg vitamin K2 per day during 12 weeks
223852641|NCT04417270|DEVICE|Freestyle Libre 14 day CGM system|The FreeStyle Libre 14 day system is a continuous glucose monitoring system consisting of a handheld reader and a sensor worn on the back of the upper arm.
223852642|NCT04417270|DEVICE|Accuchek Inform II platform|The Accu-Chek Inform II system is designed to deliver data with speed and efficiency, helping to provide optimal care. Wireless meter quickly transfers data. The Accu-Chek Inform II system is the first point-of-care blood glucose device to offer truly wireless technology at the meter level.
223852643|NCT02787109|BIOLOGICAL|CTH522-CAF01|CTH522 chlamydia antigen adjuvanted with CAF01 for IM administration
223852644|NCT02787109|BIOLOGICAL|CTH522-Al(OH)3|CTH522 chlamydia antigen adjuvanted with aluminium hydroxide, Al(OH)3 , for IM administration
223852645|NCT02787109|BIOLOGICAL|Placebo|Saline
223852646|NCT00802919|DRUG|Varenicline|Varenicline 1-2 mg/day
223852647|NCT00802919|DRUG|Placebo for varenicline|Placebo
223852648|NCT02294929|PROCEDURE|Atrial fibrillation ablation|Atrial fibrillation ablation using the Arctic Front™ Advance Cardiac CryoAblation Catheter in two balloon sizes (23mm and 28mm) for pulmonary vein isolation
223852649|NCT03646370|DRUG|Tenofovir Alafenamide|Patients with HIV infection who are virally suppressed receiving a tenofovir disoproxil fumarate-based antiretroviral therapy regimen that switched to tenofovir alafenamide without switching any other components of their treatment regimen.
223852650|NCT05358197|OTHER|yoga|laughter yoga
223852651|NCT04602936|DRUG|Solriamfetol|Solriamfetol is a novel DNRI (novel dopamine and norepinephrine reuptake inhibitor) that has recently received regulatory approval for the treatment of excessive daytime sleepiness in individuals with narcolepsy or obstructive sleep apnea.
223852652|NCT04602936|DRUG|Placebo|"A placebo is a substance or treatment which is designed to have no therapeutic value (an inactive compound, i.e. inert, often called a sugar pill)."
223852653|NCT04408274|BEHAVIORAL|Emotional Processing Training|
223852654|NCT04408274|BEHAVIORAL|Placebo Control|
223852655|NCT01568749|DRUG|Paracetamol|Paracetamol
223852656|NCT01568749|DRUG|Paracetamol formulation 1|Paracetamol
223852657|NCT01568749|DRUG|Paracetamol Formulation 2|Paracetamol
223852658|NCT01568749|DRUG|Paracetamol formulation 3|Paracetamol
223852659|NCT01568749|DRUG|Paracetamol formulation 4|paracetamol
223852660|NCT01717794|PROCEDURE|Thunderbeat technology|
223852661|NCT01717794|PROCEDURE|Standard bipolar electrosurgery|
223852662|NCT03174054|PROCEDURE|Biopsy|Biopsies are part of standard procedures in the patients recruited and will not be done due to this study.
224076091|NCT06568315|DIETARY_SUPPLEMENT|Separate multiple micronutrient and calcium supplementation|Participants counseled to take United Nations International Multiple Micronutrient Antenatal Preparation (UNIMMAP) multiple micronutrient supplement (MMS) providing 30 mg elemental iron every morning and calcium supplement providing 500 mg elemental calcium as 1250 mg calcium carbonate every evening from enrollment through the end of pregnancy
224076092|NCT05925049|DRUG|Natalizumab|Administered as specified in the treatment arm.
223852663|NCT04575493|DIETARY_SUPPLEMENT|Crano-cure|Research literatures have revealed that Tribulus terrestris (Gokhro), Vaccinium macrocarpon (karonda), Cuminum cyminum (Zeera sufaid), Rheum emodi (Revand chini) and Piper cubeba (Kabab chini) are important therapeutic plants. Many pharmacological researches have been done on these plants. For instance, antioxidant, antiseptic, anti-microbial, anti-bacterial, anticancer etc. In the above claims and facts, the study is conducted to formulate and evaluate the polyherbal capsule and to find out the most effective combination having anti-bacterial activity.
223852664|NCT04575493|DRUG|Ciprofloxacin 500 mg|Being a standard drug as antibiotic and will be used in Control group.
223852665|NCT01725854|BEHAVIORAL|Relaxation Response training|Behavioral Relaxation Response Training (Benson-Henry Institute Relaxation Response Training) Participants randomized to the intervention group will participate in the six weekly RR sessions. Examples of in-group skill building exercises are mini relaxations, diaphragmatic breathing, introduction to imagery, and eliciting RR through Yoga. Presentations topics include Introduction to Mind/Body Medicine, Introduction to the RR, Experiential RR Sessions, and Introduction to Cognitive Restructuring. Home skill building assignments include relaxation focus practice, an appreciation journal, self-monitoring with Biodots (biosensor technology that helps participants to monitor and regulate their psycho-emotional state), physical activity, balanced nutrition, and progress notes.
223852666|NCT02379546|DRUG|Desflurane|Desflurane will be used to maintain the anesthesia and the dose of desflurane will be adjusted according to the Bispectral İndex Monitoring
223852667|NCT02379546|DEVICE|Bispectral index monitoring|Bispectral index monitoring (BIS XP, A-2000, VERSİON 3.31, Aspect Medical Systems, Newton, Mass, USA)will be used to determine the depth of anesthesia
223852668|NCT01941277|BEHAVIORAL|Current Recommendations Exercise Group|
223852669|NCT01941277|BEHAVIORAL|Intensive Exercise Group|
223852670|NCT02548221|DEVICE|transthoracic echocardiogram|Thoracentesis was performed on patients with large-volume pleural effusions, and TTE was utilized to access the change of heart and lung function before and after this medical procedure.
223852671|NCT01729819|DRUG|Tolterodine tartrate extended release capsules|
223852672|NCT01729819|DRUG|Desmopressin orally disintegrating tablets|
223852673|NCT01729819|DRUG|Placebo orally disintegrating tablets|
223852674|NCT02966743|DRUG|Midazolam|administration of midazolam during spinal anesthesia for target bispectral index 75-80
223852675|NCT02966743|DRUG|Dexmedetomidine|administration of dexmedetomidine during spinal anesthesia for target bispectral index 75-80
223852676|NCT06412406|PROCEDURE|External Oblique Intercostal (EOI) block|EOI block technique A linear ultrasound transducer placed in the sagittal plane between the midclavicular and anterior axillary lines at the level of sixth rib, The transducer was then rotated so the cranial end was directed slightly medially and the caudal end laterally to produce a paramedian sagittal oblique view with a short-axis view of the ribs, The following structures were identified, from superficial to deep: subcutaneous tissue, external oblique muscle, intercostal muscles between ribs, pleura, and lung. The skin entry point for the injection was cranial to the sixth rib level just medial to the anterior axillary line, with ultrasound opaque needle advanced in plane from a superomedial-to-inferolateral direction, through the external oblique muscle hydrodissecting the tissue plane between the sixth and seventh ribs, and then the needle was directed caudally toward the eighth rib. and inject 20 ml volume of (0.25 % bupivacaine).
223852677|NCT06412406|PROCEDURE|Transversus abdominis plane (TAP) block|"TAP block technique:~abdominal skin will be prepared and covered with sterile drapes. The needle can be introduced by multiple punctures along the oblique subcostal line from the xiphoid process towards the anterior part of the iliac crest (18) . Thus, LA will be injected in the TAP along this line provides both upper and lower abdominal wall analgesia. The OSCTAP block more consistently covers L1 dermatome. After negative aspiration, a test injection with 1 ml of 0.9% normal saline will be performed to confirm the needle location. and ingect 20 ml volume of (0.25 % bupivacaine). If the intended sensation will not decreased in surgical dermatomes after 30 min, the patient will be regarded to have a failed block and will be excluded from the study."
223852678|NCT00471640|DRUG|dexamethasone|4 days 5 mg
224076093|NCT04770753|DRUG|Placebo Matching Mitapivat|Tablets
224076094|NCT04770753|DRUG|Mitapivat|Tablets
224076095|NCT02775851|PROCEDURE|Biopsy Procedure|Undergo tumor biopsy
224076096|NCT02775851|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
224076097|NCT02775851|PROCEDURE|Computed Tomography|Undergo CT scan
223852679|NCT06405867|PROCEDURE|delayed cord clamping (> 60 sec)|In the DCC group, cord pulse was checked without allowing clamping. Waited until the cord pulse stopped. It was wrapped in a sterile and warm cloth and dried. The cord was clamped when the pulse stopped. The cord clamping time was noted on the case report form. In DCC, the baby was placed on the mother's legs in cesarean section (C/S) births and on the mother's mons pubis region in normal vaginal births. The baby was administered a routine delivery room neonatal resuscitation program (NRP) by the pediatrician. After cord clamping, the baby was handed over to the pediatric team.
223852680|NCT00666939|DRUG|Gabapentin|Gabapentin 100 mg oral capsule 30 minutes prior to bedtime
223852681|NCT00666939|DRUG|Gabapentin|Gabapentin 250 mg oral capsule 30 minutes prior to bedtime
223852682|NCT00666939|DRUG|Placebo|Matched placebo 30 minutes prior to bedtime
223852683|NCT01426945|GENETIC|protein expression analysis|
223852684|NCT01426945|OTHER|immunohistochemistry staining method|
223852685|NCT01426945|OTHER|laboratory biomarker analysis|
223852686|NCT03646669|BEHAVIORAL|PEF Feedback|Patients in the PEF feedback arm will receive a one-time session including asthma management education, discussion of their asthma symptoms, review of individual PEF results and perception of symptoms, and problem-solving techniques to improve asthma self-management. After the session, the participants in this arm will be able to view in the display of the AM2 device their PEF values and will be instructed to mentally note their actual results with their pre-effort estimated BPF. They will also set a motivational message for themselves that will appear on the device.
223852687|NCT03646669|BEHAVIORAL|Asthma education|General asthma education, AM2 training, and positive counseling, but no discussion linking asthma symptom perception to SMB. Following the session, these participants will use the AM2 to track PEF actual and perceived values twice per day, but they will be blinded to the actual PEF values. Control arm patients will see a standard motivational message appear on the screen of the AM2 device.
223852688|NCT00196365|DRUG|levonorgestrel/EE 0.15/0.03 and EE 0.01 mg tablets|1 tablet daily
223852689|NCT00196365|DRUG|levonorgestrel/EE 0.15/0.03 mg tablets and placebo|1 tablet daily
223852690|NCT02292043|DRUG|HTEA|HTEA
223852691|NCT04936217|OTHER|Data collection|For each patient, the following data will be collected and analyzed: age at operation, sex, Body Mass Index (BMI), ASA score, ASIA score, type of bladder dysfunction assessed by urodynamic evaluation, urinary abnormalities assessed by morphological examination (ultrasound and / or computed tomography) and cystoscopy, creatinine clearance, operative indications, initial mictional mode, surgical assembly, immediate and later complications.
223852692|NCT04936217|OTHER|Interview using a validated questionnaire|A telephone survey will be conducted by means of a questionnaire in order to evaluate the patient's quality of life.
223852693|NCT00101725|DRUG|crofelemer|
223852694|NCT04312776|OTHER|none intervention|
223852695|NCT02678624|OTHER|Treatment according to the Collabri model|The Collabri Model is a complex intervention and consists of a number of treatment modalities. The Collabri Model includes the following elements: A multi-professional approach to treatment including a care manager, scheduled monitoring and review, enhanced inter-professional communication and a structured treatment plan. It further integrates: Recruitment of staff with psychiatric experience, training of general practitioner and care manager, use of instruments for detection and follow-up, education and treatment of the patient, supervision from a psychiatric specialist, guided self-help, patient- and relative involvement and a stepped care approach to treatment where treatment is always commenced on the least invasive and least resource-demanding level.
223852696|NCT04809402|OTHER|remote monitoring after cataract surgery|remote monitoring after cataract surgery
223852697|NCT04127058|DRUG|Iloperidone|Oral Tablet
223852698|NCT03523910|DEVICE|Magnetic Resonance Imaging (MRI) with exercise|MRI scan with a novel exercise device.
223852699|NCT05725889|DEVICE|recation time test|visual-finger tapping and auditory reaction time tests
223852700|NCT01265758|DEVICE|Prolonged telemetric Full Disclosure ECG recording.|Continuous Full Disclosure Telemetric ECG monitoring lasting 14 days
223852701|NCT01432158|BIOLOGICAL|Prevenar 13|This vaccine will be given to healthy adults without prior pneumococcal vaccination.
223852702|NCT01432158|BIOLOGICAL|Pneumovax II|This vaccine will be given to healthy adults without prior pneumococcal vaccination.
223852703|NCT04242758|DRUG|Dapagliflozin 10 MG|SGLT2-inhibitor: Diabetic oral drug with diuretic properties
223852704|NCT04242758|DRUG|Hydrochlorothiazide 12.5mg|Best known thiazide class diuretic.
223852705|NCT02442466|DRUG|Endothelin Receptor B inhibitor BQ788|
223852706|NCT02442466|DRUG|PBS|
223852707|NCT05857436|OTHER|apical periodontitis|Of these patients, 60 patients with AP and extraction indication (due to restorative causes and lesion size) were included in the study
223852708|NCT04414878|DEVICE|VitaFlow™ II Transcatheter Aortic Valve System|VitaFlow™ II Transcatheter Aortic Valve System contains a valve stent-VitaFlow™ Aortic Valve, a delivery system-VitaFlow™ Delivery System, loading tools, and a guide-wire
223852709|NCT01402271|DRUG|carboplatin|
223852710|NCT01402271|DRUG|paclitaxel|
223852711|NCT01402271|DRUG|pazopanib hydrochloride|
223852712|NCT01402271|OTHER|laboratory biomarker analysis|
223852713|NCT01402271|OTHER|pharmacological study|
223852714|NCT03202849|DIETARY_SUPPLEMENT|Vitamin D and A|A single dose of Vitamin A and Vitamin D will be given.
223852715|NCT03202849|DIETARY_SUPPLEMENT|Vitamin D and Placebo|A single dose of Vitamin D plus a placebo will be given.
223852716|NCT06553560|OTHER|Parasternal Block and Recto-İntercostal Fascial Plane Block|Superficial PSB is performed with the patient in the supine position using a high-frequency linear USG probe. The probe is placed longitudinally 2 cm lateral to the sternal border to visualize the T2-T4 intercostal space and to identify the pectoralis major muscle, intercostal muscle, and pleura. 10 ml of 0.25% bupivacaine local anesthetic is administered between the pectoralis major and intercostal muscle using an in-plane approach with a 100 mm needle. In addition, a Recto-Intercostal Fascial Plane Block is performed with a high-frequency linear USG probe. The probe is placed 2-3 cm lateral to the xiphoid so that the rectus abdominis muscle and 6-7th cartilages are visualized. The needle is advanced to the plane between the costal cartilage and the rectus abdominis muscle using the in-plane technique and 1-2 ml of saline is injected. After observing the spread to the target plane, 20 ml of 0.25% bupivacaine is applied. The same process is repeated bilaterally.
223852717|NCT06216730|PROCEDURE|Endoscopic papillectomy|"patients undergoing endoscopic papillectomy will be included and treated according to the study algorithm.~* A papillary adenoma (abnormal tissue growth/ tumour at junction of bile duct \& intestines) will be removed completely by cutting \& removing abnormal tissue growth using a flexible tube containing a camera through the mouth.~* After the procedure you will be admitted in the hospital for at least 24 hours for observation,~* You will be asked to use medications which decrease acid production (PPIs- proton pump inhibitors) in stomach for 2 weeks to decrease the risk of bleeding."
223852718|NCT02165891|DRUG|insertion of a chest drain with urokinase instillation|Other interventions except drainage procedure are the same in both arms
223852719|NCT02165891|PROCEDURE|primary video-assisted thorascopic surgery|
224076098|NCT02775851|PROCEDURE|Magnetic Resonance Elastography|Undergo MRI
224076099|NCT02775851|BIOLOGICAL|Pembrolizumab|Given IV
223852720|NCT04228055|BEHAVIORAL|CLIPP2|Diabetes Prevention Program and Comprehensive Lifestyle Improvement Program with emphasis on a low carbohydrate and Keto diet, physical activity, sleep optimization and stress management.
223852721|NCT03923725|DRUG|Artemether-lumefantrine+ Amodiaquine (AL+AQ)|"AL: Currently available as dispersible tablets containing 20 mg of artemether and 120 mg of lumefantrine, in a fixed-dose combination formulation. The flavoured dispersible tablet paediatric formulation facilitates use in young children.~The dose of artemether-lumefantrine is administered approaching the WHO-recommended target ranges of artemether 5-24 mg/kg and lumefantrine 29-144 mg/kg over 3 days.~AQ: is available as dispersible tablets of 40 mg. The weight-based treatment schedule aims for a dosage of approximately 10mg (4.5-15mg)/kg/day amodiaquine for three days."
223852722|NCT03923725|DRUG|Artemether-lumefantrine + placebo (AL+PBO)|"AL: Currently available as dispersible tablets containing 20 mg of artemether and 120 mg of lumefantrine, in a fixed-dose combination formulation. The flavoured dispersible tablet paediatric formulation facilitates use in young children.~The dose of artemether-lumefantrine is administered approaching the WHO-recommended target ranges of artemether 5-24 mg/kg and lumefantrine 29-144 mg/kg over 3 days.~PBO: Placebo tablets for amodiaquine are identical in size, shape and color to the amodiaquine tablets."
223852723|NCT03923725|DRUG|Artesunate-mefloquine+piperaquine (AS-MQ+PPQ)|"AS: Artesunate will be administered according to an optimised dosing schedule using tablets of 32 or 100 mg artesunate with a dosing target of 4 mg/kg/day.~MQ: Mefloquine will be administered according to an optimised dosing schedule using tablets of 70 or 220 mg mefloquine hydrochloride with a dosing target of 8.3 mg/kg/day.~PPQ: Piperaquine will be administered according to an optimised dosing schedule using tablets of 160 or 500 mg of piperaquine tetraphosphate. The weight-based treatment aims for a dosage of approximately.~* 24 mg/kg/day in patients \<25 kg (range 16.0 - 32.0 mg/kg) piperaquine for three days, thereby approaching the WHO-recommended target range of 20 - 32 mg/kg per day.~* 18 mg/kg/day in patients ≥25 kg (range 15.0 - 29.4 mg/kg) piperaquine for three days, thereby approaching the WHO-recommended target range of 16 - 27 mg/kg per day."
223852724|NCT03923725|DRUG|Artesunate-mefloquine+placebo (AS-MQ+PBO)|"AS: Artesunate will be administered according to an optimised dosing schedule using tablets of 32 or 100 mg artesunate with a dosing target of 4 mg/kg/day.~MQ: Mefloquine will be administered according to an optimised dosing schedule using tablets of 70 or 220 mg mefloquine hydrochloride with a dosing target of 8.3 mg/kg/day.~PBO: Placebo tablets for piperaquine are identical in size, shape and colour to the piperaquine tablets."
223852725|NCT00583843|PROCEDURE|Ultrasound|Ultrasound weekly during initial fields of radiation, and daily during the boost phase.
223852726|NCT00319943|PROCEDURE|Computer-based training for Mild Cognitive Impairment (MCI)|
223852727|NCT03439124|DRUG|ceftobiprole medocaril|"Ceftobiprole medocaril was administered at age-adjusted doses (10, 15 or 20 mg/kg) and infusion durations (2 or 4 hours) every 8 hours. The maximum dose, regardless of body weight, was 500 mg ceftobiprole every 8 hours (maximum total daily dose of 1500 mg ceftobiprole).~After a minimum of 3 days of IV treatment, patients with sufficient improvement in disease signs and symptoms could be switched to an age-appropriate oral antibiotic to complete a total minimum of 7 days and a total maximum of 14 days' antibiotic treatment."
224076100|NCT02775851|PROCEDURE|Positron Emission Tomography|Undergo PET scan
224076101|NCT02775851|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgical resection
224076102|NCT05825001|BEHAVIORAL|Smoking Cessation Intervention|Receive active EFT stimulus
223852728|NCT03439124|DRUG|IV standard-of-care cephalosporin|"Ceftriaxone was administered at 50 to 80 mg/kg IV as a single daily dose, up to a maximum dose of 2 g/day. The actual dose of ceftriaxone within this dose range was determined by the blinded investigator prior to first study drug administration and was not modified during subsequent study days.~After a minimum of 3 days of IV treatment, patients with sufficient improvement in disease signs and symptoms could be switched to an age-appropriate oral antibiotic to complete a total minimum of 7 days and a total maximum of 14 days' antibiotic treatment.~At the discretion of the blinded investigator, patients received vancomycin at a dose of 10 to 15 mg/kg IV every 6 hours, up to a maximum dose of 2 g/day, in addition to the IV standard-of-care cephalosporin when MRSA was suspected or confirmed."
223852729|NCT02049866|DRUG|Denosumab|Denosumab 60mg, administered every 6 months by subcutaneous injection for 36 months
223852730|NCT03686813|DRUG|Sildenafil Citrate|Oral sildenafil, 50 mg
223852731|NCT03686813|DRUG|Placebo Oral Tablet|Placebo
223852732|NCT02709616|BIOLOGICAL|Personalized cellular vaccine|Biological: DC-based cellular vaccine. Subjects will undergo surgical resection and standard 6-week chemo/radiotherapy and cycles of TMZ treatment. They will receive biweekly cellular vaccines.
223852733|NCT02390258|DRUG|10mg XEN-D0103|
223852734|NCT02390258|DRUG|Placebo|
223852735|NCT02390258|DRUG|30mg XEN-D0103|
223852736|NCT02390258|DRUG|60mg XEN-D0103|
223852737|NCT02390258|DRUG|120mg XEN-D0103|
223852738|NCT02390258|DRUG|200mg XEN-D0103|
223852739|NCT02390258|DRUG|150mg XEN-D0103|
223852740|NCT04286165|OTHER|Brief Peer Supported webSTAIR|The BPS webSTAIR program is an online platform where individuals are taught skills in emotion regulation. In this program they will learn how to recognize the emotions they are feeling by assessing their own body language, being attentive to their thought processes, and attempting to replace negative behaviors with positive. Throughout the platform they will engage in written exercises to help them solidify the lessons with their own life experiencing. They will also have the support of peers throughout the program to help them when they need clarification or having a difficult time applying the lesson(s).
223852741|NCT02248025|OTHER|Observational study: No special intervention will be made.|No special intervention will be made, only data will be collected before, and after a passive leg raising and a fluid challenge decided and performed by the attending physician.
223852742|NCT05039606|DRUG|Nedaplatin|Nedaplatin is a second-generation platinum-like derivative, which is a cell cycle non-specific drug, with a mechanism of action and efficacy similar to cisplatin, and a wide anti-cancer spectrum
223852743|NCT05039606|DRUG|Cisplatin|Cisplatin, aka cis-dichlorodiamineplatin, is a platinum-containing anticancer drug
223852744|NCT05395832|BEHAVIORAL|TAU + multicomponent treatment VIRTUAL FIBROWALK + 4 face-to-face sessions at sea|"Group treatment protocol of 12 weekly 60 minute virtual sessions. All sessions include the following ingredients (approx. in the same order):~Pain neuroscience education (15 min.) Cognitive restructuring (15 min.) Mindfulness techniques (15 min.) Physical exercise(15 min.) Treatment as Usual (TAU) 4 face-to-face sessions (1 per mounth) at sea Standard pharmacological treatment usually provided to patients with fibromyalgia."
223852745|NCT05395832|BEHAVIORAL|TAU + multicomponent treatment VIRTUAL FIBROWALK + 4 face-to-face sessions in nature|"Group treatment protocol of 12 weekly 60 minute virtual sessions. All sessions include the following ingredients (approx. in the same order):~Pain neuroscience education (15 min.) Cognitive restructuring (15 min.) Mindfulness techniques (15 min.) Physical exercise(15 min.) Treatment as Usual (TAU) 4 face-to-face sessions (1 per mounth) in nature Standard pharmacological treatment usually provided to patients with fibromyalgia."
223852746|NCT05395832|BEHAVIORAL|TAU + multicomponent treatment VIRTUAL FIBROWALK|"Group treatment protocol of 12 weekly 60 minute virtual sessions. All sessions include the following ingredients (approx. in the same order):~Pain neuroscience education (15 min.) Cognitive restructuring (15 min.) Mindfulness techniques (15 min.) Physical exercise(15 min.) Treatment as Usual (TAU) Standard pharmacological treatment usually provided to patients with fibromyalgia."
223852747|NCT03945942|DEVICE|Near infrared spectroscopy with INVOS device|somatic and cerebral oximetry by INVOS in pediatric liver transplantation
223852748|NCT03945942|DEVICE|Near infrared spectroscopy with Foresight device|somatic and cerebral oximetry with Foresight device in pediatric liver transplantation
224076103|NCT05825001|BEHAVIORAL|Smoking Cessation Intervention (control)|Receive control EFT stimulus
223852749|NCT05189340|OTHER|Educational Videos|Series of six videos each covering a specific aspect of post-transplant care related to medication use or monitoring
223852750|NCT00920686|DRUG|NXN-188|NXN-188 hard gelatin capsules, 600 mg administered as three 200 mg capsules
223852751|NCT00920686|DRUG|placebo|administered as 3 placebo hard gelatin capsules
223852752|NCT00920686|DRUG|sumatriptan succinate|administered in a hard gelatin capsule with 2 capsules of placebo
223852753|NCT02182414|DRUG|BI 207127 NA (TF-I)|200 mg tablet
223852754|NCT02182414|DRUG|BI 207127 NA (TF-II)|400 mg tablet
223852755|NCT02182414|DRUG|BI 207127 NA delayed release|400 mg tablet
223852756|NCT02182414|DRUG|BI 207127 NA extended release (10% HPMC)|400 mg tablet
223852757|NCT02182414|DRUG|BI 207127 NA extended release (15% PEO)|400 mg tablet
223852758|NCT02182414|DRUG|BI 207127 NA extended release (20% HPMC)|400 mg tablet
223852759|NCT03203018|BEHAVIORAL|Interactive workshop based on community specific needs|"Intervention components will include lecture on women's CVD, workshop on how to prepare for a doctor's visit, patient's rights and patient-doctor communication skills, and a know your numbers workshop, including understanding blood test results."
223852760|NCT02931435|PROCEDURE|Nerve Block with Radiofrequency Ablation|Ablation of the genicular nerves of the knee by radiofrequency
223852761|NCT02931435|PROCEDURE|Nerve Block with Sham Radiofrequency Ablation|Genicular radiofrequency of the knee without neurotomy
223852762|NCT00464672|BIOLOGICAL|Influenza virus vaccine|Two intramuscular injections of the investigational influenza virus vaccine administered 4 weeks part to group 3 to 8 years of age while one injection was administered to groups 9 to 17 years of age and 18 to 64 years of age.
223852763|NCT00464672|BIOLOGICAL|Comparator influenza vaccine|Two intramuscular injections were administered 4 weeks apart to group 3 to 8 years of age while one injection was administered to groups 9 to 17 years of age and 18 to 64 years of age.
223852764|NCT00641472|DRUG|Budesonide inhalation suspension|0.5mg
223852765|NCT00641472|DRUG|Montelukast Sodium|4mg or 5mg
223852766|NCT01645917|DEVICE|Arctic Front Advance Cardiac CryoAblation system|Standard of care ablation for indicated paroxysmal AF patients with Medtronic's Arctic Front Advance Cardiac CryoAblation system
223852767|NCT03101436|DIETARY_SUPPLEMENT|Extra Virgin Olive Oil and Red Wine|"Phase I: Extra VIrgin Olive Oil 80 grams per day (1 month)~Washout Period: 15 days~Phase II: Red Wine (270 ml per day) (1 month)"
223852768|NCT05581654|PROCEDURE|Salpingectomy|Salpingectomy by vaginal natural orifice transluminal endoscopic surgery (v-NOTES).
223852769|NCT02970708|DEVICE|EFG group|88 anisometropic amblyopia will be recruited to receive Eyetronix Flicker Glasses treatment.
223852770|NCT02970708|DEVICE|Patching group|88 anisometropic amblyopia will be recruited to receive patching treatment.
223852771|NCT02515682|DIETARY_SUPPLEMENT|High equol group|Participants will be give natural S-equol 20mg/d for 24 weeks.
223852772|NCT02515682|DIETARY_SUPPLEMENT|Low equol group|Participants will be give natural S-equol 10mg/d for 24 weeks.
223852773|NCT02515682|DIETARY_SUPPLEMENT|Placebo|Participants will be give placebo for 24 weeks.
223852774|NCT01063023|DRUG|Ortho Tri-Cyclen®|Tablets, Oral, 1 Tablet, once daily
223852775|NCT01063023|DRUG|BMS-650032|Tablets, Oral, 600 mg, BID
223852776|NCT02253719|PROCEDURE|cryotherapy, further biopsy, LEEP, surgery as indicated|These interventions and their outcomes are not part of this study. However, we will be offering at no charge appropriate treatment for neoplasia or cancer that is diagnosed.
223852777|NCT03584646|DEVICE|Nokia GO Wearable StepTracker|All participants will be provided with a Nokia GO step tracker to monitor daily step counts. The device is not subject to FDA regulation.
223852778|NCT03584646|OTHER|Medication Reminder|Medication reminders are sent to participants in Arm 2 on a daily basis.
223852779|NCT03584646|OTHER|Weekly Check-in appointment with study team or provider|Virtual meeting or telephone call between participants and study team to assess study involvement, adherence to procedures, and following of medical care recommendations.
223852780|NCT01927835|BIOLOGICAL|DNA-HIV-PT123 vaccine|4 mg of DNA encoding clade C ZM96 Gag and gp140, CN54 Pol-Nef, administered IM
223852781|NCT01927835|BIOLOGICAL|NYVAC-HIV-PT1 vaccine|≥ 5x10\^6 PFU/ml encoding clade C ZM96 gp140 for a planned maximum dose of 1.2x10\^8 PFU/ml; administered IM
223852782|NCT01927835|BIOLOGICAL|NYVAC-HIV-PT4 vaccine|≥ 5x10\^6 PFU encoding ZM96 Gag and CN54 Pol-Nef, administered IM for a planned maximum dose of 1.1x10\^7 PFU/ml; administered IM
223852783|NCT01927835|BIOLOGICAL|AIDSVAX B/E vaccine|300 mcg of subtype B (MN) HIV gp120 glycoprotein and 300 mcg of subtype E (A244) HIV gp120 glycoprotein absorbed onto 600 mcg of aluminum hydroxide gel adjuvant, administered IM
223852784|NCT01927835|BIOLOGICAL|Placebo for DNA/NYVAC/AIDSVAX|Sodium Chloride for injection, 0.9%; administered IM
223852785|NCT03875690|DRUG|Injection of methylprednisolone|Patients will receive 20mg/kg IV of methylprednisolone at the time of anaesthetic induction. Methylprednisolone will be infused in a ready-to-use 50 mL bag of sodium chloride 0.9% during 30 minutes at anaesthesic induction.
223852786|NCT03875690|DRUG|Injection of sodium chloride|patients in the placebo group will receive 50 mL of sodium chloride 0.9% in a ready-to-use bag during 30 minutes at anaesthesic induction.
223852787|NCT03875690|BIOLOGICAL|Blood samples|electrolyte panel and glycemia performed within the first 24 hours after surgery.
223852788|NCT00825435|PROCEDURE|Coronary CT Angiogram|Coronary CT Angiogram
223852789|NCT00618540|BIOLOGICAL|alemtuzumab|Administered intravenously (IV) 0.2 mg/kg on Days -8 through -4.
223852790|NCT00618540|DRUG|fludarabine phosphate|Administered 30 mg/m2 intravenously (IV) over 30-60 min on Days -7 through -3. (dose adjust if age \<12 months)
223852791|NCT00618540|DRUG|melphalan|Administered 140 mg/m2 intravenously (IV) over 30 min on Day -2 (dose adjust if age \<12 months)
223852792|NCT00618540|PROCEDURE|stem cell transplantation|Administered as allogeneic hematopoietic, peripheral blood or umbilical cord blood transplantation
223852793|NCT01854437|DRUG|Mg Oxide|250 mg orally for 4 weeks
223852794|NCT00727584|RADIATION|radiation therapy|Patients undergo external beam radiotherapy
223852795|NCT00462969|PROCEDURE|Sonohysterography|Sonohysterography
223852796|NCT00957229|DRUG|GDC-0449|capsule, 150 mg, one pill daily, 18 months
223852797|NCT03326479|DIAGNOSTIC_TEST|Caris Molecular Intelligence Profile|A comprehensive biomarker testing
223852798|NCT03906734|PROCEDURE|Septal myectomy|Transaortic septal myectomy
223852799|NCT03906734|PROCEDURE|alfieri stich|Transaortic Mitral valve repair using alfieri technique
223852800|NCT03906734|PROCEDURE|Subvalvular intervention|Transaortic Mitral valve subvalvular intervention including anterior mitral leaflet secondary cord cutting, papillary muscle release
223852801|NCT02981186|DEVICE|IOL implantation experimental|Implantation of trifocal IOL POD F GF consisting of hydrophobic material
223852802|NCT02981186|DEVICE|IOL implantation comparator|Implantation of trifocal IOL POD F consisting of hydrophilic material
223852803|NCT04042519|DIAGNOSTIC_TEST|Lung function test was performed on the subjects with Jaeger lung function instrument of Germany.|This Jaeger lung function instrument of Germany is used to test the pulmonary ventilation function of COPD patients. Since the condition requires drug control and treatment, the drug cannot be stopped.
223852804|NCT04042519|DIAGNOSTIC_TEST|Agilent 1290 Infinity LC system (UHPLC, Santa Clara CA) was used for Targeted metabolite detection.|We used the Agilent 1290 Infinity LC system mass spectrometer to analyze and detect metabolite peaks of patients according to retention time and mass/charge ratio after preliminary experiments and derivatization.
223852805|NCT04042519|DIAGNOSTIC_TEST|Routine blood test|Blood routine test results include CRP, PCT, white blood cell count, red blood cell count, neutrophil percentage, eosinophil, basophil, et al.
223852806|NCT00000646|DRUG|Pentoxifylline|
223852807|NCT04580303|DRUG|collagenase clostridium histolyticum|Delivered via uniform grid injection techniques.
223852808|NCT05037032|DRUG|Naltrexone Pill|50 mg PO one-time only
223852809|NCT05037032|DRUG|Placebo|Matching placebo for naltrexone
223852810|NCT01444287|DEVICE|narafilcon B|test product
223852811|NCT01444287|DEVICE|Polymacon|marketed product
223852812|NCT01444287|DEVICE|Lotrafilcon A|marketed product
223852813|NCT01444287|OTHER|Spectacles|None - subject used own spectacles
223852814|NCT00665379|OTHER|Regular Compression therapy (Trico bandages)|Application of marketed Trico compression bandages used for treatment by trained specialists with assessment of the subbandage pressure and volume reduction. The bandages are applicated in patients with leg lymphedema at t=0 hour, t=2 hours. Comparison is made at t=2 hours, t= 24 hours
224076104|NCT05825001|OTHER|Medical Device Usage and Evaluation|Use iCOquit Smokerlyzer carbon monoxide monitor
224076105|NCT06420531|DIETARY_SUPPLEMENT|Human milk|maternal breastmilk or donor breastmilk
223852815|NCT00665379|OTHER|New Compression therapy (C2L bandages)|Application of marketed compression bandages C2L used for treatment by trained specialists with assessment of the subbandage pressure and volume reduction. he bandages are applicated in patients with leg lymphedema at t=0 hour, t=2 hours. Comparison is made at t=2 hours, t= 24 hours
223852816|NCT02964429|DEVICE|Diacap Pro High-Flux|During dialysis treatment ultrafiltration rate will be changed following a fixed schedule and resulting changes in Transmembrane Pressure (TMP) recorded to generate data for calculation of the in-vivo KUF.
223852817|NCT01536730|BEHAVIORAL|Homework Intervention Strategy|"Participants assigned to intervention will receive a condom ditty bag containing 50 condoms (5 each of 10 types), a variety of 50 lubricants, an instructional DVD, and instructions for the intervention."
223852818|NCT00234377|DRUG|Seroquel SR|
223852819|NCT01424579|OTHER|Actual Diacutaneous Fibrolysis|Diacutaneous Fibrolysis is a non-invasive physiotherapeutic technique applied by means of a set of metallic hooks ending in a spatula with bevelled edges that allow a deeper and more precise application, which could not be achieved manually. Appropriate hook is applied following the intermuscular septum between the muscles with an anatomical or functional relationship with the painful structure, in a centripetal direction towards the pain location, in order to release adherences between musculoskeletal structures.
223852820|NCT01424579|OTHER|Placebo Diactuaneous Fibrolysis|Placebo Diacutaneous Fibrolysis was applied at a superficial level and, instead of fibrolysis, a pinch of skin was held with the thumb of the palpatory hand and the tip of the spatula, without any action taking place on the deep tissular levels.
223852821|NCT01424579|OTHER|Protocolized physiotherapeutic Treatment|Tree weeks of daily therapeutic exercises, analgesic electrotherapy and cryotherapy.
223852822|NCT05104905|DRUG|bexmarilimab|A single neoadjuvant dose will be administered prior to surgery.
223852823|NCT02887261|DEVICE|"BardPowerPort sip Implantable Port"|capable for power injection for contrast media.
223852824|NCT02887261|DEVICE|Conventional Port|not for power injection for contrast media.
223852825|NCT05416450|DEVICE|intravaginal electrical stimulation added to bladder training|BT was given as a home program. After information session, squeezing the PFM was shown in practice at least once to use in the urgency suppression strategies via digital palpation technique. The second stage strategies was aimed to delay urination, inhibit detrusor contraction, and prevent urgency by squeezing the PFM several times on a row, breathing deeply and self-motivating. In the third stage, a timed voiding program was started; a timed voiding and increasing the time between urination considering the voiding diary. IVES was applied in addition to BT in both groups. It was performed in lithotomy position via a stimulation device (Enraf Nonius Myomed 632) with a vaginal probe; three days a week, a total of 24 sessions for 8 weeks. Every session lasted 20 minutes. The stimulation parameters were a 10 Hz of frequency, a 5-10 s of work-rest cycle duration and, a 100 ms of pulse width. The symmetric biphasic pulse wave could be delivered over a range of 1-100 mA.
223852826|NCT00028132|DRUG|Tenofovir|
223852827|NCT00190216|DEVICE|Magnetic stimulator|
223852828|NCT02943382|OTHER|Fingerprick autologous blood (FAB)|Pricking of cleaned finger using diabetic lancet and applying blood droplet to affected eye. Repeated with separate finger for other affected eye.
223852829|NCT00828672|DRUG|Oxaliplatin|Administered on days 15,22,29,36 en 43; 50 mg/m2
223852830|NCT00828672|DRUG|Bevacizumab|Administered on days 1,15,29 and 43 ; 5mg/kg
223852831|NCT00828672|DRUG|Capecitabine|825 mg/m2 ; 25 days - 5days per week, concurrent with radiotherapy
223852832|NCT00828672|RADIATION|radiotherapy|Total dose 45Gy
223852833|NCT02239796|DEVICE|NeuroTrac continence stimulators|"Electrically stimulating the sacral nerve plexus modulates the L4-S3 nerve roots that control bladder function and urethral sphincter activity to eliminate inappropriate detrusor contractions while leaving the micturition reflex intact.~Transcutaneous posterior tibial nerve stimulation (TPTNS) is a technique of non-invasive retrograde electrical stimulation of the sacral plexus via the sciatic nerve. The posterior tibial nerve, a tributary of the sciatic nerve, is accessed using surface electrodes applied to the medial malleolar area. We are using NeuroTrac continence stimulators."
223852834|NCT02239796|DEVICE|NeuroTrac continence stimulators|We are using NeuroTrac continence stimulators.
223852835|NCT06463171|DRUG|Almonertinib|"Almonertinib, dosing regimen: 110mg/day orally, once daily in a 28-day cycle, continuously.~Lastet, dosing regimen: 50 mg/day orally, every 28 days in a cycle, two weeks of continuous oral administration, two weeks off."
223852836|NCT03901729|DRUG|BAY 1753011|Tablet; 30mg or 5mg unit; 30mg once daily in the morning; Oral
223852837|NCT03901729|OTHER|Placebo BAY 1753011|Tablet; Once daily in the morning; Oral
223852838|NCT03901729|DRUG|Furosemide|Tablet; 40mg unit; 80mg once daily in the morning; Oral
223852839|NCT03901729|OTHER|Placebo Furosemide|Tablet; Once daily in the morning; Oral
223852840|NCT04596579|DIAGNOSTIC_TEST|SARS-CoV-2 Antibody Analysis|10 ml of blood will be drawn for antibody analysis. Participants who test SARCS-CoV-2 positive will be invited to participate in follow-up antibody testing at 4 weeks and at 3 months.
223852841|NCT04596579|DIAGNOSTIC_TEST|Weck-cel Swab Collection|A Weck-cel swab will be used to collect secretions from the mucosal epithelium
223852842|NCT04596579|BEHAVIORAL|Web Based Questionnaire|A brief web enabled questionnaire will be administered to collect information related to demographics, SARS-CoV-2 exposure history, past symptoms, comorbidities associates with increased infection and disease risk, as well as immunosuppression status and use to immunosuppressive medications.
223852843|NCT04714450|BEHAVIORAL|Experimental: MMST+|The format of the MMST will remain the same; however, the white noise, images and math task will be modified to mitigate habituation effects.
223852844|NCT05784155|DRUG|Test Drug(JW0302) or Reference Drug(C2206)|"Test Drug: single administration of JW0302 Reference Drug: single administration of C2206~Tablet, Oral, QD for 1 Days, Washout period is more than 14 days after administration"
223852845|NCT01282775|BEHAVIORAL|WEB + Environment|Participants receive weekly lessons via the Web along with additional tools for weight loss support
223852846|NCT01282775|BEHAVIORAL|WEB + Cash Incentive for Weight Loss|Participants are paid cash based on the percent weight lost at 3, 6, and 12 months.
223852847|NCT01006746|OTHER|Remote monitoring by Home Monitoring system|Standard of care completed with remote monitoring for ICD patients follow-up
224076106|NCT06533579|GENETIC|Dose Level 1, VNX-101|Adeno-associated viral vector encoding the CD3/CD19 Bi-Specific T-Cell Engager (AAV.CD3/CD19), Single IV infusion
223852848|NCT05037344|BEHAVIORAL|Cognitive-behavioral psychotherapy|The goal is to develop an internet and smart phone delivered CBT (iCBT) for the treatment of pediatric OCD on the bases of our feasibility study. This group will start directly with therapy of 16 weeks. The waiting group gets the same intervention after 16 weeks of waiting.
223852849|NCT06314256|BIOLOGICAL|Injection|İnterdental papilla will be injected by i-PRF.
223852850|NCT06314256|DRUG|Injection|Interdental papilla will be injected by Tesoyal PureSense Glabal Action HA gel.
223852851|NCT00288964|DEVICE|Hattler Respiratory Assist Catheter|
223852852|NCT01134575|DRUG|CMC-544 (Inotuzumab Ozogamycin)|"First patients \> 16 years and \< 16 years receive CMC-544 at a dose of 1.3 mg/m\^2 by vein (IV) over 1 hour during Course 1, and 1.8 mg/m\^2 IV over 1 hour during Course 2 and subsequently. In all other patients beginning dose of 1.8 mg/m\^2 IV over 1 hour every 4 week cycle.~Part 2 CMC-544 (Inotuzumab Ozogamycin) 0.8 mg/m\^2 IV over 1 hour (+ 15 minutes) on Day 1, 0.5 mg/m\^2 IV over 1 hour (+ 15 minutes) on Day 8, and 0.5 mg/m\^2 IV over 1 hour (+ 15 minutes) on Day 15. Weekly doses can be given at + 1 day. Course may be repeated every 3 weeks. Rituximab will be given on Day 1 and CMC-544 on Day 2 of the first dose; with subsequent weekly doses, both will be given weekly, rituximab preceding CMC-544. The weekly dose of rituximab will be 375 mg/m2."
223852853|NCT01134575|DRUG|Rituximab|With no improvement after 2 courses of CMC-544, addition of Rituximab dose 375 mg/m\^2 IV (by vein) over 2-6 hours every 3-4 weeks.
223852854|NCT05415930|OTHER|Psychosocial assistance|Firs evaluation at Acceptess-T locals by a health mediator specialised in transidentity : advice for administrative procedures (health insurance, residency permit, housing, etc.) management of others social issues Orientation to Acceptess-T sexual health space for medical evaluation Orientation to Acceptess-T mental health space if needed : special focus on sexual health and gender related issues
223852855|NCT05415930|OTHER|Medical care|Sexual health clinics at Acceptess-T health space First STI risk evaluation: HIV, HCV, HBV, syphilis TROD realisation Spanish speaking Infectious Diseases (ID) specialist (from ID Department of Bichat hospital) first evaluation Proposition of PrEP if indicated Orientation for hospital follow-up in dedicate PrEP clinics Prescription and follow-up of a feminazing hormonal therapy if needed
223852856|NCT05415930|OTHER|Legal-Administrative Assistance|Legal counselling, provided by a sex worker union representative Access to FAST (fond action social trans) which give an economic help to TW in high precarity situations
223852857|NCT05415930|OTHER|Focus Group|"A group of 10-15 TW, identified through convenience sampling, along with the Acceptess-T Health Space multidisciplinary team will be invited to participate in an Human Centered Design (HCD) project.~The project will be led by a team of anthropologists and sociologists and exchanges will be recorded and fully transcribed and analysed by a person competent in qualitative methodology.~The objective will be to co-create tailored solutions that meet the needs of TW and are viable to implement within the health system, so TW can be better managed The solutions ideated will work synergistically towards improving TW PrEP access and adherence and health system retention.This is an adaptative program : if new solutions to face PrEP barriers are created during the study follow-up, new mesures will be added to the intervention."
223852858|NCT03078920|DEVICE|Naída CROS|At fitting Naída CROS and a loaner Naída CI processor are used for the duration of the study. The fitting software allows to enable a HIBAN link between the CI processor and the Naída CROS. The fitting of the CI processor is based on the clinical programming of the subject. No changes are made to the fitting parameters unless the subject requests changes. The fitting is done according to the clinical routine. The Naída CROS is pre-configured to communicate with the Naída CI when switched on.
223852859|NCT04974489|BEHAVIORAL|Emotion-based messages about the harm of VLNC|Participants in this arm will receive 3 emotion-based messages about the harm of VLNC during the survey data collection.
223852860|NCT04974489|BEHAVIORAL|Continued-harm-framed messages about the harm of VLNC|Participants in this arm will receive 3 continued-harm-framed messages about the harm of VLNC during the survey data collection.
223852861|NCT04974489|BEHAVIORAL|Myth-refuting messages about the harm of VLNC|Participants in this arm will receive 3 myth-refuting messages messages about the harm of VLNC during the survey data collection.
223852862|NCT04974489|BEHAVIORAL|Control messages about littering|Participants in this arm will receive 3 control messages about littering during the survey data collection.
223852863|NCT01735929|PROCEDURE|Neck Liposuction and Ultrasound Treatment|
223852864|NCT01735929|PROCEDURE|Sham Treatment|
223852865|NCT05608967|DEVICE|PREHapp|Prehabilitation programme through the PREHapp platform
223852866|NCT01396109|PROCEDURE|Procedure: TVH and GYNECARE PROSIMA* Pelvic Floor Repair System|Subjects of this group were submitted to surgical treatment with GYNECARE PROSIMA\* Pelvic Floor Repair System concurrently with transvaginal hysterectomy.
223852867|NCT01396109|PROCEDURE|Procedure: TVH and Modified Pelvic Floor Reconstruction Surgery with mesh|Subjects of this group were submitted to surgical treatment of Modified Pelvic Floor Reconstruction Surgery with mesh concurrently with transvaginal hysterectomy.
223852868|NCT04301388|PROCEDURE|Transvaginal ultrasound|Transvaginal ultrasound to measure cervical length if persist regular uterine contraction
223852869|NCT03744117|OTHER|Palliative care consultation|A palliative care consultation will occur via telemedicine with patients receiving maintenance dialysis.
223852870|NCT01382810|DRUG|Altaire Gel forming solution|Three times a day for two months
223852871|NCT01382810|DRUG|Refresh Tears|Three times a day for two months
223852872|NCT03148054|DEVICE|Computer Tomography and Endoscopy|"Pelvic CT scan with i.v. and rectal contrast (Siemens Healtheneers, Erlangen, Germany) with the following scan parameters: collimation 0.6 mm, pitch 1.2 mm, CareKV with reference 120 mAs and reference 120 kV, rotation time 0.5 sec. Portal venous phase (individually tailored contrast media injection of Xenetix 300, Guerbet GmbH) and rectal contrast (500cc: 470cc water + 30cc Telebrix® gastro, a water soluble iodinated contrast agent, Guerbet GmbH).~Endoscopy takes 5 minutes: A gastroscope with a diameter of 10mm is used for inspection of anus, rectum, anastomosis incl. measurements (distance to dentate line, diameter of anastomosis) and distal part of colon (to rule out ischemia) during short term insufflation of the rectum with CO2. No biopsies are taken. Digital photo documentation will be provided. In case of anastomotic insufficiency: optional sedation of patient and clip closure with endoscopic OTSC (over the scope clip) system."
223852873|NCT05760690|PROCEDURE|Retro-Auricular Single-Site Endoscopic Thyroidectomy|The strap muscles and the sternocleidomastoid muscle were separated. Upper parathyroid and lower parathyroid glands were identified and preserved. The recurrent laryngeal nerve (RLN) was identified，A lobe of thyroid specimen and central lymph nodes were dissected.
223852874|NCT05760690|PROCEDURE|Transoral Endoscopic Thyroidectomy Vestibular Approach|The patient was placed in a supine position with slight neck extension under nasotracheal intubation. The mouth was garbled with povidone iodine before surgery. Three laparoscopic ports (a 10- to 15-mm port at midline and two 5-mm ports at the lateral junction between the canine and first premolar teeth)were inserted under the lower lip at the oral vestibular area.The strap muscleswere separated in the midline to expose the thyroid and trachea. The recurrent laryngeal nerve (RLN) was identified at the insertion to the larynx, then followed downandparallel tothe trachea inferiorly.
223852875|NCT05760690|PROCEDURE|Transareola Endoscopic Thyroidectomy|The patient was in supine position. Incision was made inside the right areola and a 10mm puncture device was placed, subcutaneous separation rod was used to separate the space, and a 30° endoscope was introduced, puncture device was placed in a 5mm incision on the left areola, ultrasonic knife free flap was used, subcutaneous separation space was placed in the upper sternal segment, and a 5mm puncture device was placed outside the right areola. The anterior cervical flap was further dissociated to establish a space. The median cervical line was cut to cut off the isthmus of the thyroid, and the tracheal fascia ligament of the thyroid was separated and the nerve was exposed to protect the nerves. Then remove the lobe of thyroid and central lymph nodes
223852876|NCT00623246|BEHAVIORAL|MET|MET will involve motivational counseling sessions and phone calls, with a focus on building self-efficacy and providing personalized feedback on health and adherence patterns based on CPAP adherence monitoring.
223852877|NCT00623246|BEHAVIORAL|ED|ED will involve sessions and phone calls that include educational information, problem-solving, and adherence feedback from study staff.
223852878|NCT03828695|OTHER|uterocervical angle|uterocervical angle is the angle between lower segment of uterus and cervix
223852879|NCT01456936|DRUG|Placebo|Triple dummy placebo for each treatment arm
223852880|NCT01456936|DRUG|varenicline tartrate|Subjects will be titrated to the full dose during the first week in the following manner: 0.5 mg (tablet form) once a day for 3 days, 0.5 mg twice a day for 4 days, then 1 mg twice a day for 11 weeks
223852881|NCT01456936|DRUG|bupropion hydrochloride|Subjects will receive 150 mg (tablet form) once a day for 3 days and then will take 150 mg twice a day for the remainder of the treatment period (11 weeks and 4 days).
223852882|NCT01456936|DRUG|Nicotine Replacement Therapy Patch|Subjects will start active dosing the morning of the Week 1 visit and will receive a 21 mg transdermal patch per day x 7 weeks, followed by a 14 mg transdermal patch per day x 2 weeks, and then a 7 mg transdermal patch x 2 weeks for a total of 11 weeks of treatment.
223852883|NCT01794377|BEHAVIORAL|30 minutes of high intensity training|"This group will carry out a 5-min warm-up period on bicycle ergometer at an intensity corresponding to 50% of Vo2max before performed eight times the intermittent training exercise as follows:~* 30 sec at 120% of Vo2max,~* 1 min at 50% of Vo2max,~* 15 sec at 30-40 revolutions per minute of strength training at 100% of the maximal anaerobic power, which will be first determined by means of a force-velocity test on a Monark ergometer,~* 1 min at 50% of Vo2max.~The training session will be terminated by a 3-min cool-down period at 40% of Vo2max.~Training three times per week for 5 months under supervision of an exercise physiologist.~Initial nutritional education session at the beginning of the study Questionnaires on training experience during the 5 months training period (Exercise difficulties, pain...).~Dietary Supplement: supplementation in fruits and vegetables (5 per day) during all the study."
224076107|NCT06533579|GENETIC|Dose Level 2, VNX-101|Adeno-associated viral vector encoding the CD3/CD19 Bi-Specific T-Cell Engager (AAV.CD3/CD19), Single IV infusion
224076108|NCT06533579|GENETIC|Dose Level 3, VNX-101|Adeno-associated viral vector encoding the CD3/CD19 Bi-Specific T-Cell Engager (AAV.CD3/CD19), Single IV infusion
223852884|NCT01794377|BEHAVIORAL|40 of an endurance training|"The moderate-intensity continuous exercise group will carry out a 40-min session of continuous cycling at a moderate intensity (50 % of Vo2max).~Training three times per week for 5 months under supervision of an exercise physiologist.~Initial nutritional education session at the beginning of the study Questionnaires on training experience during the 5 months training period (Exercise difficulties, pain...).~Dietary Supplement: supplementation in fruits and vegetables (5 per day) during all the study."
223852885|NCT03389581|BEHAVIORAL|awareness and anxiety|before operation awareness and anxiety will recorded with STAIX-I score
223852886|NCT00774111|DRUG|GSK1349572|GSK1349572 50 mg in combination with Etravirine
223852887|NCT01168453|BEHAVIORAL|head position change|AL-US distance measure using the ultrasound in two different head position
223852888|NCT01105884|PROCEDURE|Normal Saline|All the subjects in Group 1 will be treated with Normal Saline for healing of their diabetic foot ulcer
223852889|NCT01105884|PROCEDURE|Biatin Ag (Foam)|All the subjects will be treated with Biatin Ag (Foam)
223852890|NCT01105884|PROCEDURE|Hydrocolloid|All the subjects in this group will be treated with Hydrocolloid
223852891|NCT01105884|PROCEDURE|Hydrogel|All the subjects in this group will be treated with Hydrogel
223852892|NCT01105884|PROCEDURE|Ceredak|All the subjects in this group will be treated with Micro-porous Ceramic Wound Dressing
223852893|NCT06378372|BEHAVIORAL|Music therapy based on piano learning|The intervention will consist of pianistic training. Patients will receive piano classes adapted to their competence designed to achieve motor, sensory and behavioral control.
223852894|NCT02028130|PROCEDURE|LAA electrical isolation + occlusion|LAA electrical isolation + Watchman device implantation to occlude LAA
223852895|NCT01250002|DRUG|Placebo|Placebo will receive the same volume of saline infusion.
223852896|NCT01250002|DRUG|Lidocaine|Lidocaine administration 1.5 mg/kg bolus followed by a 2 mg/kg/hr infusion via intravenous catheter
223852897|NCT00466791|DRUG|Methylphenidate Transdermal System|Placebo
223852898|NCT01948960|DRUG|everolimus dose escalation|patients with an AUC below mean will have dose escalation of everolimus based on their AUC
223852899|NCT01319435|PROCEDURE|Collection of biological samples|"Sparse blood samples (n=2 or 3 depending on weight) will be drawn on day 1 and day 5- 7 (or last day of treatment if the course is completed before day 7).~Monitoring of adverse events DNA for pharmacogenetics (scavenged clinical samples or buccal) CSF (if required clinically) Faeces"
223852900|NCT00029380|DRUG|Sangstat|
223852901|NCT00029380|DRUG|Cyclophosphamide|
223852902|NCT00029380|DRUG|Busulfan|
223852903|NCT00029380|DRUG|Mycophenolate Mofetil|
223852904|NCT00029380|DRUG|Cyclosporine|
223852905|NCT00029380|PROCEDURE|Cord Blood Transplantation|
223852906|NCT04440943|DRUG|CDX-527|CDX-527 is administered by infusion every 2 weeks
223852907|NCT00569738|PROCEDURE|PET scan with Ga68-DOTANOC|Imaging: PET scan with Ga68-DOTANOC
223852908|NCT02377531|OTHER|Early glucose screen group|Main intervention is randomization: half of the participants will be randomized to undergo a 50 gram oral glucose load with a 1 hour serum glucose measurement as a screen for Gestational Diabetes mellitus at 12 to 18 weeks of pregnancy instead of standard 24 to 28 weeks of pregnancy
223852909|NCT02377531|OTHER|Standard glucose screen group|Main intervention is randomization: half of the participants will be randomized to undergo a 50 gram oral glucose load with a 1 hour serum glucose measurement as a screen for Gestational Diabetes mellitus at 24 to 28 weeks of pregnancy
223852910|NCT00611832|BEHAVIORAL|"Triple P Media Series -- Standard Information-Only version"|10 episodes, 12 minutes per episode, 2 episodes viewed per week for a total of 5 weeks. Demonstrates parenting practices for effectively handling a range of difficult child behaviors.
223852911|NCT00611832|BEHAVIORAL|"Triple P Media Series -- Enhanced Behavior Activation version"|10 episodes, 12 minutes per episode, 2 episodes viewed per week for a total of 5 weeks. Demonstrates parenting practices for effectively handling a range of difficult child behaviors; includes specific content elements designed to promote parents' adoption of the targeted parenting skills
223852912|NCT01249040|PROCEDURE|Physical therapy|
223852913|NCT01249040|PROCEDURE|steroid intraarticular injection|
223852914|NCT05800821|PROCEDURE|Carotid revascularization|Carotid revascularization
223852915|NCT01271270|DRUG|Palomid 529|
223852916|NCT04735939|RADIATION|radiotherapy|Determine whether there is a difference in outcomes seen when patients are assigned to take their radiotherapy at either a morning time or evening time.
223852917|NCT05711498|OTHER|Transcutaneous spinal direct current stimulation (tsDCS)|tsDCS will be carried out using a direct current stimulator (DC-Stimulator Plus, neuroConn, Ilmenau, Germany), with one electrode placed above the thoracic spinal cord and the other electrode placed on the right shoulder. We will employ rectangular electrodes of 7 x 5 cm size (neuroConn, Ilmenau, Germany) covered by electrode paste (Ten20 Conductive Paste, Weaver and Company, Aurora, USA). Stimulation will consist of the following phases: a fade-in period of 15 seconds, a plateau period of 20 minutes (with stimulation at 2.5mA either anodally or cathodally) and a fade-out period of 15 seconds. Sham stimulation will follow the anodal montage with 15-second fade-in and fade-out periods, but only 45 seconds of plateau stimulation at 2.5 mA. Such a combination of stimulation and electrodes results in a current density of 0.071mA/cm2, well below thermal and histological limits for current density.
223852918|NCT01297972|BIOLOGICAL|Intravenous bone marrow mesenchymal stem cells infusion|After standard immunosuppressive therapy with rabbit antithymocyte globulin 3,5 mg/Kg/day during 5 days, allogeneic unrelated bone marrow derived mesenchymal stem cells will be infused intravenously. Oral cyclosporine 5 mg/Kg/day (with dose correction weekly to keep serum cyclosporine level between 150-250 mg/dl) up to 6 months will be added.
223852919|NCT03424928|DRUG|Pomalidomide 4 MG Oral Capsule|per os,capsule,4mg,1 capsule per period
223852920|NCT03424928|DRUG|Pomalidomide 4 MG Oral Capsule-Pomalyst|per os,capsule,4mg,1 capsule per period
223852921|NCT00092560|DRUG|MK0653, ezetimibe|
223852922|NCT00092560|DRUG|Comparator: fenofibrate monotherapy|
223852923|NCT03092440|OTHER|serious game|"During three hours, each learner will play with the three different cases of the LabForGames Warning serious game."
224076109|NCT06533579|GENETIC|Dose Level 4, VNX-101|Adeno-associated viral vector encoding the CD3/CD19 Bi-Specific T-Cell Engager (AAV.CD3/CD19), Single IV infusion
224076110|NCT02170181|RADIATION|SBRT|SBRT to Oligometastases
223852924|NCT03569683|PROCEDURE|External bevel gingivectomy|External bevel gingivectomy will be performed on 30 patients wherein the suprabony pockets will be eliminated with the help of a Bard parker blade no 15. The incision would be given 1mm apical to the pockets which would be marked by a Crane and Kaplan pocket marker, then the incision would be given and the tissue would be removed with the help of kirkland and orbans knives and the gingiva would be shaped. After the surgical procedure the patients would be treated either with the Diode laser(Group A), Hyaluronic acid gel (Group B), or Herbal gel(Group C).
223852925|NCT03569683|DEVICE|Diode laser Biostimulation|After gingivectomy, laser irradiation will be done using bio-stimulation tip in the anterior sextants of the mouth. (Group A)
223852926|NCT03569683|OTHER|Hyaluronic acid (Gengigel) topical application.|After gingivectomy, Hyaluronic acid gel(Gengigel) will be applied topically. Then it will be covered with a tin foil and periodontal dressing would be given. (Group B)
223852927|NCT03569683|OTHER|Herbal gel (Hiora SG) topical application|After gingivectomy, Herbal gel(Hiora SG) will be applied topically. Then it will be covered with a tin foil and periodontal dressing would be given. (Group C)
223852928|NCT02274402|BIOLOGICAL|blood sampling|Blood sample of 4 ml at enrolment and then at two following visits
223852929|NCT02588482|DEVICE|high-density electroencephalography|Auditory stimulations during electroencephalography recording
223852930|NCT02588482|DEVICE|Conventional electroencephalography|Auditory stimulations during electroencephalography recording
223852931|NCT00459264|DRUG|Folic Acid|Folic acid oral solution 2.5mg/5ml daily for up to 3 years
223852932|NCT00459264|DRUG|Placebo|Matching placebo for folic acid oral solution (2.5mg/5ml)
223852933|NCT02888158|OTHER|Robotic assistance|Robotic assistance will be implemented during Pelvic Trainer training sessions.
223852934|NCT02888158|OTHER|Pelvic Trainer|The standard Pelvic Trainer simulator for surgical training.
223852935|NCT05566405|PROCEDURE|General Anaesthesia|All patients in the general anaesthesia group will be premedicated with intravenously administered (iv) midazolam (2mg) and fentanyl (100 mcg). Induction will be performed using intravenous propofol (2.5-3mg/kg) and lidocaine (40mg); dexamethasone 8mg, metoclopramide 10mg and omeprazole 40mg will also be administered. After successful tracheal intubation, total intravenous anaesthesia will be maintained by administering propofol (0.05 mg/kg/sec iv) and remifentanil (0.2 mcg/kg/sec iv). Pain management will be achieved by paracetamol (1g iv) and tramadol (100mg iv) whereas muscle relaxation by vecuronium (0.6 mg/kg iv).
223852936|NCT05566405|PROCEDURE|Combined (Epidural and Spinal) Anaesthesia|Combined (epidural and spinal) anaesthesia will be performed using an epidural 18G needle and a spinal 27G needle, in the L2-L3 or L3-L4 interspace. Induction will be carried out by spinal intrathecal administration of levobupivacaine (2.6-3ml of 0.5%) and mild sedation by midazolam (5mg iv in bolus). All patients will be administered dexamethasone 8mg, metoclopramide 10mg and omeprazole 40mg iv. Maintenance will be performed 75 minutes after induction and obtained using an epidural administration of levobupivacaine (4-5ml of 0.5%).
223852937|NCT05566405|PROCEDURE|Open Retropubic Radical Prostatectomy|All patients will undergo a nerve-sparing open retropubic radical prostatectomy
223852938|NCT06441656|PROCEDURE|Vitrectomy with ILM flap|In both groups, a single-layer ILM temporal flap of approximately 2 times the size of the optic disc was fashioned using an ILM forceps temporal to the macula. The nasal edge of the flap was not detached from the temporal MH edge. The flap was reflected nasally to cover the MH
223852939|NCT04223362|OTHER|Community-based physical activity programme|After completing a pulmonary rehabilitation programme, participants will enrol a 6-months personalised community-based physical activity programme, which will include 2 sessions/week, with the aerobic training being the cornerstone. Patients will receive the PICk UP manual and a diary to register their physical activities. During the 1st month the physiotherapist will guide patients through 4 types of outdoors and indoors physical activities. Patients will then be asked to choose and commit to 1 or 2 activities, according to their preferences, which they shall integrate for another 5 months. During this period, the support provided by physiotherapist will decrease over time.
223852940|NCT04223362|OTHER|Pulmonary Rehabilitation|Patients will receive the same pulmonary rehabilitation programme as the experimental group, i.e., exercise training twice a week and education and psychosocial support once every other week, which integrates physical activity recommendations.
223852941|NCT06501079|PROCEDURE|ultrasound guided Erector Spinae Plane Block using 27ml bupivacaine 0.25%|"ESP block will be performed U/S at the level of T 10 paraspinal level. The ultrasound transducer should be placed in the midline of the back at the desired level. The probe should then slowly be moved laterally until the transverse process is visible. The transverse process requires differentiation from the rib at that level.~Erector spinae muscle should be identified superficial to the transverse process. The needle inserted superior to the ultrasound probe in the cephalad to caudal direction. Once the needle tip is below the erector spinae muscle.~This separation from the transverse process confirms the proper needlemposition.~The local anesthetic should then be injected in 5 ml increments. The block will be performed preoperatively."
223852942|NCT01049620|DRUG|RAD001, Capecitabine, Oxaliplatin|"Dose level -1 : Capecitabine 800mg/m2 po bid D1-14, Oxaliplatin 100mg/m2 iv D1 RAD001 5mg po qd D1-21~Dose level 1 : Capecitabine 800mg/m2 po bid D1-14, Oxaliplatin 100mg/m2 iv D1 RAD001 7.5mg po qd D1-21~Dose level 2 : Capecitabine 800mg/m2 po bid D1-14, Oxaliplatin 130mg/m2 iv D1 RAD001 7.5mg po qd D1-21~Dose level 3 : Capecitabine 1000mg/m2 po bid D1-14, Oxaliplatin 100mg/m2 iv D1 RAD001 7.5mg po qd D1-21~Dose level 3A : Capecitabine 800mg/m2 po bid D1-14, Oxaliplatin 130mg/m2 iv D1 RAD001 10mg po qd D1-21~Dose level 3B : Capecitabine 1000mg/m2 po bid D1-14, Oxaliplatin 100mg/m2 iv D1 RAD001 10mg po qd D1-21~Dose level 4 : Capecitabine 1000mg/m2 po bid D1-14, Oxaliplatin 130mg/m2 iv D1 RAD001 7.5mg po qd D1-21~Dose level 5 : Capecitabine 1000mg/m2 po bid D1-14, Oxaliplatin 130mg/m2 iv D1 RAD001 10mg po qd D1-21"
223852943|NCT01766167|DRUG|MP-424|Low
223852944|NCT01766167|DRUG|MP-424|Middle
223852945|NCT01766167|DRUG|MP-424|High
223852946|NCT01766167|DRUG|MP-424|Multiple
223852947|NCT02828605|DEVICE|Virtual Interactive Platform (VIP) Transplant|
223852948|NCT01813903|BEHAVIORAL|Intensified dietary counseling|The intervention is completed by public health nurses who will be trained to provide family-centered empowering and motivational lifestyle counseling at the normal health check visit. Parents expecting child will use web application developed for nutritional counseling. Web application consists of dietary questionnaire from which the parents will receive immediately automatic feedback. Feedback concerns the quality of diet in relation to the Finnish nutrition recommendations. Feedback will be given in an encouraging format. Own targets of food changes can also be recorded in the application, and the application can be used to monitor how they are achieved.
223852949|NCT01813903|BEHAVIORAL|Mobile application|Mothers expecting child will use mobile application. Mobile application consists of text, audio and video exercises, which are aimed to increase the psychological flexibility and thus mental and physical well-being.
223852950|NCT03035656|DRUG|Ropivacaine|Administration of Ropivaciane via epidural injection intra-operatively
223852951|NCT03035656|OTHER|Saline|Administration of saline via epidural injection intra-operatively
223852952|NCT03047590|BEHAVIORAL|Choice-based Exercise Intensity|Participants are instructed to choose whichever intensity they want, rather than regulate their intensity based on heart rate.
223852953|NCT03047590|BEHAVIORAL|Positive Affect Focus|Participants are instructed to focus on feeling good while exercising.
223852954|NCT03047590|BEHAVIORAL|Heart rate-based Exercise Intensity|Participants are instructed to regulate their exercise intensity based on their heart rate.
223852955|NCT01276990|DRUG|BI 224436|Oral drinking solution
223852956|NCT01276990|DRUG|BI 224436|Oral drinking solution
224265850|NCT05141474|DRUG|Interleukin-2|"Patients will receive sequential doses of 720,000 IU/kg IV IL-2 every 8-24 hours depending on patient tolerance. It will be administered on Days 0 to 2, starting between 3 and 24 hours after the completion of NEXTGEN-TIL infusion.~IL-2 doses may be skipped in case of toxicity. If 2 sequential doses or more than 2 non-sequential doses of IL-2 are skipped due to patient intolerance or the discretion of the investigator, IL-2 administration must be stopped."
223852957|NCT01276990|DRUG|BI 224436|Oral drinking solution
223852958|NCT01276990|DRUG|BI 224436|Oral drinking solution
223852959|NCT01276990|DRUG|BI 224436|Oral drinking solution
223852960|NCT01276990|DRUG|BI 224436|Oral drinking solution
223852961|NCT01276990|DRUG|BI 224436|Oral drinking solution
223852962|NCT01276990|DRUG|BI 224436|Oral drinking solution
223852963|NCT01276990|DRUG|BI 224436|Oral drinking solution
223852964|NCT01276990|DRUG|Placebo|Oral drinking solution
223852965|NCT03646331|DRUG|Imeglimin Reference product|Reference product
223852966|NCT03646331|DRUG|Imeglimin|Test product (new formulation tablet)
223852967|NCT02780947|PROCEDURE|Ventricular tachycardia substrate ablation|"Study protocol~1. Baseline programmed ventricular stimulation performed from the LV~2. High density endocardial LV mapping using CARTO® 3 System~3. Randomized substrate ablation in half patients. Ablation end-point is considered the elimination of all endocardial late and early potentials (LPs and EPs)~4. Final programmed ventricular stimulation performed from the LV~Programmed ventricular stimulation with up to 4 extrastimuli from LV is performed and repeated at the end of the procedure in patients undergoing substrate ablation."
223852968|NCT01710514|DRUG|FE 999913 vaginal tablet|
223852969|NCT05166174|PROCEDURE|Transvaginal ultrasound in the third trimester pregnancy|Ultrasonographic transvaginal exam in patients at third trimester pregnancy (34-38 weeks of gestation)
223852970|NCT00382135|DRUG|tadalafil|20mg tadalafil tablet taken by mouth once a day for 40 weeks
223852971|NCT00382135|DRUG|placebo|Placebo tablet taken by mouth once a day for 40 weeks
223852972|NCT01398930|OTHER|acupuncture|This is a 3-armed single-blinded randomized sham-controlled trial, comparing acupuncture along with pharmacological treatment, sham acupuncture including pharmacological treatment, and pharmacological treatment alone.
223852973|NCT02393898|DRUG|Bevacizumab|Bevacizumab will be prescribed by the local clinician according to the SmPC and standard of care for up to 15 months. No treatment will be provided by the Sponsor in this non-interventional study.
223852974|NCT02393898|DRUG|Carboplatin|Carboplatin will be prescribed by the local clinician according to local labeling and standard of care for up to 18 weeks. No treatment will be provided by the Sponsor in this non-interventional study.
223852975|NCT02393898|DRUG|Paclitaxel|Paclitaxel will be prescribed by the local clinician according to local labeling and standard of care for up to 18 weeks. No treatment will be provided by the Sponsor in this non-interventional study.
223852976|NCT02615522|DEVICE|BPK-S Integration|
223852977|NCT00589732|DRUG|Valsartan|Valsartan 160mg per day
223852978|NCT02020018|DEVICE|Prevena Incision Management System|negative pressure therapy that will be applied instead of the regular dressing immediately postoperatively in high risk patients and kept for 6-7 days
223852979|NCT02020018|OTHER|Conventional sterile dry wound dressing|regular dressing that is applied immediately postoperatively for high risk patients in the operating room after sternotomy
223852980|NCT00667693|DEVICE|Macintosh laryngoscope|Intubation with Macintosh laryngoscope
223852981|NCT00667693|DEVICE|Pentax AWS|Intubation with Pentax AWS
223852982|NCT02265731|DRUG|azacitadine|75 mg/m2 by IV infusion or subcutaneous dosing
223852983|NCT02265731|DRUG|venetoclax|Step-up doses of venetoclax to the designated cohort dose
223852984|NCT02265731|DRUG|rituximab / IDEC-C2B8|375 mg/m2 on Week 6
223852985|NCT02265731|DRUG|rituximab / IDEC-C2B8|500 mg/m2 Week 10 Day 1 and thereafter
223852986|NCT01320709|DRUG|Piroxicam ( BAYl1902)|Single dose of 20 mg piroxicam (i.e., 1 piroxicam capsule + 3 placebo capsule)
223852987|NCT01320709|DRUG|Piroxicam ( BAYl1902)|Single dose of 40 mg piroxicam (i.e., 2 piroxicam capsules + 2 placebo capsule)
223852988|NCT01320709|DRUG|Placebo|Single dose of placebo (i.e., 4 placebo capsules)
223852989|NCT01320709|DRUG|Piroxicam ( BAYl1902)|Single dose of 80 mg piroxicam (i.e., 4 piroxicam capsules)
224265851|NCT05285319|RADIATION|Prostate Only Radiation|Prostate Only Radiation for Intermediate and High Risk Prostate cancer
223852990|NCT02518243|OTHER|Patient's answer with non pharmacological therapeutic|"Installation at patient's home of :~* aromatherapy~* music therapy~* cognitive training in multimedia application offering cognitive games"
223852991|NCT04044664|DRUG|Placebo oral capsule|Matching placebo capsules.
223852992|NCT04044664|DRUG|NYX-783|NYX-783 is a small molecule that modulates the N-methyl-D-aspartate receptor (NMDAR).
223852993|NCT02601703|DRUG|Tacrolimus Ointment 0.1%|apply thin layer of ointment to affected area
224265852|NCT05285319|RADIATION|Prostate and Pelvic Lymph Node Radiation|Prostate and Pelvic Lymph Node Radiation for Intermediate and High Risk Prostate cancer
223852994|NCT02601703|DRUG|Protopic® ointment, 0.1%|apply thin layer of ointment to affected area
223852995|NCT02601703|DRUG|Placebo of Tacrolimus Ointment|apply thin layer of ointment to affected area
223852996|NCT04975243|DEVICE|GentleMax Pro Plus 755nm and 1064nm laser system|The GentleMax Pro Plus is a 755nm and 1064nm laser system. The GentleMax Pro PlusTM is indicated for stable long-term or permanent hair reduction using varying spot sizes and fluences.
223852997|NCT02005666|DRUG|Clindamycin Phosphate 1.2% / Benzoyl Peroxide 5% Gel|Drug:-1.2% Clindamycin Phosphate/ 5% Benzoyl Peroxide Gel of Cadila healthcare limited Dosage Form:-Gel Dosage:-Thin Layer/Pea sized Frequency:-Once a day ,every evening Duration:-77 consecutive days
223852998|NCT02005666|DRUG|DUAC® Gel|Drug:-DUAC® Gel Dosage Form:-Gel Dosage:-Thin Layer/Pea sized Frequency:-Once a day ,every evening Duration:-77 consecutive days
223852999|NCT02005666|DRUG|Placebo|Drug:-Placebo, Dosage Form:-Gel Dosage:-Thin Layer/Pea sized Frequency:-Once a day ,every evening Duration:-77 consecutive days
223853000|NCT03163862|PROCEDURE|Endometrial scratch|the intervention group, endometrial biopsy will be performed with a pipelle de Cornier® (Laboratoires Prodimed, Neully-En-Thelle, France). The pipelle was introduced gently through the cervix up to the uterine fundus. the examiner applied regular back-and-forth movements (2-4 cm) during a period of 30 s. The obtained specimens will be sent for histology evaluation.
223853001|NCT03163862|DRUG|G-CSF administration|1- 300 µg trans cervical intrauterine of G-CSF was administered at the oocyte retrieval day, subcutaneous 300 micrograms G-CSF on the day of embryo transfer
223853002|NCT03163862|DRUG|Saline Solution|saline infusion every day from the day of embryo transfer through the day of beta HCG test
223853003|NCT00001575|BIOLOGICAL|Y-90 Humanized Anti-Tac|10 mCi (if a bone marrow transplant was part of the patient's previous therapy) or 15 mCi of yttrium labeled anti-TAC; followed by calcium trisodium Inj (Ca DTPA).
223853004|NCT00001575|DRUG|Calcium-DTPA|Ca-DTPA will be administered intravenously on Days 1-3 to clear the radioactive agent from the body
223853005|NCT01700569|DRUG|Temozolomide|All the Patients are treated by oral Temozolomide 75 mg/m²/day every day during 42 days, 30 minutes after Folinic acid and 120 min before the radiation dose to the brain tumor. After one month rest, the maintenance phase consists of:Temozolomide is given orally (30 min after Folinic acid), at 200 mg/m²/day every day during 5 days: one course every month during 6 months (6 maintenance course).
223853006|NCT01700569|DRUG|folinic acid at pharmacological dose is the escalated drug|
223853007|NCT01700569|RADIATION|High voltage radiation therapy (linear accelerator)|Brain tumor field is irradiated Five days a week, during Stupp regimen during 6 weeks. During the sams time, Folinic acid and Temozolomide are given orally every days (six weeks).
223853008|NCT05583240|DRUG|Essences and Essential Oils|Participants will received Essential Oils through a nasal stick during 4 weeks.
223853009|NCT00728845|BIOLOGICAL|bevacizumab|Only patients eligible for bevacizumab will receive bevacizumab. Dose is at 15 mg/kg on day 1 of each cycle.
223853010|NCT00728845|DRUG|carboplatin|Carboplatin will be given at AUC = 6 by IV over 15-30 minutes on Day 1 immediately following paclitaxel
223853011|NCT00728845|DRUG|hydroxychloroquine|200 mg orally BID (total daily dose of 400 mg)
223853012|NCT00728845|DRUG|paclitaxel|Dose of 200 mg/m2 IV on day 1 of each cycle
223853013|NCT00300456|DRUG|ABT-335|135 mg, daily, 12 weeks
223853014|NCT00300456|DRUG|Simvastatin|daily, 12 weeks, see Arm Description for dosage information
223853015|NCT00300456|DRUG|Placebo|Daily, 12 weeks, see Arm Description for placebo information
223853016|NCT00247143|DRUG|Kaletra (drug)|
223853017|NCT01801319|DEVICE|Libra Deep Brain Stimulation System|
223853018|NCT04258774|OTHER|Carbon Dioxide|The study team will administer inhaled carbon dioxide to the participants during an MRI at a level
223853019|NCT04874571|OTHER|Muscle Energy Technique group|In addition to the home exercise program of 12 sessions for 4 weeks, 3 days a week, muscle energy technique will be applied to the individuals in the MET(Musculer Energy Technique) group.
223853020|NCT00438555|BEHAVIORAL|Parents and children group|3 months workshops of parents and children intervention, guided by dietician and phycologist
223853021|NCT00438555|BEHAVIORAL|Parent's group|3 months workshop of parents intervention, guided by dietician and phycologist
223853022|NCT05097573|DEVICE|Venus Viva|The Venus Viva™ fractional RF device has been shown in clinical studies to improve various skin conditions related to aging and alter collagen structures such as wrinkles, stretch marks, rhytids and scars. Beginning with the Baseline visit (Visit 1), subjects will receive a total of 4 treatments approximately 4 weeks apart.
223853023|NCT03208101|BIOLOGICAL|DTP-HepB-IPV-Hib vaccine|Hexavalent vaccine (DTP-HepB-IPV-Hib vaccine: Diphtheria-Tetanus-Pertussis-Hepatitis B-Inactivated Poliovirus-Haemophilus influenzae type b vaccine)
223853024|NCT03208101|BIOLOGICAL|DTP-HepB-Hib vaccine & IPV|Pentavalent vaccine (DTP-HepB-Hib vaccine: Diphtheria-Tetanus-Pertussis-Hepatitis B-Haemophilus influenzae type b vaccine)+ IPV(Inactivated poliovirus vaccine)
223853025|NCT01909232|DEVICE|Active Cervel Neurotech Multi-Coil Transcranial Magnetic Stimulator|The Cervel Neurotech multi-coil transcranial magnetic stimulator is an investigational repetitive transcranial stimulation (rTMS) device. In the active group, magnetic power output will be delivered to the subject through the coils.
223853026|NCT01909232|DEVICE|Inactive Cervel Neurotech Multi-Coil Transcranial Magnetic Stimulator|The Cervel Neurotech multi-coil transcranial magnetic stimulator is an investigational repetitive transcranial stimulation (rTMS) device. In the inactive group, no magnetic power output will be delivered to the subject through the coils.
223853027|NCT02175537|BEHAVIORAL|Microclinic Social Induction Diabetes and Obesity Program|Microclinics consist of 2-8 individuals from pre-existing social networks (friends, relatives, coworkers, neighbors, etc) that voluntarily participate in ongoing education and medical monitoring from local health care professionals, learning and practicing diabetes management strategies, sharing much-needed medical supplies, and exchanging social support.
223853028|NCT03370055|DEVICE|LeucoPatch®|LeucoPatch® is an elastic membrane produced by the patients own venous blood by centrifugation, and one or two is placed on the wound once a week The LeucoPatch® consist of the fibrin Leucocytes and growth factors from the patients own blood
223853029|NCT03370055|OTHER|Control,|Usual wound care in a specialized clinic
223853030|NCT04990791|DRUG|Aspirin 75mg|Aspirin 75mg OD for 14 days
223853031|NCT04990791|DRUG|Aspirin 20mg|Aspirin 20mg BD for 14 days
223853032|NCT04990791|DRUG|Rivaroxaban 2.5 mg|Rivaroxaban 2.5mg BD
223853033|NCT02637271|OTHER|Low calorie total meal replacement|Participants will be provided instruction in the appropriate use of the meal replacement product. The participants will be directed to refrain from all items of food for a period of 21 days except for the meal replacement products and vitamin supplements provided by the investigators (1120 kcal/day). Optifast™ 800 total meal replacement shakes will be provided to the participants for the 21 day intervention period.
223853034|NCT02637271|OTHER|Low calorie typical diet|Participants will be directed to use portion control to maintain a calorie level no greater than 1120 kcal per day. The participants will be directed to continue to consume food and beverage items that are representative of their typical diet (with the exception of reduced portions). Participants will be provided resources to assist them in determining caloric content of foods eaten.
223853035|NCT02797405|RADIATION|Standard treatment|Sarcoma patients will undergo radiotherapy followed by surgery Rectum cancer patients will undergo radio-chemotherapy followed by surgery Esophagus cancer patients will undergo radio-chemotherapy followed by surgery
223853036|NCT01407900|DRUG|CD-NP|CD-NP as a four hour infusion at 10 ng/kg/min IV
223853037|NCT01407900|DRUG|5% Dextrose in Water|four hour infusion IV
223853038|NCT02303444|DRUG|Sorafenib (Nexavar, BAY43-9006)|Patients can get sorafenib at any time during study.
223853039|NCT02303444|DRUG|Other Multikinase inhibitors|Patients can get MKIs at any time during study.
223853040|NCT01549496|DRUG|Amlodipine|amlodipine 2.5 mg QD
223853041|NCT01549496|DRUG|Diltiazem|diltiazem 120 mg qd
223853042|NCT02870270|OTHER|Cancer treatment|Patients undergoing treatment for cancer in the head and neck region
223853043|NCT02750709|DRUG|Nitisinone|A single oral dose of Nitisinone 10 mg tablet will be administered in fasted state.
223853044|NCT02750709|DRUG|Nitisinone 10 mg Tablet High Compritol|A single oral dose of Nitisinone 10 mg High Compritol tablet will be administered in fasted state.
223853045|NCT02750709|DRUG|Orfadin|A single oral dose of Orfadin 10 mg hard capsule will be administered in fasted state.
223853046|NCT05095675|BEHAVIORAL|psychological questionnaires|Participants have to fulfill psychological questionnaires in different time points during medical oncological treatment
223853047|NCT02864238|OTHER|electronic milestone pathway|an electronic based, clinical milestone driven pathway developed to guide the care of cardiac valve surgery patients.
223853048|NCT01317134|DEVICE|EndoPAT measurement|EndoPAT (Itamar Medical Ltd, Ceasarea, Isreal) quantifies the endothelium-mediated changes in vascular tone, elicited by a 5-minute occlusion of the brachial artery (using a standard blood pressure cuff). When the cuff is released, the surge of blood flow causes an endothelium-dependent Flow Mediated Dilatation (FMD). The dilatation, manifested as Reactive Hyperemia, is captured by EndoPAT as an increase in the PAT Signal amplitude. A post-occlusion to pre-occlusion ratio is calculated by the EndoPAT software, providing the EndoPAT index. EndoPAT is FDA-cleared and CE-marked.
223853049|NCT01317134|BIOLOGICAL|Blood Test|It is hypothesized that L-arginine/NO-metabolites are altered in pulmonary hypertension depending on disease severity. Moreover, polymorphisms in L-arginine/NO-metabolism modifying factors may influence disease severity. Analysis will be performed following established/published protocols after isolation from whole blood.
223853050|NCT01693965|OTHER|sputum samples|
223853051|NCT03034252|PROCEDURE|Patients with Liposarcoma|Evaluation of Liposarcoma treated in a single center
223853052|NCT02628691|OTHER|Liver fibrosis progression|A history taking and physical examination focused on hepatic disease and blood sampling for basic hematologic and hepatic function parameters will be performed. Patients will also be referred every year for ultrasound and transient elastography measurements and sampling for some additional liver function tests and measurement of HCV-RNA viral load.
223853053|NCT01506362|DRUG|BL-7040|"BL-7040 is an orally available new chemical entity for the treatment of IBD. BL-7040 is a synthetic oligonucleotide with dual activity on both the nervous and immune systems.~Study duration can last up to 8 weeks, including up to 9 days in the screening period, up to 5 weeks of treatment with BL-7040, and up to 2 weeks for follow up.~BL-7040 12 mg QD for 19-21 days followed by BL-7040 40 mg QD for 14 days."
223853054|NCT03917706|OTHER|Questionnaire|Patients will be contacted by phone in order to fill in a questionnaire regarding their quality of life.
223853055|NCT00290732|DRUG|Intraductal arm|Patients will receive PLD intraductally according to the dose escalation schema (Dose Level -1=1 mg, Dose Level 1=2 mg, Dose Level 2= 5mg, Dose Level 3=10 mg). The PLD dose will be diluted in 5% dextrose in water and will be mixed for a total volume of 5 ml. The PLD will be administered via a breast duct (i.e., intraductally) using a microcatheter
223853056|NCT00290732|DRUG|Intravenous arm|Blood samples and a breast tissue biopsy collected to look at levels of doxorubincol from patients receiving intravenous pegylated liposomal doxorubin to compare to the group receiving drug intraductally.
223853057|NCT04408287|OTHER|WebEx Physical Activity Program|The program will be delivered twice-weekly through 45-minute sessions over 6 weeks. An experienced fitness instructor with lived experience and a graduate student from the Department of Health and Rehabilitation Sciences, will lead a class of 4-6 participants. The sessions will be comprised of a 10-minute warm-up phase, a 25-minute aerobic phase and a 10-minute cool-down phase that will incorporate upper-extremity flexibility exercises and mindfulness meditation. Over the duration the instructor will be sensitive to varying levels of function and fitness and will structure the classes to enable a slow progression of intensity. Individual semi-structured interviews will be completed over the WebEx platform to garner feedback and improve study programming for future implementation of a health care service at Parkwood Institute Outpatient Clinic.
223853058|NCT02595398|DRUG|4mg CLS-TA Suprachoriodal Injection|CLS-TA, 40 mg/mL (4 mg in 100 µL), administered as a single injection at 2 timepoints
223853059|NCT02595398|DRUG|Sham Procedure|Sham procedure administered at 2 timepoints
223853060|NCT04175886|DRUG|Tofacitinib|Patients will be treated with tofacitinib
223853061|NCT00542386|DRUG|MCI-196|3g to 15g/day (3 times a day), Tablet, 12 weeks of fixed dose of study
223853062|NCT00542386|DRUG|Placebo|3g to 15g/day (3 times a day), Tablet, 12 weeks of fixed dose of study
223853063|NCT01573858|OTHER|Acupuncture treatment 1|Two sets of acupuncture points will be alternated every second treatment. The first set consists of CV3, CV 6, and ST 29 bilaterally，SP 6 and SP 9 bilaterally. Needles will also be placed in LI bilaterally and GV 20. CV 3, CV 6, ST 29, SP 6, and SP 9 will be connected to and electrical stimulator and stimulated with low-frequency EA of 2Hz, 0.3 ms.
223853064|NCT01573858|OTHER|Acupuncture treatment 2|Needles will be inserted to a depth of \<5 mm, one in each shoulder and on in each upper arm at non-acupuncture points. Electrodes will be attached to the needles and the stimulator will be turned on at an intensity of zero (no active current) in order to mimic EA in the acupuncture treatment 1. No manual stimulation of the needles will be performed.
223853065|NCT01573858|OTHER|CC|CC 50 mg every day for 5 days (day 3-7 of cycle), for a total of 4 cycles. Non-response will be defined after 4 weeks of CC placebo administration with 3 consecutive weekly negative P4 and hCG levels. Then during the fifth week a higher dose consisting of one more tablet per day (up to 3 tablets per day at third or fourth cycles, if they remain non-responders) will be given 5 days.
223853066|NCT01573858|OTHER|CC placebo|CC placebo 50 mg every day for 5 days (day 3-7 of cycle), for a total of 4 cycles. Non-response will be defined after 4 weeks of CC Placebo administration with 3 consecutive weekly negative P4 and hCG levels. Then during the fifth week a higher dose consisting of one more tablet per day (up to 3 tablets per day at third or fourth cycles, if they remain non-responders) will be given 5 days.
223853067|NCT00197015|BIOLOGICAL|Havrix®|2 doses administered intramuscularly
223853068|NCT00197015|BIOLOGICAL|M-M-R®II|1 dose administered subcutaneously
223853069|NCT00197015|BIOLOGICAL|VARIVAX®|1 dose administered subcutaneously
223853070|NCT00921739|RADIATION|Esophageal sparing IMRT|6 fractions/week of 2Gy each for 29 fx (58 Gy), 31 fx (62 Gy), 33 fx (66 Gy), 35 fx (70 Gy), or 37 fx (74 Gy).
223853071|NCT01191463|OTHER|Mung Bean Meal|50g mung beans will be cooked to a curry with oil, spices and small amounts of vegetables.
223853072|NCT01191463|OTHER|Guava|A fresh Guava fruit will be provided raw (approx 100g fresh weight)
223853073|NCT01367912|DRUG|estradiol tablet|received 2 mg estradiol tablets orally two times daily beginning from the first day after hCG injection, in addition to vaginal progesterone gel
223853074|NCT01367912|DRUG|estradiol tablet|received 2 mg estradiol tablets orally two times daily beginning from the fifth day after hCG injection, in addition to vaginal progesterone gel.
223853075|NCT03525041|PROCEDURE|CABG|CABG will be performed using standard surgical techniques. All procedures will be performed with cardiopulmonary bypass(CPB). Saphenous vein(SV)will be used as conduit but harvesting methods will not be prescribed, and utilization of the left internal mammary artery (LIMA) is recommended when a left anterior descending (LAD) graft is indicated. The technical details of bypass grafting will not be prescribed. Complete revascularization will be performed, judging by the surgical investigator.
223853076|NCT03525041|PROCEDURE|mitral valve annuloplasty|Surgical techniques for mitral valve annuloplasty may need to be adjusted at the discretion of the surgeon, as based on intra-operative findings that may not be previously recognized in the pre-operative evaluation.
223853077|NCT03097237|OTHER|Wholegrain rye|Cereal products based on wholegrain rye
223853078|NCT03097237|OTHER|Refined wheat|Cereal products based on refined wheat
223853079|NCT04163224|DEVICE|RibFix Advantage|Class II device in the United States; consists of bridges (with locking posts) and locking caps for the thoracoscopic fixation and stabilization of ribs. These implants are manufactured from commercially pure titanium and titanium alloys. When fully assembled, the bridge plate is placed on the underside of the rib (pleural cortex); the threaded locking posts extend through pre-drilled holes in the rib, and the locking caps are fixed to the locking post on the anterior (cutaneous) side of the rib. The combined threaded locking post and cap provides for fixation of the bridge and stabilization of the fracture.
223853080|NCT04806113|BIOLOGICAL|Moderna COVID-19 vaccine|Two doses from the Moderna vaccine will be administered intramuscularly. The time between dose 1 and dose 2 of the vaccine will be 28 days.
223853081|NCT01534910|DRUG|aged garlic extract|2400 mg a day
223853082|NCT01534910|DRUG|placebo|placebo
223853083|NCT05027087|DIETARY_SUPPLEMENT|Blueberry gummy|Gummy bear containing blueberry powder
223853084|NCT05027087|DIETARY_SUPPLEMENT|Placebo gummy|Gummy bear with no active ingredients
223853085|NCT04966572|DEVICE|Presurgical vacuum formed nasoalveolar molding aligners|at first visit, the infants will receive this appliance which is a maxillary vacuum plate incorporated with palatal screw, the infant's parents will be instructed to activate the screw and apply horizontal tap which will be placed at the base of nose in order to approximate lip segments and to change tape daily. After that, The infants will be recalled one week after the first visit to add the nasal stents into the appliance.
223853086|NCT04966572|DEVICE|Conventional Grayson acrylic formed nasoalveolar molding appliances|"at first visit, the infants will receive this appliance which is a maxillary acrylic plate without adding taping, the infants will be recalled bi weekly for activating the appliance.~When the cleft alveolar gap is reduced to 6mm or less, a pair of nasal stents will be added to mold the nasal cartilage. the infants will be followed up for 4-6 months."
223853087|NCT02929511|PROCEDURE|Reciprocating single-file system|The device is moving in CW and CCW direction with different angles. It is a single-file endodontic file. The intervention is Reciproc Blue reciprocating single-file system.
223853088|NCT02929511|PROCEDURE|Rotational single-file system.|The device is moving in continuous rotational. It is a single-fie endodontic file.
223853089|NCT02929511|PROCEDURE|Active comparator Protaper multi-file system|
223853090|NCT03682328|PROCEDURE|vertebroplasty|Cement augmentation of the vertebral body
223853091|NCT03682328|PROCEDURE|kyphoplaty|Cement augmentation of the vertebral body
223853092|NCT03581968|DEVICE|Artificial Pancreas|"The system is composed of 3 main components:~1. Insulin infusion pump to infuse insulin. The pump model used in the study is t:slim, Tandem Diabetes Care.~2. Continuous glucose monitor (CGM) to continuously measure glucose levels in the interstitial fluid. Glucose levels will be measured by Dexcom G5® CGM.~3. MAP application (iMAP) that computes insulin infusion based on the glucose values. The application also alarms the user when glucose sensor values are approaching the hypoglycemic or hyperglycemic range. The iMAP runs on an android smartphone.~Every 10 minutes, iMAP retrieves the glucose values from the Dexcom G5 CGM via Bluetooth. The application computes an optimal insulin infusion rate based on i) the current glucose reading, ii) the glucose trend (i.e. how quickly the glucose level is rising or falling) and iii) the open-loop basal rates (study parameters). The insulin recommendations are then sent wirelessly via Bluetooth to the insulin pump."
223853093|NCT00454792|OTHER|Exercise|Back exercise: At home every day. In groups once a week. Duration 10 weeks.
223853094|NCT00454792|OTHER|Restitution|Restitution: At home 2 times one hour. Meetings every 2 weeks. Duration 10 weeks.
223853095|NCT02047851|OTHER|Acupuncture|Patients are randomized to real acupuncture or sham acupuncture if they are in the intervention group
223853096|NCT01007344|DIETARY_SUPPLEMENT|flaxseed|1 muffin for breakfast, 1 muffin for afternoon snack and 1 slice of bread for evening snack every day for 4 weeks
223853097|NCT01007344|DIETARY_SUPPLEMENT|whole wheat flour|1 muffin for breakfast, 1 muffin for afternoon snack and 1 slice of bread for evening snack every day for 4 weeks
223853098|NCT04744519|OTHER|Collect data|\- Controlled ovarian stimulation with GnRH antagonists effected to the patients in order to get their eggs through follicular puncture, which will be trigger by GnRH analogue. The eggs will be isolated and processed according to the standard protocol.
223853099|NCT00513734|OTHER|Hydrogel dressing|3x3cm hydrogel dressing over closed eye
223853100|NCT00513734|OTHER|Lacrilube ointment|lubricant put into eye (inferior formix)
223853101|NCT01848548|PROCEDURE|Superior Laryngeal Nerve Block using the Thyrohyoid Membrane as an Anatomic Landmark|The needle is introduced just lateral to midline above the thyroid notch in a slightly medial direction so as to enter the thyrohyoid membrane, and inserted about 1-1.5 cm. Three milliliters of 2% lidocaine is injected.
223853102|NCT02982213|OTHER|Companion Present|A companion will be present during the epidural catheter placement.
223853103|NCT06360016|BEHAVIORAL|Recreation Activity Program|Students in the study group were subjected to a 24-session RAP, including entertaining games. This program was conducted by the first-name researcher, who had completed their undergraduate education in preschool education and was supported by the second and third-named researchers as assistant instructors. The 24-session program, which included rhythm, balance, and patience acquisition games, was planned according to a game theory model that primarily aimed to entertain children. The program, aimed at developing children's self-regulation skills based on fundamental reflections of the model, would consist of simple rule-based entertaining games. Before the program's application, researchers provided information about the research and program to the experimental group, and verbal consent was obtained.
223853104|NCT02646670|DRUG|Ranibizumab|\- In the first group will be held three applications of intravitreal ranibizumab 0.1 ml, with one application every month and follow up with Optical Coherence Tomography
223853105|NCT02646670|DRUG|Aflibercept|\- In the second group will be held three applications of Intravitreal Aflibercept 0.1 ml, with one application each month followed by monitoring with Optical Coherence Tomography
223853106|NCT02646670|DRUG|Ranibizumab and Aflibercept|\- The third group will be held two applications of Ranibizumab 0.1 ml interspersed with one application of Aflibercept 0.1 ml in the second month and subsequent evaluation with Optical Coherence Tomography
223853107|NCT02646670|DRUG|Aflibercept and ranibizumab|\- In the fourth group will be held two applications of 0.1 ml Aflibercept interspersed with one application of Ranibizumab 0.1 ml in the second month and subsequent evaluation with Optical Coherence Tomography
223853108|NCT03651531|DRUG|Insulin|Weight based insulin will be calculated using 0.7 units/kg/day in the first trimester, 0.8 units/kg/day in the second trimester and 1 units/kg/day in the third trimester. This total insulin will then be divided into short acting insulin and intermediate acting insulin per provider discretion.
223853109|NCT03651531|DRUG|Metformin|Will be initiated at dose of 500 mg twice daily. If glycemic control is suboptimal, the dose of metformin will be increased to 1000 mg twice a day. Metformin will be titrated prior to increases in insulin.
223853110|NCT02247258|DRUG|Azathioprine|See arm/group descriptions
223853111|NCT02247258|DRUG|Azathioprine in case of endoscopic recurrence|See arm/group descriptions
223853112|NCT02247258|PROCEDURE|Ileocolonoscopy|See arm/group descriptions
223853113|NCT02247258|PROCEDURE|Small bowel follow trough|See arm/group descriptions
223853114|NCT01549652|DRUG|Ondansetron|Ondansetron 8 mg oral tablet
223853115|NCT01549652|DRUG|Placebo|Placebo to Match Ondansetron
223853116|NCT01549652|DRUG|Morphine|Sustained release oral morphine, beginning at 30 mg/d, titrated up by 15 mg/d every 2 days until adequate analgesia is achieved
223853117|NCT01549652|DRUG|Naloxone 0.4 mg/70 kg|Naloxone 0.4 mg/70 kg intravenous
223853118|NCT01549652|DRUG|Naloxone 0.8 mg/70 kg|Naloxone 0.8 mg/70 kg intravenous
223853119|NCT04619303|DRUG|Dexamethasone intravitreal implant|Intravitreal injection of 0.7mg dexamethasone implant
223853120|NCT04619303|DRUG|Bevacizumab Injectable Product|Invtravitreal injection of 1.25mg/0.05mL bevacizumab
223853121|NCT03610997|PROCEDURE|Photorefractive keratectomy|
223853122|NCT05939648|BIOLOGICAL|SARS-CoV-2 Bivalent mRNA Vaccine|100 μg /1.0 mL/dose, slightly milky white and clear liquid, intramuscular injection into the lateral deltoid muscle of the upper arm.
223853123|NCT05939648|OTHER|Saline|100 μg /1.0 mL/dose, intramuscular injection into the lateral deltoid muscle of the upper arm.
223853124|NCT05826678|DEVICE|Continuous Glucose Monitor|The Clinical Diabetes Educator (CDE) will follow up with the participants at Month 1 after the baseline study visit, at the study midpoint (Month 3), and at the end of the study (Month 6) to check CGM usage, including timely calibration and change adherence. At the end of the study, participants will be invited to complete a survey and participate in virtual interviews to assess changes in their health behaviors and the acceptability of CGM devices.
223853125|NCT05826678|BEHAVIORAL|Finger stick glucose monitoring|Participants will adhere to the standard care protocol and continue self-monitoring of blood glucose through fingersticks as per usual practice\[46\]. The Clinical Diabetes Educator (CDE) will monitor and provide follow-up to the control group participants as per the same schedule followed for the intervention group.
223853126|NCT06479733|PROCEDURE|buccal pedicle flap|For the first group (buccal pedicle flap group), outlining the full-thickness palatal flap 1 mm greater than the diameter of the underlying cover screw will be done, making a partial incision at the hinge portion of the created mini-pedicle flap to facilitate buccal rolling, de-epithelializing the mini-pedicle flap, then two small vertical incisions will be performed similarly mesial and distal to the screw border as wide as possible preserving the papilla and extending labially to include all the keratinized mucosa, elevating a full-thickness flap, then rolling of the pedicle flap into the created buccal pouch. The flap will be then sutured all around in place using a 5/0 vicryl suture
223853127|NCT06479733|PROCEDURE|connective tissue graft|For the second group (free CTG group), masticatory mucosa on the palate between palatal raphae and maxillary posterior teeth is the most common location for the donor site for free CTG. It will be obtained by harvesting and de-epithelializing FGG asbeing a CTG derived from de-epithelialization of FGG mainly composed of lamina propria. Then the donor site will be covered by gel foam , sutured and protected.
224076111|NCT06549478|PROCEDURE|Computed Tomography|Undergo PET/CT
224076112|NCT06549478|RADIATION|Image Guided Radiation Therapy|Undergo BgRT
223853128|NCT06479733|PROCEDURE|acellular dermal matrix|"* For the third group (ADM group) , The matrix will be trimmed so that it is gently adapted to the artificial envelope created on the buccal aspect of the ridge.The matrix will be trimmed and beveled to make its adaptation into the artificial envelope easier. Before placement, matrix will be hydrated for 10 minutes in fresh human blood collected after flap elevation in each patient.~* For both second and third groups, graft will be carefully positioned under the buccal pouch, sutured to it, light pressure will be applied over the inserted graft with moist gauze for 10 minutes to minimize blood clot and dead space formation between the graft and the underlying bone."
223853129|NCT06479733|PROCEDURE|control group|only placement of dental implant without soft tissue augmentation
223853130|NCT00789919|PROCEDURE|Delivery of infant|Vaginal delivery or cesarean section, whichever is indicated
223853131|NCT02001714|BEHAVIORAL|Group Behavioral Treatment|Group Behavioral Treatment class is a two hour class taught by certified interventionist covering urinary system anatomy, bladder health and self management strategies, pelvic floor training, pelvic floor muscle contracting techniques, and bladder training. Slides and handouts supplement the content of the class.
223853132|NCT03329742|OTHER|Low protein diet|Patients on this arm will receive a prescribed diet (including all food and recommendations for beverages) that contains 10% protein to begin eating 1 week prior to treatment with sipuleucel-T and throughout treatment (i.e. diet will last approximately 49 days).
223853133|NCT03329742|OTHER|Control protein diet|Patients on this arm will receive a prescribed diet (including all food and recommendations for beverages) that contains 20% protein to begin eating 1 week prior to treatment with sipuleucel-T and throughout treatment (i.e. diet will last approximately 49 days).
223853134|NCT04366882|PROCEDURE|CT-scan with minimal invasive autopsy|CT-guided biopsies will be performed directly following the diagnostic CT-scan. Biopsies will be taken from heart, liver, lungs, spleen, kidneys and abdominal fat according to a standard operation procedure. Biopsies will be taken for further histological examination and storage in the biobank. Of the lung, additional samples will be taken for microbiological examination. Additional samples will be taken in case of (focal) abnormalities on CT-imaging. In case of pleural, cardiac or abdominal fluid, this will be aspirated for further cytological, biochemical and microbiological examination. Finally, 15 cc blood will be drawn from the heart.
223853135|NCT01559506|DEVICE|Air Barrier System device|Device is deployed adjacent to the surgery site and activated.
223853136|NCT03376399|OTHER|Gastroparesis Cardinal Symptom Index Questionnaire|Patients with an established diagnosis of Diabetic Gastroparesis that are interested in a sleeve gastrectomy for weight loss will be asked to participate in the registry. Once the consent process is complete the patient will be asked to complete the Gastroparesis Cardinal Symptom Index Questionnaire prior to weight loss surgery and 30 days, 3 months, 6 months and 12 months after surgery.
223853137|NCT05312866|PROCEDURE|Standard analgesia (paracetamol +fentanyl)|Patients will receive standard analgesia (paracetamol 15mg/kg plus fentanyl 1ug/kg) iv
223853138|NCT05312866|PROCEDURE|Retrolaminar block with bupivacaine + magnesium sulfate + dexamethasone|Patients will receive intraopertative retrolaminar block: 15 ml of bupivacaine 0. 25 % plus 2ml magnesium sulfate 10% (200mg) plus 2ml (8mg) dexamethasone on each side by slipping the needle of injection on the bone of spinous process and lamina.
223853139|NCT05739513|DIAGNOSTIC_TEST|miRNA analysis in plasma|blood sample
223853140|NCT04067960|PROCEDURE|Biospecimen Collection|Undergo collection of saliva
223853141|NCT04067960|OTHER|Genetic Testing|Undergo pharmacogenomics testing
223853142|NCT04067960|OTHER|Quality-of-Life Assessment|Ancillary studies
223853143|NCT04067960|OTHER|Questionnaire Administration|Ancillary studies
223853144|NCT04178954|DIAGNOSTIC_TEST|semen fluid analysis|semen fluid analysis
223853145|NCT01105143|BEHAVIORAL|multimodal lifestyle intervention|multimodal lifestyle intervention will be performed to reduce body weight
223853146|NCT01105143|BEHAVIORAL|placebo|no intervention, only follow up
223853147|NCT05975788|DRUG|Staphylococcus and Neisseria Tablets|Staphylococcus and Neisseria tablets is used as an adjuvant treatment drug for respiratory disease in acute attack period, such as chronic tracheitis, bronchitis and various types of colds. It has been proved to effectively shorten the course of disease. In this study, Staphylococcus and Neisseria tablets will be administered with 4 tablets each time and 3 times a day, and treatment period ranges from 3 to 6 months according to clinicians.
223853148|NCT03651713|BEHAVIORAL|GLU+EX|Subjects will complete 45 minutes of recumbent cycling at 60-65% of age-predicted maximal heart rate five times over seven days while ingesting a 75g glucose beverage three times daily.
223853149|NCT03651713|DIETARY_SUPPLEMENT|GLU|Subjects will consume a 75g glucose beverage three times daily over a seven-day period.
223853150|NCT03168646|PROCEDURE|wafer procedure|wrist arthroscopy and debridement of Triangular fibrocartilage and shortening of the head ulna by burr
224076113|NCT06549478|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
223853151|NCT03168646|PROCEDURE|arthroscopy and ulnar shortening osteotomy|wrist arthroscopy,debride debridement of Triangular fibrocartilage and shortening of the ulna by osteotomy and plate
223853152|NCT06644430|PROCEDURE|Ablation|Ablation including (microwave ablation, radiofrequency ablation, cryoblation), this surgery was conducted under CT guidence. The pulmonary was completely ablated.
223853153|NCT06644430|DRUG|system therapy|Paticipants received systemic therapy according the instructions.
223853154|NCT05933122|OTHER|sexologist consult|"in the cohort called here, after the diagnosis of rectal cancer, patients will be seen by a sexologist before any kind of treatment for rectal cancer. Sexual dysfunctions will be assessed by a sexologist. After the surgery of rectal cancer, the sexologist will see them again to assess sexual dysfunctions after such a management of rectal cancer. If there is any discovery of a sexual dysfunction or aggravation of a previous one or alteration of sexual life, the sexologist will help the patients to improve their sexual quality of life."
223853155|NCT05933122|OTHER|standart of care|"in the cohort called elsewhere , patients will be treated according to standards of care, without specific care by a sexologist"
223853156|NCT06041893|DRUG|ATG-LDPTCy|antithymocyte globulin with low dose post-transplant cyclophosphamide
223853157|NCT02012543|DIETARY_SUPPLEMENT|Agar jelly|
223853158|NCT04241224|DEVICE|Atherectomy|Endovascular treatment of peripheral arterial disease
223853159|NCT01640821|BEHAVIORAL|CdM? program|The program is conducted in small groups of 12 to 15 women for 14 weekly sessions (13 3h-evening sessions and 1 intensive-day session of 6 hours). Two health professionals (a registered dietician and a social worker or psychologist) lead the group. Sessions include lectures, guided self-examination and observations, group discussions, and practical exercises. Different topics are discussed during sessions such as enjoyment of physical activity and healthy nutrition, setting realistic objectives with regard to weight loss, and acceptation of their own and others' body image. A weekly food diary and group discussions are used to facilitate the recognition of internal cues of hunger and satiety and the identification of external influences on eating behaviors and food intake.
223853160|NCT06442254|OTHER|Virtual Reality|In the application, which will be done with VR glasses, a video of walking on Istiklal Street in Istanbul's Beyoğlu district will be watched.
223853161|NCT06513234|DRUG|Orelabrutinib and obinutuzumab|Orelabrutinib and obinutuzumab 6cycles ;orelabrutinib 150mg
223853163|NCT00292383|PROCEDURE|Leads to be implanted according randomization on specified sites. Vitatron pacemakers to be implanted: T60 DR, T70 DR, T20 SR, C60 DR|
223853164|NCT01966055|DRUG|Solithromycin|
223853165|NCT04609618|DEVICE|Appscent Device|computer-controlled, low pressure compressed air based, with disposable odorant capsules solution provided an odor environment at the nose,
223853166|NCT00561743|DRUG|Bortezomib + pegylated liposomal doxorubicin HCl + dexamethasone|
223853167|NCT00988637|DRUG|Vectical™ Ointment weekdays and Clobex® Spray weekends regimen|Vectical™ Ointment 3 µg/g, topical, apply twice daily on weekdays (Mon-Fri) and Clobex® Spray 0.05% twice daily on weekends (Sat-Sun) for 28 days
223853168|NCT00988637|DRUG|Clobex® Spray morning and Vectical™ Ointment evening regimen|Clobex® Spray 0.05%, topical, apply once each morning and Vectical™ Ointment 3 µg/g, topical, apply once each evening for 28 days
223853169|NCT03593070|BEHAVIORAL|Chronic Grief Management Intervention-Video|The CGMI-V participant manual will be provided to participants either mailed or emailed. We will mail hard copies of the manual to caregivers who prefer them over the e-format. The technology assistant will review with each participant the use of technology Cisco WebEx and iPads) via e-mailed step-by-step written instructions and over-the-phone conferencing. Group sessions will take place using WebEx (an internet platform providing video connection) and iPads, at mutually agreed-upon times and days of the week. All group sessions will be audio and video-recorded for fidelity purposes, with caregivers' approval documented in the informed consent. The interventionists will label each recorded meeting group identification number, session number, and date.
223853170|NCT06339918|OTHER|KegelExercise|Kegel exercises (also called pelvic floor exercises)will be used to strengthen the pelvic floor muscles it will involve repeatedly contracting and relaxing the muscles that form part of the pelvic floor.
223853171|NCT06339918|OTHER|4-7-8 breathing technique|This can be performed in the following way: Participants taking part should locate a comfy spot to sit. Inhale to the count of 4. Hold their breath for 7 counts. To the count of 8, release air via their mouth.
223853172|NCT06630312|DIETARY_SUPPLEMENT|Alpha galactosidase|Alpha galactosidase capsule, 600 GALU, manufacturer Equate brand, Walmart. Powder contents from one capsule were stirred into 16 g spaghetti sauce and served before the main meal.
223853173|NCT06630312|DIETARY_SUPPLEMENT|Placebo|Placebo is 16 gm of spaghetti sauce served before the meal in a condiment cup. It is the same set up as the intervention except the \&#39;intervention\&#39; contains the AGS.
224076114|NCT06549478|OTHER|Questionnaire Administration|Ancillary studies
224076115|NCT05379946|DRUG|D-1553|D-1553 is a oral dosed novel, targeted KRasG12C inhibitor that is being developed as a potential oral agent for advanced or metastatic solid tumors with KRasG12C mutation
224076116|NCT05379946|DRUG|IN10018|IN10018 orally once daily at approximately the same time each day
224076117|NCT05643131|DEVICE|Hyivy Intravaginal Device|Intravaginal use of Hyivy device three times per week for 12 weeks, with each session consisting of 10 minutes of heat (37-39ºC) and 10 minutes of dilation.
224076118|NCT04880031|DRUG|Efimosfermin|Efimosfermin will be administered by subcutaneous injection
224076119|NCT04880031|DRUG|Placebo|Placebo will be administered by subcutaneous injection
224076120|NCT04862663|DRUG|Capivasertib|Phase Ib: Capivasertib 320 mg/ 400 mg administered PO BD 4 days on /3 days off per week for 4 weeks (28 days cycle) Phase III: : Capivasertib, administered PO BD 4 days on / 3 days off per week for 4 weeks (28 days cycle) at the dose confirmed in the phase Ib portion
224076121|NCT04862663|DRUG|Fulvestrant|Phase Ib and Phase III: 500 mg (2 injections of 250 mg) on Day 1 of Weeks 1 and 3 of Cycle 1, and then on Day 1, Week 1 of each cycle thereafter
224076122|NCT04862663|DRUG|Palbociclib|Phase Ib: 100 mg/ 125 mg. Once daily for 21 consecutive days followed by 7 days off treatment to comprise a complete 28-day cycle Phase III: Administered once daily for 21 days of 28-day cycle, at the dose of 125 mg.
223853174|NCT06630910|PROCEDURE|Pancreaticojejunostomy without stenting and omental patch|A traditional pancreaticoduodenectomy with pylorus preservation was performed on each patient. A pancreaticojejunostomy was created by double-layered, end-to-side, duct-to-mucosa anastomosis between the primary pancreatic duct and jejunal wall without stenting or omental patch.
223853175|NCT06630910|PROCEDURE|Pancreaticojejunostomy with stenting and omental patch|A traditional pancreaticoduodenectomy with pylorus preservation was performed on each patient. A pancreaticojejunostomy was created by double-layered, end-to-side, duct-to-mucosa anastomosis between the primary pancreatic duct and jejunal wall, a nelaton stent 6f was inserted into the pancreatic duct and jejunum of each patient receiving PJ. The larger omentum was separated longitudinally over an avascular zone, and one or two omental branches of the gastroepiploic arteries were preserved using pedicle omental flaps. The omental flap was pushed between the posterior surface of PJ and the portal vein, then wrapped over the anterior surface of PJ. The omentum was rolled up and secured with a few PDS sutures.
223853176|NCT06631911|BEHAVIORAL|Emotional Awareness and Expression Therapy (EAET)|"Emotional Awareness and Expression Therapy (EAET) is a manualized, short-term psychodynamic therapy that, in this instance, is delivered in a group format.~The core of Emotional Awareness and Expression Therapy (EAET) involves helping individuals identify, understand, and express their emotions in a therapeutic setting. The therapy emphasizes the connection between unprocessed emotions and physical symptoms, encouraging participants to explore the emotional underpinnings of their distress. Through guided discussions, psychoeducation, and expressive exercises, participants learn to recognize patterns of emotional avoidance, develop self-compassion, and improve interpersonal communication. This process aims to reduce somatic symptoms and enhance overall emotional well-being by fostering a greater awareness of emotional experiences."
223853177|NCT06631300|DRUG|Prednisone|A prednisone taper will be given to the subjects as follows: prednisone 40mg for 3 days, prednisone 30mg for 3 days, prednisone 20mg for 3 days, prednisone 10mg for 3 days, prednisone 5mg for 3 days, then off for a total of 15 days.
223853178|NCT06631300|DRUG|Placebo|A placebo taper will be given to match the same number of pills administered in each stage of the prednisone taper.
223853179|NCT06631651|PROCEDURE|Brachioradialis release|During distal radius fracture surgery (open reduction+internal fixation) partial brachioradialis release from the insertion of brachioradialis muscle was performed in order to perform reduction of fracture
223853180|NCT06631651|PROCEDURE|Brachioradialis not released|During distal radius fracture surgery (open reduction+internal fixation) brachioradialis release was not performed.
223853181|NCT03614234|DRUG|pegunigalsidase alfa|Recombinant human alpha galactosidase A
223853182|NCT06629571|OTHER|Education|Training for the patient before surgery
223853183|NCT01582945|DRUG|Ketamine|Ketamine IV 0.5mg/kg infusion twice a week for 3 weeks as augmentation of ongoing antidepressant regimen
223853184|NCT00910702|DEVICE|foldable capsular vitreous body(FCVB)|the vitreous cavity is tamponaded with the foldable capsular vitreous body (FCVB) after PPV
223853185|NCT01855464|PROCEDURE|wedge resection|Complementary to parietal pleurectomy lung tissue is resected.
223853186|NCT01855464|PROCEDURE|parietal pleurectomy|The parietal pleura is resected for treating primary pneumothorax.
223853187|NCT02647749|DEVICE|Cardioinsight® mapping system|
223853188|NCT02647749|OTHER|Conventional method without non-invasive mapping|
223853189|NCT02920359|DRUG|LEUPRORELIN ACETATE|
223853190|NCT06156007|BEHAVIORAL|progressive muscle relaxation exercises|Progressive muscle relaxation exercises (PKGE); 16 large muscles (right hand and forearm, right upper arm, left hand and forearm of left arm, left upper arm, forehead, upper cheek and nose, chin, neck, abdomen, upper right arm, which people can do on their own after learning) leg, right calf, right foot, left upper leg, left thigh and left foot), followed by the contraction and then relaxation and accompanied by deep breathing, is a preferred method for reducing pain, anxiety and depression in individuals.The relaxation will be required to take 10-20 before stretching the next muscle group. In this way, the muscle groups in the hands, arms, neck, shoulder, chest, abdomen, hips, feet and fingers, face and the whole body will be voluntarily stretched and relaxed, and pregnant women will be relieved.
223853191|NCT04559724|DEVICE|Indego Therapy|Indego Therapy consists of 15 + 2 sessions of Indego - Therapy, each lasting 30 minutes for a maximum of 6 weeks. All the device parameters such as step height (knee and hip), step length, step cycle speed, single and bilateral assistance are customizable. The use of aids during Idego-Therapy is allowed if needed. The Indego specialist should initially be positioned behind the patient, checking the exoskeleton and patient's gait pattern. The supervision of an assistant placed on the patient's healthy side is recommended in the first sessions in order to ensure greater safety to the patient. Constant supervision should be provided by Indego specialist during the whole treatment.
223853192|NCT02197234|PROCEDURE|Pharmacokinetic sampling - AZD9291|Blood sampling to measure AZD9291
223853193|NCT02197234|DRUG|Simvastatin|Simvastatin (CYP substrate) 40mg taken once daily on Days 1 and 31 (Part A)
223853194|NCT02197234|DRUG|AZD9291 tablet dosing|AZD9291 80mg tablet taken from Days 3 to 32. (Part B) AZD9291 80mg tablet taken daily for 12 months.
223853195|NCT02197234|PROCEDURE|Pharmacokinetic sampling - simvastatin|Blood sampling to measure simvastatin levels
223853196|NCT02197234|PROCEDURE|Pharmacokinetic sampling - AZ5140 and AZ7550|Blood samples to measure levels of AZ5140 and AZ7550
223853197|NCT05974605|BEHAVIORAL|MM+HighC|In this intervention, participants will be trained on a available mindfulness meditation app, followed by a working memory updating game, developed by Dr. Chandramallika Basak. This game requires high degree of attentional control (Unpredictable Bird Watch), also known as High-C. The app and the game are delivered through an Android tablet for this home-based training.
223853198|NCT05751200|OTHER|No Intervention.|No Intervention.
223853199|NCT01151033|DEVICE|Drug Eluting Stent implantation|ProNOVA XR Drug Eluting Stent implantation
223853200|NCT00469118|DEVICE|DRX9000™|Nonsurgical spinal decompression
223853201|NCT04480814|DIAGNOSTIC_TEST|PIK3CA kit|Prospective investigation of clinical samples for evaluation of IVD clinical performance
223853202|NCT01322958|DEVICE|Pelvic Ultrasound|Pelvic ultrasound performed by the emergency physician
223853203|NCT06631924|DEVICE|Implant|Intramedullary headless hardware systems were utilized to place hardware in85 a retrograde manner from the metacarpophalangeal joint.
223853204|NCT01543685|DRUG|Indomethacin|40 mg TID capsules
223853205|NCT01543685|DRUG|Indomethacin|40 mg BID capsules
223853206|NCT01543685|DRUG|Indomethacin|20 mg TID capsules
223853207|NCT01543685|DRUG|Celecoxib|200 mg capsules
223853208|NCT01543685|DRUG|Placebo|Capsules
223853209|NCT00051974|DRUG|VELCADE™ (bortezomib) for Injection (formerly PS-341)|
223853210|NCT02321358|BEHAVIORAL|Two-time implementation intention|Will be given intervention and booster at six weeks
223853211|NCT02321358|BEHAVIORAL|One-time implementation intention|Will only be given the intervention once
223853212|NCT02321358|BEHAVIORAL|Sham Comparator|Canada's Food Guide for Healthy Eating will be provided. This contains a small amount of physical activity information.
223853213|NCT02321358|BEHAVIORAL|Physical Activity Materials|Thera-Bands, instructional DVD and exercise handout, instructional stretching handout, CSEP Physical activity guidelines.
223853214|NCT03739411|RADIATION|Hyperpolarized Carbon C 13 Pyruvate|Given IV
223853215|NCT03739411|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223853216|NCT03739411|RADIATION|Radiation Therapy|Undergo radiation therapy for cancer outside of this study.
223853217|NCT03739411|DRUG|Chemotherapy|Undergo chemotherapy for cancer outside of this study.
223853218|NCT04277689|PROCEDURE|Brain signal data collection|Collection of speech related electrophysiological data at the time of DBS.
223853219|NCT02524444|DRUG|Mefloquine|Tabs Mefloquine 250mg
223853220|NCT02524444|DRUG|Sulphadoxine-Pyrimethamine|Sulphadoxine 500mg , Pyrimethamine 25mg
223853221|NCT02967237|DRUG|insulin glargine (U300)|Pharmaceutical form: solution Route of administration: subcutaneous
223853222|NCT01871818|BEHAVIORAL|Combined program|Combined program with physiotherapy, endurance training and resistance training
223853223|NCT01871818|BEHAVIORAL|Physiotherapy in private practice|Physiotherapy in private practice
223853224|NCT02163915|DRUG|TAK-137|TAK-137 tablets
223853225|NCT02163915|DRUG|TAK-137 Placebo|TAK-137 placebo-matching tablets
223853226|NCT00555867|DRUG|Anastrozole|oral
223853227|NCT02377206|OTHER|ADAS-Cog evaluation|\[18F\]DPA-714 PET imaging
223853228|NCT04678934|PROCEDURE|TAVR|Transcatheter aortic valve replacement
223853229|NCT02712866|DRUG|Vedolizumab|Administration of intravenous Vedolizumab in inflammatory bowel disease patients
223853230|NCT02063607|BIOLOGICAL|Peginterferon lambda|
223853231|NCT04735354|DRUG|sacubitril/valsartan|There was no treatment allocation. Patients administered sacubitril/valsartan by prescription that started before inclusion of the patient into the study were enrolled.
223853232|NCT02931396|DEVICE|FES|
223853233|NCT06055712|DRUG|Cefazolin|Intravenous dose(s).
223853234|NCT06055712|DRUG|Cephalexin|Five days oral.
223853235|NCT04139694|DIETARY_SUPPLEMENT|Food plan with cinnamon supplementation|cinnamon twice daily plus follow Cardiometabolic diet
223853236|NCT04139694|BEHAVIORAL|Food plan without cinnamon supplementation|Cardiometabolic diet only
223853237|NCT05956600|DRUG|Amisulpride 50 MG|Amisulpride 50 mg titrated to dose range of 50 to 1200 mg
223853238|NCT03981549|BIOLOGICAL|Autologous Bone Marrow CD34+ Stem Cells|Single intravitreal injection of autologous bone marrow CD34+ stem cells. The number of cells to be injected per eye will range from 800,000 to 10 million, depending on the yield of the bone marrow aspiration and the isolation procedure.
223853239|NCT03981549|BIOLOGICAL|Sham Therapy|Sham bone marrow aspiration procedure that penetrates the skin, but does not penetrate the bone followed by sham intravitreal injection without penetration of the eye
223853240|NCT04043611|OTHER|Conservative physical therapy management|Tens and hot pack for at least 10 minutes at low back Soft tissue mobilization (Myofascial Release Technique) Maitland's Lumbar segmental mobilization (Grade I \& II for pain, Grade III \& IV for ROM) Traction (Manual general traction) Neurodynamics (Tensioner technique) Home plan after session (Guided low back exercises):Active Stretching (5-10 repetition with 15-20 second hold), Hamstring, Piriformis McKenzie Prone Extension Exercises
223853241|NCT04043611|OTHER|ELDOA|ELDOA positions (hold for 1 minute,4 alternate days a week) under supervision during session Conservative physical therapy management Tens and hot pack for at least 10 minutes at low back Soft tissue mobilization (Myofascial Release Technique) Maitland's Lumbar segmental mobilization (Grade I \& II for pain, Grade III \& IV for ROM) Traction (Manual general traction) Neurodynamics (Tensioner technique) Home plan after session (Guided low back exercises):Active Stretching (5-10 repetition with 15-20 second hold),Hamstring,Piriformis
224076123|NCT04862663|DRUG|Ribociclib|Phase Ib: 200 mg/ 400 mg/ 600 mg. Once daily for 21 consecutive days followed by 7 days off treatment to comprise a complete 28-day cycle Phase III: Administered once daily for 21 days of 28-day cycle, at the dose confirmed in the phase 1b portion.
223853242|NCT06709677|BEHAVIORAL|Arabic version of The Nordic Musculoskeletal Questionnaire (NMQ) is a standardized questionnaire used to assess musculoskeletal symptoms and disorders in the workplace|"The Nordic Musculoskeletal Questionnaire (NMQ) is a standardized questionnaire used to assess musculoskeletal symptoms and disorders in the workplace. It is commonly used in occupational health and ergonomic assessments to gather information about the prevalence and severity of musculoskeletal issues such as pain, discomfort, and limitations in movement. The NMQ typically includes questions about specific body regions (e.g. neck, shoulders, back, wrists) and asks individuals to report any symptoms they may be experiencing in those areas. This information can help identify potential risk factors for musculoskeletal disorders and guide interventions to prevent or manage these conditions in the workplace (Namnik et al., 2016).~• Section 1: a general questionnaire of 40 forced-choice items identifying areas of the body causing musculoskeletal problems. Completion is aided by a body map to indicate nine symptom sites being neck, shoulders, upper back, elbows, low back, wrist/hands, hips/thi"
223853243|NCT06696482|DRUG|Escitalopram 10mg|Escitalopram 10 mg, encapsulated in an opaque capsule to facilitate blinding of participant and researcher
223853244|NCT06696482|DRUG|Placebo 10 mg|Placebo 10 mg, encapsulated in an opaque capsule to facilitate blinding of participant and researcher
223853245|NCT06696560|OTHER|Minimal Invasive Approaches in Aortic surgeries.|Minimal Invasive Approaches For Aortic Valvular and Subvalvular Surgeries
223853246|NCT06713122|BEHAVIORAL|İntervention Group- Group receiving Symptom Management Training with Mobile Application|"The application to be developed in the research will be both Android and IOS supported.~Monitoring the active use of the patients from the interface by the researcher and receiving individual and collective notifications in line with the profile that the patients receiving chemotherapy will create in the application will increase the usability of the application. Thus, the benefit that users receive after active use can be determined.~The content of the Let's fight the symptoms together module will be created by experts in the field and people will be able to actively use these methods while struggling with the symptoms they experience.~Patients may not always have the opportunity to reach a nurse or health professional. In symptom management with the mobile application, artificial intelligence will be trained by the researcher and integrated into the application will help patients reach the right information without wasting time."
223853247|NCT06713135|DRUG|vamorolone 40 mg/mL oral suspension|Vamorolone is administered at a dose range between 2 mg/kg/day and 6 mg/kg/day for boys weighing \<40 kg. For boys weighing 40 kg or above, the dose range will be 80 mg to 240 mg once daily. Doses can be adjusted within the dose range as determined by the Investigator based on tolerability. The highest tolerated dose should be used.
223853248|NCT06713057|DRUG|Cyclophosphamide+Pemetrexed+5-Fluorouracil|IV or PO
223853249|NCT06713057|DRUG|Cyclophosphamide+Doxorubicin+5-Fluorouracil|IV or PO
223853250|NCT06713057|DRUG|Vindesine + Cisplatin|IV or PO
223853251|NCT06713057|DRUG|Doxorubicin + Cisplatin|IV or PO
223853252|NCT06713057|DRUG|Doxorubicin + Cyclophosphamide + Cisplatin|IV or PO
223853253|NCT06713057|DRUG|Docetaxel + Doxorubicin|IV or PO
223853254|NCT06713057|DRUG|Paclitaxel + Carboplatin|IV or PO
223853255|NCT06713057|DRUG|Paclitaxel + Doxorubicin|IV or PO
223853256|NCT06713057|DRUG|Paclitaxel + Cisplatin|IV or PO
223853257|NCT06713057|DRUG|Gemcitabine alone|IV or PO
223853258|NCT06714409|DIAGNOSTIC_TEST|VExUS guided decongestion|Treatment team will be provided information about venous organ congestion status.
223853259|NCT06714474|OTHER|Virtual Simulation Game|The Virtual Simulation Game (VSG) is an interactive, scenario-based digital training tool designed to enhance venous blood sampling (VBS) skills. Participants engage with the VSG platform to complete modules that simulate real-life clinical scenarios, allowing them to refine decision-making and procedural skills in a safe, controlled environment. This intervention is used in addition to traditional training to reinforce learning through repetition and feedback.
223853260|NCT06714474|OTHER|Traditional Training|Traditional training consists of theoretical instruction and hands-on practice sessions conducted in a laboratory setting. Participants observe VBS demonstrations, followed by supervised practice on peers to develop their procedural skills. This intervention represents the standard educational approach for VBS and serves as the comparator in this study.
223853261|NCT06714097|DEVICE|AI|STRATIF-AI apps will be used as an integral part of the dialogue with patients during thesecondary prevention phase
223853262|NCT06714097|OTHER|healthy dialogue|Patients allocated to arm 2 will receive only standard secondary prevention, which includes typical treatments and monitoring protocols used for patients with stroke, Moyamoya disease, and CAA
223853263|NCT06711913|DRUG|Dexmedetomidine|intravenous dexmedetomidine given in form of 100ml infusion over 10 minutes
223853264|NCT06711913|OTHER|Normal Saline (Placebo)|control group receive normal saline as placebo
224265853|NCT03594617|BEHAVIORAL|Interaction Competencies with Children - for Caregiver|"Interaction Competencies with Children - for Caregiver (ICC-C) aims to reduce maltreatment and to improve care quality in institutional care facilities. Following the idea of a train-the-trainer approach, ICC-C is designed to be delivered by trained local facilitators. ICC-C is based on attachment, behavioral and social learning theories.~The key principles are its feasibility in low-resource contexts, participatory approach, and practical orientation. ICC-C includes sessions on (a) caregiver-child interaction, (b) maltreatment prevention, (c) effective non-violent caregiving strategies, and (d) identifying and supporting burdened children."
224265854|NCT01338090|DRUG|89Zr-bevacizumab|Intravenous injection 120 MBq
224265855|NCT01338090|DRUG|Everolimus|Oral use, 10 mg per day
224265856|NCT03789487|DEVICE|Device programming of CRT pacemaker or defibrillator|Stimulation vector optimization then AV delay optimization in order to obtain the highest systolic blood pressure (SBP) by using the Finapress® NOVA noninvasive device
224265857|NCT02646488|BEHAVIORAL|Million Hearts ABCS 6 Months|The ABCS refer to the following: Aspirin in high-risk individuals (A), Blood pressure control and management (B), Cholesterol management (C), and Smoking cessation (S).
224265858|NCT02646488|BEHAVIORAL|Million Hearts ABCS 9 Months|The ABCS refer to the following: Aspirin in high-risk individuals (A), Blood pressure control and management (B), Cholesterol management (C), and Smoking cessation (S).
224265859|NCT02646488|BEHAVIORAL|Million Hearts ABCS 12 Months|The ABCS refer to the following: Aspirin in high-risk individuals (A), Blood pressure control and management (B), Cholesterol management (C), and Smoking cessation (S).
224265860|NCT02646488|BEHAVIORAL|Million Hearts ABCS 15 Months|The ABCS refer to the following: Aspirin in high-risk individuals (A), Blood pressure control and management (B), Cholesterol management (C), and Smoking cessation (S).
224265861|NCT02646488|BEHAVIORAL|Standard Care Regimen 9 Months|
224265862|NCT02646488|BEHAVIORAL|Standard Care Regimen 12 Months|
224265863|NCT02646488|BEHAVIORAL|Standard Care Regimen 15 Months|
224265864|NCT02646488|BEHAVIORAL|Standard Care Regimen 18 Months|
224265865|NCT02646488|BEHAVIORAL|Standard Care Regimen 21 Months|
224265866|NCT02646488|BEHAVIORAL|Standard Care Regimen 24 Months|
224265867|NCT02646488|BEHAVIORAL|Standard Care Regimen 27 Months|
224265868|NCT02646488|BEHAVIORAL|Follow Up Post Intervention 21 Months|
224265869|NCT02646488|BEHAVIORAL|Follow Up Post Intervention 24 Months|
224265870|NCT02646488|BEHAVIORAL|Follow Up Post Intervention 27 Months|
224265871|NCT02646488|BEHAVIORAL|Follow Up Post Intervention 30 Months|
224265872|NCT02646488|BEHAVIORAL|Follow Up Post Intervention 33 Months|
224265873|NCT03134053|DEVICE|extracorporeal shock-wave|to treat painful and retracting scars
224265874|NCT03134053|OTHER|massage|to treat painful and retracting scars
224265875|NCT03414151|OTHER|Observation|No intervention administered.
224265876|NCT02282124|BEHAVIORAL|Self-management program with monthly sessions|Patients participate in 9 sessions during the first 8th month after transplantaiton
224265877|NCT02282124|BEHAVIORAL|Usual Care, containing one session|Session takes place within the first three months after transplantation
224265878|NCT06520904|DRUG|PCSK9 inhibitor|PCSK9 inhibitors combined with moderate-intensity statin therapy
224265879|NCT06520904|DRUG|Statin|Intensive statin therapy
224265880|NCT01232049|DRUG|Multiple Oral Dose of|Pitavastatin 4mg
224265881|NCT01232049|DRUG|Multiple Oral Dose of|Valsartan 320mg
224265882|NCT06677749|PROCEDURE|Eccentric resistance-exercise|Each participant will complete 300 repetitions of eccentric knee extensions using an isokinetic dynamometer after a baseline skeletal muscle biopsy is taken. Three hours following this, a second muscle biopsy will be taken to evaluate the changes in the dependent variables being measured (myokines).
224265883|NCT02428348|OTHER|Interview about prototype EEG-cap|
224265884|NCT00680940|DRUG|Paclitaxel & Cisplatin|Chemotherapeutic agent
224265885|NCT00680940|BIOLOGICAL|Mycobacterium w.|Immunomodulator
224265886|NCT00758797|OTHER|Photoimmunotherapy|DIOMED laser + photosensitizing agent injected intralesionally and topical immuno-modulating cream
224265887|NCT02015832|DEVICE|Coronary stent|
224265888|NCT02015832|RADIATION|Multi Slice Computed Tomography|A coronary non-invasive Multi Slice Computed Tomography will be performed in patients
224265889|NCT02015832|DEVICE|instantaneous wave-free ratio|Pressure-derived, adenosine-free index on physiological assessment of stenosis severity
224265890|NCT02015832|DEVICE|Fractional flow reserve|Pressure-derived index on physiological assessment of stenosis severity
224265891|NCT02015832|DEVICE|Intravascular Ultrasound|Allows the application of ultrasound technology to see from inside blood vessels out through the surrounding blood column, visualizing the inner wall of blood vessels
224265892|NCT02132910|OTHER|RESTORE Intervention|
224265893|NCT02600247|DRUG|Duloxetine|"Experimental: Duloxetine group~1. Phase I (preemptive): 1day before operation (30mg for 1 day)~2. Phase II (maintenance): 6weeks after operation (30mg for 6 weeks) plus routine pain control (celecoxib, pregabalin, acetaminophen/tramadol, oxycodone)~Other Name: cymbalta Drug: Celebrex, Lyrica, Ultracet, Ircodon~Preemptive analgesia : celebrex 200mg 1C#1, Lyrica 150mg 1C#1 (preoperation. 2 hours), Patient controlled analgesia (postoperation 28 hours) During admission : celebrex 200mg#1, Ircodon 5mg 2T#2, Ultracet 2T#2 (Postoperation 1 week) Discharge medication: celebrex 200mg 1C#1 x 5Weeks, Ultracet 2T#2 x 1 week~Other name : celecoxib, Pregabalin, acetaminophen/tramadol, oxycodone"
223853265|NCT06712277|OTHER|Video training|After the procedure, caregivers will be trained on tube care and patient feeding by demonstrating and performing the procedure on an iPad.
223853266|NCT06711016|OTHER|fluid resuscitation, vasoactive drug dose,hemoglobin transfusion,sedative analgesic muscle relaxant drugs, antiepileptic drugs, etc|ECMO flow, IABP , ventilator support parameters, temperature management level and time
223853267|NCT06712394|PROCEDURE|IPACK|The IPACK block involves infiltration of the space between the popliteal artery and the posterior knee joint capsule with 20 ml of 0.25% local anesthetic (bupivacain) under ultrasound guidance.
223853268|NCT06714266|DRUG|Trilaciclib|"Trilaciclib 240mg/m2, intravenous infusion for 30 minutes, completed within 4 hours before daily chemotherapy; Chemotherapy regimen: FP regimen (cisplatin/carboplatin +5-FU regimen: cisplatin 75mg/m2 D1, D2, D3 or carboplatin AUC 5, intravenous infusion D1; 5-FU 1000 mg/m2, intravenous infusion, D1-4; Q3W); TP regimen (cisplatin/carboplatin +5-FU regimen: cisplatin 75mg/m2 D1, D2, D3 or carboplatin AUC 5, intravenous infusion D1; Docetaxel 75mg/m2 or albumin paclitaxel 200mg, IV infusion, D1, 8; Q3W). The specific dose can be adjusted according to the situation.~Immunotherapy: Pembrolizumab 200mg q2w Targeted therapy: cetuximab (400mg/m2 qw 250mg/m2 qw) Some patients can be treated with maintenance therapy, and the treatment regimen is immunotherapy or targeted therapy combined with Trilaciclib"
223853269|NCT06710574|DRUG|PD-RBD|Bifidobacterium triple viable capsule (Bifico Capsule, Shanghai Shangyao Xinyi Pharmaceutical Factory Co., LTD.) 420mg, two times a day, 4 capsules each time; At the same time give the bacillus licheniformis living bacterium capsule (whole bowel capsule, northeast pharmaceutical) 0.5 g, three times a day, two at a time, keep the original anti Parkinson's drugs
223853270|NCT06710574|DRUG|iRBD|Bifidobacterium triple viable capsule (Bifico Capsule, Shanghai Shangyao Xinyi Pharmaceutical Factory Co., LTD.) 420mg, two times a day, 4 capsules each time; At the same time give the bacillus licheniformis living bacterium capsule (whole bowel capsule, northeast pharmaceutical) 0.5 g, three times a day, two at a time.
223853271|NCT06713681|DIAGNOSTIC_TEST|TTP-ICG incubation solution|Fresh breast massed and lymph nodes will be incubated with TTP-ICG with different concentrations and times
223853272|NCT06712030|DRUG|Sacubitril / Valsartan|Dose titration of Sacubitril/Valsartán to the maximum tolerated dose (maximum 97/103 mg)
223853273|NCT06714604|DRUG|FOLFIRINOX or gemcitabine-nab-paclitaxel|4 months if treatment
223853274|NCT06714604|DRUG|FOLFIRINOX or gemcitabine-nab-paclitaxel|6 months of treatment
223853275|NCT06711029|OTHER|Conventional needle irrigation|Conventional needle irrigation method was applied. As a final irrigation, 6 ml NaOCl was applied with 60 seconds of needle irrigation followed by 60 seconds of rest.
223853276|NCT06711029|OTHER|Passive Ultrasonic Irrigation with 3*20 sn|In the final irrigation, 6 ml (3×2 ml) NaOCl was activated by PUI for 20 seconds in 3 cycles (60 seconds total). Before each cycle, 2 ml of NaOCl solution was refreshment.
223853277|NCT06711029|OTHER|Passive Ultrasonic Irrigation with 6*10 sn|For the final irrigation, 6 ml (6×1 ml) NaOCl was activated with PUI for 10 seconds in 6 cycles (60 seconds total). Before each cycle, 1 ml of NaOCl solution was refreshment.
223853278|NCT05708261|BEHAVIORAL|MR Intervention|Grounded in Social Cognitive Theory, the intervention delivers five 2-hour sessions with 3 post-session group check-in's to develop skills in partnership communication, HIV disclosure and prevention. The intervention utilizes self-assessments on skills learned and then action plan for these developed and then finalized in the last session.
223853279|NCT05708261|OTHER|Be Well Attention Match|Attention match control arm providing one-way SMS of general health content delivered once per week during the first 5 weeks after enrollment.
223853280|NCT02494830|DRUG|Ketamine|Intravenous infusion of 5 mg ketamine solution, diluted in 240 ml 0.9% saline within 30 min under fasting conditions on study day 1 and oral administration of one prolonged release tablet ketamine together with 240 ml table water under fasting conditions with increased dose (10, 20, 40 and 80 mg) and at least 7 days wash-out between the study days
223853281|NCT04341298|OTHER|11-point pain scale|Subjects will be asked to rate their headache pain using an 11-point scale, i.e. on an integer scale from 0 to 10 inclusive, with 0 indicating no pain and 10 indicating the worst pain imaginable.
223853282|NCT04341298|OTHER|Headache diary|Subjects will be asked to record specific information for the first (and all subsequent) severe or very severe migraine headaches that they experience while enrolled in the study.
223853283|NCT04341298|DEVICE|Avulux®|Avulux® device
223853284|NCT04341298|DEVICE|Sham Avulux®|Sham Avulux®
223853285|NCT05974072|DRUG|Usual Care|The pharmacological treatment will be individualised according to pain intensity, contraindications and the appearance of adverse effects.
223853286|NCT05974072|OTHER|PAINDOC Program|"The PAINDOC Program consists in:~* Therapeutic education: The therapeutic education block consists of two parts: an education session called Empowered Relief (ER) and two pain neuroscience education (NDT) sessions.~* Psychotherapy: The psychotherapy part consists of one group session of one hour, face-to-face and with groups of up to 15 people, given by the psychologist of the pain unit.~* Mindfulness Meditation: The Mindfulness Meditation consists of one group session of one hour, face-to-face and with groups of up to 15 people. These are given by a nurse from the pain unit. T~* Therapeutic exercise: The therapeutic exercise module consists of three sessions of one hour each, face-to-face, with small groups of between 6 and 10 patients, and given by the physiotherapist of the pain unit."
223853287|NCT06711445|OTHER|Tele-assessment|"The participants were evaluated in two settings on different days (24-48 h apart): (i) in clinical settings (face-to-face) and (ii) at home via 'WhatsApp' phone application (both asynchronized and synchronized tele-assessment).~The evaluations steps were as follows:~1. Face-to-face/ Clinic assessment: Rater 1 completed all clinical assessments.~2. Synchronized tele-assessment: Rater 1 repeated the same evaluations via video calls to the patients (these were recorded to be used in step 3).~3. Asynchronized tele-assessment: Rater 2 evaluated the recordings of the remote evaluations (made in step 2).~4. Retest of synchronized tele-assessment: Rater 1 evaluated patients via video calls (these were recorded to be used in step 5).~5. Retest of asynchronized tele-assessment: Rater 2 evaluated the recordings of the remote evaluations (made in step 4)."
223853288|NCT06711549|PROCEDURE|Serratus Posterior Superior Plane Intercostal Plane block|Under ultrasound guidance; local anesthetic will be injected in the plane between the posterior aspect of the serratus posterior superior plane and the ribs
223853289|NCT06711549|PROCEDURE|Serratus Anterior Plane block|Under ultrasound guidance; local anesthetic will be injected in the plane between the posterior aspect of the serratus anterior and the external intercostal muscles and ribs
223853290|NCT06714643|DEVICE|Active tDCS|The active tDCS protocol consist of 15 excitatory tDCS sessions distributed over 3 weeks (5 sessions per week, from Monday to Friday), at the same time each day, administered by the same operators and under identical experimental conditions. Each session last 30 minutes, with the Anode electrode placed on the left dorsal lateral prefrontal cortex (DLPFC) and the Cathode electrode on the right DLPFC at an intensity of 2 mA. The electrodes are positioned according to the 10-20 electroencephalography system (Anode on F3 and Cathode on F4).
223853291|NCT06714643|DEVICE|Sham treatment|The sham-tDCS intervention consist of a placebo 15 tDCS sessions distributed over 3 weeks (5 sessions per week, from Monday to Friday), at the same time each day, administered by the same operators and under identical experimental conditions. Each session last 30 minutes, with the Anode electrode placed on the left dorsal lateral prefrontal cortex (DLPFC) and the Cathode electrode on the right DLPFC. During the sessions only a 15-second initiation current is applied, providing the patient with the sensation of receiving an electric current on the scalp. Participants will also experience sounds and stimuli similar to those produced by active tDCS.
223853292|NCT06713434|BIOLOGICAL|ELK-003 (Standarized Amniotic Fluid Secretome Eye Drops)|ELK-003 eye drops are a standardized amniotic fluid secretome formulation. It contains essential extracellular matrix proteins, such as collagen type VII and laminin-332, which are critical for maintaining corneal integrity in EB patients. In addition, ELK-003 also includes growth factors that stimulate corneal healing and tissue regeneration. This combination of matrix proteins and growth factors aims to enhance corneal surface stability.
223853293|NCT06714110|DEVICE|Intramedullary Limb Lengthening Device|The Precice IMLL System is composed of the Precice nail, screws, and uses an external remote controller (ERC) for rod distraction. The Precice IMLL System is designed to fit the anatomy of long bones and is intended to be placed internally in an intramedullary manner. It achieves limb correction through gradual lengthening or compression and providing intramedullary fixation for fractures of long bones.
223853294|NCT06714110|DEVICE|External Fixator Limb Lengthening Device|External fixator devices consist of an external frame (ring, half-ring, monolateral, and rail); bone fixation is accomplished by the transcutaneous bone fixations implants (pins, wires, cables, screws), and the lengthening is accomplished by the vertical components (struts). Generally, femoral lengthening devices are monolateral and tibial lengthening devices have ring or half-ring frames. The external fixators are made of a variety of materials, including stainless steel, titanium, carbon fiber, and aluminum.
223853295|NCT06406101|OTHER|Floor|Uninterrupted 2-minute chest compressions on a manikin that has been moved from the bed to the floor in a simulated scenario of out-of-hospital cardiac arrest
223853296|NCT06406101|OTHER|Bed|Uninterrupted 2-minute chest compressions on a manikin that is laying on bed in a simulated scenario of out-of-hospital cardiac arrest
223853297|NCT01838200|BIOLOGICAL|Bacillus Calmette-Guérin (BCG) vaccine|BCG was to be administered as a single intralesional injection (200 µL volume) on Day 1 at varying doses depending on cohort assignment.
223853298|NCT01838200|DRUG|Ipilimumab|Ipilimumab was to be administered as a 90-minute IV infusion at a dose of 3 mg/kg every 3 weeks (± 3 days) on Days 36, 57, 78, and 99.
223853299|NCT01838200|DRUG|Isoniazid|Isoniazid was to be administered orally at a dose of 300 mg (3 × 100 mg tablets) every day from Days 29 through 56.
223853300|NCT04423588|DIAGNOSTIC_TEST|dexlansoprazole serum concentration|6 blood samples are collected at fixed time Points after oral Administration of 1 dose of dexilant at regular patients visits preoperatively and 3 and 6 months post-surgery.
223853301|NCT04423588|DIAGNOSTIC_TEST|upper endoscopy|6 and 12 months after surgery the occurrence of marginal ulcers in the same Patient Group is examined by upper endoscopy. The 12-month endoscopy is part of the Routine postoperative diagnosis, the 6-month endoscopy is for study purpose.
223853302|NCT06353243|BEHAVIORAL|Bilateral alternating stimulation|positive touch intervention provided by parent to infant using alternating stimulation
223853303|NCT02777983|BEHAVIORAL|Educational Video App|The content of the app will be grounded in a biopsychosocial model and modeled on the Back Book, a booklet developed to help modify beliefs and behavior of patients with LBP. Essentially this will take the primary concepts and ideas often given in print or verbal form, and present it in a more engaging and dynamic fashion.
223853304|NCT00557804|DEVICE|MUSE clinical system|non-invasive external monitoring device
223853305|NCT05438732|DEVICE|smaller incision, new generation implantable miniature telescope (SING-IMT)|The IMT (model SING) is an intraocular implant comprised of 2 micro lenses in a glass tube (optics) in a flexible silicone carrier (haptics)
223853306|NCT05198089|OTHER|Internet-Based Intervention|Use MyInspiration website
223853307|NCT02772614|DRUG|BIA 3-202 (200 mg)|200 mg powder for oral use of unlabelled BIA 3-202
223853308|NCT00394407|DRUG|sliding scale regular insulin|SSRI acqhs
223853309|NCT00394407|DRUG|glargine basal insulin and glulisine prandial insulin|glargine insulin once a day and glulisine insulin three times a day as long as patient eating
223853310|NCT06630975|DEVICE|Hemiepiphysiodesis|8 plate
223853311|NCT06630975|PROCEDURE|Eight-Plates first described by Stevens are simple to use|fewer complications in terms of implant loosening and fracture can be expected.Good results as well as low rebound and complication rates have been recorded
223853312|NCT06630975|DEVICE|Hemiepiphysiodesis by eight Plate|Extraperiosteal eight plate insertion
223853313|NCT05553613|DRUG|Ticagrelor 90 MG Oral Tablet|Efficacy and safety of 180 mg loading dose of ticagrelor administered within 24 hours of first-ever ischemic stroke followed by 90 mg bid for 3 months will be assessed through NIHSS, mRS, duration of hospital stay, new ischemic stroke, and possible adverse effects.
223853314|NCT05553613|DRUG|Clopidogrel tablet|efficacy and safety of 300 mg clopidogrel followed by 75 mg once daily for 3 months will be assessed through NIHSS, mRS, duration of hospital stay, new ischemic stroke and possible adverse effects.
223853315|NCT03745118|DEVICE|EpiTel EpiLog|Plastic pad that is about the size of a house key, and will be adhered to your scalp with gel
223853316|NCT03745118|DEVICE|Byte Flies Sensor Dots|Plastic pads that will be adhered to your chest area
223853317|NCT03745118|DEVICE|Empatica E4|wearable seizure detection wristband
223853318|NCT03745118|DEVICE|Biovotion Everion|wearable seizure detection device armband that is attached to upper arm
223853319|NCT03745118|DEVICE|GeneActiv|wearable seizure detection watch
223853320|NCT04981015|DIAGNOSTIC_TEST|Three-day bladder diary|A three-day bladder diary for recording voiding-flow pattern of a women
223853321|NCT03784963|DRUG|Omega 3 fatty acids|Patients will receive 4 grams fish oil once daily
223853322|NCT03784963|OTHER|Placebo|Standard of care
223853323|NCT03680391|PROCEDURE|Cesarean section|"Both groups cesarean section will be held with the same technique:~* spinal anethesia~* pfennenstiel imcision~* lower segment cesarean section~* suturing uterus in two layers while exterionezed~* gentle manibulation~* no towels in gutters will be used"
223853324|NCT03181958|DEVICE|NHFOV|Nasal high frequency oscillation ventilation (NHFOV) is used as the noninvasive supporting mode after extubation.
223853325|NCT03181958|DEVICE|NCPAP|Nasal continuous positive airway pressure(NCPAP) is used as the noninvasive supporting mode after extubation.
223853326|NCT03181958|DEVICE|NIPPV|Nasal intermittent positive pressure ventilation(NIPPV) is used as the noninvasive supporting mode after extubation.
223853327|NCT00575523|DRUG|Atropine|Atropine 0,5mg is administered once intravenously immediately before starting percutaneous ethanol instillation.
223853328|NCT00575523|DRUG|Placebo|1ml 0,9% Saline solution is administered intravenously immediately before starting percutaneous ethanol instillation.
224076124|NCT04862663|DRUG|Abemaciclib|Phase Ib: 50 mg/ 100 mg/ 150 mg. Twice daily for 28 consecutive days to comprise a complete 28-day cycle
223853329|NCT02502396|OTHER|Retrospective Chart Review|Retrospective chart review study to evaluate Rivaroxaban's utilization in cancer patients for venous-thromboembolism (VTE) or non-valvular atrial fibrillation (NVAF). Study conducted from from January 1, 2012 to November 7, 2016 at MD Anderson Cancer Center in Houston, Texas.
223853330|NCT02313090|OTHER|Welltang|The intervention group installed Welltang (downloaded from www.welltang.com for free) designed by Shanghai Geping Information and Technique Company Ltd (Shanghai, China) on their cell phones. Welltang is a cell phone- based diabetes management application that consists of three main parts: knowledge, self-management, communication between patients and clinicians
223853331|NCT01091233|PROCEDURE|paracentesis|as indicated according to the treating physician (the indication for Paracentesis is not the subject of study)
223853332|NCT03696771|DRUG|NJH395|Immune stimulator antibody conjugate (ISAC), consisting of a monoclonal antibody which targets HER2 conjugated to an immune-stimulatory agent
223853333|NCT04358354|DRUG|Irinotecan|Irinotecan 150 mg/m2
223853334|NCT04358354|DRUG|Oxaliplatin|Oxaliplatin 85 mg/m2
223853335|NCT04358354|DRUG|5-fluorouracil|5-fluorouracil 400 mg/m2 iv bolus and 2400 mg/m2 civ 46 hours
223853336|NCT00394069|DRUG|MK-0476, montelukast sodium|Duration of Treatment: 14 Days
223853337|NCT02830152|DEVICE|LAAO|The left atrial appendage is occluded with the AMPLATZER™ Amulet™ device, which offers a conformable disc and lobe designed for complete occlusion of the left atrial appendage.
223853338|NCT02830152|DRUG|Medical Therapy|Available options included in Medical therapy are: anticoagulation with OAC or NOAC, antiplatelet therapy (including monotherapy and dual antiplatelet therapy) and no pharmacological antithrombotic therapy.
223853339|NCT02315391|DIETARY_SUPPLEMENT|isolated whey protein|isolated whey protein
223853340|NCT02315391|DIETARY_SUPPLEMENT|micellar whey protein|micellar whey protein
223853341|NCT02315391|DIETARY_SUPPLEMENT|glycine|glycine
223853342|NCT02315391|DIETARY_SUPPLEMENT|citrulline|citrulline
223853343|NCT01257503|DRUG|Hyland's Cold 'n Cough 4 kids|5 ml PO q4h prn cold symptoms
223853344|NCT01257503|DRUG|placebo|liquid made to look like the active homeopathic remedy
223853345|NCT01805414|OTHER|Modified Carbohydrate Breakfast|
223853346|NCT01805414|OTHER|Control Breakfast|
223853347|NCT00219687|OTHER|dispatcher-assisted CPR with compressions & ventilations|Delivery of telephone CPR instructions to lay callers with chest compressions and ventilations when the patient is identified to be in cardiac arrest
223853348|NCT00219687|OTHER|dispatcher-assisted CPR instructions with compressions only|Delivery of telephone CPR instructions to lay callers with hands-only chest compressions when the patient is identified to be in cardiac arrest
223853349|NCT05942768|DRUG|regorafenib plus anti-PD-1 antibodies|The patients were treated orally with regorafenib (80 mg once daily for 21 days on/7 days off, over a 28-day cycle), combined with 1 of the 5 anti-PD-1 antibodies (i.e., nivolumab, pembrolizumab, camrelizumab, sintilimab, or toripalimab). The anti-PD-1 antibody was administered intravenously on day 1, and its recommended dosage was as follows: nivolumab: 240 mg, every 2 weeks; pembrolizumab, camrelizumab, and sintilimab: 200 mg every 3 weeks; and toripalimab: 240 mg every 3 weeks
223853350|NCT01343290|DRUG|Canagliflozin|Type = 1, unit = mg, number = 300, form = tablet, route = oral use. Single tablet taken with or without a meal during 2 treatment periods
223853351|NCT03728725|DEVICE|Cepheid Gene Xpert MTB/XDR|The Xpert MTB/RIF assay (Cepheid, Sunnyvale, CA) is an integrated, automated, cartridge-based system for MDR-TB diagnosis that uses the GeneXpert instrument platform. WHO confirmed evidence to support the widespread use of the Xpert MTB/RIF assay in 2010 and the assay has since been widely used in TB programs, but it is only capable of identifying Mycobacterium tuberculosis (Mtb) and detecting RIF resistance. The Xpert MTB/XDR assay will be evaluated for INH and second-line resistance detection, and to recommend its use in diverse clinical settings. The focus of this protocol is the multicentre clinical evaluation.
223853352|NCT03814395|OTHER|No intervention|This is an observational study without any intervention
223853353|NCT04752735|OTHER|endovascular treatment|all enrolled patients must receive endovascular treatment.
223853354|NCT04473638|PROCEDURE|Arthroscopic Deltoid Repair|. A 4.5 mm arthroscopic set was used to clean the joint and assess medial and associated injuries. After deltoid injury confirmation through the method already mentioned, the medial gutter was prepared. The ideal positioning for the bone anchor in the medial malleolus followed Vega's recommendations and was located in the inferolateral quadrant created by the intersection of two lines: (1) tibia-talar joint line and (2) tangent line to the medial malleolus joint surface.(14). Sutures were passed respecting the safe zone illustrated by Acevedo at al, at the area between the posterior tibial tendon and the saphenous vein (16-25mm) (15). Sutures were passed but not tightened.
223853355|NCT00043264|DRUG|Rifampin|
223853356|NCT00043264|DRUG|Azithromycin|
223853357|NCT01603784|BEHAVIORAL|Intensive Exercise|"Standardized aerobic training program that is individualized to each participant's fitness level, and supervised by a certified exercise specialist. Participants attend 3 training sessions per week for 6 months. The session begins with a 10-15 minute warm-up. Participants then exercise on a treadmill or stationary bike, followed by cool-down activities. Heart rate and rating of perceived exertion are used to evaluate exercise intensity. Participants begin at \~30 min/day 60-70% of HR max and/or an equivalent level of RPE, and progress to 45-50 minutes at 75-85% for HR max."
224076125|NCT06416371|DIAGNOSTIC_TEST|Fundus fluorescein angiography, with ultrawide field retinal imaging|Intravenous injection of sodium fluorescein for angiography of retinal blood vessels
224076126|NCT04570423|DRUG|Eflapegrastim|Eflapegrastim supplied in prefilled, single-use syringes for SC injection.
223853358|NCT01603784|BEHAVIORAL|Home Exercise|Exercise program consisting of stretching, range of motion, and simple yoga exercises designed to improve flexibility. Each participant has a 60-minute sessions with an exercise trainer to teach them how to perform the exercises correctly. They are also given diagrams illustrating the exercises, along with written instructions. They are instructed to perform these exercises at home at least 3 times per week for 30 - 45 minutes. They also go to the recreational center monthly to meet with an exercise trainer to ensure that they are doing the exercises correctly. Participants record their exercise activities on a calendar for the 6 months.
223853359|NCT01603784|BEHAVIORAL|Cognitive Training|Computer-based training that is is administered 3 days per week for 8 weeks during months 5 and 6. The training program focuses on 3 types of cognitive processes: task coordination, prospective memory, and retrospective memory retrieval. One day of the week is devoted to each of the three cognitive processes. Some training sessions include a homework assignment for application and practice of the target cognitive processes in everyday activities.
223853360|NCT01603784|BEHAVIORAL|Health Education|"Weekly educational sessions are administered during months 5 and 6, conducted at the recreational center by research staff. Sessions last 1 hour, and cover health and other topics unrelated to exercise or cognition, such as nutrition, hearing loss, stroke, and saving energy in one's home. At the completion of each session, participants are given a homework assignment."
223853361|NCT04738565|DIETARY_SUPPLEMENT|Probiotic preparation|The mixture of Lactobacillus rhamnosus ŁOCK 0900, Lactobacillus rhamnosus ŁOCK 0908 and Lactobacillus casei ŁOCK 0919 administered once a day at a dose of one billion for 3 months.
223853362|NCT04738565|DIETARY_SUPPLEMENT|Maltodextrin|Maltodextrin comparable in color, texture and taste to the probiotic mixture administered once a day for 3 months.
223853363|NCT02824939|OTHER|Transversus Abdominis Plane (TAP) Block|0.5 ml/kg of 0.25 % Bupivacaine deposited in the transversus abdominis plane under ultrasound guidance postoperatively
223853364|NCT02824939|OTHER|Quadratus Lumborum (QL) Block|0.5 ml/kg of 0.25 % Bupivacaine deposited in the anterolateral aspect of the quadratus lumborum muscle under ultrasound guidance postoperatively
223853365|NCT01750554|OTHER|intermediate-acting digital nerve block|non-therapeutic Bupivacaine digital nerve block to assess effect on accuracy of diagnostic readings
223853366|NCT00678158|RADIATION|intensity modulated radiation therapy|Patients will be accrued at each dose level beginning at 22 Gy with increments of 2 Gy up to 28 Gy. Patients with a soft tissue mass, lymph nodes or focal bone metastases with lesions large enough to be imaged on CT scan will be accrued. Starting at 24 Gy, patients will be stratified in to 3 treatment categories: lesions involving bone, bowel, or spinal cord. Patients will be enrolled in each treatment category until 10 patients in that cohort reach an evaluable timepoint of 3 months post-RT. The maximum accrual is 20 for 22 Gy, and 90 (30 per treatment category) for each subsequent dose level (24-28 Gy). Some of these patients have participated in the optional FLT-PET scan portion of the study. Some of these patients have under gone an optional MRI scan which take place within one hour of the radiation treatment .
223853367|NCT02657629|OTHER|Continuous Feeding Regimen|Nocturnal continuous enteral feedings given from 8pm-8am with intermittent bolus feedings every 3 hours between 11am and 5pm. Continuous feedings given via gavage (nasogastric tube, orogastric tube or gastrostomy tube) and intermittent bolus feeds via gavage or nipple. Total caloric intake maintained at 120-130 kcal/kg/d.
223853368|NCT02657629|OTHER|Intermittent Bolus Feeding Regimen|Intermittent bolus enteral feedings given after 3 hours for entire 24 hours period. Feedings given via gavage or nipple. Total caloric intake maintained at 120-130 kcal/kg/d.
223853369|NCT06438406|DEVICE|Orthotic devices and therapeutic exercise (Group A)|Group A consisting of patients who were prescribed orthoses, to use gradually, and a 20-session rehabilitation programme, based on the Back School method
223853370|NCT06438406|DEVICE|Orthotic devices (Group B)|Group B consisting of patients who were only prescribed orthoses for the lower limbs
223853371|NCT05478772|DRUG|CTP-543|12 mg on Day 1 and Day 7
223853372|NCT05478772|DRUG|Fluconazole|200 mg once daily on Days 3 through to Day 8
223853373|NCT03787706|OTHER|Dry Needling|Patients will receive dry needling over active trigger points in the upper trapezius muscle
223853374|NCT03787706|OTHER|Manual Therapy|Patients will receive a manual compression for 30seconds over active trigger points in the upper trapezius muscle
223853375|NCT03145337|BIOLOGICAL|FlexHD ADM (Cohort A)|Tissue assisted breast reconstruction with FlexHD pliable perforated ADM
223853376|NCT03145337|BIOLOGICAL|AlloDerm RTU ADM (Cohort B)|Tissue assisted breast reconstruction with AlloDerm RTU perforated ADM
223853377|NCT02987543|DRUG|olaparib|300 mg (2x 150 mg tablets) twice daily
223853378|NCT02987543|DRUG|enzalutamide|160 mg (4 x 40 mg capsules) once daily
223853379|NCT02987543|DRUG|abiraterone acetate|1,000 mg (4 x 250 mg tablets) once daily
223853380|NCT02987543|DRUG|abiraterone acetate|1,000 mg (2 x 500 mg tablets) once daily
223853381|NCT02987543|DRUG|enzalutamide|160 mg (4 x 40 mg tablets) once daily
223853382|NCT00092599|DRUG|MK0653, ezetimibe|
223853383|NCT00092599|DRUG|Comparator: ezetimibe, placebo|
223853384|NCT03980964|DEVICE|Active NMES|Daily home-based, mobile-app controlled, neuromuscular electrical stimulation (NMES) therapy
223853385|NCT04630457|DEVICE|Conventional ankle prosthesis|At the first visit, 3D motion analysis, dynamic EMG analysis, energy consumption analysis, 6 minute walk test, Berg balance scale, Locomotor Capabilities Index, and Korean-Prosthesis Evaluation Questionnaire will be evaluated using the conventional prosthesis that the patient had.
223853386|NCT04630457|DEVICE|Meridium® (Microprocessor ankle prosthesis)|There are two weeks apart between each visit. Depending on the group to which the patient belongs, at the second or third visit, 3D motion analysis, dynamic EMG analysis, energy consumption analysis, 6 minute walk test, Berg balance scale, Locomotor Capabilities Index, and Korean-Prosthesis Evaluation Questionnaire will be evaluated using Meridium®. For example, if visit 2 was evaluated using Meridium®, visit 3 was evaluated using RoFT®. In another example, visit 2 is evaluated using RoFT®, while Visit 3 is evaluated using Meridium®.
223853387|NCT04630457|DEVICE|RoFT® (Microprocessor ankle prosthesis)|There are two weeks apart between each visit. Depending on the group to which the patient belongs, at the second or third visit, 3D motion analysis, dynamic EMG analysis, energy consumption analysis, 6 minute walk test, Berg balance scale, Locomotor Capabilities Index, and Korean-Prosthesis Evaluation Questionnaire will be evaluated using RoFT®. For example, if visit 2 was evaluated using RoFT®, visit 3 was evaluated using Meridium®. In another example, visit 2 is evaluated using Meridium®, while Visit 3 is evaluated using RoFT®.
223853388|NCT04866407|OTHER|Mentha x piperita|2% solution of Mentha x piperita diluted in fractionated coconut oil for topical application will be applied to one extremity of the subjects in the 'Mentha x piperita' group.
223853389|NCT04866407|OTHER|Eucalyptus globulus|2% solution of Eucalyptus globulus diluted in fractionated coconut oil for topical application will be applied to one extremity of the subjects in the 'Eucalyptus globulus' group.
223853390|NCT01990937|DRUG|Oral midazolam|5 mg in 15 mL of apple juice, orally 30 minutes before undergoing EGD
223853391|NCT05864482|OTHER|Psychosocial nursing intervention|The sessions were planned to be at least 45 minutes in a time suitable for the groups, with the bed curtains drawn if possible. Session 1: The purpose of this session; Brief CIS information will be provided. Session 2: The session starts with mood control of individuals. It is discussed whether they have experienced an event that occupies their minds and is likely to affect their illness. Session 3: It starts with mood control of individuals. They are asked if there is anything from the places where the guests are. Cognitive reviews are reviewed. It aims to describe recent stressful observations, negative automatic outcome descriptions, and evaluation of such experiences. 4.Session: The session starts with the mood control of the patient. It is discussed whether the patient has experienced an event that occupies his mind. Continuous analysis of negative thoughts and review of cognitive techniques and coping mechanisms are provided.
223853392|NCT02899286|BIOLOGICAL|PEG-BCT-100|PEGylated recombinant human arginase
223853393|NCT06532760|OTHER|Blood sampling|Blood sampling to study sodium fragment kinetics
223853394|NCT03669562|DRUG|Alprostadil Liposome for Injection|intravenous infusion Alprostadil Liposome
223853395|NCT03669562|DRUG|Placebo|intravenous infusion liposome control
223853396|NCT04156724|DEVICE|Helmet vetilation|We will apply non-invasive positive pressure ventilation via a helmet as interface
223853397|NCT04965467|DIAGNOSTIC_TEST|Screening for Fabry disease|A questionnaire specifically designed to assess Fabry disease-associated phenotypes in infancy, childhood and adolescence: pain in the hands and feet, angiokeratomas, hypohidrosis, corneal whorls, unexplained renal failure, unexplained hypertrophic myocardiopathy and unexplained early onset stroke. The questionnaire consisted mainly of quantitative, closed questions with pre- defined response options.The diagnosis of FD will be performed by standard procedures following international recommendations. These require the search for a deficiency of alphagalactosidase A activity on leucocytes in males and genetic analysis of the GLA gene in females (Germain et al. 2010). In females plasma Gb3, globotriaosyl- sphingosine (lyso-Gb3) will be measured for screening.
223853398|NCT04928872|COMBINATION_PRODUCT|Predefined meal|Nine predefined meals are administered in a randomized fashion, one meal per one study day, 2-3 study days per week. Meals have a form of drinks with different compositions of protein, carbohydrates and fat in relation to the US diet
223853399|NCT00370448|BEHAVIORAL|school-based social support system|Training gatekeeper recruited from students and tutors and counselors for group 1; training counsellors for group 2; No special intervention for group 3
223853400|NCT03458780|DRUG|Yellow Fever Vaccine|Yellow Fever Vaccine .5 ml
223853401|NCT00590668|DIAGNOSTIC_TEST|Transesophageal Echocardiography|Measurement of peak diastolic flow velocity
223853402|NCT00149279|PROCEDURE|Surgery: D2 dissection|
223853403|NCT00149279|PROCEDURE|Surgery: D2+paraaortic dissection|
223853404|NCT04582344|BIOLOGICAL|CoronaVac|Two doses at 14-day interval, each inoculation dose is 0.5 mL. Two doses of dosage (each prefilled syringe of the vaccine contains 600 SU of SARS-CoV-2 virus antigen) experimental vaccine at the schedule of day 0,14
223853405|NCT04582344|BIOLOGICAL|Placebo|Aluminium hydroxide, disodium hydrogen phosphate, sodium dihydrogen phosphate, sodium chloride 0.5mL/dose, two doses given 14 days apart.
223853406|NCT06249633|DRUG|Nitric Oxide|Inhaled nitric oxide
223853407|NCT04776993|DRUG|Methimazole|Methimazole for 72 weeks
223853408|NCT04776993|PROCEDURE|Radioiodine or thyroidectomy|Treatment with radioiodine or with thyroidectomy
223853409|NCT01906060|DEVICE|Air-Q Intubation Laryngeal Mask|Patients will be intubated using the Air-Q Laryngeal Mask.
223853410|NCT05351372|RADIATION|Ultra-low dose protocol|
223853411|NCT05351372|RADIATION|Standard dose protocol|
223853412|NCT04323995|OTHER|Sprint Interval Training|Sprint interval training of 2 weeks and more.
223853413|NCT04588337|DRUG|rhTNK-tPA|Thrombolysis
223853414|NCT00541606|OTHER|Pharmacist collaboration in diabetes care|Patients attended a minimum of 3 clinic visits (month 0, 6, 12) with one of the clinical pharmacists, where targeted physical assessment, education, and medication changes and follow up were recommended. Additional visits were arranged as clinically appropriate for drug monitoring. Referrals were facilitated to other clinicians where indicated, including ophthalmology, podiatry, CDEs, nutrition, and primary care. The pharmacists' recommendations for medication adjustment, laboratory monitoring and referrals were based upon the most recent guidelines and clinical trial evidence. Any therapy adjustment, lab testing or referrals required approval by the referring physician. A1c, lipid and BP values were collected prospectively at months 0, 6 and 12.
223853415|NCT00541606|OTHER|Usual care|Control patients received usual care directed by their physician, and the same data were gathered from chart review during the 12-month study period.
223853416|NCT00105794|PROCEDURE|Psychiatric Advance Directives intervention|
223853417|NCT05376930|DRUG|DWP16001 Amg|DWP16001 Amg, Tablets, Orally, Once daily
223853418|NCT02012166|DRUG|MK-0893 10 mg|MK-0893 10 mg administered orally in 240 mL of water
223853419|NCT02012166|DRUG|MK-0893 40 mg|MK-0893 40 mg administered orally in 240 mL of water
223853420|NCT02012166|DRUG|MK-0893 200 mg|MK-0893 200 mg administered orally in 240 mL of water
223853421|NCT02012166|DRUG|MK-0893 1000 mg|MK-0893 1000 mg administered orally in 240 mL of water
223853422|NCT02012166|DRUG|Placebo|Placebo administered orally in 240 mL of water
224076127|NCT04570423|DRUG|Chemotherapy|Chemotherapy agents may include doxorubicin, ifosfamide, docetaxel, CHOP regimen, etoposide, cyclophosphamide and vincristine which will be administered as per standard of care per the Primary Care physician's treatment plan.
223853423|NCT02012166|BIOLOGICAL|Sandostatine®|Sandostatine® is a somatostatin analogue. At 24 and at 72 (Part I) or 120 (Part II) hours postdose, simultaneous infusions of the Sandostatine®, insulin, and glucagon will be administered over a 2-hour period. These compounds are IV compatible and will be combined in one syringe. Intravenous Sandostatine® will be administered at 30 ng/kg/min.
223853424|NCT02012166|BIOLOGICAL|Insulin|At 24 and at 72 (Part I) or 120 (Part II) hours postdose, simultaneous infusions of the Sandostatine®, insulin, and glucagon will be administered over a 2-hour period. These compounds are IV compatible and will be combined in one syringe. Intravenous insulin will be administered at 0.10 milli-international unit (mIU)/kg/min.
223853425|NCT02012166|BIOLOGICAL|Glucagon|At 24 and at 72 (Part I) or 120 (Part II) hours postdose, simultaneous infusions of the Sandostatine®, insulin, and glucagon will be administered over a 2-hour period. These compounds are IV compatible and will be combined in one syringe. Intravenous glucagon will be administered at 3 ng/kg/min.
223853426|NCT02485041|DRUG|Dapoxetine 30mg|Tablet, Orally administered
223853427|NCT02485041|DRUG|Mirodenafil 100mg|Table, Orally administered
223853428|NCT05574530|DIETARY_SUPPLEMENT|Colon-delivered multivitamin supplement|6-week intervention of one dietary supplement a day, containing vitamin B2 (10mg), vitamin B3 (4mg), vitamin B6 (1.4mg), vitamin B9 (400μg), vitamin C (200mg) and vitamin D3 (15ug).
223853429|NCT05574530|DIETARY_SUPPLEMENT|Placebo supplement|6-week intervention of one dietary supplement a day, containing 200 mg of microcrystalline cellulose.
223853430|NCT04957654|OTHER|VST with collagen plug soaked in blood|-A sub mucoperiosteal tunnel will be created, a membrane shield will be trimmed to fit the facial wall of the socket and introduced through the tunnel lying over the facial bone plate, and the facial gap will be filled with collagen plug soaked in blood
223853431|NCT04957654|OTHER|VST with Allograft Demineralized bone matrix Grafton|-A sub mucoperiosteal tunnel will be created, a membrane shield will be trimmed to fit the facial wall of the socket and introduced through the tunnel lying over the facial bone plate, and the facial gap will be filled with Allograft Demineralized bone matrix Grafton
223853432|NCT04957654|OTHER|VST with a particulate bone graft composed of two thirds autogenous cortical chips harvested from the surgical site and one third of bovine deprotinzed particles|-A sub mucoperiosteal tunnel will be created, a membrane shield will be trimmed to fit the facial wall of the socket and introduced through the tunnel lying over the facial bone plate, and the facial gap will be filled with a particulate bone graft composed of two thirds autogenous cortical chips harvested from the surgical site and one third of bovine deprotinzed particles
223853433|NCT05264467|BIOLOGICAL|Platelet rich fibrin on colorectal anastomosis|Platelet rich fibrin on colorectal anastomosis
223853434|NCT01315899|DRUG|ORM-12471 30mg|Given as a single dose once during the crossover study as per Williams design
223853435|NCT01315899|DRUG|ORM-12471|Given as a single dose once during the study as per Williams crossover design
223853436|NCT01315899|DRUG|placebo|Given once as a single dose during the study as per Williams crossover design
223853437|NCT04009070|DEVICE|Acupuncture Pres Needle: 0.22x1.5 mm needle|Acupunctur group; Acupunctur preoperatively 24 hours before bilateral PC6 (approximately two cm above the midline of the wrist line) and ST 36 (approximately 1-2 cm laterally from the tuberocyte tibia). The tape (Needle Press) will remain for 24 hours after surgery.
223853438|NCT03874156|DRUG|Atorvastatin 40mg|Oral tablet fabricated and labelled at Krageroe Tablettproduksjon AS
223853439|NCT03874156|DRUG|Placebo Oral Tablet|Oral tablet fabricated and labelled at KrageroeTablettproduksjon AS
223853440|NCT04993391|DRUG|JS111(AP-L1898 Capsules)|40 mg, QD
223853441|NCT04993391|DRUG|JS111(AP-L1898 Capsules)|80 mg, QD
223853442|NCT04993391|DRUG|JS111(AP-L1898 Capsules)|160 mg, QD
223853443|NCT04993391|DRUG|JS111(AP-L1898 Capsules)|240 mg, QD
223853444|NCT04993391|DRUG|JS111(AP-L1898 Capsules)|320 mg, QD
223853445|NCT00753168|DRUG|OT-730 ophthalmic solution|one eye drop twice daily
223853446|NCT00753168|DRUG|timolol maleate ophthalmic solution|one eye drop twice daily
223853447|NCT00753168|DRUG|OT-730 placebo|one eye drop twice daily
223853448|NCT01977612|DEVICE|4-0 monofilament suture|Skin closure using 4-0 monofilament suture
223853449|NCT01977612|DEVICE|Stainless steel staples|Skin closure using stainless steel staples.
223853450|NCT00079664|BEHAVIORAL|Tai Chi|
223853451|NCT02188758|OTHER|Adults - CFPE Treatment|Hospitalization for comprehensive treatment of CF pulmonary exacerbation, including intravenous (IV) antibiotics, nutritional assessment and support, airway clearance of mucus, use of inhaled mucolytic agents and bronchodilators, glycemic control with insulin, and psychosocial support.
223853452|NCT06320119|OTHER|PDO Group|Patients in the intervention gruop with set a personalized outcome within a usual asthma review consultation
223853453|NCT02504619|BIOLOGICAL|CordIn|CordIn™ is a cryopreserved stem/progenitor cell-based product of purified CD133+ cells composed of ex vivo expanded allogeneic UCB cells.
223853454|NCT04228536|PROCEDURE|Totally ExtraPeritoneal (TEP) repair|
223853455|NCT04228536|PROCEDURE|TransAbdominal PrePeritoneal (TAPP) repair|
223853456|NCT04228536|PROCEDURE|Open anterior mesh repair (OAM)|
223853457|NCT04228536|PROCEDURE|Combined Anterior and Posterior technique (CAP)|
223853458|NCT04228536|PROCEDURE|Open PrePeritoneal Mesh technique (OPPM)|
223853459|NCT04228536|PROCEDURE|Sutured Repair|
223853460|NCT01886430|OTHER|Functional electrical stimulation|Functional electrical stimulation for 10 days
223853461|NCT01886430|OTHER|Placebo electrical stimulation|Placebo electrical stimulation for 10 days
223853462|NCT02396979|DRUG|Methadone|
223853463|NCT02396979|BEHAVIORAL|Holistic Health Recovery Program|
223853464|NCT00641654|DRUG|Pegylated interferon alfa-2a and ribavirin|Arm A: Pegylated interferon alfa-2a Injection, 180 µg sc x 1/w for 48 weeks Ribavirin Tablet 200 mg weight based 5 or 6 per day for 48 weeks
223853465|NCT00641654|DRUG|Pegylated interferon alfa-2a and ribavirin|Arm B:Pegylated interferon alfa-2a Injection, 180 µg sc x 1/w for 48 weeks Ribavirin Tablet 200 mg weight based 5 or 6 per day for 48 weeks
223853466|NCT00641654|DRUG|Pegylated interferon alfa-2a and ribavirin|Arm C:Pegylated interferon alfa-2a Injection, 180 µg sc x 1/w for 24 weeks Ribavirin Tablet 200 mg weight based 5 or 6 per day for 24 weeks
223853467|NCT05323682|OTHER|Individualized physical exercise program|An individualized physical exercise program was programmed, monitored remotely by e-mail or the use of an activity wristband
223853468|NCT05323682|OTHER|NO Individualized physical exercise program|Usual medication
223853469|NCT06231069|DIETARY_SUPPLEMENT|Multi-nutrient supplement|12 weeks of supplement intake of milk proteins, N-3 PUFAs, creatine, and vitamin D at levels previously shown to augment muscle protein synthesis in young individuals.
223853470|NCT06231069|OTHER|Exercise|12 weeks of short-duration mixed endurance and resistance exercise.
223853471|NCT03426683|OTHER|Intestinal Microbiota Transplantation|the bacteria will be transplanted to mid-gut by nose-jejunum nutrition tube. Patients in this study will be assigned to receive standardized IMT three times or traditional medicine and would be followed up for at least 3 year.
223853472|NCT00950404|DRUG|Viagra 50 mg tablet|Commercial tablet, 50 mg, single dose administered with water
223853473|NCT00950404|DRUG|Formulation B ODT tablet 50 mg|Oral disintegrating tablet (ODT), 50 mg, single dose administered without water
223853474|NCT00950404|DRUG|Formulation C ODT tablet 50 mg|ODT, 50 mg, single dose administered without water
223853475|NCT00950404|DRUG|Formulation D ODT tablet 50 mg|ODT, 50 mg, single dose, administered without water
223853476|NCT05178758|DEVICE|Virtual Reality (VR)|Patients in the intervention (VR) group will receive a series of occupational and physical therapy rehabilitation training using the VR system. All training is consists of daily activities oriented by an occupational therapist, including grasp, grip, pinch, gross, and finger-hand coordination movement. Each training will take around 1 hour for one session per day 5 times per week over a maximum of 4 weeks. The training presented a one-on-one that allowed interaction between instructor (or VR system) and participant.
223853477|NCT01921140|DRUG|Olaparib tablets|Olaparib dosing (2X 150mg tablets) following allocated meal
223853478|NCT01921140|PROCEDURE|Pharmacokinetic sampling|Blood samples taken pre and post dosing with 2x 150 mg olaparib tablet
223853479|NCT01921140|OTHER|Dietary Fasted|2x 150 mg olaparib tablet formulation taken in fasted state. 5-14 days washout period
223853480|NCT01921140|OTHER|Dietary High Fat|2x 150 mg olaparib tablet formulation taken 30 minutes after allocated meal. 5-14 days washout period.
223853481|NCT04206046|PROCEDURE|Spinal anaesthesia|Patients will receive a spinal anaesthetic
223853482|NCT04206046|PROCEDURE|General anaesthesia|patients will receive a general anaesthetic and a femoral nerve block
223853483|NCT05699213|DIAGNOSTIC_TEST|Lung MRI|MRI of the lung
223853484|NCT05699213|DIAGNOSTIC_TEST|Blood Draw|Blood Draw
223853485|NCT01606553|DEVICE|High-intensity IMT|High intensity short duration respiratory muscle training with a valve prototype
223853486|NCT01606553|DEVICE|Sham High-intensity IMT|High intensity short duration respiratory muscle training using a sham valve prototype
223853487|NCT04074148|BEHAVIORAL|Diabetes Prevention Education Program|An educational lifestyle modification program, offering 4 sessions of 30 minutes theory and 30 minutes practice each, total duration 6 months
223853488|NCT04074148|BEHAVIORAL|Diabetes Prevention Education brochure|An educational lifestyle modification brochure
223853489|NCT01883492|DEVICE|Femoral Stem|JMDN classification/Class III device
223853490|NCT01883492|DEVICE|Acetabular Cup|JMDN classification: Class III device
223853491|NCT01883492|DEVICE|Acetabular Liner|JMDN classification: Class III device
223853492|NCT03721432|DRUG|Pregabalin 150mg|pregabalin 150 mg capsules (Lyrica®,Pfizer) given 60 minutes prior to epidural anesthesia
223853493|NCT03721432|DRUG|Placebo oral capsule|Placebo oral capsule given 60 minutes prior to epidural anesthesia
223853494|NCT05181579|OTHER|Manuel therapy|Some sacroiliac manipulation and mobilization techniques will be applied to patients by an experienced physiatrist. Patients in the manual therapy group will receive 5 sessions of sacroiliac joint manipulation once a week.
223853495|NCT05181579|OTHER|Sacroiliac joint injection|Corticosteroid (1 ml 40 mg methylprednisolone) and local anesthetic (1 ml 1% lidocaine) will be injected into the sacroiliac joint using a 22 G spinal needle, guided by fluoroscopy (C-arm fluoroscopy) by an experienced physiatrist. It will be applied just one time.
223853496|NCT01259102|DRUG|Buprenorphine transdermal patch|Buprenorphine 10 mcg/hour patch applied transdermally for 7-day wear.
223853497|NCT04436055|OTHER|No Intervention will be used|Since this is an observational study, there are no interventions.
223853498|NCT06492889|DRUG|Levonorgestrel|Participants in the levonorgestrel plus mifepristone group will receive one tablet of 1.5 mg levonorgestrel
223853499|NCT06492889|DRUG|Mifepristone|Participants in both groups will receive one tablet of 200 mg mifepristone
223853500|NCT05737238|BEHAVIORAL|Intervention during phase B: Compensatory brain game supporting Goal Management Training intervention|The investigational treatment is only given during the intervention phase (phase B), and consists of six treatment sessions. In the treatment sessions, patients learn and apply the GMT algorithm. This means that the multiple steps of the GMT as well as the actual performance of the IADL-task goals will be learned under guidance of a therapist. In order to facilitate generalization, patients will learn to use the algorithm during the performance of untrained tasks by playing the treatment supporting Plan Game. Because of this, patients are able to practice the application of the GMT algorithm independently at their own home. Besides, the intervention also includes a Plan Tool. This is a mobile application that can be used as an aid during the performance of (instrumental) activities of daily living (IADL) tasks in order to perform activities more independently. The GMT treatment sessions are given twice a week (max. 60 minutes for each attendance).
223853501|NCT01615835|OTHER|EnSite NavX System|EnSite NavX system is a 3D Mapping system
223853502|NCT01803646|DRUG|AM-101|AM-101 gel for intratympanic injection
223853503|NCT01803646|DRUG|Placebo|Placebo gel for intratympanic injection
223853504|NCT00878618|DRUG|AZD0837|Extended-release tablets, test formulation. 2 tablets given in the morning for 6 days
223853505|NCT00878618|DRUG|AZD0837|Extended-release tablets, reference formulation. 2 tablets given in the morning for 6 days
223853506|NCT02162667|DRUG|Trastuzumab|Trastuzumab 6mg/kg is ongoing to be administered for both arms after 8mg/kg loading dose.
223853507|NCT00652119|DRUG|Paclitaxel|Cycle 1 = 60 mg/m\^2 IV weekly over 1 hour x 3 weeks; Cycles 2-6 = 60 mg/m\^2 IP weekly over 1 hour x 3 weeks of each cycle.
223853508|NCT00652119|DRUG|Carboplatin|Cycle 1 = AUC 6 IV over 1 hour on day 1; Cycles 2-6 = AUC 6 IP over 1 hour on day 1 of each cycle.
223853509|NCT00652119|DRUG|Avastin|Cycle 2 = 15 mg/kg IV over 90 minutes on day 8; Cycles 3-6 = 15 mg/kg IV on day 1 of each cycle.
223853510|NCT03282786|OTHER|carbon dioxide insufflation during colonoscopy|Use of Carbon dioxide instead of air insufflation
223853511|NCT00888108|DRUG|ABT-263|150 mg of ABT-263 is taken orally once daily on Days 1-5 or Days 1-3 of each 21 day cycle. 150 mg of ABT-263 on Days 1-3, 8-10 and 15-17 of each 28-day cycle. This is a dose escalation study, therefore the dose of ABT-263 will change throughout the study.
223853512|NCT00888108|DRUG|Docetaxel|75 mg/m2 will be given by intravenous infusion on day 1 of each 21 -day cycle. 30 mg/m2 will be given by intravenous infusion on day 1, 8, 15 of each 28 -day cycle.
223853513|NCT01541358|RADIATION|fluorine F 18 sodium fluoride|Undergo fluorine F 18 sodium fluoride PET/CT scan
223853514|NCT01541358|PROCEDURE|positron emission tomography/computed tomography|Undergo fluorine F 18 sodium fluoride PET/CT scan
223853515|NCT00773708|DRUG|raltegravir|intensify their therapy with Raltegravir(RAL):1 Protease inhibitor plus 2 nucleoside reverse transcriptase inhibitor plus RAL or 1 non-nucleoside reverse transcriptase inhibitor plus 2 nucleoside reverse transcriptase inhibitor plus RAL
223853516|NCT02864095|DRUG|Tranexamic acid (TXA)|IV and topical administration
223853517|NCT02864095|DRUG|Epinephrine|
223853518|NCT02092077|DRUG|TV-1106|TV-1106 0.554mg, TV-1106 0.924 mg, TV-1106 1.20 mg
223853519|NCT02092077|DRUG|somatropin|Dose may be adjusted as required
223853520|NCT05896319|DEVICE|Hyaluronic acid gel|"Post-operative application of Hyaluronic acid gel 3 times per day (8 hours distance between each application) for 7 days after oral hygiene and without swallowing, eating or drinking for one hour after the application, as follows: wash your hands thoroughly before each application, apply a layer of gel on the injured mucosa, massage with a finger in order to facilitate spreading of the product over the treated area."
223853521|NCT06152484|OTHER|Pentacam, Corvis ST and CASIA2|morphological and biomechanical parameters of corneal were obtain by CASIA2, Pentacam and Corvis ST
223853522|NCT01188252|DRUG|Roniciclib (BAY1000394)|Oral administration twice daily in a 3 days on / 4 days off schedule. Starting dose will be 0.3 mg corresponding to approximately 0.005 mg/kg and dose will be escalated dependent on any dose limiting toxicities.
223853523|NCT02260310|OTHER|Weizhong and Huantiao|
223853524|NCT02260310|OTHER|A-shi point|
223853525|NCT06225882|DRUG|Oxaluria evolution.|To collect real data from the specific French experience by collecting data from patients treated throughout the country and to monitor in particular the evolution of oxaluria before and after treatment.
223853526|NCT05193188|DRUG|Anlotinib hydrochloride|Anlotinib 12mg per person per day, continuous medication for 2 weeks and 1 week off, 3 weeks 1 cycle, until disease progression or intolerable toxicity
223853527|NCT05193188|DRUG|PD-1 inhibitor|Intravenous injection, once every 3 weeks, until the disease progression or intolerable toxicity
223853528|NCT02615912|OTHER|PEG-40 Hydrogenated Castor Oil (Tagat CH40, Evonik) 1.5%|
223853529|NCT02615912|OTHER|Lauryl glucoside (Plantacare® 1200UP, BASF) 1.5%|
223853530|NCT02615912|OTHER|Sorbitan palmitate (SPANTM 40 (powder), Croda) 1.5%|
223853531|NCT02615912|OTHER|Silwet* DA-63 (Momentive) 1.5%|
223853532|NCT02615912|OTHER|Sodium lauryl sulfate (Sigma Aldrich) 1.0%|
223853533|NCT02615912|OTHER|Water (control)|
223853534|NCT01876511|DRUG|MK-3475|MK-3475 10 mg/kg every 14 days
223853535|NCT05983484|DEVICE|Skiin Underwear|All participants enrolled will wear simultaneously the PocketECG (Standard Holter) and the Skiin Underwear Chestband (wearable textile). Each participant will wear both systems for the duration prescribed by their physician (1 to 14 days).
223853536|NCT02400151|DRUG|Vitamin D supplementation|Patients randomized to this group will receive 4000 UI of Vitamin D3 per day for 90 days.
223853537|NCT02400151|DRUG|Placebo|Patients randomized to this group will receive placebo for 90 days.
223853538|NCT02400151|OTHER|3 months lifestyle and dietary management|Lifestyle and dietary management at the Saint Pierre Institute (Palavas-les-Flots, France) occurs for three months. Nutritionally speaking, each child or adolescent receives a controlled and balanced diet, consistent with the recommendations appropriate for his/her age, slightly hypocaloric or normocaloric. This dietary approach is complemented by a nutrition education program and supervision by a doctor and a dietician. Three hours of exercise training per week are scheduled; these sessions include adapted aerobic activities supervised by instructors and educators at the center.
223853539|NCT02400151|OTHER|Normal control|Patients in this group do not have experimental intervention in order to provide measures of a real-life control group.
223853540|NCT03996746|DIAGNOSTIC_TEST|No intervention|No intervention
223853541|NCT03008499|BIOLOGICAL|High-activity natural killer|Each treatment: 8\~10 billion cells in all, transfuion in 3 times, i.v.
223853542|NCT02882048|PROCEDURE|NADA Protocol|NADA Protocol is a standardized acupuncture technique in which five designated points in the ear are needled.
223853543|NCT02882048|OTHER|Medication management|Standard of care medication management defined by an opioid weaning protocol with specific, symptomatic medication regimens.
223853544|NCT02410538|OTHER|"list of FAQ"|
223853545|NCT03921450|DEVICE|1 Hz rTMS|1 Hz stimulation at 110% of resting motor threshold over supplementary motor area
223853546|NCT03921450|DEVICE|iTBS|50 Hz theta burst stimulation at 80% of resting motor threshold over supplementary motor area
223853547|NCT03921450|DRUG|Placebo|1 Hz stimulation with the placebo TMS coil without any magnetic emission
223853548|NCT04765163|DEVICE|Intelligent Operating Handle|Intelligent Operating Handle
223853549|NCT03106142|PROCEDURE|Academic detailing visit arm|General Practitioners in the intervention group will receive one academic detailing visit. During this visit the GPs will receive information about the importance of physical therapy in the non-surgical management of knee osteoarthritis. The information will be summarized on an information leaflet for the GP.
223853550|NCT03774914|DRUG|Alemtuzumab (GZ402673)|Pharmaceutical form:Concentrate for solution for infusion Route of administration: Intravenous infusion
223853551|NCT02272400|OTHER|IGRT for prone partial breast irradiation (PBI)|IGRT for prone partial breast irradiation (PBI): All patients will be treated prone with 6 Gy/fraction delivered in 5 fractions over a 1-week period for a total dose of 30 Gy. Simulation and treatment will be started within 50 days from surgery in order to maximize the chances of optimal lumpectomy cavity visualization on the planning and cone beam CT scans. All patients will be followed monthly for the first 90 days then q3 months for the first year, then yearly for the next 10 years.
223853552|NCT02925000|DRUG|TLC178|TLC178
223853553|NCT06202599|DRUG|Fruquintinib|For patients with pulmonary metastasis only, we mostly gave them fruquintinib with 7 mg in adults and 3-5 mg in children (\<10 years) orally per day (5 days on and 2 days off). If patients were extrapulmonary metastasis, we usually used combinations with metronomic chemotherapy (2/3 or 3/5 or even 1/2 of the usual dose) or immunotherapy.
223853554|NCT04104698|DIAGNOSTIC_TEST|Quantitative EEG|"1. Both groups will undergo evaluation of depression severity using Beck Depression Inventory Scale-II (Arabic Version)~2. Both groups will be assessed for psychological \& cognitive contributes respectively using:~   A. Connor and Davidson Scale for resilience (Arabic Version) B. The scale of Islamic Religiosity Attitude (SIRA)~3. Both groups will do Quantitative EEG (qEEG) to detect electrical, functional and brain mapping changes {Using Neurovirtual BW III, Florida, USA)~4. The quantitative analysis of EEG will focus on the following functions:~Histogram, Topography, Spectrum Analysis, Spectral Differences, Propagation, Positional Diagram, Medium Amplitude, Ranges of Absolute Frequencies, Ranges of Relative Frequencies, CSA, Spectrum, and CSA Compressed."
223853555|NCT04416971|PROCEDURE|AVF puncture|For patients with mature/immature AVF on HD initiation, AVF puncture will be conducted.
223853556|NCT01048788|DRUG|OPC-41061|OPC-41061 tablets will be orally administered once daily after breakfast at 7.5 mg on Day 1 to 7 and at either 7.5 or 15 mg on Day 8 to 14.
223853557|NCT00480012|DEVICE|rTMS|repetitive transcranial meagnetic stimulation of the brain
223853558|NCT03360552|OTHER|Multidimensional fragility index questionnaire RAI-Home Care|Questionnaire for assessing deficits in Alzheimer's disease
223853559|NCT03360552|OTHER|Usual care|Usual clinical evaluation
224076128|NCT06487247|BEHAVIORAL|HEME-Hospice Program|A care delivery program that combines home-based transfusions with routine home hospice care. Transfusions are administered by trained transfusion nurses. Standard hospice care is provided by an interdisciplinary team of non-transfusion nurse case managers, hospice aides, social workers, and chaplains.
224076129|NCT03686397|DRUG|SVT-15652|1 vial twice daily
224076130|NCT03686397|DRUG|Placebo|1 vial twice daily
223853560|NCT01131494|OTHER|Motor exercises for swallowing, breathing and phonation|This exercises aimed to increase strength and range of motion of mouth, larynx and pharynx structures. All patients made sustained vowel phonation of /a/, pushing plosive phonemes /pa/, /ta/, /ka/ in a forceful manner, suction of wet gauze, swallowing with tongue hold and modified supraglottic maneuver, in ten repetitions, ascending and descending gliding phonation of vowel /a/ and /u/, five repetitions of each vowel, and tongue rotation in oral vestibule, 3 series of 5 repetitions to each side. Patients underwent oral motor exercises twice a day, five days a week, for five weeks.
223853561|NCT01284907|DIETARY_SUPPLEMENT|Vitamin D3 (Cholecalciferol)|Vit D3 ( Cholecalciferol) 1200 IU oral daily for 6 months
223853562|NCT01284907|DIETARY_SUPPLEMENT|Placebo Drops|
223853563|NCT05657041|DRUG|Clopidogrel|Body weight adjusted clopidogrel dosing
223853564|NCT02156687|DEVICE|Y mesh|Y mesh
223853565|NCT02156687|DEVICE|Dual flat mesh|Dual flat mesh
223853566|NCT01691963|DEVICE|C-MAC® videolaryngoscope (Karl Storz, Tuttlingen, Germany)|"Endotracheal intubation will be achieved using a C-MAC® videolaryngoscope (Karl Storz, Tuttlingen, Germany) with a size 3 Macintosh blade.~The best possible view of the glottic inlet will be scored with the blade tip positioned in the vallecula.~Next, the view of the glottic inlet will be scored with the blade advanced further into the vallecula, until the epiglottis flips infero-posteriorly and becomes downfolded into the trachea.~The glottic view will be scored in both positions using the Cormack and Lehane classification system.~After successful intubation, the blade will slowly be withdrawn into the vallecula to elevate the epiglottis back to its normal position."
223853567|NCT05860140|OTHER|Education video|Six minutes long education video focusing on protein and energy meals
223853568|NCT04538755|DRUG|Placebo oral capsule|Placebo before sleep
223853569|NCT04538755|DRUG|DAW2020 oral capsule|DAW2020 34 mg 4 h before sleep, single night administration
223853570|NCT00307450|DRUG|Levetiracetam|up to 200 mg per day in two dosages per day.
223853571|NCT06461637|BEHAVIORAL|Stepped Care Mental Health for Foreign Domestic Helpers (SCMH-FDH)|The SCMH-FDH intervention consists of 4 steps. Step 1 involves a self-help intervention (through 12 mental health booklets) delivered in 6 sessions and an online peer support group. Those who did not respond to Step 1 will be referred to Step 2 (group-based resilience workshop). The intervention will be also be delivered in 6 weekly sessions lasting 1-1.5-hours. Those who did not respond to Step 2 will be referred to Step 3 (guided self-help cognitive behavioral therapy, CBT) with guidance from a trained therapist. Self-help materials will be provided. The sessions are spread out over six weeks, with each sessions lasting 30-45 minutes. Those who did not respond to Step 3 will be referred to Step 4 (high intensity interventions provided by mental health professionals). Stepping up is determined by the IAPT-minimum data set. If assessment scores after previous treatment exceeds the defined threshold (PHQ-9 ≥ 10 or GAD-7 ≥ 8), then participants need to step up to the next intervention.
223853572|NCT04584489|OTHER|iron stores assessment.|assessment of iron stores by measuring serum ferritin level (mandatory), serum iron and transferrin saturation.
223853573|NCT04950855|DIAGNOSTIC_TEST|Optical Coherence Tomography,Optical Coherence Tomography Angiography(Topcon)|Optical coherence tomography optical coherence tomography angiography
223853574|NCT04440124|OTHER|Incremental shuttle walk test|All patients were reviewed by a physiotherapist during their pre-assessment clinic one week prior to surgery to complete an incremental shuttle walk test (ISWT). The ISWT was completed according to a standardised protocol and involved patients walking around 2 cones set up 9 metres apart. Patients were asked to cover the distance between the cones in time to auditory cues. Oxygen levels and heart rate were recorded during the assessment with the use of a portable pulse oximeter. The test was stopped when patients could no longer keep pace with the auditory cues or were too breathless to continue. The total distance mobilised was recorded.
223853575|NCT06553014|OTHER|Endovascular Plug Embolization|Effectiveness of Endovascular Plug Embolization in Pelvic Congestion Syndrome
223853576|NCT01233050|DRUG|2% Chlorhexidine Gluconate/70% Isopropyl Alcohol|Preoperative skin antisepsis preparation
223853577|NCT01233050|DRUG|Iodine Povacrylex/74% Isopropyl Alcohol|preoperative skin antisepsis preparation
223853578|NCT04674332|DRUG|Long acting insulin|long acting insulin analogue once daily at bed time
223853579|NCT04674332|DRUG|multiple dose regimen|intermediate and short acting insulin
223853580|NCT00887835|DEVICE|PERPOS™ PLS|To stabilize the spine as an aid to fusion through bilateral immobilization of the facet joints.
223853581|NCT05672446|OTHER|simulation with standardized child patient|49 students in the experimental group experienced the ability to prepare a school-age child for the procedure with a simulation using standardized pediatric patients. In the simulation, a school-aged child was used as the standard patient.
223853582|NCT01771666|DEVICE|SPY Elite Imaging|A camera that is directed into the axillary cavity to try to capture an image of the tumor site labeled with Indocyanine green before and after excising sentinel nodes
223853583|NCT01771666|DRUG|Indocyanine Green|"started at 1mg /mL~If fluorescence is not detected with this dose, then it will be increased by 50%."
223853584|NCT01771666|DRUG|Isosulfan blue|"3 to 5 mL~If fluorescence is not detected with this dose, then it will be increased by 50%."
223853585|NCT01771666|DRUG|99technetium-sulfur colloid radiolabel|
223853586|NCT03824262|DEVICE|HICO-VARIOTHERM 550|Warming during perioperative period.
223853587|NCT03824262|DEVICE|Mistral-Air Plus forced air warming device|Warming during perioperative period.
223853588|NCT02854761|DRUG|EF-022 (Modified Vitamin D Binding Protein Macrophage Activator)|
223853589|NCT02890368|DRUG|TTI-621 Monotherapy|"TTI-621 (SIRPα-IgG1 Fc) is a soluble recombinant fusion protein created by directly linking the sequences encoding the N-terminal CD47 binding domain of human SIRPα with the Fc domain of human immunoglobulin (IgG1). TTI-621 acts by binding human CD47 and preventing it from delivering an inhibitory do not eat (antiphagocytic) signal to macrophages."
223853590|NCT02890368|DRUG|TTI-621 + PD-1/PD-L1 Inhibitor|TTI-621 will be given in combination with one of the following programmed death-1 (PD-1) or programmed death-ligand-1 (PD-L1) inhibitors: nivolumab, pembrolizumab, durvalumab, avelumab, or atezolizumab administered on Day 1. Subjects in this cohort must have a cancer diagnosis for which a PD-1/PD-L1 inhibitor is approved by the FDA or listed in the National Comprehensive Cancer Network (NCCN) Guidelines.
223853591|NCT02890368|DRUG|TTI-621 + pegylated interferon-α2a|TTI-621 will be given in combination with pegylated interferon-α2a. Subjects in this cohort must have a cancer diagnosis for which pegylated interferon-α2a is approved by the FDA or listed in the National Comprehensive Cancer Network (NCCN) Guidelines.
223853592|NCT02890368|OTHER|TTI-621 + T-Vec|TTI-621 will be given in combination with talimogene laherparepvec (T-Vec). Subjects in this cohort must have unresectable melanoma.
223853593|NCT02890368|OTHER|TTI-621 + radiation|TTI-621 will be given following radiation to the target plasmacytoma. Subjects in this cohort must have relapsed multiple myeloma with bony or soft tissue plasmacytoma(s).
223853594|NCT02533908|DRUG|Fentanyl intranasal|fentanyl is applied intranasally with a MAD (mucosal atomization device) prior to the application of nitrous oxide 70% analgosedation
223853595|NCT02533908|DRUG|NaCl 0.9% intranasal|Placebo is applied intranasally with a MAD (mucosal atomization device) Prior to the application of nitrous oxide 70% analgosedation
223853596|NCT01590836|DRUG|insulin degludec|Administered subcutaneously (s.c., under the skin) once daily (plus insulin aspart as bolus insulin as required).
223853597|NCT01590836|DRUG|insulin degludec/insulin aspart|Single dose administered subcutaneously (s.c., under the skin).
223853598|NCT03988504|DIAGNOSTIC_TEST|Routine check up including genetic testing|Intervention is a routine check up including preemptive genetic testing
223853599|NCT04797416|DEVICE|FGM infiltration 1 hour group|The sensor is activated immediately after wearing (including the time between the sensor activation and the first blood glucose value stored，about 1 hour).
223853600|NCT04797416|DEVICE|FGM infiltration 6-hour group|Reactivate the sensor 5 hours after wearing (including the time between the sensor activation and the first blood glucose value stored，about 1 hour).
223853601|NCT04797416|DEVICE|FGM infiltration 12-hour group|Reactivate the sensor 11 hours after wearing (including the time between the sensor activation and the first blood glucose value stored，about 1 hour).
223853602|NCT01247337|DRUG|Oxaliplatin, capecitabine, gemcitabine, cetuximab|Intrahepatic oxaliplatin
223853603|NCT01247337|DRUG|Oxaliplatin, capecitabine, gemcitabine cetuximab|Oxaliplatin given intravenous
223853604|NCT01013441|BIOLOGICAL|Infusion of CD3/CD28 stimulated T cells|Receive CD3/CD28 stimulated T cells after fludarabine or alemtuzumab based chemotherapy
223853605|NCT02704819|OTHER|Decision Support System (DSS)|"The EMBalance DSS is a program which summarises and structures clinical information. The structuring of medical information is based on algorithms that have been developed and are employed via the DSS platform. The non-specialist doctors who use the DSS will be asked to exercise their clinical judgement in order to come up with a diagnosis or management plan. The DSS use has the following characteristics:~1. Doctors can pace the process anyway they see fit (e.g. by switching from history taking to examination, stopping at any point, or going back to medical history) or by stopping the process entirely.~2. Although the EMBalance platform will propose 2-3 diagnosis (with probability estimation for each), doctors will be asked to either choose one of these or discard and choose their own."
223853606|NCT02704819|OTHER|Specialist Audiovestibular Consultation|"After the initial appointment with the non-specialist doctor, all patients will be invited to attend a specialist neuro-otology clinic where they will be seen by an overseeing expert in order to undergo a Gold Standard diagnostic process, and determine the management plan appropriate to the diagnosis, which will be compared to the management plan previously advised by the non-specialist doctor. The overseeing expert will review investigations carried out, results assessed by the non-specialist doctor."
223853607|NCT02704819|OTHER|DSS Customised Vestibular Physiotherapy|"Customised vestibular exercise programme suggested by the DSS. Such exercises are based on the eye, head, and postural exercises that provoke a patient's symptoms.~1. Adaptation exercises incorporating gaze fixation and head movements and postural exercises are prescribed to promote recovery of the vestibule-ocular reflex (VOR) and vestibulo-spinal reflex function. Up to 5 exercises will be practised by the patient at home for approximately 1-2 minutes each, twice daily initially at a slow speed which gradually increases as symptoms improve.~2. Patients presenting vestibular migraine will perform a maximum of three exercises. These exercises will be chosen by the DSS from a range of established exercises and chosen according to the patient's symptoms when performing the exercise/type of movement."
223853608|NCT02704819|OTHER|Standard Physiotherapy Practice|Patient will be referred to a local physiotherapy service by his/her non-specialist doctor within 18 weeks from referral. Standard vestibular rehabilitation practice consists of a customised exercise programme, this is service dependent and tailored for patient's symptoms. The rehabilitation programme might include lifestyle advice and education, sometimes accompanied by a leaflet.
223853609|NCT02704819|OTHER|Follow-up|All patients will be reviewed after three months follow-up by the overseeing expert.
223853610|NCT00241930|BEHAVIORAL|Integrating drug treatment into HIV services|
223853611|NCT03375255|DRUG|SRP-5051|Single dose of SRP-5051 administered as an intravenous (IV) infusion.
223853612|NCT04486222|DEVICE|Repeated Transcranial Magnetic Stimulation|Magstim® Super Rapid² Transcranial Magnetic Stimulation System
223853613|NCT00257348|DRUG|Capecitabine|
223853614|NCT00257348|DRUG|Docetaxel|
223853615|NCT04187664|BEHAVIORAL|Postoperative Monitoring|Nursing and medical staff will monitor patients vital signs and clinical deterioration triggers twice as often as in previous ward care.
223853616|NCT04187664|DIAGNOSTIC_TEST|High-sensitivity cardiac troponin testing|High-risk patients will have their high-sensitivity cardiac troponin tested preoperatively and daily for the first 48h postoperatively
223853617|NCT00035542|DRUG|Glucovance (metformin HCl/glyburide)|
223853618|NCT00035542|DRUG|metformin HCl|
223853619|NCT00035542|DRUG|glyburide|
223853620|NCT06360744|BIOLOGICAL|Johnson & Johnson|Vaccination with the Johnson \& Johnson vaccine which is NOT part of the Danish National Government programme
223853621|NCT02708069|OTHER|e-Unstuck|An e-learning software that delivers the evidence-based Executive Functioning intervention to parents of children with Autism Spectrum Disorder without Intellectual Disability (ASDwoID) with personalized training and feedback on the evidence-based Unstuck and On Target (UOT) curriculum. Through video modeling, intelligent games, adaptive interactive exercises, and personalized feedback, e-Unstuck will provide parents with new tools for applying UOT principles to real world settings, above and beyond learning UOT principles.
223853622|NCT02708069|OTHER|Unstuck and On Target|An executive functioning intervention specifically targeted to the needs of the Autism Spectrum Disorder without Intellectual Disability (ASDwoID) population.
223853623|NCT02411942|DRUG|Adapalene Gel 0.3%|Adapalene Gel 0.3% applied to the entire face once daily for 84 consecutive days
223853624|NCT02411942|DRUG|Differin®|Differin® applied to the entire face once daily for 84 consecutive days
223853625|NCT02411942|DRUG|Placebo|Placebo (vehicle of the test product) applied to the entire face once daily for 84 consecutive days
223853626|NCT05712941|DRUG|Lerociclib|"All participants should be treated according to the best-current-practice guidelines and standard of care within each institution or country where the study is conducted.~Participants will be randomized to receive either lerociclib (administered at 150 mg twice a day (BID) in combination with letrozole (administered at 2.5 mg once a day (QD), or placebo administered in combination with letrozole (2.5 mg QD).~Participants will also be stratified, using interactive response technology (IRT), by the following randomization strata:~* Endometrial Cancer (EC) tumor staging (Federation Internationale de Gynecologie et d'Obstetrique \[FIGO\] Stage III versus FIGO Stage IV versus recurrent)~* EC tumor grade (Grade 1 versus Grade 2)~* Geographic location (US versus Europe versus Rest of World)"
223853627|NCT05712941|DRUG|Letrozole 2.5mg|"All participants should be treated according to the best-current-practice guidelines and standard of care within each institution or country where the study is conducted.~Participants will be randomized to receive either lerociclib (administered at 150 mg twice daily (BID) in combination with letrozole (administered at 2.5 mg once a day (QD), or placebo administered in combination with letrozole (2.5 mg QD).~Participants will also be stratified, using interactive response technology (IRT), by the following randomization strata:~* Endometrial Cancer (EC) tumor staging (Federation Internationale de Gynecologie et d'Obstetrique \[FIGO\] Stage III versus FIGO Stage IV versus recurrent)~* EC tumor grade (Grade 1 versus Grade 2)~* Geographic location (US versus Europe versus Rest of World)"
223853628|NCT05712941|DRUG|Placebo|"All participants should be treated according to the best-current-practice guidelines and standard of care within each institution or country where the study is conducted.~Participants will be randomized to receive either lerociclib (administered at 150 mg twice day (BID) in combination with letrozole (administered at 2.5 mg once a day (QD), or placebo administered in combination with letrozole (2.5 mg QD).~Participants will also be stratified, using interactive response technology (IRT), by the following randomization strata:~* Endometrial Cancer (EC) tumor staging (Federation Internationale de Gynecologie et d'Obstetrique \[FIGO\] Stage III versus FIGO Stage IV versus recurrent)~* EC tumor grade (Grade 1 versus Grade 2)~* Geographic location (US versus Europe versus Rest of World)"
223853629|NCT01611831|BEHAVIORAL|ACT in group|A protocol based on the main research studies describing the therapy and adapted for fibromyalgia treatment by our research group will be used. This protocol is available for the investigators. There will be 9 group sessions of 90 minutes duration each. Patients assigned to this arm will be allowed to occasionally take minor analgesics.
223853630|NCT01611831|BEHAVIORAL|Improved treatment as usual by General Practitioners|General practitioners (GPs) will administer treatment as usual to the patients with fibromyalgia. To enhance the intervention, the Clinical Guidelines on the Treatment of Fibromyalgia approved by the Health Services of Aragon will be provided to the GPs.
223853631|NCT03597841|DRUG|Combination therapy|Patients who are given combination therapy will be allocated to this group.
223853632|NCT03010553|PROCEDURE|Detection and resection of sentinel lymph node|
223853633|NCT04178291|DEVICE|Ultrasonic scaler and Gracey currettes|Full mouth subgingival debridement using ultrasonic scaler and Gracey currettes
223853634|NCT04178291|DEVICE|Air polishing with erythritol powder|Air flow PLUS
223853635|NCT01064817|DRUG|PRM-151|PRM-151 2 milligrams (mg) (0.1 mL volume) by subconjunctival injection Days 1 (immediately following trabeculectomy), 2, 3, 5 and 9
223853636|NCT01064817|DRUG|Placebo|Placebo solution (0.1 mL volume) by subconjunctival injection Days 1 (immediately following trabeculectomy), 2, 3, 5 and 9
223853637|NCT01130467|DRUG|methylphenidate|IR-MPH were started on a dose of 5 mg tid po, and this was increased to 10 mg tid and then to 15 mg tid as necessary. OROS-MPH was started on a dose of 18 mg qd, and this was increased to 36 mg qd and then to 54 mg qd as necessary.
223853638|NCT01130467|DRUG|Atomoxetine|Atomexetine was started (weight of 70 kg or less) 0.5 mg/kg/day orally and increased after a minimum of 3 days to a target dose of 1.2 mg/kg/day. The maximum dosage is 1.4 mg/kg/day or 100 mg/day (whichever is less).
223853639|NCT01130467|BEHAVIORAL|behavioral modification|Parenting and teaching skill education
223853640|NCT00257283|DRUG|Omega-3-acid ethyl esters 90|
223853641|NCT00334594|DRUG|Cisplatin|Cisplatin 75 mg/m2 i.v. over approximately 2 hours on day 1 every 21 days
223853642|NCT00334594|DRUG|Pemetrexed|Pemetrexed 500 mg/m2 i.v. over approximately 10 minutes on day 1 every 21 days
223853643|NCT00334594|PROCEDURE|Therapeutic conventional surgery|Extrapleural pneumonectomy
223853644|NCT00334594|RADIATION|Radiotherapy|CTV1 will receive 45 or 46 Gy. CTV2 will be treated up to a total dose of 55,9 to 56,2 Gy.
223853645|NCT02267967|DRUG|Sulfatinib|Sulfatinib 300 mg once a day (QD) will be orally administrated on a 28-day cycle.
223853646|NCT04880694|DRUG|STC3141|"To receive continuous infusion of STC3141 at rate 58.3mg/hr up to 3 days (72hours).~Also to receive appropriate standard of care."
223853647|NCT04880694|DRUG|STC3141|"To receive continuous infusion of STC3141 at rate 87.5mg/hr up to 3 days (72hours).~Also to receive appropriate standard of care."
223853648|NCT03126656|DRUG|Testosterone Undecanoate|just hypogonadic patients enrolled received hormone replacement therapy with testosterone undecanoate 1000 mg/4ml intramuscular (IM) at baseline, after 6 weeks and 12 weeks after the first evaluation
223853649|NCT04375449|DIETARY_SUPPLEMENT|Pep2dia|what is the effect of Pep2dia on postprandial glycemia after a meal rich in carbohydrates (75g)
223853650|NCT04375449|DIETARY_SUPPLEMENT|maltodextrin|maltodextrin
223853651|NCT03334019|OTHER|blood test|Data collected on general population, farmers and veterinarians though questionnaires and blood samples.
223853652|NCT00086892|BIOLOGICAL|cetuximab|
223853653|NCT00086892|DRUG|carboplatin|
223853654|NCT03347942|BEHAVIORAL|Intervention group|Wait at least 20 minutes after finishing the first portion of meals previously considered sufficient by the individual before serving again if he or she feels the need. The intervention time will be monitored by the participants themselves, who will be instructed by the researcher when the methodology to be performed.
223853655|NCT03347942|OTHER|Control group|The control group will also serve the dish of the form, but can serve additional portion without waiting.
223853656|NCT05714358|BEHAVIORAL|Education|"* The patients were given face-to-face training on nutrition, physical activity and drug use in chronic renal failure .~* After the training, the biochemical parameters of the patients were followed for 6 months.~* In this process, the questions asked by the patients in order not to hinder their right to receive information were answered."
223853657|NCT01213706|DEVICE|Whole Body Periodic Acceleration (WBPA)|Subjects will undergo to the Whole Body Periodic Acceleration platform for treatment (shaking period) for 45 min.
223853658|NCT01213706|DEVICE|Sham WBPA|The subjects will rest for 45 minutes in the Whole Body Periodic Acceleration (WBPA) platform without movement as a control challenge.
223853659|NCT03899818|DEVICE|drug-eluting balloon|Patients will be randomized to drug-eluting balloon (DEB) or standard therapy with second generation drug-eluting stent (DES)
223853660|NCT03899818|DEVICE|drug-eluting stent|Patients will be randomized to drug-eluting balloon (DEB) or standard therapy with second generation drug-eluting stent (DES).
223853661|NCT01368406|BEHAVIORAL|wellness program|12-week weight management intervention in patients with severe mental disorders. In the 1-hour weekly group sessions topics like dietary choices, lifestyle, physical activity and self-esteem were discussed with outpatients and their relatives
223853662|NCT00868192|DRUG|Pemetrexed|
223853663|NCT00868192|DRUG|Bevacizumab|
223853664|NCT01539655|DRUG|vandetanib|Oral tablets, 300 mg, single dose
223853665|NCT01539655|DRUG|omeprazole|Oral capsules, 40 mg, multiple doses
223853666|NCT01539655|DRUG|ranitidine|Oral tables, 150 mg, multiple doses
223853667|NCT04691778|PROCEDURE|CTO PCI with the first-choice Gladius guidewire|CTO PCI using antegrade wiring strategy with the first-choice Gladius guidewire
223853668|NCT04691778|PROCEDURE|CTO PCI without the first-choice Gladius guidewire|CTO PCI using standard antegrade wire escalation strategy
223853669|NCT04538248|OTHER|Combined rehabilitation during hemodialysis|Combined rehabilitation during hemodialysis
223853670|NCT04304534|DRUG|BAY2433334|Tablet, taken orally once a day.
223853671|NCT04304534|OTHER|BAY2433334 matching placebo|Tablet, taken orally once a day.
223853672|NCT03551132|OTHER|Exercise test|Fat mass, Functional autonomy, muscular strength, quality of life questionnaire
223853673|NCT02521844|DRUG|ETC-1922159|Oral administration
223853674|NCT02521844|DRUG|Pembrolizumab|IV administration
223853675|NCT06225999|DRUG|Irinotecan liposome injection (S095013)|Irinotecan liposome injection (S095013) will be administered via intravenous (IV) infusion on days 1 and 15 of each 28-day cycle.
223853676|NCT06225999|DRUG|Oxaliplatin|Oxaliplatin will be administered via intravenous (IV) infusion on days 1 and 15 of each 28-day cycle.
223853677|NCT06225999|DRUG|LLV (levoisomer form of leucovorin)|LLV will be administered via intravenous (IV) infusion on days 1 and 15 of each 28-day cycle.
223853678|NCT06225999|DRUG|5- FU (5-Fluorouracil)|5-FU will be administered via intravenous (IV) infusion on days 1 and 15 of each 28-day cycle.
223853679|NCT04386733|OTHER|no intervention, it was an observational study which looked at the reasons for surgical cancellations|the investigators observed how many patients had their surgeries cancelled and analysed the reasons of these cancellations
223853680|NCT04102449|DRUG|Apremilast|Single arm receiving Apremilast and ultrasound examinations
223853681|NCT00112983|BIOLOGICAL|eculizumab|
223853682|NCT05043987|DRUG|CPO102|Anti-claudin 18.2 Antibody-MMAE Drug Conjugate
223853683|NCT04900142|PROCEDURE|Micropulsed laser trabeculoplasty|Trabeculoplasty
223853684|NCT03728595|DIAGNOSTIC_TEST|Venepuncture|A blood sample will be taken for serum bicarbonate
223853685|NCT03728595|DIAGNOSTIC_TEST|Spirometry|All patients who have not had a spirometry in the 12 months prior to the HAST will undergo one on the day of the HAST.
223853686|NCT03728595|DIAGNOSTIC_TEST|Hypoxic altitude simulation test (HAST)|HAST will be performed as per clinical team request. No changes to this intervention will be made for research purposes.
223853687|NCT04566042|BEHAVIORAL|Acceptance and commitment therapy video game|The intervention is a videogame which teaches the participant about acceptance and commitment therapy.
223853688|NCT04910919|DIETARY_SUPPLEMENT|Honey|Participants 51 - 100 will receive the standard of care treatment as usual plus 1 tsp of honey with every dose of acetaminophen.
223853689|NCT04910919|OTHER|Standard of Care|The first 50 participants will receive treatment as usual (alternating weight-based dosing of acetaminophen and ibuprofen with a PRN three-day supply of opioid analgesic).
223853690|NCT05218408|BIOLOGICAL|CYNK-001 systemic and Intra cavity administration|"Phase 1 Lymphodepletion Days -5,-4 and -3 Cyclophosphamide 900 mg/m2, Fludarabine 30 mg/m2 and Mesna per SOC~IL 2 at 6M IU subcutaneous administration:~For IV cycle ( cycle1) rhIL2 will be administered on Days 1,3,5,8,9,11 and 15 . On days 1, 8 and 15 rhIL-2 will be administered 1 to 3 hours prior to CYNK-001 infusions For IC cycles rhIL2 will be administered 1 to 3 hours prior to each CYNK-001 IC dose.~CYNK-001 : for IV at 2.4 x10\^9 or 3.6 x10\^9 cells Days 1,8 and 15~Tumor resection will take place 7 to 14 day follow by first IC cycle ( Cycle 2) at 100 Million cells or 200 Million cells~IC cycles 3,4,5 once a week for three weeks , 28 days cycle at100 Million cells or 200 Million cells only for Phase 1 cohort 4 and Phase 2a"
223853691|NCT04172948|DEVICE|Oculus go headset/virtual reality headset|10 minute virtual reality tutorial on diaphragmatic breathing, a game in practicing diaphragmatic breathing, and two scenarios in which the patient can also practice diaphragmatic breathing.
223853692|NCT04172948|BEHAVIORAL|Diaphragmatic breathing|10 minute tutorial on diaphragmatic breathing by a medical professional.
223853693|NCT06152198|DEVICE|Treatment|Allocation to hip arthroplasty or internal fixation. The choice between hemi- or total hip arthroplasty in the arthroplasty group and type of osteosynthesis are the surgeon preference.
223853694|NCT02173444|OTHER|Blood test|
223853695|NCT05639023|OTHER|Manipulation Techniques|Subjects will received 12 times orthopedic manipulation. Three times of treatment per months, and less than twice a week.
223853696|NCT05639023|OTHER|Physiotherapy Scoliosis-Specific Exercise|Subjects will receive 14 supervise training, 5 times of intensive supervise training for first two weeks and then 1-2 trainings per month for the rest. Subjects are encouraged to perform home exercise everyday on their own throughout the study.
223853697|NCT05824338|DRUG|Spinal anesthesia for lumbar surgery: ropivacaine|The anesthesiologist will administer 4 mL of ropivacaine 0.5% plus fentanyl 15 mcg intrathecally
223853698|NCT05824338|DRUG|Spinal anesthesia for lumbar surgery: bupivacaine|The anesthesiologist will administer 3 mL of bupivacaine 0.5% plus fentanyl 15 mcg intrathecally.
223853699|NCT05824338|DRUG|General anesthesia for lumbar surgery|Patient will be intubated and ventilated under general anesthesia.
223853700|NCT03425630|DIETARY_SUPPLEMENT|Argicolina|8 weeks
223853701|NCT03425630|DIETARY_SUPPLEMENT|Normolip|8 weeks
223853702|NCT06230874|BEHAVIORAL|HOME Protocol|The HOME Protocol is a newly developed nine-minute mindfulness and engagement protocol designed to decrease stress and to promote re-engagement in meaningful occupations of daily life by applying mindfulness strategies in a specific, timed format. The protocol requires special training for students: a) to recognize times of disengagement in occupations, and b) to learn how to apply specific mindfulness strategies to increase re-engagement in meaningful occupations. Five components of the HOME Protocol include Reflect (1 minute of self-reflection and self-talk), Reset (2 minutes for breathing with stillness/silence and body check), Reach (3 minutes for stretching and progressive muscular relaxation), Renew (2 minutes for breathing with meditation/gratitude), and Re-engage (1 minute for self-reflection and self-talk).
223853703|NCT06230874|BEHAVIORAL|Control Journaling Protocol|The control journaling protocol is a nine-minute mindfulness and engagement protocol designed to decrease stress and to promote re-engagement in meaningful occupations of daily life by applying mindfulness self-talk and journaling strategies in a specific, timed format. The protocol requires special training for students: a) to recognize times of disengagement in occupations, and b) to learn how to apply specific mindfulness strategies to increase re-engagement in meaningful occupations. Three components of the control journaling protocol include Reflect (1 minute of self-reflection and self-talk), Write (journaling), and Re-engage (1 minute for self-reflection and self-talk).
223853704|NCT06337110|DRUG|Lu AF28996|Oral solution containing radiolabelled \[14C\]-Lu AF28996.
223853705|NCT06409637|DRUG|FOLFOX4 regimen|FOLFOX4 regimen: Oxaliplatin 85mg/m2 intravenous infusion over 2 hours on Day 1; Leucovorin 400mg/m2 intravenous infusion over 2 hours on Days 1-2; 5-Fluorouracil (5-FU) initially 400mg/m2 intravenous bolus followed by 2400mg/m2 continuous intravenous infusion over 46 hours. Each cycle lasts for 4 weeks, repeated every 4 weeks for a total of 6-8 cycles.
223853706|NCT06409637|DRUG|lenvatinib|Lenvatinib: For patients with a body weight \<60 kg, the recommended daily dose of lenvatinib is 8 mg (2 capsules of 4 mg each), once daily; for patients with a body weight ≥60 kg, the recommended daily dose of lenvatinib is 12 mg (3 capsules of 4 mg each), once daily. Treatment should be continued until disease progression, intolerable adverse effects, or the end of the study.
223853707|NCT01466881|DRUG|Alisertib|Given PO
223853708|NCT01466881|OTHER|Laboratory Biomarker Analysis|Correlative studies
223853709|NCT01466881|OTHER|Pharmacological Study|Correlative studies
223853710|NCT01228448|PROCEDURE|PET scan|In-Room PET scan
223853711|NCT00662324|BEHAVIORAL|focus groups|"Focus group with MSKCC patients with lung, breast and prostate cancer who have taken part in clinical trials and other caregivers. This focus group will be audio recorded.~During the focus group, you will discuss a Question Prompt List that will be handed out to you. You will be asked about what you think of it and if you think it would have been useful to the patient you care for in his/her experience in a clinical trial.~The focus group to last from 60 to 90 minutes."
223853712|NCT00662324|BEHAVIORAL|focus groups|"Focus group with MSKCC patients with lung, breast and prostate cancer who have not taken part in clinical trials and other caregivers. This focus group will be audio recorded.~During the focus group, you will discuss a Question Prompt List that will be handed out to you. You will be asked about what you think of it and if you think it would be useful if the patient you care for were ever to take part in a clinical trial sometime in the future.~We expect the focus group to last from 60 to 90 minutes."
223853713|NCT00662324|BEHAVIORAL|focus groups|"MSKCC clinicians who work with lung, breast and prostate cancer patients. This focus group will be audio recorded.~During the focus group, you will discuss a Question Prompt List that will be handed out to you. You will be asked about what you think of it and if you think it would be useful to your patients who take part in clinical trials.~Expect the focus group to last from 60 to 90 minutes."
223853714|NCT02817217|DRUG|SP2086|SP2086 will be administered orally (by mouth) as 100mg on Days 4, 5, 6, 7, and 8 and Valsartan will be administered orally as two 80mg tablets on Days 1 and 8. Both SP2086 and Valsartan tablets will be taken with 8 ounces (240 mL) of water.
223853715|NCT02817217|DRUG|Valsartan|SP2086 will be administered orally (by mouth) as100mg on Days 4, 5, 6, 7, and 8 and Valsartan will be administered orally as two 80mg tablets on Days 1 and 8. Both SP2086 and Valsartan tablets will be taken with 8 ounces (240 mL) of water.
223853716|NCT04590924|PROCEDURE|Hip arthroscopy|Patients that had hip arthroscopic surgery 5 years ago will be invited for 5 year follow up. The surgical procedures consisted of femoral osteoplasty, labral refixation and acetabular osteoplasty
223853717|NCT03896841|OTHER|Observation|Ocular Findings Observations
223853718|NCT05463354|BIOLOGICAL|Recombinant COVID-19 Vaccine (Sf9 Cell)|1dose, Intramuscular Injection
223853719|NCT05463354|BIOLOGICAL|COVID-19 Vaccine (Vero Cell), Inactivated|1dose, Intramuscular Injection
223853720|NCT01428895|PROCEDURE|Surgery Alone|Although we are looking at two groups, this intervention is not protocol specific but is part of the patient's standard management plan. The protocol specific part of the study is completely observational. This involves data being recorded by the attending physician during assessment and patient accounts recorded in the form of questionnaires.
223853721|NCT01428895|OTHER|Combined Surgery and Radiation therapy|Although we are looking at two groups, this intervention is not protocol specific but is part of the patient's standard management plan. The protocol specific part of the study is completely observational. This involves data being recorded by the attending physician during assessment and patient accounts recorded in the form of questionnaires.
223853722|NCT00906620|OTHER|QPR: question, persuade and refer (SEYLE)|"The QPR prevention program will be used in two modules, one for school staff and one for parents. According to the US Surgeon General's National Strategy for Suicide Prevention (2001), key gatekeepers are people who regularly come into contact with individuals or families in distress and gatekeeper training has been identified as one of a number of promising prevention strategies."
223853723|NCT00199108|DRUG|Depocyt|
223853724|NCT00199108|DRUG|Dexamethasone|
223853725|NCT02490176|DRUG|liraglutide|Liraglutide were taken daily for 7 days
223853726|NCT02490176|DRUG|placebo|Placebo were taken daily for 7 days
223853727|NCT05453955|DRUG|Propofol|Anesthesia induction and maintenance with propofol 60 minutes later, change the maintenance drug to remimazolam
223853728|NCT05453955|DRUG|Remimazolam Besylate|Anesthesia induction and maintenance with remimazolam 60 minutes later, change the maintenance drug to propofol
223853729|NCT00001934|DRUG|Zenapax|
223853730|NCT03835572|OTHER|CircaHealth: a course on circadian rhythms and health|Participants will receive videos, behavioral modification checklists, and quizzes every week for six weeks.
223853731|NCT03835572|OTHER|Sleep hygiene materials|Participants in the control group will receive weekly materials from the National Sleep Foundation and American Academy of Sleep Medicine on sleep hygiene
223853732|NCT03015454|OTHER|Severe Sepsis Prediction|Upon receiving an InSight alert, healthcare provider follows standard practices in assessing possible (severe) sepsis and intervening accordingly.
223853733|NCT03015454|OTHER|Severe Sepsis Detection|Upon receiving information from the severe sepsis detector in the UCSF electronic health record, healthcare provider follows standard practices in assessing possible (severe) sepsis and intervening accordingly.
223853734|NCT02960139|DEVICE|Test- Treatment with Sylys Surgical Sealan|Standard closure of stapled anastomosis plus treatment with Sylys Surgical Sealant
223853735|NCT01065636|BEHAVIORAL|Diet + Resistance Training|Behavioral Therapy through a lifestyle modification program, Diet therapy once weekly through a dietician prescribed diet for 26 weeks, and resistance exercise training 3-days/week for 24 weeks.
223853736|NCT01065636|BEHAVIORAL|Diet + Aerobic Training|Behavioral Therapy through a lifestyle modification program, Diet therapy once weekly through a dietician prescribed diet for 26 weeks, and aerobic exercise training 3-days/week for 24 weeks
223853737|NCT01065636|BEHAVIORAL|Diet + Resistance/Aerobic Exercise|Behavioral Therapy through a lifestyle modification program, Diet therapy once weekly through a dietician prescribed diet for 26 weeks, and combined resistance/aerobic exercise training 3-days/week for 24 weeks
223853738|NCT05451199|DRUG|ICP-488|ICP-488 will be administered as tablet
223853739|NCT05451199|DRUG|Placebo|Matching placebo will be administered as tablet
223853740|NCT02372019|BEHAVIORAL|CBM With Active Fear Reactivation|"Participants will undergo a fear reactivation trial, which involves giving a one-minute impromptu speech after only 30 seconds of preparation time. 10 minutes afterwards, they will be given CBM for interpretation bias. Training will involve 84 social scenario vignettes, with 70 resolving positively, 7 resolving negatively, and 7 resolving neutrally. This training takes places during the memory reconsolidation window that opens after fear reactivation, during which time the fear memory is in a labile state and thus more amenable to rewriting."
223853741|NCT02372019|BEHAVIORAL|CBM With Inert Fear Reactivation|"Participants will undergo a fear reactivation trial, which involves giving a one-minute impromptu speech after only 30 seconds of preparation time. 12 to 36 hours afterwards, they will be given CBM for interpretation bias. Training will involve 84 social scenario vignettes, with 70 resolving positively, 7 resolving negatively, and 7 resolving neutrally. Because this training takes places well outside of the memory reconsolidation window that opens shortly after fear reactivation, the reactivation is not expected to have any effect, and only serves as a control."
223853742|NCT02372019|BEHAVIORAL|Inert CBM With Inert Fear Reactivation|"Participants will undergo a fear reactivation trial, which involves giving a one-minute impromptu speech after only 30 seconds of preparation time. 12 to 36 hours afterwards, they will be given an inert form of CBM, which should not influence the direction of interpretation bias. Training will involve 84 social scenario vignettes, with 70 resolving neutrally, 7 resolving positively, and 7 resolving negatively. Because the CBM training takes places well outside of the memory reconsolidation window that opens after fear reactivation, the reactivation is not expected to have any effect, and the inert CBM training is not expected to have any effect either. This condition only serves as a control for the other two conditions."
223853743|NCT02773017|DRUG|Dexmedetomidine A|initial dose was 1.0 μg/kg dexmedetomidine, with dose adjustment intervals of 0.1μg/kg in first three turning points and 0.05μg/kg in the last three turning points.
223853744|NCT02773017|DRUG|Dexmedetomidine B|initial dose was 1.0 μg/kg dexmedetomidine, with dose adjustment intervals of 0.1μg/kg in first three turning points and 0.05μg/kg in the last three turning points.
223853745|NCT02773017|DRUG|Dexmedetomidine C|initial dose was 1.0 μg/kg dexmedetomidine, with dose adjustment intervals of 0.1μg/kg in first three turning points and 0.05μg/kg in the last three turning points.
223853746|NCT00439933|BEHAVIORAL|low fat and polysaccharide rich diet|
223853747|NCT00439933|BEHAVIORAL|specific physical training program for obese children|
223853748|NCT02299635|DRUG|PF-03084014|Tablet, 10 mg, twice a day.
223853749|NCT02299635|DRUG|PF-03084014|Tablet, 50 mg, twice a day
223853750|NCT02299635|DRUG|PF-03084014|Tablet, 100 mg, twice a day
223853751|NCT06474806|DRUG|64Cu-DOTA-AE105|AE105 is a uPAR-specific peptide that is bound to the chelator DOTA, which in turn holds the diagnostic radionuclide copper-64 (64Cu), which can be detected upon decay by PET imaging.
223853752|NCT04128839|DIETARY_SUPPLEMENT|Aronia berry juice|A juice blend of three different cultivars was used: Viking, MacKenzie and Autumn Magic. Raw juice was heat pasteurized before provided to participants. Participants consumed 100 mL of juice per day.
223853753|NCT04128839|OTHER|Sham comparator|The placebo was flavor, color, and carbohydrate-matched to aronia juice. The placebo consisted of 28.8 g black cherry Koolaid mix (no sugar added), 128.5 g sorbitol, 74.5 g glucose, 77.9 g fructose, 4 oz lemon juice, 16 drops of blue food coloring, and enough water to create 1 L of solution. Participants consumed 100 mL of juice per day.
223853754|NCT04470817|DRUG|Azilsartan Medoxomil|Azilsartan Medoxomil
223853755|NCT02047461|DRUG|ORGN001 (formerly ALXN1101)|IV infusion
223853756|NCT01970943|OTHER|Placebo|Placebo will be compared to No Intervention.
223853757|NCT02876146|DRUG|Benzimidazole|Withdrawal of benzimidazole after 4 years (non operable AE) or one year after surgery (curative hepatectomy)
223853758|NCT05990569|OTHER|Ultrasound guided Pudendal nerve block|Ultrasound guided bilateral pudendal nerve block
223853759|NCT04103736|DIETARY_SUPPLEMENT|Beet It Sport Shot|Source of naturally occurring dietary nitrates
223853760|NCT04103736|DIETARY_SUPPLEMENT|Nitrate-depleted placebo|Placebo
223853761|NCT00432029|PROCEDURE|Forearm blood flow measurement, Flow mediated dilation (FMD)|Forearm blood flow measurement: baseline 1 min, 3 min after inflation of cuff, 4 min after 0.8mg Nitroglycerin
223853762|NCT00432029|DEVICE|Zeiss Retinal Vessel Analyzer (RVA), Stimulation with Flicker-light|Stimulation with Flicker-light: 1 min, measurement without flickering light 4 min after 0.8 mg Nitroglycerin
223853763|NCT00590850|PROCEDURE|ORIF with Plate and Screws|ORIF with plate and screws
223853764|NCT00590850|PROCEDURE|Pin Fixation|Clavicle fixation with clavicle pin
223853765|NCT03354169|BEHAVIORAL|Eating Condition|Participants will be randomly assigned to eat per the prescribed eating condition for 8 weeks during eating condition 1. They will complete the alternate eating condition for 8 weeks during eating condition 2.
223853766|NCT02637908|BEHAVIORAL|Mindfulness training|6-weeks of group-based mindfulness training for parents
223853767|NCT04878796|DIAGNOSTIC_TEST|Serum collection, adverse events collection|Measuring Abs variation at different timepoints compared to baseline. LIAISON SARS-Cov-2 TrimericS IgG and Elecsys anti-SARS-Cov-2 tests will be adopted. The level of Abs will be evaluated at baseline and 30(±7), 180(±7),365(±7)days after the 2nd dose of vaccine
223853768|NCT03099824|DRUG|GC4711 Oral Capsule G-101|82 mg (1 capsule)
223853769|NCT03099824|DRUG|IV GC4419|GC4419 will be infused IV as a single dose of 27 mg in 247 mL normal saline, totaling 250 mL, over a 60-minute period using a programmable pump.
223853770|NCT03099824|DRUG|GC4711 Oral Capsule G-101|164 mg (2 capsules)
223853771|NCT03099824|DRUG|GC4711 Oral Capsule G-101|246 mg (3 capsules)
223853772|NCT03099824|DRUG|GC4711 Oral Capsule G-111|175 mg (1 capsule)
223853773|NCT03099824|DRUG|GC4711 Oral Capsule G-112|145 mg (1 capsule)
223853774|NCT03099824|DRUG|GC4711 Oral Capsule G-119|233 mg (1 capsule)
223853775|NCT03099824|DRUG|GC4711 Oral Capsule G-125|233 mg (1 capsule)
223853776|NCT03099824|DRUG|IV GC4711|GC4711 will be infused IV as a single dose of 30 mg in 250 mL normal saline, totaling 251 mL, over a 60-minute period using a programmable pump.
223853777|NCT01972152|DRUG|G-Pen(TM) 1 mg|
223853778|NCT01972152|DRUG|Lilly Glucagon(TM) 1 mg|
223853779|NCT01972152|DRUG|G-Pen(TM) 0.5 mg|
223853780|NCT02932358|OTHER|Flexible Family Visitation Model (FFVM)|Visitation to ICU patients allowed during the period of 12 consecutive hours per day.
223853781|NCT02932358|OTHER|Restrictive Family Visitation Model (RFVM)|Visitation to ICU patients allowed during intermittent periods according local ICU regulation.
223853782|NCT05936892|OTHER|upper extremity aerobic training|upper extremity aerobic training \& baseline treatment will be given. Overall session time will be 40-45 minutes
223853783|NCT05936892|OTHER|upper extremity resistance training|upper extremity resistance training Overall session time will be 40-45 minutes
223853784|NCT00546520|DRUG|Ciclesonide|
223853785|NCT03211637|COMBINATION_PRODUCT|Wounds Protocol|Nurses who have been trained to use wound dressing supplies and also on the use of the protocol.
223853786|NCT03469154|OTHER|Dyad training method|The training model for paediatric basic life support for laypersons involves a course based on pairs training together guided by instructional videos and with hands-on practice on resuscitation manikins.
223853787|NCT03469154|OTHER|Instructor led training method|The training model for paediatric basic life support for laypersons involves a course led by an instructor including hands-on practice on resuscitation manikins.
223853788|NCT02883088|PROCEDURE|Frequency Domain - Optical Coherence Tomography (FD-OCT)|FD-OCT assessment of the native proximal-mid left descending artery during clinically indicated coronary angiography
223853789|NCT00001886|PROCEDURE|Real time 3-dimensional stress echocardiography|
223853790|NCT05853224|DEVICE|Crosslinked Hyaluronic Acid (CLHA) Hydrogel with and without Lidocaine|The injection should be performed at variable depth of the skin (dermal or subdermal), depending on the area to be treated and on the product variants, in accordance to the IFU of the IPs
223853791|NCT05337657|DRUG|GB491+Letrozole|Drug：The dose of GB491 is 150 mg, which should be taken with a meal and taken twice daily at approximately the same time each day, approximately 12 hours apart
223853792|NCT01967407|PROCEDURE|Irreversible Electroporation (IRE)|Percutaneous CT-fluoroscopic-guided Irreversible Electroporation.
223853793|NCT02512042|DRUG|Test-Brinzolamide 1% Ophthalmic suspension|
223853794|NCT02512042|DRUG|Reference-Brinzolamide 1% Ophthalmic suspension|
223853795|NCT00950144|OTHER|medical chart review|
223853796|NCT00950144|OTHER|questionnaire administration|
223853797|NCT00950144|OTHER|study of socioeconomic and demographic variables|
223853798|NCT00950144|PROCEDURE|quality-of-life assessment|
223853799|NCT01194258|DRUG|Insulin lispro|
223853800|NCT01194258|DRUG|Insulin aspart|
223853801|NCT01194258|DRUG|Recombinant human hyaluronidase PH20|
223853802|NCT01194258|DRUG|Insulin glulisine|
223853803|NCT01194258|DRUG|Insulin glargine|
223853804|NCT00065052|BEHAVIORAL|Behavior modification|
223853805|NCT05653037|DRUG|RBD4059|Subcutaneously Administered RBD4059 in Healthy Subjects.
223853806|NCT05653037|DRUG|Placebo|Subcutaneously Administered Placebo in Healthys Subject.
223853807|NCT04881136|DEVICE|Reveal LINQ™|The physical device is the Reveal LINQ™, which is a small implantable loop recorder that is used to monitor cardiac parameters at present. The Investigational Falls Prediction RAMware is software that will be downloaded on to the Reveal LINQ™ that will enable it to collect additional sensor information including accelerometer and posture count data that will be used for gait analysis.
223853808|NCT02428088|DRUG|Dasotraline|Dasotraline 2 mg once daily
223853809|NCT02428088|DRUG|Dasotraline|Dasotraline 4 mg once daily
223853810|NCT02428088|DRUG|Placebo Comparator|Placebo once daily
223853811|NCT04184804|BEHAVIORAL|Behavioral Intervention|"The intervention package will be consisted of:~1. Introduction of organic fruits and vegetables (by replacing the conventional ones) in school lunch menus~2. Signs in school areas about organic fruits and vegetables~3. Workshops and interactive games for children~4. Seminars for parents"
223853812|NCT04321642|DRUG|Entonox|Entonox gas with mouth piece
223853813|NCT04321642|DRUG|Not receive Entonox|Not receive any gas
223853814|NCT03699293|DRUG|celecoxib 200mg capsule|celecoxib 200mg twice a day for 4 weeks
223853815|NCT03699293|DRUG|naproxen sodium 550mg tablet|naproxen sodium 550mg twice a day for 4 weeks
223853816|NCT03699293|DRUG|Aspirin 81mg tablet|81mg aspirin for 4 weeks in the run-in period, and for 8 weeks during treatment and crossover period
223853817|NCT04696250|DRUG|Antineoplastic and Immunomodulating Agents|Antineoplastic agents, endocrine therapy, immunostimulants and immunosuppressants drugs included in the ATC classification L
223853818|NCT01253226|DRUG|LY2127399 (Tabalumab)|Administered subcutaneously
223853819|NCT01253226|DRUG|Placebo|Administered subcutaneously
223853820|NCT02036931|DEVICE|Metal on Polyethylene articulation|G7 Acetabular Cup System with Metal head on Polyethylene liner articulation (MOP)
223853821|NCT02036931|DRUG|Ceramic on Polyethylene articulation|G7 Acetabular Cup System with Ceramic head on Polyethylene liner articulation (COP)
223853822|NCT02036931|DEVICE|Ceramic on Ceramic articulation|G7 Acetabular Cup System with Ceramic head on Ceramic linear articulation (COC) - Outside the United States ONLY
223853823|NCT06053931|BEHAVIORAL|white noise music|"Before the mother starts breastfeeding her baby, white noise music will be turned on to help the baby relax during 2 minutes and during the breastfeeding process, music will be played to the baby and mother for approximately 15 minutes.~(https://www.youtube.com/watch?v=5NFHiKMCPvw\&t=6478s)."
223853824|NCT06053931|BEHAVIORAL|lullaby music|"Before the mother starts breastfeeding her baby, lullaby music will be turned on to help the baby relax during 2 minutes and during the breastfeeding process, music will be played to the baby and mother for approximately 15 minutes.~(https://www.youtube.com/watch?v=h0QO8bgysPg)"
223853825|NCT04352452|PROCEDURE|laparoscopic surgery|differences in musculoskeletal and cognitive stress
223853826|NCT02560818|OTHER|collection of a blood sample and breast and ovarian tissue|a blood sample and a breast and ovarian tissue sample will be collected in healthy women during their surgery (breast or ovarian surgery according to selection group :A, B or C)
223853827|NCT02560818|OTHER|use of a previous blood collection for patients|
223853828|NCT03502278|BEHAVIORAL|Islamic Trauma Healing|A lay-led, six-session group intervention that combines empirically supported exposure-based and cognitive restructuring techniques with Islamic principles
223853829|NCT04858425|DRUG|Niclosamide|Niclosamide tablets 400 mg 3 times daily for 14 days
223853830|NCT04858425|DRUG|Placebo|Matched placebo tablets 400 mg 3 times daily for 14 days
223853831|NCT04163484|OTHER|Iodinated contrast|Intra-arterial injection of iodinated contrast media during percutaneous coronary intervention
223853832|NCT02687243|DEVICE|Interactive Virtual Application|Online application via tablet
223853833|NCT03066596|BEHAVIORAL|PRAGMATIC|Provider educational seminar, EHR prompt, outreach-worker care coordination
223853834|NCT04536077|DRUG|CDX-301|The drug will be supplied free of charge by Celldex
223853835|NCT04536077|DRUG|CDX-1140|The drug will be supplied free of charge by Celldex
223853836|NCT04536077|PROCEDURE|Research blood draw|At screening; prior to first therapeutic dose of CDX-1140, on the day of the infusion; and at the time of surgery
223853837|NCT05995782|DRUG|FB418|Oral dose
223853838|NCT04798521|OTHER|Tele-HCV|Patients will be prescribed HCV medication treatment for 4 weeks at a time. The study pharmacist will check in with the participant by telephone or telemedicine visit at week 0, week 4, and end of treatment to 1) determine general medication tolerance, 2) assess quality of adherence and 3) dispense medications. Peers will assist participants in keeping telehealth appointments and navigating medication pick up or storage. HCV labs will be repeated at 12 weeks post end of treatment and results will be relayed to the participant in the SVR12 follow up visit with the research assistant, along with follow up surveys. Those successfully achieving SVR12 will be counseled on ongoing harm reduction methods. Those showing persistent HCV viremia at 12 weeks post treatment will be referred to community-based HCV treatment providers for treatment re-initiation.
223853839|NCT04798521|OTHER|Community Linkage to Care|Following study inclusion and enrollment, research staff will refer the participant to a local community health clinic to engage in hepatitis C care and seek treatment. Peers will assist patients to engage with local primary care and health plan resources and will receive an information sheet on optional clinics to attend and questions to ask their provider.
223853840|NCT05917717|PROCEDURE|Neuroprotective 'bundle of care'|"This includes the 3 devices:~* Head up cardiopulmonary resuscitation (HUP-CPR)~* Active compression decompression CPR~* Impedance threshold device (ITD)"
223853841|NCT05228860|BEHAVIORAL|Vida Sana (a Group Lifestyle Intervention)|"Vida Sana is a Group Lifestyle intervention that has been shown to be effective among patients with type 2 diabetes (T2DM). Vida Sana includes 23 group sessions with a trained health coach:~* Months 1-4: 1 family-wide orientation + 12 weekly sessions~* Months 5-6: 4 bimonthly group sessions~* Months 7-12: 6 monthly group sessions~All regular primary care and diabetes care will remain as usual."
223853842|NCT05228860|BEHAVIORAL|Supplemental Healthy Food Deliveries|"Participants will receive 12 weeks of weekly food deliveries from Dig Deep Farms.~Each delivery will include a selection of seasonal fresh vegetables and a rotation of either a whole grain or a whole-grain food (3+ grams of fiber/serving). Whole grains will include brown rice, oatmeal, barley, quinoa; whole grain foods will include cereal, pasta, tortillas, bread, crackers. Delivery sizes will be scaled to the three corresponding household sizes: 2-3 people; 4-5 people; or 6 or more people.~Food will be delivered by Dig Deep Farms, which already has an established food subscription delivery system.~(Control group participants will receive the same delivery schedule, but delayed to begin 6 months after their study enrollment.)"
223853843|NCT03356483|DRUG|Psilocybin (0.25mg/kg)|Psilocybin is a naturally occurring hallucinogenic ingredient found in some varieties of mushrooms that can be produced synthetically. It is considered to be a serotonergic psychedelic.
223853844|NCT03356483|DRUG|Niacin (250mg)|A medication used to treat high cholesterol, triglyceride levels, and niacin deficiency.
223853845|NCT00870350|BIOLOGICAL|Td5ap|Intramuscular injection of 0.5 mL Td5ap (COVAXiS) on day 1.
223853846|NCT00870350|BIOLOGICAL|Td1aP|Intramuscular injection of 0.5 mL Td1aP (diTekiBooster) on day 1.
223853847|NCT02443792|PROCEDURE|Unicirc with tissue adhesive|As above
223853848|NCT02443792|PROCEDURE|Open Surgical|As above
223853849|NCT01560143|DRUG|Tigecycline|100 mg IV as a single infusion over 30 minutes
223853850|NCT02783183|DRUG|YHD1119|2 by 2
223853851|NCT02783183|DRUG|Lyrica|2 by 2
223853852|NCT02573740|DRUG|ABT-957|
223853853|NCT02573740|OTHER|Placebo|
223853854|NCT04415112|BEHAVIORAL|Mediterranean Diet|A list of foods high consumption of vegetables, fruits, non-refined cereals, legumes and potatoes, moderate consumption of fish and poultry and low consumption of full fat dairies, red meat and its products and homemade sweets.
223853855|NCT04415112|BEHAVIORAL|Low Fat Diet|These children are forbidden to eat high-fat foods such as fried foods, butter, cream cheese, while foods such as fruits, vegetables (starchy and non-starch), cereals, poultry, lean meat and low-fat dairy products are allowed.
223853856|NCT01656304|BIOLOGICAL|bevacizumab|Given IV
223853857|NCT01656304|OTHER|laboratory biomarker analysis|Correlative studies
223853858|NCT05161403|DRUG|Hyaluronic acid|"Wound healing is still a clinical challenge especially in patients who undergo several tooth extractions under general anesthesia or those undergoing major surgeries or those with systemic conditions that disrupt the wound healing process.~use of this natural substance is a simple and cost-effective technique and is easily tolerated by children."
223853859|NCT05161403|DIETARY_SUPPLEMENT|honey|"Wound healing is still a clinical challenge especially in patients who undergo several tooth extractions under general anesthesia or those undergoing major surgeries or those with systemic conditions that disrupt the wound healing process.~Use of this natural substance is a simple and cost-effective technique and is easily tolerated by children."
223853860|NCT01155869|DRUG|Depot naltrexone|Depot naltrexone 380 mg. IM monthly
223853861|NCT01155869|DRUG|Oral Naltrexone|Naltrexone 50 mg tablet PO daily
223853862|NCT01888406|BEHAVIORAL|Guided Self-Help|
223853863|NCT01888406|BEHAVIORAL|Pure Self-Help|
223853864|NCT00875628|DRUG|PF-00868554 or Placebo|Dosage Form: Oral solution Dosage: PF-00868554 100 mg or placebo under fasting conditions Frequency: BID (twice daily) Duration: 14 days
223853865|NCT00875628|DRUG|PF-00868554 or Placebo|Dosage Form: Oral solution Dosage: PF-00868554 300 mg or placebo under fasting conditions Frequency: BID (twice daily) Duration: 14 days
223853866|NCT00875628|DRUG|PF-00868554 or Placebo|Dosage Form: Tablet Dosage: PF-00868554 600 mg or placebo under fed conditions Frequency: BID (twice daily) Duration: 14 days
223853867|NCT02824432|DRUG|TAK-085|TAK-085 capsules
223853868|NCT01615809|DRUG|AMPHOTERICIN B|The study drug will be administered by inhalation, to hospitalised patients or outpatients in the day hospital.
223853869|NCT05511454|OTHER|Salivary and crevicular samples|The samples will be taken from patients in both groups who meet the selection criteria during consultations at the Montpellier University Hospital's Odontology Department. During these consultations, a sample will be taken after rinsing the oral cavity with a glass of water. The samples will be taken before the periodontal assessment in order to avoid bleeding.
223853870|NCT02785978|DRUG|Levodopa acute challenge|"Inclusion visit (simultaneous video + ActiMyo recording):~Levodopa acute challenge and 2 hours of recording and medical monitoring"
223853871|NCT02785978|OTHER|Controlled environment tests (series of tasks of everyday life)|"Inclusion visit (simultaneous video + ActiMyo recording):~Controlled environment tests (series of tasks of everyday life)"
223853872|NCT02785978|OTHER|Standardized scales: MDS-UPDRS (Part II to IV) and RDRS|"Inclusion visit (simultaneous video + ActiMyo recording):~Standardized scales: MDS-UPDRS (Part II to IV) and RDRS"
223853873|NCT02785978|DEVICE|ActiMyo recording|Continuous activity recording with ActiMyo during the 2 weeks of study participation
223853874|NCT02785978|OTHER|Diary completion|Daily patient logbook completion during the 2 weeks of study participation
223853875|NCT03896828|DIETARY_SUPPLEMENT|Mixed-macronutrient meal|"Participants will be provided a mixed-macronutrient meal (liquid drink) at hours 0 and 3, mimicking the energy and macronutrient composition of breakfast and lunch in Western society (38). 20% of daily energy intake will be provided as breakfast and 30% at lunch. Macronutrient composition will reflect a diet providing 55% energy needs from carbohydrate (CHO) and 1.2g/kg/d protein. The remaining energy requirements, as determined by total energy intake, will be met with dietary fat (estimated to be \~0.2 and 0.3g/kg fat for breakfast and lunch, respectively), similar to previous liquid mixed-meal approaches."
223853876|NCT01521585|DRUG|SEN0014196|50 mg oral once daily tablet
223853877|NCT01521585|DRUG|SEN0014196|200 mg oral once daily tablet
223853878|NCT01521585|DRUG|Placebo|oral once daily tablet
223853879|NCT05826431|DEVICE|Cubii elliptical|Low impact, portable, and compact elliptical for seated use.
223853880|NCT00284973|BIOLOGICAL|Plasmodium falciparum Chimeric Prot. 2.9 - Montanide ISA 720|
223853881|NCT00475813|DRUG|FLUTIFORM® (Formoterol fumarate / Fluticasone propionate)|
223853882|NCT04654936|BEHAVIORAL|MIND diet|12 week MIND diet study: Participants access a website that is theory driven using the Behaviour Change Wheel to help motivate and promote MIND diet adherence. Participants are to consume MIND diet foods daily and meet MIND diet weekly recommendations
223853883|NCT04654936|BEHAVIORAL|MIND diet with no support|Participants are to consume MIND diet food recommendations over a 12 week period with no support except for a self-monitoring resource and MIND diet guidelines
223853884|NCT04658615|PROCEDURE|Non-surgical periodontal therapy|A single 1-hour session of full-mouth debridement with an ultrasonic device under local anesthesia
223853885|NCT00782639|DRUG|Iopamidol injection 76%|Iopamiro-370 (Iopamidol injection 76%) is provided in single dose bottles/vials, ready to use, aqueous, nonpyrogenic, colorless to pale yellow sterile solution
223853886|NCT00782639|DRUG|iodixanol|Visipaque 320 (iodixanol) injection is provided in bottles/flexible containers, ready to use sterile, pyrogen-free colorless to pale yellow solution
223853887|NCT06457568|DIAGNOSTIC_TEST|Blood pressure measurement|The blood pressure measurement was taken simultaneously by two observers using mercury sphygmomanometer and by a supervisor using the tested device, CONTEC08C.
223853888|NCT04705857|COMBINATION_PRODUCT|"Histograft, a bone substitute based on octacalcium phosphate (OCP) and plasmid DNA encoding VEGFA gene"|gene-activated bone substitute in granular form, concentration of the plasmid DNA is 100 μg per 1.0 g of the OCP scaffold
223853889|NCT03357549|OTHER|Brief Motivational Intervention|The Brief Motivational Intervention is an intervention that use strategies are typical of patient-centered interventions. These strategies will help the interviewer to listen, to elicit important information, and to build rapport with the patient and should be used throughout the intervention. The four strategies are Open-Ended Questions, Affirmations, Reflections and Summaries. The objective of de BMI is to increase the client motivation to adopt healthy initiatives, and to increase their self-efficacy to reach their own objectives.
223853890|NCT03357549|OTHER|Breastfeeding education|It's a common educational intervention about breastfeeding. The women will receive the information by a leaflet with information about breastfeeding and community resources and they will receive verbal information during 20-30 minutes to resolve their doubts.
223853891|NCT04771273|DRUG|Survodutide|Survodutide
223853892|NCT04771273|DRUG|Placebo|Placebo
223853893|NCT01624168|BEHAVIORAL|Anxiety Management Education|written materials on management of anxiety for self-study
223853894|NCT01624168|BEHAVIORAL|10 week tai chi intervention|10 weeks of instruction in Evidence Based Tai Chi meeting 2 times per week
223853895|NCT01624168|BEHAVIORAL|Enhanced tai chi instruction|10 weeks of instruction in Evidence Based Tai Chi meeting 2 times per week plus DVD for home practice
223853896|NCT05744128|BIOLOGICAL|Zirconium 89Zr crefmirlimab berdoxam|Zirconium-89 labelled minibody for whole body PET imaging to visualize CD8+ cell distribution.
223853897|NCT02582411|DEVICE|Laser Speckle Flowgraphy|A commercially available LSFG (Softcare, Fukutsu, Japan) system will be used in the present study. The LSFG device consists of a fundus camera equipped with a diode laser with a wavelength if 830 nm and charge-coupled device. NB, the relative velocity of blood flow, is derived from the pattern of speckle contrast produced by the interference of a laser scattered by blood cells moving in the ocular fundus. Images are acquired continuously at the rate of 30 frames per seconds in a 4-second time period and stored on a personal computer. Heartbeat map of the optic nerve head and the retina/choroid is generated
224076131|NCT06241586|PROCEDURE|The novel PMMI surgical strategy|"Immediate drainagewas advocated within 24 hours once necrosis was diagnosed. During the treatment course, a hybrid approach was available by flexibly switching interventions. Open surgery was only applied when patients required emergency surgery.~The minimally invasive surgery was selected based on the size, location, and maturity of the necrotic area and stepwise response to intervention. Repeated peritoneal purification was performed until the infected or devitalized tissue was controlled. Patients were subsequently discharged with a drainage catheter and readmitted at 7- to 10-day intervals to receive repeated planned surgery without postoperative irrigation. Patients received a whole-course assessment for individual patients at 7-day predetermined intervals."
223853898|NCT02582411|DEVICE|Doppler Optical Coherence Tomography|"A dual-beam bidirectional Doppler OCT system comprises a broadband superluminescent diode (SLD) with a central wavelength of 840 (spectral bandwidth 54 nm) and two CCD cameras with a maximum readout rate of 20 kHz. The system provides a resolution (in tissue) of about 6 and 18 μm in axial and lateral direction, respectively. The sample, i.e. the retinal vessel under study, is illuminated by two probe beams separated by their polarization properties. Light back scattered and backreflected from the sample is spectrally detected by two identical spectrometers and postprocessing, i.e.~calculation the phase shift due moving scatterers within the sample, is carried out by a personal computer with software written in National Instruments LabView. The power of both probe beams incident on the cornea is 650 μW, which is below the ANSI (American National Standard Institute) limits for small source ocular exposure to a laser beam within the measuring time."
223853899|NCT06155253|PROCEDURE|Erector spinae plane block|"ESP block is a paraspinal fascial plane block that involves injection of local anesthetic underneath the anterior fascia of the erector spinae muscles.~Local anaesthetic mixture (lignocaine 2% with adrenaline, bupivacaine 0.25%) will be delivered with insulated needle in bolus(es) to above-mentioned levels (L1 in 1ESP group, T12 \& L1 in 2ESP group)"
223853900|NCT01712113|DRUG|Irbesartan|
223853901|NCT01712113|DRUG|Avapro|
223853902|NCT00572000|BIOLOGICAL|HPV-16/18 L1 VLP AS04 vaccine|Representation: 0.5ml monodose vials Administration: intramuscular Schedule: 0, 1, 6 month
223853903|NCT02698241|DEVICE|Diagnostic & Medication Management|Single Arm Study. Subjects will be managed using integrated diagnostics.
223853904|NCT05838664|DRUG|No OAC|AF Patient who were not exposed to oral anticoagulation
223853905|NCT05838664|DRUG|VKA|AF patients who received VKA
223853906|NCT05838664|DRUG|apixaban|AF patients who received apixaban
223853907|NCT05838664|DRUG|rivaroxaban|AF patients who received rivaroxaban
223853908|NCT05838664|DRUG|dabigatran|AF patients who received dabigatran
223853909|NCT03519373|BIOLOGICAL|TDaP|Tetanus, Diphteria and Acellular Pertussis vaccine (Boostrix)
223853910|NCT05414929|DIAGNOSTIC_TEST|HPV self-sampling|HPV self-sampling (Cobas Uniswab)
223853911|NCT04068545|DEVICE|Device: Thoraguard Surgical Drainage System|Fluid drainage following thoracic surgery
223853912|NCT03392532|DEVICE|Lotrafilcon B toric contact lenses with HYDRAGLYDE|Silicone hydrogel soft contact lenses for astigmatism
223853913|NCT03392532|DEVICE|Lotrafilcon B toric contact lenses|Silicone hydrogel soft contact lenses for astigmatism
223853914|NCT04796285|DEVICE|Lab Clasp|Finger-based interstitial fluid assessment device
223853915|NCT00906282|DRUG|Pemetrexed|500 mg/m2 IV over 10 minutes on Day 1 of every 3-week treatment cycle for a total of 4 cycles (12 weeks).
223853916|NCT00906282|DRUG|Carboplatin|AUC 6.0 IV on Day 1 of every 3-week treatment cycle for a total of 4 cycles (12 weeks).
223853917|NCT00991744|DRUG|Liposomal cytarabine|Intrathecal liposomal cytarabine combined with intrathecal prednisolone and oral dexamethasone during maintenance treatment for high-risk ALL
223853918|NCT00991744|DRUG|Intrathecal triple|Intrathecal methotrexate (8-12 mg), cytarabine (20 - 30 mg) and prednisolone sodium succinate (12,5 - 20 mg) 6 times during maintenance treatment in high-risk ALL protocol
223853919|NCT01506843|BIOLOGICAL|Mite, Mite and Bacterial or Placebo|All treatments were given by sublingual route according to schedule of EAACI, with some modification. Patients received up-dosing sublingual drops once a day, reaching in approximately 3 months a monthly maintenance dose of 36 μg of Der p 1 given three times a week in alternate days for mite, mite and bacterial allergen extract, and no Der p 1 and no bacterial components in the placebo group. Doses were delivered by using vials equipped with a metered-dose dropper, and subjects were instructed to hold the solution under the tongue for 2 min and not to eat or drink for 60 min after the dose. Subjects self-administered the treatment at home. Adjustments in the schedule were made on an individual basis according to standard guidelines for specific immunotherapy
224265894|NCT02600247|DRUG|celecoxib, Pregabalin, acetaminophen/tramadol, oxycodone|"Preemptive analgesia : celebrex 200mg 1C#1, Lyrica 150mg 1C#1 (preoperation. 2 hours), Patient controlled analgesia (postoperation 28 hours) During admission : celebrex 200mg#1, Ircodon 5mg 2T#2, Ultracet 2T#2 (Postoperation 1 week) Discharge medication: celebrex 200mg 1C#1 x 5Weeks, Ultracet 2T#2 x 1 week~Other name : celecoxib, Pregabalin, acetaminophen/tramadol, oxycodone"
224265895|NCT04857333|DIAGNOSTIC_TEST|CT scan|For patients with low-risk pulmonary nodules, follow-up CT scan is recommended
224265896|NCT04857333|DRUG|Antibiotics|For pulmonary nodules with features of infectious disease, antibiotics is recommended
224265897|NCT04857333|PROCEDURE|Surgical Resection|For persistent high-risk pulmonary nodules, surgical resection is recommended
224265898|NCT04823533|DIETARY_SUPPLEMENT|Probiotic-placebo supplement|A probiotic formulation containing two well-documented probiotic strains. The finished product is a lyophilized powder packaged in single-dose sticks sachets Excipients used were as follows: xylitol, maltodextrin, plum flavor, and malic acid.
224265899|NCT05385835|OTHER|Training|A training module was prepared by explaining the theoretical and practical parts of the application of blood pressure measurement from the brachial artery with a slide presentation and an animation video. The knowledge and skills of nurses in blood pressure measurement before education were measured. The training module was delivered to the nurses from the online system. At the end of the two-week training period, the knowledge and skill levels of the nurses will be measured again.
224265900|NCT03410030|DRUG|Ascorbic Acid|combination therapy
224265901|NCT03410030|DRUG|Paclitaxel protein-bound|combination therapy
224265902|NCT03410030|DRUG|Cisplatin|combination therapy
224265903|NCT03410030|DRUG|Gemcitabine|combination therapy
224265904|NCT06137846|DEVICE|Air-Polish|Dental implant will be cleaned with an airpolishing device
224265905|NCT06137846|DEVICE|Ultrasonic|Dental implant will be cleaned with an ultrasonic device with a plastic tip
224265906|NCT05947097|DRUG|HSK21542 Injection|1ug/kg bolus for 2min±5s
224265907|NCT01742403|RADIATION|R/T gating kV intrafraction monitoring|This is a Phase I Pilot study to assess the feasibility of implementing prostate radiotherapy gating using kV intrafraction monitoring.
224265908|NCT03375749|BEHAVIORAL|Standing desk intervention|Standing desk converter
224265909|NCT03375749|BEHAVIORAL|Waitlist control|Control
224265910|NCT04020016|DRUG|Nalbuphine ER|Cohort 1: 6-8 subjects will receive 1 dose of 27mg and observed for 4 days. Cohort 2: 6-7 subjects will receive 1 dose of 54 mg and observed for 4 days. Cohort 3: 6-7 subjects will receive 1 dose of 108 mg and observed for 4 days. Cohort 4: 6-8 subjects will receive 1 dose of 162 mg and observed for 4 days. Cohort 5: 6-8 healthy subjects will receive dosing of NAL ER and observed for 4 days.
224265911|NCT04020016|DRUG|Nalbuphine ER -|Cohort 6: • 6-8 subjects with mild hepatic impairment and 6-8 subjects with moderate hepatic impairment. Doses will be subsequently escalated for each subject starting at 27 mg on Day 1 to twice daily, 12 hours apart, 27 mg, 54 mg, 108 mg, and 162 mg over 13 days.
224265912|NCT03326167|OTHER|Myocardial Perfusion Imaging by Single Photon Emission Computed Tomography (MPI SPECT)|Evaluation of the improvement of the sensitivity, in tri-truncular patients, provided by the estimation of the coronal reserve by territory, during the realization of a myocardial perfusion tomoscintigraphy on CZT camera dedicated to cardiology (Discovery NM 530 ).
224265913|NCT05909241|DRUG|BA1202|"BA1202 will be administered intravenously (IV) once every 3 weeks (Q3W) until confirmed progression, death, unaccepted toxicity, initiation of other antitumor therapies, or any other conditions requiring treatment discontinuation, and the duration of administration was no more than 2 years.~Part A: Patients will receive one of the following dosages of BA1202: 0.016mg, 0.08mg, 0.4mg, 1.6mg, 6.4mg, 19mg, 38mg, 56mg.~Part B: Based on the data of part A, one or two dose levels will be discussed for further evaluation in part B."
224265914|NCT04158687|DRUG|CTP-692|Administered as powder for oral solution.
224265915|NCT04158687|DRUG|Placebo|Administered as powder for oral solution.
224265916|NCT05483608|OTHER|Vertical climbing ergometer exercise|Exercise using the CLMBR, a vertical climbing exercise ergometer.
224265917|NCT05483608|OTHER|Recumbent cycling|Exercise using a recumbent cycle ergometer
224265918|NCT03523650|DRUG|Propranolol Oral Tablet|A randomized group of patients with cerebral or spinal cavernous malformations, will receive a Propranolol Oral tablets, tid, for 36 months.
224265919|NCT03523650|DRUG|Placebo Oral Tablet|A randomized group of patients with cerebral or spinal cavernous malformations, will receive a Placebo Oral Tablet, tid, for 36 months.
223853920|NCT02540213|DEVICE|MIRCERA|Methoxy polyethylene glycol epoetin beta (0.6 mcg/kg q2w) will be administered using MIRCERA ready-to-use-syringes up to 9 months.
223853921|NCT02987335|DRUG|Pancreatic Clamp|We are not performing any interventions; we are only characterizing participants using tests. The hormones that we are administering are not a treatment but are typically used in context of routine care.
223853922|NCT06123585|OTHER|Invisalign® SmileView™|Pretreatment smiles were captured using the Invisalign® SmileView™ to simulate their new smiles before treatment was started.
223853923|NCT06123585|OTHER|Invisalign aligners|Patients were then treated using upper and lower Invisalign aligners with average treatment time of 12±3 months.
223853924|NCT05754463|OTHER|The effect of plyometric training on balance and proprioception in athletes in different branches|Investigating the effect of plyometric training on balance and proprioception in athletes in different branches
224265920|NCT04229914|OTHER|stroke patinets|3-m backwards walk test, timed up and go test, 10 m walk test, Berg BalanceTest, Functional Reach Test
224265921|NCT01595841|DRUG|Sirolimus|3 mg po od loading dose for two days, then 2 mg po od for thirty days
224265922|NCT03256227|BEHAVIORAL|Family Supported Prolonged Exposure|The investigators propose to bring a family member into early educational sessions of PE, one of the most researched and efficacious treatments for PTSD, to increase family support for PE adherence. Strategies for how to engage with families are drawn from existing evidence-based approaches, including Motivational Interviewing and Behavioral Couples Therapy.
224265923|NCT03256227|BEHAVIORAL|Standard Prolonged Exposure|Standard Prolonged Exposure for PTSD as delivered in routine VA care.
224265924|NCT02026362|BIOLOGICAL|MASCT:Multiple Antigens Specific Cellular Therapy|autologous immune cytotoxic of T-lymphocytes (CTL) induced by dendritic cells, (DC) loaded with multiple antigens DC loaded with survivin p53 her2 ect total 17 antigens .
224265925|NCT02026362|OTHER|The foundation treatment including against hepatitis b virus treatment using nucleoside analogue drug and protect liver treatment|
224265926|NCT04523480|DRUG|Testopel 75mg Drug Implant|75 mg Testosterone pellets administered subcutaneously.
224265927|NCT04523480|DRUG|Testopel 100mg Drug Implant|100 mg Testosterone pellets administered subcutaneously.
224265928|NCT04523480|DRUG|Testopel 200mg Drug Implant|200 mg Testosterone pellets administered subcutaneously.
224265929|NCT06432140|GENETIC|VGN-R09b injection|Two levels of VGN-R09b will be injected into bilateral putamen in dose-escalating phase, and one dose level will be injected in dose confirming phase
224265930|NCT00114322|DEVICE|light exposure from LED source at narrow 468 nm or broader 400-700 nm wavelength|
224265931|NCT05774522|OTHER|Measurement of pharyngeal critical airway closing pressure|The Pcrit will be measured on an automatic controlled device specially designed by the engineers of the inserm neophen team capable of varying the pressures from +4 to -20 centimeters of water, by a nasal mask whose pressures are connected to a pneumotachograph. The measurements will be performed in supine position.
224265932|NCT05774522|OTHER|Acoustic pharyngometry|Acoustic pharyngometry is an non-invasive technique consisting of the propagation of an acoustic wave from the lips to the larynx providing information on the lengths, cross-sectional areas and volumes of the air spaces.
224265933|NCT05774522|OTHER|Upper airway ultrasound|Airway ultrasound is a non-invasive imaging allowing visualization and measurements of the tongue base and retrovascular fatty infiltration. Its main interest remains the evaluation of the tongue base which is clinically difficult.
224265934|NCT01169272|DEVICE|CRT-SonR 9770|Active implantable defibrillator with capacity of cardiac resynchronization therapy
224265935|NCT00721916|DRUG|SOL(The combination therapy of S-1, Leucovorin, and Oxaliplatin)|L-OHP 85 mg/m2 iv. for 2 hr on day 1 of each 2 weeks cycle S-1 40-60 mg bid day 1～day 7 LV 25 mg bid day 1～day 7
224265936|NCT00721916|DRUG|mFOLFOX6(The combination therapy of 5-FU, l-LV and Oxaliplatin)|L-OHP 85 mg/m2 iv. for 2 hr on day 1 of each 2 weeks cycle l-LV 200 mg/m2 iv. for 2 hr on day 1 5-FU 400 mg/m2 bolus on day 1 5-FU 2400 mg/m2 ci for 46 hr (day 1, 2hr～48hr)
224265937|NCT03470116|DEVICE|Laryngoscopy with Mac Grath|Patients of this group will benefit MacGrath MAC video laryngoscopy for intubation after curarization
224265938|NCT03470116|DEVICE|direct laryngoscopy|Patients of this group will benefit direct laryngoscopy for intubation after curarization
224265939|NCT05228717|DIAGNOSTIC_TEST|Point of Care Ultrasound|q48-72h point of care ultrasound of the lungs, heart, and IVC (inferior vena cava)
224265940|NCT04733508|DRUG|111In-DTPA-exendin-4|Injection of 111In-DTPA-exendin-4 and localization of the tracer in excised pancreatic tissue using autoradiography
224265941|NCT04733508|DRUG|IRDye800CW-exendin-4|Injection of IRDye800CW-exendin-4 and localization of the tracer in excised pancreatic tissue using fluorescence microscopy
224265942|NCT05688358|DIAGNOSTIC_TEST|serum levels of interleukin-17A in JIA|IL17 A by Enzyme linked immunosorbent assay method
224265943|NCT04334096|BEHAVIORAL|quality of life pathway|The first quality of life (QoL) measurement is conducted in the hospital after surgery via a digital questionnaire (EORTC QLQ-C30, QLQ-BR23) on a tablet computer. Further QoL measures are accomplished via paper-pencil in the practice of the patient's physician during aftercare (3, 6, 9, 12, 18, 24 months after surgery). Paper questionnaires are transferred by fax to a local server, automatically processed, digitized and stored in a database, and transferred back to the physician's practice (email or fax depending on preference) in form of a QoL profile. The immediate response enables patient and physician to discuss the QoL profile right away. Specific therapeutic options for the treatment of QoL have been defined: psychotherapy, social counseling, pain therapy, physiotherapy, nutrition counseling, fitness. To provide continuous medical education, quality circles for each therapeutic option have been founded. Physicians receive a list with addresses of all quality circle members.
224265944|NCT02189603|BIOLOGICAL|Recombinant (E. Coli) Hepatitis E Vaccine|
224265945|NCT02244554|DEVICE|enLighten Laser|Picosecond pulse-duration or Nanosecond pulse-duration tattoo treatment with enLighten Q-switched Laser Treatment
224265946|NCT04410705|OTHER|Extracorporeal shockwave theraphy for hamstring tendinopathy|For hamstring tendinopathy; a total of 2000 impulses will be done. We will apply twice a week and 5 times in total.
224265947|NCT04410705|OTHER|Extracorporeal shockwave theraphy for quadriceps tendinopathy|Energy flux density will be 0.58mJ/mm2 (2 bar) with 2000 impulses. We will perform twice a week, 5 times in total.
223853925|NCT02555631|BEHAVIORAL|lifestyle|In this pilot study, each subject will receive the lifestyle intervention of the diabetes prevention program, a modified program for men from disadvantaged neighborhoods--a 16 weekly sessions of 1 hour each session
223853926|NCT00290706|DRUG|bortezomib|Bortezomib 1.6mg/m2 on days 1 and 15 of each cycle, given over 3-5 seconds on day 1 and day 15 of each cycle every 28 days for up to 8 cycles.
223853927|NCT00290706|DRUG|gemcitabine hydrochloride|Gemcitabine dose of 800 mg/m2 over 30 minutes on day 1 and day 15 of each cycle every 28 days for up to 8 cycles.
223853928|NCT01372163|DRUG|PF-05190457 or Placebo|Twice daily oral doses of PF-05190457 or placebo is administered as a suspension for 14 days immediately before breakfast and dinner in healthy volunteers.
223853929|NCT01372163|DRUG|PF-05190457 or Placebo|Twice daily oral doses of PF-05190457 or placebo is administered as a suspension for 14 days immediately before breakfast and dinner in healthy volunteers.
223853930|NCT01372163|DRUG|PF-05190457 or Placebo|Twice daily oral doses of PF-05190457 or placebo is administered as a suspension for 14 days immediately before breakfast and dinner in healthy volunteers.
223853931|NCT01372163|DRUG|PF-05190457 or Placebo|Twice daily oral doses of PF-05190457 or placebo is administered as a suspension for 14 days immediately before breakfast and dinner in healthy volunteers.
223853932|NCT01372163|DRUG|PF-05190457 or Placebo|Once daily oral doses of PF-05190457 or placebo is administered as a suspension for 14 days immediately before breakfast in healthy volunteers.
223853933|NCT01372163|DRUG|PF-05190457 or Placebo|Once daily oral doses of PF-05190457 or placebo is administered as a suspension for 14 days immediately before breakfast in healthy volunteers.
223853934|NCT01372163|DRUG|PF-05190457 or Placebo|Once (or twice) daily oral doses of PF-05190457 or placebo is administered as a suspension for 14 days immediately before breakfast (and dinner if twice) in Type 2 Diabetic patients.
223853935|NCT05591001|DRUG|ketamine and dexmeditomidine combination|Dexmedetomidine( 0.4 -0.6 μg/.kg /.hr)) ketamine,( 1 -2m/.kg/.hr) infusion
223853936|NCT05591001|DRUG|Propofol|propofol (100 ug /kg/min) infusion
223853937|NCT03693742|DIAGNOSTIC_TEST|18F-DCFPyL PET/CT scan|"Participants will have their weight recorded and baseline vital signs (blood pressure, heart rate, and oxygen saturation level) measured prior to the tomato juice ingestion, immediately prior to 18F-DCFPyL injection and 5 to 15 minutes after injection.~The participant will receive a bolus intravenous dose of 18F-DCFPyL.~After 60 min, the vital signs will be recorded and again two hours after 18F-DCFPyL. Immediately before scanning, the participants will be taken to a designated washroom and asked to void.~The PET/CT image acquisition time will be approximately 30 minutes."
223853938|NCT03693742|OTHER|Placebo drink|Participants will consume 300mL of tomato juice 30 minutes prior to 18F-DCFPyL injection.
223853939|NCT03693742|OTHER|MSG drink|Participants will consume 300mL of tomato juice with MSG 30 minutes prior to 18F-DCFPyL injection.
223853940|NCT03910517|OTHER|No intervention|No intervention
223853941|NCT06713733|DRUG|Dexamethasone|local infiltration
223853942|NCT06713733|DRUG|Chymotrypsin|orally given
223853943|NCT03074851|DIETARY_SUPPLEMENT|low sodium salt|To give free low sodium salt intervention for 2 months
223853944|NCT03074851|OTHER|informational intervention|to give reporter informational intervention.
223853945|NCT00123799|PROCEDURE|Positron Emission Tomography Imaging|
223853946|NCT06599021|BEHAVIORAL|Muscular strengthening training|6 weeks daily muscular strengthening training.
223853947|NCT06599021|BEHAVIORAL|Skill-based training|15 sessions skill based swallowing training lead by a speech and language pathologist during 3 weeks.
223853948|NCT02465359|DRUG|Immune Globulin Subcutaneous (Human)|Patients who have CIDP and are on IVIG will be allowed in the study to try subcutaneous immune Globulin (SCIG) as part of an open label study.
223853949|NCT01425762|OTHER|Drug Dose|100 versus 200 mcg IT morphine
223853950|NCT00865956|BEHAVIORAL|Contingency Management|Rite Aid vouchers (stepped value) for reinforcement of adherence to primary care
223853951|NCT00865956|OTHER|Case management|Nurse case manager assigned to participant
223853952|NCT00705991|PROCEDURE|ROTEM|
223853953|NCT01304147|DRUG|Ketamine|A single dose of intranasal ketamine up to 50 mg
223853954|NCT01304147|DRUG|placebo|Single dose of saline intranasal
223853955|NCT00689156|DRUG|Epirubicin, cyclophosphamide and docetaxel|Epirubicin 90 mg/m2 iv day 1 every 3 weeks plus Cyclophosphamide 600 mg/m2 iv day 1 every 3 weeks times 3 followed by Docetaxel 100 mg/m2 iv day 1 every 3 weeks times 3
223853956|NCT00689156|DRUG|docetaxel, cyclophosphamide|Docetaxel 75 mg/m2 plus cyclophosphamide 600 mg/m2 intravenously day 1 every 3 weeks times six
223853957|NCT03537573|BEHAVIORAL|Usual Care/Guideline|The Usual Care group (also known as the Guideline group) follows the recent CDC guidelines and, when triggered by an opioid prescription during a qualifying visit, will be delivered real-time in a short checklist of recommendations to: 1) check the state-specific Prescription Drug Monitoring Program; 2) assess risk factors for opioid-related harms (e.g., history of substance use disorder, history of mental health problems, benzodiazepine use); 3) avoid extended-release or long-acting opioids; 4) use a low dose of immediate-release opioid for short period of time (3-7 days); and 5) consider non-opioid management such as acetaminophen, non-steroidal anti-inflammatory agents (NSAIDS), and physical therapy. Epic EHR order sets will be linked to enable easing ordering of non-opioid therapy.
223853958|NCT03537573|BEHAVIORAL|Opioid Justification|Providers will be required asked to enter a free text justification for their decision to prescribe an opioid analgesic for the acute pain condition. The provider will be notified that the justification provided will be visible in the Epic EHR. The provider has the option of entering a justification or not. If no justification is entered, nothing will be entered into the record (i.e., the Opioid Justification area in the encounter record will be left blank). The provider does not need to enter a justification if they choose to cancel the opioid prescription.
224265948|NCT04410705|OTHER|Extracorporeal shockwave theraphy for achilles tendinopathy|Each session consisted of 2400 impulses will be administered with an energy flux density ranged from 0.17 to 0.25 mJ/mm2 (1.7-2.5 bar). We will perform once a week, 3 times in total.
224265949|NCT01221649|DEVICE|ICD/CRT-D|BIOTRONIK ICD family Lumax 540 and its successors
224265950|NCT03609333|DEVICE|Multimodal Neuromonitoring|Application of multimodal neuromonitoring
224265951|NCT04241341|PROCEDURE|Axillary Lymph Node Dissection with Immediate Lymphatic Reconstruction|Axillary Lymph Node Dissection with Immediate Lymphatic Reconstruction
223853959|NCT03537573|BEHAVIORAL|Provider Comparison|Providers will receive monthly feedback via e-mail on their status in regards to initial opioid prescriptions for acute pain, adherence to safe opioid prescribing guidelines, and proportion of patients started on opioids or acute pain who transition to chronic opioid therapy (\> 3 months). Providers in the lowest decile overall for proportion of patients with initial opioid prescriptions, unsafe opioid prescribing, and transition to chronic opioid therapy (\> 3 months) will be given positive feedback for providing high quality, evidence-based care to their patients with acute pain. Providers outside the lowest decile will be notified they are outside the high quality, evidence-based care range and will be provided with their proportions compared to the high performers.
223853960|NCT06609863|PROCEDURE|dTACE-HAIC|dTACE procedure was a 2.8-F microcatheter was super-selectively inserted into the tumor feeding artery using the coaxial technique. Then drug-eluting microspheres were used (100-300um). The microcatheter was reserved at the proper/left/right hepatic artery according tumor location. After the patient returned to the ward, the following FOLFOX-based regime was intra-arterially administered through the microcatheter. The FOLFOX regimen was administered via the hepatic artery as follows: 85 or 135 mg/m2 oxaliplatin from hour 0 to 2 on day 1, and 400 mg/m2 leucovorin from hour 2 to 4 on day 1, and 400 mg/m2 fluorouracil bolus at hour 5 on the day 1; and 2400 mg/m2 fluorouracil over 46 h on days 1 and 2. Hepatic arterial infusion chemotherapy administration of oxaliplatin, fluorouracil, and leucovorin via the tumor feeding arteries every 4 weeks
223853961|NCT06610799|DRUG|IBI363|IBI363 Q3W Oxaliplatin 130 mg/m2，IV，Q3W, Capecitabine ,1000mg/ m2，PO，Bid，d1-14，Q3W
223853962|NCT01238497|DEVICE|TAVR Implantation of the Transcatheter Aortic Valve Prosthesis|Patients eligible for either transfemoral or transapical access and any of the 3 valve sizes (23, 26 or 29)
223853963|NCT01238497|DEVICE|TAVR Implantation of the Transcatheter Aortic Valve Prosthesis|Patients eligible for transapical or transaortic access and any of the 3 valve sizes (23mm, 26mm or 29mm)
223853964|NCT01238497|DEVICE|TAVR Implantation of the Transcatheter Aortic Valve Prosthesis|Patients eligible for transfemoral access and requiring a 29mm valve.
223853965|NCT02525705|BIOLOGICAL|Oral Glucose|1.75g/kg of glucose is orally taken by the patient. Capillary glycemia is systematically realised before ingestion (H0) and after 30, 60, 90, 120, 180 and 240 min and/or if clinical signs of hypoglycemia are presented by the patient.
223853966|NCT06615297|DIAGNOSTIC_TEST|ultrasonographic evaluation|facial nerve thickness (right/left), depressor labi inferior, depressor anguli oris, buccinator and risorius muscles will be evaluated.
223853967|NCT06613425|COMBINATION_PRODUCT|Combined platelets|1 therapeutic dose combined platelet contained no less than 2.5 ×10\^11 platelets as a quality standard.
223853968|NCT06614413|OTHER|Neurodevelopment and behaviour assesment 2 years old|Mothers: Monthly visits guided or not by nutritionist (intervention vs control group) will consist in food questionnaires and 3-day food diary collection during pregnancy. Every three months during lactation. Children: From one year of age onwards, the KIDMED questionnaire will be administered quarterly Neurodevelopment and behavior assessment 18-24 months of age
223853969|NCT06613399|PROCEDURE|MTI-TME|Multi-Technology Tntegrated Total Mesorectal Excision，MTI-TME
223853970|NCT06613399|PROCEDURE|C-TME|Conventional Total Mesorectal Excision，C-TME
223853971|NCT06613815|OTHER|radiofrequency of the geniculate nerves|radiofrequency of the geniculate nerveswith a scopy-guided technique versus the ultrasound-guided technique
223853972|NCT06615453|DEVICE|Thermo-mechanical action based peri-orbital fractional skin treatment|Participants will receive three Tixel® treatments at 2-weeks intervals
223853973|NCT06615453|DEVICE|Sham treatment|Participants will receive three sham treatments at 2-weeks intervals
223853974|NCT06615492|DEVICE|Routine ECMO|Routine intraoperative venoarterial ECMO during lung transplant
223853975|NCT06615492|DEVICE|On-demand ECMO|"Selective, indication-based intraoperative cardiopulmonary support. In this group, the transplant will be planned without cardiopulmonary support. intraoperative venoarterial ECMO will be used selectively based on hemodynamic and/or gas exchange abnormalities :~1. Inability to maintain adequate hemodynamics and stable perfusion despite volume resuscitation and vasopressor administration and in the absence of readily correctable cause~2. Inability to tolerate pulmonary artery clamping~3. Inadequate gas exchange despite attempts at the optimization of ventilator parameters and treatments related to respiratory mechanics and ventilation/perfusion matching~4. Inadequate exposure to the surgical field~5. The transplant team is concerned about the ability to maintain organ perfusion or ventilate with a lung protective strategy, even if the aforementioned criteria are unmet.~6. Concerns about donor lung quality and a desire to protect the implanted lung from single lung perfusion"
223853976|NCT05218915|DRUG|Dulaglutide|Dulaglutide once weekly subcutaneous
223853977|NCT05218915|DRUG|Insulin Degludec|Insulin degludec once daily
223853978|NCT05218915|DEVICE|Continuous glucose monitor|Dexcom G6 CGM system
223853979|NCT06609850|PROCEDURE|TACE|TACE procedure was a 2.8-F microcatheter was super-selectively inserted into the tumor feeding artery using the coaxial technique. Then a combination of lipiodol (5-15 ml), lobaplatin (30-50 mg), and Pirarubicin (30-50 mg) was infused into each tumor. We defined technical success as complete embolization of the tumor-feeding artery resulting in no tumor staining observed by angiogram at the end of procedure.
223853980|NCT06609850|PROCEDURE|Ablation|Ablation (radiofrequency ablation, microwave ablation, cryoablation), ablation followed TACE within 6-8 weeks and Lenvatinib continued. Percutaneous ablation was performed by ultrasound or CT. The ablation success is evaluated by achieving an ablative margin of 0.5 cm or more than the tumor size.
223853981|NCT06609850|DRUG|Lenvatinb|Lenvatinb (12 mg (body weight ≥60 kg) , 8 mg (body weight \<60 kg) orally once a day )
223853982|NCT04332276|DRUG|A-dopamine|"During the phase 1 (titration), it is planned to increase dopamine by maximum 0.25 mg per hour over the daytime period, which corresponds to a maximum increase of 4.5 mg per day (based on the 18 hours of the daytime period, since nocturnal needs are much less important).~Then, depending on tolerance and efficacy, conservative titration will be continued for a target dose of 30-87 mg per day.~During the phase 2 (efficacy), the treatment will be maintained at the minimum effective dose, planned between 30 and 87 mg per day, for 30 days."
223853983|NCT04332276|DRUG|optimized oral treatment|The patient will received his usual dopaminergic treatment.
223853984|NCT06615128|DIAGNOSTIC_TEST|blood sampling|blood sample to detect sCD25 from systemic sclerosis and Healthy control.
223853985|NCT06614426|PROCEDURE|Test group 1 (T1)|Test group 1 (T1): Open flap debridement using electrolysis decontamination
223853986|NCT06614426|PROCEDURE|Test group 2 (T2)|Test group 2 (T2): Open flap debridement using electrolysis decontamination combined with L-PRF application
223853987|NCT06614426|PROCEDURE|Control group (C)|Conventional open flap debridement
223853988|NCT01244828|DRUG|Asenapine|5 mg or 10 mg fast-dissolving sublingual tablets BID for up to 52 weeks
223853989|NCT06615024|DIAGNOSTIC_TEST|G6pd enzyme sickling test|Measuring the enzyme level of G6PD and presence of Hbs
223853990|NCT06615024|DIAGNOSTIC_TEST|G6PD enzyme and sickling test|Measuring enzyme level of G6PD and level of HbS
223853991|NCT06615024|DIAGNOSTIC_TEST|G6PD enzyme and HPLC|Measuring G6PD enzyme level in neonates and measuring level of HbS
223853992|NCT06527768|BEHAVIORAL|Theory-based health behaviour change interventio|The online individual education sessions are related to MetS, CKD, healthy dietary and PA, displayed in the form of texts and pictures, and online instant conversations via WeChat. The online group music-paced brisk walking training includes a 5-minute warm-up, 30-minute music-paced brisk walking, and 5-minute stretching exercises to promote cool-down. The group discussion is related to current health status, recommended dietary regimens, and exercise and personal goals. The telephone follow-up after the group discussion is to reinforce the predetermined goals and the practice of healthy dietary and music-paced brisk walking, and to provide opportunities for answering any questions related to the practice of healthy dietary and music-paced brisk walking. All the education session contents are based on a well-structured health handbook. The self-music-paced brisk walking is required to be performed for 30 minutes/day, 5 days/week.
223853993|NCT03484182|BEHAVIORAL|Web-based Home Exercise Program|Home exercises that are guided by a web-based program
223853994|NCT03484182|BEHAVIORAL|Standard Home Exercise Program|Standard paper-based home exercise program
223853995|NCT05397470|DRUG|Losmapimod|Losmapimod 15 mg will be administered BID by mouth along with food.
223853996|NCT05397470|DRUG|Placebo oral tablet|Placebo will be administered BID by mouth along with food.
223853997|NCT06616688|OTHER|Organoid-guided treatment|After specimen removal as per clinical practice and pathological examination, a small piece of tumor tissue will be sent to the Axo-Glial Interaction Unit and cultured to build up organoid cultures
223853998|NCT06607731|OTHER|Collecting data from medical records|Data collected: clinical data (particularly pain), biological data, imaging.
223853999|NCT06668740|BEHAVIORAL|The use of Virtual Reality Glasses in Elderly|The group first completed a pretest, after which they watched 360-degree VR videos, such as nature walks and trips, for 10 minutes once a week over four weeks. Following this, a posttest was conducted. The outcomes will be used to measure changes in Quality of Life.
223854000|NCT05621655|BIOLOGICAL|Mid dose Recombinant Trivalent Subunit Rotavirus Vaccine|0.5 mL of vaccine containing a total of 60 µg of protein (20 µg of each P type) adjuvanted with 0.5 mg aluminum hydroxide.
223854001|NCT05621655|BIOLOGICAL|High dose Recombinant Trivalent Subunit Rotavirus Vaccine|0.5 mL of vaccine containing a total of 90 µg of protein (30 µg of each P type) adjuvanted with 0.5 mg aluminum hydroxide.
223854002|NCT05621655|BIOLOGICAL|Placebo|0.5 mL per dose, containing 0.5 mg aluminium hydroxide adjuvant.
223854003|NCT06614634|OTHER|Remotely supervised exercise at home or outdoors|Aerobic and strengthening exercise program at home/outdoors at least three days a week for four weeks using a Polar H9 heart rate monitor and elastic band.
223854004|NCT06614634|OTHER|Hospital-based exercise program|The aerobic and strengthening exercise program three days a week for four weeks under supervision in our cardiopulmonary rehabilitation unit.
223854005|NCT06614634|BEHAVIORAL|Cardiovascular risk modification|Psychosocial support for physical activity counselling, heart-healthy diet, referral for smoking cessation and stress management.
223854006|NCT06614634|OTHER|Phone calls with reinforcement feedback|Calls once a week that include symptom inquiries and encouraging feedback on exercise logs.
223854007|NCT05518110|DRUG|Trametinib|2mg of Trametinib (orally) daily.
223854008|NCT05518110|DRUG|Hydroxychloroquine|1200mg of Hydroxychloroquine (orally; 600mg twice a day (BID)) daily.
223854009|NCT01278862|DEVICE|DVS veneer|CAD/CAM milled porcelain veneer for Lava crown
223854010|NCT01278862|DEVICE|Conventional Veneer|CAD/CAM milled Lava crown with lab fabricated veneer
223854011|NCT06622408|OTHER|HypnoVR© virtual reality headset|Adherence to the use of the virtual reality headset will be reported by a percentage of use at each stage of care.
223854012|NCT05799222|DIETARY_SUPPLEMENT|Bariatrix Meal Replacement Products|Meal replacement products offered through the Massachusetts General Hospital Weight Center.
223854013|NCT03808922|DRUG|DAS181|DAS181 4.5mg nebulized qd x 7 OR 10 days
223854014|NCT03808922|DRUG|Placebo|Placebo nebulized qd x 7 OR 10 days
223854015|NCT03808922|DRUG|DAS181 COVID-19|DAS181 4.5mg nebulized q12h/day x 7 OR 10 days
223854016|NCT03808922|DRUG|DAS181 OL|DAS181 4.5mg nebulized qd x 7 OR 10 days ≥ 40kg DAS181 2.5mg nebulized qd x 7 OR 10 days \< 40kg
223854017|NCT05870930|OTHER|Carob beverage|Volunteers will consume 2 tablespoons of carob powder in 200mL drinking water.
223854018|NCT04968574|DRUG|taladegib|hedgehog pathway inhibitor dosed once daily
223854019|NCT04968574|DRUG|placebo|identical tablets to the experimental arm with no active ingredient
223854020|NCT05210894|BIOLOGICAL|Anti-IL8|
223854021|NCT02952261|DEVICE|template-guided localization|Based on CT data, digital model of the navigational template was created using CAD software and imported to 3D printer. The navigational template serves as a guider to the localizer in lung nodule localization.
223854022|NCT02952261|OTHER|CT-guided localization|Percutaneous lung nodule localization was conducted under the real-time guidance of CT scan. This is the conventional method of transthoracic lung nodule localization.
223854023|NCT06615063|OTHER|Hasi's Splint|A splint made up of cotton and gauze piece rolled over a hard cardboard piece and covered by adhesive tape was applied to the limb immediately after fixing the cannula, as per the standardised method, to prevent movement at the underlying joint. Dimensions of the splints used were standardised as length extending two and a half inches on either side of the joint and width equal to the width of the limb just proximal to the joint.
223854024|NCT06613958|BEHAVIORAL|Physical activity timing|The investigators will compare our interventions to a 14-day period of sedentary behavior, during which the participant will refrain from any moderate to vigorous exercise. Next, participants will participate in two interventions consisting each of a 14-day physical activity regimen. The active morning and active evening interventions are equal in content. Both groups will be instructed to refrain from any moderate to vigorous exercise for the rest of the day. Per intervention, a total of eight Vitality Club training session comprising of a combination of aerobic endurance training and resistance exercise training will be given by a trained sports coach or physical therapist specialized in geriatric physical therapy. During the weekends, participants will be asked to perform a 'relative rest' session with some light activity during the training time window of the intervention arm.
223854025|NCT06614231|DRUG|Tislelizumab Combined With Chemotherapy|Tislelizumab 200mg Q3W，Platinum-containing dual drug chemotherapy
223854026|NCT00603447|DRUG|Carfilzomib|Carfilzomib for Injection was administered intravenously over 10 minutes on Days 1, 2, 8, 9, 15, and 16 of a 28-day cycle for the first 12 cycles. Each dose of Carfilzomib for Injection was normalized to body surface area.
223854027|NCT00603447|DRUG|Lenalidomide|Lenalidomide was administered orally on Days 1 to 21 of each 28-day cycle.
223854028|NCT00603447|DRUG|Dexamethasone|Dexamethasone 40 mg orally or intravenous equivalent was administered 30 minutes to 4 hours before carfilzomib on Days 1, 8, and 15, as well as on Day 22 of each 28-day cycle.
223854029|NCT06614257|DRUG|LG-TAP block with local anesthetic|The laparoscopic guided TAP Block was performed by surgeon at the beginning of surgery, injecting 15 ml of Ropivacaine 0.5% on each side, using an atraumatic needle (10/15 cm length, 20 Gauge diameter) close to the anterior axillary line, between the iliac crest and the subcostal margin. Correct needle tip positioning between the transverse muscle of the abdomen and the internal oblique was verified through laparoscopic guidance.
223854030|NCT06614257|PROCEDURE|Port site infiltration|Prior the surgical incision, an infiltration of the laparoscopic access using a total of 10 ml Ropivacaine 0.5% was performed by surgeon
223854031|NCT06614257|DRUG|LG-TAP block with saline solution|The laparoscopic guided TAP Block was performed by surgeon at the beginning of surgery, injecting 15 ml of Saline solution (NaCl 0.9%) on each side, using an atraumatic needle (10/15 cm length, 20 Gauge diameter) close to the anterior axillary line, between the iliac crest and the subcostal margin. Correct needle tip positioning between the transverse muscle of the abdomen and the internal oblique was verified through laparoscopic guidance.
223854032|NCT02165059|PROCEDURE|Surgical Full Thickness Biopsy|Eligible subjects will undergo a surgical full thickness biopsy of the stomach and/or proximal jejunum as part of their planned surgery.
223854033|NCT03193567|BIOLOGICAL|HEKT cell|3 cycles of HEKT cell treatment
223854034|NCT05233085|DRUG|AZD4041|Participants will receive oral solution of AZD4041 as stated in arm description.
223854035|NCT05233085|OTHER|Placebo|Participants will receive oral solution of placebo as stated in arm description.
223854036|NCT06693739|PROCEDURE|Platelet rich fibrin|PRF membrane is placed as a scaffold inside the canal with no hyaluronic acid
223854037|NCT06693739|PROCEDURE|hyaluronic acid|hyaluronic acid gel is placed as a scaffold inside the canal with no PRF
223854038|NCT06693739|PROCEDURE|no scaffold|initiate bleeding using hand files size beyond apex with sharp strokes with no PRF or hyaluronic acid placed
223854039|NCT05416749|DRUG|8MW2311|All subjects will receive a single intravenous (IV) infusion of 8MW2311 every 21 days (q21d), other dosing frequencies may be used.
223854040|NCT00798265|BIOLOGICAL|Gardasil|.5 mL dose injected intramuscular (IM) at 0, 2 and 6 months
223854041|NCT00798265|BEHAVIORAL|Survey|Administration of online risk behavior and knowledge survey done at week 0.
223854042|NCT05177341|OTHER|Determining Preferred Walking Speed|In the beginning, sensors of the gait analysis system (RehaGait®), which can record the time-distance characteristics of consecutive multiple steps (step length, step width, double step length, and timing information, etc.) will be installed. The 7 sensors of this system are attached to the shoes of the individual, proximal to the ankle, distal thigh, and sacroiliac joint level (Aminian et al., 2014). Individuals will be required to wear casual athletic shoes and comfortable, non-knee-covering shorts. Next; Each individual will walk freely on the treadmill at their own pace. To find the preferred walking speed of the individual, Hinton et al. protocol will be used (Hinton et al., 2018). The speed of the treadmill will be increased or decreased in line with the direction of the participants. After being determined according to the protocol, the individual will practice walking at this speed for 4-5 minutes. The individual will rest as much as he or she wants.
223854043|NCT06630520|COMBINATION_PRODUCT|Periarticular injection|"A 50ml periarticular injection was introduced intraoperatively before the time of closing. The injection contained 150mg bupivacaine (3mg/mL), 60mg ketorolac(1.2mg/mL) and 1mg morphine.~Before wound closure, periarticular cocktail was injected around the knee joint including the adductor canal from the hamstring harvest side in PAI group. All patients had oral paracetamol 500mg, 4 times/day and diclofenac 75mg, 1 times/day after surgery."
223854044|NCT06630559|BIOLOGICAL|CT-P55|CT-P55, 300 mg by 2 subcutaneous (SC) injections of 150 mg/mL via Pre-Filled Syringe (PFS) every week for 5 doses (up to Week 4 after starting dose at Day 1), followed by every 4 weeks (Q4W) for 11doses (up to Week 48).
223854045|NCT06630559|BIOLOGICAL|EU-approved Cosentyx|European Union (EU)-approved Cosentyx, 300 mg by 2 SC injections of 150 mg/mL via PFS every week for 5 doses (up to Week 4 after starting dose at Day 1), followed by Q4W for 11 doses (up to Week 48).
223854046|NCT06629636|DIETARY_SUPPLEMENT|NMN capsule|Total of 900mg/day for 8 weeks
223854047|NCT06629636|OTHER|Placebo|NMN-free placebo capsules for 8 weeks
223854048|NCT06631118|PROCEDURE|pericapsular nerve group block for group A,low dose intravenous Propofol [0.7mg/kg] over 30 seconds for group B|Patients in group A will receive ultrasound guided pericapsular nerve group block (PENG) while patients in group B will receive low dose intravenous Propofol0.7mg/kg\] over 30 seconds followed by spinal anesthesia in both groups
223854049|NCT06697262|DEVICE|Remote temperature monitoring device|"* Use of the Tucky® remote monitoring device for continuous temperature monitoring at home,~* In combination with education sessions on temperature monitoring and the device."
223854050|NCT06697262|DIAGNOSTIC_TEST|Home temperature monitoring by a nurse|"* Home temperature monitoring by a nyrse, twice a day,~* In association with education sessions on temperature monitoring."
223854051|NCT06698198|BIOLOGICAL|Pneumococcal Conjugate Vaccine|Suspension for Intramuscular injection
223854052|NCT06698198|BIOLOGICAL|Prevnar 13®|Suspension for Intramuscular injection
223854053|NCT06696547|DEVICE|Transcranial Magnetic Stimulation|Magstim Rapid2 Magnetic Stimulator (Magstim, Whitland Dyfed, UK), 70 mm Figure-of-eight Coil
223854054|NCT06696547|DEVICE|Transcranial Magnetic Stimulation Sham|Magstim Rapid2 Magnetic Stimulator (Magstim, Whitland Dyfed, UK), 70 mm Figure-of-eight Sham Coil
223854055|NCT02482493|DEVICE|Sigma PFC|patients will receive either an all polyethylene tibial component or a metal- backed component
223854056|NCT05948098|BEHAVIORAL|Facilitated Tucking Position|a sub-form of method of nesting the baby and the procedure of bringing the body to middle or even close position by holding the upper and lower extremities of the baby in flexion with hands
223854057|NCT05948098|BEHAVIORAL|Gentle Human Touch|It is a form of healing touch
223854058|NCT06696378|DIETARY_SUPPLEMENT|Melatonin 6 mg|wo capsules per day; Each capsule includes 3mg Melatonin Nutrifoods® Laboratories, Barcelona, Spain) by the Magistral Formulation Laboratory of a Pharmacy (Soria, Spain), following the rules of the Royal Spanish Pharmacopoeia (Ministry of Health, Government of Spain). Melatonin has a technical data sheet that guarantees its composition and purity (Reference No.: DIE-134).
223854059|NCT06696378|OTHER|Placebo|Two capsules per day; Each capsule includes 100-mg maltodextrin capsules were used as a placebo to match the color and texture of the Melatonin tablets to ensure blinding.
223854060|NCT06706518|PROCEDURE|Single-shot ablation technologies|"Comparison of fluoroscopy time and dose-area product (DAP) between different single-shot ablation technologies.~* PolarFit balloon catheter with adjustable diameter 28 to 31 mm. This catheter will be used in patients with persistent AF and dilated left atrium, where the ability to encompass more of the atrial myocardium at the level of the antrum of the pulmonary veins allows a greater number of potential AF perpetuating regions to be covered.~* ArcticFront Advance Pro 28 mm diameter balloon catheter\*.~* 28 mm diameter PolarX balloon catheter\*."
223854061|NCT06712212|PROCEDURE|Inguinal Hernias repair: Desarda|A splitting incision is made in this sutured medial leaf, partially separating a strip 1.5-2 cm wide. This splitting incision is extended medially up to the pubic symphysis and 1-2 cm beyond the abdominal ring laterally. The medial insertion and lateral continuation of this strip is kept intact. The upper free border of the strip is now sutured to the internal oblique with number 1 Monofilament Polydioxanone Violet continuous sutures all along its length. This will result in the strip of the EOA being placed behind the cord to form a new posterior wall of the inguinal canal. The spermatic cord is placed in the inguinal canal and the lateral leaf of the EOA is sutured to the newly formed medial leaf of the EOA in front of the cord. As before, number 1 Monofilament Polydioxanone Violet continuous sutures were used. Undermining of the newly formed medial leaf on both its surfaces and excision of the bulky cremasteric muscle facilitate its approximation to the lateral leaf
223854062|NCT06712212|PROCEDURE|Inguinal hernia repair: Darn|Skin and fascia are incised using a regular, oblique inguinal incision to expose the external oblique aponeurosis (EOA) the inguinal canal is opened into by dividing the external oblique aponeurosis through the external ring. After dealing with the hernia sac, a 0-size monofilament suture was used to reconstruct the inguinal bed with a tension-free darn starting with a good strong bite of the tough tendinous structures near the pubic tubercle and emerging out through the lateral edge of the internal oblique/rectus sheath from one side and through the inguinal ligament on the other side. The loosely interwoven bites continued laterally and the back-forming two rows of continuous stitches were placed in a staggered manner to spread the tension between the fibres of the inguinal ligament. Afterwards, the external oblique and other superficial layers with the skin are classically closed
223854063|NCT06711120|PROCEDURE|Radiofrequency ablation and microwave ablation are used to treat small saphenous varicose veins, respectively|During the procedure, 2% lidocaine was injected subcutaneously along the course of the saphenous vein under ultrasound guidance, and after local anaesthesia, an incision was made at the ankle joint of the saphenous vein to locate the saphenous vein, and a radiofrequency guidewire and catheter sheath were introduced.The saphenous vein was incised at the ankle joint under local anaesthesia. Under ultrasound monitoring, the radiofrequency catheter was placed in the saphenous popliteal vein at a distance of 1\~2 cm and the position of the catheter was fixed, and then anaesthesia and swelling fluid was injected into the fascial tissues around the main trunk of the small saphenous vein in segments.The two groups were treated with radiofrequency ablation and microwave ablation surgery, respectively.
224265952|NCT04241341|PROCEDURE|Axillary Lymph Node Dissection without Immediate Lymphatic Reconstruction|Current standard treatment at Memorial Sloan Kettering \[MSK\]).
223854064|NCT06708325|OTHER|Resistance Training Program|The 12-week resistance training program consisted of three supervised sessions per week, each lasting approximately 55-60 minutes. Sessions were structured as follows: 5-7 minute dynamic warm-up, 35-40 minutes of resistance training, and 4-5 minutes of stretching for active recovery.Participants were paired based on similar strength fitness levels and progressed according to the principle of periodized progressive overload. Training was delivered using a circuit protocol with 2-3 sets per exercise. The initial 4-week phase included 2 sets per exercise, with 8-20 repetitions and 1-2 minutes rest between sets. .The program incorporated functional exercises targeting the lower extremities, core, and upper extremities, utilizing equipment such as resistance bands, medicine balls, jump ropes, dumbbells, bars, and stability balls. Participants performed exercises in a circuit sequence, with the intensity, number of sets, and repetitions
223854065|NCT06711848|BEHAVIORAL|A web-based educational intervention on oral cancer|This intervention will involve administering education, via a website, on the meaning, risks, clinical features, prevention, treatment, and supports on oral cancer.
223854066|NCT06711848|BEHAVIORAL|A mobile health app-based educational intervention on oral cancer|This intervention will involve administering education, via a mhealth application prototype, on the meaning, risks, clinical features, prevention, treatment, and supports on oral cancer.
223854067|NCT06712225|BEHAVIORAL|Anomia therapy: semantic feature analysis and phonological components analysis;|After the initial assessment + functional Magnetic Resonance Imaging (fMRI), participants will first receive their usual speech therapy rehabilitation for 10 to 15 sessions (baseline phase), and then enter the experimental phase: 18 sessions (3 per week) of either anomia therapy alone or anomia therapy + executive function training, according to the arm they were assigned to. All sessions will last 45 minutes. Naming skills will be repeatedly measured during both phases. A second assessment of language + fMRI will then be conducted and participants will return to their usual rehabilitation. Four weeks later, a final assessment of naming and discourse will be conducted.
223854068|NCT06712225|BEHAVIORAL|Executive function training: computerized equipment|Executive function training will be conducted by means of a computerized material specifically designed for the study, consisting of verbal and nonverbal exercises targeting, always in the same order, inhibition, shifting, working memory and planning functions, with a gradient of difficulty. Training will always be done at the beginning of the session, during 20 minutes, before anomia therapy.
223854069|NCT06712056|BEHAVIORAL|Mindfulness|study of focusing attention
223854070|NCT06711185|DRUG|Dapagliflozin 10 mg|Patients in this group will receive 1 tablet of 10mg dapagliflozin daily for 9 months, starting 7-10 days before chemotherapy treatment.
223854071|NCT06711185|OTHER|Placebo|Patients in this group will receive 1 placebo tablet per day, with identical characteristics to the group receiving dapagliflozin, for 9 months, starting 7-10 days before the start of chemotherapy treatment
223854072|NCT06705491|BEHAVIORAL|TIPPI-R|The TIPPI-R intervention protocol consists of a one session, during which time the interventionist offers psychoeducation related to the following content areas: procedural pain related to oncology treatment, factors that may affect the perception of pain, evidenced-based tools for assessing and monitoring pain, cognitive and behavioral pain management interventions, and resources to facilitate family to advocacy for pain management in a medical setting. During this session, the interventionist discusses opportunities for families to utilize skills throughout treatment, and addresses family questions as needed. A follow-up session 4 weeks after the initial intervention session will assess family knowledge and skills and offer a referral for a mental health provider, if further pain management support is needed. TIPPI-R is designed to be delivered by a psychologist, psychology trainee, or social worker working in the oncology context.
223854073|NCT06712771|DRUG|VSA003|subcutaneous injections
223854074|NCT06712771|DRUG|Placebo|subcutaneous injections
223854075|NCT06711575|DRUG|Anti-Infective Drugs|Anti-infective drugs are administered using the traditional clinical dosing regimen, with no interventions.
223854076|NCT06711250|PROCEDURE|khoury technique|autogenous bone augmentation
223854077|NCT06711250|PROCEDURE|khoury technique with i-PRF injections|autogenous bone augmentation with repeated i-PRF injections
223854078|NCT06713980|OTHER|sham acupuncture|In the sham acupuncture group, sham acupuncture was applied at 14 specific non-acupuncture points on the back.
223854079|NCT06713980|OTHER|acupuncture|acupuncture:the choice of acupoints was based on the theory of traditional Chinese medicine (TCM). All needles were manually manipulated to achieve the deqi sensation
223854080|NCT06711341|DEVICE|Whole-body Vibration (WBV) Training|"Participants use the Compex Winplate, designed specifically for vibration training. The device is set with a frequency of 30 Hz and an amplitude of 4 mm. Participants perform a total of 5 exercises consisting of static and dynamic squat exercises, with a 30-second rest period between sets and between different exercises. The exercises and progression over the weeks are as follows:~Week 1:~* Static squat with knees flexed at 30° - 2 sets of 30 seconds each~* Dynamic squat with knees flexed between 0-60° - 2 sets of 30 seconds each~* Fingertip-to-sole partial dynamic squat with knees flexed at 30° - 2 sets of 30 seconds each~* Consecutive weight transfer with knees flexed at 45° - 2 sets of 30 seconds each~* Single leg static squat with knees flexed at 30° - 30 seconds per leg~Subsequent Weeks: The duration of each set increases by 10 seconds each week. Each training session includes a 5-minute warm-up and a 5-minute cooldown, consisting of joint motion and muscle stretching exercises."
223854081|NCT06711341|BEHAVIORAL|Progressive Resistance Exercise (PRE)|"Training Duration: Participants undergo approximately 15-20 minute training sessions, 3 days per week for 3 weeks.~Exercise Regimen: The training focuses on strengthening the quadriceps muscles using ankle weights. The load is determined using the DeLorme principle:~* At the beginning of each week, the 10-repetition maximum (10RM) is measured.~* During that week, participants perform their training sets as follows:~  * First set: 50% of 10RM~ * Second set: 75% of 10RM~ * Final set: 100% of 10RM Each training session includes a 5-minute warm-up and a 5-minute cooldown, consisting of joint motion and muscle stretching exercises."
223854082|NCT06711341|BEHAVIORAL|Home-Based Exercise|"Protocol: Participants receive a printed document with instructions for home exercises and are instructed on how to perform the exercises.~Training Duration: Sessions are conducted three days per week for 3 weeks.~Exercise Regimen: The exercises include:~* Bilateral Quadriceps Isometric Exercise: Participants lie on their backs with a roll below each knee, pressing for 10-second holds, totaling 20 repetitions.~* Knee Extensions: Participants performed knee extensions while seated, holding each extension for 5 seconds, completing 10 repetitions per leg.~* Knee Range of Motion (ROM) Exercises: Participants lie face down and alternately bend their knees, completing 10 repetitions.~Each training session includes a 5-minute warm-up and a 5-minute cooldown, consisting of joint motion and muscle stretching exercises"
223854083|NCT06713252|BEHAVIORAL|Art therapy|Through music, painting, dance and other forms, art therapy can not only help patients regulate their emotions, relieve anxiety and depression, but also activate different areas of the brain to promote neuroplasticity, thereby promoting the recovery of motor function
223854084|NCT06713252|BEHAVIORAL|Regular therapy|Standard treatment
223854085|NCT06714331|DIETARY_SUPPLEMENT|Supplements|Supplements provided to subjects 2 hours prior to testing and drank at 2 hours, 90 minutes and 45 minutes before testing.
223854086|NCT06714669|DRUG|propofol|"Control Group (Propofol Anesthesia Arm):~Patients in this arm will receive Propofol as the primary anesthetic agent for general anesthesia. Propofol is a well-established anesthetic drug commonly used in clinical practice for its rapid onset and short duration of action. Similar to the experimental group, the dosing regimen and administration protocol for Propofol will be tailored to the individual patient's needs and the surgical procedure. Hemodynamic stability and other vital signs will also be closely monitored in this group to assess the safety and effectiveness of Propofol in comparison to Remimazolam."
223854087|NCT06714669|DRUG|Remimazolam|"Experimental Group (Remimazolam Anesthesia Arm):~Patients in this arm will receive Remimazolam as the primary anesthetic agent for inducing and maintaining general anesthesia. Remimazolam belongs to a new class of benzodiazepines and acts by enhancing the activity of GABAA receptors, leading to sedation and anesthesia. The specific dosing regimen and administration protocol for Remimazolam will be determined based on the patient's characteristics and the surgical procedure being performed. Close monitoring of the patient's vital signs, particularly hemodynamic parameters, will be conducted throughout the anesthesia period to ensure safety and efficacy."
223854088|NCT06713564|DRUG|LS301-IT|LS301 is composed of: 1) a cyclic peptide that binds phosphorylated Annexin A2 (ANXA2) which is found on the surface of malignant cells typically located in solid tumors and in malignant lymph nodes; and 2) cypate, a near infrared (NIR) molecule conjugated to the peptide, which fluoresces when illuminated using NIR light.
223854089|NCT06714487|OTHER|cognitive stimulation through games|cognitive stimulation through games
223854090|NCT06713174|DIAGNOSTIC_TEST|Assessment of Interleukin 8 and 10 Level Changes Before and During Root Canal Treatment for Necrotic Pulp with Apical Periodontitis|This study will be performed to investigate interleukin-8 (IL-8) and interleukin-10 (IL-10) level changes in gingival crevicular fluid (GCF) and periapical fluid before and during root canal treatment (RCT) in patients with necrotic pulp and apical periodontitis. The null hypothesis tested will be There is no significant difference in (IL-8) and (IL-10) levels in gingival crevicular fluid (GCF) and periapical before and during root canal treatment (RCT) for necrotic pulp with apical periodontitis.
223854091|NCT06714383|DRUG|Trilaciclib|Trilaciclib: 240mg/m2, IV, within 4 hours before each chemotherapy agent infused.
223854092|NCT06714383|DRUG|Pirarubicin|Pirarubicin: 60 mg/m2，IV，d1-2
223854093|NCT06714383|DRUG|Lobaplatin|LobaplLatin: 40 mg/m2,，IV，d1
223854094|NCT06698068|OTHER|Equine-assisted therapy|15 equine therapy sessions, twice a week, over 7 to 8 weeks. Each session will last 60 minutes, including various activities such as emotional expression, contact with the horse, grooming, activities on foot or on horseback, and a debriefing time.
223854095|NCT06712368|DEVICE|virtual reality glasses|Designed cardiac physical therapy program applied through virtual reality glasses for study group
223854096|NCT06712368|OTHER|Designed cardiac physical therapy program|Designed cardiac physical therapy program without virtual reality glasses
223854097|NCT06711328|DEVICE|New oropharyngeal airway|This product is produced and sold by Shanghai Elifu Medical Technology Co., LTD., and has been officially put into clinical use in March 2023.The product is named oropharyngeal airway for disposable endoscope, which is composed of nasal plug, bite, oropharyngeal channel, oxygen supply tube, lanyard and optional accessories carbon dioxide gas catheter and carbon dioxide collection tube.The model used in this study is JK (Oropharyngeal airway for endoscope with end-expiratory carbon dioxide Collection) with L/M/S three specifications, which is used to prevent airway obstruction caused by backward tongue fall during endoscopic surgery/examination, establish oropharyngeal airway for patients, and provide nasal oxygen at the same time
223854098|NCT06457607|DEVICE|LinearZ|High Intensity Focues Ultrasound
223854099|NCT05971225|OTHER|remote monitoring only|remote monitoring only can replace in-office device monitoring
223854100|NCT06421597|DRUG|Prednisolone|prednisoline 25 mg/day for seven days
223854101|NCT06421597|DRUG|Placebo|Placebo treatment for seven days
223854102|NCT01764451|DRUG|Simvastatin|
223854103|NCT06398626|DRUG|Etrasimod|As provided in real world practice
223854104|NCT03426280|DEVICE|Apple Watch Series 1|Clinic pharmacists will issue Apple Watches to study arm patients and teach them the usage of the Activity app. In addition to usual care, these patients will each receive an in-person 3-minute coaching session during clinic visit at 2, 4, 6 and 12 months.
223854105|NCT03208270|DRUG|Antithrombin supplementation|antithrombin concentrate will be supplemented to maintain a functional antithrombin level between 80%-120%
223854106|NCT03208270|DRUG|No antithrombin supplementation|"supplementation of antithrombin will not be provided unless heparin resistance occurs"
223854107|NCT02117401|DRUG|mivacurium chloride|intravenously injected during induction with the dose according to allocated group, and intravenously injected with the dose of 0.1 mg/kg when T1 recovers to 25% during period of maintenance.
223854108|NCT02117401|DRUG|midazolam|"Before induction: after moving into operating room, oral administration with dose of 0.5 mg/kg or mixed with ketamine (midazolam 10 mg+ ketamine 100 mg) with dose of 0.1 ml/kg by intramuscular route for uncooperative children~Induction: for children who didn't receive mixture of midazolam and ketamine before induction, it will be given with the dose of 0.05 ml/kg"
223854109|NCT02117401|DRUG|ketamine|"mixed with ketamine (midazolam 10 mg+ ketamine 100 mg) with dose of 0.1 ml/kg by intramuscular route for uncooperative children~Induction: for children who didn't receive mixture of midazolam and ketamine before induction, it will be given with the dose of 0.05 ml/kg"
223854110|NCT02117401|DRUG|propofol|Induction: 2 to 3 mg/kg Maintenance: 50 to 100 mcg/kg/min
223854111|NCT02117401|DRUG|Remifentanil|Induction: 2 mcg/kg Maintenance: 0.1 to 0.3 mcg/kg/min
223854112|NCT03297112|DRUG|Perflutren Lipid Microspheres|Given IV
223854113|NCT03297112|PROCEDURE|Contrast-Enhanced Subharmonic Ultrasound Imaging|Undergo contrast-enhanced subharmonic ultrasound imaging
223854114|NCT02738840|PROCEDURE|MRI scan|MRI scan
223854115|NCT05780788|DEVICE|Monitoring Tooth Movement|Monitoring Canine Retraction
223854116|NCT01801449|DRUG|Rilonacept|
223854117|NCT01082289|DRUG|Lurasidone|
223854118|NCT01327469|DRUG|Albendazole, 2 x 400mg|Albendazole 2 x 400mg
223854119|NCT01327469|DRUG|Albendazole 400mg|Albendazole 400mg
223854120|NCT01327469|DRUG|Mebendazole 500mg|Mebendazole 500mg
223854121|NCT01327469|DRUG|Mebendazole 2 x 500mg|Mebendazole 2 x 500mg
223854122|NCT01327469|DRUG|Pyrantel-oxantel + mebendazole|Pyrantel-oxantel + mebendazole
223854123|NCT01311648|BIOLOGICAL|Recombinant Factor VIII (Kovaltry, BAY81-8973)|Main study: 25-50 IU/kg at least 2x/week for 6 months and at least 50 EDs, IV infusion; Extension study: 25-50 IU/kg at least 2x/week for at least 100 cumulative EDs (main study - Part A and extension study), IV infusion. Exposure day (ED): An ED is a unit of time (1 day) in which replacement treatment of Hemophilia is given to a patient.
223854124|NCT01311648|BIOLOGICAL|Recombinant Factor VIII (Kovaltry, BAY81-8973)|Main study: 15-50 IU/kg at least 1x/week for at least 50 EDs or until inhibitor development, IV infusion; Extension study: For participants having reached at least 50 EDs in main study - Part B: 25-50 IU/kg at least 2x/week for at least 100 cumulative EDs (main study - Part B and extension study), IV infusion. For participants who developed an inhibitor in main study - Part B: up to 200 IU/kg per day or 100 IU/kg twice a day at the discretion of the investigator and coordinating investigator until successful eradication of the inhibitor, or until failure, for up to18 months (treatment beyond 18 months required an agreement with the sponsor and coordinating investigator), IV infusion
223854125|NCT00181909|BEHAVIORAL|Smoking cessation counseling delivered by telephone|
223854126|NCT04755530|DIETARY_SUPPLEMENT|Regular whole milk|400 g/day of regular whole milk
223854127|NCT04755530|DIETARY_SUPPLEMENT|Yogurt with live bacteria|400 g/day of yogurt with live bacteria
223854128|NCT04755530|DIETARY_SUPPLEMENT|Yogurt with inactivated bacteria|400 g/day of yogurt with inactivated bacteria
223854129|NCT04755530|DIETARY_SUPPLEMENT|Acidified whole milk|400 g/day of yogurt with acidified whole milk
223854130|NCT00407082|DRUG|fluocinolone acetonide intravitreal implant|Fluocinolone acetonide ocular implant 0.59mg
223854131|NCT00407082|DRUG|Fluocinolone acetonide 2.1mg|Fluocinolone acetonide ocular implant 2.1mg
223854132|NCT02391246|OTHER|Positron Emission Tomography Imaging|Participants will receive an intravenous injection of 250 MBq (megabecquerels) of 18F-Fluorodeoxyglucose (18F-FDG). The first Positron Emission Tomography (PET) acquisition of the head will occur one hour post-injection. The second acquisition will take place 3 hours post-injection. Both early and late PET images will be manually co-registered with the participant's most recent magnetic resonance images.
223854133|NCT05605743|BEHAVIORAL|breathing exercise|Thirty hypertensive geriatric with high tension type primary open angle glaucoma will perform breathing exercise (alternate nostril breathing). The daily breathing exercise will be performed by the geriatrics in evening (for half an hour) and morning (for half an hour) for one month.
223854134|NCT04010643|BEHAVIORAL|online cognitive behavioural therapy|oCBT: MoodGym is a 5-week oCBT program developed by the Centre for Mental Health Research at the Australian National University. This program has been shown to be clinically effective at reducing mood symptoms in depression studies (see meta-analytical review of Twomey \& O'Reilly, 2017). MoodGym consists of a number of interactive modules to be completed sequentially and including work on own feelings, thoughts, methods to change dysfunctional thinking patterns, de-stressing, and relaxation. Each module is followed by an associated practical homework, while a personalised workbook allows the participant to track their mood profile and progress throughout the modules.
223854135|NCT04010643|BEHAVIORAL|online neurocognitive remediation therapy|NCRT involves the behavioural application of structured exercises targeting neurocognitive processes by mobilising neuroplasticity that is the brain's ability to adjust its function in response to environmental change. Computerised NCRT has demonstrated efficacy to improve attention, working memory and global functioning in depression (Motter et al., 2016; Semkovska et al., 2015). NCRT is delivered through the Cognifit online programme. The Cognifit modules were selected as targeting remediation of neurocognitive domains known to be impaired in depression, i.e. selective and divided attention, visual and verbal working memory, and everyday planning (Hammar and Ardal, 2009; Semkovska et al., 2019).
223854136|NCT00676533|DRUG|Cipro XR (Ciprofloxacin, BAYQ3939)|3 tablets of Cipro XR 500 mg and were instructed to take 1 tablet per day for 3 days.
223854137|NCT04810260|BEHAVIORAL|Use mobile health app (WellXcel) to increase knowledge|Download the app (WellXcel) to the mobile device
223854138|NCT04036162|BEHAVIORAL|Cognitive tasks|MagnetoEncephaloGraphy (MEG) records
223854139|NCT03758339|DRUG|tucatinib|Single dose of 300 mg of \[¹⁴C\]-tucatinib containing approximately 150 μCi of \[¹⁴C\] radioactivity
223854140|NCT06232226|OTHER|Patients suffering from the co-occurrence of ADHD and addiction(s)|All eligible patients over 15 years and 3 months (age limit between child psychiatry and adult psychiatry), presenting both a diagnosis of ADHD and a diagnosis of at least one addictive disorder (SUD, AUD (Alcohol Use Disorder) and/ or behavioral addiction), starting care in one of the three participating centers, and meeting the indication for treatment with MPH according to European recommendations (J. J. S. Kooij et al., 2019)
223854141|NCT01064843|DEVICE|Imtec MDI|4 Imtec MDI
223854142|NCT02695381|DRUG|Etodolac-lidocaine topical patch|Once daily
223854143|NCT02695381|DRUG|Placebo|Once daily
223854144|NCT03811587|OTHER|Fasting Mimicking diet|The fasting mimicking diet is though to activate the metabolism as fasting would do, although the diet does include several meals a day and more calories than conventional fasting diets.
223854145|NCT02210806|DRUG|A006 DPI|Single dose 110 mcg, 1 inhalation
223854146|NCT02210806|DRUG|A006 DPI|Single dose 220 mcg, 1 inhalation
223854147|NCT02210806|OTHER|Placebo DPI|Placebo, 1 inhalation
223854148|NCT02210806|DRUG|Proventil® MDI|Single dose 90 mcg, 1 inhalation
223854149|NCT02210806|DRUG|Proventil® MDI|Single dose 90 mcg, 2 inhalations
223854150|NCT06120699|OTHER|Pelvic floor muscle training with 360 degree expanded diaphragm exercises|Women in this group will be taught 360-degree expanded diaphragm exercises with the Ohmbelt device. Two Ohmbelt devices will be used in this study. The anterior sensor will be placed in the inguinal cavity to visualize the expansion of the anterior abdominal wall, and the posterior sensor will be placed contralaterally in the upper lumbar triangle to visualize the expansion of the posterior wall. The protocol of breathing exercises is inspiration and expiration time of 6 seconds, 10 repetitions and 3 sets. Pelvic floor muscle training will be given with the NeuroTract Myoplus 4 PRO EMG biofeedback device. The training protocol: Each patient will be asked to contract close to the maximum pelvic floor muscle contraction for slow muscle contraction, maintain the contraction for 6-8 seconds, and then perform fast muscle contractions 3-4 times. This cycle is 1 set, 8-12 repetitions. A total of 3 sets will be applied.
223854151|NCT06120699|OTHER|Pelvic floor muscle training with standard diaphragm exercises|"Women in this group will be taught standard diaphragm exercises. In the supine position, with the head and knees supported by a pillow, the patient will first be asked to close his or her eyes to focus. With one hand on the chest and the other hand on the abdomen, Take a deep breath through your nose and direct all the air as much as possible under your lower hand. inflate your belly. Now exhale all the air slowly through your mouth. The protocol of breathing exercises is inspiration and expiration time of 6 seconds, 10 repetitions and 3 sets. Pelvic floor muscle training will be given with the NeuroTract Myoplus 4 PRO EMG biofeedback device. The training protocol: Each patient will be asked to contract close to the maximum pelvic floor muscle contraction for slow muscle contraction, maintain the contraction for 6-8 seconds, and then perform fast muscle contractions 3-4 times. This cycle is 1 set, 8-12 repetitions. A total of 3 sets will be applied."
223854152|NCT02888535|OTHER|Internal Medicine consultation|
223854153|NCT04057196|BEHAVIORAL|Self-System Therapy for Older Adults with Advanced Lung Cancer (SST-LC)|The SST-LC is a brief structured intervention deliverable by video conference. The new SST-LC protocol will incorporate behavioral strategies designed to meet the needs of older adults with lung cancer, including examining individual and shared expectations for lung cancer care, identifying discrepancies between expectations and realistic possibilities, and modifying stress-exacerbating behaviors.
223854154|NCT01796093|DRUG|Digoxin and ivabradine|No more details
223854155|NCT02555449|DRUG|[¹⁴C]-LY3202626|Administered as solution by mouth
223854156|NCT02466516|DRUG|SEL|SEL tablet administered orally once daily
223854157|NCT02466516|BIOLOGICAL|SIM|Simtuzumab (SIM) 125 mg/mL single-dose vials administered subcutaneously once weekly
223854158|NCT03712930|DRUG|Pamiparib|60 mg orally twice daily (BID)
223854159|NCT03573999|DRUG|Mannitol|4.6 ml/kg will be administered before dura opening
223854160|NCT03573999|DRUG|NaCl 7.5%|2 ml/kg will be administered before dura opening
223854161|NCT03297346|OTHER|Cardiac imaging and circulating biomarkers|Automated 2D-speckle-tracking echocardiography (ECHO-ST); Computed tomography coronary angiography (CT); Cardiac magnetic resonance imaging (MRI); Blood samples for circulating biomarkers measurements (BLOOD)
223854162|NCT02085356|BEHAVIORAL|Protect your family|"Protect Your Family intervention is a manualized, closed, structured behavioral risk reduction program targeting HIV, stigma, disclosure, communication, intimate partner violence (IPV), PMTCT knowledge, safer conception, family planning and dual method sexual barrier use.~Intervention participants will attend 3 prenatal weekly 2 hour gender-specific (male or female, 5-7 participants) group sessions followed by 1 individual counseling session and 2 monthly couples or individual (women-only) counseling sessions (1 prenatal, 2 postpartum) led by study-trained clinic staff (e.g., nurses, HIV counseling and testing (HCT) counselors) plus standard of care (PMTCT)"
223854163|NCT03465488|DRUG|Albendazole Pill 400mg (GSK)|One single dose of 400mg Albendazole is provided at baseline.
223854164|NCT02833155|DRUG|Entinostat|Given PO
223854165|NCT02833155|DRUG|Exemestane|Given PO
223854166|NCT01250548|BIOLOGICAL|apremilast|30 mg BID apremilast taken orally for the first 12 weeks followed by responders randomized to either 30 mg BID apremilast (oral) or 30 mg BID placebo (oral) for 8 weeks
223854167|NCT01250548|OTHER|Placebo|
223854168|NCT01332058|BEHAVIORAL|Motivational Interviewing|8 possible weeks of motivational interviewing sessions
223854169|NCT00914823|DRUG|kisspeptin 112-121|One or more IV or SC doses of kisspeptin 112-121, and/or short infusion (up to 12 hours) of kisspeptin 112-121
223854170|NCT00914823|DRUG|GnRH|One or more IV doses of GnRH, and/or SC administration of GnRH
223854171|NCT03126084|DRUG|Acetaminophen|1000 mg of intravenous acetaminophen will be administered twice a day
223854172|NCT03126084|DRUG|0.25% Bupivacaine|20 ml of 0.25% bupivacaine will be administered to the fascia of the transversus abdominis muscle under ultrasound guidance.
223854173|NCT03126084|DRUG|0.5% Bupivacaine+Glucose|15mg of 0.5% bupivacaine will be administered to subarachnoid space through 25G spinal needle
223854174|NCT03126084|DRUG|Tramadol HCl|50mg of intramuscular tramadol will be administered when pain score is greater than 3 according to NRS
223854175|NCT03126084|PROCEDURE|Inguinal Hernia Repair|Patients will undergo open inguinal hernia repair with one of the tension free mesh techniques
223854176|NCT03126084|DRUG|0.25% Bupivacaine|10 ml 0.25% bupivacaine will be administered quadratus lumborum muscle and erector spinae muscle
223854177|NCT04095403|OTHER|Tarp Assisted Cooling|Body cooling utilizing a tarp and water
223854178|NCT04095403|OTHER|passive cooling|Supine rest.
223854179|NCT03583021|DRUG|Sugammadex Injectable Product|Sugammadex of 3 mg/kg is injected.
223854180|NCT03583021|DRUG|Neostigmine Injectable Product|Neostigmine of 50 ug/kg and Glycopyrrolate of 10 ug/kg are injected.
223854181|NCT01414231|DRUG|Cytarabine|Intermediate dose against low dose; IDA 12 mg/m2 iv days 1 - 3 and AraC 2 x 1 g/m2 bid on days 1+3+5+7 vs. AraC 100 mg/m2/day i.v.-for 7 days and Daunorubicin 60 mg/m2/Tag on days 3, 4 und 5.
223854182|NCT03221569|DRUG|Intravenous ketamine|0.3mg/kg IVPB over 15 minutes
223854183|NCT03221569|DRUG|Ketorolac|as active comparator, will be administered together with metoclopramide in one normal saline 50ml bag
223854184|NCT03221569|DRUG|Normal saline|"Will be given as 50ml intravenous bag as placebo for double-blinding purposes in patients who will also receive intranasal ketamine.~Will be prepared in intranasal syringe for double blinding purposes for patients who are randomized to receive intranasal ketamine."
223854185|NCT03221569|DRUG|Normal saline|1ml intravenous push as placebo for double-blinding purposes
223854186|NCT05396976|BEHAVIORAL|Yoga and Muscle Relaxation Exercise Practices|Yoga and Muscle Relaxation Exercise Practices will be done two days a week for 10 weeks.
223854187|NCT02178020|DEVICE|knee arthroplasty, standard polyethylene|total knee replacement follow-up; clinical and radiographic; revision rate
223854188|NCT02178020|DEVICE|knee arthroplasty, XLP polyethylene|total knee arthroplasty with highly crosslinked polyethylene tibial liner
223854189|NCT03018119|OTHER|Survey|
223854190|NCT05599399|DIETARY_SUPPLEMENT|Gum acacia|25 grams of gum acacia powder is administered on daily-basis
223854191|NCT06221618|OTHER|High-frequency carotid arteries ultrasound, CCTA, Cranial MRA|CCTA and carotid high-frequency ultrasound for all patients in the coronary heart disease cohort. Cranial MRA and carotid high-frequency ultrasound for all people in the stroke cohort.Carotid high-frequency ultrasound for all patients in the normal control group.All patients were treated optimally according to guidelines
223854192|NCT00739102|DEVICE|S.M.A.R.T. ® Stent|The Cordis S.M.A.R.T.® Nitinol Stent System is a self-expandable, crush recoverable stent with a diameter larger than that of the arterial lumen. The stent is indicated for use in a vessel with a diameter 1 to 2 mm smaller than the nominal stent diameter. This stent will open to the diameter of the artery and will continue to apply expanding force on the artery.
223854193|NCT03147456|DIETARY_SUPPLEMENT|(Cubitan Protein, Nutricia, Netherlands).|Supplement contains (per 200 ml can) 20 g of protein, 250Kacl plus different micronutrient and macronutrient.
223854194|NCT03147456|DIETARY_SUPPLEMENT|(preOp, Nutricia, Netherlands).|contains per can (200 ml), 0g protein, fat free, 100 kcal and enriched with electrolytes
223854195|NCT03244696|BEHAVIORAL|Step Tracking|The step tracking intervention is designed to increase physical activity through the use of self-monitoring and brief motivational materials. The motivational materials will be delivered at various points during the intervention. Participants are not required to access and read these materials, however, the hope is these materials will aid in study and goal adherence. Engagement in the intervention will be tracked by the experimenters using the behavioral data gathered by the tracker.
223854196|NCT03244696|BEHAVIORAL|Water Tracking|The water tracking intervention is designed to increase water intake, to a healthy level, through the use of self-monitoring and brief motivational materials.The motivational materials will be delivered at various points during the intervention. Participants are not required to access and read these materials, however, the hope is these materials will aid in study and goal adherence. Engagement in the intervention will be tracked by the experimenters using the behavioral data gathered by the tracker.
223854197|NCT01391442|BIOLOGICAL|blood and urine samples|58 ml of blood 120 ml of urine
223854198|NCT01391442|GENETIC|blood sample|11 ml of blood
223854199|NCT01391442|OTHER|cardiovascular assessment|echography, echodoppler, measure of blood pressure...
223854200|NCT01391442|OTHER|Stanislas ancillary study : MRI examination with GRICS technique|
223854201|NCT03285685|DEVICE|active tDCS|Duration: 20 minutes; Intensity: 2 mA; Placement: anodal over left M1 and cathodal over supraorbital contralateral area
223854202|NCT03285685|DEVICE|active tDCS|Duration: 20 minutes; Intensity: 2 mA; Placement: anodal over left DLPFC and cathodal over supraorbital contralateral area.
223854203|NCT03285685|DEVICE|sham tDCS|The procedure is the same as for active tDCS anodal over left M1 and cathodal over supraorbital contralateral area, but the in the placebo tDCS the stimulation is non-active / sham.
223854204|NCT02108743|DRUG|Albuterol.|2.5 mg of albuterol inhaled via jet nebulizer 15 minutes prior to symptom-limited maximal CPET.
223854205|NCT02108743|DRUG|Normal saline placebo|Placebo inhaled via jet nebulizer 15 minutes prior to symptom-limited maximal CPET.
223854206|NCT02457702|OTHER|Orally administered labeled glycerol|Oral administration of labeled glycerol
223854207|NCT05318885|OTHER|A Randomized Controlled Study|For forward-leaning position, the child is first placed on a suitable chair with a soft pillow on their knees. The child will remain in the same position for the duration of the nebulization, and the pillow provides support, ensuring the child does not get tired. The child leans forward at an angle of 45°, places their arms on the pillow as shown in the figure and holds their head upright with their eyes facing forward (slight hyperextension). The upright head position of the child prevents spillage of the liquid medicine from the nebulizer chamber.
223854208|NCT01331824|DRUG|Amrubicin|Patients will receive 35 mg/m2/day of amrubicin intravenously for 3 consecutive days as the initial dose starting on Day 1 of a 21-day cycle for up to 6 cycles
223854209|NCT00868595|BIOLOGICAL|BPX-101|Vaccine
223854210|NCT00868595|DRUG|AP1903|Activating agent, infusion
223854211|NCT03617653|DIAGNOSTIC_TEST|Group A|Refer to detailed study Description
223854212|NCT04455399|DEVICE|Intravitreal injection guide (Malosa)|A single use, multifunction device will be used to push away an eyelid to expose injection site, indicate injection point about 4 millimeters from surgical limbus, and directs needle perpendicular to the ocular surface while limiting intraocular needle incursion
223854213|NCT04455399|DEVICE|Dual Blade Eyelid Speculum|A conventional dual blade eyelid speculum will be use to push away eyelids. A Castroviejo surgical caliper will be used to mark the injection site.
223854214|NCT03196167|DRUG|Sugammadex|The administration of the study and placebo compounds will be performed by CTICU nurses who will receive the drugs in a blinded fashion from the departmental research pharmacy.
223854215|NCT03196167|OTHER|Placebo|The administration of the study and placebo compounds will be performed by CTICU nurses who will receive the drugs in a blinded fashion from the departmental research pharmacy.
223854216|NCT01091454|DRUG|brostallicin|Given IV
223854217|NCT01091454|DRUG|cisplatin|Given IV
223854218|NCT04043767|PROCEDURE|Measurements of thyromental distances, hyomental distances and neck circumferences|thyromental distances, hyomental distances and neck circumferences using measurement tape by two independent investigators.
223854219|NCT01204528|DRUG|Zemplar|Vitamin D receptor activator (VDRA)
223854220|NCT02772315|OTHER|omics|diagnostic procedures applying omics results
223854221|NCT00271167|DRUG|INO-1001|
223854222|NCT03284905|DIETARY_SUPPLEMENT|Probiotic supplement|Capsule containing freeze dried probiotic bacteria together with maize starch
223854223|NCT03284905|DIETARY_SUPPLEMENT|Placebo supplement|Capsule containing maize starch
223854224|NCT02139748|PROCEDURE|Dental Implant & ADM|A dental implant will be placed and the buccal soft tissue will be grafted using an acellular dermal matrix allograft.
223854225|NCT02139748|PROCEDURE|Dental Implant & ADM & bone xenograft|A dental implant will be placed along with a buccal acellular dermal matrix allograft which will cover a bone xenograft.
224265953|NCT04241341|OTHER|quality-of-life questionnaires|Four validated patient reported outcome measures (PROMs): the Upper Limb Lymphedema-27 (ULL-27), the Quality of Life Measure for Limb Lymphedema (LYMQOL), the Center for Epidemiologic Studies Depression Scale-Revised (CESD-R), and the Beck Anxiety Inventory (BAI). Study participants will undergo standard lymphedema measurements and quality-of-life questionnaires at baseline before ALND and postoperatively at 6 weeks (+/- 30 days) and at 6, 12, 18, and 24 months (+/- 30 days). If patients are unable to complete their questionnaires at the time of their in-office visit, a link to the questionnaires in REDCap will be emailed to them.
223854226|NCT01158196|DEVICE|infra-red diode laser|"laser treatment of scar after keloid excision~laser treatment of surgery scar"
223854227|NCT03179787|DRUG|Aripiprazole oral product|oral administration of aripiprazole
223854228|NCT01510912|DRUG|Diclofenac|35 mg bid or tid Capsules
223854229|NCT03849495|DRUG|CKD-370|Test drug
223854230|NCT03849495|DRUG|D745|Reference drug
223854231|NCT05377151|OTHER|Mobile application|"Nutrition intervention using either mHealth interventions or conventional methods will be carried out among pregnant women).~Subjects will be allocated into three groups, namely, two interventions group which are:~Group 1: mHealth intervention group (98 subjects)~Group 2: mHealth intervention group + dietitian consultation (98 subjects)~Group 3: control group (98 subjects)"
223854232|NCT01958541|BEHAVIORAL|Sleep Intervention I|Insomnia-focused behavioral treatment (4 sessions).
223854233|NCT01958541|BEHAVIORAL|Sleep Intervention II|Insomnia-focused behavioral treatment (4 sessions).
223854234|NCT04778124|PROCEDURE|Hemorrhoidal Arterial Ligation (HAL) and Recto Anal Repair (RAR)|All patients underwent hemorrhoidal artery ligation on multiple sites according to pulsations detected by the doppler transducer and mucopexy (RAR) at the sites of prolapse.
224265954|NCT04241341|OTHER|measured by arm volume|Bilateral arm volumes will be measured with sequential circumferential measurements with the truncated cone formula. If a patient cannot return to Manhattan for these assessments but is seen by a lymphedema therapist in a regional location or at an institution outside of MSK as part of their routine cancer treatment, this data can be used in the final analysis
224265955|NCT03815409|OTHER|Treadmill with partial weight unload|10-minute treadmill walk with a support corresponding to 20% of his/her own weight, followed by a 5-minute rest and a second 10-minute session on the treadmill with a support corresponding to 10% of his/her own weight. In the initial treadmill session, the starting speed of the treadmill was set to 0.5 km/h, subsequent increments of 0.5 km/h per minute were added to reach the maximum speed that was comfortably tolerated by the patient. This latter was used for the entire training period.
224265956|NCT03815409|OTHER|Traditional PT rehabilitation treatment|Every 40-minute treatment session consisted in isotonic and isometric exercises for the major muscles of the limbs and trunk including cardiovascular warm-up exercises (5 minutes), muscle stretching exercises (10 minutes), muscle stretching exercises for functional purposes (10 minutes), balance training exercises (10 minutes), relaxation exercises (5 minutes)
224265957|NCT06043375|DIETARY_SUPPLEMENT|Licorice Root Powder Capsule|Fresh licorice root will be obtained from local market of Lahore. The root will be washed and dried at room temperature. Then it will be converted into powder using grinder. After sieving the ground powder, it will be filled in capsules. One capsule will contain 1000mg of powder. Participants in experimental group will be instructed to consume one capsule per day.
224265958|NCT01182519|BEHAVIORAL|questionnaire, blood draw and urine sample|Patients will be asked to participate on a single day. After study registration they will be asked to complete the questionnaire. All participants will complete a questionnaire detailing tobacco and NSAID exposure, as well as detailing any other inflammatory conditions of the lung. Then the patient will give a single blood sample (up to 3 tubes) and a single urine sample.
224265959|NCT03121079|DRUG|Interferon-alpha|patients in Interferon-alpha group will receive Interferon-alpha injection since the third month after transplantation for six months.
224265960|NCT06819735|DRUG|DT-7012|Intravenous infusion
224265961|NCT06819735|DRUG|Immune checkpoint inhibitor|Intravenous infusion
224265962|NCT06395883|DRUG|Glucocorticoid Effect|Patients with or without glucocorticoid treatment will be observed regarding the level of bone turnover markers (P1NP and CTX1) every 4 weeks til 6 months after the last glucocorticoid dose.
224265963|NCT02064673|DRUG|Curcumin|Curcumin or placebo 500mg by mouth twice a day for 6 months
224265964|NCT02064673|DRUG|placebo|placebo orally twice a day
224265965|NCT06002126|DIAGNOSTIC_TEST|Xpert HPV|The Cepheid Xpert HPV Assay (Xpert HPV) is a qualitative, real-time polymerase chain reaction (PCR) assay for the detection of hrHPV DNA. The assay is formatted in a single-use, Xpert HPV test cartridge and is run on the Cepheid Xpert® System, a multi-analyte, random access, molecular-diagnostic platform ranging in capacity from 1 to 80 test processing modules. Importantly, a single hrHPV DNA test can be completed in one hour, permitting same-day screening and diagnosis (e.g. colposcopy) or treatment (e.g. cryotherapy), reducing the potential for loss to follow-up in lower-resource settings. It uses liquid-based cytologic media and yields five separate results or channels: HPV 16, HPV 18/45, HPV 31/33/35/52/58, HPV 51/59, HPV 39/68/56/66 all with a corresponding cycle threshold.
224265966|NCT06002126|DIAGNOSTIC_TEST|QIAsure Methylation Test|The Qiagen QIAsure assay is a multiplex real-time PCR test that amplifies the methylated promoter regions of the tumor suppressor genes, FAM19A4 and has-mir124-2, as well as a methylation-unspecific fragment of the ACTB reference gene. Hypermethylation of the host genes FAM19A4 and has-mir124-2 has been shown to detect high-grade cervical lesions and cancer.
224265967|NCT06217601|BEHAVIORAL|Digital intervention through Tablet|Web-based multi-domain lifestyle training intervention will be conducted to promoted and focus three lifestyles: nutritional advice, exercise and cognitive training; chat communication with research team, and personalized agenda on daily activities and an information library.
224265968|NCT04509596|DRUG|DZD1516 mono therapy in Part A, DZD1516 in combination with trastuzumab and/or capecitabine in Part B, DZD1516 in combination with T-DM1 in Part C|"Part A is twice daily (except Cycle 0) oral dosing of DZD1516, starting from 50 mg. If tolerated, dose will be escalated in subsequent cohorts until MTD.~Part B is twice daily oral dosing of DZD1516 in combination with capecitabine 1000 mg/m2 orally twice daily on Days 1-14 of each 21-day cycle or with trastuzumab 8 mg/kg intravenously (IV) on Day 1 of Cycle 1, followed by 6 mg/kg on Day 1 of each 21-day cycle.~Part C is twice daily oral dosing of DZD1516 in combination with T-DM1 3.6 mg/kg intravenously (IV) once every 21 days"
224265969|NCT00834964|DRUG|Venlafaxine 25 mg Tablets|1 x 25 mg, single-dose fasting
224265970|NCT00834964|DRUG|Effexor® 25 mg Tablets|1 x 25 mg, single-dose fasting
224265971|NCT05095181|GENETIC|SNP analysis of the DNA|SNP analysis of the DNA obtained from peripheral blood sample
224265972|NCT04101396|DIETARY_SUPPLEMENT|diabetic diet|Patients with gestational diabetes will be seen by the dietitian to be taught diet modification
224265973|NCT01147939|DRUG|Elacytarabine|Elacytarabine 2000 mg/m2/d administered as a continuous intravenous infusion (CIV) in a d 1-5 q3w cycle.
224265974|NCT01147939|DRUG|Investigator's Choice|E.g. cytarabine single agent/combinations, hypomethylating agents, best supportive care (BSC)
224265975|NCT05937841|DRUG|Compound 21|"AT2R sensitivity: compound 21, and compound 21+ L-NAME (nitric oxide synthase inhibitor) are locally and acutely delivered to the cutaneous microvasculature to assess AT2R-mediated dilation and role of nitric oxide in this response~Local heating: compound 21 is locally and acutely delivered to the cutaneous microvasculature during local heating of the skin to assess endothelium-dependent dilation, L-NAME is added to assess nitric oxide-dependent dilation during this response"
224265976|NCT02440607|OTHER|Electronic Cognitive Aid|
224265977|NCT02440607|OTHER|Static Cognitive Aid|
224265978|NCT02722239|DRUG|Xigduo XR|a single oral dose of modified release fixed dose combination film-coated tablet consisting of 10 mg dapagliflozin IR and 1000 mg metformin hydrochloride extended release
224265979|NCT02722239|DRUG|Metformin ER (Glucophage® long)|co-administration of a single oral dose of 10 mg dapagliflozin film-coated tablet (Forxiga™) and two tablets 500 mg metformin hydrochloride extended release tablets (Glucophage® long).
224265980|NCT02722239|DRUG|Dapagliflozin (Forxiga)|co-administration of a single oral dose of 10 mg dapagliflozin film-coated tablet (Forxiga™) and two tablets 500 mg metformin hydrochloride extended release tablets (Glucophage® long).
223854235|NCT04778124|PROCEDURE|Excision of thrombosed hemorrhoid / Hemorrhoidectomy /|One patient with mucosal necrosis of the hemorrhoidal cushion postoperatively underwent hemorrhoidectomy with excision of necrotic tissues.Furthermore, 2 patients who presented with hemorrhoidal thrombosis postoperatively underwent emergency surgery with supplementary excision of the thrombosed hemorrhoid. In addition, 9 patients who experienced recurrence of hemorrhoidal disease after undergoing HAL-RAR surgery, were treated with hemorrhoidectomy according to the Milligan-Morgan procedure.
223854236|NCT05883475|OTHER|Disabilities of the Arm, Shoulder, and Hand Questionnaire|Upper limb function was assessed with the Turkish version of the Disabilities of the Arm, Shoulder, and Hand Questionnaire (DASH). The questionnaire DASH is a self-report instrument with 30 items. The total score ranges from 0 to 100, with higher scores indicating a worse upper limb function.
223854237|NCT05883475|OTHER|Arm Motor Ability Test|The test assesses hemiparetic upper extremity functional tasks.The increase in the scores of both subparameters of the scale, which is composed of the parameters of functional ability and quality of movement, indicates an improvement in the motor functions of the upper limbs.
223854238|NCT05883475|OTHER|Nine Hole Peg Test|Fine motor skills of the upper extremities were assessed.The patient was asked to insert the nine sticks in the box on the table into the holes in the other box as quickly as possible and then remove them immediately. As time increases, fine motor skills of the upper extremities decrease
223854239|NCT05883475|OTHER|Pittsburg Sleep Quality Index|"Sleep quality was assessed using the this test.This scale, which provides a quantitative measure of sleep quality, is a 19-item self-report scale. The total score greater than 5 indicates poor sleep quality."
223854240|NCT05883475|OTHER|Functional Independence Measure|This test assessed functional capacity in activities of daily living.The higher a person's score, the higher the level of independence.
223854241|NCT02318381|PROCEDURE|Dissection of the superior transverse scapular ligament|After treatment of the rotator cuff tear, the arthroscopic procedure will also proceed with the dissection of the superior transverse scapular ligament, in order to release pressure from the suprascapular nerve.
223854242|NCT05904535|OTHER|Cerbrospinal fluid sampling.|Routine sampling of cerebrospinal fluid from the proximal external ventricular drain port.
223854243|NCT05216692|PROCEDURE|La Tour Hospital Foot Strengthening Protocol|"First exercise : NMES forward lean doming. Doming exercise assisted by NMES placed on the IFM. 8 sec of contraction (6 sec rest) moving the trunk forward. 12 repetitions, 3 sets. Progressive increase of the intensity of NEMS during 4 weeks and increase of body load while decreasing the number of repetitions.~Second exercise : MTP joint flexion. Isometric MTP joint flexion contractions. 4 contractions of 5 sec (10 sec rest), 3 sets. Progressive increase of the number of MVIC during 4 weeks and of increase body load while keeping the same intensity.~Third exercise : Foot-ankle rebound. Multiple jumps with only plantar flexion. Keeping the knee stiff and straight and pushing off the ground with only ankle and MTP plantar flexion by a forefoot contact with the ground. 10 seconds of jump (1 min of rest) during 5 sets. Progressive increase of body load while keeping the same intensity."
223854244|NCT05216692|PROCEDURE|Standard Literature Foot Strengthening Protocol|"During the 1st week, the participants will perform the Short foot exercise (SFE) during 3 series of 10 repetitions of 5 seconds of contractions in sitting position. 1 minute of rest will be give between series.~During the 2nd week, the participants will perform the SFE during 3 series of 15 repetitions of 5 seconds of contractions in sitting position. 1 minute of rest will be give between series.~During the 3rd week, the participants will perform the SFE during 3 series of 15 repetitions of 5 seconds of contractions in standing bipedal position. 1 minute of rest will be give between series.~During the 4th week, the participants will perform the SFE during 3 series of 15 repetitions of 5 seconds of contractions in standing unipedal position. 1 minute of rest will be give between series.~The progression of the exercise during the protocol will be based on passing from a sitting position to a unipedal standing position."
223854245|NCT04143919|DIAGNOSTIC_TEST|NYHA assessment|The New York Heart Association (NYHA) functional classification of HF
223854246|NCT04143919|PROCEDURE|Serum NT-proBNP concentration|Subjects with NYHA score ≥ II will undergo a rapid, on site serum NT-proBNP test on the same day of the visit. Roche CARDIAC proBNP+ test, using the Cobas h 232 device, is a quantitative immunological test for the determination of NT-proBNP in heparinized venous blood.
223854247|NCT04143919|DIAGNOSTIC_TEST|Transthoracic Ecocardiogram|Subjects with a serum NT-proBNP result of ≥ 125 pg/mL at Visit 1 will be referred to a study cardiologist for a transthoracic echocardiogram to assess LVEF and relevant structural heart disease
223854248|NCT05823350|OTHER|Abdominal massage|Abdominal massage after colonoscopy
224265981|NCT04404439|DRUG|Nortriptyline + topiramate|Treatment group 1
224265982|NCT04404439|DRUG|Verapamil + paroxetine|Treatment group 2
224265983|NCT04404439|OTHER|Placebo|Placebo comparator
224265984|NCT06356636|BEHAVIORAL|Financial Inclusion Improves Sanitation and Health|This innovative model engages transformative partnerships which include four key stakeholders (communities, communities, governments, entrepreneurs, and financiers) to improve sanitation services and supply value chains. The work is two-sided: to create demand for improved sanitation facilities in communities while facilitating microcredit access for people and sanitation businesses on the supply side.
224265985|NCT05411276|DRUG|Pyrotinib maleate|Pyrotinib maleate tablets 400 mg/day, oral within 30 minutes after breakfast, every 4 weeks is a cycle
224265986|NCT01899352|PROCEDURE|Tracheostomy|Percutaneous and surgical tracheostomies will be performed with the procedure currently available in clinical practice.
224265987|NCT01664767|OTHER|Sulfur Thermal water|
224265988|NCT01664767|OTHER|Placebo|
224265989|NCT00081653|DRUG|ibandronate [Bonviva/Boniva]|150mg po monthly for 3 years
224265990|NCT00081653|DRUG|ibandronate [Bonviva/Boniva]|100mg po monthly for 3 years
224265991|NCT00000653|DRUG|Zalcitabine|
224265992|NCT06371703|RADIATION|automated system in reducing radiation exposure|evaluate the effectiveness of the automated system in reducing radiation exposure for radiographers involved in PET/CT procedures.
224265993|NCT01876992|DRUG|Metformin|
224265994|NCT04925791|DIAGNOSTIC_TEST|standardized pre-conditioning treatment|3 rounds of 5 minutes of full occlusion alternating with 5 minutes of reperfusion while seated.
224265995|NCT04925791|DIAGNOSTIC_TEST|Partial occlusion|3 rounds of 5 minutes of partial occlusion alternating with 5 minutes of reperfusion while seated.
223854249|NCT05999864|OTHER|Rehabilitation|Proprioceptive neuromuscular facilitation exercise will be given to the study group as previously described (Gstoettner et al., 2011). These applications will be applied to the patients for 8 weeks, 2 days a week in the clinical environment after the initial evaluation. In addition, both groups will be told that they can contact the researcher when requested.
223854250|NCT02030028|DRUG|ACTHAR gel|Subjects are given the ACTHAR gel subcutaneously twice per week for 12 weeks.
223854251|NCT05184361|BEHAVIORAL|Intermittent energy restriction (IER)|"Both groups will be accompanied by a registered dietitian in order to provide an individual and personalized diet plan that will suppress the respective daily requirements for each phase. Macronutrient distribution will be the following: 35% protein, 35% carbohydrate and 30% fat.~Daily energy requirements (DER) will be calculated by multiplying measured RMR (through indirect calorimetry) by physical activity level (PAL), assessed by accelerometry.~In order to achieve a neutral EB, 100% of their daily energy requirements (DER) will be prescribed for each participant. For both groups, an energy restriction of 33% of one's DER will be created. The IER group will alternate between 2-weeks in energy restriction (67% DER) and 1-week in neutral EB (100% DER), in a total of 23-weeks.~The IER group will alternate between 2-weeks in energy restriction (67% DER) and 1-week in neutral EB (100% DER), in a total of 23-weeks."
223854252|NCT05184361|BEHAVIORAL|Continuous energy restriction (CER)|A dietary plan comprising 67% of DER will be prescribed to the CER group. Participants will be asked to follow this plan in a total of 16-weeks, without interruptions.
223854253|NCT01304849|DRUG|Escalated BEACOPP|"Escalated BEACOPP chemotherapy will be delivered for those patients who are interim PET CT positive after 2 cycles of ABVD chemotherapy. The patients will receive 2-4 cycles of Escalated BEACOPP once in 3 weeks. The cycles will be delivered as follows:~Bleomycin 10mg/m2 IV in day 8, Etoposide 200mg/m2 Day 1 to Day 3, Adriamycin 35mg/m2 on Day 1 IV, Cyclophosphamide 1200mg/m2 on Day 1 IV, Vincristine 1.4mg/m2 on Day 8 IV, Cap Procarbazine 100mg/m2 Day 1 to Day 7 PO, T Prednisolone 40mg D1-D7 of a 21 day cycle. With Inj Mesna 400mg/m2 0, 4 and 8 hours on the day of Cyclophosphamide Inj G-CSF will be started routinely from Day 9 till recovery of Absolute neutrophil counts ≥5000/cmm or Total WBC counts≥ 8000/cmm"
223854254|NCT04491032|PROCEDURE|Caudal anesthesia|Caudal epidural injection will be performed after induction of general anesthesia.
223854255|NCT01970358|BIOLOGICAL|Poly-ICLC|
223854256|NCT01970358|BIOLOGICAL|Peptides|
223854257|NCT03935308|RADIATION|MR guided Linear Accelerator|The aim is to perform treatment planning to compute the highest feasible simultaneous boosting dose to the intraprostatic lesion while respecting normal tissue dose constraints. Patients will be treated with MR-guided localization and adaptive planning techniques.
223854258|NCT03643029|DEVICE|Video-laryngoscopy following SAD insertion|Following insertion of a supraglottic airway device (SAD), the placement and performance tests are carried out. If the tests are successful, a video-laryngoscopy will be performed to confirm the placement of the SAD in the hypopharynx.
223854259|NCT04800224|DRUG|Standardized Brazilian Green Propolis Extract|900mg/day of Standardized Brazilian Green Propolis Extract for 10 days.
223854260|NCT04800224|DRUG|Placebo|900mg/day of Placebo for 10 days.
223854261|NCT01371201|DRUG|Sunitinib|sunitinib 37.5 mg per day
223854262|NCT01371201|DRUG|Placebo|Placebo 37.5 mg per day
223854263|NCT02122848|DEVICE|BiLevel|The intervention will be performed using BiLevel ventilation mode with EPAP=10 cmH2O and a IPAP which manages 6-8ml/kg tidal volume.
223854264|NCT06353958|DRUG|MiSaver|"MiSaver vials was thawed using a thermostat-controlled mini bath, drawn into a 20ml syringe, and diluted with normal saline and intravenous infused following standard operating procedures, consecutively, until reasching the dosage.~Patients were premedicated with intravenous antihistamines (such as diphenhydramine) and corticosteroids (such as hydrocortisone) 30-60 minutes before the stem cell infusion. Any unused solution was discarded, and the total volume of injected solution was adjusted to accommodate the total daily fluid volume administered."
223854265|NCT02118935|OTHER|Previously marketed cow's mlik-based infant formula|
223854266|NCT02118935|OTHER|Marketed cow's milk-based infant formula with prebiotics|
223854267|NCT03970811|PROCEDURE|Immediate Implants|dental implants are immediately placed after tooth extraction
224265996|NCT04911218|DEVICE|GlideSheath Slender 5Fr arterial sheath|Placement of GlideSheath Slender 5Fr arterial sheath for coronary angiography through the distal radial artery (anatomical snuffbox).
224265997|NCT04911218|DEVICE|Conventional 5Fr arterial sheath|Placement of conventional 5Fr arterial sheath for coronary angiography through the distal radial artery (anatomical snuffbox).
224265998|NCT04584138|BEHAVIORAL|Study of eye movements|The assessment of eye movement during autobiographical retrieval (i.e., retrieval of personal memories) in patients with Alzheimer's Disease.
224265999|NCT02582190|DRUG|Colchicine group|antiarrhythmic therapy plus colchicine \& antiarrhythmic therapy alone.
224266000|NCT02694536|DRUG|Erlotinib|Participants will receive erlotinib tablets as 100 milligrams (mg) orally (PO) once daily.
224266001|NCT02694536|DRUG|Gemcitabine|Participants will receive gemcitabine as 1000 milligrams per meter-squared (mg/m\^2) via intravenous (IV) infusion on Days 1, 8, 15, 22, 29, 36, and 43 of the first 8-week cycle, and thereafter on Days 1, 8, and 15 of every 4-week cycle.
224266002|NCT05869136|PROCEDURE|microneedling and hyaluronic acid for increasing gingival thickness in thin gingival phenotype|"All the participants will undergo phase-I therapy. Oral hygiene instructions will be imparted and will be reinforced at each appointment.~Local anaesthesia in the form of xylocaine spray will be administered.~Hyaluronic acid:~HA will be injected in the attached gingiva and MN will be carried out 1mm below the gingival margin on the keratinized gingiva of the tooth to be treated with thirty-gauge (0.255 mm) lancet needles in the test group."
224266003|NCT05869136|PROCEDURE|microneedling for increasing gingival thickness in thin gingival phenotype|"All the participants will undergo phase-I therapy. Oral hygiene instructions will be imparted and will be reinforced at each appointment.~Local anaesthesia in the form of xylocaine spray will be administered and microneedling alone will be performed in control group"
224266004|NCT03368209|DEVICE|WM3.4|Investigational Medical Device collecting spectral raman data from tissue.
224266005|NCT06307288|DRUG|minocycline|The patient was treated with oral minocycline, 50mg each time, once a day, for 12 weeks.
223854268|NCT03970811|PROCEDURE|temporary restoration|temporary restoration will be placed immediately after implant placement
223854269|NCT03970811|PROCEDURE|final restoration|final restoration (loading) will be placed 3 months postsurgical
223854270|NCT03778593|DRUG|5-Fluorouracil|D1-2 5-Fluorouracil 1000 mg/m2 + 5DW 1L continuous IV over 23 hours q 2 weeks
223854271|NCT03778593|DRUG|Leucovorin|D1 Leucovorin 400 mg/m2 + 5DW 200 ml mix IV over 2 hours q 2 weeks
223854272|NCT03778593|DRUG|Irinotecan|D1 Irinotecan 135 mg/m2 + 5DW 500 mL mix IV over 2 hours (concurrent with the leucovorin infusion) q 2weeks
223854273|NCT03778593|DRUG|Oxaliplatin|D1 Oxaliplatin 65 mg/m2 + 5DW 200 mL mix IV over 2 hours q 2 weeks
223854274|NCT03778593|DRUG|5% dextrose water|mix fluid with 5-FU, leucovorin, irinotecan, and oxaliplatin
223854275|NCT04470102|PROCEDURE|mitral valve repair by edge-to-edge technique|transaortic access for mitral valve repair edge-to-edge
223854276|NCT04470102|PROCEDURE|Septal myectomy|isolated extended septal myectomy
223854277|NCT03359031|OTHER|Patient education|This group will be given a pamphlet on pain control, narcotic medication, and compartment syndrome including its pathophysiology, signs/symptoms, and treatment.
223854278|NCT04588285|DRUG|Ambroxol|Oral ambroxol medication (60 mg) from day 1 to study end (at 60 mg TID (day 1-7), 120 mg TID (day 8- 14), 315 mg BID (day 15-21), 315 mg TID (day 22-28) and 420 mg TID (day 29-550)
223854279|NCT04588285|DRUG|Placebo|Oral placebo medication (60 mg) from day 1 to study end (at 60 mg TID (day 1-7), 120 mg TID (day 8- 14), 315 mg BID (day 15-21), 315 mg TID (day 22-28) and 420 mg TID (day 29-550)
223854280|NCT05155371|OTHER|Titration of Optimal Positive End-expiratory Pressure|Titration of Optimal Positive End-expiratory Pressure with two different methods
223854281|NCT03720990|DRUG|Cholic Acid|Participants will be treated with cholic acid for 8 weeks
223854282|NCT03838796|DRUG|lenvatinib|for patients \<60kg, lenvatinib 8mg bid po for patients \>60kg, lenvatinib 12mg bid po
223854283|NCT03838796|PROCEDURE|TACE|The patient underwent transfemoral hepatic artery angiography one month after surgery to observe whether there was tumor staining in the liver. If there was suspicious tumor staining, micro-catheter was superselected to the tumor blood vessel, the embolization agents and chemotherapy drugs were injected. If there was no tumor staining, a small amount of embolization agents were slowly injected into the artery.
223854284|NCT01517542|OTHER|Nutritional Counseling|2 groups: 1 with nutritional counseling and other with usual diet without nutritional counseling
223854285|NCT05550922|BEHAVIORAL|Healthcare Transition-Based Education|The goal is for asthmatic adolescents to take responsibility for their own disease, be prepared for transition to adult pulmonology services, increase their self-efficacy, and gain management skills as a result of health care transition education.
223854286|NCT01025583|DIETARY_SUPPLEMENT|hypotonic oral rehydration solution|30-50 ml/kg of ORS in 3-4 h for mild dehydration and with 50-100 ml/kg of ORS in 3-4 h for moderate dehydration, and to administer 10 ml/kg/die of ORS in a graduated glass or bottle for dehydration prevention until cessation of symptoms.
223854287|NCT01025583|DIETARY_SUPPLEMENT|Hypotonic oral rehydration solution with Zn and prebiotics|30-50 ml/kg of ORS in 3-4 h for mild dehydration and with 50-100 ml/kg of ORS in 3-4 h for moderate dehydration, and to administer 10 ml/kg/die of ORS in a graduated glass or bottle for dehydration prevention until cessation of symptoms.
223854288|NCT02794948|OTHER|Chinese medicine granules (HuYang Yang Kun Formula)|Take Chinese medicine granules (HuYang Yang Kun Formula), 1 sack every time,twice a day Take DHEA(dehydroepiandrosterone) placebo,1 capsule every time ,once a day. Treatment for 3 months Both Chinese Medicine formula granules and DHEA placebo were produced by Jiangyin Medical \&pharmaceutical limited company in Jiangsu province
223854289|NCT02794948|DIETARY_SUPPLEMENT|dehydroepiandrosterone|The DHEA( dehydroepiandrosterone)25mg,1 capsule every time once a day. Take Chinese medicine granules placebo , 1 sack every time,twice a day Treatment is 3 months. DHEA were produced by General Nutrition Center(GNC)company in America and The placebo granules of Chinese Medicine were produced by Jiangyin Medical \&pharmaceutical limited company in Jiangsu province.
223854290|NCT02721225|DIETARY_SUPPLEMENT|Fructooligosaccharide|"A prebiotics defined as selectively fermented ingredients that allow specific changes, both in the composition and/or activity in the gastrointestinal microbiota that confers benefits upon host well-being and health"
223854291|NCT02721225|DIETARY_SUPPLEMENT|Pocari-Sweat|Commercially used isotonic solution produced by Otsuka Pharmaceuticals Co. Ltd., Tokyo, Japan.
223854292|NCT04240730|PROCEDURE|Transvaginal natural orifice endoscopic surgery for endometrial cancer staging|Cases of extreme obese patients with early stage endometrial cancer who underwent v-NOTES
223854293|NCT00373555|PROCEDURE|Bronchoscopy|
223854294|NCT05280964|BEHAVIORAL|Better Together Physician Coaching|6 month, online group coaching program
223854295|NCT00087269|DRUG|erlotinib hydrochloride|Given orally
223854296|NCT00087269|PROCEDURE|therapeutic endoscopic surgery|Undergo surgical resection
223854297|NCT00087269|OTHER|laboratory biomarker analysis|Correlative studies
223854298|NCT05928364|PROCEDURE|Buccal mucosa for proximal ureter stricture|Patients with inclusion criteria of uretral stricture will be treated with open uretroplasty with buccal graft and omental wrapping
223854299|NCT02904707|OTHER|Questionary EQ-5D|In addition to the pain questionary that is filled filled as usual, the EQ-5D questionary will be distributed at the beginning of hospitalization and completed by each patient, and will evaluate the impact of painful ulcers in their daily lives.
223854300|NCT02869620|OTHER|Data collection|
223854301|NCT03563391|OTHER|New Infant Formula|New Infant Formula is a specialized, nutritionally complete, nutrient-dense infant formula specifically formulated for infants with growth failure.
223854302|NCT06630208|OTHER|Myofascial release|The experimental group will undergo a 5-day consecutive myofascial release treatment, administered as Osteopathic Manipulative Treatment (OMT), with each session lasting a maximum of 15 minutes. The treatment will consist of three phases targeting the entire mediastinum: Thoracic Inlet (Indirect) Myofascial Release, Rib Raising with continued stretch of the paraspinal muscles to the L2 vertebral level, and Soft Tissue Cervical Paraspinal Muscle Stretch with Suboccipital Muscle Release. Participants will be positioned in a supine posture to enhance diaphragmatic excursion, with each session following a fixed, prearranged sequence of these techniques.
223854303|NCT06630208|OTHER|Breathing exercises|Following the 3 phases of myofascial release, breathing exercises will be done for patients.
223854304|NCT06630208|DRUG|Pharmacological treatment|Patients will take pharmacological treatment prescribed by the cardiologist.
223854305|NCT02380742|DRUG|lidocaine-prilocaine cream|The patient will then be positioned in dorsal lithotomy position with the use of stirrups. Two mL of EMLA cream will be placed into the vagina and 2 mL will be spread on the perineum. The cream placed into the vagina will be introduced to the level of the pessary with the practitioners' finger. Once application is completed, a timer will be set for five minutes. After five minutes, the patient will again be placed into dorsal lithotomy position with the use of stirrups. The pessary will be removed per practitioners' usual practice. The patient will be asked to mark her pain score for at this point
223854306|NCT02380742|DRUG|Placebo cream|The patient will then be positioned in dorsal lithotomy position with the use of stirrups. Two mL of placebo cream will be placed into the vagina and 2 mL will be spread on the perineum. The cream placed into the vagina will be introduced to the level of the pessary with the practitioners' finger. Once application is completed, a timer will be set for five minutes. After five minutes, the patient will again be placed into dorsal lithotomy position with the use of stirrups. The pessary will be removed per practitioners' usual practice. The patient will be asked to mark her pain score for at this point
223854307|NCT06188962|BEHAVIORAL|CBT-informed school-based counselling|Knowledge Insight Tools (KIT) is a CBT-based model of one-to-one therapy for secondary school pupils who are struggling with low mood and/or anxiety. KIT incorporates the key features of CBT (e.g., agenda setting, formulation around maintenance cycles, inter-session work involving exposure and/or behavioural activation) but is delivered in a semi-structured way that meets the young person's needs and pace of learning. Whilst there is an emphasis on symptom reduction, the primary focus is on the young person's goals for living and co-producing an understanding of how symptoms can interfere with these goals. Practitioners are encouraged to incorporate different therapeutic tools and modalities that complement the young person's strengths and ways of learning, including non-verbal forms of expression like arts and crafts, music, and dance. By being flexible, person-led, goal-focused, and integrative, KIT was designed to suit the needs of secondary school students.
223854308|NCT01714557|DRUG|Piperacillin|4.0g q8h 3-5 days
223854309|NCT01714557|DRUG|Piperacillin-tazobactam combination product|4.5g q8h 3-5 days
223854310|NCT00580073|DRUG|FOLFOX4|oxaliplatin (85mg/m2 on days 1 and 15 of each cycle)+ 5FU Bolus (400mg/m2 on days 1, 2, 15, and 16 of each cycle) + 5FU CI (600mg/m2 on days 1, 2, 15, and 16 of each cycle) + Leucovorin (200mg/m2 on days 1, 2, 15, and 16 of each cycle)
223854311|NCT00580073|DRUG|Cetuximab|Cetuximab 400mg/m2 on day 1 only, 250mg/mr on days 8, 15, and 22 of each cycle.
223854312|NCT00424320|DRUG|Sodium bicarbonate|
223854313|NCT00778739|DRUG|CEFPROZIL FOR ORAL SUSPENSION USP 250 mg/ 5 mL|
223854314|NCT04740359|OTHER|Functional training|The therapy program was planned for 8 weeks and the sessions were performed in 45 minutes (min) for 3 days a week. The functional reach (forward-lateral-cross), trunk rotation exercises were performed in the sitting positions.(25min) Facilitation of trunk extension and elongation in the prone position (10 min). Thoracic mobilization on exercise ball (10min).
223854315|NCT04740359|OTHER|Routine training|The therapy program was planned for 8 weeks and the sessions were performed in 45 minutes (min) for 3 days a week. The strengthening exercises were applied on the mat (3x10 for the first 4 weeks and 3x15 repetition for the last 4 weeks). Eyes open-closed perturbation training was performed for trunk control in sitting and standing positions (10 min.).
223854316|NCT00203580|DRUG|Tinzaparin sodium|
223854317|NCT03887546|DEVICE|Inspiratory muscle trainer|The device incorporate a unidirectional valve independent of flow to guarantee constant resistance and included a specific pressure setting (in cm H2O).
223854318|NCT03887546|PROCEDURE|Respiratory exercise|Respiratory exercise program involving nasal breathing and maximum exhalation during 12 weeks, 5 days/week, 15 minutes/day.
223854319|NCT02930343|DRUG|Methotrexate|Methotrexate, a structural analogue of folic acid, can be administered orally or parenterally to treat a variety of rheumatic diseases
223854320|NCT02930343|DRUG|Leflunomide|Leflunomide inhibits pyrimidine synthesis, resulting in blockade of T-cell proliferation. Leflunomide is used in patients with moderate to severe active rheumatoid arthritis with early or late disease
223854321|NCT02930343|DRUG|Hydroxychloroquine|Hydroxychloroquine (HCQ) is a well-tolerated DMARD that is commonly used in combination therapy regimens for RA. HCQ is more commonly used than chloroquine.
223854322|NCT02930343|DRUG|Prednisolone|Low dose prednisolone (weeks 1-2: 7.5 mg/day, weeks 2-4: 5 mg/day, weeks 4-6: 5 mg on alternate day and then stop)
223854323|NCT02930343|DRUG|Folic Acid|Folic acid is to be given to all patients receiving methotrexate at a dose of 5 mg twice a week.
223854324|NCT02930343|DRUG|Sulfasalazine|5-aminosalicylic acid (5-ASA) is the active component of sulfasalazine; the specific mechanism of action of 5-ASA is unknown; however, it is thought that it modulates local chemical mediators of the inflammatory response, especially leukotrienes, and is also postulated to be a free radical scavenger or an inhibitor of tumor necrosis factor (TNF)
223854325|NCT05356923|RADIATION|68Gallium FAPI PET/MR scan|68Gallium FAPI PET/MR scan
223854326|NCT00449813|DRUG|Pantoprazole|40 mg Pantoprazole
223854327|NCT00424216|PROCEDURE|DC Polarization|
223854328|NCT04648436|OTHER|Early neurosurgical hematoma evacuation|Early neurosurgical hematoma evacuation (preferably within 2 hours)
223854329|NCT04648436|OTHER|Conservative treatment (best medical management)|Conservative treatment (best medical management) on the ICU or ward
223854330|NCT04096144|DRUG|Neuromuscular Blocking Agents|Neuromuscular agents will be used to block muscle function for the safety and efficiency of the procedure. At the procedure's conclusion, neuromusclar agents such as Neostigmine or Sugammadex will be used to reverse the neuromuscular reversal.
223854331|NCT00004367|PROCEDURE|Clinical vestibular tests|
223854332|NCT00516503|DRUG|baclofen/amitriptyline/ketamine gel|Applied topically
223854333|NCT00516503|OTHER|placebo|Applied topically
223854334|NCT01181180|DIETARY_SUPPLEMENT|water consumption|The effect of water consumption on postural stability of old adults (65 years old and over) will be measured using RCT study design
223854335|NCT01552304|OTHER|Oxygen therapy|Besides perioperative routine care provided by anesthesiologists and surgeons, patients will receive postoperative oxygen supplementation with nasal prolong at 3 liters/min during the first 3 nights after surgery.
223854336|NCT01552304|OTHER|Control group|
223854337|NCT05139264|OTHER|Observational|Observation of diet, physical activity, sleep and interstitial glucose
223854338|NCT02305082|OTHER|Fast-track group|Enhanced recovery after surgery pathway. Postoperatively, a set of well-defined discharge criteria will be assessed daily at 9:00 and 15:00, as well as pain, nausea, time to flatus, saturation and drain production.
223854339|NCT02535624|PROCEDURE|PACKING|By retroperitoneal access the space in front of the pelvic fracture is compressed with surgical towels, which stops effectively venous bleeding
223854340|NCT02535624|PROCEDURE|ANGIO|Using en endovascular approach, bleeding arteries are identified and clotted using embolizing agents, or coils.
223854341|NCT00024531|DRUG|Atorvastatin calcium|
223854342|NCT00917358|DRUG|Pegylated interferon alfa-2a|Pegylated interferon alfa-2a 135 ug/week for 24 weeks
223854343|NCT04881318|OTHER|Waist-High Compression Tights|Waist-high compression tights providing 15-40 mmHg of pressure.
223854344|NCT04881318|OTHER|Abdominal Compression Garments|Abdominal compression garment compressing the abdomen, buttocks, and upper thighs.
223854345|NCT04881318|DRUG|Medications that modulate heart rate and blood pressure|Medications that modulate heart rate and blood pressure that participants regularly take. These medications include beta-blockers, midodrine, ivabradine and stimulants.
224266006|NCT06307288|DRUG|tranilast|The patient was treated with oral tranilast, 0.1g each time, three times a day, for 12 weeks.
224266007|NCT05912335|DRUG|Topical anesthetic|The topical anesthetic, or topical formulation, was applied to the palatal mucosa for 2 minutes.
224266008|NCT00470379|DRUG|resiquimod|Escalating the dose of resiquimod applied to a fixed area of skin followed by application of topical NY-ESO-1b.
224266009|NCT04852133|OTHER|Burn subjects|see eligibility criteria
224266010|NCT03515473|DEVICE|cochlear implant|cochlear implant surgery
224266011|NCT00235560|DRUG|rapamycin|sirolimus
224266012|NCT00325182|DRUG|Levetiracetam|
224266013|NCT00325182|OTHER|Historical controls|
224266014|NCT04199494|OTHER|Antibiotic Stewardship Program|The patient do the routinely preoperative lab tests, including the rectal swab (RS). The Antibiotic Stewardship Program (ASP) has been shown to effectively reduce unnecessary antibiotic use and optimize the treatment of infectious diseases. To be successful, multiple aspects should be considered in the ASP. Initially, the infection control specialists will follow the routine activity of each department in order to define what could immediately be improved. Internal antibiotic prophylaxis and therapy guidelines will be defined and shared between groups. The RS, collected at the preoperative testing, is evaluated by the infection control specialist. In case of identification of MDR bacteria, each patient will receive a tailored AP based on the antibiograms of the RS. In any case, the infection control specialist will choose the best solution for the patient avoiding the key antibiotics
224266015|NCT01426360|OTHER|control dentifrice|use the dentifrice to brush teeth twice a day for one minute for 3 days
224266016|NCT01426360|OTHER|strontium chloride/potassium nitrate dentifrice|use the dentifrice to brush teeth twice daily for 3 days
224266017|NCT00529191|DRUG|Atorvastatin|Pill, initially at 10 mg, then after 4 weeks, 20 mg Once daily for a total of 12 months
224266018|NCT00529191|OTHER|Placebo|One out of three subjects will receive a placebo.
224266019|NCT01911429|DRUG|Lurasidone 40 mg|Lurasidone 40 mg once daily
224266020|NCT01911429|DRUG|Lurasidone 80 mg|Lurasidone 80 mg once daily
224266021|NCT01911429|DRUG|Placebo 40 or 80 mg|Placebo 40 or 80 mg once daily
224266022|NCT06563284|OTHER|AURORA Mobile App|"Enrolled subjects will be asked to download the app for free from their smartphone store.~Weekly/bi-weekly updates were collected, and therapy adherence was facilitated with timed alerts. Patients completed the EQ-5D-5L, PSQI, PHQ-9 and GAD-7 questionnaires every four months to track quality of life, sleep quality, depression and anxiety."
224266023|NCT03695354|DEVICE|whole body vibration plus conventional therapy|"Subjects enrolled in whole body vibration training group are exposed to side-to-side alternating vertical sinusoidal vibration. Galileo system(Novotec Medical GmbH, Pforzheim, Germany) is used to training. Frequency of whole body vibration is 12Hz and amplitude is 4mm. After 10 minutes of vibration training, subjects rest 3 minutes. Then, additional 10 minutes of training will be given.~conventional physical therapy is consisted of passive range of motion exercise and walking exercise."
224266024|NCT03695354|PROCEDURE|conventional therapy|conventional physical therapy is consisted of passive range of motion exercise and walking exercise.
224266025|NCT01252758|DRUG|albuterol sufate DPI (TBS-7) dose 1|
224266026|NCT01252758|DRUG|albuterol sufate DPI (TBS-7) dose 2|
224266027|NCT01252758|DRUG|albuterol sufate DPI (TBS-7) dose 3|
224266028|NCT01252758|OTHER|Placebo|
224266029|NCT01252758|DRUG|Albuterol|
224266030|NCT01252758|DRUG|Albuterol|
224266031|NCT03002935|DRUG|BPM31510 Oral Nanosuspension 4%|Oral nanosuspension formulation of BPM31510 (ubidecarenone, USP)
224266032|NCT03171194|DRUG|Low Dose Mesenchymal Stem Cells (MSCs)|Mesenchymal stromal/stem cells (MSCs) are cells that can be derived from umbilical cords, bone marrow, adipose tissue, and dental pulp, among other sites. MSCs have the ability to mediate a range of immuno-modulatory actions for both the innate and adaptive immune systems.
224266033|NCT03864094|DRUG|Ephedrine|0,1 mg/kg
224266034|NCT03864094|DRUG|Phenylephrine|1 microg/kg
224266035|NCT03864094|DRUG|Norepinephrine|0,1 microg/kg
224266036|NCT03864094|DRUG|Sodium chloride|0,1 ml/kg
224266037|NCT03864094|DRUG|Propofol|2 mg/kg
224266038|NCT03864094|DRUG|Remifentanil|1,7 microg/kg
224266039|NCT06144060|DRUG|HRS -8427|The dose and frequency of administration were adjusted according to the eGFR.
224266040|NCT06144060|DRUG|Imipenem and Cilastatin Sodium|The dose and frequency of administration were adjusted according to the eGFR .
224266041|NCT01662960|BEHAVIORAL|Mirror therapy|A home-based therapy involving mirrored visual feedback
224266042|NCT01662960|BEHAVIORAL|Divider therapy|A home-based therapy involving removed visual feedback.
224266043|NCT00213590|DRUG|cyclosporine A|The usual-exposure level was based on the mean area-under-the-concentration-time curve (AUC0-12h). In the usual-exposure group, the cyclosporine AUC0-12h target was 4.3 (3.5 to 4.8, range) mg•h/L and in the low-exposure group the target was 50% or 2.2 (2.0 to 2.6, range) mg•h/L. Ranges were asymmetrical for safety reasons, i.e., to prevent the occurrence of rejection in the low-exposure arm and nephrotoxicity in the usual-exposure arm.The AUC 0-12h was estimated using a Bayesian estimator and a three-point limited sampling strategy (0, 1, and 3 hours). A computer program was used to calculate the dose adjustment required to reach the therapeutic target. Doses were adjusted in increments of 25% to reach the target within 2 months. Cyclosporine AUC0-12h was determined every 2 months.
224266044|NCT00327145|DRUG|valsartan|
224266045|NCT00327145|DRUG|hydrochlorothiazide|
224266046|NCT00327145|DRUG|amlodipine|
224266047|NCT00433745|DRUG|WT1 Peptide Vaccine|WT1 vaccination (9 doses of WT-1:126-134 peptide (in Montanide adjuvant) administered concomitantly with GM-CSF (Sargramostim)
223854346|NCT06002360|BEHAVIORAL|Reach Out and Read|Families will be provided with a book and ROR programming from trained study team members (either the principal investigator or a research assistant, both of whom are ROR trained). ROR programming will include discussion of current reading practices, anticipatory guidance on the importance and benefits of reading, modeling of active reading, discussion of how to incorporate reading into a daily routine and answering any questions parents/caregivers may have.
223854347|NCT02794064|DEVICE|Tri-modal imaging|This tri-modal imaging system was developed in collaboration with Sogang University and is composed of three subsystems: ultrasound, photoacoustic and fluorescence. For this study, the fluorescence subsystem will not be used. The photoacoustic and ultrasound subsystems and data acquisition are controlled by a single workstation. The complete system is Canadian Standards Association (CSA) certified
223854348|NCT00174317|DRUG|Celecoxib|
223854349|NCT00174317|DRUG|Diclofenac|
223854350|NCT05112146|DIETARY_SUPPLEMENT|Whey protein isolate|Oral administration
223854351|NCT05112146|DIETARY_SUPPLEMENT|Whey protein microgel|Oral administration
223854352|NCT05112146|DIETARY_SUPPLEMENT|Water|Oral administration
223854353|NCT00109967|BIOLOGICAL|rituximab|375 mg/m\^2 Given IV
223854354|NCT00109967|DRUG|temsirolimus|25 mg given IV
223854355|NCT04313543|DIETARY_SUPPLEMENT|Glucose and Longan syrup|Volunteers take 50 g of glucose in 250 ml of water in 5 minutes. Then, they take 50g of longan syrup in 250 ml of water in 5 minutes
223854356|NCT05745376|BEHAVIORAL|Farm to ECE programming|Students and parents at this center will receive program elements described in arm descriptions.
223854357|NCT02076919|DRUG|LHA510 Ophthalmic Suspension|Ophthalmic suspension in 4 concentration levels topically administered in Part 1 and Part 2
223854358|NCT02076919|DRUG|LHA510 Vehicle|Inactive ingredients used for masking purposes
223854359|NCT00105820|PROCEDURE|System level depression care quality improvement|
223854360|NCT00169780|RADIATION|High definition helical CT (64 head scanner)|"Patients who require a CT scan for diagnostic purposes prior to kidney stone surgery will undergo a high definition helical CT rather than the standard CT scan. This high resolution scan will then be reviewed by the researchers to help determine the type of treatment needed for the kidney stone removal. The aim is to see if the higher resolution will show more of the stone anatomy which will help the surgeon determine if the stone will be amenable to shock wave lithotripsy or if another type of treatment would best serve the patient needs."
223854361|NCT02857491|DRUG|ranibizumab|intravitreal injection of 0.5 mg ranibizumab before vitrectomy
223854362|NCT02857491|DRUG|sham|sham intravitreal injection before vitrectomy
223854363|NCT02857491|PROCEDURE|pars plana vitrectomy|surgical procedure to remove the intravitreal hemorrhage and fibrosis membrane, and re-attach the retina, and perform endo laser photocoagulation on retina.
223854364|NCT02590042|BIOLOGICAL|ADSC-SVF-002|"ADSC-SVF with the following identity:~Less than or equal to 10% each CD34 and CD45 positive cells At least 70% each CD90, CD73 and CD105 positive cells Viability of at least 85% Mean Florescence Intensity of less than or equal to 100 C12FDG 0-5-2.5x10\^6 cells/g of liposuctioned (hydrated fat)"
223854365|NCT03427255|BEHAVIORAL|CBT group treatment-plus|The CBT group program-plus consists of 3 1- hr CBT couple sessions and 10 2-hr CBT group sessions over a period of 6 months. The manualized treatment comprise, pain- and sexual education, relaxation and gradual exposure exercises as well as sensate focus and sexual communication exercises for the couple. 6-8 women participate in each group. Two psychologists conduct the couple and group sessions.
223854366|NCT03427255|OTHER|Waiting-list control condition|Waiting-list control condition during length of active treatment (6 months).
223854367|NCT01819493|BEHAVIORAL|Lifestyle Intervention|Family-based group lifestyle intervention
223854368|NCT01819493|BEHAVIORAL|Standard Family-Based intervention|Comparison intervention
223854369|NCT04635358|BEHAVIORAL|Hypnosis|Setting up hypnosis sessions
223854370|NCT04635358|BEHAVIORAL|Psychological support|Setting up psychological support
223854371|NCT04635358|BEHAVIORAL|Nutrional support|Setting up nutritional support
223854372|NCT01280591|DRUG|Naproxen sodium 440 mg / DPH 50 mg (BAY98-7111)|Participants received two Naproxen sodium 220 mg / DPH (Diphenhydramine hydrochloride) 25 mg tablets orally, single dose
223854373|NCT01280591|DRUG|Naproxen sodium 220 mg / DPH 50 mg (BAY98-7111)|Participants received one Naproxen sodium 220 mg / DPH 50 mg tablet and one matching placebo capsule orally, single dose
223854374|NCT01280591|DRUG|Naproxen sodium 440 mg (BAYH6689)|Participants received two Naproxen sodium 220 mg tablets orally, single dose
223854375|NCT01280591|DRUG|DPH 50 mg|Participants received two DPH (Diphenhydramine hydrochloride) 25mg tablets orally, single dose
223854376|NCT04779892|DRUG|Infliximab|100mg/vial
223854377|NCT03943719|DIAGNOSTIC_TEST|FilmArray blood culture identification panel|FilmArray blood culture identification panel is performed 24 hours on 24hours and 7 days a week on positive blood cultures to accelerate pathogens detection
223854378|NCT01672619|PROCEDURE|dynamic craniotomy|Surgical technique of craniotomy spiral without detachment of dura mater
223854379|NCT06260696|OTHER|No treatment is given|No treatment is given
223854380|NCT05963308|BEHAVIORAL|Healthy Minds|"The group intervention (approximately 5 participants per group, 8 groups) is facilitated by two clinicians and consists of 8 sessions (one per week for 8 weeks), with each session focusing on a specific aspect of the return-to-work process from a cognitive-behavioral perspective:~Week1: Coping with work stress at work W2 and W3: Recognizing and modifying my dysfunctional beliefs linked to work W4: Overcoming obstacles linked to work functioning and maintaining work W5: To put in place needed work accommodations with the support of the immediate supervisor W6: My strengths and competencies related to work W7: Accepting criticism and asserting myself appropriately W7: My strengths and related skills W8: My best coping strategies for work Both intervention and control participants receive their standard individualized care from their clinician. However, for the experimental participants, the Healthy Minds intervention is an added component to their regular care."
223854381|NCT00130819|BEHAVIORAL|Clinic-based substance abuse treatment with buprenorphine|Subjects receive integrated opioid-dependence treatment with buprenorphine/naloxone at the HIV clinic
223854382|NCT00130819|BEHAVIORAL|Case management and referred substance abuse treatment|Subjects receive case management and referral to an off-site opioid treatment program for their opioid dependence
223854383|NCT03284411|DEVICE|Spinal Cord Stimulation|Programming
223854384|NCT04667988|DIAGNOSTIC_TEST|JAK expression|JAK2 assessment in blood by PCR
223854385|NCT00796068|DRUG|Cyclosporine|Given IV or PO
223854386|NCT00796068|DRUG|Fludarabine Phosphate|Given IV
223854387|NCT00796068|OTHER|Laboratory Biomarker Analysis|Correlative studies
223854388|NCT00796068|DRUG|Mycophenolate Mofetil|Given IV
223854389|NCT00796068|RADIATION|Total-Body Irradiation|TBI administered day -1: 200 cGy (or escalated to 300 cGy, 400 cGy, or 450 cGy per protocol statistical section)
223854390|NCT00796068|DRUG|Treosulfan|Given IV
223854391|NCT00796068|PROCEDURE|Umbilical Cord Blood Transplantation|Undergo single or double unit UCBT
223854392|NCT03357341|DEVICE|Mobile spirometer|Mobile spirometer will be used to measure FEV1 values weekly.
223854393|NCT03357341|DEVICE|Device sensor|Sensors will be attached to rescue and maintenance inhalers to measure use of rescue medication and maintenance therapy.
223854394|NCT03357341|DRUG|Salbutamol|Salbutamol MDI will be given as a rescue medication to be used on an as needed basis in this study.
223854395|NCT03357341|DEVICE|Activity monitor|Subjects will be required to wear activity monitors daily to record their physical activity.
223854396|NCT03357341|OTHER|electronic diary card|Electronic diary card will be completed daily by subjects in COPD cohort.
223854397|NCT03357341|OTHER|CAT|Subjects will be required to complete CAT monthly.
223854398|NCT03357341|OTHER|ACT|Subjects will be required to complete ACT monthly.
223854399|NCT05042791|COMBINATION_PRODUCT|radiation combined with pyrotinib and capecitabine|This study selects different radiation (SRT or WBRT) combined with pyrotinib and capecitabine to treat HER2-positive advanced breast cancer patients with brain metastases
223854400|NCT01101152|DRUG|Desvenlafaxine succinate|"Tablets of 50 mg,100 mg; Dosing regimen: 50, 100, 200 mg/day; 1 week for each dose regimen;~1 tablet a day for doses of 50 and 100mg/day, and 2 tablets of 100mg for dose of 200mg/day"
223854401|NCT00386204|DEVICE|Q-switched Ruby Laser|
223854402|NCT03709628|DRUG|EB8018 (First-in-class FimH blocker)|"Drug: EB8018 EB8018 is an orally administered, first-in-class, FimH blocker~• In Part 1, a single oral dose of EB8018 3000 mg will be administered to the 2 sentinel patients in the morning on Day 1. In the multi-dose treatment period (part 1 and 2), multiple oral doses of EB8018 1500 mg will be administered to 2 + 6 patients BID (in the morning and evening) on Days 1 through 13."
223854403|NCT00010946|PROCEDURE|Acupuncture|
223854404|NCT00740415|BIOLOGICAL|rituximab|Rituximab, 375 mg/m2 Intraveinous
223854405|NCT00740415|DRUG|bortezomib|-Velcade®, 1,3 mg/m2 Intraveinous on days 1, 4, 8 and 11
223854406|NCT00740415|DRUG|dexamethasone|day - Dexamethasone, 40 mg Intraveinous
223854407|NCT00740415|DRUG|Bendamustine|-Day 1 and day 2 Bendamustine/Levact ®,, 90 mg/m2 Intraveinous
223854408|NCT00918957|DRUG|Tobramycin Inhalation Powder|Tobramycin Inhalation Powder as produced by a modified manufacturing process TIP. TIP was provided in hard capsules each containing 28 mg active ingredient (tobramycin); Capsules were packaged in blister cards and administered by the T-326 Inhaler.
223854409|NCT00918957|DRUG|Placebo|Placebo inhalation powder consisting of the excipients used for TIP. Placebo was provided in hard capsules, containing 20 mg placebo powder, which were packaged in blister cards, matching in appearance to TIP. Capsules were administered by the T-326 Inhaler.
223854410|NCT03313206|DRUG|Pembrolizumab|"Neo-adjuvant therapy :~* Anti-PD1 antibody will be used (pembrolizumab, Merck®) intravenously at a dose of 200 mg every 3 weeks. The patient will receive 4 injections maximum over 12 weeks. According to the investigator's opinion, the 4th injection might be cancelled in order to perform surgery from week 10 and not after week 13.~* Tumor response will be assessed 2 weeks after the last injection both clinically and radiologically (by CT-scan and MRI).~Maintenance therapy by anti-PD1 antibody (pembrolizumab, Merck®) will be then used intravenously at a dose of 200 mg every 3 weeks for a maximum period of one year, starting one month after the end of radiotherapy."
223854411|NCT03313206|PROCEDURE|Surgery|Surgery will be performed (endoscopically if possible) 3 weeks after the last injection, at the earliest week 10 and at the latest at week 13 and will be completed by radiotherapy using IMRT technology according to the International and European Rhinologic Societies guidelines.
223854412|NCT03313206|RADIATION|IMRT|Surgery will be performed (endoscopically if possible) 3 weeks after the last injection, at the earliest week 10 and at the latest at week 13 and will be completed by radiotherapy using IMRT technology according to the International and European Rhinologic Societies guidelines.
223854413|NCT03313206|DRUG|Lenvatinib|up to 26 evaluable patients will be treated with pembrolizumab combined with orally lenvatinib at a daily dose of 20 mg for 6 weeks started on the day of the first anti-PD1 dose.
223854414|NCT06076434|OTHER|The Effect of Different Pressure Periods on Bruising and Pain After Subcutaneous Heparin Injection Applied to the Upper Arm Region|The injection site on the upper arm of each patient was cleaned with alcohol and after the alcohol was dried, 0.6 ml of subcutaneous heparin was injected into the tissue at a 90° angle with a 27 gauge needle. The heparin was injected in approximately 10 seconds without aspirating the syringe. After the injection, pressure was applied to the area with dry cotton for specified periods (10 second, 35 second and 60 second).
223854415|NCT01060137|DRUG|fentanyl matrix|Fentanyl transdermal patch 12 - 25mcg/hr
223854416|NCT05153551|OTHER|Play-based assessment (RITA-T)|"The RITA-T is a play-based assessment that involves nine different activities that can be done safely with a child seated in the exam room. After scoring the RITA-T, the PEARS PCP will immediately provide feedback to the parent regarding results and next steps.~In addition, parents will complete certain assessments/surveys during the study to evaluate the program."
223854417|NCT00572078|DRUG|Sorafenib|Cohort 1 200 mg po BID D1-5; Cohort 2 200 mg po BID; Cohort 3 400 mg po BID D1-5 Cohort 4 400 mg po BID
223854418|NCT02932709|BEHAVIORAL|suicide attempt|suicide attempt : We evaluated the effectiveness of telephone follow-up of patients who had referred to an emergency psychiatric unit for attempted suicide on any further attempt/s over the following year.
223854419|NCT02675920|DRUG|non-ionic monomer iodinated CT contrast media|patients underwent contrast-enhanced CT using aforementioned CT contrast media (non-ionic monomer iodinated CT contrast media)
223854420|NCT05227066|OTHER|adding lower extremity weights|All children in the two groups received physical therapy protocol for 30 minutes in addition to half kg of sandbags weights attached for each leg
223854421|NCT05227066|OTHER|traditional physical therapy group|traditional physical therapy group
223854422|NCT05975749|DRUG|Serplulimab|Serplulimab: 4.5mg/Kg on day 1
223854423|NCT05975749|DRUG|Trastuzuma|Trastuzuma: 8mg/Kg ( the first cycle)，6mg/Kg (the rest of cycles) on day 1
223854424|NCT05975749|DRUG|Chemotherapy|Chemotherapy: Capecitabine or S-1 and Oxaliplatin (eight 3-week cycles of oral capecitabine 1000 mg/m² or S-1 40 mg/m2 twice daily on days 1-14 plus intravenous oxaliplatin 130 mg/m² on day 1) for 6 months or progress of disease
223854425|NCT06000618|DEVICE|Intrapulmonary Percussive ventilator|The volunteers will undergo three minutes low frequency and high frequency intrapulmonary percussive treatments.
223854426|NCT04517331|PROCEDURE|Thoracic paravertebral block-single injection|The blocks were performed at the T3-T4 level bilaterally to block the dermatomes between the T2 and T6 levels (breast innervation area).
223854427|NCT04517331|PROCEDURE|Thoracic paravertebral block-double injection|The blocks were performed at both T2-T3 and T4-T5 levels bilaterally to block the dermatomes between the T2 and T6 levels (breast innervation area).
223854428|NCT00579189|DRUG|Moxidex otic solution|4 drops into the infected ear(s) twice daily (morning and evening) for 7 days
223854429|NCT00579189|DRUG|Moxifloxacin otic solution|4 drops into the infected ear(s) twice daily (morning and evening) for 7 days
223854430|NCT00579189|DEVICE|Tympanostomy tubes|Tubes surgically inserted through the ear drum for the treatment of recurrent otitis media in children
223854431|NCT02850055|OTHER|Conventional Physiotherapy|"1. Leaflet care and health habits of the temporomandibular joint.~2. Program of cranio-cervical and temporomandibular exercises.~3. Massage of the cervical muscles and self care document for home."
223854432|NCT02850055|OTHER|Specific Manual Therapy|"1. Leaflet care and health habits of the temporomandibular joint.~2. Program of cranio-cervical and temporomandibular exercises.~3. Massage of the cervical muscles and self care document for home.~4. Specific manual therapy techniques focusing on the temporomandibular joint and temporomandibular muscles."
223854433|NCT03258619|BIOLOGICAL|Aldosterone / renin dosage|Plasma levels of aldosterone and renin
223854434|NCT03258619|BIOLOGICAL|Natriuresis|natriuresis levels
223854435|NCT03014830|DRUG|Alirocumab|150 mg SQ every 2 weeks
223854436|NCT03014830|DRUG|Placebos|Placebo injections SQ every 2 weeks
223854437|NCT02309567|OTHER|Blood Collection|
223854438|NCT00610688|DRUG|Prenatal Vitamin|Once daily, prenatal vitamin containing 400IU of Vitamin D, until delivery
223854439|NCT00610688|DRUG|Cholecalciferol (Vitamin D3)|Once daily, 1600IU dose of Vitamin D from 12 weeks gestation to delivery
223854440|NCT00610688|DRUG|Cholecalciferol (Vitamin D3)|Once daily, 3600IU dose of Vitamin D, from 12 weeks until delivery
223854441|NCT00000878|DRUG|Lamivudine|
223854442|NCT00000878|DRUG|Stavudine|
223854443|NCT00000878|DRUG|Zidovudine|
223854444|NCT02228408|DRUG|Hydralazine/Isorsorbide Dinitrate|"Hydralazine/Isorsorbide Dinitrate (ISD/HY) will be administered with a target dose of 40 mg of ISD and 75 mg of Hydralazine 3x/daily. Doses will be titrated between weeks 0-4 and may be decreased as necessary for treatment of adverse events.~Target Dose:~Hydralazine 75 mg 3x day Isorsorbide Dintrate 40 mg 3x/day~Allowable Dosage Forms:~ISD/HY 10 mg/10-3x/day ISD/HY 20 mg/35 mg-3x/day ISD/HY 40 mg/75 mg-3x/day~Dose Titration:~ISD/HY will be administered at a starting dose ISD/HY 10 mg/10-3x/day and titrated to ISD/HY 20 mg/35 mg-3x/day after 4 days and to ISD/HY 40 mg/75 mg-3x/day at 4 weeks. Dose will be decreased as necessary for dose-limiting side effects."
223854445|NCT02228408|DRUG|Placebo|Placebo titration will mimic titration of active study arm
223854446|NCT01230619|DRUG|RV568|RV568 400 ug administered as nasal drops twice daily on Day 1, RV568 800 ug administered as nasal drops once daily on Day 2
223854447|NCT01230619|DRUG|Placebo|Placebo administered as nasal drops twice daily on Day 1, Placebo administered as nasal drops once daily on Day 2
223854448|NCT01559480|DRUG|Desogestrel|Desogestrel 75 mcg Takes 1 capsule before bedtime for 6 months
223854449|NCT01559480|DRUG|Placebo|Placebo capsule takes 1 capsule before bedtime for 6 months
223854450|NCT02742896|OTHER|Erectile dysfunction|"The changes of erectile function by using official questionnaire-The International Index of Erectile Function (IIEF)-5 1 year after conversion to sinus rhythm.~The changes of cognitive function by using validated assessment form-The Montreal Cognitive assessment (MoCA) 1 year after conversion to sinus rhythm."
223854451|NCT05388344|OTHER|Booklet reading|Submission of the questionnaire before and after booklet reading
223854452|NCT00810550|OTHER|Carotid ultrasound|Measurement of intima-media thickness
223854453|NCT06140680|BEHAVIORAL|LifelongU|"The LifelongU intervention is an abbreviation name from LifelongU: Cultivating Physical Literacy for University \& Beyond. LifelongU is a unique and coined term that symbolizes the program's commitment to promoting physical literacy as a lifelong journey. It combines the words Lifelong and University to represent an intervention that focuses on physical literacy development not only during the university years but also throughout a person's entire life. The name is designed to convey the idea that physical literacy is an asset that will benefit individuals in all aspects of life, even after they leave the university."
223854454|NCT06140680|BEHAVIORAL|Physical education|The control group received 12-week traditional physical education lesson as usual.
223854455|NCT03087539|BIOLOGICAL|Abciximab|
223854456|NCT03087539|BIOLOGICAL|Placebo|
223854457|NCT02064569|GENETIC|GS010|
223854458|NCT05257733|OTHER|None, pure observationnal study|pure observationnal study
223854459|NCT04911049|DIAGNOSTIC_TEST|Blood Pressure measurement|Blood Pressure measurement
223854460|NCT00130741|DRUG|CHT - herbal therapy|
223854461|NCT03496649|DRUG|Dysport 500 Unit Powder for Injection|Dysport administered by intramuscular injection
223854462|NCT01240941|DRUG|MK-2206|dose to be determined on the Phase 1b trial (listed under a separate NCT number)
223854463|NCT01240941|DRUG|Exemestane|25 mg orally daily
223854464|NCT01240941|DRUG|Goserelin|3.6 mg orally monthly
223854465|NCT00130780|DRUG|Pre-surgical Treatment with Bevacizumab plus Chemotherapy|On Cycle 1 Day 1,patient will receive bevacizumab 15 mg/kg. On Cycle 1 Day 15, patients receive docetaxel (75 mg/m2), cisplatin (75 mg/m2). Cycle 2 begins 21 days after administration of docetaxel and cisplatin in Cycle 1. In Cycles 2 thru 3, patients will receive 2 preoperative 21-day cycles of docetaxel (75 mg/m2), cisplatin (75 mg/m2), and bevacizumab (15 mg/kg), all given on Day 1 of each cycle. The sequence of administration will be docetaxel, followed by cisplatin, followed by bevacizumab according to MSKCC Chemotherapy Guidelines. In Cycle 4 Day 1, patients will receive docetaxel (75 mg/m2) and cisplatin (75 mg/m2). Bevacizumab will not be given with Cycle 4. During Cycle 4, the only scheduled clinic visit will be on Day 1. Surgery will occur at least 42 days after the last treatment with bevacizumab. Every attempt will be made to administer the treatment on schedule. The treatment may be given +/- 3 days, and additionally 2 weeks after it is scheduled, if necessary.
223854466|NCT00130780|DRUG|Pre-Surgical Docetaxel and Cisplatin and Adjuvant Bevacizumab|Patients will receive preoperative 21-day cycles of cisplatin (75 mg/m2) and docetaxel (75 mg/m2) both given on Day 1 of each cycle.Patients will undergo repeat CT imaging after 2 cycles of therapy and patients with at least 10% reduction in bidimensional tumor volume will receive 2 additional neoadjuvant cycles of therapy (total 4 cycles of therapy).Surgery will occur at least 4 weeks after the last treatment with docetaxel and cisplatin.Adjuvant bevacizumab (15 mg/kg q21 days for 1 year, total 18 cycles) will be administered to all patients who undergo resection. Adjuvant bevacizumab will begin between days 42 and 56 after surgery.Patients may be referred for post-operative radiation therapy at the discretion of the treating physician. Every attempt will be made to administer the treatment on schedule. The treatment may be given +/- 3 days, and additionally 2 weeks after it is scheduled, if necessary.
223854467|NCT00633854|PROCEDURE|Ultrasound examination|Immersion Ultrasound Exam: In the immersion technique, the patient lies down on the examination table. A steridrape with a central aperture is used to form a water-tight seal around the eye. After installation of 2 drops of 0.5% proparacaine HCl, a wire lid speculum is used to hold the patient's lids open. Warm 0.9% sterile saline solution is then used to create a waterbath about 1/2 inch deep to provide acoustic coupling between the transducer and the eye. The transducer (either the 10- and 20-MHz sector scan probe or the annular array) is placed in the waterbath, but does not touch the eye.
223854468|NCT03812003|DRUG|Remifentanil|remifentanil 1mcg/kg added in 0.9% saline and diluted to 50ml
223854469|NCT04114383|OTHER|D3-Creatine|30mg D3-Creatine to measure muscle mass
223854470|NCT04114383|OTHER|Deuterium Oxide|D2O provided to measure muscle protein synthesis
223854471|NCT04114383|OTHER|D3-3-methylhistidine|D3-3-methylhistidine is provided to measure muscle protein breakdown
223854472|NCT06181318|DIAGNOSTIC_TEST|Multiparametric MRI scan of the liver|MRI scans will be performed at the Champalimaud Foundation using a 1.5T scanner after patients have fasted for 4 hours. Transverse abdominal T1 maps will be acquired to estimate extracellular fluid (which increases in cases of fibrosis and inflammation) and T2\* maps will be acquired to estimate liver iron levels. These quantitative MRI maps will be laid onto the volumetric images of Couinaud segments. Multi-slice quantitative maps will be generated using Liver MultiScan software (Perspectum, UK) with operators blinded to patient status. T1 measurements will be adjusted for the iron level to give iron-corrected T1 maps (cT1). Reference ranges for cT1 have been defined in the general population. PDFF maps of the liver will be calculated using MRI multi-echo and spoiled-gradient-echo acquisition. No intravenous contrast agents will be used in Liver MultiScan maps and the total scan duration will be approximately 30 minutes.
223854473|NCT03336450|DRUG|SHP615|SHP615 oromucosal solution will be administered as a single age-specific dose (2.5, 5, 7.5 and 10 mg).
223854474|NCT03336450|DRUG|MHOS/SHP615|MHOS/SHP615
223854475|NCT02278848|OTHER|Diagnosis of ICAH using new investigative techniques (computerised gait analysis, ultrasound, MRI flow, urinary incontinence scale)|Diagnosis of ICAH using new investigative techniques (computerised gait analysis, ultrasound, MRI flow, urinary incontinence scale)
223854476|NCT02735486|DIETARY_SUPPLEMENT|Ginger drink|300 ml ginger drink
223854477|NCT02735486|DIETARY_SUPPLEMENT|Placebo: Super pure water|Placebo: Super pure water
223854478|NCT04241653|PROCEDURE|Pressure Support Ventilation|Ventilator will be adjusted to administer pressure at 10 cmH2O.
223854479|NCT04241653|PROCEDURE|Unparalyzed Pressure Control Ventilation|Pressure controlled ventilation mode will be applied to obtain a volume of 8 ml/kg up to 20 cmH2O. The set respiratory rate will be 15 breaths/min then it is adjusted to achieve the end tidal CO2 levels between 35 and 40 mmHg as measured by capnography.
223854480|NCT04241653|PROCEDURE|Paralyzed Pressure Control Ventilation|Pressure controlled ventilation mode will be applied to obtain a volume of 8 ml/kg up to 20 cmH2O. The set respiratory rate will be 15 breaths/min then it is adjusted to achieve the end tidal CO2 levels between 35 and 40 mmHg as measured by capnography. Also, neuromuscular blockade will be achieved.
223854481|NCT04241653|DEVICE|Laryngeal Mask Airway|Capnography connected to laryngeal mask airway is introduced after adequate jaw relaxation; its size is chosen according to the body weight of the child.
223854482|NCT04241653|DRUG|Sevoflurane|Sevoflurane in air/oxygen mixture of 40% will be titrated to achieve adequate depth of anesthesia to maintain immobilization of the eye.
223854483|NCT01955694|DRUG|BAY94-8862|2.5 mg, 5 mg, 7.5 mg, 10 mg, 15 mg, and 20 mg of BAY94-8862 tablets
223854484|NCT01955694|DRUG|Eplerenone|INSPRA 25 and 50 mg tablets (MAH: Pfizer) will be used for eplerenone 25 and 50 mg tablets
223854485|NCT01955694|DRUG|Placebo|matching placebo
223854486|NCT04293783|DIETARY_SUPPLEMENT|L.Reuteri|daily supplementation with two tablet for six months
223854487|NCT04293783|DIETARY_SUPPLEMENT|Placebo|daily supplementation with two tablet for six months
223854488|NCT05997654|DEVICE|MEDGEL ANTIAGE|The MEDGEL ANTIAGE is a medical grade silicone plate, biocompatible.
223854489|NCT01928511|DRUG|peg-interferon alpha 2b, 1.5mcg/kg s/c given weekly|
223854490|NCT01928511|DRUG|Nucleos(t)ide analogue therapy|
223854491|NCT02473120|BIOLOGICAL|Determination of ESR1 mutations|Blood sample prelevement. Plasma issued from patient with metastatic breast cancer will be analysed at progression by Digital PCR to detect ESR1 mutations
223854492|NCT04292093|BEHAVIORAL|Home rehabilitation training|The rehabilitation training will be provided via Lumosity platform. Participants will be asked to play computer video-games aimed at strengthening specific sub-functions pertaining to the macro area of executive functions for 30 minutes a day, 5 days a week, for a total of 8 weeks. Specifically, 20 games out of a total of 64 available games provided by the platform have been selected. The selected games are aimed at training 4 cognitive skills: memory, attention, cognitive flexibility and problem solving. In particular, 5 different games were chosen for each cognitive ability.
223854493|NCT04292093|BEHAVIORAL|Home control activity|The control group will watch a series of animated / TV shows suitable for the sample age, again for 30 minutes a day, 5 days a week, for 8 weeks. The videos will be provided by the experimenter and participants will watch them on their personal computer. At the end of each videos, participants will answer a series of multiple-choice questions aimed at evaluating the attention deployed to the content of the videos.
223854494|NCT02675348|DIETARY_SUPPLEMENT|Dietary Supplement: Beef Protein|Participants will combine a 10-week periodized and controlled endurance programme with the ingestion of beef protein supplement after training. Measurements pre and post intervention will be endurance performance (vo2max) and blood markers: haemoglobin; red blood cell; erythrocyte; haematocrit; mean corpuscular volume, transferrin; neutrophils; lymphocyte; monocytes
223854495|NCT02675348|DIETARY_SUPPLEMENT|Dietary Supplement: whey Protein|Participants will combine a 10-week periodized and controlled endurance programme with the ingestion of whey protein supplement after training. Measurements pre and post intervention will be endurance performance (vo2max) and blood markers: haemoglobin; red blood cell; erythrocyte; haematocrit; mean corpuscular volume, transferrin; neutrophils; lymphocyte; monocytes
223854496|NCT02675348|DIETARY_SUPPLEMENT|Dietary Supplement: CHO|Participants will combine a 10-week periodized and controlled endurance programme with the ingestion of maltdextrin after training. Measurements pre and post intervention will be endurance performance (vo2max) and blood markers: haemoglobin; red blood cell; erythrocyte; haematocrit; mean corpuscular volume, transferrin; neutrophils; lymphocyte; monocytes
223854497|NCT00242853|PROCEDURE|Power doppler ultrasonography|
223854498|NCT00242853|PROCEDURE|High frequency ultrasonography|
223854499|NCT00242853|PROCEDURE|Exhaled nitric oxide assessment|
223854500|NCT06290544|OTHER|Standard of care plus additional examinations|The patient will undergo good clinical practice examinations according to guidelines plus The patient will undergo to the evaluation of endothelial dysfunction with ENDOPAT 2000 and whole blood sampling for future omics studies
223854501|NCT03923387|DEVICE|MynxGrip|Vascular Closure
223854502|NCT03923387|OTHER|Manual compression|Manual compression is a commonly used method to achieve hemostasis of femoral artery
223854503|NCT03794180|DRUG|TJ003234|Brownish-yellow liquid containing TJ003234, a recombinant humanized immunoglobulin (Ig) G1 monoclonal antibody diluted with normal saline
223854504|NCT03794180|DRUG|Placebo|Colorless to slightly brownish-yellow liquid without TJ003234 diluted with normal saline
223854505|NCT00574743|DRUG|Enteric-coated Mycophenolate Sodium|
223854506|NCT00762099|DRUG|Pregabalin|Pre-operative dose 150 mg Post-operative dose 75 mg BID
223854507|NCT00762099|DRUG|Placebo|Placebo/sugar tabs will look identical to active drug.
223854508|NCT05478902|PROCEDURE|Exercise Therapy|Exercise protocol for rotator cuff related shoulder pain
223854509|NCT05478902|PROCEDURE|Extracorporeal Shockwave Therapy|High Energy Extracorporeal Shockwave Therapy
223854510|NCT05478902|PROCEDURE|Ultrasound-Guided Percutaneous Irrigation|Two sessions of Ultrasound-Guided Percutaneous Irrigation
224266048|NCT02207582|DEVICE|Verum Prefrontal tRNS|2mA of tRNS (DC-Stimulator, NeuroConn GmbH, Germany) with a zero offset will be applied to the left and right dorsolateral prefrontal cortex. Treatment will consist of 15 days with 20 minutes stimulation per day. Voltage will be ramped at the begin and end of a stimulation for 10 seconds.
224266049|NCT02207582|DEVICE|Placebo Prefrontal tRNS|2mA of tRNS (DC-Stimulator, NeuroConn GmbH, Germany) with a zero offset will be applied to the left and right dorsolateral prefrontal cortex. Treatment will consist of 15 days with 20 minutes stimulation per day. Voltage will be ramped at the begin and end of a stimulation for 10 seconds. Placebo stimulation will consist of just applying the ramps at the begin and end of the stimulation.
224266050|NCT05783089|BIOLOGICAL|Anti-mesothelin CAR-T cells|Anti-mesothelin CAR-T cells are autologous genetically modified T cells. Cells will be infused intravenously.
223854511|NCT03670602|BEHAVIORAL|Episodic Future Thinking|Participants will practice using these cues when making decisions about health choices. Participants will implement EFT while using The Traffic Light Diet, The Traffic Light Activity Program, and a variety of behavioral techniques including stimulus control, self-monitoring, goal setting, problem solving, resetting rewarding mechanisms by reducing need for immediate gratification, finding behavioral substitutes for highly reinforcing food.
223854512|NCT03670602|BEHAVIORAL|Daily Check in|Participants will be asked to access the electronic app at the same rate as the experimental group (e.g. daily). Participants will receive behavioral weight loss treatment including The Traffic Light Diet, The Traffic Light Activity Program, and a variety of behavioral techniques including stimulus control, self-monitoring, goal setting, problem solving, and finding behavioral substitutes for highly reinforcing food.
223854513|NCT01772056|DRUG|Fluticasone, cream|Experimental Group: on treatment with twice weekly on consecutive days FP cream of 0.05% for 16 weeks or at relapse
223854514|NCT01772056|DRUG|Placebo,|Control Group: on treatment with twice weekly on consecutive days vehicle cream for 16 weeks or at relapse.
224266051|NCT01509391|DRUG|keyhole-limpet hemocyanin|Subcutaneous administration keyhole-limpet hemocyanin
224266052|NCT02967926|PROCEDURE|Endoscopic Retrograde Cholangioscopy by SpyGlass (ERCS)|Digital SpyGlass Cholangioscopy to facilitate common bile duct stone removal
224266053|NCT00625157|DRUG|ASF 1096 0.5 % cream|
223854515|NCT02396056|OTHER|BioMend Extend|Biomend Extend is a resorbable collagen membrane used for guided tissue and bone regeneration.
223854516|NCT02396056|OTHER|Modified BioMend Extend|Biomend Extend is a resorbable collagen membrane used for guided tissue and bone regeneration. This membrane will be perforated to allow the passage of cells and growth factors that can potentially enhanced bone augmentation.
223854517|NCT02544282|DRUG|Levobupivacaine|Pecs II Block
223854518|NCT02544282|DRUG|NaCl 0.9%|Placebo Pecs II block
223854519|NCT02544282|DRUG|Sevoflurane|General Anesthesia
223854520|NCT02544282|DRUG|Propofol|General Anesthesia
223854521|NCT02544282|DRUG|Sufentanil|General Anesthesia
223854522|NCT02544282|DRUG|Atracurium|General Anesthesia
223854523|NCT02544282|DRUG|Paracetamol|Pain Relief
223854524|NCT02544282|DRUG|Tramadol|Pain Relief
223854525|NCT02544282|DRUG|Piritramide|Pain Relief
223854526|NCT01571778|BEHAVIORAL|Hand Hygiene before Donning Non-sterile Gloves|"In the No Intervention arm, healthcare workers will be assigned to first perform hand hygiene before donning non-sterile gloves prior to patient contact (usual practice). Samples will be obtained from hands prior to donning gloves and from the gloves after donning to determine total aerobic colony counts and to identify important hospital pathogens~In the Experimental arm, they will be instructed to don gloves without washing their hands as described."
223854527|NCT00003790|GENETIC|polymerase chain reaction|
223854528|NCT00003790|OTHER|flow cytometry|
224266054|NCT00625157|DRUG|ASF 1096 placebo cream|
224266055|NCT00901524|DRUG|Peg-interféron alpha 2a + ribavirin|Pilot study, multicenter, open label
224266056|NCT04448730|DIAGNOSTIC_TEST|serum marker levels|two groups comparisons
223854529|NCT00543725|DRUG|TMC278|25 mg tablet once daily for 96 weeks
223854530|NCT00543725|DRUG|efavirenz|600 mg tablet once daily for 96 weeks
223854531|NCT04109690|DRUG|CPX-351|Patients in both Phase I and II can receive a maximum of two induction and six consolidation cycles on an inpatient or outpatient basis per local hospital standard of care.
224266057|NCT03330496|OTHER|Pain Measurement|Measurement of infant responses (behavioral and physiological) during a painful procedure.
224266058|NCT01367782|DEVICE|repetitive transcranial stimulation (r-TMS)|Active treatment with the H-coil will include stimulation over the motor cortex (1 Hz stimulation 110% of the motor threshold for 15 minutes) and over the prefrontal cortex (10Hz stimulation 100% of the motor threshold, 2 seconds each train, 20 seconds between trains, for 15 minutes).
224266059|NCT01367782|DEVICE|repetitive transcranial stimulation (r-TMS)|Sham treatment with the H-coil will include sham stimulation over the motor cortex and over the prefrontal cortex.
224266060|NCT00422045|DEVICE|Low Level Laser Therapy|Low Level Laser Therapy done after surgery.
223854532|NCT04301674|DEVICE|Breath Biopsy|ReCIVA breath sampler (Owlstone Medical, Cambridge, UK)
223854533|NCT04483843|OTHER|No intervention|No intervention will be performed while it is retrospective observational study.
223854534|NCT01526603|DRUG|Carboplatin|Carboplatin intravenously (IV), 425 mg/m2/dose (or if ≤ 12kg, 14.2 mg/kg/dose) once daily x 4 doses on days 7 through 4 pretransplant.
223854535|NCT01526603|BIOLOGICAL|Autologous stem cell infusion|On day 0 the stem cells will be infused immediately after thawing over 15-60 minutes per institutional guidelines.
223854536|NCT01526603|BIOLOGICAL|Granulocyte colony stimulating factor|Beginning on day 0 after infusion of the PBSC, patients will receive G-CSF subcutaneously (SQ) or IV (SQ preferred) 5 micrograms/kg once daily and continuing once daily until post-nadir absolute neutrophil count (ANC) \> 2000/μL for 3 consecutive days.
223854537|NCT01526603|RADIATION|Radiation therapy|It is suggested that patients who have a complete surgical resection of the primary tumor receive 21.6 Gy external beam radiation therapy (EBRT) to the post-induction chemotherapy, pre-operative primary tumor volume. It is suggested that patients who have an incomplete surgical resection of the primary tumor (residual soft tissue mass measuring \>1 cm3) will receive 21.6 Gy EBRT to the postinduction chemotherapy, pre-operative primary tumor volume and an additional boost of 14.4 Gy EBRT to the gross residual tumor (total dose 36 Gy to gross residual tumor volume). Radiation should be given after stem cell transplantation and should start no sooner than 28 days post transplant.
223854538|NCT01526603|DRUG|Isotretinoin (13-cis-retinoic acid)|Post-transplant maintenance therapy with cis-RA daily for 14 days every 28 days repeated for 6 months. This phase of the therapy can be initiated by the BMT team and continued by the referring physician. It is recommended to begin Isotretinoin at day 66 post-transplant and no later than day 100. For patients ≤12 kg, isotretinoin (accutane) should be administered at 5.33 mg/kg/dose divided twice daily. For patients \>12 kg isotretinoin (accutane) should be administered at 160 mg/m\^2/day divided twice a day. Patients should be considered for monoclonal antibody therapy against GD2, such as ch14.18 if such trials are available.
223854539|NCT01526603|DRUG|Melphalan|Melphalan Intravenously (IV), 70 mg/m2/dose (or if ≤ 12 kg, 2.3 mg/kg/dose) once daily x 3 doses on days 7 through 5 pretransplant
223854540|NCT01526603|DRUG|Etoposide|Etoposide intravenously (IV), 338 mg/m2/dose (or if ≤ 12kg, 11.3 mg/kg/dose) once daily x 4 doses on days 7 through 4 pretransplant
223854541|NCT00906698|DRUG|BIBW 2992 low (20mg) dosage|Patients will receive 20mg dosage per day of BIBW 2992 plus standard dosage of vinorelbine.
223854542|NCT00906698|DRUG|BIBW 2992 medium (40mg) dosage|Patients will receive 40mg dosage per day of BIBW 2992 plus standard dosage of vinorelbine.
223854543|NCT00906698|DRUG|BIBW 2992 high (50mg) dosage|Patients will receive 50mg dosage of BIBW 2992 plus standard dosage of vinorelbine.
223854544|NCT00906698|DRUG|Vinorelbine per os 60 mg/m²|Patients will receive 60 mg/m² Vinorelbine per os at J1 J8 and J15
223854545|NCT00906698|DRUG|Vinorelbine per os 80 mg/m²|Patients will receive 80 mg/m² Vinorelbine per os at J22
223854546|NCT00906698|DRUG|Vinorelbine i.v. 25 mg/m²|Patients will receive 25 mg/m² of Vinorelbine i.v.
223854547|NCT02892799|OTHER|NICOM-Guided Diuresis|NICOM-based assessment of PLR-induced change in cardiac index
223854548|NCT02892799|OTHER|Standard of Care|
223854549|NCT03095508|DRUG|Angal S, topical spray [Menthol]|0,5 mg + 2 mg (Sandoz d.d., Slovenia), administered as three to five consecutive presses on the actuator button, 6-10 times per day, for a maximum 4 days or until full illness resolution
223854550|NCT03095508|DRUG|ANTI-ANGIN® FORMULA, topical metered spray|"0,12 mg + 0,24 mg (LLC Valeant, Russia) administered as one to two consecutive presses on the actuator button, up to 6 times per day, , for a maximum 5 days or until full illness resolution"
223854551|NCT05460936|OTHER|Lower Extremity Functional Training|motor learning, skill progression, and resistance training to target the balance, strength, and coordination impairments of the lower extremities. Motor learning will be based on strength and balance training using tandem walks, balance boards, and one-leg standing. Skill progression will be used to challenge the LIFT and the strength training will be achieved by performing sit-to-stand, sit-ups, stair climbs, and vertical jumps
223854552|NCT05460936|OTHER|conventional physical therapy|Resistive Exercises Stretching exercise of quadriceps , hamstring adductors and abductors.
223854553|NCT00637676|PROCEDURE|VATS, Talc-Pleurodesis, tunneled pleural drainage|poudrage of 4 gr talc into the pleural cavity implantation of tunneled pleural catheter
223854554|NCT00637676|PROCEDURE|VATS, Talc-pleurodesis|poudrage of 4 gr. talc into the pleural cavity no tunneled pleural catheter
223854555|NCT04215341|BEHAVIORAL|Physiotherapy|A course of breathing retraining delivered by a physiotherapist and practiced by the participant at home.
223854556|NCT00000251|DRUG|30% N2O|
223854557|NCT00000251|DRUG|0.2% isoflurane|
223854558|NCT00000251|DRUG|0.4% isoflurane|
223854559|NCT00000251|OTHER|100% oxygen|Placebo
223854560|NCT02886741|OTHER|Quality Improvement Campaign|"How To Guide addressed development of a QI plan; small-scale tests of change- (PDSA cycles) to refine implementation approaches through iterative learning; and reliance on multi-disciplinary implementation teams. IHI recruited relevant professional organizations to identify faculty."
223854561|NCT01231113|DRUG|artesunate-amodiaquine|The 452 pregnant women in this arm will receive artesunate-amodiaquine tablets(artesunate 4mg/kg and amodiaquine 10mg/kg in twelve hourly doses over 3 days
223854562|NCT01231113|DRUG|Dihydroartemisinin-piperaquine|a fixed-dose combination to be administered to the other 452 pregnant women in this arm at an estimated total dosing of 6.75mg/kg dihydroartemisinin and 55mg/kg piperaquine over 3 days
223854563|NCT02830750|PROCEDURE|Ablation|
223854564|NCT04570761|DEVICE|Dreem headband|acoustic stimulation
223854565|NCT04570761|DEVICE|Dreem headband|acoustic stimulation
223854566|NCT00361621|DRUG|bortezomib|Given intravenously on day 1 and day 4 of a 21-day cycle for 6 cycles
223854567|NCT00361621|DRUG|Rituximab|Given intravenously on day 1 of a 21-day cycle for 6 cycles
223854568|NCT00361621|DRUG|Cyclophosphamide|Given intravenously on day 1 of a 21-day cycle for 6 cycles
223854569|NCT00361621|DRUG|Doxorubicin|Given intravenously on day 1 of a 21-day cycle for 6 cycles
223854570|NCT00361621|DRUG|Vincristine|Given intravenously on day 1 of a 21-day cycle for 6 cycles
223854571|NCT00361621|DRUG|Prednisone|Taken orally on days 2, 3, 4 and 5 or a 21-day cycle for 6 cycles
223854572|NCT00361621|RADIATION|Radiation therapy|After 6 cycles of chemotherapy there will be 3 weeks of radiation therapy
223854573|NCT05403307|BIOLOGICAL|Pfizer/BioNTech BNT162b2 mRNA COVID-19 vaccine|Pfizer/BioNTech BNT162b2 mRNA COVID-19 vaccine
223854574|NCT05403307|BIOLOGICAL|CoronaVac COVID-19 vaccine|CoronaVac COVID-19 vaccine
223854575|NCT03767764|DIAGNOSTIC_TEST|Test Yliver|Test Yliver is used to detect autoantibodies against alpha fetoprotein in serum by an ELISA technique
223854576|NCT05653089|PROCEDURE|Choice and adjustment of the wheelchair according to the patient's needs|"After a personalized analysis of the patient and his needs, the occupational therapists define the equipment necessary for the good positioning of the patient:~* Choice and adjustments of the wheelchair~* Choice and adjustments of the wheelchair/patient interface"
223854577|NCT03921684|DRUG|Capecitabine|Capecitabine 825 mg/m2 orally twice-daily, 5 days a week for a total of 28 days, given with radiation therapy
223854578|NCT03921684|RADIATION|Radiation therapy|1.8 Gy/day, 5 days a week for a total of 28 days, given with Capecitabine
223854579|NCT03921684|DRUG|mFOLFOX6|oxaliplatin 85 mg/m2, leucovorin 400 mg/m2 and fluorouracil 400 mg/m2 IV, fluorouracil 2400 mg/m2 IV (a 46 hrs CI), day 1 of each treatment cycle, every 2 weeks, given with nivolumab
223854580|NCT03921684|DRUG|Nivolumab|Nivolumab 240mg IV, day 1 of each treatment cycle, every two weeks, given with mFOLFOX6
223854581|NCT02860260|BIOLOGICAL|Blood samples|
223854582|NCT02860260|OTHER|Cerebral MRI|
223854583|NCT03942822|DIETARY_SUPPLEMENT|Milled chia seeds|8 weeks of an isocaloric diet supplemented with 25 g/day of milled chia
223854584|NCT04138862|BEHAVIORAL|Product Labelling and Sensory modifications|the beverages varied in the label that was attached (no label or a 'Healthier Choice' label) and the sensory matching of the calorie reduction (sensory matched, reduced or enhanced).
223854585|NCT02325050|BIOLOGICAL|MVA-BN-Filo|One 0.5 milliliter (ml) intramuscular (IM) injection of 1\*10\^8, (50%Tissue Culture Infectious Dose \[TCID50\]).
223854586|NCT02325050|BIOLOGICAL|Ad26. ZEBOV|One 0.5 mL IM injection of 5\*10\^10 viral particles (vp).
223854587|NCT02325050|BIOLOGICAL|MVA-BN-Filo|One 0.5 milliliter (ml) intramuscular (IM) injection of 4.4\*10\^8, (50%Tissue Culture Infectious Dose \[TCID50\]).
223854588|NCT02325050|BIOLOGICAL|Ad26. ZEBOV|One 0.5 mL IM injection of 1\*10\^11 viral particles (vp).
223854589|NCT02325050|OTHER|Placebo|One 0.5 mL IM injection of 0.9% saline.
223854590|NCT05674370|DEVICE|GRIP Electronic Diagnostic Chip|Graphene-based point-of-care device for detection of respiratory viruses (e.g., COVID-19 and influenza) from a nasal swab
223854591|NCT05674370|DIAGNOSTIC_TEST|Laboratory-based nucleic acid amplification tests (NAATs)|Polymerase Chain Reaction (PCR) analysis for detection of viruses (e.g., Roche cobas SARS-CoV-2 or influenza A/B) from nasal swab
223854592|NCT02951117|DRUG|Venetoclax|Tablet
223854593|NCT02951117|DRUG|ABBV-838|Intravenous infusion
223854594|NCT02951117|DRUG|Dexamethasone|Tablet or intravenous infusion
223854595|NCT04373187|DRUG|CC-93538|one injection of 2mL
223854596|NCT04373187|DRUG|CC-93538|two injections of 1.2mL
223854597|NCT03368378|PROCEDURE|Early DVC ligation|After the posterior isolation of seminal vesicles, the Retzius space will be accessed and the endopelvic fascia will be incised. The DVC will be identified and incised. The DVC will be then selectively ligated using a V-lok 3/0 barbed suture. This approach would allow for the preservation of the external urethral sphincter and for the identification and preservation of the neurovascular bundles that are located in the anterolateral aspect of the prostate. After the early DVC isolation, incision and ligation, the bladder neck will be incised and preserved when possible. A posterior nerve sparing approach will be then performed. During apical dissection, the urethral sphincter will be identified and carefully preserved. Posterior reconstruction and anastomosis will be then performed.
223854598|NCT03634189|DRUG|Cannabidiol|Patients with ACC/AHA stage A-C will receive 5 mg/kg to a maximum tolerated dose of 25 mg/kg PO BID of Cannabidiol
223854599|NCT02846415|BEHAVIORAL|Play Intervention for Dementia|"1. 8 weekly session, 45-75 minutes each~2. Play with toys~3. Sessions will be facilitated by a play specialist, trained play assistants, and centre staff."
223854600|NCT04178395|DEVICE|bihemispheric transcranial direct stimulation|"tDCS was applied with the anode placed over the M1 hand area of the ipsilesional motor cortex and the cathode over the same area of the contralesional motor cortex (C3/C4). For the active condition, patients received 5 consecutive daily sessions of 2 mA anodal tDCS over the AH and cathodal tDCS over the UH of 20 minutes each, with fade-in and fade-out periods of 1s. For the sham condition, the stimulation applied in the same sites and with the same parameters, was turned off after a fade-in period, 30 seconds of direct current stimulation and a fade-out period.~Repetitive peripheral nerve stimulation was performed by a peripheral nerve stimulator to the radial nerve and applied at the same time as tDCS. Radial nerve was chosen to improve wrist extension. Trains of 40 stimuli (ISI: 10 ms, duration: 1ms) were delivered every 6 seconds to the radial nerve through bipolar electrodes (5 cm diameter) at an intensity that could elicit a visible wrist extension (20-30 mA)."
223854601|NCT03038503|DRUG|Methylene Blue|after defined refractory shock (need NE\>0.5 mcg/kg/min) add Methylene blue 1 mg/kg iv drip then 2 hr later drip 0.5 mg/kg/hr\*4 hr (intervention add on to standard care)
223854602|NCT03038503|DRUG|Terlipressin|after defined refractory shock (need NE\>0.5 mcg/kg/min) add terlipressin 1 mg IV then repeated dose 20 min later if unstable BP (intervention add on to standard care)
223854603|NCT06089629|PROCEDURE|Lingual frenuloplasty|Surgical release of ankyloglossia with suture reorientation of the wound to improve lingual mobility, done under local or general anesthesia
223854604|NCT01588015|BIOLOGICAL|tetanus-CMV fusion peptide vaccine|Given SC
223854605|NCT01588015|OTHER|laboratory biomarker analysis|Correlative studies
223854606|NCT05933720|DRUG|Polypeptides|The patients will undergo treatment with a drug based on vascular polypeptides Slavinorm®, a derivative from cattle vessels, registered in Russia for the treatment of patients with peripheral atherosclerotic occlusive disease.
223854607|NCT05933720|DEVICE|Femoral-popliteal bypass grafting with a synthetic graft above the knee|The patients with undergo an arterial revascularization - Femoral-popliteal bypass grafting with a synthetic graft above the knee
223854608|NCT05933720|OTHER|Routine conservative treatment|The patients will undergo routine conservative treatment as per clinical guidelines (acetylsalicylic acid 100mg daily, atorvastatin 20mg daily)
223854609|NCT02934958|BEHAVIORAL|Colon Cancer Screening Navigation|Patients with FIT Positive results that have been given the choice will be followed and navigated from referral to colonoscopy to assist in obtaining colonoscopy.
223854610|NCT02934958|BEHAVIORAL|Standard of Care|Patients will be tracked to compare how effective are usual care methods
223854611|NCT05702294|DEVICE|Diary pod ( measuring vessel that automatically calculates voided volume)|Women in the control arm of the study will be required to void in the measuring cup and write down their estimates on the paper diary and then transfer the voided volume to the diary pod provided (or vice versa).
223854612|NCT05702294|DEVICE|Diary pod ( measuring vessel that automatically calculates voided volume)|Women in the Lower Urinary Tract Symptoms ( LUTS) arm of the study will be required to void in the measuring cup and write down their estimates on the paper diary and then transfer the voided volume to the diary pod provided (or vice versa).
223854613|NCT05230875|BEHAVIORAL|self-administered questionnaire|"All patients participating in the therapeutic education program will complete a self-administered questionnaire before participation in educational program.~A new identical self-questionnaire will be distributed to patients 3 to 6 months after their participation in the therapeutic education program."
224266061|NCT01557751|GENETIC|Whole blood for genotyping|This study requires genotyping by extracting DNA from blood sample. A blood sample will be drawn once during visit 2 (day of surgery) or any other time prior to that after the signing of informed consent. Four vacutainers of which hold 8.5 mL will be drawn during this time totaling approximately 34 mL of blood which completes the genomic sampling portion of the study.
224266062|NCT01125527|BIOLOGICAL|Monovalent glyco-conjugated vaccine against Haemophilus influenzae type b (Hib)|a single dose was administered
224266063|NCT01125527|BIOLOGICAL|Tetanus toxoid polysaccharide-conjugated vaccine against Haemophilus influenzae type b (Hib)|a single dose was administered
224266064|NCT04220606|DRUG|Glyceryl trinitrate (I.V. infusion 0.5 µg/kg/min over 20 min)|
224266065|NCT01949922|PROCEDURE|Injection of autologous muscle fibers into the anal sphincter.|
223854614|NCT00078533|BIOLOGICAL|CMV CTL infusion|Three dose levels will be explored. The lowest dose level will be 1x10\^7cells/m2 and the highest will be 1x10\^8/m2. 3-6 pts will be entered at each dose level (depending on toxicity). If there are no toxicities and immunological efficacy is not seen at any dose, then the doses will be further escalated after additional local and federal approval. Additional patients will be treated at dose level 1 in order to assess the secondary objective of virus-specific immunity from the CTL infusions
223854615|NCT03383887|DRUG|Placebo oral capsule|Placebo before sleep
223854616|NCT03383887|DRUG|DAW1033D oral capsule|DAW1033D before sleep
223854617|NCT00831792|DRUG|TK1258|4 capsules (100 mg/capsules) of TKI 258 by mouth once daily (total of 400 mg of TKI258 per day).
223854618|NCT06554132|OTHER|Scleroderma Group|Scleroderma patients will be evaluated in terms of respiratory muscle strength, aerobic capacity, pulmonary function test and fatigue.
223854619|NCT06554132|OTHER|Healthy group|Healthy people will be evaluated in terms of respiratory muscle strength, aerobic capacity, pulmonary function test and fatigue.
223854620|NCT02837380|DRUG|FF|FF is a dry white powder blended with lactose. It is the first strip of DPI. Per blister contains 100 mcg of dose
223854621|NCT02837380|DRUG|VI/UMEC|VI and UMEC bromide combination is a dry white powder blended with lactose and magnesium stearate. It is the second strip of DPI. Per blister contains 25 mcg/62.5 mcg of VI/UMEC dose
223854622|NCT04991259|PROCEDURE|Continuous Renal Replacement Therapy (CRRT)|Continuous renal replacement therapy will be administered as continuous venovenous hemodiafiltration (CVVHDF) using Prisma and Prismaflex (Gambro) devices, with blood flows ranging from 150-180 mL/hr and target effluent rates of 20 - 25 mL/kg/hr. Anticoagulation was not used during dialysis. CRRT would be continued until resolution of cerebral edema and in decrease in ammonia levels below 150 ug/dl or in those who develop adverse effects of therapy.
223854623|NCT04991259|OTHER|Standard Medical Treatment|In the L- ICU, patients will be managed by a multidisciplinary team. Intubation and ventilation will be undertaken for standard indications in addition to the development of grade 3 encephalopathy or evidence of cerebral edema on CT-scan. Fluid management will be done with crystalloids, with the use of colloids (5% albumin) in patients with severe hypoalbuminemia (serum albumin less than 2.5gm/dl). Norepinephrine will be the primary vasopressor used to target a mean arterial pressure of 65-70 mm of Hg. with adjunctive use of intravenous low dose hydrocortisone and vasopressin in patients not responsive to initial therapy.
224266066|NCT01949922|PROCEDURE|Pelvic floor muscle training|Pelvic floor muscle training 3 months to optimize pelvic floor muscle function. Autologous muscle stem cell injection will only be offered to patients that still have problems after completion of pelvic floor muscle training.
223854624|NCT03742713|DRUG|CPC634 (CriPec® docetaxel)|Docetaxel containing CriPec® nanoparticles
223854625|NCT02703129|OTHER|Nutritional intervention|Women with the diagnosis of migraine received individualized diet meal plan and nutritional orientations for three months according to their nutritional diagnosis
223854626|NCT00742573|DRUG|Antidepressants through Texas Medication Algorithm (TMA)|Treatment with medication will follow the TMA for depression. Antidepressant medications may include any of the following: citalopram, escitalopram, paroxetine, sertraline, venlafaxine XR, bupropion SR, duloxetine, nortriptyline, and mirtazapine.
223854627|NCT00742573|BEHAVIORAL|Brief Interpersonal Psychotherapy (IPT-B)|IPT-B consists of twelve 50-minute sessions, divided into three phases, focusing on an interpersonal problem or problems.
223854628|NCT00647205|DEVICE|QuantiFERON TB Gold In-Tube|
223854629|NCT00647205|DEVICE|T-SPOT.TB®|
223854630|NCT02509390|PROCEDURE|Blood samples|Investigators analyze hematological parameters with blood sampled daily in severe trauma patients
223854631|NCT01142713|RADIATION|Patient Position During Radiotherapy|Two simulations, one in the supine position on a flat table and another in the prone position on belly board
223854632|NCT00640666|BEHAVIORAL|Exercise Behavior Change|Multidisciplinary
223854633|NCT03775447|PROCEDURE|Lumbar Puncture|Lumbar Puncture for collection of Cerebrospinal Fluids
223854634|NCT00697229|BIOLOGICAL|Engerix™-B|Intramuscular injection, 1 or 3 doses
223854635|NCT00697229|BIOLOGICAL|HBV-MPL vaccine|Intramuscular injection, 1 or 3 doses
223854636|NCT02860091|DRUG|Ropivacaine infusion|Delivered via paravertebral nerve block catheter.
223854637|NCT04045743|DRUG|MABp1 (Bermekimab) OR Placebo|Period A: patients randomized 1:1 to weekly subcutaneous treatment with 400mg Bermekimab or matched Placebo for 12 weeks
223854638|NCT04045743|DRUG|MABp1 (Bermekimab)|Period B: all patients treated weekly with subcutaneous 400mg Bermekimab for 12 weeks
224266067|NCT01949922|BEHAVIORAL|Dietary intervention|Dietary intervention 3 months to optimize defecatory function. Autologous muscle stem cell injection will only be offered to patients that still have problems after completion of pelvic floor muscle training and dietary intervention.
224266068|NCT01949922|DRUG|Analgesia|Patients will be offered analgesia as needed during and after surgery. Specific products will depend on allergy and preferences of doctors involved and patient's requirements.
224266069|NCT01323127|PROCEDURE|Sagital xrays|5 xrays will be taken: (1) Upright standing position; (2) Upright, straight chair position; (3) Slouching, straight chair position; (4) Upright, ergonomic chair position; (5) Slouching, ergonomic chair position.
224266070|NCT05866588|BEHAVIORAL|Physical, psychological and spiritual nursing care (Nursing Therapeutics)|"1. Follow-up: To make a presentation about the physiological and psychological changes during pregnancy. do dream work~2. Follow-up: Providing education and counseling for childbirth.~3. Follow-up: Training and role rehearsal on mother-infant interaction, breastfeeding and infant care.~4. Follow-up: To provide counseling on the issues needed with the approaching of the birth.~5. Follow-up: Teaching about conscious parenting and mother-infant, father-infant interaction.~6. Tracking. To provide education, counseling and social support on the other roles of the mother in life such as wife role, working woman role, social role.~7. Follow-up: To evaluate the transition to motherhood.~8. Follow-up: To evaluate the outcomes of transition to motherhood and adjustment to motherhood according to expected completion time."
224266071|NCT02584907|OTHER|High Fat Enteral Nutrition|Diet in high fat group will be 20% from protein, 45% from fat and 35% from carbohydrate
224266072|NCT05992454|DEVICE|EOLIFE|Measurement of ventilatory parameters during manual ventilation by professional rescuers during out-of-hospital cardiac arrest
223854639|NCT01242085|PROCEDURE|trumatch group|these patient will have CT based customized knee instruments used for surgery
223854640|NCT01242085|PROCEDURE|control group|these patients will have standard instrumentation used for for knee replacement
223854641|NCT03511885|OTHER|There is no intervention|
223854642|NCT05465811|OTHER|Program of physical exercises and health education by telerehabilitation|"To carry out the telerehabilitation program, the Google Meet platform will be used in order to provide the synchronous service model. This will occur for a period of 16 weeks, three weekly sessions lasting 50 minutes, (total of 48 sessions). The sessions will be given by physiotherapists and students in their final year of graduation in physiotherapy, which will consist of the following phases: initial rest, warm-up, resistance exercises, stretching exercises, relaxation and final rest.~In addition, in exchange for the warm-up phase, every 12 sessions, the telerehabilitation program also will have an approach through health education, using presentations, digital booklets and direct conversation between therapist and participants. The themes exhibited (importance of physical exercise in the pandemic context, reduction of the risk of falls through changes in the home environment and physiological changes resulting from aging) will intend to make them aware of better lifestyle habits."
223854643|NCT05424159|RADIATION|Carbon ion radiotherapy|Patients with locally advanced unresectable pancreatic cancer without invasion of gastrointestinal tract will received ablative carbon ion radiotherapy. The prescription dose for primary pancreatic lesion, positive lymph node, and retroperitoneal high-risk recurrence area is 67.5 Gy (RBE weighted dose) in 15 fractions for 3 weeks; Pancreatic primary lesion and positive lymph node SIB to 75 Gy (RBE weighted dose) in 15 fractions for 3 weeks.
223854644|NCT01003015|DRUG|BAY73-4506|160 mg BAY73-4506
223854645|NCT03489265|DRUG|Eluxadoline 100 mg|100 mg capsule-shaped tablet by mouth taken twice per day
223854646|NCT03489265|OTHER|Placebo|Matching capsule-shaped placebo tablets taken by mouth twice per day
223854647|NCT00065390|DRUG|Pyrimethamine|
223854648|NCT02410291|OTHER|Educational video|Patients in the control group will receive standard patient education Patients in the experimental group will receive standard education and an educational video
223854649|NCT01638624|DRUG|Propofol|Propofol :Propofol is an anesthetic agent, has structure similar to that of known such as alfa tocopherol.
223854650|NCT01638624|DRUG|Placebo|
223854651|NCT02950779|OTHER|Handgrip Strength Measurement|
223854652|NCT00904527|BEHAVIORAL|relaxation (Schultz)|Patients have relaxation consultations during 2 months
223854653|NCT02422121|DRUG|RNS60|
223854654|NCT02422121|DRUG|Placebo|
223854655|NCT03636451|DRUG|40cc buffered 0.5% lidocaine with 2 units of vasopressin paracervical block|Women undergoing D\&C in the first trimester for either surgical abortion or miscarriage management will receive 40cc buffered 0.5% lidocaine with 2 units of vasopressin paracervical block before cervical dilation.
223854656|NCT03636451|DRUG|20cc 1% lidocaine with 2 units of vasopressin paracervical block|Women undergoing D\&C in the first trimester for either surgical abortion or miscarriage management will be randomly assigned to receive 20cc 1% lidocaine with 2 units of vasopressin paracervical block before cervical dilation.
223854657|NCT01651949|BIOLOGICAL|9vHPV Vaccine|9vHPV, V503 (9-valent HPV \[Types 6, 11, 16, 18, 31, 33, 45, 52, and 58\] L1 virus-like particle vaccine), 0.5 mL injection in 3-dose regimen
223854658|NCT02997618|BEHAVIORAL|Community based exercise programme|20 week community (home or gym based) exercise programme
223854659|NCT02997618|OTHER|Control|Usual care consisting of advice.
223854660|NCT03149406|OTHER|Comparing the expression of miRNAs|by PCR, in symptomatic and asymptomatic carotid plaques.
223854661|NCT00346931|PROCEDURE|Phacoemulsification, implantation of intraocular lens|
223854662|NCT00346931|PROCEDURE|Phacoemulsification, Implantation of IOL, trabeculotomy|
223854663|NCT02438800|BEHAVIORAL|LARC First Video|LARC First is an evidence-based, 12-minute video developed by the CHOICE project that features women of all racial and ethnic backgrounds describing LARC methods of contraception in simple, understandable language with summary text when appropriate.
223854664|NCT00000433|DRUG|Anti-Tumor Necrosis Factor|
223854665|NCT01806714|OTHER|Text-based reminder for recommended HPV vaccine or WCC|Patients due for a well visit or HPV vaccine received a text reminder
223854666|NCT01806714|OTHER|Non-specific text-based reminder (general health tip)|Parents of adolescents receive preventive health tips via text messages (not specific to services for which child is due)
223854667|NCT02186405|DRUG|LEVOTHYROXINE|administration of levothyroxine
223854668|NCT05905406|OTHER|Electrical estimulation|Electrical estimulation during the fatigue protocol. Frequency = 100 Hz, pulse duration = 500 µs, time ON = 20 s (including rise time = 1.0 s and descent time = 1.0 s) and off time = 20 sec
223854669|NCT02469064|OTHER|Respiratory muscle training|Respiratory muscle training is done twice every day, with 3 series of 10 repetitions each, with a resting pause of two minutes between series (during resting time, patient is connected to mechanical ventilation again). We adjust initial load for respiratory muscle training as 50% of MIP. At the end of every training session, we assess dyspnea (perceived effort) using Modified Borg Scale (23). Four physical therapists are in charge of Respiratory muscle training, these therapists work at ICU and have experience with critically ill patients.
223854670|NCT02469064|OTHER|Cardiopulmonary Physical Therapy|Control group receives Cardiopulmonary Physical Therapy every 6 hours, physical therapy and mechanical ventilation management
223854671|NCT02155829|DRUG|Riluzole|
223854672|NCT02155829|DRUG|Placebo (for Riluzole)|
223854673|NCT00866762|DRUG|HDAC inhibitor (MK-0683)|400 mg once daily for 6 months
223854674|NCT03096184|DRUG|Apatinib Mesylate Tablets|500 mg qd.p.o. every day for 21 days as a cycle
223854675|NCT03096184|DRUG|Tegafur Gimeracil Oteracil Potassium Capsules|50mg bid p.o. every day for 14 days as a cycle
223854676|NCT05971355|DEVICE|LimpiAD cream 2,5% plus|A topical formulation that contains Hyaluronic Acid conjugated with a bacterial wall fragment of Cutibacterium species (HAc-40) and an emollient base. LimpiAD exerts its post-biotic action through the seizure/ trapping and inactivation of catabolites and / or toxins produced by S. aureus as well as protecting the hydrolipidic film, especially in case of dryness, itching, and, in conditions of altered microbiome
223854677|NCT05971355|OTHER|Vehicle|"Vehicle of LimpiAD cream 2.5 % plus which has the qualities of an emollient technically enriched with active ingredients known for their use in AD (plus emollient) - having the same ingredients of LimpiAD 2.5% Plus cream but without the HAc-40 component."
223854678|NCT05971355|OTHER|Emollient|Standard emollient used as neutral control, having only a moisturizing and skin barrier action, which represents the basic standard treatment (basic therapy) of atopic dermatitis according to the European Guidelines.
223854679|NCT02057354|BEHAVIORAL|Aerobic Exercise|The goal of the aerobic exercise training is to increase aerobic endurance. Walking on treadmill at moderate intensity with grade adjusted. Exercise tailored to individual ability level.
223854680|NCT02057354|BEHAVIORAL|Non-Aerobic Exercise|The goal of this training is to improve overall muscle strength, balance and flexibility. Participants will do strength, balance and stretching exercises. Exercises tailored to individual ability level.
223854681|NCT01884389|OTHER|Patient Navigation|Home-based medical and social support services, as an extension of and collaboration with primary care services provided. Phone calls and visits scheduled based on patient's level of need. Communication with primary care team via navigation plan faxed / emailed as needed. Volunteers will also be matched with intervention patients to provide additional support services by phone / in-person visits.
223854682|NCT04272073|OTHER|High-Protein Mediterranean Diet|As in arm/group descriptions
223854683|NCT04272073|OTHER|Resistance Exercise|As in arm/group descriptions
223854684|NCT04272073|OTHER|Standard Dietary Advice|As in arm/group descriptions
223854685|NCT04272073|OTHER|Standard Cardiac Rehabilitation Exercise|As in arm/group descriptions
223854686|NCT00680537|PROCEDURE|Exercises|Completion of a series of shoulder exercises for 6 weeks post device implant
223854687|NCT02534441|OTHER|Skin patch test|
223854688|NCT04656236|BIOLOGICAL|3-hydroxybutyrate|3-hydroxybutyrate is a metabolite, produced in the human body.
223854689|NCT03724370|BEHAVIORAL|Telehealth Monitoring System|TES will be conducted daily via Interactive Voice Response System (IVRS) during the 12 week study period.TES will be added to VHA-SRM.
223854690|NCT03724370|OTHER|VHA-SRM|Veterans Health Administration Suicide Risk Management supportive services will be provided to participant during the 12 weeks of study participation.
223854691|NCT01585038|DRUG|Efavirenz|600mg orally every evening
223854692|NCT01585038|DRUG|Rilpivirine|25mg orally once daily
223854693|NCT02678104|PROCEDURE|Tooth extraction|Tooth removal
223854694|NCT02678104|DRUG|Chlorhexidine mouth wash|Chlorhexidine mouth wash
224076132|NCT06241586|PROCEDURE|The conventional step-up strategy|Interventions were postponed until 4 weeks after the onset of pancreatitis in line with international guidelines unless the patient showed evidence of progressive clinical deterioration despite the use of maximal supportive care. Patients underwent CT-guided percutaneous catheter drainage as the first step. Treatment response was evaluated after 3 days. If drainage was clinically unsuccessful, a VARD procedure was performed. Similarly, open surgery, which was described by Beger et al., was performed if the VARD procedure failed. Postoperative continuous lavage is performed as a routine procedure.
223854695|NCT02678104|DRUG|Intra-alveolar application of Manuka Honey|Intra-alveolar application of Manuka Honey directly after extraction.
223854696|NCT04007302|OTHER|measurement of bilateral activity of the prefrontal cortex by a NIRS system (near infrared spectroscopy)|measurement of the cerebral oxygenation response by the use of the Near Infrared Spectroscopy (NIRS) method
223854697|NCT04007302|OTHER|completion of questionnaires|igroup presence questionnaire (IPQ), Dallas Pain Questionnaire (DRAD), Fear-Avoidance Beliefs (FABQ) and Quebec Back Lumbago Scale
223854698|NCT04007302|OTHER|completion of questionnaires for pain|analogical visual and numerical scale and Borg scale
224266073|NCT00493805|DRUG|Combination of pegylated interferon alfa-2b and ribavirin|"1. Powder for injection in Redipen (50, 80, 100, 120, and 150 microgram strengths), subcutaneous, dose of 1.5 micrograms/kg, weekly for 12 weeks, then up to 4 weeks until HCV PCR results are available, and then for another 36 weeks(Group A) or 60 weeks (Group B) postrandomization.~2. 200 mg capsules, oral, weight based dose of 800-1400 mg, daily for up to 12 weeks, then up to 4 weeks until HCV PCR results are available, and then for another 36 weeks (Group A) or 60 weeks (Group B) postrandomization"
224266074|NCT00493805|DRUG|Combination of pegylated interferon alfa-2b and ribavirin|"1. Powder for injection in Redipen (50, 80, 100, 120, and 150 microgram strengths), subcutaneous, dose of 1.5 micrograms/kg, weekly for 48 weeks~2. 200 mg capsules, oral, weight based dose of 800-1400 mg, daily for 48 weeks"
224266075|NCT02287480|BIOLOGICAL|VSV-ZEBOV|See arm/group descriptions.
224266076|NCT05289440|DRUG|Low-dose esketamine infusion|Patients received a bolus infusion of esketamine (0.5 mg/kg) before cutting the skin, and then esketamine was infused at a rate of 2 µg/kg/min until before suture the skin.
224266077|NCT05289440|DRUG|High-dose esketamine infusion|Patients received a bolus infusion of esketamine (0.5 mg/kg) before cutting the skin, and then esketamine was infused at a rate of 4 µg/kg/min until before suture the skin.
224266078|NCT05289440|DRUG|Saline infusion|Patients received a bolus infusion of the same volume saline before cutting the skin, and then the same volume saline was infused until before suture the skin.
224266079|NCT04501848|PROCEDURE|adenotonsillectomy|adenotonsillectomy surgery
224266080|NCT05497063|DRUG|Sulfadoxine/Pyrimethamine dispersible tablets, 250 mg sulfadoxine / 12.5 mg pyrimethamine & 500 mg sulfadoxine / 25 mg pyrimethamine|Two tablets of 250 mg sulfadoxine / 12.5 mg pyrimethamine or 500 mg sulfadoxine / 25 mg pyrimethamine to be given as single dose once under fasting condition
224266081|NCT05497063|DRUG|G-COSPE® tablets|One tablet of G-COSPE® tablets, 500 mg sulfadoxine / 25 mg pyrimethamine to be given as single dose once under fasting condition
224266082|NCT06272617|DEVICE|verum acupuncture|a type of acupuncture which is useful
224266083|NCT06272617|DEVICE|sham acupuncture|a type of acupuncture which is useless
224266084|NCT02991196|DRUG|DS-8273a + nivolumab|Nivolumab will be administered at 240 mg intravenously (IV) once every two weeks (Q2W) over 30 (± 5) minutes (on Days 1 and 15 of each cycle of 28 days). DS-8273a will be administered \[90 (± 15) minutes on Day 1 of Cycle 1, and 60 (± 15) minutes in subsequent infusions\] after the end of the nivolumab infusion in ascending doses up to 1200 mg IV Q2W. The regimen is adjusted based on injection site reactions or adverse events. Additional dose combinations may be considered based on the assessment of safety, primary pharmacodynamic (PDy) effects, and preliminary anti-tumor activities.
223854699|NCT00678795|DRUG|Sativex®|"Containing ∆9 tetrahydrocannabinol (THC), 27 mg/ml and cannabidiol (CBD), 25 mg/ml as extract of Cannabis sativa L.~Subjects received study medication delivered in 100 µl actuations by a pump action oromucosal spray. Maximum permitted dose was eight actuations in any three-hour period and 48 actuations (THC 130 mg:CBD 120 mg) in 24 hours"
223854700|NCT00678795|DRUG|Placebo|containing excipients only. Subjects received study medication delivered in 100 µl actuations from a pump action oromucosal spray. Maximum permitted dose was eight actuations in any three-hour period and 48 actuations in 24 hours.
223854701|NCT00272935|DRUG|Cenestin 0.3 mg Tablets|1 tablet daily
223854702|NCT00272935|OTHER|Placebo|1 tablet daily
223854703|NCT01947179|BEHAVIORAL|Anxiety Risk Reduction|Involves psychoeducation and interoceptive exposure exercises
223854704|NCT02392156|BIOLOGICAL|rFVIIIFc|As described in the treatment arm
223854705|NCT02392156|BIOLOGICAL|rFIXFc|As described in the treatment arm
223854706|NCT02392156|DRUG|non-Fc FVIII replacement products|Standard plasma-derived (pd) or recombinant (r) FVIII concentrate and other traditional treatment options
223854707|NCT02392156|DRUG|non-Fc FIX replacement products|Standard plasma-derived (pd) or recombinant (r) FIX concentrate and other traditional treatment options
223854708|NCT04107805|DRUG|BI 1323495|Tablet
223854709|NCT04107805|DRUG|Placebo|Tablet
223854710|NCT04107805|DRUG|Midazolam|Oral administration
223854711|NCT01760044|DEVICE|Tissue oxygenation monitoring|The device provides continuous measures with updates based on the previous 10 seconds worth of data. Data is continuously stored.
223854712|NCT01304394|DRUG|Ped3CB|The Ped3CB is a ready to use, triple-chamber bag containing a sterile, nonpyrogenic combination of amino acids (Primene®, Baxter) with electrolytes, glucose, and lipids (ClinOleic®, Baxter) in separate compartments for intravenous (IV) PN. The dosage, frequency and duration is dependent on patient's weight, age, clinical status as well as addition energy or protein given enterally/orally.
223854713|NCT00768131|DRUG|Cetuximab|Vial, Intravenous, 400 mg/m² week 1 then 250 mg/m², Weekly, Until PD/Toxicity/Pt-PI Decision
223854714|NCT00768131|DRUG|Paclitaxel|Vial, Intravenous, 225 mg/m2, Every 3 weeks, 6 cycles maximum
223854715|NCT00768131|DRUG|Carboplatin|Vial, Intravenous, AUC = 6.0, Every 3 weeks, 6 cycles maximum
223854716|NCT00966966|DRUG|SAM-531 and gemfibrozil|2 single doses of 5 mg SAM-531 (capsules) a daily dose of 1200 mg Gemfibrozil (one tablet of 600mg at approximately 8 a.m. and one tablet of 600 mg at approximately 6 p.m.) for 14 days
223854717|NCT04590651|PROCEDURE|Cataract surgery|Routine phacoemulsification cataract surgery using the Alcon Centurion® device.
223854718|NCT04590651|PROCEDURE|Cataract surgery with extra anterior chamber angle aspiration|Routine phacoemulsification cataract surgery using the Alcon Centurion® device. At the end of the case a one minute extra anterior chamber angle aspiration will be preformed after the removal of the viscoelastic agent.
223854719|NCT03960983|DEVICE|Treatment with tongue scraper|Treatment with tongue scraper. the evaluation of halitosis will be repeated before this step.
223854720|NCT03960983|PROCEDURE|Hygiene procedures for the mucosa and dentures|Hygiene procedures for the mucosa and dentures edentulous participants will be submitted to hygiene procedures for the mucosa and dentures. The evaluation of halitosis will be repeated before this step
223854721|NCT03960983|RADIATION|Photodynamic Therapy|Treatment with Photodynamic therapy. The evaluation of halitosis will be repeated before this step
223854722|NCT03960983|PROCEDURE|Hygiene procedures for the mucosa and dentures|Hygiene procedures for the mucosa and dentures edentulous participants will be submitted to hygiene procedures for the mucosa and dentures. The evaluation of halitosis will be repeated before this step
223854723|NCT02869958|OTHER|Digital action plan for asthma exacerbations + Written action plan|Digital action plan for asthma exacerbation available through an AppWeb and requiring a connected device such as a Smartphone or a tablet computer. The patient must connect and describe the situation to obtain the names, doses and dosing of the treatment his/her physician has recommended for him/her according to the level of severity of the exacerbation
223854724|NCT02869958|OTHER|Written action plan|
223854725|NCT04820101|DRUG|Dexmedetomidine|administrating dexmedetomidine in order to evaluate the efficacy in achieving sedation for LISA procedure
223854726|NCT01450124|DRUG|Boswellic acids (BOSWELAN)|8 months of treatment at a t.i.d. (Ter In Die (Latin: Three Times A Day) dose of between 400-1600 mg Boswelan
223854727|NCT06206473|OTHER|mEEG assessment|mEEG assessment (V1) will be performed at the patient's bed within 72 hours of the diagnosis of delirium. The mEEG recording, which lasts approximately 2 hours, will be performed by one of the investigators with expertise in electrophysiological acquisition. This non-invasive assessment consists of placing an EEG net on the scalp of the participants and earphones through which the auditory stimuli will be delivered.
223854728|NCT02286999|DRUG|B. infantis|Infants in the intervention group will receive two doses of B. infantis on Day 7 and Day 14 of life, while infants in the placebo group will be dosed with placebo on Day 7 and Day 14
223854729|NCT02286999|DRUG|Placebo|
223854730|NCT04238234|DEVICE|IVC Ultrasonography|Ultrasound measurements will be performed using a curved transducer set to abdominal mode (1-5 MHz; Acuson x300; Siemens Healthcare, Seoul, Korea). IVC variation will be assessed using ultrasound in the long-axis (sagittal) view. IVC diameter will be measured 1 cm distal to its junction with hepatic vein either by 2-D or M modes via a subcostal approach according to the methodology described by the American Society of Echocardiography . A two-dimensional image of the IVC as it enters the right atrium will be first obtained.
223854731|NCT04238234|DEVICE|Plethysmographic variability index (PVI) and perfusion index readings (PI)|"The PVI and PI will be recorded in the supine position by an anaesthesiologist who was not involved in the further intraoperative monitoring of the patient using Masimo SET (MightySat 9900, Masimo Corporation, Irvine, CA, USA).~PVI (%) is a measure of the dynamic change in PI that occurs during one or more complete respiratory cycles, calculated as:~PVI= \[(PImax-PImin)/PImax\] x100"
223854732|NCT02563704|DRUG|Artesunate|
223854733|NCT02563704|DRUG|Quinine|
223854734|NCT02261688|DIETARY_SUPPLEMENT|Low salt diet|Low salt diet, 10mmoL of sodium per day, for 6 days
223854735|NCT02261688|DIETARY_SUPPLEMENT|Low salt diet + IV normal saline|Low salt diet, 10 mmoL of sodium per day, for 4 days with normal saline infusion x 12 hours per day for 200 mmoL of sodium chloride. Total daily sodium is 210 mmoL/day.
223854736|NCT02261688|DIETARY_SUPPLEMENT|Liberal salt diet|Liberal salt diet targeting 200 mmoL of sodium per day x 7 days
223854737|NCT06055114|DIAGNOSTIC_TEST|Microscopic examination of vaginal discharge|Using gram-stained smears to detect vaginal secretions, and then the concentration and diversity of bacterial flora are observed using a microscope.
223854738|NCT02777632|PROCEDURE|Living donor liver transplantation|
223854739|NCT05196438|OTHER|Collecting statistics about congenital heart patterns and investigations done and interventions done to them|Collecting statistics about congenital heart patterns and investigations done and treatment given or interventions e.g. catheterization or surgical operations done to them
223854740|NCT03558204|PROCEDURE|Denervation of the thumb CMC joint|Removal/disconnection of the nerve branches to the joint from their attachments to the joint
223854741|NCT03558204|PROCEDURE|trapeziectomy with ligament reconstruction (LRTI)|excision of the trapezium and suspension of the thumb metacarpal with the flexor carpi radialis tendon
223854742|NCT05623384|PROCEDURE|Stellate ganglion block|A cross-sectional scan with a high-frequency line array probe reveals the pre-C6 transverse nodule or C7 transverse process, and the structures of the thyroid, carotid sheath, vertebral artery, inferior thyroid artery, trachea, and esophagus are identified by observation. The carotid sheath is pushed out as far as possible laterally, the needle is inserted in the paratracheal sulcus, and the tip of the needle is passed through the lateral border of the thyroid into the deep anterior fascial surface of the long cervical muscle.After backdrawing no blood, cerebrospinal fluid or gas, 5 ml of lidocaine was injected.（lidocaine 80mg；Physiological saline 1ml）
223854743|NCT05623384|PROCEDURE|Facial and glossopharyngeal nerve blocks|The operator touches the position of the mastoid process and needles vertically at the front of the mastoid process directly below the external auditory canal. When the surface of the mastoid is touched, the needle is adjusted to pass through the front of the mastoid and then slowly needled for about 1 cm, and when the patient develops swelling and pain, 3 ml of the drug is injected. then the needle is slowly needled backward for about 1 cm, and when the patient develops swelling and pain, 2 ml of the drug is injected. （mecobalamin injection 1mg；lidocaine 20mg； dexamethasone 10mg ；Physiological saline 2ml）
223854744|NCT05623384|DRUG|Mecobalamin Tablets|oral Mecobalamin Tablets tid-8
223854745|NCT05787730|DEVICE|Transobturator tape|
223854746|NCT01356225|DRUG|Ketorolac tromethamine|30 mg Intranasal (2 x 100 uL of a 15% solution), single dose
223854747|NCT01356225|DRUG|Placebo|IN placebo
223854748|NCT05159141|BEHAVIORAL|Behavioral sleep intervention|The intervention consists of an infant behavioral sleep protocol. In the tailored intervention approach, parents are asked to implement the behavioral protocol at bedtime and at subsequent night wakings.
223854749|NCT05753644|PROCEDURE|stellate ganglion blocks|At the level between C6 and C7, a 25-gauge needle is inserted laterally, and the needle tip is placed posterior to the carotid artery and anterior to the longus colli muscle using an in-plane approach.
223854750|NCT05753644|DRUG|Ropivacaine|5 mL of 0.5% ropivacaine injected in the plane of the right stellate ganglion
223854751|NCT05753644|DRUG|Sham treatment|5 mL of saline injected in the plane of the right stellate ganglion
223854752|NCT00404079|DRUG|Glucosamine sulphate|Oral intake of 1500 mg glucosamine sulfate(from Pharma Nord) daily for 6 months
223854753|NCT00404079|DRUG|Placebo|Oral intake of 3 placebo capsules (similiar looking to the glucosamine sulfate capsules)daily for 6 months
223854754|NCT01120275|DRUG|gamma-secretase/Notch signalling pathway inhibitor RO4929097|Given PO
223854755|NCT01120275|OTHER|laboratory biomarker analysis|Correlative studies
223854756|NCT04269850|BIOLOGICAL|allogeneic fecal microbiota|Single dose of capsules with fecal transplant (capsules for adults - 400-815mg, for adolescents - 280-500mg, for children - 160-320mg) - 2 capsules/kg body weight, divided in two consecutive days Additional supportive therapy after FMT include omeprazole 40mg po, inulin 1gr x 4 times a day po, metoclopramide 40mg po.
223854757|NCT04269850|DRUG|Ruxolitinib|Ruxolitinib starting dose 10 mg bid. In case of grade 4 hematological toxicity dose can be reduced by 25-75%.
223854758|NCT04269850|DRUG|Methylprednisone|Methylprednisone starting dose 0.5 mg/kg bid IV or oral, with subsequent tapper by 0.1 mg/kg every 5 days.
223854759|NCT04767035|DRUG|midazolam / ketamine sublingual tablet|sublingual tablet
223854760|NCT02886793|DRUG|fludeoxyglucose|
223854761|NCT04898192|OTHER|questionnaire|questionnaire - the complex of 6 questionnaires aimed to recognize the fear of delivery, perinatal anxiety, depressive disorder, obsessive-compulsive disorder, general anxiety disorder, postpartal depression and domestic violence.
223854762|NCT00404794|DRUG|prednisolone and mycophenolate mofetil|
223854763|NCT00404794|DRUG|prednisolone and tacrolimus|
223854764|NCT06121310|OTHER|Survey|Non interventional. Pediatric anesthesia satisfaction scale validity and reliability is going to investigate by survey analyses
223854765|NCT06204796|DRUG|vitamin D supplement was given as 60,000 IU weekly in conjunction with systemic prednisone|All participants received 40-60 mg of systemic prednisone as a single morning dose according to the severity of the condition until a 50% reduction in lesion size was achieved then the dose was tapered by 10mg each week and finally to 5 mg/day for the last week. Patients were followed up weekly for up to 60 days. The length and dose of treatment were adjusted according to clinical needs in each case. In addition, a vitamin D supplement was given as 60,000 IU weekly in conjunction with systemic steroids.
223854766|NCT06204796|DRUG|Systemic prednisone|All participants received 40-60 mg of systemic prednisone as a single morning dose according to the severity of the condition until a 50% reduction in lesion size was achieved then the dose was tapered by 10mg each week and finally to 5 mg/day for the last week. Patients were followed up weekly for up to 60 days. The length and dose of treatment were adjusted according to clinical needs in each case.
223854767|NCT02909049|DRUG|MIDAZOLAM|Intravenous bolus anesthesia 5 minutes previous to saturation prostate biopsy.
223854768|NCT02909049|DRUG|MEPIVACAÍNE|Local periprostatic anesthesia infiltration, previous to saturation prostate biopsy.
223854769|NCT02909049|DRUG|FENTANILE|Intravenous bolus anesthesia 3 minutes previous to saturation prostate biopsy.
223854770|NCT02909049|DRUG|KETAMINE|Intravenous bolus anesthesia 1 minute previous to saturation prostate biopsy.
223854771|NCT01087177|OTHER|Exposure to practice that has been trained in Pedialink CEASE|Child has had an appointment at a practice that was trained in Pedialink CEASE at the time of the interview.
223854772|NCT04564391|DIETARY_SUPPLEMENT|protein supplement|protein supplement, daily 60 g of protein, 3 weeks of intervention; blinded to patients
223854773|NCT04564391|DIETARY_SUPPLEMENT|placebo supplement|Placebo supplement, daily intake of placebo, 3 weeks of intervention; blinded to patients
223854774|NCT00880906|PROCEDURE|Esophageal dilation|The esophagus is stretched during the upper endoscopy using Maloney dilators or balloon dilatation.
223854775|NCT00880906|DRUG|Steroid and Proton Pump Inhibitor Therapy|
223854776|NCT02622230|DRUG|Mianhuahua Flavonoids Tablets|"Tolerability Study:~Period I:Single oral administration,dose-escalation of Mianhuahua Flavonoids Tablets(seven dose groups:0.3g-5.4g) Period II:Repeated oral administration of Mianhuahua Flavonoids Tablets (group 1:MTD（maximum tolerated dose）/1.5g, TID, group 2:depending on the adverse drug reaction,1.8g/1.2g, TID)~Pharmacokinetic Study:~Period I:Single oral administration,dose-escalation of Mianhuahua Flavonoids Tablets(six dose groups: 0.9g, 1.8g, 2.7g, 3.6g, 4.5g, 5.4g) Period II:Repeated oral administration of Mianhuahua Flavonoids Tablets (group 1:MTD（maximum tolerated dose）/1.5g, TID, group 2:depending on the adverse drug reaction,1.8g/1.2g, TID)"
223854777|NCT02622230|DRUG|Placebo|Placebo to match with experimental groups
223854778|NCT00564967|BEHAVIORAL|CBT via the Internet|15 weeks, patients learn about CBT primarily thru a self-help book published on teh Internet, Minimal therapy contact via e-mail(10 minutes/week),
223854779|NCT00564967|BEHAVIORAL|CBT group therapy|15 weeks, 1 session/week, (2,5 hours.)
223854780|NCT03930823|OTHER|Interview|One to one interview
223854781|NCT00937846|DRUG|GSK1034702|Single oral 5 mg dose in liquid formulation
223854782|NCT05359224|DRUG|Prasugrel group|Prescribe the drugs according to the assigned group, and take them 5 days before the procedure. Perform platelet function test (VerifyNow assay; Accumetrics, San Diego, California) one day before the procedure to check the P2Y12 reaction reactivity. And the hyporesponsive group patient is given prasugrel 5mg once. And aspirin 100mg and prasugrel 5mg will be maintained for 30 days.
223854783|NCT05359224|DRUG|Clopidogrel group|Prescribe the drugs according to the assigned group, and take them 5 days before the procedure. Perform platelet function test (VerifyNow assay; Accumetrics, San Diego, California) one day before the procedure to check the P2Y12 reaction reactivity. And the hyporesponsive group patient is given pletaal 100mg once. And aspirin 100mg and clopidogrel 75mg mg will be maintained for 30 days.
223854784|NCT05844748|OTHER|diabetes education with motivational interview technique|Techniques such as developing empathy, developing disengagement, turning with resistance, supporting self-efficacy, avoiding advice, a simple decision, importance-trust scale, open-ended questions, reflection and segmentation in motivational interviews.
223854785|NCT06345534|DEVICE|Questionnaire|"Patients will be asked to complete questionnaires at different times (before, during and after radiation) to evaluate which schedule gives the fewest side effects and the best quality of life.~The basic questionnaire and questionnaire about early side effects will be completed weekly up to 6 weeks after radiotherapy. The questionnaire about late side effects will be completed: after 6 months, 1 year, 2 years, 3 years, 4 years and 5 years."
223854786|NCT03203356|DRUG|growth hormone|Children with a diagnosis of GHD will practice GH replacement therapy in line with normal clinical practice and international guidelines. Controls will be evaluated just at baseline.
223854787|NCT00559949|OTHER|Laboratory Biomarker Analysis|Correlative studies
223854788|NCT00559949|DRUG|Selumetinib|Selumetinib was administered orally as a free base suspension at a dose of 100 mg twice daily for 28-day cycles. Those participants experiencing Common Terminology Criteria for Adverse Events (CTCAE) v3.0 grade 3 toxicity or worse had their dose reduced to 50 mg twice daily and then to 50 mg once daily, if necessary.
223854789|NCT01830010|DRUG|Study Part 1: KRP203|All subjects will receive KRP203 for 111 days
223854790|NCT01830010|DRUG|Study Part 2: KRP203 lower dose|
223854791|NCT01830010|DRUG|Study Part 2: KRP203 higher dose|
223854792|NCT01456819|BIOLOGICAL|Mononuclear and mesenchymal stem cells|Intramuscular administration into the ischemic limb
223854793|NCT01456819|BIOLOGICAL|Mononuclear cells|Intramuscular administration into the ischemic limb
223854794|NCT02668263|PROCEDURE|Surgery alone|Surgery
223854795|NCT02668263|PROCEDURE|Surgery and Drain(s)|Drains inserted as per standard practice
223854796|NCT02668263|PROCEDURE|Surgery and Quilting Sutures|Quilting sutures to mastectomy flaps
223854797|NCT06010888|DRUG|Fruquintinib+mFOLFOX6/FOLFIRI|Fruquintinib: 4mg po qd, d1-d21, q4w with mFOLFOX6/FOLFIRI (standard)
223854798|NCT00607503|DRUG|Terbutaline|"Each subject will be treated with terbutaline for 21-28 days following the initiation of treatment during the CRC admission.~Subjects weighing between 25 and 45 kg will be treated with a nightly oral dose of 2.5 mg and subjects who weigh more than 45 kg will be treated with 3.75 mg.~The standard 2.5 mg terbutaline tablets available in a pharmacy will be used in the study, with subjects taking either 1 or 1.5 tablets nightly."
223854799|NCT00929721|PROCEDURE|Blood draw|culture for Streptococcus pneumoniae Frequency-1
223854800|NCT00929721|PROCEDURE|Chest X-ray|image of the lungs to assess changes consistent with pneumonia Frequency-1
223854801|NCT00929721|PROCEDURE|urine specimen|assay for the presence of Streptococcus pneumoniae Binax and UAD
223854802|NCT00929721|PROCEDURE|Nasopharyngeal swab|culture for Streptococcus pneumoniae Frequency-1
223854803|NCT00929721|PROCEDURE|sputum|culture for Streptococcus pneumoniae Frequency-1
223854804|NCT00855153|OTHER|VR (Virtual reality)|VR stimulation of combat scenarios utilized as the exposure therapy tool.
223854805|NCT00855153|DRUG|D-Cycloserine|50 mg DCS 30 min prior to individual 90 min session with graded VR exposure treatment
223854806|NCT05696977|DRUG|Cyclosporine Capsule|Determination of the most appropriate weight based dose of Cyclosporine to achieve the target therapeutic drug level and response and its relation with fat percentage and lipid profile
223854807|NCT03552913|PROCEDURE|One year before awareness-raising phase in favour of Enhanced Recovery After Surgery|One year before awareness-raising phase in favour of Enhanced Recovery After Surgery
223854808|NCT03552913|PROCEDURE|One year after awareness-raising phase in favour of Enhanced Recovery After Surgery|One year after awareness-raising phase in favour of Enhanced Recovery After Surgery
223854809|NCT03552913|PROCEDURE|No specific program toward improving practices|No specific program toward improving practices
223854810|NCT04361253|BIOLOGICAL|High-Titer COVID-19 Convalescent Plasma (HT-CCP)|250mL HT-CCP x2 doses given sequentially.
223854811|NCT04361253|BIOLOGICAL|Standard Plasma (FFP)|250mL FFP or FP24 x2 doses given sequentially.
223854812|NCT01335932|DRUG|IV Ganciclovir|For first 5 days, dosing of intravenous ganciclovir is 10 mg/kg daily, given as 5 mg/kg every 12 hours (adjusted for renal function). After first 5 days (up to 28 days) IV ganciclovir 5 mg/kg QD ( adjusted for renal function). A minimum interval of 6 hours is required between the first and second dose.
223854813|NCT01335932|DRUG|Placebo|"For first 5 days, dosing of intravenous placebo is daily, given every 12 hours. After first 5 days (up to 28 days), IV placebo QD. A minimum interval of 6 hours is required between the first and second dose.~The placebo is an IV solution that does not contain any active medications."
223854814|NCT02035735|PROCEDURE|WL and NBI|For each patient with a suspicion of squamous cell carcinoma of the oropharynx, hypopharynx or larynx for whom a laryngoscopy under general anesthesia (LGA) is expected benefit the day before a transnasal endoscopy with white lamp (WL) and NBI by two different operators. Suspected mucosal abnormalities showed by one or the two technics are reported in a table wich describes the different areas of the pharynx and the larynx. During the LGA, several biopsies are performed and identified (WL and/or NBI).
223854815|NCT01169363|GENETIC|proteomic profiling|
223854816|NCT01169363|OTHER|flow cytometry|
223854817|NCT01169363|OTHER|laboratory biomarker analysis|
223854818|NCT05158361|OTHER|Acupuncture|Participants will receive acupuncture, three times per week for eight weeks. The selected acupoints include bilateral BL33, BL35, SP6, and ST36. All acupoints areas have been sterilized before acupuncture. For BL33, a needle (Ф0.40×100mm) will be inserted with an angle of 60° in an inferomedial direction at a depth of 90-100mm. For BL35, the same needle will be inserted with a direction to the ischial rectal fossa at a depth of 60-70 mm deep. For SP6 and ST36, needles (Ф0.30×50mm) will be directly inserted at a depth of 25-30 mm deep. After the needles are inserted, a portable electro-acupuncture machine will be connected to the handles of needles located in BL33 and BL35 to provide the electrical stimulation for 30 minutes with a disperse-dense wave (4/20Hz). All current intensities will be as high as can be tolerated.
223854819|NCT05158361|OTHER|Sham acupuncture|The sham acupoints will be located at 20 mm outward to BL33, BL35, SP6, and ST36, and the needless will be inserted with a depth of 2 mm. The BL33 and BL35 will not receive any electrical stimulation, though the handles of needles will be connected to the same machine as the acupuncture group, and the parameter setting and course are also the same.
223854820|NCT01998555|OTHER|CBT|
223854821|NCT04589130|DRUG|Contrave 8Mg-90Mg Extended-Release Tablet|"Each Contrave Extended Release Tablet contains 8Mg of naltrexone HCl and 90Mg of bupropion HCl and will be administered orally. Total daily dose is 32Mg / 360Mg.~Participants randomized to the treatment arm will be administered 4 Contrave tablets a day for 1 year (2 tablets taken twice a day).~Participants randomized to the control arm for the first 6 months will crossover and be administered 4 Contrave tablets a day during the second 6 months (2 tablets taken twice a day). All participants will be in the treatment group (Contrave) during the second 6 month phase of the study."
223854822|NCT04589130|DRUG|Placebo|Placebo tablets will be administered orally. Participants randomized to the control arm will be administered 4 placebo tablets a day (2 tablets, taken twice a day) during the first 6 months of the study. These participants will crossover to treatment with Contrave for the second 6 months of the study.
223854823|NCT00161018|DRUG|Quetiapine, Risperidone, Fluphenazine|
223854824|NCT06269536|OTHER|HRV biofeedback|Daily deep paced breathing 3-times (minimum 7 minutes each) for 3 months
223854825|NCT01235949|BIOLOGICAL|GSK1024850A (SynflorixTM)|Intramuscular injection, 4 doses
223854826|NCT01235949|BIOLOGICAL|Infanrix hexa|Intramuscular injection, 3 doses
223854827|NCT01235949|BIOLOGICAL|Infanrix-IPV/Hib|Intramuscular injection, 1 dose
223854828|NCT01235949|DRUG|Ibuprofen|Oral administration, 3 doses in the 24 hours following vaccination with an interval of 6-8 hours between doses and with dosage based on the subject's body weight
223854829|NCT01235949|DRUG|Paracetamol|Oral administration, 3 doses in the 24 hours following vaccination with an interval of 6-8 hours between doses and with dosage based on the subject's body weight
223854830|NCT00383188|DRUG|placebo|Capsule, once daily (QD) for 12 weeks
223854831|NCT00383188|DRUG|PH-797804|Capsule, 0.5 mg of PH-797804, once daily (QD) for 12 weeks
223854832|NCT00383188|DRUG|PH-797804|Capsule, 3 mg of PH-797804, once daily (QD) for 12 weeks
223854833|NCT00383188|DRUG|PH-797804|Capsule, 6 mg of PH-797804, once daily (QD) for 12 weeks
223854834|NCT00383188|DRUG|PH-797804|Capsule, 10 mg of PH-797804, once daily (QD) for 12 weeks
223854835|NCT01847651|PROCEDURE|Vastus Muscle Biopsy|Both Arms, all 3 visits at 0, 4 and 12 weeks
223854836|NCT01847651|DRUG|LOLA or placebo|Hepa-Merz Granulat 3000 Hepa-Merz granules 3g (Each 5g sachet contains 3g of L-ornithine L-aspartate) L-ornithine L-aspartate LOLA Randomised to a daily dose 18g per day, two sachets of Hepa-Merz granules three times a day (or placebo)for 12 weeks
223854837|NCT01847651|OTHER|Cognitive assessment (PHES)|Both Arms, all 3 visits at 0, 4 and 12 weeks
223854838|NCT01847651|OTHER|Cognitive Assessement (Cogstate)|Both Arms, all 3 visits at 0, 4 and 12 weeks
223854839|NCT01847651|OTHER|blood and urine sampling|Both Arms, all 3 visits at 0, 4 and 12 weeks
223854840|NCT01847651|OTHER|Nutritional assessment|Both Arms, all 3 visits at 0, 4 and 12 weeks
223854841|NCT01847651|OTHER|MRI brain and spectroscopy|Both Arms, all 3 visits at 0, 4 and 12 weeks
223854842|NCT01847651|OTHER|MRI leg cross section|Both Arms, all 3 visits at 0, 4 and 12 weeks
223854843|NCT01847651|OTHER|Functional MRI (working memory and attention tasks)|Both Arms, all 3 visits at 0, 4 and 12 weeks
223854844|NCT03660917|DRUG|Riluzole|Study drug will be orally dispensed in doses of 50 mg twice daily for 12 months in the treated group.
223854845|NCT03660917|DRUG|Placebo|Placebo drug for 6 months, however they will receive riluzole during the last 6 months of study, so that all patients will undergo the active drug in the last phase of the study.
223854846|NCT03206736|OTHER|Loop DS surgery|these patients will receive a loop DS bariatric procedure
223854847|NCT05037851|DRUG|Opelconazole|Nebulizer suspension
223854848|NCT05037851|DRUG|Standard of Care|Standard of Care
223854849|NCT04033042|DEVICE|Prototype 0.5|Subjects will perform daily measurements on the IMD (Prototype 0.5) for 41 days.
223854850|NCT04964479|DRUG|TQB2450 injection|1200mg injection once every 3 week
223854851|NCT04964479|DRUG|Anlotinib Hydrochloride Capsules|12mg capsule once daily
223854852|NCT04964479|DRUG|Pembrolizumab injection|200mg injection once every 3 week
223854853|NCT04964479|DRUG|Placebo|Placebo capsule once daily
223854854|NCT02469337|DRUG|Dichloroacetate|Dichloroacetate, an analog of acetic acid has been shown to increase the activation of PDC by inhibiting PDK4 in humans. This drug is expected to shift the metabolism of pyruvate from glycolysis and towards oxidative pathway in the mitochondria
223854855|NCT02469337|DIETARY_SUPPLEMENT|Carbohydrate drinks|preoperative carbohydrate drinks
223854856|NCT02469337|BEHAVIORAL|Moderate intensity exercise|30 min exercise using a semi-recumbent exercise bike, at about 70% of their age estimated heart rate
223854857|NCT03936348|DEVICE|Exercise training program with and without FB|"Participants carried out a supervised RP for 8 weeks, 3 days per week. The training sessions lasted 60 minutes and included a warning up phase, the main phase and a recovery phase. After each session, Borg's perceived exertion was measured. The Rehabilitation Program (RP) included aerobic exercise on cycle ergometer and on treadmill (progressing since 10' to 30' and since 40 to 75% of the reserve heart rate (RHR) or 6-7 score based on Borg's perceived exertion), strengthening of lower and upper limb muscles groups, breathing exercises (pursed lip breathing, diaphragmatic and abdominal breathing and diaphragmatic mobility) and finally stretching exercises.~In the FB group, for restricted nasal breathing, at the beginning of the training program, the small size device was used (4 mm). The size of the device was progressively increasing according to the patient adaptation to the 5 or 6 mm device, depending on the score on Borg's perceived exertion scale."
223854858|NCT02491749|PROCEDURE|Ultra Fast-Track Anesthesia|early extubation at the end or within one hour post operatively
223854859|NCT02892968|PROCEDURE|Fascia-Iliaca Block(FIB)|The target of the FIB is the potential space between the fascia iliaca and the iliacus muscle, at least 4 cm lateral to the Femoral artery. This is neither a drug nor a device.
223854860|NCT02892968|PROCEDURE|Femoral Nerve Block(FNB)|The target of the FNB technique is the intersection of the fascia iliaca and the femoral nerve. This is neither a drug nor a device.
223854861|NCT02332369|DEVICE|Capsular Tension Ring|
223854862|NCT06000072|OTHER|Core Exercise Program|Core exercises
223854863|NCT04286529|DRUG|Calcitriol capsules|0.25micrograms, taken daily for eight weeks, orally
223854864|NCT04286529|DRUG|Oral Placebo|Placebo will be created to mimic the appearance of the study drug
223854865|NCT02341625|DRUG|BMS-986148|
223854866|NCT02341625|BIOLOGICAL|Nivolumab|
223854867|NCT02026778|DRUG|ondansetron|"The ondansetron group is given placebo (pyridoxin) instead of betahistine.~The ondansetron group is given ondansetron 4 mg bolus at the end of surgery and ondansetron 8 mg added to the IV-PCA."
223854868|NCT02026778|DRUG|ondansetron-betahistine|"The ondansetron-betahistine group is given betahistine 18mg orally in the morning of surgery and postoperative day 1.~The ondansetron-betahistine group is given ondansetron 4 mg bolus at the end of surgery and ondansetron 8 mg added to the IV-PCA."
223854869|NCT02616835|DEVICE|theta-burst TMS|This protocol involves short periods of pulse delivery in combination with long periods of silent intervals.
223854870|NCT02616835|DEVICE|sham theta-burst TMS|This protocol delivers theta-burst pulses from a sham device (i.e. at same speed and timeframe but without the magnetic output)
223854871|NCT03551067|DRUG|Dexmedetomidine|Dexmedetomidine mixed with juice was given to the child orally preoperatively.
223854872|NCT03551067|COMBINATION_PRODUCT|Midazolam/Ketamine|Midazolam/Ketamine was mixed with juice and given to the child orally preoperatively
223854873|NCT06364150|BIOLOGICAL|Autologous Peripheral Blood Stem Cell injection|For peripheral blood stem cell mobilization, G-CSF and EPO will be injected for a total of 4 days, followed by collection of mobPBSC via apheresis. In ex-vivo setting, mobPBSC will be primed with Ang1 for 1 hour. A total of 2 X109 Ang1 primed mobPBSC will be injected to the culprit artery.
223854874|NCT06393244|BEHAVIORAL|a theory-based home-based multi-component exercise training|The participants in the intervention group will receive a 12-week theory-based home-based MCE program, which consists of three phases: exercise mobilization phase, exercise preparation phase (exercise instructions and exercise plan determination), and home-based autonomous exercise training. Structured guidelines have been developed for the intervention by the research team. This allowed interveners to deliver the intervention in a structured way with the same dosage.
223854875|NCT05633368|OTHER|Questionnaires|"Participants will be contacted every three weeks to assess depressive symptomatology and possible relapse.~* Patient Health Questionnaire (PHQ-9)~* Clinical Global Impression (CGI)~* Scaling question regarding depressive symptomatology"
223854876|NCT04307407|BEHAVIORAL|Aerobic Exercise|Participants will be randomized to supervised aerobic exercise or standard care. Women with no current or past malignant disease will comprise the reference group and will be matched for age to participants in the Aerobic Exercise arm
223854877|NCT00917865|DRUG|anti [18F]FACBC|Anti\[18F\]FACBC (10mci) will be given intravenously over 1-2 minutes prior to obtaining PET-CT images At 4 minutes, 10 consecutive/4minutes images will be obtained of the pelvis to include the prostate.
223854878|NCT02040935|DRUG|Trastuzumab|600 mg SC Q3W by SID
223854879|NCT06512649|BEHAVIORAL|Early intervention|90-minute parent-coaching session once a week for 6 months with an expert developmental therapist, supported by a child neuropsychiatrist or psychologist. A parent will always be present and actively involved in the intervention. The intervention is individualized and tailored to each child's needs and identifies with caregivers the ways to embody objectives in daily life.
223854880|NCT06512649|BEHAVIORAL|Active monitoring|90-minute session once a month for 6 months. Sessions will be performed by an expert developmental therapist, supported by a child neuropsychiatrist or psychologist. A parent will always be present and actively involved in the intervention.
223854881|NCT01777893|BEHAVIORAL|High protein/ high intensity physical activity (HP-HI)|Participants follow a high protein diet and a high intensity physical activity intervention
223854882|NCT01777893|BEHAVIORAL|High protein / moderate intensity physical activity (HP-MI)|Participants follow a high protein diet and moderate intensity physical activity intervention
223854883|NCT01777893|BEHAVIORAL|Moderate protein/ high intensity physical activity (MP-HI)|Participants follow a moderate protein diet and a high intensity physical activity intervention
223854884|NCT01777893|BEHAVIORAL|Moderate protein/ moderate intensity physical activity (MP-MI)|Participants follow a moderate protein diet and moderate intensity physical activity intervention
223854885|NCT03907098|DRUG|Endostar|an anti-angiogenesis drug
223854886|NCT03907098|DRUG|Chemotherapy|Physician's choice
223854887|NCT03816124|PROCEDURE|radiofrequency ablation|radiofrequency ablation of the genicular nerves
223854888|NCT01220336|BEHAVIORAL|Health coaching by medical assistants in primary care|Patients with uncontrolled diabetes, hypertension, hyperlipidemia will receive health coaching by medical assistants working with primary care providers in the Teamlet Model \[Bodenheimer 2007\] for 12 months.
223854889|NCT06040333|OTHER|Exercise|Dynamic Neuromuscular Stabilisation Exercise
223854890|NCT06040333|OTHER|Standard therapy|Patient education, massage, diaphragmatic breathing, kegel exercise
223854891|NCT01669382|DEVICE|percutaneous coronary intervention|after the intervention patients are randomized to either Angio Seal or Exo Seal
223854892|NCT04599946|DIETARY_SUPPLEMENT|Infant formula and follow-on formula made from whole goat milk|Infant formula and follow-on formula made from whole goat milk
223854893|NCT04599946|DIETARY_SUPPLEMENT|Infant formula and follow-on formula made from cow's milk ingredients|Infant formula and follow-on formula made from cow's milk ingredients
223854894|NCT00684034|OTHER|Sampling of blood|A sampling of blood will be made
223854895|NCT00684034|OTHER|Sampling of blood|A sampling of bood will be made before the dialysis
223854896|NCT00684034|OTHER|Sampling of blood|A sampling of blood will be made.
223854897|NCT05246956|OTHER|Intradialytic exercise|Intradialytic exercise group
223854898|NCT04285762|OTHER|LVEEA|lymphaticovenous end-to-end
223854899|NCT04285762|OTHER|LVESA|lymphaticovenous end-to-side
223854900|NCT04285762|OTHER|LVSEA|lymphaticovenous side-to-end
223854901|NCT00414206|DRUG|Mecamylamine|
223854902|NCT00414206|DRUG|Placebo|
223854903|NCT01726023|DRUG|Ceftazidime-avibactam|Ceftazidime-Avibactam powder for concentrate for solution for infusion 2000 mg/500 mg
223854904|NCT01726023|DRUG|metronidazole|Metronidazole 500mg/100ml solution for infusion
223854905|NCT01726023|DRUG|Meropenem|Meropenem powder for solution for infusion 1000mg
223854906|NCT02158481|DIETARY_SUPPLEMENT|A capsule containing both polyphenols and carotenoids|
223854907|NCT02158481|DIETARY_SUPPLEMENT|Placebo intervention|Placebo intervention
223854908|NCT04756401|DRUG|Carfilzomib|Given IV
223854909|NCT04756401|BIOLOGICAL|Daratumumab|Given IV
223854910|NCT04756401|DRUG|Dexamethasone|Given PO
223854911|NCT04756401|OTHER|Quality-of-Life Assessment|Ancillary studies
223854912|NCT04756401|DRUG|Selinexor|Given PO
223854913|NCT05300451|BIOLOGICAL|Daratumumab and hyaluronidase-fihj|Daratumumab and hyaluronidase-fihj for subcutaneous (under the skin) injection has different dosing and administration instructions compared to daratumumab for intravenous (in the vein) infusion. Daratumumab and hyaluronidase-fihj contains recombinant hyaluronidase, which mimics hyaluronidase, a naturally occurring substance that increases permeability of subcutaneous tissue. This makes it possible for 15 mL containing 1,800 mg of daratumumab to be administered in approximately 3 to 5 minutes. Subjects will receive a 1800mg/30000u injection subcutaneously weekly for a total of 8 doses
223854914|NCT04789850|DRUG|Itacitinib|200 mg oral for 360 days
223854915|NCT04789850|DRUG|Placebo|200 mg oral for 360 days
223854916|NCT05457491|BIOLOGICAL|Human platelet extract (cosmetic product)|A leukocyte depleted allogeneic product derived from human U.S. sourced pooled apheresed platelets (derived from screened healthy donors). Applied to face twice daily for 12 weeks.
223854917|NCT05457491|OTHER|Vanicream Gentle Facial Cleanser|A mild cleanser specifically formulated for daily facial use. Applied to face twice daily for 12 weeks
223854918|NCT05457491|OTHER|EltaMD UV Daily Broad-Spectrum SPF 40|A daily moisturizer with a lightweight formula that provides broad-spectrum sunscreen protection. EltaMD UV Daily Broad-Spectrum SPF 40 provides powerful protection against the sun's harmful UV rays, as it hydrates and is gentle enough for post-procedure skin. Powered by hyaluronic acid, this face sunscreen plumps the skin with lightweight moisture, while micronized zinc and octinoxate shield skin from UVA/UVB rays to prevent the visible signs of environmentally caused aging. Applied to face once daily for 12 weeks.
223854919|NCT05457491|OTHER|EltaMD PM Therapy Facial Moisturizer|A fortifying face moisturizer to repair elasticity and vitality. EltaMD PM Therapy Facial Moisturizer restores youthfulness while strengthening the skin's natural moisture barrier. Niacinamide blends with antioxidants to boost the skin color and tone, as it speeds up the skin's repair processes. Rice protein peptides aid in encouraging cell growth, promoting collagen formation and improving elasticity. Applied to face once daily for 12 weeks.
223854920|NCT05457491|OTHER|Vanicream Lite Lotion|Lotion to restore and maintain a normal moisture level. Applied to face twice daily for 12 weeks.
223854921|NCT02884583|OTHER|Pulmonary function test|Patients hospitalized for OFC realise a Resting pulmonary function tests (PFT) which include the assessment of ventilatory capacity: spirometry (forced expiratory flows and mobilisable volumes) and static volume assessment, by using body plethysmography, were realized before, during and after the OFC. An exhaled fraction of NO (FeNO) is also realized to characterize asthma.
223854922|NCT01890889|DIETARY_SUPPLEMENT|Ad-Chol-Pre|
223854923|NCT01890889|DIETARY_SUPPLEMENT|Half-dose Ad-Chol-Pre|
223854924|NCT01890889|OTHER|Defatted egg yolk without the active ingredient of the other two interventions|
223854925|NCT00127647|DRUG|montelukast sodium|montelukast sodium; 5 mg, 10 mg QD 2-weeks.
223854926|NCT00127647|DRUG|Comparator: pranlukast|Pranlukast 225 mg BID 2-weeks.
224266085|NCT02674711|BEHAVIORAL|Educational Video|The content of the education focus on providing a historical perspective for opioid prescription from the time when the risk of dependence was highly underestimated. The video discusses the current evidence for the effect of opioid medications in non-cancer non-acute pain. It also discusses some of the dangers of long-term opioid usage. The video is 11 and ½ minutes long.
224266086|NCT00979147|PROCEDURE|TKA surgery with modular polished tibial baseplate/XLK design|TKA surgery with modular polished tibial baseplate/XLK design
223854927|NCT00431509|PROCEDURE|conventional vs. navigated total knee arthroplasty|
224266087|NCT00979147|PROCEDURE|TKA surgery with the nonmodular APT/GVF design|TKA surgery with the nonmodular APT/GVF design
224266088|NCT00979147|DEVICE|P.F.C.® Sigma Knee System|P.F.C.® Sigma Knee System with modular XLK poly
224266089|NCT00979147|DEVICE|P.F.C.® Sigma Knee System|P.F.C. ® Sigma Knee System with an all-poly GVF tibia
224266090|NCT04567329|DRUG|NOV03|100% perfluorohexyloctane
224266091|NCT04567329|DRUG|Saline Solution|0.6% sodium chloride solution
224266092|NCT00137644|BEHAVIORAL|Preventing AIDS Through Live Movement and Sound (PALMS)|
223854928|NCT03227757|DEVICE|Tricuspid Valve Repair System|Subjects who received TVRS will be included in this arm. The TVRS is intended for reconstruction of the insufficient tricuspid valve through tissue approximation.
223854929|NCT05409664|BEHAVIORAL|Physical activity adoption|webMFT will be delivered via a web-based platform. Coaches will be trained to deliver the intervention prior to being assigned a study participant. Upon successful completion of the informed consent for coaches and participants, coaches will be assigned a participant for their 3-month duration in the study. Coaches and participants will complete weekly phone calls focused on increasing the participants' MVPA up to the recommended 150 min/week.
223854930|NCT05409664|BEHAVIORAL|Self monitoring|Participants will be asked to gradually increase their activity up to the recommended 150 minutes of moderate-intensity/week during the 12-week intervention. Self-monitoring will be completed using a Fitbit tracker.
223854931|NCT03047083|OTHER|Treatment patterns among AML patients|This is a retrospective cohort study of AML patients with or without FLT3 mutation who were exposed to treatments for AML per treating physician's decision between 1 January 2013 and 31 December 2015.
223854932|NCT03047083|OTHER|AML-related healthcare resources|This is a retrospective cohort study of AML patients with or without FLT3 mutation who were exposed to treatments for AML per treating physician's decision between 1 January 2013 and 31 December 2015.
223854933|NCT02101905|OTHER|Laboratory Biomarker Analysis|Correlative studies
223854934|NCT02101905|DRUG|Lapatinib|Given PO
223854935|NCT02101905|DRUG|Lapatinib Ditosylate|Given PO
223854936|NCT02101905|OTHER|Pharmacological Study|Correlative studies
223854937|NCT02101905|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgical resection of tumor
223854938|NCT03203525|BIOLOGICAL|Bevacizumab|Given IV
223854939|NCT03203525|DRUG|Fluorouracil|Given via pump
223854940|NCT03203525|DRUG|Leucovorin|Given via pump
223854941|NCT03203525|DRUG|Oxaliplatin|Given via pump
223854942|NCT03203525|DRUG|Pegylated Liposomal Doxorubicin Hydrochloride|Given IV
223854943|NCT03203525|DRUG|Temsirolimus|Given IV
223854944|NCT03203525|PROCEDURE|Tumor Treating Fields Therapy|Use NovoTTF-100L(P) system
223854945|NCT05394779|DEVICE|DTXO APP|DTXO is an investigational therapeutic intervention (Digital Therapeutics - DTx) for obese patients, under clinical validation with a randomized and placebo-controlled clinical trial for confirmatory purposes. It is intended to improve weight loss, weight-loss maintenance, and overall health in patients with obesity by increasing their self-engagement, self-monitoring and adherence to dietary/exercise and behavioral programs. The App integrates different non-pharmacological approaches, engaging the patient through monitoring of her/his non-vital parameters, monitoring of patient diet and exercise, monitoring of patient psychological status, prescription of exercise and diet in a weight-loss program.
223854946|NCT05394779|DEVICE|PLACEBO APP - Control group|The placebo App will include only the non-medical modules of the digital therapy and has been introduced to make the experience of subjects in the control arm more similar to that of subjects in the experimental arm; moreover, data collection through the placebo app (questionnaires) will streamline the data collection process, avoiding manual data entry and reducing the possibility of entry errors.
223854947|NCT05904340|DEVICE|Transcutaneous Electrical Nerve Stimulation|Transcutaneous Electrical Nerve Stimulation (TENS) uses machines to generate electric current, flows through the skin and conducts to the nerves, triggers a chain reaction of nerves through a new stimulus source, and achieves the effect of pain relief. Using different frequencies and intensities will Produce different effects and trigger different physiological mechanisms.
223854948|NCT02960659|DRUG|Liraglutide|Liraglutide (6mg/ml, 3ml ) solution for subcutaneous injection, pre-filled, multi-dose pen that delivers doses of 0.6mg, 1.2mg or 1.8mg.
223854949|NCT02960659|DRUG|Metformin|Metformin 500mg oral tablet
223854950|NCT06499584|PROCEDURE|near field recording of human auditory nerve activity during retro sigmoid approach with contact electrode|"During surgery using a retro-sigmoid approach in the cerebellopontine angle (microvascular decompression), near-field recording of human auditory nerve activity using a contact electrode is performed on patients with normal or impaired hearing threshold.~Each patient is explored preoperatively by hearing tests. During the surgery, stimuli are delivered."
223854951|NCT01356069|OTHER|SB-APP|"SB-APP, derived from Brief-Adlerian Psychodynamic Psychotherapy (B-APP) is a time-limited (40 weekly sessions) psychodynamic psychotherapy based on Alfred Adler's theory and delivered in sequential and repeatable modules.~SB-APP is focused specifically on four personality functioning levels (PFL). These are assessed by the therapists on the basis of symptoms, quality of interpersonal relationships, overall social behaviors, cognitive and emotional patterns, and defense mechanisms"
223854952|NCT01356069|OTHER|treatment as usual|This treatment consisted in a combination of medication, unstructured psychological support focused on socio-relational impairment and rehabilitative interventions provided by nurses and educators.
223854953|NCT01716858|DIETARY_SUPPLEMENT|Sulforaphane-rich Broccoli Sprout Extract|
223854954|NCT04476472|DEVICE|Omnipod Horizon™ Automated Glucose Control System|The Omnipod Horizon™ Automated Glucose Control System will provide automated insulin delivery.
223854955|NCT03806907|RADIATION|Computed tomography lung subtraction iodine mapping|Subtraction of the non-contrast CT from the contrast-enhance CTPA produces the CT-LSIM
223854956|NCT02817282|OTHER|Hand hygiene implementation strategy|Implementation strategy: Individual oriented activities. Education based on the different determinants influencing HCWs' behavior. Reminders for supporting the actual performance of HH; by distributing posters. Performance feedback for awareness. Goal setting will be encouraged and the feedback will be used to help HCWs evaluate their success and determine how they could best adapt their behavior in order to reach their goal. Organisational oriented activities. Products and facilities: The physical environment will be adapted by improving the availability of hand based hand rub. Team-oriented activities; The social environment will be adapted by training at a group and individual level, to improve social and descriptive norms. Positive role models will be stimulated through this training.
223854957|NCT03640403|DRUG|Dihydroartemisinin-piperaquine|Dihydroartemisinin-piperaquine (DP). One of the Artemisinin combination therapy(ACTs), indicated for treatment of uncomplicated malaria. It will to be given every 4 months 3 rounds for a year.
223854958|NCT03640403|DRUG|Artesunate-amodiaquine|Artesunate-amodiaquine (ASAQ). One of the Artemisinin combination therapy(ACTs), indicated for treatment of uncomplicated malaria. It will to be given every 4 months 3 rounds for a year.
223854959|NCT05486312|DEVICE|CT-155 smartphone app|The CT-155 study app is designed to provide treatment monitoring and educational components of a full treatment cycle with CT-155. This design allows inferences to be made about the usability and acceptability of CT-155. Eligible participants will be enrolled during an in-person clinic visit on Day 1. Participants will then be directed to access the study app and perform tasks each day for the 49-day engagement period.
223854960|NCT01326039|DRUG|bupivacaine|perineural bupivacaine 5 mg/ml 20 ml
223854961|NCT01326039|DRUG|saline|perineural isotonic saline 20 ml
223854962|NCT01357044|DIETARY_SUPPLEMENT|Extracts of Punica granatum and Alpinia galanga|Tablets, two in the morning and two in the evening
223854963|NCT01357044|DIETARY_SUPPLEMENT|Placebo|Tablets, two in the morning and two in the evening
223854964|NCT01645111|DRUG|Clevidipine|
223854965|NCT05601830|DRUG|QN-030a|NK cell therapy
223854966|NCT05601830|DRUG|Cyclophosphamid|Lympho-conditioning Agent
223854967|NCT05601830|DRUG|Fludarabine|Lympho-conditioning Agent
223854968|NCT05601830|DRUG|Cytarabine|Lympho-conditioning Agent
223854969|NCT00821184|DRUG|Vesicare (solifenacin)|5mg po qd
223854970|NCT00821184|BEHAVIORAL|Vesicare (solifenacin) plus behavioral modification|5 mg dose po once daily plus behavioral modification
223854971|NCT02995460|BEHAVIORAL|interval training|4x4 high intensity interval training
223854972|NCT02211898|DRUG|BNS003|
223854973|NCT02414906|OTHER|Goal-directed therapy|Goal-directed therapy with fluids and dobutamine
223854974|NCT04655118|DRUG|TL-895|TL-895 is an experimental tyrosine kinase inhibitor drug taken by mouth.
223854975|NCT04655118|DRUG|Placebo|Placebo to match TL-895
223854976|NCT05348096|DRUG|Low-dose ibrutinib|Daily ibrutinib (140mg QD) and itraconazole (100mg BID) for six months.
223854977|NCT02550067|DRUG|DMPA|Women randomized to DMPA, will receive an intramuscular injection of DMPA (medroxyprogesterone acetate sterile aqueous suspension 150 mg per 1 mL) at enrolment. Subsequent injections will be given every 3 months (i.e., at quarterly study visits) at the study site.
223854978|NCT02550067|DRUG|LNG|Women randomized to implants will receive LNG implants in the arm, at enrolment from trained clinicians.
223854979|NCT02550067|DRUG|Copper IUD|Women randomized to IUDs will receive their IUDs at enrolment. Trained providers will insert T380a copper IUDs using standard insertion techniques.
223854980|NCT05604885|DRUG|AP1189, 60 mg|AP1189 tablets for oral use
223854981|NCT05604885|DRUG|AP1189, 80 mg|AP1189 tablets for oral use
223854982|NCT05604885|DRUG|AP1189, 100 mg|AP1189 tablets for oral use
223854983|NCT05604885|DRUG|Placebo|Matching placebo tablets for oral use
223854984|NCT02703714|DRUG|Pembrolizumab|200 mg given intravenously (IV)
223854985|NCT02703714|DRUG|Sargramostim|250 µg given subcutaneously (SC)
223854986|NCT05991999|OTHER|Stretching|"Master swimmers will be taught iliopsoas, sternocleidomastoid and pectoralis major stretching exercises as stretching exercises. Participants will stretch daily for 3 repetitions, each stretching for 20 seconds.~Participants will continue their swimming training 2 days a week."
223854987|NCT05991999|OTHER|Training|Participants continued their swimming training 2 days a week.
223854988|NCT03482804|OTHER|Questionnaires|"Parents will be interviewed before being seen in consultation in the emergency room. The reason for consultation will not be taken into account, the only criterion being the age of the child. There will be no sign in the waiting room, the study will be proposed to them by the principal investigator.~The questionnaires will be collected on live paper. The answers will be transferred in a second time on an Excel database protected by a password."
223854989|NCT03872362|DIAGNOSTIC_TEST|radiomics|The high-throughput extraction of large amounts of quantitative image features from medical images
223854990|NCT01013012|DRUG|ramosetron with saline|Group A : saline 1 ml, ramosetron 6μg/kg
223854991|NCT01013012|DRUG|ramosetron with dexamethasone|Group B : dexamethasone 4 mg, ramosetron 6μg/kg
224266093|NCT04637360|DRUG|Cinacalcet Tablets|All study subjects were treated with a fixed dose of oral Cinacalcet (25 mg/day) from baseline to 6 months.
224266094|NCT04637360|DRUG|calcitriol|All hyperparathyroidism were treated as traditional therapy with oral calcitriol 0.25 mcg(dosage according to IPTH serum level) from baseline to 6 months.
224266095|NCT02399462|DRUG|Acthar|"Agent Dose Route Schedule H.P. Acthar Gel 40 units SC twice weekly\* Weeks 1 and 2~H.P. Acthar Gel 80 units SC twice weekly\* Weeks 3 through 24~H.P. Acthar Gel 80 units SC once weekly\* Weeks 25 through 26~H.P. Acthar Gel 40 units SC once weekly\* Weeks 27 through 28~\*Injections are to be spaced 72-96 hours apart (+/-6 hours)."
224266096|NCT06311929|DRUG|PD-1 monoclonal antibody and lenvatinib|Patient receives first adjuvant PD-1 monoclonal antibody 2-4 weeks postoperatively, 200 mg IV, every 21 days for a total of 9 cycles; lenvatinib is initiated orally 2-4 weeks postoperatively for 6 months.
224266097|NCT06311929|DRUG|PD-1 monoclonal antibody|Patient receives first adjuvant PD-1 monoclonal antibody 2-4 weeks postoperatively, 200mg IV over 21 days for 9 cycles.
224266098|NCT00211562|DRUG|Olanzapine, Omega 3, Vitamin E+C|No adverse event nor SAE noted.
224266099|NCT02373462|DRUG|Olmesartan|
224266100|NCT02373462|DRUG|other anti-hypertensive drug|CCB, diuretics, alpha blocker, direct vasodilator, beta blocker
224266101|NCT04249765|OTHER|Assessing grasping force, pinch force,|"Grip Strength The participants sat upright on a chair with their feet supported. The tested arm was positioned on a table with the shoulders slightly abducted and neutrally rotated, the elbow in 90° of flexion, the forearm in 0° between pronation and supination, and the wrist in neutral resting position. The participants were instructed to maintain that position during the test. The grip strength of both hands was measured using the Hand Dynamometer.~3\. Pinch Strength Participants were seated at a table on which the dynamometers were positioned. The subjects were told to keep their elbow flexed without resting their arm or the grip handle of the dynamometer on the table."
224266102|NCT00185757|DRUG|Cytokine Induced Killer Cells|CIK cell dose escalation will be performed in cohorts of three patients per group. The initial dose utilized will be 1x107 expanded cells/kg. Previously, unmanipulated donor lymphocytes administered at this dose did not result in significant GVHD 7. The expansion of the CIK cell population is expected to diminish the T cell subsets responsible for GVHD further reducing the risk of GVHD to recipients. The dose will be increased to 5x107 expanded cells/kg and 1x108 expanded cells/kg in successive escalations based on no significant infusional toxicity or GVHD in the recipients
223854992|NCT02388139|PROCEDURE|renal artery angiography|preprocedural renal arteriogram is obtained after sterile preparation and draping of the patient, conscious sedation, infiltration of local anesthetic (lidocaine solution) at the femoral access site, placement of an arterial sheath in the femoral artery, and advancement of the renal guide catheter over a 0.035-in guidewire under fluoroscopic guidance. After the tip of the guide catheter is positioned at the ostium of the renal artery, an angiogram is obtained. After the guidewire is removed, the proximal end of the catheter is connected to a manifold, and 4-8 mL of contrast is manually injected during cineangiographic recording. An intravenous antithrombotic agent, usually heparin, is administered before the clinician proceeds with angioplasty.
223854993|NCT02388139|PROCEDURE|coronarography|
223854994|NCT02388139|PROCEDURE|coronary angioplasty|
223854995|NCT02388139|PROCEDURE|pulse wave velocity measurement|is a measure of arterial stiffness with Sphigmocore device.
223854996|NCT02388139|PROCEDURE|body composition monitoring|using Fresenius device
223854997|NCT06315777|GENETIC|cumulus cell oocytes complex (COC) among women with poor ovarian reserve|level of expression of Gremlin-1 (GREM1), Hyaluronic acid synthetase-2 (HAS2), and Prostaglandin-endoperoxide synthase-2 (PTGS2) in cumulus cell oocytes complex (COC) among women with poor ovarian reserve were analyzed
223854998|NCT02749968|DRUG|Liposomal bupivacaine|1 mL of liposomal bupivacaine injected with a 25-G needle just below each affected rib by the intercostal neurovascular bundle in a paraspinal position
223854999|NCT02749968|DRUG|0.9% sodium chloride|1 mL of 0.9% saline injected with a 25-G needle just below each affected rib by the intercostal neurovascular bundle in a paraspinal position
223855000|NCT03068468|DRUG|BIIB092|BIIB092 intravenous infusion on specified days
223855001|NCT03068468|DRUG|Placebo|Placebo intravenous infusion on specified days
224266103|NCT00339157|DRUG|Anakinra|
223855002|NCT00129948|DRUG|Troxatyl™ (troxacitabine)|
223855003|NCT02986906|DRUG|5% dextrose|Ultrasound-guided 5cc 5% dextrose injection between medial epicondyle and ulnar nerve
224266104|NCT00339157|BIOLOGICAL|Pneumo23|
224266105|NCT05576831|PROCEDURE|Re-excision|Re-excise (one take back only) Excise scar aiming for 1-2cm margin
224266106|NCT01659073|PROCEDURE|Caloric Vestibular Stimulation|
224266107|NCT01323491|DRUG|Nicotine replacement therapy|Nicorette® TX tape 10mg, 15mg, 25mg Nicorette® microtab 2mg Nicorette® inhaler 10mg Nicorette® chewing gum 2 mg, 4mg freshfruit, freshmint, mint, whitemint
224266108|NCT05174390|DIAGNOSTIC_TEST|Coala Heart Monitor Pro|thumb- and chest-ECG
224266109|NCT01003938|DRUG|Topotecan|
224266110|NCT01003938|DRUG|Erlotinib|
223855004|NCT02986906|DRUG|2cc 0.9% normal saline+3cc Triamcinolone (30mg)|Ultrasound-guided 2cc 0.9% normal saline+3cc Triamcinolone (30mg) injection between medial epicondyle and ulnar nerve
223855005|NCT02986906|DEVICE|Ultrasound|The ultrasound was used for injection guidance
223855006|NCT05800041|DRUG|WTX221|Drug: WTX221 WTX221 infusion once every 30 days for two doses in total Drug: CTX Co-administration of CTX and WTX221 at the initial infusion
223855007|NCT05068037|OTHER|ACUPUNCTURE|standard acupuncture TCM (analgesia, vomiting)
223855008|NCT05068037|OTHER|ANTIEMETICS|NO ACUPUNCTURE, WITH ANTIEMETICS
223855009|NCT05068037|OTHER|NOTHING|NO ACUPUNCTURE, NO ANTIEMETICS
223855010|NCT04565522|OTHER|Prospective observation|Prospective observation until one year follow-up
223855011|NCT05826444|DIAGNOSTIC_TEST|Echocardiography|Echocardiography with afterload change
223855012|NCT05826444|DIAGNOSTIC_TEST|Magnetic resonance imaging|Stress-MRI
223855013|NCT05826444|DIAGNOSTIC_TEST|Magnetocardiography|Magnetocardiography
223855014|NCT05826444|DIAGNOSTIC_TEST|Histology|Histological analysis
223855015|NCT05826444|DIAGNOSTIC_TEST|Genetics|miRNA sequencing
223855016|NCT05826444|DIAGNOSTIC_TEST|calcium signaling|cardiomyocyte calcium signaling
223855017|NCT05826444|DIAGNOSTIC_TEST|IMR|Index of microvascular resistance measurement
224266111|NCT03583398|PROCEDURE|transcatheter aortic valve implantation, surgical aortic valve replacement|Transcatheter aortic valve implantation using transaortic and transfemoral access and surgical aortic valve replacement.
223855018|NCT05826444|DIAGNOSTIC_TEST|Angio-IMR|Angiography derived post-processing index if microvascular resistance
223855019|NCT03619616|DRUG|ZSP1603 7.5 mg|ZSP1603 capsule administered orally once daily under fasted condition.
224266112|NCT05860777|OTHER|Complexity score and implementation|AI machine learning model to identify patients with complex care needs and implementation with active reaching out to clinicians to offer interpreter services
224266113|NCT05614453|DRUG|Tislelizumab|Tislelizumab is an investigational, humanised-IgG4 monoclonal antibody with high affinity/binding specificity for PD-1. It is engineered to minimise binding to FcγR on macrophages to abrogate antibody-dependent cellular phagocytosis.
223855020|NCT03619616|DRUG|ZSP1603 12.5 mg|ZSP1603 capsule administered orally once daily in the fasting state.
223855021|NCT03619616|DRUG|Placebo 12.5mg|Participants will receive placebo matching to ZSP1603 orally once daily under fasted condition.
223855022|NCT03619616|DRUG|ZSP1603 25 mg|ZSP1603 capsule administered orally once daily under fasted condition.
223855023|NCT03619616|DRUG|Placebo 25mg|Participants will receive placebo matching to ZSP1603 orally once daily in the fasting state.
223855024|NCT03619616|DRUG|ZSP1603 50 mg|ZSP1603 capsule administered orally once daily under fasted state.
223855025|NCT03619616|DRUG|Placebo 50mg|Participants will receive placebo matching to ZSP1603 orally once daily in the fasting state.
223855026|NCT02452294|DRUG|Buparlisib|Patients will receive oral buparlisib 100 mg once daily and continue on study treatment until evidence of disease progression, death, or unacceptable adverse events
223855027|NCT00695006|OTHER|Sham Traction|Traction \<5lbs
223855028|NCT00695006|OTHER|Traction|Standard supine intermittent traction
223855029|NCT00718848|PROCEDURE|Incentre nocturnal hemodialysis|This is a hemodialysis schedule that consists of 3 weekly hemodialysis sessions administered overnight (8 hours/session) in-hospital.
223855030|NCT00718848|PROCEDURE|Remaining on conventional hemodialysis|These patients will remain on their current conventional hemodialysis schedule that consists of 4 hours/session, 3 sessions/week.
223855031|NCT00773435|BIOLOGICAL|Echinacea purpurea 100 mg/ml in liquid formulation|10 ml BID for 10 consecutive days at the start of 3 consecutive 30 day periods
223855032|NCT00773435|OTHER|placebo|10 ml PO BID for 10 consecutive days at the beginning of 3 consecutive 30 day periods
224266114|NCT05614453|DRUG|Sitravatinib|Sitravatinib is an orally bioavailable receptor tyrosine kinase (RTK) inhibitor with potential anti-neoplastic activity.
224266115|NCT04224753|DEVICE|INVSENSOR00027|Investigational, noninvasive sensor that will be placed on the subject's chest. INVSENSOR00027 detects falls for each subject.
224266116|NCT05283954|DRUG|Combination regimen: Fluoxetine, Prednisolone, Ivermectin|"Subjects will receive the following treatments:~Fluoxetine 20 mg oral tablets: One tablet right after randomization (Day 0) followed by one daily tablet for the following 09 days.~Prednisolone 25 mg oral tablets: One tablet right after randomization (Day 0) followed by one daily tablet for the following 04 days.~Ivermectin 3 mg oral tablets: Tablets started right after randomization (Day 0; 400mcg/ kg dosing), administered once a day for 05 consecutive days."
224266117|NCT05283954|DRUG|Combination regimen: Albendazole, Vitamin C|"Subjects will receive the following treatments:~Vitamin C 50 mg oral tablets: One tablet right after randomization (Day 0) followed by one daily tablet for the following 09 days.~Albendazole 200 mg oral tablets: One tablet right after randomization (Day 0) followed by one daily tablet for the following 04 days.~Vitamin C 50 mg oral tablets: Tablets started right after randomization (Day 0; 130mcg/ kg dosing), administered once a day for 05 consecutive days."
224266118|NCT01572051|BEHAVIORAL|Educational Course|2 Educational courses
224266119|NCT01572051|BEHAVIORAL|Phone Calls|Phone Calls
224266120|NCT01572051|BEHAVIORAL|Printed Material|Printed Material
224266121|NCT03209505|DEVICE|Acuvue Oasys|FDA approved contact lens, fit for daily wear
224266122|NCT03209505|DEVICE|Air Optix Night & Day Aqua|FDA approved contact lens, fit for daily wear
224266123|NCT04431505|OTHER|apoptosis|study of apoptotic changes due to anaesthesia
224266124|NCT00253305|DRUG|Organogel of naftifine, 2%|
224266125|NCT00253305|DRUG|Organogel of terbinafine, 2%|
224266126|NCT00253305|DRUG|Organogel of naftifine, 6%|
224266127|NCT00253305|DRUG|Organogel of terbinafine, 6%|
224266128|NCT06562920|DRUG|adebrelimab and chemotherapy|3 cycles of adebrelimab combined with chemotherapy and concurrent SBRT, and undergo surgery within 4-6 weeks after treatment.
224266129|NCT02412358|DEVICE|toothbrush|
223855033|NCT00505323|DEVICE|Implantation of neurostimulators and their auxiliary components|"Implantation neurostimulators and their auxiliary components :~Stimulateur KINETRA TM modèle 7428, Electrode Resume II modèle 3587A, Extension kit DBS 7482"
223855034|NCT04490252|DIETARY_SUPPLEMENT|Fasting mimetic diet|Fasting mimetic diet for 5 days, another cycle after 25 days
223855035|NCT04870060|DRUG|Curcumin Lozenges|Curcumin lozenges - 4 lozenges to be chewed BD. Each lozenge contained 100 mg of curcumin and the formulation was Solid Lipid Curcumin Particle (SLCP)
223855036|NCT02695290|DRUG|Afatinib|
223855037|NCT02959957|DRUG|Temocillin|Total antibiotic treatment 7-10 days, of which at least 72 hours (9 doses) initial temocillin administration. In case of bacteraemia at baseline the total antibiotic treatment can be extended up to 14 days.
223855038|NCT02959957|DRUG|Cefotaxime|Total antibiotic treatment 7-10 days, of which at least 72 hours (9 doses) initial cefotaxime administration. In case of bacteraemia at baseline the total antibiotic treatment can be extended up to 14 days.
223855039|NCT03282526|DIAGNOSTIC_TEST|Whole body plethysmography|Whole body plethysmography : measure lung volumes Spirometry : to assess severity of chronic obstructive pulmonary disease also reversibility testing
223855040|NCT00646451|DRUG|pregabalin (Lyrica)|75 mg bid to 300 mg bid based on per subject tolerability
223855041|NCT00646451|DRUG|placebo|up to 4 capsules bid as tolerated
223855042|NCT03353467|PROCEDURE|Endoscopic surgery|Endoscopic nasopharyngectomy included endoscopic resection, with or without posterior pedicle nasal mucoperiosteal flap resurfacing the nasopharyngeal defects.
223855043|NCT03353467|RADIATION|Intensity-modulated radiotherapy|All of the patients were received irradiation by IMRT. The target volumes were delineated according to a previously described institutional treatment protocol, which is in accordance with the International Commission on Radiation Units and Measurements reports 50 and 62.
223855044|NCT01462058|DIETARY_SUPPLEMENT|Vitamin D3|70µg Vitamin D3, daily, 12 weeks
223855045|NCT01462058|DRUG|Placebo|Placebo, daily, 12 weeks
223855046|NCT05003570|DRUG|Remifentanil|Dosage forms and strengths: 3 mL Vial/1 mg lyophilized powder. Manufacturer: Yichang Humanwell Pharmaceutical Co.,Ltd
223855047|NCT05003570|DRUG|Fentanyl|Dosage forms and strengths: 50 mcg/mL Fentanyl base/10 mL ampules. Manufacturer: Yichang Humanwell Pharmaceutical Co.,Ltd
223855048|NCT00005113|DRUG|Cyclosporine|Oral tablet taken daily. Dosage is dependent on weight and is titrated to target trough level.
223855049|NCT00005113|DRUG|Sirolimus|Dosage in liquid or tablet form is dependent on body surface area and is titrated to target trough level.
223855050|NCT00005113|DRUG|Tacrolimus|dosage is in oral form titrated to target trough level
223855051|NCT02669524|DRUG|LY2409021|
223855052|NCT02669524|DRUG|LY2409021 placebo|
223855053|NCT02669524|PROCEDURE|OGTT|
223855054|NCT02669524|PROCEDURE|IIGI|
223855055|NCT02669524|PROCEDURE|Standardised liquid meal|
223855056|NCT03751891|DEVICE|Phonak Audéo B90-Direct|The Phonak Audéo B90-Direct is the most recent Receiver-in-the-canal Hearing aid from Phonak which will be fitted to the participants individual Hearing loss.
223855057|NCT03751891|DEVICE|HearingAid_A|HearingAid\_A is the most recent Receiver-in-the-canal Hearing aid from manufacturer\_A which will be fitted to the participants individual Hearing loss.
223855058|NCT03751891|DEVICE|HearingAid_B|HearingAid\_B is the most recent Receiver-in-the-canal Hearing aid from manufacturer\_B which will be fitted to the participants individual Hearing loss.
223855059|NCT04722094|DIAGNOSTIC_TEST|Full periodontal chart|A full periodontal chart will be carried out including all biometric periodontal variables: Probing Pocket Depth (PPD), Bleeding on Probing (BoP), presence of Plaque, recession (REC), Full Mouth Plaque Score (FMPS), Full Mouth Bleeding Score (FMBS), presence of furcation and mobility. Periodontal status, as assessed by the periodontal chart, will be evaluated following the New Classification of Periodontal and Peri implant diseases.
223855060|NCT04722094|OTHER|Saliva sampling|Saliva samples for miRNAs detection will be taken before starting the visit.
223855061|NCT05911256|BEHAVIORAL|Pharmacist Only|Clinical pharmacists conduct encounters with patients by videoconferencing or phone. Pharmacists conduct a broad range of activities including ongoing evaluation of medication and lifestyle adherence, setting therapeutic goals, formulating a provider-approved plan of care, and documenting the plan in the electronic health record. Pharmacists propose medication changes based on algorithms and protocols derived from national guidelines under physician guidance.
223855062|NCT05911256|DEVICE|Continuous Glucose Monitor (CGM)|Patients will receive the Continuous Glucose Monitoring (CGM) system. The instruction on use of device is the intervention being tested, not the effectiveness of the device itself. Participants will receive instruction and training on how to use the device and will wear the device for 14 days.
223855063|NCT05911256|BEHAVIORAL|Community Health Worker (CHW)|Patients are connected to a community health worker(CHW). CHWs conduct home visits and facilitate 3-way Telehealth visits (Patients, pharmacists, and CHWs) via an iPad with cellular plan. Additional CHW activities include social determinants of health screening, health behavior education, problem solving, goal setting, and medication adherence support.
223855064|NCT00253240|PROCEDURE|Screening|
223855065|NCT00253240|PROCEDURE|Management|
223855066|NCT04689321|OTHER|No intervention|This is not an interventional study.
223855067|NCT01921543|DEVICE|ITP Stimulation|"Model 7428 Kinetra® Neurostimulator~Model 3887 DBSTM Pisces Quad Compact Model 3389 DBSTM Brain Lead~Model 3387 DBSTM Brain Lead~Model 7482-51 Extension~Model 7482-66 Extension~Model 7482-95 Extension~Model 7436 AccessTM Therapy Controller~Model 3628 Dual Screener TM~Model 8840 N'Vision"
223855068|NCT01921543|DEVICE|CI/BNST stimulation|"Model 7428 Kinetra® Neurostimulator~Model 3887 DBSTM Pisces Quad Compact Model 3389 DBSTM Brain Lead~Model 3387 DBSTM Brain Lead~Model 7482-51 Extension~Model 7482-66 Extension~Model 7482-95 Extension~Model 7436 AccessTM Therapy Controller~Model 3628 Dual Screener TM~Model 8840 N'Vision"
223855069|NCT01921543|DEVICE|No stimulation|
223855070|NCT04687553|DIAGNOSTIC_TEST|Simplified Evaluation of CONsciousness Disorders (SECONDs)|All patients were assessed by the Simplified Evaluation of CONsciousness Disorders (SECONDs)
223855071|NCT03223883|DRUG|Curcumin|Oral supplement for 12 months
223855072|NCT03223883|OTHER|Placebo|Oral placebo for 12 months
223855073|NCT02338739|BEHAVIORAL|REC; Outreach if Failure|Routine education and counseling (REC) services, delivered per Kenya Ministry of Health Guidelines; followed by standard of care (SOC) outreach to encourage return to clinic for patients 14 days late for a scheduled visit in year 1.
223855074|NCT02338739|BEHAVIORAL|REC; SMS + Voucher if Failure|Routine education and counseling services, delivered per Kenya Ministry of Health (MOH) Guidelines; followed by SMS text messages for patients and reimbursement at a fixed amount (KSH 400) for transport to the clinic for patients 14 days late for a scheduled visit in year 1.
223855075|NCT02338739|BEHAVIORAL|REC; Navigator if Failure|REC services, delivered per Kenya MOH Guidelines; followed by Peer Navigator (tailored outreach and support) for patients 14 days late for a scheduled visit
223855076|NCT02338739|BEHAVIORAL|SMS; Outreach if Failure|SMS text messages for patients; followed by SOC outreach for patients 14 days late for a scheduled visit
223855077|NCT02338739|BEHAVIORAL|SMS; Outreach if Failure; Stop SMS if Success|SMS text messages for patients, followed by SOC outreach for patients 14 days late for a scheduled visit, and discontinuation of SMS text messages if never 14 days late
223855078|NCT02338739|BEHAVIORAL|SMS; SMS+Voucher if Failure|SMS text messages for patients, followed by reimbursement at a fixed amount (KSH 400) for transport to the clinic for patients 14 days late for a scheduled visit in year 1.
223855079|NCT02338739|BEHAVIORAL|SMS; SMS+Voucher if Failure; Stop SMS if Success|SMS text messages for patients, followed by reimbursement at a fixed amount (KSH 400) for transport to the clinic for patients 14 days late for a scheduled visit in year 1, and discontinuation of SMS text messages if never 14 days late
223855080|NCT02338739|BEHAVIORAL|SMS; Navigator if Failure|SMS text messages for patents, followed by Peer Navigator (tailored outreach and support) for patients 14 days late for a scheduled visit
223855081|NCT02338739|BEHAVIORAL|SMS; Navigator if Failure; Stop SMS if Success|SMS text messages for patents, followed by Peer Navigator (tailored outreach and support) for patients 14 days late for a scheduled visit, and discontinuation of SMS text messages if never 14 days late
223855082|NCT02338739|BEHAVIORAL|Voucher; Outreach if Failure|Reimbursement at a fixed amount (KSH 400) for transport to the clinic for patients, followed by SOC outreach for patients 14 days late for a scheduled visit
223855083|NCT02338739|BEHAVIORAL|Voucher; Outreach if Failure; Stop Voucher if Success|Reimbursement at a fixed amount (KSH 400) for transport to the clinic for patients, followed by SOC outreach for patients 14 days late for a scheduled visit, and discontinuation of voucher for patients if never 14 days late
223855084|NCT02338739|BEHAVIORAL|Voucher; SMS+Voucher if Failure|Reimbursement at a fixed amount (KSH 400) for transport to the clinic for patients, followed by SMS text message and reimbursement (KSH 400) for transport to the clinic for patients 14 days late for a scheduled visit
223855085|NCT02338739|BEHAVIORAL|Voucher; SMS+Voucher if Failure; Stop Voucher if Success|Reimbursement at a fixed amount (KSH 400) for transport to the clinic for patients, followed by SMS text message and reimbursement (KSH 400) for transport to the clinic for patients 14 days late for a scheduled visit, and discontinuation of voucher for patients if never 14 days late
223855086|NCT02338739|BEHAVIORAL|Voucher; Navigator if Failure|Reimbursement at a fixed amount (KSH 400) for transport to the clinic for patients, followed by Peer Navigator (tailored outreach and support) for patients 14 days late for a scheduled visit
223855087|NCT02338739|BEHAVIORAL|Voucher; Navigator if Failure; Stop Voucher if Success|Reimbursement at a fixed amount (KSH 400) for transport to the clinic for patients, followed by Peer Navigator (tailored outreach and support) for patients 14 days late for a scheduled visit, and discontinuation of voucher for patients if never 14 days late
223855088|NCT02540551|PROCEDURE|Injection of radioactive tracer combined with Patent Blue|Blue dye and the radioactive isotope will be injected in the remains of the ligamentum ovarium proprium (median side) and the ligamentum infundibulo-pelvicum (lateral side), just below the peritoneum. Four syringes containing 0,2 ml patent blue and 0,15 ml (20-MBq) radioactive isotope (99mTc-nanocolloid or Nanocoll®, GE Healthcare, Eindhoven, The Netherlands) will be given. After a 15-minute interval the radioactivity the SN(s) will be identified either by the mobile gamma-camera and /or gamma-probe and / or visually (blue dye) after opening the retroperitoneal space.
223855089|NCT00462410|OTHER|counseling intervention|
223855090|NCT00462410|PROCEDURE|psychosocial assessment and care|
223855091|NCT01249092|DRUG|Pentoxifylline|Patients will take 400mg of pentoxifylline three times daily for a total duration of 6 months.
223855092|NCT00751491|DRUG|Adenosin|Intracoronary Adenosin 50 microg;
223855093|NCT00751491|OTHER|placebo|no intervention
223855094|NCT00751491|DRUG|Clopidogrel|Clopidogrel 300/600 mg
223855095|NCT06140745|DRUG|0 ppm Fluoride Dentifrice 1|Each subject will use this product during one of the five treatment periods in the crossover study design.
223855096|NCT06140745|DRUG|1100 ppm NaF Fluoride Dentifrice|Each subject will use this product during one of the five treatment periods in the crossover study design.
223855097|NCT06140745|DRUG|1500 ppm NaMFP Fluoride Dentifrice|Each subject will use this product during one of the five treatment periods in the crossover study design.
223855098|NCT06140745|DRUG|0 ppm Fluoride Dentifrice 2|Each subject will use this product during one of the five treatment periods in the crossover study design.
223855099|NCT06140745|DRUG|0 ppm Fluoride Dentifrice 3|Each subject will use this product during one of the five treatment periods in the crossover study design.
223855100|NCT04621682|OTHER|Non technical skills and checklist training in simulation|using structured debrifing, in three random medical simulation crises, training in non-technical skills will be carried out
223855101|NCT04621682|OTHER|Checklist training simulation|using structured debrifing, in three random medical simulation crises, training in checklist will be carried out
223855102|NCT00143689|DRUG|lopinavir/ritonavir; nevirapine; Zidovudine; Lamivudine|See Detailed Description.
223855103|NCT01711710|DEVICE|Cohesive Gel Breast Implant|"Cohesive Silicone Gel-Filled Breast Implant insert under the submuscular with axillary incision in breast augmentation mammoplasty.~Remove tissue expander and insert Cohesive Silicone Gel-Filled Breast Implant in breast reconstruction."
223855104|NCT05185921|BEHAVIORAL|Trial-based Cognitive therapy|The virtual CBT will be provided by 02 psychotherapists, who will follow a protocol developed for this study. The number of sessions will be eight, which will be held weekly, projecting an intervention time of 2 to 3 months considering the possibility of rescheduling any of the sessions for reasons derived from the participant People with relevant cognitive impairment that prevents them from answering the questionnaire questions or providing informed consent are excluded.
223855105|NCT04307199|PROCEDURE|Amniotic membrane sweep|Amniotic membrane sweeping is defined as the manual detachment of the inferior pole of the amniotic membranes from the lower uterine segment. This is performed with consent by a clinician digitally through a circular motion during a vaginal examination. If the cervical os is closed massage of the cervix will be accepted.
223855106|NCT02313441|OTHER|Remote Ischemic Pre-Conditioning|The blood pressure cuff was inflated to a pressure of 200 mm Hg for 5 minutes, followed by 5 minutes of deflation to allow reperfusion. This procedure was repeated 3 times by the resident doctors in the pre-cath room
223855107|NCT03407131|PROCEDURE|Joint replacement surgery|Joint replacement surgery is to replace the original joint function, so that the patient can recover the joint function as soon as possible.
223855108|NCT03407131|PROCEDURE|Intramedullary nail fixation|Internal fixation surgery is the stable fixation of fracture, which provides the condition for the restoration of joint function.
223855109|NCT03392558|OTHER|Burt's Bees Skin Care Regimen|Burt's Bees Facial Cleanser (twice daily), Burt's Bees Sensitive Daily Moisturizing Cream (morning), Burt's Bees Sensitive Night Cream (at bedtime)
223855110|NCT03392558|OTHER|Control Regimen|Cetaphil Gentle Skin Cleanser (twice daily), Cetaphil Moisturizing Lotion (twice daily)
223855111|NCT06321913|DRUG|IBI343 combined with IBI308|IBI343 Specifications: 100 mg/bottle Approval method: TBD Q3W intravenous infusion (IV) sintilimab Specifications: 100mg (10ml)/bottle Afghan way: 200 mg Q3W IV infusion
223855112|NCT01936753|BEHAVIORAL|Trained Mentor Mother and Supervisor|Trained, closely supervised Mentor Mothers guide and support the mother-infant pair to achieve timely and complete access to, and retention in PMTCT services along the entire cascade.
223855113|NCT00486759|DRUG|Bevacizumab|Bevacizumab was administered at a dose of 15 mg/kg IV on Day 1 of each 21-day cycle for 8 cycles or at a dose 10 mg/kg IV on Day 1 of each 14-day cycle for 8 cycles. The cycle duration (14- or 21-day) was chosen by each center prior to initiation of the study and was the same for all patients enrolled at that center.
223855114|NCT00486759|DRUG|Rituximab|Rituximab was administered at a dose of 375 mg/m\^2 IV on Day 1 of each 14- or 21-day cycle for 8 cycles. The cycle duration (14- or 21-day) was chosen by each center prior to initiation of the study and was the same for all patients enrolled at that center.
223855115|NCT00486759|DRUG|CHOP|Cyclophosphamide was administered at a dose of 750 mg/m\^2 IV on Day 1 of each cycle. Doxorubicin was administered at a dose of 50 mg/m\^2 IV on Day 1 of each cycle. Vincristine was administered at a dose of 1.4 mg/m\^2 IV (maximum of 2 mg) on Day 1 of each cycle. Prednisone was administered at a dose of 100 mg orally on Days 1-5 of each cycle. All 4 drugs were administered either every 21 days for 8 cycles or every 14 days for 6 cycles. The cycle duration (14- or 21-day) was chosen by each center prior to initiation of the study and was the same for all patients enrolled at that center.
223855116|NCT00486759|DRUG|Placebo|Placebo to bevacizumab was administered on Day 1 of each 14- or 21-day cycle for 8 cycles. The cycle duration (14- or 21-day) was chosen by each center prior to initiation of the study and was the same for all patients enrolled at that center.
223855117|NCT01830166|RADIATION|Low Dose Radiation Focal Brachytherapy|Low Dose Radiation Focal Brachytherapy
223855125|NCT05518201|BIOLOGICAL|Placebo among 18-45 yrs|Subjects received 3 doses of placebo according to a 0, 2, 6-month schedule (0.5mL/each dose).
223855126|NCT05518201|BIOLOGICAL|Placebo among 9-17 yrs|Subjects received 3 doses of placebo according to a 0, 2, 6-month schedule (0.5mL/each dose).
223855127|NCT02469467|DIETARY_SUPPLEMENT|VS-505|VS-505 is orally administered with meal for 8 weeks
223855128|NCT02541643|DRUG|Elotuzumab|"Elotuzumab will be administered intravenously at a dose of 10mg/kg weekly (Days 1, 8, 15, and 22 of a 4-233k cycle) of the first 2 cycles and every 2 weeks (Day 1 and Day 15) thereafter.~A window of -1 to +3 days is permitted in Cycles 1 and 2. In Cycle 1 and 2, an elotuzumab dose that falls outside of the pre-specified window must be skipped. In Cycles 3 and beyond, elotuzumab dosing may be delayed for up to 1 week as clinically indicated. If unable to administer within 1 week, then the dose should be skipped and resumption of the elotuzumab continues per the guidance document defined schedule. In addition the following premedication must also be administered 30-90 minutes prior to any elotuzumab:~* H1 blocker: diphenhydramine (25-50mg PO or IV) or equivalent~* H2 blocker: ranitidine (50mg IV) or equivalent~* acetaminophen (650-1000mg PO)"
223855129|NCT01299974|OTHER|Parents and Residents in Session|Family Faculty members agreed to participate in meetings with pediatric residents who agree to participate. Standardized meetings include discussions of the following: 1. Impact of hospitalization on the behavior and development of each participating parent's child. 2. Effective communication with a parent 3. How to gain trust 4. The family meeting: who participates, the agenda 5. Troubleshooting: how to deal with difficult situations (the parents will present a few instances, from their own experience, which they think might be challenging to the clinicians who treated their children). Other core components will be added (or existing ones deleted) based on participants' feedback. The meeting will be attended by two residents, a family council member, and a senior faculty who will serve as monitor. Following the meeting, the residents will have an opportunity to ask questions and offer comments about the experience in a dedicated feedback interview with a senior faculty member.
223855130|NCT05167253|BIOLOGICAL|UB-612|UB-612 includes a designer S1-RBD-sFc fusion protein formulated with designer Th and CTL epitope peptides selected from immunodominant M, S2 and N regions known to bind to human MHC I and II.
223855131|NCT03738137|DEVICE|Narotrend|Narcotrend motoring
223855132|NCT03738137|DEVICE|BIS|Bispectral index monitoring
223855133|NCT03738137|DRUG|Sufentanil|sufentanil is applied.
223855134|NCT03738137|DRUG|Lidocaine|Topical Anesthesia
223855135|NCT03738137|DRUG|Midazolam|midazolam is applied.
223855136|NCT02491554|DEVICE|Conventional AC-PC based implantation of ACTIVA INS DBS system|Conventional AC-PC based implantation of ACTIVA INS DBS system (manufactured by Medtronic) in the thalamic/subthalamic region (Vim-cZI).
223855137|NCT02491554|DEVICE|MR-tractography guided implantation of ACTIVA INS DBS system|MR-tractography guided implantation of ACTIVA INS DBS system (manufactured by Medtronic) in the DRT.
223855138|NCT04459988|DRUG|Ocrelizumab|Description Needed
223855139|NCT01740570|DRUG|Cabazitaxel|"Phase I Starting Dose: Cohort 1A) 25 mg/m2 by vein over 1 hour every 3 weeks. Cohort 1B) 20 mg/m2 by vein over 30 minutes every 3 weeks.~Phase II: Maximum tolerated dose from Phase I."
223855140|NCT04235283|DEVICE|Primary total knee replacement by pinless navigation (Orthomap Express,Stryker, Michigan)|The varus/valgus, extension/flexion, thickness of distal cut of femur was determined and done by pinless navigation system. After cutting, the instant information of resection level can show on the display screen. If the alignment is satisfying, the anterior/posterior femoral cut, chamfer cut and box resection were done by conventional jig
223855141|NCT04235283|PROCEDURE|Primary total knee replacement by traditional jig and minimally invasive technique|The femoral alignment was determined by intramedullary guide. The femoral alignment jig was set to 5-7 degree valgus dependent on the preoperative radiograph. A bone plug is impacted into the entry hole of femoral medullary canal before prosthesis placement.
223855142|NCT02715258|DRUG|Bexagliflozin|tablets containing 20 mg bexagliflozin
223855143|NCT02715258|DRUG|Placebo|tablets matching the appearance of bexagliflozin tablets
223855144|NCT03002246|OTHER|Ultrasound Examination|Research volunteers will be invited to have a 2D/3D ultrasound research scan 4-7 days from delivery.This ultrasound scan will take approximately 30 minutes to complete.
223855145|NCT03443037|DRUG|amantadine sulphate|
223855146|NCT05113355|DRUG|Chidamide|30mg; administered orally; twice a week (d1, d4, d8, d11, d15, d18). Repeat every 3 weeks for up to 24 months.
223855147|NCT05113355|DRUG|Sintilimab|200mg; intravenous infusion; d1. Repeat every 3 weeks for up to 24 months.
223855148|NCT01944410|BIOLOGICAL|PRP injection|injection of PRP to traumatic bone cyst defect
223855149|NCT02814643|DRUG|Benralizumab|Benralizumab SC administered every 4 weeks for 3 doses (Weeks 0, 4, and 8).
223855150|NCT02814643|DRUG|Benralizumab Placebo|Placebo administered every 4 weeks for 3 doses (Weeks 0, 4, and 8).
223855151|NCT02814643|DRUG|Seasonal influenza virus vaccine|Patients will receive 1 dose of seasonal influenza virus vaccine Intramuscular (IM) at Week 8.
223855152|NCT02263508|DRUG|Talimogene Laherparepvec|Talimogene laherparepvec administered by intratumoral injection
223855153|NCT02263508|DRUG|Pembrolizumab|Administered at a dose of 200 mg as an intravenous infusion over approximately 30 minutes.
223855154|NCT02263508|DRUG|Placebo|Administered by intratumoral injection
223855155|NCT01809964|BIOLOGICAL|ANT-1401|
223855156|NCT01809964|BIOLOGICAL|Vehicle|
223855157|NCT05857358|PROCEDURE|lipoaspiration|"Adipose tissue harvest will be conducted by a surgeon under under local and intra-veinous sedation anesthesia. Once the patient is asleep and just before the laying of the operating drapes, the skin will be thoroughly disinfected, in order to avoid bacteriological contamination. Each entry point will be disinfected with betadine before and regularly during the procedure and will receive local anesthesia.~The lipoaspiration sites will be infiltrated using a closed system, thanks to a Khoury canula. Adipose tissue will be harvested after waiting at least 5 minutes, in order to limit hematoma and excessive blood harvesting. A 3mm incision will be made then the tissue collection will be performed using a canula, manually, by gentle aspirations into a syringe then directly transferred into a connected sterile bag.~The incision will be closed with 1 stitch of 6-0 absorbable and a paraffin gauze dressing. Then, patient will be awaken and transported to the recovery room."
223855158|NCT05857358|DRUG|Injection of the autologous adipose-derived stromal vascular fraction (AD-SVF)|"Autologous uncultured (AD-SVF) will be isolated by digestion and centrifugation of adipose tissue from lipoaspiration.~Then, AD-SVF will be injected in 6 sites :~* 2 for the accessory labial glands (0.5mL in the upper lip and 0.5mL in the lower lip)~* 2 for the sublingual glands (0.5mL for each gland)~* 2 for the inner face of cheeks (0.5mL for each side)~The volume of injection will be of 3 mL containing 30 millions of AD-SVF viable nucleated cells for the total safety dose."
223855159|NCT05573854|DIETARY_SUPPLEMENT|Gastric emptying after an oral supplement containing carbohydrates and whey protein|Ingestion of an oral supplement containing carbohydrates and whey protein
223855160|NCT05573854|DIETARY_SUPPLEMENT|Overnight Fast|Residual Gastric Volume assessed by MRI after overnight fast (8h)
223855161|NCT02008019|DRUG|Everolimus 2.5 mg/day|Comparison between 2,5 mg/day of Everolimus per os to 10 mg/day, or to no treatment, taken during 30 days before chondrosarcoma surgery
223855162|NCT02008019|DRUG|Everolimus 10 mg/day|Comparison between 10 mg/day of Everolimus per os to 2.5 mg/day, or to no treatment taken during 30 days before chondrosarcoma surgery
223855163|NCT03483519|OTHER|Rehabilitation|Patients randomized to the Experimental Group will undergo a 6 Week Exercise Program plus Standard of Care
223855164|NCT03483519|OTHER|Standard of Care|Patients randomized to the Active Comparator Group will not undergo an exercise program, patients will receive the standard of care used at The Ottawa Hospital for hip and knee surgeries. Standard of care protocol will be explained by each individual surgeon.
223855165|NCT02241668|PROCEDURE|PET Scan|FLT Pet Scan performed about 60 minutes after 3'-Deoxy-3'-18f-Fluorothymidine solution injected.
223855166|NCT02241668|DRUG|3'-Deoxy-3'-18f-Fluorothymidine|3'-Deoxy-3'-18f-Fluorothymidine solution injected through a central venous catheter after MRI scan. After solution injected into a vein, PET scanner takes pictures of the radioactive solution as it moves through the body and collects at various sites in the body. Entire procedure should last about 60-70 minutes.
223855167|NCT00531518|DRUG|aripiprazole; fluoxetine; bupropion; sertraline; lamotrigine|Oral, daily, generally at lower than manufacturer's recommendations
223855168|NCT00531518|BEHAVIORAL|Psychoeducational multifamily group treatment|Families and patients are educated on psychobiology of psychosis and trained in coping skills to avoid psychosis by reducing stress and optimizing social environment at home, school, work
223855169|NCT00531518|BEHAVIORAL|Supported employment and education|Participants are provided direct assistance, guidance and ongoing support to gain employment and succeed in their educational goals.
223855170|NCT02783235|OTHER|cervical cancer screening|for 50 ANMs/ASHAs/PHWs/ in conducting cervical cancer related health education , screening for cervical cancers using VIA, collection of PAP smears and HPV samples.
223855171|NCT00873691|DEVICE|ICD|Intervention isn an ICD. Patients in experimental group will have their ICDs programmed to Tuned waveform and those in the control group will have their ICDs programmed to Fixed Tilt waveform.
223855172|NCT06302491|DRUG|AND017 capsules|Administer AND017 capsules once per day (QD)
223855173|NCT06302491|DRUG|AND017 Placebo|Administer AND017 matching placebo capsules once per day (QD)
223855174|NCT01833507|BEHAVIORAL|Self-Exercise|Behavioral Goal Setting
223855175|NCT01833507|BEHAVIORAL|Usual Care|Participants will have full access to all of the educational materials which are available to all Mayo Clinic patients in literature racks in the individual clinics. Participants will subsequently be given entry into the active intervention at the 2-month check.
223855176|NCT03265210|BEHAVIORAL|RELIEF|A 9-week behavioral intervention for primary care designed to reduce depression and pain-related disability.
223855177|NCT00182845|DRUG|Donepezil|
223855178|NCT00411996|DRUG|indinavir/ritonavir|IDV/r 600/100 mg BID + rifampicin OD for at least 2 weeks
223855179|NCT00598208|DRUG|corifollitropin alfa|On Cycle Day 2, a single injection of 60 μg, 120 μg, or 180 μg Org 36286 was administered. One week later (Treatment Day 8), treatment was continued with a fixed daily subcutaneous (SC) dose of 150 IU Puregon® up to and including the Day of hCG. Orgalutran® (0.25 mg) was administered once daily SC starting on Treatment Day 5 and up to and including the Day of hCG. The maximum total treatment duration was 19 days.
223855180|NCT00598208|DRUG|Follitropin beta injection|Starting on Cycle Day 2, a fixed daily dose of 150 IU Puregon® SC was administered for the entire stimulation period up to and including the Day of hCG. Orgalutran® (0.25 mg) was administered once daily SC starting on Treatment Day 5 and given up to and including the day of hCG. The maximum total treatment duration was 19 days.
223855181|NCT06125106|DRUG|Blinatumomab|Haploidentical hematopoietic stem cell transplantation was performed using a Conditioning regimen containing Blinatumomab. 28ug of Blinatumomab was administered intravenously once a day for a total of 7 days, followed by a routine conditioning regimen and haploid hematopoietic stem cell transplantation.
223855182|NCT00686517|BIOLOGICAL|Pegylated interferon alfa-2b|1.5 ug/kg/week SC for 12 or 24 weeks
223855183|NCT00686517|DRUG|Ribavirin|Ribavirin at the dose of 10.6 mg/kg/day for 12 weeks
223855184|NCT03861741|GENETIC|WES|A peripheral venous blood sample will be processed internally, and externally subjected to WES. Only genetic material from relatives of probands in which a mutation has been identified will be sequenced.
223855185|NCT03861741|DIAGNOSTIC_TEST|MRI|A MRI of the thoracic aorta will be performed in all relatives able to attend the Glenfield Hospital and who have no contra-indications to this imaging modality; pulse-wave velocity will be recorded.
223855186|NCT03861741|DIAGNOSTIC_TEST|TTE|TTE screening will be performed by a trained physiologist. Aortic diameter will be measured from the parasternal long-axis view at the sinuses of Valsalva and at the widest level of the ascending aorta. All measurements will be made in end-diastole.
223855187|NCT03861741|OTHER|Questionnaire|Acceptability questionnaires will be submitted to assess a baseline score of depression/anxiety that will be compared with a follow up value at three months
223855188|NCT04289610|DEVICE|Transcutaneous pulse radiofrequency therapy|Transcutaneous pulse radiofrequency therapy (TCPRF) is a painless and outpatient physiotherapy modality
223855189|NCT01153451|OTHER|Email Notification|BWH inpatient clinical information systems will automatically file all non-finalized chemistry, hematology, pathology, and radiology tests, as well as inpatient and ambulatory provider email addresses for all study patients discharged. This process will be initiated using a time stamp most proximate to actual discharge time. At midnight on every day, all tests filed at time of discharge will be updated if final results have become available. An email with all finalized and pending test results for each patient discharged will be sent to the inpatient and primary care provider at this time. For patients discharged with more than one pending test, subsequent email notification(s) will be sent out until all pending tests are finalized (no more than one email per day).
223855190|NCT00140088|DRUG|ALGRX 3268|
223855191|NCT03302546|PROCEDURE|Incremental hemodialysis|Patients randomized to this arm of treatment will be treated during at least 4 hours of hemodialysis twice per week
223855192|NCT03302546|PROCEDURE|Conventional hemodialysis|Patients randomized to this arm of treatment will be treated during at least 3.5 hours of hemodialysis three times per week
223855193|NCT06422650|DRUG|Nigella Sativa capsule 500mg|Nigella Sativa capsule 500mg twice daily for 8 weeks
223855194|NCT06422650|DRUG|Placebo|Oral placebo identical to astaxanthin
223855195|NCT02281318|BIOLOGICAL|Mepolizumab|Humanised Immunoglobulin G (IgG) antibody (IgG1, kappa) with human heavy and light chain frameworks, provided as a lyophilised cake in sterile vial. Vial to be reconstituted with sterile water for injection, just prior to use
223855196|NCT02281318|DRUG|Placebo|Sterile 0.9% sodium chloride solution
223855197|NCT02281318|DRUG|SOC|Standard of Care (SOC) will differ by participants, however it will include high dose ICS with at least one other controller, e.g. LABA, with or without maintenance OCS
223855198|NCT05876130|RADIATION|POHIM_EM|hypofractionated intensity-modulated radiation therapy (2.5 Gy/fraction, 16 fractions)
223855199|NCT02804516|BEHAVIORAL|the nurse did early mobilization|the nurses know and do what is the early mobilization in ICU
223855200|NCT02804516|BEHAVIORAL|the nurse do not do early mobilization|the nurses do not know and do what is the early mobilization in ICU
223855201|NCT06400446|OTHER|Standard care|The babies in this group will receive the standard care of the unit. The vital signs and pain scores of the babies will be recorded before the mother's visit for seven days. The vital signs and pain scores of the infants who received the standard care of the unit during one hour, which is the time of the mother's visit, will be recorded every 15 minutes for a total of 4 times. The vital signs and pain scores of the infant will be recorded in the first 15 minutes after the mother's visit.
223855202|NCT06400446|OTHER|Kangaroo care|Kangaroo care will be applied to the experimental group for seven days. Kangaroo care will be started for the babies in the intervention group when the baby is extubated, when the baby starts oral feeding and when the chest incision is closed. Consistent with previous research, mothers will provide skin-to-skin contact for at least 1 hour per day for seven days, starting immediately after feeding. The vital signs and pain scores of the babies will be recorded during the kangaroo care of the mother for seven days. During the kangaroo care, vital signs and pain scores of the infants will be recorded every 15 minutes for a total of 4 times. The vital signs and pain scores of the infant will be recorded in the first 15 minutes after the mother's visit.
223855203|NCT00812877|DRUG|Mineral Trioxide Aggregate|Pulp capping agent, Mineral TrioxideAggregate
223855204|NCT00812877|DRUG|Calcium Hydroxide|Pulp capping agent, Calcium Hydroxide
223855205|NCT04809090|BEHAVIORAL|SMT|Standard 8 SMT (Stress Management Training) psychological interviews.
223855206|NCT04809090|DEVICE|App CA|An APP together a CA (Conversational Agent).
223855207|NCT05948358|OTHER|Menstrual Distress Questionnaire|The Menstrual Distress Questionnaire (MEDI-Q) is a new tool originally developed in Italian that comprehensively evaluates menstrual-related distress.
223855208|NCT00130013|DRUG|Oral Amoxicillin|
223855209|NCT01000129|OTHER|Adaptive-Planning Organ Localisation (A-POLO) (Planning CT scan)|Planning CT scan performed by qualified planning radiographers
223855210|NCT01000129|OTHER|Cone beam CT acquisition|Cone beam CT acquisition performed by therapy radiographers who have training and experience of using cone beam CT.
223855211|NCT02614560|DRUG|Fludarabine|30 mg/m2/day intravenously, 5 to 2 days before the transplant (total dose of 120 mg/m2)
223855212|NCT02614560|DRUG|Melphalan|Melphalan 140 mg/m2 intravenously, 2 days before the transplant
223855213|NCT02614560|DRUG|vadastuximab talirine|Pre-allo (before stem cell transplant) given 14 days before the stem cell transplant
223855214|NCT02614560|DRUG|vadastuximab talirine|Post-allo (after stem cell transplant) given on Day 1 of each cycle
223855215|NCT00703911|DRUG|eptacog alfa (activated)|Treatment of patients experiencing bleeds at the discretion of the physician/caregiver
223855216|NCT03173105|DEVICE|active tDCS|TDCS will be administered using with two sponge (non-metallic) surface electrodes (5 x 7 cm2) moistened with saline solution. For stimulation of the motor motor, somatosensory, and visual cortices with a current of 2mA for 20 minutes. The cathode will be positioned in the medial supraorbital region.
223855217|NCT03173105|DEVICE|sham tDCS|Sham TDCS will be administered using with two sponge (non-metallic) surface electrodes (5 x 7 cm2) moistened with saline solution The stimulator will only be switched on for the first 30 seconds, giving the participant the initial sensation of tDCS, but no active stimulation throughout the remainder of the session the proprioceptive exercise session
223855218|NCT03173105|OTHER|Dynamic proprioceptive exercises|The dynamic proprioceptive exercises will be conducted as follows: 1) walking slowly then more quickly on a trampoline; 2) walking backward with one foot behind the other; 3) walking forward on a beam; 4) going up and down a flight of stairs; and 5) sitting on a Swiss exercise ball (65 cm) and performing laterolateral, anteroposterior, circling movements and bouncing. Activities will be performed in three one-minute sets.
223855219|NCT03173105|OTHER|static proprioceptive exercises|The static exercises will be conducted as follows: 1) standing on toes with feet apart; and 2) with feet together; 3) standing on only right leg without support; and 4) on only left leg without support; and 5) standing with heel of right (or left) foot touching toes of left (or right) foot with feet in a straight line over on an unstable surface (wobble board) performed in six sets of 30 seconds each, with a one-minute rest interval between sets
223855220|NCT00596310|OTHER|CT|Screening CT
223855221|NCT00919685|BIOLOGICAL|blood sample|from rest of blood sample collected for other measurements
223855222|NCT05495477|DEVICE|EIT|Evaluation of ventilation distrinution during deep sedation through EIT
223855223|NCT06375291|OTHER|splint /steroid injection/both|pregnant women treated in pain department by splint /steroid injection/both
223855224|NCT05287282|OTHER|TECAR application|Radiofrequency (RF) is the emission of high frequency waves via an applicator. The transfer of electromagnetic energy stimulates targeted tissues. RF can be used in two ways: capacitive or resistive The capacitive mode (CET) concentrates the energy to target soft tissues containing electrolytes: muscles, vascular or lymphatic tissues. The resistive mode (RET) targets denser tissues containing more fat and fiber (such as bones, ligaments and tendons). High frequency waves penetrate deep into tissues and increase both exchanges and temperature and a recent study has demonstrated the effects of RF on the skin microcirculation and the intramuscular blood flow
223855225|NCT01551056|DRUG|AC-170 0.24%|1 drop in each eye at 2 separate times during a 14 day period
223855226|NCT01551056|DRUG|AC-170 0%|1 drop in each eye at 2 separate times during a 14 day period
223855227|NCT06404710|BEHAVIORAL|Exercise|Participants in this group will be given a gradual muscle relaxation exercise.
223855228|NCT00337545|DRUG|RAD001|
223855229|NCT00613782|DRUG|Reandron 1000|1000mg at 0,6,18,30 weeks
223855230|NCT00613782|DRUG|placebo|placebo injection 0,6.18.30 weeks
223855231|NCT05857306|DIETARY_SUPPLEMENT|Olvanil|"Nutritional recommendation along with 4 mg Olvanil (1 capsule daily)~Subects within the Intervention group will be provided with a nutritional recommendation along with Olvanil capsules. Subjects will be asked to consume one capsule per day. Every capsule contains: 4 mg Olvanil and 255 mg soy lecithin as excipient"
223855232|NCT05857306|DIETARY_SUPPLEMENT|Placebo|"Nutritional recommendation along with 255 mg soy lecithin (1 capsule daily)~Subects within the placebo group will be provided with a nutritional recommendation along with placebo capsules. Subjects will be asked to consume one capsule per day. Every capsule contains: 255 mg soy lecithin"
223855233|NCT00545376|PROCEDURE|Osteopathic Manipulative Treatment - in clinic|I will do a thoracic/rib screening and treatment with muscle energy or facilitated positional release, a diaphragm soft tissue release, suboccipital release, and a thoracic compression. This treatment takes 10 minutes and is only done at the first visit.
223855234|NCT00545376|PROCEDURE|Osteopathic Manipulative Treatment - at home|One group will learn how to do three home OMT techniques: suboccipital release, pectoral traction, and rib raising. They will be asked to do this at least 4 times a week for two weeks.
223855235|NCT00545376|OTHER|Education to physicians|I will educate physicians using demonstration and reading material as to the possible benefits of incorporating it into the treatment of asthma.
223855236|NCT02970461|OTHER|Gamified Group|See Gamified Group in Arms description.
223855237|NCT02970461|OTHER|Control Group|See Control Group in Arms description.
223855238|NCT02293421|OTHER|Obstructive sleep apnea|
223855239|NCT01178762|DRUG|Azithromycin|Oral Azithromycin in the Treatment of Chlamydial Conjunctivitis
223855240|NCT02301221|PROCEDURE|Fecal microbiota transplantation (FMT)|Standardized Frozen Fecal Microbiota will be infused via nasointestinal tube.
223855241|NCT02301221|DRUG|Vancomycin and bowel lavage|An initial vancomycin regimen (500 mg orally two times per day for 3 days), followed by bowel lavage before the infusion of a solution of donor fecal microbiota.
223855242|NCT02377362|DRUG|GLWL-01, Part A|Capsules administered orally, in 2 out of 3 periods
223855243|NCT02377362|DRUG|Placebo, Part A|Capsules administered orally in 1 out of 3 periods
223855244|NCT02377362|DRUG|GLWL-01, Part B|Capsules administered orally either once or twice daily for 27 days, with a single dose on Day 28
223855245|NCT02377362|DRUG|Placebo, Part B|Capsules administered orally either once or twice daily for 27 days with a single dose on Day 28
223855246|NCT02377362|DRUG|GLWL-01, Part C|Capsules administered orally either once or twice daily for 27 days with a single dose on Day 28
223855247|NCT02377362|DRUG|Placebo, Part C|Capsules administered orally either once or twice daily for 27 days with a single dose on Day 28
223855248|NCT00409058|BEHAVIORAL|Teen Online Problem Solving|We will test the following hypotheses: 1) Children with TBI receiving TOPS will have fewer behavior problems, greater social competence, and better functioning than those receiving IRC at both post-treatment and at a 6-month follow-up assessment. 2) Caregivers of children receiving TOPS will report less depression and psychological distress, less parent-child conflict, and better family functioning than those receiving IRC at both post-treatment and at a 6-month follow-up assessment. 3) Social resources will moderate treatment efficacy, such that children with limited social and economic resources will show greater improvements in the more comprehensive TOPS intervention. We hypothesize better teen problem solving and communication skills, fewer teen emotional/behavioral problems, less parental burden and distress, and less parent-teen conflict at follow-up among the TOPS group compared to the IRC group.
223855249|NCT01819038|PROCEDURE|continuous renal replacement therapy|
223855250|NCT04333069|PROCEDURE|cataract surgery|cataract surgery in form of phaco emulsification or irrigation aspiration
223855251|NCT01723436|OTHER|Hypothetical scenarios and related decisions|Surrogates are exposed to three hypothetical medical scenarios that require varying levels of decision making. We will be assessing how this experience alters their subsequent choice to forego life sustaining therapy.
223855252|NCT03172208|BIOLOGICAL|Caplacizumab Dose 1 iv (single-dose)|Single intravenous (iv) administration of Caplacizumab Dose 1
223855253|NCT03172208|BIOLOGICAL|Caplacizumab Dose 2 iv (single-dose)|Single intravenous (iv) administration of Caplacizumab Dose 2
223855254|NCT03172208|BIOLOGICAL|Caplacizumab Dose 2 sc (single-dose)|Single subcutaneous (sc) administration of Caplacizumab Dose 2
223855255|NCT03172208|BIOLOGICAL|Caplacizumab Dose 2 sc (multiple-dose)|Once daily subcutaneous (sc) administration of Caplacizumab Dose 2 during 7 consecutive days
223855256|NCT03172208|OTHER|Placebo iv (single-dose)|Single intravenous (iv) administration of Placebo
223855257|NCT03172208|OTHER|Placebo sc (single-dose)|Single subcutaneous (sc) administration of Placebo
223855258|NCT03172208|OTHER|Placebo sc (multiple-dose)|Once daily subcutaneous (sc) administration of Placebo during 7 consecutive days
223855259|NCT03693443|BEHAVIORAL|early childhood caries|a questionnaire evaluates the oral health beliefs, knowledge, and behaviors of a sample representing Egyptian mothers toward early childhood caries
223855260|NCT03665701|PROCEDURE|Blood Sampling|Blood samples used within in vitro experiments to investigate the activation potency of Prostaglandin D2 metabolites to the DP2 receptor in comparison to Prostaglandin D2.
223855261|NCT03787875|PROCEDURE|periodontal treatment|In the study group, periodontal scaling and root planning treatment of the 4 quadrants was performed for two consecutive weeks without the use of antiseptics or antibiotics, and the patients were instructed in oral hygiene, including both brushing techniques and proximal hygiene.
223855262|NCT02888431|DEVICE|bedside point-of-care device|A bedside point-of-care device is routinely used in the operating room to measure lactate, base deficit, and pH.
223855263|NCT00990678|DRUG|Rocaltrol|tablet, Vitamin 1-OH-D3, total 1.25-2.5 mg daily
223855264|NCT00990678|DRUG|Vitamin D|tablets, vitamin D3, 30 microgram daily
223855265|NCT00990678|DRUG|Calcium|tablets, 400 mg calcium, 3 times daily
223855266|NCT02219906|DIETARY_SUPPLEMENT|Resveratrol|1000mg tid
223855267|NCT02219906|DIETARY_SUPPLEMENT|Placebo|1000mg tid placebo
223855268|NCT00457990|DRUG|Oral administration of ferrous sulphate|
223855269|NCT02117843|DEVICE|AVI® Arsenic trioxide drug eluting stent|AVI® Arsenic trioxide drug eluting stent
223855270|NCT04653714|PROCEDURE|Scaling and root planing|Patients with periodontitis in the test group will be treated by conventional non-surgical root debridement and in the control group by low-intensive supragingival plaque removal with mechanical brush and professional tooth paste only.
223855271|NCT04653714|DEVICE|Probiotic lozenges|Patients with gingivitis in the test group will be treated with supragingival debridement and with probiotic lozenges with strains of Lactobacillus brevis and Lactobacillus plantarum once a day for 3 months and in the control group by low-intensive supragingival plaque removal, as a placebo treatment, and placebo probiotics lozenges.
223855272|NCT04581837|DIAGNOSTIC_TEST|2D-speckle tracking echocardiography|Two-dimensional speckle tracking echocardiography (2D-STE) allows for an angle-independent evaluation of myocardial strain, and provides comprehensive information on LV myocardial contractility. Thus, 2DSTE is superior in detecting subtle deteriorations of contractility. we will take 2D speckle tracking views for LV and RV strain (4ch, 2ch, 3ch, RV modified view).
223855273|NCT04889664|DRUG|Ketamine|Repeated intravenous Ketamine infusions.
223855274|NCT04889664|BEHAVIORAL|Written Exposure Therapy|WET is a brief, 5-session evidence-based written trauma-focused therapy
223855275|NCT05328076|DRUG|Indocyanine green|Indocyanine green is used to perform intraoperative angiography.
223855276|NCT05328076|DEVICE|SPY Portable Handheld Imaging (SPY-PHI)|The device is used to perform intraoperative angiography.
223855277|NCT02205086|OTHER|Diagnosis|"Unaided: The testers will record a differential diagnosis consisting of a list of diseases and their ranking and a prioritized list of test orders, as well as the most appropriate referral for further evaluation and treatment of the patient.~Aided: Then testers will enter the case into diagnostic decision support software and after getting advice from the software, the testers will record the same information as in Unaided, but allowing for the possibility that responses could differ as a result of using the software."
223855278|NCT02322216|DRUG|Olopatadine Hydrochloride Ophthalmic Solution 0.2%|
223855279|NCT02322216|DRUG|Olopatadine Hydrochloride Ophthalmic Solution 0.1%|
223855280|NCT02322216|DRUG|Olopatadine 0.2% Vehicle|Inactive ingredients used as placebo comparator
223855281|NCT02313844|BIOLOGICAL|Viralym-B|"Follow-up Assessments: The timing of follow-up visits is based on the date of Viralym-B infusion. If a patient has multiple Viralym-B infusions the schedule resets again at the beginning so follow up relates to the last Viralym-B infusion.~Follow up will occur at 7 days, 14 days, 21 days, 28 days, 42 days, 90 days, 180 days, and 365 days post enrollment."
223855282|NCT00698802|DRUG|EX1000|Treat-to-target titration scheme, s.c. injection
223855283|NCT00698802|DRUG|biphasic human insulin|Treat-to-target titration scheme, s.c. injection
223855284|NCT04246697|DRUG|Tylenol|Used for both arms, scheduled
223855285|NCT04246697|DRUG|Oxycodone|Used for both arms PRN
223855286|NCT04246697|DRUG|Morphine|Used for both arms PRN
223855287|NCT04246697|DRUG|Gabapentin|Used for Arm B
223855288|NCT04246697|DRUG|toradol|Used for Arm B
223855289|NCT04246697|DRUG|Bupivacaine|Used for Arm B - anesthesia block
223855290|NCT00461799|DRUG|orlistat|
223855291|NCT06175923|BIOLOGICAL|Collection of EDTA (disodium salt of ethylenediaminetetraacetic acid) tubes of marrow during routine care|When bone marrow is collected as part of a patient's care (diagnosis, follow-up, suspected AML/MDS hemopathy), one or two additional EDTA tubes of marrow are collected. Certain hematological data (NFP, genetic and molecular characteristics) will be collected in anonymized form and correlated with the BMP pathway alterations measured.
223855292|NCT04181632|DEVICE|Buzzy Bee with Ice pack|Buzzy uses natural pain relief to block needle pain for blood draws and shots. This intervention will be used with an ice pack.
223855293|NCT04181632|DEVICE|Buzzy Bee without Ice pack|Buzzy uses natural pain relief to block needle pain for blood draws and shots. This intervention will be used without an ice pack.
223855294|NCT04181632|DEVICE|Shot Blocker|Shot Blocker is a device that instantly alleviates the pain and anxiety of needle injections when pressed firmly against the skin at the injection site.
223855295|NCT04991233|PROCEDURE|Endoscopic surgery|The endoscopic surgery will be conducted to evacuate the hemorrhage within 24 hours after SCH.
223855296|NCT04991233|PROCEDURE|Suboccipital craniotomy surgery|The suboccipital craniotomy surgery will be conducted to evacuate the hemorrhage within 24 hours after SCH.
223855297|NCT03608670|DEVICE|Defibrillation using the Extravascular ICD|VT/VF induction attempted for defibrillation testing, as well as requisite electrical testing.
223855298|NCT04602052|PROCEDURE|Dilation and evacuation|Abortion is termination of pregannacy by evaccuating the uterus using either medical or surgical technique
223855299|NCT00440284|DRUG|conventional vs. flexible, intensive insulin therapy|
223855300|NCT02867046|DRUG|S1 transforaminal epidural steroid(dexamethasone) injection|"medial approach group (n=85): check intravascular injection while performing S1 transforaminal epidural steroid(dexamethasone) injection in medial side of S1 foramen under fluoroscopy~lateral approach group (n=85): same as medial approach group except using lateral side of S1 foramen"
224266130|NCT04888767|OTHER|Interval Training Hight Intensity Program|"* Rehabilitation stay in hospitalization with 18 days of training sessions~* Training on an ergometer~* Sessions supervised by an Adapted Physical Activities (APA) teacher or a physiotherapist~  * Control group: 5 times / week; continuous work 20 to 30 min; around the 1st aerobic ventilation threshold~ * Intervention group: 2 times / week: maintenance sessions + 3 times / week: IHTI sessions - alternating 30s work / 30s rest repeated 6 times; at 60% of the maximum heart rate at the 1st session then increase as fast and large as possible"
224266131|NCT05239585|DEVICE|Epilog device|Pilot the use of wireless EEG technology in neonates with mild neonatal encephalopathy and neonates with spells to see if this device can be used to determine the risk for neonatal seizure and need for escalation of care and full scalp EEG
223855301|NCT01784146|OTHER|Oxygen|"For inhalation of oxygen, we used a noninvasive delivery system, semi - closed (Figure 3) consisting of a non-toxic face mask with two unidirectional valves - inspiratory and expiratory branch - connected to the~nebulizer (Airlife Misty Neb, Baxter; Valencia, CA, USA). In the inspiratory branch, a reservoir bag (Hudson RCI, USA) with capacity of 2.5 L was connected, in order to avoid dilution of the gas. This skin was fixed to the patient's face to prevent leakage and to maintain adequate pressurization and improved patient compliance to the PEEP. The nebulizer was fed by a flow of 8 l / min of oxygen."
223855302|NCT01784146|OTHER|Heliox|"For inhalation of heliox, we used a noninvasive delivery system, semi - closed consisting of a non-toxic face mask with two unidirectional valves - inspiratory and expiratory branch - connected to the~nebulizer (Airlife Misty Neb, Baxter; Valencia, CA, USA). In the inspiratory branch, a reservoir bag (Hudson RCI, USA) with capacity of 2.5 L was connected, in order to avoid dilution of the gas. This skin was fixed to the patient's face to prevent leakage and to maintain adequate pressurization and improved patient compliance to the PEEP. The nebulizer was fed by a 11 l / min of heliox for the heliox group in accordance with a protocol of Hess et al."
223855303|NCT01784146|OTHER|PEEP|PEEP supplied was 10 cm H2O through valve (Vital Signs,Totowa, USA) attached to the expiratory branch.
223855304|NCT01043406|DEVICE|Seizure Advisory System|Implant of Seizure Advisory System followed by data collection for algorithm training and subsequent enabling of seizure advisory indicators.
223855305|NCT05069935|DRUG|FT538|FT538 is an allogeneic natural killer (NK)-cell immunotherapy
223855306|NCT05069935|DRUG|Cyclophosphamide|Lympho-conditioning agent
223855307|NCT05069935|DRUG|Fludarabine|Lympho-conditioning agent
223855308|NCT05069935|COMBINATION_PRODUCT|Monoclonal antibody - Dose Escalation|either avelumab, trastuzumab or cetuximab
223855309|NCT05069935|COMBINATION_PRODUCT|Monoclonal antibody - Dose Expansion|either avelumab, atezolizumab, nivolumab, pembrolizumab, trastuzumab or cetuximab
223855310|NCT02520570|DRUG|ulinastatin|We wouldn't intervene the doctors how to treat with the patients or how to use the drug, we just observe the react of patients after treated with ulinastatin.
223855311|NCT02916719|DEVICE|MRI|MRI examination after the neo-adjuvant radiotherapy, but before the surgical treatment
223855312|NCT03012919|OTHER|active decision support system|The active decision support system in this study is a goal directed therapy (GDT) protocol where threshold hemodynamic values are defined when to give fluid, vasopressors and inotropes. Hemodynamic values are measured with the LiDCOrapid device, which uses pulse contour analysis to continuously monitor cardiac output and respiratory variations in stroke volume (SVV).
223855313|NCT02755363|OTHER|osteopathic manual therapy|"* suboccipital decompression - atlanto-occipital joint relaxation technique.~* deep cervical fascia release - the technique aims to improve mobility of the first and second ribs during expiration and to relaxation of the vagus and phrenic nerve course area.~* thoracic lymphatic pump with activation is designed to reduce the tension of mediastinal structures, improve lymphatic flow, and thus reduce the breathing resistance.~* stretching the diaphragm in order to relax and reduce adhesion within the fascial system between the diaphragm and abdominal organs."
223855314|NCT02755363|OTHER|control group|"* manual mobilization techniques of the slides in the shoulder joint toward the front, rear and bottom.~* manual techniques to increase range of motion in the shoulder joints using the patient's breathing manoeuvres."
223855315|NCT02834143|OTHER|No intervention|The is no intervention. This study is a descriptive one
223855316|NCT05701592|PROCEDURE|DB-PCLR|DB-PCLR with reconstruction of both PCL bundles: anterolateral and posteromedial bundle will be performed.
223855317|NCT04570644|DRUG|ALZT-OP1 (cromolyn and ibuprofen) ALZT-OP1a (cromolyn) and ALZT-OP1b (ibuprofen)|"Drug : ALZT-OP1a~1. Mast cell stabilizer~2. Neuroinflammatory microglial modulator~ALZT-OP1b anti-inflammatory~Device: Dry Powder Inhaler The inhaler will be used to deliver ALZT-OP1a via oral inhalation for dosing on study."
223855318|NCT06421688|DRUG|Ascorbic acid|After participants underwent induction of anesthesia, Ascorbic acid (Vitamin C Injection) was administered at a dosage of 50 mg/kg, diluted to 50 ml using saline, with a total amount not exceeding 4 g; pumping was performed using a micro pump at a rate of 25 ml/h.
223855319|NCT06421688|DRUG|Saline|After participants underwent induction of anesthesia, 50 ml of saline was used and pumped using a micro pump at a rate of 25 ml/h.
223855320|NCT06228807|COMBINATION_PRODUCT|The study involved a comparison of clinical characteristics, medical history, laboratory biomarkers, echocardiographic measurements, angiographic findings, and clinical outcomes between two groups.|Differences in clinical characteristics, history, laboratory biomarkers, echocardiographic measurements, angiographic findings, coronary microvascular function using caIMR and clinical outcomes were assessed between the two groups to identify potential risk factors. Subsequently, the incidence of clinical outcomes and mortality was compared. Univariate logistic regression and multivariate logistic regression analyses, adjusted for significant risk factors, were conducted to identify independent predictive factors. Finally, a Receiver Operating Characteristic (ROC) curve was generated, and the area under the curve was evaluated to assess the predictive accuracy of the regression model.
223855321|NCT02834689|BEHAVIORAL|Walking|Walking on a treadmill at 3.5 METS for 50 minutes
223855322|NCT02834689|BEHAVIORAL|Seated Control|Sitting for 50 minutes
223855323|NCT00470743|DRUG|Ibuprofen|
223855324|NCT00470743|DRUG|Indomethacin|
223855325|NCT00001421|DRUG|methimazole|
223855326|NCT01982019|BEHAVIORAL|Meal test taking and hormones measure including 26RFa|Meal test taking and blood sampling for the measure of 26RFa and classical hormones implicated in glucose control and obesity
223855327|NCT01805362|OTHER|Randomization that determine the time of treatment|
223855328|NCT00768781|BEHAVIORAL|Mindfulness-Based Stress Reduction|The rationale for treatment is that MBSR targets arousal, which is a prominent perpetuating factor of insomnia. Each session meets weekly for 120 minutes and consists of a therapist-led mindfulness meditation, followed by a discussion of the meditation and its application into the participant's everyday life. For homework, each participant is required to practice formal meditation at least 45 minutes a day, 6 days per week. Participants will be provided a tape, an mp3 file, or CD to aid in the participant's personal practice at home. Formal meditations that will be led and discussed include eating meditation, body scan, sitting meditation, Hatha Yoga, and walking meditation. In addition, informal mindfulness practices will be discussed.
223855329|NCT00768781|BEHAVIORAL|Mindfulness-Based Therapy for Insomnia|MBTI treatment includes the hypothesized active elements of both mindfulness meditation and behavior therapy for insomnia. The intervention includes 8 weekly sessions. Each session meets weekly for approximately 120 minutes. The general format of each session includes formal mindfulness meditation (quiet and movement meditations) and instructions for the behavioral intervention, with a focus on integrating the principles of mindfulness with these instructions. Each participant is required to practice formal meditation for at least 45 minutes a day, 6 days per week as homework. Participants are provided a tape, mp3 file, or CD to aid in the participant's personal practice at home.
223855330|NCT00768781|BEHAVIORAL|Wait-List + Behavioral Therapy for Insomnia|This delayed treatment condition consists of an 8-week monitoring period (sleep diaries, PSAS) and then BT. The BT treatment consists of 8 sessions of behavioral interventions for insomnia, with instructions targeting the nighttime symptoms of insomnia. The primary components of this treatment package are stimulus control, sleep restriction, and sleep hygiene education. In the BT condition, each weekly session lasts 120 minutes and consists of formal instructions for the behavioral interventions along with a time for discussion of the application of these instructions into each participant's unique circumstances.
223855331|NCT06394791|DRUG|Tislelizumab + IL-2 Combined with Capox|Tislelizumab + IL-2 Combined with Capox
223855332|NCT00368719|DRUG|Tacrolimus|Participants will be followed for 10 years to study the effects of Tacrolimus.
223855333|NCT00232011|DRUG|Pimecrolimus Cream 1%|Pimecrolimus cream 1 %
223855334|NCT04061408|RADIATION|Fractionated stereotactic radiotherapy(FSRT)|3 to 5 fractions and 8Gy per fraction will be used for breast cancer patients with 1-10 brain metastases based on the lesion number and volume.
223855335|NCT00759837|DRUG|Bosutinib|
223855336|NCT02952053|DEVICE|MTrP Group|"Deep Dry Needling into the site of the latent medial Myofascial Trigger Point of the soleus muscle.~1 session in soleus muscle. 10 fast in and fast out needle insertions."
223855337|NCT02952053|DEVICE|TB Group|"Deep Dry Needling distal to Myofascial Trigger Point but into the same taut band.~1 session in soleus muscle. 10 fast in and fast out needle insertions."
223855338|NCT01919697|DRUG|Plecanatide|
223855339|NCT01934829|DRUG|urea-based cream|"urea-based cream (10% urea; Eucerin) 3 times per day plus best supportive care, starting on day 1 of sorafenib treatment, for a maximum of 12 weeks .~BSC included the ad libitum use of non-urea-based moisturizing creams, alcohol-free moisturizer and petroleum jelly. Once HFSR occurred, patients were allowed any cream, including urea based creams, as guided by the investigator."
223855340|NCT03098290|PROCEDURE|Catheter-based endovascular revascularization|(e.g. PTA-alone, Bare-Metal or Drug-Eluting-Stent, Covered Stent, Atherectomy, Mechanical Thrombectomy, Scoring Ballon, Cutting Ballon)
223855341|NCT03098290|PROCEDURE|Bypass-Surgery|Venous or alloplastic or comparable Bypass
223855342|NCT03098290|PROCEDURE|Endarterectomy|Endarterectomy, Patchplasty
223855343|NCT06256211|DRUG|Paracetamol|"All cases will be randomized simply by opaque closed envelop and treated with either rectal or intravenous paracetamol according to the following doses.~* Rectal dose~  * Rectal paracetamol at a dose of 25 mg/kg body weight with started and then continued at a dose of 15 mg/kg body weight every 8 hours for 3 days (ten doses in total) in neonates weighing more than 1000 gm.11~ * The patient's weight is less than 1000 gm, the initial dose was 15 mg/kg body weight, and the suspense doses are 7.5 mg/kg body weight every 8 hours for 3 days (10 doses in total).11~* Intravenous dose~  * Intravenous paracetamol dose 15 mg/kg body weight every 6 hours for 3 days (12 doses in total).12~ * After the 3-day follow up echocardiogram will be done.12 This will be the end of randomization for the purpose of the study."
223855344|NCT05333887|BEHAVIORAL|PFC+|Therapists instruct parents in ways to coach their children to display better friendship behaviours using skill teaching and home practice. The program includes 2 intake sessions, a group workshop where all strategies are reviewed, and 3 consultation sessions to work on implementing strategies with therapist support. Emphasis throughout the program is placed on parents' connection and engagement with the material and therapist.
223855345|NCT05318950|BEHAVIORAL|E-learning|8 lessons about nutrition and lifestyle
223855346|NCT05318950|DIETARY_SUPPLEMENT|Diet|Diet A: MedDASH diet (55% carbohydrates, 25% amino acids, 20% fatty acids) Diet B: MedDASHfat diet (10% carbohydrates, 25% amino acids, 65% fatty acids)
223855347|NCT04354610|PROCEDURE|Biological samples specific to research|Blood samples, saliva collection, and urine collection to carry out biomarker assays and for the constitution of a biological collection.
223855348|NCT04354610|PROCEDURE|Clinical examination|Clinical examination
223855349|NCT04354610|PROCEDURE|Telephone follow-up|Telephone follow-up at 3 months after discharge from hospital
223855350|NCT06064032|BEHAVIORAL|cognitive behavioral therapy|In control group there is 10 min session of PMR, 2 min deep breathing exercises,3 min training for life style modification which include use of planner, setting alarms breaking a task into parts positive reinforcement and communication.
223855351|NCT06064032|BEHAVIORAL|Motor Learning Techniques|In experimental group, participants will be given a 10 min PMR ,2 min deep breathing exercises, 3 min training for life style modification which include the use of planners setting alarms, breaking a difficult task into parts, positive reinforcement and communication combined with 3 min session of drawing a specific pattern with installing pegs on pegboard, 2 min session of balance board training, 3 min session of jigsaw puzzle training, 1 min session of squeezing a ball with maximum repetition and 1 min session of finding beads in puttey.
223855352|NCT02000505|DEVICE|PocketCPR|5 minutes chest-compression-only CPR, using Zoll PocketCPR
223855353|NCT02000505|DEVICE|Metronome|5 minutes chest-compression-only CPR, using a metronome
223855354|NCT02000505|DEVICE|110bpm Song|5 minutes chest-compression-only CPR, using a song with 110bpm for support
223855355|NCT03408860|OTHER|Countering Emotional Behaviors Module from Unified Protocol|This is a 4-week behavioral treatment that teaches patients to counter problematic emotional avoidance by approaching behaviors and situations that may bring up strong emotions in the short-term, but prevent interfering emotional difficulties in the long-term.
223855356|NCT01645852|DIETARY_SUPPLEMENT|Optifast 800|Five units of Optifast 800 plus an unlimited volume of calorie-free fluids per day for one week prior to hepatic resection.
223855357|NCT00744250|DRUG|Pancrelipase|PANCRECARB MS-16
223855358|NCT03718793|DIAGNOSTIC_TEST|Peripheral exhaled nitric oxide|Small airway inflammation and dysfunction will be measured using the above mentioned tests.
223855359|NCT03425890|BEHAVIORAL|SURE program|SURE program is a self-exercise program which aims to empower people with stroke and their caregivers to increase early UL practice outside therapy
223855360|NCT01234532|DRUG|entinostat|orally
223855361|NCT01234532|DRUG|anastrozole|Given PO
223855362|NCT01234532|OTHER|diagnostic laboratory biomarker analysis|"Correlative studies will be performed utilizing tissue and blood. A baseline tumor biopsy is done prior to study entry or archival tissue from diagnosis may be used and a representative tumor sample is submitted at time of surgery.~Bloods are drawn for correlative sciences on day 1 and 15 of treatment prior to entinostat dosing and 30 mins post and again on day of surgery."
223855363|NCT01234532|PROCEDURE|therapeutic conventional surgery|Lumpectomy or mastectomy will be performed follwoing day 29 of study therapy
223855364|NCT03678116|DRUG|Sugar Pill (placebo)|Taken orally in capsule form
223855365|NCT03678116|DIETARY_SUPPLEMENT|Caffeine (plus Teacrine and Cayenne)|Taken orally in capsule form
223855366|NCT03678116|DIETARY_SUPPLEMENT|Caffeine (plus Teacrine)|Taken orally in capsule form
223855367|NCT05771090|DEVICE|Sokru device|Different induced glycaemic states in people living with diabetes (PwD).
223855368|NCT03736005|OTHER|Exposure of significant critical illness|Exposure. Observational study with all patients invited to follow-up clinic for kidney, muscle and functional assessments.
223855369|NCT04763213|DIAGNOSTIC_TEST|Coronary Angiography|Patients diagnosed with occlusive or nonocclusive coronary artery disease who were treated invasive techniques (Percutaneous Coronary Intervention and Coronary Artery Bypass Grafting)
223855370|NCT04763213|DIAGNOSTIC_TEST|Coronary Angiography|Patients diagnosed with oclusive or nonoclusive coronary artery disease who were treated medically
223855371|NCT02716649|OTHER|No intervention|
223855372|NCT01596751|DRUG|PLX3397|Dosage Form: 100 mg or 200 mg capsules, Dosage: 400 - 1000 mg, oral administration
223855373|NCT01596751|DRUG|Eribulin|Dosage Form: 1 mg per 2 mL (0.5 mg per mL); Solution (clear, colorless, sterile, packaged in glass vial) Dosage: 1.4 mg/m2, 2-5 min IV, Day 1, 8 q21 days
223855374|NCT01191086|DRUG|USL255|
223855375|NCT02205151|DRUG|Fimasartan|
223855376|NCT02205151|DRUG|Amlodipine|
223855377|NCT02205151|DRUG|Fimasartan/Amlodipine combination|
223855378|NCT03168204|BEHAVIORAL|Tailored care and support|Offering tailored care and support whereby the competences, strengths and resources of the older person are taken into account.The intervention will be an enhancement of usual care and will depend on the availability of the municipality, and could be formal (i.e., home care) or informal (e.g. activities of an older adult's association).
223855379|NCT02181348|DRUG|Vitamin E|dl-alpha tocopheryl acetate 400 mg once daily for 3 months
223855380|NCT02181348|DRUG|placebo (edible oil)|
223855381|NCT01014858|DRUG|Donepezil|5mg donepezil daily for first 8 weeks and then increased to 10mg daily for the remainder of the study.
223855382|NCT03445130|OTHER|Lavandula Angustifolia oil (LO)|two drops on the inside of an oxygen face mask for 15 minutes.
223855383|NCT03445130|OTHER|Michelia Alba Leaf oil (MA)|two drops on the inside of an oxygen face mask for 15 minutes.
223855384|NCT03445130|OTHER|Almond oil (AO)|two drops on the inside of an oxygen face mask for 15 minutes.
223855385|NCT03445130|OTHER|Water|two drops on the inside of an oxygen face mask for 15 minutes.
223855386|NCT05097924|OTHER|NAN Supreme HypoAllergenic Starter Infant Formula in ready-to-feed format|Post-market observational study with formula feeding administered via standard of care
223855387|NCT00431808|BIOLOGICAL|Malaria vaccine AMA1 (PfAMA-1-FVO[25-545]|3 doses of AMA 1 vaccine
223855388|NCT00431808|BIOLOGICAL|AMA1|50 micrograms of AMA1
223855389|NCT00853827|DRUG|Placebo|Placebo
223855390|NCT00853827|DRUG|Aliskiren|300 mg
223855391|NCT01208467|OTHER|Laboratory Biomarker Analysis|Correlative studies
223855392|NCT01636206|DRUG|Lifitegrast|Dosage Form: Ophthalmic Solution Dosage: 5.0% Frequency: BID Duration: \~1 year
223855393|NCT01636206|DRUG|Placebo|Dosage Form: Ophthalmic Solution Dosage: placebo Frequency: BID Duration: \~1 year
223855394|NCT03939572|BEHAVIORAL|Accurate step count feedback|After one week of baseline step count measurement, participants will receive the intervention. Starting day 8, participants' Apple Watches will start displaying their step count. In this arm, they will simply see their accurate step count.
223855395|NCT03939572|BEHAVIORAL|Deflated step count feedback|After one week of baseline step count measurement, participants will receive the intervention. Starting day 8, participants' Apple Watches will start displaying their step count. In this arm, they will see their step count deflated by 40% (i.e., their step count multiplied by 0.6).
223855396|NCT03939572|BEHAVIORAL|Inflated step count feedback|After one week of baseline step count measurement, participants will receive the intervention. Starting day 8, participants' Apple Watches will start displaying their step count. In this arm, they will see their step count inflated by 40% (i.e., their step count multiplied by 1.4).
223855397|NCT03939572|BEHAVIORAL|Accurate feedback + mindset intervention|"After one week of baseline step count measurement, participants will receive the intervention. Starting day 8, participants' Apple Watches will start displaying their step count. In this arm, they will simply see their accurate step count.~Additionally, participants in this arm will receive a meta-mindset intervention in the first weekly survey on day 7, which consists of a series of videos and reflection exercises to teach participants about the power of mindsets and encourage them to choose adaptive mindsets that will benefit their health. There are also short booster reflection exercises in all subsequent daily and weekly surveys, reinforcing the message about adaptive mindsets."
223855398|NCT04216823|DEVICE|perfusion index|perfusion index in the prediction of peripheral block success was previously reported for infraclavicular brachial plexus block, axillary brachial plexus block, interscalene brachial plexus block, and supraclavicular brachial plexus in adult patients
223855399|NCT02087306|DRUG|Brincidofovir|BCV administered twice weekly, dose depending on weight.
223855400|NCT04376385|BEHAVIORAL|GROw: An Internet based Self Applied Treatment Program for Prolonged Grief Disorder (PGD)|"It is a self-applied treatment through the web psicologíaytecnología.labpsitec.es. There are 8 treatment modules. Each module lasts approximately 60 minutes. It contains written information, videos, audios, photos and interactive questionnaires. The total duration of treatment is 8-10 weeks. A support call will be made a week (maximum 10 minutes) to answer questions and reinforce and motivate the patient. No additional clinical content or counselling will be provided.~Main components of the treatment: Motivation for change, Psychoeducation, Behavioral activation, Exposure, Mindfulness and compassion strategies, integration of loss, restoration and reconstruction of meaning, Cognitive reappraisal and Relapse prevention"
223855401|NCT00913328|DRUG|Montelukast (Singulair)|10 mg tablet once daily
223855402|NCT00913328|DRUG|Placebo|Oral placebo once daily
223855403|NCT06326866|DIAGNOSTIC_TEST|Otoacoustic emissions (non-invasive)|There is no invasive intervention in the study. Individuals with predetermined blood types will be included in the study.
223855404|NCT02754011|DRUG|Combination of ribociclib + capecitabine|RIBOCICLIB from 200 to 600mg once daily + CAPECITABINE from 750 to 1000 mg/m² BID, cycles are defined in 21-day periods, 2 weeks on treatment, 1 week off treatment
223855405|NCT02887313|DRUG|mFOLFOX6|Patients receive mFOLFOX6 for 4 cycles during neoadjuvant radiotherapy, and after CRT, another 4 cycles of mFOLFOX6 would be given before surgery.
223855406|NCT02887313|RADIATION|Radiotherapy|Patietns received preoperative radiotherapy, 1.8-2.0GY/23-25F
223855407|NCT02306343|DEVICE|InsuPad|The InsuPad device is composed of a disposable heating pad and a reusable control unit. The heating pad is intended for one day use. The user would attach the InsuPad device to a site where insulin can be injected. When there is a need for insulin bolus injection the user would inject the insulin to a location designate for that. The device would start heating the area around the injection site without over heating the insulin. At the end of the day the subject would remove the device, dispose of the disposable unit and put the reusable unit for recharging.
223855408|NCT02909699|OTHER|Observation|In this trial, cardiovascular function will be measured without drug administration. The drug will be administered within the main trial.
223855409|NCT04509713|BEHAVIORAL|Collection of odour samples|Samples of breath odours will be passively collected while participants wear the mask while breathing naturally, for at least 3 h. Skin odours will be passively collected by participants wearing the shirt and nylon socks for at least 12 h.
223855410|NCT00614406|DRUG|Celebrex|One 400mg tablet daily.
223855411|NCT00614406|DRUG|Placebo|One tablet daily.
223855412|NCT00003435|BIOLOGICAL|anti-thymocyte globulin|
223855413|NCT00003435|DRUG|melphalan|
223855414|NCT00003435|PROCEDURE|antiviral therapy|
223855415|NCT00003435|PROCEDURE|bone marrow ablation with stem cell support|
223855416|NCT00003435|PROCEDURE|peripheral blood stem cell transplantation|
223855417|NCT00003435|PROCEDURE|umbilical cord blood transplantation|
223855418|NCT00003435|RADIATION|radiation therapy|
223855419|NCT03985917|OTHER|Singing Group Intervention Program|Each session will start with (1) relaxation, vocal warm-up and breething exercises; (2) vocal technique training; (3) memorization and interpretation of music and lyrics; (4) session breaks of 20 minutes for socialization; (5) preparation of a final choir show; (6) vocal tuning tests.
223855420|NCT03985917|OTHER|Alternative Social and Leisure Activities|Day care centers provide social and leisure activities opportunities for older adults. The control group is free to enroll in these activities.
223855421|NCT00221078|DEVICE|Neuroprosthesis|The Compex Motion neuroprosthesis, developed by Drs.R. Popovic and Thierry Keller, and company Compex SA, is a flexible device designed to improve grasping function in both SCI and stroke patients. This multi-channel surface stimulation system for grasping provides both palmar and lateral grasp, and holds a number of advantages over the other existing neuroprostesis.
223855422|NCT04998799|BEHAVIORAL|Current clinical practices of participating physicians|Current clinical practice of participating physicians on management of antithrombotics for COVID-19 during hospitalisation and post-discharge
223855423|NCT03269019|DIAGNOSTIC_TEST|HIT with thrombosis|Testing thrombin-antithrombin complex, d-dimer, fibrin degradation products and Thrombelastograghy.
223855424|NCT00434018|BEHAVIORAL|Wheelchair Skills Training|Subjects are provided with five weeks of wheelchair skills training, tailored to meet their needs.
223855425|NCT00434018|BEHAVIORAL|Basic Health Education|Five sessions are held with subjects to provide them with educational information regarding health related issues - such as nutrition, proper hand hygiene, sports, etc.
223855426|NCT05334758|DEVICE|Bio-Self COVID-19 Antigen Home Test|At home COVID-19 antigen test kit
223855427|NCT05334758|DEVICE|Standard of Care COVID-19 Test|Standard of care
223855428|NCT05334758|DIAGNOSTIC_TEST|RT-PCR Test|High Sensitivity RT-PCR COVID-19 Test
223855429|NCT06435338|BEHAVIORAL|Patient decision aid|The patient decision aid for HPV vaccination among mid-adults, named HPV Decide. It is delivered online on a website.
223855430|NCT06435338|BEHAVIORAL|Control|Vaccine information sheet on HPV vaccination. Attention control condition.
223855431|NCT03045900|OTHER|Shaded bulk-fill resin composite|Dental bulk-fill resin composite with shades A1, A2, A3
223855432|NCT05527236|OTHER|Breathing Exercise|The research was carried out in two stages. In the first stage, for the experimental groups at the 36th-39th weeks of pregnancy, a 10-minute breathing exercise was performed 3 times a week using virtual reality glasses and a breathing exercise device. In the second stage of the study (when the cervical dilatation was 4 cm), the breathing exercise group was made breathing exercises again. As soon as the virtual reality glasses and breathing exercise device were removed, VAS was applied. In order to evaluate the second and third stages of labor, the birth evaluation section of the labor observation form was filled out. Satisfaction with birth was evaluated with the ''Birth Satisfaction Scale'' within the first 4 hours after birth after the delivery was completed.
223855433|NCT05527236|OTHER|Virtual Reality|The research was carried out in two stages. In the first stage, for the experimental groups at the 36th-39th weeks of pregnancy, a 10-minute breathing exercise was performed 3 times a week using virtual reality glasses and a breathing exercise device. In the second stage of the study (when the cervical dilatation was 4 cm) the virtual reality group watched a 10-minute video with virtual reality glasses. Once the virtual reality glasses were removed from experimental groups Visual Analogue Scale was applied. Birth satisfaction was evaluated with the Birth Satisfaction Scale within the first 4 hours after the delivery was completed.
223855434|NCT01080599|PROCEDURE|obturator nerve block|
223855435|NCT00132717|DRUG|MK0653A (ezetimibe [+] simvastatin)|
223855436|NCT00132717|DRUG|Comparator: atorvastatin|
223855437|NCT00132717|DRUG|Comparator: fluvastatin|
223855438|NCT00132717|DRUG|Comparator: lovastatin|
223855439|NCT00132717|DRUG|Comparator: pravastatin|
223855440|NCT00132717|DRUG|Comparator: rosuvastatin|
223855441|NCT00132717|DRUG|Comparator: simvastatin|
223855442|NCT06360042|DRUG|Adebrelimab plus Apatinib|Adebrelimab 1200mg intravenously every 3 weeks plus Apatinib 250mg orally once daily
223855443|NCT06360042|DRUG|Adebrelimab plus Bevacizumab|Adebrelimab 1200mg intravenously plus Bevacizumab 15 mg/kg intravenously every 3 weeks
223855444|NCT06360042|DRUG|Camrelizumab plus Apatinib|camrelizumab 200mg intravenously every 2 weeks plus Apatinib 250mg orally once daily
223855445|NCT00635895|OTHER|Manual Lymph Drainage Therapy and Connective Tissue Massage|The treatment program was carried out five times a week, during a 3-week period for both Manual Lymph Drainage Therapy and Connective Tissue Massage groups
223855446|NCT02559258|DRUG|0.1 mg/kg epsi-gam or placebo (6:2)|administered as a single intravenous infusion on Day 1, infused over 30 minutes
223855447|NCT02559258|DRUG|0.3 mg/kg epsi-gam or placebo (6:2)|administered as a single intravenous infusion on Day 1 infused over 30 minutes
223855448|NCT02559258|DRUG|1.0 mg/kg epsi-gam or placebo (6:2)|administered as a single intravenous infusion on Day 1 infused over 30 minutes
223855449|NCT02559258|DRUG|3 mg/kg epsi-gam or placebo (6:2)|administered as a single intravenous infusion on Day 1 infused over 60 minutes
223855450|NCT02559258|DRUG|10 mg/kg epsi-gam or placebo (6:2)|administered as a single intravenous infusion on Day 1 infused over 120 minutes
223855451|NCT01606163|BIOLOGICAL|GC1102|"1. Description: GC1102 IV bolus injection during 10\~ 30 seconds.~2. Amount: group1-3ml, group2-5ml, group3-8ml~3. Subject number: group1-8, group2-8, group3-8~4. Administration time: 1day, 2day, 3day, 4day, 5day, 6day, 7day(total: 7 times)"
223855452|NCT01606163|OTHER|JW normal saline|"1. Description: Normal saline IV bolus injection through 10\~ 30 seconds.~   * Each 3 subjects of this placebo comparator group will match with group 1,2,3 respectively. Placebo comparator subjects in each group will be treated with same condition of each group(group 1, group 2, group 3) except being administered JW normal saline.~2. Subject number: 9~3. Administration time: 1day, 2day, 3day, 4day, 5day, 6day, 7day(total: 7 times)"
223855453|NCT05379881|BEHAVIORAL|Common Elements Toolbox (COMET)|COMET is an unguided single-session intervention (SSI) combining elements of cognitive-behavioral therapy (CBT) and positive psychology.
223855454|NCT02596035|DRUG|Nivolumab|
223855455|NCT02066441|DIETARY_SUPPLEMENT|Bio-D-Mulsion Forte®|According to the company's literature, Bio-D-Mulsion Forte® contains: vitamin D (as cholecalciferol), a water and gum Arabic emulsifier base, and sesame oil. This product is documented online at the following web address: http://www.bioticsresearch.com/node/1570
223855456|NCT02066441|OTHER|Placebo|
223855457|NCT00414648|DRUG|Sirolimus|A sirolimus dose of 2 tablets (1 mg/tablet) per day for 1 year.
223855458|NCT00414648|DRUG|Placebo|A placebo dose of 2 tablets per day for 1 year.
223855459|NCT01513135|BIOLOGICAL|Tat|Recombinant biologically active Tat 30 mcg in Phosphate saline buffer, pH 7.4, 1% sucrose, 1% Human Serum Albumin
223855460|NCT01513135|BIOLOGICAL|Placebo|Phosphate saline buffer, pH 7.4, 1% sucrose, 1% Human Serum Albumin
223855461|NCT00956306|DRUG|Udenafil|100mg Single Oral Dose of Udenafil
223855462|NCT03163953|BEHAVIORAL|TPAG with long break|PA coaching based on Thai Physical Activity Guideline (TPAG) and long break or break 15 minutes for every 2 hours (TPAG with LB)
223855463|NCT03163953|BEHAVIORAL|TPAG with short break|PA coaching based on TPAG and short break or break 1-2 minutes for every 1 hours (TPAG with SB)
223855464|NCT03163953|OTHER|Control|No intervention
223855465|NCT01604447|PROCEDURE|Hypothermia prevention with plastic bag|Upon removal from the incubator, infant will be placed into a plastic bag to his/her axillae, and the bag will be folded and taped to itself to prevent it from covering the infant's nose or mouth. The infant will be wrapped in a blanket and receive a cloth hat. The bag will be changed when soiled and the infant will remain in the bag for 72 hours or until discharge, whichever comes first. The infant's temperature will be monitored for 72 hours or until discharge, whichever comes first.
223855466|NCT01604447|PROCEDURE|Hypothermia prevention without plastic bag|Upon removal from incubator, the infant will be wrapped in a blanket and receive a cloth hat, according to standard bundling practices. The infant's temperature will be monitored for 72 hours or until discharge, whichever comes first.
223855467|NCT02839369|OTHER|walking under varies conditions|The children were asked to walk an electronic mat, three cycles for each one of the different trials as comfortable regular speed, walking as fast and as slow as possible, walking on straight line etc
223855468|NCT02839369|OTHER|walking under varies conditions|walking on electronic walkway under different conditions
223855469|NCT06555354|DIAGNOSTIC_TEST|miRNA targeted analysis on breast cancer tissues|Total RNA is extracted from tissue sample and selected miRNA quantified by PCR based relative quantification method (QPCR) with a standard curve.
223855470|NCT06555354|DIAGNOSTIC_TEST|miRNA targeted analysis on plasma samples|miRNAs extracted from plasma samples are analysed by QPCR and/or ddPCR .
223855471|NCT06555354|DIAGNOSTIC_TEST|miRNA profiling of breast cancer tissues|Selected samples from the retrospective cohort are profiled for miRNA expression by using GeneChip® miRNA 4.0 Array.
223855472|NCT05490654|PROCEDURE|Abdominal Massage|Abdominal Massage delivered by manual method or by Mowoot device
223855473|NCT06233812|PROCEDURE|Simple interrupted suturing technique|Both simple interrupted and running epidermal sutures are considered acceptable, appropriate techniques for FTSG placement. Therefore, this study would be important in determining whether running sutures, the more efficient method, are non-inferior to simple interrupted sutures.
223855474|NCT06233812|PROCEDURE|Running suturing technique|Both simple interrupted and running epidermal sutures are considered acceptable, appropriate techniques for FTSG placement. Therefore, this study would be important in determining whether running sutures, the more efficient method, are non-inferior to simple interrupted sutures.
223855475|NCT04531137|DIETARY_SUPPLEMENT|CLA-fortified milk powder|3.4 gram of CLA-fortified milk powder one a day for 12 weeks
223855476|NCT04531137|OTHER|Placebo|Placebo milk powder one a day for 12 weeks
223855477|NCT04531137|OTHER|Nutrition Counseling|Individualized nutrition counseling using nutrition module at week 0, 4, and 8 for 30-45 minutes each session
223855478|NCT00952718|OTHER|Inspiratory muscle training|A pressure threshold device (Threshold® IMT HS730, RESPIRONICS Inc, Cedar Grove, NJ, USA) was used for the inspiratory muscle training program. The individualized training program was started at an intensity of 30% MIP, which was increased by 2 cmH2O each week, but the maximal intensity did not exceed 50% of MIP. Patients were encouraged to perform IMT for 30 minutes per day, at least 5 days a week for 8 weeks.
223855479|NCT02171663|DRUG|BIBW 2992|
223855480|NCT02560519|DRUG|Albumin solution|"Albumin solution will used for priming of the CPB(cardio-pulmonary bypass) tubing. : A mixture of 20% (200 mg/mL) albumin (Albuman® 200 g/L, Sanquin, the Netherlands) with Ringer's acetate solution in the final albumin concentration of 4%.~During surgery and the first 24 hours of ICU treatment, albumin 4% solution will be used up to 3200 mL for volume replacement therapy. Ringer's acetate solution is used thereafter, i.e. if more than 3200 mL are needed for volume replacement therapy.The volume replacement therapy is not determined but will be based on the clinical decision."
223855481|NCT02560519|DRUG|Ringers acetate solution|"The Ringers acetate solution will be used for priming of the CPB tubing. The CPB priming volume comprises only of Ringer´s solution.~During surgery and the first 24 hours of ICU treatment,Ringer´s acetate solution will be used up to 3200 mL for volume replacement therapy. Ringer's acetate solution is used thereafter, i.e. if more than 3200 mL are needed for volume replacement therapy during the second study phase. The volume replacement therapy is not determined but will be based on the clinical decision."
223855482|NCT05056753|DEVICE|HWBV chair|vibration-actuated, saddle-seat type stool
223855483|NCT04308746|BEHAVIORAL|Online Individualistic Prime (statement writing)|Participants write 3 statements each about (1) themselves, (2) why they are not like others, and (3) why it is beneficial to stand out from others
223855484|NCT04308746|BEHAVIORAL|Online Collectivistic Prime (statement writing)|Participants think about a social group and write 3 statements each about (1) their social group, (2) why they are like others, and (3) why it is beneficial to blend in with others
223855485|NCT05230641|OTHER|No intervention|This is a prospective observational study
223855486|NCT05906225|PROCEDURE|EEG guided anesthesia|Monitoring of electroencephalogram via Sedline probe by MASIMO corporation. Adjust concentration of inhalational sevoflurane during anesthesia, according to component of slow\&delta wave and alpha wave, so that slow/delta oscillation (with or without alpha oscillation) is maintained.
223855487|NCT05906225|PROCEDURE|Conventional anesthesia|Adjust concentration of inhalational sevoflurane during anesthesia, according to vital signs, so that mean blood pressure and heart rate are maintained between 80% and 120% of baseline values measured at ward before anesthesia.
223855488|NCT02466048|PROCEDURE|Spinal Fusion|Spinal fusion, also known as spondylodesis or spondylosyndesis, is a surgical technique used to join two or more vertebrae. Supplementary bone tissue, from the patient (autograft), is used in conjunction with the body's natural bone growth (osteoblastic) processes to fuse the vertebrae. Either the right or left side of one patient will be selected for the study group, and the other, for the control group, through randomization. In the study group site, SurgiFill™ and the autogenous bone mixture shall be transplanted, whereas in the control group site, only the autogenous bone shall be transplanted. The autogenous bones are from iliac part.
223855489|NCT02466048|DEVICE|SurgiFill™|SurgiFill™ is a gel-type high-purity ateolcollagen for bone grafting. SurgiFill™ is used with autogenous iliac graft for dorsolateral spinal fusion.
223855490|NCT04173572|BEHAVIORAL|PACE-Life|PACE-Life Groups will occur twice per week for 15 minutes in the first two weeks, progressing to 30-minute walking sessions over the course of the intervention without changes in frequency. The intensity of virtual walks will increase throughout this intervention in a stepwise fashion to create an exercise dose response to maximize impact on CRF.
223855491|NCT04173572|BEHAVIORAL|Exercise Intervention|Data from Fitbit devices will be synced and accessed through Fitbit.com. Participants will be provided account information to view data but will be asked not to change any of the settings as the investigators will be using data for tracking steps/day and minutes spent walking.
223855492|NCT01094041|OTHER|Gluten free diet|A 4-week gluten free diet provided
223855493|NCT01094041|OTHER|Gluten rich diet|A 4-week gluten rich diet is provided
223855494|NCT02476890|DRUG|Gefapixant 100 mg|Gefapixant 100 mg (2 x 50 mg tablets), administered orally as a single dose in treatment Period 1 or treatment Period 2
223855495|NCT02476890|DRUG|Placebo|Placebo (two tablets matching gefapixant 50 mg), administered orally as a single dose in treatment Period 1 or treatment Period 2
223855496|NCT04908982|DRUG|Aspirin 81mg|81mg aspirin daily beginning between 12 and 16 weeks of pregnancy and continuing until delivery.
223855497|NCT00835380|BIOLOGICAL|Hepatitis A Vaccine, Purified Inactivated (VAQTA™)|Subjects will be given a 25-U/0.5 mL intramuscular injections of VAQTA™ at Day 1 and Month 6.
223855498|NCT05735444|DEVICE|Continuous positive airway pressure|Continuous positive airway pressure (CPAP) is one of the standard medical treatments for patients with OSAS. The mechanism of CPAP probably involves maintenance of a positive pharyngeal transmural pressure so that the intraluminal pressure exceeds the surrounding pressure. CPAP also increases end-expiratory lung volume, which stabilises the upper airway through caudal traction.
223855499|NCT03614546|RADIATION|SBRT|Stereotactic Body Radiation Therapy (SBRT)
223855500|NCT03614546|RADIATION|IMRT|Intensity-modulated Radiation Therapy (IMRT)
223855501|NCT03614546|PROCEDURE|Hepatectomy|Hepatectomy
223855502|NCT03614546|PROCEDURE|TACE|transarterial chemoembolization (TACE)
223855503|NCT04610008|OTHER|No intervention. Purely observation|Retrospective image analysis of the shape of the optic nerve head in both groups
223855504|NCT02779608|DRUG|intraperitoneal docetaxel|One peritoneal access port will be implanted in subcutaneous space of patients' abdominal wall after laparoscopic exploration.Then intraperitoneal docetaxel in 1litre normal saline will be administered through the port
223855505|NCT02779608|DRUG|oral S-1|40mg/m² twice daily on day 1-14 every 3 weeks
223855506|NCT03247543|DRUG|Placebo|Placebo was administered once daily
223855507|NCT03247543|DRUG|200mg SPN-812|200mg SPN-812 was administered once daily and compared to placebo
223855508|NCT03247543|DRUG|400mg SPN-812|400mg SPN-812 was administered once daily and compared to placebo
223855509|NCT01377259|OTHER|tissue oxygen saturation, spinal anesthesia|regional tissue oxygen saturation(rSO2)detected over upper and lower extremities before and after spinal anesthesia
223855510|NCT00491517|DRUG|Sirolimus|Patients will be given Sirolimus starting at the oral daily dose of 3 mg with periodically whole blood level measurements. The daily dose will be adjusted to keep sirolimus concentration within 10-15 ng/ml.
223855511|NCT00491517|DRUG|conventional therapy|Antihypertensive drugs for patients with high blood pressure.
223855512|NCT00484575|DRUG|Sevoflurane|given by infusion via AnaConDa for sedation with target MAAS 2-3
223855513|NCT00484575|DRUG|propofol|propofol given intravenously for sedation in control group
223855514|NCT01097343|DRUG|clopidogrel 75 mg|75 mg once daily
223855515|NCT01097343|DRUG|Clopidogrel 150 mg|clopidogrel 150 mg
223855516|NCT02243813|DRUG|Psilocybin|Participants will receive 20 mg/70 kg of psilocybin in the first session and will receive either 20 or 30 mg/70 kg in the second session.
223855517|NCT02059980|BEHAVIORAL|Response inhibition training|This is a computerized video game that offers 40 training levels, which aims to enhance the individual's response inhibition performance
223855518|NCT02059980|BEHAVIORAL|Placebo Control Training|This placebo control training looks very similar to the response inhibition training program in its appearance. However, it does not offer any practice related to response inhibition capabilities.
223855519|NCT04462107|OTHER|Surveys|All participants will complete surveys that range in time from baseline to 3 months post partum.
223855520|NCT01104415|DRUG|Telotristat etiprate|Telotristat etiprate capsules orally three times daily.
223855521|NCT01537003|DEVICE|Promogran|Promogran is a collagen/ORC dressing which modulates the wound environment
223855522|NCT01537003|DEVICE|Coban 2 layer|Compression bandage
223855523|NCT06351787|BEHAVIORAL|Resting and movement-based focused awareness meditations|Resting and movement-based focused awareness meditations
223855524|NCT04392713|DRUG|Ivermectin 6 MG Oral Tablet (2 tablets)|12 mg single dose of Ivermectin will be given to intervention arm
223855525|NCT06511817|OTHER|No intervention will be performed|No intervention will be performed
223855526|NCT00155363|DEVICE|conventional artificial kidney (AK) vs. high flux AK|
223855527|NCT03501173|OTHER|Standard of Care|Participants will not receive any intervention in this study. Participants will receive standard of care therapy.
223855528|NCT05368025|DEVICE|Mobili-T/Noona|Use of two mobile health systems over a period of 6 months
223855529|NCT02748265|DRUG|Inhaled Epoprostenol and phenylephrine|After 30 minutes of one-lung ventilation, Epoprostenol 50 ng/kg/min is administered via nebuliser in the anesthesia circuit with phenylephrine administered intravenously
223855530|NCT02748265|DRUG|Sevoflurane|Volatile maintenance anesthesia
223855531|NCT02748265|DRUG|Propofol|Intravenous maintenance anesthesia
223855532|NCT00165451|DRUG|Thalidomide|Oral administration once daily at night starting at 3mg/Kg for 6 months.
223855533|NCT00165451|DRUG|Celecoxib|Oral administration twice daily starting at 100mg/dose for 6 months.
223855534|NCT00165451|DRUG|Etoposide|Oral administration once daily at night starting at 50mg/m2 3 weeks on and 3 weeks off for 6 months.
223855535|NCT00165451|DRUG|Cyclophosphamide|Oral administration once daily at night starting at 3.5mg/m2 3 weeks on and 3 weeks off for 6 months.
223855536|NCT02275325|OTHER|Preoperative vestibular rehabilitation|12 one-hour sessions with exercises of balance on unstable conditions (foam, tilt of the platform, biofeedback)
223855537|NCT00319566|DRUG|Premarin .625 mg daily plus medroxyprogesterone 2.5 mg daily|
223855538|NCT04055766|DEVICE|DeepDoc AI-based Decision Support System|Patients are diagnosed by the DeepDoc within 24 hours of admission.
223855539|NCT02168751|DRUG|propofol|
223855540|NCT02168751|DRUG|Sevoflurane|
223855541|NCT04418323|PROCEDURE|Video-assisted anal fistula treatment (VAAFT) versus Fistula-tract Laser Closure (filac) versus Conventional seton in the Management of anal fistula|Video-assisted anal fistula treatment (VAAFT) versus Fistula-tract Laser Closure (filac) versus Conventional seton in the Management of anal fistula
223855542|NCT04628715|DEVICE|RSA biofeedback|Biofeedback intervention based on breathing at resonance frequency
223855543|NCT01263730|BEHAVIORAL|Tai Chi|Tai Chi training consists of a sequence of slow, soft, and graceful movements derived from the martial arts. It is considered as a moving form of yoga and meditation combined. Tai Chi has been considered as one form of oriental healing arts, like acupuncture, which fosters the circulation of this 'chi' or energy within the body.
223855544|NCT05325853|DRUG|AG-920|AG-920 Sterile Topical Ophthalmic Solution
223855545|NCT05325853|DRUG|Proparacaine Ophthalmic|0.5% Proparacaine Hydrochloride
223855546|NCT01598636|PROCEDURE|Lateral tibial tunnel|To reduce the rehabilitation time after ACL revision surgery due to a better surgical technique
223855547|NCT01839877|DRUG|HIA DEBIRI + systemic FOLFOX|
223855548|NCT04678128|BEHAVIORAL|Dance4Healing Telehealth Live Zoom Sessions|"Week 1: 2-hour introduction session on Zoom platform with a live dance instructor at the participant's desired level of activity intensity (low, mild, or moderate).~Weeks 2-8: All participants will be asked to participate in a 1 hour online, instructor-led live class."
223855549|NCT04678128|BEHAVIORAL|Dance Buddy|"Following randomization (beginning of intervention period) half of the participants will be assigned a dance buddy, and will be asked to dance with their buddies using the Dance4Healing TLVP at least 2 additional times/week. This group will have 24/7 access to Dance4Healing Platform during the intervention and post-intervention periods."
223855550|NCT03072355|OTHER|Elastic Band|Localized muscle resistance test for shoulder
223855551|NCT03072355|OTHER|Isokinetic dynamometer|Localized muscle resistance test for shoulder
223855552|NCT03897309|BIOLOGICAL|VXA-G1.1-NN|Monovalent GI.1 tableted vaccine
223855553|NCT03897309|BIOLOGICAL|VXA-G2.4-NS|Monovalent GII.4 tableted vaccine
223855554|NCT03897309|BIOLOGICAL|Placebo Tablets|Tablets matching in number and appearance to active vaccine doses
223855555|NCT02286765|DEVICE|Ulthera System treatment|Micro-focused ultrasound energy delivered below the surface of the skin
223855556|NCT01805349|RADIATION|Hand X-rays|Hand X-rays to assess the digital arthrosis
223855557|NCT03098030|BIOLOGICAL|Dinutuximab|Dinutuximab injection, for intravenous (IV) use
223855558|NCT03098030|DRUG|Irinotecan|Irinotecan injection, IV infusion
223855559|NCT03098030|DRUG|Topotecan|Topotecan for injection
223855560|NCT04479254|DIETARY_SUPPLEMENT|Enteral Nutrients ( Nutren Optimum, Nutren Diabetes, Novasource Renal ), Parenteral Nutrient ( Smofkabiven)|Enteral nutrition feeding formula is used in powder form and will be reconstituted by attending nurses, Continuous feeding is commonly used which will be prescribed by the attending clinicians, Energy and protein intake from EN will be estimated by multiplying the volume of feed given to energy (kcal) and protein (g) in 1 ml of standard dilution, and for Standard PN product, energy and protein intake will also be calculated based on the volume infused.
223855561|NCT02008253|PROCEDURE|INTRASTROMAL CORNEAL RING SEGMENT|Corneal tunnels were created by means of mechanical dissection in all eyes. Main outcome measures included UCVA, BCVA, refraction, keratometry and computerized analysis of corneal topography.
223855562|NCT05211063|DIETARY_SUPPLEMENT|Saffron extract (Crocus sativus)|Daily intake of one tablet for 42 days.
223855563|NCT05211063|DIETARY_SUPPLEMENT|Placebo|Daily intake of one tablet for 42 days.
223855564|NCT05903066|PROCEDURE|Magnetic Resonance Enterography (MRE)|MRE performed as part of the standard of care follow up of the patient, the exam will be recorded for the study and analysed by central readers.
223855565|NCT05515770|DRUG|Cabotegravir Injection|Long action cabotegravir injection
223855566|NCT06316674|BEHAVIORAL|sixth finger illusion|Participants will undertake the sixth finger illusion that is a body illusion which elicits the presence of an extra numerary finger due to visuo-tactile stimulation.
223855567|NCT04968132|OTHER|Multicomponent opioid reduction and pain management pathway|Pre-operative pain education and expectation setting, identification and modification of risk factors in high risk patients, postoperative individualized analgesic prescriptions, and continued support for pan control and recovery facilitated by an interventions coordinator.
223855568|NCT04968132|OTHER|Standard care|Standard perioperative care, surgical treatment, and pain medications.
223855569|NCT03368001|BEHAVIORAL|SENSE Theatre|SENSE Theatre is a peer-mediated, theatre-based intervention targeting social competence in youth with autism spectrum disorder. The 40 hour intervention is comprised of 10 sessions in which trained typically peers are paired with children with autism spectrum disorder (ASD).
223855570|NCT03368001|BEHAVIORAL|Tackling Teenage Together|The Tackling Teenage Together is a psychosocial and sexual education program developed for youth with ASD. It is comprised of 10 sessions.
223855571|NCT00362843|DRUG|[15-O]water|
223855572|NCT06549309|DRUG|JMKX003801|"For Ascending Single Dose of JMKX003801，Five（5）cohorts of 40 participants (each cohort contains 6 active and 2 placebo) are planned for evaluation.~For Ascending Multiple Dose of JMKX003801，Three（3）cohort of 30 participants (each cohort contains 8 active and 2 placebo) are planned for evaluation."
223855573|NCT06549309|DRUG|Placebo|"For Ascending Single Dose of JMKX003801，Five（5）cohorts of 40 participants (each cohort contains 6 active and 2 placebo) are planned for evaluation.~For Ascending Multiple Dose of JMKX003801，Three（3）cohorts of 30 participants (each cohort contains 8 active and 2 placebo) are planned for evaluation."
223855574|NCT01243801|DRUG|Ketamine|Intravenous ketamine 0.5mg/kg(induction of anesthesia)and 0.25 mg/kg/h for 48h Epidural Ketamine 0.5 mg/kg(induction of anesthesia)and 0.25 mg/kg/h for 48h
223855575|NCT06037616|OTHER|powerpoint and tutor|Powerpoint on indication of skin suture and tutor for the skill to perform skin suture
223855576|NCT06037616|OTHER|video skill|Video showing skill to perform a skin suture
223855577|NCT06037616|OTHER|video errors|Video showing errors of skin suture
223855578|NCT01077245|DRUG|MIYA-BM Fine Granules (CBM588)|MIYA-BM Fine Granules (CBM588)
223855579|NCT01077245|DRUG|Placebo Fine Granules (without CBM588)|Placebo Fine Granules (without CBM588)
223855580|NCT00554801|PROCEDURE|Audiological testing|Subjects will take part in a battery of audiological tests meant to evaluate the function and status of the auditory system. These tests are similar to the kinds of testing carried out routinely in audiology clinics, and include behavioral tests of pure tone hearing, speech perception, and central auditory function, and electrophysiological testing of the middle ear and of the central auditory system.
223855581|NCT04005313|DEVICE|vibroacoustic device|the participants will receive the vibroacustic device or music therapy
223855582|NCT04436120|PROCEDURE|De novo tumor tissue biopsy|De novo tissue biopsy performed following disease progression
223855583|NCT04436120|PROCEDURE|Research blood draws|Blood biospecimens collected following disease progression
223855584|NCT05724173|DEVICE|BrainGate Neural Interface System|Placement of the BrainGate2 sensor(s) into the speech-related cortex
223855585|NCT04313452|OTHER|the effect of Mediterranean diet on insulin sensitivity among obese children and adolescents aged|to find the effect of Mediterranean diet on insulin resistance among obese children and adolescents aged 10-16 years with insulin resistance compared to the regular diet
223855586|NCT02357784|DEVICE|Neurometer|The purpose of Current Perception Threshold (CPT) testing is to help physicians better understand how Sacral Neuromodulation affects the nerves of patients with dual incontinence. CPT Testing involves the use of a portable battery-operated machine which will stimulate the subject's nerves via an electrical stimulation. Electrodes will be placed via a catheter in to the subject's urethra and rectum, and the electrical current will be increased gradually until the subject feels the onset of tingling, buzzing, or warmth at the site of the electrode. The electrical current will then gradually decrease until no sensation of stimulation is felt. The procedure will then be repeated where the subject will be asked to hold the test button to increase the stimulus intensity above their sensory threshold (above the point where they can feel it) until the device automatically shuts off.
223855587|NCT00282776|BEHAVIORAL|Care Management for Postpartum Depression|Depression Care Manager calls postpartum women and encourages women to seek appropriate depression care. In this context the depression care manager helps the women to identify barriers to appropriate care, her preferred method of care, and resources available. Calls are made initially at 2 calls per month, followed by one call per month and calls every other month for women who are doing well. Women assigned to this group receive research assessments at 3, 6, and 12 months postpartum. They also receive information about community and health plan resources available for women with depression.
223855588|NCT00282776|BEHAVIORAL|TAU|Participants receive treatment as usual for postpartum depression. Women assigned to this arm receive research assessments at 3, 6, and 12 months postpartum. At the baseline home visit where diagnostic assessments are completed women are given information about community and health plan resources if they choose to seek care for depression symptoms. Women are also given phone contact numbers for the research program.
223855589|NCT05203913|DRUG|Nivolumab|The recommended dose for nivolumab is 480 mg administered as 30 minutes IV infusions every 28 days for 13 infusions.
223855590|NCT05203913|DRUG|Nab paclitaxel|The recommended dose for nab-paclitaxel is 60 mg per square meter administered as 30 minutes IV infusions every 7 days (weekly), during the radiotherapy period.
223855591|NCT05203913|DRUG|Cisplatin|The recommended dose for cisplatin is 20 mg per square meter administered as 60 minutes IV infusions every 7 days (weekly), during the radiotherapy period.
223855592|NCT05203913|RADIATION|Radiotherapy|Radiotherapy will be delivered over approximately 5 weeks.The total radiotherapy dose will be: 60 Gray in 25 fractions over 5 weeks on original bladder tumour, 50 Gray in 25 fractions over 5 weeks on whole bladder and pelvic nodes if included, administered as concomitant boost. Radiation therapy will be delivered once daily (Monday-Friday) continuously without a planned break for tumour response assessment during treatment.
223855593|NCT04003428|DEVICE|High Intensity Focused Ultrasound|HIFU shots will be performed on the placental tissue to produce necrotic lesions of approximately 30% of the total volume. A latency time of 2 minutes between each shot will be observed to avoid the accumulative heat effect, and to ensure optimal positioning of the treatment probe. The maximum duration of the operating time for HIFU shooting shall not exceed 60 minutes.
223855594|NCT04797533|DEVICE|The Body Information Management Systems (BIMS)|"The Body Information Management Systems (BIMS) are advanced biological sensors which monitor human behaviour, activity and basic vital signs. There is a combination of four separate ultra-sensitive weighing scales attached to each of the individual legs of a hospital bed measuring:~* Micro-changes in weight distribution~* Activity/sleep pattern~In addition to the bed-based system, there will be a wrist worn wearable (Samsung fit gear) that will monitor participants when they are both in and out of bed. These are about the size of a small watch, light weight, water resistant, and will be worn 24/7 by participants. These measure:~* Movement and sleep~* Heart rate"
223855595|NCT03211325|PROCEDURE|Biopsy|
223855596|NCT02942056|DRUG|Cinnamon|Cinnamon tablets to treat type 2 DM
223855597|NCT02942056|DRUG|placebo|placebo
223855598|NCT04700007|DRUG|Capsaicin|A capsaicin patch will be applied on a 3x3 cm squared area on the volar forearm. The patch will be left in place for 24h after which it will be removed.
223855599|NCT04700007|DRUG|Diphenhydramine|Diphenhydramin cream 1% (Restamine®) will be applied on a 3x3 cm squared predetermined area on the volar forearm for 24 hours.
223855600|NCT04700007|DRUG|Morphine Chloride|Morphine solution (0.1mg/ml, Morphine Hydrochloride) 50 μl will be applied intradermally to the center of a predetermined area on the volar forearm by a 1 ml syringe.
223855601|NCT04700007|DRUG|Isotonic saline|injections of isotonic saline (0.05 ml, 0.9%) as vehicle will be performed.
223855602|NCT04700007|DRUG|Histamine|A small drop of histamine dihydrochloride (1%, in saline) will be applied to a previously determined area on the volar forearm followed by a prick through the drop.
223855603|NCT06037135|DRUG|dexmedetomidine|In the dexmedetomidine group, dexmedetomidine is administered at a rate of 0.5 μg/kg/h immediately after anesthesia induction and continued until the completion of the surgery. The research nurse, who did not participate in the study other than the management and preparation of the study medication, prepared 50mL of 0.9% normal saline for the control group and a mixture of dexmedetomidine 2 mL and 0.9% normal saline 48 mL (at a concentration of 4 μg/mL) for the dexmedetomidine group.
223855604|NCT06037135|DRUG|0.9% normal saline|In the control group, a 0.9% normal saline infusion is initiated at the same rate immediately after anesthesia induction and continued until the end of the operation.
223855605|NCT02814266|OTHER|difficult intubation|Goniomastoid Distance: The distance between gonion and mastoid while the neck is fully extension and the mouth maximally open. Thyrogonial Distance: The distance between thyroidea and gonion while the neck is fully extension and the mouth maximally open.
223855606|NCT02814266|OTHER|easy intubation|Goniomastoid Distance: The distance between gonion and mastoid while the neck is fully extension and the mouth maximally open. Thyrogonial Distance: The distance between thyroidea and gonion while the neck is fully extension and the mouth maximally open.
223855607|NCT00126009|DRUG|Amisulpride|
223855608|NCT01874184|OTHER|counseling intervention|Take part in weekly group counseling sessions
223855609|NCT01874184|BEHAVIORAL|behavioral dietary intervention|Set goals for changing dietary habits
223855610|NCT01874184|BEHAVIORAL|exercise intervention|Attend group exercise activities
223855611|NCT01874184|OTHER|questionnaire administration|Ancillary studies
223855612|NCT01874184|OTHER|laboratory biomarker analysis|Correlative studies
223855613|NCT06359054|DIAGNOSTIC_TEST|18F FDG PET/CT|"18F-FDG PET/CT Imaging: Preparation: Participants will be instructed to fast for at least 6 hours before the procedure to ensure low insulin levels and high FDG uptake by cancer cells.~Radiopharmaceutical Administration: Each participant will receive an intravenous injection of 18F-FDG, dosed at approximately 5.2 MBq/kg (0.14 mCi/kg) of body weight.~Imaging Protocol: After the injection, participants will rest in a quiet and dimly lit room for approximately 60 minutes to allow for optimal distribution and uptake of 18F-FDG by the tissues. Subsequently, they will be positioned on the PET/CT scanner bed, and imaging will be performed from the vertex to the proximal thighs. The scan will include a low-dose CT for attenuation correction followed by PET imaging, with the acquisition time adjusted based on the specific protocol (typically 2-3 minutes per bed position)."
223855614|NCT06359054|DIAGNOSTIC_TEST|68Ga DOTATATE PET/CT|"68Ga-DOTATATE PET/CT Imaging: Preparation: No specific fasting is required for 68Ga-DOTATATE PET/CT. However, participants may be advised to hydrate well before the procedure.~Radiopharmaceutical Administration: Participants will receive an intravenous injection of 68Ga-DOTATATE, dosed at approximately 2.2 MBq/kg (0.06 mCi/kg) of body weight.~Imaging Protocol: Similar to the 18F-FDG protocol, after receiving 68Ga-DOTATATE, participants will wait for about 60 minutes to allow for sufficient uptake of the tracer. They will then undergo PET/CT scanning in a supine position, covering the same body regions as the FDG scan. A low-dose CT scan will be conducted first for attenuation correction, followed by the PET scan, with acquisition parameters tailored to the optimal detection of somatostatin receptor expression."
223855615|NCT01285258|PROCEDURE|hysterectomy|excluding the uterus with saving ovaries
223855616|NCT03328949|DEVICE|IVL Coronary Lithotripsy System|The coronary intravascular lithotripsy catheter is similar to other balloon devices that are routinely used during angioplasty procedures; however, it has electrodes inside the balloon which are designed to deliver energy to crack the calcified blockage using lithotripsy (acoustic energy).
223855617|NCT06165549|OTHER|Light therapy|The light therapy will be administered by custom-made light boxes (LED) with adjustable brightness. The light intensity will be set at 5000 Lux. The intervention will consist of daily exposure for 30 minutes in the morning. The whole intervention includes 14 days.
223855618|NCT06165549|OTHER|Light placebo therapy|The light placebo intervention will be administered by custom-made light boxes (LED) with adjustable brightness. The light intensity will be set at less than 200 Lux. The intervention will consist of daily exposure for 30 minutes in the morning. The whole intervention includes 14 days.
223855619|NCT06165549|OTHER|Emotion Bias Modification Training|The training aims at associating gaming pictures with negative words and pictures of healthy activities with positive words. Gaming pictures are always presented with a pair of negative words. Pictures of healthy activities are always presented with a pair of positive words. Each picture is presented with a fixed pair of words. Participants will be instructed to select one word to get the most monetary reward. Specifically, selecting a fixed word of the word-pair will be associated with a high probability (eighty percent) of getting a monetary reward and a low probability (twenty percent) of no reward, and probabilities will be reversed for the other word. Each training run will comprise 100 gaming picture trials and 100 healthy-activity picture trials, presented in a pseudo-randomized order. Participants will receive two training runs every day. The whole training includes 14 days.
223855620|NCT01876654|DEVICE|TruMatch® patient specific cutting guide|
223855621|NCT02048709|DRUG|GDC-0919|Supplied in 50 mg and 200 mg capsules. To be taken every 12 hours with water by mouth on an empty stomach (no food or drink other than water for 2 hours prior to dose). Taken twice daily for 21 days each cycle, followed by 7 days off; or taken twice daily on 28 consecutive days of a 28-day cycle
223855622|NCT00380627|DRUG|MK0663, Arcoxia, etoricoxib / Duration of Treatment: 3 Days|
223855623|NCT05388565|BEHAVIORAL|Domestic Violence Enhanced Perinatal Care Program|Our intervention consists of four major components: a) information about IPV and its effects on maternal and infant health, b) danger assessment, c) options and safety plan, and d) resources.
223855624|NCT05388565|BEHAVIORAL|Standard of Care|Usual perinatal care (e.g., prenatal health education) and a list of resource information (e.g., crisis lines, local IPV and mental health resources)
223855625|NCT04511806|OTHER|Registry|This prospective registry and biorepository will collect clinical data and specimens for research in childhood cancer predisposition.
223855626|NCT06628414|DEVICE|transcranial Direct Current Stimulation|transcranial Direct Current Stimulation
223855627|NCT05761080|DRUG|Amoxicillin clavulanic acid IV during hospitalization|Amoxicillin clavulanic acid IV 5 days during hospitalization. Application of discharge criteria at 5 postoperative days, according to guidelines current clinic.
223855628|NCT05761080|DRUG|Amoxicillin clavulanic acid IV 3 days and PO until day 5|"Amoxicillin clavulanic acid IV 3 days during hospitalization and at discharge Amoxicillin clavulanic acid PO until day 5.~Application of discharge criteria at 72 postoperative hours, administering oral antibiotic therapy with a spectrum similar to that of the control group total of 5 days and sending the patient home with oral analgesia."
223855629|NCT02819193|OTHER|raw mother's own milk|Infants receive mother's own milk before day 7.
223855630|NCT03286205|DRUG|IV iron|IV iron infusion based on weekly or every 3 week dosage.
223855631|NCT04776213|DRUG|Mavenclad®|This low interventional extension study involves the follow up of participants in the parent study. The participants were followed up for an additional 2 year period (until 4 years after initial administration of Mavenclad® tablets), during which the participants were not treated with Mavenclad®, as per European Medicines Agency (EMA) label of Mavenclad®.
223855632|NCT02993497|DEVICE|Infrared camera|In patients undergoing spinal anesthesia, the respiratory parameters are measured using an Infrared camera.
223855633|NCT02993497|DEVICE|RVM(Respiratory Volume Monitor)|In patients undergoing spinal anesthesia, the respiratory parameters are measured using an RVM(Respiratory Volume Monitor).
223855634|NCT02704481|DRUG|Mifepristone|200mg oral mifepristone
223855635|NCT02704481|DRUG|Misoprostol|800mcg buccal misoprostol
223855636|NCT02704481|DRUG|Placebo mifepristone|Matching placebo pill of 200mg mifepristone
223855637|NCT02704481|DRUG|Placebo misoprostol|Matching placebo pills of 800mcg misoprostol
223855638|NCT00708279|PROCEDURE|Osteopathic manipulation|Participant will be evaluated and treated for somatic dysfunction utilizing osteopathic manipulation once a week for 3 weeks, then once every 3 weeks for three more visits; a total of 6 interventions in 3 months.
223855639|NCT01139697|OTHER|Hair sampling|Hair sampling for the measurement of cortisol and testosterone
223855640|NCT01838551|DRUG|Levoketoconazole|Levoketoconazole is the 2S,4R- enantiomer derived from racemic ketoconazole
223855641|NCT04006860|DRUG|SHC014748M Capsules|SHC014748M Capsules: 200mg
223855642|NCT01026662|PROCEDURE|Ablation and skin resurfacing|Subjects will receive treatment on the abdomen at different timepoints prior to a scheduled abdominoplasty. Following tissues excision samples of the treated tissue will be taken for analysis.
223855643|NCT01026662|DEVICE|eMatrixCO2|
223855644|NCT01792609|PROCEDURE|Maximum Number of Screws|The tools used for this arm of study are FDA approved with section 510 (k) K122433. These screws are regularly used in all procedures pertaining to Cobb angle correction surgeries outside of the context of this study.
223855645|NCT01792609|PROCEDURE|Minimum Number of Screws|The tools used for this arm of study are FDA approved with section 510 (k) K122433. These screws are regularly used in all procedures pertaining to Cobb angle correction surgeries outside of the context of this study.
223855646|NCT00071643|BEHAVIORAL|Problem Solving Therapy|Problem solving therapy aims to make patients aware of symptoms of problems and link those with behaviors associated with solving them.
223855647|NCT00071643|DRUG|Escitalopram|Participants will receive escitalopram, a selective serotonin reuptake inhibitor.
223855648|NCT00071643|OTHER|Placebo|Participants will receive a placebo pill.
223855649|NCT00395811|PROCEDURE|Bone Marrow Stem Cell Therapy combined CABG|Bone Marrow Stem Cell inject into myocardium
223855650|NCT05497869|OTHER|active release group|Patient is in supine lying position with 15-20° shoulder abduction. Then place finger tips under Pectoralis minor tendon and position the arm in 90°/90° shoulder abduction and elbow flexion. Apply the pressure while stroking the tender area and ask the patient to adduct the arm then bring shoulder backward while maintain the pressure 3 sets of 10 repetition/ 4 days per week for 3 weeks.
223855651|NCT05497869|OTHER|active control group|Conventional treatment- includes gentle shoulder ROMs i.e. flexion, extension, abduction, adduction, internal rotation and external rotation with-in pain free range, 10 repetitions each for 3 times a day
223855652|NCT02661646|DEVICE|Advanced Pneumatic Compression Device|Advanced Pneumatic Compression Device
223855653|NCT04210856|OTHER|Contemplative landscape exposure|landscapes classified as contemplative (through a CLM psychometric measure) are expected to elicit different brainwave oscillations as compared to non-contemplative ones.
223855654|NCT06085950|DEVICE|Transcranial Ultrasonic Stimulation prototype|Transcranial Ultrasonic Stimulation prototype delivers personalized low-intensity ultrasound stimulation
223855655|NCT03949322|BEHAVIORAL|Adapted Physical Activity Program|The sessions in this program are similar to the adapted physical activity sessions already offered by sports therapy practitioners. This is an aerobic exercise session, with Nordic walking, and a combined session of muscle building and breathing exercises.
223855656|NCT04822129|BEHAVIORAL|Treatment as Usual|Treatment as usual will provide participants with basic information that is readily available as well as the encouragement to develop a brain health program that may be available from medical professionals.
223855657|NCT04822129|BEHAVIORAL|Cogtrastim Model|The study intervention for this group will include a review of the Cogtrastim model and explicit discussion of the possible mechanisms of action of various activities that have been shown to be associated with better health in general and, where supported by evidence, better mental functioning in older persons. Persons in this group will be encouraged to select brain health activities based on the model.
223855658|NCT01771900|BEHAVIORAL|Heart Camp Group|In Week 1, 2, and 3 subjects will attend the HEART CAMP. Subjects will set specific exercise goals. Subjects will be taught how to record exercise data on the computer at the exercise facility. Specific activities will teach subjects aerobic and resistance training exercises and build self-efficacy to exercise. During the period from month 3 to the end of study subjects will continue the training program independently and no formal sessions will be scheduled.
223855659|NCT01771900|BEHAVIORAL|Attention Control Group|Subjects will receive a 60 minute group session led by a specifically designated control group intervention nurse. Phone calls will be placed to the subject if they miss a Friday group session and attendance to meetings will be encouraged.
223855660|NCT04310059|DIETARY_SUPPLEMENT|Folic acid|women will be randomised into one of the three groups. Group A - Folic acid 5mg/day Group B - Folic acid 0.5mg/day Group C - Materna one tablet/day (a pregnancy supplement containing 0.6mg folic acid)
223855661|NCT04310059|DIETARY_SUPPLEMENT|Materna|Materna
223855662|NCT01019577|DRUG|Ixabepilone|Lyophilized and solvent, IV, 10-50 mg/m2, Q3W, Maximum 9 cycles
223855663|NCT01037933|OTHER|Humor intervention|"A 45-minute humorous DVD (Bananas Bunch) using a portable DVD player."
223855664|NCT01037933|OTHER|Non-humor intervention (distraction)|"A 45-minute non-humorous DVD (The A to Z of Steam Railways) using a portable DVD player"
223855665|NCT02289560|DEVICE|Transcranial ExAblate|Transcranial ExAblate
223855666|NCT00573703|PROCEDURE|Laparoscopic Burch colposuspension|Lapaparoscopic approach. One or two nonadsorbable sutures are placed at the level of the midurethra without penetrating the vaginal mucosa and fixed to Cooper's ligament with a tension free knotting technique.
223855667|NCT00573703|PROCEDURE|Transobturator tape procedure|Small incision sites in the vagina and in the femoral/pelvic fold. Bilateral transobturator insertion of mesh by means of needle. Application of resorbable tensioning suture that maintains the mesh and enables fine adjustments in mesh tension during the procedure and in the immediate postoperative period.
223855668|NCT04465578|PROCEDURE|Sling tension adjustment by classic technique|We will adjust the tension of the sling by using the classic technique (2 fingers between the fascia and the knot)
223855669|NCT04465578|PROCEDURE|Sling tension adjustment by height of 4 cm|We will adjust the tension of the sling by using the height between the fascia and the knot of 4cm
223855670|NCT02214251|DEVICE|PK-16CH EXG system|
223855671|NCT03265873|OTHER|Systematic consideration of the advice of the ENT surgeon in the determination of the radiotherapy target volumes in head and neck cancers.|The contouring of the different target volumes will be first performed by the radiotherapists. During the Head and Neck Tumor Board, the volumes initially determined by the radiotherapists will be analyzed jointly by the radiotherapists and the patient's ENT surgeon to carry out, if necessary, modifications, taking into account clinical observations, intraoperative findings (if any) and endoscopy findings. Concordance parameters will be calculated in a second time with the determined volumes (in particular, index of concordance, coefficient of similarity).
223855672|NCT04651361|DRUG|Dinalbuphine sebacate|Naldebain dissolved in benzyl benzoate and sesame oil (a total volume of 2ml) will be prepared in a 5-ml syringe 30 min before administration. Intramuscular injection into the gluteal muscles will be performed by an anesthesiologist under sonography-guidance.
223855673|NCT04651361|DRUG|Placebo solution|Benzyl benzoate and sesame oil served as placebo solution (a total volume of 2ml) will be prepared in a 5-ml syringe 30 min before administration. Intramuscular injection into the gluteal muscles will be performed by an anesthesiologist under sonography-guidance.
223855674|NCT00035230|DRUG|Topiramate|
223855675|NCT03254329|OTHER|Assessment of human milk nutrient composition|Observational study to measure nutrients in human milk during lactation and their relationship to maternal and infant nutritional status.
223855676|NCT01247558|OTHER|Metanx® (a medical food)|Patient cohort compliant on Metanx® BID therapy for \>120 days
223855677|NCT01247558|OTHER|Not treated with Metanx®|Non-treated comparative cohort
223855678|NCT02696629|PROCEDURE|upper airway surgery|Uvulopalatopharyngoplasty, concomitant transpalatal advancement pharyngoplasty, nasal surgery or multi-level upper airway surgery
223855679|NCT02696629|DEVICE|Continues positive airway pressure|Participants who are treated with continues positive airway pressure during sleep.
223855680|NCT02696629|BEHAVIORAL|education and follow up|Patients education and follow up:The impact of weight loss, sleep position, alcohol avoidance, risk factor modification and medication effects and follow-up are provided for patients' education.
223855681|NCT03650322|BEHAVIORAL|Yoga|12 weeks, total of 150 minutes of exercise per week.
223855682|NCT03650322|BEHAVIORAL|Stretching and Toning|12 weeks, total of 150 minutes of exercise per week.
223855683|NCT03650322|BEHAVIORAL|Aerobic Walking|12 weeks, total of 150 minutes of exercise per week.
223855684|NCT01286402|DRUG|Bupropion SR|"* 150mg, taken orally, taken daily for the 1st 3 days~* 300mg, taken orally, taken daily for the rest of the 8 weeks of drug treatment"
223855685|NCT01286402|OTHER|Placebo|-Avicel PH 302, Emcocel 50M, Cab-O-Sil M5P, Magnesium Stearate (appearance, taste, and dosing instructions were identical to the bupropion group), i.e., 1 pill orally, taken daily for the 1st 3 days; 2 pills, taken orally, taken daily for the rest of the 8 weeks of drug treatment
223855686|NCT02784327|DRUG|PRF110|
223855687|NCT00684970|DRUG|Hamsa-1™ TL-118|Once daily Hamsa-1™ TL-118
223855688|NCT02780362|DRUG|Prodactariv|1 tablet contains 60 mg Daclatasvir
223855689|NCT02780362|DRUG|Clatazev|1 tablet contains 60 mg Daclatasvir
223855690|NCT02989961|OTHER|Resticutis|Autologous, Activated-Platelets type of Preparation
223855691|NCT02989961|OTHER|Platelet-Poor Plasma (PPP)|A preparation of low platelet plasma obtained by a high-speed centrifugation step.
223855692|NCT04247711|BEHAVIORAL|OTCH|OTCH is structured in three phrases (i. engagement and initial needs assessment, ii. ongoing intervention and monitoring, and iii. transition to long-term services) and lasts an average of two years. OTCH will maintain the central characteristics of the OnTrack model, as well as its core principles, which include (1) Person-centered care, (2) Shared decision-making, (3) Recovery orientation, and (4) Culturally-competent care.
223855693|NCT04247711|BEHAVIORAL|Usual FEP Services|These include services such as psychiatric medication, psychotherapy, and psychoeducation for people with FEP and are usually provided at outpatient mental health clinics.
223855694|NCT01981356|BEHAVIORAL|Acceptance and Commitment Therapy|"The goal of ACT is to help the patient increase psychological flexibility, a core component of mental health and well-being. ACT teaches clients to be mindfully aware but nonreactive to delusions/ hallucinations and to increase willingness to~experience associated distressing emotions while simultaneously engaging in meaningful behavioral actions.~Patients expand their repertoire of behaviors to live according to their values and to pursue valued goals, thereby increasing adaptive functioning and quality of life."
223855695|NCT01981356|OTHER|Treatment as Usual (TAU)|All patients admitted to the acute psychiatry unit are administered anti-psychotic and/or other psychotropic medication during their inpatient stay. Patients participate in standard milieu therapy on the unit (group and activities therapies, and individual therapy as needed). Therapy on the unit focuses on psycho-education about illness, symptom identification, mood management techniques, stress reduction, and relapse prevention. Patients also receive unstructured individual therapy and case management as appropriate.
223855696|NCT06141980|DRUG|DWP16001 0.3 mg|DWP16001 0.3mg, Tablets, Orally, Once daily
223855697|NCT02493933|DRUG|Phytoestrogens, Isosorbid mononitrate, N-acetyl cysteine|
223855698|NCT05851768|DRUG|Bupivacaine|Bupivacaine 0.25%
223855699|NCT05851768|DRUG|Bupivacaine + Magnesium|Bupivacaine 0.25% + Magnesium
223855700|NCT05851768|DRUG|Bupivacaine + Dexmedetomidine|Bupivacaine 0.25% + Dexmedetomidine
223855701|NCT02685033|DRUG|Dalbavancin|
223855702|NCT02685033|DRUG|Comparator|
223855703|NCT00961142|DRUG|Fludarabine, Thiotepa, Melphalan, Thymoglobuline (ATG)|Conditioning with Fludarabine 30 mg/m2/24h day-8 to -4, Thiotepa 2x5 mg/kg day -3, Melphalan 60 mg/m2 day -2 to -1 and Thymoglobuline (ATG)1.5mg/kg/day day -9 to -6. PBSC depleted of CD3 and CD19 cells by immunomagnetic depletion on CliniMACS.
223855704|NCT05264337|OTHER|Self-reported lymphedema|Lymphedema as reported by LymQOL questionnaire.
223855705|NCT05264337|OTHER|Dielectric constant ratio|Measurement of percentage tissue water content of lower extremities by dielectric constant ratio measured by MoistureMeter D.
223855706|NCT05264337|OTHER|Limb volume|Measurement of lymphedema by limb volume of lower extremities by multiple measurements of circumference.
223855707|NCT00968331|DRUG|Lenalidomide plus Rituximab|Oral Lenalidomide is initiated on day 1 of cycle 1 at the dose of 20 mg daily for 21 days with 7 days rest (28 day cycle) for a total of 4 cycles. Rituximab is administered on day 1 and day 21 of each cycle at the dose of 375 mg/m2 for a total of 4 cycles.
223855708|NCT04573374|PROCEDURE|Pulpotomy|Pulpotomy is the term for removal of the coronal pulp with the intent of maintaining the vitality of the remaining radicular pulp tissue.
223855709|NCT01394809|BEHAVIORAL|motor cognitive therapies|pre-test; 6 weeks intervention: week 1-3: 5 times per week 60 minutes a day. Week 4-6: 3 times per week 60 minutes a day; post-test; follow-up)
223855710|NCT02013037|DRUG|Eculizumab|"At the time of transplantation, 1200mg of Eculizumab will be administered via a 35 minute IV infusion, followed by thymoglobulin 1.5 mg/kg intravenous piggyback (IVPB). The administration of thymoglobulin will be repeated (if blood counts permit) for a total of five doses.~On Day 1 post-transplant, 900 mg of Eculizumab will be given via an IV infusion.~On Day 5 post-transplant, intravenous immunoglobulin (IVIG) 1 gram/kg will be administered daily for two consecutive days.~On post-transplant days 7, 14, and 21 (+/- 2 days) 900mg of Eculizumab will be given via an IV infusion at each scheduled visit.~On post-transplant days 28, 42, and 56 (+/- 2 days) 1200 mg of Eculizumab will be given via an IV infusion at each scheduled visit."
223855711|NCT05201768|OTHER|balance tests,questionnaire|Individuals will be tested and recorded.
223855712|NCT06609876|PROCEDURE|Thermal ablation|Thermal ablation of tumors
223855713|NCT06609876|DRUG|Donafenib|Donafenib ( 100 mg，bid)
223855714|NCT04092985|DEVICE|iECG recording|iECG tracings will be recorded simultaneously, starting and ending at the same time as the standard 12-lead ECG, using the built-in sensors of a smart watch (Apple Watch Series 4) with the ECG application
223855715|NCT00759200|DRUG|alb-interferon alfa 2b|900 mcg every 4 weeks
223855716|NCT00759200|DRUG|alb-interferon alfa 2b|1200 mcg every 4 weeks
223855717|NCT00759200|DRUG|alb-interferon alfa 2b|1500 mcg every 4 weeks
223855718|NCT00759200|DRUG|alb-interferon alfa 2b|1800 mcg every 4 weeks
223855719|NCT00759200|DRUG|peg-interferon|Peg-interferon alfa 2a: 180 mcg 1x per wk.
223855720|NCT06614387|DRUG|Infliximab|Patients meeting the inclusion criteria and not having any of the exclusion criteria will be randomized 1:1 to one of two study arms - intravenous administration of blinded active drug, infliximab or vedolizumab at weeks 0, 2, 6 and 14. Infliximab will be administered at a dose 5mg/kg body weight, and vedolizumab at a dose of 300 mg (body mass \> 40 kg) and 10 mg/kg (body mass \< 40kg).
223855721|NCT06692556|RADIATION|Adjuvant radiotherapy|"Patients will receive an adjuvant radiotherapy corresponding to an equivalent dose of 45 to 50 Gy (Equivalent Dose in 2 Gy Fractions \[EQD2\] with a tumor alpha/beta ratio of 10 Gy) delivered on the operating bed.~Patients will be treated by :~* either external radiation therapy using high-energy electrons or photons:~  * 45 Gy in 15 fractions of 3 Gy~ * 50 Gy in 25 fractions of 2 Gy~* or interstitial brachytherapy or brachytherapy via skin applicators:~  * 36 Gy in 8 fractions of 4.5 Gy~ * 36 Gy in 9 fractions of 4 Gy~ * 40 Gy in 8 fractions of 5 Gy~Radiation therapy should be started within 8 weeks after surgery (or 10 if delayed healing).~Patients will be monitored regularly until the date of the first relapse (local, regional or metastatic), or until the date of death (if no relapse).~Regardless of the type of relapse, remedial treatments will be left to the the investigator's discretion up to the first metastatic relapse."
223855722|NCT06629545|OTHER|irrigation activation with PUI|The irrigation solution was used by adapting an ultrasonic tip (IRRI S 21/25; VDW, Munich, Germany) to an ultrasonic device. The power setting of the ultrasonic device was 30% (VDW Ultra; VDW, Munich, Germany). The tip was activated a total of three times, with each cycle lasting 20 s and involving the use of 1 ml of 2.5% NaOCl. Then, 2 ml of 17% EDTA solution was activated for 1 min as describe above. The ultrasonic tip was placed 1 mm behind the working length without touching the canal walls.
223855723|NCT06629545|OTHER|irrigation with sonic activation|A suitable-size activator tip (#25/.04) attached to an EndoActivator sonic handpiece (Dentsply Tulsa Dental Specialties, Tulsa, OK, USA) was inserted into the canal 1 mm short of the working length. 3 ml of 2.5% NaOCl solution was activated in three periods of 20 s (1 ml of 2.5% NaOCl in each cycle). Then, the same procedure was repeated with 2 ml of 17% EDTA solution.
223855724|NCT06628726|DIAGNOSTIC_TEST|Liver biopsy|surgical biopsy from liver
223855725|NCT06698172|OTHER|Virtual Reality rehabilitation|"The study includes 12 weekly 45-minute visual rehabilitation sessions using a Virtual Reality device with Visionary Sport software. Originally designed for sports visual training, this software features gamified exercises to improve visual response times under professional supervision. Activities include games to enhance fixation, ocular motility, peripheral vision, and vergence.~The Peripheral Attention activity trains reaction times to static stimuli perceived in the peripheral retina, adjustable to the patient's visual field defect. Stimuli can be placed at 10, 20, or 30 degrees in the peripheral field. The VR headset (Vive Focus 3) includes an eye tracker to monitor and adapt stimuli based on patient performance.~Patients also perform 30 minutes of daily exercises at home, using proprietary software and Tobii 4C and 5C eye-tracking devices for ocular monitoring."
223855726|NCT06709209|PROCEDURE|Colonoscopy after bowel cleansing|Colonoscopy will be performed using HD-WLE; TXI; RDI and NBI.
223855727|NCT06709209|PROCEDURE|Intestinal biopsies|During colonoscopy, at least 2 biopsies from each segment will be taken as standard of care to assess inflammation in UC
223855728|NCT06709209|DIAGNOSTIC_TEST|blood sampling|Blood samples will be taken for standard of care by appropriately trained members of the clinical research team. The results of the standard of care blood will be used in the research.
223855729|NCT06709209|DIAGNOSTIC_TEST|Stool|The stool sample will be sent to the laboratory for Faecal Calprotectin (FCP) as a marker of disease activity.
223855730|NCT06709209|OTHER|Clinical follow-up|Patients will be followed-up at 6 and 12 months after index endoscopy. Patients will be evaluated in clinic or by telephone call and the disease will be reassessed. Partial Mayo Score (PMS) and occurrence of clinical outcomes will be evaluated.
223855731|NCT06708429|DIAGNOSTIC_TEST|LYNX EYE (Lynch syndrome X-Talk of Enteral mucosa with Immune System)|"A combination of blood-based, mucosal-based, and hair-based analyses that evaluate the presence and the expression of:~* a set of microRNAs (blood)~* antibodies anti-frame shift peptides (blood)~* mucosal-resident bacteria (healthy mucosa and cancer)~* environmental exposure to potential carcinogens (hair matrix)"
223855732|NCT06711003|DEVICE|enhanced external counterpulsation|Enhanced External Counterpulsation (EECP) is a non-invasive treatment primarily used for patients with angina or heart failure. It involves the application of pressure cuffs to the legs, which inflate and deflate in sync with the cardiac cycle. This enhances blood flow to the heart during diastole, the phase when the heart is resting between beats. The increased pressure promotes coronary artery perfusion, helping to improve oxygen delivery to the heart muscle, reduce angina symptoms, and enhance cardiovascular function. EECP is typically recommended for patients who are not good candidates for invasive procedures like angioplasty or bypass surgery, or for those seeking supplementary treatment for angina. Over time, it may promote the development of new blood vessels (collateral circulation), further improving heart health. The treatment is generally administered over several weeks in outpatient settings, with each session lasting around one hour.
223855733|NCT06711003|PROCEDURE|post acute care|Post-Acute Care (PAC) for stroke patients focuses on improving functional independence, reducing disability, and preventing secondary complications.
223855734|NCT06714032|DRUG|TCM plus conventional drug|All patients were treated according to international guidelines. The Experimental group will receive TCM according to the TCM syndrome.
223855735|NCT06714032|DRUG|TCM placebo plus conventional drug|All patients were treated according to international guidelines. The control group will receive TCM placebo according to the TCM syndrome.
223855736|NCT06713915|DIAGNOSTIC_TEST|Contrast-Enhanced Mammography|Only patients in the prospective cohort will undergo CEM in addition to breast ultrasound.
223855737|NCT06711172|OTHER|Health coaching intervention|The health coaching intervention will consist of seventeen, 30 to 60-minute telehealth sessions that were dispersed over six months. Participants will work closely with a health coach to create a plan for making appropriate lifestyle changes and for accomplishing the clinical recommendations that were received from their comprehensive evaluation at the War Related Illness and Injury Study Center.
223855738|NCT06706882|BEHAVIORAL|Experimental Training: VIRTRAEL/LUCCIDY|"Cognitive stimulation of the different cognitive functions to be addressed will be conducted in the following sessions:~* Session 1: Shopping lists. Balls. Gift shopping. Long-term memory of the Shopping List.~* Session 2: Disordered objects. Whats different? Semantic series. Logical series. Puzzle pieces. Semantic analogies.~* Session 3: Classifiable objects. Gift shopping. Bag of objects.~* Session 4: Shopping lists. Balls. Disordered objects. Long-term memory of the Shopping List.~* Session 5: Semantic series. Logical series. Puzzle pieces. Semantic analogies. Gift shopping.~* Session 6: Classifiable objects. Bag of objects. Disordered objects.~* Session 7: Shopping lists. Semantic series. Logical series. Puzzle pieces. What\&amp;#39;s different? Semantic analogies. Long-term memory of the Shopping List.~* Session 8: Disordered objects. Gift shopping. Balls.~* Session 9: Bag of objects. Semantic series. Logical series. Whats different? Semantic analogies. Classifiable objects."
223855739|NCT06706882|BEHAVIORAL|Active Comparator: Standard Training: Reflection Group (TAU) (Andalusian Institute of Women, 2010)|This 9-session program explores how societal norms shape women\&amp;#39;s roles and identities. In Session 1, it discusses how women are socially positioned as caretakers in relationships and introduces the concept of the self in relation. Session 2 delves into gender conflicts, focusing on the tension between societal demands and personal desires. Session 3 explores guilt when women fail to meet expected roles, and the fear of being selfish when prioritizing their own needs. Session 4 examines how dependence is fostered by seeking external validation for self-worth. Session 5 critiques romantic love as a cultural tool to prioritize men desires over women. Session 6 analyzes how intimate partner violence (IPV) emerges as a means to maintain power imbalances in relationships. Session 7 looks at the family role in socializing women, while Session 8 explores fears of abandonment. Finally, Session 9 focuses on building life skills and concludes the program.
223855740|NCT06707324|PROCEDURE|drug injected between the rectus abdominis muscle and the transversus abdominis muscle|20 ml of 0.25% bupivacaine + 8 mg dexamethasone between the rectus abdominis muscle and the transversus abdominis muscle on both sides
223855741|NCT06707324|PROCEDURE|drug injected in the external oblique intercostal plane on both sides|20 ml of 0.25% bupivacaine+ 8 mg dexamethasone into the external oblique intercostal plane on both sides
223855742|NCT06711263|OTHER|Mouthwash Product|"* In the Initial Visit-Baseline, and subsequent visits, participants will be called in the morning. Morning hours will be chosen for examination, as it will reduce the risk of bias and also help in quantifying results. plaque and gingival scores will be recorded and the First herbal mouthwashes will be given, participants will also be provided new tooth-brushes (Oral B-soft).~* They will be asked to follow their routine oral hygiene habits. They will be asked to come back after 2 weeks for plaque and gingival bleeding scores recording for the second visit and again after 2weeks post the second visit for the third and final visit to record their plaque and gingival bleeding scores."
223855743|NCT04893421|DEVICE|MOLLI Localization|Patients will be implanted with a MOLLI seed using a specialized introducer needle under imaging guidance. A special handhold probe and detection system will be used intraoperatively to assist in excision.
223855744|NCT06009419|OTHER|Rehabilitation|The control group will receive the usual post-operative care of stretching, lower extremity strengthening, balance exercises, activities of daily living recommendations. The study group will be given a dual task program in addition to the program given to the control group.
223855745|NCT06524700|PROCEDURE|pectopexy mesh|pectopexy with mesh
223855746|NCT06524700|PROCEDURE|pectopexy autologous|pectopexy using autologous graft
223855747|NCT01366898|DRUG|Dexamethasona, Idarubicine, ARA-C, Methotrexate|
223855748|NCT06195891|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223855749|NCT06195891|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
223855750|NCT06195891|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
223855751|NCT06195891|PROCEDURE|Dual-Energy Computed Tomography|Undergo DECT/MRI scan
223855752|NCT06195891|PROCEDURE|Echocardiography|Undergo echocardiography
223855753|NCT06195891|DRUG|Fludarabine|Given IV
223855754|NCT06195891|PROCEDURE|Magnetic Resonance Imaging|Undergo DECT/MRI scan
223855755|NCT06195891|DRUG|Melphalan|Given IV
223855756|NCT06195891|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA scan
223855757|NCT06195891|BIOLOGICAL|Partially Engineered T-regulatory Cell Donor Graft TRGFT-201|Given IV
223855758|NCT06195891|DRUG|Tacrolimus|Given tacrolimus
223855759|NCT06195891|DRUG|Thiotepa|Given IV
223855760|NCT06195891|RADIATION|Total Marrow and Lymphoid Irradiation|Undergo TMLI
223855761|NCT02342210|BEHAVIORAL|Mindfulness Ambassador Council for Early Psychosis (MAC-EP)|MAC is a 12-week facilitated group mindfulness intervention promoting the development of social-emotional competence in youth created by Mindfulness Without Borders (MWB; www.mwb.org). A meditative practice, mindfulness focuses one's awareness on the present, acknowledging and accepting without judging one's feelings, thoughts, or bodily sensations. Each session has a unique focus (e.g., paying attention, practicing gratitude) and consists of facilitated group learning, discussion and mindfulness skills practice. Home assignments to help reinforce specific lesson are also assigned. Although MAC has demonstrated acceptability, feasibility, and promising beneficial effects in schools, it has yet to be implemented and/or evaluated in a clinical population. Its youth-focus and emphasis on building social and emotional competencies through mindfulness, in addition to teaching core mindfulness skills make it a promising intervention for youth recovering from their first episode of psychosis.
223855762|NCT04618224|DIAGNOSTIC_TEST|DDART Testing|One randomly selected eye is included for each study participant. Participants respond to the DDART near vision test with defined environmental conditions at 40 cm viewing distance. All four parameters (RA, MRS, CPS and ACC) are evaluated.
223855763|NCT04618224|DIAGNOSTIC_TEST|wDDART Testing|One randomly selected eye is included for each study participant. Participants respond to the wDDART near vision test with defined environmental conditions at 40 cm viewing distance. All four parameters (RA, MRS, CPS and ACC) are evaluated.
223855764|NCT02571816|DRUG|ASP2215|oral
223855765|NCT04944446|OTHER|Treatment|Myofascial release of various muscle groups Treatment of mobilization of the shoulder joint
223855766|NCT04681079|DRUG|albuterol sulfate (MDI)|albuterol sulfate inhalation aerosol delivered via metered-dose inhaler (MDI) with spacer
223855767|NCT04681079|DRUG|albuterol sulfate (nebulizer)|albuterol sulfate inhalation aerosol delivered via nebulizer with filtered mouthpiece
223855768|NCT01875250|BIOLOGICAL|PROSTVAC-F (Fowlpox)/TRICOM|A recombinant fowlpox virus vector vaccine containing the genes for human prostate specific antigen (PSA) and three co-stimulatory molecules.
223855769|NCT01875250|BIOLOGICAL|PROSTVAC-V (Vaccinia)/TRICOM|A recombinant vaccinia virus vector vaccine containing the genes for human prostate specific antigen (PSA) and three co-stimulatory molecules.
223855770|NCT01875250|DRUG|Enzalutamide (Xtandi)|An androgen receptor inhibitor.
223855771|NCT06188611|DRUG|Huazhi Rougan Granule Placebo granule|Experimental: Huazhi Rougan granule Placebo Comparator: Placebo granule Placebo Comparator: Placebo granule
223855772|NCT00502229|DRUG|Clomiphene citrate, metformin, highly purified urinary FSH|
223855773|NCT03547791|DRUG|Betamethason Sodium Phosphate|The antecorticosteroid that will be administered to Group 1 is betamethasone, produced by Dawon Parm(Korea). It contains betamethason sodium phosphate 5.2mg(Betamethasone 4.0mg) in 1 ample(1mL). Each drug is carried in a syringe by pharmacist who does not participate in study after the patient was enrolled in the study and administered to the patient twice 24hours apart.
223855774|NCT03547791|DRUG|Normal saline|Intramuscular injection of normal saline 3ml twice 24hours apart
223855775|NCT02273986|DRUG|Digoxin|
223855776|NCT02273986|DRUG|K-877|
223855777|NCT03167034|DRUG|ACETAZOLAMIDE oral capsule|Administration of 125mg acetazolamide in the morning, 250mg in the evening, starting 24 hours before departure to 3200m
223855778|NCT03167034|DRUG|Placebo oral capsule|Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3200m
223855779|NCT04689061|DEVICE|Arthrex FastThread Interference Screw|The Arthrex PEEK and Biocomposite FastThread Interference Screws have a tapered hexalobe design along the entire length of the screw to maximize transfer of torque and reduce screw stripping. The Arthrex PEEK and Biocomposite FastThread Interference Screws have a tapered hexalobe design along the entire length of the screw to maximize transfer of torque and reduce screw stripping
223855780|NCT03861221|DEVICE|CBBCT|To compare the differences between various lesions' presentation on CBBCT and on other approaches under diverse breast conditions.
223855781|NCT06478992|PROCEDURE|A:hysteroscopic suture fixation of Mirena|A(the thickness of the thickest uterine myometrium ≥30mm ):The Mirena is fixed to the uterine wall under hysteroscopy, and the endometrial tissue was routinely aspirated and scraped during the operation and sent for pathological examination.
223855782|NCT06478992|PROCEDURE|A: simple Mirena placement under hysteroscopy|A(the thickness of the thickest uterine myometrium ≥30mm):Mirena is routinely placed in the uterine cavity under hysteroscopy, and endometrial tissue was routinely aspirated and scraped during the operation and sent for pathological examination.
223855783|NCT06478992|PROCEDURE|B: hysteroscopic suture fixation of Mirena|B(the thickness of the thickest uterine myometrium\<30mm):The Mirena is fixed to the uterine wall under hysteroscopy, and the endometrial tissue was routinely aspirated and scraped during the operation and sent for pathological examination.
223855784|NCT06478992|PROCEDURE|B：simple Mirena placement under hysteroscopy|B(the thickness of the thickest uterine myometrium\<30mm):Mirena is routinely placed in the uterine cavity under hysteroscopy, and endometrial tissue was routinely aspirated and scraped during the operation and sent for pathological examination.
223855785|NCT00538213|BIOLOGICAL|Fluarix™|Single dose, Intramuscular injection
223855786|NCT00538213|BIOLOGICAL|GSK Bio's Influenza Vaccine GSK576389A|Single dose, Intramuscular injection
223855787|NCT02675088|RADIATION|high-dose TRT|every day, Monday-Friday, for a total of 3 weeks, 45 Gy/ 3 Gy/ 15 f
223855788|NCT02675088|RADIATION|standard-dose TRT|every day, Monday-Friday, for a total of 2 weeks, 30 Gy/ 3 Gy/ 10 f
223855789|NCT03181464|DRUG|Lidocaine 4%|lidocaine solution
223855790|NCT03181464|DRUG|Placebo|saline .9% injection
223855791|NCT05709873|BEHAVIORAL|Imagery rehearsal therapy|Therapy to reduce nightmares, delivered via videoconference sessions
223855792|NCT05709873|BEHAVIORAL|Targeted dream control|Therapy to reduce nightmares, delivered in videoconference sessions and lab session. Lab session will involve a sleep study during a daytime nap.
223855793|NCT01645423|DRUG|Atorvastatin Calcium Tablets, 80 mg|Atorvastatin Calcium Tablets, 80 of Dr. Reddy's Laboratories Limited
223855794|NCT02556034|OTHER|Disease evaluation.|Patients will complete a self-evaluation of 28 joint counts for swelling and tenderness and assess their disease activity on a Visual Analog Scale. A 28 joint count and VAS will then be assessed by a nurse and by a rheumatologist. The same rheumatologist will examine all patients and two nurses will each randomly assess half the total enrolled patients. The nurse will be blinded to the patient's joint count and VAS, and similarly, the rheumatologist will be blinded to both the patient and nurse's assessments.
223855795|NCT03140176|DRUG|Sunitinib|Sunitinib is an FDA approved targeted therapy for use as first line therapy for patients with metastatic renal cell carcinoma.
223855796|NCT04611360|OTHER|Anodal Transcranial Direct Current Stimulation Group|"Experimental group were received anodal transcranial direct current stimulation and conventional training exercises for 3 days a weeks for 6 consecutive weeks on alternate days.~Anodal tDCS were given through:~i. Anodal electrode:It has been placed over primary motor cortex(ipsilesional) ii. Cathodal electrode: It has been above contralateral eye. iii. Intensity: 2mA iv Density: 0.07C/cm2 iv. Duration:20 min vi Rectangular electrodes(25cm2 ) inserted in saline soaked sponge used"
223855797|NCT04611360|OTHER|Conventional Training Exercises Group|Conventional physical exercises were given for 3 days a week on alternate days upto 6 weeks. It includes: progressive Conventional Training Exercises : From Bridging,Sitting: weight-bearing, Standing: weight-bearing, Sit to stand, Squat exercises and Tandem walk.
223855798|NCT03379740|OTHER|E-cigarette|Subject's own e-cigarette
223855799|NCT03379740|OTHER|P4M3-1.7%|P4M3 e-liquid concentration of 1.7% nicotine without lactic acid
223855800|NCT03379740|OTHER|P4M3-1.7%LA|P4M3 e-liquid concentration of 1.7% nicotine with lactic acid
223855801|NCT03379740|OTHER|P4M3-3%LA|P4M3 e-liquid concentration of 3% nicotine with lactic acid
223855802|NCT03379740|OTHER|P4M3-4%LA|P4M3 e-liquid concentration of 4% nicotine with lactic acid
223855803|NCT04815616|RADIATION|Radiotherapy|Capecitabine with adjuvant radiotherapy in treatment of Early Stages Breast Cancer
223855804|NCT02242929|DRUG|Imiquimod 5% cream with prior curettage|
223855805|NCT02242929|PROCEDURE|Standard surgical excision|
223855806|NCT04075357|OTHER|Amniotic membrane transplantation|Amniotic membrane was located over median nerve during surgery of CTS, prior of closing.
223855807|NCT05734924|DEVICE|low Frequency High Intensity magnetic therapy|low Frequency High Intensity magnetic therapy with frequency 50 Hz and high intensity 60mT
223855808|NCT05365633|BEHAVIORAL|Empowerment activity-enhanced tobacco cessation assistance|Participants will receive standard Tobacco Treatment Research Program (TTRP) tobacco cessation assistance either remotely or in-person: 6 weekly counseling sessions and 12 weeks of combination NRT (nicotine patches + nicotine gum or lozenges). During the 6 weeks of counseling, participants will also engage in at least 4 'empowerment activities' (i.e., SGM social change mobilization and community-building activities48) for a total of at least 8 hours. Activities will be tailored to each participant's comfort level and skills. Examples are compiling publicly-available information about school board meetings to support community members in participating in their school districts and making follow-up phone calls with a script to Freedom OK's name change clinic participants.
223855809|NCT01824030|DEVICE|FFR guided PCI|FFR to assess coronary artery stenosis severity and indication to perform and eventually optimize percutaneous coronary intervention
223855810|NCT01824030|DEVICE|OCT guided PCI|OCT to assess coronary artery stenosis severity and indication to perform and eventually optimize percutaneous coronary intervention
223855811|NCT02234778|DEVICE|TGI SVF material via intramuscular injection|Each SVF-treated subject will receive up to 30 cc of the TGI SVF material via intramuscular injection (injections at multiple locations on the lower leg - up to 20 total injections) through a 23 gauge needle over a 2- to 4- minute period.
223855812|NCT02312336|OTHER|Cohort A - Room temperature coronary perfusate|Patients recruited into the study will receive standard PPCI and in addition a transcoronary infusion of Hartmans solution at room temperature (Cohort A). The research intervention is the infusion of room temperature Hartmans solution.
223855813|NCT02312336|OTHER|Cohort B - Cooled coronary perfusate|"Patients recruited into the study will receive standard PPCI and in addition a transcoronary infusion of Hartmans solution cooled at 15 degrees (Cohort B).~The research intervention is the infusion of Hartmans solution cooled to 15 degrees."
223855814|NCT00318019|DIETARY_SUPPLEMENT|OPC Factor(TM)|Evervescent poweder containing oligomeric proanthocyanidins (OPCs)and other nutrients.
223855815|NCT00318019|OTHER|Placebo|Effervescent powder similar in taste and appearance to the intervention but without the OPCs and nutrients.
223855816|NCT03988036|DRUG|Pembrolizumab|Intravenous infusion; 200 mg; every 3 weeks
223855817|NCT03988036|DRUG|Trastuzumab Biosimilar ABP 980|Intravenous infusion; 8 mg/kg loading dose, thereafter 6 mg/kg; every 3 weeks
223855818|NCT03988036|DRUG|Pertuzumab|Intravenous infusion; 840 mg/kg loading dose, thereafter 420 mg/kg; every 3 weeks
223855819|NCT02764645|DEVICE|CardioGard Cannula|"CardioGard Cannula is a specially designed arterial (aortic) cannula for use in cardiac surgery for the purpose of removal of gaseous and solid embolic material emanating during the CPB procedure.~The CardioGard cannula is a double lumen cannula where the primary lumen provides blood from the heart-lung machine similar to ordinary cannulas and the secondary lumen performs suction of blood and embolic matter away from the aortic arch and back to the cardiopulmonary bypass machine for filtration."
223855820|NCT02764645|DEVICE|22Fr curved Cannula|arterial cannula for use in cardiac surgery
223855821|NCT02086370|PROCEDURE|Standard PBS|the tube will be removed by coagulation and section of the tissue beginning from the very distal fimbrial and proceeding toward the uterine cornu. The resection will be performed at the level of the posterior tubal margin, sparing the mesosalpinx.
223855822|NCT02086370|PROCEDURE|Radical PBS|the tube will be removed by coagulation and section of the tissue beginning from the very distal fimbrial and proceeding toward the uterine cornu. The resection will be performed at the level of ovarian margin and the uterus-ovarian ligament, including the mesosalpinx removal.
223855823|NCT05819450|PROCEDURE|Volumetric rejuvenation|Volumetric Rejuvenation with FDA-approved fillers on the skin of the dorsal hands
223855824|NCT05573191|DRUG|Lidocaine|The experimental group was injected with lidocaine 1.5mg/kg, and propofol was pumped intravenously at 90s after lidocaine injection.The dose of propofol was further set according to groups. The heart rate, mean arterial pressure, pulse oxygen saturation and NTI values of subjects were recorded in tne basic state,during the 90s after lidocaine administration, 60s after propofol administration and consciousness loss.The control group simply replaced lidocaine with equal volume normal saline
223855825|NCT05573191|DRUG|Normal saline|Normal saline
223855826|NCT06101992|DRUG|Mesoglycan|Mesoglycan capsules 50 mg are composed by heparan sulphate 47.5%, dermathan sulphate 35.5%, chondroitin sulfate 8.5%,slow heparin 8.5%, excipients: lactose monohydrate, corn starch, croscarmellose sodium, magnesium stearate, gelatin, titanium dioxide, erythrosine
223855827|NCT06101992|OTHER|Placebo|placebo capsules are composed by lactose monohydrate, corn starch, croscarmellose sodium, magnesium stearate
223855828|NCT00003880|BIOLOGICAL|recombinant adenovirus-p53 SCH-58500|
223855829|NCT00003880|DRUG|carboplatin|
223855830|NCT00003880|DRUG|paclitaxel|
223855831|NCT05571436|BEHAVIORAL|iCan Diabetes Self-management and Prevention Support Group|"Participants will be asked to attend six weekly sessions and complete pre-and post-assessments with an optional focus group.~The intervention will cover the following topics: 1) Yes, iCan! - Affirmations and Empowerment, 2) The Language of Diabetes - Diabetes Synopsis, 3) Diabetes and Me - Management Strategies, 4) Extraordinary Health - Dream Team, 5) Food for Thought - Food Conscious, and 6) Discussion - Stories/Goals.~Each session is composed of a Check-in, Affirmation/Empowerment Activity, Short Presentation, Q\&A and Discussion, Goal setting, and Testing Healthy Snacks."
223855832|NCT00652301|DRUG|ezetimibe|ezetimibe 10 mg tablet. Duration of Treatment 31 Weeks.
223855833|NCT00652301|DRUG|Comparator: Placebo (unspecified)|matching placebo tablet. Duration of Treatment 31 Weeks.
223855834|NCT00652301|DRUG|simvastatin|simvastatin 20 mg tablet. Duration of Treatment 31 Weeks.
223855835|NCT01748318|DRUG|New Mexico Honey|Apply 15 ml of NM Honey to CA-MRSA Abscess compare to standard antibiotic treatment
223855836|NCT01748318|DRUG|Bactrim DS|Bactrim DS
223855837|NCT01841437|DEVICE|iStent|
223855838|NCT00666094|BEHAVIORAL|Endurance training|supervised endurance training. Three sessions per week in three months.
223855839|NCT00666094|BEHAVIORAL|strength training|Supervised strength training. Three sessions per week in three months.
223855840|NCT00616733|DRUG|CS-0777 tablets|0.1 mg, once-weekly, for 12 weeks
223855841|NCT00616733|DRUG|CS-0777 tablets|0.3 mg, once-weekly or once every 2 weeks, for 12 weeks
223855842|NCT00616733|DRUG|CS-0777 tablets|0.6 mg, once-weekly or once every 2 weeks, for 12 weeks
223855843|NCT06242041|DRUG|sodium zirconium cyclic silicate|On the non-dialysis day, the drug was given to patients in the treatment group, four times a week, starting from 5g/day each time, and the blood potassium before dialysis was maintained at 4.0-5.0mmol/L, which could be adjusted at 10g/week each time, and the highest dose could be increased to 80g/ week.
223855844|NCT02892903|DEVICE|Routine Measurement of FFR|FFR measurement will be performed in all major vessels with normal (TIMI 3) flow. Occluded vessels and vessels with TIMI flow \<3 will not be examined but will be 'awarded' an FFR value of 0.5
223855845|NCT04439747|OTHER|Ultrasound, DXA, hormonal tests|Diagnostic tests in selected groups with investigation of revealed hormonal disorders
223855846|NCT03084744|BEHAVIORAL|Schema therapy|Schema therapy for chronic depression, a face-to-face psychological intervention by clinical psychologists.
223855847|NCT03084744|BEHAVIORAL|Active monitoring|Active tele-monitoring by clinical psychologists.
223855848|NCT04036877|OTHER|Mood Disorder Assessment|Assess depression, anxiety, HRQOL, and financial toxicity in both bladder cancer patients and their caregivers via telephone survey
223855849|NCT04265378|DEVICE|anodal tDCS|Anodal transcranial direct current stimulation (tDCS), 9 sessions with 20 minutes stimulation each (current intensity of 1mA)
223855850|NCT04265378|BEHAVIORAL|Intensive cognitive training|Intensive cognitive training of a letter memory updating task and a 3-stage Markov decision making task, 9 sessions
223855851|NCT06211907|DEVICE|Postoperative intraocular tamponade|Flushing the eye cavity with a tamponade at the end of surgery
223855852|NCT00221208|BEHAVIORAL|Resistance Training|
223855853|NCT05371288|DRUG|NAC (N-acetyl cysteine), Alpha lipoic acid (ALA), liposomal glutathione (GSH)|Nutritional supplements hypothesized to help reverse some of the COVID long-haul symptoms.
223855854|NCT00149630|DRUG|Disulfiram|Disulfiram 250 mg/day by mouth daily during study weeks 2-13. Disulfiram discontinued during study weeks 14-15.
223855855|NCT00149630|DRUG|Methadone|Initial dose 25 mg; increased by 5 mg at each subsequent daily dosing until 60 mg maintenace dose reached.
223855856|NCT00149630|BEHAVIORAL|CBT|1-hour weekly, individual, manual-guided Cognitive Behaviorial Therapy.
223855857|NCT00149630|OTHER|Lactose|Lactose was added to both the active disulfiram and placebo doses so they tasted identical.
223855858|NCT00427557|DRUG|Fludarabine|30 mg/m\^2 by vein for 4 Days (Day -10 through Day -7).
223855859|NCT00427557|DRUG|Melphalan|140 mg/m\^2 by vein for 1 Day (Day -7).
223855860|NCT00427557|PROCEDURE|Umbilical Cord Blood|1 UCB Unit by vein on Day -5.
223855861|NCT00427557|DRUG|Rituximab|375 mg/m\^2 by vein once weekly (Days -7, -1, +7, +14) for 4 Weeks (if appropriate).
223855862|NCT00427557|OTHER|Peripheral Blood Stem Cell Infusion|Infusion of blood stem cells on Day 0.
223855863|NCT01174329|DEVICE|"Automatic neuro-electrostimulation by Saliwell Crown"|"Continuous stimulation of the lingual nerve by Saliwell Crown"
223855864|NCT01174329|DEVICE|"Patient-regulated neuro-electrostimulation by Saliwell Crown"|"On-demand stimulation of the lingual nerveby Saliwell Crown"
223855865|NCT03667547|DRUG|Raltegravir|Raltegravir 600 mg tablet
223855866|NCT05283460|BEHAVIORAL|mandala|The Life Satisfaction Scale was administered to patients in the control group at the first encounter (pre-test) and three weeks after the first encounter (post-test). Although the pre- and post-test treatment protocols were the same for both intervention and control groups, the only difference between their treament was the mandala activity, which was not applied to those in the control group. Patients in the control group continued their routine lives at home for three weeks. After the application, the mandala activity was applied to all patients who wanted it.
223855867|NCT04090320|DEVICE|CATERPILLAR™ Arterial Embolization Device|Placement of the CATERPILLAR™ Arterial Embolization Device for patients requiring arterial embolization in the peripheral vasculature.
223855868|NCT02932293|DRUG|SOF+DCV+SMV|Sofosbuvir (SOF) 400 mg tablet administered orally once daily; Daclatasvir (DCV) 60 mg tablet administered orally once daily; Simeprevir (SMV) 150 mg tablet orally once daily.
223855869|NCT00154648|PROCEDURE|CE-MRA|
223855870|NCT03683862|OTHER|orthodontic appliance|Orthodontic device for retention in the upper arch, after the end of orthodontic treatment
223855871|NCT00470795|OTHER|Acupuncture|acupuncture treatment (or placebo), 20 minute treatment each; twice weekly for four weeks (total of eight treatments). repeat treatment schedule following crossover (placebo-treatment)
223855872|NCT00470795|PROCEDURE|placebo/sham acupuncture|acupuncture at sham points without skin penetration
223855873|NCT02491931|DIETARY_SUPPLEMENT|Supplement/placebo intake|Patients will receive either GLN or placebo prior to cardiovascular surgery under extracorporeal circulation, during 3 days and one final dose 4 hours prior to anesthesia.
223855874|NCT04769609|DEVICE|bioresorbable membrane|reconstructive surgical treatment of peri-implant bone defects
223855875|NCT06063356|PROCEDURE|Intra-articular and extra-articular Dextrose Prolotherapy injection|In the prolotherapy group, 28 patients will receive intra-articular 5 cc 25% dextrose solution (4 cc 30% dextrose + 1 cc saline) and extra-articular 10 cc 15% dextrose solution (5 cc 30% dextrose + 2.5 cc saline + 2.5 cc 1% lidocaine) in 3 sessions.Extra-articular Injection: Using a sterile syringe with a 27 gauge needle tip (Dental), the points previously found and marked with US (medial collateral ligament, lateral collateral ligament, patellar ligament and adhesion sites of coronary ligaments; pes anserine and superior patellar regions) perpendicular to the surface, using peppering technique, a total of 10 cc of 15% dextrose solution (5 cc 30% dextrose + 2.5 cc saline + 2.5 cc 1% lidocaine) will be injected in small volumes (0.5cc-1cc) at each point.Injection applications will be done at weeks 0 - 3 - 6.
223855876|NCT06063356|PROCEDURE|Intra-articular and extra-articular Saline injection|In the saline group, 28 patients are planned to receive 3 sessions of intra-articular 5 cc saline and extra-articular 10 cc lidocaine-serum physiologic solution (5 cc saline + 5 cc 1% lidocaine).Injection applications will be done at weeks 0 - 3 - 6.
223855877|NCT03668327|OTHER||
223855878|NCT05298111|OTHER|Formulation 3|Respondents were consumed 36 g of Formulation 3 containing 4.5 g of available carbohydrate dissolved in 180 ml water with study breakfast
223855879|NCT05298111|OTHER|Control|Respondents were consumed 4.5 g of control containing 4.5 g of available carbohydrate dissolved in 180 ml water with study breakfast
223855880|NCT04538820|DRUG|Dexamethasone 4 mg IV-control|dexamethasone 4 mg will be administered at induction of anesthesia for postoperative nausea and vomiting proflaxis to normal weight patients.
223855881|NCT04538820|DRUG|Dexamethasone 4 mg IV|dexamethasone 4 mg will be administered at induction of anesthesia for postoperative nausea and vomiting proflaxis to obese patients
223855882|NCT04538820|DRUG|Dexamethasone 8 mg IV|dexamethasone 8 mg will be administered at induction of anesthesia for postoperative nausea and vomiting proflaxis to obese patients
223855883|NCT04895007|BIOLOGICAL|Covid-19 Inactive Vaccine, recombinant human adenovirus serotype number 26, mRNA VAccine|Anti-SARS-CoV-2 IgG Antibody and Neutralizing Antibody will be evaluated 2, 6, 12 Months after second dose.
223855884|NCT00218556|BEHAVIORAL|Cognitive behavioral treatment for depression|Cognitive behavioral intervention to prevent depressive symptoms during treatment for hepatitis C
223855885|NCT02689349|DEVICE|Implantation of Esteem|Subjects meeting indications are implanted with the Esteem Totally Implantable Hearing System
223855886|NCT03518112|BIOLOGICAL|Blinatumomab|Given IV
223855887|NCT03518112|DRUG|Cyclophosphamide|Given IV
223855888|NCT03518112|DRUG|Cytarabine|Given IT or IV
223855889|NCT03518112|DRUG|Dexamethasone|PO or IV
223855890|NCT03518112|BIOLOGICAL|Filgrastim|Given SC
223855891|NCT03518112|OTHER|Laboratory Biomarker Analysis|Correlative studies
223855892|NCT03518112|DRUG|Leucovorin Calcium|Given IV
223855893|NCT03518112|DRUG|Mercaptopurine|Given PO
223855894|NCT03518112|DRUG|Methotrexate|Given IT or IV
223855895|NCT03518112|BIOLOGICAL|Pegfilgrastim|Given SC
223855896|NCT03518112|BIOLOGICAL|Rituximab|Given IV
223855897|NCT03518112|DRUG|Vincristine Sulfate|Given IV
223855898|NCT03723512|DEVICE|Non contrast-enhanced magnetic resonance imaging|Non contrast-enhanced magnetic resonance imaging
223855899|NCT06055595|DIAGNOSTIC_TEST|genetic sequencing|sequencing the susceptibility genes for CP, including serine protease inhibitor Kazal type 1, cationic trypsinogen, cystic fibrosis transmembrane conductance regulator, chymotrypsin C, etc.
223855900|NCT00752817|OTHER|Proficiency-based virtual reality simulation training|Subjects (surgical trainees) will be trained under a proficiency-based virtual reality simulation training programme before performing their first live case
223855901|NCT00752817|OTHER|Training under the current surgical training programme|Subjects (surgical trainees) will continue to train under the current training methodology offered at their institution before they perform their first live case.
223855902|NCT00837499|BEHAVIORAL|Questionnaire|Interview and survey during visit or by phone, 30 - 40 minutes.
223855903|NCT03094104|OTHER|News items with spin|Interpretation of news items with spin
223855904|NCT03094104|OTHER|News items without spin|Interpretation of news items without spin
223855905|NCT01087684|PROCEDURE|Argon laser trabeculoplasty|Argon laser 600-800 mW, 0.1seconds, 50 micron spot size, 45 - 55 burns over 180 degrees of trabecular meshwork
223855906|NCT01087684|PROCEDURE|Selective laser trabeculoplasty|Selective laser trabeculoplasty 0.7 - 0.8 mJ, 400 micron spot size, 3 nanosecond, 45 - 55 burns over 180 degrees of trabecular meshwork.
223855907|NCT04405063|DEVICE|Paclitaxel Coated PTCA Balloon Catheter|Drug coated balloon
223855908|NCT04665661|BEHAVIORAL|High-intensity aerobic training|Women will perform treadmill-based aerobic exercise for three days a week, at 70%-85% of MHR for 30 minutes and perceived exertion of 14-16, based on the Borg RPE scale. This range39 is considered to represent HIAT. Aerobic training will be preceded by warm-up exercises for 10 minutes and followed by cool-down exercises for 10 minutes, at a perceived exertion of 11.0 (Borg RPE).
223855909|NCT04665661|BEHAVIORAL|Wait-list control|Women in the wait-list control group will be instructed to continue with their usual activities and manage their pain as normal (i.e., with analgesics).
223855910|NCT04612894|DRUG|Camrelizumab and Apatinib|All patients will receive Camrelizumab and Apatinib for at least two cycles of neoadjuvant treatment
223855911|NCT04612894|PROCEDURE|surgery|Perform surgery if operable after neoadjuvant therapy
223855912|NCT04612894|PROCEDURE|core needle biopsy|Perform core needle biopsy if inoperable after neoadjuvant therapy
223855913|NCT01576133|BEHAVIORAL|CAPABLE|Occupational therapy visits plus nursing visits plus handyman repair
223855914|NCT01576133|BEHAVIORAL|Attention visits|Participants in the attention control arm will receive 10 one hour visits over the course of 16 weeks. These visits will consist of sedentary activities
223855915|NCT02899000|DRUG|Adapalene 0.3% / benzoyl peroxide 2.5% emulsion gel|Topical acne therapy
223855916|NCT02899000|DRUG|Oral doxycycline hyclate|Tetracycline-class oral antibacterial 200 mg daily (2 tablets \[50 mg\], twice daily)
223855917|NCT02319122|OTHER|High Intensity Interval Training|See arm description
223855918|NCT02319122|OTHER|Progressive Resistance Training|See arm description
223855919|NCT04275193|DRUG|Zishenqing|Zishenqing Granule
223855920|NCT04275193|DRUG|Placebo|Granule manufactured to mimic Zishenqing(containing 10% composition)
223855921|NCT03712306|OTHER|Dietary advice|Dietary advice to increase protein intake to at least 1.2 g/kg adjusted body weight/d
223855922|NCT03712306|OTHER|Dietary advice and advice on timing|Dietary advice to increase protein intake to at least 1.2 g/kg adjusted body weight/d plus advice on consuming protein in close proximity of usual physical activity
223855923|NCT06420713|PROCEDURE|Horizontal Bone Augmentation of Alveolar Ridge|Elevation of the flap in the anterior region of atrophic maxilla to receive particulate autogenous bone mixed with deproteinized bovine bone graft (Group A) or Leukocyte-and-Platelet-Rich Fibrin (L-PRF) mixed with deproteinized bovine bone graft (Group B). In both groups, bone augmentations were covered with a collagen membrane stabilized with pins.
223855924|NCT06420713|PROCEDURE|Groups|"The patients underwent Guided Bone Regeneration (GBR) procedures for the reconstruction of atrophic edentulous alveolar ridges and were divided into two groups according to the proposed treatment:~Group A - GBR using a mixture of particulate autogenous bone graft and deproteinized bovine bone graft (Bio-Oss® Small; Geistlich AG, Wolhusen, Switzerland).~Group B - GBR using a mixture of deproteinized bovine bone graft (Bio-Oss® Small) and L-PRF + Liquid Fibrinogen."
223855925|NCT06420713|PROCEDURE|Dental Implants|"After 8 months of GBR healing, dental implants were placed in the grafted regions using guided surgery techniques.~Cone beam computed tomography (CBCT) scans were performed preoperatively, immediately after the surgical procedure, and after 8 months of follow-up to measure the linear and volumetric changes in the alveolar ridge. At the time of dental implant placement, after an 8-month period following the GBR procedures, bone biopsies were obtained from the grafted area for histological and micro-CT analysis.~The stability of the implants was assessed using resonance frequency analysis in the immediate postoperative period and at 6 months postoperatively.~After the 6-month period following dental implant placement, the patients were cleared for implant-supported prosthetic rehabilitation."
223855926|NCT05099575|DRUG|Syntocinon, papal, misotac|Using different drugs to prevent atonic PPH during CD in high risk group
223855927|NCT05824377|OTHER|Continuous Feeds|Continuous feeds will be delivered via an indwelling nasogastric/orogastric tube with a continuous infusion pump.
223855928|NCT05824377|OTHER|Intermittent Bolus Feeds|Intermittent bolus feedings will be given by gravity every 3 hours over 15- 30 minutes.
223855929|NCT00954707|DRUG|Clopidogrel & Aspirin, Prasugrel & Aspirin|This population consists of subjects enrolled in the study who are free from death, MI, stroke, repeat coronary revascularization, major bleeding, and ST 12 months after stent implantation and who are compliant with 12 months of dual antiplatelet therapy following stent implantation and who are subsequently randomized to receive 18 months of thienopyridine treatment in addition to aspirin.
223855930|NCT00954707|DRUG|Placebo & Aspirin|This population consists of subjects enrolled in the study who are free from death, MI, stroke, repeat coronary revascularization, major bleeding, and ST 12 months after stent implantation and who are compliant with 12 months of dual antiplatelet therapy following stent implantation and who are subsequently randomized to receive 18 months of placebo treatment in addition to aspirin.
223855931|NCT05218837|OTHER|Vaginal birth|Obstetric anal sphincter injury occurs at the final stage of vaginal delivery.
223855932|NCT06126536|PROCEDURE|Crestal Maxillary Sinus Floor Elevation using Osseodensification|Patients will be prepared for surgery with local anesthesia and thorough oral cavity disinfection. A full thickness crestal incision will be made slightly towards the palate to enhance the possibility of achieving primary wound closure. A conservative flap will be raised, extending slightly beyond the alveolar crest, to minimize flap-related issues. After preparing the osteotomy site using Densah burs and elevating the sinus to the desired height, the implant will be inserted into the osteotomy site.
223855933|NCT06126536|PROCEDURE|Lateral Maxillary Sinus Floor Elevation|A crestal incision with an anterior vertical releasing incision exposes the sinus's lateral wall. A mucoperiosteal flap is carefully reflected, revealing the sinus. A bony window is created using a Piezoelectric device, and after elevation, the sinus floor is carefully lifted with various curettes. Implant osteotomies follow standard placement protocol, with precautions against sinus membrane perforation. Nanobone is used as graft material, mixed with saline and gently packed into the sinus. A resorbable membrane is placed on the window's outer surface, secured with circumferential resorbable sutures, and the flap is sutured for closure.
223855934|NCT01103219|DIETARY_SUPPLEMENT|Nutrition|The control (placebo) group will be fed according to the routines of the participating institutions. The intervention (active) group will receive increased supply of energy, protein, vitamin A and long-chain unsaturated fatty acids.
223855935|NCT03967886|DRUG|YYD601 20mg|Patients should take drugs an hour before breakfast.
223855936|NCT03967886|DRUG|Nexium 20mg|Patients should take drugs an hour before breakfast.
223855937|NCT03967886|DRUG|Placebos|The placebo YYD601 is made from microcrystalline cellulose covered with hard shell. The placebo Nexium is made from microcrystalline cellulose, Crospovidone, Magnesiumstearat and other ingredients.
223855938|NCT00444990|DEVICE|Magnetic Flex Pad|
223855939|NCT06220058|PROCEDURE|"Closure of the midline laparotomy using the small bites technique"|"Closure of the midline laparotomy using the small bites technique will involve employing a monofilament polydioxanone suture with a gauge of 0 (PDS® II Ethicon, Bridgewater, NJ). No Redon drainage system will be left in the subcutaneous tissue."
223855940|NCT06220058|PROCEDURE|"Closure of the midline laparotomy using the small bites technique with an absorbable PP mesh"|"Closure of the midline laparotomy using the small bites technique will involve employing a monofilament polydioxanone suture with a gauge of 0 (PDS® II Ethicon, Bridgewater, NJ). A partially absorbable low-density polypropylene suprapubic mesh (Ultrapro®, Ethicon) will be added. Mesh fixation will be done with absorbable staples (Ethicon SecurestrapTM) +/- slow-absorbing resorbable sutures at the discretion of the surgical team.~In the case of a diverting stoma, the prophylactic mesh will not encircle it. A Redon-type drainage will be left at the subcutaneous tissue level. One or two drains will be left at the discretion of the surgical team. Closure of the subcutaneous tissue will be performed with 2/0 or 3/0 absorbable, multifilament, interlocking sutures."
223855941|NCT03003988|DIETARY_SUPPLEMENT|Creatine monohydrate|Creatine monohydrate (6.0 g) + dextrose (0.5 g)
223855942|NCT03003988|DIETARY_SUPPLEMENT|Creatine nitrate|Creatine nitrate (5.0 g creatine monohydrate + 1.5 g. creatine nitrate that provides 1.0 g. of creatine and 0.5 g. nitrate in 2:1 ratio)
223855943|NCT03003988|DIETARY_SUPPLEMENT|Placebo|Placebo (6.5 g dextrose)
223855944|NCT02947815|DRUG|Clostridium Botulinum Toxin Type A|
223855945|NCT02947815|DRUG|Clostridium Botulinum Toxin Type A|
223855946|NCT04182087|BEHAVIORAL|Cognitive tasks|Attention, language, memory, decision-making or executive functions
223855947|NCT02882230|DRUG|prescription of at least one of the following drugs: rilpivirine, elvitegravir, dolutegravir|chemical dosage ARV
223855948|NCT03109886|DRUG|Milciclib maleate|100 mg/day once daily, for 4 consecutive days a week in a 4-week cycle (4 days on/3 days off x q4 wks) for a total of 12 weeks (i.e. 3 cycles) unless patient refusal, consent withdrawal, Investigator's decision, unacceptable toxicity or death whichever occurs earlier. After the completion of three cycles, patients who, in the Investigator's judgment, are benefiting from treatment with milciclib, will resume treatment and will remain on study up to Day 180 from treatment start, unless withdrawal criteria are met earlier.
223855949|NCT04928053|GENETIC|ocytocine dosage and genetic analyse|All patients are assessed using 4 paradigms: Reading the Mind in the Eyes Test (RMET), Interpersonal Reactivity Index (IRI), Empathy Quotient (QE), and a modified Delay Discounting task. They have a blood prelevment
223855950|NCT02860884|PROCEDURE|liver biopsy|
223855951|NCT02860884|OTHER|infrared spectroscopy|
223855952|NCT01496638|PROCEDURE|Implantation of coronary stent in bifurcation lesion|Implantation of coronary stent in bifurcation lesion with no side branch treatment
223855953|NCT01496638|PROCEDURE|Implantation of coronary stent in bifurcation lesion|Implantation of coronary stent in bifurcation lesion with stenting of main vessel and side branch
223855954|NCT05534100|DEVICE|Biostrap EVO Wristband|Participants in both groups will wear the Biostrap wearable device
223855955|NCT03200587|DRUG|Avelumab|Avelumab 10 mg/kg infusion every 2 weeks (Days 1 and 15) of every 28 day cycle for up to 12 cycles
223855956|NCT03200587|DRUG|Cabozantinib|Cabozantinib oral daily at 20 (starting dose 1), 40 (Dose Level 2) or 60 mg (Dose Level 3)
223855957|NCT02001623|DRUG|Tisotumab Vedotin (HuMax-TF-ADC)|
223855958|NCT04481386|DEVICE|Vitargus, BFC-1401|A single intravitreal (IVT) dose of BFC-1401 in participants as a vitreous substitute during vitrectomy surgery.
223855959|NCT02846194|BEHAVIORAL|brief guided imagery|
223855960|NCT03042520|OTHER|Observation only|
223855961|NCT00309452|BEHAVIORAL|Cognitive Behavioral Group Therapy|once per week
223855962|NCT00309452|BEHAVIORAL|Cognitive remediation|as needed
223855963|NCT00309452|DRUG|Medications|Individualized prescription of psychotropic medications including but not restricted to antipsychotic, antidepressant and mood stabilizers.
223855964|NCT00309452|BEHAVIORAL|MFG|Multi-Family psychoeducation Group based on the model published by McFarlane et al.
223855965|NCT00309452|BEHAVIORAL|Assertive case management|Meetings with an individual clinician (social work or nursing) who provides supportive psychotherapy, helps assist with vocational and educational supports.
223855966|NCT00309452|OTHER|Treatment as Usual in the community|Subjects randomized to this arm either return to their existing outpatient psychiatrist or, if they do not have one yet, are referred by the clinic to preferred providers in the community. The nature of the interventions provided is variable and is being monitored by the research clinic.
223855967|NCT00596648|DRUG|XL184|Capsules administered orally daily
223855968|NCT00596648|DRUG|erlotinib|Tablets administered orally daily.
223855969|NCT01036113|DRUG|EZN-2208|EZN-2208 will be administered as an i.v. infusion on weekly basis for 3 weeks and repeated every 28 days.
223855970|NCT04815057|BEHAVIORAL|Wellness Education|The wellness education given to fifth grade students and the quality of life, its effect on physical activity status
223855971|NCT05722106|BEHAVIORAL|Persuasive Appeal|Persuasive appeals were manipulated using promotional flyers ostensibly distributed by the Public Health Agency of Canada.
223855972|NCT02452242|DRUG|ABX464|25, 50, 75, 100, 150 mg, i.e. 1, 2, 3, 4 or 6 capsules respectively, every 3 days or every day for 2 weeks
223855973|NCT02452242|OTHER|Placebo|1, 2, 3, 4 or 6 capsules respectively, every 3 days or every day for 2 weeks
223855974|NCT06392451|DIAGNOSTIC_TEST|LIAISON NES FLU A/B, RSV, & COVID-19|The LIAISON® NES FLU A/B, RSV \& COVID-19 real-time (RT) PCR assay is a Point of Care (POC) system that enables the extraction, amplification, detection and differentiation of influenza A, Influenza B, respiratory syncytial virus (RSV) and SARS-CoV-2 viral RNA from dry nasal swabs (NS). The system consists of the LIAISON® NES FLU A/B, RSV \& COVID-19 cartridge, the LIAISON® NES system (with LIAISON® NES Software), and associated accessories. In the LIAISON® NES FLU A/B, RSV \& COVID-19 cartridge, extraction reagents and lyophilized fluorescent probes are used together with corresponding forward and reverse primers to extract and amplify influenza A, influenza B, RSV, SARS-CoV-2 and internal control RNA targets.
223855975|NCT06392451|DIAGNOSTIC_TEST|LIAISON PLEX Respiratory Flex Assay|"The LIAISON PLEX® (also known as VERIGENE® II) RSP Flex Assay is an automated test for the detection and identification of common viruses and bacteria, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA, from upper respiratory specimens. The VERIGENE® II Respiratory Flex (RSP Flex) Assay is performed on the VERIGENE® II System. The VERIGENE® II System is an automated platform that performs sample preparation and is capable of polymerase chain reaction (PCR) for the detection of target-specific nucleic acids. The VERIGENE® II System is a fully automated, bench-top sample-to-answer device. The test reagents are supplied in a single, disposable test cartridge."
223855976|NCT03391908|DIAGNOSTIC_TEST|cardiac imaging tests|Patients will undergo non-invasive Cardiac Computed Tomography for assessment of coronary plaques and myocardial perfusion, and invasive intracoronary imaging tests (coronary angiography, Intravascular ultrasound, optical coherence tomography and FFR). If imaging will reveal existence of a significant coronary plaque, a percutaneous coronary intervention (PCI - stenting) will be performed.
223855977|NCT00771667|DRUG|Placebo (IP)|Induction phase (Week 0-8) (IP) - Placebo IV group
223855978|NCT00771667|DRUG|Ustekinumab 1mg/kg (IP)|Induction phase (Week 0-8) (IP) - Ustekinumab 1 mg/kg IV group
223855979|NCT00771667|DRUG|Ustekinumab 3 mg/kg (IP)|Induction phase (Week 0-8) (IP) - Ustekinumab 3mg/kg IV group
223855980|NCT00771667|DRUG|Ustekinumab 6 mg/kg (IP)|Induction phase (Week 0-8) (IP) - Ustekinumab 6mg/kg IV group
223855981|NCT00771667|DRUG|Placebo IV - Responder - Placebo SC (MP)|Maintenance phase (Week 8-36) (MP) - Receiving Placebo IV at Week 0 - Responder at week 6 - Receiving Placebo SC at Week 8 and Week 16
223855982|NCT00771667|DRUG|Placebo IV - Nonresponder - Ustekinumab 270/90 mg SC (MP)|Maintenance phase (Week 8-36) (MP) - Receiving Placebo IV at Week 0 - Nonresponder at week 6 - Receiving Ustekinumab 270 mg SC at Week 8 and 90 mg at Week 16
223855983|NCT00771667|DRUG|Ustekinumab IV - Responder - Placebo SC (MP)|Maintenance phase (Week 8-36) (MP) - Receiving Ustekinumab IV at Week 0 - Responder at week 6 - Receiving Placebo SC at Week 8 and Week 16
223855984|NCT00771667|DRUG|Ustekinumab IV - Responder - Ustekinumab 90mg SC (MP)|Maintenance phase (Week 8-36) (MP) - Receiving Ustekinumab IV at Week 0 - Responder at week 6 - Receiving Ustekinumab 90 mg SC at Week 8 and Week 16
223855985|NCT00771667|DRUG|Ustekinumab IV - Nonresponder - Placebo SC (MP)|Maintenance phase (Week 8-36) (MP) - Receiving Ustekinumab IV at Week 0 - Nonresponder at week 6 - Receiving Placebo SC at Week 8 and Week 16
223855986|NCT00771667|DRUG|Ustekinumab IV - Nonresponder - Ustekinumab 90mg SC (MP)|Maintenance phase (Week 8-36) (MP) - Receiving Ustekinumab IV at Week 0 - Nonresponder at week 6 - Receiving Ustekinumab 90 mg SC at Week 8 and Week 16
223855987|NCT02289625|OTHER|Exercise Training|six month of Exercise training will be conducted in individuals with moderate to severe sleep apnea. The training include aerobic exercise, resistance exercise, flexibility.
223855988|NCT01557998|BEHAVIORAL|POC CD4 and Peer Case Management|HIV-positives will receive prevention with positives (PwP) counseling and point of care CD4 counts. Those with CD4 \<500/μL will be assigned a peer case manager to link the person to ART at study-participating HIV clinics, support ART and PwP adherence and care retention.
223855989|NCT01557998|DRUG|HCV+PWID|Deliver direct acting antiviral (DAA) regimens for HCV+PWID. We will treat both active and inactive confirmed HCV viremic PWID from either Medication Assisted Treatment (MAT) clinics in Nairobi, Mombasa, and Malindi, Kenya or Collaborating partners' sites/Drop-in Centers (DICs) in Mombasa and Mtwapa, Kenya with direct acting antiviral (DAA) regimens. The mode of treatment delivery will be Directly Observed Therapy (DOT) for 84 consecutive doses (one dose per day). All participants will receive pre, post and ongoing counseling as per study protocol.
223855990|NCT01557998|BEHAVIORAL|Control - No intervention|
223855991|NCT06133452|PROCEDURE|skin reducing mastectomy|"The goal of mastectomy skin reducing is to create a breast reconstruction that appears natural and aesthetically harmonious by minimizing excess skin. Excess skin can be removed in two main ways: as a conventional ellipse around the nipple-areola complex or, preferably, as part of an inverted T-shaped incision, commonly used in reduction mammoplasty. This procedure adheres to oncological principles of skin-conserving mastectomy and also incorporates a lower dermal flap, used to create a dermo-muscular pocket that reinforces the coverage of the prosthetic implant.~This technique allows complete detachment of the pectoral muscle at the bottom while ensuring full coverage of the prosthetic implant with a dermo-muscular layer. By increasing the implant pocket and providing an additional tissue layer at the bottom of the breast, this technique can reduce the risk of complications and improve aesthetic outcomes."
223855992|NCT02049697|DRUG|14C-JNJ-39823277|Participants will receive a single oral dose of 25 mg 14C-JNJ-39823277 as a 50-mL solution.
223855993|NCT00573339|OTHER|Cardiac MRI|up to 3 Cardiac MRI scans per participant in 1-4 months
223855994|NCT03586596|BEHAVIORAL|The Decídetext program|Decídetext participants will be directed to the tablet-based software. Participants will receive an interactive education session that will lead them through language-appropriate, culturally-relevant information about stopping smoking, collection of basic smoking history data, and choices/plans about preparing to quit. Quit plans include: 1) choice of quit date, 2) NRT preference, 3) plan to remove smoking cues, 4) identification of trigger situations and 5) choice of suggested coping strategies. Participant data and choices are used to generate a printed 1-page individualized treatment plan. Tablet components, assessment items, audio narrative, brief multimedia instructional video clips, and the printed treatment plan have been developed to address low-literacy levels.
223855995|NCT03586596|BEHAVIORAL|Standard Care Control|Educational Material provided as of suggested by American Cancer Society and, the National Cancer Institute
223855996|NCT03899480|BIOLOGICAL|Haploidentical Natural Killer (NK) Cells|infusion with N-803 activated NK cells
223855997|NCT00628862|DRUG|Formoterol Turbuhaler® 4.5mg|4.5 mg inhaled twice daily
223855998|NCT00628862|DRUG|Formoterol Turbuhaler® 9 mg|9 mg inhaled twice daily
223855999|NCT00628862|DRUG|Turbuhaler® placebo|placebo inhaled twice daily
223856000|NCT01063036|DRUG|Entecavir|Tablets, Oral, 1 mg, once daily, 96 weeks
223856001|NCT01063036|DRUG|Tenofovir|Tablets, Oral, 300 mg, once daily, 96 weeks
223856002|NCT05295134|DIETARY_SUPPLEMENT|Placebo|Participants were directed to consume 1 placebo capsule containing maltodextrin, three times daily, for 90 days. Subjects were directed to consume the capsules with their three largest eating occasions of the day.
223856003|NCT05295134|DIETARY_SUPPLEMENT|Candida cylindracea lipase (225,000 FIP lipase units per day)|Participants were directed to consume 1 capsule containing lipase (75,000 FIP lipase units per capsule), three times daily, for 90 days. Subjects were directed to consume the capsules with their three largest eating occasions of the day.
223856004|NCT05295134|DIETARY_SUPPLEMENT|Candida cylindracea lipase (450,000 FIP lipase units per day)|Participants were directed to consume 2 capsules containing lipase (75,000 FIP lipase units per capsule), three times daily, for 90 days. Subjects were directed to consume the capsules with their three largest eating occasions of the day.
223856005|NCT05295134|DIETARY_SUPPLEMENT|Candida cylindracea lipase (675,000 FIP lipase units per day)|Participants were directed to consume 2 capsules containing lipase (112,500 FIP lipase units per capsule), three times daily, for 90 days. Subjects were directed to consume the capsules with their three largest eating occasions of the day.
223856006|NCT02834871|DEVICE|Electromyogram|
223856007|NCT04215198|DIETARY_SUPPLEMENT|Move3™ (NEM® brand eggshell membrane + KD PUR® brand fish oil)|Dietary supplement combination for the support of joint health.
223856008|NCT04215198|DIETARY_SUPPLEMENT|Placebo|Placebo
223856009|NCT00440973|DRUG|Bevacizumab|monoclonal antibody with anti-angiogenesis properties used as chemotherapy
223856010|NCT00440973|DRUG|Interleukin-2|immunotherapy - cytokine signaling molecule used as an immune system regulator to trigger T \& B lymphocyte proliferation
223856011|NCT00992238|DRUG|Flavoxate Hydrochloride Tablets, 100mg|
223856012|NCT00992238|DRUG|Urispas® Tablets, 100mg|
223856013|NCT05756140|OTHER|No intervention|No Control
223856014|NCT02169102|OTHER|No additional Intervention (control)|No additional intervention previously to the urgency endodontic treatment (Control)
223856015|NCT02169102|RADIATION|Sham Laser Irradiation|Fifteen minutes previously the urgency endodontic treatment, sham laser irradiation was performed in the tooth with irreversible inflammation in pulp.
223856016|NCT02169102|RADIATION|Laser 1 (at 0,16 Joules/point of irradiation)|Fifteen minutes previously the urgency endodontic treatment, laser irradiation will be performed in the tooth with irreversible inflammation in pulp at 0,16 Joules/point at 2 points (perpendicularly to tooth crown and in periapex region)
223856017|NCT02169102|RADIATION|Laser 2 (1,6 Joules/point of irradiation)|Fifteen minutes previously the urgency endodontic treatment, laser irradiation will be performed in the tooth with irreversible inflammation in pulp at 1,6 Joules/point at 2 points (perpendicularly to tooth crown and in periapex region)
223856018|NCT01567683|DRUG|Imiquimod (topical use)|
223856019|NCT05936671|PROCEDURE|EEG-and-ANI-guided anesthesia|During anesthetic maintenance, sevoflurane concentration will be titrated according to EEG monitoring. Sevoflurane concentration will be titrated to maintain intraoperative Patient state index (PSi) ≥ 35 and to avoid burst suppression. Intraoperative target-controlled infusion of remifentanil will be titrated to maintain intraoperative ANI between 50 and 70.
223856020|NCT05936671|PROCEDURE|standard anesthesia|During anesthetic maintenance, the attending anesthesiologists will provide a routine standard care for anesthetic and analgesic titration. In brief, hemodynamic variables and clinical situations will be used to titrate the sevoflurane concentration and remifentanil infusion rates.
223856021|NCT05936671|DRUG|Sevoflurane and remifentanil|For anesthetic maintenance, balanced anesthesia with sevoflurane inhalation and target controlled infusion of remifentanil will be performed.
223856022|NCT05936671|DEVICE|EEG and ANI|EEG monitoring using SEDline (Masimo, Irvine, California, USA) and Analgesia Nociception Index (ANI; MetroDoloris Medical Systems, Lille, France) monitoring will be performed.
223856023|NCT01698255|BEHAVIORAL|ENGAGE|
223856024|NCT01698255|BEHAVIORAL|Standard of Care Psychotherapy|
223856025|NCT00044148|DRUG|LY333531|
223856026|NCT00565110|BEHAVIORAL|ADAPt-C intervention|Experimental Arm patients receive: first-line choice of antidepressant medication management,psychotherapy or both; depression education, and maintenance/relapse prevention counseling based on a stepped care depression treatment algorithm, treatment follow-up and feedback to the oncologist, and systems navigation; a psychiatric consultant who prescribes antidepressant medication for individual patients; and a didactic for oncologists on depression management. Cultural adaptations include: patient choice of first line treatment and degree of family participation in their depression care; PST tailored for literacy and patients with cancer; bilingual, bicultural CDCS; Spanish educational materials.
223856027|NCT06242899|OTHER|Exercise|"Exercise with a cycle ergometer in three phases:~* Warm-up: the exercise intensity was determined at 50-60% of HRmax obtained in the effort test, and lasted 2 minutes.~* Short exercise at moderate intensity for 8, 10 or 15 minutes according to group allocation. The exercise was cycling at 75% HRmax determined with an effort test.~* Cool down: the exercise intensity was determined at 50-60% of HRmax obtained in the effort test, and lasted 2 minutes."
223856028|NCT05054764|DEVICE|Promus PREMIER BTK DES|Collect one year data of the Promus PREMIER BTK drug eluting stent in CLTI patients
223856029|NCT02965248|DRUG|Standard adjuvant systemic chemotherapy|"Patients undergo radical surgery with standard adjuvant systemic chemotherapy (mFOLFOX6/CapeOx/sLV5FU2/Cape).~mFOLFOX6: oxaliplatin 85 mg/m2 IV d1 + leucovorin calcium 400 mg/m2 IV d1 + 5-FU 400 mg/m2 IV bolus d1 + 5-FU 2400 mg/m2 continuous IV over 46-48 hours d1-2. Repeat every two weeks for twelve cycles.~CapeOx: oxaliplatin 130 mg/m2 IV d1 + capecitabine 1000mg/m2 po bid d1-14. Repeat every three weeks for eight cycles.~sLV5FU2: leucovorin calcium 400 mg/m2 IV d1 + 5-FU 400 mg/m2 IV bolus d1 + 5-FU 2400 mg/m2 IV over 46-48 hours d1-2. Repeat every two weeks for twelve cycles.~Cape: capecitabine 1000mg/m2 po bid d1-14. Repeat every three weeks for eight cycles."
223856030|NCT02965248|PROCEDURE|Hyperthermic intraperitoneal chemotherapy (HIPEC) with raltitrexed|Raltitrexed (3 mg/m2) is added to the perfusate after attaining 42 degrees of inflow temperature and last for 60 minutes.
223856031|NCT02965248|PROCEDURE|Hyperthermic intraperitoneal chemotherapy (HIPEC) with oxaliplatin|Before the beginning of HIPEC, 5-FU 400 mg/m2 and leucovorin calcium 20 mg/m2 will be administered intravenously to potentiate oxaliplatin activity. Oxaliplatin (130 mg/m2) is added to the perfusate after attaining 42 degrees inflow temperature with a total of 30 minutes perfusion time.
223856032|NCT04946487|PROCEDURE|total laminectomy|Total laminectomy removes the posterior ligamentous complex (PLC) at the fusion and superior levels.
223856033|NCT04369807|DIAGNOSTIC_TEST|Outpatient MRI|"Participation in the study includes up to 3 visits to a partnering imaging facility - this will include measurement of height and weight (to calculate BMI), blood pressure measurement, 3 sets of blood tests, 3 Questionnaires and 3 MRI tests.~There will be no medical interventions as part of the study. All participants will receive standard-of-care by their healthcare provider/s. With the participant's consent, the participant's primary care physician will be made aware of their participation in the study. Furthermore, participants will be informed of any structural abnormalities found in the MRI scan (e.g. abnormal vessels, haemangioma, tumour, cyst, among others) and abnormal blood test results as these may have clinical implications."
223856034|NCT00286741|OTHER|Diabetes Group Management Visits|Patients meet in groups and receive education about diabetes, reinforcing each other with their own experiences. Each patient also gets medication management by a physician and pharmacist.
223856035|NCT02174562|BEHAVIORAL|Primary Care-Occupational Therapy|PC-OT consists of: 1) primary care physician (PCP) - occupational therapist (OT) collaboration; 2) DM education tailored to cognitive impairment; 3) in-home OT cognitive-functional assessment; and 4) OT-delivered Behavior Activation to increase adherence to medications and other diabetes self-management (DSM) practices (e.g., diet).
223856036|NCT02174562|BEHAVIORAL|Enhanced Usual Care|Usual care enhanced with education and attention
223856037|NCT04533464|BIOLOGICAL|MultiStem|Intravenous Infusion
223856038|NCT04533464|BIOLOGICAL|Placebo|Intravenous Infusion
223856039|NCT03005249|PROCEDURE|neural stem cells therapy group|The patients will be assigned to neural stem cells therapy group for cerebral palsy.
223856040|NCT03005249|OTHER|the control group|The patients will be assigned to the control group for cerebral palsy.
223856041|NCT05829096|OTHER|The COMBINED approach|"1. Patient-level intervention:~   * Assessment of existing lifestyle factors (smoking status, physical activity levels, and weight) that may be relevant to shoulder pain;~  * Brief intervention to support health behaviour change: smoking cessation, increasing physical activity levels and consuming a healthy diet~  * Supporting tools for behaviour change, including an activity workbook for goal-setting and a diary for self-monitoring.~2. Clinician-level implementation toolkit:~   * Training package including a face-to-face workshop, training manual, recorded role play simulations and an online follow-up training session~  * Additional supporting resources; a step-by-step guide to The COMBINED approach, scripts, patient signposting information to support services and a lay summary infographic to explain the links between the health behaviours and RC disorders to patients~  * Audit and feedback via observations of consultations to address any 'drift' from the intervention delivery as intended"
223856042|NCT06554067|DEVICE|Active transcranial direct current stimulation|Ten minutes of active transcranial direct current stimulation
223856043|NCT06554067|DEVICE|Active vagus nerve stimulation|Ten minutes of active vagus nerve stimulation
223856044|NCT06554067|OTHER|Sham transcranial direct current stimulation|Ten minutes of sham tDCS
223856045|NCT06554067|OTHER|Sham vagus nerve stimulation|Ten minutes of sham VNS
223856046|NCT05193318|DRUG|Ketamine-assisted psychotherapy|Subjects will receive 8 weekly intramuscular injections of ketamine hydrochloride starting at 0.5 mg/kg and increasing to a maximum dose of 1.5 mg/kg or a total dose of 60 mg, whichever is lower. Ketamine administration will be accompanied by psychotherapy before, after and during the session.
223856047|NCT01291004|DRUG|Desogestrel/ethinyl estradiol and ethinyl estradiol|Desogestrel/ethinyl estradiol 0.15/0.02 mg and ethinyl estradiol 0.01 mg tablet
223856048|NCT01291004|DRUG|28-day drospirenone oral contraceptive|Drospirenone/ethinyl estradiol 0.3/0.02 mg
223856049|NCT01291004|DRUG|28-day levonorgestrel oral contraceptive|Levonorgestrel/ethinyl estradiol 0.1/0.02 mg
223856050|NCT00798096|DRUG|Fostamatinib Disodium|200 mg PO BID
223856051|NCT02054299|DRUG|Drug application Amitriptyline|Amitriptyline: 25 mg, single oral application
223856052|NCT02054299|DRUG|Drug application Desvenlafaxine|Desvenlafaxine: 50 mg, single oral application
223856053|NCT02054299|DRUG|Drug application Sumatriptan|Sumatriptan: 50 mg, single oral application
223856054|NCT02054299|DRUG|Drug application Proguanil|Proguanil: 200mg, single oral application
223856055|NCT02054299|DRUG|Drug application Fenoterol|Fenoterol: 180 mcg, single intravenous application
223856056|NCT02054299|DRUG|Drug application Thiamine|Thiamine: 200mg, single oral application
223856057|NCT05154942|DEVICE|DOXO+electroacupuncture|DOXO+electroacupuncture
223856058|NCT01833065|DRUG|Elobixibat 10 mg/day|Elobixibat 10 mg/day
223856059|NCT01833065|DRUG|Elobixibat 5 mg/day|Elobixibat 5 mg/day
223856060|NCT01833065|DRUG|Placebo|Placebo
223856061|NCT00774436|PROCEDURE|focal cryotherapy|Those men meeting the re-staging biopsy criteria will subsequently be treated with focal cryotherapy. Clinical follow-up visits will be scheduled at 6 + 2 weeks, 3 + 1 months and 6 + 1 months after focal cryotherapy, at which time, a digital rectal examination and PSA test will be performed. Standard quality-of-life questionnaires, are completed by all patients treated by the Urology Service (whether on not they are treated on an IRB protocol).
223856062|NCT03020108|OTHER|Blood sample|2 cc blood samples will be drawn from antecubital vein
223856063|NCT01772420|DRUG|Eltrombopag Olamine|Given PO
223856064|NCT01772420|OTHER|Laboratory Biomarker Analysis|Correlative studies
223856065|NCT01772420|DRUG|Lenalidomide|Given PO
223856066|NCT05541757|DRUG|In vitro heparin|In vitro heparin and in vitro LMWH
223856067|NCT01429779|DRUG|Movicol|Movicol® in sachets of 13,81 gram each. One sachet consists of 13,125 gr Macrogol 3350, 178,5 mg Sodium bicarbonate, 350,7 mg Sodium chloride and 46,6 mg Potassium chloride. Administration of 1 sachet of Movicol® daily during one week preoperatively and 2 sachets of Movicol® daily postoperatively.
223856068|NCT02949570|DRUG|Inecalcitol|Prospective open label, non-comparative, multicentre exploratory study. Divided in 2 parts Part1: Inecalcitol treatment will be added to imatinib for 12 months. Part 2: Follow-up after discontinuation of inecalcitol. Imatinib will be maintained for 2 years and then will be stopped for those still in MR4.5. These patients will then be followed for 2 additional years after discontinuation of imatinib.
223856069|NCT03983889|DRUG|Midazolam|Midazolam is used as a common medication for sedation in all groups.
223856070|NCT03983889|DRUG|Fentanyl|Fentanyl is another opioid drug used for analgesia to prevent bronchoscopy induced cough.
223856071|NCT03983889|DRUG|Dexmedetomidine|Dexmedetomidine is used for sedation in bronchoscopy with less impact on respiration.
223856072|NCT03983889|DRUG|Remifentanil|Remifentanil is used for analgesia to prevent bronchoscopy induced cough.
223856073|NCT03983889|DRUG|Propofol|Propofol is used for sedation with high efficacy but more side effect on respiration than dexmedetomidine.
223856074|NCT03308487|DIETARY_SUPPLEMENT|vitamin D3 (1000 IU)|
223856075|NCT03308487|DIETARY_SUPPLEMENT|Vitamin D3 (2000 IU)|
223856076|NCT02476773|BIOLOGICAL|Na-GST-1/Alhydrogel plus GLA-AF|
223856077|NCT02476773|BIOLOGICAL|Na-APR-1 (M74)/Alhydrogel|
223856078|NCT02476773|BIOLOGICAL|Na-APR-1 (M74)/Alhydrogel plus GLA-AF|
223856079|NCT02476773|BIOLOGICAL|Sterile Saline Placebo|
223856080|NCT02690103|DRUG|pegylated IFN|Patients are treated with 180µg of pegylated IFN (Pegasys-Roche) subcutaneously weekly for three months.
223856081|NCT02690103|DIETARY_SUPPLEMENT|Biobran|Biobran, at a dose of 1g per day, allocated in packets, taken orally with meals for the three months duration of the study. Biobran is a denatured hemicellulose that is obtained by reacting rice bran hemicellulose with multiple carbohydrate hydrolyzing enzymes from Shiitake mushrooms. It is a polysaccharide that contains ß-1, 3-glucans, and activated hemicellulose. Biobran was kindly provided by Daiwa Pharmaceuticals Co. Ltd., Tokyo, Japan.
223856082|NCT02690103|DRUG|Ribavirin|Ribavirin is prescribed according to patients body weight (1200 mg for those over 75 kg and 1000 mg for those under 75 kg).
223856083|NCT04722276|OTHER|positive end expiratory pressure|7cmH2O of positive end expiratory pressure with fraction of inspired oxygen 80% applied during induction of anesthesia
223856084|NCT04722276|OTHER|fraction of inspired oxygen 80%|fraction of inspired oxygen 80% applied during induction of anesthesia
223856085|NCT02890693|BEHAVIORAL|interdisciplinary lifestyle and psychosocial intervention|The multidimensional interdisciplinary lifestyle and psychosocial intervention will be offered on top of usual care. It will consist of individual sessions (face-to-face or telephone contact) with different members of the interdisciplinary team (dietician, physiotherapist, clinical psychologist or coach) and two group sessions. It will take place during pregnancy and during the first year postpartum.
223856086|NCT04399525|DRUG|Desloratadine Single Dose|Desloratadine (H1-antihistamine): oral tablet (1 x 5 mg), taken with 240 ml water, 4 hours prior to the histamine skin prick
223856087|NCT04399525|DRUG|Levocetirizine Single Dose|Levocetirizine (H1-antihistamine): oral tablet (1 x 5 mg), taken with 240 ml water, 4 hours prior to the histamine skin prick
223856088|NCT04399525|DRUG|Desloratadine Fourfold Dose|Desloratadine (H1-antihistamine): 2 oral tablets of 5 mg in the evening and 2 oral tablets of 5 mg in the morning, taken with 240 ml water, 14 and 4 hours prior to the histamine skin prick, respectively
223856089|NCT04399525|DRUG|Levocetirizine Fourfold Dose|Levocetirizine (H1-antihistamine): 2 oral tablets of 5 mg in the evening and 2 oral tablets of 5 mg in the morning, taken with 240 ml water, 14 and 4 hours prior to the histamine skin prick, respectively.
223856090|NCT00013143|BEHAVIORAL|Patient risk profiling (potential ADEs) w/provider feedback|
223856091|NCT01816113|BIOLOGICAL|ChAd63 PvDBP 5 x 10^9|1 dose of ChAd63 PvDBP 5 x 10\^9 vp intramuscularly
223856092|NCT01816113|BIOLOGICAL|ChAd63 PvDBP 5 x 10^10|1 dose of ChAd63 PvDBP 5 x 10\^10 vp intramuscularly
223856093|NCT01816113|BIOLOGICAL|MVA PvDBP 1 x 10^8|1 dose MVA PvDBP 1 x 108 pfu 8 weeks later intramuscularly
223856094|NCT01816113|BIOLOGICAL|MVA PvDBP 2 x 10^8|1 dose MVA PvDBP 2 x 108 pfu 8 weeks later intramuscularly
223856095|NCT03201809|DEVICE|On-Q|0.2% Ropivicaine at 4 mL/h via On-Q catheter placed sub-pectoral
223856096|NCT03201809|DRUG|Ultrasound guided pectoral nerve block|Single Shot Pre-operative injections of 10 mL of 0.25% Ropivicaine for the Pecs 1 injection, and 20 mL of 0.25% Ropivacaine for the Pecs 2 injection
223856097|NCT03557333|COMBINATION_PRODUCT|INP104|No more than 2 doses within 24 hours, 3 doses within 7 days. 1.45 mg in a divided dose, one actuation per nostril.
223856098|NCT02824003|DRUG|ISIS-GCGRRx|once weekly dosing for 13 weeks
223856099|NCT02824003|DRUG|Placebo|once weekly dosing for 13 weeks
223856100|NCT02272517|DRUG|Vortioxetine 10-20 mg|
223856101|NCT02272517|DRUG|Escitalopram 10-20 mg|
223856102|NCT04601311|BEHAVIORAL|Guided self-determination|"Before randomisation, the participants are supported in formulating one personal value-clarifying goal: 'One thing I want to achieve in my life with diabetes within a year is'….~The goal is registered.~Patients go through a guided self-determination intervention preparing themselves by completing reflection sheets, analogue or digital by patient's choice, and individually facilitated by a guided self-determination-certified nurse, face-to-face, over video or over telephone. Sessions scheduled every second week. Number of sessions 3-5 is decided at session 2.~A relative may take part in one session completing an analogue reflection sheet as preparation.~Participants continue usual care."
223856103|NCT04601311|BEHAVIORAL|Personal support in goal-pursuing|"Before randomisation, the participants are supported in formulating one personal value-clarifying goal: 'One thing I want to achieve in my life with diabetes within a year is'….~The goal is registered.~Patients receive personal goal pursuing support up to five sessions, lasting up to one hour with a communication trained healthcare professional following up on the goal, face-to-face, digitally, or over telephone. The sessions are scheduled every second week. A relative may take part in one session.~Participants continue usual care."
223856104|NCT01793740|BEHAVIORAL|Cogmed|Computer based program that aims to improve children's memory, attention, and processing speed.
223856105|NCT00864682|DRUG|Saline|3.3 mL normal saline
223856106|NCT00864682|DRUG|Lidocaine / propofol admixture|lidocaine 50 mg plus propofol 50 mg intravenous (iv)
223856107|NCT00864682|DRUG|lidocaine pretreatment|lidocaine 50 mg iv under tourniquet-control
223856108|NCT00957658|DEVICE|Accolade® TMZF® Hip Stem|Accolade® TMZF® Hip Stem
223856109|NCT04455009|DIETARY_SUPPLEMENT|Fitness Drink Formula|Single drink provided following baseline assessments
223856110|NCT00565708|OTHER|placebo|Placebo Comparator
223856111|NCT00565708|DRUG|Acetylsalicylic acid|Adjuvant Therapy
223856112|NCT00975806|DRUG|Lenalidomide|Lenalidomide MTD mg by mouth (PO) daily for Days 1- 21 in combination
223856113|NCT00975806|DRUG|Sunitinib|Sunitinib 37.5 mg PO daily on days 1-21 of each 21-day cycle in Cohort A or on days 1-14 in Cohorts F and G
223856114|NCT00246012|DRUG|Intetumumab|Intetumumab will be administered at the dose of 3 milligram per kilogram (mg/kg) as intravenous infusion (a fluid or a medicine delivered into a vein by way of a needle) over a period of 2 hours (hr) (± 15 minutes) once every 3 weeks until the occurrence of dose limiting toxicities (DLTs). In Phase 2, intetumumab (5 mg/kg or 10 mg/kg) will be administered for 8 cycles until no evidence of disease progression or unacceptable toxicity. If a participant responds to therapy with stable disease (SD) or better, the participant will be eligible to receive up to 8 cycles of extended administrations.
223856115|NCT00246012|DRUG|Dacarbazine|Commercially available dacarbazine will be administered intravenously over a 60-minute period (+30 minutes/-30 minutes) and prior to the intetumumab/placebo infusion. In case participants are unable to tolerate dacarbazine even after 2 dose reductions, they will be given the option to continue on intetumumab alone.
223856116|NCT00246012|DRUG|Placebo|Placebo will be administered intravenously over a period of 2 hours (+15 minutes/-15 minutes).
223856117|NCT04708743|DIAGNOSTIC_TEST|Automatic Tongue Diagnosis System|tongue image capture tongue images by Automatic Tongue Diagnosis System
223856118|NCT05171998|PROCEDURE|venous blood sample|Phlebotomy procedure for a venous blood draw.
223856119|NCT00094809|DRUG|Placebo|Subjects randomized to placebo will receive a 6 mg subcutaneous injection once per cycle at least 24 hours after completion of 5-FU chemotherapy infusion. Subjects will continue to receive one injection per cycle until completion of 4 cycles, or until early termination from the study treatment period, whichever occurs first.
223856120|NCT00094809|DRUG|Pegfilgrastim|Subjects randomized to pegfilgrastim will receive a 6 mg subcutaneous injection once per cycle at least 24 hours after completion of 5-FU chemotherapy infusion. Subjects will continue to receive one injection per cycle until completion of 4 cycles, or until early termination from the study treatment period, whichever occurs first.
223856121|NCT06116019|RADIATION|Online adaptive radiation therapy|Daily cone-beam CT based online adaptive radiation therapy
223856122|NCT06062706|PROCEDURE|Donor hepatectomy|"Donor hepatectomy is a surgical procedure to resect a portion of the liver from a living donor for transplantation. This usually involved the right lobe, the left lobe or the left lateral section of the liver. Depending on the surgical method, this can be achieved through open, laparoscopic, or robotic-assisted techniques.~As for the recipient, liver transplantation involves a total hepatectomy of the diseased liver from the recipient and implantation of the liver graft from the donor. This is typically performed using the open surgical approach."
223856123|NCT02562352|OTHER|TAPER program|Patients will be randomized to receive the TAPER program at study start or delayed intervention at 6 months.
223856124|NCT00588965|DRUG|Placebo|Placebo will be given 1 pill daily for a week, then 2 pills daily, followed by the exercise test.
223856125|NCT00588965|DRUG|Propranolol LA|Subjects will receive propranolol LA 80 mg one pill daily for 1 week then 2 pills daily for 1 week followed by exercise test.
223856126|NCT00422201|DRUG|Mifepristone|Singe dose
223856127|NCT05460806|OTHER|Aerobic Exercise|Participants assigned to aerobic exercise training will walk on a treadmill (RodbyTM, RL 1600E, Enhorna, Sweden) for 40 minutes at an intensity of 60-75% of maximum heart rate (220-age formula) three times per week for 8 weeks. The heart rate of the participants will be measured with an electric heart rate monitor throughout the session.
223856128|NCT03248011|OTHER|Stretching|Lower extremity flexibility exercises will be performed
223856129|NCT03248011|OTHER|Strengthening|Eccentric hamstring strengthening exercises will be performed
223856130|NCT03248011|OTHER|Neuromuscular|Dynamic lower extremity balance and movement control exercises will be performed
223856131|NCT03817736|PROCEDURE|TACE|Procedure of TACE will be standardized.
223856132|NCT03817736|RADIATION|SBRT|SBRT screening and planning will be performed by radiation therapists, medical physicists, and oncologists.
223856133|NCT03817736|DRUG|Immune Checkpoint Inhibitor|An immune checkpoint inhibitor may be administered up to 3 days before or after the scheduled day of administration of each cycle due to administrative reasons.
223856134|NCT00771849|BIOLOGICAL|Meningococcal Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
223856135|NCT00771849|BIOLOGICAL|Haemophilus Influenzae Type b (Hib) vaccine|0.5 mL, Intramuscular
223856136|NCT01762072|DIETARY_SUPPLEMENT|Fish oil|
223856137|NCT01762072|DIETARY_SUPPLEMENT|vitaminB12|
223856138|NCT02167243|BEHAVIORAL|Reinforcement for BG testing|Subjects will receive reinforcement for BG tests. The intervention will reinforce subjects for conducting Self Monitoring of Blood Glucose (SMBG), with escalating reinforcers provided when subjects achieved sustained periods of testing at least 4 times/day at appropriate intervals.
223856139|NCT02167243|OTHER|Standard of care|Subjects receive standard of care
223856140|NCT02377505|DEVICE|On-Stimulation|"The surgical electrode implanted in target 1 (mPFC) or target 2 (NAcc) by a pulse generating device (Kinetra, Medtronic Inc) is on"
223856141|NCT02377505|DEVICE|Off-Stimulation|"The surgical electrode implanted in target 1 (mPFC) or target 2 (NAcc) by a pulse generating device (Kinetra, Medtronic Inc) is off"
223856142|NCT06234865|OTHER|Control Group|Patients in the control group will receive standard education plus a brochure education. Standard education includes education provided by the doctor, nurse and/or physiotherapist before and after surgery. The brochure education includes information about constipation and interventions that can be used to prevent constipation such as nutrition, fluid intake, physical activity, leg exercises, abdominal massage, and toilet habits.
223856143|NCT06234865|OTHER|Video Education Group|Patients in the experimental group will receive standard education plus a video education. Standard education includes education provided by the doctor, nurse and/or physiotherapist before and after surgery. The video education includes information about constipation and interventions that can be used to prevent constipation such as nutrition, fluid intake, physical activity, leg exercises, abdominal massage, and toilet habits.
223856144|NCT03748433|DEVICE|Dexcom G6 CGM|Commercially available Dexcom G6 Continuous Glucose Monitoring
223856145|NCT03748433|DEVICE|Tandem t:slim X2 Insulin Pump|sensor augmented insulin pump with predictive low glucose suspend
223856146|NCT00893373|DRUG|sorafenib|Standard AML chemotherapy plus sorafenib 400 mg BID
223856147|NCT00893373|DRUG|placebo|Standard AML chemotherapy plus placebo
223856148|NCT00061672|DRUG|ABT-510 - Thrombospondin-1 Mimetic|
223856149|NCT02592837|DEVICE|Flexible 19G EBUS-TBNA needle|
223856150|NCT02592837|DEVICE|21G EBUS-TBNA needle|
223856151|NCT03591809|OTHER|combined exercise training|The combined exercise training group will be given combined exercise training, consisting of Pilates and aerobic exercise, three times during 8 weeks.
223856152|NCT02046616|DRUG|Tocilizumab|Tocilizumab 162 mg will be administered subcutaneously QW.
223856153|NCT02046616|DRUG|Methotrexate|Methotrexate dosing is not specified by the protocol and will be given as per standard practice. Participants must be at a stable dose that was initiated at least 4 weeks prior to baseline.
223856154|NCT02046616|DRUG|Non-Biologic DMARDs|Participants will receive non-biologic DMARDs (same non-biologic DMARD that participant was receiving at time of study entry). Dosing is not specified by the protocol and will be given as per standard practice. Participants must be at a stable dose that was initiated at least 4 weeks prior to baseline.
223856155|NCT05468606|BIOLOGICAL|GA2|GA2 sporozoites administered by 50 mosquito bites
223856156|NCT05468606|BIOLOGICAL|BCG|0.1 mL BCG vaccine intradermally
223856157|NCT05468606|BIOLOGICAL|YF-17D (fractional ID dose)|0.1 mL YF17D vaccine intradermally
223856158|NCT05468606|DRUG|Imiquimod|250mg imiquimod 5% cream topical
223856159|NCT05468606|OTHER|Mock immunization|50 bites by uninfected mosquitoes
223856160|NCT05420168|OTHER|Automatic tool to identify inappropriate antibiotic prescriptions|The system will identify inappropriate antibiotic prescriptions.
223856161|NCT04983745|DRUG|Combination drug|niraparib and dostarlimab combination
223856162|NCT02736799|DEVICE|Sham vibrating capsule|Sham device without vibration
223856163|NCT02736799|DEVICE|Vibrant Capsule (1 vibration)|1 vibration/min
223856164|NCT02736799|DEVICE|Vibrant Capsule (3 vibration)|3 vibration/min
223856165|NCT02736799|DEVICE|Vibrant Capsule (5 vibration)|5 vibration/min
223856166|NCT01183533|DRUG|Alteplase (iv t-PA)|0.9 mg/kg (maximum of 90 mg) IV t-PA will be administered with 10% bolus given over 1 minute, the rest given as an infusion over the remaining hour.
223856167|NCT05640596|DRUG|Betamethasone|
223856168|NCT03316794|DRUG|SC-005|intravenous
223856169|NCT01833832|DRUG|Cisplatin|Patients who are successfully debulked will then undergo hyperthermic intraperitoneal chemotherapy (HIPEC) with cisplatin.
223856170|NCT01833832|PROCEDURE|Cytoreductive surgery|Patients will undergo cytoreductive surgery to achieve a Completeness of Cytoreduction Score (CC) of 0 or 1.
223856171|NCT01833832|DRUG|sodium thiosulfate|sodium thiosulfate will be given to limit the toxicity of cisplatin
223856172|NCT03684096|DIETARY_SUPPLEMENT|non-estrogenic pollen extract PCC-100|non-estrogenic pollen extract PCC-100
223856173|NCT03684096|OTHER|placebo|placebo -non-estrogenic pollen extract PCC-100
223856174|NCT01558921|OTHER|M1 scheme|short course 5 x 5 Gy radiation scheme is followed by six cycles of combination chemotherapy (capecitabine and oxaliplatin (CAPOX)) and surgery. FOLFOX4 may be given as alternative for CAPOX
223856175|NCT01558921|OTHER|standard long course chemoradiotherapy|long course chemoradiotherapy followed by surgery. Optional adjuvant chemotherapy (CAPOX or FOLFOX) is allowed in the control group.
223856176|NCT00533013|OTHER|Usual Care|Management of heart failure is provided by primary practitioners and consultant cardiologists
223856177|NCT00533013|OTHER|Disease Management and Tele-Monitoring|Management of heart failure is provided by cardiologists at regional heart failure clinics and by nurse practitioners at regional heart failure clinics and a designated call center. Decisions on treatment are guided by designated protocols and information derived for tele-monitoring of blood pressure, body weight and pulse rate.
223856178|NCT02034149|BEHAVIORAL|general management|All participants received a general education with the knowledge on care for early chronic kidney disease recently establishes by the National Health Insurance system. We then used the cross-theoretical model to assess the intervention among the three groups.
223856179|NCT02034149|BEHAVIORAL|self-management|Participants in the self-management group are expected to emphasize on self-managed interventions, including self-monitoring and records keeping, self-education with DVD courses. We negotiated their behavior change set goals for them etc.
223856180|NCT02034149|BEHAVIORAL|peer-assisted management|The peer-assisted management group received similar program for 3 months, the peer oriented group activities followed, including group discussions to share experience and sports map etc.
223856181|NCT03036735|DEVICE|steroid eluting spacer|The Restora Mometasone Furate Eluting Spacer will be compared to the Silastic spacer.
223856182|NCT00685893|BEHAVIORAL|Education|We include information about end-of-life decision-making, communication skills, pain and symptom management, and withdrawal of life support. The primary methods of delivery will be a grand rounds lecture by one of the physician investigators and the viewing of an educational video for nurses and respiratory therapists. The content of the educational components will be structured to cover four topics: the principles of decision-making about end-of-life care in the ICU; communication with patients, families and the ICU team; pain and symptom management; and, the principles and practice of withdrawal of life support.
223856183|NCT00685893|BEHAVIORAL|Local Champions|We identify physicians, nurses and other clinicians from each hospital to serve as the local champions. The role of the local champions is to help implement the intervention and be a role model for end-of-life care in the ICU. Local champions participate in interactive education and training sessions with the investigators and the other local champions from their institution to discuss barriers to good end-of-life care at their location and to strategize about how to overcome those barriers.
223856184|NCT00685893|BEHAVIORAL|Institution Feedback|We provide feedback to the institution from the hospital specific family satisfaction data we collect. All feedback is presented as aggregated data for the institution without any personal identifiers.
223856185|NCT00685893|BEHAVIORAL|Academic Detailing|Study staff meet with ICU directors with 4 goals. The first goal is to familiarize the director with the educational content of the intervention. Secondly, the results of the family satisfaction data collected are shared without identifying information. The aggregated results of the other participating hospitals are disclosed, also without identifiers. Third, we elicit and discuss the institution-specific barriers to providing high quality end-of-life care in the ICU. Lastly, we hope that by educating the directors we can engage these clinical leaders to serve as role models in their institutions.
223856186|NCT00685893|BEHAVIORAL|Institutional Forms|We have developed a set of orders that encompass the various aspects of withdrawing life support from patients. Individual department directors at each hospital will decide if they want to implement a similar order form at their institution and whether they want to modify the form to fit their specific institutional needs. In addition to the order forms, we encourage hospitals to develop a family pamphlets and resources that can be given to families to provide education about the intensive care unit experience.
223856187|NCT05576051|OTHER|patterns of use of combination therapy and monotherapy|
223856188|NCT01156116|DEVICE|CPAP mask|"The subjects who are randomized to CPAP treatment will undergo an overnight CPAP titration in the laboratory, which will be performed manually by a registered technician according to American Academy of Sleep Medicine (AASM) guidelines .Subjects will be admitted in the early evening and will receive positive airway pressure education, hands on demonstration, careful mask fitting and acclimatization prior to titration. The goal during the titration will be to determine the optimal CPAP pressure setting that eliminates obstructive respiratory events, restore oxygen saturations and sleep continuity.~\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_"
223856189|NCT01156116|DRUG|Placebo|oral placebo tablet
223856190|NCT00344019|DRUG|Placebo Oral Tablet|placebo pre-PCI for ACS
223856191|NCT00344019|DRUG|Atorvastatin 80mg|atorvastatin 80 mg pre-angio/PCI
223856192|NCT00344019|OTHER|Screening|Patients signed consent to be screened for eligibility for randomization to placebo vs. study drug (atorvastatin)
223856193|NCT01365637|DRUG|PF-05089771|PF-05089771 will be dosed as a suspension twice daily
224076133|NCT02257580|DRUG|E-Aminocaproic acid|E-Aminocaproic acid (EACA) is a synthetic lysine analog that competitively inhibits the activation of plasminogen to plasmin and subsequently decreases the degree of fibrinolysis (Faraoni,2014} and is currently being used to decrease blood loss and transfusion requirements after orthopaedic procedures.(Eubanks,2010} Multiple meta analyses and retrospective and prospective studies have shown that EACA decreases blood loss and transfusion requirements after orthopaedic surgery{ McLeod,2013; Thompson, 2005; Thompson,2008; Gill,2008; Florentino-Pineda,2001}.Results from these studies also suggest that EACA will decreased post-operative morbidity, length of hospital stay, hospital costs, and complications.{Chimento,2013; Thompson,2005; Florentino-Pineda,2001}
223856194|NCT01365637|DRUG|PF-05089771|PF-05089771 will be dosed as a suspension twice daily
223856195|NCT01365637|DRUG|PF-05089771|PF-05089771 will be dosed as a suspension either twice or thrice daily
223856196|NCT01365637|DRUG|PF-05089771|PF-05089771 will be dosed as a suspension either twice or thrice daily
223856197|NCT00684528|DRUG|Metformin 1500 mg daily|500 mg thrice daily
223856198|NCT00684528|DRUG|Metformin + Janufer (Janumet)|Titration up to 1500/150 mg daily
223856199|NCT02057718|DRUG|LUM001 (Maralixibat)|LUM001 also known as Maralixibat (MRX) oral dose up to twice a day (BID).
223856200|NCT03031756|DEVICE|glycine powder air-polishing (Air-Flows)Perio Powder|
224076134|NCT00598975|DRUG|NKTR-102 100 mg/m2|"NKTR-102 100 mg/m2 + Cetuximab Arm:~All patients received NKTR-102 in combination with cetuximab. NKTR-102 was administered intravenously (IV) once every 3 weeks (q3w) over 90 minutes on Day 1. Patients were to be enrolled in one of the following sequential dosing cohorts of NKTR-102: 100, 125, 150, or 175 mg/m2. Only the 100 and 125 mg/m2 were enrolled."
223856201|NCT03031756|DEVICE|ultrasonic (Piezon Master 700; EMS, Nyon, Switzerland)|
223856202|NCT03857334|BIOLOGICAL|Injection of autologous platelet rich plasma|
223856203|NCT03857334|DRUG|Injection of cortivazol : Altim®|Corticosteroids
223856204|NCT01367548|DRUG|IV Methylnaltrexone (MNTX)|
223856205|NCT01367548|DRUG|Placebo|
223856206|NCT01952795|BEHAVIORAL|Diet and exercise|Total caloric intake aimed at maintaining a diet with\> 50% of the caloric content in the form of carbohydrates, less than 10% in the form of saturated fats and 20% from monounsaturated / polyunsaturated (if applicable, up to 25% fat monounsaturated), less than 300 mg / day of dietary cholesterol and about 1.0 g of protein / kg ideal body weight / day.
223856207|NCT04008394|GENETIC|Anti-CD30 CAR T cells|Patients receive CD30 CAR-T cells transduced with a lentiviral vector on day 0 in the absence of disease progression or unacceptable toxicity. Autologous 3th generation anti-CD30 CAR T cells.
223856208|NCT05095558|BIOLOGICAL|microtransplantation, HLA-mismatched donor peripheral stem cell infusion|infusion of granulocyte colony stimulating factor (G-CSF) mobilized HLA-mismatched peripheral blood stem cells (GPBSC)
223856209|NCT06288152|DRUG|Sodium Thiosulfate|0.15 mL administered
223856210|NCT01563991|PROCEDURE|Normal fluid volume|Normal fluid group will receive lactated ringes at 8 cc / Kg/ hr total
223856211|NCT01563991|PROCEDURE|Reduced fluid volume|Subject receives 80 cc/ hr LR during the peri-operative period
223856212|NCT00864812|DRUG|tiotropium with fluticasone propionate/salmeterol (FSC)|COPD patients treated with tiotropium with fluticasone propionate/salmeterol (FSC)
223856213|NCT00864812|DRUG|tiotropium|COPD patients treated with tiotropium
223856214|NCT00508963|DRUG|sodium stibogluconate (Pentostam)|20 mg/kg IV every day for 20 or 28 days
223856215|NCT03187782|DIAGNOSTIC_TEST|ANSWatch|
223856216|NCT03183232|PROCEDURE|Cryosurgery or IRE surgery|Cryosurgery or IRE surgery will be used in local tumor
223856217|NCT03183232|BIOLOGICAL|γδ T cell|γδ T cells will be used against Lung Cancer
223856218|NCT03183232|OTHER|γδ T cells/ A Cryosurgery or IRE|Combination γδ T cell and Cryosurgery or IRE surgery will be used in Lung Cancer
223856219|NCT02343744|DRUG|Guselkumab|"Participants will receive 50 milligram (mg) guselkumab subcutaneously at Weeks 0, 4 and 12. At Week 16 through the study end (Week 52) participants who are defined Very much improved or Much improved in Clinical Global Impression (CGI) will continue to receive guselkumab 50 mg every 8 weeks from Week 20 to the study end (Week 52). At each visit timing from Week 20, participants who are defined No change or Worsened in CGI will receive guselkumab 100 mg and continue 100 mg every 8 weeks dosing until the study end (Week 52). Participants who are defined Minimally improved in CGI will also receive guselkumab 100 mg only if the investigator considers that it is necessary."
223856220|NCT04089618|BEHAVIORAL|MBLM|Complex 8 week Mind-Body program.
223856221|NCT00320502|DRUG|BXT-51072|
223856222|NCT02703155|DEVICE|Home Oral Glucose Tolerance Test kit|Providing Home Oral glucose tolerance test kit to children with Cystic fibrosis for screening Cystic Fibrosis Related Diabetes
223856223|NCT02503202|BIOLOGICAL|V920 Consistency Lot A|V920 (rVSV-ZEBOV-GP) Ebola Zaire vaccine consistency Lot A, live, attenuated, sterile solution for intramuscular injection
223856224|NCT02503202|BIOLOGICAL|V920 Consistency Lot B|V920 (rVSV-ZEBOV-GP) Ebola Zaire vaccine consistency Lot B, live, attenuated, sterile solution for intramuscular injection
223856225|NCT02503202|BIOLOGICAL|V920 Consistency Lot C|V920 (rVSV-ZEBOV-GP) Ebola Zaire vaccine consistency Lot C, live, attenuated, sterile solution for intramuscular injection
223856226|NCT02503202|BIOLOGICAL|V920 High-dose Lot|V920 (rVSV-ZEBOV-GP) Ebola Zaire vaccine high-dose lot, live, attenuated, sterile solution for intramuscular injection
223856227|NCT02503202|BIOLOGICAL|Placebo to V920|Sodium chloride 0.9%, sterile solution for intramuscular injection
223856228|NCT05689268|DIAGNOSTIC_TEST|EUS-PPG and HVPG|"EUS-PPG and HVPG will be measured in all patients. Under deep sedation with propofol, an echoendoscopy will be performed. After identifying the left or middle suprahepatic vein, it will be punctured with a standard 22 G needle. The needle will be previously purged with heparinized saline and connected to a venous pressure monitor via an arterial pressure system, which will be calibrated to zero at the level of the axillary midline, at the level of the atrium. Subsequently, the left portal vein will be identified from the stomach or duodenum, repeating the procedure. From each vessel 3 measurements will be taken by flushing 1-2 ml of heparinized saline. The mean of the three measurements will be obtained.~On the same day or on successive days HVPG measurement will be performed."
223856229|NCT05427890|BEHAVIORAL|T2D Risk Communication Tool: Relative Risk|Risk of T2D is presented in comparison to the rest of the Singapore population in a scale 1-10. Suggestions on different lifestyle changes and its potential to reduce the individual's relative risk is presented for user to observe impact of preventative behaviours.
223856230|NCT05427890|BEHAVIORAL|T2D Risk Communication Tool: Metabolic Age|Risk of T2D is presented as an age, compared to their chronological age as a proxy for their current health status. Suggestions on different lifestyle changes and its potential to reduce the individual's metabolic age is presented for user to observe impact of preventative behaviours.
223856231|NCT05427890|BEHAVIORAL|T2D Risk Communication Tool: Traffic Light|Risk of T2D is presented as either High (Red) or Low (Green). Generic tips on how to reduce risk of diabetes are included. This imitates the tool that is currently available for residents of Singapore to use to assess their risk of T2D.
223856232|NCT00920296|DRUG|GSK1265744|GSK drug
223856233|NCT01738802|DIETARY_SUPPLEMENT|Anti-oxidant and micronutrient|This group will be randomized to take the anti-oxidant and micronutrient supplement.
223856234|NCT01738802|DRUG|Placebo|This group will take a placebo.
223856235|NCT00339469|DIETARY_SUPPLEMENT|LIFE|We are evaluating the effects of a legume enriched, low glycemic index, high fermentable fiber diet, on CRP, and C-peptide participants with four possible combinations of the risk factors insulin resistance and history of adenomatous polyps. In a randomized crossover design controlled feeding study each participant consumed the above experimental diet and a control diet for four weeks with a two week washout period between diets. 65 male participants were recruited and randomized into four groups. A secondary objective is to assess whether these endpoints change by IR status or a history of adenomas. In addition, potential fecal markers of CRC risk are being measured to assess changes in gastrointestinal inflammation, including mRNA from exfoliated fecal colonocytes. To our knowledge this is the first controlled feeding study: 1. to examine the effects of legumes or a low GI diet on markers of inflammation
223856236|NCT03965702|DEVICE|Use of a decision support system on the EV1000 monitoring (AFM mode)|The way to administer fluid is based on the same monitoring device but will differ by the way fluid is given ( following a manual GDFT protocol versus following recommendation from an active clinical decision support system for fluid administration called AFM (assisted fluid management) Measurement of all microvascumlar parameters in blinded way. Blood pressure wil standardized in both group.
223856237|NCT03965702|OTHER|Manual application of the GDFT protocol (standard of care)|Manual application of a GDFT protocol to guide fluid administration. Measurement of all microvascumlar parameters in blinded way. Blood pressure wil standardized in both group.
223856238|NCT00209443|DRUG|Gadodiamide Injection|
223856239|NCT00651378|DRUG|Rosuvastatin|oral tablets: rosuvastatin 10 mg once daily for 6 weeks (switch from previous run-in with atorvastatin 10 mg daily)
223856240|NCT00651378|DRUG|Ezetimibe + Atorvastatin|oral tablets: ezetimibe 10 mg plus atorvastatin 10 mg once daily for 6 weeks (add ezetimibe to previous run-in with atorvastatin 10 mg daily)
223856241|NCT00651378|DRUG|Double Atorvastatin|oral tablets: atorvastatin 20 mg once daily for 6 weeks (double dose from previous run-in with atorvastatin 10 mg daily)
223856242|NCT05187767|DIAGNOSTIC_TEST|cf DNA and ct DNA|Quantification of the circulating free DNA and the presence of targeted circulating tumor DNA
223856243|NCT01254591|OTHER|18F-fluoromisonidazole|
223856244|NCT01254591|OTHER|fluorescence angiography|
223856245|NCT01254591|OTHER|laboratory biomarker analysis|
223856246|NCT01254591|PROCEDURE|infrared thermography|
223856247|NCT01254591|PROCEDURE|magnetic resonance imaging|
223856248|NCT01254591|PROCEDURE|therapeutic conventional surgery|
223856249|NCT01254591|RADIATION|[18F]-ML-10|
223856250|NCT01254591|RADIATION|fludeoxyglucose F 18|
223856251|NCT01254591|RADIATION|rubidium Rb-82|
223856252|NCT04577170|DIAGNOSTIC_TEST|Transcranial Doppler (TCD) and Transcranial Color-Coded Duplex (TCCD) ultrasonography|Transcranial Doppler (TCD) and Transcranial Color-Coded Duplex (TCCD) ultrasonography will be performed in consecutive FD patients. All TCD and TCCD studies will be performed by stroke neurologists experienced in vascular sonography.
223856253|NCT04454892|OTHER|Amyotrophic lateral sclerosis|AMYOTROPHIC lateral sclerosis (ALS) is a degenerative disorder of motor neurons in the cortex, brainstem and spinal cord1,2. Its cause is unknown and it is uniformly fatal, typically within five years3
223856254|NCT00235040|BEHAVIORAL|Smart Form|Computer Decision Support System
224076135|NCT00598975|DRUG|NKTR-102 125 mg/m2|"NKTR-102 125 mg/m2 + Cetuximab Arm:~All patients received NKTR-102 in combination with cetuximab. NKTR-102 was administered intravenously (IV) once every 3 weeks (q3w) over 90 minutes on Day 1. Patients were to be enrolled in one of the following sequential dosing cohorts of NKTR-102: 100, 125, 150, or 175 mg/m2. Only the 100 and 125 mg/m2 were enrolled."
224076136|NCT00598975|DRUG|Cetuximab|Cetuximab was administered once weekly via a 2-hour IV infusion at a starting dose of 400 mg/m2 on Day 1 and subsequently administered weekly at 250 mg/m2 via a 1-hour infusion thereafter.
223856255|NCT05444179|BEHAVIORAL|Mommies can Eat & Exercise with No Stress (MomEENS)|This intervention involving behaviour modification, incorporates nutrition and physical activity modification. The intervention encourages participants to consume a healthy diet and active lifestyle during postpartum period. For nutrition modification, a general advice on healthy nutrition were given and several nutrients are highlighted which evidenced can reduce postpartum depression. While for physical activity, the mothers are encouraged to do exercise, targeting aerobic, flexibility, and strength type of exercise. The exercise protocol is progressive. During the first month, the participants will be advised to conduct flexibility and strength exercises for 8 repetitions (1 set), at least 3 days per week for both aerobic and flexibility exercise. While during the second month, participants are asked to increase repetitions and frequency of exercises, up to 16 repetitions (2 set) for each flexibility exercise, and conduct exercise at least 5 days per week.
223856256|NCT02931851|OTHER|ICU Families Website|Professionally developed website for relatives of ICU patients
223856257|NCT02931851|OTHER|Placebo|Standard Information provided online
223856258|NCT04897737|BEHAVIORAL|HIVST and enhanced adherence biofeedback|"The intervention includes the provision of an OraQuick HIV self-test (HIVST) for the woman and one test for each of her reported sex partners, along with instructions on how to use and interpret the results. Women were asked to report back within one month if their partner was able to test via a SMS, WhatsApp or by bringing in the test to confirm that he had tested.~Women then received adherence based feedback following the urine lateral flow assay (that measures recent tenofovir use in past 48 hours). Study counsellors requested that women provide a urine sample that was tested using the UrSure/Orasure test that provides feedback on the result in 2-3 minutes. Counselors provided counseling based on the results including how to improve daily adherence (for women without tenofovir present in their urine) and importance of condom use."
223856259|NCT04897737|DIAGNOSTIC_TEST|Orasure/UrSure test|See above
223856260|NCT02521116|OTHER|Dynamic Vessel Analyzer|
223856261|NCT02521116|OTHER|Oxymap T1|
223856262|NCT04554823|BEHAVIORAL|Health Education|Will attend lectures on health education about Health and Physical Education, healthy eating, overcoming barriers, Back to routine, Physical Activity Options and Dealing with Stress and Depression
223856263|NCT04554823|BEHAVIORAL|Physical Exercise|Supervised physical training program of combined exercises for 24 weeks, with frequency of 3 times weekly and duration of 60 minutes, an unsupervised flexibility training program 2 times a week.
223856264|NCT00250562|DRUG|valsartan plus hydrochlorothiazide|
223856265|NCT00477100|PROCEDURE|Biospecimen Collection|Undergo collection of blood, tissue, and stool
223856266|NCT00477100|OTHER|Interview|Participate in interview
223856267|NCT00477100|OTHER|Medical Chart Review|Undergo collection of medical data
223856268|NCT00477100|OTHER|Questionnaire Administration|Ancillary Studies
223856269|NCT00405951|DRUG|Obatoclax mesylate 250 ml|
223856270|NCT00405951|DRUG|Docetaxel|
223856271|NCT04059237|BEHAVIORAL|Web based decision aid intervention|Decision aid tool (website) to assist young adult female cancer survivors in making decisions and preparing for family-building after cancer.
223856272|NCT00608907|DRUG|bortezomib|1.3 mg/m\^3 on days 1, 4, 8, 11 over a 21-day treatment cycle
223856273|NCT00608907|DRUG|bortezomib, rifampicin|bortezomib 1.3 mg/m\^2 on days 1, 4, 8, 11 over a 21-day treatment cycle, rifampicin 600 mg once daily days 4 to 10 in cycle 3
223856274|NCT00608907|DRUG|bortezomib, dexamethasone|bortezomib 1.3 mg/m\^2 on days 1, 4, 8, 11 over a 21-day treatment cycle, dexamethasone 40 mg once daily days 1 to 4, and 9 to 12 in cycle 3
223856275|NCT04921423|BEHAVIORAL|Situational simulation teaching|The intervention included communication theory and skills, aging trend and knowledge, teaching plans for elderly nursing, activities for the elderly and visual experience, application and debriefing of empathy.
223856276|NCT01887041|PROCEDURE|Stent|Endoscopically inserted biliary tract drainage
223856277|NCT01887041|PROCEDURE|Biliodigestive anastomosis|Biliodigestive anastomosis
223856278|NCT04875858|DRUG|ProDiax-23 (PPSV23)|diabetic old adults aged 70-75 years who received PPSV23 in previous 5-7 years (Persons 65-70 years old who have been inoculated with PPSV23 and 5-7 years have passed) and healthy old adults aged 70-75 years who received PPSV23 in previous 5-7 years (Persons 65-70 years old who have been inoculated with PPSV23 and 5-7 years have passed)
223856279|NCT03869918|OTHER|Exercise Program|Exercise at home or through a class as chosen by the subject.
223856280|NCT00135135|DRUG|Gefitinib, Irinotecan, Cycophosphamide, Doxorubicin, Etoposide, Cisplatin, Topotecan, Carboplatin, Melphalan, 13-cis retinoic acid|See Detailed Description.
223856281|NCT00135135|PROCEDURE|Radiation therapy, Surgery, Peripheral Stem cell transplant|See Detailed Description.
223856282|NCT06341491|BEHAVIORAL|Pé-de-Meia Program|"The Pé-de-Meia Program was established by the Brazilian Federal Government with the aim of encouraging the retention of low-income students in high school by providing maintenance scholarships and savings opportunities. To be eligible for the program, a young person must: Be properly enrolled in a regular public high school course, be between 14 to 24 years old, come from a low-income family, and be registered in the Bolsa Família Program. The Program offers four types of incentives:~An enrollment grant registered at the beginning of the academic year, paid once a year in the amount of 200 BRL.~A minimum school attendance of 80% of the total class hours, paid in nine installments throughout the year at 200 BRL each.~Proven participation in the National High School Exam (ENEM), paid once to the student enrolled in the third year of high school, in the amount of 200 BRL.~Completion of the high school academic years, paid in a single installment of 1,000 BRL."
223856283|NCT02458599|DIETARY_SUPPLEMENT|Test product|Whey protein hydrolysate (20 g)
223856284|NCT02458599|DIETARY_SUPPLEMENT|Reference product 1|Iso-energetic carbohydrate (20 g)
223856285|NCT02458599|DIETARY_SUPPLEMENT|Reference product 2|Negligible energy placebo (20 g)
223856286|NCT02050308|OTHER|Internet-All Nations Breath of Life (I-ANBL)|"* Participants will be asked to log into the website prior to the first session to allow for any problems with the site to be fixed prior to sessions starting. Topics we anticipate covering include, but are not limited to: preparing to quit, dealing with cravings, support systems, traditional tobacco, stress reduction, weight management, and staying quit, along with other topics determined during program development. For each session, the tribal college student will begin the session by answering a series of questions to produce an individually-tailored report that will be provided on the screen at the end of each week's session so that the smoker can work on strategies during the week before the next internet session~* Weekly procedures will follow the same format as for the first session"
223856287|NCT02050308|OTHER|Honoring the Gift of Heart Health|"These sessions help American Indians learn about what they can do to prevent heart disease. We will emphasize the increase consumption of fruits and vegetables as well as addressing other heart healthy activities. Honoring the Gift of Heart Health is a user-friendly program developed especially for American Indians. The manual provides the how-to for leading group education sessions. It offers hands-on activities that help people build the skills they need to make simple, practical, and lasting changes to help them fight heart disease. The protocol will follow procedures as the I-ANBL arm, however, this fruit and vegetable arm will not include individually tailored components, but just interactive web-based materials related to increasing heart health, including certain activities."
223856288|NCT02050308|DRUG|Nicotine gum, Patch, or Lozenge or Zyban® or Chantix®|Regardless of the intervention arm to which subjects are assigned, they will choose the option of nicotine replacement therapy they want, as long as they are eligible for it. All participants are offered the medications, but they do not have to take any medication to participate in the study.
223856289|NCT00906035|DRUG|Dipyridamole 200mg and Aspirin 25mg bid:|All subjects will receive their randomly assigned study medication to be taken each morning and evening approximately 8am and 8 pm for the 180 day duration of the study.
223856290|NCT00906035|DRUG|Dipyridamole 200 mg bid|All subjects will receive their randomly assigned study medication to be taken each morning and evening approximately 8am and 8 pm for the 180 day duration of the study.
223856291|NCT00906035|DRUG|Aspirin 25 mg bid|All subjects will receive their randomly assigned study medication to be taken each morning and evening approximately 8am and 8 pm for the 180 day duration of the study.
223856292|NCT03109704|PROCEDURE|Supine upper thoracic spine thrust manipulation|The supine thrust manipulation will target the upper thoracic spine and will be performed as previously described. The patient will be asked to lace his or her fingers behind the neck and bring his or her elbows close together in front of the chest. The therapist will place one hand just below the targeted upper thoracic region (at either the T3 or T4 level) using a pistol grip or loose fist to make contact with both transverse processes of the T3 or T4 vertebrae. The therapist will then use his or her body to push down through the patient's upper arms to provide a high-velocity, low-amplitude thrust in the anterior-to-posterior direction.
223856293|NCT03109704|PROCEDURE|Seated upper thoracic spine thrust manipulation|The seated thrust manipulation will target the cervicothoracic junction with the patient sitting with fingers laced behind the neck. The therapist will stand behind the patient and thread his or her arms through the patient's arms and clasp his or her hands near the C7-T1 level. The therapist will make contact with his or her chest against the patient's upper thoracic region to serve as a fulcrum. The patient will then be instructed to take a deep breath, and upon exhalation the therapist will apply a high-velocity, low-amplitude distraction thrust in a cephalad direction.
223856294|NCT03109704|PROCEDURE|Sham manipulation|"The sham manipulation will be performed with the patient and the examiner positioned in the same manner as for the seated manipulation, however the examiner will apply only minimal pressure to maintain physical contact and skin lock with the patient. The examiner will then move the patient through the same range of motion but deliver no manipulative thrust."
223856295|NCT06051500|BEHAVIORAL|Nostril focus followed by belly focus|Focused breathing on the nostrils followed by focus breathing on the belly.
223856296|NCT06051500|BEHAVIORAL|Belly focus followed by nostril focus|Focused breathing on the bellyfollowed by focus breathing on the nostrils.
223856297|NCT00048828|DRUG|Olanzapine|Participants will receive olanzapine for 12 weeks.
223856298|NCT00048828|DRUG|Clozapine|Participants will receive 12 weeks of clozapine.
223856299|NCT00481234|DEVICE|Heart Rate Variability analysis|
223856300|NCT00540202|DRUG|artemether-lumefantrine|Tablets taken twice daily for 3 days according to weight based guidelines.
223856301|NCT00540202|DRUG|Oral quinine|Quinine tablets given at 10mg/kg 8 hourly for 7 days
223856302|NCT01191788|BEHAVIORAL|Group Cognitive Behavioral Therapy|16 two hour sessions of group CBT
223856303|NCT01191788|BEHAVIORAL|Group CBT for Depression|16 of group CBT for depression delivered in 2 hour groups for up to 8 weeks by a trained substance abuse treatment counselor
223856304|NCT04081506|OTHER|Individualized perfusion targets|Targeting +/-5mmHg of the optimal mean arterial pressure
223856305|NCT01245439|DRUG|tocilizumab [RoActemra/Actemra]|8 mg/kg intravenous infusion every 4 weeks for a total of 6 infusions
223856306|NCT06238154|DRUG|Flurbiprofen|The efficacy of two different forms and amounts of active ingredient (100mg tablet vs 25% oral spray) on postoperative pain of different flurbiprofen
223856307|NCT01082809|DRUG|Sunitinib|Sunitinib 37.5 mg orally once daily continuously, comprising a 4-week cycle
223856308|NCT02276508|DRUG|E. coli Nissle 1917|Participants will all take E. coli Nissle 1917 orally administered medication for 30 days
223856309|NCT06319664|PROCEDURE|retrosigmoid approach (RSA)|The skull base approach choice was fundamentally followed by the modified classification.
223856310|NCT06319664|PROCEDURE|subtemporal transtentorial transpetrosal approach (STTA)|The skull base approach choice was fundamentally followed by the modified classification.
223856311|NCT06319664|PROCEDURE|extended pterional transtentorial approach (EPTA)|The skull base approach choice was fundamentally followed by the modified classification.
223856312|NCT06319664|PROCEDURE|pretemporal trancavernous anterior transpetrosal approach (PTCA)|The skull base approach choice was fundamentally followed by the modified classification.
223856313|NCT06319664|PROCEDURE|presigmoid combined supra-infratentorial approach (PCA)|The skull base approach choice was fundamentally followed by the modified classification.
223856314|NCT06319664|PROCEDURE|inoperable|The skull base approach choice was fundamentally followed by the modified classification.
223856315|NCT04249388|OTHER|No Intervention, just observation|No Intervention, just observation
223856316|NCT01507948|BEHAVIORAL|Prolonged exposure|PE will be delivered in 9-12 90-minute sessions. Therapy will be delivered by PhD-level therapists at Stanford and Palo Alto VA. PE consists of four components: psychoeducation about PTSD symptoms and the behavioral or cognitive factors maintaining it, a brief breathing retraining that can be used as a stress management tool, prolonged imaginal exposure to the trauma memory both within-session and repeated as homework, and prolonged in vivo exposure to avoided scenarios in patients' day-to-day lives.
223856317|NCT03178994|DRUG|2% ketoconazole cream|2% ketoconazole cream applies twice daily
223856318|NCT03178994|DRUG|Hydrophilic Cream|Hydrophilic cream (in-house preparation) applies twice daily
223856319|NCT03956641|OTHER|Adaptated Physical Activity|Evaluation of the physical condition and the quality of life during the course of treatment (after 8 weeks of treatment) and at the end of the treatment's line (except for breast cancer patients)
223856320|NCT01955668|DRUG|Administration of AZD6738|An oral formulation of AZD6738 will be used. The starting dose of 20 mg BD will be escalated to reach a maximum tolerated dose in patients as defined by dose-limiting toxicity. A '3 week on, 1 week off' schedule, as deemed optimal in modelling of data from non-clinical studies, will be used initially
223856321|NCT05451017|DRUG|3ß-(4-methoxybenzyloxy)pregn-5-en-20-one in fed condition|a single dose of 1 mg AEF0117 in fed condition
223856322|NCT05451017|DRUG|3ß-(4-methoxybenzyloxy)pregn-5-en-20-one in fasting condition|a single dose of 1 mg AEF0117 in fasting condition
223856323|NCT05046132|DRUG|Setmelanotide|Administered once daily via SC injection.
223856324|NCT05046132|DRUG|Moxifloxacin|Moxifloxacin capsules via oral administration.
223856325|NCT05046132|DRUG|Oral Placebo|Placebo capsules via oral administration.
223856326|NCT05046132|DRUG|SC Placebo|Placebo via SC injection.
223856327|NCT02425254|DRUG|Intravenous paracetamol|1000mg intravenous solution for infusion
223856328|NCT02425254|DRUG|Intravenous saline 0.9%|0.9% sodium chloride in order to ensure double-blinding
223856329|NCT05042193|OTHER|SARS-CoV-2|Observational
223856330|NCT01959412|DRUG|Indacaterol 27.5 mcg|indacaterol 27.5 mcg twice daily inhaled once via inhaler
223856331|NCT01959412|DRUG|Indacaterol 37.5|Indacaterol 37.5 mcg once daily, inhaled once via inhaler
223856332|NCT01959412|DRUG|Indacaterol 55 mcg|Indacaterol 55 mcg once daily, inhaled once via inhaler
223856333|NCT01959412|DRUG|Indacaterol 75 mcg|Indacaterol 75 mcg once daily, inhaled once via inhaler
223856334|NCT01959412|DRUG|Indacaterol 150 mcg|Indacaterol 150 mcg once daily, inhaled once via inhaler
223856335|NCT01959412|DRUG|Placebo|Placebo to indacaterol once or twice daily (depending on assigned sequence) via inlaher
223856336|NCT04327882|DIAGNOSTIC_TEST|Point-of-care ultrasound|performance of a POCUS: lung and cardiac ultrasound mainly
223856337|NCT01130818|DRUG|GLPG0492|single ascending doses, oral solution (25 to max. 120 mg/intake, 10 to 200 mg/mL)
223856338|NCT01130818|DRUG|placebo|single dose, oral solution
223856339|NCT01130818|DRUG|GLPG0492|single dose, solid formulation, 50 mg (2\*25 mg/capsule), fasting
223856340|NCT01130818|DRUG|GLPG0492|single dose, solid formulation, 50 mg (2\*25 mg/capsule), after high fat breakfast
223856341|NCT05004272|PROCEDURE|Massage|20-minute manual full-body massage
223856342|NCT05004272|PROCEDURE|Gymnastics|20-minute moderate body workout
223856343|NCT05004272|OTHER|Lecture|20-minute lecture on medicinal herbs
223856344|NCT00199589|DRUG|Botulinic toxin (Botox)|Patients may benefit, depending on the draw, in addition to their orthosis, intramuscular injections of botulinum toxin.These injections are among 6 in the muscles posterior (rear) of the leg paralyzed with tracking electromyographic to ensure the accuracy of the injection.
223856345|NCT03966794|DEVICE|Epidural Electrical Stimulation|Participants had finished the previous clinical trial with functional neural regeneration collagen scaffold transplantation, and will receive epidural electrical stimulation of the spinal cord in this group.
223856346|NCT03966794|COMBINATION_PRODUCT|Functional scaffold & Epidural Electrical Stimulation|Participants with acute complete SCI or chronic complete SCI will receive functional neural regeneration scaffold transplantation and epidural electrical stimulation of the spinal cord.
223856347|NCT00365638|DRUG|simvastatin|
223856348|NCT04935749|DEVICE|Ultra wide-field retinal imaging|Diabetic patients will be imaged with an ultra wide-field retinal imaging device (Optos, California). Patients will be imaged either with or without mydriasis.
223856349|NCT04159636|OTHER|Carbohydrate beverage|The participants in this group are allowed to drink carbohydrate until 2 hours before surgery
223856350|NCT05147389|DIAGNOSTIC_TEST|AI model classification|AIWorks is an artificial intelligence model for real-time cholangioscopic detection of neoplastic and non-neoplastic bile duct lesions. It allows you to choose using a video file or a USB camera input as the detection source. Once the input source has been selected, the software performs real-time detection by surrounding the area of interest (i.e., the area with malignancy features) inside a bounding box. All detections made are displayed on the right side of the screen and can also be reviewed afterwards.
223856351|NCT05147389|DIAGNOSTIC_TEST|DSOC endoscopist experts' classification|"Six endoscopists with high DSOC expertise will observe and classify a set of videos among neoplastic or non-neoplastic bile duct lesions following a Bernoulli distribution; blinded to clinical records and should have never attended said patients.~Gastroenterologists from each center, with non-DSOC responsibility, will select DSOC videos and corresponding baseline data. DSOC videos and data will be gathered in one set. Each video represents a full DSOC for a single patient. The patient will be the unit of this study.~The neoplastic bile duct criteria are in accordance with the Robles-Medranda et al and the Mendoza classifications (ie. Irregular mucosa surface, Tortuous and dilated vascularity, Irregular nodulations, Polyps, Ulceration, Honeycomb pattern, etc.). The experts will assess neoplastic bile duct by presence or absence of disaggregated criteria. Likewise, by Boolean logical operators, the statistical software will compute disaggregated answers."
223856352|NCT04806256|BEHAVIORAL|Clinical Decision Support System|This project is based on the artificial intelligence (AI) algorithm to screen the effective methods of traditional Chinese medicine intervention for dry eye and its applicable conditions, and optimize the traditional Chinese medicine intervention plan for dry eye through the evaluation of evidence-based medicine and expert consensus, and construct the traditional Chinese medicine intervention Clinical Decision Support Systems (CDSS) for dry eye. At the same time, the CDSS is provided to clinicians for their selection.
223856353|NCT04806256|OTHER|Routine intervention|The routine intervention without CDSS is also the clinically common intervention at present.
223856354|NCT01669148|DEVICE|Tomosynthesis|The mean glandular radiation dose for each image will be approximately 145 millirads (mrad) for a standard size breast (4.2 cm compressed breast thickness).
223856355|NCT01669148|DEVICE|Conventional|conventional (2D) imaging (standard mammography)
223856356|NCT01872819|OTHER|antitumor drug screening assay|Undergo high throughput drug sensitivity assay
223856357|NCT01872819|DRUG|chemotherapy|Patients receive 1 of 160 possible interventions
223856358|NCT01872819|BIOLOGICAL|biological therapy|Patients receive 1 of 160 possible interventions
223856359|NCT04652817|DEVICE|MMI-22-04-2019|A cross-linked form of the Hyaluronic Acid is used in intradermal injection to augment the labia majora area.
223856360|NCT00702806|DRUG|Org 36286|Intra-abdominal injection of Org 36286
223856361|NCT00702806|DRUG|Puregon®|Subcutaneous Puregon® 150 IU
223856362|NCT00702806|DRUG|Orgalutran®|Subcutaneous Orgalutran® 0.25 mg
223856363|NCT00702806|DRUG|Pregnyl®|Subcutaneous Pregnyl® 10,000 IU
223856364|NCT02209740|OTHER|Tenofovir switch|Patients switched tenofovir to different antiretroviral regimen according to physicians decision
223856365|NCT00374699|DRUG|Velcade|
223856366|NCT02717299|DEVICE|Verasense|Verasense will collect balancing data on all patients in this trial.
224076137|NCT03294551|BEHAVIORAL|HPV Vaccine Reminder Recall - Autodialer|Investigators will send out HPV vaccine reminder recall notices via autodialer message to the parents of adolescents 11-14 years of age who are eligible to receive a dose of the HPV vaccine per the records in the New York State Immunization Information System (NYSIIS). The investigators will be testing the effectiveness and cost effectiveness of the various modalities or reminders as compared to the standard of care control (no reminders)
223856367|NCT00931593|DEVICE|Esophageal high resolution manometry associated or not with manometry with perfused Dentsleeve probe (as determined by randomization)|"Visit V0 (day 0 - 2 to 14 days):~* Subject selection~* Obtaining of written informed consent~Visit V1 (day 0):~* Fasting subject~* Randomization to determine the examination order~* Esophageal high resolution manometry (Sierra Scientific Instruments, California CA) associated or not with manometry with perfused Dentsleeve probe (as determined by randomisation): 3-hour recording (1 hour fasting, ingestion of a 600-kcal liquid meal in 10 minutes, 2 hours post prandial)~Visit V2 (day 0 + 1 day): Phone contact~Visit V3 (day 0 + 2 to 7 days):~* Same as V1~Visit V4 (V3 + 1 day): Phone contact and end of the study"
223856368|NCT01505946|OTHER|TGA (Thrombin generation Assay)|"TGA will be performed on plasma in order to evaluate differences in the ability to stimulate the thrombin generation among the different class of FVIII concentrates and possibly identify the most effective. The TGA will be quarterly repeated in order to verify if it is also adequate to check the therapy effectiveness during the study period"
223856369|NCT05977933|DEVICE|Shape II CPET|Submaximal Cardiopulmonary exercise test equipment
223856370|NCT01597154|BEHAVIORAL|Lifestyle Counselling|Participants will take part in 2-3 group based peer-led sessions per week in which they will learn about healthy lifestyle choices
223856371|NCT00509769|DRUG|Trastuzumab emtansine [Kadcyla]|Trastuzumab emtansine was provided in either a liquid or a lyophilized formulation.
223856372|NCT05001750|DRUG|long term prophylactic antibiotics (Nafcillin or Doxycycline)|VRIs in patients who also receive a pre-procedural dose of antibiotics with continued dosing of antibiotics for the duration of the external ventricular drain IRB NUMBER: 2021-12680 IRB APPROVAL DATE: 06/14/2021 NOABX in EVD Study 3 (EVD).
223856373|NCT04956224|BIOLOGICAL|VLA2001|"whole virus inactivated SARS-CoV-2 vaccine adjuvanted with cytosine phospho-guanine (CpG) 1018 in combination with aluminium hydroxide (Wuhan strain)~2 vaccinations 28 days apart~Booster Vaccination on Visit B1"
223856374|NCT05407142|BIOLOGICAL|"CoviVac vaccine (inactivated whole-virion concentrated purified) manufactured by FSBSI Chumakov FSC R&D IBP RAS"|"Subgroup 1 - 2100 volunteers who will be vaccinated with the Nobivac vaccine twice with an interval of 21 days intramuscularly at a dose of 0.5 ml and revaccinated at 6 months with one dose of the KoviVac vaccine (0.5 ml).~Subgroup 2 - 1400 volunteers who will be vaccinated with CoviVac vaccine three times at intervals of 21 days intramuscularly at a dose of 0.5 ml."
223856375|NCT05407142|OTHER|The data from volunteers from the control group|Official data on the number of Covid-19 cases during the study period among 3,500 unvaccinated individuals.
223856376|NCT04009356|PROCEDURE|bariatric surgical procedures|gastric bypass, sleeve, banding,biliopancreatic diversion
223856377|NCT03870854|PROCEDURE|PEFA VT ablation technique|Catheter ablation guided by PEFA technique
223856378|NCT01826695|OTHER|Neurodynamic technique group|"Neurodynamic techniques are used in order to move most of the nerves between the neck and hand, including the median nerve, radial and ulnar, brachial plexus, spinal nerves and cervical nerve roots.~The patient is placed supine position. The treatment will be carry out 3 times per week during 8 weeks."
223856379|NCT01826695|OTHER|Placebo group|Women in this group realized standard treatment in the Fibromyalgia Association without neurodynamic techniques.
223856380|NCT01191619|PROCEDURE|McIvor retractor|The Mclvor blade- guided technique (McIvor group) involved the following steps. The PLMA was lubricated on the posterior aspect of the deflated mask with a water-based lubricant. The McIvor blade was fully inserted beneath the tongue of the patients. The tongue was lifted gently with the McIvor blade and PLMA was introduced into a space between the McIvor blade and maxillary incisors holding the bite block of the PLMA. The PLMA was advanced into the hypopharynx until definite resistance was felt and McIvor blade was removed.
223856381|NCT03101618|OTHER|Animal allergy|Allergic symptom occurs during exposure to laboratory or pet animal
223856382|NCT03101618|OTHER|Non-animal allergy|Allergic symptom does not occur during exposure to laboratory or pet animal
223856383|NCT00754936|DRUG|Escitalopram|20 mg by mouth daily
223856384|NCT02370563|DRUG|18F-FSPG|18F-FSPG is a novel F18-labelled, radiopharmaceutical agent for PET imaging. It is administered intravenously at a dose of 300 MBq (8.1mCi ± 10%).
223856385|NCT01992354|DEVICE|PET MR Device|GE PET/MRI system
223856386|NCT01387113|OTHER|Computed tomography perfusion imaging|As per standard of care at CPMC
223856387|NCT04963049|OTHER|Protocol with Mask|Look at differences in group with facemask and no mask
223856388|NCT03665090|BEHAVIORAL|Diabetic eye disease screening|Community-based, prospective cohort study from three consecutive years (2016 to 2018) to determine the prevalence and impact of diabetic eye disease, especially diabetic retinopathy (DR), in adults with diabetes living in Shanghai.
223856389|NCT04480593|DRUG|Brazilian Green Propolis Extract (EPP-AF)|Green propolis extract (EPP-AF) administered orally or via nasoenteral tube.
223856390|NCT04480593|OTHER|Standard care|Standard treatment includes, as needed, supplemental oxygen (non-invasive and invasive), antibiotics or antivirals, corticosteroids, vasopressor support, renal replacement therapy and extracorporeal membrane oxygenation (ECMO).
223856391|NCT00005786|DRUG|arsenic trioxide|Given IV
223856392|NCT00005786|OTHER|laboratory biomarker analysis|Correlative studies
223856393|NCT03773861|OTHER|errors made in one BLS session|BLS instructors have to oversee a standardized BLS training session, where standardized errors are made by trained volunteers.
223856394|NCT02460484|BIOLOGICAL|Autologous Cord Blood Infusion|Intravenous infusion
223856395|NCT04302519|BIOLOGICAL|Dental pulp mesenchymal stem cells|On the basis of clinical standard treatment, the injection of dental mesenchymal stem cells was increased on day 1, 3 and 7 of the trial.
223856396|NCT04807725|GENETIC|Analysis of genetic polymorphisms|For the investigation of genetic polymorphisms, it will be collected a sample of cells from the jugal mucosa with the aid of a swab. The genetic analysis will be done with the DNA extraction technique followed by PCR-RFLP techniques (polymerase chain reaction followed by restriction fragment length polymorphism).
223856397|NCT04807725|OTHER|Biochemical analysis|For the biochemical analysis of the inflammatory mediators IL-1beta, TNF-alpha and PGE2 a peri-implant crevicular fluid collection will be performed by inserting paper strips into peri-implant sulcus or pocket, in situations of peri-implantitis from the most affected location, while in situations of peri-implant health from the mesio-buccal location.
223856398|NCT06631040|BIOLOGICAL|anti CD19 CAR NK cells|Ten eligible patients with relapsed Acute Lymphoblastic Leukemia will be enrolled based on inclusion criteria and informed consent. After conditioning with Fludarabine and Cyclophosphamide, patients will receive a single infusion of anti-CD19 CAR NK cells with close monitoring using one of the following dose levels: • Dose Level 1: 1×10\^7/Kg • Dose Level 2: 5×10\^7/Kg • Dose Level 3: 1×10\^8/Kg Safety Assessment: Adverse events will be recorded and graded. Laboratory parameters and cytokine release syndrome (CRS) markers will be closely monitored. Efficacy Evaluation: Response assessments will follow International Lymphoma Party (LWP) Group guidelines, including complete response (CR), partial response (PR), stable disease (SD), and progressive disease.
223856399|NCT04979988|DRUG|Lortlatinib|as provided in real world practice
223856400|NCT05585775|BEHAVIORAL|Mindfulness-Based Cognitive Therapy|MBCT classes are comprised of weekly, 2.5-hour classes in which participants learn cognitive therapy techniques and practice meditation exercises. Participants will complete group and/or individual orientation to MBCT with the MBCT instructor, 1-2 weeks prior to the first scheduled MBCT class. Additionally, MBCT requires 45-minutes of daily home practice, and a full day, 8-hour silent meditation retreat. MBCT classes are delivered via the protocol and curriculum developed by the MBCT founders. Participants randomized to MBCT will receive 8-weeks of MBCT classes.
224076138|NCT03294551|BEHAVIORAL|HPV Vaccine Reminder Recall - Texting|Investigators will send out HPV vaccine reminder recall notices via text message to the parents of adolescents 11-14 years of age who are eligible to receive a dose of the HPV vaccine per the records in the New York State Immunization Information System (NYSIIS). The investigators will be testing the effectiveness and cost effectiveness of the various modalities or reminders as compared to the standard of care control (no reminders)
224076139|NCT06763484|DRUG|Paroxetine|20 mg PO daily
224076140|NCT06763484|DIETARY_SUPPLEMENT|Placebo|1 capsule starch
223856401|NCT05585775|BEHAVIORAL|Wellness for Wellbeing|Wellness for Wellbeing will serve as the active control for MBCT. Participants randomized to Wellness for Wellbeing will receive 1-hour group delivered classes, once per week, for 8-weeks. Participants will receive an orientation to Wellness for Wellbeing 1-2 weeks prior to the first class. Classes will be delivered by a research therapist. Topics for Wellness for Wellbeing include: nutrition, caffeine, preventing cancer, diabetes, heart health, sleep, being a smart patient, and complementary and alternative medicine. Wellness for Wellbeing classes are interactive and do not include components designed to impact affective cognition in any way. Because participants may have varying levels of health literacy, the research therapist tailors presentation of the material to the participants' level of knowledge of the topic. Information presented in Wellness for Wellbeing is regularly updated with current health guidelines.
223856402|NCT00683735|DRUG|Sitagliptin|100 mg once daily in the morning
223856403|NCT00683735|DRUG|Metformin|up to 2000 mg/day
223856404|NCT00683735|DRUG|Placebo|500mg 1-0-0-0
223856405|NCT00683735|DRUG|Placebo|100mg 1-0-0-0
223856406|NCT01545674|PROCEDURE|Blood Draw|Blood will be drawn from the mother and father
223856407|NCT04791124|OTHER|Electroencephalography|"EEG evaluation Composed by three consecutive tests~1. Resting state EEG, with either eyes open or closed~2. Auditory steady-state response (ASSR)~3. Auditory evoked potential"
223856408|NCT01228513|DRUG|ZK245186|Daily topical application
223856409|NCT01228513|DRUG|Placebo (vehicle without active ingredient)|Daily topical application
223856410|NCT00501020|DRUG|Rosiglitazone|
223856411|NCT04188028|DRUG|Dextromethorphan 5 MG|dextromethorphan 5 mg po
223856412|NCT04188028|DRUG|Paroxetine 10Mg Tablet|Paroxetine 10 mg po
223856413|NCT04188028|DRUG|Paroxetine 20Mg Tablet|Paroxetine 20 mg po
223856414|NCT05425836|DEVICE|Standard oxygen therapy|nasal cannula
223856415|NCT05425836|DEVICE|HFNC|High flow nasal cannula
223856416|NCT06409195|DRUG|SM-020 1% Gel|SM-020 gel 1.0% will be applied topically. Subjects will be treated with twice daily application to at least 1 and up to 5 Target Lesions (TLs) for 28 days.
223856417|NCT04303182|PROCEDURE|Standard 3 port TEP|3 port TEP inguinal hernia repair with 10mm. port under the umbilicus and two 5mm. port in line under the 10mm. port
223856418|NCT04303182|PROCEDURE|LESS TEP|TEP inguinal hernia repair with one vertical skin incision under the umbilicus
223856419|NCT05042271|DRUG|meropenem|each patient received a 1 hour infusion of a single dose of 1 g of meropenem diluted in 100 ml of normal saline solution, at the same time as the start of the first TPE and meropenem PK studies were carried out after the administration of meropenem. Blood samples (3 ml) were obtained by direct venipuncture at the following times: shortly before (time zero) and 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6 and 8 hours after the start of the meropenem administration.
223856420|NCT04461756|DRUG|PPP001|inhalation (vape)
223856421|NCT01512966|BIOLOGICAL|VEGF Trap-Eye (BAY86-5321)|Subjects in the VEGF Trap-Eye group will receive intravitreal injections every 8 weeks following a loading phase with injections given every 4 weeks. The overall treatment period is 48 weeks.
223856422|NCT01532232|DRUG|placebo|Pts will receive the standard 12-week dosing regimen consisting of 1 mg po of study drug twice daily for 11 weeks,along with smoking cessation counseling, for 11 weeks with an initial dose titration to full strength during the 1st week as follows: 0.5 mg po once daily for 3 days titrated to 0.5mg po twice daily for 4 days. 154 pills will be supplied for the 12 week tx. In order to compensate for any accidentally dropped or lost pills during the study duration, a total of 175 pills will be given to the patient. Along with smoking cessation counseling, for 11 weeks. Pts will receive their medication from the MSK Pharmacy \& equivalent dosing \& side effect education from our Tobacco Cessation Nurse Practitioner. Tx with the study drug will begin after the initial counseling session. Physicians \& tobacco cessation nurses will be blinded regarding pts' assignment to medication or placebo tx arm. Likewise, pts will not be informed as to which medication condition they have been assigned.
223856423|NCT01532232|DRUG|varenicline|Pts will receive the standard 12-week dosing regimen consisting of 1 mg po of study drug twice daily for 11 weeks,along with smoking cessation counseling, for 11 weeks with an initial dose titration to full strength during the 1st week as follows: 0.5 mg po once daily for 3 days titrated to 0.5mg po twice daily for 4 days. 154 pills will be supplied for the 12 week tx. In order to compensate for any accidentally dropped or lost pills during the study duration, a total of 175 pills will be given to the patient. Along with smoking cessation counseling, for 11 weeks. Pts will receive their medication from the MSK Pharmacy \& equivalent dosing \& side effect education from our Tobacco Cessation Nurse Practitioner. Tx with the study drug will begin after the initial counseling session. Physicians \& tobacco cessation nurses will be blinded regarding pts' assignment to medication or placebo tx arm. Likewise, pts will not be informed as to which medication condition they have been assigned.
223856424|NCT02501772|DEVICE|acupressure by ankle band|
223856425|NCT01712594|DEVICE|Closed Loop Procedure (Medtronic)|The procedure A is the device running under normal conditions, procedure B will incorporate an induced calibration error.
223856426|NCT03143192|COMBINATION_PRODUCT|Micropulse Laser|Aflibercept injection with Micropulse laser.
223856427|NCT03143192|DEVICE|Sham Laser|Aflibercept injection with Sham Laser
223856428|NCT05649098|DRUG|Dupilumab|The treatment period will include a 16-week open-label phase and a 20-month long-term extension phase for those who qualify and wish to continue.
223856429|NCT00143650|BEHAVIORAL|House dust|
223856430|NCT00207532|DRUG|folic acid|
223856431|NCT04729296|DRUG|Golimumab|For participants ≥45 kg, 50 mg of golimumab will be administered subcutaneously For participants \<45 kg, the dose of golimumab is 30 mg/m2 to maximum of 50 mg
223856432|NCT04729296|DRUG|Placebo|Inactive Drug
223856433|NCT03028363|DRUG|Olumacostat Glasaretil Gel, 5.0%|Gel containing Olumacostat Glasaretil
223856434|NCT03028363|OTHER|Olumacostat Glasaretil Gel, Vehicle|Vehicle (placebo) gel
223856435|NCT05506098|OTHER|no intervention|no intervention
223856436|NCT00604721|DRUG|selumetinib|Given orally
223856437|NCT00604721|OTHER|pharmacological study|
223856438|NCT04288193|DRUG|Recommendation to Deprescribe|Recommendation to Deprescribe
223856439|NCT04217785|DRUG|Optive, Ophthalmic Solution|6 drops per day, for 8 weeks
223856440|NCT04217785|BIOLOGICAL|Umbilical Cord Serum eye drops|UCS eye drops (6 drops per day, for 8 weeks)
223856441|NCT04217785|DRUG|Genteal lubricant gel|Genteal lubricant gel (2 drops per day, for 8 weeks)
223856442|NCT00556543|DEVICE|U-plate fracture repair system|All subjects meeting inclusion criteria will undergo surgery for the repair of their fractured rib/s using the U-plate device. Subjects will be monitored daily during the entire course of their hospitalization for adverse experiences. Subjects will be contacted by phone to complete the MPQ and SF-36 Health Survey. Subjects will be asked if and when they have returned to work or to their previous level of functioning. Subjects will be asked if they had any complications or problems associated with their surgery.
223856443|NCT03770624|DRUG|QL-007 tablet|QL-007 will be administered orally daily over the 28 days under fasted state.
223856444|NCT03770624|DRUG|TDF|TDF will be administered orally daily over the 28 days e.
223856445|NCT06081855|DIAGNOSTIC_TEST|CT|Measuring aortic root diameter by CT
223856446|NCT03717987|DRUG|Botulinum toxin type A|"Botulinum toxin type A will be injected in all patients at both sides into the Yonsei point, (3Units) the point that would target 3 muscles responsible for upper lip elevation during smiling, including the LLSAN, in a single injection. This landmark was identified as the center of a triangle formed by the convergence of the LLSAN, the LLS, and the Zminor muscles and is located 1 cm lateral to the ala horizontally and 3 cm above the lip line vertically in both men and women (Hwang et al. 2009) and (Nasr et al. 2015)."
223856447|NCT03717987|DIETARY_SUPPLEMENT|Zinc supplementation|zinc supplementation will be given to patients in the intervention arm 4 days prior to Botulinum toxin type A injection
223856448|NCT05052411|OTHER|App usage assessments and analytics|All participants will be given a brief overview of the purpose of the study followed by a survey on participant characteristics and barriers to accessing HIV testing and PrEP uptake and P/SUD support services. The participant will be observed downloading the JomPrEP app and instructed with a brief tutorial on the onboarding process. The participant will be told to keep the app for 1 month and encouraged to use all app components. At 30 days, the participant will complete a post-survey, to which the Systems Usability Scale will be added. App analytics will also be collected (e.g., the number of logins). Participants will be asked to provide feedback on functionality, performance, and errors encountered, motivation to use the app, overall experiences using the app, feedback for further refinement, and subjective impact of the app on HIV prevention.
223856449|NCT00124826|DRUG|Insulin|
223856450|NCT00508690|DRUG|cefmetazole|Intravenous dose of 1g cefmetazole just before surgery and additional doses every 3hs during surgery
223856451|NCT00508690|DRUG|kanamycin/metronidazole|2 doses of oral kanamycin(1g)/ metronidazole(750mg) administration on the day before surgery with intravenous dose of 1g cefmetazole just before surgery and additional doses every 3hs during surgery
223856452|NCT01930279|OTHER|Blood withdrawal|Blood withdrawal
223856453|NCT04266561|OTHER|hernia repair|Two 3-mm needle holders were used for stitching the wide IIR. Then the suture was continued along the upper margin of IIR, but in a deeper plane to include the peritoneum and the deeper fascia transversalis.
223856454|NCT03515720|PROCEDURE|Prolotherapy|It consists of injecting 5% dextrose in sterile aqueous solution without the use of lidocaine in a subcutaneous nerve to inhibit neurogenic inflammation and the release of substance P and CGRP, decreasing neurogenic inflammation.
223856455|NCT04173962|DRUG|Ketamine|administered 1 week prior to a laboratory-induced stress
223856456|NCT04173962|DRUG|Midazolam|administered 1 week prior to a laboratory-induced stress
223856457|NCT03553446|DRUG|children receiving sevoflurane|Children receiving pre-determined sevoflurane concentration using modified Dixon's up-and-down method
223856458|NCT05541237|DIETARY_SUPPLEMENT|Food|Food
223856459|NCT02350595|OTHER|Lean fish|
223856460|NCT02350595|OTHER|Fatty fish|
223856461|NCT05236543|DRUG|AZD4831|Subjects will receive single oral dose only on Day 1 and Day 11.
223856462|NCT05236543|DRUG|Itraconazole|Subjects will receive Itraconazole orally on Days 8 followed by dosing from Day 9 to Day 17.
223856463|NCT00000106|DEVICE|Whole body hyperthermia unit|
223856464|NCT00006391|DRUG|oxaliplatin|
223856465|NCT00006391|DRUG|topotecan hydrochloride|
223856466|NCT00345202|DRUG|HMG-CoA reductase inhibition (atorvastatin)|
223856467|NCT03425162|DRUG|Morphine Sulfate|patient-controlled analgesia (PCA) morphine
223856468|NCT03425162|PROCEDURE|Group P|Group P:patient-controlled analgesia (PCA) morphine
223856469|NCT03425162|PROCEDURE|Group A|Group A:Ultrasound guided unilateral anterior Quadratus Lumborum block with 20 ml %0.25 Bupivacaine
223856470|NCT06413303|BEHAVIORAL|Experiential Classroom|Experiential classroom emphasizes putting pregnant women at the center, based on their subjective willingness and previous knowledge and experience, creating an environment for free discussion, exchange, and reflection, and utilizing peer education to fully mobilize the subjective initiative of pregnant women. This approach allows them to explore, discuss, reflect, and learn autonomously, aiming to truly absorb, master, and apply theoretical knowledge.
223856471|NCT02837237|DRUG|KBP-5074|"In Part 1 of the study, non-HD patients with severe CKD in Cohort 1 will receive a single oral capsule dose of KBP-5074 on Day 1 following a fast between 2 and 4 hours.~In Part 2 of the study, HD patients with severe CKD will receive a single oral capsule dose of KBP-5074 following a fast between 2 and 4 hours. The dose of KBP 5074 will be administered on Day 1 immediately following a dialysis session."
223856472|NCT04994743|DRUG|CORT113176|CORT113176 lipid capsule formulation for oral administration
223856473|NCT04994743|DRUG|Placebo matching CORT113176|Placebo matching CORT113176 lipid capsule formulation for oral administration
223856474|NCT04181931|PROCEDURE|neo-TACE-HAIC+Surgery|transartery chemoembolization with lipiodol and EADM, FOLFOX (Oxa 85mg/m2 2h+CF 400mg/m2 2h+5FU 400mg/m2 10min+5FU 1200mg/m2 23h)-based artery infusion chemotherapy, followed by hepatic resection
223856475|NCT04181931|PROCEDURE|Surgery alone|hepatic resection remove the liver tumor and portal vein tumor thrombus
223856476|NCT03100162|DIETARY_SUPPLEMENT|Probiotic|
223856477|NCT03100162|DIETARY_SUPPLEMENT|Placebo|
223856478|NCT03332134|BEHAVIORAL|Intimate Partner Violence (IPV) Prevention Intervention|The IPV intervention consists of six sessions. Each session will cover one of 6 major modules to enhance transformation of motivation: 1) You, Me, and Us: Spending Meaningful Time Together, 2) I'm a Champion: I Can't Be Broken and I don't Accept Defeat! 3) Building Communication and conflict management strategies, and 4) Empowerment of the Couple: Planning Ahead, 5) Sexual communication and the sexual relationships, and 6) A Lens into Domestic Violence. The sessions will be audio-recorded and include a combination of didactics, interactive discussions, media use, and role play. The expected durations of session 1, 2-6, and the 3-month follow-up are 120 minutes, and 60-90 minutes, respectively.
223856479|NCT00436137|BEHAVIORAL|Patient mailing|Patient will receive a mailing recommending colonoscopy, followed by telephone outreach
223856480|NCT00006204|DRUG|naltrexone (Revia)|
223856481|NCT00006204|DRUG|fluoxetine (Prozac)|
223856482|NCT02575391|DIETARY_SUPPLEMENT|Whole Food Intervention|A combination of honey, glutamine, probiotics, and butter was administered to participants undergoing cancer.
223856483|NCT01144182|BEHAVIORAL|Comprehensive quality improvement program (QIP)|Comprehensive quality improvement program (QIP) that intervenes on patient, provider and system levels. The QIP will consist of 3 monthly phone calls to promote diet and medication adherence using the transtheoretical model as a behavioral framework and checklists to facilitate patients' self-monitoring of their diet, physical activity, weight and medication taking. Further, providers during the posttest phase will use checklists for inpatient and outpatient care of HF patients.
223856484|NCT04274751|DEVICE|Transcatheter aortic valve implantation|Transcatheter aortic valve implantation
223856485|NCT03842150|DIAGNOSTIC_TEST|biliary atresia screen score|The investigators aim to develop a scoring system according to clinical, laboratory, imaging features of biliary atresia in the derivation dataset and tested in the validation datasets.
223856486|NCT02759029|DRUG|eradication of Helicobacter pylori|"clarithromycin-based triple therapy Pantoloc 40mg, PO, BID, 1wk Amoxacillin 1g, PO, BID, 1wk Clarithromycin 500mg, PO, BID, 1wk~* concomitant therapy group Pantoloc 40mg, PO, BID, 1wk Amoxacillin 1g, PO, BID, 1wk Clarithromycin 500mg, PO, BID, 1wk Metronidazole 500mg, PO, BID, 1wk~* bismuth based quadraple therapy Pantoloc 40mg, PO, BID, 1wk Bismuth, 300mg, PO, QID, 1wk Tetracycline, 500mg, PO, QID, 1wk Metronidazole, 500mg, PO, TID, 1wk~* levofloxacine based triple therapy Pantoloc 40mg, PO, BID, 1wk Amoxacillin 1g, PO, BID, 1wk Levofloxacin 500mg, PO, QD, 1wk"
223856487|NCT00822913|DRUG|Intravesical injection of Botulinum A toxin|One treatment, 200 U vials diluted in 20 ml normal saline
223856488|NCT03165149|DRUG|group (A)|patients will receive 1mg / kg of Ketamine diluted by 20 ml saline (0.9 % ) and irrigated onto surgical field after hemostats and before skin closure.
223856489|NCT03165149|DRUG|group (B)|patients will receive 2 mg /kg of Ketamine diluted by 20 ml saline (0.9 %) and irrigated onto surgical field after hemostasis and before skin closure.
223856490|NCT03165149|DRUG|group (c)|patients will receive 3 mg /kg of Ketamine diluted by 20 ml saline (0.9 %) and irrigated onto surgical field after hemostasis and before skin closure.
223856491|NCT02317016|PROCEDURE|Pharmacokinetic sampling - AZD9291|Blood sampling to measure AZD9291
223856492|NCT02317016|DRUG|AZD9291 tablet dosing|Part A: AZD9291 80mg tablet taken from Days 4 to 35. Part B: AZD9291 80mg tablet taken daily for 12 months.
223856493|NCT02317016|DRUG|Rosuvastatin|Rosuvastatin (BCRP substrate) 20mg taken once daily on Days 1 and 32 (Part A) .
223856494|NCT02317016|PROCEDURE|Pharmacokinetic sampling - rosuvastatin|Blood sampling to measure rosuvastatin levels
223856495|NCT02317016|PROCEDURE|Pharmacokinetic sampling - AZ5140 and AZ7550|Blood samples to measure levels of AZ5140 and AZ7550
223856496|NCT00536380|DRUG|5-mg Desloratadine|5-mg desloratadine tablets, once daily for four weeks.
223856497|NCT00536380|DRUG|10-mg Desloratadine|10-mg desloratadine tablets, once daily for four weeks.
223856498|NCT00536380|DRUG|20-mg Desloratadine|20-mg desloratadine tablets, once daily for four weeks.
223856499|NCT00778804|BEHAVIORAL|telemedicine|Weekly transmission of health status (weight, activity, BP etc.) via the Internet with feeedback and reinforcement
223856500|NCT01670110|DRUG|Pasireotide LAR|Injectible, 60mg per month
223856501|NCT01670110|DRUG|Placebo|To be injected once per month
223856502|NCT06523855|PROCEDURE|bilateral alveolar cleft grafting using iliac crest particulate and microplate fixation|bilateral alveolar cleft grafting using particulate iliac crest graft accompanied with fixation of graft and premaxilla using microplate
223856503|NCT05708066|OTHER|Lavender Aromatherapy|"Participants will have the Bioesse lavender patch placed on the chest, according to manufacturer recommendations.~After the lavender patch has been in place for 5 minutes, the same VAS anxiety questionnaire will be provided"
223856504|NCT05708066|OTHER|Non-scented Tab|A non-scented tab will be placed on the participant's chest, according to manufacturer recommendations. Participants in this group will only receive the initial VAS anxiety questionnaire.
223856505|NCT04884737|OTHER|Mepilex Border Flex® (MBF) dressing|A new dressing technology (Mepilex Border Flex® (MBF)) provides increased conformability of the dressing to the skin with the ability of the dressing to move in all directions (e.g., 360-degree flexibility) with even slight body movements. Limited data exists on use of silicone foam dressings with all direction flexibility during prone surgical procedures.
223856506|NCT02633189|DRUG|Erlotinib|given orally 150 mg daily
223856507|NCT02633189|DRUG|Bevacizumab|15 mg/kg intravenously every 21 days.
223856508|NCT01768676|DRUG|avanafil|100 mg
223856509|NCT01768676|DRUG|Placebo|
223856510|NCT00770978|DRUG|ceftobiprole q12h|Ceftobiprole, 1G q12h as 4 hour infusions, on Day 1 and Ceftobiprole, 1G as single 4 hour infusion on Day 2
223856511|NCT00770978|DRUG|ceftobiprole q8h|Ceftobiprole, 1G q8h as 4 hour infusions, on Day 1 and Ceftobiprole, 1G as single 4 hour infusion on Day 2
223856512|NCT04066738|DIAGNOSTIC_TEST|Cardiac MRI with gadolinium contrast|Imaging of left ventricular scar and coronary sinus venous system
223856513|NCT04066738|DIAGNOSTIC_TEST|3D reconstruction and location of coronary sinus venous system relative to myocardial scar|Three dimensional mapping of coronary sinus venous system with Abbott Precision mapping system and Biotronik Vision wire Merge with MRI images of CS and myocardial scar
223856514|NCT04066738|DIAGNOSTIC_TEST|Acute haemodynamic measurements during CRT implant|Advancement of pressure wire to LV cavity via femoral/radial arterial access. Real time measurement of LV-dP/dTmax during conventional CRT and MPP after consecutive placement of LV lead in two different CS branches (peri-infarct region and remote myocardium)
223856515|NCT01396291|DRUG|asenapine|asenapine, sublingual tablets, 5 to 10 mg twice per day (BID)
223856516|NCT01396291|DRUG|placebo|asenapine-matched placebo, sublingual tablets, BID
223856517|NCT03395353|DRUG|Duloxetine Hydrochloride|Administered orally
223856518|NCT00195078|DRUG|ZD1839 (IRESSA)|
223856519|NCT00195078|DRUG|Cisplatin|
223856520|NCT00195078|PROCEDURE|Radiation Therapy|
223856521|NCT01196429|DRUG|Carboplatin|Given IV
223856522|NCT01196429|DRUG|Docetaxel|Given IV
223856523|NCT01196429|OTHER|Laboratory Biomarker Analysis|Correlative studies
223856524|NCT01196429|DRUG|Paclitaxel|Given IV
223856525|NCT01196429|DRUG|Temsirolimus|Given IV
223856526|NCT01260298|DEVICE|MC1 Ultrasonic Device|Ultrasonic and zonal massage device.
223856527|NCT02486588|OTHER|Messaging|See detailed study description for overview of the different messaging interventions in this study
223856528|NCT02486588|OTHER|Financial incentives|See detailed study description for overview of the different financial incentive-based interventions in this study
223856529|NCT04218669|PROCEDURE|Roux-en-Y Hepaticojejunostomy|The common hepatic duct was cut and the duodenal side is closed by suture. The small intestine was cut off 15 cm below the ligament of Treitz. The distal end was lifted, and a 1-2 cm incision was made at the jejunal wall 4-5 cm from the jejunal stump. The anastomosis is used a 5-0 PSD Ⅱ suture, with double needles, inside-out in the jejunum and outside-in in the hepatic duct. One side of needles was used to continuely penetrate and suture the whole layer of the posterior-lateral wall of the jejunum, the posterior-lateral wall of the biliary duct, and the other side of needles was used to continuely stuere the anterior part of the anastomosis. Mucosa-to-mucosa contact should be ensured with every stitch.The anastomotic stomas were then checked for leakage. Enteric-enteric anastomosis was performed 60 cm below the site of the hepatojejunal anastomosis.
223856530|NCT04218669|PROCEDURE|T-tube drainage|The T-tube was placed for biliary drainage and the common bile duct was intermittently sutured with 4-0 vicryl sutures.
223856531|NCT00111020|DRUG|Sorafenib (Nexavar, BAY43-9006)|Multi kinase inhibitor: 400 mg of Sorafenib, orally, twice a day, on a continuous basis as a single agent for the treatment of advanced RCC
223856532|NCT02589210|OTHER|EpiFix Mesh|Weekly application of EpiFix Mesh and standard of care (moist wound therapy and offloading)
223856533|NCT04167891|DIAGNOSTIC_TEST|Calculation of early prognosis score|Early prognosis score will be calculated at intensive care unit admission for each patient based on clinical and biological values as required
223856534|NCT04248829|DRUG|Lazertinib 240 mg/160 mg|The initial dose of lazertinib 240 mg (3 tablets of 80 mg lazertinib) once daily can be reduced to 160 mg once daily (2 tablets of 80 mg lazertinib) under specific circumstances
223856535|NCT04248829|DRUG|Gefitinib 250 mg|The initial dose for Gefitinib (250 mg once daily) cannot be reduced to a lower dose
223856536|NCT04248829|DRUG|Lazertinib-matching placebo 240 mg/160 mg|The initial dose of lazertinib-matching placebo 240 mg (3 tablets of 80 mg lazertinib-matching placebo) once daily can be reduced to 160 mg once daily (2 tablets of 80 mg lazertinib-matching placebo) under specific circumstances
223856537|NCT04248829|DRUG|Gefitinib-matching placebo 250 mg|The initial dose for Gefitinib-matching placebo (250 mg once daily) cannot be reduced to a lower dose
223856538|NCT05799560|OTHER|THERAPEUTIC TOUCH|Therapeutic touch will be done. It will be applied twice a week for two weeks, each application for 20 minutes.
223856539|NCT05799560|OTHER|REİKİ|It will be applied twice a week for two weeks, each application for 20 minutes.
223856540|NCT00776711|DRUG|Monovalent Influenza Subunit Virion (H5N1) Vaccine, A/Indonesia/05/2005|
223856541|NCT00776711|DRUG|VRC-AViDNA036-00-VP|
223856542|NCT02132702|DEVICE|Ekso|
223856543|NCT04375644|OTHER|Questionnaires on psychological quality of life|Assessement of evolution of the psychological quality of life of health professionals during the confinement period linked to the COVID-19 pandemic by two questionnaires (one during the confinement period and the second one month after the end of the confinement period)
223856544|NCT01477619|DRUG|Tasimelteon|20mg single dose on Day 1
223856545|NCT06652763|OTHER|Minnesota Living with Heart Failure Questionnaire|Self-administered, validated questionnaire to assess symptoms of heart failure
223856546|NCT06652763|DIAGNOSTIC_TEST|Echocardiogram|Resting transthoracic echocardiogram to exclude valvular pathology and the assess indices of systolic and diastolic function and speckle tracking for strain
223856547|NCT06652763|DIAGNOSTIC_TEST|Six-minute walk test|Standardised, objective assessment of exercise capacity
223856548|NCT06652763|DIAGNOSTIC_TEST|Manganese-enhanced MRI and 31-P magnetic resonance spectroscopy|Using a 3-Tesla scanner, 31P magnetic resonance spectroscopy will be performed to obtain information regarding cardiac energetics. An intravenous infusion of manganese dipyridoxyl diphosphate (mangafodipir, MnDPDP) will be commenced at a rate of 1mL/min using a dose of 5µmol/kg (0.1mL/kg).
223856549|NCT06652763|DIAGNOSTIC_TEST|Cardiovascular magnetic resonance scan|Scan including adenosine stress perfusion
223856550|NCT06652763|DIAGNOSTIC_TEST|Blood tests|Full blood count, Urea and electrolytes, Liver function tests, Glucose and HbA1c, Insulin and C-peptide, NTproBNP, High sensitive troponin I, storage of plasma for future analyses
223856551|NCT06374056|DEVICE|Kintsugi Voice Device|"The Kintsugi Voice Device is intended to be used to screen for the presence of voice signals consistent with a current moderate to severe depressive episode in patients aged 22 and older. The device is intended to be used by care providers licensed to screen for depression and in settings where the screening for depression occurs. The device is neither to be used in lieu of a complete patient evaluation nor to supplant any of the clinician's standard assessments for the screening or diagnosis of depression.~The Kintsugi Voice Device is comprised of a software API and machine learning model that utilizes recorded voice samples as inputs and outputs the detection of signals consistent with current moderate to severe depressive episode as outputs."
223856552|NCT03932617|DEVICE|end tidal carbon dioxide by capnography|"Moreover, since PETCO2 is mainly determined by tissue CO2 production (VCO2), alveolar ventilation and CO, when stable metabolic conditions are assumed and minute ventilation is kept constant, acute changes in PETCO2 have been shown to correlate strongly with changes in CO.~Thus, PETCO2 has been suggested as a simple economic and noninvasive alternative for continuous assessment of CO in different shock states."
223856553|NCT06214221|DEVICE|Signos System|The intervention involves the use of the Signos System, a combination of a proprietary software application with a continuous glucose monitor (CGM), to manage weight in overweight and obese adults.
223856554|NCT06214221|OTHER|Standard Lifestyle Education|"In the Standard Lifestyle Education arm, participants receive conventional advice on diet and exercise, focusing on general healthy lifestyle habits to manage weight."
223856555|NCT04774224|DRUG|Baricitinib|Participants will take one tablet of study drug per day for 48 weeks, and will be followed up for 48 weeks after study drug treatment has finished. Two-thirds of participants will receive Baricitinib.
223856556|NCT04774224|DRUG|Placebo|Participants will take one tablet of study drug per day for 48 weeks, and will be followed up for 48 weeks after study drug treatment has finished. One-third of participants will receive Placebo.
223856557|NCT06614010|DRUG|Dexmedetomidine Injection|Before anesthesia induction, an iliac fascia block was administered using 0.375% ropivacaine (30 mL) under ultrasound guidance, followed by conventional anesthesia induction. During the anesthesia maintenance phase, dexmedetomidine was infused intravenously at a rate of 0.5 µg/kg/h.
223856558|NCT06614010|DRUG|Ropivacaine and Dexmedetomidine|Before anesthesia induction, an iliac fascia block was administered using a mixture of 0.375% ropivacaine and 1ug/kg dexmedetomidine (30ml) under ultrasound guidance. During the anesthesia maintenance phase, an equivalent volume of 0.9% sodium chloride injection was infused intravenously.
223856559|NCT06614010|DRUG|Sodium Chloride Injection|Before anesthesia induction, an iliac fascia block was performed using 0.375% ropivacaine (30 mL) under ultrasound guidance, followed by conventional anesthesia induction. During the anesthesia maintenance phase, an equivalent volume of 0.9% sodium chloride injection was infused intravenously.
223856560|NCT06485596|DEVICE|XVIVO Heart Assist Transport System|Direct procurement of donor hearts from DCD donation
223856561|NCT06598852|OTHER|TPVB group|Patients undergoing thoracoscopic surgery underwent general anesthesia and patients in TPVB Group received thoracic paravertebral nerve block with 0.33% ropivacaine 30ml under ultrasound guidance after anesthesia induction for postoperative analgesia.
223856562|NCT06598852|OTHER|ESPB group|Patients undergoing thoracoscopic surgery underwent general anesthesia and patients in ESPB Group received erector spinae muscle block with 0.33% ropivacaine 30ml under ultrasound guidance after anesthesia induction for postoperative analgesia.
223856563|NCT06598852|OTHER|TPVB combined ESPB group|Patients undergoing thoracoscopic surgery underwent general anesthesia and patients in TPVB combined ESPB group received thoracic paravertebral block combined with erector spinae muscle block with 0.33% ropivacaine 30ml under ultrasound guidance after anesthesia induction for postoperative analgesia.
223856564|NCT06598852|OTHER|ICNB group|Patients undergoing thoracoscopic surgery underwent general anesthesia and patients in ICNB Group received intercostal nerve block for postoperative analgesia.
223856565|NCT05565521|RADIATION|Dose escalation + Reduced Margin Adaptive Radiotherapy|Concurrent chemoradiation with temozolomide (TMZ) over 3 weeks (40 Gy in 15 fractions). The gross tumor volume (GTV) plus margin will be boosted simultaneously (SIB) to 52.5 Gy in 15 fractions. Radiation will be delivered on the MR-Linac with a reduced clinical target volume (CTV) margin of minimum 5 mm and a weekly online adaptive approach.
223856566|NCT06696898|PROCEDURE|Somatosensory Motor Control Exercises|The Somatosensory motor control training protocol assembled into three components, 1) PNF exercises (Each patient alternately contracted trunk extensors and flexors isometrically for 10 seconds against maximum resistance while seated, then contracted trunk agonists alternately in a concentric and eccentric manner against manual resistance without relaxing, then moved his or her trunk in a twisting and diagonal orientation against maximum resistance), 2) Somatosensory exercises in which a wobbling board was used and six types of exercises were performed including hallowing, one lower limb elevation, opposite upper and lower limb elevation from a four-limb supported position (quadruped), abdominal reinforcement, maintaining a bridging posture, and one lower limb elevation from the bridging posture, and 3) finally Vestibular training which involved exercises to improve gaze focus, exercises for enhancing eye movements.
223856567|NCT06696898|PROCEDURE|Myofascial Release Technique|Manual therapy technique that applies sustained pressure to myofascial tissues around the lumbar spine and pelvis to release tension and improve mobility.Myofascial Release Technique MFR is given with the ulnar border from proximal to distal direction with a light gentle pressure over the hamstring muscle until the slack in the skin is loosened. (2) Every strike is to be held for 30 seconds, 5 repetitions per session
224076141|NCT05728866|PROCEDURE|VR immersive therapy|Participants will be asked to participate in 5 consecutive, 1-hour, 1:1 therapy sessions focused on rehabilitation of their weakened arm. Each session will involve use of a Virtual Reality (VR) system to deliver an immersive environment to encourage movement of the arm. The system also relies on 6 body-worn sensors that will detect movements of participant's arms and trunk. VR use will encompass 30-minutes of the therapy session, the remainder of the session will involve working with the therapist in addressing the functional tasks that are most meaningful for the participant and that involve the upper extremities.
224076142|NCT03225365|BIOLOGICAL|Blood and biopsy sampling|"Blood samples (52mL) will be taken at week 1, week 3, week 7, week 13, week 53 or at the progression.~Skin biopsies will be taken at week 1, week 7, week 53 or at the progression."
224076143|NCT05593029|DRUG|SEP-363856|Tablet
224076144|NCT05593029|OTHER|Placebo|Placebo
224076145|NCT06219174|DRUG|Pembrolizumab|200 mg IV Q3 weeks
224076146|NCT06219174|DRUG|Difluoromethylornithine|Dose Level -1: 4500 mg/m2 by mouth (PO) daily Dose Level 1: 6750 mg/m2 by mouth (PO) daily Dose Level 2: 9000 mg/m2 by mouth (PO) daily
224076147|NCT04392947|DEVICE|Transcranial Magnetic Stimulation|MagVenture Coil Cool B70 A/P
224076148|NCT04392947|DEVICE|Sham Transcranial Magnetic Stimulation|MagVenture Coil Cool B70 A/P without TMS being actively delivered
223856568|NCT06696898|PROCEDURE|Sensorymotor training|The Somatosensory motor control training protocol assembled into three components, 1) PNF exercises (Each patient alternately contracted trunk extensors and flexors isometrically for 10 seconds against maximum resistance while seated, then contracted trunk agonists alternately in a concentric and eccentric manner against manual resistance without relaxing, then moved his or her trunk in a twisting and diagonal orientation against maximum resistance), 2) Somatosensory exercises in which a wobbling board was used and six types of exercises were performed including hallowing, one lower limb elevation, opposite upper and lower limb elevation from a four-limb supported position (quadruped), abdominal reinforcement, maintaining a bridging posture, and one lower limb elevation from the bridging posture, and 3) finally Vestibular training which involved exercises to improve gaze focus, exercises for enhancing eye movements.
223856569|NCT06696911|PROCEDURE|Core stability Exercises|"The exercises have been divided into three difficulty categories based on the level of difficulty.~Level I: When the patients were unable to sit independently, level I core stability therapy was administered. First-level exercises were done in a supine position on a plinth. The workout program mostly included side bridging movements, leg crosses, one-leg curl-ups, and straight and diagonal reaching activities. Patients can move to level once they can sit on a plinth edge unsupported for one minute while flexing their knees and hips to 90 degrees.~Level II: Exercises included straight-arm curl-ups, diagonal-arm curl-ups, and arm curl-ups with the arms crossed. The patient will go to stage three once they can sit on an unstable surface for thirty seconds.~Level III: Using a physio ball, the exercises were done while seated. The exercises performed with the ball consisted push-ups, bird dog, side Bridge, abdominal curl-ups, and bridge movements"
223856570|NCT06696911|PROCEDURE|Motor Imagery|"The motor imagery program will be performed in three steps. STEP 1 Subjects will be instructed to watch the video provided and recorded by investigator. Two types of videos will be available to watch. One recording normal movements and the other film will contain recording the patient movements. Patient will be asked to watch the video and analyze the differences.~STEP 2 In next step participants will be asked to close the eyes to focus and then to imagine how they are doing task they had previously observed 10 times.~STEP 3 Participants will be than instructed to carry out the task in verbal commands given whenever necessary. During the recall process components of movement deviating from normal will be emphasized. The difficulty level of activities and the analysis of movement components will be increased gradually according to the patient's capacity."
223856571|NCT06711497|OTHER|global postural reeducation exercises|Subjects will be trained on global postural reeducation exercises (GPR) and active neck exercises. At each session, they will maintain two different lying postures to stretch anterior and posterior muscle chain and one standing posture to integrate the postural correction into activity of daily living (ADL.Initially, without gravity load, a lying posture was applied to the anterior muscle chain for approximately 15 min, then another lying posture to the posterior muscle chain for other 15 min, and finally the patients worked in a standing posture for postural integration under a gravity load for 5 min.
224076149|NCT04292847|OTHER|Referrals Recommendations|All participants will complete the geriatric assessment and receive Referral recommendations based on the assessment.
224076150|NCT00898222|DRUG|aspirin|81 mg orally daily for two weeks
224076151|NCT03735537|DRUG|Teriparatide Pen Injector|
224076152|NCT03735537|DRUG|Zoledronic Acid|Any brand or preparation may be used to deliver the required dose of 5mg
224076153|NCT00185393|BIOLOGICAL|Zevalin ([90]Y-ibritumomab tiuxetan, BAY86-5128)|treatment with 90 Yttrium-labeled anti CD 20 antibody
224076154|NCT00185393|OTHER|no treatment|no treatment
224076155|NCT02172157|DRUG|BI 1744 CL i.v.|
223856572|NCT06711497|OTHER|deep neck flexor activation exercise|"Subjects will be trained on deep neck flexor activation using pressure biofeedback and active neck exercises . The pressure sensor will be put under the neck and will be asked to de gentle nod as if saying yes so that the pressure sensor measures 2mmHg above baseline (20mmHg), then 4mmHg, followed by 6mmHg,8mmHg, and 10 mmHg without rests in between. the pressure sensor should read 30mmHg at the end of the movement sequence. Patient will hold each increment for 2 seconds, 10 seconds total after all 5 increments. Highest level achieved will be repeated with the correct form until a total of 10 reps with 10-second holds will be achieved in three series with 30 seconds of interval between the series plus active neck flexor exercise"
223856573|NCT06712173|DRUG|linperlisib and SHR2554|Linperlisib doses were preset at 40mg QD and 60mg QD, while SHR2554 doses were preset at 150mg BID, 200mg BID, and 300mg BID, forming six dose groups in total.
223856574|NCT06706505|BEHAVIORAL|Mindfulness-based art therapy|"MBAT combines art therapy and mindfulness to promote self-awareness and emotional well-being. It uses art to express thoughts and feelings, while cultivating mindfulness skills. MBAT addresses stress, anxiety, and emotional regulation. Grounded in research, it's an effective therapeutic approach.~The mindfulness-based art therapy sessions were designed based on the literature, drawing on the researches. By integrating art therapy techniques and mindfulness practices, the sessions were developed. Expert opinions were sought from specialists in the field to ensure the content validity of the sessions, and necessary adjustments were made accordingly. The MBAT application consists of five sessions in total. Each session has a specific theme and is designed to last 90-120 minutes."
224076156|NCT02172157|DRUG|BI 1744 CL oral|
224076157|NCT03459027|DIETARY_SUPPLEMENT|Super Beets|Nitrate rich beetroot powder (10g) acutely
224076158|NCT03459027|DIETARY_SUPPLEMENT|Beetroot powder|Nitrate devoid beetroot powder (10g) acutely
224076159|NCT06399497|OTHER|spinal manipulation|A high-velocity low-amplitude spinal manipulation at the L5 level will be performance by means of the lumbar roll technique, with the subject in right lateral decubitus.
223856575|NCT03354390|BIOLOGICAL|cell infusion|This is a phase 1 trial of HERV-E TCR transduced CD8+/CD34+ T cells in HLA-A\*11:01 positive patients with metastatic ccRCC. The study is planned based on a Phase 1 3+3 dose escalation design. The maximum tolerated dose (MTD) is defined as the highest dose at which 0 or 1 patient in six has experienced a dose limiting toxicity (DLT). Patients with evaluable advanced/metastatic ccRCC will be recruited in up to 4 dose levels.
223856576|NCT01066923|DRUG|Daily aspirin (ASA)|Two weeks 82 mg aspirin taken orally prior to exercise protocol
223856577|NCT01066923|OTHER|Active cooling|Active cooling to remediate heat stress following exercise by placing hands and forearms into cold water
223856578|NCT01066923|DRUG|Acute aspirin (ASA)|325 mg chewable aspirin administered immediately following exercise
223856579|NCT01066923|OTHER|Passive cooling|Removing protective garments for passive cooling following exercise
223856580|NCT01066923|DRUG|Daily placebo|Placebo comparator for daily aspirin therapy
223856581|NCT01066923|DRUG|Acute placebo|Placebo comparator for acute aspirin therapy
223856582|NCT06461624|BIOLOGICAL|anti-GPC3 CAR-T|All subjects were intravenous administrated with CBG166.
223856583|NCT01866969|OTHER|questionnaire administration|Ancillary studies
223856584|NCT01866969|PROCEDURE|quality-of-life assessment|Ancillary studies
223856585|NCT00121329|DRUG|Intrauterine lidocaine infusion 4%|
223856586|NCT04820621|DRUG|Runcaciguat (BAY1101042)|Given as 1 x 15 mg modified release \[MR\] tablet
223856587|NCT03286244|DRUG|CM082 plus paclitaxel|"CM082 treatment: A treatment cycle is defined as 28 days. Oral CM082 tablets was given once daily for 3 weeks followed by 1-week break with escalating dose (100 mg, 150 mg and 200mg).~Drug: Paclitaxel Paclitaxel 80 mg/m2 will be administrated by intravenous injection on days 1, 8, 15 of a 28-day cycle for no more than 6 cycles."
223856588|NCT01984086|DRUG|Salbutamol Sulphate 150mcg UD-DPI Blister(1.6% blend)|Salbutamol Sulphate 150mcg UD-DPI will be supplied as blister containing a small quantity of powder comprising of a blend of salbutamol sulphate (micronized) and excipients
223856589|NCT01984086|DRUG|Salbutamol Sulphate 200mcg UD-DPI Blister(1.6% blend)|Salbutamol Sulphate 200mcg UD-DPI will be supplied as blister containing a small quantity of powder comprising of a blend of salbutamol sulphate (micronized) and excipients
223856590|NCT01984086|DRUG|Salbutamol Sulphate 250mcg UD-DPI Blister(1.6% blend)|Salbutamol Sulphate 250mcg UD-DPI will be supplied as blister containing a small quantity of powder comprising of a blend of salbutamol sulphate (micronized) and excipients
223856591|NCT01984086|DRUG|Salbutamol Sulphate 200mcg UD-DPI Blister(1% blend)|Salbutamol Sulphate 200mcg UD-DPI will be supplied as blister containing a small quantity of powder comprising of a blend of salbutamol sulphate (micronized) and excipients
223856592|NCT01984086|DRUG|Salbutamol Diskus 200mcg Blister|Salbutamol Diskus 200mcg will be supplied as blister strip contained within the Diskus device. Each blister contains a small quantity of powder comprising of a blend of salbutamol sulphate (micronized) and excipients
223856593|NCT01984086|DRUG|Salbutamol MDI 100mcg|Salbutamol MDI 100mcg will be supplied as formulation of salbutamol sulphate (micronized) in propellant contained within the pressurised MDI device
223856594|NCT01984086|DRUG|Salbutamol Sulphate UD-DPI Blister (selected from Part A)|Formulation will be determined depending on the outcome of Part A.
223856595|NCT01984086|DRUG|Salbutamol Sulphate 250mcg UD-DPI Blister (selected from Part A)|Formulation will be determined depending on the outcome of Part A.
223856596|NCT01984086|DRUG|Salbutamol Diskus 200mcg Blister without activated charcoal|Formulation will be determined depending on the outcome of Part A.
223856597|NCT01984086|DRUG|Salbutamol Diskus 200mcg Blister with activated charcoal|Formulation will be determined depending on the outcome of Part A.
223856598|NCT01984086|DRUG|Salbutamol MDI 100mcg without activated charcoal|Formulation will be determined depending on the outcome of Part A.
223856599|NCT01984086|DRUG|Salbutamol MDI 100mcg with activated charcoal|Formulation will be determined depending on the outcome of Part A.
223856600|NCT05178225|DIETARY_SUPPLEMENT|ubiquinol (reduced coenzyme Q10)|supplementation with ubiquinol (reduced coenzyme Q10), in a daily dose of 2x100 mg. one morning after breakfast, and second dose after dinner.
223856601|NCT05178225|OTHER|mountain spa rehabilitation|special spa rehabilitation in the mountain High Tatras; Functional capacity of the lungs (6MWT) at before and after 16-18 days of rehabilitation, Borg scale for dyspnea and oxygen saturation SpO2 (%) were monitored.
223856602|NCT05178225|DIAGNOSTIC_TEST|2x14 ml of peripheral blood collected in a tube with anticoagulant|2x14 ml of peripheral blood collected in a tube with anticoagulant
223856603|NCT00846326|DRUG|oxymetazoline-fluticasone propionate|Oxymetazoline 0.05% w/v Fluticasone propionate 0.05% w/w 2 squirts in each nostril twice daily
223856604|NCT00846326|DRUG|Oxymetazoline|oxymetazoline 0.05% w/v and placebo nasal spray 2 squirts in each nostril twice daily
223856605|NCT00319306|DRUG|Budesonide/formoterol|
223856606|NCT00319306|DEVICE|Symbicort® Turbohaler®|
223856607|NCT03357640|DRUG|combined oral contraceptive pills|one package of oral contraception (Cilest containing norgestimate 250 microgram + ethinyl estradiol 35 microgram)
223856608|NCT02734056|OTHER|Music|Listening to music that the patient likes
223856609|NCT02734056|OTHER|Control|Control
223856610|NCT01546155|RADIATION|PET imaging|Up to a 120 minute PET scan using \[11C\]diprenorphine as the radiotracer
223856611|NCT01182116|PROCEDURE|J Pouch|Comparing J pouch, side to end coloanal surgery
223856612|NCT03119363|DEVICE|AYO light glasses (Experimental)|The AYO does not contain UV or infra-red light; the light spectrum begins at approximately 420nm. The circadian-effective AYO is programed at over 100 lux with 470nm frequency and irradiance of 250 qW/cm2, which is 100% intensity level. Irradiance over lux itself with AYO light glasses is believed to be more representative due to light frequency and proximity to the eye. Traditional Lightbox usual measure is Lux , AYO can be seen as comparable to 1,000 lux light box. The device is classified as a device that is safe for the eyes in accordance with the international standard IEC 62471 and is independently certified by TÜV Rheinland. AYO complies with the EU's CE marking (CE EMC EN 55014, EN 61000-4-3) as well as other national regulatory directives. AYO also complies with the United States of America's FCC marking (FCC Title 47, Chapter 1, Part 15, Class B FCC VOC: 47 CFR PART 15 OCT, 2016. CLASS B ANSI C 63.4: 2014) as well as other national marking regulatory directives.
223856613|NCT03119363|DEVICE|AYO light glasses (Comparator)|The comparison group will wear the same AYO glasses, but with a circadian ineffective (sham) light. The circadian-ineffective (sham) is programed at 1% intensity, therefore according to our calculation and checks it is below circadian threshold of 2 lux as specified.
223856614|NCT01234610|BEHAVIORAL|Supervised exercise training|Patients will be asked to attend three exercise sessions per week for 12 weeks. They will exercise in groups of up to four per session and they will be supervised by an experienced exercise physiologist. Each session will comprise 5 to 10 min warm-up period (involving very light aerobic exercise and a range of gentle movements), 30 min of light-to-moderate intensity aerobic exercise (cycle-ergometry and or treadmill-walking), and a 5 to 10 min cool-down period involving low-intensity aerobic exercise and gentle stretching. The intensity of the aerobic exercise will be individualised and will be progressed gradually (if appropriate) during the course of the study.
223856615|NCT02220478|DEVICE|Posterior Lateral Approach Total Hip Arthroplasty|All patients enrolled in the study are indicated for a total hip replacement, and will receive this replacement from the surgeon via a Posterior Lateral surgical approach.
223856616|NCT03789955|PROCEDURE|Fluoroscopic-guided TEB|When performing a fluoroscopic-guided thoracic epidural block (TEB), an 18-gauge Tuohy needle will be used for interlaminar epidural access. If the epidural space was accessed under fluoroscopic guidance and using the loss of resistance technique with air. All procedures will be performed with a paramedian approach under the true AP and lateral view at first, If the interlaminar space is not visible, the CLO view will be used. If the needle is deemed to be in the epidural space when the loss occurred, six fluoroscopic views will be obtained: true AP, CLO at 40 degrees, 50 degrees, 60 degrees, CLO measured, and lateral. The CLO measured angle will be determined by measuring the angle between the superior lamina and spinous process on the midsagittal plane on thoracic MRI or CT.
223856617|NCT00067691|PROCEDURE|Acupuncture|
223856618|NCT00042198|BEHAVIORAL|Cognitive behavior therapy|Up to 12 weekly, individual, hour-long sessions
223856619|NCT00042198|BEHAVIORAL|Supportive Stress Management|Up to 12 weekly, individual, hour-long sessions, focusing on application of relaxation and other stress management techniques to depressogenic stressors
223856620|NCT00189813|DRUG|YM060|
223856621|NCT06087549|DRUG|Pericapsular nerve group block using 0.2% ropivacaine|Unilateral ultrasound guided pericapsular nerve block using 0.5mL/kg 0.2% Ropimol (max 20mL)
223856622|NCT06087549|DRUG|Erector Spinae Plane Block using 0.2% ropivacaine|Unilateral ultrasound guided erector spinae block using 0.5mL/kg 0.2% Ropimol (max 20mL)
223856623|NCT06087549|OTHER|Standard care|No erector spinae block and no pericapsular nerve group block
223856624|NCT00382161|DRUG|Fluvastatin-sodium|
223856625|NCT01025843|DRUG|MK-5478|In Part I: Single dose administration of MK-5478 oral capsules, total doses of 1, 2, 5, 8, 12, 18, 24 or 38 mg.
223856626|NCT01025843|DRUG|Comparator: Candesartan cilexetil|Single dose administration of candesartan, 32 mg oral tablet
223856627|NCT01025843|DRUG|Comparator: Pbo|Placebo
223856628|NCT03224299|DRUG|OCT - clear|Investigational Product #1: octenidine dihydrochloride in isopropyl alcohol in a single-use applicator - clear
223856629|NCT03224299|DRUG|OCT- tinted|Investigational product #2: octenidine dihydrochloride in isopropyl alcohol in a single-use applicator - tinted
223856630|NCT03224299|OTHER|ChloraPrep|Active Control: ChloraPrep® - Hi-Lite Orange® applicator
223856631|NCT03224299|OTHER|Saline|Negative Control: sterile 0.9% saline applied with single use applicator
223856632|NCT00479206|DRUG|Artesunate|
223856633|NCT01679262|DEVICE|Guedel type color-coded OPAs|The OPAs was used four different sizes as No. 8 (80 mm, green), 9 (90 mm, yellow), 10 (100 mm, red), and 11 (110 mm, orange) in regular sequence. The curvilinear distance from the incisors to the tip of the epiglottis was measured by FOB (Olympus LF-GP; Olympus Optical Co., Tokyo, Japan) with tape marking via each size of OPAs. The distance from the distal end of OPA to the tip of the epiglottis was calculated by the difference between measured distance from the incisors to the tip of the epiglottis via each OPA by FOB and typical distance from the flange to distal end of each OPA via inside tube of OPA. When the size of OPAs was longer than distance from the incisors to the tip of the epiglottis, OPAs were partly withdrawn and repositioned the distal end of OPAs is placed just above the tip of epiglottis. Then, the length from the incisors to the flange of OPAs was measured. .
223856634|NCT03702400|DRUG|Phenylephrine 100 mcg|Phenylephrine at a dose of 100 mcg bolus at a dilution containing 20 mcg / mL of the drug, 5 mL each bolus
223856635|NCT03702400|DRUG|Norepinephrine 5 mcg|Norepinephrine at a dose of 5 mcg at dilution containing 1 mcg / mL, 5 mL each bolus
223856636|NCT00377455|DRUG|Bosentan|62.5 mg by mouth (PO) twice daily (Bid) for 1 month, followed by 125 mg PO Bid thereafter, for a total of 16 weeks
223856637|NCT00377455|DRUG|Placebo|62.5 mg PO Bid for 1 month, followed by 125 mg PO Bid thereafter, for a total of 16 weeks
223856638|NCT00959920|PROCEDURE|Indwelling catheter|Indwelling bladder catheter will remain in place until time of delivery.
223856639|NCT00959920|PROCEDURE|Intermittent straight catheterization|intermittent straight catheterization will be performed on an as needed basis until time of delivery.
223856640|NCT05453864|BEHAVIORAL|CMAP Plus TFCBT|This will include 8 individual sessions of CMAP Plus TFCBT delivered by a trained therapist over a period of 12 weeks. Each session will last between 45 to 60 minutes.
223856641|NCT05804604|PROCEDURE|Surgical treatment of proximal femur fracture and blood sample test|Open reduction of femoral neck or pertrochanteric fracture with hemi/total hip arthroplasty or gamma nail. Analysis of serum concentration of: SHBG, CTX - I, CK-MB
223856642|NCT05804604|PROCEDURE|Blood sample test|Analysis of serum concentration of: SHBG, CTX - I, CK-MB
223856643|NCT04484480|PROCEDURE|Balance training|Proprioception, balance and motor coordination training using the dynamic platform - Biodex Balance System.
223856644|NCT01897233|DRUG|Lumacaftor|
223856645|NCT01897233|DRUG|Ivacaftor|
223856646|NCT02242162|PROCEDURE|phrenic nerves magnetic stimulations|
223856647|NCT02220491|RADIATION|Single-fraction radiotherapy|Volumetric modulated arc therapy (VMAT) delivering 15 Gy in one fraction to brain metastases
223856648|NCT02220491|RADIATION|Whole-brain radiotherapy|Whole brain radiotherapy delivering 20 Gy in five fractions to brain metastases
223856649|NCT06555276|DEVICE|Disposable endoscope linear cutting stapler and components|to use the study device for excision, transection and anastomosis of lung, bronchial tissue, stomach and intestine in open or endoscopic surgery.
223856650|NCT02065050|OTHER|team-based care|Patients in the eDMS arm are called at least every month for their diabetes treatment.
223856651|NCT04962282|OTHER|Follow-up by telephone|Studies have shown that the compliance of patients at 8-12 weeks reaches a peak, so this time node is the most suitable time node to investigate compliance. Telephone follow-up is irreplaceable convenience, so the telephone follow-up survey of patient compliance with exercise prescriptions is The most feasible method The purpose of the telephone follow-up is to 1. Investigate the compliance of the patients; 2. Make the patients fill out a self-made research compliance scale influencing factors through the telephone.The purpose of the telephone follow-up is to 1. Investigate the compliance of the patients; 2. Make the patients fill out a self-made research compliance scale influencing factors through the telephone.
223856652|NCT04147910|DRUG|KW-6356|Single oral dose of KW-6356
223856653|NCT06081231|DEVICE|open-source APS;|a continuous glucose monitoring system, an insulin pump, and an intelligent algorithm.
223856654|NCT04989725|OTHER|Standard arm|Patients on the standard arm will be treated as per standard of care in our institution. Treatment options could include switching to next systemic therapy line, best supportive care or continuing on current systemic therapy.
223856655|NCT04989725|RADIATION|Experimental arm|SABR to all oligoprogressive lesions + continuation of current systemic therapy
223856656|NCT01975311|OTHER|Lumbopelvic Manipulation|High-velocity low-amplitude non-specific lumbopelvic thrust manipulation
223856657|NCT01975311|OTHER|Passive lumbar spine flexion and extension|Passive lumbar spine flexion and extension without reaching the physiological end feel for 1 min from a side lying position.
224076160|NCT06399497|OTHER|simulated manipulation|Simulated manipulation intervention, in the same position as in the Intervention Group, performance in right lateral decubitus with the left leg flexed and the left foot resting on the right popliteal fossa. Without stretching the paravertebral tissues, the participant will remain for approximately 20 seconds without receiving manual impulse.
223856658|NCT03329144|BEHAVIORAL|Cognitive Behavioural Therapy|The transdiagnostic CBT-based curriculum is based on the extensive clinical experience of the research team with young women and those struggling with perinatal mental disorders. The team also has significant expertise delivering CBT for depression and anxiety (including perinatal variants) in groups. The manual was developed by the research team and is based on the state-of-the-art in resilience and CBT interventions in adolescents and young adults (e.g., the Penn Resiliency Program (60), Treatment for Adolescent Depression Study (61)). After it was developed, it was subjected to further scrutiny by public health nurses and STRIVE staff, who have extensive experience working with young mothers.
223856659|NCT04020718|BEHAVIORAL|Brief telephone advice plus tailored text messages|All patients are offered brief advice delivered by telephone by a clinical research coordinator who underwent Tobacco Treatment Specialist core training and a text message program tailored to readiness to quit and quit date. Content is personalized with user's name and Massachusetts General Hospital resources.
223856660|NCT04020718|DRUG|Mailed nicotine replacement therapy|Patients who report continued smoking at Early or Late assessment (depending on random assignment) will be offered a 4 week supply of patches and/or lozenges dosed according to package instructions (patches dosed according to cigarettes smoked per day and lozenges dosed according to time to first cigarette).
223856661|NCT04020718|BEHAVIORAL|Proactive telephone coaching|Patients who report continued smoking at Early (4-week) or Late (8-week) assessment of response will be randomized to receive proactive telephone coaching or not. Proactive coaching will consist of an attempt to reach the patient by telephone in order to review quit activities, provide information about locally available pharmacologic and behavioral treatment options and information sharing with patient's primary care provider. The coach is trained in core Tobacco Treatment Specialist activities.
223856662|NCT00566514|DIETARY_SUPPLEMENT|D-ribose|5 grams administered orally TID
223856663|NCT00566514|OTHER|dextrose|5 grams orally TID
223856664|NCT01261234|DRUG|Cilostazol or Non-Cilostazol|Cilostazol group administrate 100-200mg/day per oral, unrestricted use of other antiplatelet agents and concomitant drugs.
223856665|NCT03546907|DRUG|SAR440340|Pharmaceutical form: Solution for injection; Route of administration: SC
223856666|NCT03546907|DRUG|Placebo|Pharmaceutical form: Solution for injection; Route of administration: SC
223856667|NCT03546907|DRUG|Any Inhaled Corticosteroids as prescribed by treating physician as standard of care|Pharmaceutical form: Aerosol or Dry Powder inhaler Route of administration: Inhaled
224076161|NCT03632395|DIAGNOSTIC_TEST|computed tomography|computed tomography
223856668|NCT03546907|DRUG|Any Long Acting Beta Agonist as prescribed by treating physician as standard of care|Pharmaceutical form: Aerosol or Dry Powder inhaler; Route of administration: Inhaled
223856669|NCT03546907|DRUG|Any Long Acting Muscarinic Agonist as prescribed by treating physician as standard of care|Pharmaceutical form: Aerosol or Dry Powder inhaler; Route of administration: Inhaled
223856670|NCT03546907|DRUG|Any short-acting β agonist as prescribed by treating physician as standard of care|Pharmaceutical form: Aerosol or Dry Powder inhaler; Route of administration: inhaled
223856671|NCT01281813|DRUG|Darunavir|Participants will receive darunavir (per parent study) as oral suspension.
223856672|NCT01281813|DRUG|Ritonavir|Participants will receive ritonavir (per parent study) as oral solution/suspension.
223856673|NCT00332644|DRUG|nicotine patch|used according to FDA package label
223856674|NCT00332644|DRUG|nicotine lozenge|used according to FDA-approved package directions
223856675|NCT00332644|DRUG|nicotine patch + nicotine lozenge|dosage of both according to FDA-approved dosing schedule
223856676|NCT00332644|DRUG|bupropion|dosage according to FDA-approved instructions
223856677|NCT00332644|DRUG|bupropion + lozenge|dosage according to FDA approved standard instructions
223856678|NCT00332644|DRUG|placebo|dosage same as active drug conditions
223856679|NCT01980069|DRUG|Sugammadex|In sugammadex group, sugammadex (Bridion, Merck Shart and Dohme (MSD), Oss, the Netherlands) will be administered intravenously in different doses according to the degree of muscle relaxation. Sugammadex 8 mg/kg will be administered if there is no response on post-tetanic count (PTC) stimulus. Sugammadex 4 mg/kg will be administered if PTC is more than 1 or 2. Sugammadex 2 mg/kg will be administered if T2 response appears on train-of-four (TOF) stimulus.
223856680|NCT01980069|DRUG|Neostigmine|In neostigmine group, neostigmine 50 ㎍/kg will be administered intravenously with glycopyrrolate 10 ㎍/kg when the T2 response appears on TOF stimuli.
223856681|NCT01189006|DRUG|Dextromethorphan|Add-On double-blind study treatment commenced at randomization for 11 weeks while patients were continuing open-label risperidone. Randomization was immediately preceded by a one week open-label Risperidone-Only Treatment period. Patients who were receiving antipsychotics medication(s) at screen other than risperidone alone was withdrawn from previous non-risperidone medication(s) and at the same time commenced risperidone in titrating doses over a week. This Antipsychotic Switch-Over Period occurred between Screen and Risperidone-Only Treatment period. Patients remained hospitalized for at least during the Risperidone-Only treatment Period and first week of Add-On treatment Period.
223856682|NCT05344014|PROCEDURE|Photobiomodulation|In experimental groups, before topical anesthesia, PBMT was applied by utilizing a diode laser (EpiX; Biolase technology, inc., USA) with a continuous wavelength of 940 nm on a 400-μm fiber with only biostimulation properties. In accordance with the recommendations of the device's manufacturer, it was applied using circular motions in a manner as slowly as possible (an average of 33-36 circular movements in 60 s)
223856683|NCT05344014|PROCEDURE|Placebo|In the control group (placebo), the laser probe was directed to the mucosa for (buccal and palatal area), but not activated, and the sound of the laser device previously recorded on the mobile telephone was played for the same time of experimental group in order to provide similar conditions
224076162|NCT00391404|DRUG|Alendronate|Alendronate 70 mg weekly (oral)
224076163|NCT00391404|DRUG|Placebo|Placebo
223856684|NCT04560855|DEVICE|Connected devices measurements|The patient has to measure everyday several vital parameters like respiration and heart rate during the night with Withings Sleep, temperature with Withings Thermo, arterial pressure with Withings Tensiometer and physical activity with Withings smartwatch.
223856685|NCT03510949|DEVICE|Nasopharyngeal airway or laryngeal mask airway|Comparing the incidence of postoperative soar throat with the use of nasopharyngeal airway versus laryngeal mask airway
223856686|NCT00588302|DRUG|Moexipril|Moexipril was given at a starting dose of 7.5 mg daily for 1 week to all enrolled patients. If tolerated (no clinically significant hypotension or medication associated adverse event), the daily dosage was increased to 15 mg daily at the beginning of the 2nd treatment week. Patients took moexipril orally in the morning and 1 hour prior to food intake. The target dose was maintained for the 1-year period of the study unless the development of toxicities warranted dose reduction or discontinuation.
223856687|NCT05432934|DRUG|Dexamethasone|Dexamethasone will be added to local anesthetic solution and injected at 4 site for for laparoscopically placed TAP blocks.
223856688|NCT04379349|BEHAVIORAL|SMS text messaging - interactive check-in|Interactive SMS text message check-ins delivered once weekly to participants.
223856689|NCT04379349|BEHAVIORAL|SMS text messaging - inactive control|Minimally interactive SMS text message delivered once weekly to participants.
223856690|NCT00432588|DRUG|misoprostol|
223856691|NCT00432588|DRUG|dinoprostone|
224076164|NCT04363372|DRUG|MRx-4DP0004|MRx-4DP0004 is a lyophilised formulation of a proprietary strain of bacteria.
224076165|NCT04363372|DRUG|Placebo|Placebo capsules will be identical in appearance to active product.
224076166|NCT01934140|BIOLOGICAL|Meningococcal vaccine GSK134612|1 dose administered intramuscularly in the non-dominant deltoid region.
223856692|NCT03903900|BEHAVIORAL|Lifestyle-oriented Occupational Therapy added to current treatment of chronic non-malignant pain|The participants are recruited from the outpatient cohort admitted at The Multidisciplinary Pain Center (MPC) at Naestved Hospital (Zealand Region, Denmark). The participants receive both, the current treatment based on Cognitive Behavioural Therapy (CBT) and delivered by physicians, nurses, physical therapists and a social worker as usual care, and a lifestyle-oriented Occupational Therapy intervention. The Occupational Therapy intervention targets meaningful daily occupations, physical activity, and eating habits and routines. The intervention is delivered by graduated occupational therapists once á week during the 15 weeks after the initial 5-weeks compulsory psychoeducation course at the MPC. The intervention contains in-person contacts with OTs every other week (e.g. two 1-hour individual sessions at the hospital and/ or at-home and five 2-hours group sessions) and seven phone consultations in the opposite weeks.
223856693|NCT02034916|DRUG|talazoparib|
223856694|NCT04748575|DIETARY_SUPPLEMENT|Acai smoothie|Smoothie containing 150g acai pulp
223856695|NCT04748575|DIETARY_SUPPLEMENT|Placebo smoothie|Control smoothie matched nutritionally (macronutrients) and sensorially to the acai smoothie.
223856696|NCT06297135|BEHAVIORAL|Behavioral Parent Training|Teaches parents antecedent- and reinforcement-based behavior management techniques and provide support to manage their stress
223856697|NCT03131206|DRUG|Alectinib|"* Oral, BID~* Phase I: A 7-day lead-in dosing period will be administered at the start of each dose level. Each treatment cycle will be defined as 28 consecutive days.~* Phase II: Participants will be treated at the RP2D identified during Phase I. Each treatment cycle will be defined as 28 consecutive days."
223856698|NCT04019509|DIAGNOSTIC_TEST|blood test|blood test for thyroid antibodies and thyroid function (TSH, FT4)
223856699|NCT04019509|OTHER|follow up treatment outcome|questionnaire for treatment outcome: pregnancy, no pregnancy, miscarriage, delivery
223856700|NCT05906940|DEVICE|Transcutaneous Vagus Nerve Stimulation|As a vagus stimulation protocol, bilateral auricular stimulation and stimulation frequency of 10 Hz, pulse width of 300 µs, biphasic application for 20 minutes, each participant will be stimulated twice, with at least 48 hours between them.
223856701|NCT00189969|BIOLOGICAL|Elstree-BN|
223856702|NCT03753152|DEVICE|experimental|Neuramis® Deep Lidocaine
223856703|NCT03753152|DEVICE|comparator|YVOIRE® Volume Plus
223856704|NCT02520856|OTHER|blood sample|
223856705|NCT01616654|DRUG|CD5789 25 µg/g cream|CD5789 25 µg/g cream applied once daily
223856706|NCT01616654|DRUG|CD5789 50 µg/g cream|CD5789 50 µg/g cream applied once daily
223856707|NCT01616654|DRUG|CD5789 100 µg/g cream|CD5789 100 µg/g cream applied once daily
223856708|NCT01616654|DRUG|Tazarotene 0.1% gel|Tazarotene 0.1% gel applied once daily
223856709|NCT01616654|DRUG|Vehicle cream|Vehicle cream applied once daily
223856710|NCT04008836|DEVICE|T-PLUS Meter|Blood Glucose Monitoring System (BGMS)
223856711|NCT04750850|OTHER|Therapeutic core stability exercises|exercises focused on trunk muscle strengthening, proprioception, selective movements of the trunk and pelvis muscle, and coordination, and will be carried out in supine, sitting on a stable surface and sitting on an unstable surface (ball). The exercise involves changes in the position of the body with or without resistance, aiming to improve strength, endurance, proprioception and coordination. Training is determined by the patient's ability to undertake easy exercises and progress to more challenging exercises.
223856712|NCT04750850|OTHER|Usual care|Usual routine as walking and activities of daily living.
223856713|NCT04038229|OTHER|Enhanced recovery pathway|The applied protocol include psychological screening for yellow flags, preoperative gabapentin, peroperative multimodal preemptive management and postoperative holistic evaluation short -and long term
223856714|NCT02093533|DRUG|Eculizumab|
223856715|NCT02057692|DRUG|LUM001|LUM001 administered orally
223856716|NCT02057692|DRUG|Placebo|Placebo administered orally
223856717|NCT05025267|OTHER|Medical Food: Peptide-Based Enteral Formula|Will be fed exclusively the study peptide-based, high protein enteral formula via a feeding tube
223856718|NCT03252106|PROCEDURE|Contour augmentation with implant placement|Contour augmentation with implant placement
223856719|NCT02401633|PROCEDURE|CO-CPR|CPR provided by bystander with chest-compressions only
223856720|NCT02401633|PROCEDURE|S-CPR|CPR with Chest Compressions and Rescue Breaths in a ratio of 30:2
223856721|NCT04911842|DEVICE|HydroMID|Hydrophilic biomaterial
223856722|NCT04911842|DEVICE|TPU|Thermoplastic polyurethane
223856723|NCT04460573|DEVICE|Boot|Smart boot in one of three configurations provided to participants
223856724|NCT04023916|DRUG|Sintilimab-R-CHOP|"Drug:Sintilimab:~Sintilimab:200 mg IV on Day 1 Cycles 2-8, during induction treatment, followed by 200 mg IV on Day 1 of Cycles 9-14.~Drug: Rituximab Rituximab:Participants with previously untreated DLBCL will receive rituximab at a dose of 375 mg/m\^2 IV on Day 1 of Cycle 1-8, during induction treatment.~Drug: Cyclophosphamide Cyclophosphamide will be administered at a dose of 750 mg/m\^2 IV on Day 2 of Cycle 1-6, during induction treatment.~Drug: Doxorubicin Hydrochloride Liposome Injection Doxorubicin Hydrochloride Liposome Injection will be administered at a dose of 35 mg/m\^2 IV on Day 2-3 of Cycle 1-6, during induction treatment.~Drug: Vincristine Vincristine will be administered at a dose of 1.4 mg/m\^2 (maximum 2 mg) IV on Day 2 of Cycle 1-6, during induction treatment.~Drug: Prednisone Prednisone will be administered at a dose of 40 mg/m\^2 orally on Days 1-5 of Cycle 1-6, during induction treatment. Prednisolone may be given if prednisone is unavailable."
223856725|NCT01326715|DRUG|Mangafodipir (Teslascan)|gadolinium enhancement on contrast enhanced brain MRI.
223856726|NCT04584021|DEVICE|Xiaomi MiBand3|Recording of sleep, activity and heart rate data to study their association with stress.
223856727|NCT04584021|OTHER|Socio-demographic questionnaire|Self-made questionnaire to be filled by the participants at the beginning of the study with the following personal data: age, gender, marital status, residential environment, cohabitation unit, educational level, socio-economic level, contract, working hours, overtime or not, number of overtime hours in a day, overtime frequency and perceived stress level
223856728|NCT04584021|OTHER|EuroQol-5D-5L|Quality of life questionnaire to be filled by the participants at the beginning, mid-term and completion of the study with the following information: severity index, social value index for each health condition. Subjective evaluation of health status from 0 to 100.
223856729|NCT04584021|OTHER|Pittsburgh Sleep Quality Index (PSQI)|Questionnaire to be filled by the participants whose outcome is the perceived quality, quantity and efficient of sleep. To be given at the beginning, mid-term, and completion of the study.
223856730|NCT04584021|OTHER|State-Trait Anxiety Inventory (STAI)|Questionnaire to be filled by the participants which measures the anxiety level. To be given at the beginning, mid-term and completion of the study.
223856731|NCT04584021|OTHER|Perceived Stress Scale-10 (PSS-10)|Questionnaire to be filled by the participants which measures the stress level. To be given at the beginning, mid-term and completion of the study.
223856732|NCT04584021|OTHER|Stress questionnaire|Questionnaire designed by a work stress psychologist professional from the research group which is focused on stress and daily functioning. This questionnaire was given for the participants to fill. It is composed by 3 daily items and 4 weekly items.
223856733|NCT05787444|DIAGNOSTIC_TEST|LumiraDx SARS-CoV-2 & Flu A/B|The LumiraDx SARS-CoV-2 \& Flu A/B test is an automated rapid microfluidic immunofluorescence assay for use with the LumiraDx Platform, for near-patient testing, intended for the qualitative and differential detection of nucleocapsid viral antigens from SARS-CoV-2, influenza A, and influenza B in an anterior nares sample (from both nostrils) collected by a healthcare professional for individuals aged 2 years and older. The test is authorized for individuals with symptoms of COVID-19, influenza A and B within the first 6 days of symptom onset.
223856734|NCT06494124|DEVICE|transcranial Alternating current stimulation (tACS)|It is a non-invasive brain stimulation technique that uses small, pulsed alternating current (1mA) to modulate lasting cortical excitability, producing facilitatory or inhibitory effects upon a variety of behaviours, with proven efficacy in various neuropsychiatric disorders.
223856735|NCT06494124|DEVICE|transcranial Direct current stimulation (tDCS)|It is a non-invasive brain stimulation technique that uses constant, low direct current to modulate lasting cortical excitability, producing facilitatory or inhibitory effects upon a variety of behaviours, with proven efficacy in various neuropsychiatric disorders.
223856736|NCT06494124|DEVICE|Sham controlled|1mA current will be applied for the first 30 seconds to provide the initial sensation of real stimulation, and then the current will be stopped, thus minimizing the stimulatory effects. It is known to have no effect on psychopathology/neuro-cognition and means to mimic the tDCS/tACS (in order to help blinding of the participants).
223856737|NCT05242926|DRUG|ModraDoc006/r|One time bi-daily dosing (30/20 mg) of ModraDoc006 in combination with ritonavir 100 mg tablets
223856738|NCT02228811|DRUG|DCC-2701 tablet|
223856739|NCT04527614|DIAGNOSTIC_TEST|qRT-PCR and serology|qRT-PCR and serology
223856740|NCT02303769|DRUG|Tamsulosin HCL 0.4mg|Tamsulosin HCL 0.4mg once a day
223856741|NCT02303769|DRUG|Tamsulosin HCL 0.2mg|Tamsulosin HCL 0.2mg once a day
223856742|NCT00545844|DRUG|montelukast sodium|montelukast sodium, 10 mg, one tablet once a day for 8 weeks as add on therapy to usual current asthma controller treatment
223856743|NCT04146818|BEHAVIORAL|Adapted Tango Dancing|Treatment will include sessions of Adapted Tango (90 min per week for a total of 6 months) together with sessions of comprehensive cognitive intervention (90 min per week for a total of 6 months) consisting in music therapy, engagement in social activities, cognitive training and psycho-education.
223856744|NCT04146818|BEHAVIORAL|Control|Sessions of psycho-education and advice on healthy life-style (once per month for a total of 6 months)
223856745|NCT03321539|DRUG|CCRT+GP|Patients receive concurrent cisplatin 100mg/m2 every 21days for three cycles during Intensity modulated-radiotherapy (IMRT) followed by adjuvant gemcitabine (1000mg/m2 on day 1 and day 8) and cisplatin (80mg/m2 on day 1) every 21 days for three cycles 4 weeks after radiotherapy.
223856746|NCT03321539|DRUG|CCRT+PF|Patients receive concurrent cisplatin 100mg/m2 every 21 days for three cycles during Intensity modulated-radiotherapy (IMRT) followed by adjuvant cisplatin (80mg/m2 on day 1) and 5-fluorouracil (1000mg/m2 civ 96h) every 28 days for three cycles 4 weeks after radiotherapy.
223856747|NCT00657280|DRUG|Sitagliptin|No one is blinded to the treatments.
223856748|NCT03114020|DRUG|Hyaluronic Acid Inhalation Solution|twice a day 3 mL of 0.03% Hyaluronic Acid Inhalation Solution
223856749|NCT03114020|DRUG|Placebo Inhalation Solution|Twice a day 3 ml of placebo inhalation solution
223856750|NCT02533206|PROCEDURE|Endoscopic Polypectomy Performed in Clinic|Endoscopic polypectomy performed in clinic under local and topical anesthesia
223856751|NCT02533206|PROCEDURE|Functional Endoscopic Sinus Surgery (FESS)|Functional Endoscopic Sinus Surgery
223856752|NCT01986686|PROCEDURE|Colon resection|Elective robotic/laparoscopic/open colon resection for diverticular disease.
223856753|NCT03058991|BEHAVIORAL|Distress Tolerance Intervention|See arm/group description.
223856754|NCT03058991|BEHAVIORAL|Working Memory Intervention|See arm/group description.
223856755|NCT03058991|BEHAVIORAL|Control Informational Intervention|See arm/group description.
223856756|NCT00057850|DRUG|cisplatin|
223856757|NCT00057850|DRUG|ixabepilone|
223856758|NCT00444613|DRUG|E0302 (mecobalamin)|Intramuscular injection, mecobalamin 25 mg twice a week for 3.5 years.
223856759|NCT00444613|DRUG|E0302 (mecobalamin)|Intramuscular injection, mecobalamin 50 mg twice a week for 3.5 years.
223856760|NCT00444613|DRUG|Placebo|Intramuscular injection, placebo twice a week for 3.5 years.
223856761|NCT03724838|DRUG|Esomeprazole with Sildenafil Citrate|Patients will take esomeprazole single dose of 40 mg orally once a day
223856762|NCT03724838|DRUG|Sildenafil Citrate|Patients will take Sildenafil Citrate 40mg every 8 hours
223856763|NCT03724838|DRUG|Placebo to Esomeprazole|Patients will take inert tablets similar in appearance, color, and consistency to esomeprazole single dose of 40 mg orally once a day
223856764|NCT03724838|DRUG|Placebo to Sildenafil Citrate|Patients will take inert tablets similar in appearance, color, and consistency to Sildenafil Citrate 40mg every 8 hours
223856765|NCT00130637|DRUG|Daclizumab|
223856766|NCT00999843|DRUG|Sorafenib|Sorafenib is administered only to the patients with non-progression disease (CR, PR and SD) 4 weeks after the completion of radiotherapy. The dose is 400 mg, p.o., twice a day. Sorafenib is continuously given for 12 months unless intolerable toxicities and/or tumor progression.
223856767|NCT00518557|PROCEDURE|Transcatheter Arterial Chemoembolization|The interventional procedure is performed as following steps: 1)transcatheter hepatic arterial angiography(including any feeding arteries to the tumor) is performed under a DSA unit; 2) super selectively catheterizaton of feeding arteries to the tumor is reached; 3)30 mg of Andostatin (Simcere Co. China) mixtured with 5 ml Lipiodol is injected into the tumor via the feeding arteries; 4) followed by 10 mg of Epifubicin mixtured with 5 ml of Lipiodol; 5) All feeding arteries to the tumor are occluded which is confirmed by re-angiography.
223856768|NCT05731648|DEVICE|Intrathecal balofen pump|Management of spasticity
223856769|NCT06187480|PROCEDURE|total parathyroidectomy (group 1) and those who underwent subtotal parathyroidectomy (group 2)|The groups were compared according to the echocardiogram findings performed in the preoperative period and the postoperative sixth month. In addition, cardiac structure, systolic and diastolic function, especially myocardial performance index, were evaluated by echocardiography and Doppler imaging.
223856770|NCT02787941|BEHAVIORAL|Pharmacist-delivered multifaceted intervention|"First counselling: A pharmacist performs a 30-minute in-person counselling within 1 week before discharge including: (1) assessment and giving advice on basic knowledge of acute coronary syndrome: definition, risk factors, possible cardiac events, and prevention; (2) assessment of past experiences of using medications, encouragement and tailored advice; (3) providing support with pill organiser and drug information leaflet; (4) teaching back and correcting misunderstanding.~Second counselling: A pharmacist performs a 30-minute telephone counselling within 1 week after discharge including: (1) assessment of general and medication-related issues patients concerning; (2) encouragement and tailored advice; (3) teaching back and correcting misunderstanding."
223856771|NCT05831917|RADIATION|Radiotherapy|"Radiotherapy: All patients were treated with Unity MRI Linac intensity modulated radiation therapy, daily imaging of MRI-IGRT and online target delineation, redesign, and total radiation dose: GTV 70Gy/33f, GTVLN 70Gy/33f, CTV 60Gy/33f, CTVLN 54Gy/33f, 5 days per week. Dose limit: The average dose to the upper, middle, and lower pharyngeal constrictor muscles is ≤ 40-50Gy, with oropharyngeal cancer requiring an average dose to the upper, middle, and lower pharyngeal constrictor muscles to be ≤ 50Gy and ≤ 20Gy; Lower pharyngeal cancer requires an average dose of ≤ 40Gy for the upper and middle pharyngeal constrictor muscles, and ≤ 50Gy for the lower pharyngeal constrictor muscles.~chemotherapy: cisplatin 75mg/m2, 21 days per cycle, a total of 3 cycles."
223856772|NCT02081898|DIETARY_SUPPLEMENT|LCD|approximate 100 kcal/d caloric deficit
223856773|NCT03122704|PROCEDURE|GBS screening|Vaginal and anal swabs of patients will be screened for GBS screening
223856774|NCT00740155|BIOLOGICAL|Bivalent CYD-1,3 Dengue (Vero) + Bivalent CYD-2,4 Dengue (Vero)|0.5 mL, Subcutaneous (SC) (CYD-1,3 Day 0; CYD-2,4 Day 105)
223856775|NCT00740155|BIOLOGICAL|Bivalent CYD-1,3 Dengue (Vero) + Bivalent CYD-2,4 Dengue (Vero)|0.5 mL, Subcutaneous (SC) (CYD-1,3 + CYD-2,4 on Day 0 and Day 105)
223856776|NCT00740155|BIOLOGICAL|Tetravalent blending VDV-2/CYD-1,3,4 Dengue (Vero)|0.5 mL, Subcutaneous (SC) (Day 0 and Day 105)
223856777|NCT00740155|BIOLOGICAL|Tetravalent CYD-1,2,3,4 Dengue (Vero)|0.5 mL, Subcutaneous (SC) (Day 0 and Day 105)
223856778|NCT00740155|BIOLOGICAL|JE-VAX®: Japanese encephalitis virus vaccine inactivated + Tetravalent CYD-1,2,3,4 Dengue (Vero)|0.5 mL, Subcutaneous (SC) (JE-VAX® Day 0 + Tetravalent CYD-1,2,3,4 on Day 105)
223856779|NCT02114749|DEVICE|a set of wearable respiration and cardiac monitoring devices|feasibility of methods for detecting physiological state changes from a set of wearable respiration and cardiac monitoring devices
223856780|NCT02881749|RADIATION|Total skin electron beam therapy (TSEBT)|"TSEBT will be given in 6 fractions at 2 Gy per fraction every Monday, Wednesday, and Friday over the course of 2 weeks (total TSEBT dosage is 12 Gy). Supplements up to 8 Gy will routinely be applied to the perineum and soles as well as any other shadowed sites involved by disease, such as the inframammary regions, scalp, etc. Discrete tumors may receive additional boost up to 8 Gy."
223856781|NCT02881749|DRUG|mechlorethamine gel 0.016%|The maintenance period for this study includes one year of weekly mechlorethamine gel 0.016%. This period will not begin until the observation period (30 days) has been completed. During the first week of the maintenance period, patients will apply mechlorethamine gel to the entire body surface daily. After the first week, patients will apply mechlorethamine gel to entire body surface one time per week for the rest of the maintenance period.
223856782|NCT02667249|OTHER|clinical pathway|implementation of a standardized clinical pathway
223856783|NCT02438124|BEHAVIORAL|Neuropsychological evaluation|The subjects are submitted in one hearing stimulus while they realize a walking test
223856784|NCT02999048|DRUG|Panax Notoginseng Saponins|Panax Notoginseng Saponins integrated with conventional therapy
223856785|NCT00942149|DRUG|Daptomycin|single dose of 6 mg/kg of daptomycin
223856786|NCT01701713|DEVICE|DKI ED2011|
223856787|NCT01701713|DEVICE|Sham-TDCS|
223856788|NCT06164249|OTHER|strength training|Strength training, three times a week, during nine weeks.
223856789|NCT01460342|DRUG|Tadalafil|5 mg (2 x 2.5-mg tablets), given once daily as oral tablet
223856790|NCT01460342|DRUG|Placebo|2 tablets (identical to 2.5-mg tadalafil tablets) given orally once daily.
223856791|NCT02170636|DRUG|BIBR 1048 MS Capsule E|50 mg BIBR 1048 MS
223856792|NCT02170636|DRUG|BIBR 1048 MS Capsule F|50 mg BIBR 1048 MS
223856793|NCT02170636|DRUG|BIBR 1048 MS Capsule G|50 mg BIBR 1048 MS
223856794|NCT02170636|DRUG|BIBR 1048 MS Tablet H|50 mg BIBR 1048 MS
223856795|NCT02170636|DRUG|BIBR 1048 MS Drinking solution|50 mg BIBR 1048 MS tartaric acid solution
223856796|NCT02170636|DRUG|Pantoprazole|40 mg Pantoprazole
223856797|NCT01689519|DRUG|Placebo|Placebo supplied as tablets
223856798|NCT01689519|DRUG|Vemurafenib|Vemurafenib supplied as tablets
223856799|NCT01689519|DRUG|Cobimetinib|Cobimetinib supplied as tablets
223856800|NCT02777099|PROCEDURE|remote ischemic postconditioning|Remote ischemic postconditioning was performed by 4 cycles of upper-limb ischemia and reperfusion.The upper-limb ischemia was induced by inflating a blood pressure cuff on a healthy upper arm to 200 mmHg for 5 min,and then deflating it for 5 min.Each patients in the PIPostC group will have the treatment once a day for 30 days.
223856801|NCT02777099|PROCEDURE|sham remote ischemic postconditioning|Sham remote ischemic postconditioning was performed by 4 cycles of upper-limb ischemia and reperfusion. The upper-limb ischemia was induced by inflating a blood pressure cuff on a healthy upper arm to the patient's actual diastolic blood pressure for 5 min,and then deflating it for 5 min.Each patients in the sham PIPostC group will have the sham treatment once a day for 30 days.
223856802|NCT00744393|DRUG|sodium oxybate|The dose of sodium oxybate will be 4.5g every 4 hours x 2 doses. The first dose of study medication will be given at 10pm followed by the next dose four hours later and crossed over the next day
223856803|NCT00744393|DRUG|placebo|The dose of placebo sodium oxybate will be 4.5g every 4 hours x 2 doses. The first dose of study medication will be given at 10pm followed by the next dose four hours later and then crossed over the next day
223856804|NCT04555954|OTHER|surveys and questionnaires|The study practised the physical activity levels of healthy adults aged 18-65 years in Turkey during the novel type of coronavirus pandemic by the International Physical Activity Questionnaires-Short Form (IPAQ-SF). Communication with the participants of the study was conducted via online survey software (Google Forms) and social media communication application (WhatsApp).
223856805|NCT03082430|BIOLOGICAL|autologous PRP.|one autologous PRP patient in this study and monitor and follow the evolution of pain and the knee function
223856806|NCT05252871|DEVICE|Progressive Additional Lenses (PAL), pre calibrated and made of polymeric material with anti-reflection coating|Subjects will be wearing three different PAL designs with different geometries of the optical progression.
223856807|NCT03285191|OTHER|Numerical rating scale|Following the concept elicitation interview, participants will be presented with a list of typical RA symptoms and asked to rank how bothersome each symptom is and how important it would be to improve with treatment on a 1-5 numerical rating scale (NRS).
223856808|NCT03285191|OTHER|Real-time data capture app|Real time data capture app is a smart-phone or web-based application which will allow the subjects to provide responses about their experience of HOA in real-time via varying video, audio, photographic and text forms using a study-specific application on their own smart device. Up to ten of the thirty interview participants can participate in the app sub study, which is voluntary.
223856809|NCT03140579|OTHER|APRV|Airway pressure release ventilation is a method of inverse ventilation, where high levels of positive end expiratory pressure are maintained to optimise oxygenation with brief releases of pressure to allow ventilation and release carbon dioxide. It is an approved and frequently used method of ventilation.
223856810|NCT02488174|OTHER|PROOFcheck|
223856811|NCT02488174|OTHER|Standard Care|
223856812|NCT00116623|DRUG|Indomethacin|
223856813|NCT00116623|DRUG|Magnesium sulfate|
223856814|NCT04353830|DRUG|IBI939|Several dose levels will be evaluated for IBI939 administered as a single agent and in combination with Sintilimab. IBI939 will be given via intravenous (IV) infusion on Day 1 of each 21-day cycle until disease progression or loss of clinical benefit. Those who discontinue treatment with single-agent IBI939 may receive combination treatment with Sintilimab or IBI939+ Sintilimab. Combination treatment may continue until disease progression or loss of clinical benefit.
223856815|NCT04353830|DRUG|IBI939+ Sintilimab|"IBI939: Several dose levels will be evaluated for IBI939 in combination with Sintilimab. IBI939 will be given via intravenous (IV) infusion on Day 1 of each 21-day cycle until disease progression or loss of clinical benefit.~Sintilimab: Sintilimab will be given as 200 mg via IV infusion on Day 1 of each 21-day cycle in combination with IBI939. Combination treatment may continue until disease progression or loss of clinical benefit."
223856816|NCT04353830|DRUG|IBI939+ Sintilimab|"IBI939: IBI939 in combination with Sintilimab will be given with RP2D. IBI939 will be given via intravenous (IV) infusion on Day 1 of each 21-day cycle until disease progression or loss of clinical benefit.~Sintilimab: Sintilimab will be given as 200 mg via IV infusion on Day 1 of each 21-day cycle in combination with IBI939. Combination treatment may continue until disease progression or loss of clinical benefit."
223856817|NCT00098280|DRUG|Eculizumab|
223856818|NCT03673943|DRUG|64Cu-DOTATATE|Detection of somatostatin positive lesions in NET
223856819|NCT01713530|DRUG|insulin degludec/insulin aspart|Dose individually adjusted. For subcutaneous (s.c, under the skin) administration twice a day.
223856820|NCT01713530|DRUG|insulin degludec|Dose individually adjusted. For subcutaneous (s.c, under the skin) administration once daily.
223856821|NCT01713530|DRUG|insulin aspart|Dose individually adjusted. For subcutaneous (s.c, under the skin) administration with the main meals 2-4 times daily in accordance with local labelling.
223856822|NCT03525119|BIOLOGICAL|TDV|TDV SC injection
223856823|NCT03525119|BIOLOGICAL|HAV Vaccine|HAV Vaccine IM injection.
223856824|NCT03525119|BIOLOGICAL|TDV Placebo|Placebo-matching (normal saline (0.9% NaCl) SC injection.
223856825|NCT03525119|BIOLOGICAL|HAV Vaccine Placebo|Placebo-matching (normal saline (0.9% NaCl) IM injection.
223856826|NCT05422716|DEVICE|Epidural implant stimulation device|Individuals randomized to the Baclofen pump device group will continue with their clinical surgical and maintenance plan while also participating in all of the outcomes (assessments). The epidural implant group will undergo the research protocol for epidural stimulator surgical implant followed by mapping studies to identify targeted stimulation configurations for spasticity.
223856827|NCT05921526|DIAGNOSTIC_TEST|Point-of-care lung ultrasound|Participants assigned to the intervention group will receive POCLUS which will be performed by one of the trained pediatricians. The procedure involves 12 views: two anterior views, two lateral views and two posterior views on both chest walls
223856828|NCT05921526|DIAGNOSTIC_TEST|Chest X-ray (digital images)|Participants assigned to the chest X--ray group will be sent to the Radiology department to get a CXR (digital) which will be performed by radio technicians like in routine care. Anteroposterior and/or posteroanterior chest images will be obtained. Reading/ reporting of the digital images will be done by both the radiologist and the enrolling pediatrician. The image/ clinical expert review panels (IERP/ CERP) will also have access to the images for review.
223856829|NCT00182936|BEHAVIORAL|Delirium Abatement Program|
223856830|NCT04033237|OTHER|Very low nicotine content cigarettes|Cigarettes containing 0.4 mg nicotine/g tobacco
223856831|NCT05156450|DRUG|TQB3616 Capsules Combined With Abiraterone Acetate Plus Prednisone|Treatment with TQB3616 in combination with abiraterone acetate plus prednisone in patients with metastatic castration-resistant prostate cancer.
223856832|NCT03522519|BEHAVIORAL|Real world performance of physical activity and arm use|Patients will be assessed by using movement sensors and standard clinical assessments
223856833|NCT02770196|BEHAVIORAL|CO-CSA plus Nutrition Education|Participants will receive subsidized share of CSA produce (50% standard member price) weekly for approximately 20 weeks each year. In addition, they will attend nine skill-based, nutrition education sessions focused on use of CSA produce.
223856834|NCT02795650|DRUG|Personalised treatment|Personalised treatments include chemotherapy, targeted therapy, immunotherapy or others based on the previous test results, chosen from a database that include more than 2000 different drugs.
223856835|NCT02795650|DRUG|Treatment chosen per investigator´s judge|Investigators are allowed to chose what they consider the best standard treatment option for their patients.
223856836|NCT01638949|BEHAVIORAL|Memory assessment|Neuropsycological tests including clinical and original tests to compare differences between each populations.
223856837|NCT01638949|BIOLOGICAL|Circulating biomarkers measure|ELISA tests from blood samples to compare differences between each populations.
223856838|NCT01638949|GENETIC|ApoE4|Evaluation of apolipoprotein E polymorphism as a risk factor.
223856839|NCT01638949|OTHER|Brain imaging examination MRI and PET examinations|Structural and functional MRI FDG-PET to compare differences between each populations.
223856840|NCT00423254|BIOLOGICAL|PSMA/PRAME|Low dose
223856841|NCT00423254|BIOLOGICAL|PSMA/PRAME|high dose
223856842|NCT00711919|DRUG|Pitavastatin|"comparison of different target levels of lipid lowering using Pitavastatin~Subjects are receiving Pitavastatin, starting at 2 mg, for 12 months."
223856843|NCT00711919|DRUG|Pitavastatin|Subjects are receiving Pitavastatin, starting at 4 mg, for 12 months.
223856844|NCT01186848|DEVICE|Combination treatment|The contralateral side received the combination of micro-focused ultrasound treatment and 1550nm-fractionated laser alternatively every 2 weeks for a total of 4 treatments with site-match control area of baseline striae on each side.
223856845|NCT01186848|DEVICE|1550-nm erbium-doped fractionated laser|Each side of thigh (or abdomen) was randomized to receive 1550nm-fractionated laser treatment every 2 weeks for a total of 4 treatments on one side.
223856846|NCT01852019|DRUG|Cangrelor|Cangrelor IV administered as a 30 µg/kg bolus, followed by 4 µg/kg/min infusion for two hours on study Days 1 and 8
223856847|NCT01852019|DRUG|Prasugrel|"Day 1: Subjects received prasugrel (60 mg) either during the initial cangrelor infusion (at 1.0 hours or 1.5 hours after infusion start) or within 5 minutes of discontinuing the cangrelor infusion.~Subjects will be given either 5 or 6 additional 10-mg doses to be taken every 24 hours between Day 1 and Day 8."
223856848|NCT04551794|BEHAVIORAL|Selfapy with therapeutic guidance|The program consists of 9 modules with many interactional exercises. Themes that are addressed in the online-program are for example self-esteem, coping with relapse, establishing a structure for daily life and attention and breathing exercises as well as depression-specific topics such as negative thoughts management and arranging and maintaining social contacts. In addition, participants were able to talk about personal experiences with a therapeutic guide.
223856849|NCT04551794|BEHAVIORAL|Selfapy with additional peer support|The program consists of 9 modules with many interactional exercises. Themes that are addressed in the online-program are for example self-esteem, coping with relapse, establishing a structure for daily life and attention and breathing exercises as well as depression-specific topics such as negative thoughts management and arranging and maintaining social contacts. In addition, participants were able to participate in exchange with peers via an internal closed forum.
224076167|NCT01294384|DRUG|carboxymethylcellulose sodium based New Eye Drop Formulation 1|1 to 2 drops of carboxymethylcellulose sodium based New Eye Drop Formulation 1 in each eye at least twice daily for 90 days.
224076168|NCT01294384|DRUG|carboxymethylcellulose sodium based New Eye Drop Formulation 2|1 to 2 drops of carboxymethylcellulose sodium based New Eye Drop Formulation 2 in each eye at least twice daily for 90 days.
224076169|NCT01294384|DRUG|carboxymethylcellulose sodium based Eye Drops|1 to 2 drops of carboxymethylcellulose sodium based Eye Drops (Refresh Tears®) in each eye at least twice daily for 90 days.
223856850|NCT04283825|BEHAVIORAL|Psychological and physical rehabilitation based humanistic care|This Psychological and physical rehabilitation based humanistic care regimen is generated from the experience of the National medical team members in Wuhan, from our hospital. In addition to the routine therapy, we will apply this comprehensive humanistic care regimen to the patients according to their condition. The patients will be stratified by the severity and receive different combinations of Psychological and physical rehabilitation activities.
223856851|NCT04061902|OTHER|Participation with enhanced patient perioperative information|Improved information and dialogue about the care goals in the fast track protocol.
223856852|NCT00208507|DEVICE|28 mm ceramic head on ceramic acetabular liner.|Total hip replacement with 28 mm ceramic head on ceramic liner articulation
223856853|NCT00208507|DEVICE|28 mm ceramic head on polyethylene liner|Total hip replacement with 28 mm ceramic head on a polyethylene liner articulation.
223856854|NCT02903836|DRUG|Nafithromycin 800 mg 3 days|
223856855|NCT02903836|DRUG|Nafithromycin 800 mg 5 days|
223856856|NCT02903836|DRUG|Moxifloxacin 400 mg|
223856857|NCT00545324|DRUG|MK0476 (singulair), montelukast sodium / Duration of Treatment: 6 Weeks|
223856858|NCT00545324|DRUG|Comparator: Fluticasone / Duration of Treatment: 6 Weeks|
223856859|NCT03465345|DRUG|Metformin|Metformin: The starting dose for Metformin is 850mg once a day, the second dose is 850mg once a day; the third dose level is 850mg twice a day; the fourth dose level is 850mg twice a day. Each dose level lasts for 28 days.
223856860|NCT03465345|DRUG|Oligomeric Procyanidin Complex|OPC: The starting dose for OPC is 500mg once a day; the second dose is 1000mg once a day; the third dose level is 1000mg once a day; the fourth dose level is 1500mg once a day. Each dose level lasts for 28 days.
223856861|NCT04593719|OTHER|Experiment|The main components of the Lactation Management Model; breastfeeding training in the prenatal period (from the 30th week of pregnancy), early postpartum period (first 48 hours) skin to skin contact, early breastfeeding, relaxation using a dreaming technique, warm application to the breast, breast massage and for the first 48 hours after postpartum 6 months of continuous support (face to face, by phone, via social media).
223856862|NCT05329454|DRUG|Ibuprofen Tablets|"Treatment A:~One tablet of IBUMR will be administered to the subjects under fasted condition, followed by a minimum of 72-hour washout interval. After the washout period, subjects will receive 1 × IBUMR every 12 hours for a total of 7 doses.~Treatment B:~One tablet of IBURed will be administered to the subjects under fasted condition, followed by a minimum of 72-hour washout interval. After the washout period, subjects will receive 1 × IBURed every 8 hours for a total of 10 doses.~Treatment C:~Single dose of IBUMR will be given to the subjects under fed condition (a standard high-fat, high calorie breakfast should be consumed within 30 minutes prior to dosing)."
223856863|NCT00982033|DRUG|aliskiren|aliskiren 300mg qd versus placebo for 24 weeks.
223856864|NCT00982033|DRUG|placebo|placebo qd for 24 weeks
223856865|NCT03259919|DRUG|Metformin|Metformin 850 mg x 1 per day for the first week, and 850 mg x 2 per day for the rest of the study period.. Orally. From inclusion (before gestational week 8) to delivery. Verbal and written diet and lifestyle advices at inclusion to the study. In addition 1 mg tablet of folate and one daily multivitamin tablet.
223856866|NCT03259919|DRUG|Placebo|Placebo, 2 tablets x 1 daily for the first week, and 2 tablets x 2 for the rest of the study period.Orally. From inclusion (that is before gestational week 12) to delivery. Verbal and written diet and lifestyle advices at inclusion to the study. In addition 1 mg tablet of folate and one daily multivitamin tablet.
223856867|NCT01081340|BEHAVIORAL|Social network building intervention|Group support and health education sessions weekly during third trimester and once every two weeks until 6 months postpartum
223856868|NCT01081340|BEHAVIORAL|Home visit|Three home visits during third trimester and three during postpartum period until 6 months postpartum
223856869|NCT02148133|DRUG|Eltrombopag 12.5 mg|White, round, film-coated tablets containing 12.5 mg of eltrombopag free acid (SB-497115-GR, eltrombopag) in each tablet
223856870|NCT02148133|DRUG|Eltrombopag 25 mg|White, round, film-coated tablets containing 25 mg of eltrombopag free acid (SB-497115-GR, eltrombopag) in each tablet
223856871|NCT01726530|DRUG|transdermal fentanyl patch (50 mcg/hour)|
223856872|NCT01726530|DRUG|Placebo|
223856873|NCT03335969|DEVICE|colon irrigation|Study is to compare bowel movement patterns before and after colon irrigation.
223856874|NCT05241119|PROCEDURE|SLNB|undergo fluorescence SLNB.
223856875|NCT05241119|PROCEDURE|pALND|undergo low axillary lymph node dissection with ICBN as the boundary
223856876|NCT05241119|PROCEDURE|ALND|undergo ALND
223856877|NCT02399696|BEHAVIORAL|Primary Care-Brief Mindfulness Program|A 4-week group program adapted from the 8-week Mindfulness Based Stress Reduction (MBSR) curriculum
223856878|NCT02399696|BEHAVIORAL|Primary Care-Treatment as Usual|Typical VA primary care treatment, including mental health services delivered by primary care staff.
223856879|NCT04680260|OTHER|Standard of care|Patients will be offered adjuvant chemotherapy according to standard of care. Follow up will be performed with imaging according to standard guidelines, equal to the experimental arm. Blood samples will be analyzed retrospectively to evaluate the ctDNA status.
223856880|NCT04680260|OTHER|Circulating tumor DNA guided treatment approach|Circulating tumor-marker positivity will lead to escalation with 6 months of intensified chemotherapy consisting of 4 months of FOLFOXIRI followed by 2 months of 5FU monotherapy. Circulating tumor-marker negativity will based on shared decision-making lead to de-escalation i.e. possibilities for observation in patients otherwise eligible for monotherapy or observation/monotherapy in patients, otherwise eligible for combination chemotherapy according to standard of care.
223856881|NCT04628572|DRUG|Ceftazidime-avibactam|Non-Interventional Study
223856882|NCT00243399|DRUG|Oxandrolone|Subjects will be started on a dose of oxandrolone 0.04 mg/kg/day orally, once/day. After 16 weeks, patients will be assessed for hematologic improvement. If this criteria is not met after 16 weeks, the dose will be escalated to 0.08 mg/kg/day. If no improvement is noted after 16 weeks on the escalated dose, oxandrolone therapy will be discontinued.
223856883|NCT02187900|DRUG|Multi-glycoside of Tripterygium Wilfordii HOOK. f. (TWH)|The dosage of 40 mg of Multi-glycoside of Tripterygium Wilfordii HOOK. f. was divided into 2 equal doses at 12-hour intervals for 6 months.
223856884|NCT02187900|DRUG|Mycophenolate mofetil (MMF)|Mycophenolate mofetil 1.5mg/day for the treatment of IgAN for 6 months
223856885|NCT05236491|BIOLOGICAL|COVID-19 vaccine|Participants are to receive a booster dose of a COVID-19 vaccine.
223856886|NCT00158054|BEHAVIORAL|Enhanced depression care|Initial patient preference for problem-solving therapy and/or pharmacotherapy, then a stepped-care approach.
223856887|NCT00158054|BEHAVIORAL|Referred depression care|Physician notified of depression symptoms, usual care followed.
223856888|NCT02470949|BEHAVIORAL|Low Social Status|The participants will be randomized to the Low Social Status Condition. On their second visit, they will undergo the condition in which they were not randomized to on their first visit.
223856889|NCT02470949|BEHAVIORAL|High Social Status|The participants will be randomized to the High Social Status Condition. On their second visit, they will undergo the condition in which they were not randomized to on their first visit.
223856890|NCT04825652|DRUG|177Lu-PSMA-617|Participants will receive 7.4 GBq (200 mCi) +/- 10% 177Lu-PSMA-617 once every 6 weeks for 6 cycles.
223856891|NCT04825652|DRUG|PSMA-11|Patients will receive a dose of gallium (68Ga) gozetotide that is 1.8-2.2 MBq/kg of body weight (0.049-0.059 mCi/kg), with a minimum dose of 111 MBq (3mCi) up to a maximum dose of 259 MBq (7 mCi).
223856892|NCT04676568|PROCEDURE|Extravesical VVF repair|Both standard transvesical and extravesical approach for VVF repair will be utilised
223856893|NCT02674646|RADIATION|Radiotherapy|Radiation as indicated by the cancer diagnosis
223856894|NCT02674646|DEVICE|Needle Acupuncture|Needle Acupuncture according to Traditional Chinese Medicine (TCM)
223856895|NCT04630080|DEVICE|Scalp cooling|Scalp cooling is a physical method to reduce chemotherapy-induced alopecia
223856896|NCT05434611|DIAGNOSTIC_TEST|S100A12|The early dynamic detection of S100A12 was used to determine whether it was an auxiliary diagnostic index for Kawasaki disease
223856897|NCT01219699|DRUG|BYL719|BYL719 is an oral α-specific phosphatidylinositol-3-kinase (PI3K) inhibitor.
223856898|NCT01219699|DRUG|Fulvestrant|"In adult patients with advanced solid malignancies whose tumors have an alteration (mutation or amplification) of the PIK3CA gene.~Fulvestrant is an estrogen receptor antagonist, administered by monthly intramuscular injection"
223856899|NCT00855465|DRUG|Riociguat (Adempas, BAY63-2521)|BAY63-2521: 1 mg tid - 2,5 mg tid orally for 16 weeks.
223856900|NCT00855465|DRUG|Placebo|Matching Placebo tid orally for 16 weeks
223856901|NCT04460612|DEVICE|Active IR sock|Subjects will be wearing the infrared socks for 60 minutes
223856902|NCT04460612|OTHER|Placebo socks|Placebo Socks will be placed on participants feet first for 60 minute
223856903|NCT03045419|PROCEDURE|gadoxetic acid-enhanced liver MRI|liver MRI using a standard dose (0.025mmol/kg) of gadoxetic acid
223856904|NCT03977116|DRUG|SLGT2|These patients will receive SLGT2 therapy after catheter ablation.
224076170|NCT01062360|DRUG|Acetylsalicylic Acid (Aspirin Complex, BAYE4465) + Pseudoephedrine|Single oral dose of 1 to 2 Aspirin Complex sachets, each containing granules of 500 mg Acetylsalicylic Acid (ASA) and 30 mg Pseudoephedrine (PSE), to be taken orally after dissolving in a glass of water; to be repeated as needed every 6 hours for a period of not more than 3 days.
223856905|NCT03977116|DRUG|Placebo|These patients will receive placebo therapy after catheter ablation.
223856906|NCT00366171|DRUG|Bifeprunox|
223856907|NCT03938428|OTHER|Survey|Patients who are eligible for this study will have been previously identified as part of the PREFACES project. The pharmacist who has conducted the clinical medication review will obtain verbal permission from the patient to be contacted by the research study team. This will be documented on the referral outcome document that is returned to the YAS clinical team. A member of YAS clinical staff from the PREFACES project will forward the name and residential address of patients who have agreed to be contacted to the research paramedic for this study. A covering letter, participant information sheet, questionnaire and consent form, will be posted to potential participants. A stamped addressed envelope will be included to enable return of the completed booklet at no costs to participants.
223856908|NCT04365400|DRUG|DS102|DS102 Epeleuton capsules
223856909|NCT04365400|DRUG|Placebo|Placebo capsules
223856910|NCT00079183|DRUG|sirolimus|Given PO
223856911|NCT03489317|DRUG|Metformin|Participants with high glucose levels will usually be prescribed Metformin 250 mg three times daily. Can be prescribed to either metabolic syndrome-partial or full groups depending on their metabolic syndrome conditions.
223856912|NCT03489317|BEHAVIORAL|lifestyle modification|Participants with metabolic syndrome will be offered advice on modifying their diets and exercise regimes. Can be prescribed to either metabolic syndrome-partial or full groups depending on their metabolic syndrome conditions.
223856913|NCT03489317|DRUG|Simvastatin 10mg|Participants with elevated lipid levels will usually be prescribed simvastatin 10 mg at night. Can be prescribed to either metabolic syndrome-partial or full groups depending on their metabolic syndrome conditions.
223856914|NCT03489317|DRUG|Amlodipine 5mg|Participants with high blood pressure could be prescribed antihypertensive medicine such as Amlodipine. Can be prescribed to either metabolic syndrome-partial or full groups depending on their metabolic syndrome conditions.
223856915|NCT06226636|OTHER|salt|After ≥8 hr overnight fasting, participants will be required to ingest 780 mg of sodium (2 g salt) and BP measured every 10 minutes for 2 hours to determine IPROS. For SSBP, Participants are put on low salt (50 mmol Na/day) followed by seven days of high salt diet (250 mmol Na/day). Participants' mean arterial pressure (MAP) difference between low- and high-salt diet will be used to define salt sensitivity (MAP≥8 mmHg) and salt resistance (MAP≤5 mmHg).
223856916|NCT05377346|OTHER|Placement of the i-gel|The lubricated i-gel is inserted into the mouth and introduced along the hard palate with a continuous and gentle push until resistance was felt in the hypopharynx.
223856917|NCT04941924|PROCEDURE|Intraductal Radio-Frequency Ablation|"The electrode employed in this study is the STARmed ELRA™ (Endo Luminal Radiofrequency Ablation) electrode; this is a CE marked device. The selected electrode will be connected to the VIVA™ Combo generator (also a CE marked device) and advanced over the guide wire.~The power of the generator should be set at either 7 or 10 W depending on the electrode used per manufacturer instructions. An ablation should then be applied at a temperature of 70 to 80℃ for 2 minutes. For longer length strictures or stent occlusions, the RFA probe is withdrawn from proximal to distal in a step by step fashion in respect to the access method used."
223856918|NCT04941924|DEVICE|Biliary Stent Placement|Taewoong Niti-S™ LCD Biliary stents (CE marked uncovered self-expanding metal stents) placed according to standard local practice.
223856919|NCT00325923|BEHAVIORAL|Decision aid|
223856920|NCT06281431|PROCEDURE|Echogenic nerve block needle|A 22G 8-cm echogenic nerve block needle (LEAPMED, CHINA) is selected for the procedure, administered under ultrasound guidance. Subsequently, a volume of 20 ml 0.375% ropivacaine is injected at the needle's tip for analgesic effect. The spread of the medication will be assessed through short- and long-axis imaging perspectives. Following this, evaluations are conducted to assess acute postoperative pain as well as chronic postoperative pain. Parameters such as the duration of nerve blockade, the incidence of punctures, and any associated complications are all meticulously appraised.
223856921|NCT06281431|PROCEDURE|Non-echogenic nerve block needle|A 22G 8-cm thin wall low bottom nerve block needle (KDL, CHINA) is selected for the procedure, administered under ultrasound guidance. Subsequently, a volume of 20 ml 0.375% ropivacaine is injected at the needle's tip for analgesic effect. The distribution of the medication will be assessed using short- and long-axis imaging perspectives. Following this, evaluations are conducted to assess acute postoperative pain as well as chronic postoperative pain. Parameters such as the duration of nerve blockade, the number of punctures, and any associated complications are all meticulously appraised.
223856922|NCT04107129|PROCEDURE|Endometrial Biopsy|An endometrial biopsy is the removal of a small piece of tissue from the endometrium, which is the lining of the uterus. Endometrial tissue will be tested for BCL6 and SIRT1 Biomarkers
223856923|NCT04107129|OTHER|Euploid embryo transfer|Patients undergoing IVF and Preimplantation genetic testing will undergo delayed euploid frozen embryo transfer per clinical protocol and standard of care.
223856924|NCT04107129|DIAGNOSTIC_TEST|Blood sample|Estradiol and Progesterone levels in the blood will be checked
223856925|NCT04524832|DRUG|Oral semaglutide|Participants will receive once daily semaglutide tablets (oral administration) in a dose escalating manner for 16 weeks
223856926|NCT00202969|DRUG|S-1|S-1 40 mg/m2 administered orally BID after breakfast and evening meal from Day 1 through Day 28 repeated 6 weeks.
223856927|NCT00202969|DRUG|S-1 plus CDDP|S-1 40 mg/m2 administered orally BID after breakfast and evening meal from Day 1 through Day 21 with a single dose of CDDP 60 mg/m2 will be administered as an 1- to 3-hour IV infusion following the morning dose of S-1 on Day 8. The combination therapy will be repeated every 5 weeks.
223856928|NCT00202969|DRUG|5-FU plus CDDP|5-FU 600 mg/m2/24 hours administered intravenously as a CI over 120 hours (Days 1 through 5) along with a 30-minute infusion CDDP 20 mg/m2 from Day 1 through Day 5. The control treatment arm will be repeated every 4 weeks.
223856929|NCT06278025|DIAGNOSTIC_TEST|assessment|"DCF Muscle Strength Evaluation~DCF muscle strength was determined using the 5-step Craniocervical Flexion Test (CCFT) performed with a Chattanooga Stabilizer ™ Pressure Biofeedback Unit which was developed by Jull et al. \[33, 34\]. The CCFT is based on the craniocervical flexion movement, which is provided by DCF muscle contraction. The CCFT includes 5 pressure increments starting with 20mmHg.Activation score ranges from 0 to 10. The performance index is determined by both the highest pressure level and the number of repetitions.~Evaluation of the DCF Endurance The DCF endurance test, which is a valid and reliable method, was used to measure DCF muscle endurance \[36\]. Conducted in supine, endurance is measured by calculating the time (in seconds) an individual can raise their head at minimal flexion angle."
223856930|NCT04352582|OTHER|Survey|Survey
223856931|NCT02959658|DRUG|Dimethyl fumarate|
223856932|NCT02959658|DRUG|Placebo|Manufactured to mimic Dimethyl Fumarate capsules
223856933|NCT00480766|DRUG|MK0217/Duration of Treatment : 12 Months|
223856934|NCT06544382|OTHER|The Long COVID Rehabilitation Intervention|The intervention is a structured rehabilitation intervention with a duration of minimum 3 months comprising 4-12 individual sessions and 1-4 group-based courses delivered by physiotherapists and occupational therapists.
223856935|NCT06544382|OTHER|Usual care|A less structured rehabilitation programme comprising individual session with a few group options with patients with long COVID or mixed diagnoses.
223856936|NCT04701294|DEVICE|Giomer Beautifil flow plusF03 Shofu-Japan|A pair of permanent first molars will be used for each participant homologs The operator will apply in the upper / lower first molars the sealant material in the order assigned according to the previous randomization. For the intervention group, they will be sealed based on a fluid resin with s-prg glass ionomer filling (Giomer F03 Beautiful -Shofu) in association with a bottle of adhesive (Single Bond) . The evaluation and monitoring process; another operator will record the retention of the sealant in a period of 6, 9 and 12 months.
223856937|NCT04701294|DEVICE|Tetric N flow ivoclar vivadent-Germany|And on the contralateral side (control) the first upper / lower molars will be sealed will be sealed with a fluid resin compound (Tetric N-Flow ivoclar vivadent) in association with a bottle of adhesive (Single Bond). Both materials have a similar color. The operator and the child will not be informed about the brand of the material used. The assistant will collect the data in the file. The evaluation and monitoring process; another operator will record the retention of the sealant in a period of 6, 9 and 12 months.
223856938|NCT05558020|DIAGNOSTIC_TEST|Continuous laryngoscopy during exercise (CLE), incremental exercise protocol|The incremental work rate exercise test will be performed using a cycle-ergometer. The exercise protocol is initiated by a five-minute warm-up at 50 Watts (W). Subsequently, they will complete a stepwise protocol, which will begin at 100 W and increase by 2 W every 6th second, until exhaustion or until the patient is unable to continue exercise, for any reason.
223856939|NCT05558020|DIAGNOSTIC_TEST|Continuous laryngoscopy during exercise (CLE), continuous work rate protocol|"Within two weeks the participants will perform an additional CLE-test at various intensities. The new exercise protocol is designed to induce EILO at different exercise intensities. Using the participants' individually calculated exercise capacity, three different workloads (70 %, 80 % and 90 %) will be calculated.~The exercise protocol will be initiated with a five-minute warm-up at 50 W, then the workload will increase to the watt equivalent to 70 % of the participant's maximal exercise capacity. This workload will be fixed for ten minutes and only terminated if the participant feels the need to stop due to exhaustion or breathing difficulties. Next, the participant will have a five-minute resting phase with a set workload of 50 W. This protocol will be repeated at a workload equivalent to 80 % and 90 %"
223856940|NCT02817724|DEVICE|BENECA System|BENECA System is a mobile application whit aims to recover a healthy lifestyle in breast cancer survivors (in terms of energy balance: physical activity and dietary).
223856941|NCT02817724|OTHER|Supervised-occupational therapy program|It is a comprehensive program that covers most of the physical, cognitive and emotional needs of these patients after oncology treatment from occupational therapy perspective.
223856942|NCT04567888|BEHAVIORAL|Happify Teens|An online platform for conveying techniques from positive psychology, cognitive-behavioral therapy, and mindfulness-based stress reduction.
223856943|NCT03874650|BEHAVIORAL|Activity Planning Group|Participants in this group will receive 8 1-hour sessions of Behavioural Activation combined with select Goal Management Training strategies over the course of 8 weeks.
223856944|NCT03874650|BEHAVIORAL|Activity Engagement Group|Participants in this group will attend 8 1-hour sessions of various social activities such as board games and puzzles.
223856945|NCT03874650|BEHAVIORAL|Waitlist Group|Participants in this group will continue on their care as usual before being re-randomised into either the Activity Planning Group or Activity Engagement Group after 8 weeks.
223856946|NCT00273949|DRUG|lactulose|
223856947|NCT00993850|BEHAVIORAL|Cognitive behavioral therapy for insomnia|Attending 6-10 treatment sessions in one of our interview rooms. The sessions will be offered on a weekly basis. Each session takes approximately 50 minutes.
223856948|NCT00993850|OTHER|Bipolar education|Psychoeducation
223856949|NCT04643236|BEHAVIORAL|Periodontal health education session|This session comprised of a condensed version of motivational interviewing and a periodontal education view/point. First, patients were analysed in terms of expectations from periodontal treatment/oral hygiene practice, knowledge about periodontal diseases and its consequences, daily oral hygiene routine, awareness of the current periodontal status and the main reasons for not doing proper brushing and interproximal cleaning. The same researcher who did not included in the clinic process informed the patients about how periodontal diseases develops, its aetiology, symptoms, consequences and the relationship with the important systemic disorders verbally and via brochure as well. The importance of the patients' own efforts about daily cleaning of the mouth were emphasized. Finally oral hygiene instructions, including brushing and flossing, were demonstrated to each patient after nonsurgical periodontal treatment.
223856950|NCT04643236|BEHAVIORAL|Oral hygiene motivation session|Standard oral hygiene instructions, including brushing and flossing, were demonstrated to each patient after nonsurgical periodontal treatment.
223856951|NCT01052233|PROCEDURE|Arthroscopic partial meniscectomy|Arthroscopic partial meniscectomy of the degenerative tear of medial meniscus
223856952|NCT01052233|PROCEDURE|Arthroscopy (diagnostic)|Diagnostic arthroscopy of the knee
223856953|NCT05128019|BEHAVIORAL|ICIT|Patients in the intervention group will receive a number of consultations with their GP based on the ICIT
223856954|NCT01137266|DEVICE|TENS|TENS
223856955|NCT02045719|DRUG|uncaria tomentosa (cat´s claw)|
223856956|NCT02376036|DRUG|MGD010|MGD010 is a CD32B x CD79B bi-specific antibody-based molecular construct referred to as a Dual Affinity Re-Targeting (DART) molecule. MGD010 will be administered as a single agent.
223856957|NCT02376036|DRUG|Placebo|Placebo comparator.
224076171|NCT01062360|DRUG|Acetylsalicylic Acid (Aspirin, BAYE4465)|Single oral dose of 1 to 2 sachets Acetylsalicylic Acid, each containing granules of 500 mg Acetylsalicylic Acid (ASA), to be taken orally after dissolving in a glass of water; to be repeated as needed every 6 hours for a period of not more than 3 days.
224076172|NCT01062360|DRUG|Pseudoephedrine|Single oral dose of 1 to 2 sachets Pseudoephedrine, each containing granules 30 mg Pseudoephedrine, to be taken orally after dissolving in a glass of water; to be repeated as needed every 6 hours for a period of not more than 3 days.
223856958|NCT02376036|BIOLOGICAL|Hepatitis A vaccine|Hepatitis A vaccine, inactivated
223856959|NCT05981534|DRUG|Vitamin D|4000IU/day vitamin D supplement will be used for 6 months
223856960|NCT05981534|DRUG|Placebo|Placebo will be used for 6 months
223856961|NCT01412034|DRUG|CER-001|Biweekly infusion
223856962|NCT03414736|DRUG|SAR425899|"Pharmaceutical form: Solution~Route of administration: Subcutaneous"
223856963|NCT04671719|BIOLOGICAL|blood sample|blood sample for circulating autotaxin measurement (5ml).
223856964|NCT04028635|BEHAVIORAL|Cognitive-behavioral therapy plus VR-based body exposure|Combine usual cognitive-behavioral treatment (CBT) sessions with additional five VR-based body-exposure therapy sessions.
223856965|NCT04028635|BEHAVIORAL|Cognitive behavioral therapy|Usual CBT
223856966|NCT00803933|DRUG|DB289|Pafuramidine maleate (DB289), 100 mg BID orally
223856967|NCT00803933|DRUG|Pentamidine|Pentamidine isethionate (Aventis) for injection (200 mg/vial), 4 mg/kg QD IM
223856968|NCT06440824|DRUG|Romiplostim N01|2.0 µg/kg, subcutaneous injection, once a week, up to a maximum of 8 weeks. Stop medication when platelet count increases by 50 × 109/L or more compared to before medication
223856969|NCT06440824|DRUG|Recombinant Human Thrombopoietin|30000 U/d, subcutaneously injected once a day, for a maximum of 8 weeks. Medication should be stopped when platelets increase by 50 × 109/L or more compared to before medication
223856970|NCT01569919|BIOLOGICAL|TroVax®|Dose of 1 x 10\^9 TCID 50/ml, in 1ml, given on day 1 of weeks 1, 3, 6, 9, 12, 15, 18, 21, 24.
223856971|NCT01569919|DRUG|Pemetrexed|500 mg/m\^2 over 10 mins, given on day 3 of weeks 4, 7, 10, 13.
223856972|NCT01569919|DRUG|Cisplatin|75mg/m\^2 over 1 hour, given on day 3 of weeks 4, 7, 10, 13
223856973|NCT01569919|DIETARY_SUPPLEMENT|Vitamin B12|1000μg intramuscular, Day 2 of weeks 3 and 12
223856974|NCT01569919|DIETARY_SUPPLEMENT|Folic Acid|400μg oral daily from Day 2 of week 3 to Day 2 of week 16
223856975|NCT01569919|DRUG|Dexamethasone|4mg BD, Days 2-6 of weeks 4, 7, 10, 13
223856976|NCT00630188|OTHER|You Decide|"For Patients: Video-based decision aid on prostate cancer screening, One-on-One values clarification session with research assistant, One-on-One coaching session with research assistant to encourage good interaction with clinician~For Physicians: a one-time educational session on prostate cancer and the value of shared decision making"
223856977|NCT00630188|OTHER|Reducing Your Risks in the Crash|Publicly available video on highway safety and reducing individual risks in a crash
223856978|NCT05300399|DEVICE|mHealth app|The local healthcare providers will be assigned to an intervention group receiving the mHealth app to be used in their daily practices or a control group.
223856979|NCT02276820|BIOLOGICAL|Viralym-A|"Follow-up Assessments: The timing of follow-up visits is based on the date of Viralym-A infusion. If a patient has multiple Viralym-A infusions the schedule resets again at the beginning so follow up relates to the last Viralym-A infusion.~Follow up will occur at 7 days, 14 days, 21 days, 28 days, 42 days, 90 days, 180 days, and 365 days post enrollment."
223856980|NCT05183906|DIAGNOSTIC_TEST|Next generation sequencing|Evaluation of microbiological culturing versus next generation sequencing for ribosomal DNA
223856981|NCT03145935|DIAGNOSTIC_TEST|Abdominal compression (AC)|An echocardiography with stroke volume measurement coupled with an abdominal compression will be performed before and after ta diuretics induced diuresis of 10ml/kg in pediatric patients hospitalized in a pediatric intensive care unit (PICU) diagnosed with fluid overload
223856982|NCT03145935|DIAGNOSTIC_TEST|blood sample|proteinemia and hematocrit will be measured before and after a diuretics induced diuresis of 10ml/kg
223856983|NCT00199342|DRUG|KW-2871|potentially therapeutic monoclonal antibody for the treatment of advanced stage four melanoma
223856984|NCT01687452|BIOLOGICAL|Blood samples|
223856985|NCT03312335|DRUG|Low-dose Aldesleukin (Proleukin®)|Subcutaneous injection of 1.5 million international units (MIU) of Aldesleukin (Proleukin®, Interleukin-2) once daily in 5-day courses every three weeks for a total of 4 cycles.
223856986|NCT03320096|DEVICE|Microfocused ultrasound with visualization|Subjects will receive 2 treatments (day 1 and day 30), each at a 3.0mm depth and 0.30 Joule of energy. Treatment will be delivered in a 3\*4 grid, 12 treatment squares, delivering 60 lines of treatment per square, i.e., 720 lines per axilla in each treatment (1440 lines total per treatment.)
223856987|NCT05456386|BEHAVIORAL|The Circadian Rhythm Approach to Weight Loss (CRAWL)|The Circadian Rhythm Approach to Weight Loss (CRAWL) is a behavioral intervention that is designed to provide support for behavioral change to improve sleep and feeding parameters that will lead to sustainable weight loss.
223856988|NCT04136496|DEVICE|Black-Eye Ink|There are two proposed studies utilizing the Ink during differing timepoints.Both will identify patients with breast cancer, with a biopsied metastatic axillary lymph node(LN) with a tissue marker clip placed, as is current practice. In Study A, 0.5mL of Black Eye Ink will be placed in the metastatic LN after neoadjuvant therapy. In Study B, 0.5mL of Black Eye Ink will be placed before neoadjuvant therapy. In both studies, the LN containing the tissue marker clip will be the one to have the radioactive seed and Ink inserted. The seed will still be inserted, in the event the dye is not well-visualized. In both studies, the surgeon will attempt to find the LN by direct visualization and then confirm the appropriate LN has been removed by using the Gamma probe and intra-operative radiographs. If the seed is not within the tattooed node, the LN containing the seed will also be removed. All lymph nodes injected with Ink will be removed by the surgeon;no Ink-injected node remains in body.
223856989|NCT01002768|DRUG|insulin degludec|Day 1-4: Once daily subcutaneous (under the skin) injection similar to 80% of individual basal insulin requirement. Day 5: Three times the individual basal insulin requirement.
223856990|NCT01002768|DRUG|insulin glargine|Day 1-4: Once daily subcutaneous (under the skin) injection similar to 80% of individual basal insulin requirement. Day 5: Three times the individual basal insulin requirement.
223856991|NCT04485156|DRUG|High-dose rifampicin|30mg/kg
223856992|NCT04485156|DRUG|Isoniazid|300mg
223856993|NCT04485156|DRUG|Pyrazinamide|20-30mg/kg
223856994|NCT04485156|DRUG|Ethambutol|15-20mg/kg
223856995|NCT04485156|DRUG|Rifampicin|10mg/kg
223856996|NCT02772653|OTHER|Blood Lactate|Analyzed at the 1rst, 8th and 24th hour from hospital admission
223856997|NCT02772653|OTHER|Blood Base Excess|Analyzed at the 1rst, 8th and 24th hour from hospital admission
223856998|NCT02772653|OTHER|Blood B-type Natriuretic Peptide|Analyzed at the 1rst, 8th and 24th hour from hospital admission
223856999|NCT02772653|OTHER|Blood Thromboelastometry (ROTEM)|Analyzed at the 1rst, 8th and 24th hour from hospital admission
223857000|NCT02772653|OTHER|Near-infrared spectroscopy|Analyzed at the 1rst, 8th and 24th hour from hospital admission
223857001|NCT02772653|OTHER|Sublingual videomicroscopy|Analyzed at the 1rst, 8th and 24th hour from hospital admission
223857002|NCT06552390|PROCEDURE|Cardiac Rehabilitation|"HRN4HTx is a phase 1 rehabilitation intervention protocol for post-heart transplant focused on the physical exercise component, and an educational plan regarding risk factors and safety criteria. The intervention protocol and its assessments are implemented by the team's rehabilitation nurses, always safeguarding the protective isolation required for these patients. The physical training protocol is divided into five stages of progressive levels of intervention. The protocol was defined following FITT parameters, international recommendations, and an integrated teaching program aimed at the therapeutic regimen exercise area. The frequency of intervention sessions is 7 days a week, twice a day (average of 13 sessions per week) throughout the hospitalization.~The intensity was defined according to Borg's modified scale of subjective perception of exertion (SPE), which must be maintained at less than 5."
223857003|NCT04577625|DIETARY_SUPPLEMENT|Lactobacillus reuteri (L. reuteri)|L.reuteri high or low dose with vitamin D3 compared to vitamin D3 only
223857004|NCT00750750|DRUG|mometasone furoate nasal spray (MFNS)|Placebo capsules three times daily for 10 days, and MFNS 50 mcg/spray, 2 sprays in each nostril once daily in the morning and placebo nasal spray once daily in the evening for 15 days, followed by 14-day no-treatment observation period
223857005|NCT00750750|DRUG|MFNS|Placebo capsules three times daily for 10 days, and MFNS 50 mcg/spray, 2 sprays in each nostril twice daily for 15 days followed by 14-day no-treatment observation period
223857006|NCT00750750|DRUG|Amoxicillin|Amoxicillin 500 mg/capsule, one capsule 3 times a day for 10 days and placebo nasal spray twice daily for 15 days, followed by a 14-day no-treatment observation period
223857007|NCT00750750|DRUG|Placebo|Placebo capsule three times daily for 10 days and placebo nasal spray twice daily for 15 days, followed by 14-day no-treatment observation
223857008|NCT02573818|DEVICE|SEDASYS System|propofol sedation with the SEDASYS System
223857009|NCT02967588|BEHAVIORAL|Intervention group|"All stages of the intervention will take place during hospitalization. Patients will complete a questionnaire about their personal beliefs about medicines. Patients responses to this questionnaire will form the basis of Session 1 where beliefs about medicines will be discussed. Any negative beliefs or concerns will be discussed and beliefs about drug necessity will be encouraged.~Session 2 will focus on developing specific action plans for taking medication at home. Patients will be asked to formulate an if-then plan ('If it is time X in place Y and I am doing Z, then I will take my pill dose').~Prior to discharge, patients will complete the beliefs questionnaire again to see if there has been any shift in their beliefs about medications. Patients will also be asked to provide detailed feedback about the study. The investigators want to know whether the intervention setting, timing, content and delivery method seem to be acceptable to patients."
223857010|NCT00001384|DRUG|Adriamycin|
223857011|NCT00001384|DRUG|cyclophosphamide|
223857012|NCT00001384|DRUG|G-CSF|
223857013|NCT00001384|DRUG|paclitaxel|
223857014|NCT05818904|OTHER|Physical Therapy|All arthrosis participants will be treated as the traditional methods using physical therapy.
223857015|NCT01899872|BEHAVIORAL|Resistance exercise session|Resistance exercise session consisting of 4 lower-limb exercises, with 4 sets, 12 repetitions per set, at an intensity of 60% of maximal strength.
223857016|NCT01899872|BEHAVIORAL|Aerobic exercise session|Aerobic exercise session consisting of 40 minutes of lower-limb bicycle.
223857017|NCT04189107|DRUG|Dexamethasone|High-dose dexamethasone peroperative and postoperative on day 2 and 4
223857018|NCT04189107|DRUG|Placebo|low dose dexamethasone peroperative and placebo postoperatively on day 2 and 4
223857019|NCT06121830|DRUG|DWP14012 20mg|DWP14012 20mg, tablet, orally, once daily for up to 4 weeks
223857020|NCT06121830|DRUG|DWP14012 40mg|DWP14012 40mg, tablet, orally, once daily for up to 4 weeks
223857021|NCT06121830|DRUG|Placebo|Placebo, tablet, orally, once daily for up to 4 weeks
223857022|NCT05843136|OTHER|physiotherapy treatment|this is an interventional study of the use of 3 physiotherapy treatment techniques in order to evaluate the effectiveness of interferential current in relieving chronic low back pain
223857023|NCT00436644|DRUG|Lapatinib|1250 mg orally days 1 -28.
223857024|NCT00436644|DRUG|Topotecan|3.2 mg/m2 IV over 30 min in 100mL D5W (5% dextrose in water) or 0.9% NS at days 1, 8 \& 15.
223857025|NCT00619645|DRUG|busulfan|
223857026|NCT00619645|DRUG|cyclosporine|
223857027|NCT00619645|DRUG|fludarabine phosphate|
223857028|NCT00619645|DRUG|mycophenolate mofetil|
223857029|NCT00619645|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
223857030|NCT00619645|PROCEDURE|peripheral blood stem cell transplantation|
223857031|NCT00261053|DRUG|i.v. recombinant human C1 inhibitor|
223857032|NCT01671241|DEVICE|Polyethylene wrap|
223857033|NCT01671241|DEVICE|Polyethylene wrap|
223857034|NCT03229707|DEVICE|Digital photography using software Photoshop|"When taking the image, a gray card is used for subsequent exposure calibration in Adobe Camera Raw (which is packaged with Photoshop).~* Images are then opened into Photoshop.~* The INFO panel must be open.~* Click on the small eyedropper in the Info panel window and click on ''Lab Color.~* Place the mouse over the center of the tooth to be measured for L value.~* Click on the HSB Color option, which stands for hue, saturation, and brightness."
224076173|NCT01062360|DRUG|Placebo|Single oral dose of 1 to 2 sachets, each containing Placebo granules, to be taken orally after dissolving in a glass of water; to be repeated as needed every 6 hours for a period of not more than 3 days.
223857035|NCT03229707|DEVICE|Vita 3D master shade guide|Alpha (A)Perfectly matched Beta (B)Not perfectly matched Charlie (C)unacceptable Determent by 10 observers
223857036|NCT04364269|DRUG|VIT-2763 once a day (QD)|Participants will receive VIT-2763 QD at a dose of 60 mg if their body weight is between 40 kg to 59 kg or at a dose of 120 mg if their body weight is between 60 kg and 100 kg, during 12 weeks.
223857037|NCT04364269|DRUG|VIT-2763 twice a day (BID)|Participants will receive VIT-2763 BID at a dose of 60 mg if their body weight is between 40 kg to 59 kg or at a dose of 120 mg if their body weight is between 60 kg and 100 kg, during 12 weeks.
223857038|NCT04364269|DRUG|Placebo|Participants will receive hard capsules of Placebo, twice a day.
223857039|NCT04629118|DEVICE|Selution SLR™ 018 Drug Eluting Balloon|Target lesion will be pre-dilated with high pressure non-compliant balloon, then treated with SELUTION SLR™ 018 DEB Balloon.
223857040|NCT04683159|DRUG|Brimonidine Tartrate 0.15% Oph Soln|1 drop of brimonidine 0.15% (\~0.05mL) 15 minutes prior to surgery
223857041|NCT04683159|DRUG|Brimonidine Tartrate 0.025% Oph Soln|1 drop of brimonidine 0.025% (\~0.05mL) 15 minutes prior to surgery
223857042|NCT01064804|DRUG|PF-04191834|PF-04191834. 100mg Immediate Release Tablets or oral suspension
223857043|NCT00005840|DRUG|Paclitaxel|Given IV
223857044|NCT00005840|DRUG|Cisplatin|Given IV
223857045|NCT00005840|RADIATION|Radiation Therapy|Undergo whole abdominal radiation therapy
223857046|NCT05481333|DRUG|REGN7999|Ascending IV or SC dose administered per protocol
223857047|NCT05481333|DRUG|Placebo|Ascending IV or SC dose administered per protocol
223857048|NCT04276402|PROCEDURE|Irradiation of implants with 808nm laser|Irradiation of implants with 808nm laser
223857049|NCT03326648|OTHER|Strength training|Heavy load strength training performed twice a week for 10 weeks.
223857050|NCT03326648|DIETARY_SUPPLEMENT|Protein supplementation|Dietary protein supplement (protein-enriched milk with 0,2 % fat). 0,33 l each day for 10 weeks.
223857051|NCT05309980|OTHER|standard of care|retrospective study : standard of care
223857052|NCT04347135|DRUG|F-18 FES|F-18 FES PET/MRI for detection of endometriosis.
223857053|NCT06116812|OTHER|the laughter yoga group|"They will gather in five-person chemotherapy rooms, and laughter therapy will be applied to the women in the application group while they are receiving chemotherapy. Sessions will last approximately 40-60 minutes.The application will last for a total of 8 weeks, twice a week.~The 9th and 16th sessions will be held face to face and the scales will be filled in face to face meetings in these weeks (at the end of the 4th week and the 8th week). Since patients receive chemotherapy treatment once a month, face-to-face sessions are planned to be administered while the patient is receiving treatment. (Those whose treatment timing frequency is not appropriate will be excluded).~* Other sessions will be held online via smartphone applications. Online sessions will be determined according to the mutual decision of the participants, at a time convenient for the participants.~* In the 12th week, all groups will have the scales filled in again."
223857054|NCT06116812|OTHER|the mindfulness based stress reduction group|"Mindfulnes therapy will be applied to the women in the application group while they are receiving chemotherapy, in five-person chemotherapy rooms. Sessions will last approximately 40-60 minutes.The application will last for a total of 8 weeks, twice a week.~The 9th and 16th sessions will be held face to face and the scales will be filled in face to face meetings in these weeks (at the end of the 4th week and the 8th week). Since patients receive chemotherapy treatment once a month, face-to-face sessions are planned to be administered while the patient is receiving treatment. (Those whose treatment timing frequency is not appropriate will be excluded).~* Other sessions will be held online via smartphone applications. Online sessions will be determined according to the mutual decision of the participants, at a time convenient for the participants.~* In the 12th week, all groups will have the scales filled in again."
223857055|NCT01490580|DRUG|atropine+ propofol|Atropine bolus: 20 µg/kg Propofol injected over 60 seconds: 1 mg/kg for infants \< 1000g - Renewable once 2.5 mg/kg for infants \> 1000G - Possible additional dose of 1 mg/kg
223857056|NCT01490580|DRUG|atropine + atracurium + sufentanil|Atropine bolus: 20 µg/kg Atracurium: 0.3 mg/kg- Possible additional dose of 0.1 mg/kg Sufentanil: 0.1 µg/kg for infants \< 1000g 0.2 µg/kg for infants \> 1000g
223857057|NCT01598948|DRUG|mipomersen|mipomersen 200 mg subcutaneously every week for 37 weeks (phase 1: 26 weeks; phase 2: 11 weeks)
223857058|NCT01846169|BEHAVIORAL|Food deliveries|Frequency of food deliveries is based on level of food insecurity at baseline (i.e., more food insecurity receives more frequent food deliveries). Deliveries are tailored to the diet of the client (e.g., consist of soft foods if participant has trouble chewing; has more fruits and vegetables if that was a food category the participant at less of at baseline). The brief nutrition education is a review of basic nutrition concepts and healthy eating ideas.
223857059|NCT03719391|OTHER|Virginia Tobacco flavored JUUL 5% ENDS|Treatment with Virginia Tobacco flavored JUUL 5% ENDS (10 puffs).
223857060|NCT03719391|OTHER|Cool Mint flavored JUUL 5% ENDS|Treatment with Cool Mint flavored JUUL 5% ENDS (10 puffs).
223857061|NCT03719391|OTHER|Mango flavored JUUL 5% ENDS|Treatment with Mango flavored JUUL 5% ENDS (10 puffs).
223857062|NCT03719391|OTHER|Creme Brulee flavored JUUL 5% ENDS|Treatment with Creme Brulee flavored JUUL 5% ENDS (10 puffs).
223857063|NCT03719391|OTHER|VUSE Solo e-cigarette|Treatment with VUSE Solo Original with 4.8% nicotine e-cigarette (10 puffs).
223857064|NCT03719391|OTHER|Nicorette White Ice Mint 4mg nicotine polacrilex gum|Treatment with Nicorette White Ice Mint 4mg Nicotine polacrilex gum (30 minutes Chew and Park method)
223857065|NCT03719391|OTHER|Usual Brand combustible cigarette|Treatment with usual brand cigarette (10 puffs).
223857066|NCT04155151|OTHER|6 minute walk test|A test of fitness that requests the participant to walk as far as they can at their own pace in 6 minutes, the distance walked in those 6 minutes is recorded.
223857067|NCT00371566|DRUG|Lapatinib oral tablets|
223857068|NCT00371566|DRUG|Placebo|
223857069|NCT02029664|DEVICE|Visual distortion increment based on the gait pattern|
223857070|NCT02009735|DEVICE|virosensor|"virosensor, which was developed for the rapid and sensitive detection of viral antigen in medical samples, will be used for analyzing the interaction kinetics between anti-influenza-virus (or anti-EV71-virus) and its influenza virus antigen (or EV71 antigen) present in patients and normal samples.~The system incorporates the use of chip formats. In antibody probing, antibodies are bound as a suitable probe, which specifically and selectively binds targeted molecules (virus antigen) in the test specimens."
223857071|NCT06444386|DEVICE|MPP + SyncAV|Cardiac resynchronization therapy (CRT) features of MultiPoint Pacing (MPP) and SyncAV (dynamic atrioventricular delay programming) enabled.
223857072|NCT02375048|RADIATION|Hypofractionated WBI|Dose prescription was 40.5 Gy to PTVWB and 48.0 Gy to PTVboost in 15 fractions over 3 weeks, with simultaneous integrated boost delivering 2.7 and 3.2Gy/fraction for each PTV respectively. Daily image guided radiotherapy (IGRT) were generated before each treatment session in each patient to verify the set-up.
223857073|NCT02375048|RADIATION|Accelerated Partial Breast Irradiation|APBI was delivered at a dose of 30 Gy in five 6-Gy/day fractions over 10 days (every other day) with IGRT at each treatment.
223857074|NCT03662399|DEVICE|Insoles|Orthotic Insoles
223857075|NCT03662399|OTHER|Standard shoe|Standard shoe
223857076|NCT04534712|DIAGNOSTIC_TEST|LYMPHOCYTE MONOCYTE RATIO|Absolute lymphicyte and absolute monocyte counts are recorded on admission of COVID -19 positive patient and ratio is derived. the patients are followed up for any progression of disease stage.
223857077|NCT04302155|OTHER|balance-specific -games focusing on dynamic aspects of COP on Wii fit system.|"The participants were randomly assigned into two groups interventional and control. Total 18 minutes session was given to both groups wii fit group and traditional balance training group. All participants were given 3 sessions per week for 6.~Total 48 participants were initially accessed initially for eligibility , 13 participants were excluded because of having good balance and good balance age score on Wii fit assessment, 35 participants were recruited for balance training. These participants were randomly divided into Wii fit and traditional training group through sealed enveloped method 18 participants was recruited in Wii fit group and 17 in traditional balance training group. 3 participants drop out from Wii fit group and 2 from traditional balance training group.~Some examples include catching apples in a basket ,moving a golf ball around barriers towards a hole , popping rising balloons/bubbles and air hockey ."
223857078|NCT04302155|OTHER|mini trampoline and inflatable discs group|"High skipping and landing on a limb every time (2 repeats of 45 s each leg).Standing on one leg and try to catch the ball thrown at them in various directions by the researcher (2 repeats of 45 s each leg) Exercises in inFlated rubber hemisphere attached toa rigid platform (BOSU)~1. Standing on BOSU's round soft surface with one foot, in an attempt to maintain balance (2 repeats of 45 s each leg).~2. Standing on BOSU's round soft surface with one foot, in an attempt to maintain balance, while lifting the non-support leg forward and backward (2 repeats of 45 s each leg).~3. Standing on BOSU flat hard surface with both legs, in an attempt to maintain balance (3 minutes on both legs).~4. Standing on BOSUs flat hard surface with both feet, in an attempt to maintain balance, while trying to catch the ball thrown at them by the experimenter in various directions (3 minutes on both leg)"
223857079|NCT00309088|DRUG|tacrolimus|oral
223857080|NCT00309088|DRUG|placebo|oral
223857081|NCT00585455|DRUG|sertraline|open label 25-50 mg daily as tolerated
223857082|NCT03547752|OTHER|observed action and motor imaginery|Observation of a video of neck movement and imagination of the same observed movement, feeling the realization of the movement but not developing it.
223857083|NCT04094155|DIAGNOSTIC_TEST|retinal vascular analysis|Retinal fundoscopy over a 3 week period in stationary patients after aneurysmatic subarachnoid hemorrhage
223857084|NCT00972504|DRUG|GSK835726 10mg|GSK835726 10mg tablet
223857085|NCT00972504|DRUG|GSK1004723 1000mcg|GSK1004723 1000mcg nasal spray solution
223857086|NCT00972504|DRUG|Cetirizine 10mg|Cetirizine 10mg active comparator
223857087|NCT00972504|DRUG|placebo|placebo to match actives
223857088|NCT06252727|DRUG|Aminolevulinic Acid|Given PO
223857089|NCT00732368|DRUG|Mometasone furoate|Two sprays mometasone nasal spray per nostril once daily (200 mcg/day). After 4 weeks, dose can be decreased to one spray per nostril daily or increased to 4 sprays per nostril daily.
223857090|NCT00234442|DRUG|Iressa (Gefitinib)|
223857091|NCT04246762|DRUG|Olokizumab|Sterile solution for subcutaneous (SC) injection, 128 mg (0.8 mL injection)
223857092|NCT04246762|DRUG|Omeprazole|Tablets, 20 mg, oral
223857093|NCT04246762|DRUG|Caffeine|Tablets, 100 mg, oral
223857094|NCT04246762|DRUG|Warfarin+ Vitamin K|Warfarin -Tablets 10 mg (containing 5 mg S-warfarin), oral. Vitamin K - solution for intravenous injection, 10 mg/mL ampoule, orally.
223857095|NCT04246762|DRUG|Midazolam|Syrup, 2 mg/mL, oral
223857096|NCT00597519|DRUG|Fludarabine, Cyclophosphamide|"Fludarabine 25 mg/m2/day IV in the morning x 3 days (days -7, -6 and -5) for a total dose of 75 mg/m2 followed by Cyclophosphamide on days -6 and -5. 60mg/kg/day IV over 30-60 minutes x 2 days (days -6 and -5). High volume fluids should commence approximately 12 hours prior to drug and continue until 24 hours after second dose.~Total Body Irradiation: 125 cGy x 11 doses (TID on days -3, -2, -1 and BID on day 0) for a total TBI dose of 1375 cGy. Pediatric patients unable to tolerate a TID dosing schedule can receive 150 cGy x 8 doses (BID on days -3, -2, -1, and 0). All patients will receive GVHD prophylaxis with 2 drugs: Cyclosporine A and Mycophenolate mofetil (MMF).~Units should be given consecutively each over approximately 10-30 minutes.Pre-medication should include acetaminophen and diphenhydramine or hydroxyzine.G-CSF 5 mcg/kg/day IV/SQ (dose rounded to vial size to a maximum of 480 mcg) will be given from day +1 until ANC recovery."
223857097|NCT00597519|PROCEDURE|Transplantation|The UCB ( Umbilical Cord Blood) collection known as a unit is processed to remove excess plasma and red cells, tested for sterility, HLA-typed, cryopreserved and stored. This protocol involves the administration of two UCB units from two different donors. The units will be thawed in the Cytotherapy Laboratory as per the current standard operating procedure.
223857098|NCT00140972|DRUG|MK0663; etoricoxib / Duration of Treatment:4 Weeks|
223857099|NCT00140972|DRUG|Comparator: diclofenac sodium tablet 75 mg / Duration of Treatment:4 Weeks|
223857100|NCT04742842|BIOLOGICAL|COVIGEN C19 0.8 mg ID or Placebo ID|2 doses of COVIGEN C19 0.8 mg ID or Placebo ID will be given at Day 1 and Day 29.
223857101|NCT04742842|BIOLOGICAL|COVIGEN C19 2.0 mg IM or Placebo IM|2 doses of COVIGEN C19 2.0 mg IM or Placebo IM will be given at Day 1 and Day 29.
223857102|NCT04742842|BIOLOGICAL|COVIGEN C19 4.0 mg IM or Placebo IM|2 doses of COVIGEN C19 4.0 mg IM or Placebo IM will be given at Day 1 and Day 29.
223857103|NCT04742842|BIOLOGICAL|COVIGEN C20 1.0mg vaccine ID|COVIGEN C20 1.0mg ID vaccine will be given at Day 1
223857104|NCT05679713|DIAGNOSTIC_TEST|Comprehensive risk assessment algorithm|Risk assessment algorithm including clinical and patient-centered information and a novel RNA-based biomarkers using next-generation sequencing technology.
223857105|NCT00212784|DRUG|asenapine|Flexible dose, 1-2 tablets sublingual two times per day (1 or 2 tablets in the morning and 1 or 2 tablets in the evening). Each tablet contains either 5 mg asenapine or matching placebo.
223857106|NCT00212784|DRUG|olanzapine|Oral capsules (5 mg or placebo); 1 to 2 tablets twice daily
223857107|NCT00410124|DRUG|RAD001|The dose of RAD001 was 10 mg/day. Patients were instructed to take two tablets (5 mg each) by mouth every day.
223857108|NCT00410124|DRUG|Placebo|
223857109|NCT01184235|DRUG|Pharmacological Intervention|This study will include those anticipating or receiving any pharmacological intervention
223857110|NCT01006551|DRUG|Ziprasidone|20mg pills, dosing will be flexible, ranging from 10 to 160 mg divided BID or TID for the duration of the 52 week trial. In very rare cases, if the subject has shown some benefit and no side effects at a dose of 160mg and the treating clinician feels a further dose increase is necessary, the case would need to be presented to all of the other Principal Investigators for special consideration of further dose increases in 20 mg increments to an absolute maximal dose of 220mg.
223857111|NCT00765492|DRUG|AZD8529|oral
223857112|NCT00765492|DRUG|Placebo|oral
223857113|NCT03908424|OTHER|Epidural Blood patch.|"An epidural blood patch is a surgical procedure that uses autologous blood in order to close one or many holes in the dura mater of the spinal cord, usually as a result of a previous lumbar puncture. A small amount of the patient's blood is injected into the epidural space near the site of the original puncture; the resulting blood clot then patches the meningeal leak. An epidural needle is inserted into the epidural space at the site of the cerebrospinal fluid leak and blood is injected. The clotting factors of the blood close the hole in the dura."
223857114|NCT02955524|DRUG|Tetracaine 0.5%|One drop of 0.5% Proparacaine to nasolacrimal Duct to numb the ethmoidal nerve in the nasal passage on the side of the eye to be treated.
223857115|NCT02955524|DRUG|Lidocaine hydrochloride ophthalmic gel 3.5%|1ml of lidocaine gel is placed over the conjunctivae of the eye to be treated after the patient is under general anesthesia and before the procedure
223857116|NCT01800513|PROCEDURE|Endometrial Biopsy|
223857117|NCT01800513|PROCEDURE|Sham Procedure|
223857118|NCT02953080|OTHER|Call for life mHealth adherence support|Daily/ weekly pill reminder support Health Info-tips Appointment visit reminders Self-reported symptom support
223857119|NCT01345838|PROCEDURE|labrum|Two years follow-up after PAO, to find any differences among patients with and without known acetabular labral tears
223857120|NCT04473586|DEVICE|Spartan Cube CYP2C19 System|Using buccal material, determine the genotype of the \*2, \*3 and \*17 SNPs of the CYP2C19 gene on the Spartan Cube CYP2C19 System.
223857121|NCT01662180|DRUG|Follicle Stimulating Hormone|All patients will receive a fixed 75 IU rec follicle stimulating hormone per day subcutaneous injection stimulation protocol starting from cycle day 3, 4 or 5. The intervention done in this study is conform normal stimulation protocol and is not the target of this study.
223857122|NCT01377129|PROCEDURE|Single bundle anterior cruciate ligament reconstruction|Single bundle anterior cruciate ligamentoplasty
223857123|NCT01377129|PROCEDURE|Double bundle anterior cruciate ligament reconstruction|Double bundle anterior cruciate ligamentoplasty
223857124|NCT05998005|BEHAVIORAL|First Face Training Program|First Face for Mental Health is a culturally-appropriate community-based mental health training for lay persons and others that prepares learners to provide assistance to someone having a mental health crisis. The course takes approximately 8 hours to complete.
223857125|NCT05404893|DIAGNOSTIC_TEST|Fecal calprotectin measurement|Stool samples will be collected and fecal calprotectin levels will be measured using an enzymatic immunoassay kit.
223857126|NCT02206386|OTHER|MHTraining-Net|See Arm Description for more details.
223857127|NCT02206386|OTHER|Enhanced Support|Nurses in agencies randomized to Enhanced Support have full access to the study protocol and to recorded training in the use of the protocol and depression screening posted by Brightree.
223857128|NCT04848441|OTHER|The COVID-19 vaccines BNT162b2, mRNA-1273 and ChAdOx1|The purpose of the study is to compare the effects of BNT162b2, mRNA-1273 and ChAdOx1 with respect to incident COVID-19 infection of different severities.
223857129|NCT04580199|PROCEDURE|thyroidectomy|to excise the thyroid gland
223857130|NCT02572024|DEVICE|BAT|Baroreflex activation therapy device ON
223857131|NCT02572024|OTHER|Placebo|Baroreflex activation therapy device OFF
223857132|NCT05353517|DEVICE|Device: focal muscle vibration and theta burst stimulation|non invasive techniques of neuromodulation for inducing plasticity in M1 and spinal cord
223857133|NCT04911933|BEHAVIORAL|Family Therapy|There will be systemic family psychotherapy sessions every two weeks. Families and individuals who require a more intensive service will be referred to a higher level of care.
223857134|NCT06468657|OTHER|mortality rates|mortality rates
223857135|NCT06629012|PROCEDURE|Breast reconstruction with neurotization|Patients received breast reconstruction with neurotization procedure
223857136|NCT06629012|PROCEDURE|Breast reconstruction without neurotization|Patients received breast reconstruction without neurotization
223857137|NCT00552552|BEHAVIORAL|Fatigue Patient Education Program (FIBS)|6 weekly sessions, 90 min each
223857138|NCT00552552|BEHAVIORAL|Fatigue Patient Education Program (FIBS)|Participation in the program after the second follow-up
223857139|NCT00765973|DRUG|Topotecan Liposomes Injection (TLI)|TLI dose on Days 1 and 8 of a 21-day treatment cycle (Starting dose: 1 mg/m2)
223857140|NCT00765973|DRUG|Topotecan Liposomes Injection (TLI)|TLI dose on Day 1 of a 21-day treatment cycle (Starting dose: 2 mg/m2)
223857141|NCT01749761|OTHER|BioLogic RR|Patients will be randomized to BP guided biofeedback arm which will entail regular hemodialysis with a software program turned on to allow frequent assessment of blood pressure and automated adjustments of the ultrafiltration rate based on these blood pressure measurements. The duration of this arm is 8 weeks
223857142|NCT01749761|OTHER|Hemodialysis without biofeedback|patients will be randomized to Standard HD (without biofeedback technology) for 8 weeks
223857143|NCT02590913|DIETARY_SUPPLEMENT|fructose|75g fructose is dissolved in 300 ml water.After overnight fasting, 300ml of solution at 0830 within 5 minutes is taken by volunteers
223857144|NCT02590913|DIETARY_SUPPLEMENT|glucose|75g glucose is dissolved in 300 ml water.After overnight fasting, 300ml of solution at 0830 within 5 minutes is taken by volunteers
223857145|NCT04329663|DEVICE|Indonesian computer-based game prototype|In order to improve the ADHD clinical symptoms and executive function of the player, this game should has challenge similar to memory game which is the player was given object to be memorized and then match the object in accordance to the task given inside the game. With some difficulty leves, this game was tried to trigger players in terms of accuracy and quickness in completing the mission.
223857146|NCT01227707|DRUG|bevacizumab [Avastin]|5 mg/kg intravenously every 2 weeks, 4 cycles
223857147|NCT01227707|DRUG|capecitabine [Xeloda]|825 mg/m2 twice daily orally, 38 days
223857148|NCT01227707|RADIATION|Radiation therapy|Total dose of 45 Gy over 38 days
223857149|NCT01227707|PROCEDURE|Mesorectal excision|6-8 weeks after completion of neoadjuvant treatment
223857150|NCT01227707|DRUG|bevacizumab [Avastin]|Post-surgery adjuvant treatment at the discretion of the investigator: 5 mg/kg iv every 2 weeks for at least 6 months
223857151|NCT01227707|DRUG|5-fluorouracil|Post-surgery adjuvant therapy: bolus of 400mg/m2 iv plus iv infusion of 600 mg/m2 on Days 1 and 2 of each 2-week cycle for 6 months
223857152|NCT01227707|DRUG|leucovorin|Post-surgery adjuvant treatment: 100 mg/m2 iv on Days 1 and 2 of each 2-week cycle for 6 months
223857153|NCT03073499|PROCEDURE|Oncological Home Hospitalization|
223857154|NCT02900326|OTHER|Endurance exercise training|In each group, there will be a comparison of aerobic capacity, quality of life (with questionnaires), functional cerebral measurements (fRMI), and telomerase activity between before and after the 8 weeks program
223857155|NCT02900326|OTHER|Mindfulness-based-stress-reduction|
223857156|NCT02900326|OTHER|Both interventions together|
223857157|NCT02900326|OTHER|Vo2max measurements|
223857158|NCT02900326|GENETIC|Telomerase activity on a blood sample|
223857159|NCT02900326|OTHER|Quality of life (questionnaires)|
223857160|NCT02900326|OTHER|Cerebral IRMf|
223857161|NCT04830722|DEVICE|Sculptra Aesthetic|One treatment side treated with Sculptra will be compared to the other side treated with bacteriostatic water (placebo) -same volume
223857162|NCT05663619|DEVICE|Virtual Reality Distraction during dental treatment of children.|One of the behavior management techniques used with children in dental clinics to allow for delivering quality dental treatment is the use of Virtual Reality distraction (VRD). Virtual reality distraction immerses the patient in an environment generated by a computer and works by simulating as many senses as possible: vision, hearing, and touch. In dentistry, VRD has exhibited great results in reducing anxiety and fear among children and adolescents compared to those who received no intervention or more conventional BMTs. VRD may allow the dentist to provide more efficient dental treatments, ranging from simple anesthesia to more advanced forms of dental treatment
223857163|NCT05663619|OTHER|Control: watching cartoon on screen as distraction during dental treatment of children.|"The American Academy of Pediatric Dentistry (AAPD) recommends a series of non-pharmacological behavior management techniques for managing children during dental care including distraction. Distraction is defined by AAPD as the technique of diverting the patient's attention from what may be perceived as an unpleasant procedure. It is widely used as it provides an effective and relaxing experience during treatment."
223857164|NCT06553573|OTHER|Parasternal Block and Recto-İntercostal Fascial Plane Block|Parasternal Block and Recto-Intercostal Fascial Plane Block:Superficial PSB is performed bilaterally with the patient in the supine position using a high-frequency linear USG probe. The probe is inserted longitudinally 2cm lateral to the sternal border to visualize the T2T4 intercostal space and identify the pectoralis major muscle, intercostal muscle, and pleura. Using an in-plane approach with a 100mm needle, 10ml of 0.25% bupivacaine is administered between the pectoralis major and intercostal muscle. Additionally, a Recto-Intercostal Fascial Plane Block is performed bilaterally with a high-frequency linear USG probe. The probe is inserted 2-3cm lateral to the xiphoid to visualize the rectus abdominis muscle and the 6th-7th cartilages. The needle is advanced to the plane between the costal cartilage and the rectus abdominis muscle using the in-plane technique, and 1-2ml of saline is injected. After spreading to the target plane is observed, 20ml of 0.25% bupivacaine is administered.
223857165|NCT06553573|OTHER|Parasternal Block and Erector Spinae Plane Block|Superficial PSB is performed with the patient in the supine position using a high-frequency linear USG probe. The probe is placed longitudinally 2cm lateral to the sternal border to identify the T2T4 intercostal space, pectoralis major muscle, intercostal muscle, and pleura. Using an in-plane approach with a 100mm needle, 10ml of 0.25% bupivacaine is applied between the pectoralis major and intercostal muscle. Additionally, an erector spinae plane block is performed with a high-frequency USG probe. Erector spinae plane block is performed under general anesthesia, in the lateral position, under USG guidance, after sterilization, by inserting a needle between the deep surface of the erector spinae muscle and the transverse process with an in-plane approach in the craniocaudal direction. If no air or blood is seen in the aspiration, a 2mL serum test dose is applied to this area and a total of 20mL of 0.25% bupivacaine is injected bilaterally to perform an erector spinae plane block.
223857166|NCT01115049|DRUG|chlorobutanol, hexetidine|3 times per day (after breakfast, lunch and dinner) for 1 minute with 15 ml of mouthwash
223857167|NCT01115049|DRUG|Chlorhexidine|3 times per day (after breakfast, lunch and dinner) for 1 minute with 15 ml of mouthwash
223857168|NCT00780663|DRUG|Quarfloxin|IV Quarfloxin 240 mg/m2 daily x5 days every 21 days
223857169|NCT05556356|DRUG|Acetaminophen|pre-operative acetaminophen (1000mg)
223857170|NCT05556356|OTHER|Placebo: Multivitamin|pre-operative Multivitamin
223857171|NCT01224678|DIETARY_SUPPLEMENT|vitamin D|Given orally
223857172|NCT01224678|OTHER|placebo|Given orally
223857173|NCT05108896|DIAGNOSTIC_TEST|3-Screenings Protocol|The 3-Screenings Protocol is a modified bedside swallow exam (BSE) consisting of a study developed five-item decision tree algorithm including voice quality assessment and a 2-ounce water consistency assessment, the Yale Swallow Test, with a scored 3-ounce Water Swallow Test (3-WST), and the Toronto Bedside Swallowing Screening Test (TOR-BSST).
223857174|NCT05108896|DIAGNOSTIC_TEST|FEES|A thin, flexible endoscope designed for assessment of laryngeal structures is passed through the nose to the oropharynx, visualizing the laryngeal structures, and the base of tongue and the pharynx. If needed 4% topical lidocaine and/or oxymetazoline (Afrin) will be administered. Swallowing will then be evaluated directly with six food boluses of 5 ml each. All patients will be allowed to swallow spontaneously without a verbal command to swallow. Video of the examinations will be recorded and presence of dysphagia will be designated independently by 3 different observers (one pulmonary physician and two speech language pathologists (SLPs)). This procedure will take 5-10 minutes. The camera will then be removed.
223857175|NCT05108896|DIAGNOSTIC_TEST|Tracheal Ultrasound|Ultrasound imaging of the trachea, measuring tracheal diameter and endotracheal tube (ETT) size ratio within 72 hours prior to extubation
224076174|NCT05129397|BEHAVIORAL|Mom Power|Virtual Mom Power is a manualized multi-family group intervention consisting of 10 virtual group + 2 individual sessions led by two masters-level co-facilitators. Virtual groups are 90 minutes, following a structured format via secure HIPAA compatible video platform. The curriculum includes 5 core components: (1) Attachment-Focused Parenting Education; (2) Self-Care; (3) Parenting Practice (4) Social Support; \& (5) Connection to Resources. Individual sessions combine motivational interviewing with MP core components and focus on identifying goals and barriers. Weekly between-group phone/text check-ins are also a part of the curriculum, used to strengthen connection, build trust, ensure safety, and assess basic needs.
223857176|NCT05117450|DEVICE|Decrease per-dialytic heparin therapy|Decrease per-dialytic heparin therapy with the HYDROLINK membrane (dialyzer NV-21U, surface 2.1m², Toray industry, Tokyo, Japan) and with the HeprAN membrane (dialyzer Evodial 2.2, surface 2.15 m2, Hospal SAS, Meyzieu, France)
223857177|NCT05671198|DIAGNOSTIC_TEST|Ultrasound of the diaphragm|"Sonographic parameters of the diaphragm:~* Thickening Fraction (TF); (Diaphragm thickness end-inspiration- Diaphragm thickness end-expiration) / Diaphragm thickness end-expiration. (continuous variable).~* Diaphragm end-expiratory thickness: Diaphragm thickness at end-expiration (continuous variable)~* Diaphragm excursion (DE): diaphragm inspiratory amplitude during deep breathing (continuous variable)."
223857178|NCT04074499|OTHER|No intervention|There is no intervention.
223857179|NCT05484726|OTHER|perioral sensory motor stimulation|"Step 1 - 6 over 5 minutes~1 With the help of the index finger, on the external surface of the cheek, make a circle starting from the angle of the mouth towards the ear then back 7x each cheek~2 While holding both sides of the cheek with help of the thumb and index finger repeat step 1 7x each cheek~3 Move index finger from one corner to opposite one over both lips separately 7x each lip~4 Gentle massage and compress the gums from center to back of mouth 7x each half of the gum~5 Move the finger from front to back on the hard palate while applying gentle pressure 7x~6 Displace the center of the tongue with gentle pressure 7x~7 Offer pacifier at the end 2 minutes~Note: 7x means 7 times"
223857180|NCT05866510|DRUG|Utidelone and anlotinib|"Pretreatment: diphenhydramine 40 mg by intramuscular injection or oral administration, and dexamethasone10 mg and cimetidine 300 mg by intravenous injection 30 minutes prior to Utidelone iv drip at the first day of each cycle.~Utidelone will be given at 30 mg/m2/d administered intravenously on days 1-5 and Anlotinib 8mg/d took orally on days 1-14 every 21 days."
223857181|NCT00133588|BIOLOGICAL|Trivalent split Inf|
223857182|NCT02744079|BEHAVIORAL|Low carbohydrate diet|45 subjects will be randomized to a dietary arm consisting of a complete, prepared very low carbohydrate diet, delivered to their homes, for the interval between positive breast biopsy and surgical tumor removal
223857183|NCT02744079|BEHAVIORAL|Low fat diet|20 subjects will be randomized to a dietary arm consisting of a complete, prepared low fat diet, delivered to their homes, for the interval between positive breast biopsy and surgical tumor removal.
223857184|NCT03468920|DRUG|IV Acetaminophen|IV Acetaminophen 1000mg in 100mL normal saline once pre-operatively
223857185|NCT03468920|DRUG|PO Acetaminophen|Acetaminophen PO 1000mg once pre-operatively
223857186|NCT03468920|DRUG|PO Placebo|PO placebo capsule compounded to match PO Acetaminophen capsule
223857187|NCT03468920|DRUG|IV Solution Placebo|This will serve as the placebo for the IV Acetaminophen intervention
223857188|NCT02283255|OTHER|Aerobic Exercise Training|Supervised aerobic and light muscle resistance exercise training
223857189|NCT02283255|OTHER|Inspiratory Muscle Training|Inspiratory muscle training with POWERbreathe device
223857190|NCT02283255|OTHER|No Exercise Training|Usual care
223857191|NCT03210727|BEHAVIORAL|Ready to CARE program|"The intervention is built upon a model of caregiver well-being that identifies four domains of quality of life: physical, psychological, social, and spiritual well-being. For each domain, there are stressors (i.e., factors that make it hard to be a caregiver) and buffers (i.e., factors that help people be effective caregivers). Our Ready to CARE intervention begins by presenting caregivers with the model in order to generate a profile of personal stressors and buffers. From there, caregivers select from a menu of strategies that can be used to minimize stressors and create buffers in their daily life. The investigators will have six 45-minute sessions with the caregivers that will primarily occur while the patient is admitted for stem cell reinfusion."
223857192|NCT04589611|DRUG|amobarbital/Gel-One (one dose)|One dose of amobarbital/Gel-One during the initial surgical intervention
223857193|NCT04589611|DRUG|Placebo (single dose)|One dose of placebo during the initial surgical intervention
223857194|NCT04589611|DRUG|amobarbital/Gel-One (two doses)|One dose of amobarbital/Gel-One during the initial surgical intervention. A second dose will be administered during the second surgical intervention.
223857195|NCT04589611|DRUG|Placebo (two doses)|One dose of placebo during the initial surgical intervention. A second dose will be administered during the second surgical intervention.
223857196|NCT03955419|DIETARY_SUPPLEMENT|NO-NPO (Daesang WelLife Co., Ltd., Korea)|800 mL of carbohydrate beverage consists of 12.8% carbohydrates, 50 kcal/100 mL, 290 mOsm/kg.
223857197|NCT02050594|DRUG|Ipilimumab|
223857198|NCT03417843|DEVICE|EUSRA RF electrode|"At the tip of the needle there is a probe that releases the peripheral energy in a continuous and continuous manner. The method is a long 50W power release for 10 seconds or 40W until white bubbles appear in a sonographic image.~Materials that come into contact with the body: electrode and grounding surfaces"
223857199|NCT04239339|DRUG|Escitalopram 20 mg|20mg daily for approximately 3 weeks.
223857200|NCT04239339|DRUG|Placebo|Placebo daily for approximately 3 weeks.
223857201|NCT03684733|DIAGNOSTIC_TEST|MRI|Clinical MRI breast screening examination
223857202|NCT04467463|PROCEDURE|peripheral nerve block by 0.25% levobupivacaine|SUBMANDIBULAR nerve block will be performed using a 25G 90 mm beveled needle . the entry point of the needle will be situated at the angle formed by the superior edge of the zygomatic arch below and the posterior orbital rim forward .The needle will be inserted perpendicular to the skin and advanced approximately 20 mm depth to reach the greater wing of the sphenoid deep to the pterygopalatine fossa. Injection of 1ml of 0.25% levobupivacaine will be done over 20 seconds afterensuring negative blood aspiration .greater Palatine Nerve will be blocked bilaterally as it leaves on palatal side through the foramen on the opposite direction of the anterior part of the 3rd molar orthe posterior part of the 2nd molar tooth.
223857203|NCT05702710|OTHER|Surgery (PIRS)|"Laparoscopic procedure for repair of inguinal hernia as described in:~1\) Thomas DT, Göcmen KB, Tulgar S, Boga I. Percutaneous internal ring suturing is a safe and effective method for the minimal invasive treatment of pediatric inguinal hernia: Experience with 250 cases. J Pediatr Surg. 2016 Aug;51(8):1330-5. doi: 10.1016/j.jpedsurg.2015.11.024. Epub 2015 Dec 11. PMID: 26777889."
224076175|NCT05129397|BEHAVIORAL|Mom Power Informational Mailing|This active comparison condition intervention includes two individual sessions along with 10 weeks of informational mailing with content related to Mom Power core concepts.
224076176|NCT02803164|DEVICE|Wound Vacuum-assisted dressing|The NPWT system (V.A.C. Therapy System, KCI USA Inc.) consisted of a medical-grade non-adherent polyvinyl alcohol white foam applied directly to the infected surface, followed by an open-pore reticulated polyurethane black foam cut to fit the wound and covered by a transparent air-tight adhesive drape. A suction cup with tubing was placed over a small slit on the drape and connected to a suction machine (V.A.C. ULTA Therapy Unit).
224076177|NCT02803164|OTHER|Control group|Retrospective review of subjects medical records with open chest wounds who were treated with the traditional treatment techniques.
223857204|NCT04810455|OTHER|Purrble|"The objective of this study is to evaluate the impact of having access to the Purrble intervention, compared to an active control in the form of a non-interactive plush toy, on child daily emotion regulation (primary outcome) as well as a range of secondary outcomes over a period of one month.~The investigators hypothesise that engagement with an in-situ, 'bottom-up' emotion regulation intervention which enables in-the-moment soothing for children, will lead to measurable changes in child self-regulatory behaviours over time."
223857205|NCT04810455|OTHER|Active control toy|The selected active control toy is the Wild Republic 8'' Hedgehog animal. The selection process was guided by: the plush toy needed to have analogous size, weight, quality of materials, and at least similar (if not higher) visual appeal. The investigators also made sure to include the design characteristics our prior work suggested were important for the narrative around the toy. These were selecting a similarly stylised animal (to enable emotion projection and feelings of care), as well as no visible mouth on the toy (to prevent setting an expectation about the toy's emotional state as a mouth would imply an emotional expression). Additionally, the investigators have adapted the one-page parent-facing descriptions of the narrative that come with Purrble also for the active control unit: as such, the active control families will receive the same general narrative-without the explicit mentions of the toy interactivity-and the same suggested activities for parents.
223857206|NCT00541697|DRUG|MK0653A, ezetimibe (+) simvastatin / Duration of Treatment: 6 Weeks|
223857207|NCT00541697|DRUG|Comparator: atorvastatin / Duration of Treatment: 6 Weeks|
223857208|NCT04966208|PROCEDURE|xenogeneic collagen matrix|xenogeneic collagen matrix called mucoderm used for root coverage for treatment of gingival recession instead of harvesting from the patients connective tissue
223857209|NCT00155610|DEVICE|intravesical current perception test|
223857210|NCT02373228|OTHER|Audio signal processing (applied offline before playback)|
223857211|NCT01093534|DRUG|Placebo|Matching solifenacin placebo tablet
223857212|NCT01093534|DRUG|solifenacin|Tablet for oral administration
223857213|NCT01792648|OTHER|Standard reference diet|50% energy as carbohydrate, 15% energy as protein, 35% energy as total fat
223857214|NCT01792648|OTHER|Almond supplemented diet|50% energy as carbohydrate, 15% energy as protein, 35% energy as total fat, 20% energy from almonds
223857215|NCT01792648|OTHER|Low carbohydrate reference diet|26% energy from carbohydrate, 29% energy from protein, 45% energy from total fat
223857216|NCT04204330|DEVICE|CardioQvark cardiac monitor and software, single-lead ECG|"Registration certificate for the medical device No. РЗН 2019/8124 dated February 15, 2019.~Product form: phone case.~Way of applying:~1. Download the CardioQVARK mobile application; create a profile.~2. Fill out the questionnaire:~   * age;~  * date of birth;~  * sex;~  * weight;~  * height;~  * blood type;~  * eye color;~  * hair color;~  * occupation;~  * town;~  * alcohol consumption;~  * tobacco use;~  * overeating;~  * insufficient sleep;~  * hypertension;~  * type 2 diabetes;~  * pacemaker;~  * the 10th revision of the International Classification of Diseases (ICD-10) code;~  * medicines.~3. Place index fingers on sensors that are on the case's backside and record 1-lead ECG of up to 3 minutes duration.~Recorded parameters:~* time parameters of the ECG intervals (RR, P, PR, QRS, QT, QTc);~* abnormal rhythms;~  * heart rate variability;~ * additional function - blood pressure and blood sugar diary. All recorded and calculated parameters are passed to the server."
223857217|NCT01970618|DRUG|RV1162 single dose|Safety and tolerability of single escalating doses
223857218|NCT01970618|DRUG|RV1162 matching placebo single dose|Safety and tolerability of single escalating doses
223857219|NCT01970618|DRUG|RV1162: 7 day repeat dose|Safety and tolerability of a repeat dose
223857220|NCT01970618|DRUG|RV1162 matching placebo: 7 day repeat dose|Safety and tolerability of a repeat dose
223857221|NCT01970618|DRUG|RV1162: 14 day repeat dose|Safety and tolerability of repeat escalating doses
223857222|NCT01970618|DRUG|RV1162 matching placebo: 14 day repeat dose|Safety and tolerability of repeat escalating doses
223857223|NCT04204564|DEVICE|pactlitaxel PAD device|Peripheral vascular intervention on femoral-popliteal occlusive disease with paclitaxel and non-paclitaxel devices.
223857224|NCT03185663|OTHER|traction-stuck|continuous pulling method: tensile force is exerted directly on the skin by means of adhesive strips, connected to weight
223857225|NCT03185663|OTHER|a pillow between the legs|setting up a pillow between the legs before the care
223857226|NCT00608933|OTHER|educational intervention|Health providers receive educational materials comprising a brief video about communicating with and providing guidance to patients regarding complimentary and alternative medicine (CAM) and a list of resources they can access to obtain information about herbs, CAM modalities, and drug/herb interactions. Approximately 2 weeks after the educational intervention, health providers receive a follow-up e-mail reminding them to ask patients about CAM use. The e-mail also includes a brief update regarding current research findings on CAM modalities and drug/herb interactions.
223857227|NCT00608933|OTHER|questionnaire administration|Patients complete questionnaires
223857228|NCT00281918|DRUG|Rituximab|Intravenous repeating dose
223857229|NCT00281918|DRUG|Cyclophosphamide|Intravenous repeating dose
223857230|NCT00281918|DRUG|Fludarabine Phosphate|Intravenous repeating dose
223857231|NCT00926939|BEHAVIORAL|Reinforcement for the abstinence of smoking|Participants in this intervention group will receive vouchers contingent upon a CO sample of 4ppm or less.
223857232|NCT00926939|BEHAVIORAL|Reinforcement for submission of videos with CO sample|This intervention group will receive vouchers contingent on their submission of videos of their CO breath tests.
223857233|NCT03593291|DIAGNOSTIC_TEST|Anti Xa|Levels of Anti Xa measure
223857234|NCT04758897|DRUG|Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell))|Intratumoral injection only. The dosing date can be the Day 1 only or Days 1 through 5.
223857235|NCT01199237|DRUG|Sevoflurane|Protective airway reflexes will be tested, judged by subject's ability to swallow 20 mL water
223857236|NCT01199237|DRUG|Desflurane|Protective airway reflexes will be tested, judged by subject's ability to swallow 20 mL water
223857237|NCT01199237|DRUG|Rocuronium|
223857238|NCT01199237|DRUG|Neostigmine|
223857239|NCT01199237|DRUG|Glycopyrrolate|
223857240|NCT03321955|DRUG|Ziconotide 100 MCG(microgram)/ML Intrathecal Solution|Initial dose at time of the implant will be 1.2 mcg/day with dose increases of no more the .4 mcg/day planned for 3, 6, 8, 9, 10, 12 weeks and 4, 5, 6 and 12 months.
223857241|NCT03321955|DIAGNOSTIC_TEST|Quantitative sensory testing|Quantitative sensory testing will be done using different types of sensory stimulation to objectively quantify sensation and pain tolerance. VonFrey fibers of various widths are used to detect sensation, a Neuropen pin prick iutilized to detect pain, along with a tuning fork to measure vibrationand a pressure guage to measure pressure felt on the skin. Cold/hot sensation is tested with Medoc Pathway system to quantitatively measure the temperature felt by patients to be done at baseline, 6 months and 12 months,
223857242|NCT03321955|DIAGNOSTIC_TEST|Serum markers: Interleukin-1, Interleukin-6, and tumor necrosis factor|Increases in these biomarkers indicate nerve pain as they are released from macrophages in patients with damaged nerves.
223857243|NCT01421654|DEVICE|S9 Elite with Acclimate|S9 Elite Flow Generator with Acclimate feature activated
223857244|NCT01421654|DEVICE|S9 Elite|S9 Elite Flow Generator
223857245|NCT02984319|DIETARY_SUPPLEMENT|Cherry versus placebo concentrate|Acute cherry concentrate
223857246|NCT01549730|PROCEDURE|18F-Fluoroazomycin Arabinoside (18F-FAZA)|A PET scan is an imaging test that uses special radioactive dyes to measure different aspects of how your cancer acts. In this study, a dye called 18F-Fluoroazomycin Arabinoside (18F-FAZA) will be used to measure hypoxia levels in tumours. Health Canada has not approved FAZA for general use, but has approved it for use in this study.
223857247|NCT01109095|BIOLOGICAL|HER.CAR CMV-specific CTLs|"HER2.CAR CMV-specific CTLs will be given by intravenous injection over 1-10 minutes through either a peripheral or a central line with a minimum 20g cannula. The patient will get one of the following doses:~* 1 x 10\^6/m\^2~* 3 x 10\^6/m\^2~* 1 x 10\^7/m\^2~* 3 x 10\^7/m\^2~* 1 x 10\^8/m\^2"
223857248|NCT00023218|DRUG|Lopinavir/Ritonavir|
223857249|NCT00023218|DRUG|Efavirenz|
223857250|NCT06409949|DIAGNOSTIC_TEST|Walking assessment|"Participating patients will undergo the following evaluations at baseline and after six months of treatment with MitoQ or placebo:~Assessment of walking impairment: Evaluation of treadmill maximum walking distances, six-minute walking distance, and daily physical activity (average steps taken daily)"
224076178|NCT04573673|DEVICE|PTNS de verum|The device will be set to program P-4: Frequency 20Htz, Pulse duration = 200 µs. The amplitude (Volt) will be adjusted by the patient according to the feeling.
224076179|NCT04573673|DEVICE|PTNS placebo|The device will be set to program P-4: Frequency 20Htz, Pulse duration = 200 µs. A resistor will be incorporated in the device to block the passage of electric current
223857251|NCT06409949|OTHER|QOL Survey|Assessment of quality of life: Survey of Quality of life with the Walking Impairment Questionnaire and Short Form 36
223857252|NCT06409949|DIAGNOSTIC_TEST|Ankle pressure at rest and after stress|Assessment of leg hemodynamics: Evaluation of post-occlusive ankle pressure and ankle/brachial index
223857253|NCT06409949|DIAGNOSTIC_TEST|Muscle Oxygen|Evaluation of calf muscle heme oxygen saturation
223857254|NCT06409949|DIAGNOSTIC_TEST|Serum MitoQ Level|Evaluation of serum concentrations of MitoQ
223857255|NCT06409949|PROCEDURE|Needle Biopsy|Needle biopsy of the calf muscle
223857256|NCT05620303|OTHER|Exercise|Parents/guardians will receive three different contents weekly (i.e., infographics, video recipes, information pills, or videos) each week related to 24-h movement behaviors (i.e., PA, sedentary behavior, sleep duration) or Mediterranean Diet for 36 weeks.
223857257|NCT01837641|BIOLOGICAL|LY3002813-IV|Administered IV
223857258|NCT01837641|BIOLOGICAL|LY3002813-SC|Administered SC
223857259|NCT01837641|DRUG|Placebo-IV|Administered IV
223857260|NCT04026620|BEHAVIORAL|Informational Pamphlet|The control group will be provided with two (2) informational pamphlets (and have it read to those who are of lower literacy). Pamphlets contain information about the harmful effects of drinking alcohol during pregnancy and the harmful effects of alcohol on the unborn baby.
223857261|NCT04026620|BEHAVIORAL|Brief Motivational Enhancement Therapy (MET) Session|The case control trial/efficacy study will provide a one-session MET session in Afrikaans (the predominant language of the region). The face-to-face session will provide information to help people and pregnant women who want to change their drinking behavior, become 'dry' and stay motivated to change their drinking behaviors. Sessions will be approximately one (1) hour and 30 minutes.
223857262|NCT04318444|DRUG|Hydroxychloroquine|Two tablets (400mg) twice daily on day 1; for days 2-5, they will be instructed to take one tablet (200mg) twice daily.
223857263|NCT04318444|DRUG|Placebo oral tablet|Two tablets (400mg) twice daily on day 1; for days 2-5, they will be instructed to take one tablet (200mg) twice daily.
223857264|NCT04217421|DRUG|Allopurinol|Allopurinol powder for solution for infusion (PFI) 20 mg/kg body weight per administration will be administered early postnatally (within 45 minutes and 12 hours after the first dose), preoperatively (12 hours before surgery), intraoperatively (during surgery) and postoperatively (24 hours after surgery) to the neonate in case of a prenatal CCHD diagnosis. Allopurinol PFI will be administered only pre-, intra- and postoperatively to the neonate in case of a postnatal CCHD diagnosis.
223857265|NCT04217421|DRUG|Mannitol|Mannitol powder for solution (PFI) placebo will be administered early postnatally (within 45 minutes and 12 hours after birth), preoperatively (12 hours before surgery), intraoperatively (during surgery), and postoperatively (24 hours after surgery) to the neonate in case of a prenatal CCHD diagnosis. Mannitol PFI-placebo will be administered only pre-, intra- and postoperatively to the neonate in case of a postnatal CCHD diagnosis.
223857266|NCT06365554|DEVICE|Remedy Robot|A trained Neurointerventionalist will operate the Remedy Robot from a computer-based user interface in a room adjacent to the patient. An entire cerebral angiogram or cerebral embolization will be performed, excluding insertion and removal of the femoral sheath.
223857267|NCT03118752|BEHAVIORAL|Collaborative Care|The CC intervention will use a novel three-pronged approach to these high-risk patients. Care managers will provide centralized care coordination and specific interventions targeting: (1) the psychiatric disorders, (2) cardiac health behaviors, and (3) the cardiac illness.
223857268|NCT02181699|DRUG|KHK2823|single agent KHK2823
223857269|NCT04699669|DRUG|CBL-514, placebo|"One side of the abdominal region will receive CBL-514, while the other will receive placebo with equal volume.~Which side of the abdominal region to receive CBL-514 or placebo would be randomized.~No PK samples will be collected in this cohort."
223857270|NCT04699669|DRUG|CBL-514, placebo|"One side of the abdominal region will receive CBL-514, while the other will receive placebo with equal volume.~Which side of the abdominal region to receive CBL-514 or placebo would be randomized."
223857271|NCT04699669|DRUG|CBL-514|Both sides of the abdominal region will receive CBL-514.
223857272|NCT01769391|DRUG|Necitumumab|Administered IV
223857273|NCT01769391|DRUG|Paclitaxel|Administered IV
223857274|NCT01769391|DRUG|Carboplatin|Administered IV
223857275|NCT04243343|DEVICE|Intervention + Standard of care|Acupuncture with electrostimulation plus standard of care prescribed home exercise program for treatment of plantar fasciosis.
223857276|NCT04243343|OTHER|Standard of care|Standard of care prescribed home exercise program for treatment of plantar fasciosis.
223857277|NCT01338727|BEHAVIORAL|Breastfeeding Peer Counseling|3 Prenatal visits, daily in-hospital visits, 11 postpartum home visits.
224076180|NCT00618748|DRUG|Olanzapine|5-20 mg/day, oral, daily
224076181|NCT03870802|OTHER|Characterization of breast stem & immune system cells infiltrated in the mammary gland|Isolation, quantification and characterization of breast stem and immune cells of samples obtained during the prophylactic mastectomy in women presenting different tumor progression risks.
223857278|NCT00394381|PROCEDURE|Infusion of autologous CIK cells|Autologous CIK cells will be infused at timed intervals after autologous transplant for AML for group 1 patients, and with or without some cytoreduction treatment for group 2 patients
223857279|NCT01991912|PROCEDURE|open lumbar decompression|A posterior midline incision is performed over the affected levels. Bilateral subperiosteal dissection of the paraspinal muscles is performed. Bilateral hemilaminotomies, foraminotomies and lateral recess decompression is performed followed by wound closure
223857280|NCT06069986|PROCEDURE|coronary artery bypass graft CABG|comparison between onpump and off pump CABG
223857281|NCT03360396|DEVICE|Endobronchial Coils|Endobronchial Coil implants
223857282|NCT02672813|PROCEDURE|Pectoral nerve I and II block|Under Ultrasound guidance, Pectoral nerve I and II block is given for every breast surgery by using 10 and 20 ml of 0.25% Ropivacaine respectively
223857283|NCT00099515|DRUG|LY041001 (HIIP)|Inhalation, capsule, TID 3 times per day min 6 IU max 60 IU
223857284|NCT00099515|DRUG|LY041001 (HIIP)|Inhalation, Capsule, TID 3 times per day min 6 IU max 60 IU
223857285|NCT00350831|DRUG|XL820|
223857286|NCT02351180|DRUG|Inhaled beclomethasone|Inhaled steroid that may decrease airway inflammation and the risk of chronic rejection
223857287|NCT02351180|DRUG|Placebo|Placebo will serve as a control treatment
223857288|NCT04666337|PROCEDURE|ultrasound-guided supraclavicular brachial plexus blockade|Ultrasound-guided supraclavicular brachial plexus block was done using an ultrasound machine (Philips; Model: OTD020, AcBel Polytech Inc., Taiwan) with a 5-10 MHz linear probe. The brachial plexus and its relation to the surrounding structures were viewed while the patient was supine and the head turned 45° to the contralateral side. In the supraclavicular fossa, the probe was placed in the coronal plane to visualize the subclavian artery and the brachial plexus in a transverse sectional view. After skin sterilization and local anesthetic administration, an insulated needle was then introduced lateral to the ultrasound probe and parallel to the long axis of the probe. Once the needle penetrated the brachial plexus cluster, the local anesthetic mixture was injected incrementally after negative aspiration for blood or air just next to the artery, then the needle was repositioned to inject on the upper pole of the artery.
223857289|NCT05288517|BEHAVIORAL|Lock to Live|Lock to Live is an anonymous web-based self-administered decision aid for safe firearm and medication storage (Public URL: http://lock2live.com/).
223857290|NCT02116855|OTHER|according to the efficacy of AJBRs|
223857291|NCT01071967|OTHER|Community-based nurse care management|The community-based nurse care management program developed by Health Quality Partners uses nurses working in the community to provide the following integrated set of services to older adults with chronic illness over the long term in order to prevent avoidable complications of their diseases and aging; geriatric assessment, care coordination, health education, self-management coaching, weight management, physical activity, gait and balance training, medication adherence, care transition support, ongoing monitoring and symptom detection, collaborative problem solving with patients, families and health care providers.
223857292|NCT04872829|DEVICE|cataract surgery|"All patients underwent cataract surgery under 1 year of age (mean age 8 months, range 6-12) performed with the same surgical technique: two 1.2 mm clear corneal incision, continuous curvilinear capsulorhexis with a diameter of approximately 6.0 mm and intraocular lens implantation, posterior capsulotomy and anterior vitrectomy.~IOL power was calculated using Sanders-Retzlaff-Kraff (SRK)/II formula. Multifocal IOL implantated was Alcon AcrySof ReSTOR SN60D3, while the monofocal one was Alcon AcrySof SN60AT.~According to the Infant Aphakia treatment Study, the IOL power was calculated as a function of the child age17, with an undercorrection ranging from 4 to 6 D."
223857293|NCT01300858|DRUG|EGEN-001-301|Patients will be treated with EGEN-001 intra-peritoneally (IP) once every week for 12 weeks and then once every two weeks until disease progression or intolerable toxicity, but for no more than one year. Patients who develop progressive metastases will receive standard chemotherapy concomitant with EGEN-001. Hence, the initial EGEN-001 treatment period will be without chemotherapy. The standard chemotherapy regimen will be FOLFOX or FOLFIRI administered every 2-3 weeks. Patient with progressive disease a second time will be taken off-study. Those who remain progression-free will receive EGEN-001 for up to one year.
223857294|NCT00673296|DRUG|Intravitreal Bevacizumab|Intravitreal injection of bevacizumab (1.25 mg in 0.05 mL) and C3F8 (0.2-0.3 mL)
223857295|NCT01123083|BIOLOGICAL|Otelixizumab|infusion
223857296|NCT01123083|BIOLOGICAL|Placebo|Infusion
223857297|NCT02095704|DRUG|paracetamol oral solution|dosage form: paracetamol oral solution;dosage:15.6ml(containing 500 mg of the active ingredient);frequency:single dose
223857298|NCT02095704|DRUG|paracetamol tablet|dosage form: paracetamol tablet;dosage: 500 mg;frequency:single dose
223857299|NCT01393912|DRUG|Crenolanib|Crenolanib orally administered as whole or crushed tablets once per day with concurrent Radiation Therapy. Crenolanib will continue at the same dose level post Radiation Therapy
223857300|NCT01556256|OTHER|Caregiver-Related Intervention or Procedure|Undergo TMV+P
223857301|NCT01556256|PROCEDURE|Music Therapy|Undergo TMV
223857302|NCT01556256|PROCEDURE|Music Therapy|Undergo TMV+P
223857303|NCT01556256|OTHER|Quality-of-Life Assessment|Ancillary studies
223857304|NCT01556256|OTHER|Questionnaire Administration|Ancillary studies
223857305|NCT00001994|DRUG|Atovaquone|
223857306|NCT02061332|BIOLOGICAL|HER-2 Pulsed Dendritic cell Vaccine|6 weekly HER-2 pulsed dendritic cell vaccines will be administered to subjects in each of the 3 arms.
223857307|NCT01751724|DRUG|Caffeine citrate|"Enrolled subjects will be randomized to receive a study drug consisting of either blinded Caffeine citrate.~Randomization and study drug preparation will be done by the NICU pharmacy. Investigators and clinicians will be blinded to the assigned drug.~After randomization, an initial loading dose of 20 mg/Kg of study drug will be followed by a 5 mg/Kg/day maintenance dose. The assigned study drug will be administered intravenous or orally as determined by the clinical team.~Infants will continue to receive the study drug until 12 hours prior to the first elective extubation."
223857308|NCT01751724|OTHER|Normal saline|"Enrolled subjects will be randomized to receive a study drug consisting of blinded Placebo (equivalent volume of normal saline).~Randomization and study drug preparation will be done by the NICU pharmacy. Investigators and clinicians will be blinded to the assigned drug.~After randomization, an initial loading dose of 20 mg/Kg of study drug will be followed by a 5 mg/Kg/day maintenance dose. The assigned study drug will be administered intravenous or orally as determined by the clinical team.~Infants will continue to receive the study drug until 12 hours prior to the first elective extubation."
223857309|NCT00627874|DEVICE|+3D Lenses|wear +3D glasses for 30 minutes per day and engage in activities which require vision at more than 1m
223857310|NCT02584153|DRUG|Fibrin Sealant|TISSEEL® fibrin sealant (Baxter Biosurgery, Deerfield, IL)
223857311|NCT02584153|DRUG|Silver Microparticles|Product Code: AG-M-04M-P.200M (American Elements, Los Angeles, CA)
223857312|NCT06315400|DRUG|Ingavirin®|60 mg/day for 5 days
223857313|NCT06315400|DRUG|Placebo|1 capsule/day for 5 days
223857314|NCT00605033|DRUG|Suboxone, Buprenorphine Hydrochloride + Naloxone, SCH 484|Suboxone sublingual tablet 4 mg/1 mg - 24 mg/6 mg, daily for 28 days
223857315|NCT00605033|DRUG|Subutex, Buprenorphine Hydrochloride, SCH 28444|Subutex sublingual tablet 4-24 mg, daily for 28 days
223857316|NCT03488056|OTHER|ICCMS|"The patient's caries risk assessment, Diagnosis of caries lesion and activity assessment~-Intraoral risk assessment, Decide on a personalized care plan for patient and clinical interventions.~After asses all the factors and defining the patient's individual risk, the system presents a personalized treatment plan, indicating the appropriate home care instructions, clinical interventions and specific treatment for each caries lesion categories.~The treatment is divided into Non-Operative Care and Tooth-Preserving Operative Care (restorations with minimal intervention to preserve maximum dental structure).~The return intervals will be scheduled according to the risk: low risk (return of 1 year), moderate risk (6 months) and high risk (3 months)"
223857317|NCT03488056|OTHER|SESC standard care|Standard care related to: Caries Diagnosis, operative and non-operative treatments, Indication of recall interval according to the dentist opinion
223857318|NCT00612391|PROCEDURE|Lateral minimally invasive approach (plate fixation)|A longitudinally oriented, 4-cm incision will be made laterally starting at the acromion. The deltoid will be split proximally at the most strategic location (vis-à-vis the fracture), and after the deltoid is bluntly elevated from the humerus more distally the axillary nerve will be identified by digital palpation. The nerve is easily identified posteriorly as it emerges from the quadrilateral space. With a finger maintained on the nerve for protection, the plate will be inserted onto the lateral side of the proximal humerus and fixed according to the described technique. A second, 2-cm longitudinal incision will then be made further distally for diaphyseal screw placement. This incision is well distal to the course of the axillary nerve.
223857319|NCT00612391|PROCEDURE|Deltopectoral approach (plate fixation)|Anterior, Delto-Pectoral Approach - A 10-cm incision will be made over the deltopectoral groove, starting at the coracoid process proximally. As the clavipectoral fascia is incised, the cephalic vein will be identified and retracted laterally with the deltoid muscle. The pectoralis major as well as the conjoint tendon will be retracted medially, and the long head of the biceps tendon will be identified and used as a guide for achieving an anatomic reduction of the different fracture parts. Next, internally rotating the humerus will allow access to the lateral side of the proximal humerus, on which the plate will then be fixed according to the described technique.
223857320|NCT05097781|DRUG|PD-1 blocking antibody|All patients with more than one distant metastatic lesions will accept at least one site of radiotherapy and PD-1 blockade at the same time.
223857321|NCT01719536|DRUG|Icotinib|Icotinib: 125 mg is administered orally three times per day.
223857322|NCT01719536|DRUG|Chemotherapy|First-line chemotherapy: pemetrexed/cisplatin for 4 cycles. Maintenance treatment: pemetrexed.
223857323|NCT05969236|DRUG|MDI-1228_mesylate Ophthalmic Solution|"MDI-1228\_mesylate Ophthalmic Solution includes 2 strengths:~* 0.1% (0.4 mL \[0.4 mg\] free base)~* 0.3% (0.4 mL \[1.2 mg\] free base)"
223857324|NCT05969236|DRUG|Placebo|The components employed in the placebo formulation are the same as those used for the active formulation except MDI-1228\_mesylate is absent.
223857325|NCT01025999|OTHER|No intervention|
223857326|NCT00095004|DRUG|MK0462, rizatriptan benzoate / Duration of Treatment: 1day|
223857327|NCT00095004|DRUG|Comparator: placebo / Duration of Treatment: 1 day|
223857328|NCT02060019|DRUG|administration of exforge 10/160mg for 3days. Next 7days administration of exforge 10/160mg and crestor 20mg.|
223857329|NCT03906968|DEVICE|SinuSonic Device|A medical device that utilizes sound and pressure combined with normal breathing to relieve nasal congestion
223857330|NCT02197299|DIETARY_SUPPLEMENT|L-carnitine|
223857331|NCT02197299|DIETARY_SUPPLEMENT|Placebo|
224076182|NCT00200850|BIOLOGICAL|House Dust Mite SLIT|low dose SLIT 143 Allergen Units(AU)/ml daily
223857332|NCT00908336|DRUG|Docetaxel and Erlotinib|Docetaxel (Taxotere®) 75 mg/m2 iv first day of each 21-day cycle. Erlotinib (Tarceva®) 150 mg po days 2-16 of each 21-day cycle. Total: 4 cycles in the absence of disease progression
223857333|NCT00908336|DRUG|Erlotinib|150 mg/day po daily
223857334|NCT04841733|OTHER|Foam Roller (FR)|Foam Roller (FR): participants will follow the Foam Roller protocol using a polyvinylchloride pipe roller (10.3-cm diameter, 0.3-cm thickness surrounded by a 1,5-cm thickness neoprene foam). They will begin with the Foam Roller at the most proximal portion of the muscle and to roll as much body mass as tolerable back and forth along it as smoothly as possible at a cadence of 1 second superior and 1 second inferior as determined with the metronome. Foam Roller will be performed for 45 seconds followed by a 15-second rest for each muscle group (quadriceps, adductors, hamstrings, abductors and calf) in each extremity and repeated once.
223857335|NCT04841733|OTHER|Stretching (STR)|Stretching (STR): participants will perform 8-min of static stretching, involving 3 bilateral repetitions of 30 seconds held stretches to the quadriceps, adductors, hamstrings, abductors and calf muscles.
223857336|NCT04841733|OTHER|Cold-Water Immersion (CWI)|Cold-Water Immersion (CWI): will be the last strategy used. Participants will immerse their lower body to the level of the hips for 10 minutes in cold water (10° C).
223857337|NCT03121950|OTHER|Dance|The primary intervention is a dance class
223857338|NCT03121950|OTHER|Music|the secondary intervention is listening to live music
223857339|NCT04803630|OTHER|Quality-of-Life Assessment|Ancillary studies
223857340|NCT04803630|OTHER|Questionnaire Administration|Ancillary studies
223857341|NCT04803630|PROCEDURE|Thermotherapy|Undergo thermal therapy
223857342|NCT04117724|OTHER|Survey|Patients will be asked to complete a 4 question survey assessing adherence. Follow up via patient's preferred method of contact will be conducted after the patient's intended antibiotic completion date and covariates for antibiotic regimens will be recorded including antibiotic type, number of doses, antibiotic duration, reason for non-adherence, pills remaining, and number of other medications.
223857343|NCT03902236|OTHER|Reaction Time and Postural Control|Reaction Time and Postural Control: With ''Fitlight TrainerTM'', 6 light emitting diode (LED) lights placed at certain points on the wall are randomly lit and expected to deactivate them as fast as possible. In the protocol, the leds will be placed according to the physical structure of the person, and the scores of 29 LED's will be kept in seconds. The scores will be compared cystic fibrosis, bronchiectasis and healthy groups.
223857344|NCT03902236|OTHER|Muscle oxygenation|Muscle oxygenation will be assessed with wearable lactate threshold predicting device in cystic fibrosis, bronchiectasis and healthy groups.
223857345|NCT03902236|OTHER|Exercise capacity|Exercise capacity will be assessed with incremental shuttle walk test in cystic fibrosis, bronchiectasis and healthy groups.The patient is required to walk around two cones set 9 metres apart (so the final track is 10 metres) in time to a set of auditory beeps played on a CD. Initially, the walking speed is very slow, but each minute the required walking speed progressively increases.The patient walks for as long as they can until they are either too breathless or can no longer keep up with the beeps, at which time the test ends The number of shuttles is recorded. Each shuttle represents a distance of ten metres
223857346|NCT03902236|OTHER|Balance|Balance will be assessed with functional reach test in cystic fibrosis, bronchiectasis and healthy groups Functional Reach measures the maximum distance a person can reach forward, the distance of the person standing at the edge of the wall with a 90-degree shoulder flexion and the maximum distance to the front of the thumb will be noted.
223857347|NCT00861510|DRUG|ON01910 Na|
223857348|NCT00639015|DRUG|Phenylephrine|Titrated phenylephrine to maintain mean arterial pressure between 65-75 mmHg over a period of 12 hours from the onset of septic shock.
223857349|NCT00639015|DRUG|Norepinephrine|Titrated norepinephrine to maintain mean arterial pressure between 65-75 mmHg over a period of 12 hours from the onset of septic shock.
223857350|NCT05722951|DRUG|Levetiracetam &/or sodium valproate|levetiracetam \&/or sodium valproate will be given to 30 patients and monitored for 6 months
223857351|NCT05722951|DRUG|Metformin|metformin + (levetiracetam \&/or sodium valproate) will be given to 30 patients and monitored for 6 months will be given to 30 patients and monitored for 6 months
223857352|NCT03245164|OTHER|Physiotherapy group exercises|Physiotherapy exercises had aerobic, balance, strength exercises with music.
223857353|NCT03245164|OTHER|Basketball program|Basketball education presented the techniques about playing basketball and basketball games were played.
223857354|NCT02043717|DIETARY_SUPPLEMENT|Vitamin D|"Supplementing oral cholecalciferol according to the new guidelines by:~Tangpricha V, Kelly a, Stephenson a, Maguiness K, Enders J, Robinson K a, et al. An update on the screening, diagnosis, management, and treatment of vitamin D deficiency in individuals with cystic fibrosis: evidence-based recommendations from the Cystic Fibrosis Foundation. The Journal of clinical endocrinology and metabolism \[Internet\]. 2012 May \[cited 2012 Oct 31\];97(4):1082-93. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22399505"
223857355|NCT04231474|DEVICE|Urodynamic testing|All data were obtained using the MMS Alfa 4T by the same urologist with use of an 8 Charr catheter.
223857356|NCT01646775|DRUG|epidural fentanyl|withold epidural fentanyl
223857357|NCT03824899|DIAGNOSTIC_TEST|Blood concentration check|Blood concentration check：the plasma concentration of SN-38 was detected by HPLC (high-performance liquid chromatography) at 1.5 h and 49.0 h after CPT-11 infusion
223857358|NCT02082366|DEVICE|TCD monitoring of microembolic signal during procedure|monitoring of microembolic signal during procedure
223857359|NCT01867580|DEVICE|V.A.C.Ulta with Prontosan instillation|NPWT with instillation of a wound cleanser (Prontosan® Wound Irrigation Solution)
223857360|NCT01867580|DEVICE|V.A.C.Ulta without instillation|NPWT only
223857361|NCT05852366|DRUG|Toothpaste Preparation|Dentifrice for management of dentinal hypersensitivity
223857362|NCT06614985|DRUG|Telitacicept|Subcutaneous injection of 160 mg is administered once a week.
223857363|NCT06614985|DRUG|Prednisone|Induction therapy period (3 months)：Eligible subjects receive induction treatment with Methylprednisone 0.5 g i. v. for 3 consecutive day and followed by orally administration of prednisone at an initial dose of 0.8 mg/kg/day, tapered gradually after 2 months (reduced by 5 mg every 2 weeks) Grouped treatment period (6 months): The maintenance induction treatment regimen is continued, with regular tapering (reducing by 5 mg every 2 weeks) until discontinuation.
223857364|NCT06614985|DRUG|Cyclophosphamide|An intravenous injection of 0.4 g is administered twice a month.
223857365|NCT03397914|DRUG|Colistimethate Sodium|Intravenous injection of colistimethate Sodium 2.5 mg/kg or 5 mg/kg for Multidrug-resistance gram negative infections
223857366|NCT06614348|DRUG|Prednisolone acetate eye drop group|Patients receive prednisolone acetate eye drops 4 times per 30min within 2 hours before cataract surgery
223857367|NCT06614348|DRUG|Sodium hyaluronate eye drops|Patients receive sodium hyaluronate eye drops 4 times per 30min within 2 hours before cataract surgery
223857368|NCT06614335|OTHER|After 6 months of observation, there was still a residual inclination of more than 15 prism degrees which needed to be corrected by a second operation|All IE patients enrolled were patients who had undergone corrective surgery for strabismus. Postoperative strabismus with 10 prism degrees of overcorrection or undercorrection is within the normal range. During postoperative follow-up, patients with more than 10 prism degrees of residual esotropia were treated conservally with foot orthoscopy according to their refractive status. After 6 months of observation, there were still more than 15 prism degrees of residual esotropia that needed to be corrected by a second operation. For extropia with overcorrection greater than 10 prism degrees, cross-eye training, negative mirror + prism stimulation and conservative observation and fusion training are given in the early stage, and can not be improved within 6 months, requiring a second surgical correction.
223857369|NCT06628583|OTHER|Magnetic Resonance Imaging with Contrast|The study was retrospective and did not set interventions
223857370|NCT05423587|PROCEDURE|Genicular Artery Embolisation|Transarterial catheter directed embolisation of hypervascularity in patients with mild to moderate knee osteoarthritis
223857371|NCT05423587|PROCEDURE|Genicular Artery Injection|Transarterial catheter directed injection of normal (0.9%) saline in patients with mild to moderate knee osteoarthritis
223857372|NCT06711380|OTHER|Peer Ambassador|Patient mentor (patient with history of gynecologic cancer who has experience with clinical trials) one on one discussion with patient mentee (patient receiving standard of care treatment for gynecologic cancers).
223857373|NCT06712238|PROCEDURE|NB-UVB|Comparison between serum Level of Gelsolin (GSN) in Psoriatic Patients and controls and correlate its level with PASI.
223857374|NCT03141788|DEVICE|Clear Aligner|Clear Aligner used to straighten teeth to desired outcome
223857375|NCT00697411|OTHER|Syndrome cause identification|
223857376|NCT00644709|DRUG|Atorvastatin|Atorvastatin tablets at starting doses of 10, 20, 40, or 80 mg once daily. Three dose adjustments were allowed at baseline, Week 17, and Week 34. Patients who did not meet the LDL-C target at any of these time points had their doses doubled except for those who were on the 80 mg dose. Treatment was given for 52 weeks.
223857377|NCT03523702|DRUG|PembroRT|"Patients whose tumors are found to have high (≥ 50%) PD-L1 expression will automatically be placed in the PembroRT group. These patients will receive three intravenous treatments with pembrolizumab, followed by four weeks of daily radiotherapy, followed by up to 12 more treatments with pembrolizumab. Pembrolizumab is given as an intravenous infusion once every three weeks. This treatment course will last, in total, up to one year.~Patients whose tumors are found to have low (\< 50%) PD-L1 will be treated with a standard-o-care regimen and not be a part of this clinical trial."
223857378|NCT05877638|DEVICE|SynePure Wound Cleanser and Catasyn Advanced Technology Hydrogel|(FDA) 510(k) cleared wound care medical devices formulated with a novel biocompatible chitosan derivative, poly (acetyl, arginyl) glucosamine. SynePure is optimized for the cleansing and debridement of wounds and thermal injuries, and Catasyn serves as a protective gel dressing.
223857379|NCT05877638|DRUG|SILVADENE Cream 1% (silver sulfadiazine)|SILVADENE Cream 1% (silver sulfadiazine) is a topical antimicrobial drug indicated as an adjunct for the prevention and treatment of wound sepsis in patients with second- and third-degree burns.
223857380|NCT04257058|BEHAVIORAL|Electronic educational material|Electronic media via email
223857381|NCT06174220|DRUG|Tideglusib|Tideglusib 1g po daily
223857382|NCT06174220|DRUG|Placebo|Matching placebo 1g po daily
223857383|NCT06788717|DEVICE|Comprehensive Primary Revision Stems|Comprehensive Primary Revision Stem (implants and instrumentation) when used for shoulder arthroplasty.
223857384|NCT05204446|BEHAVIORAL|GROW Project|"(GROW Group): Live interactive telehealth-based group meetings will be held for 60 minutes per week over six weeks using Zoom for Telehealth, a HIPAA-compliant platform provided by the PI's institution. A teen group (n=8 per cohort) and a parent group (n=8 per cohort) will be run concurrently but separately, with coordinating topics. Each group meeting will introduce and facilitate discussion of information and CBT-oriented topics for coping and management of CD. Participants will be encouraged to use their audio and video to engage with the interventionist and each other. Between sessions, resources sent through text-based SMS messages using Twilio HIPAA-compliant software 3x/week as reminders of skills and goals for the week."
223857385|NCT05204446|BEHAVIORAL|GROW+ Project|"(GROW+ Group): Will include the GROW Project with enhanced behavioral strategies and materials identified from phase 2 data (e.g., group discussion about GIP testing, text-based check-ins, etc.) In addition, teens in GROW+ will be encouraged to complete a minimum of 2 GlutenDetect tests per week (12 total) and report results in REDCap (Research Electronic Data Capture, a secure, web-based survey application) throughout the intervention."
223857386|NCT01210820|DEVICE|iFS™ Femtosecond Laser System|intrastromal arcuate cuts made with iFS™ femtosecond laser
223857387|NCT06070207|PROCEDURE|TEP group|Inguinal hernia surgery will be performed with the TEP method and the 15x12x10 cm polyprolene patch used in this surgery will be marked with small metallic clips from the lateral, superomedial and inferomedial sides.
223857388|NCT06070207|PROCEDURE|eTEP group|Inguinal hernia surgery will be performed with the eTEP method and the 15x12x10 cm polyprolene patch used in this surgery will be marked with small metallic clips from the lateral, superomedial and inferomedial sides.
223857389|NCT02948114|OTHER|Control: Cow milk-based infant formula|
223857390|NCT02948114|OTHER|Experimental 1: Cow milk-based infant formula|Experimental 1: Cow milk-based infant formula with prebiotics
223857391|NCT02948114|OTHER|Experimental 2: Cow milk-based infant formula|Experimental 2: Cow milk-based infant formula with probiotics
223857392|NCT02948114|OTHER|Experimental 3: Cow milk-based infant formula|Experimental 3: Cow milk-based infant formula with prebiotics and probiotics
223857393|NCT04633980|DRUG|Mixture 3,6% H2 in N2 (96.4%)|Route of administration: intra-nasal Debit 1L/min, 24h/24h (3 hours withdrawal tolerated) duration of treatment: 24 hours, 3 days and 6 days
223857394|NCT00661778|DRUG|Bevacizumab|Bevacizumab was supplied as a sterile liquid in glass vials.
223857395|NCT00661778|DRUG|Cisplatin|Bevacizumab was supplied as a sterile liquid in glass vials.
223857396|NCT00661778|DRUG|Docetaxel|Bevacizumab was supplied as a sterile liquid in glass vials.
223857397|NCT02468388|OTHER|maltitol|maltitol chewing gum: 66% SweetPearlTM Maltitol +30.91% gum base+1.93% Lycasin R 85/55+0.39% glycerin; two pellets for 10 min five times each day
223857398|NCT02468388|OTHER|xylitol|xylitol chewing gum: 67.73% xylitol +30.02% gum base+1.13% Lycasin R 85/55+0.38% glycerin; two pellets for 10 min five times each day
223857399|NCT02468388|OTHER|gum base|gum base: 99% gum base; two pellets for 10 min five times each day
223857400|NCT03156595|BEHAVIORAL|Nurse interview|Personal interview with nurses to evaluate the relief of neuropathic pains with the reference treatment. (If necessary send to the medical team ) It's a listening time around neuropathic pain which altered the quality of life.
223857401|NCT03156595|BEHAVIORAL|Hypnosis sessions|Hypnosis sessions with a nurse or psychologist, with deepening sessions to facilitate self-hypnosis learning.
223857402|NCT00455494|DRUG|AQ-13|
223857403|NCT01601041|OTHER|sonographic assessment of residual urine, urine culture|residual urinary volume assessed by ultrasound after bladder catheterization urinary cultures taken before and after prostate massage
223857404|NCT05408559|DRUG|Sulforaphane|Caplets containing SFN-rich broccoli sprout extracts or placebo caplets containing microcrystalline cellulose will be obtained from from Nutramax Labs.
223857405|NCT04831385|BEHAVIORAL|Cognitive Behavioural Therapy|CBT is a first line therapy for insomnia
223857406|NCT05068167|DIAGNOSTIC_TEST|Kidney function test|Creatinine twice the baseline and urine output of fewer than 0.5 ml/kg per hour for 12 hours
223857407|NCT02064660|DEVICE|massager|The patients will be doing self-stimulation using acupressure device, The acupuncture treatment will be applied two times per day for six months. Acupressure divice will stimulate for 14 minutes. Examples of acupuncture points to be used might include GB1, GB14, TE23, ST1, ST2, BL01, BL02, the Extra-point Tae-yang, In-dang.
223857408|NCT00024466|BIOLOGICAL|GVAX|
223857409|NCT00024466|PROCEDURE|Autologous transplant|
223857410|NCT02421081|PROCEDURE|vessel microsurgery|That is a surgery ro repair artery laceration.
223857411|NCT02421081|PROCEDURE|tendon repair|That is a surgery ro repair tendon cut.
223857412|NCT02421081|PROCEDURE|nerve microsurgery|That is a surgery ro repair median/ ulnar/ radial nerve cut.
223857413|NCT03692013|DRUG|Losartan|Participants will be divided into 2 groups as daytime group and nighttime group The participants in daytime group will take 100-200mg Losartan in the morning between 6AM to 8AM. The participants in nighttime group will take 100-200mg Losartan at night between 9PM to 11PM .
223857414|NCT02810080|DEVICE|Closed Loop Control Ventilation|Closed loop control ventilation using ZOLL 731 ventilator with physiologic closed-loop control software
223857415|NCT02810080|DEVICE|Manual Control Ventilation|Manual control ventilation using ZOLL 731 ventilator
223857416|NCT03973944|DEVICE|Cardiac resynchronization therapy|Atrio-biventricular pacing to shorten the prolonged PR interval
223857417|NCT06379711|DEVICE|Transcutaneous Spinal Cord Stimulation (tSCS)|Transcutaneous spinal cord stimulation (tSCS) will be delivered via a non-invasive central nervous system stimulator TESCoN or SCONE (SpineX Inc., CA - experimental type II medical devices) through self-adhesive electrode(s) placed on the skin between spinous processes over the midline of the vertebral column as the cathode(s) and two rectangular electrodes placed symmetrically on the skin over the iliac crests as anodes. Stimulation will be applied at various waveforms and frequencies (ranging between 1Hz and 90Hz) with and without a carrier frequency. Current amplitude will start at 10mA and proceed incrementally until tolerable or responses plateau. If spasticity occurs or is uncomfortable, the current will be decreased. Specific areas for electrode placement will be examined and prepared to reduce skin impedance. tSCS will be delivered under the supervision of a physician (Dr. Krassioukov/Dr. Berger) by trained doctoral/post-doctoral trainees.
223857418|NCT01446068|DIETARY_SUPPLEMENT|High-fat meal|Three caloric doses of high-fat meal (500, 1000, 1500 kcal)
223857419|NCT02599142|DEVICE|Group A: Closed-face shell|As for arm description
223857420|NCT02599142|DEVICE|Group B: Open-face shell|As for arm description
223857421|NCT01790529|PROCEDURE|Early administration of SAP (Cefuroxime (plus metronidazole in colorectal surgery)) in anesthetic room (75 to 30 minutes prior to skin incision)|
223857422|NCT01790529|PROCEDURE|Late administration of SAP (Cefuroxime (plus metronidazole in colorectal surgery)) in the operating theatre (within 30 minutes prior to skin incision)|
223857423|NCT01365208|DRUG|Chemotherapy|platinum-based chemotherapy
223857424|NCT03248271|DRUG|Insulin Lispro|Insulin
223857425|NCT05308381|BEHAVIORAL|Fasted exercise|Participants will remain fast (Fasted) 2 h prior to 45 min exercise at 65% VO2max.
223857426|NCT05308381|BEHAVIORAL|High protein breakfast exercise|Participants will consume a high protein breakfast (Protein) 2 h prior to 45 min exercise at 65% VO2max.
223857427|NCT05308381|BEHAVIORAL|High carbohydrate breakfast exercise|Participants will consume a high carbohydrate breakfast (Carbohydrate) 2 h prior to 45 min exercise at 65% VO2max.
223857428|NCT02620761|DRUG|Fenoldopam|Randomized to receive Fenoldopam or 0.9%NS
223857429|NCT02620761|DRUG|0.9%NS|Randomized to receive Fenoldopam or 0.9%NS
223857430|NCT03737097|OTHER|Online Spaced Education|Investigators created a set of fall prevention strategies for multiple sclerosis patients into an evidence-based form of online education, termed 'spaced education' (SE). Based upon two psychology research findings (the spacing and testing effects), spaced education has been shown in randomized trials to improve knowledge acquisition, boosts learning retention for up to two years, and durably improves changes in behavior.
224076183|NCT00200850|BIOLOGICAL|High dose SLIT|House Dust Mite SLIT- 10,000 Allergen units(AU)/ml daily
224076184|NCT00200850|BIOLOGICAL|Placebo SLIT|Placebo SLIT daily
223857431|NCT03737097|OTHER|Brochure Education|The investigators translated and validated the Minimizing Your Risk of Falls A GUIDE FOR PEOPLE WITH MS brochure developed by the National Multiple Sclerosis Society. The control cohort will receive the main education model for patients that has been used in the past few years.
223857432|NCT05110391|DRUG|Hormonal Therapy Agent|Consecutive patients with NOA and hypogonadism (defined by baseline total testosterone levels equal or below 350 ng/dL) subjected to microdissection testicular sperm extraction who received or not pre-sperm retrieval gonadotropin therapy.
223857433|NCT02545062|OTHER|MoCa test|The MoCa test is actually used for the screening of Mild Cognitive Impairment . It is a one page 30 points test that can be done in 10 minutes in a routine annual visit to the Diabetes Clinic. The MoCa assesses several cognitive domains, and it is available in hebrew language.
223857434|NCT05283616|DRUG|Pegfilgrastim|Pegfilgrastim 3mg per chemotherapy cycle
223857435|NCT01870479|OTHER|Live music|
223857436|NCT01870479|OTHER|Taped music|
223857437|NCT00480662|DRUG|alendronate|Duration of Treatment : 6 Months
223857438|NCT05675956|DEVICE|Experimental group with 100% intensity setting on Apollo Neuro device|The group will have the device set to 100% intensity at one of their two experimental visits.
223857439|NCT05675956|DEVICE|Active Comparator group with 10% intensity setting on the Apollo Neuro device|The group will have the device set to 10% intensity at one of their two experimental visits.
223857440|NCT05753917|DEVICE|Piezo-surgery insert OR Conventional Drills|piezo-surgery: Group A (piezoelectric device with IM1, IM2, IM2-3, or IM3 piezo-inserts according to the manufacturer's protocol (Piezosurgery, Mectron Medical Technology, Carasco, Italy) Conventional drill: Group B (conventional drills according to the manufacturer's protocol (Premium, Sweden \& Martina, Due Carrare, Padova, Italy)
223857441|NCT04362215|DIAGNOSTIC_TEST|Subjective accomodation amplitude measurement|ECG:Electrocardıography Echocardiography, Holter implementation(for Lf/Hf ratio))
223857442|NCT00192400|BIOLOGICAL|CAIV-T|
223857443|NCT02536430|DRUG|Ketorolac Tromethamine|One group received a buccal infiltration of Ketorolac Tromethamine
223857444|NCT02536430|DRUG|Placebo|buccal infiltration of Normal Saline.
223857445|NCT01085279|DEVICE|Fraxel Restore, Solta Medical Inc. (Non-ablative fractional laser)|1,550 nm non-ablative fractional laser Irradiance: 15 mJ/microbeam. Coverage: 14-20%. Number of treatment sessions: 4-5
223857446|NCT01085279|DRUG|Modified Kligman's formula (Triple topical therapy)|Hydroquinone 5%, tretinoin 0.05%, triamcinolone acetonide 0.1% once a day during 15 weeks
223857447|NCT04201327|BEHAVIORAL|Project Jumpstart|PrEP focused intervention to improve PrEP related health outcomes
223857448|NCT00227682|DIETARY_SUPPLEMENT|ascorbic acid|
223857449|NCT00227682|DRUG|arsenic trioxide|
223857450|NCT00227682|DRUG|dexamethasone|
223857451|NCT00227682|DRUG|thalidomide|
223857452|NCT05719818|DRUG|biphosphonates|Initiation of bisphosphonate therapy
223857453|NCT05719818|PROCEDURE|Dental care|Surgical dental care
223857454|NCT00141830|DRUG|Methotrexate plus ERB-041 for 12 weeks|
223857455|NCT00141830|DRUG|Placebo for 12 weeks|
223857456|NCT05372094|DEVICE|Phonak Hearing Aid|Commercially available hearing aid with various noise reduction strengths
223857457|NCT02116829|OTHER|Danish butter|The effect of butter intake versus olive oil (refined) intake on blood lipids (primarily)
223857458|NCT02116829|OTHER|Olive oil|
223857459|NCT01420718|DRUG|MTA|partial pulpotomy using White ProRoot MTA. Partial pulpotomy includes removal of 1mm of coronal pulp and covering the remaining tissue with a suitable material.
223857460|NCT01420718|DRUG|iRoot BP|Partial pulpotomy using iRoot BP. Partial pulpotomy includes removal of 1mm of coronal pulp and covering the remaining tissue with a suitable material. Bioaggregate is the first nano particle, water based root end filling material. This product includes calcium silicate, calcium hydroxide, hydroxy apatite and Tantalum oxide. Compared to MTA,this material lacks Bismuth oxide and calcium aluminate. iRoot BP is the injectable for of Bioaggregate (Injectable Root Bioaggregate Paste).
223857461|NCT01762241|BEHAVIORAL|Home based training using the Xbox Kinect system|Home based training 3 times a week for 12 weeks using the Xbox Kinect system
223857462|NCT01348191|PROCEDURE|Myometrial biopsy|At caesarean section, after birth of the baby but before closure of the uterus, a biopsy from the upper lip of the incision in the lower uterine segment will be taken. This biopsy will measure approximately 2x50mm.
223857463|NCT02897622|OTHER|Case management|Case management by Eira unit
223857464|NCT04503356|PROCEDURE|OMNI as a standalone procedure|It uses a single, self-sealing clear corneal incision with ab-interno transluminal 360 degree viscodilation of Schlemm's canal followed by up to 360 degree trabeculotomy performed using the OMNI Surgical System as a standalone procedure.
224076185|NCT02066792|DRUG|D-Cycloserine|D-cycloserine is a medication thought to be associated with fear extinction.
224076186|NCT02066792|DRUG|Placebo|Sugar pill
224076187|NCT02066792|BEHAVIORAL|Cognitive Behavioral Therapy|This will be a 5-session version of a group CBT protocol with 4-6 patients and 2 therapists per group emphasizing repeated exposure practices. Session 1 involves an introduction and orientation to the CBT model. Sessions 2-5 emphasize repeated exposure tasks, which consist of role-play activities to confront fearful situations in a group setting while disputing cognitive distortions (coupled with the fading of safety behaviors). At the conclusion of each exposure session, patients will be encouraged to continue to apply home-practice strategies (such as giving speeches in front of a mirror). Continued practice of the interventions will be considered part of treatment, and patients will be asked to refrain from alternative treatment for four weeks following completion of the last treatment session.
223857465|NCT04503356|PROCEDURE|OMNI combined with cataract surgery|Phacoemulsification with intraocular lens implantation is performed. Then, ab-interno transluminal 360 degree viscodilation of Schlemm's canal followed by up to 360 degree trabeculotomy performed using the OMNI Surgical System.
223857466|NCT04420195|DRUG|Extended-Release Tacrolimus|Envarsus XR is an FDA-approved drug for the prophylaxis of organ rejection in de novo kidney transplant patients or in kidney transplant patients converted from IR tacrolimus when used with other immunosuppressants. Envarsus XR is a novel extended-release formulation of tacrolimus created using MeltDose technology. Envarsus XR is available in tablet form. It is available in 0.75, 1, and 4 mg tablets.
223857467|NCT04420195|DRUG|Immediate-Release Tacrolimus|Historical cohort of 20 subjects who will be maintained on IR tacrolimus following transplant. Dosing will be converted on an individual basis (Capsules: 0.5 mg, 1 mg and 5 mg or Injection: 5 mg) . All patients will be initiated on IR tacrolimus either under the tongue (sublingual) or as a solution given through a tube placed through the nose into the stomach, which is standard of care for all lung transplant recipients.
223857468|NCT04154137|OTHER|Questionnaire|Enrolled patients will fill out a modified version of a previously validated written questionnaire, including two different sections. The first comprises basic demographic information, including age, sex and ethnicity, and a screening section for symptoms consistent with irritable bowel syndrome (IBS) in accordance with the Rome III criteria, also including their past gastrointestinal, allergic and psychiatric history. The second section enquires for self-reported gluten-related symptoms. Participants will be also asked for their use of a gluten-free diet and if they had seen a healthcare professional for their symptoms. A reported diagnosis of celiac disease and wheat allergy in the population group is defined by those who had a doctor diagnosis of celiac disease and wheat allergy and are also taking a gluten-free diet.
223857469|NCT01187576|BEHAVIORAL|Multi-professional team intervention with PAR, lifestyle brochure|Multi-professional team intervention with PAR, lifestyle brochure
223857470|NCT01187576|BEHAVIORAL|Ordinary recommendations on health behaviours, lifestyle brochure|Ordinary recommendations on health behaviours, lifestyle brochure
223857471|NCT03126409|PROCEDURE|No-Touch vein harvesting technique|The No-Touch technique focuses on saphenous vein graft harvesting, featured by preserving the surrounding tissue of the vein while at the same time avoiding manual distension.
223857472|NCT03126409|PROCEDURE|Conventional vein harvesting|During saphenous vein harvesting, surrounding tissue of the vein is stripped off, and manual distension is routinely performed
223857473|NCT02773160|OTHER|Sensor-based postural feedback|Motion tracking sensors will provide feedback to subjects during the learning phase of a motor control task
223857474|NCT02773160|OTHER|Mirror feedback|Subjects will receive feedback from a mirror during the learning phase of a motor control task
223857475|NCT02773160|OTHER|Control group|Subjects will receive no feedback during the learning phase of a motor control task
224076188|NCT02595879|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
224076189|NCT02595879|RADIATION|Brachytherapy|Undergo LDR brachytherapy
223857476|NCT03601351|OTHER|ELISA for MOR-1 expression|To evaluate MOR-1 expression differences by immunohistochemical analysis (ELISA - semiquantitative) in paraffin samples from patients with colorectal cancer stage II / III submitted scheduled colorectal surgery between the tumor tissue and the adjacent nontumorous tissue.
223857477|NCT05079061|DRUG|Misoprostol|sublingual misoprostol 600 micrograms in addition routine uterotonics at third stage of labour
223857478|NCT03275077|DEVICE|Thromboelastography|A viscoelastic test of coagulation
224076190|NCT02595879|DRUG|Cisplatin|Given IV
224076191|NCT02595879|PROCEDURE|Computed Tomography|Undergo FDG-PET/CT
224076192|NCT02595879|RADIATION|External Beam Radiation Therapy|Undergo pelvic EBRT
223857479|NCT05399394|DRUG|Chemotherapy|The induction phase of the treatment plan was designed to administer FOLFIRINOX protocol (oxaliplatin 85 mg/mq and irinotecan 180 mg/mq plus leucovorin 400 mg/mq followed by bolus fluorouracil (FU) 400 mg/mq on day 1, then FU 2,400 mg/mq as a 46-hour continuous infusion) every 14 days for four cycles. In the combined phase, concurrent chemotherapy consisted of weekly gemcitabine at the dose of 600 mg/mq.
223857480|NCT05399394|RADIATION|Radiation|Radiotherapy target volumes are established by CT scan and PET-CT scan. Radiotherapy is delivered with a total dose of 54-59 Gy with fractionation of 1.8 Gy daily for 5 days a week. The Planning Target Volume (PTV) is defined by the Clinical Target Volume (CTV) with a safety margin to include organ motion and set-up errors. Organs at risk for radiation-induced side effects are contoured on the dose planning CT and dose volume histograms (DVH) are calculated. All treatments are delivered with a multifield isocentric technique using a multileaf collimator. A quality-control protocol are applied through cone-beam computed tomography systems (CBCT) for all patients to evaluate the precision of the set-up.
223857481|NCT01345604|PROCEDURE|transcruciate injection of 20cc of normal saline|Group 2 (control group) will receive a transcruciate injection of 20cc of normal saline through the posterior cruciate ligament during the procedure (in addition to a subarachnoid block and femoral nerve block pre-operatively).
223857482|NCT01345604|PROCEDURE|transcruciate injection of 20 cc of 0.5% Ropivacaine|Group 1 (study group) will receive a transcruciate injection of 20 cc of 0.5% Ropivacaine through the posterior cruciate ligament during the procedure (in addition to a subarachnoid block and femoral nerve block pre-operatively).
223857483|NCT03900819|OTHER|dexterity measurement|4 non-invasive tests will be performed
223857484|NCT06167265|DRUG|Cilostazol Tablet 100 mg|Two oral doses (total daily dose of 200 mg)
223857485|NCT06167265|DRUG|PMR Tablet 145 mg|Single oral dose (total daily dose of 290 mg)
224076193|NCT02595879|OTHER|Fludeoxyglucose F-18|Undergo FDG-PET/CT
223857486|NCT03895788|DRUG|niraparib|Niraparib will be administered as a flat-fixed dose (100mg or 200 mg, daily) depending on the cohort the patient is enrolled to, and not by body weight or body surface area. Each dose should be swallowed whole without chewing. The consumption of water is permissible. Patients should take doses at approximately the same times each day, and record this information in the patient diary. Patients will be provided with a diary in which to record their intake of study drug. However, the actual number of doses taken by the patient must be calculated from the number of tablets dispensed and returned.
223857487|NCT03895788|DRUG|Brivanib|Brivanib will be administered as a flat-fixed dose (200mg, 400 mg, or 600 mg daily) depending on the cohort the patient is enrolled to, and not by body weight or body surface area.
223857488|NCT02925195|DIETARY_SUPPLEMENT|Vitamin D3|cholecalciferol (vitamin D3) 2000 IU capsules daily
223857489|NCT02925195|DRUG|Placebo|
223857490|NCT02139449|PROCEDURE|ICD/CRT|cardiac resynchronized therapy (CRT), implantable cardioverter defibrillator (ICD) implantation
223857491|NCT01296425|DEVICE|Easypod™|Saizen (Somatotropin) as per Summary of Product Characteristics administered by Easypod™
223857492|NCT04836624|DEVICE|Co-designing of personalised aids of daily living|"In the initial session the researcher will work with the participants to identify challenges in daily living for the device to overcome.~In between sessions the researcher will design and manufacture different solutions which will then be sent out for the participant to trial. The participant will then meet with the researcher to and feedback on the device provided. Feedback from the user is used to alter and improve the design of the device; new device(s) are then , enabling the design to be adapted to the participants needs. The process of design changes and feedback forms an iterative loop. This is expected to continue for 4-5 appointments over a period of serveral months until a final design is agreed upon.~After the device is issue, both qualitative and quantitative outcome measures are provided to participants to complete, including questionnaires and semi-structured interviews. ."
223857493|NCT03437746|DRUG|injection of methylprednisolone at anesthetic induction|intravenous administration : 20 mg/kg, over 30 minutes at anesthetic induction
223857494|NCT03437746|BIOLOGICAL|Blood samples|Blood samples (D0, D1, D2, D3, D4)
223857495|NCT00819819|DIETARY_SUPPLEMENT|Gluten|Purified gluten from exaploid wheat introduced per American Academy of Pediatric Recommendations. Three grams from 6-9 months and 5 grams from 9-12 months. The 3-5 grams represents the mean daily intake of gluten during the second half of the first year in infants of different countries.
223857496|NCT00819819|DIETARY_SUPPLEMENT|Gluten free diet|Non gluten containing starch added to diet. Three grams from 6-9 months and 5 grams from 9-12 months. After the age of 1 year all children will be allowed age appropriate unrestricted diet.
223857497|NCT04914936|DRUG|ACP-196|Participants will receive a single oral dose of ACP-196 100 mg capsule on Day 1 of Period 1 in Part 1, Part 2, and Part 3; and on Day 1 of Period 2 in Part 1, Day 5 of Period 2 in Part 2, and Day 1 and Day 9 of Period 2 in Part 3.
223857498|NCT04914936|DRUG|Calcium carbonate|Participants will receive a single oral dose of calcium carbonate 1 g tablet on Day 1 of Period 2 in Part 1.
223857499|NCT04914936|DRUG|Omeprazole|Participants will receive multiple oral doses of omeprazole 40 mg capsules QD for 5 consecutive days in Period 2 of Part 2.
223857500|NCT04914936|DRUG|Rifampin|Participants will receive multiple oral doses of rifampin 600 mg capsule QD for 9 consecutive days in Period 2 of Part 3.
223857501|NCT03939819|DEVICE|ViSiGi® 3D suction calibration device|ViSiGi 3D®is a non-sterile, single patient use device. The device comprises a tube with a closed, rounded tip, and holes at the distal end. The proximal end of ViSiGi 3D® includes an integral suction regulator and vented On/Off valve.
223857502|NCT03939819|DEVICE|Esophagogastroduodenoscopy (EGD) calibration|Gastroscope is an illuminated optical, slender and tubular instrument (a type of borescope) used in esophagogastroduodenoscopy.
223857503|NCT00006413|PROCEDURE|Stem cell transplantation|
223857504|NCT01229839|OTHER|Embolization|embolization with lipiodol and polyvinyl alcohol particles (PVA)
223857505|NCT01229839|OTHER|Infusion of anticancer agent|infusion with chemotherapy drugs (EADM 50mg, lobaplatin 50mg, and MMC 6mg ) desolved in water
223857506|NCT01229839|OTHER|Infusion of mixture of anticancer agent and lipiodol|infusion of mixture of lipiodol and chemotherapy drugs (EADM 50mg, lobaplatin 50mg, and MMC 6mg)dissolved in water-soluble contrast medium and distilled water
223857507|NCT06242964|BEHAVIORAL|Promoting Resilience in Stress Management - Social Needs (PRISM-SN)|The Promoting Resilience in Stress Management - Social Needs (PRISM-SN) intervention is a brief, skill-based psychosocial program. Five core sessions are delivered one-on-one, 1-2 weeks apart, in-person or via videoconference. Sessions teach evidence-based behavioral skills for managing stress, setting goals, reframing negative thoughts, meaning-making, and connecting with others. Each session lasts \<60 minutes and is supported by paper-and-pencil or mobile app-based worksheet(s) for learning and practice. A final review session may be completed individually or with a family member, caregiver, or significant other.
223857508|NCT05292638|DRUG|CKDB-501A|Intramuscular injection CKDB-501A
223857509|NCT05292638|DRUG|Botox®|Intramuscular injection Botox®
223857510|NCT05042024|PROCEDURE|Scaling and root planing|Conventional periodontal therapy, non-surgical periodontal therapy
223857511|NCT05042024|DRUG|Oral L-arginine aspartate administration|The use of L-arginine aspartate as adjuncts to local conservative treatment (scaling and root planing) of periodontitis to optimize treatment by modulating local macrophage subpopulations
223857512|NCT05042024|DRUG|Oral L-ornithine aspartate administration|The use of L-ornithine aspartate as adjuncts to local conservative treatment (scaling and root planing) of periodontitis to optimize treatment by modulating local macrophage subpopulations
223857513|NCT00444769|DRUG|GW842166|
223857514|NCT00270426|DRUG|Benazepril|
223857515|NCT06112717|OTHER|Supportive-Educative Nursing Care|Adolescents in the intervention group were received Supportive-Educative Nursing Care based on Orem's Self Care Deficit Nursing Theory
223857516|NCT03413319|DRUG|ABBV-8E12|Solution for infusion
223857517|NCT04857346|DRUG|Indocyanine green|Single application of PDT will be performed. A diode laser (HELBO®TheraLite - Bredent Medical, Germany) with 670 nm wavelength, power of 150 mW, fluency of 22 J/cm2 and density of 1.1 W/cm2 will be used in this study. Indocyanine-green photosensitizer (Sigm Aldrich, USA) with 0.005% concentration will be used as a photosensitizer which will be applied inside the periodontal pockets in a depth of 3 mm with the help of a blunt needle for 10 s. Laser irradiation will be performed for 60 s using a flexible tip. Laser irradiation will be performed at 2 points each on buccal and lingual with the tip stabilized perpendicular to the gingival tissues.
223857518|NCT00571818|PROCEDURE|Oral glucose tolerance test|test done over 2 hours
223857519|NCT00571818|PROCEDURE|IV Glucose Tolerance Test|Done over 4 hours
223857520|NCT04456348|OTHER|there is no intervention|There is no intervention
223857521|NCT05322824|DRUG|standard medical treatment|standard medical treatment
223857522|NCT05322824|PROCEDURE|Interventional stenting|Interventional stenting
223857523|NCT05421988|BEHAVIORAL|Emotional Freedom Techniques (EFT)|EFT is an efficacious method demonstrated in over 100 clinical trials. It combines cognitive and exposure techniques with acupressure, in the form of fingertip percussion on acupuncture meridian points.
223857524|NCT00756743|DRUG|PF-04802540|Multiple ascending doses for 10 days; planned doses include 5, 10 and 15 mg capsules q12 hours, doses may be adjusted based on accumulating data
223857525|NCT00756743|DRUG|Placebo|Placebo capsules q12 hours for 10 days
223857526|NCT02786602|GENETIC|pyrosequencing|
223857527|NCT00002995|BIOLOGICAL|dactinomycin|
223857528|NCT00002995|BIOLOGICAL|filgrastim|
223857529|NCT00002995|BIOLOGICAL|sargramostim|
223857530|NCT00002995|DRUG|cyclophosphamide|
223857531|NCT00002995|DRUG|vincristine sulfate|
223857532|NCT00002995|RADIATION|radiation therapy|
223857533|NCT01183780|BIOLOGICAL|Ramucirumab|8 milligrams / kilogram (mg/kg) administered intravenously every 2 weeks until disease progression, unacceptable toxicity, noncompliance or withdrawal of consent by the participant or investigator decision
223857534|NCT01183780|BIOLOGICAL|Placebo|Administered intravenously every 2 weeks until disease progression, unacceptable toxicity, noncompliance or withdrawal of consent by the participant or investigator decision
223857535|NCT01183780|DRUG|Irinotecan|180 milligrams/square meter (mg/m\^2) administered intravenously every 2 weeks until disease progression, unacceptable toxicity, noncompliance or withdrawal of consent by the participant or investigator decision
223857536|NCT01183780|DRUG|Folinic Acid|400 mg/m\^2 administered intravenously every 2 weeks until disease progression, unacceptable toxicity, noncompliance or withdrawal of consent by the participant or investigator decision
223857537|NCT01183780|DRUG|5-Fluorouracil|400 mg/m\^2 bolus immediately followed by 2400 mg/m\^2 continuous infusion every 2 weeks until disease progression, unacceptable toxicity, noncompliance or withdrawal of consent by the participant or investigator decision
223857538|NCT00092716|DRUG|MK0653, ezetimibe / Duration of Treatment: 28 weeks|
223857539|NCT00092716|DRUG|Comparator: atorvastatin / Duration of Treatment: 28 weeks|
223857540|NCT00817817|DEVICE|MF|One evening dose of dry powder inhaled MF 400 μg (Multidose device).
223857541|NCT00817817|DEVICE|MF|One evening dose of dry powder inhaled 400 μg (400 μg capsules - Monodose).
223857542|NCT04760119|PROCEDURE|Vein bypass surgery first strategy|Vein bypass will be performed with standart anaesthetic and surgical techniques using reversed great saphenous vein conduit. Location of proximal and distal anastomosis will be recorded. Post surgery completion angiography imaging will be performed.
223857543|NCT04760119|PROCEDURE|Endovascular treatment first (drug coated balloon angioplasty) strategy|Endovascular treatment using drug-coated balloons will be performed under local anaesthetic via common femoral artery. Final angiography imaging will be demonstrated.
223857544|NCT04875130|DIAGNOSTIC_TEST|blood samples|Taking blood samples (plasma, serum) and measure the level of Adrenomedullin
224076194|NCT02595879|RADIATION|High-Dose Rate Brachytherapy|Undergo HDR brachytherapy
224076195|NCT02595879|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
224076196|NCT02595879|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
224076197|NCT02595879|OTHER|Pharmacological Study|Correlative studies
224076198|NCT02595879|PROCEDURE|Positron Emission Tomography|Undergo FDG-PET/CT
224076199|NCT02595879|DRUG|Triapine|Given IV and PO
224076200|NCT06375135|BEHAVIORAL|TXTXT|Treatment Text (TXTXT) is composed of personalized 2-way SMS text message reminders and encouraging messages. Daily text message reminders will be sent according to the participants medication schedule for six months. A study coordinator will enter the participants phone number in the TXTXT system and set the program to provide daily reminders at the time consistent with the clinical dosing schedule of their ART. Participants will have the option of choosing to create a personalized message that may be changed at any time, because the messages are personalized, they may be in any language the participant desires. Fifteen minutes after this initial message, participants will be asked to send a text message response indicating if they took their medications. Participants responses will be followed by one of a set of randomly selected encouraging messages depending on their affirmative or negative response.
224076201|NCT06375135|BEHAVIORAL|e-Navigation|"Develop an e-Navigation intervention using all three components of CDCs STEPS to Care intervention:(1) patient navigation, (2) care coordination, and (3) HIV-self-management.~Patient Navigation: Remote one-on-one sessions, will help improve medication adherence, access to social services, and prompt re-engagement in care.~Care coordination: Frequent and open communication with the care team. E-navigator will share client progress and needs, support information-sharing and decision-making to improve health outcomes for clients.~HIV self-management: HIV education and guidance with goal setting. E-navigator will help clients build knowledge and skills for self-care, navigating the health care system, and independent health maintenance.~The e-Navigator will meet with participants bi-weekly at first but may meet less frequently over time as barriers are addressed. Meetings will be conducted via videoconferencing and will be used to check in and provide individualized support."
224076202|NCT06375135|BEHAVIORAL|Ecological Momentary Assessment (EMA) supported e-Navigation.|Participants in the Ecological Momentary Assessment (EMA) supported e- Navigation intervention will be asked to complete 4 to 6-minute EMAs via a secure survey link three times per week to assess adherence barriers in real or near real time. In addition to time-based EMA (study prompted), participants will also be able to submit event based EMAs (participant prompted) at any time. The e-Navigator will review responses to EMAs and remotely assist participants in addressing these barriers within 2 business days.
224076203|NCT06036966|DRUG|Hetrombopag|All the enrolled 34 patients will be given hetrombopag 5mg per day for 8 weeks when they start to take Niraparib as maintenance therapy
224076204|NCT05578690|BEHAVIORAL|Diet|An initial 8 weeks of low-calorie diet including meal replacements (total of 800 kcal/day) will be initiated with the objective to lose at least 10% of initial body weight. From week 8 until week 12, an individual food-reintroduction plan will take place with partial meal product substitution. At week 12 and until pregnancy dieticians will ensure sustained compliance with diet aligned with the general recommendations for women seeking pregnancy (low-fat diet, rich in protein and carbohydrates and in some individuals slightly carbohydrate-reduced diet (prediabetes or family disposition to diabetes) with focus on carbohydrate quality (more fiber and whole grain). Consultations with a dietician for mapping diet and eating patterns and regular follow-up with a dietitian to maintain diet changes and modify diets if needed.
224076205|NCT05578690|BEHAVIORAL|Exercise|After an initial 8-week ramp-up phase (during the initial low-calorie diet), the women will be encouraged to attend supervised exercise sessions on the study location (combination of vigorous-intensity, interval-based indoor cycling, and circuit training) twice weekly and to perform additional moderate-to vigorous-intensity exercise to obtain at least 150 min per week of moderate-intensity or 75 min per week of vigorous-intensity physical activity or a combination. The plan will include individual exercise and/or group exercise. Exercise watches with heart-rate monitors will be worn at each exercise session to determine whether the requirement regarding weekly time spent at moderate or vigorous intensity will be met. Regular follow-up with the women to maintain exercise changes and modify the exercise plan if needed.
224076206|NCT05578690|BEHAVIORAL|Mentorship|"Women are offered an individualized plan to successfully fulfil the multifactorial lifestyle intervention and the women will be offered both individual and/or group sessions with a mentor. After 8 weeks of the intervention, the women will be invited to another meeting where the choice of mentor will be evaluated, and the women will be offered to join a pre-parents-group. Group sessions will include conversational sessions, cooking classes and exercise classes with focus on changing lifestyle and maintaining a healthy lifestyle change. At the time of pregnancy groups will be reconsidered and the women will be offered participation in pregnancy-groups."
223857545|NCT01492218|DRUG|biphasic human insulin 30|Administered via the NovoLet® device and according to the instructions in the product insert or as instructed by the physician. Individually adjusted dosage as instructed by the physician.
223857546|NCT04089488|OTHER|Medical Chart Review|Correlative studies
223857547|NCT04089488|OTHER|Survey Administration|Respond to surveys
223857548|NCT05112861|BIOLOGICAL|bevacizumab|1.25 mg, intravitreal injection
223857549|NCT00258037|BEHAVIORAL|Pelvic Floor Muscle training|
223857550|NCT02762006|DRUG|Durvalumab|Durvalumab is a programmed cell death ligand-1 monoclonal antibody which has demonstrated anti-tumor efficacy renal cell carcinoma and other malignancies via activation of the immune system.
223857551|NCT02762006|DRUG|Tremelimumab|Tremelimumab is a CTLA-4 monoclonal antibody.
223857552|NCT04709796|DRUG|EmbryoGlue®, Vitrolife|The intervention under study is the application of EmbryoGlue®, a class III medical device (CE Marked). EmbryoGlue® is a bicarbonate buffered medium containing recombinant human albumin, hyaluronan and gentamicin as an antibacterial agent.
223857553|NCT04709796|DRUG|Conventional Transfer|The control arm is the conventional embryo transfer without Embryo glue medium
223857554|NCT06054867|DEVICE|Robotic Waterjet Treatment|"The Aquablation therapy is a minimally invasive, image-guided, heat-free robotic therapy delivered by the AQUABEAM Robotic System.~During Aquablation therapy, the AQUABEAM Handpiece is inserted transurethrally into the prostatic urethra. The operating physician then utilizes cystoscopy in conjunction with transrectal ultrasound (TRUS) imaging for real-time visualization. The AQUABEAM Robotic System utilizes high-velocity sterile saline waterjet to resect and remove the prostate tissue according to the operating physician's treatment plan."
223857555|NCT03808883|BEHAVIORAL|TGNC Directed Advocacy Meetings|Series of 18 meetings with TGNC cohort, including 3 facilitated dialogues with the healthcare participants, to articulate barriers to access and to enter into dialogue with medical providers and staff.
223857556|NCT03808883|BEHAVIORAL|Facilitated Dialogues between TGNC Cohort and Healthcare Participants|Healthcare Participants attend a facilitated dialogue with the TGNC cohort. 3 total facilitated dialogues were held, but each healthcare participant attends only 1 session.
223857557|NCT02727764|GENETIC|ART-I02|Single Intra-articular injection in the carpometacarpal (CMC), metacarpophalangeal (MCP), proximal interphalangeal (PIP), or distal interphalangeal (DIP) joint
224266132|NCT05448235|OTHER|conventional treatment|the patient will be asked to make pursed lip breathing (Breathe in for 2 seconds through his nose and Breathe out for 4 seconds through pursed lips)for 5-10 min ,3-4 times , 8-10 rep each cycle then asked to make diaphragmatic breathing exercise (Lie on his/her back and Inhale deeply through his/her nose for a count of three)for 5-10 min , 3-4 times , 8-10 repetition then postural drainage , furthermore the patient takes different position (prone to make percussion on lower lobes, side lying on anterior basal segment then sitting position on the upper lobe). After that a vibration on the chest (place a flat hand firmly atop the lung segment to be drained., and should apply light pressure and create a rapid, shaking movement) 1 min inhale and 5 time of repetition at the exhale and finally asked the patient to make productive cough for 5 times to get out the sputum.
224266133|NCT05448235|OTHER|thoracic mobilization|we will use A SNAG to mobilization using type 3 oscillatory and sustain for 90 second, at first put the patient in 3 position (side lying to make mobilization of upper 6 ribs in downward direction then make on lower 6 ribs ,furthermore flexion of the thoracic and next rotation toward the midline then ask the patient to transfer to supine lying position and mobilize the sternum in downward direction the next mobilize the clavicle and ask the patient to take sitting position and put his hand on his head in adduction position and make extension on the thoracic vertebrae with inward mobilize with the investigator knees ,take each 4 vertebrae along the 12 thoracic vertebrae.
224266134|NCT03082586|RADIATION|radiochemotherapy 1|concurrent radiochemotherapy: radiotherapy dose level 1: 50 Gy at 2 Gy/Fx/d, then 7.2 Gy at 1.2 Gy/Fx/bid; concurrent chemotherapy: carboplatin, area under the curve (AUC) 1.5-2, weekly; paclitaxel, 45-50 mg/m2, weekly
224266135|NCT03082586|RADIATION|radiochemotherapy 2|concurrent radiochemotherapy: radiotherapy dose level 1: 50 Gy at 2 Gy/Fx/d, then 14.4 Gy at 1.2 Gy/Fx/bid; concurrent chemotherapy: carboplatin, area under the curve (AUC) 1.5-2,weekly; paclitaxel, 45-50 mg/m2, weekly
224266136|NCT03082586|RADIATION|radiochemotherapy 3|concurrent radiochemotherapy: radiotherapy dose level 1: 50 Gy at 2 Gy/Fx/d, then 21.6 Gy at 1.2 Gy/Fx/bid; concurrent chemotherapy: carboplatin, area under the curve (AUC) 1.5-2,weekly; paclitaxel, 45-50 mg/m2, weekly
224266137|NCT03082586|RADIATION|radiochemotherapy 4|concurrent radiochemotherapy: radiotherapy dose level 1: 50 Gy at 2 Gy/Fx/d, then 28.8 Gy at 1.2 Gy/Fx/bid; concurrent chemotherapy: carboplatin, area under the curve (AUC) 1.5-2,weekly; paclitaxel, 45-50 mg/m2, weekly
224266138|NCT03082586|RADIATION|radiochemotherapy 5|concurrent radiochemotherapy: radiotherapy dose level 1: 50 Gy at 2 Gy/Fx/d, then 36 Gy at 1.2 Gy/Fx/bid; concurrent chemotherapy: carboplatin, area under the curve (AUC) 1.5-2,weekly; paclitaxel, 45-50 mg/m2, weekly;
224266139|NCT03082586|RADIATION|radiochemotherapy 6|concurrent radiochemotherapy: radiotherapy dose level 1: 50 Gy at 2 Gy/Fx/d, then 43.2 Gy at 1.2 Gy/Fx/bid concurrent chemotherapy: carboplatin, area under the curve (AUC) 1.5-2,weekly; paclitaxel, 45-50 mg/m2, weekly
224266140|NCT04758208|DIAGNOSTIC_TEST|Hematology Parameters|Measurement of hematology parameters on BC-6800Plus
224266141|NCT03340623|DEVICE|Venous coupler|A coupler can be used to perform a venous anastomosis. It is a double ring with pins on only one of its 2 faces. The technique consists in clamping the two veins, estimating the intima-to-intimal diameter of the vessels, choosing the coupler of the appropriate size, sliding the vein in the ring and evers the edges of the vessel to fix them on the pins, redo the same thing for the other vein and finally bring the two vessels together in order to clip them together.
224266142|NCT04342936|DRUG|Camrelizumab|A humanized monoclonal immunoglobulin
224266143|NCT04342936|DRUG|Investigator's choice of Chemotherapy|"Participants will receive one of the following chemotherapies for up to 6 cycles:~Gemox: Gemcitabine and Oxaliplatin； IGEV: Ifosfamide, Gemcitabine, Vinorelbine, and Prednisolone； DHAP: Dexamethasone, high-dose Cytarabine (Ara-C) and Cisplatin."
223857558|NCT03646006|DRUG|Bupivacaine|10 mL (5mg/mL)
223857559|NCT03646006|DRUG|Placebo|10 mL normal saline
223857560|NCT05026034|DEVICE|non-invasive Cardiopulmonary Management (CPM) wearable device|non-invasive Cardiopulmonary Management (CPM) wearable device with measures of congestion in heart failure
223857561|NCT02219919|OTHER|Surgical Group|The surgical group will receive a surgical procedure consisting of the decompression and release of the median nerve at the carpal tunnel performed by an experienced surgeon according to standardized protocols.
223857562|NCT02219919|OTHER|Physical Therapy Group|The physical therapy group will receive 3 treatment sessions of manual therapy including desensitization maneuvers of the central nervous system of 30 minutes of duration, once per week.
223857563|NCT03038399|DRUG|Vamorolone 0.25 mg/day/day|Oral administration of 0.25 mg/kg/day daily for 24 months.
223857564|NCT03038399|DRUG|Vamorolone 0.75 mg/day/day|Oral administration of 0.75 mg/kg/day daily for 24 months.
223857565|NCT03038399|DRUG|Vamorolone 2.0 mg/day/day|Oral administration of 2.0 mg/kg/day daily for 24 months.
223857566|NCT03038399|DRUG|Vamorolone 6.0 mg/day/day|Oral administration of 6.0 mg/kg/day daily for 24 months.
223857567|NCT06335836|BEHAVIORAL|social isolation|social isolation (0≤LSNS-6≤12)
223857568|NCT03298919|BEHAVIORAL|Exercise Video Games|12 weeks laboratory based exercise videogames
223857569|NCT03298919|BEHAVIORAL|Aerobic Exercise|Stationary bike and/or treadmill walking for 12 weeks
223857570|NCT03298919|BEHAVIORAL|Home exercise videogames|videogame console and active videogames
223857571|NCT03298919|BEHAVIORAL|Home Standard Exercise|Personalized physical activity promotion materials
223857572|NCT00155558|DRUG|5-Fluorouracil, Leucovorin|
223857573|NCT03861169|DEVICE|Transluminal viscoelastic delivery and trabeculotomy|Ab-interno transluminal viscoelastic delivery and trabeculotomy using OMNI Surgical System
223857574|NCT03337568|PROCEDURE|allogeneic hematopoietic cell transplantation|perform allogeneic hematopoietic cell transplantation (HCT) using conditioning regimen of busulfan, fludarabine, and antithymocyte globulin
223857575|NCT01595854|DRUG|dabigatran etexilate|medium dose dabigatran
223857576|NCT01595854|DRUG|Ticagrelor|high dose ticagrelor
223857577|NCT01595854|DRUG|Ticagrelor|high dose ticagrelor
223857578|NCT01595854|DRUG|dabigatran etexilate|low dose dabigatran
223857579|NCT01595854|DRUG|dabigatran etexilate|medium dose dabigatran
223857580|NCT04126109|OTHER|questionaire|A questionaire will be offered to every parents
223857581|NCT04848649|OTHER|Study arm|Questionnaires, blood sample, skin (for psoriasis patients) or digestive (for IBD patients) biopsy and swab testing
223857582|NCT03829267|BEHAVIORAL|eFIT Intervention|eFIT: social network accountability partners, a psychosocial intervention to increase physical activity in persons with multiple sclerosis
224266144|NCT02849106|PROCEDURE|biopsy to obtain a chemogram|All patients enrolled will have biopsies (on primary tumor or on a metastasis) before treatment in order to obtain a chemogram by ex vivo 3D culture cells
224266145|NCT00975754|DRUG|Pulmicort pMDI HFA|Inhalation aerosol, 200 μg/ metered dose. Each subject receive a single dose from 4 inhalations
224266146|NCT00975754|DRUG|Budesonide pMDI HFA|Inhalation aerosol, 160 μg/ metered dose. Each subject receive a single dose from 4 inhalations
224266147|NCT00975754|DRUG|Pulmicort Repulses|Suspension for nebulisation, 0.5 mg/mL. Each subject receive a single dose from 100 inhalations
224266148|NCT00975754|DRUG|Pulmicort Turbohaler|Inhaled powder, 200 μg/ metered dose. Each subject receive a single dose from 4 inhalations
224266149|NCT00919737|DRUG|NPC-08|Polifeprosan 20 with Carmustine 3.85%
224266150|NCT04431518|DRUG|JULUCA 50Mg-25Mg Tablet|One dose of JULUCA will be taken daily for up to 14 days
224266151|NCT05252377|OTHER|Breathing Exercise|"1. The patient will be asked to close their eyes~2. He will be asked to relax his head and neck in a semi-sitting position in bed~3. The patient will be asked to breathe through the nose for 3 seconds by counting~4. Then he will be told to hold his breath for 3 seconds~5. As the last step, he will be asked to breathe out again in 3 seconds."
224266152|NCT01172249|DRUG|Glucosamine sulfate + chondroitin sulfate - MANTECORP|1 capsule three times daily before meals (glucosamine sulfate 500 mg + sodium chondroitin sulfate 400 mg).
224266153|NCT01172249|DRUG|Glucosamine sulfate + chondroitin sulfate - CONDROFLEX|1 capsule three times daily before meals (glucosamine sulfate 500 mg + sodium chondroitin sulfate 400 mg).
224266154|NCT01492556|DRUG|Etoposide|Lastet (Etoposide Capsules, 25mg\*40 capsules/box), manufactured by Nippon Kayaku Co., Ltd.
224266155|NCT05406518|OTHER|Psychosocial intervention|Psychosocial intervention based on the model of family therapy.
224266156|NCT00209690|DRUG|Taxotere|X mg/m2, IV (in the vein) on day 1 of each 28 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
223857583|NCT03829267|BEHAVIORAL|eJournal Intervention|1-hour online each week engaged in an active journaling activity
223857584|NCT03829267|BEHAVIORAL|Treatment as usual|Participants in this condition will complete baseline and follow-up surveys with the same frequency as the active treatment groups, but will receive neither eFIT nor eJournal.
224266157|NCT00209690|DRUG|5-FU|800 mg/m2, CIV (conti.in the vein) on day 1\~4 of each 28 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
224266158|NCT00209690|DRUG|Briplatin|15 mg/m2, IV (in the vein) on day 1\~4 of each 28 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
224266159|NCT03354858|PROCEDURE|Follicular flushing|Repeated follicle flushing up to 5 times using a double lumen needle for oocyte recovery
223857585|NCT02371746|DRUG|ENV515-3 Travoprost XR|
224266160|NCT00827164|BEHAVIORAL|Nutrition Counseling|Patients will meet once per week with dietitian for the first 6 weeks in 60 minute sessions. Dietitian will telephone each patient weekly for the final 6 weeks of counseling and support.
223857586|NCT02371746|DRUG|ENV515-1 Travoprost XR|
223857587|NCT02371746|DRUG|ENV515-3-2 Travoprost XR|
223857588|NCT06367517|DRUG|Tocilizumab|Tocilizumab administrated at a dose of 8 mg/kg, given once every four weeks
223857589|NCT00595205|OTHER|Hospital log review.|Reviewing of the hospital log to monitor for the occurrence of intussusception.
223857590|NCT02613364|BEHAVIORAL|Behavioral Intervention|Undergo yoga intervention
223857591|NCT02613364|OTHER|Cognitive Intervention|Undergo CBT-I intervention
223857592|NCT02613364|OTHER|Educational Intervention|Receive health education
224266161|NCT00827164|BEHAVIORAL|Resistance Training|Patient will meet with an exercise specialist once per week for the first 6 weeks. Patients will receive guidance in a safe and appropriate exercise regimen based on specific medical history and preference. An exercise specialist will telephone weekly for consultation and support once per week for the final 6 weeks.
224266164|NCT04031690|OTHER|Caregiver Quality of Life Questionnaires|Measurement of quality of life at D0, M6 and M12 via SF-36, CarGOQoL and the one-dimensional Zarit score
224266165|NCT04031690|OTHER|Patient Quality of Life Questionnaires|Quality of life measurement at D0, M6 and M12 via the SF-36
224266166|NCT04879719|BEHAVIORAL|Ego-depletion|The surgery video lasts for 9 minutes and participants are asked to suppress their emotions. After the intervention several implicit aggression tests, as well as a task, measuring cognitive performance in general are assessed.
224266167|NCT04879719|BEHAVIORAL|Control|The surgery video lasts for 9 minutes and participants in the control group are asked to watch the surgery video without the need to suppress their emotions. Several implicit aggression tests, as well as a task, measuring cognitive performance in general are assessed after the 9 minute video sequence.
224266168|NCT02245503|DRUG|Tamsulosin|
224266169|NCT01852799|DRUG|PAD Followed by ASCT|"Drug: Bortezomib, Bortezomib (1.3mg/m2, iv, on day 1, 4, 8, 11, of each 28 day cycle)~Drug: Adriamycin (Doxorubicin) /EPI, Adriamycin (Doxorubicin) (9 mg/m2, iv, on days 1-4 of each 28 day cycle) or EPI (15mg/m2, iv, on days 1-4 of each 28 day cycle)~Drug: Dexamethasone, Dexamethasone (20mg, iv, on days 1-4, 8-11of each 28 day cycle)~After received induction therapy, patients will proceed to receive ASCT based on the willing of the patients and the decision of the investigators."
224266170|NCT05561088|OTHER|Scalp Acupuncture|mplementation plan of head needle: The middle frontal line (MS1), the middle parietal line (MS5) and the back parietal and temporal oblique line (MS7) in the International Standardization Program for the Name of the first needle Point in 1989 were selected, and the needles were inserted along the shape of each section. One needle was inserted into the middle frontal line and the middle parietal line, and two needles were inserted into the back parietal and temporal oblique line. The KWD-808I pulse electrotherapy instrument produced by Changzhou Wujin Great Wall Medical Equipment Co., Ltd. is used on the needle handle after lifting, inserting and twisting. The continuous waveform was used, the voltage was 2-4 V, the frequency was 60-80 times /min, the intensity was tolerated by the patient, the needle was kept for 30min, and the treatment was performed once a day.
224266171|NCT05561088|OTHER|The treatment recommended in the guidelines for acute ischemic stroke was administered|The treatment recommended in the guidelines for acute ischemic stroke was administered
224266172|NCT05453487|BIOLOGICAL|coadministration|the coadministration of an inactivated COVID-19 vaccine (BBIBP-CorV) and rabies vaccine
224266173|NCT05453487|BIOLOGICAL|COVID-19 vaccine|received one dose of inactivated COVID-19 vaccine (BBIBP-CorV)
224266174|NCT05453487|BIOLOGICAL|rabies vaccine|received three dose of rabies vaccine
224266175|NCT03162159|OTHER|Collection of growth and bone maturation data|
224266176|NCT00178178|DEVICE|Breg Pain Care 3000 Catheter|Device: Breg Pain Care 3000 Catheter
224266177|NCT00178178|DRUG|Bupivicaine 0.5%|Drug: Bupivicaine 0.5 %
224266178|NCT00178178|DRUG|Placebo|Drug: Placebo
224266179|NCT01559363|DRUG|Tesevatinib|Pharmaceutical form: Tablets Route of administration: Oral
224266180|NCT00672984|DRUG|immediate release guanfacine hydrochloride|Subjects will receive 2x2mg immediate-release guanfacine on day 1. Subjects will receive 4x2mg immediate-release guanfacine on day 6.
224266181|NCT00672984|DRUG|moxifloxacin|Subjects will receive 400mg of moxifloxacin on day 1. Subjects will receive 400mg of moxifloxacin on day 6.
224266182|NCT00672984|DRUG|Placebo|Subjects will receive placebo on Day 1. Subjects will receive placebo on Day 6.
224266183|NCT05022979|OTHER|Observational only|"The investigator collected the patient's data from the medical record and interviewed the patient to complete the nutritional questionnaire.~The required biological, blood and urine samples were collected during routine blood sampling upon entry and hospitalization."
224266184|NCT05800262|BEHAVIORAL|Dynamic stability exercises|A dynamic stability exercise program for daily home-exercise was applied during five physiotherapist led sessions distributed over seven weeks.
224266185|NCT01746472|BEHAVIORAL|Facebook app - condition t|Application components hypothesized to increase the duration (t, time) that a participant spends using the application.
224266186|NCT01746472|BEHAVIORAL|Facebook app - condition z|Application components hypothesized to increase the number of friends that a user has that are eligible to install the application.
224266187|NCT01746472|BEHAVIORAL|Facebook app - condition B-active|Application components hypothesized to increase the contagiousness of the app by increasing a users ability and desire to proactively contact others.
224266188|NCT01746472|BEHAVIORAL|Facebook app - condition B-passive|Application components hypothesized to increase the contagiousness of the app by increasing the passive diffusion of information from the user to their friends.
223857593|NCT02613364|OTHER|Laboratory Biomarker Analysis|Correlative studies
223857594|NCT02613364|DEVICE|Monitoring Device|Correlative studies
223857595|NCT02613364|OTHER|Quality-of-Life Assessment|Ancillary studies
223857596|NCT02939469|OTHER|Physiologic maneuvers|"Subjects will perform~Valsalva maneuver Hand Grip Post exercise cuff occlusion Loud Noise and Skin pinch"
223857597|NCT03582618|DRUG|Sorafenib|Sorafenib will be administered orally at a starting dose of 400mg BID daily and the necessity of dose reduction will be assessed during sorafenib tolerability assessment period
223857598|NCT03582618|DRUG|CVM-1118|CVM-1118 will be administered orally at 150 mg BID or 200 mg BID daily and combined with the tolerable dose of sorafenib for a 28-day cycle
223857599|NCT00709644|DRUG|Norgestimate; Ethinyl Estradiol; Folic acid.|
223857600|NCT04994054|DIETARY_SUPPLEMENT|silkworms (Bombyx mori L.) pupae extracts group|silkworms (Bombyx mori L.) pupae extracts 2,400 mg/day for 12 weeks
223857601|NCT04994054|DIETARY_SUPPLEMENT|Placebo group|Placebo 2,400 mg/day for 12 weeks
223857602|NCT01114945|DEVICE|McGrath|Intubation with the McGrath device
223857603|NCT01114945|DEVICE|GlideScope|Intubation with the GlideScope device
223857604|NCT01114945|DEVICE|Direct Macintosh Laryngoscopy|Intubation with Direct Macintosh Laryngoscope
223857605|NCT01114945|DEVICE|Video-Mac|Intubation with the Video-Mac device
223857606|NCT00001524|DRUG|Thalidomide|
223857607|NCT03844854|OTHER|Stabilization occlusal splint and manual therapy|Providing stabilization occlusal splint and manual therapy
223857608|NCT04615299|DEVICE|Auricular acupuncture|Auricular or Battlefield acupuncture is an auricular therapy which has been in existence for centuries, with roots tied to Eastern Asian medicine.
223857609|NCT01056835|DRUG|prostaglandin I2 analogue|
223857610|NCT03437642|BEHAVIORAL|Short Term Psychotherapy|Humanistic-existential psychotherapy derived from ontopsychological method and specifically adapted to public health systems. Individual and group sessions to be tailored to individual needs
223857611|NCT00878722|DRUG|PXD101|
223857612|NCT00878722|DRUG|idarubicin|
223857613|NCT02961127|OTHER|Venous blood was collected|Venous blood was collected by standard vein puncture in fasting condition
223857614|NCT01813825|OTHER|Registry|
223857615|NCT04955119|DIAGNOSTIC_TEST|Fusion imaging contrast-enhanced ultrasound|"Fusion imaging contrast-enhanced ultrasound will be performed for patients with invisible lesion at conventional ultrasound.~Drug: SonoVue"
223857616|NCT04630912|OTHER|Acceptance and Commitment Therapy|There is no specific protocol for ACT with dementia, therefore a published ACT protocol, 'Better Living with Illness' (Brassington et al., 2016), will be used flexibly to guide the intervention.
223857617|NCT04083833|DRUG|Tetrodotoxin|A single TTX dose in a dose ascending study
223857618|NCT04083833|DRUG|Placebos|matching placebo comparator
223857619|NCT02404337|DRUG|Betaine|
223857620|NCT04635488|PROCEDURE|lateral lymph node dissection|All participted would receive lateral lymph node dissection for rectal cancer.
223857621|NCT04302844|BEHAVIORAL|Imago Relationship Therapy|Imago relationship therapy (IRT) involves learning the Imago dialogue process, which helps couples understand more clearly why they and their partners react as they do. Couples practice communicating in a manner that helps them move from reactivity and blame to understanding and empathy. The dialogue is used to transform conflicts into opportunities for healing and growth, and to connect more deeply and effectively with one another. Specific topics of therapy are determined by the couple's needs and goals. In general, the therapist helps them use the Imago dialogue to promote understanding, heal painful emotions, and make requests of one another to change behaviors. In effort to minimize risk of exposure to the virus that causes COVID-19, since the spring of 2020, therapy sessions will be conducted via telehealth, with a HIPAA-compliant audio/visual platform, and with couples at home or in another private place during the therapy sessions and the therapist in his or her office.
223857622|NCT04302844|BEHAVIORAL|Waitlist with Bibliotherapy followed by Workshop|"Participants assigned to this group will be asked to wait for 12 weeks before receiving any intervention, and will be given a relationship-focused self-help book to read, with exercises to practice, during that time. After 12 weeks and the 12-week assessment has been completed, couples will attend an educational workshop that provides the principles and communication skills of Imago Relationship Therapy, typically in a weekend format that is usually about 18-20 hours. The workshops, called Getting the Love You Want (GTLYW), are led by certified and experienced Imago workshop presenters, and are attended by a group of couples. The workshop includes presentations, discussions, and practice of communication exercises. Participation in the workshops will also be virtual or via telehealth, as described above."
223857623|NCT05452980|PROCEDURE|reestablishment of the acute angle of His|A sleeve was fashioned starting 4 cm proximal to the pylorus using serial applications of an 60 stapler over a 36Fr oro-gastric bougie. A security distance of 15 mm lateral to the esophagus is respected to reduce the risk of high leak.
223857624|NCT05452980|PROCEDURE|sleeve gastrectomy|A sleeve was fashioned starting 4 cm proximal to the pylorus using serial applications of an 60 stapler over a 36Fr oro-gastric bougie. A security distance of 15 mm lateral to the esophagus is respected to reduce the risk of high leak.
223857625|NCT00568542|DRUG|erythropoetin beta|35 I.E. kg body weight subcutaneous once per week for 6 months
223857626|NCT00568542|DRUG|placebo|35 I.E. kg body weight placebo to erythropoetin beta
223857627|NCT02457507|DIETARY_SUPPLEMENT|Vitamin B12|2 tablets
223857628|NCT02457507|DIETARY_SUPPLEMENT|Placebo|2 tablets
223857629|NCT00576888|OTHER|no intervention|no intervention - observational only
223857630|NCT02873754|BEHAVIORAL|Cognitive Behavioral Counseling|Participants will receive five cognitive-behavioral counseling sessions designed to improve rates of smoking cessation, enhance relapse prevention, and increase physical activity.
223857631|NCT02873754|BEHAVIORAL|Mobile Contingency Management|Participants will be asked to provide video recordings of themselves taking carbon monoxide readings in order to confirm smoking abstinence. They will also be asked to wear a fitness tracker to monitor physical activity (i.e., steps walked). Participants are provided monetary reward for videos that suggest smoking abstinence, and for fitness tracker readings that suggest increased physical activity.
223857632|NCT02873754|DRUG|Bupropion|All participants who are medically eligible will be prescribed bupropion, which they will start two weeks prior to their quit day. Dosage will be 150 mg/daily for days 1-7 and 300 mg/daily (administered in two daily doses) until the 6-month follow-up.
223857633|NCT02873754|DRUG|Transdermal nicotine patch|Initiated at smoking quit date; 7 mg to 21 mg patch depending on amount smoked by participant
224266189|NCT05409651|BEHAVIORAL|Time restricted eating|Participants in this arm will adhere to a daily, consistent 8-10-hr eating window for the course of the study.
224266190|NCT06563232|DEVICE|FNA group|Fine-needle-aspiration (22G EchoTip Ultra Echo-3-22)
224266191|NCT06563232|DEVICE|Adapt FNB group|Fine-needle-biopsy (22G Adapt Aspiration)
224266192|NCT01717352|BEHAVIORAL|Weight Loss Education|
224266193|NCT01717352|BEHAVIORAL|Sleep and Eating Routine|
224266194|NCT03168503|DIETARY_SUPPLEMENT|LGG+Promitor™|synbiotic
224266195|NCT03168503|DIETARY_SUPPLEMENT|Promitor™|Soluble Corn Fiber
224266196|NCT03168503|DIETARY_SUPPLEMENT|LGG-PB12+Promitor™|synbiotic
224266197|NCT03168503|DIETARY_SUPPLEMENT|Maltodextrin|Control
224266198|NCT04736303|DEVICE|BIS|The implementation of BIS monitoring
224266199|NCT00870116|RADIATION|SBRT by cyberknife|treatment = 2x15 Gy during 2 weeks
224266200|NCT00870116|RADIATION|SBRT by linear accelerator|treatment = 2x15 Gy during 2 weeks
224266201|NCT00870116|RADIATION|Conformational radiotherapy|treatment = 5x2 Gy during 7 weeks (free breathing or breath holding)
223857634|NCT02873754|DRUG|Nicotine polacrilex|Nicotine gum will be initiated at smoking quit date; 4 mg dose administered as needed
223857635|NCT02873754|DRUG|Nicotine lozenge|Nicotine lozenge will be initiated at smoking quit date; 4 mg dose administered as needed
223857636|NCT02578108|PROCEDURE|genicular nerve diagnostic block with lidocaine (local anesthetic)|sensory denervation of the knee joint
223857637|NCT02578108|PROCEDURE|genicular nerve radiofrequency ablation|Ablation of the genicular nerves of the knee by radiofrequency energy
223857638|NCT00197886|DRUG|Changing dose of norepinephrine and blood pressure|
223857639|NCT00506181|DRUG|probiotic mixture|"Jarro-Dophilus probiotic mixture (4,400,000,000 bacteria in each capsule). One capsule X2/day."
223857640|NCT00506181|DRUG|Placebo|
224076207|NCT06580964|BEHAVIORAL|Heat therapy|Heat pads will be set to a pre-determined, optimized temperature and applied to both legs for 90 min, 6d/wk (5 at-home and 1 in-lab).
224076208|NCT06580964|BEHAVIORAL|High-intensity interval training|High-intensity interval training will be performed 3 days per week for 12 weeks.
224076209|NCT06547775|DRUG|KN069|Solution for SC injection
223857641|NCT05112718|BIOLOGICAL|Platelet Rich Plasma Injections|"PRP injected into 9 sites of the distal anterior one-third of the vagina using a small 30-gauge needle. The injections were performed at 10, 12 and 2 o'clock in 3 different levels of the urethra 1-2 cm apart (distal, mid and proximal).~The participants will receive 2 PRP injections at 4-6-week intervals. Xylocaine gel 2% is applied to the distal anterior vaginal wall 20 minutes before injections."
223857642|NCT05112718|OTHER|Normal Saline Injections|"Normal saline injected into 9 sites of the distal anterior one-third of the vagina using a small 30-gauge needle. The injections were performed at 10, 12 and 2 o'clock in 3 different levels of the urethra 1-2 cm apart (distal, mid and proximal).~The participants will receive 2 injections at 4-6-week intervals."
223857643|NCT05626504|DEVICE|Pipeline Embolization Device with Vantage Technology|Flow-diverter device occludes aneurysms through endoluminal reconstruction and remodelling of the parent artery.
223857644|NCT03574844|DIETARY_SUPPLEMENT|Saccharomyces cerevisiae, dose 500|Experimental arm
223857645|NCT03574844|DIETARY_SUPPLEMENT|Saccharomyces cerevisiae, dose 1000|Experimental arm
223857646|NCT03574844|DIETARY_SUPPLEMENT|Placebo|Placebo comparator arm
223857647|NCT06076382|PROCEDURE|endoscopic ultrasound guided colorectal ESD surgery|The experimental group first underwent endoscopic ultrasound examination, with a small ultrasound probe inserted into the intestinal cavity through the biopsy port. After water injection, the lesion was scanned and (1) the direction of gravity was determined. (2) fibrosis/infiltration under the mucosa, and the fibrosis was divided into F0 (no fibrosis), F1 (cold fibrosis), or F2 (severe fibrosis). (3) The lesion was divided into nine compartments. Mark submucosal fibrosis/infiltration sites, according to nine compartments. (4) Based on the results of endoscopic ultrasound scanning of the lesion, the surgeon draw up surgical approach and perform injection and dissection.
223857648|NCT06076382|PROCEDURE|the traditional colorectal ESD surgery|The control group underwent injection and dissection directly.
223857649|NCT01949740|OTHER|questionnaire administration|Ancillary studies
223857650|NCT01949740|PROCEDURE|quality-of-life assessment|Ancillary studies
223857651|NCT00082810|DRUG|fulvestrant|Given intramuscularly
223857652|NCT00082810|DRUG|tipifarnib|Given IV
223857653|NCT05078424|BEHAVIORAL|Cognitive Behavioural Therapy|CBT is a well-established, evidence-based intervention frequently used for easing depressive and anxiety symptoms. The intervention will be delivered for 6-7 sessions, each session lasts for 1.5 hours, in the format of a group for a period of 6-7 weeks by frontline social or youth workers trained by professional CBT clinicians. Core treatment components include mood monitoring, emotion education, behavioural activation, emotion cycle/ ABC model, identification of automatic thoughts, and cognitive restructuring. It is designed to improve youths' abilities/ skills in handling their moods to have better emotional management.
223857654|NCT01787773|DEVICE|Veniti Inferior Vena Cava Filter|
223857655|NCT04467788|OTHER|Computer-aided sessions|Changing participants' KAP of ergonomics in dentistry
223857656|NCT04467788|OTHER|Clinical simulation sessions|Changing participants' KAP of ergonomics in dentistry
223857657|NCT02979899|BIOLOGICAL|TRC105|TRC105 antibody
223857658|NCT02979899|DRUG|Votrient|pazopanib
223857659|NCT04275778|DRUG|Plaquenil 200Mg Tablet|Hydroxychloroquine will be taken at a dosage of 400 mg / day until delivery
223857660|NCT04275778|DRUG|Placebo oral tablet|placebo will be taken at a dosage of 400 mg / day until delivery
223857661|NCT06318104|DRUG|Tegoprazan|Tegoprazan 50 mg BID + amoxicillin 1 gr BID + clarithromycin 500 mg BID all for 14 days.
223857662|NCT06318104|DRUG|Esomeprazole 40mg|Esomeprazole 40 mg BID + amoxicillin 1 gr BID + clarithromycin 500 mg BID all for 14 days.
223857663|NCT02387099|DRUG|3 weeks Dose Induction of Everolimus|"Comparing a conventional dosing approach starting with 10 mg at first dose versus a dose-escalating schema over 21 days in patients receiving everolimus in combination with exemestane for treatment of metastatic breast cancer.~All patients will be treated within the approved indication of everolimus in combination with exemestane.~Patients will be randomized in a 1:1 ratio"
223857664|NCT02387099|DRUG|3 weeks Conventional Everolimus Dosing|"Comparing a conventional dosing approach starting with 10 mg at first dose versus a dose-escalating schema over 21 days in patients receiving everolimus in combination with exemestane for treatment of metastatic breast cancer.~All patients will be treated within the approved indication of everolimus in combination with exemestane.~Patients will be randomized in a 1:1 ratio"
223857665|NCT02387099|DRUG|Open Label Phase with conventional 10mg Everolimus Dosing week 4-24|All patients will receive open label Everolimus with Exemestane for 21 weeks according to label
223857666|NCT02387099|DRUG|Standard Care after 24 weeks|It is up to the discretion of the investigator to continue with Everolimus+Exemestane beyond 24 weeks
223857667|NCT02613676|DEVICE|Transcutaneous bilirubin screening|Transcutaneous bilirubin screening before hospital discharge and assessment of risk category according to the Bhutani nomogram
223857668|NCT02613676|OTHER|Standard care (Visual inspection)|Participants in this group will be assessed for jaundice by visual inspection. Blood draw for TsB will be drawn only if the participant is visibly jaundiced.
223857669|NCT03311113|OTHER|Drug adherence questionnaire|Adherence to oral antibiotic therapy will be assessed by means of a questionnaire adapted from the French standardized self-assessment questionnaire of Girerd et al. This questionnaire has six questions, each question being associated with a score. Patient's drug adherence is classified into three groups based on the total score: of high, moderate and poor adherence. The questionnaire will be carried by a phone call to the patient.
223857670|NCT04382365|OTHER|Sleep Health Using the Internet for Older Adult Sufferers of Insomnia and Sleeplessness|Cognitive-Behavioral Treatment for insomnia (CBT-I) is a non-pharmacological intervention that is effective in treating insomnia in older adults, even when present with comorbid medical and psychological conditions.25 CBT-I focuses on the maladaptive behaviors and dysfunctional thoughts that perpetuate sleep problems, and typically consists of five primary treatment components: sleep restriction, stimulus control, cognitive restructuring, sleep hygiene, and relapse prevention.
223857671|NCT03636867|OTHER|data and specimen collection|to identify laboratory, cellular and molecular determinants of clinical success after treatment, several clinical information and specimens will be collected by Authors from each patient
223857672|NCT06024369|DEVICE|CPM Device|Wearable monitor used for 5 minutes per day.
223857673|NCT05356572|DEVICE|Investigational Skin Preparation Device|Removal of hyperkeratotic skin with Investigational Skin Preparation Device
223857674|NCT05356572|DEVICE|GMDN 47102 / Electrode Skin Abrasive Pad|Removal of hyperkeratotic skin with Abrasive Pad for Skin Preparation
223857675|NCT05356572|DEVICE|UMDNS 13-230 / Biopsy punch (Dermal Curette)|Removal of hyperkeratotic skin with Disposable Dermal Curette
223857676|NCT01802866|DRUG|ACU-4429|Take orally once daily for 24 months
223857677|NCT01802866|DRUG|Placebo|Take orally once daily for 24 months
223857678|NCT00413595|OTHER|No intervention|Observational, epidemiological, prognosis study; no drug tested; only laboratory analysis and diagnostic interventions done.
223857679|NCT04300426|DRUG|"ACHIM as solute (10^9 intestinal microbes/ml)"|Culture of intesinal microbiota originally derived from a healthy subject are administered to a person with presumed dysbiotic intestinal symptoms with an objective to treat these symptoms.
223857680|NCT02200159|DRUG|Sedation with dexmedetomidine|
223857681|NCT01130558|OTHER|Diabetes Management|Using electronic insulin order template for basal-bolus insulin and education
223857682|NCT03572023|OTHER|Integrative characterization of MINOCA patients|"Characterization of MINOCA patients will be based on integrative evaluation of imaging data, blood levels of proinflammatory and anti-inflammatory cytokines, and genetic testing for thrombophilia risk.~MSCT: Imaging for the presence and vulnerability of coronary plaque as well as plaque disruption.~CMR: Imaging for identification of myocardial injury (late gadolinium enhancement and myocardial edema) as well as other concomitant findings.~SPECT: Single-Photon Emission Computed Tomography enable assessment of myocardial perfusion and viability.~Blood tests.~Genetic tests."
223857683|NCT03572023|OTHER|Characterization of MI patients with coronary obstruction|"Characterization of patients with myocardial infarction and obstructive atherosclerosis will be based on integrative evaluation of imaging data, blood levels of proinflammatory and anti-inflammatory cytokines, and genetic testing for thrombophilia risk.~MSCT: Imaging for the presence and vulnerability of coronary plaque as well as plaque disruption.~CMR: Imaging for identification of myocardial injury (late gadolinium enhancement and myocardial edema) as well as other concomitant findings.~SPECT: Single-Photon Emission Computed Tomography enable assessment of myocardial perfusion and viability.~Blood tests.~Genetic tests."
223857684|NCT01872403|DRUG|nanoparticle albumin-bound paclitaxel/carboplatin|Neoadjuvant chemotherapy of nanoparticle albumin-bound paclitaxel/carboplatin vs. paclitaxel /carboplatin in stage Ⅱ B and IIIA squamous cell carcinoma of the lung:
223857685|NCT04320186|BEHAVIORAL|Entertainment education|
223857686|NCT04320186|OTHER|video|video
223857687|NCT02323529|DRUG|Nitisinone|All patients in the study will first be put on twice daily dosing of nitisinone for 4 weeks. This will then be followed by once daily dosing of nitisinone for 4 weeks. The dose of nitisinone in the study will be the same as the one prescribed at completed screening visit. Dose will be 1-2 mg/kg body weight.
223857688|NCT00362726|DRUG|Rosiglitazone maleate|Tablets, Oral, RGZ 4 mg, once daily, 1 day.
223857689|NCT00362726|DRUG|Atazanavir Sulphate|Capsules, Oral, ATV 400 mg, once daily, 5 days.
223857690|NCT00362726|DRUG|Atazanavir Sulphate + Rosiglitazone maleate|Capsule, Oral, ATV 400 mg + RGZ 4 mg, once daily, 1 day.
223857691|NCT00362726|DRUG|Atazanavir Sulphate + Ritonavir|Capsules, Oral, ATV 300 mg + RTV 100 mg, once daily, 14 days.
223857692|NCT00362726|DRUG|Atazanavir Sulphate + Ritonavir + Rosiglitazone maleate|Capsules/Tablets, Oral, ATV 300 mg + RTV 100 mg + RGZ 4 mg, once daily, 1 day.
223857693|NCT01527253|OTHER|Synergistic food basket|A low glycemic index diet enriched in dried legumes and wholegrain cereals is compared with a control regime lacking these functional ingredients for their ability to ameliorate different markers associated with the risk for developing cardiometabolic disease
223857694|NCT03951207|DRUG|Rosuampin 10/5mg|Rosuvastatin 10mg/Amlodipine 5mg qd for 8 weeks
223857695|NCT03951207|DRUG|Rosuampin 20/5mg|Rosuampin 20/5mg qd for 8 weeks
223857696|NCT03951207|DRUG|Amlodipine/Atorvastatin 5/20mg|Amlodipine/Atorvastatin 5/20mg qd for 8 weeks
223857697|NCT02533713|DEVICE|Exoskeleton assisted gait training|Gait training will be performed 3 times a week for about an hour for 26 weeks. Gait training will be performed by a trained clinical physical therapist. The goal is to achieve 1 hour of continuous walking on a flat surface per training session. Gait training will continue for 26 weeks (78 sessions).
223857698|NCT02499471|OTHER|Levothyroxine therapy (137.75 ± 23.75 μg/day)|This study was a longitudinal study in an academic center, with a follow-up period of 6 months. Ten patients with well-differentiated thyroid carcinoma eligible for surgical treatment and subsequent radioactive iodine ablation therapy were studied in a hypothyroid state after thyroidectomy and in a subclinical hyperthyroid state (TSH-suppression according to standard treatment protocol).
223857699|NCT04719377|DEVICE|catheter placement|catheter placement
223857700|NCT06521892|BEHAVIORAL|social surveillance and health education interventions|"Social surveillance: In the intervention group retail pharmacies posted or hung signs antibiotics need to be purchased by prescription, if found without prescription sales, welcome to call 12315 hotline to report, to form social supervision intervention.~Health education: On-site training for retail pharmacy staff, inviting respiratory physicians and pediatricians to give health education lectures on disease diagnosis, treatment and medication."
223857701|NCT01816958|OTHER|co-administration of TMS and infused ketamine|co-administration of TMS and infused ketamine
223857702|NCT00812526|PROCEDURE|Suction cup application|
223857703|NCT00812526|PROCEDURE|Squatting|
223857704|NCT04476745|DIETARY_SUPPLEMENT|Vitamin D3|Dietary Supplement: Vitamin D3 (50,000) IU / week for 8 weeks
223857705|NCT00188604|DRUG|sodium selenite|
223857706|NCT00967512|DRUG|cenersen|solution for injection, intravenous infusion, 0.1 mg/kg/h x 24h x 4 days, and 0.4 mg/kg/h x 3h x 4 days
223857707|NCT00967512|DRUG|placebo|solution for injection, intravenous infusion, 0.1 mg/kg/h x 24h x 4 days, and 0.4 mg/kg/h x 3h x 4 days
223857708|NCT00967512|DRUG|idarubicin, cytarabine|idarubicin, cytarabine
223857709|NCT02010372|OTHER|Reminder Recall Report|Practices (administrators) that are randomized to this intervention will receive training in how to run reminder recall reports for patients due to receive any dose of HPV vaccine. After the training has been completed, administrators will be asked to continue running regularly scheduled reports over the course of one year. A tracking log will be sent regularly to the research team.
223857710|NCT02010372|OTHER|Audit-Feedback/Immunization Forecasting Reports|Practices (administrators) that are randomized to this intervention will receive training in how to run audit-feedback/immunization forecasting reports for patients due to receive any dose of HPV vaccine and to determine the % of patients in their practice who have received at least one dose of HPV vaccine within the study period. After the training has been completed, administrators will be asked to continue running regularly scheduled reports over the course of one year. A tracking log will be sent regularly to the research team.
223857711|NCT01245452|DRUG|Tocilizumab|Tocilizumab (8 mg/kg monthly from week 0 to 20)
223857712|NCT01245452|DRUG|Methotrexate|MTX at a dose ranging from 10 mg/week at baseline to 20 mg/week at week 8
223857713|NCT04010318|PROCEDURE|Spinal Anesthesia|The patients will receive spinal block at lumbar 3-4 space with hyperbaric bupivacaine 8 mg plus 25 mic fentanyl. After giving anesthesia and positioning for surgery with a left lateral tilt of 15 degrees, supplemental oxygen at rate of 4 liter/minute is applied.
223857714|NCT06630377|DIETARY_SUPPLEMENT|GOS|During the study period, subjects are instructed to take one pocket of galactooligosaccharide per day during the first week, followed by two pockets of galactooligosaccharide per day during the remaining 7 weeks. Aside from the dietary supplement provided, all participants are instructed to continue their normal routine and not make any changes to their dietary habits or physical activity.
223857715|NCT06630377|DIETARY_SUPPLEMENT|Placebo|During the study period, subjects are instructed to take one pocket of placebo control per day during the first week, followed by two pockets of placebo control per day during the remaining 7 weeks. Aside from the dietary supplement provided, all participants are instructed to continue their normal routine and not make any changes to their dietary habits or physical activity.
223857716|NCT06632132|OTHER|Antimicrobial resistance Training in Hemodialysis Units|"The educational program developed by the researcher is meticulously designed, drawing on extensive insights from the WHO curricula guide (nurses' education and training on antimicrobial resistance; 2019) and the literature review addressed the use of antibiotics and prevention of AMR in hemodialysis facilities. The curriculum, using simple English, provides a broad set of learning objectives tailored to the expected roles of nurses.~The education program includes four main modular outline:~1. Foundations that build awareness of antimicrobial resistance~2. Appropriate use of antimicrobial agents~3. Infection prevention and control~4. Diagnostic stewardship and surveillance~The educational material was sent by a study researcher (X) to the WhatsApp number for all members of the experimental group via Chatbot software, which was designed by software engineer. The educational materials were sent in the form of written materials, photos, and videos."
223857717|NCT01544062|DRUG|IV acetaminophen|Total of 6 doses of 1,000 mg IV acetaminophen at the following time points: (1) immediately after anesthesia induction, but prior to the incision, (2) at the end of surgery with (3) four additional doses administered postoperatively in the ICU every 6 hours for the first 24 hours.
223857718|NCT01544062|DRUG|Placebo|Total of 6 doses of 100 mL of normal saline at the following time points: (1) immediately after anesthesia induction, but prior to the incision, (2) at the end of surgery with (3) four additional doses administered postoperatively in the ICU every 6 hours for the first 24 hours.
223857719|NCT02807493|DEVICE|Occlusal Support Device|Bite plate
223857720|NCT02807493|OTHER|Control|Control group
223857721|NCT02403024|BEHAVIORAL|InterWalk|Patient allocated to the InterWalk-group will be introduced to the InterWalk app, including instructions on how to down load and use the application. and prescribed to perform Interval Walking for 150 min per week
223857722|NCT02403024|BEHAVIORAL|Waiting list control|Patients allocated to the waiting-list control group will be prescribed standard guidelines for the patient group, but will be asked not to download and use the InterWalk app (which is freely available) for the first 12 weeks of the study period. After the first 12 weeks (the control period), patients in this group will receive the same instructions for download and use of the InterWalk app in the following 12 weeks
223857723|NCT03752385|BEHAVIORAL|reducing smartphone screen time|"Cutting average smartphone screen time in half. Sleeping without smartphone in bedroom. Establishing a bedtime to stop smartphone screen time."
223857724|NCT00718406|DRUG|Metoprolol|
223857725|NCT00718406|DRUG|metoprolol plus morphine|
223857726|NCT00873899|DEVICE|The Medtronic CareLink system (Minneapolis, MN, USA).|The Medtronic CareLink system(Minneapolis, MN, USA)includes a patient monitor plugged into a standard analog telephone connection, and a lightweight wand to communicate with the implanted device. Interrogation of the device and transmission of the data occur when the patient places the wand over the implanted device. The system uses radio frequency telemetry for wireless automatic communication. This allows for data transmission without patient intervention and enables automatic transmissions at pre-specified routine intervals as well as alert-based downloads.The system can transmit data in case of programmable conditions on diagnostic variables, arrhythmias, delivered ICD therapies, battery/lead issues, and alert the physician via phone or e-mail. The patient's information is sent to a secure Network server via the telephone connection and clinical staff can review device information.Available data are equivalent to that which can be retrieved at an in-office visit.
223857727|NCT03692520|BIOLOGICAL|SCT200|Recombinant Anti-EGFR Monoclonal Antibody （SCT200）
223857728|NCT05437783|DRUG|Azithromycin Dihydrate|exclusively hospitalized at Bandarban Sadar hospital, Bandarban, Bangladesh. Participants will be fasting overnight for 10 h, all subjects will receive a single oral dose of 500mg of azithromycin with 250 ml of water. Drug intake will be ensured by direct supervision. Standardized meals will be served 4 and 10 h after dosing. Venous blood sample will be collected at multiple timepoints beginning before drug administration (0h) and containing at timepoints 1.0,2.0,3.0,4.0,6.0,8.0,12.0,24.0,48.0 and 72.0h post dosing. Two ml peripheral blood will be collected from each subject for genetic study.
223857729|NCT04495634|DEVICE|Stationary Head CT (s-HCT)|The system consists of a total of three x-ray sources and nine x-ray detectors with an estimation of approximately 150 projection angles per slice, with less than a minute per slice reconstruction. Radiation dose will be configured as to not exceed that of a conventional head CT, or 2 mSv. The subjects will be positioned on a medical procedure table that will move the subject through the scanning system at the rate of roughly 1 cm per second, during which the necessary x-ray projections will be acquired. The head will be positioned in a carbon fiber head holder from a clinical CT scanner that is secured to the table.
223857730|NCT06538558|DRUG|Tezampanel|Study drug will be given intravenously (mg/kg) at 6 timepoints during study participation
223857731|NCT06538558|DRUG|Placebo|Placebo will be given intravenously (mg/kg) at 6 timepoints during study participation to a subset of participants in each cohort.
223857732|NCT01312337|DRUG|salvage iressa|Iressa 250mg per day until progression
223857733|NCT03441048|BIOLOGICAL|Lintuzumab-Ac-225|Lintuzumab-Ac225 is an immunoconjugate \[antibody: anti-CD 33 antibody and radioactive isotope: Actinium (225Ac)\] for the treatment of relapsed/refractory acute myeloid leukemia.
223857734|NCT03441048|DRUG|Cladribine|Cladribine is a purine antimetabolite.
223857735|NCT03441048|DRUG|Cytarabine|Cytarabine is an antineoplastic anti-metabolite.
223857736|NCT03441048|DRUG|Mitoxantrone|Mitoxantrone is an anthracenedione antineoplastic agent.
223857737|NCT03441048|DRUG|G-CSF|G-CSF is a glycoprotein that stimulates the bone marrow to produce granulocytes and stem cells.
223857738|NCT03612804|BEHAVIORAL|Unsigned note to provider about cessation medication prescription|For patients of providers assigned to the proactive study group, a local coordinator will review the patient's cessation medication history. If the patient is not currently being provided cessation support medication, the coordinator will enter a note for the provider about the recommended medication indicated by VA formulary guidelines.
223857739|NCT03612804|BEHAVIORAL|Proactive Telephone Counseling from VA Quitline|Patients of providers assigned to the proactive study group will be contacted by specially trained counselors at the VA Quitline. Counselors will attempt to provide two sessions of proactive telephone support.
223857740|NCT06498453|DEVICE|Trak-Physio knee condition|The exercise protocol designed for knee conditions is carried out through Trak, the digital rehabilitation tool.
223857741|NCT06498453|DEVICE|Trak-Physio in shoulder condition|The exercise protocol designed for knee conditions is carried out through Trak, the digital rehabilitation tool.
223857742|NCT06498453|OTHER|Knee conventional rehabilitation program|Exercise protocol with the methodology of conventional clinical practice.
223857743|NCT06498453|OTHER|Shoulder conventional rehabilitation program|Exercise protocol with the methodology of conventional clinical practice.
223857744|NCT03316456|DIAGNOSTIC_TEST|Observational: Stool Sample Collection|"Observational: Stool Sample Collection~\- Samples will be collected on the day of the first dose of chemotherapy, then subsequently every Monday, Wednesday, Friday until Day 28 of chemotherapy, death, or discharge from the hospital, whichever occurs sooner."
223857745|NCT03316456|DIAGNOSTIC_TEST|Observational: Blood Sample Collection|"Observational: Blood Sample Collection~\- Samples will be collected on the day of the first dose of chemotherapy, then subsequently every Monday, Wednesday, Friday until Day 28 of chemotherapy, death, or discharge from the hospital, whichever occurs sooner."
223857746|NCT03316456|DIAGNOSTIC_TEST|Observational: Urine Sample Collection|"Observational: Urine Sample Collection~\- Samples will be collected on the day of the first dose of chemotherapy, then subsequently every Monday, Wednesday, Friday until Day 28 of chemotherapy, death, or discharge from the hospital, whichever occurs sooner."
223857747|NCT04716803|BIOLOGICAL|Bone Marrow Aspirate Concentrate|Aspiration of bone marrow will be collected from the patient's pelvic bone region and subsequently concentrated with the Angel Concentrated Platelet Rich Plasma (cPRP) System.
223857748|NCT04716803|DEVICE|Angel Concentrated Platelet Rich Plasma (cPRP) System|Aspiration of bone marrow will be collected from the patient's pelvic bone region and subsequently concentrated with the Angel Concentrated Platelet Rich Plasma (cPRP) System.
223857749|NCT03105128|DRUG|placebo for risankizumab|Placebo for risankizumab administered by intravenous infusion
224266202|NCT04060251|DEVICE|CyMedica e-vive™ System; CY-1000|"All the patients in Group 2 will be given the CyMedica Orthopedics e-vive system 3 weeks before the surgery. The patients will begin using the unit after their first pre-intervention measurements are taken.~Patients will be instructed to apply the e-vive NMES Strength therapy twice a day, 5 days a week. The NMES Strength program is 20 minutes in length. Treatment intensity (adjustable from 1 to 100 in NMES programs) is required to be set at the highest tolerable limit for the patients.~Stimulation from the garment will have the following parameters: frequency of 50 Hz; pulse duration of 5 ms; time on: 12.8 seconds; and time off: 10 seconds. The total contraction time in a 20-minute treatment will be 11 minutes. The waveform will be pulsed and asymmetrical."
223857750|NCT03105128|DRUG|risankizumab IV|Risankizumab administered by intravenous infusion
223857751|NCT03105128|DRUG|risankizumab SC|Risankizumab administered by subcutaneous (SC) injection
223857752|NCT03030950|DRUG|Dexmedetomidine|to investigate the effect of dexmedetomidine on motor and sensory properties of adductor canal block
223857753|NCT03030950|DRUG|Normal saline|to give normal saline to the other group as a placebo
223857754|NCT00629200|DRUG|Sodium Stibogluconate|400 mg/m\^2 IV daily on days 1-5.
223857755|NCT00629200|DRUG|Interferon Alpha-2b|3x10\^6 units subcutaneously three times weekly
223857756|NCT01720719|DRUG|atorvastatin|Oral atorvastatin 20mg, qd, for 24 weeks
223857757|NCT01720719|DRUG|Vitamin E|Oral Vitamin E 300mg, qd, for 24 weeks
223857758|NCT00005813|BIOLOGICAL|bispecific antibody MDX447|
223857759|NCT00005813|BIOLOGICAL|lymphokine-activated killer cells|
223857760|NCT00005813|PROCEDURE|conventional surgery|
223857761|NCT02417311|OTHER|Skin biopsy, genotyping and disease phenotyping|Major steps of the project are (i) in depths clinical phenotyping and follow-up of the clinical course of probands (ii) genotyping of candidate genes involved in heart disease development and (iii) in vitro functional tests of engineered heart tissue (EHT), miniature beating heart muscles. These EHTs are generated from hiPSC (human induced pluripotent stem cells) lines derived from skin biopsies of each participant.
223857762|NCT05776706|DIAGNOSTIC_TEST|AR-based navigation|"The surgeon will perform all surgical planning and operations with reference to the existing navigation. In this process, the errors of the existing navigation and the newly developed navigation are measured and compared in 3D at several points, and the points are as follows.~1. Fiducial markers~2. Nasion~3. Tumor's margin (anterior, posterior, superior, inferior)"
223857763|NCT01203553|PROCEDURE|Abdominal surgery|Intraoperative mesh implantation
223857764|NCT03526120|OTHER|Pistachio|Dailly 44 g unsalted pistachios snack for 12 weeks
223857765|NCT02431143|DRUG|Miltefosine|
223857766|NCT06430125|DRUG|Nicorandil 10 MG Oral Tablet|Nicorandil 10 MG oral tablet twice daily
223857767|NCT04973852|DEVICE|Ekso|Exoskeleton walking
223857768|NCT00413179|DRUG|Metformin|
223857769|NCT00413179|DRUG|Clomiphene citrate|
223857770|NCT00413179|DRUG|Placebo|
223857771|NCT04388488|DEVICE|CONNECT TF adaptable socket system|Prefabricated, adaptable socket system
223857772|NCT04388488|DEVICE|Any conventional handmade socket|Subjects current socket
223857773|NCT01413594|BEHAVIORAL|HABIT|90 hours of bimanual training over 3 weeks in a day camp environment
223857774|NCT03103412|DRUG|TD-3504|TD-3504
223857775|NCT03103412|DRUG|15N2-tofacitinib|15N2-tofacitinib
223857776|NCT03103412|DRUG|Placebo|Placebo
223857777|NCT00741988|DRUG|Ixabepilone|ixabepilone 30 mg/m2
223857778|NCT00741988|DRUG|Carboplatin|carboplatin AUC = 6 intravenously (IV) on Day 1 of one 21-day treatment cycle.
223857779|NCT00741988|DRUG|Bevacizumab|bevacizumab 15 mg/kg on Day 1 of one 21-day treatment cycle.
223857780|NCT02250716|PROCEDURE|cryotherapy|cryotherapy for cervical intraepithelial neoplasia in HIV infected women vs control arm of standard of care (repeat pap smear in 1 year)
223857781|NCT02621593|DEVICE|M22-IPL|The IPL hand piece operates at a spectrum of 400-1200nm with 7 different filters that can be easily inserted to the hand piece to treat different conditions. The IPL hand piece also includes 2 different sapphire cooled light guides of 8x15mm and 15x35mm. The cut-off filters that will be used for this evaluation are filters blocking wavelengths of 560 and 595 nm.
224266203|NCT04060251|OTHER|iGetBetter telemedicine physical therapy|Group 1 patients will only use a Post-Op program from iGetBetter for the first 3 weeks after surgery. After those 3 weeks have elapsed, Group 1 patients will receive outpatient physical therapy in addition to iGetBetter, approximately twice per week for the next 6-8 weeks as all other groups.
224266204|NCT03118063|DIAGNOSTIC_TEST|Evaluation of pain by algometry|Assessment of the level of pain and function of asymptomatic individuals, compared with the time that they evolve with acute and chronic low back pain
224266205|NCT06188663|DIETARY_SUPPLEMENT|Salt supplementation (encapsulated sodium chloride)|A high salt intake range will be achieved through unchanged dietary intake and supplementary salt in the form of 1.25g sodium chloride capsules at a dose of 5g/day in two divided doses
224266206|NCT02550535|GENETIC|Autologous WT1 TCR transduced T cells|Gene therapy: Autologous WT1 TCR transduced T cells administered by intravenous infusion
224266207|NCT03678363|OTHER|Tai chi chuan|Tai chi sessions will consist of repetition of simple and basic movements focusing mainly on breating, relaxation and body diagram. This Chinese martial art also includes coordination exercises of body parts (legs, arms, pelvis and spine), looseness and limbering up of joints and muscles.
224266208|NCT01983735|DRUG|TELMINUVO Tab. (80/2.5mg)|"* Fixed dose combination of Telmisartan 80mg and S-amlodipine 2.5mg QD 2 weeks.~* With the others investigation product placebo 1 tab QD 2 weeks."
224266209|NCT01983735|DRUG|TELMINUVO Tab. (80/5mg)|"* Fixed dose combination of Telmisartan 80mg and S-amlodipine 5mg QD 6 weeks.~* With the others investigation product placebo 1 tab QD 6 weeks."
224266210|NCT01983735|DRUG|S-amlodipine 2.5mg|"* S-amlodipine 2.5mg QD 2 weeks~* With the others investigation product placebo 1 tab QD 2 weeks."
224266211|NCT01983735|DRUG|S-amlodipine 5mg|"* S-amlodipine 5mg QD 6weeks~* With the others investigation product placebo 1 tab QD 6 weeks."
224266212|NCT03260686|OTHER|experimental|video guide for upper limb exercise
224266213|NCT03605641|OTHER|JUUL|JUUL Virginia Tobacco
224266214|NCT03605641|OTHER|VUSE Solo|VUSE SOLO Original
224266215|NCT03605641|OTHER|Conventional Cigarette|Subject preferred conventional cigarette
224266216|NCT05858333|OTHER|Extended culture for Group 2: (day 3-5 group)|To investigate thawing day three embryos and culturing them to be transferred as blastocyst that will improve pregnancy rate when compared to transfer thawed frozen blastocyst.
224266217|NCT05206851|OTHER|Manual Lymphatic Drainage and Hot Pack|"Application of hot pack for 20 minutes at low back in sitting, and then the participant will perform deep diaphragmatic breathing for 10 minutes, following these steps:~1. Sitting in comfortable position~2. One hand is placed over chest and other on abdomen.~3. Inhale deep through the nose.~4. Exhale through mouth, completely, counting back from 4 to 1. Application rotary or stationary circle over low back in side lying position, in pregnant females. A session of 20-30 minutes of Manual Lymphatic Drainage will be given biweekly.~And at the end of Manual Lymphatic Drainage application, deep breathing for 10 minutes will be performed again."
224266218|NCT05206851|OTHER|Hot Pack|Hot pack will be applied at low back, for 20 minutes as home based protocol.
224266219|NCT00064324|DRUG|perifosine|Given orally
224266220|NCT00064324|OTHER|laboratory biomarker analysis|Correlative studies
224266221|NCT00064324|OTHER|pharmacological study|Correlative studies
224266222|NCT01079858|OTHER|FID 114657 (ORB Preserved Ocular Emulsion)|Patients will dose as needed throughout the day (PRN) for 4 weeks.
224266223|NCT05870215|OTHER|Visit 1: Clinical exam and questionnaires|Medical history and examination, including vital signs, inhaler technique and adherence check (using prescript refills via the Dossier Santé Québec and/or calls to the community pharmacy), 5-item Asthma Control Questionnaire (ACQ-5), dyspnea rated on the modified Medical Research Council scale (mMRC), visual analog scale (VAS) for six respiratory symptoms, Pittsburgh Vocal Cord Dysfunction Index, Nijmegen Questionnaire, Hospital Anxiety and Depression Scale.
223857782|NCT04397172|PROCEDURE|Study Arm|"First inpatient examination (within 24 hours after admission to ICU):~* Clinical examination~* Laboratory tests, Biobanking, Mitochondrial function testing~* Neurophysiological examination (MVRC recording)~Follow-up inpatient examinations (day 2, 5 and 10 after admission):~* Clinical examination~* Laboratory tests, Biobanking, Mitochondrial functions testing~* Neurophysiological examination (MVRC recording)~* Day 10 only: Extended neurophysiological examination according to diagnostic criteria~* Day 10 only: Grading of muscle strength (Medical Research Council (MRC) system)~Follow-up outpatient examination (after discharge from intensive care):~* Clinical examination~* Grading of muscle strength (MRC)~* Modified Rankin Scale (mRS)~* Barthel Scale~* Questionnaires (Short Form (36) Health Survey, Essener Questionnaire for Coping with a Disease and Beck's Depression Inventory II)"
223857783|NCT05172154|DIAGNOSTIC_TEST|GlowTest COVID-19 Antigen Home Test Kit|The Arion Bio GlowTest COVID-19 Antigen Home Test is a lateral flow immunoassay intended for the qualitative detection of SARS-CoV-2 nucleocapsid protein antigens from individuals with or without symptoms or other epidemiological reasons to suspect a COVID-19 infection
223857784|NCT03611530|DEVICE|Coqun® ophthalmic solution|Prostaglandin analogue (PGA) monotherapy + Coqun® ophthalmic solution
223857785|NCT03611530|OTHER|Placebo ophthalmic solution|Prostaglandin analogue (PGA) monotherapy + Placebo ophthalmic solution
223857786|NCT04990219|DRUG|Lu AG06466|Lu AG06466 - capsule
223857787|NCT04990219|DRUG|Placebo|Placebo - capsule
223857788|NCT05602909|DEVICE|Guided biaxial alveolar distraction device|A crestal incision will be done, a surgical guide will be placed to assist the correct position of osteotomy, an Extraosseous alveolar distractor will be placed on the ridge to mark screw sites and then will be removed, A distractor will be stabilized to the basal segment with a monocortical screw.
223857789|NCT00819442|PROCEDURE|cardiobiopsy|5 samples will be taken from right ventricle by Cordis bioptome
223857790|NCT05365529|BEHAVIORAL|Time-Restricted Eating|Participants in the TRE group with continue to follow their physicians treatment plan for type II diabetes mellitus and consume all of their food within an 8-10 hour eating window.
223857791|NCT05365529|BEHAVIORAL|Standard of Care|Participants in the Standard of Care group will continue to follow their physician's treatment plan for type II diabetes mellitus.
223857792|NCT04463524|DEVICE|Personal ECG digital sensor|Patients in test group will receive personal ECG sensor and in control gropu will not.
223857793|NCT00811057|DRUG|1 Magnesium Sulfate|Participants randomized to this arm will receive a loading dose of 6gms intravenously followed by a maintenance dose of 2-4gm/hr, per physician discretion, until uterine quiescence is achieved. The Magnesium Sulfate dosage is then titrated down until discontinued per physician discretion.
223857794|NCT00811057|DRUG|Nifedipine|Participants randomized to receive nifedipine will receive an initial 30mg loading dose, then 10 - 20mg q 4 - 6 hours as needed, per physician discretion, until uterine quiescence is achieved.
223857795|NCT00811057|DRUG|Indomethacin|Participants randomized to receive indomethacin will receive an initial 100mg per rectum X1, may repeat x1, and then 25 - 50mg orally every 6 hours over 48 hours as needed per physician discretion until uterine quiescence has been achieved.
223857796|NCT06409988|OTHER|Safe discharge|There was no specific intervention, we only aimed to see if those admitted patients could have been safely dicharged from the emergency department.
223857797|NCT04263545|BEHAVIORAL|Group session with smoking cessation counsellor|Group session with smoking cessation counsellor
223857798|NCT04263545|BEHAVIORAL|Standard Care|standard care arm will receive very brief advice (VBA) and signposting to local organisations to support a quit.
223857799|NCT05061524|DRUG|YH35324|Subcutaneous injection of YH35324
223857800|NCT05061524|DRUG|Placebo|Subcutaneous injection of None of active ingredient
223857801|NCT05061524|DRUG|Omalizumab|Subcutaneous injection of Omalizumab
223857802|NCT03699488|BEHAVIORAL|psychotherapy via asynchronous message|Behavioral psychotherapy delivered by asynchronous message using the Talkspace application
223857803|NCT02885311|BEHAVIORAL|Motivation Enhancement Therapy|Motivation Enhancement Therapy (MET) similarly allows for goal choice in treatment, and has been shown to be effective in treating a broad spectrum of drinking problems in both abstinent and non-abstinent goal conditions. The unique goals of MET (enhancing intrinsic motivation for change and facilitating development of a self-generated change plan).
223857804|NCT02885311|BEHAVIORAL|Modified Behavioral Self-Control Therapy|Motivational Interviewing was developed to increase self-efficacy and motivation for drinking, and Cognitive Behavioral Therapy allows for individuals to develop strategies for drinking reduction. Both are evidence-based interventions that have been combined in previous studies for drinking reduction in problem drinkers.
224076210|NCT06429475|DRUG|Budesonide/formoterol|"The Investigational Medicinal Product (IMP) consists of a combination of Budesonide (corticosteroid) and Formoterol Furamate (fast-acting β2 agonist) dihydrate. The IMP is currently available and registered in dry powder form turbuhaler (Symbicort) and a pressurised metered dose inhaler (Vannair).~The recommended doses are pMDI/DPI 80/4.5 1-2 puffs twice daily OR 1 puff as needed (a maximum daily dose of 8 puffs) for children 6-11 years of age and 160/4.5 1-2 inhalations twice daily or 1 puff as needed (a maximum daily dose of 12 puffs) for adolescents 12-18 years."
223857805|NCT02885311|DRUG|Naltrexone|Participants, who choose medication treatment, will be offered naltrexone (50 mg per day), which is an FDA-Approved medication for alcohol use disorder. According to the package insert for NTX, the medication has been associated with liver toxicity at very high doses (up to 300 mg/day); however, a number of clinical trials and published studies suggest there are few serious adverse effects, including minimal hepatotoxicity, associated with daily dose of 50 mg of naltrexone. Its most common side effects in opioid-free individuals are nausea, vomiting, anxiety, headache, abdominal discomfort, difficulty sleeping, fatigue, irritability, and decreased appetite. A rare serious adverse effect may include minimal liver toxicity, but is more likely to occur at very high doses (300 mg/day).
224076211|NCT06429475|DRUG|standard of care|Any therapy that is prescribed as per asthma guidelines i.e. beclomethasone, budesonide and salbutamol, montelukast etc
223857806|NCT02885311|BEHAVIORAL|Brief Advice|Brief Advice (BA) consists of a 20-minute session delivered by a study therapist, adhering to the NIAAA's Clinician Guide to Problem Drinkers. It includes personalized, normative feedback based on NIAAA drinking norms, goal selection, instructions on self-monitoring, discussion of drink reduction strategies, and distribution of the NIAAA bibliotherapy guide.
223857807|NCT02885311|OTHER|Referral to specialty substance use disorder treatment|Participants who present with complex drinking concerns will be referred to specialty substance use disorder treatment. This treatment will be provided in a separate treatment facility that focuses on substance use disorders and will potentially provide a combination of medication management and individual/group behavioral treatment for substance use disorders.
223857808|NCT00768651|DRUG|Pantoprazole|Starting on Day 1, Pantoprazole 80 mg daily (40 mg every morning and 40 mg every evening) administered orally at the same time each day for a period of 6 months.
223857809|NCT00768651|DRUG|Sitagliptin|Starting on Day 1, Sitagliptin 100mg once daily administered orally at the same time each day for a period of 6 months.
223857810|NCT03799380|DIETARY_SUPPLEMENT|Gatorade G2|Gatorade (G2), 20 oz. bottle, daily through the entire course of radiation therapy (approximately 5-7 weeks)
223857811|NCT03799380|DIETARY_SUPPLEMENT|Standard of care nutritional support|Standard of care nutritional support
223857812|NCT00515450|BIOLOGICAL|GB-0998 (Intravenous immunoglobulin)|
223857813|NCT00515450|PROCEDURE|Plasmapheresis|
223857814|NCT03766711|OTHER|Physical Therapy|Repetitive bimanual task training for upper limb motor function recovery.
223857815|NCT02444013|DRUG|Folic acid|
223857816|NCT02444013|DRUG|Placebo|
223857817|NCT06272162|RADIATION|MR guided radiotherapy|5 fractions of 10 Gray MRgRT in addition to standard of care
223857818|NCT05134025|OTHER|Pump settings|Alteration in the pump setting prior to exercise commencement
223857819|NCT04367376|OTHER|mobilization|central postroanterion mobilization on the most painful vertebral level at the lumbar spine
223857820|NCT04367376|OTHER|manual therapy|manual therapy
223857821|NCT04367376|OTHER|instrumental manual therapy|instrumental manual therapy
223857822|NCT02156609|DEVICE|Percutaneous ventricular support with the HeartMate PHP|The HeartMate PHP device will be inserted percutaneously prior to the start of high risk coronary interventions (complex disease, reduced ejection fraction, etc.) to provide hemodynamic support,
223857823|NCT00193518|DRUG|Arsenic Trioxide|
223857824|NCT05027178|OTHER|Chiropractic Care|Chiropractic care on stroke participants
223857825|NCT02104765|DRUG|LY2951742|Administered subcutaneously.
223857826|NCT02104765|DRUG|Placebo|Administered subcutaneously.
223857827|NCT06113406|BEHAVIORAL|Classroom Training|Active Comparator
223857828|NCT06113406|BEHAVIORAL|Virtual Reality Training|Experimental
223857829|NCT03201224|DEVICE|"After Group"|
223857830|NCT03990038|DRUG|Continuous perineural infusion of ropivacaine 0.2% 5 ml/h for 48 h|Group C receive the intervention Group U receives the placebo See arm description
223857831|NCT03990038|DRUG|Extended Release Capsule|"Group C receives a placebo for extended release hydromorphone Group U receives Hydromorph Contin 3 mg PO BID~See arm description"
223857832|NCT06189105|OTHER|miss alice face it you love me serum|Facial serum with niacinamide, plant-based collagen and peptides will be applied by each participant to the treatment site according to randomization protocol every evening
223857833|NCT06189105|OTHER|No treatment (usual skincare rutine)|No treatment (usual skincare rutine)
223857834|NCT04332757|OTHER|Training intervention.|The investigators have designed a phased 18-week physical development programme to train both rehabilitative and performance enhancement elements of physical preparation. The rehabilitation element of the programme will specifically target pelvic floor function and core strength and stability (known collectively as Core Reconnection training) from weeks 6 to 24 postpartum, and the training element of the programme will contain resistance and high-intensity interval training (HIIT) from weeks 12 to 24 postpartum.
223857835|NCT03338218|DRUG|Volulyte 6%|Solution for infusion
223857836|NCT03338218|DRUG|Ionolyte|Solution for infusion
223857837|NCT05453682|RADIATION|hypo-IMRT|Twenty fractionation within 4 weeks are performed using hypofractionated intensity-modulated radiation therapy. As for the radiation dose, 2.8-3.2 Gy at a time, total dose 56-64 Gy, to the high-risk target volume, and 2-2.2 Gy at a time, and 40-44 Gy, respectively, to the low-risk target volume.
223857838|NCT00281762|DRUG|NSAID|
223857839|NCT06554197|DIAGNOSTIC_TEST|CMV/EBV-CMI|The CMV/EBV-CMI is tested before conditioning regimen and 30 days, 45 days, 60 days, 90 days, 120 days, 180 days after transplantation.
223857840|NCT01024179|DEVICE|Polymer-based sirolimus-eluting stent (Partner stent )|Partner stent (polymer-based sirolimus-eluting stent) implanted in culprit coronary artery
223857841|NCT02124460|BEHAVIORAL|Health Coaching|"Parent/child duos enrolled in the intervention group will participate in a total of six visits with a trained health coach. During these visits, the health coach will coach the parent/child duos on improving obesity-related behaviors .~The health coach will also help the family identify supports to assist with behavior change; discuss family health habits and the home environment; and review and encourage use of materials related to both specific target behaviors and available resources in the community.~Following the first call with the health coach, parents will receive semi-weekly text messages designed by the study team. The messages will alternate in structure between 2 types of messages; 1) skills training messages will deliver tips and motivational messages to help their child practice the study's goals and 2) self monitoring messages will ask parents to respond to the message and track health behaviors important to this study."
223857842|NCT00331162|DRUG|Alemtuzumab|30 mg/100ml NS intraoperatively. Start after dexamethasone administration and prior to reperfusion of the allograft. Infuse over a minimum of 2 hours.
223857843|NCT00331162|DRUG|Anti-Thymocyte Globulin|"1.5 mg/kg per dose through a central line intraoperatively and on POD# 2 and 4, then continue on alternate days until a therapeutic tacrolimus(or cyclosporine) level is achieved, or until the SCr \< 3-4 mg/dL.~Give first dose over 6 hours, subsequent doses over 4 hours.~Premedication to be given with the first 3 doses:~Tylenol 650mg PO/PR Benadryl 25-50mg PO/IV Daily scheduled corticosteroid dose or other corticosteroid as deemed appropriate.~Hold infusion if temperature \> 100.5ºF; Adjust dose for low WBC or Plt count Peripheral Thymoglobulin administration: Prepare dose in 500cc NS; Add heparin 1,000 units and hydrocortisone 20mg to the bag; Infuse over a minimum of 6 hours"
223857844|NCT05880238|BEHAVIORAL|Intervention group|The intervention consisted of a total of 3 modules, 20 sessions. These modules are: Module A: I explore my inner and outer world Module B: I am learning self-editing methods C module: discovering self-editing In these modules, students were trained to use sensorimotor strategies for self-regulation. The intervention program was carried out in one-hour sessions, twice a week, for a total of 10 weeks.
223857845|NCT05880238|OTHER|Control group|The control group will continue their education according to the preschool education curriculum.
223857846|NCT04168814|OTHER|Observational test|Nutritional risk (NutriScore), based on weight, weight loss, tumor location, and treatment, Nutritional status (VGS, Global Subjective Assessment Valoración Global Subjetiva, in Spanish), ECOG performance status; nutritional therapy (oral nutritional supplements, enteral nutrition, parenteral nutrition, dietary advice); type of treatment: chemo, type of chemo, adjuvant, neoadjuvant, palliative, curative endocrine therapy, targeted therapy +-immunotherapy vs QQT/RT therapy; cancer site. Covid-19 diagnosis.
223857847|NCT05976854|OTHER|Pain neuroscience education|The patients in the intervention group will receive, in addition to the prenatal educational content, the 12 Pain neuroscience education lessons in audiovisual format. Each lesson will last between 10-15 minutes. The contents of PNE will be an adaptation, focused on the context of a pregnant woman, of the Butler \& Moseley postulates. These contents have already been previously adapted according to the nature of the patients' pain, both in chronic pain and in acute pain. In summary, the participants will receive a detailed explanation about the biopsychosocial component of pain through the use of diagrams, metaphors and practical examples. In turn, the objectives of this program could be summarized as: (1) Reformulate erroneous beliefs about pain, (2) Inform about the biology and protective nature of pain and (3) Provide techniques to reduce kinesiophobia and, consequently, promote physical activity, with the beneficial effect it entails for patients with pain.
223857848|NCT05976854|OTHER|Prenatal education|The standard prenatal education is based on the Pregnancy and Postpartum Clinical Practice Guide, consisting of general information about pregnancy (visits and monitoring of pregnancy, diet, phases of delivery, lactation, etc.), as well as specific recommendations for lumbopelvic pain associated with pregnancy. These contents will be developed by midwives from the participating hospitals. Participants will receive 12 educational sessions, with an estimated duration of 10 minutes each.
223857849|NCT06560840|OTHER|dietary intervention|The dietary intervention targeted at gut microbiota. Each participant's dietary habits,food preferences and economic level were taken into account. The dietary intervention was delivered by sending meals. To ensure the freshness and quality of the ingredients, 2 dedicated researchers were jointly responsible for the procurement of fresh ingredients, which were purchased through regular channels on Monday, Wednesday and Friday mornings. Meals will be delivered three times a week for a 12-week intervention period. Guided dietary follow-up was conducted through WeChat or telephone follow-up. The researcher will provide cooking instruction or dietary pattern guidance every two weeks.
223857850|NCT06107517|OTHER|DREAMS-OT|"Patients will receive the DREAMS-OT protocol 3 times per day, 20 minutes per therapy session.~Intervention frequency will be confirmed with a feasibility trial. If not feasible to maintain 3 times per day, the intervention will still be maintained at the same intensity of 1 hour per day, with a graded approach."
223857851|NCT01657318|OTHER|Olivamine containing wound care products|Continuous wound care with Olivamine containing products until wound closure. Intake of dietary supplement of 1 capsule for 60 days.
223857852|NCT03256682|BEHAVIORAL|Stress management counseling|stress management counseling based on CBT and relaxation
223857853|NCT04840862|DRUG|Trikafta [orange tablet containing ELX 100mg, TEZ 50mg, and IVA 75mg]|Subjects will receive a single dose of trikafta (orange tablet) on day 1 of period 1 and on day 15 of period 2.
223857854|NCT04840862|DRUG|Rifabutin 300mg|After washout period greater or equal to 2 days, subjects will receive 300 mg/d of rifabutin on days 1 through 17 of period 2.
223857855|NCT00995709|DRUG|AIN457|
223857856|NCT00995709|DRUG|AIN457|
223857857|NCT00995709|DRUG|Placebo|
223857858|NCT05123638|DEVICE|Virtual reality cycling exercise|Daily voluntary cycling for up to 30 minutes with the virtual reality technology
223857859|NCT05123638|BEHAVIORAL|Unsupervised stationary cycling exercise|Daily voluntary cycling for up to 30 minutes (WITHOUT the virtual reality technology)
223857860|NCT00421902|PROCEDURE|Acupuncture|Patients will be have acupuncture (with electro stimulation)
223857861|NCT01137903|PROCEDURE|Conservative surgery|Osteotomy, phalangectomy, exostectomy, metatarsal head resection, articular resection, partial calcanectomy
223857862|NCT01137903|DRUG|Ciprofloxacin|500 mg/ 12 hours during 90 days
223857863|NCT01137903|DRUG|Amoxicillin-Potassium Clavulanate Combination|875/125 mg/12 hours during 90 days
223857864|NCT01137903|DRUG|Sulfamethoxazole trimethoprim|Trimethoprim 160 mg / Sulfamethoxazole 800 mg 1/12 horas.
223857865|NCT05998096|DIETARY_SUPPLEMENT|Caffeine-Based Energy Drink|Caffeine-based energy drink containing 200 mg caffeine
223857866|NCT05998096|DIETARY_SUPPLEMENT|Placebo|Placebo void of all active ingredients
223857867|NCT03317639|BEHAVIORAL|Behaviour Change Wheel model guided intervention|Interventions are developed on a psychological model, the Behaviour Change Wheel (BCW) .The fundamental of BCW consists of three essential elements: capability, motivation, and opportunity. Improving individual's capability, providing motivation, and increasing opportunities are goals of behaviour change intervention. To achieve the goals, 9 intervention components have been proposed in the BCW framework, and 6 components will be used in current study.
223857868|NCT03904199|DRUG|Insulin|Participants will receive long-acting insulin and/or rapid-acting insulin per protocol
223857869|NCT04204837|DRUG|Nivolumab|Nivolumab will be given on Day 1 of every 14-day cycle (Q2W) at a dose of 240 mg as an IV infusion until progression, unacceptable toxicity or discontinuation for other reasons for up to 2 years.
223857870|NCT04204837|DRUG|Nivolumab plus Relatlimab|Patients wil receive a fixed-dose combination of nivolumab 480 mg and relatlimab 160 mg by intravenous infusion every four weeks (Q4W) (Group 2) for up to two years after initial dosing or until PD - or absence of investigator-assessed clinical benefit
223857871|NCT02178917|OTHER|Neurofeedback therapy|
223857872|NCT02178917|OTHER|No neurofeedback therapy|
223857873|NCT00846313|OTHER|Individual dietary counseling.|Dietary advice based on individual requirement and symptom burden. Dietary intervention may be dietary advice, energy rich foods and drinks, oral nutritional supplements, appetite stimulation with Megestrol Acetate, enteral or parenteral nutrition.
223857874|NCT01111903|DRUG|Lenalidomide|Phase II: 20 mg/day in continuous regimen Phase I: 25 mg/day 21 days/28 with carboplatine AUC 5 + caelyx 30mg/m2
223857875|NCT01697319|DRUG|BMN 110|Drug will be delivered through a 4 hour (approximate) IV infusion at a dosage amount of 2.0 mg/kg/week for up to 144 weeks of treatment.
223857876|NCT05391724|DRUG|CMX001|single dose of CMX001 administered at 2 mg/kg of ideal body weight rounded to the closest 20 mg
223857877|NCT04222959|BEHAVIORAL|Girls Invest Intervention|"App-based trainings: The first 2 modules cover gender and cultural norms related to girls' social and economic empowerment, increasing girls' recognition of the importance of financial literacy and independence. The last 3 modules cover finance, educational loans, and employment.~Savings account: Participants receive $100 deposited into a savings account we set up for them, conditional upon completion of app-based trainings."
223857878|NCT03872869|OTHER|Hip school or Tai CHi for arthritis|Eighty-nine individuals were randomized to one of the three intervention groups 30 individuals to Tai Chi,30 individuals to Hip School and 29 individuals to the control group
223857879|NCT02183246|DRUG|Porfiromycin|
223857880|NCT02183246|DRUG|Placebo|
223857881|NCT02183246|RADIATION|Radiotherapy|
223857882|NCT01516788|OTHER|Phototesting|Single MED dose on Day 2
223857883|NCT02401919|BEHAVIORAL|Tell-us Card|Patients will be invited on a daily basis, during their stay in the hospital, to state what is important for them at that moment or before discharge
223857884|NCT06374784|PROCEDURE|Alveolar ridge preservation using autogenous demineralized dentin graft combined with injectable PRF loaded with metronidazole|Atraumatic extraction of non-restorable teeth, then the extracted tooth will be prepared and demineralized using hydrochloric acid (HCL) acid as particulate demineralized dentin graft and processed with injectable platelet rich fibrin. The injectable PRF will be mixed with 5mg/ml metronidazole first then added to the particulate demineralized dentin graft forming sticky demineralized tooth graft with slowly released metronidazole then inserted in the extraction socket and covered then suturing
223857885|NCT06374784|PROCEDURE|Alveolar ridge preservation using autogenous demineralized dentin graft combined with injectable PRF|Atraumatic extraction of non-restorable teeth, then the extracted tooth will be prepared and demineralized using hydrochloric acid (HCL) acid as particulate demineralized dentin graft. The injectable PRF will be added to the particulate demineralized dentin graft forming sticky demineralized tooth graft then inserted in the extraction socket and covered then suturing
223857886|NCT06374784|PROCEDURE|Alveolar ridge preservation using autogenous demineralized dentin graft alone|Atraumatic extraction of non-restorable teeth, then the extracted tooth will be prepared and demineralized using hydrochloric acid (HCL) acid inserted in the extraction socket as particulate demineralized dentin graft
223857887|NCT04710225|PROCEDURE|Upper limb fracture surgery and arterial occlusion pressure (AOP) estimation based tourniquet pressure (TP) setting|"Upper limb fracture surgery will be performed with the aid of a pneumatic tourniquet.~The cuff (11 cm) of the tourniquet will be placed around the arm with the distal edge 5 cm above the olecranon. AOP estimation formula according to initial systolic blood pressure (SBP) and Tissue Padding Coefficient (KTP) values (AOP= \[SBP+10\]/KTP) from a list (Table 1) will be used to calculate AOP (17). After calculation of AOP, a safety margin of 20 mmHg will be added to AOP to determine the TP (TP=AOP+20 mm Hg). Exsanguination of the limb will be provided with an Esmarch bandage and the cuff will be inflated to the predetermined TP. TP will be manually raised in response to each 10 mmHg increase in SBP during the surgical procedure."
223857888|NCT06206330|OTHER|Platelet rich plasma|After application of platelet rich plasma after surgery, the patients have examined for infection, hematoma, pain, recurrence and the time of epithelialization of the wound.
223857889|NCT02039713|DEVICE|DeSyne drug eluting stent group|
223857890|NCT05969665|DEVICE|Fitbit Inspire 2|A smartwatch (Fitbit Inspire 2) with its respective app will be worn by the patients in the intervention group for 3 months.
223857891|NCT05969665|DEVICE|Abbott Freestyle Libre 3|A continuous glucose measuring device (Abbott Freestyle Libre 3) with its respective app will be worn by the patients in the intervention group for 3 months.
223857892|NCT01322919|PROCEDURE|Supracor|"All patients will undergo LASIK treatment on their non-dominant eye with a new laser software algorithm designed to treat both the distance and near vision components.~The developed software algorithm uses the subjective refraction of the eye to create a treatment for the distance vision correction. This part of the treatment does not show any difference to a regular LASIK treatment for ametropic cases.~In addition to the treatment for the distance vision a central ablation component will be added to address the near vision."
223857893|NCT01623349|DRUG|BKM120 and Olaparib|Olaparib twice daily (starting dose 50 mg) and BKM120 once daily (starting dose 40 mg). Both drugs are given orally.
223857894|NCT01623349|DRUG|BYL719 and Olaparib|Olaparib twice daily (starting dose 100 mg) and BYL719 once daily (starting dose 250 mg). Both drugs are given orally.
223857895|NCT01694628|BEHAVIORAL|CLIMB (COPD Lifestyle, Mood, and Behavior)|Cognitive Behavioral Therapy delivered to patients via telephone aimed to improve mood and decrease depressive symptoms.
223857896|NCT06555146|DRUG|Semaglutide, 0.5 mg/mL|1 subcutaneous injection on baseline day
223857897|NCT06555146|DRUG|Placebo, Saline|1 subcutaneous injection on baseline day
223857898|NCT02703740|DEVICE|Hyaluronic acid dermal filler with lidocaine 0.3%|injection in labial fold of a dermal filler
223857899|NCT05262803|GENETIC|CYP2C19*2/*3|"* Non-carriers of CYP2C19\*2/\*3 loss-of-function alleles: DAPT with clopidogrel and ASA~* Carriers of CYP2C19\*2/\*3 loss-of-function alleles: DAPT with prasugrel (or ticagrelor) and ASA"
223857900|NCT05262803|OTHER|Shorter DAPT duration|Duration of DAPT is shortened to 3 months
223857901|NCT02083991|DRUG|Steroid-free low TAC-arm: Thymoglobulin Standard low-TAC arm: Simulect, prednisolon|
223857902|NCT00640029|PROCEDURE|Arthrodesis|"* posterior,~* anterior,~* circumference approach"
223857903|NCT00640029|DEVICE|Arthroplasty (PRODISC-C® , PRODISC-L®, Mobi-C®, Mobidisc®, PrestigeLP®, A-Mav®, O-Mav®, DISCOCERV®)|"* SYNTHES : PRODISC-C® , PRODISC-L®~* LDR : Mobi-C®, Mobidisc®~* MEDTRONIC : PrestigeLP®, A-Mav®, O-Mav®~* SCIENT'X : DISCOCERV®"
223857904|NCT02519699|DRUG|norepinephrine|Increase in mean arterial pressure using norepinephrine
223857905|NCT03008915|DRUG|Aspirin|81mg aspirin taken once per day in the morning
223857906|NCT03008915|DRUG|Placebo|placebo taken once per day in the morning
223857907|NCT03008915|OTHER|Withdrawal from alpha1 antitrypsin replacement therapy|After the completion of the randomization to aspirin and placebo, participants who are on alpha1 replacement therapy are asked to withhold their usual alpha1 antitrypsin replacement therapy for 5 weeks. This is not randomized.
223857908|NCT04411836|DRUG|Tafenoquine|patients are treated with schizontocidal treatment plus a single dose of Tafenoquine (TQ).
223857909|NCT04411836|DRUG|Primaquine|patients are treated with schizontocidal treatment plus high dose PQ (total dose 7 mg/kg) unsupervised over 7 days (PQ7)
223857910|NCT06554769|PROCEDURE|non rigid indirect anchorage connection|a nonrigid connection is placed between the miniscrews and the second premolar to prevent mesial tooth movement.
223857911|NCT06554769|PROCEDURE|rigid indirect anchorage connection|a rigid connection is placed between the miniscrews and the first molar to prevent mesial tooth movement.
223857912|NCT02098382|DEVICE|Dilapan-S|Dilapan-S synthetic osmotic dilator for cervical ripening prior to labor induction
223857913|NCT01944319|DRUG|Routine meropenem therapy|Participants in control group will accept meropenem therapy with regimen routinely decided by attending physician
223857914|NCT01944319|DRUG|Meropenem therapy based on a PPK and PD model|Participants in study group will accept meropenem therapy based on a software developed from a PPK and PD model
223857915|NCT01139398|DIETARY_SUPPLEMENT|Limicol (plant extract)|Artichoke extract, anti-caking agents: dicalcium phosphate, calcium citrate, vegetable magnesium stearate, red yeast rice, microcrystalline cellulose, natural vitamin E, garlic extract, sugar cane policosanols, inositol hexanicotinate, vitamin B3, vitamin B2.
223857916|NCT02994017|OTHER|cardiopulmonary exercise testing|The Cardiopulmonary exercise testing (CPET) was performed at the beginning of the study, the same at each center. Each patient underwent a symptom-limited incremental exercise test on an ergometric bicycle (Ergoline-Ergometrics 800®). The protocol included a warm-up period of 3 min at 20 W followed by a progressively increasing work rate (WR) in a ramp fashion and then 3 min recovery. The ramped WR increment was individualized (range,8-30 W/min). during exercise, heart rate (HR) was monitored continuously by 12-lead ECG, and arterial oxygen saturation (SpO2) was measured by pulse oximetry (Nellcor N-395). The expired gases were analyzed with an Ergocard®, focusing on oxygen consumption(VO2), carbon dioxide production (VCO2), minute ventilation (VE), and tidal volume (VT).
223857917|NCT06395311|OTHER|COPD psychological well-being assessment|Patients will complete the following questionnaires: Hospital Anxiety and Depression Scale (HADS), COPD Assessment Test (CAT), State Shame and Guilt Scale (SSGS), Pulmonary Rehabilitation Adapted Index of Self-Efficacy (PRAISE), Brief Fear of Negative Evaluation Scale (BFNE), Self-Compassion Scale Short Form (SCS-SF). Dyspnea will be evaluated with the mMRC scale, and functional capacity will be assessed with the six-minute walking test (6MWT).
223857918|NCT06628635|BEHAVIORAL|Exercise|Exercise involving aerobics, isometrics, and stretching
223857919|NCT06628635|BEHAVIORAL|Resting|Resting
223857921|NCT05450302|OTHER|PURE EP (Observational Study)|This is an observational study. No interventions involved in this study.
223857922|NCT03667248|DEVICE|Sorin Perceval ® Sutureless Valve (Sorin Group Italia Srl, 13040 Saluggia, Italy), available in different sizes (S 19-21mm, M 21-23mm, L 23-25mm, XL 25-27mm)|Sizing of the valve by preoperative CT scan of the heart and comparison of this measurement with the standard procedure (Sizing intraoperatively using the measuring devices provided by the product manufacturer)
223857923|NCT05448755|DRUG|ELX-02|ELX-02 is a small molecule, new chemical entity being developed for the treatment of genetic diseases caused by nonsense mutations. ELX-02 is a eukaryotic ribosomal selective glycoside (ERSG).
223857924|NCT00712166|DRUG|AZLI 75 mg three times daily (TID)|
223857925|NCT00712166|DRUG|Placebo three times daily (TID)|
223857926|NCT04457141|COMBINATION_PRODUCT|Effect of pelvic floor for the use of minimalist shoes versus shod in woman.|Measure the activity of the pelvic floor and others muscles with EMG during treadmill running with different speeds and different shoes: minimalist and shod.
223857927|NCT04995887|DEVICE|Jada® System|The Jada® System is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. It is a teardrop-shaped, soft silicone ring that is placed into the uterus, where gentle suction is applied to cause the uterus to contract and shrink in size, compressing the blood vessels so the bleeding stops.
223857928|NCT03944343|OTHER|Cereal based products|The cereal products are made from common Swedish cereals.
223857929|NCT00556062|BIOLOGICAL|seasonal split influenza vaccine|0.5 ml/dose, containing 45 μg influenza HA antigens, 15 μg each subtype; one dose regime
223857930|NCT00556062|BIOLOGICAL|seasonal split influenza vaccine|0.5 ml/dose, containing 45 μg influenza HA antigens, 15 μg each subtype; one dose regime
223857931|NCT00556062|BIOLOGICAL|seasonal split influenza vaccine|0.5 ml/dose, containing 45 μg influenza HA antigens, 15 μg each subtype; one dose regime
223857932|NCT00556062|BIOLOGICAL|seasonal split influenza vaccine|0.5 ml/dose, containing 45 μg influenza HA antigens, 15 μg each subtype; one dose regime
223857933|NCT00378677|DRUG|Cyclosporine A dry powder inhalation (Drug)|
223857934|NCT01773122|DRUG|Dapsone Formulation A|Dapsone Formulation A applied once daily to the face, upper chest, upper back, and shoulders for 28 days.
223857935|NCT01773122|DRUG|Dapsone Formulation B|Dapsone Formulation B applied once daily to the face, upper chest, upper back, and shoulders for 28 days.
223857936|NCT01773122|DRUG|Dapsone Formulation C|Dapsone Formulation C applied once daily to the face, upper chest, upper back, and shoulders for 28 days.
223857937|NCT01773122|DRUG|Dapsone 5% Gel|Dapsone 5% gel (ACZONE®) applied twice daily to the face, upper chest, upper back, and shoulders for 28 days.
223857938|NCT04374318|DRUG|Dexmedetomidine|INTRATHECAL AND INTRAVENOUS
223857939|NCT00694811|BEHAVIORAL|Re-feeding duration|1 or 6 weeks of re-feeding after VLED-induced weight loss
223857940|NCT02889822|DRUG|Alprostadil Liposomes for Injection|"1. Single-dose tolerance test:10ug/20ug/50ug/100ug/200ug/300ug/400ug of Alprostadil Liposome for Injection,ivgtt,qd~2. Multiple-dose tolerance test:100ug,ivgtt,qd,continuous administration for 7 days."
223857941|NCT05464212|PROCEDURE|USG Guided Greater Occipital Nerve Block|With 0.5 Hz sensorial stimulation, a 5-cm-long radiofrequency needle with a 0.5 cm active tip was advanced under ultrasound guidance in both pulsed PRF and nerve block groups. USG probe was located to medial one-third of the superior nuchal line between the occipital tubercle and mastoid process under sterile conditions. Finally, the placement of the needle was verified by Doppler imaging of the occipital artery. A 0.3-0.5 Hz sensory stimulus was given with the RF device, and the paresthesia sensation in the patient's occipital nerve dermatome was questioned, and location verification was performed. Then, GON block was performed in all patients by administering 5mg bupivacaine through a PRF needle. After the GON block, the PRF neuromodulation was applied at 42 degrees for 4 minutes in the GONB-PRF group. In the GONB group, the PRF generator was set for 4 minutes, and the time was waited, but no pulse was given.
224076212|NCT06089603|DEVICE|Continuous positive airway pressure|Nocturnal continuous positive airway pressure by a nasal mask. CPAP pressure will be automatically titrated using a AutoSet device (ResMed)
224076213|NCT06089603|DRUG|Conventional pharmacological treatment|Usual treatment of the patient
224076214|NCT06089603|OTHER|Sleep ,diet and life style recomendations|Daily recomendatios
223857942|NCT05464212|PROCEDURE|USG Guided Greater Occipital Nerve Block and Pulsed Radiofrequency|With 0.5 Hz sensorial stimulation, a 5-cm-long radiofrequency needle with a 0.5 cm active tip was advanced under ultrasound guidance in both pulsed PRF and nerve block groups. USG probe was located to medial one-third of the superior nuchal line between the occipital tubercle and mastoid process under sterile conditions. Finally, the placement of the needle was verified by Doppler imaging of the occipital artery. A 0.3-0.5 Hz sensory stimulus was given with the RF device, and the paresthesia sensation in the patient's occipital nerve dermatome was questioned, and location verification was performed. Then, GON block was performed in all patients by administering 5mg bupivacaine through a PRF needle. After the GON block, the PRF neuromodulation was applied at 42 degrees for 4 minutes in the GONB-PRF group. In the GONB group, the PRF generator was set for 4 minutes, and the time was waited, but no pulse was given.
223857943|NCT01264718|BEHAVIORAL|Parent Mentors|After random assignment to the Parent Mentor group, minority low-income parents of Medicaid/CHIP eligible children met with Parent Mentors to receive instruction and help on completing, submitting applications for, and maintaining Medicaid/CHIP coverage for their child.
223857944|NCT03317535|PROCEDURE|General anesthesia|Patients will be injected with propofol, remifentanil and muscular relaxant with controlled ventilation.
223857945|NCT03317535|PROCEDURE|Local anesthesia/concious sedation|Patients will be injected with propofol and remifentanil.
223857946|NCT03317535|PROCEDURE|Spontaneous breath|Patients will be kept spontaneous breath.
223857947|NCT03317535|PROCEDURE|Controlled ventilation|Patient will be kept with controlled ventilation.
223857948|NCT02712619|DRUG|Metformin|
223857949|NCT05543811|DIETARY_SUPPLEMENT|Food for special dietary use|Food for special dietary use (spread) with modified ingredients' content will be included to the diet of 70 patients without significant organic pathology for 14 days receiving standard diet, modified by the inclusion of two portions of the spread, 20 grams each for breakfast and dinner
223857950|NCT04621708|DEVICE|Repetitive transcranial magnetic stimulation|Left DLPFC iTBS rTMS
223857951|NCT02646592|DRUG|Alfentanil|Bolus of alfentanil 10 µg/kg 5 minutes before skin incision
223857952|NCT02646592|DRUG|sevoflurane or propofol|
223857953|NCT02664376|OTHER|Sarcopenia detection|"The assessment of sarcopenia is performed according to the recommendations of the EWGSOP (European Working Group on Sarcopenia in Older people). Three measurements are made:~* Muscle mass measurement by dual energy X-ray absorptiometry (DEXA).~* Walking speed measurement~* Hand grip test~A diagnosis of sarcopenia is established if the walking speed is inferior to 0.8 m/sec, the muscular strength is low and the muscular mass is low.~Data regarding the geriatric characteristics of this sarcopenic population will be collected."
223857954|NCT00598897|DRUG|clarithromycin, rifabutin|Clarithromycin three times per week (variable dosage) in combination with multiple drugs including rifabutin or rifampin three times per week (variable dosage). Dosage dependent on age, weight and other patient-specific health factors.
223857955|NCT04893135|OTHER|pratice physical activity|treadmill walking : walk at a speed of 2.7 km.h-1 in 3 stages of 3 mins with an incline of 0%, 5% and 10%
223857956|NCT00999492|DEVICE|Tecnis® Multifocal (TMF)|Aspheric, diffractive multifocal intraocular lenses
223857957|NCT04349384|PROCEDURE|Colorectal resection|Colon or rectal resection for colorectal adenocarcinoma
223857958|NCT02328820|OTHER|Percutaneous coronary intervention (PCI)|For lesions with both FFR\<=0.8 and CFR\<2.0
223857959|NCT02328820|OTHER|Optimal medical therapy (OMT)|For lesions with FFR\>0.8 or CFR\>=2.0 or both
223857960|NCT04376814|DRUG|Favipiravir|Patients will be given a stat dose of 1600mg Favipiravir tablets for the first time, and for next time they will be given 600mg of favipiravir tablets three times per day for 7 days
223857961|NCT04376814|DRUG|Hydroxychloroquine|200mg of Hydroxychloroquine two times per day will be given to patients for seven days in Test group, and Patients in Control group will be given a stat dose of 400mg Hydroxychloroquine tablets two times per day.
223857962|NCT04376814|DRUG|Lopinavir / Ritonavir|Patients will be given 200/50 mg of Lopinavir / Ritonavir two times per day for seven days.
223857963|NCT06049108|DRUG|[14C]-LY3871801|Administered orally
223857964|NCT04178343|RADIATION|tomotherapy|"1. the prescription of tomotherapy: whole brain radiation (WBRT) with 40Gy in 20 fractions and concurrent boost of 60Gy of the leptomeningeal metastases;~2. WBRT of 50Gy in 25 fractions, with dose limitation of hippocampus and brain stem; c.TMZ is used if necessary: concomitant TMZ: 75mg/m2 adjuvant TMZ: 150mg/ m2\*5d, q28d, up to 6cycles.~d. Some patients received intrathecal chemotherapy (MTX+AraC+Dex) based on the cytology of cerebrospinal fluid (CSF)."
223857965|NCT04910347|DRUG|Nivolumab|"Dosage within 12 weeks after the end of concurrent chemoradiation therapy. Nivolumab 360mg Intravenously administered every 3 weeks.~As a consolidation regimen, administration of Nivolumab is administered for up to a total of 1 year until disease progression or unacceptable to toxicity occurs."
223857966|NCT01895517|OTHER|LBC|Cervical cancer screening by using liquid based cytology as a standard screening modality
223857967|NCT01895517|OTHER|LBC plus HPV DNA testing|Cervical cancer screening by using liquid based cytology plus HPV DNA testing as an experimentally screening modality
223857968|NCT05273281|PROCEDURE|Transabdominal plane block|Peripheral nerve block
223857969|NCT05273281|PROCEDURE|Quadratus lumborum block|Peripheral nerve block
223857970|NCT03812159|DEVICE|iCSPlan|"The Investigator will acquire a routine pre-operative CT-scan to help assess the synostosis severity. A week before the surgery a routine preoperative visit will be done. If the potential subject agrees to participate in the study, a presurgical plan will be built, and based on the CT scan, it will (1) quantify shape differences between pathological and healthy cranial shapes; (2) compensates for brain and cranial growth during the months between diagnosis, treatment and recovery; and (3) guides bone-cuts and bone-placement for the simplest and optimal surgical procedure.~Finally this plan will be recorded in a software, iCSPlan, which will be reviewed by the surgeon. If it is accepted, it will be available during the surgery as a rely-on tool which may or may not be followed."
223857971|NCT03476109|DRUG|Randomisation to omalizumab|The only intervention will be that allocation of patients to omalizumab or mepolizumab (to both of which patients will be eligible) will be randomized, to avoid that the initial decision is biased by confounding factors that are likely, but unproven, to affect the treatment response. Then, in case of non-response, patients will be switched to the other drug, as routine clinical practice would indicate.
224076215|NCT03868293|DEVICE|Focused ultrasound|Pulsed low intensity focused ultrasound
223857972|NCT03476109|DRUG|Randomisation to mepolizumab|The only intervention will be that allocation of patients to omalizumab or mepolizumab (to both of which patients will be eligible) will be randomized, to avoid that the initial decision is biased by confounding factors that are likely, but unproven, to affect the treatment response. Then, in case of non-response, patients will be switched to the other drug, as routine clinical practice would indicate.
223857973|NCT03261661|BEHAVIORAL|Reading|Students are taught the processes involved in hearing, seeing, and feeling sounds as well as differences between sounds in words. New knowledge is built on previous knowledge in a step-by-step manner. Sounds build to letter-sound relationships to reading of words and syllables. Students learn the connection between reading of words (decoding) and writing/spelling words (encoding) building from simple words to multisyllabic words to text reading with fluency and understanding.
223857974|NCT03261661|BEHAVIORAL|Mindset|Blended learning program with online and teacher-directed activities related to how the brain functions, learns, and remembers, and how it changes in a physical way when we exercise it. Instruction in how students are in control of their brain and its development, and how to apply this to their schoolwork with practical strategies for tackling academic challenges.
223857975|NCT03261661|BEHAVIORAL|Reading Embedded with Mindset|Mindset training explicitly linked to the reading content through lesson openers, feedback prompts, and self-monitoring of mindset during reading work.
223857976|NCT03261661|BEHAVIORAL|Business as Usual|Reading interventions already provided to students with reading difficulties as per typical procedures at the participating school
223857977|NCT06479018|BIOLOGICAL|Blood sampling|Venous blood sampling will be carried out for each patient included in the study.
223857978|NCT06479018|BIOLOGICAL|Liquid bubble sampling|Liquid bubble sampling will be carried out for each patients with Bullous Pemphigoid included in the study.
223857979|NCT06479018|PROCEDURE|Cutaneous biopsy|At least the first cutaneous biopsy will be carried out for each patients with Bullous Pemphigoid included in the study.
223857980|NCT01045317|DRUG|PF-04776548|single intravenous or oral administration of 0.1mg PF-04776548.
223857981|NCT04945694|OTHER|Ultrasound-guided bilateral pecto-intercostal fascial block|\- PATIENT IN SUPINE POSITION, SKIN WILL BE DISINFECTED, A HIGH-FREQUENCY LINEAR PROBE WILL BE PLACED PARALLEL TO LONGITUDINAL AXIS OF STERNUM ON LATERAL BORDER AND SCANNED LATERALLY TO IDENTIFY 4TH AND 5TH COSTAL CARTILAGE. THE PECTORALIS MAJOR MUSCLE (PMM), INTERNAL INTERCOSTAL MUSCLE (IIM), TRANSVERSUS THORACIS MUSCLE (TTM), RIBS, AND PLEURA WILL BE IDENTIFIED. COLOR DOPPLER ULTRASONOGRAPHY WILL BE USED TO DETERMINE PERFORATING BRANCHES OF INTERNAL THORACIC ARTERY, WHICH TRAVEL ANTERIORLY THROUGH THE ANTERIOR CHEST WALL, PIERCING THE INTERCOSTAL MUSCLE AND PMM. A 22G NEEDLE WILL BE INSERTED IN PLANE WITH PROBE, IN CAUDAL-TO-CRANIAL DIRECTION UNTIL THE TIP IS POSITIONED IN INTER- FASCIAL PLANE BETWEEN THE PMM AND IIM. NORMAL SALINE WILL BE USED TO DETERMINE CORRECT PLACEMENT OF NEEDLE TIP IN INTER-FASCIAL PLANE, AS SHOWN BY SEPARATION OF FASCIAL LAYERS THEN LOCAL ANESTHETIC WILL BE INJECTED
223857982|NCT04945694|DRUG|Intravenous fentanyl|In this group, patients will receive only incremental doses of intravenous fentanyl
223857983|NCT04945694|DRUG|Propofol|Propofol anesthesia
223857984|NCT04945694|DRUG|Sevoflurane|Sevoflurane anesthesia
223857985|NCT04945694|DRUG|Atracurium|Intravenous atracurium
223857986|NCT04945694|DEVICE|ultrasound|ultrasound-guided block
223857987|NCT01673113|DEVICE|Zeltiq CoolSculpting device|"This is an FDA approved cooling device used for non-invasive and selective reduction of fat around the flanks, an area commonly referred to as the love handles."
223857988|NCT02058914|DIETARY_SUPPLEMENT|high fructose sweetened beverage|710 ml per day of a HF-sweetened beverage
223857989|NCT02058914|DIETARY_SUPPLEMENT|High Glucose sweetened beverage|HG-sweetened beverage
223857990|NCT05949203|DRUG|Cabotegravir Injection|Administration of HIV pre-exposure prophylaxis with cabotegravir 600 mg/3mL extended release injectable suspension every other month.
223857991|NCT00371020|DRUG|low molecular weight heparin, 5-FU|
223857992|NCT06414980|BEHAVIORAL|Experimental|The effect of suggestion given to patients with the olfactory memory method before the surgical operation on vital signs and systemic evaluation scoring during awakening.
223857993|NCT06388447|BIOLOGICAL|Umbilical cord-mesenchymal stem cells|One injection will be given at each papilla set with the volume of 0.1mL with 2.0 x 10⁶ cells per syringe at every visit. A total of 3 injections will be given at the interval of 6 weeks, with a total of 6.0 x 10⁶ cells for each interdental papilla at the end of the 3 injections. Every injection starts with locally application of local anesthetic. For the control group, participants will be injected with 0.9% sodium chloride after locally application of local anesthetic
223857994|NCT04671108|DEVICE|Hioxifilcon A standard hydrogel contact lens with Hyaluronic Acid (HA)|Daily disposable contact lens wear for 1 week
223857995|NCT03386929|DRUG|Avelumab|A human antibody of the immunoglobulin gamma-1 isotype that specifically targets and blocks the Programmed Death ligand (PD-L1) for PD-1.
223857996|NCT03386929|DRUG|Axitinib|A selective oral (tablet) inhibitor of tyrosine kinases Vascular Endothelial Growth Factor (VEGF) receptors 1, 2, and 3. These receptors are implicated in pathologic angiogenesis, tumor growth and cancer progression.
223857997|NCT03386929|DRUG|Palbociclib|A selective, reversible oral (capsule) inhibitor of cyclin-dependent kinases (CDK) 4 and 6. The inhibition of CDK 4/6 blocks DNA synthesis by prohibiting progression of the cell cycle from G1 to S phase.
223857998|NCT05310929|DRUG|Labetalol and Glyceril trinitrate|for control of blood pressure
223857999|NCT05872321|OTHER|Complication|whether or not complications occur
223858000|NCT01975467|DEVICE|CRx|The CRx is used to treat mid-shaft, with or without comminution clavicle fractures.
223858001|NCT00258518|PROCEDURE|mechanical ventilation/CT Scan|evaluation of pleural effusion and respiratory mechanics, CT scan
223858002|NCT00841958|PROCEDURE|Autologous bone marrow mononuclear stem cells or peripheral blood stem cells|Cells concentration is 150х106 cells/ml (2ml) with CD34+ cells=2.5±1.44%
223858003|NCT06015594|DRUG|Metformin|Patients treated with metformin
223858004|NCT00308958|DEVICE|High frequency chest wall oscillator|
223858005|NCT01624558|DEVICE|In-line Carbon filter (Vapor-Clean)|Carbon filter placed in anesthesia breathing circuit.
223858006|NCT00662636|DRUG|dasatinib|Given orally
223858007|NCT00662636|DRUG|lapatinib ditosylate|Given orally
223858008|NCT00662636|OTHER|pharmacological study|Correlative study (cohort II only)
223858009|NCT00662636|OTHER|laboratory biomarker analysis|Correlative study (cohort II only)
223858010|NCT00345852|PROCEDURE|Fetoscopic Selective Laser Photocoagulation|
223858011|NCT03772964|DRUG|MetFORMIN Hydrochloride ER|Subjects will be exposed to 500mg, 1000mg, or 1500mg of daily ER Metformin, by mouth, for up to 90 days. Subjects will have their venous blood sampled and baseline, throughout the trial, and following completion of their metformin exposure.
223858012|NCT03772964|DRUG|Placebo|Subjects will be exposed to placebo, by mouth, for up to 90 days. Subjects will have their venous blood sampled and baseline, throughout the trial, and following completion of their metformin exposure.
223858013|NCT01701609|BEHAVIORAL|Cognitive Remediation Therapy|
223858014|NCT05547191|DEVICE|ChloraSolv|Debridement with ChloraSolv until the wound is visually assessed as clean.
223858015|NCT03264456|DIAGNOSTIC_TEST|[18F] Fluciclovine PET/MRI|\[18F\] fluciclovine PET/MRI
223858016|NCT03264456|DRUG|[18F] fluciclovine|\[18F\] fluciclovine
223858017|NCT05527483|DRUG|[68Ga]PSMA|Patients will receive up to 6 mCi of \[Ga-68\]PSMA delivered as an intravenous (IV) bolus injection, followed by digital PET/CT imaging
223858018|NCT05527483|DRUG|Flourine-18 [F-18] Sodium Fluoride (NaF)|Patients will receive 8-12 mCi of \[F-18\]NaF delivered as an intravenous (IV) bolus injection, followed by digital PET/CT imaging.
223858019|NCT05527483|DIAGNOSTIC_TEST|PET/CT|Patients will receive \[68Ga\]PSMA with a PET/CT and Flourine-18 \[F-18\] Sodium Fluoride (NaF) with a PET/CT
223858020|NCT03538054|DRUG|Dextromethorphan|(1)10 mg, by mouth, twice daily every 12 hours.
223858021|NCT03538054|DRUG|Placebo|1 capsule, by mouth, twice daily every 12 hours.
223858022|NCT00941356|DIETARY_SUPPLEMENT|Bio-K+ CL1285|2 capsules per day before breakfast
223858023|NCT00941356|DIETARY_SUPPLEMENT|Placebo|2 capsules per day before breakfast
223858024|NCT05128305|DRUG|traditional Chinese medicine1 and traditional Chinese medicine 2|We use two traditional Chinese medicine prescriptions to intervene in patients after TIPS
223858025|NCT00798772|DIETARY_SUPPLEMENT|Micronutrients and antioxidants|8 capsules twice daily for two years
223858026|NCT00798772|DIETARY_SUPPLEMENT|Multivitamins and minerals|8 capsules twice daily for two years
223858027|NCT02078934|PROCEDURE|Endoscopic Gastric Plication|Evaluate the efficacy of endoscopic suturing for weight loss
223858028|NCT05835115|DIAGNOSTIC_TEST|A deep learning-based myopia and myopic maculopathy detection and prediction system|This deep learning system is capable of analyzing fundus images for myopia staging, myopic maculopathy detection, cycloplegic refraction estimation and prediction, and risk stratification of myopia and myopic maculopathy onset.
223858029|NCT03132324|DRUG|INCB059872|INCB059872 tablets
224076216|NCT06799520|DRUG|VIS171|VIS171 will be administered as a SC injection.
223858030|NCT04991974|BEHAVIORAL|Patient Navigation|A Patient Navigator will work with participants to facilitate their entry into OUD treatment in the community (e.g., by selecting a program, scheduling intake appointments, and addressing barriers to facilitate successful treatment linkage).
223858031|NCT04991974|DRUG|Buprenorphine|"Buprenorphine is an FDA-approved medication for opioid dependence, and will be used in this study consistent with its approved use (but will be initiated in the novel setting of sexual health clinics in this health services study).~Participants will meet with an sexual health clinic provider who holds a waiver to prescribe buprenorphine. Participants will initiate buprenorphine treatment via a home induction under the direction of the provider. Because barriers to transfer may take some time to overcome, participants will be able to receive additional bridge buprenorphine up to two times (up to 15 days' supply at a time) until successful transfer to OUD treatment in the community."
223858032|NCT02200952|DRUG|recombinant LH|recombinant LH twice/day for 10 days from pick up
223858033|NCT03279666|OTHER|Tenaculum replacement|Tenaculum replacement during colposcopic biopsy
223858034|NCT05602155|PROCEDURE|Group 1|Even numbered patients will partial weight bearing after treatment,
223858035|NCT05602155|PROCEDURE|Group 2|patients with odd numbers will walk with full weight bearing after treatment
223858036|NCT03543839|BIOLOGICAL|Belimumab|Subjects in this arm will receive 200mg belimumab subcutaneously weekly for 2 years
223858037|NCT03543839|BIOLOGICAL|Belimumab/Placebo|Subjects in this arm will receive weekly subcutaneous injections of 200mg belimumab for 1 year and then placebo subcutaneous injections for 1 year.
223858038|NCT03543839|OTHER|Placebo|Subjects in this arm will receive weekly subcutaneous injections of placebo for 2 years
223858039|NCT05341518|PROCEDURE|Subscapularis repair|To complete reverse total shoulder arthroplasty, the surgeon must cut through the subscapularis muscle. In this arm of the study, the muscle will be repaired, rather than left to heal itself.
223858040|NCT03254394|DRUG|Lidocaine Hydrochloride|"Intravenous lidocaine will be dosed as a brief 1 mg/kg infusion (based on Ideal Body Weight (IBW)) over 10 minutes, followed by a 0.04 mg/kg/min infusion over additional 120 minutes, resulting in a total dose of 5.8 mg/kg IBW.~If this dose is tolerable in four consecutive sessions of mFOLFOX6 in six or more of the eight patients in the tolerability phase, we will initiate the randomized efficacy pilot study."
223858041|NCT03254394|DRUG|Placebo|Dextrose 5% in water will be administered as active comparator.
223858042|NCT03254394|DRUG|FOLFOX regimen|"Each cycle (repeated every 14 days):~Oxaliplatin 85mg/m2 IV over 2h, Leucovorin 400 mg/m2 IV over 2h, 5-FU 400mg/m2 IV bolus, followed by a 1200mg/m2/day continuous infusion for 2 days."
223858043|NCT00076180|BIOLOGICAL|Hu-MiK-Beta-1|Hu-MiK-Beta-1 administered as an intravenous infusion over 90- minutes.
223858044|NCT05102266|DRUG|BR1016C|All subjects who have been fasting for at least 10 hours prior to administration will take 1 tablet of study drug or comparator orally with 150 mL of water at room temperature at around 8 a.m. on the administration day of each period.
223858045|NCT05102266|DRUG|BR1016D|All subjects who have been fasting for at least 10 hours prior to administration will take 1 tablet of study drug or comparator orally with 150 mL of water at room temperature at around 8 a.m. on the administration day of each period.
223858046|NCT02765373|DRUG|Exemestane|
223858047|NCT02765373|DRUG|Letrozole|
223858048|NCT02765373|DRUG|Anastrozole|
223858049|NCT05447013|BIOLOGICAL|Coronavirus-2-specific T cells|Coronavirus-2-specific T cells ex vivo expanded from selected COVID-19 recovered donors
223858050|NCT05447013|OTHER|standard of care (SOC)|standard of care (SOC)
223858051|NCT02930590|OTHER|Alternating low pressure mattress with air loss function|IsoAir, Stryker, USA
223858052|NCT02930590|OTHER|Gel mattress|IsoGel, Stryker, USA
223858053|NCT02930590|OTHER|Basic foam|Standard hospital mattress
223858054|NCT02686554|OTHER|Neuropsychological assessment|The patients perform tests to assess their cognitive abilities
223858055|NCT03764943|DIETARY_SUPPLEMENT|Impact Advanced Recovery|immunonutrition shake; nutritional supplement containing amino acids, omega-3 fatty acids, and nucleotides
223858056|NCT03545217|BEHAVIORAL|Lifestyle Intervention|a 6-month intensive lifestyle intervention program led by a multidisciplinary team of diabetes nurses and dieticians, and a follow up at 12 months for these participants. This will be a group-based activity adapted from the Diabetes Prevention Program -Thailand project
223858057|NCT03503630|DRUG|COMPOUND 2055269|COMPOUND 2055269 to be given every 2 weeks with chemotherapy for 6 cycles
223858058|NCT03503630|RADIATION|Radiation Therapy|Radiotherapy 25 Gy to be given on Days 1-5
223858059|NCT03503630|DRUG|mFOLFOX|Given every 2 weeks for 6 cycles
223858060|NCT03503630|PROCEDURE|Total Mesorectal Excision|Surgery to be done 2-3 weeks after last cycle of chemotherapy and COMPOUND 2055269
223858061|NCT05193630|DIETARY_SUPPLEMENT|Milnutri Sure™|"Milnutri Sure™, a commercially available oral nutritional support (ONS) product in powder format, for children of 1 y of age and above (1.0 kcal /ml).~For children between 1 and 3 years of age, the recommendation is to use 2 servings per day, and for children from 4 to 6 years of age, the recommendation is to give 3 servings per day. One serving contains of 45 grams of product and 180 ml water."
223858062|NCT01117441|DRUG|PEG-L-asparaginase|see detailed protocol description
223858063|NCT01117441|DRUG|cyclophosphamide|see detailed protocol description
223858064|NCT01117441|DRUG|cytarabine|see detailed protocol description
223858065|NCT01117441|DRUG|daunorubicin hydrochloride|see detailed protocol description
223858066|NCT01117441|DRUG|dexamethasone|see detailed protocol description
223858067|NCT01117441|DRUG|doxorubicin hydrochloride|see detailed protocol description
223858068|NCT01117441|DRUG|etoposide|see detailed protocol description
223858069|NCT01117441|DRUG|ifosfamide|see detailed protocol description
223858070|NCT01117441|DRUG|mercaptopurine|see detailed protocol description
223858071|NCT01117441|DRUG|methotrexate|see detailed protocol description
223858072|NCT01117441|DRUG|prednisone|see detailed protocol description
223858073|NCT01117441|DRUG|thioguanine|see detailed protocol description
223858074|NCT01117441|DRUG|vincristine sulfate|see detailed protocol description
223858075|NCT01117441|DRUG|vindesine|see detailed protocol description
223858076|NCT01117441|DRUG|daunoxome|see detailed protocol description; only given by patients with poor MRD-response during the high risk treatment
223858077|NCT01117441|DRUG|fludarabine|see detailed protocol description; only given by patients with poor MRD-response during the high risk treatment
223858078|NCT01117441|RADIATION|Radiation Therapy|for eligibility for radiotherapy see detailed protocol description
223858079|NCT00387465|DRUG|Azacitidine 30mg/m2|Azacitidine 30mg/m2 subcutaneously (SQ)
223858080|NCT00387465|DRUG|Entinostat|7mg by mouth (PO) on days 3 and 10 of each cycle
223858081|NCT00387465|DRUG|Azacitidine 40mg/m2|Azacitidine 40mg/m2 SQ
223858082|NCT03418324|DRUG|TRC105|Patients will receive TRC105 10mg weekly x 4, and then 15 mg/kg every 2 weeks
223858083|NCT03418324|DRUG|Abiraterone|Patients who are progressing on Abiraterone will undergo a washout period and then continue treatment with standard dosing of Abiraterone plus TRC105.
223858084|NCT03418324|DRUG|Enzalutamide|Patients who are progressing on Enzalutamide will undergo a washout period and then continue standard treatment with Enzalutamide plus TRC105.
223858085|NCT00159796|DRUG|Asenapine|Asenapine, 3 weeks
223858086|NCT00159796|DRUG|Olanzapine|Olanzapine, 3 weeks
223858087|NCT00159796|DRUG|Placebo|placebo, 3 weeks
223858088|NCT05679037|OTHER|Placebo|Inactive capsules
223858089|NCT05679037|DRUG|Alpha Lipoic Acid 600 MG Oral Capsule|Universal antioxidant
223858090|NCT00006450|DRUG|Phenylbutyrate|
223858091|NCT01979354|DRUG|Spinal morphine|0.15 mg spinal morphine
223858092|NCT02981706|PROCEDURE|Arteriovenous Fistula (AVF)|The location of vascular access placement in the upper extremity will be based on pre-surgery vein mapping and the appearance of the vessels at the time of the surgery, with the most distal clinically acceptable location used. When no contra-indication is present, the vascular access will be placed in the non-dominant arm per standard of care. In this case, the vascular access will be an arteriovenous fistula, or connection between a native artery and vein.
223858093|NCT02981706|PROCEDURE|Arteriovenous Graft (AVG)|The location of vascular access placement in the upper extremity will be based on pre-surgery vein mapping and the appearance of the vessels at the time of the surgery, with the most distal clinically acceptable location used. When no contra-indication is present, the vascular access will be placed in the non-dominant arm per standard of care. In this case, the vascular access will be an arteriovenous graft, or synthetic connection between a native artery and vein.
223858094|NCT05923008|DRUG|IBI130|Subjects will receive IBI130 until unacceptable toxicity, disease progression, withdrawal of consent, occurrence of other reasons for discontinuing study therapy, or for a maximum of 24 months of treatment, whichever occurs first.
223858095|NCT02328352|PROCEDURE|BP selfstanding felt|intervention of laparotomy with the incision of 10 cm navel-pubis will be performed, splaying of the skin and subcutaneous layers, then will be incised the fascia plane, and muscles. Ten rabbits (hereafter defined as BPR1-BPR10) will receive 2x2cm2 samples of BP selfstanding felt in a pocket created between muscular fascia and large muscles of the abdominal wall.
223858096|NCT02328352|PROCEDURE|PP mesh|intervention of laparotomy with the incision of 10 cm navel-pubis will be performed, splaying of the skin and subcutaneous layers, then will be incised the fascia plane, and muscles. A 2x2cm2 sample of PR (polypropylene) prosthesis was implanted without stitches into a pocket between large abdominal muscle and abdominal fascia
223858097|NCT02328352|PROCEDURE|BP intraperitoneal mesh|Laparotomy on the linea alba carried out deeply for entering into the abdominal cavity, a 2x2cm2 BP sample implantation with the rough side facing the parietal peritoneum surface and the smooth and brilliant surface facing to the visceral peritoneum and gut
223858098|NCT02328352|PROCEDURE|control group|observational intervention in 5 rabbits with the same body weight and the same age will be observed and will be feeded in the same way of the BP device intraperitoneal implanted group
223858099|NCT04533139|DRUG|Influenza vaccine|"influenza vaccine 0.5 ml intramuscularly each season~2004-2005 season antigens: A/New Caledonia/20/99(H1N1)-like, A/Wyoming/3/2003(H3N2), and B/Shanghai/361/2002-like antigens~2005-2006 season antigens: A/New Caledonia/ 20/00(H1N1)-like, A/California/7/2004 (H3N2)-like, and B/Shanghai/361/2002-like antigens"
223858100|NCT03958513|DRUG|Bupivacaine|1.5 ml 0.25% bupivacaine for 1 inch incision will be given before closure of ports in patients undergoing laparoscopic cholecystectomy
223858101|NCT03958513|DRUG|0.9% normal saline|1.5 ml 0.9% NACl for 1 inch incision will be given before closure of ports in patients undergoing laparoscopic cholecystectomy
223858102|NCT05638204|BEHAVIORAL|Suicidal Crisis Intervention (SCI)|This study's experimental condition consisted of the Suicidal Crisis Intervention (SCI), developed by the Flemish Centre of Expertise of Suicide prevention. The SCI aims to provide tools for dealing with future suicidal crises for people after a suicidal crisis or suicide attempt. The intervention attempts to provide insight into the suicidal crisis by giving suicidality meaning within the life history. It aims to increase motivation for specialized care and therefore facilitate continuity of care. In addition, the method also wants to involve the close relative(s) of the suicidal person in the treatment. The SCI offers care providers a clear structure and handles to do this within a short period of time (4 sessions). Within the SCI are a number of crucial elements: the therapeutic relationship, involving loved ones, person-centred care, the Integrated Explanatory Model for Suicidal Behavior (Van Heeringen, 2007), the safety plan (Stanley \& Brown, 2012) and continuity of care.
223858103|NCT00005890|DRUG|corticotropin|
223858104|NCT03922243|OTHER|retrospective|Retrospective study to assess treatment done by dental students
223858105|NCT00028301|DRUG|Atazanavir|
223858106|NCT00028301|DRUG|Lopinavir/Ritonavir|
223858107|NCT03795077|OTHER|Experimental group|Experimental group followed the 3-months programme based in professional ethics. A specific syllabus about Professional Ethics was developed. It consisted of 6 themes and included topics as moral values, ethics and moral, bioethics and professional ethics, ecc. Six related activities were created: to solve situations related to real clinical practices. Face to face group sessions based on cooperative learning were planned. Students were divided in small groups, and active participation techniques were used.
223858108|NCT00964184|DRUG|Metformin|
223858109|NCT00964184|BEHAVIORAL|Lifestyle modification|
223858110|NCT06650930|DRUG|Oral calcium carbonate|All participants receive a single, open-label dose of oral calcium carbonate 3000mg
223858111|NCT04783181|BIOLOGICAL|AAV BBP-631|intravenous
223858112|NCT05012644|DRUG|Palbociclib + aromatase inhibitor|Palbociclib + aromatase inhibitor
223858113|NCT05012644|DRUG|Aromatase inhibitor|Aromatase inhibitor
223858114|NCT06070415|DEVICE|Chatbot|12 week- intervention consisting of messages with an explanatory video of each exercise indicating how to do it and how many repetitions to perform
223858115|NCT06070415|OTHER|Home exercise, usual care|12 week- intervention. Printed sheets indicating how to exercises and how many repetitions to perform
223858116|NCT06070415|OTHER|Education|One-week, three sessions in alternate days, outpatient supervised education on how to perform the exercises at home
223858117|NCT02251613|DRUG|Olopatadine HCl ophthalmic solution, 0.1%|
223858118|NCT02251613|DRUG|Epinastine HCl ophthalmic solution, 0.05%|
223858119|NCT02600442|OTHER|non interventional study|
223858120|NCT02008734|DRUG|PD0332991|
223858121|NCT00255437|DRUG|ferumoxytol or oral iron|
223858122|NCT01303835|DRUG|LDN|Randomized patients received 4.5 mg low dose naltrexone (LDN) to be taken every night before bed.
223858123|NCT01303835|DRUG|Placebo|Randomized patients received placebo to be taken every night before bed.
223858124|NCT05298384|OTHER|Compression stockings|Graduated compression stockings (GCS) are used to treat chronic venous diseases and edema. They help to improve blood flow and prevent blood pooling in the legs. The use of GCS will be in accordance with this indication. The greatest pressure is exerted at the ankle with gradually decreasing pressures up the length of the stockings. GCS are designed for use out of bed and are manufactured using strict medical and technical specifications.
223858125|NCT02517411|OTHER|Standard care|The standard care of stable COPD is based on long-acting bronchodilators (LABD).
223858126|NCT02517411|OTHER|Physiotherapy added to standard care|The treatment will be based on domiciliary physiotherapy program during 8 weeks, twice a week added to standard care. The duration of the sessions will be 45-60 minutes. The physiotherapy treatment includes: breathing exercises, electrostimulation in quadriceps with voluntary contraction and exercises with theraband. This will be a home-based program supervised by a physiotherapist.
223858127|NCT00423007|DRUG|Bromfenac|
223858128|NCT00423007|DRUG|Placebo|
223858129|NCT04283409|OTHER|Graded activity|Exercise therapy using principles of cognitive behavioral therapy and education
223858130|NCT04283409|OTHER|Motor Control Exercises|Exercise therapy using principles of motor control and motor learning and education
223858131|NCT06619639|BEHAVIORAL|Social-emotional learning curriculum|EMPOWER is a 16-week social-emotional learning curriculum that is integrated into the after-school program context.
223858132|NCT06629805|DIETARY_SUPPLEMENT|Aureobasidium pullulans produced β-glucan|Aureobasidium pullulans produced β-glucan 1,000 mg/day for 12 weeks
223858133|NCT06629805|DIETARY_SUPPLEMENT|Placebo|Placebo 1,000 mg/day for 12 weeks
223858134|NCT06714539|DEVICE|Patient Specific Virtual Reality Stimulation|A novel virtual reality (VR) simulator for spine procedures that will take patient specific medical imaging (3D scans) and create a virtual patient that surgical procedures can be performed on.
223858135|NCT06713096|BEHAVIORAL|Tempos Certos protocol|Improve the enhanced recovery by using the Tempos Certos Protocol by the multiprofissional team , using interventions known by science and recommended by scientists.
223858136|NCT06713941|OTHER|Study of the treatment|Intervention Description 1 \* (Limit: 1000 characters) Study of prescribed treatments, treatments taken by the patients, and treatment discontinuation
223858137|NCT06709911|BEHAVIORAL|Basic Manipulation Stretching|This group received standard hand tenosynovitis stretching therapy, which focused on the flexor and extensor muscle groups of the wrist and hand for release. Muscle tension and tendon adhesions were relieved by basic stretching maneuvers, with each intervention lasting 20-30 minutes, twice a week, over a 4- to 8-week period.
223858138|NCT06709911|BEHAVIORAL|Massage and Tui Na Manipulation|The group received Tui Na manipulation interventions, including pointing, pressing and rolling techniques for the tendon sheath and thumb region, focusing on the stimulation of acupoints such as Hegu, Yangchi and Waiguan. The aim of Tui Na manipulation was to relieve the inflammatory reaction around the tendon sheath, promote blood circulation and improve local function. Each intervention lasts 20-30 minutes, twice a week for 4-8 weeks.
223858139|NCT06709911|BEHAVIORAL|Blood flow restriction training|This group used pressurized blood flow restriction training, in which the proximal part of the temporal joint was pressurized by a pressurized device to restrict blood flow. The training consisted of low-load wrist flexion and extension, fist clenching and unclenching, and wrist rotation. The training intensity was set at 20%-50% 1RM, and the frequency was 2 times per week for 4 to 8 weeks. Pressurization was performed before training and the pressure was set in the range of 20-50 mmHg, and the training period was supervised by a professional.
223858140|NCT06709911|BEHAVIORAL|Magnetic Bead Pressure Stimulation and Tui Na Manipulation Combined Intervention|This group received the combined intervention of magnetic bead pressure stimulation and Tui Na manipulation. Before treatment, the magnetic beads were applied to specific acupoints on the hand (e.g., Hegu, Ahshi, Waiguan, etc.), fixed by breathable patches, and combined with Tui Na manipulation. During Tui Na, the magnetic beads are pressed and kneaded to further enhance the stimulation effect of the acupoints. After Tui Na, the magnetic beads remain in the affected area and can be pressed and kneaded 2-3 times a day for 3 minutes each time to produce a slight sensation of soreness and distension. The aim of the massage is to relieve the inflammatory reaction around the tendon, loosen muscle tension and tendon sheath adhesions and promote blood circulation and joint mobility. The cycle of intervention is 4 to 8 weeks.
223858141|NCT06712043|BEHAVIORAL|Personalised Exercise|An individualized exercise program consisting of aerobic exercises, strength exercises and balance exercises. The exercises will be prescribed via the Physitrack app.
223858142|NCT06712043|BEHAVIORAL|Historical control group|Aerobic training (see study Voet 2024, Both aerobic exercise and cognitive-behavioral therapy reduce chronic fatigue in FSHD)
223858143|NCT04687085|OTHER|10 minute mindful meditation recording|10 minute mindful meditation recording
223858144|NCT06712160|DIAGNOSTIC_TEST|Artificial Intelligence|The number of canals detected by AI
223858145|NCT05052983|DRUG|Nemolizumab|Participants received either 1 \[30 milligram (mg)\] or 2 (2\*30 mg) subcutaneous (SC) injection(s) of nemolizumab every 4 weeks (Q4W) for a period of 24 weeks (with last injection at Week 20). Participants received the same dosage (1 or 2 SC injections) as received in the lead-in LTE study RD.06.SPR.202699, as assigned by interactive response technology (IRT).
223858146|NCT05052983|DRUG|Placebo|Participants received either 1 (30 mg) or 2 (2\*30 mg) SC injection(s) of placebo every 4 weeks for a period of 24 weeks (with last injection at Week 20). Participants received the same dosage (1 or 2 SC injections) as received in the lead-in LTE study RD.06.SPR.202699, as assigned by IRT.
223858147|NCT06713486|PROCEDURE|Fixed pressure obtained in the polysomnography for 28 days|home nocturnal therapy either at the fixed pressure obtained in the polysomnography for 28 days
223858148|NCT06713486|PROCEDURE|Dynamic pressure in Dreamstation AVAPS-AAM PhilipsRespironic® mode|dynamic pressure in Dreamstation AVAPS-AAM PhilipsRespironic® mode (program B) for 28 days, using the apnea threshold obtained in the titration as the maximum EPAP pressure and adjusting the support pressure for inferred Vt to 8 ml/kg of ideal body weight. After the first 28 days, a polysomnography will be performed under therapy with the device, and the next morning, cycle ergometry will be conducted.
223858149|NCT06713395|OTHER|The control group received standard postoperative care|standard postoperative care
223858150|NCT06713395|OTHER|PERMA|"1. Establishment of the Integrated Psychological Intervention Team:~   The team consisted of 2 primary nurses, 4 specialist nurses, 1 psychologist, 2 physicians at the attending level or higher, and 2 researchers.~   Team Responsibilities: The primary and specialist nurses were responsible for implementing the intervention protocol. The physicians handled any adverse reactions experienced by the patients. The researchers were in charge of developing the intervention protocol and collecting data. All team members were required to undergo specialized training from the psychologist and pass an assessment before initiating the intervention.~2. Protocol Development:~   The intervention protocol, including specific content, team responsibilities, implementation process, and responses to adverse events, was carefully developed in written form by the researchers. The protocol was discussed and approved by all team members before implementation.~3. Protocol Implementation:~Emotional Support Intervention:"
223858151|NCT03425643|BIOLOGICAL|Pembrolizumab|200 mg by IV infusion every 3 weeks (Q3W), given on cycle day 1.
223858152|NCT03425643|DRUG|Placebo|Normal saline by IV infusion Q3W, given on cycle day 1.
223858153|NCT03425643|DRUG|Cisplatin|75 mg/m\^2 by IV infusion Q3W, given on cycle day 1.
223858154|NCT03425643|DRUG|Gemcitabine|1000 mg/m\^2 by IV infusion Q3W, given on cycle days 1 and 8. Given only to participants with squamous NSCLC.
223858155|NCT03425643|DRUG|Pemetrexed|500 mg/m\^2 by IV infusion Q3W, given on cycle day 1. Given only to participants with nonsquamous NSCLC.
223858156|NCT04133363|PROCEDURE|Ridge preservation using L-PRF/FDBA layered technique|Atraumatic tooth extraction following by socket grafting using L-PRF/FDBA layered technique
223858157|NCT04133363|PROCEDURE|Ridge preservation using L-PRF/FDBA|Atraumatic tooth extraction following by socket grafting using L-PRF/FDBA
223858158|NCT04133363|PROCEDURE|Ridge preservation using L-PRF|Atraumatic tooth extraction following by socket grafting using L-PRF
223858159|NCT05144217|DRUG|Placebo|1 capsule per day of placebo
223858160|NCT05144217|DRUG|2x 140 mg per day|2 capsule per day of silimarit
223858161|NCT05144217|DRUG|3x 280 mg per day|3 capsule per day of silimarit
223858162|NCT05144217|DRUG|1x 1120 mg|8 capsule per day of silimarit
223858163|NCT05866016|BEHAVIORAL|Skill birth attendant training|It is an intervention targeted to enhance the competencies of Maternal Neonatal Health (MNH) service providers (skilled birth attendants) in Nepal. It is a capacity-building intervention that is expected to contribute to reducing maternal and neonatal morbidities and mortalities by improving the midwifery competencies (knowledge, attitudes, and skills) of MNH service providers.
223858164|NCT03315507|DRUG|PB1046 Subcutaneous Injection|Eight weekly doses of PB1046.
223858165|NCT01254981|PROCEDURE|Percutaneous coronary intervention (PCI)|Implantation of coronary stent
223858166|NCT00238446|DRUG|EC-MPS|
223858167|NCT04415333|DRUG|Sodium Butyrate 5 mmol|Enema-based delivery of 5 mmol butyrate in 0.9% saline, (60 mL total)
223858168|NCT04415333|DRUG|Sodium Butyrate 80 mmol|Enema-based delivery of 80 mmol butyrate in 0.9% saline, (60 mL total)
223858169|NCT04969991|DRUG|Varespladib|250 mg immediate-release oblong, white, film-coated tablet for oral administration
223858170|NCT04969991|DRUG|Placebo|Oral formulation matched to the oral varespladib tablet
223858171|NCT06362759|DRUG|TOUR006 - 50 MG|TOUR006 50 MG
223858172|NCT06362759|DRUG|TOUR006 - 25 MG|TOUR006 25 MG
223858173|NCT06362759|DRUG|TOUR006 - 15 MG|TOUR006 15 MG
223858174|NCT06362759|OTHER|Placebo|Placebo
223858175|NCT06479889|BEHAVIORAL|Guardians receiving counseling + lock|Guardians of patients admitted to the Pediatric Hospital Medicine behavioral health team will be provided a brief lethal means educational session and offered up to 3 secure storage devices of their choosing (lock box and or cable locks)
223858176|NCT04822753|PROCEDURE|Platelet Rich Plasma injection to the lumbar facet joint|Using standard fluoroscopic view, place a needle at the target facet joint. Inject about 1ml of study injectate.
223858177|NCT03030495|DEVICE|Comprehensive physiologic evaluation|Comprehensive physiologic evaluation using pressure-temperature sensor wire to measure fractional flow reserve, coronary flow reserve, index of microcirculatory resistance
223858178|NCT03030495|DEVICE|Intravascular imaging devices|Intravascular ultrasound or optical coherence tomography
223858179|NCT03645031|OTHER|Acute Intermittent Hypoxia|AIH entails continuous breathing as the level of oxygen in the air is decreased, then returned to normal. Participants will alternate between breathing normal air and breathing hypoxic air (air that has less oxygen). Participants will complete a single 45 minute session of acute intermittent hypoxia (AIH). Breathing, muscle activity and heart activity will be monitored before, during and after the procedure. The intervals will last 1 minute each.
223858180|NCT03645031|OTHER|Sham Acute Intermittent Hypoxia|Participants will complete the sham acute intermittent hypoxia, consisting of a single 45 minute session of breathing air with normal oxygen levels. All aspects of this procedure will otherwise be the same as for the AIH procedure. Breathing, muscle activity and heart activity will be monitored before, during and after the procedure.
223858181|NCT05138601|OTHER|Virtual Collaborative Care Clinic|Trained clinical pharmacists will monitor BP, prescribe and adjust medications and monitor for side effects of medications under the license of, and in communication with, the patient's physician.
223858182|NCT06831669|OTHER|Collecting biospecimens|Collecting blood, urine, tissue, and faecal samples
223858183|NCT04199728|DRUG|Liraglutide Pen Injector|Liraglutide will be provided using an injection pen provided by the manufacturer
223858184|NCT04199728|DRUG|Placebo|Placebo injection pen
223858185|NCT05543057|RADIATION|3DCRT|Three-dimensional conformal radiotherapy (3DCRT)
223858186|NCT00482729|DRUG|sitagliptin phosphate (+) metformin hydrochloride|sitagliptin/Metformin HCl 50/500 mg tablet bid, titrating up to sitagliptin/Metformin HCl 50/1000 mg tablet over 4 weeks; for a 44-wk treatment period.
223858187|NCT00482729|DRUG|metformin|metformin 500 mg tablet bid, titrating up to 1000 mg tablets bid for a 44-wk treatment period
223858188|NCT04487600|OTHER|Active voiding trial|
223858189|NCT02328963|DRUG|Everolimus|"Everolimus : 0.75 bid, targeted to 3-8 ng/ml~Cyclosporin A :~CsA target ranges for Arm 1 will be 100-200 ng/mL from Day 3 to Month 2, decreasing to 75-150 ng/mL from Month 2 to Month 4 and 25-50 ng/mL from Months 6 to 12.~Corticosteroids :~Méthylprednisolone: 500 mg at Day 0, 120 mg à Day 1. Prednisone or equivalent: 20 mg/d from Day 3. Corticosteroid dosing will be tapered according to center standard practice but to not less than 5 mg per day for the duration of the 12-month study~Basiliximab :Day 0: 20 mg ; Day 4: 20 mg"
224266224|NCT05870215|OTHER|Visit 1: Respiratory physiology|FeNO measurement (NIOX VERO device), pre/post-bronchodilator oscillometry (Tremoflo), and spirometry (including forced expiratory volume in 1 second (FEV1) reversibility, FEV1/FVC, peak expiratory flow).
224266225|NCT05870215|OTHER|Visit 1: Inflammometry|Nasosorption with nasal epithelial lining fluid (NELF), nasal swab for ultrarapid SARS-CoV2 molecular test (ID NOW), nasopharyngeal swab for rapid multiplex PCR viral (BIOFIRE), nasal cytology brushes, blood tests (complete blood count with differential, C-reactive protein, total and specific serum immunoglobulin E, biobank), capillary blood eosinophils (Sight OLO), urine sample (creatinine, biobank), chest x-ray
224266226|NCT05870215|OTHER|Visit 2: Clinical exam and questionnaires|Medical history and examination, including vital signs, symptom scores (ACQ-5, mMRC), visual analog scale (VAS) for six respiratory symptoms, Hospital Anxiety and Depression Scale, satisfaction questionnaire about point-of-care biomarker measurements, satisfaction questionnaire about point-of-care biomarker measurements: letter and email sent to treating doctor.
223858190|NCT02328963|DRUG|mycophenolic acid|"Mycophenolic acid :~1080 mg bid for one month, then 720 mg bid~Cyclosporin A :~CsA target ranges for Arm 1 will be 100-200 ng/mL from Day 3 to Month 2, decreasing to 75-150 ng/mL from Month 2 to Month 4 and 25-50 ng/mL from Months 6 to 12.~Corticosteroids :~Méthylprednisolone: 500 mg at Day 0, 120 mg à Day 1. Prednisone or equivalent: 20 mg/d from Day 3. Corticosteroid dosing will be tapered according to center standard practice but to not less than 5 mg per day for the duration of the 12-month study~Basiliximab :Day 0: 20 mg ; Day 4: 20 mg"
223858191|NCT05721924|PROCEDURE|Pericapsular nerve group (PENG) block|In PENG group, the patient will be given PENG block 30mls of 0.2% ropivacaine
223858192|NCT05721924|PROCEDURE|Supra-inguinal fascia iliaca compartment (S-FICB) block|Patients in group B (S-FICB group) will be supra-inguinal fascia iliaca compartment block 30mls of 0.2% ropivacaine
223858193|NCT02234128|DEVICE|Toronto EVLP System™|Extending preservation and assessment time of donor lungs using the Toronto EVLP System
223858194|NCT06093386|OTHER|Intensive Transition Support|Participants assigned to the intervention arm will transfer their transition support leadership to a transition team composed of a transition navigator (an advance practice nurse), a nurse navigator (a registered nurse) and a social worker over 2 years to support them through the multiple phases of CMC transitions including guidance, monitoring, planning, care transfer and transfer completion. CMC and their caregivers will be offered support in care planning, receiving funding, and connecting with a primary care provider and adult subspecialists.
223858195|NCT05618236|DRUG|Group N; neostigmine+atropine|"The patients included in the study will be divided into 2 groups according to the agent used in decurarization. There is no condition for the number of patients in the group to be equal. Group N; neostigmine+atropine, GROUP S; This will be the group of patients decurarized with sugammadex.~0-45 days after patients are extubated. And at the 2nd hour, FLACC Scale (Pain Diagnostic Scale), PAED (Pediatric Anesthesia Recovery Delirium) Scale assessment methods will be compared in terms of pain and agitation. Nausea and vomiting will be noted as yes/no."
223858196|NCT05618236|DRUG|GROUP S; decurarized with sugammadex.|"The patients included in the study will be divided into 2 groups according to the agent used in decurarization. There is no condition for the number of patients in the group to be equal. Group N; neostigmine+atropine, GROUP S; This will be the group of patients decurarized with sugammadex.~0-45 days after patients are extubated. And at the 2nd hour, FLACC Scale (Pain Diagnostic Scale), PAED (Pediatric Anesthesia Recovery Delirium) Scale assessment methods will be compared in terms of pain and agitation. Nausea and vomiting will be noted as yes/no."
223858197|NCT01708499|DEVICE|Ulthera System Treatment|Focused ultrasound energy delivered below the surface of the skin
223858198|NCT01573598|DRUG|Placebo|Matching placebo given orally, once per day
223858199|NCT01573598|DRUG|Vilazodone|Vilazodone, 20 mg per day, oral administration
223858200|NCT01573598|DRUG|Vilazodone|Vilazodone, 40 mg once per day, oral administration
223858201|NCT03710057|DRUG|Ivabradine|A prospective, post-marketing observational study was conducted in National Institute of cardiovascular disease, Karachi-Pakistan. Total 50 patients were advised to take 5 mg Ivabradine (SIVAB) twice daily for 8 weeks.
223858202|NCT03430414|DIAGNOSTIC_TEST|Transcriptome Analysis|Transcriptome Analysis of Formalin Fixed Paraffin Embedded biopsies
223858203|NCT04271449|DEVICE|tDCS (transcranial direct current stimulation)|"Non invasive functional brain stimulation that allows to modulate the excitability of a targeted area (inhibitory or excitatory) thanks to a small current that goes beyond two electrodes. For this arm, the targeted are will be the cerebellum.~Prismatic googles will also be used in the same way in all groups during prism exposure."
223858204|NCT04271449|BEHAVIORAL|Virtual reality device|"Non invasive functional brain stimulation that allows to modulate the excitability of a targeted area (inhibitory or excitatory) thanks to a small current that goes beyond two electrodes. For this arm, the targeted are will be the cerebellum.~Prismatic googles will also be used in the same way in all groups during prism exposure."
223858205|NCT04271449|DEVICE|tDCS (transcranial direct current stimulation)|"Non invasive functional brain stimulation that allows to modulate the excitability of a targeted area (inhibitory or excitatory) thanks to a small current that goes beyond two electrodes. For this arm, the targeted are will be either the cerebellum or the primary motor cortex, but the stimulation will be turned off after 15 seconds to insure a sham condition.~Prismatic googles will also be used in the same way in all groups during prism exposure."
223858206|NCT03980873|BEHAVIORAL|ESTEEM (Effective Sikills to Empower Effective Men)|"ESTEEM (Effective Skills to Empower Effective Men) is a 10-session intervention based on the Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders (Barlow et al., 2010).~Is an individually-delivered cognitive behavioral treatment with efficacy for reducing stress-sensitive mental health disorders (e.g., depression, anxiety) by enhancing emotion regulation abilities; reducing maladaptive cognitive, affective, and behavioral avoidance patterns; and improving motivation and self-efficacy for enacting behavior change"
223858207|NCT00019669|BIOLOGICAL|aldesleukin|
223858208|NCT00019669|BIOLOGICAL|fowlpox virus vaccine vector|
223858209|NCT00019669|BIOLOGICAL|gp100 antigen|
223858210|NCT04152616|OTHER|Instrumental evaluation of posture|"After a time of installation of the Optitrack® device's and two accelerometers (one placed on the subject's trunk facing the sternum fixed with a headband and the second at the level of the head also held with a headband), the subject will perform an evaluation of the balance sitting on the sensor pad; the movements of the head and trunk will be analyzed by the Optitrack® device and by the two accelerometers.~The subject will perform 4 30-second tests, two with eyes open and two with eyes closed. A rest period may be taken between each assessment depending on the subject.~During these evaluations, a physiotherapist will be present to avoid the risk of falling.~After a rest period of 30 minutes, a new assessment of the sitting posture will be carried out to assess the reproducibility of the tools (sensor pad, accelerometers, Optitrack®)."
223858211|NCT03635294|OTHER|Blood sample|combining genomics, transcriptomics, metabolomics and morphological analyses performed on induced pluripotent stem cell (iPSC)-derived neural cells
223858212|NCT04074902|DEVICE|Ultrasonography|Mindray dp1100 plus.
223858213|NCT04456543|PROCEDURE|pressure monitoring|garment pressures were monitored using the portable pressure measuring device and the compression garment was adjusted so that the pressure was maintained at the therapeutic range of 15 - 25 mmHg.
223858214|NCT02628093|DEVICE|THUNDERBEAT|Tissue dissection and vessels ligation
223858215|NCT02628093|DEVICE|LIGASURE|Tissue dissection and vessels ligation
223858216|NCT06134466|DIETARY_SUPPLEMENT|Liquid Extensively hydrolyzed cow's milk protein infant formula|Liquid Investigational Formula (Extensively hydrolyzed cow's milk protein infant formula) 2.8 g protein/100 kcal
223858217|NCT03749590|DRUG|Magnesium Sulfate|Patients receive 2 infusions (10 ml magnesium sulfate added to 500 ml NaCl 0.9%): the first infusion 60 min before and the second one 6 hours after ERCP
223858218|NCT03749590|DRUG|Placebo (NaCl 0,9%)|Patients receive 2 infusions (10 ml NaCl 0.9% added to 500 ml NaCl 0.9%): the first infusion 60 min before and the second one 6 hours after ERCP
223858219|NCT04368858|DIAGNOSTIC_TEST|Exploratory physiopathology study, including non-invasive functional explorations carried out in patients with chronic pathology.|In the Mobility Exploration Unit of the University Hospital of Clermont-Ferrand, patients with chronic illnesses undergo a complete assessment of their physical capacities as well as their nutritional status. For the purpose of this protocol, patients will have to perform 2 functional tests, namely the TM6 and the TUG, while being equipped with inertial sensor units (mTUG® and mGAIT®). The data of the gait analysis, posturography and strength analyses as well as the questionnaires' scores will be taken into account in this research. At 6 months and at 1 year, occurrence of a fall will be recorded in order to prospectively monitor this parameter.
223858220|NCT00190008|DRUG|piracetam|
223858221|NCT06552702|OTHER|There is no intervention|There is no intervention.
223858222|NCT02740686|OTHER|Sample collection|Frequent exacerbators and infrequent exacerbators will have blood and sputum samples obtained around pulmonary rehabilitation. No other intervention will be administered. Healthy controls will have resting blood samples taken.
223858223|NCT03865758|DEVICE|IN2L computer system|Therapists will use the IN2L computer system to choose videos, music, games and exercise specific to the rehabilitation needs and personal preferences of patients.
223858224|NCT00003339|BIOLOGICAL|gp100 antigen|
223858225|NCT00003339|BIOLOGICAL|incomplete Freund's adjuvant|
223858226|NCT00003339|BIOLOGICAL|recombinant interleukin-12|
223858227|NCT00003339|BIOLOGICAL|tyrosinase peptide|
223858228|NCT05918159|OTHER|Sarcopenia Assessment|The prevalence of sarcopenia in a group of elderly people and its correlation with other health variables was determined.
223858229|NCT04672772|DRUG|Cetuximab|Weekly cetuximab at starting dose, that could be switched to biweekly
223858230|NCT04672772|DRUG|Paclitaxel|Paclitaxel at starting dose of 80 mg/m2
223858231|NCT04505813|BIOLOGICAL|NEXI-002 T Cells|The NEXI-001 T cell product will be administered as a single IV infusion to patients within 72 hours after completing LD therapy.
223858232|NCT06416202|DEVICE|Advanced hybrid closed loop insulin pump|All groups will receive comprehensive diabetes education and extensive carbohydrate counting training. Continuous glucose monitoring (CGM) will be conducted using the Guardian 4 sensor or Dexcom G6 for the intervention group depending on the type of pump used. fructosamine levels for all patients will be checked both before and after Ramadan to provide a more immediate assessment of glycemic control.
223858233|NCT06416202|OTHER|Open Loop Insulin Delivery system|the control group will continue using their current CGM device. Data on glycemic control, hypoglycemic events, and patient satisfaction will be collected before and throughout Ramadan. Additionally, fructosamine levels for all patients will be checked both before and after Ramadan to provide a more immediate assessment of glycemic control.
223858234|NCT04431934|DIETARY_SUPPLEMENT|PROBIOTIC|"Participants assigned to the probiotic arm will receive 2 sachets of Vivomixx® dissolved in 50 L of warm water (according to the manufacturer indications) every 12 h orally or through a nasogastric tube (in this case the tube will be flushed with 50 mL of water after the administration). The probiotic will be started 24 h after the last dose of NAA and will be administered for 14 consecutive days. Each sachet of Vivomixx® contains a combination of 4 Lactobacillus (L. paracasei 24733, L. acidophilus 24735, L. delbrueckii ssp bulgaricus 24734, L. plantarum 24730), 3 Bifidobacteria (B. brief 24732, B. longum 24736, B. infantis 24737), and Streptococcus thermophilus 24731 at a concentration of 450 billion (45x1010) live lyophilized bacteria per sachet."
223858235|NCT04431934|DIETARY_SUPPLEMENT|FMT REGIMEN|The FMT preparation will be administered as 2 doses, once a week, of 14-17 capsules per dose. Each dose (14-17 capsules) will contain the fecal microbiota equivalent to 50 gr of stools from a healthy donor. If the patient is carrying a nasogastric tube, the content of capsules will be decapsulized (\~27 gr of powder), diluted in 50 mL of water and passed through it, followed by the administration of 50 mL of water to flush the tube. The first dose will be administered 24 h after the last dose of NAA and the second dose one week later. Whenever possible, the two doses of FMT will be originated from the same donor. According to our data done by flow cytometry and bacterial culture in three replicates, each absorbate capsule contains approximately 1.12x1010 live bacteria.
223858236|NCT02631148|DRUG|Melatonin|2mg controlled release melatonin tablet
223858237|NCT02631148|DRUG|Placebo|placebo tablet identical to circadin
223858238|NCT00490685|DRUG|Sorafenib (BAY-43-9006)|
223858239|NCT03503084|BEHAVIORAL|Classical Yang's TCC exercise|
223858240|NCT05752136|BIOLOGICAL|Envafolimab|This product is administered by subcutaneous injection. The recommended dose of subcutaneous injection is 150 mg, administered weekly (QW).
223858241|NCT03657017|DIAGNOSTIC_TEST|PET/MR|Performed on a hybrid PET/MR scanner before treatment start (N = 150). Among those patients, 10 patients are examined with PET/MR in the completion of neoadjuvant chemotherapy and a follow-up scan three months after the completion of radiotherapy.
223858242|NCT01256736|DRUG|Tocilizumab|intravenously at dose of 8mg/kg over 1 hour infusion every 4weeks
223858243|NCT01256736|DRUG|DMARDs|DMARDs(chloroquine, hydroxychloroquine, parenteral gold, sulfasalazine, azathioprine, and leflunomide)
223858244|NCT02391207|PROCEDURE|Hepatic vein-sparing hepatectomy|HV detachment, partial resection and section on the basis of HV-CLM relationship
223858245|NCT00168662|BIOLOGICAL|Measles and inactivated polio vaccine|
223858246|NCT03919864|BEHAVIORAL|CONNECT Intervention|Participants will be included in a multi-component e-tool with brief educational videos, an assessment of multidimensional supportive care needs, a tailored resource list and an optional automated referral to a caregiver navigator. Two weeks after baseline participants will receive re-education and an optional referral.
223858247|NCT03919864|BEHAVIORAL|CONTROL Group|Participants will receive a generic printed list of hospital, community, and national supportive care resources.
223858248|NCT01465724|PROCEDURE|Renal denervation|percutaneous selective renal sympathetic denervation with the use of the Symplicity Catheter system.
223858249|NCT02576821|OTHER|Neurological examinations|
223858250|NCT02576821|OTHER|Neuropsychological examinations|
223858251|NCT02576821|OTHER|Clinical examinations|
223858252|NCT02576821|RADIATION|MRI 3T|
223858253|NCT02576821|RADIATION|MRI 7T|
223858254|NCT04383730|DRUG|Intravenous sedation|Patients will be included retrospectively in the study by local investigators at each participating center. As this is a non-interventional study, sedation practices will be those currently used as standard practices in participating centers, including both intravenous and inhaled sedation practices
223858255|NCT04383730|DRUG|Inhaled sedation|Patients will be included retrospectively in the study by local investigators at each participating center. As this is a non-interventional study, sedation practices will be those currently used as standard practices in participating centers, including both intravenous and inhaled sedation practices
223858256|NCT01271517|DRUG|NPH insulin|Treatment twice daily with Insulatard plus Novorapid at meals. Doses adjusted according to bloodsugar
223858257|NCT01271517|DRUG|Glargine|Treatment once daily with Lantus plus Novorapid at meals. Doses adjusted according to bloodsugars
223858258|NCT01271517|DRUG|Detemir|Treatment twice daily with Levemir plus Novorapid at meals. Doses adjusted according to bloodsugars
223858259|NCT04002973|DEVICE|INVSENSOR00037|Noninvasive regional oximeter.
223858260|NCT00487578|DRUG|naratriptan HCl|naratriptan 2.5mg tablet bid x 30 days OR matching placebo
223858261|NCT03458546|DRUG|Roflumilast|All patients will receive R-CHOP therapy at standard doses according to the standard preparation and infusion procedures of each investigational site, which is to be repeated every 21 days for a total of 6 cycles. All patients will receive a fixed oral dose of one 500 microgram (μg) tablet per day with or without food for all 21 days of each cycle, which will amount to a total of 126 doses of roflumilast.
223858262|NCT04663464|COMBINATION_PRODUCT|abaloparatide-sMTS|Single-dose administration of abaloparatide 300 μg applied to the thigh for 5 minutes
223858263|NCT04663464|COMBINATION_PRODUCT|abaloparatide-SC|Single-dose administration of abaloparatide 80 μg subcutaneous injection to the periumbilical region of the abdomen
223858264|NCT04745663|DRUG|Povidone-Iodine 0.3%|Low concentration iodine
223858265|NCT04745663|DRUG|Povidone-Iodine 5%|Standard concentration iodine
223858266|NCT03233919|DEVICE|comprehensive remote ischaemic conditioning|"comprehensive remote ischaemic conditioning will be induced using an automated RIC device: Per-RIC consists of 5 cycles of 5-min inflation (200 mmHg) and 5-min deflation of cuff on a lower limb. The first inflation began immediately following randomization after admission. In case 5 cycles of RIC were not fully completed when the first balloon inflation or thrombus aspiration was ready to be performed, PCI was not to be delayed.~Post-RIC consists of 5 cycles of 5-min inflation (200 mmHg) and 5-min deflation of cuff on a lower limb immediately after PPCI.~Delayed-RIC consists of 5 cycles of 5-min inflation (200 mmHg) and 5-min deflation of cuff on a lower limb once daily on 2-28 days after MI."
223858267|NCT02378714|DRUG|Varenicline|Participants will be randomly assigned to 12 weeks of either placebo or varenicline medication (1mg twice daily). Participants and research personnel will be blind to treatment assignment.
224266227|NCT05870215|OTHER|Visit 2: Respiratory physiology|FeNO measurement (NIOX VERO device), pre/post-bronchodilator oscillometry (Tremoflo), and spirometry (including forced expiratory volume in 1 second (FEV1) reversibility, FEV1/FVC, peak expiratory flow).
224266228|NCT05870215|OTHER|Visit 2: Inflammometry|SARS-CoV2 Test (ID NOW), nasosorption, nasal cytology brushes, blood tests (complete blood count with differential, C-reactive protein, biobank), capillary blood eosinophils (Sight OLO), urine sample (creatinine, biobank)
224266229|NCT05870215|OTHER|Visit 3: e-mail|ACQ-5, peak flow measurement, and questions about the patient's asthma management.
224266230|NCT02575456|BIOLOGICAL|Ebola Vaccine|
224266231|NCT02575456|BIOLOGICAL|Placebo|control
224266232|NCT00487435|DRUG|Tapentadol (CG5503) Extended Release (ER)|100, 150, 200, 250 mg oral tablet twice daily for 52 weeks
224266233|NCT02426450|PROCEDURE|RFA|"RFA:~RFA was performed by using a commercially available system (RF 2000; Radio-Therapeutics Mountain View, CA), and a needle electrode with a 15 Ga insulated cannula with 10 hook-shaped expandable electrode tines with a diameter of 3.5 cm at expansion (LeVeen; RadioTherapeutics)."
224266234|NCT02426450|DRUG|Oxaliplatin|4 weeks after RFA; Drug: Oxaliplatin Day 1: Oxaliplatin 85mg/m² 2h IV infusion. Repeated every 2 weeks
224266235|NCT02426450|DRUG|5-Fluorouracil/Leucovorin|"4 weeks after RFA; Drug: 5-Fluorouracil/Leucovorin Day 1, after Oxaliplatin 85mg/m² 2h IV infusion: Leucovorin 200mg/m² 2h IV infusion, 5-fluorouracil 400mg/m² IV bolus, 5-fluorouracil 600mg/m2 22h IV infusion.~Day 2: Leucovorin 200mg/m² 2h IV infusion, 5-fluorouracil 400mg/m² IV bolus, 5-fluorouracil 600mg/m² 22h IV infusion.~Repeated every 2 weeks"
224266236|NCT01355835|DEVICE|deep brain stimulation (ACTIVA PC, Medtronic)|High frequent deep brain stimulation with variable (best individual) stimulation on subthalamic contacts and standard parameters on nigral contacts (125 Hz, 60µs, best individual amplitude)
224266237|NCT04193150|DIAGNOSTIC_TEST|Full pulmonary specialist assessment|Please see description for the intervention arm.
224266238|NCT02581527|DRUG|Rifampicin|Rifampicin 150mg (Control arm); Rifampicin 1200mg (Regimen 1); Rifampicin 1800mg (Regimen 2)
224266239|NCT02581527|DRUG|Isoniazid|Isoniazid 75mg - all arms
224266240|NCT02581527|DRUG|Ethambutol|Ethambutol 275mg - all arms
224266241|NCT02581527|DRUG|Pyrazinamide|Pyrazinamide 400mg - all arms
224266242|NCT04797936|DRUG|BNO 1030|Imupret 25 drops х 6 times per day for 14 days
224266243|NCT04797936|OTHER|Standard care|isolation mode symptomatic therapy as needed: antipyretic (paracetamol) saline solutions in the nose x 4 times a day -14 days
224266244|NCT06627634|PROCEDURE|Metastatectomia and standard treatment for resectable disease.|Rather than palliative chemotherapy, the intervention offered to participants is preoperative chemotherapy, resection of primary tumour and metastatectomia of oligometastatic spread to the liver. If fit for post-operative chemotherapy, this is offered as well.
224266245|NCT02290262|OTHER|Comprehensive phase one rehabilitation|"Patients allocated to the experimental group receive a rehabilitation programme consisting of physical exercise and psycho-education.~The physical exercises consist of; breathing exercises with and without using incentive spirometry with expiratory positive pressure airway, walking and cycling exercises and neck/shoulder exercises during hospitalisation and an exercise programme running from discharge until 4 weeks following surgery. The psycho-educative rehabilitation programme consists of four psycho-educative consultations with a specially trained nurse."
224266246|NCT01663662|DRUG|Tolvaptan|
224266247|NCT01663662|DRUG|placebo|
224266248|NCT06298162|OTHER|2 years after RYGB, no intervention. MRI measurement. Observational.|no intervention. MRI measurement. Observation.
224266249|NCT01127113|OTHER|Infusion of investigational product|The investigational product will be delivered via intravenous infusion
224266250|NCT01127113|OTHER|Cardiac magnetic resonance imaging|Cardiac MRI will be performed prior to infusion of investigational product and 1, 2, 7 and 30 days after.
223858268|NCT02378714|BEHAVIORAL|BASC|"The goal of behavioral activation therapy is to increase engagement in rewarding activities, a problem for smokers with depression who find smoking especially rewarding and prefer it over many other traditionally rewarding activities, by reducing patterns of behavioral avoidance, withdrawal, and inactivity. In this study, behavioral activation will be integrated with standard behavioral smoking cessation treatment.~Treatment will be delivered in eight 45-minute sessions over 12 weeks occurring weekly for the first four sessions and biweekly for the final four sessions."
223858269|NCT02378714|BEHAVIORAL|Standard treatment|Standard behavioral smoking cessation treatment is an effective treatment for nicotine dependence. Treatment focuses on self-monitoring of smoking behavior, identifying smoking triggers and alternative trigger management strategies, relaxation, social support for non-smoking, and relapse prevention. Treatment will be delivered in eight 45-minute sessions over 12 weeks occurring weekly for the first four sessions and biweekly for the final four sessions.
223858270|NCT04775290|BEHAVIORAL|Yoga lessons|2 weekly yoga classes during the 5 weeks of radiotherapy
223858271|NCT02525796|DRUG|eplerenone|eplerenone, titrated up to a maximum of 50mg BID
223858272|NCT02525796|DRUG|amiloride|amiloride, titrated up to a maximum of 10mg BID
223858273|NCT02525796|DRUG|Placebo|
223858274|NCT02525796|DRUG|Cinacalcet|Cinacalcet, as add-on therapy in addition to eplerenone/amiloride/placebo, titrated up to a maximum of 30mg BID
223858275|NCT05538455|DEVICE|PC4L solutions|Two different versions of the PC4L system will be tested. A fully equipped version and a cloud-based system that requires only a smartphone and a wearable sensor (Fitbit Versa 2). 25% of participants will use the full system, the remaining 75% will use the cloud-based system. As part of the decision support system, the PC4L platform includes a recommendation component. This component collects information from different sources available (directly from sensors, cognitive games, questionnaires, and the multimodal fusion engine), and under clinical and professional guidance, after evaluating the potential improvement or worsening of patients' conditions, issues personalized recommendations to address identified problems. The recommendations relate to the following areas: physical activities; sleep; cognitive; nutrition. These recommendations will generally be sent to the PC4L application on the patients' smartphone, where they will appear as pop-up notifications.
223858276|NCT03802032|DRUG|Lidocaine Gel|topical lidocaine gel
223858277|NCT03802032|DRUG|KY jelly|topical KY jelly
223858278|NCT02001818|DRUG|Nilotinib, Pegylated interferon alpha-2b, Imatinib|All patients joining the study will receive treatment with oral nilotinib at 300mg twice daily. This will be given as monotherapy for 3 months initially, prior to commencement of combination therapy with Pegylated interferon alpha-2b added to nilotinib. Patients intolerant of nilotinib will have the option of switching to imatinib.
223858279|NCT00001318|DRUG|interferon gamma|
223858280|NCT00785863|OTHER|Placebo|Placebo IV before placebo infusion
223858281|NCT00785863|DRUG|Remifentanil|placebo IV and remifentanil infusion
223858282|NCT00785863|DRUG|Ketorolac and remifentanil|Ketorolac IV and remifentanil infusion
223858283|NCT00785863|DRUG|Parecoxib and remifentanil|Parecoxib IV and remifentanil infusion
223858284|NCT05111483|OTHER|Tupler technique|"The subjects with DRA will receive Tupler's technique treatment plan for 18 weeks in which four steps will be followed.~1. Repositioning with diastasis rehab splint :~2. Protect the connective tissue~3. Tupler's technique exercises (elevators, contractions, standing pelvic tilt, head lifts, leg slides, low back stretch) with 10 repetitions for each exercise.~4. Diastasis safe exercises program to maintain the gains"
223858285|NCT05111483|OTHER|conventional therapy|"The subjects with DRA will receive conventional physical therapy treatment for 16 weeks in which researcher will follow these steps:~1. Tie a scarf around abdomen while performing exercises~2. Exercise program for diastasis recti abdominal muscles; sit ups, reverse sit ups, reverse trunk twist and U-seat exercises. (10 repetitions for each exercise)~3. Respiratory rehabilitation manoeuvre"
223858286|NCT02227771|DEVICE|Percutaneous coronary intervention|
223858287|NCT01499134|DRUG|nebivolol|Study medication will initially be dispensed as one capsule daily and the dose will be titrated at the study visits. Nebivolol is approved for hypertension treatment at a dose of 5-40 mg daily. Based on the study titration schedule, the maximum doses used will be 20 mg of nebivolol (each maximum dose being contained in 4 capsules for daily dosing).
223858288|NCT01499134|DRUG|Metoprolol succinate|Study medication will initially be dispensed as one capsule daily and the dose will be titrated at study visits. Metoprolol succinate at 25-400 mg daily. Based on the study titration schedule, the maximum dose used will be 200 mg of metoprolol succinate (each maximum dose being contained in 4 capsules for daily dosing).
223858289|NCT01820195|DRUG|Oral N-Acetyl Cystein|Oral N-Acetyl Cystein 600 mg bid started the day before contrast administration and continue the day after exposure to contrast
223858290|NCT01820195|DRUG|IV N-Acetyl Cystein|Bolus IV administration of 1200 mg N- Acetyl Cystein half an hour before contrast media administration
223858291|NCT01820195|DRUG|Placebo group|The patients in this group will be received both oral placebo and IV placebo
223858292|NCT02546219|OTHER|Eosinophil isolation and characterization.|Peripheral blood and esophageal biopsies will be obtained from study subjects for further analysis of eosinophils integrin profiles.
223858293|NCT03107962|DRUG|Pembrolizumab (PD-1 Blocking Antibody)|pembrolizumab 2mg/kg, ivgtt (intravenously guttae), d1. Every three weeks for one cycle and two cycles are required at least. Efficacy and safety were evaluated every two cycles.
223858294|NCT01091298|BIOLOGICAL|Live Attenuated Tetravalent (G1-G4) Bovine-Human Reassortant Rotavirus Vaccine (BRV-TV)|Single dose (0.5 mL) of the vaccine administered orally
223858295|NCT01091298|OTHER|Placebo|Single dose (0.5 mL) of the placebo administered orally
223858296|NCT01701453|DRUG|P2Y12 inhibitor (clopidogrel, ticagrelor, prasugrel)|P2Y12 inhibitor (clopidogrel, ticagrelor, prasugrel)
223858297|NCT01495936|PROCEDURE|RM + Positive End Expiratory Pressure|A recruitment maneuver (RM) will be applied to the ventilated lung by performing a valsalva maneuver for 5 seconds (holding the inspiratory pressure at 25cmH2O). Immediately after the RM, Positive End Expiratory Pressure (PEEP) will be applied to the ventilated lung at a pressure of 5cmH2O for 20 minutes. Both the RM and PEEP will be performed using the operating room ventilator.
223858298|NCT01495936|PROCEDURE|Continuous Positive Airway Pressure|Continuous positive airway pressure, at a pressure of 5cmH2O will applied to the non-ventilated lung for 20 minutes by the Mallinckrodt Bronchocath Disposable CPAP system (a recognised anesthetic breathing system design for CPAP)
223858299|NCT01198275|DRUG|n-3 PUFAs|1.0 g of EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid) in the average ratio EPA/DHA of 0.19:1.5, one capsule twice a day
223858300|NCT01198275|DRUG|Placebo|1.0 g of olive oil,one capsule twice a day
223858301|NCT01198275|DRUG|RASS inhibitors and/or RAS blockers|Patients on ACE-Is or ARBs were continued on the same agent. In those who were not on therapy, an ACE-I or an ARB was started. In all patients, an effort was made to achieve the highest tolerated dose.
223858302|NCT01198275|DRUG|Amiodarone|Patients on amiodarone were continued at a maintenance dose of 200 mg daily, whereas those who were not taking amiodarone were started at a dose of 400 mg daily for 1 week and then continued on a maintenance dose of 200 mg daily.
223858303|NCT04529278|DRUG|Liraglutide|"Liraglutide is initiated at 0.6 mg / day during week S1 (initiation D1) during weekly hospitalization in the diabetology department. Then the dose of liraglutide is increased to 1.2 mg / day on week S2 (increase in dose on D8) then to 1.8 mg / day on week S3 (increase in dose on D15).~The daily dose is then 1.8 mg until week W26."
223858304|NCT00150176|DRUG|Asenapine - Open Label|Open Label Phase: All subjects received 26 weeks of open label asenapine treatment (cross titration period up to first 4 weeks, with target dose of 10 mg twice daily by week 1).
223858305|NCT00150176|DRUG|Placebo - Double Blind|Double Blind Phase: Following Open Label Phase, matching placebo sublingual twice daily for 26 weeks.
223858306|NCT00150176|DRUG|Asenapine - Double Blind|Double Blind Phase: Following the Open Label Phase, asenapine 5 or 10 mg sublingual twice daily for 26 weeks.
223858307|NCT05019417|DRUG|Glycerol Phenylbutyrate 1100 MG/ML|Daily adminisitraion of the study drug (three times a day) in escalting dose over 4 months
223858308|NCT00041548|DRUG|nitric oxide for inhalation|given at 20 ppm for 1 hour then weaned off over 4 hours
223858309|NCT00041548|DRUG|Oxygen|given at 20 ppm for one hour, then weaned off over four hours
223858310|NCT04091425|DRUG|TAK-925|TAK-925 IV infusion
223858311|NCT04091425|DRUG|Placebo|TAK-925 placebo-matching IV infusion
223858312|NCT01126112|BIOLOGICAL|Panitumumab|Panitumumab: 6 mg/Kg Q2W
223858313|NCT02618018|PROCEDURE|AT TORBI 709M|Cataract surgery with AT TORBI 709M 4-haptic toric IOL
223858314|NCT02468297|DEVICE|Electronic Acupunture Shoes|"Experiment group receives a one-hour treatment given by Electronic Acupuncture Shoes three times a week. 6 weeks of treatment was given.~Control group received the six-week treatment as well, yet the subjects received pseudo electrotherapy."
223858315|NCT02468297|DRUG|Ibuprofen|Experiment group took placebo only in the first week. Control group took ibuprofen(400mg, TID) only in the first week. No more placebo or medicine was prescribed to either two groups since the second week.
223858316|NCT02494999|BIOLOGICAL|13-valent pneumococcal conjugate vaccine|0.5ml vaccine produced by Beijing Minhai Biotechnology Co., Ltd.,three doses with 2 month interval, a booster dose 10 months after the first dose
223858317|NCT02494999|BIOLOGICAL|Prevnar 13|0.5ml vaccine produced by Wyeth,three doses with 2 month interval, a booster dose 10 months after the first dose
223858318|NCT01162876|DRUG|saxaglipitin|oral administration of 5 mg tablet before breakfast for 14 consecutive days
223858319|NCT03915340|DRUG|Propafenone|Propafenone is manufactured by Pharmtechnology LLC, Republic of Belarus. Each tablet contains 300 mg of propafenone hydrochloride.
223858320|NCT03915340|DRUG|Rytmonorm|Rytmonorm is manufactured by Famar Lyon, France (MAH: Mylan Healthcare GmbH, Germany). Each tablet contains 300 mg of propafenone hydrochloride.
223858321|NCT04442919|DRUG|Ticagrelor followed with Methoxyflurane|patients who received ticagrelor followed with inhaled methoxyflurane due to unstable angina
223858322|NCT04442919|DRUG|Ticagrelor followed with Morphine|patients who received ticagrelor followed with intravenous morphine due to unstable angina
223858323|NCT04442919|DRUG|Ticagrelor alone|patients who received ticagrelor without any analgesia due to unstable angina
223858324|NCT03624413|BEHAVIORAL|Social Media Intervention|The social media intervention is a behavioral intervention developed by the study investigators and is delivered via mobile phones. The intervention uses the Social-ecological Model of Adolescent and Young Adult Readiness to Transition (SMART) model, highlighting modifiable targets of intervention that can be addressed through a social media platform. The SMART model incorporates modifiable factors such as knowledge, skills/self-efficacy, relationships and social support that can be targets of interventions to improve transition care. The SMART model emphasizes eight modifiable factors, three key stakeholders (adolescents, caregivers, and clinicians) and their interconnected relationship in influencing successful transition to adult care. The intervention is designed to overcome barriers and enhance facilitators to transitioning care among adolescents living with HIV who are transitioning to adult care in South Africa.
223858325|NCT03624413|OTHER|Standard of Care|Standard of care transition from pediatric to adult care for HIV.
223858326|NCT02729701|DRUG|Duavee|Once daily tablet of Duavee (Bazedoxifene (20 mg) plus conjugated estrogen (0.45 mg))
223858327|NCT04753580|GENETIC|Stool collection|"The volunteer will receive the stool collection kit as well as the procedure to follow for this collection.~Treatment of stool after collection:~The stool will be treated according to the following two procedures:~i) part of the stool will be sequenced and will be stored as quickly as possible (4 hours maximum) at -80 ° C, 3 separate aliquots of 1 g; ii) the other part will be intended for implantation in rats and must be homogenized in a final concentration of 20% glycerol (2 hours maximum) and then stored at -80 ° C, 3 aliquots of 1 g."
223858328|NCT02825225|OTHER|20 core-biopsy fragments|Using the extended sextant fashion prostate biopsy, this randomized group was submitted to a 20-fragments core-biopsy to evaluate the diagnostic power, pain perception and complications comparative to institution's standard 12 cores.
223858329|NCT02825225|PROCEDURE|Base and apex local anesthesia|Using the institution's standard local anesthesia protocol (base injection) as active comparator group, this randomized group was submitted to base and apex local anesthetic application to evaluate tolerability of the procedure, pain perception (with use of previous validated analogue pain scale) and complications.
223858330|NCT02888249|OTHER|Altered composition cigarette|This double-blind study will systematically determine the abuse liability of altered composition cigarettes using a behavioral economics abuse-liability approach. Altered composition cigarettes (e.g., cigarettes differing in casings, sugars, tar levels, moisture) may result in decreased intake and decreased dependence, although critical questions remain regarding the abuse-liability of altered composition cigarettes, whether exposure to these cigarettes reduces use, and whether altered composition cigarettes will substitute for standard cigarettes. The addictive effects and abuse liability of altered composition cigarettes, therefore, are not well understood, and will be tested in this study.
223858331|NCT02835768|OTHER|Internet-based injury prevention program|"An injury prevention website serves as the Internet-based intervention providing two key topics: 1) Types of domestic injury, and 2) how to prevent different types of domestic injury. The domestic injury prevention information Home Safety Tips is divided into four subgroups according to various safety issues relevant to infants/children's age groups. Apart from a knowledge hub, the website incorporates additional functions of feedback counselling, video demonstration, online consultation, games, safety checklist and discussion forum."
223858332|NCT01623336|DRUG|BIP 48 (Peginterferon alfa 2b 48kDA)|BIP 48 (Peginterferon alfa 2b 48kDA)will be administered in a dose of 180 micrograms, once a week, subcutaneous, for 24 to 48 weeks to genotypes 2 and 3, and for 48 to 72 weeks to genotype 1.
223858333|NCT01623336|DRUG|Peginterferon alfa 2a 40kDA|Patients will receive Pegasys ® in a dosage of 180 micrograms, once a week, subcutaneous, for 24 to 48 weeks to genotypes 2 and 3 and for 48 to 72 weeks to genotype 1.
223858334|NCT01623336|DRUG|BIP 48 (Peginterferon alfa 2b 48kDA)|Patients will receive BIP 48 in a dosage of 180 micrograms, once a week, subcutaneous, for 24 to 48 weeks to genotypes 2 and 3 and for 48 to 72 weeks to genotype 1.
223858335|NCT01885845|DEVICE|Excellent BRASSS-V Drape™.|Immediately after delivery and cord clamping, blood measurement will begin. The calibrated delivery drape should be placed under the buttocks of the woman and tied around the woman's waist with the funnel portion hanging down between her legs. Blood loss will be measured for at least one hour or, if bleeding continues after one hour, until active bleeding has stopped.
223858336|NCT01885845|OTHER|Indirect weight assesment of blood loss|"Just after delivery and cord clamping, a sheet with plastic backing will be placed under the buttocks of the woman. A basin will be placed directly under her on a small shelf on the delivery table. Blood loss will be measured for at least one hour or, if bleeding continues after one hour, until active bleeding has stopped.~After bleeding has stopped, all gauze pieces and mops will be counted and then placed in the collection basin. The basin will be placed on the scale and weighed. The weight of the blood will be assessed by subtracting the weight of the basin, gauzes and mops from the total weight of the soaked materials assuming that one gram is equivalent to 1 ml."
223858337|NCT02385669|DRUG|Ipilimumab|Checkpoint blockade inhibitor
223858338|NCT02385669|BIOLOGICAL|6MHP|6 melanoma helper vaccine comprised of 6 class II MHC-restricted helper peptides
223858339|NCT05433935|OTHER|Observation|This is an observational study.
223858340|NCT02875938|BEHAVIORAL|Simultaneous music and reading lyrics|music with sung lyrics simultaneously with silent reading of the lyrics.
223858341|NCT02875938|BEHAVIORAL|Priming with music|priming with music and sung lyrics followed by reading of the lyrics.
223858342|NCT02875938|BEHAVIORAL|Control|control condition using reading materials without music.
223858343|NCT04077151|BEHAVIORAL|PrEP Demonstration Project|In phase 2, a culturally, developmentally, and gender-affirmative intervention to increase uptake of and adherence to PrEP among TW and TM youth will be developed by incorporates the PK data from phase 1 and data gathered from focus groups and in-depth interviews with young transgender women and transgender men. During phase 3, this intervention will be given to the experimental arm and tested versus a standard-of-care control group.
223858344|NCT00970307|BIOLOGICAL|GSK2202083A vaccine|Intramuscular, three doses
223858345|NCT00970307|BIOLOGICAL|10-valent pneumococcal vaccine (GSK 1024850A)|Intramuscular, three doses
223858346|NCT00970307|BIOLOGICAL|Infanrix hexa™|Intramuscular, three doses
223858347|NCT00970307|BIOLOGICAL|Menjugate®|Intramuscular, two doses
223858348|NCT01808495|DRUG|Mitomycin C|
223858349|NCT06376513|OTHER|Evaluation|Evaluation of the manipulation abilities of patients with penile prostheses Evaluation of the rigidity of erections with penile prosthesis, the patient and partner's sexual satisfaction, the satisfaction related to pump manipulation
223858350|NCT04330768|PROCEDURE|PRF pulp capping|PRF is injected in the site of exposure
223858351|NCT04330768|PROCEDURE|MTA pulp capping|conventional pulp capping procedure
223858352|NCT04080258|OTHER|Osteopathic manipulative therapy (OMTh)|"The Osteopathic Manipulative Therapy includes both evaluation and treatment. The evaluation is semi-structured, two osteopaths will assess the presence of somatic dysfunctions which have to include the hyoid-pharyngeal, laryngeal, temporo-mandibular and lingual areas.~The therapy is based on the treatment of somatic dysfunctions with different approaches that include: the balanced ligamentous tension technique, the myofascial release, the visceral manipulation, and the balanced membranous tension technique. The OMTh lasts for 45 minutes of which 15 of evaluation and 30 of treatment."
223858353|NCT04080258|OTHER|Light Touch Therapy (LTT)|The Light Touch Therapy is a sham treatment consistent with the OMTh one during the phase of evaluation. The treatment retains the same areas used for osteopathic approach but avoids prolonged touch in any area of the body by moving the hands every few seconds and by flattening and softening the surface of the hands in order to minimize focal areas of force.
223858354|NCT02667743|DRUG|Paclitaxel Micelles for Injection|
223858355|NCT02667743|DRUG|Paclitaxel Injection|
223858356|NCT02667743|DRUG|Cisplatin|
223858357|NCT04298788|OTHER|Blue dishware|blue dishware is used for plates and bowls
223858358|NCT05964231|DIETARY_SUPPLEMENT|Heat-treated PS23|Lactobacillus paracasei PS23 heat-treated, 2caps daily use
223858359|NCT05964231|DIETARY_SUPPLEMENT|Placebo|microcrystalline cellulose, 2caps daily use
223858360|NCT00369733|DRUG|Darbepoetin alfa|Darbepoetin alfa adminstered SC every other week to acheive a Hb not to exceed 12 g/dL
223858361|NCT05061641|DRUG|Progesterone|The delivery outcomes of the three groups were compared, including the rate of premature delivery (\<37 weeks of gestation), the rate of early premature delivery (\<32 weeks of gestation), and the need for anti-tocolysis treatment. Rates of premature rupture of membranes (\<37 weeks), neonatal perinatal mortality and morbidity.
223858362|NCT00360386|DRUG|Clopidogrel|
223858363|NCT00118768|DRUG|valopicitabine|
223858364|NCT00118768|DRUG|Pegylated Interferon Alfa|
223858365|NCT02180763|BIOLOGICAL|Gammanorm|Sub-Q IgG
223858366|NCT05257798|DRUG|IFN-β inhibitor treatment|PF-06823859 (IFN-β inhibitor) 100 mg/mL solution for injection
223858367|NCT05257798|OTHER|Placebo|Placebo for PF-06823859, 0 mg/mL solution for injection
223858368|NCT01685528|BEHAVIORAL|CBT|6-8 weekly sessions of CBT, 1 of which is in person with the rest being over the telephone
223858369|NCT00816751|PROCEDURE|Paracervical block|The paracervical block was administered using 20 ml of buffered lidocaine and a 5/8 inch, 25-gauge needle. A small amount was injected at the tenaculum site, and the remainder equally distributed around the cervicovaginal junction at 3, 5, 7, and 9 o'clock. The depth was standardized at 5/8 inch by inserting the needle to the hub.
223858370|NCT00816751|PROCEDURE|Intracervical|The intracervical block was administered using 20 ml of buffered lidocaine and a 1-1/2 inch, 20 gauge needle in order to overcome the increased resistance to injection caused by the cervical stroma. A small amount was injected at the tenaculum site, and the remainder into the cervical stroma at 12, 3, 6, and 9 o'clock, at a depth of 1-1/2 inch by inserting the needle to the hub.
223858371|NCT00816751|DRUG|Buffered Lidocaine, vasopressin, sodium bicarbonate|The buffered lidocaine preparation for both block techniques consisted of 50 mL of 1% lidocaine, 5 units of vasopressin, and 5 mL 8% sodium bicarbonate.
224076217|NCT06006806|RADIATION|Pencil Beam Scanning Proton Therapy|"Part of the normal proton therapy process is to have a CT scan (called a CT simulation) performed that is used to create a proton treatment plan. A proton treatment plan is a computer model of the proton beam that is used to calculate where the protons will go inside the body. During the treatment planning process, the clinical team works to find the best possible placement of the protons. This study uses a process called Spot Delete to keep protons from stopping in the skin, which is believed to be related to skin reddening. Spot Delete is a software application that was developed at the Thompson Proton Center and is used in the treatment planning process."
224076218|NCT00152425|DRUG|Certolizumab Pegol (CDP870)|
223858372|NCT04707729|DIAGNOSTIC_TEST|ROX index algorithm|"The thresholds of the ROX index for intubation are the following:~* After 2 hours of HFNC: ROX \<2.85.~* After 4 and 6 hours of HFNC: ROX \<3.47~* After 8, 10 and 12 hours of HFNC: ROX \<3.85 If the ROX index is between the abovementioned thresholds and 4.88, the NHF support will be also increased to the maximum tolerated flow (up to 60L/min) and FIO2 of 1 and subsequently titrated with the target SpO2. If the patient is already treated with to 60L/min) and FIO2 of 1 and no further increase could be done and the ROX index will be recalculated after 30 minutes of full NHF support. The ROX index will be recalculated in 30 minutes: 1) if the ΔROX is \<0 the patient will be intubated; 2) if the ΔROX is 0-0.5, the ΔROX will be reassessed in 20 minutes; and 3) if the ΔROX is \>0.5 the patient will not be intubated, NHF will be managed as protocolized and respiratory condition will be reassessed every two hours or at any new clinical deterioration."
223858373|NCT04519671|DRUG|Mesenchymal Stem Cells|Direct injection of adult allogeneic bone marrow derived mesenchymal stem cell product, at a dose of 75 million cells into perianal fistula(s)
223858374|NCT04519671|OTHER|Placebo|Normal saline
223858375|NCT00281996|DRUG|Gemcitabine|Administered intravenously over 30 minutes on days 1 and 8 of a 21-day cycle starting at a dose of 700 mg/m2 and increasing to 1000mg/m2 by cohorts
223858376|NCT00281996|DRUG|Imatinib mesylate|Administered orally once daily with 8 ounces of water at a starting dose of 300 mg/day and increased to 600 mg/day according to cohort.
223858377|NCT02598596|BIOLOGICAL|Pegloticase|Pegloticase, IV
223858378|NCT02598596|DRUG|Azathioprine|Azathioprine (1.25 mg/kg, followed by 2.5 mg/kg) oral, daily
223858379|NCT02886221|PROCEDURE|Reverdin-Isham Osteotomy|Incision on the medial part of the foot, a Shannon Isham burr was introduced at the junction of metaphysis and epiphysis. It was applied to the flat bone surface achieved previously at approximately 45°, keeping the articular cartilage surface of the first metatarsal head as reference point on the superior cortex. In this position, under fluoroscopic control, the osteotomy was started following a distal-dorsal and proximal-plantar direction. At this point, the burr was slightly withdrawn in order to preserve a few millimetres of the lateral cortex, and the osteotomy of the plantar cortex was performed completely. Then, a Wedge burr was used to create a wedge with a medially oriented base. At the point of closing the wedge, osteoclasis of the preserved lateral cortex was achieved, modifying the orientation of the articular surface, normalizing the DMAA value, and adding an intrinsic stability to the osteotomy by producing contact of the trabecular bone.
223858380|NCT04693130|BEHAVIORAL|Mindfulness-based prenatal education|Mindfulness-based prenatal education involves mindfulness breathing and other skills with mindfulness meditations.
223858381|NCT04693130|BEHAVIORAL|Hospital-based antenatal care|Hospital-based antenatal care involves all aspects of pregnancy, childbirth and postpartum.
223858382|NCT04033432|BIOLOGICAL|Recombinant EphB4-HSA Fusion Protein|Given IV
223858383|NCT06070324|PROCEDURE|Breast surgery|Any surgery involving incisions made along the nipple areolar complex. These would include transgender mastectomy, cisgender female breast reduction/augmentation/reconstruction, and cisgender male gynecomastia correction.
223858384|NCT06070324|DEVICE|Suturing of surgical incision|The closing of a surgical incision by using sutures so appose and maintain apposition of two skin edges. Suturing may or may not require knot-tying depending on the material of suture used.
223858385|NCT05617586|OTHER|In-depth parental interview|A semi-structurerd interview will be conducted of parents with a child diagnosed with DCD. The interview will be audio-recorderded. The audiofile will be transcribed ad-verbatim and analyzed using narrative analysis methods.
223858386|NCT05617586|OTHER|Developmental Coordination Disorder Questionnaire (DCD-Q)|Parents will be asked to complete the DCD-Q. This will help us describe the sample.
223858387|NCT04790604|BEHAVIORAL|Community Health Navigator Program|Patients will be matched to a community health navigator (CHN) who will conduct a needs assessment to determine the frequency of meetings. A CHN may perform any of the following: providing information to a patient's health care provider, translation, advocating for the patient, connecting the patient with resources (e.g., social, financial, insurance), helping patients set health-related goals, facilitating health care referrals and appointments, and monitoring appointments. These activities may require the CHN to be physically present at appointments or have direct contact with the patient's health care provider. Goal setting and support will be provided in-person or over the telephone using motivational interviewing principles.
223858388|NCT04226703|DIAGNOSTIC_TEST|Ultrasonographic upper airway measurements|"Ultrasonographic upper airway measurements: Epiglottis-skin distance, Hyoid bone-skin distance, Anterior commissure-skin distance and Thickness of tounge root.~Indirect Laryngoscopy: Grading of laryngoscopic view (I=Visible anterior commissure and vocal cords, II= visible posterior part of vocal cords and posterior commissure, III= Visible posterior commissure and epiglottis, IV= Visible only epiglottis tip and posterior pharyngeal wall)"
223858389|NCT00393848|DRUG|Essential amino acid supplement|15g of essential amino acid in capsule form three times daily during hospitalization, continued through 6 weeks after discharge.
223858390|NCT00393848|DRUG|Ketoconazole|200mg ketoconazole twice daily; started night before surgery and continued through hospitalization.
223858391|NCT00393848|DRUG|Placebo|Placebo for Ketoconazole
223858392|NCT05939063|PROCEDURE|LRAMPS|For LRAMPS procedure, Gerota's fascia and perirenal fat capsule are removed, and the procedure is divided into anterior LRAMPS and posterior LRAMPS depending on whether the left adrenal gland is resected. The N1 station lymph nodes (i.e., groups 10, 11, and 18) in the body and tail of the pancreas are removed. If the tumor is located near the pancreatic body, the No. 9 lymph node group is additionally removed.
224076219|NCT05273827|DRUG|neoadjuvant immunotherapy|Anti-PD-1 antibody was added to the conventional neoadjuvant chemotherapy.
223858393|NCT05939063|PROCEDURE|LDP|For LDP procedure, the dissection plane is located behind the fusion fascia. The N1 station lymph nodes (i.e., groups 10, 11, and 18) in the body and tail of the pancreas are removed. If the tumor is located near the pancreatic body, the No. 9 lymph node group is additionally removed.
223858394|NCT04581317|OTHER|meals|Participants will receive meals delivered to them by the Meals oN wheels(MOW) program for 6 weeks.
223858395|NCT04581317|OTHER|AES 8 basic usage|For the second 6 weeks, participants will continue to have meal deliveries and will now have the AES 8 device which can be used by the cognitively impaired participant and their caregiver. AES 8 devices will be installed in participant's homes by the study team and participants will be given basic instructions on using the device as well as a one-page handout that will include instructions on how to use and maintain privacy with their device. The study staff will continue to call twice a week to ask the 5 questions. At the end of the 6 weeks, a study team member will make an in-person visit to the participants' homes to measure FFP, MHS, CES-D, MOCA, ADL/IADLs, NSI, ZCBI, and TAM.
223858396|NCT04581317|OTHER|AES 8 advanced usage|In the third 6 weeks, the participants will continue to have meal deliveries and the AES 8 will be upgraded to provide an active intervention by asking the twice a week 5 questions through the device. The questions should be answered by the cognitively impaired older adult using the device, though the caregiver can still use the device for other basic services. The participant will be able to answer the questions verbally or by touch screen options displayed on the device.At the end of the 6 weeks, a study team member will make an in-person visit to the participants' homes to measure FFP, MHS, CES-D, MOCA, ADL/IADLs, NSI, ZCBI, and TAM.
223858397|NCT03184623|OTHER|muscle mass measurement|measurement of muscle mass by echocardiography
223858398|NCT05417893|DEVICE|MeRes 100 Sirolimus-eluting Bioresorbable Vascular Scaffold System (BRS)|The MeRes100™ BRS (Meril Life Sciences Pvt. Ltd., India) is a novel thin-strut second-generation sirolimus-eluting poly-L-lactic acid (PLLA)-based bioresorbable coronary scaffold. The first-in-human MeRes-1 trial demonstrated the safety and effectiveness of MeRes100 BRS in the treatment of de novo coronary lesions with lower major adverse cardiac events (MACE) rate (0.93%) and notably, the absence of scaffold thrombosis at one-year follow-up. MeRes100 sirolimus-eluting bioresorbable vascular scaffold system is expected to bioresorb in the artery, approximately over a period of three years and thus, preventing chance of late clinical events like late scaffold thrombosis rates. The imaging analysis has shown that in-segment late lumen loss and in-scaffold late lumen loss (LLL) did not change significantly at two years follow-up as compared to six months data.
223858399|NCT03485859|DEVICE|Experimental group|In subjects allocated to the abdominal binder group, the abdomen binder with a standard height of 22 cm (Sejung Korea, Seoul, Republic of Korea) was applied before leaving the operating room. The binder was placed on the abdomen across the laparoscopic incision, with the upper border not higher than the lower margin of the rib cage, ensuring minimal restriction of lateral costal expansion and diaphragmatic excursion. Subjects were carefully instructed to use the abdominal binder during at least the first 2 consecutive days and night, and to reposition the abdominal binder correctly when needed.
223858400|NCT03485859|DEVICE|Control group|In subjects allocated in the control group, subjects were not given any opportunity to ware an abdominal binder.
223858401|NCT00920257|DRUG|GSK2141795|GSK2141795 is an oral AKT inhibitor.
223858402|NCT00637936|DRUG|Oxygen|Inspiratory fraction during anaesthesia
223858403|NCT05485402|DIETARY_SUPPLEMENT|Refined olive oil (38.6 mg hydroxytyrosol and tyrosol/kg oil)|The dosage will be 30 ml/day of refined olive oil (38.6 mg hydroxytyrosol and tyrosol/kg oil) used as a dressing (without heat).
223858404|NCT05485402|DIETARY_SUPPLEMENT|Virgin olive oil rich in phenolic compounds (156 mg hydroxytyrosol and tyrosol/kg oil)|The dosage will be 30 ml/day of virgin olive oil rich in phenolic compounds (156 mg hydroxytyrosol and tyrosol/kg oil) used as a dressing (without heat).
223858405|NCT05485402|DIETARY_SUPPLEMENT|Maltodextrin|The dosage will be 7,5 g/day of maltodextrin.
223858406|NCT05485402|DIETARY_SUPPLEMENT|Prebiotic (FOS and inulin)|The dosage will be 7,5 g/day of prebiotic supplement (FOS and inulin).
223858407|NCT05485402|OTHER|Nutritional and physical activity recommendations|The nutritional recommendations are based on DASH diet and foods rich in protein (in particular, leucine) and vitamin D, polyunsaturated acids, phosphorus and iron. The physical activity recommendations are 150 min/week of physical activity, with at least two sessions dedicated to the development of motor strength.
223858408|NCT00075491|DRUG|fenretinide|Given orally
223858409|NCT00075491|PROCEDURE|therapeutic conventional surgery|Undergo surgery
223858410|NCT00075491|OTHER|pharmacological study|Correlative studies
223858411|NCT00075491|OTHER|laboratory biomarker analysis|Correlative studies
224076220|NCT05273827|DRUG|Neoadjuvant chemotherapy|Cis-platinum combined with paclitaxel or pemetrexed
223858412|NCT03087084|DEVICE|Cardiac Pacing and Impedance Measurement system|Subjects indicated for Implantable Cardioverter Defibrillator or Cardiac Resynchronization Therapy Defibrillator device implant will be requested to perform some respiratory manoeuvres while impedance and electrogram signals are recorded by the system
223858413|NCT05751499|DIAGNOSTIC_TEST|• Blood Markers CRP, TNFα, IL-6, IL-8, IL-1, and IL-1β AND FIBRINOGEN|"* Low Back Outcome Scale~* Center for Epidemiological Studies-Depression Scale (CES-D)~* International Physical Activity Questionnaire~* Roland-Morris Disability Questionnaire~* Force Platform~* Pain Self-Efficacy Questionnaire (PSEQ)~* Numeric Rating Scale~* Job Content Questionnaire~* Pits Burgh Sleep Quality Index (PSQI)~* Orebo Musculoskeletal Pain Screening Questionnaire~* Gait \& Balance App~* Keele STarT Back Screening Tool (SBST)~* Fear-Avoidance Beliefs Questionnaire (FABQ)~* Pain Catastrophizing Scale"
223858414|NCT02107339|DRUG|Methadone|Methadone 0.2 mg/kg administered at induction of anesthesia
223858415|NCT02107339|DRUG|Hydromorphone|Hydromorphone 2 mg administered at the conclusion of anesthesia
223858416|NCT00834951|RADIATION|Low dose total body irradiation|Low dose total body irradiation is given 3 weeks after the end of chemo-immunetherapy in the form of 4 daily fractions 0.2 Gy per fraction to be repeated after 2 weeks of rest
223858417|NCT06448598|OTHER|Exercise|The exercise protocol involved twice-weekly sessions, with aerobic exercises performed at 70% of the maximum heart rate achieved during the step test, and resistance exercises at 60% of 1RM. Participants self-selected their exercise timing, either intradialytic (during HDF sessions) or interdialytic (on non-dialysis days). For the intradialytic group, exercise was seamlessly integrated into the HDF session, excluding the initial and final two hours of dialysis.
223858418|NCT03655626|OTHER|Sepsis Watch|The operational intervention comprises of a sepsis machine learning model, custom dashboard to present risk scores, and a rapid response team to monitor patients at-risk of sepsis and deliver sepsis treatment. Sepsis Watch was developed under operational management. The rapid response team will utilize information presented on the dashboard and follow a protocol that will enable them to support the primary teams of hospitalized patients.
223858419|NCT00002018|DRUG|Interferon alfa-n3|
223858420|NCT02105064|DEVICE|Active rTMS|rTMS over supplementary motor area, 1hz, no pauses, 20 minutes/sessions, 5 sessions/week, 4 weeks. Total 20 sessions.
223858421|NCT02105064|DEVICE|SHAM rTMS|Sham rTMS, without brain stimulation
223858422|NCT02464293|OTHER|Mindfulness-based cognitive therapy|An 8 week course of mindfulness-based cognitive therapy
223858423|NCT02082158|OTHER|Study Procedures|Study activities include fit-testing, wearing the respirator while performing a series of motions that simulate healthcare worker tasks and completing a survey on the comfort and tolerability of the respirator worn.
223858424|NCT01793441|DRUG|Placebo|Placebo will be administered in different stages of the study for 12 weeks.
223858425|NCT01793441|DRUG|RG7314|RG7314 will be administered orally at a dose of 1.5 mg/day in Stage I, 4 mg/day in Stage II, 10 mg/day in Stage III and 1.5 mg/day or 10 mg/day in Stage IV for 12 weeks.
223858426|NCT02192606|DEVICE|Storz 3D Laparoscopy System|The Storz 3D Laparoscopy System is a new device that allows for laparoscopic surgeons to utilize 3D imaging during surgery with a fraction of the cost of the da Vinci Surgical System, a three-dimensional visual system.
223858427|NCT02192606|DEVICE|2D Laparoscopy|The standard 2D Laparoscopy System to be used at time of the total laparoscopic hysterectomy.
223858428|NCT00947817|OTHER|ULTRASONOGRAPHY trans-esophageal and trans-thoracic , blood test and clinic test|
223858429|NCT05559281|OTHER|Botulinum|injection of Botulinum Toxin injection in lip muscles following cleft lip repair surgically.
223858430|NCT05559281|PROCEDURE|Fisher technique|The cleft lip will be treated surgically using the Fisher technique only.
223858431|NCT02212522|OTHER|Collect of environmental data on T1D patients before diagnosis|Questionnaires on large environment during mother's pregnancy and patient's childhood, health book copies, addresses' geolocation, quantification of viral exposures using Sentinel Network data
223858432|NCT02212522|GENETIC|Collect of blood samples for DNA extraction and genetic characterization (GWAS)|Collect of blood samples for DNA extraction and genetic characterization (GWAS) on Illumina platform (Centre National de Genotype)
223858433|NCT02212522|OTHER|Collect of clinical data on the disease and its evolution|Collect of clinical data on the disease and its evolution every 6 months after enrollment
223858434|NCT02212522|OTHER|Collect of environmental data on French controls (age-matched for T1D patients)|Questionnaires on large environment during mother's pregnancy and patient's childhood, health book copies, addresses' geolocation, quantification of viral exposures using Sentinel Network data
223858435|NCT02212522|GENETIC|Collect of blood samples for DNA extraction and genetic characterization (GWAS)|Collect of blood samples for DNA extraction and genetic characterization (GWAS) on Illumina platform (Centre National de Genotype)
223858436|NCT04566458|OTHER|No intervention|retrospective chart review study
223858437|NCT01443416|BIOLOGICAL|13-valent pneumococcal conjugate vaccine|The vaccine will be given to 12 month old children who have had 2 doses of Prevenar at 2 and 4 months of age
223858438|NCT01443416|BIOLOGICAL|10-valent pneumococcal conjugate vaccine|The vaccine will be given to 12 month old children who have had 2 doses of Prevenar at 2 and 4 months of age.
223858439|NCT03110458|DRUG|SENS-111 100mg|SENS-111 100mg is presented as 1 Oral Dispersible Tablet of SENS-111 100mg + 1 Oral Dispersible Tablet of placebo given twice on Day 1, second intake given approximately 12 hours (9 to 15 hours) after the first intake and thereafter given once daily on Days 2 to 5 inclusive. The corresponding total dose will be 500 mg for the entire study.
223858440|NCT03110458|DRUG|SENS-111 200mg|SENS-111 200mg is presented as 2 Oral Dispersible Tablet of SENS-111 100mg given twice on Day 1,second intake given approximately 12 hours (9 to 15 hours) after the first intake and thereafter given once daily on Days 2 to 5 inclusive. The corresponding total dose will be 1000 mg for the entire study.
223858441|NCT03110458|DRUG|Placebo Oral Tablet|Placebo is presented as 2 Oral Dispersible Tablets of placebo given twice on Day 1, second intake given approximately 12 hours (9 to 15 hours) after the first intake and thereafter given once daily on Days 2 to 5 inclusive. The corresponding total dose will be 0 mg for the entire study.
223858442|NCT06112899|BEHAVIORAL|Nordic Hamstring Exercise|The NHE, also referred to as the nordic curl, is designed to improve eccentric strength of the hamstring muscles. Individuals start in a kneeling position, with the torso from the knees upward held rigid and straight. The training partner ensures that the individual's feet are in contact with the ground throughout the exercise by applying pressure to the player's heels/lower legs. The individual then lowers his upper body to the ground, as slowly as possible to maximize loading in the eccentric phase. Hands and arms are used to break his forward fall and to push him back up after the chest has touched the ground, to minimize loading in the concentric phase.The exercise protocol is planned as 5 sets of 8 repetitions and 2 minutes of rest between each set.
223858443|NCT03201549|DIETARY_SUPPLEMENT|oral fructose challenge|Participants will consume fructose for two weeks and fast for 8 hours before study visits where they will drink a fructose beverage.
223858444|NCT02589002|OTHER|Sucralose|
223858445|NCT01736098|OTHER|Energy Flux Exercise Intervention|Comparison of high, medium and low energy flux groups with all groups matching energy intake and expenditure
224076221|NCT06446739|DEVICE|Continuous Renal Replacement Therapy (CRRT)|Continuous Renal Replacement Therapy (CRRT) is a continuous form of acute renal replacement (hemofiltration/dialysis) therapy provided to critically ill patients with multi-organ dysfunction receiving life support in the intensive care unit (ICU).
224076222|NCT04480450|DRUG|Rituximab|Rituximab is a highly purified, 1328-amino acid antibody with an approximate molecular mass of 145 kD. Rituximab is a mouse human chimeric monoclonal antibody against CD20. Administration leads to between 90 and 100% peripheral B cell depletion via complement dependent cytotoxicity.
223858446|NCT02073123|DRUG|Indoximod|"Initial dose of 600mg BID by mouth with escalation planned to 1200mg BID by mouth~Dose escalation:~* If 0 of the 3 subjects forming the first cohort experience RLT, 1200mg BID cohort will be enrolled~* If 1 of the 3 subjects in any cohort experiences a RLT, then enrollment into that cohort will increase to a total of 6 subjects~* If \> 1 of the 3-6 subjects experience a RLT, then the MTD has been exceeded and further enrollment into the cohort will cease~* If \>1 subject at 600mg BID experiences a RLT, the dose will be de-escalated to 400mg BID. If \>1 subject at this level experiences a RLT, one additional de-escalation to 200mg BID is allowed~Dosing cycles are 21 days in length during the combination immunotherapy component (first 4 cycles) and 28 days during indoximod monotherapy. Patients will continue until they experience disease progression or limiting toxicity~Phase 2 Treatment Plan (Cohort 2) Will receive fixed dose of indoximod determined in phase 1"
223858447|NCT02073123|DRUG|Ipilimumab|Ipilimumab administered intravenously at 3 mg/kg every three weeks for a total of four doses.
223858448|NCT02073123|DRUG|Nivolumab|Nivolumab administered intravenously at 240 mg every 2 weeks.
223858449|NCT02073123|DRUG|Pembrolizumab|Pembrolizumab administered intravenously at 2 mg/kg every three weeks.
223858450|NCT00497991|DRUG|AZD1152|
223858451|NCT03278769|PROCEDURE|Lung protective ventilator settings|Positive end-expiratory pressure 12, Tidal volume 6 milliliter/kilogram predicted body weight
223858452|NCT04306705|DRUG|Tocilizumab|Administered as an intravenous infusion.
223858453|NCT04306705|OTHER|Standard of care|Standard of care therapy per local written policies or guidelines and includes balancing of electrolytes and acid-base, the provision of enteral or parenteral nutrients support, antibiotics therapy, oxygen therapy and noninvasive ventilation.
223858454|NCT04306705|PROCEDURE|Continuous renal replacement therapy|Catheter insertion site is femoral vein.
223858455|NCT04807322|PROCEDURE|Reverse Total Shoulder Arthroplasty (RTSA)|Implantation of a Reverse Total Shoulder Arthroplasty
223858456|NCT05030077|DRUG|Anlotinib|Anlotinib(12mg) oral daily for days 1-14, 21 days per cycle
223858457|NCT05030077|DRUG|Cisplatin|Cisplatin (70 mg/m2) IV day 1
223858458|NCT05030077|DRUG|Carboplatin|If the patients can't tolerate cisplatin, they will be treated with carboplatin (AUC 4.5mg/mL·min) IV day 1
223858459|NCT05030077|DRUG|Gemcitabine|Gemcitabine ( 1000 mg/m2) IV days 1 and 8
223858460|NCT02351648|OTHER|a transitional care model|"Intervention extend from transfer of care to the study team from the initial admission medical team through 90 days after discharge~Intervention in hospital includes the following. Comprehensive discharge planning based on the 6 principles. Discharge planning initially within 24 hours of recruitment Daily ward review of patients Weekly multi-disciplinary meeting Consolidation of medication and follow-up appointment before discharge Assessment of needs before discharge Comprehensive discharge summary and medication record at discharge~Intervention after discharge:~Work done mainly by integrated care nurse Review of patients within 48 hours after discharge via home visit or phone call Subsequent home visit as needed based on patient's needs At least weekly contact with pt or caregiver via telephone Telephone availability working weekday 8 AM to 5 PM Multi-disciplinary meeting for problematic cases Use chronic disease pathway for suitable patients"
223858461|NCT02351648|OTHER|Control|Patients receive usual standard of care from the internal medicine team
223858462|NCT00239434|DRUG|tiotropium inhalation powder capsule|
223858463|NCT00239434|DRUG|ipratropium bromide Metered Dose Inhaler|
223858464|NCT00539799|DRUG|prednisolone|5 - 7.5 mg/day
223858465|NCT00539799|DRUG|Placebo|Matched placebo to prednisolone
223858466|NCT03179722|BEHAVIORAL|Medication review|The intervention consists of a medicines use review provided by community pharmacists in Belgium. A medicines use review is a medication review type 2a in which both a patient interview and dispensing data are used as information sources to identify drug-related problems with a specific focus on the medicines use of the patient.
223858467|NCT03179722|BEHAVIORAL|Additional data collection: questionnaires|"Pre-post study design.~At three timepoints, data is collected:~* before the medication review (T-1week)~* during the review (Tweek 3)~* after the review (Tweek12) The questionnaire provide data for the outcomes: medication related quality of life, adherence questionnaire, service satisfaction, use of emergency health services, self-management"
223858468|NCT02550197|BIOLOGICAL|Quadrivalent influenza vaccine (QIV) (split virion, inactivated) Northern Hemisphere (NH) 2015-2016|0.5 mL, Intramuscular
223858469|NCT02550197|BIOLOGICAL|Trivalent influenza vaccine (TIV) (split virion, inactivated) NH 2015-2016 formulation|0.5 mL, Intramuscular
223858470|NCT03182959|DRUG|Avmacol®|Avmacol® tablets
223858471|NCT02218502|OTHER|Ultrasound by general gynaecologist|All patients will undergo an ultrasound by a general gynaecologist at the moment of inclusion. Based on this ultrasound, the gynaecologist will use both the RMI and the simple rules to predict the chance of malignancy.
223858472|NCT02218502|OTHER|Ultrasound by an expert ultrasonographist|Patients in which the simple rules yield an inconclusive result (about 20% of all patients) will undergo a second ultrasound scan. This scan is performed by an expert in gynaecological ultrasound.
223858473|NCT02218502|OTHER|DW-MRI|Patients in which the simple rules yield an inconclusive result (about 20% of all patients) will undergo a diffusion weighted MRI.
224076223|NCT06180889|DRUG|Enoxaparin|40 mg enoxaparin administered as subcutaneous injection once daily
223858474|NCT02218502|OTHER|Give blood sample|Patients in which the simple rules yield an inconclusive result (about 20% of the patients) will be asked for an extra blood sample. We will use these materials to perform translational research and validate new biomarkers in the diagnosis of ovarian cancer.
223858475|NCT05201261|DEVICE|ltrasonic measure|In the right decubitus position, the spine was scanned with an ultrasonic convex array probe. Starting from the sacrum, the length of each vertebral body of the lumbar spine was measured on a para-midsagittal oblique view. The intervertebral space was located and the width of the subarachnoid space was measured on a midsagittal and transverse view.
223858476|NCT04302246|GENETIC|Biological testing on sequential blood sample|Biological characterization of various immune function and blood circulating leukocytes phenotyping before liver transplantation and therafter at day-3, -7, -14 postoperatively and if septic complication occurs.
223858477|NCT04792554|OTHER|Neurocognitive tests and blood taking|Battery of neurocognitive tests and questionnaires including MoCA, PHQ-9, Falls History, FIFE, STOPBANG, Nutritional Survey, Global Physical Activity Questionnaire, Brief Pain Index, Brief Psychiatric Rating Scale, NuDESC, 3D-CAM. Blood taking.
223858478|NCT03426033|DRUG|ISIS 681257|Xmg dose administered as a subcutaneous injection
223858479|NCT03426033|DRUG|Warfarin|25mg tablet administered orally
223858480|NCT03185780|OTHER|Acupuncture|"Acupuncture: the insertion of use of ultra-fine needles (diameter 0.18 - 0.30mm) into designated acupoints in the skin, along the limbs and trunk areas.~Reflexology: The massage + application of localized pressure on designated points along the plantar aspect of the feet.~Shiatsu: The application of localized pressure along designated points (similar to acupoints) along the limbs and trunk areas."
223858481|NCT03195426|PROCEDURE|distal nerves blocks group|"* ICB: US probe will be placed just below clavicle inferior to site of needle entry. Following identification of axillary artery and cords, the needle will be advanced posterior to axillary artery. 20 cc of Ropivacaine 0.375% will then be deposited in a U-shaped distribution posterior and to each side of the axillary artery.~* SSNB will be performed by locating the brachial plexus and the departure of the suprascapular nerve from the superior trunk under the inferior belly of the omohyoid muscle by sliding the transducer distally and then injecting 5 mL of ropivacaine 0.375%.~* SCNB will be performed injecting 5 mL of ropivacaine 0.375% in the intermuscular plane between the sternocleidomastoid and scalene muscles using a lateral to medial in-plane technique."
223858482|NCT03195426|PROCEDURE|Diaphragmatic function assessment|"Diaphragmatic excursion will be assessed under ultrasound immediately before and after regional anesthesia.~This a pain free and safe procedure, that we usually perform in patients at risk of respiratory failure."
223858483|NCT01184664|DRUG|Nicotine Patch|Varenicline + nicotine patch
223858484|NCT01184664|DRUG|Placebo|Varenicline + placebo patch
223858485|NCT01184664|DRUG|Varenicline|All participants will receive a standard dose of varenicline (12 weeks).
223858486|NCT00711126|DRUG|GW642444|2.5mcg IV
223858487|NCT00711126|DRUG|GW642444|5mcg IV
223858488|NCT00711126|DRUG|GW642444|10mcg IV
223858489|NCT00711126|DRUG|GW642444|100mcg inhaled
223858490|NCT00711126|DRUG|GW642444|20mcg IV
223858491|NCT00711126|DRUG|GW642444|500mcg oral
223858492|NCT00557206|DRUG|Oxaliplatin and Docetaxel|"Chemotherapy~Oxaliplatin 130mg/m2 on day 1; and Docetaxel 75mg/m2 on day 1; every 21 days."
223858493|NCT04674436|BEHAVIORAL|Walking|6 minute casual walk
223858494|NCT01458210|DRUG|Ortho-Cyclen|Administered orally
223858495|NCT01458210|BIOLOGICAL|Dulaglutide|Administered subcutaneously
223858496|NCT01551407|DRUG|Hexvix|50 ml Hexvix liquid instilled once into the bladder for 30 minutes prior to cystoscopy
223858497|NCT01562925|DIETARY_SUPPLEMENT|Red wine|Red wine First dosage: 3 ml per kg bodyweight (the evening before contrast medium exposure) Second dosage: 1.5 ml per kg bodyweight (60-120 minutes before contrast medium exposure
223858498|NCT01562925|DIETARY_SUPPLEMENT|White wine|White wine First dosage: 3.3 ml per kg bodyweight (the evening before contrast medium exposure) Second dosage: 1.7 ml per kg bodyweight (60-120 minutes before contrast medium exposure
223858499|NCT01562925|DIETARY_SUPPLEMENT|Beer|Beer First dosage: 7.8 ml per kg bodyweight (the evening before contrast medium exposure) Second dosage: 3.9 ml per kg bodyweight (60-120 minutes before contrast medium exposure
223858500|NCT01021865|DRUG|Glucagon-Like-Peptide-1/Regadenoson/Perflutren Lipid Microsphere|"GLP-1 at a rate of 1.2 pmol/kg/min~Regadenoson as a stress agent 0.4mg IV given during MCE~Definity:0.6 ml of Definity diluted with 30ml of 0.9% saline infused by SYRINGE Infusion Pump"
223858501|NCT01900834|OTHER|No treatment given|The participants will not receive any treatment
223858502|NCT02937792|DRUG|intrathecal 15 mg bupivacaine|spinal anesthesia with a large dose of bupivacaine 0.5% in elective caesarean section
223858503|NCT02921399|OTHER|eradication timing|patients who underwent ESD for gastric neoplasms were randomized to receive early (3-5 days) or late (8-9 weeks) H. pylori eradication therapy after ESD.
223858504|NCT04126239|OTHER|Online survey - questionnaire|Online survey - questionnaire
223858505|NCT05136092|DIETARY_SUPPLEMENT|Cohort 1: HFCS (fructose) fed|"Two to three hours before surgery. Subjects will prepare the sugar solutions (Fructose-containing solution: 250 mL of water containing 41.25 g of D-Fructose and 33.75 g of D-Glucose) by adding 250 ml water to the sugar powder provided by the study team and drink it between two and three hours before surgery.~Samples collected before surgery:~* Blood sample of 5 ml~* Urine Samples 5 ml~Day of Surgery The anesthesia and surgical procedure will undergo as per regular care. Samples collection at the time the surgical specimen is removed~* Blood sample of 5 ml blood will be obtained from the IV line~* Tissue samples~  * 2 Tumor tissue samples 5mmx5mmx5mm,~ * 2 Intestinal /colon tissue samples 5mmx5mmx5mm~ * 2 tissue samples from mesentery tissue 5mmx5mmx5mm~* Optional Liver Biopsy - a 3-5 mm liver tissue will be obtained for research.~* Urine Samples 5 ml"
224076224|NCT06180889|DRUG|KN060 Low|Single dose of KN060 administered as intravenous infusion
224076225|NCT06180889|DRUG|KN060 Middle|Single dose of KN060 administered as intravenous infusion
224076226|NCT06180889|DRUG|KN060 Hight|Single dose of KN060 administered as intravenous infusion
224076227|NCT01693315|DRUG|AMA0076|
224076228|NCT01693315|DRUG|Placebo|
224076229|NCT02245828|DRUG|QCC374|Single and multiple ascending doses of QCC374
224076230|NCT02245828|DRUG|Placebo|Placebo comparator
223858506|NCT05136092|DIETARY_SUPPLEMENT|Cohort 2: D-Xylose (xylose-fed)|"Two to three hours before surgery.~Subjects will prepare the sugar solutions (Xylose-containing solution: 250 mL of water containing 41.25 g of D-Xylose and 33.75g of D-Glucose) by adding 250 ml water to the sugar powder provided by the study team and drink it between two and three hours before surgery.~Samples collected before surgery:~* Blood sample of 5 ml~* Urine Samples 5 ml~Day of Surgery The anesthesia and surgical procedure will undergo as per regular care. Samples collection at the time the surgical specimen is removed~* Blood sample of 5 ml blood will be obtained from the IV line~* Tissue samples~  * 2 Tumor tissue samples 5mmx5mmx5mm,~ * 2 Intestinal /colon tissue samples 5mmx5mmx5mm~ * 2 tissue samples from mesentery tissue 5mmx5mmx5mm~* Optional Liver Biopsy - a 3-5 mm liver tissue will be obtained for research.~* Urine Samples 5 ml"
223858507|NCT05894824|DRUG|T-Dxd(Trastuzmab deruxtecan), Ramucirumab|"Phase Ib will use a standard 3+3 scheme with the planned doses of T-DXd (4.4\~6.4 mg/kg) once every 3 weeks in combination with Ramucirumab 8mg/kg administered once every 2 weeks.~* Dosing Regimen~  * Trastruzumab deruxtecan : One IV infusion every 3 weeks on Day 1 of each 21-day cycle~ * Ramucirumab : One IV infusion on every 2 weeks on Day 1,15 of each 28-day cycle"
223858508|NCT01810250|DEVICE|Endurant Stent Graft|
223858509|NCT00860353|DRUG|AZD2551|Single dose of oral solution.
223858510|NCT00860353|DRUG|Placebo|Single dose of oral solution
223858511|NCT05347199|DRUG|Amisulpride Pill|Two single low doses amisulpride (100 mg); orally
223858512|NCT05347199|DRUG|Placebo|two doses, orally
223858513|NCT06306378|DIAGNOSTIC_TEST|social memory levels and spindle levels|Take a face recognition memory test, and a car recognition memory test as a control . Then record nighttime EEG recordings after the two tasks and performed subsequent spindle analysis.So conduct the correlation between social memory levels and the level of spindles in the EEG by using machine learning to model.
223858514|NCT00839046|BEHAVIORAL|Community Health Worker Intervention|The Community Health Worker (CHW) intervention consists of visits by CHWS to help families reduce children's exposure to common asthma triggers (allergens and irritants) in the indoor environment. The content of the CHW visits and the materials distributed will follow NHLBI Expert Panel Report 2 recommendations. Each household will receive 6 visits over a 12-month period in which the CHW will provide education on environmental triggers (e.g., reduction of dust mites, cockroaches, cat and dog dander, and environmental tobacco smoke); materials including vacuum cleaners with HEPA filters, mattress and pillow covers, and cleaning supplies; social support to the caregivers; and, if indicated, referrals to other services.
223858515|NCT00839046|OTHER|Air Filter|Fifty households will receive an Air Filter, in addition to receiving the standard community health worker intervention. These households will receive a HEPA room AF (Whirlpool 510 or equivalent), a relatively high capacity unit that can be quietly operated. Similar to other studies the filter will be placed in the room where the child sleeps. The HEPA AF will be installed at the beginning of the intervention period.
223858516|NCT00839046|OTHER|Air Filter and Air Conditioner|Fifty households will receive the air filter and the air conditioner, in addition to receiving the standard community health worker intervention. The air filter will be installed at the beginning of the intervention, after baseline measurement. In the spring of the year (2009), a small window AC unit (Whirlpool Designer Style ACQ058MM or equivalent) will also be installed in the room where the child sleeps.
223858517|NCT04747392|BIOLOGICAL|SAL001|administrated once by subcutaneous injection
223858518|NCT04747392|BIOLOGICAL|FORSTEO|administrated once by subcutaneous injection
223858519|NCT03923491|BEHAVIORAL|Healthy Feeding, Healthy Eating|Home Based Motivational Interviewing to Improve Diet Quality of Preschoolers
223858520|NCT03923491|BEHAVIORAL|Reading Readiness|Active Control that uses Motivational Interviewing to improve Reading Readiness of Preschool Children
224076231|NCT02911766|DRUG|Chlorhexidine 0.2% Mouthrinse|Intervention; Rinsing 60 sec with Comparator solution twice daily for 21 days
223858521|NCT06264648|OTHER|Pressure sensitivity education|Therapists were asked to apply pressure to the scale with estimated weights of 0.5 kg, 1 kg, 2 kg and 4 kg. In each measurement, the value shown on the scale was recorded without being shown to the participant.After the measurements, the participants were made to experiment when the digital screen can be seen, in order to teach the physiotherapists how much pressure they applied to reach the target weight. Participants were given a total of 10 minutes for the trials. Then, the digital screen was hidden again, and the therapist was asked to apply 0.5 kg, 1 kg, 2 kg and 4 kg weight in a randomized order and maintain this pressure for 5 seconds. The weight fixed by the therapist for 5 seconds was noted by the researcher; the participant was not informed about the values on the digital screen.
223858522|NCT01091831|DRUG|Cyclophosphamide|Cyclophosphamide will be given orally at the dose of 300 mg/m2 on days 1, 8, 15 for 6 cycles every 28 days
223858523|NCT01091831|DRUG|Lenalidomide|Lenalidomide will be given orally at the dose of 25 mg/d for 21 days followed by a 7 days rest period (day 22 to 28)for 6 cycles every 28 days
223858524|NCT01091831|DRUG|Dexamethasone|Dexamethasone will be given orally at the dose of 40 mg on days 1, 8, 15, 22 for 6 cycles every 28 days
223858525|NCT01091831|DRUG|Melphalan|Melphalan will be given iv at the dose of 200 mg/m2 for 1 day followed by stem cell support. The second MEL200 was performed 120 days after the first if ≤ PR was achieved after the 1st MEL200.
223858526|NCT02327104|BEHAVIORAL|Mindfulness Based Relapse Prevention|The MBRP is an adjuvant treatment for people that have been treated for drug use related problems, and to prevent relapses.
224076232|NCT02911766|DRUG|Chlorhexidine 0.12% mouthrinse|Intervention; Rinsing 60 sec with Comparator solution twice daily for 21 days
223858527|NCT02327104|OTHER|Brazilian Ministry of Health Protocol|The control group will receive maintenance sessions based on the Ministry of Health protocol after the four sessions of cognitive-behavioral approach.
224076233|NCT02911766|DRUG|Chlorhexidine 0.06% mouthrinse|Intervention; Rinsing 60 sec with Comparator solution twice daily for 21 days
223858528|NCT02433795|DRUG|bendamustine plus rituximab|Bendamustine 90mg/m2 IV on days 1-2 up to 6th cycle Rituximab 375mg/m2 IV on day 1 at 1st cycle Rituximab 1400mg SC on day 1 from 2nd cycle every 4 weeks up to 8th cycle
223858529|NCT02376517|BEHAVIORAL|Educational program|The educational program consists of a short (13 pages) read-along book in English and Spanish. This book presents sun protective practices at an appropriate level for 2-6 year old children to read with their parent or caregiver. A sun protective swim shirt, which provides a sun-protection factor (SPF) of over 50, for the child will be provided. Additionally, the parent will receive weekly text message reminders to practice sun protection.
224076234|NCT04294459|DRUG|Isatuximab SAR650984|"Pharmaceutical form: Solution for infusion~Route of administration: Intravenous"
224076235|NCT04294459|DRUG|Acetaminophen (paracetamol) or equivalent|"Pharmaceutical form: Tablets~Route of administration: Oral"
224076236|NCT04294459|DRUG|Ranitidine or equivalent|"Pharmaceutical form: Solution~Route of administration: Intravenous"
224076237|NCT04294459|DRUG|Diphenhydramine or equivalent|"Pharmaceutical form: Solution~Route of administration: Intravenous"
224076238|NCT04294459|DRUG|Methylprednisolone or equivalent|"Pharmaceutical form: Solution~Route of administration: Intravenous"
224076239|NCT04294459|DRUG|Montelukast or equivalent|"Pharmaceutical form: Tablets~Route of administration: Oral"
223858530|NCT02454244|BEHAVIORAL|ART with Mindfulness|"1. Introduction of ART with Mindfulness. Visualization of 100% recovery~2. Developing Fibromyalgia and CFS. How stress triggers the central nervous system. The benefits of Mindfulness in chronic stress. Mindfulness Practice. Breathing meditation~3. The ART. Breaking the negative thoughts related to the illness. Walking meditation~4. Mindfulness and the Body Scan. Breaking the cycle of stress. Body-scan meditation~5. Mindfulness and self-compassion. Kindly awareness meditation~6. The accelerator of ART. Behaviors related to CFS and Fibromyalgia. Metta meditation~7. Aware of negative thoughts related to stress stimulus. Mindfulness in daily activities~8. Limiting beliefs, identity patterns. Motivation and sense of life. Meditation on values~9. The recovery, cycles and stages. Fear of fail about recovery. Positive Visualization of future self~10. Return to regular life. Mindfulness practice"
223858531|NCT02454244|BEHAVIORAL|Mindfulness Compassion|"1. Introduction.Definition of Compassion~2. Self-Esteemed and Compassion~3. Cultivate the understanding of the nature of inner experience. Working positive and negative thoughts.Connecting with difficult emotions~4. Identifying the causes of suffering.How participants contribute to their own suffering. Attachments.Practice of Vulnerability~5. Love,affection and self-compassion.How participants connect with the suffering of others~6. Equanimity~7. Forgiveness~8. Interdependence. Gratitude.Affection to unknown people~9. Developing affection and empathy.Empathy and burn out~10. Review of the practices and meditations"
223858532|NCT02454244|BEHAVIORAL|Relaxation|10 sessions based on relaxation techniques as active comparator intervention
223858533|NCT00223548|DRUG|sodium 2-mercaptoethane sulfonate|
224076240|NCT04788420|DRUG|Sorafenib|The initial dose of sorafenib is 400 mg orally twice daily and is adjusted in case of suspected toxicity or resistance (dose range, 200-800 mg daily).
224076241|NCT06169215|PROCEDURE|Biospecimen Collection|Undergo collection of blood and urine samples
224076242|NCT06169215|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
224076243|NCT06169215|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
224076244|NCT06169215|DRUG|Bortezomib|Given SC
224076245|NCT06169215|PROCEDURE|Computed Tomography|Undergo CT
223858534|NCT05162144|PROCEDURE|Proximal Medial Gastrocnemius Recession|Patients will be operated with PMGR as described by Barouk. No additional procedures will be performed. The surgery will be performed with the patients in a prone position under local anaesthetics. A 3-4 cm transverse skin incision is made in the popliteal fossa, the superficial fascia is opened, and the medial gastrocnemius with its tendon (aponeurosis) is located. The tendon is then cut while lifting it with clamps, and care is taken to cut only the white tendon while sparing the underlying muscle. While performing a dorsiflexion movement of the ankle, careful palpation of the muscle is done to ensure that all tendon strands are cut completely. The incision is closed in layers, and only soft dressings applied. Patients will be instructed to continue the stretching exercises and fully weight-bear from the first postoperative day. If needed, the patients will be allowed to use crutches during the first 2 weeks after surgery. Sutures are removed 2-3 weeks after surgery.
223858535|NCT00038714|DRUG|SGN-00101|
223858536|NCT00426036|DRUG|Licarbazepine|
224076246|NCT06169215|DRUG|Daratumumab and Recombinant Human Hyaluronidase|Given SC
223858537|NCT04970810|BEHAVIORAL|My Diabetes Goal|Subjects enrolled in the MDG arm will receive surveys at baseline, 6 months and 12 months, followed by monthly diabetes care management phone calls.
223858538|NCT04970810|BEHAVIORAL|My Diabetes Goal + CommunityRx|"Subjects enrolled in the MDG arm + CRx will receive surveys at baseline, 6 months and 12 months, followed by monthly diabetes care management phone calls. Participants will also receive a HealtheRx (personalized resource prescriptions) for community organizations."
223858539|NCT05359913|BEHAVIORAL|Cervical cancer podcast for African American women|"The video podcast will deliver cervical cancer prevention messages using entertainment education and behavioral journalism, and film production techniques such as talking head video, interview, animations, \& live-action skits. The research team will work closely with the production company in scripting the video vignettes and sequences, ensuring that video content reflects salient domains captured in the concept mapping research development phase of the study."
223858540|NCT04983537|DRUG|Gam-COVID-Vac / Gam-COVID-Vac|A comparison of antibody levels against protein S will be performed using the Gam-COVID-Vac / Gam-COVID-Vac group as a control group and the Gam-COVID-Vac / ChAdOx1 nCoV-19 and Gam-COVID-Vac / BBIBP-CorV groups as comparators.Comparisons will be made by contrasting the geometric means of antibody levels between each of the study arms. In addition, comparisons will be made as to whether or not the median antibody values of the alternative treatment groups are lower than: a) the 25th percentile of the median antibody value of the Gam COVID combination and b) whether the lower limit of the confidence interval of the differences in the GMC rate is lower than the conventional cut-off point of non-inferiority set at 0.67.
223858541|NCT05776680|OTHER|Psychological support|60-minute once or twice a week for 6 months of Initial Remote Psychological Support Course .
223858542|NCT04041999|BEHAVIORAL|Daily Cognition Training Program|"Tasks are carried out in which the subject has to exercise different cognitive functions (praxies, attention, language, memory orientation, gnosias and executive functions; mainly working memory decision making, planning, reasoning and temporal estimation) during the development of AIVD For this, similar materials are used to those that the elderly could find in daily tasks or when solving day-to-day problems.~Specifically we focus on tasks related to taking medication and adherence to treatment. Some examples of tasks are: the management of a medical prescription, expiration of a medication, understanding of the prescriptions made by the doctor, guidelines for taking medication (doses, schedules ...) and indications and contraindications, filling pill boxes, recall of controls doctors, medication control, prospective memory of medical management, etc."
223858543|NCT03300037|DEVICE|Kinesthetic stimulation|The kinesthetic actuator is placed on the skin near the ear and emits vibrations.
223858544|NCT05277831|OTHER|Guided Imagery Intervention|Participants in the Guided Imagery Intervention receive 6 sessions of a Guided Imagery plus standard smoking cessation coaching over 6 weeks, delivered by telephone. Sessions range from 10 - 60 minutes, and cover reasons for and benefits of quitting, triggers and alternative strategies, coping with cravings, withdrawal and NRT, and relapse prevention. In each session, coaches work with participants to create or revise guided imagery scripts. After the session, coaches record the script as a digital audio file and send to the participant. Participants listen to their audio file every day and practice behavioral skills between sessions.
223858545|NCT05277831|OTHER|Standard Behavioral Control|Participants in the Standard Behavioral Control condition receive 6 sessions of a standard smoking cessation coaching over 6 weeks, delivered by telephone. Sessions range from 10 - 60 minutes, and cover reasons for and benefits of quitting, triggers and alternative strategies, coping with cravings, withdrawal and NRT, and relapse prevention. In each session, coaches work with participants to identify lifestyle changes to support tobacco cessation, and set a schedule for practicing new behavioral strategies. Participants complete exercises in a quit booklet every day and practice behavioral skills between sessions.
223858546|NCT06961110|DIETARY_SUPPLEMENT|Hydrogen-rich water|Hydrogen-rich water with molecular hydrogen concentration 1.2-1.6 ppm. No added sugar or preservatives.
223858547|NCT06961110|DIETARY_SUPPLEMENT|Placebo|Drinking water with molecular hydrogen concentration 0.0 ppm. No added sugar or preservatives.
223858548|NCT05774587|BEHAVIORAL|mHealth control group|Cardiac rehab control group
223858549|NCT05774587|BEHAVIORAL|mHealth technology assisted exercise counselling (mHealth)|Exercise and counselling through mHealth technology
223858550|NCT03107403|BEHAVIORAL|web form|The scale assessing the bereavement process is the one reported in Teissier 2010
223858551|NCT01615432|DEVICE|V-PAP III ventilator|
223858552|NCT01615432|DEVICE|Stellar 150 ventilator|
223858553|NCT01615432|DEVICE|BiPAP vision ventilator|
223858554|NCT01615432|DEVICE|V60 ventilator|
223858555|NCT01406262|BIOLOGICAL|Albiglutide|once weekly subcutaneous injection
223858556|NCT01406262|DRUG|Moxifloxacin|oral tablet
223858557|NCT02175043|PROCEDURE|atrial electrogram and liner ablation|"1. The group of positive control is the operation to add in CFAE to conventional liner ablation in persistent atrial fibrillation patients~2. The group of negative is the operation to only doing conventional liner ablation with persistent atrial fibrillation"
223858558|NCT00692562|PROCEDURE|simultaneous islet-kidney transplantation|
223858559|NCT03484585|DRUG|Rogaratinib (BAY1163877)|Single dose, intake orally, 200 mg
223858560|NCT06251193|BEHAVIORAL|E-CBSST|E-CBSST is a blended intervention that combines Cognitive Behavioral Social Skills Training and Executive Function Training.
223858561|NCT03236064|DRUG|Polyethylene Glycols|Demonstrate more rapid and increased return of function by PEG-fusion compared to best current nerve repair techniques
223858562|NCT00819884|DRUG|AZD1656|Oral suspension
223858563|NCT02633358|DEVICE|Therapeutic hypothermia group|Therapeutic hypothermia
223858564|NCT01740063|DRUG|DAS181-F02 formulation|
223858565|NCT01740063|DRUG|DAS181-F04 formulation|
223858566|NCT01740063|DRUG|Placebo|
223858567|NCT04589000|OTHER|acupressure|"Throughout the study, acupressure will be applied to the acupressure group once on the post-op day 0, 2 times on the post-op 1st day, and once on the post-op 2nd day, 4 times in total for 15 minutes.~15 minutes after acupressure application, milk will be expressed for 15 minutes and the amount of milk expressed will be recorded in the milk measurement table."
223858568|NCT04559243|DIAGNOSTIC_TEST|Transthoracic Echocardiography|After the surgey, the tests data will be collected during 8 visits when the subjects go back to the hospital.
223858569|NCT02378116|PROCEDURE|Surgical closure of the left atrial appendage|When patients are randomized to surgical closure, the surgeon is informed to close the left appendage. Closure is documented by a member of the research group at the site.
223858570|NCT05303155|DIAGNOSTIC_TEST|16S rRNA sequencing|Fecal microbiome analysis using 16S rRNA sequencing
223858571|NCT06545994|OTHER|Observation|It's a observational cohort study and no interventions are performed.
223858572|NCT02935218|BEHAVIORAL|Parenting Skills for Mothers with BPD|The cognitive-behavioral Group Training for mothers with BPD consists of 12 weekly sessions promoting parenting skills including primary needs of children, stress and stress management, dealing with conflicts, mindfulness, emotion regulation, routine and flexibility, the role of the body in parenting, basic assumptions about parenting, and self-care.
223858573|NCT04761237|DRUG|Goal-directed fluid therapy (GDET)|Compensatory dilatation was performed firstly and 5ml/kg crystal solution was added within 30min before induction of anesthesia.When SVV≥13%, infusion of colloidal solution 2ml/kg was performed 15-20 minutes.If the increase of SV was≥10% after the liquid impact and the SVV was still≥13%, the colloidal solution was used again for 2mL/kg and the infusion was maintained until the SVV \< 13%.The infusion was stopped when the SVV \< 10%.If the increase of SV was less than 10% or CI \< 2.0L/min/m2 after infusion, dobutamine was given intravenously to observe the change of SV. If the increase of SV was greater than 10%, dobutamine could be maintained and the above fluid regimen continued.If the increase of SV was less than 10% and MAP≥65mmHg, the infusion of liquid was stopped and replaced with 4ml/kg/h infusion for maintenance.If the increase of SV was less than 10% and MAP was less than 65mmHg, the infusion was suspended.
223858574|NCT06281704|BIOLOGICAL|AK101 IV|AK101 will be administered intravenously.
223858575|NCT06281704|BIOLOGICAL|AK101 SC|AK101 will be administered subcutaneously.
223858576|NCT06281704|BIOLOGICAL|Placebo|Placebo will be administered subcutaneously or intravenously.
223858577|NCT06281704|BIOLOGICAL|AK101 IV/AK101 SC|AK101 will be administered as intravenous infusion at Week8, then subcutaneously every 8 weeks thereafter .
223858578|NCT04009642|OTHER|Surely observational based on disease state|Metabolism in T2DM vs non diabetic
223858579|NCT01169311|DEVICE|Hemorrhoidopexy|
223858580|NCT02306577|DRUG|STRIBILD|Taking oral 1 STRIBILD tablet once a day for 48 weeks
223858581|NCT03441763|DEVICE|Emed foot device|foot pressure will be measure by using emed foot pressure system
223858582|NCT04879082|OTHER|Professional course, occupational exposures|"The data collected are the following variables: age, sex, diploma, professional course coded in CITP (International Standard Classification of Professions) and NAF (French Nomenclature of Activities), occupational exposures, smoking, risk factors non-professionals, clinical elements of ILD and elements relating to an occupational disease certificate. This database is anonymized.~The precise diagnosis of ILD is retained during the multidisiciplinary meeting.~Occupational exposures are assessed in specialized consultation :~* a first professional interview phase: The professional history is traced, listing the training courses followed and the trades carried out. The questioning is precise and focuses on the different tasks performed, and the products used.~* a second step, where a questionnaire is completed by the doctor: A list of specific substances is offered to the patient, who responds whether or not he thinks he has been exposed to them in his professional past."
223858583|NCT02559518|DEVICE|tDCS|Current will be applied by a DC stimulator (NeuroConn Plus, Germany).The active electrode (anode: 5x5 cm²) will be placed over the left cerebellar hemisphere (3 cm lateral to the inion) and the reference (5x7 cm²), over the right arm with current intensity of 2mA, fade in and fade out of 10 seconds, during 20 minutes.
223858584|NCT02559518|DEVICE|tDCS|Current will be applied by a DC stimulator (NeuroConn Plus, Germany). The active electrode (cathode: 5x5 cm²) will be placed over the left cerebellar hemisphere (3 cm lateral to the inion) and the reference (5x7 cm²), over the right arm with current intensity of 2mA, fade in and fade out of 10 seconds, during 20 minutes.
223858585|NCT02559518|DEVICE|tDCS|Sham ctDCS will be applied using the same electrodes placement and parameter settings of cathodal ctDCS. However, stimulation will last only 30 seconds but volunteers will be with electrodes montage for 20 minutes.
223858586|NCT02559518|DEVICE|rTMS|High frequency c-rTMS will be applied through a figure-eight coil connected to a magnetic stimulator (Rapid², Magstim, UK) placed over the left cerebellar hemisphere (3 cm lateral to the inion), tangentially to the scalp and pointing upwards. Protocol: 10Hz, 110% RMT, 33 trains, 50 stimuli per train, intertrain interval of 25 seconds, 1650 stimuli.
224076247|NCT06169215|DRUG|Dexamethasone|Given PO
223858587|NCT02559518|DEVICE|rTMS|Low frequency c-rTMS will be applied through a figure-eight coil connected to a magnetic stimulator (Rapid², Magstim, UK) placed over the left cerebellar hemisphere (3 cm lateral to the inion), tangentially to the scalp and pointing upwards. Protocol: 1Hz, 110% RMT, 1000 stimuli (1 train).
223858588|NCT02559518|DEVICE|rTMS|Sham c-rTMS will be performed with low frequency protocol using two coils. The first one - connected to the stimulator (Rapid², Magstim, UK) - will be positioned on a coil support close to the volunteer but not visible. Therefore, characteristic stimulation noises will be audible. The second - disconnected to the stimulator - will be placed over left cerebellar hemisphere.
223858589|NCT02559518|DEVICE|pp-TMS assessment|SICI and ICF will be evaluated through pp-TMS. Subthreshold conditioning stimuli (80% of RMT) and suprathreshold test stimuli (120% of RMT) will be delivered at 2 milliseconds ISI, in order to determine SICI. ICF will be evaluated by MEP average at an ISI of 10 milliseconds. Ten stimuli will be applied at each condition (unconditioned pulse and pairs of stimuli with ISI of 2 and 10 milliseconds). Stimuli order delivery will be pseudo-randomized and SICI and ICF will be expressed as conditioned stimulus percentage regarding an unconditioned stimulus.
223858590|NCT01209546|OTHER|control group|In placebo patients were assessed and were not subjected to any respiratory physical therapy technique.
223858591|NCT01209546|OTHER|Flutter group|Patients have done exercise sessions with Flutter ®VRP1 for 30 minutes daily in a randomized, crossover, with four weeks of treatment with a therapy, a week of wash-out followed by four more weeks with the other modality (PEP).
223858592|NCT01209546|OTHER|PEP group|Patients have done exercise sessions with Flutter® VRP1 without the steel ball inside, with the closure of so many holes as necessary to produce a positive expiratory pressure equivalent to pressure achieved by patients during the performance with the ball in the Flutter®VRP1 for 30 minutes daily in a randomized, crossover, with four weeks of treatment with a therapy, a week of wash-out followed by four more weeks with the other modality (Flutter®VRP1).
223858593|NCT01209546|OTHER|Group Sham|Patients have done exercise sessions with Flutter ®VRP1 for 30 minutes without the ball inside daily in a randomized, crossover, with four weeks of treatment with a therapy, a week of wash-out followed by four more weeks with the other modality (PEP)
223858594|NCT02798718|DIETARY_SUPPLEMENT|full-fat milk|intake 250ml full-fat milk per day, do not intake any other dairy products
223858595|NCT02116543|DRUG|TD-6450|
223858596|NCT02116543|DRUG|Placebo|
223858597|NCT02899585|OTHER|Questionnaires|
223858598|NCT02899585|OTHER|Score|
223858599|NCT05394896|DEVICE|ACUMEN (Edwards Lifesciences, Irvine, USA)|ACUMEN sensor generates HPI index which should predict hypotension. Based on HPI index, Eadyn and dP/dTmax values anaesthesia should somministrate liquid or drugs to prevent hypotension.
223858600|NCT05394896|DEVICE|Invasive Blood Pressure|Invasive Blood Pressure permits continue monitoring of blood pressure (routine standard for kidney transplant surgery)
223858601|NCT01564875|DRUG|Simvast CR|Simvast CR Tab 20mg, 1 tablet once daily to be administered between 6 and 9 a.m.
223858602|NCT01564875|DRUG|Zocor|Zocor Tab 20mg, 1 tablet once daily to be administered between 6 and 9 p.m.
223858603|NCT04683718|DEVICE|Permanent implant of a BIOTRONIK Prospera SCS (Spinal Cord Stimulation) System with HomeStream Remote Management|The Prospera SCS System is a rechargeable, 16-electrode, MRI conditional Spinal Cord Stimulation system that delivers electrical stimulation to the dorsal column of the spinal cord for the treatment of chronic intractable pain of the trunk and/or limbs.
223858604|NCT04616053|BEHAVIORAL|IMPACT intervention|A referent is assigned to the patient. A referent is a health worker (nurse, nutritionist, psychologist …). Patient builds with his referent a free care program (without condition or limit). The patient can choose individual consultation (for example : nutrition, tabacology, psychology …) and/or collective care (for example : patient education, physical activity, relaxation …). A community health worker can help patient with his health administrative procedures. This intervention lasts 6 months.
223858605|NCT00845611|BIOLOGICAL|peptide vaccine|peptides emulsified with Montanide ISA51
223858606|NCT00241644|BIOLOGICAL|Rotarix™|Two or Three doses, oral administration
223858607|NCT00241644|BIOLOGICAL|Placebo|One or three doses, oral administration.
223858608|NCT00366353|OTHER|Sedation during SBT|
223858609|NCT00366353|OTHER|No sedation|
223858610|NCT00793286|PROCEDURE|Mesh fixation by staples|Mesh fixation by staples
223858611|NCT00793286|PROCEDURE|Mesh fixation by glue|Mesh fixation by glue
223858612|NCT00012506|DRUG|TNFR:Fc|
223858613|NCT05246553|PROCEDURE|Electrical stimulation of the vestibular system|Patients are implanted with a modified cochlear implant (CI) which comprises one to three extracochlear electrodes that are placed in the proximity of vestibular afferents (i.e., vestibular nerves or the ampullae of each semicircular canal), and an intracochlear array. Trains of electrical stimulation in the form of charge-balanced, biphasic pulses can be delivered through each of the implanted electrodes (cochlear or vestibular) and modulated via computer-controlled signals, audio signals (captured with a microphone) or by signals captured by head-mounted motion sensors.
223858614|NCT05246553|PROCEDURE|Electrical stimulation of the auditory system|A cochlear implant (CI) is a device providing a sense of sound to a person who suffers from severe to profound sensorineural hearing loss. A CI comprises the following parts, a microphone (capturing the sound from the environment), a speech processor (receiving and encoding the sounds captured by the mircophone), a transmitter-receiver antenna pair (transmitting the information from the external to the implanted components), an implanted stimulator (converting the signal into a tonotopically arranged set of electrical pulses) and an electrode array inserted in the cochlea that will deliver the electrical pulses to different portions of the auditory nerve. Trains of electrical stimulation in the form of charge-balanced, biphasic pulses can be delivered through each of the electrodes in the cochlear array and modulated via computer-controlled signals or audio signals (captured with a microphone).
223858615|NCT05246553|DIAGNOSTIC_TEST|Bilateral vestibulopathy Patients (BV)|Diagnosis established on the basis of the consensus document of the Classification Committee of the Bárány Society (Strupp et al., Journal of Vestibular Research, vol. 27, no. 4, pp. 177-189, 2017).
223858616|NCT05246553|DIAGNOSTIC_TEST|Unilateral vestibulopathy Patients (UV)|Patients with documented diagnosis of unrecovered unilateral vestibulopathy, consistent with the current classification of vestibular disorders of the Bárány Society (www.jvr-web.org/ICVD.html).
224076248|NCT06169215|DRUG|Lenalidomide|Given PO
224076249|NCT06169215|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223858617|NCT05662891|OTHER|Blood Flow Restriction|After randomization, a cuff was placed proximal to one lower extremity. Blood flow was restricted from 60% of the arterial occlusion pressure. The other extremity was determined as the control group. 3x5 nordic hamstring exercises were performed. Surface emg was measured for hamstring muscles during exercise.
223858618|NCT00261547|DRUG|Rituximab|All subjects will be treated with Rituximab 1000 mg (1 g) intravenously on days 1 and 15.
223858619|NCT03060642|DEVICE|Tethered capsule sponge|Subjects swallow a tethered capsule sponge sampling device, which is then withdrawn through the mouth after an interval of 5 minutes.
223858620|NCT03060642|DEVICE|Electronic nose device|Subjects breathe into the device, which then records an exhaled volatile organic compounds (VOC) signature.
223858621|NCT02079155|PROCEDURE|robot-assisted laparoscopic surgery|Undergo RALP
223858622|NCT02079155|PROCEDURE|robot-assisted laparoscopic surgery|Undergo R-LESS RP
223858623|NCT02079155|OTHER|laboratory biomarker analysis|Correlative studies
223858624|NCT02079155|OTHER|quality-of-life assessment|Ancillary studies
223858625|NCT02079155|OTHER|questionnaire administration|Ancillary studies
223858626|NCT03751150|OTHER|Exercise program|The runners will be asked to perform the training program twice a week. The intervention consist of muscle control and foam rolling exercises for the lower extremities.
223858627|NCT04136639|OTHER|Miswak|sticks
223858628|NCT04136639|OTHER|Grape Seed Extract Mouthwash|Mouthwash
223858629|NCT04136639|OTHER|fluoride|mouthwash
223858630|NCT01027286|DEVICE|Vitagel|Vitagel applied just prior to closure during primary total knee arthroplasty
223858631|NCT00003429|PROCEDURE|biopsy|
223858632|NCT00003429|PROCEDURE|computed tomography|
223858633|NCT00003429|PROCEDURE|positron emission tomography|
223858634|NCT00003429|RADIATION|fludeoxyglucose F 18|
223858635|NCT06343584|OTHER|Study will conducted over a six-month period using a quasi-experimental Pre-test/Post-test design using Stamm's (2009) ProQOL Scale.|Group 1 will receive a list of suggested tools used to decrease the amount of smartphone interruptions after business hours (Appendix B) and Group 2 will receive a work-issued smartphone with instructions for use (Appendix C). Both groups will use a pre-post test format designed to compare the outcomes between the two groups. Post-study analysis will compare pre- and post-tests within each group and will compare Group 1 and Group 2 post-intervention outcomes.
223858636|NCT04132024|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia (CBT-I)|CBT-I has a specific protocol with behavioral targets that differ significantly from standard CBT. This approach focuses on implementing sleep restriction and stimulus control interventions which are fully deployed during the first session. 5 CBT-I sessions will be delivered over the course of 8 weeks. Key recommendations include: 1) reduce time in bed; 2) get up at the same time every day; 3) do not go to bed unless sleepy; 4) do not stay in bed awake for more than 15 minutes; and 5) avoid napping. Participants are also taught relaxation strategies and cognitive therapy addresses arousal and catastrophizing.
223858637|NCT05575869|OTHER|(online) PRONEtect educational material|This is a website containing educational material like short simulation videos on how to turn a patient from supine-to-prone and prone-to-supine positioning, how to protect the skin from incontinence, or before securing endotracheal-/nasogastric tubes, how to reposition the patient to prevent pressure injuries, a full protocol regarding prone positioning etc.
223858638|NCT05575869|OTHER|Classic (normal) one hour lesson/lecture|As per normal, a classroom lecture given by the nursing school by one of the nursing school lecturers.
223858639|NCT05532813|DRUG|Treatment taken|Treatment (Metformin or placebo) will be administered orally and titrated following the same guideline that metformin in diabetic patient: start with a daily dose of 500 mg twice a day, given during or after meals; then increase to 1000 mg twice a day after a week. If digestive tolerance is good, treatment will be increased to a maximum of 1000 mg three times a day i.e. 3000 mg/day after another week.
223858640|NCT03662048|BEHAVIORAL|Safe|Feedback, according to the 2016 national American Academy of Pediatrics (AAP) guidelines on Sudden Unexplained Infant Death (SUID) risk factors, will be generated by the study team and communicated with parents. Feedback will be given to parents in the intervention group at ages 1 and 2 months. The control group parents will only receive this feedback at age 2 months.
223858641|NCT00714558|DRUG|Fentanyl citrate; Naltrexone; Naloxone|
223858642|NCT04189900|DRUG|Triptorelin|Subjects receive a single subcutaneous dose of 0,1 mg of Triptorelin acetate.
223858643|NCT06118229|DEVICE|Wearable smart devices and PROs|Patients wearing wearable smart devices to monitor physiological data while regularly utilizing PROs to report subjective assessments of their own health status.
223858644|NCT03333655|PROCEDURE|Biopsy|Participants who received or are receiving CPI therapy for metastatic cancer or hematologic malignancies.
223858645|NCT04604054|DRUG|Granulocyte Colony Stimulated Factor|GCSF was intrauterine injected once at ovum pick up day
223858646|NCT04604054|DRUG|Human Chorionic Gonadotropins|500 IU of HCG was injected intrauterine once at ovum pick up day
223858647|NCT03495284|DIETARY_SUPPLEMENT|Potato-based side dish|Daily consumption of a potato-based side dish equivalent to one medium size potato for 4 weeks
223858648|NCT03495284|DIETARY_SUPPLEMENT|Refined grain-based|Daily consumption of an isocaloric refined grain-based side dish for 4 weeks
223858649|NCT00199641|DEVICE|enteral nutrition|
223858650|NCT02918916|OTHER|Phototherapy|The dosage applied will be 30 Joules per site (180 Joules per muscle). Parameters are described in the attached document.
223858651|NCT02918916|OTHER|Placebo|The same procedures as in the active phototherapy group will be applied to the placebo phototherapy group; however the emitter will be disabled.
223858652|NCT02896894|OTHER|Big White Wall (BWW)|"The BWW is an internet-based intervention that incorporates several elements of mental health care that have been shown to be effective, in a virtual environment that provides anonymity (see www.bigwhitewall.com). The on-line portal gives users access to self-assessment tools to track symptoms for a wide range of conditions over time, educational materials, a social network that allows communication between people who may have similar problems, and access to on-line courses. The service is monitored at all times by Wall Guides to ensure that users are responded to and that the content posted is appropriate and safe."
223858653|NCT03767257|DRUG|Colesevelam Pill|For treatment with colesevelam, the starting dose will be 1250 mg (2 x 625 mg) with food which can be increased to 6 tablets max per day based on efficacy and tolerability. Coleveselam should not be taken within 4 hours before or after lenalidomide and other interacting medications. All participants will be given a pill diary to record intake of colesevelam. The effect of colesevelam on lenalidomide-associated diarrhea will be evaluated after 1, 2, 4, 12 weeks after start of treatment. If the diarrhea does not respond to the starting dose of colesevelam, the dose can be increased every 2 days to 2 tablets two times per day (2 x 625 mg BID) and later to 3 tablets two times per day (3 x 625 mg BID). The colesevelam dose can be decrease to 1 tablet per day if there has been improvement of diarrhea but emergence of side effects.
223858654|NCT05381701|PROCEDURE|Lung Ultrasound Score|Measuring the atelectasis area by ultrasound guidance from 12 different regions of the lung
223858655|NCT03080792|BEHAVIORAL|Experimental: moderate to high-intensity exercise|2x per week endurance exercise (continuous moderate and high intensity intervall training on a cycle ergometer) and progressive resistance training (machine based hypertrophy training)
223858656|NCT04194502|DIAGNOSTIC_TEST|Transesophageal echocardiogram (TEE)|All patients enrolled in the study will undergo a pre-operative research TEE and an intra-operative clinical TEE.
223858657|NCT01253499|DRUG|TRx0037|75mg and 100mg tablets used to create doses of 100mg and 175mg. Active placebo 2mg and blank placebo used as comparators.
223858658|NCT00522756|DRUG|Sodium bicarbonate|Three ampoules of 7.5% sodium bicarbonate (89.3 mOsm/ampoule; total 150 ml for three ampoules) added to 750 ml of 5% dextrose in water, given at 1 ml/kg/hour through a dedicated intravenous line for 6 hours, and completed prior to the initiation of cardiopulmonary bypass.
223858659|NCT00522756|DRUG|Sodium chloride|0.9% sodium chloride given at 1 ml/kg/hour through a dedicated intravenous line for 6 hours, and completed prior to the initiation of cardiopulmonary bypass.
223858660|NCT04437056|PROCEDURE|Cognitive nerve transfers to spastic upper extremity muscles in stroke patients|Based on the fact that upper motor neuron syndrome after stroke is presented with variable clinical features, usually without affecting in the same way the entire upper extremity, we aim to investigate the efficacy of nerve transfers to spastic muscles after stroke using as donor nerves that innervate unaffected ipsilateral volitionally controlled muscles.
223858661|NCT05610696|OTHER|Low impact immersion|Consists of a sequence of shoulder, trunk and hip movements. In this modality, the aim will be to understand the physiological effects of immersion in heat water. Resisted movements (either by turbulence or by floats) or interventional maneuvers in the knee joints will not be performed. Considering the period of 5 minutes for acclimatization to the liquid environment, the program will last approximately 47 minutes.
223858662|NCT05610696|OTHER|Conventional aquatic physiotherapy|include warm-up, strengthening and calming down activities. Aquatic steppes will be used to ensure that all participants will maintain the waterline level approximately in the xiphoid appendix. For strengthening activities, the exercises must be performed at an adequate speed, which ensures a comfortable level for the activity. For this purpose, a subjective feedback will be extracted from the participants constantly. The warm-up sequence consists of six different active hip and knee movements performed at maximum range of motion and contributes to neuromuscular activation. For strengthening, each movement should be performed for 1 minute (30 seconds for each lower limb) followed by a period of 30 seconds of rest between each movement.
224076250|NCT06169215|PROCEDURE|Positron Emission Tomography|Undergo PET
224076251|NCT06169215|DRUG|Selinexor|Given PO
223858663|NCT05610696|OTHER|High intensity aquatic physiotherapy|In this modality subjects will perform the same sequence of exercises of the Conventional Aquatic Physiotherapy program will be respected. However the work load and speed will be adjusted to the maximum level. For strengthening, each movement should be performed for 2 minutes (1 minute for each lower limb) followed by a period of 30 seconds of rest between each movement. To guarantee the maximum effort of the participants, verbal stimuli will be constantly provided. The program will last approximately 68 minutes.
223858664|NCT02507336|DRUG|Thalidomide|100-300 mg capsule taken by mouth once daily.
223858665|NCT03889678|DIAGNOSTIC_TEST|Color flow doppler|Color flow doppler proximal to vein insertion site to document flow
223858666|NCT03775551|BEHAVIORAL|Improvement cycle|at least 6 workshops (sessions) will be held with the members of the care system, in order to identify opportunities for improvement oriented to the design and application of an innovative intervention based on best practices.
223858667|NCT04270604|OTHER|Biological sample collection|Biological sample collection for biobanking and research
223858668|NCT03683628|PROCEDURE|PB-MNC therapy|The patients will receive subcutaneous injection of Granulocyte colony stimulating factor (G-CSF) for 3 day. The mononuclear cell will be collected by blood cell separator. The 120 cc of cell solution will be injected into calf or thigh of ischemic limb (1cc per site) with needle no. 25 gauge. Patients will receive ASA 81 mg once daily and walking exercise 3 times/ week
223858669|NCT03683628|DRUG|No PB-MNC therapy|Patients will receive ASA 81 mg once daily and walking exercise 3 times/ week
223858670|NCT01392872|OTHER|Neuropsychological assessment|This study will evaluate the impact of these treatments on cognitive disabilities, tiredness state, emotion and quality of life in general, on a lengthened period.
223858671|NCT01377519|PROCEDURE|MR Guided Focused Ultrasound|This is an FDA approved noninvasive treatment for fibroids that uses highly focused ultrasound waves to damage fibroid tissue.
223858672|NCT01377519|PROCEDURE|Placebo MR Guided Focused Ultrasound|This is a placebo treatment that requires a participant to undergo identical procedures as those of the actual MR Guided Focused Ultrasound procedure, but higly focused ultrasound waves are not directed at the uterine fibroid.
223858673|NCT04586036|OTHER|ankle joint brace 1|The influence of ankle joint brace 1 on gait biomechanics
223858674|NCT04586036|OTHER|ankle joint brace 2|The influence of ankle joint brace 2 on gait biomechanics
223858675|NCT04586036|OTHER|ankle joint brace 3|The influence of ankle joint brace 3 on gait biomechanics
223858676|NCT04586036|OTHER|ankle joint brace 4|The influence of ankle joint brace 4 on gait biomechanics
223858677|NCT04586036|OTHER|ankle joint brace 5|The influence of ankle joint brace 5 on gait biomechanics
223858678|NCT01455051|DRUG|Ofatumumab|We plan to add five doses of ofatumumab to the standard conditioning regimen (fludarabine + melphalan). Ofatumumab will be administered on days -20 (300 mg), -13 (2000 mg), -6 (2000 mg), +1 (1000 mg) and +8 (1000 mg) of the transplantation (day 0 being the day of the hematopoietic cell infusion). If the patient requires donor lymphocyte infusions within 3 years after the procedure, these infusions will also include one administration of 300 mg of ofatumumab, followed by a 1000 mg dose, 7 days later).
223858679|NCT04213560|DEVICE|weighted waist-hooping|weighted waist-hooping
223858680|NCT02706067|DRUG|Orlistat|Participants will receive orlistat on an intermittent basis as 120 milligrams (mg) three times a day: once with breakfast, once with lunch, and once with dinner. In case of weight relapse (increase 2.5 percent \[%\] or more from Baseline) orlistat will be administered for up to 2 months or until weight regain reaches 0% from Baseline. For special occasions (feasts, birthdays, anniversaries) orlistat will be given for up to 3 days.
223858681|NCT05566418|OTHER|mulligan mobilization|Mulligan mobilization belt will be wrapped around the subject's proximal forearm, close to the elbow joint line, and then wrapped around the therapist's shoulder. This will be done with the therapist's other hand on the distal humerus. The belt will give the subject's forearm a 10-to 15-second lateral glide.
223858682|NCT05566418|OTHER|myofascial release|Myofascial release will be performed on the patient, commencing at the common extensor origin and progressing all the way to the extensor retinaculum in the wrist. The periosteum will be engaged with the fingertips, with contact progressing inferiorly to the common extensor tendon and then to the wrist's extensor retinaculum
223858683|NCT01563354|DRUG|Pasireotide LAR|60 mg was administered as an intra muscular depot injection once every 28 days starting at Day 1
223858684|NCT01563354|DRUG|Everolimus|10 mg tables administered orally once a day
223858685|NCT01563354|DRUG|Pasireotide LAR and Everolimus Combination|Pasireotide LAR 60 mg i.m. injected once every 28 days + Everolimus 10 mg p.o. daily
223858686|NCT03522558|BEHAVIORAL|Standardized Medical Nutrition Therapy|Standardized Medical Nutrition Therapy will include nutrition assessment provided by a registered dietitian (RD) at initial clinic visit or first Well Child Check (WCC) and regularly scheduled nutrition follow-up at each WCC visit thereafter.
223858687|NCT03522558|BEHAVIORAL|Usual Care|At the primary care provider's discretion, a nutrition consult can be requested for the RD to perform nutrition assessment or discuss the patient's plan without full nutrition assessment, as is current practice. Currently in the Neonatal High-Risk Clinic (NHRC) and High Risk Children's Clinic (HRCC) at UTHealth, providers consult the RD as deemed appropriate with no established criteria for when to include the RD in patient care. Usual care will not be modified by the study protocol.
223858688|NCT04390958|DRUG|nab-paclitaxel|125mg/m2 ivgtt d1、d8
223858689|NCT04390958|DRUG|Cisplatin|60mg/m2 ivgtt d1 or d1-2
223858690|NCT04390958|DRUG|Capecitabine|1750mg/m2 po bid d1-14
223858691|NCT00316316|BEHAVIORAL|Motivational interviewing plus exposure and response prevention (MI plus EX/RP)|Participants will receive 18 sessions of MI plus EX/RP.
223858692|NCT00316316|BEHAVIORAL|Exposure and response prevention (EX/RP)|Participants will receive 18 sessions of EX/RP.
223858693|NCT02061930|PROCEDURE|single crowns supported by implants|The implant placement procedures were planned based on clinical and radiographic evaluation. During the surgeries, the mid-crestal incision and intra-crevicular incision were made following local articaine infiltration anesthesia. No releasing incisions were made. After full-thickness flaps were elevated labially and lingually to expose the alveolar ridge, the implants were placed according to the standard surgical procedures defined by the manufacturer. After a healing time of 10-16 weeks, implant-level impressions were taken. The porcelain (Ivoclar-Vivadent AG, Schaan, Lichtenstein) fused to noble metal crowns were fabricated. Abutment screws were torqued to 15 Ncm. Crowns were cemented with HY-bond Glassionomer Cement
223858694|NCT03097016|DRUG|CC-122|All subjects will receive one 3 mg CC-122 capsule the morning of Day 1 which will be administered in the fasted state.
223858695|NCT01565928|DRUG|MDV3100|4 x 40 mg capsules, orally, once per day
223858696|NCT00048529|DRUG|T900607-sodium intravenous|
223858697|NCT01119950|DRUG|NVA237 12.5 µg once daily|NVA237 12.5 µg via dry powder inhaler once daily for 28 days during either period 1 or during period 2.
223858698|NCT01119950|DRUG|NVA237 25.0 µg once daily|NVA237 25.0 µg via dry powder inhaler once daily for 28 days during either period 1 or during period 2.
223858699|NCT01119950|DRUG|NVA237 12.5 µg twice daily|NVA237 12.5 µg via dry powder inhaler twice daily for 28 days during either period 1 or during period 2.
223858700|NCT01119950|DRUG|NVA237 50.0 µg once daily|NVA237 50.0 µg via dry powder inhaler once daily for 28 days during either period 1 or during period 2.
223858701|NCT01119950|DRUG|NVA237 25.0 µg twice daily|NVA237 25.0 µg via dry powder inhaler twice daily for 28 days during either period 1 or during period 2.
223858702|NCT01119950|DRUG|NVA237 100.0 µg once daily|NVA237 100.0 µg via dry powder inhaler once daily for 28 days during either period 1 or during period 2.
223858703|NCT01119950|DRUG|NVA237 50.0 µg twice daily|NVA237 50.0 µg via dry powder inhaler twice daily for 28 days during either period 1 or during period 2.
223858704|NCT01119950|DRUG|Placebo to NVA237 once daily|Placebo to NVA237 via dry powder inhaler once daily for 28 days during either period 1 or during period 2.
223858705|NCT04353674|DEVICE|Control group|Patients randomized into this group will receive standard of care for COVID-19 infection
223858706|NCT04353674|DEVICE|SLEDD with a L-MOD|Patients randomized to this group will undergo slow low efficiency daily dialysis for approximately 12 hours, 2 days in a row with a leukocyte modulatory device.
223858707|NCT05218733|PROCEDURE|Ultrasound Guided Erector Spinae Plane Block|General anesthesia using intravenous fentanyl (1µgm/kg) and patients will receive bilateral ultrasound-guided ESPB by the an experienced anesthetist in US regional blocks, with each block 20 mL of bupivacaine 0.25%
223858708|NCT05218733|DRUG|Intra thecal morphine.|General anesthesia using intravenous fentanyl (1µgm/kg) and patients will receive intra thecal morphine with spinal needle 25G, 3 ml containing 300 ug preservative free morphine
223858709|NCT05218733|DRUG|General anesthesia using intravenous fentanyl (1µgm/kg)|Patients will receive general anesthesia using intravenous fentanyl (1µgm/kg)
223858710|NCT00319085|PROCEDURE|Total hip replacement (Preheating of femur stem)|Total hybrid hip arthroplasty, cementation of femural component, preheating, radiostereometry, DEXA
223858711|NCT03801551|DIAGNOSTIC_TEST|Validate according to psychometric criteria, a dimensional measure of apathy in a population suffering from schizophrenia spectrum disorder and other psychotic disorders (according to DSM-5 criteria).|Validate according to psychometric criteria, a dimensional measure of apathy in a population suffering from schizophrenia spectrum disorder and other psychotic disorders (according to DSM-5 criteria).
223858712|NCT05966779|OTHER|modified CDT physical therapy protocol, based on Godoy's Method|modified CDT physical therapy protocol
223858713|NCT05823181|DEVICE|laparoscopy|laparoscopic exploration of common bile duct
223858714|NCT00478335|DRUG|sildenafil|25 mg quaque die (QD) or 50 mg QD x 4 days based on subject weight
223858715|NCT00478335|DRUG|calcitonin|one nasal spray daily for 4 days
223858716|NCT00478335|DRUG|hydrochlorothiazide/amiloride|25 mg/2.5 mg BID or 50 mg/5 mg BID x 8 days depending on subject weight
223858717|NCT00478335|DRUG|indomethacin|50 mg QD or 50 mg BID x 8 days depending on subject weight
223858718|NCT00478335|DRUG|Placebo for sildenafil|one tablet daily for 4 days
223858719|NCT00478335|DRUG|placebo for calcitonin|one nasal spray daily
223858720|NCT02684565|DIETARY_SUPPLEMENT|BCAA High Protein supplement|Subjects will be randomly assigned to take high BCAA or low-BCAA protein a day for 4 weeks, then switch to BCAA or low-BCAA protein for 4 weeks after a 2-week washout.
223858721|NCT02684565|DIETARY_SUPPLEMENT|BCAA Low Protein supplement|Subjects will be randomly assigned to take high BCAA or low-BCAA protein a day for 4 weeks, then switch to BCAA or low-BCAA protein for 4 weeks after a 2-week washout.
223858722|NCT05483335|OTHER|No intervention but assessing for burnout syndrome in all group|Using Maslach Burnout inventory to assess the presence of burnout and a self reporting questionnaire to identify possible stressors or associations
223858723|NCT05879588|OTHER|immediate orthodontic retainer delivery|post orthodontic treatment patients will be given orthodontic retainer immediately after debonding
223858724|NCT05879588|OTHER|delayed orthodontic retainer delivery|post orthodontic treatment patients will be given orthodontic retainer after 3 days of debonding
223858725|NCT03990220|DIETARY_SUPPLEMENT|Lactobacillus rhamnosus yoba 2012|"Probiotics are defined by the Food and Agricultural Organization (FAO)/WHO as live microorganisms, which when consumed in adequate amounts, confer a health benefit on the host. Lactobacillus rhamnosus GG (LGG) is the most documented probiotic bacteria, with many proven unique characteristics and therewith associated health benefits. No adverse effects of the consumption of LGG in healthy infants have been reported. The Lactobacillus rhamnosus yoba containing yoghurt drink, which is locally produced and subsequently consumed by resource-poor communities in rural Uganda has been described. The strain used in this intervention is a generic variant of LGG, called Lactobacillus rhamnosus yoba 2012. LGG is consumed as part of food all over the world, and is not a drug."
223858726|NCT04943380|DIAGNOSTIC_TEST|Cxbladder|The Cxbladder Detect test, developed by Pacific Edge Ltd (O'Sullivan 2012; Holyoake 2008; National Health Committee 2015b) is a molecular diagnostic test, which consists of five mRNA transcripts measured in a small volume of urine.
223858727|NCT02710149|BIOLOGICAL|Anti-CD20-CAR-transduced T cells|Patients receive autologous-derived CD20-targeted CAR-T cells on day 1, 2 after receiving lymphodepleting chemotherapy.
223858728|NCT01689272|PROCEDURE|Kidney Transplantation from alive relative donor|Donor kidney sampling, preservation, transport and transplantation
223858729|NCT02572219|DIETARY_SUPPLEMENT|Nutraceutical compound|
223858730|NCT02572219|DIETARY_SUPPLEMENT|Placebo|
223858731|NCT01988233|BEHAVIORAL|BAILAMOS© Dance Program|
223858732|NCT01988233|BEHAVIORAL|Health Education Control Group|
223858733|NCT04369534|DRUG|Clopidogrel|Adjusting clopidogrel dosage according to platelet reactivity results during 12 months after PCI
223858734|NCT04369534|DRUG|Ticagrelor|Administration of standard dose of ticagrelor during 12 months after PCI
223858735|NCT01844141|DRUG|70% alcohol|After phenolization of the ingrown toenail the wound is irrigated with 15 cc solution of 70% alcohol plus 0.5% clorhexidine
223858736|NCT01844141|DRUG|70% alcohol - 0.5% clorhexidine|In the intervention group five rounds of 3 ml wash of 70% alcohol - 0.5% clorhexidine was used to irrigate the exposed area of the nail to neutralize any residual effect of phenol and found out how much residual phenol is still in the wound.
223858737|NCT00470106|BEHAVIORAL|Cognitive remediation|Computer exercises in attention, memory, and speed of processing.
223858738|NCT00470106|BEHAVIORAL|Social Cognitive skills training|Group training on emotion perception, social perception, and understanding others' mental states.
223858739|NCT00470106|BEHAVIORAL|hybrid intervention|A combination of the two groups listed above.
223858740|NCT00470106|BEHAVIORAL|skills training|Skills training in how to identify symptoms of illness and medication side effects.
223858741|NCT04915599|DEVICE|Cooral® mouth cooling device (MCD)|Cooral® mouth cooling device (MCD) to prevent oral mucositis (QM) in patients undergoing radiation therapy for head and neck malignancies
223858742|NCT03621761|BEHAVIORAL|Telephone-based Cognitive Behavioral Therapy|"Cognitive behavioral therapy (CBT) is a behavioral-based treatment that promotes effective self-management skills, including adaptive thought processes and behaviors (i.e. coping skills). CBT also commonly teaches goal-setting and behavioral activation strategies for engaging in physical, social, and other valued activities in the context of fatigue."
223858743|NCT03621761|DRUG|Modafinil|Modafinil is a safe, well-tolerated and effective wake-promoting agent (oral medication) that is FDA-approved for the treatment of fatigue related to sleep disorders. Modafinil is also one of the most commonly used medications for multiple sclerosis related fatigue in clinical practice, with doses ranging from 50 - 400 mg per day, in divided doses (once to twice daily).
223858744|NCT00711542|BIOLOGICAL|autologous bone marrow-derived progenitor cells|intracoronary infusion of autologous bone marrow-derived progenitor cells isolated from 50 ml bone marrow aspirate
223858745|NCT00711542|BIOLOGICAL|placebo medium|intracoronary infusion of placebo medium
223858746|NCT05392179|DRUG|ADX-2191|Monthly intravitreal injections of ADX-2191 (400 µg in 0.05 mL) for a total of three injections. Evaluation through week 16.
223858747|NCT05392179|DRUG|ADX-2191|Monthly intravitreal injections of ADX-2191 (400 µg in 0.05 mL) for a total of six injections. Evaluation through week 16.
223858748|NCT00444431|PROCEDURE|Pyeloplasty|
223858749|NCT00217672|BIOLOGICAL|bevacizumab|Patients receive bevacizumab 15 mg/kg intravenously (I.V.) every 3 weeks until disease progression, unacceptable toxicity, or consent withdrawal.
223858750|NCT00217672|DRUG|Docetaxel|docetaxel: 75 mg/m2 IV q3 weeks. Subjects continue on dosing until they experience unacceptable toxicity, disease progression, or withdrawal of patient consent.
223858751|NCT01050569|DRUG|Nicotine Patch|21 mg
223858752|NCT01050569|OTHER|VLNC Cigarette|Cigarette where the tobacco contains \<0.1 mg of nicotine yield.
223858753|NCT01050569|OTHER|VLNC Cigarette Plus Nicotine Patch|21 mg nicotine patch plus use of cigarette with tobacco containing \<0.1 mg nicotine yield.
223858754|NCT01161563|DRUG|Triptorelin pamoate|Triptorelin pamoate for injectable suspension 22.5 mg administered as a single intramuscular injection in either buttock
223858755|NCT01161563|DRUG|Leuprolide acetate|Leuprolide acetate for injectable suspension 45 mg administered as a single subcutaneous injection in the upper- or mid-abdominal area.
223858756|NCT03951649|DRUG|Occipital Nerve Block|This is an open label randomized controlled trial evaluating response to bupivacaine occipital nerve block compared to Tylenol/Caffeine cocktail in treatment of pregnant patients seeking care of headache.
223858757|NCT02852863|OTHER|Gum|Subjects will fast for a minimum of 8 hours. A baseline ultrasound assesment will be performed to evaluate gastric content. Next, subjects will chew sugarless gum for one hour with changes of gum every 20 minutes (a total of 3 gums will be chewed per subject). Once the last gum is chewed, the gum will be disposed in the trashcan. Three more ultrasound assessments will take place: immediately after one hour of chewing gum, and at the first and second hour after chewing gum has stopped. The content will be classified as empty, with fluids, or with solid. In case of fluids, volume will be measured.
223858758|NCT00869037|DRUG|Periarticular Injection|A 20 ml bolus of saline will be given through the sham femoral nerve block catheter. Periarticular infiltration solution containing 400 mg Ropivicaine, 30 mg Ketorolac, 5 mg Epidural Grade Morphine, and 0.6 ml of 1:1000 Epinephrine will be made up to a volume of 100 ml with saline. Intra-op, 20 ml will be injected into the posterior capsule; 40 ml in the quadriceps mechanism, retinacular tissues, medial and lateral collateral ligaments; 40 ml in the skin and subcutaneous tissues. The sham catheter will be connected to a saline infusion running at 15 ml/hr until the morning of post-operative day 2.
223858759|NCT00869037|DRUG|CFNB + Posterior Capsular Injection|A 20 ml bolus of 0.2% Ropivacaine will be given via a femoral nerve catheter. Periarticular infiltration will be performed intra-op. 20 ml of 1% Ropivacaine in the posterior capsule; 20 ml of normal saline in the quadriceps mechanism, retinacular tissues, medial and lateral collateral ligaments; 20 ml of normal saline for the skin and subcutaneous tissues. Postoperatively, the femoral catheter will be infused with 0.15% Ropivacaine running at 15 ml/hour until the morning of post-operative day 2
223858760|NCT05356312|BIOLOGICAL|Vaccination|Personalized neoantigen vaccination
223858761|NCT01591616|DRUG|lidocaine and prilocaine|Appropriate dose of Oraqix based on weight will be given before tooth extraction
223858762|NCT00758602|DRUG|mycophenolate mofetil|0.75-1 g PO BID from Day 0 through Month 12
223858763|NCT00758602|DRUG|tacrolimus, standard dose|Initial dose of 0.1-0.15 mg/kg PO BID to reach a target trough dose of 8-10 ng/mL from Day 0 through Month 3; the dose was adjusted to reach a target trough level of 7-10 ng/mL in Month 3 and continued through Month 12.
223858764|NCT00758602|DRUG|tacrolimus, low dose|Initial dose of 0.1-0.15 mg/kg PO BID to reach a target trough dose of 8 to 10 ng/mL from Day 0 through Month 3; 0.05-0.08 mg/kg PO BID to reach a target trough dose of 2-5 ng/mL in Month 3 and continued through Month 12.
223858765|NCT00758602|DRUG|corticosteroids|According to center's practice
223858766|NCT02508844|DIETARY_SUPPLEMENT|Vivomixx®|probiotics intake (four capsules of Vivomixx®; total of 450 billion CFU/day) from gestational age 14-20 until delivery
223858767|NCT02508844|DIETARY_SUPPLEMENT|Placebo|Four capsules/day from gestational age 14-20 until delivery. The placebo capsule contains microcrytalline cellulose, magnesium stearate and silicon dioxide.
223858768|NCT04379713|BIOLOGICAL|20-valent pneumococcal conjugate vaccine|Pneumococcal conjugate vaccine
223858769|NCT04379713|BIOLOGICAL|13-valent pneumococcal conjugate vaccine|Pneumococcal conjugate vaccine
223858770|NCT00755781|DRUG|Cyclosporine Inhalation Solution (CIS)|Cyclosporine (USP) Inhalation Solution; 300mg/4.8 mL in propylene glycol (USP) at a concentration of 62.5 mg/mL; 3 times a week for study duration (up to 3 years)
223858771|NCT05125133|OTHER|ITENs + ITWS|A dual active ingredient (dual AI) Insecticide-Treated Eave nets (ITENs) in combination with Insecticide Treated Window screens (ITWS) for house modification.
223858772|NCT04946045|OTHER|Sensorimotor Interventions (Tactile/Kinesthetic Stimulation+Nonnutritive Sucking)|"Sensorimotor interventions were applied to in preterm infants between 30-33 weeks of age for 10 days. After that, preterms were included in the Six-phase feeding progression protocol."
223858773|NCT05539248|DRUG|CAN106 20 mg/kg|"Induction and maintenance dosing for cohort 1:~12 mg/kg on Day 1, 16 mg/kg on Day 8, and 20 mg/kg on Day 15 and every 4 weeks thereafter;"
223858774|NCT05539248|DRUG|CAN106 40 mg/kg|"Induction and maintenance dosing for cohort 2:~30 mg/kg on Day 1, and 40mg/kg on Day 8 and every 4 weeks thereafter；"
223858775|NCT05539248|DRUG|CAN106 80 mg/kg|"Induction and maintenance dosing for cohort 3:~60 mg/kg on day 1, and 80 mg/kg on day 15 and every 8 weeks thereafter."
223858776|NCT03219645|DRUG|Ginkgo Diterpene Lactone Meglumine Injection|The injection must be added slowly into 0.9% sodium chloride injection and diluted to 250 ml , intravenous drip for about 2 hours.
223858777|NCT03219645|DRUG|Acetylsalicylic acid|Acetylsalicylic acid (Aspirin) given in a total dose of 300 mg on the first day, followed by 100 mg once/day from Day 2 to Day 14.
223858778|NCT05274334|OTHER|Assessment of de novo lipogenesis non-invasively in exhaled breath|"1. Healthy participants have a good nights sleep whereas they don't eat during the night and until measurements.~2. They come to the lab and make first baseline exhalation sets. An exhalation set consists of 6 exhalations in Mass Spectrometer positive mode and the same in negative mode. One exhalation set takes around 7minutes from start to finish.~3. Participants consume a single oral dose of dose of 70% 2H2O at 2 g/kg body-water.~4. Participants execute several exhalation sets over time.~5. Participants consume 300g of 'Excellence Joghurt Nature gezuckert.~6. Participants execute several exhalation sets over time.~7. After around 4.5hours with regular exhalation sets taking place, the trial is concluded."
223858779|NCT00215345|DRUG|Taxotere|
223858780|NCT00215345|DRUG|Celecoxib|
223858781|NCT01795144|DRUG|GLP-1|OGTT IGI IGI with GLP-1 infusion OGTT with Exendin 9-39 infusion
223858782|NCT01795144|DRUG|Exendin 9-39|OGTT IGI IGI with GLP-1 infusion OGTT with Exendin 9-39 infusion
223858783|NCT02309580|DRUG|Ibrutinib|Ibrutinib will be administered once daily continuously until disease progression (confirmed by two assessments for CTCL patients only) or intolerance. The dose levels for the Phase 1 portion of the study. Either 560 mg (4 X 140 mg capsules) or 840 mg (6 X 140 mg capsules) doses will be administered. After the recommended expansion dose is established, an expansion cohort of 12 additional patients will be treated at the recommended expansion dose to further characterize the safety at that dose and to further assess preliminary efficacy
223858784|NCT05541393|BEHAVIORAL|Active Intervention Group|The intervention will involve meetings with the church health ministers to discuss COVID-19 vaccines and booster shots.
223858785|NCT02749318|GENETIC|IL-1 genetic test for risk of severe periodontitis|DNA obtained by cheek swab analyzed for four variations (SNPs) in the IL-1beta gene to determine whether patient is at elevated risk for more severe periodontal disease.
223858786|NCT00908817|DRUG|triamcinolone acetonide|paste applied over tracheal tube for lubrication
223858787|NCT00908817|DRUG|chlorhexidine gluconate|jelly applied over tracheal tube for lubrication
223858788|NCT02526680|DEVICE|OrCam|The OrCam low vision aid, camera attached to glasses, used by 27 glaucoma subjects for 1 month.
223858789|NCT04066751|DRUG|Ivacaftor|Ivacaftor will be supplied as a tablet for oral administration, film-coated, 150 mg
223858790|NCT02781584|DRUG|SEL|Administered orally once daily
223858791|NCT02781584|DRUG|FIR|Administered orally once daily
223858792|NCT02781584|DRUG|CILO|Administered orally once daily
223858793|NCT02781584|DRUG|FENO|Administered orally once daily
223858794|NCT02781584|DRUG|VAS|Administered orally two times daily
223858795|NCT06258980|DRUG|Proph7|Prophylactic recombinant FVII for heavily menorrhagic adolescent Glanzmanns Thrombaesthenia females
223858796|NCT01070251|BEHAVIORAL|Participatory parent-focused intervention|Parent workshops and internet-based support to establish healthy physical activity routines, added to existing state-sponsored PA program
223858797|NCT01070251|BEHAVIORAL|State-sponsored PA program|Preschool children receive twice a week 60 minutes of physical activity lessons over 6 months by an external gym trainer
223858798|NCT02875665|DEVICE|geko(TM) device|The geko(TM) device will be used to electrically stimulate the posterior tibial nerve
223858799|NCT04008420|OTHER|monitoring of the oxygen reserve index|The investigators will enroll adult patients who will undergo robotic esophagectomy under general anesthesia. The oxygen reserve index will be monitored continuously during anesthesia. The postoperative complications will be recorded after surgery.
223858800|NCT04025606|DRUG|Thoracic epidural|Standard thoracic epidural (needle inserted into the space between the covering of spinal cord and the cord itself) preoperatively. Standard thoracic epidural analgesia mixture (2 mg/ ml bupivacaine, 2 µg/ ml fentanyl and 2 µg/ ml adrenalin) with an infusion of 6-10 ml/hour until day 2 postoperatively. Thereafter reduction by 30 % every four hours.
223858801|NCT04025606|DRUG|Paravertebral block|Paravertebral block containing 5 ml bupivacaine 5 mg/ ml (optionally 10 ml bupivacaine 2,5 mg/ ml). In addition per-oral painkillers (oxycodone and paracetamol) from the day of surgery.
223858802|NCT01267409|OTHER|STN stimulation|Manipulating emotional processing of PD patients by high and low frequency stimulation of their subthalamic area (through the 4 DBS contacts) after the surgery
223858803|NCT01774994|OTHER|stable isotope infusion for measurement of metabolism|
223858804|NCT03161691|PROCEDURE|Percutaneous treatment of ischemic stroke|An additional C-arm CT imaging scan will be done during neurovascular treatment to evaluate perfusion and collateral vessels in ischemic stroke patients.
223858805|NCT04639349|BEHAVIORAL|exercise group|the exercise group (20 patients) will receive a exercise session contains a fifty minutes exercise training at home with moderate intensity on the available training devices as bicycle or treadmill in addition to 30 minutes of exercising of upper and lower limb, the session will be repeated three times per week for eight weeks.
223858806|NCT04639349|OTHER|control group|the control group will not be trained
223858807|NCT05255718|DIETARY_SUPPLEMENT|Aronia juice|Once daily dose of 100 mL of aronia juice
223858808|NCT05255718|OTHER|Placebo|Once daily dose of 100 mL of placebo juice containing no polyphenols and matched to experimental Aronia juice in color, taste, and macronutrient content
223858809|NCT03986424|DRUG|Akatinol Memantine 20 mg|Akatinol Memantine 20 mg to be taken orally, once daily, in the same time of the day
223858810|NCT03986424|DRUG|Akatinol Memantine 10 mg|Akatinol Memantine 10 mg to be taken orally, twice daily
223858811|NCT03782558|PROCEDURE|Surgical transection of transverse ligament|Standard therapy for CTS. An incision is made at the base of the palm of the hand. Then the transverse ligament is cut, which releases the compression of the median nerve and improves the symptoms.
223858812|NCT04842669|OTHER|low level laser therapy|Endo-laser 422 with interchangeable laser probes will be used for the purpose. It is a 2-channel unit and is software operated. For treatment of small surfaces with mono laser there are diodes of 25, 100 and 500 milliWatt.Frequency will be adjusted to 500 Hz, dose 0.1/cm2 with time duration of 1-5 minutes.
223858813|NCT04842669|OTHER|Conservative treatment|(Topical ibuprofen gel) for muscle soreness will be provided
223858814|NCT01400750|DRUG|oral ciprofloxacin plus inhaled colistin|oral ciprofloxacin (30mg/kg/day divided in 2 doses) for 3 months (CC) plus inhaled colistimethate sodium(Colistineb® 2x2 mill U daily)
223858815|NCT01400750|DRUG|TOBI|tobramycin inhalation solution (TOBI® 2x300 mg) for 28 days
223858816|NCT06477302|BEHAVIORAL|Scale of Therapeutic Adherence to Respiratory Rahabilitation for Lung Cancer (STA-RR-LC)|Patients will be given a measurement instrument to determine the level of therapeutic adherence.
223858817|NCT03103971|BIOLOGICAL|Autologous Human Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ T-lymphocytes|Given IV
223858818|NCT03103971|DRUG|Cyclophosphamide|Given IV
223858819|NCT03103971|DRUG|Fludarabine|Given IV
223858820|NCT03103971|OTHER|Laboratory Biomarker Analysis|Correlative studies
223858821|NCT03103971|PROCEDURE|Leukapheresis|Undergo leukapheresis
223858822|NCT03103971|OTHER|Pharmacological Study|Correlative studies
223858823|NCT00180102|DRUG|Cytarabine vs. Cytarabine+Amsacrine+Mitoxantrone|
223858824|NCT00180102|PROCEDURE|early allogeneic PBSCT within induction therapy|
223858825|NCT00180102|PROCEDURE|autologous PBSCT|
223858826|NCT00163085|DRUG|NR2B NMDA Antagonist CP-101,606 (traxoprodil)|
223858827|NCT00241423|DRUG|exenatide|subcutaneous injection, 5mcg twice a day for one week; then 10 mcg twice a day for one week
223858828|NCT00241423|DRUG|Placebo|subcutaneous injection, equivalent volume to 5 mcg exenatide twice a day for one week; then equivalent volume to 10 mcg exenatide twice a day for one week
223858829|NCT01326988|PROCEDURE|Real-time ultrasound guided spinal anesthesia|The neuraxial US scan will be performed with the patient in the sitting or lateral position with the hip and knees slightly flexed using full aseptic technique. The spinal needle will be inserted in real-time under direct ultrasound guidance to administer the spinal anesthetic.
223858830|NCT00392678|DRUG|Salsalate|Placebo and Salsalate 3.0 g/d; 3.5 g/d; 4.0 g/d orally, divided
223858831|NCT00392678|DRUG|Placebo|Placebo to Salsalate
223858832|NCT04279171|DIAGNOSTIC_TEST|Greyson NDE scale|Questionnaire to detect occurence of NDE. A NDE is identified if score \> or = 7/32
223858833|NCT04279171|DIAGNOSTIC_TEST|DES dissociation scale|Screening for dissociative symptoms
223858834|NCT04279171|DIAGNOSTIC_TEST|WHOQOL-SRPB|WHOQOL-SRPB is an instrument developed to evaluate how spirituality, religiosity and personal beliefs (SRPB) are related to quality of life in health and health care.
223858835|NCT04279171|DIAGNOSTIC_TEST|cerebral magnetic resonance imaging|Types of images to be acquired: T1, T2, Diffusion Weighted Imaging-DWI, Fluid Attenuated Inversion Recovery and spectroscopy
223858836|NCT01638884|BEHAVIORAL|Memory assessment|Neuropsychological tests including clinical and original tests to compare differences between each populations
223858837|NCT01638884|OTHER|Structural MRI|to compare differences between each populations
223858838|NCT01638884|OTHER|Functional MRI|to compare differences between each populations
223858839|NCT01638884|OTHER|Virtual reality / Memory assessment|to compare differences between each populations
223858840|NCT00043082|DRUG|carboplatin|intravenous q 4 weeks
223858841|NCT00043082|DRUG|pegylated liposomal doxorubicin hydrochloride|intravenous q 4 weeks
223858842|NCT03409263|OTHER|Observational study|Not applicable (observational registry study)
223858843|NCT03399968|DEVICE|ESWT|at low energy, shockwaves are applied non-invasively at the injury level and 5 segments up and down of the spinal cord paravertebrally left and right
223858844|NCT03399968|DEVICE|Placebo ESWT|the ESWT therapy head is positioned at the level of injury and is moved up and down identically as described in the Verum intervention group (ESWT) but without application of shockwaves. The sound which is normally produced by shockwave generation is played by high quality sound recordings in the same amount as in the Verum group
223858845|NCT00459758|DEVICE|Hans unit|
223858846|NCT03356444|DRUG|Abiraterone Acetate|Abiraterone Acetate: orally, 1000mg, qd, plus with prednisone orally, 5mg, bid. Course of treatment: Stop the treatment until biochemical, clinical or radiographic progression occurs.
223858847|NCT03356444|DRUG|Docetaxel|"Docetaxel: intravenously, 75 mg/m\^2, over 1 h every 3 weeks, plus with prednisone, orally, 10 mg, qd.~Course of treatment: Stop the treatment until biochemical, clinical or radiographic progression occurs. If no progression, stop until 10 cycles of traetment"
223858848|NCT03232684|DIAGNOSTIC_TEST|Rapid on-site evaluation|On-site (endoscopy suite) evaluation, by a pathologist or a pulmonologist, of specimens retrieved from intrathoracic lymph nodes during EBUS-TBNA
223858849|NCT03031444|DRUG|Cetuximab plus FOLFIRI/FOLFOX|cetuximab was added into the routine perioperative chemotherapy(FOLFIRI/FOLFOX) to evaluate its safety and efficacy
223858850|NCT03031444|DRUG|FOLFIRI/FOLFOX/CapeOX|to evaluate its safety and efficacy of routine perioperative chemotherapy(FOLFIRI/FOLFOX/CapeOX)
223858851|NCT02294643|DRUG|Sarpogrelate|
223858852|NCT02294643|DRUG|Aspirin|
223858853|NCT02294643|DRUG|Clopidogrel|
223858854|NCT02294643|DRUG|Placebo (for Sarpogrelate)|
223858855|NCT00329979|BEHAVIORAL|vascular access site|Randomized vascular access site
223858856|NCT04479540|RADIATION|Angiography scanner|systematic thoracic angiography scanner to diagnose pulmonary embolism and additional blood sample (hemostasis exploration)
223858857|NCT00038103|DRUG|Exemestane|Patient will be instructed to take a 25 mg exemestane tablet, once a day, every day, with food.
223858858|NCT00038103|DRUG|Celecoxib + Exemestane|Exemestane + celecoxib treatment arm, she will be instructed to take also two x 200 mg celecoxib capsules twice a day, every day, with food.
223858859|NCT06426303|DRUG|Naltrexone|12-week randomized double blinded placebo-controlled drug trial titrating drug/placebo dose after 1 week.
223858860|NCT06041087|BEHAVIORAL|High-Intensity Exercise|A single bout of high-intensity exercise (cycling intervals, resistance exercise, plyometrics) per trial.
223858861|NCT06041087|DIETARY_SUPPLEMENT|Carbohydrate (Maltodextrin powder mixed with water)|50g consumed immediately after exercise and 1h after exercise.
223858862|NCT06041087|DIETARY_SUPPLEMENT|Skim Milk|500ml consumed immediately after exercise and 1h after exercise.
223858863|NCT06041087|DIETARY_SUPPLEMENT|Greek yogurt|200g consumed immediately after exercise and 1h after exercise.
223858864|NCT06041087|DIETARY_SUPPLEMENT|Water|500ml consumed immediately after exercise and 1h after exercise.
223858865|NCT01569906|RADIATION|Narrowband Ultraviolet B phototherapy|Twice weekly exposures for a total of 24 exposures using a standard phototherapy protocol.
223858866|NCT00117364|DRUG|SACCHACHITIN patch|
223858867|NCT01597128|DEVICE|Flex HD|Flex HD mesh for hernia repair
223858868|NCT01597128|DEVICE|Strattice|Strattice mesh for hernia repair
223858869|NCT02473562|DRUG|Varenicline|Tablet 1 mg BID
223858870|NCT02473562|DRUG|Placebo (for varenicline)|Tablet 1 mg BID
223858871|NCT00719823|DRUG|Maraviroc|Maraviroc 150mg, 300 mg or 600 mg twice daily administered orally with or without food in combination with other antiretroviral agents. The recommended dose of Maraviroc differs based on concomitant medications due to drug interactions as outlined in the Prescribing Information.
223858872|NCT00208767|DRUG|Valsartan|Valsartan was titrated to a target dose of 320 mg orally daily
223858873|NCT00208767|DRUG|Placebo|A matched placebo pill will be given orally daily.
223858874|NCT01735474|OTHER|Manual technique|"A manual technique is employed in the intervention group based on passive movement and stretching of the respiratory system.~The manual technique includes:~stretching of diaphragm. Mobilization. Potentiation of the respiratory muscles."
223858875|NCT01735474|OTHER|Placebo|Usual care
223858876|NCT04593797|DIAGNOSTIC_TEST|carotid blood flow measurement with ultrasound|carotid blood flow measurement with ultrasound vs transpulmonary thermodilution calibrated continuous cardiac output measurements
223858877|NCT01805921|BIOLOGICAL|PanAd3-RSV given intra-nasally (high dose)|High dose = 5x10\^10 vp
223858878|NCT01805921|BIOLOGICAL|MVA-RSV given by intra-muscular injection (high dose)|High dose = 1x10\^8 pfu
223858879|NCT01805921|BIOLOGICAL|PanAd3-RSV given by intra-muscular injection (high dose)|High dose = 5x10\^10 vp
223858880|NCT01805921|BIOLOGICAL|PanAd3-RSV given intranasally (low dose)|Low dose = 5x10\^9 vp
223858881|NCT01805921|BIOLOGICAL|MVA-RSV given by intra-muscular injection (low dose)|Low dose = 1x10\^7 pfu
223858882|NCT01805921|BIOLOGICAL|PanAd3-RSV given by intra-muscular injection (low dose)|Low dose = 5x10\^9 vp
223858883|NCT06266858|OTHER|rehydration|The fasting patients in anaesthetised receive saline rehydration to maintain central venous pressure of 6-8 cmH2O when undergoing UCG.
223858884|NCT06266858|DIAGNOSTIC_TEST|UCG|UCG is the most common imaging modality to assess the mitral regurgitation in clinical and also is the primary modality recommended by guidelines. At the beginning of the study, the fasting patients receive UCG in the different situation such as pre-anaesthetic, post-anaesthetic and post-rehydration.
223858885|NCT06266858|DIAGNOSTIC_TEST|CMR|CMR may be more accurate than UCG in assessing MR severity. In another time, the patients receive CMR.
223858886|NCT06266858|OTHER|fasting|At the beginning of the study, the patients need to fast when receive UCG.
223858887|NCT03658499|BEHAVIORAL|two day skills group plus treatment adjuncts|The modified dialectical behavior therapy protocol for victims of intimate partner violence dedicates additional time to address validation of self and others in order to mitigate the impact of punishing social relations, and increase the victims' access to positive reinforcement (Iverson et al., 2009). The modified protocol covers the same four major modules as the original DBT protocol in an abbreviated manner. Participants in this group will be provided with the treatment adjuncts.
223858888|NCT03658499|BEHAVIORAL|two day skills group control group|The modified dialectical behavior therapy protocol for victims of intimate partner violence dedicates additional time to address validation of self and others in order to mitigate the impact of punishing social relations, and increase the victims' access to positive reinforcement (Iverson et al., 2009). The modified protocol covers the same four major modules as the original DBT protocol in an abbreviated manner. Participants in this group will not be provided with the treatment adjuncts and will serve as the control group
223858889|NCT03860220|DRUG|NEWSTATIN TS|Wash out/run in period with Amlodipine 5mg for 6 weeks and then treatment with triple therapy (Newstatin TS 40/5/10mg) ; 1 tab qd for 8 weeks
223858890|NCT03860220|DRUG|CADUET|Wash out/run in period with Amlodipine 5mg for 6 weeks and then treatment with dual therapy (Caduet 5/10mg) ; 1 tab qd for 8 weeks
223858891|NCT03342651|OTHER|Vitamin D|Vitamin D, general anesthesia, respiratory complications
223858892|NCT03545984|OTHER|Simulation-based learning|Simulation-based teaching involves using done on a mannequin to simulate actual conditions
223858893|NCT03545984|OTHER|interactive problem based learning|Standard teaching (problem based learning discussion) during cardiac/vascular rotation
223858894|NCT05678296|DIAGNOSTIC_TEST|Diagnosis|All of the patients withstand a radiological examination, including panoramic radiography, and all were handled by the same surgeon and assistant.
223858895|NCT05678296|DRUG|Analgesic|Analgesics are prescribed for the patients for all groups.
223858896|NCT05678296|PROCEDURE|traditional osteotomies|In all groups the flap incision was triangular in shape which avoids muscle involvement (Archer flap).
223858897|NCT05678296|BIOLOGICAL|Platelet Rich Fibrin|Platelet rich fibrin (PRF), is an example and popular procedure for accelerate healing of soft and hard tissue because of the presence of various growth factors.a blood sample was taken without anticoagulant in 10 mL glass-coated plastic tubes that were immediately centrifuged (Elektro-mag M415P) at 3,000 rpm for 10 min (approximately 400 g) (13). The platelet-poor plasma that accumulated at the top of the tubes was discarded.PRF was dissected approximately 2 mm below its contact point with the red corpuscles situated beneath, to include any remaining platelets that may have localized below the junction between the PRF and red corpuscles.
223858898|NCT05678296|DRUG|Antibiotic|no systemic antibiotics are prescribed for the patients for all groups.
223858899|NCT00907218|DRUG|Varenicline (Chantix)|Upon completion of screening procedures and meeting eligibility criteria, subjects will begin taking varenicline daily until Week 6 of the study. At Week 6 they will discontinue varenicline and return one week later for their final study visit to assess return of ADHD symptomatology. Subjects will start on 0.5 mg of varenicline per day for the first week of treatment. The dose will be increased to 0.5 mg twice a day at the end of week 1 visit, and then increased to 1 mg twice a day at the end of week 2 visit, to remain at this dose until the week 6 visit. At week 6, all subjects will be openly discontinued from varenicline, to return to the office the following week for re-assessment one week off the medication. If significant adverse effects (AE) occur, the daily dose may be reduced by 0.5 to 1 mg. At subsequent visits, a higher dose may be resumed if tolerated. Maximum dose will be 2 mg daily.
223858900|NCT02347163|DRUG|Zoledronate|Patients fulfilling the eligibility criteria will be registered using a centralized system and will receive a pre-operative, single administration of zol (4mg i.v.), 7 days before definitive breast surgery .
223858901|NCT02511639|DRUG|Everolimus|Everolimus is formulated as tablets of 10 mg strength for oral administration.
223858902|NCT02511639|DRUG|Aromatase Inhibitors|Anastrozole is formulated as tablets of 1 mg strength for oral administration. Letrozole is formulated as tablets of 2.5 mg strength for oral administration. Exemestane is formulated as tablets of 25 mg strength for oral administration.
223858903|NCT00156117|DRUG|asenapine|5 mg BID or 10mg BID
223858904|NCT00156117|DRUG|Placebo|Placebo
223858905|NCT00156117|DRUG|olanzapine|olanzapine 15 mg QD
223858906|NCT06345560|DRUG|Drospirenone|4 mg tablet once daily
223858907|NCT03800667|DRUG|Ascorbic Acid 1000 MG|1000 mg ascorbic acid (Vitamin C) for 1 month post-op after an elective gynecological surgery.
223858908|NCT04251143|PROCEDURE|corneal cross-linking|UV-A Irradiation and riboflavin
223858909|NCT04251143|DIAGNOSTIC_TEST|corneal topography and tomography|Detailed Information about corneal tomography is used for diagnosis
223858910|NCT04296032|BEHAVIORAL|virtual reality game traning|The controllers were attached to upper extremity to control the game. The game could train the shoulder, elbow, and wrist control.
223858911|NCT04296032|BEHAVIORAL|standard treatment|The program included bilateral hand, grasp/release, and pinch activities.
223858912|NCT02308137|DRUG|Domperidone|Simon-2-stage design for domperidone futility
223858913|NCT04117191|DIETARY_SUPPLEMENT|Doctor's Best L-Tryptophan|2g tryptophan loading once
223858914|NCT04514419|DRUG|HS627|Prior to surgery: trastuzumab, HS627, and docetaxel for 4 cycles (1 cycle = 21 days).
223858915|NCT04514419|DRUG|Pertuzumab|Prior to surgery: trastuzumab, Pertuzumab, and docetaxel for 4 cycles (1 cycle = 21 days).
223858916|NCT01843491|BIOLOGICAL|Ad-PfCA|Vaccine
223858917|NCT01159249|DRUG|Vildagliptin|
223858918|NCT04548011|OTHER|Acupuncture|The acupuncture treatment strategies in this study are based on traditional Chinese medicine theory and opinions from the acupuncture experts. The acupoints are bilateral Zhongwan（CV12）, Tianshu（ST25）, Neiguan（PC6）, Liangqiu（ST34）, Yanglinquan（GB34）, Zusanli（ST36）and Taichong（LR3）.All the acupoints will be localized according to the Nomenclature and Location of Acupuncture Points of the People's Republic of China. During the acupuncture treatment, the participants will be in supine position. After 75% alcohol pads sterilizing the skin around the acupoints routinely, the acupuncturists will use sterile disposable steel needles (0.3 mm×40 mm; Huatuo Brand, Suzhou Medical Appliance, China) to insert into the acupoints above. The acupoints will be inserted vertically at 13-40 mm with the manipulation of steady small lifting, thrusting, and twirling 3 times to induce a sensation of de qi (sourness, numbness, and heaviness).
223858919|NCT00597350|DIETARY_SUPPLEMENT|Trigonella foenum-graecum (fenugreek)|2 slices of bread containing 5 grams of the natural herb fenugreek 2 times, 1 week apart
223858920|NCT00600457|DEVICE|Polyurethane Film|The modified polyurethane film is combined with a secondary absorbent dressing and remained intact until the 10th postoperative day
223858921|NCT03775369|OTHER|endurance training|physical activity and exercising (PAE)
223858922|NCT03775369|OTHER|social support and counseling|social support and counseling
223858923|NCT03775369|OTHER|resistance training|physical activity and exercising (PAE)
223858924|NCT01970748|DRUG|Propranolol|Propranolol 10mg BID initially and titrate dosage every week to achieve 25% drop of heart rate (keep heart rate\>55 or systemic blood pressure\>90mmHg)
223858925|NCT01970748|PROCEDURE|Esophageal variceal ligation|Esophageal variceal ligation every 3-4 weeks to achieve variceal eradication under endoscopy
223858926|NCT03644537|PROCEDURE|Orthodontic intrusion|"27 female patients coming to the Orthodontic department, Cairo University seeking orthodontic treatment, where their age ranges from 15 - 18 years, where their treatment plan include extraction of upper first premolars, and using the split-mouth technique, one side will be control group without application of force where the other side will receive intrusive mechanics for the same patient in the upper arch (one side will not receive any force and the same tooth on the other side of the arch will suffer intrusive mechanics, that's why named SPLIT MOUTH TECHNIQUE - as if the arch is split into two subjects, one control subject (tooth) and the other study subject (tooth) . According to the amount of force of the working side, the total number of patients will be divided into 3 groups.~Each of 9 subjects, the first group where a light force will be applied (10 gm), the second group where moderate force will be applied (25gm), the third group where heavy force will be applied(100 gram)."
223858927|NCT03119636|BIOLOGICAL|NPC transplantation|The cells are stereotactically implanted in the striatum.
223858928|NCT03119636|DRUG|Levodopa|Levodopa is used depending on the patient's condition
223858929|NCT02545751|RADIATION|Stereotactic Body Radiation Therapy|SBRT is given during combined therapy to one of the metastatic lesions, 25Gy in 5 fractions (5Gy per fraction) over one week, conformally to maximally spare normal tissue or organ.
223858930|NCT02545751|DRUG|Thymalfasin|Thymalfasin treatment is given twice a week with an interval of 3-4 days until progression of other metastatic lesions. Tumor response is evaluated by assessing clinical and CT/MRI response for all the other measurable metastatic sites.
223858931|NCT06676423|BIOLOGICAL|Lenzumestrocel|1.0 ⅹ 10\^6 cells/kg of Neuronata-R mixed with HTS-FRS suspension are administered twice in the cerebrospinal fluid at intervals of 26 days
223858932|NCT06676423|DRUG|Riluzole|In the case of a subject who is not taking Riluzole at the time of screening (visit 1), Riluzole should be taken except when discontinued due to Adverse events. The dose can be changed within the authorization according to the medical expert's judgement
223858933|NCT06676462|DEVICE|Video laryngoscopy with visionPRO|Video laryngoscopy to be performed using the visionPRO (HEINE® Optotechnick, Gilching, Germany) during intubation.
223858934|NCT06676462|DEVICE|Video laryngoscopy with Glidescope|Video laryngoscopy to be performed using theGlideScope (Verathon Inc., Bothell, USA) during intubation.
223858935|NCT00221234|BEHAVIORAL|Print materials, pedometers/logbooks|
223858936|NCT00221234|BEHAVIORAL|Print materials, pedometers/logbooks, telephone counselling|
223858937|NCT06631404|DIAGNOSTIC_TEST|renal doppler|doppler srudy on renal arteries bilaterally , and detection of RI of renal artery
223858938|NCT06629116|DRUG|Patients with AIS receive intravascular therapy, and within 10 minutes after the surgery, they are administered 100ml of 20% human albumin intravenously (infused within 30 minutes).|Whether to administer albumin to AIS patients after intravascular thrombectomy and reperfusion.
223858939|NCT06629324|BIOLOGICAL|Autologous Bone Marrow Mononuclear Cell Transfusion|Bone marrow was collected under general anesthesia from both anterior superior iliac crests, taking 15-20 minutes, with a maximum volume of 350 mL for older children. Mononuclear cells were isolated using Ficoll density gradient centrifugation and prepared for infusion. The infusion, performed in the L4-L5 spinal space, lasted about 30 minutes at a rate of 20 mL per hour. Cerebrospinal fluid (CSF) was withdrawn before infusion, with the amount based on the child's weight. Patients received Rocephin for infection prevention and pain relief with alternating doses of Ibuprofen and Efferalgan for 2 days post-procedure. Seduxen was given once on the first night after bone marrow collection.
224076252|NCT05350462|BEHAVIORAL|Community pilot L-PZQ distribution - intervention is NOT part of this observational study|Data collection will occur at two main time points of the ADOPT-community intervention project: before (baseline assessment) and during/after the community pilot L-PZQ distribution, in order to inform the design and process of the implementation, including that of advocacy and mobilisation, of Levo-Praziquantel delivery to PSAC.
224076253|NCT01534676|PROCEDURE|Transfusion|A routine medical procedure to transfuse packed red blood cells.
224076254|NCT01534676|BIOLOGICAL|Blood|"Processing of RBC for transfusion include the following:~* Fresh~* Stored~* Washed~* Frozen (Cryopreserved)"
224076255|NCT01534676|PROCEDURE|Chelation therapy|(non-experimental) A medical procedure that involves the administration of chelating agents to remove heavy metals from the body.
223858940|NCT06629324|OTHER|Rehabilitation|Rehabilitation methods involve various therapies tailored to the patient\&#39;s mobility level. (1) Physical therapy focuses on exercises to control the head, neck, and trunk, manage muscle tone, and reduce spasticity. Patients gradually practice essential movements like rolling, sitting, crawling, standing, and walking, aligned with developmental milestones. (2) Occupational therapy aims to enhance fine motor skills and daily activities. Through hand function exercises, patients improve upper limb functionality, strengthen their ability to grasp and hold objects and refine coordination between both hands and hand-eye coordination. (3) Speech therapy improves communication, cognitive abilities, and chewing and swallowing functions. Specific exercises target lip and mouth movements, helping patients express and understand language better. Additionally, there are activities to strengthen jaw and facial muscles, which are essential for improving chewing and swallowing abilities.
223858941|NCT06631560|DIAGNOSTIC_TEST|ELISA testing|Diagnostic testing was performed by testing all serum samples using the HEV ELISA Wantai and Euroimmun kit.
223858942|NCT06629051|DRUG|Berberine Hydrochloride|post-intervention of berberine
223858943|NCT06629051|DRUG|Placebo|Looks the same as berberine
223858944|NCT06711523|DRUG|PEG-G-CSF injection (Kexing Biopharmaceutical Co., Ltd.)|This trial was conducted using the IWRS system where subjects were randomly assigned to the test group (PEG-G-CSF injection (Kexing Biopharmaceutical Co., Ltd.)) and control group (Neulasta®，Amgen Europe B.V.) in a 1:1 ratio.
223858945|NCT06711523|DRUG|PEG-G-CSF injection (Neulasta®，Amgen Europe B.V.)|This trial was conducted using the IWRS system where subjects were randomly assigned to the test group (PEG-G-CSF injection (Kexing Biopharmaceutical Co., Ltd.)) and control group (Neulasta®，Amgen Europe B.V.) in a 1:1 ratio.
223858946|NCT01212757|DRUG|Apremilast 20mg|Apremilast 20 mg twice daily, orally
223858947|NCT01212757|DRUG|Apremilast 30mg|Apremilast 30 mg twice daily, orally
223858948|NCT01212757|DRUG|Placebo + 20 mg Apremilast|Placebo + 20 mg Apremilast
223858949|NCT01212757|DRUG|Placebo + 30 mg Apremilast|Placebo + 30 mg Apremilast
223858950|NCT06712199|DRUG|oxalidine|"Opioid anesthesia group (OBA group) Anesthesia was induced with propofol 2.5mg·kg-1, rocuronium 0.6mg·kg-1 and sufentanil 0.3μg·kg-1. When BIS value reached 40-60, tracheal intubation was performed through visual laryngeal mask airway. Anesthesia was maintained with propofol 4-12 mg·kg-1·h-1 and remifentanil 0.2-0.5 μg·kg-1·min-1. Sufentanil 10μg was bridaged 30min before the end of surgery. The PCA dosing regimen was sufentanil 2 µg/kg+ dexmedetomidine 2 µg/kg+ ondansetron 24mg.~Reduced-opioid anesthesia group (OFA group)~Anesthesia was induced with propofol 2.5mg·kg-1, rocuronium 0.6mg·kg-1 and esketamine 0.3mg·kg-1. When BIS value reached 40-60, tracheal intubation was performed through visual laryngeal mask airway. Propofol 4-12 mg·kg-1·h-1 and esketamine 0.3-0.5 mg·kg-1·h-1 were pumped to maintain anesthesia during operation. Oxalidine 1.5mg was given in two divided doses of 0.75mg each time with an interval of 10min 30min before the end of surgery. The PCA regimen was as follows:"
223858951|NCT03714750|PROCEDURE|DK crush|revascularization of true coronary bifurcation stenosis in DK crush technique
223858952|NCT03714750|PROCEDURE|Reverse TAP|revascularization of true coronary bifurcation stenosis in Reverse TAP technique
223858953|NCT00284401|PROCEDURE|Evaluation of the placement of the Delta prosthesis|
223858954|NCT05946824|RADIATION|Daily-adaptive Stereotactic Body Radiation Therapy|Daily-adaptive radiation therapy to two dose levels - one to the area of radiologic recurrent nodal disease, and a lower, prophylactic dose to the standard post-prostatectomy and larger pelvic node fields
223858955|NCT05946824|RADIATION|Daily-adaptive Stereotactic Body Radiation Therapy|Daily-adaptive radiation therapy to two areas - a high dose to the area of radiologic recurrence, and a lower, prophylactic dose to the standard post-prostatectomy fields
223858956|NCT02280161|OTHER|cytology specimen collection procedure|Correlative studies
223858957|NCT00647530|BIOLOGICAL|panitumumab|
223858958|NCT00647530|DRUG|capecitabine|
223858959|NCT00647530|DRUG|fluorouracil|
223858960|NCT00647530|DRUG|oxaliplatin|
223858961|NCT01029093|OTHER|no intervention, MRI and motor skill test|Two MR Investigations at two different times
223858962|NCT02611427|BEHAVIORAL|Education/Self-efficacy|The education/self-efficacy group will 1) receive information about benefits of physical activity and national activity guidelines, 2) receive instruction on how to increase lifestyle walking, 3) use movement monitoring devices, 4) make a walking contract and 5) receive interval contract-directed encouragement from study personnel.
223858963|NCT02611427|BEHAVIORAL|Education|The education group will receive information about safe physical activity.
223858964|NCT02812966|DEVICE|Lutonix|Drug Coated Balloons
223858965|NCT02812966|DEVICE|IN.PACT|Drug Coated Balloons
223858966|NCT06220045|COMBINATION_PRODUCT|Polyvinylidene fluoride mesh|"Midline laparotomy closure using the small bites technique associated with a prophylactic suprafascial polyvinylidene fluoride mesh."
223858967|NCT06220045|COMBINATION_PRODUCT|Prophylactic polypropylene mesh|"Midline laparotomy closure using the small bites technique associated with a prophylactic suprafascial polypropylene mesh."
223858968|NCT04637750|BEHAVIORAL|Educational intervention|The GPs randomized to the intervention arm will receive a feedback informing on their absolute number of patients treated with at least one PPI during the baseline period and if they have been prescribed above or below the median of appropriate prescriptions rate in their local area. They will be also provided with a scientific document including technical details on AIFA reimbursement criteria (NOTA 1 and 48), short hints about adverse events related to PPI long- term use in older patients and recommendation on how to discontinue PPI therapy (i.e. gradual step down administration to avoid paradoxical effect).
223858969|NCT00849147|BIOLOGICAL|Haploidentical Bone Marrow Transplantation|"The transplant preparative regimen is listed below. The - sign is the number of days before the transplant.~* Fludarabine: 30 mg/m2 intravenously (IV) on Days -6, -5, -4, -3, and -2~* Cyclophosphamide (Cy): 14.5 mg/kg IV on Days -6 and -5~* Total body irradiation (TBI): 200 centigray (cGy) on Day -1~Day 0 is the day of the infusion of non-T-cell depleted bone marrow. The bone marrow will be obtained from haploidentical related donor."
223858970|NCT00849147|BIOLOGICAL|GVHD prophylaxis|"The GVHD prophylaxis regimen will consist of the following:~* Cy: 50 mg/kg IV on Days 3 and 4~* Tacrolimus: (IV or orally) beginning on Day 5 with dose adjusted to maintain a level of 5 to 15 mg/mL~* Mycophenolate mofetil (MMF): 15 mg/kg orally three times a day (TID) beginning on Day 5; maximum dose will be 1 g orally TID~* Granulocyte-colony stimulating factor (G-CSF) 5 mcg/kg/day beginning on Day 5 until absolute neutrophil count (ANC) is greater than or equal to 1,000/mm\^3 for 3 consecutive days"
223858971|NCT03244436|PROCEDURE|Surgery following catheterization|Emergency surgery following pediatric cardiac catheterization
223858972|NCT05571722|DRUG|Vancomycin Injection|Patients receive a dose of 30 mg/kg of vancomycin (2 hours infusion) starting 2.5 hours before the scheduled time of surgical incision as defined in the French guidelines.
223858973|NCT05571722|DRUG|Linezolid Injection|Patients receive a dose of 1200 mg of linezolid (30 minutes infusion) 30 minutes before the scheduled time of surgical incision.
223858974|NCT04956354|DEVICE|ANNE™ Monitoring System (2 sensors) - version B|"ANNE™ is a wireless vital sign monitoring device that uses soft, flexible, skin-mountable biosensors (ANNE™ Chest and ANNE™ Limb) with Bluetooth® 5 enabled and encrypted data communication to an iPad application. Study sensors to be applied on patients are:~Sensor 1 - A chest unit (ANNE™ Chest) with embedded battery, sensors, and a three-axis accelerometer that captures the following signals: electrocardiography (ECG), temperature, seismocardiography (SCG) and the chest wall movements.~Sensor 2 - A limb unit (ANNE™ Limb) with embedded battery that captures the photoplethysmography (PPG) and SpO2 signals."
224266251|NCT03135080|OTHER|Long-Term HEAD START Training|The Human Eyelid Analogue Device for Surgical Training And skill Reinforcement in Trachoma (HEAD START) is a surgical simulation device used to bridge the gap between classroom and live-surgery training specifically for trichiasis surgery. Long-term HEAD START practice will involve the following components, after completion of standard training (as described in the standard of care arm). Each week the participant will complete 2 surgeries on the HEAD START device. Monthly, the participant will send the accumulated cartridges to Addis Ababa for review by a senior trichiasis surgery trainer. The trainer will evaluate the cartridges and then will discuss his impression of the surgeries with the participant during a regular monthly call and note the findings. Practice will continue for 4-6 months, depending on the length of the rainy season and time of enrollment. At the end of the rainy season, an external examiner will evaluate the first 2 surgeries that the participant completes.
223858975|NCT04956354|DEVICE|ANNE™ Monitoring System (2 sensors) - version C|"ANNE™ is a wireless vital sign monitoring device that uses soft, flexible, skin-mountable biosensors (ANNE™ Arc and ANNE™ Limb) with Bluetooth® 5 enabled and encrypted data communication to an iPad application. Study sensors to be applied on patients are:~Sensor 1 - ANNE™ Arc with a Lithium-Polymer battery that contains a 6-axial inertial measurement unit (IMU), which includes a 3-axis gyroscope and 3-axis accelerometer, a power management component, an analog front-end component, passive electrodes for ECG, and bio-impedance feature that capture the following waveforms: heart rate (HR), respiratory rate (RR) and skin temperature.~Sensor 2 - A limb unit (ANNE™ Limb) with embedded battery that captures the photoplethysmography (PPG) and SpO2 signals."
223858976|NCT04956354|DEVICE|ANNE™ Monitoring System (2 sensors) - version C|"ANNE™ is a wireless vital sign monitoring device that uses soft, flexible, skin-mountable biosensors (ANNE™ Arc and ANNE™ Limb) with Bluetooth® 5 enabled and encrypted data communication to an iPad application. Study sensors to be applied on patients are:~Sensor 1 - ANNE™ Arc with a Lithium-Polymer battery that contains a 6-axial inertial measurement unit (IMU), which includes a 3-axis gyroscope and 3-axis accelerometer, a power management component, an analog front-end component, passive electrodes for ECG, and bio-impedance feature that capture the following waveforms: heart rate (HR), respiratory rate (RR) and skin temperature.~Sensor 2 - A limb unit (ANNE™ Limb) with embedded battery that captures the photoplethysmography (PPG) and SpO2 signals."
223858977|NCT06487806|BEHAVIORAL|SmokefreeSGM|Participants will be asked to set a quit date within the next 15 days before being enrolled in the SmokefreeSGM Español text messaging program. They will be mailed a 6-week supply of nicotine patches. The participants will get daily text messages for 6 weeks that will encourage them to quit smoking.
223858978|NCT05507749|PROCEDURE|cryoballoon ablation|Cryoballoon ablation for the treatment of atrial fibrillation
223858979|NCT05507749|DEVICE|implantable loop recorder insertion|The device called a implantable loop recorder, is placed just under the skin of one's chest during a minor surgery.
223858980|NCT03608202|BEHAVIORAL|POCUS protocol group|"The findings of multiorgan ultrasound can modify diagnoses and treatments and immediate interventions (eg volume loading with saline solution, pleural or pericardial drainage, initiation of diuretics, increase in positive end expiratory pressure, etc.).~This protocol is performed in the first 24 h of admission to the Intensive Care Unit (ICU) and is repeated at 24 h."
223858981|NCT03608202|OTHER|Control group|Routine protocol of the treating team is followed
223858982|NCT05900791|PROCEDURE|Primary knee arthroplasty|All patients surveyed have undergone primary knee arthroplasty approximately 1 year prior to survey distribution
223858983|NCT04922606|DIAGNOSTIC_TEST|US ot the GSV|Ultrasound of the Great Saphenous Vein
223858984|NCT02976532|OTHER|Electromagnetic tracking unit in femoral derotation surgery|Use of the electromagnetic tracking system during the surgical procedure in addition to the normal measurement with goniometer, the different devices listed are combined to form the EMT system unit
223858985|NCT01675895|DRUG|Levobupivacaine lidocaine spinal anesthesia|Spinal anesthesia
223858986|NCT01675895|DRUG|levobupivacaine Spinal anesthesia|spinal anesthesia
223858987|NCT03357289|BIOLOGICAL|Mix vaccine|Each treatment: 0.5 ml /week, Subcutaneous injection of the deltoid muscle
223858988|NCT01606124|DRUG|defined green tea catechin extract|Given PO
223858989|NCT01606124|OTHER|placebo|Given PO
223858990|NCT01606124|OTHER|questionnaire administration|Ancillary studies
223858991|NCT01606124|OTHER|laboratory biomarker analysis|Correlative studies
223858992|NCT02646969|DIETARY_SUPPLEMENT|Formula regimen 1|
223858993|NCT02646969|DIETARY_SUPPLEMENT|Formula regimen 2|
223858994|NCT00766298|BEHAVIORAL|Exercise|16 week intervention; 6 exercise sessions weekly w 3 supervised exercise sessions weekly utilizing cycling or walking/jogging. Participants maintain exercise diaries: wks 1-4; 30 minutes at 60-70% MHR, wks 5-8; 40 minutes at 60-70% MHR, weeks 9-16; 40 minutes at 75% MHR
223858995|NCT00766298|BEHAVIORAL|Weight Loss|The reduction of kcal/day through implementation of low fat diet
223858996|NCT00766298|BEHAVIORAL|Exercise and weight loss|"Exercise: 16 week intervention; 6 exercise sessions weekly w 3 supervised exercise sessions weekly utilizing cycling or walking/jogging. Participants maintain exercise diaries: wks 1-4; 30 minutes at 60-70% MHR, wks 5-8; 40 minutes at 60-70% MHR, weeks 9-16; 40 minutes at 75% MHR.~Weight Loss: Reduction of kcal/day through implementation of a low fat diet."
223858997|NCT06442969|OTHER|Education and resources provided by community health workers|The intervention will consist of implementing existing tools provided by EPA's Design for the Environment program, CalOSHA and NIOSH sector-specific guidance for agricultural workers, the Imperial County Department of Public Health and materials from California Department of Toxics Substances Control. The investigators will utilize and adjust existing educational tools such as the Heat Illness Prevention plan developed by CalOSHA. In addition to the educational materials, the investigators will give each farmworker cooling working gear to be worn during their work-shift with (specialized clothes that has been used in other occupational settings). The investigators will provide all participants with a low-cost fan filter, known as Corsi-Rosenthal box built jointly by the community health/research team to reduce chemicals at home, and a small A/C unit to reduce heat stress.
223858998|NCT00002436|DRUG|Lamivudine|
223858999|NCT00002436|DRUG|Zidovudine|
223859000|NCT00002436|DRUG|Zalcitabine|
223859001|NCT02750072|PROCEDURE|Infrapatellar Approach|Infrapatellar approach using the surgeon's incision of choice (i.e. patellar tendon split, tendon retraction medial, tendon retraction lateral)
223859002|NCT02750072|PROCEDURE|Suprapatellar Approach|Semi-extended suprapatellar approach using quadriceps split combined with purpose designed percutaneous instrumentation
223859003|NCT04961749|OTHER|Whole body vibration training|Whole-body vibration training applies a vibration stimulus to an individual as they are standing on a side-alternating platform. The vibration creates small muscle contractions in the lower extremity musculature which has been shown to improve function and ambulatory function.
223859004|NCT06174337|BEHAVIORAL|Use of Video Connection with Family via Robot|A remote family member is able to connect via video with a nursing home resident.
223859005|NCT04378062|PROCEDURE|Digital nerve procedure|The type of procedure performed on the digital nerve at the time of amputation
223859006|NCT00075972|BEHAVIORAL|Mood Tolearance|
223859007|NCT00075972|BEHAVIORAL|Mood Management|
223859008|NCT00075972|DRUG|Nicotine Replacement therapy|
223859009|NCT04246619|DRUG|Pregabalin|"Pregabalin Krka (pregabalin) hard capsules of different strenghts: 25 mg, 75 mg, 150 mg, 300 mg.~Duration: 12 weeks"
223859010|NCT04246619|DRUG|Duloxetine|"Dulsevia® (duloxetine) hard gastro-resistant capsules of different strenghts: 30 mg and 60 mg.~Duration: 12 weeks"
223859011|NCT01070888|DRUG|Budesonide/Formoterol|Budesonide/Formoterol 160/4.5, 2 puff twice daily for 2 weeks
223859012|NCT01070888|DRUG|Budesonide|Budesonide 180mcg, 2 puffs twice daily for 2 weeks
223859013|NCT01037530|DRUG|Ramipril|5 mg/day for 2 weeks then 10 mg/day for 22 weeks
223859014|NCT05047341|DRUG|SHR0302、[14C]SHR0302|8 mg SHR0302/ 80 µCi \[14C\]SHR0302, once, D1
223859015|NCT00460785|DRUG|Opioid|
223859016|NCT00669461|DRUG|Lubiprostone|Lubiprostone 24 mcg BID orally for 4 weeks
224266252|NCT03135080|OTHER|Standard of Care|All participants will receive trichiasis surgery training following Orbis' standard training approach, with the inclusion of HEAD START training between classroom and live surgery training. At the end of the surgical training session, an independent examiner will evaluate all trainees using the World Health Organization's Final Assessment of Surgeons form, as part of standard practice. The examiner also will complete a standard questionnaire focusing on the specific skill level achieved for each of the critical aspects of TT surgery. This form will be completed for all trainees undergoing training this spring, regardless of whether they are part of the long-term HEAD START assessment program.
224266253|NCT06389227|OTHER|dynamic ecological approach (DEA)|The DEA completed 18 ninety-minute sessions (3 per week) for six weeks oriented to soccer training using the dynamic ecological approach
224266254|NCT06389227|OTHER|traditional training group|The TTG followed a traditional soccer training program for the same period and number of sessions without any intervention attributable to the dynamic ecological approach
224266255|NCT04672603|PROCEDURE|Complete Preservation of Denonvilliers' Fascia|Patients accept L-PANP surgery with complete preservation of Denonvilliers Fascia
224266256|NCT02342873|PROCEDURE|NS-guided interscalene block|Patients received a standard single injection interscalene block using the modified lateral approach of Borgeat. The interscalene brachial plexus was identified using an insulated needle connected to a nerve stimulator. An insulated needle attached to a nerve stimulator was used to identify the brachial plexus. Placement of the needle was considered adequate if the deltoid, triceps, pectoralis, or biceps muscle motor response was still present at 0.2 - 0.5mA. Ropivacine 0.75% 20ml was used.
223859017|NCT06553287|DRUG|LNK01004 ointment 0.3%|LNK01004 ointment 0.3% for topical application
224266257|NCT02342873|PROCEDURE|US-guided interscalene block|Interscalene block is performed under ultrasound guidance. Linear probe is placed on the ipsilateral interscalene groove visualizing the brachial plexus located between anterior and middle scalene muscles. Using in-plane technique, an insulated needle is advanced into the brachial plexus sheath, into which 20 ml of 0.75% ropivacaine is injected
224266258|NCT01978873|DRUG|Cabazitaxel + Androgen deprivation therapy|Cabazitaxel + LHRH agonist + antiandrogens for 30 days OR surgical castration OR complete androgen blockade (CAB) by LHRH agonist + antiandrogen device.
224266259|NCT01978873|DRUG|Androgen deprivation therapy|LHRH agonist + antiandrogens for 30 days OR surgical castration OR complete androgen blockade (CAB) by LHRH agonist + antiandrogen device.
224266260|NCT02117830|DRUG|Androxal 25 mg capsules|
224266261|NCT02117830|DRUG|Androxal 250 Capsules|
224266262|NCT02117830|DRUG|Placebo Capsules|
224266263|NCT02117830|DRUG|Moxifloxacin 400 mg|
224266264|NCT01159873|DRUG|CEP-37251|up to 5 subcutaneous (sc) doses (given sequentially in cohort groups) of CEP-37251 (0.03, 0.1, 0.3, 1.0, and 3.0 mg/kg) will be studied. After all 5 sc doses have been studied, an intravenous (iv) dose of 0.3 mg/kg will be studied.
224266265|NCT01159873|DRUG|Placebo|up to 5 subcutaneous (sc) doses (given sequentially in cohort groups) of Placebo (0.03, 0.1, 0.3, 1.0, and 3.0 mg/kg) will be studied. After all 5 sc doses have been studied, an intravenous (iv) placebo dose of 0.3 mg/kg will be studied.
224266266|NCT01421862|GENETIC|DNA methylation analysis|
224266267|NCT01421862|GENETIC|RNA analysis|
224266268|NCT01421862|GENETIC|gene expression analysis|
224266269|NCT01421862|GENETIC|microarray analysis|
224266270|NCT01421862|GENETIC|mutation analysis|
224266271|NCT01421862|GENETIC|nucleic acid sequencing|
224266272|NCT01421862|OTHER|laboratory biomarker analysis|
224266273|NCT04943822|OTHER|A new APP|A new APP for prevention and treatment of complications of intestinal peristomal skin
224266274|NCT01237444|DRUG|lopinavir/ritonavir plus one nucleoside|"ARM 1:~Lopinavir/ritonavir 200mg/50mg 2 tabs bid plus 3TC 150mg x1 tab bid"
224266275|NCT01237444|DRUG|lopinavir /ritonavir plus two nucleosides|"ARM 2:~3TC 150mg x1 tab bid or FTC 200mg 1 capsule qd plus Lopinavir/ritonavir 200mg/50mg 2 tabs BID plus a second NRTI, selected at investigator's discretion, based on baseline genotype."
224266276|NCT02705716|OTHER|0.454% w/w stannous fluoride (1100ppm fluoride)|Dentifrice containing 0.454% w/w stannous fluoride (1100ppm fluoride)
224266277|NCT02705716|OTHER|0.76% sodium monofluorophosphate (1000ppm fluoride)|Dentifrice containing 0.76% sodium monofluorophosphate (1000ppm fluoride)
224266278|NCT04015024|DRUG|SKLB1028 150mg bid|150mg oral administration twice a day
224266279|NCT04015024|DRUG|SKLB1028 200mg bid|200mg oral administration twice a day
224266280|NCT04015024|DRUG|SKLB1028 300mg qd|300mg oral administration once a day
224266281|NCT05798884|DEVICE|Acupuncture|Disposable acupuncture needles (0.25 mm in diameter and 25 mm in length) are straightly into body acupuncture points (he gu (LI4), nei guan (PC6), qu chi (LI12), ba xie (EX-UE9), zu san li (ST36), san yin jiao (SP6), tai chung (LV3) and ba feng (EX-LE10)). The use of ba xie (EX-UE9) and ba feng (EX-LE10) will be optional if skin lesions of hands and feet occur due to Capecitabine (Xeloda). Electrical stimulation will be delivered with continuous waves at 2 Hz, at an intensity of each patient's minimum sensation of stimulation through the electrical acupuncture stimulation instrument. The needles will be retained in position for 25 minutes.
224266282|NCT05798884|DEVICE|Sham-acupuncture|"Streitberger's non-invasive acupuncture needles (Gauge 8 x 1.2/ 0.30 x 30mm) will be applied to serve as a sham control at the same acupoints with the same stimulation modality and then connecting the needle to the incorrect output socket of the electrical acupuncture stimulation instrument. The sham points are pseudo stimulation."
224266283|NCT03485118|DRUG|HS006+CHOP|"Drug:HS006 HS006 375 mg per square meter (mg/m\^2),administered intravenously(IV) on Day1 of each 21-day cycle for 6 cycles.~Drug :Cyclophosphamide Cyclophosphamide 750mg per square metre(mg/m\^2),administered intravenously(IV) on Day 2 of each 21-day cycle.~Drug :Doxorubicin Doxorubicin 50mg per square metre( mg/m\^2),administered intravenously(IV) on Day 2 of each 21-day cycle.~Drug :Vincristine Vincristine 1.4mg(maximum 2.0mg) per square metre (mg/m\^2),administered intravenously(IV) on Day 2 of each 21-day cycle.~Drug: Prednisone Prednisone 100 mg administered orally on Days 2-6 of each 21-day cycle."
223859018|NCT06553287|DRUG|LNK01004 ointment 1.0%|LNK01004 ointment 1.0% for topical application
223859019|NCT06553287|DRUG|LNK01004 ointment 1.5%|LNK01004 ointment 1.5% for topical application
223859020|NCT06553287|DRUG|Vehicle BID|Inactive vehicle matched to LNK01004 ointment for topical application.
223859021|NCT00091624|DRUG|CC-5013|
223859022|NCT02712411|DRUG|HCP1303|
223859023|NCT02712411|DRUG|HGP1201|
223859024|NCT02712411|DRUG|HIP1402|
223859025|NCT02768272|DEVICE|PCEA vs PIEB|We evaluate the relation between the distribution of L-bupivacaine plus fentanyl in the epidural space and the incedence of breaktrough pain during labor
223859026|NCT02768272|PROCEDURE|Epidural vs CSE|We evaluate the relation between the type of epidural technique and the incedence of breaktrough pain during labor
223859027|NCT00626418|DRUG|Aplindore|Tablets 0.05, 0.1, 0.2, 0.3, 0.5 and 0.7 mg QD for up to 6 nights
223859028|NCT00626418|DRUG|Placebo|Placebo tablets
223859029|NCT05875285|OTHER|Iontophoresis with methotrexate|"The methotrexate iontophoresis group the patient's hands are placed in direct contact with the conductive electrodes.~The patient will receive full explanation to the purpose of the treatment, the therapeutic and physiological benefits of this method of treatment. Before starting the treatment, all the previous measurements of each patient in this group is taken for a comparison.~Every patient will receive 12 sessions 3times/week every session consist of 30 minutes application of methotrexate iontophoresis using continuous direct current, the patient should feel mild tingling sensation (not painful), the polarity should be reversed halftime of treatment session, as the anodal current is more effective."
223859030|NCT05875285|OTHER|Iontophoresis with coal tar ointement|For coal tar ointement group the ointement is putted direct on the skin after describing the instruction and method of application and time of application and do alarm instead not to forget.
223859031|NCT04628286|OTHER|Sham Laser|Sham Laser in plantar fascia
223859032|NCT04628286|OTHER|Myofascial Induction|Myofascial Induction in plantar fascia
223859033|NCT00942058|OTHER|Serum and urinary CA9 level|Blood and urinary samples are collected before treatment and at 1, 3, 6, 9 and 12 months.
223859034|NCT02195713|DEVICE|Accuryn|Accuryn is a novel electronic urine output monitor
223859035|NCT00748150|BIOLOGICAL|Flu Vaccine Influenza Vaccine (Surface Antigen, Inactivated) Ph.Eur, Formulation 2008-2009|1 dose, 0.5 mL of Flu Vaccine Influenza Vaccine (Surface Antigen, Inactivated) Ph.Eur, Formulation 2008-2009
223859036|NCT04128436|OTHER|Taking blood samples for analyzing progesterone levels|As part of standard in vitro fertilization treatment, Crinone gel will be used starting the next morning following the oocyte pick-up (OPU) as a luteal phase support. On the trigger day, on the day OPU+2/3 (early luteal phase) and on the embryo transfer day (OPU+5, mid luteal phase) blood samples will be taken from patients for evaluating the progesterone levels. Blood samples will be collected at the 6th hour following the morning dose of vaginal progesterone gel. No other intervention will be done to the patients.
223859037|NCT00269516|DRUG|pardoprunox|fixed dose 6 mg
223859038|NCT00269516|DRUG|Pardoprunox|fixed dose 12 mg
223859039|NCT00269516|DRUG|Pardoprunox|12-42mg
223859040|NCT00269516|DRUG|Placebo|Placebo
223859041|NCT03521037|DRUG|Rucaparib camsylate|In Part I, eligible patients will receive a single oral dose of 600 mg rucaparib followed by intensive plasma PK sampling up to Day 7 (hour 144). In Part II, patients may continue to receive continuous oral rucaparib in 28 day cycles.
223859042|NCT06339489|DIAGNOSTIC_TEST|Testing the serum levels of bone metabolic markers|Testing serum levels of TRACP-5b and BALP, BMD values of lumbar spine L1-L4, left and right hip, left and right femoral neck et.al.
223859043|NCT02574026|BEHAVIORAL|Psychomotor tasks|the acquisition of data will be performed in one unique session no drug administration no surgery
223859044|NCT02577523|DRUG|ND0612 (Levodopa/Carbidopa solution)|The total daily dose of levodopa/carbidopa 720/90 mg. Device: CRONO TWIN pump system.
223859045|NCT02577523|DRUG|ND0612 (Levodopa/Carbidopa solution) + morning oral IR-LD/CD|The total daily dose levodopa/carbidopa from ND0612 538/67 mg. Morning dose of oral IR-LD/CD 150/15 mg. Device: CRONO TWIN pump system.
223859046|NCT02971176|RADIATION|Low-dose protocol computed tomography|Radiation dose under the low-dose protocol computed tomography (120 kilovolt, 15 milliampere seconds)
223859047|NCT02971176|RADIATION|Standard-dose protocol computed tomography|Radiation dose under the standard-dose protocol computed tomography (120 kilovolt, 150 milliampere seconds)
223859048|NCT01305733|DRUG|The injectant mixture consists of 150 mg levobupivacaine mixed with 30 mg ketorolac and 0.5 mg adrenaline|The injectant mixture consists of 150 mg levobupivacaine mixed with 30 mg ketorolac and 0.5 mg adrenaline
223859049|NCT01305733|OTHER|saline injection|saline
223859050|NCT03311568|DEVICE|ultrasound for microcirculatory assessment|"Ultrasound for microcirculatory assessment Repeated measurements within study participants for analysis of variance and explorative analyses of ultrasound signals, to identify most suitable parameters to describe microcirculatory alterations in critical disease, especially in sepsis.~Analyse blood flow velocities in several depths and from several vessels of different sizes simultaneously~US registration repeated within each study participant consecutively on seven different regions of the body surface."
223859051|NCT05133063|BEHAVIORAL|Gratitude letter|"Participants are given the following instructions:~Think of someone in your life who you feel like you have never fully or properly thanked for something meaningful or important that they did for you. . . . In the space provided below, please write a note to this person that describes why you feel like you never properly thanked them and letting them know why you feel thankful for something important that they did for you. Though this letter will not actually be sent to this person and is simply an exercise for you, please use this as an opportunity to really explore those feelings surrounding how you feel about what they have done for you and write honestly and openly from your heart. You have ten minutes."
223859052|NCT05133063|BEHAVIORAL|Control intervention|"Participants receive the following instructions:~Think of the room you are in…. In the space below, please provide a description of the room you are in. Try to focus on the specific elements in the room, the colours of the wall or objects in the room. Use this writing session as an opportunity to paint a detailed picture of this room and include as much specific information as you can. You have ten minutes."
223859053|NCT04065932|DRUG|BMS-986165-01|Participants will receive BMS- 986165 -01 in prototype formulation
223859054|NCT04065932|DRUG|BMS-986165 Tablet|Participants will receive BMS-986165 in tablet form.
223859055|NCT04065932|DRUG|Famotidine|Participants will receive a previously dosed BMS-985165-01 Prototype Tablet at the same dose level following administration of famotidine
223859056|NCT04157855|PROCEDURE|Abdominal Plane Block(s) with depot Steroids|APB Steroids treatment: under real time ultrasound guidance, a 100 mm needle is introduced into the specified plane (subcostal TAP for upper abdomen pain, posterior TAP for lower abdomen pain or TQL for flank and lower abdominal pain). Normal saline (10 ml) is used to open the fascial plane (saline hydrodissection). Then 40 mg of depomedrone diluted in 10 ml of 0.25% levo-bupivacaine is injected into the plane. . A total of 80 mg of depomedrone (steroid) will be used.
223859057|NCT00696280|BEHAVIORAL|Functional Living Index - Emesis|
223859058|NCT02828423|PROCEDURE|EMD|Regenerative surgery with EMD
223859059|NCT02828423|PROCEDURE|BC|Regenerative surgery with BC
223859060|NCT02787694|OTHER|Factor Targeted Walking Training|Individuals walk on a treadmill for 30 minutes while exposed to either endurance, balance, challenge, strength, or speed focused approaches
223859061|NCT02787694|DEVICE|treadmill|
223859062|NCT02130128|DEVICE|LungPoint ATV System|The LungPoint ATV System is an image-guided navigation system used to access tissue samples in the lungs.
223859063|NCT06533878|DRUG|HY-209|Enteric coated tablet in the following colors: pink for 100 mg and yellow for 50 mg, and white for 10 mg
223859064|NCT06533878|DRUG|HY-209 placebo|Enteric coated tablet in the following colors: pink for 100 mg and yellow for 50 mg
223859065|NCT04045977|BEHAVIORAL|Cardiac rehabilitation|Four weeks of cardiac rehabilitation conducted in an outpatient care facility. Three times per week (80 minutes per day) cardiologically monitored aerobic training consisting of: 40 minutes of interval training on a cycloergometer and 40 minutes of general fitness exercises.
223859066|NCT04045977|DEVICE|Virtual therapeutic support|"8 sessions of VR therapy (each of them 20 minutes long).~As a virtual reality source, VR Tier One device (Stolgraf®) were used. Thanks to using head mounted display and the phenomenon of total immersion VR therapy provides an intense visual, auditory and kinesthetic stimulation. It can have a calming and mood-improving effect or help the patients recognize their psychological resources and motivate to the rehabilitation process. In the virtual therapeutic garden there are a rich set of symbols and metaphors based on Ericksonian Psychotherapy approach. The most important is the Garden of Revival which symbolizes the patient's health. It used to be full of life and energy, now it is neglected, requires work to be revived. In the therapeutic process day by day, the therapist tells the patient a symbolic story about his/her situation. By performing tasks in the virtual garden, the patient becomes an active participant of the therapeutic process and sees the effects his/her work."
223859067|NCT04045977|BEHAVIORAL|Standard therapeutic support|8 sessions of Schultz Autogenic Training (each of them 20 minutes long).
223859068|NCT06555510|OTHER|InBody|Bioelectrical impedance analysis
223859069|NCT01191892|DRUG|carboplatin|
223859070|NCT01191892|DRUG|gemcitabine hydrochloride|
223859071|NCT01191892|DRUG|vandetanib|
223859072|NCT01191892|DRUG|Placebo|Placebo of vandetanib tablet
223859073|NCT03185156|DRUG|Propofol|first dose 0.3mg/Kg propofol, then 1mg/Kg/hr micro-pump
223859074|NCT03185156|DRUG|Normal saline|first dose 0.03ml/Kg placebo saline, then 0.1ml/Kg/hr micro-pump
223859075|NCT00726999|DRUG|Gabapentin|oral gabapentin in load pre-op (15mg/kg) and maintenance 5mg/kg TID for 5 days or discharge
223859076|NCT00726999|DRUG|Placebo|
223859077|NCT00726999|DRUG|Morphine|Administered as needed
223859078|NCT00955825|DRUG|300 IR|300 IR grass pollen allergen extract tablet taken daily for approximately 6 months starting 4 months before the grass pollen season and over the grass pollen season
223859079|NCT00955825|DRUG|Placebo|Placebo sublingual tablet taken daily for approximately 6 months starting 4 months before the grass pollen season and over the grass pollen season
223859080|NCT00542113|BEHAVIORAL|DvtProgram ENERGY|11 - weekly or biweekly newsletters about diabetes and its prevention and family challenges sent home with children
223859081|NCT00542113|BEHAVIORAL|DvtProgram ENERGY|6 - weekly or biweekly newsletters about diabetes and its prevention and family challenges sent home with children
223859082|NCT00542113|BEHAVIORAL|DvtProgramENERGY|Children participating in Program ENERGY but no newsletters or family challenges sent home to parents
223859083|NCT02488980|DRUG|Tafenoquine|Tafenoquine 200 mg for three days followed by Tafenoquine 200 mg once a week for 24 weeks.
223859084|NCT02488980|DRUG|Mefloquine|Mefloquine 250 mg for three days followed by Mefloquine 250 mg once a week for 24 weeks.
223859085|NCT02488980|DRUG|Placebo|Placebo for three days followed by placebo once a week for 24 weeks
223859086|NCT03003637|DRUG|Nivolumab|Nivolumab (240 mg flat dose, week 1 and week 3, twice in total) monotherapy, neoadjuvant to SOC (surgery with or without adjuvant (C)RT).
223859087|NCT03003637|DRUG|Ipilimumab|Ipilimumab (1 mg/kg) only in week 1, in combination with nivolumab (240 mg flat dose, week 1 and week 3, twice in total), neoadjuvant to SOC (surgery with or without adjuvant (C)RT).
223859088|NCT01755897|PROCEDURE|radical hysterectomy + pelvic lymph node dissection|
223859089|NCT01755897|DRUG|Paclitaxel|135-175 mg/m(2) intravenously (IV) on day 1
223859090|NCT01755897|DRUG|Cisplatin|75 mg/m(2) IV on day 2 and 3
223859091|NCT01755897|DRUG|Cisplatin|35 mg/m(2) IV once a week
223859092|NCT01755897|RADIATION|Pelvic RT|IMRT
223859093|NCT02217644|DRUG|BI 653048 H3PO4 solution|
223859094|NCT02217644|DRUG|BI 653048 H3PO4 low dose capsule|
223859095|NCT02217644|DRUG|BI 653048 H3PO4 high dose capsule|
223859096|NCT02217644|DRUG|Placebo|
223859097|NCT05598580|DRUG|Lenalidomide|Lenalidomide capsules (25 mg) were administered orally on days 1-21 of a 28-day cycle for 24 weeks with continuous antiretroviral therapy.
223859098|NCT05598580|DRUG|Adenosylmethionine|Adenosylmethionine capsules (1000 mg, twice a day) were administered orally for 24 weeks with continuous antiretroviral therapy.
223859099|NCT00366873|PROCEDURE|Calcium absorption|formula with or without prebiotics
223859100|NCT02854319|DEVICE|LOTUS Edge Valve System|Transcatheter Aortic Valve Implantation (TAVI) with the LOTUS Edge™ Valve System when used with the Lotus™ or iSleeve™ Introducer Set
223859101|NCT03597100|DEVICE|Cala TWO|Wrist-worn stimulator which applies a tremor-customized stimulation pattern to an individual's nerves
223859102|NCT04723706|DIAGNOSTIC_TEST|COVID-19 serology IgG|patients with SCT or CART who decide to get their vaccines we will measure response by therapy by measuring COVID-19 serology IgG at the following schedule: Baseline +5 days after vaccination; 1 month +/- 10 days (after the first dose), 2 months +/- 10 days (after the 2nd dose), 3 months +/- 10 days, 6 months +/- 10 days and 12 months +/- 10 days
223859103|NCT04781881|DRUG|Entresto|There is no treatment allocation. Patients administered Entresto by prescription that have started before inclusion of the patient into the study will be enrolled.
223859104|NCT05414786|BIOLOGICAL|eOD-GT8 60mer mRNA Vaccine (100µg)|"* 2 doses eOD-GT8 60mer mRNA Vaccine (100µg), 2 vaccinations, 8 weeks apart~* No control group. There is no blinding and no randomization in this open label study"
223859105|NCT00738699|DRUG|MORAb-003 (farletuzumab)|Farletuzumab (FAR) at 2.5 mg/kg was administered by intravenous (IV) infusion weekly on Day 1 of Weeks 1 to 12 (Cycle 1) and then in 4-week cycles with treatment administered on Day 1 of Weeks 1 to 3 for all subsequent cycles.
223859106|NCT00738699|DRUG|0.9% Saline|Placebo (0.9% normal saline) was administered by IV infusion weekly on Day 1 of Weeks 1 to 12 (Cycle 1) and then in 4-week cycles with treatment administered on Day 1 of Weeks 1 to 3 for all subsequent cycles.
223859107|NCT00738699|DRUG|Paclitaxel|
223859108|NCT02067026|DIETARY_SUPPLEMENT|Aleurone|
223859109|NCT02067026|DIETARY_SUPPLEMENT|Placebo|
223859110|NCT04571606|PROCEDURE|Single injection peripheral nerve block with liposomal bupivacaine (Exparel)|10 mL/133 mg liposomal bupivacaine and 10 mL 0.5% bupivacaine
223859111|NCT04571606|PROCEDURE|Single injection peripheral nerve block with 0.25% bupivacaine and subsequent peripheral nerve catheter with 0.2% bupivacaine infusion via onQ pain pump|20 mL 0.25% bupivacaine block and subsequent 10 mL/hr 0.2% bupivacaine infusion for 48 hours
223859112|NCT00160004|BEHAVIORAL|Intensive Controlled Exercise|
223859113|NCT00131144|DRUG|Octreotide Acetate in Microspheres 20 mg|
223859114|NCT00131144|DRUG|Octreotide Acetate in Microspheres|
223859115|NCT00131144|DRUG|Placebo|
223859116|NCT00554736|BIOLOGICAL|Lactobacillus acidophilus L-92|Nasal challenge and acoustic rhinometry will be performed at the first study visit and again at the end of the 4-month supplement period. Standardized perennial ryegrass pollen extract (Lolium perenne) (Hollister-Stier, Inc., Spokane, WA) will be used. Dilutions of the standard product will be made in sterile saline prior to use. The standard product strength is 100,000 BAU/mL. Provocation will start with 100 BAU/mL, delivered as a 100 microliter puff into each nostril nose during breath holding, followed by expiration. Acoustic rhinometry, performed in each nostril, will be recorded at 15 minutes. A change of 30% from baseline in the composite score is considered significant. The dose will be increased every 20 minutes if there is no response. The concentrations used will be 100 BAU, 330 BAU, 1000 BAU, 3300 BAU, 10,000 BAU or 33,000 BAU/mL.
223859117|NCT03005197|DEVICE|Laser Doppler Flowmetry|
223859118|NCT02345018|PROCEDURE|Mechano-chemical ablation|Treatment with mechano-chemical ablation
223859119|NCT01763086|BIOLOGICAL|Mesenchymal stem cells|Mesenchymal stem cells will be intravenously infused via a central venous catheter,at a dose of 1×10\^6 cells/kg, over 15 min. The vital signs of all patients will be closely monitored during and for 24h after MSCs administration. If the NEU and PLT levels do not attain the completely response(CR)standards within 14d, a second course of MSCs treatment will be given.
223859120|NCT00549848|DRUG|Prednisone, Vincristine, Daunorubicin, PEG-L-asparaginase, Erwinia L-asparaginase, Doxorubicin, Cyclophosphamide, Cytarabine, Thioguanine|See Detailed Description section for details of treatment interventions.
223859121|NCT00549848|DRUG|Clofarabine, Methotrexate, Mercaptopurine, Dexamethasone, Etoposide, Dasatinib|See Detailed Description section for details of treatment interventions.
223859122|NCT03854253|PROCEDURE|Long introducer sheath|The investigators will perform transradial coronary angiography and percutaneous coronary interventions using introducer sheath 6Fr-25cm
223859123|NCT03854253|PROCEDURE|Short introducer sheath|The investigators will perform transradial coronary angiography and percutaneous coronary interventions using introducer sheath 6Fr-10cm
223859124|NCT02389777|BIOLOGICAL|ST266 immediate|ST266 will be applied immediately to the UV light burn wound topically by spray twice per day
223859125|NCT02389777|BIOLOGICAL|ST266 delayed|ST266 will be applied to the UV light burn topically by spray twice per day beginning 6-12 hours after the burn
223859126|NCT00419094|DRUG|Keppra XR|Administered as two 500 mg tablets (1000 mg) and two placebo tablets once daily for 18 weeks
223859127|NCT00419094|DRUG|Keppra XR|Administered as four 500 mg tablets (2000 mg) once daily for 18 weeks
223859128|NCT02504086|BEHAVIORAL|Online Support|3 months online support, including access to online personal health record and 2.5 hours of online video teleconsultations with certified health professionals
223859129|NCT06427486|OTHER|Parents Telecoaching Intervention|\- Synchronous (Zoom platform) and Asynchronous coaching sessions for parents of children with autism.
223859130|NCT03262935|DRUG|(vic-)trastuzumab duocarmazine|Intravenous SYD985, Q3W
223859131|NCT03262935|DRUG|Physician's choice|See drug label
223859132|NCT01811706|DRUG|Dalfampridine|Dalfampridine will be provided at an oral dose of 10mg every 12 hours, for 4 weeks period
223859133|NCT01811706|DRUG|Placebo|Placebo will be administered orally every 12 hours, for a 4 week period.
223859134|NCT01060514|DRUG|Pazopanib|dose escalation, administered orally, daily
223859135|NCT01060514|DRUG|Vinorelbine|dose escalation, IV days 1 and 8 of every cycle (cycles begin every 3 weeks)
223859136|NCT02830906|DRUG|ramosetron|intravenous ramosetron 0.3 mg before spinal anesthesia and intrathecal morphine
223859137|NCT02830906|DRUG|Ondansetron|intravenous ondansetron 8 mg before spinal anesthesia and intrathecal morphine
223859138|NCT04030767|DRUG|Botox Injectable Product|Botulinum toxin produces partial chemical denervation of the muscle resulting in localized reduction in muscle activity
223859139|NCT01547546|DRUG|GDC-0084|Multiple doses
223859140|NCT06068439|DRUG|Acetylsalicylic Acid|aspirin 50 mg/d to be taken after dinner (in nonfasting conditions)
223859141|NCT06068439|DRUG|Placebo|Placebo 50 mg/d to be taken after dinner (in nonfasting conditions)
223859142|NCT00307463|PROCEDURE|strict volume control policy|strict volume control by UF and dietary salt restriction
223859143|NCT00307463|PROCEDURE|antihypertensive drugs administration|continue antihypertensive medications
223859144|NCT03623997|OTHER|Iron stable isotope labeled iron(II) sulfate|Administration of oral stable isotope labels using different dosings and different regimens in women with iron deficiency anemia
223859145|NCT01352533|PROCEDURE|Running polypropylene closure|Half of every wound will be closed with Standard of Care running polypropylene sutures
223859146|NCT01352533|PROCEDURE|Tissue Adhesive (Derma-Bond)|Approximately half of wounds will be randomized to be closed with tissue adhesive.
223859147|NCT01352533|PROCEDURE|Subcuticular polyglactin-910 combined with tissue adhesive|Approximately half of the experimental wounds will be randomized to be closed with a combination of subcuticular polyglactin-910 and tissue adhesive.
223859148|NCT02224924|OTHER|ABPI|If the patient was assigned to the ABPI group, a blood patch will be administered using the clotted blood in the syringe obtained at the beginning of the procedure. The guiding needle will be retracted up to 1.5-2 cm from the pleural surface, and the blood will be injected steadily and gently as the needle is pulled back out of the pleura. Injection will stop when the operator feels the needle is in subcutaneous tissues.
223859149|NCT02224924|DEVICE|BioSentry (formerly known as Bio-Seal) hydrogel Tract Plug|If the patient is assigned to BioSentry group, using the manufacturer's deployment device the introducer needle is positioned so that the tip is at least 1.5 cm deep to the visceral pleura. The coaxial introducer needle hub will be prehydrated with a drop of saline, the BioSentry plug housing will be mated and locked to the hub and the plug will be deployed.
223859150|NCT05819099|DIAGNOSTIC_TEST|An Intelligent Endoscopic Diagnosis System Developed and Verified Based on Deep Learning|This study will compare the established AI model with the diagnostic results of endoscopists to evaluate the clinical auxiliary value of the model for endoscopists.
223859151|NCT03020745|DRUG|GSK3389404|GSK3389404 is available as Clear colorless to slightly yellow solution for injection.
223859152|NCT03020745|DRUG|Placebo|Placebo is available as a Clear colorless solution.
223859153|NCT03901937|DRUG|ω-3 polyunsaturated fatty acid|CD patients are divided into two groups, which include with and without ω-3 polyunsaturated fatty acid-based PN (0.1-0.2g/kg/d).
223859154|NCT03901937|PROCEDURE|Intestinal surgery for Crohn's Disease|Patients receive bowel resection due to complications of Crohn's Disease
223859155|NCT04825028|DEVICE|Angiography-drived Index of Microcirculatory Resistance|"From coronary angiographic images, angiography-derived IMR will be calculated based on mathematical calculation.~Angiography-derived IMR = (hyperemic Pa x angiography-derived FFR) x (vessel length / {K x V diastole}).~Hyperemic Pa will be estimated from resting Pa according to prespecified equation."
223859156|NCT04829539|BEHAVIORAL|Behavioral Intervention|Receive BBT-CI
223859157|NCT04829539|BEHAVIORAL|Behavioral Intervention|Receive HEAL
223859158|NCT04829539|OTHER|Quality-of-Life Assessment|Ancillary studies
223859159|NCT04829539|OTHER|Questionnaire Administration|Ancillary studies
223859160|NCT06332040|DRUG|Gentamicin|random assignment to gentamicin or placebo bladder instillation to prevent CAUTI (catheterized urinary track infection)
223859161|NCT05231408|OTHER|High-intensity interval aerobic exercise training|"High-intensity interval aerobic exercise training will be given to training group on treadmill 3 days in a week and 15-45 minutes in a day for 8 weeks with the assistance of a physiotherapist.~The training workload of the active phase of high-intensity interval aerobic exercise training will be applied at 80-100% of peak oxygen consumption or 85-95% of peak heart rate or according to Borg scale dyspnea/fatigue 15-18 points.~The training workload of the active recovery phase of high-intensity interval aerobic exercise training will be applied at 50-60% of peak oxygen consumption or 60-75% of peak heart rate or according to Borg scale dyspnea/fatigue 11-13 points."
223859162|NCT05231408|OTHER|Control Group|Breathing exercises will be given to the control group 120 times in a day and 7 days in a week for 8 weeks as a home program. The control group will be followed-up by telephone once a week.
223859163|NCT06131359|DIAGNOSTIC_TEST|Fine wire EMG and Force Frame muscle strength testing|Insertion of fine wires for EMG study of tibialis posterior and assessment of muscle strength using a force frame
223859164|NCT03754218|DRUG|Amnion Membrane Powder|This sterilized product is composed of lyophilized, gamma-irradiated powder made from amniotic membrane for topical application with the purpose of enhanced wound healing.
223859165|NCT03754218|PROCEDURE|SOC Wound Covering|Institutional standard of care wound covering.
223859166|NCT01456715|BIOLOGICAL|Gardasil vaccine, Immunogenicity, Booster dose.|Gardasil vaccine given according to the 0,6 months schedule and a booster dose of Gardasil given 42 months later.
223859167|NCT01456715|BIOLOGICAL|Cervarix Vaccine, Immunogenicity, Booster Dose.|Gardasil vaccine given according to the 0,6 months schedule and a booster dose of Cervarix given 42 months later.
223859168|NCT03196310|DRUG|Platelet Concentrate|Platelet Rich plasma
223859169|NCT03196310|DRUG|Corticosteroid injection|Kenalog
223859170|NCT03196310|OTHER|Normal Saline|Control Group - Placebo
223859171|NCT03145649|OTHER|Dietary therapy or insulin injection|
223859172|NCT01244113|DRUG|propofol|optimization of propofol dose from 1.5 mg/kg to 2.5 mg/kg using Dixon's up and down method during MRI scanning
223859173|NCT06222918|PROCEDURE|Deep Margin Elevation (G-ænial Universal Injectable)|Deep margin elevation (DME), or coronal margin relocation (CMR), is a procedure used to raise or reposition sub-gingival margins into supra-gingival margins using several materials to increase marginal integrity and bonding strength
223859174|NCT00617331|BIOLOGICAL|Subvirion inactivated influenza A/H9N2 (G9 variant) vaccine|Inactivated subvirion influenza A/chicken/Hong Kong/G9/97 (H9N2) vaccine administered via intramuscular (IM) injection, dose 7.5 or 30 micrograms.
223859175|NCT03036644|DEVICE|e-cigarette (PG+VG without nicotine; low temperature)|
223859176|NCT03036644|DEVICE|e-cigarette (PG+VG with nicotine; low temperature)|
223859177|NCT03036644|DEVICE|e-cigarette (PG+VG without nicotine; high temperature)|
223859178|NCT03036644|DEVICE|e-cigarette (PG+VG with nicotine; high temperature)|
223859179|NCT03036644|OTHER|tobacco cigarette|
223859180|NCT06522880|DIAGNOSTIC_TEST|CMV PCR on saliva|Observational study to measure prevalence of CMV shedding by saliva PCR
223859181|NCT00989937|DRUG|Oxytocin|20 IU BID or 40 IU BID
223859182|NCT00989937|DRUG|Placebo|20 IU BID or 40 IU BID
223859183|NCT00168519|DRUG|nitroprusside, pentalong, imdur, AICAR, isoptin|"Sodium Nitroprusside - one 30 minute intravenous infusion~Pentalong - two tablets orally (total 160mg)~Imdur - two tablets orally (total 120mg)"
223859184|NCT00801658|DEVICE|selective Laser Trabeculoplasty (SLT)|
223859185|NCT00203216|DRUG|levetiracetam|Daily dose of open label levatiracetam was 3000 mg. or maximally tolerated dose. (Maximum daily dose: 3000 mg. Minimum daily dose allowed for study participation:1000 mg)
223859186|NCT00203216|PROCEDURE|Transcranial Magnetic Stimulation|
224266284|NCT03485118|DRUG|HS006+CHOP|"Drug:HS006 HS006 500 mg per square meter (mg/m\^2),administered intravenously(IV) on Day1 of each 21-day cycle for 6 cycles. During cycle 1,HS006 also infused on Day 8 and 15.~Drug :Cyclophosphamide Cyclophosphamide 750mg per square metre(mg/m\^2),administered intravenously(IV) on Day 2 of each 21-day cycle.~Drug :Doxorubicin Doxorubicin 50mg per square metre( mg/m\^2),administered intravenously(IV) on Day 2 of each 21-day cycle.~Drug :Vincristine Vincristine 1.4mg(maximum 2.0mg) per square metre (mg/m\^2),administered intravenously(IV) on Day 2 of each 21-day cycle.~Drug: Prednisone Prednisone 100 mg administered orally on Days 1-5 of each 21-day cycle."
224266285|NCT03485118|DRUG|Rituximab+CHOP|"Drug:Rituxan Rituxan 375 mg per square metre (mg/m\^2), administered by intravenous (IV) on Day 1 of each 21-day cycle.~Drug :Cyclophosphamide Cyclophosphamide 750mg per square metre(mg/m\^2),administered intravenously(IV) on Day 2 of each 21-day cycle.~Drug :Doxorubicin Doxorubicin 50mg per square metre( mg/m\^2),administered intravenously(IV) on Day 2 of each 21-day cycle.~Drug :Vincristine Vincristine 1.4mg(maximum 2.0mg) per square metre (mg/m\^2),administered intravenously(IV) on Day 2 of each 21-day cycle.~Drug: Prednisone Prednisone 100 mg administered orally on Days 2-6 of each 21-day cycle."
224266286|NCT01622764|RADIATION|Molecular imaging with 89Zr-RO5323441|Bevacizumab at a dose of 10 mg/kg body weight i.v. in 90 min on day 1 will be given every 2 weeks in cycles of 6 weeks, until documented disease progression, unacceptable toxicity, patient refusal or patient's best interest. 89Zr-RO5323441 will be administered i.v. at a tracer dose of 5 mg (37 MBq) on day -3 and on day 11 of cycle 1 of bevacizumab treatment. Four PET scans will be performed (2 brain only PET scans and 2 whole body PET scans). Brain only PET scans will be performed 2 hours after each 89Zr-RO5323441 administration on day -3 and day 11. Whole body PET scans will be performed 4 days after each 89Zr-RO5323441 administration (before dosing with bevacizumab on day 1 and day 15).
224266287|NCT00562718|DRUG|capecitabine|
224266288|NCT00562718|PROCEDURE|adjuvant therapy|
224266289|NCT00562718|RADIATION|radiation therapy|
224266290|NCT01868243|DRUG|Dabigatran|Group 1 - Dabigatran 110 mg (50 patients)
224266291|NCT01868243|DRUG|Warfarin|Warfarin adjusted-dose
224266292|NCT00452738|BEHAVIORAL|Therapy dog|
224266293|NCT00452738|BEHAVIORAL|Costumed character|
224266294|NCT00452738|BEHAVIORAL|Parents-only|
224266295|NCT02734511|DRUG|sedation with propofol|induction with propofol at 20mg/kg/h. Then, when the patient is sleeping, dosage is decreased to 6 mg/kg/h
223859187|NCT06522711|DEVICE|Virtual reality headset|A brief overview of all three virtual reality scenarios will be shown in a consolidated video prior to letting the participant select the preferred scenario. The participant's choice of scenario will then be documented. Once paravertebral blocks are completed and the participants are in supine position and the surgeon is ready to disinfect, the VR headset will be applied on the face of the participants in the intervention group and the chosen scenario will be started. If at any point the patient expresses a desire to stop using VR during the surgery, we will first offer them an alternate scenario. If they reiterate their willingness to stop, with or without having experienced the new scenario, the headset will be removed for the remainder of the surgery.
223859188|NCT06522711|OTHER|Standard of care|Standard of care in anesthesia with patient-controlled sedation.
223859189|NCT06467279|DEVICE|Target Controlled İnfusion|TCI (Target-Controlled Infusion) is a method used to maintain the dose and rate of anesthesia drugs within a target concentration range set by the anesthetist. This system delivers drugs intravenously to the patient using a computer-controlled pump. The anesthetist adjusts the drug concentration to achieve the desired depth of anesthesia. This method provides more precise control over anesthesia and facilitates maintaining the depth of anesthesia within the desired range.
223859190|NCT06467279|DRUG|Inhalation anesthetic|In the inhalation anesthesia group, maintenance sevoflurane anesthesia will be applied after routine induction.
223859191|NCT06316206|DRUG|Ethinylestradiol/Dienogest 0.03mg/2mg|Endometrial polyps underwent hysteroscopic polipectomy after starting 14-day treatment with oral Ethinylestradiol/Dienogest 0.03mg/2mg at any time of the menstrual cycle
223859192|NCT03629730|BEHAVIORAL|Coordination training|The intervention will consist of 8 weeks of exercises to decrease the variability of participants' body and gait coordination. The intervention will consist of 1 training session /week in the Mobility Research Laboratory and 4 days of home-based training. In each session participants will perform 6 trials of 4 body coordination exercises and 1 gait exercise. In the intervention sessions participants will perform interlimb coordination exercises, synchronizing body segments with auditory metronome tones. Participants also will perform a gait exercise by synchronizing steps with an auditory metronome during walking. The metronome will assist participants to retrain their movement timing to decrease coordination variability.
223859193|NCT00355914|PROCEDURE|Lumbar Facet Joint Nerve Block|Lumbar Facet Joint Nerve Block
223859194|NCT04476095|DEVICE|Active PBMT|Active PBMT will be applied using a device with 152 emitters (wavelength - 808 nm; dose - 3000 J; treatment time - 600 s), in the low back region.
223859195|NCT04476095|DEVICE|Placebo PBMT|The placebo PBMT will be applied using the same device as that of active PBMT but without any emission of therapeutic dose. Moreover, the irradiated site and the irradiation time were the same as that of active PBMT. Patients received a total dose of 0 J in the placebo mode. The sounds and signals emitted from the device as well as the information displayed on the screen will be identical, regardless of the type of treatment (active or placebo).
223859196|NCT01886625|PROCEDURE|unilateral single-port VATS sympathicotomy|
223859197|NCT02497092|OTHER|Technique of injection|
223859198|NCT03823300|DRUG|Faricimab|Faricimab will be administered by intravitreal injection into the study eye at intervals as specified in the study protocol.
223859199|NCT03823300|DRUG|Aflibercept|Aflibercept will be administered by intravitreal injection into the study eye once every 4 weeks for 3 consecutive months, followed by once every 8 weeks (Q8W).
223859200|NCT03823300|PROCEDURE|Sham Procedure|The sham is a procedure that mimics an intravitreal injection, but involves the blunt end of an empty syringe (without a needle) being pressed against the anesthetized eye. It will be administered to participants in both treatment arms at applicable visits to maintain masking.
223859201|NCT02571387|BEHAVIORAL|Mindfulness-based intervention|
223859202|NCT02571387|BEHAVIORAL|Sham meditation|
223859203|NCT00354640|DRUG|anastrozole|1 milligram tablet PO QD for 14 days
223859204|NCT00354640|DRUG|simvastatin|40 milligram tablet PO QD for 14 days
223859205|NCT00354640|OTHER|pharmacological study|laboratory analysis
223859206|NCT00354640|PROCEDURE|adjuvant therapy|laboratory analysis
223859207|NCT05390736|BEHAVIORAL|Gait and balance assessment|Patients are given Time Up and Go (TUG) tests, 30-second chair test, and 4-stage balance test (side-by-side, instep, tandem, and one foot).
223859208|NCT05390736|BEHAVIORAL|Medication review|Patients' medication history in the EHR is assessed for polypharmacy (using 5 or more medications concurrently) and use of medication in the following classes: tricyclic antidepressants, antihistamines, antiemetics, antipsychotics, antispasmotics, muscle relaxants, benzodiazepines, hypnotics, and opioids. The CRN confirms prescriptions with the patient. The CRN reports the medication risk in her provider report and provides medication management educational materials to the patient. At the patient's upcoming primary care visit, providers evaluated whether the medications associated with increased fall risk could be adjusted.
223859209|NCT05390736|BEHAVIORAL|Comorbidity review|The clinical research nurse reviews the patient's EHR problem list for diagnoses of comorbidities associated with increased fall risk including: cognition problems, Parkinson's disease, cardiac issues, depression, or incontinence. Comorbidities are shared with providers in the recommendation statement.
223859210|NCT05390736|BEHAVIORAL|Fall history|The CRN asks how many times the patient had fallen in the past 12 months, whether those with falls sought medical attention, and if they experienced blackouts, loss of consciousness, or a broken/fractured bone(s) resulting from a fall. Fall history information is added to the provider report to increase the salience of fall prevention information.
223859211|NCT05390736|BEHAVIORAL|Assessment of feet/footwear|The CRN observes or asks about the patient's current footwear, asks about foot pain or loss of sensation, and notes a diabetes diagnosis when applicable. Patient reports of foot pain, loss of sensation or diabetes result in a CRN note to the provider to examine the patient's feet and the potential need for a referral to podiatry. The CRN also reviewed a safe footwear handout with all patients regardless of their responses and emailed it to patients with other patient information following the call.
223859212|NCT05390736|BEHAVIORAL|Assessment of visual acuity|The CRN projects a Banner eye chart on Zoom for the patient to read with their contacts or glasses from five feet away for both eyes together and each eye individually. Phone patients are asked to self-report any vision problems. If either the video screening or patient self-report indicated any vision problems, the CRN notes the result and recommendation for eye care referral for the patient's provider to review and order.
223859213|NCT05390736|BEHAVIORAL|Home safety risk assessment|"The CRN reviews the CDC brochure Check for Safety: A Home Fall Prevention Checklist for Older Adults with each patient. Check for Safety asks 17 questions about the home's floors, stairs and steps, kitchen, bathrooms, and bedrooms and suggests ideas for removing or reducing fall hazards. The CRN communicates home safety risks and a recommendation for occupational therapy to the provider for indicated patients."
223859214|NCT05390736|BEHAVIORAL|Vitamin D Deficiency|The CRN asks the patient if they usually take a Vitamin D supplement with their other medications. If the patient does not take a Vitamin D supplement, the CRN recommends the provider check Vitamin D levels and consider supplementation if Vitamin D levels are less than 20 ng/mL.
223859215|NCT00316641|DRUG|Lipid-lowing Tea|
223859216|NCT00208078|DEVICE|pressure support ventilator|Non invasive ventilation 4h/d 5 days a week
223859217|NCT02894151|DRUG|Depot medroxyprogesterone acetate|
223859218|NCT02894151|DEVICE|LNG-IUS|
223859219|NCT01418118|DRUG|Epinephrine|0.2mcg/kg/min maximum infusion; to increase mean arterial pressure by 30mmHg
223859220|NCT01418118|DRUG|Norepinephrine|Maximum infusion of 0.2mcg/kg/min, to increase mean arterial pressure by 30mmHg
223859221|NCT01418118|DRUG|Dobutamine|Maximum infusion rate of 8mcg/kg/min to increase mean arterial pressure by 30mmHg
223859222|NCT01418118|DRUG|Dopexamine|Maximum infusion rate of 5mcg/kg/min to increase mean arterial pressure by 30mmHg
223859223|NCT00753012|DRUG|Lisdexamfetamine|Lisdexamfetamine daily until the completion of participation in the clinical trial (up to Week 11 or final study visit). Subjects will start on 30 mg of LDX per day for the first week of treatment. The dose will be increased weekly in 20 mg increments, up to a 70 mg daily (maximum). If significant adverse effects (AE) occur, the daily dose may be reduced by 20 mg. At subsequent visits, a higher dose may be resumed if tolerated. Both cohorts of the study will follow the same treatment plan.
223859224|NCT00590707|DEVICE|Deeper sedation|The depth of sedation, as measured by the use of the Observer's Assessment of Awareness/Sedation Scale (OAA/S), will be maintained at an OAA/S score of 0.
223859225|NCT00590707|DEVICE|Moderate sedation|The depth of sedation, as measured by the use of the Observer's Assessment of Awareness/Sedation Scale (OAA/S), will be maintained at an OAA/S score of 4-5.
223859226|NCT01982136|PROCEDURE|end-to-end urethroplasty|
223859227|NCT01982136|PROCEDURE|substitution urethroplasty (buccal mucosa)|
223859228|NCT01982136|PROCEDURE|substitution urethroplasty (pedicled skin flap)|
223859229|NCT06373744|DRUG|cyclophosphamide , methotrexate , vinorelbine ,capecitabine|The drugs used in metronomic chemotherapy are cyclophosphamide (CTX), methotrexate (M), vinorelbine (VNR), and capecitabine
223859230|NCT05647980|OTHER|TACTIC|Participants execute the three steps of TACTIC Participants fill in questionnaires Participants take laboratory and biometric tests to measure their cardiovascular risk
223859231|NCT01367483|DRUG|IV methylnaltrexone (MNTX)|
223859232|NCT00943735|DRUG|Fesoterodine|Fesoterodine 4 mg and 8 mg QD
223859233|NCT00943735|BEHAVIORAL|Your Way|early intervention after treatment initiation and before patients have an opportunity to discontinue medication; reinforcing the treatable nature of OAB
223859234|NCT00221637|DRUG|Sodium Valproate|
223859235|NCT00521937|OTHER|Dermagen®|Weekly topical applications
223859236|NCT02329613|OTHER|Standard evening meals.|Patients will receive usual evening meals.
223859237|NCT02329613|OTHER|Improved evening meal|Patients will receive improved evening meals. Improved meals will include enriched soup (with starches, butter, cheese or sour cream), a semi-liquid dairy dessert, fruit or a fruit dessert.
223859238|NCT05603520|OTHER|Collection of Clinical Data|prospectively and systematically collection of clinical research data from apparently healthy volunteers and patients with aortic stenosis and aneurysms
223859239|NCT05502458|DRUG|Desﬂurane|Propofol general anesthesia group (P group) : intravenous propofol infusion was slowly pushed until consciousness disappeared, and then anesthesia was maintained at 4-8 mg/kg/h. In the general anesthesia group with desflurane (group D), intravenous propofol infusion was slowly pushed until consciousness disappeared, and then anesthesia was maintained with 4-6% desflurane. The analgesic and muscle relaxant regimens were the same in both groups except for sedative drugs. All patients were treated with no medication before operation, and the operation was completed under endotracheal intubation and general anesthesia. The amount of propofol or desflurane was adjusted according to BIS or MAC values and hemodynamic changes during operation. Add 10mg of rocuronium every half hour. Vasoactive drugs can be used to maintain hemodynamic stability during the operation, and corresponding records should be made
223859240|NCT05502458|DRUG|Propofol|Propofol general anesthesia group (P group) : intravenous propofol infusion was slowly pushed until consciousness disappeared, and then anesthesia was maintained at 4-8 mg/kg/h.
223859241|NCT00367692|DRUG|PSI-697|
223859242|NCT02383108|DRUG|DTG +DRV/r|NRTI-sparing regimen: Once daily integrase inhibitor (INSTI) + darunavir/ritonavir (DRV/r)
223859243|NCT02383108|DRUG|SOC|Standard of care (continuing triple anti-retroviral therapy including 2 NRTIs + boosted PI/NNRTI)
223859244|NCT06476925|PROCEDURE|sonar guided stellate ganglion injection|using high frequency probe, sonar guided stellate ganglion block with 8 ml saline 0.9%
223859245|NCT06476925|PROCEDURE|sonar guided stellate ganglion block|using high frequency probe, sonar guided stellate ganglion block with 8 ml bupivacaine 0.25%
223859246|NCT03804918|OTHER|VitalTips mobile application|VitalTips is a mobile learning application with learning on breaking bad news. Participants were expected to spend at least three hours using the mobile learning resource, ensuring that the time did not impact on their clinical and academic commitments.
223859247|NCT02587130|DRUG|Ketamine|ketamine administered in bolus by subcutaneous injection
223859248|NCT00206258|DRUG|Pramlintide and glucagon|
223859249|NCT05719038|DIAGNOSTIC_TEST|observational study|observational study
223859250|NCT06131047|OTHER|High intensity Traditional Resistance Traning without Blood Flow Restriction|Group A will undergo Traditional Resistance training without blood flow Restriction. A 30-minute progressive, weight training program will be initiated 8 weeks after the ACL-reconstruction and will be conducted subsequent to the individual based program. The resistance (training loads) will be increased when the individual could do more repetitions than the number specified in the weight training protocol. The exercises will be performed at a slow speed to ensure full control of the movement
223859251|NCT06131047|OTHER|High intensity Traditional Resistance Traning with Blood Flow Restriction|Group B will recieve low-load blood flow restriction (LL-BFR) training using external loads of 20-40% 1RM has been suggested as an alternative to traditional strength rehabilitation. Minimum of 2 -3 sets and maximum total 5 sets,20-30 repetitions of each exercise with 30 to 60 seconds rest period and 2-3 times per weekly for 4-6 weeks to During LL-BFR training, a pressurized cuff is applied to the proximal thigh that oc¬cludes venous outflow while maintaining arterial in¬flow. The combination of venous occlusion and resis¬tance training is believed to induce muscle hypertrophy secondary to elevated systematic hormone production, cell swelling, production of reactive oxygen species, intramus¬cular anabolic signaling and fast-twitch fiber recruit¬ment
223859252|NCT00242190|DRUG|oxaliplatin|
223859253|NCT00242190|DRUG|gemcitabine|
223859254|NCT00242190|PROCEDURE|radiation therapy|
223859255|NCT04277299|DEVICE|IcorySolution|The ICory-solution programme is designed to be a self-guided and healthcare professional-led. Participants will have access to BuddyCare for parents and Triumf Health from time of recruitment till 2 weeks after surgery. The healthcare professional have received face-to-face training on how to use the BuddyCare dashboard and BuddyCare has been in the hospital in earlier studies.The Buddy Healthcare mobile app (BuddyCare) that provides a comprehensive day-by-day perioperative guide for parents regarding their child's surgery with an interface for health care professionals to monitor parents' and their children's needs as well as communicate with them. (2) The Triumf Health mobile game app that provides emotional support, games and distraction to children and a virtual tour to the hospital before children´s operation.
223859256|NCT06043128|OTHER|Patients With Stroke With Different Trunk Impact Levels|"Before the study, written and verbal Informed Consent Form will be obtained from all participants who meet the inclusion criteria.Trunk Impairment Scale (TRS) will be used to measure trunk control, which is our independent variable. Scores close to 23 points on the TIS will constitute the group with high trunk control, and those with scores close to 0 will constitute the group with low trunk control. Spasticity of the participants, Modified Tardiue Scale (MTS), cervical proprioceptive awareness cervical joint error test, lower extremity proprioceptive awareness Proprioception test in Technobody Prokin 252 Isokinetic Balance Platform, balance skills Dynamic and static balance in Tecnobody Prokin 252 Isonkinetic Balance Platform will be evaluated by tests. The patients' quality of life will be evaluated with the stroke-specific quality of life scale. All data obtained will be noted on a prepared evaluation form."
223859257|NCT01329328|DEVICE|vibrating platform (Bioplate RF)|whole body vibration exercise with multiple positions, with or without localized delivery of heating radiofrequency
223859258|NCT00002555|DRUG|cisplatin|
223859259|NCT00002555|RADIATION|low-LET cobalt-60 gamma ray therapy|
223859260|NCT00002555|RADIATION|low-LET electron therapy|
223859261|NCT00002555|RADIATION|low-LET photon therapy|
223859262|NCT02973919|BEHAVIORAL|Eye Movement Desensitization and Reprocessing Therapy|In 1989, Shapiro discovered that while talking about negative life events or thoughts, rhythmic eye movements on a horizontal axis can alleviate the associated vividness and burden (Shapiro, 1989). She established the psychodynamic-behavioral Eye Movement Desensitization and Reprocessing (EMDR) Therapy, which includes the induction of rhythmic eye movements as a central feature. EMDR is regarded as an efficient treatment tool. Several times it has also been successfully applied in the field of specific phobias (de Jongh, ten Broeke, \& Renssen, 1999; de Jongh, Holmshaw, Carswell, \& van Wijk, 2011; Lapsekili \& Yelboga, 2014; Muris, Merckelbach, van Haaften, \& Mayer, 1997) and there is a standard protocol for using EMDR on specific fears and phobias (de Jongh, 2015).
223859263|NCT02973919|BEHAVIORAL|Virtual Reality Exposure Therapy|Exposure to fear-evoking stimuli is conducted more often in virtual environments using simulators or similar computer-technologies (Virtual Reality Exposure Therapy, VRET). One great advantage of using VR-technologies is that it is possible to create an environment which is highly controllable by its creators. Feared stimuli or scenarios can be varied on individual purposes and presented several times. This facili- tates the practice of exposure-based treatments especially for situations or places diffi- cult to access or requiring a considerable amount of time and/or money (e.g. being in war zones or a passenger on a flight), where in vivo exposures have often not been con- ducted or only in a limited manner (Mühlberger \& Pauli, 2011).
223859264|NCT00298649|BEHAVIORAL|Lay Health Advisor|
223859265|NCT04035291|OTHER|exercise|exercises,play therapy models and positioning, handling and holding principles for babies, daily routins
223859266|NCT01033058|DRUG|atorvastatin|80mg atorvastatin immediately after enrollment, emergency PCI,atorvastatin 40mg/d and other usual medication after PCI
223859267|NCT01033058|DRUG|atorvastatin|No loading dose of statin after enrollment, emergency PCI, atorvastatin 20mg/d and other usual medication after PCI
223859268|NCT00727038|DRUG|Ranibizumab (Lucentis)|0.5 mg ranibizumab intravitreal injection single dose administration
223859269|NCT04768361|BEHAVIORAL|Behavioral Activation without Mindfulness|"Behavioral Activation without Mindfulness includes functional analysis as key to defining out-of-session and activation strategies as central to mood change."
223859270|NCT04768361|BEHAVIORAL|Behavioral Activation with Mindfulness|"Behavioral Activation with Mindfulness includes functional analysis as key to defining out-of-session and activation strategies and mindfulness as central to mood change."
223859271|NCT02760381|DEVICE|NBI + Acetic Acid (AA)|Patients belonging to the Routine colonoscopy Cohort will receive NBI + Acetic Acid (AA) chromoendoscopy for optical predictions of colonic polyps.
223859272|NCT01040741|OTHER|Non-intervention observational study|Non-intervention observational study
223859273|NCT04960176|PROCEDURE|Acupuncture|Acupuncture will be applied by using 0,25x25mm needles.
223859274|NCT04960176|PROCEDURE|Non-invasive Sham Acupuncture|Non-invasive sham acupuncture will be applied by using blunted 0,25x25mm needles.
223859275|NCT02331043|DIETARY_SUPPLEMENT|Plant stanol ester|
223859276|NCT02331043|DIETARY_SUPPLEMENT|Placebo|
223859277|NCT00455754|DRUG|Esomeprazole|
223859278|NCT01535989|DRUG|Inotuzumab Ozogamicin|starting dose 0.8 mg/m2, d1 administration, q4wks
223859279|NCT01535989|DRUG|Temsirolimus|starting dose of 15mg, weekly administration, q4ws
223859280|NCT04689568|BEHAVIORAL|Moodkit|"MoodKit is divided into four main sections: Activities, Thoughts, Mood and Journal. In the Thoughts section, the user is asked to briefly describe stressful situations and their reactions to the event and is later educated on a number of thought distortions. In the Mood section, the user is asked to give an overall rating of mood, which can be done several times per day. In the Journal section, the user can write freestanding journal entries. Additional areas of advice and goal setting are contained in a section called Thrive Tips."
223859281|NCT04689568|BEHAVIORAL|Moodgym|The program consists of five modules each taking 20- to 40-minutes to complete, which are completed in a prescribed order.
223859282|NCT04689568|BEHAVIORAL|University of Michigan Depression Center Toolkit|The Toolkit provides information, tools, support, and resources to guide individuals through their mental health journey.
223859283|NCT03022903|PROCEDURE|Aminolevulinic Acid (ALA)|Photosensitizing
223859284|NCT04993963|OTHER|Cycle Ergometery Training (Prehabilitation)|Interval training on cycle ergometer: between 40% and 60% Vo2max, perceived exertion \<13 on Borg scale 20-30 min/session/day (intermittent of exercise 2-3 mint, followed by 1-2 min of active recovery) Cool down (5 minutes) AROM +Body stretch
223859285|NCT04993963|OTHER|Control Standard Group|Breathing exercise 15 Reps and Walk (10-15 minutes)
223859286|NCT03573258|DIETARY_SUPPLEMENT|Fiber or Placebo (depending on the randomization)|ingestion of dietary fibers prior to meal intake
223859287|NCT03359460|DRUG|Ibrutinib|Given PO
223859288|NCT03359460|DRUG|Lenalidomide|Given PO
223859289|NCT04920617|DRUG|DPX-Survivac|SC injection on D7 and D28, then every 8 weeks
223859290|NCT04920617|DRUG|Pembrolizumab|IV infusion every 3 weeks
223859291|NCT04920617|DRUG|CPA|50 mg twice daily, week on then week off
223859292|NCT00520208|DRUG|Tamibarotene|For induction therapy, tamibarotene will be self-administered via tablets on an outpatient basis at a dose of 6 mg/m2 per day, taken orally, in two divided doses approximately one hour after breakfast and dinner. Induction therapy will continue for a maximum of 56 days until either a morphologic leukemia-free state or complete response (CR) has been achieved. For patients who achieve a CR with induction therapy, consolidation therapy will commence 4 to 8 weeks after the end of induction therapy. For patients who have a morphologic leukemia-free state after induction therapy but who fail to achieve a CR, consolidation therapy will commence 8 weeks after the end of induction therapy.
223859293|NCT00325858|DRUG|Tramadol HCl ER|
223859294|NCT04179227|OTHER|Questionnaire Administration|Ancillary studies
223859295|NCT04179227|OTHER|Survey Administration|Ancillary studies
223859296|NCT02023554|DRUG|Theophylline with azithromycin|"Drug: Theophylline(100mg,sustained release tablets). Multi-dose of theophylline(100mg,twice daily) will administered at 8 am and 8 pm from day 1 to day 7.~Drug:Azithromycin(250mg, capsules). Multi-dose of azithromycin(500mg,once daily) will administered at 8 pm from day 1 to day 7."
223859297|NCT02023554|DRUG|Theophylline alone|Drug: Theophylline(100mg,sustained release tablet). Multi-dose of theophylline(100mg,twice daily) will administered at 8 am and 8 pm from day 8 to day 14.
223859298|NCT04617717|PROCEDURE|Invasive cardiac electrophysiological study and ablation therapy|Invasive cardiac electrophysiological study with cathecholamine provocation and pacing procedures, as well as standard 3D mapping and PVC ablation
223859299|NCT04617717|DIAGNOSTIC_TEST|Cardiopulmonary exercise testing|Standard ergometer bicycle test
223859300|NCT04617717|DIAGNOSTIC_TEST|Cardiac MRI|Cardiac MRI with cine-imaging and late-gadolinium enhancement
223859301|NCT04617717|DIAGNOSTIC_TEST|Holter monitoring|24h 5 lead or 12 lead ECG recording
223859302|NCT04617717|DIAGNOSTIC_TEST|Transthoracic echocardiography|2D echocardiography
223859303|NCT04617717|DIAGNOSTIC_TEST|Coronary angiography|Conventional invasive coronary angiography or CT angiography as indicated
223859304|NCT05349097|DRUG|SAD IMG-004 30mg|Each participant will be randomized to receive a single oral dose of 30mg IMG-004
223859305|NCT05349097|DRUG|SAD IMG-004 100mg|Each participant will be randomized to receive a single oral dose of 100mg IMG-004
223859306|NCT05349097|DRUG|SAD IMG-004 200mg|Each participant will be randomized to receive a single oral dose of 200mg IMG-004
223859307|NCT05349097|DRUG|SAD IMG-004 400mg|Each participant will be randomized to receive a single oral dose of 400mg IMG-004
223859308|NCT05349097|DRUG|SAD IMG-004 600mg|Each participant will be randomized to receive a single oral dose of 600mg IMG-004
223859309|NCT05349097|DRUG|SAD Placebo 30mg|Each participant will be randomized to receive a single oral dose of 30mg matching placebo
223859310|NCT05349097|DRUG|SAD Placebo 100mg|Each participant will be randomized to receive a single oral dose of 100mg matching placebo
223859311|NCT05349097|DRUG|SAD Placebo 200mg|Each participant will be randomized to receive a single oral dose of 200mg matching placebo
223859312|NCT05349097|DRUG|SAD Placebo 400mg|Each participant will be randomized to receive a single oral dose of 400mg matching placebo
223859313|NCT05349097|DRUG|SAD Placebo 600mg|Each participant will be randomized to receive a single oral dose of 600mg matching placebo
223859314|NCT05349097|DRUG|MAD IMG-004 50mg|Each participant will be randomized to receive daily oral dose of 50mg IMG-004 for 10 days
223859315|NCT05349097|DRUG|MAD Placebo 50mg|Each participant will be randomized to receive daily oral dose of 50mg matching placebo for 10 days
223859316|NCT05349097|DRUG|MAD IMG-004 150mg|Each participant will be randomized to receive daily oral dose of 150mg IMG-004 for 10 days
223859317|NCT05349097|DRUG|MAD Placebo 150mg|Each participant will be randomized to receive daily oral dose of 150mg matching placebo for 10 days
223859318|NCT05349097|DRUG|MAD IMG-004 300mg|Each participant will be randomized to receive daily oral dose of 300mg IMG-004 for 10 days
223859319|NCT05349097|DRUG|MAD Placebo 300mg|Each participant will be randomized to receive daily oral dose of 300mg matching placebo for 10 days
223859320|NCT05349097|DRUG|FE IMG-004 150mg|A single dose of IMG-004 at 150 mg dose level will be administered to the participants in fed and fasted states
223859321|NCT06555380|BEHAVIORAL|The one-year intervention|A multifactorial family-centered lifestyle intervention with a maximum duration of one year, corresponding to three-four visits. Participants were offered complimentary weekly supervised physical activity. The day-to-day intervention was managed by specialized nurses at local healthcare centers, at the participants' homes, or in a local clinic.
223859322|NCT06555380|BEHAVIORAL|The three-year intervention|A multifactorial family-centered lifestyle intervention extending up to three years, with clinical visits at local healthcare centers which included repeatedly visits (up to 8 times / year). The intervention was managed by specialized nurses.
223859323|NCT01027299|DEVICE|Biventricular pacing|Optimised temporary biventricular pacing.
223859324|NCT06373549|PROCEDURE|Patients with coronary artery bypass surgery routine procedural administration of cardioplegia solutions|To investigate the effectiveness of myocardial protection methods, blood samples were collected from the coronary sinus before the aortic cross-clamping and at 4 minutes after aortic cross-clamping, through a coronary sinus cannula with a yellow-capped gel tube. The collected blood samples were kept in an upright position for 20 minutes to allow separation into serum fraction, then centrifuged at 3000 g for 10 minutes (Beckman Coulter, Microfuge 16, USA). The obtained serums were aliquoted into 250 μl portions in Eppendorf tubes, separately for each patient.
224266296|NCT00985751|BIOLOGICAL|Pneumococcal vaccine GSK2189242A (formulation 1)|Three doses will be administered intramuscularly, at Month 0, 2 and 6.
224266297|NCT00985751|BIOLOGICAL|Pneumococcal vaccine GSK2189242A (formulation 2)|Three doses will be administered intramuscularly, at Month 0, 2 and 6
224266298|NCT00985751|BIOLOGICAL|Pneumococcal vaccine GSK2189242A combined with pneumococcal vaccine GSK1024850A (formulation 3)|Three doses will be administered intramuscularly, at Month 0, 2 and 6
224266299|NCT00985751|BIOLOGICAL|Pneumococcal vaccine GSK2189242A combined with pneumococcal vaccine GSK1024850A (formulation 4)|Three doses will be administered intramuscularly, at Month 0, 2 and 6
224266300|NCT00985751|BIOLOGICAL|Pneumococcal vaccine GSK1024850A|Three doses will be administered intramuscularly, at Month 0, 2 and 6
224266301|NCT00838162|DRUG|TMC310911 75 mg twice daily|TMC310911 75 mg twice daily orally (by mouth) on Days 1 to 14.
224266302|NCT00838162|DRUG|TMC310911 150 mg twice daily|TMC310911 150 mg twice daily orally (by mouth) on Days 1 to 14
224266303|NCT00838162|DRUG|TMC310911 300 mg twice daily|TMC310911 300 mg twice daily orally (by mouth) on Days 1 to 14
224266304|NCT00838162|DRUG|TMC310911 300 mg once daily|TMC310911 300 mg once daily orally (by mouth) on Days 1 to 14
224266305|NCT00838162|DRUG|Ritonavir 100 mg twice daily|Ritonavir 100 mg twice daily orally (by mouth) on Days 1 to 14
223859325|NCT06373549|PROCEDURE|Patients who underwent heart valve surgery without coronary artery disease routine procedural administration of cardioplegia solutions|To investigate the effectiveness of myocardial protection methods, blood samples were collected from the coronary sinus before the aortic cross-clamping and at 4 minutes after aortic cross-clamping, through a coronary sinus cannula with a yellow-capped gel tube. The collected blood samples were kept in an upright position for 20 minutes to allow separation into serum fraction, then centrifuged at 3000 g for 10 minutes (Beckman Coulter, Microfuge 16, USA). The obtained serums were aliquoted into 250 μl portions in Eppendorf tubes, separately for each patient.
223859326|NCT00964366|DRUG|clindamycin and benzoyl peroxide|Daily applications, to the randomized side of the face either left or right, of clindamycin and benzoyl peroxide
223859327|NCT00964366|DRUG|Dapsone gel|Twice-daily applications of dapsone gel
223859328|NCT04286256|BEHAVIORAL|Motivational Interviewing|Participants/caregivers will receive several telephone-based and in-person motivational interviewing sessions along with specific oral health recommendations.
223859329|NCT03009513|DRUG|Teneligliptin+Glimepiride|
224266306|NCT00838162|DRUG|Ritonavir 100 mg once daily|Ritonavir 100 mg once daily orally (by mouth) on Days 1 to 14
224266307|NCT05262322|DRUG|Edoxaban|This was a non-interventional, observational study. No drug was administered in this study.
224266308|NCT05262322|DRUG|Apixaban|This was a non-interventional, observational study. No drug was administered in this study.
224266309|NCT05262322|DRUG|Rivaroxaban|This was a non-interventional, observational study. No drug was administered in this study.
224266310|NCT01200186|DRUG|EV/DNG (Qlaira, BAY86-5027)|At the discretion of the attending physician
224266311|NCT01200186|DRUG|Progestin Only Pills|At the discretion of the attending physician
224266312|NCT04627844|DIETARY_SUPPLEMENT|Immediate Feeding|Standard tube feeds begun at an earlier time point
224266313|NCT04627844|DIETARY_SUPPLEMENT|Delayed Feeding|Standard tube feeds begun at delayed time point
224266314|NCT03010657|OTHER|Intervention|Subjects will be asked to consume certain foods during chemotherapy treatment.
224266315|NCT02000258|PROCEDURE|Double-bundle ACL reconstruction|
224266316|NCT02000258|DEVICE|Magnetic resonance imaging (MRI)|MRI sequences were as follows: sagittal T1-weighted, proton density (PD)-weighted and T2-weighted fast spin echo (FSE) images with 4 mm slice and 1 mm gap, coronal T1-weighted and fat-saturated T2-weighted FSE images with 4 mm slice and 1 mm gap, axial fat saturated PD FSE images with 4 mm slice and 1 mm gap and oblique sagittal and oblique coronal T1 FSE images along AM graft plane with 3 mm slice and 0.3 mm gap.
224266317|NCT02350257|BEHAVIORAL|Internet-based CBT|12 weeks of internet-based CBT
224266318|NCT00220844|DRUG|Desipramine|
224266319|NCT00220844|DRUG|Amitriptyline|
224266320|NCT01529164|DRUG|Endostatins (Endostar)|7.5mg/m2 iv d1-10,repeat every 14 days,until progression or occurrence of untolerated toxicity
224266321|NCT01529164|DRUG|Oxaliplatin|85mg/m2 iv d1 ,repeat every 14 days,until progression or occurrence of untolerated toxicity
224266322|NCT01529164|DRUG|Leucovorin|200mg/m2 iv d1 ,repeat every 14 days
223859330|NCT04855513|DRUG|Metformin|Metformin is a medication used for treatment of diabetes. In this study it will be used to explore is potential role in prevention of preeclampsia. The drug will start before 12 week of pregnancy and continue till delivery
223859331|NCT01370694|DRUG|MK-8808|
224266323|NCT01529164|DRUG|5-fluorouracil|400mg/m2 iv bolus,then 2400mg/m2 continuous infusion for 46 hours,repeated every 14 days,until progression or occurrence of untolerated toxicity
224266324|NCT00627744|DRUG|Sitagliptin|BE 1 receives Placebo tablets od during 12 weeks BE 2 receives Sitagliptin tablets 100 mg od during 12 weeks
224266325|NCT00408304|DRUG|omega-3 fatty acid|
224266326|NCT00712816|DEVICE|Game Ready Injury Treatment System (CoolSystems Inc.)|Cold with intermittent compression postoperatively for 2 weeks
224266327|NCT00712816|OTHER|Ice with compressive bandages|Cold with static compression postoperatively for 2 weeks
224266328|NCT06013163|DRUG|Xenical® vs EMP 22|Each participant will first use Xenical® TID for 9 days and then EMP22TID for 9 days (in total 27 doses of each drug).
224266329|NCT06013163|DRUG|EMP 22 vs Xenical®|Each participant will first use EMP22 TID for 9 days and then Xenical® TID for 9 days (in total 27 doses of each drug).
224266330|NCT06013163|DRUG|EMP 16 vs Xenical®|Each participant will receive a single dose of EMP16 and then a single dose of Xenical®.
224266331|NCT06209255|PROCEDURE|Pelvic Osteotomy - Ganz Procedure|Ischial osteotomy was performed on the pubic arch; this was followed by iliac osteotomy, performed using Schanz screws in the iliac wing. The osteotomized acetabulum was overturned, and inclination was reduced.
224266332|NCT04872608|DRUG|Letrozole|Letrozole will be given daily on days 1-28.
224266333|NCT04872608|DRUG|Palbociclib|Palbociclib will be given daily on days 1-21 and held on days 22-28, as per standard FDA-approved dosing guidelines.
224266334|NCT04872608|DRUG|Onapristone ER|Onapristone will be given daily on days 1-28.
224266335|NCT00017550|BIOLOGICAL|anti-thymocyte globulin|
224266336|NCT04712838|DRUG|SHR0302|Group A subjects were given oral F1 、F2 and F3 version SHR0302
224266337|NCT04712838|DRUG|SHR0302|Group B subjects were given oral F1 、F3 and F2 version SHR0302
224266338|NCT04712838|DRUG|SHR0302|Group C subjects were given oral F2 、F1 and F3 version SHR0302
224266339|NCT04712838|DRUG|SHR0302|Group D subjects were given oral F2 、F3 and F1 version SHR0302
224266340|NCT04712838|DRUG|SHR0302|Group E subjects were given oral F3 、F1 and F2 version SHR0302
224266341|NCT04712838|DRUG|SHR0302|Group F subjects were given oral F3 、F2 and F1 version SHR0302
224266342|NCT01780350|DEVICE|ResQGARD ITD|Patients eligible for the device will receive the ResQGARD attached to a facemask or mouthpiece. The patient will use the device, provided it is tolerated, until their blood pressure is stabilized as determined by EMS personnel.
224266343|NCT03911206|BEHAVIORAL|Inspiratory muscle training (IMT)|IMT exercises at home will gradually ramp up
224266344|NCT03911206|BEHAVIORAL|Exercise alone|Subjects will be asked to exercise 2x/week for 6 weeks in person at the Duke research facility and again 2x/week at home for 30 minutes.
223859332|NCT01370694|DRUG|cyclophosphamide|
224266345|NCT03911206|BEHAVIORAL|IMT and Exercise|Combining IMT training and exercise
224266346|NCT04814628|PROCEDURE|scenario 1 : pre-oxygenation with a face mask held by the anaesthetist|"the face mask is held by the anaesthetist (reference technique) to obtain effective pre-oxygenation for Oxygen Reserve Index (ORI) which has reached a plateau value for more than 10 seconds. All the usual supplies and medicines are available and in the same place as usual.~The sequence is as follows:~1. Patient lying on the operating table, start of the stopwatch~2. Opening of the computerized anaesthesia file~3. Monitoring (ECG, non-invasive blood pressure, SaO2) of the patient~4. Preparation of the hypnotic (propofol or thiopental, as desired)~5. Preparation of curare (succinylcholine or rocuronium, as desired)~6. Pre-oxygenation of the patient with the face mask held by the participating anaesthetist~7. Waiting for an ORI which has reached a plateau value for more than 10 seconds~8. Conditions for general anaesthesia met for the participating anaesthetist~9. End of simulation, stopwatch stop"
224266347|NCT04814628|PROCEDURE|scenario 2: one anaesthetist in charge, face mask held by the patient for pre-oxygenation|"one anaesthetist is in charge of the simulated patient (volunteer), face mask held by the volunteer for pre-oxygenation for ORI which has reached a plateau value for more than 10 seconds All the usual supplies and medicines are available and in the same place as usual.~The sequence is as follows:~1. Patient entering the operating room, patient lying on the operating table, start of the stopwatch~2. Opening of the computerized anaesthesia file~3. Monitoring (ECG, non-invasive blood pressure, SaO2) of the patient~4. Preparation of the hypnotic (propofol or thiopental, as desired)~5. Preparation of curare (succinylcholine or rocuronium, as desired)~6. Face mask held by the patient for pre-oxygenation~7. Waiting for an ORI which has reached a plateau value for more than 10 seconds~8. Conditions for general anaesthesia met for the participating anaesthetist~9. End of simulation, stopwatch stop"
223859333|NCT01370694|DRUG|vincristine|
223859334|NCT01370694|DRUG|prednisolone|
223859335|NCT02393716|DEVICE|Endurant Evo AAA Stent Graft System|
223859336|NCT02393716|PROCEDURE|Endovascular aneurysm repair (EVAR)|
224266348|NCT04814628|PROCEDURE|scenario 3: one anaesthetist in charge, THRIVE used for pre-oxygenation|"All the usual supplies and medicines are available and in the same place as usual.~The sequence is as follows:~1. Patient entering the operating room, patient lying on the operating table, start of the stopwatch~2. Opening of the computerized anaesthesia file~3. Monitoring (ECG, non-invasive blood pressure, SaO2) of the patient~4. Preparation of the hypnotic (propofol or thiopental, as desired)~5. Preparation of curare (succinylcholine or rocuronium, as desired)~6. THRIVE for pre-oxygenation~7. Waiting for an ORI which has reached a plateau value for more than 10 seconds~8. Conditions for general anaesthesia met for the participating anaesthetist~9. End of simulation, stopwatch stop"
224266349|NCT04814628|PROCEDURE|scenario 4: one anaesthetist and one nurse anaesthetist in charge, the face mask is held by the anaesthetist or the nurse anaesthetist|"All the usual supplies and medicines are available and in the same place as usual.~The sequence is as follows:~1. Patient entering the operating room, patient lying on the operating table, start of the stopwatch~2. Opening of the computerized anaesthesia file~3. Monitoring (ECG, non-invasive blood pressure, SaO2) of the patient~4. Preparation of the hypnotic (propofol or thiopental, as desired)~5. Preparation of curare (succinylcholine or rocuronium, as desired)~6. Pre-oxygenation of the patient with the face mask held by the participating anaesthetist or nurse anaesthetist~7. Waiting for an ORI which has reached a plateau value for more than 10 seconds~8. Conditions for general anaesthesia met for the participating anaesthetist~9. End of simulation, stopwatch stop"
224266350|NCT05662605|DEVICE|W-PPMA|"W-PPMA is a digital health tool designed specifically for the postpartum experience and is accessed through a mobile application which delivers evidence-based therapy through brief conversations with a fully automated relational agent called Woebot."
223859337|NCT02009358|OTHER|mental health promotion|
223859338|NCT00497562|DRUG|sc recombinant growth hormone + amitriptyline, fluoxetine and tramadol (treated group)|
223859339|NCT00497562|DRUG|amitriptyline, fluoxetine and tramadol alone (control group)|
223859340|NCT00127829|DRUG|Gefitinib|Oral tablet
223859341|NCT03107286|DRUG|Tc-99M-MAG3|Participants will be asked to be imaged at an additional time point during a nuclear medicine study using Tc-99m MAG3
223859342|NCT03107286|OTHER|Modification in acquisition protocol|Participants will be asked to be imaged at an additional time point.
223859343|NCT00000634|DRUG|Nevirapine|
223859344|NCT00872417|DRUG|first line ARV (3TC+NVP+D4T or 3TC+NVP+AZT)|use the generic regimens: 3TC+NVP+D4T or 3TC+NVP+AZT to initiate the ARV therapy, after 6 months, half of the group 3TC+NVP+D4T patients switch to the the treatment of 3TC+NVP+AZT
223859345|NCT00872417|DRUG|second line ARV therapy (3TC+TDF+LPV/RTV)|Use 3TC+TDF+LPV/RTV to treat those drug resistance patients, to explore the efficiency and safety of the second line ARV available in China
223859346|NCT04806919|DRUG|Progesteron TID|increasing the dose
223859347|NCT01494246|OTHER|electronic mail|Some e-mail will be sent to participants who will be in the intervention group in order to intensify the brief advise received for stop smoking.
223859348|NCT03014596|OTHER|Assert|The Assert-method is a counselling method used to assess and systematically follow up the individual adolescents' perceived needs.
223859349|NCT00978237|DRUG|EFV|one pill QD VO.
223859350|NCT00978237|DRUG|LPV/r|2 pills QD VO
223859351|NCT02319785|BEHAVIORAL|RAT-NMES|This combined RAT- treatment involves the same protocol as the RAT regimen except that patients receive neuromuscular electrical stimulation (NMES) concurrently with RAT.
223859352|NCT02319785|BEHAVIORAL|RAT-MT|This combined RAT- treatment involves the same protocol as the RAT regimen except that patients receive mirror therapy instead of functional activities training after RAT.
223859353|NCT02319785|BEHAVIORAL|Mirror therapy|This protocol includes mirror therapy and functional training in a session. The treatment intensity is 1.5 hours/day, 5 days/week, for 4 weeks. MT focuses on symmetrical bimanual movements and simultaneously observing the mirror visual feedback reflected by the unaffected upper extremity.
223859354|NCT02319785|BEHAVIORAL|Unilateral RAT|"This protocol includes warm-up, unilateral RAT, and functional activities training. The treatment intensity is 1.5 hours/day, 5days/week for 4 consecutive weeks.~The unilateral RAT session uses the robot-assisted arm trainer, InMotion Isokinetic Testing and Evaluation System."
223859355|NCT02319785|BEHAVIORAL|Bilateral RAT|"This protocol includes warm-up, bilateral RAT, and functional activities training. The treatment intensity is 1.5 hours/day, 5days/week for 4 consecutive weeks.~The unilateral RAT session uses the robot-assisted arm trainer, Bi-Manu-Track (Reha-Stim Co., Berlin, Germany)."
224266351|NCT06144398|DEVICE|Single Use Bronchoscope|The interventional procedure is performed with a single use bronchoscope.
224266352|NCT06144398|DEVICE|Standard Bronchoscope|The interventional procedure is performed with a standard bronchoscope.
224266353|NCT06402227|OTHER|gamified instruction|"At the beginning, the speaker played the role of a laboratory rescue team, narrated the background story of the board game, and led the children into the game situation. Then, the speaker explained four types of pathogens, which the investigators defined them according to different types of transmission, including droplets, airborne, blood or body fluids, and fecal-oral. The speaker explained their characteristics and key points, representative diseases in real life, corresponding prevention methods and so on. The lecture lasted for 15 minutes, then the children were divided into different groups to play the board game for about 20 minutes. During the game, students were required to collect Prevention Method Cards made by the research team. Students must perform the correct behavior of infection control or answer questions related to the class content in order to obtain the card and win."
224266354|NCT06402227|OTHER|conventional lesson lecture|The lecture was about 35 minutes. At the beginning, the speaker explained the terms to children, including infectious diseases, symptoms and pathogens. Next, the speaker introduced the components of the infection chain and how to make infection control behaviors for different parts of it. Then the speaker focused on the four types of transmission, including droplets, airborne, blood or body fluids, and fecal-oral. The speaker illustrated their characteristics and key points, representative diseases in real life, and corresponding prevention methods. In the end, the speaker led the students to practice infection control behaviors, such as the seven correct steps of washing hands, the right steps for wearing and taking off masks, and exercises that can be done to increase immunity.
224266355|NCT02115776|DRUG|Amoxicillin-Potassium Clavulanate|Administer Amoxicillin-Potassium Clavulanate following endotracheal intubation prior to single tooth-extraction
224266356|NCT02115776|DRUG|Amoxicillin|Administer Amoxicillin following endotracheal intubation prior to single tooth-extraction
224266357|NCT02115776|DRUG|Chlorhexidine|Administer Chlorhexidine Digluconate following endotracheal intubation prior to single tooth extraction
224266358|NCT06411392|RADIATION|Stereotactic Antiarrhythmic Radiotherapy|Patients with ventricular tachycardia will undergo cardiac stereotactic antiarrhythmic radiotherapy with a single fraction of 25 Gy to the arrhythmia substrate, as determined by electrophysiological cardiac mapping.
224266359|NCT02096692|DEVICE|Patients with a ProMRI ICD System|Tachycardia Fast Heart Beat
224266360|NCT02096692|OTHER|Magnetic Resonance Imaging (MRI) scan|MRI scan of heart/chest or thoracic spine
224266361|NCT00169130|DRUG|doxorubicin|
224266362|NCT00169130|DRUG|cyclophosphamide|
224266363|NCT00169130|PROCEDURE|Autologous stem cell transplantation|
224266364|NCT06562010|BEHAVIORAL|iCT-SAD-PK|The intervention arm will receive a Pakistani version of Internet-delivered Cognitive Therapy for Social Anxiety Disorder (iCT-SAD), assessing its effectiveness in reducing social anxiety symptoms among Pakistani individuals. This will involve culturally tailored online therapy modules, therapist support, and regular progress assessments.
224266365|NCT01781117|PROCEDURE|Holmium Laser Enucleation of the Prostate (HoLEP)|Enucleation of the enlarged nodule of prostate and morcellation of the resected tissue.
224266366|NCT01781117|DEVICE|Holmium laser enucleation system and morcellator|Holmium laser enucleation and morcellation
224266367|NCT03275623|DRUG|Antibiotic|Those randomized for treatment will be prescribed the most commonly used antibiotic for urinary tract infections in pregnancy. This includes: Nitrofurantoin, Cephalexin, and Amoxicillin. It is unsure which antibiotic the participant will receive but a majority of the time it will be one of the above named antibiotic. The choice will be determined by the physician, but will accommodate participants' prior medication history and adverse events.
224266368|NCT03275623|OTHER|Standard Prenatal Care|Continued surveillance of urinary cultures
224266369|NCT01714284|BEHAVIORAL|Informative|The intervention consists in a simple informative counseling about the utility of weight loss for clinical control of psoriatic disease.
224266370|NCT01714284|BEHAVIORAL|Diet and Exercise|The intervention consists in a 20 weeks quantitative and qualitative dietary plan for weight loss associated with physical exercise. The plan will be developed with the help of qualified staff (Dieticians) and elaborated in relation to individual needs of the patient.
224266371|NCT05108935|DRUG|Suboxone|Enrolled participants will be prescribed PrEP Mavyret and/or Suboxone. Follow up visits will be conducted by telemedicine. We are testing whether telemedicine is a feasible method for follow up.
224266372|NCT05108935|DRUG|Truvada|Enrolled participants will be prescribed PrEP Mavyret and/or Suboxone. Follow up visits will be conducted by telemedicine. We are testing whether telemedicine is a feasible method for follow up.
224266373|NCT05108935|DRUG|Mavyret|Enrolled participants will be prescribed PrEP Mavyret and/or Suboxone. Follow up visits will be conducted by telemedicine. We are testing whether telemedicine is a feasible method for follow up.
224266374|NCT04966403|OTHER|Standard physical therapy|building strength, enhancing developmental skills, boosting balance, coordination, and postural control
224266375|NCT04966403|OTHER|trampoline-based stretch-shortening cycle exercises|muscle strength
224266376|NCT00940433|PROCEDURE|open properitoneal hernia repair|suprapubic retro-inguinal approach
224266377|NCT00940433|PROCEDURE|Lechtestien hernia repair|onlay mesh repair
224266378|NCT00940433|PROCEDURE|Laparoscopic transperitoneal approach|intraperitoneal insufflation followed by re-exiting to the hernia site
224266379|NCT00940433|PROCEDURE|Laparoscopic totally extraperitoneal approach|avoiding the peritoneum altogether
224266380|NCT02940652|RADIATION|Magnetic resonance imaging|No intervention - description of the position of the LMA obtained during routine elective MRI scanning of the brain and/or cervical spine
224266381|NCT00999687|DRUG|Indigo Naturalis Extract in Oil|Indigo naturalis extract in oil (INEO) was applied to the fingernails of one bilateral hand (experimental group) twice daily for the first 12 weeks. INEO was applied to all affected nails on both hands twice daily for another 12 weeks
223859356|NCT02319785|BEHAVIORAL|Conventional rehabilitation|Participants in this group receive a structured protocol based on occupational therapy such as neuro-developmental techniques and task-oriented approach. The treatment dose is matched to RAT and MT groups.
223859357|NCT01801293|DRUG|GS-5806|
223859358|NCT02957539|BEHAVIORAL|Financial rewards|Veterans in the financial reward arm receive all of the services of the usual care arm, plus rewards that are earned in two ways: an assured portion, and a random portion. For the assured reward, they will receive compensation at the end of each month (defined as a four week period) that they are at or below their target weight. For the random portion, each week that a participant is at or below their target weight, the patient is entered into a drawing to win additional compensation. Over the first eight weeks the patient has a 1-in-8 chance of winning. Over the 17-32 week period, Veterans in this group will receive token incentives for tracking and reporting their weekly weights regardless of whether it was on target. Each week that the patient enters their weight into the portal, s/he will have a 1-in-8 chance to earn the token incentive, such as a t-shirt or movie ticket. The participant will receive reminder text messages.
223859359|NCT02957539|BEHAVIORAL|Non-Financial rewards|Procedures for the non-financial rewards arm are identical to procedures for the financial reward arm, except that the Veteran will earn points rather than cash. Each weekly random drawing will be for 20 points. Veterans will choose non-financial rewards associated with the number of points they earn.
223859360|NCT02931383|DRUG|Liraglutide 3 mg (Saxenda)|
223859361|NCT02931383|DRUG|Liraglutide 3 mg placebo|
223859362|NCT05165849|DRUG|GFS101A|GFS101A will be administrated intravenously Q3W.
223859363|NCT05165849|DRUG|Toripalimab|Toripalimab with fixed dose of 240 mg Q3W administered intravenously.
223859364|NCT00947596|DRUG|atropine sulfate|dry powder for inhalation
223859365|NCT00947596|DRUG|atropine sulfate|intramuscular injection
223859366|NCT02153606|DRUG|Glycerin Suppository|The treatment intervention will be a 250 mg glycerin suppository placed in the rectum once daily starting 48-72 hours after birth.
223859367|NCT02153606|OTHER|Sham Suppository|Sham suppositories will be created by placing a 250 mg glycerin suppository in the diaper once daily starting 48-72 hours after birth. This intervention works as a non-invasive placebo to maintain blinding.
223859368|NCT00596167|DRUG|Intravenous antibiotics|Each subject will receive a single dose of 15 mg/kg vancomycin; 2 mg/kg gentamicin and 250 mg levofloxacin administered intravenously over a one-hour infusion period through the venous limb of their HD access (or tunneled catheter) via an IV pump.
223859369|NCT04835987|DIAGNOSTIC_TEST|Holter ECG|Measurement of the modification of the sympathomimetic balance
223859370|NCT04835987|BEHAVIORAL|Questionary|Lifestyle questionary (time spent in front of television, physical activity)
223859371|NCT04835987|DIAGNOSTIC_TEST|Pupillometry|Monitoring of nociception and autonomic nervous system by pupillometry in intraoperative.
223859372|NCT02242773|DEVICE|Multi-Parametric MRI|Multi-Parametric MRI
223859373|NCT02242773|DEVICE|MRI-Guided Biopsy|MRI-Guided Biopsy
223859374|NCT03094767|OTHER|Cardiovascular Rehabilitation|Aerobic and anaerobic exercises performed for 12 weeks, 3x/week, of 60 minutes each.
223859375|NCT03094767|OTHER|Initial and Final assessment|Measuring blood preassure, heart rate, Borg scale, respiratory rate, oxygen saturation and HbA1C in the first day of assessment and after 12 weeks.
224266382|NCT00999687|OTHER|Olive Oil|Olive oil was applied to the fingernails of the contra-lateral hand (control group) twice daily for the first 12 weeks. INEO was applied to all affected nails on both hands twice daily for another 12 weeks.
224266383|NCT01126606|DRUG|Dermacid Silver (Lactic acid)|Liquid soap, daily use
224266384|NCT01126606|DRUG|Glycerine Vegetal Soap Granado Traditional|Vegetal soap, daily use
224266385|NCT04599842|PROCEDURE|Erector Spinae Plane Block|Erector Spinae Plane block is performed by giving local anesthetic to the plan between the erector spinae muscle and the transverse process.
224266386|NCT04175587|DRUG|Compound Realgar-Indigo Naturalis Formula Plus Retinoic Acid|Randomization is done centrally according to trial centers Eligible patients are randomly assigned (2:1) to the Treatment Group or the Control Group, with a 24-month follow-up.
224266387|NCT05583409|RADIATION|SBRT+Osimertinib|Received SBRT after three months of Osimertinib treatment
224266388|NCT05583409|DRUG|Osimertinib 80 MG|Osimertinib 80mg, po, Qd
224266389|NCT01965093|PROCEDURE|perioperative desaturation|children aged 0-5 years old who receive general anesthesia and developed perioperative desaturation
224266390|NCT01965093|PROCEDURE|no perioperative desaturation|children aged 0-5 years who did not developed perioperative desaturation under general anesthesia
224266391|NCT05204537|PROCEDURE|Lung parenchyma resection|Lung parenchyma removal
224266392|NCT05204537|PROCEDURE|Empyemectomy|Intrapleural cavity effusion removal, parietal pleura removal.
224266393|NCT00474188|DRUG|CC-5013 (lenalidomide)|Lenalidomide 25 mg, orally, once daily, on Days 1 to 21 of every 28-day cycle administerd in combination with dexamethasone 40 mg, orally, once daily, on Days 1, 8, 15, and 22 of every 28-day cycle
224266394|NCT00474188|DRUG|dexamethasone|Dexamethasone 40 mg, orally, once daily, on Days 1, 8, 15, and 22 of every 28-day cycle administered in combination with lenalidomide 25 mg, orally, once daily, on Days 1 to 21 of every 28-day cycle.
224266395|NCT00260715|BEHAVIORAL|Community-Popular Opinion Leader Model|
224266396|NCT00260715|BEHAVIORAL|Diffusion of Innovations|
224266397|NCT03330132|BIOLOGICAL|Standard inactivated influenza vaccine (NH formulation)|0.5mL FluQuadri®, Sanofi Pasteur, containing 60μg antigen - 15μg for each influenza strain included - with strains recommended by the WHO for the northern hemisphere formulation.
224266398|NCT03330132|BIOLOGICAL|MF 59 adjuvanted inactivated influenza vaccine (NH formulation)|0.5mL FLUAD(TM), Seqirus containing 45μg antigen; 15μg for each influenza strain included and MF59C.1 adjuvant (MF59®) with strains recommended by the WHO for the northern hemisphere formulation.
224266399|NCT03330132|BIOLOGICAL|High-dose inactivated influenza vaccine (NH formulation)|0.5mL Fluzone® High-Dose, Sanofi Pasteur containing 180μg antigen; 60μg for each influenza strain included with strains recommended by the WHO for the northern hemisphere formulation.
223859376|NCT05471726|BEHAVIORAL|Prospective audit-and-feedback|The stewardship team will review patients who are on antibiotics, have an uncomplicated infection, and are eligible to continue antibiotics after discharge. Any recommendations from the stewardship team about optimizing antibiotic therapy will be presented to the primary prescriber in real-time with the goal of improving antibiotic selection and duration at hospital discharge.
223859377|NCT04842604|DRUG|Glasdegib|25 mg or 100 mg tablet
223859378|NCT04842604|DRUG|Azacitidine|100 mg/vial powder for 25 mg/mL suspension for injection
223859379|NCT02618317|DRUG|Heparin Lock Solution|Just after the insertion (since first the hemodialysis session), long-term Central Venous Catheter of CKD 5D patients on high-efficiency hemodialysis have been locked during 15 weeks (100 days) with appropriate lock solution.
223859380|NCT02618317|DRUG|Trissodium Citrate 30%|ust after the insertion (since first the hemodialysis session), long-term Central Venous Catheter of CKD 5D patients on high-efficiency hemodialysis have been locked during 15 weeks (100 days) with appropriate lock solution.
223859381|NCT02618317|DRUG|Minocycline-EDTA 30 mg/ml - 3 mg/ml|ust after the insertion (since first the hemodialysis session), long-term Central Venous Catheter of CKD 5D patients on high-efficiency hemodialysis have been locked during 15 weeks (100 days) with appropriate lock solution.
223859382|NCT01821586|OTHER|Modified ORS-1|
223859383|NCT01821586|OTHER|Modified ORS-2 (ReSoMal)|
223859384|NCT01821586|OTHER|Modified ORS-3 (Benefibre)|
223859385|NCT01193153|DRUG|Placebo|monthly by i.m. injection for 15 months
223859386|NCT01193153|DRUG|paliperidone palmitate|78, 117, 156, 234 mg (50, 75, 100, or 150 mg eq.) monthly by i.m. injection for 15 months
223859387|NCT01648140|DRUG|GSK2336805 40 mg|20 mg tablet, round, 10-mm diameter, white to off-white, no markings
223859388|NCT01648140|DRUG|GSK2336805 60 mg|30 mg tablet, round, 10-mm diameter, white to off-white, no markings
223859389|NCT01648140|DRUG|Pegylated interferon alpha-2a|180 microgram per 0.5 mL prefilled syringe for single use
223859390|NCT01648140|DRUG|Ribavirin|"200-mg tablet, capsule-shaped, light blue, film-coated, and debossed with 200 on 1 side and the logo 3RP on the other side"
223859391|NCT01648140|DRUG|Telaprevir|375 mg film-coated tablet
224266400|NCT03330132|BIOLOGICAL|Recombinant hemagglutinin inactivated influenza vaccine (NH formulation)|0.5mL Flublok®, Protein Sciences Corporation containing 180μg antigen, 45μg for each influenza strain included with strains recommended by the WHO for the northern hemisphere formulation.
224266401|NCT04385251|OTHER|Data Collection|"DATA COLLECTION AT ENROLLMENT:~Demographics; Symptoms and health status; Co-morbidities; Targeted medications; Specimen Collection (substudy at selected sites): Upper respiratory swab, blood for serum storage.~DATA COLLECTION AT DAYS 7, 14 \& 28:~Vital and hospitalization status; Symptoms and health status"
224266402|NCT00659828|DRUG|Recombinant methionyl human leptin|Recombinant methionyl human leptin, subcutaneous, once a day, 0.02 to 0.04 mg/kg (adjusted according to weight loss), indeterminate duration.
224266403|NCT05198505|DRUG|TQB2868 Injection|TQB2868 protein is a bi-functional fusion protein targeting PD-1 and TGF-β
224266404|NCT00493727|DRUG|N-acetylcysteine(Mucomyst)|
224266405|NCT03438643|DIAGNOSTIC_TEST|Blood samples|Blood samples (42mL) will be taken before and during treatment.
224266406|NCT03438643|DIAGNOSTIC_TEST|skin biopsy|skin biopsy will be taken before and during treatment.
224266407|NCT02683291|DRUG|sirolimus|
224266408|NCT02683291|DRUG|tacrolimus|
224266409|NCT02683291|DRUG|mycophenolate|
224266410|NCT02683291|DRUG|Prednisone|Prednisone 30mg/day
224266411|NCT02683291|DRUG|Basiliximab|Basiliximab 20mg (first and fourth day) if panel reactivity class I less than 50 %
224266412|NCT02683291|DRUG|Thymoglobulin|Thymoglobulin at a dose of 1mg/kg for 5 days if panel reactivity class I greater than 50 %
224266413|NCT05674188|BEHAVIORAL|Augmented Reality Headset|Augmented simulation of workplace-related scenarios of pre-recorded videos using the same actors
224266414|NCT00223093|DRUG|TAIZ|
224266415|NCT02125981|DRUG|Limaprost|taking Limaprost α-Cyclodextrin Clathrate 1 Tablets (166.67 μg), three times per day
224266416|NCT02125981|DRUG|Placebo|taking placebo drug
224266417|NCT00154258|DRUG|Clozapine|
224266418|NCT04417439|OTHER|universal goniometer. evaluate the circumference measurement. The biochemical examination of CK (creatine kinase)|The joint range of motion within the affected areas of burn patients was assessed by a universal goniometer. A 7-mm-wide tape measure was used to evaluate circumference measurement in individuals. The biochemical analysis of CK (creatine kinase) was performed by an expert on blood samples taken from patients in the hospital laboratories.
224266419|NCT04919616|DRUG|TILs（Tumor Infiltrating Lymphocytes）|10e9, 10e10, 10e11 dose range of TILs, 3+3 dose escalation
224266420|NCT01803594|DIETARY_SUPPLEMENT|Krill Oil|Neptune Krill Oil Gold
224266421|NCT01803594|DIETARY_SUPPLEMENT|Lutein|Jarrow Formulas
224266422|NCT01803594|DIETARY_SUPPLEMENT|Nicotinic acid|Natures Way
224266423|NCT01803594|DIETARY_SUPPLEMENT|Dairy phospholipids|PC700 manufactured by Fonterra
224266424|NCT01803594|OTHER|Control|Control shake without dietary supplements
224266425|NCT02835157|DRUG|Balanced crystalloid solution|Multiple electrolyte solution as boluses would be administered.
224266426|NCT02835157|DRUG|0.9%sodium chloride|saline as boluses would be administered
224266427|NCT05384457|OTHER|High intensity training|Participants will follow an exercise therapy program consisting of cardiorespiratory training, limb strength training and core muscle training.
224266428|NCT05384457|OTHER|Moderate intensity training|Participants will follow an exercise therapy program consisting of cardiorespiratory training, limb strength training and core muscle training.
224266429|NCT01949324|BIOLOGICAL|Ciliary neurotrophic factor (CNTF)|Ciliary neurotrophic factor released from NT-501 encapsulated cell implant
224266430|NCT01949324|PROCEDURE|Sham procedure|Sham surgery for Sham arm
224266431|NCT01949324|DEVICE|NT-501 Implant|NT-501 encapsulated cell implant
224266432|NCT01949324|PROCEDURE|NT-501 Implant procedure|Surgery to implant device for NT-501 encapsulated cell implant releasing human ciliary neurotrophic factor arm
224266433|NCT01246453|DRUG|Intrapleurally Alteplase vs Intrapleurally Urokinase|Alteplase 10 mg and urokinase 100000 intrapleurally administered, once daily for three days and if necessary 6 days
224266434|NCT06170762|OTHER|Pulp capping|Pulp capping material for immature permanent teeth in case of carious or traumatic pulp expures
224266435|NCT06170762|DRUG|Sodiumhexametaphosphate|Sodiumhexametaphosphate
224266436|NCT06170762|OTHER|MTA|MTA
224266437|NCT02907125|BEHAVIORAL|SEHER Intervention delivered by TSM|"SEHER Intervention The SEHER intervention will be delivered by a trained teacher, called as Teacher-as-SEHER Mitra (Mitra meaning friend) or lay health worker called as SEHER Mitra being trained to facilitate following activitiesAwareness generation activities for all stakeholders in school; Wall-magazine, Speak-out box, Competitions, School Health Promotion Committee, School health policies, Peer groups of students of class IX and X students, Workshops and talks for all the students from standard IX, and for teachers, and Counselling and referral services for all the students in the school.~This intervention will be delivered in each school over the academic year."
224266438|NCT02907125|BEHAVIORAL|SEHER Intervention delivered by SM|"The SEHER intervention will be delivered by a lay health worker called as SEHER Mitra being trained to facilitate following activities: Awareness generation activities for all stakeholders in school; Wall-magazine, Speak-out box, Competitions, School Health Promotion Committee, School health policies, Peer groups of students of class IX and X students, Workshops and talks for all the students from standard IX, and for teachers, and Counselling and referral services for all the students in the school.~This intervention will be delivered in each school over the academic year."
224266439|NCT02907125|BEHAVIORAL|Tarang AEP|The comparison arm involves 'usual care' which in the study setting is the Tarang: Adolescence Education Programme comprising of 16 classroom sessions on process of growing-up, prevention of HIV/AIDS and other Sexually Transmitted Diseases (STDs), and prevention of substance and other drug abuse. This programme is delivered by a trained nodal teacher in the school over the academic year.
224266440|NCT00858403|DRUG|Dasatinib|Take tablets of Dasatinib by mouth once a day.
224266441|NCT00001058|DRUG|Indinavir sulfate|
224266442|NCT00001058|DRUG|Ritonavir|
224266443|NCT00001058|DRUG|Ethambutol hydrochloride|
224266444|NCT00001058|DRUG|Clarithromycin|
224266445|NCT00001058|DRUG|Rifabutin|
224266446|NCT04364191|BEHAVIORAL|Multicomponent Behavioral Sleep Intervention for Insomnia|The MBSI-I will include a meaningful activity protocol during the day and ART therapy at night.
224266447|NCT04364191|BEHAVIORAL|Active Control|The sleep hygiene educational material represents an active control intervention and is recommended as part of the initial treatment of insomnia based on an NIH guide for sleep education.
224266448|NCT04495543|BEHAVIORAL|Brief Skills for Safer Living|Brief-SfSL is a single-session individual therapy adaptation of the core goals/principles of the 20-week SfSL group therapy. Brief-SfSL incorporates the SfSL guiding principles of emphasizing safety, attending to the therapeutic relationship, recognizing the participant as the expert in their own experience, taking a trauma-informed approach, working with emotions while recognizing the role of alexithymia, and incorporating solution-focused concepts. The goal is to increase a person's understanding and capacity to engage in what would enable them to keep safe, even if thoughts of suicide are present. The intervention procedure is dynamic, but includes 4 core tasks: 1) understanding the individual's suicidal experience, 2) skills building, 3) developing a safety plan, and 4) identifying obstacles to enacting or engaging with the safety plan.
224266449|NCT00363077|BIOLOGICAL|GSK1247446A Group|Low dose influenza vaccine adjuvanted with AS03 compared
224266450|NCT00363077|BIOLOGICAL|Fluarix™|GlaxoSmithKline (GSK) Biologicals' inactivated influenza split vaccine.
224266451|NCT06449690|PROCEDURE|Dog-assisted therapy|Dog-assisted therapy consists of the search for positive interactions resulting from the intentional human-animal relationship in the educational, therapeutic or social fields, practices as they are conducted in educational and medico-social institutions for example.
224266452|NCT06449690|PROCEDURE|Occupational activities|Occupational activities consist of origami, relaxation, sports or board games sessions.
224266453|NCT03961204|OTHER|Data Collection|No study treatment was administered as part of this study
224266454|NCT05173792|DRUG|AK119|Subjects will receive AK119 intravenously.
224266455|NCT00867763|PROCEDURE|In vitro maturation and in vitro fertilization|No gonadotropin, eggs harvested early
224266456|NCT00867763|PROCEDURE|Low doses of gonadotropin stimulation.|Gonadotropin followed by conventional IVF
224266457|NCT04264221|BEHAVIORAL|New management mode|"* New management mode intervention: Pharmaceutical care~* SMS text messages and Phone Calls~* Behavioural Educational leaflet~* Self-Administered Therapy A financial incentive for mobile use"
224266458|NCT02113722|PROCEDURE|Left cardiac sympathetic denervation|Left cardiac sympathetic denervation via a video
224266459|NCT02113722|PROCEDURE|Standard of Care|Medical therapy
223859392|NCT03746418|DRUG|Ultrasound Guided Bilateral single shot Erector Spinae Plane Block|Under aseptic technique and after skin infiltration with 3 ml of 2% lidocaine, a 22G, 50-mm, insulated facet type needle (visioplex® - vygon - France) was introduced in plane in a cephalad to caudad direction until (L3) transverse process was hit \[figure1(A)(B)(C)\] and the needle was slightly withdrawn. The confirmation of the correct position of the needle tip was done by injecting 0.5-1 ml of LA. Once confirmed, 20 ml of the drug was administered under vision after confirming negative aspiration of blood. LA distribution was observed in both cranial and caudal directions. This was repeated on the other side also. Twenty minutes later, sensory loss to cold was evident between (T10-T 12) and (L5-S1) vertebral level of the posterior dermatomes and dermatomes of the anterior roots of the spinal nerves (lumbar plexus, upper leg) on both sides without hemodynamic changes. Motor function of the legs was evaluated with a Bromage (0-3) score.
223859393|NCT05715151|OTHER|CQI intervention|Activity 1: Reflective sessions and problem prioritisation. Activity 2: PDSA cycles. Activity 3: Group mentoring.
223859394|NCT05715151|OTHER|Audit and Feedback|Audit and Feedback on six key AA indicators, patients reported experience about access and selected AA processes.
223859395|NCT00485940|DRUG|Prucalopride|2 mg o.d.
223859396|NCT00485940|OTHER|Placebo|Placebo o.d.
223859397|NCT00485940|DRUG|Prucalopride|4 mg o.d.
223859398|NCT03319017|PROCEDURE|Multiple-trauma patients|"The blood samples of the patients who agreed on this research are obtained in order to check their inflammatory response factor, and then their medical records are checked to find their initial ABGA result, lactate, C-reactive protein(CRP) known as initial inflammatory response, and procalcitonin.~A patient's whole blood is collected in the tube with ethylene diaminetetracetic acid (EDTA) treatment. A modified method of Boyum's technique is applied so as to separate polymorphonuclear neutrophils. The separated polymorphonuclear neutrophils is collected so as to check apoptosis. And then, in the separated plasma, interleukin(IL)-6 and tumor necrosis factor(TNF)-α are measured, and its correlation with oxygen saturation will be analyzed."
223859399|NCT01596725|BIOLOGICAL|Monovalent Avian Influenza VLP (H5N1)|Dose A without Adjuvant 2; intramuscular, deltoid, Day 0 and Day 21
223859400|NCT01596725|BIOLOGICAL|Monovalent Avian Influenza VLP (H5N1)|Dose B without Adjuvant 2; intramuscular, deltoid, Day 0 and Day 21
223859401|NCT01596725|BIOLOGICAL|Monovalent Avian Influenza VLP (H5N1); Adjuvant|Dose B with Adjuvant 2; intramuscular, deltoid, Day 0 and Day 21
223859402|NCT01596725|BIOLOGICAL|Monovalent Avian Influenza VLP (H5N1); Adjuvant|Dose C with Adjuvant 2; intramuscular, deltoid, Day 0 and Day 21
223859403|NCT01596725|BIOLOGICAL|Monovalent Avian Influenza VLP (H5N1); Adjuvant|Dose D with Adjuvant 2; intramuscular, deltoid, Day 0 and Day 21
223859404|NCT01596725|BIOLOGICAL|Saline Placebo|Placebo; intramuscular, deltoid, Day 0 and Day 21
223859405|NCT04256876|DEVICE|TTNS|See section 'arms' Stimulation settings: 200 µS, 20 Hz, 1-20 V ( depending of sensory response) Home-therapy: Daily stimulation during 60 minutes.
223859406|NCT04256876|DEVICE|TTNS Sham|See section 'arms'
223859407|NCT02562911|PROCEDURE|Data collection|"* Clinical examination~* Complete pelvic ultrasound abdominal ultrasound~* Bone age: X-ray~* biological examination~* Lung function assessed by the Maximum Volume Expired~* Brasfield radiological score (if available)"
223859408|NCT03175913|DEVICE|vapocoolant spray|As a topical pre caudal epidural block anesthesia, spinal needle insertion site was sprayed using an vapocoolant spray for 10-sec from a distance of 30 cm
223859409|NCT03175913|DRUG|local infiltration|As a topical pre caudal epidural block anesthesia, spinal needle insertion site was injected subcutaneously using 3ml of 2% lidocaine
223859410|NCT00927667|PROCEDURE|No Drug|Patients have received primary FVIII prophylaxis (started \< 2 years of age)
223859411|NCT00927667|PROCEDURE|No Drug|Patients have received secondary FVIII prophylaxis (started 2 - \< 6 years of age)
223859412|NCT00927667|PROCEDURE|No Drug|Patients have received secondary FVIII prophylaxis (started 6 - \< 12 years of age)
223859413|NCT00927667|PROCEDURE|No Drug|Patients have received secondary VIII prophylaxis(started 12 - 18 years of age)
223859414|NCT00927667|PROCEDURE|No Drug|Patients have received on-demand therapy
223859415|NCT02667535|DRUG|Isosorbide Mononitrate|"Healthy volunteers will receive 2g (2.0%) of investigational product at a single dose, and will undergo a washout period of 7 days; subsequently, they will receive 2g of investigational product once daily, for 7 consecutive days.~Participants with anal fissure will receive 2g of investigational product, either at 0.5%, 1.0% or 2.0%, at a single dose, and will undergo a washout period of 7 days; subsequently, they will receive 2g of investigational product, either at 0.5%, 1.0% or 2.0%, once daily, for 7 consecutive days."
223859416|NCT03009006|DRUG|Chlorhexidine 2% gel - Calcium Hydroxide Paste - Non-Setting|Calcium Hydroxide Mixed With Chlorhexidin efficacy of calcium hydroxide and 2 % chlorhexidine gel and combination of both on the anaerobic bacteria, It was clear from the study that calcium hydroxide had limited efficacy against facultative anaerobes, but effective against obligate anaerobes while chlorhexidine only and combination group were effective against all species of anaerobic bacteria
223859417|NCT03009006|DRUG|Calcium Hydroxide Paste - Non-Setting|Calcium Hydroxide The antimicrobial activity of calcium hydroxide Ca(OH)2 is related to the release of hydroxyl ions in an aqueous environment leading to damage in the bacterial cytoplasmic membrane, protein denaturation and DNA damage
223859418|NCT04767828|DRUG|PYRROTINI|CAPECITABINE: 800 mg/m2 twice daily, taken orally within 30 minutes after meal (one in the morning and one in the evening, 12 hours apart, equal to a daily dose of 1600 mg/m2, with one dose in the morning and one dose in the morning) .
223859419|NCT04767828|RADIATION|Brain radiation therapy|Brain radiation therapy: the dose and frequency of brain radiation therapy are determined by the doctor according to the patient's condition.
223859420|NCT05493124|DRUG|Manpixiao|A traditional Chinese medicine composition
223859421|NCT05493124|DRUG|Active comparator|Other drugs that may have therapeutic effects
223859422|NCT00034463|DRUG|ALIMTA|
223859423|NCT00034463|DRUG|folic acid|
223859424|NCT00034463|DRUG|multi-vitamins|
223859425|NCT03618849|DEVICE|tDCS|Real and sham tDCS/Mozart piano sonata (K.448)
223859426|NCT03264248|DEVICE|E-Scale|Daily bodyweight system used under legs of bed
223859427|NCT02435199|DRUG|EMA401 600mg|
223859428|NCT02435199|DRUG|Placebo|
223859429|NCT00159354|DRUG|predisolone|
223859430|NCT04977128|DRUG|89Zr-KN035|Patients will receive a tracer (10 mg, IV) dose of Zr-89 (2-3mCi) labelled KN035 (89Zr- KN035)
223859431|NCT00183638|BEHAVIORAL|Internet-based tailored prevention messages|Participants will receive five 30-second flash clips promoting condom norms, positive attitudes, self-efficacy, and risk awareness. Participants in the Youthnet program will be asked their gender and ethnicity so they may be assigned to a role model of the same gender and ethnicity via a computer program. This role model will appear online 5 times during the survey to deliver interactive messages that will be tailored to HIV/STD risk reduction and will specifically address attitudes about condom usage.
223859432|NCT00183638|BEHAVIORAL|Non-tailored messages|The control program will deliver five general, non-tailored messages containing information on reproductive health not specific to condoms or STDs.
223859433|NCT05603767|OTHER|RMT+ VR|(RMT+ VR). The responsive music therapy session combined with virtual reality involves four stages: a) Background settings; b) VR video and music selection; c) Listening experience and VR; and e) Return to alert status. The therapist will help the patient to select the video to be used for the experience. Utilizing the application created by the research team, the patient will be provided with four possible scenarios. As for the music, patients are asked to choose music that relaxes them the most. Chosen music can be instrumental music (guitar, electric piano or violin) or sung music with harmonic accompaniment (piano or guitar). In both cases the music will be played live.
223859434|NCT00391833|DRUG|Panax Ginseng|
223859435|NCT04826055|OTHER|biliary limb as fixed length|n all loop bypass procedures we will don't count the total length of small intestine and make the biliary limb as a fixed from total small intestine length as mentioned in literature
223859436|NCT04826055|OTHER|biliary limb as a percentage from small intestine length|in all loop bypass procedures we count the total length of small intestine and make the biliary limb as a percentage from total small intestine length rather than fixed length
223859437|NCT01409512|PROCEDURE|ECG recording|At baseline and following 3 months on anticholinergic medications patients, ECG recording will be conducted.
223859438|NCT02178540|DRUG|Placebo|one dose (4 capsules) of placebo
223859439|NCT02178540|DEVICE|Tobi Podhaler|The capsule containing the study medication has to be released from the blister card, be inserted into the Podhaler device, actuated and the study drug be inhaled according to instructions for use
223859440|NCT04650048|DEVICE|Active HD-tDCS|Using the Starstim 32, HD-tDCS equipment we provide 20 minutes of 2 mA anodal multimodal stimulation of dorsolateral prefrontal cortex (DLPFC) and primary motor cortex simultaneously using ring-cathode configurations around the two anodes.
223859441|NCT04650048|DEVICE|Sham HD-tDCS|"Using the Starstim 32, HD-tDCS equipment we provide sham stimulation with 30 seconds of ramping up to 2 mA intensity, then turning off for 19 minutes and then ramping down from 2 mA intensity to 0 in the last 30 seconds.~This sham-configuration is intended to mimic the sensory experience of active HD-tDCS."
223859442|NCT01787240|DRUG|Escitalopram 10mg|
223859443|NCT01787240|DRUG|Placebo|
223859444|NCT01640678|PROCEDURE|ReCell epidermal cell suspension grafting|According to current standard of care procedures the treatment site will be superficially abraded using an ablative laser (10,600nm CO2 laser) after which the prepared ReCell cell suspension will be sprayed on.
223859445|NCT01640678|PROCEDURE|CO2 laser abrasion + UV-therapy|According to current standard of care procedures the treatment site will be superficially abraded using an ablative laser (10,600nm CO2 laser)
223859446|NCT00939042|PROCEDURE|Percutaneous Coronary Intervention|common Percutaneous Coronary Intervention
223859447|NCT00939042|PROCEDURE|BMNC therapy|Injection of BMNC after common PCI
223859448|NCT04731051|DRUG|HCQ01|HCQ01 is a sterile, clear and colorless, ready-to-use aqueous nebulizer solution. Hydroxychloroquine sulfate administered via nebulization
223859449|NCT04731051|DRUG|standard of care (SOC) for COVID-19|Standard of care (SOC) for COVID-19
223859450|NCT02246816|DRUG|0.6 mL, MP-101 (10 mg/mL, Opium Tincture (OT)), USP (Deodorized)|0.6 mL, MP-101 (10 mg/mL, Opium Tincture (OT)), USP (Deodorized)
223859451|NCT03278288|DEVICE|WellWe-Intervention group|Participants (families) allocated to the intervention group get to use WellWe-app before entering to health visit to assess the current situation of their wellbeing and utilizing these results during the health visit. The access to WellWe-app is permitted throughout the data collection period. Participants (PHNs) randomized to the intervention group get standardized two hour WellWe-training, WellWe-handbook and full access to the WellWe-app during the data collection period.
223859452|NCT05796440|DRUG|LUM-201|Administered orally once daily
223859453|NCT01256034|DIETARY_SUPPLEMENT|Oral IMPACT|oral supplementation for 5 days (1L/day) before surgery of a formula enriched with arginine, omega-3 fatty acids, and RNA
223859454|NCT02655367|OTHER|Flaked oats|Test meal consisting of 264g porridge made with flaked oats
223859455|NCT02655367|OTHER|Milled oats|Test meal consisting of 264g porridge made with milled oats
223859456|NCT03013348|DEVICE|Brain Sentinel's sEMG Post-processing algorithm|Brain Sentinel has developed a post processing method that identifies sEMG signals (recorded from the biceps brachii or as muscle artifact in electroencephalography \[EEG\] recordings) that are pathognomonic for PNES activity.
223859457|NCT03259932|OTHER|no physical activity|no physical activity
223859458|NCT03259932|OTHER|physical activity|Rehabilitation program will start 4 weeks after discharge from acute care (S4), for a duration of 8 weeks (3 sessions / week). Physical training will include aerobic exercises 30-60 minutes at 50-80% of HRmax, associated with muscle building exercises in circuit training (20 min), and balance and flexibility exercises.
223859459|NCT02865733|DRUG|Remodulin|After Fontan operation, the mean pulmonary arterial pressure (mPAP)evaluated by CVP or transpulmonary pressure gradient(TPG) evaluated by Echo will be measured firstly, if the data met the criteria, and the patients were enrolled in the experimental group, the patients would be administrated intravenously of Remodulin® with the beginning of 5ng/kg/min, with the rate of 10ng/kg/min every 30 minutes up to 80ng/kg/min.
223859460|NCT02865733|DRUG|distilled water|After Fontan operation, the mPAP (evaluated by CVP) or TPG (evaluated by Echo) will be measured firstly, if the data met the criteria, and the patients were enrolled in placebo group, then the patients would be administrated intravenously of distilled water with the beginning of 0.15ml/hr, with the rate of 0.3ml/hr every 30 minutes up to 2.45ml/hr.
223859461|NCT03961152|BEHAVIORAL|PainCoach app|In response to the patient's input of the pain experienced (no pain, bearable pain, unbearable pain, or untenable pain), the app gave advice on pain medication use, exercises/rest and when to call the clinic from day 1 until day 14 after surgery.
223859462|NCT04258358|OTHER|CASCADE ways of working|Technology, learning and development resources and nursing and therapeutic care are the key drivers for the CASCADE ways of working promoting community integrated dementia care and support to optimise safety and independence for people living with dementia.
223859463|NCT04213599|DIAGNOSTIC_TEST|Coronary intervention|Patients with STEMI undergo coronary intervention
223859464|NCT00001304|DRUG|Synthetic Human Parathyroid Hormone 1-34|twice daily subcutaneous injections
223859465|NCT00001304|DRUG|Calcitriol & Calcium|Twice daily oral calcitriol with 1000 mg Calcium carbonate supplementation
223859466|NCT01125319|OTHER|blood sample|
223859467|NCT01610479|DRUG|TAS-114 + S-1|
223859468|NCT03068637|BEHAVIORAL|Carevive CPS|This intervention will focus on the use of the Carevive CPS at the point of care to enable providers to deliver evidence-based and personalized supportive care and symptom management plans to their MM patients receiving active treatment. The Carevive CPS collects electronic patient reported outcomes (ePROs) and clinical data, reported and entered by clinical staff and/or extracted from the electronic medical record (EMR), and uses these to auto-generate the personalized care plans. Care plan content is driven by practice guidelines and other peer-reviewed evidence, and includes patient education, resources, and referrals developed by expert cancer clinicians and researchers.
223859469|NCT01544569|GENETIC|DNA analysis|
223859470|NCT01544569|GENETIC|fluorescence in situ hybridization|
223859471|NCT01544569|GENETIC|gene expression analysis|
223859472|NCT01544569|GENETIC|gene mapping|
223859473|NCT01544569|GENETIC|microarray analysis|
223859474|NCT01544569|GENETIC|polymerase chain reaction|
223859475|NCT01544569|GENETIC|protein expression analysis|
223859476|NCT01544569|OTHER|laboratory biomarker analysis|
223859477|NCT01544569|OTHER|medical chart review|
223859478|NCT05516654|DIAGNOSTIC_TEST|Routine bacteriological cultures|culture of different samples on different culture media as nutrient agar, blood agar, MacConkey agar, EMB agar, TSI
223859479|NCT05516654|DIAGNOSTIC_TEST|Identification of the organism and antibiotic sensitivity will be done by VITEK II|Automated identification of the organism and antibiotic sensitivity will be done by VITEK II
223859480|NCT05516654|DIAGNOSTIC_TEST|Detection of biofilm formation|Detection of Biofilm formation to the collected organism by tissue culture plate method.
223859481|NCT05516654|DIAGNOSTIC_TEST|Molecular detection by PCR|Molecular detection of Type VI Secretion System genes, capsular serotyping( k1, k2), and FimH genes by PCR.
223859482|NCT04915885|OTHER|Routine care|Routine contraceptive counseling and routine method availability
223859483|NCT04915885|OTHER|Package of contraceptive counseling interventions|The implementation package will be co-designed by providers and clients during the formative and research design phases
223859484|NCT04915885|OTHER|Expanded methods|Expanded range of contraceptive methods as recommended by national policies
223859485|NCT00435799|PROCEDURE|corneal cross-linking (CCL)|
223859486|NCT00435799|DRUG|Riboflavin/dextran eyedrops|
223859487|NCT00435799|DEVICE|UV-X system|
223859488|NCT06223529|BEHAVIORAL|Therapeutic Instrumental Music Performance|Exercises using musical instruments to improve hemiparetic hand and arm function
223859489|NCT00153309|BEHAVIORAL|People with Arthritis Can Exercise|
223859490|NCT03516604|DRUG|PF-04995274|PF-04995274 tablets
223859491|NCT03516604|DRUG|Citalopram|Citalopram capsule
223859492|NCT03516604|DRUG|Placebo Oral Tablet|Placebo tablet, identical to PF-04995274 tablet
223859493|NCT03516604|DRUG|Placebo oral capsule|Placebo capsule, identical to citalopram capsule
223859494|NCT01151839|PROCEDURE|Esophagectomy|Patient with squamous cell carcinoma of esophagus will be treated with surgery alone
223859495|NCT01151839|PROCEDURE|Neoadjuvant chemoradiation followed by surgery|Patient with squamous cell carcinoma of esophagus will be treated by neoadjuvant chemoradiation followed by surgery
223859496|NCT03279718|PROCEDURE|Periodontal Treatment|Scaling and root planing
223859497|NCT01667354|BEHAVIORAL|Academic Detailing|"The intervention design is based on academic detailing, an effective method of changing physician behavior. The aim of the training is effective communication with parents who are hesitant about childhood vaccinations."
223859498|NCT03342872|BEHAVIORAL|Core Training: FBS System Mapping and MTFS-I Installation|Core Training will be a blended strategy wherein multiple interventions targeting multiple agency roles are combined to help ASU treatment providers increase their FBS quality. Core Training will be conducted with administrators, supervisors, data managers, and clinical staff. It will contain two 3-hour sessions focusing on FBS System Mapping and MTFS-I Installation. FBS System Mapping will focus on process mapping of existing site policies and practices for assessing family functioning at intake, educating families about intervention strategies and activities, including family members in treatment sessions, and hiring and supporting clinicians trained in and routinely delivering FBS. MTFS-Installation will focus on introducing MTFS-I components and integrating principles of DDDM.
223859499|NCT03342872|BEHAVIORAL|Core Training & Facilitation: FBS System Mapping and MTFS-I Installation plus monthly on-site meetings|Facilitation will consist of monthly on-site meetings to review progress toward FBS improvements, discuss MTFS-I feedback reports and online resource use, and provide intensive technical assistance for progressing toward site-selected FBS improvement goals. Meetings will involve a subset of site-delegated participants from Core Training sessions to serve as a local change team (quality improvement team). The efficacy of facilitation-guided change teams has been established. Although there are several models for creating change teams, at least three features are common: (1) members represent multiple organizational roles (supervisors, data managers, line staff); (2) focus on data-driven decisions; and (3) use of external expert advisors.
223859500|NCT01909336|DRUG|0.3% Saline in 3.3% dextrose|Hypotonic Solutions: 0.3% Saline in 3.3% dextrose
223859501|NCT01909336|DRUG|0.45% Saline in 5% dextrose|Hypotonic Solutions: 0.45% Saline in 5% dextrose
223859502|NCT01909336|DRUG|0.9% Saline in 5% dextrose|Isotonic Solutions 0.9% Saline in 5% dextrose
223859503|NCT01282944|BEHAVIORAL|Financial Incentive|Lottery with an approximate 3 in 10 odds of earning $50 and an approximate 3 in 100 odds of earning $200.
223859504|NCT01282944|BEHAVIORAL|Peer Network|Subjects will be connected with 4 other participants in the same study arm to form a peer network of 5 individuals.
223859505|NCT03884244|OTHER|chewing gum|The group who take chewing gum after operation
223859506|NCT02297880|OTHER|Beverage containing low calorie sweeteners|Beverage containing low calorie sweeteners
223859507|NCT02297880|OTHER|Still water|Still water (no flavour)
223859508|NCT02886754|BEHAVIORAL|Proficiency-based progression|Use of validated metrics and performance benchmarks to simulation training
223859509|NCT02886754|BEHAVIORAL|National e-learning programme only|National e-learning programme (COMPASS)
223859510|NCT02886754|BEHAVIORAL|Standard simulation|Paper based simulation cases
223859511|NCT02485236|DEVICE|Low flow oxygen via nasal cannula|In the low flow oxygen group, patients will be supplemented with 1 liter per minute via nasal cannula. Adjustment of initial setting upon floor arrival: To adjust oxygen 1-4 liters per minute to an arterial saturation of oxygen of \> 88%. Continuous oximetry will be collected up to 48 hours. Standard postsurgical care.
223859512|NCT02485236|DEVICE|Humidified Nasal High Flow Therapy|Adjustment of initial setting upon floor arrival: To adjust oxygen 1-4 liters per minute to arterial saturation of oxygen \> 88%. To adjust air flow to patient comfort (20-35 liters per minute). Continuous oximetry will be collected up to 48 hours. Standard postsurgical care.
223859513|NCT04852146|PROCEDURE|Electronic feedback|Feedbacks have been identified as one of the most effective interventions to improve practices and organisations in health care institutions. It is also a tool for facilitating and coordinating practice registers, improving the contribution of data producers and the quality of data.
223859514|NCT02845856|DRUG|Cetuximab|400 mg/m2 IV over 120 minutes on day 1 of cycle 1 only, and 250 mg/m2 IV over 60 minutes weekly on ALL subsequent administrations
223859515|NCT02845856|BIOLOGICAL|NK immunotherapy|For each procedure, 10 billion cells will be infused in 4 times
223859516|NCT01157182|DRUG|Estradiol/Norethindrone acetate|1/0.5 mg Tablets
223859517|NCT01157182|DRUG|Activella®|1/0.5 mg Tablets
223859518|NCT03163186|PROCEDURE|Transarterial embolization|Transarterial hepatic embolization of liver cancer
223859519|NCT00525850|OTHER|high fat diet|high saturated fat no starch diet
223859520|NCT00525850|OTHER|low saturated fat diet|low calorie low saturated fat low trans fat high fiber diet
223859521|NCT04505943|DRUG|Isonicotinic Acid Hydrazide|2 vaginal tablet of isonicotinic acid hydrazide inserted by the study nurse12 hours before IUD insertion.
223859522|NCT04505943|DRUG|dinoprostine|2 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia \& Upjohn, Puurs, Belgium) inserted by the study nurse 3 hours before IUD insertion.
223859523|NCT04505943|DRUG|misoprostol|2 vaginal tablet of misoprostol (200 mcg) (Misotac®; Sigma Pharma, SAE, Egypt) inserted by the study nurse 3 hours before IUD insertion
223859524|NCT00002819|DRUG|carboplatin|
223859525|NCT00002819|DRUG|cyclophosphamide|
223859526|NCT00002819|DRUG|mitoxantrone hydrochloride|
223859527|NCT00002819|DRUG|paclitaxel|
223859528|NCT00002819|PROCEDURE|autologous bone marrow transplantation|
223859529|NCT00002819|PROCEDURE|peripheral blood stem cell transplantation|
223859530|NCT04664049|DIETARY_SUPPLEMENT|NRICM101|"Direction: Take 1 sachet 2-4 times daily directly or with 400cc water before or between meals~Indication: Externally contracted seasonal epidemic~Function: Relieving Exterior and Facilitating Lung, clear heat of lung, Wide chest and resolve phlegm"
223859531|NCT02010619|BEHAVIORAL|Cognitive behavior therapy|
223859532|NCT02010619|BEHAVIORAL|Supportive therapy|
223859533|NCT00716144|DRUG|Talarozole|Oral Capsule Once Daily
223859534|NCT00866554|DRUG|administration of a LHRH agonist and Bicalutamide|3-month treatment with an LHRH agonist chosen by the treating radiation oncologist and Bicalutamide 50 mg daily for the first month of treatment with the LHRH agonist.
223859535|NCT00866554|DRUG|administration of Bicalutamide, Dutasteride and Tamoxifen|"Dutasteride given at dose of 0.5 mg daily starting three months prior to day of implant procedure and continued for 3 months up until procedure.~Bicalutamide: given at a dose of 50 mg daily for 3 the same 3 month period as dutasteride~Tamoxifen: given at dose of 10 mg daily for 3 months that dutasteride and bicalutamide are administered."
223859536|NCT06345417|OTHER|Patient Blood Management (PBM)|PBM is a strategy to manage the participant's own blood. Its focus is on anemia, bleeding and coagulation management.
223859537|NCT06345417|BIOLOGICAL|Allogeneic transfusion|Anemia is treated by administering donor red cells, and bleeding or coagulopathy by plasma, platelets or other donor blood products.
223859538|NCT02950558|DRUG|Ropivacaine|Single injection of ropivacaine immediately prior to surgery.
223859539|NCT02950558|PROCEDURE|Nerve block|insertion of catheter to deliver continuous 5 day popliteal sciatic nerve block using a disposable ambulatory pain pump.
223859540|NCT01147380|BIOLOGICAL|Liver NK cell inoculation|Liver transplant recipients will receive once liver NK cell inoculation several days after liver transplantation.
223859541|NCT01321606|DIETARY_SUPPLEMENT|Lactobacillus rhamnosus HN001|Subjects will be given a pill formulation of a probiotic L. rhamnosus HN001 to be taken once a day, at a dose of 1 x 10\^10 organisms
223859542|NCT01321606|DIETARY_SUPPLEMENT|sugar pill (placebo)|Placebo identical to the active product will be given
223859543|NCT05496816|DIAGNOSTIC_TEST|CAC in septic patients|"Data collected included demographic parameters, comorbidities, vasopressors requirement, laboratory findings, in-hospital mortality scoring and diagnostic colagulation scores. Demographic parameters were taken on the day of admission, all other variables were taken on the day of admission to the ICU and on the day of initiation of invasive mechanical ventilation or on the day of discharge from the ICU.~Demographic parameters included age and sex of the patient, followed by comorbidities which was marked with Yes or No on the day of admission in the ICU. Mortality was assessed according to the qSOFA score and vasopressor requirements on the day of admission and on the day of initation of invasive mechanical ventilation or on the day of discharge. Laboratory analysis included analysis of platelets, neutrophils, lymphocytes, PCT, CRP, fibrinogen, D-dimer on the day of admission and on the day of initation of invasive mechanical ventilation or on the day of discharge."
223859544|NCT03745001|DRUG|EHP-101 Liquid single dose|One single oral administration with EHP-101 liquid formulation. The doses will be ascending per cohort from 0.91 mg to 200 mg. The initially planned once daily dose regimen may be modified by the Safety Review Committee based on emerging PK data, eg, assigned dose levels may be divided into 2 doses administered 12 hours apart (twice a day).
223859545|NCT03745001|DRUG|EHP-101 Liquid multiple doses|One single daily administration with EHP-101 liquid formulation during 7 consecutive days. The doses will be ascending per cohort. Each ascending level will not exceed the tested dose levels in the single dose part of the study. The initially planned once daily dose regimen may be modified by the Safety Review Committee based on emerging PK data, eg, assigned dose levels may be divided into 2 doses administered 12 hours apart (twice a day)
223859546|NCT03745001|DRUG|Matching placebo|Oral liquid administration daily
223859547|NCT00021008|DRUG|picoplatin|
223859548|NCT05739903|DRUG|DA-1229_01 5/1000mg (Before)|single dose administration (one tablet once a day)
223859549|NCT05739903|DRUG|DA-1229_01 5/1000mg (After)|single dose administration (one tablet once a day)
223859550|NCT04747756|OTHER|Virtual Village|The purpose of this study is to create a virtual village for people aging with HIV, and to pilot test the virtual village intervention as a final step.
223859551|NCT05515042|DRUG|Ad26.COV2.S (VAC31518, JNJ-78436735) Vaccine, SARS-CoV-2 rS (CovovaxTM), BNT162b2 (Pfizer)|As included in arm/group descriptions
223859552|NCT01785004|DIETARY_SUPPLEMENT|Vitamin D3 (cholecalciferol), 2000 IU per day|cholecalciferol
223859553|NCT01785004|DRUG|omega-3 fatty acids (fish oil)|
223859554|NCT00117663|OTHER|temporary discontinuation of hormone therapy for 1 month|temporary discontinuation of hormone replacement therapy for 1 month prior to screening mammogram.
223859555|NCT00117663|OTHER|temporary discontinuation of hormone therapy for 2 months|temporary discontinuation of hormone replacement therapy for 2 months prior to screening mammogram
223859556|NCT00637234|DRUG|Oxcarbazepine|Oxcarbazepine (OXC), 300 mg tablets, up to 600 mg three times daily
223859557|NCT00637234|DRUG|Placebo|Placebo, 300 mg tablets, up to 600 mg three times daily
223859558|NCT04209049|DRUG|NNC0174-0833|A single subcutaneous (s.c., under the skin) dose of 0.6 mg NNC0174-0833.
223859559|NCT02789917|OTHER|Dual Therapy|Combination of Apixaban 5mg/dl (or in reduced dosing of 2.5 mg/d depending on age, renal function and body weight) in combination with Clopidogrel 75 mg/d for 6 months.
223859560|NCT02789917|OTHER|Triple Therapy|"HAS-BLED-Score \<3:~Combination of Phrenprocoumon (INR 2.0-2.5), Clopidogrel (75mg/d) and ASA (100 mg/d) for 6 months.~HAS-BLED-Score ≥ 3:~Combination of Phrenprocoumon (INR 2.0-2.5), Clopidogrel (75mg/d) and ASA (100 mg/d) for 1 month followed by Phrenprocoumon (INR 2.0-3.0) and Clopidogrel (75mg/d) for 5 months."
223859561|NCT04039984|DEVICE|Prime Cup|Patients in this group will have the Prime cementless acetabular cup used during surgery.
223859562|NCT04876573|DRUG|Cyproheptadine Hydrochloride 4 MG|"Phase 1: Cyproheptadine 4 mg three time a day for 10 days, per oral administration associated to Standard care of COVID 19 patient currently recommend by WHO~Phase 2: Cyproheptadine 8 mg three time a day for 10 days, per oral administration associated to Standard care of COVID 19 patient currently recommend by WHO~The dose will be adjusted according to the renal function."
223859563|NCT03400462|DRUG|NSAID|Nimesulide has anti-inflammatory and analgesic properties. Like other NSAIDs it inhibits the action of COX . If prostaglandins can not be further synthesized, so there is no factor able to excite local nociceptors. According to t must be taken regularly for a minimum 2 weeks to achieve appropriate blood concentration.
223859564|NCT03400462|DEVICE|oral appliance|The stabilization appliance used in this study was a removable device for maxillary arch, made of hard acrylic. Appliance was fitted over occlusal and incisal surfaces of the teeth and precisely contacted with the teeth of opposing arch. It provided canine disocclusion of the posterior teeth during eccentric movements.
223859565|NCT03400462|OTHER|dry needling|Equipment: acupuncture needle 0,6\*13 e.g. Dragon Medical Device, Visits schedule:( 1st visit - Day 1st , 2nd visit- 7 days after the 1st, 3rd visit- 7 days after the 2nd)
223859566|NCT01464736|OTHER|physical training|For both groups, the approximately hour-long sessions occurred three times a week on alternate days for six consecutive weeks (18 sessions). Each session began with five minutes of stretching that included the cervical muscles and the upper and lower limbs, which was followed by five minutes of warm-up on a treadmill at 2Km/h and 30 minutes of aerobic physical training at a constant 3% incline.
223859567|NCT02271971|DIETARY_SUPPLEMENT|Vitamin D3|A daily 5.000 IU vitamin D3 capsule during 6 weeks.
223859568|NCT02271971|DIETARY_SUPPLEMENT|Placebo|A daily placebo capsule during 6 weeks.
223859569|NCT04930393|PROCEDURE|Nerve Block - either PECS II or axillary ring|In addition to an interscalene nerve block, one of these two interventions will be administered to assess pain control after a biceps tenodesis
223859570|NCT02889237|DIETARY_SUPPLEMENT|Calcium|Immediate administration of daily calcium supplementation for 12 weeks
223859571|NCT02889237|DIETARY_SUPPLEMENT|Calcium + low dose vitamin D|Immediate administration of daily calcium and low dose vitamin D (1 sachet CaD 1000/880) supplementation for 12 weeks
223859572|NCT02889237|DIETARY_SUPPLEMENT|Calcium + high dose vitamin D|Immediate administration of daily calcium and high dose vitamin D (2 sachets CaD 500/880) supplementation for 12 weeks
223859573|NCT06240663|BEHAVIORAL|Exercise|Both groups complete the exercise intervention identically, but one is in the fasted state and one is in the fed state.
223859574|NCT01629186|OTHER|NPO with Nose-close and Abdomen-compression|Infants with body weight (BW) \<5.0 kg and receiving nasal diagnostic or interventional FB were enrolled. Under NPO (0.5 L/kg/min), when infant's heart rate (HR) \<80 beats/min or oxygen saturation (SpO2) \<85% for more than 10 seconds, rescue NC-AC was initiated. It was performed by (1) increased NPO flow to 0.5-1.0 L/kg/min; (2) NC 1 second for inspiration; and (3) AC 1 second for expiration with simultaneously released nostrils. Repeat doing steps (2) and (3) at a rate of 30 cycles/min until HR, SpO2, and blood pressure (BP) returned to normal.
224266460|NCT03867760|BEHAVIORAL|Recorded Hypnosis Intervention|The RHI consists of four digital recordings developed by the investigator using standardized hypnosis scripts for pain reduction and uploaded to a MP3 player. The scripts were developed for patients with chronic pain and tested by a psychologist who is an expert in hypnosis research. Participants will listen to the recordings daily for 28 days in the prescribed order (4 recordings for 3 days each, and then any recording for the remaining 16 days). The script includes an induction, suggestions for how to access inner resources and manage pain, and post-hypnotic suggestions for permanence of hypnosis benefits and self-hypnosis practice.
223859575|NCT06064357|OTHER|Transverese friction massage and tissue floss technique|"Transverse friction massage at Rectus femoris, hip adductors, hamstring, and calf of both lower limbs. TFM on each group of muscle for 30 seconds, 3 sets with 10 seconds rest interval.4 session / week for 6 weeks.~Tissue floss band will be applied on Rectus femoris, hip adductors, calf and hamstring of both lower limbs. Floss band will be wrap around the particular group of muscle from distal to proximal direction with 25 % stretch and 50% overlap and then 10 Reps of rom will be performed the rest interval is 2 mint. 4 sessions / week for 6 weeks.~Conventional physical therapy program included application hot pack for 15 minutes, and Bobath treatment followed by stretching of calf (10 repetitions with at least 8 seconds hold) 4 times / week for 6 weeks."
223859576|NCT04043364|BEHAVIORAL|LIVE|Learning, Innovation, Volunteers and Empowerment
223859577|NCT04825184|BEHAVIORAL|Body image chatbot|See arm/group description.
223859578|NCT01794936|DEVICE|VTI Probe|The VTI 20 MHz microvascular Laparoscopic Doppler System is a blood flow detector that compensates for the loss of tactile sensation during laparoscopic procedures by eliminating misunderstandings related to surrounding vascular anatomy. The system's sterile doppler probes fit through standard 5mm ports, making it easy to use with no special training required.
223859579|NCT01482013|DRUG|HPP854|Oral, once a day for 28 days.
223859580|NCT01482013|DRUG|Placebo|Oral, once a day for 28 days.
223859581|NCT03094013|OTHER|Assessment|Assessment
223859582|NCT01063686|DEVICE|insemination cervical cap|Primary abdominal ultrasound (US) for amniotic fluid index (AFI), Single vertical pocket, and dimensions of pocket below the presenting part. Speculum vaginal examination. In a sterile manner a cervical cap is adjusted on the cervix. the patient is kept recumbent for 6 hours. A repeat US exam is performed. The cervical cap is removed. After one hour another US is performed.
223859583|NCT04381273|OTHER|No intervention|questionnaire-based assessment
223859584|NCT03329066|BEHAVIORAL|MAST - Managing Asthma & Sleep in Teens|This behavioral intervention will teach teenagers asthma self-care strategies and sleep hygiene.
223859585|NCT03329066|BEHAVIORAL|ASMA - Asthma Self-Management for Adol|This behavioral intervention focuses only on asthma care.
223859586|NCT03329066|BEHAVIORAL|Information & Referral Control Group|Students learn basic information about asthma and sleep, as well as other health topics relevant to teenagers.
223859587|NCT03330418|BIOLOGICAL|Placebo|Starting with the forty-ninth dose,the trial went into the open phase. All participants were treated with the test drugs.
223859588|NCT03330418|BIOLOGICAL|RC18 160 mg|In the Phase B,the researchers can adjust the dose of RC18 according to the subjects' willingness and recurrence, but the maximum dose of single dose should not exceed 320g.
223859589|NCT00756730|DRUG|ATV/r|Switch to ATV/r at a dose of 300mg/100mg QD for 24 weeks. Subjects will continue to maintain their background NRTI drugs throughout the screening period and during the entire study.
223859590|NCT00756730|DRUG|DRV/r|We designed a study to determine if switching virologically suppressed patients on a regimen containing LPV/r or FPV/r to either DRV/r or ATV/r would result in improved TGs while maintaining virological suppression. Switch to DRV/r at a dose 800mg/100mg QD for 24 weeks. Subjects will continue to maintain their background NRTI drugs throughout the screening period and during the entire study.
223859591|NCT01752465|BEHAVIORAL|Health Coaching|Health Coaching sessions are 2 hours long. Participants individually receive a physical assessment, and recent blood work and medications are reviewed. When everyone has been assessed, the group reconvenes to watch a video about the importance of making healthy lifestyle choices, participates in a 10 min. fitness activity, and receives training on making SMART goals (SMART stands for specific, measurable, achievable, realistic, and timely). Each participant individually creates a SMART goal for him/herself, and this goal is reviewed as a group. Each participant rates the importance of this goal, and rates their level of confidence in succeeding. Progress is tracked in subsequent sessions, and metabolic health is continually monitored through routine blood work.
223859592|NCT01752465|BEHAVIORAL|Standard care|Standard clinical care will continue for all participants in the study, regardless of the study arm. This includes routine clinical visits to the attending psychiatrist, and receiving pharmacotherapy, standard patient education, and psychosocial training.
223859593|NCT00375453|DRUG|SH U04722|
224266461|NCT03867760|BEHAVIORAL|Recorded Relaxation Intervention|The recorded relaxation intervention consists of four digital recordings developed by the investigator using standardized relaxation scripts and uploaded to a MP3 player. Participants will listen to the recordings daily for 28 days in the prescribed order (4 recordings for 3 days each, and then any recording for the remaining 16 days).
224266462|NCT03596710|PROCEDURE|Image Guided Biopsy|Undergo image guided biopsy
224266463|NCT03155867|OTHER|Meal replacement|The study interventions contain protein, carbohydrate and fat and are intended for use as complete meal replacements for weight loss.
224266464|NCT00796796|DRUG|Temsirolimus|
224266465|NCT00796796|RADIATION|Radiation therapy|
224266466|NCT02836262|DEVICE|HIT Hip Replacement System|HIT Hip Replacement System
224266467|NCT05499728|OTHER|Telerehabilitation; physical therapy via telecommunication device (i.e. online video conferencing)|Postoperative physical therapy performed through online video conferencing with a licensed physical therapist while the patient remains remote/at home rather than in person
224266468|NCT00325312|DRUG|carbon dioxide, subcutaneous application|
224266469|NCT02179593|OTHER|2-Segment SARPE|Le Fort I osteotomy with oppening of the median palatal suture and SARPE.
224266470|NCT02179593|OTHER|3-Segment SARPE|Le Fort I osteotomy with two parallel osteotomies symetrically positioned with reference to the median palatal suture and SARPE.
224266471|NCT04903340|PROCEDURE|PET/CT Exam|PET/CT image processing application of reconstruction parameters: scan time, respiratory gating, Q-clear
224266472|NCT00808717|DRUG|Atorvastatin|Atorvastatin 10 mg vs. 80 mg before intervention
224266473|NCT00966160|DRUG|Lopinavir/Ritonavir plus Lamivudine/Zidovudine|400 mg lopinavir and 100 mg ritonavir (Kaletra capsules, Abbott Laboratories) twice daily plus 150 mg lamivudine (Epivir tablets, GlaxoSmithKline) and 300 mg zidovudine (Retrovir tablets, GlaxoSmithKline) twice daily over 476 weeks
224266474|NCT00966160|DRUG|Efavirenz plus Lamivudine/Zidovudine|600 mg efavirenz (Sustiva tablets, Bristol-Myers Squibb) once daily plus 150 mg lamivudine (Epivir tablets, GlaxoSmithKline) and 300 mg zidovudine (Retrovir tablets, GlaxoSmithKline) twice daily over 476 weeks
223859594|NCT01426178|DEVICE|Neurally Adjusted Ventilatory Assist in Non Invasive Ventilation (Device)|"After written information and consent, patients are randomised in two groups: NAVA first or PSV first.~They receive a NAVA catheter, which has exactly the same appearance as a standard naso-gastric catheter."
223859595|NCT00345761|DRUG|Bevacizumab|7.5 mg/kg(i.v.) on Day 1 of 1 cycle(3 weeks)
223859596|NCT00345761|DRUG|Oxaliplatin|130 mg/m2(i.v.) on Day 1 of 1 cycle(3 weeks)
223859597|NCT00345761|DRUG|Capecitabine|2000 mg/m2/day(p.o.) for 14 days in 1 cycle(3 weeks)
223859598|NCT05619016|DIAGNOSTIC_TEST|[68Ga]Ga-ABY-025 PET|\[68Ga\]Ga-ABY-025 PET: Each patient in Cohort 1 will be imaged with a PET/CT twice using the radiolabeled investigational product ABY-025 as a tracer. At the time of injection, a 45-minutes long dynamic scan will take place over a pre specified region of interest. Three hours after injection a full body PET scan followed by a CT scan will be performed.
223859599|NCT05619016|DIAGNOSTIC_TEST|Biopsy and analysis of HER2 expression|Biopsy: Within 3 days after the first ABY-025-PET a tissue sample from at least one metastasis \>10 mm available for biopsy, preferably shallow lymph nodes, will be analyzed for HER2 expression through immunohistochemistry- (IHC) and in situ hybridization- (ISH) analysis in patients with GEAC and HER2low mBC.
223859600|NCT03093467|BEHAVIORAL|ASCENSO|Internet-based program: an adjunct support and monitoring system for the treatment of depression.
223859601|NCT03093467|DRUG|Antidepressants or in combination with anxiolytics, neuroleptics or mood stabilizers.|Usual psychiatric treatment which may include drugs: antidepressant monotherapy or antidepressants in combination with anxiolytics, neuroleptics or mood stabilizers as needed, according to the psychiatric evaluation. Monthly controls during 5 months in average.
223859602|NCT03093467|BEHAVIORAL|Psychotherapy|Usual treatment: brief psychotherapy. One session per week, a total of 9 sessions in average.
223859603|NCT05271188|PROCEDURE|Infiltration of local anaesthetic between popliteal artery and posterior knee capsule|Adductor canal block (ACB) is a popular peripheral nerve block that has been shown to decrease pain significantly and thereby opioid consumption with minimal effect on quadriceps function \[8\]. Though ACB provides analgesia to the peripatellar and intra-articular aspect of knee joint, it does not relieve posterior knee pain which is moderate to severe in intensity \[9, 10\]. The recent technique of an ultrasound (US)-guided local anesthetic infiltration of the interspace between popliteal artery and the capsule of posterior knee (IPACK) has shown to provide significant posterior knee analgesia without affecting the common peroneal nerve (CPN) \[11\]. We postulated that IPACK will provide better pain relief and improve knee function in the immediate postoperative period compared to ACB
223859604|NCT01622075|DEVICE|SeQuent® Please|SeQuent® Please with a length of 10mm,15mm,17mm,20mm and 26mm and diameter of 2.5 mm, 2.75 mm, 3.0mm, 3.5mm and 4.0mm are to be used in the trial
223859605|NCT01622075|DEVICE|Taxus Liberte|Taxus Liberte with a length of 8mm,12mm,16mm,20mm and 24mm and diameter of 2.5 mm, 2.75 mm, 3.0mm, 3.5mm and 4.0mm are to be used in the trial
223859606|NCT03310112|BEHAVIORAL|4-week MBAT|The training is known as Mindfulness-Based Attention Training, or MBAT. The MBAT program is based on the principles of Mindfulness-Based Stress Reduction, but contextualized for military personnel using themes relevant to military life. The training content is comprised of four central themes: concentration, body awareness, open monitoring, and compassion. This content will be delivered in 4, 2-hour sessions over 4 weeks. Participants will be assigned homework mindfulness practice during the interval of course delivery as well as for the few weeks following the end of the course.
223859607|NCT03310112|BEHAVIORAL|2-week MBAT|The training is known as Mindfulness-Based Attention Training, or MBAT. The MBAT program is based on the principles of Mindfulness-Based Stress Reduction, but contextualized for military personnel using themes relevant to military life. The training content is comprised of four central themes: concentration, body awareness, open monitoring, and compassion. This content will be delivered in 4, 2-hour sessions over 2 weeks. Participants will be assigned homework mindfulness practice during the interval of course delivery as well as for the few weeks following the end of the course.
223859608|NCT04349150|DEVICE|Virtual reality|Intervention consists of providing virtual reality in place of standard sedatives and narcotics for a portion or the duration of the colonoscopy
223859609|NCT05698069|DIAGNOSTIC_TEST|Pain Modulation Index|A 18 item questionnaire assessing patients' pain characteristics for the detection of disordered pain modulation processes.
223859610|NCT05698069|OTHER|Pain Detect|A questionnaire that was validated for the assessment of neuropathic pain
223859611|NCT05698069|OTHER|Central sensitization inventory|A questionnaire developed for the detection of central sensitization.
223859612|NCT03293056|OTHER|High-intensity interval Hydrogynmastics|The HIIH to PSE group during the high intensity (HI) period should remain between 16 to 18 points, while in the moderate intensity (MI) intervals around 11. The dynamic exercises will progression, in the first month will be 1 min of HI and 2 min of MI, in the second month of 1 min of HI and 1 min of MI and in the last month of 1 min of HI and 30 s of MI, until completing 30 min in total.
223859613|NCT03293056|OTHER|Hydrogynmastics Continuous Moderate|For the HCM group the PSE will be around 11 points during the 30 min of moderate continuous exercise. In both groups the form of intensity monitoring that will be through the PSE, in which this scale will be printed in banner form and affixed next to the physical education teacher during the classes.
223859614|NCT03684213|DRUG|Control (Norepinephrine)|This intervention is aimed at assessing the vascular responsiveness to norepinephrine, an alpha 1-agonist, in white and black men and women across a series of ascending dose concentrations.
223859615|NCT03684213|DRUG|Norepinephrine + Ascorbic Acid|This intervention is meant to globally assess the impact of oxidative stress on vasoconstrictor responses by scavenging numerous oxidative molecules.
223859616|NCT03684213|DRUG|Norepinephrine + L-NAME|This intervention is meant to assess the impact of endothelium-derived nitric oxide on vasoconstrictor responses by inhibiting production of this source of nitric oxide.
223859617|NCT03684213|DRUG|Norepinephrine + L-NAME + Ascorbic Acid|This intervention is meant to assess the combined impact of scavenging oxidative stress and inhibiting endothelium-derived nitric oxide on vasoconstrictor responses.
223859618|NCT02542852|DRUG|atazanavir 300 mg + ritonavir 100 mg + dolutegravir 50 mg|Switch to single arm treatment atazanavir-ritonavir 300-100 mg + dolutegravir 50 mg therapy for 24 weeks
224266475|NCT00521586|BIOLOGICAL|13 valent pneumococcal conjugate vaccine|TIV +13vPnC at dose 1 placebo at dose 2, one month after dose 1 13vPnC at year 5
223859619|NCT00636064|DRUG|Parecoxib Sodium/Valdecoxib|Parecoxib sodium 40 mg intravenous (IV) on the day after surgery (Day 1) following recovery from anesthesia, contingent on an acceptable postoperative status, verification of baseline eligibility, and lack of perioperative complications. A second dose of parecoxib sodium 20 mg IV was administered on Day 1. On the day following surgery, patients received parecoxib 20 mg IV at 8 am and each subsequent dose was administered at 12-hour intervals. After receiving at least 6 doses of IV parecoxib sodium, patients were transitioned to oral valdecoxib 20 mg taken at 12-hour intervals until the total treatment duration of 10 days had been completed.
223859620|NCT00636064|DRUG|Placebo/Valdecoxib|Patients received placebo matched to parecoxib sodium 40 mg IV on Day 1 following recovery from anesthesia, contingent on an acceptable postoperative status, verification of baseline eligibility, and lack of perioperative complications. A second dose of placebo matched to parecoxib sodium 20 mg IV was administered on Day 1. On the day following surgery, patients received placebo matched to parecoxib sodium 20 mg IV at 8 am and each subsequent dose was administered at 12-hour intervals. After receiving at least 6 doses of IV placebo, patients were transitioned to oral valdecoxib 20 mg taken at 12-hour intervals until the total treatment duration of 10 days had been completed.
223859621|NCT00636064|OTHER|Placebo/Placebo|Patients received placebo matched to parecoxib sodium 40 mg IV on Day 1 following recovery from anesthesia, contingent on an acceptable postoperative status, verification of baseline eligibility, and lack of perioperative complications. A second dose of placebo matched to parecoxib sodium 20 mg IV was administered on Day 1. On the day following surgery, patients received placebo matched to parecoxib sodium 20 mg IV at 8 am and each subsequent dose was administered at 12-hour intervals. After receiving at least 6 doses of IV placebo, patients were transitioned to oral placebo matched to valdecoxib 20 mg taken at 12-hour intervals until the total treatment duration of 10 days had been completed.
223859622|NCT00064714|DRUG|AC2993 (exenatide)|Dose-escalation beginning with 2.5 μg administered subcutaneously twice per day (BID); then to 2.5 μg four times a day (QID); then to 5 μg four times a day; then to 10 μg four times a day.
223859623|NCT00064714|DRUG|daclizumab (immunosuppressive)|2 mg/kg intravenously infused over 30 minutes every month for 12 months
223859624|NCT05907473|OTHER|Virtual Reality Therapy|Patients in this group will play balance-based games with the Virtual Reality System.
223859625|NCT05907473|OTHER|Conventional Rehabilitation|In the conventional rehabilitation program, bed exercises, mat activities, balance exercises inside or outside the parallel bar and walking training will be given to the patients every weekday.
223859626|NCT01161498|BIOLOGICAL|Talimogene Laherparepvec|Administered by intratumoral injection
223859627|NCT01161498|RADIATION|Radiation|70 grays of radiation administered in 35 fractions over 7 weeks
223859628|NCT01161498|DRUG|Cisplatin|Administered by intravenous infusion
223859629|NCT04677322|DRUG|Adult patients diagnosed and treated for high blood pressure|Educational program interventions conducted by primary care staff to encourage adherence to a low-sodium diet consisting of direct action on the patient and provision of educational materials will be assessed. Compliance and follow-up of the low sodium diet will be done by monitoring the sodium in urine in the target population, selected according to the selection criteria described in the protocol.
223859630|NCT06271304|DEVICE|Blue blocking eyewear|Eyewear is worn daily from 6 PM to 8 AM during manic/hypomanic state Eyewear is worn daily 2 hours before planned bedtime during euthymic, depressive and mixed state
223859631|NCT06271304|DEVICE|Low filtration eyewear|Eyewear is worn daily from 6 PM to 8 AM during manic/hypomanic state Eyewear is worn daily 2 hours before planned bedtime during euthymic, depressive and mixed state
223859632|NCT00000217|DRUG|Carbamazepine|
223859633|NCT05074836|DIETARY_SUPPLEMENT|Formula milk|"Brand name: Yili (QQ star formula milk);~Type: SCI-PRO NUTRI 5+6TM formula milk designed for young children aged over 3 years;~Dosage: 195ml\*2/d;~Intervention duration: 12 months"
223859634|NCT05074836|DIETARY_SUPPLEMENT|Regular milk|"Brand name: Yili；~Type: regular milk (pure milk);~Dosage: 195ml\*2/d;~Intervention duration: 12 months"
223859635|NCT05074836|OTHER|Control foods|"Brand: N/A;~Food type: grain foods (e.g., bread);~Dosage: 20-40g \* 2/d grain foods~Intervention duration: 12 months"
223859636|NCT03950869|BEHAVIORAL|Positive Expectation Manipulation|Participants are watching a video tape of a trauma expert who provides selective information on the development of intrusive memories. This video tape aims to increase positive expectations.
223859637|NCT03950869|BEHAVIORAL|Negative Expectation Manipulation|Participants are watching a video tape of a trauma expert who provides selective information on the development of intrusive memories. This video tape aims to increase negative expectations.
223859638|NCT05095246|BIOLOGICAL|KB407 (Nebulization)|Nebulized solution of KB407, a replication-incompetent HSV-1 expressing full length human CFTR
224266476|NCT00521586|BIOLOGICAL|13 valent pneumococcal conjugate vaccine|TIV + placebo at dose 1 13vPnC at dose 2, one month after dose 1 and 13vPnC at year 5
224266477|NCT04534621|OTHER|Electronic survey|Brazilian chiropractors will be invited by email and social media to answer an electronic survey.
224266478|NCT00008060|DRUG|FOLFIRI regimen|
224266479|NCT00008060|DRUG|FOLFOX regimen|
224266480|NCT00008060|DRUG|fluorouracil|
224266481|NCT00008060|DRUG|irinotecan hydrochloride|
224266482|NCT00008060|DRUG|leucovorin calcium|
224266483|NCT00008060|DRUG|oxaliplatin|
224266484|NCT01538160|DRUG|recombinant factor VIIa|single dose of 20ug/kg of recombinant factor VIIa along with tranexamic acid of 4 gram a day for 7 days following surgery
224266485|NCT00405860|DRUG|CellCept (mycophenolate mofetil)|
224266486|NCT06203080|DRUG|ancetate gel|An acetic acid thermoreversible gel produced by Shanghai Jinxiang Latex Products Co. will be utilized for the intervention. Each product weighs 4.85 g and contains 54.45 mg of poloxamer 407-acetic acid. The investigators will stockpile the product and distribute a total of 72 doses on the first day, at the end of the second month, and at the end of the fourth month of follow-up, respectively, after concealing the product's name. Participants will receive instructions to apply the medication transvaginally, one dose at a time, during each instance of sexual activity.
223859639|NCT01052246|DRUG|Fixed combination of clindamycin 1% + benzoyl peroxide 5%|Topical monotherapy with a fixed combination of 1% clindamycin and 5% benzoyl peroxide hydrating gel (Duac® Akne Gel, Stiefel Laboratorium GmbH, Offenbach, Germany). In order to provide standardized condition within the sample, the gel was applied on the whole face regardless of the lesion location. The gel was applied once per day in the evening throughout the observation period and left in place overnight.
223859640|NCT01052246|DEVICE|Pulsed dye laser|"Patients randomized in the experimental group received two additional treatments with a pulsed dye laser using the following parameters:~* Wavelength 585 nm~* Energy fluence 3 J/cm2~* Pulse duration 0.35 msec~* Spot size 7 mm"
223859641|NCT02867566|DRUG|IBI301 plus CHOP|Six cycles. IBI301: 375 mg/m2, IV, day 1 of each cycle; Cyclophosphamide: 750 mg/m2, IV, day 2 of each cycle; Doxorubicin: 50 mg/m2, IV, day 2 of each cycle; Vindesine: 4 mg, IV, day 2 of each cycle; Prednisone: 100 mg, po, day 2 to day 6 of each cycle.
223859642|NCT02867566|DRUG|Rituximab plus CHOP|Six cycles. Rituximab: 375 mg/m2, IV, day 1 of each cycle; Cyclophosphamide: 750 mg/m2, IV, day 2 of each cycle; Doxorubicin: 50 mg/m2, IV, day 2 of each cycle; Vindesine: 4 mg, IV, day 2 of each cycle; Prednisone: 100 mg, po, day 2 to day 6 of each cycle.
223859643|NCT01548846|RADIATION|Tomotherapy|Patients receive radiotherapy by Tomotherapy for 7 weeks at the ENT
223859644|NCT01304342|DRUG|Remifentanil|1 microgram/kg/h, continuous infusion, 5 min before and during the ERCP
223859645|NCT01304342|DRUG|Fentanyl|Intranasal fentanyl 200 micrograms 5 min before the ERCP
223859646|NCT01304342|DRUG|Normal saline|Normal saline intravenously and intranasally
223859647|NCT05686421|DEVICE|OCT Imaging Using Device N|Standard conventional OCT imaging device equipped with extendable and comfortable chin and forehead rest.
223859648|NCT05686421|DEVICE|OCT Imaging Using Device C|Standard conventional OCT imaging device.
223859649|NCT02812459|OTHER|Kinesio taping|Kinesio taping is a new taping modality which act diminishing pain.
223859650|NCT02812459|OTHER|Electrical Stimulation|Electrical stimulation therapy is a electrical current that allow patients diminish pain.
223859651|NCT02196818|DEVICE|Mpact Acetabular Shell|Total Hip Replacement
223859652|NCT06628856|OTHER|Quality of life|The study proposes a 3-time longitudinal design, with evaluations at baseline, 2.5 months, and 5 months, to measure the impact of an intervention on terminally ill patients and their families, focusing on health status, quality of life, and emotional well-being.
223859653|NCT02498769|DRUG|Botulinum Toxin Type A|The botulinum toxin will be injected into epicardial fat pads shortly after cardiopulmonary bypass is initiated.
223859654|NCT02498769|DRUG|Placebo|
223859655|NCT03312439|BEHAVIORAL|Given advice|Based on results of testing the participants will be give advice with the general aim to decrease the future risk of non-communicable disease by increasing physical activity,
223859656|NCT05483374|OTHER|observation|Not applicable, it is an observational registry
223859657|NCT05966389|OTHER|No interventions|No interventions
223859658|NCT04465071|DRUG|AEONTM Repair and AEONTM Protect Plus lubricating eye drops|AEONTM Repair and AEONTM Protect Plus lubricating eye drops
223859659|NCT06292182|DEVICE|Near-infrared light|daily application of near-infrared light
223859660|NCT01737008|DRUG|dacomitinib|Tablets are administered orally or through a G-Tube, and can be taken with or without food.
223859661|NCT01737008|RADIATION|Radiotherapy|Intensity modulated radiation therapy (IMRT) delivered using 4 or 6 MV photons. Patients will receive either the standard dose fractionation radiotherapy or accelerated fractionation radiotherapy.
223859662|NCT01737008|DRUG|Cisplatin|If selected for this arm, cisplatin will be administered intravenously every three weeks after receiving premedications.
223859663|NCT02533167|OTHER|skin to skin|initiating skin to skin is not currently the standard of care at our facility so there is 1 interventional arm for this study. control group of no skin to skin until recovery room already established as is the standard of care.
223859664|NCT00367055|DRUG|rosiglitazone-metformin|
223859665|NCT00367055|DRUG|Metformin|
223859666|NCT00367055|DRUG|metformin+ gliclazide|
223859667|NCT03557788|DRUG|Rifaximin Oral Tablet|PO 550mg TDS for 2 weeks
223859668|NCT00300040|DRUG|Hemoglobin glutamer 250 - bovine|intravenous - 250ml/dose - 32.5g Hb (Concentration 13 +/- 1g/dL)
223859669|NCT00300040|DRUG|6% Hydroxyethylstarch|250ml for intravenous infusion
223859670|NCT03265717|BIOLOGICAL|INVAC-1|Patients are treated by INVAC-1 for 6 cycles at 4-week intervals
223859671|NCT05712018|DRUG|Hydroxyethyl starch coload - 0 ml/kg|No fluid coload was given. An initial infusion dose of prophylactic norepinephrine (0.025 ug/kg/min) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 0.005 ug/kg/min of prophylactic norepinephrine according to the responses of previous patients according to the up-down sequential allocation.
223859672|NCT05712018|DRUG|Hydroxyethyl starch coload - 5 ml/kg|5 ml/kg 6% Hydroxyethyl starch (130/0.4) coload combined with an initial infusion dose of prophylactic norepinephrine (0.025 ug/kg/min) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 0.005 ug/kg/min of prophylactic norepinephrine according to the responses of previous patients according to the up-down sequential allocation.
223859673|NCT05712018|DRUG|Hydroxyethyl starch coload - 10 ml/kg|10 ml/kg 6% Hydroxyethyl starch (130/0.4) coload combined with an initial infusion dose of prophylactic norepinephrine (0.025 ug/kg/min) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 0.005 ug/kg/min of prophylactic norepinephrine according to the responses of previous patients according to the up-down sequential allocation.
223859674|NCT02729272|PROCEDURE|Laparoscopic colpotomy by ultrasonic ESD|In this intervention, laparoscopic colpotomy was performed by ultrasonic ESD (Harmonic Synergy Hook Blades; Ethicon Endo-Surgery, Cincinnati, OH, USA).
223859675|NCT02729272|PROCEDURE|Laparoscopic colpotomy by monopolar ESD|In this intervention, laparoscopic colpotomy was performed by monopolar ESD (hook electrode with 90 watts of unmodulated current; Karl Storz, Tuttlingen, Germany).
223859676|NCT02729272|DEVICE|Monopolar ESD|
223859677|NCT02729272|DEVICE|Ultrasonic ESD|
223859678|NCT01586780|DIETARY_SUPPLEMENT|Protein drink|Test drink providing 9g protein
223859679|NCT01586780|DIETARY_SUPPLEMENT|Reference meal|Control meal
223859680|NCT05028712|BEHAVIORAL|Visual Information Training|Participants in this arm will receive training to improve the use of residual vision to enhance functional performance.
223859681|NCT05028712|BEHAVIORAL|Multimodal training|Participants in this arm will receive training in integrating input from different senses to enhance functional performance.
223859682|NCT03649165|DRUG|Treatment A|During Part 1 of the study, participants will receive single doses of selumetinib 25 mg granule under fasted conditions. The dose will be administered after an overnight fast of at least 10 hours. The IMP will be administered with approximately 240 mL of water. No food will be allowed for at least 4 hours post-dose.
223859683|NCT03649165|DRUG|Treatment B|During Part 1 of the study, participants will receive single doses of selumetinib 50 mg capsule under fasted conditions. The dose will be administered after an overnight fast of at least 10 hours. The IMP will be administered with approximately 240 mL of water. No food will be allowed for at least 4 hours post-dose.
223859684|NCT03649165|DRUG|Treatment C|During Part 2 of the study, participants will receive single doses of selumetinib 25 mg granule under fed conditions. Following an overnight fast of at least 10 hours, participants will start consumption of the recommended meal within 30 minutes before administration of the IMP. Participants will be required to consume the entire meal in 30 minutes or less; however, the IMP should be administered 30 minutes after start of the meal. The IMP will be administered with approximately 240 mL of water. No food will be allowed for at least 4 hours post-dose, where after a meal may be provided.
223859685|NCT03649165|DRUG|Treatment D|During Part 2 of the study, participants will receive single doses of selumetinib 50 mg capsule under fed conditions. Following an overnight fast of at least 10 hours, participants will start consumption of the recommended meal within 30 minutes before administration of the IMP. Participants will be required to consume the entire meal in 30 minutes or less; however, the IMP should be administered 30 minutes after start of the meal. The IMP will be administered with approximately 240 mL of water. No food will be allowed for at least 4 hours post-dose, where after a meal may be provided.
223859686|NCT03649165|DRUG|Acetaminophen|Participants will receive a single 500mg dose of acetaminophen at the same time.
223859687|NCT06112119|DEVICE|MSCT|Using Semi-automatic MSCT Volumetry in assessment of brain atrophy associated with septic ICU patients
224266487|NCT06203080|DRUG|nonoxinol gel|The nonoxinol gel produced by China Pharmaceutical University Pharmacy Co., Ltd will be utilized for the intervention. Each product weighs 5 g and contains 50 mg of N-9. The investigators will stockpile the product and distribute a total of 72 doses on the first day, at the end of the second month, and at the end of the fourth month of follow-up, respectively, after concealing the product's name. Participants will receive instructions to apply the medication transvaginally, one dose at a time, during each instance of sexual activity.
224266488|NCT01074827|OTHER|Strength training and treadmill training|Eight weeks of intensive strength training or treadmill training
224266489|NCT03904095|PROCEDURE|Psoas Compartment Block Group (GROUP I)|Psoas Compartment Block will perform preoperative to all patients in Group I. Patients in all groups will provide with intravenous patient- controlled analgesia device containing morphine for postoperative analgesia.
224266490|NCT03904095|PROCEDURE|Erector Spinae Plane block ( Group II)|ESP Block will perform preoperative to all patients in ESP block group. Patients in all groups will provide with intravenous patient- controlled analgesia device containing morphine for postoperative analgesia.
224266491|NCT03904095|PROCEDURE|Control Group (GROUP III)|Control group will receive no intervention. Patients in all groups will provide with intravenous patient- controlled analgesia device containing morphine for postoperative analgesia.
224266492|NCT02779400|DEVICE|Self testing INR device|the procedure involves a series of repeated measurements of INR with the studied device
224266493|NCT00400452|BEHAVIORAL|wheelchair skills training|
224266494|NCT03234907|DRUG|Vedolizumab IV|Vedolizumab IV infusion
223859688|NCT04143555|PROCEDURE|endoscopic submucosal injection of indocyanine green before laparoscopic gastrectomy|Indocyanine green was injected under endoscope within 24 hours before operation. Four points(0.5ml/point,1.25mg/ml) were evenly injected in four quadrants at the edge of the tumor. The injection method was direct submucosal injection and 0.5ml saline + 0.5ml indocyanine green solution + 0.5ml saline (sandwich method). The imaging effect was evaluated by indocyanine green fluorescence imaging system during the operation. The effect was divided into grade0 and Grade1. Grade1: The imaging of the tumor and the corresponding lymphatic drainage area in the injection area both were ideal. Grade 0: not up to grade 1, classified into tumor body and drainage area without imaging, only tumor body imaging, and even though tumor body and regional lymph drainage area imaging, the contrast agent in the gastric wall was too diffuse or even overflowing, which seriously interfered with the observation of lymph drainage area imaging.
223859689|NCT05928819|PROCEDURE|Evaluation of the proportion of gastric neoplastic lesions detected by a computer-aided diagnosis system (CADx) compared with experienced endoscopists.|Evaluation of the proportion of gastric neoplastic lesions detected by a computer-aided diagnosis system (CADx) compared with experienced endoscopists.
223859690|NCT01026636|DRUG|Ceftobiprole|
223859691|NCT00212056|DRUG|ANP(hANP)|0∙025 μg/kg per min for 3 days(intravenous)
223859692|NCT00212056|DRUG|Control|placebo
223859693|NCT01918644|RADIATION|stereotactic body radiation therapy|Undergo SBRT
223859694|NCT01918644|DRUG|capecitabine|Given PO
223859695|NCT01918644|PROCEDURE|therapeutic conventional surgery|Undergo definitive surgery
223859696|NCT01918644|PROCEDURE|magnetic resonance imaging|Optional correlative studies
223859697|NCT01918644|OTHER|laboratory biomarker analysis|Optional correlative studies
223859698|NCT01352611|DRUG|baclofen, intrathecal|Patients will undergo a standard intrathecal baclofen trial procedure. This procedure consists of a single injection of 50 micrograms of baclofen between the 4th and 5th lumbar vertebrae into the spinal fluid.
223859699|NCT06258031|DRUG|Psilocybin (COMP360)|Up to 10mg on two occasions
223859700|NCT06023186|DRUG|mavacamten|Study participants will receive mavacamten under the standard of care
223859701|NCT05062577|DRUG|ASP8062|oral
223859702|NCT05062577|DRUG|Placebo ASP8062|oral
223859703|NCT05062577|DRUG|buprenorphine/naloxone|sublingual
223859704|NCT04222270|BEHAVIORAL|Champion Caregiver peer mentoring support to caregivers on child care and medication adherence to enhance achievement of viral suppression|Caregiver to caregiver peer support intervention through group/one-on-one education and counselling
223859705|NCT00732953|DEVICE|Genous stent implantation with paclitaxel-eluting balloon dilation|Genous stent implantation with paclitaxel-eluting balloon therapy
223859706|NCT00732953|DEVICE|Genous stent implantation|Genous stent implantation
223859707|NCT03356132|DEVICE|Silimed® Textured Silicone Gel-Filled Breast Implant|Women undergoing primary and secondary breast augmentation using Silimed® Textured Silicone Gel-Filled Breast Implant.
223859708|NCT03356132|DEVICE|Silimed® Polyurethane Foam Covered Silicone Gel-Filled Breast Implant|Women undergoing primary and secondary breast augmentation using Silimed® silicone gel-filled breast implants with polyurethane foam covered surface.
223859709|NCT04470193|OTHER|MyChildCMC app|Patients/parents will self-monitor their symptoms daily using the MyChildCMC app completing the daily vitals form. After patient/parents complete the daily form, the app provides in-app alerts and graphs showing symptom data over time.
223859710|NCT04663802|BEHAVIORAL|Default order set|With the default order set strategy, some mechanical ventilation order settings will be pre-populated to be consistent with LPV, including the mode and tidal volume, automatically calculated as 6 milliliters per kilogram of predicted body weight (cc/kg PBW; as determined by each patient's height and gender). The physician will have the option to opt out of any of the specified LPV settings and select other values.
223859711|NCT04663802|BEHAVIORAL|Physician-targeted accountable justification|When a physician enters a mechanical ventilation order for a tidal volume that is greater than 6 cc/kg PBW, an alert will appear requiring the physician to enter a reason for choosing a setting inconsistent with LPV. Clinicians will be instructed to provide a reason for deviation from LPV settings and that their response will be maintained in the medical record. The physician will not be able to sign the mechanical ventilation order set until after a response is entered.
223859712|NCT04663802|BEHAVIORAL|Respiratory therapist (RT)-targeted accountable justification|If an RT enters a tidal volume in a flowsheet documentation field value greater than 6 cc/kg PBW, an alert will appear requiring them to enter a reason for entering a setting inconsistent with LPV. Clinicians will be instructed to provide a reason for deviation from LPV settings and that their response will be maintained in the medical record. The RT will not be able to save the documentation in the EHR until after a response is entered.
223859713|NCT05829681|DEVICE|Repetitive Transcranial Magnetic Stimulation|Participants will receive a 5-day course of 10x daily rTMS, with sessions delivered hourly. Each session will deliver up to 1800 pulses of theta-burst stimulation per target.
223859714|NCT04518930|OTHER|Peanuts or plain Greek yogurt|Two different types of dietary snacks
224266495|NCT03234907|DRUG|Placebo|Vedolizumab placebo-matching
224266496|NCT00642993|DRUG|SCH 497079|100 mg capsule administered orally
224266497|NCT00642993|DRUG|Placebo|Placebo capsules matching SCH 497079 administered orally
224266498|NCT02664415|BIOLOGICAL|VRC01|40 mg/kg; administered IV
224266499|NCT02664415|BIOLOGICAL|Placebo for VRC01|Sodium Chloride for Injection 0.9%, USP; administered IV
224266500|NCT00125385|BIOLOGICAL|GC1008|0.3 mg/kg, IV on Day 0 and return to the clinic on 3,7, 10, 14, 21, 28, 42, 56, 84, 112, 140 post infusion for safety follow-up.
224266501|NCT00125385|BIOLOGICAL|GC1008|1.0 mg/kg, IV on Day 0 and return to the clinic on 3,7, 10, 14, 21, 28, 42, 56, 84, 112, 140 post infusion for safety follow-up.
224266502|NCT00125385|BIOLOGICAL|GC1008|2.0 mg/kg, IV on Day 0 and return to the clinic on 3,7, 10, 14, 21, 28, 42, 56, 84, 112, 140 post infusion for safety follow-up.
224266503|NCT00125385|BIOLOGICAL|GC1008|4.0 mg/kg, IV on Day 0 and return to the clinic on 3,7, 10, 14, 21, 28, 42, 56, 84, 112, 140 post infusion for safety follow-up.
224266504|NCT00125385|BIOLOGICAL|GC1008|8.0 mg/kg, IV on Day 0 and return to the clinic on 3,7, 10, 14, 21, 28, 42, 56, 84, 112, 140 post infusion for safety follow-up.
223859715|NCT04004000|DRUG|Losmapimod|"The main study includes a treatment period of approximately one year. Subjects will receive 15 mg of losmapimod twice daily by mouth; for a total of 30 mg daily. The study drug should be taken with food and the date and time of each dose taken recorded in the subject diary.~Only subjects who participated in and completed all procedures for the main study (Week 60) will be eligible to participate in the extension.~For the extension, subjects will receive 15 mg of losmapimod by mouth twice daily for a total of 30 mg by mouth daily. Participation will continue until 90 days after commercial drug is available post regulatory approval or study termination."
223859716|NCT02517307|DRUG|Intralipid/Heparin|Co-infusion of intralipid and heparin solutions during a hyperinsulinemic euglycemic clamp
223859717|NCT02517307|DRUG|Glycerol/Saline|Co-infusion of a glycerol/saline solutions during a hyperinsulinemic euglycemic clamp
223859718|NCT02517307|DRUG|Hyperinsulinemic euglycemic clamp|Infusion of insulin at at 40 mU/m2/min for 5 hours. Blood glucose will be monitored every 5 min during the insulin infusion and euglycemia will be maintained throughout the clamp by infusing 20% dextrose at a variable rate.
223859719|NCT03035045|DRUG|Paracetamol|
223859720|NCT03035045|DRUG|Placebo Oral Tablet|
223859721|NCT05960162|DIAGNOSTIC_TEST|90K|Blood test
223859722|NCT00869570|DRUG|capecitabine|Phase II: 2 x 825 mg/m2 per day (during 5 weeks)
223859723|NCT00869570|DRUG|sorafenib tosylate|Phase II: 1 x 400 mg per day (during 5 weeks)
223859724|NCT00869570|RADIATION|radiation therapy|Phase II: 1.8 Gy per day in 25 fractions (during 5 weeks)
223859725|NCT00823979|DRUG|UK-453,061 Dose 1|UK 453,061 750 mg QD + one optimized NRTI + darunavir/ritonavir.
223859726|NCT00823979|DRUG|UK-453,061 Dose 2|UK 453,061 1000 mg QD + one optimized NRTI + darunavir/ritonavir.
223859727|NCT00823979|DRUG|Etravirine|Etravirine 200 mg BID + one optimized NRTI + darunavir/ritonavir.
223859728|NCT03771885|DRUG|BI 705564|Film-coated Tablet
223859729|NCT03771885|DRUG|Placebo|Film-coated Tablet
223859730|NCT03873324|DRUG|CPL500036 compound|IMP is a capsule with CPL500036 as an Active Pharmaceutical Ingredient (API).
223859731|NCT03873324|DRUG|Placebo|matching placebo capsules
223859732|NCT01343654|BEHAVIORAL|Text messaging plus EMA|Personalized, tailored text messaging to prompt medication adherence, with EMA random queries about nonadherence and drug use, and two-way messaging for participants to report critical events
223859733|NCT01343654|BEHAVIORAL|Treatment as usual|usual care in one of the three participating ID clinics, along with usual care (if any) in the community for problematic drug and alcohol use
223859734|NCT04878341|OTHER|Erector Spinae Plane Block|The ESP is fascial plane block performed by injecting local anesthetic between the erector spinae muscle and the transverse process. Its proposed mechanism of action is via blockade of the dorsal and ventral rami of the thoracic spinal nerves and sympathetic fibers.
223859735|NCT04598529|OTHER|A2 milk|a variety of cow's milk that contains only A2 beta-casein (and therefore lacks of A1 beta-casein).
223859736|NCT04598529|OTHER|Conventional milk|cow's milk with a mixture of A1 and A2 beta-casein.
223859737|NCT04895566|BIOLOGICAL|Monoclonal antibody (Mab) sB24M|200 mg monoclonal antibody (Mab) sB24 by injection into the affected areas.
223859738|NCT00387361|PROCEDURE|Osteopathic Manipulative Treatment|20 minute post-operative osteopathic manipulation as described in the protocol
223859739|NCT04083651|DRUG|Methylnaltrexone bromide|Methylnaltrexone bromide will be administered per dose and schedule specified in the respective arm.
223859740|NCT04083651|DRUG|Placebo|Placebo matching to methylnaltrexone bromide will be administered as mentioned in the respective arm.
223859741|NCT04135378|DRUG|ascorbic acid|Study Group :- ascorbic acid ( 500 mg per day) for one week before presentation
223859742|NCT04135378|OTHER|placebo|:- included 30 students given placebo for one week before presentation.
223859743|NCT05895760|OTHER|Multi-component physical exercise online intervention|"A multicomponent exercise program was implemented consisting of a combined program of endurance, strength, coordination, balance, and flexibility exercises depending on the level of functional capacity.~Three types of physical exercise programs were designed according to the physical performance level of each participant. The first type of exercise program training was performed for frail adults with an SPPB score of 4 to 6, the second was for the pre-frail adults with an SPPB score of 7 to 9 and the third for robust adults with an SPPB of 10 to 12."
223859744|NCT01928004|DEVICE|Implant placement|Participants received two Straumann Standard Implants® in the interforaminal region using the recommended surgical protocol. The implants were loaded using Locator® attachments after six to eight weeks healing time by transforming the existing lower denture to an IOD.
223859745|NCT01928004|PROCEDURE|Conventional reline|conventional reline of the existing mandibular complete denture
223859746|NCT01393470|PROCEDURE|Screening for cervical cancer|Organized screening for cervical cancer start for all cohorts at the age of 25 years with 5 year interval.
223859747|NCT03955640|DRUG|Olaparib|Given PO
223859748|NCT03955640|PROCEDURE|Hyperthermia Treatment|Undergo hyperthermia treatment
223859749|NCT03955640|OTHER|Questionnaire Administration|Ancillary studies
223859750|NCT03955640|OTHER|Quality-of-Life Assessment|Ancillary studies
223859751|NCT01761396|BEHAVIORAL|CBT|
223859752|NCT01761396|BEHAVIORAL|UC|
223859753|NCT06306365|BEHAVIORAL|Modern board game-based learning|Modern board game-based learning involves using contemporary board games as educational tools. It emphasizes active participation, critical thinking, and social interaction among participants. By integrating strategic thinking and problem-solving within a game context, this approach aims to enhance learning experiences in an engaging and enjoyable manner. In this study, board games have been selected to target and engage executive functions.
223859754|NCT05019729|DRUG|VRC-MALMAB0114-00-AB|VRC-MALMAB0114-00-AB (L9LS) is a monoclonal antibody that binds an epitope of the Plasmodium falciparum circumsporozoite protein.
223859755|NCT05019729|OTHER|Plasmodium falciparum (P. falciparum) sporozoite challenge|Participants were exposed to bites on the forearm from mosquitoes infected with Plasmodium falciparum
223859756|NCT04561037|DEVICE|Pulsed Electromagnetic Field therapy (PEMFT)|PEMFT was connected to electrical mains supplying 220v. Pair of applicators sized 16x10x3 cm was adjust to be over TMJ, on both sides of the face; the appliance was adjusted to the frequency of 50 HZ and intensity of 90 Gauss. Twelve PEMF treatment sessions of 30 min duration were provided 3 times per week TMJ mobilization techniques and isometric exercises against resistance for muscles of mastication
223859757|NCT04561037|OTHER|TMJ physical therapy program|TMJ manual physical therapy program (mobilization and gentle isometric exercises) for 30, 3 times a week, for 4 weeks.
223859758|NCT01778712|BEHAVIORAL|Multi-level intervention|The development of a lifestyle program intended to intervene on the individual, social network and community over two years
223859759|NCT01126307|DRUG|Verapamil|80 mg tid
223859760|NCT01126307|DRUG|placebo|placebo tid
223859761|NCT02964780|PROCEDURE|Gastric bypass surgery|
223859762|NCT02964780|BEHAVIORAL|Conservative weight loss program|
223859763|NCT04481906|PROCEDURE|Vaginal mesh for female cystocele|Vaginal mesh procedures (e.g. Perigee) were susgested for women with POP-Q stage III or more cystocele
223859764|NCT00612001|BIOLOGICAL|glioma-associated antigen peptide-pulsed autologous dendritic cell vaccine|
223859765|NCT01177852|DRUG|diphenhydramine + dropropizine + pseudoephedrine|"Group 1: fixed dose combination of diphenhydramine + dropropizine + pseudoephedrine (Notuss® syrup).~Posology: The medicine treat will be as follows:~\- Notuss® syrup Age: 2-5 years / Dosage: 5,0 mL Age: 6-12 years / Dosage: 10,0 ml"
223859766|NCT01177852|DRUG|Dropropizine and fixed dose combination of pseudoephedrine hydrochloride + brompheniramine maleate (Dimetapp® elixir).|"Dropropizine:~Age: 2 - 3 years / Dosage: 5,0 ml Age: 4 - 12 years / Dosage: 10,0 ml~Pseudoephedrine hydrochloride + brompheniramine maleate:~Age: 2 - 3 years / Dosage: 2,5 ml Age: 4 - 6 years / Dosage: 5,0 ml Age: 7 - 9 years / Dosage: 7,5 ml Age: 10 - 12 years / Dosage: 10,0 ml"
223859767|NCT06028451|OTHER|Record the information data|Record the information data
223859768|NCT02824094|DRUG|crizotinib|Crizotinib, 250 mg BID, will be administered orally on a continuous daily dosing schedule
223859769|NCT02135341|DRUG|Botulinum toxin A|BoNT-A 100 units in normal saline 10ml, suburothelial injection at 20 sites of bladder wall in single treatment
223859770|NCT02135341|DRUG|Botulinum toxin A|BoNT-A 100 units in normal saline 10ml, suburothelial injection 50 U in 10 sites and 50 U urethral injections in 5 sites
223859771|NCT00032799|DRUG|natalizumab|
223859772|NCT00839540|DRUG|micafungin|100 mg qd by slow IV infusion for 24 h
223859773|NCT00839540|DRUG|Micafungin|200 mg qd by slow IV infusion for 24 h
223859774|NCT00839540|DRUG|Caspofungin|70 mg LD followed by 50 mg qd by slow IV infusion for 24 h
223859775|NCT05311319|DRUG|HAIC+TQB2450+Anlotinib|HAIC: FOLFOX for 24hour perfusion chemotherapy. Anlotinib: 10mg orally daily on day 1 to 14 of a 21-day cycle. TQB2450: 1200 milligrams (mg) administered intravenously (IV) on Day 1 of each 21-day cycle.
223859776|NCT00299741|DRUG|Sunitinib|Sunitinib 50 mg daily, 4/2 schedule
223859777|NCT04402320|DRUG|Midazolam|reconnected to mechanical ventilation before extubation for one hour with sedation with midazolam 3-5 milligram/hour intravenous infusion to achieve score 0 or -1on Richmond Agitation - Sedation Scale (RASS). 20 minutes before the end of this hour midazolam infusion discontinued and patients awaked. Patient put on mechanical ventilation (MV) with the following parameters, FIO2 40%, pressure SIMV mode, PEEP 8 cmH2O, Pressure support 15 cmH2O, Respiratory rate 14/min, Peak inspiratory pressure (PIP) of 35 cmH2O. Then patients extubated and followed our previous protocol without the use
223859778|NCT04402320|DEVICE|ventilator|reconnected to mechanical ventilation before extubation for one hour with sedation
223859779|NCT06369090|DEVICE|Electrical impedance tomography (EIT)|Non-invasive, radiation-free bedside lung monitoring using small alternating currents with no known side effects.
223859780|NCT06031350|DIAGNOSTIC_TEST|Optical Coherence Tomography Angiography|Optovue, Inc., Fremont, CA, USA
223859781|NCT02885350|DRUG|Spinal analgesia for labour pain|Intrathecal dose of either fentanyl or sufentanil delivered by combined spinal-epidural technique
223859782|NCT02885350|DRUG|Epidural analgesia for labour pain|Epidural dose of either fentanyl or sufentanil delivered through an epidural catheter.
223859783|NCT05632731|PROCEDURE|double cleavage-stage or single blastocyst stage embryos transfer|Infertile women requesting in vitro fertilization treatment were randomly assigned to undergo transfer of either two cleavage-stage embryos or a single blastocyst-stage embryo.
223859784|NCT02770430|BIOLOGICAL|mesenchymal stem cells|MSCs derived from bone marrow (BM) will be isolated and expanded in the laboratory under conditions of Good Manufacturing Practice. The quality control involves immunophenotyping, differentiation, microbiological control, mycoplasma and endotoxin tests. Patients will receive five infusions of MSC. Dosage: 2x10E6 cells/Kg
223859785|NCT02770430|DRUG|conventional treatment|"1. Basiliximab 20mg dose for adults and 10mg for children, 1 time a week or every 3 days if worsens the stage of GVHD until reaching Very Good Partial Response (VGPR) or for a maximum of 4 doses, whichever comes first.~2. If after the item (1) will not obtained VGPR: Infliximab 5 to 10 mg/kg dose, 1 time a week, four weeks or even VGPR."
223859786|NCT04304859|DIAGNOSTIC_TEST|BASIC|Validation
223859787|NCT01551433|DEVICE|wireless pulse oximeter (Wipox)|In addition to the one Wipox measurement at the planned anastomotic site, the RSA will collect the systemic pulse oximeter reading, blood pressure, and heart rate at the time of the Wipox measurement. These measurements will be obtained as both internal controls of the accuracy of the Wipox (matching the Wipox pulse rate with the patient's), as well as additional variables to control for when assessing factors which might contribute to oxygen saturation at the anastomotic site. Pre-operative demographic information will be collected. This will include age, sex, any co-morbidities (cardiac, diabetes, respiratory), and use of pre-operative chemotherapy or chemo-radiotherapy.
223859788|NCT02398565|OTHER|No intervention|
223859789|NCT01972763|DRUG|Ranibizumab|Ranibizumab is formulated as a sterile solution and will be used in the case of an intervention.
223859790|NCT00361283|DRUG|Atorvastatin|atorvastatin 80mg tablets given by mouth once daily for 16 weeks with follow-up visits every 4 weeks
223859791|NCT04446689|BEHAVIORAL|Biofeedback|This intervention will be measured by the Software Emwave Pro Plus during 4 weeks, which send out a sign captured by a non-invasive sensor such as an ear lobe fixed photoplethysmograph.
223859792|NCT03201614|DEVICE|A-CP HA Kit|Patients randomized in this group will receive two injections of platelet-rich plasma/hyaluronic acid prepared with the A-CP HA Kit at Day 0 and Month 2
223859793|NCT03201614|DEVICE|ArthroVisc 40|Patients randomized in this group will receive two injections of hyaluronic acid only (ArthroVisc 40) at Day 0 and Month 2
223859794|NCT03201614|DRUG|Placebo|Patients randomized in this group will receive two injections of a saline placebo at Day 0 and Month 2
224266505|NCT00128219|BIOLOGICAL|GBS III-TT|50 mcg GBS Type III capsular polysaccharide conjugated to 32 mcg of tetanus toxoid. A single dose of vaccine administered by intramuscular (IM) injection in the upper arm. All subjects will receive a volume of 0.5 ml.
224266506|NCT00128219|BIOLOGICAL|Tetanus and diptheria toxoids vaccine|Td vaccine is a sterile solution of alum-precipitated toxoids in isotonic sodium chloride solution. A single dose of vaccine will be administered by intramuscular (IM) injection in the upper arm. All subjects will receive a volume of 0.5 ml. Each 0.5 ml dose is formulated to contain 5 Lf (flocculation units) of tetanus toxoid and 2 Lf of diphtheria toxoid.
224266507|NCT01188590|DEVICE|TOSCA 500 monitor|transcutaneous ear lobe probe that monitors pulse rate, oxygen saturation and carbon dioxide levels
224266508|NCT04224584|DRUG|Duloxetine|Duloxetine will be administrated with a two weeks up titration followed by a 10 weeks full treatment (60 mg/daily) and finalized by a two weeks discontinuation.
224266509|NCT04224584|DRUG|Placebo oral tablet|Placebo will act as a control for duloxetine.
224266510|NCT05878132|DEVICE|Wearable device -'Smart Reminder'|The wearable device, a wristwatch, has a Bluetooth function to link to mobile devices for the participants to view the prescribed videos and engage in telerehabilitation. It has sensors to monitor arm movements and provides multiple feedbacks (auditory, visual and tactile). Participants were instructed to practice the prescribed exercises -tailored according to the severity of UL paresis for the recommended therapy dose. The device recorded the angles of arm movement and the number of repetitions completed and data collected is uploaded to an encrypted cloud server for remote monitoring. Weekly, the participants will receive a 30-minute consultation session to review their progress and modify prescribed exercises based on the wearable device data.
224266511|NCT05878132|OTHER|Conventional therapy|The participants in the control group received similar in-home upper limb exercises as the wearable device group, with the prescribed exercises presented in the form of a pictorial handout rather than an in-app video. They were instructed to perform the exercises for the recommended therapy dose and received a weekly therapy consultation as well. To monitor the participant's exercise compliance, they were instructed to record their daily exercise progress in the exercise log.
224266512|NCT04885751|DRUG|Eupatilin|take eupatilin to prevent NSAID induced gastroenteropathy
224266513|NCT04885751|DRUG|Rebamipide|take rebamipide to prevent NSAID induced gastroenteropathy
224266514|NCT03968328|OTHER|Interview|Take part in interview
224266515|NCT03968328|OTHER|Survey Administration|Respond to survey
224266516|NCT03611387|DEVICE|CASIA 2 OCT|Using CASIA 2 OCT to assess the anterior chamber angle of the eye in the glaucomatous patients withconventional imaging methods
224266517|NCT04341883|DRUG|anti-PD-1+Albumin-Bound Paclitaxel|"anti-PD-1: 200mg/3w+Albumin-bound paclitaxel: 260 mg/m2/3w.Albumin-bound paclitaxel may be used for up to 6 cycles, and anti-PD-1 for up to 2 years.~Other Name: Programmed cell death 1 antibody"
224266518|NCT04039022|DRUG|AXS-05 (dextromethorphan and bupropion) oral tablets|Oral tablets, taken twice daily for up to 12 months.
224266519|NCT01020825|DRUG|ASCs|Intralesional injection of adult-stem-cells at a dose of 20 and 40 million.
224266520|NCT01020825|DRUG|Fibrin glue|After curettage, the fistulous tract was sealed with fibrin glue.
224266521|NCT01020825|DRUG|ASCs|Intralesional injection of adult-stem-cells at a dose of 20 and 40 million in combination with fibrin glue.
224266522|NCT02986139|DRUG|Commercial Formulation Etanercept|Etanercept was supplied in a single-use SureClick autoinjector as a sterile, preservative-free solution for SC injection containing 0.98 mL of 50 mg/mL etanercept in the commercial formulation.
224266523|NCT02986139|DRUG|New Formulation Etanercept|Etanercept was supplied in a single-use SureClick autoinjector as a sterile, preservative-free solution for SC injection containing 0.98 mL of 50 mg/mL etanercept in the new formulation.
224266524|NCT02235558|DRUG|Verapamil|Super-selective intra-arterial administration of 10mg verapamil in 20cc of normal saline will be administered over 20 minutes (1cc/minute) through the microcatheter and into the vessel previously obstructed by clot, immediately following successful intra-arterial thrombolysis. Half-life is 2.8-7.4 hrs.
224266525|NCT05474651|OTHER|Questionnaires set|Participants will be asked to respond to the demographic information sheet, characteristics of smoking sheet, the Fagerstrom Test of Nicotine Dependence,Smoking Self-efficacy Questionnaire, Cigarette Withdrawal Scale, smoking hazard questionnaire, motivation to quit smoking sheet, ability to quit smoking sheet, alcohol consumption, International Physical Activity Questionnaire.
224266526|NCT00414726|DRUG|NBO (Normobaric Oxygen)|High-flow oxygen delivered via a facemask. A total of 240 individuals with acute ischemic stroke will be randomized 1:1 to receive either room air or oxygen administered at 30-45 L/min via a simple facemask for 8 hours.
224266527|NCT00414726|DRUG|Room Air|Room Air delivered via a facemask. A total of 240 individuals with acute ischemic stroke will be randomized 1:1 to receive either room air or oxygen administered at 30-45 L/min via a simple facemask for 8 hours.
224266528|NCT05492292|DIAGNOSTIC_TEST|Perfusion brain scintigraphy imaging|The cerebral perfusion scintigraphy via a SPECT examination aims to analyze the cerebral blood flow and detect possible lesions or inflammations.
224266529|NCT02107196|DRUG|Ibodutant 10 mg|Oral tablet, to be given once daily.
224266530|NCT02107196|DRUG|Placebo|Oral tablet, (identical in appearance and weight to ibodutant tablets), to be given once daily.
224266531|NCT00136448|DRUG|cytosine arabinoside (ara-C)|
224266532|NCT00136448|DRUG|daunomycin|
224266533|NCT00136448|DRUG|interleukin-2|
224266534|NCT03647917|BIOLOGICAL|Platelet Rich Plasma|"Autologous Platelet Rich Plasma (PRP) will be isolated from the blood collected from each subject at each treatment time point.~Face: Using a 30 gage needle, about four points of PRP or saline will be injected into the malar area; about six points will be injected into the mandibular area; and seven points will be injected into the forehead (0.2 mL per point) with a total volume of approximately 3.5 mL. PRP and saline application will be followed by microneedling.~Hands: Using a 30 gage needle about 1 cc of PRP or saline will be injected into the dorsal area of the hands (0.2mL per point) at five points. No microneedling will be performed on the hands."
223859795|NCT05931107|OTHER|Stress ball practice group (Stress ball squeezing)|The stress ball is made of round, colorful, high-quality silicone. A stress ball of medium hardness and 6 cm in diameter (suitable for adult use) will be used in the research. When it is loosened, it returns to its original state. In the experimental group, the patients are required to squeeze the ball once after counting to three, inhale each time they squeeze the ball, exhale when they loosen their grip, and focus only on the ball. The experimental group has to squeeze the stress ball for 10-15 minutes every day for 4 weeks.
223859796|NCT03234816|DRUG|Norepinephrine 0.05 mcg /Kg/min|Norepinephrine infusion by rate of 0.05 mcg /Kg/min after spinal anesthesia
223859797|NCT03234816|DRUG|Norepinephrine 0.1 mcg /Kg/min|Norepinephrine infusion by rate of 0.05 mcg /Kg/min after spinal anesthesia
223859798|NCT03234816|DRUG|Norepinephrine 0.15 mcg /Kg/min|Norepinephrine infusion by rate of 0.05 mcg /Kg/min after spinal anesthesia
223859799|NCT03234816|DRUG|Bupivacaine|10 mg Bupivacaine intra-thecal for spinal anesthesia
223859800|NCT01070056|BEHAVIORAL|Therapeutic Lifestyle Changes (MINT-TLC)|This intervention is based on established clinical practice guidelines for prevention and treatment of hypertension(HTN), which recommends weight loss (if overweight), limiting sodium and alcohol intake, regular physical activity, reducing alcohol intake, and eating a low-fat diet that is rich in fruit and vegetables. MINT-TLC will be conducted by trained research personnel. Patients will attend 10 classes over 12 weeks (intensive phase) followed by individual monthly MINT sessions for 3 months (maintenance phase). We chose the intervention schedules to pattern after the methodology of therapeutic lifestyle interventions with proven efficacy in hypertensive patients, specifically, Trial of Nonpharmacologic Approaches in Elderly Hypertensives (TONE) and PREMIER trials.
223859801|NCT01070056|BEHAVIORAL|Usual Care|Patients randomized to the Usual Care (UC) condition will receive standard hypertension (HTN) treatment recommendations as determined by their physicians. In addition, they will receive a 30-minute individual counseling session on therapeutic lifestyle modification, similar to PREMIER. We feel obligated ethically to provide this minimal intervention to patients in the UC group given that counseling on TLC is a standard recommendation for treatment of hypertension. To match the MINT-TLC group for content of intervention material, those in the UC group will receive print versions of the intervention materials.
223859802|NCT03007589|DRUG|otc sunscreens|Sunscreens of various SPF levels and ingredients
223859803|NCT03007589|OTHER|sun protection fabrics|fabrics
223859804|NCT03007589|OTHER|Optical Filters|Optical band pass or long pass filters or surfaces/mirrors used in solar simulators
223859805|NCT03849716|OTHER|Blood sample|Blood samples obtained for biomarker analyses
223859806|NCT03849716|OTHER|Cheek swab|Cheek swab obtained for genetic analysis
223859807|NCT04482894|OTHER|Palliative Care Visits|Regular visits with a palliative (supportive) care specialist
223859808|NCT03729011|DRUG|Volatile agent|Patients will receive volatile agent to provide general anaesthesia, including CPB period. Volatile agents will be administered from anesthesia induction to the end of surgery. Concentration (MAC) of volatile agent will be selected by anaesthesiologist according to clinical situation and patient features.
223859809|NCT03729011|DRUG|Propofol|Patients will receive propofol and no volatile agent. Propofol will be used for induction and maintenance of anesthesia.
223859810|NCT06159127|BEHAVIORAL|SMART@Home|Daily medication and diary completion reminders are provided to participants. Additional educational content regarding self-management skills will be provided.
223859811|NCT05208359|BEHAVIORAL|Supporting Transition Resilience Of Newcomer Groups (STRONG)|10 group sessions that offer skills, strengths, support, and affirmation for newcomer youth
223859812|NCT05147233|DRUG|OCS-01|Dexamethasone ophthalmic suspension, 1.5%
223859813|NCT05147233|DRUG|Vehicle|Vehicle
223859814|NCT04670822|BEHAVIORAL|Breastfeeding promotion|The intervention group will receive multicomponent interventions consisting of 7 half-hour postnatal visits for lactation counseling, family/peer/employer support, contingent financial incentives, and early limited formula milk via syringe (optional for at-risk infants).
223859815|NCT04670822|BEHAVIORAL|Attention placebo control|The attention placebo control group will complete the same frequency and duration of study visits as the intervention group but focus on general infant care counseling and support.
223859816|NCT06154265|DEVICE|TEE probe|Transesophageal echocardiography, ultrasound probe
223859817|NCT04225403|BEHAVIORAL|Telephone-based motivational interviewing for smoking cessation|"The motivational brief intervention is known by the acronym 5 R and lasts about 5-10 minutes. It is an approach based on the principles of motivational interviewing and develops the intervention in five short steps:~* Relevance. Help patients identify why personal reasons may be relevant to quitting smoking.~* Risks. Help identify what negative consequences tobacco use has.~* Rewards. Help identify potential benefits of quitting smoking.~* Resistors. Help patients identify barriers to smoking cessation, which can often include fear of withdrawal symptoms, failure, wainweight, face social situations, etc.~* Repeat. Repeat the intervention at 3 months if you do not advance at the stage of change."
223859818|NCT06953180|OTHER|Genetic: DNA analysis|Investigation of telomere length (TL) and DNA methylation level analysis
223859819|NCT06789367|DRUG|perineural Dexamethasone 4mg|PENG block with 20ml 0.2% ropivacaine + 4mg perineural Dexamethasone
223859820|NCT06789367|DRUG|intravenous Dexamethsone 4mg|PENG block with 20ml 0.2% ropivacaine + 4mg intravenous Dexamethasone
223859821|NCT06434389|DIAGNOSTIC_TEST|the Electrochemical-based device|Electrochemical-based device for rapid detection of fibrinogen is a novel POC diagnostic method, which is suitable for operating theatres and emergency rooms.
223859822|NCT04517864|DRUG|PF-06651600|50 mg tablet, dosed as 200 mg QD or 50 mg QD 50 mg capsule, dosed as 50 mg QD
223859823|NCT04517864|DRUG|Placebo|tablet, dosed as 4 tablets QD or 1 tablet QD
223859824|NCT04662710|BIOLOGICAL|Pembrolizumab|400 mg Q6W by IV infusion
223859825|NCT04662710|BIOLOGICAL|Lenvatinib|Administered PO QD, 8 mg induction/20 mg consolidation.
223859826|NCT04662710|DRUG|Oxaliplatin|130 mg/m\^2 administered by IV infusion on Day 1 of Weeks 1 and 4 of each Q6W cycle as part of CAPOX chemotherapy, or 85 mg/m\^2 administered by IV infusion on Day 1 and Week 1, 3 and 5 of each Q6W cycle as part of mFOLFOX6 chemotherapy.
223859827|NCT04662710|DRUG|Capecitabine|1000 mg/m\^2 administered PO twice daily (BID) on Days 1-14, 22-35 of each Q6W cycle as part of CAPOX chemotherapy.
223859828|NCT04662710|DRUG|Leucovorin (or Levoleucovorin)|Administered by IV infusion at 400 mg/m\^2 (leucovorin) or 200 mg/m\^2 (levoleucovorin) on Day 1, and Week 1, 3 and 5 of each Q6W cycle as part of mFOLFOX6 chemotherapy.
223859829|NCT04662710|DRUG|5-FU|400 mg/m\^2 bolus IV infusion followed by 2400 mg/m\^2 continuous IV infusion administered on Day 1, and Week 1, 3, 5, of each Q2W cycle as part of mFOLFOX6 chemotherapy.
223859830|NCT02201043|DRUG|Thalidomide 150mg|
223859831|NCT02201043|DRUG|Thalidomide 100mg|
223859832|NCT02201043|DRUG|Placebo|
223859833|NCT06013514|DEVICE|PERLE Sterile Smooth Opaque gel filled mammary implants|Sterile smooth opaque gel filled mammary implants will be implanted in adult women having breast surgery for either augmentation, reconstruction or revision surgery. Different ranges of implants will be used to suit patient needs
223859834|NCT04722003|BIOLOGICAL|Meningococcal Group B Vaccine|A combination vaccine consisting of recombinant proteins Neisserial adhesin A (NadA), Neisserial Heparin Binding Antigen (NHBA), and factor H binding protein (fHbp), Outer Membrane Vesicles (OMV), aluminum hydroxide, sodium chloride, histidine, and sucrose.
223859835|NCT04722003|OTHER|Placebo|0.9% Sodium Chloride, USP injection.
223859836|NCT05260359|DRUG|6% Bemotrizinol (BEMT) in a basic sunscreen oil formulation|SU E 101413 85
223859837|NCT05260359|DRUG|6% Bemotrizinol (BEMT) dispersion in petrolatum|SU-E-101413-82
223859838|NCT05260359|OTHER|Sunscreen oil vehicle with 10% ethanol as penetration enhancer without BEMT|SU E 101413 91
223859839|NCT05260359|OTHER|Petrolatum vehicle|SU-E-101413-83
223859840|NCT05260359|OTHER|0.9% Saline|low irritancy control
223859841|NCT05260359|OTHER|Sodium Lauryl Sulfate 0.1% (SLS)|positive control
223859842|NCT05260359|OTHER|Undosed patch|negative control
223859843|NCT03255928|DIAGNOSTIC_TEST|PAS assay, TGT|Evaluation of platelet function
223859844|NCT05583526|DRUG|Ritlecitinib|50 mg capsule
223859845|NCT05583526|DRUG|Placebo|Matching capsule
223859846|NCT02703623|DRUG|Abiraterone Acetate|Given PO
223859847|NCT02703623|DRUG|Apalutamide|Given PO
223859848|NCT02703623|DRUG|Cabazitaxel|Given IV
223859849|NCT02703623|DRUG|Carboplatin|Given IV
223859850|NCT02703623|BIOLOGICAL|Ipilimumab|Given IV
223859851|NCT02703623|OTHER|Laboratory Biomarker Analysis|Correlative studies
223859852|NCT02703623|DRUG|Prednisone|Given PO
223859853|NCT04246177|DRUG|Lenvatinib|Administered at a dose of 12 mg (for participants with screening body weight ≥60 kg) or 8 mg (for participants with screening body weight \<60 kg) via oral capsules once a day during each 21-day cycle.
223859854|NCT04246177|BIOLOGICAL|Pembrolizumab|Administered via IV infusion at a dose of 400 mg once every 6 weeks (Q6W).
223859855|NCT04246177|DRUG|Oral Placebo|Lenvatinib-matching placebo administered via oral capsules once a day during each 21-day cycle.
223859856|NCT04246177|DRUG|IV Placebo|Pembrolizumab-matching placebo administered via IV infusion once every 6 weeks (Q6W).
223859857|NCT04246177|PROCEDURE|TACE|Conducted as a background procedure of chemotherapeutic and embolic agent(s).
223859858|NCT01416558|DRUG|Nab-Paclitaxel|"Nab-Paclitaxel 125 mg/m2 i.v. over 30 min. weekly in 5 out of 6 weeks~Given until progression, unacceptable toxicity, patient's request or withdrawal from Study"
223859859|NCT00092014|DRUG|Alendronate|Alendronate sodium, 70 mg, once weekly for up to 24 months. Medications were taken fasting which was maintained for 30 minutes postdose.
223859860|NCT00092014|DRUG|Risedronate 35 mg|Risendronate, 35 mg, once weekly for up to 24 months. Medications were taken fasting which was maintained for 30 minutes postdose.
223859861|NCT00092014|DIETARY_SUPPLEMENT|Elemental Calcium|Elemental calcium at least 1,000 mg daily (diet plus supplements). Medications were taken fasting which was maintained for 30 minutes postdose.
223859862|NCT00092014|DIETARY_SUPPLEMENT|Vitamin D|Vitamin D at least 400 international units daily (diet plus supplements). Medications were taken fasting which was maintained for 30 minutes postdose.
223859863|NCT00092014|DRUG|Risendronate placebo|Risendronate placebo was taken once weekly for up to 24 months. Medications were taken fasting which was maintained for 30 minutes postdose.
223859864|NCT00092014|DRUG|Alendronate placebo|Alendronate placebo was taken once weekly for up to 24 months. Medications were taken fasting which was maintained for 30 minutes postdose.
223859865|NCT02126878|DRUG|Kenalog|
223859866|NCT05242653|PROCEDURE|pressure by a cotton swab|All patients undergo uneventful phacoemulsification by a 2.2 mm temporal transparent corneal incision using Centurion Vision System (Alcon Laboratories, Fort Worth, TX, USA). After the nucleus and cortex are removed, IOL is implanted in the capsular bag. Finally, the clear corneal incision is closed with pressure by a cotton swab.
223859867|NCT05242653|PROCEDURE|stromal hydration with the balanced salt solution（BSS）|All patients undergo uneventful phacoemulsification by a 2.2 mm temporal transparent corneal incision using Centurion Vision System (Alcon Laboratories, Fort Worth, TX, USA). After the nucleus and cortex are removed, IOL is implanted in the capsular bag. Finally, the clear corneal incision is closed with stromal hydration.
223859868|NCT05215925|DRUG|HLX07+carboplatin+pemetrexed|HLX07 1500mg q3w+carboplatin+pemetrexed
223859869|NCT05215925|DRUG|HLX07+docetaxel|HLX07 1500mg q3w+docetaxel
223859870|NCT05215925|DRUG|HLX07|HLX07 1500mg q3w
223859871|NCT02515838|DRUG|Sevuparin|The Drug Product sevuparin solution for IV infusion
223859872|NCT02515838|OTHER|Placebo|Placebo for IV infusion
223859873|NCT05013606|DIETARY_SUPPLEMENT|Hydrogen water|This is an over the counter pill supplement that is dissolved in water.
223859874|NCT05250336|OTHER|Observational Study|Assessment of Prognostic and Predictive value of Tumor-Infiltrating Lymphocytes and Programmed cell Death - Ligand 1 in Breast cancer
223859875|NCT06030713|DRUG|Cefazolin|Cord clamping before or after antibiotic (cefazolin) prophylaxis
223859876|NCT03556137|DRUG|[18F]FTC-146|Adult participants will be injected with 5-10 mCi of \[18F\]FTC-146 and undergo a PET/MRI scan.
223859877|NCT02845063|BEHAVIORAL|concentric cardiovascular training|Subjects will carry out 8 weeks of cardiovascular training by an interval type of protocol that includes a high repetition number of concentric type contractions on a softrobotic device.
223859878|NCT02845063|BEHAVIORAL|eccentric cardiovascular training|Subjects will carry out 8 weeks of cardiovascular training by an interval type of protocol that includes a high repetition number of eccentric type contractions on a softrobotic device.
223859879|NCT02845063|GENETIC|ACE genotyping|Subjects will be genotyped for the ACE-I/D gene polymorphism.
223859880|NCT01773980|OTHER|Clinic Intervention|The Clinic intervention consists of an educational video, an interactive meeting with clinicians and clinic staff, and a facilitated follow-up meeting with clinic staff.
223859881|NCT01773980|OTHER|Patient Intervention|The patient intervention consists of a single 90-minute interactive in-person session.
223859882|NCT05339763|RADIATION|chemoradiotherapy|exposure of patients with rectal cancer to radiotherapy and assessment of their bowel function after surgery
223859883|NCT04847219|DEVICE|Professional flash glucose mornitoring|Subjects will use Professional flash glucose mornitoring once a month for 3 months.
223859884|NCT04847219|DEVICE|Personal flash glucose mornitoring|Subjects will use Personal flash glucose mornitoring once a month for 3 months.
223859885|NCT03703219|OTHER|Mothers Touch Program|Combination of diet, massage, body binding methods along with 40 days of rest following the traditional way of delivering
223859886|NCT04707430|OTHER|blood progesterone test|progesterone levels on blood sample
223859887|NCT02108106|DRUG|AG-348|A range of doses of AG-348 will be tested based on assessment of safety and tolerability.
223859888|NCT02108106|DRUG|Placebo|
223859889|NCT04860258|BIOLOGICAL|CVnCoV Vaccine|Intramuscular (IM) injection in the deltoid area, preferably in the non-dominant arm.
223859890|NCT00001637|PROCEDURE|Blood cell transplantation|
223859891|NCT02607384|BEHAVIORAL|Eyeglass wearing|Children found to require eyeglasses will be given two pairs free of charge
223859892|NCT02607384|BEHAVIORAL|Orthoptic exercises|Children found to have convergence insufficiency will be prescribed orthoptic exercises
223859893|NCT02607384|OTHER|Specialist referral|Children found to any other eye condition will be referred to a pediatric eye care specialist
223859894|NCT02416076|DEVICE|Ulthera Treatment at EL2|Focused ultrasound energy delivered below the surface of the skin.
223859895|NCT02416076|DEVICE|Ulthera Treatment at EL4|Focused ultrasound energy delivered below the surface of the skin.
223859896|NCT00014248|DRUG|adenosine triphosphate|
223859897|NCT00014248|PROCEDURE|quality-of-life assessment|
223859898|NCT04947072|PROCEDURE|Erector Spinae Plane Block|The block will be performed at the level of T9 on the site that will be operated and patient will be given Bupivacaine isobaric 0.5% 25 ml with epinephrine 1:200.000
223859899|NCT04947072|PROCEDURE|Spinal anesthesia|Patient will be given bupivacaine hyperbaric 0.5% 16-18 mg at the level of L3-L4 or L4-L5
223859900|NCT01750307|DIETARY_SUPPLEMENT|Experimental fatty acid supplementation|4 x capsules per day. Daily dose: 1584mg EFA
223859901|NCT01750307|DIETARY_SUPPLEMENT|Placebo comparator: MCT oil softgel|4 x capsules per day. Medium chain triglyceride pill manufactured to mimic essential fatty acid pill
223859902|NCT03336424|DIAGNOSTIC_TEST|Non-invasive investigations|Ultrasound, blood tests, urine analysis and culture, uroflowmetry
223859903|NCT03336424|DIAGNOSTIC_TEST|Invasive investigations|Cystomanometry, pressure flow study, EMG
223859904|NCT05731466|DEVICE|CardioMems HF System|"1. Implantation CardioMems device.~2. Evaluation of right ventricular-arterial coupling during exercise using a hybrid technique of real-time CMR-derived volume measures and CardioMems-derived pulmonary artery pressure measurements."
223859905|NCT01976936|DRUG|Low Dose Lovastatin|80 mg daily for 3 days
223859906|NCT01976936|OTHER|Placebo|Placebo for 3 days
223859907|NCT01976936|DRUG|High Dose Lovastatin|640 mg daily for 3 days
223859908|NCT00357396|BIOLOGICAL|graft versus host disease prophylaxis/therapy|
223859909|NCT00357396|DRUG|busulfan|
223859910|NCT00357396|DRUG|melphalan|
223859911|NCT00357396|DRUG|thiotepa|
223859912|NCT00357396|PROCEDURE|allogeneic bone marrow transplantation|
223859913|NCT00357396|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
223859914|NCT00357396|PROCEDURE|peripheral blood stem cell transplantation|
223859915|NCT02496702|DEVICE|Training on Interactive Modulare Tiles|Training with the Interactive Modulare Tiles
223859916|NCT00552097|DRUG|ezetimibe (plus simvastatin)|oral tablets; ezetimibe 10 mg (plus simvastatin 80 mg) once daily for 24 months
223859917|NCT00552097|DRUG|placebo (plus simvastatin)|tablets; placebo to match ezetimibe 10 mg (plus simvastatin 80 mg) once daily for 24 months
223859918|NCT03565939|BIOLOGICAL|Trichuris suis ova|Eggs from the pig whipworm
223859919|NCT03565939|BIOLOGICAL|Placebo|Solution without TSO
223859920|NCT02042898|OTHER|Restrictive Transfusion Strategy|
223859921|NCT02042898|OTHER|Liberal transfusion strategy|
223859922|NCT01517347|DRUG|Interleukin-2|Patients receive low dose interleukin-2(Daily 1×106 IU per square meter of body-surface area) on days 60 after unmanipulated blood and marrow transplantation. Interleukin-2 treatment repeats every 14 days for 6 courses in the absence of disease progression or unacceptable toxicity.
223859923|NCT01199783|DRUG|Daptomycin|Infusion (6 mg/kg/bodyweight) once daily
223859924|NCT01199783|DRUG|Vancomycin|vancomycin once daily (effective blood-plasma concentration of 15 mg/L)
223859925|NCT05967338|DEVICE|using McGrath Video Laryngoscope|glottis visualization in indirect and direct lifting methods by using McGrath Video Laryngoscope
223859926|NCT00649935|DRUG|Azithromycin Tablets 600 mg|600mg, single dose fed
223859927|NCT00649935|DRUG|Zithromax® Tablets 600 mg|600mg, single dose fed
223859928|NCT00391846|DRUG|Captopril|
223859929|NCT00391846|DRUG|Enalapril|
223859930|NCT00391846|DRUG|Lisinopril|
223859931|NCT00391846|DRUG|Ramipril|
223859932|NCT00391846|DRUG|Trandolapril|
223859933|NCT00391846|DRUG|Bisoprolol|
223859934|NCT00391846|DRUG|Carvedilol|
223859935|NCT00391846|DRUG|Metoprolol succinate|
223859936|NCT00391846|DRUG|Candesartan|
223859937|NCT00391846|DRUG|Valsartan|
223859938|NCT00391846|DRUG|Eplerenone|
223859939|NCT00391846|DRUG|Spironolactone|
223859940|NCT00391846|DRUG|Diuretics|
223859941|NCT00391846|DRUG|HF treatment according to Swedish guidelines|
223859942|NCT00391846|PROCEDURE|Blood samples|
223859943|NCT00391846|PROCEDURE|The Kansas City Cardiomyopathy Questionnaire (KCCQ)|
223859944|NCT04040530|PROCEDURE|CT-guided cryoablation|Percutaneous computed tomography guided cryoablation with the patient in sedation or general anaesthesia.
223859945|NCT04040530|PROCEDURE|Partial nephrectomy|Surgical removal of the renal cancer, leaving the healthy renal tissue. Surgery is either done laparoscopically, robot-assisted laparoscopically or as an open surgery. The patient is under general anaesthesia.
223859946|NCT01086917|BIOLOGICAL|PfSPZ Challenge|each volunteer to receive a single dose
223859947|NCT00212745|BEHAVIORAL|Andrews/Reiter behavioral treatment for epilepsy|The behavioral intervention in this study uses lifestyle counseling to avoid triggers for seizures and strategies to stop beginning seizures. Participants are taught to practice meditative relaxation exercises.
223859948|NCT00184041|DRUG|Daunorubicin, Vincristine, Prednisone, Methotrexate, PEG-Asparaginase, 6-Mercaptopurine, Cytoxan, Cytosine Arabinoside, VM-26 and 6-Thioguanine|Induction I/II, consolidation I/II/III/IV and Maintenance
223859949|NCT01227278|OTHER|Placebo|Placebo matched to benralizumab (MEDI-563) injection subcutaneously every 4 weeks for the first 3 doses and then every 8 weeks for the next 5 doses (Day 1, 29, 57, 113, 169, 225, 281 and 337).
223859950|NCT01227278|BIOLOGICAL|Benralizumab 100 mg|Benralizumab (MEDI-563) 100 mg injection subcutaneously every 4 weeks for the first 3 doses and then every 8 weeks for the next 5 doses (Day 1, 29, 57, 113, 169, 225, 281 and 337).
223859951|NCT04035668|DRUG|Remibrutinib|Remibrutinib 100 mg was administered orally as two 50 mg hard gelatin capsules. Patients in the remibrutinib 100 mg bid dose group took 2 capsules of active medication in the morning and 2 capsules of active medication in the evening. Patients in the remibrutinib 100 mg qd dose group took 2 capsules of active medication in the morning and 2 capsules of the placebo in the evening.
223859952|NCT04035668|DRUG|Placebo|Placebo was administered orally as two hard gelatin capsules. Patients in the placebo dose group took 2 capsules of placebo in the morning and 2 capsules of placebo in the evening.
223859953|NCT05516004|DEVICE|PXL Platinum 330 system|to determine the efficacy of riboflavin solution and UV light to treat cornea thinning conditions
223859954|NCT05673252|DIAGNOSTIC_TEST|Venous blood sample|Blood chemistry tests: neutrophil;lymphocyte; monocyte; platelet counts
223859955|NCT05673252|PROCEDURE|biopsy|histopathology findings
223859956|NCT02320123|BEHAVIORAL|Educational DVD|African American patients and their primary non-professional caregivers will watch a DVD created to introduce end-of-life care planning to African Americans receiving palliative care.
223859957|NCT04675944|DRUG|BIA 5-1058|200 mg (2 x 100 mg tablets), oral route
223859958|NCT04675944|DRUG|treprostinil|1 mg (1 extended-release tablet), oral route
223859959|NCT00422617|DRUG|Alefacept (Amevive)|
224266535|NCT03647917|BIOLOGICAL|Platelet Rich Plasma|"Autologous Platelet Rich Plasma (PRP) will be isolated from the blood collected from each subject at each treatment time point.~Face: Using a 30 gage needle, about four points of PRP or saline will be injected into the malar area; about six points will be injected into the mandibular area; and seven points will be injected into the forehead (0.2 mL per point) with a total volume of approximately 3.5 mL. PRP and saline application will be followed by microneedling.~Hands: Using a 30 gage needle about 1 cc of PRP or saline will be injected into the dorsal area of the hands (0.2mL per point) at five points. No microneedling will be performed on the hands."
223859960|NCT04666506|OTHER|Virtual reality|"The VR intervention, Relaxation-VR, is a VR application developed by Psylaris aiming to reduce anxiety/stress and pain by distracting the patient in a relaxing environment. Relaxation-VR will be administered via a commercially available VR headset (Oculus Go). The VR headset is a piece of equipment that a person wears over their eyes that allows them to experience images and sounds produced by a computer as if they were part of real life (Cambridge Dictionary, 2020). As such, the patient is immersed in a novel, calming and distracting environment where the he/she is asked to perform tasks that will help the patients to relax when distressed before and/or during a medical procedure or during their stay in hospital.~The Relaxation-VR application consists of three modules: two modules make use of relaxation principles (i.e. breathing exercises, meditation) and one module presents a scene with different interactive animations and objects (i.e. popping bubbles, playing fetch with a dog)."
223859961|NCT06552663|DEVICE|CCTA|Coronary CT angiography
224266536|NCT04000945|DEVICE|BTL-899|Treatment with BTL-899 device, 3 therapies
224266537|NCT04000945|DEVICE|Sham|Sham treatment with BTL-899 device, 3 visits
224266538|NCT00516295|DRUG|topotecan hydrochloride|Given IV
224266539|NCT00516295|DRUG|vincristine sulfate|Given IV
224266540|NCT00516295|DRUG|cyclophosphamide|Given IV
224266541|NCT00516295|BIOLOGICAL|bevacizumab|Given IV
224266542|NCT05475548|DEVICE|powerscope|The PowerScope is the latest innovation in the treatment of Class II malocclusion which is a direct derivative of the Herbst Type II appliance. Dr. Andy Hayes worked in conjunction with American Orthodontics to develop PowerScope in 2016. This appliance supports intermaxillary wire-to-wire installation via a nut and hexagonal screw. A ball and socket joint is used to maximize lateral movement while improving patient comfort. The appliance is made up of a telescopic mechanism made up of an inner shaft/push rod, middle and outer tubing, and a spacer between the middle and outer tubing. A nickel-titanium (NiTi) spring provides a constant 260 g force. According to the present knowledge no studies regarding treatment outcomes of comprehensive fixed appliance treatment combined with the PowerScope in Class ΙII patients have been reported
224266543|NCT03622229|DIAGNOSTIC_TEST|Histologic evaluation|Samples collected by EUS-FNB without ROSE will be processed as histologic samples
224266544|NCT05270044|DRUG|Encorafenib and Binimetinib|Encorafenib 450 mg (6 × 75 mg capsules) once daily (QD) and binimetinib 45 mg (3 x 15 mg tablets) twice daily (BID) orally for a maximum of 12 months.
224266545|NCT05270044|DRUG|Placebo to match Encorafenib ; Placebo to match Binimetinib|Encorafenib (6 × 75 mg placebo capsules) QD and binimetinib (3 × 15 mg placebo tablets) BID placebos orally for a maximum of 12 months.
224266546|NCT00686868|OTHER|placebo|placebo
224266547|NCT00686868|DRUG|ofatumumab|fully human anti-CD20 monoclonal antibody
224266548|NCT03318289|BEHAVIORAL|Ving Tsun|The VT training regimen is designed to improve reactive balance control, lower extremity muscle strength and balance confidence in the elderly. It comprises 9 VT sticking-hand drills that must be practised with a partner. Participants will be trained to respond rapidly to upper body perturbations and to maintain body balance. Those joined the VT training group will attend a one-hour supervised VT training session at an elderly community centre 2 times per week for 12 weeks.
224266549|NCT05434091|DRUG|PF-07291177|PF-07291177 will be prepared as an oral solution and/or suspension given in escalating single doses to be determined
224266550|NCT05434091|DRUG|Placebo|Matching placebo will be prepared as an oral solution and/or suspension given in each cohort
224266551|NCT05436626|PROCEDURE|Early BDI reconstruction without abdominal sepsis control|BDI reconstruction within 6 weeks after the injury without abdominal sepsis control
224266552|NCT05436626|PROCEDURE|Early BDI reconstruction with abdominal sepsis control|BDI reconstruction within 6 weeks after the injury with abdominal sepsis control
224266553|NCT05436626|PROCEDURE|Delayed reconstruction|BDI reconstruction after 6 weeks after the injury
224266554|NCT05963269|OTHER|Computer assisted intramuscular learning game|It is an educational game that can only be opened from the computer, with questions and answers and cases. The game is currently under development by the developers. The researcher will be able to see how many times the students entered the game and how many points they got.
224266555|NCT04956289|DRUG|Viltolarsen|Received during weekly intravenous infusions
224266556|NCT02579226|DRUG|AZD2811|The study will be conducted in 2 parts, dose-escalation (A) and dose-expansion (B). All patients in both parts of the study with receive AZD2811.
224266557|NCT05397977|DEVICE|mechanical traction group|"In the mechanical traction group, 26 people with cervicogenic headache will be traction with the Chattanooga Tru Trac traction device, 6 days a week for 2 weeks.~Persons to be mechanically traction will be placed on their backs on the treatment bed with their necks on the neck collar of the device. After the patients are fixed to the head, the pulling force of the device will start with 10% of the patient's body weight, the device will be set as 60 seconds of pulling force and 20 seconds of relaxation. In subsequent sessions, the pulling force will be gradually adjusted based on the patient's previous traction therapy, tolerance, and symptom response. Each session will take 15 minutes.~Participants will be given 20 minutes of TENS, 20 minutes of hotpack and 4 minutes of ultrasound, and the exercise will be given as a home program."
224266558|NCT05397977|OTHER|manuel traction group|"Manual traction, one of Cyriax's neck mobilization techniques, will be applied to the MTG. Vertebrobasilar artery test will be applied to the patients before starting the treatment, and manual traction will be applied to the patients in case the vertebrobasilar artery test is negative. Manual traction technique will be applied to the cervical region for 15 minutes. While applying manual traction, the patient will be placed on his back with his head hanging off the bed. Grasp the occiput with one hand and under the chin with the other. Manual traction will be applied by keeping the neck neutral and the occiput slightly extended. After applying traction for a few seconds, it will be slowly released and returned to the starting position, and the application will be made for 15 minutes.~20 minutes of TENS, 20 minutes of hotpack and 4 minutes of ultrasound will be applied to the participants, and the exercise will be given as a home program."
224266559|NCT01626339|DRUG|Intravitreal Ranibizumab|
224266560|NCT01626339|DRUG|Intravitreal bevacizumab|
224266561|NCT03007706|PROCEDURE|Women undergo cesarean section delivery|
223859962|NCT05756335|BEHAVIORAL|(Un)predictable and (un)attended stimuli|Subjects will complete four task conditions in each scan session: (1) Visual Unpredictable, (2) Visual Predictable, (3) Auditory Unpredictable, and (4) Auditory Predictable. In visual and auditory conditions subjects attend to visual or auditory stimuli and ignore the other domain, pressing a button when they detect an infrequently occurring stimulus inversion in the target domain. In unpredictable and predictable conditions, the attended domain either presents random (unpredictable) stimuli, or the same face or word stimuli repeated (predictable).
223859963|NCT01521013|BEHAVIORAL|Supported self-care|"Subjects will receive a package of depression self-care materials, to include the Antidepressant Skills Workbook, a mood monitoring tool, an informational video on depression, information for family members, and information on additional resources (reading materials, internet sites, community groups).~Subjects will be contacted (by telephone) by their coach, initially at weekly intervals. The frequency of calls will thereafter be mutually determined by subject and coach, but will not exceed weekly calls during the first 3 months, or monthly calls from months 3 to 6. Calls will last an average of 10 minutes. The coach will follow a script to educate/ motivate/guide the subject in the use of the Workbook."
223859964|NCT01521013|BEHAVIORAL|Unsupported self-care|Subjects will receive a package of depression self-care materials, to include the Antidepressant Skills Workbook, a mood monitoring tool, an informational video on depression, information for family members, and information on additional resources (reading materials, internet sites, community groups).
223859965|NCT00005137|OTHER|exercise program|subjects were measured before and after a 20-week long on-site exercise training program
223859966|NCT04369495|OTHER|BAFF serum levels|BAFF levels in serum in visit 0,1,2 during induction therapy
223859967|NCT02278393|OTHER|1-Fermented Dairy Product with Phytosterols (test)|1- 3 bottles of test product/day
223859968|NCT02278393|OTHER|2-Fermented dairy Product with No Phytosterols (control)|2-3 bottles of control product/day
223859969|NCT04168619|DRUG|Discontinue methotrexate|According to the international guideline, patients with Roenigk grade 3a which indicate methotrexate-induced liver injury may continue methotrexate with a repeat biopsy in 6 months. In patients with Roenigk grades 3b or 4, indicate significant liver fibrosis/cirrhosis, methotrexate should be discontinued.
223859970|NCT04168619|OTHER|Medication depends on clinical judgement|Once discontinued methotrexate, based on subject's clinical condition and prescribe alternative treatment
223859971|NCT05319457|OTHER|The radon app|Participants will be asked to use the radon app.
223859972|NCT05319457|OTHER|Print brochure|Participants will receive print brochures.
224266562|NCT00844350|DRUG|letrozole , oxytocin,hCG,clomiphene citrate|
224266563|NCT03544242|OTHER|Control|A saline infusion will be administered during the pre-isolation and post-isolation phases.
224266564|NCT03544242|DRUG|Pre-Isolation Infusion|A nitrite infusion will be administered during the pre-isolation phase and a saline infusion will be administered during the post-isolation phase.
224266565|NCT03544242|DRUG|Post-Isolation Infusion|A saline infusion will be administered during the pre-isolation phase and a nitrite infusion will be administered during the reperfusion phase.
224266566|NCT06504355|BEHAVIORAL|Training program incorporating video aerobic exercise, action video game and resistive action video game|Participants in the experimental group participated in three 60-minute training sessions each week for 12 weeks. One of the session was group training. The other two session were individual training. In the group training session, the participants participate in the video aerobic exercise; in the individual sessions, the participants play action and resistive action video games: Fitness Boxing 2 and Adventure Ring-Fit. All participants in the experimental group wore a hear rate monitoring watch so that the researchers make sure that medium level of physical activities was achieved in each session.
224266567|NCT01517919|BEHAVIORAL|Peer-Led Self-Management|"The PLSM intervention is designed to improve and sustain participants' self-management and health-related gains associated with type 2 diabetes. The role of peer leaders is to provide support for (1) ongoing self-management efforts (including the 5-step action-planning process), (2) psychosocial and emotional adjustment, and (3) linkage to needed health care resources.~PLSM intervention will consist of three main components provided by the Peer Leaders: weekly self-management support sessions; outreach telephone contacts and inbound telephone call from participants."
224266568|NCT05263713|OTHER|Suture Closure of Linear Wounds|Half of the wound is repaired with running subcuticular sutures and the other half is repaired with running horizontal mattress sutures.
224266569|NCT04146090|OTHER|Low-pressure pneumoperitoneum|Pneumoperitoneum will be maintained in 10 mmHg
224266570|NCT04146090|OTHER|Standard pressure pneumoperitoneum|Pneumoperitoneum will be maintained in 14 mmHg
224266571|NCT00494741|DRUG|mycophenolate mofetil|Patients randomized in this group will receive 750 mg of MMF per os twice a day starting on the day of transplant. MMF dose will be reduced in case of white blood cell count lower than 2,000/mm3 and whenever deemed clinically appropriate.
224266572|NCT00494741|DRUG|azathioprine|Patients randomized in this group will receive 75 mg of AZA per os (or 125 mg if body weight \> 75 kg) once a day starting on the day of transplant. AZA dose will be reduced in case of white blood cell count lower than 2,000/mm3 and whenever deemed clinically appropriate.
224266573|NCT01600313|DIETARY_SUPPLEMENT|rice bran oil|Treatment group received the low - calorie diet with(30g/day) rice bran oil
224266574|NCT01269645|BEHAVIORAL|Clinical Trial educational materials|Usual care and (1) a 10-minute clinical trials educational video; and (2) a 12-page educational booklet to accompany the educational video. Content includes basic information about clinical trials and patient testimonials about the value and benefits of participating in clinical trials. The video also addresses common misperceptions about clinical trials using patient and physician testimonials. After watching the video, participants will be provided a copy of the video for home viewing, along with the educational booklet to be reviewed at home.
224266575|NCT00916045|DRUG|Thiotepa|
224266576|NCT00916045|DRUG|Fludarabine|
224266577|NCT00916045|DRUG|Intravenous busulphan|
224266578|NCT00916045|DRUG|Thymoglobulin|
224266579|NCT00916045|DRUG|Ciclosporin|
224266580|NCT00916045|DRUG|Mycophenolate mofetil (MMF)|
224266581|NCT00916045|DRUG|Fludarabine|
224266582|NCT00916045|DRUG|Cyclophosphamide|
224266583|NCT00916045|RADIATION|Radiotherapy|
224266584|NCT00916045|DRUG|Thymoglobulin|
224266585|NCT00916045|DRUG|Ciclosporin|
224266586|NCT00916045|DRUG|Mycophenolate mofetil (MMF)|
224266587|NCT00916045|DRUG|Fludarabine|
224266588|NCT00916045|DRUG|Melphalan|
224266589|NCT00916045|DRUG|Thymoglobulin|
224266590|NCT00916045|DRUG|Ciclosporin|
224266591|NCT00916045|DRUG|Mycophenolate mofetil (MMF)|
224266592|NCT04133116|DRUG|LY3471851|Administered SC
224266593|NCT04133116|DRUG|Placebo|Administered SC
224266594|NCT01630616|DRUG|Odanacatib|single oral dose, tablets, 10 or 50 mg
224266595|NCT01630616|DRUG|Placebo|single oral dose, tablets
224266596|NCT01156441|PROCEDURE|surgical mitral valve repair w/ mitral valve annuloplasty|"Mitral valve repair will be performed via median sternotomy, utilizing cardiopulmonary bypass and moderate hypothermia. The mitral valve will be approached through a left atrial incision. Following inspection of the valve, mitral valve annuloplasty will be accomplished with a complete semi-rigid annuloplasty ring. Additional techniques to address residual regurgitation will be at the discretion of the surgeon. The left atriotomy will then be closed and the patient weaned off and separated from the cardiopulmonary bypass.~Intraoperative transesophageal echocardiography will be performed on all study volunteers."
224266597|NCT02218541|DEVICE|abutment margin 0.5 mm subgingival|
224266598|NCT02218541|DEVICE|abutment margin 1.5 mm subgingival|
224266599|NCT00425841|DRUG|gemcitabine hydrochloride|
224266600|NCT00425841|DRUG|oxaliplatin|
224266601|NCT00425841|PROCEDURE|adjuvant therapy|
224266602|NCT00425841|PROCEDURE|neoadjuvant therapy|
224266603|NCT00425841|RADIATION|hypofractionated radiation therapy|
224266604|NCT00425841|RADIATION|stereotactic radiosurgery|
223859973|NCT05254769|DEVICE|Neurofeedback Equipment (Cygnet) by BEE Medic GmbH Technologies, Baden-Wurttemberg, Germany.|The EEG NeuroAmp (Electroencephalogram Amplifier) is a user-friendly high-performance interface between client and clinician computer. It can be used in two different functionalities: In an EEG/ERP (Event related potential) measurement and in an EEG biofeedback (neurofeedback) and/or peripheral biofeedback setting.
223859974|NCT00457769|DRUG|Donepezil and self-generated memory training|Aricept 5 mg PO qd for 4 weeks followed by Aricept 10 mg PO qd for 8 weeks
223859975|NCT00457769|DRUG|Donepezil and experimenter-administered memory training|Aricept 5 mg PO daily for 4 weeks followed by Aricept 10 mg PO qd for 8 weeks
223859976|NCT04700930|OTHER|CBD-Cigarettes|CBD-Cigarettes instead of normal Cigarettes: The participants in this arm receive CBD-Cigarettes which are then inhaled/smoked instead of their normal tobacco cigarettes
223859977|NCT03696862|PROCEDURE|free gingival graft|Use of free gingival graft to seal the socket after flapless atraumatic tooth extraction is performed, implant placement and filling the socket with bone graft.
223859978|NCT04310072|DEVICE|Neuromuscular electrical stimulation|NMES therapy induces visible rhythmic and repeated muscle contractions without volitional effort from the patient by applying electrodes to the thigh and/or calf muscles.
223859979|NCT03426228|DIAGNOSTIC_TEST|HbA1C|"After overnight fasting, 10 ml of blood will be collected at four different timings during the IVF protocol:~1. At baseline (second day of the menstrual period)~2. Triggering phase (post-egg retrieval procedure)~3. Embryo transfer phase (post-transfer procedure)~4. Week 4 (positive bHCG)~4\. Week 8 of pregnancy"
223859980|NCT00831272|DRUG|naltrexone|50mg/day
223859981|NCT00831272|DRUG|Placebo|Placebo
223859982|NCT04676984|OTHER|Consultations|The intervention will comprise a series of consultations between the patient and general practitioner (at least three), where the patient and general practitioner will continuously adjust the patient's medication according to the patient's goals, needs, and preferences.
223859983|NCT05245825|OTHER|Flaxseed|A total of 30 g of ground flaxseed per day divided into two portions of 15 grams each, subjects will be asked to take 15 g in the morning and 15 g in the night dissolved in 400 ml of water. They will receive a dietary plan with a distribution of 20-30% of protein, 25-30% of lipids, and 40 to 45% of carbohydrates.
223859984|NCT05245825|OTHER|Dietary plan|Dietary plan with a distribution of 20-30% of protein, 25-30% of lipids, and 40 to 45% of carbohydrates, controlled consumption of alpha-linolenic acid (no more than 6.8 g/day, the amount provided by 30 g of flaxseed).
223859985|NCT00516386|DRUG|RhIGF-1|35-40 mcg/k/dose twice daily SC
223859986|NCT01609517|DRUG|Spinal anesthesia (heavy bupivacaine)|Spinal anesthesia with heavy bupivacaine of 6, 7, 8, 9, 10, 11 mg
223859987|NCT02176538|DRUG|Product 0405|Product 0405 will be administered topically twice daily for 28 days
223859988|NCT02176538|DRUG|Placebo for Product 0405|Placebo for Product 0405 will be administered topically twice daily for 28 days.
223859989|NCT03231722|DRUG|Panitumumab|6 mg/kg iv over 60 minutes, day 1
223859990|NCT03231722|DRUG|Irinotecan|150 mg/sqm iv over 60 minutes day 1
223859991|NCT03231722|DRUG|Oxaliplatin|85 mg/sqm iv over 2 hours day 1
223859992|NCT03231722|DRUG|l-leucovorin|200 mg/sqm iv over 2 hours
223859993|NCT03231722|DRUG|5-fluorouracil|400 mg/sqm iv bolus, day 1 followed by 2400 mg/sqm 48 h-continuous infusion, starting on day 1;
223859994|NCT03789786|DIAGNOSTIC_TEST|Gait and Motion Analysis|Gait and motion analysis is comprised of 3-dimensional kinematics and kinetics, electromyography, energy expenditure, and physical exam (range of motion, strength, spasticity, etc.)
223859995|NCT03789786|DIAGNOSTIC_TEST|Gross Motor Function Measure (GMFM)|Gross Motor Function Measure (GMFM) is an assessment used to evaluate gross motor function over time in individuals with cerebral palsy. The assessment is comprised of movement activities like standing, walking, running, and jumping
223859996|NCT03789786|BEHAVIORAL|Surveys|Six surveys are used to assess function, activity, participation, pain, quality of life, and treatment history
223859997|NCT01580319|OTHER|physical exercise|150 minutes per week
223859998|NCT00904852|DRUG|Tandutinib, bevacizumab, and temozolomide|All patients will have completed treatment with concurrent radiation therapy and temozolomide. Patients will be entered into different dosing groups of tandutinib. Patients will receive up to 6 cycles of treatment with oral temozolomide at 150 mg/m2 daily for the first 5 days of a 28 day cycle, oral tandutinib at escalating doses 250, 375, 500, or 625 mg twice daily on days 1 to 28, and intravenous bevacizumab at 10 mg/kg on days 1 and 15 of each cycle
223859999|NCT04763044|DRUG|0 ppm F|Each subject will be randomly assigned to this treatment during one of the four periods for this crossover study.
223860000|NCT04763044|DRUG|250 ppm F as MFP|Each subject will be randomly assigned to this treatment during one of the four periods for this crossover study.
223860001|NCT04763044|DRUG|1100 ppm as MFP|Each subject will be randomly assigned to this treatment during one of the four periods for this crossover study.
223860002|NCT04763044|DRUG|2800 ppm F as MFP|Each subject will be randomly assigned to this treatment during one of the four periods for this crossover study.
223860003|NCT04763044|DRUG|1100 ppm SnF2|Each subject will be assigned to this treatment during the fifth period for this crossover study.
223860004|NCT01149395|DRUG|Dexlansoprazole|Dosage: 30 mg once per day for 4 weeks by mouth
223860005|NCT01376089|DRUG|Iodixanol|Iodixanol 320 mg I/mL as a single iv. administration.
223860006|NCT01376089|DRUG|Iopamidol|Comparator agent iopamidol (Isovue) 370 mg I/mL as a single iv. administration.
223860007|NCT01354795|PROCEDURE|1.EUS-FNA with or without suction|During EUS-FNA of the peri-pancreatic mass was performed, with or without self-retracting 10-mL syringe applied.
223860008|NCT01354795|PROCEDURE|2.Pushing the stylet or injecting air|EUS-FNA specimen is expelled from a needle with pushing the stylet or injecting air into the needle
223860009|NCT03204968|DEVICE|Vagus nerve stimulation|transcutaneous Intermittent stimulation of the vagus nerve using neurostimulator V (Ducest®, Germany)
223860010|NCT05489536|BEHAVIORAL|A web/smartphone-based lifestyle program package|"There are two platforms for the lifestyle program, namely Health and Nutrition Education (HNE) website and HNE app. The participants are requested to download and register on the HNE website and the HNE app. The HNE app is Android and IOS compatible. Both the HNE website and app are designed to support self-directed learning and independently monitor their GWG and dietary intake during pregnancy. Both the HNE website and app will be passcode protected throughout the study period such that access is restricted to only participants in the intervention group.~The web/smartphone-based lifestyle program package consists of:~I. Health and Nutrition Education (HNE) resources II. Gestational Weight Gain (GWG) monitoring III. Dietary intake monitoring"
223860011|NCT02817984|BIOLOGICAL|Acellular Adipose Tissue (AAT)|The components of the adipose-derived scaffold are all naturally occurring AAT proteins and proteoglycans that provide a natural scaffold. The nature of the AAT also enhances host tissue integration since matrix components can be easily degraded by cell-secreted enzymes as tissue remodeling takes place. Mechanisms for matrix turnover are already established in host cells, avoiding any concerns over proper clearance of scaffold materials from the body.
223860012|NCT05471635|BIOLOGICAL|COVID-19 Vaccine|All COVID-19 vaccines approved by national or international regulatory agency, despite the vaccine technology, manufacturer, and regulatory agency that granted marketing authorization.
223860013|NCT05312021|DRUG|IMR-687|150 mg and 200 mg tablets
223860014|NCT05312021|OTHER|IMR-687 Placebo|Matching placebo to IMR-687
223860015|NCT04583306|OTHER|Raman analysis of saliva, characterization of the Raman database and building of the classification model|Saliva will be collected, processed and analysed through Raman spectroscopy. Data acquired will be normalized and treated for the creation of the classification model.
223860016|NCT01495663|DRUG|I-131-CLR1404|"Description:~* Dosimetry: IV, 5 mCi, single dose, 6-day duration~* Therapy: IV, starting dose level of 12.5 mCi/m2, single dose, 56-day duration with follow up to one year"
223860017|NCT02680457|DRUG|Insulin Degludec|Insulin Degludec 10 IU SC every 24 hours for 6 days
223860018|NCT02680457|DRUG|Insulin Glargine|Insulin Glargine 10 IU SC every 24 hours for 6 days
223860019|NCT02349503|DRUG|NBI-77860|
223860020|NCT02349503|DRUG|NBI-77860|
223860021|NCT02349503|DRUG|NBI-77860|
223860022|NCT01965119|DRUG|Ruxolitinib|20 mg orally twice a day for 4 weeks (One cycle) Treatment continued until documented disease progression or unacceptable toxicity.
223860023|NCT05717218|DEVICE|Ultra-protective mechanical ventilation monitored by electrical impedance tomography|"A silicone EIT belt will be placed around the patient's thorax (sixth intercostal parasternal space). EIT data will be generated by application of a small alternating electrical current (5 mA at 50 kHz). Introduction of ultraprotective mechanical ventilation will be monitored."
223860024|NCT06070688|DIAGNOSTIC_TEST|MeMed BV® biomarker test|one purple top tube of whole blood (2-3 cc) to be used for the MeMed Key® device processing without the need for centrifuge. The MeMed BV® test takes approximately 15 minutes to process and result. After, the sample has been processed and the MeMed BV® test has resulted, the sample of blood will be discarded for each patient enrolled in the study.
223860025|NCT06070688|DIAGNOSTIC_TEST|Usual care|Usual care includes diagnostic hematology, chemistry, biomarkers, and culture results along with imaging, consults, and medications, in the treatment of acute viral and/or bacterial illness.
223860026|NCT04957485|DRUG|Tecovirimat|oral antiviral
223860027|NCT04957485|DRUG|Smallpox and Mpox Vaccine|vaccine
223860028|NCT04957485|OTHER|Placebo|TPOXX Placebo
223860029|NCT01192542|DEVICE|galyfilcon A prototype lens|Prototype silicone hydrogel contact lens
223860030|NCT01192542|DEVICE|enfilcon A lens|Marketed silicone hydrogel contact lens
223860031|NCT05142137|DIETARY_SUPPLEMENT|Drinkable solution|The volunteers will consume 300 ml of liquid solution containing the novel alpha glucan or glucose syrup
223860032|NCT02797249|DRUG|Aspirin|Low dose aspirin（100mg）per day starting between 12+ and 20 weeks of pregnancy until 34 weeks of pregnancy,taking at night.
223860033|NCT02797249|OTHER|Blank|Routine examination during pregnancy.
223860034|NCT03590288|PROCEDURE|Transjugular intrahepatic portosystemic shunt|"Covered stents will be used, that will be dilated to 8 mm. The aim will be to reduce the portacaval pressure gradient (PPG) below to 25-75% of baseline. Not paralleled TIPS or over-dilatation are allowed.~Embolisation, either with coils or bucrylate, can be performed, if it is felt necessary, especially in patients where portography shows the filling of big portosystemic collaterals feeding the varices.~After TIPS, anticoagulation will not be used as a rule, but is allowed if the attending physician thinks that it is warranted.~Measurement of portacaval pressure gradient will be done immediate after TIPS, then repeated 1-3 days and at 1 month after the procedure.~A TIPS revision will be performed once shunt dysfunction is suspected."
223860035|NCT05845710|DEVICE|Neuroguard IEP Direct System|carotid artery stenting, direct access with blood flow redirection
223860036|NCT05761834|OTHER|Sample blood and 2D-echocardiography with Doppler|Investigate whether patients with FD and HCM have a different inflammatory phenotype defined by plasma biomarkers, serum proteomic profile and transcriptomic analysis in peripheral blood mononuclear cells.
223860037|NCT03703037|DIAGNOSTIC_TEST|Ultrasound and Doppler ultrasound|Assessment of fetal cerebral and maternal uterine pulsatility index using Doppler ultrasound. Measurement of amniotic fluid index according to four-quadrant technique.
223860038|NCT05633199|OTHER|cytoreductive surgery|Open surgery is conducted by senior doctors in gynecological oncology. The following parameters should be recorded: period of operation, location and number of recurrent lesions, location and number of resected lesions, amount of intraoperative bleeding and blood transfusion, whether R0 is reached, size and distribution of residual lesions, surgical complications, hospital stay, and period to adjuvant chemotherapy. Patients are required to start intravenous chemotherapy within 4W after surgery, at least for 4 cycles.
223860039|NCT05752513|PROCEDURE|Late bladder dissection|The bladder dissection is reserved as the last step of the cesarean hysterectomy with excellent dissection of the ureteric course till the ureteric tunnel to reduce the incidence of inadvertent ureteric clamping during uterine vessel ligating and transection
223860040|NCT05752513|PROCEDURE|early bladder dissection|The bladder dissection is early as in classic cesarean hysterectomy
223860041|NCT03743246|DRUG|JCAR017|JCAR017
223860042|NCT03743246|DRUG|Lymphodepleting|Lymphodepleting
223860043|NCT03743246|DRUG|Fludarabine|Fludarabine
223860044|NCT03743246|DRUG|Cyclophosphamide|Cyclophosphamide
223860045|NCT01901276|DRUG|Omeprazole 40 mg bid|As above.
223860046|NCT01596504|DRUG|Lixisenatide (AVE0010)|"Pharmaceutical form: solution for injection self-administered with a pen-like injector (OptiClik®).~Route of administration: subcutaneous"
223860047|NCT01596504|DRUG|Liraglutide|"Pharmaceutical form:solution for injection~Route of administration: subcutaneous"
223860048|NCT01596504|DRUG|Insulin Glargine|Doses to be adjusted to maintain a fasting self-measured plasma glucose (SMPG) between 4.4 to 5.6 mmol/L (80 to 100 mg/dL)
223860049|NCT01596504|DRUG|Metformin|If previously taken metformin to be continued at stable dose throughout the study
223860050|NCT00979056|DRUG|Rifaximin|400 mg per day, oral use, maximum duration 28 days
223860051|NCT00979056|DRUG|Lactose|Coated Tablet, Oral Use
223860052|NCT00878462|DRUG|Asenapine WHITE raspberry flavor (Treatment A)|Asenapine (Org 5222), 5 mg white raspberry flavored as fast dissolving tablets
223860053|NCT00878462|DRUG|Asenapine RED raspberry flavor (Treatment B)|Asenapine (Org 5222), 5 mg red raspberry flavored as fast dissolving tablets
223860054|NCT00878462|DRUG|Asenapine WHITE UNFLAVORED (Treatment C)|Asenapine (Org 5222), 5 mg WHITE UNflavored as fast dissolving tablets
223860055|NCT04000269|DEVICE|Soterix MxN Neuromodulation device|Up to 2 mA stimulation to primary motor cortex for 10 sessions at 20min per session
223860056|NCT04000269|DEVICE|Sham Stimulation|Uses slight stimulation initially then turns of and provides no stimulation after a few seconds.
223860057|NCT04666818|DEVICE|Use of Flash Glucose Monitoring|Participants in the intervention group were advised to monitor glucose levels by means of flash glucose system.
223860058|NCT02785718|OTHER|Global Haemostasis assays|
223860059|NCT02015741|DEVICE|EEG monitoring with Bispectral Index and NeuroSENSE|
223860060|NCT02015741|BEHAVIORAL|Clinical observation|Patients will be observed during awake periods and during natural sleep.
223860061|NCT02894749|RADIATION|3D rotational angiography (3DRA)|3DRA allows CT-like reconstructions. It requires less X-rays and contrast medium than standard angioCT-scan. Furthermore, it can be performed in the operative room, during the procedure. Therefore, use of 3DRA should allow reduction of dose, contrast-medium and reintervention when compared to technical success assessment with angioCT-scan.
223860062|NCT00294905|BEHAVIORAL|Implementation of a combined smoking cessation strategy|
223860063|NCT03988569|OTHER|audiovisual decision aid|Will view AVDA and then have opportunity for questions with physician before signing consent forms
223860064|NCT03890640|PROCEDURE|Ultrasound-guided TECI|When performing an ultrasound-guided thoracic epidural catheter insertion (TECI), an 18-gauge Tuohy needle will be used for interlaminar epidural access. All procedures will be performed with a paramedian approach under ultrasound-guidance and using the loss of resistance technique with saline. If the needle is deemed to be in the epidural space when the loss of resistance occurred, fluoroscopic views will be obtained to confirm which the catheter tip is located in the epidural space or not.
223860065|NCT00703625|DRUG|Temsirolimus|
223860066|NCT00703625|DRUG|Docetaxel|
223860067|NCT00000313|DRUG|Fenfluramine|
223860068|NCT05045703|DIETARY_SUPPLEMENT|Vitamin A palmitate|Vitamin A palmitate, 15,000 IU daily for 4 months
223860069|NCT04679519|OTHER|Drop Jumps|Perform 100 drop jumps from 40 cm height. The protocol is divided into 5 sets of 20 repetitions. Between each repetition participants get 10 seconds, and between each set 2 minutes rest. Stand on the box, drop of the box and land with feet shoulder width apart. Then immediately bend knee to approx 45 degrees and jump straight up. Throughout each jump hands are placed on hips and should not move.
223860070|NCT04440046|OTHER|Manual therapy thoracic spine|Manual therapy mobilization directed to the costovertebral joint.
223860071|NCT04440046|OTHER|Manual therapy glenohumeral joint|Manual therapy mobilization directed to the glenohumeral joint.
223860072|NCT04440046|OTHER|Sham thoracic manual therapy|Sham manual therapy directed to the costovertebral joint.
223860073|NCT04440046|OTHER|Sham glenohumeral manual therapy|Sham manual therapy directed to the glenohumeral joint.
223860074|NCT04440046|OTHER|Therapeutic exercise|Therapeutic exercise program consisting on isometric exercise with progressive load.
223860075|NCT03629119|DIETARY_SUPPLEMENT|Dietary Fiber Supplement|Participants will be instructed to consume 1 tea spoon of psyllium per day for 3 months and otherwise maintain their habitual diet. Participants will be asked to keep a diary assessing bowel movement and intestinal symptoms such as bloating and flatulence beginning two weeks prior to the intervention.
223860076|NCT02026258|PROCEDURE|Piezotome-Corticision|Local anesthetic will be administered to the labial sulcus of the mandibular incisors. A scalpel will be used to make three vertical incisions through the gingiva, 4mm below the interdental papilla, interproximally between mandibular canines and lateral incisors, and central incisors on the labial aspect of the mandible. The incisions will be 4mm in length. A piezosurgery knife will be used to create the cortical alveolar incisions to a depth of 1mm within the cortical bone. The depth of the cortical incision will be limited to 1mm for a safety margin. Postoperatively, subjects will be advised to rinse with chlorhexidine mouthwash twice a day for one week and take acetaminophen as needed.
223860077|NCT02026258|DEVICE|Orthodontics|Subjects will be followed every 4-5 weeks after the first wire placement until full alignment of the lower arch (irregularity index 0-2mm). The archwire sequence will be 0.014-in Cu-NiTi wire for the first two visits followed by a 0.014 X 0.025-in Cu-NiTi wire until completion of alignment.
223860078|NCT00492791|DEVICE|wireless endoscopy capsule|Firslty patency ingestion then wireless endoscopy capsule exam done
223860079|NCT03321344|DEVICE|Focused Ultrasound Thermal ablation|Focused Ultrasound Thermal ablation of the Medial Nerve Branch
223860080|NCT04459819|OTHER|Respiratory physiotherapy|"Respiratory physiotherapy consists of:~* early mobilization (passive and active mobilization, muscle-strengthening exercises, mobilization out of bed, standing, walking, ADL)~* patients positioning~* non-invasive mechanical ventilation / CPAP~* tracheostomy management~* invasive mechanical ventilation weaning~* airway clearance~* oxygen titration"
223860081|NCT04090762|BEHAVIORAL|Conditional cash transfer|Pregnant women receive cash payments conditioned on their use of prenatal services and use of a health facility for child birth.
223860082|NCT04090762|BEHAVIORAL|Risk information provision|Pregnant women who exhibit characteristics associated with a greater risk of a poor birth outcome - these will be identified from the medical and epidemiological literature - will be informed that they possess these characteristics.
223860083|NCT03502317|BEHAVIORAL|Physical Prehabilitation|Physical prehabilitation will comprise a personalized, home-based exercise program designed to meet the Cancer Care Ontario Exercise Guidelines for Cancer Survivors. A Registered Kinesiologist (RKin) will complete a baseline physical assessment and prescribe an individualized multi-modal exercise program consisting of 4-5 days of 30+ minutes of aerobic exercise (brisk walking or equivalent to target heart rate of 40-60% of max) and 2-3 days of moderate intensity resistance training of major muscle groups (8-10 repetitions). Participants will be provided with a Fitbit with a heart rate monitor, resistance bands, and a stability ball. Patients will be required to wear their Fitbit and record the number of steps at the end of each day from randomization to 90 days post-surgery.
223860084|NCT03502317|BEHAVIORAL|Psychological Prehabilitation|Psychological prehabilitation will consist of one in-person coaching session of a 'mindfulness' informed intervention conducted by a specially trained RKin. The 40 minute coaching session will include a guided mindfulness session and debriefing. Participants will be asked to practice for 20 minutes twice a day. The patients will be given access to an audio file that will walk them through the 20 minute sessions.
223860085|NCT05061342|OTHER|No experimental interventions 1. Observation; 2. Anticancer treatments, including surgery, systemic therapy, radiotherapy, Chinese traditional medicine, or palliative/supportive care.|Any anticancer or palliative care
223860086|NCT04620018|DRUG|Amoxicillin|Subjects received Amoxicillin before surgery, before and after surgery ,and only after surgery.
223860087|NCT06315049|OTHER|Music therapy|Music therapy sessions to reduce anxiety
223860088|NCT03400488|DRUG|AZD5718 oral suspension|In all cohorts, randomized subjects will receive orally AZD5718 oral suspension SAD (60 mg) on Day 1 and MAD (180 mg, 360 mg and 600 mg) from Days 3 to 10. On Day 2, no dose will be given. In total each subject will receive 9 doses of AZD5718.
223860089|NCT03400488|OTHER|Placebo matching AZD5817 oral suspension|In all cohorts, randomized subjects will receive orally placebo matching AZD5718 oral suspension on Day 1 and from Days 3 to 10. On Day 2, no dose will be given.
223860090|NCT05967819|BEHAVIORAL|Exercise Stress|Increased exercise volume
223860091|NCT05967819|BEHAVIORAL|Psychosocial Stress|cognitive tasks
223860092|NCT01159704|BEHAVIORAL|Peer Education Model|The peer education intervention will be delivered by trained outreach workers in a group format with 8-10 indexes over five sessions spanning three weeks. The sessions will focus on knowledge of HIV transmission, self-efficacy and skills-building regarding HIV risk reduction, with an emphasis on the dissemination of such information and skills to network members.
223860093|NCT01159704|BEHAVIORAL|HIV Counseling and Education Model|"The C \& E intervention is a manualized individual-level model consisting of two education and counseling sessions that structurally bracket confidential HIV antibody screening."
223860094|NCT06184854|OTHER|3D-Enhanced Training Models|3D-enhanced Jenga polo model for task 1 and 3D-enhanced suturing model for task 2
223860095|NCT06184854|OTHER|Standard 3D LapPass Training Models|Standard 3D LapPass polo model for task 1 and standard 3D LapPass model for task 2
223860096|NCT05590273|BEHAVIORAL|CALM Therapy|"The CALM intervention includes 3 to 6 individual therapy Zoom teletherapy sessions, each approximately 50-60 minutes in length biweekly, delivered over 3 months. Participants (caregivers) will be asked to complete self-report surveys of behavioral and psychological variables surveys at the following timepoints:~Within one week before initiating the CALM intervention therapy (baseline) and immediately after the program (post-intervention)~In addition, after each intervention session, participants will complete a brief post-session survey to assess acceptability of CALM session components.~Lastly, participants will complete an exit interview immediately following the end of the intervention."
223860097|NCT04658212|PROCEDURE|3D LCBDE|three-dimensional (3D) video system for LCBDE (laparoscopic cholecystectomy and laparoscopic common bile duct exploration )
223860098|NCT04658212|PROCEDURE|ERCP|Endoscopic retrograde cholangiopancreatography (ERCP)
223860099|NCT03835390|BEHAVIORAL|SIMDiscovery|The SIMDiscovery program consists of nine stations that were designed to mirror the different stages of the perioperative process. The stations mirror the different stages of the surgical process and provide patients and their families with education regarding what they can anticipate during each aspect of the intervention.
223860100|NCT03753594|DEVICE|tissue oxygenation saturation|tissue oxygenation saturation
223860101|NCT01465243|DRUG|Icotinib|125 mg Tid (375 mg per day) 250 mg Tid (750 mg per day)
223860102|NCT00530842|DRUG|Tiotropium plus Salmeterol|
223860103|NCT00530842|DRUG|Fluticasone/Salmeterol|
223860104|NCT03617406|DIAGNOSTIC_TEST|Volume Challenge|Addition volume challenge with passive leg raising method in LDDSE as well as administration of normal saline and dobutamine during TEE
223860105|NCT00027820|DRUG|Fludarabine Phosphate|Given IV
223860106|NCT00027820|RADIATION|Total-Body Irradiation|Undergo TBI
223860107|NCT00027820|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo nonmyeloablative PBSCT
223860108|NCT00027820|PROCEDURE|Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation|Undergo nonmyeloablative PBSCT
223860109|NCT00027820|DRUG|Cyclosporine|Given PO
223860110|NCT00027820|DRUG|Mycophenolate Mofetil|Given PO
223860111|NCT03016455|OTHER|Presence of DSA w/ cAMR|
223860112|NCT03016455|OTHER|Presence of DSA w/o cAMR|
223860113|NCT03016455|OTHER|No DSA No cAMR|
223860114|NCT04962906|DRUG|Gam-COVID-Vac / Gam-COVID-Vac|A comparison of antibody levels against protein S will be performed using the Gam-COVID-Vac / Gam-COVID-Vac group as a control group and the Gam-COVID-Vac / ChAdOx1 nCoV-19 and Gam-COVID-Vac / BBIBP-CorV groups as comparators.
223860115|NCT00949975|DRUG|AZD9668|2 x 30 mg oral tablets twice daily (bid) for 12 weeks
223860116|NCT00949975|DRUG|AZD9668|2 x 10 mg oral tablets twice daily (bid) for 12 weeks
223860117|NCT00949975|DRUG|AZD9668|2 x 2.5 mg oral tablets twice daily (bid) for 12 weeks
223860118|NCT00949975|DRUG|AZD9668 Placebo|2 x Matched placebo to oral tablet twice daily (bid) for 12 weeks
223860119|NCT04347954|DRUG|Povidone-Iodine 2%|Two sprays to each nare of PVP-I 2% via nasal spray bottle, four times a day
223860120|NCT04347954|DRUG|Povidone-Iodine 0.5%|Two sprays to each nare of PVP-I 0.5% via nasal spray bottle, four times a day
223860121|NCT04347954|DRUG|Isotonic saline 0.9%|Two sprays to each nare of isotonic saline (0.9% NaCl) via nasal spray bottle, four times a day
223860122|NCT05988307|DEVICE|Percussion massage gun|Percussion massage gun on hamstrings flexibility in patients with knee Osteoarthritis.
224266605|NCT02826395|DRUG|Carbon-11 Sodium Acetate|PET/CT Scans will be performed with or without oral and IV contrast. All investigational scans will be read by at least one board-certified nuclear medicine physician with established expertise in PET/CT of at least 5 years' experience. Fifteen minutes after injection of 11C-Sodium Acetate, we will acquire a scan Emission images will be acquired for 3-5min/bed position. Intravenous and oral contrast will be given for the CT portion of the study.
224266606|NCT00657254|DRUG|Nexavar (Sorafenib, BAY43-9006)|Bay 43-9006 400mg (2 x 200mg tablets) orally twice daily until withdrawal.
224266607|NCT03212651|DRUG|Pembrolizumab|Pembrolizumab 200mg IV infusion
224266608|NCT05435833|PROCEDURE|bilateral ultrasound guided GPN block|a linear high frequency ultrasound probe will be initially positioned over the hyoid bone in the transverse plane, then the probe will be rotated to keep in line with the mandibular angle and the pharyngeal wall is identified by US. Using an in plane approach, a 22 G ,5 cm needle will be advanced till it reaches just superficial to the pharyngeal wall and 2.2 ml of 0.25% bupivacaine will be injected.
224266609|NCT01732328|DIETARY_SUPPLEMENT|Calcium plus vitamin D|
224266610|NCT02331628|DEVICE|ESWT - Extracorporeal Shockwave Therapy|"Patients will receive:~* Four applications of EWST to be delivered to the affected hip and /or knee over a period of eight weeks : starting week 8\\52 from baseline until and including week 14\\52, one dose every two weeks ± 3 days), administered by the principal investigator.~* Dosage will be calculated for each participant, by the manufacturer, according to the size of NHO as recorded on X-ray.~* The energy flux density (EFD) will be 'high level'~* All participants will be supplied with headphones to reduce the noise level emitted by the machine."
224266611|NCT01993186|DRUG|UX007|oral liquid
224266612|NCT01993186|DRUG|Placebo|oral liquid
223860123|NCT03906942|BEHAVIORAL|Fun For Wellness (FFW)|FFW consists of videos, games, and content in the form of 152 BET I CAN challenges \[1\]. Behavior challenges are intended to increase a participant's capabilities to set a goal and to create positive habits. Emotion challenges are intended to increase a participant's capabilities to cope with negative emotions and to cultivate positive emotions. Thought challenges are intended to increase a participant's capabilities to challenge negative assumptions and to create a new narrative for their life. Interaction challenges are intended to increase a participant's capabilities to communicate and connect with others. Context challenges are intended to increase a participant's capabilities to read cues and to change cues in the environment. Awareness challenges are intended to increase a participant's capabilities to know herself/himself and to know the issue. Next steps challenges are intended to increase a participant's capabilities to make a plan and to stick with a plan.
223860124|NCT03653013|BEHAVIORAL|Usual standard of care|Participants will receive treatment and diabetes management as usual standard of care from their diabetes care team. They will also complete as part of the study visit: a pediatric quality of life scale(PedsQL,GenericScale and Diabetes Module) and diabetes related family conflict scale (DFCS-R) to assess quality of life and family stress at the start of the study.
223860125|NCT03653013|BEHAVIORAL|Neuropsychological Consultation|Children and parents in Group 2 will also complete a pediatric quality of life scale (PedsQL,Generic Scale and Diabetes Module),diabetes related family conflict scale (DFCS-R) to assess quality of life and family stress at the start of the study, as well as the self-report form of the BRIEF-2 if they are over age 11. Parents will also undergo a brief literacy and numeracy screening using the Wide Range Achievement Test, complete a parent report assessing their children's executive functioning skills at the start of the study (BRIEF-2) and they will fill out the Family Impact Module.
223860126|NCT05781555|DEVICE|Experimental: DaRT seeds|DaRT source will be inserted using preplanned radiotherapy parameters and reassessed by volumetric imaging 2-3 weeks after placement and then removed. The study objectives are to collect data on the general safety and efficacy of DaRT among patients who do not fit the entry criteria of existing investigational trials.
223860127|NCT02534350|DRUG|Presatovir|Tablets administered orally or via nasogastric (NG) tube once daily
223860128|NCT02534350|DRUG|Placebo|Tablets administered orally or via NG tube once daily
223860129|NCT01510041|OTHER|Inspiratory muscle training|A group will be associated with inspiratory muscle training (GTMI). The inspiratory muscle strength training will be done in the POWERbreathe ®, and the patient will breathe for two minutes, seven times with one minute rest between them, with 15% MIP, the first week, then, increased 5-10% to reach 60% of the initial MIP after four weeks. After the first month, every fifteen days the charge will be adjusted to 60% of the new value of MIP. The breathing pattern will remain free
223860130|NCT01510041|OTHER|Respiratory exercise|Specific exercise program for mobility and biomechanics of the rib cage, as exercises of the trunk and upper limbs, and stretching of large muscle groups of the trunk.
223860131|NCT00128193|BIOLOGICAL|Tuberculin, Purified Protein Derivative|A tuberculin skin test used to diagnose latent tuberculosis (TB) infection. 2 TU dose
223860132|NCT00128193|OTHER|MLSA-LAM|Mycobacterium leprae soluble antigen with minimal amounts of immunosuppressive lipoglycans; dosages 0.1 and 1.0 micrograms; administered in sterile diluent 0.9% saline (NaCl).
223860133|NCT00128193|OTHER|MLCwA|Cell wall-associated proteins of Mycobacterium leprae; dosages 0.1 and 1.0 micrograms; administered in sterile diluent 0.9% saline (NaCl).
223860134|NCT00128193|BIOLOGICAL|Tuberculin, Purified Protein Derivative|Licensed TB reagent, 100 microliters, 5 TU dose.
223860135|NCT00128193|OTHER|Placebo|Saline (NaCl) serves as a diluent control in Stage A and B only.
223860136|NCT00761930|DRUG|Fluoride|Brush twice daily
223860137|NCT00761930|DRUG|Triclosan and fluoride|Brush twice daily
223860138|NCT00761930|DRUG|Herbal Ingredient and fluoride|Brush twice daily
223860139|NCT00355940|DEVICE|Technological Methods|"Usage of technological methods and devices to improve intravascular navigation during endovascular aortic repair.~In this arm we first use an optical pointer to allocate the femoral artery ramification (point of incision) and the lower renal artery (upper confinement of stent graft). Later we use an electromagnetically tracked catheter to find and enter the opening in the main stent graft before placing the second limb. For both optical and electromagnetic tracking we use a custom made navigation system based on 3 dimensional CT images"
223860140|NCT00355940|DEVICE|Regular Fluoroscopy|Usage of conventional fluoroscopy and angiography for intravascular navigation. In this arm standard endovascular aortic repair is performed. The only means of navigation are fluoroscopy and angiography with overlay function (standard).
223860141|NCT03257813|DRUG|PRO-122|1 drop every 12 hours for 30 days of alternating treatment with 30 days
223860142|NCT03257813|DRUG|Krytantek Ofteno®|1 drop every 12 hours for 30 days of alternating treatment with 30 days
223860143|NCT02878330|DRUG|MEDI8897|A single IM dose of 50 mg on Day 1 of the study.
223860144|NCT02878330|DRUG|Placebo|A single IM dose of placebo matched to MEDI8897 on Day 1 of the study.
223860145|NCT02274896|DEVICE|PD Catheter group|PD catheter
223860146|NCT04673851|DEVICE|Horyzons USA|Participants will be oriented to the site (online platform) and how to use it. The site includes curated therapeutic content surrounding issues such as generalized anxiety, social anxiety, social functioning, depression, and distress tolerance. The site also includes a social media function, in which participants and peer support specialists can post text, images, and videos. The site is monitored by graduate students and trained clinicians.
223860147|NCT00578656|DIETARY_SUPPLEMENT|Baked Milk|Extensively heated milk
223860148|NCT00003900|DRUG|docetaxel|
223860149|NCT00003900|DRUG|irinotecan hydrochloride|
223860150|NCT05505279|DEVICE|THRIVE (High Flow Nasal Cannula)|2 different rates of nasal flow compared to each other and a baseline of level of nasal oxygen
223860151|NCT05214235|DRUG|Hypoglycemic Drugs|Patients were divided into metformin group and sitagliptin group according to the type of hypoglycemic drugs they took.
223860152|NCT04801836|DRUG|Estetrol monohydrate 15 mg|One Estetrol monohydrate (E4) 15 mg tablet once per day
223860153|NCT04801836|DRUG|Placebo|One placebo tablet once per day
223860154|NCT02683811|BEHAVIORAL|Diario della Salute (DDS-2)|The updated version of Diario della Salute program (DDS-2) includes: 1) teachers' manual, 2) a booklet for teens telling the story of four same-age students (e.g. experimenting with risky behaviours, conflicting feelings and thoughts, need for independence and control, etc.), 3) a booklet for parents telling the experience of a mum and a dad with teenage children (e.g. problems in the relationship with teenage children, family conflicts, parental control and supervision, family communication, etc.).
223860155|NCT02698007|DEVICE|Laryngeal Mask Airway (LMA)|Fiberoptic bronchoscopy with the use of LMA
223860156|NCT00349583|DRUG|Topical Cyclosporine, Tears|
223860157|NCT00107835|DRUG|S-Caine™ Peel (lidocaine and tetracaine cream 7%/7%)|S-Caine Peel comprising a 1:1 eutectic mixture of 7% lidocaine, and 7% tetracaine was applied topically. The study drug remained on the treatment area for 20-30 minutes for minor dermal procedures and 60 minutes for major dermal procedures
223860158|NCT05641311|DRUG|ALXN1840|Tablet for oral use.
223860159|NCT06466564|DEVICE|Nufairy® Coil embolization system for intracranial aneurysm|Nufairy® Coil embolization system for intracranial aneurysm
223860160|NCT00909363|DRUG|Promacta|"WAS Patients receiving treatment will start on 1 mg/kg of eltrombopag daily and be seen weekly for 12 weeks. Dose adjustment will be based on the weekly monitoring of the platelet count as utilized in ongoing studies in ITP as well as on liver tests.~they will also have diagnostic blood testing prior to initiating treatment"
223860161|NCT00909363|DIAGNOSTIC_TEST|blood drawing in patients with WAS|blood will be drawn for platelet parameters in WAS patients not receiving treatment either because they declined or because they were ineligible
223860162|NCT00909363|DIAGNOSTIC_TEST|blood drawing in healthy controls|blood will be drawn once in healthy children as controls for platelet parameters
223860163|NCT02511197|DRUG|68Ga-NOTA-PRGD2|68Ga-NOTA-PRGD2 were injected into the patients before the PET/CT scans
223860164|NCT02511197|DEVICE|PET/CT|
223860165|NCT02732678|DRUG|PROPRANOLOL|
223860166|NCT01424540|DRUG|GSK2336805 150mg|Single Dose
223860167|NCT01424540|OTHER|Placebo|Single Dose
223860168|NCT03725371|OTHER|No intervention was administered for the purpose of this study.|No intervention was administered for the purpose of this study. Observations were carried out for all participants.
223860169|NCT02805439|DRUG|S47445 15mg|One tablet of S47445 15 mg taken orally once a day during breakfast concomitantly to the current selective serotonin reuptake inhibitor treatment, starting the day after inclusion visit and ending the day of the W8 visit.
223860170|NCT02805439|DRUG|S47445 50mg|One tablet of S47445 50 mg taken orally once a day during breakfast concomitantly to the current selective serotonin reuptake inhibitor treatment, starting the day after inclusion visit and ending the day of the W8 visit.
223860171|NCT02805439|DRUG|Placebo|One tablet of placebo taken orally once a day during breakfast concomitantly to the current selective serotonin reuptake inhibitor treatment, starting the day after inclusion visit and ending the day of the W8 visit.
223860172|NCT01315886|DRUG|SL fentanyl|SL fentanyl will be administered during 7- 15 BTcP episodes during a maximum period of 21 days, following a baseline period with standard BTcP treatment. The start dose of SL fentanyl is selected individually according to a standardized conversion ratio. The maximum start dose is limited to 400 μg. For a single BTcP episode no more than two (2) tablets or a maximum dose of 800 μg should be given.
223860173|NCT03070938|DEVICE|PuraPly™ Antimicrobial Wound Matrix|PuraPly AM consists of a collagen sheet coated with polyhexamethylenbiguanide hydrochloride (PHMB) intended for the management of wounds. PuraPly AM is supplied dry in sheet form. The device is packaged in sterile, sealed single patches.
223860174|NCT02939378|DIETARY_SUPPLEMENT|Ketogenic diet|Ketogenic diet adjuvant to salvage chemotherapy is given to recurrent glioblastomas.
223860175|NCT02939378|DIETARY_SUPPLEMENT|Standard diet|Standard diet adjuvant to salvage chemotherapy is given to recurrent glioblastomas.
223860176|NCT05146817|OTHER|Oral care|Treatment group - original protocol of oral care: special device for tooth brushing 3 times a day with chlorhexidine . Control group - traditional protocol of oral care ( traditional tooth brushing 1 time a day + chlorhexidine rinsing
223860177|NCT06354283|BEHAVIORAL|Progressive Muscle Relaxation Exercises|Progressive muscle relaxation techniques were explained to the women from the couples assigned to the Intervention Group by a researcher. In addition to relaxation exercises, deep breathing movements were also explained to the women and progressive muscle relaxation exercises and breathing exercises were performed together. The importance of the exercises and how to do them were explained to the women by the researcher for about 30 minutes and then demonstrated practically for 30 minutes. Each progressive muscle relaxation exercise session lasted approximately 20-25 minutes. The women in the intervention group continued the exercises at home three times a week for four weeks.
223860178|NCT03899675|DIETARY_SUPPLEMENT|Placebo|On the first day of collection, the volunteers will not take placebo intake, the data will be collected in a standardized way, respecting the times defined for the analysis of the cardiac activity. Then the collection will be continued. On the next day of evaluation, volunteers will receive a capsule containing 300 mg of placebo and will be advised to consume 1 hour before the procedure.
223860179|NCT03899675|OTHER|Caffeine|On the first day of collection, the volunteers will not take caffeine intake, the data will be collected in a standardized way, respecting the times defined for the analysis of the cardiac activity. Then the collection will be continued. On the next day of evaluation, volunteers will receive a capsule containing 300 mg of caffeine and will be advised to consume 1 hour before the procedure.
223860180|NCT02618239|DIETARY_SUPPLEMENT|Bimuno Galacto-oligo-saccharide|
223860181|NCT01026233|DRUG|brentuximab vedotin|1.8 mg/kg IV every 21 days
223860182|NCT03179969|OTHER|paravalvular leak|Observational study on patients with paravalvular leak
223860183|NCT01273844|DRUG|Bortezomib|Bortezomib
223860184|NCT03498170|DRUG|BCT197|Single dose of BCT197
223860185|NCT03498170|DRUG|Itraconazole 200 mg|Single dose of itraconazole
223860186|NCT01989910|DRUG|Raltegravir|Raltegravir 400mg oral twice daily
223860187|NCT01989910|DRUG|Efavirenz|Efavirenz 600mg oral at bedtime
223860188|NCT02467296|OTHER|Dietary plan with controlled amount of Sodium|Dietary plan with 1.5 gr vs 3 gr of Sodium
223860189|NCT00974025|DIETARY_SUPPLEMENT|Vitamin C|High-dose Vitamin C will be administered in 4 age-based dosing groups
223860190|NCT00974025|DIETARY_SUPPLEMENT|Placebo|Placebo will be administered twice daily for four weeks
223860191|NCT04060537|OTHER|Laboratory analysis of samples|RNA sequencing, immunohistochemistry, immunofluorescence, and cytometry of tumour tissues
223860192|NCT04060537|OTHER|Application of machine learning|Using machine learning to interrogate data generated from analysis of Renal Cell Cancer tumours using RNA sequencing, immunohistochemistry, immunofluorescence, cytometry, and MRI imaging of tumours.
223860193|NCT01760837|OTHER|Baked milk products to cow's milk allergic patients|
223860194|NCT02747732|DRUG|Bendamustine 90 mg/m2 IV on Days 1-2, Cycles 1-6|"Therapy initiation 30 days max from screening.~Bendamustine 90 mg/m2 IV on Days 1-2, Cycles 1-6 Rituximab 375 mg/m2 IV Day 1, Cycles 1-6; a cycle is defined as 28 days Ibrutinib, 560 mg orally, once daily, continuously starting on Cycle 1, Day 1 until disease progression, toxicity or referral for allo-SCT"
223860195|NCT04948151|DRUG|Sildenafil|Patients will apply 2-gram applications up to 9 times per month.
223860196|NCT04948151|DRUG|Placebo|Patients will apply 2-gram applications up to 9 times per month
223860197|NCT02528591|DEVICE|oscillometric device (Arteriograph®, Medexpert)|Central blood pressure recorded in the non-fistula arm using a validated oscillometric device (Arteriograph®, Medexpert).
223860198|NCT04097210|DIAGNOSTIC_TEST|POC|
223860199|NCT00166192|PROCEDURE|Jessner's solution chemical peel|
223860200|NCT00166192|PROCEDURE|Trichloroacetic acid chemical peel|
223860201|NCT00688948|DRUG|Alfuzosin|Alfuzosin 10 mg once daily po for 12 weeks
223860202|NCT00809120|DEVICE|Neuromuscular Electrical stimulator (Cefar rehab 4 pro)|50Hz 30 min 7 sessions
223860203|NCT02674451|PROCEDURE|Remote ischemic preconditioning|Blood pressure cuff inflation to 200 mmHG for three 5-minute periods each separated by 5 minute intervals within 1 hour of planned coronary angiography.
223860204|NCT01555684|PROCEDURE|percutaneous venoplasty to alleviate chronic cerebrospinal venous insufficiency|percutaneous venoplasty is where a balloon is inserted and inflated into the jugular vein has been developed to improve this drainage of the CNS, reduce venous hypertension and improve symptoms associated with MS
223860205|NCT03145246|PROCEDURE|regeneration treated teeth loss|number of regeneration treated teeth loss
223860206|NCT03145246|PROCEDURE|regenerated treated teeth with clinical attachment loss|regenerated treated teeth with clinical attachment loss ≥ 2 mm
223860207|NCT03448757|OTHER|measuring hemodynamic parameters heart beat to heart beat during single-frequency exposure|"This study aims to create a method for non-invasive diagnosis of biofeedback effect exposure to LEEF modulated to specific frequencies in individuals exposed to hepatocellular carcinoma -specific frequencies in increasing sequential manner, frequency to frequency in patients with advanced hepatocellular carcinoma and healthy individuals.~Patients with advanced hepatocellular carcinoma will be exposed to specific LEEF-modulated frequencies (3 to 10 Hz difference) to identify the optimal frequency associated with greater response to the biofeedback effect in patients with advanced hepatocellular carcinoma."
223860208|NCT01099891|DRUG|rhEGF|rhEGF 50 μg/ml, spray type, twice a day
223860209|NCT01099891|DRUG|Placebo|Placebo, Spray type, Twice a day
223860210|NCT02526641|PROCEDURE|Functional Hepatic Nitrogen Clearance (FHNC)|
223860211|NCT02526641|PROCEDURE|Galactose Elimination Capacity (GEC)|
223860212|NCT02526641|PROCEDURE|Liver vein catheterization|
223860213|NCT05171218|BEHAVIORAL|Music & Auditory Beat Stimulation|Listening to calm music and auditory beat stimulation Participants listened to calm music with theta auditory beat stimulation for 24 minutes
223860214|NCT05171218|BEHAVIORAL|Music Alone|Listening to calm music Participants listened to calm music for 24 minutes
223860215|NCT05171218|BEHAVIORAL|Auditory Beat Stimulation|Listening to theta auditory beat stimulation Participants listened to theta auditory beat stimulation for 24 minutes
223860216|NCT05171218|BEHAVIORAL|Pink Noise|Listening to pink noise Participants listened to pink noise for 24 minutes
223860217|NCT04988048|BIOLOGICAL|COVID-19 vaccines|"Gam-COVID-Vac Gamaleya National Center for Epidemiology and Microbiology - Russia. Non-replicative viral vector. Multi-dose vial (5 doses in 3 mL) Single-dose vial (1 dose in 0.5 mL). Intramuscular T° less than -18 ° C~BBIBP-CorV Beijing Institute of Biological Products - People's Republic of China. Inactivated viruses. Single-dose vials (1 dose in 0.5 mL) or multi-dose vial (2 doses per vial). Intramuscular T° 2 to 8 ° C~ChAdOx1 nCoV-19 vaccine AZD1222 AstraZeneca-Oxford - United Kingdom. Non-replicative viral vector. Multi-dose vial (10 doses in 5 mL). Intramuscular T°: 2 to 8 ° C~mRNA-1273 or Spikevax Moderna Switzerland GmbH and the National Institute of Allergy and Infectious Diseases (NIAID) of the United States. mRNA. Multi-dose vial (maximum 15 doses per 0.5ml vial). Intramuscular. T°-15 ° to -50 °"
223860218|NCT03429062|OTHER|Personal training exercises|Personal training: strengthening, stretching, endurance, balance Whole body vibration: strengthening, balance, stretching, endurance, balance
223860219|NCT05705700|DRUG|Dutasteride|High dose Dutasteride (3.5 mg daily) as add-on therapy at time of PSA progression
223860220|NCT05705700|DRUG|Abiraterone|1000 mg PO daily
223860221|NCT00025987|DEVICE|Head and Neck Cooling System|
223860222|NCT00025987|DEVICE|Thermometer Pill|
223860223|NCT04224181|RADIATION|Cardiac PET|A scan examining blood flow to the heart
223860224|NCT04224181|RADIATION|99mTc-tilmanocept SPECT/CT|A scan to look at inflammation in the arteries
223860225|NCT04224181|RADIATION|Contrast Enhanced Coronary and Aortic Computed Tomography Angiography|A scan of the heart and surrounding blood vessels
223860226|NCT00226148|PROCEDURE|Use of a membrane to cover bonedefects around implant|
223860227|NCT00226148|DEVICE|Use of bonechips to fill up defects around implant|
223860228|NCT00226148|PROCEDURE|Use of membrane and bonechips to manage defects|
223860229|NCT00269880|DRUG|Placebo|Placebo is administered as bolus or 12 hour infusion prior to index percutaneous coronary intervention.
223860230|NCT00269880|DRUG|Heparin|Heparin is administered as either high dose (100 units/kg of body weight) or low dose (70 units/kg of body weight) boluses.
223860231|NCT00269880|DRUG|Abciximab|Abciximab is administered as bolus followed by 12 hour infusion prior to index percutaneous coronary intervention.
223860232|NCT03471611|DRUG|Autologous CD34+ Cells|The dose will be 1x10\^5 cells/kg, injected at the rate of 10 ml/min
223860233|NCT03471611|DRUG|Granulocyte Colony-Stimulating Factor (G-CSF)|5mg/kg twice daily
223860234|NCT00922207|DRUG|Adefovir|From week -4 to week 2
223860235|NCT00922207|DRUG|Entecavir|From week -4 to week 2
223860236|NCT00922207|DRUG|Placebo|From week -4 to week 2
223860237|NCT00922207|DRUG|peginterferon alfa-2a [Pegasys]|180 micrograms sc weekly, from week 1-48
223860238|NCT02326649|DEVICE|Physioflow|impedance cardiography instrument that measures cardiac output non-invasively
223860239|NCT02342119|OTHER|Talking About Living Kidney Donation|TALK participants receive a culturally sensitive educational booklet and video. A study interventionist encourages participants to share the materials with their family members or friends. Materials provide information to encourage patient and families shared and informed consideration of LDKT, including: 1) information about eligibility for LDKT, 2) the clinical evaluation required for LDKT, 3) the donor selection process, 4) surgical procedures for transplantation and donation, 5), and concerns brought forth about these factors, identified through structured group interviews.
223860240|NCT02342119|OTHER|Kidney Transplant Fast Track|KTFT is a one-day streamlined transplant evaluation process. Every patient who is evaluated at the University of Pittsburgh Starzl Transplant Center receives the KTFT. This approach involves completion of most or all testing on the same day that patients arrive for their first pre-transplant clinic appointment, rather than providing them with a list of tests they complete on their own with their referring physician. If patients are unable to be scheduled the same day, the transplant clinic scheduler secures appointment times and preparatory material for all testing to be completed within a 2 week period.
223860241|NCT03890016|DIAGNOSTIC_TEST|20'Whole Blood ClottingTest (WBCT)|"1ml of blood drawn from snake bite victims in clean glass test tubes of 1 cm diameter Kept undisturbed for a period of 20 minutes (measured by a stop watch). At the end of 20 minutes the tube is tilted to see if the blood has clotted or not.~If a well formed clot is not formed, the test is recorded as 'abnormal'.~If the clot seems well formed, it is further observed for a period of 30 minutes to look for dissolution of the formed clot and would be termed clot lysis. Clot lysis indicates an unstable clot."
223860242|NCT03890016|DIAGNOSTIC_TEST|Modified Lee and White (MLW) Method Clotting Time|"The blood collected in three additional test tubes would be utilised for MLW.~The three test tubes would be kept on a rack at ambient temperature.~The blood sample would be drawn in a 5cc syringe and 1 ml would be added in the three test tubes consecutively.~The test tube would be left undisturbed for 5 minutes, after that the first tube would be tilted approximately to check for clot formation every 30 seconds while the other tubes are left undisturbed.~After the blood in the first tube has clotted, the time would be noted and the second tube would be tilted every 30 seconds and examined.~Following its clotting, the third tube would be examined. The time at which the third tube is recorded as the CT value.~Once clotted, then the sample in the all three test tube would be assessed at 20 minute and 30 min to look for breakup or lysis of the clot."
223860243|NCT05702996|DRUG|Eculizumab administration|Patient with Thrombotic microangiopathies induced by gemcitabine will be treat with Eculizumab
223860244|NCT03814668|DIETARY_SUPPLEMENT|Probiotic|Intake of probiotic
223860245|NCT03814668|DIETARY_SUPPLEMENT|Lactase|Intake of lactase
223860246|NCT03814668|OTHER|Placebo|Intake of placebo
223860247|NCT03705299|DEVICE|Non-Invasive CVP vs Standard CVP|
223860248|NCT03781206|DEVICE|PICO™ 7|PICO™ system (Smith\&Nephew Healthcare, Hull, UK) is a Single-Use Negative Pressure Wound Therapy (NPWT) System consisting of a small portable pump, 2 lithium batteries, 2 dressings and fixation strips.
223860249|NCT03404154|DIAGNOSTIC_TEST|3D ultrasound|it describes the diagnostic test which is 3D us to diagnose the cause of postmenopausal bleeding
223860250|NCT03404154|PROCEDURE|Dilatation and curretage|it describes the surgical maneuver that will be made to diagnose cause of bleeding
223860251|NCT03390569|BEHAVIORAL|Exercise|The patients meet with a registered physiotherapist and receive individualized exercise programs starting the second week of treatment, and continuing up to 3 months later.
223860252|NCT05402735|DIAGNOSTIC_TEST|Serum uric acid level|Serum uric acid level
223860253|NCT06333132|BEHAVIORAL|Weight loss-induced Diabetes Remission|Patients will undergo a dietary intervention plus drugs (if needed) with the purpose to obtain a 10% (or at least 10 kg) body weight reduction to achieve diabetes remission
223860254|NCT00243854|DRUG|Tarceva|Tarceva: 100mg/day x 2 weeks (Days 1-14) +
223860255|NCT00354406|DRUG|abciximab|standard i.v. bolus of abciximab is administered at time of randomization in arm A, and at time of primary angioplasty in arm B.
223860256|NCT01052454|BEHAVIORAL|Mindfulness-based stress reduction|Participants in the MBSR arm attend eight weekly classes.
223860257|NCT01628237|DEVICE|comparison of spinal cord stimulation|
223860258|NCT02578615|OTHER|physiotherapy|physiotherapeutic intervention according to the principles of the Spiraldynamik® concept
223860259|NCT02418806|BEHAVIORAL|Psychotherapy groups|
223860260|NCT02418806|BEHAVIORAL|Self-help groups|
223860261|NCT05053009|DRUG|Brufen Retard|800 mg tablet of Brufen Retard will be adminstered orally one hour before local anesthesia
223860262|NCT00109785|PROCEDURE|positron emission tomography|
223860263|NCT00109785|RADIATION|fludeoxyglucose F 18|
223860264|NCT00109785|RADIATION|iodine I 124 iododeoxyuridine|
223860265|NCT06554548|DRUG|HS-10518|Treatment A: Single oral dose of HS-10518 160 mg tablet under fasted conditions Treatment B: Single oral dose of HS-10518 160 mg tablet after a high-fat meal
223860266|NCT02770599|OTHER|IBD multidisciplinary team model including IBD nurse|IBD multidisciplinary team model including IBD nurse
223860267|NCT01953757|OTHER|Vegan diet and vitamin B12 supplement|A low-fat, vegan diet (no meat, fish, eggs or dairy products) and a vitamin B12 supplement in the form of 2000mcg of methylcobalamin
223860268|NCT01953757|DIETARY_SUPPLEMENT|Vitamin B12 supplement|A daily vitamin B12 supplement in the form of 2000mcg of methylcobalamin
223860269|NCT04558424|DIETARY_SUPPLEMENT|zinc gluconate and ascorbic acid|This group will consist of 50 patients who will receive 220 mg zinc and 1gm ascorbic acid for 10 days in addition to their standard treatment.
223860270|NCT00288691|DRUG|Asoprisnil (BAY86-5294)|5mg/day
223860271|NCT00288691|DRUG|Asoprisnil (BAY86-5294)|10mg/day
223860272|NCT00288691|DRUG|Asoprisnil (BAY86-5294)|25mg/day
223860273|NCT00288691|DRUG|Placebo|Placebo
223860274|NCT02061228|DEVICE|Pipelle de Cornier®|Women in the intervention group will undergo an endometrial biopsy on the 6th day of ovarian stimulation using a Pipelle de Cornier® (CCD International, Paris, France). This class I individually and sterile-packaged medical device, complies with Directive 93/42/European Economic Community (EEC) and is routinely used in our centre for endometrial sampling. It is comprised of a flexible disposable polypropylene suction cannula with an outer diameter of 3.1 mm and a 2.4 mm diameter opening on the distal end, on one side of the cannula. An inner plunger creates a vacuum essential for the blind endometrial biopsy. After the introduction of the Pipelle into the uterine cavity, it will be rotated 360 degrees and moved up and down four times after withdrawing the piston.
223860275|NCT03385967|DRUG|Dexmedetomidine|Addition of Dexmedetomidine in block .25mcg/kg of dexmedetomidine
223860276|NCT03385967|DRUG|ropivacaine|Standard of care 0.5%ropivacaine
223860277|NCT02892162|PROCEDURE|Additional LAAW linear ablation|Additional linear ablation on LAAW using ThermoCool SmartTouch ablation catheter.
223860278|NCT01230840|DIETARY_SUPPLEMENT|wheat dextrin|5 grams of wheat dextrin baked in cookies will be taken 3 times a day for 2 weeks
223860279|NCT01230840|DIETARY_SUPPLEMENT|placebo|cookies not containing wheat dextrin will be taken 3 times a day for 2 weeks
223860280|NCT00920725|DRUG|Insulin (Aspart Insulin [Novolog], Regular Insulin)|"Aspart Insulin 0.2units/sq q 2 hours~Regular Insulin 0.1units/kg/hr intravenous~Aspart Insulin 0.1 units/kg/hr intravenous"
223860281|NCT06017167|DRUG|Ondansetron 4mg + dexmedetomidine 0.5 ug/kg + normal saline .|compare antiemetic effects between dexmedetomidine and ondansetron in the first group versus dexamethasone and ondansetron in the second group
223860282|NCT06017167|DRUG|Ondansetron 4mg + dexamethasone 8mg + normal saline.|Group II: Ondansetron 4mg + dexamethasone 8mg + normal saline.
223860283|NCT04810793|DRUG|Amoxicillin , Levofloxacin and Esomeprazole|Esomeprazole-Bismuth-Amoxicillin-Levofloxacin-containing quadruple regimens
223860284|NCT04810793|DRUG|Amoxicillin , Furazolidone and Esomeprazole|Esomeprazole-Bismuth-Amoxicillin-Furazolidone-containing quadruple regimens
223860285|NCT04810793|DRUG|Tetracycline , Furazolidone and Esomeprazole|Esomeprazole-Bismuth-Tetracycline-Furazolidone-containing quadruple regimens
223860286|NCT04810793|DRUG|Amoxicillin,Levofloxacin and Vonoprazan fumarate|Amoxicillin-Levofloxacin-Vonoprazan fumarate-containing quadruple group
223860287|NCT04810793|DRUG|Amoxicillin,Furazolidone and Vonoprazan fumarate|Amoxicillin-Furazolidone-Vonoprazan fumarate-containing quadruple group
223860288|NCT04810793|DRUG|Tetracycline,Furazolidone and Vonoprazan fumarate|Tetracycline-Furazolidone-Vonoprazan fumarate-containing quadruple group
223860289|NCT01392313|DIETARY_SUPPLEMENT|Carnitine|Carnitine Ingestion
223860290|NCT01392313|DIETARY_SUPPLEMENT|Placebo|Carnitine placebo
223860291|NCT03969472|DRUG|probiotics|apply probiotic after operation
223860292|NCT03969472|DEVICE|Electrophysiologic Therapy|Pelvic floor electrophysiological therapy is used after surgery
223860293|NCT03630224|DRUG|Plasmalyte Viaflo|Intervention description: fluid resuscitation using exclusively Plasmalyte up to 20L during the first 5 days
223860294|NCT03630224|DRUG|NaCl 0.9%|Intervention name: NaCl 0.9% Intervention description: fluid resuscitation using exclusively NaCl 0.9% up to 20L during the first 5 days
223860295|NCT05769517|DIAGNOSTIC_TEST|Germinal BRCA|We will conduct a multicenter prospective observational study aimed at automatically implementing the predictive model and collecting US images of healthy ovaries from patients tested for germline BRCA pathogenetic variants according to current indications.
223860296|NCT03058965|DRUG|[18F]MNI-958|Subjects will undergo PET imaging using \[18F\]MNI-958, a PET radioligand for imaging tau.
223860297|NCT03058965|DRUG|[18F]Florbetapir|Subjects with Alzheimer's disease will receive a \[18F\]florbetapir scan to compare distribution of tau in the brain compared to that of \[18F\]MNI-958.
223860298|NCT03058965|DRUG|DaTscan|DaTscan SPECT imaging will be completed in those PSP subjects who have not previously had DATScan imaging as part of the screening procedures.
223860299|NCT04424836|DEVICE|high flow nasal cannula device|device is supplying oxygen with heated and humidified air in a high flow rate
223860300|NCT06342063|DEVICE|Blood Flow Restriction Therapy|Patients wear a personalized tourniquet pressure system on their involved thigh while they perform a series of leg press machine exercises. This tourniquet is inflated.
223860301|NCT06342063|DEVICE|Blood Flow Restriction Therapy Sham|Patients wear a personalized tourniquet pressure system on their involved thigh while they perform a series of leg press machine exercises. This tourniquet is not inflated.
224266613|NCT05267444|PROCEDURE|Individualized motion-based interactive game program|The participants will receive a 12-session, 4.5 months home visit service that is provided by the young adults, and supervised by an occupational therapist. Young adults will follow the individualized exercise plan with the older adults, facilitate their use of interactive games, provide psychological and technological support to help older adults cope with their fear of using technologies to perform physical activity.
224266614|NCT00691704|DRUG|Lenalidomide Induction|Induction: Lenalidomide 25 mg daily on Days 1-21 followed by 7 day rest and Dexamethasone 40 mg by mouth (po) daily on Days 1, 8, 15 and 22 every 28 days for 4 cycles.
224266615|NCT00691704|DRUG|Sequential Maintenance Therapy|"Subjects who achieve \>partial response (PR) following induction therapy will receive repeating triplet cycles of alternating low dose therapy until progression, poor tolerance or toxicity. Subjects who complete 24 months of maintenance will be removed from study unless they achieved \> stable disease (SD) from maintenance (per discussion with physician):~* 325 mg aspirin for deep vein thrombosis (DVT) prophylaxis~* Cycle 1, 4, 7, etc. - bortezomib 1.3 mg/m2 on day 1 and 8 of a 28-day cycle~* Cycle 2, 5, 8 etc. - Melphalan 6 mg/m2 by mouth (po) daily on Days 1-7~* Prednisone 60 mg /m2 po daily on Days 1-7 of a 28-day cycle~* Cycle 3, 6, 9, etc. Lenalidomide 10 mg po daily on Days 1-21 of a 28 day cycle."
224266616|NCT03390257|DEVICE|3NT flexible endoscope|The nasal anatomy will be accessed and viewed with the device during Balloon Sinus Dilation
224266617|NCT05959486|DRUG|BR6002A|One tablet administered alone
224266618|NCT05959486|DRUG|BR6002B|One tablet administered alone
224266619|NCT05959486|DRUG|BR6002|One capsule administered alone
224266620|NCT02578290|OTHER|Clinical Decision Support (CDS)|"A best practices alert (BPA) pop-up screen providing CDS will appear at physician sign-off for all scans scored 1-3, and scans scored 4-6 for which an alternative scan scored 7-9 exists.~This screen will show the appropriateness score of the original scan order, and will display any alternative scans that are scored 7-9 for the same indications and patient characteristics. It will also display a link to relevant ACR documentation relevant to the selected scan and indication.~Any time the pop-up alert appears, a checkbox removing the selected scan from unsigned orders will be checked by default."
224266621|NCT04661202|OTHER|multimodal exercise training|"A supervised moderate-intensity exercise training session, which will include aerobic exercise with a stationary exercise bike, resistance exercise using dumbbell, theraband band, or gym ball for each major muscle groups and core muscles (including pelvic floor muscle (PFM) training with biofeedback), and stretching exercise, twice a week for 8 weeks. All exercises will be individualized based on participant's heart rate reserve and Rate of Perceived Exertion (RPE). An oximeter and a sphygmomanometer will be used to monitor the heart rate, oxygen saturation and blood pressure of the participants to ensure safety.~A home exercise program will include a walking exercise for 30 minutes per day and a PFM training with the aim of completing 1\~3 sets of 8\~12 submaximal contraction of PFM by holding 6\~10 seconds with 12\~20 seconds of rest between each contraction, and it will end with 3 maximal PFM contractions by holding 1\~3 seconds 3\~6 seconds of rest between each contraction."
224266622|NCT05919199|OTHER|No intervention|No intervention
224266623|NCT05998980|PROCEDURE|Componeer prefabricated veneers|Individual Randomized Clinical Trial
224266624|NCT05998980|PROCEDURE|Essentia resin composite veneers|Individual Randomized Clinical Trial
224266625|NCT06676813|BEHAVIORAL|Alternate day fasting|Alternate day fasting
224266626|NCT01861249|DRUG|SAR339658|"Pharmaceutical form: Solution for infusion~Route of administration: Intravenous"
224266627|NCT03100357|OTHER|Thyroidectomy|Thyroid surgery for benign nodular goiter
224266628|NCT05306496|DEVICE|Pre-shaped 4DMESH®|The 4DMESH® mesh is semi-resorbable parietal reinforcement implant made of 25% Polypropylene (non-resorbable) and 75% Poly-L-Lactic Acid (resorbable). 4DMESH® meshes are designed for the repair and reinforcement of inguinal and femoral hernias. 4DMesh is a CE-marked, class III medical device manufactured by Cousin Biotech.
223860302|NCT00319436|BEHAVIORAL|Mentalizing Therapy for Substance Using Mothers|This 12 session individual therapy aims to enhance maternal reflective functioning and soften harsh and distorted mental representations about the child. The intervention adopts a developmental progression based on attachment theory, supporting the mother in her parenting role and offering assistance with basic needs. Mothers are encouraged to reflect on their thoughts and feelings and how they affect behavior. The therapist assists mother's thinking about representations of herself as a parent and encourages her to explore opportunities for new understanding of her emotional needs. Therapist and mother explore representations of her child and their relationship in detail in order to understand their meaning and promote more balanced representations and affect regulation. Therapist and mother also explore child's emotional experiences underlying behavior. The goal is to support the mother in becoming more aware of her child's emotional needs.
223860303|NCT00319436|BEHAVIORAL|Standard Parent Education for Substance Using Mothers|This 12 session comparison was designed to match the experimental intervention on time spent with the counselor and maternal expectations for help with parenting. PE counselors helped mothers get connected to services (e.g. medical and pediatric care, child guidance services, housing assistance, vocational training), solve problems of daily living and make parenting-related decisions. PE mothers also received a pamphlet each week on a parenting topic of their choice. Pamphlets focused on common issues in caring for infants (e.g., soothing a crying baby, managing bedtime routines, and establishing routines ) and toddlers (e.g., helping toddlers dress, managing bedtime battles, managing difficult behavior in public, and setting limits without using punishment). Pamphlets provided behavioral guidance at a 5th grade reading level without reference to underlying mental states or emotional needs.
223860304|NCT00751075|DRUG|mometasone furoate nasal spray (MFNS)|Placebo capsules three times daily for 10 days, and MFNS 50 mcg/spray, 2 sprays in each nostril once daily in the morning and placebo nasal spray once daily in the evening for 15 days, followed by 14-day no-treatment observation period
223860305|NCT00751075|DRUG|MFNS|Placebo capsules three times daily for 10 days, and MFNS 50 mcg/spray, 2 sprays in each nostril twice daily for 15 days followed by 14-day no-treatment observation period
223860306|NCT00751075|DRUG|Amoxicillin|Amoxicillin 500 mg/capsule, one capsule 3 times a day for 10 days and placebo nasal spray twice daily for 15 days, followed by a 14-day no-treatment observation period
223860307|NCT00751075|DRUG|Placebo|Placebo capsule three times daily for 10 days and placebo nasal spray twice daily for 15 days, followed by 14-day no-treatment observation
223860308|NCT00476255|BEHAVIORAL|Enhanced Standard Care (ESC)|Reading material
223860309|NCT00476255|BEHAVIORAL|Brief Motivational Intervention (BMI)|Motivational interview with trained therapist
223860310|NCT03922412|PROCEDURE|PLANTAR BLOCK|"1. Sciatic popliteal block : patient in lateral position, injection of 20 ml of the mixture labelled  BLOC POPLITE  containing 20 ml of mepivacain 1% (200mg)~2. Plantar block 10 minutes later : patient in supine position. Medial midfoot injection of 5 ml of the mixture labelled  BLOC PLANTAIRE  containing 5 ml of Ropivacaine 0,5% (25mg) with 0,5 ml dexaméthasone (2mg)~3. Distal deep fibular block : patient in supine position, injection around the dorsal foot artery of 2 ml of the mixture labelled  BLOC FIBULAIRE  containing 2 ml of Ropivacaine 0,5% (10mg)."
223860311|NCT03922412|PROCEDURE|Sciatic popliteal block|"1-Sciatic popliteal block : patient in lateral position, injection of 20 ml of the mixture labelled  BLOC POPLITE  containing 20 ml of ropivacaine 0,5% (100mg) with 2mg (0,5 ml) of dexamethasone"
224266629|NCT02313558|DRUG|Dentifrice Containing Ilex Rotunda Thunb|Use the dentifrice to brush teeth twice a day for 12 weeks
224266630|NCT02313558|DRUG|Control dentifrice|Use the dentifrice to brush teeth twice a day for 12 weeks
224266631|NCT02131077|BIOLOGICAL|ALLO-ASC-TI|
224266632|NCT02131077|DRUG|Placebo|
224266633|NCT01903057|DRUG|azithromycin|
224266634|NCT01903057|DRUG|ivermectin|
224266635|NCT01903057|DRUG|albendazole|
224266636|NCT01903057|DRUG|placebo|
223860312|NCT01518478|DRUG|Fluzone® Intradermal (Sanofi Pasteur Inc.)|"Fluzone® Intradermal trivalent vaccine is a clear-to-slightly opalescent, preservative-free suspension containing formaldehyde-inactivated split influenza viruses for intradermal delivery of 0.1 mL via an ultra-fine micro-needle. The vaccine is supplied as a single-dose, in a latex-free, pre-filled microinjection system. The active substance is prepared from influenza viruses propagated in embryonated chicken eggs.~Fluzone® Intradermal is standardized according to United States Public Health Service (US PHS) requirements and is formulated to contain HA of each of the following three influenza strains recommended for the 2011-2012 influenza season: A/California/07/2009 X-179A (H1N1)-like virus, A/Perth/16/2009 (H3N2)-like virus, and B/Brisbane/60/2008-like virus."
223860313|NCT03698708|BEHAVIORAL|CARES Intervention|A group-based telemedicine intervention to treat depression in parents/caregivers of children with T1D using a cognitive-behavioral approach.
223860314|NCT05577611|COMBINATION_PRODUCT|Basic chemotherapy + UCB transplantation|"The basic chemotherapy regimen was the same as that of the control group~UCB micro transplantation scheme:~Aza 100mg, 75mg/m2/d, IVGTT, D-10 to D-4~Ara-C 1000mg/m2/q12h, IVGTT, D-3 to D-2~Single non consanguineous umbilical cord blood (NC \> 1.5 \* 10 \^ 7 / kg), IVGTT, D0~Bone marrow aspiration smear, MRD and bone marrow chimerism were detected on D14, d30 and D60 after transplantation."
223860315|NCT00004878|BIOLOGICAL|therapeutic allogeneic lymphocytes|
223860316|NCT00004878|DRUG|cytarabine|
223860317|NCT00004878|DRUG|fludarabine phosphate|
223860318|NCT00004878|DRUG|idarubicin|
223860319|NCT00004878|DRUG|methotrexate|
223860320|NCT00004878|DRUG|tacrolimus|
223860321|NCT00004878|PROCEDURE|in vitro-treated peripheral blood stem cell transplantation|
223860322|NCT00004878|PROCEDURE|peripheral blood stem cell transplantation|
223860323|NCT04635267|OTHER|Prone position in patients with ARDS|Transpulmonary thermodilution, arterial blood gas and recruitment/inflation calculation will be made every 8 hours: at baseline (just before prone position), after eight hours of prone position, after 16 hours of prone position (end of prone position), after 24 hours ( 8 hours after the end of prone position).
223860324|NCT02806869|DRUG|Single dose of ibuprofen (800 mg tablet)|
223860325|NCT02806869|DIETARY_SUPPLEMENT|Pulmocare, two 8.0 oz (236.6 mL) cans|
223860326|NCT02652936|DRUG|AF-130|AF-130 oral capsules (50 mg) administered as a single dose or once daily for 7 days
223860327|NCT02652936|DRUG|Placebo comparator|AF-130 matching placebo capsule
223860328|NCT03495713|DRUG|Nivolumab|Nivolumab 3 mg/kg will be administered on day 1 (pre-response assessment week 0) and on day 1 and continued per standard of care and institutional practices. A
223860329|NCT00360451|BEHAVIORAL|Adolescent only Penn Resiliency Program (Adolescent PRP)|In adolescent PRP, students learn both cognitive skills (recognizing the link between beliefs and emotions, challenging negative beliefs with evidence, making accurate attributions for events, and accurately assessing the ramifications of negative events) and behavioral problem-solving skills (decision making, assertiveness and negotiation, social skills, and relaxation).
223860330|NCT00360451|BEHAVIORAL|Parent Penn Resiliency Program (Parent PRP)|Parent PRP teaches parents to model and reinforce the skills taught in the adolescent program.
223860331|NCT05081310|DEVICE|superior vena cava isolation|SVC isolation by the means of cryoballoon
223860332|NCT05081310|DEVICE|pulmonary vein isolation|conventional pulmonary vein isolation by the means of cryoballoon
223860333|NCT04001517|DRUG|Neflamapimod|Double-Blind, Placebo-Controlled
223860334|NCT05516641|DIETARY_SUPPLEMENT|Soluble Corn Fiber|once daily additive to diet
223860335|NCT05516641|DIETARY_SUPPLEMENT|Maltodextrin|once daily additive to diet
223860336|NCT03253913|DRUG|Sirolimus|Patients will have been on a stable dose of sirolimus prior to enrolling and will continue that throughout the study.
223860337|NCT03253913|DRUG|Resveratrol|Escalating doses of resveratrol will be given throughout the study. Patients will start at 250mg daily for 8 weeks, followed by 500mg daily for 8 weeks, and 500mg BID for the last 8 weeks.
223860338|NCT04812951|DRUG|CycloSPORINE Ophthalmic 0.1% Ophthalmic Emulsion|one cyclosporine 0.1% eye drop twice a day for 30 preoperative days
223860339|NCT04812951|DEVICE|cationorm eye drops|one cationorm eye drop twice a day for 30 preoperative days
223860340|NCT02110056|DEVICE|tDCS|transcranial direct current stimulation (tDCS)
223860341|NCT02110056|BEHAVIORAL|training|intensive training of visual-spatial abilities (in LOCATO task)
223860342|NCT04014803|DRUG|Dual antiplatelet therapy with a P2Y12 inhibitor plus aspirin|"Dual antiplatelet therapy with a P2Y12 inhibitor plus aspirin will be given according to the allocated arms in patients undergoing elective percutaneous coronary intervention for complex coronary lesion~1. Prasugrel plus Aspirin arm~2. Clopidogrel plus Aspirin arm"
223860343|NCT03189316|OTHER|peritoneal fluid and blood sample|Peritoneal fluid sample obtained from peritoneal dialysis fluid of patients with chronic renal insufficiency and blood sample or Peritoneal fluid obtained from coelioscopy for exploration of ovarian cysts and blood cell
223860344|NCT01420393|PROCEDURE|Rhythm control|Patients randomized to catheter ablation-based AF rhythm control group will receive optimal HF therapy and one or more aggressive catheter ablation, which include PV antral ablation and LA substrate ablation with or without adjunctive antiarrhythmic drug
223860345|NCT01420393|OTHER|Rate Control|Patients in the rate control group will receive optimal HF therapy and rate control measures to achieve a resting HR \< 80 bpm and 6-minute walk HR \< 110 bpm.
223860346|NCT05237921|BEHAVIORAL|Combined Exercise and Dietary Intervention (CEDI)|"Intervention aimed at conveying a supervised combined moderate aerobic and resistance training, once a week with a duration of 40-60 minutes plus daily home exercise, personalized according to patients' age and functional status.~Dietary intervention aimed at a one-on-one nutritional counseling. In the first visit a dietary plan is designed and one daily oral nutritional supplement (Forticare®, Nutricia) is given to meet the European Society of Parenteral and Enteral Nutrition (ESPEN) recommended intake."
223860347|NCT05237921|BEHAVIORAL|Standard Care|Standard Care
223860348|NCT02194933|DRUG|Brexpiprazole|Brexpiprazole 2 mg/day, once daily dose, tablet, orally, for 6 weeks - Brexpiprazole 4 mg/day, once daily dose, tablet, orally, for 6 weeks
223860349|NCT03053388|DRUG|Nitric Oxide|Nitric Oxide given via inhalation in cycles
223860350|NCT03053388|OTHER|Supportive treatment|Supportive treatment (including oxygen)
223860351|NCT05254171|DRUG|SBP-101|small molecule polyamine metabolic inhibitor for subcutaneous injection
223860352|NCT05254171|DRUG|Nab-paclitaxel|paclitaxel protein-bound particles for injectable suspension
223860353|NCT05254171|DRUG|Gemcitabine|gemcitabine for injection
223860354|NCT05254171|OTHER|Placebo|Normal Saline
223860355|NCT00537563|DRUG|Telithromycin|
223860356|NCT01312441|DRUG|Ergocalciferol|Ergocalciferol capsules 50,000 IU once weekly for 6 months
223860357|NCT01312441|DRUG|Placebo|Placebo by mouth once weekly for 6 months
223860358|NCT00933088|OTHER|questionnaires|"The study instruments will be given in the following order to the adolescent daughters: 1. Responses to Stress questionnaire; 2. Inventory of Peer and Family Attachment; 3. Youth Self-Report; and, 4. Adolescent data form.~Mothers will be asked to complete data form."
223860359|NCT05561036|DRUG|Liposome doxorubicin|Liposome doxorubicin (50mg/m2) or intravenous placebo with a treatment cycle of once every 28 days
223860360|NCT05561036|DRUG|Saline Solution|saline solution
223860361|NCT02914522|DRUG|Filgotinib|Tablet(s) administered orally once daily
223860362|NCT02914522|DRUG|PTM filgotinib|Tablet(s) administered orally once daily
223860363|NCT05033509|OTHER|supervision the Kidney fonction on ECMO|patients who benefited from ECMO, and presented an acute kidney injury afterwards
223860364|NCT05676190|COMBINATION_PRODUCT|CIK combined with chemotherapy group|Combination of chemotherapy and autologous cytokine induced killer cells
223860365|NCT05676190|COMBINATION_PRODUCT|CIK combined immunotherapy group|Combination of immunotherapy and autologous cytokine induced killer cells
223860366|NCT05676190|COMBINATION_PRODUCT|CIK combined targeted therapy group|Combination of targeted therapy and autologous cytokine induced killer cells
223860367|NCT05676190|COMBINATION_PRODUCT|CIK in combination with other therapies|CIK combined with any two or three of them (i.e. chemotherapy, immunotherapy and targeted therapy)
223860368|NCT04878198|BEHAVIORAL|Jogging program|This intervention consists of 50 sessions of morning jogging sessions at moderate intensity level. Each intervention session will be administered by a trained research assistant assisted by student helpers. All the research staff (i.e. student helpers and research assistant) will be required to attend a workshop (see educational plan) to standardize the procedure on implementing the intervention, as well as handling and motivating their ASD partners. Motivation techniques in previous protocol will be used to enhance the compliance rate.
223860369|NCT04878198|DRUG|Melatonin supplement intervention|This intervention is a 10-week melatonin supplement intervention where melatonin supplement will be provided 30 minutes before bedtime.
223860370|NCT03276104|PROCEDURE|IOL repositioning|Intraocular lens repositioning by scleral suturing
223860371|NCT03276104|PROCEDURE|IOL exchange|Intraocular lens exchange with retropupillary iris-claw lens
223860372|NCT04838158|DIAGNOSTIC_TEST|Isokinetic measurements|Each patient underwent an isokinetic examination on Biodex System 3 (Biodex Multi-Joint System - Pro, Biodex Medical Systems, Inc. New York, USA). In the study group, both side hamstring muscle were evaluated at the velocities of 60 and180 deg/s for the following parameters: peak torque (PT), torque in 30 degree of the knee flexion (T 30 deg.), angle of peak torque (APT) and peak torque hamstring to quadriceps ratio (H/Q ratio).
223860373|NCT04273412|BEHAVIORAL|moderate-intensity lifestyle intervention|standardized 12- week program and would be delivered in 4 sessions (2 individual, 2 telephonic). This lifestyle modification program is a combination of diet therapy (optimum calorie), increased daily physical activity and behavioral modification (self-monitoring, stimulus control, motivational interviewing)
223860374|NCT03949348|PROCEDURE|Mid-urethral sling placement using autologous rectus fascia|Mid-urethral sling placement using autologous rectus fascia
223860375|NCT03949348|PROCEDURE|Mid-urethral sling placement using synthetic mesh|Mid-urethral sling placement using synthetic mesh
223860376|NCT02662530|DRUG|Botulinum Toxin Type A|A serotype of botulinum toxin type A (BoNT-A) that has specificity for cleavage of SYNAPTOSOMAL-ASSOCIATED PROTEIN 25 (SNAP-25). BoNT-A's pharmacological action is to inhibit the release of acetylcholine from the neuromuscular junction. BoNT-A peripherally applied using optimal parameters by intramuscular injections solely determined either by visual/clinical or by biomechanical analysis of dystonic movements for cervical dystonia therapy in neck and shoulder muscles every 12 weeks over 30 weeks. BoNT-A dose will range from 50-300 U.
223860377|NCT03731312|OTHER|No intervention|This is an observational study and no interventions will be administered.
223860378|NCT03812978|OTHER|Smart phone application|Smart phone application including exercise videos, push notifications for exercise, questions and answers, exercise diary.
223860379|NCT00113971|DRUG|epratuzumab|
223860380|NCT03857971|DEVICE|Coronary Optical Coherence tomography|Optical coherence tomography imaging is performed of non-obstructive, non-culprit coronary lesions to assess plaque morphology.
223860381|NCT02849535|BEHAVIORAL|PRISM care program|PRISM care is a multidisciplinary program that includes sessions with a hospital pharmacist about the oral chemotherapy: information is given to the patient on adverse events occurrence and management, optimizing drug dosage plan, including drug-drug interactions. Physical sessions will be planned at the beginning of month 1, month 2 and month 3 after the inclusion, then telephone interviews of physical sessions will be planned at month 4, month 5 and month 6. During all these sessions and during the final physical session at the end of month 6, data will be recorded for outcomes assessment.
223860382|NCT03383146|DRUG|Placebo|Placebo injected subcutaneously twice daily.
223860383|NCT03383146|DRUG|Relamorelin|Relamorelin 10 μg injected subcutaneously twice daily.
223860384|NCT03399370|DRUG|Inclisiran Sodium|Inclisiran is a small interfering ribonucleic acid (RNA) that inhibits PCSK9 synthesis.
223860385|NCT03399370|DRUG|Placebo|Placebo will be supplied as sterile normal saline (0.9% sodium chloride in water for injection).
223860386|NCT00319397|BEHAVIORAL|Exercise-Training Program|
223860387|NCT05382104|DRUG|Maribavir|Maribavir single 400 mg tablet under three different food conditions (fasted, low fat/low calorie meal, and high fat/high calorie meal) depending upon the treatment sequence allocation on Day 1 of each treatment period.
223860388|NCT00639002|DRUG|Ruxolitinib 25 mg|Ruxolitinib was supplied as 5 and 25 mg tablets.
223860389|NCT00639002|DRUG|Dexamethasone 40 mg|Dexamethasone was obtained commercially by Investigators in tablet strengths of 20 or 40 mg.
223860390|NCT03506880|BEHAVIORAL|MADD Materials|Handbook developed by MADD and the PI to guide parents in discussing underage drinking, behaviors, and consequences with their teens
223860391|NCT03506880|BEHAVIORAL|Surgeon General Materials|Information published by the Surgeon General about teens and drinking
223860392|NCT03462589|DRUG|SY-008|The study will be initiated in healthy subjects at a 2-mg dose that is expected to have minimal pharmacologic effect. Doses will be escalated in subsequent dosing process, after appropriate review of safety data. The subsequent planned doses are 6, 12, 18, 24, 30mg successively. The increment of the dose escalation may be reduced, a lower dose may be administered following data review.
223860393|NCT00298597|DRUG|granulocyte - colony stimulating factor (G-CSF)|
223860394|NCT00298597|DRUG|erythropoetin (EPO)|
223860395|NCT06231277|DRUG|BH002|Every 21 days constitutes a treatment cycle, and administration begins on the first day of each cycle
223860396|NCT02354885|DRUG|Tranexamic Acid|Coagulation Management / Efficiency
223860397|NCT02052375|DRUG|ASP2408|subcutaneous injection
223860398|NCT02052375|DRUG|Placebo|subcutaneous injection
223860399|NCT05261997|PROCEDURE|extracorporeal shock wave lithotripsy and endoscopic drainage of the main pancreatic duct|In addition to drug administrated in the control group, patients in this group would be treated with ESWL and endoscopic drainage of the main pancreatic duct.
223860400|NCT05261997|DRUG|pancreatic enzyme(Pancreatin Enteric-coated Capsules or Oryz-Aspergillus Enzyme and Pancreatin Table), antidiabetic medicine(Acarbose Tablets, Glucophage, Glimepirde Tablets)|Patients will receive drugs to control pancreatic insufficiency
223860401|NCT02509585|DRUG|Tc99m tilmanocept|A single dose of 2 mCi (74 MBq) and 50 ug of Tc99m tilmanocept administered peritumorally no more than 20 hours before surgery
223860402|NCT00102258|DRUG|Growth Hormone Therapy|
223860403|NCT00848627|OTHER|Specimen and questionnaires only|Specimen and questionnaires only
223860404|NCT01148719|OTHER|Index group|Diagnostic triage strategy includes; electrocardiography, echocardiography, spirometry and blood testing
223860405|NCT00739765|BEHAVIORAL|Interpersonal Psychotherapy|14 weekly 50-minute sessions of interpersonal psychotherapy, a time-limited treatment that focuses on interpersonal functioning and social supports
223860406|NCT00739765|BEHAVIORAL|Prolonged Exposure Therapy|Ten 90-minute sessions, distributed over 14 weeks, of prolonged exposure, which involves the repeated, detailed recounting of the trauma to develop a coherent narrative and repeated exposure to reminders of the trauma
223860407|NCT00739765|BEHAVIORAL|Relaxation Therapy|Nine 90-minute sessions and one 30-minute session, distributed over 14 weeks, that focus on muscle relaxation to address the physical symptoms of PTSD
223860408|NCT06628518|BEHAVIORAL|FAmily oriented Mindfulness informed Legal Education (FAMiLE)|The FAmily oriented Mindfulness informed Legal Education (FAMiLE) is a low-intensity intervention involving four sessions. The session will cover relevant aspects of brief mindfulness, legal education, awareness of human rights and challenges of complaint, including support. The Family oriented component will include stress management, including coping techniques and problem-solving, positive communication, behaviour modification and parenting, and a session on consolidation including sustaining gains. The intervention will also incorporate positive parenting and interactions with children.
223860409|NCT05838495|OTHER|formulated liquid diet|will be fed exclusively the pediatric enteral study formula with a feeding tube
223860410|NCT05469802|BIOLOGICAL|Purified Inactivated Zika Virus Vaccine (PIZV)|PIZV vaccine with aluminium hydroxide adjuvant IM injection.
223860411|NCT05469802|OTHER|Placebo|Placebo (normal saline (0.9% NaCl) IM injection.
223860412|NCT00388661|DRUG|Melatonin tablet 3 mg once daily|Melatonin tablet 3 mg once daily
223860413|NCT00388661|DRUG|Placebo comparator|Placebo comparator
223860414|NCT04193215|BIOLOGICAL|V114|IM injection
223860415|NCT04193215|OTHER|Pediatric vaccines|Standard of care vaccines administered according to the local recommended schedule.
223860416|NCT05639699|OTHER|motivational interview|Quitting smoking with motivational interviewing
223860417|NCT00822055|DRUG|brimonidine tartrate 0.2%/timolol maleate 0.5% fixed combination|1 drop BID in each eye
223860418|NCT00822055|DRUG|dorzolamide hcl 2%/timolol maleate 0.5% fixed combination|1 drop BID in each eye
223860419|NCT00822055|DRUG|brimonidine tartrate 0.2%/timolol maleate 0.5% fixed combination as adjunctive to current prostaglandin therapy|1 drop BID in each eye
223860420|NCT00822055|DRUG|dorzolamide hcl 2%/timolol maleate 0.5% fixed combination as adjunctive to current prostaglandin therapy|1 drop BID in each eye
223860421|NCT02847117|OTHER|Mastiha|The volunteers will follow a low-phytochemical diet for five days, meaning that they will exclude fruits, vegetables, legumes, coffee, tea, alcoholic beverages and chocolate. On the day of the experiment and after overnight fasting, the volunteers will consume 10g of natural Mastiha and blood samples will be obtained on timepoints 0h, 30min, 1h, 2h, 4h, 6h and 24h after Mastiha intake. Until timepoint 6h, will be allowed to consume only water. Urine samples will also be collected on timepoints 0h, 4h, 8h and 24h.
223860422|NCT01866566|BIOLOGICAL|HBV-3|Give a single 0.5 mL HBV and get blood samples at 0,1.5,4.5 month
223860423|NCT01866566|BIOLOGICAL|HBV-6|Give a single 0.5 mL HBV and get blood samples at 0,1.5,7.5 month
223860424|NCT01866566|BIOLOGICAL|varicella-3|Give 2 doses varicella vaccine (a single 0.5 mL) and get blood samples at 0,1.5,4.5 month
223860425|NCT01866566|BIOLOGICAL|varicella-6|Give 2 doses varicella vaccine (a single 0.5 mL) and get blood samples at 0,1.5,7.5 month
223860426|NCT00940992|DRUG|DER 45 EV|Topical application to face for 12 weeks
223860427|NCT00940992|DRUG|Vehicle|Topical application to face for 12 weeks
223860428|NCT04426045|PROCEDURE|Pericapsular nerve group block|A curvilinear 2-5MHz ultrasound probe will be initially placed in a transverse plane over the anterior superior iliac spine and then aligned with the pubic ramus by rotating the probe counterclockwise approximately 45 degrees. In this view, the iliopubic eminence, the iliopsoas muscle and tendon, the femoral artery, and pectineus muscle will be observed. A 22-gauge, 80-mm needle will be inserted from lateral to medial in an in-plane approach to place the tip in the musculofascial plane between the psoas tendon anteriorly and the pubic ramus posteriorly. A total volume of 20 ml of ropivacaine 0.2% will be injected.
223860429|NCT04426045|PROCEDURE|Supra-inguinal fascia iliaca compartment block|"A linear 6-13-MHz ultrasound probe will be placed in the sagittal plane to obtain an image of the anterior superior iliac spine. The fascia iliaca and sartorius, iliopsoas, and oblique internal muscles will be identified by sliding the probe medially. After identifying the bow-tie sign formed by the muscle fascias, a 22-gauge, 80-mm needle will be introduced 1 cm cephalad to the inguinal ligament. Using an in-plane approach, the fascia iliaca will be penetrated and hydrodissected, separating the fascia iliaca from the iliac muscle. A total volume of 30 ml of ropivacaine 0.2% will be injected."
223860430|NCT06147245|BEHAVIORAL|Person-centred culturally sensitive course of treatment|12-month person-centred and culturally sensitive intervention: Participants will attend 6 visits at SDCC including visits with a diabetes nurse, physician and dietitian. The course of treatment is focusing on extended time in consultations, use of technology for diabetes monitoring, meeting the same healthcare professionals, awareness of language barriers and use of accurate communication and dialogue tools in participants native language.
223860431|NCT03210402|DEVICE|Elevated night pacing on|Device will be programmed to 100 beats per minute (bpm) for five hours during normal sleep times
223860432|NCT03210402|DEVICE|Elevated night pacing off|Device will be programmed to normal lower rates
223860433|NCT05819190|DEVICE|Healsea Rescue*|Subjects will be administered with Healsea Rescue\* by spraying 2 puffs in each nostril 2 times per day during 7 days.
223860434|NCT05819190|DEVICE|Placebo|Subjects will be administered with isotonic saline nasal spray indistinguishable from the Healsea Rescue\* by spraying 2 puffs in each nostril 2 times per day during 7 days.
223860435|NCT05384132|OTHER|SRP + Livfresh Dental Gel|SRP at baseline with use of LDG (test dentifrice) for twice daily brushing between study visits. Scaling and root planing is the physical removal of dental plaque, calculus, and bacterial exotoxins embedded onto the root surface of effected teeth with hand instruments and ultrasonic devices. In addition to scaling and root planing, the participants will use LDG as their primary dentrifice (toothpaste) for the next 6 months. They're instructed to use LDG twice daily with toothbrushing for 2 minutes. LDG in previous studies have been reported to be superior to conventional over-the-counter toothpaste in terms of reducing bacterial plaque and gingival inflammation due to its EDTA (ethylenediaminetetraacetic acid) ingredient. EDTA prevents adhesion of bacterial plaque to teeth.
223860436|NCT05384132|OTHER|SRP + standard flouride dentifrice|SRP at baseline with use of standard fluoride dentifrice (control dentifrice) for twice daily brushing between study visits. Scaling and root planing is the physical removal of dental plaque, calculus, and bacterial exotoxins embedded onto the root surface of effected teeth with hand instruments and ultrasonic devices. In addition to scaling and root planing, the participants will use standard fluoride toothpaste (commercial over-the-counter toothpaste) as their primary dentrifice (toothpaste). They're instructed to use standard fluoride toothpaste twice daily with toothbrushing for 2 minutes.
223860437|NCT05638945|BEHAVIORAL|ED Delirium Screening and Detection Program (ED-DDP)|The intervention arm will have standardized delirium screening by nurses using the brief confusion assessment method (bCAM) in the EHR and will receive the ED-DDP. The ED-DDP will consist of: 1) a multicomponent 1-day delirium champion workshop; 2) real-time direct observation/training via telehealth (tele-training); and 3) training of nurses by champions. Champions will participate in a 1-day workshop, consisting of patient testimonials, small group discussions, delirium and screening tool use (didactics), and role-playing. Following the workshop, champions will receive 3 tele-training sessions; 2 to provide direct observation/feedback while the champion performs a bedside delirium screen, and 1 to provide direct observation/feedback of the champion providing training to the nurse. Once delirium champions complete training, they will provide bedside delirium training for all ED nurses.
223860438|NCT05175248|BEHAVIORAL|Plant-based Intervention Group|Participants in the intervention group will be instructed in ways to adopt a plant-based diet, use appropriate methods of food preparation, and make meals enjoyable and appetizing. The plant-based diet primarily emphasizes whole grains, vegetables, beans and legumes, and fruits. Animal products and added oils will be proscribed and the use of ultra-processed foods, sugar, and sugar-sweetened beverages will be discouraged. Fat intake will be limited to 20-30 g/day.
223860439|NCT00391755|DRUG|ramelteon|"1. ramelteon 8mg po qhs with sleep and headache diary~2. placebo 1 po qhs with sleep and headache diary"
223860440|NCT04443153|DEVICE|Personalized Feedback|Provides tailored information to the user about what glycemic risk they may be facing as well as how glycemic control and system use looked in the past week. Treatment decision and therapy changes are entirely left to the decision of the user.
223860441|NCT04443153|DEVICE|Decision Support System|CGM-based system that includes Personalized Feedback (PF) and further assists with treatment recommendations for common metabolic challenges
223860442|NCT04443153|DEVICE|Sensor Augmented Mode|A mode in Diabetes Assistant (DiAs) that combines Diabetes Assistant, Insulin pump or Multiple Daily Injections, CGM, ketone meters, and glycemic treatment guidelines together to manage diabetes.
223860443|NCT05131919|DRUG|Pembrolizumab|Treatment with pembrolizumab 200 mg intravenously on day 1 of each 3-week cycle. Treatment will be continued for a maximum duration of 2 years, or until the tumor becomes resectable.
223860444|NCT00193297|DRUG|Topotecan|
223860445|NCT00193297|DRUG|Paclitaxel|
223860446|NCT00193297|DRUG|Carboplatin|
223860447|NCT04499131|DRUG|Progesterone|Subjects will undergo an artificial cycle with hormone replacement therapy (HRT) with the aim of comparing the endometrial gene expression profile in the different types of exogenous progesterone with different doses and routes of administration.
223860448|NCT04499131|OTHER|Artificial Cycle (no intervention)|Control group of 19 subjects in the context of a natural cycle with only endogenous progesterone present
223860449|NCT02051439|PROCEDURE|Valsava|The patients were randomized to 2 groups. The first group performed conventional Valsava 3 times before balloon assisted Valsava 3 times. The second group performed balloon assisted Valsava 3 times before conventional Valsava 3 times for venous reflux examination by duplex scan.
223860450|NCT02939690|DEVICE|UVC|UVC insertion depth calculated by \[(3× birth weight (Kg) + 9)/2+1)\]
223860451|NCT02939690|DEVICE|UVC|UVC insertion depth calculated by umbilicus to nipple distance-1
223860452|NCT02939690|DEVICE|Ultrasound|
223860453|NCT03586544|DRUG|Albuterol Sulfate|Participants will inhale 2 puffs of albuterol (90mcg per actuation). After 15 minutes, participants will undergo an exercise induced bronchoconstriction test
223860454|NCT03586544|BEHAVIORAL|Interval Warm-up exercise|Participants will undergo eight 30 sec bouts of high intensity exercise with 45 second recovery between bouts. After 15 minutes, participants will undergo an exercise induced bronchoconstriction test
223860455|NCT03490851|OTHER|Oatmeal + OatWell28CF Int 1|Intervention involves consumption of one cereal in the beginning of each visit of the crossover sequence.
223860456|NCT03490851|OTHER|Oatmeal + OatWell28CF Int 2|Intervention involves consumption of one cereal in the beginning of each visit of the crossover sequence.
223860457|NCT03490851|OTHER|Oatmeal + OatWell28CF Int 3|Intervention involves consumption of one cereal in the beginning of each visit of the crossover sequence.
223860458|NCT03490851|OTHER|Cream of Rice|Intervention involves consumption of one cereal in the beginning of each visit of the crossover sequence.
223860459|NCT03523091|DRUG|OnabotulinumtoxinA 100Unit Injection|Initial treatment with the option of repeat injections every 3 months
223860460|NCT06414382|OTHER|Tape-stripping|22mm tapes x 40 will be attached and removed to skin of all for limbs (tape stripping). On left arm and leg skin will also be subject to micro needling.
223860461|NCT00984087|DEVICE|TMS with Neurostar TMS Therapy System|20 sessions with 1680 pulses per session at 10 Hz with a 4-second pulse train, stimulation at 100% motor threshold,
223860462|NCT03451435|DRUG|N acetyl cysteine|N acetyl cysteine at 20mM will be utilized as the final stage of irrigation prior to induction of bleeding during endodontic revascularization procedure.
223860463|NCT05790941|COMBINATION_PRODUCT|Latanoprost and Minoxidil|Latanoprost and Minoxidil formulation for the treatment of hypotrichosis of the eyebrows.
223860464|NCT00471029|DRUG|esomeprazole|
223860465|NCT02888002|BEHAVIORAL|Guide to better alcohol habits|A 5-module therapeutic program wich includes self-help material in printed or web-based form with interactive exercises. The program includes instructions for the therapist.
223860466|NCT00820079|DRUG|ADX10059|oral administration
223860467|NCT00820079|DRUG|ADX10059 Matching Placebo|oral administration
223860468|NCT01832506|DRUG|MSC2156119J|Subjects will be administered with MSC2156119J 215 mg, 300 mg and 500 mg orally once daily for repeated 21-day cycles until disease progression or unacceptable toxicity.
223860469|NCT04743128|BEHAVIORAL|Exercise|The experimental group started an exercise program to achieve 65% to 80% of the maximum heart rate by using a pulsometer that measured the heart rate in order to get to the moderate intensity activity goal. The exercise session was 60 minutes long, three times per week, completing 180 minutes per week of moderate intensity exercise, for 12 weeks in total.
223860470|NCT00670020|PROCEDURE|supplemental perioperative oxygen|increased perioperative oxygen verses non-interventional oxygen
223860471|NCT02200341|BEHAVIORAL|MBCT|
223860472|NCT02200341|BEHAVIORAL|PRT-PsyEd|
223860473|NCT02563613|BEHAVIORAL|Physical Exercise (PE)|Core session: 2 hours, Booster session: 1 hour
223860474|NCT02563613|BEHAVIORAL|Healthy Diet (HD)|Core session: 2 hours, Booster session: 1 hour
223860475|NCT02563613|OTHER|Wait-list Control (C)|The wait-list control group will receive the intervention at 3 months.
223860476|NCT01001078|DEVICE|I-Gel supraglottic airway device|2 attempts to secure the airway will be tried. If they both fail, there will be a crossover with a Supreme LMA.
223860477|NCT01001078|DEVICE|LMA Supreme supraglottic airway device|In the LMA Supreme group, the same interventions will be done as in the I-Gel group. The cuff of the LMA Supreme will be inflated with 25 mL of air and then by intervals of 5 mL until no leak is heard (max 45 mL). Leak pressure will also be measure at 45 mL. Once the leak test is done, the cuff will be deflated to initial volume necessary to avoid audible leaks.
223860478|NCT01001078|DEVICE|Standard endotracheal tube|In case both supraglottic airway devices fail, a standard endotracheal tube will be inserted
223860479|NCT00270803|DRUG|Tetra Hydro Cannabinol (THC)|Oral THC 13mg and 17mg smoked in low nicotine cigarettes
223860480|NCT03629444|RADIATION|ct scan|all patients will be subjected to CT scan and anthroprometric measurments
223860481|NCT03776890|BEHAVIORAL|DeStress for Health Program|The program will consist of 4 in person sessions that are based on empirically supported Positive Psychosocial Well-Being PPWB components including Optimism, Mindfulness, Positive Reprisal as well as Strengths-based Cognitive Behavioral Therapy (SBCBT) to improve behavioral self-regulation towards health-related goals. Research staff will conduct face-to-face surveys with participants at baseline and at end of program. Finally, we will conduct a phone-based survey 30 days after program completion to assess sustainability of intervention effects.
223860482|NCT03863834|DEVICE|InModeRF|InModeRF minimally invasive treatment based on Radiofrequency-assisted lipolysis (RFAL) technology
223860483|NCT02685488|DEVICE|Transcranial Ultrasound Power|Transcranial ultrasound will be to stimulate at the right fronto-temporal cortex. 30 seconds of stimulation at 500 kHZ with duty cycle 0.24% and pulse rate frequency at 40 Hz.
223860484|NCT02685488|DEVICE|Transcranial Ultrasound Sham|"Transcranial ultrasound will be used without power for a sham condition."
223860485|NCT02006017|OTHER|Evidence summary alone plus a recommendation|
223860486|NCT02006017|OTHER|Evidence summary alone|
223860487|NCT04118374|OTHER|Standard Carb Diet|Approximately 50% of caloric intake will come from carbohydrate consumption.
223860488|NCT04118374|OTHER|Low Carb Diet|Approximately 25% of caloric intake will come from carbohydrate consumption.
223860489|NCT04441242|OTHER|Ambient lighting|Use of ambient lighting (75-150 lux) in endoscopy room.
223860490|NCT04441242|OTHER|Low lighting|Use of low lighting (\<75 lux) in endoscopy room.
223860492|NCT00191035|DRUG|Atomoxetine|
223860493|NCT00185016|BEHAVIORAL|a training to improve recognition of partner abuse.|
223860494|NCT01940003|OTHER|Aquatic exercise|The aquatic exercise program will be under the professional guidance of a physiotherapist, with water at a temperature of around 26 to 28°C. The exercise sessions will be executed following the steps: 1) Heating (stretching and flexibility, static method, during 5'); 2) Aerobic exercise (running, displacements and combined movements of arms and legs, with 1minute interval, to 1minute activity and of during 20') 3) Spot exercises (strength / endurance of the upper and lower limbs and abdomen, using the resistance of water for 15') 4) Relaxation (slow walks for 5'). During the sessions of exercises the pregnant women will have heart rate monitored by the frequency meter (Polar Electro OY) to control the intensity of the exercises that will focus on the range of moderate intensity.
223860495|NCT05937919|DRUG|Intravenous injection of 68Ga-PMD22|68Ga-PMD22 were intravenous injected into the patients before PET/CT scans
223860496|NCT00924534|DRUG|Placebo|Placebo
223860497|NCT00924534|DRUG|SLV337|SLV337 400 mg/day
223860498|NCT00924534|DRUG|SLV337|SLV337 800 mg/day
223860499|NCT00924534|DRUG|SLV337|SLV337 1400 mg/day
223860500|NCT04483063|DRUG|2% chlorhexidine gluconate skin cleanser|2% chlorhexidine gluconate skin cleanser over shoulder region before shoulder surgery
223860501|NCT06553521|OTHER|MyHEARTSMAP Youth Self-assessment Tool (At Admission)|MyHEARTSMAP is a validated self-assessment tool for pediatric populations, demonstrating high sensitivity and specificity for identifying psychosocial concerns. Adapted from HEARTSMAP, it allows self- and proxy-reporting across 10 well-being domains, providing personalized recommendations. Currently, the clinician-reported HEARTSMAP is the standard of care at BC Children's Hospital ED for the initial assessment of youth with primary psychiatric concerns
223860502|NCT00092755|DRUG|MK0663, etoricoxib|
223860503|NCT00092755|DRUG|Comparators: ibuprofen and placebo|
223860504|NCT03773120|DEVICE|Using Neuromonitoring to find EBSLN|intraoperative neuromonitoring to preserving external branch of superior laryngeal nerve during thyroid surgery
223860505|NCT01326130|BEHAVIORAL|Chronic care management 1-6|1- an interdisciplinary team in an education center working with primary care physicians and offering to referred patients a pre-determined sequence of clinical interventions over a 2-year-period; 2- a program supporting primary care physicians (continuing education, documentation and clinical guidelines, referral system to second line of care); 3- networking between actors insuring clinical information transfer required for efficient patient management.
223860506|NCT05132686|BEHAVIORAL|IER+MED|Over a 6 month period follow a euenergetic Mediterranean diet 5 days per week and a 20% energy restriction over 2 contiguous days as a 70% energy restriction using the same macronutrient distribution of 45% carbohydrate, 25% energy from protein, and 30% energy from fat. For each participant a tailored diet plan is created based on sex, weight, height, and age. Complete a 1 hour walk five days per week.
223860507|NCT05132686|BEHAVIORAL|MED/DER|Over a 6 month period follow a Mediterranean diet 7 days per week with a 20% energy restriction 7 days a week using the macronutrient distribution of 45% carbohydrate, 25% energy from protein, and 30% energy from fat. For each participant a tailored diet plan is created based on sex, weight, height, and age. Complete a 1 hour walk five days per week.
223860508|NCT00509535|DRUG|vitreoscilla filiformis cream|
223860509|NCT02701855|BEHAVIORAL|Cognitive tests|"Cognitive tests include:~* The MMSE (Mini Mental State Examination)~* Free and Cued Selective Recall Reminding Test (FCSRT).~* Executive functions (fluencies, TMT A and B, span).~* Tests of verbal fluency (literal and category)~* Digit symbol substitution test or Wechsler adult intelligence scale (W.A.I.S)~* The Clinical Dementia Rating Scale~* The IADL scale evaluates autonomy.~* Geriatric Depression screening Scale (GDS)"
223860510|NCT02701855|BIOLOGICAL|Blood test|A blood test will be performed in order to collect following parameters: Urea, BUN, Creatinine, Potassium, Sodium, hematocrit, hsCRP, NFS, Pq, LDL-C, HDL-C, Triglycerides, Lp(a), Lp-PLA2 as well as fasting glucose, HbA1C and microalbuminuria
223860511|NCT02701855|RADIATION|Brain and aorta RMI|A magnetic resonance imaging exam will be performed at the Neuroimaging Research Center of the Pitié-Salpêtrière Hospital. This exam will be optimized to fit in 30 minutes. Indeed brain 3D T1 and T2 FLAIR imaging lasts 15 minutes while cine and velocity encoded imaging of the aorta lasts 15 minutes.
223860512|NCT02701855|OTHER|Adaptative optics|"The retina adaptative optic imaging will be performed at the Unité de prevention des maladies cardiovasculaires Pitié Salpetrière Hospital. This exam lasts 10 minutes including patient positioning and imaging."
223860513|NCT04776265|OTHER|Evaluation of therapeutical approach after ASCT|Evaluation of therapeutical approach after ASCT
223860514|NCT06318624|OTHER|Mobilisation with Movement and Taping|For MWM for the talocrural joint, the hemiparetic side of the participant is positioned in a standing position on a stool. A non-elastic belt is passed behind the patient's distal tibia and secured around the therapist's pelvis. The patient is asked to perform active knee flexion and ankle dorsiflexion with weight on the hemiparetic side. Meanwhile, the therapist performs forward sliding of the tibia with the help of the belt. For 10 seconds active and painless sliding takes place and then return to the starting position. This application is applied as 10 repetitions, 6 sets, and 1 minute rest between sets. Following the MWM application, Mulligan talus stabilization taping is performed. For this taping, the participants' ankles are placed on a stool at a height of 30 cm and their feet are placed in the dorsiflexion position. The therapist starts taping from the plantar surface of the calcaneus using rigid tape and will wrap and stabilize the talus.
223860515|NCT06318624|OTHER|Sham|During joint mobilization with movement, the therapist will stabilize the ankle while performing knee flexion and ankle dorsiflexion by actively moving the center of mass to the affected side, but the shear force required to slide the tibia forward with the belt will not be given. Placebo taping following the application will be applied in such a way that there is no stabilization effect without tension between the same start and end points.
223860516|NCT00476060|PROCEDURE|Autologous mesenchymal stem cell transplantation|Arm A: 300 million cells will be infused one time through a peripheral vein/// Arm B: Infusion of placebo one time through a peripheral vein
223860517|NCT03644329|OTHER|Control group|The volunteers will not performed the interventions.
223860518|NCT03644329|OTHER|Lower-load resistance training (LL)|The volunteers will be perform the resistance training, three times a week for 12 weeks on non-consecutive days, three sets with 30% of 1RM and repetition until or close to failure in each set and 1.5-min of rest between sets and exercises.
223860519|NCT03644329|OTHER|Higher-load resistance training (HL)|The volunteers will be perform the resistance training, three times a week for 12 weeks on non-consecutive days, three sets with 80% of 1RM and repetition until or close to failure in each set and 1.5-min of rest between sets and exercises.
223860520|NCT03644329|OTHER|Higher-volume resistance training (HV)|The volunteers will be perform the resistance training, three times a week for 12 weeks on non-consecutive days, six sets with 80% of 1RM and repetition until or close to failure in each set and 1.5-min of rest between sets and exercises.
223860521|NCT00694681|BEHAVIORAL|Telephonic care management|Individuals received intensive outreach from care managers, first to help them to enter treatment and then, if treatment began, to remain in it for an appropriate time. Treatment is based on the American Psychiatric Association's Evidence-Based Practice Guidelines for Major Depression, which includes psychotherapy and antidepressant medications. Outreach and care management took place by telephone.
223860522|NCT06974409|DEVICE|foam roller|foam rollers with grids, knobs, and spikes
223860523|NCT02380209|OTHER|CEST MRI|CEST MRI will be performed on patients prior to surgical resection of their tumor
223860524|NCT04561544|BEHAVIORAL|Knowing Who You Are (Becoming): Cultural Identity Intervention|8-week cultural identity development program led by Alaska Native Elders
223860525|NCT00476333|DEVICE|APOS biomechanical gait system|
223860526|NCT04850482|OTHER|MyJourney|MyJourney is an online self-help interactive program based on Contextual Cognitive Behavioural Therapy.
223860527|NCT04546997|DIAGNOSTIC_TEST|Optical Coherence Tomography Angiography|Patients underwent non-invasive, fast, diagnostic imaging technique (optical coherence tomography angiography)
223860528|NCT02160106|DRUG|TEW-7197|Single daily doses by oral administration on Days 1, 2, 3, 4, 5, Days 8, 9, 10, 11, 12, Days 15, 16, 17, 18, 19 and Days 22, 23, 24, 25, 26 of each 28 day cycle. Starting dose is 30 mg, with escalation to 60 mg, and subsequent dose escalation using a modified Fibonacci algorithm.
223860529|NCT01606995|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Patients with non-valvular atrial fibrillation who are prescribed rivaroxaban under routine treatment conditions to prevent stroke or non-central nervous system systemic embolism. Decision regarding dose and duration of treatment made at the discretion of the attending investigator
223860530|NCT03768206|BEHAVIORAL|Standard Physical Therapy|Participants will receive standard outpatient physical therapy that is typical following knee replacement
223860531|NCT03768206|BEHAVIORAL|Physical therapist discuss aerobic physical activity|Physical therapists will provide recommendations to increase aerobic physical activity and set goals during standard physical therapy sessions after knee replacement.
223860532|NCT03768206|BEHAVIORAL|Physical activity session|Participants will receive a one hour coaching session on aerobic physical activity and goal setting after knee replacement.
223860533|NCT01233154|DIETARY_SUPPLEMENT|probiotic|
223860534|NCT01233154|DIETARY_SUPPLEMENT|probiotic|
223860535|NCT03037502|BEHAVIORAL|Tailor Made: Solutions for your health (A su Medida: Soluciones para su salud)|Assess the effectiveness of a person-specific, randomized controlled pilot weight loss study of 80 African American and 40 Latino men; to compare changes in chronic disease risk behaviors (e.g., diet and physical activity), adiposity measures (e.g., body fat), and psychosocial mediators (e.g., social support, autonomous motivation) between data collected at baseline and at 3-months.
223860536|NCT04954040|DRUG|Hydroxychloroquine Pill + Azithromycin Pill|"Hydroxychloroquine. 1st day 200mg 2-0-2; 2nd to 5th day 200mg 1-0-1 Azithromycin.~1st day 500m 0-1-0, 2nd to 5th day 250mg 0-1-0"
223860537|NCT04954040|DRUG|SOC|Acetaminophen or Metamizole. Antitussives if needed.
223860538|NCT00332436|DRUG|brimonidine/timolol fixed combination|
223860539|NCT00329732|DRUG|0.5% bupivicaine and 2% lidocaine|The injectors will infiltrate an area of 2cm along the occipital ridge centering around the occipital artery or around the site 1/3 from the mastoid to the inion. If the subject has a bilateral headache or the headache is known to switch sides then the block will be performed bilaterally. If the headache is strictly unilateral, the block will be performed only on the side of the headache
223860540|NCT00329732|DRUG|Saline placebo|matching volume of saline (placebo)
223860541|NCT05658198|BEHAVIORAL|Counseling|Patients who first decline HPV vaccination receive a 3-5 minute counseling session on HPV and the benefits of the vaccine.
223860542|NCT00664911|OTHER|chemotherapy|
223860543|NCT02864628|BIOLOGICAL|MVA-BN-RSV|MVA-mBN294B
223860544|NCT02864628|OTHER|Placebo|Tris Buffered Saline
223860545|NCT04812938|DIAGNOSTIC_TEST|Patients with Ovarian cancer and pap test available|Define the possibility to detect through the pap test the presence of ovarian cancer cells in vaginal smear in patients with no evidence of ginecological malignancies.
223860546|NCT06073158|PROCEDURE|Esophageal biopsy collection during anastomosis|During the anastomosis, the surgeon will collect an esophageal mucosa biopsy
223860547|NCT00411099|DRUG|agomelatine|
223860548|NCT00411099|DRUG|placebo|
223860549|NCT00466414|DEVICE|Polycaprolactone Scaffold|
223860550|NCT01125306|DEVICE|Xal-Ease|Xal-Ease device used to facilitate application of Xalatan/Xalacom eye drops.
223860551|NCT01038349|OTHER|Avise PG - Diagnostic test|Eligible patients will receive an Avise PG test
223860552|NCT01884636|DRUG|isavuconazole|oral
223860553|NCT01884636|DRUG|methotrexate|oral
223860554|NCT00127179|DRUG|MK0906, finasteride / Duration of Treatment: 48 weeks|
223860555|NCT00127179|DRUG|Comparator: placebo / Duration of Treatment: 48 weeks|
223860556|NCT00220350|DRUG|leuprolide acetate|
223860557|NCT01948804|DRUG|GnrH Antagonist/letrozole protocol (Cetrotide; serono + Femara; Novartis Pharma AG)|
223860558|NCT01948804|DRUG|microdose flare-up protocol (Lucrin; Abbott + Gonal F, Serono)|
223860559|NCT01948804|DRUG|Antagonist/clomiphene protocol (Cetrotide; serono + Klomen, Kocak pharma)|
223860560|NCT01948804|DRUG|GnRH antagonist protocol (Cetrotide, Serono)|
223860561|NCT00000635|DRUG|Trifluridine|
223860562|NCT00000635|DRUG|Bacitracin zinc/Polymyxin B sulfate|
223860563|NCT02551055|DRUG|MLN1117|MLN1117 Tablets
223860564|NCT02551055|DRUG|TAK-659|TAK-659 Tablets
223860565|NCT02551055|DRUG|Alisertib|Alisertib Tablets
223860566|NCT02551055|DRUG|Paclitaxel|Paclitaxel intravenous infusion
223860567|NCT02551055|DRUG|Docetaxel|Docetaxel intravenous infusion
223860568|NCT05861388|PROCEDURE|implant placement|2 implants were placed at position of lower 2nd premolar and 2nd molar
223860569|NCT05393336|OTHER|V-sitting posture stabilization|15 patients will be given a hot pack with TENS for 15 minutes. Followed by static stretching of the gluteus, hamstrings, and Iliopsoas muscles for 10 to 30 seconds hold and 2 to 4 repetitions. Then the patient will perform the V-sitting exercise for 10 seconds starting with 5 repetitions and progressing to 15 overtime. Each patient will receive treatment for 6 days per week and 6 weeks.
223860570|NCT05393336|OTHER|Modified clamshell exercises|15 patients will be given a hot pack with TENS for 15 minutes. Followed by static stretching of the gluteus, hamstrings, and Iliopsoas muscles for 10 to 30 seconds hold and 2 to 4 repetitions. Then the patient will perform the modified clamshell exercise for 10 seconds starting with 5 repetitions and progressing to 15 overtime. Each patient will receive treatment for 6 days per week and 6 weeks.
223860571|NCT05213715|OTHER|assessment|assessment of upper extremity functions, somatosensorial functions and proprioseption of upper extremity
223860572|NCT05826704|DIETARY_SUPPLEMENT|Probiotics|Participants will be taking 2 capsule a day for 6 weeks
223860573|NCT00430300|DRUG|UK-432,097|Formulated as a dry powder, supplied as capsules and administered using an atomizer device. Given as either 150mcg, 450mcg or 1350mcg BID.
223860574|NCT00430300|DRUG|Placebo|Capsules containing 100% lactose administered BID using an atomizer device
223860575|NCT02969954|OTHER|Self-efficacy for diabetes management|Participants at both sites will watch a 12 minute video featuring the digital stories on diabetes. Following the video, participants will engage in a brief facilitated discussion regarding motivations and barriers to diabetes management, led by a trained Spanish-speaking facilitator.
223860576|NCT02023125|DRUG|Alectinib|A single 600-mg oral dose of alectinib will be administered in a fasted or fed condition.
223860577|NCT02023125|DRUG|Esomeprazole|Esomeprazole 40 mg will be administered orally once daily for 6 days prior to alectinib administration.
223860578|NCT02023125|OTHER|High Fat and Calorie Meal|High fat and calorie meal served prior to alectinib administration
223860579|NCT02023125|OTHER|Standard Meal|Standard meal served prior to alectinib administration
223860580|NCT03463135|DRUG|Glucopyranosyl Lipid A (GLA)|Pharmaceutical form:Colloidal aqueous dispersion Route of administration: Sublingual
223860581|NCT03463135|DRUG|Sublingual Immuno Therapy (SLIT) Peanut Extract (PE)|Pharmaceutical form:Solution Route of administration: Sublingual
223860582|NCT03463135|DRUG|Placebo for GLA|Pharmaceutical form:Colloidal aqueous dispersion Route of administration: Sublingual
223860583|NCT03463135|DRUG|Placebo for SLIT PE|Pharmaceutical form:Solution Route of administration: Sublingual
223860584|NCT02044588|BIOLOGICAL|HBsAg positive kidney allograft donor|
223860585|NCT01597752|BIOLOGICAL|Four different concentrations of Blomia tropicalis allergen extract, positive control and negative control|Four concentrations of Blomia tropicalis allergen extract, together with a positive and negative control will be tested in every patient in duplicate on the volar surface of the forearm.
223860586|NCT02754479|DEVICE|Nd:YAG laser|Treatment of lower extremity spider veins
223860587|NCT03012230|OTHER|Laboratory Biomarker Analysis|Correlative studies
223860588|NCT03012230|BIOLOGICAL|Pembrolizumab|Given IV
223860589|NCT03012230|DRUG|Ruxolitinib Phosphate|Given PO
223860590|NCT03655938|PROCEDURE|Piezocision combined minimally invasive alveolar bone regeneration|The piezocision surgery was performed two weeks after orthodontic appliance placement. The patients received local anesthesia in mandibular arch and vertical interproximal incisions were made below the interdental papillae in the midline, from the mesial aspect of each canine and in between each of the posterior lower teeth. The periostium was then released in order to create two subperiotal envelopes connecting the vertical incisions together. Thereafter, corticotomies were performed in the region of the incisions with a piezotome (Acteon, Merignac, France) and the envelopes were filled with a beta tricalcium phosphate, a resorbable biomaterial in order to thicken the buccal bone plate. Resorbable 5-0 sutures were used to close the flaps. Careful tooth brushing and the use of a mouthwash (chlorhexidine 0.2% Perio-Aid, Dentaid Benelux, Houten, Netherlands) were recommended for 7 days.
223860591|NCT00402155|BEHAVIORAL|Stress on visual discomfort|Effects of visual discomfort are measured by contrast sensitivity, ERGs, and accommodative stability.
223860592|NCT03911479|PROCEDURE|Bariatric Surgery|Bariatric Surgery - convencionals Roux-en-Y gastric bypass (RYGB) and vertical gastrectomy (Sleeve; SG)
223860593|NCT04408937|DRUG|triopifexor|Tropifexor as a dry blend in hard gelatin capsules for oral administration
223860594|NCT04408937|DRUG|Placebo|Placebo capsules for oral administration
223860595|NCT02666742|DRUG|DOAC|DOAC is a blood thinning drug, also called direct oral anticoagulant. These group of drugs are approved by the U.S. Food and Drug Administration (FDA) for the treatment of stroke prophylaxis in atrial fibrillation and deep vein thrombosis and pulmonary embolism, which are blood clots in the veins or lungs.
223860596|NCT02666742|DRUG|Aspirin|Aspirin works by reducing substances in the body that cause pain, fever, and inflammation. Aspirin is used to treat pain, and reduce fever or inflammation.
223860597|NCT05559346|OTHER|Diaphragmatic exercises|Diaphragm exercises will be applied to the research group in addition to conventional rehabilitation.The content of the individualized conventional rehabilitation program consists of passive stretching exercises, strengthening exercises to antagonists of spastic muscles and exercises aimed at improving weight transfer, balance and correction reactions, and postural control. In addition to conventional rehabilitation, manual diaphragmatic relaxation exercises and diaphragmatic breathing exercises will be applied to the children in the research group two days a week.
223860598|NCT05559346|OTHER|conventional physiotherapy|The control group will only be taken to the conventional rehabilitation program. e content of the individualized conventional rehabilitation program consists of passive stretching exercises, strengthening exercises to antagonists of spastic muscles and exercises aimed at improving weight transfer, balance and correction reactions, and postural control.
223860599|NCT00002972|DRUG|paclitaxel|
223860600|NCT01535144|DEVICE|Fracture compressing screw ZfW 102 Königsee Implantate GmbH|Comparison of two metallic implantable fracture compressing screws
223860601|NCT01535144|DEVICE|Fracture compressing screw titanium Königsee Implantate GmbH|Comparison of two metallic implantable fracture compressing screws
223860602|NCT04656886|DRUG|Intravenous Infusion|
223860603|NCT04028336|OTHER|TITRATION|PEP titration pulmonary opening (PEP-OP) was performed in all patients followed by new LUS and Peso measurement.
223860604|NCT01277796|DEVICE|Heat pack conduction-heat therapy|Hand warmer heat pack with reliable (and monitored) temperature (50-52 degrees Celsius) will be applied to lesion borders for 3 minutes (fractionated to 90 second intervals or less) every day, for 7 consecutive days.
223860605|NCT04128423|BIOLOGICAL|AMV564|AMV564 will be administered daily
223860606|NCT05338996|BEHAVIORAL|iENGAGE for PrEP|This intervention originally developed for people living with HIV (PLWH), is designed to promote engagement, retention, and adherence to treatment by addressing the social determinants of health that often act as barrier to remaining in care and achieving viral suppression. Based on our experience with this intervention we believe that it is well suited to similarly promote engagement, retention, and utilization of PrEP care among our proposed target population of WOC by a) removing barriers to care and b) addressing unmet needs by providing c) point-to-point linkage to care services delivered by multi-disciplinary teams of individuals within or outside of the health facility, and d) the use of telehealth visits to facilitate engagement in care and improve health visit attendance. The original iENGAGE is a 4-session, in-clinic behavioral intervention.
223860607|NCT02205307|DEVICE|PINPOINT|
223860608|NCT02205307|DEVICE|SPY Elite|
223860609|NCT03026036|RADIATION|PET Scan with Raclopride|A subsample (21 per group) will complete the PET imaging.
223860610|NCT04878081|BEHAVIORAL|hot flush|"Hot Flash Diaries to record the change of daily hot flush symptoms for 30 days. The Hot Flash Related Daily Interference Scale to record how much did hot flush effect daily life.~The Kupperman menopausal index to evaluate the severity of menopausal symptoms. The Pittsburgh Sleep Quality Index to evaluate sleep disorder. Wireless temperature monitor to record hot flush and body temperature during sleeping.~Classify patients' traditional Chinese constitution by using Physical classification and judgment self-test table."
223860611|NCT01941563|DRUG|Condoliase|1.25U, intradiscal injection, one time
223860612|NCT01941563|DRUG|placebo|
223860613|NCT05828550|DIAGNOSTIC_TEST|antibiotic sensitivity|"The resistance pattern of the isolates will be detected by disc diffusion method.~Detection of efflux pump genes responsible for the resistance ( norA , norB , norC ) by PCR"
223860614|NCT06964282|PROCEDURE|PENG Block|Also performed under ultrasound guidance with an 80 mm B-Braun X360 needle and a 3-5 MHz curved probe. The femoral nerve, femoral artery, iliopsoas muscle, and pubic ramus are identified. The needle is inserted in-plane, and 14 ml of ropivacaine 3.75 mg/ml is injected between the psoas tendon and pubic ramus.
223860615|NCT06964282|PROCEDURE|Iliopsoas nerve block|Performed under ultrasound guidance with a curvilinear probe (5-2 MHz). The transducer is positioned transversely below the anterior superior iliac spine (ASIS), then pivoted medially. After identifying the femoral head and acetabular rim, a 22G 80 mm needle is inserted in-plane to reach the iliopsoas plane, lateral to the iliopsoas tendon. 7 ml of ropivacaine 7.5 mg/ml is then injected.
223860616|NCT04323202|DRUG|Pembrolizumab|Post Fine-cut CT: 4 doses of pembrolizumab (200mg) IV q 3 weeks. Post standard resection and reconstruction: 1 year of pembrolizumab (200mg) q 3 weeks (another 13 doses, thus 17 doses total)
223860617|NCT04323202|OTHER|Tissue collection|Non-marginal tissue as well as pre-op biopsy tissue to be stored
223860618|NCT06139315|DRUG|BI 765845|BI 765845
223860619|NCT06139315|DRUG|Placebo|Placebo
223860620|NCT05520658|DRUG|combined digoxin and furosemide|one session every 2 weeks for maximum 6 sessions
223860621|NCT05520658|DRUG|5 fluorouracil|5 fluorouracil mixed with1ml of 2% lignocaine and epinephrine one session every 2 weeks for maximum 6 sessions .
223860622|NCT03883542|GENETIC|genomic mutations study|"Sequencing of the DNA samples extracted from the subgroups~1. serous BOT tissue,~2. serous BOT tissue with non-invasive implants and~3. serous BOT tissue with micropapillary grow pattern will undergo a panel testing for Type 1 genes (small panel 15-40 mutations) AND p53 AND BRCA testing~Sequencing of the DNA samples extracted from the serous BOT tissue with invasive implants will undergo a more comprehensive examination (large panel +- 1000 genes checked)"
223860623|NCT06795763|DEVICE|CTO-PCI Procedure with Acolyte Catheter System|Acolyte Catheter System is used to facilitate placement and positioning of guidewires and catheters within the coronary vasculature for the treatment of patients with coronary chronic total occlusions with persistent symptoms following medical therapy. The device provides real-time visualization of a coronary chronic total occlusion allowing for guidewire placement in the true lumen of the target vessel and subsequent revascularization.
223860624|NCT06108934|DEVICE|Hip stem prosthesis|The Insignia hip stem prosthesis will be used in cementless total hip replacement surgery (THA). The surgery typically takes approximately two hours. All study participants will receive the Insignia hip stem and compatible components. Experienced Orthopaedic Surgeons trained in THA will perform the surgeries as per the standard surgical technique guide for this prosthesis.
223860625|NCT03922880|DRUG|ADI PEG20|ADI-PEG 20 will be administered at a dose of 36mg/m2 intramuscularly once a week.
223860626|NCT03922880|DRUG|Nivolumab|Nivolumab 240mg + Ipilimumab 1mg/kg for up to 8 total doses of ipilimumab. One ipilimumab has completed, nivolumab 480mg will be given every 4 weeks.
223860627|NCT03922880|DRUG|Ipilimumab|Ipilimumab 1mg/kg with Nivolumab 240mg for up to 8 total doses of ipilimumab. The first four doses of ipilimumab will be scheduled once every 3 weeks. The 5th-8th doses of ipilimumab will be scheduled once every 6 weeks with nivoumab 240mg every 3 weeks.
223860628|NCT03827369|DIAGNOSTIC_TEST|ICU patient|Our study is to measure the coefficient of variation of the HCV of the radial arterial pulse among ICU patients with multiple organ failures (MOF). Patients admitted to Taoyuan General Hospital were recorded during the 6 months study.
223860629|NCT02301559|BEHAVIORAL|Pilates exercises|Pilates exercises with emphasis on pelvic region
223860630|NCT00131066|OTHER|Follow up from previous treatment with MEDI-507|There will be no investigational drugs administered under this protocol.
223860631|NCT03310645|DRUG|BAY1817080|4 different doses over the course of study
223860632|NCT03310645|DRUG|Matching Placebo|Matching placebo for BAY1817080
223860633|NCT04737681|OTHER|body composition|This is an observational study to determine immune response and skin barrier restoration in individuals with and without obesity.
223860634|NCT00867867|DRUG|Ferrous fumarate|9.3 mg once per day, 6 days per week, for 9 months
223860635|NCT00867867|DRUG|Ferric pyrophosphate|9.3 mg once per day, 6 days per week, for 9 months
223860636|NCT00867867|DRUG|Placebo|9.3 mg once per day, 6 days per week, for 9 months
223860637|NCT00071253|DRUG|Divalproex Sodium (Delayed-Release Tablets)|
223860638|NCT00071253|DRUG|Divalproex Sodium (Extended-Release Tablets)|
223860639|NCT00071253|DRUG|Olanzapine|
224266637|NCT00869713|BIOLOGICAL|Inactivated, Dried (TSI-GSD 200), RVF Vaccine|All subjects: 1.0-mL (SQ)doses on day 0, once between days 7 \& 14, \& once between days 28-42. Initial responders: A 6-month mandatory vaccine booster dose (1.0 mL, SQ) will be given if the PRNT80 is ≥1:40 after the primary series. Subsequent booster doses will be given for PRNT80 titer \<1:40. Initial non-responders: Individual who has a PRNT80 titer \<1:40 following the primary series may be administered a booster dose before 6 months. The individual will not receive the mandatory 6-month booster dose. Once an initial non-responder achieves PRNT80 ≥1:40, additional booster doses will be given for subsequent PRNT80 \<1:40). All subjects: RVF booster dose will be administered within 90 days after a PRNT80 result of \<1:40.
224266638|NCT05501158|DRUG|Tamoxifen|Suggesting an increase in the dose of tamoxifen to those who have suboptimum level of endoxifen due to their genetic variations
224266639|NCT02090933|DRUG|Celecoxib|Given PO
224266640|NCT02090933|OTHER|Laboratory Biomarker Analysis|Correlative studies
224266641|NCT02090933|PROCEDURE|UV Light Therapy|Undergo UV-irradiation
224266642|NCT05458960|BEHAVIORAL|Social needs navigator program|4 months of assistance tailored to the needs of the participant
224266643|NCT05458960|BEHAVIORAL|Enhanced usual care|Referral to United Way 2-1-1
224266644|NCT03062176|DRUG|Anakinra|Anakinra (Kineret)
224266645|NCT05001191|OTHER|Gentle Human Touch|Gentle human touch, which has a pain and stress-reducing effect, is a sensitive tactile stimulus applied to the skin, without caress or massage, which provides a kind of relaxation.
224266646|NCT02563418|DEVICE|Eye-tracking|
224266647|NCT02663856|OTHER|observational|Self assessment of ageing transition using a frailty index through MySAwH app
224266648|NCT06504121|DEVICE|Septal Occluder Device|Transcatheter PFO closure with any commercially available septal occluder device
224266649|NCT04381013|DEVICE|Emergency Ventilator Splitter|Device to enable oxygen delivery to two patients independently from a single ventilator.
224266650|NCT03856034|DEVICE|Fetoscopy|Patients will receive fetoscopic repair of myelomeningocele. Patients with an anterior placenta will undergo the laparotomy with uterine exteriorization approach. Patients with a posterior placenta will undergo the percutaneous approach (or, if patient prefers, the laparotomy with uterine exteriorization approach).
224266651|NCT04102345|OTHER|Lavender Aromatherapy|Commercially available lavender essential oil and diffuser.
224266652|NCT04102345|DRUG|Zolpidem|Physician directed, pre-prescribed. Study team does not prescribe zolpidem.
224266653|NCT00385736|BIOLOGICAL|adalimumab|Prefilled syringe, 40 mg (loading dose then every other week dosing). 80 mg at Week 0, 40 mg at Week 2, and 40 mg every other week starting at Week 4.
224266654|NCT00385736|BIOLOGICAL|adalimumab|Prefilled syringe, 40 mg (loading dose then every other week dosing). 160 mg at Week 0, 80 mg at Week 2, and 40 mg every other week starting at Week 4.
224266655|NCT00385736|BIOLOGICAL|placebo|Placebo for 40 mg syringe. Matching placebo for loading dose and every other week dosing. Subjects received placebo at Weeks 0, 2, 4, and 6, followed by 160 mg adalimumab at Week 8, 80 mg adalimumab at Week 10, and 40 mg adalimumab eow thereafter (prior to Amendment 3) or 40 mg adalimumab eow starting at Week 8 (after Amendment 3).
224266656|NCT06298123|DRUG|Anti-PD-1 monoclonal antibody|The independent risk factors for hepatocellular carcinoma (HCC) patients undergoing adjuvant immunotherapy after hepatic resection surgery were analysed by retrospectively collecting patient data from the Centre for Liver Surgery, Tongji Hospital, during the period of February 2019 to February 2023, and comprehensively evaluating the patients' demographic characteristics, oncological parameters, surgical details, and response to immunotherapy, and establishing a prognostic model based on these factors.
224266657|NCT04628975|DEVICE|transillumination dispositif|infrared light
224266658|NCT04381871|DIETARY_SUPPLEMENT|Acacia Senegal|Oral Digestion of Gum Arabic to be consumed early morning on daily basis for 4weeks
224266659|NCT04381871|DIETARY_SUPPLEMENT|Pectin|Oral Digestion of Pectin to be consumed early morning on daily basis for 12 weeks
224266660|NCT02341690|OTHER|Interval walking training|"Interval Walking Training with the InterWalk Application An Interval-walking bout will consist of repeated cycles of 3 minutes of fast and 3 minutes of slow walking at 70% and 40% of the smart-phone assessed peak VO2-rate, respectively.~IWT is conducted for at least 60 minutes per day, three days per week. Compliance is monitored continuously using the on-board accelerometer logger"
224266661|NCT02341690|OTHER|control|Standard care at the promotion centre in the municipality
224266662|NCT06359275|DRUG|PD-1|Toripalimab，240 mg/time，D1， Q3W
224266663|NCT06359275|DRUG|Nab-paclitaxel|Nab-paclitaxel, 125mg/m2，IV，D1，8, Q3W
224266664|NCT06359275|DRUG|Gemcitabine|Gemcitabine，1000mg/m2，IV，D1，8，Q3W
224266665|NCT06359275|RADIATION|PULSAR|5-10 Gy per session, a total of 5 times.
224266666|NCT00198133|DRUG|Premetrexed (Alimta)|Pemetrexed will be 500 mg/m2 IV every 3 weeks
224266667|NCT03332264|DEVICE|SeQuent Please OTW|Dilatation of occluded or highly stenosed vessel with paclitaxel-coated balloon catheter
224266668|NCT03332264|DEVICE|Eluvia Vascular Stent System|Dilatation of occluded or highly stenosed vessel with paclitaxel-coated stent
224266669|NCT03332264|DEVICE|Nitinol stent|Dilatation of occluded or highly stenosed vessel with uncoated bare nitinol stent
224266670|NCT00175669|DRUG|Botox injections|Data not known.
224266671|NCT04323527|DRUG|Chloroquine diphosphate|150mg chloroquine diphosphate tablets. Note: Tablets used in the study were Chloroquine Diphosphate (produced by Farmanguinhos/Fiocruz), and the dosing stated in the clinicaltrials.gov refers to chloroquine base (in mg).
223860640|NCT03868397|DIAGNOSTIC_TEST|Liver MRI|"Liver MRI including 4D flow sequence is performed twice in liver transplantation recipients, before and 1 month-after transplantation.~In donor candidates, liver MRI including 4D flow sequence is performed twice in 1-3 weeks to assess repeatability of the technique."
223860641|NCT01049503|OTHER|Low fluoride and conventional dentifrices with different pH|Comparison of different dentifrice fluoride concentrations and pH on caries control
223860642|NCT00726596|DRUG|hydroxychloroquine|Hydroxychloroquine will be taken at a dose of 200 mg twice per day in the first 27 patients (cohort A). Once cohort A completed, the dose of hydroxychloroquine will then be increased to 600mg per day (200mg three times per day)(cohort B).
223860643|NCT02952209|DEVICE|Xenograft|
223860644|NCT05966350|DIAGNOSTIC_TEST|Diagnosis of sensitive neuronopathy - phase 1|Search of positivity with anti-AGO antibodies test
223860645|NCT05966350|DIAGNOSTIC_TEST|Diagnosis of sensitive neuronopathy - phase 2|Title of anti-AGO antibodies
224266672|NCT02573662|BIOLOGICAL|Blood and Urine sampling|Blood and Urine Sampling
224266673|NCT02573662|RADIATION|DXA scan|Scan of Lumbar columna and neck of femur/hip Scan of visceral/subcutaneous fatty tissue
224266674|NCT02573662|BIOLOGICAL|OGTT|Oral Glucose Tolerance Test for Minimal Model analysis for insulin sensitivity and Lipid oxidation
224266675|NCT02997891|DIAGNOSTIC_TEST|everyday activity|To objectively quantify the everyday activity, there are a variety of instruments, without a currently gold standard. Therefore, in addition the investigators use objectified measurement parameters with the aid of a pedometer (GARMIN vivofit) on every three measuring time points (before surgery, 3 months after surgery, 6 months after surgery).
224266676|NCT02997891|DIAGNOSTIC_TEST|cognitive performance|Standardized neuropsychological assessment methods are used to assess the cognitive performance. To assess the degree of mobility, health status and the physical activity standardized questionnaires are used.
224266677|NCT05356091|DRUG|Sevoflurane|Sevoflurane is chosen as an anesthetic agent for general anesthesia. General anesthesia for the patients in this group will be induced with propofol (1-1.5 mg/kg), and will be maintained with sevoflurane to keep patient state index of 25-50.
224266678|NCT05356091|DRUG|Remimazolam|Remimazolam is chosen as an anesthetic agent for general anesthesia. General anesthesia for the patients in this group will be induced with remimazolam, and will be maintained with remimazolam to keep patient state index of 25-50.
224266679|NCT05361252|PROCEDURE|SVV-guided fluid management|fluid will be guided by value of stroke volume variation
224266680|NCT01531790|DRUG|Carboplatin|d1, AUC 5, i.v.
224266681|NCT01531790|DRUG|Pemetrexed|d1, 500 mg/m2, i.v.
224266682|NCT01531790|DRUG|Endostar|d2-d21, continuous Endostar intravenous infusion, 7.5 mg/m2/d, 15 mg/m2/d or 30 mg/m2/d, etc.
224266683|NCT01531790|DRUG|Centrum|1 tablet/day
224266684|NCT06152796|DRUG|Paracetamol|Anti\_inflammatory drug
224266685|NCT06152796|DRUG|Ibuprofen|Non steroidal anti\_inflammatory drug
224266686|NCT03200145|OTHER|ACP intervention|"The intervention group made by persons living in nursing homes using a person centered attention model relying on two dimensions:~1. \- Attention to the person based on:~   * Knowledge of the person in several dimensions (biological, psychological, social, etc), interests and preferences.~  * Respect and acknowledge of the person.~  * Promotion of the autonomy.~  * Personalized treatment, with tailored attention and integrative cures~  * Protection of physical well-being, preventing damages and risks and promoting healthy habits.~  * Promotion of independence on daily activities.~  * Protection of privacy and personal matters~2. \- Positive environment based on:~   * Physical space, including accessibility, comfort, homely environment, with stimulating spaces for physical activity, social relationships and significant activities for the persons.~  * Social relationships, with proximity and collaboration with families.~  * Friendly organization, with empathetic professionals empowering users."
224266687|NCT00496860|BIOLOGICAL|ALT-801|Dose escalation (0.015 mg/kg, 0.04 mg/kg, 0.08 mg/kg, 0.12 mg/kg, 0.14 mg/kg, 0.16 mg/kg), intravenous infusions, two treatment cycle, each cycle with 4 daily on-dose infusion, 10 days rest between cycles.
224266688|NCT03694106|BEHAVIORAL|TEAM PSYCHOTHERAPY|Patients data will be collected from the first to the final psychotherapy session as performed normally by TEAM trained clinicians. The treatment-as-usual includes therapy sessions of 50 to 110minutes long, typically once or twice per week for an average of 8-12 sessions. Treatment as usual by these clinicians includes the use of psychological symptoms survey immediately before and after each psychotherapy session. Typically patients will fill out these surveys in the clinic's waiting area before and after each session.
224266689|NCT05461716|DEVICE|periodic use of Continuous Glucose Monitoring (CGM)|Identification of hypoglycaemia events, based on use of Continuous Glucose Monitoring (CGM) for at least 14days, in subgroups of T2DM patients with high risk of hypoglycaemia
224266690|NCT01219140|DIETARY_SUPPLEMENT|2 POMx Capsules|2 POMx Capsules daily
224266691|NCT01219140|DIETARY_SUPPLEMENT|2 placebo Capsules|2 placebo Capsules daily
224266692|NCT05206162|DEVICE|theta burst stimulation|TBS over the left motor hotspot, delivered at 80% of resting motor threshold (RMT), according to the Huang et al. protocol, consisting of bursts of stimuli that are presented every 200ms (5Hz), with bursts consisting of 3 stimuli at 50 Hz. A total of 600 pulses are delivered.
224266693|NCT05320237|OTHER|Immersive Virtual Reality Intervention|Eight week intervention with two sessions a week. Each session will be 30 minutes in duration and will involve participants partaking in VR and such games include targeting individual finger movement (playing piano); grasp and release and one game (catching falling stars) includes holding a controller for elbow flexion and extension (Whack-a-mole).
224266694|NCT05797207|DIAGNOSTIC_TEST|Artificial Intelligence-assisted Fecal Microbiome Testing|Next-generation sequencing of fecal samples and artificial intelligence analysis of test results
224266695|NCT05797207|PROCEDURE|Colonoscopy|Colonoscopy procedure
224266696|NCT01449188|DRUG|ondansetron|FDA approved drug used to treat nausea and vomiting
224266697|NCT01449188|DRUG|moxifloxacin|FDA approved antibiotic commonly used as a positive control in thorough QT studies
224266698|NCT01449188|OTHER|saline|USP saline IV solution used as placebo for ondansetron IV.
224266699|NCT00835666|DRUG|Finasteride 5 mg tablets|1 x 5 mg, single dose fasting
224266700|NCT00835666|DRUG|PROSCAR®|1 x 5 mg, single dose fasting
223860646|NCT05966350|OTHER|Comparison with Chi2 method|Clinical data from positive Argonaute (AGO) patients (age, sex, type of neuropathy, clinical manifestations of neuropathy, electroneuromyography , evolution of neuropathy, presence of associated autoimmune disease, response to possible immunomodulatory treatment) will be compared with those of negative patients using a Chi2 method for qualitative data.
223860647|NCT05966350|OTHER|Comparison of data with parametric Test (T-test)|Clinical data from positive Argonaute (AGO) patients (age, sex, type of neuropathy, clinical manifestations of neuropathy, electroneuromyography, evolution of neuropathy, presence of associated autoimmune disease, response to possible immunomodulatory treatment) will be compared with those of negative patients using a parametric test (T-test).
223860648|NCT05966350|OTHER|Comparison of data with non-parametric test (ANNOVA)|Clinical data from positive Argonaute (AGO) patients (age, sex, type of neuropathy, clinical manifestations of neuropathy, electroneuromyography , evolution of neuropathy, presence of associated autoimmune disease, response to possible immunomodulatory treatment) will be compared with those of negative patients using a non-parametric (ANNOVA).
223860649|NCT06242782|PROCEDURE|VRA + d-PTFE membrane|VRA using a 50/50 particulate bone mix (xenograft+ autograft) + Ti-Reinforced d-PTFE membrane
223860650|NCT06242782|PROCEDURE|VRA + e-PTFE membrane|VRA using a 50/50 particulate bone mix (xenograft+ autograft) + Ti-Reinforced e-PTFE membrane
223860651|NCT06242782|PROCEDURE|VRA + customised Ti-mesh|VRA using a 50/50 particulate bone mix (xenograft+ autograft) + 3D printed Titanium mesh
223860652|NCT06242782|PROCEDURE|VRA + RPM|VRA using a 50/50 particulate bone mix (xenograft+ autograft) + Reinforced PTFE mesh
223860653|NCT01566916|PROCEDURE|Total Hip Arthroplasty|
223860654|NCT06185738|OTHER|WCM app|WCM app evaluation at baseline, at completion of WCM program and 4 weeks after completion of WCM program, by completing PROMIS and Self Efficacy for managing disease scale questionnaires
223860655|NCT02370758|DRUG|Valganciclovir or Ganciclovir|
223860656|NCT02036307|DIETARY_SUPPLEMENT|DHA-enriched|DHA 3g + 600 mg EPA in 6 g of fish oil/day given for 4 weeks
223860657|NCT02036307|DIETARY_SUPPLEMENT|EPA-enriched|EPA 2.4 g + DHA 600mg in 6 g of fish oil/day for 4 weeks
223860658|NCT04591067|OTHER|Testing of physical capacity|"This cross-sectional study will involve evaluation of physical capacity by assessment of:~1. Gait function~2. Muscle activity during walking~3. Endurance during walking~4. Hip muscle strength~5. Hip range of motion~6. Hip and muscle-tendon-related groin pain~7. Hip and groin related patient-reported outcome measures (PROMs)"
223860659|NCT04901312|BEHAVIORAL|Adolescent Community Reinforcement Approach|The Adolescent Community Reinforcement Approach (A-CRA) is a developmentally-appropriate behavioral treatment for youth and young adults ages 12 to 24 years old with substance use disorders. A-CRA seeks to increase the family, social, and educational/vocational reinforces to support recovery. This intervention has been implemented in outpatient, intensive outpatient, and residential treatment settings. A-CRA includes guidelines for three types of sessions: individuals alone, parents/caregivers alone, and individuals and parents/caregivers together. According to the individual's needs and self-assessment of happiness in multiple life areas, clinicians choose from a variety of A-CRA procedures that address, for example, problem-solving skills to cope with day-to-day stressors, communication skills, and active participation in positive social and recreational activities with the goal of improving life satisfaction and eliminating alcohol and substance use problems.
223860660|NCT04901312|BEHAVIORAL|Assertive Continuing Care|Assertive Continuing Care (ACC) uses Community Reinforcement Approach (CRA) procedures, home visits, and case management for individuals following an initial substance use treatment episode. It stresses rapid initiation of services after discharge from residential, intensive outpatient, or regular outpatient treatment in order to promote recovery and prevent relapse.
223860661|NCT04901312|BEHAVIORAL|Trauma Affect Regulation Guide for Education and Therapy|Trauma Affect Regulation: Guide for Education and Therapy is a psychosocial intervention for traumatized adolescents, adults, and families, and for workforce and organizational responses to secondary/vicarious traumatization. T4, the 4-session version, provides education about the impact of complex traumatic stress on the brain's stress response system, and strengths-based practical skills for re-setting the trauma-related alarm/survival reactions that occur in complex PTSD.
223860662|NCT04901312|BEHAVIORAL|Motivational Interviewing|Motivational interviewing is a collaborative, person-centered form of guiding to elicit and strengthen motivation for change.
223860663|NCT04901312|OTHER|Opioid Education Workbook|A digital workbook designed to be completed on a computer in about 2 hours. Topics include opioid use, opioid use disorder, and prevention and treatment of opioid overdose.
223860664|NCT04459169|PROCEDURE|diagnostic algorithm|Cardiac amyloidosis diagnosed according to Gillmore's algorithm
223860665|NCT02549313|PROCEDURE|position changes of the head|Registration of blood flow changes induced when the patient's head will be tilted at 0 ° (that is to say flat), 15 ° and 30 ° (the order of actions will be determined by drawing lots). The patient will remain 10 minutes in each of these positions.
224266701|NCT03599362|DRUG|Nivolumab + Cabiralizumab|Will be administered on Day 1 and Day 14; Subjects will continue treatment every 2 weeks with subsequent imaging every 8 weeks.
224266702|NCT03599362|RADIATION|Stereotactic Body Radiotherapy (SBRT)|Patients will be simulated supine with the addition of a 4D C T if appropriate. A stereotactic immobilization device with abdominal compression will be used.
224266703|NCT01887522|DRUG|Vinblastine + Nilotinib|"* Vinblastine: administered in a 15-minute infusion, once weekly on Days 1, 8, 15 and 22 of each 28-day cycle.~* Nilotinib (Tasigna®): orally BID given continuously on Days 1- 28"
224266704|NCT01887522|DRUG|Vinblastine|· Vinblastine 6 mg/m2 given in a 15-minute infusion, once weekly on Days 1, 8, 15 and 22 of each 28-day cycle.
224266705|NCT04823169|OTHER|podobarometry|podobarometric measures on day 7 and day 30
224266706|NCT06150963|DEVICE|Virtual Reality|Study participants assigned to the VR intervention group were fitted with an HP Reverb G2 Head Mounted Display (HMD) and a wireless mouse prior to preparation for procedure. One virtual environment was utilized, integrating passive and active participant input via gyroscopic motion detection and computer mouse input.
224266707|NCT06150963|PROCEDURE|Standard Procedure Thyroid Biopsy|In this procedure the patient lies down on a bed with their neck tilted back to reveal the thyroid gland. The doctor cleans the skin over the nodule and numbs it with a local anesthetic. The doctor will then use an ultrasound device to visualize the nodule and guide a needle to obtain cells through the syringe. This process may be repeated several times to retrieve adequate tissue for analysis.
224266708|NCT06150963|PROCEDURE|Standard Procedure PICC Placement|In this procedure the patient lies down on a bed and has their arm cleaned and then numbed with a local anesthetic. The doctor then uses an ultrasound to locate a suitable vein in the arm, typically above the elbow. The physician then makes a small incision in the skin and inserts a needle into the vein, followed by guidance of the Peripherally Inserted Central Catheter (PICC) through the needle until it reaches a large vein near the heart. The final position is confirmed by X-ray and the PICC line is secured at the site of insertion.
224266709|NCT00197938|PROCEDURE|Measurement of rectal lactic acid.|
224266710|NCT00007423|BIOLOGICAL|ALVAC-HIV MN120TMG (vCP205)|
224266711|NCT00007423|BIOLOGICAL|ALVAC-RG Rabies Glycoprotein (vCP65)|
224266712|NCT00348764|DRUG|lauromacrogol|
224266713|NCT04533620|RADIATION|Standardized CIRT|CIRT with a dose of 63 GyE/21 fx
224266714|NCT04533620|RADIATION|Individualized CIRT|A predictive model will be used to predict the chance of developing mucosal necrosis after salvage carbon-ion radiotherapy, and individualized dose prescription will be given. A dose of 60 GyE/20 fx, 63 GyE/21 fx and 66 GyE/22 fx will be given to patients with high, moderate and low risk of developing mucosal necrosis, respectively.
224266715|NCT00028587|DRUG|bortezomib|Given IV
224266716|NCT00028587|DRUG|paclitaxel|Given IV
224266717|NCT00028587|DRUG|carboplatin|Given IV
224266718|NCT00028587|OTHER|laboratory biomarker analysis|Optional correlative studies
224266719|NCT03707587|DRUG|M7824|Patients will receive 1200 mg intravenous (IV) of M7824 on day 1 of a 14 day cycle, every other week, for up to 12 weeks total treatment (6 cycles).
224266720|NCT01537887|DRUG|LY2484595|Administered orally once daily for 10 days.
224266721|NCT01537887|DRUG|Placebo|Administered orally once daily for 10 days.
224266722|NCT01537887|DRUG|Moxifloxacin|Single dose administered orally.
224266723|NCT05476588|OTHER|Screening|Screening and validation of assessment tool translated into Spanish
224266724|NCT02312154|DEVICE|Restylane Vital|stabilized hyaluronic acid (HA)-based gel of nonanimal origin
224266725|NCT00603499|DIETARY_SUPPLEMENT|Magnesium chloride|Subjects in the intervention group received 2.5 gr of MgCl2 daily during 4 months, from a solution solution containing 50 gr of MgCl2 by 1000 ml.
224266726|NCT00603499|OTHER|Placebo|Subjects in the control group received inert placebo once per day during 4 months
223860666|NCT04191954|DRUG|Fasudil eye drops (concentration 0.5 percent)|receive Fasudil eye drops (concentration 0.5 percent) twice daily
223860667|NCT04191954|DRUG|receive artificial tears drop|receive artificial tears drop with the same frequency
223860668|NCT05747313|DRUG|Chidamide|"Phase Ib:~The dose of vincristine administered in this phase is 40 mg on days 1,3,5 of each cycle.~The timepoint for chidamide dosing in this phase is twice weekly, i.e., dosing on days 1,4,8,11,15,18 of each cycle. Take 30 minutes after a meal.~Phase II:~This phase is based on the MTD/RP2D determined in phase I. The phase II expansion group study was conducted. Vincristine is administered at a dose of 40 mg on days 1,3,5 of each cycle. Chidamide was administered at a dose of MTD/RP2D twice a week on days 1,4,8,11,15 and 18 of each cycle. It is to be taken 30 minutes after a meal."
223860669|NCT06203197|OTHER|Patients in the intervention group will use the mobile-based care support application (M-Breast cancer personal care and monitoring system (M-MEKKBİS)|intervention group will use the mobile-based care support application (M-Breast cancer personal care and monitoring system (M-MEKKBİS).
224266727|NCT06468254|DRUG|Statin|Statin Group: Conventional chemotherapy and maintenance therapy combined with statins.
224266728|NCT06468254|DRUG|Sugar pill|Control Group: Conventional chemotherapy and maintenance therapy alone.
224266729|NCT05581407|BIOLOGICAL|TETRALITE|LiteVax Adjuvanted Seasonal Influenza Vaccine
224266730|NCT04413266|DIETARY_SUPPLEMENT|Curcumin supplementation|The patients will receive 3 capsules per day containing 500mg of curcumin for 4 weeks
224266731|NCT02871076|DEVICE|Acupuncture|Patients will be randomized to either treatment arm, verum acupuncture or sham placebo acupuncture.
224266732|NCT03785730|PROCEDURE|Non-restorative cavity control - NRCC group|The proximal cavities will be enlarged with metallic sandpaper, exposing the cavity, to allow access for toothbrushing associated with 1000 ppm fluoride toothpaste.
224266733|NCT03785730|PROCEDURE|Restoration with resin composite - RCR group|In control group, the treatment will be performed after prophylaxis and relative isolation. The selective carious tissue removal will be performed with appropriate dentin curettes. The acid conditioning will be performed only in enamel for 15 s with 37% phosphoric acid gel, and then the application of the adhesive system and restoration of resin composite will be conducted.
224266734|NCT00955448|DEVICE|SIS mesh (Cook Medical)|Anterior prolapse repair will be reinforced using surgical mesh made from porcine small intestine mucosa (Cook Medical)
224266735|NCT00955448|PROCEDURE|Anterior prolapse repair|Anterior prolapse repair will be conducted without using mesh reinforcement
224266736|NCT03578939|PROCEDURE|Biopsy EUS guided|NGS Sequencing on Biopsy samples
224266737|NCT01634139|DRUG|Tiotropium low dose QD|2 actuations once daily in the evening
224266738|NCT01634139|DRUG|Tiotropium high dose QD|2 actuations once daily in the evening
224266739|NCT01634139|DRUG|Placebo|2 actuations once daily in the evening
224266740|NCT04724616|OTHER|Educational Program (CARTOON)|CARTOON is an interdisciplinary psychoeducational intervention program. It consists of five teaching sessions: 1) hand hygiene, not grasping the face, 2) sneezing etiquette, 3) wearing a mask, 4) social distancing, and 5) theoretical knowledge about the coronavirus. Using special exercises and games, information about the coronavirus is conveyed in a child friendly manner.
224266741|NCT03680313|PROCEDURE|Hypertension outpatient treatment|Patients who have been diagnosed with primary hypertension and meet the conditions of the study will receive outpatient treatment
224266742|NCT05900713|OTHER|dynamic neuromuscular stabilization training|DNS methods demonstrated efficacy in improving global trunk stabilizing patterns with noted gains in extremity movement and strength
224266743|NCT05900713|OTHER|balance exercises plus diaphragmatic breathing|The balance exercises is balance exercises while standing and walking The patient assume a semi-Fowler's position and perform diaphragmatic breathing.
224266744|NCT06562400|DIETARY_SUPPLEMENT|Palmitoyl ethanolamide|PEA supplementation (600mg twice a day for three months)
224266745|NCT06562400|BEHAVIORAL|Ketogenic diet|Diet characterized by the following percentages of macronutrients: 65% fat, 27% protein and 8% carbohydrates
224266746|NCT05685498|BEHAVIORAL|Peer-led HIV self-testing among male fisherfolk in Uganda|This behavioral intervention is centered on the distribution of HIV self-test kits to men through their respective peer-leaders. The investigators have identified up to 18 social network groups; each group is represented by 1-2 peer-leaders who were selected during community engagement meetings. Peer-leaders have received a 3-day training in the HIV self-testing processes, communication skills, existing referral mechanisms, and basic counseling skills. After the training, each peer-leader nominated up to 20 male members (15+ years) from within their social networks who were screened for study eligibility. Eligible male social network members were administered a baseline interview and requested to go to their peer-leaders to obtain their HIV self-test kits.
224266747|NCT00217113|BEHAVIORAL|Geriatric home visit and Action Plan|
224266748|NCT01044537|DRUG|Placebo|Placebo to match PF-04937319 will be provided.
224266749|NCT01044537|DRUG|PF-04937319|The initial planned dosing schedule is: 10, 30, 100, 200, and 400 mg, with one cohort to be determined. Doses shown may be adjusted upwards or downwards and may be adjusted to include intermediate doses. All doses will be administered as a single oral dose as a powder-in-capsule (PIC) formulation. PF-04937319 will be supplied as 10 mg and 80 mg (and potentially 1 mg) PIC.
224266750|NCT00774189|DRUG|clarithromycin 250 mg tablets|
224266751|NCT03798457|OTHER|No intervention|In this study there is no intervention
224266752|NCT00425308|DRUG|Everolimus + Cyclosporine|
224266753|NCT00425308|DRUG|Everolimus + Enteric-coated Mycophenolate Sodium (EC-MPS)|
224266754|NCT00425308|DRUG|Steroids|
224266755|NCT05069571|OTHER|Endoangel|Collecting the colonoscopy videos and analyzing the correlation between withdrawal overspeed proportion and adenoma detection rate.
224266756|NCT05412485|OTHER|Robotic assisted gait training|Robotic assisted gait training is advanced technology used in the rehabilitation of neurological injuries and conditions like spinal cord injury, brain injury, stroke, multiple sclerosis, Parkinson's, cerebral palsy. It provides a repetitive task-specific motor training and modulates afferent input to spinal cord to generate rhythmic gait patterns that may be transformed to overground walking. The intensive repetitions of the rhythmic stepping movement during the training stimulates dependent plasticity and it may lead to brain reorganization. It facilitates cortical neural activities associated with motor control of walking.
223860670|NCT02974634|OTHER|Ostomy self management training|Ostomy Self management Training group in which subject will learn using pouches and equipment, skin care, ostomy complications, nutritional needs, Impact on feelings, clothing changes, social relationships, being prepared for emergencies, Intimacy and sexuality, communication skills, tips for travelling and physical activity recommendations
223860671|NCT02067949|DRUG|Simvastatin|single oral tablet 40 mg / day If the patient is able to swallow; the tablet will be given orally. Otherwise, it will be crushed, suspended in water and administered via any existing enteral feeding or gastric drainage tube
223860672|NCT02645006|BEHAVIORAL|3 session workshop|The intervention group will attend a three session workshop, will learn to recognize their risk factors for fall, will be encouraged to adopt a healthy diet (vitamin D consumption), modify home hazards , and increase physical activity (a strength and balance program at home and a group walking route). After a monthly telephone follow-up they are invited to attend a recall session, were they realize the change in the strength and balance tests results.
224266757|NCT04748991|DRUG|Vernakalant|Post operative AF after cardiac surgery. Vernakalant 3mg/kg over 10 minutes followed by 2mg/kg over 10 minutes if still in AF.
224266758|NCT04748991|DRUG|Amiodarone|Post operative AF after cardiac surgery. Amiodarone 150mg IV followed by 1 mg/min x 6 hours then 0.5 mg/min x 12 hours
224266759|NCT01058213|BEHAVIORAL|Resistance training|Supervised training will be performed on a cable exercise system (Body Solid, Forest Park, IL) using six exercises that involve concentric and eccentric muscle actions: leg press, knee flexion, knee extension, calf raise, hip adduction, hip abduction. Subjects will perform the lower extremity exercises under the direct supervision of an exercise specialist three times per week. Subjects will perform 2 sets of 8-10 repetitions at 70% of their maximum strength for 2 weeks, then will perform 2 sets of 8-10 repetitions at 80% of their maximal strength for 2 weeks, and for the next 4 weeks they will perform 3 sets of 8-10 repetitions at 80% of their maximal strength. Sets will be separated by at least a 2-3 minute rest period for multiple-joint exercises and at least 1-2 minutes for single-joint exercises. A moderate velocity of muscle contraction (\~1-2 seconds for concentric and eccentric contraction) will be used.
224266760|NCT01058213|BEHAVIORAL|Aerobic training|Cycle ergometry training will be performed in the lab on a stationary cycle ergometer, calibrated with a 4 kg weight (Monark 828E, Varberg, Sweden). Initial work rate will be 50% of peak work rate (PWR) as tolerated and will be evaluated weekly with progressive increases targeted to achieve the highest work rate tolerated for 3-5 minutes{: wks 1-2 50% PWR, wks 3-4 60% PWR, wks 5-6 70% PWR, wks 7-8 80% PWR}. An interval training protocol will be used with subjects performing four work sets of five minutes duration separated by rest intervals of unloaded cycling lasting 2-4 minutes.
224266761|NCT03520972|DRUG|PB-119 75ug|60 eligible patients will be included in this group
224266762|NCT03520972|DRUG|PB-119 150ug|60 eligible patients will be included in this group
224266763|NCT03520972|DRUG|PB-119 200ug|60 eligible patients will be included in this group
224266764|NCT03520972|DRUG|placebo|60 eligible patients will be included in this group
224266765|NCT03392051|DRUG|ISIS 681257|Xmg dose administered as a subcutaneous injection
224266766|NCT03392051|DRUG|Clopidogrel|75mg tablet administered orally
224266767|NCT05778630|OTHER|Focus group meetings|Focus group meetings with different experts in the domain of CPCs (health care professionals) and/or parents or family members of a child with CPC. Focus group meetings will be facilitated by one or two study investigators. Group discussions will be audio-recorded.
224266768|NCT05778630|OTHER|Individual interviews|Individual qualitative interviews (semi-directive), conducted by one or two study facilitators.
224266769|NCT03271125|BEHAVIORAL|Treadmill|Participants in the experimental group received supervised treadmill training, 4-5 sessions per week. The treatment protocol was aimed at improving participants' resistance, walking velocity, balance and cognitive functions during motor and cognitive (dual) tasks. The treadmill training was carried out without body weight support but if needed the participants were attached to a safety harness.
224266770|NCT03271125|BEHAVIORAL|Resistance|Participants in the control group were treated with Resistance exercises, 4-5 sessions per week. The treatment protocol was aimed at improving strength in muscles involved in walking (hip abductors, quadriceps, plantar flexors, dorsal flexors) according to current guidelines from the American College of Sports Medicine (2009). Three sets of 10 repetitions were performed bilaterally with appropriate weights for each exercise
224266771|NCT04732325|DEVICE|Spinal cord stimulation|Researchers will program the spinal cord stimulation (SCS) system to deliver, according to the randomization status of the participant, burst, kHz, tonic, and sham stimulation.
224266772|NCT06622330|OTHER|Positioning|Children in the experimental group were given 30 minutes of wrapping and 30 minutes of fetal position after aspiration.
224266773|NCT02705573|DRUG|Mannitol|In the study, mannitol 20% with a dose of 1g / kg / BW (5 ml / kg / BW) will be compared to placebo with NaCl 0.9% in the dose of 5 ml / kg / BW. The study medication will be administered immediately before organ reperfusion. The follow-up of the study is 24 hours.
224266774|NCT00114504|DRUG|simvastatin|simvastatin 5-10 mg/day
224266775|NCT01719770|DRUG|rocuronium|continuous application of rocuronium 0,25mg/kg/h (blinded), in case of shivering episode bolus sodium-chloride (blinded)
224266776|NCT01719770|OTHER|placebo|continuous infusion of sodium-chloride (blinded), in case of shivering episode application of rocuronium 0,25mg/kg (blinded)
224266777|NCT00383916|DRUG|pantoprazole|
224266778|NCT01649921|DRUG|Interferon-gamma, Recombinant|Interferon-gamma (Immukine, Boehringer-Ingelheim, Alkmaar, the Netherlands), 100mcg subcutaneously, on days 0-2-4-7-9-11. Interferon-gamma treatment will be initiated when the noradrenalin dose is reduced to 50% of maximum dose, ensuring that the sepsis-induced pro-inflammatory phase has passed
224266779|NCT01649921|OTHER|Saline 0.9%|subcutaneous administration on days 0, 2, 4, 7, 9, and 11.
224266780|NCT04442503|DRUG|SAGE-217|SAGE-217 oral capsules.
224266781|NCT04442503|DRUG|Placebo|SAGE-217 matched-placebo oral capsules.
224266782|NCT00614861|OTHER|Non-cancer pain management survey|Non-cancer pain management survey
223860673|NCT02645006|BEHAVIORAL|1 session workshop|The control group will attend a single workshop session summarizing the major points of prevention of falls ( risk factors of fall, healthy diet and vitamin D consumption, home hazards, physical activity). After a monthly telephone follow-up they are invited to attend the three session workshop for further prevention.
223860674|NCT00881842|BIOLOGICAL|Trivalent influenza subunit vaccine Influvac|3x 15mcg HA per 0.5 ml,trivalent one injection at Day 1
223860675|NCT05603013|DRUG|Vinorelbine|Vinorelbine Tartrate Oral
223860676|NCT05603013|RADIATION|Radiotherapy|hypofractionated radiotherapy
223860677|NCT05603013|DRUG|PD-1/PD-L1 inhibitor|PD-1/PD-L1 inhibitor subcutaneous injection or intravenous injection
223860678|NCT05603013|DRUG|GM-CSF|GM-CSF subcutaneous injection
223860679|NCT05603013|DRUG|IL-2|IL-2 subcutaneous injection
223860680|NCT01263002|DRUG|clevudine, Adefovir|"Nucleoside-analogue naive patient : Clevudine 30mg qd~1. Assess the complete virological response(HBV DNA \< 60 IU/ml) at 24 weeks: Only Clevudine 30mg qd~2. Assess not the complete virological response at 24 weeks : Add Adefovir 10mg qd~3. During medication of Clevudine, virological breakthrough : add adefovir 10mg qd~4. During treatment period, composite virological response : stop the medication and F/U for 2 years~5. Recurrence after stopping treatment(HBV DNA \> 2,000IU/ml) retreat medication at composite virological response.~   * complete virological response: HBV DNA \< 60 IU/ml~  * virological breakthrough : During antiviral treatment, HBV DNA increased from nadir to 1 log10IU/ml continuously."
223860681|NCT04233632|DEVICE|FC2 Condom|FC2: FC2 is composed of a synthetic nitrile rubber latex and 170mm in length. It has a flexible inner ring as the internal retention mechanism and a circular ring as the outer retention mechanism at the open end of the condom. It is pre-lubricated with silicone oil. It has a shelf-life of 5 years and is available in clear and other colors/scents. It is manufactured by Female Health Company, USA and has USFDA, World Health Organisation (WHO)/United Nations Populations Fund (UNFPA) and South African Bureau of Standards (SABS) approval
223860682|NCT04233632|DEVICE|Cupid Condom|Cupid is composed of a Natural rubber latex and is 155mm in length. It has a Medical grade sponge as the internal retention mechanism and an octagonal outer frame as the outer retention mechanism. It is pre-lubricated with silicone oil. It has a shelf-life of 3 years and is available in clear and red color, vanilla scented variety. It is manufactured by Cupid Ltd, India and has WHO)/UNFPA, India Drug Control Authority, Conformitè Europëenne (CE) Mark of the European Union (EU) and SABS approval
223860683|NCT04233632|DEVICE|Cupid 2 Condom|Cupid2 is composed of a Natural rubber latex and is 125mm in length. It has a Medical grade sponge as the internal retention mechanism and an octagonal outer frame as the outer retention mechanism. It is pre-lubricated with silicone oil. It has a shelf-life of 3 years and is available in Clear and purple color, vanilla scented variety. It is manufactured by Cupid Ltd, India and has WHO)/UNFPA, India Drug Control Authority, CE Mark of the EU and SABS approval
223860684|NCT02743078|DRUG|Bevacizumab|10 mg/kg every 2 weeks intravenously over 30 minutes.
223860685|NCT02743078|DEVICE|TTFields Therapy|Device is worn continuously at least 18 hours a day on average, with 1-3 days off every four weeks.
223860686|NCT01399671|OTHER|vestibular stimulation|vestibular stimulation
223860687|NCT05653583|DEVICE|Wrist Device|peripheral nerve stimulation via wrist-worn device
223860688|NCT05653583|DEVICE|Ear Device|peripheral nerve stimulation via ear-worn device
223860689|NCT05653583|DEVICE|Sham Device|Wrist-worn device that does not actually deliver stimulation
223860690|NCT01985269|OTHER|Home visits|The participants' vital signs (blood pressure, temperature, pulse rate, respiratory rate, and arterial oxygen saturation) will be taken and a limited physical examination (e.g. oral cavity for thrush, Kaposi's lesions, ulcers and dehydration; skin for rash, herpes zoster and dehydration; eyes for jaundice and pallor, gross neurological function such as ability to walk without difficulty, presence of facial droop, one-sided body weakness etc.) conducted. The nurse will then review medications adherence before observing the study participant swallow their pills (antiretrovirals, anti-TB, antibiotics, and analgesics).
223860691|NCT02002052|DRUG|Concurrent platinum-based chemotherapy|Platinum-based concurrent chemotherapy in both arms
223860692|NCT02002052|RADIATION|Standard Radiotherapy, 60 Gy in 30 fractions.|
223860693|NCT02002052|RADIATION|Functional Lung Avoidance Radiotherapy, 60 Gy in 30 fractions|
223860694|NCT06411834|BEHAVIORAL|Decision navigation tool|An electronic, interactive form that guides patients through the major factors that influence their decision-making in thyroid cancer
223860695|NCT06235294|DIETARY_SUPPLEMENT|Resveratrol|Daily capsule of 200 mg Polygonum cuspidatum (Solgar®, Dietimport, Lisboa, Portugal) yielding 100 mg/day resveratrol (trans-3,5,4'-trihydroxystilbene), by morning, every day during the 3 months preceding in vitro fertilization treatment.
223860696|NCT06235294|DIETARY_SUPPLEMENT|Folic acid|Daily capsule of 400 mcg folic acid (Solgar®, Dietimport, Lisboa, Portugal), by morning, every day during the 3 months preceding in vitro fertilization treatment.
223860697|NCT01517815|DRUG|Doripenem or Piperacillin/Tazobactam|"This arm is composed of 26 no overweight patients, Antibiotic (Doripenem or Piperacillin/Tazobactam) is chosen by the intensivist in charge of the case:~* in 13 no overweight patients, Pipéracilline/tazobactam will be administered in 4g IV (1h) and then 16g/24h IV continuously. Piperacillin/Tazobactam plasma dosage: after the first dose and then every 12h.~* in 13 patients no overweight: doripénème will be administered in 1g/8h with a 4h IV infusion. Doripenem plasma dosage: after the first dose and then twice a day, at peak and residual value."
223860698|NCT01517815|DRUG|Doripenem or Piperacillin/Tazobactam|"This arm is composed of 26 overweight patients, Antibiotic (Doripenem or Piperacillin/Tazobactam) is chosen by the intensivist in charge of the case:~* in 13 overweight patients, Pipéracilline/tazobactam will be administered in 4g IV (1h) and then 16g/24h IV continuously. Piperacillin/Tazobactam plasma dosage: after the first dose and then every 12h.~* in 13 patients overweight: doripénème will be administered in 1g/8h with a 4h IV infusion. Doripenem plasma dosage: after the first dose and then twice a day, at peak and residual value."
223860699|NCT02444130|DEVICE|contact lenses|Presbyopia was compensated with contact lenses by monovision and multifocality.
223860700|NCT04308330|DRUG|Vorinostat|This is a phase I study of the combination of four drugs: vorinostat, vincristine, irinotecan, and temozolomide. This is called a Phase I study because the goal is to find the highest dose of vorinostat that investigators can give safely when it is used together with the chemotherapy drugs vincristine, irinotecan and temozolomide. Investigators are using vorinostat because it seems to work against cancer in test tubes and animals. It may be most effective when it is given with chemotherapy. The combination of these three agents together has never been given to children. Vincristine, irinotecan, and temozolomide are approved and used for the treatment of other types of cancer in adults and children. Vorinostat is approved and used to treat cancer in adults. The combination of these four drugs together is experimental. Investigators do not know if this combination of medicines will work in people. There is a lot that investigators do not yet know about this combination of medicines.
223860701|NCT03143842|DEVICE|Vagus Nerve Stimulation|Delivering electrical pulses to the Vagus Nerve
223860702|NCT03090776|DRUG|Ketamine|low dose bolus and infusion ketamine, administered under general anesthesia
223860703|NCT03090776|OTHER|Placebo saline|bolus and infusion saline, administered under general anesthesia
223860704|NCT05646004|DEVICE|Cataract surgery|Implantation of 621 lens
223860705|NCT01275287|DRUG|Standard of care treatment|"induction : pulse methyl prednisolone (7 mg/kg/day x3) then prednisone 1 mg/kg/day (not to exceed 60 mg/day) for 4 weeks, then taper over the following 12 weeks. Cyclophosphamide starting at 0.75 gm/m2 IV (decreased to 0.5 gm/m\^2 for patients \> than 70 or with estimated Glomerular Filtration Rate (eGFR) \< 20 ml/min) to be titrated up to 1 gm/m\^2 depending on the 2 week white blood count (WBC) nadir \> 3000 cell/μL. Subsequent cyclophosphamide will be given every 4 weeks for at least 2 more doses. Once complete remission for 2 months, patient may be switched from cyclophosphamide to maintenance therapy with azathioprine 1.5-2 mg/kg/day for 6-9 months (to a total of 12 months of therapy) .~For patients who cannot tolerate cyclophosphamide, or who have received it in large doses previously, another medication called rituximab may be used instead. However, if rituximab is indicated for the patient, he cannot participate in the study."
223860706|NCT01275287|DRUG|eculizumab|In addition to conventional therapy, patients randomized to eculizumab will receive 600 mg by IV infusion over 35 minutes every 7 days for the first 4 weeks, then 900 mg by IV infusion for the fifth dose 7 days later (week 5), then 900 mg every 14 days thereafter, for a total of 9 doses (about 3 months of treatment). This dosing scheme is based on that used for the treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH). The length of treatment is shorter than for PNH, based on a desire to target the addition of eculizumab to the period of maximal disease activity, while limiting the risks of infectious complications in this first pilot study.
223860707|NCT05162391|BEHAVIORAL|Contingency Management|Contingency management intervention with incentives tied to provision of urine samples with no detectable levels of methamphetamine (MA).
223860708|NCT03406936|DRUG|Daily interruption of midazolam|daily at 7 am midazolam infusion will be stopped spontaneous breath trial will be done
223860709|NCT00550394|DRUG|quetiapine and placebo|"Dosing Schedule and Titration of Quetiapine: open-label quetiapine beginning day 1 at 100 mg/day titrated to 400 mg/day by the end of week 1~Dosing Schedule and Titration of Topiramate:~All subjects will be randomized to topiramate or matching placebo which will be administered in a double-blind manner.~Topiramate/Placebo titrated from 25 mg twice daily to 150 mg bid by week 4."
223860710|NCT00550394|DRUG|Quetiapine and Topiramate|"Dosing Schedule and Titration of Quetiapine:~open-label quetiapine beginning day 1 at 100 mg/day titrated to 400 mg/day by the end of week 1~Dosing Schedule and Titration of Topiramate:~All subjects will be randomized to topiramate or matching placebo which will be administered in a double-blind manner.~Topiramate/Placebo titrated from 25 mg twice daily to 150 mg bid by week 4."
223860711|NCT06208397|DIAGNOSTIC_TEST|Magnetic Resonance Elastography and routine MRI|Assessed boundary conditions through MRE-base SII before surgery and recorded HGP of tumor after surgery.
223860712|NCT06572163|DEVICE|Eximis CS (Contained Segmentation) System|The Eximis CS System is an integrated system consisting of a 900 mL Capture Bag, Inflation Mechanism, two Eximis Segmenters, and the Eximis RF Generator.
223860713|NCT06333990|DRUG|Quetiapine Fumarate|Quetiapine is an atypical antipsychotic approved by the FDA for the treatment of schizophrenia, bipolar disorder, and as an adjunct to treat major depression. It has a broad spectrum of actions at dopaminergic (D1, D2, D3 and D4), serotonergic (5-HT2A, 5-HT2C and 5-HT7), adrenergic (α1), histaminic (H1) and muscarinic (mACh), and partial agonist at 5-HT1A receptors.
223860714|NCT06333990|DRUG|TAU|Standard of care psychotropic medications for treatment of patients with mTBI.
223860715|NCT06399679|DRUG|Rivastigmine|Rivastigmine 3mg by mouth once, followed by rivastigmine 1.5mg by mouth every 1 hour as needed for ongoing delirium or agitation (at the discretion of the treating physician), for a maximum of three doses
223860716|NCT06399679|DRUG|Placebo|Matching oral placebo by mouth once, followed by placebo by mouth every 1 hour as needed for ongoing delirium or agitation (at the discretion of the treating physician), for a maximum of three doses
224266783|NCT03552328|OTHER|Lunch with Medical Student|Each student will bring provided lunches once a week to their elder participant's residence, and they will share lunch together for an hour once a week for six weeks. Students will enroll as Meals on Wheels volunteers and participate in the Meals on Wheels pre-program training. On the day of their scheduled lunch, students will first arrive at the Meals on Wheels designated meal-drop location and pick up two lunches, one for them and one for their assigned elder. They will then drive to their assigned elder's residence and eat lunch with them for one hour.
223860717|NCT06140303|BIOLOGICAL|SkinTE|SkinTE is an Autologous Heterogeneous Skin Construct (AHSC), which is manufactured from a small piece of healthy full-thickness skin harvested from the patient at the time of randomization to the SkinTE arm. SkinTE is manufactured aseptically by PolarityTE following current Good Manufacturing Practice (cGMP). SkinTE is not cultured ex vivo; rather, it is returned to the provider expeditiously to maintain cellular viability. SkinTE includes various multicellular segments as a result of the manufacturing process. The different multicellular segments contain different types of skin cells, such as keratinocytes, dermal fibroblasts, dermal endothelial cells, and follicular cells, as well as extracellular matrix. The multicellular segments have a surface area-to-volume ratio for improved sustenance by imbibition prior to engraftment.
223860718|NCT06140303|OTHER|Control|"Standard care is defined in this protocol to include the following:~* Debridement~* Collagen dressing~* Local offloading~* Foam~* Multi-layer compression dressing~* Off-loading device such as a controlled ankle motion (CAM) boot"
223860719|NCT06415448|DRUG|Donidalorsen|Donidalorsen administered once monthly or every other month by subcutaneous (SC) injections in the abdomen, thigh, or upper arm.
223860720|NCT05791448|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
223860721|NCT05791448|PROCEDURE|Computed Tomography|Undergo CT scan
223860722|NCT05791448|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223860723|NCT05791448|DRUG|RNA Transcription Modulator AU-409|Given PO
223860724|NCT04123132|OTHER|Kinesiophobia|The presence of kinesiofobia in patients with metabolic syndrome
223860725|NCT05304663|DRUG|Onfekafusp alfa|Patients will be treated with 10 µg/kg L19TNF on Days 1, 3 and 5, and on Days 22, 24 and 26
223860726|NCT05304663|DRUG|Lomustine|"Arm 1: Patients will be treated in escalating cohorts of 6 patients with lomustine at different doses (60 mg/m2 and 75 mg/m2) on Day 1 and Day 22 (taken in the evening after L19TNF infusion) of a 42-day cycle for up to a maximum of 6 cycles.~Arm 2: Patients will be treated in escalating cohorts of 6 patients with lomustine at different doses (90 mg/m2 and 110 mg/m2) on Day 5 (in the evening after infusion of L19TNF) of a 42-day cycle for up to a maximum of 6 cycles."
223860727|NCT02425449|DRUG|Succinylcholine|will be administered succinylcholine in a dose of 0.1 mg/kg in Arm 1, 0.15 mg/kg in Arm 2, 0.2 mg/kg in Arm 3, 0.25 mg/kgin Arm 4, 0.3 mg/kg in Arm 5.
223860728|NCT02947217|BIOLOGICAL|Influenza Vaccine|Inactivated influenza vaccine indicated for immunization against disease caused by influenza virus subtype A and type B present in the vaccine. Approved for use in persons 5 years of age and older. Single Dose prefilled 0.5 ml syringe.
223860729|NCT02947217|OTHER|Sterile Saline|0.5 mL of sterile Saline administered im
223860730|NCT04455516|PROCEDURE|Meniscus repair; partial meniscectomy|69 cases of meniscus repair (repair group) and 96 cases of partial meniscectomy (partial meniscectomy group), were retrospectively analyzed. The 69 patients of the repair group were divided into the nonfailure group (62 cases) and the failure group (7 cases) depending on the repair effect.
223860731|NCT02962674|DEVICE|prostaFix System|
223860732|NCT02091336|DRUG|Metformin|patients treatment
223860733|NCT02091336|DRUG|Glyburide|patients treatment
223860734|NCT04438668|DEVICE|Centaflow and Standard Care|The intervention is screening methods
223860735|NCT04438668|DIAGNOSTIC_TEST|Standard Care|The intervention is screening methods
223860736|NCT00092781|DRUG|MK0663, etoricoxib|
223860737|NCT00092781|DRUG|Comparator: celecoxib|
223860738|NCT03780816|OTHER|Observation of provider-patient interactions and interviews|Clinical interactions between cancer patients and providers will be observed and hand-written field notes recorded and later transcribed. Semi-structured interviews with providers, patients, caregivers, and other informants will take place following initial observation.
223860739|NCT00364286|DRUG|Dasatinib (BMS-354825)|50mg Orally twice daily
223860740|NCT01299753|DRUG|placebo|identically packed placebo
223860741|NCT01299753|DRUG|propranolol|20-40 mg q6-8h
223860742|NCT01061424|BEHAVIORAL|community health worker|community health worker provides home visits for education
223860743|NCT01061424|BEHAVIORAL|mailed information|information on asthma is mailed to the home on the same schedule as the other arm
223860744|NCT04668742|DEVICE|DYNAtraq|Tracheostomy alignment with DYNAtraq
223860745|NCT01566708|BEHAVIORAL|Neuro-Music Therapy immediately|20 patients are randomized to receive Neuro-Music Therapy immediately. Neuro-Music Therapy takes 5 days and comprises 9 consecutive 50-minutes sessions of individual therapy. Immediately before and after treatment extensive diagnostics are performed, including psychological assessment, functional neuroimaging and electro-physiological examinations.
223860746|NCT01566708|BEHAVIORAL|Neuro-Music Therapy after waiting time|20 Patients were randomized to receive Neuro-Music Therapy after a waiting period not exceeding 6 weeks. Within this waiting time, patients undergo exactly the same diagnostic procedure as the patients of the treatment group.
223860747|NCT01566708|BEHAVIORAL|Music-therapeutical stress management coaching|20 non-tinnitus controls matched in age, gender and hearing ability receive a music-therapeutical stress coaching program. This intervention is based on the main treatment components of the Neuro-Music Therapy for acute tinnitus with alterations of the tinnitus specific elements. Immediately before and after this five-day coaching, controls undergo exactly the same diagnostic procedure as the patients of the treatment group.
223860748|NCT02577419|OTHER|Target Fortification|
223860749|NCT02577419|OTHER|Higher Initial Concentration|
223860750|NCT02577419|OTHER|Portagen Formula|
223860751|NCT04292054|DRUG|active intervention|The antibiotic prophylaxis will be cefazolin 2 g, or piperacilline-tazobactam 4 g, powder for solution for injection diluted in 50mL of NaCl 0.9%, IV infusion on 30 minutes with syringe pump.
223860752|NCT04292054|OTHER|placebo intervention|The control group will received, as placebo NaCl 0.9% solution for injection diluted in 50mL of NaCl 0.9%, IV infusion on 30 minutes with syringe pump.
223860753|NCT02716220|DEVICE|Percutaneous Coronary Intervention|Implanttaion fo the DREAMS 2G Scaffold
223860754|NCT06156319|OTHER|No intervention|No intervention
223860755|NCT03737682|DIAGNOSTIC_TEST|ENzyme linked immunity-sorbet assays|Hemostasis achievement reflecting inflammatory status of the pulp based on cytokine levels
223860756|NCT05570188|BIOLOGICAL|anti-CD19 UCAR-NK cells|"Enrolled participants are chosen to receive one of three different dose levels of U-CAR-NK cells:~Dose level one: 5-10×10\^6/kg; Dose level two:1-2×10\^7/kg; Dose level three:2-5×10\^7/kg."
223860757|NCT06376357|OTHER|Foot Massage with roller|The intervention group is expected to apply roller massage to the soles of both feet in a sitting position on a chair (8 hours apart at 08.00, 16.00, 24.00 hours) every day for 6 weeks, 3x5 minutes a day. Video recording will be used as a reminder in the application.
223860758|NCT01624844|OTHER|Geometrical calculation of dural sac volume|Geometrical calculation of the lumbar dural sac volume following multilevel measurements by ultrasound imaging before spinal anesthesia
223860759|NCT05635604|DRUG|Eptinezumab|Eptinezumab or ALD403 is a humanized anti-calcitonin gene-related peptide IgG1 monoclonal antibody that binds to calcitonin gene-related peptide (CGRP). It selectively binds human CGRP ligand to prevent activation of the CGRP receptor and blocks its binding to the receptor for the prevention of migraine.
223860760|NCT05635604|DRUG|PACAP-38|PACAP-38 is a naturally occurring peptide diffusely expressed throughout the body. The Danish Headache Center has used infusion of PACAP-38 for several years and the first time in 2007 where infusion of PACAP-38 triggered headaches and migraines in migraine patients.
223860761|NCT06076980|DRUG|Paracetamol|compare the hemodynamic parameters of paracetamol as bolus versus extended infusion
223860762|NCT06076980|DRUG|Normal saline|as placebo
223860763|NCT03746665|BIOLOGICAL|meningococcal serogroup A conjugate vaccine|Once final eligibility has been confirmed by a study clinician on the day, expectant mothers will be administered a single intramuscular dose of MenAfriVac™.
223860764|NCT01124188|DRUG|Higher-dose venlafaxine|Dosing of venlafaxine will range from 187.5-300 mg/day.
223860765|NCT01124188|BEHAVIORAL|Supportive management|Supportive management encourages participants to take the medication and manages any treatment-emergent side effects. Ten sessions will be delivered over the course of 14 weeks.
223860766|NCT01124188|BEHAVIORAL|Problem Solving Therapy for Depression and Pain|PST-DP will be delivered over the course of 10 sessions over 14 weeks. Along with teaching the participant 7 steps of problem solving, PST-DP also includes a medication support and management component.
223860767|NCT02120599|DIETARY_SUPPLEMENT|ready-to-use supplementary food|
223860768|NCT02120599|DIETARY_SUPPLEMENT|corn-soy blend|
223860769|NCT02120599|DIETARY_SUPPLEMENT|iron|
223860770|NCT02120599|DIETARY_SUPPLEMENT|folic acid|
223860771|NCT02120599|DIETARY_SUPPLEMENT|UNIMMAP|
223860772|NCT05640869|BEHAVIORAL|Modified Diabetes Prevention Program Curriculum|The modified DPP curriculum will be an exact copy of the current DPP curriculum except that references to the prevention of diabetes will be modified to prevention of health outcomes associated with overweight/obesity and/or management of overweight/obesity.
223860773|NCT01796782|DRUG|Xeloda|Xeloda dose is calculated according to body surface area.The recommended dose is 1000 mg/m² administered orally twice daily (morning and evening; equivalent to 2000 mg/m² total daily dose) for 2 weeks followed by a 1-week rest period given as 3-week cycles
223860774|NCT01796782|DRUG|QYHJ Granules|1-4 bags bid , days 1-42, every 6 weeks
223860775|NCT03579368|DEVICE|Symfony implantation|Bilateral Symfony IOL Implantation
223860776|NCT00719459|DRUG|Iron Sucrose|Venofer 20 mg/mL
223860777|NCT00719459|DRUG|Iron Sucrose|Iron sucrose 20 mg/mL
223860778|NCT00812617|DIETARY_SUPPLEMENT|Mineral water (Hita, Oita, Japan)|
223860779|NCT00812617|DIETARY_SUPPLEMENT|Mineral water (Aso-gun, Kumamoto, Japan)|
224266784|NCT03552328|OTHER|Control|Students will not bring provided lunches to an elder participant's residence. The elder participants in this arm will simply continue receiving daily meals from Meals on Wheels with no accompanying student.
224266785|NCT02570828|DEVICE|Thermal Imaging|FLIR ONE attachment to an iPhone
224266786|NCT03124511|PROCEDURE|Surgery for breast cancer|Breast cancer resection performed via lumpectomy or mastectomy with or without sentinal node biopsy and axillary lymph node dissection.
224266787|NCT03769428|PROCEDURE|erector spinae plane block|The ESPB will be done in a sitting position using linear ultrasound probe (L10) of MySonoU6 machine. The blocks will be performed at the T4-T5 level of the spine using an in-plane approach. A linear probe will be placed 2-3 cm laterally to the spine using a sagittal approach. Three muscles will be identified superficial to the transverse process shadow as follows: trapezius, rhomboid major, and erector spinae. Local anesthetic (LA) is injected between the erector spinae muscle and transverse process. Following confirmation of the correct position of the needle tip with administration of 0.5-1 ml of the fluid. Then 40cc of Ropivacaine (3.75mg/cc) will be injected .The distribution will be observed in both cranial and caudal directions.
224266788|NCT03769428|PROCEDURE|sham erector spinae plane block|The sham ESPB will be done in a sitting position using linear ultrasound probe (L10) of MySonoU6 machine. The blocks will be performed at the T4-T5 level of the spine using an in-plane approach. A linear probe will be placed 2-3 cm laterally to the spine using a sagittal approach. Three muscles will be identified superficial to the transverse process shadow as follows: trapezius, rhomboid major, and erector spinae. Following confirmation of the correct position of the needle tip with administration of 0.5-1 ml of the fluid a total of 40 mL of fluid will be injected next between the erector spinae muscle and transverse process. Then 40cc of normal saline will be injected.The distribution will be observed in both cranial and caudal directions.
224266789|NCT04332198|OTHER|biological test|dyspnea evaluation, ventilatory evaluation and biological test before and after non invasive ventilation
224266790|NCT05411653|OTHER|Virtual reality training with motor imagery|comprised of 30 minutes, VRT (15 minutes) and MI (15 minutes) daily for 3 days respectively. Five Xbox Kinect gaming will be selected and explained to the patients for the virtual training session and additional 15 minutes will be given to them for practice. The games consists of 20,000 water leaks, river rush, reflex ridge, soccer and football for the patients.
224266791|NCT05411653|OTHER|Conventional physical therapy|range of motion exercises, muscle strengthening, functional training, balance training, and gait training. The specific tasks will be selected by the therapist based on the requirement of each patient. It will be performed for 30 minutes for 3 days a week for 6 weeks
224266792|NCT01567553|OTHER|USPIO MRI - Gadolinium MRI|"USPIO MRI scanning will be performed at :~* baseline, month 3, month 6, month 9 and month 12 for patients recruited prior to the 1st of May 2010.~* baseline, month3, month 6 and month 9 for patients recruited between the 1st of May 2010 and the 31st of July 2010,~* baseline, month 3 and month 6 for patients recruited between the 1st of August 2010 and the 31st of October 2010,~* baseline and month 3 for patients recruited between the 1st of November 2010 and the 31st of January 2011,~* baseline for patients recruited between the 1st of February 2011 and the 30rd of April 2011.~Gadolinium MRI scanning will be performed at baseline, month 3, month 6, month 9, month 12, month 18, month 24 and month 36."
224266793|NCT00003953|BIOLOGICAL|filgrastim|Filgrastim (G-CSF) is administered subcutaneously on days 3-10 of each 2 week course.
224266794|NCT00003953|DRUG|CMF regimen|Stratum I and II: receive cyclophosphamide, methotrexate, and fluorouracil (CMF) for 4 courses
224266795|NCT00003953|DRUG|docetaxel|Docetaxel IV over 1 hour on days 43, 57, and 71.
224266796|NCT00003953|DRUG|doxorubicin hydrochloride|Doxorubicin IV on days 1, 15, and 29.
224266797|NCT00003953|DRUG|tamoxifen citrate|Patients with positive estrogen or progesterone receptors receive oral tamoxifen daily for 5 years.
224266798|NCT00003953|PROCEDURE|autologous bone marrow transplantation|Stratum III:may receive high dose chemotherapy with stem cell support
224266799|NCT00003953|PROCEDURE|surgical procedure|Fourteen to 21 days following preoperative chemotherapy, patients undergo a radical, modified radical, or breast sparing surgery plus axillary lymph node dissection.
224266800|NCT00003953|RADIATION|radiation therapy|Radiotherapy is administered 5 days a week for 5.5 weeks.
224266801|NCT05766553|OTHER|Virtual reality pod|The first two sessions provide guided training in relaxation and mindfulness through immersion in a virtual forest environment for the first session, and in a virtual beach environment for the second. Sessions 3 and 4 present environments with addiction-related stimuli (Cues). The session 3 consists of a walk through the virtual street environment, buying a bottle of water from the store, and then ordering a coffee from a virtual bar. The session 4 takes place in a virtual party environment in an apartment: people smoke and drink alcohol in the living room, the session consists of sitting with them, then going to the kitchen to get a water bottle. Sessions 5 and 6 present stressful environments. Session 5 consists of a virtual parachute jump. The 6th session takes place in a virtual airplane environment, which will encounter turbulence.
224266802|NCT05766553|OTHER|nicotine patches and chewing gum|Participants in this group will be prescribed a Gold Standard smoking cessation treatment with nicotine patches adapted to their consumption and 4mg nicotine chewing gum for a period of 3 months.
224266803|NCT04469751|DIAGNOSTIC_TEST|invasive blood pressure monitoring|radial artery and dorsalis pedis artery intubated with BD Insyte-W 22G artery puncture needle under local anaesthesia
223860780|NCT05922215|OTHER|Dynamic Balance training|The Experimental group will be given the Baseline treatment comprising of Stretching \& Static balance training (i.e. heel and toe raises, alternate rising of the left and right foot above the floor and tandem standing.) alongside Dynamic Balance training which will include (weight shifting forward, backward, sideward, and diagonally with eyes opened and eyes closed, walking toe-to-heel barefoot, side walking, reverse walking and one-foot jumps), and Progressive activity training (such as stepping over/on obstacles, throwing and catching a ball, and kicking a ball.) for 40 minutes per day, twice each week for 8 weeks.
223860781|NCT05922215|OTHER|Static balance training|The Control group will continue their regular school schedule, which will include participation in physical education activities at the same frequency. Along with that Baseline treatment including Static balance training (i.e. alternate rising of the left and right foot above the floor and tandem standing.) only, at the same intervals and for the same length of time as the intervention group, with the exception of additional Dynamic balance training and progressive activity training.
223860782|NCT01134562|DRUG|Placebo|Single IV injection.
223860783|NCT01134562|DRUG|Etelcalcetide|Single IV injection. The initial dose was 5 mg and dose escalation proceeded with subsequent doses of 10 mg, 20 mg, 40 mg and 60 mg.
223860784|NCT00009217|DRUG|Haloperidol-Haloperidol|Haloperidol open label flexible dose 1-5 mg daily for 20 weeks followed by haloperidol double-blind 1-5 mg for 24 weeks
223860785|NCT00009217|DRUG|Haloperidol-Placebo|Haloperidol open-label flexible dose of 1-5 mg for 20 weeks followed by placebo double-blind for 24 weeks
223860786|NCT01967186|PROCEDURE|Intraportal islet transplantation|
223860787|NCT01967186|PROCEDURE|Intramuscular islet transplantation|
223860788|NCT01967186|PROCEDURE|Intramuscular transpl with stemcells|
223860789|NCT01967186|PROCEDURE|Kidney transplantation|All patients will undergo kidney transplantation regardless of arm
223860790|NCT03932188|BEHAVIORAL|Mental Health Assessments and Computerized Cognitive Test|Participants will be asked to complete questionnaires and will be asked questions that address a broad range of personal life experiences involving social, occupational, domestic, and other behaviors.
223860791|NCT03932188|DEVICE|MRI scan|Up to two MRI scan sessions will be done, altogether totaling just under 3 hours of scanning. MR scanners measure brain anatomy and activity using very strong magnets. No X-rays or radiation are involved.
223860792|NCT02806518|PROCEDURE|DIRT|An infrared camera is used to capture video sequences of thermal images before, during and after exposure of the lower abdomen to a cold challenge.
223860793|NCT02561871|BIOLOGICAL|Ad26.RSV.FA2|Participants will receive Intramuscular injection of Ad26.RSV.FA2 (5x10\^10 virus particles \[vp\]) on day 1 and 85 in Group 1. Intramuscular injection of Ad26.RSV.FA2 (5x10\^10 virus particles \[vp\]) on day 1 in Group 2.
223860794|NCT02561871|BIOLOGICAL|Ad35.RSV.FA2|Participants will receive Intramuscular injection of Ad35.RSV.FA2 (1x10\^11 virus particles \[vp\]) on day 169 in Group 1. Intramuscular injection of Ad35.RSV.FA2 (1x10\^11 virus particles \[vp\]) on day 85 in Group 2.
223860795|NCT02561871|DRUG|Placebo|Participants will receive Intramuscular injection of Placebo control on day 169 in Group 2. Intramuscular injection of Placebo control on day 1, 85 and 169 in Group 3.
223860796|NCT03656094|DRUG|Pembrolizumab plus chemotherapy|Pembrolizumab plus chemotherapy
223860797|NCT03656094|DRUG|Placebo plus chemotherapy|Placebo plus chemotherapy
223860798|NCT02152813|BEHAVIORAL|TENS and Task-orientated training|All subjects will undergo 16 sessions of their assigned intervention (60 minutes, twice a week, for 8 weeks). All subjects will receive 60 minutes task-oriented lower limb training (TOT) with electrical stimulation protocol assigned concurrently:
223860799|NCT01324453|PROCEDURE|Post Conditioning + Primary PCI|Four, 30-second PTCA balloon occlusions followed by 30-seconds of reperfusion over a total of 4 minutes, in addition to Percutaneous Coronary Intervention as clinically indicated.
223860800|NCT01324453|PROCEDURE|Standard Primary PCI|Routine Percutaneous Coronary Intervention as clinically indicated.
223860801|NCT05783726|OTHER|Control|Participants will be shown images of juice, bread, yogurt, cookies, and cereal without any added front-of-package labels.
223860802|NCT05783726|BEHAVIORAL|Nutriscore Label|A front-of-package Nutriscore label will be applied to images of juice, bread, yogurt, cookies, and cereal. This label applies a score of A, B, C, D, or E based on the product's nutrition profile.
223860803|NCT05783726|BEHAVIORAL|Adapted Peruvian Nutrient Label|A front-of-package octagonal nutrient label will be applied to images of juice, bread, yogurt, cookies, and cereal. The label text informs consumers if a product is high in sugar, saturated fat, or salt/sodium. These labels were developed by the Peruvian government and adapted by investigators.
223860804|NCT05783726|BEHAVIORAL|Guideline Daily Amount Label|A front-of-package Guideline Daily Amount label will be applied to images of juice, bread, yogurt, cookies, and cereal. The label shows the amount and percent of daily value of calories, total fat, saturated fat, sugar, and sodium in one serving of a product.
223860805|NCT03315884|PROCEDURE|Iliac segment recanalization and stenting Iliac segment Common Femoral Artery (CFA)|"Retrograde femoral access. Brachial access. Standard endovascular access is performed under local anesthesia and affected arterial segment is visualized. Stenosis or artery occlusion is passed with hydrophilic guide. In case of occlusion transluminal or subintimal (often mixed) artery recanalization is performed. To maximize the preservation of the affected artery initial patency, occlusion recanalization is performed by ante-and retrograde accesses. Then stenosis or occlusion predilation is performed with balloon catheter (balloon catheter diameter is smaller than the affected artery diameter for 1-2 mm). After control angiography stent is installed in the aorta-iliac area throughout the lesion (lesion diameter corresponds to the stenotic arteries diameter). In aorta-iliac zone balloon-expandable and self-expandable stents are used."
223860806|NCT03315884|PROCEDURE|Iliac segment recanalization, stenting and plastic Common Femoral Artery (CFA) patch|Standard access to the CFA is performed. Outflow ways and CFA capability for reconstruction are determined. The puncture of the general CFA (retrograde) is performed and the introducer 7Fr. is set. Recanalization of iliac artery occlusion. It is necessary to cross the iliac occlusion in a retrograde fashion first and secure aortic inflow before making the arteriotomy. An ipsilateral, a contralateral and a brachial approaches are used depending on the clinical situation. If the retrograde access to the aorta failed, you use the antegrade crossing of the iliac occlusion with no intention to reenter the lumen in the CFA. After the recanalization and balloon angioplasty of iliac artery we completed the procedure with endarterectomy of CFA, patch closure and iliac stenting. The preference is to perform endarterectomy and patch before iliac stenting because it can be difficult to access the true lumen in a difficult CFA lesion. Controlling angiography were performed. Closing approach.
223860807|NCT03636919|OTHER|e-BOOK|Patients will filled an e (carnet) included the questionnaire includes the Control of Allergic Rhinitis and Asthma Test (CARAT)
223860808|NCT01639638|DRUG|PROAPOPTOTIC PEPTIDE CIGB 300|CIGB 300,in INTRALESIONAL on day 3 of each 48 HOURS.
223860809|NCT04651881|DRUG|Reference drug|1 Cap., single oral administration under fed condition
223860810|NCT04651881|DRUG|Test drug 1|1 Tab., single oral administration under fed condition
223860811|NCT04651881|DRUG|Test drug 2|1 Tab., single oral administration under fed condition
223860812|NCT05686434|DRUG|Osimertinib|This is a prospective, open, single-center, single-arm phase II clinical study with EGFR-sensitive mutations (Ex19del and L858R) identified in the central laboratory，to evaluate the efficacy and safety of adjuvant Osimertinib therapy in completely resected stage I non-squamous non-small cell lung cancer (NSCLC) with high-risk factors (solid and/or micropapillary component ≥10%, and/or airway spread).
223860813|NCT00168467|DRUG|Ramipril|
223860814|NCT01437358|OTHER|Epidural analgesia|The purpose of this observational prospective study is to describe the safety and feasibility of this analgesia technique in ICU patients
223860815|NCT01767714|DRUG|Granulocyte-colony stimulating factor (G-CSF)|10 µg/kg/day G-CSF, administered by subcutaneous (SC) injection
223860816|NCT01767714|DRUG|Plerixafor|0.24 mg/kg/day subcutaneous injection
223860817|NCT01767714|DRUG|Placebo|0.24mg/kg/day placebo (0.9% Sodium Chloride) administered by subcutaneous injection
223860818|NCT06261372|BEHAVIORAL|The mindfulness meditation combined with progressive muscle relaxation training .|The first part is progressive muscle relaxation training. The second part is mindfulness meditation training.
223860819|NCT04828642|DIETARY_SUPPLEMENT|Vitamin C and vitamin E|1000 mg 235 mg
223860820|NCT04828642|DIETARY_SUPPLEMENT|Placebo|Placebo
223860821|NCT01500395|PROCEDURE|Hybrid operation|Hybrid Operations including debranching technique+Thoracic Endovascular Aortic Repair (TEVAR), Frozen elephant trunk technique, aortic arch replacement with concommitant TEVAR, et al. Devices include Medtronic Stent Graft（Medtronic Medtronic, Inc., US） Microport Stent Graft（Microport Co.,LTD.，Shanghai, China） Ankura Stent Graft（Lifetech Scientific Co.,LTD.，Shenzhen, China）.
223860822|NCT06357910|DRUG|HCP2303|Take 1 tablet once per period
223860823|NCT06357910|DRUG|RLD2302|Take 1 tablet once per period
223860824|NCT06357910|DRUG|RLD2102|Take 1 tablet once per period
223860825|NCT00609908|PROCEDURE|Split skin graft|After wound bed preparation the skin defect is covered with a skin transplant (split skin graft)
223860826|NCT00609908|PROCEDURE|skin stretching device|after woundbed preparation the wound is primarily closed by aid of the skin stretching device
223860827|NCT00609908|PROCEDURE|serial excision|as much scar as possible is excised, whereafter the wound is closed
223860828|NCT00609908|PROCEDURE|skin stretching device|after the scar is excised, the wound is primarily closed by aid of the skin stretching device
223860829|NCT02694835|DEVICE|Delefilcon A contact lenses with UV Absorber|
223860830|NCT02694835|DEVICE|Delefilcon A contact lenses|
223860831|NCT02064959|DEVICE|Temperature management Zoll Intravascular Temperature Management device|
223860832|NCT00018226|BEHAVIORAL|Case Management|
223860833|NCT03396848|OTHER|SHAReClinic|Online clinic with educational modules
223860834|NCT04407325|DEVICE|electronic nose device|electronic nose device will be tested as a triage instrument for tuberculosis in a high risk population
223860835|NCT04407325|DEVICE|dig chest Xray with automated readings|software for tuberculosis detection on digital Chest Xray providing a probability score from 0-100
223860836|NCT00228007|DRUG|Antidepressant Medication|
223860837|NCT05222399|DRUG|LY3871801|Administered orally.
223860838|NCT03997682|OTHER|Hands-Up Program|In addition to the usual care, being allocated to the intervention group would require the participant to attend an exercise and education program once their cast has been removed and they've restored some strength and function in their hand and wrist. The exercise portion of the intervention will focus on strength and balance training, with aspects of managing our distal radius fracture healing as well. The education will focus on learning about risk factors for a distal radius fracture, osteoporosis, exercise for adults, nutrition for adults and falls prevention strategies.
223860839|NCT06463054|BEHAVIORAL|Dialectical Behavior Therapy Skills Group Training|The investigators will employ Dialectical Behavior Therapy Skills Training in order to experimentally manipulate maternal emotion dysregulation, the targeted mechanism.
223860840|NCT06463054|BEHAVIORAL|Safety Planning Intervention|Safety Planning Intervention (SPI) or SPI only for 6 months, such that all mothers with history of suicidal behavior + ER difficulties will receive SPI.
223860841|NCT00003728|DRUG|asparaginase|
223860842|NCT00003728|DRUG|cyclophosphamide|
223860843|NCT00003728|DRUG|cytarabine|
223860844|NCT00003728|DRUG|daunorubicin hydrochloride|
223860845|NCT00003728|DRUG|dexamethasone|
223860846|NCT00003728|DRUG|doxorubicin hydrochloride|
223860847|NCT00003728|DRUG|etoposide|
223860848|NCT00003728|DRUG|leucovorin calcium|
223860849|NCT00003728|DRUG|mercaptopurine|
223860850|NCT00003728|DRUG|methotrexate|
223860851|NCT00003728|DRUG|methylprednisolone|
223860852|NCT00003728|DRUG|mitoxantrone hydrochloride|
223860853|NCT00003728|DRUG|prednisolone|
223860854|NCT00003728|DRUG|therapeutic hydrocortisone|
223860855|NCT00003728|DRUG|thioguanine|
223860856|NCT00003728|DRUG|vincristine sulfate|
223860857|NCT00003728|DRUG|vindesine|
223860858|NCT00003728|PROCEDURE|allogeneic bone marrow transplantation|
223860859|NCT00003728|PROCEDURE|peripheral blood stem cell transplantation|
223860860|NCT05018325|PROCEDURE|Colonoscopy with 6 minute withdrawal|Withdrawal time will be determined using a digital stopwatch by the nursing staff.
223860861|NCT05018325|PROCEDURE|Colonoscopy 9 minute withdrawal|Withdrawal time will be determined using a digital stopwatch by the nursing staff.
223860862|NCT05018325|PROCEDURE|Colonoscopy 12 minute withdrawal|Withdrawal time will be determined using a digital stopwatch by the nursing staff.
223860863|NCT02319434|DEVICE|Ostom-i Alert Sensor|Sensor on ostomy bag.
223860864|NCT00006035|BIOLOGICAL|bleomycin sulfate|
223860865|NCT00006035|DRUG|electroporation therapy|
223860866|NCT06237751|DRUG|Sildenafil 100 MG|Sildenafil 100mg orally half an hour before surgery
223860867|NCT03245580|DIAGNOSTIC_TEST|Core Liver Biopsy|Diagnostic EUS examination followed by liver biopsy to obtain core sample in benign liver disease.
223860868|NCT02363192|BEHAVIORAL|Pharmacist intervention and pharmacist support|Patients randomised to this group will undergo an asthma assessment to assess asthma control, adherence and inhaler technique, by an Advanced Clinical Pharmacist specialising in Respiratory Medicine.
224266804|NCT03292705|BEHAVIORAL|PEP|The PEP system is built on a picture-based touch-screen interface on tablet computers. PEP allows users to explore and participate in entertainment, educational, spiritual, and other recreational activities and content personalized according to their interests and preferences. It provides easy access to the Internet and communication applications, and has hundreds of modules spanning music, travel, trivia, games, and religious and inspirational domains. For instance, if music is among a person's lifelong interests, the system provides access to multiple music genres through jukebox, karaoke and therapeutic music applications that can be tailored to a particular activity and by individual interest (for instance, a preference for classic jazz). As another example, for someone who likes travel or visiting new places, the interface offers access to Google Earth, guided tours, slide shows and regional facts and history.
224266805|NCT03292705|BEHAVIORAL|CCI|VSOP training will use five training paradigms (Eye for detail, Peripheral challenge, Visual sweep, Double decision, Target tracker) that practice processing speed and attention. All exercises share visual components and focus on accuracy and fast reaction times. Participants respond either by identifying what object they see or where they see it on the screen. The training will automatically adjust the difficulty of each task based on the participant's performance, ensuring that the participants always operate near their optimal capacity. The training programs will automatically record the percentage of completion of each game and scores.
224266806|NCT00000956|BIOLOGICAL|gp160 Vaccine (MicroGeneSys)|
223860869|NCT04562636|OTHER|Environmental message|Participants will be randomized to view a set of four messages about the environmental harms of meat production from the Meatless Monday campaign.
223860870|NCT04562636|OTHER|Health message|Participants will be randomized to view a set of four messages about the health harms of meat consumption from the Meatless Monday campaign.
223860871|NCT04562636|OTHER|Neutral Message|Participants will be randomized to view a set of four messages about checking their credit score.
223860872|NCT04997746|BEHAVIORAL|Multiprofessional educational interventions|Preventive educational interventions
223860873|NCT04997746|OTHER|Measurement of anthropometric measurements|Measurement of height (in meters), weight (in kilograms), knee height, arm circumference and calf circumference (in centimeters)
223860874|NCT03270124|BEHAVIORAL|Daily Activity Goal|Patients are given a tailored daily activity goal in terms of steps per day for which to aim.
223860875|NCT03270124|BEHAVIORAL|Resistance Exercises|Patients will instructed to perform 3 different resistance exercises targeting muscles pertinent to activities of daily living on 6 out of 7 days a week.
223860876|NCT03270124|BEHAVIORAL|Daily Activity Recording|A Fitbit will be worn by all participants to record daily activity.
223860877|NCT00553683|DRUG|cyclophosphamide|
223860878|NCT00553683|DRUG|poly ICLC|
224266807|NCT02940457|DEVICE|Verum tDCS|Neuropsychological (working memory) training for 30 minutes, 6 sessions tDCS during training with 2 mA
224266808|NCT02940457|DEVICE|Sham tDCS|Neuropsychological (working memory) training for 30 minutes, 6 sessions tDCS during training with 0 mA
224266809|NCT02933060|OTHER|Normal saline (1000 mL)|
224266810|NCT02933060|OTHER|Control|
224266811|NCT04635020|PROCEDURE|iStent|2 trabecular Stent injected at the end of the cataract surgery to the trabecular meshwork
224266812|NCT04635020|PROCEDURE|SLT-laser|1 month after cataract surgery laser treatment to the trabecular meshwork (100 applications, 360 degrees)
224266813|NCT04635020|PROCEDURE|Cataract surgery|Conventional cataract surgery
224266814|NCT05132426|PROCEDURE|Osteopathic Manipulative Treatment (OMT)|"Myofascial release of the thoracic inlet is a treatment involving gentle pressure applied to shoulders and neck to move the tissue in different directions.~Pectoral traction will have the doctor gently grasp and slowly pull the armpit area with a slow pulling force applied towards the shoulders.~Diaphragm release with MFR consists of the doctor touching below the ribs on each side and gently applying pressure to move the tissue from side to side.~Fascial release of the breast will have the doctor encircling the breast with their hands and inducing anterior traction. The doctor then induces motion in all directions. The doctor will then locate the affected spot and use a direct stripping motion from the base of the breast toward the areola until the restriction is released.~Thoracic pump has the doctor placing their hands over the chest wall on each side and applying pressure and releasing pressure several times to generate a pumping action of about 100 times per minute."
224266815|NCT05729048|DEVICE|Starling|"Starling is a portable, non-invasive, cardiac output detector system. The Starling monitor measures the cardiac output by employing electrical bioreactance. Bioreactance is a measure of the electrical characteristics of a volume of tissue and fluid. In the case of cardiac output measurements, the relevant tissue includes the heart and the immediate surrounding volume of the thorax. The relevant fluid is blood.~The Starling electrode is a double electrode sensor. Within each sensor, one electrode is used to transmit a high frequency sine wave into the body, while the resulting voltage is measured at the adjacent electrode.~This information is used to determine cardiac output. The Starling monitor also measures and displays associated hemodynamic parameters based on calculations of measurements already incorporated into the Starling monitor."
224266816|NCT00387530|DRUG|oral sodium phenylbutyrate|
224266817|NCT00387530|DRUG|valganciclovir|
224266818|NCT00387530|GENETIC|polymerase chain reaction|
224266819|NCT00387530|GENETIC|protein expression analysis|
224266820|NCT00387530|PROCEDURE|biopsy|
224266821|NCT00989950|DRUG|Daytrana|Daytrana patch 10-30 mg administered once daily for 9hr
224266822|NCT00989950|DRUG|Daytrana|Daytrana 10-30 mg worn once daily for 10 hr wear
224266823|NCT00989950|DRUG|Daytrana|Daytrana 10-30 mg worn once daily for 11 hr
224266824|NCT00989950|DRUG|Daytrana|Daytrana 10-30 mg worn once daily for 12 hrs
224266825|NCT00101439|DRUG|ezetimibe|
224266826|NCT00101439|DRUG|Comparator: placebo|
224266827|NCT02863822|BEHAVIORAL|Low FODMAP Diet|Subjects in the experimental arm, will be educated in the low fermentable oligo-di-monosaccharides and polyols (FODMAP) diet.
224266828|NCT02863822|BEHAVIORAL|Choose My Plate Diet|Subjects in the active comparator arm will be educated in the ChooseMyPlate.gov Diet.
224266829|NCT05966922|PROCEDURE|Transcutaneous Electrical Stimulation|Electrical Stimulation and a sham will be administered through the skin in random consecutive sessions in a study group. A single monophasic square electrical pulse and transcutaneous electrical nerve stimulation will be applied to the forearm volar aspect.
224266830|NCT00500201|DRUG|SB- 773812 60 mg|SB- 773812 will be available dose strength of 60 mg and administered orally by subjects.
224266831|NCT00500201|DRUG|SB- 773812 120 mg|SB- 773812 will be available dose strength of 120 mg and administered orally by subjects.
224266832|NCT00500201|DRUG|Placebo|Placebo tablets will be administered orally by subjects.
224266833|NCT03415867|DRUG|Glasdegib|A dose escalation/de-escalation design will be applied in successive patient cohorts until identification of MTD (dose range: 25-200 mg OD).
224266834|NCT06452758|OTHER|2000 meter ergometer test|Rowers will perform 2000m ergometer test. A 2,000-meter trial is a standard test used to assess performance in rowers.
224266835|NCT05988840|OTHER|Acquisition and analysis of relationships between Longitudinal Emotional Signals produced by a software and Self-questionnaires.|Using the tool developed by Emobot, EMOACQ-1 is a study that passively and non-interventionaly collects data by capturing patients' facial expressions throughout the day, and then measures the correlation between emotional signals and the results of measurement questionnaires used in psychiatry.
224266836|NCT05934695|OTHER|Lymphedema severity stratification|"Participants will be stratified into one of three lymphedema severity groups based on the International Society of Lymphology lymphedema severity staging:~Mild (stage 1): swelling with pitting; normal skin and tissue turgor Moderate (stage 2): swelling with pitting; dermal thickening; skin changes without distortional warty-overgrowth Severe (stage 3): swelling with non-pitting; warty overgrowth or elephantiasis folds"
224266837|NCT00768963|DRUG|ranibizumab|0.5 mg subconjunctival ranibizumab 3 days prior to surgery
224266838|NCT00768963|DRUG|ranibizumab|0.5 mg subconjunctival ranibizumab at the time of surgery
224266839|NCT03245658|DRUG|THC and CBD Mixture|Individually titrated doses on daily basis
224266840|NCT02956096|DEVICE|Transcranial direct current stimulation (tDCS)|The active tDCS and placebo will be applied to anode electrode on left temporal cortex placed on the scalp in the region T3. The cathode electrode on the middle deltoid muscle contralateral to the anode.
224266841|NCT02956096|DEVICE|training on the running belt|The running in the treadmill will be held on a single training session and the speed of the cardiopulmonary exercise testing and slope from 60 to 80% of the maximum achieved in cardiopulmonary testing, in order that the patient reaches 60% to 70% of the heart rate reserve.
224266842|NCT05710458|DEVICE|25 gauge 20,000 cpm Hypervit Dual Blade|Vitrectomy blade with increased cutting rate to 20,000 cut/min
224266843|NCT05710458|DEVICE|25 gauge 10,000 cpm Ultravit Vitrectomy Cutter|Existing Vitrectomy blade with cutting rate 10,000 cut/min
223860879|NCT00553683|PROCEDURE|hepatic artery embolization|
223860880|NCT00553683|RADIATION|3-dimensional conformal radiation therapy|
223860881|NCT00255281|DRUG|AZD7009, no generic name available|
223860882|NCT00596609|DRUG|Intrathecal Morphine|"* In the IT morphine group, prior to IT morphine injection (within 15 minutes of the injection), the neurophysiologist will be asked to obtain a set of TceMEP recordings. The recordings collected at this time will be labeled Baseline. These will serve as controls for subsequent recording comparisons.~* In the IT morphine group, the time of IT morphine injection will be recorded, as well as the dose. A timer will be started. The neurophysiologist will then be asked to collect four additional sets of TceMEP recordings, at 5, 10, 20, and 30 minutes after morphine injection."
223860883|NCT04940117|DIETARY_SUPPLEMENT|Eefooton oral solution|Check eGFR value, liver and kidney function every month
223860884|NCT00795054|OTHER|Household financial data collection|Baseline financial survey pre-transplant, financial diary post-transplant every two weeks for 3 months, and financial questionnaire via phone survey at 6, 12, 18 and 24 months post-transplant.
223860885|NCT03411278|DEVICE|Deep Oscillation (DO)|"DO self treatment with the device mobile (Physiomed, Laipersdorf, Germany; U.S. patent 7,343,203 B2).The device produces an alternating electrostatic field, which results in a low-frequency vibration penetrating the tissue. The Field is pulsed at a frequency of 90 Hz. For self-treatment, each volunteer is given an apparatus to take home. An applicator with a diameter of 9 cm is used. The treatment will be carried out in the morning and evening for 15 minutes each in supine position on a sofa. In accordance with the technique of classical manual lymphatic drainage, stroking and circular movements in the upper and lower leg and the inguinal area take place in a fixed order."
223860886|NCT03417869|DEVICE|QuickVue Influenza A+B|Rapid diagnostic test with IVD, QuickVue Influenza A+B
223860887|NCT00191412|DRUG|Pemetrexed|
223860888|NCT04827654|DIETARY_SUPPLEMENT|Weekly produce box and gift card|Weekly box of produce (5-10 lbs) and $10.00 gift card to a local grocery store to purchase preferred produce. If progress on self-goals completed, an additional $10.00 card provided, weekly, for 3 weeks.
223860889|NCT04484753|OTHER|Home Exercise Sheet|Received a sheet with pelvic floor muscle training guidelines to be performed at home. After 3 months all volunteers were reevaluated.
223860890|NCT04484753|OTHER|Ipelvis mobile application|Received the iPelvis® Application with pelvic floor muscle training guidelines to be performed at home. After 3 months all volunteers were reevaluated.
223860891|NCT04484753|BEHAVIORAL|Home exercise sheet + Pelvic Physiotherapy|Performed 12 Pelvic Physiotherapy sessions, in group, once a week and received a sheet with pelvic floor muscle training guidelines to be performed at home. After 3 months all volunteers were reevaluated.
223860892|NCT04484753|BEHAVIORAL|Ipelvis mobile application + Pelvic Physiotherapy|Performed 12 pelvic physiotherapy sessions, in group, once a week and received the iPelvis® Application with pelvic floor muscle training guidelines to be performed at home. After 3 months all volunteers were reevaluated.
223860893|NCT00328731|PROCEDURE|Procedure|
223860894|NCT03621826|OTHER|Questionnaire/Interview|A convenience sample of patients/parents and stakeholders will be asked to participate in a survey and/or interview to evaluate barriers to care in sickle cell.
223860895|NCT00317577|DRUG|brimonidine, timolol|
223860896|NCT05520294|OTHER|High-performance liquid chromatography-tandem mass spectrometry assays|Paraffin blocks will be requested for slide creation, and at least 12 mL of whole blood will be collected in 2 green top tubes, centrifuged, and plasma transferred for storage at -80 C until further processing
223860897|NCT05948644|DRUG|TPN171H|TPN171H 2.5mg TPN171H 5mg TPN171H 10mg
223860898|NCT02731885|DRUG|ABX464 Single dose|Two-periods, subjects received a single dose of 50mg of ABX464 in fed and fasted condition, separated by a wash-out period of at least 45 days.
223860899|NCT02731885|DRUG|ABX464 Repeated dose|Subjects received 50mg of ABX464 every 3 days during 10 days in fasted or fed condition.
223860900|NCT04056039|DRUG|Atorvastatin|Efficacy of atorvastatin 40 mg orally every 24 hours for four weeks vs colchicine with an initial dose of 0.25 mg every 8 hours, with titration in the first 3 days according to tolerance up to a maximum dose of 0.5 mg every 8 hours for four weeks in decrease of troponin I of high sensitivity
223860901|NCT04056039|DRUG|Colchicine|Efficacy of atorvastatin 40 mg orally every 24 hours for four weeks vs colchicine with an initial dose of 0.25 mg every 8 hours, with titration in the first 3 days according to tolerance up to a maximum dose of 0.5 mg every 8 hours for four weeks in decrease of troponin I of high sensitivity
223860902|NCT04525170|DEVICE|HPT treatment|
223860903|NCT04525170|DEVICE|untreated|
223860904|NCT02273544|DRUG|Asasantin ER (new formulation - low)|
223860905|NCT02273544|DRUG|Asasantin ER (new formulation - medium)|
223860906|NCT02273544|DRUG|Asasantin ER (new formulation - high)|
223860907|NCT02273544|DRUG|Asasantin ER - commercial formulation|
223860908|NCT05174013|DRUG|GSK3858279|GSK3858279 will be administered
223860909|NCT05174013|DRUG|Placebo|Placebo will be administered
223860910|NCT06516809|DEVICE|DormoTech Vlab SpO2 sensor|The Dormotech Vlab sensor was applied to one of the subject's forehead. Reference pulse oximeters were applied to the right fingers. Blood gas analysis to determine hemoglobin saturation (SaO2) was performed using an ABL-90 Flex Plus multi-wavelength oximeter (Hemoximeter, Radiometer, Copenhagen). The ABL90 Flex Plus contains factory calibration standards and automatically performs regular quality controls.
223860911|NCT03287622|BEHAVIORAL|Educational Intervention|This intervention provides scenario-tailored opioid risk message feedback immediately following interactive analgesic decision-making exercises.
223860912|NCT03287622|BEHAVIORAL|Nudge|Behavioral Nudge in this study is a simple, take-home kit (ziplock baggy of used coffee grounds) to be used to dispose of left-over prescription opioids
223860913|NCT00016250|DRUG|MKC-1|
223860914|NCT02889341|DIETARY_SUPPLEMENT|DHA|
223860915|NCT02889341|OTHER|Placebo|
224266844|NCT03101358|DRUG|SOR007 (Uncoated Nanoparticle Paclitaxel) Ointment|One (1) Finger Tip Unit (FTU), or approximately 0.5 g, of SOR007 ointment will be applied topically to a 50 cm2 treatment area.
224266845|NCT00474058|DRUG|Rotigotine|"Rotigotine transdermal patches:~10cm2 (2mg/24h); 20cm2 (4mg/24h); 30cm2 (6mg/24h); 40cm2 (8mg/24h)~Optimal dosing: The maximum Rotigotine dose allowed is 16mg/24h"
224266846|NCT00474058|OTHER|Placebo|Placebo transdermal patches
224266847|NCT05323981|DRUG|HS627(210mg/7ml)|Intravenous drip of 420mg HS627
224266848|NCT05323981|DRUG|HS627(420mg/14ml)|Intravenous drip of 420mg HS627
224266849|NCT05323981|DRUG|Perjeta|Intravenous drip of 420mg PERJETA
224266850|NCT05544123|OTHER|pathological stage|breast cancer molecular subtyping and pathological TNM stage
224266851|NCT00894855|BEHAVIORAL|education about sun protection|This comprehensive education program included a visit with a health educator, on the education van, who gave education about sun safety.
224266852|NCT00894855|BEHAVIORAL|biometric feedback|Participants received biometric feedback using a Dermascan Analyzer and Ultra Violet (UV) Reflectance Photography. The Dermascan Analyzer is an educational tool that enhances visibility of skin texture, markings or lesions and is commonly used in health fairs and at schools all over the country. The analyzer highlights the sun damage on the participants skin as dark purple blotches, which the participants are able to see in the mirror placed inside the analyzer. Ultra Violet (UV) Reflectance Photography provides participants with a visual image of their skin damage that can be taken with them.
224266853|NCT00894855|OTHER|dermatologist skin exam|Full body skin exam.
224266854|NCT02426918|DRUG|Debio 1450 IV|Intravenous (IV) form of Debio 1450 will be supplied in vials containing 50 mg of active pharmaceutical ingredient (API). Intravenous infusions of Debio 1450 (160 mg and 80 mg) will be administered over a 2-hour period BID every 12 hours within a 2-hour window (12 ± 2 hours).
224266855|NCT02426918|DRUG|Debio 1450 Oral|Oral forms of Debio 1450 will be provided as white, opaque, hard gelatin capsules containing 50 mg drug substance (equivalent to 40 mg of Debio 1450).
224266856|NCT02426918|DRUG|Linezolid|Linezolid for oral administration will be provided as 600-mg film-coated compressed tablets.
224266857|NCT02426918|DRUG|Debio 1450 Oral Placebo|Debio 1450 placebo will be supplied as white, opaque, hard gelatin capsules.
224266858|NCT02426918|DRUG|Linezolid Placebo|Linezolid placebo will be supplied as film-coated compressed tablets.
224266859|NCT02426918|DRUG|Vancomycin IV|Vancomycin will be administered BID every 12 ± 2 hours at doses of 1 g or 15 mg/kg as specified in local protocols, with the infusion rate adjusted to 2 hours.
224266860|NCT06114836|DRUG|Omeprazole|Omeprazole will be the PPI prescribed for 4 weeks.
224266861|NCT06114836|OTHER|AR formula|Added rice formula will be ordered for 4 weeks.
224266862|NCT01496118|DRUG|panobinostat|Specified dose on specified days
224266863|NCT01496118|DRUG|carfilzomib|Specified dose on specified days
224266864|NCT02386358|DRUG|Benznidazole|Benznidazole at a dose 5 mg/Kg/day until 60 days have been completed or development of non-acceptable toxicity-
224266865|NCT02386358|DRUG|Placebo|Placebo at a dose 5 m/Kg/day until 60 days
224266866|NCT03793803|BEHAVIORAL|Home Palliative Care|Patients/caregivers will be cared for by an interdisciplinary team that includes a social worker, nurse, community health worker, nurse practitioner, and physician.
224266867|NCT03723733|BEHAVIORAL|screen high and low triat subjects|use a range of questionniares to screen screen high and low triat subjects (eg. Autism, Anxiety, Depression traits and social network size)
224266868|NCT03780608|DRUG|AZD6738|AZD6738 will be administered at 240 mg twice daily on days 1 to 7 in Cycle 0 (lead-in period) and therafter at 240 mg BD on days 22 to 28 in a 28-day cycle.
224266869|NCT03780608|DRUG|Durvalumab|. Durvalumab will be administered at 1500 mg every 4 weeks from cycle 1 day 1.
224266870|NCT06003933|DRUG|Bupivacaine Hydrochloride|10 ml of 0.25% bupivacaine on each side of cervical region at C5
224266871|NCT06003933|DRUG|Lidocaine Hydrochloride|10ml xylocaine on each side of cervical region at C5
224266872|NCT06003933|DEVICE|Ultrasound|The same anesthesiologist who is experienced in US guided regional anesthesia will perform the block.The five-layered posterior cervical muscles were identified at the level of C5 with a 6-15-MHz linear probe oriented in the transverse plane (SonoSite Edge, Bothell, Washington). The fifth cervical spine was counted from the C7 spinous process with the probe sliding cranially.
224266873|NCT06003933|DEVICE|Needle|the needle (22- G, 50-mm block needle (Visioplex, Vygon) was introduced in-plane through the skin and advanced into the fascial plane between the semispinalis cervicis and semispinalis capitis muscles. After negative aspiration for blood, 20 ml of bupivacaine 0.25% was injected5.
224266874|NCT02024048|OTHER|OCT|Optical coherence tomography in enhanced depth imaging mode
224266875|NCT05616728|DRUG|EDP-235|capsule
224266876|NCT05616728|DRUG|Placebo|capsule
224266877|NCT00690495|DRUG|Propofol|Propofol (drug), intravenous, induction of anesthesia
224266878|NCT00690495|DRUG|Propofol 1%|Propofol (drug), intravenous, induction of anesthesia
224266879|NCT03958812|DIAGNOSTIC_TEST|Circulating tumor cells, Volatile organic compounds|Alveolar exhaled breath samples and peripheral venous blood(10ml) will be collected from each patients
224266880|NCT01572623|DRUG|Clopidogrel|Loading dose of Clopidogrel 600 mg versus 300 mg before carotid artery stenting
224266881|NCT01572623|DRUG|Atorvastatin|Reloading dose of Atorvastatin (80 mg at 12 hours and 40 mg at 6-8 hours before carotid artery stenting) versus no reload.
224266882|NCT01024855|DEVICE|RevitaLens OcuTec MPS (Investigational MPS) and Opti-Free RepleniSH MPS (control)|multi-purpose lens care solution
224266883|NCT04275349|DRUG|Xingnaojing injection within 24 hours of symptom onset|intravenously administered Xingnaojing injection within 24 hours of symptom onset on ambulance or at hospital
224266884|NCT00076622|DRUG|Antidepressant medication|Participants assigned to continue current medication will be monitored over a period of one year for recurrence of depression and related symptoms.
224266885|NCT00076622|DRUG|No antidepressant medication|Participants assigned to discontinue current medication (no antidepressant medication) will be monitored over a period of one year for recurrence of depression and related symptoms.
224266886|NCT03306277|BIOLOGICAL|Onasemnogene Abeparvovec-xioi|Non-replicating recombinant adeno-associated virus serotype 9 (AAV9) containing the complimentary deoxyribonucleic acid (cDNA) of the human SMN gene under the control of the cytomegalovirus (CMV) enhancer/chicken-β-actin-hybrid promoter (CB). The AAV inverted terminal repeat (ITR) has been modified to promote intramolecular annealing of the transgene, thus forming a double-stranded transgene ready for transcription.
224266887|NCT05210647|DEVICE|robotic surgery|by da Vinci Xi
224266888|NCT05603351|DIAGNOSTIC_TEST|magnetic resonance|biparametric MRI with protocol including anatomical T2 sequence and diffusion-weighted images (DWI), according to the standards
224266889|NCT05603351|DIAGNOSTIC_TEST|serum PSA examination|testing of prostate-specific antigen (PSA) in serum
224266890|NCT05603351|PROCEDURE|Biopsy|"Men with a positive MR test are planned for a targeted MRI/US fusion and systematic prostate biopsy.~Men with a positive blood marker (either PSA, PSAD, or PHI) are planned for a systematic 12 core biopsy. Positive test results are PSA ≥ 3, integrated marker PSAD ≥ 0.15, and PHI ≥ 35."
224266891|NCT04046705|PROCEDURE|Allogeneic matched related haematopoietic stem cell transplantation|Allogeneic matched related haematopoietic stem cell transplantation after a reduced intensity conditioning regimen
224266892|NCT04046705|OTHER|Standard arm|In the standard arm, patients who will not be transplanted, will receive the best standard care according to their situation and their previous treatment: initiation of hydroxyurea, continuation or optimization of the dose of hydroxyurea, initiation or continuation of transfusion program, initiation of a new drug proved to improve SCD and having authorization to use in France
224266893|NCT03097198|OTHER|Plum-blossom Needle|"* acupoint selection: Zhengguang 1, Zhengguang 2, GB20, GV14, LI4.~* plum-blossom needle manipulation methods: After the skin has been wiped with 75 % alcohol, plum-blossom needles will be tapped perpendicularly on the skin at the selected acupoints with wrist force and then lifted immediately. Each point will be tapped repeatedly for 20 to 50 times and both sides of cervical vertebra and temporal region, Suprao-infraorbital margin will be tapped repeatedly. Acupuncturists should tap the points gently to make patients feel only a little pain and stop when the skin gets flushed but is not bleeding."
224266894|NCT03097198|DRUG|Tropicamide Eye Drops|Instill one drop in both eyes every night before bed.
224266895|NCT04058977|OTHER|Power training|Progressive exercise protocol with focus on velocity of movement
224266896|NCT06007729|DRUG|HS-20093|Participants in all subjucts will receive HS-20093 at 10mg/kg
224266897|NCT03461380|DIETARY_SUPPLEMENT|Menopause Relief EP-40|Fixed combination of black cohosh and Rhodiola rosea
224266898|NCT03461380|DIETARY_SUPPLEMENT|Low Dose Black Cohosh|6.5 mg black cohosh
224266899|NCT03461380|DIETARY_SUPPLEMENT|High Dose Black Cohosh|500 mg black cohosh
224266900|NCT03461380|DIETARY_SUPPLEMENT|Placebo|600 mg excipient
224266901|NCT03249844|DRUG|Methylprednisolone + prednisolone|"The experimental intervention consists of 5 consecutive days Methylprednisolone at a daily single intravenous dose of 20 mg/kg body-weight (max 1 g/day) followed by a 4-week course of tapering Prednisolone given at a daily single oral dose in the morning:~* week 1 and 2, oral Prednisolone 1 mg/kg/day (max 40 mg/day), ,~* week 3 and 4, oral Prednisolone 0,5 mg/kg/day (max 20 mg/day),"
224266902|NCT00672373|DRUG|Extract of Ginkgo Biloba (EGb-761 capsules)|EGb-761 240mg/d, 1 capsule(80mg) tid,po,12 weeks; Each capsule contains 19.6mg flavonol glycosides and 4.8mg terpene lactones.
224266903|NCT00672373|DRUG|Placebo|Wheat flour placebo capsule,1 capsule tid, po,12 weeks
224266904|NCT02942082|OTHER|ACP oral care gel|a desensitizing agent will be applied on tooth before and/or after bleaching
224266905|NCT02942082|OTHER|glycrin|glycrin will be applied on tooth surface before and/or after bleaching
224266906|NCT04432558|DIAGNOSTIC_TEST|Spielberger's State-Trait Anxiety Inventory|Patients will be wanted to fill the Spielberger's State-Trait Anxiety Inventory the night before the surgery.
224266907|NCT04432558|OTHER|Visual analog scale, Ramsay's sedation scale|The analgesic consumption of the patients will be recorded by evaluating the pain with VAS (Visual analog scale) and sedation status with Ramsay's sedation scale in the 1st, 4th, 12th and 24th hour of postoperative period.
224266908|NCT04432558|DRUG|Tramadol, paracetamol, diclofenac sodium|The analgesic consumption of the patients will be recorded
224266909|NCT03542669|DRUG|6B11-OCIK Injection|Two infusions of 6B11-OCIK will be performed at each chemotherapy cycle (Day 3 an Day 7) during the first three cycles, while PBMC will be collected before each cycle (Day -12) during the first three cycles.
224266910|NCT03542669|DRUG|Doxorubicin|Subjects will be adminitered 4\~6 cycles of chemotherapy (Doxorubicin, 30 mg/m\^2 IV on Day 1 of every cycle)
224266911|NCT02672267|BIOLOGICAL|Stem cells|human Allogeneic Low Oxygen mesenchymal stem cells; Ischemia tolerant
224266912|NCT02672267|OTHER|Placebo|Lactated Ringer's Solution
224266913|NCT05945472|OTHER|Positive reinforcement method|"A 30-minute talk based on mindfulness, positive thinking and teaching for the application of the cosmetic through positive messages (Ayuna method). Adapts the teachings of mindfulness to the field of beauty and stimulates the skin-brain connection through self-care. By applying cosmetics through intentional massages, with this technique is stimulated the brain in a positive positively in the general wellbeing.~The cosmetic is applied with a massage aimed at loving oneself, a ceremony for the skin and an invitation to enjoy the moment; positive messages are included during the application. In addition to favoring the penetration of the products, these maneuvers help to disconnect and achieve, in the long term, a healthier appearance. The technique consists of slow, intentional movements to create an ideal space to become aware of the present moment and draw a love story with oneself."
224266914|NCT05945472|OTHER|Standard method|"A 30-minute talk based on how to administer it according to the guidelines of general cosmetology, related to the use and application of the cream, following conventional techniques of the cosmetic industry, which focus on the application of the product in the areas of wrinkles or with more treatment needs: anti-aging anti-stain anti-sagging anti-sagging product, anti-sagging anti-sagging anti-sagging anti-sagging anti-sagging anti-sagging product. rejuvenating results to try to reduce the skin years, reduce wrinkles, loss of firmness, flaccidity and spots."
224266915|NCT04339634|OTHER|Simulation of Repurposed Drugs for COVID-19|This study is a simulation of adding repurposed drugs for COVID-19. We are using drug claims, and will not intervene with patient care.
224266916|NCT01371617|DRUG|IPI-926|Single Arm study of oral IPI-926 at 160 mg, 130 mg or 110 mg daily, until progressive disease or intolerability to study treatments or withdrawal of ICF
224266917|NCT06560034|DEVICE|VicorderCS|"1. Vascular Sensor (VCS-VAS-1000) measurement device used with accessories (cuffs and tubes) connected to the device;~2. Data Station (VCS-DAT-1000) for data collection and analysis"
224266918|NCT06251349|RADIATION|Radiation|Single dose radiation with 7-8 Gy
224266919|NCT06251349|DRUG|Diclofenac|postoperative treatment with diclofenac to prevent HO
224266920|NCT01174849|DRUG|Synflorix|The 10-valent vaccine contains 1 µg of purified capsular polysaccharide of pneumococcal serotypes 1, 5, 6B, 7F, 9V, 14, and 23F conjugated to protein D, 3 µg of serotype 4 conjugated to protein D, 3 µg of serotype 18C conjugated to tetanus toxoid and 3 µg of serotype 19F conjugated to diphtheria toxoid.
224266921|NCT01174849|DRUG|Prevenar13|"The vaccine is a ready to use homogeneous white suspension for intramuscular injection, supplied as a pre-filled syringe.~Active ingredients~Each 0.5 mL dose contains:~2.2 μg of pneumococcal purified capsular polysaccharides for serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F and 23F 4.4 μg of pneumococcal purified capsular polysaccharides for serotype 6B. Each serotype is individually conjugated to non-toxic diphtheria CRM197 protein and adsorbed on aluminium phosphate (0.565 mg). CRM197 is a nontoxic variant of diphtheria toxin isolated from cultures of Corynebacterium diphtheriae strain C7 (β197) grown in a casamino acids and yeast extract-based medium."
224266922|NCT01174849|DRUG|COMBO|COMBINATION SCHEDULE of vaccine 1 and vaccine 2: Synflorix (PHiD-CV) at 1,2,4 months then Prevenar13 (PCV13) at 6 months of age.
224266923|NCT00981838|DRUG|Rituximab|Rituximab (375 mg/m2) will be given as a single intravenous infusion after reconstitution in normal saline to a concentration of 1 mg/ml given though a 0.22 micron in line filter. The initial infusion rate will be 1 ml/kg/h and will be progressively increased up to 4 ml/kg/h according to drug tolerability. Pre-medication with steroids and/or antihistaminic agents will be done according to per-center's practice.Rituximab administration will be repeated in those patients \> 5 B cells/mm3 in the peripheral blood on the day after first Rituximab administration.
224266924|NCT02784236|DEVICE|telemedicine|The study population corresponds to patients\> 18 and \<65 years with DM1 of\> 1 year of evolution, and treated with MDI HbA1c\> 7%. It is changing one group of subjects between two observation times due to any intervention in this case the addition of a tele
224266925|NCT00881751|BIOLOGICAL|bevacizumab|Given IV
224266926|NCT00881751|DRUG|erlotinib hydrochloride|Given orally
224266927|NCT00881751|DRUG|sorafenib tosylate|Given orally
224266928|NCT04866979|DEVICE|Experimental: Continuous TBS (cTBS)|Application of cTBS. cTBS will be applied to the left dorsolateral prefrontal cortex (left DLPFC). The coil will be placed at the EEG 10-20 International System position of the F3 electrode. Stimulation parameters will be TBS delivery of 600 pulses divided into blocks of 3 pulses at 50 Hz, which are applied at 5 Hz (every 200 ms), with a stimulation intensity equal to 80% of the motor threshold value at rest.
224266929|NCT04866979|DEVICE|Intermittent TBS (iTBS)|Application of iTBS. iTBS will be applied to the left dorsolateral prefrontal cortex (left DLPFC). The coil will be placed at the EEG 10-20 International System position of the F3 electrode. Stimulation parameters will be TBS delivery of of 600 pulses divided into blocks of 3 pulses at 50 Hz, which are applied at 5 Hz (every 200 ms), alternating 2 seconds of stimulation with a pause of 8 seconds, with a stimulation intensity equal to 80% of the motor threshold value at rest.
224266930|NCT04866979|BEHAVIORAL|Cognitive training (CT).|Cognitive training (memory rehabilitation via RehaCom computer software) of 25 min. The training will be focused on memory rehabilitation, implementing a face-name association paradigm. The software uses an individualized adaptive methodology based on the participant's performance.
224266931|NCT04866979|DEVICE|Sham Stimulation (shamTBS)|"Sham rTMS (TBS) will be administered by applying a 30mm thick piece of wood or plastic to a real TMS coil during stimulation, and this additional element will be constructed in such a way that it appears to be an integral part of the apparatus such that the patient remains unaware that they are not receiving stimulation (Rossi et al., 2007 ).This 30mm distance is adequate to ensure that the magnetic pulse does not reach the cortex."
223860916|NCT00919594|BEHAVIORAL|Interpersonal Psychotherapy for Mothers (IPT-MOMS)|Interventions will be administered during the 3 Month Acute Randomized Phase and will consist of nine individual 45-minute sessions conducted over the course of three months. Treatment cannot exceed nine sessions. In addition to standard IPT techniques, IPT-MOMS includes a specific focus on the challenges associated with managing a child who suffers from psychiatric problems.
223860917|NCT00919594|BEHAVIORAL|Brief Supportive Psychotherapy|Interventions will be administered during the 3 Month Acute Randomized Phase and will consist of nine individual 45-minute sessions conducted over the course of three months. Treatment cannot exceed 9 sessions. Brief supportive therapy (BSP) is a manualized form of supportive psychotherapy which emphasizes reflective listening and elicitation of affect (Markowitz et al., 2008). Therapists are instructed to allow patients to determine the focus of each session, pulling for emotion, validating emotions when possible, and offering empathic comments.
223860918|NCT01709266|DIETARY_SUPPLEMENT|Probiotics|
223860919|NCT01709266|DIETARY_SUPPLEMENT|Placebo|
223860920|NCT00271700|BEHAVIORAL|Order Set, Education, Feedback|
223860921|NCT06037824|OTHER|cryotherapy|"cryotherapy was added to rehabilitation\*. One group received compressive cryotherapy and the other conventional cold pack cryotherapy.~\* rehabilitation includes (=classic rehabilitation) passive and active of mobilization of knee and patella, treat arthrogenic muscular inhibition, learn to lock the quadriceps, progressive muscular strengthening of the periarticular muscles of the knee, stretching of the quadriceps and the posterior muscular chain, proprioceptive exercises with bi- and unipodal balance, transfer of support and resumption of the walking pattern."
223860922|NCT01924975|PROCEDURE|Saphenous vein cannulation|Intravenous cannulation to saphenous vein
223860923|NCT01924975|DEVICE|ultrasound with a linear transducer (L15-7io)|Portable, bed-side ultrasound to detect saphenous vein
223860924|NCT01924975|DEVICE|A 22 or 24 G intravenous catheter|
223860925|NCT06567119|BIOLOGICAL|SPOT-mRNA01|SPOT-mRNA01 (COL1A1 mRNA-loaded by EVs) ,single-dose subcutaneous injection
223860926|NCT06567119|OTHER|Placebo|Sterile isotonic solution, subcutaneous injection
223860927|NCT05193994|DRUG|Dolutegravir, Abacavir and Lamivudine|Dolutegravir 50mg, Abacavir 600mg and Lamivudine 300mg.
223860928|NCT05193994|DRUG|Placebo|Matching placebo.
223860929|NCT03457246|OTHER|D-Pigment rich texture|
223860930|NCT03457246|OTHER|Hydrance optimale riche|
223860931|NCT04017169|OTHER|No intervention as observational study|
223860932|NCT00003717|DRUG|estramustine phosphate sodium|
223860933|NCT00003717|DRUG|paclitaxel|
223860934|NCT04190342|OTHER|control group|A booklet on the self-management of cancer symptoms. After the pilot RCT is completed, if the participants allocated to the control group are interested in practising tai chi, the intervention will be provided
223860935|NCT04190342|BEHAVIORAL|tai chi group|Around 60 minutes practising easy tai chi movements/postures twice per week
223860936|NCT03477110|DRUG|Temozolomide|Given PO
223860937|NCT03477110|RADIATION|Radiation Therapy|Undergo radiation therapy
223860938|NCT03477110|DEVICE|NovoTTF-200A Device|Undergo tumor treatment fields therapy using NovoTTF-200A device
223860939|NCT03477110|PROCEDURE|Tumor Treating Fields Therapy|Undergo tumor treatment fields therapy using NovoTTF-200A device
223860940|NCT04352803|BIOLOGICAL|Autologous Adipose MSC's|Autologous Adipose Derived Mesenchymal Cells 500,000/kg IV
223860941|NCT03368833|DIAGNOSTIC_TEST|Electrocardiogram|12-lead ECG will be obtained after induction and at 5, 10, 20, 30, and 60 minutes after the caudal epidural block.
223860942|NCT06369922|PROCEDURE|TENS|"This device will then be used for deep transcutaneous nerve stimulation at the T10-L1 and S2-S4 levels. The device will be placed and activated 5 minutes before the procedure. and the device will remain active during the procedure and will be turned off as soon as the procedure is complete (the procedure typically takes 5-15 minutes). The TENS units have pre-program settings, improving convenience, reproducibility, and reliability. Study staff will be instructed to perform TENS using an Acupuncture mode on the provided TENS units. The amplitude will be adjusted to a comfortable sensation that does not cause pain using adhesive electrodes. One TENS unit is able to support 4 TENS electrodes. The TENS electrodes (8 cm x 5 cm) will be placed on bilateral paraspinal muscles. The intensity of the stimulation (Hz) will be adjusted to the subjective comfort of the subject."
223860943|NCT06369922|PROCEDURE|Control TENS|"This device will then be used for deep transcutaneous nerve stimulation at the T10-L1 and S2-S4 levels. The device will be placed and activated 5 minutes before the procedure. and the device will remain active during the procedure and will be turned off as soon as the procedure is complete (the procedure typically takes 5-15 minutes). The TENS units have pre-program settings, improving convenience, reproducibility, and reliability. Study staff will be instructed to perform TENS using an Acupuncture mode on the provided TENS units. The amplitude will be adjusted to a comfortable sensation that does not cause pain using adhesive electrodes. One TENS unit is able to support 4 TENS electrodes. The TENS electrodes (8 cm x 5 cm) will be placed on bilateral paraspinal muscles. The intensity of the stimulation (Hz) will be adjusted to the subjective comfort of the subject."
223860944|NCT05058469|DEVICE|Tracheotomy|Tracheotomy in patients +/- antiplatelet therapy
223860945|NCT00660478|DEVICE|Endeavor|Comparison of two different drug eluting coronary stents
223860946|NCT00660478|DEVICE|Cypher Select|Comparison of two different drug eluting coronary stents
223860947|NCT04429230|DEVICE|Active Transcranial pulsed current stimulation (tPCS)|Active tPCS will be delivered through a pair of saline soaked (0.9% NaCl) surface sponge electrodes. Anodal stimulation will be given to brain area based on qEEG findings
223860948|NCT04429230|DEVICE|Sham Transcranial pulsed current stimulation (tPCS)|Electrode placement will be the same as active stimulation but the electric current will be ramped down 5 seconds after the beginning of the stimulation to make this condition indistinguishable from the experimental active stimulation.
223860949|NCT05650268|DRUG|Vitamin D3|Receiving 576000 international units in single oral dose of liquid vitamin D 3\~7 days prior to the surgery.
223860950|NCT05650268|OTHER|95% MCT|95% MCT supplement 3-7 day before surgery
223860951|NCT05565859|BEHAVIORAL|Planetary Health Plate signage|A Planetary Health Plate graphic was developed based on the healthy reference diet proposed by the Eat Lancet Commission. The graphic was designed to capture the food groups and proportions of food groups promoted by the Planetary Health diet.
223860952|NCT01930045|DRUG|Raltegravir (ISENTRESS™)|Raltegravir 400 mg oral tablet once every 12 hours. Participants will continue with their other prescribed antiretroviral agents throughout the study.
223860953|NCT01930045|DRUG|MAALOX (MAL)|MAL (or generic equivalent) 20 mL oral single dose on Day 1
223860954|NCT01018524|PROCEDURE|abdominal wall reconstruction|suture repair, mesh repair, onlay mesh reconstruction, sublay mesh reconstruction, recurrence rate
223860955|NCT01373398|DRUG|EO9(Apaziquone)|immediate instillation after TURBT + 6 weekly instillation 4mg/mL Apaziquone
223860956|NCT01927965|DRUG|Minnelide™ 001|Minnelide™ will be given as a single agent intravenously as a 30-minute infusion daily x 21 days followed by a 7-day rest period. One cycle will equal 28 days.
223860957|NCT03244579|BEHAVIORAL|Dietary Intervention|Adjusting the quantity and quality of food intake to improve glycemic control, maternal and newborn health outcomes of women with gestational diabetes.
223860958|NCT01028118|OTHER|Identifying experience with violence|Asking about life experience with violence and Cognitive Behavior Therapy.
224266932|NCT02385708|DRUG|2% Chlorohexidine Gluconate Standard of Care|Patients will perform the current standard of care treatment using 2% Chlorohexidine Gluconate Cloths on the abdomen and buttocks prior to colorectal surgery night before surgery and morning of surgery.
224266933|NCT02385708|DRUG|2% Chlorohexidine Gluconate Chin to Toe|Patients will perform treatment with 2% Chlorohexidine Gluconate cloths chin to toe night before and morning of surgery then daily post operative until post op day 4 or discharge
224266934|NCT03475433|DEVICE|Actigraphy device|Both groups will receive an actigraphy device that will passively measure their movement data.
224266935|NCT01305109|BIOLOGICAL|ORV 116E|Oral Rotavirus Vaccine 116E (ORV 116E), 10\^5.0 FFU of Bharat Biotech International Limited, 3 doses of 0.5mL at 4 week intervals
224266936|NCT01305109|BIOLOGICAL|Placebo|3 doses of 0.5 mL at 4 week intervals
224266937|NCT03791307|OTHER|Traditional Pilates group|The participants will perform only exercises based on the traditional Pilates method, 2 times a week, for 50 minutes, for 16 weeks.
224266938|NCT03791307|OTHER|Modified Pilates group|The participants will perform exercises based on the Pilates method alternated with active rest periods on treadmill ergometer, 2 times a week, for 50 minutes, for 16 weeks.
224266939|NCT02761915|OTHER|Leukapheresis|
224266940|NCT02761915|DRUG|Cyclophosphamide|
224266941|NCT02761915|DRUG|Fludarabine|
224266942|NCT02761915|GENETIC|1RG-CART|
224266943|NCT02162615|DEVICE|Restorelle Direct Fix A|
224266944|NCT02162615|DEVICE|Restorelle Direct Fix P|
224266945|NCT02162615|PROCEDURE|Native Tissue Repair Anterior|
224266946|NCT02162615|PROCEDURE|Native Tissue Repair Posterior|
224266947|NCT03276559|BEHAVIORAL|EMPOWER|"EMPOWER is a manualized treatment delivered based in cognitive behavioral and acceptance and commitment therapies delivered by a trained mental health professional that utilizes breathing and grounding exercises, mindfulness meditation, psychoeducation, imaginal dialogue with the patient, and coping rehearsal techniques.~The total amount of time EMPOWER intervention is about 90 minutes, about 15 minutes each module. It can either be administered in one session or many sessions to accommodate the dynamic nature of ICU, and has two booster follow-up calls (roughly 45 minutes each) in the month following initial treatment."
224266948|NCT03276559|OTHER|Enhanced Usual Care|Enhanced usual care consists of standard ICU psychosocial support for caregivers like social work, chaplaincy, or palliative care team visits as charted in the patient's medical record. Participants assigned to EUC will also receive a general information guide for caregivers as well as a site-specific list of caregiver resources.
224266949|NCT00645853|DRUG|AZD0837|Treatment with AZD0837 starting with 4 different doses, 150 mg od, 300 mg od, 200 mg bid or 450 mg od and then switching to one general common dose, 300 mg od
224266950|NCT00645853|DRUG|VKA INR 2-3|Vitamin K antagonists (VKA), titrated to an international normalised ratio (INR) of 2.0 to 3.0 with a target value of 2.5
224266951|NCT02327559|BEHAVIORAL|Mind in Labor (MIL): Working with Pain in Childbirth|The Mind in Labor (MIL) mindfulness intervention for pregnant women and their partners integrates mindfulness strategies for coping with labor pain and fear and formal mindfulness meditation with traditional childbirth education. The MIL intervention is held over 3 consecutive weekend days (Friday - Sunday) for a total of 16 hours of mindfulness skills training for childbirth preparation and labor pain management. Mindfulness strategies for coping with labor-related pain and fear are taught in an interactive, experiential format, with periods of didactic instruction.
224266952|NCT02327559|BEHAVIORAL|Treatment as usual (TAU)|"The treatment as usual TAU active comparison condition includes participation in a standard care childbirth education course, chosen by participants in the TAU arm from a pre-approved list of hospital- and community-based childbirth education courses comparable in length and quality to MIL, but without any mindfulness meditation, mindful movement/yoga, or other core mind/body component (e.g., hypnosis)."
224266953|NCT06410638|DIAGNOSTIC_TEST|Six Minute Walking Test|It is applied in a 30 m long corridor in an indoor environment, and the distance walked by the patient in a six-minute period, oxygen saturation, heart rate, and change in dyspnea are recorded. For this, before starting the test, oxygen saturation, heart rate, arterial blood pressure and dyspnea level according to the Borg scale are recorded. The same parameters are measured again at the end of the test. The feature of this test is that the person walks at his own pace, stopping when necessary and allowing the use of oxygen. It is an exercise test that is easy to perform and well tolerated.
224266954|NCT06410638|DIAGNOSTIC_TEST|Shuttle walking test|Shuttle walking test at increasing speed is an exercise test in which walk between two cones 10 m apart at an increasing speed throughout the test and each 10-meter journey between the two cones is counted as a shuttle.
224266955|NCT04837664|DRUG|Curcumin|Curcumin was bought from Sigma®, USA, and its solution was freshly prepared by mixing curcumin powder with phosphate-buffered saline.
224266956|NCT04837664|DRUG|Rose Bengal|Rose bengal was bought from Sigma®, USA, and its solution was freshly prepared by mixing rose bengal powder with phosphate-buffered saline.
224266957|NCT04837664|DRUG|Nystatin|Rinsing with topical nystatin (100,000 UI/mL) suspension for 60 seconds
224266958|NCT04200872|OTHER|biological adjuvants|patients with aseptic pseudarthrosis clinically treated with biological adjuvants
224266959|NCT04200872|OTHER|no biological adjuvants|patients with aseptic pseudarthrosis clinically treated without biological adjuvants
224266960|NCT05123443|BIOLOGICAL|Blood sample provided|Individuals who consent to provide a blood sample will be included in the cross-sectional genetics study.
223860959|NCT04878991|DIAGNOSTIC_TEST|Overture Metabolomics Embryo Selection|Patients will have their embryos selected for transfer based on morphology alone. The embryo transfer outcome will be compared to the metabolomics result to determine the NPV and PPV of metabolomics vs implantation.
223860960|NCT02083029|PROCEDURE|Simulated dive reflex|All subjects undergo simulated dive reflex, with 30s facial immersion and continuous HR and BP monitoring with Nexfin over a period of 6 minutes.
223860961|NCT00023725|DRUG|semaxanib|
223860962|NCT00023725|PROCEDURE|conventional surgery|
223860963|NCT00023725|RADIATION|radiation therapy|
223860964|NCT00541749|DRUG|rhuMAb IFNalpha|Intravenous repeating dose
223860965|NCT04606251|OTHER|Exercise|The intervention to be carried out in the study consists of physical exercises for the neck, upper and lower extremities, and trunk; It is a program that includes the addition of cognitive tasks such as memory, word finding, processing during each repetition.
224266961|NCT05123443|DIAGNOSTIC_TEST|7-T MRI scan|Individuals who consent to receive an additional 7-T MRI scan will be invited to the Sir Peter Mansfield Imaging Centre. This current MRI will be compared against the baseline 7-T scan performed between 2008 - 2012.
224266962|NCT03708536|DRUG|S-1|S-1 is administered orally on days 1 to 14 of a 21-day cycle. Patients are assigned on the basis of body surface area (BSA) to receive one of the following oral doses twice daily: 40 mg (BSA \<1.25m2), 50 mg (BSA \>1.25 to \<1.50 m2), or 60 mg (BSA \>1.50 m2).
224266963|NCT03708536|DRUG|Bevacizumab|Bevacizumab (7.5 mg/kg) is administered by intravenous infusion over the course of 30 to 90 min on day 1 of each 3-week cycle.
224266964|NCT03708536|DRUG|Capecitabine|Capecitabine 2000mg/m2/d is administered orally on days 1 to 14 of a 21-day cycle.
224266965|NCT05212987|DRUG|FCN-098|FCN-098 will be given orally in ascending doses starting at 40 mg Q12h until the maximum tolerated dose or recommended dose is reached.
224266966|NCT05624424|DRUG|Rematazolam Besylate|Anesthesia was induced with Rematazolam Besylate 0.3\~0.5 mg/kg (about 1 minute) by intravenous injection until the loss of consciousness (LoC) and BIS\<60, followed by remimazolam 1-3 mg/kg/h until the end of surgery.
224266967|NCT05624424|DRUG|Propofol|Anesthesia was induced with Propofol 2\~2.5 mg/kg (about 1 minute) by intravenous injection until the loss of consciousness (LoC) and BIS\<60, followed by remimazolam 5\~12 mg/kg/h until the end of surgery.
224266968|NCT05624424|DRUG|Sevoflurane|Anesthesia was induced with etomidate 0.03 mg/kg (about 1 minute) by intravenous injection until the loss of consciousness (LoC) and BIS\<60, followed by 2 %-3 % Sevoflorane until the end of surgery.
224266969|NCT05624424|DRUG|Sufentanil|Anesthesia was induced with Sufentanil 0.3\~0.5 ug/kg by intravenous injection after the LoC and BIS\<60.
224266970|NCT05624424|DRUG|Cisatracurium Besylate|Anesthesia was induced with cisatracurium besilate 0.2-0.3 mg/kg by intravenous injection after the LoC and BIS\<60, followed by 0.1 mg/kg/h Cisatracurium Besylate during the operation.
224266971|NCT05624424|DRUG|Remifentanil|After the LoC, remifentanil 0.1\~0.3 ug/kg/min inject intravenously until the end of surgery.
224266972|NCT04971512|DRUG|EDP-721|Oral administration (Part 1)
224266973|NCT04971512|DRUG|Placebo (Part 1)|Placebo to match EDP-721, oral administration (Part 1)
224266974|NCT04971512|DRUG|EDP-721 (Part 2)|Oral administration (Part 2)
224266975|NCT04971512|DRUG|Placebo (Part 2)|Placebo to match EDP-721 (Part 2)
224266976|NCT04971512|DRUG|EDP-514|Oral administration
224266977|NCT04971512|DRUG|Placebo (Part 2)|Placebo to match EDP-514
223860966|NCT04859595|OTHER|Telephone follow-up|"Monthly follow-up by telephone from M1 to M6. The interview will unroll in 2 stages, a first stage of discussion during which the speech therapist will take news of the patient. The second, more formal phase will be the opportunity to collect the data necessary for the validation of the primary and secondary outcomes. To do this, the speech therapist will use the Functional Oral Intake Scale (FOIS) score, the DHI and an interview grid.~The interview will be conducted using an interview sheet previously written by the project team. The following elements will be discussed: the description of oral food intakes (TIMES), the perceived swallowing handicap (DHI), the instructions related to the diet and their daily application, ongoing rehabilitation follow-ups, notable events as well, then his emotional and psychological experience in relation to the disorder."
223860967|NCT02506257|DRUG|0.04% PHMB|0.04% PHMB eye drops, 1 drop 12 times daily for 7 days, followed by 1 drop 6 times daily for additional 7 days
223860968|NCT02506257|DRUG|0.06% PHMB|0.06% PHMB eye drops, 1 drop 12 times daily for 7 days, followed by 1 drop 6 times daily for additional 7 days
223860969|NCT02506257|DRUG|0.08% PHMB|0.08% PHMB eye drops, 1 drop 12 times daily for 7 days, followed by 1 drop 6 times daily for additional 7 days
223860970|NCT02506257|DRUG|PHMB Vehicle|PHMB vehicle eye drops, 1 drop 12 times daily for 7 days, followed by 1 drop 6 times daily for additional 7 days
223860971|NCT00148291|DRUG|Patients were randomized to receive either docetaxel 60 mg/m2 on day 1 or vinorelbine 25 mg/m2 on days 1and 8, repeated every 21 days over four cycles.|
223860972|NCT04360057|OTHER|PMD|A script used to train the physician to engage with the patient in the topic of hand hygiene compliance used on the initial visit.
223860973|NCT04360057|OTHER|PMDPlus|A script used to train the physician to engage with the patient in the topic of hand hygiene compliance on follow up visits
223860974|NCT01924767|DRUG|BI 10773 Placebo|po taken fasting with 240 mL water
223860975|NCT01924767|DRUG|BI 10773|po taken fasting with 240 mL water
223860976|NCT01924767|DRUG|BI 10773 Placebo|po taken fasting with 240 mL water
223860977|NCT01924767|DRUG|BI 10773|po taken fasting with 240 mL water
223860978|NCT01924767|DRUG|BI 10773 Placebo|po taken fasting with 240 mL water
223860979|NCT01924767|DRUG|BI 10773 Placebo|po taken fasting with 240 mL water
223860980|NCT01924767|DRUG|BI 10773|po taken fasting with 240 mL water
223860981|NCT01924767|DRUG|BI 10773|po taken fasting with 240 mL water
223860982|NCT03514251|PROCEDURE|The suture marks the location of the parathyroid gland|When the lower parathyroid gland is first seen, the parathyroid gland is sutured with a suture during the operation, and then during this subsequent cleaning, rapid parathyroid localization and parathyroid glands are performed through this marker. Vascular protection.
223860983|NCT00877435|BEHAVIORAL|Cognitive behavioral therapy (CBT)|
223860984|NCT03829917|DRUG|Miltefosine and Paromomycin|28 days of miltefosine plus 28 days of Paromomycin cream
223860985|NCT03829917|DRUG|miltefosine|28 days of miltefosine
223860986|NCT03829917|DRUG|paromomycin|28 days of paromomycin creaam
223860987|NCT03052946|PROCEDURE|Bulking agent|Filling bulking agent in the anal canal
223860988|NCT03052946|PROCEDURE|Endoanal electrostimulation|The technique used will be with a frequency of 30 to 40 Hz with pulse width of 200 ms with maximum intensity of 800mAmp and duration of 30 minutes
223860989|NCT01678196|BEHAVIORAL|VA-CRAFT|VA-CRAFT is an on-line training program that teaches family members how to communicate and interact with Veterans to promote their engagement in needed mental health services for PTSD or Alcohol Use Disorders. 12 on-line sessions.
223860990|NCT01678196|OTHER|Control|Participants will have the opportunity to complete the VA-CRAFT training program after 3 months; otherwise no intervention
223860991|NCT03827512|OTHER|Doppler arterial waveforms analysis|terminology used when describing arterial Doppler waveforms
223860992|NCT04247204|BIOLOGICAL|Platelet-rich plasma intrauterine infusion|For all women, basic transvaginal sonography will be done in the 2nd day of frozen embryo transfer (FET) cycle and they will receive standard hormone replacement therapy (HRT) in the form of estradiol valerate tablets (white tablets of Cyclo-Progynova; Bayer Schering Pharma AG, Germany) at a dose of 4mg for 7 days then 6mg for 6 days. Endometrial assessment will be done on day 15 of FET cycle. Those with endometrial thickness between 8-14 mm will be evaluated for endometrial and sub-endometrial vasculature pattern by 3D power Doppler analysis. Then 1 ml of PRP (prepared from autologous blood) will be infused in the uterine cavity and vaginal progesterone 400 mg twice daily will be prescribed for 3 days. Subsequently, D3 embryos will be transferred. Endometrial, sub-endometrial and uterine arterial vascularity pattern will be re-evaluated on the day of ET. Both estradiol valerate tablets and vaginal progesterone will be continued up to 12th week of gestation in case of pregnancy.
223860993|NCT02355535|DRUG|PAC-1|PAC-1 is taken orally on days 1-21 of a 28-day cycle.
223860994|NCT01377623|DRUG|Dexmedetomidine group|Subjects undergoing one or two level spinal fusion surgery will be screened for eligibility to participate in the study. Subject will be screened, recruited and randomized during the preadmission visit or the day of surgery. Eligible subjects will be randomized to one of the two treatment group in1:1 ratio to receive either DEX or matching placebo (PBO, LR).
223860995|NCT01377623|DRUG|Placebo group|Fifty six subjects (28 in each arm) will be enrolled. Subjects undergoing one or two level spinal fusion surgery will be screened for eligibility to participate in the study. Subject will be screened, recruited and randomized during the preadmission visit or the day of surgery. Eligible subjects will be randomized to one of the two treatment group in1:1 ratio to receive either DEX or matching placebo (PBO, LR).
223860996|NCT00401323|DRUG|docetaxel (XRP6976)|
223860997|NCT00401323|DRUG|cisplatin|
223860998|NCT00401323|DRUG|5-fluorouracil (5-FU)|
223860999|NCT01740817|DRUG|Intralipid 20%|30 ml/h for 48 h
223861000|NCT01740817|DRUG|Saline|30 ml/h for 48 h
223861001|NCT01320280|DRUG|BIBW 2992 (Afatinib)|50 mg BIBW 2992 (Afatinib) tablets daily continuously
223861002|NCT06186739|BEHAVIORAL|home-based motor rehabilitation training participated by caregivers|The knowledge provider was a multi-disciplinary home-based rehabilitation nursing team, which is composed of advanced practice nurse (APN) who engaged in professional rehabilitation of stroke, neurologists, rehabilitation doctors and physical therapists. Among them, APN mainly carry out and supervise family rehabilitation education and all members are collectively responsible for the adjustment and optimization of the program content. After the assessment is completed, the patient's current functional status will be confirmed. based on this, team members recommend home-exercise items that match the patient's motor function state . In this intervention programme, the content of the intervention was developed based on the recommendations of internationally published guidelines related to the rehabilitation of ischemic patients, with some adjustments to consider the cultural appropriateness of implementation in China.
223861003|NCT06186739|BEHAVIORAL|routine self-care|the patients in this group will be routinely given post-discharge health education, such as secondary prevention measures, education on medication adherence, universal guidance on the content of home care, universal rehabilitation-related education such as correct limb positioning, post-discharge precautions, and medical referral-related assistance.
223861004|NCT05340244|DEVICE|Investigational ultrasound exam|"Eligible subjects will be enrolled into the study and positioned for their ultrasound exam. Standard clinical practice procedures will be followed using the standard of care device at the site to complete the clinically indicated exams.~After the clinically indicated exam, portions of the TTE and/or TEE exam will be repeated with the investigational ultrasound device."
223861005|NCT00139737|DRUG|Ziprasidone|20mg capsules BID, 40mg capsules BID, 60mg BID or 80mg BID until drug commercialisation in Italy.
223861006|NCT05857319|BEHAVIORAL|Nutritional Psycho-Behavioral Reeducation Program|"The RNPC Program is based on a clinical protocol in three successive phases:~1. A weight loss phase during which food intake is restricted to 800-1000 kcal per day, with a nutrient distribution of 60% protein, 25% carbohydrates and 15% lipids. Patients eat two meals a day consisting of meat/fish/eggs/shellfish and vegetables, supplemented by products enriched in proteins, vitamins and minerals, and depleted in carbohydrates and lipids.~2. A stabilization phase specifically established for each patient according to their weight loss and their daily caloric needs, allowing them to gradually return to a balanced diet, with a nutrient distribution of 25% protein, 45% carbohydrates and 30% lipids. During this phase, the consumption of meal supplements gradually decreases.~3. A phase of return to dietary balance, unlimited in time, based on the precepts of the Mediterranean diet.~Each patient is followed every 14 days by a dietitian during the entire program."
223861007|NCT00653341|DRUG|insulin glargine|
223861008|NCT00653341|DRUG|NPH human insulin|
223861009|NCT05257785|BEHAVIORAL|Lymfit exercise intervention|Participants randomized to this arm will be allocated a pre-registered Inspire II / Charge IV model Fitbit. The kinesiologist of the study will meet with the participants for a baseline fitness assessment. The kinesiologist will examine the baseline physical activity levels, fitness level and sedentary behaviours of the participants, to design a personalized exercise prescription. Within one week after the baseline fitness assessment, the kinesiologist will contact the participants to discuss the exercise prescription. Every two weeks there-after, the kinesiologist will follow up with the participants via videoconferencing to discuss their progress and to modify or advance their exercise prescriptions as needed. Participants will be followed-up at 6 months and 12 months.
223861010|NCT05257785|BEHAVIORAL|Waitlist control|Participants will be contacted by the study kinesiologist for a baseline fitness assessment 3 months after they consent, participants will be given a Fitbit, a personalized exercise prescription and receive bi-weekly follow-ups for 12 weeks.
223861011|NCT03781336|BEHAVIORAL|Mindfulness-based self care|Experimental: an abridged mindfulness-based program that is incorporated into the work day, which consists of five weekly 1.5 hour sessions.
223861012|NCT02346006|BEHAVIORAL|More physical activity.|Subjects receiving more physical activity in school.
223861013|NCT00151606|PROCEDURE|Reinforced isolation + Muciprocine|
223861014|NCT00773019|DEVICE|Refills (SynchroMed® II Programmable Drug Infusion Pump)|Refill information at 1, 6, and 12 months post-implant, as well as any additional refills required from implant through end of study. Amount removed from the pump (taken from syringe), Amount placed in the pump (from syringe),Pump predicted amount remaining in the pump.
223861015|NCT03165071|DRUG|ACT-132577|Capsule
223861016|NCT03460756|DRUG|Ganaxolone|Oral
223861017|NCT03460756|DRUG|Placebo|Oral
223861018|NCT02950948|DRUG|Progesterone|Progesterone will be administered subcutaneously once a day for 14 days/month, for 12 months.
223861019|NCT02950948|DRUG|Placebo|A placebo solution will be administered subcutaneously once a day for 14 days/month, for 12 months.
223861020|NCT05622786|OTHER|HIGT - physical rehab|High Intensity Gait Training using treadmill and overhead harness for fall prevention
223861021|NCT05622786|OTHER|Low intensity physical therapy|Low Intensity Gait Activities
223861022|NCT03987451|DRUG|Semaglutide|Semaglutide given subcutaneously (s.c., under the skin) once-weekly for 48 weeks
223861023|NCT03987451|DRUG|Placebo (semaglutide)|Semaglutide placebo s.c. given once-weekly for 48 weeks
223861024|NCT04372394|DRUG|surufatinib|Surufatinib: 300 mg as a single dose on Days 1 and 8 with or without food
223861025|NCT01491399|DEVICE|INFUSE™ Bone Graft/CORNERSTONE-SR™ /ATLANTIS™|Cornerstone-SR™ allograft bone containing recombinant human Bone Morphogenetic Protein (rhBMP-2) soaked into an absorbable collagen sponge (ACS) used in conjunction with ATLANTIS™ anterior cervical plate system.
223861026|NCT01491399|DEVICE|Autogenous bone/CORNERSTONE-SR™ /ATLANTIS™|Cornerstone-SR™ allograft bone packed with autogenous iliac crest bone graft used in conjunction with ATLANTIS™ anterior cervical plate system.
223861027|NCT02441036|DEVICE|Ultherapy Treatment|Focused ultrasound energy delivered below the surface of the skin.
223861028|NCT00932022|DRUG|Trospium Chloride, Extended Release (XR)|Trospium chloride extended release 60 mg capsule taken orally once daily for 12 weeks.
223861029|NCT00932022|OTHER|placebo|Placebo capsule taken orally once daily for either 2 weeks or 14 weeks.
223861030|NCT03888755|DRUG|Icatibant|Participants will receive icatibant 30 mg SC injection in the abdominal area.
223861031|NCT05695833|DEVICE|Radiofrequency|Device emitting electric waves generating heat
223861032|NCT03396692|PROCEDURE|Intravenous morphine patient-controlled analgesia (PCA)|"Group 1 control:~* Morphine titration at 0.1 mg/kg~* Establishment of PCA morphine:~* concentration 1mg/ml~* 1ml bolus~* refractory period of 7 minutes~* no maximum dose per day. Premedication of the patient with Ketamine 0.15 mg/kg and Propofol 0.5 mg /kg"
223861033|NCT03396692|PROCEDURE|Block of the posterior exo-thoracic fascia with Ropivacaine|"Group 2 PEF block:~* Establishment of PCA morphine:~* concentration 1mg / ml~* 1ml bolus~* refractory period of 7 minutes~* no maximum dose per day.~* Realization of a block of the posterior exo-thoracic fascia (PEF block) at the median level of ribs fractures with ropivacaine 5mg / mL, 3 mg / kg under echography guidance. ALR needle (type neurostimulation) with a length of 100 mm is used. When the injection is performed an analgesia catheter is deposited in the space created by local anesthetics. Realization of ropivacaine bolus 2mg / ml at 0.1ml/kg every 4 hours. Possibility of an additional bolus of 0.1ml / kg every hour if insufficient analgesia."
223861034|NCT03396692|PROCEDURE|Block of paravertebral space with Ropivacaine|"Group 3 paravertebral block:~* Establishment of PCA morphine:~* concentration 1mg / ml~* 1ml bolus~* refractory period of 7 minutes~* no maximum dose per day.~* Realization of a paravertebral block (BPV) at the median level of ribs fractures ropivacaine 5mg / mL, (0.3ml / kg) 1.5 mg / kg under echography guidance. ALR needle (type neurostimulation) with a length of 100 mm is used. When the injection is performed an analgesia catheter is deposited in the space created by local anesthetics. Realization of bolus of ropivacaine 2mg / ml at 0.1ml / kg every 4 hours.~Possibility of an additional bolus of 0.1ml / kg every hour if insufficient analgesia.~In the case of failure of initial management with significant pain despite the iterative boli, epidural analgesia is used in recourse."
223861035|NCT03284086|DIAGNOSTIC_TEST|upper-body double-poling|An incremental peak test to exhaustion and four 5-min submaximal stages were performed in the upper-body double-poling mode.
223861036|NCT03284086|DIAGNOSTIC_TEST|arm crank ergometry|An incremental peak test to exhaustion and four 5-min submaximal stages were performed in the arm crank ergometry mode.
223861037|NCT05983068|DRUG|dupilumab|solution for injection; by subcutaneous (SC) injection
223861038|NCT00325013|DRUG|Docosahexaenoic Acid (DHA)|800mg twice a day for 1 year
223861039|NCT04838886|OTHER|Telerehabilitation-based Pilates Exercise|The group that will receive telerehabilitation-based pilates training via telerehabilitation
223861040|NCT01434134|DRUG|Metoprolol|Tablet, target dose 100 mg once daily
223861041|NCT01434134|DRUG|Placebo|Tablet, target dose 100 mg once daily
223861042|NCT01434134|DRUG|Candesartan|Tablet, target dose 32 mg once daily
223861043|NCT01434134|DRUG|Placebo|Tablet, 32 mg once daily
223861044|NCT04645069|BIOLOGICAL|ADG126 Mono|ADG126 will be administered as an IV infusion over 30-60 minutes ± 15 minutes.
223861045|NCT04645069|BIOLOGICAL|ADG126-anti PD1|ADG126-toripalimab combination regimen will receive of toripalimab 15 to 30 minutes after the end of the ADG126 infusion
223861046|NCT04645069|BIOLOGICAL|ADG126-ADG106|ADG126-ADG106 combination regimen will be receive of ADG106 15 to 30 minutes after the end of the ADG126 infusion
223861047|NCT02033018|DRUG|Aflibercept Injection|Aflibercept intravitreal injection
223861048|NCT02120313|OTHER|inpatient rehabilitation|
223861049|NCT02120313|OTHER|outpatient rehabilitation|
223861050|NCT00532220|DRUG|Ibandronate IV|Ibandronate IV (Bonviva® IV), 10.5 mg divided in 4 single infusions within 2 weeks(1x1.5 mg, 3x3 mg), followed by a fifth infusion after 3 months (V4)
223861051|NCT00532220|DRUG|Placebo|Placebo IV, divided in 4 single infusions within 2 weeks, followed by a fifth infusion after 3 months (V4)
223861052|NCT01738308|PROCEDURE|Healing Touch|"When enter PACU + usual standard of care.~The Healing Touch practitioner will be at the bedside when the patient is first brought to the PACU. The HT practitioner will center and then attune with the child, connecting their energy with the child and setting the intention for healing for the child's highest good. The practitioner will then place one hand on the center of the patient's chest in the high heart area. The practitioner will hold this position until they feel a deep connection and quieting within the patient's energy. When the patient is awake and parents have been called to the bedside the HT practitioner will energetically ground and release the patient,"
223861053|NCT01738308|PROCEDURE|Healing Touch Sham Treatment|"The untrained in energy work study staff will be at the bedside when the patient is first brought to the PACU. The practitioner will then place one hand on the center of the patient's chest in the high heart area. This will continue until parents are called to the bedside"
223861054|NCT01102049|DIETARY_SUPPLEMENT|fish, beef, fruit|
223861055|NCT01957319|DRUG|Silybin 94 mg + vitamin E 90 mg + phospholipids 194 mg|
223861056|NCT01957319|DRUG|sugar pill|
223861057|NCT03565796|BEHAVIORAL|Personalized active referral plus financial incentive|Smokers will be introduced to various SC services in Hong Kong and be motivated to use the services.Written consents will be obtained from smokers who are ready to book the service onsite for transfer of their contact telephone numbers to their chosen service providers. Our research staff will transfer the information to the service providers within a week since the enrollment.Smokers are informed at baseline that they will receive financial incentive (supermarket coupon HK$300) if they attend or use any of the SC services within 3-month.
223861058|NCT03565796|BEHAVIORAL|AWARD advice|Ask about smoking history, Warn about the high risk of smoking, Advise to quit as soon as possible, Refer to the smoking cessation services, and Do it again (if the smokers refused to set quit date).
223861059|NCT03565796|BEHAVIORAL|Warning leaflet|The 2-sided color printed A4 leaflet, which systematically covers the most important messages to motivate smoking cessation
223861060|NCT03565796|BEHAVIORAL|Referral card|"The 3-folded Smoking Cessation Services card consists of brief information and highlights of existing smoking cessation services, contact methods, motivation information and strong supporting messages or slogans"
223861061|NCT03565796|BEHAVIORAL|COSH booklet|A general smoking cessation self-help booklet
223861062|NCT05038072|DRUG|suprachoroidal injection of Triamcinolone Acetonide.|4 mg /0.1 ml TA was injected in the SCS using an individualized microinjector according to scleral thickness measured by anterior segment OCT (AS-OCT) at the injection point (4 mm from the limbus in the inferotemporal quadrant).
223861063|NCT00612586|DRUG|Enzastaurin|1125 milligram (mg) loading dose, then 250 mg twice daily, oral up to 1 year (yr) or until progressive disease
223861064|NCT00612586|DRUG|Placebo|oral, daily (up to 1 yr or until progressive disease)
223861065|NCT00612586|DRUG|Leucovorin (LV)|400 milligram per meter squared (mg/m\^2) intravenously (IV), Day 1 of 14 day cycle (up to 1 yr or until progressive disease)
223861066|NCT00612586|DRUG|5-fluorouracil (5-FU)|400 mg/m\^2 bolus then 2400 mg/m\^2 IV over 46 hours, Day 1 of 14 day cycle (up to 1 yr or until progressive disease)
223861067|NCT00612586|DRUG|Bevacizumab (Bev)|5 milligram per kilogram (mg/kg) IV, Day 1 of 14 day cycle (up to 1 yr or until progressive disease)
223861068|NCT02631343|BEHAVIORAL|KMC|Promotion of, and support for lactation management and skin to skin care as soon as possible after birth by study ANM supported by study ASHA in addition to routine visits by government health workers
223861069|NCT02631343|OTHER|Essential newborn care|
223861070|NCT05379491|DRUG|3 L PEG + linaclotide|Participants take a linaclotide capsule on the day before colonoscopy at least 30 minutes before the first meal (if this is impossible, take the capsule as early as possible on that day). Participants take 1 L polyethylene glycol electrolyte solution within 1 hour from 8 p.m the night before the examination and take another linaclotide capsule and 2 L polyethylene glycol electrolyte solution 4 hours before the colonoscopy.
223861071|NCT05379491|DRUG|3 L PEG + placebo|Participants take a placebo capsule on the day before colonoscopy at least 30 minutes before the first meal (if this is impossible, take the capsule as early as possible on that day). Participants take 1 L polyethylene glycol electrolyte solution within 1 hour from 8 p.m the night before the examination and take another placebo capsule and 2 L polyethylene glycol electrolyte solution 4 hours before the colonoscopy.
223861072|NCT02500654|DEVICE|Emdogain®|Surgery and Emdogain®
223861073|NCT02500654|DEVICE|Surgery alone|Surgery alone
223861074|NCT01194154|DRUG|Methoxy polyethylene glycol-epoetin beta|Methoxy polyethylene glycol-epoetin beta 30 microgram (mcg) subcutaneous injection once monthly up to 24 months with sequential dose adjustments to 50 mcg or 75 mcg depending on change of hemoglobin values of more than 1.0 gram (g)/ deciliter (dL).
223861075|NCT01194154|DRUG|Placebo|Placebo matching to Methoxy polyethylene glycol-epoetin beta subcutaneous injection once monthly up to 24 months.
223861076|NCT05056051|DEVICE|WATS-3D tissue sampling prior to forceps biopsies|WATS-3D is a brush-based tissue sampling technique. Abrasive brush sampling of large areas of the esophagus pick up cells to obtain trans-epithelial specimens. This technique samples much larger tissue areas than standard forceps biopsies. Analysis is then done by proprietary neural-network based computer scanning and molecular diagnostics to identify abnormal cells.
223861077|NCT05056051|DEVICE|WATS-3D tissue sampling following forceps biopsies|WATS-3D is a brush-based tissue sampling technique. Abrasive brush sampling of large areas of the esophagus pick up cells to obtain trans-epithelial specimens. This technique samples much larger tissue areas than standard forceps biopsies. Analysis is then done by proprietary neural-network based computer scanning and molecular diagnostics to identify abnormal cells. This will be done after forceps biopsies in this arm.
223861078|NCT02314117|DRUG|Ramucirumab|Administered IV
223861079|NCT02314117|DRUG|Capecitabine|Administered orally
223861080|NCT02314117|DRUG|Cisplatin|Administered IV
223861081|NCT02314117|DRUG|Placebo|Administered IV
223861082|NCT02314117|DRUG|Fluorouracil|Administered IV
223861083|NCT05570019|PROCEDURE|Revascularization|Open surgery (arterial endarterectomy with or without bypass surgery) and/or angioplasty (with or without stent placement)
223861084|NCT05339256|DRUG|Buprenorphine SL|Up to 24 mg per day
223861085|NCT05339256|OTHER|Telehealth|Telehealth MOUD, utilizing a standardized protocol for each healthcare provider session
223861086|NCT05339256|OTHER|In-person treatment as usual|in-person induction and maintenance dosing of sublingual buprenorphine, or MOUD as usual.
223861087|NCT06020131|PROCEDURE|Thoracic Mobility Rehabilitation|Thoracic mobility exercises: Thoracic extension on foam roller, Sidelying thoracic rotation, Quadruped thoracic rotation, Squat with extension and rotation ( 10 reps x 3 set - 2 times x wk - 8 wk)
223861088|NCT06020131|PROCEDURE|Lumbopelvic Stability Rehabilitation|Lumbopelvic Stabilization Exercises : Bridge with alternate leg, Single leg bridge, Four point kneeling with arm and leg extension, Side plank on front arm with knee flexed (right, left), Sitting on a Swiss Ball and hip flexion (10 reps x 3 set - 2times/wk - 8 wk)
223861089|NCT06020131|PROCEDURE|Ankle Strengthening Home Exercises|Ankle Strengthening exercises with resistive band (dorsiflexion, plantarflexion, inversion, eversion) (10 reps x 3 set - 3 times/wk)
223861090|NCT00099619|DRUG|exenatide/insulin glargine|Subcutaneously injected exenaide 10 mcg twice daily for 16 weeks; then insulin glargine subcutaneously injected once daily for 16 weeks given in a dose that varies for individuals to achieve target glucose levels
223861091|NCT00099619|DRUG|insulin glargine/exenatide|Subcutaneously injected insulin glargine subcutaneously injected once daily for 16 weeks given in a dose that varies for individuals to achieve target glucose levels; then exenaide 10 mcg twice daily for 16 weeks
223861092|NCT05573711|OTHER|assessments|Assessments, no specific intervention
223861093|NCT05270551|PROCEDURE|ACL Reconstruction|All participants will do ACL reconstruction with and without Augmentation and will receive Accelerated rehabilitation program
223861094|NCT01714193|DRUG|Oral contraceptive|One tablet (0.150 mg of levonorgestrel and 0.030 mg of ethinyl estradiol) taken orally (by mouth) on Day 1 and Day 9.
223861095|NCT01714193|DRUG|Canagliflozin (JNJ-28431754)|One 200 mg tablet taken orally (by mouth) on Days 4 through 9.
223861096|NCT03758950|DRUG|Placebo|Once daily inhaled placebo for 48 weeks
223861097|NCT03758950|DRUG|Mometasone|Inhaled Mometasone for 48 weeks (with 4-week washout at study completion)
223861098|NCT04108754|OTHER|microangiopathic burden|to determine the value of the global microangiopathic burden on the prediction of early stroke risk in a homogeneous cohort of TIA.
223861099|NCT04925739|OTHER|Self-questionnaire on the comfort and general appreciation of a nasal mask|Self-questionnaire on the comfort and general appreciation of a nasal mask after 30 days of use
223861100|NCT04925739|OTHER|Self-questionnaire on the appearance of CPAP side effects related to the mask|Self-questionnaire on the appearance of CPAP side effects related to the mask (air leaks, injury to the nasal bridge, etc.) after 30 days of use
223861101|NCT04925739|OTHER|Self-questionnaire on the patient's appreciation of the mask headgear,|Self-questionnaire NOSE (Nasal Obstruction Symptom Evaluation) on the patient's appreciation of the mask headgear, which includes indications to help with the installation in the form of graduated markers, as well as the appreciation of the general aesthetics of the mask, after 30 days of use.
223861102|NCT04925739|OTHER|Self-questionnaire NOSE on the discomfort caused by the nasal obstruction|Self-questionnaire NOSE on the discomfort caused by the nasal obstruction reported by the patient, after 30 days of use, compared to the inclusion.
223861103|NCT04925739|OTHER|Self-questionnaire Epworth on the daytime sleepiness|"Self-questionnaire Epworth on the daytime sleepiness of the patient, after 30 days of treatment, compared to the inclusion.~To study the parameters of the CPAP treatment."
223861104|NCT04925739|OTHER|To study the CPAP compliance|To collect the treatment compliance through telemonitoring of the data recorded by the CPAP machine, during the 30 days of treatment.
223861105|NCT04925739|OTHER|To study the unintentional leakage|To collect the unintentional leakage estimated by the CPAP machine, during the 30 days of treatment.
223861106|NCT04925739|OTHER|To study the therapeutic pressures of CPAP|To collect the therapeutic pressures of CPAP, during the 30 days of treatment.
223861107|NCT00549536|DIETARY_SUPPLEMENT|tablets each containing of 1000mg elemental calcium (Mega-Calcium Sandoz)|1500 mg of elemental calcium per day.
224266978|NCT05264207|BEHAVIORAL|Nursing students' home-visit programme|"12-week home-visit program conducted by nursing students. Participants will receive weekly 45-minute visits. The visits will aim to promote self-care behaviours and will focus on:~1. Self-care of chronic conditions and medication management~2. Healthy habits: physical activity and healthy eating~3. Access to social support resources~4. Patients' rights and autonomous decision-making~The visits program will follow the WHO recommendations for the implementation of health promotion activities. All topics will be assigned 3 visits. In the first visit, the students will assess the participants' information needs and preferences in relation to the topic addressed and will provide generic information about it. In the second visit, the students will present individually-tailored information and will use individually-adapted strategies to convey such information. In the third visit, the student will explore the impact of the two previous visits and reinforce self-care behaviours."
224266979|NCT05264207|BEHAVIORAL|Standard care from Public Andalusian Health Service|Standard care offered by the Public Andalusian Health Service in its portfolio of services for older adults with multiple chronic conditions and complex health conditions. As part of these services, older adults with multiple chronic conditions receive generic, written information on healthy eating, adapted physical activity, abandonment of toxic habits, environmental safety and emotional management when they are first diagnosed with a chronic condition. The action plans or protocols established in the care processes aimed at older people with chronic multimnorbidity do not include periodic home visits.
224266980|NCT00070122|DRUG|oxaliplatin|Given IV
224266981|NCT00070122|DRUG|leucovorin calcium|Given IV
224266982|NCT00070122|DRUG|capecitabine|Given orally
224266983|NCT00070122|BIOLOGICAL|bevacizumab|Given IV
224266984|NCT00070122|DRUG|fluorouracil|Given IV
224266985|NCT00070122|OTHER|laboratory biomarker analysis|Correlative studies
224266986|NCT00988468|PROCEDURE|Manual Therapy|Grade 1 and 2 oscillatory manual mobilization of the tibiofemoral joint at various ranges of motion.
224266987|NCT00988468|BEHAVIORAL|Therapeutic Exercise|Subjects will perform 5 minutes of lower extremity cycle ergometer with minimal resistance followed by 10 minutes of resistance exercise to the quadriceps at 3 tibiofemoral positions (0 degrees, 30 degrees and 60 degrees of knee flexion).
224266988|NCT00988468|BEHAVIORAL|Video Observation|Subjects will watch a 15 minute video on a health topic unrelated to knee osteoarthritis.
224266989|NCT00380588|DRUG|gemcitabine|1000 milligrams per square meter (mg/m2), intravenous (IV)
224266990|NCT00380588|DRUG|cisplatin|25 milligrams per square meter (mg/m2), intravenous (IV)
224266991|NCT00919516|PROCEDURE|Bone marrow mononuclear cell implantation|Dual intramuscular and intra-arterial injections of bone marrow mononuclear cells harvested from the iliac crest. Injection sites are determined by location of stenosis and/or occlusion on angiogram obtained prior to implantation and typically occur in three medial and three lateral sites approximating the disease location.
224266992|NCT02313662|DEVICE|NBI and PDD|
224266993|NCT04965831|DRUG|Furmonertinib|Furmonertinib 80mg/d as neoadjuvant therapy for 8 weeks before surgery, then as adjuvant therapy for 3 years after surgery.
224266994|NCT01175330|DRUG|Omega-3 fish oil emulsion (Omegaven)|Lipid emulsion (omegaven) for intravenous use, 1 ml/kg/day daily for 7 days post-surgery period (The first infusion beginning in operative period)
224266995|NCT01175330|DRUG|Intralipid|Lipid emulsion (Intralipid) for intravenous use, 1 ml/kg/day daily for 7 days post-surgery period (The first infusion beginning in operative period)
224266996|NCT02663661|PROCEDURE|Metabolic Challenge Admission|A ten hour clinical test involving drinking a liquid mixed meal followed four hours later by the induction of hypoglycemia with intravenous insulin administration.
224266997|NCT02663661|OTHER|CGM home test|A home study starting immediately after the clinical test during which participants will wear a continuous glucose monitor (CGM) for one week.
224266998|NCT02667769|OTHER|Fasting day|A day of fasting started at 18.00 clock with a blood glucose test and is only started when on the same day no significant hypoglycemia (blood glucose \<55 mg / dl) occurred, and when at 18.00 clock the blood sugar in the defined target range (70-180 mg / dl) is. Carried out during the fasting day standardized blood samples for measurement of plasma glucose with an appropriate laboratory method at 18.00, 20:00, 22:00, 12:00, 2:00, 4:00, 6:45, 9:00, 12:00, 14:00 and again at 18.00 clock. Because the determination of plasma glucose in the laboratory will take some time, is always for guidance and also measured with a fast measurement method, in order to treat at high levels of blood sugar with additional insulin correction, and to treat hypoglycaemia low blood sugar or to prevent hypoglycaemia.
224266999|NCT02701101|DEVICE|Use of SEM200 Scanner daily|From enrollment to exit,daily SEM Scanner readings collected on Sacrum and Heels
224267000|NCT02701101|OTHER|Assessment and treatment of Pressure Ulcers using SOC|Nurse review of Skin risk and skin assessment, notes in chart to assess the frequency to turn patient, use of a specialist bed to prevent or treat early pressure ulcers
224267001|NCT00834314|PROCEDURE|Vacuum-Pack-technique for temporary abdominal closure|"Negative-pressure-wound-therapy applying a method described by Brock, Barker et al 1995: Temporary Closure of Open Abdominal Wounds - the Vacuum Pack (see citations)."
224267002|NCT00834314|PROCEDURE|Abdominal-dressing-technique for temporary abdominal closure|Negative-pressure-wound-therapy for temporary abdominal closure applying a device of KCI International (V.A.C.® Abdominal Dressing System). see: http://www.kci-medical.com/kci/corporate/kcitherapies/vactherapy/dressings/abdominal/#
224267003|NCT00408577|DRUG|L-arginine|
223861108|NCT00092833|DRUG|Comparator: ezetimibe|Ezetimibe (MK0653) 10 mg once daily for 3 years.
223861109|NCT04203264|DIAGNOSTIC_TEST|Real-time artificial intelligence identification system|The patients swallowed the MCE with a small amount of water in the left lateral decubitus position. Once the capsule reached the stomach after investigating the esophagus, it was lifted away from the posterior wall, rotated and advanced to the fundus and cardiac regions, and then to the gastric body, angulus, antrum and pylorus. The magnetic steering time for passing through the pylorus was not allowed more than 15 min. The real-time auxiliary system implemented real-time processing for the output image of MCE system. Professional operators guarantee the integrity of the examination and the diagnostic results of professional endoscopist was used as the gold standard. The system diagnosis results was recorded at the same time. The sensitivity, delay time, specificity of lesions and anatomical landmarks will be analyzed.
223861110|NCT02215278|DIETARY_SUPPLEMENT|10 x 55 g/ bean per arm|
223861111|NCT04557488|OTHER|Music therapy|Each session will follow a similar structure with a hello song, musical activities, and a goodbye song. The musical activities will vary in each session and will be mixed in later sessions to revisit and practice social skills
223861112|NCT04557488|BEHAVIORAL|Behavioral-based social skill training|Each intervention session will follow a standard structure of opening greetings, social activities according to the theme of the session, and a closing activity. The activities and games will vary in each session and will be mixed in later session to revisit and practice social skills.
224267004|NCT02958176|BEHAVIORAL|HRV Biofeedback|At-home heart rate variability biofeedback using Elite HRV app and Polar H7 chest strap
224267005|NCT02958176|BEHAVIORAL|Autogenic Training|Autogenic training recording provided on a CD
224267006|NCT02818894|DRUG|Lidocaine|Spinal anesthesia administered prior to participant's THA
224267007|NCT02818894|DRUG|Bupivacaine|Spinal anesthesia administered prior to participant's THA
224267008|NCT04915339|BEHAVIORAL|Physical activity|The intervention is administrated through a computerized application as prescribed exercises (cognitive or physical). The specific measures that will be used to determine the effect of the intervention are psychological variables (mood, anxiety, well-being, cognitive variables…) and physical ones (Heart rate variability, stress biomarkers, fat and muscle mass, blood circulation…).
224267009|NCT04915339|BEHAVIORAL|cognitive training|The intervention is administrated through a computerized application as prescribed exercises (cognitive or physical). The specific measures that will be used to determine the effect of the intervention are psychological variables (mood, anxiety, well-being, cognitive variables…) and physical ones (Heart rate variability, stress biomarkers, fat and muscle mass, blood circulation…).
224267010|NCT04915339|BEHAVIORAL|combined physical and cognitive training|The intervention is administrated through a computerized application as prescribed exercises (cognitive or physical). The specific measures that will be used to determine the effect of the intervention are psychological variables (mood, anxiety, well-being, cognitive variables…) and physical ones (Heart rate variability, stress biomarkers, fat and muscle mass, blood circulation…).
224267011|NCT05233254|BEHAVIORAL|Abdominal Hollowing exercise|Gently and slowly draw in your lower abdomen below your navel without moving your upper stomach, back and pelvis. Breathe in and out. Gently and slowly draw in your lower abdomen below your navel without moving your upper stomach, back and pelvis. Breathe in and out.
224267012|NCT02539628|DRUG|ropivacaine 0.2%|Adductor canal block. Placed immediately postoperative. Intervention stops on POD2 12PM
224267013|NCT01300273|DIETARY_SUPPLEMENT|Compound α-Ketoacid Tablet|30 patients will be treated with a LPD containing 0.6g protein/kg BW per day and 120-125 kJ/kg BW per day and supplemented with keto-amino acids (Ketosteril®, Fresenius Kabi) at a dosage of 100 mg/kg BW per day.
224267014|NCT04358367|DRUG|Dexmedetomidine Injectable Product|Spinal anesthesia and intravenous dexmedetomidine (1μg/kg). The administrated drugs were slowly injected intravenously over 10 minutes then intrathecal block was achieved using 2-2.2 ml of hyperbaric bupivacaine (10 -12.5 mg) introduced at L3/4 or L4/5 interspace.
224267015|NCT04358367|DRUG|Saline|Spinal anesthesia and intravenous saline. The administrated drugs were slowly injected intravenously over 10 minutes then intrathecal block was achieved using 2-2.2 ml of hyperbaric bupivacaine (10 -12.5 mg) introduced at L3/4 or L4/5 interspace.
224267016|NCT01148069|PROCEDURE|Surgery combined with IMRT-IGRT|Patients will have surgery consisting in extensive pelvic dissection and ablation of seminal vesicles. Surgery will be followed by prolonged hormonotherapy (3 years) associated, after 2 months, with prostatic only irradiation.
224267017|NCT05919901|OTHER|HPV Vaccine Communication Strategy|The intervention will include health promotions materials and provision of HPV vaccine
224267018|NCT02775994|DRUG|Canakinumab|interleukin beta (IL-1) antagonist
224267019|NCT06181422|DRUG|Metformin|metformin 500 mg
224267020|NCT06181422|DRUG|Lactoferrin|lactoferrin 100 mg
224267021|NCT01120028|DRUG|Alemtuzumab|Alemtuzumab 30 mg intravenously or subcutaneously, two doses 24 hours apart
224267022|NCT01120028|DRUG|Basiliximab|20 mg intravenously, two doses 96 hours apart
224267023|NCT01120028|DRUG|Sirolimus|Sirolimus: target trough levels 6-12 ng/mL for first 6-months after maintenance therapy randomization, then 5-10 ng/mL
224267024|NCT01120028|DRUG|Tacrolimus|Tacrolimus: target trough levels 5-7 ng/mL after maintenance therapy randomization.
224267025|NCT04106063|OTHER|KID SSQ12 questionnaire|During a face to face interview (maximum 15 minutes), the child will complete a short questionnaire (KID SSQ12 questionnaire) to assess his auditory difficulties
224267026|NCT02553863|PROCEDURE|Acupuncture|Acupuncture for 30min \[twice weekly for 8 weeks\]
224267027|NCT02553863|PROCEDURE|Standard care|Standard care
224267028|NCT01923909|DRUG|Intra-articular platelet-rich plasma|Intra-articular platelet-rich plasma This involves withdrawal of 10-15cc of patient's blood, which is collected and centrifuged in Rotofix 32 A Centrifuge machine at 1500 cycles/minute for 5 minutes. 3-4cc of the PRP is obtained and injected into the supra patellar pouch using an aseptic technique. The procedure will be performed by the principal investigator, a qualified consultant Orthopedic surgeon. Analgesia will be administered as needed.
224267029|NCT01923909|DRUG|Intra-articular corticosteroid injections|Patients receiving the IA corticosteroid will be injected 3mL of 0.5% Bupivacaine and 2mL of 80mg Depo Medrol in a 10cc syringe, using an aseptic technique into the supra patellar pouch. After an IA corticosteroid injection, patients are always advised to rest for 24 hours, and weigh bear as little as possible for the following 3 days. The procedure will be performed by a senior resident with several years of experience or a consultant Orthopedic surgeon.
224267030|NCT04817722|DRUG|Intravenous Solution|Intraoperative hydration
224267031|NCT01401062|DRUG|Fresolimumab|
224267032|NCT01401062|RADIATION|Radiation Therapy|
224267033|NCT01034215|BEHAVIORAL|Envision the Rhythms of Life Program|Patients learn to practice passive, active and targeted imagery for the purpose of improving mood state, modifying physiology (HRV, Body temperature, pain reduction) and also to mitigate the effects of their treatments, as defined by the IOM: chemo brain, fatigue, sleep deprivation, stress, anxiety, depression, and/or PTSD. Program is delivered with trainer present in the room.
223861113|NCT06234644|OTHER|Standardized Walking Obstacle Course (SWOC)|The Standardized Walking Obstacle Course (SWOC) is a test that allows interaction of a child with environmental demands and obstructions while examining differences in functional ambulation performances. The Group A (experimental group) will receive the treatment with Standardized walking obstacle course (SWOC), the group of 13 participants will receive the treatment. This group will receive therapy session for 45 min, thrice a week for 6 weeks, total sessions will be 18. 45 minutes session time will be divided into 15 min warm up period, 25 minutes of SWOC training and 5 minutes of cool down period.
223861114|NCT06234644|OTHER|Conventional Gait Training|Conventional gait training protocol including walking on a treadmill, parallel bar walk, seated marching. The Group B (Control group) will receive the treatment with conventional Gait training, the group of 13 participants will receive the treatment. This group will receive therapy session for 45 min, thrice a week for 6 weeks, total sessions will be 18. 45 minutes session time will be divided into 15 min warm up period, 25 minutes of Conventional gait training and 5 minutes of cool down period.
223861115|NCT01767259|DRUG|Valsartan/Hydrochlorothiazide|Co-administration or fixed dose combination
223861116|NCT01767259|DRUG|Valsartan|Valsartan alone
223861117|NCT01767259|DRUG|Hydrochlorothiazide|Hydrochlorothiazide alone
223861118|NCT01132794|DRUG|Intranasal dexmedetomidine|1mcg per kg dexmedetomidine given intranasally 45 minutes before operation
223861119|NCT01132794|DRUG|Placebo|Intranasal nasal saline
223861120|NCT00676234|DRUG|epoetinum|Administration of intravenous rhu Epo on Day 0 20000 IU rhu Epo (20 patients) administered by the i.v. route 40000 IU rhu Epo (20 patients) administered by the i.v. route
223861121|NCT01566513|BEHAVIORAL|Community Connector|The participant randomized into this arm of the study is invited to work with a person trained as a community connector, someone who is trained in Intentional Peer Support but does not have a lived experience of mental illness.
223861122|NCT01566513|BEHAVIORAL|Peer Recovery Mentor|A participant randomized into this arm of the study is offered the chance to work with a Peer Recovery Mentor, who is trained in Intentional Peer Support.
223861123|NCT01566513|BEHAVIORAL|Peer Case Manager|A participant randomized into this arm of the study is offered the chance to work with a Peer Recovery Mentor, who is trained in Intentional Peer Support.
223861124|NCT02886897|BIOLOGICAL|D-CIK and anti-PD-1 antibody|Autologous dendritic and cytokine-induced killer cells (D-CIK)(1.0-1.5\*10\^10 cells)were incubated with anti-PD-1 antibody and infused into participants.
223861125|NCT01311180|DRUG|Sensoril®|Start with 250 mg po QAM for 7 days and then 250 mg po bid for 7 weeks
223861126|NCT01311180|DRUG|Placebo|Start with 250 mg po QAM for 7 days and then 250 mg po bid for 7 weeks
223861127|NCT05826951|DRUG|Alcohol|Alcohol (0.8g/kg)
223861128|NCT05826951|DRUG|Placebo|Placebo
223861129|NCT02983370|PROCEDURE|Minicraniotomy|The surgical method for the implantation of the intracortical microelectrodes is straightforward and follows the standard neurosurgical procedures. Briefly, after the scalp is prepped with an antiseptic, a small skin incision is made. Then the skin and muscles are lifted off from the bone and folded back. Next, one small burr hole or a minicraniotomy of approximately 1.5 cm is made in the skull. This is a minimally invasive procedure that allows an easy access to the brain and is a standard procedure widely used in neurosurgery.
223861130|NCT02713048|OTHER|Blood sample collection|Eight blood samples in each patient within 48 hours to perform Troponin I measurement.
224267034|NCT01034215|BEHAVIORAL|Envision the Rhythms of Life Program/Distance|Patients learn to practice passive, active and targeted imagery for the purpose of improving mood state, modifying physiology (HRV, Body temperature, pain reduction) and also to mitigate the effects of their treatments, as defined by the IOM: chemo brain, fatigue, sleep deprivation, stress, anxiety, depression, and/or PTSD. Program is delivered by videoconference equipment
223861131|NCT04126330|DIETARY_SUPPLEMENT|Probiotic, Omega-3, Vitamin D supplement|"The first supplement we would like to assess is named VNP and is composed by Omega-3 Active and vitamin D. It contains a total of 1100 mg fish oils: 640 mg Omega-3 and with 300 mg eicosapentaenoic acid (EPA), 220 mg docosahexaenoic acid (DHA) plus 200 IU Vitamin D per daily dose (2 capsules).~The second supplement we investigate is four-strain probiotics combination based on the commercially available formulation HOWARU® by DuPont; two capsules containing 10 billion CFU total (supplied by Pfizer but manufactured by Danisco, DuPont). The probiotic specific composition, contains equal amounts of each strain per capsule (1.25 x 109 CFU each): Bifidobacterium lactis Bi-07, Lactobacillus paracasei Lpc-37, Lactobacillus acidophilus NCFM, Bifidobacterium lactis Bl-04. One capsule contains 5 billion CFU (Swedish milliards)."
223861132|NCT04126330|DIETARY_SUPPLEMENT|Placebo|Placebo generated for probiotic and omega-3/vitamin D supplements
223861133|NCT00968448|BEHAVIORAL|Respiratory muscle training|Daily training with a handheld device (Pressure threshold loading). 1x50 breaths with adjustments (gradually increasing levels).
223861134|NCT00968448|BEHAVIORAL|Sham training|Sham training with same handheld device. 50 breaths daily on the lowest level
223861135|NCT01069341|DRUG|Ranibizumab|Intravitreally administered 0.5mg ranibizumab, 3 doses administered monthly.
223861136|NCT01215019|DRUG|Mannitol|20% Mannitol, 1-5 doses as needed to control ICP
223861137|NCT01215019|DRUG|NaCl|3% sodium chloride injection, 1-5 doses, as needed to control ICP
223861138|NCT03631537|OTHER|NST group|Nutrition-support-team based intervention on nutrition, including dietary supplement, parenteral nutrient solutions and patient education
223861139|NCT01802632|DRUG|AZD9291|Starting dose 20 mg, administered once daily. If tolerated subsequent cohorts will test increasing doses of AZD9291, until a maximum tolerated dose or maximum feasible dose is defined
223861140|NCT00176813|DRUG|Gemcitabine|
223861141|NCT00176813|DRUG|Cisplatin|
223861142|NCT00176813|DRUG|Celecoxib|
223861143|NCT02423135|BIOLOGICAL|Autologous blood transfusion|Volunteers make a blood donation and after 36 days of storage this blood is re-infused in the same volunteers.
223861144|NCT02135172|BEHAVIORAL|Sitting|
223861145|NCT02135172|BEHAVIORAL|Standing|
223861146|NCT02135172|BEHAVIORAL|Walking|
223861147|NCT03343938|OTHER|Embryo handling in a closed station|Embryo handling is performed inside a closed station with a controlled environment: 6% CO2 and 37 degrees.
223861148|NCT02955498|DRUG|Sevikar tab. 10/40mg|Reference drug: Sevikar tab. 10/40mg, 1T, single oral administration in the fasted state
223861149|NCT02955498|DRUG|Lodivikar tab. 5/40mg|Test drug: Lodivikar tab 5/40mg, 1T, single oral administration in the fasted state
223861150|NCT00980135|DEVICE|Sinecort cream|Application over 29 days
223861151|NCT00980135|DRUG|Hydrocortison cream|Application over 29 days
223861152|NCT00980135|OTHER|Untreated skin|
223861153|NCT01490112|DRUG|insulin aspart|Subjects who had a first drug date on NovoRapid® were prescribed to inject insulin aspart using vial, FlexPen, NovoLet or Penfill devices. Injected subcutaneously (s.c., under the skin) immediately before meals for 24 weeks
223861154|NCT06356116|OTHER|Usual care|"During hospitalization, physical therapist visits the patient once or twice on day one or two post-operative (treatments including bedside standing, ambulation, stepping, active-assisted range of motion exercises).~Educational material will be given at discharge from hospital."
223861155|NCT06356116|OTHER|Accelerated rehabilitation|"Physical therapist visits 5 times during hospitalization, including~1. Pre-operatively: instruction regarding range of motion exercises, use of assistive device.~2. Post-operative day zero: bedside standing, ambulation, stepping, active-assisted range of motion exercises.~3. Post-operative day one: visit #1 continuing the day-zero exercises;~4. Post-operative day one: visit #2 mini-squat against wall; stair negotiation training (1/2 flight).~5. Post-operative day two: continuing the day-zero exercises; stair negotiation (1 flight); discharge from hospital in the afternoon.~After discharge from hospital: post-operative day three \~ week 4: telerehabilitation"
223861156|NCT02880241|DRUG|MMV390048|Tablets of 20mg each
223861157|NCT02566707|DRUG|Atazanavir|HIV therapy will be adapted: atazanavir 400mg QD
223861158|NCT02566707|DRUG|Dolutegravir|HIV therapy will be adapted: dolutegravir 50mg QD
223861159|NCT02566707|DRUG|Lamivudine|HIV therapy will be adapted: lamivudine 300mg QD
223861160|NCT01131624|DRUG|ferrous sulphate|200 mg iron per day in a convenient dosage schedule.
223861161|NCT01131624|DRUG|Ferinject|1000-1500mg diluted only in sterile 0.9% sodium chloride, The maximum single dose of FCM that can be administered by intravenous infusion is 20 mL (1,000 mg iron) but should not exceed 15 mg of iron per kg of body weight. This means that for subjects with a bw below 66 kg a maximal dose of 500 mg iron per infusion is allowed.
223861162|NCT04250285|OTHER|descriptive method|After obtaining relevant permissions from the university and organization of education and selecting participants, the study was explained for students and their satisfaction obtained. Then questionnaires were given to participants. To observe ethical considerations, questionnaires were anonymous and has been confided that the participants' responses was maintained in the study and is not given anyone
223861163|NCT04505982|OTHER|Data extraction from medical files|Data extraction from medical files
223861164|NCT05263115|OTHER|Resistance Exercise intervention|12-week progressive resistance exercise intervention
223861165|NCT05263115|OTHER|Functional stair climbing and stepping-based exercise intervention|12-week progressive stair climbing and stepping-based exercise intervention
223861166|NCT05983107|DRUG|Everolimus|Everolimus combined with endocrine therapy（tamoxifen, letrozole, anastrozole, exemestane, fulvestrant, etc.Goserelin, leuprolide, premenopausal patients only, selected at the discretion of the investigator）
223861167|NCT05983107|DRUG|Chidamide|Chidamide combined with endocrine therapy（tamoxifen, letrozole, anastrozole, exemestane, fulvestrant, etc.goserelin, leuprolide, premenopausal patients only, selected at the discretion of the investigator）
223861168|NCT05983107|DRUG|Endocrine therapy|Tamoxifen, letrozole, anastrozole, exemestane, fulvestrant, etc, selected at the discretion of the investigator.
223861169|NCT05983107|DRUG|Ovarian function suppression(OFS)|Goserelin, leuprolide, premenopausal patients only, selected at the discretion of the investigator.
223861170|NCT02018224|PROCEDURE|End-to-end suturation without augmentation|End-to-end suturation without augmentation; Irregular tendon ends were cleaned and repaired by the Krackow technique with two separate 0-gauge absorbable sutures.
223861171|NCT02018224|PROCEDURE|End-to-end suturation with augmentation.|End-to-end suturation with augmentation; End-to-end suturation as above with a 10 mm wide central gastrocnemius aponeurosis flap, as proposed by Silfverskjöld.
223861172|NCT03332992|BEHAVIORAL|Viral changes|Telephone script language provided pre-questions regarding the fact that influenza viruses change each year
223861173|NCT03332992|BEHAVIORAL|Protect others|Telephone script language provided pre-questions emphasizing the need to protect vulnerable others
223861174|NCT03332992|BEHAVIORAL|General intentions|Question language asking about general interest in getting influenza vaccination
223861175|NCT03332992|BEHAVIORAL|Behavioral intentions|Question language asking individual to make specific plans to be vaccinated
223861176|NCT03332992|BEHAVIORAL|Accountability|Question language asking individual whether their care team can learn about their vaccination intentions
223861177|NCT02841150|DRUG|IMBRUVICA (Treatment A)|IMBRUVICA (reference treatment), 4\*140 milligram (mg), capsules.
223861178|NCT02841150|DRUG|Ibrutinib (Treatment B)|Ibrutinib (test treatment), 1\*560 mg, tablet.
223861179|NCT06467253|DEVICE|1. rTMS + CS|"In the first phase each participant will receive 15 sessions of rTMS and 9 sessions of CS divided in 3 weeks, in the maintenance phase each participant will receive 1 session of rTMS and 1 session of CS per week for 12 weeks. Each session will consist of 10 trains of 10 stimuli, at a 5-Hz frequency and a stimulation intensity of 120% of the resting motor threshold.~rTMS will be administered by a MagPro R30 stimulator (MagVenture) and an active/placebo 8-shape coil model MCF-B70.~Two surface electrodes will be employed to replicate rTMS skin sensations near the stimulation site. The rTMS condition will be double-blinded through the use of a USB stick.~Cognitive stimulation will be a Mexican adaptation of the Memory Training and Cognitive Stimulation for Mild Cognitive Impairment from the Center for the Prevention of Cognitive Impairment of the Madrid City Council.~In total, each participant will receive 27 sessions of rTMS and 21 sessions of CS."
223861180|NCT06467253|DEVICE|2. rTMS Sham + CS|"In the first phase each participant will receive 15 sessions of rTMS Sham and 9 sessions of CS divided in 3 weeks, in the maintenance phase each participant will receive 1 session of Sham rTMS and 1 session of CS per week for 12 weeks.~In total, each participant will receive 27 sessions of Sham rTMS and 21 sessions of CS.~rTMS will be administered by a MagPro R30 stimulator (MagVenture) and an active/placebo 8-shape coil model MCF-B70.~Two surface electrodes will be employed to replicate rTMS skin sensations near the stimulation site. The sham condition will be double-blinded through the use of a USB stick.~Cognitive stimulation will be a Mexican adaptation of the Memory Training and Cognitive Stimulation for Mild Cognitive Impairment from the Center for the Prevention of Cognitive Impairment of the Madrid City Council.~In total, each participant will receive 27 sessions of rTMS and 21 sessions of CS."
223861181|NCT06467253|DEVICE|3. tDCS + CS|"In the first phase each participant will receive 15 sessions of tDCS and 9 sessions of CS divided in 3 weeks, in the maintenance phase each participant will receive 1 session of tDCS and 1 session of CS per week for 12 weeks. Each session will consist of the delivery of a weak direct current of 2mA for 30 minutes.~tDCS will be administered by the Sooma tDCS stimulator. The tDCS condition will be double-blinded, and a third operator will program the stimulator.~Cognitive stimulation will be a Mexican adaptation of the Memory Training and Cognitive Stimulation for Mild Cognitive Impairment from the Center for the Prevention of Cognitive Impairment of the Madrid City Council.~In total, each participant will receive 27 sessions of tCDS and 21 sessions of CS."
223861182|NCT06467253|DEVICE|4. tDCS Sham + CS|"In the first phase each participant will receive 15 sessions of tDCS Sham and 9 sessions of CS divided in 3 weeks, in the maintenance phase each participant will receive 1 session of Sham tDCS and 1 session of CS per week for 12 weeks.~tDCS will be administered by the Sooma tDCS stimulator. The sham condition will be double-blinded, and a third operator will program the stimulator.~Cognitive stimulation will be a Mexican adaptation of the Memory Training and Cognitive Stimulation for Mild Cognitive Impairment from the Center for the Prevention of Cognitive Impairment of the Madrid City Council.~In total, each participant will receive 27 sessions of Sham tDCS and 21 sessions of CS."
223861183|NCT04713371|DRUG|Keytruda Injectable Product|"Keytruda (pembrolizumab): PD-1 inhibitor antibody~Injectable 50mg/mL, only 2 mL injected."
223861184|NCT04713371|DRUG|Yervoy Injectable Product|"Yervoy (ipilimumab): Anti-CTLA-4 antibody~Injectable 5mg/mL, only 2 mL injected."
223861185|NCT04713371|DRUG|Cytoxan|Injectable 250mg/m2, only 1 mL injected. Oral low dose cyclophosphamide: 50mg once daily pill for 5 days prior to first treatment, 3 days prior to 2nd and 3rd treatment.
223861186|NCT04713371|PROCEDURE|Cryosurgical freezing (cryosurgery)|Cryosurgery, also known as cryoablation, for metastatic cancer works by freezing the cancer cells inside the tumor. Cryoablation will release intact antigens to prime the immune system.
223861187|NCT04713371|DRUG|GM-CSF Injectable|Daily injection administered subcutaneously. 250 mcg daily injections for a total of 25 days post after each treatment.
223861188|NCT02705586|BEHAVIORAL|Mindfulness|Mindfulness focuses on helping participants understand their personal reactions to stress, teaches skills that provide means to modify stress reactions, and promotes self-care and feelings of competence and mastery. In addition to weekly class sessions, participants are asked to do an hour of home practice the days that the class does not meet.
223861189|NCT01185769|DIETARY_SUPPLEMENT|Tocotrienol|500 mg of tocotrienol will be administered after consumption of high fat diet
223861190|NCT01185769|DIETARY_SUPPLEMENT|Tocotrienol|500 mg of tocotrienol will be administered after consumption of low fat diet
223861191|NCT02068430|DRUG|Riboflavin 0.1%|After topical anesthesia, 1 drop of Riboﬂavin 0.1% ophthalmic solution will be instilled topically in the eye every 2 minutes for 30 minutes. At the end of the 30 minute riboﬂavin pre-treatment period, the eye will be examined with blue light for the presence of a yellow ﬂare in the anterior chamber.
224267035|NCT00755235|OTHER|Depression care management by secure messaging|Participants will receive electronic messages welcoming them and monitoring their antidepressant treatment. Care managers will use monitoring data to aid participants' physicians, coordinate physician follow-ups, facilitate emergency care, and facilitate specialty referrals. Care managers will also provide motivation and education to participants.
224267036|NCT03860441|OTHER|Computerized cognitive training|Intervention used CogniFit platform with Personalized brain training sub-option
224267037|NCT01131260|DEVICE|fetal STAN monitor|The STAN monitor is a system for fetal surveillance that displays the FHR, the uterine activity and information resulting from the analysis of the ST segment of the fetal ECG.
224267038|NCT02417571|DEVICE|Ambulatory blood pressure monitoring (ABPM)|24-hour ambulatory BP monitoring using TM-2430 device (A\&D Company, Tokyo, Japan)
224267039|NCT06627257|DRUG|LepVax (2 μg LEP-F1 + 5 μg GLA-S): Low dose|2 μg LEP-F1 + 5 μg GLA-SE will be administered by IM injection on Days 0,28, and 56 in healthy participants.
224267040|NCT06627257|DRUG|LepVax (10 μg LEP-F1 + 5 μg GLA-SE): High dose|10 μg LEP-F1 + 5 μg GLA-SE will be administered by IM injection on Days 0,28, and 56 in healthy participants.
224267041|NCT06627257|OTHER|Placebo Comparator: Placebo|Sterile normal saline for injection will be administered by IM injection on Days 0, 28, and 56 in healthy participants and paucibacillary leprosy patients.
224267042|NCT06238388|DRUG|HSK21542 Injection|A single intravenous dose of 0.8 μg/kg HSK21542 in boluses after D1 dialysis completed.
224267043|NCT00792753|DEVICE|Medtronic Endeavor Coronary Stent System|coronary stent implantation
224267044|NCT00792753|DEVICE|DESyne BD Novolimus Stent System|coronary stent implantation
224267045|NCT00792753|DEVICE|DESyne Novolimus Stent System|coronary stent implantation
224267046|NCT04976179|DRUG|Ferric carboxymaltose|Ferric carboxymaltose to be given as an intravenous infusion
224267047|NCT04976179|DRUG|Ferrous sulfate|Ferrous sulphate tablet to be taken orally
224267048|NCT01177657|PROCEDURE|Stool sampling|Stool samples collected and checked for the presence of rotavirus
224267049|NCT03050424|DRUG|Ferric Carboxymaltose|Ferric Carboxymaltose injectable Product
224267050|NCT03050424|DRUG|Sodium Chloride 0.9%|Sodium Chloride 0.9%
224267051|NCT04699396|PROCEDURE|Mobilisation With Movement 1|"Application of a sustained passive accessory movement to a joint (talus or fibula) while the patient actively performs a forward lean/lunge that was previously limited.~3 sets of 10 repetitions of a glide applied to the talus were performed, followed by 3 sets of 10 repetitions of a glide applied to the fibula."
224267052|NCT04699396|PROCEDURE|Mobilisation With Movement 2|"Application of a sustained passive accessory movement to a joint (talus or fibula) while the patient actively performs a forward lean/lunge that was previously limited.~3 sets of 10 repetitions of a glide applied to the fibula were performed, followed by 3 sets of 10 repetitions of a glide applied to the talus."
224267053|NCT04699396|OTHER|Placebo|The Placebo group participants performed the same number of sets and repetitions (6 sets of 20 repetitions) of lean/lunge forward into dorsiflexion, without any glide application.
224267054|NCT03929016|DRUG|DNDI-0690|capsules of 10, 100 and 200 mg
224267055|NCT03929016|DRUG|Placebo of DNDI-0690|capsules of matching placebo
224267056|NCT03544216|DEVICE|Multifocal Contact Lens|The multifocal contact lens (Bausch + Lomb ULTRA® for Presbyopia) will be worn for two weeks
224267057|NCT03544216|DEVICE|Single Vision Contact Lens|The single vision contact lens (Bausch + Lomb ULTRA®) will be worn for two weeks
224267058|NCT05017935|DEVICE|Renal Denervation|Renal angiogram and renal denervation (Paradise ultrasound Renal Denervation System)
224267059|NCT00757419|DRUG|AZD3355|capsules, oral, single or twice daily dose
224267060|NCT00757419|DRUG|Placebo|To match dosing of AZD3355
224267061|NCT04969562|BEHAVIORAL|Emotional Freedom Technique|Emotional Freedom Technique (EFT, Emotional Freedom Technique) is a psychophysiological interpretation that combines elements of cognitive behavioral therapy (CBT), exposure therapy, and somatic stimulation using acupuncture points.
224267062|NCT06050239|DRUG|177Lu-PSMA-0057|The enrolled subjects will be administrated with 177Lu-PSMA-0057, and then enter the post administration observation phase while completing safety checks.
224267063|NCT03844334|DEVICE|WEB Aneurysm Embolization System|Subjects aged ≥ 18 years, but ≤ 80 years requiring treatment for single ruptured or unruptured intracranial aneurysms.
224267064|NCT07009093|OTHER|Mighty Pro Application|Access to Mighty Pro Application
224267065|NCT00052221|BIOLOGICAL|Epoetin alfa|
224267066|NCT00052221|OTHER|Placebo|
224267067|NCT01621945|BIOLOGICAL|MenBvac|Blood test
224267068|NCT02153645|DRUG|240mg Amantadine HCl ER tablets|
224267069|NCT02153645|DRUG|Placebo tablets|
224267070|NCT02153645|DRUG|320mg Amantadine HCl ER tablets|
223861192|NCT02068430|OTHER|UV-X™ Illumination System|When the yellow ﬂare in the anterior chamber is conﬁrmed, the eye will be aligned under the UV-X™ light with the treatment plane at a working distance that is 50mm from the UV-X™ beam aperture. The correct aperture setting will be selected for the size of the eye (7.5 , 9.5, or 11 mm), and the eye will be irradiated for 30 minutes, during which time instillation of riboﬂavin will continue (1 drop every 2 minutes). At the end of 30 minutes, the UV light source will automatically switch to the off position. The operator will keep track of irradiation time independently to conﬁrm the actual treatment time.
223861193|NCT00892593|DEVICE|Fecal Immunochemical Testing|Fecal Immunochemical Testing is a stool test specific for human hemoglobin.
223861194|NCT00892593|DEVICE|Fecal Immunochemical Testing|Fecal Immunochemical Testing is a stool test specific for human hemoglobin.
223861195|NCT01454661|DIETARY_SUPPLEMENT|LGG|Lactobacillus rhamnosus GG 10E9 cfu / day
223861196|NCT01454661|DIETARY_SUPPLEMENT|LGG+Bb-12|A combination of the probiotics Lactobacillus rhamnosus GG and Bifidobacterium lactis Bb-12 administered 10E9 cfu / day each.
223861197|NCT01454661|DIETARY_SUPPLEMENT|Placebo|Microcrystalline cellulose is used as placebo.
223861198|NCT03608839|DRUG|Intravitreous Dexamethasone Solution 4mg/ml - vol 0,01 ml|0,01 ml intravitreous dexamethasone solution 4mg/ml injection.
223861199|NCT03608839|DRUG|Intravitreous Dexamethasone Solution 4mg/ml - vol 0,03 ml|0,03 ml intravitreous dexamethasone solution 4mg/ml injection.
223861200|NCT03608839|DRUG|Intravitreous Dexamethasone Solution 4mg/ml - vol 0,05 ml|0,05 ml intravitreous dexamethasone solution 4mg/ml injection.
223861201|NCT02747563|OTHER|Blood test (PSA)|Measurement of blood PSA levels
223861202|NCT02447263|PROCEDURE|interventional therapy|liver cancer patients received HepaSphere interventional therapy using the digital subtraction angiography（DSA）
224267071|NCT00754858|DRUG|belotecan hydrochloride|
224267072|NCT00754858|DRUG|cisplatin|
224267073|NCT04820829|OTHER|High RM, low NSS|Participants in this group will consume nine 3-oz-eq servings of RM per week and 2-oz-eq servings of NSS per week.
224267074|NCT04820829|OTHER|Moderate RM, Moderate NSS|Participants in this group will consume five 3-oz-eq servings of RM per week and 5-oz-eq servings of NSS per week.
224267075|NCT04820829|OTHER|Low RM, High NSS|Participants in this group will consume one 3-oz-eq serving of RM per week and 8-oz-eq servings of NSS per week.
224267076|NCT02224586|DEVICE|light treatment|clinical routine treatment according to the doctor's advice
224267077|NCT00704639|DRUG|Cetuximab|Patients will receive weekly intravenous cetuximab (initial dose 400mg/m2 in the week prior to commencing radiotherapy, then weekly 250mg/m2)for the duration of the radiotherapy
224267078|NCT00704639|DRUG|Carboplatin|Weekly intravenous carboplatin (AUC 2) for the duration of the RT
224267079|NCT00704639|RADIATION|Radiotherapy|"The radiotherapy schedule will be the infield boost (IFB) regimen, that is 66 Gy in 35 fractions over 5 weeks: daily for 3 weeks, then twice daily for 2 weeks (or 70 Gy in 35 fractions over 7 weeks for a specific subgroup of patients where IFB is not recommended)."
224267080|NCT03742063|DRUG|first-line chemotherapy|patients who routinely received neoadjuvant chemotherapy according to Peking University People's Hospital chemo-protocols (PKUPH-OS and PKUPH-ES)
224267081|NCT04823832|PROCEDURE|pancreaticoduodenectomy|resection of the head of pancreas and the duodenum followed by triple anastomosis
224267082|NCT03857828|OTHER|semen sample|• seminal sample for measuring clusterin level.
224267083|NCT00414180|DRUG|Bupropion SR|
224267084|NCT05941390|DEVICE|VR without positive psychology|Using VR goggles showing relaxing short videos without sound
224267085|NCT05941390|DEVICE|VR with positive psychology|Using VR goggles showing relaxing short videos with positive psychological messages
224267086|NCT03746795|DEVICE|Spirometric examinations realized using the EIT|Spirometric examinations will be realized using the EIT alone.
224267087|NCT03746795|DEVICE|Simultaneous measurement by spirometer and EIT|Spirometric examinations will be realized using the simultaneous measurement by spirometer and EIT
224267088|NCT04023981|DEVICE|Parafricta bootees|Parafricta bootees are a medical device designed to eliminate skin damage due to friction and shear. The basis of Parafricta bootees is a low friction material and bi-layer construction to make the material of the bootee slide on itself when movement of the foot would otherwise bring friction and shear to bear on the skin.
224267089|NCT00860938|DRUG|Budesonide|After 4 weeks of inhalative therapy with tiotropium (all patients), patient get randomized to receive either inhalative budesonide (1600ug per day or placebo
224267090|NCT00412464|DRUG|Fondaparinux|Fondaparinux 0.1 mg/kg (up to 7.5 mg max initial dose) once daily for up to 21 days.
224267091|NCT01600963|DRUG|Arm A Double-blind Phase: TMC207|Type=exact number, unit=mg, number=400 mg for the first 2 weeks and 200 mg 3 times per week for the remainder of the treatment period, form=tablet, route=oral administration.
224267092|NCT01600963|DRUG|Arm B Double-blind Phase: Placebo|Form=tablet, route=oral administration, taken once daily for 2 weeks then 3 times per week for the remainder of the treatment period.
224267093|NCT01600963|DRUG|Treatment Failure During Double-blind Phase: TMC207|Type=exact number, unit=mg, number=200 mg 3 times per week, form=tablet, route=oral administration.
224267094|NCT01600963|DRUG|Treatment Failure During Follow-up Phase: TMC207|Type=exact number, unit=mg, number=400 mg once daily for 2 wks and 200mg three times per week for 22 weeks, form=tablet, route=oral administration.
224267095|NCT02469363|DEVICE|Macintosh laryngoscope|Hemodynamic parameters after endotracheal intubation with Classic laryngoscope (Macintosh)
224267096|NCT02469363|DEVICE|Mc-Coy laryngoscope|Hemodynamic parameters after endotracheal intubation with Mc-Coy laryngoscope
224267097|NCT02469363|DEVICE|C-Mac videolaryngoscope|Hemodynamic parameters after endotracheal intubation with C-Mac videolaryngoscope
224267098|NCT02469363|DEVICE|McGrath videolaryngoscope|Hemodynamic parameters after endotracheal intubation with McGrath videolaryngoscope
224267099|NCT01730846|DRUG|Doxazosin 4mg/day|4 mg/day with 3-week lead-in medication period. Maintained at steady state for duration of the study. 5-day taper at the end of the study.
224267100|NCT01730846|DRUG|Placebo|Placebo
224267101|NCT01730846|DRUG|Doxazosin 8mg/day|8 mg/day with 3-week lead-in medication period. Maintained at steady state for duration of the study. 5-day taper at the end of the study.
224267102|NCT05329311|PROCEDURE|ERATS protocol applied|Inflammatory parameters (such as; C-reactive protein (CRP), white blood cell count, neutrophil/lymphocyte ratio (NLR), platelet/ lymphocyte ratio (PLR), lymphocyte/monocytes ratio (LMR) of the operated patients by applying the ERATS protocol will be investigated.
224267103|NCT05329311|PROCEDURE|ERATS protocol not applied|Inflammatory parameters (such as; C-reactive protein (CRP), white blood cell count, neutrophil/lymphocyte ratio (NLR), platelet/ lymphocyte ratio (PLR), lymphocyte/monocytes ratio (LMR) of the operated patients by applying without the ERATS protocol will be investigated.
224267104|NCT03121898|DEVICE|Platelet function test|Measurement of P2Y12 and PAR-dependent platelet function activity before and after cardiac surgery by ADPtest and TRAPtest
224267105|NCT01018862|DRUG|Azelastine hydrochloride nasal spray 0.15%|822 mcg, Topical/intranasal spray, 1 spray per nostril twice daily/ 4 weeks
223861203|NCT06513442|OTHER|Trabecular bone score software|To assess the clinical utility of trabecular bone score (TBS) on fracture risk prediction including the new version (TBS V4) and future TBS versions at the spine and hip.
223861204|NCT02045836|BIOLOGICAL|Herpes Zoster vaccine GSK 1437173A|2 doses administered intramuscularly (IM) in the deltoid region of the non-dominant arm.
223861205|NCT02045836|BIOLOGICAL|Licensed pneumococcal polysaccharide conjugate vaccine (23-valent, adsorbed), Pneumovax 23™|One dose administered intramuscularly (IM) in the deltoid region of the non-dominant arm.
223861206|NCT02053363|DRUG|Tranexamic Acid (Cyklokapron)|
223861207|NCT02582710|DIETARY_SUPPLEMENT|VASCAZEN|6 weeks treatment with an optimized formulation of omega 3 before the carotid endarterectomy
223861208|NCT02582710|DIETARY_SUPPLEMENT|PLACEBO|6 weeks treatment with a placebo before the carotid endarterectomy
223861209|NCT01895218|DRUG|Iron isomaltoside 1000|A single dose of 1200 mg iron isomaltoside 1000 is given. The dose is diluted in 100 ml 0.9 % sodium chloride and given over approximately 15 min.
223861210|NCT01895218|OTHER|Standard medical Care|Standard medical Care is most often to recommend women with PPH to continue oral iron supplementation as recommended during pregnancy or to advise the subject to take 100 mg oral iron 1-2 times a day
223861211|NCT01183871|PROCEDURE|Monitoring of cerebral oxygenation|The internal jugular vein will be cannulated using ultrasound guidance in a cephalad direction, using the Seldinger J-shaped guidewire and it will be advanced only for 2-3 cm beyond the needle insertion site to avoid vascular injury to the jugular bulb. At which point the catheter is advanced until resistance is met at the jugular bulb, usually about 15 cm. The catheter is then pulled back 0.5-1.0 cm so that the catheter does not continue to abut the roof of the jugular bulb and to minimize the cephalad vascular impact with head movement, thereby reducing the risk of vascular injury. Skull x-ray will be used to confirm placement.
223861212|NCT01550666|BEHAVIORAL|MOVE|MOVE Program group: MOVE consists of medication follow-up at the CHCS or ATCMHMR and meeting once a week for 9 months with a MOVE trainer in your home. You and your trainer will work on interviews for the first three visits that will talk about negative symptoms, thoughts, attitudes, and social skills that will help each of you develop goals together. Activities will be developed around improving initiation, enjoyment, success and outcome. These activities will be customized to you and will change based on your needs weekly throughout the 9 months
223861213|NCT03305003|OTHER|Spiral notebook|
223861214|NCT03305003|OTHER|Mobile application|
223861215|NCT03391635|DEVICE|Electroacupuncture|Participants will receive electroacupuncture at bilateral ST25, SP14 and ST37 for 30 minutes each time，3 times a week for 8 weeks.
223861216|NCT03391635|DEVICE|TranscutaneousElectricNerveStimulation|Participants will receive transcutaneous electric nerve stimulation at bilateral ST25, SP14 and ST37 for 30 minutes each time，3 times a week for 8 weeks.
223861217|NCT02874326|DRUG|Octreotide LAR|
223861218|NCT03920215|DRUG|OC-01 Low Dose, 0.12 mg/mL|OC-01 (varenicline) nasal spray
223861219|NCT03920215|DRUG|OC-01 Mid Dose, 0.6 mg/mL|OC-01 (varenicline) nasal spray
223861220|NCT03920215|DRUG|OC-01 High Dose, 1.2 mg/mL|OC-01 (varenicline) nasal spray
223861221|NCT03920215|DRUG|Placebo (vehicle) nasal spray|Placebo (vehicle) nasal spray
223861222|NCT04866069|BIOLOGICAL|SARS-CoV-2 vaccine|Adjuvanted inactivated vaccine
223861223|NCT04866069|BIOLOGICAL|Placebo|0.9% NaCl
223861224|NCT02000817|BIOLOGICAL|Otelixizumab|Otelixizumab is available at unit dose strength of 5 milligram/mL provided as 1 mL solution per vial to be diluted to 0.1 mg/mL in 0.9% sodium chloride. The 0.1 mg/mL solution is to be administered by intravenous infusion using a syringe pump and an in-line 0.2 micron filter by study personnel following specified regimens
223861225|NCT02000817|BIOLOGICAL|Placebo|Placebo is available 0.9% w/v sodium chloride
223861226|NCT01038648|DRUG|Sitagliptin|100mg/day
223861227|NCT01038648|OTHER|life style modification at base line|Advice on physical activity, diet and drug adherence.
223861228|NCT01141322|DRUG|Ursodeoxycholic Acid|ursodeoxycholic acid 13-15 mg/kg BW/day into 3 divided doses after meal till endpoint or the 8th week.
223861229|NCT01141322|DRUG|Placebo|The placebo is of the same color, size and shape as UDCA, and assumed 100 mg per tab. Patients in this group will orally intake 13-15 mg/Kg BW/day of placebo into 3 divided doses after meal as UDCA treatment group, till the endpoint or the 8th week.
223861230|NCT02785380|PROCEDURE|laparoscopic surgery(LS)|For LS, the patient was usually placed in the lithotomy position. Pneumoperitoneum was maintained at a pressure between 12 and 14 mmHg. Three to 4 working ports sized between 5 mm and 12 mm were used . Intra-operative ultrasonography was performed routinely. Parenchymal transection was performed using a Cavitron ultrasonic surgical aspirator (CUSA, Valleylab, Boulder, CO, USA). Large bile duct branches or vessels were clipped before division and minor hemostasis was carried out using bipolar diathermy. Large hepatic vein branches were divided by endovascular staplers. A 1.0-cm safety margin was planed to get during the liver resection.
223861231|NCT02785380|PROCEDURE|RFA|RFA was performed according to the Guidelines of Radiofrequency Ablation Therapy for Liver Cancer: Chinese Expert Consensus Statement issued by the Chinese Society of Liver Cancer and Chinese Society of Clinical Oncology RFA was performed under real-time ultrasound guidance. RFA was performed by using a commercially available Cool-tipTM RFA system (Valleylab, Boulder, CO, USA), or a RF 2000 system (Radio-Therapeutics Mountain View, CA). Grounding was achieved by attaching 2 pads to the patient's back or legs.
223861232|NCT02644174|PROCEDURE|Bariatric Surgery|
223861233|NCT01405872|OTHER|AVONEX PEN|Participants receive Avonex PEN commercially prescribed according to the local prescribing information.
223861234|NCT00166166|DRUG|Tetraethylammonium (TEA)|5 minute intra-arterial infusion of Tetraethylammonium at 1 mg/min
223861235|NCT00166166|DRUG|L-NG-monomethyl Arginine (L-NMMA)|5 minute intra-arterial infusion of L-NMMA 8 μmol/min
223861236|NCT00166166|DRUG|Bradykinin|Intra-arterial infusion of bradykinin at 100, 200, and 400 ng/min. Each dose will be given for 5 minutes.
223861237|NCT00166166|DRUG|Sodium nitroprusside|Intra-arterial infusion of sodium nitroprusside at 1.6 and 3.2 mg/min. Each dose will be given for 5 minutes.
223861238|NCT00166166|DRUG|Acetylcholine|Intra-arterial infusion of acetylcholine at 7.5, 15 and 30 μg/min. Each dose will be given for 5 minutes.
223861239|NCT00166166|DRUG|Saline|5 minute intra-arterial infusion of 0.9% saline at 2.5ml/min
223861240|NCT00166166|DRUG|Fluconazole|5 minute intra-arterial infusion of fluconazole at 0.4 mg/L/min
223861241|NCT00097188|DRUG|rituximab|
223861242|NCT02886637|OTHER|None intervention|
223861243|NCT05989646|DEVICE|Sacral TENS|Sacral TENS applied two hours daily for 10 weeks
223861244|NCT02798835|DRUG|Adductor canal block|Spinal anesthesia with 2-3 ml 0.5% bupivacaine and 0-20mcg of fentanyl. At the end of the case, the surgeon will infiltrate 30ml 0.5% ropivacaine peri-articularly. 20ml 0.5% ropivacaine in the adductor canal in PACU.
223861245|NCT02798835|DRUG|Adductor canal block with dexamethasone|Spinal anesthesia with 2-3 ml 0.5% bupivacaine and 0-20mcg of fentanyl. At the end of the case, the surgeon will infiltrate 30ml 0.5% ropivacaine peri-articularly. 20ml 0.5% ropivacaine in the adductor canal along with 8mg dexamethasone IV in PACU.
223861246|NCT02798835|DRUG|Adductor canal catheter|Spinal anesthesia with 2-3 ml 0.5% bupivacaine and 0-20mcg of fentanyl. At the end of the case, the surgeon will infiltrate 30ml 0.5% ropivacaine peri-articularly. 20ml 0.5% ropivacaine and a catheter placed in PACU, with a continuous infusion of 0.2% ropivacaine started.
223861247|NCT02798835|DRUG|Bupivacaine|Used in spinal anesthetic
223861248|NCT02798835|DRUG|Fentanyl|May or may not be used in spinal anesthetic
223861249|NCT02798835|DRUG|Ropivacaine 0.5% Injectable Solution|Local anesthetic to be used by surgeon as local infiltration and by anesthesiologist in adductor canal block.
223861250|NCT02798835|DRUG|Dexamethasone|To be given intravenously at time of nerve block to one of the study arms.
223861251|NCT04178226|OTHER|Manual Acupuncture|The acupoints choose are (RN6) (RN4) (SP6) (PC6) (SP10) (SP4)
223861252|NCT04178226|DEVICE|Laser Acupuncture|The acupoints choose are (RN6) (RN4) (SP6) (PC6) (SP10) (SP4)
223861253|NCT00177216|DRUG|Zolpidem|The benzodiazepine receptor agonist (BzRA), zolpidem was given in an initial dose of 5 mg by mouth every night, 30 minutes prior to bedtime. The dose was increased to a maximum of 10 mg after the first week if there was no improvement in overall symptoms (CGI score of 4 or \>). The dose was decreased to 5 mg if side effects occurred.
223861254|NCT00177216|DRUG|Escitalopram|The antidepressant, escitalopram was initiated at 5 mg by mouth every night, 30 minutes prior to bedtime. If there were no side effects, the dose was increased every four days until the target dose of 20 mg (maximum dose) was reached by day 13. If significant side effects appeared, the highest tolerated dose was used.
223861255|NCT00177216|DRUG|Placebo|A placebo capsule was given with instructions to take it every night by mouth, 30 minutes prior to bedtime.
223861256|NCT01315314|DRUG|Balance, Fresenius Medical Care, Germany|low glucose degradation product (GDP)-containing peritoneal dialysis fluid (PDF)
223861257|NCT04042545|DRUG|PPP001|1 cannabis dosing capsule inhaled 3 times a day with a vaporizer device
223861258|NCT04042545|DRUG|Placebo|1 placebo dosing capsule inhaled 3 times a day with a vaporizer device
223861259|NCT04943770|PROCEDURE|Spinal cord stimulator implant|"Patients will undergo spinal cord implant procedures as per standard of care and be implanted with the WaveWriter™ Alpha Spinal Cord Stimulator (SCS) system.~Implant Procedures will be followed by a healing period (4-6 weeks) during which patients will be offered therapy (up to one 1Khz). Patients will then be randomised to receive therapy at four different rates (A, B, C, D) in no particular order for 3-6 weeks each. Patients will then be followed up at 3 and 6 months after the last randomization visit."
223861260|NCT04943770|DIAGNOSTIC_TEST|Healing period|Acute opioid pain medications may be continued. No additional scheduled assessments will be completed during this period.
223861261|NCT04943770|DEVICE|WaveWriter™ Alpha Spinal Cord Stimulator (SCS) system|Patients will then be randomised to receive therapy (up to 1KHz) at four different rates in no particular order for 3-6 weeks each. Patients will then be followed up at 3 and 6 months after the last randomization visit.
223861262|NCT00168922|DRUG|Bendamustin/Ribomustin|
223861263|NCT03320434|DRUG|PRT-2761 0.5%|Six drops in each eye over a 17 day period.
223861264|NCT03320434|DRUG|PRT-2761 1%|Six drops in each eye over a 17 day period.
223861265|NCT03320434|DRUG|Patanol|Six drops in each eye over a 17 day period.
223861266|NCT03320434|DRUG|Pred-forte|Four drops in each eye over a 3 day period.
223861267|NCT03320434|DRUG|PRT-2761 0%|Six drops in each eye over a 17 day period.
223861268|NCT05475405|OTHER|scapulothoracic mobilization|Patient in prone lying position. The left hand of the physical therapist lifts the scapula to distract from the thoracic wall while the right hand mobilizes and stretches the inferior muscle groups attached to the scapula.
223861269|NCT05475405|OTHER|IASTM|"Restrictions and myofascial adhesions should be assessed prior to treatment along both sides using IASTM tool and a lubricant.~Once restrictions are assessed, fanning strokes at 45 degree angles to skin should be applied using the tool. This technique should be performed for 20 seconds parallel to the muscle fibers and 20 seconds perpendicular to the muscle fibers for each muscle group in scapulothoracic region. Total time for IASTM application is 10 mints. Upon completing all this patient should be given a home plan consisting of 2 different self-stretches targeting levator scapulae and upper trapezius"
223861270|NCT03665298|BEHAVIORAL|Smartphone Application|App that helps patients find syringe exchange programs, safe way to dispose of needles, access to naloxone kits and access to free medical care and addiction treatment programs.
223861271|NCT00033163|DRUG|Adefovir dipivoxil|
223861272|NCT00033163|DRUG|Tenofovir disoproxil fumarate|
223861273|NCT05342766|DIETARY_SUPPLEMENT|Nutrigenetic|"Each grup will receive two interventions (Nutrigenetic and Standard), in a cross-over design (3 months each), spaced by a wash-out period (3 months)."
223861274|NCT00307307|DRUG|Niacin/simvastatin compared to simvastatin alone at 2 doses|
223861275|NCT06554080|PROCEDURE|Platform-switched implant placement|NobelParallel or NobelActive implants placed
223861276|NCT06554080|PROCEDURE|Platform-matched implant placement|Nobel Brånemark, NobelSpeedy Groovy implants placed
223861277|NCT02459899|DRUG|Placebo|Placebo, once daily, before the first meal of the day
223861278|NCT02459899|DRUG|Sotagliflozin|Sotagliflozin,once daily, before the first meal of the day
223861279|NCT01118338|DEVICE|Redesigned Purevision Contact Lens|Lenses will be dispensed at screening visit, subjects will wear lenses on a daily wear basis for one month.
223861280|NCT01118338|DEVICE|PureVision Contact Lens|Lenses will be dispensed at screening visit, subjects will wear lenses on a daily wear basis for one month.
223861281|NCT02739035|DRUG|Dexamethasone|8 mg of IV dexamethasone immediately before MUA.
223861282|NCT02739035|DRUG|Celecoxib|2 weeks per mouth of celecoxib (200 mg daily)
223861283|NCT00293865|PROCEDURE|sentinel node|detection of the sentinel node in breast cancer
223861284|NCT00293865|PROCEDURE|GAS|
223861285|NCT03384069|BEHAVIORAL|Group-based Cognitive Behavioral Therapy (CBT)|The group-based CBT intervention will include twelve 1-hour group sessions held biweekly for six months. Each sixty-minute session will consist of 15 minutes of Alzheimer's disease (AD) prevention education and approximately 45 minutes of CBT presentations/engagement activities. A physician and a Behavioral Interventionist will collaboratively facilitate the group sessions.
223861286|NCT03384069|BEHAVIORAL|Phone-based Cognitive Behavioral Therapy (CBT)|Participants in the phone-based CBT will be asked to reserve a 1-hour period for a phone call from the Behavioral Interventionist biweekly for six months. Text reminders will be sent to the participant's prior the sessions. This intervention will follow the same frequency and format as the group-based CBT and will use an established protocol incorporating the same elements of cognitive behavior change as in the group-based CBT, but without the opportunity for group-interaction.
223861287|NCT00552942|PROCEDURE|laparoscopic gastric bypass plus omentectomy|
223861288|NCT01343342|DIETARY_SUPPLEMENT|n-3 PUFA supplementation|3g per day of n-3 PUFA supplementation (1.9g EPA, 1.1g DHA). 5 capsules per day (1g fish oil each, 5g of fish oil/day)
223861289|NCT01242150|DEVICE|NCPAP by helmet|The infant helmet (Castar Starmed© Mirandola, Italy) is secured to a soft collar that adheres to the child's neck and is connected to a high flow NCPAP circuit (high fresh gas flow \>40 L/min to avoid carbon dioxide rebreathing). To facilitate tolerance up to a maximum of 2 boluses of midazolam 0.1 mg/kg i.v. can be administered eventually followed by an i.v. continuous infusion rate according to OPS scale. Once the interface is positioned, a baseline Continuous Positive Airway Pressure (CPAP) level is set at 4 cm H2O and then raised in increments of 2 cm H2O every 20 min up to a maximum of 10 cm H2O. FiO2 is set to achieve a SpO2 ≥ 92%. If intolerance persisted despite sedative administration, the alternate interface can be used before considering tracheal intubation. All patients are kept in semirecumbent position.
223861290|NCT01242150|DEVICE|NCPAP by facial mask|The size of NCPAP full face or nasal masks are chosen to be more comfortable for the infants (Respironics, Murrysville). The masks are secured by head straps while avoiding a tight fit and air leaks. A protective hydrocolloid sheet was applied over the nasal bridge (DuoDERM, ConvaTec, Deeside, UK). After a short adaptation period, it is firmly applied on the face by a pediatric head cap (Respironics, Murrysville ) to minimize air leaks. The mask is then connected to the same circuit previously described for helmet NCPAP.
223861291|NCT04242732|DIAGNOSTIC_TEST|CT scan of the knee under weight-bearing with the Cone Beam Computed Tomography (CBCT) scanner system.|The patient will be evaluated under weight-bearing, with knee flexed at 30 ° and therefore with contracted thigh muscles. The measurement and maintenance of the 30 ° of flexion will be controlled by a goniometer applied laterally to the knee and fixed by means of an elastic band.
223861292|NCT04242732|DIAGNOSTIC_TEST|Conventional CT scan|The patient will be evaluated in supine position, with the muscles relaxed and the knee in full extension by conventional CT scan
223861293|NCT02767219|DRUG|bevacizumab|Patients will be randomised to study arms with a 1:1 ratio. Once randomised, Group 2 will receive a subconjunctival injection of bevacizumab and a subconjunctival injection of dexamethasone 3.3mg/ml. This will be given for 4 consecutive weeks from time of entry into trial.
223861294|NCT02767219|DRUG|5-fluorouracil|Patients will be randomised to study arms with a 1:1 ratio. Once randomised, Group 1 will receive a subconjunctival injection of 5-fluorouracil and a subconjunctival injection of dexamethasone 3.3mg/ml. This will be given as required for 4 consecutive weeks from time of entry into trial. This is current standard practice.
223861295|NCT02767219|DRUG|Dexamethasone|Both intervention groups will be given a subconjunctival injection of dexamethasone at the time of injection of either bevacizumab or 5-fluorouracil
223861296|NCT05216120|DRUG|Pemigatinib 4.5 MG|"Pemigatinib 4.5 mg tablets taken 3 times per day \[daily dose of 13.5 mg (3 tablets)\] for 14 consecutive days followed by 7 days off medication in 21-day cycles~Doses will be self-administered at home. Participants will be instructed to take study medication at the same time each day, with or without food."
223861297|NCT03313128|OTHER|Sanitation|Improved sanitation facility
224267106|NCT01018862|DRUG|Azelastine hydrochloride nasal spray 0.10%|548 mcg, Topical/intranasal spray, 1 spray per nostril twice daily/ 4 weeks
224267107|NCT01018862|DRUG|Placebo|0 mcg, Topical/intranasal spray, 1 spray per nostril twice daily/ 4 weeks
224267108|NCT01968031|DRUG|Istradefylline 40 mg|Istradefylline 40 mg and placebo
224267109|NCT01968031|DRUG|Istradefylline 20 mg|Istradefylline 20 mg and placebo
224267110|NCT01968031|DRUG|Placebo|Placebo
224267111|NCT02708251|DRUG|glyceryl trinitrate cream|
224267112|NCT02708251|DRUG|lidocaine cream|
224267113|NCT02708251|DRUG|placebo cream|
224267114|NCT06626971|DRUG|ARA290|4 mg subcutaneous injections of ARA290 over an 84 day period
224267115|NCT02119988|PROCEDURE|TIPS|TIPS will be performed with a standard technique. TIPS revision will be planned if any evidence of shunt dysfunction is observed.
224267116|NCT02119988|PROCEDURE|Variceal Embolization|Embolization of gastroesophageal collaterals will be conducted via the same jugular vein before TIPS implantation. The major procedures includ (a) angiography of gastroesophageal collaterals after successful intrahepatic puncture of a branch of the portal vein and (b) embolization of gastroesophageal collaterals with coils of varying diameters, which result in the gastroesophageal collaterals disappearing at postembolization angiography.
224267117|NCT04440150|PROCEDURE|Appendectomy|Open or Laparascopic Surgery
224267118|NCT07024199|OTHER|The initial pain assessment|The initial pain assessment will be carried out according to pain assessment scales in children adapted to the patient's age and cognitive abilities (NRS, FLACC).
223861298|NCT05016713|COMBINATION_PRODUCT|Chlorhexidine mouthwash|"Chlorhexidine mouthwash is added to the oral hygiene protocol being used beside fluoride-based toothpaste and interdental brushes. CHX mouthwash is used by patients according to the manufacturer's instructions 15 min after tooth-brushing: 5 mL of 0.2% CHX was applied for 60s in the morning and at bedtime. The patients will be instructed not to consume any liquid or food at least 30 min after using the prescribed mouthwash. All patients are asked to bring the mouthwash bottle, so we could determine patient compliance based on how much liquid was left.~If any participant shows any signs of CHX hypersensitivity, the intervention will be discontinued."
223861299|NCT05016713|DEVICE|Interdental brush|Fluoride-based toothpaste is used for tooth-brushing beside using interdental brushes.
223861300|NCT05016713|OTHER|Fluoride-based toothpaste|Regular tooth-brushing is carried out using fluoride-based toothpaste supplied only.
223861301|NCT01215695|DEVICE|aScope (Ambu Inc. 6740 Baymeadow Drive Glen Burnie, MD)|The aScope is a flexible, disposable plastic tracheoscope that incorporates a high-resolution video camera with an LED light at its flexible tip and has attached monitor.
223861302|NCT01215695|DEVICE|Control|pre-formed stylet provided by the manufacturer of the GlideScope® video laryngoscope
223861303|NCT02770248|DRUG|Brinzolamide 1%/brimonidine 0.2% tartrate ophthalmic suspension|
223861304|NCT02770248|DRUG|Vehicle|Inactive ingredients used as a placebo for masking purposes
223861305|NCT02296619|PROCEDURE|TAP block|Using real time ultrasound imaging, bilateral, 20 ml 0,25% bupivacaine inject into the area between the internal oblique and transverse abdominis muscle
223861306|NCT02296619|PROCEDURE|Control|A sham band-aid will be applied to the abdomen of subjects
223861307|NCT04935489|DEVICE|Intermittent Theta Burst Stimulation (form of repetitive transcranial magnetic stimulation) given in an accelerated form|The intervention is used regularly for patients with treatment resistant depression, however, in this trial it will be given multiple times per day and over less days than the usual protocol
223861308|NCT03105505|DRUG|Permethrin 5%|Facial skin application once a night for 3 months.
223861309|NCT03105505|DRUG|Synthomycine 5%|Eye ointment, eyelids and eyelashes application (chloramphenicol), once a night for 3 months.
223861310|NCT03105505|DRUG|Fusidic Acid 1% M/R Eye Drops|viscous eye drops application once a night for 3 months.
223861311|NCT04970342|DRUG|Placebo (Lactose) Capsule|Single dose on two of the three study visits, orally administered 40 minutes prior to cannabis dose
223861312|NCT04970342|DRUG|0.75 mg Alprazolam Capsule|Single dose on one of the three study visits, orally administered 40 minutes prior to cannabis dose
223861313|NCT04970342|DRUG|Cannabis (6.18% THC / <0.025% CBD)|Cannabis vapor is produced from 500 mg of dried plant material (6.18% THC / \<0.025% CBD). Subjects will inhale using the Foltin Puff Procedure over 10 minutes. Single inflated bag/dose consumed via inhalation 40 minutes after alprazolam dose on one of the three study visits.
223861314|NCT04970342|DRUG|Cannabis (0%/ THC / 0% CBD)|Cannabis vapor is produced from 500 mg of dried plant material (0% THC / 0% CBD). Subjects will inhale using the Foltin Puff Procedure over 10 minutes. Single inflated bag/dose consumed via inhalation 40 minutes after alprazolam dose at two of the three study visits.
223861315|NCT05625334|DRUG|ASA|powder for oral inhalation via a Dry Powder Inhaler (DPI)
223861316|NCT05625334|DRUG|non-enteric-coated chewable aspirin|Orally administered
223861317|NCT04077632|DEVICE|Transcranial direct current stimulation|tDCS: 20 minutes, 2mA, primary motor cortex anode (contralateral to the lesion) and supraorbital cathode (ipsilateral to the lesion).Technique based on the application of weak, direct electrical current to the brain through relatively large electrodes that are placed over the scalp, in which anodal and cathodal stimulation increases and decreases cortical excitability, respectively.
223861318|NCT03830736|COMBINATION_PRODUCT|Oat Beverage 1|Oat based beverage with added different concentration of extracted oat component.
223861319|NCT03830736|COMBINATION_PRODUCT|Oat Beverage 2|Oat based beverage with added different concentration of extracted oat component.
223861320|NCT03830736|COMBINATION_PRODUCT|Oat Beverage 3|Oat based beverage with added different concentration of extracted oat component.
223861321|NCT03830736|COMBINATION_PRODUCT|Oat Beverage 4|Oat based beverage with added different concentration of extracted oat component.
223861322|NCT03830736|COMBINATION_PRODUCT|Control product|Glucose based beverage without added test components is used as control product
223861323|NCT05035004|DEVICE|Post exercise hot water immersion|Participants will complete 30 minutes of cycling on a lode bicycle ergometer (50% of VO2max), followed by a 10-minute transfer period and then 30 minutes of whole-body hot water immersion in a hot tub (water temperature 40°C).
223861324|NCT05035004|DEVICE|Exercise|Participants will complete 30 minutes of cycling on a lode bicycle ergometer (50% of VO2max).
223861325|NCT05035004|DEVICE|Hot water immersion|Participants will complete 30 minutes of whole-body hot water immersion in a hot tub (water temperature 40°C), followed by a 10-minute transfer period and then an additional 30 minutes of whole-body hot water immersion in a hot tub (water temperature 40°C).
223861326|NCT04189744|DRUG|IPTp-sulphadoxine-pyrimethamine plus metronidazole|Metronidazole (MTZ) is indicated for the treatment of BV and TV and is also safe to administer in the second and third trimesters of pregnancy, and its use with SP or DP may result in better birth outcomes than SP alone. Malaria parasites have developed resistance against SP and the treatment is sub-optimal at clearing malaria infection compared to dihydroartemisinin-piperaquine (DP), therapy that has a suitable profile for use in IPTp. This intervention arm can be compared to the intervention arm IPTp-DP plus MTZ to assess whether DP is superior to SP in preventing adverse birth outcomes. This intervention arm will also be compared to the IPTp-SP plus MTZ placebo arm to assess whether the combination of MTZ with IPTp-SP is superior to IPTp-SP alone in reducing adverse pregnancy outcomes.
223861327|NCT04189744|DRUG|IPTp-dihydroartemisinin-piperaquine plus metronidazole|Metronidazole (MTZ) is indicated for the treatment of BV and TV and is also safe to administer in the second and third trimesters of pregnancy, and its use with SP or DP may result in better birth outcomes than SP alone. Malaria parasites have developed resistance against SP and the treatment is sub-optimal at clearing malaria infection compared to dihydroartemisinin-piperaquine (DP), therapy that has a suitable profile for use in IPTp. This intervention arm can be compared to the intervention arm IPTp-SP plus MTZ to assess whether DP is superior to SP in in reducing adverse pregnancy outcomes.
223861328|NCT04189744|DRUG|IPTp-sulphadoxine-pyrimethamine|The World Health Organization (WHO) recommends providing intermittent preventive treatment (IPTp) using sulphadoxine-pyrimethamine (SP) to pregnant women during the second and third trimesters of pregnancy to clear placental infection.
223861329|NCT05220215|OTHER|Nordic Hamstring Exercise|To perform Nordic Hamstring Exercise, the subject was in kneeling position on the mat, arms by the side or in front of the chest, knee in 90-degree flexion and ankles well stabilized with the help of a therapist which is positioned behind the subject. Then subject was asked to lean forward by using the hamstring muscles by extending while trying to resist the forward fall, he should lean forward from the knee and not from the hip. The only time one can put his hands in front of him is when he can't rely on his legs and then push himself back to starting position and them repeat the procedure again.
223861330|NCT05220215|OTHER|Hamstring Curl with Resistance band|"Traditional Hamstring Curl by using Resistance band.~Resistance Band: Thera-band Green, 4.6 kg resistance at 100% elongation"
223861331|NCT00922675|PROCEDURE|Postconditioning|After opening of IRA and establishment of TIMI-flow grade 2 or 3, the control group continues the procedure with stenting. In the postconditioning group 4 additional balloon inflations separated by 1 minute reperfusion are given, starting after 1 minute of reperfusion.
223861332|NCT00922675|PROCEDURE|Control intervention|After opening of IRA and establishment of TIMI-flow grade 2 or 3, the control group continues the procedure with stenting.
223861333|NCT01632930|OTHER|urinary PCA3 test using Progensa® PCA3 assay kit (Gen-Probe)|urinary PCA3 test will be performed in patients before they undergo prostate biopsy for increased serum PSA and/or abnormal digital rectal examination. Patients with negative biopsies will be definitively enrolled in the study. The physician in charge will have knowledge of PCA3 test results and will be asked to determine the subsequent follow-up taking these results into account.
223861334|NCT04709744|DRUG|Vitamin D|Impact of serum vit D level in SLE patients with COVID-19 disease on severity of infection, duration of COVID-19 disease course, fatigue development as a complication for both SLE and COVID-19 and assess impact of prior chloroquine on COVID-19 disease outcomes
223861335|NCT04709744|DIAGNOSTIC_TEST|ELISA|Measure vitamin D level
223861336|NCT00667745|DRUG|Lithium Carbonate|Lithium was started at 300 mg and then increased to 600 mg after 3 days. Lithium doses were maintained at 600 mg per day for 8 weeks, but may have been adjusted after that time as needed up to a serum level of 1.2 mEq/L.
223861337|NCT00667745|DRUG|Optimized Treatment (OPT)|The foundation of OPT was to maintain treatment that will typically include at least one FDA-approved mood stabilizer other than lithium (e.g., divalproex, carbamazepine, risperidone, quetiapine, olanzapine, aripiprazole, ziprasidone) and to follow the recommendations summarized in the evidence-based stages of the Texas Implementation of Medication Algorithm (TIMA) revised guidelines.
223861338|NCT03985150|OTHER|Biomechanical analysis of femoralis superficialis atherosclerotic tissue|Tissue collection during above-knee amputation; mechanical testing of tissue; microstructural testing of tissue
223861339|NCT03985150|RADIATION|CT or MR angiogram|Obtaining in vivo geometry of diseased artery
224267119|NCT07024199|DRUG|Drug administration according to protocol (paracetamol + ibuprofen OR paracetamol + metamizol)|"Group A will receive a dose of Paracetamol B. Braun/Paracetamol Kabi intravenously 15 mg/kg body weight (maximum 1000 mg/dose) and Ibuprofen B.Braun/Ibuprofen Kabi intravenously 10 mg/kg body weight (maximum 400 mg/dose).~Group B will receive a dose of Paracetamol B. Braun/Paracetamol Kabi intravenously 15 mg/kg body weight (maximum 1000 mg/dose) and Metamizol-SF/Metamizole Kabi/Pyralgin intravenously 15 mg/kg body weight (maximum 100 mg/dose)."
224267120|NCT07024199|OTHER|The effectiveness of the treatment|The effectiveness of the treatment will be assessed 60 minutes after the start of the intervention according to pain assessment scales in children adapted to the patient's age and cognitive abilities (NRS, FLACC).
224267121|NCT06705192|DRUG|VES001|"VES001 is an oral, blood brain barrier ligand of sortilin.~VES001 will be administered orally as a solid within a gelatine capsule without excipients; the capsule strength will be 180 mg."
223861340|NCT05301556|OTHER|Experimental Product|"* Before the surgery: FSMP provides daily target energy needed by participants~* 1-2 days after surgery: Start FSMP and advance as tolerated to achieve 20% of the daily target energy needed by participants~* 3rd-5th day after surgery: Gradually increase FSMP intake every day as tolerated to provide 30-80% of the daily target energy needed by participants~* 6th to 11th day after surgery. FSMP provides daily target energy needed by participants"
223861341|NCT05301556|OTHER|Control Product|"* Before surgery: TPF-T provides daily target energy needed by participants~* 1-2 days after surgery: Start TPF-T and advance as tolerated to achieve 20% of the daily target energy needed by participants~* 3rd-5th day after surgery: Gradually increase TPF-T intake every day as tolerated to provide 30-80% of the daily target energy needed by participants~* 6th to 11th day after surgery. TPF-T provides daily target energy needed by participants"
223861342|NCT05356819|DEVICE|Smart Capnography™, Microstream®|patients monitored by capnograph
223861343|NCT00762619|DRUG|Fluoride|Brush twice daily
223861344|NCT00762619|DRUG|Triclosan, fluoride|Brush twice daily
223861345|NCT00890786|DRUG|Temozolomide|"High Grade Glioma Temozolomide during radiotherapy: 90mg/m2/day PO daily (for patients ≤ 18 years of age); 75mg/m2/day PO daily (for patients ≥ 19 years of age); must begin by Day 5 of radiotherapy for a total of 42 days consecutively.~High Grade Glioma Temozolomide during maintenance chemotherapy: 150mg/m2/day PO on Days 1-5."
223861346|NCT00890786|DRUG|Bevacizumab|"High Grade Glioma Bevacizumab during radiotherapy: 10 mg/kg as a 90 minute infusion on Day 22 (± 2 days)and Day 36 (± 2 days) of radiotherapy.~High Grade Glioma Bevacizumab during maintenance chemotherapy:10 mg/kg as a 90 minute infusion on Day 1 (+ 2 days)and Day 15 (± 2 days) of each course.~Diffuse Intrinsic Pontine Gliomas Bevacizumab during radiotherapy: 10 mg/kg as a 90 minute infusion on Days 1 (+ 2 days),15, 29, and 43(±2 days for all 3 doses) of radiotherapy.~Diffuse Intrinsic Pontine Gliomas Bevacizumab during maintenance chemotherapy: 10 mg/kg as a 90 minute infusion on Day 1 (+2 days)and 15 (±2 days)."
223861347|NCT00890786|DRUG|Irinotecan|"High Grade Glioma Irinotecan during maintenance chemotherapy:125 mg/m2/day IV over 90 minutes on Days 1 (+ 2 days)and 15 (±2 days) of each course, given no sooner than one hour after temozolomide on Day 1.~Diffuse Intrinsic Pontine Gliomas Irinotecan maintenance chemotherapy: 125 mg/m2/day IV on Day 1 (+2 days)and Day 15 (±2 days)."
223861348|NCT05073718|DRUG|Low-dose acetylsalicylic acid|In case of being positive for SARS-CoV-2 PCR or antigen test, she will be randomised 1:1 to receive daily LDASA (125 mg) or placebo, up to 36 weeks of pregnancy.
223861349|NCT05073718|DRUG|Placebo|Placebo
223861350|NCT04891887|BEHAVIORAL|Health education program|"Seven face to face sessions and group discussion health education sessions. Two prepared booklets were distributed to all attendants titled Diabetes mellitus and how to control its complications and Mild cognitive impairment and how to prevent it.~Lab results were discussed individually with each participant to discuss his adherence to the lifestyle modification program.~Clinical follow-up and management with endocrinology and neurology specialists. Individualized Medical Nutrition. Participants were then counselled on healthy eating habits.~Individualized biweekly follow-up scheme through mobile phone. A WhatsApp group was created for all participants to contact the research team whenever they have any inquiry concerning life style modifications. Through this group, 12 HE audio electronic messages were shared with participants.~Final reassessment of clinical status and laboratory profile was carried out with participants who continued till the end of the study."
223861351|NCT01138215|BIOLOGICAL|VZV vaccination|Dose : 0.5 ml Route : subcutaneous injection (SC)
223861352|NCT02341924|OTHER|Portfolio of functional foods|
223861353|NCT02341924|OTHER|Control foods|
223861354|NCT01523249|DEVICE|Lumbar 3D ultrasound scanning and palpation (Ultrasonix )|Paramedian ultrasound scanning of L2-3 and L3-4 lumbar interspaces to visualize ligamentum flavum. Palpation of the same intervertebral spaces to identify spine midline and needle insertion point.
223861355|NCT00227032|DRUG|erlotinib hydrochloride|"300 mg, per day for subjects taking EIAEDs~150 mg, per day for those NOT taking EIAEDs"
223861356|NCT01705249|DRUG|1.0 mg estradiol / 0.5 mg norethisterone acetate (NETA)|After a screening period of 12 weeks (three lunar months) in which the subjects still are on Trisekvens® followed by a treatment period of 24 weeks (six lunar months) in which the subjects are treated with Activelle®.
223861357|NCT04158999|DEVICE|milk analyzer|Human Milk Sample
223861358|NCT04158999|BEHAVIORAL|Mother's nutrition values|evaluation of nutritional elements of maternal onset with Bebis Program
223861359|NCT01370707|DRUG|Metformin|1000\~1500mg/day, 24weeks
223861360|NCT01370707|DRUG|CJ-30001/CJ-30002|0.6/1500mg\~0.9/1500mg/day, 24weeks
223861361|NCT00202748|BEHAVIORAL|Increase in activity to control weight|
223861362|NCT00202748|BEHAVIORAL|Increase in activity to control weight.|
223861363|NCT02813252|GENETIC|JCAR015|No study drug is administered in this study. Patients who received JCAR015 in a previous trial will be evaluated in this trial for long-term safety and efficacy.
223861364|NCT06027372|DEVICE|"LARGAN ECG Holter"|"wear LARGAN ECG Holter during sleep once after completion of pulmonary function test"
223861365|NCT05032937|DRUG|domestic polysaccharide superparamagnetic iron oxide nanoparticle|Patients will receive contrast-enhanced cardiac magnetic resonance with polysaccharide superparamagnetic iron oxide nanoparticle before percutaneous coronary angiography.Patients received intravenous polysaccharide superparamagnetic iron oxide nanoparticle before magnetic resonance imaging.
223861366|NCT01964469|BEHAVIORAL|mobile & web-based action plan|Evidence-based best practice primary care asthma program including asthma self-management education replacing the written self-management action plan with the Breathe mobile health and web-based application
223861367|NCT00622830|DRUG|SB-480848 (Darapladib)|
223861368|NCT05250141|DRUG|Levodopa 250mg and Carbidopa 25mg Test Drug tablet|Investigational Medicinal Product
223861369|NCT05250141|DRUG|Levodopa 250mg and Carbidopa 25mg Referent Product tablet|Sinemet (Savio Industrial S.R.L, Brazil)
223861370|NCT00002527|DRUG|aspirin|
223861371|NCT00002527|OTHER|placebo|
223861372|NCT03824080|DRUG|Bemcentinib|"Bemcentinib will be self-administered orally (fasted) at a dose mentioned above for a total of at least 4 cycles daily.~Responding patients (defined as at least stable disease) are eligible for up to 5 additional cycles according to the maintenance daily dosing of 2 x 1 capsules of 100 mg for each 28 days cycle (up to 9 cycles in total)."
223861373|NCT01063517|DRUG|olaparib|100mg BID oral tablet continuous
223861374|NCT01063517|DRUG|paclitaxel|iv infusion 80mg/m2 on Day 1, 8 and 15 of a 28 day cycle
223861375|NCT01063517|DRUG|Placebo|100mg BID oral tablet to match olaparib tablet
223861376|NCT02041104|DIETARY_SUPPLEMENT|Bread with added beta-glucans|Participants will daily consume bread with high content of beta-glucans. They will approximately consume 6 g beta-glucans per day in 200 g of bread. Intervention period will be 4 weeks. Meanwhile the participants will remain their usual eating habits except consuming any pro- or pre-biotics
223861377|NCT02041104|DIETARY_SUPPLEMENT|Placebo Comparator: Bread without added beta-glucans|Participants will daily consume placebo bread without any added beta-glucans (approximately 200 g per day). Intervention period will be 4 weeks. Meanwhile the participants will remain their usual eating habits except consuming any pro- or pre-biotics.
223861378|NCT04013646|DRUG|Umbilical cord blood infusion|The umbilical cord blood is donated umbilical cord blood which is stored in the cord blood bank donated by Cha Hospital. The total number of nuclear cells should be at least 2 x 10 7 / kg, and at least three out of six of the six human leukocyte antigens (HLA-A, B, DR) should be selected. The cord blood that matches ABO and Rh blood type is preferentially used. Umbilical cord blood infusion is administered intravenously and is performed at the stem cell clinical trial center. The procedure is performed by the doctor who is enrolled in this study. Monitor pulse and oxygen saturation during the procedure.
223861379|NCT04013646|DRUG|Erythropoietin injection|Recombinant human erythropoietin is used and is administered intravenously at a maximum of 5 times at a rate of 500 IU / kg 2 times/week after cord blood peripheral blood infusion, calculated as the dose per body weight. Or subcutaneous administration if intravenous administration is not possible. Store in a sealed container at 2-8 °C in the refrigerator before dosing. Erythropoietin injection is performed at the stem cell clinical trial center. The procedure is performed by the doctor who is enrolled in this study. Monitor pulse and oxygen saturation during the procedure.
223861380|NCT04013646|DRUG|Placebo umbilical cord blood infusion|Placebo umbilical cord blood infusion is administered intravenously and is performed at the stem cell clinical trial center. The procedure is performed by the doctor who is enrolled in this study. Monitor pulse and oxygen saturation during the procedure.
223861381|NCT04013646|DRUG|Placebo erythropoietin injection|Placebo erythropoietin injection is performed at the stem cell clinical trial center. The procedure is performed by the doctor who is enrolled in this study. Monitor pulse and oxygen saturation during the procedure.
223861382|NCT04013646|PROCEDURE|Active rehabilitation|Physical therapy and occupational therapy are performed daily.
223861383|NCT04423328|BEHAVIORAL|acupressure|self-acupressure
223861384|NCT03799536|DRUG|Sotalol|Sotalol, Tablets,160 mg, manufactured by Pharmtechnology LLC, Belarus
223861385|NCT03799536|DRUG|Sotalex|Sotalex, Tablets,160 mg, manufactured by Bristol-Myers Squibb GmbH \& Co. KGaA, Germany
223861386|NCT06512714|OTHER|A diagnosis of mycetoma in a medical, radiologic, or laboratory record.|For each patient, data will be extracted for each clinical, laboratory or radiologic visit related to the condition that may meet this study's case definition.
223861387|NCT03984617|OTHER|Emergency visit in a French tertiary Maternity hospital (Maternity of Nancy)|total number of visits (hospitalizations and consultations)
223861388|NCT04181307|BEHAVIORAL|BE-EHR module|The BE-EHR module includes six components: 1) a tailored advisory for patients over 75 with diabetes, 2) medication refill protocol with information on Choosing Wisely guidelines, 3) pre-population of the medication preference list with metformin, 4) lab result protocol with information on Choosing Wisely guidelines, 5) peer comparisons regarding performance meeting guidelines, and 6) media campaign with information about Choosing Wisely guidelines. The set of nudges is referred to collectively as the BE-EHR module.
223861389|NCT00333658|BEHAVIORAL|Goal setting and work feedback group|Goal setting and feedback using WBI
223861390|NCT04063410|PROCEDURE|Angiography|Undergo standard of care CTA
223861391|NCT04063410|PROCEDURE|MRI-Based Angiogram|Undergo pPCA
223861392|NCT04063410|OTHER|Quality-of-Life Assessment|Ancillary studies
223861393|NCT01682200|DRUG|ProOxy|Clean the face with ProOxy facial wash before spraying ProOxy on the face enough to wet it twice daily, upon waking up and before bedtime.
223861394|NCT01257074|DRUG|Acyclovir 50mg/g|Cream, dose 5 times daily during 5 days
223861395|NCT01257074|DRUG|Penciclovir 10mg/g|Cream, dose 5 times daily during 5 days
223861396|NCT01382030|DRUG|EIA chemotherapy|ifosfamide 1500 mg/m² iv days 1 - 4, etoposide 125 mg/m² iv days 1 and 4, and adriamycin 50 mg/m² iv day 1
223861397|NCT00617201|DRUG|atomoxetine|Once daily oral dosing
223861398|NCT00617201|DRUG|placebo|Once daily oral dosing - matched placebo
223861399|NCT00184925|PROCEDURE|Tracheostomy|trachesotomy with subglottic drainage
223861400|NCT00184925|DEVICE|cannula with subglottic drainage|
223861401|NCT04680871|DEVICE|In-Ear Sensor|The device will passively monitor participants' biometrics
223861402|NCT03943459|DRUG|Quercetin|Quercetin 250 mg BID
223861403|NCT05619107|DEVICE|Active Transauricular nerve stimulation|The first allocated intervention will be undertaken for 30 minutes. The electrode placement and stimulation parameters are described in the arm/group section. After the 30-minute intervention, day 1 of the protocol will be complete. The investigator will remain present in the room with the participant to ensure compliance and adherence to the protocol. The allocated intervention will then be repeated by the participant at a similar time of day for 7 consecutive days. The investigator will arrange video-calls with the participant whilst off-site to ensure ongoing compliance and adherence to the protocol. On the seventh day, participants return to the clinical research facility to take the final first allocated intervention. A 14-day rest period will follow. Then the participants will perform the same 7-day protocol for the opposite intervention to their first treatment allocation.
223861404|NCT05619107|DEVICE|Sham transauricular nerve stimulation|Protocol as for active but sham ear leads are applied, unable to deliver current.
223861405|NCT00003292|DRUG|ifosfamide|
223861406|NCT04220359|DEVICE|non-invasive monitoring|Prospective monitoring with retrospective big-data analysis
223861407|NCT00546871|DRUG|Immune Globulin Intravenous (Human), 10%|Intravenous administration in Study Part 1, subcutaneous administration in Study Parts 2 and 3
223861408|NCT06060002|PROCEDURE|Group A - Stent exchange if cholecystectomy dated beyond 3 months|Stent removal and cholangiogram and stone clearance (if recurrent stone/s is/are found). Stent exchange if cholecystectomy dated beyond 3 months
223861409|NCT06060002|DIAGNOSTIC_TEST|Group B - Diagnostic EUS/MRCP/USG abdomen and LFT at 3 months|Diagnostic EUS/MRCP/USG abdomen and LFT at 3 months to see recurrence of CDL. ERC and stone clearance (if recurrent stone/s found on EUS/MRCP/USG abdomen)
223861410|NCT00396851|DRUG|Gurmar|
223861411|NCT00396851|DRUG|Metformin|
223861412|NCT01713946|DRUG|RAD001|Everolimus tablets for oral suspension (dispersible tablets) were packaged as 2 mg tablets in blister packs and placed in boxes with color-coded labels, color 1 or color 2.
223861413|NCT01713946|DRUG|Placebo|Placebo tablets for oral suspension (dispersible tablets) were packaged as 2 mg tablets in blister packs and placed in boxes with color-coded labels, color 1 or color 2.
223861414|NCT01713946|DRUG|Antiepileptic drug (1 to 3 only)|no more than any 3 of the listed antiepileptic drugs could be taken with the study drug or placebo. List of allowed antiepileptic drugs were: valporic acid, carbamazepine, clobazam, N-desmethylclobazam, topiramate,TRI477, TRI476, clonazepam, zonisamide, phenobarbital, phenytoin
223861415|NCT01713946|DRUG|open label RAD001 (only used for post-extension phase)|everolimus tablets for oral suspension (dispersible tablets) were packaged as 2 mg tablets in blister backs in boxes with open label design and were taken during the Post-Extension phase, where all the participants, including those who were previously on placebo, took the 2mg tablets.
223861416|NCT03183518|OTHER|Facial micellar cleanser|Each participant will have the test product applied topically via semi occlusive patch, on-site by a technician.
223861417|NCT03183518|OTHER|Saline Solution: Sodium Chloride (NaCl; 0.9%)|Each participant will have the reference product applied topically via semi occlusive patch, on-site by a technician.
223861418|NCT02827617|DRUG|Ibrutinib|Treatment with ibrutinib 420 mg quaque die in the clinical practice
223861419|NCT05265559|PROCEDURE|Partial Indirect Restoration|Dental restorative treatment
223861420|NCT03446482|OTHER|observation of differents tasks|Evaluation by an external observer (nurse student in research stage or clinical research technician) of the distribution of medical time for the performance of the different tasks of anesthesiologist (in minutes)
223861421|NCT00681252|BIOLOGICAL|URLC10, VEGFR1 and VEGFR2|Patients will be vaccinated twice a week for 8 weeks. On each vaccination day, the URLC10 peptide (1mg), VEGFR1 peptide (1mg) and VEGFR2 peptide (1mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection in combination with S-1 chemotherapy.
223861422|NCT01910636|DRUG|Sofosbuvir|Sofosbuvir 400 mg tablet administered orally once daily
223861423|NCT01910636|DRUG|RBV|Ribavirin (RBV) tablets were administered orally in a divided daily dose according to package insert weight-based dosing according to the approved Copegus labeling in Japan (\< 60 kg = 600 mg , \> 60 kg to ≤ 80 kg = 800 mg, and ≥ 80 kg = 1000 mg)
223861424|NCT00283374|PROCEDURE|Laparoscopic Roux-en-Y Gastric Bypass|
223861425|NCT04851561|DIAGNOSTIC_TEST|Cardiopulmonary stress test (CPET)|Cardiopulmonary stress test will be conducted under the guidance of sports and exercise physicians and nursing staff. Electrocardiogram, spirometry, blood pressure and gas exchange measuring will be assessed at rest. The participants will then undergo CPET according to a modified Astrand treadmill test protocol. The test will be terminated at maximal exercise or upon the appearance of limiting symptoms. Continuous electrocardiogram and repeated blood pressure measuring will be conducted at the recovery phase. Post-exercise spirometry will also be assessed.
223861426|NCT06269874|DIAGNOSTIC_TEST|microvascular function assessment|mircovascular function parameters will be measured by administering adenosine in two different pathways
223861427|NCT01946035|DRUG|Doxazosin XL|
223861428|NCT01946035|OTHER|Placebo|
223861429|NCT05358730|OTHER|Standard Exercise|Glenohumeral exercises, scapulothoracic exercises, stretching exercises and mobilization exercises were performed under the supervision of a physiotherapist two days per week for six weeks at the clinical setting (Celik and Kaya Mutlu, 2016).
223861430|NCT05358730|OTHER|Instrument Assisted Soft Tissue Mobilization (IASTM)|IASTM treatment was applied to the posterior-anterior-middle deltoid, latissimus dorsi, teres major, teres minor, supraspinatus and infraspinatus muscle fibers, superficial and deep fascia. IASTM was applied in parallel and vertical direction to the muscle fibers treated with the instrument at a 45° angle, each technique (SWEEP, BRUSH (straight short steps) techniques) for 20 seconds (Ikeda, Otsuka, Kawanishi, and Kawakami, 2019). It was performed two days per week for six weeks.
223861431|NCT05358730|OTHER|Home Exercise|"Hme exercise program consisted of glenohumeral exercises, scapulothoracic exercises, stretching exercises and mobilization exercises.~It was asked to perform two days per week for six weeks."
223861432|NCT06673602|DRUG|FCYC+Conventional treatment|Conventional treatment combined with oral administration of FCYC (four capsules, three times a day, orally) for a 12-week course of treatment.
223861433|NCT06673602|DRUG|conventional treatment|The control group will receive the current gold standard treatment for ICH according to the guidelines (AHA/ASA 2022). This involves blood pressure and care.
223861434|NCT06675994|DRUG|PCSK9 Antibody, PCSK9 Enzyme|In-vitro demonstration of the direct effect if the PCSK9 enzyme on platelets. The study will use commercially available recombinant PCSK9 enzyme to promote platelet activity and the PCSK9 antibody to inhibit activity. In each patient, platelet function testing will occur in the absence of PCSK9 enzyme, after the addition of PCSK9 enzyme, and after the addition of both PCSK9 enzyme and antibody reagent to the blood sample prior to testing.
223861435|NCT06676956|PROCEDURE|Order of bronchoscopy procedures for peripheral nodule biopsy|Patient scheduled to undergo peripheral nodule biopsy of the lung under bronchoscopy typically get both a nodule biopsy as well as a linear EBUS of the lymph nodes to assess for any disease spread. This procedure will randomize patients to either getting the peripheral nodule first or linear EBUS of the lymph nodes first and assess overall diagnostic yield as the primary outcome.
223861436|NCT06677333|OTHER|Whey Protein|This intervention will add 50 g of a whey or pea protein supplement to their usual dietary intake.
223861437|NCT06677333|OTHER|Pea protein|This intervention will add 50 g of a pea protein supplement to their usual dietary intake.
223861438|NCT06620614|COMBINATION_PRODUCT|0.5% Heavy Bupivacaine|There are two groups.
223861439|NCT06631716|DEVICE|CVT|During mechanical ventilation, patients with atelectasis confirmed by chest CT, chest X-ray or lung ultrasound should be treated with mechanical assisted sputum evacuation, and the mechanical assisted sputum evacuation equipment used is CVT.
223861440|NCT06631716|DEVICE|HFCWO|During mechanical ventilation, patients with atelectasis confirmed by chest CT, chest X-ray or lung ultrasound should be treated with mechanical assisted sputum evacuation, and the mechanical assisted sputum evacuation equipment used is HFCWO.
223861441|NCT06631716|DEVICE|MetaNeb|During mechanical ventilation, patients with atelectasis confirmed by chest CT, chest X-ray or lung ultrasound should be treated with mechanical assisted sputum evacuation, and the mechanical assisted sputum evacuation equipment used is MetaNeb.
223861442|NCT06632067|DRUG|sugammadex|sugammadex used for neuromuscular reversal
223861443|NCT06632067|DRUG|Neostigmine + Atropine|Neostigmine and Atropine used for neuromuscular reversal
223861444|NCT06628661|PROCEDURE|Surgery for HCC larger than 6.5 cm|Surgery for HCC larger than 6.5 cm without mVI
223861445|NCT06628661|PROCEDURE|Surgery for HCC larger than 2 cm|Surgery for HCC larger than 2 cm with mVI
223861446|NCT06713200|PROCEDURE|High intensity percutaneous electrolysis|A sterile, disposable stainless steel needle of different lengths depending on the area to be treated will be connected to the EP device; the gauge of these needles will be 0.25 mm. A current of 3 mA will be applied for 3 times with a duration of 3 seconds each. In order to avoid biases, the technique will be performed for 90 seconds as in the low intensity treatment group and in the last 20 seconds the current will be applied with the parameters previously described. Three sessions divided in three consecutive weeks will be applied.
223861447|NCT06713200|PROCEDURE|Low intensity Percutaneous Electrolysis|This technique will be performed with the same instrument as the high intensity technique. It differs from the previous treatment group in that the current intensity in this case will be of an amperage of 0.3mA during 90 seconds. In the same way, 3 sessions divided in 21 consecutive days will be applied.
223861448|NCT06713200|PROCEDURE|Simulated Percutaneous Electrolysis|The needle and PD device will be connected in the same way as for the other treatment groups. The needle will be inserted without reaching the lesion area and the characteristic sound of turning on the PD machine will be made. It will last 90 seconds and at no time the galvanic current will be applied. The same aseptic precautions will be applied, in addition to performing the same final hemostasis guidelines and providing the same post-treatment guidelines as for all the other subjects in the study.
223861449|NCT06711393|OTHER|Exercise|Traditional home exercise including balance and muscle strength training 15 minutes at the time and three times over the week. In addition, game-based exercises 15 minutes at the time and three times over the week.
223861450|NCT06711393|OTHER|Exercise as usual|Traditional home exercise including balance and muscle strength training 15 minutes at the time and three times over the week without exergaming.
223861451|NCT06711900|DRUG|SKB264|IV Infusion
223861452|NCT06711900|DRUG|Pembrolizumab|IV Infusion
223861453|NCT06711900|DRUG|pemetrexed|IV Infusion
223861454|NCT06711900|DRUG|carboplatin or cisplatin|IV Infusion
223861455|NCT06713876|DEVICE|VA-ECMO-assisted PCI|A total of 220 consecutive patients with VA-ECMO-assisted PCI will be enrolled. Data related to medical history, procedural characteristics, and outcomes were collected. Clinical follow-up will be conducted in the periprocedural and postoperative at 1 month, 1 year, 2 years, 3 years, 4 years, and 5 years.
223861456|NCT06711237|OTHER|self-adhesive resin cement (RC)|Single-unit implant-supported single crowns were cemented to the abutments using a self-adhesive resin cement (RC). Residual cement was removed, and the restorations were retrieved for analysis of cement remnants.
223861457|NCT06711237|OTHER|resin-modified glass-ionomer cement (RMGIC)|Single-unit implant-supported single crowns were cemented to the abutments using a resin-modified glass-ionomer cement (RMGIC). Residual cement was removed, and the restorations were retrieved for analysis of cement remnants.
223861458|NCT04493242|BIOLOGICAL|ExoFlo|Intravenous administration of bone marrow mesenchymal stem cell derived extracellular vesicles
223861459|NCT04493242|OTHER|Intravenous normal saline|Placebo
223861460|NCT05632068|DRUG|Xian-Hua-Cha|Zizyphus jujuba Mill., Nelumbo nucifera Gaertn, Citrus reticulata Blanco, Rosa rugosa Thunb., Cassia obtusifolia L., Stevioside, resistant starch, and water
223861461|NCT01125761|DRUG|dexamethasone 0.5 mg and 1.0 mg clemastine cream|The treatment should be administered every 12 hours so that a thin layer is applied on the lesions, for 14 days.
223861462|NCT01125761|DRUG|Dexamethasone 0,5 mg cream|The treatment should be administered every 12 hours so that a thin layer is applied on the lesions, for 14 days.
223861463|NCT01942707|PROCEDURE|abdominoplasty with Scarpa's Fascia|During surgical detachment of the abdominal flap the Scarpa´s fascia is preserved.
223861464|NCT01942707|PROCEDURE|Abdominoplasty without Scarpa´s Facia|During surgical detachment of the abdominal flap the Scarpa´s fascia is removed.
223861465|NCT04045470|DEVICE|Microdevices|The microdevice was developed as a tool with the ultimate goal to help screen several existing and investigational drugs directly within a patient's tumor to identify what drugs are the most effective for treating a patient's cancer.
223861466|NCT04045470|OTHER|Standard of care therapy|Participant to receive standard of care therapy as previously determined by participant's treating oncologist and/or dermatologist, which may include a skin-directed or systemic therapy
223861467|NCT04045470|OTHER|Standard of care systemic therapy|Participant to receive standard of care therapy as previously determined by participant's treating oncologist and/or dermatologist, which must include a systemic therapy.
223861468|NCT01473719|BEHAVIORAL|motivational intervention|7-session individual motivationally-based intervention
223861469|NCT01473719|BEHAVIORAL|health education|7 individual sessions focusing on health education
223861470|NCT01230047|BEHAVIORAL|Psychoeducational course|Psychoeducational course on mindfulness and lifestyle interventions for depression and anxiety
223861471|NCT04857944|BEHAVIORAL|IDEA program (Improving depressive symptoms through personalised exercise and activation)|The program will consist of six 90-minute group sessions composed of four to six participants. These short intervention sessions will be distributed in one month, with a frequency of once or twice a week depending on the week of the program. Of the six sessions, two will be exercise-oriented and will include on-site practice. The remaining four sessions will include definitions of depressive symptomatology, the relationship between depression and having an active lifestyle, motivation and barriers towards exercise, and maintenance strategies.
223861472|NCT04857944|DEVICE|IDEApp|An ad-hoc app (IDEApp) combined with a fitness tracker to register and store participants' physical activity, exercise compliance, and sleep patterns. The app will deliver motivational or awareness messages when the fitness tracker detects non-compliance with the exercise prescription, physical activity decreases, or altered sleep patterns.
223861473|NCT03180905|DEVICE|ImPACT Online/Paper Pencil Tests|Compare ImPACT Online versus Paper and Pencil Neurocognitive Tests
223861474|NCT03180905|DEVICE|ImPACT Online|ImPACT Online will be administered at 2 time points.
223861475|NCT05903027|DRUG|Rimegepant 75 MG Disintegrating Oral Tablet|Patients using Rimegepant 75 mg orally disintegrating tablet to treat acute migraine attacks
223861476|NCT00590382|DEVICE|AMPLATZER Muscular VSD Occluder|AMPLATZER Muscular VSD Occluder
223861477|NCT05709899|OTHER|nerve blocks|Comparison of ultrasound-guided erector spinae plane block and transmuscular quadratus lumborum block for postoperative analgesia in abdominal cancer surgeries.
223861478|NCT05564533|BEHAVIORAL|Heart-Smile Training Intensive Introduction Program (HST-IIP)|"Heart-Smile Training (HST) is an interoceptive compassion program designed to develop the qualities of compassion, empathy, and kindness for oneself and others with a focus on interoceptive awareness. It is unique from other compassion trainings in its focus on 1) embodiment of warmth and tenderness of compassionate feeling with a compassionate body scan meditation, 2) development of an authentic presence, characterized by a warm feeling of loosened attachment to ego-based self, and 3) cultivation of joy triggered by genuine smile to oneself. HST-IIP is a 3-day/4-week/1-day interoceptive compassion program that shares the same core elements and practices as HST 3-day intensive program. Unlike HST, the format of the HST-IIP has an extended duration to develop self-regulation through the cultivation of emotional and behavioral regulation."
223861479|NCT04513522|BIOLOGICAL|Nivolumab|Specified dose on specified days
223861480|NCT04513522|BIOLOGICAL|Ipilimumab|Specified dose on specified days
223861481|NCT05218044|PROCEDURE|Cryoablation|The cryoprobe tip will be inserted into the breast and directed under ultrasound guidance to the location where the ultrasound visible marker is located. Next, the cryoprobe will be used to freeze a 4 X 3 X 3 cm diameter area of DCIS using two separate 10-minute freeze cycles separated by a single 10-minute thaw cycle. The cryoprobe will remain in place the entire time. After the second freeze, the cryoprobe will be withdrawn from the breast and a bandage will be applied to the skin.
223861482|NCT04599764|OTHER|HD-tDCS|Transcranial direct current stimulation (tDCS) is a non-invasive brain stimulation tool that alters cortical excitability and activity via application of weak direct currents.HD-tDCS was administered using the Soterix 1×1 tDCS Low-Intensity Stimulator and the Soterix 4×1 Adapter. The selection of the electrode montage was based on computational models generating simulated current topography using HD Explore, which demonstrated good current distribution in the left dorsolateral prefrontal cortex (DLPFC). For left DLPFC stimulation, the anodal electrode was placed at the F3 position (using the International 10-20 EEG system), and the 4 return electrodes (cathodes) were placed at positions AFz, FCz, F7, and C5 (4-6 cm from the anode). The center position CZ was aligned with the vertex of the head. During anodal DLPFC stimulation, participants received stimulation at 2 mA for 30 minutes, including a 30-second ramp-up period at the start and a 30-second ramp-down period at the end.
223861483|NCT04599764|OTHER|computer-based cognitive training|Computer-based cognitive training (CCT) is a potentially important tool for individuals at risk of dementia. This trial will employ a computerized multi-domain adaptive training program. This program and training model have been demonstrated to be effective and beneficial in patients with vascular cognitive impairment. In the CCT intervention group, participants will undergo 2 weeks of computerized, multi-domain, adaptive training. The training domains include processing speed, attention, perception, long-term memory, working memory, calculation, executive control, reasoning, and problem-solving. Task rigor varies across domains and determines task grouping. Participants are required to complete 30 minutes of daily training(one session each of six 5-minute tasks).
223861484|NCT04599764|OTHER|Sham tDCS|Transcranial direct current stimulation (tDCS) is a non-invasive brain stimulation tool that alters cortical excitability and activity via application of weak direct currents.HD-tDCS was administered using the Soterix 1×1 tDCS Low-Intensity Stimulator and the Soterix 4×1 Adapter. The selection of the electrode montage was based on computational models generating simulated current topography using HD Explore, which demonstrated good current distribution in the left dorsolateral prefrontal cortex (DLPFC). For left DLPFC stimulation, the anodal electrode was placed at the F3 position (using the International 10-20 EEG system), and the 4 return electrodes (cathodes) were placed at positions AFz, FCz, F7, and C5 (4-6 cm from the anode). The center position CZ was aligned with the vertex of the head. For sham stimulation, participants received only the initial 30-second ramp-up to 2 mA, after which stimulation was immediately terminated.
223861485|NCT06337526|DEVICE|Apple Watch v8|Apple Watch used for data collection only
223861486|NCT00589667|DRUG|Pemetrexed plus Gemcitabine|"Patients will receive pemetrexed (500 mg/m2 IV infusion over approximately 10 minutes) followed immediately by gemcitabine (1250 mg/m2 IV infusion given over approximately 30 minutes) on day 1 and day 15 of a 28-day cycle. Vitamin supplementation will be as follows: Vitamin B12: 1000 µg IM injection no less than 1 week prior to the first dose of pemetrexed, and continuing approximately every 9 weeks until 3 weeks after the last dose of pemetrexed.~Folic acid: The preferred oral daily dose of folic acid is 350 to 1000 µg. Daily folate supplementation begins no less than 1 week prior to the first dose of pemetrexed and continues until 3 weeks after the last dose of pemetrexed.~For rash prophylaxis, dexamethasone (4 mg po twice per day) should be taken on the day before, the day of, and the day after each dose of pemetrexed unless clinical contraindications exist."
223861487|NCT04541303|DRUG|Tranexamic acid|tranexamic acid diluted to concentration of 25ml/mg
223861488|NCT04541303|DRUG|normal saline|0.9% sodium chloride
223861489|NCT05967637|OTHER|Whole body vibration|The vibration will be applied for 10 minutes (30 seconds rest, 30 seconds training, 10 reps) in total with a low frequency (20 HZ) and low amplitude (2mm). Participants will be asked to stand in a squatting position by semi-flexing (30°) their knees during the 30-second vibration period.
223861490|NCT05967637|OTHER|Sham-Whole body vibration|The sham-whole body vibration treatment will follow the same procedures with the vibration machine off.
223861491|NCT03538041|DRUG|Parsaclisib|Parsaclisib administered orally.
223861492|NCT01850836|PROCEDURE|repetitive transcranial magnetic stimulation|
223861493|NCT03759743|DIETARY_SUPPLEMENT|LMT1-48|capsules containing Probiotics
223861494|NCT03759743|DIETARY_SUPPLEMENT|Placebo|capsules that did not contain any probiotics
223861495|NCT02990754|BEHAVIORAL|Physical activity education|Instruction in suitable physical activity options and education about physical activity with CHD.
223861496|NCT06324201|DEVICE|Ablation Procedure|Ablation Procedure for paroxysmal atrial fibrillation
223861497|NCT01266265|DRUG|inhaled prostacyclin|Tyvaso
223861498|NCT01266265|DRUG|inhaled prostacyclin|As prescribed by the physician
223861499|NCT01266265|DRUG|prostacyclin|As prescribed by the physician
223861500|NCT01266265|DRUG|subcutaneous and intravenous prostacyclin|As prescribed by physician
223861501|NCT01266265|DRUG|oral ERA|As prescribed by physician
223861502|NCT01266265|DRUG|oral PDE5 inhibitors|As prescribed by physician
223861503|NCT01580293|BIOLOGICAL|BAY94-9027|Intravenous infusion of BAY94-9027
223861504|NCT00028769|DRUG|bicalutamide|
223861505|NCT00028769|DRUG|estramustine|
223861506|NCT00028769|DRUG|etoposide|
223861507|NCT00028769|DRUG|flutamide|
223861508|NCT00028769|DRUG|goserelin|
223861509|NCT00028769|DRUG|leuprolide|
223861510|NCT00028769|DRUG|nilutamide|
223861511|NCT00028769|DRUG|paclitaxel|
223861512|NCT02170324|DRUG|Exenatide|
223861513|NCT02170324|DRUG|Placebo|
223861514|NCT01645098|DRUG|Ketamine|1 mg/kg IV, additional doses of 0.5 mg/kg as needed
223861515|NCT01645098|DRUG|Dexmedetomidine|0.5 mcg/kg/hr IV
223861516|NCT03816228|DRUG|F 18 T807 Flortaucipir|Participants will receive a single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807. For those who cannot tolerate the full exam, participants will receive single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807.
223861517|NCT00479648|BIOLOGICAL|CSL412|
223861518|NCT00479648|BIOLOGICAL|Inactivated trivalent influenza vaccine|
223861519|NCT04949607|DIETARY_SUPPLEMENT|Inulin fructooligosaccharide|Subjects will be administered inulin at a starting dose of 1g twice daily (2g/day) and ramping up an additional 2g/day until the final dose of 4g twice daily (8g/day), which will continue on until the end of month 3 (week 12). After the month 3 study visit, inulin dosing will begin to ramp down over the next week.
223861520|NCT03814265|BEHAVIORAL|Laughter yoga|440/5000 Laughter yoga; It is an exercise program that combines breathing techniques with unconditional laughter. During the sessions, laughter is simulated by hand clapping and warm-up exercises and by eye contact with other members in the group and by playing childish games with group members. Most of the time this simulation turns into genuine and contagious laughter. Laughter yoga is based on the argument that the brain cannot distinguish between real and unreal laugh.
223861521|NCT06513117|BEHAVIORAL|Behaviour change|healthy conversations to support behaviour change
223861522|NCT06513117|BEHAVIORAL|Dietary support|Guidance on healthy eating
223861523|NCT06513117|BEHAVIORAL|Breathing pattern retraining|guidance on breathing pattern in exercise
223861524|NCT06513117|BEHAVIORAL|Exercise training|Exercise intervention prescribed to participant fitness level
223861525|NCT05499039|DEVICE|High flow nasal cannula (HFNC)|"High flow nasal cannula consists of an apparatus that allows adjustable FiO2 from 21 to 100% and delivers a modified gas flow up to 60 l/ min .~will be set with: -~Temperature at 37°C or 34°C Flow rate 30: 50 L/min. FiO2 will be adjusted to achieve a SpO2 at least 95%"
224076256|NCT04568668|DEVICE|ActionADE|"ActionADE is a software application that allows healthcare providers to document standardized adverse drug event information in a user-friendly and standardized manner. We integrated ActionADE uni-directionally with PharmaNet, a secure province-wide network that links all pharmacies in British Columbia to a central data system. This allows care providers to pull in demographic information and visualize their patient's medication dispensing history.~In 2020, we enabled bi-directional integration with PharmaNet allowing clinicians to transmit standardized adverse drug event information back to the PharmaNet database. The three dominant community pharmacy systems in the geographic area of the trial will display the adverse drug event information in their systems, and generate patient-specific medication-level alerts when pharmacists attempt to re-dispense a culprit medication."
223861526|NCT05499039|DEVICE|Non-Invasive Mechanical Ventilation (NIV)|"Respiratory assistance is provided by a NIV either Puritan Bennet 840 , Engström Carestation or Hamilton-G5 , will be used for conventional non-invasive ventilation via an oronasal mask. Settings will be adjusted based on the clinical assessment of the respiratory therapist . Initial setting includes: -~Positive End Expiratory Pressure (PEEP): 5 cmH2O. Pressure support (PS): 12-20 cmH2O. FiO2 will be adjusted to achieve a SpO2 at least 95% Intervention: Device: non-invasive ventilation"
223861527|NCT02048592|DIETARY_SUPPLEMENT|Impact-Nutridrink|"IMPACT (immunonutrition) will be given in the first 8 weeks. Afterwards the patients will be returned to their previous nutrition support \|(Nutridrink) for another 8 weeks."
223861528|NCT02048592|DIETARY_SUPPLEMENT|Nutridrink-Impact|In this group of patients - the study starts with period of 8 weeks with no change of previous nutrition support (Nutridrink). After 8 weeks the laboratory results will be examined ant the patients will switch to immunonutrition (Impact) for another 8 weeks. After the laboratory examination including oxidative stress parameters will be evaluated.
223861529|NCT01522092|DRUG|escitalopram|5mg-20mg, tablet, od, 12 months
223861530|NCT01664871|DEVICE|DIammine SIlver Fluoride|Concentrations of Silver and Fluoride in the DSF used for study were 24.9% and 5.5%, respectively Average total weight (calculated volume) of Diammine Silver Fluoride applied was 7.57 mg (6.04 µL), corresponding to a mean application of 0.33 mg Fluoride based on the lot analysis. The mean total amount of Silver applied to the 3 teeth was 1.50 mg.
223861531|NCT00939419|OTHER|Health workers TB care group|Patients received daily tuberculosis care in public health facilities by trained health worker during the first 8 weeks followed by self-treatment for the remaining 6 months. Patients were expected to visit public health facility every month for follow up. Supervisory support was given to TB focal persons by the respective district TB coordinators on a monthly basis. Anti-TB drugs were delivered to health institutions on a quarterly basis by district TB coordinators during supervision
223861532|NCT00939419|OTHER|Community health workers TB care group|Patients had daily TB care including observation of treatment by the CHWs in their villages for the second month. Thereafter, treatment was self-administered with a monthly follow up visit to a CHW home for the remaining 6 months. Technical support and anti-TB drugs were given to CHWs by the respective public health facility TB health worker every fortnight.
223861533|NCT00939419|OTHER|Self-administered treatment group|Patients took their medication at home for seven months after one month of daily care in public health facilities by TB health workers. They were taught by the TB health worker to collect their anti-TB drugs fortnightly and report missed daily doses. Follow up assessment and continued support was made by TB health worker on a monthly basis in their nearby health facility.
223861534|NCT01340261|BEHAVIORAL|Questionnaires|Questionnaires are completed at admission, discharge, 1-month, 6 month, and yearly follow-up.
223861535|NCT00768664|DRUG|PF-00299804|45 mg by continuous oral dosing
223861536|NCT03926884|DIETARY_SUPPLEMENT|Three-seeds mixture|mixture of white mustard seeds, radish seeds and beefsteak plant (Korean perilla, a species of Perilla in the mint family, widely cultivated and edible for humans; a daily food for Korean people; many Japanese people drink as tea) seeds
223861537|NCT03926884|DIETARY_SUPPLEMENT|Control|warm water with negligible amount of the three-seeds mixture
223861538|NCT00484614|PROCEDURE|Positron Emission Mammography|Molecular Imaging Device
223861539|NCT00484614|PROCEDURE|Magnetic Resonance Imaging|Imaging Device
223861540|NCT00096967|DRUG|Avastin (bevacizumab)|
223861541|NCT00015990|DRUG|thalidomide|Given orally
223861542|NCT00015990|OTHER|laboratory biomarker analysis|Correlative studies
223861543|NCT04730999|DRUG|Etoposide|Induction phase: 100 mg/sqm on days 1-3, for a maximum of 6 cycles (each one of 21 days duration). Intravenous administration. Treatment will continue until progression of disease, unacceptable toxicity, patient refusal.
223861544|NCT04730999|DRUG|Carboplatin|Induction phase: AUC 5 on day 1 for a maximum of 6 cycles (each one of 21 days duration). Intravenous administration. Treatment will continue until progression of disease, unacceptable toxicity, patient refusal.
223861545|NCT04730999|DRUG|Bevacizumab|"Induction phase: 7.5 mg/kg on day 1, for a maximum of 6 cycles (each one of 21 days duration). Intravenous administration.~Maintenance phase: 7.5 mg/kg on day 1, for a maximum of 12 cycles (each one of 21 days duration). Intravenous administration.~In both phases, the treatment will continue until progression of disease, unacceptable toxicity, patient refusal."
223861546|NCT04730999|DRUG|Atezolizumab|"Induction phase: flat dosing of 1200 mg on day 1, for a maximum of 6 cycles ( each one of 21 days duration). Intravenous administration.~Maintenance phase: flat dosing of 1200 mg on day 1, for a maximum of 12 cycles (each one of 21 days duration). Intravenous administration.~In both phases, the treatment will continue until progression of disease, unacceptable toxicity, patient refusal, loss of clinical benefit."
223861547|NCT02675309|DRUG|MT-8554|
223861548|NCT02675309|DRUG|rosuvastatin|
223861549|NCT02675309|DRUG|simvastatin|
223861550|NCT05790096|BIOLOGICAL|Granulokine|Granulokine is presented in boxes containing vials containing 1,0 mL of solution for injection and 300µg of filgrastim.
223861551|NCT05790096|BIOLOGICAL|Filgrastine|Filgrastine is presented in boxes containing vials containing 1,0 mL of solution for injection and 300µg of filgrastim.
223861552|NCT05505071|DEVICE|DANTE SPACE sequence|investigational MRI sequence less than 15 minutes
223861553|NCT06239948|OTHER|With Music|each subject was placed in a TMS laboratory with music for 20 minutes
223861554|NCT06239948|OTHER|Without Music|each subject was placed in a TMS laboratory without music for 20 minutes
223861555|NCT05263609|DRUG|Axitinib|If pembrolizumab infusions alone do not reduce the patient's tumor size by at least 60%,the patient will be placed in Arm B and start axitinib in addition to continuing pembrolizumab therapy (see Arm B).
223861556|NCT05263609|DRUG|Pembrolizumab|If pembrolizumab results in a reduction in tumor size that is greater than 60%, the patient will be placed in Arm A and continue pembrolizumab infusions (see Arm A).
223861557|NCT00708032|DEVICE|spectacles|habitual spectacles
223861558|NCT00708032|DEVICE|narafilcon A soft contact lenses|narafilcon A daily disposable contact lenses
224076257|NCT02460211|DIETARY_SUPPLEMENT|Vitamin D3|Those randomized to the treatment arm will receive three 50,000 unit oral doses of vitamin D3 supplementation. The first dose will be given the evening before surgery. The second and third doses will be given either orally or per NG tube on days 1 and 2 after surgery.
224076258|NCT02460211|DIETARY_SUPPLEMENT|Placebo|Those randomized to the control arm will receive three placebo doses. The first dose will be given the evening before surgery. The second and third doses will be given either orally or per NG tube on days 1 and 2 after surgery.
224076259|NCT00610142|DRUG|pimecrolimus 1% cream|twice a day one fingertip at a 2 times 2 cm2 area of uninvolved skin on the lateral forehead for 4 weeks
223861559|NCT01012453|BEHAVIORAL|A randomised clinical trial of the effect of classification and individual counselling|The trial to be conducted is a randomised single-blinded parallel study. It is divided in two stages, T = 0 and follow-up at T = 6 months. All included participants will have a clinical examination at the beginning and at follow-up in the trial. Half of the participants will be randomised to intervention, the other half to control. The participants in the intervention group will, after the first clinical examination, pass on directly to the intervention which includes an allergological examination (patch and prick testing). Three days later they will be examined by a physician who will interpret the patch test and give a thorough, individual guidance in skin protection and occupational safety. The clinical examination of all participants at follow-up will reveal the difference in outcomes in the intervention and the control group.
223861560|NCT01807546|DRUG|rigosertib|Oral rigosertib capsules at a dose of 560 mg twice a day for 14 consecutive days of a 21-day cycle (2 weeks on, 1 week off regimen).
223861561|NCT01400776|DRUG|WC3011 Estradiol Vaginal Cream|WC3011 estradiol vaginal cream administered once daily for 2 weeks followed by 2X/week or 3X/week for 10 weeks, total treatment duration 12 weeks
223861562|NCT01400776|DRUG|Vehicle|Vehicle administered once daily for 2 weeks followed by 2X/week or 3X/week for 10 weeks, total treatment duration 12 weeks.
223861563|NCT02624219|DRUG|AS03|AS03 oil-in-water emulsion adjuvant.
223861564|NCT02624219|DRUG|MF59 adjuvant|Microfluoridized adjuvant 59 (MF59) is an oil-in-water emulsion.
224076260|NCT00610142|DRUG|hydrocortison 1% cream|twice a day one fingertip at a 2 times 2 cm2 area of uninvolved skin on the lateral forehead for 4 weeks
223861565|NCT02624219|BIOLOGICAL|Monovalent Influenza A/H5N8 vaccine|Monovalent inactivated influenza A/H5N8 virus vaccine for IM injection. prepared from influenza virus propagated in chicken egg fluid using seed virus prepared from the candidate vaccine virus (CVV), influenza virus A/gyrfalcon/Washington/41088-6/2014(H5N8)-PR8-IDCDC-RG43A (abbreviated as IDCDC-RG43A).
223861566|NCT00002450|DRUG|Tenofovir disoproxil fumarate|
223861567|NCT03648346|DRUG|Cohort 1: HL217 Ophathalmic Solution BID|Two drops of 3 mg/mL of the treatment in one eye twice a day
223861568|NCT03648346|DRUG|Cohort 2: HL217 Ophathalmic Solution QID|Two drops of 3 mg/mL of the treatment in one eye 4 times a day
223861569|NCT03648346|DRUG|Placebo|Placebo eye drops
223861570|NCT00837746|DRUG|risedronate|risedronate tablet, 5 mg daily or 35 mg once weekly for 5 years
223861571|NCT01314352|DRUG|Desloratadine|Desloratadine Tablets, 5 mg
223861572|NCT02174393|DRUG|Universal Peel|Universal Peel: is a chemical peel consisting of a mild acid solution. (5 min Peel and 5 min Retinol)
224076261|NCT00880815|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo ASCT
224076262|NCT00880815|BIOLOGICAL|Anti-Thymocyte Globulin|Given IV
224076263|NCT00880815|DRUG|Bendamustine|Given IV
224076264|NCT00880815|BIOLOGICAL|Filgrastim|Given IV
224076265|NCT00880815|DRUG|Fludarabine|Given IV
224076266|NCT00880815|DRUG|Methotrexate|Given IV
224076267|NCT00880815|BIOLOGICAL|Rituximab|Given IV
224076268|NCT00880815|DRUG|Tacrolimus|Given IV and PO
223861573|NCT02174393|PROCEDURE|Microneedling|"Microneedling: is a device for all skin types that creates micro injuries in the dermis (layer of the skin underneath the outermost layer) in an attempt to trigger new collagen (natural component of skin tissue) production for smoother, firmer and younger-looking skin.~For this protocol, the needle depth will be increased over the 3 sessions:~Forehead: 0.75 mm, 0.85 mm, 1.0 mm. Cheeks/Chin: 1.0 mm, 1.5 mm, 2.0 mm.~Each Session: Microneedling procedure on Day 1, followed by skin care regimen"
223861574|NCT02174393|DRUG|Post-Microneedling Skin Care|"On Day 1 (after Microneedling procedure):~* Gentle Antioxidant Soothing Cleanser daily~* Soothing Recovery Ointment and Sheer Physical Sunscreen~On Day 2-7:~* AM: Physical sheer sunscreen and recovery ointment~* PM: Retinol/Vitamin C in the evening and soothing recovery ointment~On Day 7:~* AM: BD Hydrating Day/Night Cream~* PM: Retinol and Vitamin C and the BD Hydrating Day/Night Cream (if necessary)"
223861575|NCT02174393|DRUG|Post-Universal Peel Skin Care|"* Gentle Antioxidant Soothing Cleanser daily~* Physical Sunscreen daily~* Soothing recovery ointment fortified with silver only when peeling occurs~* After completely peeling, vitamin c product in the morning and the retinol in the evening"
223861576|NCT02797717|RADIATION|Radiotherapy:|"All patients will have 2 OPEAcycles(chemotherapy cycle:Vincristine,Etoposide,Prednisone,doxorubicin) ,After assignment ( by randomization) to one of the arms the patient will be treated accordingly . response assessment will be done after OPEA cycles (ERA) and after cycles of copdac 28 or DECOPDAC 21(LRA).according to the assessments results patients will have radiotherapy or not."
223861577|NCT02797717|DRUG|Vincristine|ARM A and ARM B
223861578|NCT02797717|DRUG|Etoposide|ARM B , 100mg/m2/day
223861579|NCT02797717|DRUG|Prednisone|ARM A and ARM B , 40mg/m2/day p.o
223861580|NCT02797717|DRUG|Doxorubicin|ARM B , 25mg/m2
223861581|NCT02797717|DRUG|Dacarbazine|ARM A and ARM B , 250mg/m2 i.v
223861582|NCT02797717|DRUG|Cyclophosphamide|ARM A and ARM B , 625mg/m2 i.v
223861583|NCT01291290|PROCEDURE|Platelet|2 portions of platelets (one portion = pooled from 4 donors, 350ml) infused when diagnosed with rAAA and vascular surgeon accepts to receive the patient, infused before transportation.
223861584|NCT00944333|DRUG|Clopidogrel|300-600 loading dose 75 mg/die for 6 months
223861585|NCT00944333|DRUG|Clopidogrel|300-600 loading dose 75 mg/die for 12 months
223861586|NCT03109223|OTHER|sole source nutrition|Infant formula
223861587|NCT00423098|DRUG|Mycophenolate sodium|Mycophenolate sodium as administered orally for 2 weeks at 1440mg daily and then increased to 2160mg daily for 22 weeks.
223861588|NCT00423098|DRUG|Prednisone|Oral prednisone or prednisone equivalent was started on Day 4 and subsequently tapered every 2 weeks according to the patient's weight.
223861589|NCT00423098|DRUG|Methylprednisolone|All patients received bolus therapy with 0.5 g of intravenous Methylprednisolone per day for 3 consecutive days.
223861590|NCT04891835|OTHER|Data extraction from medical files|Data extraction from medical files
223861591|NCT06020963|PROCEDURE|Low Intensity Shockwave Therapy (LiSWT)|Low Intensity Shockwave Therapy (LiSWT) has been used for many years. Its mechanism is to use shock wave energy to promote angiogenesis to achieve the functions of tissue repair and cell regeneration.
223861592|NCT06020963|DRUG|Tamsulosin|Tamsulosin is a selective alpha-1 blocker, its main function is to relax the smooth muscles of the base of the prostate, urethra, and bladder, and improve lower urinary tract symptoms.
223861593|NCT05813899|DIETARY_SUPPLEMENT|PS23 heat-treated|PS23 heat-treated, 2 caps daily use
223861594|NCT04184336|OTHER|surveillance|
223861595|NCT00309595|DEVICE|stent|Cordis SMART™ Nitinol Stent System
223861596|NCT00309595|DEVICE|balloon|balloon angioplasty
223861597|NCT00014794|DRUG|15-O labeled water|
223861598|NCT06552676|PROCEDURE|Percutaneous tracheostomy|Percutaneous tracheostomy is a widely used technique in intensive care. It involves creating a passage between the tracheal lumen and the outside, through which a cannula is placed.
223861599|NCT01012388|DEVICE|Radiesse® Injectable Dermal Filler|Calcium hydroxylapatite particles suspected in an aqueous based gel carrier
223861600|NCT06210334|DRUG|Tislelizumab|Tislelizumab 200mg, iv, d3, q3w
223861601|NCT06210334|DRUG|Lenvatinib|Lenvatinib 8mg (\<60kg) or 12mg (≥60kg), po, qd
223861602|NCT04528706|DRUG|MIN-102|Once-daily dosing with a volume specified by the pharmacokineteic specialist to achive the desired plasma exposure. Min-102 Oral suspension, strength 15mg/ml.
223861603|NCT04618757|BEHAVIORAL|Hedonic Reward|A reimbursement credit for hedonic expenses worth up to $50 will be awarded to each participant if they log at least 10,000 daily steps on at least 25 days during the first 28 days of each calendar month on Fitbit activity trackers provided by the study.
223861604|NCT04618757|BEHAVIORAL|Cash Reward|A reimbursement credit for $50 in cash will be awarded to each participant if they log at least 10,000 daily steps on at least 25 days during the first 28 days of each calendar month on Fitbit activity trackers provided by the study.
223861605|NCT04618757|DEVICE|Fitbit|Fitbit devices are wireless pedometers that track the steps of participants, and will be offered in conjunction with a tailored website with customized information for participants.
223861606|NCT06552884|BEHAVIORAL|(Maternity Identity Development Training)|Monitoring the Effect of the Education Given to Parents According to Maternal Role Ability Theory on Maternal Role Mother-Baby and Father-Infant Attachment
223861607|NCT00211913|BIOLOGICAL|S. aureus Type 5 & 8 Capsular Polysaccharide Conjugate|single IM dose totalling 200 mcg of conjugate
223861608|NCT00211913|BIOLOGICAL|placebo|single IM dose
223861609|NCT00006505|DRUG|Islet Transplantation|Islet cell transplantation. This study will test whether a new islet transplant procedure will enable patients with type 1 diabetes mellitus to stop insulin therapy
223861610|NCT04544761|OTHER|Structured Interview|Structured interview with research staff about your experience living with spinal cord injury
223861611|NCT06552325|BEHAVIORAL|Single Session Narrative Therapy|The proposed single session narrative therapy intervention has been widely implemented in walk-in therapy clinics in Ontario Province, Canada. In these clinics, 60-minute psychotherapy sessions, informed by narrative therapy, are available on a walk-in basis. The therapist collaborates with a patient to co-develop a useful and meaningful focus for the session and then engages the patient in conversation that is respectful but shifts their way of thinking about the presenting problem. The therapist highlights and documents the patient's values and skills and works with the patient to create an action plan. If the therapist identifies additional treatment needs, the patient is offered an external referral to specialty mental health services.
224076269|NCT06211010|DIAGNOSTIC_TEST|the semiconductor metal oxide sensors.|The method of analyzing the VOCs was through analyzing the evaporated VOCs from the urine in the container when they evaporated into the sealed chamber. The VOCs in the chamber were then analyzed at the same time by the five different gas semiconductor sensors which were located on the top of the chamber.
224076270|NCT00540579|DRUG|Pomalidomide|Phase 1: Subjects will be enrolled in dose-escalating cohorts to be treated with CC-4047 on days 1-21 Phase II: Subjects will be enrolled to receive oral CC-4047 at the MTD days 1 - 21
223861612|NCT05457127|DEVICE|Automatic Positive Airway Pressure (APAP)|"If eligible, participants will be given a clinical Automatic Positive Airway Pressure (APAP) device for up to 3 months, while they are waiting for their clinical evaluation from a sleep physician. The APAP device will we will be using is the ResMed Airsense 11 Autoset. APAP is a smart positive airway pressure (PAP) device, where the pressure changes as needed to provide optimal pressure to splint the upper airway. Dr. Lee and Dr. Schmickl will oversee management of the device.~During the first month of APAP use, individuals will participate in weekly phone calls or in-person visits to ensure optimal adherence and troubleshoot any issues (improper mask fitting, discomfort, etc) that may arise."
223861613|NCT05572801|DIAGNOSTIC_TEST|AMR B: HPV positive ctDNA guided imaging in follow-up|Blood samples in follow-up positive for ctDNA leads to an extra PET-CT scan to detect early treatment failure
223861614|NCT00432523|BIOLOGICAL|M-M-R™II manufactured with recombinant Human Albumin (rHA) and VARIVAX®|
223861615|NCT04480827|DRUG|Aramchol free acid tablet 600mg, single dose|Aramchol free acid tablet 600mg, single dose
223861616|NCT04480827|DRUG|Aramchol free acid tablet 300mg, bid|Aramchol acid tablet 300mg, bid for 12 days
223861617|NCT01129232|DRUG|GAD-alum|20 µg of GAD-alum injected sc after the biopsy, and repeated after one month
223861618|NCT01129232|OTHER|Placebo|Placebo injected after the biopsy and repeated after one month (similar to the GAD-alum-arm)
223861619|NCT00680342|DRUG|Silymarin|700mg dose (5 pills, three times daily) for 24-week treatment period
223861620|NCT00680342|DRUG|Silymarin|420mg dose (5 pills, three times daily) for 24-week treatment period
223861621|NCT00680342|OTHER|Placebo|Placebo (5 pills, three times daily) for 24-week treatment period
223861622|NCT00703950|PROCEDURE|cup feeding|Method to feed: cup. This is a method to feed preterm babies when breastfeeding is impossible. Feed is provided using cup
223861623|NCT00703950|PROCEDURE|bottle feeding|bottle feeding This is a method to feed preterm babies when breastfeeding is impossible. Feed is provided using bottle
223861624|NCT02011698|PROCEDURE|Lichtenstein technique groin hernia repair with mesh. Use of absorbale sutures for mesh fixation|
223861625|NCT02011698|PROCEDURE|Lichtenstein technique groin hernia repair with mesh. Use of non absorbable sutures for mesh fixation|
223861626|NCT02011698|PROCEDURE|Lichtenstein technique groin hernia repair with mesh. Use of fibrin biological glue for mesh fixation|
223861627|NCT01533870|DRUG|NKTR-118|Oral 25 mg
223861628|NCT01533870|DRUG|Rifampin|Oral 600 mg
223861629|NCT04781595|DIETARY_SUPPLEMENT|Watermelon|A single dose of watermelon powder containing 3g of L-citrulline
223861630|NCT04781595|DIETARY_SUPPLEMENT|Beetroot|A single dose of beetroot powder containing 8 mmol of nitrate
223861631|NCT04781595|DIETARY_SUPPLEMENT|Watermelon + beetroot|A single dose of watermelon and beetroot powder containing 3g of L-citrulline and 8 mmol of nitrate
223861632|NCT04781595|DIETARY_SUPPLEMENT|Placebo|A single dose of maltodextrin
223861633|NCT04583046|DRUG|normal saline inhalation|When anesthesia induction finishes, change patients' position from supine to lateral position and measure ABGA, VBGA while two lung is ventilated (T0). After 20 minutes of applying one-lung ventilation, measure ABGA and VBGA (T1). Apply normal saline inhalation for control group and measure ABGA at the time of 20 min after normal saline inhalation has finished (T2).
223861634|NCT04583046|DRUG|iloprost inhalation|When anesthesia induction finishes, change patients' position from supine to lateral position and measure ABGA, VBGA while two lung is ventilated (T0). After 20 minutes of applying one-lung ventilation, measure ABGA and VBGA (T1). Apply iloprost inhalation for iloprost group and measure ABGA at the time of 20 min after iloprost inhalation has finished (T2).
224076271|NCT00540579|DRUG|Gemcitabine|1000 mg/m2 IV on days 1, 8, and 15 of 28 day cycle
223861635|NCT00078572|DRUG|capecitabine|Capecitabine daily dose divided and given twice daily orally, for 14 days, every 21 days. The capecitabine starting dose for the monotherapy arm was 2500 mg/m2 and for the combination arm was 2000 mg/m2.
223861636|NCT00078572|DRUG|lapatinib (GW572016)|Lapatinib 1250 mg orally once daily
223861637|NCT05118581|DEVICE|ultrasound guided vascular access|Arterial or venous catheterization guided by ultrasound
223861638|NCT06219642|BEHAVIORAL|Mindfulness using virtual reality|"In each session, participants will be led through the following mindfulness script while using the VR device here is an abbreviated version with excerpts:~Look around. Try to bring yourself to the moment you are in. Notice the presence of the scene around you. How does the air feel against your skin? How do your feet feel against the ground? Where are you? What do you see? Do you hear anything? What do you smell? What do you taste? While you stay seated, imagine you are walking. What body sensations are you experiencing? What thoughts are you having? What emotions are you feeling? At the end of the intervention, participants are asked questions like, What did you notice about your thoughts and mood before, during, and after the VR session? Did you notice a change in how your body felt or your emotions? Was there anything difficult or uncomfortable about the experience that you feel comfortable sharing?"
223861639|NCT00897546|OTHER|laboratory biomarker analysis|
223861640|NCT02208258|DEVICE|Consure 120 Stool Management System|Novel device designed to manage fecal incontinence in hospitalized bedridden patients with liquid to semi-formed stool.
223861641|NCT05315336|DRUG|L-DEP and PD-1 antibody|Doxorubicin (doxorubicin hydrochloride liposome injection) 25 mg/m2 day 1; etoposide 100 mg/m2 was administered day1; methylprednisolone 2mg/kg days 1 to 3,then 0.25mg/kg day 4 to 14; PD-1 antibody injection 200mg day 5; L-asparaginases 6000iu/m2 day2, day4. This regimen was repeated after 2 weeks.
223861642|NCT02552186|OTHER|Caliper measurement|Clinical caliper measurements will be taken and used to calculate the Clinical PI
223861643|NCT02712658|DRUG|Terbutaline|K+ transport and Ca2+ release and uptake function are stimulated by administration of terbutaline
223861644|NCT02712658|DRUG|Placebo|
223861645|NCT01328418|PROCEDURE|Lengthening over nail|External fixator is used to lengthen either the femur or the tibia over an intramedullary nail
223861646|NCT02531568|DRUG|Warfarin|
223861647|NCT02531568|DRUG|MT-3995|
223861648|NCT00622531|DEVICE|BNP assay (Siemens ADVIA Centaur BNP)|Diagnostic test
223861649|NCT00622531|OTHER|hidden BNP value|no intervention
223861650|NCT03690037|DRUG|Tranexamic Acid 100 MG/ML|Tranexamic Acid: 100 MG/ML Solution for injection
223861651|NCT03690037|DRUG|Tranexamic Acid 500 MG|Tranexamic Acid: Tranexamic Acid 500mg Tablets
223861652|NCT04162119|BIOLOGICAL|BCMA-PD1-CART Cell|This study was a single-center, open-label, single-arm, non-randomized clinical trial, which was divided into 3 groups by infusion dose level. Firstly, each dose group has 3 patients. The pretreatment regimen of cyclophosphamide (25mg/m2 for 3 consecutive days) and fludarabine (10mg/kg for 3 consecutive days) was given before CART cells were reinfused. CART cells were reinfused on the third day after the pretreatment. If no serious side effects emerges in the group, then the next group uses the subsequent higher dose. If serious side effects emerges in a single patient in any dose level, 3 more patients will be enrolled to the same dose level. After 9 or more patients, we select the safest dose and recruit more patients for CART test to explore its effectiveness.
223861653|NCT04931446|PROCEDURE|Biopsy/surgical tissue and peripheral blood|Retrieve specimens stored in the tissue bank, the main types of samples are RNAlater specimens, liquid nitrogen frozen specimens and peripheral blood specimens
223861654|NCT02711839|DIETARY_SUPPLEMENT|Commercial diabetic formula|The formula were supplied 1500\~1800 kcal daily depend on the patient's individual situation
223861655|NCT02711839|DIETARY_SUPPLEMENT|White sweet potato formula|The formula were supplied 1500\~1800 kcal daily depend on the patient's individual situation
223861656|NCT03450278|PROCEDURE|micro-osteoperforation|Minor surgical procedure including performance of limited and shallow perforations of the cortical plate of bone to increase the expression of inflammatory cytokines, hence accelerating orthodontic tooth movement.
223861657|NCT00941655|DRUG|Oxaliplatin|"Oxaliplatin 460 mg/m\^2 diluted in 2.0 L/m\^2 of dextrose 5% in water (D5W) given as a heated intraperitoneal perfusion.~Systemic chemotherapy - Oxaliplatin 85 mg/m\^2 over 120 minutes,"
223861658|NCT00941655|DRUG|Irinotecan|Irinotecan 165 mg/m\^2 IV over 90 minutes
223861659|NCT00941655|DRUG|5-Fluorouracil|"Surgery and heated intraperitoneal chemotherapy with Fluouracil (5-FU) 400 mg/m\^2 intravenous (IV) over 5 minutes.~systemic chemotherapy -3200 mg/m\^2 continuous intravenous over 48 hours."
223861660|NCT00941655|DRUG|Leucovorin|"surgery and heated intraperitoneal chemotherapy -20 mg/m\^2 intravenous over 5 minutes.~systemic chemotherapy - 200 mg/m\^2 intravenous over 120 minutes."
223861661|NCT00941655|PROCEDURE|Gastrectomy and/or metastasectomy|"Gastrectomy: tumor resection and a bypass; palliative treatment for pain, bleeding, obstruction and/or if deemed in the best interest of the patient.~Metastasectomy: anatomical segmental resection to render the patient no evidence of disease (NED) with at least 1cm negative margins when possible, followed by systemic chemotherapy."
223861662|NCT02704741|DEVICE|CO2RE|The CO2RE system device is intended for dermatological procedures requiring ablation, coagulation and resurfacing of soft tissue, including skin
223861663|NCT03192319|BIOLOGICAL|Zostavax|Zostavax will be administrated by subcutaneous injection
223861664|NCT02541916|OTHER|Controlled weaning of immunosuppression|At week 0 patients have liver biopsy and liver functional tests (LFTs). Week 1-4 medication reduction to 1.5mg Tacrolimus (Tac) daily or 150mg Cyclosporine A (CsA). At week 4 LFTs. Week 5-8 medication reduction to 1mg Tac / 100mg CsA. Week 8 LFTs. Week 9-12 reduction to 0.5mg Tac/ 50mg CsA. Week 12 LFTs. Week 13-16 reduction to 0mg. Week 16 liver biopsy \& LFTs. Weekly LFTs performed Week 17-20. Monthly LFTs for the next 3 months. LFTs every 3 months for monitoring.
223861665|NCT04563156|DIAGNOSTIC_TEST|Lung Function Test|Lung Function Test at 1, 4, 6 and 12 months after discharge. Computerized tomography scan at 6 months after discharge. Cardiopulmonary Exercise Testing at 6 months after discharge
223861666|NCT04683263|OTHER|Placebo|topical cream with same composition as Intervention but without active ingredients
223861667|NCT04683263|OTHER|Fisiocrem|a natural topical composition containing Arnica montana, Hypericum perforatum, Calendula officinalis, Melaleuca sp. and menthol
223861668|NCT02731339|DEVICE|Spinal Mouse® measurement|The sagittal thoracic spinal curvature and mobility of all participants were assessed with Spinal Mouse® (Idiag, Fehraltorf, Switzerland) in standing position.
223861669|NCT02731339|BEHAVIORAL|Low back pain intensity measurement|Low back pain intensity of the patients was questioned by Visual Analogue Scale
223861670|NCT02731339|BEHAVIORAL|Urogenital symptoms measurement|The presence and severity of various urogenital symptoms was assessed with the Urogenital Distress Inventory-6
223861671|NCT02731339|BEHAVIORAL|Disability caused by low back pain|Disability caused by low back pain was assessed with the Oswestry Disability Index
223861672|NCT00561886|DRUG|Formoterol|One inhalation of 24µg Formoterol
223861673|NCT03290248|BIOLOGICAL|B244 suspension|B244 suspension in 30ml/bottle
223861674|NCT03290248|BIOLOGICAL|Vehicle|Vehicle, 30ml/bottle
223861675|NCT04307316|OTHER|ACBT group|"ACBT:~Breathing control 3 to 4 Thoracic Expansion Exercise A: 3 seconds hold B: Chest clapping C: Chest vibration Forced Expiratory Technique Breathing control A: 3 seconds hold B: Chest clapping C: Chest vibration 3 to 4 Thoracic Expansion Exercise Breathing control 1-2 Huff combine with breathing control Huff and cough~Chest Physical Therapy Early mobilization"
223861676|NCT04307316|OTHER|Conventional Physical therapy|Chest percussion, deep breathing, Huff and cough. Early mobilization
223861677|NCT02482519|OTHER|High calorie diet|High calorie diet for 10 days
223861678|NCT02482519|OTHER|Fasting|10 day fast
223861679|NCT02477670|DRUG|AVP-786|
223861680|NCT02477670|DRUG|Placebo|
223861681|NCT03273348|PROCEDURE|Oncoplastic breast surgery|, Skin sparing mastectomy and immediate breast reconstruction will be conducted to all women included in the study, transverse rectus abdominis musculocutaneous flap recostruction and latissimus dorsi myocutaneous pedicle-flap with and without implant
223861682|NCT00983593|BEHAVIORAL|Mind-Body Bridging|16 weeks of weekly Mind-Body Bridging group treatment lasting 60-90 minutes per session.
223861683|NCT04848233|DIETARY_SUPPLEMENT|Drinks containing 5AA+CrPic and Placebo|Same diet will be repeated for 3 days in a row and the beverage switched every day. 3 periods of 3 days are included in the study.
223861684|NCT01815008|DRUG|Clopidogrel|Clopidogrel 75 mg daily
223861685|NCT01815008|DRUG|Aspirin|Aspirin 81 mg daily
223861686|NCT03493269|DRUG|BAY1834845|Orally administered.
223861687|NCT03493269|OTHER|Matching Placebo|Orally administered.
223861688|NCT03493269|DRUG|Midazolam|Part 1: Orally administered 1mg as a single dose.
223861689|NCT02026076|OTHER|mechanical lumbar traction|15 minutes at up to 50% body weight lumbar traction in supine hooklying with split table open
223861690|NCT00851240|DRUG|BTT-1023|intravenous
223861691|NCT00851240|DRUG|Placebo|Intravenous
223861692|NCT00787033|DRUG|PF-04554878|Oral pills at increasing dose twice daily, 21 day cycle, continuous treatment schedule until progression of disease, unacceptable toxicity, or patient request. Some patients will undergo serial biopsy and/or FDG-PET imaging
223861693|NCT05859542|DEVICE|Videolaryngoscope first|started the session with 3 intubations using the videolaryngoscope
223861694|NCT05859542|DEVICE|Direct laryngoscope first|started the session with 3 intubations using the Direct laryngoscope
223861695|NCT03825133|PROCEDURE|Bone Marrow Aspirate Concentrate|Bone marrow ( 100 ml) is aspirated from proximal tibia, concentrated in Arthrex Angel Centrifuge, and after concentration 6 ml of BMAC is injected in the knee
223861696|NCT03825133|PROCEDURE|Leukocyte Rich Platelet Rich Plasma|Blood sample is taken ( 100 ml), centrifuged in Arthrex Angel Centrifuge and after double spinning process about 6 ml of PRP is injected in the knee
223861697|NCT03825133|DRUG|Hyaluronic Acid|Three injections of Cartinorm (1% Sodium Hyaluronat (20mg/2 ml) by Goodwill Pharma) is injected in the knee weekly
223861698|NCT00446550|DRUG|afegostat tartrate|
223861699|NCT02937831|BIOLOGICAL|RIXUBIS|
223861700|NCT03356665|DIAGNOSTIC_TEST|Rapid diagnostic test (RDT)|The 4 rapid diagnostic tests (RDT) will be carried out on fresh blood from clinical suspects. Only those subjects that are positive in at least 1 RDT will 1) undergo tests on DBS (immune trypanolysis, ELISA and DNA detection); 2) undergo parasitological confirmation (reference standard) at inclusion.
224076272|NCT01113203|BEHAVIORAL|Resistance training|Progressive high intensity resistance training performed twice a week for 16 weeks, and achieving in 7 exercises for the main muscles, the protocol of 4 sets of 6RM and 2 of 4RM.
224076273|NCT00142896|DRUG|Tramadol|
224076274|NCT00142896|DRUG|Naloxone|
224076275|NCT00142896|DRUG|Morphine|
223861701|NCT03356665|DIAGNOSTIC_TEST|Serological and molecular tests on DBS|Serological and molecular reference tests on dried blood spots (DBS) are carried out on RDT positive clinical suspects, which also undergo parasitological examination at inclusion (reference standard). If at least one of the serological or molecular reference tests on dried blood spots is positive, parasitological examination is repeated 3 and 6 months after inclusion. The combined results of parasitological examinations (at inclusion and if applicable at 3 and 6 months) serve as reference standard
223861702|NCT02379299|DEVICE|DiaCon dual-hormone closed-loop glucose control algorithm|Dual-hormone closed-loop glucose control
223861703|NCT02379299|DEVICE|DiaCon single-hormone closed-loop glucose control algorithm|Single-hormone closed-loop glucose control
223861704|NCT02630719|DRUG|Timolol eye drops|eye drops
223861705|NCT02630719|DRUG|Artificial tears|Placebo drop
223861706|NCT05000944|OTHER|breakfast omission (BO)|this group will not be provided with a breakfast until lunch time (at 12:30).
223861707|NCT05000944|OTHER|early-morning breakfast consumption (EM-BC)|this group will be provided with an early morning breakfast (at 08:30).
223861708|NCT05000944|OTHER|mid-morning breakfast consumption (MM-BC)|this group will be provided with a mid (late) morning breakfast (at 10:30).
223861709|NCT01301716|DRUG|GDC-0980|Oral escalating dose
223861710|NCT01301716|DRUG|bevacizumab|Intravenous repeating dose
223861711|NCT01301716|DRUG|carboplatin|Intravenous repeating dose
223861712|NCT01301716|DRUG|cisplatin|intravenous repeating dose
223861713|NCT01301716|DRUG|paclitaxel|Intravenous repeating dose
223861714|NCT01301716|DRUG|pemetrexed|intravenous repeating dose
223861715|NCT04573803|DRUG|Phenytoin Sodium|Dosing will be as prescribed clinically by the treating physician. Phenytoin Sodium may be administered orally, intravenously or via nasogastric tube.
223861716|NCT04573803|DRUG|Levetiracetam|Dosing will be as prescribed clinically by the treating physician.Levetiracetam may be administered orally, intravenously or via nasogastric tube.
223861717|NCT00502736|DRUG|ibandronate [Bondronat]|6mg iv on days 1-3
223861718|NCT01552980|DRUG|S-1 and Oxaliplatin|"Oxaliplatin 85mg/m2 D1 and S-1 40mg/m2 BID D1-D10, repeat every two weeks;~Efficacy will be evaluated every three cycles."
223861719|NCT04133740|DRUG|Oxygen|Liberal versus conservative oxygen therapy.
223861720|NCT02888457|OTHER|Nasopharyngeal sampling with a swab|
223861721|NCT04761146|RADIATION|DaRT Diffusing Alpha-emitters Radiation Therapy|DaRT is a brachytherapy treatment comprising stainless-steel 316LVM wires coated with radium-224 (Alpha DaRT seeds). The radioactive seeds are inserted directly into the tumour on the perineum and will be removed after 14 days.
223861722|NCT03733522|PROCEDURE|Rubber dam isolation|Local anesthesia, use of dental clamp and rubber dam, followed by restoration using universal adhesive system and bulkfill composite restoration
223861723|NCT03733522|PROCEDURE|Relative isolation|No local anesthesia, use of cotton rollers and saliva ejector, followed by restoration using universal adhesive system and bulkfill composite restoration
223861724|NCT05344326|OTHER|Cognitive Analytic Therapy - Guided Self Help (CAT-GSH)|CAT-GSH is a novel intervention designed to help those with depression by focusing on the relationships within their life. GSH is used in step two of IAPT services and is typically six fortnightly sessions where the PWP helps the service user complete the self help manual.
223861725|NCT02640781|PROCEDURE|self-expandable metal stent insertion(covered stent)|Stent insertion was performed by experienced endoscopists under fluoroscopy and by using through-the-scope methods. After the obstructing tumor was identified by endoscopy, a guidewire was introduced through the stricture under endoscopic and fluoroscopic controls. Then, the self-expandable colorectal covered stent delivery catheter was advanced through the working channel of the endoscope over the guidewire until the stent was positioned across the stricture. Upon releasing the stent delivery catheter, stent deployment was initiated proximally and progressed distally. Simple abdominal radiography was performed during and after the procedures to confirm proper stent placement and expansion.
224076276|NCT00280995|DRUG|ISIS 301012|100 mg subcutaneous injections on days 1, 4, 8, 11, 15, 22, 29, and 36
224076277|NCT00280995|DRUG|ISIS 301012|200 mg subcutaneous injections on days 1, 4, 8, 11, 15, 22, 29, and 36
224076278|NCT00280995|DRUG|ISIS 301012|300 mg subcutaneous injections on days 1, 4, 8, 11, 15, 22, 29, 36, 43, 50, 57, 64,71, 78, and 85
224076279|NCT00280995|DRUG|ISIS 301012|50 mg subcutaneous injections on days 1, 4, 8, 11, 15, 22, 29, and 36
223861726|NCT02640781|PROCEDURE|self-expandable metal stent insertion(uncovered stent)|Stent insertion was performed by experienced endoscopists under fluoroscopy and by using through-the-scope methods. After the obstructing tumor was identified by endoscopy, a guidewire was introduced through the stricture under endoscopic and fluoroscopic controls. Then, the self-expandable colorectal stent delivery uncovered catheter was advanced through the working channel of the endoscope over the guidewire until the stent was positioned across the stricture. Upon releasing the stent delivery catheter, stent deployment was initiated proximally and progressed distally. Simple abdominal radiography was performed during and after the procedures to confirm proper stent placement and expansion.
224076280|NCT02268435|DRUG|dovitinib plus imatinib|Dovitinib once daily on a 5 days on/2 days off dosing schedule, and imatinib once daily on a continuous dosing schedule
224076281|NCT03799900|DRUG|Rapastinel|During the Treatment Phase in Part 2, participants will be administered single IV doses of rapastinel, ketamine, and placebo in a randomized crossover manner.
223861727|NCT05591040|DEVICE|Biofeedback|Each participant will attend 5 sessions per week for a total duration of 4 weeks. The duration of each session will take 1 hour, including bio-feedback preparation. At the beginning of the bio-feedback session, two surface electrodes will be applied to the mylohyoid muscle. The patient will be required to swallow at a given time, with food bolus if possible, and perform maneuvers that favour swallowing strength and efficacy: effortful swallow, specific task for timing and coordination, Masako maneuver. The experimental group will perform this training for 45 minutes, plus they will receive a verbal feedback from the speech and language therapist in relation to the efficacy of the performance.
223861728|NCT05591040|OTHER|Conventional|Each participant will attend 5 sessions per week for a total duration of 4 weeks. The patient will be required to swallow at a given time, with food bolus if possible, and perform maneuvers that favour swallowing strength and efficacy: effortful swallow, specific task for timing and coordination, Masako maneuver. The control group will perform this training for 45 minutes, with a verbal feedback from the speech and language therapist in relation to the efficacy of the performance.
223861729|NCT01489982|DEVICE|Light box (Litebook company)|Light therapy will be administered daily for a duration of 30 minutes, starting two hours (+/- 1 hour) prior to usual bedtime
223861730|NCT01489982|BEHAVIORAL|CBT and sleep hygiene|6 weekly sessions totalling 90 minutes
223861731|NCT01489982|DRUG|Doxepin and Zopiclone|Zopiclone 3.75 mg at h.s., increasing to 7.5 mg after one week if insufficient clinical effects ( and no troublesome side effects) or Doxepin 5 mg at h.s. followed by increase up to 10 mg after the first week if insufficient clinical effect (and no troublesome side effects)
223861732|NCT01489982|DEVICE|Light box ( Litebook company)|The intervention will be 30 minutes of light therapy, using red light below the threshold required to entrain light cycles
223861733|NCT02983617|DRUG|Tirabrutinib|Administered orally once daily
223861734|NCT02983617|DRUG|Entospletinib|Administered orally once daily
223861735|NCT02983617|DRUG|Obinutuzumab|Administered intravenously
223861736|NCT03646136|PROCEDURE|Retained fluid|Retained fluid
223861737|NCT03646136|PROCEDURE|Emptied fluid|Emptied fluid
223861738|NCT02894463|OTHER|questionnaire|
223861739|NCT04783454|OTHER|Exercise program|educational video on training program design and healthy lifestyle 24 training sessions (12 on cardiovascular endurance training, 12 on mobility and strength)
223861740|NCT03791905|DRUG|Paclitaxel|chemotherapy drug
223861741|NCT03791905|DRUG|Cisplatin|chemotherapy drug
223861742|NCT03791905|DRUG|Oxaliplatin|chemotherapy drug
223861743|NCT03791905|DRUG|5-FU|chemotherapy drug
223861744|NCT03791905|DRUG|Leucovorin|chemotherapy drug
223861745|NCT03791905|RADIATION|Intensity-modulated radiotherapy|radiotherapy technique
223861746|NCT03791905|DEVICE|PET|Using PET to evaluate response to induction chemotherapy
223861747|NCT02027558|BEHAVIORAL|Insomnia treatment & PAP adherence|Manual-based cognitive behavioral treatment focusing on sleep, sleep apnea, and PAP adherence provided by allied health personnel in individual sessions.
223861748|NCT02027558|BEHAVIORAL|General sleep education|Manual-based non-directive general sleep education program provided by allied health personnel in individual sessions.
223861749|NCT03720210|DEVICE|RFA|Radiofrequency ablation of a portion of thyroid parenchyma to treat amiodarone-induced thyrotoxicosis
223861750|NCT00459446|DRUG|MS-325 Injection (Gadofosveset Trisodium)|
223861751|NCT05380791|OTHER|Follow-up visits|Regular follow-up visits to record information about the patient's surgery and routine post-operative examinations
223861752|NCT02698891|DRUG|Paclitaxel|
223861753|NCT02698891|DRUG|Neulasta|
223861754|NCT00114244|DRUG|sorafenib tosylate|Given PO
223861755|NCT00114244|DRUG|gemcitabine hydrochloride|Given IV
223861756|NCT00114244|OTHER|laboratory biomarker analysis|Correlative studies
224076282|NCT03799900|DRUG|Ketamine|"Part 1~Part 2, Qualification Phase:~Participants will be administered single IV doses of ketamine and placebo in a randomized crossover manner~Part 2, Treatment Phase:~Participants will be administered single IV doses of rapastinel, ketamine, and placebo in a randomized crossover manner."
223861757|NCT05539755|PROCEDURE|Non surgical debridement of peri-implantitis|"The procedure was standardized as follows: the implants' prosthesis was checked for its cleansability, and retrieved when possible. Then, the prosthesis was modified following a previously described elsewhere (de Tapia et al., 2019). After local anaesthesia (articaine 4% and adrenaline 1:100,000), the implant surfaces were cleaned with ultrasonic devices (Newtron P5, Satelec Acteon; Olliergues, France) with the steel alloy H3 dental ultrasonic scaler tip (H3, Satelec Acteon; Olliergues, France), curettage (SyG 7/89 Everdge, Hu-Friedy; Chicago, IL, USA) of the bone defect was performed, and glycine air powder applied submucosally (Air-flow® powder subgingival PERIO, EMS; Nyon, France) with an air-flow piezon device (Air-flow master piezon®, EMS, Nyon; France).~Oral hygiene instructions were given and metronidazole 500 mg every 8 h for 7 days was prescribed. Patients were scheduled at 3 months for supragingival plaque control and supragingival debridement, if needed."
223861758|NCT02817334|DRUG|indocyanine green|As inject only indocyanine green (ICG), it provide the surgeon visual guidance to ensure better outcome.
223861759|NCT01908296|DRUG|FK949E|Oral
223861760|NCT01908296|DRUG|fluvoxamine|Oral
223861761|NCT00711958|DRUG|HX575, solution for injection (s.c.)|1000, 2000, 4000, 8000 and 10.000 IU of rh erythropoiethin
223861762|NCT00711958|DRUG|ERYPO®, Janssen-Cilag, solution for injection (s.c.)|1000, 2000, 4000, 8000 and 10.000 IU of epoetin alfa
224076283|NCT03799900|DRUG|Placebo|"Part 1~Part 2, Qualification Phase:~Participants will be administered single IV doses of ketamine and placebo in a randomized crossover manner~Part 2, Treatment Phase:~Participants will be administered single IV doses of rapastinel, ketamine, and placebo in a randomized crossover manner."
223861763|NCT02296463|BIOLOGICAL|RSV F Vaccine with adjuvant (0.5mL injection)|
224076284|NCT02908880|DEVICE|MANTA vascular closure device|The appropriate size of MANTA closure device will be selected and used for the closure of femoral arterial access sites following the use of 10-14F devices or sheaths or the use of 15-18F devices or sheaths.
223861764|NCT02296463|BIOLOGICAL|RSV F Vaccine (0.5mL injection)|
223861765|NCT02296463|BIOLOGICAL|Hepatitis A Vaccine (0.5mL injection)|
223861766|NCT02296463|BIOLOGICAL|Placebo (0.5mL injection)|
223861767|NCT00203372|DRUG|Bevacizumab 7.5 and TAC|Bevacizumab given intravenously at a dose of 7.5mg/kg every 3 weeks, followed by docetaxel, doxorubicin and cyclophosphamide (TAC).
223861768|NCT00203372|DRUG|Placebo 7.5 and Docetaxel, Doxorubicin, and Cyclophosphamide (TAC)|placebo 7.5 will be adminitered intravenously every 3 weeks followed by TAC
223861769|NCT00203372|DRUG|Bevacizumab 15 and TAC|one dose of Bevacizumab (15 mg/kg) will be administered intravenously every 3 weeks followed by TAC.
223861770|NCT00203372|DRUG|Placebo 15 and TAC|one dose of placebo 15 will be administered intravenously every 3 weeks followed by TAC.
223861771|NCT01689844|BEHAVIORAL|DASH Plus|DASH diet advice and guided shopping for high postassium foods at a local supermarket
223861772|NCT01689844|BEHAVIORAL|DASH - C|Brief DASH dietary advice, No shopping guidance at the local supermarket.
223861773|NCT03022123|DRUG|PL-doxorubicin and epirubicin|PL-doxorubicin 35-40 mg/m(2) and epirubicin 70 mg/m(2) were given in combination with standard dosage of prednisone, vincristine, cyclophosphamide, rituximab (according to CHOP-R regimen) every 21 days for six courses.
223861774|NCT04627493|BEHAVIORAL|Online exercise|Participants will participate in an online exercise program on Zoom delivered by Registered Kinesiologists and Physiotherapists three times a week.
223861775|NCT03881449|COMBINATION_PRODUCT|ABILIFY MYCITE|Initiation of ABILIFY MYCITE will commence immediately, with subjects wearing the patch and using the smartphone app for a total of 3 months from baseline visit to the 3 month visit. Following the initial 90-days, the physician and patient may determine to use ABILIFY MYCITE anytime during the following 9 months. Following this period (up to 12 months), the subjects will not use ABILIFY MYCITE and return to standard care. A safety follow-up phone call will occur at 2 weeks after the 12 month/early termination (ET) visit. In addition, individuals in the ABILIFY MYCITE arm will evaluate satisfaction with the use of ABILIFY MYCITE.
223861776|NCT01111526|DRUG|Panobinostat (LBH589)|"Phase I Initial Treatment Plan - Intravenous (IV) Formulation: Up to 4 dose levels (DL) of LBH589 IV formulation to establish LBH589 Maximum Tolerated Dose (MTD) in acute GVHD treatment. The first 4 participants began this treatment plan, before the IV Formulation became unavailable.~DL -1: 1.25 mg/m\^2 IV; DL 1: 2.5 mg/m\^2 IV; DL 2: 5 mg/m\^2 IV; DL 3: 7.5 mg/m\^2 IV; DL 4: 10 mg/m\^2 IV.~Phase I Revised Treatment Plan - Oral Formulation (to replace IV Formulation): Dose escalation levels for LBH589; participants treated with LBH589 by mouth (PO) 3 times a week (48 hours apart) every week for 4 weeks.~DL -1: 5 mg PO; DL 1: 10 mg PO (starting dose level); DL 2: 15 mg PO; DL 3: 20 mg PO; DL 4: 25 mg PO.~Phase II Treatment Plan: LBH589 PO at MTD, 3 times a week (48 hours apart) every week for 4 weeks."
223861777|NCT00012935|BEHAVIORAL|Help with decision making on prostate cancer treatment|
223861778|NCT03981042|DEVICE|Monitoring|"After the anesthetic induction with sufentanil, propofol and atracurium, patients will be ventilated with mask until:~\- Monitoring group: TOF ratio at the corrugator supercilli will be measured every 15 s after injection of atracurium. When TOF ratio reach 0, laryngoscopy with intubation will be performed"
223861779|NCT02200523|DEVICE|SARA electrode|
223861780|NCT02200523|DEVICE|Gold cup|
223861781|NCT04424641|BIOLOGICAL|GEN1044 is an immunoglobulin G1 (IgG1) bispecific antibody targeting CD3 and 5T4.|GEN1044 will be administered intravenously in cycles of 21 days.
223861782|NCT03446859|OTHER|TENS|"First, there was explanation of the overall test procedure. The subject was placed in supine lying in a comfortable position.A pair of electrodes (inactive electrodes) was placed a little below the umbilicus (Right and Left) and the other pair (active electrode) along the inguinal region at the level of pubic symphysis (Right and Left) according to (Akinbo et al 2000).~The TENS equipment was switched on and the intensity was set at a level tolerable by each participant's. The treatment period lasted for 30 minutes for each treatment sessions and the procedure was carried out once a day on the 1st, 3rd and 5th days (Akinbo et.al 2000). Pain intensity was measured pre treatment and post treatment each day of treatment using the visual analogue scale (VAS)."
223861783|NCT04238429|DRUG|Toothpaste containing 10% high cleaning silica base, 0.5% sodium phytate and 0.5% sodium pyrophosphate|Use the toothpaste to brush teeth twice a day for 8 weeks
223861784|NCT04238429|DRUG|Control toothpaste|Use the toothpaste to brush teeth twice a day for 8 weeks
223861785|NCT05177601|DEVICE|iTBS repetitive Transcranial Magnetic Stimulation (rTMS)|rTMS is a non-invasive procedure in which cerebral electrical activity is influenced by a rapidly changing magnetic field. The magnetic field is created by a plastic-encased coil which is placed over the patient's scalp. The magnetic field can be directed onto specific areas of the brain. rTMS can modulate cerebral activity by low or high frequencies. Over time, the magnetic field pulses can gradually change the activity level of the stimulated brain region and help symptoms of mood disorders.
223861786|NCT05177601|DEVICE|Sham rTMS|Sham rTMS involves a click replicating the sound of the magnetic discharge, without any magnetic pulse being delivered.
223861787|NCT05177601|DRUG|D-cycloserine|Daily oral D-cycloserine 100mg during TMS treatments (20 days).
223861788|NCT05177601|DRUG|Placebo oral capsule|Daily oral placebo during the TMS treatments (20 days).
223861789|NCT06007118|RADIATION|APBI|accelerated partial breast irradiation to the surgery bed (5 x 6,0 Gy; in 5 working days)
223861790|NCT06007118|RADIATION|WBI|accelerated whole breast irradiation with the boost to tumor bed (15x 2,67 Gy + 5x 2,0 Gy, every working day)
223861791|NCT00781378|DRUG|rt-PA|rt-PA 100 mg continuous intravenous infusion for 2 hours
223861792|NCT00781378|DRUG|rt-PA|rt-PA 50 mg continuous intravenous infusion for 2 hours
223861793|NCT00304135|DRUG|cisplatin|
223861794|NCT00304135|DRUG|gemcitabine hydrochloride|
223861795|NCT00304135|DRUG|oxaliplatin|
223861796|NCT02769468|OTHER|The Back|
223861797|NCT02769468|OTHER|Chest|
223861798|NCT02769468|OTHER|Left Axilla|
223861799|NCT05597280|DRUG|BE-PEP Bedaquiline|bedaquiline
223861800|NCT05597280|DRUG|SDR-PEP Rifampicin|SDR-PEP: rifampicin
223861801|NCT05597280|DRUG|BE-PEP Rifampicin|BE-PEP rifampicin
223861802|NCT01180088|PROCEDURE|RIGHT HEPATECTOMY WITH CLASSIC APPROACH|The right portal branch and the right branch of the hepatic artery were identified, dissected and divided. Extraparenchymal ligation of pedicles for Sg4 was performed in case of extended right hepatectomy. The falciform and the right triangular ligaments were sectioned and the right liver up to the retrohepatic vena cava was totally mobilized by section and sutures of the accessory right hepatic veins. The right hepatic vein was controlled in an extrahepatic plane and encircled with a tape. At the end of parenchymal transection right hepatic vein was sectioned with endovascular stapler. The right bile duct and middle hepatic vein (in case of extended right hepatectomy) were divided intraparenchymally
223861803|NCT02560649|DRUG|Peginterferon alfa-2a plus Entecavir|Peginterferon alfa-2a 180μg /wk plus Entecavir 0.5mg qd for 48 weeks(Arm A and B)
223861804|NCT02560649|DRUG|Peginterferon alfa-2a plus Lamivudine|Peginterferon alfa-2a 180μg /wk plus Lamivudine 0.1g qd for 48 weeks(Arm A and B)
223861805|NCT02560649|DRUG|Peginterferon alfa-2a plus Adefovir|Peginterferon alfa-2a 180μg /wk plus Adefovir 10mg qd for 48 weeks(Arm A and B)
223861806|NCT02560649|DRUG|Peginterferon alfa-2a plus Tenofovir|Peginterferon alfa-2a 180μg /wk plus Tenofovir 300mg qd for 48 weeks(Arm A and B)
223861807|NCT02560649|DRUG|Entecavir|Entecavir 0.5mg qd for 24 weeks(Arm C)
223861808|NCT02560649|DRUG|Lamivudine|Lamivudine 0.1g qd for 24 weeks(Arm C)
223861809|NCT02560649|DRUG|Adefovir|Adefovir 10mg qd for 24 weeks(ArmC)
223861810|NCT02560649|DRUG|Tenofovir disoproxil|Tenofovir 300mg qd for 24 weeks(Arm C)
223861811|NCT02694978|DRUG|Ferumoxytol|
223861812|NCT02694978|DRUG|FCM|
223861813|NCT03489915|DEVICE|OCT|Assessment of macular edema secondary to retinal vein occlusion usin optical coherence tomography and its correlation with visual acuity
223861814|NCT01613716|DRUG|Ozurdex|Ozurdex .7 mg injected into the treated eye
223861815|NCT01171625|DEVICE|Implantation of CEP Magna Ease Model 3300TFX|Heart Valve Surgery
223861816|NCT02759588|BIOLOGICAL|GL-ONC1 alone, or in combination with chemotherapy with or without bevacizumab|GL-ONC1 is a genetically-engineered oncolytic vaccinia virus, which is administered via intraperitoneal infusion as multiple doses.
223861817|NCT00404417|DRUG|Botulinum Toxin A / Placebo|Botulinum Toxin A at first injection / Placebo at second injection
223861818|NCT00404417|DRUG|Botulinum Toxin A / Botulinum Toxin A|Botulinum Toxin A at first injection / Botulinum Toxin A at second injection
223861819|NCT00404417|DRUG|Placebo / Botulinum Toxin A|Placebo at first injection / Botulinum Toxin A at second injection
223861820|NCT00404417|DRUG|Placebo / Placebo|Placebo at first injection / Placebo at second injection
223861821|NCT00743444|DRUG|AZD3355|65 mg capsules, oral, 3 single doses
223861822|NCT00743444|DRUG|Placebo|capsules, oral, 3 single doses
223861823|NCT06367816|PROCEDURE|INTELLiVENT|Closed-loop mode of ventilation
223861824|NCT06367816|PROCEDURE|Conventional ventilation|Mode of ventilation
223861825|NCT03168048|OTHER|mobile application|Oncologic therapy support by means of a mobile application
223861826|NCT02452918|DRUG|Oritavancin|Administered intravenously
223861827|NCT02452918|DRUG|Warfarin|Administered as a concomitant medication at a standard dose and dosing schedule
223861828|NCT00617812|BIOLOGICAL|Shan5|Diphtheria, tetanus, whole cell pertussis, recombinant hepatitis B and Hib tetanus toxoid conjugate pentavalent liquid combination vaccine
223861829|NCT03352596|OTHER|low frutose diet|
223861830|NCT05728008|DRUG|Ustekinumab|a human monoclonal antibody to interleukin IL 12/23 p40. It is indicated in the treatment of adult patients with moderately to severely active UC. The induction phase consists of approximately 6 mg/kg intravenous dose administration. After the induction, the maintenance phase consists of a 90mg subcutaneous dose every 8 weeks.
223861831|NCT05728008|DRUG|Tofacitinib|Jak inhibitor. It is indicated in the treatment of adult patients with moderately to severely active UC who have experienced inadequate response or have lost the response or who are intolerant to conventional therapy or to a biological agent. The induction phase consists of 10mg twice daily for 8 to 16 weeks. After the induction, the maintenance phase consists of 5mg x twice daily.
223861832|NCT01956552|OTHER|biopsy or cytopuncture|
224076285|NCT05639855|OTHER|Mental Health Literacy Programme|Mental Health Literacy Program. This program is part of the training of third-year students of the occupational therapy degree at the University of A Coruña. We will follow a mixed method following a sequential explanatory design. The quantitative part corresponds to a quasi-experimental study, where a comparison will be made between the phase before and after the students take the program. The qualitative part will comprise a phenomenological study to collect the knowledge acquired by the students after taking the program.
224076286|NCT05313867|DIETARY_SUPPLEMENT|Nutri VX 1|1 sequence of 10 tablets (one intake)
224076287|NCT05313867|DIETARY_SUPPLEMENT|Placebo|1 sequence of 10 tablets (one intake)
224076288|NCT03931356|OTHER|Pulmonary function tests|analysis of lung volume and diffusion capacity
223861833|NCT06242379|BIOLOGICAL|GMP compliant-BM-MSC derived sEVs|The procedure will be performed under topical anesthesia (0.5% tetracaine hydrochloride ophthalmic solution). The intravitreal injection will be performed by the retina specialist. Topical antiseptic (5% povidone iodine solution) will be applied on the periorbital and ocular surface. Eyelid speculum will be inserted to expose the injection area. It will include an intravitreal injection at the superotemporal quadrant (right eye) and superonasal quadrant (left eye), 3.5 to 4 mm posterior to the limbus. A 30-gauge needle will be used to deliver a 0.05 to 0.1 ml sEV suspension into the vitreous cavity. Indirect ophthalmoscopy will be performed immediately after the procedure to ensure no occlusion of the central retinal artery. The eye will be rinsed thoroughly by normal saline to wash out remaining antiseptic. The total duration for an intravitreal injection will be approximately 30 minutes.
223861834|NCT01134237|DRUG|urokinase|intrapleural urokinase injection
223861835|NCT01134237|DRUG|placebo|Normal saline as a placebo for control arm
223861836|NCT02568644|DIETARY_SUPPLEMENT|Extract of ginger|People (both genders) who went to the emergency room of the Hospital Vera Cruz (Belo Horizonte, MG, BR) with a migraine attack received two capsules of ginger extract (containing 5% of gingerols).
223861837|NCT02568644|OTHER|Cellulose|People (both genders) who went to the emergency room of the Hospital Vera Cruz (Belo Horizonte, MG, BR) with a migraine attack received two placebo capsules (cellulose).
223861838|NCT02568644|DRUG|Intravenous ketoprofen|People (both genders) who went to the emergency room of the Hospital Vera Cruz (Belo Horizonte, MG, BR) with a migraine attack received intravenous ketoprofen (100mg).
223861839|NCT06352541|DRUG|PRO-232|Moxifloxacin 0.5% and Dexamethasone Phosphate 0.1%
223861840|NCT06352541|OTHER|Placebo|Vehicle Control, ophthalmic solution
223861841|NCT04163081|BEHAVIORAL|Quit Card Intervention (QCI)|"The intervention is comprised of a behavioural incentive in the form of a gift card as well as tailored smoking cessation counseling. Eligible consenting smokers randomized to the QCI group will receive: a Quit Card (a gift card worth $300 that can be used to buy nicotine replacement therapies at any pharmacy); self-help information; and, enrollment in six months of telephone follow-up support tailored by treatment goal with a Nicotine Addiction Treatment Specialist."
223861842|NCT00486330|DRUG|Buprenorphine, Tipranavir and ritonavir|After determining buprenorphine/naloxone pharmacokinetics over a 24-hour period, tipranavir/ritonavir and buprenorphine/naloxone will be coadministered for 7 days.
223861843|NCT06449300|OTHER|Resistance exercise-LVT|(low volume training - 3 sessions of 12 exercises per week)
223861844|NCT06449300|OTHER|Resistance exercise-MVT|(moderate volume training - 4 sessions of 12 exercises per week)
223861845|NCT06449300|OTHER|Resistance exercise-HVT|(high volume training - 5 sessions of 12 exercises per week)
223861846|NCT03145480|DRUG|Obinutuzumab|100 mg on day 1 and 900 mg on day 2 Cycle 1, 1000 mg on day 8 and 15 of Cycle 1, and 1000 mg on day 1 of Cycles 2-6
223861847|NCT03145480|DRUG|Ibrutinib|560mg po daily
223861848|NCT03145480|OTHER|CHOP|cyclophosphamide, doxorubicin, vincristine, and prednisone
223861849|NCT03416842|DEVICE|Training with 4D Motion Capture Device|Participants will be given access to a tablet-based application and non-invasive sensors that will track movements of the upper extremity and will prompt daily exercise. Participants will be encouraged to use the device daily for 30 consecutive days, up to one hour per day.
223861850|NCT04668391|PROCEDURE|Ultrasound-guided anterior quadratus lumborum block at the lateral supra-arcuate ligament|Bilateral single-injection 20 ml 0.56% ropivacaine. Intravenous analgesia was started postoperatively and consisted of 1ug/ml sufentanil，2 ml/h with a 5-minute lockout period, a limited 12 ml/h dose.
223861851|NCT04668391|PROCEDURE|Thoracic epidural analgesia|A thoracic epidural at the level of T7-10. Epidural infusion was started postoperatively and consisted of sufentanil (0.6ug/mL) and ropivacaine（0.2%） at 3ml/h.
223861852|NCT04800302|PROCEDURE|Continous Quadratum Lumborum Block III|Continuous infusion of Bupivacaine 0.125 % at a rate of 0.1 ml/kg/hr (not exceeding 12 ml/hour), infused through a catheter inserted in the plane between quadratus lumborum \& psoas major muscles with ultrasound guidance.
223861853|NCT04800302|PROCEDURE|Single dose Quadratum Lumborum Block III|Single injection of a mixture solution of 20 ml Bupivacaine 0.5% + 10 ml Lidocaine 2%, injected through a needle inserted at the posterior aspect of the quadratus lumborum muscle between it and erector spinae muscle with ultrasound guidance.
223861854|NCT04800302|PROCEDURE|Intra-venous Morphine|Intra-venous Morphine \[0.1 mg/kg\] as rescue analgesic shots when the Visual Analogue Score (VAS) for pain exceeds 4.
223861855|NCT03949686|DRUG|Saline Solution|0.5 ml/kg saline
223861856|NCT03949686|DRUG|Bupivacaine|0.5 ml/kg %0.25 bupivacaine
223861857|NCT05890521|BIOLOGICAL|Recombinant new coronavirus vaccine (CHO cell)|"Subjects who have not received any Novel Coronavirus vaccine or the full dose of recombinant Novel Coronavirus protein vaccine (CHO cells) shall receive 3 doses of the experimental vaccine intramuscular in the deltoid muscle of the upper arm or complete the remaining doses of the experimental vaccine as per the vaccination schedule at 0, 1, and 2 months, with a dose of 0.5ml for each person.~Immunized subjects: intramuscular injection of one dose of the experimental vaccine into the deltoid muscle of the upper arm, 0.5ml for each person."
223861858|NCT04255888|PROCEDURE|Laterally positioned flap in thick periodontal phenotype.|Laterally positioned flap will be performed in isolated gingival recession belonging thick periodontal phenotype .
223861859|NCT04255888|PROCEDURE|Laterally positioned flap in thin periodontal phenotype.|Laterally positioned flap will be performed in isolated gingival recession belonging thin periodontal phenotype .
223861860|NCT00629941|DRUG|AzaSite®|Ophthalmic solution; 1 drop in each eye BID for two days, then 1 drop in each eye QD for \~26 days
223861861|NCT02138006|DRUG|Intensive insulin treatment|Mealtime insulin (Actrapid) Basal insulin (Monotard)
223861862|NCT02138006|DRUG|Standard insulin treatment|Insulin Mixtard
223861863|NCT04893980|DRUG|Recombinant human interleukin-2 (rhIL-2)|During Day 0-14, patients in this group will receive treatment with antihistamines at the same dosage as pre-recruitment, together with a low-dose recombinant human Interleukin-2 (rhIL-2) at a dosage of 1 million international units every other day by intramuscular injection (rhIL-2, 1 MIU, im, Qod). During Day 15-28, the injections of rhIL-2 will be continued at the same dosage and the dose of antihistamines may be adjusted according to the control of symptoms.
223861864|NCT04893980|DRUG|Control group|During Day 0-14, patients in the control group receive treatment with only antihistamines at the same dosage as pre-recruitment, but no injection of rhIL-2. During Day 15-28, treatment with low dose recombinant human Interleukin-2 (rhIL-2), i.e., 1 million international units every other day by subcutaneous or intramuscular injection (rhIL-2, 1MIU, im, Qod), will be added.
223861865|NCT01087762|BIOLOGICAL|CZP 200 mg Q2W|200 mg subcutaneous (sc) injection of Certolizumab Pegol (CZP) every 2 weeks (Q2W).
223861866|NCT01087762|BIOLOGICAL|CZP 400 mg Q4W|400 mg subcutaneous (sc) injection of Certolizumab Pegol (CZP) every 4 weeks (Q4W).
223861867|NCT01087762|OTHER|Placebo|Matching Placebo to CZP injection.
223861868|NCT01436838|DRUG|Interferon beta-1b (Betaseron, BAY86-5046)|All patients will be prescribed with Betaseron and be instructed on treatment by their phisicians
223861869|NCT04215406|OTHER|The level of air pollution|The intervention measure is the level of air pollution, it is a non-human interventional measure based on the weighted average of various air pollutants monitored by air pollution monitoring stations during different period of pregnancy.
223861870|NCT01829386|OTHER|MRI scans with non heme iron levels|"MRI scans of the head will be performed to determine the amount of Non heme iron in areas of the brain of hemorrhagic stroke patients and hopefully predict the amount of brain damage.~Each MRI will take up to 1 hour to complete and will be done on day 3, day 14 and day 30. Some of the (MRIs) Magnetic Resonance Imaging will be clinically indicated and sequences will be added to the clinical scan with each sequence adding 10 minutes to the scan. Some sequences will be done only for research."
223861871|NCT06554262|OTHER|No intervention|No intervention was involved in this study
223861872|NCT05302713|DIETARY_SUPPLEMENT|Ionic Calcium|Ionic calcium (IC), a calcium in a free ionic state (i.e., non-protein bound), is purported to improve calcium uptake and homeostasis leading to improved cellular signaling that may have been disrupted through environmental and lifestyle stressors.
223861873|NCT05302713|DIETARY_SUPPLEMENT|Calcium Carbonate|Calcium carbonate supplementation in a solution identical in appearance, consistency, and taste to the intervention supplement.
223861874|NCT02311972|DEVICE|Philips InnerSense Esophageal Temperature Sensor/Feeding Tube|
223861875|NCT02311972|DEVICE|Standard of care feeding tube|
223861876|NCT05490277|DEVICE|Active Vibrotactile coordinated reset|Participants will receive active vibrotactile coordinated reset (vCR) which sends gentle vibrations to the fingertips at a specific pattern. The purpose of the intervention is to test the efficacy of active vCR in comparison to sham vCR.
223861877|NCT05490277|DEVICE|Sham vibrotactile coordinated reset|Participants will receive sham vibrotactile coordinated reset (vCR) which sends gentle vibrations to the fingertips at a specific pattern. The purpose of the intervention is to test the efficacy of active vCR in comparison to sham vCR.
223861878|NCT02401646|DIETARY_SUPPLEMENT|Polygoni Multiflori Radix complex extract|Intervention is manufactured by Chun-Ho food
223861879|NCT02401646|DIETARY_SUPPLEMENT|Placebo|The placebo is filled with starch, so does not contain the active ingredient.
223861880|NCT04965987|DRUG|Oxaloacetate|Oxaloacetate (OAA) is a four-carbon molecule involved in many metabolic pathways, including gluconeogenesis, citric acid cycle, glyoxylate cycle, urea cycle, and amino acid metabolism. In the glyoxylate and citric acid cycles, oxaloacetate is formed as the result of the catalysis by malate dehydrogenase. In this reaction, the hydrogen atoms from malate are transferred to NAD+, forming NADH, H+ and oxaloacetate. Oxaloacetate can be converted to citrate with the addition of acetyl-CoA by the enzyme citrate synthase. Oxaloacetate is a critical component in the production of ATP and must be constantly regenerated in order for the citric acid cycle and the electron transport chain to continue
223861881|NCT04965987|DRUG|Placebo|Placebo
223861882|NCT02054455|DIETARY_SUPPLEMENT|Lactobacillus paracasei F19|25x10E9 live bacterial cells for 3 days/week for 6 months
223861883|NCT02054455|DIETARY_SUPPLEMENT|Placebo|Placebo will consist of a preparation similar to that of probiotic but with no added microorganisms.
223861884|NCT01405924|DRUG|Fosaprepitant dimeglumine|Fosaprepitant 150 mg, IV on Day 1 of chemotherapy in Cycle 2
223861885|NCT01405924|DRUG|5-HT3 RA|5-HT3 RA will be administered at the same dosage in Cycle 2 of chemotherapy as was used for each particpant in Cycle 1 of chemotherapy.
223861886|NCT01405924|DRUG|Dexamethasone|Dexamethasone will be administered at the same dosage in Cycle 2 of chemotherapy as was used for each particpant in Cycle 1 of chemotherapy.
223861887|NCT01405924|DRUG|Rescue medication|Rescue medication is defined as any medication used to relieve the symptoms of established nausea or vomiting. Multiple medications are permitted by the protocol and may be taken by the participant, including 5-HT3 antagonists, phenothiazines and benzodiazepines.
223861888|NCT00154791|DRUG|oxaliplatin|
223861889|NCT00154791|DRUG|gemcitabine|
223861890|NCT00154791|DRUG|5-FU/LV|
223861891|NCT02087644|BIOLOGICAL|CYT003|Injections
223861892|NCT02087644|BIOLOGICAL|Placebo|Injections
223861893|NCT05501249|BEHAVIORAL|Aquatic Integrated Cognitive Motor Training|Aquatic exercise class with focus on cognitive and physical exercise
223861894|NCT05817630|OTHER|Silicone oil Tamponade for Retinal Detachment|eyes with Rhegmatogenous Retinal Detachment (RRD, for whom pars plana vitrectomy and silicone oil had been performed
223861895|NCT04709055|OTHER|Co-management|Personalized and intensive geriatric peri-operative care
223861896|NCT04709055|OTHER|Usual care|Pre-operative and post-operative geriatric care as per usual practice
223861897|NCT04686942|DIAGNOSTIC_TEST|After sonazoid|0.015ml/mg sonazoid enhanced US to detection of liver metastases.
223861898|NCT05314400|DIAGNOSTIC_TEST|Full Gadoxetate-enhanced liver MRI|Standard pulse sequences
223861899|NCT05314400|DIAGNOSTIC_TEST|Shortened Gadoxetate-enhanced liver MRI|Fewer pulse sequences
223861900|NCT01596946|BEHAVIORAL|Contact tracing mode test at clinic|
223861901|NCT01596946|BEHAVIORAL|Self-sampling at home - Sent Test Kit|
223861902|NCT03148990|BIOLOGICAL|Measles and Rubella vaccine|Administration of the experimental vaccine (MR).
223861903|NCT03148990|BIOLOGICAL|Measles, Mumps and Rubella vaccine|Administration of the comparator vaccine (MMR).
223861904|NCT00620217|GENETIC|intramyocardial injection of VEGF-A165/bFGF:placebo plasmid|The plasmid will be given at a total dose of 0.5 mg, 10 injections of 0,2 ml each into the region of reversible ischemia. The process of injecting the solution into each of ten points within the ischemic zone will take 20 to 40 seconds to minimize muscle disruption
223861905|NCT00877422|DIETARY_SUPPLEMENT|Vitamin D3|Group A and Group C are followed without drugs and Group B is followed with vitamin D3.
223861906|NCT03184558|DRUG|Bemcentinib; pembrolizumab|Bemcentinib is a selective Axl kinase inhibitor; pembrolizumab is a programmed death receptor-1 (PD-1) inhibitor.
223861907|NCT03879811|DRUG|TMZ|Oral TMZ at 150mg/m2
223861908|NCT03879811|DRUG|Nivolumab|Nivolumab via IV infusion at 480 mg every four weeks (Q4W) starting 4 weeks after TMZ day 1
223861909|NCT05676736|OTHER|No intervention|No intervention to be done for the group
223861910|NCT04771234|BEHAVIORAL|Digital self-guided CBT-i|A brief version of CBT-i consisting of brief psychoeducation, and the core components sleep restricion and stimulus control, where sleep restriction is based on a simplified sleep diary.
223861911|NCT06269822|DIAGNOSTIC_TEST|Sympathetic skin response, heart rate variability test, quantitative EEG|Sympathetic skin test (electrodermal activity) to test for sympathetic function Heart rate variability test to assess cardiovagal function Quantitative EEG to quantitatively assessing the brain function using fast fourier transform technique
223861912|NCT03126812|DRUG|Carboplatin|Carboplatin AUC=6
223861913|NCT03126812|DRUG|Paclitaxel|paclitaxel 80 mg/m2
223861914|NCT03126812|DRUG|Pembrolizumab|200 mg flat dose, starting cycle 2
223861915|NCT00958386|DRUG|Panitumumab+irinotecan|"Panitumumab will be administered as a 60 minute ± 15 minutes IV infusion, just prior to administration of chemotherapy at a dose of 6 mg/kg on day 1 of each cycle. A cycle of Panitumumab is defined as 14 days.~Irinotecan chemotherapy (180 mg/m2 in 90 min on day 1 of each cycle) will be administered after the administration of Panitumumab.~Each treatment cycle will have a duration of 14 days."
223861916|NCT03769233|BEHAVIORAL|Mindfulness-based Intervention|MBI will be delivered in group format, 90 minutes per week, for 5 consecutive weeks with 6-15 participants per group.
223861917|NCT01306513|BIOLOGICAL|autologous bone marrow derived mesenchymal stromal cells|Intravenous administration of autologous bone marrow-derived mesenchymal stromal cells.
223861918|NCT04832542|OTHER|outpatient follow-up|The patients were evaluated every six months in order to assess the incidence of traumatic syncope recurrence during follow-up after implantable loop recorder implantation.
223861919|NCT00395018|DRUG|entecavir|Tablets, Oral, 1 mg, once daily, up to 72 weeks
223861920|NCT04707417|OTHER|Home care|Advanced home care
223861921|NCT03709719|DRUG|Blinatumomab Injection|Blinatumomab 28 μg/day : D1 to D28
223861922|NCT00888979|DRUG|Nicotrol Inhaler|10 mg of nicotine per one inhaler cartridge. Inhaler use will substitute the usual smoking pattern
223861923|NCT06373107|BEHAVIORAL|High intensity gait training|Participants will practice walking that is vigorous enough to keep their heart rate over a certain level during their physical therapy sessions. During the sessions, participants will walk and step vigorously enough to keep the heart rate between 60-80% of their maximum heart rate. Maintaining this heart rate during exercise helps to improve heart health and walking, which can affect people after a stroke.
223861924|NCT00662480|PROCEDURE|Screening for hypertension, lower limb atherosclerosis and abdominal aortic aneurysm|Invited to vascular screening
223861925|NCT05827393|PROCEDURE|muscle transplantation|the resected extra stump of rectus muscle was transplanted to the other horizontal rectus muscle which was recessed by a standard recession technique
223861926|NCT01391130|DRUG|LY2510924|Administered subcutaneously
223861927|NCT01391130|DRUG|Sunitinib|Administered orally
223861928|NCT03961633|BEHAVIORAL|AWARE intervention|"will attend the AWARE group counseling sessions, which are 90 minutes, once a week, for 8 weeks. Each week's session is focused on a specific theme related to the cultural and gender-specific issues typical among young Asian American women. The sessions are led by staff therapists at either institution. For more info on each session's content, please see the Study Description - Detailed Description section.~Participants will fill out forms that detail their therapeutic goals (commitments) and any adverse emotional / behavioral events from the past week. Participants will also receive daily text messages that reinforce the group session themes."
223861929|NCT02533635|DIETARY_SUPPLEMENT|A Master Ganoderma Detox Tea|A Master Ganoderma Detox Tea is consisted of GANODERMA, HERBA HOUTTUYNIAE, GLYCYRRHIZAE RADIX ET RHIZOMA and RUCTUS MOMORDICAE.
223861930|NCT06391619|OTHER|No intervention|Study is observational
223861931|NCT00653276|DRUG|ezetimibe|ezetimibe 20 mg (2 x 10 mg tablets) on Days 1 through Day 7.
223861932|NCT00653276|DRUG|Comparator: cyclosporine|single oral dose of cyclosporine 100 mg capsules on Day 1 or Day 7.
223861933|NCT04330469|PROCEDURE|Periodontal therapy|"Treatment will be performed by a periodontist.~1. Intensive removal of subgingival and supragingival calculus and plaque biofilm by scaling, root-planing and polishing. The procedures will be carried out with the use of hand scalers and a piezoelectric ultrasonic scaler with universal tips. Disclosing solution will be used to visualize the plaque for the clinician.~2. One to four sessions of subgingival scaling and root planing by quadrant, under local anesthesia as may be deemed necessary during the study period.~3. Subgingival irrigation using an antiseptic mouth rinse (chlorhexidine 0.12%).~4. Polishing of the coronal and radicular surfaces of the teeth."
223861934|NCT04330469|PROCEDURE|Oral hygiene advice|Oral hygiene advised by Periodontist
223861935|NCT06343103|OTHER|Workers exposed|Workers exposed to cytotoxic agents
223861936|NCT06343103|OTHER|Workers not exposed|Workers not exposed to cytotoxic agents
223861937|NCT03478696|DRUG|budesonide/formoterol|Subjects will be administered two inhalations of budesonide/formoterol via MDI twice daily
223861938|NCT03478696|DRUG|albuterol/salbutamol|Subjects will be provided short-acting albuterol/salbutamol as-rescue medication to be used on an as-needed basis throughout the study.
223861939|NCT03478696|DRUG|FF/UMEC/VI|Subjects will receive FF/UMEC/VI 100/62.5/25 mcg via ELLIPTA once daily in the morning
223861940|NCT03478696|DRUG|Placebo to match budesonide/formoterol|Subjects will be administered two inhalations of matching placebo twice daily via MDI
223861941|NCT03478696|DRUG|tiotropium|Subjects will receive tiotropium (18 mcg) once daily in the morning via HandiHaler device
223861942|NCT03478696|DRUG|Placebo to match FF/UMEC/VI|Matching placebo to FF/UMEC/VI will be administered via ELLIPTA once daily in the morning.
223861943|NCT03478696|DRUG|placebo to match tiotropium|Subjects will receive tiotropium matching placebo via Handihaler once daily in the morning
223861944|NCT03478696|DEVICE|ELLIPTA|Subjects will receive FF/UMEC/VI 100/62.5/25 mcg and matching placebo via ELLIPTA in the treatment period. Budesonide/formoterol plus tiotropium once daily plus placebo will be administered via ELLIPTA during the run-in period.
223861945|NCT03478696|DEVICE|MDI|Subjects will receive budesonide/formoterol and placebo to match budesonide/formoterol via MDI in the treatment period.
223861946|NCT03478696|DEVICE|HandiHaler|Subjects will be administered tiotropium (18 mcg) or placebo to match tiotropium via HandiHaler during the treatment period.
223861947|NCT03491696|DRUG|Metyrapone|Association of Selective Serotonin Reuptake Inhibitor or Serotonin and Norepinephrine Reuptake Inhibitor and METYRAPONE. Duration of the association : 28 days.
223861948|NCT00431431|DRUG|tibolone|2 years treatment with tibolone (1.25 mg Org OD-14)
223861949|NCT00431431|DRUG|raloxifen|2 years treatment with raloxifene (60 mg)
223861950|NCT03068858|DIAGNOSTIC_TEST|real-time feedback of SYNTAX score category|
223861951|NCT03615924|DRUG|Ticagrelor|"The double-blinded study drug dose will be weight dependent:~* ≥12 to ≤24kg: Ticagrelor 15 mg, twice a day~* \>24 to ≤48 kg: Ticagrelor 30 mg, twice a day~* \>48 kg: Ticagrelor 45 mg, twice a day."
223861952|NCT03615924|DRUG|Placebo|"The double-blinded study drug dose will be weight dependent:~* ≥12 to ≤24kg: Placebo to match ticagrelor 15 mg, twice a day~* \>24 to ≤48 kg: Placebo to match ticagrelor 30 mg, twice a day~* \>48 kg: Placebo to match ticagrelor 45 mg, twice a day."
223861953|NCT03782350|DRUG|Tranexamic Acid Dosage 1|Tranexamic Acid Dosage 1
223861954|NCT03782350|DRUG|Tranexamic Acid Dosage 2|Tranexamic Acid Dosage 2
223861955|NCT02562391|DEVICE|Surgical ablation of the left atrium (PVI+Box lesions)|
223861956|NCT02562391|DEVICE|Surgical ablation of the left atrium (PVI+Box lesions) and left atrial appendage cutting|
223861957|NCT05103748|BEHAVIORAL|Traditional vestibular rehabilitation|The patient shook his head horizontally and looked in the direction of head rotation. Repeated 10 times, and then shook his head with eyes closed and repeated 10 times. The patient holds a small visual target to practice. The small visual target is placed about 30cm in front of the patient. The subject moves his head back and forth while keeping his sight on the target.
224076289|NCT06486181|OTHER|Thrombolysis/Thrombectomy|"Endovascular interventions will be either catheter directed thrombolysis or mechanical thrombectomy procedures both of which have been cleared by FDA for the treatment of acute DVT.~Catheter-directed thrombolysis involves the use of a catheter to deliver thrombolytic agents directly to the site of the clot, effectively dissolving the thrombus. Mechanical thrombectomy, on the other hand, employs specialized devices to physically remove the clot from the vessel. These procedures have been cleared by FDA as they are targeted approaches to safely and effectively restore blood flow and reduce the risk of complications associated with acute DVT."
224076290|NCT02821858|DRUG|Odalasvir (ODV)|ODV 50 mg (1 tablet) in Treatment A, 100 mg (2 tablets of 50 mg) in Treatment B and 300 mg (6 tablets of 50 mg) in Treatment C.
223861958|NCT05103748|BEHAVIORAL|Cognitive and vestibular dual task training|The patient shook his head horizontally and looked in the direction of head rotation. Repeated 10 times, and then shook his head with eyes closed and repeated 10 times. The patient holds a small visual target to practice. The small visual target is placed about 30cm in front of the patient. The subject moves his head back and forth while keeping his sight on the target. Besides, patients wear headphones to listen to the numbers at the same time. The numbers contain 1 and 2, and they are played randomly. They shake their heads when they hear 1, and nod when they hear 2. The training takes 30 minutes, once a day in the morning and evening.
223861959|NCT05127551|DEVICE|iStent Infinite|Implantation of the iStent Infinite
223861960|NCT05127551|DEVICE|Competitor Device|Implantation of competitor device
223861961|NCT01305291|OTHER|placebo|
223861962|NCT01305291|DIETARY_SUPPLEMENT|digestion-resistant maltodextrin|
223861963|NCT01685788|OTHER|No intervention|
223861964|NCT02794350|DEVICE|Cochlear implant|
223861965|NCT02612818|DEVICE|Coelioscopy|
223861966|NCT05800639|PROCEDURE|Ophthalmic surgery|Ophthalmic surgery will be performed as standard practice of our institution.
223861967|NCT05800639|PROCEDURE|General anesthesia|General anesthesia will be performed as standard practice of our institution.
223861968|NCT02828254|DRUG|PRI-724|
223861969|NCT02602743|DRUG|Remifentanyl|0,25 µg/kg remifentanyl will be administered for induction in 1 minute. Then 0,1 µg/kg/h remifentanyl infusion will be started.
223861970|NCT02602743|DRUG|Propofol|1 mg/kg propofol will be administered for induction and then 1 mg/kg/h propofol infusion will be started.
223861971|NCT02602743|DRUG|Ketamine|2 mg/kg ketamine will be administered for induction in 1 minute.
223861972|NCT04642794|OTHER|observational study|patients admitted for AP with portosplenomesenteric vein thrombosis.
223861973|NCT03580798|PROCEDURE|Delayed graft|8 weeks post-extraction 15 test patients will receive implant placement plus osseous grafting.
223861974|NCT03580798|PROCEDURE|Simultaneous graft|At the time of extraction osseous graft will be placed in the socket and implant placed 4 months later.
223861975|NCT00420654|DRUG|Growth Hormone|1.25 mg, 6 months
223861976|NCT00420654|DRUG|Placebo|Equivalent to 1.25 mg, 6 months
223861977|NCT00420654|OTHER|Healthy controls|Healthy controls
223861978|NCT04484415|COMBINATION_PRODUCT|Cevira®|The device is a single-use, disposable, LED-based red light source. The device will automatically switch on the light 5 hours after administration, and provide continuous photoactivation of 125 J/cm2 over 4.6 hours before automatically shutting down.
223861979|NCT04484415|COMBINATION_PRODUCT|Placebo|The placebo device is identical in appearance as the Cevira® device, but does not provide light.
223861980|NCT01568918|DRUG|Tamsulosin hydrochloride|Participants will receive 0.4 mg/day tamsulosin hydrochloride from 5 days prior to the operation until hospital discharge.
224076291|NCT02821858|DRUG|AL-335|AL-335 400 mg (1 tablet) in Treatment D, 800 mg (2 tablets of 400 mg) in Treatment E and 1200 mg (3 tablets of 400 mg) in Treatment F.
223861981|NCT01568918|OTHER|Placebo|The placebo capsule matching the active study drug will be given daily from 5 days prior to the operation until hospital discharge.
223861982|NCT05076318|OTHER|Aminoacid, alanine-infusion|During 3 hours, patient will receive alanine-infusion, while amino-acid and urea will be monitored by blood samples.
224076292|NCT02821858|DRUG|Placebo|Matching placebo will be administered.
224076293|NCT02421887|DRUG|Antioxidant Supplement|An antioxidant combination including Vitamin C, Vitamin E, folic acid, selenium, zinc, and L-carnitine
224076294|NCT02421887|OTHER|Placebo|Placebo
224076295|NCT01742429|DRUG|Proton pump inhibitor|
223861983|NCT05790928|DEVICE|Lotrafilcon A spherical contact lenses|CE-marked silicone hydrogel contact lenses indicated for the optical correction of refractive ametropia (myopia and hyperopia) in persons with minimal astigmatism that does not interfere with visual acuity
223861984|NCT03958500|PROCEDURE|Indocyanine green fluorescent angiography intraluminally and intraperitoneally|The use of indocyanine green fluorescent angiography to check bowel and anastomosis viability in standard low anterior rectal anastomosis
223861985|NCT01198340|PROCEDURE|PC-FNB with basal administration of local anesthetics|Administration of 0.2% ropivacaine for femoral nerve block with 3 ml/h of basal dose, 5ml bolus by the patient, 60 minutes of lock out time.
223861986|NCT01198340|PROCEDURE|PC-FNB without basal local anesthetics|Administration of 0.2% ropivacaine for femoral nerve block without basal dose, with 8 ml bolus by the patient, 60 minutes of lockout time.
223861987|NCT01285830|DIETARY_SUPPLEMENT|Lactobacillus reuteri|The mothers started taking Lactobacillus reuteri ATCC 55730 (BioGaia AB, Stockholm, Sweden) or placebo four weeks before term and continued to do so daily until delivery. After birth, the baby commenced with the same study product as the mother at 1-3 days of age and continued daily for one year. The daily intake, five oil droplets, corresponded to 1 x 100 000 000 colony forming units (CFU)
223861988|NCT01285830|DIETARY_SUPPLEMENT|Placebo|The placebo consists of the same oil that the active study product but without any bacteria and is not possible to differentiate from the active product by smell, taste or visual appearance
223861989|NCT04788433|DIAGNOSTIC_TEST|glycomic analysis|Analysis of glycans on plasma samples
223861990|NCT04788433|OTHER|Phone interview|patients are followed up by phone up to 1 year
223861991|NCT02639013|PROCEDURE|transducer technique|the nurses will receive the intervention ( the transducer method) to measure intraabdominal pressure intraabdominal hypertension and how to measure intraabdominal pressure in the third section
223861992|NCT04301986|DEVICE|Cytosponge|In a seated position, subjects will swallow the Cytosponge capsule with 150-250 mL of water. Seven minutes and 30 seconds to ten minutes after ingestion, the sponge is then withdrawn by gentle traction on the suture. After retrieval, the string is cut and the retrieved foam sphere containing the cytological specimen is immersed in fixative and stored refrigerated (1° to 12°C \[34° to 54°F\]).
223861993|NCT04301986|DEVICE|Transnasal Endoscopy (TNE)|In an upright position, the scope will be inserted via the nares to examine the posterior pharynx, esophagus and proximal stomach with the transnasal endoscopy approach. The scope will be withdrawn from the nares following completion of the exam.
223861994|NCT04301986|DEVICE|Esophagogastroduodenoscopy|Laying on the subjects' left side, the flexible endoscope is inserted through the mouth to allow visualization of the esophageal mucosa from the upper esophageal sphincter all the way to the esophagogastric junction (EGJ).
223861995|NCT01679951|DRUG|Placebo|Form=tablet, route=oral. Placebo will be administered once daily from week 0 to week 24.
223861996|NCT01679951|DRUG|JNJ-38518168 (3 mg)|Type=exact number, unit=mg, number=3, form=tablet, route=oral. JNJ-38518168 will be administered once daily up to 24 weeks.
223861997|NCT01679951|DRUG|JNJ-38518168 (10 mg)|Type=exact number, unit=mg, number=10, form=tablet, route=oral. JNJ-38518168 will be administered once daily up to 24 weeks.
223861998|NCT01679951|DRUG|JNJ-38518168 (30 mg)|Type=exact number, unit=mg, number=30, form=tablet, route=oral. JNJ-38518168 will be administered once daily up to 24 weeks.
223861999|NCT01679951|DRUG|Methotrexate|Participants must have been treated with and tolerated Methotrexate (MTX) treatment at dosages from 10 to 25 milligram per week (mg/week) inclusive, for a minimum of 6 months prior to the date of signing the informed consent at screening and must have a stable MTX dose for a minimum of 8 weeks prior to the date of signing the informed consent at screening and continue to receive the same MTX dose at Week 0 through Week 24.
223862000|NCT01799148|OTHER|Particulate air pollutants|We will determined the average concentrations of different sizes of particulate matter from 1 day or up to 7 days prior to admission in patients with acute coronary syndrome.
223862001|NCT03522467|DRUG|MRCP001|MRCP001 is a formulated whole-plant cannabis oil extract, that may help manage poorly controlled chronic pain.
223862002|NCT03280836|BEHAVIORAL|Exercise|"All participants randomized to the intervention group will be asked to keep an exercise log with the date, time, average heart rate obtained from a heart rate monitor, duration of workout and stretching, and any comments regarding the workout. Participants will be instructed to bring workout logs to infusion sessions for review. Participants will also wear a Polar Heart Rate monitor (US model RS400, Polar Electro Inc., Lake Success, NY) during exercise to monitor exercise intensity.~The aerobic exercise intervention will work toward the target of 75 minutes physical activity per week at 60%-85% of baseline VO2max."
223862003|NCT04176367|DRUG|Nicergoline from China|This is the test arm of China local manufactured Nicergoline
223862004|NCT04176367|DRUG|Nicergoline from Italy|This is the reference arm of Italy originator Nicergoline.
223862005|NCT03747354|DIAGNOSTIC_TEST|blood samples|blood samples
223862006|NCT06111937|OTHER|after ultrasound gastric assessment to ensure gastric empty, painless colonoscopy was performed within 2 hours|Patients received gastric ultrasound examination every 15 minutes 2 or 4 hours immediately after taking the last dose of MgSO4 solution in group A or B respectively.
223862007|NCT01891968|DRUG|Bortezomib|1.3 mg/m2 subcutaneously on days 1, 4, 8 and 11 of a 21 day cycle.
223862008|NCT03432780|DRUG|Docetaxel|
223862009|NCT03432780|BIOLOGICAL|Hormone and radiation therapy|
223862010|NCT03432780|RADIATION|Radiation therapy|
223862011|NCT03778099|DRUG|Cinnamon Cap 500 MG|The Cinnamomum cassia (C. aromaticum) capsules will be purchase from Spring Valley company (distributed by Wal-Mart Stores, Inc. USA) by the investigator.
223862012|NCT03778099|DRUG|Placebo|450 mg of starch and 50 mg of cinnamon powder
223862013|NCT04233931|BEHAVIORAL|PrEP medication adherence mobile app|Participants use a PrEP medication adherence mobile app for six weeks.
223862014|NCT00880048|DRUG|orvepitant|neurokinin-1 antagonist
223862015|NCT00880048|OTHER|Placebo|Placebo to match orvepitant 30 mg and 60 mg
223862016|NCT03731936|OTHER|No intervention|No intervention
223862017|NCT04141917|COMBINATION_PRODUCT|Point-of-care molecular testing and treatment of influenza|Eligible individuals will be tested on site with a point-of-care molecular influenza test and, if positive, offered antiviral treatment with baloxavir for those aged ≥12 years, or oseltamivir for those aged \<12 years; pregnant; breastfeeding; liver disease; or are immunosuppressed. Follow-up nasal swabs and symptom diaries will be collected from participants 2 or 3 days after receiving the antiviral, and again 5, 6, or 7 days after receiving.
223862018|NCT00964197|DEVICE|FemmeJock|The participant will be fitted with the girdle. The participant will use the girdle for the next 3 months. The girdle is only to be worn during the daytime during times of physical activity. The length of time you choose to wear it during the day is the patients choice. In two weeks the participant will be asked to fill out a 5 question survey in a follow up visit. The participant will be asked to return 3 months after wearing the FemmeJock girdle and to fill out a 5 question survey, as well as to complete a 20 question survey.
223862019|NCT04021615|OTHER|Comprehensive physical therapy rehabilitation program combined with inspiratory muscle training|A threshold inspiratory muscle trainer will be connected to the artificial airway with 15 mm and 22 mm adaptors. Training bouts consist of three to five sets of six repetitions breathing through the trainer. Training will be conducted with the patient in bed with an approximately 30° head-up tilt and with intensity about 40 %- 50 % of maximal inspiratory pressure. Patients will be returned to mechanical ventilation for rest between training sets as needed. Three to five sets of six training breaths will be completed for a total of 18 to 30 training breaths per session. Following each training set, the patient indicated a rating of perceived inspiratory exertion on modified Borg scale . The study group will also receive comprehensive rehabilitation program consist of upper-extremity exercises, lower extremity exercises, pedaling exercises, trunk control exercises and bedside functional training
223862020|NCT04021615|OTHER|Traditional chest physical therapy rehabilitation program combined with inspiratory muscle training|The same inspiratory muscle training for the study group combined with the traditional physical therapy program consist of positioning , modified postural drainage , percussion , vibration.
223862021|NCT00480519|PROCEDURE|Meatotomy|
223862022|NCT02954848|DRUG|Placebo|TAK-438 placebo-matching tablets
223862023|NCT02954848|DRUG|TAK-438 10 mg|TAK-438 tablets
223862024|NCT04048018|DIAGNOSTIC_TEST|Blood draw and IGRA test|One to two blood samples will be obtained from participants in all arms in order to conduct testing.
223862025|NCT00861458|DRUG|Pharmacokinetics|Single dose of 750 mg PF-00868554 as a solution and tablets.
224076296|NCT01742429|DRUG|Bismuth subsalicylate|
224076297|NCT01742429|DRUG|Metronidazole|antibiotic
224076298|NCT01742429|DRUG|Tetracycline|antibiotic
224076299|NCT01742429|DRUG|Amoxicillin|antibiotic
224076300|NCT01742429|DRUG|Levofloxacin|antibiotic
223862026|NCT05381571|OTHER|Motivating reminiscence physical therapy|The jDome BikeAround system involves participants using a stationary bike while their selected location is displayed in front of them on a domed projector screen using Google Street View. Using pedals on the bike they can propel themselves down the street, steer and change direction as they wish.
223862027|NCT01765686|DEVICE|Harmonic Scalpel (Ethicon Endo-Surgery, USA)|
223862028|NCT01765686|DEVICE|Ligasure Small Jaw (Covidien, USA)|
223862029|NCT00427752|PROCEDURE|Transgastric endoscopic peritoneoscopy.|Exploration of the abdominal area
223862030|NCT00541125|BIOLOGICAL|bevacizumab|
223862031|NCT00541125|BIOLOGICAL|filgrastim|
223862032|NCT00541125|DRUG|fluorouracil|
223862033|NCT00541125|DRUG|irinotecan hydrochloride|
223862034|NCT00541125|DRUG|leucovorin calcium|
223862035|NCT01983306|DRUG|SP-333 1 mg|Tablet
223862036|NCT01983306|DRUG|SP-333 3 mg|Tablet
223862037|NCT01983306|DRUG|SP-333 6 mg|Tablet
223862038|NCT01983306|DRUG|Placebo|Tablet
223862039|NCT04045106|OTHER|Proprioceptive Neuromuscular Facilitation Patterns|The participants were asked to sit on a chair, the therapist performed the pattern of movement himself then passively applied the pattern on the participant then asked the participant to perform the pattern, and the therapist observed and corrected the movement if it was done improperly.Then participants were told that the therapist will resist their movement, they were also told to keep breathing normally and to report any discomfort and/or pain.After mastering the pattern,the therapist placed one hand on the participant's mandibular and the other hand approximately between parietal and occipital bones to apply resistance through out the ROM, each pattern performed for 3 sets of 10 repetitions with 1-2-minute rest between sets.
223862040|NCT04045106|OTHER|Proprioceptive Neuromuscular Facilitation stretching|was done for 6 repetitions with hold for 6 seconds in position of stretch and sub maximal isometric contraction for 6 seconds, 1-2-minute rest was given before changing the target muscle group
223862041|NCT04045106|OTHER|Passive range of motion|ineffective passive ROM for 10 repetitions for flexion, extension, right and left side bending and right and left rotation, it was done from neutral position to the limit of motion without causing any stretch to the muscle.
224076301|NCT03521505|DRUG|Dexmedetomidine arm|Induction: Dexmedetomidine 1ug/kg infusion for 10 minutes. 5 mg/kg alfentanil (1:10 dilution) slow injection 2 min before complete Dexmedetomidine induction Maintenance: Dexmedetomidine 0.5\~1.4ug/kg/hour infusion±0.2ug/kg/hour to maintain stable vital signs and The Observer Assessment of Alertness and Sedation scale (OAA/S) 3\~2. the infusion rate was increased by 0.2ug/kg/hour if the patient persistently had eye opening, talked, or became irritable and interfered with the procedure. The infusion rate was reduced by 0.2ug/kg/hour, if the following adverse events occurred: hypoxemia (SpO2 \< 90%) or hypotension (mean arterial pressure (MAP) \< 65 mmHg, or systolic blood pressure (SBP) \< 90 mmHg) in any duration
223862042|NCT03444506|DRUG|Molo 1 (also referred as GSP 301-2 NS)|
223862043|NCT03444506|DRUG|Molo 2 (also referred as GSP 301-1 NS)|
223862044|NCT03444506|DRUG|Placebo nasal spray|
223862045|NCT03444506|DRUG|DYMISTA nasal spray|
223862046|NCT03444506|DRUG|PATANASE nasal spray|
223862047|NCT04735341|DEVICE|Ion Endoluminal System|Ion Endoluminal Procedure for pulmonary nodule
223862048|NCT06233591|DRUG|LP-10 (Liposomal Tacrolimus)|Liposomal oral rinse formulation of Tacrolimus
223862049|NCT04554628|DIAGNOSTIC_TEST|ELISA test in urine|enzyme linked immunosorbent assay technology for detection of UNGAL and UKIM1 in urine in postoperative ICU patients
223862050|NCT03368937|DEVICE|Tandem t:slim X2 with Control-IQ Technology|Subjects will wear the Tandem t:slim X2 with Control-IQ Technology during a 36-48 hour hotel admission.
223862051|NCT03411239|DEVICE|Adult esophageal balloon catheter (obc)|Using OBC to determine airway pressure changes in patients undergoing general anaesthesia for laparoscopic surgery
223862052|NCT02485444|DRUG|Oxytocin|20 IU oxytocin in 500 ml normal saline will be infused 100 ml/h i.v. after fetus is delivered
223862053|NCT00509639|DRUG|10% Metronidazole Ointment|Metronidazole 10% ointment applied perianally three times daily for four weeks. Placebo ointment applied perianally three times daily for four weeks
223862054|NCT01681251|OTHER|Fluid titrated with the use of arterial pulse contour cardiac output monitor if SVV >13%|"Following induction of anesthesia, Voluven boluses of 250ml will be given if SVV increases above 10%. Further Voluven boluses will be given in 250ml aliquots should the SVV increase to greater than 10%. If a total of 55ml/kg of Voluven is given, the fluid will be changed to lactated ringers and no further colloid will be given, as this is the maximum dose recommend by the manufacturer.~Vasoactive agents (type and dose at the discretion of the attending anesthesiologist) may be given to maintain a mean arterial pressure that the clinical team feels adequate to maintain adequate organ perfusion. In the intervention group, however, vasoactive agents will not be given unless fluid administration has resulted in a maximal value of SV."
223862055|NCT01681251|OTHER|Fluid titrated at the discretion of the attending anesthesiologist|In the control group, the data from the FloTrac monitor will not be available to the anesthesia care provider. Fluid replacement will be at a rate and of a type that is entirely up to the anesthesiologist; the only stipulation being that Voluven is to be used should the provider desire to use a colloid solution.
223862056|NCT03354039|DRUG|Tamoxifen|DMD patients randomised to verum will receive 20 mg (0.6mg/kg) of Tamoxifen daily. Treatment will be given for the total period of 48 weeks.
223862057|NCT03354039|DRUG|Matching placebo|Patients randomised to placebo will be administered matching placebo. Treatment will be given for the total period of 48 weeks.
223862058|NCT01018836|DRUG|riluzole|The first dose of Riluzole will be day 0 of study enrollment. WBRT must begin within 48 hours of the initiation of Riluzole therapy. At the completion of radiation, Riluzole should be discontinued and steroids should be tapered over the course of 1-3 weeks, at the discretion of the treating physicians.
223862059|NCT01018836|RADIATION|whole-brain radiation therapy|Standard whole brain irradiation will be carried out at 250 cGy per day fractions times 15 to a total dose of 3750 cGy using a standard opposed lateral helmet field with the inferior border inclusive of C1.
223862060|NCT04893213|OTHER|Manipulation of availability of lower energy meal options|Menus provided differ in % of menu options that are higher vs. lower in energy
223862061|NCT03686891|OTHER|Skin prick tests with four native legumes|Skin prick tests with four native legumes
223862062|NCT01184508|DRUG|Placebo|Administered orally, once daily, for 12 weeks
223862063|NCT01184508|DRUG|LY2300559|300 milligrams (mg) administered orally, once daily, for 12 weeks
223862064|NCT02462551|DEVICE|Focal Electrically Administered Seizure Therapy|A focal administration of the right unilateral configuration of electro-convulsive therapy for the treatment of recurrent and treatment-resistant depression.
223862065|NCT02537704|BEHAVIORAL|Group Lifestyle Balance Program|
223862066|NCT01414842|DEVICE|Automated sodium profiling in endogenous hemodiafiltration|Automated sodium profiling during endogenous reinfusion hemodiafiltration technique. The device processes the dialysate sodium and ultrafiltration rate during dialysis to achieve a preset sodium target at the end of the treatment. Sodium dialysate and maximal ultrafiltration rate are constraint within safety limits during dialysis.
223862067|NCT01414842|DEVICE|Standard sodium dialysate|Standard constant (no profiled) sodium dialysate used during endogenous hemodiafiltration
223862068|NCT05566080|PROCEDURE|Carotid endarterectomy|Patients who have a significant carotid stenosis and who undergo surgical carotid endarterectomy
223862069|NCT01269736|BEHAVIORAL|Education|Online ECG monitoring education program and strategies to implement and sustain change for nurses
223862070|NCT02887768|DEVICE|Epicardial Infarct Repair with CorMatrix-ECM|CorMatrix-ECM-biomaterial will be surgically applied to the epicardial surface of the infarct myocardium at the time of coronary artery bypass surgery
223862071|NCT02887768|PROCEDURE|Coronary Artery Bypass Grafting Surgery|All participants will undergo standard coronary artery bypass grafting surgery to treat coronary artery disease
223862072|NCT01229358|OTHER|Surgical dressing|Acticoat Absorbant™ vs standard dry gauze as the immediate post operative dressing
223862073|NCT02032329|DEVICE|FastFES|Fast treadmill walking supplemented with FES to ankle plantarflexor and dorsiflexor muscles, using a VFT stimulation pattern. 12 weeks of 2-3x/week. Stimulation delivered using the customKYnetics study device.
223862074|NCT05790616|PROCEDURE|Arterial blood draw|"For the IN(Fast-Sitting) arm arterial blood will be collected to derive Gold-standard SaO2 reference values."
223862075|NCT05790616|OTHER|Oxygen reduction|Volunteers undergo an ambient oxygen decrease from 21% to 10%
223862076|NCT04014933|DIAGNOSTIC_TEST|LASER SPECKLE FLOWGRAPHY|Non-invasive, real-time imaging and measurement of ocular blood flow of the optic disc and peripapillary region
223862077|NCT05685095|BEHAVIORAL|Physical training|Supervised gait training program 3 times a week, 12 weeks
223862078|NCT02861937|PROCEDURE|non surgical periodontal therapy|and root planing (SRP) was performed in two to four appointments lasting approximately 60 minutes each under local anaesthesia (2% lignocaine hydrochloride with 1:2,00,000 adrenaline) using area specific Gracey periodontal curettes and an ultrasonic device. The treatment was concluded in 3 weeks. Within the duration of the study, all subjects received supportive therapy, which included professional plaque control and reinstruction of oral hygiene.
223862079|NCT00002810|BIOLOGICAL|filgrastim|
223862080|NCT00002810|DRUG|melphalan|
223862081|NCT00002810|PROCEDURE|bone marrow ablation with stem cell support|
223862082|NCT00002810|PROCEDURE|peripheral blood stem cell transplantation|
223862083|NCT05131386|DRUG|Trabectedin|ET-743, Yondelis (vials of 1 mg). Route of administration: intravenous infusion
223862084|NCT03178110|BEHAVIORAL|Physical therapy and dynasplint|Participants will receive a session of 30-45 minutes of manual therapy two times per week, for eight weeks. All participants will be instructed how to use the Dynasplint® Trismus System at home. Participants will start the use of the DTS for 10-30 minutes three times per day, every day. If the exercises are well tolerated, time will be progressively increased to 30 minutes and then intensity (force) will be increased.
223862085|NCT03684265|DRUG|Meloxicam Capsule (Test)|single dose
223862086|NCT03684265|DRUG|Meloxicam Tablet (Reference)|single dose
223862087|NCT02724085|DRUG|TP-271|TP-271 is a novel, broad-spectrum tetracycline with potent activity against multidrug-resistant pathogens. It will be administered intravenously (IV) in doses ranging from 0.15 to 5.0 mg/kg
223862088|NCT05692908|BIOLOGICAL|STI-6129|Four cycles of intravenous infusion of STI-6129 will be given (one infusion every four weeks).
223862089|NCT05723510|DRUG|Tegoprazan 50mg|Oral administration of one tablet of tegoprazan 50 mg once daily
223862090|NCT05723510|DRUG|Edoxaban 60mg|Oral administration of one tablet of edoxaban 60 mg once daily
223862091|NCT05723510|DRUG|Apixaban 5mg|Oral administration of one tablet of apixaban 5 mg twice daily
223862092|NCT05723510|DRUG|Rivaroxaban 20mg|Oral administration of one tablet of rivaroxaban 20 mg once daily
224076302|NCT03521505|DRUG|Propofol arm|"5 mg/kg alfentanil (1:10 dilution) slow injection 2 min before induction Induction: The initial effect-site concentration (Ce) of propofol was targeted to 2.0 μg/ml for induction (Schneider model of target-controlled infusion (TCI), Injectomat total intravenous anaesthesia (TIVA) Agilia, Fresenius Kabi, France). If OAA/S did not reach 3 while Ce achieved 2.0 μg/ml, Ce was increased by 0.2 μg/ml every 90 seconds until OAA/S 3\~2.~Maintenance: the Ce was increased by 2.0 μg/mL every 90 seconds if the patient persistently had eye opening, talked, or became irritable and interfered with the procedure. The Ce was reduced by 0.2 μg/ml every 90 seconds, if the following adverse events occurred: hypoxemia (SpO2 \< 90%) or hypotension (mean arterial pressure (MAP) \< 65 mmHg, or systolic blood pressure (SBP) \< 90 mmHg) in any duration."
223862093|NCT04820439|DRUG|recombinant monoclonal antibody against human epidermal growth factor receptor injection (HS627)|A single intravenous infusion of HS627 420mg
223862094|NCT04820439|DRUG|Perjeta ®|A single intravenous infusion of Perjeta ®420mg
223862095|NCT01356758|DRUG|biological treatment|patients treated with anti-psoriatic biological agents
223862096|NCT03141333|BEHAVIORAL|Teleintervention|Participants of this group will have access to the following sections in the web plate-form: information, forum, chat and live online consultation. The teleintervention consists of having access to the forum, chat and live online consultation sections of the web plate-form.
223862097|NCT01301469|DRUG|6% HES 130/0.42 in plasma adapted Ringer's solution|60 g/l hydroxyethyl starch 130 dissolved in plasma adapted Ringer's solution (balanced solution)
223862098|NCT01301469|DRUG|6% HES 130/0.4 in a saline solution|60 g/l Hydroxyethyl starch (HES) with a mean molecular weight of 130 kDalton which is dissolved in a saline solution
223862099|NCT05817968|DEVICE|intelligent Esophageal Pressure Catheter (iEPC)|"Placement of the iEPC nasogastric catheter with solid state sensor for esophageal manometry.~Comparator: Esophageal balloon catheter (NutriVent)."
223862100|NCT01783977|BIOLOGICAL|DNA-HIV-PT123 vaccine|DNA-HIV-PT123 4 mg/mL; administered as 1 mL IM in participant's deltoid
223862101|NCT01783977|BIOLOGICAL|NYVAC-HIV-PT1 vaccine|NYVAC-HIV-PT1 at greater than or equal to 5x10\^6 plaque-forming units (PFU)/ml for a planned maximum dose of 1.2x10\^8 PFU/ml; administered as 1 mL IM in participant's deltoid
223862102|NCT01783977|BIOLOGICAL|NYVAC-HIV-PT4 vaccine|NYVAC-HIV-PT4 at greater than or equal to 5x10\^6 PFU/ml for a planned maximum dose of 1.1x10\^7 PFU/ml; administered as 1 mL IM in participant's deltoid
223862103|NCT01783977|BIOLOGICAL|Placebo for DNA-HIV-PT123 vaccine|Placebo for DNA-HIV-PT123 administered as 1 mL IM in participant's deltoid
223862104|NCT01783977|BIOLOGICAL|Placebo for NYVAC-HIV-PT1 vaccine|Placebo for NYVAC-HIV-PT1 vaccine administered as 1 mL IM in participant's deltoid
223862105|NCT01783977|BIOLOGICAL|Placebo for NYVAC-HIV-PT4 vaccine|Placebo for NYVAC-HIV-PT4 vaccine administered as 1 mL IM in the participant's deltoid
223862106|NCT05727202|DIAGNOSTIC_TEST|The Applied Biosystems™ TaqPath™ COVID-19, Flu A, Flu B, RSV Select Panel|A multiplex real-time PCR IVD test for the qualitative detection and identification of SARS-CoV-2, influenza A virus, influenza B virus, and respiratory syncytial virus (RSV).
223862107|NCT05159297|OTHER|Reference values|Normative reference values of coordination tests will be obtained
223862108|NCT03255096|DRUG|RO6870810|RO6870810 subcutaneously (SC) at dose of 0.30, 0.45, or 0.65 milligram per kilogram (mg/kg) on Days 1-14 of 21-day cycles.
223862109|NCT03255096|DRUG|Venetoclax|Venetoclax tablets orally at dose of 400 mg once daily (QD) continuously for 21 days.
223862110|NCT03255096|DRUG|Rituximab|Rituximab intravenously (IV) at dose of 375 mg/m\^2 weekly during the first 21-day cycle (C1) and on day 1 of each cycle thereafter.
223862111|NCT03385824|BEHAVIORAL|Self-Advocacy for Independent Life (SAIL)|SAIL program is based on an interactive workshop model. In -person sessions will focus on: enhancement of self-efficacy beliefs; enhancement of knowledge of TBI self-advocacy information; group process to instill hope and universality; and practice of self-advocacy behaviors in a supportive neuro-rehabilitation structured group environment.
223862112|NCT03292315|DRUG|Semaglutide 1MG Injection [Ozempic]|Once weekly injection of 1mg of Semaglutide.
223862113|NCT03292315|OTHER|No Intervention|No injection will be administered
223862114|NCT02905812|OTHER|RGI & Massage|A trained intervention nurse will administer a 15 min moderate pressure massage as well as guided imagery with music once daily for up to five consecutive days.
223862115|NCT03264235|DEVICE|Keeogo|"Keeogo is a computer-controlled lower extremity motorized orthosis worn over the user's hips and legs. The controller box contains sensors that supply information about the kinematics and the kinetics of the user's lower extremities and includes software that recognizes the user's mobility intentions. The system is powered by a lithium-polymer battery. The leg brace assembly is mainly comprised of the actuator, the electronic boards, hip joint, and soft goods (cuffs, belts) for affixing the assembly to the user's legs. The waist belt comes in various sizes adapted to each wearer, and adds additional support of the device on the user.~Keeogo does not initiate any movement but waits for the user's lead. Once the user makes the first move, Keeogo assists according to the activity. The individual must be able to initiate and terminate steps."
223862116|NCT03264235|OTHER|Traditional Stair Training|Individuals will participate in traditional stair training physical therapy for the same duration of time as Group 1.
223862117|NCT03646435|DEVICE|Fitbit Charge 2|The Fitbit Charge 2 is the electronic wearable chosen for this pilot study. This particular Fitbit is capable of measuring patient heart rate, sleep and physical activity. The data collected will then be analyzed with respect to the outcomes of this study. To determine the accuracy of the Fitbit, data collected will be compared to the nurses' standard patient assessment (for HR and physical activity) and to patient responses on the Richards-Campbell Sleep Questionnaire (for sleep).
224076303|NCT03450928|PROCEDURE|Peroral Endoscopic Myotomy (POEM)|"Peroral endoscopic myotomy (POEM) is a minimally invasive intervention for the treatment of esophageal achalasia.~POEM includes different steps:~1. Lifting of the esophageal mucosa, with the injection of saline solution, and mucosal incision on the esophageal body (approximately 12 or 7 cm above the esophagogastric junction, for about 1-2cm)~2. Advance of the endoscope into the submucosa, repeated submucosal injection and dissection of a submucosal tunnel into the distal esophagus up to 3 cm into the gastric wall.~3. Myotomy of the distal esophagus, cardia and gastric wall, starting 3 cm below the mucosal incision~4. After the completion of myotomy, and check for mucosal integrity, the mucosal incision is closed using endoscopic clips"
224076304|NCT03201055|DEVICE|Snore PAP System|The Snore PAP system delivers a set Continuous Positive Airway Pressure (CPAP) and consists of a CPAP flow generator and an approved pillows mask.The system will deliver a fixed positive airflow to the participant via approved tubing and pillows mask.
223862118|NCT03916835|DEVICE|Pain evaluation ( FLACC scale) before and during the cleaning care with and without music therapy.|"Each child will benefit two cleaning cares during hospitalization. One with music therapy and the other without music therapy.~Every time, the preparation will be the same with an equipment installation in order to keep comparability and blind.~Child will be videotaped without sound during the care. The order of music therapy intervention will be randomized."
223862119|NCT05132348|DIAGNOSTIC_TEST|Immunological markers|Markers of blood samples of patients suffering from osteoporosis will be analyzed
223862120|NCT01599897|BIOLOGICAL|ID93 + GLA-SE|ID93 antigen and GLA-SE adjuvant. 3 injections at Days 0, 28, and 56.
223862121|NCT01599897|BIOLOGICAL|ID93 alone|ID93 antigen alone. 3 injections and Days 0, 28, and 56.
223862122|NCT05767294|OTHER|Observation|clinical manifestation (body temperature, fever days before admission, cough, red throat/sore throat, runny nose, shortness of breath, wheezing, vomiting), physical signs (auscultation of lungs, X-ray results), length of stay, therapeutic measures (oxygen therapy, ICU admission, antibiotic therapy, etc.)
223862123|NCT00984737|DRUG|Insulin|"Capillary glucose measurements of Group 2 and Group 3 will be performed during hospitalization and will be treated when they are over 180mg/dl.~Short acting oral anti-diabetic drugs will be given to patients who refuse insulin injection."
223862124|NCT02534311|DRUG|Tocilizumab|Tocilizumab will be administered at 162 mg SC injection for 48 weeks.
224076305|NCT00933049|DRUG|Amoxicillin|Oral amoxicillin (25mg/kg/dose)for 5 days
224076306|NCT00933049|DRUG|Cotrimoxazole|Cotrimoxazole (8 mg/kg/dose trimethoprim + 40 mg/kg/dose sulphamethoxazole)
223862125|NCT06461871|OTHER|BALANCE TRAINING WITH MODERATE INTESITY AEROBIC VERSUS RESISTED TRAINING (RT)|The duration of study is 6 months. Three to five sessions of both aerobic and resistance exercise training in combination with balance training are taken out per week . Each session lasting 15 minutes. GROUP A: Baseline treatment + Moderate intensity aerobic exercises in combination with balance training
224076307|NCT00933049|DRUG|Amoxicillin placebo|
224076308|NCT00933049|DRUG|Cotrimoxazole placebo|
223862126|NCT06461871|OTHER|Moderate intensity resistance exercises in combination with balance training|The duration of study is 6 months. Three to five sessions of both aerobic and resistance exercise training in combination with balance training are taken out per week . Each session lasting 15 minutes. GROUP B: Baseline treatment + Moderate intensity resistance exercises in combination with balance training
223862127|NCT00099086|DRUG|Bicalutamide|Bicalutamide will be administered for approximately 28 months: prior to radiotherapy (2 months), during radiotherapy (2 months), and after radiotherapy (24 months)
223862128|NCT00099086|DRUG|docetaxel|Docetaxel will be administered weekly during radiotherapy. The docetaxel dose will be escalated as part of the study. Dose levels are: 10mg/m2; 15 mg/m2; 20 mg/m2 and 25 mg/m2
223862129|NCT00099086|DRUG|GnRh analog|"A GnRH analog (goserelin acetate, leuprolide acetate) will be administered for approximately 28 months: prior to radiotherapy (2 months), during radiotherapy (2 months), and after radiotherapy (24 months)~Bicalutamide will be administered for approximately 28 months: prior to radiotherapy (2 months), during radiotherapy (2 months), and after radiotherapy (24 months)"
223862130|NCT00099086|RADIATION|radiotherapy|External beam photon radiotherapy utilizing 3-D-conformal or intensity modulated radiotherapy (IMRT) shall be used to deliver 77.4 4 Gy in 43 fractions of 1.8 Gy fractions.
223862131|NCT03834792|OTHER|No intervention but exposure|Different sleep disorders will be considered as an exposure. The data elements included in the database: demographics, date of the sleep study, study type, all available polysomnography indices, symptoms, sleep schedule, comorbidities, medications, social history, electrocardiography, positive airway pressure treatment related variables.
223862132|NCT05319288|DEVICE|Acupuncture|In DPOG, motion style acupuncture would be used; in LPMG, Traditional Chinese Medicine acupuncture is used.
223862133|NCT03082846|RADIATION|hypofractionated radiation|The simultaneous integrated boost-intensity modulated technology is adopted to increase both the dose in the surgical cavity and residual tumor (PTV1).The dose at each fraction is gradually increased from 2.8 Gy/f (total of 20 times) with an escalating dose interval of 0.4 Gy in PTV1, until dose-limiting toxicity is present,the highest target single dose is 4 Gy/f. The planning target volume (PTV2) including the 2 cm region around surgical cavity and residual tumor remain unchanged, with 2.5 Gy each time and a total of 50 Gy/20f.
223862134|NCT03082846|DRUG|Temozolomide chemotherapy|Temozolomide(TMZ) is administered orally every day at 75 mg/m2 during radiotherapy and at 150-200 mg/m2 for 12 cycles following completion of chemoradiotherapy.
223862135|NCT05404906|DRUG|Azacitidine|Given SC
223862136|NCT05404906|DRUG|Venetoclax|Given PO
223862137|NCT05404906|OTHER|Supportive care|Patients will receive disease monitoring and supportive care for any complication.
223862138|NCT03900637|DRUG|Leuprorelin acetate|In premenopausal women, 3.75mg of leuprorelin acetate is subcutaneously administered once every 4 weeks for 16 weeks. (if needed, maximum for 24 weeks)
223862139|NCT03900637|DRUG|Letrozole|2.5 mg tablet is orally administered once a day, without regard to meals, for 16 weeks (if needed, maximum for 24 weeks)
223862140|NCT03900637|GENETIC|MammaPrint|In this study, patients with MammaPrint test is performed, neoadjuvant chemotherapy is conducted to genomic High Risk patients, and neoadjuvant endocrine therapy is conducted to Low Risk patients.
223862141|NCT04425408|DEVICE|Consecutive trial of two different devices for the treatment of positional sleep apnoea, for 3 nights with each device (positional pillow and vibrating belt).|Patients will be randomly allocated to use either a positional pillow or a vibrating belt for three consecutive nights at home followed by three nights with the other device.
223862142|NCT04558112|DRUG|L-DOPA|two gel capsules with 100mg L-DOPA (with 25 mg carbidopa to inhibit peripheral decarboxylase)
223862143|NCT04558112|DRUG|Placebo|two gel capsules of placebo
223862144|NCT00003375|DRUG|lomustine|
223862145|NCT00003375|DRUG|procarbazine hydrochloride|
223862146|NCT00003375|DRUG|vincristine sulfate|
223862147|NCT00003375|RADIATION|radiation therapy|
223862148|NCT01015404|DRUG|Trafermin|Administered to the bone defect during flap operation
223862149|NCT02903615|OTHER|Novel diet|Novel diet to optimise glucose levels and minimise systemic inflammation: altered macronutrient composition: lower carbohydrate, Mediterranean-style, prebiotic fibre focus.
223862150|NCT02903615|OTHER|Standard diet|Standard diabetes diet recommendations
223862151|NCT01576523|BIOLOGICAL|C1-esterase inhibitor - single intravenous dose|A single intravenous dose of C1-esterase inhibitor (Berinert) at 20 units per kg body weight will be administered to all subjects prior to receiving the first dose of subcutaneous C1-esterase inhibitor.
223862152|NCT01576523|BIOLOGICAL|C1-esterase inhibitor - subcutaneous low dose|A low dose of C1-esterase inhibitor will be administered subcutaneously twice a week for four weeks.
223862153|NCT01576523|BIOLOGICAL|C1-esterase inhibitor - subcutaneous medium dose|A medium dose of C1-esterase inhibitor will be administered subcutaneously twice a week for four weeks.
223862154|NCT01576523|BIOLOGICAL|C1-esterase inhibitor - subcutaneous high dose|A high dose of C1-esterase inhibitor will administered subcutaneously twice a week for four weeks.
223862155|NCT03385681|OTHER|Tailored Educational Intervention|The intervention will be a one-day seminar for nurses working at the units, with lectures and workshops with main focus on the subjects showing the lowest pediatric pain management competence. In addition, there will be clinical supervision in pediatric postoperative pain management (two or three days per unit). The intervention will be conducted by two experts (nurse and physician) in pediatric postoperative pain management. After the intervention there will be different reminders every week for the first month, and then every month (in different forms) about pediatric pain management during six months of time.
223862156|NCT04970979|OTHER|survey|questionnaire about the influencing factors of home-based cardiac rehabilitation
223862157|NCT03107767|PROCEDURE|PRO-malleol algorithm|An evidence based algorithm for ankle fractures
223862158|NCT03573063|OTHER|Androgen metabolism after starvation|"The 20 women will all undergo the same process of starvation for 48 hours. During this time three blood samples and three 24-hours urine samples will be collected. At baseline, the investigators will draw blood, perform a pregnancy test and collect the 24 hours urine as well as a spot urine.~Then the 48 hours starvation starts and two blood and two 24 hours urine samples and spot urines will be collected after 24 and 48 hours in the morning. After the third visit the study is completed for the participant."
223862159|NCT01996917|DEVICE|Prineo|After a Wise pattern breast reduction, one breast will have final layer closure with Prineo, while the other breast will be closed in the standard fashion with sutures.
223862160|NCT01867632|DEVICE|Acellular Dermal Matrix|
223862161|NCT03772457|DRUG|Rivaroxaban|new oral anticoagulant molecules which is the selective factor Xa inhibitor
223862162|NCT05777317|DEVICE|10 kHz SCS|Spinal cord stimulation programmed to a frequency of 10 kHz
223862163|NCT05777317|OTHER|CMM alone|Conventional medical management alone
223862164|NCT00739141|DRUG|fludarabine, cyclophosphamide, thiotepa, radiation therapy, unrelated donor umbilical cord blood graft|Cyclophosphamide 50 mg/kg/dose x 1 IV day -6 (1 dose) Fludarabine 30 mg/m2/dose x 5 IV days -6 to -2 (5 doses) Thiotepa 5 mg/kg/dose x 2 IV days -5 to -4 (2 doses) TBI 200 cGy/dose x 2 days -2 to -1 (2 doses). On transplant day, the cord blood cells will be given through your catheter. The immune suppressing drugs you will receive are called cyclosporine-A (CSA) and mycophenolate mofetil (MMF). These will be started 3 days before the transplant and will be given through your catheter. Later they can be given as tablets.
223862165|NCT06484504|DIETARY_SUPPLEMENT|Kombucha beverage|After 4-weeks of consuming a beige diet (i.e. low-fiber, low polyphenol diet), 20 subjects (kombucha group) will consume one bottle (two servings) of kombucha daily for 4 weeks and 10 subjects (control group) will not change their dietary habits
223862166|NCT01317420|DRUG|BI 836845|Intravenous infusion
223862167|NCT02993588|DRUG|Melatonin|Melatonin 6 mg tablet once daily
223862168|NCT02993588|OTHER|Placebo|one tablet once daily
223862169|NCT06359327|DIETARY_SUPPLEMENT|Placebo|Subjects will be given an informed consent as per the form submitted to Advarra IRB. 8 randomized subjects will be given placebo for 60 days. Placebo will be formulated as a dietary supplement in veggie capsules with microcrystalline cellulose excipient.
223862170|NCT06359327|DIETARY_SUPPLEMENT|Pep19 2 mg|Subjects will be given an informed consent as per the form submitted to Advarra IRB. 8 randomized subjects will be given 2 mg of Pep19 for 60 days. Placebo will be formulated as a dietary supplement in veggie capsules with microcrystalline cellulose excipient.
223862171|NCT06359327|DIETARY_SUPPLEMENT|Pep19 5 mg|Subjects will be given an informed consent as per the form submitted to Advarra IRB. 8 randomized subjects will be given 5 mg of Pep19 for 60 days. Placebo will be formulated as a dietary supplement in veggie capsules with microcrystalline cellulose excipient.
223862172|NCT04716855|OTHER|Quality of life and daily living activities assessment tests|
223862173|NCT04707313|DRUG|Placebo (Cohorts 1 and 2)|4 matching placebo tablets taken twice daily
223862174|NCT04707313|DRUG|PF-06882961 (Cohorts 1 and 2)|Participants will be randomized to one of 5 active target dose levels (40, 80, 120, 160 or 200 mg BID) achieved through 1-week titration steps, or 3 active target dose levels (120, 160 or 200 mg BID) achieved through 2-week titration steps, taking 4 tablets twice daily
223862175|NCT04707313|DRUG|Placebo (Cohort 3)|2 matching placebo tablets taken twice daily
223862176|NCT04707313|DRUG|PF-06882961 (Cohort 3)|Participants will be randomized to one of 3 active target dose levels (80, 140 or 200 mg BID) achieved through 4-week titration steps, taking 2 tablets twice daily.
223862177|NCT03165175|BEHAVIORAL|prescription drug-abuse education smartphone application|As a patient-centered prevention effort, this brief intervention in a mobile phone app format focuses on helping military members reduce their risk for prescription drug misuse. It contains modules to: (1) assess risk for misuse and related behavioral health concerns; (2) provide individualized feedback on risk level; (3) store information on current medications and look up drug interaction and related information; (4) enhance communication and decision-making skills within healthcare and other interpersonal contexts by providing interactive scenarios; (5) teach about the risks of prescription drug misuse; and (6) provide available resources for help with prescription drug misuse.
223862178|NCT03525951|BEHAVIORAL|Enhanced Milieu Teaching|The parent training will incorporate the EMT strategies of responsive interaction, matched turns, language modeling, and expansions. There will be three, hour-long parent training sessions following the teach-model-coach-review format (TMCR). The TMCR framework teaching component will involve 10 minutes of verbal and visual instruction on the language stimulation target of interest. The teaching component will be followed by 15 minutes of clinician modeling of the target strategies with the child while the parent watches. The parent will then have the opportunity to practice using the strategy during naturalistic interaction with their child. The clinician will provide individualized coaching on the use of the target strategy during this 20-minute, parent-child interaction. Finally, the clinician will review the target strategies and set goals.
223862179|NCT03525951|OTHER|no intervention comparison group|No intervention for observational (Study 1 and 2) and training (Study 2) data comparison.
223862180|NCT02709174|PROCEDURE|blood draw|blood draw
223862181|NCT04761562|DRUG|Platelet- and extracellular vesicle-rich plasma|PVRP will initially be applied to the gelatine sponge without prior exogenous activation, which will first be inserted into the middle ear cavity to support the reconstructed tympanic membrane. The remainder of the PVRP will then be exogenously activated with calcium chloride. Gel rich with platelets and extracellular vesicles will be created and applied on top of the reconstructed tympanic membrane. Finally, the external auditory canal will be filled with pieces of gelatine sponge soaked with PVRP.
223862182|NCT04761562|PROCEDURE|Control group|Edges of the tympanic membrane perforation will be refreshed and the tympanomeatal flap raised. Under the tympanic membrane perforation, a guide (fascia of the temporalis muscle, perichondrium, cartilage or fat) will be placed. An absorbent gelatin sponge will be placed under the guide and on the outer surface of the reconstructed tympanic membrane.
223862183|NCT02491723|DRUG|Azithromycin|Patients with bronchiectasis treated with Azithromycin for three to five days.
223862184|NCT05885126|OTHER|MANDALA TECHNIQUE|The ambient light and the position of the laptop table were adjusted appropriately during the intervention to help the participants move freely and eliminate the environmental stimulus. In addition, there was no communication between the patient and the practitioner during the application.
223862185|NCT05839938|OTHER|Vitamin D|Vitamin D (2000IU/day) for 6 months
223862186|NCT05839938|OTHER|Placebo|Placebo
223862187|NCT03770507|OTHER|Exercise Training|Comparison of stationary bike and treadmill exercise among adolescents and adults
223862188|NCT00383513|BIOLOGICAL|Epratuzumab|360 mg/m\^2 four consecutive 12-week maintenance cycles beginning with 2 consecutive weekly administrations each lasting ≤ 1 hour
223862189|NCT02156635|DEVICE|Transcranial direct current stimulation|
223862190|NCT02156635|BEHAVIORAL|Constraint-Induced Movement Therapy|
223862191|NCT02156635|OTHER|Placebo|
223862192|NCT02176096|DIETARY_SUPPLEMENT|Glycosade|
223862193|NCT00145041|DRUG|Vincristine Sulfate Liposomes Injection|Marqibo (VSLI) 1.0 mg/m2 delivered by intravenous infusion over 1 hour every 2 weeks.
223862194|NCT03433950|OTHER|No Intervention|Observational
223862195|NCT05899335|DEVICE|SmartCP (mobile phone app)|As described
223862196|NCT00253058|DRUG|Cetirizine Dry Syrup|
223862197|NCT01550978|DEVICE|AnapnoGuard 100 System|AnapnoGuard™ 100 Respiratory Guard System is intended for airway management by oral/nasal intubation while providing continuous endotracheal cuff pressure control using non-invasive measurement and monitoring of carbon dioxide concentration in the subglottic space and evacuation of secretions from above the endotracheal tube's cuff.
223862198|NCT02618278|OTHER|Physiotherapy|The aims of physiotherapy are to promote physical and psychological health for the patient, and in doing so promote and improve function. In light of the evidence to suggest spontaneous resorption of the disc fragment occurs, physiotherapy provides support and guidance for the patient to manage their symptoms whilst resorption takes place. The physiotherapy regimen will be tailored to the individuals' requirements. It will be goal orientated, and assessed using a biopsychosocial approach based on 7 different elements; neurological dysfunction, motor control of movement of the lumbar spine and pelvis, movement restriction in the lumbar spine and pelvis, psychological barriers to recovery, advice and education, functional-based exercise and pain.
223862199|NCT03128658|DIAGNOSTIC_TEST|Thromboelastography|Thromboelastography (TEG) tests for parameters related to efficiency of blood coagulation. The parameters are: reaction time (R value), the K value, the angle and the maximum amplitude (MA)
223862200|NCT03128658|DIAGNOSTIC_TEST|Computational model|The computational whole-patient systems model is a multiscale, multi-compartment model whose state-space is defined by a very large and heterogeneous set of variables as well as a large number of input parameters. The model will be integrated in time for various initial trauma conditions in an attempt to determine whether the model can be predictive, and help us discover new variables that are more predictive of clinical outcomes than those employed in current clinical protocols.
223862201|NCT04076202|DEVICE|Cementless Vanguard DD RP|Patients treated with the Cementless Vanguard DD RP knee implant
223862202|NCT00595218|BEHAVIORAL|Physician behavior related to Patient Preference Survey|Access to initial Patient preference survey results
223862203|NCT00595218|OTHER|Patient Preference Results|Knowledge of Patient Preference Results
223862204|NCT02709863|DRUG|Sevoflurane|1-1.5 MAC, inhalation route, during operation
223862205|NCT02709863|DRUG|Desflurane|1-1.5 MAC, inhalation route, during operation
223862206|NCT02709863|DRUG|Propofol|6-10 mg/kg/h, iv infusion, during operation
223862207|NCT03398837|DRUG|Lenabasum 5 mg|Subjects will receive lenabasum 5 mg twice daily.
223862208|NCT03398837|DRUG|Lenabasum 20 mg|Subjects will receive lenabasum 20 mg twice daily.
223862209|NCT03398837|OTHER|Placebo oral capsule|Subjects will receive placebo twice daily.
223862210|NCT04052919|OTHER|Cardiac dysfunction in adolescents with type 1 diabetes|"to identify specific parameters related to glucoregulation which correlate with cardiac function and structure in adolescent with T1DM.~In T1DM, exercise training to have beneficial effects on HbA1c levels, cardiovascular risk profile.~To evaluate the association between cardiac function/structure and cardiopulmonary exercise capacity in adolescent T1DM patients (in the perspective of their physical activity behavior). This study thus may provide greater insights in the etiology and consequences of a disturbed cardiac function/structure in adolescents with T1DM."
223862211|NCT04298086|OTHER|Exercise Treatment|Exercise treatment will consist of individualized walking delivered up to 7 times weekly to achieve the patient-specific goal energy expenditure. Training sessions will be performed on a treadmill at under remote surveillance using a telemedicine approach (i.e.,TeleEx) established in the Exercise-Oncology (ExOnc) Service.
223862212|NCT04298086|OTHER|Plant-Based Diet|Pre-prepared meals, including 6 dinners and 6 lunches per week, will be shipped to the partipant's home during the intervention.
223862213|NCT04298086|OTHER|Physical activity|Treadmills and low-calorie recipes will be provided to patients in the counseling arm.
223862214|NCT04298086|OTHER|Nutrition counseling|Nutrition program including regular counseling by exercise physiologists and registered dieticians (RDs).
223862215|NCT04298086|OTHER|Replication Exercise Test|Exercise capacity will be reassessed by a replication exercise test at week 6 in the intervention group only.
223862216|NCT04584450|OTHER|Questionnaire|data collection using questionnaire
223862217|NCT01671124|OTHER|Soline capsule|
223862218|NCT00132119|DRUG|nalmefene HCl|Nalmefene HCl film-coated tablets, 20 or 40 mg, administered orally once daily for 10 weeks.
223862219|NCT00132119|OTHER|Placebo|Placebo tablet
223862220|NCT05060562|OTHER|COVID 19 positive|Diagnosed as COVID 19 patient using Real-Time Polymerase Chain Reaction (RT-PCR) with the nasopharyngeal swab, or Rapid Antigen test of nasopharyngeal swab with suggestive symptoms.
223862221|NCT05060562|OTHER|COVID 19 negative|Suspected COVID 19 patients who were tested negative using either Real-Time Polymerase Chain Reaction (RT-PCR) with the nasopharyngeal swab, or Rapid Antigen test of nasopharyngeal swab.
223862222|NCT00324038|DRUG|Buprenorphine|buprenorphine transdermal system 5, 10 and 20 mg
223862223|NCT00324038|DRUG|Codeine paracetamol|combination tablet of codeine and paracetamol taken orally 3 or 4 times daily. Dosage form ranges from 8/500, 15/500 and 30/500
223862224|NCT04575285|DIAGNOSTIC_TEST|Electroencephalogram (EEG)|EEG measures brain activity by recording the spontaneous brain electrical activity and evoked responses non-invasively from the scalp. Reusable Tangle Free 10mm EEG Cup Electrodes will be placed on the subject's scalp using the 10-20 system montage.
223862225|NCT00628719|DRUG|Liposomal Amphotericin B|a single dose of 10 mg/kg of liposomal amphotericin B
223862226|NCT00628719|DRUG|amphotericin B deoxycholate|amphotericin B as a 1x test dose and then at a dose of 1 mg/kg/every other day for a total of 15 doses over 30 days.
223862227|NCT03070483|DRUG|Cholecalciferol|5000 IU cholecalciferol with 1000 mg calcium citrate daily
223862228|NCT00920244|PROCEDURE|Cardiopulmonary resuscitation (CPR)|CPR is performed according to international and national guidelines on all patients.
223862229|NCT00920244|DRUG|Epinephrine|According to guidelines epinephrine 1 mg i.v. is administered every 3 minutes during cardiopulmonary resuscitation.
223862230|NCT00920244|DRUG|Atropine|According to CPR guidelines atropine 3 mg i.v. is administered if asystole og PEA with frequency \< 60 beat/min.
223862231|NCT00920244|DRUG|Amiodarone|According to guidelines amiodarone 300 mg i.v. is administered if recurrent ventricular fibrillation/tachycardia (VF/VT) during CPR.
223862232|NCT00920244|DEVICE|External defibrillator|According to CPR guidelines patients with shockable rhythms may receive DC shocks. The defibrillator also stores physiological information regarding cardiac rhythm, pulse-oximetry, and end-tidal carbon dioxide (CO2) from endotracheal tube.
223862233|NCT01514903|DRUG|HIP0908|SINGLE DOSE , CROSS OVER
223862234|NCT01514903|DRUG|viagra|single dose, cross over
223862235|NCT04913779|DRUG|Anti-SARS-CoV-2|Purified F(ab')2 Fragments of Equine hyperimmune Serum with anti-SARS-CoV-2 neutralizing activity (titer 1/5120 or higher)
223862236|NCT04913779|DRUG|Placebo|Administration of 10 ml of a control-solution without neutralizing activity against SARS-CoV-2, administered in slow intravenous infusion (10 ml diluted in 100 ml of saline solution, administered over 50 to 60 minutes in slow drip), produced by ANLIS-Malbrán, administered twice (time 0 when incorporated into the study -initial dose- and at 48 hours -second dose-).
223862237|NCT01291563|DRUG|Moxifloxacin|1 capsule of moxifloxacin (400 mg/capsule) on Day 2
223862238|NCT01291563|DRUG|TMC207|8 tablets of TMC207 (100 mg/tablet) on Day 1
223862239|NCT01291563|DRUG|TMC207 placebo|8 tablets of TMC207 placebo on Day 1
223862240|NCT01291563|DRUG|Moxifloxacin placebo|1 capsule of moxifloxacin placebo on Day 2
223862241|NCT06972563|OTHER|Psychoeducation Based on Acceptance and Commitment Therapy Applied to Patients Diagnosed with Generalized Anxiety Disorder|Psychoeducation Based on Acceptance and Commitment Therapy Applied to Patients Diagnosed with Generalized Anxiety Disorder
223862242|NCT06972563|OTHER|The initiative was not implemented.|The initiative was not implemented.
223862243|NCT01376336|DEVICE|Safe storage device|This device is a specially designed water storage container that is intended to reduce the likelihood of re-contamination of household stored drinking water.
223862244|NCT04415086|BIOLOGICAL|convalescent plasma|The study will be interrupted if the efficacy of the convalescent plasma group is proven, so that all severely ill patients as defined in the study can receive the convalescent plasma treatment. The same will occur if there is no difference in primary outcome with the use of convalescent plasma or serious adverse effects.
223862245|NCT04183959|DEVICE|video stylet|trachea will be intubated using laryngoscopic assisted video stylet device in lateral position
223862246|NCT04183959|DEVICE|fiberoptic|intubation will be done using fiberoptic device by the same anesthesiologist in lateral position
223862247|NCT01036412|DRUG|1% Chlorhexidine Gluconate Gel|Following two 2.5 ml 5-minute applications performed in clinic on Day 1, 2 x 5.0 ml syringes of chlorhexidine gel self-administered for one 5-minute application using the custom-made carriers carriers on week 2 (12-14 days from baseline visit study drug administration) and week 4 (12-14 days from Week 2 study drug administration).
223862248|NCT01036412|BEHAVIORAL|Surveys|M. D. Anderson Symptom Inventory for Head and Neck Cancer (MDASI-HN) questionnaire, in addition to a 2nd subjective, study-specific questionnaire administered during visit taking about 5 minutes to complete each assessment.
223862249|NCT01585558|DRUG|Ospemifene (Dose 1)|
223862250|NCT01585558|DRUG|Ospemifene (Dose 2)|
223862251|NCT01585558|DRUG|Placebo|
223862252|NCT01378065|DEVICE|Restorelle Direct Fix A&P|Restorelle Direct Fix A\&P is a permanently implantable synthetic mesh for reconstruction of the pelvic floor secondary to the prolapse or protrusion of the pelvic organs into or out of the vaginal canal.
223862253|NCT00841035|DRUG|erlotinib|Preoperative dosing of 150 mg oral erlotinib for 7 days before surgery. followed by erlotinib 100 mg daily 6 month/6 chemotherapy cycles. Gemcitabine 1000 m2 weekly after surgery for 6 cycles.
223862254|NCT00566124|DRUG|Insulin detemir|0.4 U/kg bw insulin detemir injected s.c. in the thigh.
223862255|NCT00566124|DRUG|Insulin glargine|0.4 U/kg bw insulin glargine injected s.c. in the thigh
223862256|NCT00566124|DRUG|Insulatard|0.4 U/kg bw NPH insulin injected s.c. in the thigh
223862257|NCT00891176|BIOLOGICAL|MenitorixTM|Intramuscular injection into the thigh as primary vaccination at 2, 4 and 6 months of age and as booster dose at 11-18 months of age. No vaccine was administered during this long-term follow up study.
223862258|NCT00891176|BIOLOGICAL|Pneumococcal conjugate vaccine GSK1024850A|Intramuscular injection into the thigh as primary vaccination at 2, 4 and 6 months of age and as booster dose at 11-18 months of age. No vaccine was administered during this long-term follow up study.
223862259|NCT00891176|BIOLOGICAL|PrevenarTM|Intramuscular injection into the thigh as primary vaccination at 2, 4 and 6 months of age and as booster dose at 11-18 months of age. No vaccine was administered during this long-term follow up study.
223862260|NCT00891176|BIOLOGICAL|MeningitecTM|Intramuscular injection into the thigh as primary vaccination at 2 and 4 months of age and as booster dose at 11-18 months of age. No vaccine was administered during this long-term follow up study
223862261|NCT00891176|BIOLOGICAL|NeisVac-CTM|Intramuscular injection into the thigh as primary vaccination at 2 and 4 months of age and as booster dose at 11-18 months of age. No vaccine was administered during this long-term follow up study
223862262|NCT00891176|BIOLOGICAL|InfanrixTM hexa|Intramuscular injection into the thigh as primary vaccination at 2, 4 and 6 months of age (all countries) and as booster dose at 11-18 months of age (Germany and Poland). No vaccine was administered during this long-term follow up study
223862263|NCT00891176|BIOLOGICAL|InfanrixTM penta|Intramuscular injection into the thigh as primary vaccination at 2, 4 and 6 months of age (all countries) and as booster dose at 11-18 months of age (Germany and Poland). No vaccine was administered during this long-term follow up study
223862264|NCT00891176|BIOLOGICAL|InfanrixTM IPV/Hib|Intramuscular injection into the thigh as booster dose at 11-18 months of age (Spain). No vaccine was administered during this long-term follow up study
223862265|NCT00891176|BIOLOGICAL|InfanrixTM IPV|Intramuscular injection into the thigh as booster dose at 11-18 months of age (Spain). No vaccine was administered during this long-term follow up study
223862266|NCT00501618|DRUG|Fazaclo|single-arm
223862267|NCT04704739|DRUG|GLPG1205 film-coated tablets|Single oral dose of GLPG1205
223862268|NCT04704739|DRUG|[14C]-GLPG1205 solution for infusion|A 15-minute IV infusion of \[14C\]-GLPG1205
223862269|NCT04704739|DRUG|GLPG1205 capsules|Single oral dose of GLPG1205 as solid formulation
223862270|NCT05656846|DEVICE|PulseNmore ES™|The patients will be instructed on the mode of operation of home ultrasound device (pulsenmore), the frequency and means of communication with the study team.
223862271|NCT05656846|DEVICE|Standard Ultrasound|These patients will not receive the additional intervention and will use the Standard Ultrasound. A population of patients between 12 and 22 weeks of gestation with history of recurrent pregnancy losses who will be subjected to routine antenatal care as per clinic protocol. These patients will not receive the additional intervention.
223862272|NCT05834946|OTHER|Megagen implant placement|Megagen implant with sand-blasted, large-grit, acid-etched (SLA) and nano-calcium ions incorporated surface
223862273|NCT05834946|OTHER|Biomate-Swiss implant|Biomate-Swiss implant with precision dimension laser (PDL) surface
223862274|NCT00111709|DRUG|MK0462, rizatriptan benzoate / Duration of Treatment -1 day|
223862275|NCT00111709|DRUG|Comparator: placebo / Duration of Treatment - 1 day|
223862276|NCT06460688|OTHER|Mother Rehabilitative Aid Education Program|Routine neuro physical therapy will be given which includes Stretching, truck control and independent transition, train standing and activation of base, gain walking with minimal assistance, Gain ground clearance with stair climbing. A class will be organized to educate Mothers/ Caregivers through PPT presentation, video and pictures. This class will contain 3 domains (Counseling, Educating, Practicing). Feedback will be taken on daily basis through video recordings. Mothers will take part in treatment session, 45 minutes for 5 days a week for 8 weeks.
223862277|NCT06460688|OTHER|Neuro physical Therapy|Routine neuro physical therapy will be given which includes Stretching, truck control and independent transition, train standing and activation of base, gain walking with minimal assistance, Gain ground clearance with stair climbing. for 45 minutes, 5 days a week for 8 weeks. Participants in group B will not be educated about treatment plan. Routine home plan was given in this group once in a week, for 8 weeks.
223862278|NCT02869022|DRUG|Custodiol-N|comparison of two Solutions, Custodiol-N versus Custodiol, for organ Perfusion in heart transplantation
223862279|NCT02869022|DRUG|Custodiol|comparison of two Solutions, Custodiol-N versus Custodiol, for organ Perfusion in heart transplantation
223862280|NCT02869022|PROCEDURE|organ perfusion for heart transplantation|
223862281|NCT06553248|DRUG|GZR4|Administered once weekly subcutaneously (s.c., under the skin) for 6 weeks
223862282|NCT06553248|DRUG|Insulin Degludec|Administered once daily subcutaneously (s.c., under the skin) for 6 weeks
223862283|NCT05593042|BIOLOGICAL|CoronaVac®|The active ingredient is the SARS-CoV-2 virus (CZ02 strain, ancestral) grown in Vero cells and inactivated, in aluminum hydroxide. The vaccine is preservative-free, and it is packed in pre-load syringes (0.5 mL) with 600 SU/0.5mL of inactivated SARS-CoV-2.
223862284|NCT05593042|BIOLOGICAL|Omicron Vaccine|"An experimental intervention consisting of a booster dose of an inactivated Omicron variant vaccine.~The active ingredient is the SARS-CoV-2 virus (Omicron variant) grown in Vero cells and inactivated, in aluminum hydroxide. The vaccine is preservative-free, packed in a pre-load syringe, and contains one dose (0.5mL) of 1200 SU of inactivated SARS-CoV-2 Omicron variant."
223862285|NCT05593042|BIOLOGICAL|Trivalent Vaccine|"An experimental intervention consisting of a booster dose of an inactivated trivalent (CZ02 strain, ancestral, Delta, and Omicron variants) variant vaccine.~The active ingredient is the SARS-CoV-2 virus (CZ02 strain, ancestral, Delta, and Omicron variants) grown in Vero cells and inactivated, in aluminum hydroxide. The vaccine is preservative-free, and it is packed in a pre-load syringe containing one dose (0.5mL) (1200 SU of inactivated SARS-CoV-2 WT, 1200 SU of inactivated SARS-CoV-2 Delta variant, and 1200 SU of inactivated SARS-CoV-2 Omicron variant)."
223862286|NCT04814043|DRUG|PD-1 inhibitor|systemic PD-1 antibody (Sintilimab) and lenvatinib plus transarterial chemobolization and FOLFOX-based chemotherapy infusion
223862287|NCT00862680|PROCEDURE|4-Dimensional Computed Tomography|Undergo 4D PET/CT
223862288|NCT00862680|PROCEDURE|4D PET Scan|Undergo 4D PET/CT scan
223862289|NCT05647967|DIAGNOSTIC_TEST|Ultrasound|Each patient underwent ultrasound after admission of ICU.
223862290|NCT01390402|DRUG|Fludarabine|40 mg/m2 intravenous over one (1) hour on each of four (4) consecutive days, Days -13 to -10.
223862291|NCT01390402|DRUG|Busulfan|130 mg/ m2 by vein for 2 doses on Days -11 to -10.
223862292|NCT01390402|PROCEDURE|NK cell infusion:|Natural killer cell infusion will be administered by vein on Day -8.
223862293|NCT01390402|DRUG|Interleukin-2|0.5 million units subcutaneously daily for 5 days on Day -8 to day -4.
223862294|NCT01390402|DRUG|Anti-Thymocyte Globulin|2.5 mg/kg by vein for 3 doses on Days -3 to -1.
223862295|NCT01390402|PROCEDURE|Allogeneic related Stem Cell Transplant|Allogeneic related stem cell transplant by vein on day 0.
223862296|NCT01390402|DRUG|Tacrolimus|Starting dose of 0.015 mg/kg (ideal body weight) as a 24 hour continuous infusion daily adjusted to achieve a therapeutic level of 5-15 ng/ml.
223862297|NCT01390402|DRUG|Methotrexate|5 mg/m2 by vein Days 1, 3 and 6 post transplant.
223862298|NCT01390402|DRUG|G-CSF|5 mcg/kg/day subcutaneously beginning on Day + 7, and continuing until the absolute neutrophil count (ANC) is \> 500 x 10/L for 3 consecutive days.
223862299|NCT03598972|OTHER|intervention|elementary analysis
223862300|NCT02383472|DEVICE|MedX Health Console model 1100|"All treatments will be administered using the MedX Health Console model 1100. These units were cleared by the FDA as non-significant risk in 2003 and approved for home treatment use in 2005 for temporary increase in local blood flow circulation . . . for temporary relief of minor muscle and joint aches. Cluster heads are 2 inches in diameter. Each contains 9 red (633nm wavelength) diodes and 52 near infrared (870 nm wavelength) diodes. LED cluster heads would be applied to the frontal, parietal and temporal areas, as well as the mid sagittal suture line"
223862301|NCT02383472|DEVICE|MedX Health Console model 1100-placebo|The placebo machine is identical in appearance as the treatment machine; It vibrates, warms, and does everything the treatment machine does except it does not have LED lights on the marker, therefore it cannot emit light. Subjects enrolled in the placebo group will be on the same schedule as the treatment group. They will have two, 10 minute treatments, three times a week totaling 18 visits. The placebo allows the researchers to isolate the effect of the study treatment. If patient's in the LED treatment group fare significantly better than those in the placebo treatment group, the study helps support the conclusion that the LED therapy is effective.
223862302|NCT00136058|PROCEDURE|bone densitometry (DEXA)|
223862303|NCT00136058|DRUG|alendronate or risedronate|
223862304|NCT00597038|DRUG|Dasatinib and Dacarbazine (DTIC)|"Arm A/ Phase I Potential Dose Levels.~Dose Level -1: Dasatinib 40 mg; DTIC 600 mg/m\^2. Dose Level 1: Dasatinib 50 mg; DTIC 800 mg/m\^2. Dose Level 2: Dasatinib 70 mg; DTIC 800 mg/m\^2. Dose Level 3: Dasatinib 70 mg; DTIC 1000 mg/m\^2.~Arm B/Phase II Potential Dose Levels.~MTD1: Dasatinib 70 mg; DTIC 1000 mg/m\^2. MTD2: Dasatinib 70 mg; DTIC 800 mg/m\^2. MTD3: Dasatinib 100 mg: DTIC 1000 mg/m\^2."
223862305|NCT04094532|DRUG|Bupivacaine|Ultrasound guided 20 ml % 0.250 bupivacaine injection to transverse thoracic muscle plane bilaterally
223862306|NCT04094532|DRUG|Saline|Ultrasound guided 20 ml % 0.9 saline injection to transverse thoracic muscle plane bilaterally
223862307|NCT01087255|DEVICE|Electronic Pillbox Monitoring System|Daily exposure for six months
223862308|NCT04014114|OTHER|Digital Genetic Assistant|An end-to-end digital solution to the carrier screening process from participant registration to receipt of the test results and their interpretations. These steps are provided using personalized animated videos.
223862309|NCT05632471|BEHAVIORAL|"web-based I know digital games training for intervation grup"|"I know digital games training consisting of 10 web-based videos"
223862310|NCT05632471|OTHER|The control group was not trained|The control group was not trained
223862311|NCT00818454|DRUG|Combivent CFC MDI|
223862312|NCT00818454|DRUG|Albuterol HFA MDI|
223862313|NCT00818454|DRUG|Respimat Combivent|
223862314|NCT03848910|DEVICE|Investigational device - Sound Processor|"At visit 1 the subjects will complete self-reported assessments with respect to pre-study experience using precursor Sound Processor (comparator). At visit 1 the subjects will then receive the Investigational device (Sound Processor) which should be used during the following 6 weeks. At visit 3 the subjects will complete self-reported assessments regarding Investigational device and participate in audiology tests regarding both Sound Processors, comparator and Investigational device. The subject shall decide their preferred choice made by selection between Investigational device and the comparator."
223862315|NCT01689090|OTHER|COX inhibitor|Administration of 1 drop voltaren 45 minutes before recordings of diameter changes of retinal vessels are initiated
223862316|NCT01689090|OTHER|L-NG-monomethyl arginine citrate|Intravenous administration of L-NMMA during recordings of diameter changes of retinal vessels
223862317|NCT01689090|OTHER|COX inhibitor + L-NG-monomethyl arginine citrate|Combination of interventions. Administration of an eye drop voltaren and 45 minutes later infusion with L-NMMA is started and recording of diameter changes of retinal vessels is performed
223862318|NCT01377428|DRUG|Indacaterol|Indacaterol 150 µg once daily (od) via single-dose dry powder inhaler (SDDPI)
223862319|NCT01377428|DRUG|Formoterol|Formoterol 12 µg twice daily (bid) via single-dose dry powder inhaler (SDDPI)
223862320|NCT02014142|DRUG|Latanoprost Punctal Plug Delivery System (L-PPDS)|Latanoprost Punctal Plug Delivery System (L-PPDS)
223862321|NCT02296424|DRUG|ACZ885 150 mg (Canakinumab)|Active canakinumab in individual 2 mL glass vials, each containing 150 mg canakinumab liquid in vial.
223862322|NCT01525446|RADIATION|SBRT with proton beam radiation|4 consecutive days for the delivery of 48 Gy (tumors 3 cm or less) or 5 consecutive days for the delivery of 60 Gy (tumors of \> 3 cm)
223862323|NCT05723133|DEVICE|Electric toothbrush|Patients will receive oral hygiene instructions and an electric toothbrush with or without daily personal feedback using the brushing app (Oral-B app).
223862324|NCT05723133|BEHAVIORAL|Oral hygiene instructions|The same oral hygiene instructions are given to all patients. It is important for the patient to scrupulously follow these oral hygiene instructions at home and carry them out daily.
223862325|NCT03002805|DRUG|CBT-1®|"CBT-1®, oral, on days 1-7 of each cycle 21-day cycle. Participants will be assigned to dose level of CBT-1®:~Dose level 1 - 50 mg/m2/day Dose level 2 - 100 mg/m2/day Dose level 3 - 150 mg/m2/day Dose level 4 - 200 mg/m2/day Dose level 5 - 250 mg/m2/day Dose level 6 - 300 mg/m2/day doxorubicin, 37.5 mg/m2, IV, on days 5 and 6 of each cycle Study treatment discontinued after 450 mg/m2 lifetime cumulative dose of doxorubicin reached or after 4-5 cycles completed."
223862326|NCT02794194|OTHER|Proprioceptive training on a whole body vibration platform|The Training programme consisted of three series of 4 exercises of 45 seconds with 45 seconds rest between exercises. In this intervention participants trained with the BOSU® on a Fitvibe Excel Pro vibration platform (Fitvibe, Bilzen, Belgium).
223862327|NCT02794194|OTHER|Proprioceptive training with the BOSU® on the floor|The Training programme consisted of three series of 4 exercises of 45 seconds with 45 seconds rest between exercises. In this intervention participants trained with the BOSU® on the floor.
223862328|NCT00807144|DRUG|Tacrolimus (Kidney transplant maintenance immunosuppression)|Standard-release Tacrolimus 1 to 20mg daily in two divided doses to maintain trough drug levels 6-9ng/ml
223862329|NCT00807144|DRUG|Kidney transplant maintenance immunosuppression|Prolonged-release Tacrolimus 1 to 20mg daily in a single am dose adjusted to trough drug levels 6-9ng/ml
223862330|NCT06131385|DRUG|intravenous thrombolysis|Intravenous thrombolysis using thrombolytic drugs such as ateplase and teneplase.
223862331|NCT02784132|OTHER|Video diversion|The intervention is playing a video on a computer or iPad (using www.youtube.com) while performing fundoscopy.
223862332|NCT04523922|DRUG|40 IU Intranasal Oxytocin|40 IU Intranasal Oxytocin self administered 30 minutes prior to each COPE session.
223862333|NCT04523922|DRUG|Placebo|Placebo (intranasal saline spray) self administered 30 minutes prior to each COPE session.
223862334|NCT04523922|BEHAVIORAL|Concurrent Treatment of PTSD and Substance Use Disorders using Prolonged Exposure|12 weekly sessions of COPE therapy for PTSD and AUD.
223862335|NCT03567941|DRUG|Placebo|Tablet orally administered under fasting
223862336|NCT03567941|DRUG|Hydrocodon bitartrate-acetaminophen arm 1|Tablet orally administered under fasted conditions
223862337|NCT03567941|DRUG|Hydrocodon bitartrate-acetaminophen arm 2|Tablet orally administered under fed conditions
223862338|NCT03567941|DRUG|Reference|Tablet orally administered under fasted conditions
223862339|NCT03804580|DRUG|osimertinib|Non-randomized trial, all patients receive therapy
223862340|NCT06033287|DRUG|Different treatment regimens following progression on CDK4/6 inhibitors.|This study is a single-arm, non-interventional study that evaluates the efficacy and safety of the first-line treatment regimen, which includes CDK4/6 inhibitors combined with endocrine therapy. After disease progression on first-line treatment, the second-line systemic treatment regimen (including but not limited to switching to another CDK4/6 inhibitor combined with endocrine therapy, other types of endocrine therapy, chemotherapy, targeted therapy, etc.) will be evaluated.
223862341|NCT03667911|OTHER|virtual reality videos|Watch virtual reality videos after routine patient education(both oral and written instructions). Videos give instructions on correct steps of bowel preparation, points for attention, as well as actual images of bowel during colonoscopy in the case of both excellent and unsatisfactory bowel preparation.
223862342|NCT01204346|OTHER|MBT|The intervention consists of twice weekly individual MBT therapy, group therapy with an MBT focus and weekly MBFT, which is MBT for families. The treatment duration will be 6-8 weeks.
223862343|NCT01204346|OTHER|treatment as usual|less intensive and structured psychotherapeutic program
223862344|NCT05136807|OTHER|Quality-of-Life Assessment|Complete questionnaires
223862345|NCT05136807|OTHER|Questionnaire Administration|Complete questionnaires
223862346|NCT03409913|RADIATION|FDG PET/CT|Conventional FDG PET/CT including head in order to asses cranial arteries.
223862347|NCT03704350|DIETARY_SUPPLEMENT|controlled diet|Participants will consume a diet that is controlled in its daily contents of oxalate, calcium, vitamin C and sodium, and in its content of carbohydrate, fat, and protein. Participants will be asked not to take any dietary supplements (vitamins, calcium or other minerals, herbal supplements, nutritional aids), to exercise strenuously, or to consume food or drink that is not provided to them as part of the controlled diet.
223862348|NCT03725059|BIOLOGICAL|Pembrolizumab (K)|IV infusion Q3W
223862349|NCT03725059|DRUG|Placebo (P)|Normal saline or dextrose IV infusion Q3W
223862350|NCT03725059|DRUG|Paclitaxel (X)|IV infusion QW
223862351|NCT03725059|DRUG|Doxorubicin (A)|IV infusion either in Q2W or Q3W
223862352|NCT03725059|DRUG|Epirubicin (E)|IV infusion either in Q2W or Q3W
223862353|NCT03725059|DRUG|Cyclophosphamide (C)|IV infusion either in Q2W or Q3W
223862354|NCT03725059|DRUG|Endocrine therapy|Variable endocrine therapy for up 10 years
223862355|NCT03725059|RADIATION|Radiation therapy|Variable radiation therapy per local standard of care
223862356|NCT03725059|PROCEDURE|Surgery|Surgery for breast cancer
223862357|NCT06129149|BEHAVIORAL|Trauma-Informed Care-adapted and Checklist-guided ACP intervention|The intervention will consist of a single one- to two-hour visit wherein the PI (Kimpel) will facilitate a flexible conversational approach with the resident (and, optionally, a healthcare decision-maker) in a quiet, private location in the resiliency hub. Using a conversation checklist adapted from a narrative synthesis of advance care planning (ACP) guides (Fahner et al., 2019), the PI will explore ACP with participants and use each visit to continually adapt the checklist and approach with trauma-informed care (TIC) principles: safety, trustworthiness and transparency, peer support, collaboration and mutuality, empowerment, and choice, and cultural, historical, and gender issues. Adverse Childhood Experiences and previous death-related experiences assessed during baseline data collection will be used to tailor the discussion to carefully explore relevant history to assess resident ACP values, preferences, and goals.
223862358|NCT06025019|BEHAVIORAL|parent-based Electronic Health intervention|"The eHealth intervention comprises 12 modules on three interaction modules related to physical activity, dietary behavior, and sleep. The intervention groups will be invited to a WeChat group. A 3-minute video (made on the TikTok APP) will be sent to each WeChat group. Based upon the social media studies recommendation, five to nine members in a group will produce the desirable group interactive effect. Therefore, the present study allocates eight parents to one WeChat group. In total, there will be 26 groups (206 parents) according to the sample size calculation. Consistent with Social Cognitive THeory, the content of each module will follow the four steps: 1. Attention (Read educational material and watch TikTok/Douyin video (less than 3 minutes). 2.Retention (parental interaction). 3.Reproduction (Set goals and conduct behaviors). 4.Motivation (feedback and making changes)."
223862359|NCT05955898|BEHAVIORAL|Parents THRIVE|Parents THRIVE is a digital, one-time intervention that will give parents strategies to cope with their emotions and improve their distress tolerance. Parents will learn how to increase their emotion awareness to better tolerate strong emotions, such as anxiety, sadness, anger, and frustration.
223862360|NCT05955898|BEHAVIORAL|Sharing Feelings Project|Sharing Feelings Project is a digital, one-time program that focuses on the benefit of sharing emotions with others and will be used as a control. Parents will read about how sharing their emotions can be helpful and anecdotes from others' experiences sharing emotions.
223862361|NCT01418794|DEVICE|High dose rapamycin stent|Concentration of rapamycin is 2.5%
223862362|NCT01418794|DEVICE|Low dose rapamycin stent|Concentration of rapamycin is 1.5%
223862363|NCT04151472|DRUG|Placebo|Placebo oral tablet, three times a day
223862364|NCT04151472|DRUG|90mg Idebenone|Idebenone 30 MG Oral Tablet, three times a day
223862365|NCT04151472|DRUG|270mg Idebenone|Idebenone 90 MG Oral Tablet, three times a day
223862366|NCT01470508|BEHAVIORAL|Cognitive Behavioral Therapy|Individuals meet with a therapist once a week for 25 sessions, 50 minutes in length, for a period of 27 weeks for therapy. Cognitive Behavioral Therapy is manualized and is the standard form of care at the UNC Eating Disorders Program.
223862367|NCT01470508|BEHAVIORAL|Cognitive Behavioral Therapy with Family Enhancement|Individuals will meet with a therapist once a week for 25 sessions, 50 minutes in length, for a period of 27 weeks for therapy. Cognitive Behavioral Therapy with Family Enhancement is manualized and will involve the participation of family members during six (6) weeks of treatment.
223862368|NCT03568799|RADIATION|18F-(2S,4R)4-fluoroglutamine|Undergo 18F-(2S,4R)4-fluoroglutamine PET/CT
223862369|NCT05688761|DRUG|Proton pump inhibitor|Long-term use of medications, particularly proton pump inhibitors
223862370|NCT02960269|OTHER|interprofessional back pain assessment|team assessment and education with urban physical therapist and rural nurse practitioner via telehealth
223862371|NCT04726813|BEHAVIORAL|MyADHD|The main goals of the intervention are to help participants with better functioning in daily life; offer strategies that will lead to stress reduction and reduce inattention and improve quality of life.The intervention includes: a short introductory chapter (open to everyone), followed by a start module (goal setting), followed by 6 different themed optional modules. Module content is based on GMT, DBT and CBT techniques and is tailored towards key concerns and difficulties experienced adults with ADHD as informed by previous research (focus-groups, lived experience groups) and experiences from group GMT and DBT.
223862372|NCT04726813|BEHAVIORAL|Psychoeducation|Participants in the control condition will be assigned to psychoeducation modules (see Table 2) and will receive restricted access to the platform. They can contact or be contacted if their symptoms levels increases.
223862373|NCT01727128|DRUG|BKM120|
223862374|NCT00657943|DRUG|metformin|metformin tablets 2 g x 2
223862375|NCT00657943|DRUG|insulin detemir|insulin as requested
223862376|NCT00657943|DRUG|insulin aspart + insulin aspart protamin|insulin as requested
223862377|NCT00657943|DRUG|Insulin aspart|insulin as requested
223862378|NCT00813449|DRUG|dacarbazine plus Endostar (Experimental group)|dacarbazine plus Endostar
223862379|NCT00813449|DRUG|dacarbazine plus placebo (control group)|dacarbazine plus placebo
223862380|NCT00783133|DRUG|Desloratadine 5 mg|Clarinex 5 mg daily x 7 days
223862381|NCT00783133|DRUG|fexofenadine|Allegra 180 mg daily x 7 days
223862382|NCT02178111|OTHER|Never perform episiotomy|In this group birth attendants will be sought to avoid at all cost episiotomy. The intention is to never perform episiotomy in this group.
223862383|NCT02178111|PROCEDURE|episiotomy|
223862384|NCT05951218|OTHER|inhibition technique|Inhibition treatment consists of applying progressive pressure with the finger until resistance is felt. The patient should feel discomfort but not pain. They should stop when they consider that the trigger point has been sufficiently relaxed. All the techniques should last less than 5 minutes. Osteopaths will be trained to have a close strength during techniques. The number of Newton that will be apply will be decided during training with the investigator
223862385|NCT05951218|OTHER|placebo|"The osteopath will perform a light touch on 4 areas for 30 seconds each time. The trigger point area must be lightly touched, followed by the upper part of the pectoralis major, the elbow and finally the anterior part of the opposite glenohumeral region.~Osteopaths will be trained to have a close strength during techniques. The number of Newton that will be apply will be decided during training with the investigator with a palpatory pressure measurement tool. A proposition of 1N will be proposed to have a very light touch, without activating the C-tactile sensors."
223862386|NCT00006369|DRUG|ERA-923|
223862387|NCT05319041|DRUG|Wei's Qi Ju Gan Lu Formula|"The formulation, Wei's Qi Ju Gan Lu Formula, is initiated by the senior TCM collaborator, Prof Wei QP, is formulated to treat the dry eye patients with liver-kidney yin deficiency. The treatment regulation aims to nourish the Liver and Kidney, enrich yin deficiency, in order to promote tears production, hence treatment of Dry Eye."
223862388|NCT05319041|DRUG|Placebo|0.5g maltodextrin without any herbs medicine
223862389|NCT06568536|OTHER|Repeated behavioral assessments, functional electroencephalography and brain imagery, TMS-EEG|The presence of consciousness will be classified considering the highest level of consciousness revealed by repeated behavioral examinations, functional electroencephalography (task-based EEG), and functional brain imagery (task-based fMRI). Based on the results of this composite standard reference, we will evaluate the diagnostic and prognostic accuracy of TMS-EEG measurements of brain complexity
223862390|NCT05502900|DRUG|Melatonin|White round tablets, each with a dose of 5 mg Melatonin. 4 tablets taken simultaneously at night. Tablets can be crushed and/or taken with a glass of water if the patient wish.
223862391|NCT06622083|OTHER|Education|Students in both groups will be given 40 minutes of both theoretical and practical training on the anatomy of the pelvic floor, its contraction mechanism, function and dysfunctions, evaluation and physiotherapy and rehabilitation. Theoretical training will be given through presentation and question-answer techniques containing this information, and practical training will be given through a pelvic model and gynecological examination simulator.
223862392|NCT06622083|OTHER|Education and Aerobic exercise|Participants in the exercise group will undergo an aerobic exercise program using the Monark 938E Nova Ergometer and software before the training session. The bike operates with its computer software integrated with the ECG system. The aerobic exercise program will consist of 3-5 minutes of warm-up, 20 minutes of exercise, and 3-5 minutes of cool-down, performed at a moderate intensity. During the exercise session, heart rate will be recorded every 5 minutes using a Polar ECG sensor connected via Bluetooth to the 938E Nova Ergometer, while perceived exertion will be measured using Borg's 6-20 rating scale
223862393|NCT04131166|BEHAVIORAL|Mediterranean diet|A Mediterranean-type diet will be consumed for 4 to 8 weeks in the weight stable state with all meals provided.
223862394|NCT04131166|BEHAVIORAL|Low-carbohydrate, ketogenic diet|A low-carbohydrate, ketogenic diet will be consumed for 4 to 8 weeks in the weight stable state with all meals provided.
223862395|NCT04131166|BEHAVIORAL|Low-fat diet|A low-fat diet will be consumed for 4 to 8 weeks in the weight stable state with all meals provided.
223862396|NCT04131166|OTHER|Annual follow-up testing for 5 years|Annual follow-up testing with no restrictions on dietary intake during periods between annual testing.
223862397|NCT03520673|DIAGNOSTIC_TEST|Urodynamics|All the men in the study will receive the urodynamics procedure as a reference test.
223862398|NCT05390099|DRUG|Moringa oleifera leaf|Moringa toothpaste
223862399|NCT05767099|DIAGNOSTIC_TEST|Ultrasound mesurements|Compare various clinical test with ultrasound parameters to predict difficult videolaryngoscopy intubation.
223862400|NCT06960590|OTHER|Training - static streching|The intervention group performed one training session per week. Each training session consisted of 2 series of static stretching of the back band. The rest time between series was 45 s. The intervention lasted 6 weeks.
223862401|NCT02028637|OTHER|TLRs|Recently it has involved the role of TLR (toll-like receptors) in the pathogenesis of asthma.The possible role that TLRs play in the asthma and its recognition as a new endotype asthma, could open new therapeutic expectations.
223862402|NCT01976910|DRUG|DM-CHOC-PEN|"DM-CHOC-PEN will be dosed @ 39 mg/M2, escalated in 1-patient cohorts at 40% dosage.~At the 1st DLT - expand to 3-6 patient cohorts/dose with escalations at 33% increments.~The MTD will be where 2 DLTs are noted and the study is discontinued."
223862403|NCT00502372|DIETARY_SUPPLEMENT|Nutritional Supplement/Amino acids and HMB|Subjects will be randomized to receive enriched dietary supplement (Juven) v arginine only (Argenaid) dietary supplement
223862404|NCT00502372|DIETARY_SUPPLEMENT|Juven|comparison of Juven with arginine only product in wound healing
223862405|NCT06504368|DRUG|DCR-PDL1|Solution for IV Infusion
223862406|NCT04063826|DEVICE|PET MRI|All participants will have a liver scan
223862407|NCT00814346|DRUG|EGb761®|Four weeks for AD patients, 18 months for MC and CNE patients
223862408|NCT00814346|DRUG|Placebo|Placebo 1 tablet BID
223862409|NCT02713334|BEHAVIORAL|survey|
223862410|NCT02713334|BEHAVIORAL|semi-structured interview|
223862411|NCT04800016|DEVICE|AcrySof IQ Vivity Extended Vision IOL|UV and blue-light filtering extended depth of focus foldable IOL intended to provide a full range of vision from distance to functional near.
223862412|NCT04800016|PROCEDURE|Cataract surgery|Cataract extraction by phacoemulsification, followed by implantation of the AcrySof IQ Vivity Extended Vision IOL
223862413|NCT03622580|DRUG|Aflibercept|Aflibercept 2 mg was administered by intravitreal (IVT) injection into the study eye once every 8 weeks (Q8W).
223862414|NCT03622580|DRUG|Faricimab|Faricimab 6 mg was administered by IVT injection into the study eye either once every 8 weeks (Q8W) in arm A or according to a personalized treatment interval (PTI) in arm B.
223862415|NCT03622580|PROCEDURE|Sham Procedure|The sham is a procedure that mimics an IVT injection and involves the blunt end of an empty syringe (without a needle) being pressed against the anesthetized eye. It was administered to participants in all three treatments arms at applicable clinic visits to maintain masking among treatment arms.
223862416|NCT01441453|PROCEDURE|FibroScan (Transient Elastography measurement)|Preoperative evaluation of liver stiffness through FibroScan
223862417|NCT02279017|BEHAVIORAL|mHealth Texting for Weight Loss|
223862418|NCT04181255|DRUG|Curosurf|This arm will consist of a single dose of Curosurf (200 mg/kg) that will be given in the Pediatric Cardiothoracic Unit (PCTU) after surgery once the subject has reached a normalized body temperature.
223862419|NCT04181255|DRUG|Sham|This arm will consist of a single dose of sham (air) that will be given through the endotracheal tube in the Pediatric Cardiothoracic Intensive Care Unit after surgery once the subject has reached a normalized body temperature.
223862420|NCT00587925|OTHER|Bone Mineral Density|Clinic visits twice during the first 2 years of the study with medical care directed by your treating doctor.BMD is measured by an X-ray test. The most common type of BMD testing is by energy x-ray absorptiometry (DEXA). Usually BMD is measured every other year, but to closely monitor women on this study, the BMD will be evaluated more often. The BMD will be measured 3 times (baseline, 12 months and 24 months) on this study. Study blood work is obtained three times (baseline, 6 months, and 12 months). Blood (about 3 teaspoons).
223862421|NCT05266599|OTHER|MTA Fillapex root canal sealer|Root canal treatments were performed with MTA Fillapex
223862422|NCT05266599|OTHER|AH Plus root canal sealer|Root canal treatments were performed with AH plus
223862423|NCT06000748|DRUG|MAP-Target Algorithm|This is a clinical treatment algorithm that will determine the escalation and deescalation of vasoconstrictor utilization based on a target MAP, either high (≥80 mmHg) in the treatment group and low (\< 80 mmHg) in the comparator group.
223862424|NCT00910754|DRUG|Abiraterone acetate|Abiraterone acetate 1000 mg (4 x 250 mg tablets) administered orally once daily.
223862425|NCT00910754|DRUG|Prednisone|Prednisone 5 mg tablets administered orally twice daily.
223862426|NCT01806454|DRUG|calcium|
223862427|NCT04536441|BEHAVIORAL|Ultra Brief Online Mindfulness-based Intervention|We adapted and contextualized the original RAIN protocol to local pandemic-induced lockdown situation, with short journaling prompts that engage participants in self-reflection. Journaling is known to be a creative way to engage people in a therapeutic activity which promotes self-awareness (Utley \& Garza, 2011). Creating a visual narration of thoughts, feelings and experiences help individuals make internal experiences more tangible and manageable, especially during these uncertain times.
223862428|NCT04536441|BEHAVIORAL|Control|The control group participants were asked to report preventive measures that they have taken to prevent COVID-19, ways that they obtained Movement Control Order news, and things that they wished to do once the Movement Control Order is lifted.
223862429|NCT03612882|OTHER|Online questionnaire|Online questionnaire assessing sedentary behaviour, physical activity, subjective well-being, life satisfaction, depression, anxiety, and demographics
223862430|NCT02402920|DRUG|Carboplatin|Given IV
223862431|NCT02402920|DRUG|Cisplatin|Given IV
223862432|NCT02402920|DRUG|Etoposide|Given IV
223862433|NCT02402920|OTHER|Laboratory Biomarker Analysis|Correlative studies
223862434|NCT02402920|BIOLOGICAL|Pembrolizumab|Given IV
223862435|NCT02402920|PROCEDURE|Radiation Therapy|Undergo radiation therapy
223862436|NCT03071848|OTHER|No Intervention|This was an observational study.
223862437|NCT03444649|DRUG|Epacadostat|Epacadostat orally two times daily (BID) for two cycles (28 days each) in combination with standard induction chemotherapy (Idarubicin and Cytarabine)
223862438|NCT03444649|DRUG|Idarubicin|Standard chemotherapy d1-d3 cycle 1
223862439|NCT03444649|DRUG|Cytarabine|Standard chemotherapy d1-d7 cycle 1 and 2
223862440|NCT03444649|DRUG|Daunorubicin|Standard chemotherapy d1-3 cycle 2
223862441|NCT03007836|BIOLOGICAL|High-activity natural killer|Each treatment: 8\~10 billion cells in all, transfuion in 3 times, i.v.
223862442|NCT00326924|BIOLOGICAL|Transfusion|PRBC blood transfusions.
223862443|NCT02613871|DRUG|LDV/SOF|90/400 mg FDC tablet administered orally once daily
223862444|NCT01203618|DRUG|Farletuzumab|Farletuzumab initial loading dose 5.0 mg/kg intravenous followed by 2.5 mg/kg intravenous for all subsequent doses every 2 weeks for up to 12 months.
223862445|NCT06155071|OTHER|Plyometric Training|"The group will receive plyometric exercises in a controlled environment. Following Plyometrics would be performed.~1. Plyo Pushup.~2. Chest Pass.~3. Overhead Throw.~4. Squat jump.~5. Plyo Step-up.~6. Cone jumps.~7. Med Ball drop.~8. Kneeling Squat jump.~9. Lateral jump over hurdle.~10. Overhead throw.~11. Under hand throws.~12. Dynamic Rotational Chest pass.~13. Overhead throw with step."
223862446|NCT06155071|OTHER|Conventional Exercises|"The group will receive conventional exercises in a controlled environment. Following conventional exercises would be performed.~1. Pushups.~2. Situps.~3. Lunges 4.500m running.~5.Squats"
223862447|NCT05300061|BEHAVIORAL|Personal Values Intervention|A 15 minute personal values intervention. Aim is to help participants clarify their own values around flying and promote committed action towards airplanes.
223862448|NCT05300061|BEHAVIORAL|Prosocial Values Intervention|A 15 minute prosocial values intervention. Aim is to help participants clarify their prosocial values around flying and promote committed action towards airplanes.
223862449|NCT06555653|OTHER|Video based multimedia information|The intervention group was shown a 5 minute informational video before amniocentesis including definition of amniocentesis, its indications, the setup of amniocentesis room, the purpose and steps of the procedure, potential complications and how to manage them
223862450|NCT02873312|DEVICE|StimRouter|"The StimRouter System is a neuromodulation system consisting of the following components and accessories:~* An implantable multi-electrode lead with integrated receiver in loader and surgical tools for implantation of the implantable lead.~* An external programming system with a clinician programmer, a clinician programmer cradle and charger, an external pulse transmitter tester and accessories.~* A patient-operated system with an external pulse transmitter (StimRouter EPT), a disposable StimRouter Electrode, an external patient programmer and charger, and accessories."
223862451|NCT01240837|OTHER|Arenga Pinnata Sugar|50 g palm sugar given orally 1 time in 250 ml of water. Blood glucose measurements will then be taken at time points, 0, 15, 30, 45, 60, 90 and 120 minutes.
223862452|NCT01240837|OTHER|Glucose|50 g glucose given orally 3 time in 250 ml of water. Blood glucose measurements will then be taken at time points, 0, 15, 30, 45, 60, 90 and 120 minutes.
223862453|NCT01240837|OTHER|Sucrose|50 g sucrose given orally 1 time in 250 ml of water. Blood glucose measurements will then be taken at time points, 0, 15, 30, 45, 60, 90 and 120 minutes.
223862454|NCT03954015|DIAGNOSTIC_TEST|Contrast Enhanced imaging|Contrast Enhanced Ultrasound (CEUS) with US Microvessel Imaging, Contrast Enhanced Dual Energy Mammography (CEDM) and Contrast Enhanced Breast MR (CEMR): Comparison of Three Methods for Early Detection of Breast Cancer.
223862455|NCT03954015|DRUG|Lumason|FDA approved and used routinely for ultrasound exams of the heart and liver as well as the urinary tract in children. It contains microbubbles that are small enough to pass through the blood stream.
223862456|NCT02876471|OTHER|CPAP|OSA complicated with hypertension：In order to avoid the effects of drugs on this study, we calculated the time to stop based on the half-life of patients taking oral drugs and last time administration time. The subject who withdrawal time was less than three days was enrolled in our study. These patients were hospitalized and close monitoring of blood pressure, for blood pressure three times greater than 180/110mmHg or appearing dizziness, headache and other clinical syndrome, we give a timely clinical intervention and get rid of our study. Screening of 40 newly diagnosed patients with hypertension and subjects with poor blood control,the investigators would give one-night CPAP
223862457|NCT06849778|DRUG|TS-172|oral administration of TS-172 20 mg
223862458|NCT02169154|DRUG|1% Diclofenac Sodium|1% diclofenac sodium
223862459|NCT02169154|DRUG|3% Menthol|3% Menthol
223862460|NCT02169154|DRUG|0.09% Menthol|0.09% Menthol
223862461|NCT02169154|DRUG|0.2% Sodium Lauryl Sulfate|0.2% Sodium Lauryl Sulfate
223862462|NCT02169154|DRUG|0.9% Saline|0.9% Saline
223862463|NCT00437346|PROCEDURE|Individualized and comprehensive information|Thorough verbal and written information about results of the tests. Individualized meals recommendation based on the results.
223862464|NCT00437346|DRUG|Lanzo Melt|30mg, od, 1/2 h before meal
223862465|NCT00437346|DRUG|Lanzo Melt|30mg, od, 1/2 h before meal
223862466|NCT01483248|BIOLOGICAL|conventional therapy plus MenSC transplantation|"patients will receive conventional treatment,such as antiviral drugs, lowering aminotransferase and jaundice medicine.~MenSCs transplantation: taken i.v., twice per week, at a dose of 1\*10E6 MSC/kg body for 2 weeks."
223862467|NCT01483248|DRUG|Conventional therapy plus placebo treatment|25 of the enrolled patients were assigned to receive comprehensive treatment including antiviral drugs, lowering aminotransferase and jaundice medicine.
223862468|NCT01845428|DRUG|Pravastatin|After collecting baseline plasma samples, participants will receive pravastatin 20mg daily. After 6 weeks, we will collect samples and safety data. Subsequent statin therapy will be at the discretion of the treating physician.
223862469|NCT01197807|PROCEDURE|Bulb Suctioning|Bulb suctioning of the mouth then the nose immediately following delivery
223862470|NCT01197807|PROCEDURE|Wiping|Gentle wiping of mouth then nose with a soft cloth immediately following delivery
223862471|NCT04971447|DRUG|gender affirming hormonal treatment in transgender men|testosterone enanthate
223862472|NCT04971447|DRUG|gender affirming hormonal treatment in transgender women|GnRH agonists + estrogen
223862473|NCT04824443|OTHER|Aerobic Exercise Therapy|Aerobic Exercise Therapy/AT will consist of 30 weeks of treadmill walking sessions. AT will consist of supervised, individualized walking delivered up to 6 times weekly (over a 7-day period) to achieve a cumulative total duration ranging from 90 mins/wk up to 375 mins/wk following a non-linear dosing schedule. The planned dose and scheduling of AT will be continually altered and progressed in conjunction with appropriate rest/recovery sessions across the entire intervention period (i.e., non-linear periodized schedule).
223862474|NCT03558893|BEHAVIORAL|Forced Desynchrony|All sleep opportunities and other activities will be scheduled by the experimenter so that by the end of the study these activities are spread evenly across all phases of the internal body clock.
223862475|NCT02616237|BEHAVIORAL|Lifestyle Intervention|East-meets-West Lifestyle Intervention elements include nutrition and exercise from the Western perspective, food therapy and acupressure from the Traditional Chinese Medicine perspective, self-monitoring, and motivational videos of successful stories from working colleagues. The group participants in the Facebook are encouraged to post their health behaviors and questions, self-monitor, pledge for weight loss, seek social support and interact with health partners and other participants.
223862476|NCT02662855|OTHER|WHO-recommended therapies|symptomatic and supportive treatments according to the WHO manual
223862477|NCT02662855|DRUG|Favipiravir|oral administration of Favipiravir tablets
223862478|NCT02891278|DRUG|Sertraline|"Sertraline is a selective serotonin reuptake inhibitor (SSRI) that is FDA approved to treat major depressive disorder, obsessive-compulsive disorder, panic disorder, post-traumatic stress disorder, premenstrual dysphoric disorder, and social anxiety disorder.~Sertraline will be administered orally twice a day starting on day -3. Sertraline will be administered at one of 4 pre-defined dose levels in the following dose-escalation: 50 mg daily, 50 mg twice a day, 50 mg every morning (QAM) and 100 mg every evening (QPM), 100 mg twice a day. 100 mg QAM and 150 mg QPM."
223862479|NCT02891278|DRUG|Cytosine arabinoside|"Cytarabine is a cytotoxic chemotherapy approved for use in acute myeloid leukemia, acute lymphoblastic leukemia, and chronic myelogenous leukemia. It is also approved to prevent and treat meningeal leukemia. Cytarabine kills cells in S-phase through inhibition of DNA polymerase, as well as by halting DNA synthesis after its incorporation into DNA.~Cytosine arabinoside (Ara-C) will be administered as a 72 hour intravenous continuous infusion (IVCI) beginning Day 1 of therapy and again beginning Day 10 of therapy. The total dose of ara-C for each 72 hour period is 2 gm/m2 (0.667 gm/m2/24 hours)."
223862480|NCT02891278|PROCEDURE|allogeneic stem cell transplantation|Allogeneic stem cell transplantation involves transferring the stem cells from a healthy person (the donor) to a patient after high-intensity chemotherapy or radiation.
223862481|NCT00507689|DRUG|FTC/TDF|Emtricitabine (FTC) 200 mg/tenofovir disoproxil fumarate (TDF) 300 mg was administered as a fixed-dose combination tablet orally once daily.
223862482|NCT00507689|DRUG|Hepatitis B Immunoglobulin (HBIg)|HBIg was administered either intravenously or by intramuscular injection at a dose and frequency as prescribed by the investigative site protocol.
223862483|NCT02997917|BEHAVIORAL|Education|
223862484|NCT02997917|BEHAVIORAL|Sham|
223862485|NCT05590650|DRUG|SZKJT(San-Zhong-Kui-Jian-Tang)|The SZKJT samples were made and packed by Kaiser Pharmaceutical Co. Ltd. with lot number of 2019023247.
223862486|NCT05383313|DRUG|Psilocybin|Effect of psilocybin on treatment-resistant depression
223862487|NCT05383313|DRUG|Ketamine Hydrochloride|Effect of ketamine on treatment-resistant depression
223862488|NCT05383313|DRUG|Midazolam Ph. Eur 9.0|Effect of midazolam on treatment-resistant depression
223862489|NCT00494442|DRUG|KU-0059436 (AZD2281)(PARP inhibitor)|oral
223862490|NCT00494442|DRUG|KU-0059436 (AZD2281)(PARP inhibitor)|oral
223862491|NCT04368403|DRUG|KHK4827|210 mg every 2 weeks (Q2W), subcutaneous (SC) injection
223862492|NCT02749578|DRUG|Atorvastatin|
223862493|NCT02749578|DRUG|MGL-3196|
223862494|NCT00831415|DRUG|desvenlafaxine succinate sustained release tablets|25-mg or 50-mg DVS SR tablets taken orally, once daily, at the same time each day. 100 mg dose will be supplied as 2 tablets of 50-mg tablet.
223862495|NCT01290224|OTHER|scrambler therapy|Undergo MC5-A therapy
223862496|NCT01290224|PROCEDURE|sham intervention|Undergo sham procedure
223862497|NCT01290224|OTHER|questionnaire administration|Ancillary studies
223862498|NCT05347108|PROCEDURE|laser-assisted neural decompression (LAND) procedure|"The LAND procedure is a minimally invasive spinal decompression procedure that uses a focused laser beam to reduce and remove disc herniations that are causing nerve compressions and impingements within the spinal canal. It is performed in an outpatient setting and the patient receives local anesthesia.~The LAND procedure has been performed extensively over the past 2-years on hundreds of patients, so including patients that have previously had the surgery allows for additional data points and improved reporting."
223862499|NCT03895268|DEVICE|ALiA Analyser|NPS specimens shall be tested with the investigational device
223862500|NCT03895268|DEVICE|Influenza A+B Test Kit|NPS specimens shall be tested with the investigational device
223862501|NCT04271410|BIOLOGICAL|CD19 CAR-T cells|CD19 CAR-T cell therapy
223862502|NCT03852836|OTHER|ultra-rapid acquisition of bile ducts images|On top of the conventional SPACE sequence, 2 supplementary sequences will be performed with the ultra-rapid sequence (sequence CS-SPACE) either acquired in apnoea or synchronized with the breath.
223862503|NCT01241292|BIOLOGICAL|BMS-901608 (Elotuzumab) 10 mg|Injection, Intravenous, 10 mg/kg, Weekly at cycle 1 and 2, bi-weekly at cycle 3 and thereafter, Until disease progression or unacceptable toxicity became apparent
223862504|NCT01241292|BIOLOGICAL|BMS-901608 (Elotuzumab) 20 mg|Injection, Intravenous, 20 mg/kg, Weekly at cycle 1 and 2, bi-weekly at cycle 3 and thereafter, Until disease progression or unacceptable toxicity became apparent
223862505|NCT04299360|DEVICE|Cardiac Resynchronization Therapy device programming|Implanted CRT-D devices settings will be programmed based on the best acute hemodynamic response assessed non-invasively
223862506|NCT02128607|DEVICE|SNAG|sustained natural apophyseal glide: SNAG / Mulligan technique
223862507|NCT02128607|DEVICE|Sham|
223862508|NCT02076958|BEHAVIORAL|Community Health Advisor education|
223862509|NCT06259058|DRUG|Irinotecan liposome injection|50 mg/m² on Day 1 of a 14-day cycle
223862510|NCT06259058|DRUG|Oxaliplatin|60 mg/m² on Day 1 of a 14-day cycle
223862511|NCT06259058|DRUG|5-Fluorouracil|2400 mg/m² continuous IV infusion in 46 h
223862512|NCT06259058|DRUG|Leucovorin|400 mg/m² on Day 1 of a 14-day cycle
223862513|NCT06259058|RADIATION|SBRT|30Gy/5Fx
223862514|NCT03531853|DEVICE|hand-held swept source optical coherence tomography|images the eye
223862515|NCT00447733|BEHAVIORAL|Integrated mental health and substance use treatment|Psychosocial and drug treatment targeting both the substance use disorder and the psychiatric disorder in an integrated and comprehensive way.
223862516|NCT00447733|BEHAVIORAL|Treatment as usual|Non-standardized psychiatric outpatient treatment
223862517|NCT03861767|DRUG|Metformin ER|tablet
223862518|NCT03861767|DRUG|Placebo|Matched placebo in doses of 1, 2 and 3 tablets to coincide with the 500, 1000, and 1500 mg arms.
223862519|NCT03023280|PROCEDURE|Radiofrequency ablation|
223862520|NCT00813904|BIOLOGICAL|rThrombin, 1000 IU/mL|At least 1 application of reconstituted rThrombin, 1000 IU/mL, applied topically directly to the bleeding site, per product labeling.
223862521|NCT00346333|DRUG|Lutein|12mg/d
223862522|NCT00346333|DIETARY_SUPPLEMENT|Cornstarch control|Daily intake of cornstarch control plus 15,000 IU/d Vitamin A palmitate
223862523|NCT06400394|DEVICE|Hydrocyn Aqua®|The study solution comes in a liquid form containing hypochlorous acid (HOCl) in a concentration of 0.003%. It is used as a topical agent for wound and peritoneal lavage before wound closure
223862524|NCT06400394|DEVICE|Normal Saline|aqueous solution of electrolytes and other hydrophilic molecules
223862525|NCT00971711|BIOLOGICAL|Probiotic|The subjects will be randomized into either a 4 week or 8 week treatment period with the probiotic. The treatment will be open label. They will take 2 packets once daily.
223862526|NCT05949749|DIAGNOSTIC_TEST|Epitope exploration|Explore the epitope landscape of gp42-IgG of cases in comparison with that of controls.
223862527|NCT00391547|DRUG|Frio Oral Rinse|
223862528|NCT06194734|DRUG|KC1036|KC1036 60mg QD orally, before a meal, continuous administration, 21 days as a cycle
223862529|NCT06194734|DRUG|Irinotecan|Irinotecan intravenously administered at 130-150 mg/m2 once every 2 weeks
223862530|NCT06194734|DRUG|Docetaxel|Docetaxel intravenously administered at 60-75 mg/m2 once every 3 weeks；
223862531|NCT06194734|DRUG|S-1|S-1 orally administered 40-60mg Bid on Day 1 to Day 14 of every 3 weeks, 21 days as a cycle
223862532|NCT04364789|DRUG|TT-00920|Tablets
223862533|NCT04364789|DRUG|Placebos|Tablets
223862534|NCT01051583|PROCEDURE|Diode laser cyclophotocoagulation enhanced by intravitreal injection of Avastin|The operative procedure involved retro-bulbar anesthesia, draping the patient in an aseptic manner, introduction of an eye speculum, 30 laser shots over 270 degrees of the circumference of the limbus. For our study we used the Iris Diode laser machine, the G-probe and we adjusted the settings for 2500 millisecond duration and the 3000 milli-joule and reduced the power progressively until just below the energy level that produced a pop.then after applying the laser, we performed a paracentesis with a 27 gauge needle to soften the globe, followed by intravitreal injection of the Avastin from a site 3.5 millimeter posterior to the limbus. The dose we administered was one milligram of bevacizumab (0.04 mL of 25 mg/mL).
223862535|NCT03123172|DIAGNOSTIC_TEST|arterial and central venous blood gases|withdrawal of arterial and central venous blood gases to measure Co2 gap
223862536|NCT03081949|DRUG|Oral Sodium Selenite 200 µg/day for 3 months|PPCM patients with selenium deficiency, who have not achieved LV reverse remodelling (LVRR) (LV end-diastolic dimension indexed to body surface area (LVEDDi) ≤33.0 mm/m2) at 6 months after diagnosis.
223862537|NCT03760419|BEHAVIORAL|Clinical Decision Support|For enrolled subjects assigned to the decision support arm, providers will receive antibiotic recommendations in accordance with the 2011 PIDS/IDSA guideline, tailored to site of care and illness severity. The tool will offer treatment recommendations only and will not proscribe a specific treatment plan.
223862538|NCT01122420|OTHER|Goal-Setting Tool|Access to an online health-related goal-setting tool through the MyHealthAtVanderbilt patient portal
223862539|NCT01122420|OTHER|Health Web Sites|Access to publicly available health-related web sites
223862540|NCT05979324|DEVICE|ABAStroke Digital Therapeutics|The total time of the study is 30 weeks in total, i.e. 15 weeks of patient recruitment and then a maximum of another 15 weeks until the end of the observation of the last patient. Within 2 weeks from the last patient, the last Monitor's visit will be performed to close the study. The patient will use the ABAStroke application for a maximum of 91 days (the minimum time is 28 days) and standard therapy, including rehabilitation (as recommended by researchers or other physicians rehabilitating a patient after a stroke).
223862541|NCT04018508|OTHER|Massage|Massage intervention including effleurage, petrissage and energy work/Reiki at a pressure of 2 or less (Walton Pressure Scale)
223862542|NCT02655380|DRUG|Ketamine 1|Anesthesia induction is performed with 1 mg ketamine.
223862543|NCT02655380|DRUG|Ketamine 2|Anesthesia induction is performed with 2 mg ketamine.
223862544|NCT02655380|DRUG|Remifentanil|After anesthesia induction with ketamine, predetermined remifentanil using Dixon's up and dowm method is administered.
223862545|NCT03914170|DRUG|Folfirinox + cetuximab|Cetuximab 250 mg/m² iv infusion for 2h, Oxaliplatin 85 mg/m² administered as an iv infusion for 2h Elvorine 200 mg/m² administered as an iv infusion for 2h, Irinotecan 180 mg/m² iv infusion, 5FU 400 mg/m2 bolus then 5FU 2,400 mg/m² iv infusion for 46h D1=D15 (12 cycles max)
223862546|NCT04148417|DEVICE|Solo+ Tympanostomy Tube Device|The Solo+ Tympanostomy Tube Device is intended to deliver a tympanostomy tube through the tympanic membrane of a patient during a tympanostomy procedure
223862547|NCT03387319|BEHAVIORAL|Racialized Stressful Event Recall|"Participants will undergo a moderate psychological stress adapted from the Trier Social Stress Test (TSST) where they will be asked to recall a stressful, real-life, race-related event.~After instructions are provided, participants will be given two minutes to prepare their statement, and three minutes to deliver their statement. There will be an 'audience' present at each participant's speaking task which will include two observers who are of same race as the participant (African American), to heighten stress responses."
223862548|NCT03387319|BEHAVIORAL|Non-Racialized Stressful Event Recall|"Participants will undergo a moderate psychological stress adapted from the Trier Social Stress Test (TSST) where they will be asked to recall a stressful, real-life, event unrelated to race.~After instructions are provided, participants will be given two minutes to prepare their statement, and three minutes to deliver their statement. There will be an 'audience' present at each participant's speaking task which will include two observers who are of same race as the participant (African American), to heighten stress responses."
223862549|NCT02212054|BEHAVIORAL|conservative|anal dilatation; colonic lavage; oral probiotic
223862550|NCT02212054|PROCEDURE|operative|one stage pull through radical colectomy
223862551|NCT03308461|DRUG|Fecal Microbiota suspension|The prepared microbiota suspension was infused into mid-gut.
223862552|NCT00786448|DRUG|Darifenacin, Emselex (BAY79-4998)|Patients from routine practice
223862553|NCT04314830|DEVICE|Gait training with perturbations|Changes in speed of one of the belt of the split belt treadmill during swing phase
223862554|NCT04314830|DEVICE|Gait training without perturbation|Walking on a treadmill with steady belt speed
223862555|NCT02020824|BEHAVIORAL|Exposure to anxiogenous environments|"The anxiogenous environments are defined by several levels of possible anxiety classified progressively and independently by each patient at the beginning of the study. The exposure is applied during the 8 sessions for each of the arms Exposure to anxiogenous environments (with or without control)."
223862556|NCT02020824|OTHER|Imagery with functional MRI initial|Subjects will be submitted to 1 session of fMRI during their first visit, in order to identify and evaluate the activation of cerebral fields involved during the exposure to anxiogenous environments.
223862557|NCT02020824|OTHER|Imagery with PET-scanner initial|Subjects will be submitted to 1 session of PET-scanner during their first visit, in order to measure the synaptic activity during the exposure to anxiogenous environments.
223862558|NCT02020824|OTHER|Imagery with functional MRI final|Patients will be submitted to 1 session of fMRI during a follow-up visit, in order to identify and evaluate the activation of cerebral fields involved during the exposure to anxiogenous environments.
223862559|NCT02020824|OTHER|Imagery with PET-scanner final|Patients will be submitted to 1 session of PET-scanner during a follow-up visit, in order to measure the synaptic activity during the exposure to anxiogenous environments.
223862560|NCT00764413|DRUG|methylprednisolone|1 gram intravenous a day for 3 days
223862561|NCT00764413|DRUG|Sodium chlorid|Sodium chlorid 9mg/ml 500 ml per day in 3 days
223862562|NCT03692117|DEVICE|Extracorporeal Carbon Dioxide Removal|Place a double lumen catheter in jugular vein, drainage the venous blood in vitro tube, after blood-gas exchange and remove CO2, then return back to the Superior vena cava
223862563|NCT04010955|DRUG|Edoxaban Monotherapy|when the patients will be initially registered in this study, duty physicians will make a decision to give additional antiplatelet therapy in addition to standard edoxaban therapy.
223862564|NCT02863900|OTHER|cohort of BC of each subtypes|
223862565|NCT06389071|DEVICE|Fractional 2940 nm Laser|Fractional 2940 nm Laser
223862566|NCT01387334|BEHAVIORAL|Resistance Exercise Training Program With Rubber Bands|Resistive exercise consist of 5-min warm up, at least 30 min resistive exercise using rubber band as recommendation (8-12 times per set, at least 3 sets per day and at least 3 days per week) and 5-min cool down
223862567|NCT01122901|DRUG|gamma-secretase/Notch signalling pathway inhibitor RO4929097|Given PO
223862568|NCT01122901|PROCEDURE|therapeutic conventional surgery|Undergo surgery
223862569|NCT01122901|OTHER|pharmacological study|Correlative studies
223862570|NCT01122901|OTHER|laboratory biomarker analysis|Correlative studies
223862571|NCT01128530|DRUG|JNJ-32729463|250 mg tablet twice daily
223862572|NCT01128530|DRUG|linezolid|600 mg tablet twice daily
223862573|NCT01128530|DRUG|JNJ-32729463 placebo|1 placebo tablet twice daily
224267122|NCT07138495|DEVICE|AI-personalized virtual reality rehabilitation system for unsupervised home-based stroke therapy|The personalized RGS app rehabilitation is a home-based, virtual reality therapy platform for motor and cognitive stroke recovery. Therapy tasks are gamified, task-specific, and adapt in difficulty based on real-time performance. An AI-driven clinical decision support system personalizes and updates exercise prescriptions after each session, with optional clinician adjustments. Integrated wearable sensors (RGSwear) track real-world activity and adherence. Data are securely uploaded to a cloud-based platform for remote monitoring. This is the first multicenter, international RCT to test AI-personalized VR rehabilitation at home with up to 12-month follow-up, combined with cost-effectiveness and usability evaluation.
223862574|NCT01128530|DRUG|linezolid placebo|1 placebo tablet, twice daily
224267123|NCT03864380|DIAGNOSTIC_TEST|Color retinography|Non mydriatic color retinography within 1 month before and within 1 hour after the marathon
224267124|NCT03864380|DIAGNOSTIC_TEST|OCT-A|Optical Coherence Tomography - Angiography within 1 month before and within 1 hour after the marathon
224267125|NCT03864380|DIAGNOSTIC_TEST|Blood pressure measurement|Blood pressure measurement within 1 month before and within 1 hour after the marathon
224267126|NCT02230605|OTHER|Mini-Mental State Examination|To be completed at the Screening Visit and Post-Operative Day 7 Visit (or Discharge)
224267127|NCT02230605|OTHER|Self-Administered Gerocognitive Examination|To be completed at the Screening Visit and Post-Operative Day 7 Visit (or Discharge)
224267128|NCT02230605|OTHER|Geriatric Depression Scale|To be completed at the Screening Visit and at POD 90
224267129|NCT02230605|OTHER|Charlson Comorbidity Index|To be completed at the Screening Visit and at POD 90
224267130|NCT02230605|OTHER|Short Form 36 Health Survey|To be completed at the Screening Visit
224267131|NCT02230605|OTHER|Confusion Assessment Method|To be completed at the Day 0 (Pre-Operative) Visit, Day 0 (Post-Operative) Visit, and Day 1-7 Visits at 7:30AM ± 1.5 hrs and 6:30PM ± 1.5 hrs. (or until hospital discharge)
224267132|NCT02230605|OTHER|Memorial Delirium Assessment Scale|To be completed at the Day 0 (Pre-Operative) Visit, Day 0 (Post-Operative) Visit, and Day 1-7 Visits at 7:30AM ± 1.5 hrs and 6:30PM ± 1.5 hrs. (or until hospital discharge)
224267133|NCT02230605|OTHER|Postoperative Quality of Recovery Scale|To be completed at Day 0 (Post-Operative) Visit, and Day 1-7 Visits at 6:30PM ± 1.5 hrs (or until hospital discharge). Will be completed POD 7 over the phone if patient already discharged. Will be completed on POD 30 and POD 90.
224267134|NCT05920447|DEVICE|LMA|Monitor the ventilatory parameter and incidence of complications
224267135|NCT02089282|DEVICE|Ultrasound|
224267136|NCT06716580|DEVICE|Circulating Tumor DNA (ctDNA) Assay|Screening investigational blood test to test for EGFR L858R and exon 19 deletions, which comprise 85-90% of total EGFR mutations. A positive or indeterminate investigational test will be followed up by CLIA verification of results. A positive or indeterminate CLIA result will be followed up by a lung CT scan. A positive CT scan will be followed up by referral for further evaluation. A negative CT scan will be followed up by a repeat scan in 12 months.
224267137|NCT01263353|DRUG|Pasireotide LAR followed by Pasireotide LAR + Everolimus|
224267138|NCT01263353|DRUG|Everolimus followed by Pasireotide LAR + Everolimus|
224267139|NCT06804486|BEHAVIORAL|Exercise|Exercise and physical-sports activity program
224267140|NCT06804486|OTHER|Recommendation to Deprescribe|Recommendation to Deprescribe
224267141|NCT06764680|DRUG|Trifluorouracil tepidopyrimidine|30mg/m2. P.O. bid. d1-d5 and d15-d19. q4w
224267142|NCT06764680|DRUG|Bevacizumab|5mg/kg. ivgtt. d1 and d15. q4w
224267143|NCT06764680|DRUG|Sindilizumab|200mg. ivgtt. d1. q4w
224267144|NCT06764680|RADIATION|IMRT|In terms of obstruction, bleeding, compression, or pain due to a tumor that requires local treatment. IMRT was delivered to the involved lesions.
224267145|NCT07064538|DIETARY_SUPPLEMENT|Neuralli® MP|Neuralli® MP containing 60 billion CFU (administered as two capsules per day)
224267146|NCT07064161|DRUG|Mupirocin (drug)|Wounds were dressed with gauze impregnated with mupirocin ointment covered by a transparent dressing (Tegaderm)
224267147|NCT07064161|DRUG|Hydrocolloid Dressing (DuoDERM CGF)|Wounds were dressed with a 1-inch size Duoderm Control Gel Formula hydrocolloid dressing
224267148|NCT07075146|DRUG|DOR/3TC/TDF|It is a triple-drug antiretroviral drug co-formulated in a single tablet. It contains Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate 100/300/300 mg
224267149|NCT07075146|DRUG|BIC/FTC/TAF|It is a triple-drug antiretroviral drug co-formulated in a single tablet. It contains bictegravir 50 mg, tenofovir alafenamide 25 mg, and emtricitabine 200 mg. It is the standard therapy.
224267150|NCT04428281|DRUG|RO7248824|In the MAD part, RO7248824 will be administered as IT injection of varing dose levels over a period of 8 weeks, with a minimum of approximately 4 weeks between each dose administration. In the LTE part, RO7248824 will be administered as IT injection of varying dose levels over a period of 144 weeks, with a minimum of approximately 16 weeks between each dose administration. In the OOE part, participants will receive RO7248824 as an IT injection with the same dosing regime as the LTE part over a period of up to 48 weeks.
224267151|NCT05291819|OTHER|Imaging informed treat-to-target|"A treat-to-target treatment strategy incorporating information from ultrasound assessment of joints, tendons and entheses (at every visit), and magnetic resonance imaging (MRI) of spine and sacroiliac (SI)-joints at baseline and 1 year, in addition to clinical information~Specifically, this means that these additional measures will be added to conventional treat to target:~* If evidence of enthesitis (power Doppler\>0 in enthesis) or axial inflammation (SPARCC score ≥ 2\* in SI-joint or SPARCC score ≥ 5 in presence of clinical symptoms of axial disease) on imaging the patient will progress directly to biological disease modifying antirheumatic drug in the treatment algorithm~* If evidence of ongoing inflammation (power Doppler\>0) on ultrasound assessment of joints, tendons or enthesis, the patient will be classified as not having reached their treatment target"
224267152|NCT05291819|OTHER|Conventional treat-to-target|Patients are treated according to an algorithm based on current European recommendations. The conventional treatment target, applicable to both arms and the target in the conventional arm, is all of: Disease Activity index in PSoriatic Arthritis (DAPSA) remission (≤4), Enthesitis ≤1, Psoriasis Body Surface Area ≤3%
224267153|NCT05564715|DEVICE|NeuroElectric StarStim|10 sessions of active stimulation (1 mA anodal HD-tDCS targeting preSMA/dACC for 20 min) across 2 weeks
224267154|NCT05564715|DEVICE|Sham Treatment|Sham stimulation for 10 sessions over 2 weeks
224267155|NCT05544292|OTHER|Antiinflammatory/DMARDs|Antiinflammatory/DMARDs
223862575|NCT01899027|DRUG|Rosuvastatin|Patients will receive two overnight high doses of Rosuvastatin (40 mg 12 h before RNA and another 10 mg dose 2 h before the procedure
223862576|NCT01899027|DRUG|Placebo|Patients will receive two overnight doses of Placebo 12 h before RNA and another dose 2 h before the procedure
223862577|NCT03197337|PROCEDURE|Pressure-test|Pressure will be applied to the posterior fornix using a speculum.
223862578|NCT02488252|DRUG|Semi-individualised Chinese Medicine treatment|"A: Panax ginseng, Atractylodes macrocephala, Pinellia ternate, Pericarpium citri reticulatae, Herba Pogostemonis, Glycyrrhiza uralensis, Rehmannia-6 decoction~B: Cortex magnoliae officinalis, Atractylodes macrocephala, Common Floweringquince Fruit, Common Vladimiria Root, Tsaoko Amomum Fruit, Palmae Fruit, Radixaconiti laterlis perparata, Zingiber officinale Rosc., Glycyrrhiza uralensis, Rehmannia-8 decoction~C: Root of Pilose Asiabell, Astragalus membranaceus, Rehmannia glutinosa, Common Macrocarpium Fruit, Dioscorea opposita , Barbary Wolfberry Fruit, Cortex eucommiae, Chinese Angelica, Glycyrrhiza uralensis~D: Rehmannia-6 decoction, Fructus Ligustri Lucidi, Yerbadetajo Herb~E: Rehmannia-8 decoction, Fructus Ligustri Lucidi, Yerbadetajo Herb"
223862579|NCT02488252|DRUG|Routine medical care (active comparator)|Angiotensin converting enzyme inhibitor or angiotensin receptor blocker at stable dose
223862580|NCT01140113|PROCEDURE|Modified Ultrafiltration|After weaning from bypass patients had undergone to modified ultrafiltration for 15 minutes with a filtration flow at 300 ml/min
223862581|NCT04501276|DRUG|ADG116|For monotherapy ADG116 (Part A), ADG116 will be administered IV over 60 90 minutes until disease progression, intolerable toxicities, or withdrawal of consent, or up to 2 years.
223862582|NCT04501276|DRUG|ADG106|For the ADG116-ADG106 combination regimen, ADG116 and ADG106 will be administered until disease progression, intolerable toxicities, or withdrawal of consent, or up to 2 years.
223862583|NCT04501276|DRUG|anti PD1 drug|For the ADG116-anti PD1 combination regimen, ADG116 and anti PD1 will be administered until disease progression, intolerable toxicities, or withdrawal of consent, or up to 2 years.
223862584|NCT00079482|DRUG|CEP-701|
223862585|NCT00079482|DRUG|high-dose cytarabine|Chemotherapy
223862586|NCT00079482|DRUG|Mitozantrone, Etoposide, Cytarabine (combination Chemotherapy)|Chemotherapy
223862587|NCT01700400|DRUG|Everolimus|
223862588|NCT01700400|DRUG|Pemetrexed|
223862589|NCT01700400|DRUG|Carboplatin|
223862590|NCT01700400|DRUG|Bevacizumab|
223862591|NCT05586113|DRUG|10-day Tegoprazan bismuth-containing quadruple therapy|10-day Tegoprazan bismuth-containing quadruple therapy: Tegoprazan（Luo Xin Pharmaceutical Group Co. LTD）50mg bid Amoxicillin (Amoxicillin, United Laboratories Co., LTD) 1000mg bid Tetracycline (Huanan Brand, Guangdong Huanan Pharmaceutical Co. LTD.) 500mg qid Bismuth potassium Citrate (Lizhu Delle, Lizhu Group Pharmaceutical Factory) 2g bid
223862592|NCT04333758|DEVICE|Jintronix Virtual Reality Telerehabilitation System|"System consists of an internet-based rehabilitation software linked to a Microsoft Kinect camera for motion detection.~Study team therapist prescribed a list of guided exercises and therapeutic activities (games) for training of whole body, lower and upper extremities. These can be done in sitting or standing, depending on individual participant's capacity.~Telemonitoring is done by study team therapist during each of the training day (Mondays-Fridays) of the home-based training phase. Training performance results are reviewed and training games are adjusted or changed to optimise home training."
223862593|NCT00188461|DEVICE|CT Thorax|
224267157|NCT05543720|DEVICE|Medly|Medly will enable patients with HF, COPD, Hypertension, Mental Health, or Diabetes to input measurements with wireless home medical devices and to answer symptom questions on the smartphone. The measurements will be automatically and wirelessly transmitted to the mobile phone and then to a data server. Automated self-care instructions/messages will be sent to the patient based on the readings and reported symptoms. If there are signs of their status deteriorating, an alert will be sent to a clinician that is responsible for the particular chronic condition of concern. The clinicians will have all the relevant patient data sent to them and will be able to access (through a secure web portal) to view historical and trending data for their patients.
223862594|NCT01305434|DIETARY_SUPPLEMENT|Mulberry leaf extract effect on post prandial blood glucose|"Mulberry leaf extract (400 mg, Mulberry Zuccarin, New Nordic) or placebo will be administered with meals to type 2 diabetics. Half the patients will receive mulberry leaf extract for the first two weeks and half will receive placebo. Following a one week wash out period, the interventions will be reversed for another 2 weeks, followed by a final wash out period. Subjects will keep diaries of food, exercise, daily fasting glucose, and at least one 2 hour pc glucose per day for the 6 weeks of the trial.~Baseline renal function blood work and urine, liver function blood work, hemoglobin A1C, weight, and blood pressure will be done. These will be repeated at the end of each subject's 6 weeks in the trial. In addition, blood pressure will be checked with the distribution of the each 2 week batch of medications."
223862595|NCT01170299|DIETARY_SUPPLEMENT|dietary intervention|
223862596|NCT01170299|OTHER|laboratory biomarker analysis|
223862597|NCT01170299|PROCEDURE|gastrointestinal complications management/prevention|
223862598|NCT01170299|PROCEDURE|management of therapy complications|
223862599|NCT01170299|RADIATION|selective external radiation therapy|
223862600|NCT03851549|DEVICE|New BGMS (US)|New blood glucose monitoring system / In vitro diagnostic device (IVDD)
223862601|NCT01611467|DRUG|CC-223|20 mg oral CC-223 capsule containing a microtracer of \[14C\]-CC-223 solution
223862602|NCT01611467|DRUG|CC-223|20-mg oral CC-223 tablet under fasting or fed conditions
223862603|NCT00002472|DRUG|cisplatin|
223862604|NCT00002472|DRUG|etoposide|
223862605|NCT00002472|PROCEDURE|conventional surgery|
223862606|NCT00002472|PROCEDURE|neoadjuvant therapy|
223862607|NCT00002472|RADIATION|radiation therapy|
223862608|NCT00723450|DRUG|lamictal|Flexible Dosing
223862609|NCT00770965|BIOLOGICAL|AIN457|
223862610|NCT00770965|BIOLOGICAL|Placebo|
223862611|NCT02158754|DIAGNOSTIC_TEST|Corus CAD (ASGES)|
223862612|NCT02458911|DEVICE|Paclitaxel-eluting balloon|
223862613|NCT05023512|BEHAVIORAL|Communication about the COVID-19 vaccination from the Massachusetts Department of Public Health|Participants will be randomized to receive one of two different versions of messages from the Massachusetts Department of Public Health. The message that participants in each experimental group receive will vary slightly and systematically. Specific content and wording of these messages were developed to address and mitigate concerns about the Covid-19 vaccination.
223862614|NCT04208802|OTHER|Use of fluoridated toothpaste|Use of fluoridated toothpaste
223862615|NCT04208802|OTHER|Wearing of an intraoral device with bovine tooth samples|Wearing of an intraoral device with bovine tooth samples
223862616|NCT04208802|OTHER|Wearing of an intraoral device with resin samples|Wearing of an intraoral device with resin samples
223862617|NCT00487305|BIOLOGICAL|Lethally Irradiated Lymphoma cells with GM-CSF K562 Cells|Dose will vary depending upon number of cells collected and when the participant is enrolled on the study: the vaccine is given as an injection under the skin once weekly for 3 weeks then every other week for 3 vaccines.
223862618|NCT05987969|OTHER|"Alena mobile application"|This mobile application primarily comprises CBT-based therapy for social anxiety based on the Clark and Wells model, as well as cognitive assessments, calming exercises and a community forum.
223862619|NCT00001182|PROCEDURE|current standard of care treatments|
223862620|NCT01842724|PROCEDURE|Motec total wrist arthroplasty|
223862621|NCT01842724|PROCEDURE|Remotion total wrist arthroplasty|
223862622|NCT02523391|DRUG|TA-8995|Capsule
223862623|NCT02523391|DRUG|TA-8995|Tablet
223862624|NCT03309488|DIAGNOSTIC_TEST|Oral food challenge|Patients with suspected food allergy will undergo clinical and dietary assessments and oral food challenge. Different allergy tests will be performed, including skin prick test, specific IgE test and basophil activation test, and its diagnostic utility will be determined against the clinical gold-standard.
224267158|NCT05853445|OTHER|Jakavi|Prospective observational study. There is no treatment allocation. Patients administered Jakavi by prescription and administered according to the SmPC.
223862625|NCT00473811|BEHAVIORAL|Low GI|low-GI education
223862626|NCT00473811|BEHAVIORAL|ADA diet|ADA dietary education
224267159|NCT04981925|BEHAVIORAL|MBSR treatment|"Participants will complete pre-treatment surveys followed by 8-weekly 2-hour group sessions and one 4-hour retreat (may take place virtually or in-person). Participants will also be asked to practice daily formal mindfulness at home using assigned audio recordings of 30-45 minute guided mindfulness exercises. Participants will complete surveys during treatment as well as after treatment and then at 2 months follow-up."
224267160|NCT07107516|BIOLOGICAL|PanChol|Panchol is a novel live attenuated oral cholera vaccine. It is the first vaccine created with the variant El Tor background that is predominant in the world today. The vaccine has ten different genetic modifications to minimize reactogenicity but maintain the ability to colonize the intestine.
224267161|NCT05121844|DEVICE|Continuous Glucose Monitor Device|Continuous glucose monitoring automatically tracks blood glucose levels, also called blood sugar, throughout the day and night. You can see your glucose level anytime at a glance. You can also review how your glucose changes over a few hours or days to see trends. Seeing glucose levels in real time can help you make more informed decisions throughout the day about how to balance your food and physical activity.
224267162|NCT01900340|DIETARY_SUPPLEMENT|Saline|Intravenous saline infusion and intraduodenal administration of saline via feeding tube
224267163|NCT01900340|DRUG|Exendin 9-39|IV exendin(9-39) infusion and intraduodenal administration of saline via feeding tube
224267164|NCT01900340|DIETARY_SUPPLEMENT|Saline|IV saline infusion and intraduodenal administration of nutrients
223862627|NCT01807663|DEVICE|healthy volonteers|Monitoring respiratory function of both acute and chronic neuromuscular patients during weaning or free breath period.
223862628|NCT01807663|DEVICE|Free breath monitoring|Monitoring respiratory function of both acute and chronic neuromuscular patients during weaning or free breath period.
224267165|NCT01900340|DRUG|Exendin(9-39) plus ID nutrient|Exendin(9-39) as intravenous infusion plus intraduodenal nutrient administration
224267166|NCT00667212|BEHAVIORAL|Cognitive Behavioral Therapy|Twelve weekly therapy sessions, approximately one hour each in duration
224267167|NCT00667212|BEHAVIORAL|Supportive Psychotherapy|Twelve weekly therapy sessions, approximately one hour each in duration
224267168|NCT06910228|DEVICE|Near infrared spectroscopy (NIRS)|A non-invasive technique that uses light to assess brain function and tissue oxygenation.
224267169|NCT05196334|OTHER|No intervention|No intervention
224267170|NCT07131072|OTHER|daiphragm mobility by ultrsound|fibrosis score, alveolitis score by CT Chest
224267171|NCT07131072|OTHER|spirometry ,DLCo|FEV1, FVC, FEV1/FVC, DLCo
224267172|NCT02257554|BEHAVIORAL|education|Discussion of surgical expectations with patients
224267173|NCT07140068|DEVICE|Handled dental flossing system (GumChucks®)|Handled dental flossing system (GumChucks®) designed for easier C-shape flossing. Participants were instructed to clean all interdental spaces on the assigned side twice daily after toothbrushing with fluoride toothpaste using a medium-bristle toothbrush. Proper technique was demonstrated and written instructions provided.
224267174|NCT07140068|DEVICE|Interdental Brush|Appropriately sized interdental brushes for cleaning interdental spaces on the assigned side. Participants were instructed to clean twice daily after toothbrushing with fluoride toothpaste using a medium-bristle toothbrush. Proper technique was demonstrated and written instructions provided.
224267175|NCT07138560|DRUG|CREXONT ER|exploring shorter dose intervals of Crexont (IPX203) and allowing for higher dosing frequency, as practiced in real-world settings, combined with objective monitoring of on-time periods
224267176|NCT07139262|BEHAVIORAL|Climate-Resilient Disaster Preparedness Education Program|A structured educational program designed to enhance nursing students' knowledge and skills in climate-resilient disaster preparedness. The program consisted of four weekly sessions (2 hours each) delivered through lectures, interactive group discussions, and simulation-based exercises. Core content included disaster risk reduction principles, emergency response protocols, climate-related hazard preparedness, psychological first aid, triage procedures, and resilience-building strategies. Training materials were validated by subject matter experts and culturally adapted for the Saudi nursing education context.
224267177|NCT07139262|OTHER|Standard Nursing Curriculum|Participants continued their regular undergraduate nursing curriculum without additional specialized training in disaster preparedness or climate resilience. This curriculum provided foundational nursing education but did not include structured sessions on climate-related disaster management or resilience-building.
224267178|NCT07138716|DIAGNOSTIC_TEST|68Ga-DOTA-CCK-FS PET/CT|For 68Ga-DOTA-CCK-FS, imaging begins 60±5 minutes post-injection to evaluate cholecystokinin receptor (CCK-R) expression, using a time-of-flight PET/CT system with low-dose CT (120 kVp, 30-50 mAs) for attenuation correction followed by whole-body PET acquisition (2-3 min/bed position). Images are reconstructed using OSEM algorithms.
224267179|NCT07138963|DIAGNOSTIC_TEST|Genetic Testing and Muscle Biopsy|Comprehensive diagnostic assessment including clinical examination, electromyography (EMG), muscle biopsy for histopathological evaluation, and genetic testing to determine phenotype-genotype correlation in congenital myopathies and muscular dystrophies.
224267180|NCT07139834|DRUG|SSRI (escitalopram or sertraline)|11 weeks of open-label treatment with an SSRI, of which the last 6 weeks are augmented with memantine vs placebo. Primary SSRI for the study is escitalopram. In cases of prior intolerance or non-response to escitalopram, individuals will be treated with sertraline instead of escitalopram.
224267181|NCT07139834|DRUG|Extended-Release Memantine|6 weeks of treatment with extended-release memantine as augmentation to ongoing escitalopram treatment
224267182|NCT07139834|DRUG|Placebo|6 weeks of treatment with placebo as augmentation to ongoing escitalopram treatment
224267183|NCT07140458|OTHER|Buteyko Breathing|"Buteyko Breathing is a technique focusing on controlled, reduced breathing to improve oxygen uptake and reduce hyperventilation-related symptoms using Air hunger.~Procedure:-~After gaining proper relaxation:~1. Exhale slowly, and then hold that breath.~2. Use the index finger and thumb to plug the nose.~3. Hold that breath until there is an urge to breathe, and then inhale.~4. Breathe normally for at least 10 seconds.~5. Repeat several times."
224267184|NCT07140458|OTHER|Box breathing|"Box Breathing (4-4-4-4 Technique) - Box Breathing exercises boosts lung function by optimizing oxygen flow and activating relaxation responses.Each exercise Sessions included 20 cycles of Box Breathing.~The procedure of the box breathing cycle includes:~1. inhale for 4 seconds~2. Hold the breath for 4 seconds~3. Exhale for 4 seconds~4. Hold the breath for 4 seconds, and repeat."
224267185|NCT07138534|BEHAVIORAL|prehabilitation|In addition to exercise programmes, it includes nutritional optimisation, psychosocial preparation and smoking cessation.
224267186|NCT07138872|PROCEDURE|Prone Position Percutaneous Nephrolithotomy|Patients in this arm will undergo percutaneous nephrolithotomy (PNL) in the prone position. The procedure begins with ureteral catheter placement in lithotomy position, followed by prone positioning for renal access under C-arm fluoroscopic guidance. Stone fragmentation will be performed using pneumatic or ultrasonic lithotripters, and nephrostomy placement will be completed according to standard protocol.
224267187|NCT07138872|PROCEDURE|Supine Position Percutaneous Nephrolithotomy (Galdakao-modified Valdivia)|Patients in this arm will undergo percutaneous nephrolithotomy (PNL) in the Galdakao-modified Valdivia supine position. Following general anesthesia, the ipsilateral side will be elevated 20-30°, with the ipsilateral leg extended and the contralateral leg abducted. Ureteral catheter placement will be followed by renal access under C-arm fluoroscopy. Stone fragmentation and removal will be performed using the same standardized lithotripsy and irrigation protocols as in the prone group.
224267188|NCT07139340|OTHER|HA gel|Hyaluronic Acid gel 0.8% 1 mL
224267189|NCT07138885|PROCEDURE|HAI-FOLFOX + bevacizumab + QL1706|"Arm 1:~HAI-FOLFOX Administration (Day 1 of Each Cycle) Super-selective insertion the arterial catheter into the tumor-feeding artery, then infusion: Oxaliplatin: 85 mg/m², Leucovorin: 400 mg/m², 5-FU: 2500 mg/m²~Administer bevacizumab (7.5 mg/kg; total dose capped at 300 mg or 400 mg) via arterial infusion.~Then QL1706 (5 mg/kg, IV infusion, Q3W).~Treatment Schedule: Repeat HAI-FOLFOX + arterial bevacizumab every 3 weeks (max 6 cycles), followed by QL1706 maintenance (Q3W)."
224267190|NCT07138885|PROCEDURE|TACE + bevacizumab + TAS-102 + QL1706|"Arm 2:~On-Demand TACE (Lipiodol: ≤10 mL, mixed with platinum + doxorubicin agent, each ≤50 mg) to form an emulsion. Repeat TACE until TACE resistance develops (typically \~4 sessions).~Administer bevacizumab (7.5 mg/kg; total dose capped at 300 mg or 400 mg) via intra-arterial route.~After first TACE, begin TAS-102 (15 mg/m² po BID) once liver function recovers to acceptable levels.~Then QL1706 (5 mg/kg, IV infusion, Q3W)."
224267191|NCT07140107|BEHAVIORAL|AI-generated PLS|Reading AI-generated Plain Language Summaries of two Cochrane systematic reviews covering the same two evidence-based topics: exercise during adjuvant therapy and psychological interventions for non-metastatic breast cancer.
224267192|NCT07140107|BEHAVIORAL|Original PLS|Reading original Plain Language Summaries of two Cochrane systematic reviews covering the same two evidence-based topics: exercise during adjuvant therapy and psychological interventions for non-metastatic breast cancer.
224267193|NCT07139561|BEHAVIORAL|Oral Health in Hands - Parent Digital Program|"The 16-week parent-focused digital intervention aims to improve oral health practices in children aged 6-10 by empowering parents through structured, engaging, and cost-effective activities. Parents receive daily reminders, including two brushing cues and one snack tip, to reinforce healthy routines. Weekly quizzes with 3-5 questions enhance knowledge retention, while interactive photo or video tasks such as Show your foam smile or Healthy lunchbox challenge promote family involvement and fun. Gamification strategies include awarding digital badges for streaks, such as the 7-day brushing badge and snack swap champion, to maintain motivation. Parents track brushing, flossing, and snack swaps using a simple 1-tap tracker, ensuring easy and consistent reporting. An optional moderated WhatsApp group provides a platform for sharing tips, photos, and encouragement, fostering a supportive peer community. The intervention combines education, habit formation, and social support to sustainab"
224267194|NCT07139782|DEVICE|Riancorp LTU-904 Laser and Handycure® (Medical Quant)|"Riancorp: At the first intervention session the therapist will apply the device for 60 secs each at 14 - 25 points on the face and neck. Most patients will need application of the device at 15 to 20 points The Riancorp runs for 60 seconds, providing 1.5 j/cm2 in 60 seconds.~Handycure: used by patients at home once/day on the prescribed days (Wks 1-6 3x/wk; Wks 7-10 x2/wk; Wks 11-12 x1/wk) 1. Patients will apply the device for 5 minutes at each point as instructed by the physiotherapist."
224267195|NCT07140250|OTHER|Education with AI Technology|Shared decision making (SDM) about sinusitis treatment will be facilitated by AI technology via ChatGPT
224267196|NCT07140250|OTHER|Education using Traditional Internet Search Engines|Participant Education in Sinusitis using Traditional Internet Search Engines through Google
223862629|NCT03193619|DEVICE|PTA (UltraScore Focused Force PTA Balloon)|"Percutaneous Transluminal Angioplasty (PTA) will involve the insertion of a catheter into one of the femoral arteries. Once the catheter is in place, a tiny balloon on the end of the catheter will be inflated to press against the narrowing (or blockage) in the artery to try to open the blockage, and allow more blood to flow through the artery. The balloon may need to be inflated several times in order for the narrowed area to open up sufficiently to improve the blood flow. The area will be viewed with specialized x-ray or other imaging devices to see if the artery has opened enough.~The UltraScore Focused Force PTA balloon through the blood vessel to the narrowed area to be treated."
223862630|NCT01696578|BEHAVIORAL|BF-CBT and group physiotherapy|Multivitamin+10 individual therapy sessions (BF-CBT) and 10 group therapy sessions (physical exercises) on a weekly basis
223862631|NCT03920371|OTHER|gamma camera imaging|Following the administration of the routine radiopharmaceutical and the standard wait before clinical diagnostic imaging, additional research gamma camera imaging is carried out
223862632|NCT02770495|OTHER|blood sample|
223862633|NCT00559286|DRUG|Telmisartan|application of 80mg or 20mg Telmisartan per day for 30 days
223862634|NCT00765934|DRUG|Rapydan|lidocaine / tetracaine 70/70 mg patch
223862635|NCT02537769|DEVICE|Left ventricular assist device (LVAD)|Left ventricular assist device placement (LVAD). All participants will receive an LVAD as a part of routine care for their advanced heart failure.
223862636|NCT02537769|PROCEDURE|Tricuspid Valve Repair (TVR)|Participants will be randomly assigned to receive a tricuspid valve repair (TVR) to repair their tricuspid valve regurgitation in addition to an LVAD placement. Only half of enrolled participants will receive this procedure.
223862637|NCT03353116|PROCEDURE|the mandible first|the mandible osteotomy is going to be done and fixed first
223862638|NCT03353116|PROCEDURE|the maxilla first|the maxilla osteotomy is going to be done and fixed first
223862639|NCT05380869|DIAGNOSTIC_TEST|Point-of-care Test|to test Point-of-care procalcitonin in suspected pneumonia
223862640|NCT03608618|BIOLOGICAL|MCY-M11|Intraperitoneal administration
223862641|NCT03608618|DRUG|Cyclophosphamide|Intravenous administration for preconditioning
223862642|NCT02968472|GENETIC|prophylactic 4SCAR19 cells|Autologous 4th generation withdrawal lentiviral-transduced 4S CAR-T19
223862643|NCT06068699|OTHER|Postcard|Participants received a postcard asking them to address non-adherence to remote monitoring.
223862644|NCT05247749|DEVICE|CONVIVO Confocal Endomicroscopy System|Confocal Laser Endomicroscopy (CEM) system intended for viewing intra-operative blood flow in the cerebral vascular area. Manufacturer - Zeiss
223862645|NCT04891458|DRUG|Patients received lighter sedation with propofol after spinal anesthesia.|MOAA/S 0-2.
223862646|NCT04891458|DRUG|Patients received heavier sedation with propofol after spinal anesthesia|MOAA/S 3-5.
223862647|NCT04891458|DRUG|Patients received lighter sedation with dexmedetomidine after spinal anesthesia|MOAA/S 0-2.
223862648|NCT04891458|DRUG|Patients received heavier sedation with dexmedetomidine after spinal anesthesia.|MOAA/S 3-5.
223862649|NCT00318253|PROCEDURE|cranberry juice|
223862650|NCT05168553|OTHER|Revascualrization|Regain pulp vascularity for mature permenant teeth
223862651|NCT05168553|OTHER|Conventional endodontic treatment|Root canal treatment of permenant mature teeth with mechanical preparation and cleaning followed by canal obturation by inert material ( gutta percha)
223862652|NCT02678091|DEVICE|Ultrasound exam with Doppler|Ultrasound exam of the orbit
223862653|NCT05569837|OTHER|Regular meal pattern|6 meals every day
223862654|NCT05569837|OTHER|Irregular meal pattern|It consists of consuming a different number of meals every day (between 3 and 9).
224267197|NCT07139015|OTHER|CONSTRAINT-INDUCED MOVEMENT THERAPY|Constraint-Induced Movement Therapy (CIMT) involves restricting the unaffected arm to promote use of the affected limb through task-specific exercises. It is delivered 5 days a week for 6 weeks, with sessions lasting 60-90 minutes, focusing on improving strength, dexterity, and function.
224267198|NCT07139015|OTHER|MIRROR THERAPY|"Mirror Therapy (MT) uses a mirror to reflect movements of the unaffected limb, creating the illusion of movement in the affected limb.~Participants will do 60-90 minute sessions, 5 days a week for 6 weeks.~Exercises include hand opening/closing, finger movements, and simple object tasks to improve motor function and coordination through visual feedback."
223862655|NCT03504072|DRUG|Tofacitinib 5 mg,|tofacitinib 5 mg 12 hourly daily for 9 months
223862656|NCT03504072|DRUG|Etanercept|Etanercept 50 mg sc every 7 days interval in 1st month, every 15 days interval in 2nd month and then every 21 days interval from 3rd month onward upto 9 months
223862657|NCT06410963|BEHAVIORAL|Reactivate|The study period is 84 days (12 weeks). Depending on the length of the baseline period (randomly assigned to be 7, 14 or 21 days), the treatment period varies between 63-77 days and contains 6-11 sessions. The intervention consists of 2-4 educational sessions in pain mechanisms and fear avoidance and 4-9 sessions of individually tailored intervention with graded exposure and reactivation to avoided physical activities. Intervention will take place from one time per week to one time every two weeks, 30-60 minutes per session. Number of treatment sessions will depend on when the individual participants' goals are considered reached. If necessary, given the participants consent, their legal guardians will be invited to attend the sessions.
224076309|NCT06127641|OTHER|Standard care plus pulmonary rehabilitation|A 12-week rehabilitation program, 3X/week. Each outpatient session will last 2 hours including: guidance on the care of inhalation techniques and/or oxygen therapy, when prescribed; aerobic training on a cycle ergometer supervised by a physiotherapist (30 min each: 5 min warm-up, 20 min training and 5 min cool-down) at constant load calculated with Hill's equation (HILL et al., 2008). Optional components of RP will include: inspiratory muscle conditioning using a threshold-loading device, inspiratory muscle training with powerbreathe, breathing exercises, airway clearance, psychological support, relaxation and nutritional counseling. Patients will participate in two group educational sessions, managed by a respiratory physiotherapist, on lifestyle, physical activity and maintenance programs (VISCA et al., 2019; FUGAZZARO et al., 2017; TENCONI et al., 2021).
224267199|NCT05541198|OTHER|Pressure Injury Prevention Care Bundle|"1. Risk Assessment~2. Skin Assessment~3. Skin Care~4. Positioning~5. Regulation of Nutrition and Liquid Management"
224267200|NCT03834077|OTHER|Tissue flossing|Electrotherapy (transcutaneous electrical nerve stimulation) and Ultrasound in addition to tissue flossing.
224267201|NCT03834077|OTHER|Placebo comparator|Conventional physiotherapy in addition to flossing without tension
224267202|NCT06933602|OTHER|relaxin|"Progressive Muscle Relaxation (PMR) exercises help alleviate symptoms in patients with COPD by reducing the effects of anxiety and stress, distracting attention from pain, and relieving muscle tension and spasms.~These exercises are beneficial in managing:~Tension headaches Back pain Tension and pain in jaw muscles Tension and pain around the eye muscles Muscle spasms Insomnia Stress-related muscle tension The required content of the exercises for relieving stress-related tension will be provided in a booklet. The booklet will be given to the patients following the training session."
224267203|NCT07140627|DRUG|Bupivacain|A 22G cannula was used to perform a caudal block in the left lateral position under sterile conditions following the induction of anesthesia and before the surgery. 30 participants had received 1 mL/kg 0.25% bupivacaine. Post operative pain was assessed.
224267204|NCT07140627|DRUG|Dexmedetomidine & Bupivacaine.|A 22G cannula was used to perform a caudal block in the left lateral position under sterile conditions following the induction of anesthesia and before the surgery. 30 participants were included and administered 1 mL/kg 0.25% bupivacaine and 1 μg/kg dexmedetomidine. Post operative pain was assessed.
223862658|NCT05646745|PROCEDURE|Autologous Transobturator Fascia Lata Sling|"Hydro-distention of the anterior vaginal wall, and a midline incision is made based on the mid-urethra. Dissection is carried out bilaterally to the obturator Foramen on both sides.~Through incision in the lower lateral aspect of the thigh, 4 cm above the knee, \~1 cm× \~5 cm fascial strip is isolated from the fascia lata. Two stay sutures are secured to the corners of the fascial segment on each side.~About 1cm skin incision is performed at the thigh fold on each side. Next, two separate trocar passages are performed on each side using a reusable C-shaped trocar, with care taken to ensure at least a 1 cm tissue bridge in the obturator membrane between the superior and inferior passes. Following this, the stay sutures are tied external to the obturator membrane on both sides, leaving the sling secured and flush with the mid-urethra. Sutures are also placed to secure the sling to the periurethral tissue to prevent rolling or migration of the fascial strip."
223862659|NCT03922867|BEHAVIORAL|CBT|A web-based educational platform to deliver cognitive behavioral therapy (CBT) for insomnia
223862660|NCT02952768|BEHAVIORAL|ultrasound training|Through the ultrasound-circulation-airway-breathing training curriculum to integrate the ultrasound into clinical practice.
223862661|NCT03192046|DEVICE|Carbon Fiber Ankle Foot Orthosis (AFO)|Custom AFOs in conjunction with a walking program, working up to walking 30 minutes 6 days a week.
223862662|NCT03192046|OTHER|Standardized walking/exercise program|standardized walking/exercise program without any brace or AFO
223862663|NCT04412018|DRUG|Icosapent ethyl|Icosapent ethyl (4 g BID for 3 days, then 2 g BID for the subsequent 11 days)
223862664|NCT04563559|DRUG|Dextenza 0.4Mg Ophthalmic Insert|The eye will have a sustained release device of Dexamethasone 0.4 mg placed in the inferior nasal lacrimal system.
223862665|NCT04563559|DRUG|Prednisolone Acetate 1% Ophthalmic Suspension [PRED FORTE]|The eye will be randomized to receive topical treatment with prednisolone acetate 1% on a tapering dose schedule
223862666|NCT00762606|PROCEDURE|Phacoemulsification cataract extraction surgery|Surgical removal of cataract using phacoemulsification followed by implantation of an AcrySof Intraocular Lens (Model SN60WF)
223862667|NCT00762606|PROCEDURE|Small incision cataract surgery|Surgical removal of cataract using small incision cataract surgery (SICS) followed by implantation of a Polymethyl methacrylate(PMMA) Intraocular Lens (Model MZ60BD).
223862668|NCT02230358|PROCEDURE|Regional anesthesia|Regional anesthesia
223862669|NCT02230358|PROCEDURE|General anesthesia|General anesthesia
223862670|NCT02230358|DEVICE|Transcranial Doppler ultrasonography|6x for 4 hours
223862671|NCT02230358|PROCEDURE|blood gas analysis|6 x 3 ml blood withdrawal (18 ml) within 4 hours
223862672|NCT02230358|PROCEDURE|invasive arterial blood pressure measurement|before operation, 8 hours, as done in clinical routine
223862673|NCT02230358|PROCEDURE|arterial blood gas measurement|perioperative, 4-6 times within 8 hours, as done in clinical routine
223862674|NCT02230358|BEHAVIORAL|Neurological Control|perioperative, 2-3 days, as done in clinical routine
223862675|NCT02230358|BEHAVIORAL|NIRS monitoring|perioperative, for 5 hours, as done in clinical routine
223862676|NCT02230358|DEVICE|oxygen supply (not invasive 'Vigileo')|perioperative for 5 hours, as done in clinical routine
223862677|NCT05998525|DRUG|Dapagliflozin 10Mg Tab|patients who meet the inclusion criteria and after catheterization will be randomized to receive Dapagliflozin 10 mg every 24 hours and upon dischargetreatment will continue for 12 months
223862678|NCT05998525|DRUG|Placebo|patients who meet the inclusion criteria and after catheterization will be randomized to receive a placebo pill 24 hours and upon discharge treatment will continue for 12 months
223862679|NCT01045655|BEHAVIORAL|MOMCare|8 sessions of brief interpersonal psychotherapy or medication management; maintenance sessions through 12 months postpartum.
223862680|NCT00031512|OTHER|Placebo|Placebo.
223862681|NCT00031512|DRUG|Pleconaril|5 mg/kg /dose oral every 8 hours for 7 days (21 doses) of a 40 mg/mL oral liquid formulation and 8.5 mg/kg/dose oral every 8 hours for 7 days (21 doses) of a 40 mg/mL oral suspension formulation.
223862682|NCT04421391|DIETARY_SUPPLEMENT|QuadraMune(TM)|QuadraMune(TM) is a commercially available nutritional supplement
223862683|NCT00781196|DRUG|folic acid|capsule 0.5 mg once a day
223862684|NCT00781196|DRUG|placebo|capsule, once a day
223862685|NCT05697081|OTHER|Medical doctors infected with COVID-19|web-based survey
223862686|NCT00731523|DRUG|fingolimod (FTY720)|
223862687|NCT01335165|DRUG|ALXN1102|Single Ascending Dose IV
223862688|NCT01335165|DRUG|ALXN1103|Single Ascending Dose IV or SC
223862689|NCT03450096|OTHER|LPB|A bolus injection for LPB of 0.5 ml/kg ropivacaine 3.75 mg/ml (max 40 ml will be performed and the catheter will be placed before surgical interventions. A continuous perineural infusion of 0.2 ml/kg/h ropivacaine 0.2%, starting immediately after initial bolus injection will be then administered
223862690|NCT05206266|OTHER|Turmeric|Three amounts of dietary turmeric will be tested: 1) turmeric 300 mg/day, 2) turmeric 1 g/day, 3) turmeric 3 g/day.
223862691|NCT05206266|OTHER|Turmeric+Black Pepper|Three amounts of dietary turmeric (300mg/day, 1g/day or 3g/day) with black pepper (300 mg) added to the turmeric.
223862692|NCT04738903|PROCEDURE|Femtosecond laser assisted LASIK eye surgery|FS-LASIK eye surgery includes corneal flap creation with femtosecond laser using the Femtosecond laser WaveLight FS200 followed by excimer laser vision correction of the patient's refractive error using excimer laser WaveLight EX500.
223862693|NCT04794530|DRUG|cocoa flavanols|The cocoa flavanols intervention is manufactured by Mars Inc. Participants randomized to cocoa flavanols will take two capsules daily of cocoa flavanols. The two capsules of cocoa flavanols will contain approximately 500 mg of cocoa flavanols and appoximately 80 mg of (-)-epicatechin.
224076310|NCT06127641|OTHER|Standard Care|Participants will receive standard care (SC): a therapeutic education session upon admission, as well as pulmonary rehabilitation (PR) taught by a physical therapist. This therapeutic educational session will involve counseling and self-care management, emphasizing breathing exercises and sputum clearance and self-care techniques. It will consist of smoking cessation education (if this is the case, as tobacco is associated with TB), respiratory retraining (pursed lip breathing, diaphragmatic breathing and segmental breathing) and secretion removal training (coughing exercise, huffing , assisted cough and postural drainage).
224076311|NCT05878652|DEVICE|3D printed knee extender device|Participants will receive the standard of prehabilitation education at Sanford as well as a 3D printed knee extension device with sealed water bottles and a home prehabilitation program designed to be used with the 3D printed knee extension device.
223862694|NCT04794530|DRUG|placebo|The placebo intervention will be manufactured by Mars Inc. and will appear identical to the cocoa flavanols intervention. Participants will take two capsules daily of placebo. The placebo will be a cellulose based capsule and will not contain cocoa flavanols or (-)-epicatechin.
223862695|NCT01418391|PROCEDURE|Transversus Abdominis Plane block|"TAP BLOCK:~dosage form: 0.5% bupivacaine 75mg with 2% xylocaine 300 mg mixed dosage: total 30 ml frequency: single shot duration: 12\~18 hours upon to the regional anesthetics choose"
223862696|NCT01080872|DEVICE|CFR|CFR will be assessed using transthoracic echocardiography with adenosine infusion.
223862697|NCT03197246|DEVICE|IVECG|Monitoring IVECG signals for verification for exact tip placement during the actual insertion of the PICC. When the p-wave amplitude increases the PICC-tip is in the superior vena cava. When max positive amplitude, the PICC-tip is by definition at the cavo atriale junction, and thereby in correct position.
223862698|NCT03197246|DEVICE|Chest X-ray|Standard method; PICC confirmed by chest X-ray after the insertion (postoperatively)
223862699|NCT01505881|DRUG|dabigatran etexilate low dose|active treatment (low)
223862700|NCT01505881|DRUG|warfarin 5mg|comparator warfarin
223862701|NCT01505881|DRUG|dabigatran etexilate intermediate dose|active treatment (medium)
223862702|NCT01505881|DRUG|warfarin 1mg|comparator warfarin
223862703|NCT01505881|DRUG|dabigatran etexilate high dose|active treatment (high)
223862704|NCT01505881|DRUG|warfarin 3mg|comparator warfarin
223862705|NCT02361437|DIETARY_SUPPLEMENT|Vasculera|Vasculera 630 mg b.i.d.
223862706|NCT00842257|DRUG|panitumumab|Panitumumab is administered intravenously (IV) by an infusion pump through a peripheral line or indwelling catheter using a 0.2 or 0.22-micron in-line filter infusion set-up over 1 hour 15 minutes. The starting panitumumab dose is 6 mg/kg administered every 14 days for as long as patients are on study without evidence of disease progression or demonstrating intolerance to treatment. The total dose may be rounded up or down by no greater than 10 mg. The panitumumab dose will be calculated based on the subject's actual body weight at each visit. Panitumumab will be diluted in a minimum of 100 mL of pyrogen-free 0.9% sodium chloride solution (normal saline solution, supplied by the site). The maximum concentration of the diluted solution to be infused should not exceed 10 mg/mL.
223862707|NCT05261568|BEHAVIORAL|PROGRESSIVE RELAXATION EXERCISE|Progressive relaxation exercise will be done for 6 weeks by watching the animation video in the mobile application program.
223862708|NCT04267744|OTHER|Myia Health® remote patient monitoring unblinded treatment arm|"After consenting to the study, the Myia in-home suite of devices will be provided to all recruited patients. The data flowing from the Myia platform will be available to clinicians and patients for the duration of the pilot and utilized to complete study activities.~Device: Myia Health platform and in-home suite of devices®:~Emfit Ballistocardiograph® Withings Connected Scale® VitalScout (VivaLink) ECG Accelerometer® Omron Blood Pressure Monitor® (Sphygmomanometer) Cradlepoint - Hotspot / Adaptor® (LTE Connection) Samsung Galaxy Tab A 8.0® (User Interface)"
224076312|NCT05878652|OTHER|Standard Prehabilitation Education|Participants in the control group will receive the standard prehabilitation education at Sanford and provided exercises to do at home.
223862709|NCT04956146|DRUG|Fruquintinib，Sintilimab，Pemetrexed，Carboplatin|Fruquintinib,fruquintinib at the dose determined in phase safety lead-in,5mg-intermittent (2 weeks on/ 1 week off) ，po，every 3 weeks(q3w) ; Sintilimab at the dose 200mg，iv, d1, given every 3 weeks (q3w); Pemetrexed at the dose 500 mg/m2，iv，d1，given every 3 weeks (q3w); Carboplatin at the dose AUC=4\~5，iv，d1；given every 3 weeks (q3w); Maintenance treatment：After 4\~6 cycles of carboplatin treatment, Sintilimab 200mg, iv, d1, q3w；Fruquintinib RP2D intermittent(2 weeks on/1 weeks off), po，q3w； pemetrexed 500mg/m2, d1,iv, q3w until progressive disease, death from any cause, unacceptable toxicity or informed consent withdrawal
223862710|NCT04164680|DIAGNOSTIC_TEST|Multimodal Neuroimaging|fludeoxyglucose (FDG-)PET/MR imaging
223862711|NCT03768843|PROCEDURE|Harms technique|Atlantoaxial fusion
223862712|NCT00398606|DRUG|MK0217, alendronate sodium / Duration of Treatment : 2 Years|
223862713|NCT00398606|DRUG|Comparator : calcium carbonate /Duration of Treatment : 2 Years|
223862714|NCT03694288|PROCEDURE|Implant removal|Surgical Implant removal
223862715|NCT02245334|DRUG|Povidone-Iodine|1 pill per biopsy
224076313|NCT01610635|OTHER|Reduced versus standard intervals between blood donations|Over a period of two years participants will be invited to give blood either at usual donation intervals or more frequently. Men will be invited to donate every 12, 10 or 8 weeks and women every 16, 14 or 12 weeks.
223862716|NCT04696341|PROCEDURE|Matrix Rhythm Therapy|Hot pack to cervical and upper thoracic regions (20 min), conventional TENS (100 Hz for 40 μsec), therapeutic ultrasound (1 MHz for 5 min) and conventional massage (using stroking, kneading and friction techniques for 5 minutes) were applied as passive physiotherapy modalities. Normal range of motion exercises, posture exercises, stretching exercises and isometric exercises were instructed as part of active physiotherapy.Five sessions of MRT (2., 5., 6., 8., 10. sessions of combined physiotherapy programme) was added at combined physiotherapy to Matrix Rhythm Group. Matrix Rhythm Therapy was applied to cervical and thoracic regions using 10 Hz frequency for 30 min (15 min for right and left sides each) according to the instructions of the technique developer.
223862717|NCT04696341|PROCEDURE|Control|Hot pack to cervical and upper thoracic regions (20 min), conventional TENS (100 Hz for 40 μsec), therapeutic ultrasound (1 MHz for 5 min) and conventional massage (using stroking, kneading and friction techniques for 5 minutes) were applied as passive physiotherapy modalities. Normal range of motion exercises, posture exercises, stretching exercises and isometric exercises were instructed as part of active physiotherapy.
223862718|NCT01985906|PROCEDURE|Multiple overlapping uncovered stents|Endovascular management of complex aortic aneurysms with multiple overlapping uncovered stents
223862719|NCT01985906|DEVICE|Uncovered stents|The number of uncovered stents implanted was determined by intraoperative angiography with the criterion that a decrease of velocity in the aneurysmal sac was achieved. Side branches, including segmental arteries and visceral branches, were covered wherever necessary.
223862720|NCT03795428|DRUG|Pemziviptadil (PB1046) Injection|Once-weekly subcutaneous injection
223862721|NCT06556186|PROCEDURE|Transnasal transsphenoidal pituitary lesion resection under neuroendoscopy|Transnasal transsphenoidal pituitary lesion resection under neuroendoscopy
223862722|NCT06556186|DRUG|Bromocriptin 2.5mg, 2-3 times a day|Bromocriptin 2.5mg, 2-3 times a day
223862723|NCT00015236|BEHAVIORAL|Amantadine|
223862724|NCT05603338|PROCEDURE|LSG with omental band|LSG with omental band
223862725|NCT05603338|PROCEDURE|LSG|just to do sleeve gastrectomy
223862726|NCT04439799|DRUG|Testosterone Cypionate 200 Mg/ML|Participants in this group will receive intramuscular testosterone cypionate injections of 1 cc (200mg) once every 14 days for four months.
223862727|NCT04439799|DRUG|Intranasal Testosterone|Participant in this group will receive Intranasal testosterone administered using a multi-dose dispenser, as two or three daily doses (5.5 mg per nostril, 11.0 mg single dose) for 4 consecutive months,
223862728|NCT05565391|DRUG|Elranatamab|BCMA-CD3 bispecific antibody
223862729|NCT05565391|DRUG|Standard of care|Standard of care
223862730|NCT05925686|DRUG|Tramadol.|Orally single dose administration of Tramadol 75 mg for ultra-rapid metabolizers and 100 mg for extensive and poor metabolizers.
223862731|NCT03175432|DRUG|Atezolizumab|Given IV
223862732|NCT03175432|BIOLOGICAL|Bevacizumab|Given IV
223862733|NCT03175432|DRUG|Cobimetinib|Given PO
223862734|NCT03175432|PROCEDURE|Quality-of-Life Assessment|Ancillary studies
223862735|NCT00362206|DRUG|Fenofibrate/Simvastatin|Combination of Fenofibrate and Simvastatin 20mg
223862736|NCT00362206|DRUG|Fenofibrate/Simvastatin|Combination of Fenofibrate and Simvastatin 40 mg
223862737|NCT00362206|DRUG|Pravastatin|Pravastatin 40 mg
223862738|NCT04296227|DEVICE|The Vital Detect blood pressure monitor|The end goal is to provide Non-invasive Blood Pressure (NIBP) accuracy data to support validation of the Vital Detect blood pressure monitor.
223862739|NCT02228356|RADIATION|Stereotactic Body Radiation Therapy|Stereotactic Body Radiation Therapy with either Dynamic Tumor Tracking/Internal Target Volume approach on the Vero machine, and/or Internal Target Volume approach on the Tomotherapy machine.
223862740|NCT01426750|DIETARY_SUPPLEMENT|industrialized oral supplementation (IOS) and tube feeding regimen (TFR) with Nutren|The oral and tube supplement offered was Nutren Jr® (for patients aged 1 - 9 years) or Nutren 1.0- Nestlé Clinical Nutrition-Brazil (for those aged 10 years or over). This supplement was a whole powder formulation that presented a macro composition of 52% carbohydrates, 12% proteins and 36% lipids. Its vitamins were A, D, E, K, B complex, biotin and choline; its trace elements were iron, copper, zinc, manganese, selenium, chromium and molybdenum; its macroelements were potassium, calcium, sodium, chlorine, iodine, magnesium and phosphorus; and it contained taurine and L-carnitine presenting 1.0 kcal/ml.
223862741|NCT02716324|BEHAVIORAL|Care Manager CM)|The CM was an individual responsible for communicating and coordinating ADHD care. The CM established rapport with families and communicated with them every 3 months or more frequently if needed to assess treatment use, identify new concerns, and help problem-solve. The CM also communicated with the patient's ADHD care team (pediatrician, teacher, mental health providers) to clarify family goals, communicate information, and coordinate treatment.
223862742|NCT02716324|OTHER|ADHD Portal|The ADHD portal was a web-based platform that permits access to parts of the hospital's electronic health record. The portal permits (1) capture and sharing of patient and family treatment preferences and goals, (2) monitoring of ADHD symptoms, treatment receipt, and side effects, and (3) assessing goal attainment. The system prompts for completion of periodic check-in surveys (bi-weekly to 3 months) with parents and teachers. Within the portal, preferences and goals for ADHD treatment were measured using the ADHD Preference Goal Instrument (PGI) (Fiks et al., 2012). Parents were encouraged to consult with their children when completing the tool.
223862743|NCT04558437|OTHER|Questionnaire|"Questionnaire at M0 M3 M6:~PCL-5 (Post-Traumatic Stress Disorder Checklist Scale, version DSM-5) HAD (Hospital Anxiety and Depression Scale) SDS (Sheehan Disability Scales)"
223862744|NCT00510601|DEVICE|Kaneka Liposorber|LDL-apheresis on a bi-weekly basis
223862745|NCT01113333|DRUG|placebo|"Pharmaceutical form:injection~Route of administration: intra-articular"
223862746|NCT01113333|DRUG|SAR113945|"Pharmaceutical form:injection~Route of administration: intra-articular"
223862747|NCT03215251|OTHER|Intervention bundle|Assessment of the patient's mouth and lips determined, to check any stickiness or dryness in the mouth or around lips or split skin at the corners of the mouth or cracked lips. Intervention bundle consisted of sterile cold wet oral swab wipes and sterile ice cold water sprays administered for in two sessions of 15 minutes each. First session was given in 15 minutes, patients received cold wet oral swab wipes in oral cavity 2 to 3 times and mouth spray with 5 to 6 sprays. A maximum of 9 wipes and 18 sprays of sterile water. After administration of intervention bundle, Posttest 1 was taken after 15 minutes observation with the same tools. Then researcher waited for 15 minutes after post test1 and session two was administered in 15 minutes with a maximum of 9 wipes and 18 sprays of sterile water. Post test 2 was taken after 15 minutes of session two.
223862748|NCT01771588|DIETARY_SUPPLEMENT|Human milk fortifier|
223862749|NCT05692947|DEVICE|Core body temperature device|This study is to verify the claims of CORE™ body temperature system to estimate core body temperature from skin temperature and heart rate during exercise under varying environmental conditions. Subjects will ingest a temperature sensing pill and be outfitted with skin temperature sensors, a chest strap heart rate monitor, and the CORE and CaleraResearch devices. Athletes will run or cycle in hot/dry and hot/humid conditions for 45 minutes at an absolute workload of 60% VO2 Max/Peak.
223862750|NCT00783354|DRUG|desloratadine|"Patients received desloratadine 5 mg daily, given as one tablet in the evening, and were asked to take one tablet of rescue medication (Placebo) in case of symptoms for 2 months."
223862751|NCT00783354|DRUG|desloratadine|"Patients received Placebo daily, given as one tablet in the evening, and were asked to take one tablet of rescue medication (desloratadine 5 mg) in case of symptoms for 2 months."
223862752|NCT06212167|BEHAVIORAL|Nursing Interventions for Stroke Patient Care|In the first phase of the research, the relatives of the patients who are in the hospital every day for a week during the routine and discharge process will be included in a training program. These trainings will be explained didactically to the caregiver at the bedside by the research supervisor and the intensive care nurse, the practices will be demonstrated with demonstrations, and the caregiver will be asked to apply them themselves. Then, the researchers will call the caregivers and make an appointment for an online meeting twice a week (7 weeks - 14 times). During these meetings, the training the caregivers need will be explained again and any questions they have will be answered. The researcher will also conduct motivational interviews with the caregivers.
223862753|NCT02009839|BEHAVIORAL|Meeky Mouse program|
223862754|NCT02009839|OTHER|Computer Games|
223862755|NCT05942963|DRUG|Empagliflozin 10 MG|10-25 mg/day
223862756|NCT05942963|DRUG|Pioglitazone 15mg|15-45 mg/day
223862757|NCT05942963|DRUG|Metformin|1000mg-2850mg/ day
223862758|NCT00790790|DRUG|Placebo|LY545694 placebo BID po for 5 weeks
223862759|NCT00790790|DRUG|LY545694 49 mg|LY545694 49 mg BID po for 5 weeks.
223862760|NCT00790790|DRUG|LY545694 105 mg|LY545694 105 mg BID po for 5 weeks.
223862761|NCT02570295|OTHER|Swiss Army Physical Fitness Training|2 x 90 minutes strength training and sport games and 2 x 30 minutes endurance training per week during 18 weeks of basic military training
223862762|NCT01112644|DRUG|Oxycodone naloxone prolonged release tablets (OXN PR)|Different daily doses; intake every 12 hours
223862763|NCT01112644|OTHER|Placebo (PLA)|Different daily doses; intake every 12 hours
223862764|NCT06282744|OTHER|Outpatient physical therapy improvement in movement assessment log|The Outpatient Physical Therapy Improvement in Movement Assessment Log (OPTIMAL) is an instrument that measures difficulty and self-confidence in performing 22 movements that a patient needs to accomplish in order to do various functional activities.
223862765|NCT01764815|DEVICE|directSTN Acute lead connected to external neurostimulator|Test phase will be performed intra-operatively, prior to chronic lead implant
223862766|NCT06469684|BEHAVIORAL|Health education session|1 hour health education session religious teaching promoting health-seeking behaviour, and question and answer session with healthcare professional.
223862767|NCT02808338|DEVICE|Philips BiPAP AutoSV Advanced System One|Auto SV Auto Servo Ventilation is a mode of positive airway pressure used to treat obstructive and complex central sleep apnea. This devices is FDA approved and will be set according to a predetermined setting.
223862768|NCT02808338|DEVICE|Modified Philips BiPAP ASV|This Modified BiPAP ASV will be set to a predetermined setting. This is the investigational device.
223862769|NCT02808338|DEVICE|ResMed S7 VPAP Adapt|This device is FDA approved and will be set to predetermined setting.
223862770|NCT02808338|DEVICE|ResMed S9 VPAP Adapt|This device is FDA approved and will be set to predetermined setting.
223862771|NCT00903266|BEHAVIORAL|Melodic Intonation Therapy|MIT emphasizes the prosody of speech through the use of slow, pitched vocalization (singing).
223862772|NCT00903266|BEHAVIORAL|Speech-Repetition-Therapy|Speech-Reception-Therapy is an equally intensive, alternative verbal treatment method developed for this study.
223862773|NCT00057837|BIOLOGICAL|G-CSF|G-CSF will be administered subcutaneously at a dose of 5 mcg/kg once a day starting on day 11 until WBC recovery \> 10,000 dL.
223862774|NCT00057837|DRUG|Cisplatin|Arm PET: 20 mg/m2 IV on days 8, 9 and 10 of each cycle following Etoposide. Arm PIE: 20 mg/m2 IV on days 1 and 8 of each cycle following Irinotecan.
223862775|NCT00057837|DRUG|Etoposide|Arm PET: 70 mg/m2 IV over 60 minutes on days 8, 9 and 10 of each cycle. Arm PIE: 85 mg/m2 orally (divided into 2 doses, 12 hours apart) on day 3 and 10 of each cycle.
223862776|NCT00057837|DRUG|Irinotecan|50 mg/m2 IV over 90 minutes on days 1 and 8 of each cycle (Arm PIE only).
223862777|NCT00057837|DRUG|Topotecan|Topotecan 0.75 mg/m2 IV over 30 minutes on days 1,2 and 3 of each cycle (Arm PET only).
223862778|NCT02940704|PROCEDURE|Reciproc|"* Canals will be instrumented using Reciproc reciprocating system set on an electric motor, with adjusted torque and speed according to the manufacturer's instructions.~* There is no need for coronal preflaring with a Gates Glidden drill or an orifice opener since the design of the Reciproc instrument allows any obstructions in the coronal third to be removed, as claimed by the manufacturer.~* Reciproc file selection: R40 (40/0.06) is to be used."
223862779|NCT02940704|PROCEDURE|One Shape|"* Coronal preflaring will be performed using Gates Glidden drill.~* Canals will be instrumented using One Shape single-file (25/0.06) set on an electric motor with adjusted torque and speed according to the manufacturer's instructions.~* For wide canals, One Shape Apical (30/0.06, 37/0.06) will be used."
223862780|NCT02537522|DEVICE|Contact Lenses with 8.5 BC|Subjects will wear the marketed, daily disposable contact lenses in 8.5 BC.
223862781|NCT02537522|DEVICE|Contact Lenses with 9.0 BC|Subjects will wear the marketed, daily disposable contact lenses in 9.0 BC.
223862782|NCT01382342|DRUG|Rasagiline|1 mg daily
223862783|NCT01382342|DRUG|Placebo|1 mg daily
223862784|NCT04393246|DRUG|EDP1815|EDP1815 is an orally administered pharmaceutical preparation of a single strain of Prevotella histicola isolated from the duodenum of a human donor. EDP1815 is currently in phase 2 clinical development and has European and US approval to initiate a multinational psoriasis study.
223862785|NCT04393246|DRUG|Dapagliflozin|Dapagliflozin is a sodium-glucose co-transporter 2 (SGLT-2) inhibitor. Dapagliflozin is licensed for use in the UK for treatment of Type II diabetes. Since this trial is evaluating Dapagliflozin in an unlicensed indication, it is being carried out under a Clinical Trial Authorisation (CTA)
223862786|NCT04393246|DRUG|Ambrisentan|Ambrisentan is an endothelin receptor antagonist, and is selective for the type A endothelin receptor (ETA). Ambrisentan was approved by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) and indicated for the treatment of pulmonary arterial hypertension.
223862787|NCT04393246|OTHER|Standard of care|Regular standard of care for COVID-19 patients
223862788|NCT06170593|DRUG|Triamcinolone Injection|0.1mL of triamcinolone 1% solution per lesion
223862789|NCT00192491|BIOLOGICAL|FluMist|Nasal Sprayer of one dosage of FluMist and other experimental
223862790|NCT00192491|BIOLOGICAL|FluMist|Nasal sprayer of FluMist
223862791|NCT00192491|OTHER|Placebo|Nasal Sprayer of Placebo
223862792|NCT05496907|BEHAVIORAL|Diabetes specialist nurse-led collaborative care intervention|10 sessions with a diabetes nurse to help improve physical and mental health outcomes
223862793|NCT02655835|BEHAVIORAL|Internet Mindfulness Meditation|
223862794|NCT02655835|BEHAVIORAL|Access|
223862795|NCT02995096|PROCEDURE|Pre-treatment|Non-transplantation pre-treatments prior to transplantation (e.g. radiofrequency ablation, transcatheter arterial chemoembolization)
223862796|NCT02995096|DRUG|Sirolimus based immunosuppression|Immunosuppression regimens containing Sirolimus
223862797|NCT03774459|DRUG|High dose ANAVEX2-73|Active oral capsule
223862798|NCT03774459|DRUG|Mid dose ANAVEX2-73|Active oral capsule
223862799|NCT03774459|DRUG|Placebo oral capsule|Placebo oral capsule
223862800|NCT02337569|DRUG|NPC-02|
223862801|NCT02337569|DRUG|Placebos|
223862802|NCT06081686|DRUG|Phase I:[177Lu]Lu-XT033 Injection|Six subjects were enrolled in the 1.11 Gbq (30 mCi) group of \[177Lu\] Lu-XT033 Injection. The last subject in this group completed the 4-week observation period after the first dose, With the consent of the Safety Monitoring Committee (SRC), 6 subjects were enrolled in the 1.85 Gbq (50 mCi) group. Both groups used 8 ± 1 weeks as the dosing interval .
223862803|NCT06081686|DRUG|Phase II:[177Lu]Lu-XT033 Injection|Patients received \[177Lu\]Lu-XT033 Injection every 8 weeks (+/- 1 week) for a maximum of 6 cycles.
223862804|NCT00952263|BIOLOGICAL|MBL-HCV1|Single infusion of MBL-HCV1 at escalating doses as determined by cohort assignment: Cohort 1 @ 1 mg/kg, Cohort 2 @ 3 mg/kg, Cohort 3 @ 10 mg/kg, Cohort 4 @ 30 mg/kg, Cohort 5 @ 50 mg/kg.
223862805|NCT00588809|DRUG|selumetinib|Given PO
223862806|NCT00106054|DRUG|Combination therapy of irinotecan with 5-FU, leucovorin plus bevacizumab in the neoadjuvant setting.|
223862807|NCT03146065|BIOLOGICAL|PF-06730512|Comparison of different dosages of PF-06730512 to Placebo
223862808|NCT03146065|DRUG|Placebo|Comparison of Placebo to different doses of PF-06730512
223862809|NCT02570711|DRUG|ACP-196|ACP-196 capsule
223862810|NCT02570711|DRUG|Nab-paclitaxel|Nab-paclitaxel infusion
223862811|NCT02570711|DRUG|Gemcitabine|Gemcitabine infusion
223862812|NCT00695071|DRUG|Itraconazole|Oral
223862813|NCT02547922|BIOLOGICAL|Anifrolumab|Administration every 4 week from Week 0 to Week 100 in addition to SOC which will continue until Week 112
223862814|NCT02547922|DRUG|Placebo|Administration every 4 week from Week 0 to Week 100 in addition to SOC which will continue until Week 112
223862815|NCT03023800|PROCEDURE|Macular buckling|Surgical procedures of macular buckling, drainage of aqueous fluid (0.1-0.2 ml) through limbal paracentesis, and inject gas ( C3F8 100%, 0.2ml-0.3ml) into vitreous body through pars plana, under systemic anesthesia.
223862816|NCT03023800|PROCEDURE|Vitrectomy|Surgical procedures of small gauge vitrectomy, internal limiting membrane peeling, and gas (C3F8, 14%) tamponage, under local or systemic anesthesia
223862817|NCT03738111|DRUG|TG02 Citrate|TG02 citrate capsules
223862818|NCT02336438|DIETARY_SUPPLEMENT|glucomannan|Glucomannan is a natural, odorless soluble fiber that is found in the konjac plant. It will be given during the Intervention Phase in conjunction with the MMTT and then for 5 days at home with meals.
223862819|NCT04003805|DRUG|Standardized Research E-cigarette (SREC)|The device operates at a single output voltage (3.30 ± 0.05 V) and uses sealed disposable 3-mL cartridges with tobacco-flavored e-liquid (\~350 puffs/cartridge). The concentration of nicotine in e-liquid is 15 mg/mL, and the vehicle composition is 50:50 propylene glycol and glycerin. The device uses a battery that can be recharged via a micro USB port. A single charge is designed to sustain more than 400 puffs, which is more than the capacity of an e-liquid cartridge. The e-liquid and the aerosol are well-characterized in terms of chemical impurities and by-products (such as aldehydes), which are minimal. Additional information, including the results of pharmacokinetics study is available via NIDA website: https://www.drugabuse.gov/funding/supplemental-information-nida-e-cig
223862820|NCT04003805|DRUG|Nicotine Mini-Lozenge|We will use commercially available nicotine mini-lozenges containing 2 or 4 mg nicotine/lozenge (Nicorette, manufactured by GlaxoSmithKline). Dose will be determined per instructions on the package (e.g, if smoking within 30 minutes upon awakening, then 4 mg dose will be prescribed).
223862821|NCT04828148|BEHAVIORAL|Survey|An online survey made by the authors was used, which is comprised of a total of 48 questions where different types of information are distinguished regarding the participant who is answering it such as age, gender, medical degree, comorbidities if during the pandemic they have been in contact with patients suspected or confirmed of COVID-19 infection if they have been infected by COVID-19 and the outcome of this infection. It also refers to whether they know doctors in the same specialty or others who have died from COVID-19 infection.
223862822|NCT02511613|DRUG|Squalamine Lactate Ophthalmic Solution, 0.2%|Squalamine Lactate Ophthalmic Solution, 0.2% administered BID
223862823|NCT02511613|DRUG|Placebo Ophthalmic Solution|Placebo Ophthalmic Solution, administered BID
223862824|NCT02511613|DRUG|ranibizumab|ranibizumab intravitreal injection
223862825|NCT00259961|PROCEDURE|open fundoplication|
223862826|NCT00259961|PROCEDURE|laparoscopic fundopliaction|
223862827|NCT06331611|DEVICE|TOF monitoring|Reversal with Sugammadex will be based on TOF monitoring
223862828|NCT05932082|PROCEDURE|myomectomy or not|The study group receive myomectomy, while the control group don't receive myomectomy.
223862829|NCT02010138|PROCEDURE|small-extent peeling|The internal limiting membrane was peeled in round shape with the radius of 0.75-disc diameter radius (1.5-disc diameter in total) centering at the center of the macular hole.
223862830|NCT02010138|PROCEDURE|large-extent peeling|The internal limiting membrane was peeled in round shape with the radius of 1.5-disc diameter radius (3.0-disc diameter in total) centering at the center of the macular hole.
223862831|NCT05786898|OTHER|NEAR-TSA|"Neuropsychological and Educational Approach of Cognitive Remediation adapted to autism~32 sessions spread over 4 to 8 months (1 session per week for minors, 2 sessions per week for adults), lasting 90 to 120 minutes"
223862832|NCT01323777|DEVICE|AcrySof® IQ ReSTOR® +3.0 D Multifocal Toric IOL|Multifocal IOL with extended secondary focal point and astigmatism correction implanted for long-term use over the lifetime of the cataract patient
223862833|NCT02202824|OTHER|Survey questionnaire|Each of the scale versions elicits personal attitudes toward intimate partner violence and perceived norms about intimate partner violence, in a different fashion
223862834|NCT00102063|DRUG|Aripiprazole tablet, 10 mg|Aripiprazole tablet 10 mg po qd x 42 days
223862835|NCT00102063|DRUG|Aripiprazole tablet, 30 mg|Aripiprazole tablet 30 mg po qd x 42 days
223862836|NCT00102063|DRUG|Placebo tablet|Placebo tablet po qd x 42 days
223862837|NCT02771171|RADIATION|CT Scan|CT imaging
223862838|NCT01493778|DRUG|turoctocog alfa|Patients will be scheduled to receive treatment with turoctocog alfa for at least 100 exposure days. In most cases, treatment will be given at home with intravenous (i.v., into the vein) self-injection by the parent/caregiver/support person.
223862839|NCT04230148|DRUG|Egaten (Triclabendazole) 250 mg tablets|Egaten 250 mg scored tablets for oral use.
223862840|NCT00224601|PROCEDURE|Colonoscopy with chromoscopy|
223862841|NCT03695536|BEHAVIORAL|ultrasound use during resuscitation|ultrasound use during resuscitation
223862842|NCT03309579|OTHER|Liberal RBC Transfusion Strategy|RBC transfusion is triggered by a Hemoglobin value of ≤100g/L
223862843|NCT03309579|OTHER|Restrictive RBC Transfusion Strategy|Optional RBC transfusion is triggered by a Hemoglobin value of ≤80g/L
223862844|NCT06335654|DIAGNOSTIC_TEST|artificial intelligence system|The colorectal lesions had been observed with EC-NBI and EC-stained by endoscopists before treatment that were ultimately performed histopathologic examination. The endocytoscopies (CF-H290ECI, Olympus, Tokyo, Japan) have a maximum magnification of ×520, focusing depth, 35 μm; field of view, 570 × 500μm. During EC-NBI , the endoscopist pushed the button of the endoscope to switch from white-light imaging to NBI and observed the lesion with full magnification. After endocytoscopic observation, the artificial intelligence system will be open and display the predictive result. Finally, the endoscopist performed EC-stained mode diagnosis after staining the lesion surface with 1.0% methylene blue. After endocytoscopic observation, the artificial intelligence system will be open again and display the predictive result.
223862845|NCT05082025|DRUG|Copanlisib|Given by IV
223862846|NCT05082025|DRUG|fulvestrant|Given by IM
223862847|NCT04210180|DRUG|Varenicline|0.5 mg nightly for days 1-3, then 0.5 mg twice daily for days 4-7; then 1 mg twice daily for the remaining 11 weeks.
223862848|NCT04210180|OTHER|e-cigarette|Each G6 prefilled cartomizer contains a 50/50 blend nicotine salt with 35mg nicotine strength.
223862849|NCT02220816|BEHAVIORAL|Competitive training|30 sessions of competitive cognitive training; 3 - 5 sessions/week; duration 45 min
223862850|NCT02220816|BEHAVIORAL|Non-Competitive Training|30 sessions of non-competitive cognitive training; 3 - 5 sessions/week; duration 45 min
223862851|NCT00857649|DRUG|Memantine|20 mg Oral Tablets Once Daily
223862852|NCT00857649|DRUG|Placebo|Oral Tablets Once Daily
223862853|NCT01325558|BIOLOGICAL|ALT-836 in combination with gemcitabine|Study participants will receive up to four courses of a 28-day biochemotherapy with the study drug (ALT-836) and gemcitabine. Each treatment course consists of five doses of ALT-836 (on Day 1, 4, 8, 15 and 22) and three doses of gemcitabine (Day 1, 8 and 15). Participants with persistent responses will receive additional two cycles, three doses each, of standard of care gemcitabine therapy.
223862854|NCT01912131|BEHAVIORAL|single pilot interview|Part 1 participants will be scheduled for their single pilot interview. There are no additional assessments.
223862855|NCT01912131|BEHAVIORAL|goals-of-care (GOC) video|Subjects will be shown the goals-of-care (GOC) video but not undergo a narrative interview process - they will be contacted as per re-assessment.
223862856|NCT01912131|BEHAVIORAL|goals-of-care (GOC) video and narrative question|subjects will watch the goals-of-care (GOC) video (described in detail in the next paragraph) and then be given the narrative question stem vetted/assessed in part 1 including any changes made to that stem in the process of Part 1 testing. Subjects in P-COCC arm will then be contacted for a telephone interview and audio-taping of their narrative. Interviews will be semi- structured and based off the narrative stem that subjects were previously given for review. Interviews will last approximately 30-45 minutes and will be conducted by staff from the MSKCC Department of Psychiatry \& Behavioral Sciences,
223862857|NCT01912131|BEHAVIORAL|usual care|Subjects in the usual care arm will neither be given the narrative stem nor watch the video.
223862858|NCT01912131|BEHAVIORAL|Part 2|Will be a proof-of-concept, small scale, RCT to measure P-COCC acceptability and other quantitative and qualitative effects. Seventy five participants will be randomized to Usual Care, Video, or Video and Interview.
223862859|NCT00043654|DRUG|Mifepristone|
223862860|NCT04329793|DEVICE|Assisted gait training with Walkbot System|The experimental group will receive at least 3 treatment sessions per week consisting of 40 minutes in robot-assisted gait training with Walkbot System in addition to their usual Physical therapy sessions. In total, the number of Walkbot sessions will be 20, in uninterrupted weeks.
223862861|NCT04329793|OTHER|Physical Therapy|The control group will receive their usual Physical therapy sessions during 6 weeks.
223862862|NCT05357365|OTHER|questionnaire survey|Questionnaire survey about occupational, mental, physical factors on one's health.
223862863|NCT06289348|BEHAVIORAL|socio-psychological questionnaire|ton collecte socio-demographic variable
223862864|NCT06289348|BEHAVIORAL|revised event impact scale (IER-S)|22 items assessed on a scale of frequency from 0 (not at all) to 4 (extremely)
223862865|NCT06289348|OTHER|Non directive interview|composed of a very broad opening sentence to encourage the parents' discourse
223862866|NCT06289348|OTHER|Stern interview|54 questions to investigate the impact of the announcement and the parenthood construction
223862867|NCT06289348|OTHER|semi-directive interview|to propose ideas for improving and harmonizing practices
223862868|NCT05190419|DRUG|Orismilast modified release tablets|Orismilast modified release is a next generation phosphodiesterase-4 (PDE4) inhibitor with high selectivity for the PDE4 subtypes linked to inflammation.
223862869|NCT05190419|DRUG|Placebo|Matching placebo tablets
223862870|NCT04537065|OTHER|cycloplegic refraction|"Cycloplegic refraction and the average corneal radius of curvature were performed using a handheld auto kerato-refractometer (Righton Retinomax K-plus2). Refraction was confirmed by retinoscopy and refractive errors were calculated as spherical equivalent and astigmatism in cylinder.~The biometric optic components, including anterior chamber depth, lens thickness, and axial length, were measured using A-scan ultrasound (model Echoscan US-4000 / 500; Nidek)."
223862871|NCT05787964|PROCEDURE|Biological sample collection|Whole blood (blood draw/phlebotomy) will be obtained to proceed with immunologic analysis of samples. Collection of biologic samples will occur up to 12 months.
223862872|NCT04643340|OTHER|real-time fMRI|Brain regions can be trained, i.e. fMRI activity can be actively modulated online by humans, using rt-fMRI (Bruhl, Scherpiet et al. 2014, Bruhl 2015, Emmert, Kopel et al. 2016).
223862873|NCT03426072|OTHER|modified IHI breakthrough series|"There are five main elements to the intervention:~1. Establishment of the team and set up~2. Establishing baseline performance and knowledge~3. Ongoing developmental support~4. Learning sessions (3)~5. Action periods (3)~6. The actual facilitative actions (e.g., coaching, guiding, mentoring, supporting) occur in combination with limited teaching, largely during telephone conferences but also in any visit, which may occur up to quarterly.~5\. The concluding session is an opportunity for networking, sharing successes and making plans for the continuation of project work following the end of formal support"
223862874|NCT00114699|DRUG|CCR5mAb004|
223862875|NCT01094405|BIOLOGICAL|Recombinant Epstein-Barr Virus (EBV) Vaccine|
223862876|NCT01591733|DRUG|FOLFIRINOX|Up to Eight-14 day cycles
223862877|NCT01591733|DRUG|Capecitabine|Orally, for 10 days
223862878|NCT01591733|RADIATION|Short Course Radiation|Five or ten days
224076314|NCT04040569|RADIATION|Radiomics on MRI|"Through extracting and analyzing a large number of features from medical imaging, radiomics has shown promising results in treatment outcome prediction for many diseases including breast cancer (45-50). UTSW physics group has developed several new radiomic approaches and radiomic features, such as a multi-objective radiomics model(51) and a new radiomic Shell feature(52). As an exploratory end point for this trial, the investigators will explore the application radiomics using pre-treatment MRI, treatment parameters and clinical characteristics as input to predict pathological response of radiation therapy (XRT) based on pathology report of surgical tissues and local recurrence."
223862879|NCT01591733|PROCEDURE|Surgery|1-4 weeks after completion of capecitabine therapy
223862880|NCT00833365|DRUG|Ibuprofen|Ibuprofen 10 mg/kg/dose for one dose, then repeated 24 hrs later at 5 mg/kg/dose and repeated 24 hrs later at 5 mg/kg/dose
223862881|NCT00833365|DRUG|Ibuprofen|Initial dose of ibuprofen is 10 mg/kg and then repeated every 24 hours times two with doses of 5 mg/kg
223862882|NCT04705922|DRUG|TT-00420 Capsule|TT-00420 capsule formulation, administered orally
223862883|NCT04705922|DRUG|TT-00420 Tablet|TT-00420 tablet formulation, administered orally
223862884|NCT03516435|DEVICE|Parasacral transcutaneous electrical stimulation|Asymmetrical biphasic square current pulse Frequency：10 Hz pulse width：1.0 ms Intensity：highest tolerable intensity(≦80 mA.) Parasacral transcutaneous electrical stimulation：Clinic using 2 superficial 3.5 cm electrodes placed on each side of S3 and S4.
223862885|NCT03516435|DEVICE|Intravaginal electrical stimulation|Asymmetrical biphasic square current pulse Frequency：10 Hz pulse width：1.0 ms Intensity：highest tolerable intensity(≦80 mA.) Intravaginal electrical stimulation：The electrode plug for vaginal plug was cylinder-formed with ring-formed placed into vaginal.
223862886|NCT03133117|RADIATION|Functional Magnetic Resonance Imaging (fMRI)|Functional Magnetic Resonance Imaging (fMRI)
223862887|NCT01336283|OTHER|Endurance training|compare the efficacy of endurance, strength, and the combination of strength and endurance exercise training in patients with COPD.
223862888|NCT01336283|OTHER|Strength training|compare the efficacy of endurance, strength, and the combination of strength and endurance exercise training in patients with COPD.
223862889|NCT01336283|OTHER|Combined training|compare the efficacy of endurance, strength, and the combination of strength and endurance exercise training in patients with COPD.
223862890|NCT03697538|PROCEDURE|Nerve Block for pain control post-revision total knee arthroplasty|A 20g catheter will be introduced and advanced 2-3 cm beyond the tip of the needle under ultrasound visualization. After needle withdrawal, catheter placement will be checked by visualizing local anesthetic spread under ultrasound. 0.5% ropivacaine will be used for catheter placement. At the conclusion of surgery, the catheters will be connected to a pump that will infuse ropivacaine 0.2% at 6 mL/hr with a patient controlled bolus of 5mL and a lockout of 30 minutes.
223862891|NCT04520490|BEHAVIORAL|Family Based Behavioral Treatment|Children with obesity accompanied by at least one parent or caregiver will attend 24 weekly sessions. Most sessions will be held via video-conference and include 25-30 min. meetings between an interventionist and each child/parent pair to individualize treatment, followed by separate child and parent group meetings lasting 40 - 45 min. A select few sessions will be held in-person between an interventionist and each child/parent pair with no group session. Parents will serve as primary agents of change for their child and for themselves. Training will focus on food and physical activity education, parenting around food and physical activity, and use of behavioral skills (e.g., self-monitoring, environmental control, contingency management). Intervention groups of 8-12 children/families will be initiated every 3-6 mos. in study yrs. 2-3.
223862892|NCT04520490|DRUG|Exenatide 2 mg [Bydureon]|Weekly injections of active drug.
223862893|NCT04520490|DRUG|Placebo|Weekly placebo injections
223862894|NCT05927935|OTHER|Supervised strength exercise intervention|A 6 months exercise intervention of training 2 times a week. Patients will be instructed by a physiotherapist during the first session, in order to be able to perform the exercises at home or in a local gymnasium based on personal preference. Subsequently, there are supervised sessions once every second week (12 sessions in total). The intervention will consist of 6 exercises. 4 targeting planes of hip movement (i.e., flexion, extension, abduction and adduction), a general lower extremity- and a trunk exercise. Progression is made when an exercise is performed with the designated number of sets and repetitions, with good performance quality and tolerable pain. Progression is provided by 3 levels of difficulty and secondly by the number of repetitions or where possible by increasing the external load. In addition, patient information and education is identical to what is delivered in the usual care group.
223862895|NCT05927935|OTHER|Minimal educational intervention (usual care)|Usual care varies slightly across regions in Denmark and between Denmark and Australia. The consensus is that the patient should be advised to remain physically active and reduce symptom provoking activities. Therefore, patients will receive a referral for physiotherapy and supplementary a minimal educational intervention is provided as usual care. Patients allocated to the usual care group will receive written information on self-management of hip symptoms including advice about staying physically active in accordance with the World Health Organization guidelines on physical activity and sedentary behavior. Moreover, self-management of hip symptoms will include advice to reduce symptoms by focusing on symptom-lowering activities and sports. The content of the information provided as usual care will be identical to the information provided to the patients in the intervention group. Patients in the usual care group can continue to seek any additional treatment they would like.
223862896|NCT03992417|DRUG|Dupilumab SAR231893 (REGN668)|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous injection"
223862897|NCT05722535|BEHAVIORAL|Family Media Check-In (FMC)|An interactive, web-based tool to support within-family media use planning will be developed and shared with families.
223862898|NCT06086925|DRUG|Black Raspberry|Each BRB contains 1 gram of black raspberry powder equal to roughly 6 black raspberries.
223862899|NCT05019144|PROCEDURE|Face-to-face burn care|If the participants are assigned to FTF care, they will receive standard burn care including a return follow-up in the burn clinic on a routine basis as prescribed by the clinical burn team (at least once per week) until the burn has healed.
223862900|NCT05019144|PROCEDURE|Telemedicine enhanced burn care|Participants assigned to TOBI will be given instructions how to download and use TOBI on a smartphone, including how to interface with burn clinicians using text-messaging, videoconferencing, and sending photos of the child's burn(s). The participants will have scheduled video visits with the care provider at least weekly until the burn has healed. The participants will be able to use other features of the app, such as text-messaging and sending photos of the burn(s), as needed. The participants will be able to use standard FTF burn care as well. They will be given instructions how to contact the burn team through the hospital paging operator if TOBI is unavailable or there is an emergency.
223862901|NCT05868122|DRUG|Acetaminophen/Naproxen Sodium Fixed Combination|Fixed combination of Acetaminophen/Naproxen Sodium will be administered orally.
223862902|NCT05868122|DRUG|Placebo|Placebo will be administered orally.
223862903|NCT05931887|DEVICE|SILQ ClearTract 100% Silicone 2-Way Foley Catheter|A foley catheter is assigned and used according to regular standard of care
223862904|NCT02024542|OTHER|Surgery|Patients wishing to participate in the research will complete all necessary pre-operative work-up labs, testing \& counseling, complete and sign the informed consent. During weight loss surgery a small amount of subcutaneous and omental fat will be collected for analysis, with subsequent blood collection post surgery for analysis.
223862905|NCT05839873|DEVICE|FlexAbility SE Ablation Catheter|Subjects receive ablation treatment.
223862906|NCT04137536|DRUG|anti-EGFR-bispecific antibody armed activated T-cells|"Phase I:~* First 3 participants, twice weekly infusions of 10\^10 EGFR BATs infusions~* If there is toxicity in 0 or 1 of 3 participants, 3 additional participants will be added to the dose level of up to 10\^10.~* If \>/= 2 of 6 participants experience DLTs, then the dose will be reduced to 7.5 x 10\^9 per infusion~* If only 0 or 1 participants has toxicity in the first 6, then the study will proceed to enroll in the expansion cohort~Expansion cohort:~\- 8 infusions of 7.5 x 10\^9 or 10\^10 EGFR BATs in 22 evaluable participants (including the 6 participants treated at the maximum tolerated dose in Phase I)"
223862907|NCT06132854|OTHER|VR|The virtual environment is provided by the Oculus Quest 2 or 3 VR headset, providing a high-quality and immersive visual experience.
223862908|NCT06132854|OTHER|Booklet|Children in the booklet condition will be prepared by using an educational booklet containing colorful illustrations of the MRI examination room and about the procedure.
223862909|NCT04580901|BEHAVIORAL|Group Interpersonal Psychotherapy|Group IPT consists of 12 weeks of virtually delivered therapy by two co-therapists via Zoom to a group of 6-8 women. The 12 weeks consist of 15 sessions over 12 weeks of group IPT taking place virtually via Zoom (2 sessions per week for the first 4 weeks (acute phase) then once a week for 6 weeks, then a two-week space before the last session).
223862910|NCT04426773|DEVICE|High-Definition transcranial direct current stimulation|The tDCS device will deliver a direct current of 1.5mA for 20 minutes. Cathode electrode will be localized in front of the OFC on the Fp2 point according to the EEG international reference. Four anode electrodes will be placed around FP2 (i.e. Fpz, AFz, AF4, AF8).
223862911|NCT05732207|PROCEDURE|cerebellar transcranial direct current stimulation|TDCS is a safe and non-invasive technique for modulating cortical excitability and behavior. TDCS, delivered via surface electrodes, induces an intracerebral current flow sufficient to achieve changes in cortical excitability. Anodal stimulation up-regulates cortical excitability, while cathodal stimulation decreases excitability.
223862912|NCT06425042|DIETARY_SUPPLEMENT|Nicotinamide Riboside (NR)|Participants will ingest 1g/d of NR orally during 12 weeks in parallel to a exercise training program
223862913|NCT06425042|DIETARY_SUPPLEMENT|Placebo|Participants will ingest 1g/d of placebo orally during 12 weeks in parallel to a exercise training program
223862914|NCT06223152|OTHER|parental support|parental support
223862915|NCT03557957|OTHER|Targeted correction of plasma sodium levels|Targeted correction of hyponatremia
223862916|NCT03557957|OTHER|Standard care|Standard care of hyponatremia
223862917|NCT04602598|DRUG|Zanubrutinib 80 MG|Zanubrutinib 80 MG for 24 weeks
223862918|NCT04704830|BIOLOGICAL|R21/Matrix-M|Adjuvanted malaria vaccine
223862919|NCT04704830|BIOLOGICAL|Rabies vaccine, Hepatitis A vaccine or Meningococcal vaccine|Placebo Comparator
223862920|NCT04187131|BEHAVIORAL|augmented reality|The participants will be wearing an EEG cap and Augmented Reality headset (AR-based EEG-guided system) for 10 sessions with a licensed occupational therapist, provided in addition to usual rehabilitation care (either in inpatient rehabilitation or at home). These sessions will focus on activities of daily living that the participants want to practice. All sessions will last approximately 1 hour. These sessions will be scheduled around the existing therapy schedule to cause the least amount of interference with planned clinical activities.
223862921|NCT04834414|BIOLOGICAL|Cold Stored Platelets|Platelets stored at 1-6 degree Celsius
223862922|NCT04834414|BIOLOGICAL|Room Temperature Platelets|Platelets stored at 20-24 degrees Celsius
223862923|NCT03729453|DEVICE|SpyGlass|Visualization of main pancreatic duct with SpyGlass catheter.
223862924|NCT06470334|DRUG|Ropivacaine|Ultrasound-guided PENG block - 20ml 0,2% ropivacaine
223862925|NCT06470334|DRUG|Ropivacaine+Dexamethasone|Ultrasound-guided PENG block - 10ml 0,2% ropivacaine + 4mg Dexamethasone
223862926|NCT06581939|PROCEDURE|Rehabilitation group|In the rehabilitation group, patients will follow an individualized rehabilitation program started early in the ICU and continued in the post-ICU ward then at home for 12 weeks, combining goal-directed nutrition and physical activity, tailored to gains made over time by each patient, with the involvement of dieticians, physiotherapists, and adapted-physical-activity instructors.
223862927|NCT06581939|PROCEDURE|Control group|In the control group, patients will receive usual care from day-0 to day-180.
223862928|NCT05323734|DRUG|Ganaxolone|GNX will be administered
223862929|NCT05323734|DRUG|Placebo|Placebo will be administered
223862930|NCT06649097|DEVICE|IRRAflow® CNS (Active Fluid Exchange) System|The IRRAflow system offers automated irrigation, controlled drainage and intracranial pressure (ICP) monitoring all in one system. It consists of three main parts - IRRAflow 2.0 Catheter, IRRAflow Tube Set, IRRAflow Control Unit.
223862931|NCT05452720|DEVICE|Surgical Right Ventricular Outflow Tract Reconstruction|Surgical replacement of the Pulmonary Valve or a previously implanted prosthetic with the investigational device (MASA Valve)
223862932|NCT04652076|DRUG|NP137|Recombinant humanized IgG1 monoclonal antibody against Netrin 1. NP137 will be administred IV, Q3W until disease progression, unacceptable toxicity, death, patient or physician decision to withdraw, pregnancy or SMPC guidance, whichever occurs first.
223862933|NCT04652076|DRUG|Pembrolizumab|Humanised monoclonal anti-programmed cell death-1 (PD-1) antibody will be administred in IV Q3W. A maximum 35 cycles of treatments (approximately 2 years) with pembrolizumab can be administered to patients.
223862934|NCT04652076|DRUG|Paclitaxel|Standard Chemotherapy agent will be administred IV, Q3W, up to 6 cycles of treatment.
224267205|NCT07138924|OTHER|Graston Technique|Firstly, apply a moisturizer or gel to affected part. Then gentle strokes are applied from proximal to distal direction to assess trigger point or taut band. After knowing the exact area, apply strokes gently with minimum force in all directions by keeping tool in 30- 60-degree angle. Total Application time will be between 40-120 seconds. conservative physiotherapy treatment plan is hot pack for 10-15 min, calf stetches 10 reps x 2 sets and post session cold pack for 5 min. Home exercise plan is william training i.e. single knee to chest, double knee to chest, pelvic tilts, iliospoas stretch, hamstring stretch and squat (10reps x1 set)
223862935|NCT04652076|DRUG|Carboplatin|Standard Chemotherapy agent will be administred IV, Q3W, up to 6 cycles of treatment.
223862936|NCT04408898|GENETIC|ADP-A2M4 in combination with pembrolizumab.|Single infusion of autologous genetically modified ADP-A2M4 Dose: 1.0 x109 to 10x109 transduced cells by a single intravenous infusion Repeat doses of pembrolizumab every 3 weeks. Dose: 200mg
223862937|NCT05907668|DRUG|IMVT-1401 (batoclimab)|Batoclimab is a fully human anti-neonatal fragment crystallizable receptor (FcRn) monoclonal antibody.
223862938|NCT06489886|OTHER|Conventional Chicken|This arm will be given a meal of 100 grams (\~32g of protein) boneless-skinless convential chicken breast meat together with 250mL of water
223862939|NCT06489886|OTHER|Regenerative Chicken|This arm will be given a meal of 100 grams (\~32g of protein) boneless-skinless regenerative chicken breast meat together with 250mL of water
223862940|NCT05548621|OTHER|Decision aid|Online interactive decision aid for RCC
223862941|NCT05562271|RADIATION|low-dose radiation therapy|low-dose radiation therapy to involved knee joint
223862942|NCT05562271|RADIATION|sham radiation therapy|sham radiation therapy to involved knee joint
223862943|NCT06779188|DEVICE|Transcranial Magnetic Stimulation|TMS (in the form of theta burst stimulations) will be delivered over Supplementary Motor Area while the subject is seated in the Treatment group. TMS is capable to induce neuroplastic facilitatory changes in the brain that last beyond the duration of stimulation. TMS will be delivered once daily, 5 days per week, for 4 weeks.
223862944|NCT06779188|DEVICE|Transcranial Magnetic Stimulation Sham|Sham TMS will be delivered in the sham group using a sham coil once daily, 5 days per week, for 4 weeks.
223862945|NCT06237842|DIAGNOSTIC_TEST|Diagnostic Test: EEG headband+Ring oximeter (RO)+Actigraphy (ACT)|Combination of ACT+RO+EEG. This is not an intervention, but rather a combination of devices to be tested regarding its diagnostic validity.
223862946|NCT05697497|BEHAVIORAL|Daily exercise intervention|Participants will complete four exercises each day, The first two weeks they will be instructed to complete as many repetitions as possible, each day, for 15 seconds and progressing to 30 seconds per exercise after the first two weeks. Participants are asked to increase their goal repetitions by 1 or 2 from their previous best each week. For all exercises with modifications, we will encourage participants to move to the next most difficult modification once they can do 15 repetitions of that exercise.
223862947|NCT05065736|DRUG|18F-Clofarabine|The participants enrolled will receive a baseline CFA PET/CT evaluation. Then, the participants will undergo the routine follow up would normally occur for their cancer and its treatment. If this routine follow up and care involves repeat imaging of the cancer, then the CFA PET/CT scan will be repeated at that time (timed according to standard-of-care follow-up imaging), which is expected between a month to about 4 months after the first CFA PET/CT scan. The study period will end 24 hours after this repeat PET/CT scan.
223862948|NCT05848583|OTHER|Compleat 1.5|EN Formula
223862949|NCT06849401|BIOLOGICAL|VGO-Cs01p|Off-the-shelf NK cell products derived from human embryonic stem cells (hESCs)
223862950|NCT01047735|PROCEDURE|Roux-en-Y Gastric Bypass Surgery|Participants assigned to the Roux-en-Y Gastric Bypass treatment group will undergo a surgical procedure that limit foods intake and causes nutrients malabsorption. The procedure is performed with small incisions or laparoscopically. A small stomach pouch is created, the size of an egg, and the small intestine is connected to the pouch. Some of the stomach and small intestine are consequently bypassed by this anatomic change. Those in this treatment group will begin a gradual diet post surgery and will take life long vitamin supplements.
223862951|NCT01047735|PROCEDURE|Laparoscopic Adjustable Gastric Banding|Those assigned to the Laparoscopic Adjustable Gastric Banding study group will undergo a surgical procedure where an adjustable silicone band is placed around the upper stomach to decrease its capacity so that you will feel full sooner. It will assist in weight loss by helping you to limit intake of calories. The band will be placed by using several small incisions and telescopic instruments. A thin tube connects the band to an access port just under the skin that you may be able to feel but you will not be able to see it. This allows the band to be tightened or loosened to decrease or increase your stomach capacity as needed. The surgery will take on average 30-45 minutes.
224267206|NCT07138924|OTHER|Dynamic Oscillatory Stretch Technique|Passively stretch that is at the first point of stretch sensation. The next component to DOS, 2-sec, passive stretch with slow oscillation. Total 10 reps x 2 sec hold oscillations x 3 sets.conservative physiotherapy treatment plan is hot pack for 10-15 min, calf stetches 10 reps x 2 sets and post session cold pack for 5 min. Home exercise plan is william training i.e. single knee to chest, double knee to chest, pelvic tilts, iliospoas stretch, hamstring stretch and squat (10reps x1 set)
224267207|NCT07138911|OTHER|Intervention group|Walking at home for 15-30 minutes 3 times per day for 4 weeks. Activity plan is calendar on mobile health app. Mobile placed in pocket or bag before starting walk and mark activity on calendar.
224267208|NCT07138911|OTHER|Control group|Walking at home for 15-30 minutes 3 times per day for 4 weeks. Manual record of walking and date.
224267209|NCT07135921|BEHAVIORAL|Sleep Hygiene Education|This intervention consists of a nurse-led sleep hygiene education program delivered through a 30-minute PowerPoint presentation. Participants in the intervention group will also receive twice-daily reminder messages via WhatsApp for four weeks to reinforce healthy sleep habits. The program aims to improve sleep quality and disease management in individuals with cardiovascular disease. After the study, the educational materials will also be shared with the control group.
224267210|NCT07140393|DRUG|HRS-4508+ Capecitabine|HRS-4508+ Capecitabine
224267211|NCT07140393|DRUG|HRS-4508+ Trastuzumab|HRS-4508+ Trastuzumab
224267212|NCT07140393|DRUG|HRS-4508+ Trastuzumab+ Pertuzumab|HRS-4508+ Trastuzumab+ Pertuzumab
224267213|NCT07140393|DRUG|HRS-4508+ Trastuzumab+ Capecitabine|HRS-4508+ Trastuzumab+ Capecitabine
224267214|NCT07140393|DRUG|Trastuzumab+ Capecitabine|Trastuzumab+ Capecitabine
224267215|NCT07140393|DRUG|HRS-4508+A1811|HRS-4508+A1811
224267216|NCT07140562|DEVICE|Tricuspid Annular Therapy System|A transcatheter device designed for tricuspid valve repair.
224267217|NCT07139548|DRUG|RAY1225|Administered SC
224267218|NCT07139548|DRUG|Semaglutide|Administered SC
224267219|NCT07139366|DRUG|Bismuth|Bismuth-containing quadruple therapy: given for 14 days at a dose of bismuth 110 mg 2 capsules BID plus esomeprazole 20 mg 1 tablets BID#tetracycline 250mg 2 capsules TID and furazolidone 100mg 1 tablets BID
224267220|NCT07139366|DRUG|Esomeprazole|Bismuth-containing quadruple therapy: given for 14 days at a dose of esomeprazole 20mg 1 tablets BID plus bismuth 110 mg 2 capsules BID#tetracycline 250mg 2 capsules TID and furazolidone 100mg 1 tablets BID
224267221|NCT07139366|DRUG|Tetracycline|Bismuth-containing quadruple therapy:given for 14 days at a dose of tetracycline 250mg 2 capsules TID plus furazolidone 100mg 1 tablets BID#esomeprazole 20 mg 1 tablets BID and bismuth 110 mg 2 capsules BID
224267222|NCT07139366|DRUG|Furazolidone|Bismuth-containing quadruple therapy:given for 14 days at a dose of furazolidone 100mg 1 tablets BID plus tetracycline 250mg 2 capsules TID#esomeprazole 20 mg 1 tablets BID and bismuth 110 mg 2 capsules BID
224267223|NCT07139366|DRUG|Saccharomyces Boulardii Oral Powder|Saccharomyces boulardii combined with Bismuth-containing quadruple therapy:given for 14 days at a dose of Saccharomyces boulardii powder 250 mg 2 packets BID#bismuth 110 mg 2 capsules BID plus esomeprazole 20 mg 1 tablets BID#tetracycline 250mg 2 capsules TID and furazolidone 100mg 1 tablets BID
224267224|NCT07140575|DEVICE|repetitive transcranial magnetic stimulation (rTMS)|twice daily rTMS, intermittent theta burst stimulation targeting the left dorsolateral prefrontal cortex with a figure-8 coil
224267225|NCT07140549|OTHER|Survey using a questionnaire.|"A monocentric experimental study conducted as a survey, including patients enrolled in our fertility preservation program between May 2005 and May 2020.~Participants were asked about their current reproductive health status, their experience with the fertility preservation process, and their overall satisfaction with the care they received."
224267226|NCT07139470|DRUG|Sacituzumab Tirumotecan + anlotinib|"Phase I part: 3 prespecified doses (sac-TMT 4mg/kg Q2W +anlotinib 8mg Q3W, sac-TMT 4mg/kg Q2W +anlotinib10mg Q3W, sac-TMT 4mg/kg Q2W +anlotinib12 mg Q3W).~Phase II part: sac-TMT patients Q2W +anlotinib RP2D Q3W."
224267227|NCT07139249|OTHER|The high intensity interval training|The training program for students in groups 1 and 2 involves high intensity interval training exercises, conducted three times per week for six weeks. The sessions include a 10-minute warm-up at 40% Heart Rate Reserve, four high-intensity work periods at 85-95% Heart Rate Reserve, three low-intensity work periods at 60-70% Heart Rate Reserve, and a 5- 10 minute cool down at 30% Heart Rate Reserve.
224267228|NCT07139249|OTHER|The study moderate continuous training|All students in groups 3\&4 will receive moderate continuous training 3 times per week for 6 weeks. Each session 40 to 50 minutes included a 5 to 10 minute warm-up, fo followed by 30 minutes of moderate aerobic exercise (treadmill walking exercise) with constant intensity at 60% to 70% Heart Rate Reserve and 5 to 10 minutes cool-down
224267229|NCT07139002|OTHER|Bobath Therapy|The group will repeat 10 exercises (facilitated rolling, sitting balance exercises, weight shifting in standing, functional sit-to-stand, stepping practice, reaching activities, wall slides, therapeutic ball exercises, stair climbing practice, and breathing and relaxation techniques) for 8 weeks.
224267230|NCT07139002|OTHER|Sensory Training|The group will repeat 9 exercises (texture discrimination, shape, size, and discrimination, tactile recognition, proprioception training, temperature differentiation, tactile localization, sensory mapping, sensory training through functional activities, and tabletop sensory exercises) for 8 weeks.
223862952|NCT01047735|BEHAVIORAL|Lifestyle Weight Loss Intervention|Participants will receive a standard behavior weight control program in an in-person format over a period of 12 months conducted by an experienced team of weight loss counselors. During the initial 6 months of study treatment, will attend weekly in-person individual sessions with a weight loss counselor. During months 7-12, will attend in-person sessions on the 1st and 3rd week of the month and will receive a brief (less than 10 minutes in duration) telephone call on the 2nd and 4th week of the month. Each session will focus on a specific behavioral topic related to weight loss, eating behaviors, or exercise behaviors.
223862953|NCT05437588|GENETIC|Genetic testing|Attempting to identify the genetic biomarker that can identify risk for suicidal ideation and action
223862954|NCT04143646|BEHAVIORAL|Web-based prevention program|"Telemetric control of risk factors, e-learning, contacts by e-mails/apps. If no response telephone calls.~In a substudy evaluation of disclosure of genetic risk."
223862955|NCT03845114|OTHER|Continous exercise|60-minute continuous exercise on the ergocycle at 60% of VO2 peak (moderate intensity).
223862956|NCT03845114|OTHER|Interval exercise|Participants will perform a 60-minute interval exercise on the ergocycle at 60% of VO2 peak (moderate intensity).
223862957|NCT03845114|OTHER|Reduction of basal insulin by 40%|Participant's insulin basal rate will be reduced by 40% 1 hour before exercise onset.
223862958|NCT03845114|OTHER|Reduction of basal insulin by 80%|Participant's insulin basal rate will be reduced by 80% 1 hour before exercise onset.
223862959|NCT05674825|DRUG|Targeted agent|"The Molecular Tumor Board (MTB) will suggest molecularly targeted matched treatment."
223862960|NCT05674825|DRUG|Standard of care agent|Subjects will receive treating physician's choice of traditional systemic therapy treatment for their malignancy, defined by National Comprehensive Cancer Network (NCCN) guidelines and/or tumor board recommendation(s).
223862961|NCT03096262|DEVICE|Citizen Science intervention using kinect|Users are asked to tag objects on a screen
223862962|NCT05610111|DEVICE|CLC + BAM|Closed Loop Control with the Behavioral Adaption Module for 4 weeks
223862963|NCT05610111|DEVICE|CLC + ABC|Closed Loop Control with Adaptive Biobehavioral Control for 16 weeks
223862964|NCT03752840|OTHER|Visual acuity (presenting and pinhole)|Presenting and pinhole visual acuity will be assessed using the Peek Acuity mobile application. Participants meeting referral criteria will be referred to the nearest eye care center or eye hospital.
224267231|NCT07138521|DRUG|Linezolid (IV and PO)|No dose change and continued linezolid 600 mg every 12 hours.
224267232|NCT07138521|DRUG|Linezolid (IV and PO)|Intervention and adjustment of the linezolid dose from 600 mg every 12 hours to 300 mg every 12 hours.
224267233|NCT07138521|DRUG|Linezolid (IV and PO)|Intervention and adjustment of the linezolid dose from 600 mg every 12 hours to 600 mg every 24 hours.
224267234|NCT07139613|OTHER|Control group(PS)Planer occlusal scheme with rounded shoulder finish line|Control group (PS) will have planer occlusal scheme with rounded shoulder finish line.
224267235|NCT07139613|PROCEDURE|First intervention group(FF) flat occlusal scheme with feather edge finish line|First intervention group we will have flat occlusal scheme with feather edge finish line
224267236|NCT07139613|PROCEDURE|Second intervention group(FS) flat occlusal with rounded shoulder finish line design|Second intervention will have flat occlusal scheme with rounded shoulder finish line design
224267237|NCT05885568|BIOLOGICAL|blood sampling|Blood sampling from healthy volunteers
224267238|NCT05885568|OTHER|drone transportation|drone transportation
224267239|NCT05885568|OTHER|car transportation|car transportation
224267240|NCT00469521|DRUG|Refresh Tears, 9582X|
224267241|NCT02347111|DRUG|Flecainide|flecainide up to 150mg twice daily for the control of atrial fibrillation
224267242|NCT02347111|DRUG|Sotalol|sotalol up to 120mg twice daily for the control of atrial fibrillation
224267243|NCT05984290|DEVICE|orthokeratology lens|Each subject will wear the study lenses in both eyes overnight for approximately 3 months.
224267244|NCT07140042|OTHER|Survey|Survey
224267245|NCT07140510|DRUG|Dinalbuphine Sebacate|Dinalbuphine Sebacate 150 mg intramuscular injection after spinal anesthesia and adductor canal block in the same side of TKA
224267246|NCT07140510|DRUG|Normal Saline|Normal saline 2 mL intramuscular injection after spinal anesthesia and adddutor canal block
224267247|NCT07139912|DEVICE|Thoracic Aortic Multi-Branch Stent Graft System|The Thoracic Aortic Multi-Branch Stent Graft Systemm consists of the Single-Branch Aortic Stent-Graft System, the aortic extension stent graft system and the branch stent system.
224267248|NCT07139028|OTHER|Tibialis Anterior resistance training and ladder drills|19 participants will be in experimental group A, they will perform tibialis anterior resistance training exercises with ladder drills (3 times/ week for 6 weeks) along with traditional training
224267249|NCT07139028|OTHER|Traditional training|19 participants will be in control group B,they will perform only traditional training (guided by coach)
224267250|NCT07139275|OTHER|aerobic exercise|exercise protocol was applied following these characteristics (frequency: 3-5 times /week along the whole study period, intensity: 60-70% of the maximal heart rate (220- age x 60/100), duration: 50 min including warming exercise movements in standing position, active phase in form of walking on a computerized treadmill and cooling down exercise movements performed in the seated position
224267251|NCT07139275|BEHAVIORAL|added sugar elimination|specialized programme of eliminating all kinds of added sugar (all kinds of sugars that are not naturally occurring in natural foods
224267252|NCT07139275|COMBINATION_PRODUCT|aerobic exercise and added sugar elimination|a specialized program of combining added sugar elimination protocols ( elimination of all kinds of added sugars and allowing only sugars naturally occurring in foods) combined with the same aerobic exercise protocol that applied following these characteristics (frequency: 3-5 times /week along the whole study period, intensity: 60-70% of the maximal heart rate (220- age x 60/100), duration: 50 min including warming exercise movements in standing position, active phase in form of walking on a computerized treadmill and cooling down exercise movements performed in the seated position
224267253|NCT07140003|PROCEDURE|pleural biopsy|To assess whether pleural tissue culture can improve the identification of causative organisms in pleural infections (using the pleural fluid culture), which can aid in selecting appropriate antimicrobial therapy and improve treatment outcomes, thus may provide valuable insights into the utility of pleural tissue culture in managing pleural infection and may guide clinicians in selecting the most appropriate diagnostic approach.
223862965|NCT03752840|OTHER|Optical coherence tomography (OCT)|OCT will be used to image the anterior segment, the macula, and the retinal nerve fiber layer. The images will be assessed for abnormalities and participants meeting referral criteria will be referred to the local eye hospital.
223862966|NCT03752840|OTHER|Intraocular pressure|Intraocular pressure will be measured using an iCare tonometer. Participants meeting referral criteria will be referred to the nearest eye care center or eye hospital.
223862967|NCT03752840|OTHER|Active linkage to care|Referred participants will be followed closely by study staff to ensure completion of follow-up visits.
223862968|NCT03752840|OTHER|Fundus Photography|Fundus cameras will be used to image the macula and optic nerve. The images will be assessed for abnormalities and participants meeting referral criteria will be referred to the local eye hospital.
223862969|NCT02819336|DEVICE|Electroacupuncture (EA)|"The EA group will receive the verum therapies using the following procedures.~1. Let the patient lie down on lateral decubitus.~2. The practitioners install the same guide-tubes as Park sham needle on CV2, CV3, CV4, CV6 and bilateral points of SP11 and SP6.~3. The verum acupunctures are inserted on each acupoint inside the installed guide-tube. (stainless steel, 0.25 mm in diameter and 4.0 mm in length, Dong Bang Acupuncture Inc., Republic of Korea)~4. After de qi response is elicited, the electrical stimulation is presented for 20 minutes by middle frequency (30 Hz). (STN-111, Stratek, Republic of Korea)~5. The practitioner should have at least 1-year clinical experiences.~The procedure will be repeated 10 times (once a session) within 21 days."
223862970|NCT02819336|DEVICE|Sham electroacupuncture|"1. Let the patient lie down on lateral decubitus.~2. The practitioners install the same guide-tubes as Park sham needle on CV2, CV3, CV4, and CV6 unilaterally \& SP11 and SP6 bilaterally.~3. The non-penetrating sham acupunctures are implemented on each acupoint inside the installed guide-tube.~4. The electrical stimulation is presented for 20 minutes by middle frequency (30 Hz), (STN-111, Stratek, Republic of Korea) even though the electrical stimulation is not delivered through the skin because the needles are not penetrated through the skin.~5. The practitioner should have at least 1-year clinical experiences.~The procedure will be repeated 10 times (once a session) within 21 days."
223862971|NCT02343211|DRUG|Immunoglobulin|
223862972|NCT05997836|OTHER|Implementation Facilitation|Implementation Facilitation involves and External Facilitator (from outside of the participating medical center) and an Internal Facilitator (from inside the participating medical center) working together to help BHIP teams within the site adopt care practices that are more consistent with the CCM
223862973|NCT05997836|OTHER|Centralized Technical Assistance|Centralized Technical Assistance involves having external experts available for ad hoc consultation related to collaborative BHIP care practices.
223862974|NCT01918163|DIETARY_SUPPLEMENT|Pomegranate pills|
223862975|NCT00128596|DRUG|arsenic trioxide|
223862976|NCT06047522|DEVICE|Casque Lumeen|Participants will take part in virtual reality sessions via headset. They will benefit from a before/after evaluation, and a 3-week intervention where they will have 1 virtual reality session per week.
223862977|NCT02315469|OTHER|Comprehensive Geriatric Assessment|Complete pre-operative geriatric assessment
223862978|NCT02315469|OTHER|Questionnaire Administration|Ancillary studies
223862979|NCT06164327|DRUG|BEBT-908 for Injection|BEBT-908 for Injection,dosage of administration:15mg/m\^2 or 22.5mg/m\^2，frequency and duration of administration:on the 1st,3rd,5th,8th,10th and 12th days of each cycle,and 21 days as a cycle.
223862980|NCT06164327|DRUG|Rituximab Injection|Rituximab Injection,dosage of administration:375 mg/m\^2,frequency and duration of administration:on the 1st day of each cycle, and 21 days as a cycle.
223862981|NCT06164327|DRUG|Gemcitabine Hydrochloride for Injection|Gemcitabine Hydrochloride for Injection，dosage of administration:1g/m\^2,frequency and duration of administration:on the 2nd day of each cycle, and 21 days as a cycle.
223862982|NCT06164327|DRUG|Oxaliplatin Injection|Oxaliplatin Injection，dosage of administration:100mg/m\^2,frequency and duration of administration:on the 2nd day of each cycle, and 21 days as a cycle.
223862983|NCT06164327|DRUG|Etoposide Injection|Etoposide Injection,dosage of administration:100mg/m\^2，frequency and duration of administration:on the 1st,2nd and 3rd days of each cycle,and 21 days as a cycle.
223862984|NCT06164327|DRUG|Ifosfamide for Injection|Ifosfamide for Injection,dosage of administration:5000mg/m\^2,24 hours of continuous intravenous drip，frequency and duration of administration:on the 2nd day of each cycle, and 21 days as a cycle.
223862985|NCT06164327|DRUG|Carboplatin Injection|Carboplatin Injection，dosage of administration:based on AUC=5, single dose ≤800 mg，frequency and duration of administration:on the 2nd day of each cycle, and 21 days as a cycle.
223862986|NCT04364594|DIAGNOSTIC_TEST|conjunctival swab|analysis of conjunctival cells (real time PCR) collected by conjunctival swabs in both eyes
224267254|NCT07140094|BEHAVIORAL|Structured mindfulness intervention|The mindfulness intervention is a series of recorded mindfulness sessions, which were created by the study team. The mindfulness recordings are between two and twenty minutes long and are accessed online.
224267255|NCT07138599|DEVICE|Virtual Reality ECMO Simulation Training|The intervention is a virtual reality simulation of an ECMO system, whereby the user is guided through the steps of how to perform an 11 step ECMO circuit check, and specific indicators of abnormal functioning are highlighted. The simulation is produced in Unreal Engine 4.23, and it simulates a virtual ICU and a virtual patient.
224267256|NCT07138599|OTHER|Instructional Video of Certified Perfusionists on Performing a Circuit Check|This intervention is a seven minute narrated high definition video in which a two certified perfusionist describe how to perform the identical eleven step circuit check on a primed Cardiohelp circuit, what to look for in terms of pathology or abnormal function, and . Participants will view the clip once on a laptop with headphones in a quiet room and may ask questions or receive clarification from the study coordinator, and this will be demonstrated on the physical ECMO machine and/or circuit present. The video conveys the checklist at reduced speed and explaining the purpose of each step and has been reviewed by the expert panel for accuracy and completeness.
224267257|NCT07138742|DRUG|Steroid eye drops|steroid eye drops will be used in control group as usual regimen in treatment of vernal keratoconjunctivitis
224267258|NCT07138742|DRUG|Tacrolimus eye drops|Compound Tacrolimus eye drops in 2 different concentrations will be assessed in treatment of vernal keratoconjunctivitis in terms of efficacy and safety being compared with steroid eye drops
224267259|NCT07139730|DRUG|Lignocaine 2% concentration solution|the effect of preoperative nebulized lidocaine on the stress response to intubation, monitored by rise in serum cortisol level post intubation
224267260|NCT07138846|DRUG|MRG004A plus best supportive care|MRG004A will be administrated as specified in the protocol.
224267261|NCT07138846|DRUG|Placebo plus best supportive care|Placebo will be administrated as specified in the protocol, following the same dose regimen as MRG004A.
224267262|NCT07139964|DIETARY_SUPPLEMENT|Vitamin D3|Participants receive oral vitamin D3 (cholecalciferol) 10,000 IU daily for 28 consecutive days, in addition to standard diabetic foot ulcer care according to hospital protocols. Vitamin D3 is provided in identical-appearing capsules. Compliance is monitored using the MMAS-8 adherence scale.
224267263|NCT07139964|OTHER|Placebo|Participants receive an oral placebo capsule daily for 28 consecutive days, in addition to standard diabetic foot ulcer care according to hospital protocols. The placebo is identical in appearance to the vitamin D3 capsule. Compliance is monitored using the MMAS-8 adherence scale.
224267264|NCT07138950|OTHER|Mulligan Bent Leg Raise (BLR) Technique|The Mulligan bent leg raise technique involves isometric contraction followed by stretches applied to the hamstring muscle in specific directions. The aim is to increase hamstring flexibility and active knee extension range of motion. The participant lay supine on an elevated bed, while the physiotherapist sat lateral to the leg to be stretched, placing the popliteal fossa of the participant's knee on their shoulder. The hip and knee of the leg to be stretched were flexed to 90°. Distraction was applied to the lower end of the femur, and the participant was asked to push the physiotherapist's shoulder with their leg and then relax. At this point of relaxation, the physiotherapist pushed the flexed knee as far forward as possible in the direction of hip flexion within a painless range. This position was held for 5 seconds at the end of the movement. Then, the neutral position was returned, and the procedure was repeated three times
224267265|NCT07138950|OTHER|Static Stretching|Participants lay supine on a stretcher with their backs straight. With the knee fully extended, the physical therapist placed the participant's leg on their shoulder and supported the ankle
224267266|NCT07140523|DRUG|SRSD107|SRSD107 is an investigational siRNA product for anticoagulants.
224267267|NCT07140523|DRUG|enoxaparin|Enoxaparin is a low molecular weight heparin \[LMWH\] indicated for Prophylaxis of deep vein thrombosis (DVT) in abdominal surgery, hip replacement surgery, knee replacement surgery, or medical patients with severely restricted mobility during acute illness.
224267268|NCT07140081|DRUG|BLX-0871|BLX-0871 Single or Multiple doses administered orally as a tablet
224267269|NCT07140081|DRUG|Placebo|Participants will receive matching placebo of BLX-0871 for each of the oral cohorts.
224267270|NCT07139600|BIOLOGICAL|CD7 CAR-T cells infusion|Autologous T cells are collected by leukapheresis, activated, and transduced with a retroviral vector encoding a CD7-specific CAR. Following fludarabine/cyclophosphamide lymphodepletion, CD7-CAR-T cells (3 × 10\^6/kg) are infused intravenously. This intervention is distinguished by its CD7 target, aiming to suppress aberrant T-cell-mediated marrow destruction and restore hematopoiesis in aplastic anemia.
224267271|NCT07139769|OTHER|No Intervention: Observational Cohort|This study phase is a qualitative exploration of participants' needs and preferences for psychosocial intervention.
224267272|NCT07138755|DRUG|Experimental|Drug: Sintilimab, 200mg IV D1 Q3W, Cisplatin, 75mg/m2 D1 IV Q3W or Carboplatin AUC 5 D1 IV Q3W, Paclitaxel or Paclitaxel liposome 135-175mg/m2 D1 IV Q3W(Squamous） Drug: Sintilimab, 200mg IV D1 Q3W, Cisplatin, 75mg/m2 D1 IV Q3W or Carboplatin AUC 5 D1 IV Q3W, Pemetrexed, 500mg/m2 D1 IV Q3W(adenocarcinoma） Radiation:Adaptive radiotherapy with V20\<20%: 1.PGTV60-66Gy/2.0-2.2Gy/30F;PTV54Gy/1.8Gy/30F;2.PGTV54-66Gy/2.0-2.2Gy/30F；3.PGTV50Gy/2.0Gy/25F
224267273|NCT03366948|OTHER|IGDT-10 self-administered questionnaire|"Patients and their parents will answer the French version of the IGDT-10 self-administered questionnaire (IGDT-10-P in the parents 'questionnaire).~The IGDT-10 is a self-administered questionnaire based on DSM-5 internet gaming disorder criteria and the IGDT-10-P is a parental version specially adapted from the IGDT-10 for this study."
224267274|NCT06894199|OTHER|The Work Shop|Employment intervention consists of 2 days (about 5 hours each) of interactive educational content focused on a variety of topics.
224267275|NCT06949410|DRUG|HER2 Vaccine|MVF-HER2 266-296 and MVF HER2 597-626 peptide vaccines
224267276|NCT07138833|DRUG|Dimethyl Fumarate Enteric-coated Capsules|Eligible 50 RMS patients will orally take dimethyl fumarate enteric-coated capsules during treatment, with an initial dose of 120 mg twice daily for 7 days, followed by a maintenance dose of 240 mg twice daily for 48 weeks
224267277|NCT07139210|OTHER|perceptual motor training|"Perceptual -motor training program:~1. Balance exercises~2. Awareness training exercises~3. Spatial awareness exercises~4. Training of shape perception exercises~5. Visual perception training exercises~6. Auditory perception training~7. Touch-kinetic perception training~8. Coordination of eye and hand, eye and leg, subtle motor actions"
224267278|NCT07139145|BEHAVIORAL|Progressive Muscle Relaxation + Standard Physiotherapy|Standard physiotherapy exercises plus PMR sessions. PMR is gradually transitioned from therapist-guided to self-directed practice across the 6 weeks.
224267279|NCT07139145|BEHAVIORAL|Standard Physiotherapy|Participants receive a 6-week standard physiotherapy program delivered twice weekly. Sessions include warm-up, weight-bearing training, balance exercises, gait training, and functional activities. The protocol focuses on improving mobility, weight-bearing capacity, balance, and functional independence. No Progressive Muscle Relaxation or additional behavioral techniques are included.
224267280|NCT07139522|DRUG|Bupivacaine|Patients will receive 20 ml of 0.25% isobaric bupivacaine.
224267281|NCT07139522|DRUG|Dexamethasone|Patients will receive 20 ml of (0.25% isobaric bupivacaine and 4mg of dexamethasone).
224267282|NCT07139522|DRUG|Magnesium sulphate|Patients will receive 20 ml of (0.25% isobaric bupivacaine and 200mg of magnesium sulphate).
224267283|NCT07139353|DRUG|Linperlisib|Linperlisib: 80 mg or 60 mg, po, qd (phase Ib); RP2D (phase II)
224267284|NCT07139353|DRUG|Chidamide|Chidamide: 20mg, po, biw
224267285|NCT07139847|DRUG|Magnesium Sulfate Infusion|Magnesium Sulfate (Experimental Group) Intravenous bolus of magnesium sulfate 30 mg/kg administered over 15 minutes immediately after induction of general anesthesia, followed by continuous infusion at 10 mg/kg/h until the end of surgery. Solutions were prepared in identical syringes and infusion bags by an anesthesia technician not involved in patient care. The preparation and administration protocol ensured blinding of participants, anesthesia providers, and outcome assessors.
224267286|NCT07139847|DRUG|0.9% Saline Infusion|ntravenous bolus and continuous infusion of 0.9% sodium chloride solution in the same volume, infusion rate, and duration as the magnesium sulfate group. Solutions were indistinguishable in appearance and prepared under the same blinding procedures.
224267287|NCT07139951|PROCEDURE|Biopsy Procedure|Undergo laparoscopy with biopsy
224267288|NCT07139951|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
224267289|NCT07139951|DRUG|Cisplatin|Given IP
224267290|NCT07139951|PROCEDURE|Computed Tomography|Undergo PET/CT
224267291|NCT07139951|DRUG|Hyperthermic Intraperitoneal Chemotherapy|Given p-HIPEC
224267292|NCT07139951|PROCEDURE|Laparoscopy|Undergo laparoscopy with biopsy
224267293|NCT07139951|PROCEDURE|Lymphadenectomy|Undergo D2 lymphadenectomy
224267294|NCT07139951|PROCEDURE|Magnetic Resonance Imaging|Undergo PET/MRI
224267295|NCT07139951|DRUG|Paclitaxel|Given IP
224267296|NCT07139951|PROCEDURE|Positron Emission Tomography|Undergo PET/CT or PET/MRI
224267297|NCT07139951|PROCEDURE|Surgical Procedure|Undergo gastrectomy and reconstruction
224267298|NCT07138638|DEVICE|High-Frequency QRS|All enrolled patients underwent HF-QRS assessment, with subsequent recording of MACE to evaluate the predictive value of HF-QRS parameters for clinical outcomes
224267299|NCT07140354|DEVICE|cervical transcutaneous spinal cord stimulation|Cervical transcutaneous spinal cord stimulation (tSCS) delivers electrical currents over the cervical spinal cord to modulate neural circuits controlling the upper extremities. This approach has been shown to facilitate motor output, improve hand and arm function, and promote neuroplasticity in individuals with cervical spinal cord injury.
224267300|NCT07138664|BEHAVIORAL|Super Skills for Life program|Study-Skills program will be implemented in a group format (45-60 minutes per session) in 8 weekly sessions, covering: note-taking skills, effective study strategies, and time management.
224267301|NCT07138664|BEHAVIORAL|Study-Skills program|Study-Skills program will be used as a comparator intervention, which will be implemented in a group format (45-60 minutes per session) in 8 weekly sessions, covering: note-taking skills, effective study strategies, and time management.
224267302|NCT07138703|BEHAVIORAL|Mobile based intervention program|The participants in this group will be using the mobile application
224267303|NCT07139704|BEHAVIORAL|Mindfulness-Based Sexual Counseling (MBSR-BA)|A MBSR-based sexual counseling program applied to women after episiotomy, 2 sessions per week for 4 weeks, 8 sessions in total.
224267304|NCT00023166|DRUG|PEG-paclitaxel|
224267305|NCT05738421|DIAGNOSTIC_TEST|fiberoptic endoscopic evaluation of swallowing|Questionnaire, FEES, OPES
224267306|NCT04247243|DEVICE|Rapid testing|Abbott ID NOW Strep A testing
224267307|NCT04247243|DIAGNOSTIC_TEST|Reference testing|Culture-based testing
224267308|NCT06358963|DRUG|Receive 30 mg of Coq10|Group A received 30 mg of CoQ10, Group B was given 200 mg of Omega-3 daily supplements, and Group C did not receive any medication; after the two-month study period, teh clinical periodontal parameters were reassessed. Additionally, to compare teh total antioxidant capacity in saliva before and after teh intake of these supplements, as well as in patients who did not receive any medication, 2 ml of non-stimulated saliva was collected from each participant at teh beginning and end of teh study for analysis using UV-spectrophotometric methods, furthermore, teh following criteria determined teh selection of eligible participants for dis study.
224267309|NCT06358963|DRUG|Non-Medicare Drugs|and Group C did not receive any medication; after the two-month study period, the clinical periodontal parameters were reassessed. Additionally, to compare teh total antioxidant capacity in saliva before and after teh intake of these supplements, as well as in patients who did not receive any medication, 2 ml of non-stimulated saliva was collected from each participant at teh beginning and end of teh study for analysis using UV-spectrophotometric methods, furthermore, teh following criteria determined teh selection of eligible participants for dis study.
224267310|NCT01016340|DRUG|MCS|MCS-5 Softgel 5 mg
224267311|NCT06361550|OTHER|VENREDI group|Practical seminars aimed at improving the Mediterranean diet, guided by researchers.
224267312|NCT06361550|OTHER|Health education|Health education on Mediterranean diet
224267313|NCT00605150|RADIATION|TheraSphere-Yttrium 90 microsphere|TheraSphere is delivered to the liver via a catheter placed into the femoral artery and guided by fluoroscopy to the hepatic artery. Once the catheter is properly positioned, the physician infuses TheraSphere, which localizes preferentially in the tumor.
224267314|NCT06024031|DRUG|N-acetyl-L-cysteine|N-acetyl-L-cysteine (Yiweishi) capsules (Guangdong Renrenkang Pharmaceutical Industry) will be given orally 400mg three times a day from day 1 to day 28 after chemotherapy. In case of drug allergy such as nausea, vomiting, rash and bronchospasm, and disease relapse, to discontinue the drug immediately.
224267315|NCT02760355|DRUG|Ledipasvir 90 mg/Sofosbuvir 400 mg|Oral administration on one fixed dose combination tablet for 12 weeks
224267316|NCT02760355|DRUG|Ribavirin|Oral administration of body weight-dose adjusted, 200 mg-tablets of ribavirin (1,000 mg in two administration in patients \<75 Kg of body weight, or 1,200 mg in two administrations for those \>75 Kg) for 12 weeks.
224267317|NCT00107016|DRUG|RAD001, Letrozole 2.5mg|
224267318|NCT00107016|DRUG|Letrozole 2.5mg|
224267319|NCT04067193|OTHER|usability survey|usability survey composed of subpart: System Usability Scale, questions about ergonomic, questions about design, question about global satisfaction.
224267320|NCT06467097|RADIATION|SBRT(Stereotatic Body Radiation Therapy)|Patients will receive treatment for one to two weeks, one to five times per region.
224267321|NCT05356481|DEVICE|segmental muscle vibration|Segmental muscle vibration will delivered over the target muscles by means of vibrator with general physical therapy session
224267322|NCT03224143|BEHAVIORAL|Doll Therapy Intervention|"Daily sessions, lasting an hour, will take place in a room known to patients (P). The only people in the room will be a nurse (N) and the researcher with video-tape, never interacting with P. The procedure is: the N will accompany the P in the room and the P will take a seat. The N will put the doll in front of the P and will say Good morning Mr./Mrs....look, with a quiet voice. If the P will not take it at the first attempt, the N will sit down in front of her holding the doll in the arms and will wait for 2 minutes. The N will invite the PWD again. If the P will not take the doll after the second request, the N will not insist and she will leave. If the doll will be taken, the N will leave the P and say I have to go, goodbye Mr./Mrs. . . ... The gaze will always be upon the P."
224267323|NCT03224143|BEHAVIORAL|active control group (SI)|"Daily sessions, lasting an hour, will take place in a room known to patients (P). The only people in the room will be a nurse (N) and the researcher with video-tape, never interacting with P. The procedure is: the N will accompany the P in the room and the P will take a seat. The N will put the cube in front of the P and will say Good morning Mr./Mrs....look, with a quiet voice. If the P will not take it at the first attempt, the N will sit down in front of her holding the cube in the arms and will wait for 2 minutes. The N will invite the PWD again. If the P will not take the cube after the second request, the N will not insist and she will leave. If the cube will be taken, the N will leave the P and say I have to go, goodbye Mr./Mrs. . . ... The gaze will always be upon the P."
224267324|NCT00337493|DRUG|mycophenolate mofetil [CellCept]|Concentration-controlled
224267325|NCT00337493|DRUG|mycophenolate mofetil [CellCept]|1g po bid
224267326|NCT00337493|DRUG|Cyclosporine or tacrolimus|Reduced
224267327|NCT00337493|DRUG|Cyclosporine or tacrolimus|Standard, as prescribed
224267328|NCT04964687|PROCEDURE|Liver transplantation|Liver transplantation
224267329|NCT01872676|OTHER|Spine manipulation|
224267330|NCT01872676|OTHER|Manipulation sham|
224267331|NCT04852627|BEHAVIORAL|Brisk walking|Walking
224267332|NCT04899934|BEHAVIORAL|mobile and technology assisted aftercare|The mobile and technology assisted aftercare consists of mobile mental health professionals who travel to participants to provide mental health services including counseling, navigation of community referrals, motivational interviewing, solution focused therapy, psycho-education, and social support. Participants randomized to this condition will also receive 24/7 access to evidence-based behavioral health mobile applications that are recommended based on the participant's diagnostic status, learning style, and goals. Frequency of app use is up to the participant's discretion. However, during weekly aftercare sessions, the CSS may assist the participant with creation of an app use schedule that is realistic for the participant's needs and treatment goals.
224267333|NCT04899934|OTHER|Treatment as usual|Treatment as usual services include a personalized discharge plan, a follow up appointment within a month of discharge for evaluation and connection to other agency services if applicable. Some of these services may include outpatient counseling for behavioral and emotional problems, psychiatric services, group therapy, case management, rehabilitation services, homeless recovery services, employment services, medication-assisted treatment, group-based team building activities, primary care clinic, and forensic services. Individuals may also receive ancillary referrals for applicable healthcare services, access to residential and outpatient substance abuse treatment services, and access to a tablet.
224267334|NCT04605835|DIAGNOSTIC_TEST|ULTRASONIC VISUALIZATION OF OBSTRUCTIVE UROPATHIES IN CHILDREN.|The purpose of this study was to develop proposals and recommendations for improving the safety of urological examination of children with obstructive uropathy by using Doppler ultrasound. Based on the results of a comprehensive urological examination of 665 children with congenital ureteral obstruction, a program for scoring the results of ultrasound examination has been developed, which allows using the safest and most informative methods to reliably determine the functional state of the renal parenchyma and the degree of urodynamic disorders in children with obstructive uropathy.
224267335|NCT06174558|DEVICE|Sleep Tracking Devices|Observational Study, Smartwatches and home sleep device for sleep and respiratory monitoring
224267336|NCT04388358|DRUG|Shin-yi-san + Xiao-qing-long-tang + Xiang-sha-liu-jun-zi-tang by the weight of 9g+3g+3g/day|All patients were treated with mixed formula of Chinese medicine for one month
224267337|NCT03007524|DRUG|High dose Rosuvastatin|20mg/d qN, at least 6 months
224267338|NCT03007524|DRUG|Low dose Rosuvastatin|10mg/d qN, at least 6 months
224267339|NCT01939990|DRUG|Placebo|The placebo looks like the study drug but it does not contain active ingredients.
224267340|NCT01939990|DRUG|Nebivolol|5 to 10mg per day
224267341|NCT00483743|DRUG|TPI 1020|250 mcg/caps 2 caps BID x 42 days
224267342|NCT00483743|DRUG|Budesonide|400mcg mcg capsules- 2 capsules BID
224267343|NCT00483743|DRUG|Placebo|2 caps BID x42 days
224267344|NCT06314633|OTHER|Hair cut|Hair locks and follicles will be cut twice in winter and spring
223862987|NCT05824546|PROCEDURE|Intervention Arm (uSINE-PAMS-technique)|Patients will be lying in a lateral recumbent position and in a fetal position with the neck, back and limbs held in flexion. L3-L4 inter-vertebral space will be identified by palpation of external landmarks of the patients' iliac crests and spinous process of lumbar vertebrae L3, L4 and L5 and confirmed using uSINE-integrated ultrasound. The angle of needle during needle advancement will also be determined using the uSINE-integrated ultrasound. Markings on the patients' skin surface will be made using PAMS (non-sterile component) to enable relocation of the site and angle of the needle entry. Patients' back will be cleaned and draped using aseptic technique. Next, local anaesthesia is infiltrated into the previously identified needle entry site before the LP needle is inserted with location and angulation according to PAMS (sterile component) guidance.
223862988|NCT03829813|OTHER|Music therapy|20 to 40 minute music therapy treatment session with a qualified music therapist.
223862989|NCT03749044|OTHER|Patient Educational Tool|This tool is a modified version of the patient educational sheet elaborated and validated by You et al in collaboration with the Preeclampsia Foundation. This patient educational sheet graphically defines preeclampsia and its. A licensing agreement has been obtained from the Preeclampsia Foundation, with the rights to modify the educational tool for this RCT. The SLE-specific educational tool will consist in a sheet displaying the previously developed patient educational form on the recto. However, on the verso of the sheet, SLE-specific information related to the risk of preeclampsia in SLE pregnancies and the estimated efficacy of ASA in reducing preeclampsia risk in women at high risk are displayed.
223862990|NCT01852526|DEVICE|Experimental: hybrid system|The intervention group will receive a hybrid system with PLIF and a flexible pedicle screw system above the fusion. Surgery will be performed using the following devices (Dynamic Rod® Hersteller: AESCULAP AG, Tuttlingen
223862991|NCT01852526|DEVICE|Active Comparator: Plif|monosegmental PLIF
223862992|NCT00094575|PROCEDURE|Endovascular Repair|Endovascular Repair
223862993|NCT00094575|PROCEDURE|Standard Open Repair|Standard Open Repair
223862994|NCT03199781|DEVICE|Motorized mechanical massage with the Dermothonus Slim® Ibramed with cosmetics|Patients will be treated with motorized mechanical massage with the Dermothonus Slim® electromedical equipment (Ibramed- Brazilian Industry of Electrical Equipment) associated with cosmetics with lipolytic active principle, being performed twice a week totaling 10 sessions by a dermato-functional physiotherapist.
223862995|NCT00188136|DRUG|Melphalan, ATG, Fludarabine|allo Tx during aplasia
223862996|NCT01625013|DEVICE|Synvisc-One (G-F 20)|Synvisc G-F 20 will be injected in the symptomatic knee using a standard supine lateral approach using a 20-gauge needle. Patients will be treated at baseline and followed out to three years. Patients may return for retreatment as early as 4 months post their prior injection if they meet the retreatment criteria pain levels for Worst Knee Pain. If the subjects need another injection, the follow-up cycle will restart at Visit 1 and the subject will be seen every 6 months and followed-up for 3 years.
223862997|NCT03958734|OTHER|High-fat meal|Participants will be given a serving of Marie Callendar's Chocolate Satin Pie to eat over a period of 20 minutes
223862998|NCT01398124|BIOLOGICAL|Cyclin B1 Peptide|vaccine
223862999|NCT05516927|DIAGNOSTIC_TEST|Freenome Test|Participants who provide informed consent, meet the eligibility criteria and provide a blood sample for this study will be enrolled.
223863000|NCT03809299|OTHER|Ad libitum meal timing|Research participants will eat meals provided by the study throughout the day, ad libitum
223863001|NCT03809299|OTHER|Twice a day meals|Research participants will eat meals provided by the study at two intervals during the day, and fast in between.
223863002|NCT04133974|BEHAVIORAL|methadone induced memory retrieval-extinction procedure|Drug memory is not invariably stable and can be induced transiently labile again by drug-related cues or drug itself, which is termed as 'reconsolidation'. Previously we and other groups have demonstrated that extinction coincided with reconsolidation weakened the drug memory and decreased drug craving and relapse. In the present study, we tried to interfere the methadone-induced heroin addiction memory reconsolidation by extinction given at different times following methadone administration.
223863003|NCT03855709|DIAGNOSTIC_TEST|microbiological culture and sensetivity|microbioloical culture will be used to detect microbiological profile in hepatic patients with infections, drug sensitivity to detect resistent bacteria which will be confirmed using PCR detection of resistent gene
223863004|NCT03367494|DIAGNOSTIC_TEST|Measurement of Sweat Chloride and Sweat Bromide|Sweat Chloride comparisons between ion exchange chromatography and fluorescence citrate-based sensors
223863005|NCT01981330|BIOLOGICAL|aMSC|aMSC injected into the vocal fold of the patient
223863006|NCT01981330|BIOLOGICAL|aMSC+hyaluronan gel|aMSC+ hyaluronan gel is injected into the patients vocal fold
223863007|NCT06208696|OTHER|"Tomando control de su salud (Spanish Chronic Disease Self-Management)"|"Tomando control de su salud (Spanish Chronic Disease Self-Management) is a culturally appropriate program developed in Spanish to support Hispanics patients to build confidence in their ability to manage their health. This intervention was developed by Lorig et al. at Stanford University and has been widely used by the Puerto Rico Department of Health since it is recommended by the CDC as an evidenced-based intervention for chronic disease management."
223863008|NCT04346888|DRUG|HBM9161 Injection (680mg and 340 mg)|HBM9161 Injection (680mg and 340mg)
223863009|NCT04346888|DRUG|Placebos|Placebo, HBM9161 Injection (340mg)
223863010|NCT04346888|DRUG|HBM9161 Injection (340 mg)|HBM9161 Injection (340 mg)
223863011|NCT03414710|BEHAVIORAL|Health education booklet plus video plus brief counseling|Participants in the intervention group will receive a health education booklet, watch a 10-minute video and receive counseling provided by the clinicians
223863012|NCT03414710|BEHAVIORAL|Health education booklet only|Participants in the intervention group will only receive a health education booklet
223863013|NCT06141577|DRUG|UI059|take UI059 1cap/day for 7 days
223863014|NCT06141577|DRUG|UIC202201|take UIC202201 1cap/day for 7 days
223863015|NCT01927952|PROCEDURE|Kirschner wire|Surgical fixation utiliziing Kirschner wire
223863016|NCT01927952|PROCEDURE|Integra IPP-On PIP Fusion System|surgical fixation utilizing the Integra IPP-On PIP Fusion System
223863017|NCT01927952|PROCEDURE|Stryker Smart-Toe Implant|surgical fixation utilizing the Stryker Smart-Toe Implant
223863018|NCT05161507|PROCEDURE|Magseed|Patients with the non-palpable histologically confirmed breast cancer lesion - the tumor lesion will be labeled with Magseed and patient will undergo breast-conserving surgery and sentinel lymph node detection with Tc99.
224267345|NCT06314633|OTHER|Socio-economic questionnaires|Information about parents education levels and professional occupation, geographic area, children gender, indoor and outdoor children's environmental exposures
224267346|NCT00533156|DEVICE|Vascular access site closure (7F Ensure)|
224267347|NCT05183451|PROCEDURE|En- masse retraction and LLLT|"Retraction will start on a 0.019x0.025 Stainless steel wire using NiTi closed coils (force applied will be 200 g per side) extending between the crimpable hooks and the TADs. LLLT will be applied on days 0,3,7,14 from extraction then repeated biweekly till the end of retraction."
224267348|NCT05183451|PROCEDURE|En- masse retraction without LLLT|"Retraction will start on a 0.019x0.025 Stainless steel wire using NiTi closed coils (force applied will be 200 g per side) extending between the crimpable hooks and the TADs."
224267349|NCT02750878|OTHER|Informational Handout|
224267350|NCT02579577|OTHER|Observation|Observation of clinic appointments and ward rounds if the child is admitted to hospital during the study period.
224267351|NCT02579577|OTHER|Interviews|Semi-structured interviews will be conducted approximately 3 times during the study period with each participant.
224267352|NCT02579577|OTHER|Medical notes review|The child's electronic medical record will be accessed periodically to identify any planned appointments or periods of hospitalisation and their medical notes will also be reviewed at the end of the study.
224267353|NCT04218487|DRUG|Xuefu-Zhuyu Capsule|treatment with 2.4g (6 capsules) of XFZY three times daily for 12 weeks.
224267354|NCT04218487|DRUG|placebo|treatment with 2.4g (6 capsules) of placebo three times daily for 12 weeks.
224267355|NCT04218487|OTHER|conventional therapy|conventional therapy will be given according to the suffering diseases including stable coronary heart disease, chronic insomnia, headache, endometriosis.
224267356|NCT01216865|BIOLOGICAL|umbilical cord mesenchymal stem cells|5\*10/7 per ischemic limb
224267357|NCT01216865|DRUG|Standard Therapy|Any thing directed to improve blood perfusion in the limb example.Heparin,Antiplatelet agents etc
224267358|NCT02772822|DRUG|SCT400 plus CHOP|
224267359|NCT02772822|DRUG|Rituximab plus CHOP|
224267360|NCT05946239|OTHER|Manage My Pain App|This digital application helps patients measure, track, and manage chronic pain, functionality, and medication use. MMP can also be used to share patient pain experiences with their circle of care via reports and offers educational resources for patients.
224267361|NCT02583048|DRUG|Bedaquiline|Four 100 mg tablets (400 mg) orally once a day for 2 weeks, followed by two 100 mg tablets (200 mg) orally three times a week for 22 weeks.
224267362|NCT02583048|DRUG|Delamanid|Two 50 mg tablets (100 mg) orally with food twice a day for 24 weeks.
224267363|NCT02583048|DRUG|Dolutegravir|For HIV-positive participants only: one 50 mg tablet orally once daily, to be used in combination with two NRTIs until study completion. (NRTIs were not provided by the study.)
224267364|NCT02583048|DRUG|Multidrug Background Treatment (MBT) for TB|A standardized MBT regimen for MDR- or RR-TB except in cases where a participant had known resistance to one of the components of local standard treatment. MBT was provided by the local program.
224267365|NCT00015925|DRUG|entinostat|
224267366|NCT02155257|DRUG|Modafinil|
224267367|NCT02155257|DRUG|Gabapentin|
224267368|NCT02155257|DRUG|Placebo|
224267369|NCT01030796|BEHAVIORAL|Caffeine abstinence|Brief instruction on beginning and maintaining caffeine abstinence.
224267370|NCT06103383|DRUG|Controlled ovarian stimuation|3 days stimullation protocol using hMG-HP
224267371|NCT06103383|PROCEDURE|Oocyte pick up|Surgical oocyte pick up without triggering
224267372|NCT06103383|PROCEDURE|Oocyte in vitro maturation|In vitro maturation procedure
224267373|NCT06103383|PROCEDURE|Oocyte in vitro activation|In vitro oocyte activation procedure
224267374|NCT01851876|DEVICE|Endometrial injury|Endometrial injury with Endometrial Suction Curette (pipelle) will be performed.
224267375|NCT00162929|BIOLOGICAL|AdHer-2/neu transduced dendritic cells|Group 1 1 ×10'7 expanded cells (2.5 ×106 DCs per injection site) Group 2 5 ×10'7 expanded cells (1.25 ×107 DCs per injection site) Group 3 1 ×10'8 expanded cells (2.5 ×107 DCs per injection site)
224267376|NCT01151280|DEVICE|WallFlex Biliary Fully Covered Stent|Investigational device evaluated for the treatment for benign biliary strictures
224267377|NCT06113549|PROCEDURE|Knee Joint Distraction (KD)|Knee joint distraction (KJD) is a joint-preserving treatment for knee OA for younger patients, where the knee joint is temporarily fully unloaded by distraction of tibia and femur, using an external fixation frame.KJD treatment is performed according to the current approved concept NOV recommendations for clinical practice.
224267378|NCT06113549|PROCEDURE|Knee Prosthesis|A total or unicompartmental knee prosthesis
224267379|NCT01243151|BIOLOGICAL|PF-04950615 (RN316)|Infusion every week
224267380|NCT01243151|BIOLOGICAL|PF-04950615 (RN316)|Infusion every week
224267381|NCT01243151|BIOLOGICAL|PF-04950615 (RN316)|Infusion every week
224267382|NCT01243151|BIOLOGICAL|PF-04950615 (RN316)|Infusion every week
224267383|NCT01243151|BIOLOGICAL|PF-04950615 (RN316)|Infusion every week
224267384|NCT04210544|DIETARY_SUPPLEMENT|Experimental dietary protein|Breakfast intake consisted on a 250 g custard intake mixed with 20 g of the experimental protein accompanied by a glass with 50 mL water.
224267385|NCT04210544|DIETARY_SUPPLEMENT|Casein|Breakfast intake consisted on a 250 g custard intake mixed with 20 g of casein accompanied by a glass with 50 mL water.
224267386|NCT04210544|DIETARY_SUPPLEMENT|Water|Breakfast intake consisted on a 250 g custard intake mixed with 20 g of water accompanied by a glass with 50 mL water.
224267387|NCT01816789|DRUG|rFSH|
224267388|NCT01816789|DRUG|buserelin|
224267389|NCT01780467|BEHAVIORAL|Role of dopamine|
224267390|NCT03123874|DEVICE|Sterile pump set-up|Medela symphony breast pump (model number 0240108) and disposable, sterile collection kits (model number 67399S).
224267391|NCT03123874|DEVICE|Mother's Own pump set-up|Mother's own electric breast pump and own collection kit (previously used and cleaned at home using her usual practices).
224267392|NCT00057226|DRUG|Radafaxine|
224267393|NCT03997890|PROCEDURE|Cataract surgery with binocular implantation of either Symfony (ZXR00) or Symfony toric (ZXT) IOLs|After creating an initial side port incision with a 15-degree blade, 3-step clear corneal incisions were made using a 2.5 mm disposable metal blade. Sodium hyaluronate 1.0% (Healon; Abbott Medical Optics) was then injected into the anterior chamber. A continuous curvilinear capsulorrhexis, measuring 5.5 mm in diameter, was generated using a 26 gauge bent needle. After hydrodissection, phacoemulsification was done to remove nuclear fragments and aspiration of residual cortex. In all eyes, a Symfony or Symfony toric IOL was implanted in the capsular bag using a disposable implantation system. Irrigation and aspiration were performed to minimize ophthalmic viscoelastic surgical device retention at the end of surgery. The main incision and side port were sealed with stromal hydration using a balanced salt solution.
224267394|NCT06266741|DIAGNOSTIC_TEST|Lubricin|Plasma lubricin levels can potentially serve as a biomarker in situations like endocardial injury and infection.
224267395|NCT02308241|DRUG|Ribavirin|self-administer ribavirin 1400 mg PO BID (total dose, 2800 mg/day)
224267396|NCT01756313|PROCEDURE|Laser+Methylaminolevulinat|It's a single arm study. Intervention as described in detailed description.
224267397|NCT04383249|DIAGNOSTIC_TEST|Pathology result|Pathology result of the hernia sac
224267398|NCT04381741|BIOLOGICAL|CD19-7×19 CAR-T plus PD1 monoclonal antibody|Three different doses of CD19-7×19 CAR-T (1×106/kg、2×106/kg、3×106/kg) plus 200mg Tislelizumab every 3 weeks for 6 times
224267399|NCT00850551|OTHER|Early Intervention|Twice a week home spirometry and symptom assessment
224267400|NCT04889365|DIAGNOSTIC_TEST|SG Diagnostics COVID-19 Antigen Rapid Test Kit|SG Diagnostics COVID-19 Antigen Rapid Test Kit (self-use)
224267401|NCT04889365|DIAGNOSTIC_TEST|Polymerase chain reaction (PCR) test|Professional collection of a second swab sample, for confirmation by PCR
224267402|NCT04408924|DRUG|Abemaciclib|Administered orally
224267403|NCT04842019|DRUG|KRN23|KRN23 is a sterile clear colourless and preservative free solution supplied in single use 5 mL vials containing 1 mL of KRN23 at a concentration of 30mg/mL
224267404|NCT05440968|OTHER|Point of Care - Glycated Hemoglobin (A1c)|Test for diagnosis of Diabetes through a Point of care device
224267405|NCT05440968|OTHER|Oral Glucose Tolerance Test|Routinary diagnosis diabetes test by venous blood sample
224267406|NCT06332690|DEVICE|dexamethasone implant|Intravitreal dexamethasone implant (Dex) slowly releases steroids into the vitreous over a period of up to 6 months. Dex 0.7 mg (Ozurdex™; Allergan, Irvine, CA, USA) has been used to reduce ME in patients with DR and RVO and its efficacy in terms of best corrected visual acuity (BCVA) improvement and central macular thickness (CMT) reduction has been demonstrated in many different studies.
224267407|NCT01273467|DRUG|CNTO 0007 or placebo (Stage A)|a single IV infusion of a selected dose of CNTO 0007 or placebo administered IV within 1-5 days (depending on cohort) after stroke (first cohort of patients will receive the lowest dose of CNTO 0007 or placebo and each subsequent group will be administered a higher dose (to be determined)
224267408|NCT01273467|DRUG|CNTO 0007 or placebo (Stage B)|a single IV infusion of the MTD of CNTO 0007 or placebo administered IV within a specified number of days after stroke
224267409|NCT02385760|DRUG|CTX-4430|
224267410|NCT02385760|DRUG|Placebo|
224267411|NCT03184649|DRUG|Ibuprofen|It is a pre-analgesic will be taken before painful procedures.
224267412|NCT03184649|DRUG|paracetamol|it is a pre-analgesic drug will be taken before painful procedure.
224267413|NCT03184649|DIETARY_SUPPLEMENT|A fruit-flavored orange color placebo solution|orange juice as a comparative group.
224267414|NCT02578641|BIOLOGICAL|autologous EBV specific Cytotoxic T cells|The CTL line will be prepared by co-cultivation of the irradiated EBV-LCL with patient PBMC. A proportion of peripheral blood will be used to generate EBV specific CTLs.
224267415|NCT02578641|DRUG|combination IV gemcitabine and IV carboplatin (AUC2)|4 cycles for Arm A and 6 cycles for Arm B
224267416|NCT06628089|OTHER|Questionnaire|A questionnaire for primary healthcare physicians designed to evaluate knowledge about H. Pylori mode of transmission, symptoms, complications and treatment.
224267417|NCT04510792|OTHER|No intervention|No intervention
224267418|NCT01444196|DRUG|Desloratadine|Every day,per mouth,in the evening, for 14 +- 2 days.
224267419|NCT05376423|BIOLOGICAL|OBI-833/OBI-821|OBI-833 and OBI-821 are individually formulated into separate glass vials. The articles are mixed prior to subcutaneous administration at the clinic.
224267420|NCT04027023|DRUG|Diabetes mellitus Type 2 De-escalation treatment (DET)|"All employed drugs are approved in the US for treatment of type 2 diabetes and are used within their label. There will be defined individual treatment drug combinations at an earlier stage of diabetes as in standard treatment. The DET combination will be composed out of one each or more of the drugs and interventions listed below.~A. Relieve for the insulin-producing ß-cells insulin glargine (6 to 20 U at bedtime) insulin degludec (5 to 15 U at bedtime) B. Reduction of hormonal visceral lipid tissue activity/chronic inflammation Weight loss liraglutide (0.6 mg/day) exenatide (15 µg/day) C. Treatment of metabolic and vascular insulin resistance Pioglitazone (30 mg) D. Treatment of glucose toxicity Empagliflozin (SGLT-II inhibitor; 10 mg) Dapagliflozin (SGLTII-Inhibitor, 10 mg) Canagliflozin (SGLT-II inhibitor, 100 mg) Metformin (inhibition of hepatic glucose production, 500 mg)~To avoid hypos, all drugs are initially given in the lowest possible dose."
224267421|NCT02963350|DRUG|BMN190, recombinant human tripeptidyl peptidase-1 (rhTPP1)|
224267422|NCT02597257|DRUG|Lidocaine HCl|lidocaine continuous infusion
224267423|NCT02597257|DRUG|Normal saline|Normal saline continuous infusion
224267424|NCT00479531|DEVICE|AirCast Sequential Compression Device|
223863019|NCT05161507|PROCEDURE|Magtrace|Patients with the palpable histologically confirmed breast cancer lesion - The Magtrace will be injected preoperatively into the tumor and detected by Sentimag. Patient will undergo sentinel lymph node detection with Tc99 and Sentimag localization system with breast surgery.
223863020|NCT05161507|PROCEDURE|Axillary lymph node metastasis - needle biopsy|Patients with the histologically confirmed breast cancer lesion with Axillary lymph node metastasis with pathologic confirmation by needle biopsy - the positive axillary lymph node lesion will be labeled with Magseed before the neoadjuvant systemic therapy, and later during target axillary dissection will be performed the biopsy of labeled lymph node during breast surgery.
223863021|NCT04747457|DEVICE|Research FibroScan|"After having obtained the patient's Informed Consent Form signature, the following 3 examinations will be done:~1. Standard examination \[Reference CE-marked FibroScan\]: the operator will need to find an optimal measurement area, and perform 10 valid measurements.~2. Standard examination \[Research FibroScan\]: the operator must take 15 valid measurements at the same measurement point as the one used for the examination with the Reference FibroScan.~3. Exploratory examination \[Research FibroScan\]: the operator needs to perform15 invalid measurements to acquire data in non-optimal regions of measurement (lungs, vessels, intestines, ribs, edges of the liver)."
223863022|NCT02050724|DRUG|Radioactive labelling of pulmonary nodules|Application directly into a pulmonary nodule
223863023|NCT02050724|DEVICE|CT guided radioactive labelling|CT guided puncture is a standard procedure in radiology. In this study it is used to mark pulmonary nodules for the following thoracoscopic surgery, done with a handheld-SPECT device.
223863024|NCT02050724|DEVICE|Electromagnetic guided bronchoscopic radioactive labelling|Electromagnetic guided bronchoscopy is a standard procedure. In this study it is used to mark pulmonary nodules.
223863025|NCT00003604|BIOLOGICAL|aldesleukin|
223863026|NCT03324152|OTHER|High-intensity interval training (HIIT) - myositis|12-weeks of 3 days/week HIIT. 6 sets of 30-60 seconds on 85-100% of maximal heart rate performed on a stationary bike followed by resistance training on 10 voluntary repetition maximum.
223863027|NCT03324152|OTHER|Standard low-intensity home exercise|12 weeks of 5 days/week low-intensity resistance home exercise in combination with outdoor walks of 20 minutes.
224267425|NCT04385043|OTHER|plasma hyperimmune|patients will receive this as add on therapy
224267426|NCT04385043|DRUG|standard therapy|patients will receive only standard therapy for Covid-19 infection
224267427|NCT02889393|DRUG|Teduglutide|Daily 0.05 mg/kg Teduglutide administered subcutaneously.
224267428|NCT02889393|OTHER|Standard of Care|The standard of care treatment of ECF which includes meticulous wound care, optimizations of nutrition, use of acid-suppression medications and anti-motility agents as per treating physician discretion.
224267429|NCT03755180|OTHER|Exercise Training|In exercise training, aerobic exercise and strengthening exercises, especially for gastrocnemius and tibialis anterior muscles, will be applied to the patients. In addition the exercise training, Compression Therapy is applied to patients.
224267430|NCT03755180|OTHER|Compression Therapy|Compression therapy is a treatment applied to patients in the form of Four Layer Compression Bandage and Compression Stocking. Four Layer Compression Bandage is a treatment that requires four different types of bandages. The compression stocking is an elastic stock with various tension and length.
224267431|NCT04516096|DRUG|AMX0035|Tauroursodeoxycholic Acid and Sodium Phenylbutyrate orally given twice a day
224267432|NCT02263768|PROCEDURE|Oral clinical conditions|Caries incidence assessment dental anxiety assessment oral health related quality of life assessment time and costs assessment
224267433|NCT00084864|DIETARY_SUPPLEMENT|calcitriol|Given orally
224267434|NCT00084864|DRUG|dexamethasone|Given orally
224267435|NCT00084864|OTHER|clinical observation|No intervention before surgery
224267436|NCT01459601|DRUG|Cabergoline|0,5mg per week
224267437|NCT02355262|OTHER|Informational Intervention|Receive CATCH-UP intervention
224267438|NCT05205096|BIOLOGICAL|Recombinant novel coronavirus vaccine (CHO cells)|At 3-9 months after the immunization with 2 doses of inactivated vaccine (CoronaVac), 1 dose of recombinant novel coronavirus vaccine (CHO cells) is vaccinated.
224267439|NCT04589364|DRUG|Injection botulinum toxin A ( Dysport 100 unit or Neuronox 33.33 unit)|injection of toxin on facial muscle
224267440|NCT01600339|DRUG|CABAZITAXEL|The patients are planned to receive cabazitaxel at a starting dose of 25 mg/m(2) intravenously over 1 h, following premedication as accepted with cabazitaxel. Treatment cycles are every 3 weeks. All patients will receive primary GCSF support.
224267441|NCT00599105|PROCEDURE|magnetic resonance imaging|MRI contrast agent, 0.1 mmol/kg
224267442|NCT00209547|DRUG|fospropofol disodium|
224267443|NCT03334149|OTHER|Self-Monitoring of Blood Pressure|"BUMP 1: Women randomised to the self-monitoring arm will be asked to measure blood pressures at least three times a week. They will perform two readings with a one minute interval and will be asked to act on the second reading if it falls outside their normal range thresholds described in their instructions, and aided by the tele monitoring system.~BUMP 2: Women randomised to the self-monitoring arm will be asked to measure blood pressures daily. They will perform two readings with a one minute interval and will be asked to act on the second reading if it falls outside their normal range thresholds described in their instructions, aided by a tele monitoring system."
224267444|NCT04271072|OTHER|No intervention|No intervention
224267445|NCT06330649|DIETARY_SUPPLEMENT|Energy Drink|This is a commercially available energy drink
224267446|NCT06330649|OTHER|Water Control|This is a commercially available bottled water
224267447|NCT02466490|DRUG|Fimasartan|Fimasartan tablets
224267448|NCT02466490|DRUG|Fimasartan; Hydrochlorothiazide|Fimasartan plus hydrochlorothiazide fixed dose combination tablets
224267449|NCT02501863|DRUG|Femoral nerve block with ropivacaine+fentanyl|Ropivacaine+fentanyl are used for continuous femoral nerve block, spinal anesthesia, IV-PCA with hydromorphone
224267450|NCT02501863|DRUG|Femoral nerve block with ropivacaine|Ropivacaine is used for continuous femoral nerve block, spinal anesthesia, IV-PCA with hydromorphone
224267451|NCT05031858|OTHER|Respiratory physiotherapy|Respiratory physiotherapy
224267452|NCT04594434|OTHER|Scale SUD|Subjective Units of Distress Scale ou Subjective Units of Disturbance Scale is a scale of subjective appreciation of emotions
224267453|NCT04594434|OTHER|VOC scale|The VOC (Validity Of Cognition) scale is a scale of value given to cognition.
224267454|NCT04594434|OTHER|DES II scale|The Dissociative Experiences Scale (DES), which is translated as the Dissociative Experiences Scale, is a self-questionnaire to assess the frequency of various dissociative symptoms in the patient's daily life.
224267455|NCT01545349|BIOLOGICAL|Lactobacillus rhamnosus GG ATCC 53103 (LGG)|Study drug capsules (1x10\^10 LGG/capsule) are to be taken orally twice a day every day on an outpatient basis for 28 days
224267456|NCT01545349|BIOLOGICAL|Placebo|Placebo capsules composed of microcrystalline cellulose are to be taken orally twice a day on an outpatient basis for 28 days.
224267457|NCT01545349|BIOLOGICAL|Live attenuated influenza vaccine|0.2 mL pre-filled, single use intranasal spray
224267458|NCT03028545|BEHAVIORAL|Collection of the individual narrative, semi-directed interviews|Visit one : individual interview Individual narrative Passing Psychometric Measurement Scales of Recovery: Score at Warwick and Wellness Scale Andreasen scale score Visit two Focus group
224267459|NCT00199654|PROCEDURE|PET|
224267460|NCT03406845|BEHAVIORAL|Chair-side mindfulness intervention|"Tailored mindfulness intervention to chair-side type, based from Mindfulness Based Cognitive Therapy (MBCT).~Health promotion based on the Health Enhancement Program (HEP)."
224267461|NCT01741545|BIOLOGICAL|Pegylated-Interferon-lambda|
223863028|NCT03324152|OTHER|High-intensity interval training (HIIT) - healthy|12-weeks of 3 days/week HIIT. 6 sets of 30-60 seconds on 85-100% of maximal heart rate performed on a stationary bike followed by resistance training on 10 voluntary repetition maximum.
223863029|NCT00961636|DRUG|ER niacin (+) laropiprant (ERN/LRPT)|One 1g/20 mg tablet ERN/LRPT once daily for 4 weeks, then two 1g/20 mg tablets daily (2g/40 mg total) for 28 weeks
223863030|NCT00961636|DRUG|ER niacin (+) laropiprant (ERN/LRPT)|One 1g/20mg tablet ERN/LRPT once daily for 4 weeks, then two 1g/20 mg tablets daily (2g/40 mg total) for 16 weeks.
223863031|NCT00961636|DRUG|Extended-release niacin (ERN)|Two 1g tablets ERN (2g total) once daily for 12 weeks.
223863032|NCT00961636|DRUG|Placebo to ERN/LRPT|One tablet placebo to ERN/LRPT once daily for 4 weeks, then two tablets placebo to ERN/LRPT daily for 28 weeks
224267462|NCT01741545|DRUG|Ribavirin|
224267463|NCT01741545|DRUG|Daclatasvir|
224267464|NCT01828294|DRUG|Subcutaneous immunoglobulins|Immunoglobulins used subcutaneously for maintenance of other immune mediated disorders.
224267465|NCT00015665|DRUG|Voriconazole|
224267466|NCT06560450|DEVICE|Stride One|Stride One is a smart insole that provides real-time audio feedback (cues) to the patient when performing a certain exercise. The goal of Stride One is to allow patients to practice walking more intensively and with higher quality during rehabilitation.
224267467|NCT05015595|DRUG|Memantine Oral Tablet|Thirty-two-week double-blind up-titration treatment period (from T0 to T4): patients will be randomly assigned to one of two arms (Memantine or placebo) in a 1:1 ratio and will receive a daily administration of Memantine/placebo up to 20mg/day. Eight-week double-blind down-titration treatment period (from T4 to T5): At T4, the dose of Memantine/placebo will be reduced at 10mg/day due to safety reasons before the end of treatment (T5).
224267468|NCT05015595|DRUG|Placebo|Thirty-two-week double-blind up-titration treatment period (from T0 to T4): patients will be randomly assigned to one of two arms (Memantine or placebo) in a 1:1 ratio and will receive a daily administration of Memantine/placebo up to 20mg/day. Eight-week double-blind down-titration treatment period (from T4 to T5): At T4, the dose of Memantine/placebo will be reduced at 10mg/day due to safety reasons before the end of treatment (T5).
224267469|NCT05063630|PROCEDURE|Medical treatment plus intracranial stenting|This group will be both given medical treatment (aspirin 100 mg and clopidogrel 75 mg per day for 90 consecutive days and clopidogrel 75 mg per day thereafter) and performed with intracranial stenting.
224267470|NCT05063630|DRUG|Medical treatment alone|This group will be given medical treatment including aspirin 100 mg and clopidogrel 75 mg per day for 90 consecutive days and clopidogrel 75 mg per day thereafter.
224267471|NCT02464904|PROCEDURE|Cryotherapy|Subjects will have their blood drawn prior to undergoing a staging pleuroscopy. During the pleuroscopy pleural fluid will be collected as well as pleural biopsies (4 to 8 research biopsies). The procedure will involve 2 to 3 applications of cryospray on the location of the disease. After establishing cryofrost over a minimum of a 2 x 2 cm area, cryospray will continue for 15 to 20 seconds, allow a thaw period of 60 seconds followed by one to two repeats in the same location before proceeding onto the next location. We will treat a minimum of 6 x 6 cm area in aggregate. The freezing procedure will be video-recorded and freezing locations and time will be recorded. Approximately, 14 days following the staging pleuroscopy patients will undergo surgical treatment as per standard of care, with repeat blood, pleural fluid and tissue collection.
224267472|NCT02464904|OTHER|Control|Subjects will have their blood drawn prior to undergoing a staging pleuroscopy. During the pleuroscopy pleural fluid will be collected as well as pleural biopsies (4 to 8 research biopsies). Approximately, 14 days following the staging pleuroscopy patients will undergo surgical treatment as per standard of care, with repeat blood, pleural fluid and tissue collection
224267473|NCT00731367|DEVICE|Aquacel Ag Gelled|AQUACEL Ag is produced by changing a small fraction of the sodium ions present in AQUACEL for silver ions and then stabilizing the complex formed by adding chloride. This produces a characteristic silver gray product. There are no counter ions (such as nitrate or sulphadiazine ions) present: these compounds, found in many silver containing products, are known to retard wound healing. AQUACEL Ag maintains a moist wound-healing environment while, at the same time, killing wound pathogens that are immobilized within the dressing. It also reduces bioburden at the wound-dressing surface, thus minimizing the risk of wound infection and facilitating wound healing.
224267474|NCT00731367|DEVICE|Aquacel Ag Adherent|AQUACEL Ag is produced by changing a small fraction of the sodium ions present in AQUACEL for silver ions and then stabilizing the complex formed by adding chloride. This produces a characteristic silver gray product. There are no counter ions (such as nitrate or sulphadiazine ions) present: these compounds, found in many silver containing products, are known to retard wound healing. AQUACEL Ag maintains a moist wound-healing environment while, at the same time, killing wound pathogens that are immobilized within the dressing. It also reduces bioburden at the wound-dressing surface, thus minimizing the risk of wound infection and facilitating wound healing.
224267475|NCT01816360|OTHER|Olfactory aromatherapy|Inhalation of essential oils.
224267476|NCT01816360|OTHER|Yogatherapy|Yogatherapy respiratory exercises.
224267477|NCT02401139|DRUG|Ketamine|
224267478|NCT02401139|DRUG|Placebo|
224267479|NCT03271996|PROCEDURE|Primary closure|Asymmetric skin incision and total excision of the lesion with monopolar scalpel. Accurate hemostasis, creation of a cutaneous-subcutaneous flap, primary closure with non-absorbable sutures, optional aspiration drainage.
224267480|NCT03271996|PROCEDURE|Fistulectomy|Evaluation of the cavity using a 0.5-1 mm metal probe which will be inserted into the skin orifice. Excision of the skin around the orifice and debridement/excision of the cavity by monopolar scalpel or Trephines
224267481|NCT05056519|BIOLOGICAL|Live Attenuated Influenza Vaccine|Live Attenuated Influenza Vaccine placebo, containing H1, H3 and B type influenza Live Attenuated virus.
224267482|NCT05056519|BIOLOGICAL|Live Attenuated Influenza Vaccine placebo|Live Attenuated Influenza Vaccine placebo, not containing H1, H3 and B type influenza Live Attenuated virus.
224267483|NCT01853176|DRUG|Liposomal Injection Bupivacaine (Exparel)|
224267484|NCT01853176|DRUG|Standard bupivicaine|
224267485|NCT02082834|OTHER|abdominal MDCT examination|
223863033|NCT03603717|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|The intervention will consist of a standard, structured, multi-component intervention for insomnia that includes sleep education, sleep hygiene, sleep restriction, stimulus control, and cognitive therapy.
223863034|NCT03603717|BEHAVIORAL|Sleep Hygiene|The intervention will include basic psychoeducation about sleep, discussion of sleep hygiene factors that disrupt and improve sleep, setting sleep hygiene goals, and developing action steps to achieve those goals.
223863035|NCT03854006|PROCEDURE|Cryoballoon pulmonary vein isolation|During cryoballoon pulmonary vein isolation, under local anaesthesia, diagnostic catheters are placed in the coronary sinus. The cryoballoon is advanced to the left atrium via a steerable sheath after single transseptal puncture and inflated at the PV(pulmonary vein) ostia. A spiral mapping catheter is advanced through the balloon inner lumen and positioned in the PV at the closest achievable proximity to the cryoballoon in order to record real-time PV potentials during PV isolation. During PV isolation the potentials from the PV are recorded. The TTI is defined as the time of the last recording of a PV potential before sustained isolation. Isolation of all PVs is reassessed at the end of the procedure by documentation of entrance- and exit-block.
223863036|NCT00732381|DRUG|Mometasone furoate nasal spray (MFNS)|MFNS 50 mcg/spray: two sprays in each nostril once daily (ie, 200 mcg QD) for 15 days
223863037|NCT00732381|DRUG|Matching placebo nasal spray|Matching placebo nasal spray: 2 sprays in each nostril once daily for 15 days
223863038|NCT04297982|OTHER|Mandala Activity|Mandala is a method of expressing one's feelings and thoughts. The person draws and paints the paper in a round shape.
223863039|NCT04297982|OTHER|Routine nursing care|Interventions routinely implemented by nurses in the clinic
223863040|NCT02310295|DEVICE|Laser|focal macular laser therapy
223863041|NCT02310295|DRUG|Bevacizumab|Intravitreal injection of Bevacizumab
223863042|NCT02310295|DRUG|Triamcinolone Acetonide|Intravitreal injection of Triamcinolone Acetonide
223863043|NCT02614118|DRUG|Ketorolac tromethamine|10 mg oral Ketorolac tromethamine 45 minutes before root canal treatment
223863044|NCT02614118|DRUG|Acetaminophen|1000 mg oral Acetaminophen along with10 mg oral Ketorolac tromethamine 45 minutes before root canal treatment.
223863045|NCT02614118|DRUG|Placebo|placebo 45 minutes before root canal treatment
223863046|NCT02204618|DEVICE|cochlear implantation|
223863047|NCT02204618|OTHER|6 months initial abstention|Our experimental protocol relies on real life therapeutic strategy, where a cochlear implant may be proposed once CROS and bone conductions systems have failed. Thus, all subjects enrolled in our study will try CROS and bone conduction devices. If these trials are ineffective, the remaining subjects will be randomized between two arms (cochlear implantation vs 6 months abstention followed by cochlear implantation).
223863048|NCT02707913|DRUG|BF-Amlodipine Tablet 10mg|BF-Amlodipine Tablet 10mg is a generic product manufactured by Bright Future Pharmaceuticals Factory O/B Bright Future Pharmaceutical Laboratories Limited
223863049|NCT02707913|DRUG|Norvasc Tablet 10mg|Norvasc Tablet 10mg will be used as a comparator drug for the BE study
223863050|NCT04280913|OTHER|retrospective analysis|The investigators retrospectively analyzed the hospitalized patients with COVID-19.
223863051|NCT01252316|OTHER|CPR Training using the Family and Friends CPR Anytime VSI Kit|Subjects will be trained using the American Heart Association's Family and Friends CPR Anytime Kit. The subject's will undergo training in-hospital then they will be encouraged to take the kit home with them to practice CPR with their family members and friends.
223863052|NCT01252316|OTHER|Implementation of an In-Hospital CPR Training Model|UPHS Nurses and Volunteers will be trained in our in-hospital CPR Training Model using VSI Kits, and encouraged to implement the training program in their respective hospitals.
223863053|NCT02026219|DRUG|Clopidogrel|Clopidogrel 600mg loading
223863054|NCT02026219|DRUG|Ticagrelor|Ticagrelor 180mg loading
223863055|NCT00939991|DRUG|Vorinostst/Bevacizumab/Temozolomide|Bevacizumab will be administered intravenously at the dose 10 mg/kg every other week. Temozolomide will be administered on a continuous daily dosing schedule at 50 mg/m2/day. Vorinostat will be administered daily on days 1-7 and 15-21 of each 28 day cycle. The dose of Vorinostat will be escalated in successive cohorts of patients to determine the MTD of this regimen. Bevacizumab doses may be given by the local oncologists under the direction of the Duke investigators.
223863056|NCT03398811|DRUG|Depot medroxy-progesterone acetate|Injection every 3 months
223863057|NCT03398811|DRUG|Etonogestrel|68 mg implant
223863058|NCT03398811|DRUG|Desogestrel 75 µg|one pill every day for 28 days without pill-free interval.
223863059|NCT05907551|OTHER|Questionnaires|25-items questionnaire
223863060|NCT02754999|DRUG|SANGUINATE™|As needed (PRN) infusions of 500 mL of SANGUINATE
223863061|NCT06199648|OTHER|web-based documentation and advice|Caregivers will be supported with a web-based documentation and advice system for home care for elderly people
223863062|NCT01018212|OTHER|Cicatrix cream|"We will be carried out the topical application of the product (Cicatrix cream) in the lesions auto administration three times a day during four months, being controlled by the specialist in months consultations.~The dose of 0,1 ml of cream for each cm. of surface, To the patient will be explained the technique of the application."
223863063|NCT01350804|BIOLOGICAL|AIN457|AIN457 (Secukinumab) is a human monoclonal antibody. Secukinumab binds and reduces the activity of Interleukin 17 (IL-17). AIN457 was given as i.v. (10mg/kg) at baseline, week 2 and week 4, and then s.c. (75 or 150mg) every 4 weeks starting at week 8.
223863064|NCT01350804|BIOLOGICAL|Placebo|Placebo was given as i.v. at baseline, week 2 and week 4, and then s.c. every 4 weeks starting at week 8.
223863065|NCT01350804|BIOLOGICAL|Abatacept|Abatacept (from 500 to 1000 mg i.v. based on weight) was given as i.v. at baseline, weeks 2 and 4, and then every 4 weeks starting at week 8.
223863066|NCT03688659|DRUG|Vancomycin and gentamycin|intravenous
223863067|NCT02206672|OTHER|Micro reinjection of autologus adipose tissue|
223863068|NCT04134143|BIOLOGICAL|ExpressGraft-C9T1 Skin Tissue|A round patch of experimental skin tissue that the doctor applies over the ulcer
223863069|NCT04049435|DEVICE|Assessment of Horizontal Bone gain using patient specific titanium sheet: a novel protocol for treatment of horizontal deficiency in the anterior maxilla|Assessment of Horizontal Bone gain using patient specific titanium sheet: a novel protocol for treatment of horizontal deficiency in the anterior maxilla
223863070|NCT04225780|DRUG|Low-dose IL-2 and ganciclovir|If patients are eligible, which CMV-DNA are more than 10\^3 copies, it will be randomly distributed in low-dose IL-2 and ganciclovir group, or ganciclovir group. Low-dose IL-2 is defined as 1 million IU per day subcutaneously.
223863071|NCT03349736|OTHER|Pelvic Floor Muscle Training|All the women will receive information and instruction/guidance exercise individually and in groups on PFMT on the first day of their visit. Following this, the women are advised to perform daily PFMT at home which includes 10 sec hold X 10 times X 3 sets. Women will record their home PFMT using an exercise diary. During the follow-up, women will attend the PFMT in a group or individual led by a Physiotherapists (to motivate and to ensure women are performing the PFMT correctly). Exercise diary will be collected in every follow up so that the information is retained even if the women discontinued or deviate from intervention protocols.
223863072|NCT05574452|DEVICE|ACL reconstruction using the SONAR Femoral Aimer PSI|ACL reconstruction using the SONAR Femoral Aimer PSI
223863073|NCT03328117|DRUG|Imatinib|Over-encapsulated 100 mg imatinib mesilate tablets
223863074|NCT03328117|DRUG|Placebo oral capsule|Matching placebo oral capsule
223863075|NCT03815396|DRUG|INBRX-101/rhAAT-Fc|INBRX-101 is a recombinant human alpha-1 antitrypsin (AAT) Fc fusion protein (rhAAT-Fc).
223863076|NCT06937879|OTHER|Hand Grip Strength|The grip strength of the participants will be performed with a hydraulic hand dynamometer on a chair with back and arm support. The participant will be asked to squeeze the dynamometer with maximum force. The measurement will be performed 3 times and the average value will be recorded.
223863077|NCT05190861|DIAGNOSTIC_TEST|droplet digital PCR method|The droplet digital PCR method can detect nucleic acids from the most common pathogens (approximately 90%) responsible for BSIs according to Chinet2020 and takes about 4 hours to perform, reporting within the first 24h of suspected sepsis/septic shock.
223863078|NCT05190861|DIAGNOSTIC_TEST|blood culture|Blood culture is a conventional microbiological method of pathogen detection. Results from blood cultures are usually not available until 24 to 72 hours after sampling.
223863079|NCT04055454|BIOLOGICAL|MV-LASV|The MV-LASV vaccine candidate is a recombinant live attenuated viral vectored vaccine, based on the backbone of the measles Schwarz virus strain for prophylaxis of Lassa infection and will be administered in two different dose levels by intra muscular (i.m.) injection.
223863080|NCT04055454|OTHER|Placebo|A sterile physiological saline solution will be used as placebo to ensure blinding of the treatment with low dose MV-LASV and placebo within treatment group A. Additionally, the Placebo will be used as a control arm to enable comparison of treatment reactions within treatment groups B and C.
223863081|NCT07060989|DRUG|NTS071|Oral administration
223863082|NCT07060729|BEHAVIORAL|Behavioral: 2 exercise sessions (2X)|The (1) control group (2X) will receive an exercise screening checklist and 24 group training sessions, 2 times per week during a 12-week period, based on International Exercise Recommendations in Older Adults (ICFSR; Izquierdo et al., 2021). These are the recommendations commonly used for older adults.
223863083|NCT07060729|BEHAVIORAL|Behavioral: 2 exercise sessions (3X)|The (3) experimental group (3X) will receive an exercise screening checklist and 36 group training sessions, 3 times per week during a 12-week period, based on International Exercise Recommendations in Older Adults (ICFSR; Izquierdo et al., 2021). These are the recommendations commonly used for older adults. This additional session will increase weekly exercise volume compared to the control group, also being closer to complying to the WHO International Guidelines of weekly physical activity (Bull et al., 2020)
223863084|NCT05756504|DRUG|Ketorolac|Injection ketorolac 30 mg IV x TDS will be given to each patient in each group.
223863085|NCT05756504|DRUG|Tramadol|Injection Tramadol 25-50 mg IV x TDs wil be given to each patient in this group. Maximum dose will be 400 mg/ day
223863086|NCT03371966|DIETARY_SUPPLEMENT|High Nitrate Beetroot Juice|High nitrate beetroot juice (120 ml) will be administered for 7 days consecutively followed by a 7 day washout period then 7 consecutive days of low nitrate beetroot juice.
223863087|NCT03371966|DIETARY_SUPPLEMENT|Low Nitrate Beetroot Juice|Low nitrate beetroot juice (120 ml) will be administered for 7 days consecutively followed by a 7 day washout period then 7 consecutive days of high nitrate beetroot juice..
223863088|NCT03047239|DEVICE|SENSIMED Triggerfish|Smart contact lens based device indicated to detect the peak patterns of variation in intraocular pressure over a maximum period of 24 hours
223863089|NCT06382649|DRUG|Rivastigmine|Rivastigmine 3mg by mouth once, followed by rivastigmine 1.5mg by mouth every 1 hour as needed for ongoing delirium or agitation (at the discretion of the treating physician), for a maximum of three doses
223863090|NCT06382649|DRUG|Placebo|Matching oral placebo by mouth once, followed by placebo by mouth every 1 hour as needed for ongoing delirium or agitation (at the discretion of the treating physician), for a maximum of three doses
223863091|NCT04516135|RADIATION|3-Dimensional Conformal Radiation Therapy|Undergo 3D CRT
223863092|NCT04516135|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
223863093|NCT04516135|OTHER|Quality-of-Life Assessment|Ancillary studies
223863094|NCT04516135|OTHER|Questionnaire Administration|Ancillary studies
223863095|NCT04516135|RADIATION|Volume Modulated Arc Therapy|Undergo VMAT
223863096|NCT06814717|DRUG|cP12|cP12 is a novel fibronectin derived, 14-mer peptide
223863097|NCT05300308|OTHER|usual care|The information about lymphoedema and its prevention is given during the hospital stay by the physical therapist of the department of urology. Skincare consists of daily skin moisturizer of feet and legs and prevention and care of wounds. Active exercises are performed to gain endurance and muscle strength after surgery and to stimulate the blood and lymph circulation. The exercises are supervised by the home physical therapist. Frequency of the supervised exercises is gradually decreased. If a patient develops lymphoedema, he/she receives compression stockings.
223863098|NCT05909683|DIAGNOSTIC_TEST|Change of antimicrobials based on BCID2 and Reveal Rapid AST tests. Stop of antimicrobials based on PCT results.|After the patient's blood flask is flagged positive for bloodstream infection, the blood sample will be assessed in the BCID2 diagnostic test in order to identify the underlying pathogens the patient is infected with. After the identification, and in the presence of gram-negative bacteria, the sample will be assessed in the Reveal Rapid AST test to provide information about which antimicrobials the specific pathogens are sensitive to. When both the identification of the pathogen and the sensitivities are available, the central laboratory will inform the attending physicians, who are obliged to change the standard of care antimicrobial therapy administered based on the rule in Box1 of the protocol. Finally, based on the results of the procalcitonin (PCT) on the first day by day 5 when PCT value is less than 80% of the initial value or it remains below 0.5 ng/ml, the attending physicians should discontinue the antimicrobial therapy.
223863099|NCT05909683|OTHER|Standard of Care|Standard of care practices of the specific study site. Antimicrobials will be administered based on the attending physicians' critical opinion, and discontinuation will be done based on the standard procedures of the study site.
223863100|NCT04411082|DRUG|IMR-687|Oral administration of once daily IMR-687
223863101|NCT04411082|DRUG|Placebo|Oral administration of once daily Placebo
223863102|NCT04710771|OTHER|Prone Lying Position|patient lies on his/ her stomach facing floor.
223863103|NCT04710771|OTHER|alternate nostril breathing|patient inspires with one nostril at a time, right or left one by one and expires by mouth.
223863104|NCT02804594|DRUG|N-acetyl cysteine|1250 mg of N- acetyl cysteine taken three times daily
223863105|NCT02804594|DRUG|Placebo|placebo taken three times daily
223863106|NCT00343486|DRUG|Solabegron|
223863107|NCT05897996|DEVICE|creation of vascular access for hemodialysis|endo-AVfs created with Wavelinq
223863108|NCT03877159|OTHER|There is no intervention.|There is no intervention. This is a retrospective study analysing archived tumour samples.
223863109|NCT04620902|OTHER|Tear sampling|Tear sampling using Schirmer's strips
223863110|NCT02077426|OTHER|Regional Specific Training (RSTS)|The RSTS protocol was designed to focus on specific peripheral muscle groups without imposing a significant cardiorespiratory strain. Each exercise involved contractions with moderate load but with an extended duration of up to six minutes. Eight specific exercises were performed to target all major muscle groups and enable the routine to be completed within 60 minutes including warm-up, rest periods and stretching between exercises, and cool down exercises.
223863111|NCT04435236|PROCEDURE|Cervical ESP block|Cervical ESP block will be performed as described by Elsharkawy at al. (7). ISB block will be performed in transverse orientation of the ultrasound probe to visualize the trunks of the brachial plexus between the anterior and middle scalene muscles
223863112|NCT03720236|PROCEDURE|Implant bed preparation protocol|This is the first surgical phase, we prepare the implant bed by using different increasing size drills.
223863113|NCT03720236|PROCEDURE|Implant loading|This is the second phase, based on prosthetic procedures, to design the crown over the dental implant
223863114|NCT04498624|PROCEDURE|inverted flap|full thickness macular hole surgery
223863115|NCT04498624|PROCEDURE|peeling internal limiting membrane (ILM)|full thickness macular hole surgery
223863116|NCT03175172|BIOLOGICAL|CRS-207|Administered by IV infusion over approximately 1 hour.
223863117|NCT03175172|BIOLOGICAL|Pembrolizumab|Administered by IV infusion over approximately 30 minutes.
223863118|NCT02753192|OTHER|Patients|Individuals with PD will be enrolled in the study in Aix-en-Provence, France (N = 60) and Lisbon, Portugal (N = 60). Their global motor disability and orofacial motor functions will be assessed with specific clinical rating scales, without (OFF) and with (ON) medical treatment. Two groups of 60 healthy age-matched volunteers will provide the reference for between-group comparisons. Along with the clinical examinations, several speech tasks will be recorded to obtain acoustic and perceptual measures. Self-evaluation questionnaires will be used to assess the psychosocial impact of dysarthria on quality of life.
223863119|NCT02810184|RADIATION|cone-beam computed tomography (CBCT)|additional CBCT scan at 24 and 36 months, for analysis of evolution of bone volume
223863120|NCT05887063|OTHER|Dementia Awareness Course UK|An online course delivered to a small group of informal caregivers in between 3 and 4 hours. The course is made up of three modules: what is dementia, positive engagement and caring for someone with dementia. The course is delivered by one facilitator and includes teaching, discussions and activities.
223863121|NCT02889718|DEVICE|CONCERT-CL® station|"During cancer surgery (surgery \> 1 hour), CONCERT-CL® station will be used in accordance with its CE marking to administer anesthetic agents:~* Port B = open loop: Analgesic~* Port A = closed loop: Hypnotic~* Port C = closed loop: Curare"
223863122|NCT02889718|OTHER|Surgery|Regardless of the type of surgery the patient receives for his cancer, this surgery must be greater than 1 hour.
223863123|NCT01662336|DRUG|Lopinavir / ritonavir|Prescribed according to the product monograph and physician's discretion.
223863124|NCT01662336|BEHAVIORAL|Kaletra Adherence Support Assistance Program|A customized support network for patients treated with lopinavir / ritonavir that offers individual counseling with an HIV experienced nurse who assists patients with various aspects of their therapy including life-style changes, emotional stress, and adverse events, and may provide access to various healthcare professionals or may offer other types of support such as transportation, exercise, etc.
223863125|NCT06248229|DRUG|Dyanavel XR|"Dosing will begin the morning following Visit 2. Subjects in the active group will begin the study on 5 mg of Dyanavel XR. Subjects will be advised to take one capsule each morning upon awakening, dosed consistently with respect to time. Subjects will be advised that tablets should be swallowed whole, not crushed, chewed, or cut. Subjects can take Dyanavel XR with or without food.~Subjects will return to the study site on a weekly (and later, bi-weekly) basis for evaluation of symptoms and possible side effects. Subjects will be titrated to their optimal dose based on the dose titration schedule displayed in Section 5.1. The PI will be available to consult with patients as needed between Week 0 and Week 4 to adjust dosage per the PI's clinical judgment."
223863126|NCT06248229|DRUG|Placebo|"Dosing will begin the morning following Visit 2. Subjects in the placebo group will begin the study on 5 mg of placebo. Subjects will be advised to take one tablet each morning upon awakening, dosed consistently with respect to time. Subjects will be advised that tablets should be swallowed whole, not crushed, chewed, or cut. Subjects can take Dyanavel XR with or without food.~Subjects will return to the study site on a weekly (and later, bi-weekly) basis for evaluation of symptoms and possible side effects. Subjects will be titrated to their optimal dose based on the dose titration schedule displayed in Section 5.1. The PI will be available to consult with patients as needed between Week 0 and Week 4 to adjust dosage per the PI's clinical judgment."
223863127|NCT01725464|DEVICE|oxygen cannular|Patient receives oxygen supplementation 5 LPM via oxygen cannular for 120 minutes after the operative
223863128|NCT04373590|BEHAVIORAL|Decision aid|The chosen intervention is a one-page DA developed by the first author, published and fully described elsewhere (Zisman-Ilani et al., 2017; Zisman et al., 2018) for use during the psychiatric consultation to help patients and clinicians discuss relevant treatment options pertaining to antipsychotics such as medication nonadherence and self-tapering. The DA format is a simple one-page table with rows containing frequently asked questions by patients about their treatment options and the benefits, risks, and implications of differing decisions. The columns display the treatment options available for the treatment decision in question: continuing, adjusting, or discontinuing antipsychotic medications.
223863129|NCT00105313|DRUG|MEDI-507|
223863130|NCT05133154|BIOLOGICAL|Blood samples|In total, about 20 ml of blood will be collected on EDTA tubes : collection of CTCs, TEPs and biobanking (V0, V1 and V2)
223863131|NCT05714332|OTHER|Advanced practice physiotherapy and orthopedic surgeon management|Management of their musculoskeletal condition by an advanced practice physiotherapist and an orthopedic surgeon.
223863132|NCT05714332|OTHER|Orthopedic surgeon management|Management of their musculoskeletal condition by an orthopedic surgeon.
223863133|NCT06005051|OTHER|Dietary intervention|Using different combination of foods to see if the glucose response to a load of carbohydrates can be mitigated.
223863134|NCT04532658|BEHAVIORAL|Coaching program|"* Charting system for outcomes feedback~* Profiling of individual surgeon~* Modules of improvement"
223863135|NCT06123195|OTHER|Constipation treatment|Lactulose 15 mL (10 g) will be taken orally once daily (in the evening), which can be titrated at 1-week intervals in 15 mL (10 g) increments or decrements up to 60 mL (40 g) as a total daily dose.
223863136|NCT02840149|DRUG|68Ga-DOTATATE PET/CT|68Ga-DOTATATE PET/CT scan
223863137|NCT05610280|DRUG|Olezarsen|Olezarsen will be administered by SC injection.
223863138|NCT05610280|DRUG|Placebo|Olezarsen-matching placebo will be administered by SC injection.
223863139|NCT04425733|DRUG|Frespaciguat|Frespaciguat administered at a dose of 180 µg or ≤360 µg QD via inhalation
223863140|NCT04425733|DRUG|Placebo|Frespaciguat-matching placebo administered QD via inhalation
223863141|NCT04668339|BIOLOGICAL|ARCT-021 single dose priming|ARCT-021 higher dose (one dose) + placebo (one dose)
223863142|NCT04668339|BIOLOGICAL|ARCT-021 two lower dose priming|ARCT-021 lower dose (two doses, Day 0 and Day 28)
223863143|NCT04668339|BIOLOGICAL|ARCT-021 two higher dose priming|ARCT-021 higher dose (two doses, Day 0 and Day 28)
223863144|NCT04668339|BIOLOGICAL|Placebo (two doses), priming|Placebo (two doses, Day 0 and Day 28)
223863145|NCT04668339|BIOLOGICAL|Randomized booster|ARCT-021 (single dose) OR placebo, booster
223863146|NCT04668339|BIOLOGICAL|Placebo booster|Placebo (single dose)
223863147|NCT04872478|DRUG|MRX-2843|MRX-2843 capsules
223863148|NCT01627093|OTHER|Medical Chart Review|Review of medical records
223863149|NCT01627093|OTHER|Questionnaire Administration|Complete questionnaires
223863150|NCT06419231|DIETARY_SUPPLEMENT|Butyrate Formulation|Butyrate Formulation capsule: Take daily
223863151|NCT06419231|DIETARY_SUPPLEMENT|Butyrate + Polyphenol Formulation|Butyrate + Polyphenol Formulation capsule: Take daily
223863152|NCT06419231|DIETARY_SUPPLEMENT|Placebo|Placebo: Take daily
223863153|NCT05318105|DEVICE|Aquadex Smartflow® System|ultrafiltration
223863154|NCT05318105|DRUG|IV Loop Diuretics|diuretics
224267486|NCT04863144|OTHER|Blood samples|Plasma concentrations of paclitaxel and its metabolites will be obtained during the first treatment cycle. The samples for paclitaxel analysis will be collected in ethylenediamine tetraacetic acid tubes at 7-time points: just before infusion, in the middle of the infusion, at the end of infusion, at 1, 2, 4 and 6 hours post-infusion.
224267487|NCT05037318|BEHAVIORAL|Stress arousal reappraisal|Participants will watch a video explaining that stress arousal is not harmful but rather functional and adaptive for performance in stressful situations.
224267488|NCT05037318|BEHAVIORAL|Worked examples|The worked example will be in form of brief video sequences showing a physician (played by an actor) delivering the bad diagnosis of lung cancer to an SP following the SPIKES protocol.
224267489|NCT00000124|PROCEDURE|Brachytherapy|
224267490|NCT00000124|PROCEDURE|Eye Removal|
224267491|NCT03099915|OTHER|completion of self-reported questionnaires|Single completion: Participants will have to complete self-reported questionnaires based on gina criteria and 12-item general health questionnaire
224267492|NCT00636545|DRUG|Oblimersen (Genasense)|Intravenous
224267493|NCT00636545|DRUG|Oblimersen (Genasense)|Intravenous
224267494|NCT02518945|DRUG|Dapagliflozin|Dapagliflozin or Farxiga is a SGLT-2 inhibitor
224267495|NCT02518945|DRUG|Insulin|
224267496|NCT02518945|DRUG|Liraglutide|Victoza(Liraglutide) is a GLP-1 agent.
224267497|NCT02518945|DRUG|Dapagliflozin placebo|Dapagliflozin placebo looking similar to active drug Dapagliflozin in external appearance but not containing active ingredient dapagliflozin
224267498|NCT04716582|BEHAVIORAL|Sitting interrupted by light physical activity|Each 30 minutes will be 25 minutes sitting followed by 5 minutes walking that designed as prescribed walking route outside laboratory corridor.
224267499|NCT04716582|BEHAVIORAL|Sitting with cognitive task|Participants will perform online cognitive task during prolonged sitting.
224267500|NCT04716582|BEHAVIORAL|uninterrupted sitting|Participants will watch documentary during prolonged sitting.
224267501|NCT02247362|BIOLOGICAL|VAX2012Q|Recombinant influenza HA vaccine consisting of two Influenza A subtypes and two Influenza B lineages and delivered IM
224267502|NCT02247362|OTHER|Placebo|Vaccine Diluent
224267503|NCT04993274|DIAGNOSTIC_TEST|PASS-MS|protocol using short motor tasks performed by the subject and recorded by a depth camera, motion analysis by visuo-perceptive computing
224267504|NCT02531620|OTHER|Physiatry Assessment|Physiatrists are physicians who are medical experts in maximizing a patient's overall ability to function well and live independently. The Investigators are proposing your participation in an initial pilot study in order to test the question as to whether or not participation with a physiatrist and any interventions recommended by said physician would help improve a patient's postoperative recovery.
224267505|NCT02531620|OTHER|Routine Care|Usual care for your disease process
224267506|NCT01370083|BEHAVIORAL|Tongue Pressure Profile Training|60 tongue-pressure tasks per session, emphasizing control of the slope of tongue pressure release, informed by biofeedback. Pressures will be measured using a hand-held oral manometer (Iowa Oral Performance Instrument) with signals displayed on a computer.
224267507|NCT01370083|BEHAVIORAL|Tongue-Pressure Strength-and-Accuracy Training|60 tongue-pressure tasks per session, emphasizing maximum effort strength tasks and accuracy targets within 20-95% of each patient's maximum, informed by biofeedback. Pressures will be measured using a hand-held oral manometer (Iowa Oral Performance Instrument) with amplitude output in kiloPascals displayed on an LCD screen.
224267508|NCT05251727|DRUG|thrombomodulin alfa|Weight based dose of reconstituted treatment
224267509|NCT05251727|DRUG|Placebo|Weight based dose of reconstituted treatment
224267510|NCT04286074|OTHER|50% resistance|Prior to training, the muscle training technique will be performed. The objective of applying the intervention using the Powerbreathe® device is to produce an increase in inspiratory force. The technique will be performed with the athlete standing, holding the device with his hand and his lips sealed on the mouthpiece. After a full expiration, you will make a quick and deep inspiration. The principal investigator of the study will ensure that the technique is performed correctly. There will be 2 series of 30 maximum inspirations. These interventions will be faced with a resistance of 50% of the maximum inspiratory pressure of each athlete
224267511|NCT04286074|OTHER|10% resistance|Prior to training, the muscle training technique will be performed. The objective of applying the intervention using the Powerbreathe® device is to produce an increase in inspiratory force. The technique will be performed with the athlete standing, holding the device with his hand and his lips sealed on the mouthpiece. After a full expiration, you will make a quick and deep inspiration. The principal investigator of the study will ensure that the technique is performed correctly. There will be 2 series of 30 maximum inspirations. These interventions will be faced with a resistance of 10% of the maximum inspiratory pressure of each athlete
224267512|NCT01167829|DRUG|Oral Testosterone|Oral Testosterone: 300 mg, pills, three times daily Day 1 - 10 (total of 27 pills)
224267513|NCT01167829|DRUG|Acyline|300 ug/kg injection on Day 0
223863155|NCT06104397|OTHER|Written exercise guidance by neurologist|Neurologists will provide written exercise education and guidance to their patients with Parkinson's Disease during neurologist visits and/or in after visit summary in the patient's EMR patient portal. The research team will facilitate the development of the written exercise guidance with input and feedback from each site's neurology, clinical, and administrative teams.
223863156|NCT06104397|OTHER|Physical therapy|A consultative model of physical therapy - a lower dose of physical therapy focused on physical activity and exercise promotion and coaching - will be implemented into each site. In the consultative model of physical therapy, visits are scheduled around needs of the patient, however will involve 1-4 additional visits within 3 months of evaluation and is based on personal factors that influence their exercise prognosis such as self-efficacy, readiness to change, fitness level, age, health literacy, comorbidities, and Parkinson's Disease-related motor and non-motor impairments.
223863157|NCT06108375|OTHER|music therapy|music played live by a music therapist
223863158|NCT06108375|OTHER|recording|a recording of the same music played by the music therapist
223863159|NCT04947189|DRUG|Seviteronel-D (Seivteronel in combination with dexamethasone)|Use of Seviteronel-D (Serivteronel and dexamethasone) in the treatment of androgen receptor positive solid tumours.
223863160|NCT04947189|DRUG|Docetaxel|Use of docetaxel chemotherapy for solid tumours
223863161|NCT05537038|BIOLOGICAL|BNT164a1|Multi-antigen ribonucleic acid (RNA) vaccine for active immunization against tuberculosis administered as intramuscular injection
223863162|NCT05537038|BIOLOGICAL|BNT164b1|Multi-antigen ribonucleic acid (RNA) vaccine for active immunization against tuberculosis administered as intramuscular injection
223863163|NCT05537038|OTHER|Placebo|Placebo
223863164|NCT02206841|PROCEDURE|Liver biopsy|Percutaneously liver biopsy will be performed for evaluate steatosis and fibrosis.
223863165|NCT02206841|DEVICE|ARFI|Acoustic radiation force impulse (ARFI) imaging will be performed for evaluate fibrosis of liver.
223863166|NCT02206841|DEVICE|SWE|Supersonic shear wave elastography (SWE) will be performed for evaluate fibrosis of liver.
223863167|NCT02206841|DEVICE|Transient elastography|Transient elastography will be performed for evaluate fibrosis of liver.
223863168|NCT03023631|BIOLOGICAL|Recombinant Human Papillomavirus Nonavalent Vaccine|Given IM
223863169|NCT03622593|DRUG|Aflibercept|Aflibercept 2 mg was administered by intravitreal (IVT) injection into the study eye once every 8 weeks (Q8W).
223863170|NCT03622593|DRUG|Faricimab|Faricimab 6 mg was administered by IVT injection into the study eye either once every 8 weeks (Q8W) in arm A or according to a personalized treatment interval (PTI) in arm B.
223863171|NCT03622593|PROCEDURE|Sham Procedure|The sham is a procedure that mimics an IVT injection and involves the blunt end of an empty syringe (without a needle) being pressed against the anesthetized eye. It was administered to participants in all three treatments arms at applicable visits to maintain masking among treatment arms.
223863172|NCT06325111|OTHER|Determinants of T1D glycaemic control|DNA genotyping, microbiome, DNA methylation and microRNAs analysis
223863173|NCT02957812|DEVICE|Custom-made Foot Orthotics (CFO)|Provides longitudinal arch support
223863174|NCT05685030|DIETARY_SUPPLEMENT|Placebo|product vehicle (sunflower oil)
223863175|NCT05685030|DIETARY_SUPPLEMENT|Limosilactobacillus reuteri CCT 7862|Limosilactobacillus reuteri CCT 7862 - 1 x 10e9 UFC/ day.
223863176|NCT05685030|DIETARY_SUPPLEMENT|Bifidobacterium lactis CCT 7858 + Lactobacillus rhamnosus CCT 7863|Bifidobacterium lactis CCT 7858 + Lactobacillus rhamnosus CCT 7863 - 1 x 10e9 UFC/ day
223863177|NCT02016352|BIOLOGICAL|patient CSF extraction with hydrocephalus|CSF extraction
223863178|NCT02016352|BIOLOGICAL|witness CSF extraction|CSF extraction from patient not suffering from hydrocephalus
223863179|NCT03432403|DEVICE|Ambu LMA|Will be randomized to either the new Gastro LMA or old Ambu LMA for EGD procedure and the intracuff pressure will be measured
223863180|NCT03432403|DEVICE|Gastro LMA|Will be randomized to either the new Gastro LMA or old Ambu LMA for EGD procedure and the intracuff pressure will be measured
223863181|NCT03762668|DEVICE|Modified delefilcon A contact lenses|Spherical soft daily disposable contact lens
223863182|NCT03762668|DEVICE|Delefilcon A contact lenses|Spherical soft daily disposable contact lens
223863183|NCT04219930|DIAGNOSTIC_TEST|Expression of nucleotide protein -3|Expression of nucleotide protein -3 will be measured in serum by ELISA
223863184|NCT02206763|DRUG|Momelotinib (MMB)|Tablet(s) administered orally once or twice daily
223863185|NCT02206763|DRUG|Erlotinib|Tablet(s) administered orally once daily.
223863186|NCT03886116|OTHER|Exercise|3 sets of 10 forearm exercises performed twice in the Morning and Evening for 6 weeks.
223863187|NCT04658030|DEVICE|VR 360 video surgery preparation|Preparing children on the surgery by a virtual reality 360 degrees video tour from the pediatric ward to the surgery room. In this video all information is given necessary for the surgery. This takes a maximum of 30 minutes and will be performed 1 time.
223863188|NCT04658030|OTHER|Care as usual|Preparing the children for surgery with the care as usual. A booklet that can be viewed by the children and parents at home.
223863189|NCT00470899|PROCEDURE|drainage of placenta of fetal blood|
223863190|NCT01393119|DRUG|GTx-758|3-fluoro-N-( 4-fluorophenyl)-4-hydroxy-N-( 4-hydroxyphenyl) benzamide; a nonsteroidal selective estrogen receptor (ER) a agonist
223863191|NCT03118804|DIAGNOSTIC_TEST|Assessment of Lung Tidal Distribution With EIT|Changes of lung tidal distribution during SBT with mechanical ventilation were recorded by EIT can be used to predict weaning success or failure
223863192|NCT05223205|PROCEDURE|Air|Test if air is sufficient for macular hole closure.
223863193|NCT05223205|PROCEDURE|10% SF6 and 90% air|Test if 10% SF6 and 90% air is sufficient for macular hole closure.
223863194|NCT04399148|DRUG|Desloratadine 5 mg|Desloratadine (H1-antihistamine): oral tablet (1 x 5 mg), taken with 240 ml water, 4 hours prior to the histamine skin prick
223863195|NCT04399148|DRUG|Aprepitant 125 mg|Aprepitant (NK1-antagonist): hard capsule (1 x 125 mg), taken with 240 ml water, 4 hours prior to the histamine skin prick
223863196|NCT04399148|DRUG|Ketotifen 1 MG|Ketotifen (H1-antihistamine and mast cell stabilizer): capsule (1 x 1 mg), taken with 240 ml water, 4 hours prior to the histamine skin prick
223863197|NCT05747495|OTHER|Online training in CPR-AED|"The online training has been designed according to the Catalan Resuscitation Council (CCR) and the European Resuscitation Council (ERC) guidelines. The aim of this training is to provide theoretical and practical knowledge to respond to aid situations (from unconscious people to drowning, both adults and children), as well as the use of the AED.~The contents are available at the link \[https://register.magnore.com/registre-curs-de-reanimacio-cardiopulmonar-dea/\]."
223863198|NCT06412341|BEHAVIORAL|Accepting your Body after Cancer|See 'Arm Description'
223863199|NCT06412341|BEHAVIORAL|Macmillan body image booklet|See 'Arm Description'
223863200|NCT02284555|DRUG|Mupirocin|Mupirocin (Bactroban 2% Nasal Ointment) will be administered twice daily for five days in accordance with the SmPC.
223863201|NCT06048991|DIAGNOSTIC_TEST|Thermographic assessment|Patients will undergo a termographic evaluation of the operated knee of ACL reconstruction and of the controlateral knee.
223863202|NCT00465816|BIOLOGICAL|Nimenrix (Meningococcal vaccine 134612)|Single dose intramuscular injection
223863203|NCT00465816|BIOLOGICAL|Twinrix|3-dose intramuscular injection. Twinrix Adult will be administered to subjects aged 16 years and above and Twinrix Junior will be administered to subjects aged from 11 years up to and including 15 years of age.
223863204|NCT02384577|DRUG|Budesonide, Formoterol Fumarate Dihydrate|
223863205|NCT04305574|BEHAVIORAL|Use of social media during COVID-19|Participants' self-reported use of an official WhatsApp channel to receive and share news about COVID-19
223863206|NCT06456970|DEVICE|fibroscan|"Fibroscan examination with controlled attenuation parameterCAP (Echosens FibroScan ® Compact 530) for evaluation of steatosis and its degree (by CAP score) and fibrosis stage by liver stiffness measurement(LSM)"
223863207|NCT03802708|DIAGNOSTIC_TEST|Metabolomic analysis urine sample|a urine sample will be anlayzed for metabolic pathways involving Nitric Oxide Nitric Oxide level will be measured at the exhaled air sample
223863208|NCT00004124|DRUG|bicalutamide|
223863209|NCT00004124|DRUG|goserelin|
223863210|NCT00004124|DRUG|mitoxantrone hydrochloride|
223863211|NCT00004124|DRUG|prednisone|
223863212|NCT06241989|OTHER|health education supported by motivational interviewing|The intervention group will receive health education supported by motivational interviewing consisting of 6 sessions. Within the scope of the intervention, the first two sessions will be health education and the last four sessions will be motivational interviewing.
223863213|NCT00018668|DRUG|Risperidone|
223863214|NCT00018668|DRUG|Olanzapine|
223863215|NCT00018668|DRUG|Quetiapine|
223863216|NCT05486260|DIETARY_SUPPLEMENT|DMB lowest dose|Intake of 150 mg of DMB
223863217|NCT05486260|DIETARY_SUPPLEMENT|DMB highest dose|Intake of 300 mg of DMB
223863218|NCT05486260|DIETARY_SUPPLEMENT|Strawberry lyophilisate|Intake of 300 mg of strawberry lyophilisate
223863219|NCT02488200|OTHER|No intervention|No intervention
223863220|NCT00651105|DRUG|Vildagliptin|
223863221|NCT00651105|DRUG|Placebo|
223863222|NCT05209230|PROCEDURE|Continuous renal replacement therapy|Continuous renal replacement therapy (veno venous hemofiltration) without net ultrafiltration, through a dedicated central venous catheter
223863223|NCT05209230|OTHER|Control group|Continuous renal replacement therapy is differed from 6 hours to allowed 2 control echocardiographic evaluations
223863224|NCT01751958|RADIATION|Epidural steroid injection|Epidural steroid injection
223863225|NCT04306354|DRUG|Oxytocin nasal spray|Oxytocin nasal spray 24 UI twice daily as adjunctive treatment to conventional treatment during 10 days of detoxification of crack cocaine
223863226|NCT04306354|DRUG|placebo nasal spray|Nasal spray with placebo solution (2% odor-generating propolis essence + the same vehicle as intra-nasal oxytocin: 0.05% citric acid, 0.9% sodium chloride, 1% glycerol, 0.54% disodium phosphate, 0.2% methylparaben + propylparaben, 1% sorbitol, 80% water) twice daily as adjunctive treatment to conventional treatment.
223863227|NCT02329457|BIOLOGICAL|Zostavax|varicella zoster vaccine
223863228|NCT02329457|BIOLOGICAL|Normal Saline|normal saline placebo vaccine
223863229|NCT03778645|PROCEDURE|Adrenal Venous Sampling|Adrenal Venous Sampling via an Antecubital Approach
223863230|NCT06399029|DRUG|Ruxolitinib Topical Cream|Ruxolitinib cream will be applied topically twice daily on up to 20% of the body surface over 12 weeks in patients with lichenoid skin toxicity under anti PD1 treatment.
223863231|NCT05319626|OTHER|compression socks|The compression socks have a clinical pressure of 23-30 mm Hg. The socks are dressed to the participants based on the manufacturer's sizing guidelines.
223863232|NCT05319626|OTHER|textured insoles|The textured insoles have small, pyramidal peaks with centre-to-centre distances of approximately 2.5 mm (Evalite Pyramid EVA, 3 mm thickness, shore value A50, black). The insoles cut to a range of men's and women's standard EU shoe sizes. During the testing process, they are worn within a standardised shoe.
223863233|NCT05319626|OTHER|smooth socks|The smooth socks are a commercial stocking that does not have a compression feature, but has a similar thickness and color to the compression stocking. They have standard size.
223863234|NCT05319626|OTHER|smooth insoles|The smooth insoles have a completely flat surface (Evalite Pyramid EVA, 3 mm thickness, shore value A50, black). The insoles cut to a range of men's and women's standard EU shoe sizes. During the testing process, they are worn within a standardised shoe.
223863235|NCT01574859|OTHER|levothyroxine|titration of T4 according to biochemical values
223863236|NCT06436690|BEHAVIORAL|Diagnosis Mandate and Feedback|The intervention consists of: a) a Refresher Training on AMR, (b) a Diagnosis Mandate, and (c) an Individualized Feedback.
223863237|NCT02719600|BEHAVIORAL|Virtual reality|Evaluation of observational motor learning using virtual reality
223863238|NCT02013830|DRUG|bevacizumab [Avastin]|7.5mg/kg iv on day 1 of each 3 week cycle.
223863239|NCT02013830|DRUG|capecitabine [Xeloda]|1600mg/m2/day po in 2 divided doses, on days 1 to 14 of each 3 week cycle.
223863240|NCT04436393|DIAGNOSTIC_TEST|Guardant360 test|tumor cfDNA testing
223863241|NCT01438086|DRUG|mecasermin|Intracoronary bolus
223863242|NCT01438086|DRUG|mecasermin|Intracoronary bolus
223863243|NCT01438086|DRUG|0.9% sodium chloride injection|Intracoronary bolus
223863244|NCT06313125|OTHER|3-dimensional foot-ankle extension exercises|In three-dimensional foot-ankle extension exercises, an elastic band will be used to create resistance to the movement and the intensity/severity of the exercise will be between 13 (somewhat difficult) and 15 (difficult) according to the perceived difficulty level on the Borg scale. Exercises will begin with red (light) tape; Progression will be achieved by moving to a higher level band color \[green (medium) and blue (difficult) in that order\] every two weeks. Exercises will be performed 3 days a week (2 days supervised, 1 day at home), in 3 sets of 10 repetitions, and a 1-minute rest period will be given between sets to reduce fatigue. Short-foot exercises will be performed in 3 sets of 15 repetitions, with a 45-second rest period between sets, every day a week (2 days/week with a physiotherapist; 5 days/week at home) for 6 weeks.
223863245|NCT06313125|OTHER|Clam exercise|In three-dimensional foot-ankle extension exercises and clam exercise, an elastic band will be used to create resistance to the movement and the intensity/severity of the exercise will be between 13 (somewhat difficult) and 15 (difficult) according to the perceived difficulty level on the Borg scale. Exercises will begin with red (light) tape; Progression will be achieved by moving to a higher level band color \[green (medium) and blue (difficult) in that order\] every two weeks. Exercises will be performed 3 days a week (2 days supervised, 1 day at home), in 3 sets of 10 repetitions, and a 1-minute rest period will be given between sets to reduce fatigue. Short-foot exercises will be performed in 3 sets of 15 repetitions, with a 45-second rest period between sets, every day a week (2 days/week with a physiotherapist; 5 days/week at home) for 6 weeks.
223863246|NCT06313125|OTHER|Short-foot exercise|In clam exercise, an elastic band will be used to create resistance to the movement and the intensity/severity of the exercise will be between 13 (somewhat difficult) and 15 (difficult) according to the perceived difficulty level on the Borg scale. Exercises will begin with red (light) tape; Progression will be achieved by moving to a higher level band color \[green (medium) and blue (difficult) in that order\] every two weeks. Exercises will be performed 3 days a week (2 days supervised, 1 day at home), in 3 sets of 10 repetitions, and a 1-minute rest period will be given between sets to reduce fatigue. Short-foot exercises will be performed in 3 sets of 15 repetitions, with a 45-second rest period between sets, every day a week (2 days/week with a physiotherapist; 5 days/week at home) for 6 weeks.
223863247|NCT06480942|OTHER|Detection of preload responders by a PLR test|Detection of preload dependency by using PLR test and echocardiography
223863248|NCT01876602|BEHAVIORAL|feeling states exercise intervention|exercise prescription based on intensity of exercise that feels good.
223863249|NCT05857371|PROCEDURE|lipoaspiration|The surgeon will perform lipoaspiration under local anesthesia for the ADSVF production.
223863250|NCT05857371|PROCEDURE|urethrotomy|The urologist will perform an endoscopic urethrotomy (standard care).
223863251|NCT05857371|DRUG|autologous ADSVF administration|ADSVF will be administrated in fibrotic lesion during urethrotomy by the urologist.
223863252|NCT04580160|DEVICE|Duo Venous Stent System|Subjects with nonmalignant iliofemoral venous outflow obstruction presenting with nonthrombotic (NT), acute thrombotic (AT) or chronic postthrombotic (CPT) disease pathogenesis will be selected for study participation.
223863253|NCT04128358|DIAGNOSTIC_TEST|Serological assay for blood born viral hepatitis|Qualitative PCR for patients with hepatitis C antibody positive
223863254|NCT04128358|DIAGNOSTIC_TEST|Quantitative microbiological test for HCV|Quantitative PCR in those with proven HCV infection
223863255|NCT05906875|OTHER|Lateral Stepping Exercise 1|1\. Standing hip abduction: Performed without and with resistance bands and/or support. The participant will raise one leg out to the side and return. If using a resistance band, one end of the band will be secured to a stable surface and the other end placed around one of the participants' ankles. The banded leg will be raised to the side. Three sets of 8-12 repetitions will be performed per side.
223863256|NCT05906875|OTHER|Active Control Group Exercise 1|1\. Seated ankle movements (dorsi-/plantarflexion)hree sets of 8-12 repetitions will be performed per limb with the maintenance of end-range contraction of 6 seconds.
223863257|NCT05906875|OTHER|Active Control Group Exercise 2|2\. Knee extension Three sets of 8-12 repetitions will be performed per limb with the maintenance of end-range contraction of 6 seconds.
223863258|NCT05906875|OTHER|Active Control Group Exercise 3|3\. Hip flexion Three sets of 8-12 repetitions will be performed per limb with the maintenance of end-range contraction of 6 seconds.
223863259|NCT05906875|OTHER|Active Control Group Exercise 4|4\. Hip abduction Three sets of 8-12 repetitions will be performed per limb with the maintenance of end-range contraction of 6 seconds.
223863260|NCT05906875|OTHER|Lateral Stepping Exercise 2|2\. Lateral stepping: Performed without and with resistance bands. The participant will perform a series of steps to the side. If using a resistance band, the band will be placed around both ankles in a 'loop' and the participant will perform the lateral stepping. Three sets of 8-12 repetitions will be performed per side per subject.
223863261|NCT05906875|OTHER|Lateral Stepping Exercise 3|3\. Single leg stance: The participant will stand on one leg with support as needed. The contralateral knee will be held at 45 degrees throughout the exercise. The instructor will observe to ensure the bent leg does not contact the ground. Three repetitions of static stance per side will be performed with a goal of 30 seconds, and a maximum time of 60 seconds, per repetition.
223863262|NCT05906875|OTHER|Lateral Stepping Exercise 4|4\. Staggered stance mini-squat: Participants will stand with the feet hip-width apart and one leg placed a short step forward. The participant will squat straight down keeping the trunk upright and return to an upright position.
223863263|NCT05906875|OTHER|Lateral Stepping Exercise 5|5\. Lateral Reactive Postural Control: The participant will lean into the researcher's hand to shift their center of mass outside of their base of support. Hand placement will be at the glenohumeral joint and the pelvis. The researcher will withdraw support and guard the participant as the participant regains their balance. This is item 6 on the Mini-BESTest assessment that will be incorporated as an intervention. To be performed 3x per side.
223863264|NCT00155415|BEHAVIORAL|Different timing of taking polyethylene glycol(PEG)|
223863265|NCT05260086|DEVICE|Neuronavigated aiTBS|Accelerated intermittent theta burst stimulation (aiTBS, 4 sessions per day with at least 20 minutes pause between sessions) in the left dorsolateral prefrontal cortex (DLPFC)
223863266|NCT00051272|DRUG|Extended-release Bupropion Hydrochloride|
223863267|NCT00701896|DRUG|Varenicline tartrate|1 mMg tablet form; daily during week 1 (pre-quit week) followed by 1 mg twice daily for weeks 2-12.
223863268|NCT00701896|DRUG|Nicotine Replacement Therapy|Nicotine gum and nicotine patch
223863269|NCT00701896|OTHER|Biological Control|No treatment intervention only information and procedures.
223863270|NCT00701896|BEHAVIORAL|Motivational Interview|60 minute one-on-one Interview
223863271|NCT02722070|DEVICE|3 Tesla Siemens Skyra MRI scanner|Standardly used Magnetic resonance imaging (MRI) protocols, including resting state fMRI, task fMRI, T1 weighted imaging
223863272|NCT02807467|DRUG|Dexmedetomidine|Continuous infusion of dexmedetomidine between 8pm and 6am after diagnosis of hyperactive or mixed delirium. The infusion might have to be repeated several times to achieve resolution of delirium.
223863273|NCT02807467|DRUG|Propofol|Continuous infusion of propofol between 8pm and 6am after diagnosis of hyperactive or mixed delirium. The infusion might have to be repeated several times to achieve resolution of delirium.
223863274|NCT01374893|BEHAVIORAL|Exercise|The intervention group will perform the multi-session per day training program
223863275|NCT01374893|BEHAVIORAL|Control|Usual care
223863276|NCT00084045|PROCEDURE|Intrapartum HIV counseling/testing|
223863277|NCT00084045|PROCEDURE|Postpartum HIV counseling/testing|
223863278|NCT05317572|DRUG|80 mcg intrathecal morphine|"İntraoperative Management:~Spinal anesthesia was administered to each patient in a sitting position, after aseptic conditions were achieved with a midline approach. A 25 gauge pencil point spinal needle was placed in the L3-4 or L4-5 space. Upon aspiration of clear cerebrospinal fluid (CSF), 10 mg of hyperbaric bupivacaine, 20 mcg of fentanyl and 80 micrograms of morphine were injected into the intrathecal space together with the determined morphine doses.~Postoperative analgesia management:~Diclofenac sodium 2 × 75 mg was administered intramuscularly to all patients. All patients received iv Patient Controlled Analgesia (PCA) prepared with fentanyl postoperatively. For patients with pain VAS score of 5 or more, meperidine was administered at a rate of 25 mg each time and with a total daily dose of 200 mg."
223863279|NCT05317572|DRUG|120 mcg intrathecal morphine|"İntraoperative Management:~Spinal anesthesia was administered to each patient in a sitting position, after aseptic conditions were achieved with a midline approach. A 25 gauge pencil point spinal needle was placed in the L3-4 or L4-5 space. Upon aspiration of clear cerebrospinal fluid (CSF), 10 mg of hyperbaric bupivacaine, 20 mcg of fentanyl and 120 micrograms of morphine were injected into the intrathecal space together with the determined morphine doses.~Postoperative analgesia management:~Diclofenac sodium 2 × 75 mg was administered intramuscularly to all patients. All patients received iv Patient Controlled Analgesia (PCA) prepared with fentanyl postoperatively. For patients with pain VAS score of 5 or more, meperidine was administered at a rate of 25 mg each time and with a total daily dose of 200 mg."
223863280|NCT05317572|DRUG|160 mcg intrathecal morphine|"İntraoperative Management:~Spinal anesthesia was administered to each patient in a sitting position, after aseptic conditions were achieved with a midline approach. A 25 gauge pencil point spinal needle was placed in the L3-4 or L4-5 space. Upon aspiration of clear cerebrospinal fluid (CSF), 10 mg of hyperbaric bupivacaine, 20 mcg of fentanyl and 160 mcg of morphine were injected into the intrathecal space together with the determined morphine doses.~Postoperative analgesia management:~Diclofenac sodium 2 × 75 mg was administered intramuscularly to all patients. All patients received iv Patient Controlled Analgesia (PCA) prepared with fentanyl postoperatively. For patients with pain VAS score of 5 or more, meperidine was administered at a rate of 25 mg each time and with a total daily dose of 200 mg."
223863281|NCT00000152|DRUG|Aspirin|
223863282|NCT00000152|DRUG|Beta-Carotene|
223863283|NCT00006327|BIOLOGICAL|MN rgp120/HIV-1 and A244 rgp120/HIV-1|
223863284|NCT03473522|DEVICE|tDCS|Transcranial direct current stimulation is a modulation technique of neuronal excitability which has very promising results in Parkinson's disease. In addition to the possibility of increasing the excitability of areas to tDCS, it can also facilitate the execution of the exercises by increasing the excitability of the primary motor cortex and changing the recruitment strategies of the motor units.
223863285|NCT03473522|BEHAVIORAL|Exercise Therapy|Therapeutic exercises will be based on the literature (O'Sullivan and Schmitz 2004, Klamroth et al 2016, Reynolds et al., 2016, Pérez et al 2016, Smania et al., 2010, Pastor et al., 1993, Traub et al., 1980, Schoneburg et al., 2013) Each session will be divided into warm-up exercises; balance and relaxation, with a duration of 50 minutes and a frequency of 3 times a week. Training progresses and intensifies every two weeks. The subjects will perform five repeated movements of each exercise, evolving according to the condition of each patient (according to the Hoehn and Yahr staging scale).
223863286|NCT00186186|DRUG|Depakote ER|Depakote ER
223863287|NCT02327611|DRUG|Custodiol|
223863288|NCT02327611|DRUG|Enriched Ringer's lactate solution|
223863289|NCT05910918|BEHAVIORAL|Intensive Care Nurses' Training Package|For the study group, the researcher will explain the method of the training package program application to critical care nurses as follows; firstly, the researchers will assess the nurses' roster, then the researchers will classify the subjects into groups in order to conduct the training package for a group of them while the other subjects taking care of the patients in the intensive care units and repeat the same session to the others in the same manner.
223863290|NCT00016471|PROCEDURE|Audiogram|
223863291|NCT00016471|PROCEDURE|Electroretinogram|
223863292|NCT06176482|DEVICE|Magnetic markers implantation|Surgical implantation of magnetic markers in the upper limb stump to allow the management of an external hand prosthesis
223863293|NCT05496777|PROCEDURE|Home-based prehabilitation program|The home-based prehabilitation program will consist of a four-week program, where patients are expected to perform a high-intensity interval training on a home-trainer combined with functional mobility training three times a week. The program is partly supervised by a trained physiotherapist.
223863294|NCT05972915|DIAGNOSTIC_TEST|Separation sign|The separation sign was recorded as positive if separation of the myometrium from the placenta was observed in all areas of the placenta. The sign was recorded as negative if the myometrium and placenta moved as one structure and no clear zone could be seen over any part of the placenta after release, even if separation was noted at the margins of the placenta.
223863295|NCT02735291|BIOLOGICAL|CD19-targeted CAR-T cells|This study have only one arm that is CAR-T experimental arm. Firstly all participators will be attended the screening, who passed the screening for the treatment of CAR-T cells, the CAR-CD19-modified T cells can recognize and kill tumor cells in the body，follow-up 35 months..
223863296|NCT00427323|PROCEDURE|light exposure|
223863297|NCT05377567|BEHAVIORAL|TAU + FIBRO-On|Group treatment protocol of 12 weekly 60 minute sessions (virtual intervention)
223863298|NCT05377567|BEHAVIORAL|TAU + FIBRO-Out|Group treatment protocol of 12 weekly 120 minute sessions (outdoor intervention)
223863299|NCT05377567|OTHER|Treatment as Usual (TAU)|Standard pharmacological treatment usually provided to patients with fibromyalgia.
223863300|NCT00900211|GENETIC|microarray analysis|
223863301|NCT00900211|GENETIC|molecular diagnostic method|
223863302|NCT00900211|OTHER|biologic sample preservation procedure|
223863303|NCT00003540|DRUG|gemcitabine hydrochloride|
223863304|NCT00394615|PROCEDURE|Metabolic Imaging|
223863305|NCT06290297|DEVICE|Telerehabilitation VRRS|Telerehabilitation programs delivered at home, aiming to improve cognitive, motor and/or speech-language skills, through VRRS - Khymeia or Niurion devices. Such technologies are equipped with a wide library of activities to be performed also with the use of peripheral sensors. A one-shot assessment is also proposed to children admitted to institutes adhering to the project in order to understand the feasibility of the use of such devices. Ad hoc feasibility questionnaire are administered at the end of the one shot session and after the home training to the main stakeholders (children, families, clinicians)
223863306|NCT00142558|DRUG|MK0663; etoricoxib / Duration of Treatment: 5 Days|
223863307|NCT00142558|DRUG|Comparator: indomethacin 75 mg sustained release capsule / Duration of Treatment: 5 Days|
223863308|NCT01337635|DRUG|Vitamin D|Ergocalciferol 300,000 IU single oral dose Cholecalciferol 400 IU orally every day for 6 weeks
223863309|NCT01673516|PROCEDURE|The SymplicityTM Renal Denervation System|For patients who will be randomly assigned to undergo renal denervation (group RDN), the femoral artery will be accessed with the standard endovascular technique and the catheter will be advanced into the renal artery and connected to a radiofrequency generator. As in Simplicity HTN 1 and 2 trials, four-to-six discrete, low-power radiofrequency ablations lasting up to 2 min each and of 8 watts or less to obtain up to four-six ablations separated both longitudinally and rotationally within each renal artery. During ablation, the catheter system monitored tip temperature and impedance, altering radiofrequency energy delivery in response to a predetermined algorithm.
223863310|NCT01673516|DEVICE|The HOTMAN® System|"Impedance Cardiography by HOTMAN system will evaluates non-invasively hemodynamic parameters in patients randomized to group Co"
223863311|NCT05977179|OTHER|Dietary intervention to mitigate Post-Acute COVID-19 Syndrome|As it was described in the arm/group descriptions.
223863312|NCT05977179|OTHER|Attention Control|As it was described in the arm/group descriptions.
223863313|NCT01536834|DEVICE|Medical Device|
223863314|NCT04413838|DRUG|NIVOLUMAB|IV injection within 30 minutes of 24ml file (=240 mg) containing NIVOLUMAB BMS(Bristol-Myers Squibb) 10mg/ml (immune check point inhibitor targeting PD-1) on top of routine standard of care for COVID-19 infection
223863315|NCT04413838|OTHER|Routine standard of care|No intervention is planned in this arm. Patients will follow routine standard of care for the COVID-19 treatment
223863316|NCT05774119|OTHER|breakfast with coffee|breakfast with coffee with 6 mg/caffeine/kg body weight
223863317|NCT05774119|OTHER|breakfast with water|breakfast with 250 mL of water
223863318|NCT06336473|PROCEDURE|skin biopsy|Samples will be taken under local anaesthetic (after injection of 1 cc of Xylocaine without adrenaline) using a 4 mm diameter dermal biopsy punch. The biopsy will be performed on the buttocks. Fragments are stored in 15-mL polypropylene tubes in PBS at 4°C.
223863319|NCT01239758|BIOLOGICAL|ACE-031 (Extension of cohort 1 from core study, A031-03)|ACE-031 0.5 mg/kg subcutaneously once every 4 weeks for 24 weeks.
223863320|NCT01239758|BIOLOGICAL|ACE-031 (Extension of cohort 2 from core study, A031-03)|Up to 1.0 mg/kg subcutaneously once every 2 weeks for 24 weeks.
223863321|NCT01239758|BIOLOGICAL|ACE-031 (Extension of cohort 3 from core study, A031-03)|Up to 2.5 mg/kg subcutaneously once every 4 weeks for 24 weeks.
223863322|NCT03176654|PROCEDURE|HVLAT manipulation|HVLAT will be performed 10 minutes after the first blood draw.
223863323|NCT03176654|PROCEDURE|Sham HVLAT manipulation|Sham HVLAT will be performed 10 minutes after the first blood draw.
223863324|NCT05704920|OTHER|IA|The multidisciplinary team meeting discussion is informed of the AI-based analysis of their chest computed tomography
223863325|NCT05704920|OTHER|Not IA|The multidisciplinary team meeting discussion is not informed of the AI-based analysis of their chest computed tomography
223863326|NCT02567656|DRUG|RP6530|Tablet starting at 200 mg
223863327|NCT02759913|PROCEDURE|Lumbar puncture|Collection of biofluids to determine the accuracy, sensitivity and specificity of a diagnostic test developed by Iron Horse Diagnostics
223863328|NCT06118827|DRUG|HS-10518|QD, orally for 7 days
223863329|NCT06118827|DRUG|Placebo|QD, orally for 7 days
223863330|NCT01307267|DRUG|PF-05082566|Intravenous, Dose escalation, once per month
223863331|NCT01307267|DRUG|rituximab|Intravenous, 375 mg/m2, once per week for 4 weeks
223863332|NCT01307267|DRUG|PF-05082566|IV, Dose escalation, once per month
223863333|NCT02135042|DRUG|Cisplatin|Given IV
223863334|NCT02135042|OTHER|Clinical Observation|Undergo clinical observation
223863335|NCT02135042|DRUG|Fluorouracil|Given IV
223863336|NCT02135042|DRUG|Gemcitabine Hydrochloride|Given IV
223863337|NCT02135042|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
223863338|NCT02135042|OTHER|Laboratory Biomarker Analysis|Correlative studies
223863339|NCT02135042|DRUG|Paclitaxel|Given IV
223863340|NCT02135042|OTHER|Quality-of-Life Assessment|Ancillary studies
223863341|NCT00734240|DRUG|ISIS 353512|50 mg via 2 hour IV infusion, single dose
223863342|NCT00734240|DRUG|ISIS 353512|50 mg via 2 hour IV infusion, 6 doses over 22 days
223863343|NCT00734240|DRUG|ISIS 353512|50 mg via SC injection, single dose
223863344|NCT00734240|DRUG|ISIS 353512|50 mg via SC injection, 6 doses over 22 days
223863345|NCT00734240|DRUG|ISIS 353512|2 hour IV infusion, 50 mg on day 3, 100 mg on day 5, and 200 mg on day 8
223863346|NCT00734240|DRUG|ISIS 353512|100 mg via 2 hour IV infusion, single dose
223863347|NCT00734240|DRUG|ISIS 353512|200 mg via 2 hour IV infusion, single dose
223863348|NCT00734240|DRUG|ISIS 353512|100 mg via SC injection, single dose
223863349|NCT00734240|DRUG|ISIS 353512|200 mg via SC injection, single-dose
223863350|NCT00734240|DRUG|ISIS 353512|100 mg via 2 hour IV infusion, 6 doses over 22 days
223863351|NCT00734240|DRUG|ISIS 353512|200 mg via 2 hour IV infusion, 6 doses over 22 days
223863352|NCT00734240|DRUG|ISIS 353512|100 mg via SC injection, 6 doses over 22 days
223863353|NCT00734240|DRUG|ISIS 353512|200 mg via SC injection, 6 doses over 22 days
223863354|NCT00734240|DRUG|ISIS 353512|100 mg via SC injection PLUS an oral treatment of a NSAID, acetaminophen, or oral placebo
223863355|NCT00734240|DRUG|ISIS 353512|200 mg via SC injection PLUS an oral treatment of a NSAID, acetaminophen, or steroid
223863356|NCT00734240|DRUG|ISIS 353512|2 hour IV infusion, 50 mg on day 1, 100 mg on day 3, 100 mg on day 5 and 200mg on day 8
223863357|NCT06520137|PROCEDURE|Tooth extraction|Extraction of maxillary third molars
223863358|NCT02887898|DEVICE|Automated bolus calculator|
223863359|NCT02887898|OTHER|Education|
223863360|NCT00252278|DRUG|atomoxetine|
223863361|NCT04956575|BIOLOGICAL|mRNA-1010|Sterile liquid for injection
223863362|NCT04956575|BIOLOGICAL|Placebo|0.9% sodium chloride solution for injection
223863363|NCT04956575|BIOLOGICAL|Active Comparator|0.5 milliliter (mL) intramuscular (IM) injection
223863364|NCT04536519|OTHER|osteoarthritis management|"The conventional physical therapy will be consisted of an array of protocols being deployed in parallel. This will consist of~* Patient education regarding deforming forces, strategies of prevention and home exercise program~* Decreasing stiffness by controlled active range of motion and mobilization techniques involving join play.~* Mechanical stresses will be controlled in form of support provided by foot wear modification~* Range of motion will be increased muscle stretches and manual mobilization techniques~* Muscle performance and neuromuscular control will be addressed by gentle exercises of low intensity and repetitive exercises.~* Balance improvement by employing balance training activities as part of treatment~* Physical conditioning low impact or non-impact aerobics This conventional exercise will be given as baseline treatment to both of groups."
223863365|NCT03593876|BEHAVIORAL|Strategy Training|This study will use an adapted form of strategy training for people with communication impairments.
223863366|NCT00258635|BIOLOGICAL|RagweedMATAMPL|
223863367|NCT00002893|DRUG|fluorouracil|
223863368|NCT00002893|DRUG|leucovorin calcium|
223863369|NCT00002893|DRUG|raltitrexed|
223863370|NCT04456218|DEVICE|NCKU-scope-01 (a custom-made biliary endoscope system)|The NCKU-scope-01 is a custom-made endoscope system for this study and it will be applied to help biliary disorders diagnosis
223863371|NCT00281424|DEVICE|pedometer|gave pedometer and info
223863372|NCT05882812|DEVICE|Sustained Acoustic Device with 2.5% Diclofenac Patch|Patients apply the SAM Ultrasonic Diathermy Device daily for 1-4 hours of continuous therapeutic ultrasound at 3 megahertz(MHz) frequency and 0.132 Watts/cm\^2 with 2.5% Diclofenac patches.
223863373|NCT05882812|DEVICE|Sustained Acoustic Device with 0% Diclofenac Patch|Patients apply the SAM Ultrasonic Diathermy Device daily for 1-4 hours with 0% diclofenac patches.
223863374|NCT05882812|DRUG|2.5% Diclofenac Patches|Topical pain relief-gel worn for 4 hours at least 5 days a week via SAM patch.
223863375|NCT03195075|PROCEDURE|Endoscopic ultrasonography guided biliary drainage|Endoscopic ultrasonography guided biliary drainage includes rendezvous techniques, endoscopic ultrasonography guided choledochoduodenostomy, and endoscopic ultrasonography-guided hepatogastrostomy using self-expandable metal stent will be done for group 1
223863376|NCT03195075|PROCEDURE|Percutaneous trans-hepatic biliary drainage|Percutaneous trans-hepatic biliary drainage in interventional radiology department using self-expandable metal stent will be done for group 2
223863377|NCT02682446|DRUG|H pylori eradication|The regimen of H. pylori eradication was like that: 1-week conventional proton pump inhibitor (PPI) based triple therapy (lansoprazole 40 mg b.i.d., clarithromycin 500 mg b.i.d., and amoxicillin 1 g b.i.d. for a week) after confirmation of H. pylori infection. If the participants who initially failed to respond to the first eradication, they recommended to underwent second-line eradication therapy with the regimen of 7-day bismuth containing quadruple regimen \[lansoprazole 40 mg b.i.d., tripotassium dicitrate bismuthate (Denol; Greencross Co., Seoul, Korea) 300 mg q.i.d. (three tablets 30 min before meals and one tablet 2 hours after dinner), metronidazole 500 mg t.i.d., and tetracycline 500 mg q.i.d. for 1 week\]
223863378|NCT00432458|DRUG|Thalidomide|200 mg orally on days 1-28 of 28 day cycle
223863379|NCT00432458|DRUG|zoledronic acid|4 mg\^2 by IV on day 1 every 84 days for 1 year and once per year thereafter
223863380|NCT00289835|DEVICE|Paclitaxel eluting stent|Patients are randomized to either stenting the moderate SVG lesion with the paclitaxel stent or standard medical treatment
223863381|NCT01721434|DRUG|Levosimendan|
223863382|NCT01721434|DRUG|Placebo|Similar coloured placebo
223863383|NCT06340646|OTHER|Return of Genetic Results: Biomarker information from cancer cells|Participants will receive a novel return of results report that is tailored to their choices.
223863384|NCT06340646|OTHER|Return of Genetic Results: Inherited mutations related to cancer|Participants will receive a novel return of results report that is tailored to their choices.
223863385|NCT06340646|OTHER|Return of Genetic Results: Inherited mutations related to other medical issues|Participants will receive a novel return of results report that is tailored to their choices.
223863386|NCT05837806|DRUG|tislelizumab+disitamab-vedotin|Patients enrolled will receive 3 cycles of tislelizumab 200 mg in combination with disitamab-vedotin (RC48) 2.0mg/kg intravenously.
223863387|NCT05978037|BIOLOGICAL|RH5.1 and/or RH5.2-VLP with Matrix-M|"The RH5.1 protein consists of the entire full-length ectodomain of the PfRH5 antigen (amino acids E26 - Q526) with the sequence based on the 3D7 clone of P. falciparum.~The RH5.2 protein consists of the stabilised core region of PfRH5 antigen with SpyTag fused at the C-terminus. The RH5.2-SpyTag protein is conjugated to hepatitis B surface antigen (HBsAg)-SpyCatcher to produce the final RH5.2-VLP vaccine.~The Matrix-M has been developed and manufactured by Novavax AB and is presented as a liquid solution in a glass vial."
223863388|NCT01221779|BEHAVIORAL|Intensive language therapy|2 weeks of daily computerized naming training, daily, 3 hours
223863389|NCT01221779|BEHAVIORAL|Intensive language therapy|2 weeks of daily computerized naming training, daily, 3 hours
223863390|NCT03990272|DRUG|AIT drops|once a day
223863391|NCT03990272|DRUG|placebo drops|once a day
223863392|NCT00161733|DRUG|Fibrin Sealant Vapor Heated Solvent/Detergent Treated (FS VH S/D)|
223863393|NCT00161733|DRUG|TISSEEL VH fibrin sealant|
223863394|NCT04551781|DRUG|20 Mg Prednisone for 14 days|20 Mg Prednisone for 14 days
223863395|NCT04551781|DRUG|control|symptomatic ttt
223863396|NCT05095051|DEVICE|Paxman Cryocompression System (PCCS)|"Establishing optimal temperature and pressure for limb cryocompression therapy. Healthy subjects will undergo 3 hours of limb cryocompression.~The cryocompression device used in this study consists of a control unit, and limb wraps. The control unit contains the coolant reservoir and pump to circulate the coolant and air for compression. It is able to thermoregulate (control the temperature of the circulating coolant) and offer cyclic air pressure in the wraps. The wraps cover the limbs from the elbow/knee to the fingers/toes."
223863397|NCT05095051|DEVICE|Paxman Cryocompression System (PCCS)|"The study population will comprise of cancer patients scheduled to receive weekly paclitaxel chemotherapy for a maximum of 12 cycles.~Paclitaxel will be administered as a one-hour infusion. Limb cryocompression sessions comprised of a pre-cooling period (up to one hour), continued with paclitaxel infusion and a post-cooling period (on average 30 minutes after the end of paclitaxel infusion). Overall, limb cryocompression will be administered for no longer than four hours."
223863398|NCT03382080|OTHER|Dream School Program|The Dream School program is a whole school program, involving staff and students, with the aim of creating learning environments where students are confident and experience a sense of belonging, and where mental health is promoted.
223863399|NCT03382080|OTHER|Mental Health Support Team|"MHST is also a whole school project but aimed at specific students at risk of dropping out. It is a systematisation of the student services through~1. Co-location of services and staff working in services~2. One open door to increase accessibility to the services and staff for students~3. Focus on the transition from lower to upper secondary school~4. Close follow-up of students at risk to ensure tailored help to each student~5. Early intervention and follow up when students starts being absent from school This work demands cross- and multidisciplinary collaborations within the MHST, between MHST and school leadership, and between lower and upper secondary schools."
223863400|NCT03941912|DEVICE|Erchonia EVRL|Single treatment with the Erchonia EVRL to the neck and shoulders. The treatment applies 635 nanometers (nm) red diode light and 405 nm violet diode light simultaneously.
223863401|NCT00816049|DRUG|6MPindividualized|Oral 6-mercaptopurine with a starting dose of 25 mg/m2 and upward adjusted in steps of 25 mg/m2 (i.e. 50 or 75 mg/m2) if unacceptable bone-marrox toxicity is not encountered
223863402|NCT00816049|DRUG|6MPfixed|Oral 6-mercaptopurine at a fixed dose of 25 mg/m2 treatment days 30-85
223863403|NCT02692742|DRUG|Myelo001|Intake of study drug once daily per os for a maximum of 28 days in addition to Epirubicin and Cyclophosphamide treatment
223863404|NCT02692742|DRUG|Placebo|Intake of study drug once daily per os for a maximum of 28 days in addition to Epirubicin and Cyclophosphamide treatment
223863405|NCT06395870|BIOLOGICAL|LUCAR-G39D cells product|Prior to infusion of the LUCAR-G39D, subjects will receive a conditioning premedication regimen consisting of cyclophosphamide and fludarabine.
223863406|NCT01443117|BIOLOGICAL|PPV-23 Vaccine|Administered as a 0.5 mL IM dose
223863407|NCT01443117|BIOLOGICAL|PCV-13 Vaccine|Administered as a 0.5 mL IM dose
223863408|NCT01443117|BIOLOGICAL|Placebo Vaccine|Administered as a 0.5 mL IM dose
223863409|NCT03419156|OTHER|Text Message Arm Intervention|Patients in the Text Message Arm will receive a weekly set of text messages inquiring about the patients' symptoms instead of a weekly phone call from the nurse team (standard of care). Potentially harmful symptoms identified by the automated system will generate an alert that will be sent to the medical team. The alert will be immediately sent via email to the nursing team. The nurse will be able to contact the patient to decide the best further treatment. The nurses will check patient response rates daily. If a patient does not respond to their weekly message, then the patient will be called.
223863410|NCT04483856|DEVICE|DermoRelizema cream|Fingertip units (FTU) depending from the extent of the affected skin to treat, two times per day for 7 (±3) days prior RT until about 14 (±3) days post RT end. The product can be used for further 2 weeks (from V3 to V4) in case of need, according to the investigator's judgment
223863411|NCT04483856|DEVICE|Dexeryl|FTUs depending on the extent of the affected skin to treat, two times per day. The treatment will be applied since 7 (±3) days prior to RT start and will continue until 14 days post RT end (98-112 applications in total).
223863412|NCT04143126|BEHAVIORAL|Cognitive Enhancement Therapy|An 18-month comprehensive, small group approach for the remediation of cognitive deficits in neurodevelopmental disorders consisting of individual sessions and 45 group training sessions in social cognition that are integrated with approximately 60 hours of computer assisted training in attention, memory, and problem solving skills.
223863413|NCT04143126|BEHAVIORAL|Enriched Supportive Therapy|An 18-month intervention that uses individual supportive therapy to help patients learn about schizophrenia, manage their emotions and stress, improve their social skills, and cope with everyday problems. Participants will learn about the impact of stress on their lives, and how to identify their own early cues of distress and apply effective coping strategies.
223863414|NCT02513238|DRUG|Mesenchymal stem cell|Stemcells injected into submandibularis
223863415|NCT02513238|DRUG|Isotonic NaCl|
223863416|NCT03105219|DRUG|Ivabradine|Ivabradine 5mg twice a day (on day 0), heart rate evaluated at day 14 and 28 repeatedly, and the targeted value of heart rate 50-60bpm, the largest dosage 7.5mg twice a day.
223863417|NCT03105219|OTHER|Sham Comparator|Urinary albumin excretion (UAE) assessment will be performed before randomization (Day 0), 28-day after randomization (Day 28), and 90-day after randomization (Day 28).
223863418|NCT05599256|DRUG|Ruxolitinib|"Model-predicted high-risk patients: weight ≤ 25 kg, ruxolitinib, 2.5mg bid po until at least day 60 post-transplant and terminated after day 100; weight \> 25 kg, ruxolitinib, 5mg bid po until at least day 60 post-transplant and terminated after day 100. If 'azoles' are taken concomitantly, ruxolitinib will start at half dose. If the patient tolerates ruxolitinib, the dose can be increased to 10mg bid po.~Model-predicted low risk: regular aGVHD prophylactic regimens."
223863419|NCT05136443|DRUG|loteprednol etabonate 0.25% ophthalmic suspension|tapering dose
223863420|NCT01486550|DRUG|Voluven (Hydroxyethyl starch 130/0,4)|7,5 ml/kg in the first hour and then 5 ml/kg minimum
223863421|NCT01486550|DRUG|Sodium Chloride 9mg/ml|7,5 ml/kg in the first hour and then 5 ml/kg
223863422|NCT03097744|DEVICE|Ceterix NovoStitch|The device allows the physician to place a circumferential compression stitch around meniscal tears. This stitch is placed by passing suture from the tibial side to the femoral side of the meniscus and across the tear. This allows compression across the entire tear surface.
223863423|NCT03575819|DRUG|FOR46|FOR46 is an intravenously (IV) administered antibody-drug conjugate (ADC) directed against CD46
223863424|NCT01241435|DRUG|LY2216684|Administered orally
223863425|NCT02221219|DRUG|Indomethacin|indomethacin at standard dose for prevention of intraventricular hemorrhage in preterm infants
223863426|NCT02221219|PROCEDURE|delay in umbilical cord clamp at birth|provision of a \~45 second delay of umbilical cord clamping at birth in preterm infants (recorded in delivery note)
223863427|NCT02221219|DRUG|placebo infusion|saline infusion to match input of indomethacin treatment group (and serve as drug-dosing 'blinding' for bedside staff)
223863428|NCT02221219|PROCEDURE|immediate cord clamp at birth|no delay in umbilical cord clamp; \<10sec (recorded in delivery note)
223863429|NCT04559555|DRUG|Nilotinib|The compassionate use dose of nilotinib is 400 mg orally twice daily and should not be taken with food
223863430|NCT03794193|PROCEDURE|Radical resection of colon cancer|The patients with colon cancer will receive radical surgery. Adjuvant chemotherapy will be given according to the results of postoperative histological results.
223863431|NCT02783755|BEHAVIORAL|Device: smartphone|Coping Skills Training for pain will be delivered to participants using video-conferencing
223863432|NCT03600935|OTHER|Vancouver Clinical Pathway|Vancouver Clinical Pathway
223863433|NCT06479668|BEHAVIORAL|Trier Social Stress Task|Specify details not covered in associated Arm Description.
223863434|NCT00232895|DRUG|lipuro propofol|
223863435|NCT00232895|DRUG|standard formulation propofol|
223863436|NCT05345119|DRUG|Sirolimus|2 mg orally on the first day followed by 0.5 mg per day for 12 weeks
223863437|NCT05345119|DRUG|Methylprednisolone|500 mg/weekly (6 weeks) intravenously, 250 mg/weekly (6 weeks) (cumulative dose 4.5 g).
223863438|NCT00604019|DRUG|Dopamine|Dopamine 5-20 mcg/kg/min to pre-determined max of 20
223863439|NCT00604019|DRUG|Norepinephrine|Norepinephrine 5-20 mcg/min, to a pre-determined max of 20
223863440|NCT00779545|DRUG|Placebo|One, two, or four sprays of placebo are administered to the left and right nostrils twice a day (in the morning and at night) for 2 weeks.
223863441|NCT00779545|DRUG|Mometasone furoate|One spray of mometasone furoate 50 mcg is administered to the left and right nostrils in the morning, and one spray of placebo to the left and right nostrils at night for 2 weeks. The daily dose of mometasone furoate is 100 mcg.
223863442|NCT00779545|DRUG|Mometasone furoate|Two sprays of mometasone furoate 50 mcg are administered to the left and right nostrils in the morning, and two sprays of placebo to the left and right at night for 2 weeks. The daily dose of mometasone furoate is 200 mcg.
223863443|NCT00779545|DRUG|Mometasone furoate|Four sprays of mometasone furoate 50 mcg are administered to the left and right nostrils in the morning, and four sprays of placebo to the left and right nostrils at night for 2 weeks. The daily dose of mometasone furoate is 400 mcg.
223863444|NCT00779545|DRUG|Mometasone furoate|One spray of mometasone furoate 50 mcg is administered to the left and right nostrils twice a day (in the morning and at night) for 2 weeks. The daily dose of mometasone furoate is 200 mcg.
223863445|NCT00779545|DRUG|Mometasone furoate|Two sprays of mometasone furoate 50 mcg are administered to the left and right nostrils twice a day (in the morning and at night) for 2 weeks. The daily dose of mometasone furoate is 400 mcg.
223863446|NCT05222087|RADIATION|Radiotherapy|35Gy/5# Central 40Gy/5# Large Tumours \>5cm (non-central) 36Gy/12# or 40Gy/15# Ultracentral lesions 50Gy/5# Peripheral Tumours ≤5cm
223863447|NCT05222087|DRUG|SoC systemic therapy|Permitted SoC chemoimmunotherapy for squamous patients will include single agent immunotherapy with Pembrolizumab or in combination with Carboplatin or Paclitaxel. Carbo/Paclitaxel/Pembro intravenous infusions are given every 3 weeks for cycle 1-4, followed by ongoing maintainence with Pembrolizumab from Cycle 5. For non-squamous patients, SoC chemoimmunotherapy will include single agent immunotherapy with Pembrolizumab or in combination with Carboplatin or Permetrexed. Carboplatin/Pemetrexed/Pembrolizumab infusions are given every 3 weeks for four cycles followed by maintenance with Pemetrexed/Pembrolizumab from Cycle 5.
223863448|NCT05018754|DEVICE|TREATMENT OF ORAL MUCOSITIS USING PLATELET-RICH-FIBRIN (PRF)|All patients were affected by oral mucositis (9 RIOM, 6 chemotherapy-related oral mucositis). They were treated with almost 2 different systemic therapies before and during platelets gel applications. Median of time before the lesions were treated with platelets gel were 7 days. Lesions affected buccal mucosa, tongue, labial commissure and lower lip. Preliminar parameters were the microbiological contamination of lesions and presence of pain. Patients refer spontaneous widespread pain worsened by swallowing and feeding. Response to treatment has been evaluated in relation to the reduction of lesions dimensions, to the involution of pain and presence of granulation tissue after every application of platelet gel.
223863449|NCT05758727|OTHER|Exercise intervention|The exercise programme is progressive and has three levels. Each bout of exercise and Tai-chi snacking consists of 5 exercises. Each exercise is performed for one minute with one minute rest in between. For exercise snacking movements (including leg exercise, shoulder exercise, single leg exercise, arm exercise, and ankle exercise), participants are encouraged to complete as many repetitions as possible of that exercise in that minute. For Tai-chi snacking movements (including single leg squat, trunk rotation, single leg stand, hip and knee exercise, and ankle mobility exercise), participants are encouraged to complete repetitions of each exercise at a self-selected pace that is comfortable for them to maintain for the full minute, with the aim being to complete the movements as accurately and smoothly as possible (based on correct posture and proper alignment).
223863450|NCT03034915|DRUG|UMEC/VI 62.5/25 mcg via ELLIPTA|ELLIPTA DPI inhaler will contain two individual blister strips with 30 blisters per strip; the first strip contains umeclidinium bromide (62.5 mcg per blister) blended with lactose monohydrate and magnesium stearate and second strip contains vilanterol trifenatae (25 mcg per blister) blended with lactose monohydrate and magnesium stearate.
223863451|NCT03034915|DRUG|UMEC 62.5 mcg via ELLIPTA|The ELLIPTA inhaler will contain one blister strip, which will have 30 blisters of umeclidinium bromide (62.5 mcg).
223863452|NCT03034915|DRUG|Salmeterol 50 mcg via DISKUS|The DISKUS inhaler will contain one blister strip, which will have 60 blisters of salmeterol xinafoate (50 mcg). The DISKUS will provide a total of 60 doses (60 blisters) and will deliver, when actuated, the contents of a single blister strip.
223863453|NCT03034915|DRUG|Placebo via ELLIPTA|Lactose dry powder will be administered using ELLIPTA for both treatment periods. ELLIPTA DPI inhaler will contain two individual blister strips with 30 blisters per strip; containing lactose dry powder.
223863454|NCT03034915|DRUG|Placebo via DISKUS|Lactose dry powder will be administered using DISKUS for both treatment periods. The DISKUS inhaler will contain one blister strip, which will have 60 blisters of lactose dry powder. The DISKUS will provide a total of 60 doses (60 blisters) and will deliver, when actuated, the contents of a single blister strip.
223863455|NCT05493462|DRUG|Human FGF-1|Intranasal administration of human FGF-1
223863456|NCT04986683|DIAGNOSTIC_TEST|Brain magnetic resonance imaging|Brain magnetic resonance imaging (MRI) will be done using multiple sequences to evaluate the presence, type, and severity of brain abnormalities in enrolled subjects.
223863457|NCT04986683|BEHAVIORAL|Neuro-psychology testing|Participants will undergo age-appropriate neuro-psychology testing to assess motor, language, and other neurocognitive functions potentially affected by drug-resistant epilepsy.
223863458|NCT06117683|DEVICE|ADULT Sotair Device|Sotair® device employs a flow limiting and pressure control valve mechanism.
223863459|NCT05935319|OTHER|Vivifrail|Assess the physical activity status of the elderly, use the Vivifrail grade, provide exercise intervention, and improve physical activity function.
223863460|NCT00162331|DRUG|Technetium Tc99m Sestamibi|
223863461|NCT03624140|DEVICE|blood measurement|Hemoglobin measurement
223863462|NCT03624140|DEVICE|pulse co-oxymeter (SpHb)|non invasive method of hemoglobin measurement
223863463|NCT03624140|DEVICE|hemoCue|non invasive method of hemoglobin measurement
223863464|NCT00243256|DRUG|Cholecalciferol|
223863465|NCT03763721|DEVICE|intraoperative optical coherence tomography (iOCT)|"The OCT technology is fully integrated in a conventional ophthalmic surgical microscope (Zeiss LUMERA 700 platform). The OCT consists of A-scans (length/thickness) and B-scans (X-Y plane) to create the three dimensional image. Alternatively C-scans (3D cube scans) are available. All scans are non-invasive. The surgeon can continue surgery whilst using the iOCT and view a live image projected in the binocular or on the external screen and the video stream can be recorded as well.~The iOCT features are controlled using the foot paddle and the images are recorded on device. Investigations will be performed in a standardized matter: iOCT imagery and cube-scans after graft insertion, air injection, and the end of surgery."
223863466|NCT01188499|DRUG|Birinapant|
223863467|NCT00424762|DRUG|rosiglitazone|6 months of treatment of blinded study drug
223863468|NCT00424762|DRUG|placebo|blinded treatment with matching placebo
223863469|NCT03652207|OTHER|isomaltulose (Palatinose(TM)|isomaltulose containing food products, i.e. low-fat yogurt drink, fruits drink and sweetener sachet for cereals, consumed within an energy-reduced diet
223863470|NCT03652207|OTHER|Sucrose|sucrose containing food products, i.e. low-fat yogurt drink, fruits drink and sweetener sachet for cereals, consumed within an energy-reduced diet
223863471|NCT05513300|OTHER|Exercise intervention|12 weeks of exercise training, 3 times per week, \~1h long
223863472|NCT06184308|BEHAVIORAL|Home-based Physical Rehabilitation|Six out of seven days a week, gentle flexibility practice (upper arm and shoulder movements) that can be done seated or standing and two slow walking sessions focused on balance. In addition, complete a breathing practice focused on breathing in through the nose and exhaling through the mouth.
223863473|NCT06184308|BEHAVIORAL|Health Coaching|Study-trained nurse whom utilizes participant data to guide interactions in weekly calls.
223863474|NCT02847312|OTHER|High avenanthramide, phenolic acid|High avenanthramide and high phenolic acid, matched with energy and insoluable fibre.
223863475|NCT02847312|OTHER|Low avenanthramide, medium phenolic acid|Low avenanthramide and moderate phenolic acid, matched with energy and insoluable fibre.
223863476|NCT02847312|OTHER|Control|Control are matched with energy and insoluable fibre.
223863477|NCT02272959|BEHAVIORAL|Attention bias modification treatment (ABMT)|Attention training using a computerized spatial attention task (dot-probe) modified to alter threat-related attention patterns using threat and neutral stimuli.
223863478|NCT02272959|BEHAVIORAL|Attention Control Condition|Attention training using a computerized spatial attention task (dot-probe) not intended to alter threat-related attention patterns using only neutral stimuli.
223863479|NCT03030248|DRUG|Vancomycin Oral Capsule|We have chosen oral vancomycin capsules as it is currently a standard of care for Clostridium difficile infections, is poorly absorbed by the intestines, and is easier to blind compared to oral vancomycin solution.
223863480|NCT03030248|DRUG|Placebo Oral Capsule|A capsule containing gelatin, polyethylene glycol, titanium dioxide, iron oxide, and FD\&C blue No. 2. Contains the inactive ingredients of the vancomycin oral capsule, as mixed by the Froedtert Health Research Pharmacy.
223863481|NCT01564199|DRUG|salmeterol / fluticasone propionate|100/1000 μg oral capsule
223863482|NCT00232635|DRUG|A-60444|
223863483|NCT02916836|OTHER|therapeutic drug conciliation sheet (TDC)|Use of therapeutic drug conciliation sheet (TDC)
223863484|NCT02916836|OTHER|No Use of therapeutic drug conciliation sheet (TDC)|
223863485|NCT03557658|DRUG|Bexagliflozin|Single oral dose of bexagliflozin tablet, 20 mg
223863486|NCT01147341|DRUG|Cimzia|prefilled 200mg Cimzia syringe SC q 2 weeks
223863487|NCT01147341|DRUG|Placebo|prefilled saline syringe
223863488|NCT00877513|BEHAVIORAL|Smoking cessation|Smoking cessation program over 8 weeks, consisting of cognitive behavioral counseling every 2 weeks along with adjunctive use of bupropion
223863489|NCT00306449|BEHAVIORAL|Small group seminar-based educational intervention|
223863490|NCT03183999|DIETARY_SUPPLEMENT|fermented ginseng (GINST)|Intervention group should take fermented ginseng (GINST) capsule 3 times a day, 2 capsules at one time for 12 weeks
223863491|NCT03183999|DIETARY_SUPPLEMENT|Placebo|Control group should take placebo capsule 3 times a day, 2 capsules at one time for 12 weeks
223863492|NCT04323358|DIAGNOSTIC_TEST|Biometry|Patients will be asked to place the chin in position and open their eyes wide. In between measurements, the patient will be arranged so his eyes are in one horizontal line and each time before measurement the patient will be asked to blink several times.
223863493|NCT04323358|DIAGNOSTIC_TEST|Keratometry|Patients will be asked to place the chin in position and open their eyes wide. In between measurements, the patient will be arranged so his eyes are in one horizontal line and each time before measurement the patient will be asked to blink several times.
223863494|NCT01174199|DRUG|vorinostat|Given orally
223863495|NCT01174199|DRUG|temsirolimus|Given IV
223863496|NCT01174199|OTHER|laboratory biomarker analysis|Correlative study
223863497|NCT01174199|PROCEDURE|positron emission tomography/computed tomography|PET scan
223863498|NCT00367991|DRUG|Recombinant human erythropoietin alfa (drug)|200 U/kg IV daily for 3 days vs. matched volume of normal saline IV daily for 3 days
223863499|NCT00367991|DRUG|Placebo|Normal saline to match active drug (rHuEpo)
223863500|NCT06640387|DIAGNOSTIC_TEST|Daily Influenza, RSV or SARS-CoV-2 PCR testing for 10 days|Each participant will undergo daily PCR testing for Influenza, RSV or SARS-CoV-2 to assess viral dynamics
223863501|NCT06556160|PROCEDURE|near field recording of human auditory nerve activity during retro sigmoid approach with contact electrode|"During surgery using a retro-sigmoid approach in the cerebellopontine angle (microvascular decompression), near-field recording of human auditory nerve activity using a contact electrode is performed on patients with normal or impaired hearing threshold.~Each patient is explored preoperatively by hearing tests to search synaptopathie. During the surgery, stimuli are delivered."
223863502|NCT02203630|DRUG|Phenylephrine|Phenylephrine, in intravenous formulation, will be administered as the primary vasopressor for the treatment of septic shock
223863503|NCT02203630|DRUG|Norepinephrine|Norepinephrine, in intravenous formulation, will be administered as the primary vasopressor for the treatment of septic shock
223863504|NCT04962074|DEVICE|Microfluidic sperm sorting chip|Fertile Ultimate® (Koek Biotechnology, Turkey) microfluidic sperm sorting chips
223863505|NCT04962074|DEVICE|Density gradient|Density gradient centrifugation
223863506|NCT03870607|DIETARY_SUPPLEMENT|prebiotics in combination with probiotics|Administration of prebiotics in combination with probiotics before the start of Ch-RT
223863507|NCT00566904|DRUG|Epikeia coatings with aspirin|Applied to affected skin area using a roll-on ball applicator
223863508|NCT00566904|DRUG|Epikeia coatings with lidocaine|Applied to affected skin area using a roll-on ball applicator
223863509|NCT00566904|OTHER|Epikeia coatings alone|Applied to affected skin area using a roll-on ball applicator
223863510|NCT03441204|DRUG|LTOT 24 h/day|LTOT prescribed for 24 h/day.
223863511|NCT03441204|DRUG|LTOT 15h/day|: LTOT prescribed for 15 h/day. The patient is instructed to use LTOT during sleep and not to use LTOT for about 9 hours during daytime, totalling 15 h/day.
223863512|NCT04778917|DRUG|Low-Molecular-Weight Heparins Calcium Injection|We use different dose of low-molecular-weight heparins calcium injection to different interventions
223863513|NCT00969371|DEVICE|posterior chamber IOL implantation|
223863514|NCT00969371|DEVICE|Experimental TetraFlex Study IOL|TetraFlex IOL implanted
223863515|NCT01379014|BEHAVIORAL|Decision Aid Tool|A booklet which outlines to pros and cons of different decision outcomes, and is designed to assist the user in making a decision according to their own specific circumstances
223863516|NCT01379014|OTHER|Treatment as Usual|The control group does not receive a copy of the decision aid tool booklet, instead received treatment as usual from vocational specialist
223863517|NCT00346684|DRUG|Rituximab|
223863518|NCT03630939|DRUG|ESR-114|ESR-114 Topical Gel
223863519|NCT03630939|OTHER|Placebo|Placebo Topical Gel
223863520|NCT00506298|DRUG|bezafibrate + diflunisal|bezafibrate + diflunisal
223863521|NCT00506298|DRUG|bezafibrate + placebo|bezafibrate + placebo
223863522|NCT02878772|DRUG|vinpocetine|30 mg of the drug by intravenous infusion once daily, for fourteen consecutive days, beginning within one hour after the baseline MRI and no later than 48 hours after the onset of symptoms.
223863523|NCT02878772|DRUG|Aspirin|100mg, once daily, oral medication
223863524|NCT00977223|DRUG|aprepitant/placebo|Aprepitant, 125 MG at day 1 then 80 MG day 2-7, once a day, per os, at 8 AM during breakfast
223863525|NCT00281008|DRUG|ISIS 301012 or Placebo|50 mg subcutaneous injections on days 1, 4, 8, 11, 15, 22, 29, and 36
223863526|NCT00281008|DRUG|ISIS 301012 or Placebo|100 mg subcutaneous injections on days 1, 4, 8, 11, 15, 22, 29, and 36
223863527|NCT00281008|DRUG|ISIS 301012 or Placebo|200 mg subcutaneous injections on days 1, 4, 8, 11, 15, 22, 29, and 36
223863528|NCT00281008|DRUG|ISIS 301012 or Placebo|300 mg subcutaneous injections on days 1, 4, 8, 11, 15, 22, 29, 36, 43, 50, 57, 64, 71, 78, and 85
223863529|NCT05709431|OTHER|Questionnaire CIQoL-35|The Cochlear Implant - Quality of Life (CIQoL) PROM is a quality-of-life assessment questionnaire for adults with cochlear implants (1-7). The CIQoL responds to an important need for a questionnaire that captures the benefits of cochlear implantation as perceived by patients and that can be used in clinical practice. The CIQoL is available in two lengths: 35 questions (CIQoL-35) and 10 questions (CIQoL-10). The CIQoL-35 has interesting measurement properties including good construct validity, convergent validity, and test-retest reliability.
223863530|NCT04088032|DRUG|Abemaciclib, durvalumab and aromatase inhibitor|Subjects will receive standard therapy with an aromatase inhibitor (exemestane, anastrozole, or letrozole), combined with the experimental treatment of abemaciclib and durvalumab
223863531|NCT01042639|BEHAVIORAL|passive physical activity|extension and flexion range-of-motion exercise against passive resistance of both the upper and lower extremities. Both extension and flexion were performed five times at the wrist, elbow, shoulder, ankle, knee, and hip joints
223863532|NCT01059877|DEVICE|1072nm infrared Photobiomodulation|1072nm infrared light delivering 2.6 Joules (2.6J)/sq cm over a 6 minute treatment period.
223863533|NCT01059877|DEVICE|Photobiomodulation SIMULATED|Device mounted and procedure followed but with no stimulation.
223863534|NCT04062760|DRUG|Standard diuretic therapy|The patients in this arm will be randomized to receiving oral furosemide in 2 daily divided doses at twice the intravenous dose administered during the past 24 hours. Unless serum potassium value is higher than 5 mmol/L, oral spironolactone or potassium canrenoate will be added; dose will be established based on serum creatinine value.
223863535|NCT04062760|DRUG|Early sequential nephron blockade|"After 24-72 hours of an algorithm-based treatment with high-dose intravenous furosemide started at the time of hospital admission, the patients in this arm will be randomized to receiving:~1. oral furosemide in 2 daily divided doses at a dose equivalent to that administered intravenously during the past 24 hours~2. metolazone at a dose based on serum creatinine value~3. acetazolamide at a dose based on serum creatinine value~4. spironolactone or potassium canrenoate (unless serum potassium value is higher than 5 mmol/L); dose will be established based on serum creatinine value"
223863536|NCT05142202|RADIATION|Breast Irradiation after Breast-Conserving Surgery|All recruited participants will be treated with adjuvant to breast-conserving surgery accelerated partial breast irradiation with multicatheter interstitial brachytherapy technique and prescribed five times 5,4 Gy delivered in 3 consecutive days (6 hours minimum gap between the fractions). Treatment starts not later than 12 weeks after surgery (optimally 4-8 weeks), after wound healing, and obtaining the final pathological report with full immunohistochemistry and proper risk group assignment.
223863537|NCT05858073|OTHER|Kinesio Taping|"Standard 5 cm Kinesio Tex will be used. Initially, a Y-strip was paper-off (without tension) from the starting point to the insertion of the supraspinatus, while the participants were reaching with their upper extremities behind their backs and flexing their necks to the contralateral side. Second, an I-strip from the coracoid process will be applied around the posterior deltoid using approximately 50% to 75% downward flexion. Initially, the shoulder will be externally rotated without elevation, and then slightly horizontally adduction and forward elevation as the end of the band is applied without stretching. This I strip is shaped like a Y at the end of the tape.~Finally, a Y-strip will be applied using paper-off tension from the T10-T12 region to the medial border of the scapula to facilitate the lower trapezius muscle. For this technique, the shoulder was adducted horizontally and the middle tail was applied with the hands crossed over the chest."
223863538|NCT05858073|OTHER|Placebo Kinesio Taping|Standard placebo taping will be applied to the placebo Kinesio taping group with a standard 5 cm Kinesio Tex. Two tension-free strips will be applied separately to the acromioclavicular joint and lower trapezius muscle. Suspicious participants will be excluded from the study.
223863539|NCT02975310|PROCEDURE|Endoscopic polypectomy in clinic (EPIC)|The experimental intervention is endoscopic polypectomy performed in clinic (EPIC) where nasal polyps are removed using a microdebrider under local and topical anesthesia in the outpatient clinic.
223863540|NCT02975310|PROCEDURE|Endoscopic Sinus Surgery (ESS)|The control intervention is endoscopic sinus surgery (ESS), a minimally invasive procedure that is the current standard that involves polypectomy with a microdebrider as well as sinus ostia enlargement of the affected sinuses performed in the operating room under general anesthesia.
223863541|NCT02975310|OTHER|General Anesthesia|ESS will be performed under general anesthesia in the operating room
223863542|NCT02975310|OTHER|Local and topical anesthesia|EPIC will be performed under topical and local anesthesia in a clinic setting
223863543|NCT03024606|BEHAVIORAL|text messages focused on smoking cessation and pregnancy|The impact of a text-message service on smoking cessation in medically underserved, obstetric patients when added to the usual care of pharmacist-driven CBT smoking cessation program and smoking cessation pharmacotherapy with either the nicotine replacement patch or bupropion.
223863544|NCT06103630|OTHER|Oropharyngeal Exercises|Oropharyngeal Exercises
223863545|NCT06103630|OTHER|Mandibular advancement device|Mandibular advancement device
223863546|NCT02838342|DRUG|Metronomic cyclophosphamide|50 mg oral tablet, one tablet per day, every day for 6 months; abort if progression or intolerance
223863547|NCT02838342|DRUG|Interferon-alpha|3 months of treatment from the 4th cycle metronomic cyclophosphamide : subcutaneous injection, initial dose of 3 MIU three times a week. The dose may be adjusted as tolerated to achieve a T cell counts greater than 500 / mm3
223863548|NCT00502424|DEVICE|Splint|
223863549|NCT04068207|DRUG|Minocycline|Tab. Minocycline 100mg po per day for 12 months
223863550|NCT04949035|DIAGNOSTIC_TEST|Assessment of mental state and quality of life|Patients qualified for rehabilitation will be assessed for stress levels as well as symptoms of anxiety and depression and quality of life before rehabilitation began
223863551|NCT06478680|BEHAVIORAL|Exoskeleton mediated gait training|"1 session of Forward Walking with EksoGT per week~1 session of conventional neurorehabilitation intervention per week~* Transfer training~* Gait training~* Balance (sitting/standing; static/dynamic)~* Strength~* Neuromuscular re-education~* Orthotics~* Positioning~* Caregiver education~* Assistive device~* Wheelchair assessment and mobility~* Endurance training"
223863552|NCT06478680|BEHAVIORAL|High intensity gait training|"2 sessions of High-Intensity Gait Training at a target heart rate of 60-80% of the maximum heart rate or target RPE of 15-18~* Forward stepping practice~* Backwards stepping practices~* Sidestepping~* Stairs~* Balance and compliant surface training while walking~* Propulsion~* Lateral balance training~* Stability training~* Stance control training~* Limb advancement"
223863553|NCT00448721|DRUG|Perifosine|Perifosine will be administered orally at 100mg PO daily with food.
223863554|NCT04444258|OTHER|Application of computer aided virtual reality glasses|Experimental I Group: After the Fetal Development Assessment Information Form (FEGBF), a computer-aided and guided virtual reality application prepared by the researchers including the phases of the fetus week by week will be watched and then FEGBF will be applied again by changing the locations of the questions.
223863555|NCT04444258|OTHER|Teaching fetal development theoretically|Control Group: FEGBF will be applied after 4 hours of theory training. Virtual pregnancy application will not be watched.
223863556|NCT04836806|DRUG|Cetirizine and Famotidine|Participants will take 10 milligrams (mg) of cetirizine once a day and 20 mg of famotidine twice a day for 10 days (two pills in the morning and one in the evening).
223863557|NCT04836806|DRUG|Placebo|Participants will take placebos to match 10 mg of cetirizine once a day and 20 mg of famotidine twice a day for 10 days (two pills in the morning and one in the evening).
223863558|NCT02167906|OTHER|arterial stiffness measurement|
223863559|NCT04614675|PROCEDURE|Distal soft tissue procedure with TALR|TALR group: Transarticular lateral release as the distal soft tissue procedure
223863560|NCT04614675|PROCEDURE|Distal soft tissue procedure with PCLR|PCLR: Percutaneous soft tissue procedures as the distal soft tissue procedure
223863561|NCT05429034|BEHAVIORAL|MIST paradigm|Patients are exposed to psychosocial stress = receive mental arithmetic challenges, together with social evaluative threat components from the program and/or the investigator.
223863562|NCT05429034|BEHAVIORAL|Sham paradigm|Patients are not exposed to psychosocial stress = threat components from the program and/or the investigator are absent
223863563|NCT01528306|BIOLOGICAL|HP802-247|"Wounds up to 12 cm2: 1 spray each component (0.5 x 106 cells per mL allogeneic human keratinocytes and fibroblasts) applied weekly as a topical spray for up to 4 weeks in each of 2 treatment periods~Larger wounds:~(\>12 cm2 and ≤ 24 cm2) 2 sprays each; (\>24 cm2 and ≤ 36 cm2) 3 sprays each; (\>36 cm2 and ≤ 48 cm2) 4 sprays each"
223863564|NCT01528306|OTHER|Placebo|"Wounds up to 12 cm2: 1 spray each component (thrombin solution and fibrinogen solution) applied weekly as a topical spray for up to 4 weeks in each of 2 treatment periods~Larger wounds:~(\>12 cm2 and ≤ 24 cm2) 2 sprays each; (\>24 cm2 and ≤ 36 cm2) 3 sprays each; (\>36 cm2 and ≤ 48 cm2) 4 sprays each"
223863565|NCT06307223|DRUG|30% supramolecular salicylic acid|The patients received weekly application of 30% supramolecular salicylic acid for a duration of 8 weeks.
223863566|NCT06307223|DRUG|supramolecular active zinc|The patients received daily application of topical supramolecular active zinc anti-dandruff lotion for a duration of 8 weeks.
223863567|NCT03401112|DRUG|IMR-687|Oral administration of IMR-687 once daily with or without HU.
223863568|NCT03401112|DRUG|Placebo|Oral administration of placebo once daily with or without HU.
223863569|NCT04676321|OTHER|Patient pathway|Investigation on the appropriateness and quality of NSCLC care among participating sites
223863570|NCT02607670|DRUG|TAT4 Gel|
223863571|NCT02607670|DRUG|Matching placebo|
223863572|NCT06190522|DIAGNOSTIC_TEST|Emergency physician clinical ultrasound|Clinical ultrasound by emergency doctor consisting in obtaining frontal sections of the 2 kidneys and a transverse section of the bladder
223863573|NCT04476810|DEVICE|kahook dual blade|Combined Phacoemulsification and Excisional Goniotomy with the Kahook Dual Blade
223863574|NCT04210505|DRUG|Povidone-Iodine Topical Ointment|Intranasal povidone-iodine will be applied to the lower anterior nares (i.e. nostril) of patients undergoing hemodialysis before each session.
223863575|NCT04210505|OTHER|Standard Care|Control group will receive standard care as provided by the dialysis center
223863576|NCT00986466|DIETARY_SUPPLEMENT|exercise and vitamin D supplementation|20 µg (800 IU) of vitamin D per day for two years supervised training two times a week for 12 months, and once a week during the next 12 months
223863577|NCT00986466|DIETARY_SUPPLEMENT|exercise and vitamin D supplementation|placebo per day for two years supervised training two times a week for 12 months, and once a week during the next 12 months
223863578|NCT00986466|DIETARY_SUPPLEMENT|exercise and vitamin D supplementation|20 µg (800 IU) of vitamin D per day for two years no supervised training (maintenance of their current level of physical activity)
223863579|NCT00986466|DIETARY_SUPPLEMENT|exercise and vitamin D supplementation|placebo per day for two years no supervised training (maintenance of their current level of physical activity)
223863580|NCT01968226|DRUG|[F-18] RDG-K5|Up to fifteen (15) subjects with carotid stenosis \>50% who are undergoing planned carotid endarterectomy will be imaged under PET with \[F-18\] RDG-K5
223863581|NCT05757388|DRUG|Parecoxib + paracetamol|Administers after induction of anesthesia.
223863582|NCT05757388|DRUG|Normal saline|Administers after induction of anesthesia.
223863583|NCT00886145|DEVICE|Vibration: Right Leg and No Vibration: Left Leg.|"Vibration- right leg: The subjects will undergo a mechanical vibration intervention (Juvent Vibrating plate) in the seated position, with a load of 50lbs will be added to the right leg by using an extra wide strap equipped with bungee cords, 5 sessions a week, and each session lasting 20 minutes for a total of 6 month.~No Vibration-left leg: At each vibration training session, the left leg will serve as a control with a load of 50lbs added to the left leg using an extra wide strap equipped with bungee cords, 5 sessions a week, and each session lasting 20 minutes for a total of 6 month."
223863584|NCT00903227|DRUG|Fluticasone Evohaler pMDI|One puff of inhaled Fluticasone Evohaler pMDI 50 µg twice a day (Total FP dose 100 µg)
223863585|NCT00903227|DRUG|Placebo|1 puff of inhaled Placebo twice a day
223863586|NCT00903227|DRUG|Fluticasone Evohaler|One puff of inhaled Fluticasone Evohaler 250µg twice a day (Total daily FP dose 500µg)
223863587|NCT00903227|DRUG|Placebo intranasal spray|placebo intranasal spray 2 squirts each nostril once a day
223863588|NCT00903227|DRUG|fluticasone propionate (Flixonase®)|intranasal fluticasone propionate (Flixonase®) 50ug 2 squirts
223863589|NCT02971488|OTHER|Screening for HCV in PWID and Linkage-To-Care|"Screening, diagnosis and treatment of HCV in PWID, will be part of a harm reduction strategy.~Treatment of HCV infected PWID will be delivered in a multidisciplinary care setting with services to reduce the risk of reinfection and for management of the common social and psychiatric comorbidities in this population."
223863590|NCT04431388|DEVICE|ultrasound device|We performe a differnt analgesic techniques to know if some of then are better
223863591|NCT04431388|DRUG|Levobupivacaine|using the same AL
223863592|NCT02456506|RADIATION|Hyperfractionated IMRT|
223863593|NCT02456506|RADIATION|Conventional Fraction IMRT|
223863594|NCT01368198|OTHER|Systane Balance Lubricating Eye Drops|One instillation of the eye drop in each eye
223863595|NCT01368198|OTHER|OPTIVE™|One instillation of the eye drop in each eye
223863596|NCT00237770|DRUG|N-Nitro L-arginine-methylester (L-NAME)|A non-specific inhibitor of the nitric oxide synthase enzyme.
223863597|NCT00237770|PROCEDURE|Head-up Tilt maneuver|Participant will be placed onto tilt table and brought to 15 degrees of head up tilt for 60 minutes (intravenous infusion time). After this time, a progressive increase to 45 degrees will be completed with a 10 degree increase every 5 minutes. Participant will remain at 45 degrees for 45 minutes or until symptom onset.
223863598|NCT01827345|DIETARY_SUPPLEMENT|Vitamin D|Participants will take the Institute of Medicine's recommended daily dose of vitamin D (800 IU/day) for six months.
223863599|NCT05704751|DEVICE|spinal cord stimulation|EVOKE ECAP-Controlled Lead Placement and Programming in Chronic Pain Patients
223863600|NCT00392054|PROCEDURE|Pulmonary Vein Isolation performed by Catheter Ablation|Ablation will be done to achieve entrance block into all pulmonary veins.
223863601|NCT00392054|DRUG|Conventional Antiarrhythmic Drug Therapy|Anti-Arrhythmic Drugs per ACC/AHA 2006 Guidelines for the Management of Patients with AF
223863602|NCT02176772|OTHER|Stable iron isotopes, non-drug intervention|
223863603|NCT04975308|DRUG|Imlunestrant|Administered orally.
223863604|NCT04975308|DRUG|Exemestane|Administered orally.
223863605|NCT04975308|DRUG|Fulvestrant|Administered IM.
223863606|NCT04975308|DRUG|Abemaciclib|Administered orally.
223863607|NCT04333355|BIOLOGICAL|Convalescent Plasma|Along with the administration of convalescent plasma, patients will continue to receive supportive standard care.
223863608|NCT02709655|DRUG|Vortioxetine 10 mg/day|"10 mg/day, encapsulated tablet, orally (with addition of lower initial dose levels).~Based on tolerability the dose may be reduced by 5 mg/day. No dose increase will be allowed"
223863609|NCT02709655|DRUG|Vortioxetine 20 mg/day|"20 mg/day, encapsulated tablet, orally (with addition of lower initial dose levels).~Based on tolerability the dose may be reduced by 5 mg/day. No dose increase will be allowed"
223863610|NCT02709655|DRUG|Fluoxetine 20mg/day|"20 mg/day, encapsulated tablet, orally (with addition of lower initial dose levels).~Based on tolerability the dose may be reduced by 10 mg/day. No dose increase will be allowed"
223863611|NCT02709655|OTHER|Placebo|Encapsulated tablet, orally
223863612|NCT03461575|DRUG|HU007|cyclosporine 0.02%, trehalose 3%
223863613|NCT03461575|DRUG|Restasis|cyclosporine 0.05%
223863614|NCT03461575|DRUG|Moisview|trehalose 3%
223863615|NCT03957213|DEVICE|Acute Intermittent Hypoxia|Acute intermittent hypoxia is a safe, non-invasive technique. All sessions will be monitored by research study staff trained in delivering acute intermittent hypoxia. Hypoxic intervals will be delivered with a commercially available sports performance hypoxicator. A unit capable of delivering a fraction of inspired oxygen ranging from 21%-9% will be used. Air will be delivered into a mask that will be secured comfortably over the subject's nose and mouth. Intervention sessions will occur for 10 days over a 2 week period.
223863616|NCT03957213|BEHAVIORAL|Computerized Cognitive Training|60 minutes of Double Decision cognitive training for 10 days over a 2 week period.
223863617|NCT05150054|DEVICE|CardioFlux|Not an intervention
223863618|NCT01179334|DRUG|Riociguat (Adempas, BAY63-2521)|BAY63-2521: 1 mg tid - 2,5 mg tid oral for 12 weeks.
223863619|NCT01179334|DRUG|Placebo|Placebo for 12 weeks
223863620|NCT01179334|DRUG|Sildenafil|Participants continued to take daily stable sildenafil background treatment according to their prescriptions.
223863621|NCT00092898|DRUG|MK0653, ezetimibe|
223863622|NCT00092898|DRUG|Comparator: placebo|
223863623|NCT05893459|BEHAVIORAL|Debrief|Post-Stressor Discussion with a Friend
223863624|NCT00316953|DRUG|dasatinib|Given orally
223863625|NCT00316953|OTHER|pharmacological study|Correlative studies
223863626|NCT00316953|OTHER|laboratory biomarker analysis|Correlative studies
223863627|NCT05261815|OTHER|Ultrasound Therapy|Ultrasound Therapy improves the pain management in patients with herniation. It eases down the severity of symptoms as well.
223863628|NCT05261815|OTHER|High Intensity Laser Therapy|Treatment of low disc herniation should be non-surgical, pharmacological and by physical therapy modalities. Laser radiation with high intensity used as a modality called high intensity laser therapy. It is used to relieve the pain by three process; Photo-chemical, Photo-thermal, Photo-mechanical. High Intensity Laser Therapy uses high intensity laser irradiation and low light absorption.
223863629|NCT06456255|DRUG|Sensorcaine with Epinephrine|The combination contains 0.25% bupivacaine hydrochloride (2.5 mg/mL) and epinephrine bitartrate \[(1:200,000) 5 mcg/mL\] per vial.
223863630|NCT06456255|OTHER|Sham injection|Punctures without any medication injected onto the septum
223863631|NCT04231721|DEVICE|High Resolution Colonic Manometry and 3D-Transit system|Measurement of colonic pressure changes and passage patterns in healthy.
223863632|NCT00919763|DRUG|CD2027 Ointment 3 mcg/g, twice daily|Topical Ointment
223863633|NCT00919763|DRUG|Vehicle Ointment, twice daily|Topical Ointment
223863634|NCT00036036|DRUG|CP-461|
223863635|NCT04036630|DEVICE|Transcranial alternating current stimulation (tACS)|"The main study intervention is tACS stimulation. TACS is a non-invasive brain stimulation (NIBS) techniques that belong to the class of low current transcranial electric stimulation. In contrast to the better known transcranial direct current stimulation (tDCS), the tACS current is not constant, but alternates with a certain frequency.~The aim of the tACS stimulation is to enhance degraded speech comprehension in healthy individuals.~TACS stimulation will be applied over the left ventral motor cortex, with a current intensity of 2mA (peak-to-peak)~The arm will be compared to the tACS sham stimulation condition."
223863636|NCT04036630|DEVICE|Transcranial magnetic stimulation (TMS) induced motor-evoked potentials (MEPs)|"TMS is a technique where a transient magnetic field (or pulse) is used to cause an electric current to flow in a targeted brain area via electromagnetic induction. The pulse causes the rapid and above-threshold depolarisation of cell membranes affected by the current. Therefore, TMS induces a current that elicits action potentials in neurons.~MEPs are electrical potentials recorded from a target muscle after TMS stimulation. In experiment 1, so-called articulatory MEPs will be recorded from participants' lip muscle (orbicularis oris). Articulatory MEPs will be recorded by placing two recording electrodes on the right part of orbicularis oris and a reference electrode on the right temple."
223863637|NCT05682183|BEHAVIORAL|Multi-domain Psychoeducation Self-management Programme|The MPSP is a 5-weeks psychoeducation programme aimed at improving the biopsychosocial health of people with MDD (PMDD). It will be conducted on every Saturday in the morning, afternoon and evening. Specific time of each session will be further discussed with the centre. Each session will last for approximately 45 minutes to 60 minutes and will be capped at 10 participants. The mode of session will be face-to-face (F2F) session conducted at MindCare.
223863638|NCT05682183|OTHER|Treatment as usual|Care management from assigned care manager
223863639|NCT00624026|DRUG|Memantine-HCl|20 mg per day (once daily)
223863640|NCT00147485|DRUG|AG-024322|
223863641|NCT03666403|PROCEDURE|NIV rate: 0/min|A basic PhO2 flow was routinely provided. A small pharyngeal catheter with warmed, humidified and fixed pure oxygen flow was inserted via one nostril to ensured catheter tip positioning in the oropharynx. The NIV was performed in the following steps. Firmly closed the mouth, then intermittently applied a) assisted inspiration by nose-closure accompanied with cricoid depression; and b) assisted expiration by the release of above nose and cricoid maneuver but with simultaneous abdomen-compression. The above assisted ventilation cycle was maintained at a rate of 0-20 cycles per minute. The scopist executed both the FB and the nose-closure and release, whereas an assistant delivered the abdomen compression.
223863642|NCT03666403|PROCEDURE|NIV rate: 10-20/min|A basic PhO2 flow was routinely provided. A small pharyngeal catheter with warmed, humidified and fixed pure oxygen flow was inserted via one nostril to ensured catheter tip positioning in the oropharynx. The NIV was performed in the following steps. Firmly closed the mouth, then intermittently applied a) assisted inspiration by nose-closure accompanied with cricoid depression; and b) assisted expiration by the release of above nose and cricoid maneuver but with simultaneous abdomen-compression. The above assisted ventilation cycle was maintained at a rate of 0-20 cycles per minute. The scopist executed both the FB and the nose-closure and release, whereas an assistant delivered the abdomen compression.
223863643|NCT03666403|PROCEDURE|NIV rate: 5-10/min|A basic PhO2 flow was routinely provided. A small pharyngeal catheter with warmed, humidified and fixed pure oxygen flow was inserted via one nostril to ensured catheter tip positioning in the oropharynx. The NIV was performed in the following steps. Firmly closed the mouth, then intermittently applied a) assisted inspiration by nose-closure accompanied with cricoid depression; and b) assisted expiration by the release of above nose and cricoid maneuver but with simultaneous abdomen-compression. The above assisted ventilation cycle was maintained at a rate of 0-20 cycles per minute. The scopist executed both the FB and the nose-closure and release, whereas an assistant delivered the abdomen compression.
223863644|NCT03681652|DRUG|Azathioprine|Children with Crohn's disease who are treated with azathioprine for post-operative prophylaxis following ileo-cecal resection
223863645|NCT03681652|DRUG|Anti-TNF Drug|Children with Crohn's disease who are treated with anti-TNF monotherapy for post-operative prophylaxis following ileo-cecal resection
223863646|NCT06221046|DRUG|Control (Standard treatment)|Patients in the control arm will be treated with a standard zinc oxide barrier cream. Scotiaderm will supply the control product, such that the formula is identical to the intervention with the only difference being the addition of plant extract in the investigational product.
223863647|NCT06221046|OTHER|Novel Barrier Cream|Patients randomized to the intervention arm will receive treatment with Scotiaderm's proprietary barrier cream formula. This product contains soy extract for enhanced healing of MASD secondary to fecal incontinence.
223863648|NCT05286632|DEVICE|KidneYou APP|KidneYou is a medical device designed to deliver digital therapy (DT) to patients. The DT utilizes high quality digital technologies to stimulate lifestyle changes in patients. KidneYou has been set up to improve the commitment of patients in following therapeutic directives (i.e. nutritional programs, daily/weekly physical activities) to manage their chronic diseases like CKD. Moreover, KidneYou can improve patient's awareness about his/her disease (mindfulness) so as to increase the individual human ability to be fully present at the ongoing disease's condition and react to it in active and positive manner. Particularly, the mindfulness program contained in this App has been designed to increase the patient's psychological and mental health, aiming at decreasing the perceived stress due to the underlying disease and to the attempts of life-style changes (i.e., healthy diet and physical activity) which may initially negatively affect the subject's natural attitudes.
223863649|NCT03618654|DRUG|Metformin|Given PO
223863650|NCT03618654|BIOLOGICAL|Durvalumab|Given IV
223863651|NCT00710892|BIOLOGICAL|Allodepleted T Cells|"Dose Level 1 = 1 x 10e6 T cells/kg; Dose Level 2 = 3 x 10e6 T cells/kg; Dose Level 3 = 1 x 10e7 T cells/kg.~Patients may be enrolled at the next dose level of T cells when all patients at the previous dose level have reached Day 42 post-T cell infusion without unacceptable toxicity."
223863652|NCT05389644|DEVICE|Intermittent Theta Burst Stimulation (iTBS)|iTBS is a form of repetitive TMS. TMS is a form of non-invasive brain stimulation. In this modality, a current is rapidly passed through a TMS coil. This coil is placed on a subject's scalp. The rapidly discharging current creates a magnetic field perpendicular to the plane of the coil. This magnetic field diffuses through the subject's scalp and skull until it reaches the brain parenchyma. There, it causes focal neuronal depolarization.
223863653|NCT04785989|OTHER|[U-13C]glucose|\[U-13C\]glucose will be administered as a bolus of 8 g (grams) over 10 minutes followed by 8 g/hour continuous infusion over 2 hours . This infusion rate will allow glucose tracer to reach sufficient enrichment without causing significant metabolic perturbation such as hyperglycemia.
223863654|NCT04785989|OTHER|[13C5]glutamine|6mg/kg of body weight of \[13C5\]glutamine will be administered as a bolus over 10 minutes (± 1 minute) followed by 6mg/kg/hr body weight continuous infusion for 2 hours through a peripheral IV catheter/line. This infusion rate will allow glutamine tracer to reach sufficient enrichment without causing significant metabolic perturbation such as hyperglycemia.
223863655|NCT05677633|DRUG|Sargramostim|Recombinant human GM-CSF produced by recombinant DNA technology using a yeast (S. cerevisiae) expression system
223863656|NCT05657249|DIAGNOSTIC_TEST|Non-contrast focused MRI|non-contrast liver MRI focusing on HCC surveillance in a short scan time.
223863657|NCT06288932|DRUG|Mycophenolate Mofetil (MMF) Treatment|The first-line treatment of immune thrombocytopenia purpura with Mycophenolate Mofetil produced a significant response, a lowered likelihood of refractory ITP, a better outcome, and less financial burden.
223863658|NCT06500377|PROCEDURE|Biospecimen Collection|Undergo saliva sample collection
223863659|NCT06500377|PROCEDURE|Meditation Therapy|Learn breathing only meditation
223863660|NCT06500377|PROCEDURE|Meditation Therapy|Learn focused attention only meditation
223863661|NCT06500377|PROCEDURE|Meditation Therapy|Learn mindfulness only meditation
223863662|NCT06500377|PROCEDURE|Meditation Therapy|Learn breathing, focused attention, and mindfulness combined meditation
223863663|NCT06500377|OTHER|Questionnaire Administration|Ancillary studies
223863664|NCT03893487|DRUG|Fimepinostat|Fimepinostat capsules
223863665|NCT03893487|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
223863666|NCT06192394|OTHER|Chewing Gum|Patients will be asked to chew xylitol gum for 20 minutes every 2 hours (17.00-19.00, 19.00-21.00, 21.00-23.00) after drinking the X-M Diet syrup prescribed the day before the colonoscopy procedure. After the enema is given on the day of the colonoscopy, they will be asked to chew gum for 20 minutes every 2 hours until one hour before the scheduled procedure time. Xylitol is a naturally occurring five-carbon sugar alcohol (C5H12O5) found in fruits and vegetables such as plums, strawberries, cauliflower, and pumpkin. It is similar in taste to sucrose but contains 40% fewer calories than other carbohydrates (1 gram of xylitol = 2.4 calories). Xylitol has positive effects on dental health and may also have beneficial impacts on other systems such as immunity, respiratory, and digestive systems. Since xylitol is not digested by human enzymes, it has a laxative effect. In the study, sugar-free gum with xylitol will be used.
223863667|NCT06192394|OTHER|Walking Exercise|Patients will be given a pedometer to count their steps and will be asked to walk at least 3000 steps before the colonoscopy procedure.
223863668|NCT06192394|OTHER|Control|Patients will undergo standard bowel preparation determined by the hospital.
223863669|NCT06458101|PROCEDURE|Ureteroscopy (including flexible endoscope) lithotripsy without indwelling urinary catheter|Ureteroscopy (including flexible endoscope) lithotripsy without indwelling urinary catheter
223863670|NCT06458101|PROCEDURE|Ureteroscopy (including flexible endoscope) lithotripsy with indwelling urinary catheter|Ureteroscopy (including flexible endoscope) lithotripsy with indwelling urinary catheter
223863671|NCT06342778|DRUG|Doxylamine + Pyridoxine|A single dose of R or T drug in each of 2 periods of the study under fed conditions
223863672|NCT06342778|DRUG|Diclectin|A single dose of R or T drug in each of 2 periods of the study under fed conditions
223863673|NCT05574192|BEHAVIORAL|Social Engagement Intervention|"The intervention includes social visiting with women affected by violence. Social visiting is carried out by trained peer-workers. Peers are women who share life histories with the target study population. Peer-workers will establish a visiting schedule (day/time) and provide a detailed list of activities in two categories:~1. arts-based activities.~2. physical activities.~The peer will meet with the participant at the scheduled place and times to accompany the participant and engage in the activities with the participant.~Participation in scheduled social activities that target the interest and ability of women affected by violence is considered to improve social connectedness by increasing the quality and quantity of a woman's social interactions with a supportive, trained person who shares life experiences. Shared, consistent and reliable social activities also are hypothesized to reduce loneliness by contributing to a sense of belonging and sense of being cared for."
223863674|NCT04975048|DIETARY_SUPPLEMENT|Egg yolks|Two egg yolks/day was designed for the study. However, uneven egg sizes during period 1 made the intervention unable to achieve the protocol's recommended cholesterol intake level, and the intervention was modified in period 2 to be 0.8 g egg yolk/day/kg body weight. This dosage was calculated by dividing the 35 g egg yolk with the lightest weight among the volunteers, which was 45 kg. This provides a more consistent cholesterol intake between persons as the egg yolk dosage is standardized for persons with different weights.
223863675|NCT04975048|DIETARY_SUPPLEMENT|Macronutrients equivalent control|The macronutrients equivalent control group was served 42 g egg white cooked with 10 g olive oil, designed to best imitate the energy and macronutrients of 35 g egg yolk (energy 119 kcal, protein 5 g, fat 10 g, carbohydrate 1 g) since the average weight of two large egg yolk was presumed to be 35 g. As an egg yolk dose of 0.8 g egg yolk per kg body weight per day was served during the intervention period 2, the macronutrients equivalent control was likewise adjusted as follow: subjects who weighed less than 55 kg were served 51 g egg white cooked with 12 g olive oil, which is equivalent to 40 g egg yolk; those who weighed from 55 kg to 65 kg were served 61 g egg white cooked with 14 g olive oil, which is equivalent to 48 g egg yolk; and those who weighed more than 65 kg were served 71 g egg white cooked with 17 g olive oil, which is equivalent to 56 g egg yolk.
223863676|NCT06097000|DEVICE|powered exoskeletons|Whether to use powered exoskeletons for exercise rehabilitation
223863677|NCT05431192|BEHAVIORAL|Mindfulness Training + Enhanced Usual Care|"Participants will receive a 30-minute, individual, phone-delivered session once a week for 8 weeks. MT involves training in the following (1) Awareness of breath; (2) Body scan; (3) Directing attention to simple activities of daily life; (4) Becoming aware of own thoughts and emotions; (5) Open awareness - a technique by which the participant is invited to direct his/her attention to any event arising in their field of experience at a given moment.~In addition, participants will practice mindfulness techniques for 20 minutes daily on their own with the guidance of a digitally recorded, standardized guided mindfulness practice."
223863678|NCT05431192|OTHER|Enhanced Usual Care|"Usual care will be enhanced in BOTH conditions with printed education materials provided to all participants using publicly available materials (the Healthier Living with Heart Failure guide available at the AHA Heart Failure Resource Center).66 The guide is organized in 7 chapters containing information on topics such as understanding HF, making healthy lifestyle changes, managing HF symptoms, taking medications, and living well with HF. Printed materials will be mailed weekly to all participants during the first 8 weeks of the study."
223863679|NCT04426786|OTHER|Active exercise|Thrice-weekly supervised intense aerobic exercise classes on cycle ergometers, in groups, for six months. Percentage of VO2 max will be used to regulate exercise intensity, based on an initial aerobic exercise test.
223863680|NCT04426786|OTHER|Passive exercise|Thrice-weekly supervised passive exercise classes consisting of stretching and/or yoga, in groups, for six months.
223863681|NCT06369623|OTHER|Monetary Incentive Delay Task|The Monetary Incentive Delay functional Magnetic Resonance Imaging task is well-characterized and commonly utilized in research settings to measure neural activation between win and loss conditions, as well as between phases of anticipation and consummation/outcome. A recent meta-analysis indicates that the task has been used in over 80 studies and 5,000 subjects as of Year 2022. The task is also valid and appropriate for use in children and adolescents, as demonstrated by its inclusion in National Institute on Drug Abuse ABCD study. The task is utilized for its short-lived, reversible, and/or benign effects on brain activation (e.g., brief processing of a reward cue).
223863682|NCT06488625|DRUG|Low-Dose CICR-NAM|2 g/d CICR-NAM (blinded)
223863683|NCT06488625|DRUG|High-Dose CICR-NAM|3 g/d CICR-NAM (blinded)
223863684|NCT06488625|DRUG|0 g/d CICR-NAM (blinded)|Placebo (blinded)
223863685|NCT06488625|DRUG|Open-Label|3 g/d CICR-NAM (open label)
223863686|NCT05746247|BEHAVIORAL|Testing centralized referral mechanism for PCPs|"For patients with a Penn PCP, we are testing a centralized referral mechanism to increase the number of referrals to preventive cardiology (default/opt out referrals)~For default/opt out: PCPs will receive a pended order for a referral for their patient to see a lipid specialist for a formal FH evaluation. Not interacting with the pended order or accepting the pended order will indicate that the referral to a lipid specialist should be placed."
224076315|NCT04773405|DRUG|a 1: 1 mixture of 2% lidocaine with 5ug/ml epinephrine and 0.5% levobupivacaine|"This study adopts a Modified Narayana rule (MNR), a sequential up-and-down pharmacodynamics method (UDM) to estimate the minimum effective local anesthetic volume of 90% (MELAV90) of cases of the aforementioned local anaesthetic (LA) mixture, in order to produce the surgical anaesthesia of the whole upper extremity of the patients scheduled for upper limb surgeries. Based on the principal investigator's clinical experience, the initial volume of 21ml will be used. Depending on the success or failure of the SeTB, which is defined as the readiness for surgery at 30 minutes after the block, the volume for the next patient will be adjusted up or down by 3ml (1ml for each trunk of brachial plexus located above the clavicle). The upper dose limit of the study to minimize the potential for local anaesthetic systemic toxicity will be 30ml and the lower dose limit will be 12ml, which will be of no clinical importance."
224076316|NCT06849115|DRUG|L-Carnitine Injection，1000mg once daily|All patients were given L-carnitine therapy administered every 8 weeks, consisting of 1g L-carnitine diluted in 500 mL of 0.9% sodium chloride solution via intravenous infusion once daily. Each treatment cycle lasted 2 weeks, repeated at 8-week intervals for a total of 3 cycles, with L-carnitine 1g is administered orally once daily during the intervals between intravenous therapies.
224076317|NCT01178060|OTHER|Personalized Heart Attack and Stroke Risk|Personalized assessment of heart attack and stroke risk based on 10yr predictors with individual risk factors.
224076318|NCT01178060|OTHER|Standard Education|Patients received a general handout describing risk factors for heart attack and stroke.
223863687|NCT05746247|BEHAVIORAL|Inviting patients to complete a telehealth appointment with a lipid specialist for an FH evaluation|All eligible patients will be informed that they have been identified by the FIND FH tool as potentially having familial hypercholesterolemia. All patients will be invited to schedule a telehealth appointment with a lipid specialist for a formal evaluation for FH.
223863688|NCT05924412|DRUG|Intravenous study drug|40mg parecoxib will be administered intravenously after general anesthesia induction and before tourniquet inflation and surgical incisión
223863689|NCT05924412|OTHER|Intravenous saline solution|Saline solution (same volume as the study drug) will be administered intravenously after general anesthesia induction and before tourniquet inflation and surgical incision
223863690|NCT00547118|DRUG|Rimonabant|One 20 mg tablet given 1 time per day for 112 days.
223863691|NCT00547118|DRUG|Placebo|One placebo tablet given 1 time per day for 112 days.
223863692|NCT03080038|OTHER|Fluid Sparing Resuscitation Strategy|"Tier 1: Initiate IV/IO vasoactive medication infusion support immediately. Further IV/IO isotonic fluid bolus therapy \[crystalloid (0.9% Normal Saline or Ringers Lactate) or colloid (5% Albumin)\] should be avoided; small volume isotonic fluid boluses \[5-10 mL/kg (250-500 mL for participants ≥ 50 kg)\] may be provided if required due to A. Clinically unacceptable delay in ability to initiate vasoactive medication infusion(s) and/or 2. Documented intravascular hypovolemia.~Tier 2: Vasoactive medication(s) should be preferentially titrated/escalated to achieve recommended ACCM hemodynamic goals. Further IV/IO isotonic fluid bolus therapy \[crystalloid (0.9% Normal Saline or Ringers Lactate) or colloid (5% Albumin)\] should be avoided; small volume isotonic fluid boluses \[5-10 mL/kg (250-500 mL for participants ≥ 50 kg)\] may be provided if required due to A. Documented intravascular hypovolemia.~Intervention end: Patient is free from vasoactive medication support and shock is reversed."
223863693|NCT00518726|BIOLOGICAL|Surface Antigen, Inactivated, Adjuvanted, Influenza Vaccine, Formulation 2007-2008|seasonal influenza vaccine 15ug
223863694|NCT02404233|DRUG|darunavir/cobicistat|Darunavir/ cobicistat 800/ 150 mg tablet once daily taken with food
223863695|NCT02404233|DRUG|rilpivirine|Rilpivirine tablet 25 mg once daily taken with food
223863696|NCT04288219|DEVICE|Non-Invasive Positive Pressure Ventilation|Continuous positive airway pressure delivered by face mask at 10cmH2O
223863697|NCT04288219|DRUG|Nifedipine|Nifedipine 30mg, Pharmacotherapy
223863698|NCT04288219|OTHER|supplemental oxygen|supplemental oxygen
223863699|NCT02608528|RADIATION|[18F]fluoroglucose(FDG)|
223863700|NCT03806751|DRUG|[O-15]Water|All study participants with undergo brain imaging with \[O-15\]water-PET/MRI without and with administration of the carbonic anhydrase inhibitor acetazolamide. The PET tracer will be used to measure regional cerebral perfusion, and the administration of acetazolamide will lead to increased cerebral perfusion compared to baseline cerebral perfusion.
223863701|NCT03806751|DRUG|Acetazolamide|The administration of acetazolamide will lead to increased cerebral perfusion compared to baseline cerebral perfusion.
223863702|NCT02248480|DRUG|Duloxetine|Administered orally
223863703|NCT02248480|DRUG|Placebo|Administered orally
223863704|NCT00920881|DEVICE|FreeStyle Navigator Continuous Glucose Monitoring System|Subjects wore 2 Navigator sensors for approximately 122 hours. Subjects and clinical staff were masked to continuous glucose data. During the time the subjects wore the continuous sensor, they were instructed to continue with their current diabetes management plan. Subjects stayed at the clinic for approximately 50 hours during the study period. While in the clinic, venous blood samples were collected every 15 minutes to determine whole blood reference glucose concentrations using the Yellow Springs Instrument. Subjects were also asked to obtain up to 50 FreeStyle finger blood glucose measurements using the system in the Navigator receiver for comparative analysis and system calibration. This was not a treatment study.
223863705|NCT01233713|PROCEDURE|Hartmann's operation|Hartmann's operation is the surgical resection of the rectosigmoid colon with closure of the rectal stump and end colostomy, followed by a stoma reversal operation.
223863706|NCT01233713|PROCEDURE|Primary anastomosis|Primary anastomosis refers to a colonic resection with primary anastomosis and covering proximal ileostomy, followed by a stoma reversal operation.
223863707|NCT04978935|OTHER|Care protocol|"Before starting the application, the investigator (DS) will fill out the Introductory Characteristics Form of all patients, the Pre-thoracotomy Pulmonary Function Test (PFT) section of the Patient Results Form. The PFT section will be re-evaluated on the 1st, 5th day and on the day of discharge after thoracotomy.~Nursing interventions will be applied to the study group (n=40), starting from the 0th day (the first day spent in the intensive care unit) after the thoracotomy in line with the prepared care protocol application steps until discharge. Care protocol consists of patient's position, mobilization, use of spirometer and shoulder exercises."
223863708|NCT01638611|DRUG|HIP2B|Total daily doses of 60, 120, 240, 480, and 720 mg are planned in five separate dosing cohorts. Single or split dose (depending on dose volume) will be given by subcutaneous injection in the abdomen to six subjects per dosing cohort.
223863709|NCT01638611|DRUG|Placebo|Equal volumes of placebo will be given by subcutaneous injection in the abdomen to 2 randomized subjects per dosing cohort.
223863710|NCT01595321|DRUG|Cyclophosphamide|Cyclophosphamide (Cy) 200 mg/m\^2 administered one day prior to GVAX (day 0). One dose will be given prior to SBRT and FOLFIRINOX and four additional doses after FOLFIRINOX completion for a total of 5 doses. Additional CY/GVAX boosts may be given every 6 months thereafter until disease recurrence.
223863711|NCT01595321|BIOLOGICAL|GVAX Pancreas Vaccine|GVAX administered one day after Cy (day 1). One dose will be given prior to SBRT and FOLFIRINOX and four additional doses after FOLFIRINOX completion for a total of 5 doses. Additional CY/GVAX boosts may be given every 6 months thereafter until disease recurrence.
223863712|NCT01595321|RADIATION|Stereotactic Body Radiation|"Cohort 1 and 2: SBRT (6.6 Gy per day, 33 Gy total dose) will be administered over 5 days within 6-10 weeks of pancreas surgery (Whipple).~Cohort 3: SBRT (6.6 Gy) will be administered over 5 days starting between 13-17 days after the first dose of CY/GVAX."
223863713|NCT01595321|DRUG|FOLFIRINOX|"FOLFIRINOX is given over six 28-day cycles, starting at least 1 weeks after SBRT.~FOLFIRINOX consists of the following drugs given IV on days 1 and 15 of each cycle:~Oxaliplatin (85 mg/m\^2), Irinotecan (180 mg/m\^2), Leucovorin (400 mg/m\^2), Fluorouracil (400 mg/m\^2 bolus followed by 2,400 mg/m\^2 continuous infusion over 46-48 hours);~modified FOLFIRINOX consists of the same regimen described above but without the 400 mg/m\^2 Fluorouracil bolus."
223863714|NCT01641913|OTHER|Absorbable sugars|Lactulose (1,000 mg) and mannitol (200 mg). For the liquid formulation, these sugars will be administered in 250 ml of water. After oral ingestion of the sugars in liquid form, urine will be collected every 30 minutes for the first 2 hours.
223863715|NCT00982618|DRUG|Lidocaine|1% Lidocaine 1mg/kg/hr IV drip x 48hr
223863716|NCT00982618|PROCEDURE|Epidural Block|0.1% Epidural bupivacaine + Morphine 0.02 mg/ml drip via epidural x48 hr
223863717|NCT00982618|DRUG|PCA Morphine|PCA Morphine is set to the patient for 48 hours postoperative. 2 mg. of morphine is given to a patient as much as patient requires, maximum at every 7 minutes.
223863718|NCT01533519|DRUG|Neuropeptide Y|Intranasal administration will be administered with a nasal drug delivery device.
223863719|NCT04504916|DRUG|Zilovertamab vedotin|Intravenous infusion
223863720|NCT02927132|BEHAVIORAL|Expressive Writing|Expressive writing is a brief intervention that has been linked to various health and social benefits. Expressing emotions through writing can lead to decreased levels of stress and negative affect, thereby serving as a coping mechanism. Furthermore, expressive writing allows participants to reconstruct their traumatic experiences and reorganize their memory of these events into a narrative. Expressive writing has been used to target drinking. Research has found that students have reduced drinking intentions after writing about a negative drinking event compared to control,suggesting that a narrative intervention may be effective in reducing drinking. Other research suggests that feelings of guilt were more strongly associated with intentions to reduce drinking after writing about a negative drinking event, and that this event-related guilt mediated intervention effects.
223863721|NCT02927132|BEHAVIORAL|Personalized Normative Feedback|"PNF approaches use information designed to correct normative misperceptions to reduce heavy drinking. Three pieces of information are necessary when providing personalized normative feedback: information about a student's own drinking, information about the student's perceptions of others' drinking, and information about others' actual drinking. The presentation of this information is designed to change students' perceptions of normal drinking by exposing their misperceptions of the norm as well as by comparing their behavior with normal behavior."
223863722|NCT02950896|OTHER|observational fetal heart rate monitoring|Patients will have fetal heart rate monitoring
223863723|NCT02602106|BEHAVIORAL|Aquatic activities intervention|Women were suggested to exercise regularly through aquatic activities. A professional in physical exercise and sports designed and conducted the aquatic exercise program.
223863724|NCT03083119|DRUG|Xuesaitong soft capsule|Panax Notoginseng Saponins, Specification:0.33 per bag, once take two pills and twice a day during a month.
223863725|NCT03083119|DRUG|Placebo oral capsule|Xuesaitong soft capsule Placebo, soft capsule, once take two pills and twice a day during a month.
223863726|NCT00567515|DEVICE|AtriCure LAA Exclusion System|Placement of clip of LAA.
223863727|NCT03561610|DIETARY_SUPPLEMENT|sip feed|normal oral Nutrition + sip feed (Fresubin2.0®; covers individual energy and nutrient demands; high in protein)
223863728|NCT03561610|DIETARY_SUPPLEMENT|gumdrops|normal oral Nutrition + gumdrops (Nutrimed®; covers individual energy and nutrient demands; high in protein)
223863729|NCT05510544|DRUG|Plerixafor,G-CSF|"G-CSF: 10 μg/kg/day, subcutaneously injected, every morning from day 1 to day 8.~Plerixafor injection: 0.24 mg/kg/day, subcutaneous injection, starting on the 4th day, once a day, up to 4 times in a row. Plerixafor injection and G-CSF administration site should be separated. The interval between plerixafor injection and stem cell collection was 10-11 hours."
223863730|NCT02331004|OTHER|Intervention for fine motor skills|Implementation of an well known activity to improve the function of upper extremities
223863731|NCT02331004|OTHER|Support to activities of daily living|Participants are supported and orientated when they are performing some activity of daily living scheduled by the institution
223863732|NCT00834834|DRUG|Fluoxetine|Starting dose of 20 mg daily will increase over 4 weeks, depending on tolerability, up to 40 mg daily. Treatment will last 6 months.
223863733|NCT00834834|BEHAVIORAL|DBT|One 60-minute individual therapy session and one 90-minute group therapy session every week. Treatment will last 6 months.
223863734|NCT00834834|DRUG|Citalopram|Dose set by study psychiatrist, up to 60 mg daily. Treatment will last 6 months.
223863735|NCT00234091|DRUG|Abacavir|8 mg/kg (up to 300 mg/dose) take orally twice daily
223863736|NCT00234091|DRUG|Efavirenz|200 to 600 mg taken orally once daily
223863737|NCT00234091|DRUG|Lamivudine|4 mg/kg (up to 150 mg/dose) taken orally twice daily
223863738|NCT00234091|DRUG|Lopinavir/Ritonavir|230 mg/57.5 mg/m\^2 body surface area taken orally twice daily with food
223863739|NCT00234091|DRUG|Nelfinavir|45-55 mg/kg taken orally twice daily with food
223863740|NCT00234091|DRUG|Nevirapine|120 mg/m\^2 once daily for first 14 days, tehn 200 mg/m\^2 (up to 400 mg/day) twice daily
223863741|NCT00234091|DRUG|Zidovudine|180-240 mg/m\^2 every 12 hours (up to 300 mg/dose)
223863742|NCT02238210|DRUG|Atrovent®|
223863743|NCT00687388|DRUG|selective alpha 1-blockers|Continued medication that the patient had before the enrollment of this study (tamsulosin 0.2mg, alfuzosin 10mg, doxazosin 4, 8mg, or terazosin 2-10mg daily for 8 weeks)
223863744|NCT00687388|DRUG|celecoxib|200mg daily for 8 weeks
223863745|NCT00687388|DRUG|alpha-blocker and NSAID|amsulosin 0.2mg, alfuzosin 10mg, doxazosin 4, 8mg, or terazosin 2-10mg daily for 8 weeks and celecoxib 200mg daily for 8 weeks
223863746|NCT01334320|PROCEDURE|elective neck dissection|patient underwent elective neck dissection as initial treatment, along with the excision of the primary tumor
223863747|NCT05026086|OTHER|pressure biofeedback|10 patients will be treated with isometric exercises and pressure biofeedback.
223863748|NCT05026086|OTHER|isometric exercises|10 patients will be treated with isometric exercises
223863749|NCT03726268|DRUG|Methadone|"Dose is 0.15-0.3 mg/kg IV methadone HCl given intraoperatively and in the immediate post-operative period. Intraoperative methadone doses are 15 mg in short-stay, anticipated next-day discharge patients (10 mg if ≤55kg), and 10 mg in same-day surgery patients."
223863750|NCT03726268|DRUG|Fentanyl|Given per clinical provider discretion intraoperatively and in the immediate post-operative period (while patient remains in the post anesthesia care unit (PACU)).
223863751|NCT03726268|DRUG|Hydromorphone|Given per clinical provider discretion intraoperatively and in the immediate post-operative period (while patient remains in the post anesthesia care unit (PACU)).
223863752|NCT03726268|DRUG|Morphine|Given per clinical provider discretion intraoperatively and in the immediate post-operative period (while patient remains in the post anesthesia care unit (PACU)).
223863753|NCT03726268|DRUG|Sufentanil|Given per clinical provider discretion intraoperatively and in the immediate post-operative period (while patient remains in the post anesthesia care unit (PACU)).
223863754|NCT03400124|PROCEDURE|ISBCS|The intervention group will undergo cataract surgery in both eyes on the same day (ISBCS)
223863755|NCT03400124|PROCEDURE|DSBCS|The usual care / control group will undergo cataract surgery in both eyes on separate days, with a time period of at least two weeks between surgeries.
223863756|NCT02430740|DRUG|recFSH|
223863757|NCT02884544|DRUG|HLD100|Treatment
223863758|NCT00001992|BIOLOGICAL|rgp120/HIV-1IIIB|
223863759|NCT00947986|OTHER|1% Johnson's Baby Shampoo|nasal irrigation 2x a day for 4 weeks
223863760|NCT03034681|OTHER|Physiotherapy technique: TENS|
223863761|NCT03034681|OTHER|Physiotherapy technique: Vojta Therapy|
223863762|NCT05088629|DIAGNOSTIC_TEST|Clinical Tests|Clinical Tests
223863763|NCT04528264|DEVICE|Intraoperative ultrasound guided|Samsung Mysono U6 machine with LN 15 linear (https://www.samsunghealthcare.com/en/products/UltrasoundSystem/MySono%20U6/General%20Imaging/transducers) probe capable of Musculoskeletal imaging will be used for visualization and location of fracture after which elevation and reduction of fracture will be attempted. The ultrasound probe will be used as described by McCann. Radiographic continuity of periosteal shadow without any step will be taken as end point for reduction and the procedure will be terminated.
223863764|NCT04528264|OTHER|Conventional blind reduction technique|Conventional blind reduction technique
223863765|NCT04042129|OTHER|gynecologic operations with urological complications|
223863766|NCT00539292|PROCEDURE|Primary placement of a spring-loaded silo|
223863767|NCT00539292|PROCEDURE|Primary Closure|primary closure of abdomen
223863768|NCT05717114|PROCEDURE|Pecs block|(Pecs block):the block will be performed with the patients in the supine position.The infraclavicular and axillary regions will be cleaned with antiseptic solution. the inplane technique will be used from proximal and medial to distal and lateral in an oblique manner at dermatome level T2and T3.The puncture site was infiltrated with 2%lidocaine and once the structures is identified with ultrasound.
223863769|NCT01649180|DRUG|Axitinib|Axitinib 5 mg orally with food every 12 hours. One cycle=28 days.
223863770|NCT01987154|OTHER|Marketed cow milk-based premature infant formula|
223863771|NCT01987154|OTHER|Marketed extensively hydrolyzed casein infant formula|
223863772|NCT03795558|DRUG|Etelcalcetide|Up-Titration
223863773|NCT01235884|DIETARY_SUPPLEMENT|Lactobacillus reuteri|1000000000 CFU per day (5 drops) for 28 days
223863774|NCT01235884|DIETARY_SUPPLEMENT|Placebo|5 drops daily for 28 days
223863775|NCT02705937|OTHER|Dairy product|Dairy products are given to patients with the instruction to eat as many products as necessary to provide them with some relief (within a limit of 6 per day) for 14 days
223863776|NCT02705937|DEVICE|Aequasyal mouth spray|The mouth spray will be used by patients as needed (according to the package leaflet) for 14 days
223863777|NCT01270633|DEVICE|PriMatrix|Following sharp debridement, application of PriMatrix dermal repair scaffold in conjunction with moist wound therapy
223863778|NCT01270633|OTHER|Standard of Care|Following sharp debridement, moist wound therapy
223863779|NCT00997386|DRUG|busulfan, and melphalan, and alemtuzumab|"intravenous busulfan 3.2 mg/kg/dose daily for 2 days, on days -5 and -4 (i.e., 5 and 4 days, respectively, before PBSCT).~intravenous melphalan 100 mg/m2 on day -3.~intravenous alemtuzumab 30 mg/dose for 2 days, on days -2 and -1."
223863780|NCT03932981|DRUG|Temozolomide|Temozolomide at a monthly standard dose of 150-200 mg/m2/day at day 1 to day 5 for a duration of treatment of 12 months
223863781|NCT01579916|BIOLOGICAL|Trivalent Influenza Virus Vaccine|Trivalent vaccine is supplied in intranasal sprayers containing a total volume of 0.5 mL of sucrose phosphate buffer, egg allantoic fluid and approximately 10\^7 FFU (fluorescent focus units) of each of 3 cold-adapted, attenuated 6:2 reassortant influenza strains: A/H1N1 (A/California/7/2009), A/H3N2 (A/Victoria/361/2011), B (B Wisconsin/1/2010). A single dose of investigational product was administered on Day 1.
223863782|NCT01579916|OTHER|Placebo|Placebo is suppllied in intranasal sprayers containing 0.5 mL of sucrose-phosphate buffer. A single dose of investigational product was administered on Day 1.
223863783|NCT03950609|DRUG|Everolimus|Given PO
223863784|NCT03950609|DRUG|Lenvatinib|Given PO
223863785|NCT04658771|DEVICE|MR-HIFU treatment|"MR-HIFU is an innovative technology that allows for non-invasive thermal ablation of tissues and tumors by integrating an external high intensity focused ultrasound (HIFU) transducer with a conventional MRI scanner.~The focused ultrasound transducer is placed outside of the body and generates and focuses acoustic energy to heat tumors or other pre-defined focal regions of tissues inside the body. Because the acoustic energy is precisely focused over tiny areas of tissue, potential thermal injury to surrounding tissues is minimal. Cell death inside the selected treatment area occurs via coagulative necrosis while avoiding injury to intervening and adjacent tissues."
223863786|NCT06778642|PROCEDURE|Serratus Posterior Superior Intercostal Plane Block|Patients undergoing Video-Assisted Thoracoscopic Surgery (VATS) will receive either a Serratus Posterior Superior Intercostal Plane Block (SPSIPB) with bupivacaine after induction and before the surgical procedure begins.
223863787|NCT06778642|PROCEDURE|Serratus Anterior Plane Block|Patients undergoing Video-Assisted Thoracoscopic Surgery (VATS) will receive either a Serratus Anterior Plane Block (SAPB) with bupivacaine after induction and before the surgical procedure begins.
223863788|NCT03667443|DIETARY_SUPPLEMENT|Myo-inositol + folic a. + α-lactalbumin|3 months of treatment
223863789|NCT03667443|DIETARY_SUPPLEMENT|Myo-inositol + folic a.|3 months of treatment
223863790|NCT06369350|DRUG|Vitamin B6 25 MG|Vitamin B6 25 mg/day will be given for up to 31 days.
223863791|NCT06369350|DRUG|Vitamin B6 50 MG|Vitamin B6 50 mg/day will be given for up to 31 days.
223863792|NCT06369350|DRUG|Vitamin B6 100 MG|Vitamin B6 100 mg/day will be given for up to 31 days.
223863793|NCT06369350|DRUG|Placebo|Placebo capsule will be given for up to 31 days.
223863794|NCT06459817|DEVICE|BB-02 therapy|Biophysical stimulation with magnetic fields
223863795|NCT05076656|DIETARY_SUPPLEMENT|Lactobacillus fermentum D3|Lactobacillus fermentum D3 in a white, gelatin capsule (orally), with lyophilized L. fermentum D3 without preservatives, sugars, or additives.
223863796|NCT05076656|BIOLOGICAL|Fecal microbiota transplant (FMT)|Fecal microbiota transplant (FMT) in a green, gelatin capsule (orally), with lyophilized fecal material.
224076319|NCT02963805|BEHAVIORAL|High intensity physical activity (HIPA)|This arm consisted of a twice-weekly after-school club at the intervention school for 26 weeks during school term time, delivered by qualified coaches. Each 60 minute session engaged participants in high-intensity vigorous activity using a combination of playground-style games and circuit training activities that aimed to keep children moving and maintain a mean heart rate above 70% of age-predicted maximum heart rate (\~145 beats/min) for the session duration. Intensity was verified by heart rate monitoring. Coaches delivered and monitored sessions and increased the intensity over time to allow for the children to progress. The mean heart rate for HIPA sessions was 150 beats/min, with children spending 52 min at this intensity during the session.
223863797|NCT05076656|DRUG|Placebo|Placebo in a white, gelatin capsule (orally), with powder milk
223863798|NCT02763124|PROCEDURE|Verion-LenSx|The Verion-LenSx femtosecond laser system will be used to create one or two partial-depth corneal arcuate incisions
223863799|NCT02994654|DEVICE|ReCell|"The ReCell-assigned treatment area will be treated as described in the product's Instructions for Use. In summary, 1ml of fluid physically covers a treatment area of 80 cm2. Each milliliter of fluid contains cells harvested from a square centimeter of thin split-thickness skin sample.~The reagents and components of the ReCell kit are used, in a scalable fashion, to facilitate disaggregation of cells from skin samples into filtered cell suspension. Areas to be harvested for skin samples are to be clean and show no evidence of surrounding cellulitis or infection. Treatment area sizes and cell suspension volumes are to be recorded."
223863800|NCT02207075|DRUG|[C11]PK-1195 PET scan|PET scan with tracer \[C11\]PK-1195
223863801|NCT05917249|DEVICE|Capacitive-Resistive Noninvasive Radiofrequency|The two passive plates were under the back of the patient. The active capacitive plates of the machine (CAPENGERY, C200, Spain) will be applied initially for 20 minutes over the sole of both feet, with the machine adjusted on the A-thermal mode (37 oC). During the remaining 20 minutes, active capacitive plates are relocated over femoral vessels at the femoral triangle with the machine adjusted on the frank thermal mode (41 oC).
223863802|NCT03276039|DIAGNOSTIC_TEST|plasma pentraxin-3|Plasma pentraxin-3 was measured using ELISA
223863803|NCT01611376|DEVICE|Niccomo™ (Medis, Ilmenau, Germany) impedance cardiography|
223863804|NCT00385801|DRUG|Risperidone|
223863805|NCT00385801|DRUG|Placebo|
223863806|NCT03659201|DRUG|Neosil complete|Oral, during 24 weeks.
223863807|NCT03659201|DRUG|Pantogar|Oral, placebo for 12 weeks and pantogar for 12 weeks.
223863808|NCT03659201|DRUG|Neosil|Oral, during only 12 weeks.
223863809|NCT05535530|DEVICE|Active PSIO|new designed active orthopedic appliance will be used. Impressions will be taken before starting the treatment (T1) and at the end of treatment (T2) three months later. The effectiveness of the two appliances will be assessed and measured on digital models of the maxillary arch before and after the treatment.
223863810|NCT03870191|OTHER|Injection of either twin block or trigger point injection.|Study participants will be randomized into either group and will receive the intervention.
223863811|NCT00605904|DRUG|Acamprosate|orally administered tablet, 333mg, three times daily for a minimum of 2 weeks (14 days)
223863812|NCT00605904|DRUG|Yohimbine|Intravenous infusion of yohimbine (0.4 mg/kg) administered once over 10 minutes
223863813|NCT00605904|DRUG|mCPP|Intravenous infusion of mCPP (0.05 mg/kg) over 10 minutes, two times, for a total of 0.1 mg/kg
223863814|NCT00605904|DRUG|Saline|"Intravenous infusion of 0.9% sodium chloride solution over 10 minutes, three times during the study (2 times for the Saline Infusion milestone, and one time immediately following the Yohimbine Infusion milestone)"
223863815|NCT04552886|BIOLOGICAL|TH-1 Dendritic Cell Immunotherapy|Adult patients with histopathologically diagnosed glioblastoma will be eligible for this novel, personalized dendritic cell vaccine after completing standard of care chemoradiation.
223863816|NCT06116058|OTHER|Experimental: Group A: integrated neuromuscular inhibition technique|will receive integrated neuromuscular inhibition in addition to conventional treatment,INIT which included IC, SCS, and MET for the low back region for the quadratus lumborum( QL) and erector spinae (ES) muscles
223863817|NCT06116058|OTHER|Experimental: Group B :Instrument assissted soft tissue mobilization|IASTM performed on lumbar posterior muscle erector spinae (iliocostalis, longissimus), and quadratus lumborum(QL) The IASTM treatment was applied for approximately 20-seconds in a direction parallel to the muscle fibers being treated with the instrument at a 45° angle. Followed immediately by treating the muscles in a direction perpendicular to the muscle fibers with the instrument at a 45° angle for an additional 20-seconds, resulting in a total treatment time of approximately 40 seconds.
223863818|NCT06116058|OTHER|control group C conventional physical therapy|. The control group will applied general exercise. General exercise were applied with stretching exercises and stationary bicycling for 10-15 minutes14, 15) . Three sets of fifteen repetitions will performed, with rest times of 1 minute between sets during 4 weeks.
223863819|NCT03143309|BEHAVIORAL|Intervention|Brief introductory session, pedometer instruction, daily pedometer use, and health messages delivered via WhatsApp 2-3 times per week.
223863820|NCT03143309|OTHER|Control|Non-health related messages delivered via WhatsApp 2-3 times per week.
223863821|NCT02403219|DRUG|Botulinum toxin type A injection|Injection of botulinum toxin type A
223863822|NCT02403219|OTHER|Saline solution injection|Injection of saline solution
223863823|NCT00158639|BEHAVIORAL|Home BP;secure messaging;pharmaceutical care;|
223863824|NCT02464852|BEHAVIORAL|Head movements|Participants will be asked to perform a series of movements of exploration of their maximum neck range of motion, including: flexion, extension, right and left lateral flexion, right and left axial rotation.
223863825|NCT02464852|BEHAVIORAL|Activities of daily living (drinking, washing hand and eating)|Patients will be asked to perform a series of activities of daily living (drinking, eating and washing hands).
223863826|NCT02464852|DEVICE|Sheffield Support Snood|
223863827|NCT02464852|DEVICE|sEMG|
223863828|NCT02299336|DRUG|Aflibercept|pro re nata (PRN)
223863829|NCT02299336|PROCEDURE|Focal Laser|Focal laser administered based on pre-specified criteria
223863830|NCT01359371|BEHAVIORAL|Peer telephone cessation counseling|For Veterans who received the inpatient Tobacco Tactics intervention, trained volunteers initiated follow-up telephone cessation counseling at 2, 14, 21 and 60 days after in-patient discharge; three attempts were made per time point.
223863831|NCT02940561|DRUG|Methotrexate - Amneal|"Methotrexate Tablets, USP contain an amount of methotrexate sodium equivalent to 2.5 mg of methotrexate, USP and are round, biconvex, yellow tablets, scored in half on one side, engraved with A above the score and 1 below"
223863832|NCT02940561|DRUG|Methotrexate - DAVA|Methotrexate Tablets, USP contain an amount of methotrexate sodium equivalent to 2.5 mg of methotrexate and are round, convex, yellow tablets, scored in half on one side, engraved with M above the score, and 1 below
223863833|NCT03203798|PROCEDURE|Training of pelvic floor muscles|The pelvic floor muscle training group will be composed of randomized women and participated for 12 weeks of intervention, where it was performed in groups of a maximum of 4 patients, starting in the first 4 weeks with 3 sets of 8 repetitions of contraction maintained for 5 seconds In antigravity postures, with two lying postures and one sitting posture, and evolving to the next 4 weeks for 3 sets with 10 repetitions of contraction maintained for 5 seconds being a lying posture, a seated posture and orthostatic posture in the last 4 weeks 3 Series of 12 repetitions of contraction maintained for 5 seconds in the gravitational postures, being one sitting posture and two orthostatic postures.
223863834|NCT03203798|PROCEDURE|Hipopressive abdominal gymnastics|The hipopressiva abdominal gymnastics group will be composed of randomized women who participated for 12 weeks of intervention, where it was performed in groups of a maximum of 4 patients, being performed respecting the basic sequence of the exercise proposed by Marcel Caufriez: 1) Inspiration, 2) Maximum Expiration, 3) Diaphragmatic aspiration being performed 3 series of 8 to 12 repetitions. The exercises will be performed in groups of a maximum of 4 patients, starting in the first 4 weeks with 3 sets of 8 repetitions in antigravity postures, with two lying postures and one sitting posture, and evolving over the next 4 weeks to 3 sets with 10 repetitions A lying posture, a sitting posture and orthostatic posture, in the last 4 weeks 3 sets of 12 repetitions in the gravitational postures, being a sitting posture and two orthostatic postures.
223863835|NCT04948593|PROCEDURE|Native kidney biopsy|
223863836|NCT01897298|BEHAVIORAL|Urban training|Recommendation to walk a minimum of 5 days per week in urban walkable trails appropriate for the patient.
223863837|NCT04204720|DEVICE|needle (Chiba)|intravascular injection using chiba needle during caudal epidural block
223863838|NCT04204720|DEVICE|needle (Whitacre)|intravascular injection using whitacre needle during caudal epidural block
223863839|NCT06656689|PROCEDURE|Rezum (water vapor thermal therapy)|Rezum or water vapor thermal therapy is a procedure that involves injecting steam at 103°C into the prostate tissue to induce necrosis and reduce the size of the enlarged prostate.
223863840|NCT05035199|BEHAVIORAL|Spiritual Distress and Resources Questionnaire (SDRQ)|The SDRQ is a validated self-rating instrument to assess spiritual distress and resources. It focuses on beliefs, attitudes, experiences and practices of various kinds (every day and extraordinary), as well as on (dis-)connectedness. It consists of 22 items covering three subscales: spiritual resources, spiritual distress, and spiritual coping (Peng-Keller et. al., 2020, submitted). We constructed five additional questions to find out more why patients want to include spiritual aspects in their treatment.
223863841|NCT02106442|DRUG|Sodium risedronate|Sodium risedronate tablets
223863842|NCT06600685|OTHER|Functionally oriented music therapy (FMT)|There are different methods of music therapy and one of these is FMT. It is a body-based and music therapeutic treatment method that is used for health-promoting purposes. With the help of i.e. drums, cymbals, various custom-made drumsticks, flutes, chairs, balance balls and balance cushions. FMT strives to support, strengthen and develop the person's physical, mental and social abilities. FMT-sessions (20 minuets/1 time a week) are performed individuelly (a patient with a educated music therapist).
223863843|NCT05402891|DRUG|Lithium Carbonate|Patients will be administered lithiumcarbonate by an oral tablet of 300mg once a day for a duration of 6 months. Starting dose is 200mg for the first 5 days, dosage will be then increased to 300mg. To limit adverse events and side-effects, the lowest effective dose will be administered. The target serum level of lithium is 0.20 - 0.40 mmol/L and this will be maintained by regular lithium level testing.
223863844|NCT01181089|BIOLOGICAL|Placebo|
223863845|NCT01181089|BIOLOGICAL|Baminercept|
223863846|NCT06990984|DRUG|TTI-0102: cysteamine-pantetheine disulfide|TTI-0102: cysteamine-pantetheine disulfide, powder for dissolution in water for oral administration
223863847|NCT06990984|DRUG|D-Mannitol|D-Mannitol
223863848|NCT06604533|PROCEDURE|Intervention: MRI-Linac SABR|The treatment planning protocol follows the UK SABR Consortium Guidelines. Patients will be prescribed the maximum isotoxic dose achievable while meeting normal organ tolerances (normal liver, kidney, spinal cord, stomach, duodenum, small and large bowel, heart, lungs, chest wall). The lowest acceptable SABR doses are indicated in the dose range Table within the protocol. The maximum dose/fraction also indicates the maximum the dose can be escalated to for each adaptive session on the MRI-Linac.
223863849|NCT00003516|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|Antineoplaston therapy (Atengenal + Astugenal) capsules orally six to seven times a day. Treatment continues in the absence of disease progression or unacceptable toxicity. absence of disease progression or unacceptable toxicity.
223863850|NCT06677411|OTHER|Observention of vitamin D|It is an observational study
223863851|NCT07002073|DRUG|ketamine-dexmedetomidine admixture induction of Anesthesia|To compare incidence of hypotension following ketodex versus ketofol during induction of general anesthesia in elderly patients
223863852|NCT03134235|OTHER|Dietary Intervention|Subjects consumed a raw, vegan diet for 4-weeks with an emphasis on raw fruit and vegetable consumption.
223863853|NCT00634452|BIOLOGICAL|MDX-1401|IV weekly for 4 weeks
223863854|NCT06628427|DIAGNOSTIC_TEST|MoCA Test|MoCA (Montreal Cognitive Assessment or The MoCA Test) was validated as a highly sensitive tool for early detection of mild cognitive impairment (MCI) in hundreds of peer-reviewed studies since 2000. MoCA has been widely adopted in clinical settings and used in academic and non-academic research around the world. The sensitivity of MoCA for detecting MCI is 90%, compared to 18% for the MMSE. Prospective participants meeting the eligibility criteria, as determined by the Montreal Cognitive Assessment (MoCA) test, will be invited to the Brain- Computer Interface (BCI) laboratory at the Kroto Research Centre on the University of Sheffield north campus to participate in the study.
223863855|NCT06628427|DEVICE|Random Dot Motion (RDM) task|Random Dot Motion task (RDM) has been widely used in research on spatial attention, and decision-making ability, etc., and its results (accuracy and reaction time) can be used as indicators to detect spatial attention. During the assessment, participants were required to monitor a series of dots in constant random motion on the screen. The dots sometimes moved coherently together to the left or right, and participants were required to press the left mouse button when they perceived them moving to the left and the right mouse button when they observed them moving to the right. We are going to use the motion coherence level of 50%. The higher the coherence level, the greater the number of dots moving together, and the combination of the moving direction and coherence level of the dots appear randomly during the task.
223863856|NCT06628427|DEVICE|P300-BCI task without feedback|Two different speller matrix sizes: 3×3 and 5×5, two inter-stimulus intervals (ISIs): 117ms (i.e., commonly used ISI for healthy adults) and 175ms (i.e., 50% longer than the widely used ISI) and two spelling words (QUICK and JUMP) are designed in this experiment to explore the calibration accuracy of these eight parameter combinations in the young and old groups and obtain the best parameter combination. The matrix contains letters and digits, and the target letters will be displayed below the matrix letter by letter. When the speller runs, the rows and columns in the matrix will flash 15 times each randomly. Each flash will last for 55ms, and the subsequent ISI will last for different times according to different parameter designs. Participants only need to focus on the target letter and silently count the number it flashes, as flashing target letters can generate P300 if well attended.
223863857|NCT06631976|DRUG|1ml of Depo-Medrol® injection|1ml of methylprednisolone acetate (40mg/ml) injection into subacromial bursa.
223863858|NCT06631976|OTHER|Rehabilitation|Rehabilitation
223863859|NCT06631976|DRUG|Nerve block with 4ml of 2% lidocaine|Nerve block with 4ml of 2% lidocaine around the suprascapular nerve
223863860|NCT06631976|DRUG|Tropocells® PRP injection|Tropocells® PRP injection. Patients will have an 11ml venous blood sample taken. After centrifugation, the obtained preparation will be administered to the patients intratendinously.
223863861|NCT06631664|OTHER|Traditional physical therapy|Participants received a traditional physical therapy program three times a week, for three successive months. Each session lasted for approximately 30 minutes and composed of the following: 1) Massage (spiral effleurage, longitudinal and transverse thumb effleurage for 5 minutes or until hyperemia), 2) Facilitation of muscle contraction through a variety of tactile and proprioceptive stimulation techniques - this was applied for the shoulder flexors, abductors, and external rotators, elbow flexors, and wrist/finger extensors. In patients whose lesion extend to involve C7, The facilitation techniques were also applied to elbow extensors. 3) Weight-bearing exercise, considering the developmental milestone (prone forearm support, prone full hand support). 4) Range of motion exercises - all joints of the affected side were moved through the full range of motion. 5) Sucking exercise.
223863862|NCT06631664|DEVICE|A computerized electrical stimulator (Vectra®2C; Chattanooga, TS, USA)|"The patient was positioned in supine lying position with the affected arm beside the body and elbow extended, the skin over the anterior and posterior comportment of the upper arm was cleaned using medical cotton sacked in alcohol before the application.~The first two stimulating electrodes for the biceps muscle were placed at the superior and inferior 1/3 of anterior surface of the upper arm with a distance in between the two electrodes at least the size of one of them, while the other two electrodes for the triceps muscle were placed at the superior and inferior 1/3 of the posterior surface of the upper arm.~One millisecond pulse duration and a frequency of 50Hz with a rectangular shaped pulse were utilized and stimulation was applied for 15 minutes. At first a low-intensity current is applied and gradually increased till a gentle contraction of the muscles appears and allow time for the child to become accustomed to the current and maintained sufficient and observable contraction."
223863863|NCT06630065|BEHAVIORAL|fMRI with emotional task and pupillometry|"Anatomical and functional magnetic resonance imaging (fMRI) imaging sequences with pupillometry (\~90 min)~A functional sequence - Task (\~20min):~* Emotional task in fMRI: Instructions: simply look images, then evaluate the emotions triggered at the end of each block; rating on a valence and intensity scale and intensity (arousal) scale.~* Experimental conditions: positive, negative and neutral~* Paradigm: block validated image banks: IAPS, GAPED, EMOPICS, OASIS, etc. Pupillometry: In order to collect objective data on emotional bias, we will use pupillometry (or eye-tracking) during functional MRI sequences."
223863864|NCT06630065|BEHAVIORAL|Behavioral task with emotional facial expressions|Description of the recognized emotion joy - sadness. Test to assess the hedonic value of an olfactory stimulus (10 min)
223863865|NCT06630065|GENETIC|Biological investigation|Standard biological assessment, immuno-inflammatory profile and the association of 8 mRNA editing variants
223863866|NCT06631014|DIAGNOSTIC_TEST|Early Rehab|The first group of 25 Patients was fitted with Prosthesis with in 6months of duration after amputation.
223863867|NCT06631014|COMBINATION_PRODUCT|Delayed Rehab|The 2nd group of 25 patients that was fitted with Prosthesis after the time period of 6months after amputation. No physical rehab was done during this time period including physiotherapy and prosthetic treatment. Main aim was to check the significant impact of delayed rehabilitation.
223863868|NCT06632106|PROCEDURE|hepatic artery infusion chemotherapy|Hepatic arterial infusion chemotherapy including FOLFOX and RALOX
223863869|NCT06632106|DRUG|Tyrosine kinase inhibitor (TKIs)|TKIs including Lenvatinib, Sorafenib, Apatinib, Donafenib, Bevacizumab
223863870|NCT06632106|DRUG|Immune Checkpoint Inhibitors|ICIs including Camrelizumab, Sintilimab, Tislelizumab, Pembrolizumab, Atezolizumab
223863871|NCT07023965|DRUG|NL003|This is an observational study, and the interventions have already been administered in the preceding Phase III clinical trials.
223863872|NCT07023965|DRUG|Placebo|This is an observational study, and the interventions have already been administered in the preceding Phase III clinical trials.
223863873|NCT05535491|OTHER|Educational and Research Hospital|breathing exercise
223863874|NCT03911245|OTHER|Retrospective study. Analyze of data in medical records|Retrospective study. Analyze of data in medical records
223863875|NCT03719092|DIETARY_SUPPLEMENT|Vitamin A Compound|Given PO or enterally
223863876|NCT03719092|OTHER|Best Practice|Receive usual care
223863877|NCT07033585|DRUG|Farxiga® (dapagliflozin) + Onglyza® (saxagliptin) + Metformin Oral Mix Treat type 2 diabetes|Farxiga® (dapagliflozin) 10 mg, Onglyza® (saxagliptin) 5 mg, Metformin 500 mg, Oral Mix Prescription Treat type 2 diabetes patients with controlled cancers
223863878|NCT07033585|DRUG|China Import (dapagliflozin) + China Import (saxagliptin) + Metformin Oral Mix Treat type 2 diabetes|China Import (dapagliflozin) 10 mg, China Import (saxagliptin) 5 mg, Metformin 500 mg, Oral Mix Prescription Treat type 2 diabetes patients with controlled cancers
223863879|NCT06712615|BIOLOGICAL|PG-102|"* Participants will receive PG-102 by subcutaneous (SC) injection.~* Other Names: MG12"
223863880|NCT06712615|OTHER|Placebo|Participants will receive placebo by SC injection
223863881|NCT06697873|OTHER|Experimental Group: A|21 participants will receive both Rhythmical stabilization and closed chain kinetic exercise followed by a warm up session with stretching 5 minutes and cool down session with 5 minutes
223863882|NCT06697873|OTHER|Experimental: Group B|21 participants will receive Rhythmical stabilization training program followed by a warm up session with stretching 5 minutes and cool down session with 5 minutes.
223863883|NCT06714162|DIETARY_SUPPLEMENT|Longevity pill|vitamins and herbs
223863884|NCT00573833|OTHER|questionnaire administration|
223863885|NCT00573833|PROCEDURE|quality-of-life assessment|
223863886|NCT00573833|RADIATION|brachytherapy|
223863887|NCT07047274|BEHAVIORAL|Education group (DBM/BMP)|A structured web-based training program, consisting of ten one-hour sessions, was delivered to students in the intervention group. To foster active engagement and reinforce learning outcomes, each session incorporated interactive, game-based activities through the Kahoot platform. The content of the training was developed in collaboration with a panel of 12 subject-matter experts, including specialists in emergency care, public health, internal medicine, surgery, and education. Additionally, the structure and thematic scope of the program were aligned with the emergency action guidelines of AFAD, Türkiye's official disaster management authority. The curriculum encompassed a comprehensive range of topics, including the classification of disasters, disaster awareness, risk assessment, use of personal protective equipment, triage procedures, post-disaster management, basic first aid practices, and the psychosocial dimensions of disaster response.
223863888|NCT07046351|BEHAVIORAL|weSIPsmarter|weSIPsmarter is grounded by the Theory of Planned Behavior as well as Satter's Feeding Dynamic Model. weSIPsmarter will also integrate relevant behavior change techniques and target concepts from health literacy, health numerary, media literacy, and eHealth literacy.
223863889|NCT07046351|BEHAVIORAL|weLearn2Read|weLearn2Read participants will have access to a website with resources to improve reading readiness, including 6 structured parent lessons, setting reading goals, and 6 children's books (one mailed home each week), and options to receive weekly reminders (e.g., email or text) to encourage reading readiness.
223863890|NCT07041684|DIETARY_SUPPLEMENT|Very Low Energy Ketogenic Therapy with vegan meal replacements|Metagenomics analysis of gut microbiota at baseline and after 45 days
223863891|NCT07049861|OTHER|Comprehensive Multidisciplinary Obesity Care|CMOC is an innovative approach to obesity care delivery that leverages policy, clinical and community linkages, and digital technology for scalability. CMOC involves training providers (medical providers, registered dietitians, and behavioral health providers) to deliver guideline-based obesity care for youth and adults with obesity who receive Medicaid. Guidelines-based care involves screening, identification, weight counseling, and referral to intensive behavioral treatment by medical providers, and delivery of multicomponent intensive behavioral treatment by behavioral health providers and registered dietitians.
223863892|NCT07049861|OTHER|Implementation as Usual Control|The standard of care implemented in FQHCs in the absence of CMOC training.
223863893|NCT07052916|OTHER|Music Therapy/MT|Therapeutic music lessons are the core component of the Music Therapy/MT intervention. Other components include guided music listening to help participants use music as a tool for regulating mood, energy, and attention, as well as music-centered discussions to help participants discover songs with personal meaning that they will enjoy learning to play.
223863894|NCT07052916|OTHER|Therapist-Attention Music Education/TAME Control|Participants will receive 12, weekly 60-minute TAME sessions (+/- 1 week) with homework in-between sessions to reinforce in-session concepts and serve as transitions to subsequent sessions. The TAME control group will involve board-certified music therapists guiding participants through music listening exercises.
223863895|NCT06896162|OTHER|Expert Review|Expert reflexive review of next-generation sequencing (NGS) results will be visible in electronic health records (EPIC) for provider review at the University of North Carolina Health System. Expert review will include recommendations for Genome-informed therapy (GIT), identification of available clinical trials, recommendations for additional testing, and/or referrals for genetic counseling.
223863896|NCT06896162|OTHER|Blood or tissue samples collection.|Blood or tissue samples will be collected for next-generation sequencing (NGS) per standard of care.
223863897|NCT06896162|OTHER|The Precision Oncology Navigation|The precision oncology navigator will coordinate the collection of blood and /or tissue for next-generation sequencing (NGS), as well as order the NGS if not already ordered. Precision oncology navigator will also assist in NGS financial aid applications, if applicable.
223863898|NCT02216500|DIETARY_SUPPLEMENT|Ketogenic Therapy|Ketogenic Therapy is based on a ratio of fat: protein+carbohydrate in which protein intake is adequate, fat intake is high, and carbohydrate intake is minimal.
223863899|NCT03995069|BEHAVIORAL|3D|Practice generating grip force to the target shown on the computer screen in 3 dimensions.
223863900|NCT03995069|BEHAVIORAL|1D|Practice generating grip force to the target shown on the computer screen in 1 dimension.
223863901|NCT07061886|DRUG|LSD|The serotonin 2A receptor agonist LSD
223863902|NCT07061886|DRUG|Placebo|Distilled water (0.26 mL)
223863903|NCT07060430|PROCEDURE|Kaltenborn Mobilization|All participants received a standardized treatment regimen first. This began with the application of a hot pack or infrared therapy for 10 to 15 minutes at the start of each session. then this group will receive Kaltenborn mobilizations with each mobilization technique performed for 10 repetitions, and each repetition maintained for 2 to 3 seconds. Mobilizations included palmar (volar) glide, dorsal glide, radial glide, and ulnar glide. In addition to wrist mobilizations, anterior and posterior glides were applied to the distal radioulnar joint.
223863904|NCT07060430|PROCEDURE|Mulligan Mobilization with Movement|All participants received a standardized treatment regimen first. This began with the application of a hot pack or infrared therapy for 10 to 15 minutes at the start of each session. then this group will receive Mulligan's Mobilization with Movement (MWM) technique, which involved 10 repetitions of each mobilization, with each repetition held for 2 to 3 seconds. First, a lateral glide or rotational movement of the carpal bones on the radius was applied, accompanied by the patient actively performing the intended wrist movement, such as flexion, extension, or deviation. Second, an ulnar-directed mobilization of the radius was provided simultaneously with active patient movement.
223863905|NCT07061639|DRUG|QLS5133|antibody drug conjugate (ADC)
223863906|NCT07060625|BEHAVIORAL|Semi-reclining position|During anesthesia recovery, the patient's position should be in a semi-recumbent position
223863907|NCT07060196|DIAGNOSTIC_TEST|Distant Visual Acuity|Distant Visual acuity of all participants using DDART web-application monocularly in both eyes.
223863908|NCT07060196|DIAGNOSTIC_TEST|Optical Coherence Tomography|Optical Coherence Tomography of the macula will be performed to all patients.
223863909|NCT07060196|DIAGNOSTIC_TEST|Optical Coherence Tomography Angiography|Optical Coherence Tomography Angiography of the macula will be performed to all patients.
223863910|NCT07060196|DIAGNOSTIC_TEST|Autofluorescence imaging|Autofluorescence imaging using fundus camera for AMD staging.
223863911|NCT07060313|PROCEDURE|Ganglion Impar Block|The ganglion impar was accessed with a Quincke spinal needle, transsacrococcygeally (from between the first and second coccygeal vertebrae if sacrococcygeal access could not be achieved). Then, 1 mL of non-ionic contrast medium was administered, and fluoroscopic anterior-posterior and lateral imaging was performed to confirm the appropriate spread of contrast (Figure 1). After this confirmation, 2 mL of 0.5% bupivacaine, 2 mL of saline, and 40 mg of methylprednisolone acetate were injected.
223863912|NCT07060313|PROCEDURE|Ganglion Impar Block and Pericoccygeal Injection|In the combination therapy group who underwent pericoccygeal injection in addition to impar block, following the same procedure, 5 mL of 0.25% bupivacaine and 20 mg of methylprednisolone were injected into the posterior pericoccygeal region while the needle was withdrawn, thus also targeting blockade of the anococcygeal nerve.
223863913|NCT05508737|DRUG|Pembrolizumab (Keytruda®), Trifluridine/Tipiracil (Lonsurf®)|arms : Pembrolizumab 400 mg every 6 weeks (Q6W), trifluridine/tipiracil at 35 or 30 mg/m2 twice daily (BID) for 5 days a week (D1-5, D8-12) with 2 days rest for 2 weeks, followed by a 14-day rest, repeated every 4 weeks (Q4W)
223863914|NCT02290834|OTHER|Cognitive, functional and subjective assessments|Cognitive and functional assessments
223863915|NCT02290834|DEVICE|MRI|Magnetic Resonance Imaging (MRI) Scan
223863916|NCT02290834|RADIATION|PET Scan|Positron Emission Tomography (PET) Scan
223863917|NCT05399329|DRUG|Palbociclib|Palbociclib plus ET as first-line/second-line treatment for hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2-) ABC
223863918|NCT05399329|DRUG|Endocrine therapy|Palbociclib plus ET as first-line/second-line treatment for HR+/HER2- ABC
223863919|NCT06909838|DEVICE|radial Extracorporeal shockwave therapy (rESWT)|4 rESWT interventions, with a one week interval, are added to the conventional treatment plan
223863920|NCT06909838|OTHER|Conventional treatment|Usual conventional therapy, including physiotherapy, ergotherapy, hippotherapy,..
223863921|NCT06325696|DRUG|hymecromone|400 mg
223863922|NCT06905626|DRUG|Qsymia 7.5 miligrams (mg)-46 mg Extended Release Capsule|Qsymia
223863923|NCT06905626|DRUG|Placebo|Placebo
223863924|NCT03996083|OTHER|Multicomponent exercise intervention|"Strength exercises were focused on lower limb strengthening. Individual bilateral intensities were calculated to estimate one repetition maximum (1-RM) for the leg and arm. This test was performed on the 2nd and 7th weeks of the intervention. A gradual and progressive intensity starting at 40% 1-RM and up 70% 1-RM was used. No external loads were applied to the rest of the exercises due to their complex execution technique and subsequent risk of adverse events. In these cases, training progression was achieved through volume (number of repetitions) and execution velocity increments.~Balance exercises included standing with their feet together, semi-tandem, tandem and one-legged stand positions and moving on to dynamic exercises (circuits, stepping and so on). Difficulty was increased by reducing arm and base support and by varying the type and complexity of exercises. An individualized progression was applied to each participant based on their progress throughout the intervention."
223863925|NCT03996083|OTHER|Walking intervention|"To comply with the walking goals, walking distance was calculated based on each participant´s performance on the 6-minute walking test and using a rule of thumb. Therefore, every participant had an itinerary to follow to comply with the minimum walking time each week. Distance rather than time was used with participants for practical reasons and the inability of most of them to measure time. Moreover, time and distance were individually adapted according to each participant´s performance on the previous week.~To ensure that participants complied with the walking goals, each of them (if they were cognitively able) was given a record sheet in which they had to write down their everyday walking routines. In addition, the caregivers were also informed about the walking routines and ensured that those participants who needed close supervision had someone to walk with and filled the sheet of those that were unable to do so."
223863926|NCT03043638|PROCEDURE|CAF+ADM+PRP|CAF+ADM+PRP group treated with coronally advanced flap technique including ADM placement, In CAF+ADM+PRP group, ADM was hydrated in the platelet-poor plasma (PPP) and the PRP was applied to surgical sites prior to final suturing.
223863927|NCT03043638|PROCEDURE|CAF+ADM|CAF+ADM group treated with coronally advanced flap technique including ADM placement without PRP application
223863928|NCT06473506|DIAGNOSTIC_TEST|Saliva collection|Self-collected saliva sample with molecular testing performed. Results are compared to rapid antigen testing, bacterial throat culture and bacterial throat molecular testing
223863929|NCT06295614|DEVICE|ARC-IM System implantation|Implantation of a stimulation lead on the lumbar level of the spinal cord and implantation of a neurostimulator in the abdominal region.
223863930|NCT03290937|BIOLOGICAL|Cetuximab|Given IV
223863931|NCT03290937|DRUG|Irinotecan Hydrochloride|Given IV
223863932|NCT03290937|OTHER|Pharmacodynamic Study|Correlative studies
223863933|NCT03290937|BIOLOGICAL|Utomilumab|Given IV
223863934|NCT06834633|OTHER|Standard-of-care|Management according to current ICU practices
223863935|NCT06834633|OTHER|Systematic nephroprotection bundle-of-care|"The nephroprotection bundle-of-care includes 5 components:~1. Prevention of drugs' nephrotoxicity~2. Hemodynamic optimization, for 24h~3. Blood glucose control and avoidance of hyperglycemia~4. Early detection of rhabdomyolysis~5. Monitoring of renal function"
223863936|NCT05328297|DRUG|JNJ-55308942|JNJ-55308942 capsules will be administered orally.
223863937|NCT05328297|DRUG|Placebo|Matching placebo capsules will be administered orally.
223863938|NCT06104514|DEVICE|Sofwave|The Sofwave System, comprised of an applicator and a console, generates high intensity, non-focused ultrasonic energy which can be delivered percutaneously to tissues.
223863939|NCT04019327|DRUG|Talazoparib|"Phase I maximum tolerated dose portion:~Level 1, 2, 3 - 1 mg QD Days 1-6 Level 4, 5 - 1.25 mg QD Days 1-6 Level 6 - 1.5 mg QD Days 1-6"
223863940|NCT04019327|DRUG|Temozolomide|"Phase I maximum tolerated dose portion:~Level 1 - 37.5 mg/m2 QD Days 2-8 Level 2 - 75 mg/m2 QD Days 2-8 Level 3 \& 4 - 100 mg/m2 QD Days 2-8 Level 5 \& 6 - 125 mg/m2 QD Days 2-8"
223863941|NCT04029194|BEHAVIORAL|Assistance with old age pension application|The intervention will offer elderly assistance in applying for the old age pension.
223863942|NCT05217628|DRUG|Basimglurant|"Period 1: Basimglurant 1.5 to 3.5 mg QD titrated on individual tolerability.~Period 2: Patients randomized to receive either double blind Basimglurant at the tolerated dose from Period 1 or Placebo.~OLE: Open label Basimglurant at the dose tolerated from Period 2, patients previously assigned placebo in period to be titrated to the Period 1."
223863943|NCT05217628|OTHER|Placebo|Participant randomized to receive matching placebo once daily.
223863944|NCT06019299|BEHAVIORAL|Mindfulness Practice|Participants were instructed to practice mindfulness daily using their instructed approaches for a period of 4 weeks.
223863945|NCT03882554|DEVICE|PoNS Treatment|"PoNS Treatment will consist of three stages: an in-clinic training program, a home training program, and an extended home training program. During all stages of the study, subjects will complete three training sessions per day, morning, afternoon and evening, 6 days per week.~Daily Training Program: The same daily training program will be performed during all stages with the exception of the morning BAT session, which is not performed during stage 2 or 3:~Morning:~Warm Up Exercises without the PoNS Balance Training with PoNS Gait Training with PoNS Breathing and Awareness Training (BAT) with PoNS 3- to 4-hour break between morning and afternoon sessions~Afternoon:~Balance Training with PoNS Movement Control Training without PoNS Gait Training with PoNS~Evening:~Breathing and Awareness Training with PoNS To be performed at home during all stages"
223863946|NCT03967704|PROCEDURE|Life quality evaluation|As part of this research, 2 additional consultations at 12 months and 24 months will be carried out by one of the rheumatologists in the department. At the consultation 12 months after his inclusion, the patient will have a clinical examination, a quality of life questionnaire to complete and additional images (x-rays). For the 24-month consultation, the patient will have a clinical examination, a quality of life questionnaire to complete and the patient may have an additional X-ray of the spine if there is height loss \> 2 cm and/or pain.
223863947|NCT02139696|RADIATION|PET and MRI|Patients will be imaged using PET and MRI at baseline, and twice during treatment
223863948|NCT06795152|OTHER|No intervention|Observational. Natural history study.
223863949|NCT06545604|OTHER|Yoga Therapy for Nutritional, Physical, and Psychosocial Prehabilitation|Two visits per week with a yoga therapist while receiving neoadjuvant chemotherapy to cover dietary counseling, yoga-based movement practices, breathwork practices, mind practices, and behavioral support for the purpose of preparing patients' mind and body for a planned surgery.
223863950|NCT06545604|OTHER|Usual care supportive services including nutrition counseling per usual care|Usual care supportive services while receiving neoadjuvant chemotherapy.
223863951|NCT06105333|PROCEDURE|standard care plus cerebral oxygen saturation monitoring with a dedicated treatment guideline|CrSO2 (Cerebral regional oxygen saturation) monitoring was visible to the clinical team with the same SpO2 target as in the control group. If SpO2 (oxygen saturation) remained between the 10th and 90th centiles and within local limits, and crSO2 was \<10th centile according to published reference ranges, FiO2 (fraction of inspired oxygen) was increased by 10-20% every 60 seconds or respiratory support was started or increased. If crSO2 remained \>10th centile for \>60 seconds or if rSO2 was \>90th centile,FiO2 was reduced by 10-20% or respiratory support was adjusted accordingly. If there was a history of blood loss or clinical signs of blood loss, intravenous fluids (10 mL/kg) were considered.
223863952|NCT01522898|PROCEDURE|AV nodal ablation|Percutaneous catheter ablation of the AV node.
223863953|NCT01522898|DRUG|Medical Ventricular Rate Control|Ventricular Rate Control with target ventricular rate of 90 beats per minute.
224076320|NCT02963805|BEHAVIORAL|Fundamental movement skill (FMS)|This arm consisted of a twice-weekly after-school club at the intervention school for 26 weeks during school term time, delivered by qualified coaches. Each 60 minute session focused on improving two skills from the vertical jump, hop, sprint run, dodge, kick, catch, overarm throw, and strike. All skills were taught in equal quantities. Each session was designed to maximise participation and enjoyment, and consisted of various games, drills, self-learning activities, and offered numerous opportunities for practice. Skill components were taught to the children using simple learning cues, and skill related questions were used to develop purposeful feedback. The mean heart rate for FMS sessions was recorded at 141 beats/min, with children spending 55 min at this intensity during the session.
223863954|NCT03344588|PROCEDURE|artery preserving varicocelectomy|During sub-inguinal varicocelectomy, testicular arteries will be spared with aid of by intraoperative Doppler US (VTI intraoperative Doppler system 20 MHz). The arteries will be carefully dissected by a micro-dissector, separated over a vessel loupe, and then the remaining veins will be ligated using vicryl 3/0.
223863955|NCT03344588|PROCEDURE|artery ligation varicocelectomy|During sub-inguinal varicocelectomy, all vascular channels will be ligated without identifying or sparing the internal spermatic arteries.
223863956|NCT02496377|DRUG|ferrous glycine sulfate Tardyferon|
223863957|NCT02496377|DRUG|Epoetin Alfa|
223863958|NCT02496377|DRUG|ferric carboxymaltose Ferinject|
223863959|NCT05437094|DRUG|CRD-740|CRD-740
223863960|NCT05437094|DRUG|Itraconazole|Itraconazole
223863961|NCT01613118|DRUG|RE-021 (Sparsentan)|Oral, once-daily
223863962|NCT01613118|DRUG|Irbesartan|Oral, once-daily
223863963|NCT00038506|DRUG|abacavir/lamivudine/zidovudine|
223863964|NCT00038506|DRUG|tenofovir|
223863965|NCT03332758|PROCEDURE|Pars plana vitrectomy|Standard of care treatment for retinal detachment, macular hole, or epiretinal membrane.
223863966|NCT03332758|PROCEDURE|External drainage|Standard of care treatment for retinal detachment.
223863967|NCT06630884|BIOLOGICAL|Typhoid VI Polysaccharide Vaccine Injectable Solution|Salmonella typhi capsular polysaccharide vaccine (Typhoid Vi Polysaccharide Vaccine): Each dose of 0.5ml Salmonella typhi capsular polysaccharide vaccine (Sanofi Pasteur, SA) is formulated to contain 25μg of purified Vi polysaccharide in a colorless isotonic phosphate buffered saline (pH 7±0.3), 4.150mg of sodium chloride, 0.065mg of disodium phosphate, 0.023mg of monosodium phosphate and 0.5ml of sterile water for injection. It is indicated for use by humans aged 2 years and older for protection against typhoid fever.
223863968|NCT06630884|OTHER|Saline Placebo (0.5mL injection)|The placebo injection will consist of 0.5mL of saline.
223863969|NCT00443001|DEVICE|Non invasive blood pressure monitor|Updated device and software to improve performance in patients with dysrhythmia
223863970|NCT03656406|BEHAVIORAL|Lateral decubitus positioning|After the DLT intubation, the patient is placed in lateral decubitus position
223863971|NCT03656406|DEVICE|Cuff-manometer|The pressure of the bronchial cuff should be measured with cuff-manometer in supine position, and then measurement should be repeated after lateral positioning.
223863972|NCT02968225|BEHAVIORAL|Computer Game|The game involves viewing subtle nonverbal behaviors of game characters for the purpose of executing their own goal-directed behavior in the game related to solving various crimes. The learning involves interpreting nonverbal cues on the animated characters, such as pointing, head turns, eye gaze cues.
223863973|NCT00117130|DRUG|Aranesp®|
223863974|NCT06081049|DRUG|Colchicine|0.5 mg once daily
223863975|NCT06081049|DRUG|Placebo|Once daily
223863976|NCT02861846|BIOLOGICAL|profile of CSF biomarkers of AD|dosage of biomarker of AD
223863977|NCT05888961|BIOLOGICAL|Blood samples|"Fasting at the first session for hormonal measurements of leptin, insulin, acylated and non-acylated ghrelin, serotonin, albumin, protidemia and blood glucose.~Repeated at 6 and 12 months for follow-up"
223863978|NCT05888961|OTHER|Interviewing the subject and scales|"Collection of sociodemographic data, personal and family neurological history, treatments, MADRS depression scale and CDR autonomy scale.~Carried out at the 1st session"
223863979|NCT05888961|OTHER|Neurocognitive evaluation|cognitive complaint questionnaire (CCQ), taste, smell, MoCA and MMSE (if not performed in the previous 6 months) Carried out at the 1st session. Repeated at 6 and 12 months for follow-up.
223863980|NCT05888961|OTHER|Taste tests|"Sweet and salty flavors at the 1st session and acid and umami flavors at the 2nd session. Repeated at 6 and 12 months for follow-up.~Placement of electrodes on the scalp, recording of gustatory evoked potentials, subjective gustatory evaluation by means of visual analogue scales rated from 0 to 10, identification and naming of each of the primary flavors"
223863981|NCT05888961|OTHER|Computerized food preference questionnaires|Performed at the 1st session on a tactile tablet. Repeated at 6 and 12 months for follow-up.
223863982|NCT05888961|OTHER|Nutritional status - body composition|Measurement of anthropometric data, bioelectrical impedancemetry (measurement of fat mass, lean mass, water mass and bone mass in kg), measurement of blood pressure and heart rate Performed at the 2nd session Repeated at 6 and 12 months for follow-up.
223863983|NCT05208372|DIAGNOSTIC_TEST|CTC test|Circulating tumor cells test of ascites and blood for patients with gastric cancer.
223863984|NCT05208372|DIAGNOSTIC_TEST|ctDNA test|Circulating tumor DNA test of ascites and blood for patients with gastric cancer.
223863985|NCT02297061|BIOLOGICAL|Thrombelastography analysis (TEG)|TEG analysis is performed on admission
223863986|NCT04921293|BEHAVIORAL|Ketogenic diet|A diet with \<50gr of carbohydrates per day. Monosaturated fats consumption will encourage over saturated fats
223863987|NCT04921293|DIETARY_SUPPLEMENT|Exogenous ketones|Administration of ketone monoester 25 ml t.i.d
223863988|NCT04921293|BEHAVIORAL|Standard diet + placebo|A standard diet incorporating current recommendations (low in sodium and low in liquids) for heart failure patients.
223863989|NCT01450228|DRUG|KI1001|Prolonged release melatonin 2mg
223863990|NCT01450228|DRUG|Placebo KI1001|Placebo KI1001 tablets
223863991|NCT02788604|OTHER|Summary of psychosocial risk factors|The treatment team will receive a psychosocial risk summary shortly following diagnosis based on parent report.
223863992|NCT02788604|OTHER|Control|The treatment team will NOT receive a psychosocial risk summary shortly following diagnosis based on parent report.
223863993|NCT04922853|DRUG|Capox chemotherapy|oxaliplatin: 130 mg/m2 iv d 1, capecitabine: 1000 mg/m2 bid d 1-14, repeated at 3 week intervals
223863994|NCT06667557|DEVICE|Superpulse Thulium Fiber Laser (sTFL) Treatment|The superpulse thulium fiber laser (sTFL) was used as a minimally invasive surgical treatment for kidney and upper ureteral stones. All procedures were performed by experienced urologists using standard techniques for laser lithotripsy. Laser settings, such as pulse energy and frequency, were adjusted according to stone characteristics and the surgeon's judgment to optimize treatment efficacy and safety.
223863995|NCT06667557|DEVICE|Holmium:YAG Laser (Ho:YAG) Treatment|The holmium:YAG laser (Ho:YAG) was used as a minimally invasive surgical treatment for kidney and upper ureteral stones. All procedures were performed by experienced urologists using standard techniques for laser lithotripsy. Laser settings, such as pulse energy and frequency, were adjusted according to stone characteristics and the surgeon's judgment to optimize treatment efficacy and safety.
223863996|NCT05425199|OTHER|Habituation exercises + vestibular treatment|"Exercises will include Intensity: 10 repetitions of each set Frequency= 3 sessions per week for 6 weeks.~Time= 30 minutes"
223863997|NCT05425199|OTHER|proprioceptive training + vestibular therapy|Exercise protocol will include Time= total session of 30 minutes . Each exercise will be hold for 30 seconds . Frequency= 3 session per week for 6 weeks Intensity= 10 repetitions and 3 sets
223863998|NCT05425199|OTHER|conventional vestibular treatment|Epley's Manuever. Frequency= It will be performed once in a week . Time= 10-15 minutes per session
223863999|NCT05961462|BEHAVIORAL|Exercise training|Patients randomized to the exercise group will be offered aerobic exercise plan containing 12 sessions over 4 weeks (3 times per week).
223864000|NCT03584152|DRUG|Norco 5Mg-325Mg Tablet|Opioid Analgesics
223864001|NCT03584152|DRUG|Tylenol 325Mg Caplet|Non opioid analgesics
223864002|NCT03584152|DRUG|Ibuprofen 200 mg|Non opioid analgesics
223864003|NCT03544515|DEVICE|Er,Cr:YSGG laser|Application of Er,Cr:YSGG in peri-implantitis cases as a coadjutant has shown reduction in the pocket depths and bleeding on probing
223864004|NCT03544515|PROCEDURE|Scaling|Scaling and debridement of the implant surface with hand scalers and curettes and an ultrasonic scaling unit (Cavitron -Dentsply Sirona)
223864005|NCT03544515|DEVICE|Inactive Er,Cr:YSGG|Er,Cr:YSGG laser (inactive form - sham procedure) applied to the surface of the implant
223864006|NCT05929105|PROCEDURE|artificial intelligence (AI)-assisted three-dimensional preoperative planning technology|In the AI planning group, AI was used to assist in the 3D planning to complete the preoperative design. Preoperative planning was performed by two experienced surgeons and without the chief physician to ensure that the results of the preoperative planning did not affect the selection of intraoperative procedures and prosthesis size.
223864007|NCT05929105|OTHER|X-ray film template for 2D planning|A traditional X-ray film template was used to complete the preoperative design in the traditional planning group. The position and size of the prosthesis, the level of femoral neck osteotomy, the length of the LLs and the restoration of eccentricity were estimated by X-ray. A plastic template provided by the manufacturer was used to take the line of the lower edge of the teardrop on both sides as the horizontal reference line, and the acetabular template was placed at 40 abduction on the inner edge of the teardrop so that the lower edge of the acetabular cup was adjacent to the teardrop. An appropriate type of acetabular component was selected to fill the acetabulum and maintain coverage, and the femoral component that best matched the femoral medullary cavity was chosen. The height of the osteotomy was determined, and the planning model was recorded after the surgeons were happy with the placement and outcome.
223864008|NCT00962234|OTHER|Blood draws|Up to 4 blood draws will be required, in the amount of about 10 mL each
223864009|NCT00962234|BIOLOGICAL|Oral administration of stable isotope (deuterium)|1 mg deuterium-labeled water/kg body water (loading dose), and 0.5 mg/kg body water diluted in 1 L of normal water (maintenance dose) to be consumed over the following 16 hours
223864010|NCT00962234|PROCEDURE|Metabolic rate testing|Metabolic rate testing is a painless, non-invasive test that takes about 1h. A metabolic cart is used, which detects the amount of oxygen and carbon dioxide the body uses. Patients will lie down on a bed for 30 minutes with lights dimmed and soft music to help them relax. After 30 minutes, a canopy will be placed over the patient's head and shoulders for 30 minutes for the analysis of breath samples. This test will be performed only once for this study.
223864011|NCT06258668|DRUG|Deucravacitinib|As per product label
223864012|NCT06345027|BIOLOGICAL|Treatment Arm A|"Each patient will receive one T cell infusion.~CD70.CAR Dose Levels / Cell Dose (transduced cells):~Dose Level -1: 3 x 10\^5 cells/kg Dose Level 1 (starting dose level): 1 x 10\^6 cells/kg Dose Level 2: 3 x 10\^6 cells/kg Dose Level 3: 1 x 10\^7 cells/kg~\*First three patients treated on the study will be adults 18 years of age or older."
223864013|NCT03472573|DRUG|Palbociclib|Given PO
223864014|NCT03472573|DRUG|Dexamethasone|Given PO
223864015|NCT02986178|BIOLOGICAL|lerapolturev|A single dose of lerapolturev, an oncolytic polio/rhinovirus recombinant
223864016|NCT02986178|DRUG|Lomustine|one cycle of oral lomustine
223864017|NCT05575024|DEVICE|oXiris membrane|Perform continuous renal replacement therapy with oXiris membrane
223864018|NCT05575024|DEVICE|Polysulfone membrane|Perform continuous renal replacement therapy with polysulfone membrane
223864019|NCT05936333|PROCEDURE|Biological collection|up to 25 mL of blood collection for the adults and saliva collection for the minor at inclusion, and placenta collection at childbirth
223864020|NCT03522064|DRUG|Testosterone Enanthate 100 MG/ML Injectable Solution|Testosterone Enanthate is the oil-soluble ester of the androgenic hormone testosterone. Testosterone Enanthate is a clear to pale yellow solution for intramuscular injection. Each pre-filled syringe contains 250mg testosterone enanthate/1mL.
223864021|NCT03522064|DRUG|Testosterone Enanthate 100 MG/ML Injectable Solution / Carboplatin AUC 5|Testosterone Enanthate is the oil-soluble ester of the androgenic hormone testosterone. Testosterone Enanthate is a clear to pale yellow solution for intramuscular injection. Each pre-filled syringe contains 250mg testosterone enanthate/1mL. Carboplatin as per standard procedures
223864022|NCT03061552|DIAGNOSTIC_TEST|sonographic measurement of inferior vena cava diameter|pre-dialysis measurement of inferior vena cava diameter using echocardiography
223864023|NCT06396429|DRUG|HRS9531 injection|HRS9531 injection; low dose
223864024|NCT06396429|DRUG|HRS9531 injection|HRS9531 injection; medium dose
223864025|NCT06396429|DRUG|HRS9531 injection|HRS9531 injection, high dose
223864026|NCT06396429|DRUG|Placebo|blank preparation, participants received matching placebo.
223864027|NCT00178399|PROCEDURE|Stereotactic Body Radiation Therapy|
223864028|NCT01750463|OTHER|Masimo Pronto Rad 7 Non-Invasive hemoglobin monitor|Patients admitted to PICU requiring hemoglobin monitoring will have a total hemoglobin (SpHb) assessment from Masimo non-invasive monitor, prior to standard, required blood draw and laboratory analysis.
223864029|NCT01750463|OTHER|Standard Laboratory Blood Draw and Hemoglobin Analysis|Patients admitted to PICU requiring hemoglobin monitoring will have a reading from Masimo non-invasive monitor, prior to standard, required blood draw and laboratory analysis.
223864030|NCT04992156|DRUG|Palbociclib|Palbociclib 125mg/d
223864031|NCT02894242|DEVICE|F&P Deimos Nasal Pillows Mask|Investigative Nasal Pillows Mask to be used for OSA therapy
223864032|NCT03830658|BEHAVIORAL|Structured Intervention on Self-care with AVF (SISC-AVF)|"Theoretical Part: structured intervention involved an educational group session with the purpose of teaching patients how to identify situations that can compromise AVF working. Each presentation allowed a maximum of eight patients and took 30 minutes. Each presentation was assessed in the end by asking participants to identify the signs and symptoms of infection, thrombosis and steal syndrome and to describe the care to be taken during dialysis and in the period outside dialysis.~Practical Part: started a week after the theoretical part, lasting for two weeks, and was given to each participant in an appropriate room at the beginning of the HD treatment. Interactive training sessions were conducted using an informal approach with the objective of developing skills of inspection and palpation of the AVF arm. Inspection had the purpose of enabling participants to identify situations that could compromise the working of the AVF. Each patient was given two 15-minute sessions."
223864033|NCT06475508|BIOLOGICAL|Complarate®|The investigational drug Complarate® was administered as an intravenous infusion at a dose of 8 mg/kg once every 4 weeks for 24 weeks.
223864034|NCT06475508|BIOLOGICAL|Actemra®|The reference drug Actemra® was administered as an intravenous infusion at a dose of 8 mg/kg once every 4 weeks for 24 weeks.
223864035|NCT05543837|DRUG|Capsaicin|Patients will receive a fixed dose of capsaicin
223864036|NCT00842049|DEVICE|Lumbar Drain (Medtronic lumbar drainage system)|Insertion of lumbar drain to drain cerebrospinal fluid
223864037|NCT00842049|OTHER|No lumbar drain|No lumbar drain
223864038|NCT06246435|OTHER|moderate aerobic exercise|
223864039|NCT00001730|DRUG|Thyrogen|
223864040|NCT00238212|DRUG|sorafenib tosylate|Given orally
223864041|NCT00238212|OTHER|laboratory biomarker analysis|Correlative studies
223864042|NCT02544152|DRUG|Lubiprostone|8 mcg administered orally twice daily (BID)
223864043|NCT02544152|DRUG|Placebo|Matching placebo, 0 mcg administered orally twice daily (BID)
223864044|NCT06638112|PROCEDURE|Brachial Plexus Block|Interscalene brachial plexus block with 0.75% ropivacaine. Intraoperative sedation with remimazolam or propofol.
223864045|NCT06638112|PROCEDURE|General Anesthesia (control group)|General anesthesia with propofol, fentanyl and rocuronium for induction, and with sevoflurane for maintenance. Brachial plexus block with 0.5% ropivacaine for intra- and postoperative analgesia.
223864046|NCT01723410|BEHAVIORAL|Writing about people|Subjects will be asked to write about other people in their lives once a week for 6-weeks.
223864047|NCT01723410|OTHER|Writing about places, objects|
223864048|NCT02338245|DRUG|ASLAN001|ASLAN001 400mg BID
223864049|NCT02338245|DRUG|Lapatinib|Lapatinib 1250mg QD
223864050|NCT02338245|DRUG|Capecitabine|Capecitabine 1000mg/kg BID days 1-14 of a 21-day cycle
223864051|NCT03571191|DRUG|Denosumab|Denosumab will be administered at 120 mg per dose every 4 weeks for six months, with loading doses on days 8 and 15 of month 1.
223864052|NCT06565208|DRUG|SAT-3247|SAT-3247 is an oral tablet that is a potent, muscle penetrant, small molecule inhibitor of AAK1; inhibition of AAK1 rescues perturbed asymmetric division of satellite stem cells, resulting in increased muscle regeneration in animal models of DMD. In vitro and in vivo animal pharmacology studies have demonstrated the efficacy of SAT-3247 in improving muscle strength and the necessary target coverage to maximize functional muscle improvement.
223864053|NCT06565208|DRUG|matched placebo|matched placebo
223864054|NCT04157426|OTHER|Percutaneous electrolysis|Ultrasound-guided percutaneous electrolysis in the active myofascial trigger point of the levator scapulae muscle
223864055|NCT04157426|OTHER|Dry needling|Ultrasound-guided dry needling the active myofascial trigger point of the levator scapulae muscle
223864056|NCT00646035|DRUG|paricalcitol capsules|baseline iPTH/60
223864057|NCT06266780|BEHAVIORAL|PROMPTS Enhanced Family Planning Counselling|Based on a targeted human-centered-design process with pregnant and early postpartum mothers, the intervention consists of informative messages, counselling and reminders regarding postpartum family planning and birth spacing, leveraging an existing mobile health platform (PROMPTS) for intervention delivery and Jacaranda's established partnership with the Kenyan Ministry of Health, county health offices and public maternity hospitals method options. The intervention includes several features: activation of family planning discussions between pregnant and postpartum women and their health care providers, information provision, method selection support to help women choose their preferred method, and reminders to follow-up. The key feature is to help women make an informed plan about family planning in the prenatal or early postpartum period and follow through with this plan.
223864058|NCT00534937|PROCEDURE|Compression wrapping|Short-stretch compression wrap will be applied at least once a week.
223864059|NCT00534937|PROCEDURE|Flexitouch compression pump|In addition to short-stretch wrapping, this group will received once-daily Flexitouch compression pump, both at home and during the once-a-week clinic visits.
223864060|NCT06490159|DRUG|Paclitaxel|Gastric cancer second-line chemotherapy
223864061|NCT00844636|DEVICE|Sharp needle|
223864062|NCT00844636|DEVICE|Blunt needles|
223864063|NCT04432688|DRUG|Lurasidone HCl|This is a non-interventional, observational study
224076321|NCT02963805|BEHAVIORAL|Physical activity signposting (PASS)|A researcher visited participants once per week in 6 weekly blocks to set an activity mission to complete outside school with family and friends. Twenty missions were set over 4 x 6 week blocks, each separated by a 6 week break. Each mission suggests a task as a prompt to participate in physical activity and decrease sedentariness during the week. Children received a sticker on a wall chart for returning the mission; children were rewarded with prizes if all missions were returned in each block. If all missions were returned in a block, a reward was given. 58% of children returned all twenty missions. In addition to the missions, pedometers were issued as a promotional tool for the duration of the project for self-monitoring of activity.
224076322|NCT01058343|BIOLOGICAL|IFN-K|3 to 4 IM injections over 3 months
223864064|NCT04114149|DEVICE|TENS (transcutaneous electrical nerve stimulation)|TENS as first line of treatment. If insufficient pain relief, i.e. postoperative pain intensity according to NRS (numeric rating scale) ≥ 3 after two treatment sessions à 1 minute, the patient receives conventional treatment with iv opioids.
223864065|NCT04114149|DRUG|iv opioid|Conventional treatment with iv opioid if postoperative pain intensity according to NRS (numeric rating scale) ≥ 3.
223864066|NCT05185830|OTHER|Interactive robots|Children will mobilize with the interactive robot when control group will mobilize with nurse.
223864067|NCT01474707|BEHAVIORAL|Group one|Group 1 will view the knowledge-based video only
223864068|NCT01474707|BEHAVIORAL|Group two|Group two will view the motivational video only
223864069|NCT01474707|BEHAVIORAL|Group three|Group three will view both knowledge-based and motivational videos
223864070|NCT01474707|BEHAVIORAL|Group four|Group four will view the printed educational pamphlet and will not view either video
223864071|NCT03700853|DIAGNOSTIC_TEST|Dysphagia Trained Nurse Assessment (DTNAx)|Bedside swallowing assessment carried out by trained nurses
223864072|NCT06515951|DIAGNOSTIC_TEST|STANDING algorithm|The STANDING algorithm is composed by four steps. The first phase consists in evaluating the presence of spontaneous nystagmus at rest for at least five minutes with and without Frenzel goggles in order to assess if a acute vestibular syndrome is present. If there is not a spontaneous nystagmus, then positional maneuvers (Pagnini-Mc Cure and Dix-Hallpike) have to be performed. Otherwise if spontaneous nystagmus is observed, its feature are fundamental to diagnose a central vertigo. If nystagmus characteristics suggest a peripheral form, the head impulse test is performed by instructing the patient to keep eyes on a fixed target and then turned the head quickly. An abnormal response is typical of vestibular neuritis. In any cases after the described maneuvers, the patient must be evaluated when standing up and walking: if this turn out to be impossibile, the test is indicative of central nervous system disease.
223864073|NCT00516321|DRUG|eltrombopag|25, 50, 75, 100 mg tablets taken once daily orally
223864074|NCT00516321|DRUG|placebo|matched placebo taken once daily orally
223864075|NCT05674136|DEVICE|INVSENSOR00061|Noninvasive pulse oximeter sensor
223864076|NCT00583817|DEVICE|Endovascular stent-graft implantation|Endovascular repair of aorta
223864077|NCT06426823|OTHER|Saline / placebo|NaCl (9 mg/ml)
223864078|NCT06426823|OTHER|GIPR antagonist / study tool|GIP(3-30)NH2
223864079|NCT02015546|DRUG|Vilazodone|All subjects will receive Vilazodone at 10, 20 or 40mg.
223864080|NCT03431922|DEVICE|endovascular denervation|multi-electrode catheter-based endovascular denervation
223864081|NCT02207972|DEVICE|Use of Ultrasound|The ultrasound imaging of the lumbar spine in different scanning planes facilitates the identification of the landmarks necessary for appropriate epidural space location in pregnant patients. There are two acoustic windows that are effective for lumbar spine sonographic assessment: one seen on the transverse approach, and the other seen on the longitudinal paramedian approach. The ultrasound single-screen method using the transverse approach of the lumbar spine provides reliable information regarding the landmarks required for labor epidurals. The correct interspace and midline position are identified for correct placement of the CSE analgesia.
223864082|NCT02207972|PROCEDURE|No ultrasound used|Palpation of anatomical landmarks is used for placement of labor analgesia
223864083|NCT04988568|OTHER|None. This is a qualitative interview study.|There is no intervention in this study. This is a qualitative research study where patients will be interviewed.
223864084|NCT05554185|DIETARY_SUPPLEMENT|aspirin 100mg and probiotics 1 bag|taking aspirin 100mg and probiotics 1 bag per day from 14-16 weeks of pregnancy until 35 + 6 weeks of pregnancy or emergency delivery.
223864085|NCT01426269|DRUG|Doxycycline|During phase 1 (baseline - week 12): Oracea (doxycycline 40 mg USP (30 mg immediate release \& 10 mg delayed release beads)), oral, one capsule daily in the morning During phase 1 (baseline - week 12) and phase 2 (week 12 - week 52): Oracea (doxycycline 40 mg USP (30 mg immediate release \& 10 mg delayed release beads), oral, one capsule daily in the morning
223864086|NCT01426269|DRUG|Metronidazole|During Phase 1: MetroGel 1% (metronidazole 1% gel), topical, apply a thin layer once daily to the affected area
223864087|NCT01426269|DRUG|Placebo|During phase 2 (week 12 - week 52): placebo, oral, one capsule daily in the morning
223864088|NCT04739280|DEVICE|CardioFlux Magnetocardiography|Magnetocardiography
223864089|NCT01909258|OTHER|Goniometric measure of pelvic extension reserve.|"The pelvic extension reserve (°) is measured via goniometry.~The goniometric measurements will be taken once by an investigator on all subjects and once by a different investigator on half of the subjects (with balanced distribution of morphotypes)."
223864090|NCT01909258|OTHER|Photographic measure of pelvic extension reserve.|"The pelvic extension reserve (°) is measured using photography.~Photographic measurements will be performed twice one investigator and 1 time by a different investigator (total of three measurements)."
223864091|NCT01909258|OTHER|EOS measure of pelvic extension reserve.|"The pelvic extension reserve (°) is measured using the imaging system EOS.~Five X-rays will be made for each volunteer on the EOS system. The first is a frontal shot in a bipedal position, reference snapshot for verifying the absence of spinal deformity or hip pathology. The second and third are profile shots, one on the left and one on the right, whole body, bipedal position; serving as a reference picture. The fourth is profile shot, whole body, with the left hip in hyperextension. For maximum left hip hyperextension, the right leg rests on a step of varying height, and the hip is maximally flexed. The fifth is a profile shot, full body, with the right hip in hyperextension. For a maximum right hip hyperextension, the left leg rests on a step of varying height, and the hip is maximally flexed."
224076323|NCT02406807|OTHER|HVLA manipulation|participant is laying on the left side, the practitioner stands in front of the participant's abdomen. The practitioner contacts the interspinous space of the L5-S1 level with the caudal; with the cephalic hand, the practitioner rotates the participant's upper body until a sense of tension is palpated at the L5-S1 segment. The practitioner places his cephalic hand at interspinous, brings participant's leg to a flexion and places the foot at the popliteal fossa, places the forearm at the participant's deltopectoral groove and the caudal forearm at the gluteal region. Following the participant's expiration, the practitioner brings the L5-S1 level to the restrictive barrier by rotating the trunk and hips to opposite directions.
224076324|NCT02406807|OTHER|Sham Spinal lumbar manipulation|Sham manipulation
224076325|NCT01956812|DRUG|IMMU-107|Arm A: gemcitabine 200 mg/m2 administered weekly x 4 and IMMU-107 administered weekly x 3 for multiple cycles
224076326|NCT01956812|DRUG|placebo|placebo weekly x 3 and gemcitabine 200 mg/m2 weekly x 4 for multiple cycles
224076327|NCT01956812|DRUG|Gemcitabine|Gemcitabine, 200 mg/m2, given weekly x 4 in both arms
223864092|NCT06322797|DEVICE|rTMS|"Stimulation was performed using a biphasic stimulator (ALTMS® Remed, Republic of Korea) and a 70-mm figure-eight coil. The routine stimulation procedure is described as follows. First, the resting motor threshold was measured for each patient. At the lowest stimulus output, a stimulus was applied to the M1 cortex of the uninjured hemisphere aiming at the site that caused the largest visible twitch in the participant's thumb. The resting motor threshold was defined as the intensity required to generate a motor-induced potential of \> 50 uV in the contralateral abductor pollicis brevis muscle at least 5 out of 10 times with 30 s of inter-stimulus time interval.~Stimulation was given at 100% of the resting motor threshold stimulator output: 20 Hz, 5-s train duration, 55-s inter-train interval, and a total number of stimulations of 2000 pulses per session for 20 min."
224076328|NCT06427460|RADIATION|Central-boost ablative dose delivered by stereotactic body radiation therapy|An inner and complete gross tumor volume (iGTV) is created within the gross tumor volume (GTV). For the liver or lung tumor, the convetional radiation dose is 35-45Gy/5f. Regarding the pancreatic tumor or retroperitoneal tumor, the radiation dose is 30-40Gy/5f. Hence, the radiation dose of iGTV should not be less than 120% of the dose of GTV.
224076329|NCT03073135|BEHAVIORAL|Psychodrama Group Therapy (PGT)|"The psychotherapeutic focus is on the here and now aspect of the patient's relationships. Conflicts are acted out during the sessions, yielding intense emotional re-experience in a safe environment, which will bring further cognitive understanding of past distressful life experiences and hopefully new adaptive ways of expressing and dealing with the problem."
223864093|NCT06322797|DEVICE|rTMS|Stimulation was performed using a biphasic stimulator (ALTMS® Remed, Republic of Korea) and a 70-mm figure-eight coil. The routine stimulation procedure is described as follows. After identifying the brain site that is activated during finger tapping during fMI, Stimulation was given at 100% of the resting motor threshold stimulator output: 20 Hz, 5-s train duration, 55-s inter-train interval, and a total number of stimulations of 2000 pulses per session for 20 min. the resting motor threshold was measured for each patient at target brain site.
223864094|NCT06322797|DEVICE|Sham|In Sound Mode, no actual stimulation is applied, and 20 minutes of treatment is performed like other experimental groups.
223864095|NCT02764944|PROCEDURE|simple non-exposure EFTR|This intervention includes the steps of laparoscopic seromuscular suturing with a barbed suture thread (V-Loc), which results in inversion of the stomach wall; EFTR of the inverted stomach wall from inside the stomach; and finally, endoscopic mucosal suturing with endoloops and clips.
223864096|NCT00959582|PROCEDURE|Comparator: 18-F-FDG PET/CT and Volumetric CT|Patients will receive standard-of-care therapy (carboplatin or cisplatin monotherapy, or a two-drug combination where one is platinum). FDG-PET/CT scans will be performed at baseline following enrollment, after Cycles 1 and 2 of chemotherapy, and if patients are progression-free at the end of Cycle 6. Volumetric CT scans will be performed at baseline following enrollment, after Cycles 1 and 2 of chemotherapy, after Cycle 3 of chemotherapy (optional), and if patients are progression-free at the end of Cycle 6 and at 40 weeks after Cycle 1 dosing.
223864097|NCT00300131|DEVICE|Bioabsorbable Everolimus Eluting Coronary Stent|Bioabsorbable drug eluting stent implantation stent in the treatment of coronary artery disease
223864098|NCT01098344|DRUG|Notch signaling pathway inhibitor MK0752|
223864099|NCT01098344|DRUG|gemcitabine hydrochloride|
224076330|NCT03073135|BEHAVIORAL|Supportive Group Therapy (SGT)|SGT is a form of treatment in which the therapist maintains a therapeutic relationship and a working alliance based on reality, support, clarification, assistance in troubleshooting, strong leadership, partial gratification of dependency needs, legitimating independence, development of pleasurable activities and adequate rest, guidance and advice to deal with current problems. This approach uses techniques to help patients feel safe, accepted, protected, encouraged and not anxious.
223864100|NCT01098344|OTHER|imaging biomarker analysis|
223864101|NCT01098344|OTHER|laboratory biomarker analysis|
223864102|NCT01098344|OTHER|pharmacological study|
223864103|NCT05157022|DEVICE|ESWT|Extracorporeal Shock-wave Therapy
223864104|NCT00141349|DRUG|UK-369,003|
224076331|NCT00098917|DRUG|autologous tumor cell vaccine|
224076332|NCT00098917|DRUG|therapeutic autologous dendritic cells|
224076333|NCT00098917|PROCEDURE|adjuvant therapy|
224076334|NCT00098917|PROCEDURE|biological therapy|
223864105|NCT01123408|DRUG|Clozapine|500 mg/day
224076335|NCT00098917|PROCEDURE|conventional surgery|
224076336|NCT00098917|PROCEDURE|surgery|
224076337|NCT00098917|PROCEDURE|tumor cell derivative vaccine|
224076338|NCT00098917|PROCEDURE|vaccine therapy|
223864106|NCT01123408|DRUG|Olanzapine|20 mg/day
223864107|NCT01123408|DRUG|Haloperidol|20 mg/day
223864108|NCT04670159|BEHAVIORAL|Online Education|Online ergonomics, exercise and physical activity training will be provided 3 times a week for 6 weeks. The trainings it is planned to be made with a video-based online platform called Edpuzzle. With the online classroom created, the student education will be provided. A total of 18 training videos will be prepared, each video is 6-10 minutes. After the training there will be an individual motivational interview with the students in the this group with the zoom application. With motivational interview solutions by revealing the willingness, obstacles and indecision of the student to transfer the learned information to his daily life will be recommended.
223864109|NCT04670159|BEHAVIORAL|Information With Brochure|An e-brochure will be prepared for students in this group to provide information on ergonomics, physical activity and exercise. and the e-brochure will be sent to the students via e-mail after the initial evaluation.
223864110|NCT03203538|DEVICE|LED-light, 1000 lux|Full-spectrum light, 1000 lux, 4000 K. Represent a light intensity within acceptable range (light that is not too glary); 4000 K is among the most commonly used indoor light colour temperatures.
223864111|NCT03203538|DEVICE|LED-light, 100 lux|Full-spectrum light, 100 lux, 4000 K. Represent a light intensity within acceptable range (light that provides sufficient eye sight); 4000 K is among the most commonly used indoor light colour temperatures.
223864112|NCT03203538|DEVICE|LED-light, 7000 K|Full-spectrum light, 7000 K, 200 lux. Represent the upper border of common colour indoor light temperature, 200 lux is a common indoor light intensity.
223864113|NCT03203538|DEVICE|LED-light, 2500 K|Full-spectrum light, 2500 K, 200 lux. Represent the lower border of common colour indoor light temperature, 200 lux is a common indoor light intensity.
223864114|NCT03203538|DEVICE|Blue LED-light|Blue light with peak wavelength 455 nm. Known to delay the circadian rhythm, suppress melatonin, and increase alertness.
223864115|NCT03203538|DEVICE|Red LED-light|Red light with peak wavelength 615 nm. Known not to affect the circadian rhythm, melatonin, and alertness.
223864116|NCT02301442|BEHAVIORAL|Exercise + behaviour change intervention|In addition to the same exercise intervention as the control group, this group will receive a behaviour change intervention. This will be delivered after each exercise session and will incorporate the elements: self-efficacy, outcome expectations, impediments and goal-setting. On the weeks when the participants do not attend group sessions, they will receive telephone calls from physiotherapists. This will consist of guided conversations that consider content delivered in previous sessions.
224076339|NCT05461079|DIAGNOSTIC_TEST|obtention of up to three semen samples|sorting of spermatozoa with flow cytometry. In the presence of insufficient numbers of spermatozoa after sorting (\<15 mill), up to three semen samples will be collected.
224076340|NCT06068387|PROCEDURE|surgical staging|para-aortic lymphadenectomy from the inferior mesenteric artery cranially to the aorta caudally via laparoscopy or laparotomy
224076341|NCT04408495|PROCEDURE|Intervention group_MRA|"Tidal Volume (Vt) =6-8 mL/kg of predicted body weight (PBW), Peep=8 cmH2O, recruitment maneuvers=30cm H2O every 30 min after intubation (except during CPB), after any disconnection and at the admission in ICU.~Recruitment maneuvers are performed in accordance with the surgical team an if SAP≥90 mmHg or MAP≥65 mmHg.~Ventilation is maintained during CPB Vt=2.5 mL/kg, Peep= 5 cmH2O"
223864117|NCT02301442|BEHAVIORAL|Exercise + control education|The control group will receive exercise and education components. The exercise intervention includes aerobic \& strengthening components and are in line with MS exercise guidelines (Latimer-Cheung et al 2013). The aerobic activity is walking, measured using pedometers \& exercise logs. The strengthening programme consists of 10 exercises targeting major muscle groups for the upper and lower extremities using elastic resistance band. Over the 10-week programme participants will attend 6 group exercise class, supplemented with telephone calls in the weeks without classes. After each group exercise class this group will receive an education session about the following: diet, vitamin D, sleep, temperature and hydration, and immunisations and vaccinations.
223864118|NCT02522468|PROCEDURE|Radioactive Seed Localization|
223864119|NCT02522468|PROCEDURE|Wire Localization|
223864120|NCT02405559|DRUG|Indocyanine Green|Intradermal injection of Indocyanine Green in the first interdigital space of the studied leg
224076342|NCT04408495|PROCEDURE|Control group|Vt=6-8 mL/kg of PBW, Peep=5 cmH2O , No recruitment maneuvers. Ventilation maintained during CPB Vt=2.5 mL/kg, Peep= 5 cmH2O.
224076343|NCT03489733|OTHER|Hydrolyzed Formula|Infant formula with extensively hydrolyzed proteins and pre- and probiotics.
224076344|NCT03489733|OTHER|Control formula|Infant formula with intact proteins and pre- and probiotics.
223864121|NCT04134793|PROCEDURE|radiofrequency ablation|bipolar radiofrequency ablation by ablation forceps
223864122|NCT02459782|PROCEDURE|Ultrasound guided Dual Quadrant Peribulbar Anaesthesia|Landmark Guided single injection vs Ultrasound guided dual quadrant injection
223864123|NCT00839371|DRUG|Propofol|i.v. propofol titration until adequate depth of sedation
223864124|NCT00839371|DRUG|Midazolam|i.v. midazolam titration until adequate depth of sedation
223864125|NCT06096142|DEVICE|Solaris DE|Percutaneous Transluminal Angioplasty (PTA) followed by Solaris DE implantation in the treated vessel.
223864126|NCT06096142|DEVICE|PTA|Percutaneous Transluminal Angioplasty (PTA) in the treated vessel alone.
223864127|NCT04608955|DRUG|WX-081|WX-081 is not licensed yet. WX-081 will be used in arms A, B, C, WX-081+MBT.
223864128|NCT04608955|DRUG|Bedaquiline|This licensed drug will be used in arm F as positive comparator.
223864129|NCT04608955|DRUG|Standard treatment|Standard treatment will be used in arm D as positive comparator, according to the recommendations of WHO guidelines for diagnosis and treatment of tuberculosis.
223864130|NCT04608955|DRUG|Multi-drug background treatment (MBT)|MBT will be used in arm E, F as background treatment. The drugs used in MBT are all licensed drugs, and the treatment complies with the recommendations of WHO guidelines for diagnosis and treatment of tuberculosis.
223864131|NCT04561219|DRUG|Nitazoxanide|Nitazoxanide 500mg three times a day for 5 days
223864132|NCT04561219|DRUG|Placebo|Placebo three times a day for 5 days
223864133|NCT04873336|DEVICE|Intellivent ASV|A closed loop mechanical ventilation mode that adjusts oxygenization and ventilation automatically
223864134|NCT04555265|DEVICE|Radiofrequency ablation or microwave ablation|Hepatocellular carcinoma treated by either radiofrequency ablation or microwave ablation
223864135|NCT01026064|OTHER|Cantharidin|Cantharone topical liquid containing 0.7% cantharidin (blistering agent) is applied as 25 µL of 0.1% cantharone solution in acetone
223864136|NCT01026064|DRUG|Azithromycin|Zithromax (250 mg oral capsule).
223864137|NCT01026064|DRUG|Placebo|Matching placebo
223864138|NCT03671525|DRUG|Nimodipine|Subject will receive two 30mg capsules of nimodipine during study visit.
223864139|NCT03671525|DRUG|Placebo oral capsule|Two coconut oil capsules that mimic the size and color of the nimodipine capsules
223864140|NCT01301196|BEHAVIORAL|Educational workshop|3h attendance at educational workshop plus self-monitoring
223864141|NCT06530264|OTHER|DCR|6\. An H shaped incision at the postero-inferior lacrimal sac is made, with a long anterior flap and shorter posterior flap. Similarly an H shaped incision at the nasal mucosa is made. The posterior flap of lacrimal sac is sutured with posterior flap of nasal mucosa in interrupted fashion using 6-0 vicryl sutures in Group A, while in Group B the posterior flap is trimmed without suturing.
223864142|NCT06002542|BEHAVIORAL|Information provided|get information at every stage of care in emergency room
223864143|NCT06002542|BEHAVIORAL|Control|Information is only provided when participants request it.
223864144|NCT06089694|DEVICE|Enabling Sensor Research Holter Mode feature|The Sensor Research Holter Mode feature within the Crome and Cobalt ICD and CRT-D devices will be enabled for a short period of time at the In-clinic Testing Visit to allow for desired data collection.
223864145|NCT00867191|DRUG|Placebo|Placebo, 1 tablet daily, per os., 15 days
223864146|NCT00867191|DRUG|Desloratadine|Desloratadine, one 5 mg tablet daily, per os, 15 days
223864147|NCT00777244|DRUG|MITOTANE|mitotane will be administered at a starting dose of 1.5 g/day and increased in case of good gastrointestinal tolerance on day 2 to 3 g/day, on day 3 to 4.5 g/day, and on day 4 to 6 g/day. A dose of 6 g/day will be administered until first mitotane blood level is assessed. Further adjustment of dosage will be performed according to blood concentrations and tolerability.
223864148|NCT05289349|DRUG|Propofol|Propofol (2 mg/kg) for induction of anesthesia , and ( 6 mg/kg/h) for maintenance of anesthesia
223864149|NCT05289349|DRUG|Sevoflurane|Sevoflurane 1.0-1.5 minimum alveolar concentration (MAC)
223864150|NCT01422616|DRUG|Low-dose rtPA|Patients allocated to low-dose will receive 0.6 mg/kg (maximum of 60 mg) i.v. (15% bolus \[maximum bolus dose of 9mg\] and 85% infusion over 60 mins) recombinant tissue plasminogen activator (rtPA).
223864151|NCT01422616|DRUG|Standard-dose rtPA|Patients allocated to standard-dose will receive 0.9 mg/kg (maximum of 90 mg) i.v. (10% bolus and 90% infusion over 60 mins) rtPA.
224076345|NCT06031428|BEHAVIORAL|MANAGe-DM - novel nurse case management|Participants assigned to MANAGe-DM will receive the standard diabetes education mailing in addition to a novel nurse case management intervention. Each month of the study period, the NCM will conduct two phone call intervention sessions with individual participants.
223864152|NCT01422616|OTHER|Intensive blood pressure (BP) lowering|"Intensive blood pressure (BP) lowering to a target systolic BP range 130-140 mmHg within one hour and to maintain this level for at least 72 hours (or until hospital discharge or death if this should occur earlier). A standardised i.v. BP lowering regimen using locally available and approved i.v. BP lowering agents will be used, commenced in the emergency department and later in a high dependency area (e.g. acute stroke or neurointensive care unit) as is usual for patients receiving rtPA.~The trial is an assessment of BP lowering management strategies, using routinely available drugs. There is some flexibility in the use of particular BP lowering agents to achieve BP targets."
223864153|NCT01422616|OTHER|BP management policies|"Patients allocated to the control group will receive management of BP that is based on a standard guideline, as published by the AHA. For this group, the attending clinician may consider commencing BP treatment if the systolic level is greater than 180 mmHg, however and the first line treatment will be oral (including nasogastric if required) and/or transdermal routes. Should control of systolic BP not be achieved via these routes, i.v. treatment may be started until the target systolic BP of 180 mmHg is achieved.~The trial is an assessment of BP lowering management strategies, using routinely available drugs. There is some flexibility in the use of particular BP lowering agents to achieve BP targets."
223864154|NCT04177017|BEHAVIORAL|Mindfulness-based intervention|"The behavioral intervention was carried out once a week during 60 minutes from May to November, and included mindfulness-based practices sought to foster self-awareness, and dyadic activities sought to awakening subtle perception of the other.~Group activities, which entailed more than two participants, were also conducted to foster empathic collaboration and prosocialness. Diverse collaborative games were carried out in which mutual help was needed for achieving shared goals in an amusing way .~Perspective-taking was encouraged within the group, by sharing each participant's experience, which included expressing how each child had felt (i.e., if neglected, ignored or cared for) and whether they had enjoyed helping their peers or no."
223864155|NCT04852432|DEVICE|high flow nasal cannula|The heated air is administered at a rate of 2L/kg/min using an Optiflow device (Fisher and Paykel Healthcare, Auckland, New Zealand). Inhalation oxygen concentration starts with 50%.
223864156|NCT04852432|DEVICE|nasal prong|Oxygen is administered via nasal prong
223864157|NCT01471392|DEVICE|STD Diagnostic Kit (Identigene)|The Identigene STD Test Collection Kit is an at-home kit that allows individuals to utilize the Gen-Probe technology to test for CT and NG in privacy and in a more convenient manner. The primary technology is the approved Gen-Probe APTIMA Combo 2 assay, which is repackaged into the Identigene kit for use by consumers. As such, the laboratory technology and testing method is identical to that of the Gen-Probe APTIMA Combo 2 assay, which has been cleared for in vitro diagnostic use.
223864158|NCT06176924|DEVICE|tDCS|tDCS (2mA, 20 min anode placed on DLFPC of left side and cathode on supraorbital cortex of right side) along with relaxation technique.
223864159|NCT06176924|OTHER|Relaxation technique|Relaxation technique
223864160|NCT04303156|DRUG|Islatravir|Single oral dose of 60 mg Islatravir administered in capsule form
223864161|NCT05746273|DRUG|Transdermal Nicotine Patch|Participants will wear nicotine transdermal patches daily for 12-15 weeks. They will apply a study patch each morning and remove at bedtime. Active dose will titrate up from 3.5mg to 7mg, and then can optionally be further titrated to a maximum dose of 14mg. After week12, the dose will be slowly tapered over 2-3 weeks.
223864162|NCT05746273|DRUG|Transdermal Placebo Patch|Participants will wear placebo transdermal patches daily for 12-15 weeks. They will apply a study patch each morning and remove at bedtime. Placebo patch dose will titrate up from 3.5mg to 7mg, and then can optionally be further titrated to a maximum dose of 14mg. After week12, the dose will be slowly tapered over 2-3 weeks.
223864163|NCT02055794|PROCEDURE|Suturing of the perineal skin|
223864164|NCT02055794|PROCEDURE|Closing perineal skin with surgical glue|
223864165|NCT02055794|PROCEDURE|No suturing of the perineal skin|
223864166|NCT02886858|DEVICE|Device : Transcranial direct current stimulation|The anode will be applied over the F3 area and the cathode over the F4 area. The current dose is 2mA. Electrodes will be 7x5cm in size. The investigators will apply 2 daily, tDCS sessions of 30 minutes, weekly the first month, fortnightly the second and third month, monthly the following 3 months.
223864167|NCT02886858|DEVICE|Device : sham Transcranial direct current stimulation|The anode will be applied over the F3 area and the cathode over the F4 area. Electrodes will be 7x5cm in size. The investigators will apply 2 daily, tDCS sessions of 30 minutes, weekly the first month, fortnightly the second and third month, monthly the following 3 months.
223864168|NCT03328715|DEVICE|intraoperative OCT|before and after surgery intraoperative OCT is performed
223864169|NCT03328715|DEVICE|stand-alone OCT|before and after surgery stand-alone OCT is performed
223864170|NCT01444235|DRUG|Custodiol-N|Route of administration: by infusion Dosage: will be infused antegrade into the root of the aorta until 1500-2000 mL of solution have been infused Duration: infusion technique will be continued for seven minutes
223864171|NCT01444235|DRUG|Custodiol|Route of administration: by infusion duration: infusion technique will be continued for seven minutes dosage: until 1500-2000 mL of solution have been infused
223864172|NCT04034745|DRUG|telotristat ethyl|250 mg tablets of Xermelo (telotristat ethyl) is administered orally 3x daily in combination with somatostatin analogs (SSAs) for approximately 84 days as per standard of care
223864173|NCT01435395|DRUG|Temozolomide, bevacizumab and bortezomib|Escalating temozolomide with standard dose bevacizumab and bortezomib
223864174|NCT04332666|DRUG|Angiotensin 1-7|endogenous peptide dilution: angiotensin-(1-7) 0.5 mg / L NaCl 0.9%
223864175|NCT04332666|DRUG|Placebos|infusion of NaCl 0.9% without diluted peptide in it
223864176|NCT02129049|OTHER|educational intervention|Participate in the Enhancing Connections Telephone Program
223864177|NCT02129049|BEHAVIORAL|telephone-based intervention|Participate in the Enhancing Connections Telephone Program
223864178|NCT02129049|OTHER|questionnaire administration|Ancillary studies
224076346|NCT06031428|BEHAVIORAL|Monthly Educational Mailing|All participants in the study will receive diabetes education mailers. This includes monthly mailings of diabetes education, based off the American Diabetes Association guidelines for Diabetes Education. Topics covered will include diabetes basics, monitoring and medications, healthy eating and exercise, overview of common comorbidities, basics of foot care, and strategies for overcoming common pitfalls.
224076347|NCT05489237|DRUG|IDRX-42|Administered at assigned doses and schedules once or twice daily in continuous cycles of 28 days each.
223864179|NCT04593914|DEVICE|Cavilon Advanced Skin Protectant|"3M™ Cavilon™ Advanced Skin Protectant is a polymeric-cyanoacrylate solution intended for the protection of intact or damaged skin. Upon application to skin, the liquid dries rapidly to form a primary long-lasting waterproof, highly durable film barrier. It is elastomeric, adhering to the contours of the skin and providing a uniform film. The film is transparent and possesses good oxygen and moisture vapor permeability.~The polymer-cyanoacrylate is dispersed in a non-stinging solvent. The film is colorless, non-cytotoxic and has a low dermatitis potential. The film adheres to dry, moist or wet skin surfaces and remains intact during conditions of continuous or repeated exposure to moisture or caustic irritants. It will wear off the skin and does not require removal."
223864180|NCT03408925|OTHER|Exercise program|The orienteerers are asked to perform specific exercises four times a week throughout the entire study period. The exercises are heel rises, runners pose, single leg stance and one-leg jumps with three difficult levels aiming to mainly improve lower extremity strength and neuromuscular function. Each second week the exercises' difficulty level is increased.
223864181|NCT04283552|DEVICE|Dynamic PET/CT Imaging|-Will take approximately 60 minutes
223864182|NCT02033148|DRUG|icotinib hydrochloride|Given PO
223864183|NCT02033148|OTHER|laboratory biomarker analysis|Correlative studies
223864184|NCT02033148|OTHER|pharmacological study|Correlative studies
223864185|NCT05520086|DRUG|Single Dose|Single Dose: Administration of 12,5 million allogeneic mesenchymal stem cells derived from adipose tissue by subcnjunctival injection and topical conjunctival injection.
223864186|NCT05520086|DRUG|Double Dose|Repetead Dose: Administration of 2 doses, separated by 14 days, of 12,5 million allogeneic mesenchymal stem cells derived from adipose tissue by subcnjunctival injection and topical conjunctival injection.
223864187|NCT05116839|DEVICE|the first 15 minutes with pressure support ventilation|PSV pressure support ventilation:triggered by minute volume \< 3 Liter ,with no frequency
223864188|NCT05116839|DEVICE|the following 15 minutes ventilation will be changed to continous positive air way pressureCPAP mode|continous positive air way pressure CPAP mode at 10 cm H2o .
223864189|NCT05116839|DEVICE|i gel air way|supraglottic air way device
223864190|NCT00545077|DRUG|Letrozole|
223864191|NCT00545077|DRUG|Bevacizumab|
223864192|NCT00545077|DRUG|Fulvestrant|
224076348|NCT05159596|DEVICE|In-Home Technology System|Intelligent bots monitor the in-home sensors, learn typical patterns, and provide caregivers with text messages and alerts via cell phone when worrisome behaviors occur. Caregivers are able to: (a) select services (e.g., warnings for falls, wandering, late night activity); (b) access daily reports (summaries of daily activities that can also be shared with health care providers); and (c) obtain support (e.g. Caregiver Support Groups that connect caregivers with knowledgeable experts and other caregivers, Caregiver Events that provide virtual meetings about relevant topics, and Trusted Circle task management to distribute the caregiving work load).
224076349|NCT05159596|DEVICE|Limited In-Home Technology|Intelligent bots monitor the in-home water leak sensor and provide caregivers with text messages and alerts via cell phone when worrisome conditions occur.
224076350|NCT06121401|DRUG|Olaparib|Olaparib is considered the study treatment. Olaparib tablets will be taken at the dose of 300 mg (2 x 150 mg tablet) twice daily adding to bevacizumab at a dose of 15 mg per kilogram of body weight every 3 weeks
223864193|NCT05733936|OTHER|rehabilitation protocol|rehabilitation protocols after ACLR have been described, aiming to improve muscle strength and knee stability through muscle strengthening exercises in addition to exercises to improve joint proprioception
224076351|NCT06121401|DRUG|Bevacizumab|Bevacizumab will be taken at a dose of 15 mg per kilogram of body weight every 3 weeks
223864194|NCT01501188|OTHER|Kinesio Taping|The participants were randomly assigned to an experimental group, to received Kinesio Taping application for gastrocnemius muscle enhancement and functional correction of the ankle.The treatment was performed three times a week during a 4-week period.
223864195|NCT01501188|OTHER|Placebo kinesio taping|Placebo-control group received treatment with a sham Kinesio Taping protocol to enhance gastrocnemius muscle function and dorsal ankle flexion.The strips used in this group did not follow the principles of tension and anatomic distribution of Kinesio technique.The treatment was performed three times a week during a 4-week period
223864196|NCT00600548|DRUG|Miltefosine.|Miltefosine: Capsules containing 10 mg or 50 mg miltefosine; administered orally for 28 days at dosage of 2.5 mg/kg body weight per day.
223864197|NCT00600548|DRUG|Meglumine antimoniate.|Meglumine antimoniate administered by intravenous route for 20 days at the dosage of 20mg/kg/day.
223864198|NCT00600548|DRUG|Miltefosine.|Miltefosine: Capsules containing 10 mg or 50 mg miltefosine; administered orally for 28 days at dosage of 2.5 mg/kg body weight per day.
223864199|NCT00600548|DRUG|Meglumine antimoniate.|Meglumine antimoniate administered by intravenous route for 20 days at the dosage of 20mg/kg/day.
223864200|NCT04957225|BEHAVIORAL|MIRAA (Multimodal Intensive Rehabilitation of Aphasia and Apraxia of speech)|Multimodal intensive treatment of aphasia and AOS
223864201|NCT01331863|PROCEDURE|Airway and/or pulmonary Vessels Transplantation|Use of a stent-supported aortic allograft to prevent pneumonectomy in lung cancer SURGERY
223864202|NCT04554082|PROCEDURE|laparoscopic sleeve gastrectomy|bariatric surgery to loss weight
224076352|NCT06047561|RADIATION|PET-CT|PET combined with CT or MRI
223864203|NCT04136470|BIOLOGICAL|Collection of stool, blood (PBMC) and biopsy (FFPE)|Patients receiving routine treatment (immunotherapy using anti-PD1 / anti-PDL1 and / or anti CTLA4 antibodies), financed by the Polish National Health Fund (NFZ).
223864204|NCT01688089|DRUG|ODM103|
223864205|NCT01688089|DRUG|Placebo|
223864206|NCT01688089|DRUG|Entacapone|
223864207|NCT01688089|DRUG|Levodopa/carbidopa|
223864208|NCT01465516|DRUG|Boceprevir|"Baseline assessments must be obtained on the day of or prior to enrollment and prior to administration of the first dose of any study drug (BOC, PEG-IFN alfa-2b, or ribavirin).~Using the RGT guidelines in patients who are previously untreated: all patients will receive a lead-in treatment of PR for 4 weeks, then BOC will be added to PR for 4 weeks; based on patient's week 8 HCV RNA results"
223864209|NCT02202499|DRUG|Varenicline|All participants will take the following dose of varenicline: 0.5 mg once a day on days 1-3, 0.5 mg twice a day on days 4-7, and 1 mg twice a day through week 16 of the study. Arm descriptions show specific details for each group.
223864210|NCT02202499|OTHER|Counseling and Support Materials|Counseling and support materials (including a review and self-monitoring workbook tentatively titled, Winding Down: A Guide to Quitting Smoking using Varenicline) instructing participants to systematically utilize the FE techniques provided.
223864211|NCT02202499|OTHER|Laboratory Assessments|The first laboratory assessment will consist of completion of questionnaires and a cue-reactivity test. The second laboratory assessment will be scheduled for the end of the week before the participant's quit date. It will involve completion of questionnaires and another cue reactivity test. A follow-up session conducted by research staff will occur one month after the target quit date to collect information about each participant's current smoking status, smoking rate, varenicline use, and opinion about the treatment. A second follow-up session will be conducted by telephone and will occur three months after the target quit date, at the end of varenicline use. At the end of the study, participants will be asked to complete a brief survey asking basic information, similar to the questions during the screening period.
223864212|NCT06196177|DRUG|Levosimontane injection|Levosimendan injection was given once intravenously with a micro-pump: 12.5mg levosimendan injection was diluted with 5% glucose injection to 50ml at the initial pump speed of 2ml/h for 24h.
223864213|NCT00239083|DRUG|Enteric-Coated Mycophenolate Sodium (EC-MPS)|
223864214|NCT00724217|OTHER|Standard Process 21 Day Purification Program (SPPP)|The Standard Process 21 Day Purification Program (SPPP) consists of a controlled food intake regimen of mostly fruit and vegetables with restricted calories, protein and fats plus daily use of herbal and whole food based supplements.
224076353|NCT05029921|DRUG|Ustekinumab|Ustekinumab will be administered as an IV injection in induction phase and as a SC injection in maintenance phase.
223864215|NCT00724217|OTHER|Standard Process 21 Day Purification Program (SPPP)|The Standard Process 21 Day Purification Program (SPPP) consists of a controlled food intake regimen of mostly fruit and vegetables with restricted calories, protein and fats plus daily use of herbal and whole food based
223864216|NCT01240330|DEVICE|Pneumatic Compression therapy|Subject comparison analysis of femoral venous Peak Flow Velocity at rest and during compression therapy.
223864217|NCT01812148|PROCEDURE|Cytoreductive surgery and HIPEC|Cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy (HIPEC) with Oxaliplatin as chemotherapeutic agent
223864218|NCT01288326|DRUG|liraglutide|Liraglutide will be prescribed and titrated (individually adjusted) by the treating physician.
223864219|NCT03123198|BEHAVIORAL|Dialectical Behavior Therapy|DBT is a multimodal comprehensive psychosocial treatment.
223864220|NCT02976116|DRUG|Fruquintinib|Fruquintinib will be administered orally once daily from Day 1 to Day 21 per 28-day cycle until disease progression or unacceptable toxicity
223864221|NCT02976116|DRUG|Gefitinib|Gefitinib will be administered orally once daily per 28-day cycle or unacceptable toxicity
223864222|NCT04358939|OTHER|Prone decubitus|According to the tolerance, the objective is to spend as much time as possible, up to 16 hours and beyond in prone position every 24 hours. At least two sessions of at least 30 minutes each must be performed daily.
223864223|NCT01219205|PROCEDURE|intravitreal bevacizumab|Intravitreal injections of bevacizumab were performed under sterile conditions in the operating room. a 27-gauge needle was inserted through the corneal limbus to withdraw 0.05 ml of aqueous humor and soften the globe. Then, 1.25 mg (0.05 ㎖) of bevacizumab was injected into the vitreous in the superior temporal quadrant with a 30-gauge needle that was inserted into the eye 3.5 mm from the limbus. The postoperative medications included topical antibiotics.
223864224|NCT04956679|DIAGNOSTIC_TEST|carbon 13 breath test|Patients with positive Helicobacter pylori infection were determined by carbon 13 breath test ,The diagnosis and treatment of positive patients were followed up without other intervention.
223864225|NCT02092519|DEVICE|Needle with sideport (NA-230H-8020)|EUSFNA using needle with sideport
223864226|NCT02092519|DEVICE|Needle without sideport (NA-220H-8022)|EUSFNA using needle without sideport
223864227|NCT00535145|DRUG|Treatment as usual (TAU), Paliperidone ER|Treatment as usual is the subject's current antipsychotic and doses for 4 weeks; TAU AND Paliperidone ER - per site investigator for 1 week; Paliperidone ER 6mg once daily for 1 week; Paliperidone ER-3 to 12mg tablets once daily for 4 weeks
223864228|NCT00177086|OTHER|Alfuzosin Hydrochloride|One tablet every day for 4 weeks
223864229|NCT03267966|DIAGNOSTIC_TEST|Leeds Pathology Protocol (LEEPP)|LEEPP includes: 1) multicolor inking; 2) axial slicing; 3) circumferential margin; 4) 1-mm clearance
223864230|NCT03260140|BEHAVIORAL|behavioral lifestyle intervention|The investigators will provide participants with the behavioral lifestyle intervention
223864231|NCT00478478|PROCEDURE|Mechanical Thrombectomy|Thrombectomy performed with the Merci Retriever in the setting of acute ischemic stroke.
223864232|NCT02304952|PROCEDURE|Radiofrequency microtenotomy|For the minimally invasive surgery will Arthrocare Topaz MicroDebrider device be used. A small incision will be made and the tip of the device is placed on surface of the tendon to structure and activated for 0.5 second, at 5 mm distance intervals on the tendon creating a grid-like pattern.
223864233|NCT02304952|OTHER|Eccentric exercise|Eccentric exercise for 3 months. The exercise will be performed once a day with 3 set and 5 reps, women start with 0.5 and men 1.0 kilo with a 10 % increase every week.
223864234|NCT02304952|DEVICE|Arthrocare Topaz MicroDebrider|
223864235|NCT01257932|DEVICE|Diffuse Optical Spectroscopy Imaging|Diffuse Optical Spectroscopy Imaging Breast Cancer Response to Neoadjuvant Chemotherapy
223864236|NCT00463788|DRUG|cetuximab, cisplatin|"Subjects will receive an initial dose of cetuximab 400 milligram per square meter (mg/m\^2) followed by weekly doses of 250 mg/m\^2. All doses will be given by intravenous (IV) infusion.~Subjects will receive cisplatin (75 mg/m\^2 IV on Day 1) every 3 weeks, with a maximum of 6 cycles.~Administration of the Investigational Medicinal Product (IMP) will be stopped upon the first occurrence of disease progression, unacceptable toxicity or withdrawal of consent."
223864237|NCT00463788|DRUG|cisplatin|"Subjects will receive cisplatin (75 mg/m\^2 IV on Day 1) every 3 weeks, with a maximum of 6 cycles.~Subjects have the option of receiving cetuximab plus cisplatin at progression within the first 6 cycles, or cetuximab alone at progression after the 6 cycles.~Administration of the IMP will be stopped upon the first occurrence of disease progression (except in cisplatin arm where switch to cetuximab plus cisplatin, or cetuximab alone is possible), unacceptable toxicity or withdrawal of consent."
223864238|NCT03178292|DRUG|Levofloxacin|Levofloxacin 500Mg daily for 5 days
223864239|NCT03178292|DRUG|Placebo|Placebo Oral Tablet daily for 5 days
223864240|NCT00360698|DRUG|Insulin Glargine|One daily injection at bedtime
223864241|NCT00360698|DRUG|Glimepiride|At same dosage as during the run-in period
223864242|NCT00360698|DRUG|Insulin Glulisine|One bolus given before the main meal
223864243|NCT00360698|DRUG|Metformin|At same dosage as during the run-in period
223864244|NCT00957411|BIOLOGICAL|cetuximab|Given IV
223864245|NCT00957411|DRUG|cisplatin|Given IV
223864246|NCT05943171|DEVICE|Cognitive Behavioral Therapy|All participants will receive Cognitive Behavioral Therapy. They will be randomized to either Digital RITch®CBT or Standard CBT
223864247|NCT01043458|DRUG|ABT-126|ABT-126 Low Dose \& ABT-126 High Dose
223864248|NCT01043458|DRUG|Placebo for ABT-126|Matching Placebo for Arms 1 \& 2
223864249|NCT03961906|BEHAVIORAL|physiotherapy|Will receive two trainings. First training in week one after baseline assessment for three consecutive days 60 min twice daily by trained physiotherapists and in week three further two days with 60min once daily.
223864250|NCT03270358|PROCEDURE|Blood sampling in arterioveinous fistula without stenosis|"Plasmatic osteopontin level (ng/ml) collected in the patient's arteriovenous fistula.~Blood sampling in arterioveinous fistula right before a dialysis session"
223864251|NCT03270358|PROCEDURE|Blood sampling in arterioveinous fistula with stenosis|Blood sampling in arterioveinous fistula right before the surgery for stenosis of the fistula
223864252|NCT02622672|DIETARY_SUPPLEMENT|water-soluble ubiquinol|100 mg/d
223864253|NCT02622672|DIETARY_SUPPLEMENT|Placebo|glycerin.soy-lecithin, and water
223864254|NCT04129619|DRUG|ORP-101|Oral tablet
223864255|NCT04129619|DRUG|Placebo|Oral tablet
223864256|NCT05789771|DRUG|Abemaciclib|Abemaciclib 150 mg orally every 12 hours plus Aromatase Inhibitor ( Anastrozole 1 mg, Letrozole 2.5 mg or exemestane 25 mg orally every 24 hours on Days 1 to 28 of a 28-day cycle)
223864257|NCT05789771|DRUG|Abemaciclib|Abemaciclib 150 mg orally every 12 hours plus Fulvestrant (500 mg intramuscularly on Days 1 and 15 of Cycle 1, then on Day 1 of Cycle 2 and beyond on Day 1 of a 28-day cycle)
223864258|NCT05789771|DRUG|Abemaciclib|Abemaciclib 200 mg orally every 12 hours
224076354|NCT05072483|DEVICE|MRI|Research pulse sequences.
224076355|NCT06397833|DEVICE|Acorai ICPM system|Patient will have the handheld Acorai ICPM system placed on their chest, for a period of 5 minutes for sensor recording time
224076356|NCT04500275|DRUG|Vancomycin Hydrochloride|Vancomycin will be spread on sternal edge immediately after sternotomy and before sternal closure
223864259|NCT01839578|DRUG|Anticoagulation to prevent clotting of the extracorporeal circuit. (regional citrate anticoagulation)|"Anticoagulation to prevent clotting of the extracorporeal circuit. Unfractionated heparin and regional citrate anticoagulation will be compared.~Ci-Ca protocole for MultiFiltrate® CRRT machine :~* 4% trisodium citrate solution~* Calcium chloride solution (100 mmol/L)~* Dialysate flow rate: 35 ml/kg/h~* Blood flow rate: adjusted to maintain a ratio blood flow rate / dialysate flow rate of 3~* Citrate infusion titrated to maintain postfilter ionized calcium between 0.25 and 0.35 mmol/L.~* Calcium chloride infusion titrated to maintain systemic ionized calcium between 1.12 and 1.2 mmol/L.~* Blood flow adapted to the acid-base status"
224076357|NCT04500275|OTHER|Normal Saline|2 ml normal saline will be spread on sternal edge immediately after sternotomy and before sternal closure
224076358|NCT06545786|DEVICE|Intraoperative electroencephalography|"EEG recording will be performed using the standard 16-electrode configuration according to the international 10-20 system. During the recording, electrode impedances will be maintained at a level not exceeding 5 kilo-ohms."
223864260|NCT01839578|DRUG|Anticoagulation to prevent clotting of the extracorporeal circuit (Unfractionated heparin)|"Anticoagulation to prevent clotting of the extracorporeal circuit. Unfractionated heparin and regional citrate anticoagulation will be compared.~* Continuous infusion of unfractionated heparin: starting infusion rate at 600 IU/h then adjusted to maintain partial thromboplastin time at 1-1.4 times the normal value.~* Standard dialysate for CRRT : Prismasol® K2 solution~* Dialysate flow rate: 35 ml/kg/h~* Blood flow rate: adjusted to maintain a ratio blood flow rate / dialysate flow rate of"
223864261|NCT05372588|DRUG|NVX-CoV2515|Intramuscular (deltoid) injection of co-formulated Omicron BA.1 SARS-CoV-2 rS vaccine with Matrix-M adjuvant (0.5 mL).
223864262|NCT05372588|DRUG|NVX-Cov2373|Intramuscular (deltoid) injection of co-formulated prototype SARS-CoV-2 rS vaccine with Matrix-M adjuvant(0.5 mL).
223864263|NCT05372588|DRUG|NVX-CoV2373 + NVX-CoV2515|Intramuscular (deltoid) injection of 5 µg total (2.5 µg NVX-CoV2373 + 2.5 µg NVX-CoV2515) with 50 µg Matrix-M adjuvant.
223864264|NCT05372588|DRUG|NVX-CoV2540|Intramuscular (deltoid) injection of co-formulated prototype SARS-CoV-2 rS vaccine with Matrix-M adjuvant(0.5 mL).
224076359|NCT00517972|DRUG|Omacor (omega-3-acid ethyl esters)|
223864265|NCT05372588|DRUG|NVX-CoV2373 + NVX-CoV2540|Intramuscular (deltoid) injection of 5 µg total (2.5 µg NVX-CoV2373 + 2.5 µg NVX-CoV2515) with 50 µg Matrix-M adjuvant.
223864266|NCT04461197|DEVICE|customised foot orthoses|The foot orthoses for group A were custom made using phenolic foam molds of the feet. Separated molds were made of both feet for all the participants. . The insole was made based on a positive mold of plaster with 45 Shore cork materials with horizontal thrusts just proximal to the metatarsal heads, with the intention of correcting the pathological subtalar pronation, with a 3mm bilateral raising of the heel and a bilateral latex metatarsal bar.
223864267|NCT04461197|DEVICE|orthotic insole|For group B, a flat insole of polyester resin was made, fitting it to the foot's size.
223864268|NCT02277288|OTHER|Filled bladder arm|Bladder to be instilled with 200 cc fluid during cystoscopy and no catheter for all mid-urethral sling procedures.
224076360|NCT06553612|OTHER|Multidisciplinary assessment|Delivery of a personalized post-cancer plan with multidisciplinary assessment of oncology support care needs in a day hospital
224076361|NCT06553612|OTHER|Standard assesment|Delivery of a personalized post-cancer plan without a day hospital
224076362|NCT06553612|OTHER|Observational cohort|Patients with no cancer sequelae, no adverse effects and no need for oncological support care will not be randomized, but will be followed as part of an observational cohort
223864269|NCT04414098|DRUG|INC424 / Ruxolitinib|"1. Ruxolitinib 5 mg orally every 12 hours during 14 days.~2. Total Follow-up time will be of 45 days.~3. The reduction of ruxolitinib dose will be considered in cases of drug-related cytopenias.~4. During hospitalization, clinical and laboratory evolution parameters will be recorded daily in the medical history of the patient and in the data collection table of the study. Upon patient's discharge, a follow-up will be conducted until day +45~5. During hospitalization, adverse events will be monitored daily by means of clinical assessment and laboratory data.~6. After discharge, monitoring of adverse events will continue during the outpatient follow-up.~7. Pro-inflammatory parameters will be assessed at baseline, after one week (day +7) and at the end of treatment (day +14)~8. Ruxolitinib will be associated to the standard of care for COVID-19 of each center.~9. In case of an adverse effect or a need to discontinue the treatment, ruxolitinib should be suspended."
223864270|NCT01906788|DRUG|Artemether Lumefantrine|
223864271|NCT01906788|DRUG|Artemether Lumefantrine 6 dose regimen & single dose of Primaquine on day 0|
223864272|NCT01906788|DRUG|Artemether Lumefantrine 6 dose regimen and single dose Primaquine on day 2|
223864273|NCT02929485|DRUG|Tolcapone|Tolcapone 200mg (single dose) administered at study visit
223864274|NCT02929485|DRUG|Placebo|Placebo (200mg) administered at study visit
223864275|NCT02929485|DRUG|Bromocriptine|Drug: Bromocriptine 1.25 mg (single dose) administered at study visit
223864276|NCT02872753|BIOLOGICAL|ACP|Autologous Conditioned Plasma will be obtained directly in the operatory room from the peripheral venous blood of the patient, and injected intra-articularly at the end of arthroscopic meniscectomy
223864277|NCT02872753|OTHER|Standard Meniscectomy|Patients will receive standard arthroscopic meniscectomy
223864278|NCT05816486|DIAGNOSTIC_TEST|Immunobiogram|This is not an interventional study. However the assay being tested on the blood samples of all enrolled participants is the Immunobiogram (IMBG). IMBG is an in vitro diagnostic immunoassay which can obtain dose-response curves that describe the inhibitory effect of each immunosuppressant on immune response cells (immunologically stimulated PBMCs) in kidney transplant patients.
223864279|NCT02147535|DRUG|Methylphenidate|10 mg as a single dose followed by one blood sample 3 hours post-dose
223864280|NCT03161990|PROCEDURE|Transgluteal approach to the hip joint|Operative approach to the hip joint where the abductors are partly detached from the greater trochanter and the hip joint is approached through the anterior part of the capsule.
223864281|NCT03161990|PROCEDURE|Posterior approach to the hip joint|Operative approach to the hip joint where the short external rotators are detached from the greater trochanter and the hip joint is approached through the posterior part of the capsule.
223864282|NCT00831675|BIOLOGICAL|Influenza Vaccine 2004-2005 Paediatric Formulation|0.25 mL (Day 0 and Day 28), Intramuscular
223864283|NCT00831675|BIOLOGICAL|Influenza Vaccine 2004-2005 Paediatric Formulation|0.25 mL (Day 0 and Day 28), Intramuscular
223864284|NCT01211093|PROCEDURE|High frequency whole body vibration|1 single session (10 minutes) of whole body vibration therapy at 30 Hz
223864285|NCT01211093|PROCEDURE|Low frequency whole body vibration|1 single session of whole body vibration therapy at 20 Hz
223864286|NCT01211093|PROCEDURE|control|1 single session of standing on the vibration platform, with no vibration signals delivered.
223864287|NCT00656721|DEVICE|Flutter Valve|"Flutter Valve (Scandipharm, Birmingham, AL) is shaped like a pipe with a hardened plastic mouthpiece at one end, a plastic protective, perforated cover at the other end, and a high-density stainless steel ball resting in a plastic circular cone on the inside. When the patient expires, a vibratory effect is transmitted to airways by the steel ball oscillation in order to facilitate mucociliary clearance.~In our study, the use of the equipment was guided by a registered physical therapist, but the position (angle) was determined by the patient, according to his/her adaptation and perception of effectiveness of sputum clearance. The patients remained comfortably seated, breathing through the device for 15 minutes, starting from the total pulmonary capacity, and being free to cough. Thereafter, a 5-minute session of cough was done."
224076363|NCT03542175|DRUG|Rucaparib|one dose level (300 mg BID, 400 mg BID, 500 mg BID or 600 mg BID) concurrently with a 6-week course of radiotherapy and 4 additional weeks of maintenance rucaparib at the same dose level.
223864288|NCT04559659|OTHER|Respiratory muscle strength|Pimax and Pmax will be performed according to the (ATS) and (ERS). A Manovacuometer (Analog M 120, GlobalMed) with a range between 0-120cmH2O will be used. The elderly should undergo forced inspiration after maximal expiration and forced expiration after maximal inspiration through a mouthpiece with a hole to prevent closure of the glottis to evaluate Pimax and Pmax. The elderly should sustain the inspiration for 1 second. Three measurements will be performed, with a one-minute interval between them, with less difference equal to 10% between them, the higher value will be used.
223864289|NCT04195516|OTHER|web based training,individual counseling, using reminders|"Health Promotion Model based Health Promotion Program will be applied to the experimental group. Health promotion program; The Web-based Health Promotion Program includes individual counseling and reminder practices.~Within the context of the Web Based Health Promotion Program, 8 weeks of training to improve healthy eating and physical activity behaviors, individual counseling will be given.~Colorful picture reminders will be sent to the experimental group through Whatsapp groups.~At the end of the intervention, cognitive and physical measurements of the students will be done at 1st, 3rd and 6th months."
223864290|NCT03996863|DEVICE|Otoband|Participants during infusion following chemotherapy will wear the Otoband set at normal power (effective) for four days following treatment and nausea outcomes will be recorded by questionnaire or by the investigator during site visits.
223864291|NCT03996863|DEVICE|Placebo device|Participants during infusion following chemotherapy will wear the placebo device set at low power (6 decibels lower than normal power, ineffective power) for four days following treatment and nausea outcomes will be recorded by questionnaire or by the investigator during site visits.
223864292|NCT02249988|DRUG|ABX203 therapeutic Hepatitis B vaccine treatment arm|
223864293|NCT01667796|DIETARY_SUPPLEMENT|Vitamin D3|
223864294|NCT00880477|BIOLOGICAL|DTPa-HBV-IPV/Hib vaccine|Vaccination according to a 3-dose schedule at 1 ½, 3 ½ and 6 months of age with booster at 15-18 months of age.
223864295|NCT00880477|BIOLOGICAL|DTPa-IPV/Hib vaccine|Vaccination according to a 3-dose schedule at at 1 ½, 3 ½ and 6 months of age with booster at 15-18 months of age.
223864296|NCT00880477|BIOLOGICAL|EngerixTM-B|The vaccine was administered according to a 2-dose schedule at 1½ and 6 months of age with booster at 15-18 months of age.
223864297|NCT00885157|BIOLOGICAL|Inactivated types 1, 2, and 3 poliovirus, D antigens|0.1 mL, intradermal
223864298|NCT00885157|BIOLOGICAL|Inactivated types 1, 2, and 3 poliovirus, D antigens|0.5 mL, Intramuscular
223864299|NCT00710515|DRUG|AZD6244|75mg
223864300|NCT02747381|DIETARY_SUPPLEMENT|Alfacalcidol|1-alpha hydroxy cholecalciferol 1 mcg
223864301|NCT00432718|PROCEDURE|Saline Instillation before Tracheal Suctioning|
223864302|NCT04843306|BEHAVIORAL|Biofeedback|Relaxation coaching will be used in this study.
223864303|NCT04843306|BEHAVIORAL|Active Breathing Control Technique|Active breathing control (ABC) requires patients to reproducibly perform multiple deep-inspiratory breath holds during treatment.
223864304|NCT05727241|DIAGNOSTIC_TEST|Ultrasound|The intervention is ultrasound examination with three dimensional umbilical cord index, two-dimensional umbilical cord index, and doppler examination of the umbilical cord artery.
223864305|NCT03436277|DRUG|L-Carnitine|L-Carnitine oral solution 1.5 g diluted in 250 ml of water, before crossfit training, 5 times a week for 8 weeks
223864306|NCT03436277|DIETARY_SUPPLEMENT|Sucralose|Sucralose 1.5 g diluted in 250 ml of water, before crossfit training, 5 times a week for 8 weeks
223864307|NCT03423277|DEVICE|Easy Stretch Toolkit|Study the use of novel intraoral tools for management of facial burns and other facial disorders
223864308|NCT03221777|DIAGNOSTIC_TEST|14 Day ECG Patch (Zio XT Patch, iRhythm Technologies)|The ZIO XT Patch (http://www.irhythmtech.com/zio-solution/zio-patch/) is an ultra-portable wearable adhesive patch monitor that provides continuous single-lead ECG recording for up to 14 days. It has been cleared by the FDA for arrhythmia detection and is in current clinical use in the U.S.\[87\]. It will be used in this study under an investigational testing authorization by Health Canada. The ZIO XT Patch is a single-use device worn over the left pectoral region with a skin adhesive (Figure 4). Its small, lightweight, water-resistant, patch-based design has advantages for patients compared with traditional ECG screening methods (e.g. Holter, event loop recorders, mobile outpatient telemetry systems), which are all more cumbersome and require detachable wired leads, two or more removable skin contact electrodes, plus separate recording units (+/- smartphone attachment).
223864309|NCT02282085|DRUG|Aripiprazole Once-Monthly|
223864310|NCT02282085|DRUG|Oral Antipsychotic (i.e. aripiprazole, risperidone, lurasidone, quetiapine, olanzapine, ziprasidone, etc)|Oral antipsychotic medication
223864311|NCT00712335|DRUG|Fluticasone Propionate|DPI 250 mcg BID for 3 weeks
223864312|NCT00712335|DRUG|Montelukast|PO 10 mg QHS for 3 weeks
223864313|NCT00712335|DRUG|Salmeterol|DPI 50mg BID for 3 weeks
223864314|NCT03148600|BEHAVIORAL|Pelvic floor and bowel behavioural training|Physiotherapist-led pelvic floor muscle and bowel behavioural training
223864315|NCT03148600|OTHER|Standard arm|Standard medical and nursing care
223864316|NCT03806348|PROCEDURE|Resuturing|Early reconstruction of the perineal body after wound dehiscence within two weeks of delivery.
223864317|NCT00368186|BIOLOGICAL|Pneumo 23|
223864318|NCT06412445|PROCEDURE|Laparoscopic transabdominal preperitoneal (TAPP) inguinal hernia repair applying tissue glue for mesh fixation|The operation will be performed using 3 trocars, with 10 mm trocar above the umbilicus and 5 mm and 12 mm trocars at the level of the umbilicus in the left and right midclavicular lines. Pneumoperitoneum will be established and a 30° optic will be used. After accessing the inguinal region, dissection of the parietal peritoneum will be performed in the direction from the anterior superior iliac spine up to the medial umbilical ligament. During dissection, gonadal vessels, vas deferens, Cooper's ligament and the posterior fascia of the rectus abdominis muscle will be visualized and prepared. Then, the prepared implant sized 15×15 cm will be introduced, spread out in the abdominal cavity and placed in the groin in order to cover the hernia opening by 2-3 cm in all directions. Fixation will be based on a mechanical effect involving applying tissue glue for mesh fixation. Reconstruction of the parietal peritoneum will be followed, with continuous absorbable sutures.
224076364|NCT03542175|RADIATION|Radiotherapy|50 Gy in 2 Gy per fraction to the breast or chest wall with or without regional nodes plus a 10 Gy boost to the lumpectomy cavity, to a total dose of 60 Gy. A 10 Gy boost to the post-mastectomy scar is allowed at the discretion of the treating physician.
224076365|NCT03946670|DRUG|MBG453|MBG453 is being administered i.v.
224076366|NCT03946670|DRUG|Placebo|Placebo is being administered i.v.
224076367|NCT03946670|DRUG|Hypomethylating agents|Decitabine is being administered i.v. Azacitidine is being administered i.v or s.c.
224076368|NCT06674863|OTHER|Educational Intervention|Receive a low literacy educational supplement
224076369|NCT06674863|OTHER|Interview|Undergo a structured interview
224076370|NCT06674863|OTHER|Questionnaire Administration|Ancillary studies
224076371|NCT06674863|OTHER|Supportive Care|Receive standard SCP
223864319|NCT06412445|PROCEDURE|Laparoscopic transabdominal preperitoneal (TAPP) inguinal hernia repair using self-fixating mesh|The operation will be performed using 3 trocars, with 10 mm trocar above the umbilicus and 5 mm and 12 mm trocars at the level of the umbilicus in the left and right midclavicular lines. Pneumoperitoneum will be established and a 30° optic will be used. After accessing the inguinal region, dissection of the parietal peritoneum will be performed in the direction from the anterior superior iliac spine up to the medial umbilical ligament. During dissection, gonadal vessels, vas deferens, Cooper's ligament and the posterior fascia of the rectus abdominis muscle will be visualized and prepared. Then, the prepared implant sized 15×15 cm will be introduced, spread out in the abdominal cavity and placed in the groin in order to cover the hernia opening by 2-3 cm in all directions. Fixation will be based on a mechanical effect involving the adherence of grips to tissue using self-fixating mesh. Reconstruction of the parietal peritoneum will be followed, with continuous absorbable sutures.
223864320|NCT04236973|DEVICE|Molbio Truenat™ HCV assay (the investigational product)|The Molbio Truenat™ HCV assay (the investigational product) is a quantitative chip-based Real Time Reverse Transcription Polymerase Chain Reaction (qRT-PCR) tests for the detection of HCV genomic RNA from human whole blood, EDTA plasma and serum. The Truenat™ HCV assay runs on the Truelab™ Uno, Truelab™ Duo or Truelab™ Quadro Dx. Results of testing by Truenat™ HCV assay will not be used to make any clinical decisions, and should not be communicated to study participants.
223864321|NCT04236973|OTHER|Abbott RealTime HCV assay|Plasma specimens will be also tested on Abbott RealTime HCV assay that is approved for HCV diagnostics use by countries' authorities. Only the results of Abbott RealTime HCV assay may be used to make clinical decisions.
224076372|NCT06674863|OTHER|Supportive Care|Receive a tailored SCP
224076373|NCT05487599|GENETIC|LY3884961|• LY3884961 is a replication-incompetent recombinant adeno-associated virus (AAV) vector. The vector is composed of a ss DNA genome packaged in an AAV-derived protein capsid.
224076374|NCT06801275|OTHER|1 shower with 4% chlorhexidine gluconate|Comparison of the effect of showering once with 4% Chlorhexidine Gluconate before lumbar disc herniation surgery on surgical site infections
223864322|NCT03194958|BEHAVIORAL|Specialized Quitline|Very low-income smokers are different from other smokers in important ways not always addressed by standard quitline services. The research team and Alere staff has created custom protocols, scripts, prompts and other content to maximize intervention relevance and acceptability to very low-income smokers. Research Implementation Unit (RIU) coaches who will be delivering the Specialized Quitline services have received training from clinical quitline staff, the research team and 2-1-1 staff who have extensive experience with the target population. Focus areas for training and distinctive content and protocol for the Specialized Quitline include: health literacy, abstract vs. concrete language, lived experience, resource constraints, future orientation, getting cigarettes, living situation, phone/internet access.
223864323|NCT03194958|BEHAVIORAL|Basic Needs Navigator|Navigators will: (1) identify and assess smokers' needs, including the reasons they called 2-1-1; (2) jointly generate solutions to address the needs; (3) develop plans to carry out the solutions, including; (4) help prioritize among multiple needs; (5) identify community resources that could help solve the problem; (6) determine eligibility for services; (7) help smokers access available resources by scheduling appointments and provide appointment reminders; (8) prepare smokers to interact with service agencies and/or act as an advocate on their behalf; (9) provide instrumental support such as arranging transportation; (10) actively intervene to resolve barriers to basic needs solutions; (11) oversee follow-up of problem solving actions; and (12) review progress made towards resolving unmet basic needs and adapt solutions accordingly.
223864324|NCT00317226|DRUG|Ferric Carboxymaltose (FCM)|maximum dose of 1,000 mg over 15 minutes IV administered within 7 days of the qualifying visit
223864325|NCT04206215|DEVICE|transcranial Direct Current Stimulation (tDCS)|Subjects will receive 20 minutes of either active or sham tDCS at intensity of 2mA. In the sham group, the tDCS device will not be active for the full 20 minutes.
223864326|NCT04206215|DEVICE|Transcranial Ultrasound (TUS)|Subjects will receive 20 minutes of either active or sham TUS. During active stimulation the ultrasound will be active for the full 20 minutes- however, during sham stimulation the ultrasound will not be active for the full 20 minutes.
223864327|NCT04777968|DRUG|Silver diamine fluoride|a layer of 38% SDF solution was topically applied to the cavity using a micro brush, immediately followed by a saturated Potassium Iodide KI solution using a micro brush also, then a creamy white precipitate was immediately formed, KI was applied until the white precipitate turned clear.
223864328|NCT01202955|DRUG|Tolcapone|Day 1 100mg three times per day Day 2 - Day 7 200mg three times per day Day 8 200mg twice a day Day 9 200mg once a day Day 10 100mg once a day
223864329|NCT01202955|DRUG|Placebo|Day 1 100mg three times per day Day 2 - Day 7 200mg three times per day Day 8 200mg twice a day Day 9 200mg once a day Day 10 100mg once a day
223864330|NCT04324333|BEHAVIORAL|Digital wearable system|Owlytics Healthcare's system is dedicated to improving the lives of all seniors by using the predictive power of data analytics.
223864331|NCT00223535|BEHAVIORAL|Cognitive Remediation|
223864332|NCT00223535|BEHAVIORAL|Social Skills Training|
223864333|NCT01845259|DRUG|Liraglutide|Once a day 1,8 mg subcutaneous injection for 16 weeks
223864334|NCT01845259|DRUG|Liraglutide Placebo|Once a day 1,8 mg subcutaneous injection for 16 weeks
224076375|NCT06801275|OTHER|2 shower with 4% chlorhexidine gluconate|Comparison of the effect of showering twice with 4% Chlorhexidine Gluconate before lumbar disc herniation surgery on surgical site infections
224076376|NCT05851677|DRUG|Disitamab vedotin|recommended but not required regimen of 2.0mg/kg, iv, day1, every 2 weeks
224076377|NCT05286801|BIOLOGICAL|Atezolizumab|Given IV
224076378|NCT05286801|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223864335|NCT04782635|DEVICE|mobile based application|Application basic function would be support and improve nutrition status of children. Personalization of goals and challenges, daily intake of calories, carbohydrates, proteins, fats, minerals and vitamins will be tracked, food logging, food tracking, meal and supplement reminders, recipes, visual cues (remaining calories) will be notified, episodes of vomiting, meals missed, diarrhea, nausea will be recorded , meal planned according to the food preferences of child, food composition table, nutrition blogs and articles
223864336|NCT04782635|BEHAVIORAL|Pamphlet|A pamphlet which will be provide knowledge to the patients
223864337|NCT05082077|DEVICE|LIVERguard|The LIVERguard is an FDA cleared and is a CE-marked medical device intended to be used for the static hypothermic preservation of livers during transportation and eventual transplantation into a recipient using cold storage solutions indicated for use with the liver. The intended organ storage time for the LIVERguard is up to 16 hours.
223864338|NCT03982303|DRUG|Hemay102|Hemay102 was administered through i.v. infusion for 4hrs.
223864339|NCT06554353|DEVICE|Oscillometer|The tremoFlo C-100 Airwave Oscillometry System is intended to measure respiratory system impedance using the Forced Oscillation Technique (FOT).
223864340|NCT01736891|DRUG|Rasagiline|Tablets, qd
223864341|NCT01736891|DRUG|Placebo|Tablets, qd
223864342|NCT06178588|PROCEDURE|Biopsy|Undergo tumor biopsy
223864343|NCT06178588|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223864344|NCT06178588|PROCEDURE|Computed Tomography|Undergo PET/CT scan
223864345|NCT06178588|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223864346|NCT06178588|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
223864347|NCT06178588|BIOLOGICAL|Sacituzumab Govitecan|Given IV
223864348|NCT00841633|DRUG|Induced hypertension with norepinephrine|Hypertension will be induced with norepinephrine. Administration of norepinephrine results in vasoconstriction, leading to an increase in blood pressure. The normal blood pressure of the patient will be calculated as the average MAP of the day before the start of the study. To achieve the intended hypertension (30 mmHg above the normal MAP for patients allocated to index group 2) in most cases a dose of 100-300 ng/kg/minute must be administered. Norepinephrine will be started on a dose of 100 ng/kg/minute, after which the dosing will be adjusted to achieve the desired blood pressure level. The maximum dose to be used in the study is 1000 ng/kg/minute. Norepinephrine is administered through the central venous catheter.
223864349|NCT01909778|DRUG|BI 201335|single oral doses
224076379|NCT05286801|PROCEDURE|Computed Tomography|Undergo CT and/or PET-CT
224076380|NCT05286801|PROCEDURE|Echocardiography Test|Undergo ECHO
224076381|NCT05286801|OTHER|Fludeoxyglucose F-18|Given FDG
224076382|NCT05286801|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
224076383|NCT05286801|PROCEDURE|Positron Emission Tomography|Undergo PET-CT and/or FDG-PET
224076384|NCT05286801|BIOLOGICAL|Tiragolumab|Given IV
224076385|NCT05286801|PROCEDURE|X-Ray Imaging|Undergo x-rays
223864350|NCT06480812|DIETARY_SUPPLEMENT|Synbiotic|"The proposed protocol will provide a simple but robust intervention study using a synbiotic (pre and probiotic combination) in order to improve our understanding of the mechanisms linking nutrition to health outcomes that are mediated by the gut microbiome.~This pilot study will comprise a controlled randomised intervention in which participants will be grouped into the active synbiotic arm or the control arm. The ratios will be 10g of the prebiotic supplement and 170ml of kefir. Randomisation will control for equal distribution of age and biological sex; characteristics that may confound between group comparisons and will be assessed by analysis of baseline data."
223864351|NCT05750823|DRUG|Ruxolitinib Cream|Ruxolitinib cream will be applied twice daily for upto 48 weeks
224076386|NCT03470129|DEVICE|fissure sealing|sealing of occlusal fissures with either the conventional sealant, Helioseal F, or the new sealant, Helioseal F Plus, which provides an additional feature and an improved formulation
224076387|NCT06378346|OTHER|Observation|Participants will not receive glycyrrhizin
224076388|NCT06378346|DRUG|Glycyrrhizin - 75 mg|Participants will either receive 75 mg orally daily
224076389|NCT06378346|DRUG|Glycyrrhizin - 150 mg|Participants will receive 150 mg orally daily
224076390|NCT04537208|BIOLOGICAL|CoV2 preS dTM-AF03 (low-dose)|Pharmaceutical form: liquid; route of administration: intramuscular injection
224076391|NCT04537208|BIOLOGICAL|CoV2 preS dTM-AF03 (high-dose)|Pharmaceutical form: liquid; route of administration: intramuscular injection
224076392|NCT04537208|BIOLOGICAL|CoV2 preS dTM-AS03 (low-dose)|Pharmaceutical form: liquid; route of administration: intramuscular injection
224076393|NCT04537208|BIOLOGICAL|CoV2 preS dTM-AS03 (high-dose)|Pharmaceutical form: liquid; route of administration: intramuscular injection
224076394|NCT04537208|BIOLOGICAL|CoV2 preS dTM (high-dose) without adjuvant|Pharmaceutical form: liquid; route of administration: intramuscular injection
223864352|NCT06357143|OTHER|REMOVE|"INITIAL STAGE:~* Aim: Recover mobility~* Exercises: Passive therapy, isometric exercises focused on middle deltoid.~* Goal: 80º passive flexion, 45º abduction, 5 N of abduction force STRENGTHENING STAGE~* Aim: Enhance scapulohumeral rhythm and strength rotator cura~* Exercises: Active-assisted therapy, isotonic exercises between 45-90º of forward flexión and abduction with dumbbells and isometric exercises focused on internal and external rotation.~* Goal: 100º passive flexion, 90º lateral abduction, 10 N of abduction force INTENSIVE STAGE~* Aim: Improve motor control and increase cross-sectional muscular área~* Exercises: Rowe with resistance band, wall push ups, lateral elevation with dumbbles, active external and internal rotation.~* Goal: 15 N of abduction force FUNCTIONAL STAGE~* Aim: Develope daily life activities~* Exercises: Overhead tasks, rowe with Kettlebell, internal and external rotations with resistance bands~* Goal: 20 N of abduction force"
223864353|NCT06357143|OTHER|CONTROL|Patients will undergo standard care which consists of an initial consultation with the physiotherapist to receive some recommendations about exercises, progression and health education
223864354|NCT03687892|DEVICE|continuous Theta Burst Stimulation|Continuous Theta Burst Simulation will be applied in a continuous manner resulting in cortical excitability.
223864355|NCT03687892|DEVICE|intermittent Theta Burst Stimulation|Intermittent Theta Burst Stimulation will be applied in an intermittent manner resulting in cortical inhibition.
223864356|NCT05754814|OTHER|Malignant lymph nodes|Patients with a condition; either lymphoma on the neck or head and neck cancer with lymph node metastases on the neck.
223864357|NCT05245786|BIOLOGICAL|Copper Cu 64 Anti-CEA Monoclonal Antibody M5A|Given IV
223864358|NCT05245786|PROCEDURE|Imaging Technique|Undergo imaging
223864359|NCT05968573|OTHER|Video Format with Captions|A video with captions created by the research team will be played to persuade patients to participate in HIV and Hepatitis C (HCV) screening.
223864360|NCT05968573|OTHER|Video Format without Captions|A video without captions created by the research team will be played to persuade patients to participate in HIV and Hepatitis C (HCV) screening.
223864361|NCT05968573|OTHER|Health Educator|The video created by the research will be compared to a healthcare provider in terms of effectiveness in getting patients screened for HIV/HCV.
223864362|NCT05854017|DIETARY_SUPPLEMENT|Theanine for stress relief formulation|Theanine for stress relief formulation tablet
223864363|NCT05854017|DIETARY_SUPPLEMENT|Placebo|Placebo tablet
223864364|NCT06261398|BEHAVIORAL|BETTER: motivational interviewing and text messaging|Motivational interviewing to encourage individuals to address their social needs and engage with text messages that allow individuals to connect to their care team, a local organization that can help them address their social needs, and/or a resource that enables them to find help to address their needs based on their zip code.
223864365|NCT06261398|BEHAVIORAL|Standard of care|No motivational interviewing or text messages will be provided.
223864366|NCT04860336|OTHER|Observational|Observational
223864367|NCT06476067|PROCEDURE|Surgery|Esophagectomy
223864368|NCT06229392|BIOLOGICAL|Fluzone Quadrivalent|Successive cohorts of participants (3 participants per tumor type per cohort) will each be started on a fixed dose of the influenza vaccine. For the first cohort, patients will receive Fluzone Quadrivalent - (Sanofi Pasteur) - 60mcg/0.5mL (standard dose IT flu shot, or dose level 0) intratumorally on day -6 +/- 1 day and day 0 or 1. For the second cohort, patients will receive Fluzone High-Dose Quadrivalent - (Sanofi Pasteur) - 240mcg/0.7mL (high dose IT flu shot, or dose level 1) intratumorally on day -6 +/- 1 day and day 0 or 1. has context menu
223864369|NCT04482400|BEHAVIORAL|NEAT!2|8 week sedentary reduction program
223864370|NCT04482400|BEHAVIORAL|MyKneeGuide|8 week surgery recovery education program
223864371|NCT05216510|BIOLOGICAL|TNX-2110|TNX-2110 represents epitopes of multiple proteins from SARS-CoV-2 and is administered intradermally.
223864372|NCT05216510|BIOLOGICAL|TNX-2120|TNX-2120 represents the spike protein and is administered intradermally.
223864373|NCT05216510|BIOLOGICAL|TNX-2130|TNX-2130 represents non-spike proteins and is administered intradermally.
223864374|NCT05216510|BIOLOGICAL|CANDIN|Candida albicans antigens to be administered intradermally as a positive control.
223864375|NCT05216510|BIOLOGICAL|Diluent|Diluent consists of phosphate buffer, polysorbate 20 and mannitol and will be administered intradermally as a negative control.
223864376|NCT02281838|DRUG|labetalol/hydralazine/enalapril|Blood pressure will be treated with intravenous labetalol (10 mg starting dose)/hydralazine (5 mg starting dose)/enalapril (1.25 mg starting dose).
223864377|NCT04541914|DIAGNOSTIC_TEST|5-gene classification model|Peripheral blood marker-based molecular diagnostic method for AMR in ABOiKT
223864378|NCT05930041|PROCEDURE|Experimental CSP|Either CSP is performed for 10-19 mm nonpedunculated colorectal polyps.
223864379|NCT05930041|PROCEDURE|Active Comparator HS-EMR|Either HS-EMR is performed for 10-19 mm nonpedunculated colorectal polyps.
224076395|NCT04537208|BIOLOGICAL|Placebo (0.9% normal saline)|Pharmaceutical form: liquid; route of administration: intramuscular injection
224076396|NCT05869773|DRUG|JZP258|0.5 g/ml calcium, magnesium, potassium, and sodium oxybates oral solution
224076397|NCT05105100|PROCEDURE|Biopsy|Tumor tissue collection
223864380|NCT06779448|OTHER|Evaluation of objective and subjective stress parameters caused by local anesthesia during treatments|Patients were divided according to the randomization procedure. infiltration anesthesia (Maxicaine Forte, Artikain, VEM Drug, Turkey) was performed with a 20-gauge needle. Following the administration of anesthetic, an appropriate size rubber dam and metal clamp was placed i and pit and fissure sealant was applied. The stress parameters of the subjects were recorded at three measurement points. At the conclusion of the treatment, pain perception was evaluated subjectively using the WBFPRS and VAS.
224076398|NCT05105100|PROCEDURE|Biospecimen Collection|Intravenously Blood draw
224076399|NCT06136234|BEHAVIORAL|Caring Contacts|Caring Contacts are brief, periodic messages sent over 1 year that express unconditional care and concern
223864381|NCT06779448|OTHER|Evaluation of objective and subjective stress parameters caused by topical anesthesia during treatments|Patients were divided i according to the randomization procedure. The topical anesthetic agent (EMLA, AstraZeneca, Cotia, São Paulo, Brazil) was applied using a disposable dental Q-tip for 10-20 seconds. Following the administration of anesthetic, an appropriate size rubber dam and metal clamp was placed i and pit and fissure sealant was applied. The stress parameters of the subjects were recorded at three measurement points. At the conclusion of the treatment, pain perception was evaluated subjectively using the WBFPRS and VAS.
223864382|NCT06779448|OTHER|Evaluation of objective and subjective stress parameters caused by the application of rubber dam during treatments in the patient and dentist|Patients were divided into 4 subgroups according to the randomization procedure: topical anesthesia and infiltrative anesthesia before the placement of the clamp and also cotton roll application other side of the arch. The topical anesthetic agent (EMLA, AstraZeneca, Cotia, São Paulo, Brazil) was applied using a disposable dental Q-tip for 10-20 seconds and infiltration anesthesia (Maxicaine Forte, Artikain, VEM Drug, Turkey) was performed with a 20-gauge needle. Following the administration of anesthetics, an appropriate size rubber dam and metal clamp was placed in the mandibular arch, and pit and fissure sealant was applied to the opposite arch. The stress parameters of the subjects and dentist were recorded at three measurement points. At the conclusion of the treatment, pain perception was evaluated subjectively using the WBFPRS and VAS.
223864383|NCT06779448|OTHER|Evaluation of the objective and subjective stress parameters caused by the application of cotton rolls during treatments in the patient and dentist|Patients were divided into 4 subgroups according to the randomization procedure: topical anesthesia and infiltrative anesthesia before the placement of the clamp and also cotton roll application other side of the arch. The topical anesthetic agent (EMLA, AstraZeneca, Cotia, São Paulo, Brazil) was applied using a disposable dental Q-tip for 10-20 seconds and infiltration anesthesia (Maxicaine Forte, Artikain, VEM Drug, Turkey) was performed with a 20-gauge needle. Following the administration of anesthetics, an appropriate size rubber dam and metal clamp was placed in the mandibular arch, and pit and fissure sealant was applied to the opposite arch. The stress parameters of the subjects and dentist were recorded at three measurement points. At the conclusion of the treatment, pain perception was evaluated subjectively using the WBFPRS and VAS.
223864384|NCT04811053|DRUG|HR021618|Treatment group A: HR021618 injection
223864385|NCT04811053|DRUG|Placebo|Treatment group B: Saline injection
223864386|NCT04795128|BIOLOGICAL|IBI322|Recombinant anti-human CD47/PD-L1 bispecific antibody injection
223864387|NCT05489211|DRUG|Datopotamab deruxtecan (Dato-DXd)|Intravenous (IV) Antibody drug conjugate
223864388|NCT05489211|DRUG|Capecitabine|Administered orally
223864389|NCT05489211|DRUG|5-Fluorouracil|Administered as an IV
223864390|NCT05489211|DRUG|Volrustomig|Administered as an IV
223864391|NCT05489211|DRUG|Carboplatin|Administered as an IV
223864392|NCT05489211|DRUG|Leucovorin LV|Administered as an IV
223864393|NCT05489211|DRUG|Bevacizumab|Administered as an IV
223864394|NCT05489211|DRUG|Rilvegostomig|Administered as an IV
223864395|NCT05489211|DRUG|Prednisone/ prednisolone|Administered orally
223864396|NCT05489211|DRUG|Cisplatin|Administered as an IV
223864397|NCT05959356|DRUG|Cetuximab + Envafolimab + mFOLFOXIRI|Cetuximab 500mg/m² + envafolimab 200mg + irinotecan 150 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5-FU 2400 mg/m² civ. 46h all on day 1 of each 2 weeks cycle up to max 8 cycles, followed by maintenance with cetuximab 500mg/m² + envafolimab 200mg + leucovorin 200 mg/m² + 5-FU 2400 mg/m² civ. 46h all on day 1 of each 2 weeks cycle until PD, unacceptable toxicity or patient's refusal.
223864398|NCT05959356|DRUG|Cetuximab + mFOLFOX6/FOLFIRI|Cetuximab 500mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5-FU 2400 mg/m² civ. 46h or cetuximab 500mg/m² + irinotecan 180 mg/m² + leucovorin 200 mg/m² + 5-FU 2400 mg/m² civ. 46h all on day 1 of each 2 weeks cycle up to max 8 cycles, followed by maintenance with cetuximab 500mg/m² + leucovorin 200 mg/m² + 5-FU 2400 mg/m² civ. 46h all on day 1 of each 2 weeks cycle until PD, unacceptable toxicity or patient's refusal.
223864399|NCT06448364|BIOLOGICAL|PF-07329640|an anti-lymphotoxin beta receptor agonist
223864400|NCT06448364|BIOLOGICAL|sasanlimab|A monoclonal antibody that blocks the interaction between PD-1 and PD-L1/L2
223864401|NCT06448364|BIOLOGICAL|bevacizumab|a monoclonal antibody that blocks VEGF
223864402|NCT05748067|PROCEDURE|SDF|Silver diamine fluoride
223864403|NCT05748067|PROCEDURE|HVGIC restoration|High viscosity glass ionomer restoration
223864404|NCT05748067|PROCEDURE|SSC|Stainless steel crown
223864405|NCT03858205|OTHER|Quality-of-Life Assessment|Ancillary studies
223864406|NCT03858205|OTHER|Questionnaire Administration|Ancillary studies
223864407|NCT03858205|RADIATION|Radiation Therapy|Receive low-dose radiation therapy
223864408|NCT05514717|DRUG|XMT-2056|XMT-2056 will be administered through a vein in your arm or port catheter (intravenously)
223864409|NCT05133362|DEVICE|Gait training with EksoNR|Participants will receive forward gait training with EksoNR
223864410|NCT05133362|PROCEDURE|Backward gait training with EksoNR|Participants will receive backward gait training with EksoNR
224076400|NCT06136234|BEHAVIORAL|Best Available Resources Alone|Participants will be offered information about best available resources and will receive an email summarizing the resources with links and contact information. These resources are tailored to best serve the participant based on information they share during the online survey or during conversations with study staff.
223864411|NCT01491698|PROCEDURE|Roux-en-Y pouch reconstruction (RYP)|Patients will be consented to the study and complete pre-surgical questionnaires. Final randomization will occur once the surgeon in the operating room has confirmed eligibility intraoperatively. The envelope will be opened, and the patient randomized to either receive RYP or RYC. There are no restrictions on how surgeons may create the RYC or RYP reconstruction, except that the pouch must be a minimum of 15 cm in length (from esophago-jejunal anastomosis to end of jejuno-jejunal anastomosis).
223864412|NCT01491698|PROCEDURE|conventional Roux-en-Y reconstruction (RYC)|Patients will be consented to the study and complete pre-surgical questionnaires. Final randomization will occur once the surgeon in the operating room has confirmed eligibility intraoperatively. The envelope will be opened, and the patient randomized to either receive RYP or RYC. There are no restrictions on how surgeons may create the RYC or RYP reconstruction, except that the pouch must be a minimum of 15 cm in length (from esophago-jejunal anastomosis to end of jejuno-jejunal anastomosis).
223864413|NCT04414683|PROCEDURE|staging surgery|laparoscopic or laparotomic staging surgery
223864414|NCT04510454|DIAGNOSTIC_TEST|Nasopharyngeal and throat/oropharyngeal swabs analyses by RT-PCR and ddPCR|Nasopharyngeal and throat/oropharyngeal swabs analyzed by both RT-PCR and ddPCR
223864415|NCT05947045|OTHER|Cognitive training via iPad|Participants will complete five sessions of the Cogmed training program on an iPad. Participants will complete sessions over the course of one to two weeks while on campus for radiotherapy. Each session will take place in the Psychology Clinic and consist of 15 to 20 minutes of Cogmed training.
223864416|NCT05947045|OTHER|Cognitive training via virtual reality|Participants will complete five sessions of the Cogmed training program within virtual reality. Participants will complete sessions over the course of one to two weeks while on campus for radiotherapy. Each session will take place in the Psychology Clinic and consist of 15 to 20 minutes of Cogmed training.
224076401|NCT05647226|COMBINATION_PRODUCT|Digital therapeutic and intensive lifestyle programme|Initial 12-week LED and behaviour education app.
224076402|NCT05647226|OTHER|Standard of care|Standard of care.
223864417|NCT06368089|OTHER|Inspiratory muscle training (IMT) group|The IMT group receives inspiratory muscle training of 50%MIP, 6 breaths/set 10 sets/day for 7 days combined with conventional chest physiotherapy including; percussion, vibration, postural draining, positioning, and passive range of motion.
223864418|NCT06368089|OTHER|Early mobilization (EM) group|The ER group received active exercise in sitting, standing, and marching 30 minutes/day for 7 days with conventional chest physical therapy
223864419|NCT05800977|BIOLOGICAL|Prizloncabtagene autoleucel|Prizlon-cel is a novel 2nd generation 4-1BB bispecific chimeric antigen receptor T-cell (CAR-T) targeting both CD19 and CD20 antigens
223864420|NCT00256243|DRUG|Doxorubicin|60 mg/m2 IV, bolus once every 14 days x 2-4 cycles
223864421|NCT00256243|DRUG|Cyclophosphamide|600 mg/m2 IV once every 14 days x 2-4 cycles
223864422|NCT00256243|DRUG|Paclitaxel|80 mg/m2 IV over 1 hour once weekly for 9-12 doses beginning two weeks after completion of last AC dose
223864423|NCT00256243|DRUG|Carboplatin|Area under the concentration curve (AUC) 2 IV once weekly for 9-12 doses beginning two weeks after completion of last AC dose
223864424|NCT00256243|DRUG|GM-CSF|250 μg/mL IV on day 5-14 of each subcutaneous cycle of doxorubicin and injection cyclophosphamide
223864425|NCT00256243|DRUG|Trastuzumab|AUC 2 IV weekly for 12-16 doses beginning two weeks after completion of last AC dose
223864426|NCT03969823|DRUG|Tagrisso|Osimertinib 80mg once daily until disease progression
223864427|NCT02813486|BIOLOGICAL|Biological: GC3111 vaccine|0.5mL, Intramuscular
223864428|NCT02813486|BIOLOGICAL|Biological: Boostrix® vaccine|0.5mL, Intramuscular
223864429|NCT01603810|OTHER|OCT|Optical coherence tomography of periocular basal cell carcinoma
223864430|NCT02490982|DRUG|Teriflunomide|The prescription of Teriflunomide administered orally as a 14mg daily compound to RRMS patients.
223864431|NCT03310996|OTHER|Transcranial direct current stimulation|tDCS is an established research tool for non-invasive modulation of neuroplasticity. It has shown promise as a neurorehabilitation tool and demonstrated positive effects in various clinical conditions such as Alzheimer's, stroke, childhood psychosis, epilepsy and dystonias. tDCS uses low-intensity DC currents to modulate spontaneous neuronal network activity by altering the resting membrane potential.
223864432|NCT01267838|PROCEDURE|PCI|PCI of bifurcation lesions with double stenting
223864433|NCT03207854|PROCEDURE|Biospecimen Collection|Undergo collection of peripheral blood, bone marrow, and tissue
223864434|NCT03207854|OTHER|Laboratory Biomarker Analysis|Correlative studies
223864435|NCT03207854|OTHER|Questionnaire Administration|Ancillary studies
223864436|NCT04894318|BEHAVIORAL|Low-fat and low-cholesterol diet|Low-fat (\<30% of total energy) and low-cholesterol (\<200mg/day) diet total of 12 weeks
223864437|NCT05061693|DRUG|INCB054707|Oral; Tablet
223864438|NCT05061693|DRUG|Placebo|Oral; Tablet
223864439|NCT06129370|DEVICE|Standard practice|Lexicomp and manual calculator
223864440|NCT06129370|DEVICE|Medication dosing software|Medication dosing software
223864441|NCT04472806|DRUG|Toripalimab|"Toripalimab, humanized anti-PD-1 monoclonal antibody is a programmed death-1 (PD-1) immune checkpoint inhibitor antibody, which selectively interferes with the combination of PD-1 with its ligands, PD-L1 and PD-L2, resulting in the activation of lymphocytes and elimination of malignancy theoretically.~Toripalimab treatment after chemotherapy in combination with Endostar, 240 mg, Q3W, up to 2 years."
223864442|NCT04472806|DRUG|chemotherapy in combination with Endostar|chemotherapy+ Endostar
223864443|NCT05561803|RADIATION|Photobiomodulation Therapy|Focal low-level laser therapy, Red Laser (wavelength 633 nm to 685 nm), or Infrared Laser Laser (wavelength 780 nm to 830 nm), with a low-intensity laser equipment of 100 mW and a cross-sectional area of the device beam of 0.0434 cm². The parameters are 1 to 3 J per point, with equidistant points of 1.5 to 2 cm, covering the entire length of the open lesion. Therapy is carried out every 48 hours until the total wound healing, regardless of the number of sessions required.
223864444|NCT01219218|DEVICE|Cardiac Extracorporeal Shockwave Therapy generator (Cardiospec)|Energy Density - 0.09 mJ/mm2
223864445|NCT06966297|DIAGNOSTIC_TEST|Multispectral optoacoustic tomography|Measurement of calf muscle Perfusion via Multispectral optoacoustic Tomography
223864446|NCT06966076|PROCEDURE|calisthenic training|"COMMAND AND TARGET MUSCLE GROUP~1. LEG RAISES (LEG STRENGTH) LIE ON YOUR BACK WITH YOUR LEGS STRAIGHT. LIFT LEGS OFF THE GROUND IN FRONT. LOWER THEM BACK DOWN WITHOUT TOUCHING THE FLOOR.~   TARGETS HIP FLEXOR~2. SIDE LEG RAISES (LEG STRENGTH) LIE ON YOUR BACK WITH YOUR LEGS STRAIGHT. LIFT LEGS OFF THE GROUND AND TAKE IT TO SIDE MAXIMALL WITHOUT TOUCHING THE FLOOR.~   TARGETS LOWER ABS AND HIP ABDUCTORS~3. GLUTE BRIDGES ( BACK STRENGTH) LIE ON YOUR BACK WITH YOUR KNEES BENT. LIFT YOUR HIPS OFF THE GROUND, SQUEEZING YOUR GLUTES. LOWER AND REPEAT. TARGETS GLUTES AND HAMSTRINGS.~4. QUADRUPTED POSITION:~   ASK THE PATIENT TO RIDE YOUR KNEES PLAY 'HORSY' AND SLOWLY MOVE YOUR KNEES TO AND FRO AND SIDEWAYS SO THAT TO SHIFT WEIGHT FROM SIDE TO SIDE.~5. WALL LEG LIFTS IN STANDING STAND WITH YOUR SIDE FACING A WALL. LIFT YOUR LEG OUT TO THE SIDE AS HIGH AS POSSIBLE.~   LOWER AND REPEAT WITH THE OTHER LEG. TARGETS HIP ABDUCTERS~6. KNEELING~7. VERTICLE LIFT~8. Squats"
223864447|NCT06966076|PROCEDURE|Conventional physical therapy group|CONVENTIONAL PHYSICAL THERAPY CONVENTIONAL PHYSICAL THERAPY Week 1 Orientation of exercises Week 2-3 UPPER LIMB (20 MINS) Lifting a glass of water with elbow extended Moving objects from the table to a box Combing Hairs LOWER LIMB (20 MINS) Lifting the lower extremity and lowering in o nto a footstool sit to stand Standing up with loaded trey in hand corner hamstring stretch butterfly stretch Week 4-5 UPPER LIMB (20 MINS) Grasping and releasing objects lifting a glass of water to a level of 90° shoul der flexion with an extended elbow Moving objects from the table to a box LOWER LIMB (20 MINS) Reciprocal leg flexion and extension single leg stance Kicking a ball Week 5-8 UPPER LIMB (20 MINS) Opening Jars Throwing Balls Same As previous weeks LOWER LIMB (20 MINS) Squatting
223864448|NCT03261596|DRUG|Mebendazole|Participants will be randomized using a 1:1 ratio to one of the two arms. Study participants eligible for treatment will be randomly assigned to one of the two treatment arms using a computer-generated stratified block randomization code.
224076403|NCT05746767|BEHAVIORAL|Supported dCBT|In the supported dCBT condition, each patient will receive complete access to the SilverCloud platform. In addition, patients will be assigned a supporter who will provide regular support based on an established coaching support protocol. Supporters will conduct a brief engagement call (30-40 minutes) to provide an overview of SilverCloud, identify goals, and set expectations, introduce themselves, and orient the participant to the role of the peer supporter. Supporters will then provide weekly check-ins through phone calls or messaging. Participants will be able to communicate with the supporters through the platform through messaging or sharing activities for additional discussion. The major goal of the support is to promote use of the platform.
223864449|NCT06423742|DEVICE|Transcranial direct current stimulation|The device used for tDCS in this study was DC-Stimulator Plus (NeuroConn GmbH, Ilmenau, Germany). The localization of stimulation area (DLPFC) was determined according to the 10/20 EEG system. Non-conducting, elastic head strap was placed around the head to prevent displacement during stimulation. The recording electrode covered with 5 x 7 cm sized traditional rectangular sponge was soaked with 6-7 mL of 0.9% NaCl saline solution per side and placed on the F3 (anode, left frontal) and F4 (cathode, right frontal) EEG location. Subjects were given 2 mA stimulation intensity for 20 min per session including fade-in and fade-out times for 20 seconds each. Interval between each session was 20 min. Sham procedure has been adopted a Fade In of current, Short Stimulation, Fade Out (FISSFO) protocol that consist of initial ramp up for 20 seconds, 2 mA stimulation for 40 seconds, and 20 seconds for ramp down. To check to impendence, brief current of 110 µA over 15ms every 550ms was delivered.
223864450|NCT03052361|DRUG|Ondansetron|Patients allocated to this arm will receive ondansetron in the ED triage.
223864451|NCT03052361|DRUG|Placebos|similar looking and tasting liquid placebo
223864452|NCT02266641|BEHAVIORAL|nutrition counseling|Pregnancy diet (include one-carbon nutrients)
223864453|NCT02266641|DIETARY_SUPPLEMENT|multivitamin supplement|
223864454|NCT01677104|DRUG|GLP-1|GLP-1 and its analogues will be compared with placebo with and without prior DPP-IV inhibition
223864455|NCT01677104|DRUG|Placebo|
223864456|NCT01789489|DEVICE|Medison Accuvix V20, sonde 3D5-9EK (Endovaginal 3 dimensional echography)|
223864457|NCT03439904|OTHER|Pharmaceutical care|Patients receive pharmaceutical care including individualized evaluation and intervention of adherence, efficacy and safety in cancer pain treatment.
223864458|NCT03709693|DEVICE|SternaLock Blu|Sternal closure will be accomplished using SternaLock Blu plates and screws in combination with single-wire method of sternal reduction.
223864459|NCT00258895|BIOLOGICAL|DAPTACEL®: DTaP|0.5 mL, Intramuscular
223864460|NCT00258895|BIOLOGICAL|DAPTACEL®: DTaP|0.5 mL, Intramuscular
223864461|NCT06325969|DIAGNOSTIC_TEST|Detect the immune function of peripheral blood samples|Flow cytometry was used to detect the immune function of peripheral blood samples of PCOS patients.
223864462|NCT02318771|RADIATION|Radiation Therapy (RT)|Undergo RT
223864463|NCT02318771|DRUG|MK-3475|Given IV
223864464|NCT04267250|DRUG|PF-06700841|60 mg by mouth (PO) once daily (QD).
223864465|NCT04267250|DRUG|Ethinyl estradiol (EE) and levonorgestrel (LN)|Oral tablet containing 30 mcg EE and 150 mcg LN.
223864466|NCT03213249|OTHER|Normal saline|Intraoperative pocket irrigation with normal saline
223864467|NCT03213249|DRUG|Cefazolin|Cefazolin, gentamicin, and bacitracin will be mixed together in 1 L of normal saline and placed in the pocket created by the breast once it is removed
223864468|NCT03213249|PROCEDURE|Skin biopsy|Biopsies will be taken from the skin at the time of mastectomy and at the time of implant exchange.
223864469|NCT03213249|PROCEDURE|Bilateral skin- or nipple-sparing mastectomies|Standard of care
223864470|NCT03213249|DEVICE|Tissue expander|Standard of care
223864471|NCT03213249|DEVICE|Breast implant|"* Standard of care~* Either breast implant or autologous flap"
223864472|NCT03213249|PROCEDURE|Autologous flap|"* Standard of care~* Either breast implant or autologous flap"
223864473|NCT03213249|OTHER|Acellular dermal matrix sling|Standard of care
223864474|NCT03213249|DRUG|Gentamicin|Cefazolin, gentamicin, and bacitracin will be mixed together in 1 L of normal saline and placed in the pocket created by the breast once it is removed
223864475|NCT03213249|DRUG|Bacitracin|Cefazolin, gentamicin, and bacitracin will be mixed together in 1 L of normal saline and placed in the pocket created by the breast once it is removed
223864476|NCT03750942|DEVICE|Adhesix® monofilament polypropylene mesh (Bard Davol)|The intervention group will receive preventive mesh placement and in the control group no mesh is placed, the stoma is closed according to standard practise.
223864477|NCT04010448|BIOLOGICAL|TV P2-VP8|90 µg of the TV P2-VP8 vaccine IM plus oral placebo administered on study days 1, 29 and 57
223864478|NCT04010448|BIOLOGICAL|Rotarix|Rotarix® PO plus IM placebo administered on study days 1, 29 and 57
223864479|NCT00373529|DRUG|clofarabine|"Induction cycle 1: cycle 1 of clofarabine 30 mg/m\^2/day as a 1-hour intravenous infusion for 5 consecutive days.~Reinduction (cycle 2) and/or Consolidation cycles (cycles 2-6): cycles repeated minimally every 28 days, of clofarabine 20 mg/m\^2/day as a 1-hour intravenous infusion for 5 consecutive days."
223864480|NCT01714882|BEHAVIORAL|Stress Management & Resiliency Training|The couples in this group will attend the SMART in-person training class at the beginning of the study and will be taught a structured relaxation program.
223864481|NCT01714882|BEHAVIORAL|Stress Management DVD|The couples in this group will receive a Mayo Clinic Stress Management DVD.
223864482|NCT00442117|DRUG|mometasone furoate dry powder inhaler|MF DPI 200 mcg, two puffs once daily PM (total of 400 mcg/day) for 12 weeks.
223864483|NCT00442117|DRUG|Budesonide DPI|Budesonide (BUD) DPI 200 mcg, two puffs twice daily (total of 800 mcg/day) for 12 weeks.
223864484|NCT02140138|BIOLOGICAL|CV9104|
223864485|NCT02140138|DEVICE|needle free injection device (Tropis®)|
223864486|NCT04016025|BEHAVIORAL|Adherence to topical standard therapy assessed|Adherence defined as percentage of patients applying at least aimed daily dose
223864487|NCT01477879|OTHER|Versabase gel with sarracenia purpurea 20% liquid extract|Topical application of gel/plant mix to lesions
223864488|NCT01477879|OTHER|placebo (versabase gel only)|versabase gel only
223864489|NCT04151407|DRUG|Drug 601|Drug is a kind of recombinant anti-VEGF humanized monoclonal antibody injection.
223864490|NCT00305591|DRUG|l-ornithine l-aspartate|
223864491|NCT00707135|DRUG|Rapamycin|Rapamycin given once weekly in escalating doses. Higher dose levels will be split with the half the dose given on day 1 and half the dose on day 2 (24 hours later).
223864492|NCT00486005|DRUG|Olanzapine Hydrochloride|
223864493|NCT00486005|DRUG|Nizatidine|
223864494|NCT00486005|DRUG|Placebo|
223864495|NCT02801071|DRUG|15g L-citrulline daily p.o.|
223864496|NCT02801071|DRUG|Placebo|
223864497|NCT00630786|DRUG|Panitumumab|Administered by intravenous infusion
223864498|NCT00630786|DRUG|Conatumumab|Administered by intravenous infusion
223864499|NCT02412774|BEHAVIORAL|DBs at the end of the main meal + Diet|Subjects are asked to have 250 ml DBs at the end of their lunch as the main meal, while they are on a multidisciplinary diet plan for 24 weeks.
223864500|NCT02412774|BEHAVIORAL|Water at the end of the main meal+ Diet|Subjects are asked to have 250 ml water at the end of their lunch as the main meal, while they are on a multidisciplinary diet plan for 24 weeks.
223864501|NCT04009577|DRUG|LEM 5 mg|LEM tablet.
223864502|NCT04009577|DRUG|LEM 10 mg|LEM tablet.
223864503|NCT00866866|DRUG|N-Acetyl Cysteine|600 mg PO BID
223864504|NCT00866866|DRUG|Placebo|1 tab PO BID
223864505|NCT03690596|OTHER|NRT + QuitBuddy|QuitBuddy treatment app and 1 month supply of 4 mg nicotine lozenge
223864506|NCT03690596|OTHER|NRT + QuitBuddy-Recall|QuitBuddy-Recall treatment app and 1 month supply of 4 mg nicotine lozenge
223864507|NCT03690596|OTHER|Treatment as Usual|1 month supply of 4 mg nicotine lozenge
223864508|NCT03393078|DEVICE|transcranial magnetic stimulation with real coil|TMS with real coil is a noninvasive technique to activate and modify the activity of the neurons
223864509|NCT03393078|DEVICE|transcranial magnetic stimulation with sham coil|TMS with sham coil is a placebo
223864510|NCT02234739|DRUG|Voriconazole|2-week long intravenous instillation of voriconazole
223864511|NCT02165761|DEVICE|GORE® Hybrid Vascular Graft|
223864512|NCT02165761|DEVICE|Non-heparin bonded synthetic graft|
223864513|NCT00238836|BEHAVIORAL|Self-management of chronic illness|
223864514|NCT00176839|PROCEDURE|Stem Cell Transplant|Certain cancers can be treated by giving patients stem cells that come from someone else. This is called a stem-cell transplant. As part of the transplant process, patients receive high doses of chemotherapy and/or radiation to treat their underlying disease, such as cancer. As one of its effects, this treatment also kills the healthy stem cells that are already in the marrow. The transplant provides new stem cells for the patient from a healthy donor; that replace the bone marrow and allow the blood counts to recover.
223864515|NCT00176839|DRUG|Busulfan|Prior to transplantation, subjects will receive BUSULFAN via the central venous line, four times a day for four days (days -7 through -4).
223864516|NCT00176839|DRUG|Cyclophosphamide|Prior to stem cell transplantation, subjects will receive CYCLOPHOSPHAMIDE via the central venous line once a day for two days on days -3 and -2.
223864517|NCT00176839|DRUG|Melphalan|MELPHALAN will be given via the central venous line for one day, on day -1, prior to stem cell transplantation.
223864518|NCT00176839|DRUG|G-CSF|G-CSF is to be given daily IV beginning on day +1 until ANC 2.5 x 109/L.
223864519|NCT00176839|DRUG|ATG|ATG will be administered to umbilical cord blood recipients.
223864520|NCT00788853|OTHER|No treatment given|No treatment is given
223864521|NCT02951013|OTHER|restrictive transfusion|Transfusion will start when the hemoglobin concentration falls below 6.0 g/dL
223864522|NCT02951013|OTHER|liberal transfusion|
223864523|NCT01227876|DRUG|Ster|prednisolone 1% ophthalmic suspension
223864524|NCT01227876|DRUG|Pred Fort|prednisolone 1% ophthalmic suspension
223864525|NCT06522295|DEVICE|ultrasonography|Ultrasonographic Measurement of Optic Nerve Sheath Diameter
223864526|NCT05004935|DIETARY_SUPPLEMENT|beetroot juice|single intake of beetroot juice containing 800mg nitrates
223864527|NCT05004935|OTHER|nitrate|single intake of 800mg nitrates
223864528|NCT02534064|DIETARY_SUPPLEMENT|CALIN+|Consumption of 2 CALIN+ pots per day during 16 weeks and follow up without product intake during 8 weeks.
223864529|NCT02534064|DIETARY_SUPPLEMENT|CALIN+|Consumption of 1 CALIN+ pot per day during 16 weeks and follow up without product intake during 8 weeks.
223864530|NCT04605016|DEVICE|Hydrophilic surface implants|A dental implant with hydrophilic surface will be placed and restored in single-tooh gaps of the posterior region of the mandible or maxilla.
223864531|NCT04605016|DEVICE|Hydrophobic surface implants|A dental implant with hydrophobic surface will be placed and restored in single-tooh gaps of the posterior region of the mandible or maxilla.
224076404|NCT05746767|BEHAVIORAL|Unsupported dCBT|Unsupported dCBT provides all features of the SilverCloud platform with the exception of support features (structured interactions with supporter and share features). Patients will be provided complete access to SilverCloud and instructed to use it for 8-weeks. Patients will receive weekly automated messages to encourage engagement.
223864532|NCT04826575|OTHER|High intensity inspiratory and expiratory muscle training|"Inspiratory Muscle Training will be performed using the Threshold inspiratory muscle trainer device (Threshold IMT®, Philips Respironics, Inc., Murrysville, PA, USA).~Expiratory muscle training (EMT) will be performed using the Threshold positive expiratory pressure device (Threshold PEP®, Philips Respironics, Inc., Murrysville, PA, USA) or Expiratory Muscle Strength Trainer EMST 150TM (Aspire Products), depending on the initial MEP.~Patients will train 2 times a day, 7 days per week, for 2 weeks."
223864533|NCT00202865|BIOLOGICAL|infliximab|Infliximab 3 mg/kg infusions at Weeks 0, 2, and 6 and every 8 weeks thereafter. Subjects who lose response according to a pre-specified criteria at weeks 22 or 38 visit will increase the dose of infliximab to 5 mg/kg (rounded up to the nearest vial).
224076405|NCT06367920|DIAGNOSTIC_TEST|Magnetic Resonance Imaging, Behavioral assessments|Magnetic Resonance Imaging, Behavioral assessments
223864534|NCT00202865|BIOLOGICAL|Placebo|Placebo infusions at Weeks 0, 2, and 6. Subjects will be evaluated at Week 12 after which they will receive infliximab 3 mg/kg at Weeks 16, 18, and 22 then every 8 weeks. Subjects who lose response according to a pre-specified criteria at weeks 22 or 38 visit will increase the dose of infliximab to 5 mg/kg (rounded up to the nearest vial).
223864535|NCT05323838|BEHAVIORAL|Subjective quality of live|The groups fill out scientifically validated questionnaires to know the differences in perceived stress, anxiety, quality of life, depression, quality of sleep, pain, fatigue, and impact of the disease on daily life.
223864536|NCT05323838|PROCEDURE|Blood extraction|Blood collection by qualified personnel.
223864537|NCT05323838|BEHAVIORAL|Accelerometry|To know the objective differences between physical activity/sedentary lifestyle, caloric expenditure and quality of sleep, we used the accelerometry technique
223864538|NCT05323838|DIETARY_SUPPLEMENT|Synbiotic complement|"On two separate days, the baseline-tests and final-tests were conducted. All participants performed a series of tests, before which they had to fast. The order and schedule (8 am) of the tests was the same for the final-test and the same materials and procedures were used. A period of 30 consecutive days elapsed between the base-line and final tests, during which the participants had to ingest their supplement (synbiotic)."
223864539|NCT02881944|BEHAVIORAL|Low FODMAP Diet|Diet low in foods containing Fermentable Oligo-, Di-, and Mono-saccharides and Polyols
223864540|NCT02881944|BEHAVIORAL|High FODMAP Diet|Typical diet of foods containing Fermentable Oligo-, Di-, and Mono-saccharides and Polyols
223864541|NCT02020616|DRUG|LY3053102|Administered SC
223864542|NCT02020616|DRUG|Exenatide ER|Administered SC
223864543|NCT02020616|DRUG|Placebo|Administered SC
223864544|NCT02020616|DRUG|Metformin|Administered orally (PO)
223864545|NCT03199235|DEVICE|Lucky Iron Fish|200g iron ingot that is placed in boiling water for 10+ minutes, and then removed. The water is then used to eating and drinking.
223864546|NCT03199235|OTHER|enhanced standard of care|parents of subjects are provided oral iron supplementation per usual clinical care at clinic and followed for their anemia in addition to study visits
223864547|NCT06334549|DRUG|Ephedrine-P|after induction of anesthesia, use total intravenous anesthesia maintained with propofol
223864548|NCT06334549|DRUG|Phenylephrine-P|after induction of anesthesia, use total intravenous anesthesia maintained with propofol
223864549|NCT06334549|DRUG|Norepinephrine-P|after induction of anesthesia, use total intravenous anesthesia maintained with propofol
223864550|NCT06334549|DRUG|Ephedrine-S|after induction of anesthesia, use inhalation anesthesia maintained with sevoflurane
223864551|NCT06334549|DRUG|Phenylephrine-S|after induction of anesthesia, use inhalation anesthesia maintained with sevoflurane
223864552|NCT06334549|DRUG|Norepinephrine-S|after induction of anesthesia, use inhalation anesthesia maintained with sevoflurane
223864553|NCT00786942|PROCEDURE|high tibial osteotomy|addition of bone graft to fill the osteotomy gap
223864554|NCT00786942|PROCEDURE|higi tibial osteotomy|the gap of the tibia is unfilled
223864555|NCT00006276|DRUG|Micellar Paclitaxel|
223864556|NCT02771938|OTHER|Radiotherapy before surgery|Radiotherapy followed by mastectomy and DIEP flap reconstruction
223864557|NCT05235789|OTHER|Rational-Emotive-Behavioral Therapy|"The structure of the REBT sessions includes the following points:~1. Determine specific goals that explain what the participant want to achieve through the content of the session.~2. Explain the level of skills to be achieved in each session.~3. Development of the session, reminder of the previous session, review of homework (from the second session to the 8th). Irrational beliefs and disruptive thoughts will be worked on together with the participant in order to achieve an improvement in their emotional state. Key messages with healthier alternatives that make your daily life easier.~4. Establishing homework. Using the REBT Toolbox with Key Messages.~5. Individual psychosocial work will be recorded in the computerized medical history."
223864558|NCT05235789|OTHER|Control Group usual care|In the control group, for each center , the depression is treated as usual with the conventional treatment, according to national and international guidelines.
223864559|NCT02523651|GENETIC|DPSC injection|A 0.5ml saline preparation containing 1000000 DPSCs were injected at the local periodontal defects immediately after periodontal scaling and root planing.
223864560|NCT02523651|OTHER|Placebo|A 0.5ml saline preparation were injected at the local periodontal defects immediately after periodontal scaling and root planing.
223864561|NCT04576858|DIAGNOSTIC_TEST|Circulating tumor DNA|Measurement of circulating tumor DNA from plasma over a period of 2 years.
223864562|NCT02980718|BEHAVIORAL|intensive olfactory training|
223864563|NCT02980718|BEHAVIORAL|ordinary olfactory training|
223864564|NCT02620618|DRUG|Intravitreal Infliximab|ocular safety and efficacy in treating inflammation in uveitis patients with Behcets Disease
223864565|NCT05632432|PROCEDURE|Epicardial AAMs-patch transplantation|Perioperative assembly of an AAMs-patch with epicardial transplantation onto the epicardium of the scarred myocardium at the end of CABG surgery
223864566|NCT05632432|DIAGNOSTIC_TEST|RNA-stabilized whole blood sampling|Collection (preoperative and at 6-month-follow-up) of TEMPUS(TM) stabilizing whole blood for epitranscriptomics-oriented measurements
223864567|NCT05632432|DIAGNOSTIC_TEST|Plasma sampling|Collection (preoperative and at 6-month follow-up) of blood-derived both RNA-stabilized and non-stabilized plasma aliquots for epitranscriptomic-oriented and other CVD biomarker oriented measurements, respectively
223864568|NCT05632432|DIAGNOSTIC_TEST|Transthoracic echocardiography|To assess cardiac structure and function both pre- and postoperatively (at both hospital discharge and 3-month follow-up)
223864569|NCT05632432|DIAGNOSTIC_TEST|Late-gadolinium enhancement cardiac magnetic resonance imaging (LGE-CMRI)|To assess detailed cardiac structure (i.e. interstitial fibrosis) and function both preoperatively and at 6-month follow-up postoperatively.
223864570|NCT05632432|OTHER|Symptom-scaling|Standardised evaluation of IHD and HF-related angina pectoris (CCS) and dyspnea (NYHA) and life quality (RAND36) pre- and postoperatively (at both 3- and 6-month follow-up).
223864571|NCT05632432|OTHER|6-minute walking test (6MWT)|Standardised assessment of physcial capacity pre- and postoperatively (at 6-month follow-up)
223864572|NCT05632432|DIAGNOSTIC_TEST|Blood sampling (NT-proBNP)|Collection of a blood sample measurement of NT-proBNP by an accredited hospital laboratory pre- and postoperatively (at both 3- and 6-month follow-up).
223864573|NCT05632432|DIAGNOSTIC_TEST|Transesophageal echocardiography|Performed by the perfusion-anesthesiologist at the beginning of the CABG surgery to evaluate both LAA and RAA for blood flow velocities, anatomy, possible sludge and thrombus.
223864574|NCT05632432|PROCEDURE|Epicardial collagen-based patch transplantation|Epicardial transplantation of the collaged-based patch material without the AAMs onto the epicardium of the scarred myocardium at the end of CABG surgery.
223864575|NCT04215471|DRUG|PD-L1 Antibody SHR-1316|Neoadjuvant therapy with immunoreagent (PD-L1 antibody SHR-1316) for resectable oesophageal squamous cell carcinoma
223864576|NCT01595906|PROCEDURE|Ventilated Helmet|The ventilation system is installed on the inner part of the helmet and connected to a bellows and an energy source placed on the vest worn by the soldier. The system's working principal is based on air perfusion with a small ventilator.
223864577|NCT00412321|DRUG|CNTO 328|Patients will receive administrations of CNTO 328 with dose ranging from 3 mg/kg to 12 mg/kg weekly, every 2 or 3 weeks till Day 43 in cohorts 1 to 6. After cohort 6, if the clinical response is found to be suboptimal, the patients will receive 9 mg/kg or 12 mg/kg every 3 weeks in cohorts 7a. Participants in Cohort 7a who will experience intolerable toxicity after escalating to or receiving 12 mg/kg every 3 weeks will have the option of reverting to a dose of 9 mg/kg every 3 weeks if the investigator felt it was clinically indicated. In cohort 7b participants will receive 12 mg/kg CNTO 328 every 3 weeks.
223864578|NCT00028678|DRUG|dalteparin|
223864579|NCT00028678|RADIATION|radiation therapy|
223864580|NCT00327665|BIOLOGICAL|11-valent pneumococcal vaccine GSK513026|Two-dose intramuscular injection. Each group receiving one of the 3 formulations
223864581|NCT00327665|BIOLOGICAL|Pneumo 23™|Single-dose intramuscular injection.
223864582|NCT00327665|BIOLOGICAL|Placebo|1 intramuscular injection.
223864583|NCT00327665|BIOLOGICAL|10-valent pneumococcal vaccine GSK513026|Two-dose intramuscular injection
224076406|NCT04748874|PROCEDURE|Immediate mNC-FET|In the immediate arm, patients undergo mNC-FET in the menstrual cycle immediately following oocyte retrieval and failed fresh embryo transfer or freeze-all.
224076407|NCT06408077|OTHER|Water administration|Intravenous administration of water (Aqua ad injectabilia) until a decrease of plasma sodium of 5 to 8 mmol/l has been achieved
224076408|NCT06408077|OTHER|NaCl-Administration|Intravenous administration of NaCl 3% until an increase of plasma sodium of 5 to 8 mmol/l has been achieved
224076409|NCT06420245|DEVICE|Orion TM Amniotic Membrane Allograft|The intervention is a sterile allograft made from dehydrated extracellular matrix, designed to promote wound healing by providing a reliable and protective wound covering. Amniotic membranes are hypothesized to promote healing in open wounds by serving as a scaffold to support native tissue ingrowth, encouraging angiogenesis, and limiting microbial spread.
224076410|NCT06420245|PROCEDURE|Standard of Care (SOC)|Standard wound care entails surgical debridement as needed to remove all non-viable tissue, screening for infection and probing of the wound for bone, weekly application of a collagen alginate primary dressing, and off-loading using a removable diabetic offloading cam-walker or total contact cast.
223864584|NCT04905225|PROCEDURE|Ascending aortic replacement|Surgical access will be performed through a median sternotomy. Ascending aortic repair is performed under conditions of cardiopulmonary bypass (CPB) and MHCA with unilateral ACP via innominate artery with a flow rate of 8-10 ml/kg/min and perfusion pressure of 60-80 mmHg. Once CPB is instituted, the aortic cross-clamp is applied, and the heart is arrested with antegrade cardioplegia. Hemiarch replacement involves resection lesser curve of the aortic arch from the base of the innominate artery (Zone 0) to a point immediately distal to the nadir of the lesser curvature (Zone 3 or Zone 2 if the left subclavian artery was too far).
223864585|NCT03978468|OTHER|Interagency Collaboration (ICollab)|The intervention has the following components: 1) ICollab Component 1: The Nurse Clinician will review clinic and emergency room (ER) visit notes for clinicians' recommendations and communicate these to the home health nurse (HHN). 2) ICollab Component 2a: The intervention team will meet weekly by phone with HHNs (6 times/ child). The Nurse Clinician will document meeting notes for each child in the ER, communicate this information with the HHN, and share it with the primary care provider (PCP) by routing the note through the ER or faxing the note. 3) ICollab Component 2b: The Nurse Clinician will be available as a resource for the HHN during regular work hours for clinical problem-solving. 4) ICollab Component 2c: the intervention team physician will offer her contact information for clinical problem-solving about the child to the PCP. The Nurse Clinician will communicate with the PCP about the plan developed in the meetings, and changes to plan of care.
223864586|NCT03978468|OTHER|Usual Care|The primary medical team identifies the need for home health nursing services for Children with Medical Complexity(CMC), and the hospital care coordinators help caregivers choose a home health agency. Hospital-based physicians write home health orders that are communicated to the home health agency. The clinic manager of the home health agency uses these orders to develop the home health plan of care, Centers for Medicare \& Medicaid Services(Form CMS-485) and communicates the plan to the agencies' HHNs. PCPs oversee the home health plan of care.
223864587|NCT06974292|DRUG|[14C]VC005|Take a suspension of 50 mg VC005 ,containing about 120 μCi \[14C\]VC005, in fasting within 5 minutes
223864588|NCT05990894|DRUG|Methylprednisolone|In the steroid therapy group, patients received standard treatment plus steroid therapy. Steroid therapy protocol is as follows: 500 mg methylprednisolone once a day, intravenous drip for 3 days, then reduced to 80 mg once a day, intravenous drip for 5 days, and changed to oral methylprednisolone/prednisone 1 mg per kilogram body weight, gradually tapered off by a dose of 10 mg per week.
223864589|NCT01071993|DRUG|placebo|pre-treatment with placebo (80 mg 12 hours prior to the procedure and 40 mg pre-procedure)
223864590|NCT01071993|DRUG|atorvastatin|pre-treatment with atorvastatin (80 mg 12 hours prior to the procedure and 40 mg pre-procedure)
223864591|NCT00296907|BEHAVIORAL|Brief psychological intervention|Psychoeducation, provision of medical knowledge, coping skills training
223864592|NCT06266455|DIETARY_SUPPLEMENT|Standardized Fortification|Fortification with liquid, bovine-based HMF to assumed human milk content of 24kcal/oz
223864593|NCT06266455|DIETARY_SUPPLEMENT|Adjustable Fortification|Additional liquid protein supplementation to maintain serum BUN levels within goal range (9-14mmol/dL)
223864594|NCT06266455|DIETARY_SUPPLEMENT|Adjustable Fortification|Additional liquid protein and/or MCT oil supplementation to maintain protein, fat, and energy intake within goal range based upon mid-infrared human milk analysis
223864595|NCT03467555|DEVICE|Class II correction using miniplates in zygomatic region|
223864596|NCT01967654|OTHER|Technical Assistance, training and clinical reminders|
223864597|NCT01967654|OTHER|Referral to Community Health Worker|
223864598|NCT00147277|DEVICE|Implantable Cardiac Defibrillator|Medtronic Marquis Family ICD, capable of Anti Tachy Pacing (ATP) for Fast Ventricular Tachycardia (FVT) via Ventricular Fibrillation (VF) zone
223864599|NCT05127499|OTHER|progressive relaxation exercises|progressive relaxation exercises will do
223864600|NCT02496806|DIETARY_SUPPLEMENT|Seaweed extract|Treatment capsule containing seaweed extract (treatment)
223864601|NCT06372912|PROCEDURE|Sleeve gastrectomy, Roux-en-Y gastric bypass, mini-gastric bypass, SADIS, intragastric balloon insertion, and gastric band placement are bariatric surgeries.|Sleeve gastrectomy: reduces stomach size. Roux-en-Y gastric bypass: limits calorie absorption. Mini gastric bypass: achieves weight loss with fewer incisions. SADIS: combines sleeve gastrectomy with small bowel bypass. Intragastric balloon: reduces stomach volume. Gastric banding: restricts food intake.
223864602|NCT03092713|BEHAVIORAL|Combined cognitive (Compensatory Cognitive Training - CCT) and vocational rehabilitation (Supported Employment)|The CCI-SE Group receives a manualized Group-based cognitive psycho-educational intervention (10 sessions), combined with supported employment at their work-place.
223864603|NCT03092713|BEHAVIORAL|Control Group|The Control Group receives usual assessment and treatment at Oslo University Hospital.
223864604|NCT04324242|OTHER|abdominal hallowing maneuver|abdominal hallowing maneuver includes tucking navel in and up. To be able to control the effect of breathing it was instructed to start the maneuver at the end of the expiration. During the maneuver it was instructed to focus on increasing the thickness of TrA without increasing the thickness of IO and EO
223864605|NCT04157530|DEVICE|wang-bu-liu-xing|wang-bu-liu-xing applied on the surface of Jinming and Qiuhou acupoints
223864606|NCT04157530|DEVICE|acupuncture|acupuncture applied to Qingming and Qiuhou with Der-qi
223864607|NCT04157530|DEVICE|Electroacupuncture|acupuncture, but the needles of Qinming and Qiuhou connected to the electroacupuncture machine after Der-qi, the frequencies of stimulus were 6 Hz, the intensity of stimulus was minimal visible muscle twitch
223864608|NCT05817409|DRUG|Intrathecal Baclofen Pump|intrathecal baclofen treatment
223864609|NCT02031471|DRUG|tocilizumab|Fixed dose of 162 mg subcutaneously weekly
223864610|NCT03960619|BEHAVIORAL|coping skills training|We aim to test a combined coping skills training and activity coaching protocol that: first, is feasible and acceptable, and second, improves physical disability, as well as pain, fatigue, distress, and physical activity in HCT patients. We propose a novel intervention protocol that uses a hybrid in-person and mHealth intervention delivery model.
223864611|NCT04050631|BEHAVIORAL|maternal arrest simulation on L&D floor|AFE on L\&D
224076411|NCT04298658|DIAGNOSTIC_TEST|Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders-5 (DSM-5)sleep disorders-revised|Structured Clinical Interview For DSM-5 Sleep Disorders-Revised (SCISD-R) - is a semi structured interview for diagnosing sleep disorders according to Diagnostic and Statistical Manual of Mental Disorders-5 (DSM-5)
224076412|NCT04298658|DIAGNOSTIC_TEST|Resmed ApneaLink Air device (Resmed, San Diego, CA).|Home Sleep Test (HST) will measure airflow (i.e., nasal pressure) using a nasal cannula and oxygen saturation to identify apnea and hypopnea and calculate an apnea hypopnea index (AHI; number of apnea and hypopnea per hour).
223864612|NCT05112354|DRUG|systemic and intratympanic injection of steoid|"-If the patient come at first two weeks of onset of hearing loss the patient will be manged by oral corticosteroid in the form of ,prednisolone60mg in two divided doses for 2 weeks.~2-Patient will be manged by 5 sessions of intratympanic steroid after failure of systemic steroid and patient who come after 2 weeks of onset of hearing loss , each session will be 3 days apart. The injectable material will be 1ml of hydrocortisone 8ml. The injection will be done under local anesthesia and microscope magnification. A pack of lidocaine gel will be applied in the external canal for 10 minutes in EAC to induce anesthesia by using insulin syringe 1ml bore.~An 8 ml of hydrocortisone will be injected in the ME through posteroinferior part of TM All patients will receive antiviral therapy in the form of acyclovir,valcyclovir All the patient will receive vasodilator."
223864613|NCT03301454|DRUG|pursuit of chemotherapy|Treatment with LV5FU2 (5-FU, Calcium Levofolinate) - paclitaxel, regular tumor evaluation, best supportive care Other authorized treatment : usual paclitaxel pre-treatment consisting of Dexamethasone, Chlorpheniramine and ranitidine, at 15 and 1 day before the actual paclitaxel treatment
223864614|NCT00002415|DRUG|Tenofovir disoproxil fumarate|
223864615|NCT03505619|BEHAVIORAL|ASSIST 1.0|10 weeks intervention applying a person-centred approach by using goal setting and smart products.
223864616|NCT05059730|OTHER|Zero Degrees Cold Environment|Participants will be exposed to zero degrees celsius environment.
223864617|NCT05059730|OTHER|Eight Degrees Cold Environment|Participants will be exposed to eight degrees celsius environment.
223864618|NCT05059730|OTHER|Ten Degrees Cold Environment|Participants will be exposed to Ten degrees celsius environment.
223864619|NCT05059730|OTHER|40 degrees Hot Environment|Participants will be exposed to 40 degrees celsius hot environment.
223864620|NCT02657200|OTHER|survey|questionnaire assessing the knowlegde, attitude and practices regarding spontaneous abortion
223864621|NCT00233519|DRUG|SomatoKine/IPLEX|"Cohort 1: self-administered subcuteanous injections of 0.5 mg/kg/day of iPlex for 8 weeks, followed by 1.0 mg/kg/day of iPlex for 16 weeks.~Cohort 2: consecutive 8 week treatments of 0.5, 1.0, and 2.0 mg/kg/day of iPlex for a total of 24 weeks by self-administered subcuteanous injection."
223864622|NCT00868569|PROCEDURE|TACE + folfox 4|"tace: oxaliplatin 100mg + fudr 1g + mmc 10mg + iodine 2ml~folfox4"
223864623|NCT00868569|PROCEDURE|TAC + folfox4|"tac: oxaliplatin 100mg + fudr 1g + mmc 10mg~folfox4"
223864624|NCT03230396|DIETARY_SUPPLEMENT|Vitamingum Sport|Vitamin -supplemented chewing gum
223864625|NCT03230396|DIETARY_SUPPLEMENT|Vitamingum Immunity|Vitamin -supplemented chewing gum
223864626|NCT03230396|DIETARY_SUPPLEMENT|Placebo|Control chewing gum. No vitamin content.
223864627|NCT04704778|COMBINATION_PRODUCT|Transcutaneus electrostimulation therapies|"Sterile steel acupuncture needles of 0.25x13mm, disposable AcuBEST brand, and portable electro-stimulator equipment KWD- will be used. The superficial area of the skin of the masseter muscle will be cleaned with alcohol.~Two needles will be placed in each masseter muscle, the area to be punctured is the origin of the masseter muscle or superficial area of the mandibular condyle anterior to the atrial tragus approximately 1cm away, insertion of the masseter muscle at the angle of the mandible. The two double alligator cables will be connected to the head of the needles. The positive pole will be connected at the origin of the masseter muscle and the negative pole at the insertion.~The parameters to be used will be are two frequency bands (210Hz-10140Hz.); amplitude 3050 volts, pulse duration: 40100 msec; and the output intensity: 0.70 (for 100Hz). The treatment time will be 20 minutes."
223864628|NCT04704778|COMBINATION_PRODUCT|Percutaneus electrostimulation therapies|"Kendall® MediTrace 100 conductive adhesive ECG electrodes (pediatric) 2.4 cm in diameter, and portable KWD-808 electrostimulator equipment will be used.~The superficial area of the skin will be cleaned, two electrodes will be placed on each muscle (superficial area of the mandibular condyle and at the angle of the jaw). The current leads will then be connected to the KWD-808 electroacupuncturist to the patient.~Current will be transmitted with a square waveform, 210Hz-10140Hz of frequency, 3050 volts of amplitude and 40100 msec pulse time. The treatment time will be 20 minutes."
223864629|NCT04704778|DIAGNOSTIC_TEST|Oclusal splint|"The occlusal splint is worn 24 hours a day, removed for eating and brushing teeth. It is washed with neutral liquid hand soap.~For the preparation, an impression of the maxillary dental arches will be taken with alginate; It is made with acetate .060 and .080.~Relining is done with self-curing acrylic on the occlusal surface of the splint"
223864630|NCT03289611|BIOLOGICAL|sFlt-1 / PlGF ratio|"* Ambulatory management if sFlt-1 / PlGF ratio is below 38~* usual management if sFlt-1/PlGF is between 38 and 85.~* If the ratio is \> 85, monitoring will be intensified and patient hospitalization will be continued"
223864631|NCT02891525|DIETARY_SUPPLEMENT|50g glucose|
223864632|NCT02891525|DIETARY_SUPPLEMENT|25g fructose|
223864633|NCT02891525|DIETARY_SUPPLEMENT|220mg acesulfame-K|
223864634|NCT02891525|DIETARY_SUPPLEMENT|250mL tap water|
223864635|NCT02425917|DEVICE|geko|neuromuscular electrostimulator
223864636|NCT02425917|DEVICE|IPC-Calf|IPC used on calf with or without geko
223864637|NCT00000760|DRUG|Ro 24-7429|
223864638|NCT00000760|DRUG|Zidovudine|
223864639|NCT00000760|DRUG|Didanosine|
223864640|NCT04279548|DEVICE|Deep Brain Stimulation|Patients will have a stimulation electrode inserted neurosurgically by neuronavigation to the PSI, on the target used for drTMS, on the insula contralateral to the pain side. After surgery will be randomized to be in in either the ON or OFF DBS
223864641|NCT05619861|BIOLOGICAL|CAR-T|Patients will receive CAR-T treatment
223864642|NCT01980641|BEHAVIORAL|Educational intervention|All subjects received an educational intervention consist in an educational advice provides by the therapist to improve the adherence of the treatment.
223864643|NCT01980641|DEVICE|Smartphone-based application|Smartphone-based application group (SG) sample will have a reminder. The app will provide the advice previously given by the therapist in the participants' homes.
223864644|NCT03122574|OTHER|Lavender Aromatherapy|100% pure lavender aromatherapy was administered using person essential oil diffusor sachets, consisting of three drops of oil on a surgical sponge covered in a sealed plastic packet.
223864645|NCT03122574|OTHER|Jojoba Aromatherapy|100% pure jojoba aromatherapy was administered using person essential oil diffusor sachets, consisting of three drops of oil on a surgical sponge covered in a sealed plastic packet. This colorless, odorless oil was used as a placebo comparator.
223864646|NCT04074577|DIAGNOSTIC_TEST|Standard technique First|colonoscopy without automated polyp detection software
223864647|NCT04074577|DIAGNOSTIC_TEST|combination technique First|automated polyp detection software
223864648|NCT00005772|DEVICE|Induced hypothermia|Whole-body cooling using the Blanketrol II or III Units in the Automatic Control Mode with a YSI 400 series temperature probe placed in the distal esophagus over a 96-hour period
223864649|NCT00005772|DEVICE|Control|Control group: standard care
223864650|NCT05905913|DRUG|ANT3310|ANT3310 will be infused over 3 hours
223864651|NCT05905913|DRUG|ANT3310-placebo|ANT3310-placebo will be infused over 3 hours
223864652|NCT05905913|DRUG|ANT3310|ANT3310 will be infused over 3 hours every 8 hours
223864653|NCT05905913|DRUG|ANT3310-placebo|ANT3310-placebo will be infused over 3 hours every 8 hours
223864654|NCT05905913|DRUG|ANT3310-placebo|ANT3310-placebo will be infused over 3 hours as a single dose as part of the drug drug interaction study, then every 8 hours as part of the repeat doses study.
223864655|NCT05905913|DRUG|ANT3310|ANT3310 will be infused over 3 hours as a single dose as part of the drug-drug interaction study, then every 8 hours as part of the repeat doses study.
223864656|NCT05905913|DRUG|Meropenem|Meropenem will be infused over 3 hours as a single dose as part of the drug-drug interaction study, then every 8 hours as part of the repeat doses study.
223864657|NCT05905913|DRUG|Meropenem-placebo|Meropenem-placebo will be infused over 3 hours as a single dose as part of the drug-drug interaction study, then every 8 hours as part of the repeat doses study.
223864658|NCT00658996|DEVICE|SofLens DD Toric|daily disposable wear contact lens for 2 weeks
223864659|NCT00658996|DEVICE|Ciba Vision Focus Dailies Toric Contact Lens|daily disposable wear contact lens for 2 weeks
223864660|NCT06261996|DRUG|Fospropofol|Fospropofol is administered after admission to the room at a pumping rate of 1 mg/kg/h.
223864661|NCT03072953|DRUG|APD334|APD334 active treatment
223864662|NCT06174636|PROCEDURE|Application of abdominal weight|Application of variable weight on the abdomen to reach a 5 mmHg increase in IAP
223864663|NCT03956004|OTHER|OM1 Dell Shared Decision Making Tool|Decision aid meant to improve shared decision making among patients and providers.
223864664|NCT03956004|OTHER|Education material from OM1 Dell Shared Decision Making Tool|Investigator-written educational material and quiz to test knowledge of osteoarthritis and treatment options.
223864665|NCT06575413|OTHER|Direct Electrical Stimulation|The patients underwent SEEG with at least one electrode targeting the claustrum. The investigators used the claustrum as a target for both mapping and CCEP, recording changes in cortical electrical activity.
223864666|NCT06974305|RADIATION|FDG-PET/fMRI/EEG imaging|Subject will undergo simultaneous EEG, fMRI, and FDG-PET imaging. This includes the use of a standard injected radioactive marker used in PET imaging.
223864667|NCT05503251|OTHER|Best Practice|Receive usual care
223864668|NCT05503251|BEHAVIORAL|Neuropsychological Assessment|Undergo neuropsychological evaluation
223864669|NCT05503251|OTHER|Quality-of-Life Assessment|Ancillary studies
223864670|NCT05503251|OTHER|Questionnaire Administration|Ancillary studies
223864671|NCT02570542|PROCEDURE|leukapheresis|
223864672|NCT02570542|DRUG|Plerixafor|Following enrollment, patients will be CD34+ stem cell mobilized at the discretion of the treating attending physician with the plerixafor for a maximum of 4 apheresis days, for the achievement of ≥ 7 x106 CD34+ cells/kg.
223864673|NCT02570542|DRUG|carmustine, etoposide, cytarabine, melphalan|Carmustine 300 mg/m2 day -6 Etoposide 100 mg/m2 q12hrs x 8 doses day - 5 thru day -2 Cytarabine 100 mg/m2 q12hrs x 8 doses day - 5 thru day -2 Melphalan 140 mg/m2 day -1 BEAM dosages may be adjusted per institutional dose adjustments based on body weight.
223864674|NCT02570542|PROCEDURE|Autologous Stem Cell Transplantation|
223864675|NCT02619266|OTHER|Acupuncture|Acupuncture is the practice of inserting thin needles into specific points to improve health and well-being.
223864676|NCT02619266|OTHER|Sham Acupuncture|Sham acupuncture is used as a control in scientific studies that test the efficacy of acupuncture in the treatment of various illness or disorders.
223864677|NCT02619266|DRUG|Megestrol Acetate|Megestrol Acetate 160mg tablet
223864678|NCT02619266|DRUG|Placebo(Megestrol Acetate)|Starch pill manufactured to mimic Megestrol Acetate 160mg tablet
223864679|NCT01123928|BEHAVIORAL|Video and counseling for cataract patients|Intervention includes: (1) a 5-10 min video consisting of testimony from a previous cataract patient and a doctor; (2) a 10-15 min pre-operative counseling session with a trained nurse, and (3) a 5 min post-operative counseling session with a trained nurse.
223864680|NCT04178941|BEHAVIORAL|Audit and Feedback|The audit and feedback intervention includes providing each hospital's own continuous pulse oximetry use data back to them on a weekly basis for review and action.
223864681|NCT04178941|BEHAVIORAL|Educational outreach|Educational outreach includes staff-targeted educational materials and outreach sessions summarizing the current evidence and guideline recommendations for continuous pulse oximetry use in bronchiolitis.
223864682|NCT04073914|BEHAVIORAL|Type 1 Teamwork Program|Psychoeducational web program
223864683|NCT03161392|DIAGNOSTIC_TEST|Follow-up|"Group No ductal lesion will be submitted to follow-up with periodic breast ultrasonography/mammography every 6 months for 2 years."
223864684|NCT03161392|DIAGNOSTIC_TEST|Ultrasound-guided percutaneous biopsy|"Group Ductal lesion will be submitted to ultrasound-guided percutaneous biopsy and the specimen will be histologically analysed."
223864685|NCT00755118|DRUG|Oxaliplatin|Oxaliplatin (I.V) 85mg/m2 on week 1 and week 3 every six weeks for 2 continuously until disease progression or the appearance of unacceptable toxicity
223864686|NCT00755118|DRUG|5-Fluorouracil|5-Fluorouracil (I.V) 1750mg/m2 on week 1,2,3 and 4 every six weeks for 2 continuously until disease progression or the appearance of unacceptable toxicity
223864687|NCT00755118|DRUG|Leucovorin|Leucovorin (I.V) 500mg/m2 on week 1,2,3 and 4 every six weeks for 2 continuously until disease progression or the appearance of unacceptable toxicity
223864688|NCT00755118|DRUG|Bevacizumab|Bevacizumab (I.V) 10mg/Kg on week 1 and week 3 every six weeks for 2 continuously until disease progression or the appearance of unacceptable toxicity
223864689|NCT00755118|DRUG|Irinotecan|Irinotecan (I.V) 110mg/m2 on week 2 and week 4 every six weeks for 2 continuously until disease progression or the appearance of unacceptable toxicity
223864690|NCT00755118|DRUG|Cetuximab|Cetuximab (I.V) 500mg/m2 on week 2 and week 4 every six weeks for 2 continuously until disease progression or the appearance of unacceptable toxicity
223864691|NCT01810263|DIETARY_SUPPLEMENT|high protein supplement|Dietary Supplement: high protein supplement
223864692|NCT00390728|DRUG|Insulin Glargine|
223864693|NCT04391283|DRUG|Osimertinib|The recommended dose is 80 mg osimertinib once a day until disease progression or unacceptable toxicity according to the prescription information and clinical practice. It can be taken with or without food at the same time each day.
223864694|NCT05593146|BEHAVIORAL|modified anteversion angle placement(( α-15°)±10°)|"Preoperative examination was conducted to determine a safe surgical margin in all patients. A 3D printed osteotomy guide combined with a 3D printed prosthesis pre- designed anteversion angle is assembled for reconstruction after tumor resection.~Once completed, intraoperative X-ray fluoroscopy was applied to evaluate the anteversion angle of the acetabular component. If the anteversion angle doesn't meet the predetermined criteria, it needs to be adjusted until it does."
223864695|NCT05593146|BEHAVIORAL|conventional anteversion angle placement ( α±10°)|"Preoperative examination was conducted to determine a safe surgical margin in all patients. A 3D printed osteotomy guide combined with a 3D printed prosthesis with predesigned anteversion angle is assembled for reconstruction following tumor resection.~Once completed, intraoperative X-ray fluoroscopy was applied to evaluate the anteversion angle of the acetabular component. If the anteversion angle doesn't meet the predetermined criteria, it needs to be adjusted until it does."
223864696|NCT06020651|DIAGNOSTIC_TEST|Arterial Doppler for Flow Mediated Reserve measurement|Arterial Doppler (ultrasound, no radiation, no contrast agent) and blood sampling twice for participants on ICIs
223864697|NCT02168335|OTHER|OrasaltsTM|OrasaltsTM mouthwash is composed of 119.5g of natural sea salt, Arnica montana 30C, Echinacea angustifolia 30C, Staphysagria 30C, Phosphorus 30C, Hepar sulphuris 30C, 0.27g cinnamon and 0.27g of liquorice
223864698|NCT02168335|OTHER|Sea salt|Unmedicated sea salt
223864699|NCT04727424|DIETARY_SUPPLEMENT|Spirulin Platensis|Two tablets every 12 hours since randomization through day 09 following randomization
223864700|NCT04727424|DRUG|Budesonide Powder|"One Fluvoxamine tablet every 12 hours since randomization through day 09. PLUS~01 Budesonide powder (inhalation) every 12 hours since randomization through day 09."
223864701|NCT04727424|DRUG|Fluoxetine 20 MG|"Two Fluoxetine tablets every day starting just after randomization through day 07.~PLUS~01 Budesonide powder (inhalation) every 12 hours since randomization through day 07."
223864702|NCT04727424|DRUG|Placebo|"Placebo oral tablets (10-day schedule):~Matching tablets started after randomization using the dosing regimen of 01 tablet every 12 hs starting at Randomization Day (Day 0) until end of Day 09 (total of 10 day schedule)~PLUS~Placebo Inhalation Therapy:~One dosing (inhalation puff) right after randomization (Day 0) followed by one puff BID for the following 09 days~OR~Paracetamol (07-day schedule - active comparator):~Paracetamol 500 mg tablets started after randomization using the dosing regimen of 01 tablet BID starting at Rand. Day (Day 0) until end of Day 06 (total of 07 days schedule - ANTICOV Arm)~OR~Matching tablets started after randomization using the dosing regimen of 02 tablets every 12 hs starting at Randomization Day (Day 0) until end of Day 09 (total of 10 day schedule)"
223864703|NCT05344300|OTHER|Temperature-measurement in lungs under sauna bath|Through a bronchoscopy procedure under an 88-92℃ environment, the air temperature is measured in the 1st, 2nd and 3rd bronchial segment, at 4th and 5th bronchial segment and at 6th-10th bronchial segment in resp. the right and left lung. The temperature is measured at time: 0 seconds (s), 15 s, 30 s, 45 s, 60 s, 75 s, 90 s, 105 s, 120 s, 135 s and 150 s.
223864704|NCT02163954|DRUG|Ticagrelor|After randomization, an initial loading dose of ticagrelor (180 mg) was given and maintenance doses (ticagrelor 90 mg twice daily) was treated for 14 days.
223864705|NCT02163954|DRUG|Clopidogrel|After randomization, an initial loading dose of clopidogrel (300 mg) was given and maintenance doses (clopidogrel 75 mg once daily) was treated for 14 days.
223864706|NCT00688519|DRUG|U0267|All treatments will be administered topically twice daily (morning and evening) for 8 weeks to areas affected with psoriasis (excluding face and scalp).
223864707|NCT00688519|DRUG|Vehicle|All treatments will be administered topically twice daily (morning and evening) for 8 weeks to areas affected with psoriasis (excluding face and scalp).
223864708|NCT04670419|OTHER|Viral clade|Disease outcomes are compared for patients infected with 2 different clades of a HEV gt 3 infection
223864709|NCT05429424|OTHER|Verum acupuncture group|"The acupuncturist disinfected the skin of the selected acupoints with alcohol, then vertically penetrated the skin with disposable stainless-steel needles (size, brand, Taiwan) to the depth predetermined for each point (between 8-25 mm, depending on the location of the acupoint) and achieved a deqi response, often described as a pressure, fullness, or achiness feeling around the acupoints."
223864710|NCT05429424|OTHER|Sham control group I|The needle does not penetrate the skin and retract in the handle while the acupuncturist needling into the skin. The participants easily believe their intervention owing to the sensation of needling into the skin that the device mimics. The needles were fixed with a plastic ring and micropore on the body of the participants without manipulation.
223864711|NCT05429424|OTHER|Sham control group II|"The acupuncturist disinfected the skin of the selected acupoints with alcohol, then vertically penetrated the skin with disposable stainless-steel needles (size, brand, Taiwan) to the depth predetermined for each point (between 8-25 mm, depending on the location of the acupoint) and achieved a deqi response, often described as a pressure, fullness, or achiness feeling around the acupoints."
223864712|NCT03546634|BIOLOGICAL|Sabin IPV|We select one Sabin IPV product, produced by China National Biotec Group, which is available for China's National Immunization Program in the selected study sites.
223864713|NCT05944822|OTHER|pro-inflammatory cytokines|compare the levels of pro-inflammatory cytokines in patients with Essure® contraceptive implants and in control patients with endometriosis or adenomyosis.
223864714|NCT00138138|DRUG|Ritalin|
223864715|NCT01180153|DRUG|S-1 oxaliplatin|S-1 (20mg, 25mg); L-OHP (50 mg)
223864716|NCT01353963|DRUG|desvenlafaxine succinate|50 mg tablet once daily
223864717|NCT03654235|OTHER|Health Education|6 pain neuroscience education sessions (10 hours) and delivery of printed reinforcement material.
223864718|NCT03654235|OTHER|Physical exercise|Group physical exercise program (18 sessions; 3 sessions/week) leaded by a physiotherapist. It includes exercises to improve strength, coordination, balance and aerobic capacity. Work with double tasks, recreational activities to overcome kinesiophobia and activities to do at home are used in the program.
223864719|NCT03654235|OTHER|Usual care in Primary Care Physiotherapy Units|"Treatment supported by the protocol of primary care of physiotherapy in the health service of Castilla y León that was in force at the time of the intervention.~Patients receive 15 sessions of analgesic electrotherapy, thermotherapy and standardized physical exercise"
224076413|NCT04298658|OTHER|Quantitative Sensory testing (QST)|All participants will undergo quantitative sensory testing for assessment of endogenous pain modulation using painful heat, mechanical, and cold stimuli in a laboratory session lasting approximately 1 hour.
224076414|NCT04298658|DIAGNOSTIC_TEST|OraQuick Advance Rapid HIV 1/2 Swab test|Participants who have an HIV negative status will complete the OraQuick Advance Rapid HIV 1/2 Swab test to confirm negative status.
223864720|NCT03210129|BEHAVIORAL|Motivational interviewing|"the patients of the motivational interviewing group will receive 12 motivational interviewing sessions within 12 weeks: 2 face-to-face sessions and 10 phone call sessions. The first and the seventh motivational interviewing sessions will be face-to-face sessions. An intervention is considered valid if a minimum of 10 sessions has been completed. The face-to-face motivational interviewing sessions will be administered at the Luxembourg Institute of Health (Strassen, Luxembourg). They generally last up to 30 minutes, while the motivational interviewing phone calls generally last up to 15 minutes. Thereby, patients in the motivational interviewing group will receive a total of approximately 3.5 hours of contact time over a period of 12 weeks.~Motivational interviewing techniques will explore self-assessed confidence, ambivalence, and personal values concerning changes in active lifestyle."
223864721|NCT03861949|OTHER|5 cmH2O CPAP|
223864722|NCT03861949|OTHER|head-up position|
223864723|NCT03055416|OTHER|Mobile Men App Prototype|Testing of app functionality
223864724|NCT06401174|BEHAVIORAL|Delivery of patient navigation|Clinics will receive educational materials and access a referral order for patient navigation. Iterative strategies will be used to increase CRC screening
223864725|NCT01694823|DRUG|CS-ACI|"Procedure: Self-control. Cells Sheet-Autologous Chondrocyte Implantation(CS-ACI) includes an arthroscopy for harvesting of cartilage 6-8 weeks prior to the open cartilage surgery. Other Names:~Cells Sheet-Autologous Chondrocyte Implantation （CS-ACI）"
223864726|NCT06974318|OTHER|ABCDEF Bundle to Prevent Delirium|The ABCDEF Care Bundle-comprising components focused on pain management (A), spontaneous awakening and breathing trials (B), choice of sedation and analgesia (C), delirium assessment and management (D), early mobility (E), and family engagement (F)-was developed to promote patient-centered care in the ICU and improve clinical outcomes. Nurses play a central role in the effective implementation of this bundle, given their continuous patient interaction and responsibility for early detection and response to delirium symptoms.
223864727|NCT06974318|OTHER|Standard Care to Prevent Delirium|Standard care inclued pain management, Glasgow Coma Scale evaluation, Richmond Agitation-Sedation Scale evaluation and control of the stimulations.
223864728|NCT06813976|DRUG|mFOLFORINOX|"mFOLFIRINOX every 2 weeks during 12 cycles (24 weeks):~* Oxaliplatin 85 mg/m²~* Irinotecan 150 mg/m²~* Leucovorin 400 mg/m²~* Fluorouracil 2400 mg/m² during 46 hours"
223864729|NCT06813976|DRUG|Capecitabine or gemcitabine|"investigator's choice:~* Capecitabine 1250 mg/m² BID, 2 weeks on, 1 week off during 8 cycles (24 weeks) OR~* Gemcitabine 1000 mg/m² in 30 min; 3 weeks on, 1 week of, during 6 cycles ((24 weeks)"
223864730|NCT06813976|OTHER|Quality of life questionnaires: QLQ-C30 and PAN26|Before treatment, during treatment (every 12 weeks in any treatment arm Until disease progression or end of follow-up) and after treatment discontinuation (30 days after the end of treatment)
223864731|NCT06813976|BIOLOGICAL|Biological assessment|Before each course of treatment and between courses of treatment if necessary
223864732|NCT06813976|DIAGNOSTIC_TEST|Paraclinical examinations|Every 3 months
223864733|NCT04592211|DRUG|olaparib+pembrolizumab+paclitaxel|olaparib, 100\~200mg, PO, bid, continuous Pembrolizumab 200mg, IV, q 3 weeks Paclitaxel 80mg/m2 IV, Q weekly
223864734|NCT02355158|DRUG|clonidine hydrochloride topical gel, 0.1%|
223864735|NCT04036058|OTHER|Universal gloving|The intervention will consist of all healthcare workers (nurses, providers, respiratory therapists, radiology and laboratory technicians, etc) utilizing universal gloving (non-sterile gloves) for all patient contacts in the units that are randomized to receive the intervention. If a patient in the intervention unit is known to have CDI or a multidrug-resistant organisms, both gowns and gloves will be used as is currently recommended. Signage denoting what type of precautions are needed will be utilized.
223864736|NCT06862908|OTHER|placebo|placebo administered subcutaneously(SC), once a week
223864737|NCT06862908|DRUG|IBI362|IBI362 administered subcutaneously(SC), once a week
223864738|NCT06240715|PROCEDURE|Umbilical cord milking|At delivery, the umbilical cord is grasped, and blood is pushed toward the infant 4 times before the cord is clamped. This procedure infuses a placental transfusion of blood into the infant and can be done in 1--15 seconds.
223864739|NCT06423781|DRUG|BHV-7000|BHV-7000 75 mg taken once daily
223864740|NCT06711315|BEHAVIORAL|Oral Mucosit Care Protocol|"The children in the intervention group were subjected to a four-stage intervention carried out by the nurse researcher. The practices in each stage were as follows.~Stage 1: Oral care protocol training to prevent oral mucositis Stage 2: Introduction and application of training material (brochure) Stage 3: Introduction and implementation of oral care calendar Stage 4: Implementation of oral care protocol"
223864741|NCT07041099|DRUG|CLN-978|Specified dose on specified days
223864742|NCT01128790|OTHER|Remote ischemic preconditioning|4 cycles x 5 mins upper limb blood pressure cuff inflation 20mmHg above systolic blood pressure
223864743|NCT01128790|OTHER|Sham Control|4 cycles x 5mins blood pressure cuff inflation to 10mmHg
223864744|NCT02186197|OTHER|Critical Care Ultrasound|A critical care ultrasound exam will be performed on all patients included in this study
223864745|NCT07059780|DEVICE|Virtual Reality Glasses|Participants in the intervention group wore virtual reality (VR) glasses during the gynecological examination. The VR content included immersive nature-themed scenes accompanied by calming background music. The intervention aimed to provide a multisensory distraction to reduce perceived anxiety and pain levels during the procedure.
223864746|NCT07060066|DEVICE|Active rTMS stimulation|Active H-coil delivered rTMS sessions will be given three times per treatment visit for up to 20 visits for about 4 weeks. There are about 30 minutes breaks between adjacent TMS sessions. Each TMS session takes about 3 to 4 minutes to complete.
223864747|NCT07060066|DEVICE|Sham rTMS stimulation|Sham H-coil delivered rTMS sessions will be given three times per treatment visit for up to 20 visits for about 4 weeks. There are about 30 minutes breaks between adjacent TMS sessions. Each TMS session takes about 3 to 4 minutes to complete.
223864748|NCT07061444|OTHER|Inspiratory Muscle Training|Inspiratory muscle training will be performed at 40% of MIP workload, 1 set of 8-10 diaphragmatic respirations for 15 minutes, with 5-10 seconds rest intervals between sets. 5 days a week, 2 sessions per day.
223864749|NCT07061444|OTHER|Functional Inspiratory Muscle Training|This study investigates the integration of functional inspiratory muscle training (IMT) with conventional physiotherapy. Patients will perform inspiratory muscle training using the threshold loading technique with the POWERbreathe IMT device, combined with functional exercises. The functional IMT protocol will be administered face-to-face, 3 days a week, for 30 minutes per session over a 6-week period. Resistance on the IMT device will be set to 40% of the patient's maximal inspiratory pressure (MIP) and adjusted weekly based on measured MIP values. Exercises will be categorized into three progressive difficulty levels (easy, medium, and hard), with each stage lasting 2 weeks. Patients will inhale through the POWERbreathe IMT device during exercise movements and exhale during the return phase, ensuring simultaneous respiratory muscle activation and functional training.
223864750|NCT07061444|OTHER|Sham Inspiratory Muscle Training|Control group will be performed at 10% of the MIP workload, 1 set of 8-10 diaphragmatic breaths for 15 minutes, with 5-10 seconds rest intervals between sets. 2 sessions per day, 5 days a week.
223864751|NCT07059676|DRUG|Zejula (Niraparib)|PARPi inhibitors have been incorporated into managing first-line advanced ovarian cancer with different approvals depending on homologous recombination (HR) status. Niraparib has received approval independent from HR status. Although the benefit is more remarkable in HR-deficient patients, there is no biomarker to predict sustained response to niraparib at the start of treatment helping the clinician to make decisions among the different treatment options.
223864752|NCT07060872|DIETARY_SUPPLEMENT|Spirulina Syrup|A natural dietary supplement derived from Spirulina algae, administered orally as a syrup formulation. Used as an adjunct therapy to assess its potential effect on reducing anxiety symptoms in children with non-idiopathic autism. Dosage and duration are standardized according to study protocol.
223864753|NCT07060872|DIETARY_SUPPLEMENT|Placebo Syrup|Placebo Syrup
223864754|NCT07060872|DRUG|Risperidone|Risperidone
224076415|NCT04298658|DIAGNOSTIC_TEST|Cluster of Differentiation 4 (CD4) and Viral load|Participants who have an HIV positive status will have blood tested for cluster of differentiation 4 (CD4) and Viral load to confirm positive status.
224076416|NCT05183568|BEHAVIORAL|Mindful Self-Compassion|Self-guided bibliotherapy (specific chapters to read each week) and daily use of a meditation app for 45 minutes
224076417|NCT06307106|DRUG|ketorolac and light marcaine|local injection at surgical site of 30 mg ketorolac and 7-1.5 mg\\kg\\dose light marcaine
224076418|NCT06307106|DRUG|light marcaine|local injection at surgical site of 7-1.5 mg\\kg\\dose light marcaine
224076419|NCT06307106|DRUG|Corticosteroids injection|local injection at surgical site of 40 mg\\ dose of dexamethasone
224076420|NCT06307106|DRUG|Diclofenac Sodium Gel|topical application of Diclofenac Sodium Gel
224076421|NCT06307106|OTHER|the standard analgesic protocol|the routine analgesia was given without local analgesia application
223864755|NCT07061665|BEHAVIORAL|Multi-level, Multi-component Intervention Package|The CBH COPI intervention applies multi-level strategies to improve children's environments and foster healthy behaviors. In schools, activities include schoolyard enhancements (e.g., hopscotch), inter-school sports events, nutrition lectures, healthy snacks, and educational materials linking health and academics. In parks and roads, improvements include cycling/walking promotions, signage, healthier vending machines, and community events. Supermarkets support healthy choices through menu information, loyalty incentives, cooking classes, product placement, and healthy food sales. At home and in communities, the Min-Challe app supports habit formation, with athletes, mascots, and ambassadors promoting healthy living. The coordinated program aims to naturally promote healthy eating, physical activity, and sustained lifestyle change among children aged 6-12 in Chiba City.
223864756|NCT07061574|DRUG|Anti-thymocyte globulin (ATG)|ATG (brand name Thymoglobulin) a polyclonal T cell antibody preparation. The first dose (0.5 mg/kg) will be infused on day 0, during a period of 6 hours. The second dose (2 mg/kg) will be given on day 1, over a period of 4 to 6 hours.
223864757|NCT07061574|DRUG|verapamil extended-release capsule|Daily oral (pill) administration at 60, 120, 240 or 360 mg based on weight and ECG findings.
223864758|NCT07061574|DRUG|Adalimumab|40 mg administered subcutaneously every other week beginning 6 weeks after the last dose of ATG until the 156-week visit.
223864759|NCT07061028|BEHAVIORAL|Progressive Muscle Relaxation|This intervention involves five weekly 30-minute sessions of Progressive Muscle Relaxation (PMR) based on the ABC relaxation theory. The PMR protocol developed by Smith (2005) involve tense-and-release exercises for 11 different muscle groups, including hands, arms, sides, back, shoulders, face, neck, stomach, chest, legs, and feet. For five to ten seconds, each muscle group is contracted, and for twenty to thirty seconds, it is relaxed. The sensations of stress and relaxation were the participants' main concern. To release any residual tension, they looked at each muscle group after the workout. With the exception of the time needed for measurements and instructions, the entire operation took roughly thirty minutes.
224076422|NCT05140499|DRUG|Liposomal bupivacaine|Popliteal nerve block
224076423|NCT05140499|DRUG|Bupivacaine Hydrochloride 0.5 % Injectable Solution|Continuous nerve catheter
223864760|NCT07061028|OTHER|Control Group|The control group received no intervention from the researcher during the study. However, following the intervention, the control group participants were given the audio recordings of the intervention protocol along with an explanation of them.
223864761|NCT07061353|BEHAVIORAL|Therapeutic touch|Therapeutic touch will be performed
223864762|NCT07060833|DEVICE|External pressure transducer|The delivered CPAP pressure will be measured using an ultra-thin, multi-use catheter pressure transducer inserted into a port in the expiratory limb of the bubble CPAP circuit.
223864763|NCT07060833|DEVICE|Standard microphone|The bubble sound of the water tank will be collected with a standard condenser microphone directly affixed to the pole holding the water tank, with a secure clip.
224076424|NCT06560021|OTHER|Biopsy strategy|Number of random biopsies, in addition to targeted biopsies, taken during colonoscopies where at least one indication for the colonoscopy is surveillance for dysplasia
223864764|NCT07060833|DEVICE|Wireless acoustic sensor|The wireless acoustic sensor contains a dual microphone capable of capturing target sounds as well as ambient noise. The frequencies associated with ambient noise will be subtracted to maximize the signal-to-noise ratio of the bubble sound waveform. The wireless sensor will be placed on the suprasternal notch of the infant for monitoring the bubble sounds transmitted to the lungs and secured using a silicone-based tape approved for use in neonates. Data will be transmitted in real-time to a research-dedicated tablet using the Bluetooth Communication Controller and stored for future analysis.
224267514|NCT05744492|OTHER|Vivifrail multicomponent exercise program|"Resistance: 3 sets of 2 repetitions of 3-4 exercises with a 1 to 3-minute break between sets. Intensity from 30-repetition maximum (RM) at weeks 1-6 to 20-RM at weeks 7-12.~Balance training: both static and dynamic. Subjects will increase the number of repetitions, the difficulty of the exercises or will add external perturbations to the tasks (unstable surfaces, obstacles, or visual deprivation) along the duration of the interventions to guaranteeing progression. In the case of high risk of falling the number, frequency and volume of balance exercises will be increased.~Flexibility: a set of stretching exercises at the end of each session. Subjects will be instructed to stretch until they feel tension in their muscles without reaching discomfort. Stretching will be maintained for 10 sec. and repeated 2-3 times.~Cardiovascular: walking-based activities oriented to increase cardiorespiratory fitness. They will range from 5-10 sec. to 45 min/session."
223864765|NCT07060833|DEVICE|Internal pressure transducer|The transmitted CPAP pressure will be measured using an ultra-thin, single-use catheter pressure transducer inserted through the mouth to the level of the infant's nasopharynx. The data will be acquired with a sampling rate of 10kHz and stored for later analysis.
223864766|NCT07060651|OTHER|Present odors to participants while recording and stimulating brain activity|Present odors to participants while recording brain activity
224267515|NCT03774329|OTHER|Usual care|Patients included in the control group will not benefit from the intervention in adapted physical activity. However, this will not affect their support. Patients will be seen by their specialist doctor as part of the usual management of their IBD.
224267516|NCT03774329|OTHER|adapted physical activity|Patients in the experimental group will have, in addition to their usual follow-up with their specialist doctor, an intervention in adapted physical activity at home, at the rate of 3 sessions (of a duration of 10 to 20 minutes) per week during 9 consecutive months.
224267517|NCT03291145|DRUG|Beta Blockers|With and without Beta Blockers
224267518|NCT03291145|DRUG|Spironolactone|Brisk Standing before and after seven days treatment with Spironolactone
224267519|NCT00731939|DEVICE|Inflatable Penile Prosthesis|Hydraulic system designed to be surgically implanted into the penis for the management of erectile dysfunction.
224267520|NCT04652622|DEVICE|Mindful Garden|Mindful Garden is an interactive digital behavior modification platform utilizing inbuilt sensors and screen based delivery system. The platform delivers calming visual output of real nature video layered with hyper-real animations of growing and receding flowers and butterflies in flight in a volume directly responsive to measured patient activity. Patient movement and vocalization are the surrogate markers for agitation and using proprietary algorithms drive onscreen content.
224267521|NCT05247723|DEVICE|Standard IV Cannula for aspiration of testicular sperm|After local anesthesia, a wide bore 14-G standard IV cannula was introduced near the lower pole of the testis. The needle was withdrawn and the catheter introduced into the testicular tissue. A 20-ml syringe was secured to the catheter and constant negative pressure applied and secured with a clamp. Back and forth motions were performed covering as many areas of the testis as possible.
224267522|NCT05247723|PROCEDURE|Micro-TESE|Conventional Microscopic Testicular Sperm Extraction (Micro-TESE), Open Testicular Biopsy using surgical Microscope
224267523|NCT00394485|DRUG|Procaterol|
224267524|NCT00394485|DRUG|Tiotropium|
224267525|NCT03123315|DEVICE|Ureteral Illuminating Catheter|This is a very thin tube that goes into a ureter to more effectively find and track the ureter during surgeries
224267526|NCT02072096|DRUG|Glimepiride|Administered orally
224267527|NCT02072096|DRUG|Metformin|Administered orally
224267528|NCT02072096|DRUG|Pioglitazone|Administered orally
224267529|NCT02072096|DRUG|Acarbose|Administered orally
224267530|NCT02072096|DRUG|Linagliptin|Administered orally
224267531|NCT02072096|DRUG|Sitagliptin|Administered orally
224267532|NCT02072096|DRUG|Liraglutide|Administered subcutaneously (SC)
224267533|NCT02072096|DRUG|Insulin Glargine|Administered SC
224267534|NCT02072096|DRUG|Exenatide once weekly (QW)|Administered SC
224267535|NCT02072096|DRUG|Exenatide twice daily (BID)|Administered SC
223864767|NCT07061002|OTHER|Lung Recruitment Maneuver|Lung Recruitment Maneuver (LRM) is a method that allows the alveoli to reopen by applying high positive pressure in order to prevent or treat alveolar collapse (atelectasis) that develops during or after anesthesia. LRM improves oxygenation by increasing functional residual capacity. Clinical studies have shown that LRM increases oxygenation levels, reduces areas of atelectasis, and shortens hospital stay. In this study, the effects of different recruitment maneuvers on postoperative atelectasis will be evaluated. In this group, just before extubation, the patients in this group will be given 6 breaths with a tidal volume of 2 times the vital capacity, an inspiratory/expiratory ratio of 1/1 and a lung plateau pressure of \< 35 cmH2O, and a recruitment maneuver will be performed at the end of the surgery.
224267536|NCT06626750|BEHAVIORAL|Summer Treatment Program for Pre-Kindergarteners and Kindergarteners|Children will be concurrently enrolled in our Summer Treatment Program for Pre-Kindergarteners and Kindergarteners (STP-PreK/K). The STP-PreK/K simulates a school-like schedule and runs for 7-weeks and last 7 hours/day, Monday through Friday, with periods of seatwork, large/small group activities, circle time, and classroom meetings along with a recreational period. Academic curriculum are individualized depending upon child's current level. The behavioral modification program uses a visual response cost system in which children lose points for not following classroom rules (these rules are operationalized and determined during the development phase). Dots earned are then used for daily and weekly rewards. In addition to the academic and behavioral modification program, one group of children will participate in social-emotional/self-regulation training exercises on a daily basis designed to teach them social skills and how to control their emotions, behaviors, and attention.
223864768|NCT07061002|OTHER|Positional Lung Recruitment Maneuver|Lung Recruitment Maneuver (LRM) is a method that allows the alveoli to reopen by applying high positive pressure in order to prevent or treat alveolar collapse (atelectasis) that develops during or after anesthesia. LRM improves oxygenation by increasing functional residual capacity. Clinical studies have shown that LRM increases oxygenation levels, reduces areas of atelectasis, and shortens the length of hospital stay. In this study, the effects of different recruitment maneuvers on postoperative atelectasis will be evaluated. Patients in this group will be placed in the right and then left lateral decubitus position before extubation at the end of surgery and a recruitment maneuver will be performed by giving 6 breaths in each position, with a tidal volume twice the vital capacity, a 1/1 inspiratory/expiratory ratio, and a lung plateau pressure \< 35 cmH2O.
224267537|NCT06626750|BEHAVIORAL|School Readiness Parenting Program (SRPP)|The School Readiness Parenting Program (SRPP) helps parents of young children develop skills that support their child\&#39;s readiness for kindergarten and first grade. It focuses on positive parenting practices that enhance social, emotional, and cognitive development. The sessions cover managing child behaviors, promoting early literacy, and fostering problem-solving skills. Parents learn effective communication, consistent routines, and how to create a supportive home environment.
224267538|NCT06626750|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|Cognitive Behavioral Therapy (CBT) is a structured, goal-oriented therapy that helps individuals identify and change negative thought patterns and behaviors. It focuses on the link between thoughts, emotions, and actions to improve mental health. Specific to the current project, CBT can reduce stress by teaching parents to reframe unhelpful thoughts, manage challenging emotions, and develop effective coping strategies for difficult situations, leading to more positive parenting experiences.
224267539|NCT01748773|DRUG|Oxaliplatin|Participants will receive oxaliplatin 100 mg/m\^2 IV on Day 1 of Cycles 1-3.
224267540|NCT01748773|RADIATION|Radiation|Participants will receive radiotherapy at total dose of 45 Gy divided into 25 doses, 5 treatments per week for 5 weeks starting on Day 1 of Cycle 4.
224267541|NCT01748773|DRUG|Capecitabine|Participants will receive capecitabine 850 mg/m\^2 orally twice daily on Days 1-14 of Cycles 1-3 and on 5 days per week during chemoradiotherapy.
224267542|NCT01748773|DRUG|Trastuzumab|Participants will receive trastuzumab 8 mg/kg IV on Day 1 Cycle 1, 6 mg/kg IV on Day 1 of each following 3-week cycle for 12 months (a total of 17 doses).
223864769|NCT05541458|OTHER|Food as medicine|"* Encourage participants to make dietary changes by increasing consumption of nutritious foods, particularly fruits and vegetables.~* Reduce food insecurity by making it easier for participants to access nutritious foods to ensure they are eating a balanced diet.~* Increase nutrition literacy.~* Improve health-related outcomes of participants by decreasing chronic health conditions by decreasing health metrics using food as medicine."
223864770|NCT06666608|DEVICE|Bone Stimulator|Subjects will be asked to wear their device (if applicable) for a minimum of 30 minutes a day for 12 weeks with no maximum usage time. The device will track compliance. Bone stimulator should be worn at rest.
223864771|NCT06666608|OTHER|Standard of Care Spondylolysis Treatment|Participants will follow the standard of care regimen for spondylolysis treatment at Houston Methodist which will involve physical therapy and wearing a back brace.
223864772|NCT04390529|OTHER|quality-of-life questionnaire: BREAST-Q|quality-of-life questionnaire: BREAST-Q
224267543|NCT05138094|PROCEDURE|Minimally invasive simultaneous resection|One minimally invasive surgical procedure wherein both the primary colorectal carcinoma and the liver metastases are removed.
224267544|NCT05138094|PROCEDURE|Minimally invasive two-stage resection|Two minimally invasive surgical procedures wherein the primary colorectal carcinoma and the liver metastases are removed
224267545|NCT05912062|DRUG|Trastuzumab (neoadjuvant)|Trastuzumab loading dose at 8mg/kg at day 1 followed by Trastuzumab at 6mg/kg in a 21-day cycle for six cycles
224267546|NCT05912062|DRUG|Pertuzumab (neoadjuvant)|Pertuzumab loading dose at 840mg at day 1 followed by Pertuzumab at 420mg in a 21-day cycle for six cycles
224267547|NCT05912062|DRUG|Paclitaxel (neoadjuvant)|Paclitaxel starting at day 8 at 80mg/m2, days 1, 8, and 15 of a 21-day cycle for up to fifteen weeks
224267548|NCT00764712|DRUG|insulin|Insulin was was administered according to each protocol rules/suggestions into a central venous line as a continuous infusion (Bath and eMPC protocols) or as a combination of a continuous infusion and boluses (Matias protocol). A standard concentration of 50 IU of insulin in 50 ml of 0.9% NaCl was used. In all patients, infusion of 10% glucose solution was initiated upon admission to ICU with glucose dose of 2.5 g/kg of ideal body weight (height in centimetres minus 100) per hour and lasted for 18 hours, when normal oral food intake was started. In ventilated patients, the glucose infusion lasted for 48 hours, and then standard enteral nutrition was initiated.
224267549|NCT02620137|DRUG|Multicentrum® (Pfizer, Spain) 3 months|The multivitamin supplement (Multicentrum® (Pfizer, Spain) 1 tablet/day) will be maintained during 3 months
224267550|NCT02620137|DRUG|Multicentrum® (Pfizer, Spain) 12 months|The multivitamin supplement (Multicentrum® (Pfizer, Spain) 1 tablet/day) will be maintained during 12 months
224267551|NCT02754076|DRUG|AX 250|Chimeric fusion of recombinant human alpha-N-acetylglucosaminidase and truncated human insulin-like growth factor 2 (rhNAGLU-IGF2)
224267552|NCT05444803|OTHER|femoral nerve block|Patients will be performed a femoral nerve block using bupivacaine thirty minutes before the performing of spinal block.
224267553|NCT05444803|OTHER|peri-capsular nerve group block|Patients will be performed a peri-capsular nerve group block using bupivacaine thirty minutes before the performing of spinal block.
224267554|NCT01758601|OTHER|Dietary intervention with 7 servings oh white fish per week (each serve consisted of 100g of frozen Namibia hake, Pescanova S.A., Pontevedra, Spain)|
224267555|NCT01758601|OTHER|Previous alimentary habits, avoiding any significant nutritional imbalance, as well as any fish or seafood|
224267556|NCT00822744|DRUG|SSR411298|"Form: capsule~Route: oral administration with food"
224267557|NCT00822744|DRUG|Escitalopram|"Form: capsule (commercial escitalopram tablets were encapsulated within opaque capsules)~Route: oral administration with food"
224267558|NCT00822744|DRUG|Placebo (for SSR411298)|"Form: capsule~Route: oral administration with food"
224267559|NCT04443790|DRUG|Leptin Human|
224267560|NCT01754935|DRUG|VX-509|50 mg oral tablet
224267561|NCT01754935|DRUG|VX-509 matching placebo|0 mg oral tablet
224267562|NCT01694563|DEVICE|Synergy Ablation System|"Patient will undergo an elective open cardiac surgical procedure to be performed on cardiopulmonary bypass for one or more of the following:~* Coronary Artery Bypass Grafting (CABG)~* Mitral valve repair or replacement~* Aortic valve repair or replacement~* Tricuspid valve repair or replacement The aim of the treatment is a complete bi-atrial Maze IV procedure which includes pulmonary vein isolation coupled with lesions made on both the left and right atria."
224267563|NCT00018616|BEHAVIORAL|MEMS caps|
224267564|NCT05716490|DEVICE|Incisional negative pressure wound therapy|Application of negative pressure wound therapy for prophylaxis of surgical site occurrences
224267565|NCT05716490|OTHER|Control group - standard wound dressing|Covering of surgical wound with standard wound dressing
224267566|NCT01266902|DRUG|Rilpivirine|25 mg once daily
224267567|NCT00387153|DRUG|MPC-2130|MPC-2130 10 mg/mL administered by intravenous infusion over 1-2 hours
224267568|NCT00833534|BIOLOGICAL|rituximab|Given IV
224267569|NCT00833534|DRUG|lenalidomide|Given orally
224267570|NCT03118687|OTHER|Biospecimen and survey collection|Blood, microbiota, surveys/questionnaires, electronic medical records.
224267571|NCT06558812|DEVICE|prefabricated space maintainer|"i. Prefabricated band will be selected for the abutment tooth by measuring the mesiodistal diameter of the abutment tooth with a caliper and will be adjusted with the internal diameter of the prefabricated band.~ii. The loop will be selected based on the available mesiodistal space and buccolingual width of the abutment tooth, excessive length with be cut by cutting plier and will then place inside the band's tube by using a HOWE pliers.~iii. Cotton roll isolation will use, then will be cemented with glass ionomer,"
224267572|NCT06558812|DEVICE|conventional space maintainer|"i. A full arch Impressions will be taken with alginate material. ii. Impressions will be poured up using dental stone within 30 min of the impression taking.~iii. The children will be given an appointment for space maintainer insertion. iv. In the second visit , Cotton roll isolation will use, cementation will be performed with glass ionomer ."
224267573|NCT02352233|PROCEDURE|RETROVIEW colonoscope|withdrawal in retro vision and forward vision was performed by segments (right, transverse, left, sigmoid colon and rectum). Retroflexed therapeutics procedures were executed when needed.
224267574|NCT01466894|BIOLOGICAL|IMM 124-E|Tablets orally twice a day for 24 weeks
224267575|NCT01466894|BIOLOGICAL|Placebo|Tablets orally twice daily for 24 weeks
224267576|NCT03068780|DRUG|Oleogel-S10|10% birch bark extract in 90% sunflower oil
224267577|NCT03068780|DRUG|Control gel|Sunflower oil, Cera flava/yellow wax, and Carnauba wax (matched Oleogel-S10 in terms of texture and visual appearance)
224267578|NCT01945580|PROCEDURE|Prolapse Repair|Transvaginal anterior/apical pelvic organ prolapse repair
224267579|NCT04540094|DRUG|Human albumin|Any preparation of 5% Human Albumin Solution which has marketing authorisation in the UK to be used for this indication and is stocked by local hospital pharmacies at the participating sites, may be prescribed in this study
224267580|NCT04540094|DRUG|Balanced crystalloid solution|"Any preparation of intravenous balanced crystalloid which has marketing authorisation in the UK to be used for this indication and is stocked by local hospital pharmacies at the participating sites, may be prescribed in this study."
224267581|NCT04999280|OTHER|Fiber Croissant (FIBCRO) Group|Subjects will consume for 2 weeks at breakfast a fiber-enriched sourdough croissant. All subjects will be requested not to change other dietary habits and their physical activity during the 2 week intervention period.
224267582|NCT04999280|OTHER|Control Croissant (CONCRO) Group|Subjects will consume for 2 weeks at breakfast a sourdough croissant. All subjects will be requested not to change other dietary habits and their physical activity during the 2 week intervention period.
224267583|NCT05034874|DRUG|IXT-m200|IXT-m200 binds METH with high selectivity and affinity. The product contains a murine METH-binding variable region and the constant domains of a human immunoglobulin G (IgG) 2κ. This antibody isotype was chosen because of the lower risk of immune response compared to an IgG1 or IgG3. IXT-m200 targets METH, does not rely on binding to any endogenous target for its action, and has been well-tolerated in previous clinical studies.
224267584|NCT05034874|OTHER|Placebo|Saline
224267585|NCT00003357|BIOLOGICAL|GM2-KLH vaccine|
224267586|NCT00003357|BIOLOGICAL|QS21|
224267587|NCT05801822|DIAGNOSTIC_TEST|serum T.S.H level test|, the blood samples will be collected and to be assessed for the routine antenatal screening CBC, random blood sugar, HBV and HIV, the same blood sample will be used to asses TSH level.
224267588|NCT01851772|DEVICE|Treatment with Electronic Brachytherapy|
224267589|NCT04830540|DEVICE|OOFOS Recovery Footwear|The OOFOS shoes/ sandals are a commercially available footwear with a compliant, energy absorbing midsole material.
224267590|NCT01679158|DEVICE|Using The IOP system from USGI to place suture anchors|"Sutures are placed in the distal body in one of three randomized techniques:~A = reduction in ring opening to antrum using plications B = continuous horizontal row, running from distal body into proximal antrum C = Control. Current V shape as Control"
224267591|NCT00633672|DRUG|Esomeprazole|20mg Oral tablet once daily
224267592|NCT00633672|DRUG|Ranitidine|150mg oral twice daily
224267593|NCT00633672|DRUG|Esomeprazole|40mg oral tablet once daily
224267594|NCT01867658|DEVICE|Progel® Pleural Air Leak Sealant|Video-assisted or robotic-assisted surgical lung procedures plus Progel® Pleural Air Leak Sealant
224267595|NCT01870258|OTHER|ANN prediction of myocardial infarction|
224267596|NCT00840658|BEHAVIORAL|Interactive injection and sexual risk intervention|This is a one-on-one intervention that incorporates elements of motivational interviewing (MI) and principles of Social Cognitive Theory (SCT) and Theory of Reasoned Action (TRA) to address the context of both, a) unsafe injection sharing and the extent to which syringes and other injection paraphernalia is shared; and b) unsafe sex and condom use with clients, and associated risks (e.g., HIV (Human Immuno-deficiency Virus), STIs (Sexually Transmitted Infections), pregnancy).
224267597|NCT00840658|BEHAVIORAL|Interactive Sexual Risk Intervention|This is a one-on-one intervention that incorporates elements of motivational interviewing (MI) and principles of Social Cognitive Theory (SCT) and Theory of Reasoned Action (TRA) to address the context of unsafe sex and condom use with clients, and associated risks (e.g., HIV (Human Immuno-deficiency Virus), STIs (Sexually Transmitted Infections), pregnancy).
224267598|NCT00840658|BEHAVIORAL|Interactive Injection Risk Intervention|This is a one-on-one intervention that incorporates elements of motivational interviewing (MI) and principles of Social Cognitive Theory (SCT) and Theory of Reasoned Action (TRA) to address the context of unsafe injection sharing and the extent to which syringes and other injection paraphernalia is shared.
224267599|NCT00840658|BEHAVIORAL|Lecture-format presentation|60 minute lecture-format presentation on safer sex and safer injection based on CDC guidelines for HIV counseling, testing, and referral and materials from Mexico's National Center for AIDS Studies (CENSIDA). There are no theory-driven active skill building elements oriented towards safer sex or safer injection.
224267600|NCT04846686|BIOLOGICAL|Placenta pathological examination|a placenta pathological examination will be analyzed to examine quantification of EG-VEGF, PROKR1 and PROKR2 receptors.
224267601|NCT05803135|DRUG|Iguratimod combined with Tofacitinib;|Iguratimod (taken orally, 25mg, bid, daily) combined with Tofacitinib (taken orally, 5mg, bid, daily); Placebo of Iguratimod (taken orally, 25mg, bid, daily) combined with Tofacitinib (taken orally, 5mg, bid, daily)
224267602|NCT03334734|DRUG|PBTZ169|Once a day for 14 days
224267603|NCT03334734|DRUG|Isoniazid|Once a day for 14 days
224267604|NCT00830414|DRUG|medroxyprogesterone acetate|IM Injection
224267605|NCT00830414|DRUG|medroxyprogesterone acetate|IM injection
224267606|NCT04275895|BEHAVIORAL|Evaluation of different attention or/and postural activities|"1. The children, equipped with a head-mounted display (HMD), will indicate as quickly as possible the direction of a fish that can be surrounded by congruent or not flankers (Inhibition) and/or preceded by signal (Alert)~2. The children, equipped with a HMD and a joystick, will vertically turn a randomly inclined stick~3. The children will stand on a force plate watching a cartoon, gazing a fixation cross or eyes closed~4. The children, equipped with an augmented reality headset, will perform 2 levels of difficulty of 3 attention tasks standing on a force plate:~   * They will click as quickly as possible when they see a frog among successively appearing animals (vigilance task)~  * They will give the name of an animal appearing at one of the windows displayed (visual search task)~  * They will count the number of yellow lions oriented to the right among several animals of different color and direction (inhibition task)~5. Growth trajectory will be retrieved from health booklet"
224267607|NCT04356313|DEVICE|GORE® EXCLUDER® Iliac Branch Endoprosthesis|Compare between patients where Gore Excluder Iliac Branch Endoprosthesis and the Hipogastric component can be used with the group where the Hipogastric component can't be used for anatomical issues and a Gore Viabahn VBX is used instead of the Hipogastric component
224267608|NCT02845336|DRUG|Celecoxib|celecoxib 100mg PO twice per day for 3 months
224267609|NCT02845336|DRUG|artificial tears|Standard care for mild thyroid eye disease is lubrication with artificial tears (over the counter), avoidance of cigarette smoke.
224267610|NCT04756921|DRUG|Pyrotinib|Pyrotinib 400mg po qd
224267611|NCT00976443|DRUG|BTA|BTA 100 or 300 U, endoscopic ultrasound (EUS) guided injections into gastric antrum
224267612|NCT00976443|DRUG|Placebo (normal saline)|Placebo (normal saline), gastric injections of normal saline
224267613|NCT02045108|BEHAVIORAL|Active Retraining|
224267614|NCT02045108|DEVICE|Sham TDCS|
224267615|NCT02045108|DEVICE|Active TDCS|
224267616|NCT02045108|BEHAVIORAL|Sham Retraining|
224267617|NCT05448209|BEHAVIORAL|walking exercise|Intervention Group Afterwards, patients taking paclitaxel-paclitaxel-herceptin will be given a nurse-led Motivational Interview about CIPN, physical activity and regular physical activity-walking. Patients will be instructed that the goal is to beat the previous number of steps each time. If he/she has problems/shortness of breath, chest pain, palpitation complaints during walking, he/she will be told to take a break from walking and rest. The study will be conducted under the supervision of a Medical Oncology specialist throughout the study, as well as the controls of patients with ongoing symptoms. Participants will be given a pedometer for regular follow-up, its use will be explained, and it will be told to mark it on the walking tracking chart. It will be emphasized that rhythmic walking is important for the pedometer to count correctly. Motivational Interview sessions will be conducted face-to-face at the beginning, week 4 and week 8.
224267618|NCT04702685|DRUG|Ropivacaine|Local anesthetic for injection
224267619|NCT04702685|OTHER|Placebo|Bandage will be placed in the presumed injection site while patients in under general anesthesia
224267620|NCT05865652|DIAGNOSTIC_TEST|Cerebral MRI with Phosphorus 31 Magnetic Resonance Spectroscopy|Cerebral MRI with Phosphorus 31 Magnetic Resonance Spectroscopy
224267621|NCT02974907|DRUG|RGN-259|A preservative-free, sterile eye drop solution containing Tβ4 for direct instillation into each eye, four times a day (QID) for 28 days
224267622|NCT02974907|DRUG|Placebo|It is composed of the same excipients as RGN-259 but does not contain Tβ4
224267623|NCT04076007|DIETARY_SUPPLEMENT|Beetroot juice|
224267624|NCT04076007|DIETARY_SUPPLEMENT|Nitrate depleted beetroot juice|
224267625|NCT04302961|OTHER|Auditory Feedback|Participants will complete 8 sessions over a 2-week period of walking gait retraining on a treadmill while receiving no feedback. Participants will be instructed to walk on a treadmill at their desired pace in a manner that does not cause the auditory tool to elicit a noise.
224267626|NCT04302961|OTHER|No Feedback|Participants will complete 8 sessions over a 2-week period of walking gait retraining on a treadmill while receiving no feedback. Participants will be instructed to walk on a treadmill at their desired pace in a manner that they perceive to be their normal walking speed and mechanics.
224267627|NCT00004933|DRUG|hydroxyurea|0.5 to 5 grams PO per day
224267628|NCT00004933|DRUG|Homoharringtonine|2.5 mg/ sq m/ day CIVI for 14 days
224267629|NCT02420353|DRUG|Somatropin|GH dose will be calculated by nomogram estimation of body surface area, and will be administered via subcutaneous injection in the abdominal area twice per day (BID) at a dose of 0.5mg GH per body surface area (BSA) in m2 (0.5mg/m2). Patients will begin GH treatment one week prior to surgery and will continue through 5 weeks after surgery. On the day of surgery, patients will not take GH, but otherwise patients will take GH every day over this 6 week period.
224267630|NCT02420353|DRUG|Placebo|A placebo diluent that will be administered via subcutaneous injection in the abdominal area twice per day (BID) at a dose of the equivalent concentration of 0.5mg GH per body surface area (BSA) in m2 (0.5mg/m2). Patients will begin treatment one week prior to surgery and will continue through 5 weeks after surgery. On the day of surgery, patients will not take medication, but otherwise patients will take medication every day over this 6 week period.
224267631|NCT01430533|DRUG|azelaic acid pre foam formulation|
224267632|NCT01430533|DRUG|Vehicle pre foam formulation|
224267633|NCT01430533|DRUG|Water|
224267634|NCT02827097|DRUG|denogan and rectus sheath block|administration of denogan and rectus sheath block with 0.375% ropivacaine
224267635|NCT02827097|DRUG|denogan|administration of denogan
224267636|NCT04146805|DRUG|BLD-0409|For each cohort in both study parts, 8 subjects will be randomized in a 6:2 ratio to active (BLD-0409) : control (matched placebo). Study drug will be administered orally once a day, with an option to evaluate twice daily dosing (BID) in Part 2 MAD cohort(s).
224267637|NCT04146805|DRUG|Control: Placebo|Subjects will be randomized in a 6:2 ratio to control (matched placebo). Study drug will be administered orally once a with an option to evaluate twice daily dosing (BID) in Part 2 MAD cohort(s).
224267638|NCT03106545|DRUG|Liposome bupivacaine|
224267639|NCT03954483|DRUG|Buspirone 10 Mg Oral Tablet|Orally administered prior to experiments.
224267640|NCT03954483|DRUG|Triazolam 0.25 MG Oral Tablet|Orally administered prior to experiments.
224267641|NCT03954483|DRUG|Placebo oral tablet|Orally administered prior to experiments.
224267642|NCT01337427|DRUG|BIIB017|BIIB017 is supplied as a liquid in pre-filled syringes to deliver 0.5 mL of 0.25 mg/mL (125 mcg dose) of 20 kDa mPEG-O-2-methylpropionaldehyde-modified human IFN β-1a in 20 mM acetic acid/sodium acetate buffer pH 4.8, 150 mM arginine hydrochloride, and 0.005% Polysorbate 20.
224267643|NCT00182260|DRUG|Proton Pump Inhibitors|
224267644|NCT00182260|PROCEDURE|Laparoscopic Nissen Fundoplication|
224267645|NCT04847401|DIAGNOSTIC_TEST|H. pylori stool antigen|using H. pylori antigen kits in stool
224267646|NCT04125862|DIAGNOSTIC_TEST|MRI-based Neuroimaging|During evoked pain fMRI, noxious pressure and heat stimuli will be applied in the two anatomical sites noted above. During fMRI data acquisition, a total of 5 pressure stimulations and 5 heat stimulations will be delivered. Both types of pain stimuli will be applied in a 36/17-sec off/on cycle. The off-condition will correspond to a baseline temperature of 35C and the on condition will match the subject-specific and site-specific 7/10 pressure and heat pain thresholds defined during QST procedures. VAS pain ratings associated with evoked pain stimulation will be collected at the end of each scan. The investigators will also explore the structural properties of the CNS by implementing high-resolution anatomical MRI (gray matter volumes) and diffusion tensor imaging (white matter pathway integrity). All CNS imaging will take approximately 50-60 minutes to complete
224267647|NCT04125862|DIAGNOSTIC_TEST|Non-contrast MRI|Musculoskeletal imaging of the affected lower extremity. Patients will be allowed to watch a movie during data acquisition. The following MRI procedures will be completed in order to identify soft tissue lesions in active or painful regions. Fast spin echo (FSE) T2 fat saturated, T1 weighted MRI, FSE proton density MRI, Short-TI Inversion Recovery (STIR), Diffusion weighted MRI (DW-MRI) and 3D Double Echo Steady State (DESS) will be collected. All musculoskeletal MRI will take approximately 30 minutes to complete.
224267648|NCT04125862|DIAGNOSTIC_TEST|18F-FDG-PET/CT|Data will be collected 30 min after the intravenous administration of 18F-FDG with an expected average dose of approximately 200 MBq. CT data will be collected at a low-dose to minimize radiation exposure. Patients will be positioned supine head-first with arms on the side. The investigators project whole body data to be collected, but in some cases, the field of view may be limited to the patient's skull to below the knees. The data acquisition period is expected to last between 15-30 minutes and total radiation dose will be \~3-4 mSv.
224267649|NCT04125862|DIAGNOSTIC_TEST|18F-NaF-PET/CT|Data will be collected 30 min after the intravenous administration of 18F-NaF with an expected average dose of approximately 200 MBq. CT data will be collected at a low-dose to minimize radiation exposure. Patients will be positioned supine head-first with arms on the side. The investigators project whole body data to be collected, but in some cases, the field of view may be limited to the patient's skull to below the knees. The data acquisition period is expected to last between 15-30 minutes and total radiation dose will be \~3-4 mSv.
224267650|NCT04703504|OTHER|Multiple intervention program|Support for patient follow-up assisted by a computer program
224267651|NCT01149057|DRUG|tocilizumab [RoActemra/Actemra]|8 mg/kg intravenously, every 4 weeks for 96 weeks
224267652|NCT04608448|DRUG|Rapamycin Topical Ointment|8% topical rapamycin ointment
224267653|NCT04608448|OTHER|Placebo|Petrolatum ointment containing no active ingredient
224267654|NCT01325740|DRUG|STX107|STX107 10 mg single dose po capsule, STX107 30 mg single dose po capsule, Placebo single po capsule
224267655|NCT02749604|PROCEDURE|Non-ejaculatory sparring PVP|Greenlight laser photoslective vaporization of the prostate
224267656|NCT02749604|PROCEDURE|Ejaculatory sparring PVP|Greenlight laser photoslective vaporization of the prostate with preservation of the ejaculatory hood
224267657|NCT02028039|DRUG|IPI-145|75 mg orally twice daily for 4 weeks.
224267658|NCT02028039|BEHAVIORAL|Follow-up Visit/Call|Follow-up visit 30 days after last dose of study drug. If patient cannot make it to the clinic for this visit, they may speak by phone with a member of the study staff. This phone call should last about 10 minutes.
224267659|NCT04598763|OTHER|smell the odors of the olfactory rehabilitation kit according to the classic or intensive method|regardless of the randomization group, the patient will smell each odor for 10 seconds with a 10 second interval between odors.
224267660|NCT00654186|DRUG|Revlimid|25mg daily on days 1 - 21 followed by 7 days of rest repeated every 28 days
224267661|NCT06562179|DEVICE|da Vinci SP® Single-Port Robotic Surgical System|The da Vinci SP® Surgical System is designed to enable the performance of surgical procedures using a minimally invasive single-port approach. The system consists of a Surgeon Console, a Vision Cart, and a Patient Cart and is used with a camera, instruments, and accessories.
224267662|NCT01394419|DRUG|N-acetylcysteine|N-acetylcysteine 150 mg/kg bolus over 15 min after induction of anesthesia, followed by an infusion of 150 mg/kg/day for 24 hrs
224267663|NCT01394419|DRUG|Saline|Equal volume of normal saline
224267664|NCT06377410|DRUG|Syrup Prospan|Participant with stable COPD who received Syrup prospan for 1 month
224267665|NCT06377410|DRUG|N-Acetylcysteine|Participant with stable COPD who received N-Acetylcysteine for 1 month
224267666|NCT00577655|DRUG|Albuterol|Albuterol HFA MDI 180 mcg four times a day (q.i.d) for a total daily albuterol dose of 720 mcg for 21 days.
224267667|NCT00577655|DRUG|Placebo|Placebo HFA MDI four times a day (q.i.d) for 21 days.
224267668|NCT00577655|DRUG|Proventil® HFA|Proventil® HFA (albuterol sulfate) Inhalation Aerosol (Key Pharmaceuticals) was used as rescue medication in this study. The rescue medication was over-labeled with instructions for emergency use in which subjects were instructed to self-administer up to two puffs every 20 minutes to a maximum of six puffs for any given episode while attempting to seek medical assistance.
224267669|NCT01685255|DRUG|Epacadostat|
224267670|NCT01685255|DRUG|tamoxifen|
224267671|NCT01632423|DRUG|bimatoprost 0.01%|Patients with POAG or OHT prescribed Lumigan® (bimatoprost 0.01%) treatment in a dose determined by the physician prior to study entry
224267672|NCT02504450|DRUG|Adasuve|Inhaled medication to treat acute agitation in the emergency department
224267673|NCT02504450|DRUG|Alternative medications|Medication given to treat acute agitation in the emergency department
224267674|NCT01198938|OTHER|Melatonin|Melatonin 5 mg sublingually given at 9 p.m. for 5 postoperative days or until discharge
224267675|NCT03008655|PROCEDURE|intradermal tranexamic acid|intradermal tranexamic acid injection
224267676|NCT03008655|DEVICE|Nd-YAG|six session at two-week interval of low influence 1064 Nd:YAG laser (6 mm spot size, energy fluence 1.2 - 1.4 J/cm 2 at 10 Hz)
224267677|NCT04778358|DRUG|Follitropin Delta, Recombinant|15 µg of follitropin delta will be administered subcutaneously daily
224267678|NCT02236858|DEVICE|HEPA Air Cleaner|Air cleaners containing HEPA and carbon filters (Austin HealthMate HM400) and capable of removing PM and NO2 will be placed in the bedroom and room where the participant reports spending the most time.
224267679|NCT02236858|DEVICE|Sham HEPA Air Cleaner|Homes in the control group will receive sham air cleaners that have the internal HEPA and carbon filters removed, but which will run normally, including similar noise, airflow and overall appearance compared to active air cleaners, thus blinding participants to filter status.
224267680|NCT00837564|OTHER|CBASP psychotherapy|specific psychotherapy for chronic depression
224267681|NCT00837564|DRUG|Escitalopram|Escitalopram 10-20 mg once daily for the treatment of depression in combination with clinical management
224267682|NCT02757703|DRUG|Somatostatin|A decision to use vasoactive drugs (either somatostatin or terlipressin) depended on the favorite of participating attending physicians who were requested to fill out the enclosed questionnaires immediately after the administration of the first dose for further understanding the underlying reason of the chosen medication.
224267683|NCT02757703|DRUG|Terlipressin|A decision to use vasoactive drugs (either somatostatin or terlipressin) depended on the favorite of participating attending physicians who were requested to fill out the enclosed questionnaires immediately after the administration of the first dose for further understanding the underlying reason of the chosen medication.
224267684|NCT02757703|DRUG|Pantoprazole|Both study groups were administered with 40mg pantoprazole intravenously after EVL for 3 days, and following oral form for 12 days to hasten the process of healing of ulcers induced by ligation.
224267685|NCT02757703|DEVICE|Endoscopic variceal ligation|Two experienced endoscopists performed emergent EVL for the enrolled patients with acute EVB. Pneumoactive ligation device (Sumitomo Bakelite Co., Ltd, Tokyo, Japan) and endoscopes (GIF XQ260; Olympus Co. Ltd, Tokyo, Japan) were applied. The targeted varix was suctioned and entrapped by a cap on endoscope. Ligation was aimed at active bleeding sites, red color spots or white nipple signs during the procedure.
224267686|NCT01793584|PROCEDURE|Laparoscopic hysterectomy|LAVH, TLH
224267687|NCT01793584|PROCEDURE|Abdominal hysterectomy|TAH
224267688|NCT03049384|OTHER|Traditional Exercise|The traditional exercise group will undertake a supervised exercise intervention involving aerobic exercise and light resistance training, in line with published guidelines for exercise in cancer survivors.
224267689|NCT03049384|OTHER|Tailored Exercise|The tailored training group will be prescribed an individualized exercise intervention designed specifically to counteract deficits (e.g. neuromuscular) of difficulties (e.g. sleep disturbance) identified during pre-intervention testing.
224267690|NCT04461587|DRUG|Pirfenidone|see previous entries
224267691|NCT04565587|OTHER|Xanthan-gum based thickener|Participants will undergo a screening procedure (V-VST) with two of the viscosities levels determined and prepared with mineral water and Tsururinko Quickly (200 and 800mPa·s). After the V-VST, a Videofluoroscopy (VFS) will be performed with thin liquid and 5 viscosity levels prepared with X-Ray contrast (Omnipaque), mineral water and Tsururinko Quickly (100, 200, 400, 800, 1600mPa·s). Participants swallow will be studied with VFS in a lateral projection and images will include the oral cavity, pharynx, larynx and cervical oesophagus. Swallows will be analysed by equipment developed to capture and digitize the swallowing sequences to assess VFS signs of safety and efficacy according to accepted definitions and to measure the timing and spatial events of the swallow response.
223864773|NCT04925674|DRUG|HEC53856|"The 100mg dose cohort in the hemodialysis: D1 single oral administration of the investigation product 2.5h before hemodialysis; Three times a week for 6 weeks starting from D8, oral administration of the test drug 2.5h after hemodialysis.~The rest dose cohorts in the hemodialysis: Three times a week for 6 weeks starting from D1, oral administration of the investigation product 2.5h after hemodialysis.~The dose cohort in the peritoneal dialysis: Three times a week for 6 weeks starting from D1, oral administration of the investigation product after fasting."
223864774|NCT05363345|DEVICE|bile duct stone removal|Common bile duct stones (≧ 10 mm) are removed by using Vortic Catch V basket catheter or ordinary basket catheter following endoscopic papillary large balloon dilation.
223864775|NCT04632901|DIAGNOSTIC_TEST|VA assessment|"The VA of all participants will be evaluated by counting the smallest line that can be read within a time duration greater than or equal to the average reading time of the larger lines minus 2.58 times the SD of the reading time of these lines.~In clinical practice, the VA is the common parameter of VA adding a tolerant time limit to clearly determine the end of the test."
223864776|NCT04632901|DIAGNOSTIC_TEST|CVA assessment|"The CVA of all participants will be evaluated by counting the smallest line that can be read within a time duration greater than or equal to the average reading time of the larger lines minus 1.96 times the SD of the reading time of these lines.~In clinical practice, the CVA is the minimum VA that can be read in maximal speed."
223864778|NCT03063944|DRUG|STAT Inhibitor OPB-111077|Given PO
223864779|NCT03063944|DRUG|Decitabine|Given IV
223864780|NCT03063944|DRUG|Venetoclax|Given PO
223864781|NCT03063944|OTHER|Laboratory Biomarker Analysis|Correlative studies
223864782|NCT05972720|DRUG|Fludarabine (Conditional therapy)|Lymphodepletion chemotherapy
223864783|NCT05972720|DRUG|Cyclophosphamide Monohydrate (Conditional therapy)|Lymphodepletion chemotherapy
223864784|NCT05972720|DRUG|firi-cel (Experimental drug)|Investigational agent
223864785|NCT06023329|DRUG|ropivacaine|will receive SCPB with ropivacaine via regional anesthesia team
223864786|NCT06023329|DRUG|Saline|will receive SCPB with saline via regional anesthesia team
223864787|NCT06381570|DRUG|Tovorafenib|"Tovorafenib for oral dosing is provided as an immediate-release tablet in 100 mg strength. The 100 mg tablets are red to yellowish red oval tablets. All products are labeled tovorafenib. In addition, tovorafenib is provided as a powder for reconstitution (PfR) in bottles (430mg per bottle to deliver 300 mg dose). Upon reconstitution with water, the concentration is 25 mg/mL.~Vinblastine is administered by intravenous route as IV push, sites to follow local administration guidelines, once weekly (central line, but peripheral line is also permitted)"
223864788|NCT06381570|DRUG|Vinblastine|vinblastine in combination with tovorafenib
223864789|NCT06792188|DEVICE|Galaxy Watch 4, Samsung Electronics Co., Ltd., South Korea|Use of the Galaxy Watch 4 during sleep for approximately two weeks prior to the polysomnography test, including the night of the test.
223864790|NCT06791525|DRUG|Tirbanibulin ointment 1%|Topical application
223864791|NCT05798117|DRUG|YTB323|Single infusion of YTB323
223864792|NCT03882671|DEVICE|EpiTel Epilog|EEG recording device
223864793|NCT03882671|DEVICE|Empatica E4|PPG, sweat level, temperature and accelerometry recording device
223864794|NCT03882671|DEVICE|GENEActiv|Temperature, light level and accelerometry recording device
223864795|NCT05952934|BIOLOGICAL|0.5 mL Candin®/injection|Candin or placebo injection every 3 weeks until 4 injections then every 3 months until a total of 7 injections.
223864796|NCT05952934|OTHER|Placebo: 0.5 mL Intravenous 0.9% NaCl solution (Saline)|Placebo injection every 3 weeks until 4 injections then every 3 months until a total of 7 injections.
223864797|NCT06453798|OTHER|cervical spine exercises|Cervical spine exercise training is a method to improve the neck function through the patient's self-exercise.
223864798|NCT06453798|OTHER|Neuromobilization|Neuromobilization is a technical technique for rehabilitation therapists to loosen the trapped nerves of patients with professional methods.
223864799|NCT05317390|DIAGNOSTIC_TEST|DystoniaNet-based diagnosis of isolated dystonia|DystoniaNet will be used for the diagnosis of dystonia and its differential diagnosis from other neurological and non-neurological disorders mimicking symptoms of dystonia
223864800|NCT01494103|BIOLOGICAL|iCaspase9-transduced T cells|Patients will receive the T cells between 30 and 90 days following transplantation. The T cells will be infused through a catheter line.
223864801|NCT01494103|DRUG|AP1903|"AP1903 will be administered if there is development of Grade 1 or greater GvHD.~Dose: 0.4 mg/kg by IV over 2 hours.~Up to 3 additional doses may be administered if the GvHD does not respond or gets worse."
223864802|NCT04848909|RADIATION|stereotactic body radiotherapy (SBRT)|Stereotactic body or external-beam radiation therapy (SBRT) is a method of delivery of radiation in precision manner to the prostate bed in this study. The SBRT dose prescription will be 3000 cGy in 5 fractions to the prostate bed and 2500 cGy in 5 fractions to the pelvic nodes if elective nodal irradiation (ENI) is used, delivered every other business day.
223864803|NCT01284920|DRUG|MDV3100|oral
223864804|NCT02594813|PROCEDURE|Biopsy, cold or hot snare polypectomy, or EMR|
223864805|NCT06634030|DRUG|RhPDGF-BB|0.3 mg/mL rhPDGF-BB
223864806|NCT06634030|DRUG|Saline|Normal saline
223864807|NCT04666090|DRUG|Carillizumab|administration regimen: Carillizumab 200mg, IV, D1; Albumin paclitaxel 150mg/m2, D1; Nedaplatin 50 mg/m2, D1; Apatinib 250mg Po D2-4. Preoperative neoadjuvant therapy for 2-3 cycles, one cycle every 14 days.
223864808|NCT04666090|PROCEDURE|Esophagectomy|Laparoscopy combined with thoracoscope radical resection of esophageal carcinoma
223864809|NCT04666090|OTHER|Samples|Blood, Tumour and Saliva will be Collected from participant. Fate of sample is Destruction after use
223864810|NCT04925661|DRUG|HEC53856|Either dose of HEC53856 will be administered after fasting .
223864811|NCT04925661|DRUG|Roxadustat|Roxadustat will be administered after fasting .
223864812|NCT04925661|DRUG|Placebo|Either dose of placebo will be administered after fasting .
223864813|NCT01420250|DRUG|Cabazitaxel|"Administered weekly on the same day of radiation according to the following infusion levels:~Level 1 (Initial): 4 mg/m2; Level -1: 2 mg/m2; Level 2: 6 mg/m2; Level 3: 8 mg/m2; Level 4: 10 mg/2;"
223864814|NCT01420250|RADIATION|Intensity Modulated Radiation Therapy (IMRT)|Starts 8 weeks after initiation of androgen deprivation therapy, given daily at 1.8 Gy for a total of 75.6 Gy
223864815|NCT01420250|DRUG|Anti-Androgen Therapy: Bicalutamide|"* Taken once daily by mouth starting between 2 weeks and 1 day before the first administration of Luteinizing Hormone-Releasing Hormone (LHRH)~* Will continue once daily until the final day of IMRT"
223864816|NCT01420250|GENETIC|Luteinizing Hormone-Releasing Hormone (LHRH) Agonist|"* First administration will occur 1 day to 2 weeks after the start of Bicalutamide and 8 weeks prior to the start of IMRT (+/- 4 weeks)~* Will continue for 24 months after IMRT~* Total administered duration and agent used must be documented on the case report form"
223864817|NCT06513572|DEVICE|FlowSense|This study collects data using non-invasive devices for assessing CSF shunt flow using thermal anisotropy measurements in a prospective study setting. The study will collect data to compare measurements from flowing shunts, non-flowing shunts, and off-shunt locations.
223864818|NCT05073159|BIOLOGICAL|Allocating head-of-bed position|Patients would be randomized 1:1 to elevated head of bed (30-degrees or more) or flat (0-degree) position
223864819|NCT04995627|DIETARY_SUPPLEMENT|Salt (NaCl)|12 grams of salt (NaCl) per day
223864820|NCT04995627|OTHER|Placebo|Placebo
223864821|NCT04816799|BEHAVIORAL|Startle Adjuvant Rehabilitation Therapy (START)|Exposure to loud acoustic stimulus during training of motor task (in this case speech).
223864822|NCT06205303|OTHER|Patient Decision Aid (Video)|Patient decision aid on thyroxine replacement is a video designed to assist the hypothyroid adults with under-replacement. It provides clear and balanced information about hypothyroidism, the role of thyroxine, treatment benefits, potential risks, and factors interfering thyroxine absorption and bioavailability. The PDA aims to empower patients to engage in shared decision-making with their healthcare provider, ensuring they understand the options and can make choices aligned with their preferences and values.
223864823|NCT04257409|OTHER|Physical intervention by exercise|12 week lasting exercise intervention
223864824|NCT03204565|PROCEDURE|coronally advanced flap|coronally advanced flap alone (CAF- control)
223864825|NCT03204565|DEVICE|hyaluronic acid|hyaluronic acid associated to coronally advanced flap (CAF + HA- test)
223864826|NCT01366677|BEHAVIORAL|Yoga Intervention|Three yoga classes per week for 8 weeks.
223864827|NCT03351075|OTHER|Standard physical therapy program|"Mobilisations, stretching, scar tissue treatment and exercises~* Start immediately after surgery, sessions are individual and take 30 minutes~* Intensive phase (4 months): 1-2x/week~* Maintenance phase (8 months, 3 sessions): 6, 8 and 12 months post-surgery"
223864828|NCT03351075|OTHER|Modern educational program|"This modern neuroscience educational approach is suited to explain more complex issues associated with pain such as the involvement of peripheral and central mechanisms, neuroplasticity and pain behaviour.~* Sessions are individual and take 30 minutes, in addition to the standard physical therapy sessions~* 3 sessions during week 1-2, 3 booster sessions at 6, 8 and 12 months post-surgery"
223864829|NCT03351075|OTHER|Traditional biomedical educational program|"Traditional educational interventions are applied according to the biomedical model. This means that the patient's pain experience is explained from a tissue (injured versus healthy tissue) and biomechanics perspective~* Sessions are individual and take 30 minutes, in addition to the standard physical therapy sessions~* 3 sessions during week 1-2, 3 booster sessions at 6, 8 and 12 months post-surgery"
223864830|NCT04993898|OTHER|Plyometric training with warm up and cool down|These Include Squat to Squat Jump, Lunge to Plyo Lunge, Step Jack to Star Jumps, Plank to Plyo Spider Lunge, Plank to Frogger Frequency = 2 days per week for 2 weeks and then 4 days per week after 2nd week to 4th week Intensity =500 jumps Time = 30 min
223864831|NCT04993898|OTHER|Conventional training with warm up & cool down|These include Squats, Single leg squat, Cork hip lift, Press ups, Normal warm-up time 15 min before game.
223864832|NCT06837142|DRUG|Triazolam and TS-172|Oral single administration of triazolam 0.25 mg at single administration phase, followed by a oral single administration of triazolam 0.25 mg and TS-172 20 mg at concomitant administration phase
223864833|NCT06837142|DRUG|TS-172 and itraconazole|Oral single administrtation of TS-172 20 mg at single administration phase, followed by a oral single administration of TS-172 and itoraconazole 200 mg at concomitant administration phase
223864834|NCT02755181|BEHAVIORAL|Experimental|with functional imaging and behavioural measurements at baseline and 4 weeks
223864835|NCT05053321|DRUG|Valbenazine|All participants will be treated with Valbenazine for 6 weeks.
223864836|NCT05664204|PROCEDURE|Veno-arterial extracorporeal membrane oxygenation|Strategy would reduce the need for invasive mechanical ventilation in the first 28 days without increasing adverse events
223864837|NCT02639286|DRUG|ISIS 304801|300 mg of ISIS 304801 administered as SC
223864838|NCT02639286|DRUG|Placebo|Placebo administered via SC
223864839|NCT05341869|PROCEDURE|Para-cervical block|Block of inferior hypogastric plexus with local anesthetic
223864840|NCT06459063|DRUG|Allocetra - Safety run-in phase|Intra-articular injection of Allocetra performed once on Day 1 of the study at different doses.
223864841|NCT06459063|OTHER|Placebo|Intra-articular injection of placebo solution containing all excipients except for the Allocetra cells.
223864842|NCT06459063|DRUG|Allocetra - Randomization phase|Intra-articular injection of selected dose of Allocetra based on the safety run-in, performed on Day 1 of the study.
223864843|NCT05583253|PROCEDURE|Vitrectomy|Small gauge pars-plana vitrectomy for management of retinal detachment.
223864844|NCT00425152|DRUG|fluorouracil|
223864845|NCT00425152|DRUG|leucovorin calcium|
223864846|NCT00425152|DRUG|levamisole hydrochloride|
223864847|NCT03160599|OTHER|ketogenic diet|The treatment is mainly restricted calorie ketogenic diet. KD will consist of 4:1-1:1\[fat\]:\[protein+carbohydrate\].Carbohydrate is limited to 10-30 g / day.
223864848|NCT00457275|DRUG|MK0653, ezetimibe / Duration of Treatment: 4 Weeks|
223864849|NCT03169244|DRUG|Bupropion|Bupropion XL will be initiated at 150 mg/d on Days 1-4 and increased to 300 mg/d for Days 5-84.
223864850|NCT03169244|DRUG|Placebo Oral Tablet|Placebo will be initiated on Day 1 and continue throughout the course of the study.
224076425|NCT04666155|DEVICE|Intermittent Colonic Exoperistalsis with MOWOOT device|"Patients under the experimental arm of the study should place the belt of the Mowoot device on the abdomen and use it for 20 minutes every day for 12 weeks. They should continue with their individualized standard of care againts constipation for the first 4 weeks. During the following 8 weeks of the interventional period of 12weeks, their use of SocTAI will be considered rescue intervention. The 8weeks following the 12weeks of intervention, they can keep on using ICE device.or SocTAI or both."
223864851|NCT01947088|BEHAVIORAL|Music Therapy|Will consist of meeting with the music therapists, Certified Child Life Specialists (CCLS), or Child Life Assistants (CLA) for either music therapy for about 45 minutes, twice per week, for Weeks 1-8. The Music Therapy group will partake in interventions such as singing and playing musical instruments. All brain surgery candidates receive a neuropsychological assessment before and after surgery (9-12 months after surgery). In addition, patients who agree to participate in the study will receive cognitive screening and a music therapy evaluation prior to surgery (Baseline 1). These evaluations will also be given within 3 days of epilepsy surgery (Baseline 2), 8 weeks after surgery (Baseline 3), and 9-12 months after surgery (Baseline 4.)
223864852|NCT06846684|DRUG|SB17170|PO, QD
223864853|NCT06846684|DRUG|SB_MDZ|IV
223864854|NCT06162897|BEHAVIORAL|Dyadic Case Management|Subjects enrolled in the intervention arm will be offered focused case management centered around goal setting and future orientation. Subjects will be assigned two case managers to support their goals.
223864855|NCT04185571|DEVICE|PEPA|
223864856|NCT02343029|OTHER|Individualised aerobic exercise training|During the first 4 weeks of intervention two of the three weekly training sessions are offered as group training supervised by the respective qualified exercise physiologist of the Department of Sports Medicine. After 4 weeks, participants' physical performance is reassessed at the Department of Sports Medicine. If necessary, workload is readjusted to achieve the initially defined exercise intensity.
223864857|NCT02343029|OTHER|Waiting Control|After waiting for 12 weeks with normal daily activity, patients are allocated to a individualised aerobic exercise training, too.
223864858|NCT04663698|OTHER|Baseline|Lung function testing with MasterScreen™ Body, CareFusion Germany GmbH
223864859|NCT04663698|OTHER|MESH-Resistor 5|Lung funtion testing with MasterScreen™ Body, CareFusion Germany GmbH, Mouthpiece with mesh-resistor (5hPa/L) to create laminar airflow
223864860|NCT04663698|OTHER|MESH-Resistor 10|Lung funtion testing with MasterScreen™ Body, CareFusion Germany GmbH, Mouthpiece with mesh-resistor (10hPa/L) to create laminar airflow
223864861|NCT04663698|OTHER|Perforated Resistor 7|Lung function testing with MasterScreen™ Body, CareFusion Germany GmbH, Mouthpiece with perforated resistor (inside diameter 7mm) to create a turbulent airflow
223864862|NCT04663698|OTHER|Perforated Resistor 11|Lung function testing with MasterScreen™ Body, CareFusion Germany GmbH, Mouthpiece with perforated resistor (inside diameter 11mm) to create a turbulent airflow
223864863|NCT01946854|BEHAVIORAL|Questionnaire|"Completion of 3 questionnaires at baseline and at final visit about quality of life, and 1 questionnaire about symptoms, diagnosis, treatment, prognosis, and patient's relationship with caregivers. These will take about 35-50 minutes to complete.~Completion of 3 quality of life questionnaires every 3 months for 1 year."
223864864|NCT05049382|PROCEDURE|Extraction of impacted mandibular third molar|surgical extraction of impacted mandibular third molar tooth
223864865|NCT05398861|DRUG|Utidelone Combined with Bevacizumab|Utidelone： 30 mg/m2/day, IV transfusing over 90 min. on day 1-day 5 of each 21 day cycle Bevacizumab：10mg/kg (IV), on day 1 of each 21 days.
223864866|NCT04679662|DEVICE|Transcatheter mitral valve repair (PLAR Implant and Delivery System)|The PLAR Implant is placed mitral valve posterior annulus using its delivery system via femoral vein access and a transeptal puncture
223864867|NCT06522724|OTHER|Education program|Patients in a study group will participate in daily education program using an original brochure containing information about self-management during the treatment process, the benefits of appropriately adapted physical activity, practical tips on airway clearance techniques or physical exercise.
223864868|NCT06522724|OTHER|Pulmonary rehabilitation|The patients will participate in a 14-day rehabilitation program (Monday to Saturday). Treatments and therapies will be continued for a maximum of three hours daily. The program will be applied individually to each patient and include in-bed assisted exercises, airway clearance techniques, effective cough exercises, pursed-lips breathing, exercises to strengthen the diaphragm and intercostal muscles and cardiopulmonary exercises.
223864869|NCT05212675|OTHER|Short daily dialysis|7 days 2hours dialysis
223864870|NCT04229368|DIETARY_SUPPLEMENT|Vitamin D3|Vitamin D will be given at doses commonly given to patients with low vitamin D levels
223864871|NCT04603924|DRUG|Niclosamide|Niclosamide is an antihelmintic with in-vitro antiviral activity
223864872|NCT04603924|DRUG|Placebo|Matching hydroxypropylmethylcellulose HPMC capsules with no active ingredients
223864873|NCT03808558|DRUG|TVB-2640|TVB-2640 will be administered 100mg/m2 orally once a day for 8 weeks.
223864874|NCT05379608|PROCEDURE|Intermittent hypoxic-hyperoxic training|"IHHT will be carried out using the ReOxy normobaric hypoxic therapy apparatus (Bitmos GmbH, Germany, 26790/10221, 04/10/2019).~Each patient will undergo a hypoxic test to assess the individual response to hypoxia. The minimum safe SpO2 value is 82%, and the maximum allowable heart rate increase during exercise is + 50% of the starting value. When these parameters are reached, an automatic switch to the supply of a hyperoxic gas mixture (35-40% oxygen) occurs till the SpO2 level is 100%. During each training session a hypoxic gas mixture is supplied to the patient in an intermittent mode, alternating with the supply of a hyperoxic gas mixture. On average, each workout includes 6 of the above cycles. The total time of inhalation of a hypoxic gas mixture during one procedure is 20-30 minutes."
223864875|NCT05379608|PROCEDURE|Intermittent hypoxic-hyperoxic training/control|"IHHT will be carried out using the ReOxy normobaric hypoxic therapy apparatus (Bitmos GmbH, Germany, 26790/10221, 04/10/2019).~A control group of 30 patients will undergo a simulated IHHT course (with the same exposure time and number of sessions as intervention group - 15 sessions, 40-minutes long each, 5 workouts per week for 3 weeks). Patients of this group will breathe normoxic gas mixture (ordinary humidified air is supplied through the mask) during the entire session."
223864876|NCT05856084|BIOLOGICAL|Low dose Recombinant Herpes Zoster Vaccine (CHO cells)|0.5 mL per dose, containing a total of 50 µg recombinant varicella zoster virus glycoprotein E, adjuvanted with low dose MA105.
223864877|NCT05856084|BIOLOGICAL|High dose Recombinant Herpes Zoster Vaccine (CHO cells)|0.5 mL per dose, containing a total of 50 µg recombinant varicella zoster virus glycoprotein E, adjuvanted with high dose MA105.
223864878|NCT05856084|BIOLOGICAL|Positive control|0.5 mL per dose, containing a total of 50 µg recombinant varicella zoster virus glycoprotein E, adjuvanted with AS01B.
223864879|NCT05856084|BIOLOGICAL|Placebo|0.5 mL per dose, containing 4.5 mg sodium chloride.
223864880|NCT04779333|BEHAVIORAL|LEAP|LEAP will be delivered through the typical 9 weekly BMT group sessions lasting 90 minutes. Plus wrist worn activity tracker \& facebook group.
223864881|NCT04779333|BEHAVIORAL|Standard BMT|Weekly BMT groups sessions which follow the Barkley curriculum
223864882|NCT03594500|OTHER|PockeTalker|The intervention group will receive PockeTalkers (hearing assistance devices) while they receive care in the ED
223864883|NCT03594500|OTHER|No PockeTalker|The control group will not receive PockeTalkers while they receive care in the ED
223864884|NCT04297371|DIAGNOSTIC_TEST|CMR examination|After recruiting participants and collecting the baseline information, a CMR scan and a post-processed imaging procedure will be carried on in order to detect the cardiac impairment.
223864885|NCT05390749|DRUG|Orelabrutinib|Orelabrutinib will be given as 150mg orally d1-d21 for 6 cycles,every 21 days for 1 cycle.
223864886|NCT05390749|DRUG|Pomalidomide|Pomalidomide will be given as 4mg d1-d14 for 4 cycles,every 21 days for 1 cycle.
223864887|NCT05390749|DRUG|Rituximab|Rituximab 375mg/m2 intravenous infusion d1, every 21 days for 1 cycle. 6 cycles will be prescribed as protocol
223864888|NCT05390749|DRUG|Methotrexate|methotrexate 3.5g/m2 civ d1/cycle5-6
223864889|NCT02823106|DRUG|Verapamil and Citicoline|Single dosing strategy will be used.
223864890|NCT02823106|OTHER|Placebo|Single matching dosing strategy will be used.
223864891|NCT00964730|DRUG|Talampanel|titrated to 50mg three times a day over 9 days and a single dose administered on Day 10
223864892|NCT00964730|DRUG|Moxifloxacin|Placebo administered three times a day over 9 days and a single dose of moxifloxacin administered on Day 10
223864893|NCT00964730|DRUG|Placebo|administered three times a day over 9 days and a single dose administered on Day 10
223864894|NCT05011734|OTHER|Fast Track recovery pathway|Multidisciplinary approach alongside the orthopedic surgeon
223864895|NCT01180192|DRUG|oxygen|either 8 L/minute O2 via face mask for 2 hours
223864896|NCT00415272|BEHAVIORAL|Pulmonary Rehabilitation|
223864897|NCT05965388|DRUG|nucleoside analogues or interferon|ETV、TDF、TAF、TAF、IFN-a-2b
223864898|NCT05834842|BEHAVIORAL|Unisalud|"The UNISALUD intervention will be made up of 42 videos, made using the visual collage technique, where illustration, video fragments and visual interactions are mixed and in some there will be a presenter to achieve captivating visual material. to the participant. Likewise, it will be accompanied by digital infographics that will help reinforce the information proposed by the intervention."
223864899|NCT04738058|DRUG|Bovine Lactoferrin Supplement|Bovine lactoferrin or placebo will be given to both arms with each feed for 30 days or till discharge from NICU the Lactoferrin dose 100mg/day Then determin is effect by serum zonulin level
223864900|NCT04738058|DRUG|placebo|placebo
223864901|NCT04906369|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
223864902|NCT03230786|DRUG|Daily injection of KBP/placebo for 12 weeks as add-on to metformin|Daily subcutaneous injection
223864903|NCT02329132|DRUG|Ranibizumab|Each eye will be treated with three initial monthly injections of intravitreal ranibizumab 0.5 mg (Lucentis), followed by retreatment as needed, guided by monthly clinical examinations including biomicroscopy, VA measurement, and optical coherence tomography (OCT) examination.
223864904|NCT00598377|DRUG|Tetracosactin|1 microgram tetracosactin, intravenous injection, once for the test
223864905|NCT04625257|OTHER|Saliva based assay: crude RNA extraction|Crude RNA extraction to inactivate the virus and stabilize the RNA for transport at room temperature. Validation of the crude RNA extraction from saliva in combination with NGS diagnostics and LAMP assays and point of care test (POCT) for rapid detection of viral antigens on patients' samples.
223864906|NCT04625257|OTHER|Validation of the NGS method|Compare the results obtained with the next-generation sequencing (NGS) method to the nasopharyngeal swabs analysed in a FAMH certified lab.
223864907|NCT04625257|OTHER|Validation of the LAMP assays|The RNA will be analyzed onsite using the loop mediated amplification (LAMP) assay.
223864908|NCT04625257|OTHER|Validation of the POCT Antigen and Antibody tests|Rapid point of care tests (POCT) detecting viral protein antigens (Ag) and antibodies (Ab) on patients' samples. POCT are often employed in low income countries, but for COVID-19 they are not yet characterized. Their performance is to be characterized that they can be used as a safe guard if the lab diagnostics fail.
223864909|NCT04529382|DIAGNOSTIC_TEST|Cognitive testing (Bayley III, WPPSI III and WISC V)|Parents and children will be invited to come for an outpatient clinic visit where cognitive testing and neurologic examination will be performed. In addition to this parents will be asked to fill in questionnaires, provide latest school results and medical files will be requested from treating physicians.
223864910|NCT02139046|DRUG|Febuxostat IR|Febuxostat IR over-encapsulated tablets
223864911|NCT02139046|DRUG|Febuxostat XR|Febuxostat XR over-encapsulated capsules
223864912|NCT02139046|DRUG|Febuxostat placebo|Febuxostat placebo-matching capsules
223864913|NCT02139046|DRUG|Colchicine|Colchicine tablets
223864914|NCT02139046|DRUG|Naproxen|Naproxen tablets
223864915|NCT02139046|DRUG|Lansoprazole|Lansoprazole capsules
223864916|NCT05816902|OTHER|The location of the patient's treatment|The location of the patient's treatment
223864917|NCT01354769|DEVICE|CapnoStream20|The monitor used for data gathering is a CapnoStream20-multi parameter monitor
223864918|NCT04133298|PROCEDURE|Tunneling with laser de-epithelized gingival graft|After the administration of local anesthesia, the dimension of the needed graft will be marked by a #15c blade and then diode laser de-epithelization will take place. The de-epithelized area will be then harvested using a # 15c blade. The donor site will be covered by cyanoacrylate tissue adhesive dressing .
223864919|NCT04133298|PROCEDURE|Tunnelingwith subepithelial connective tissue graf|After administration of local anesthesia. A single incision will be made to the bone in a horizontal direction 3mm apical to the gingival margin of the maxillary teeth. The length of the incision will be determined by the dimensions of the graft required. A partial-thickness dissection will be then made within the single incision aiming to harvest an average thickness of two mm subepithelial connective tissue. Then, the graft will be carefully elevated from the palate with the use of the blade. Primary closure will be obtained using 4-0 polyglycolic acid
223864920|NCT00540748|DRUG|oxytocin|5 U i.v. during surgical abortion
223864921|NCT05672888|DRUG|Jaktinib|100mg of Jaktinib (given as two 50mg tablets) administered orally Twice daily(BID) with best available treatment.
223864922|NCT05672888|DRUG|Placebo|Placebo (given as two placebo tablets) administered orally BID with best available treatment.
223864923|NCT04978051|DRUG|Firazyr|Icatibant 10 MG/ML Prefilled Syringe
223864924|NCT04978051|OTHER|SoC|The SoC could include respiratory support measures, fluid therapy, antipyretic treatment, postural measures, low-molecular-weight-heparins, corticosteroids, such as dexamethasone, remdesivir and other therapeutic options
223864925|NCT03939195|OTHER|Follow-up|4 follow-up visits with OCT Angiography and Structural OCT B
223864926|NCT03801967|DRUG|AZD9977|Randomized participants will receive oral dose of AZD9977.
223864927|NCT03801967|DRUG|Placebo|Randomized participants will receive oral dose of matching placebo.
223864928|NCT03381820|OTHER|instrumental folk music|The music was composed and edited by a professor of Folk Musical Department, Faculty of Arts, Khon Kaen University. There were total of 6 songs, 32-minute length. The music was slow-instrumental, 60-80 beats per minute and ranged between 40-60 decibel levels.
223864929|NCT03557008|BIOLOGICAL|Rabies Vaccine|A 1.0 milliliter (mL) dose of Imovax® will be given to participants on Day 0 and Day 28 of the study.
223864930|NCT03557008|DRUG|Metronidazole|The antibiotic regimen will be given for five days beginning 3 days prior to vaccination, on the vaccination day, and one day after vaccination for a total for 5. The regimen will include 500 milligrams (mg) of Flagyl taken by mouth three times a day.
223864931|NCT03557008|DRUG|Vancomycin|The antibiotic regimen will be given for five days beginning 3 days prior to vaccination, on the vaccination day, and one day after vaccination for a total for 5. The regimen will include 125 mg of Vancocin taken by mouth four times a day.
223864932|NCT03557008|DRUG|Neomycin Sulfate|The antibiotic regimen will be given for five days beginning 3 days prior to vaccination, on the vaccination day, and one day after vaccination for a total for 5. The regimen will include 500 milligrams (mg) of Neomycin sulfate taken by mouth three times a day.
223864933|NCT03675581|DRUG|Microgynon|fixed sequence trial
223864934|NCT03675581|DRUG|Nintedanib|fixed sequence trial
223864935|NCT00523146|DRUG|Kanion Capsule|
223864936|NCT00853918|OTHER|$20 cash|$20 cash incentive mailed with survey
223864937|NCT00853918|OTHER|$50 cash|$50 cash incentive mailed with survey
223864938|NCT00853918|OTHER|$50 check|$50 check incentive mailed with survey
223864939|NCT00853918|OTHER|$100 check|$100 check incentive mailed with survey
223864940|NCT03335748|OTHER|Cognitive training Cogmed program|Cognitive training Cogmed program
223864941|NCT04830501|DRUG|TT-00434|Once daily \[QD\], 28 days/cycle.
223864942|NCT04898140|DIAGNOSTIC_TEST|SARS-CoV-2 specific IgM and IgG detection|Detection of IgM and IgG antibodies specific to the SARS-CoV-2 antigens in the blood serum using enzyme-linked immunosorbent assay (ELISA).
223864943|NCT04898140|DIAGNOSTIC_TEST|ELISpot: detection of the T cells specific to different SARS-CoV-2 proteins|Detection of peripheral blood T lymphocytes which are activated and secrete interferon gamma (IFNgamma) upon stimulation with peptides, covering the immunodominant sequence domains of the nucleocapsid N, membrane M, or spike glycoprotein S proteins of SARS-CoV-2 coronavirus.
223864944|NCT04898140|DIAGNOSTIC_TEST|Flow cytometry: detection of the SARS-CoV-2 specific T-helpers and cytotoxic T lymphocytes|Detection of peripheral blood T-helpers (CD45+CD3+CD4+)\* and cytotoxic T cells (CD45+CD3+CD8+)\* which are activated and secrete IFNgamma and/or interleukin-2 (IL2) upon stimulation with mixture of peptides, covering the immunodominant sequence domains of the nucleocapsid N, membrane M, and spike glycoprotein S proteins of SARS-CoV-2 coronavirus. \* CD, cluster of differentiation
223864945|NCT00004423|DRUG|-aminosalicylic acid|
223864946|NCT00921154|DRUG|ivermectin|Each subject will receive single doses of (i) 30 ml ivermectin oral solution (30 mg) and (ii) 10 x 3 mg tablets of ivermectin (30 mg) in 2 separate dosing periods with a 14 day wash-out period. Doses will be administered after an overnight fast.
223864947|NCT04630600|OTHER|No intervention|Normal waiting room without an aquarium
223864948|NCT04630600|OTHER|Partially-equipped aquarium in the waiting area|Waiting room with a partially-equipped Aquarium
223864949|NCT04630600|OTHER|Fully-equipped aquarium in the waiting area|Waiting room with a fully-equipped Aquarium
223864950|NCT01742169|BEHAVIORAL|Outreach and Reminder Intervention|This intervention includes (1) phone calls and text messages to inform participants that they are due for colorectal cancer (CRC) screening (2) mailed fecal occult blood test (FOBT) to participants so they can perform the test conveniently at home and mail them to the clinic, avoiding the need for a visit (3) plain language information and instructions to support understanding of CRC and FOBT use (4) a CRC screening coordinator to contact those still failing to complete testing by telephone or text (5) a feedback loop to patients regarding test results.
223864951|NCT05492409|BIOLOGICAL|GNR-069|Once a week as a subcutaneous injection.
223864952|NCT01113931|DRUG|Doxycyline Hyclate tablet|200 mg tablet, once daily for 7 days
223864953|NCT01113931|DRUG|Vibramycin (doxycyline hyclate) capsule|100 mg capsule, twice daily for 7 days, over-encapsulated
223864954|NCT02250118|DRUG|Bevacizumab|Intrapleural Bevacizumab
223864955|NCT00525486|DRUG|Nifedipine extended release|Nifedipine extended release PO 30 mg X2/d until 34 weeks' gestation
223864956|NCT06116708|DEVICE|Kalogon AF Prototype Smart Cushion|The Kalogon cushion is a dynamic smart cushion that utilizes a combination of foam and 5 adjustable air cells to intelligently redistribute weight and increase comfort for users. The air cells are used to modulate interface pressures and adjust where support or pressure reductions are provided based on input from the controller's pressure sensing system.
223864957|NCT06116708|DEVICE|Standard Seat Cushion from Air Force|This is the standard seat cushion that was provided by the United States Air Force to use for this study. It is a high-density, molded polyurethane foam.
223864958|NCT01402531|DRUG|Submucosal Bevacizumab|200 mg Bevacizumab, injected submucosally- 100 mg per nostril
223864959|NCT04559126|DRUG|EDP-297|EDP-297 Oral solution
223864960|NCT04559126|DRUG|Placebo|placebo to match EDP-297
223864961|NCT00071799|DRUG|Azacitidine|Azacitidine was injected subcutaneously (SC) at an initial dose of 75mg/m\^2/day for 7 days. The 7-day dosing was repeated every 28 days with dose adjustment based on predefined hematology and renal laboratory results. Number of cycles: Azacitidine treatment was to be continued until the end of the study unless treatment was discontinued due to unacceptable toxicity, relapse after complete or partial response, transformation to AML or disease progression.
223864962|NCT00071799|OTHER|Physician Choice|"Physician Choice was one of three options:~* Best supportive care (BSC) alone,~* Low-dose cytarabine subcutaneously for 14 days every 28 to 42 days, or~* Standard chemotherapy administered for induction as a continuous intravenous infusion of cytarabine over 7 days plus an anthracycline (daunorubicin, idarubicin, or mitoxantrone) on Days 1, 2, and 3; and, for those eligible, 1 or 2 consolidation cycles administered as continuous intravenous infusions of cytarabine for 3 to 7 days with the same anthracycline that was used at induction on Days 1 and 2 (each cycle between 28 to 70 days from the start of the previous cycle).~All three options included best supportive care"
224076426|NCT04666155|DEVICE|Standard of care with Trans-Anal Irrigation|Patients under the active comparator arm of the study should continue with their individualized standard of care againts constipation for the 12weeks of intervention. The following 8 weeks they can keep on using SocTAI or ICE device or both.
223864963|NCT05728684|BIOLOGICAL|CM310|CM310 Injection
223864964|NCT02393001|OTHER|Dermatology patients|Cleanse an area of unafflicted (control) skin with a cotton 2 x 2 dampened with saline.
223864965|NCT02393001|OTHER|Dermatology patients|Cleanse a suspicious lesion (potential melanoma) with a saline cotton swab.
224076427|NCT05880368|OTHER|Patient partnership tools|The intervention consists of two patient partnership tools: (1) a one-page 'visit prep guide' given to relevant patients by clinic staff before seeing the primary care provider, with the intention to improve communication and shared decision-making; and (2) a series of short educational videos that clinic staff can encourage patients to watch. The interventions will be included in the workflow of the clinics during the intervention periods (i.e., clinics either do not use the intervention or use them for all relevant patients depending on study period).
223864966|NCT02393001|OTHER|Dermatology patients|This intervention follows the standard of care for patients with a suspicious skin lesion (potential melanoma) the physician plans to biopsy. The alcohol swab used to prep the site will be stored for testing rather than discarded.
223864967|NCT02393001|OTHER|Dermatology patients|Cleanse an area of unafflicted (control) skin with an alcohol swab.
223864968|NCT04735315|OTHER|Preterm birth|The study compares young adult subjects born premature (\< 29 weeks) versus term \> 37-41 weeks)
223864969|NCT00111722|DRUG|MK0462, rizatriptan benzoate / Duration of Treatment -1day|
223864970|NCT00111722|DRUG|Comparator: placebo / Duration of Treatment - 1 day|
223864971|NCT05094050|DRUG|ABBV-951|Continuous Subcutaneous Infusion (CSCI)
223864972|NCT02623868|DRUG|CKD-519 50mg 2Tabs.|after taking Standard meal, CKD-519 50mg 2Tabs. administration.
223864973|NCT02623868|DRUG|CKD-519 100mg 1Tab.|after taking Standard meal, CKD-519 100mg 1Tab. administration.
223864974|NCT02623868|DRUG|CKD-519 100mg 1Cap.|after taking Standard meal, CKD-519 100mg 1Cap. administration.
223864975|NCT00002919|BIOLOGICAL|filgrastim|
223864976|NCT00002919|DRUG|cisplatin|
223864977|NCT00002919|DRUG|doxorubicin hydrochloride|
223864978|NCT00002919|DRUG|methotrexate|
223864979|NCT00002919|DRUG|vinblastine sulfate|
223864980|NCT00002919|PROCEDURE|conventional surgery|
223864981|NCT04032353|OTHER|Medical Consortium|subjects received intensive follow-up by coordinators according to the predifined protocol of MCSC
223864982|NCT03959241|PROCEDURE|Mobilized Peripheral Blood Stem Cell graft with Tacrolimus/Methotrexate|Mobilized PBSC grafts will be administered on Day 0 to all patients according to individual institutional guidelines after appropriate processing and quantification has been performed by the local laboratory. Stem cells are administered through an indwelling central venous catheter. If infusion occurs over two days, Day 0 is the first day the infusion is initiated.
223864983|NCT03959241|DRUG|Tacrolimus|Tacrolimus will be given per institutional practices, orally at a dose of 0.05-0.06 mg/kg/day or intravenously at a dose of 0.02-0.03 mg/kg/day starting on Day -3. The dose of tacrolimus may be rounded to the nearest 0.5 mg for oral formulations. Subsequent dosing will be based on blood levels per institutional guidelines with a suggested range of 5-15. If patients are on medications which alter the metabolism of tacrolimus (e.g.concurrent CYP3A4 inhibitors), the initial starting dose and subsequent doses should be altered as per institutional practices. Tacrolimus taper can be initiated at a minimum of 90 days post HCT if there is no evidence of active GVHD. The rate of tapering will be done according institutional practices and patients should be off tacrolimus by Day 180 post HCT if there is no evidence of active GVHD.
223864984|NCT03959241|DRUG|Methotrexate|Methotrexate will be administered at the doses of 15 mg/m2 IV bolus on Day +1, and 10 mg/m2 IV bolus on Days +3, +6 and +11 after hematopoietic stem cell infusion. Methotrexate should be dose reduced, given with leucovorin rescue, or held for complications such as severe mucositis per institutional guidelines.
223864985|NCT03959241|PROCEDURE|Mobilized Peripheral Blood Stem Cell graft with Tacrolimus/Mycophenolate Mofetil/Post-Transplant Cyclophosphamide|Mobilized PBSC grafts will be administered on Day 0 to all patients according to individual institutional guidelines after appropriate processing and quantification has been performed by the local laboratory. Stem cells are administered through an indwelling central venous catheter. If infusion occurs over two days, Day 0 is the first day the infusion is initiated.
223864986|NCT03959241|DRUG|Tacrolimus|Tacrolimus will be given per institutional practices, orally at a dose of 0.05-0.06 mg/kg/day or intravenously at a dose of 0.02-0.03 mg/kg/day starting Day +5. Starting tacrolimus dose can be modified to account for possible drug interactions (e.g. concurrent CYP3A4 inhibitor use) according to institutional guides. Serum levels of tacrolimus will be measured at Day +7 and then should be checked weekly thereafter, and the dose adjusted accordingly to maintain a suggested level of 5-15 ng/mL. Tacrolimus taper can be initiated at a minimum of 90 days post HCT if there is no evidence of active GVHD. The rate of tapering will be done according to institutional practices but patients should be off tacrolimus by Day 180 post HCT if there is no evidence of active GVHD
223864987|NCT03959241|DRUG|Mycophenolate Mofetil|MMF will be given at a dose of 15 mg/kg/dose ter in die (TID) (based upon actual body weight) with the maximum total daily dose not to exceed 3 grams (1g TID, IV or PO). MMF prophylaxis will start Day +5 and discontinue after the last dose on Day +35, or may be continued if active GVHD is present.
223864988|NCT03959241|DRUG|Cyclophosphamide|Cyclophosphamide \[50 mg/kg ideal body weight (IBW); if actual body weight (ABW) \< IBW, use ABW\] will be given on Day +3 (between 60 and 72 hours after the start of the PBSC infusion) and on Day +4 post-transplant (approximately 24 hours after Day +3 cyclophosphamide). Cyclophosphamide will be given as an IV infusion over 1-2 hours (depending on volume).
223864989|NCT02418013|OTHER|Fresh cord blood(experimental group A)|"1. Cord blood is administered through intravenous at CHA clinical trail institute.~2. Chlorpheniramine maleate at the concentration of 0.6ml/10kg is administered prior to the treatment."
223864990|NCT02418013|OTHER|Frozen cord blood(experimental group B)|"1. Cord blood is administered through intravenous at CHA clinical trail institute.~2. Chlorpheniramine maleate at the concentration of 0.6ml/10kg is administered"
223864991|NCT02418013|OTHER|Frozen plasma(experimental group C)|"1. Cord blood is administered through intravenous at CHA clinical trail institute.~2. Chlorpheniramine maleate at the concentration of 0.6ml/10kg is administered"
223864992|NCT02418013|OTHER|Placebo group|"A placebo agent is administered through intravenous at CHA clinical trail institute.~It should be certain that when administered, participants are not aware of which treatments are preformed."
223864993|NCT06537167|DEVICE|Transcutaneous electrical acupoint stimulation|Participants will receive proper transcutaneous electrical acupoint stimulation treatment for three consecutive days. Each day, the selected five target acupoints (Renying, Quchi, Taichong, Zusanli, and Hegu) will be stimulated in rotation. Each acupoint will be stimulated once a day for 10 minutes, with a 2-minute interval between each acupoint, totaling 60 minutes. Throughout the trial, the stimulation parameters for each participant will remain constant, and the treatment will begin between 8:00 and 10:00 AM each day.
223864994|NCT06537167|DEVICE|Sham stimulation|Participants will receive sham stimulation treatment, where the left-side skin near the selected five target acupoints (avoiding other functional acupoints) will be stimulated in rotation. The stimulation time and method will be the same as in the experimental group. Throughout the trial, the stimulation parameters for each participant will remain constant, and the treatment will begin between 8:00 and 10:00 AM each day.
223864995|NCT05230680|DRUG|ACHOP|"1. Phase I Azacitidine D-2\~D1, starting from dose level 1. Based on the BOIN design described above, if no DLT is identified in level 1, the dose will be escalated stepwise to levels 2, 3, and then 4.~   Azacitidine combined with CHOP regimen every 3 weeks as below:~  * Level 1 - Azacitidine 50mg/m2 D-2, -1, 1~  * Level 2 - Azacitidine 75mg/m2 D-2, -1, 1~  * Level 3 - Azacitidine 100mg/m2 D-2, -1, 1~  * Level 4 - Azacitidine 125mg/m2 D-2, -1, 1~   Azacitidine at each level will be combined with the corresponding CHOP regimen as follows:~  * Cyclophosphamide 750mg/m2 d1~  * Doxorubicin 50 mg/m2 d1~  * Vincristine 1.4 mg/m2 (Max: 2 mg) d1~  * Prednisolone 100mg PO d1-5~2. Phase II~   * Azacitidine determined dose daily for D-2, -1, 1~  * CHOP (Cyclophosphamide 750mg/m2 d1, Doxorubicin 50 mg/m2 d1, Vincristine 1.4 mg/m2 (Max: 2 mg) d1, Prednisolone 100mg PO d1-5), 6 cycles in total"
223864996|NCT02919176|DRUG|Mirabegron|Mirabegron 50 mg/day
223864997|NCT02919176|DRUG|Pioglitazone|Pioglitazone 30 mg/day
223864998|NCT02919176|DRUG|Mirabegron and Pioglitazone|Mirabegron 50 mg/day and Pioglitazone 30 mg/day
223864999|NCT01145885|DRUG|BI 6727|PLK-1 inhibitor
223865000|NCT01023490|DRUG|Vitamin D|34,5000 IU vitamin D per week
223865001|NCT01023490|DRUG|Placebo|Placebo
223865002|NCT02673788|OTHER|observation without intervention in this follow up study|observation without intervention in this follow up study
223865003|NCT04243304|OTHER|11C-UCB-J PET-CT|Positron Emission Tomography (PET) of synaptic vesicle protein 2A (SV2A) using the radioligand 11C-UCB-J.
223865004|NCT04243304|OTHER|18F-PE2I PET-MR|Positron Emission Tomography (PET) of dopamine transporter (DAT) using the radioligand 18F-FE-PE2I, and brain MRI performed simultaneously.
223865005|NCT03329391|BEHAVIORAL|Nurse-led cognitive-behavioral-based group intervention|The intervention focused on the following topics of symptom awareness(i.e. provision of literacy in depression and stress), stress management, lifestyle restructuring and emotional self-care. These topics have been integrated as four major domains for discussions in the eight-weekly sessions. Each session starts with open discussion for participants' daily concerns to activate group dynamics, followed by second part of domain-oriented discussions, and then the third part of session review and homework reminder.
223865006|NCT02144584|DRUG|Memantine XR|The active drug will be encapsulated by the University of Utah Research Pharmacy to maintain blinding.
223865007|NCT02144584|DRUG|Placebo (for memantine)|Placebo to be capsuled to look identical to active drug (memantine)
223865008|NCT02667808|OTHER|Focus Group|Subjects will participate in four to eight group discussions aimed to evaluate fertility intentions, family planning, and sexual health behaviors. Discussions will be 1-2 hours in length. Groups will be conducted among men and women.
223865009|NCT02667808|OTHER|Questionnaire|Participants will complete a questionnaire assessing reproductive health knowledge, attitudes and practices related to family planning, and fertility and sexual health. The questionnaire will take no longer than 30 minutes to complete.
223865010|NCT00488410|DEVICE|Doppler echocardiography|
223865011|NCT03702673|DRUG|K-877 CR Tablet A|K-877 Controlled Release Tablet A
223865012|NCT03702673|DRUG|K-877 CR Tablet B|K-877 Controlled Release Tablet B
223865013|NCT03702673|DRUG|K-877 CR Tablet E|K-877 Controlled Release Tablet E
223865014|NCT03702673|DRUG|K-877 IR Tablet|K-877 Immediate Release Tablet
223865015|NCT05800405|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223865016|NCT05800405|BIOLOGICAL|Chimeric Antigen Receptor T-Cell Therapy|Receive CAR-T per standard of care
223865017|NCT05800405|PROCEDURE|Computed Tomography|Undergo PET/CT
223865018|NCT05800405|RADIATION|External Beam Radiation Therapy|Undergo radiation therapy
223865019|NCT05800405|PROCEDURE|Leukapheresis|Receive leukapheresis
223865020|NCT05800405|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223865021|NCT05800405|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
223865022|NCT04116515|BEHAVIORAL|Xbox / active video games|The investigators would expect children to play active video games as a way to reduce their sedentary activities and increase their moderate and vigorous physical activities.
223865023|NCT04116515|BEHAVIORAL|Animated cartoon narratives|The investigators would expect the animated cartoon narratives to motivate children to play more active video games as a way to reduce their sedentary activities and increase their moderate and vigorous physical activities.
223865024|NCT04116515|BEHAVIORAL|Standard clinical care|Each clinic will provide standard clinical care to the participants.
223865025|NCT01234844|BEHAVIORAL|care of guinea pigs|twice weekly sessions of care with guinea pigs
223865026|NCT01234844|BEHAVIORAL|guinea pigs|"twice weekly pet therapy and twice weekly usual  occupational therapy"
223865027|NCT04925648|DRUG|Dasatinib|Dasatinib 100mg once daily orally for 14 Days
223865028|NCT04925648|DRUG|Darolutamide|Darolumatide 600 mg twice daily orally for 14 Days
223865029|NCT01511471|DRUG|Ticagrelor|Ticagrelor 90mg twice a day for 15 days
223865030|NCT06109831|DRUG|SHR-1918|SHR-1918
223865031|NCT06109831|DRUG|SHR-1918 placebo|SHR-1918 placebo
223865032|NCT06257693|DRUG|enzalutamide|Localized single delivery of the Enolen implant (polymer + enzalutamide) with planned radical prostatectomy
223865033|NCT03993613|BIOLOGICAL|human apotransferrin|Intravenous infusions
223865034|NCT00482378|DRUG|Pamidronate|90 mg by IV monthly.
223865035|NCT00482378|DRUG|Zoledronic acid|4 mg by IV monthly.
223865036|NCT00482378|RADIATION|Sm 153 lexidronam|0.5 mCi/kg or 1 mCi/kg by IV.
223865037|NCT06326632|OTHER|Constant-load Aerobic Exercise|The CL-AE group received a 12-week aerobic training, three times in addition to the respiratory re-training. the program included a moderate-intensity aerobic training program, with an intensity set at 65% of the maximum age-predicted heart rate for 45 minutes. The training intensity and duration were maintained at the same level throughout the program. The CL-AE program included a warm-up for 5 minutes and a cool-down for 5 minutes
223865038|NCT06326632|OTHER|Graded Aerobic exercise|The G-AE group received a 12-week intensity- and duration-graded aerobic training, three times in addition to the respiratory re-training. The G-AE program commenced with a training intensity corresponding to 50% of the maximum age-predicted heart rate for 25 minutes in the first two weeks, which progressed on a two-week basis, and ended up with a training intensity corresponding to 75% of the maximum age-predicted heart rate for 50 minutes in the last two weeks. The G-AE program also included a warm-up for 5 minutes and a cool-down for 5 minutes.
223865039|NCT06326632|OTHER|Respiratory Re-training|The respiratory re-training lasted for 30 minutes per session and was repeated three times a week for 12 consecutive weeks. The program consisted of diaphragmatic breathing exercises, breath-hold, and breathing control exercises, pursed lip breathing, respiratory muscle strengthening, postural correction exercises, and relaxation techniques.
223865040|NCT01637662|DRUG|Natriuretic peptides|I.V. infusion between 0.2-3 microgram over 20 minutes
223865041|NCT05214287|DRUG|Hypoxic Gas Mixture|Using a commercially available hypoxicator, varying gas mixtures as described will be administered via a tight-fitting oxygen mask. In the circuitry, a three-way valve is placed that allows for the intermittent administration of hypoxia: the valve either passes the hypoxic mixture from the hypoxicator or room air.
223865042|NCT06174662|DEVICE|Music|The patient can decide the music genre (a standard playlist) and receives a noise-cancelling headphone playing the chosen music during mobilization.
223865043|NCT02846480|OTHER|physical therapy|"Pre-surgical Physical Therapy: physical therapy aimed to correct the posture, to the awareness and the strengthening of the pelvic floor muscles.~Post-surgical Physical Therapy: checking the correct contraction of the pelvic floor muscles and hypopressive exercises."
223865044|NCT02846480|OTHER|surgical treatment|Surgical correction of POP.
224267692|NCT06559800|BEHAVIORAL|YourSkills: Cognitive behavioral therapy for children/youth with role-plays in virtual reality|A program for children/youth with anger problems or aggressive behaviors based on social learning theory and cognitive behavior therapy (CBT), incorporating virtual reality (VR) when conducting brief role-plays. The program includes similar strategies as other CBT-oriented programs for anger problems, with the addition of VR for practicing skills.
224267693|NCT01930409|BEHAVIORAL|Telephone Support and Coaching|"The participants will receive up to 5 telephone calls of 30-45 minutes each after hospital discharge to provide support and education for the transition from acute to community care. The first call will be made within 48-72 hours of hospital discharge and will have the following elements:~* Health Status~* Medication Management~* Activity/Exercise Prescription and Goal-Setting~* Falls Prevention~* Clarification of Appointments~* Coordination of Post-Discharge Home Services~* What To Do If a Problem Arises"
224267694|NCT01930409|BEHAVIORAL|Education Only|An educational toolkit will be provided, with materials to self manage at home after hospital discharge following a fall related hip fracture
224267695|NCT03103711|BEHAVIORAL|Virtual Reality Intervention|"Participants receive two sessions oriented to joy and two focused on relax. In the first 2 sessions patients can choose the environment (Emotional Parks or Walk through Nature) and in the following ones participants visit the alternate environments."
224267696|NCT03948022|DRUG|Dydrogesterone 10Mg Tablet (duphaston)|40 mg daily oral tablets
224267697|NCT03948022|DRUG|Progesterone 50Mg/mL Oil|100 mg daily intramuscular injections
224267698|NCT03948022|DRUG|Crinone 8% Vaginal Gel|180 mg daily vaginal gels
224267699|NCT03141853|OTHER|Equine-assisted Therapy|Participants will groom and ride horses. Horses will be kept at a walk with tasks such as serpentine, circles, and zig zags to complete. Stretching, and tasks like throwing a ball into a net from horseback will be completed
224267700|NCT03141853|OTHER|Arthritis Exercise Education|Standard of Care from the Arthritis Foundation - How-to Exercise With Arthritis. (n.d.). Retrieved April 18, 2016, from http://www.arthritis.org/living-with-arthritis/exercise/how-to). This intervention will consist of 6 -1 hour education sessions once a week on exercise to improve symptoms of arthritis
224267701|NCT05643833|OTHER|no intervention|no intervention
224267702|NCT03639077|DEVICE|Allograft bone alone|The subject will receive an allograft as graft material of choice for sinus augmentation
224267703|NCT03639077|DEVICE|Allograft and xenograft mixture|The subjects will receive a mixture of allograft and anorganic bovine bone xenograft as graft material of choice for sinus augmentation
224267704|NCT02949167|BEHAVIORAL|MyHealth|The MyHealth intervention is a nurse-led individually tailored symptom management program, focused on patient education and regularly collection of Patient Reported Outcomes (PRO) subsequently evaluated by specialist nurses and navigation to health care service. The nurse will meet with the patient on three-five planned appointments focused on adjustment of life after breast cancer treatment including information on symptoms of relapse or late effects and how to react on these. Close relatives are invited if patients accept. Patients will report PRO´s on symptoms of recurrence and late effects every three months during the first year and thereafter every six months.The appointments with the nurse are finalized within 3-6 month and patients will be followed with PRO for three years.
224267705|NCT02095054|DRUG|Regorafenib|"Dose Escalation Group Starting Dose of Regorafenib: 80 mg by mouth once a day for 21 days (5 days on and 2 days off) in a 28 days cycle.~Dose Expansion Group Starting Dose of Regorafenib : MTD from Dose Escalation Group."
224267706|NCT02095054|DRUG|Cetuximab|"Dose Escalation Group Starting Dose of Cetuximab: 200 mg/m2 initial dose, then 150 mg/m2 by vein over about 1-2 hours on Days 1, 8, 15, and 22 of each 28 day cycle.~Dose Expansion Group Starting Dose of Cetuximab: MTD from Dose Escalation Group."
224267707|NCT02095054|BEHAVIORAL|Questionnaire|Symptom questionnaire completed at each study visit.
224267708|NCT05319847|DIETARY_SUPPLEMENT|Daily Skin Supplement - Fountain of Youth|Skincare supplement
224267709|NCT05153304|BIOLOGICAL|personalized vaccine|Vaccine will be constructed for each subject that express multiple candidate tumor-derived neoantigens.
224267710|NCT05153304|DRUG|Nivolumab|3mg/kg nivolumab will be administered intravenous (IV) infusion every 3 weeks for 4 doses. After 4 doses, 480 mg nivolumab will be administered intravenous (IV) infusion every 4 weeks.
224267711|NCT01193972|OTHER|Decision aid|Decision aid to assist patients in making a decision about smoking during the perioperative period
224267712|NCT00875524|BIOLOGICAL|CYD dengue vaccine serotypes (1, 2, 3, 4).|0.5 mL, Subcutaneous
224267713|NCT00875524|BIOLOGICAL|Meningococcal Polysaccharide A+C; NaCl; Typhoid Vi polysaccharide|Each at 0.5 mL, Subcutaneous, respectively
224267714|NCT06445049|OTHER|brief test|"The intervention is a simple brief test as follows: With the ventilator set with the patient clinical settings, it will be performed an up to 30sec-long or two inspiratory effort and-expiratory occlusion maneuver on the ventilator and/or switch the patient to pressure support for up to 30sec-long to assess the presence of intrinsic respiratory rate.~If an intrinsic respiratory rate ≥8 breaths per minute is present and P/F ratio is ≥150 it will be performed a 5-minute test in pressure support ventilation with the pressure support level to match the clinical setting of the patient. If the patient tolerates well 5 minutes in pressure support (see criteria below) the clinical team will be informed:~\- It will be indicated that the patient tolerated 5 min of PSV and suggest to the clinicians and physician in charge to transition the patient to pressure support ventilation plus suggest reducing sedation."
224267715|NCT06562101|PROCEDURE|Intra-articular Stromal Vascular Fraction Injection|Adipose tissue was harvested using the Q-graft system (Human Med®) from the abdominal subcutaneous fat of patients under local anesthesia. After concentration and resuspension in normal saline, 5 mL of the SVF suspension was injected into the knee joint cavity under sterile conditions.
224267716|NCT02495207|DEVICE|Piezosurgery|This intervention is dependent on use of piezosurgery to conduct the required bone cuts to remove third molars.
224267717|NCT00629304|DEVICE|placebo|Patients will have face to face visits at 3 and 6 months and no PDA-FIT system. Patients will record glycemia on paper support.
224267718|NCT00629304|DEVICE|VISITS + PDA-FIT system|patients will have face to face visits at 3 and 6 months + PDA-FIT system
223865045|NCT02846480|OTHER|behavior therapy|At hospital discharge, patients will receive a fact sheet on the sanitary and behavioral measures recommended for the prevention of POP and urinary incontinence (proper weight, prevent constipation, avoid weight bearing and cough and high impact exercise).
223865046|NCT02120911|DRUG|Pertuzumab, trastuzumab|Pertuzumab and trastuzumab will be combined with standard chemoradiation with carboplatin and paclitaxel.
223865047|NCT03855891|DIAGNOSTIC_TEST|blood test|Blood test for spectrum and level of cardiospecific micro-RNA
224267719|NCT00629304|DEVICE|PDA-FIT System + telephone follow-up|patients will received PDA-FIT system + a telephone follow up (12 phone calls) and a face to face visit at 6 months
224267720|NCT01521715|DRUG|Pazopanib|800 mg (2x400mg) pazopanib per day should be taken orally without food at least one hour before or two hours after a meal until progression or occurrence of intolerable toxicity.
224267721|NCT04019015|DRUG|Prothrombin Complex Concentrate, Human|Prothrombin Complex Concentrate (PCC) prepared from human plasma and contains blood coagulation factors
224267722|NCT04019015|DRUG|Placebo|Normal saline solution
224267723|NCT01370863|DRUG|SPD557|0.5 mg tablet t.i.d. for 4 weeks on top of stable PPI treatment
224267724|NCT01370863|DRUG|placebo|matching placebo tablet t.i.d. for 4 weeks on top of stable PPI treatment
224267725|NCT00000595|DRUG|deferoxamine|
224267726|NCT00375284|DRUG|Pramipexole|
224267727|NCT06557603|DRUG|Ivermectin cream|\[1 gm ± 0.030 gm\] of product was applied in a thin layer over the entire face (avoiding the eyes, lips, and mucous membranes).
224267728|NCT06557603|DRUG|Soolantra ® (Ivermectin) cream|\[1 gm ± 0.030 gm\] of product was applied in a thin layer over the entire face (avoiding the eyes, lips, and mucous membranes).
224267729|NCT01195233|DRUG|bioxtra|spray /mouth rinse
224267730|NCT01143337|DRUG|MP-435(dose1) + Methotrexate|MP-435 dose1 + stable weekly dose of Methotrexate
224267731|NCT01143337|DRUG|Placebo + Methotrexate|Placebo + stable weekly dose of Methotrexate
224267732|NCT02225015|BEHAVIORAL|Follow-up Telephone Genetic Counselling|Individualized theoretical genetic counselling among women with BRCA mutations to assess the impact it has on the uptake of cancer prevention strategies.
224267733|NCT05533411|DRUG|Donanemab|Administered IV.
224267734|NCT05533411|DRUG|Placebo|Administered IV.
224267735|NCT00834561|DRUG|Lamotrigine|200 mg Tablet
224267736|NCT00834561|DRUG|Lamictal®|200 mg Tablet
224267737|NCT00538109|DRUG|Glivec®/Gleevec®|Chemotherapy
224267738|NCT04968951|DRUG|Metronidazole|Antibiotic treatment - 250 mg every 6 hrs for 5 days
224267739|NCT04968951|DRUG|Placebo|Placebo treatment
224267740|NCT04968951|DRUG|Vancomycin|Antibiotic treatment - 125 mg every 6 hrs for 5 days
224267741|NCT04968951|BIOLOGICAL|Fecal Microbiota Transplantation|Encapsulated biologically active human fecal material (donor stool) is provided in capsule form. The fecal material is homogenized with sterile saline, then pelleted and re-suspended in sterile saline/40% glycerol. Participants will receive 15 FMT capsules per day for 3 consecutive days. Capsule are to be swallowed under direct supervision.
224267742|NCT03065751|DEVICE|Plasmaexchange|TPE against fresh frozen plasma
223865048|NCT06639282|DRUG|Siponimod|Siponimod (formerly known as BAF312 and completed trial NCT #01665144) has been FDA approved since 2019 (IND #076122) for the treatment of multiple sclerosis. Siponimod is an immunomodulator that prevents the egression of T lymphocytes from peripheral lymphoid organs.
223865049|NCT06639282|DRUG|Placebo|A placebo that resembles siponimod will be given once daily to participants randomly assigned into the placebo arm.
223865050|NCT01271452|BIOLOGICAL|botulinum toxin type A|20 units (total dose) botulinum toxin type A injected into glabellar region on Day 0
223865051|NCT01271452|BIOLOGICAL|botulinum toxin type A|30 units (total dose) botulinum toxin type A injected into glabellar region on Day 0
223865052|NCT03616639|DRUG|Oxycodone|Both continuous administration by a syringe driver as well as bolus administration every 4 hours will be regarded as continuous subcutaneous infusion (CSCI). Dosage and dosage modifications are in accordance with the Dutch national guideline.
223865053|NCT03616639|DRUG|Morphine|Both continuous administration by a syringe driver as well as bolus administration every 4 hours will be regarded as continuous subcutaneous infusion (CSCI). Dosage and dosage modifications are in accordance with the Dutch national guideline.
223865054|NCT03590080|DRUG|Methylprednisolone|
223865055|NCT05022251|PROCEDURE|Lumbar discectomy|surgically removing a hernia
223865056|NCT00346151|DRUG|Belatacept|10 mg/kg given intravenously (IV) on transplant (day 1), day 5, and at weeks 2, 4, 8 and 12, then 5 mg/kg IV every 4 weeks
223865057|NCT00346151|DRUG|Sirolimus|4 mg/day (oral tablet) at transplant (day 1), then dose adjusted to maintain serum trough level of 8-12 ng/mL for at least 1 year
223865058|NCT00346151|DRUG|Anti-thymocyte globulin|1.5 mg/kg given IV daily on days 1 through 4. Subjects are premedicated with glucocorticoids, acetaminophen 650 mg by mouth, and diphenhydramine 25- 50 mg by mouth prior to each dose.
223865059|NCT00346151|DRUG|methylprednisolone|500 mg given IV at transplant (day 1), then given 250 mg IV on day 2 and given 0.5 mg/kg IV or prednisone 0.5 mg/kg given by mouth on days 3 and 4
224076428|NCT05723653|BEHAVIORAL|Social Network Support Intervention|The Social Network Support Intervention is an evidence-based, flexible, and tailored intervention that leverages existing social network members to promote retention in care and viral suppression among people living with HIV. The intervention consists of (1) selection and invitation of a Support Confidant, (2) a face-to-face intervention between the Intervention Case Manager and the Index and Support Confidant, and (3) quarterly interactive mini-booster sessions delivered to the Index and Support Confidant via text or telephone, based on participant preference.
224076429|NCT06414473|DRUG|Cannabidiol (CBD) Extract|Administered thrice daily (with food) using a sublingual route of administration
224076430|NCT06414473|DRUG|Placebo|Administered thrice daily (with food) using a sublingual route of administration
223865060|NCT04051255|DRUG|full mouth ultrassonic debridement associated to Amoxicilin 500 + Metronidazole 400 mg|The patients were treated by a single-session of periodontal debridement under local anaesthesia during 45 minutes, using an ultrasonic instrument#, using subgengival tips\* and irrigation with sterile saline solution, by the same operator (MGC, Paulista University, São Paulo, Brazil). After the debridement, all patients was prescribed with Amoxicillin 500 mg and Metronidazole 400 mg, every 8 hours, for 10 days (Casarin et al., 2012). Subjects were extensively informed about the intake of the prescribed medication. Subjects were clinically and microbiologically monitored at baseline (before therapy) and at 3 and 6 months post-therapy. During the monitored sessions, oral hygiene was evaluated and home care instructions were re-emphasized. Additionally, all subjects were recalled monthly for oral hygiene instructions.
223865061|NCT05677438|DRUG|CKD-498 dose#1|oral, once daily, 24 weeks
223865062|NCT05677438|DRUG|CKD-498 dose#2|oral, once daily, 24 weeks
223865063|NCT05677438|DRUG|CKD-498 dose#3|oral, once daily, 24 weeks
223865064|NCT05677438|DRUG|Placebo of CKD-498 dose#1|oral, once daily, 24 weeks
223865065|NCT05677438|DRUG|Placebo of CKD-498 dose#2|oral, once daily, 24 weeks
223865066|NCT05677438|DRUG|Placebo of CKD-498 dose#3|oral, once daily, 24 weeks
223865067|NCT00910767|DEVICE|Conventional insulin pump delivery|Subcutaneous delivery of Novorapid insulin according to usual pump regime
223865068|NCT00910767|DEVICE|Closed loop|Subcutaneous delivery of Novorapid insulin, dose calculated by control algorithm, based on continuous glucose sensor readings
223865069|NCT03089840|DEVICE|OrganOx metra|Following the routine retrieval procedure at the donor hospital the liver will be flushed with cold preservation solution and prepared for cannulation. The donor organ is then placed on the OrganOx metra device and will be perfused with warmed solution. The OrganOx metra device containing the donor organ is then transported to the recipient transplant centre. The donor liver is then removed from the device and flushed with standard of care preservation solution. Alternatively, where more practical, the livers will be transported to the University of Alberta hospital with ≤ 6 hours of cold storage and then placed on the metra™ for ≥ 4 hours. Implantation and reperfusion of the liver proceed as per the usual practice of the recipient transplant centre.
223865070|NCT00477776|DRUG|Metoclopramide (Maxolon)|Metoclopramide 10 mg 3 times a day for 7 days, 2 times a day from day 8 to day 10, once a day for day 11 and 12
223865071|NCT00477776|DRUG|Placebo|Placebo 10 mg 3 times a day for 7 days, 2 times a day from day 8 to 10, once a day from day 11 to 12
223865072|NCT06441539|DEVICE|Bingo® Paclitaxel coated balloon|Treat the main vessel and side branch of bifurcation lesion with drug-eluting balloon
223865073|NCT06441539|DEVICE|Xience® Alpine Everolimus Eluting Coronary Stent System|Treat the main vessel of bifurcation lesion with drug-eluting stent, and treat the side branch with uncoated balloon or drug-eluting stent
223865074|NCT00281489|DEVICE|BIS Monitor guided algorithm|BIS guided algorithm (BIS target 40 to 60) during anesthesia. Alarms when BIS is outside this range.
223865075|NCT00281489|BEHAVIORAL|Volatile anesthetic guided algorithm|Volatile anesthetic guided algorithm. Target anesthetic concentration 0.7 to 1.3 minimum alveolar concentration during anesthesia. Alarms when anesthetic concentration not in this range.
223865076|NCT03842488|DRUG|Experimental: RAL QD|Prescription of 2x RAL 600mg (1200MG) once daily
223865077|NCT03842488|DRUG|Active comparator: DRV/cb|Prescription of DARUNAVIR/COBICISTAT 800 Mg-150 Mg once daily
223865078|NCT00246714|DRUG|repeated injections of endotoxin during 5 days|
223865079|NCT03897413|DRUG|S-888711|Administered orally as three 0.25 mg tablets
223865080|NCT03897413|DIETARY_SUPPLEMENT|Calcium Antacid|Calcium carbonate 4000 mg chewable tablets
223865081|NCT01948648|DRUG|Colesevelam|Drug is in powder form, each packet contains 3.75g of colesevelam hydrochloride. Participant will mixed it with water and have 1 packet per day during the treatment session.
223865082|NCT01948648|DIETARY_SUPPLEMENT|Fish Oil|In softgel form, contains 660mg EPA and 330mg DHA. Participant consume 1 softgel per day during treatment session.
223865083|NCT01948648|DRUG|Combination of fish oil and colesevelam|combination of both colesevelam and fish oil. Participant will consume 1 packet and 1 softgel per day during treatment session.
223865084|NCT02651233|OTHER|ADRCs therapy|Patients are submitted to manual liposuction and extraction of ADRCS is done with closed system. All patients were candidates for subcutaneous transplantation of autologous cell enriched adipose tissue for different indications.
223865085|NCT00814047|DRUG|Yohimbine hydrochloride|
223865086|NCT00929617|BEHAVIORAL|Experimental 1: exercise with 2 counseling types|Patients will participate in 12 individual exercise sessions with an exercise specialist which will include stretching exercises and aerobic treadmill walking; plus attend 6 discussion group sessions with a trained facilitator; plus 3 face-to-face, individual counseling sessions with an exercise specialist
223865087|NCT00929617|OTHER|Usual Care - written materials|Patients will receive written materials about exercise for cancer survivors
223865088|NCT04911439|OTHER|Low Arousal|This group will see affective images of the International Affective Picture System with low arousal level
223865089|NCT04911439|OTHER|Medium arousal|This group will see affective images of the International Affective Picture System with medium arousal level
223865090|NCT04911439|OTHER|High arousal|This group will see affective images of the International Affective Picture System with high arousal level
223865091|NCT03883529|OTHER|Writing about and reviewing birth experience|Writing about and reviewing birth experience with a known midwife from antenatal care about 6 weeks post-partum.
223865092|NCT01043263|DRUG|EN3324 (axomadol)|twice daily dosing
223865093|NCT01043263|DRUG|Placebo|twice daily dosing
223865094|NCT02219178|DRUG|lenalidomide|25mg days 1 - 14 of 21 day schedule
223865095|NCT02219178|DRUG|Subcutaneous bortezomib|1.3mg/m2 days 1, 4, 8, 11 of 21 day schedule
223865096|NCT02219178|DRUG|Dexamethasone|20mg on days 1, 2, 4, 5, 8, 9, 11, 12 of 21 day schedule
223865097|NCT05881577|OTHER|Observational|Impact of AR on educational outcomes
223865098|NCT05284812|BIOLOGICAL|Low-dose freeze-dried recombinant tuberculosis vaccine (AEC / BC02)|Subjects receive low-dose freeze-dried recombinant tuberculosis vaccine (AEC / BC02) injection into the deltoid muscle of the upper arm
223865099|NCT05284812|BIOLOGICAL|High-dose freeze-dried recombinant tuberculosis vaccine (AEC / BC02)|Subjects receive high-dose freeze-dried recombinant tuberculosis vaccine (AEC / BC02) injection into the deltoid muscle of the upper arm
223865100|NCT05284812|BIOLOGICAL|High-dose adjuvant for freeze-dried recombinant tuberculosis vaccine (AEC / BC02)|Subjects receive high-dose adjuvant for freeze-dried recombinant tuberculosis vaccine (AEC / BC02) injection into the deltoid muscle of the upper arm
223865101|NCT05284812|BIOLOGICAL|Lyophilized recombinant tuberculosis vaccine (AEC / BC02) placebo|Subjects receive Lyophilized recombinant tuberculosis vaccine (AEC / BC02) placebo injection into the deltoid muscle of the upper arm
224076431|NCT04608110|DRUG|ASTX030|In Cycle 1 (28 days per cycle), single dose oral azacitidine formulations will be administered on day -3, followed by subcutaneous (SC) azacitidine on day 1, oral azacitidine formulations and cedazuridine tablets on day 2-7; in Cycle 2 and onward, oral azacitidine formulations and cedazuridine tablets will be administered on day 1-7
223865102|NCT02744521|OTHER|Symptom-based screening intervention|The objective of this study is to evaluate whether empowering and involving inmate peer educators in TB control has an impact on increasing TB case detection rate and improving treatment success in resource-limited prison settings. In this interventional study, inmate peer educators will be trained about TB, its prevention, and control. Once tested for their capability, peer educators will then provide education about TB, its prevention and control for their fellows every two weeks on a regular basis for one year. They will also undertake routine TB screening using a standardized TB screening protocol to identify presumptive TB cases for a referral.
223865103|NCT00717626|DRUG|Kogenate FS, Advate, or Humate-P, Recombinate, Helixate FS|Starting at the 4-month visit, subjects will receive 250 units per day (if their weight is \< 50 kg.) or 500 units per day (weight ≥ 50 kg.) of their usual preparation of factor VIII.
224076432|NCT05238714|DRUG|venglustat|Powder for Oral solution
224267743|NCT04838353|DEVICE|ALV1 System|The ALV1 system is designed to create a controlled size interatrial shunt via a proprietary intra-cardiac catheter. There is no temporary or permanent implant used to create or maintain the interatrial shunt. The therapy is intended to be delivered in a single procedure administered under general anesthesia in a cardiac catheterization laboratory.
224267744|NCT01987128|PROCEDURE|Intraneural injection|BBraun Ropivacaine 1% 12ml injection divided in each sciatic components under echographic guidance with a PAJUNK SonoPlex 22G needle.
224267745|NCT01987128|PROCEDURE|Extraneural injection|BBraun Ropivacaine 1% 12ml extraneural injection around sciatic nerve under echographic guidance with a PAJUNK SonoPlex 22G needle.
224267746|NCT01987128|DRUG|Ropivacaine|
224267747|NCT01987128|DEVICE|PAJUNK SonoPlex 22G needle.|
224267748|NCT06000085|PROCEDURE|restoration of proximal cavities of primary molars with flowable giomer|removal of proximal caries of primary molars and restoration of the cavities prepared by beautifil flow plus x
224267749|NCT06000085|PROCEDURE|restoration of proximal cavities of primary molars with highly viscous glass ionomer cement|removal of proximal caries of primary molars and restoration of the cavities prepared by equia forte
224267750|NCT01371435|DRUG|Paroxetine|
224267751|NCT01501786|DRUG|control|propofol 8mg/kg/h saline 0.24 ml/kg/h
224267752|NCT01501786|DRUG|Ket10|propofol 6.4 mg/kg/h ketamine 10 microg/kg/min
224267753|NCT01501786|DRUG|Ket20|propofol 4.8 mg/kg/h ketamine 20 microg/kg/min
224267754|NCT02442687|DRUG|JKB-121: 5 mg twice daily|
224267755|NCT02442687|DRUG|JKB-121: 10 mg twice daily|
224267756|NCT02442687|DRUG|Placebo|
224267757|NCT06403033|DEVICE|Mini-implant-supported Twin-Block|Mini-implants will support the Twin-Block appliance during the functional treatment.
224267758|NCT06403033|DEVICE|Twin-Block|This is the main appliance that will be used to correct the Class II deformity.
224267759|NCT05077449|DRUG|XZP-3287+Fulvestrant|XZP-3287 360 mg orally Twice daily(Q12H) of every 28-day cycle Fulvestrant 500mg intramuscular injection on day 1 and day 15 for the first cycle and then on day 1 for every cycle (28-day) until progressive disease
224267760|NCT05077449|DRUG|Placebo + Fulvestrant|Placebo 360 mg orally Twice daily(Q12H) of every 28-day cycle Fulvestrant 500mg intramuscular injection on day 1 and day 15 for the first cycle and then on day 1 for every cycle (28-day) until progressive disease
224267761|NCT05853653|BEHAVIORAL|Using dolls in breastfeeding education|Using dolls in breastfeeding education
224267762|NCT00406393|DRUG|Tacrolimus|"Adults and Children: Tacrolimus will be given at a dose of 0.02 mg/kg every 24 hours as a continuous intravenous infusion beginning on Day -3. An effort will be made to convert the tacrolimus to oral dosing at 2-3 times the total 24-hour intravenous dose, split into 2 doses given every 12 hours as soon as clinically feasible.~The target serum level for tacrolimus is 5-10 ng/mL."
224267763|NCT00406393|DRUG|Methotrexate|Methotrexate will be given at a dose of 15 mg/m2 on Day 1 after transplantation, and at a dose of 10 mg/m2 on Days 3, 6 and 11 after transplantation.
224267764|NCT00406393|DRUG|Sirolimus|"Adults: Sirolimus will be given in a loading dose of 12 mg on Day -3 followed by a daily oral dose of 4 mg per day. Doses may be repeated if the subject vomits within 15 minutes of an oral dose.~Children: Children aged \< 12.0 years OR weighing \< 40.0 kg will be given an oral loading dose of sirolimus of 3 mg/m2 followed by a daily oral dose of 1 mg/m2, rounded to the nearest full milligram.~The target serum level for sirolimus is 3-12 ng/mL."
224267765|NCT00841022|OTHER|Information with comics|Information of children with comic leaflet
224267766|NCT00310115|BEHAVIORAL|Smoking Prevention Usual Care|Usual care of self-help materials and advice for staying cigarette free
224267767|NCT00310115|BEHAVIORAL|Counseling Intervention|6 x 30 minute counseling sessions over the telephone
224267768|NCT00310115|BEHAVIORAL|Counseling Intervention|2 in-person counseling sessions
224267769|NCT00002033|DRUG|Zidovudine|
224267770|NCT00002033|DRUG|AS-101|
224267771|NCT03562182|OTHER|blood draw|Blood draw (2.5mL) to assess mRNA LPCAT1 levels
224267772|NCT01597791|DEVICE|Foley catheter|Foley catheter placement after CSE.
224267773|NCT01597791|OTHER|No foley catheter|Spontaneous Micturation/ Post Void Residual. the spontaneous micturition algorithm will be assessed for spontaneous micturition and post void residual (PVR) volumes via ultrasonography at regular time intervals.
224267774|NCT01232660|DRUG|Hydroxychloroquine|Hydroxychloroquine 400mg once daily orally
224267775|NCT05369039|DRUG|Roflumilust|A selective phosphodiesterase 4 Inhibitor
224267776|NCT05369039|DRUG|Prednisolone|Systemic corticosteroid
224267777|NCT02364869|DIETARY_SUPPLEMENT|Fructooligosaccharide|Patients will be evaluated at baseline, week 6 and 12.
224267778|NCT02364869|DIETARY_SUPPLEMENT|Maltodextrin|Placebo Comparator. Patients will be evaluated at baseline, week 6 and 12.
224267779|NCT01087502|DRUG|Glimepiride|1-4 mg daily after 12 weeks
224267780|NCT01087502|DRUG|Placebo|Placebo mach to 5 mg linagliptin first 12 weeks of treatment once daily
224267781|NCT01087502|DRUG|Placebo|Placebo maching Glimepiride 1-4 mg after 12 weeks of treatment
224267782|NCT01087502|DRUG|Placebo|Placebo mach to 5 mg linagliptin once daily after 12 weeks
224267783|NCT01087502|DRUG|Linagliptin|5 mg once daily
224267784|NCT00053339|DRUG|tamoxifen|
224267785|NCT00053339|DRUG|trastuzumab|
224267786|NCT04941313|DRUG|3D229|3D229 is an investigational drug.
224267787|NCT04941313|OTHER|Placebo|Matching placebo
224076433|NCT06431425|BEHAVIORAL|eCG Family Clinic|The DNA-poli is an online tool which is designed as an addition to the current genetic counseling method to make the process more efficient and to increase the uptake without compromising counseling quality. Probands can invite their at-risk family members by entering their email addresses. The family members are invited to the DNA-poli via which they can get all the information needed to make a well-considered decision about genetic testing. The information is provided in different formats, for example via a virtual assistant and via videos, which they can evaluate at their own pace, and which can be reread or rewatched. Afterwards they can request an appointment with a health care professional and make a definite decision about genetic testing.
223865104|NCT01740310|BEHAVIORAL|Maternal Vaccine Education|It is assumed that the women will also receive vaccine education materials from the OB/GYN practices as part of routine care. The intervention for all three arms will be conducted during routine prenatal office visits. Participants will complete a baseline questionnaire to assess attitudes regarding vaccination and will then be randomized to one of three enrollment arms and will be exposed to an intervention designed to take no longer than 20 minutes, so that patients can complete it during the time they are waiting to be seen. While participants are completing the handheld/electronic tablet device-based intervention, the study recruiter will observe them and document dose exposure to the messages being presented. The enrolled women will be contacted a month after the expected date of delivery and a follow up interview will be conducted to ascertain their vaccination status for receipt of influenza vaccine in pregnancy and Tdap during pregnancy or immediately post-partum.
223865105|NCT04688801|DRUG|Chemotherapy Drugs, Cancer|Chemotherapy± Radiotherapy after surgery
223865106|NCT04688801|DRUG|Immunotherapy|Chemotherapy + Immuonotherapy ± Radiotherapy after surgery
223865107|NCT05700513|COMBINATION_PRODUCT|Capsules containing the combination products|Capsules containing dog-rose, Cranberry leaves, Cranberry Berries, Alfalfa, Fenugreek, Lemon Beebrush, Urtica, and Sumac
223865108|NCT05700513|DRUG|Placebo capsules|Placebo capsules containing maltodextrin
223865109|NCT03897348|DRUG|Placebo|Oral medication
223865110|NCT03897348|DRUG|Lacosamide 100 mg|Oral medication
223865111|NCT03897348|DRUG|Lacosamide 200 mg|Oral medication
223865112|NCT00084903|PROCEDURE|Colposcopic biopsy|Two small samples of cervical tissue (biopsy) removed from 2 sites as spectroscopy readings.
223865113|NCT00084903|PROCEDURE|Light-Scattering Spectroscopy|Spectroscopy readings taken in 2 regions of cervix.
223865114|NCT01901510|DRUG|Chromoendoscopy (Indigo Carmine)|Indigo Carmine will be added to the colonic prep to attempt indirect chromoendoscopy
223865115|NCT01901510|OTHER|Control|The control will have minimal Indigo Carmine added to the colonic prep. This will serve to color the solution blue for blinding but not enough to provide significant staining for chromoendoscopy.
223865116|NCT05971680|DRUG|VITAMIN B1 500mg|VITAMIN B1 (High Potency) 500mg tab every day for 3 months
223865117|NCT05971680|DEVICE|intra-uterine contraceptive device|intra-uterine contraceptive device
223865118|NCT04562259|RADIATION|Verification of Kimmerle's anomaly by x-ray methods of research|In patients with Kimmerle's anomaly, using computed tomography of the brain with the capture of the upper cervical spine and cervical spine, it is planned to determine at what age this pathology is more common, localization of the anomaly (right, left), complete or incomplete form of the anomaly.
223865119|NCT03783754|DRUG|telmisartan 20 mg + amlodipine 2.5mg + indapamide 1.25mg|low-dose combination therapy
223865120|NCT03783754|DRUG|Placebo oral capsule|matched placebo
224076434|NCT03212742|DRUG|Olaparib|We propose 7 dose levels to reach the target dose of 400 mg per day (200 mg twice daily) of olaparib continuously DL1 (starting dose level) : Olaparib 50 mg Q12H Monday to wednesday DL2 : Olaparib 100mg Q12H Monday to wednesday DL3: Olaparib 100mg Q12H Monday to friday DL4 : Olaparib 200mg Q12H Monday to wednesday DL5: Olaparib 200mg Q12H Monday to friday DL6: Olaparib 200mg Q12H, continously
223865121|NCT05084612|DEVICE|standard LMA insertion|"Following pre-oxygenation, anaesthesia will be induced with atropine 0.1mg/kg, Fentanyl 2 µg /kg, Propofol 2 mg/kg and atracurium 0.5 mg/kg. When neuromuscular blockade will be complete~the laryngeal mask will be inserted with using the standard method described by Brain; after lubrication of the posterior aspect of the partially deflated mask, the patient's head will be positioned with head extended at the atlanto-axial joint and flexed at the neck with non-dominant hand. The LMA will be held like a pen and index finger will be placed at the junction of LMA tube and cuff. Index finger will be used to press the LMA against hard palate and posterior pharyngeal wall until definite resistance felt at the base of the hypopharynx. LMA will then be held with non-dominant hand and index finger will be removed."
223865122|NCT05084612|DEVICE|New technique LMA insertion|Following pre-oxygenation, anaesthesia will be induced with atropine 0.1mg/kg, Fentanyl 2 µg /kg, Propofol 2 mg/kg and atracurium 0.5 mg/kg. When neuromuscular blockade will be complete LMA will be inserted by a two Person Insertion with lateral rotation Technique; after lubrication of the posterior aspect of the partially deflated mask, the assistant will achieve jaw thrust and mouth opening then LMA will be inserted by the anaesthiologist. LMA will be inserted by holding the mask by index, middle finger and thumb; after insertion of the entire cuff inside the mouth, the LMA will be rotated anticlockwise through 90° (the inner surface of LMA will be directed medially towards the mouth cavity) and advanced through the side of the tongue until resistance felt, then turned back in the hypopharynx.
223865123|NCT04054635|DEVICE|Silver diamine fluoride|Antibiotic liquid with anti-caries effects. A non-restorative option to manage cavitated caries lesions. Approved for clinical use in Canada in 2017.
223865124|NCT01573130|BEHAVIORAL|Physical exercise program|An individualized physical exercise program, administered per internet. Some therapist-support will also be included.
223865125|NCT02457117|RADIATION|CyberKnife Stereotactic Accelerated Partial Breast Irradiation (CK-SAPBI)|Five fraction radiation therapy to the lumpectomy cavity
223865126|NCT05491031|OTHER|magnetic resonance spectroscopy|Investigation of the association, in patients with multiple sclerosis, between MRI biomarker data at inclusion and progression of physical disability during follow-up (6, 12, 18 and 24 months) assessed by a composite endpoint EDSS plus (EDSS, 9HPT, T25FW)
223865127|NCT05919017|DRUG|Naltrexone implant|Naltrexone implant
223865128|NCT05919017|DRUG|Placebo|Placebo
223865129|NCT05296811|PROCEDURE|Lateral Arm Free Flap|Primary Reconstruction of intraoral defects by use of Lateral Arm Free Flap.
223865130|NCT03567369|DRUG|Dexamethasone|Dexamethasone 4,0 mg/mL
223865131|NCT03567369|DRUG|Traumeel S|Traummel S 2,2 mg/mL
223865132|NCT04660214|DEVICE|septotomy|endoscopic diverticulotomy
223865133|NCT02576613|OTHER|MPP-S|\> 30 weekly sessions of modified psychodynamic psychotherapy in addition to standard treatment
223865134|NCT02576613|OTHER|TAU|standard medical treatment without structured psychotherapeutic intervention
223865135|NCT00148369|DRUG|Safety observation|Subjects previously enrolled in a GDNF protocol observed for 2 years after discontinuation of drug.
223865136|NCT04450199|DRUG|Vitamin D2|Vitamin D tablets
223865137|NCT04450199|OTHER|Placebo|Over encapsulated sugar pills
223865138|NCT04353102|DRUG|YH002|YH002 will be administered intravenously every three weeks (Q3W) for up to 2 years at doses of Dose A, Dose B, Dose C, Dose D, Dose E, Dose F, Dose G, and Dose H.
223865139|NCT02700191|DEVICE|uCor|
223865140|NCT04109534|DIAGNOSTIC_TEST|Bronchial allergen provocation (BAP)|Nebulized Dermatophagoides farina administered at following doses: 10AE, 20 AE, 40 AE, 80 160 AE, etc… until the FEV1 decreases 20% below the initial FEV1-value
223865141|NCT04109534|DIAGNOSTIC_TEST|Nasal provocation test (NPT)|Dermatophagoides farina will be administered in both nostrils
223865142|NCT04109534|DIAGNOSTIC_TEST|Methacholine test|Nebulized metacholine will be administered at following doses: 0,01mg, 0,1mg, 0,4mg, 0,8mg und 1,6mg until the FEV1 decreases 20% below the initial FEV1-value
223865143|NCT04109534|DIAGNOSTIC_TEST|Peak nasal expiratory flow (PNIF)|Comparison of peak nasal expiratory flow (PNIF) after NPT between groups
223865144|NCT00004266|DRUG|Lisinopril|
223865145|NCT00004266|DRUG|Nifedipine|
223865146|NCT00004266|DRUG|Simvastatin|
223865147|NCT03234088|BEHAVIORAL|Daily weight measured by digital scale and symptom reporting|All subjects will be provided the intervention.
223865148|NCT01926678|OTHER|Swedish massage therapy|
223865149|NCT01926678|OTHER|Light touch therapy|
223865150|NCT00004004|DRUG|procarbazine hydrochloride|
223865151|NCT02399865|OTHER|Youth Social Behaviour and Network Therapy|"The Y-SBNT will be delivered according to the developed purpose-designed therapy manual. Participants randomised to Y-SBNT will be offered six, 50 minute SBNT sessions for over a maximum period of 12 weeks. Where consent is obtained, sessions will audio-recorded and reviewed by the research team to ensure fidelity with the YSBNT manual and principles of practice.~Using the identification of the social network of the young person conducted in the first session as a platform, subsequent core strategies of the adapted YSBNT approach include motivational techniques, improving communication and coping mechanisms, and crucially given the nature of substance misuse, developing a network-based relapse management plan. Participants will be given the opportunity to invite members of their network to the treatment sessions. The therapeutic approach also has scope to address client-focussed elective areas, for example, educational requirements."
223865152|NCT00846066|OTHER|Hands on training|Hands on training by a pediatric dentist on preventive oral health
223865153|NCT00846066|OTHER|Web based training|Web based training alone
223865154|NCT01574807|DRUG|mepivacaine + lidocaine followed by lidocaine +lidocaine|1.8 mL of 3% mepivacaine followed by 1.8 mL of 2% lidocaine with 1:100,000 epinephrine followed by 1.8 mL of 2% lidocaine with 1:100,000 epinephrine followed by 1.8 mL of 2% lidocaine with 1:100,000 epinephrine
223865155|NCT01574807|DRUG|lidocaine + lidocaine followed by mepivacaine + lidocaine|1.8 mL of 2% lidocaine with 1:100,000 epinephrine followed by 1.8 mL of 2% lidocaine with 1:100,000 epinephrine followed by 1.8 mL of 3% mepivacaine followed by 1.8 mL of 2% lidocaine with 1:100,000 epinephrine
223865156|NCT03151590|BEHAVIORAL|exercise training|
223865157|NCT03573284|DIAGNOSTIC_TEST|fractional exhaled nitric oxide(FeNO)|FeNO level was evaluated according to the American Thoracic Society (ATS)/ERS recommendations using a NIOX MINO analyzer (Aerocrine, Solna, Sweden) .Subjects were informed to deeply inhale NO-free air and immediately exhale in full via a mouthpiece at a constant flow rate (50 ml/s) for 10s.
223865158|NCT03573284|DIAGNOSTIC_TEST|impulse oscillometry(IOS)|The patient take seats, body relax, make sure the mouthpiece is fully covered by mouth, then clip nose with both hands to cover both sides of the cheek, and then calm breathing 1 minutes, the computer is automatically collected data calculation and print out the measurement results.
223865159|NCT05126004|DRUG|Azacitidine|28 days for one cycle, evaluation post 3 cycles of treatment. Continue if response exists, otherwise, quit the trial and seek for other therapies.
223865160|NCT05126004|DRUG|N Acetyl L Cysteine|28 days for one cycle, evaluation post 3 cycles of treatment. Continue if response exists, otherwise, quit the trial and seek for other therapies.
223865161|NCT05500664|DRUG|Lavender Oil|three drops of the designated lavender will be placed on a 2-inch by 2-inch impermeable, backed gauze pad and patient was asked to inhale deeply for 5 minutes
223865162|NCT06319586|PROCEDURE|Radial Forearm Flap|"* Elevate the flap from ulnar to radial side toward the FCR~* Elevate flap from radial to ulnar side to the brachioradialis tendon. Ligate and divide the radial artery and venae comitantes distally.~* incise the skin over the cephalic vein proximally to the cubital fossa. Identify the venous branching pattern and perforating vein.~* Elevate the skin and subcutaneous paddles proximally off of the FCR and brachioradialis.~* Define the venous anatomy at the cubital fossa. In most cases, the median basilic vein and continuation of the median vein contribution to the cephalic vein can be harvested proximal to the perforating vein. This anatomy allows two large veins to be harvested that drain both the deep and superficial systems. Occasionally, one large vein will be identified.~* Closure is performed by harvesting a 0.018-inch skin graft to cover the donor defect. The radial skin edge should be advanced to cover the exposed radial nerve."
223865163|NCT03133039|PROCEDURE|surgery, bioabsorbable screw|In this study we compare bioabsorbable and titanium screw in the hallux valgus and hallux rigidus surgery
223865164|NCT05233007|PROCEDURE|Minor endoscopic biopsy|As per standard of care
223865165|NCT06491888|DIAGNOSTIC_TEST|Detection of Cervical Lesions by Fluorescence Photoelectric Image|Photoelectric detection was carried out on the subjects of the experimental group.
223865166|NCT05072171|PROCEDURE|Inguinal hernia repair with dynamic prosthesis|Tissue specimens excised at the above defined postoperative stages were fixed in neutral-buffered 10% formalin and routinely processed to paraffin wax. Sections (4 μm thick) were cut and stored at room temperature until use. Sections were stained with hematoxylin and eosin (H\&E) for histological analysis and Azan trichrome (Bioptica) staining to evaluate muscular tissue in the implant fabric.
223865167|NCT06092697|OTHER|3D printed PEEK restorations|Indirect dental restoration
223865168|NCT02201173|BEHAVIORAL|Locomotor Training|Progressive retraining in functional skills including balance, transfers, activities of daily living and ambulation. Compliance to eliminate or minimize lower limb orthotics is also expected to optimize sensory input to the spinal cord and promote optimal recovery. Intensive therapy occurs in all three environments 5 times/ week for 90 minutes
223865169|NCT02539212|DEVICE|microwave ablation|ultrasound-guided microwave ablation is performed to treat hepatocellular carcinoma patients
223865170|NCT02539212|DEVICE|radiofrequency ablation|ultrasound-guided radiofrequency ablation is performed to treat hepatocellular carcinoma patients
223865171|NCT04367415|DIAGNOSTIC_TEST|Darwish test for a free endometrial cavity|Darwish test (Office hysteroscopic bubble suction and tubal peristalsis). If the uterine cavity is normal the patient will be allocated as group A
223865172|NCT04367415|DIAGNOSTIC_TEST|Darwish test for an endometrial cavity with endometrial polyps|Darwish test (Office hysteroscopic bubble suction and tubal peristalsis).If there is one or more polyp(s) the patient will be allocated as group B.
223865173|NCT05987878|PROCEDURE|single minimal conjunctival incision|A 5-0 PGA traction suture was used near the corneal limbus corresponding to the operated muscle. A 3-4 mm single conjunctival incision posterior and parallel to the insertion in medial, lateral or superior rectus muscle was used. A hang-back recession of the muscle was done using 6-0 PGA suture. The conjunctiva was closed by an 8-0 PGA single stitch with knot burial
223865174|NCT01801410|DEVICE|Foley Catheter|Transcervical Foley catheter (silicone, size 18F with 30ml balloon)
223865175|NCT01801410|DRUG|Misoprostol|25mcg every 2 hours for maximum of 12 doses
223865176|NCT01663519|OTHER|Custom made insoles 35 shore|Insoles in Ethyl Vinyl Acetate (EVA) manufactured over an individual positive cast.
223865177|NCT01663519|OTHER|Prefabricated insoles|Prefabricated insoles
223865178|NCT01663519|OTHER|55 shore Custom made insole|Insoles in Ethyl Vinyl Acetate (EVA) manufactured over an individual positive cast.
223865179|NCT04385355|DEVICE|Conventional transmucosal abutment design|The macroscopic design of the intermediate transmucosal abutment will be evaluated on terms of the marginal peri-implant bone levels using two identical devices, if only being the test device narrower than the control one
223865180|NCT04385355|DEVICE|Narrow transmucosal abutment design|The macroscopic design of the intermediate transmucosal abutment will be evaluated on terms of the marginal peri-implant bone levels using two identical devices, if only being the test device narrower than the control one
223865181|NCT00411138|RADIATION|Radiation Therapy|External beam pelvic radiotherapy (48.6 Gy in 1.8 Gy fractions) Vaginal brachytherapy boost in case of cervical involvement
223865182|NCT00411138|DRUG|cisplatin|cisplatin 50 mg/m2 i.v., 2 cycles during radiotherapy, 3 wks interval
223865183|NCT00411138|DRUG|carboplatin|carboplatin AUC 5, 4 cycles after completion of radiotherapy, 3 wks interval
223865184|NCT00411138|DRUG|Paclitaxel|paclitaxel 175 mg/m2, 4 cycles after completion of radiotherapy, 3 wks interval
224076435|NCT03212742|DRUG|Temozolomide (TMZ)|TMZ will be given at the dose of 75mg/m²/day during radiotherapy period. TMZ will be re-introduced 4 weeks after the end of radiotherapy at the dose of 150mg/m²/day on days 1 to 5 every 28 days, for a total of 6 cycles.
224267788|NCT04922957|DRUG|ALLOCETRA-OTS|The product contains allogeneic donor mononuclear enriched cells in the form of a liquid suspension containing early apoptotic cells.
224267789|NCT04922957|OTHER|Placebo|Ringer's lactate solution
224267790|NCT05999916|DEVICE|Personalized Miamind Neurostimulator|60 min. 40 Hz max. 1mA / electrode \& total of max. 2 mA across all electrodes. 30- s ramp-up personalised intervention based on individual modelling of electric field distribution to maximise therapeutic effect in the target region. Three target regions, consecutively stimulated (20min each).
224267791|NCT00157521|DRUG|L-arginine|
224267792|NCT04403035|DIAGNOSTIC_TEST|ID NOW vs. Accula|Comparison of the ID Now assay vs. the Accula assay in detecting Covid-19.
224267793|NCT02588781|DRUG|Pemetrexed|Alimta 500mg/m2 + NS 100ml IV infusion for 10mins Every 3weeks
224267794|NCT00937664|DRUG|AZD7762|solution, intravenous, weekly
224267795|NCT00937664|DRUG|gemcitabine|intravenous, weekly
224267796|NCT04031235|BEHAVIORAL|Sleep Baby, Safe and Snug|Specially designed children's book, 14 pages, rhyming, illustrated in color, written at a Kindergarten reading level. Each page spread highlights AAP-recommended safe sleep practices. AAP safe sleep recommendations listed on the back cover.
224076436|NCT03212742|RADIATION|IMRT (Intensity Modulated Radiation Therapy)|Radiotherapy consists of fractionated focal irradiation at a dose of 2 Gy per fraction given once daily five days per week over 6 weeks, for a total dose of 60 Gy by 3D- Intensity-Modulated RT (IMRT)
223865185|NCT06178978|DEVICE|KalEYEdoscope|"KalEYEdoscope is a digital, handheld device utilizing shape-discrimination hyperacuity to distinguish the severity of age-related macular degeneration. In the future, developing such a device for home monitoring of macular degeneration may increase access to timely treatment to prevent vision loss.~This study was conducted at the Kellogg Eye Center in Ann Arbor. Participants in the outpatient setting who agreed to enroll in the study tested the device and provided user feedback via a questionnaire as well as completed questionnaires about their visual function. This study assessed the usability, comfort, duration, ergonomics, and ease of use of the device among AMD patients in a single session."
223865186|NCT03598478|BEHAVIORAL|TC-MPT|Participants will receive two levels of training within each 90-minute session over a 12-week period: (1) TC training and (2) MPT. The TC training protocol consists of five basic TC movements. After receiving TC training, the participants in this group will take a 5-minute break and then receive MPT. During MPT, the participants will contract their major postural muscles bilaterally as fast as possible against a resistance equivalent to 70% of one repetition maximum.
223865187|NCT03598478|BEHAVIORAL|TC|Children in the TC group will skip the MPT session and practice TC movements repeatedly for 90 minutes. The exercise progression pattern in the TC-alone group will be the same as that in the TC-MPT group.
223865188|NCT03598478|BEHAVIORAL|MPT|Those children in the MPT group will perform strengthening exercises repeatedly for 90 minutes, with a short 5-minute break between the three sets of exercises if necessary. The exercise progression pattern in the MPT-alone group will be the same as that in the TC-MPT group.
223865189|NCT06142851|OTHER|Data collection|data collection
223865190|NCT03127995|RADIATION|HYPOFRACTIONATED|40 Gy/ 15 fractions / 3 weeks
223865191|NCT03127995|RADIATION|NORMOFRACTIONATED|50 Gy/ 25 fractions / 5 weeks
223865192|NCT03009305|OTHER|Lower body negative pressure|Model of hypovolemia: Lower body negative pressure down to -80 mmHg (maximum).
223865193|NCT03009305|DEVICE|Continuous positive airway pressure|CPAP of 0, 5 and 10 cm water (H2O).
223865194|NCT03009305|DEVICE|Positive expiratory pressure|PEP of 0, 5 and 10 cm H2O.
223865195|NCT06386237|OTHER|Dietary intervention: Standardized breakfast with varying amounts of macronutrients (in particular carbohydrate/protein ratios)|Participants receive a standardized meal with one type of macronutrient composition in one experimental session and the other type in a different experimental session a few days apart (within-subjects crossover design; i.e. order counterbalanced)
223865196|NCT02756377|DRUG|cetylpyridinium chloride mouthwash|cetylpyridinium chloride mouthwash, 10 ml by patients routinely washed two times in one day for about 30 seconds for two weeks.
223865197|NCT02756377|DRUG|Chlorhexidine mouthwash|Chlorhexidine mouthwash,10 ml by patients routinely washed two times in one day for about 30 seconds for two weeks.
223865198|NCT03379935|PROCEDURE|Type of radial head arthroplasty|Patiens are either treated with a unipolar or a bipolar radial head arthroplasty. At Sundsvall hospital all patients were treated with a unipolar and at Umeå university hospital all patients were treated with a bipolar arthroplasty.
223865199|NCT05375188|DRUG|Dexmedetomidine|DOSAGE FORM: IV Infusion DOSAGE: 0.4 mcg/kg/hr
223865200|NCT05375188|DRUG|Normal Saline|DOSAGE FORM: IV Infusion DOSAGE: Equal Volume
224076437|NCT03083886|OTHER|Identify, Coordinated, Enhanced (ICE) Decision Making + PCP led care|Subjects seeking care at a clinic assigned to this arm will receive the ICE care model through referral by their primary care provider. The ICE care model was developed by the Clinical Excellence Research Center at Stanford University based on a review of the peer-reviewed literature for adult subjects with incident neck or back pain less than six weeks in duration who are not using high-dose opioid medications or receiving spine-related long-term disability payments.
223865201|NCT04201041|PROCEDURE|pudendal nerve pulsed radiofrequency|received pudendal nerve pulsed radiofrequency through trans-vaginal approach or trans-gluteal approach
223865202|NCT06300489|DRUG|irinotecan liposomes+capecitabine|"Radiotherapy：IMRT DT 50Gy/25Fx. Capecitabine: 625mg/m2 bid po d1-5 qw. For patients are double sites mutant (GG+7/7 or AA+6/6 or GA+6/7)，the intial dose of Irinotecan liposomes is 25mg/m2 weekly，for four weeks。 This study stratify cases by the 3+3 rule according to UGT1A1 \* 6 and UGT1A1 \* 28 phenotypes. Three cases were enrolled in each dose group, and if there was no DLT, they were promoted to the next dose group（an increase of 5mg/m2）; If there is 1 case of DLT, 3 cases will be reenrolled in the same dose group. If there is no new occurrence of DLT, it will be promoted to the next dose group. Otherwise, the study will be terminated; If there are 2 cases of DLT, the study will be terminated, and the previous dose group will be the maximum tolerated dose (MTD)."
223865203|NCT06306313|DEVICE|ReoGo|ReoGo is a fixed arm rehabilitation exoskeleton that comes on a small and compact wheeled platform. The end-effector extension is capable of producing a wide range or repeatable movements in 3D space. ReoGo can be used by both adults and children. It is an arm rehabilitation exoskeleton with a fixed base. Its design allows limited controlled movements of the shoulder as well as the elbow and wrist.
223865204|NCT06306313|OTHER|Conventional Physiotherapy|Physiotherapy protocols will be created with traditional physiotherapy practices such as neurodevelopmental techniques based on muscle strengthening and task-oriented exercises. Protocols in general terms; It will include passive and active joint range of motion exercises, stretching exercises, stimulation and facilitation techniques, strengthening exercises, fine motor skills and functional task training for daily living activities. Protocols will be tailored to each patient's level of motor impairment and functional needs.
223865205|NCT04906278|DEVICE|Foley catheter balloon|A Cusco speculum will be placed and a 16F Foley catheter will be inserted into the cervix using ring forceps. Then the balloon will be inflated with 40 ml of saline and it will be pulled out to ensure the balloon covered the internal os of the cervix
223865206|NCT04906278|PROCEDURE|Amniotomy|Amniotomy will be performed by toothed forceps. The handle of the device will be held with one hand outside the vagina while 2 fingers of the opposite hand will be placed in the vagina to guide the tip. Care should be taken to protect maternal vaginal tissues from the forceps. Once the forceps reach the amniotic sac, the tip is pushed up against the sac with the index or middle finger of the internal hand to pierce the membranes. The nature of amniotic fluid will be checked.
223865207|NCT04906278|DRUG|Oxytocin|The intravenous oxytocin infusion will be administered as 10 IU oxytocin/ 500 ml glucose/ 30 mIU/minute were every 6 hours till complete abortion occurs.
223865208|NCT05165082|DRUG|Timolol maleate 0.5% ophthalmic solution|Apply on affected finger or toes twice daily for 8 weeks
223865209|NCT05165082|PROCEDURE|Cryotherapy with liquid nitrogen|Conducted on affected finger or toes every other week for four sessions.
223865210|NCT00548574|DRUG|SPD476 is a polymeric matrix formulation that displays both delayed- and extended-release of mesalazine|
223865211|NCT00548574|DRUG|Mesalazine|
223865212|NCT01372761|DRUG|ZGN-433|Subjects will receive placebo or ZGN-433 twice-weekly over a 4-week treatment period for a total of 8 doses. A range of doses will be evaluated.
223865213|NCT01372761|DRUG|Normal Saline|Subjects will receive placebo or ZGN-433 twice-weekly over a 4-week treatment period for a total of 8 doses. A range of doses will be evaluated.
223865214|NCT00024141|DRUG|fluorouracil|
223865215|NCT00024141|DRUG|irinotecan hydrochloride|
223865216|NCT00126646|DRUG|BL22 immunotoxin|
223865217|NCT00126646|PROCEDURE|antibody-drug conjugate therapy|
223865218|NCT00126646|PROCEDURE|immunotoxin therapy|
223865219|NCT04598321|DRUG|Talazoparib Oral Capsule|An orally available PARP inhibitor for the treatment of advanced breast cancer with germline BRCA mutations.
223865220|NCT03339024|DRUG|intranasal oxytocin spray|6 insufflations (24 IU of oxytocin total) given twice daily, day 1-3. 2 insufflations (8 IU of oxytocin total) as needed, max thrice daily, day 3-30 Day 30 - 12 months: No further oxytocin treatment, i.e. treatment-as-usual.
223865221|NCT03339024|OTHER|intranasal spray without oxytocin|6 insufflations (24 IU of placebo total) given twice daily, day 1-3. 2 insufflations (8 IU of placebo total) as needed, max thrice daily, day 3-30 Day 30 - 12 months: No further oxytocin treatment, i.e. treatment-as-usual.
223865222|NCT00640250|BIOLOGICAL|T.R.U.E. TEST® Skin Patch Test: Dose Response Allergens|"Disperse blue 106 in PVP, 0.15 mg/cm2 Disperse blue 106 in PVP, 0.050 mg/cm2 Disperse blue 106 in PVP, 0.017 mg/cm2 PVP Negative Control Bronopol in PVP, 0.75 mg/cm2 Bronopol in PVP, 0.50 mg/cm2 Bronopol in PVP, 0.25 mg/cm2 Bronopol in PVP, 0.125 mg/cm2~Test patches, with allergens, are placed at day one and removed 48 hours later. The duration of the study lasts 21 days. However, the subject is only exposed to the study allergens for 48 hours."
223865223|NCT02244060|OTHER|Priming effect from vignette|In the arm of DCV, the self-assessed vision (PSAV) is listed after the vignette questions; however, in the arm of ICV, the self-assessment of vision (SAV) is listed before the vignette questions. Priming effect from vignette will be estimated by comparing those two randomized variables (i.e., SAV and PSAV).
223865224|NCT05420090|BEHAVIORAL|Banana arm|Venous blood samples will be taken from the participants in 3 groups before starting the study. Pittsburgh Sleep Quality Index will be applied.Food consumption frequency and food-based follow-up will be carried out.Participants will consume 1 portion of banana (gross 80-85 g) given to them for 6 weeks, approximately 45 minutes-1 hour before bedtime. The frequency of food consumption will be taken from the participants each week.
223865225|NCT05420090|BEHAVIORAL|Milk arm|Venous blood samples will be taken from the participants in 3 groups before starting the study. Pittsburgh Sleep Quality Index will be applied. Food consumption frequency and food-based follow-up will be carried out. Participants will consume 200 ml of whole milk given to them for 6 weeks, approximately 45 minutes-1 hour before bedtime. The frequency of food consumption will be taken from the participants each week.
223865226|NCT05420090|BEHAVIORAL|No intervention|Venous blood samples will be taken from the participants in 3 groups before starting the study. Pittsburgh Sleep Quality Index will be applied. The frequency of food consumption will be taken from the participants each week.Participants are expected not to make any changes in their diet. As in other groups, the frequency of food consumption will be taken from the participants every week in this group. In order to observe the possible changes in the experimental arms, the individuals in the control arm will be asked not to consume bananas and whole milk after 16:00 and they will be informed about this.
223865227|NCT01708798|DRUG|Eplerenone|
223865228|NCT01708798|DRUG|Placebo|
223865229|NCT03189329|DRUG|2% lidocaine hydrochloride|Retrobulbar block was performed with 5 ml of 2% lidocaine hydrochloride (AritmalR, Osel, Istanbul, Turkey) in Group L patients. The block was performed by the same practitioner (fourth year assistant of Ophthalmology Department) using inferotemporal approach as described by Sanderson using 27 gage disposable needles (Atkinson Retrobulbar NeedleR, Asico, USA)
223865230|NCT03189329|DRUG|0.5% levobupivacaine|and 5ml of 0.5% levobupivacaine (ChirocaineR, Abbvie, Chicago, USA) in Group LB patients. The block was performed by the same practitioner (fourth year assistant of Ophthalmology Department) using inferotemporal approach as described by Sanderson using 27 gage disposable needles (Atkinson Retrobulbar NeedleR, Asico, USA)
223865231|NCT05133375|PROCEDURE|Tracheal Intubation|Before reporting to Operation theatre, a detailed pre anesthesia assessment was done in all patients, all necessary laboratory investigations were collected. On OT table pulse and systolic blood pressure was checked by non-invasive method. 18G cannula was passed and ECG was attached. A pillow was placed under the head to obtain classical sniffing position for intubation. All the patients were pre medicated with injection midazolam 0.08mg/kg, injection nalbuphine 0.1 mg/kg, injection dexamethasone 0.08mg/kg and injection metoclopramide 0.1 mg/kg. Pre oxygenation was done with 100% oxygen for 3 mins. Induction was done with injection propofol2 mg/kg, muscle relaxation achieved with injection atracurium 0.5mg/kg. Laryngoscopy was started after 3 minutes by a qualified anesthetist. Pulse and systolic blood pressure was recorded by non-invasive measures before laryngoscopy and at 30 seconds, 2 and 3 minutes after intubation.
223865232|NCT03132922|GENETIC|Autologous genetically modified MAGE-A4ᶜ¹º³²T cells|Infusion of autologous genetically modified MAGE-A4ᶜ¹º³²T on Day 1
223865233|NCT03132922|RADIATION|Autologous genetically modified MAGE-A4c1032T cells combined with low dose radiation|Up to 10 subjects will be considered for Radiation sub-study. Radiation with an intensity of 1.4Gy for 5 days before infusion of MAGE-A4c1032T cells
223865234|NCT06552624|DRUG|Magaldrate|A dose of T drug in one of 2 periods of the study 2 h prior to food intake, 3 times per day
223865235|NCT06552624|DRUG|Magaldrate|A dose of R drug in one of 2 periods of the study 2 h prior to food intake, 3 times per day
223865236|NCT03626558|OTHER|ultrasound measures|It is three diaphragmatic ultrasounds measures of a duration of twenty minutes each approximately. The diaphragmatic ultrasound is practised by trans-thoracic way and is non-invasive, completely painless and does not require the exposure of patients to radiation.
223865237|NCT04949581|OTHER|bioelectric therapy|the patient will receive microcurrent therapy from a supine lying position. the negative electrode on the incision area and the positive electrode proximal. the intensity will be less than 20 microamperes and frequency at 20 HZ.
223865238|NCT04949581|OTHER|cardiac rehabilitation program|the patient will receive cardiac rehabilitation program
223865239|NCT04957069|PROCEDURE|fixation|double row fixation with 3-4 wire anchors
223865240|NCT04957069|PROCEDURE|primary repair|end-to-end repair
223865241|NCT00176371|BEHAVIORAL|physical exercise|
223865242|NCT00107796|DRUG|Modafinil|
223865243|NCT06554041|DEVICE|Dental Crown with Titanium-Abutment|Participants in this clinical trial will receive dental implants and single screw-retained crowns made from one of four different materials: titanium, PEEK (Polyetheretherketone), zirconia, or lithium disilicate (e.max). The implants will be placed in the posterior region of the mandible or maxillae. The study will evaluate the impact of these materials on peri-implant soft tissue health by measuring inflammatory markers in the peri-implant crevicular fluid and assessing clinical outcomes such as bleeding on probing and pocket depth at 3 and 6 months post-implantation.
223865244|NCT06554041|DEVICE|Dental Crown with PEEK (Polyetheretherketone)-Abutment|Participants in this clinical trial will receive dental implants and single screw-retained crowns made from one of four different materials: titanium, PEEK (Polyetheretherketone), zirconia, or lithium disilicate (e.max). The implants will be placed in the posterior region of the mandible or maxillae. The study will evaluate the impact of these materials on peri-implant soft tissue health by measuring inflammatory markers in the peri-implant crevicular fluid and assessing clinical outcomes such as bleeding on probing and pocket depth at 3 and 6 months post-implantation.
223865245|NCT06554041|DEVICE|Dental Crown with Zirconia-Abutment|Participants in this clinical trial will receive dental implants and single screw-retained crowns made from one of four different materials: titanium, PEEK (Polyetheretherketone), zirconia, or lithium disilicate (e.max). The implants will be placed in the posterior region of the mandible or maxillae. The study will evaluate the impact of these materials on peri-implant soft tissue health by measuring inflammatory markers in the peri-implant crevicular fluid and assessing clinical outcomes such as bleeding on probing and pocket depth at 3 and 6 months post-implantation.
224267797|NCT04031235|BEHAVIORAL|Read Baby, Every Day|Specially designed children's book, 14 pages, rhyming, illustrated in color, written at a Kindergarten reading level. Each page spread highlights AAP-recommendations regarding the importance of reading and talking to infants. Recommendations and benefits of reading with infants are listed on the back cover as well.
224267798|NCT01151618|DEVICE|Respironics Synchrony ventilator (Non Invasive Ventilation)|Non Invasive Ventilation using forced oscillation technique (FOT)
224267799|NCT02545179|OTHER|web-based daily care training|12 week interactive web based caring training education
224267800|NCT05789121|DEVICE|walking 25 m in 4 different conditions|"The protocol consisted of walking 25 m in 4 different conditions in the following order:~Gait1, RAS-Slow, RAS-fast, Gait2.~* Gait 1 : preferred cadence without auditory stimulation~* RAS-Slow : Gait with low tempo rhythmic auditory stimulation by music (68.5 per minute).~* RAS-Fast : Gait with fast tempo (10% above each Gait1 cadence).~* Gait2 : preferred cadence without auditory stimulation"
224267801|NCT01632306|DRUG|LY2090314|LY2090314 administered IV
224267802|NCT01632306|DRUG|FOLFOX|FOLFOX administered IV
224267803|NCT01632306|DRUG|Gemcitabine|Gemcitabine administered IV
224267804|NCT01632306|DRUG|Nab-paclitaxel|Nab-paclitaxel administered IV
224267805|NCT02510872|OTHER|18F-FDG PET combined with CT with iodinated contrast injection|
224267806|NCT02510872|OTHER|18F-FDG PET combined with CT without injection|
224267807|NCT04385485|PROCEDURE|Active mobilisation|We investigate if active mobilisation is as good as passive mobilisation with place and hold after flexor tendon suture.
224267808|NCT04385485|PROCEDURE|Passive mobilisation with place and hold|We investigate if active mobilisation is as good as passive mobilisation with place and hold after flexor tendon suture.
224267809|NCT01102907|OTHER|Liquid Breakfast|The liquid breakfast meal will contain 370 calories and will consist of fruit juices and skim milk
224267810|NCT01102907|OTHER|Solid Breakfast Meal|The solid breakfast will contain 370 calories and will consist of oatmeal, golden delicious apples, blueberries, skim milk, and brown sugar.
224267811|NCT05388071|OTHER|Usage of telemedicine and tele-consultation for treatment|Telemedicine will be used to treat patients at an ambulance station. The medical interventions will be performed by a TeleSAN after delegation through a tele-EMS-physician if possible.
224267812|NCT04091763|DRUG|Polidocanol Injectable Foam|"Two distinct periods were considered: intervention and follow-up. During the intervention period patients were observed at 3-week intervals (minimum of 3 weeks and maximum of 9 weeks depending on the number of instrumental treatments performed). The required number of sessions of any of the office-based treatments (maximum of 3 sessions) was determined by clinical and anoscopy response (if after the treatment the participant scored zero points in the Sodergren scale or the anoscopy did not reveal significant hemorrhoidal disease, there was no place for additional instrumental therapy and the patient started the follow-up period.~If there was therapeutic failure at the end of the third session or if there was a significant complication (moderate or severe) the patient's participation in the study ended and he was referred for treatment with other type of office-based procedure or surgery."
224267813|NCT04091763|DEVICE|Rubber band ligation|"Two distinct periods were considered: intervention and follow-up. During the intervention period patients were observed at 3-week intervals (minimum of 3 weeks and maximum of 9 weeks depending on the number of instrumental treatments performed). The required number of sessions of any of the office-based treatments (maximum of 3 sessions) was determined by clinical and anoscopy response (if after the treatment the participant scored zero points in the Sodergren scale or the anoscopy did not reveal significant hemorrhoidal disease, there was no place for additional instrumental therapy and the patient started the follow-up period.~If there was therapeutic failure at the end of the third session or if there was a significant complication (moderate or severe) the patient's participation in the study ended and he was referred for treatment with other type of office-based procedure or surgery."
224267814|NCT04551183|OTHER|Surgeons CT scan analysis|Surgeons extract diameter by hand (Gold Standard method) then realised a semi-manual segmentation of the images to extract volumes and diameters of the aorta (espacially AAA)
224267815|NCT04551183|DEVICE|PRAEVAorta CT scan analysis|CT scans are analysed by the software under investigation : PRAEVAorta. It will extract volumes and diameters of the aorta (AAA espacially)
223865246|NCT06554041|DEVICE|Dental Crown with Lithium-Disilicate-Abutment (e.max)|Participants in this clinical trial will receive dental implants and single screw-retained crowns made from one of four different materials: titanium, PEEK (Polyetheretherketone), zirconia, or lithium disilicate (e.max). The implants will be placed in the posterior region of the mandible or maxillae. The study will evaluate the impact of these materials on peri-implant soft tissue health by measuring inflammatory markers in the peri-implant crevicular fluid and assessing clinical outcomes such as bleeding on probing and pocket depth at 3 and 6 months post-implantation.
224076438|NCT03083886|OTHER|Individualized Postural Therapy (IPT) + PCP led care|IPT involves the evaluation of a subject's posture to identify postural and alignment deviations and, based on this, a personalized corrective exercise program is prescribed. This method does involve the use of prescription medications, surgery, or manipulation. A treatment course typically lasts eight sessions over eight weeks. In order to allow for the consistent delivery of this arm of the study at multiple study-sites across the country, IPT will be delivered by The Egoscue Method. Egoscue was founded in 1971 and has 25 clinics worldwide.
223865247|NCT01480505|PROCEDURE|Pars plana vitrectomy with gas tamponade|"A standard three-port 20 Gauge vitrectomy under a wide-angle-viewing contact lens was performed. Peripheral vitreous shaving was completed under slit-lamp illumination without contact lens by gentle scleral indentation. Posterior hyaloid detachment was checked and completed if necessary without dye. The epiretinal membrane removal or internal limiting membrane (ILM) peeling was performed if necessary. In general this latter procedure was not conducted for RD secondary to peripheral retinal tears without any sign of PVR or ERM but was done in almost all cases related to posterior break.~Subretinal fluid was aspirated through the retinal tear, the MH, the PVT or through a retinotomy to obtain a complete peroperative retinal reattachment."
223865248|NCT00678912|DEVICE|Smartcare/PS|computer-driven protocol that adjusts pressure support level in pressure support mode to patient respiratory status
223865249|NCT02324010|DRUG|Sitagliptin|100mg mane for 2 days
223865250|NCT02324010|DRUG|Placebo|Inactive drug (Placebo)
223865251|NCT06552819|OTHER|No intervention|No intervention
223865252|NCT00002380|DRUG|Nelfinavir mesylate|
223865253|NCT00002380|DRUG|Saquinavir|
223865254|NCT00478738|DRUG|GSK961081|
223865255|NCT01407393|DEVICE|Glucosanol|2 tablets 3x daily for 12 weeks
223865256|NCT01407393|DEVICE|Placebo|2 tablets 3x daily for 12 weeks
223865257|NCT04206098|OTHER|Factors associated with Hospital admission for an Acute Exacerbation Chronic Obstructive Pulmonary Disease (AECOPD)|Develop a descriptive predictive model fo factors that influence clinical characteristic of patients that require hospital admission
223865258|NCT00405535|DRUG|glycine|
223865259|NCT00405535|OTHER|placebo|
223865260|NCT03601910|DRUG|D308 10mg Tab.|D308 10mg Tab.1T single oral administration under fasting condition
223865261|NCT03601910|DRUG|CKD-380 10mg Tab.|CKD-380(Dapagliflozin) 10mg Tab.1T single oral administration under fasting condition
223865262|NCT05167877|OTHER|No intervention will be given to the participants|This is an observational feasibility study with no intervention.
223865263|NCT01595802|DEVICE|Nautilus NeuroWave|"The Nautilus NeuroWave device will be utilized on subjects with sub-arachnoid hemorrhage that undergo TCD measurements to diagnose Vasospasm. A recording will be obtained using the device each time a TCD measurement is made.~In this intervention, patients are recorded using the Nautilus Neurowave device."
224076439|NCT03083886|OTHER|Usual PCP led care|Primary care provider will direct patients' care pathway.
223865264|NCT01595802|DEVICE|Transcranial Doppler (TCD)|Subjects with sub-arachnoid hemorrhage undergo TCD measurements to diagnose Vasospasm. Patients that were detected to have a vasospasm using TCD will also be classified as having mild, moderate and severe vasospasm.
223865265|NCT05458817|OTHER|digital platform|Patients in the digital group complete the tests in the patient's mobile application and/or in the Internet-based research environment of the Institute of Psychology of the University of Tartu kaemus.psych.ut.ee. Patients and specialists of the control group fill in the tests and the satisfaction questionnaire in the kaemus.psych.ut.ee environment.
223865266|NCT02364349|DRUG|Bee Venom (BV)|Raw Bee Venom
223865267|NCT02364349|DRUG|Essential Bee Venom (e-BV)|Bee venom without Hyaluronidase, Lysophospholipase, α-D-glucosidase, PLA2, Adolapin
223865268|NCT00761436|BIOLOGICAL|Spheramine (BAY86-5280)|Stereotactic Intrastriatal Implantation
223865269|NCT04906161|DIAGNOSTIC_TEST|Vitamin D and calcium levels|Mini VIDAS® compact multiparametric immunoanalyzer for vitamin D analysis (BIOMERIEUX- France)
223865270|NCT02423291|DRUG|Brentuximab Vedotin|Brentuximab vedotin, 1.8 mg/kg, administered via outpatient IV infusion on Day 1 of each 21-day cycle.
223865271|NCT00322920|DRUG|Topotecan|
223865272|NCT00322920|DRUG|Cisplatin|
223865273|NCT01653834|PROCEDURE|Lymphocyte harvesting & reinfusion|Lymphocytes will be collected and stored approximately one week prior to initiating concurrent radiation therapy (RT) and temozolomide (TMZ). Two lymphocyte collections are allowed. After the patient has completed 6 weeks of RT/TMZ, all of the collected lymphocytes will be re-infused. After lymphocyte re-infusion, Heme-8 and absolute lymphocyte count (ALC) will be checked per standard of care. The absolute increase in ALC as the primary endpoint will be assessed 4 weeks after lymphocyte re-infusion.
223865274|NCT02367924|DRUG|trabectedin|The administration of chemotherapy regimen with trabectedin (according to Summary of Product Characteristics (SmPC)) will be determined by the Investigator's discretion depending on the patients' conditions and previous chemotherapy.
223865275|NCT04925765|OTHER|Virtual Reality Biofeedback Session|"The Flowly intervention treatment utilizes virtual reality and biofeedback to train patients to auto-regulate themselves and improve their pain/anxiety/depression."
223865276|NCT04297306|BEHAVIORAL|Exercise Prescription|Standardised Exercise Prescription.
223865277|NCT04297306|DEVICE|Exercise Prescription and Virtual Reality Exercise Gaming support|Standardised Exercise Prescription with the additional support of Virtual Reality Promoted Exercise Games.
223865278|NCT01683149|DRUG|Topotecan|Topotecan will be given by mouth as outlined in treatment arm.
223865279|NCT01683149|DRUG|Sorafenib|Sorafenib will be given by mouth as outlined in treatment arm.
223865280|NCT06161844|DRUG|semaglutide injection (HD1916)|Up to 1.0 mg semaglutide injected subcutaneously once-weekly for 32 weeks Other Name: HD1916
223865281|NCT06161844|DRUG|Ozempic®|Up to 1.0 mg semaglutide injected subcutaneously once-weekly for 32 weeks Other Name: Ozempic Injectable Product
224076440|NCT05333341|BEHAVIORAL|TCM|TCM care is remotely-delivered and medium-term (up to 12 months), with the objective of improving CP and OUD/misuse symptoms primarily through medication management.
224076441|NCT05333341|BEHAVIORAL|TCM plus COPES|The COPES program will augment the effectiveness of TCM alone. COPES is a 12-week, Interactive Voice Response (IVR)-facilitated program of CBT for CP and common sequelae (depressive symptoms, sleep difficulties, low physical activity). Ongoing COPES engagement will be tracked by the COPES system. The primary components of the intervention are: 1) a self-help handbook containing the rationale and instructions for using ten pain self-management skills and their corresponding weekly skill practice goals; 2) a pedometer-facilitated walking program; 3) daily, automated IVR calls to collect pain interference, sleep quality, pedometer-measured step count, and adherence to the pain coping skill practice ratings; and 4) weekly, two to four minute pre-recorded, personalized therapist messages based on participant IVR-reported data.
223865282|NCT04246307|DIAGNOSTIC_TEST|TEG® and ClotPro® parameters|"Systemic sampling is performed six times:~* before the surgery (S1)~* during the hepatectomy, 10 minutes before the anhepatic phase (S2)~* in the anhepatic phase, before starting portal vein anastomosis: (S3)~* in the neohepatic phase, 15 minutes after releasing portal vein clamping: (S4)~* in the neohepatic phase, at the end of the surgery: (S5)~Regional sampling from the portal vein representing afferent flow to the liver is performed once:~• in the anhepatic phase, before starting portal vein anastomosis: (R)~Simultaneously with haemostasis and blood gas analyses, the following investigations will be performed (the following tests are also routinely performed at the given time points, independently of this study):~* haemodynamic measurements by PiCCO~* arterial blood gas analysis from radial artery catheter~* central venous blood gas analysis from subclavian vein catheter~* blood temperature measurement in the femoral artery by PiCCO catheter~* hourly urinary output"
223865283|NCT03094182|DRUG|Iron Isomaltoside 1000|Randomly selected patients of the monofer group are given 1000mg of iron isomaltoside, which are mixed in 100ml normal saline, intravenous after induction for 30 minutes.
223865284|NCT03094182|DRUG|Normal saline|Randomly selected patients in the control group receive an equivalent volume of normal saline as a placebo.
223865285|NCT01680250|DRUG|Sirolimus|Sirolimus administration for 12 months followed by conventional therapy alone for additional 12 months
223865286|NCT05339893|DEVICE|In Motion Rehabilitation Robot|Patients will wear the taVNS device on the left ear for the duration of the subsequent phase of the robotic training. During this phase the patient will engage the robotic device with the affected limb and complete the protocol and the stimulation or sham stimulation will occur with every extensor movement.
223865287|NCT05283395|DRUG|Netarsudil 0.02%/latanoprost 0.005% fixed dose combination ophthalmic solution|Commercially available ophthalmic solution indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension
223865288|NCT01531075|BIOLOGICAL|ENGERIX-B (HBV Vaccine)|ENGERIX-B (Hepatitis B Vaccine) 20 mcg, A series of 3 doses (1 mL each) given on a 0-, 1-, 6-month schedule.
223865289|NCT01531075|BIOLOGICAL|Sci-B-Vac|Sci-B-Vac (Hepatitis B Vaccine) 10 μg/ml, A series of 3 doses (1 mL each) given on a 0-, 1-, 6-month schedule.
223865290|NCT03697655|DRUG|Daratumumab 20 MG/ML [Darzalex]|Daratumumab dose 16 mg/kg body weight to be administered as an IV infusion. treatment given until clinical progression or SPR but no longer than 73 weeks
223865291|NCT01068756|DRUG|Dapagliflozin|Tablets, Oral, 10 mg, 2 single oral 10 mg doses, 2 days
223865292|NCT01068756|DRUG|Rifampin|Capsules, Oral, 600 mg, Once daily on days 4 to 11, 8 days
223865293|NCT01854229|DEVICE|Prometra Programmable Intrathecal Infusion Pump|There are two enrollment groups (arms). One is for new patients who are going to have a Prometra Pump implanted. The other arm is for patients who were part of the IDE study prior to FDA approval of the pump, and are willing to continue to be followed as part of a study.
223865294|NCT04452539|PROCEDURE|Paediatric cardiac surgery|All patients undergoing paediatric cardiac surgery
224076442|NCT05405179|PROCEDURE|Simultaneous dental implantation|To perform dental implantation simultaneously in free vascularized bone flaps for jaw reconstruction using patient-specific surgical guides and titanium plates
224076443|NCT00083083|DRUG|carboplatin|
224076444|NCT00083083|DRUG|cisplatin|
224076445|NCT00083083|DRUG|docetaxel|
223865295|NCT05579106|DEVICE|Nociception Level Monitor (NOL) by Medasense Biometrics Ltd., Israel|"The NOL monitor measures various parameters via a sensor in a finger probe that is attached to the patient.~These parameters are:~* Temperature~* Galvanic skin response~* Accelerometer~* Photoplethysmograph (pulse rate, pulse rate variability, photoplethysmograph amplitude)~All this data is combined in an algorithm which produces a number between 0-100. Between 10-25 indicates adequate analgesia, below 10 too much analgesia, above 25 too little analgesia. No actions are taken based on this measurement."
224076446|NCT00083083|DRUG|etoposide|
224076447|NCT00083083|DRUG|paclitaxel|
224267816|NCT01156987|DEVICE|Magnetic resonance imaging|"Patients and healthy volunteers will be first screened for MRI contraindications. The SWIFT MRI workflow will be performed as follows:~* an IV line is placed by nurse,~* patient is placed in the 4 T MRI scanner at CMRR,~* initial scout images and manual linear shims are adjusted,~* Pre-contrast SWIFT T1 weighted images and T1 map are obtained,~* continuous SWIFT acquisition begins immediately before contrast injection,~* contrast injection,~* continuous SWIFT acquisition continues for 12 min after contrast,~* late enhancement images may also be obtained.~  10 and 30 patients will be scanned in the first and second year, respectively. Thresholds will be set for prospective analysis. SWIFT-DCE diagnostic performance will be compared to prior FLASH-DCE methods."
223865296|NCT05579106|DEVICE|Bispectral index (BIS)|The BIS processes EEG information to provide a direct measurement of the patient's level of consciousness and insight into the effects of anesthesia on the brain.
224076448|NCT00083083|DRUG|vinblastine sulfate|
224076449|NCT00083083|DRUG|vinorelbine tartrate|
223865297|NCT05579106|OTHER|Questionnaire perception of the nurse on pain patient|The investigators developed a questionnaire with 7-questions regarding the perception of the responsible nurse on the pain of the patient. When the investigators measured for 8 hours with the BIS and the NOL they will ask the nurse what his or her perception was of the pain of the patient. Eventually the investigators will compare the answers of this questionnaire with the NOL and BIS values that they observed, whether the information corresponds or not.
223865298|NCT03875963|OTHER|Antibiotic loaded bone filler|Defect management by placement of antibiotic loaded Stimulan as a bone void filler \[calcium sulfate bone void filler (10 cc of STIMULAN(R) Rapid Cure, Biocomposites Ltd, UK) combined with the following antibiotic combination: 1g Vancomycin, 240mg Tobramycin\].
223865299|NCT01587053|OTHER|therapeutic education program|
223865300|NCT01224015|DRUG|normal saline|Normal Saline injected into bilateral Crow's Feet Line and Frown Line areas per treatment. Patients may receive up to 2 treatments during the study.
223865301|NCT01224015|BIOLOGICAL|onabotulinumtoxinA 44 U|44 units onabotulinumtoxinA (botulinum toxin type A) total dose injected into bilateral Crow's Feet Line and Frown Line areas per treatment. Patients may receive up to 2 treatments during the study.
223865302|NCT01224015|BIOLOGICAL|onabotulinumtoxinA 24 U|24 units onabotulinumtoxinA (botulinum toxin type A) total dose injected into bilateral Crow's Feet Line and Frown Line areas per treatment. Patients may receive up to 2 treatments during the study.
223865303|NCT04877067|BIOLOGICAL|Wharton jelly derived mesenchymal stem cell|WJ-MSC
223865304|NCT04877067|DEVICE|Repetitive electromagnetic stimulation|rEMS
223865305|NCT02646358|DRUG|Vepoloxamer|
223865306|NCT00424645|DRUG|Voraxaze (Glucarpidase)|50 units/kg IV within 12 hours of study eligibility being confirmed.
223865307|NCT00424645|DRUG|Placebo|Administered by IV within 12 hours of study eligibility being confirmed.
224076450|NCT00083083|GENETIC|gene expression analysis|
223865308|NCT01622413|PROCEDURE|joimax TESSYS|Transforaminal Endoscopic Surgery System
223865309|NCT01622413|PROCEDURE|Microdiscectomy|Standard procedure for disc surgery
223865310|NCT03675256|BIOLOGICAL|immediate Gardasil 9, delayed MenVeo vaccine|Intervention is immediate administration of 9-valent HPV vaccine and delayed MenVeo vaccine
223865311|NCT03675256|BIOLOGICAL|immediate MenVeo vaccine, delayed Gardasil 9|Intervention is immediate administration of MenVeo vaccine and delayed administration of Gardasil 9
223865312|NCT03675256|BIOLOGICAL|immediate Cervarix, delayed MenVeo vaccine|Intervention is immediate administration of bivalent HPV vaccine and delayed MenVeo vaccine
223865313|NCT04082611|BEHAVIORAL|Data-Driven Clinical Recommendations|Data-driven clinical recommendations. Participants will receive routine care with data-driven, personalized, multi-modal clinical recommendations by a study physician based on study assessments and clinical lab values and be monitored and re-assessed for a period of 12 months.
224076451|NCT00083083|PROCEDURE|positron emission tomography|
224076452|NCT00083083|RADIATION|fludeoxyglucose F 18|
224076453|NCT00083083|RADIATION|radiation therapy|
223865314|NCT04082611|BEHAVIORAL|Coached Data-Driven Clinical Recommendations|Data-driven multi-modal lifestyle intervention with coaching. Participants will receive coached routine care with data-driven, personalized, multimodal recommendations. MMIC participants will receive an intensive multi-modal intervention with health coaching, support and resources to carry out these recommendations. This additional intervention services include: 13 personal, data-driven brain health coaching sessions (with an RDN), 7 personal dietary counseling sessions (with an RDN), 33 group-based cognitive and physical exercise classes (CogFit) with a certified personal trainer and a computer-based neurocognitive program at home and be monitored and re-assessed for a period of 12 months.
224076454|NCT04532060|DRUG|Nystatin|
224076455|NCT04532060|PROCEDURE|Antimicrobial Photodynamic Therapy|
224076456|NCT04163068|OTHER|Interview|The interview will last approximately 45 minutes, will be audio-recorded, transcribed, and analysed
223865315|NCT01820182|DEVICE|capsule endoscopies|Patients inclusion following inclusion criterias Randomization of capsule ingestion order Videocapsule recording by the two capsules Reading of the two capsules films in randomized order by two different readers in each center Reviewing of discordant capsule films by an expert panel
223865316|NCT06175572|DEVICE|coronary physiological indices|coronary physiological indices
223865317|NCT00857545|OTHER|Laboratory Biomarker Analysis|Correlative studies
223865318|NCT00857545|BIOLOGICAL|Polyvalent Antigen-KLH Conjugate Vaccine|Given SC
223865319|NCT00857545|BIOLOGICAL|Saponin-based Immunoadjuvant OBI-821|Given SC
223865320|NCT00959946|DRUG|Bosutinib|Doses in part 1 include bosutinib 200 mg QD; bosutinib 300 mg QD. Depending on safety bosutinib can be administered at 200 mg/m2 QD. The MTD of the combination treatment determined from part 1, will be administered in part 2 (phase 2).
223865321|NCT00959946|DRUG|Capecitabine|Doses in part 1 include capecitabine 750 mg/m2 BID on days 1-14; capecitabine 625 mg/m2 BID on days 1-14. Depending on safety, capecitabine can also be administered at 1000 mg/m2 BID. The MTD of the combination treatment determined from part 1, will be administered in part 2 (phase 2).
224076457|NCT05511168|PROCEDURE|Craniostnostosis surgery|Surgery of craniosynostosis
223865322|NCT05288868|OTHER|Educational Intervention: online didactic lecture and educational simulation activity|"The didactic was created by the research team and provides information on Autism Spectrum Disorder (ASD) and an approach to taking vital signs in these children. The didactic will be pre-recorded and sent by email to employee study participants. The didactic will last about 10 minutes.~The simulation activity will have the premise of a child with ASD and their caregiver at clinic visit. The employee participant will be asked to take vital signs on the patient. The caregiver will be played by an actor and the child will be played by a mannequin. An iterative script will be used by the actor during the scenario. The simulation will last about 20 minutes and will be followed by a 10 minute debrief."
223865323|NCT02348658|DRUG|TAK-536TCH|TAK-536TCH tablets
223865324|NCT04592393|DIAGNOSTIC_TEST|Abbreviated PB MRI|Annual non-contrast PB MRI.
223865325|NCT04592393|GENETIC|Gene mutation test|K-ras and GNAS mutation test. Being performed once as a baseline test at the enrollment.
223865326|NCT04592393|DIAGNOSTIC_TEST|Conventional follow-up|Any of followings: scheduled CECT, MRI, USG, EUS, tumor marker (CA 19-9) during the study period.
224076458|NCT04161495|BIOLOGICAL|efanesoctocog alfa (BIVV001)|Pharmaceutical form: solution for injection Route of administration: IV injection
224076459|NCT01281410|PROCEDURE|Inspiratory Muscle Training|Inspiratory Muscle Training with Respifit (5 times per week)
224076460|NCT01281410|OTHER|inspiratory muscle training|Inspiratory muscle training with a device named Respifit for patients receiving a hematopoetic stem cell transplantation (till 30 days after their transplantation)
223865327|NCT05675150|BEHAVIORAL|Expressive Arts-Based Intervention|The intervention brings together the strengths of different art modalities, such as visual art, music, movement, dance, drama and writing to assist reflection and response in individuals to their personal issues. Such variety of art forms multiplies the avenues by which a person in intervention may seek meaning, clarity, insight and healing.
223865328|NCT02308618|OTHER|Traditional Immobilization|"After surgery subjects were immobilized in a plaster cast, with the ankle positioned in gravitational equinus; weight bearing was not allowed. Two weeks post-operatively, the cast was removed and the patient was immobilized with a new plaster cast, with the ankle in the same position. Four weeks post-operatively, the ankle was plastered in neutral position (i.e. with the sole of the foot perpendicular to the shank), and weight bearing was encouraged. Six weeks post-operatively, the plaster cast was removed~The home exercise program consisted of active exercises and stretches to improve ankle range of motion, and resistance and balance exercises"
224076461|NCT04451954|BIOLOGICAL|Quadrivalent RIV with H3 strain 1|Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
223865329|NCT02308618|OTHER|Early Mobilization|The physical therapy started two weeks after the surgery and lasted six weeks, during which a removable brace was used. Therapy sessions, three times per week in the six-week period, included one to two hours of exercises for regaining range of motion and muscular endurance.
223865330|NCT00988975|PROCEDURE|Insertion of pelvicol graft|Pelvicol graft
223865331|NCT00813059|DRUG|Intra-vitreal injection of bevacizumab (1.25mg/0.05ml)|Pars plana intra-vitreal injection of bevacizumab (1.25 mg/0.05 ml)
223865332|NCT01860820|DEVICE|Geko device|
224076462|NCT04451954|BIOLOGICAL|Quadrivalent RIV with H3 strain 1 and adjuvant|Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
224076463|NCT04451954|BIOLOGICAL|Quadrivalent RIV with H3 strain 2|Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
224076464|NCT04451954|BIOLOGICAL|Quadrivalent RIV with H3 strain 2 and adjuvant|Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
224076465|NCT04451954|BIOLOGICAL|Quadrivalent RIV with 2018-2019 NH H3 strain|Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
224076466|NCT04451954|BIOLOGICAL|Quadrivalent RIV with 2018-2019 NH H3 strain and adjuvant|Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
224076467|NCT03655756|BIOLOGICAL|IFx-Hu2.0|Subjects enrolled will receive a fixed IFx-Hu2.0 (plasmid DNA) dose of 0.1 mg injected in up to 3 lesions at a single time point (28-day follow-up post last injection).
223865333|NCT06405880|OTHER|Pharmacist-led care pathway|Participants in the intervention arm will receive the care using a shared decision-making pharmacist-led care pathway designed to guide the cardiovascular (CV) risk reduction process. The pharmacist-led care pathway is modelled after the largest CV risk reduction randomized controlled trial in a community pharmacy setting (RxEACH Study), and based upon the latest CV risk reduction guidelines, such as C-CHANGE. This pathway will be built into a computer web-based program and include step-by-step, algorithm-guided patient assessment to calculate the participant's estimated CV risk. The participant and pharmacist will be guided by the care pathway to review the participant's estimated CV risk and contributing CV risk factors and engage in shared decision-making to manage the participant's CV risk factors using lifestyle changes and/or pharmacological treatment as clinically appropriate.
223865334|NCT01320215|PROCEDURE|Robot-assisted promontofixation|Sacrohysteropexy with robotic assistance (da Vinci robot)
223865335|NCT01320215|PROCEDURE|Non-robot assisted promontofixation|Laparoscopic sacrohysteropexy, without robot assistance
223865336|NCT01993160|DRUG|Fluorocholine (18F-FCH) Injection|Before the PET-CT scan, the tracer (fluorocholine/FCH) will be injected into a vein in your arm just before the scan. This is the agent we are investigating in this study (not part of the standard procedure)
223865337|NCT01993160|RADIATION|PET scan|A whole body PET scan will be performed, integrated with either whole body low dose CT or whole body MRI
223865338|NCT01993160|RADIATION|Whole body MRI|A whole body MRI scan will be performed. This may be integrated with PET scan or performed separately.
223865339|NCT05028673|DRUG|Lu AG06466 Capsule|Hard capsule
223865340|NCT05028673|DRUG|Lu AG06466 Tablet|Film-coated tablet
223865341|NCT05028673|DRUG|Antacid|Oral suspension
223865342|NCT02115139|DRUG|Ipilimumab|Ipilimumab 3mg/Kg iv q 3 weeks for 4 cycles
223865343|NCT04783168|OTHER|Best Practice|Receive usual care
223865344|NCT04783168|OTHER|Health Promotion and Education|Install and use Fitbit app
223865345|NCT04783168|OTHER|Medical Device Usage and Evaluation|Use Fitbit to monitor step count
223865346|NCT04783168|OTHER|Quality-of-Life Assessment|Ancillary studies
223865347|NCT04783168|OTHER|Questionnaire Administration|Ancillary studies
223865348|NCT06513455|DRUG|Irinotecan liposome（40mg/m2）|irinotecan Liposome was administered 40mg/m2, D1，iv. q2w
223865349|NCT06513455|DRUG|Nab-paclitaxel|Nab-paclitaxel was administered 125mg/m2 D1、D8、D15，iv. q4w
223865350|NCT06513455|DRUG|Gemcitabine|gemcitabine was administered 1000 mg D1、D8、D15，iv. q4w
223865351|NCT06513455|DRUG|Irinotecan Liposome（60mg/m2）|irinotecan Liposome was administered 60mg/m2, D1，iv. q2w
223865352|NCT04088123|DRUG|Ticagrelor Oral Tablet [Brilinta]|A single loading dose of ticagrelor (180 mg) will be administered to each participant in this study.
223865353|NCT02284412|DRUG|Neostigmine|At a train-of-four (TOF) ratio of 0.5: administration of neostigmine 0.06 mg/kg for reversal of neuromuscular blockade.
223865354|NCT02284412|DRUG|Sugammadex|At a train-of-four (TOF) ratio of 0.5: administration of sugammadex 15 mg/kg for reversal of neuromuscular blockade.
223865355|NCT02284412|DRUG|Water for injection|At a train-of-four (TOF) ratio of 0.5: administration of placebo for spontaneous recovery of neuromuscular blockade.
223865356|NCT05855291|DIAGNOSTIC_TEST|PET/MRI|The participants receive 18F-FDG PET/MRI before and after neoadjuvant chemoradiotherapy.
224076468|NCT05409547|DRUG|PEG-rhG-CSF|PEG-rhG-CSF 6 mg/d (single dose) will be given on the second day after chemotherapy.
224076469|NCT01476657|DRUG|IPI-145 (duvelisib)|Oral Twice A Day (BID) Dosing
224076470|NCT04623450|OTHER|Smoothie|Preload smoothies that are matched for taste, smell, appearance, quantity and calorie but different caloric content.
224076471|NCT03894930|BEHAVIORAL|Metta meditation|Administered 5 days per week for 8 weeks.
223865357|NCT02471755|DEVICE|Eelectro-acupuncture|The bilateral acupoints of EX-CA1, ST25, SP6 and RN4 were selected for the treatment program.After regular disinfection,adhesive pads were placed on surface of all these acupoints. For RN4, EX-CA1, ST25, needles (0.30\*75mm) were inserted into the points vertically throughout the pads, skin, fat tissue, and abdominal muscles until the participant had feeling of pricking. For SP6, needles were inserted into the acupoint to a depth of 1 cun,accompanied by manipulation of lifting, thrusting, and twisting 3 times. Electronic stimulator was connected to EX-CA1 and ST25 with dilatational wave, 10/50HZ, 0.1 to 1.0mA. The current intensity was adjusted to abdomen shivering without pain. Treatment lasted for 30 minutes and acupuncture manipulation for RN4 and SP6 were performed every 10 minutes.
223865358|NCT02471755|DEVICE|Sham Eelectro-acupuncture|Non-acupoints approximate to RN4, ST25, EX-CA1 and SP6 were selected bilaterally, and adhesive pads were placed on the surface of selected non-acupoints' location. Blunt needles were inserted into the pads and to touch, rather than penetrate the surface of skin. Meanwhile, like EA group, manipulations of lifting, thrusting and twisting on non-acupoint approximate to RN4 and SP6 were performed 3 times. Sham Electronic stimulator was applied to the non-acupoint approximate to EX-CA1 and ST25, providing the outward appearance of the procedure in EA group but with no current intensity actually applied. Any other interventions were rigorously maintained the same as in the EA group.
223865359|NCT04783610|OTHER|Ethanol|Ethanol will be administered via oral route.
223865360|NCT04740164|PROCEDURE|Endoscopic Retrograde Cholangiopancreatography|Undergo ERCP with LMA Gastro
223865361|NCT04740164|PROCEDURE|Endoscopic Retrograde Cholangiopancreatography|Undergo ERCP with standard nasal cannula
223865362|NCT04177394|DEVICE|MitraClip G4 System|Percutaneous mitral valve repair using the MitraClip G4 system.
223865363|NCT05707052|OTHER|Neck-Trunk Stabilization Exercises and conventional physical therapy|Neck-Trunk Stabilization Exercises along with conventional physical therapy in which stretching, strengthening, ROMs positioning and electrical stimulation are included.
223865364|NCT05707052|OTHER|Bobath Therapy and conventional physical therapy|Bobath based exercises along with conventional physical therapy in which stretching, strengthening, ROMs positioning and electrical stimulation are included.
223865365|NCT06153641|OTHER|N/A-Observational Study|N/A-Observational Study
223865366|NCT03823911|DRUG|Elbasvir / Grazoprevir Oral Tablet [Zepatier]|All approved direct-acting antivirals for hepatitis C will be used as the intervention.
223865367|NCT03823911|PROCEDURE|Cardiac MRI|Cardiac MRI to assess for myocardial function and fibrosis
223865368|NCT01469949|OTHER|Watching or imagining movement|Mental imagery are administered in two forms : kinesthetic when subjects imagine the movement of flexion and extension of the lumbar spine and Visual when subjects watch a video of a third person doing the flexion and extension movement
223865369|NCT01152190|DRUG|Tadalafil|Administered orally, once daily for 8 weeks
223865370|NCT01152190|DRUG|Placebo|Administered orally, once daily for 8 weeks
223865371|NCT04539951|DRUG|Sertraline 200 milligram(mg)|All included participants will receive sertraline, initially at 50mg/d, with a weekly 50mg/d further increase, to the maximum recommended dosage (200mg/d) or to the maximum tolerated dosage (less than 200mg/d). Patients will be on their maximum dose by week 4, so allowing an assessment of response at 12 weeks
223865372|NCT04539951|DRUG|Sertraline 300 milligram(mg)|In experimental phase II, the patients in this group will remain on sertraline (higher dosage): where sertraline 200mg has been tolerated, dosage will be increased by 50mg fortnightly to a maximal dose of 300mg/d or to the maximum tolerable dose (less than 300mg/d).
223865373|NCT04539951|DRUG|Fluvoxamine|Fluvoxamine will be initiated at a dose of 50mg/d, increasing quickly to a maximal dose of 300mg/d or the maximum tolerated dose by week 4.
223865374|NCT04539951|DRUG|Venlafaxine|venlafaxine will be initiated at 75mg/d, increasingly weekly by 75mg/day, to a maximal dose of 300 mg/d or the maximum tolerated dose.
223865375|NCT04539951|DRUG|Augment with Memantine|Sertraline will be augmented with memantine initially at 5mg/d, and increasing by 5mg/d weekly to a maximal dose of 20mg/d (10mg twice daily) or the maximum tolerated dose
223865376|NCT04539951|DRUG|Augment with Aripiprazole|Sertraline will be augmented with aripiprazole, initially at 5mg/d, and increasing by 5mg/d weekly to a maximal dose of 20mg/d or the maximum tolerated dose
223865377|NCT01335542|PROCEDURE|Peri-Articular Injection|Pre-operative anesthesia/analgesia: meloxicam (7.5 or 15mg), dexamethasone (6mg) Anesthetic:: Combined Spinal-Epidural with 0.5% bupivacaine. IV sedation with midazolam, propofol Antiemetic: 20mg famotidine, 4mg ondansetron Postoperative pain management: hydromorphone/bupivacaine PCEA (4/4/10/20, initially). Meloxicam (7.5 or 15mg), Oxycodone/Acetaminophen (5/325 3hr PRN)
223865378|NCT01335542|PROCEDURE|Epidural Pathway (PCEA+FNB)|Pre-operative anesthesia/analgesia: meloxicam (7.5 or 15mg), extended release oxycodone (10mg or 20mg), dexamethasone (6mg), clonidine patch (100 mcg/24 hr) Anesthetic: Spinal with 0.5% bupivacaine, IV sedation with midazolam, propofol Antiemetic: 20mg famotidine, 4mg ondansetron Post-operative analgesia:Prilosec (20mg), Meloxicam (7.5mg or 15 mg PO), extended release oxycodone (10mg or 20mg), Oxycodone (5mg q 3 hr PRN), Acetaminophen (1000mg), ketorolac 15mg IV
223865379|NCT04789798|DEVICE|TeleDiab (Telemedicine)|"TeleDiab program components consist of:~1. Electronic transmission of capillary blood glucose measurement results~2. Electronic transmission of blood pressure measurements~3. Synchronized video-conferencing, secure messaging~4. Access to clinical data from patient files when necessary~5. Reminding of routine follow-up tests and examinations~6. Providing web-based educational materials to patients."
223865380|NCT04789798|OTHER|Usual care|Usual diabetes care, as provided by primary care providers
223865381|NCT00381173|DRUG|Cyclophosphamide & ZYC300 (ZYC300 with cyclophosphamide pre-dosing)|Patients who meet all entry criteria will be administered 600 mg/m\^2 cyclophosphamide intravenously 3 days before each dose of ZYC300. ZYC300 will be administered at 400 micrograms DNA/total dose every two weeks for a maximum of six doses (6 cycles).
223865382|NCT05672797|OTHER|Wellth app|The Wellth app will be provided to treatment groups 1 and 2 for free and it is available for download through all common mobile app stores for both iOS and Android phones. The Wellth App is a private company that serves over five million clients that range from patients of healthcare providers and beneficiaries of various health insurance companies to employees of large corporations, where the Wellth App is offered as a behavioral tool for increasing meditation adherence among individuals who are managing chronic conditions through daily meditations, e.g. chronic obstructive pulmonary disease, asthma, high blood pressure, coronary artery disease, and HIV. The Wellth App has already been offered to some members of Arizona Complete Health, so both Wellth and Arizona Complete Health are familiar with implementing this program among this target population.
223865383|NCT05672797|BEHAVIORAL|Habit training|"Participants in treatment groups 1 and 2 will be asked to identify an existing routine behavior that will act as a cue for their daily pill-taking behavior to. However, only participants in treatment group 2 will have to submit visual evidence of their cue to the Wellth app in addition to photos of their medication in order to receive credit for the medication check-in (i.e., financial incentives conditional on using their cue)."
223865384|NCT06355388|DEVICE|Active tVNS|"As for the short-term phase, the ear clip of the Parasym device (Parasym, London, United Kingdom), containing the stimulation electrode, will be positioned at the level of the patient's tragus, and a 10-minute stimulation will be initiated with a pulse width of 200 μs, a frequency of 30 Hz, and an intensity of one mA lower than the patient's sensitivity threshold.~As fort he mid-term phase, a device will be given to the patient, which will be instructed to position the ear clip of the device at the level of the tragus and to set stimulation parameters as established in the laboratory (see above). Each patient will be asked to undergo at least one hour daily stimulation for a period of 4 weeks, reporting on a diary the timing and details of the each session."
223865385|NCT06355388|DEVICE|Sham tVNS|"As for the short-term phase, the ear clip of the Parasym device (Parasym, London, United Kingdom), containing the stimulation electrode, will be positioned at the level of the patient's tragus for 10-minute but no current will be delivered.~As fort he mid-term phase, a device (configured to withhold power delivery) will be given to the patient, which will be instructed to position the ear clip of the device at the level of the tragus and to set stimulation parameters as established in the laboratory (see above). Each patient will be asked to undergo at least one hour daily stimulation for a period of 4 weeks, reporting on a diary the timing and details of the each session."
223865386|NCT01568073|DRUG|BIA 9-1067|5, 25 and 50 mg of BIA 9-1067 (once-daily)
223865387|NCT01568073|DRUG|Entacapone|200 mg entacapone (concomitantly with each L-dopa/DDCI dose)
223865388|NCT01568073|DRUG|Placebo|200 mg
223865389|NCT01568073|DRUG|Levodopa|
223865390|NCT01568073|DRUG|Carbidopa|DOPA decarboxylase inhibitor
223865391|NCT01568073|DRUG|Benserazide|DOPA decarboxylase inhibitor
223865392|NCT02008084|DRUG|TRIA-662|Following Baseline randomized to active TRIA-662 2 x 500 mg tablets, three times daily with meals for 2 weeks and then active TRIA-662 2 x 1000 mg tablets, three times daily with meals for 12 weeks.
223865393|NCT02008084|DRUG|Placebo|Following Baseline randomized to placebo TRIA-662 2 x 500 mg tablets, three times daily with meals for 2 weeks and then placebo TRIA-662 2 x 1000 mg tablets, three times daily with meals for 12 weeks.
223865394|NCT04796337|BIOLOGICAL|Sotatercept|Sotatercept SC injection at a dose of 0.3 to 0.7 mg/kg.
223865395|NCT03207568|DEVICE|Thoracic Endovascular Aortic Repair (TEVAR)|thoracic endovascular repair (TEVAR) with a thoracic stent-graft
223865396|NCT00488657|DEVICE|SpeechEasy Model ITC|The delayed auditory feedback ranging from 50 to 220 ms, and the altered frequency feedback ranging from 500 to 2,000 Hz.
223865397|NCT02613806|DRUG|Dexmeditomidine|Dexmeditomidine 0.2 ug/kg·h will be administered to participants by intravenous infusion at the beginning of the surgery,and continued till end of surgery.
223865398|NCT02613806|DRUG|normal saline|Isovolumetric normal saline will be administered to participants by intravenous infusion at the beginning of the surgery,and continued till end of surgery.
223865399|NCT01600729|DRUG|No Intervention|No intervention.
223865400|NCT05503212|OTHER|Conservative treatment (CT)|Best medical treatment without intravenous thrombolysis nor endovascular thrombectomy
223865401|NCT05503212|OTHER|Intravenous thrombolysis (IVT)|Best medical treatment with intravenous thrombolysis but without endovascular thrombectomy
223865402|NCT05503212|OTHER|Endovascular thrombectomy (EVT) ± intravenous thrombolysis (IVT)|Best medical treatment with endovascular thrombectomy with or without intravenous thrombolysis
223865403|NCT00748410|DRUG|SB-656933|7 days repeat dose
223865404|NCT04382963|OTHER|High Risk - intensive coaching|"The following assessment will occur: health assessment, blood pressure, BMI, history TIA/stroke, blood mRNA and protein analysis, ultrasound, cognitive assessment, stroke education, intensive coaching face-to-face.~Furthermore, this group will receive intensive initiation of the American Heart Association Guidelines for Management of Risk Factors with individual face-to-face coaching meetings on lifestyle change and adherence to treatment on at a least quarterly basis."
223865405|NCT04382963|OTHER|High Risk - standard care|The following assessment will occur: health assessment, blood pressure, BMI, history TIA/stroke, blood mRNA and protein analysis, ultrasound, cognitive assessment, stroke education.
223865406|NCT04382963|OTHER|Low Risk - control|Control participants will undergo the same study events as the Low Risk group, except without receiving information and advice about eliminating stroke risk factors.
223865407|NCT03614611|DEVICE|Contiform pessary|"Patients will be asked to use the device for 12 weeks and to become comfortable with self-insertion and self-removal. The device can be worn continuously for 1 month. When placed in the vagina it retains its shape and supports the urethra during episodes of varied intraabdominal pressure. During the assessment test (24 hours pad test), patients will be encouraged to undertake any activity that would normally induce stress leakage.~The contiform device is approved by Health Canada since 2017-04-10 (Licence No.: 98950, Company ID: 134089, Device identifier: SKU 184)"
223865408|NCT02538263|DEVICE|Volume-targeted noninvasive ventilation|
224267817|NCT04509154|OTHER|Multimodal pain therapy|For the elaboration of the contents of the multi-component treatment of the mobile device application (APP), a set of guidelines has been developed for the care of one's own health, based on scientific evidence and adapted to the language of citizens, applying participatory methodology (Loewenson et al. 2014) and consensus, both by professionals (physicians,, nurses, psychologists, pharmacists, social educators and health professionals), and expert patients, who guarantee their validity, allowing the analysis and selection of the interventions that respond to the health problem. This intervention consists in the implementation of a protocol of standard activities of the interactive psychosocial therapy type.
224267818|NCT04509154|OTHER|Standardized treatment.|Face-to-face health education sessions led by nurses and physicians, with the possibility to have access to a non-interactive website with pain management materials from a self-help approach.
224267819|NCT00109057|DRUG|Avastin (bevacizumab)|
224267820|NCT04584086|DEVICE|MRI 3 tesla|"1.5 Tesla MRIs, usually used as pre-treatment and, between 3 and 6 months after irradiation, are replaced in the study by 3 Tesla MRIs (pre-treatment and at 6 months)~In addition, two additional MRIs, also performed with a 3 Tesla magnetic field, will be performed:~* During treatment when half of the prescribed dose has been delivered.~* 1 month after the end of the irradiation."
224267821|NCT03835845|DEVICE|PICO7Y|The PICO 7Y pump maintains NPWT at -80 mmHg (nominal) to two wound surfaces simultaneously. Exudate is managed by the dressings through a combination of absorption and evaporation of moisture through the outer film. The PICO 7Y kit is intended to be used for up to 7 days on low exuding wounds. For moderately exuding wounds the system is intended to be used for up to 4 days without a dressing change. For 7 days use on moderately exuding wounds additional dressings will be supplied.
224267822|NCT01723683|DRUG|Surfactant|
224267823|NCT05088551|OTHER|Patient Education|The education was divided into three parts. The information in the first part of the booklet (general information, preoperative preparation, and operation day) is given in the preoperative period. In the postoperative period, the patients were visited and the information in the second part (postoperative hospital stay, first, second, and third-day goals after surgery) was given. Before the patients were discharged, the information in the third section (things to be considered in the recovery process at home) was presented. According to the physical conditions of the clinic, patient education was carried out in an area suitable for teaching as much as possible.
224267824|NCT05578794|OTHER|Straining types|Valsalva, spontaneous and natural strainings are supported in 2nd stage of labor. Duration of delivery, perineal trauma status and Apgar Scores were evaluated.
224267825|NCT01880476|OTHER|Home visits and group program|Participants will receive up to three home visits by a Registered Nurse and two home visits by a Registered Dietitian over the 6-month intervention period. Participants will also be invited to attend a monthly Diabetes Wellness Day group program which will include diabetes education, interaction with peer volunteers, group exercise, and a meal. The Registered Nurse will coordinate care to help participants access necessary community supports and services and lead monthly interprofessional case conferences to develop a client-centred plan of care for each study participant.
224267826|NCT00241982|DRUG|long-circulating liposomal prednisolone|
224267827|NCT03682276|BIOLOGICAL|Ipilimumab|Ipilimumab is a monoclonal antibody given as an immunotherapy
224267828|NCT03682276|BIOLOGICAL|Nivolumab|Nivolumab is a monoclonal antibody given as an immunotherapy
223865409|NCT06969495|OTHER|xLr oral gel|25% of Cold water extract of Tiger milk mushroom sclerotial powder in a gel form containing xanthan gum as a thickening agent and 0.5% sodium benzoate as a preservative.
223865410|NCT06969495|OTHER|Placebo|oral gel base formulation without the Lignosus rhinocerus extract
223865411|NCT06969495|DRUG|Kanolone|Kanolone Oral Base Paste (Triamcinolone acetonide 0.1%)
223865412|NCT05857969|DEVICE|Functional Precision Medicine|Ex Vivo Drug Sensitivity Testing + Genomic Tumor Profiling
223865413|NCT00092885|DRUG|MK0476, montelukast sodium|
223865414|NCT00092885|DRUG|Comparator: placebo|
223865415|NCT04988451|BEHAVIORAL|ASL Services|ASL specialist meets with participants and provides ASL instruction
223865416|NCT01547741|DRUG|Doxorubicin|
223865417|NCT01547741|DRUG|Cyclophosphamide|
223865418|NCT01547741|DRUG|Docetaxel|
223865419|NCT01547741|DRUG|Paclitaxel|
223865420|NCT00466076|DRUG|Copaxone (Glatiramer acetate)|
223865421|NCT02247063|DEVICE|High-Definition Transcranial Direct Current Stimulation (HD-tDCS)|HD-tDCS is a non-invasive brain neuromodulatory method for M1 that involves sending a weak electrical current into your brain.
223865422|NCT03505099|BIOLOGICAL|onasemnogene abeparvovec-xioi|A non-replicating recombinant AAV9 containing the complimentary deoxyribonucleic acid (cDNA) of the human SMN gene under the control of the cytomegalovirus (CMV) enhancer/chicken-β-actin-hybrid promoter (CB). The AAV inverted terminal repeat (ITR) has been modified to promote intramolecular annealing of the transgene, thus forming a double-stranded transgene ready for transcription.
223865423|NCT01979913|DRUG|Saflutan® 15 microgram/ml Augentropfen im Einzeldosisbehältnis|
223865424|NCT04910932|OTHER|Breathing Exercises|Breathing exercises including diaphragmatic breathing, thoracic expansion and breathing control exercises
223865425|NCT04910932|OTHER|Information on COVID-19|"Information about COVID-19 based on the advices in COVID-19 advice for the public section of World Health Organization website."
223865426|NCT04316234|OTHER|Passive vape|On days with passive vape, 2-3 vapers in an adjacent chamber were vaping by turn, and vape was passed on to the exposure chamber continuously .
223865427|NCT01818401|DEVICE|the prosthesis GMK ® without the ancillary MyKnee ® LBS|
223865428|NCT01818401|DEVICE|Matched patient cutting blocks MyKnee ® LBS|
223865429|NCT01803516|BEHAVIORAL|questionnaires|This study will be offered to patients who, at the time of consultation are identified as having had adjuvant breast radiation treatment following surgical treatment for breast cancer and developed radiation-induced telangiectasias. The Skindex-16 and BREAST-Q questionnaires will be used to evaluate the quality of life of The study participants. For each instrument, for each evaluation time point, QOL scores will be summed and transformed into a scale from 0-100. Descriptive statistics will be used to describe the QOL of the study participants.
223865430|NCT01348880|DRUG|Vardenafil ODT, (Staxyn, BAY38-9456)|Single dose of 10 mg of vardenafil ODT, taken without water
223865431|NCT01348880|DRUG|Placebo|Single dose of placebo to match 10 mg vardenafil ODT. taken without water
223865432|NCT01121549|DRUG|Aromasin|25 mg daily continuously
223865433|NCT03967717|OTHER|Characterization of parameters of medical history, examination and diagnostics.|Patients receive standard of care diuretics. The study only collects data to characterize parameters of medical history, examination and diagnostics.
223865434|NCT04789408|DRUG|Cyclophosphamide|Administered intravenously
223865435|NCT04789408|DRUG|Fludarabine|Administered intravenously
223865436|NCT04789408|BIOLOGICAL|KITE-222|A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells administered intravenously
223865437|NCT01278888|PROCEDURE|Anterolateral thoracotomy|Standard anterolateral thoracotomy
223865438|NCT01278888|PROCEDURE|Posterolateral thoracotomy|Standard muscle sparing posterolateral thoracotomy
223865439|NCT01278888|PROCEDURE|VATS|Standard video assisted thoracic surgery, no use of rib-spreader.
223865440|NCT01278888|PROCEDURE|Anterolateral Thoracotomy|Standard anterolateral thoracotomy
224076472|NCT03656861|OTHER|Physical load|The impact of training on cardiac structure and function depends on the type, intensity and duration of the activity, as well as previous physical activity engagement, genetics and gender type. More knowledge about cardiac pathophysiologic training adaptation is needed.
224076473|NCT02117765|DRUG|Ustekinumab|
224076474|NCT00253630|OTHER|Laboratory Biomarker Analysis|Correlative studies
224076475|NCT00253630|DRUG|Vorinostat|Given PO
223865441|NCT04021667|OTHER|educational intervention|İndividual and Group Breastfeeding Education:It was taken into consideration that mothers and fathers who do not have breastfeeding experience in the antenatal period feel better in terms of their perception of the education given, and education is provided with adult education principles.Breastfeeding training slides, cloth nipple model, dummy dolls were used during the training and lecture, demonstration and application and breastfeeding training were provided.At the end of the training, they were given time to ask questions and their feedback was received.Control Group:Routine procedures in the clinic were performed for the mother and father candidates.The data of the mother and father who came to the hospital for antenatal follow-up and control were collected in four stages.
223865442|NCT02808039|OTHER|Platelet reactivity testing|assessment of platelet aggregation using the VerifyNow purinergic receptor P2Y, G-protein coupled, 12 (P2Y12) platelet function assay (Accumetrics, San Diego, California)
223865443|NCT00687011|DRUG|Palonosetron and Dexamethasone|0.25 mg IV single dose, 30 minutes prior to the administration of the major chemotherapeutic agent, plus single IV dose of dexamethasone 8 mg administered 15 minutes before chemotherapy (in the event of a shortage of IV dexamethasone, a single oral dose of dexamethasone 20 mg or a single IV dose of methylprednisolone 125 mg could be administered).
223865444|NCT03547804|DRUG|Apatinib|500 mg qd/250mg
223865445|NCT03547804|DRUG|chemotherapy|Chemotherapeutic agents are limited to irinotecan or docetaxel alone.
223865446|NCT00012740|BEHAVIORAL|Casefinding and Referral System|
223865447|NCT00211731|BEHAVIORAL|Chronic Disease Self Management Course|
223865448|NCT04771351|BIOLOGICAL|COVI-AMG|COVI-AMG is a fully human SARS-CoV-2 neutralizing monoclonal antibody (mAb)
223865449|NCT04771351|DRUG|Placebo|Diluent solution
224076476|NCT05364242|BIOLOGICAL|VLA2001|whole virus inactivated SARS-CoV-2 vaccine adjuvanted with cytosine phospho-guanine (CpG)1018 in combination with aluminium hydroxide
223865450|NCT01420549|DRUG|Rosuvastatin 10 mg + Ezetimibe 10 mg and Rosuvastatin 20 mg + Ezetimibe 10 mg, according to clinical evaluation.|Tables containing: Rosuvastatin 10 mg + Ezetimibe 10 mg and Rosuvastatin 20 mg + Ezetimibe 10 mg, according to clinical evaluation.
223865451|NCT01420549|DRUG|Simvastatin 20 mg + Ezetimibe 10 mg and Simvastatin 40 mg + Ezetimibe 10 mg, according to clinical evaluation.|Tables containing: Simvastatin 20 mg + Ezetimibe 10 mg and Simvastatin 40 mg + Ezetimibe 10 mg, according to clinical evaluation.
223865452|NCT00593697|DRUG|trastuzumab (9 weeks) + docetaxel|"Patients diagnosed with early breast cancer with a high risk of disease recurrence will be randomly allocated to one of the following 2 arms in a 1:1 ratio:~A. Weekly or 3-weekly trastuzumab plus 3-weekly docetaxel (3 cycles) (HT) -\> 3-weekly FE75C (3 cycles) (HT x3 -\>FE75C x3) B. Weekly or 3-weekly trastuzumab plus 3-weekly docetaxel (3 cycles) (HT) -\> 3-weekly FE75C (3 cycles) -\> trastuzumab to complete 1 year (14 3-weekly infusions) (HT x3 -\>FE75C x3 -\> H3wkly x14)"
223865453|NCT00593697|DRUG|trastuzumab (9 weeks) + docetaxel + CEF + trastuzumab (up to 51 weeks)|Weekly or 3-weekly trastuzumab plus 3-weekly docetaxel (3 cycles) (HT) -\> 3-weekly FE75C (3 cycles) -\> trastuzumab to complete 1 year (14 3-weekly infusions) (HT x3 -\>FE75C x3 -\> H3wkly x14)
223865454|NCT06011525|OTHER|standard cold cap|"Standard cold-cap applied throughout anthracycline- and taxane-based chemotherapy treatment.~This device will be supplemented by a compressive bandage in order to add to the vasoconstriction action of the cold, the compression of the bandage on the scalp and thus optimise the efficacy of the device."
223865455|NCT06011525|OTHER|scalp-cooling technique|Scalp-cooling technique applied throughout anthracycline- and taxane-based chemotherapy treatment
223865456|NCT02791750|OTHER|questionnary of quality of life|
223865457|NCT02021760|PROCEDURE|Primary Percutaneous Coronary Intervention|Primary Percutanous Coronary Intervention is performed in both Groups.
223865458|NCT04414904|OTHER|Exposure: Covid-19 infection|Previous history of COVID-19 infection.
223865459|NCT06184451|OTHER|Therapeutic exercise|The therapeutic exercise program includes a warm-up, resistance, neuromuscular, mobility, and balance exercises. Therapeutic exercises will be performed in up to three sets of 8-12 repetitions or 30-60 seconds each, with rest intervals of 90 seconds between sets.
224076477|NCT01169077|DRUG|Placebo|Injections of normal saline to be used as control; given at Days 0, 28, and 56. Administered via electroporation, using a DNA vaccine delivery device, in the deltoid.
224076478|NCT01169077|BIOLOGICAL|EP-1300|Single DNA plasmid dissolved in phosphate-buffered saline (PBS). Dose levels: 0.25, 1 and 4 mg based on DNA content, administered on Days 0, 28 and 56 via electroporation using a DNA vaccine delivery device, in the deltoid.
224076479|NCT03771365|PROCEDURE|Standard-PCNL|percutaneous nephrostolithotomy (PCNL) with ≥24 Fr access tract for the treatment of ≥2 cm renal stone
223865460|NCT06184451|DEVICE|Transcutaneous electrical nerve stimulation|"TENS will be applied with a portable device, Neurodyn Portable System from Ibramed, while carrying out the entire therapeutic exercise program. The equipment has a two-phase and pulsed symmetric quadratic waveform. 5x5cm adhesive electrodes will be applied to the lateral and medial edges and superior and inferior to the patella, in a crossed manner, surrounding the region.~The parameters established for the protocol of this study are based on a survey already carried out, with continuous pulse mode, frequency of 150Hz, duration of 150us, and amplitude varying from 1-60mA or more as long as tolerated by the study participant, without causing pain. The application time will be proportional to the time of the exercise session, approximately 60 minutes. The researcher will evaluate the need to adjust the current intensity through the pulse amplitude regularly so that the stimulus does not accommodate."
224076480|NCT03771365|PROCEDURE|Mini-PCNL|percutaneous nephrostolithotomy (PCNL) with 12-20 Fr access tract for the treatment of ≥2 cm renal stone
223865461|NCT06184451|DEVICE|Placebo transcutaneous electrical nerve stimulation|"The equipment has a two-phase and pulsed symmetric quadratic waveform. 5x5cm adhesive electrodes will be applied to the lateral and medial edges and superior and inferior to the patella, in a crossed manner, surrounding the region.~The parameters established for the protocol of this study are based on a survey already carried out, with continuous pulse mode, frequency of 150Hz, duration of 150us, and amplitude varying from 1-60mA or more as long as tolerated by the study participant, without causing pain. To do this, the device will only be turned on during the first minute of therapeutic exercises. The same TENS parameters as the experimental group will be applied for this."
223865462|NCT01403168|OTHER|OSTEOPATHY + conventional analgesic treatments|"5 sessions for osteopathy are planned and will start in the 15 days following the enrollment.~The conventional analgesic treatments will be administered in the 15 days following the enrollment."
223865463|NCT01403168|OTHER|Conventional analgesic treatments|These treatments will be administered in the 15 days following the enrollment. Dose and frequence will depend on patients.
223865464|NCT06972992|DRUG|ASC47 +Semaglutide|ASC47 single subcutaneous injection + Semaglutide QW for 4 weeks
223865465|NCT06972992|DRUG|Placebo+Semaglutide|Placebo single subcutaneous injection + Semaglutide QW for 4 weeks
223865466|NCT06546605|DEVICE|Whole-Body Electrical Muscle Stimulation (WB-EMS) Training|Whole-Body Electrical Muscle Stimulation (WB-EMS) Training is a novel training modality that involves the simultaneous electrical stimulation of multiple muscle groups while performing dynamic exercises. Participants in the WB-EMS Training Group will use the miha bodytec device (Augsburg, Germany), which consists of a special suit with integrated electrodes covering major muscle groups. The device generates electrical impulses (85 Hz, 350 μs) that cause involuntary muscle contractions during exercises like squats, lunges, and trunk rotations.Each 20-25-minute WB-EMS session will be conducted twice a week during the two 8-week intervention periods. Sessions will include a warm-up followed by 4-6 WB-EMS exercises performed for 4-6 seconds each, with 4 seconds of rest between exercises. The intensity of the stimulation and exercises will be progressively increased based on individual adaptation and tolerance, with the stimulation intensity set at 70-85% of the maximal tolerable level.
223865467|NCT06546605|BEHAVIORAL|Plyometric Training|"Plyometric Training is a high-intensity, explosive strength training modality that involves quick, powerful movements designed to increase muscle power, speed, and agility. Participants in the Plyometric Training Group will engage in a progressive plyometric training program that emphasizes eccentric muscle loading followed by rapid concentric contractions.~The plyometric exercises will include various types of jumps, hops, and bounds, such as box jumps, depth jumps, split squat jumps, and single-leg hops. Each training session will begin with a dynamic warm-up, followed by 4-6 plyometric drills performed for 3-5 sets of 8-12 repetitions, with 60-90 seconds of rest between sets. The intensity and volume of the exercises will be gradually increased over the two 8-week intervention periods."
223865468|NCT06546605|BEHAVIORAL|Functional Training|"Functional Training is a training approach that focuses on exercises that simulate the demands of specific sports or daily activities, targeting multiple muscle groups and movement patterns simultaneously. Participants in the Functional Training Group will engage in a tailored functional training program designed to enhance their performance in basketball or volleyball.~The functional training exercises will incorporate multi-joint, multi-planar movements that mimic game-specific actions, such as multidirectional lunges, rotational medicine ball throws, and single-leg balance drills. Each session will start with a dynamic warm-up, followed by 6-8 functional exercises performed for 3-4 sets of 8-12 repetitions, with 60 seconds of rest between sets. The program will also include core stability and injury prevention exercises."
223865469|NCT06429852|BEHAVIORAL|The DeST-ACT Trauma-Focused Acceptance and Commitment Therapy Program|The Trauma-focused psychosocial intervention program consists of 4 sessions online therapy.
224076481|NCT03771365|PROCEDURE|SMP|percutaneous nephrostolithotomy (PCNL) with 10-14 Fr access tract for the treatment of ≥2 cm renal stone
223865470|NCT05857813|BEHAVIORAL|Program for the Education and Enrichment of Relational Skills (PEERS®)|developed at the University of California, Los Angeles (E. A. Laugeson \& F. Frankel, 2010). This is a parent-assisted, manualized social skills training program that addresses crucial areas of social functioning for adolescents. Psycho-education and cognitive-behavioral therapy techniques are employed to help adolescents develop ecologically valid skills for making and maintaining friendships.
223865471|NCT06602596|BEHAVIORAL|Hoosier Sport|The Hoosier Sport intervention is an 8-week program designed for students in PE classes, focusing on enhancing physical activity and promoting health through sport. The curriculum includes unique sports activities, leadership exercises, and health education, aimed at improving students' physical and psychological well-being. The program also addresses the effects of screen time and social media on physical activity, encouraging healthier behaviors. Throughout the intervention, students wear AX3 accelerometers to track changes in their physical activity levels, helping to assess the program's impact.
223865472|NCT01228916|BEHAVIORAL|Tobacco Cessation and Secondhand Smoke Reduction|Awareness raising and resources for cessation and secondhand smoke reduction
223865473|NCT03957681|DRUG|KHK4827|210 mg Q2W, SC
223865474|NCT03957681|DRUG|Placebo|Q2W, SC
223865475|NCT02578589|PROCEDURE|Plica resection vs conservative treatment|Plica resection vs conservative treatment
223865476|NCT06657976|BEHAVIORAL|Supervised Treadmill Exercise|This is a 12 week intervention where participants will walk for exercise 3 times a week on a treadmill at a center while being supervised by healthcare personnel.
223865477|NCT06657976|BEHAVIORAL|Attention Control|This group will attend weekly one-hour educational sessions either on Zoom or in-person for 12 weeks. These sessions are on topics of interest to the typical PAD patient and may be led by study staff, physicians, or other health care workers.
223865478|NCT06657976|COMBINATION_PRODUCT|Nitrate-Rich Beetroot Juice + supervised exercise therapy|Participants randomized to this group will drink nitrate-rich beetroot juice while engaged in supervised exercise.
223865479|NCT06657976|COMBINATION_PRODUCT|Placebo + supervised exercise therapy|Participants randomized to this group will drink placebo while engaged in supervised exercise.
223865480|NCT06463470|BEHAVIORAL|Cognitive Behavioural Therapy for Avoidant/Restrictive Food Intake Disorder (CBT-AR)|CBT-AR describes an adaption of cognitive behavioural therapy for use with individuals diagnosed with Avoidant/Restrictive Food Intake Disorder (ARFID).
223865481|NCT00541333|DRUG|Copaxone Injection|
223865482|NCT05485129|DEVICE|BIORICS|Wearing BIORICS in their ear and perform mental arrhythmic test, relaxation exercises and Stroop test
223865483|NCT01048931|PROCEDURE|single-port LAVH|single-port LAVH
223865484|NCT05604937|OTHER|Shi's traumatology osteopathic manipulation|Patients receive treatment twice a week and continues for 2 weeks. Receive a total of 4 manipulative treatments. The manipulation intervention has mainly two steps: First, doctors perform soft-tissue manipulation on neck and shoulders to relax for 10 min; Second, doctors perform manipulation to reconstruct atlantoaxial joint. The strength of manipulation is based on the patient's tolerance. Do not use too much force.
223865485|NCT05604937|DRUG|Merislon|Merislon (Betahistine Mesilate Tablets), specification 6mg, Sinopharm H20040130, Eisai (China) Pharmaceutical Co., LTD., is given to patients of the control group, for 2 weeks, 6mg a day, three times a day.
223865486|NCT06994806|DRUG|KQB168|Oral KQB168
223865487|NCT06994806|DRUG|Pembrolizumab|Intravenous pembrolizumab
224076482|NCT05172739|DRUG|Opioid-Based Anesthesia-Analgesia Strategy|"A perioperative Opioid-Based multimodal Anesthesia- Analgesia strategy will be implemented that incorporates the following pharmacological agents:~Premedication: Midazolam, Anaesthesia induction \& maintenance: Midazolam, Propofol, Fentanyl, Cisatracurium or alternatively Rocuronium, Desflurane, Morphine, Paracetamol, Dexketoprofen trometamol, Ondansetron or Droperidol, Ropivacaine Surgical ward: Morphine, Paracetamol, Dexketoprofen trometamol Rescue therapy only: Tramadol"
223865488|NCT06671717|OTHER|Pralatrexate combined with Chidamide bridging Allogeneic Hematopoietic Stem Cell Transplantation|"Drug: Pralatrexate, Chidamide~1. Pralatrexate: 30 mg/m2 intravenously (IV) administered weekly in 6-week cycles. Chidamide: 20mg, twice a week in 3-week cycles (2 weeks on treatment, 1 week off treatment)~2. After the 6-week therapy, the patients should receive PET/CT evaluation.~3. Patients would receive allo-HSCT if they could achieve at least PR after the first cycle of therapy. For the patients could not achieve a least PR after the first cycle of therapy, they should receive a second cycle of pralatrexate combined with chidamide. The interval between two cycles of pralatrexate combined with chidamide should be at least 1 week.~4. After the second cycle of 6-week therapy, the patients should receive PET/CT evaluation. Patients would receive allo-HSCT if they could achieve at least SD after the second cycle of therapy. For the patients could not achieve a least SD after the second cycle of therapy, they should receive other salvage therapies."
223865489|NCT06993870|DRUG|HBT-708|bispecific antibody
223865490|NCT06674122|DIETARY_SUPPLEMENT|Enteral vitamin D supplementation of 800 IU/day|Higher dose of enteral vitamin D supplementations (800 IU/day) are given for 28 days, and vitamin D status are examined before and after supplementation
223865491|NCT06674122|DIETARY_SUPPLEMENT|Enteral vitamin D supplementation of 400 IU/day|Standard recommended dose of enteral vitamin D supplementations (400 IU/day) are given for 28 days, and vitamin D status are examined before and after supplementation
223865492|NCT06677515|OTHER|VR training|The different VR scenarios comprise the following learning goals: 1) Social cognition. Interpreting social situations, understanding others; 2) Social communication. Express oneself, being understood by others; 3) Social competence. Interacting with others The investigators will use an MSI Raider GE78HX with a GeForce RTX4080 12GB GPU, running Windows 11, Unreal Engine 5.4, and the Meta Quest Link app, with a Meta Quest Pro as a PCVR headset connected via a Meta Quest Link cable. The setup works 100% locally, and no Wi-Fi or internet connection is used on the head-mounted-display or PC. The VR program itself does not store any data and will discard all that has happened inside the program, when restarted.
223865493|NCT06677099|PROCEDURE|chest physiotherapy|Two sessions of CPT (morning and afternoon, 20 minutes each) were conducted. The CPT session consisted of modified postural drainage, assisted cough technique , positive expiratory pressure and chest percussion, vibration. The appointed therapist performed pulmonary auscultation and thoracic palpation to assess the status of pulmonary ventilation and secretion retention, and whether the patient's cough ability can complete effective airway clearance. Individualized program was formed according to the assessment, internal guidelines, the patient's tolerance, education level, and patient's preference prior to the randomization. All CPT sessions were performed by the same physiotherapist to avoid potential bias.
223865494|NCT06677099|PROCEDURE|EIT-guided chest physiotherapy|EIT-guided modified postural drainage combined with vibrations and chest percussion: tidal variation images in EIT reveals heterogeneously ventilated regions. Physiotherapist identified such regions at the bedside and instructed the patient to take the appropriate drainage position, so that the poorly ventilated regions became gravity non-dependent regions. Subsequently, the physiotherapist put her hands on the poorly ventilated area with a vibratory force. A compressive pressure was produced by the therapist's arms.
223865495|NCT06861894|DRUG|Adebrelimab and nab-paclitaxel and carboplatin|Adebrelimab combined with nab-paclitaxel and carboplatin as neoadjuvant therapy
223865496|NCT06861894|RADIATION|Radiation|concurrent chemoradiotherapy
223865497|NCT06861894|PROCEDURE|standard oesophagectomy|standard oesophagectomy
223865498|NCT06861894|OTHER|active surveillance|active surveillance
223865499|NCT06377345|DEVICE|AeviceMD device|The intervention group will receive the AeviceMD device on top of standard care provided by the Polyclinic. They will use the AeviceMD device for 12 weeks. They are expected to use the device for at least 5 hours at night when they are asleep. However, they can also use the device at any time of the time, based on their own preference. The AeviceMD device will provide patients with objective information of their breathing (respiratory rate) and lung sounds. This objective information can be used for participants to self-manage their asthma following the asthma action plan. During the clinical follow-up, participants can show the clinician their lung parameters, to improve clinical management
223865500|NCT06377345|BEHAVIORAL|Standard care|All participants will receive the standard care provided by the Polyclinic. This can include a telephone follow-up by a nurse within 5 days, and follow-ups with a doctor after one week. All patients with asthma should also have an asthma action plan which provides them instructions on how to manage their asthma and the medications required when they experience symptoms. These symptoms include wheezing, chest tightness, difficulty breathing, coughing, night-waking, and symptom interfering with day-to-day activities.
223865501|NCT07060391|PROCEDURE|Deep cervical lymphatic-venous anastomosis|Lymph node reconstruction was carried out using microsurgical techniques,improve cerebral lymphatic circulation and return, accelerate the excretion of pathological proteins, the metabolic products of the brain, from the brain. This is to delay the degenerative changes of the brain and the progression of Alzheimer's disease.
223865502|NCT07060391|DRUG|Donepezil drug treatment|All patients stopped taking cognitive-enhancing drugs after enrollment, and marketed therapeutic drugs include ginkgo biloba, high-dose vitamin E, lecithin, estrogen, non-steroidal anti-inflammatory drugs, memegan, etc.
223865503|NCT07059611|BIOLOGICAL|RP2|Upper endoscopy with RP2 intra-tumoral injection of 1 x 10(6) plaque forming units (PFU)/mL for first intra-tumoral injection, up to 10mL of 1x107 PFU/mL of RP2 for subsequent intra-tumoral injections. Injection will occur within 4 days prior of each cycle FLOT.
223865504|NCT07059611|COMBINATION_PRODUCT|5-Fluorouracil|5-Fluorouracil as part of the FLOT regimen 2,600mg/m2 intravenous infusion over 24 hours on day 1 of each 14-day cycle for 4 cycles.
223865505|NCT07059611|COMBINATION_PRODUCT|Leucovorin|Leucovorin as part of the FLOT regimen 200mg/m2 intravenous infusion on day 1 of a 14-day cycle for 4 cycles.
223865506|NCT07059611|COMBINATION_PRODUCT|Oxaliplatin|Oxaliplatin as part of the FLOT regimen 85mg/m2 intravenous infusion on day 1 of a 14-day cycle for 4 cycles.
223865507|NCT07059611|COMBINATION_PRODUCT|Docetaxel|Docetaxel as part of the FLOT regimen 50mg/m2 intravenous infusion on day 1 of a 14-day cycle for 4 cycles.
223865508|NCT07059611|DRUG|Pegfilgrastim|Pegfilgrastim or Filgrastim is required on the study and should be administered per the package insert of the commercially obtained drug following each cycle of FLOT for 4 cycles.
223865509|NCT07059611|DRUG|Filgrastim|Filgrastim or Pegfilgrastim is required on the study and should be administered per the package insert of the commercially obtained drug following each cycle of FLOT for 4 cycles.
223865510|NCT07059611|PROCEDURE|Surgical Resection of Primary Tumor|Following 4 cycles of preoperative FLOT with RP2 injections, surgical resection of esophageal, GEJ, or gastric primary tumor per standard of care practice.
223865511|NCT07060274|PROCEDURE|Doppler Ultrasound|Doppler ultrasound of temporal arteries at D0, D3 and D7 (+ D15 if halo detected at D7) after initiation of corticosteroid therapy.
223865512|NCT07060534|BEHAVIORAL|Building Healthy Eating and Self-Esteem Together for University Students|Building Healthy Eating and Self-Esteem Together for University Students (BEST-U) is an mHealth program that includes modules based on second- and third-wave behavior therapy deployed through a smart phone app paired with 20-30-minute coaching sessions. BEST-U incorporates a range of evidence-based skills, and the electronic format allows coaches immediate and easy access to participant reports. BEST-U provides a comprehensive all-in-one assessment and intervention package, is easy-to-implement, brief, and has been tested across genders and in diverse ages and ethnic groups. BEST-U, therefore, has the potential to deliver effective, time-limited, interventions applicable to all university students in routine student healthcare settings.
223865513|NCT07060534|BEHAVIORAL|Present-Centered Therapy|"Present-Centered Therapy (PCT) is a brief intervention that focuses on building adaptive responses to current life stressors that are directly or indirectly related to psychopathology. PCT focuses on resolving interpersonal disconnection through the development of a positive therapeutic relationship, encouraging connection with others, and addressing interpersonal concerns. PCT was originally developed as a placebo intervention for post-traumatic stress disorder but is significantly more efficacious than wait-list in reducing psychiatric symptoms."
223865514|NCT07061561|DEVICE|Peak Expiratory Flow Measurement Using Peak Flow Meter and Lorio Device|This intervention involves the use of two respiratory measurement devices to assess cough strength in tracheotomized patients: the traditional Peak Flow meter, which measures peak expiratory flow (PEF), and the Lorio device, a novel tool designed for respiratory rehabilitation with customizable training exercises. Measurements are taken at multiple time points before and after decannulation to compare accuracy, reproducibility, and patient usability.
223865515|NCT07060664|PROCEDURE|open reduction internal fixation|treatment with open reduction and plates/screws
223865516|NCT07060664|PROCEDURE|intramedullary nail|open reduction and intramedullary nail
223865517|NCT07060664|PROCEDURE|reverse total shoulder arthroplasty|reverse total shoulder arthroplasty
223865518|NCT07061184|DRUG|FLCWK|FLCWK and matching placebo to be taken in a randomised order for 9 months
223865519|NCT07061184|DRUG|Placebo|FLCWK and matching placebo to be taken in a randomised order for 9 months
223865520|NCT07061158|BEHAVIORAL|Structured Yoga Course Intervention|Participants in this arm received a structured yoga course intervention for a period of 4 months. Sessions were held twice weekly, with each lasting 60 minutes. The curriculum was specifically designed to be gentle, slow-paced, and low-impact, making it suitable for older adults while emphasizing body awareness, mind-body integration, and psychological regulation. The course content included: breathing exercises (e.g., basic abdominal breathing combined with simple movements), asana (posture) practice (e.g., seated chair exercises, standing poses, prone poses, supine poses, and side-lying poses, emphasizing muscle activation, joint flexibility, body balance training, and coordination of breath with movement), and meditation and relaxation (e.g., supine rest, moon breath training, and OM chanting). All classes were instructed by experienced yoga teachers certified by the Yoga Alliance.
223865521|NCT04080427|DRUG|Placebo capsule|Placebo is administered just prior to weekly exposure sessions by the oral route and contains only dextrose in opaque capsules.
223865522|NCT04080427|DRUG|Dronabinol 7.5 milligram oral capsule|Dronabinol (7.5mg) is administered just prior to weekly exposure sessions by the oral route and is placed in an opaque capsule with dextrose filler.
223865523|NCT07060183|PROCEDURE|Ross procedure|aortic valve replacement
223865524|NCT07061418|OTHER|Dental Implant|Dental implants were placed to volunteers in need of implantation in mandible, maxilla or both
223865525|NCT07060937|OTHER|Physiotherapy Protocol|Each participant consenting to the study will be given a physiotherapy session on post-op day 1 and day 2 by a physiotherapist. The session will include bed mobility exercises including active ROM exercises of all extremities, breathing exercises, nebulization and chest physical therapy, incentive spirometer. Progressing to supported sitting at the edge of bed, sitting on a chair under supervision, supported walk inside the room , sitting independently in chair and lastly before discharge climbing 2 flights of stair.
223865526|NCT07059741|OTHER|integrated low-dose RT with reduced SEAM/TB conditioning before ASCT sequential CAR-T|"1. RT regimen:~   localized low dose RT: 1-1.5Gy/fraction\*5fractions~2. Reduced dose SEAM regimen (CNS uninvolved):~   * Simustine 250mg/m2 d-6 orally~  * Cytarabine 200mg/m2 q12h d-5\~d-4 intravenous infusion~  * Etoposide 100mg/m2 q12h d-5\~d-4 intravenous infusion~  * Melphalan 140mg/m2 q12h d-3 intravenous infusion~3. TB regimen (CNS involvement):~   * Thiotepa 250mg/m2 qd, d-8\~d-6 intravenous infusion~  * Busulfan 0.8mg/kg q6h d-5\~d-3 intravenous infusion"
223865527|NCT07059741|OTHER|integrated high-dose RT with reduced SEAM/TB conditioning before ASCT sequential CAR-T|"1. RT regimen:~   localized high dose RT: 3-6Gy/fraction\*5fractions~2. Reduced dose SEAM regimen (CNS uninvolved):~   * Simustine 250mg/m2 d-6 orally~  * Cytarabine 200mg/m2 q12h d-5\~d-4 intravenous infusion~  * Etoposide 100mg/m2 q12h d-5\~d-4 intravenous infusion~  * Melphalan 140mg/m2 q12h d-3 intravenous infusion~3. TB regimen (CNS involvement):~   * Thiotepa 250mg/m2 qd, d-8\~d-6 intravenous infusion~  * Busulfan 0.8mg/kg q6h d-5\~d-3 intravenous infusion"
223865528|NCT05242744|DRUG|[18F]FluorThanatrace|Investigational radiopharmaceutical used with Positron Emission Tomography (PET/CT) imaging that may provide a non-invasive measurement of PARP-1 expression
223865529|NCT04580485|DRUG|INCB106385|INCB106385 will be administered orally QD
223865530|NCT04580485|DRUG|INCMGA00012|INCMGA0012 will be administered IV once every 4 weeks (Q4W)
223865531|NCT06835400|DRUG|Paclitaxel Capsule|Paclitaxel Capsule
223865532|NCT06835400|DRUG|IV Paclitaxel|IV Paclitaxel
223865533|NCT06835400|DRUG|Encequidar tablet|Encequidar tablet
223865534|NCT07056335|BEHAVIORAL|Self-monitoring|Self-monitoring as a behavior change technique to support pain self-care behaviors
223865535|NCT07056335|BEHAVIORAL|Physical activity and percussive massage therapy education|Participants will receive education on why physical activity and massage are important for pain self-care. They will also receive daily physical activity and massage goals.
223865536|NCT07056335|DEVICE|Percussive massage therapy|Participants will receive a massage gun to support daily pain self-care.
223865537|NCT07061535|DRUG|Tafolecimab|Patients will receive Tafolecimab 300 mg every 3 weeks.
223865538|NCT07061535|DRUG|Sintilimab (approved)|Patients will receive Sintilimab 200 mg every 3 weeks.
223865539|NCT07061535|DRUG|Etoposide|Patients will recieve Etoposide (100 mg/m2) intravenously on days 1, 2, and 3 of each 3-week cycle.
223865540|NCT07061535|DRUG|Carboplatin / Cisplatin|Patients will receive carboplatin (AUC 5 mg/mL/min) or cisplatin (75 mg/m2) intravenously on day 1 of each 3-week cycle for up to 4 to 6 cycles.
223865541|NCT07061730|BEHAVIORAL|Traditional Therapy|The child would receive standard speech therapy, meeting with the SLP once a week for therapy sessions for 8 weeks. These sessions will focus on articulation practice, where your child will work on speech sounds with direct feedback from the SLP.
224267829|NCT01230229|PROCEDURE|Stenting|The stent should be deployed percutaneously, appropriate stent(s) size selected based upon the angiogram. The diameter must be 1-2 mm larger than the vessel. Length is chosen to cover lesion with one stent if possible. The choice of brand will be made through random selection among those offering possibility to cover the lesion with one stent. If more than one stent is required, overlap between 0.5 and 1 cm is acceptable. Postdilatation must be performed with a PTA balloon shorter than the length and less than the diameter of the stent. An angiogram should be made to compare the pre- and post-implant minimum lumen diameters. The non-diseased artery diameters shall be measured and residual % stenosis calculated.
224267830|NCT01230229|OTHER|Best medical treatment|Patients randomised to conservative treatment will receive appropriate medication with target levels of cholesterol 4,5 mmol/l, LDL 2,5 mmol/l and blood pressure level of 130/80 mmHg in addition to instruction how to engage in an exercise program. Each patient will receive a 'step-meter' which has to be carried during all activity during the first month and then during one week before each follow up visit. Step-meter read-outs will be recorded during each follow up visit. Smokers will be actively advised to quit smoking.
224267831|NCT04865120|OTHER|cream cyclic merocyanine|cream long-UVA absorber
223865542|NCT07061730|BEHAVIORAL|Hybrid therapy|The child would receive standard speech therapy, meeting with the SLP once a week for therapy sessions for 8 weeks. These sessions will focus on articulation practice, where your child will work on speech sounds with direct feedback from the SLP. In addition to these weekly sessions, the child will practice using the AI-based speech therapy tool, Jessica, at home between sessions for 60 minutes per week. The tool will provide real-time feedback on the child's articulation and track their progress. The child will be asked to practice specific speech exercises, such as producing target sounds (e.g., /r/, /s/) in words, phrases, or sentences.
223865543|NCT07061873|PROCEDURE|Aerobic excersise|20 aerobic exercise sessions, with a duration of 45 to 60 minutes, for 10 weeks.
223865544|NCT07061873|PROCEDURE|Muscle strength limbs, inspiratory muscle strength|20 sessions of exercise Muscle strength limbs, inspiratory muscle strength, with a duration of 60 minutes, for 10 weeks
224267832|NCT04865120|OTHER|placebo|placebo
224267833|NCT05692791|DIAGNOSTIC_TEST|Two-point Discrimination Test|Two-point discrimination (2PD) is the ability to discern that two nearby objects touching the skin are truly two distinct points, not one. It is often tested with two sharp points during a neurological examination and is assumed to reflect how finely innervated an area of skin is.
224267834|NCT05692791|DIAGNOSTIC_TEST|Semmes-Weinstein monofilament test|Semmes-Weinstein monofilament test is used to assess light touch sensations.
224267835|NCT03567122|OTHER|Internal Focus of Attention|Information already included in arm/group descriptions.
224267836|NCT03567122|OTHER|External Focus of Attention|Information already included in arm/group descriptions.
224267837|NCT03567122|OTHER|Control|Information already included in arm/group descriptions.
224267838|NCT03720548|DRUG|LY3372993|Administered IV.
224267839|NCT03720548|DRUG|Placebo|Administered IV.
224267840|NCT01663896|DEVICE|OCT stent guidance|Participants undergoing pre- and post-PCI fractional flow reserve (FFR) and OCT
224267841|NCT01451541|DRUG|Ciclesonide nasal aerosol 37 mcg|ciclesonide nasal aerosol 37mcg - the dose is administered as 1 actuation per nostril to give a total dose of 37
224267842|NCT01451541|DRUG|ciclesonide nasal aerosol 74 mcg|ciclesonide nasal aerosol 74 mcg - the dose is administered as 1 actuation per nostril to give a total dose of 74 mcg
224267843|NCT01451541|DRUG|Placebo|Placebo - one dose per nostril
224267844|NCT04003363|OTHER|Patient Registry|Participants who have volunteered to participate will complete various questionnaires relating to their condition.
224267845|NCT03058107|DIETARY_SUPPLEMENT|Nutrition Therapy|At the time of diagnosis, patients will immediately be screened and started with Nutrition Therapy if assigned to group A. This regimen will stay in place for 6 weeks to 3 months, after which a switch will be made towards normal dietary counselling. Nutrition Therapy can be given orally, parenterally or via tube feeding (enteral nutrition), depending on the patient's status and aims at matching Caloric Intake with Resting Energy Expenditure. Moreover, a switch between these modalities is possible. Afterwards, standard dietary counselling will be given during the remainder of the study. Follow-up will last one year. If 6 months after the last enrolment the study shows a large difference with the control group, the study will be stopped for ethical reasons.
224267846|NCT03058107|DIETARY_SUPPLEMENT|Control Therapy|At the time of diagnosis, patients will immediately be screened and started with standard dietary counselling for 1 year if assigned to group B. Dietary intervention can be orally, parenterally or via tube feeding (enteral nutrition), depending on the patient's status. Moreover, a switch between these modalities is possible. Follow-up will last 1 year. If 6 months after the last enrolment the study shows a large difference with the control group, the study will be stopped for ethical reasons.
224267847|NCT03366428|DRUG|DS-8201a|DS-8201a is supplied as a lyophilized powder which is reconstituted for infusion
224267848|NCT02638428|PROCEDURE|CancerSCAN™|Targeted deep sequencing
224267849|NCT02638428|DRUG|Ifosfamide|
224267850|NCT02638428|DRUG|Carboplatin|
224267851|NCT02638428|DRUG|Etoposide|
224267852|NCT02638428|DRUG|Fludarabine|
224267853|NCT02638428|DRUG|Cytarabine|
224267854|NCT02638428|DRUG|Pazopanib|
224267855|NCT02638428|DRUG|Sorafenib|
224267856|NCT02638428|DRUG|Axitinib|
224267857|NCT02638428|DRUG|Crizotinib|
224267858|NCT02638428|DRUG|Dasatinib|
224267859|NCT02638428|DRUG|Erlotinib|
224267860|NCT02638428|DRUG|Everolimus|
224267861|NCT02638428|DRUG|Imatinib|
224267862|NCT02638428|DRUG|Ruxolitinib|
224267863|NCT02638428|DRUG|Vandetanib|
224267864|NCT02638428|DRUG|Vemurafenib|
224267865|NCT02638428|DRUG|Trastuzumab|
224267866|NCT02579005|BIOLOGICAL|Patients with a living donor|The day of allogeneic cell infusion will be referred to as Day 0 and the n-th day before that, as Day -n. The dose of external radiation will be 15 Gy divided in 3 fractions, from Day -3. Cyclophosphamide, 250 mg/m2 will be given on Day -2. Donors will receive 5 daily doses of GCSF, 10 µg/kg, by subcutaneous injection from Day -4. PBMC will be collected through apheresis on Day 0. A dose of 5 x 10exp7 CD3 cells/kg will be administered. The infused volume will be adjusted to contain this T cell dose.
224267867|NCT02579005|BIOLOGICAL|Patients with a UCB donor|The day of allogeneic cell infusion will be referred to as Day 0 and the n-th day before that, as Day -n. The UCB unit should have at least 4 of 6 HLA compatibility and at least 3 x 10exp6 TNC per kg patient weight. The dose of external radiation will be 15 Gy, divided in 3 fractions, starting on Day -3. Cyclophosphamide, 250 mg/m2 intravenously, will be given on Day -2.
224267868|NCT05818345|BEHAVIORAL|Pricing intervention|Participants will be provided with a menu with manipulated prices for products with lower kilocalories
224267869|NCT02684786|DRUG|reserpine|Patients with qualifying hemodynamics from prior right heart catheterization will receive open label reserpine, 0.05 mg by mouth daily for two weeks, then 0.10 mg by mouth daily for two weeks, and then have repeat non-invasive assessments of status
223865545|NCT07060482|DIAGNOSTIC_TEST|Panel of biomarkers including Gastrin 17, pepsinogen 1 and 2, and anti-helicobacter pylori antibodies.|This study will be assessing the diagnostic accuracy of this panel of biomarkers for diagnosing gastric atrophy in the Irish population for the first time. This reflects the assessment of these biomarkers in diagnosing gastric atrophy in a low-risk Western population.
224076483|NCT05172739|DRUG|Opioid-free Anesthesia-Analgesia Strategy|"A perioperative Opioid-Based multimodal Anesthesia- Analgesia strategy will be implemented that incorporates the following pharmacological agents:~Premedication: Pregabalin, Midazolam, Anesthesia induction \& maintenance: Midazolam, Dexmedetomidine, Lidocaine, Propofol, Ketamine, Hyoscine, Cisatracurium or alternatively Rocuronium, Magnesium sulphate, Dexamethasone, Desflurane, Paracetamol, Dexketoprofen trometamol, Ondansetron or Droperidol, Ropivacaine, Surgical ward: Ketamine, Lidocaine, Clonidine, Droperidol and Midazolam, Pregabalin, Paracetamol, Dexketoprofen trometamol Rescue therapy only: Tramadol"
224076484|NCT02555423|DRUG|Local anaesthetic - chirocaine|
223865546|NCT07061782|PROCEDURE|Group A|"Treatment protocol given to the both groups will be carried out for 7 sessions for 2 weeks on alternative days.~It will consist of a 10 minute hot pack.~Neuromuscular reeducation for following muscles. Pectoralis major Upper trapezius Levator scapulae~Strengthening exercises of:~Rhomboids Lower \& middle trapezius Deep flexors Neuromuscular reeducation It will break adhesion result in loosen the scar tissue will increase the temperature and cause in increase of blood flow . Muscles contract when myosin pulls actin filaments together using energy from ATP shortening the muscle fiber and causing contraction. They relax when calcium is removed, allowing the filaments to slide apart muscle will return to its resting state. The continuously muscle contraction and relaxation help to loosen up and become more flexible .~Strengthening exercises"
224076485|NCT00429858|DRUG|S-1|S-1 is given as follows: 25 mg/m2 bid on days 1-7 and 15-21 of the cycle (28 days)
224076486|NCT00429858|DRUG|gemcitabine hydrochloride|Patients will receive gemcitabine at a dose of 1,000 mg/m2 i.v. at a fixed-dose rate (FDR) infusion of 10 mg/m2/minute (100 minutes), once a week for 3 consecutive weeks, followed by one week rest. Each 4 week period is referred to as a treatment cycle
224076487|NCT00161629|DRUG|rhBMP-2/CPM|
223865547|NCT07061782|PROCEDURE|Group B|"Treatment protocol was given to both groups for 7 session sessions for 2 weeks on alternative days.~It was comprises of HOT PACK for 10 minutes . Post facilitation stretch for following muscles. Pectoralis major Upper trapezius Levator scapulae~Strengthening exercises of:~Rhomboids Lower \& middle trapezius Deep flexors~Post facilitation stretch :~Post Facilitation Stretch is an isometric Contraction in which he participants were instructed to contract the muscles to the maximum voluntary capacity that involves first putting the target muscle through a high-intensity isometric contraction (roughly 75-100% of maximal effort) for 5-10 seconds, and then quickly and continuously passively stretching the same muscle for at least 10 seconds.~Strengthening exercises"
223865548|NCT07059806|BEHAVIORAL|T1CARE|The intervention includes navigation by a Community Health Navigator (CHN), who will assess and help address patients' SDOH-related needs, coordinate care, and provide social support.
223865549|NCT06655675|DEVICE|Ultrasound|Ultrasound scan of the umbilical artery
223865550|NCT06816979|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223865551|NCT06816979|PROCEDURE|Lumbar Puncture|Undergo LP
223865552|NCT06816979|DEVICE|Magnetic Resonance Imaging|Undergo MRI
223865553|NCT06835569|DRUG|ALTA3263|Oral ALTA3263 tablets will be administered at a protocol-defined dose
223865554|NCT02479698|BIOLOGICAL|Allogeneic BK-specific Cytotoxic T-lymphocytes|Given IV
223865555|NCT02479698|OTHER|Laboratory Biomarker Analysis|Correlative studies
223865556|NCT06773026|DRUG|Sodium phenylbutyrate|Open-label design with doses of sodium phenylbutyrate at 4.0 g/m2/day
223865557|NCT02677974|DEVICE|On-X Aortic Heart Valve replacement|Aortic valve replacement with low dose warfarin
224076488|NCT01184482|DRUG|cetuximab and lapatinib|"Cetuximab: 400 mg/m2 on Day 1 then 250 mg/m2 weekly~Lapatinib: Start once daily on Day 1. Dose escalating cohorts:~1. 750 mg (3 tabs)~2. 1000 mg (4 tabs)~3. 1250 mg (5 tabs)"
224076489|NCT03005054|BIOLOGICAL|StrataGraft Skin Tissue|StrataGraft® skin tissue is provided as a suturable rectangular piece of stratified epithelial tissue composed of a living dermal matrix containing dermal fibroblasts overlaid with human epidermal keratinocytes (NIKS®).
224076490|NCT03005054|PROCEDURE|Autograft|The current standard of care procedure for the treatment of severe complex skin defects. The procedure involves the removal of a sheet of healthy skin from an uninjured site on the patient and using it to cover the original wound.
224267870|NCT02684786|PROCEDURE|stellate ganglion block|Patients with suspected group 2 pulmonary hypertension by clinical and non-invasive assessments and are scheduled to undergo clinically indicated right heart catheterization will have pulmonary artery pressures measured. If qualifying severity of group 2 pulmonary hypertension is present, after clinically indicated assessment of inhaled nitric oxide, their baseline hemodynamics will be allowed to re-equilibrate over 10 minutes, and then ultrasound guided left stellate ganglion block with lidocaine will be performed, and hemodynamics reassessed 10 minutes afterward
224267871|NCT02684786|DRUG|lidocaine|Patients with suspected group 2 pulmonary hypertension by clinical and non-invasive assessments and are scheduled to undergo clinically indicated right heart catheterization will have pulmonary artery pressures measured. If qualifying severity of group 2 pulmonary hypertension is present, after clinically indicated assessment of inhaled nitric oxide, their baseline hemodynamics will be allowed to re-equilibrate over 10 minutes, and then ultrasound guided left stellate ganglion block with lidocaine will be performed, and hemodynamics reassessed 10 minutes afterward
224267872|NCT01980173|PROCEDURE|Routine care|Following diagnosis with post-partum hemorrhage, an initial 30 minute phase corresponding to current recommendations, an injection of sulprostone, a demonstrated inefficacy of sulprostone 20 minutes after the injection and finally randomization, patients in this arm of the study will continue to have routine care.
224267873|NCT01980173|DEVICE|Bakri balloon|Following diagnosis with post-partum hemorrhage, an initial 30 minute phase corresponding to current recommendations, an injection of sulprostone, a demonstrated inefficacy of sulprostone 20 minutes after the injection and finally randomization, patients in this arm will be treated with the immediate placement of a Bakri balloon, followed by routine care if necessary.
224267874|NCT00804973|DRUG|LY2590443|200 milligrams (mg) as four 50-mg capsules, oral, once
224267875|NCT00804973|DRUG|Placebo injection|saline solution, injection, once
224267876|NCT00804973|DRUG|Sumatriptan|6 milligrams (mg) injection (0.5 milliliter \[mL\] of 12 mg/mL solution), once
224267877|NCT00804973|DRUG|Placebo capsule|4 capsules, once
224267878|NCT00185120|DRUG|Olmesartan medoxomil|
224267879|NCT00185120|DRUG|Hydroclorothiazide|
224267880|NCT00185120|DRUG|Benazepril|
224267881|NCT00185120|DRUG|Amlodipine|
224267882|NCT01916694|DEVICE|Blue tooth enabled glucose meter with smart phone application|
224267883|NCT01916694|BEHAVIORAL|Self home blood glucose monitoring|Fingerprick testing of blood glucose levels before and 2 hours after meals
224267884|NCT00061776|DRUG|Capsaicin Dermal Patch|
224267885|NCT00844974|OTHER|Prevalence|Mood and cognitive assessments
224267886|NCT06316180|DRUG|drospirenone/estetrol 3mg/14.2mg|Hysteroscopic polipectomy after starting 14-day treatment with oral drospirenone/estetrol 3mg/14.2mg at any time of the menstrual cycle.
224267887|NCT01820091|DRUG|Folotyn|A cycle of Folotyn treatment is 28 days, with treatment on Days 1 and 15 in each cycle.
224267888|NCT01820091|DRUG|Fusilev|Fusilev will be administered either four times a day (QID) (6 hours apart, ±10 minutes), twice a day (BID) (8 hours apart, ±10 minutes) or once a day (QD) by IV push (3-5 minutes) at a dose of 5 mg/m2 according to the cohort to which patients are assigned.
224267889|NCT00990574|DEVICE|Wiley Spinal Catheter|The WSCG (wiley spinal catheter group) will have a Wiley spinal catheter placed, but it will not be dosed until the patient is in the supine position with left uterine displacement. Participants will receive the medication (12 mg of 0.75% hyperbaric bupivacaine, 10 mcg of fentanyl, and 100 mcg of morphine) in sequential doses.
224267890|NCT00990574|DEVICE|Spinal Anesthesia Group (SAG)|"The SAG (spinal anesthesia group) will have their drugs (12 mg of 0.75% hyperbaric bupivacaine, 10 mcg of fentanyl, and 100 mcg of morphine) dosed intrathecally as a single shot while still in the sitting position."
224267891|NCT00903292|DRUG|erlotinib (Tarceva)|chemotherapy with erlotinib
224267892|NCT00903292|DRUG|pemetrexed (Alimta)|Chemotherapy with pemetrexed
224267893|NCT05232773|PROCEDURE|Assessment|Evaluation of clinical and kinematic parameters
224267894|NCT04266548|PROCEDURE|Superselective Intra-arterial Hepatic Injection of Indocyanine Green (ICG) for Fluorescence Image-guided Segmental Positive Staining|The patients with single HCC which is planned to received laparoscopic hepatectomy were involved. Procedures were performed in conventional angiography room. The celiac trunk was catheterized and a microcatheter was advanced into segmental hepatic artery branches which supplied the HCC. The 5cc 0.125 mg/cc ICG was injected from super-selective hepatic artery in operative room. A Near-Infrared laparoscope was used to detect the fluorescent signal to assess the correspondence between arterial-based fluorescence demarcation and ultrasound-based surgical demarcation.
224267895|NCT04898504|DRUG|Floxuridine|A laparotomy will be performed and a catheter placed in the hepatic artery Connected to a subcutaneous pump. This pump will be percutaneously filled with Floxuridine 6 times in 2 weeks cycles, alternating with heparin-solution.
224267896|NCT04898504|PROCEDURE|Liver Transplantation|Patients randomized to this arm will be given 2nd line chemotherapy (regimen given at the discression of the treating oncologist) followed by liver-Tx
224267897|NCT05002140|DRUG|XRD-0394|Single ascending dose
224267898|NCT05002140|RADIATION|Palliative radiotherapy|4 Gy × 5 daily fractions
224267899|NCT04914546|DRUG|LY3819469|Administered SC.
224267900|NCT04914546|DRUG|Placebo|Administered SC.
224267901|NCT04869995|OTHER|Interview|An individual semi-structured interview per surgeon, according to an interview guide.
224267902|NCT01046084|DRUG|Lansoprazole|30 mg Delayed-Release Capsule
224267903|NCT01046084|DRUG|Prevacid®|30 mg Delayed-Release Capsule
224267904|NCT01728987|DRUG|cholecalciferol|as in arm description
224267905|NCT01728987|DRUG|placebo|capsule looking identical to the cholecalciferol capsule
224267906|NCT00459407|DIETARY_SUPPLEMENT|defined green tea catechin extract|Given orally
224267907|NCT00459407|DRUG|placebo|Given orally
224267908|NCT00459407|OTHER|immunohistochemistry staining method|Correlative studies
224267909|NCT00459407|OTHER|immunoenzyme technique|Correlative studies
224267910|NCT00459407|OTHER|laboratory biomarker analysis|Correlative studies
224267911|NCT00459407|PROCEDURE|biopsy|Undergo biopsy
224267912|NCT00459407|OTHER|mass spectrometry|Correlative studies
224267913|NCT00459407|OTHER|high performance liquid chromatography|Correlative studies
224267914|NCT01942278|OTHER|BHOMA|A complex health systems, clinical care, and community intervention to improve outcomes
224267915|NCT03618615|BIOLOGICAL|artericitc surgery|biological sample (leg) from leg amputation surgery used for research
224267916|NCT05698407|DRUG|Dexmedetomidine|loading dose of 0.45 microgram/ml dexmedetomidine plus 0.09% ropivacaine, maintenance dose of 0.36 microgram/ml dexmedetomidine plus 0.07% ropivacaine.
224267917|NCT05698407|DRUG|Sufentanil|loading dose of 0.45 microgram/ml sufentanil plus 0.09% ropivacaine, maintenance dose of 0.36 microgram/ml sufentanil plus 0.07% ropivacaine.
224267918|NCT01336088|DRUG|ADX48621|oral administration
224267919|NCT01336088|DRUG|Placebo|oral administration
224267920|NCT02342509|DRUG|Desflurane|Group A: Desflurane 5.0-6.0 Vol% (1.0 MAC) in Oxygen (FiO2 0.8-0.95)
224267921|NCT02342509|DRUG|Sevoflurane|Group B: Sevoflurane 1.4-2.1 Vol% (1.0 MAC) in Oxygen (FiO2 0.8-0.95)
224267922|NCT02342509|DRUG|Isoflurane|Group C: Isoflurane 0.9-1.2 Vol% (1.0 MAC) in Oxygen (FiO2 0.8-0.95)
224267923|NCT02439515|DEVICE|Cycling|Voluntary cycling augmented by electrical stimulation and biofeedback
224267924|NCT02439515|DEVICE|Balance|Balance control exercises with visual biofeedback
224267925|NCT02439515|OTHER|Standard physical therapy|It consists of stretching, muscular conditioning, exercises for trunk control, standing, and walking training, and upper limb rehabilitation.
224267926|NCT06180915|BEHAVIORAL|The peer trainer will be subjected to assertiveness training based on dating violence and internalized misogyny by the researcher for 2 hours a day for 5 days.|The peer trainer will be subjected to assertiveness training based on dating violence and internalized misogyny by the researcher for 2 hours a day for 5 days. The peer educator will create a Whatsapp group with the experimental group participants and a name for the group will be found by mutual decision. The peer educator will schedule a time and date with the group. Each session will last approximately 60 minutes and the total training duration will be planned to be 3 weeks. One week and one month after the training is completed, the participants will fill out the scales again.
224267927|NCT05472415|OTHER|cognicise|"a combination of cognition and exercise training"
224267928|NCT05472415|DEVICE|arch support insoles|The FootDisc insole is designed with curEVA for shock absorption and motion reduction, poron for secondary heel and metatarsal protection, and dynamic arch support for returning energy for propulsion
224267929|NCT00379353|DRUG|Thalidomide|100 mg capsules orally, once a day for 14 days.
224267930|NCT00379353|DRUG|Placebo|Two placebo capsules orally, once a day for 14 days.
224267931|NCT03614728|DRUG|GSK3326595|GSK3326595 will be administered.
224267932|NCT03614728|DRUG|5-Azacitidine|5-Azacitidine will be administered.
224267933|NCT02928627|OTHER|Analysis of microRNA expression|sample analysis
224267934|NCT01958476|DRUG|Neonatal Morphine Solution|"Infants randomized to this arm will receive neonatal morphine solution (0.2mg/mL) for first line therapy. Infants will be scored using the standardized Finnegan scoring system and will be initiated on treatment if they have 2 consecutive scores greater than or equal to 8 or 1 score greater than 12. Dosing will be weight and symptom based. A double dummy design will be used - each infant will be ordered for both a methadone/placebo study drug at 0.4 mg/mL and a morphine/placebo study drug at 0.2 mg/mL. Starting doses will range from 0.3mg/kg/day to 0.9mg/kg/day divided every 4 hours depending on the severity of the Finnegan scores. Doses will be increased to a maximum of 0.9mg/kg/day for continued scores generally \>8 caused primarily by worsening NAS. Infants will be weaned by 10% of the maximum dose once every 24 - 48 hours and the medication will be discontinued once at 25% of the maximum dose."
224267935|NCT01958476|DRUG|Methadone|"Infants randomized to this group will receive methadone oral solution (0.4mg/mL) for first line therapy. Infants will be scored using the standardized Finnegan scoring system and will be initiated on treatment if they have 2 consecutive scores greater than or equal to 8 or 1 score greater than or equal to 12. Dosing will be weight and symptom based. Starting doses will range from 0.3mg/kg/day to 0.9mg/kg/day divided every 8 hours depending on the severity of the Finnegan scores. To maintain blinding of the two study arms, a double dummy design will be used - each infant will receive both methadone/placebo study drug at 0.4 mg/mL and a morphine/placebo study drug at 0.2 mg/mL. Doses will be increased to a maximum of 0.9mg/kg/day for continued scores generally \>8 caused primarily by worsening NAS as needed. Infants will be weaned by 10% of the maximum dose once every 24-48 hours and the medication will be discontinued once at 25% of the maximum dose."
224267936|NCT01958476|DRUG|Phenobarbital|"A second line medication will be added once the infant reaches maximum doses of the study drug (morphine or methadone) for continued scores generally \>8. Infants will be loaded with 20mg/kg of phenobarbital with the option to re-load with 10mg/kg q8-12 hours for 2 more doses if needed for continued high scores. Maintenance therapy of 5mg/kg/day will be initiated 12 - 24 hours after the last loading dose. Phenobarbital trough levels will be monitored with goal levels of 20 - 30 mcg/mL.~Phenobarbital will be weaned only after the infant has been weaned off of the study drug. Weaning will begin 48 hours after the study drug has been stopped by 20% of the maximum total daily dose every 3 days for scores \<8. An infant may be discharged home 48 - 72 hours after the first wean. The remaining wean will be outlined in the discharge prescription, and followed up on by study staff with the goal of the phenobarbital discontinuation within a 2 week period."
224267937|NCT01824576|DEVICE|ITPR|Single use noninvasive device that is connected to a vacuum source and a means to deliver a positive pressure breath. The device generates negative pressure during the expiratory phase, thus creating subatmospheric intrathoracic pressure between the periods of positive pressure ventilations.
224267938|NCT00085501|DRUG|cetuximab|"Arm 1: 400 mg/m2 (Initial dose), 2 hour IV infusion on Day 1, Week 1 only. 250 mg/m2 (Subsequent doses), 1 hour IV infusion, on Day 1 weekly starting at Week 2.~Arm 2: 400 mg/m2 (Initial dose), 2 hour IV infusion on Week 13 ONLY 250 mg/m2 (Subsequent doses), 1 hour IV infusion, weekly starting at Week 14."
224267939|NCT00085501|DRUG|carboplatin|"Arm 1: AUC=6 30 minute IV infusion immediately following paclitaxel on Day 1 q 21 days x 4 starting at Week 2~Arm 2: AUC=6 30 minute IV infusion immediately following paclitaxel on Day 1 q 21 days x 4 starting at Week 1"
224267940|NCT00085501|DRUG|paclitaxel|"Arm 1: 225 mg/m2 3 hour IV infusion 1 hour following cetuximab on Day 1, q 21 days x 4 Starting at Week 4.~Arm 2: 225 mg/m2 3 hour IV infusion 1 hour following cetuximab on Day 1, q 21 days x 4 Starting at Week 1."
224267941|NCT00028873|DRUG|docetaxel|
224267942|NCT00028873|DRUG|laniquidar|
224267943|NCT00028873|DRUG|paclitaxel|
224267944|NCT03647722|OTHER|Assessment of leukocyte function.|The function and phenotype of regulatory B-cells, regulatory T-cells and alternatively-activated monocytes will be assessed directly ex vivo from PBMC.
224267945|NCT02152618|OTHER|Parent Management Training - Oregon Model (PMTO)|Evidence-based, behavioral parent management training model, Parent Management Training - Oregon Model (PMTO) tailored to address permanency barriers of parents of children with SED.
224267946|NCT00002160|DRUG|Ziconotide|
224267947|NCT02032927|DRUG|Codeine/paracetamol|"Randomization to one of the two treatments will be done through appropriate randomization list.~During the first 15 days of treatment in the event of failure of efficacy, understood as the average pain intensity higher than 4 (monitored with NRS) with the need to take more than two rescue doses of paracetamol per day, and in the absence of side effects, the patients will be instructed on how to proceed with dosage adjustments according to specific guidelines.~The patient will be evaluated at 15 days, 1 month, 2 months and three months. Your health care professional who administer the assessment scales (WOMAC, SF-12, BFI, TMT) will not know in any way which treatment the patient is taking."
224267948|NCT02032927|DRUG|Oxycodone/naloxone|"Randomization to one of the two treatments will be done through appropriate randomization list.~During the first 15 days of treatment in the event of failure of efficacy, understood as the average pain intensity higher than 4 (monitored with NRS) with the need to take more than two rescue doses of paracetamol per day, and in the absence of side effects, the patients will be instructed on how to proceed with dosage adjustments according to specific guidelines.~The patient will be evaluated at 15 days, 1 month, 2 months and three months. Your health care professional who administer the assessment scales (WOMAC, SF-12, BFI, TMT) will not know in any way which treatment the patient is taking."
224267949|NCT00614276|BEHAVIORAL|Focus Group|To evaluate a multimedia intervention program for women with cancer-related sexual dysfunction.
224267950|NCT00614276|BEHAVIORAL|TENDRILS|Tendrils: A Sexual Renewal Program for Women Surviving Cancer - a website designed to give women information about sexual problems related to cancer and its treatment, and the website suggests ways to overcome those problems.
224267951|NCT00614276|BEHAVIORAL|Questionnaires|The questionnaires ask about your background (such as age, education, relationships), your cancer diagnosis and treatment, and the quality of your life in terms of your health, your general emotions, and your sexual function. The questionnaires take about 30-45 minutes to complete.
224267952|NCT00614276|BEHAVIORAL|Sexual Counseling Sessions|Attend 3 sexual counseling sessions at M. D. Anderson.
224267953|NCT00415935|DRUG|methotrexate|
224267954|NCT05348616|OTHER|epidemiology|To review of medical records to describe diagnosis and severity of the disease.
224267955|NCT05348616|OTHER|epidemiology|To compare pre- and per-Covid-19 epidemics in terms of numbers of admissions, and proportion of severe disease.
224267956|NCT00895050|OTHER|Review of clinical records|
224267957|NCT04402892|OTHER|35 ml blood, 5 tubes LITHIUM HEPARINATE at each time (hospitalized Patients )|Patients hospitalized for CoV-2-SARS will be sampled at inclusion (Day 0), at day 21, at 3 months and at 6 months .
224267958|NCT04402892|OTHER|35 ml blood, 5 tubes LITHIUM HEPARINATE at each time (cured Patients)|Patients who have recovered from CoV-2-SARS will be sampled at inclusion (Day 0), at 3 months and at 6 months .
224267959|NCT02208973|DRUG|PBF-680|5, 10, 20, 40 and 60 mg of PBF-680
224267960|NCT02208973|DRUG|Placebo|placebo for the dose of 5, 10, 20 and 40 mg of PBF-680
224267961|NCT02901730|PROCEDURE|532nm laser group|LPI with 532nm laser.
224267962|NCT02901730|PROCEDURE|561nm laser group|LPI with 561nm laser.
224267963|NCT00734825|OTHER|Omnipaque|oral contrast for CT scan
224267964|NCT00006453|DRUG|carboplatin|
224267965|NCT00006453|DRUG|gemcitabine hydrochloride|
224267966|NCT03008616|BIOLOGICAL|AMAG-423 (digoxin immune fab)|AMAG-423 (digoxin immune fab) 3.2 mg/kg, 30 minute IV infusion, every 6 hours x 4 days
224267967|NCT03008616|OTHER|Placebo|Normal saline, 30 minute IV infusion, every 6 hours x 4 days
224267968|NCT05815394|DRUG|177Lu-labeled NY108|Patients will receive a tracer (40-60ug) dose of 177Lu(28.5-31.5mCi) labelled NY108.
224267969|NCT05412121|DEVICE|Acupressure|"The MeTime Acupressure app will be loaded onto computer tablets or smart phones by the participants. Participants will also receive an AcuWand to be used in association with the acupressure app to help participants apply the correct amount of pressure to acupoints. There are 9 acupressure points, totaling 27 minutes of stimulation per day. Participants will perform daily acupressure for a total of six weeks.~In addition all participants will complete a battery of validated questionnaires before, during and after completion of treatment intervention."
224267970|NCT05545436|DRUG|Camrelizumab + SOX (oxaliplatin + Teggio) /XELOX (oxaliplatin + capecitabine )|Camrelizumab + SOX (oxaliplatin + Teggio) /XELOX (oxaliplatin + capecitabine ) Drug: Camrelizumab 200mg Drug: oxaliplatin 130 mg/m2 Drug: Teggio 40 mg/m2 Drug: oxaliplatin 130 mg/m2 Drug: capecitabine 1000 mg/m2 Q3W for 3 cycles. Radical surgery was performed 3 weeks after the last neoadjuvant treatment.
224267971|NCT00905008|PROCEDURE|transluminal percutaneous coronary intervention|All interventions were done according to current practice guidelines. The operator was responsible for the decision to choose a specific treatment strategy. Angiographic success was defined as residual stenosis \<30% by visual analysis in the presence of TIMI 3 flow grade. The patients were prescribed aspirin plus clopidogrel 75 mg per day, after a loading dose of 300 mg or 600 mg, before or during the index coronary intervention. After procedure, all patients were advised to maintain lifelong use of aspirin. The use of clopidogrel (75 mg per day) was always adapted according to guideline recommendations. Heparin was infused throughout the procedure to maintain an activated clotting time of at least 250 sec. The administration of platelet glycoprotein IIb/IIIa receptor blocker was encouraged, unless in existing contraindications.
223865558|NCT06906029|DRUG|Catheter Sclerotherapy|Place a drainage catheter of minimum 14F in caliber and obtain an antimicrobial sample. Saline lavage will be performed by irrigating the abscess and aspirating the contents until the character of the instilled and aspirated fluid are similar. Following this step the cavity will be drained in full and a volume of approximately equal to the cavity of povidone iodine or ethanol will be instilled through the catheter with the catheter turned off to drainage. After approximately two minutes the drain will be opened to gravity and two minutes of additional time will be allotted to drain any excess povidone iodine or ethanol. The catheter will then be removed, and the site dressed with gauze and film dressing. The patient will then be followed clinically in the hospital for at least 48 hours and by phone check in for 7 days.
223865559|NCT03619226|OTHER|test patch|the test patch consists of an adhesive patch
223865560|NCT04120454|BIOLOGICAL|Pembrolizumab|Given IV
223865561|NCT04120454|BIOLOGICAL|Ramucirumab|Given IV
223865562|NCT05114980|PROCEDURE|Parathyroid Allotransplant|Patients that meet inclusion criteria and are enrolled in the trial will undergo parathyroid allotransplantation
223865563|NCT06923670|DIAGNOSTIC_TEST|NGS testing|The investigators will test in NGS the presence of mutations in the following genes: ABRAXAS1, ACD, ANKRD26, APC, ATG2B, ATM, BARD1, BMPR1A, BRCA1/2, BRIP1, CDH1, CDKN2A, CEBPA, CHECK2, CSF3R, DDX41, EPCAM, ERCC6L2, ETV6, FANCA, FANCB, FANCC, FANCD1, FANCD2, FANCE, FANCF, FANCG, FANCL, GATA2, GSKIP, MBD4, MECOM, MEN1, MLH1, MLH3, MRE11, MSH2, MSH6, MUTYH, NBN, NF1, NF2, PALB2, PIK3CA, POLD1, POLE, PMS2, PMS2CL, PTEN, PTPN11, RAD50, RAD51C, RAD51D, RET, RTEL1, RUNX1, SAMD9, SAMD9L, SBDS, SRP72, STK11, TERC, TERT, TP53, TSC1, TSC2, VHL, WAS, XRCC2
224267972|NCT00905008|DEVICE|Drug-Eluting and Bare-Metal stents|Sirolimus-eluting stents (Cypher®), Paclitaxel-eluting stents (Taxus®) Zotarolimus-eluting stents (Endeavor®) and uncoated (bare-metal) stents
224267973|NCT01873391|PROCEDURE|Diagnostic hysteroscopy|
224267974|NCT05753904|PROCEDURE|Conjoint Tendon Resection|For conjoint tendon resection in the experimental group, the conjoint tendon will be released completely via a transverse incision made at a level 2 cm distal to the coracoid process for the patients assigned the conjoint resection group. Electrocautery will be used for the resection, and the underlying muscular portion of the conjoint tendon will be preserved.
224267975|NCT00735176|PROCEDURE|Cervical arthroplasty|Anterior cervical discectomy, followed by insertion of the Discover™ Artificial Cervical Disc
224267976|NCT00735176|PROCEDURE|Anterior cervical discectomy and fusion (ACDF)|Anterior cervical discectomy and decompression, followed by insertion of a PEEK cage, which induces fusion.
224267977|NCT06416449|OTHER|kinesiotape application|"In the Star Balance Test, lines are drawn on the ground. The individual stands on their dominant foot and reaches out with the tip of the contralateral foot to touch these lines, and points are recorded. For the T-Agility Test, a course is set up, and the participant is asked to complete it as quickly as possible, with time being recorded.~As implied by its name, cones are placed in a T-shape for the T-Agility Test, and the individual is required to touch the cones and return to the starting point as quickly as possible. In the Vertical Jump Test, the individual is asked to jump as high as possible against a wall-mounted ruler, and the highest point reached is recorded. The Kinesio tape used in the study is designed to reflect the characteristics of the skin and allow for approximately 55-60% elongation of its original length. These tests are first conducted without Kinesio tape and then repeated with Kinesio tape applied. Rest intervals are provided between tests."
224267978|NCT06462495|DRUG|[18F]F-PSMA-N5|Each subject receive a single intravenous injection of \[18F\]F-PSMA-N5, and undergo PET/CT imaging within the specificed time.
224267979|NCT06462495|DRUG|[18F]F-PSMA-1007|Each subject receive a single intravenous injection of \[18F\]F-PSMA-1007, and undergo PET/CT imaging within the specificed time.
224267980|NCT05756218|OTHER|nursing diagnoses - taboo game|Playing 7 weeks nursing diagnoses taboo cards
224267981|NCT01588743|DRUG|insulin aspart|Insulin Aspart will be administrated by insulin pump with an initial dose of 0.4-0.6u/kg body weight, of which 50% basal rate and the other 50% bolus dose. Time interval for administration will be as follows: 0-3Am-9Am-12Am-5Pm-9Pm-0Am. Specific adjustment will be made according to individual difference.
224267982|NCT05456438|OTHER|İntervention 1|Group 1 applied coconut oil to the nipple
224267983|NCT05456438|OTHER|İntervention 2|Group 2 applied tea tree oil to the nipple
224267984|NCT02646800|DRUG|Micafungin|Injection
224267985|NCT03102385|BEHAVIORAL|Motivational Interview|A web-based computer-tailored intervention that includes open-ended questions, reflective responses, affirmations, and summarizing, as well as informing and advising. Specific topics include 1) individual motivations for giving, 2) the relationship between past donation behavior and the individual's personal goals/values, 3) donation importance and confidence rulers, 4) addressing donor concerns, and 5) summarizing.
224267986|NCT03102385|BEHAVIORAL|Knowledge Interview|A web-based interview that includes open-ended questions regarding blood donation knowledge.
224267987|NCT05336487|OTHER|Physical activity|2 hours of physical activity per day, 5 days per week, for the intervention period
224267988|NCT00073632|BEHAVIORAL|Acceptance Based Behavioral Therapy|
224267989|NCT00948909|DRUG|Placebo|Placebo intervention
224267990|NCT00948909|DRUG|ABT-126|Experimental intervention
224267991|NCT00948909|DRUG|donepezil|Active comparator intervention
224267992|NCT01231737|DRUG|prulifloxacin|Prulifloxacin 1 tablet/week for 12 weeks.
224267993|NCT03337893|DIAGNOSTIC_TEST|blood pressure|it will be done both right and left arms
224267994|NCT00651651|DRUG|budesonide/formoterol|
224267995|NCT00651651|DRUG|budesonide|
224267996|NCT00651651|DRUG|formoterol|
224267997|NCT01611506|BIOLOGICAL|Cetuximab|"Induction chemotherapy:~Cetuximab 400mg/m2 (loading dose) on day 1 Cetuximab 250mg/m2 weekly thereafter~Followed by:~Cetuximab 250mg/m2 weekly on day 1 during chemoradiation~Postoperative treatment:~3 cycles of Cetuximab 250mg/m2 weekly on day 1"
224267998|NCT01611506|DRUG|Capecitabine|"Induction chemotherapy:~Capecitabine 1000mg/m2 twice daily from the evening of day 1 to the morning of day 15 within each 3 weeks cycle~Postoperative treatment:~Capecitabine 1000mg/m2 twice daily from the evening of day 1 to the morning of day 15 within each 3 weeks cycle"
224267999|NCT01611506|DRUG|Cisplatin|"Induction chemotherapy:~Cisplatin 80mg/m2 on day 1 of each 21 day cycle~Followed by:~Cisplatin 30mg/m2 weekly on day 1 during chemoradiation~Postoperative treatment:~Cisplatin 80mg/m2 on day 1 of each 21 day cycle"
224268000|NCT06505005|DEVICE|Drug- free, non-invasive patch (FREEDOM or REM Patch) with haptic vibrotactile trigger technology (VTT) Other Names:|Drug- free, non-invasive patch (FREEDOM or REM Patch) with haptic vibrotactile trigger technology (VTT)
224268001|NCT06505005|DEVICE|Sham Patch without haptic vibrotactile trigger technology (VTT)|Sham Patch without haptic vibrotactile trigger technology (VTT)
224268002|NCT03227939|PROCEDURE|Laparoscopic sleeve gastrectomy（LSG）|LSG：All these operations were performed by the same surgeon team. Dissect the greater omentum alongside the greater gastric curvature, make sure that the greater gastric curvature and fundus of stomach were completely made free from pancreas and spleen.Fully Exposed left and right diaphragm angle and taking care not to injure the esophagus. Resection was started 2 to 4 cm from pylorus and alongside a 40Fr tube up to the esophagogastric junction and created a 60 to 80ml gastric lumen, removed the fundus of stomach thoroughly and take care of the esophagus and preventriculus. Repaired the hiatal hernia if it was exsit.
223865564|NCT06923670|DIAGNOSTIC_TEST|NGS analysis for mutations in genes involved in familial predisposition to hematological malignancies|The investigators will evaluate the presence of mutations in the following genes: ABRAXAS1, ACD, ANKRD26, APC, ATG2B, ATM, BARD1, BMPR1A, BRCA1/2, BRIP1, CDH1, CDKN2A, CEBPA, CHECK2, CSF3R, DDX41, EPCAM, ERCC6L2, ETV6, FANCA, FANCB, FANCC, FANCD1, FANCD2, FANCE, FANCF, FANCG, FANCL, GATA2, GSKIP, MBD4, MECOM, MEN1, MLH1, MLH3, MRE11, MSH2, MSH6, MUTYH, NBN, NF1, NF2, PALB2, PIK3CA, POLD1, POLE, PMS2, PMS2CL, PTEN, PTPN11, RAD50, RAD51C, RAD51D, RET, RTEL1, RUNX1, SAMD9, SAMD9L, SBDS, SRP72, STK11, TERC, TERT, TP53, TSC1, TSC2, VHL, WAS, XRCC2
223865565|NCT06943599|OTHER|Text Message Reminder|Participants referred to the eye hospital after screening will receive a text message reminding them to attend their referral visit.
223865566|NCT06943599|OTHER|Health Worker Visit|Participants referred to the eye hospital after screening will receive a home visit from a health worker reminding them to attend their referral visit.
223865567|NCT06940414|OTHER|No Intervention|This is an observational study with no interventions. POCT devices, provided by Eaglenos Sciences, Inc., are used to measure blood glucose, creatinine, uric acid, hemoglobin, and potassium levels in non-dialysis CKD patients for data collection purposes only.
223865568|NCT07060547|DEVICE|HepQuant DuO Test|HepQuant DuO is commercially available in the U.S. as a Laboratory Developed Test (LDT), but it will be used in this study as a nonsignificant risk investigational device to measure change in liver function over time.
223865569|NCT04584099|DEVICE|Radiofrequency device treatment|TempSure firm
223865570|NCT04143204|OTHER|Oral nutritional intake|The exposure are oral nutritional intake and all nutritional intake during early life (28 days), and insulin-like growth factor 1, leptin, Ghrelin, and C-peptide in serum at corrected age 40 gestational weeks.
223865571|NCT00493649|DRUG|Taxotere|On Day 1 of each 21-day cycle for a total of 4 cycles, patients will receive, in this order: docetaxel 75 mg/m2 IV (over 1 hour), plus cyclophosphamide 600 mg/m2 IV (over 15-30 minutes), plus weekly trastuzumab 4 mg/kg IV (loading dose, over 90 minutes Day 1, Cycle 1 only) and 2 mg/kg IV (over 30-60 minutes on Days 1, 8, and 15) thereafter. Once 4 cycles of TC+H have been received, patients will continue with trastuzumab 6 mg/kg every 3 weeks to complete 1 year of anti-HER2 therapy as per the current standard of care. The anticipated time to study completion is 5 years.
223865572|NCT00493649|DRUG|Cytoxan|On Day 1 of each 21-day cycle for a total of 4 cycles, patients will receive, in this order: docetaxel 75 mg/m2 IV (over 1 hour), plus cyclophosphamide 600 mg/m2 IV (over 15-30 minutes), plus weekly trastuzumab 4 mg/kg IV (loading dose, over 90 minutes Day 1, Cycle 1 only) and 2 mg/kg IV (over 30-60 minutes on Days 1, 8, and 15) thereafter. Once 4 cycles of TC+H have been received, patients will continue with trastuzumab 6 mg/kg every 3 weeks to complete 1 year of anti-HER2 therapy as per the current standard of care. The anticipated time to study completion is 5 years.
224268003|NCT03227939|PROCEDURE|Uvulopalatopharyngoplasty(UPPP) and Adenoidectomy/Tonsillectomy|UPPP：PPP is typically administered to patients with obstructive sleep apnea in isolation. It is administered as a stand-alone procedure in the hope that the tissue which obstructs the patient's airway is localized in the back of the throat. The rationale is that, by removing the tissue, the patient's airway will be wider and breathing will become easier.
224268004|NCT01370122|OTHER|Survey|
224268005|NCT01828203|DRUG|Minocycline|
224268006|NCT01828203|DRUG|Placebo|
224268007|NCT01828203|PROCEDURE|Surgical spinal cord decompression|Surgical decompression by means at the discretion of the clinical management team will occur within 24 hours of injury in all subjects. Stabilization will occur at that time but may also include further interventions at a later time.
224268008|NCT01828203|PROCEDURE|Maintenance of minimum mean arterial pressure (MAP)|Standardized hemodynamic management protocol aimed at maintaining MAP ≥ 85 mm Hg for 7 days using volume augmentation with isotonic crystalloid followed by inotropic support if needed will be applied to all subjects.
224268009|NCT01445860|DRUG|Simvastatin/PF-03882845|Single dose 20 mg simvastatin on Day 1, 30 mg PF-03882845 once daily from Days 2 to 13, the single dose 20 mg simvastatin on Day 12.
224268010|NCT00904280|DRUG|Oxymorphone ER|Open label
224268011|NCT03727139|DRUG|Rasagiline|Rasagiline Tablets
224268012|NCT00344513|DRUG|Beta-blockers including Carvedilol|
224268013|NCT00344513|DRUG|ACE inhibitors|
224268014|NCT00510848|PROCEDURE|autograft tendon|Reconstruction with an autograft tendon (hamstrings)
224268015|NCT00510848|PROCEDURE|allograft tendon|Reconstruction with an allograft tendon (tibialis posterior)
224268016|NCT03324139|DRUG|Low molecular weight heparin|Patients included in this study group will receive 3,500 IU / 0.2 ml / day of Bemiparina sc, from inclusion to delivery (estimated median of 5-6 weeks, with a maximum of 13 weeks).
224268017|NCT03324139|DRUG|Placebos|Patients included in this study group will placebo (same presentation as the active drug), from inclusion to delivery (estimated median of 5-6 weeks, with a maximum of 13 weeks).
224268018|NCT01202435|DRUG|Pregabalin controlled release, 82.5 mg|82.5 mg controlled release tablet administered once daily for four days.
224268019|NCT01202435|DRUG|Pregabalin immediate release, 25 mg|25 mg immediate release capsules administered three times daily for four days
224268020|NCT04401137|DRUG|Topiramate|Topiramate
224268021|NCT01665404|DRUG|Fluvoxamine|Multiple doses of fluvoxamine
224268022|NCT01665404|DRUG|RO4917523|Single dose of RO4917523
224268023|NCT05659316|OTHER|MRI imaging|Knee MRI imaging
224268024|NCT00757172|BIOLOGICAL|panitumumab|
224268025|NCT00757172|DRUG|cisplatin|
224268026|NCT00757172|DRUG|docetaxel|
224268027|NCT00757172|PROCEDURE|neoadjuvant therapy|
224268028|NCT00757172|PROCEDURE|therapeutic conventional surgery|
224268029|NCT00757172|RADIATION|radiation therapy|
224268030|NCT03409315|PROCEDURE|Centralized Therapeutic Drug Monitoring|Plasma samples will be drawn at peripheral centres en shipped to a central laboratory for analysis. Results and dosing advice will be returned by email to local physician.
224268031|NCT02975856|DIETARY_SUPPLEMENT|Table Red Wine|
224268032|NCT02975856|DIETARY_SUPPLEMENT|Young Port Red Wine|
224268033|NCT00120783|DRUG|Indinavir|
224268034|NCT00120783|DRUG|Lamivudine|
224268035|NCT00120783|DRUG|Ritonavir|
224268036|NCT06108557|DIAGNOSTIC_TEST|Serum Pararoxonase -1 level|"The individual's venous blood will be taken five milliliters under strict aseptic conditions of both control and case groups (before antidotal therapy). Then the blood will be left to be coagulated for 10-20 minutes at room temperature, then centrifugation will be done by laboratory centrifuge. Serum samples were obtained, then half of the separated serum will be used for pseudocholinesterase enzyme assay and the other one will be used for Paraoxanase-1 (PON-1) analysis .~Serum PON-1: The enzyme-linked immunosorbent assay (ELISA) will be used to measure it using human Pararoxonase (PON) ELISA kits.~Serum pseudocholinesterase: is based on spectrophotometric measurement."
224268037|NCT06108557|DIAGNOSTIC_TEST|Diagnostic Test: Serum pseudocholinesterase enzyme level|"The individual's venous blood will be taken five milliliters under strict aseptic conditions of both control and case groups (before antidotal therapy). Then the blood will be left to be coagulated for 10-20 minutes at room temperature, then centrifugation will be done by laboratory centrifuge. Serum samples were obtained, then half of the separated serum will be used for pseudocholinesterase enzyme assay and the other one will be used for Paraoxanase-1 (PON-1) analysis .~Serum PON-1: The enzyme-linked immunosorbent assay (ELISA) will be used to measure it using human Pararoxonase (PON) ELISA kits.~Serum pseudocholinesterase: is based on spectrophotometric measurement."
224268038|NCT01257633|PROCEDURE|Transoral robot-assisted tumor resection using the da Vinci robot|Transoral robot-assisted tumor resection using the da Vinci robot
224268039|NCT06144034|DEVICE|Air polishing with erythritol powder|Air polishing with erythritol powder utilized for biofilm disclosing and, followed by an ultrasonic scaler to remove calculus if present.
224268040|NCT06144034|DEVICE|Conventional treatment|Rubber cup polishing with prophy paste after biofilm disclosing, followed by ultrasonic scaling of calculus if present.
224268041|NCT00866580|BIOLOGICAL|GSK's candidate influenza vaccine 1562902A|Intramuscular dose on Day 0 and Day 21
223865573|NCT00493649|DRUG|Herceptin|On Day 1 of each 21-day cycle for a total of 4 cycles, patients will receive, in this order: docetaxel 75 mg/m2 IV (over 1 hour), plus cyclophosphamide 600 mg/m2 IV (over 15-30 minutes), plus weekly trastuzumab 4 mg/kg IV (loading dose, over 90 minutes Day 1, Cycle 1 only) and 2 mg/kg IV (over 30-60 minutes on Days 1, 8, and 15) thereafter. Once 4 cycles of TC+H have been received, patients will continue with trastuzumab 6 mg/kg every 3 weeks to complete 1 year of anti-HER2 therapy as per the current standard of care. The anticipated time to study completion is 5 years.
223865574|NCT05219253|BIOLOGICAL|HZ/su|Two doses of the HZ/su vaccine administered intramuscularly, one each at Day 1 and Month 2.
223865575|NCT05219253|DRUG|Placebo|Two doses of Placebo (lyophilised sucrose reconstituted with saline \[NaCl\] solution) administered intramuscularly, one each at Day 1 and Month 2.
223865576|NCT03086369|DRUG|Olaratumab|Administered IV
223865577|NCT03086369|DRUG|Nab-paclitaxel|Administered IV
223865578|NCT03086369|DRUG|Gemcitabine|Administered IV
223865579|NCT03086369|DRUG|Placebo|Administered IV
223865580|NCT06394284|DRUG|MDMA-AT|As described above in arm description
223865581|NCT06394284|BEHAVIORAL|SEA-IT|As described in arm description
223865582|NCT03475524|DRUG|MetFORMIN 1000 Mg Oral Tablet|oral tablet 1ooomg systemic metformin will be given to group
223865583|NCT03475524|DRUG|Placebos|oral placebos will be given to control beside trichloracetic acid peeling
223865584|NCT03475524|DRUG|Trichloroacetic Acid Peeling|Trichloroacetic acid peeling to the three groups
223865585|NCT03475524|DRUG|MetFORMIN 500 Mg Oral Tablet|oral tablet 500 mg
223865586|NCT00003868|DRUG|cyclophosphamide|
223865587|NCT00003868|DRUG|methotrexate|
223865588|NCT00003868|PROCEDURE|allogeneic bone marrow transplantation|
223865589|NCT00003868|PROCEDURE|peripheral blood stem cell transplantation|
223865590|NCT00003868|RADIATION|iodine I 131 monoclonal antibody BC8|
223865591|NCT00003868|RADIATION|radiation therapy|
223865592|NCT01890811|DIETARY_SUPPLEMENT|Boost High Protein|Subjects will receive stable amino acid isotopes IV and will receive Boost High Protein with added isotopes to measure anabolic response to a meal.
223865593|NCT00506727|DRUG|Mixed amphetamine salts (ADDERALL XR)|
223865594|NCT00506727|DRUG|Atomoxetine hydrochloride|
223865595|NCT06335576|OTHER|This study is a single-arm and observational study with no intervention.|This study is a single-arm and observational study with no intervention.
223865596|NCT06480552|DRUG|TEV-56278|Administered intravenously
223865597|NCT06480552|DRUG|Pembrolizumab|Administered intravenously
223865598|NCT06123871|OTHER|Grouping based on previous laboratory results, no intervention.|The patients were grouped according to the results of previous inpatient tests, and no intervention measures were taken
223865599|NCT01904071|PROCEDURE|UFNB (Ultrasound guided femoral nerve block)|Ultrasound Guided Femoral Nerve Block
223865600|NCT01904071|PROCEDURE|UFIB (Ultrasound Guided Fascia Iliaca Compartment Block)|
223865601|NCT01904071|DRUG|IVMS (IV Morphine)|Intravenous Morphine
223865602|NCT06355492|DEVICE|Virtual reality goggles (VR )|Patients will take buccal infiltration anaethesia using (Virtual reality goggles) that properly adjusted around the patient's head and in front of his/her eyes.
223865603|NCT06355492|DEVICE|regular screen|Patients will take buccal infiltration anaethesia using (regular screen ).
223865604|NCT04409912|DEVICE|Sirolimus coated balloon|"Sirolimus has a high transfer rate to the vessel wall and effectively inhibit neointimal hyperplasia in the porcine coronary model. In coronary artery interventions, preliminary clinical studies using sirolimus coated balloon have shown excellent procedural and 6 month patency. The effectiveness of sirolimus coated balloon in patients with dialysis access dysfunction has been shown in a small pilot study in the salvage of thrombosed arteriovenous graft.~When compared to Paclitaxel, sirolimus is cytostatic in its mode of action with a high margin of safety."
223865605|NCT04409912|DEVICE|Plain balloon|Plain balloon angioplasty is the current standard therapy to treat stenosis in dialysis access. However, the mid and long term patency of plain balloon angioplasty in patients with end stage renal disease is poor. The average primary patency is around 40 to 50 percent at 1 year and multiple repeated angioplasty is required to maintain the patency of the vascular access.
223865606|NCT03601780|DRUG|local wound infiltration plus usual care|local wound infiltration plus usual care
223865607|NCT03601780|DRUG|usual care only|usual care only
223865608|NCT03784768|OTHER|Plantar Vibration Group|Patients in plantar vibration group will be received 45-minute conventional physiotherapy session for 5-days in a week, over 4-week. Each physiotherapy sessions will consist of range of motion exercises, strengthening exercises, exercises such as activities of daily living, mobility and transfer activities. In addition, three sessions a week will be applied to the soles of the feet for 15 minutes with a 15-100 Hz vibration device on both sides of the soles of the feet before conventional physical therapy.
224268042|NCT00866580|BIOLOGICAL|FluarixTM|Intramuscular dose on Day 42 or on Day -30, according to the vaccination schedule
224268043|NCT00866580|BIOLOGICAL|Placebo|Intramuscular dose on Day 42 or on Day -30, according to the vaccination schedule
224268044|NCT02438735|PROCEDURE|laparoscopic endometrioma excision|
224268045|NCT02438735|OTHER|Conservative follow up|
224268046|NCT02992964|DRUG|Nivolumab|Nivolumab (also referred to as BMS-936558 or MDX1106) is a human monoclonal antibody (HuMAb; immunoglobulin G4 \[IgG4\]-S228P) that targets the programmed death-1 (PD-1) cluster of differentiation 279 (CD279) cell surface membrane receptor.
224268047|NCT01296607|DRUG|Urocortin 2|"Protocol 4a: Onset/Offset protocol: (Visits 1 or 3)~Following a 20-minute period of saline infusion for equilibration of the set-up, subjects will receive incremental doses of Urocortin 2 in the presence of a saline washout between each dose.~Urocortin 2 will be infused at 3.6, 12, 36 and 120 pmol/min (15, 50, 150 and 498 nanograms/min) to achieve estimated end-organ concentrations of 0.6, 2, 6 and 20 micrograms/L respectively.~Protocol 4b: Reproducibility protocol (Visit 2 or 4)~Following a 20-minute period of saline infusion for equilibration of the set-up, subjects will receive ascending doses of urocortin 2 in the absence of saline washout between each dose. This protocol aims to assess the reproducibility of the vasodilatory effect of urocortin 2 on repeated dosing. The doses used for this protocol will be identical to Protocol a."
224268048|NCT01296607|DRUG|Urocortin 3|"Protocol 4a: Onset/ Offset protocol: (Visit 1 or 3)~Following a 20-minute period of saline infusion for equilibration of the set-up, subjects will receive incremental doses of Urocortin 2 or Urocortin 3 in the presence of a saline washout between each dose.~Urocortin 3 will be infused at 1200, 3600, 12000 and 36000 pmol/min (5, 15, 50 and 150 micrograms/min) to achieve estimated end organ concentrations of 199, 600, 2000 and 6000 micrograms/L respectively.~Protocol 4b: Reproducibility protocol (Visit 2 or 4)~Following a 20-minute period of saline infusion for equilibration of the set-up, subjects will receive ascending doses of urocortin 3 in the absence of saline washout between each dose. This protocol aims to assess the reproducibility of the vasodilatory effect of 3 on repeated dosing. The doses used for this protocol will be identical to Protocol a."
224268049|NCT03587545|OTHER|Probiotic nasal spray|Total daily nasal administration of 2\*10\^8 CFU of probiotic bacteria delivered via 2 servings.
224268050|NCT03587545|OTHER|Placebo nasal spray|Two servings of nasal administration of placebo nasal spray (not containing probiotic bacteria)
224268051|NCT01812993|DEVICE|Non-invasive ventilatory treatment with auto-BPAP|
224268052|NCT00959790|DIETARY_SUPPLEMENT|Vegetables|200 or 50 grams of vegetables daily for four weeks
224268053|NCT00959790|DIETARY_SUPPLEMENT|energy restriction|Consume about 1000 kcal less daily, for four weeks, as a positive control to the vegetables interventions.
224268054|NCT02081105|OTHER|PEEP of 5 or 15 cm H2O|PEEP of 5 or 15 cm H2O set at the respirator and applied to the patient for 10 minutes. Then, measurements are made at each PEEP in the following order: arterial blood gas, CXR, pressure-volume curve.
224268055|NCT05316454|BEHAVIORAL|self-efficacy support|self-efficacy support
224268056|NCT07025330|DRUG|Efgartigimod|efgartigimod 1000 mg subcutaneous injection given once weekly
224268057|NCT00840879|DRUG|Meloxicam 15 mg Tablets|1 x 15 mg, single-dose fed
224268058|NCT00840879|DRUG|Mobic® 15 mg Tablets|1 x 15 mg, single-dose fed
224268059|NCT01008709|DEVICE|Teleflex HemoLock clip|Patients randomized to the Aesculap U-clip device or the HemoLock clip will undergo their respective surgery (robotic prostatectomy and laparoscopic and robotic renal surgery) as per standard protocols. During the surgical procedure, when primary vascular control is warranted the appropriate clip to which the patient has been randomized will be utilized. Immediate assessment of the vascular pedicle will subsequently occur; if hemostasis is not adequate, additional clipping, endomechanical stapling or suture ligation will then be performed as necessary.
224268060|NCT01008709|DEVICE|Aesculap U-clip|Patients randomized to the Aesculap U-clip device or the HemoLock clip will undergo their respective surgery (robotic prostatectomy and laparoscopic and robotic renal surgery) as per standard protocols. During the surgical procedure, when primary vascular control is warranted the appropriate clip to which the patient has been randomized will be utilized. Immediate assessment of the vascular pedicle will subsequently occur; if hemostasis is not adequate, additional clipping, endomechanical stapling or suture ligation will then be performed as necessary.
224268061|NCT05800899|BEHAVIORAL|Brief Motivational Interviewing|Standard non-adapted brief motivational interviewing based on motivational interviewing.
223865609|NCT03784768|OTHER|Control Group|Patients in control group will be received 60-minute conventional physiotherapy session for 5-days in a week, over 4-week. Each physiotherapy sessions will consist of range of motion exercises, strengthening exercises, exercises such as activities of daily living, mobility and transfer activities.
223865610|NCT01287286|DIETARY_SUPPLEMENT|AC-Can|Antrodia cinnamomea compounds of 15 milliliters liquid per pack, oral post meal, twice in a day for 30 days
223865611|NCT01287286|DIETARY_SUPPLEMENT|placebo|Placebo of 15 milliliters liquid per pack, oral post meal, twice in a day for 30 days
223865612|NCT01681381|DEVICE|Tivoli® DES|Device:Tivoli® DES The Tivoli® DES drug eluting stent(Tivoli® DES) is an open cell balloon expandable cobalt chromium stent coated with a bio-gradable polymer (PLGA) containing rapamycin at a dose of 8 micrograms per millimeter of stent length. In vitro assays have shown that about 50% of the drug releasing in 1 week and approximately 80% releasing in 28 days. The polymer may be degraded in 3 to 6 months in human body. This stent is supplied pre-mounted on a delivery catheter and is available in the following sizes: lengths of 10、15、18、21、25、30、35 mm and diameters of 2.5、2.75、3.0、3.5、4.0 mm.
224268062|NCT05800899|BEHAVIORAL|Culturally adaptation brief motivational interviewing|culturally adapted brief motivational interviewing based on motivational interviewing.
224268063|NCT07129837|DIAGNOSTIC_TEST|Clinical evaluation, disease activity and disability scoring, and laboratory testing including RF, anti-CCP, and serum anti-PCOLCE antibody measurement by ELISA.|"For rheumatoid arthritis (RA) patients: participants will undergo comprehensive clinical evaluation including demographic data, detailed history, musculoskeletal and systemic examination, assessment of disease activity using DAS-28 score, functional disability evaluation by modified Health Assessment Questionnaire (mHAQ), and laboratory investigations including CBC, ESR, CRP, rheumatoid factor (RF), anti-cyclic citrullinated peptide (anti-CCP) antibodies, and serum anti-procollagen C-endopeptidase enhancer (anti-PCOLCE) antibodies measured by ELISA.~For healthy controls: participants will undergo comprehensive clinical evaluation including demographic data, detailed history, musculoskeletal and systemic examination, and laboratory testing limited to serum anti-PCOLCE antibodies measured by ELISA."
224268064|NCT04838678|DRUG|Neuropeptide Y|intra-arterial infusion of neuropeptide Y
224268065|NCT04296123|BEHAVIORAL|Step training|A 12-week step training consisting of two 30-minute training session per week. The participants will be instructed to stand upright and step on different targets on a plastic mat repeatedly.
224268066|NCT01427062|OTHER|experimental|Subjects in the experimental group were trained the speed and amplitude of anticipatory postural adjustment during fall-prone activities and postural response to perturbation during walking. Training was provided with preparatory cues, computerized machines and treadmill.
224268067|NCT01427062|OTHER|control|Subjects in control group were provided with strength training of leg muscles using machines and during functional activities.
224268068|NCT07054554|OTHER|NTRI-MH|NTRI-MH intervention will use evidence-based instructional strategies for adult professional development (i.e., lecture, discussion, case studies, role-playing). NTRI-MH training includes 20 hours of didactic and interactive sessions (5 sessions of 4 hours each) covering the following areas specific to MH needs in young children at-risk: 1) benefits and barriers (professional and family) to early intervention for children with MH concerns, 2) approaches for empowering caregivers, 3) supporting strategies to assist families through early MH access and service engagement , 4) use of the dashboard to track and monitor the course of clinical, functional, and behavioral outcomes, 5) evidence-based working alliances with PCPs and teachers (including a 2 hour session with the child's teacher), and 6) MH resources, treatments and services, and strategies to support parental management of young child behaviors.
224268069|NCT07059403|BIOLOGICAL|SN2001|100 µg, for subcutaneous (SC) injection
224268070|NCT07059403|BIOLOGICAL|SN2001|200 µg, for subcutaneous (SC) injection
224268071|NCT07059403|BIOLOGICAL|SN2001|300 µg, for subcutaneous (SC) injection
224268072|NCT07058662|GENETIC|Single dose intravenous of BBM-D101|BBM-D101 is a gene addition therapy based on engineered AAV delivery therapeutic protein gene cassette into muscle for treating DMD. Therapeutic protein could mediate the dystrophin-associated protein complex to prevent muscular dystrophy and to rescue the function of muscle.The administration is completed by a single intravenous infusion.
224268073|NCT04236596|DEVICE|Participants received a Neurostimulator, which was used to map the pudendal nerve|Participants in study received neurostimulator at their pudendal nerve as part of their normal clinical care. This neurostimulator was used to map the nerve.
224268074|NCT07065357|DRUG|Empagliflozin (oral)|Participants received Empagliflozin 10 mg orally once daily for six months.
224268075|NCT07065357|OTHER|Matching placebo|Participants received matching placebo orally once daily for six months.
224268076|NCT00919113|DRUG|2% sodium chondroitin sulfate|Weekly 20 mL Intravesical instillation
224268077|NCT00919113|DRUG|Placebo|The identical buffer used in Uracyst for the same administration
224268078|NCT07097493|DRUG|Liposomal Bupivacaine|10 ml of 0.25% bupivacaine expanded with 133 mg (10 ml volume) of liposomal bupivacaine into both the adductor canal and iPACK blocks (total of 40 ml)
224268079|NCT07097493|DRUG|Bupivacaine, Clonidine, Epinephrine, Buprenorphine and Dexamethasone (BPV-CEBD) Combination|20 ml of solution consisting of 0.25% bupivacaine, 1.667mcg/ml of clonidine, 1:400,000 epinephrine, 0.15 mg total of buprenorphine, and 2 mg total of preservative free dexamethasone which will be used in both the adductor canal block and iPACK block (total of 40 ml)
224268080|NCT04571801|DIAGNOSTIC_TEST|Standard diagnostics|Standard diagnostics (Microbial diagnostics by means of standard culture methods + optional consultation of experts in the field of infectious diseases) within the first 72 h after diagnosis of sepsis / septic shock
224268081|NCT04571801|DIAGNOSTIC_TEST|Next Generation Sequencing (NGS)|Standard diagnostics + NGS (Microbial diagnostics using standard culture methods + Next Generation Sequencing + optional consultation of experts in the field of infectious diseases) within the first 72 h after diagnosis of sepsis / septic shock
224268082|NCT02957331|DRUG|Propranolol|
224268083|NCT00856167|DRUG|TCM|whole system Traditional Chinese Medicine, including acupuncture, herbs, tuina, lifestyle counseling
224268084|NCT00856167|BEHAVIORAL|Self-care for TMD|a 5-session 8 hour intervention targeting TMD knowledge, stretching and exercises, stress reduction, lifestyle modification
224268085|NCT07102875|BEHAVIORAL|Sailing Intervention Plus Home-Based Telerehabilitation|A two-phase rehabilitation program combining 5 days of intensive sailing therapy with a 3-month home-based telerehabilitation plan. The sailing component includes group-based activities in adapted sailing environments, conducted in Marina di Ravenna or Palermo, with daily debriefing and psychosocial support. The telerehabilitation component includes twice-weekly supervised sessions delivered via a digital platform, focusing on progressive motor, proprioceptive, and postural exercises. The intervention aims to improve motor function, quality of life, and psychosocial well-being in individuals with rare skeletal disorders.
223865613|NCT01681381|DEVICE|Firebird2® DES|The Firebird2® rapamycin-eluting stent (Firebird2® DES) is an open cell balloon expandable cobalt chromium stent coated with a biocompatible durable styrene-butylenes-styrene (SBS) polymer containing rapamycin at a dose of 9 micrograms per millimeter of stent length. In vitro assays have shown that about 50% of the drug elutes in 1 week and approximately 90% elutes in 1 month. This stent is supplied pre-mounted on a delivery catheter and is available in the following sizes: lengths of 13, 18, 23, 29, 33 mm and diameters of 2.25, 2.5, 2.75, 3.0, 3.5, 4.0 mm.
223865614|NCT01959126|BEHAVIORAL|Stress-reduction class|Study participants enrolled in a 12-week stress reduction course based on the principles of mindfulness. They attended four six-hour workshops and participated in 12 weekly hour-long web video conferencing calls to reinforce what was taught in the workshops. We have two groups: chronically-stressed maternal caregivers of children on the autism spectrum and control mothers whose children have no significant psychiatric or physical impairment. Both groups received similar instruction.
223865615|NCT06255795|DRUG|chidamide, anti-PD1 antibody, and pegaspargase|6 cycles of pegaspargase 2500IU/m2 intramuscularly on day1, anti-PD1 antibody 200mg intravenously on day 2, chidamide 30mg biw orally, every 21 days.
223865616|NCT06255795|DRUG|DDGP|6 cycles of pegaspargase 2500IU/m2 intramuscularly on day1, cisplatin 20mg/m2 intravenously on days 1 through 4, dexamethasone 15mg/m2 intravenously on days 1 through 5, gemcitabine 800mg/m2 on day 1 and day 8, every 21 days.
223865617|NCT02860286|DRUG|Tazemetostat|Tazemetostat (EPZ-6438) is a selective small molecule inhibitor of the histone-lysine methyltransferase EZH2 gene.
223865618|NCT00164333|BEHAVIORAL|TAP: Treatment Advocacy Program|
223865619|NCT05701397|DIAGNOSTIC_TEST|DPD scintigraphy|Bone tracer scintigraphy, diagnostic for transthyretin cardiac amyloidsis
223865620|NCT02833506|OTHER|Laboratory Biomarker Analysis|Correlative studies
223865621|NCT02833506|BIOLOGICAL|Recombinant NY-ESO-1 Protein|Given recombinant NY-ESO-1 protein SC
223865622|NCT02833506|DRUG|Sirolimus|Given PO
223865623|NCT06224946|DIAGNOSTIC_TEST|soluble fms-like tyrosine kinase (sFlt-1) / placental growth factor (PlGF) ratio|the soluble fms-like tyrosine kinase (sFlt-1) / placental growth factor (PlGF) ratio for pre-eclampsia diagnostic
223865624|NCT05918614|DRUG|Belumosudil mesylate|Pharmaceutical form: capsule; Route of administration: oral
223865625|NCT05918614|DRUG|Placebo|Pharmaceutical form: capsule; Route of administration: oral
223865626|NCT02355197|DRUG|L-ascorbic acid|1 gram L-ascorbic acid (vitamin C …..) per day from the time of diagnosis until the time of delivery
223865627|NCT02290067|DEVICE|Blood glucose monitoring system (Omnitest 3)|
223865628|NCT02290067|DEVICE|Blood glucose monitoring system (Omnitest 5)|
223865629|NCT02290067|DEVICE|Blood glucose monitoring system (Omnitest 5D)|
223865630|NCT00003005|DRUG|Cordycepin|"Dose escalation study using the following doses:~6mg/m2, 12 mg/m2, 24mg/m2, 48mg/m2"
223865631|NCT00003005|DRUG|Deoxycoformycin|Dose escalation using the Fibonacci dose escalation sequence starting dose 2mg/m2, escalating to 3mg/m3 intravenous
223865632|NCT04149548|DIAGNOSTIC_TEST|ultrasound|Obstetric ultrasound to pregnant women
223865633|NCT00767754|DRUG|Paxil CR|12 week treatment of Paxil(20-40mg)
223865634|NCT03402633|OTHER|Examination of leukotrichia in vitiligo patients|Examination of leukotrichia will be enhanced by wood's light and dermoscopy for better enhancing of the lesions and good magnification
223865635|NCT01426295|DEVICE|Caphosol|"The Caphosol ™ is a recently launched medical in France (2009). (source: laboratory EUSA Pharma ®)~The product is an aqueous solution for mouthwash that comes in the form of a hyper-saturated mixture of calcium phosphate at neutral pH to reconstitute immediately before use.~Each patient randomized to the treatment arms in the study will receive daily at least 4 (maximum 10) mouthwash Caphosol ™.~The treatments are to begin preventive J1 to chemotherapy and continued until out of aplasia (ANC\> 500/mm3), and / or mucositis grade 0."
223865636|NCT01426295|DRUG|Bicarbonate de sodium|"Treatment of the early start on the day of conditioning and stop when the ANC\> 500/mm3 and / or mucositis grade zero, provisional date of bone exceeded.~Versylène: Method of administration: gargle made with a minute from 15 to 30 mL, 2-5 times a day, alternating with PAROEX ®."
223865637|NCT05452759|DEVICE|high-flow oxygen therapy device for Severe pneumonia patients with artificial airway|Using NTHF, adjust the MR850 humidifier to invasive automatic gear, the temperature sensor automatically adjusts and maintains the gas temperature at the entrance of the tracheal tube at 37°C according to the feedback temperature, and monitors and maintains SpO2 between 94% and 100%. The monitored pulse oxygen saturation (SpO2) is used to adjust the concentration of the venturi valve and the corresponding oxygen flow rate. At the preset gas flow rate levels of 40L/min, 50L/min and 60L/min, the test pipeline is connected to optimize the breath. The actual gas flow rate value and the gas flow rate loss difference before and after the gas joint (screw joint), and at the corresponding gas flow rate, measure the gas temperature and humidity at the near-patient end of the pipeline.
223865638|NCT05452759|DEVICE|AIRVOTM2 device for Severe pneumonia patients with artificial airway|Use AIRVOTM2 (Fisher \& Paykel, Auckland, New Zealand), select the output gas temperature of 37°C, monitor and maintain SpO2 between 94% and 100%, and adjust the output gas flow rate of the therapy device to 40L/min, 50L/min and 60L/min, respectively. min, measure the actual gas flow rate value and the gas flow rate loss difference before and after each flow rate horizontal pipeline is connected to the conventional exhalation joint (matching special exhalation joint), and measure the gas temperature and humidity near the patient end of the pipeline at the corresponding gas flow rate.
223865639|NCT05658406|DRUG|Ringer's Lactate|infusion of 15 mL/kg/hour Ringer's lactate intraoperative
223865640|NCT05658406|DRUG|Ringer's Lactate|infusion of 10 mL/kg/hour Ringer's lactate intraoperative .
223865641|NCT05658406|DRUG|Ringer's Lactate|infusion of 6 mL/kg/hour Ringer's lactate intraoperative .
223865642|NCT05658406|DRUG|normal Saline|standard fluid management: 4 ml for 1st 10 kg, 2 ml for the next 10 kg , 1 ml rest of body weight
223865643|NCT05511766|DRUG|Allopurinol 300 MG|a competitive xanthine oxidase inhibitor, reduces oxidative stress and attenuates bacterial translocation
223865644|NCT05511766|DRUG|Atorvastatin 20mg|is lipid-lowering agent with anti-oxidative stress and anti-inflammation properties
223865645|NCT05511766|DRUG|Placebo|not containing drugs
223865646|NCT04064866|DEVICE|High yield pure PRP|"The investigational product is hemocyte autograft derived from the subject's own blood. Subjects with a clinical diagnosis of discogenic pain had a discogram with ¼ cc to ½ cc of contrast injected by hand (leaving up to ½ cc contrast in the needle lumen and connecting tube); any concordant pain will be noted. Subjects received the injectant delineated by coordinator-provided randomization. Subjects were awake for the entirety of study treatment procedure.~All subjects had blood drawn (50 cc) from any access site and double-centrifuged using the EmCyte Hemocyte Autograft system; the first spin separated the buffy coat, the second spin and subsequent siphoning separated a purified platelet sample."
223865647|NCT04064866|OTHER|Placebo|Placebo injections will have saline placed in centrifuges and run for the duration required for PRP preparation. 3cc of saline will be placed in 3 cc syringes with opaque tape around the barrel to cover the fluid chamber. 1-2 cc of saline will be injected into the nucleus pulposus of each treatment level disc under fluoroscopy for lumbar; 0.5-1 cc for thoracic and 0.5-1 cc for cervical.
223865648|NCT04064866|DEVICE|ProPlaz PPC|Trademarked name of an FDA-cleared product
223865649|NCT00002964|DRUG|porfimer sodium|
223865650|NCT00002964|OTHER|fluorophotometry|
223865651|NCT00232349|DRUG|galantamine|open label galantamine, dosed at 4-12 mg/b.i.d., with a target dose of 12 mg/b.i.d.
223865652|NCT00048217|DRUG|T-1249|
223865653|NCT03197090|DEVICE|Zenicor ECG|Participants will place their thumbs on the device twice daily and whenever they notice palpitations.
223865654|NCT04413812|BEHAVIORAL|FREEBASE exercise programme|"The exercise programme will be initialized 1-10 months following bariatric surgery and last for 3 months. The programme will be mainly delivered in two groups consisting of 10-12 subjects each and will be held in the facilities of a fitness studio and remotely at home. The programme consists of 24 units (two per week, the lesson in the fitness studio lasting for 75 minutes and the remote lesson lasting for 45 minutes.This is due to the COVID-19-related social distancing restrictions. The intervention combines the following elements: a) exercise training in a group, b) interactive workshops on basic knowledge of training sciences and techniques of behavior change and c) an individual exercise counselling session.~The programme will be medically supervised and the content will be taught and instructed by members of the research team qualified in exercise science and sports physiology."
223865655|NCT04866238|DEVICE|Vestibular fixed appliances|The fixed appliances will be applied in class1 malocclusion patients who have dental crowding, then they will be followed up for 12 months.
223865656|NCT04866238|DEVICE|Clear aligners|The clear aligners will be applied in class1 malocclusion patients who have dental crowding, then they will be followed up for 12 months.
223865657|NCT00069901|DRUG|CT-2103 (poly(L)glutamate-paclitaxel)|
223865658|NCT00069901|DRUG|carboplatin|
223865659|NCT01765543|DRUG|Rifampin|Rifampin at a dose of 600 mg as capsules orally once daily will be administered from Days 8 through 23 (Periods B and C).
223865660|NCT01765543|DRUG|Vemurafenib|Participants, after an overnight fast of at least 10 hours, will receive vemurafenib at a dose of 960 mg as film-coated tablets orally on Day 1 (Period A) and on Day 17 (Period C).
223865661|NCT03658460|OTHER|DNA sequencing|Targeted next generation sequencing and gene expression analysis with focus on immuno-oncology signatures
224268086|NCT07102875|BEHAVIORAL|Home-Based Telerehabilitation|Participants perform a 3-month home-based rehabilitation program consisting of two remote sessions per week via a supervised digital platform. Each session includes warm-up, strength and coordination exercises, and cool-down. Exercises are progressive and standardized, but adapted to individual needs to ensure safety and adherence. The intervention targets motor function, balance, proprioception, and psychosocial outcomes, without any sailing component. This arm serves as the active comparator.
224268087|NCT07127861|OTHER|Treadmill gait training|Participants will undergo a 15-minute treadmill gait training session using a safety harness and under the continuous supervision of a physiotherapist to ensure patient safety. The study will be carried out for 12 weeks with a frequency of two weekly sessions. During them, the participants will receive treadmill training. All participants will walk at a speed exceeding 2.5 km/h. The speed will be individually adjusted to provide a challenging yet appropriate intensity based on each participant's capabilities.
224268088|NCT07140276|BEHAVIORAL|Individual Therapy|12 weeks individual psychotherapy
224268089|NCT07140276|BEHAVIORAL|Individual Drug Counseling manual|12 weeks using the manual provided
224268090|NCT07139691|PROCEDURE|Pre-incisional Transversus Abdominis Plane (TAP) block performed under ultrasound guidance. The block will be administered bilaterally using a mixture of lidocaine and ropivacaine 0.2%|After the induction of general anesthesia, bilateral TAP block will be performed in patients from Group 1. The administered dose will include 0.2% lidocaine combined with 0.2% ropivacaine, at a dose of 0.4 ml/kg per side, without exceeding toxic dose limits per kg.
224268091|NCT07139691|DRUG|Participants in this arm will receive standard analgesia for postoperative pain management following elective hysterectomy|Participants in this arm will receive standard multimodal systemic analgesia for postoperative pain management following elective hysterectomy. The regimen includes Paracetamol (oral or intravenous) 1g/24 hour, Ibuprofen IV 1200 mg/24 hour, or Parecoxib 80 mg/24 hour IV, and Tramadol 100 mg IV. Additional rescue doses of Tramadol (50-100 mg IV every 4-6 hours) may be administered based on pain intensity, with a maximum of 400 mg/24 hours (or 300 mg/24 hours for patients aged ≥75 years). No Transversus Abdominis Plane (TAP) block will be performed in this group. Pain intensity, opioid use, and postoperative recovery scores will be evaluated and compared with the TAP block intervention group.
224268092|NCT07138573|PROCEDURE|Kinesio Taping (KT) applied to the knee then ankle|"Procedure/Surgery: Procedure/Surgery: Kinesio Taping (KT) applied to the knee or ankle Kinesio taping was applied using a standard Y-strip with approximately 50% tension over the dominant lower extremity. In the Knee Taping condition, the tape was applied over the vastus medialis oblique and patellar tendon. In the Ankle Taping condition, the tape was applied over the peroneus longus and tibialis anterior muscles. Each taping intervention was performed by a trained physiotherapist and remained in place during the assessment session. The purpose of the intervention is to examine the acute effects of kinesio taping on balance, proprioception, and ACL injury risk using the Landing Error Scoring System (LESS)."
224268093|NCT07138573|PROCEDURE|Kinesio Taping (KT) applied to the ankle then knee|"Kinesio taping was applied using a standard Y-strip with approximately 50% tension over the dominant lower extremity. In the Knee Taping condition, the tape was applied over the vastus medialis oblique and patellar tendon. In the Ankle Taping condition, the tape was applied over the peroneus longus and tibialis anterior muscles. Each taping intervention was performed by a trained physiotherapist and remained in place during the assessment session. The purpose of the intervention is to examine the acute effects of kinesio taping on balance, proprioception, and ACL injury risk using the Landing Error Scoring System (LESS)."
224268094|NCT07139431|BIOLOGICAL|NCR100|Subjects will receive a single injection of NCR100
224268095|NCT07139535|DRUG|RAY1225|Administered SC
224268096|NCT07139535|DRUG|placebo|Administered SC
224268097|NCT07138729|DIAGNOSTIC_TEST|68Ga-FAPI PET/CT and 99mTc-CTR-FAPI SPECT|"For 68Ga-FAPI PET/CT scan，each patient was injected with 1.8-2.2 MBq/kg (0.05-0.06 mCi/kg) body weight of 68Ga-FAPI. PET/CT from skull to feet was performed 60±5 min post-injection.~For 99mTc-CTR-FAPI SPECT scan:each patient was injected with 10-20mCi 99mTc-CTR-FAPI . Planar SPECT scan and SPECT/CT were performed 60±5 min post-injection."
224268098|NCT07139041|DRUG|Iparomlimab and tuvonralimab plus chemotherapy|"Squamous Cell Carcinoma: 2-4 cycles of Iparomlimab and tuvonralimab 5mg/kg Q3W (Day 1) + Albumin-bound Paclitaxel (100mg/m² Q3W D1/D8/D15 or130mg/m²D1/D8 or 260mg/m²D1) + Carboplatin (AUC=5) Q3W (D1) Non-Squamous Cell Carcinoma: 2-4 cycles of Iparomlimab and tuvonralimab 5mg/kg Q3W (D1) + Pemetrexed 500mg/m² Q3W (D1) + Carboplatin (AUC=5) Q3W (D1) Radical Chemoradiotherapy for Patients Unable to Undergo Surgery:Patients still unresectable after conversion therapy should start radical chemoradiotherapy within 6 weeks after the last conversion therapy dose. Chemoradiotherapy follows standard clinical practice, recommended as Cisplatin 30mg/m² QW (D1) + 60Gy radiotherapy.~Adjuvant Therapy Phase:Iparomlimab and tuvonralimab 5mg/kg Q3W (D1) for up to 16 cycles."
224268099|NCT07139119|BEHAVIORAL|Health Belief Model-Based Educational Program for Skin Cancer Prevention Among Female Healthcare Workers|"This blended educational intervention employs the Health Belief Model (HBM) to promote skin cancer preventive behaviors in female healthcare workers in Ahvaz, Iran. The 7-session program (each 45 minutes) combines in-person training with WhatsApp-based follow-ups.~Participant Components:~* Structured sessions targeting knowledge and HBM constructs such as perceived susceptibility, severity, benefits, barriers, self-efficacy, and cues to action.~* Use of multimedia tools including videos, pamphlets, and interactive discussions.~* Motivational messaging, stress management clips, and role-modeling techniques to build self-efficacy.~* Visual cues such as posters placed in healthcare workplaces.~* Daily reminder messages to reinforce behavior change.~Unique aspects distinguishing this intervention include its specific tailoring for female healthcare workers in a high UV-exposure region, the combined digital and face-to-face delivery approach, and comprehensive focus on all HBM construc"
224268100|NCT07139574|OTHER|Music Therapy During Labor|This intervention involves the use of patient-selected, slow-tempo (60-80 bpm), non-lyrical instrumental music administered via headphones or speakers during the latent and active phases of labor. The music selection is guided to ensure therapeutic suitability (e.g., calming rhythm, absence of lyrics) and is delivered for a minimum of 30 minutes. The intervention is non-pharmacological, individualized, and adheres to WHO and clinical music therapy recommendations. It is distinguished by its personalized music choice, delivery timing, and structured application within labor progression monitoring.
224268101|NCT07139899|COMBINATION_PRODUCT|Hyperpolarized Xenon 129|Pulmonary magnetic resonance imaging using hyperpolarized xenon-129 gas as an inhaled contrast agent
223865662|NCT06347172|BEHAVIORAL|Nudge Intervention|"PCPs will receive an enhanced EHR alert (nudge) that triggers when a PCP opens an encounter for an eligible patient living with dementia (PLWD). The nudge will provide information about the risks of continued medication use as well as tips and tools to help providers discuss medication discontinuation with patients and care partners. Additionally, the providers will receive a brief message in their in-basket 10 days before the patient's appointment as a reminder.~Eligible PLWD of a randomized PCP will receive the nudge intervention which includes a brief recommendation for the PLWD (and care partner, if available) via the linked patient portal prior to upcoming visits (unless explicitly opted out by the PCP) to discuss medications with the PCP at the visit and link to a general handout about medications, unless explicitly opted out by the PCP. For PLWD without a portal account, the handout will be sent to their mailing address recorded in the EHR."
223865663|NCT02086097|DRUG|Dexketoprofen trometamol|25m of dexketoprofen (oral intake) every 8 hours
223865664|NCT02086097|DRUG|Ibuprofen|600 mg of Ibuprofen (Oral Intake) every 8 hours
223865665|NCT02086097|DRUG|PLACEBO|INACTIVE SUGAR PILLS
223865666|NCT00134069|DRUG|sorafenib tosylate|Given orally
223865667|NCT00134069|DRUG|cetuximab|Given IV
223865668|NCT00134069|DRUG|irinotecan hydrochloride|Given IV
223865669|NCT06041373|DEVICE|Verily Watch Cardio|The Verily Watch Cardio is an investigational wrist-worn wearable device containing multiple sensors to measure physiological and environmental metrics, including electrodes that enable a single-lead electrocardiogram (ECG) measurement and a photoplethysmogram (PPG) sensor to monitor for irregular pulses.
223865670|NCT06041373|DEVICE|iRhythm Zio monitor|The iRhythm Zio monitor, the reference device, is an FDA-cleared single-patient use, continuously recording ECG monitor that can be worn for up to 14 days.
223865671|NCT06041373|DEVICE|Schiller CARDIOVIT FT-1|The Schiller CARDIOVIT FT-1, the reference device, is an FDA-cleared portable 12-lead ECG machine capable of recording continuous standard 12-lead resting ECG for up to 4 minutes.
223865672|NCT00354653|DRUG|LAMIVUDINE|
223865673|NCT00034528|DRUG|Busulfan|0.8 mg/kg/d administered as a single intravenous infusion over 3 hours for 4 days. All infusions are anticipated to be given in the outpatient clinic.
223865674|NCT00034528|DRUG|Fludarabine|30 mg/m\^2/d administered as a bolus infusion over 30 minutes for 4 days. All infusions are anticipated to be given in the outpatient clinic.
223865675|NCT00034528|DRUG|FK506|0.15 mg/kg taken orally daily for 12 to 14 weeks
223865676|NCT00034528|DRUG|Prednisone|0.5 mg/kg taken orally four times daily on Day 7 and increase to 1 mg/kg taken orally four times daily on Day 14. Participants will continue regimen until Day 30 before a 20-25% taper per week.
224268102|NCT07140328|DRUG|HSK39004 Dry Powder Inhaler -0.75mg BID|HSK39004 Dry Powder Inhaler: Inhale through the mouth, 0.75mg each time, twice a day； And HSK39004 Inhalation Suspension Simulants,administered via oral inhalation, Two units each time, twice daily ；
224268103|NCT07140328|DRUG|HSK39004 Dry Powder Inhaler -1.5mg BID|HSK39004 Dry Powder Inhaler: Inhale through the mouth, 1.5mg each time, twice a day； And HSK39004 Inhalation Suspension Simulants,administered via oral inhalation, Two units each time, twice daily ；
224268104|NCT07140328|DRUG|HSK39004 Inhalation Suspension -3mg BID|HSK39004 Inhalation Suspension: Inhale through the mouth, 3mg each time, twice a day； And HSK39004 Dry Powder Inhaler Simulants,administered via oral inhalation, 1 tablet each time, twice daily ；
224268105|NCT07140328|DRUG|HSK39004 Placebo|HSK39004 Dry Powder Inhaler Simulants,administered via oral inhalation, 1 tablet each time, twice daily ； And HSK39004 Inhalation Suspension Simulants,administered via oral inhalation, Two units each time, twice daily ；
224268106|NCT06558682|DRUG|Disitamab Vedotin and Cisplatin|Disitamab Vedotin: 2mg/Kg,ivdrip, 3 weeks/cycle,3 cycles. Cisplatin: 75-80mg/m2, ivdrip, 3 weeks/cycle,3 cycles.
224268107|NCT03749720|OTHER|Blood sample|Blood sample taken from cervical cancer patients at time of diagnosis (baseline) and follow-up visits.
224268108|NCT03773653|BEHAVIORAL|BMT to be combined with BAT|Specifically, the participants will first receive 40 to 45 minutes of bilateral robotic priming using the BMT. After the robotic priming, participants will receive another 40 to 45 minutes training in tasks focusing on bilateral symmetric movements of both ULs.
224268109|NCT03773653|BEHAVIORAL|BMT to be combined with MT|Similar to the RT+BAT group, the participants will first receive 40 to 45 minutes of bilateral robotic priming delivered by the BMT with the same priming protocol. After bilateral robotic priming, participants will receive 40 to 45 minutes of mirror therapy.
224268110|NCT03773653|BEHAVIORAL|BMT to be combined with IOT|Similar to the RT+BAT group, the participants will first receive 40 to 45 minutes of bilateral robotic priming delivered by the BMT with the same priming protocol. After bilateral robotic priming, participants will receive 40 to 45 minutes of impairment-oriented training.
224268111|NCT06275542|DEVICE|Train of four monitoring device intraoperative|Only group B will receive reversal strategy based on the presence of TOF monitoring device prior to extubation. If they meet the criteria, patients will then be extubated.
223865677|NCT03632811|OTHER|A structured interview with every patient|The comprehension test will be done through structured interviews in which the principal investigator will ask if the patient has had difficulty understanding the recommendations and questions, will check the interpretation of all items and the understanding of each word by the patient. In case of problems, the investigator will propose and / or test translation alternatives, or will ask the patient to propose alternatives.
223865678|NCT05622123|DRUG|68Ga-NODAGA-Exendin-4|PET/CT imaging after injection with 68Ga-NODAGA-exendin-4
223865679|NCT01424397|DRUG|SB-705498|12mg intranasal
223865680|NCT01424397|DRUG|FP|200ug intranasal
223865681|NCT01424397|DRUG|placebo|placebo intranasal
223865682|NCT01340859|BEHAVIORAL|Post Admission Cognitive Therapy (PACT)|Individual psychotherapy; 60-90 minutes sessions; 6 sessions over preferably 3 days of inpatient stay
223865683|NCT01718041|DRUG|Experimental: VRS-317|Active treatment arm
223865684|NCT05898191|OTHER|vaginal laser treatment|non-ablative vaginal laser application
223865685|NCT03097679|DEVICE|Pulsar Stent|Percutane transluminal stent angioplasty with a Pulsar Stent of the superficial femoral artery for the treatment of peripheral arterial occlusive disease.
223865686|NCT03097679|DEVICE|LifeStent Flexstar Vascular Stent|Percutane transluminal stent angioplasty with a LifeStent Flexstar Vascular Stent of the superficial femoral artery for the treatment of peripheral arterial occlusive disease.
223865687|NCT02263573|OTHER|PEP'C-R|"Preliminary session of calibration and tolerance: Test of Borg: determination of VT1 for 10 minutes, 3 min pedaling at 25 W and then 20 minutes pedaling on VT1 determined during the exercise test (ET) -10%.~Session 1: 30 min of pedaling at constant load VT1 determined during exercise testing (EE) - 10%.~Session 2 Session 17: increase in the burden of BASE (5 BASE \* 5 min: 25 min) by 10% and decrease in relation to the load of the PIC (5 PIC \* 1 min: 5 min) to get a cumulative charge of the same session. Changes in heart rate (HR) determine the evolution of sustained loads: a decrease of 10 bpm in heart rate leads to an increase by 10% in the intensity of the base (PIC load remains constant).~Session 18 = Session 1."
223865688|NCT02263573|OTHER|Control group usual activities|Participants in the control group will not follow the intervention PEP'C-R. They will continue their usual activities for 9.5 weeks and will be assessed before and after this period. After the study, they will be offered the benefit of the conventional program of the PEP'C.
223865689|NCT04572945|DIAGNOSTIC_TEST|kidney function test|laboratory and imaging
223865690|NCT03753308|BIOLOGICAL|Blood Sampling|5 x Lithium Heparin Tubes WITHOUT DARK GREEN GEL, 5 ml- v. 4 ml Blood volumes collected as part of the usual care and this research comply with the recommendations of Jarde's law for an observational study (less than 80 ml in one day and less than 160 ml over 30 consecutive days for a subject over 40kg).
224268112|NCT06275542|DRUG|Neostigmine|For subjects in Group A, the first researcher calculated the time of the last administration of the muscle relaxant and the subject's spontaneous breathing efforts. Neostigmine was administered based on the reversal protocol. For subjects in the TOF monitoring group (Group B), the first researcher attached the TOF monitoring device. After it was attached and turned on, TOF stimulation was provided without calibration, with a stimulation intensity of 50 mA. Measurements were taken in a 12-second cycle mode. Neostigmine was administered according to the measured TOF value at the start of skin/muscle closure as the protocol.
224268113|NCT06275542|PROCEDURE|Air chalenge prior to extubation|After surgery was completed and the TOF ratio was ≥ 0.90, the TOF device was removed, and extubation was performed in Group B. In Group A, after a minimum of 15 minutes following reversal, patients received only ambient air without supplemental O2. Extubation was performed if the patient could maintain an SpO2 \> 95% for a minimum of 3 minutes. If within 15 minutes after reversal the patient did not meet the extubation criteria, the degree of blockade was reassessed, and a repeat dose of neostigmine and atropine was administered as needed. If there was suspicion of opioid-induced hypoventilation, naloxone was administered at 0.4-0.8 mcg intravenously.If the patient was unable to maintain oxygen saturation for the 3-minute duration, oxygen supplementation was reinstated, the degree of blockade was reassessed, and a repeat dose of neostigmine and atropine was administered as needed.
224268114|NCT06275542|DEVICE|Train of Four monitoring device in recovery room|Upon arrival in the recovery room, all subjects were fitted with SpO2, EKG, NIBP monitors, and the TOF monitoring device. TOF values were measured by a second researcher who was unaware of the type of intervention. Measurements were taken twice sequential
224268115|NCT04735172|OTHER|specific MRI Acquisition (NMR spectroscopy) at 7T|"The MRI protocol will be performed at 7T on a Siemens NMR imaging system (Magnetom Terra, Siemens Healthcare, Erlangen, Germany), the radio frequency emission and signal reception will be done through a head quadrature resonator (64-channel phase-array coil). To avoid motion-related artifacts, the patient will be seated in a supine position, with the arms along the body and the head immobilized using a suitable head restraint. The MR protocol will take place in two phases:~* Acquisition of 3D multi-slice T1 and T2-weighted morphological images to identify areas of interest;~* Acquisition of 1D RMN spectra in the right and left putamen and STN. Spectra will be acquired in volumes of interest of 15mmx15mmx15mm using a localized spectroscopy sequence with and without suppression of the water signal. Main parameters are: TR (repetition time)=3000ms; TE (echo time)=20 ms; number of repetitions=128; scan time 6min)."
224268116|NCT03426540|DRUG|Conbercept|Three-port 25-G PPV was performed in all patients using a Constellation system. Patients in the treatment group received an intravitreal injection of conbercept (10 mg/mL, 0.5 mg) using a sterile technique after 25-G vitrectomy.
224268117|NCT06179693|DIAGNOSTIC_TEST|Diagnostic accuracy|As per standard procedure, patients will undergo FDG PET. Following the PET exam it will be acquired a standard CT with intravenous contrast medium, using the CT tomograph inserted inside the PET one.
224268118|NCT03853096|DRUG|Cefazolin|Cefazolin 100mg/mL, 3mL in three locations will be administered around a surgical incision on the anterior shoulder in a standard deltopectoral approach interval. This will be a one time administration. Administration and route will be subcutaneous.
224268119|NCT04688515|BEHAVIORAL|Nutrition program developed using positive deviance approach|It is a 3-month nutrition program including nutrition education session and rehabilitation session. The education session consists of half hour education lesson and one and half hours peer-led cooking session. The cooking demonstration will be led by volunteers from PD family. Participating mothers will need to bring along their children during this session, prepare meal according to pre-planned menu and feed their children with the prepared meal after cooking as snack or additional meal. The rehabilitation session will be the rest of the days following each education session until the next education session. Growth monitoring session will also be conducted in each session, whereby mothers will be taught and trained to weigh their children.
224268120|NCT03247686|DRUG|RSLV-132|RNase Fc fusion protein
224268121|NCT03247686|DRUG|Placebo|Placebo
224268122|NCT05215938|DIAGNOSTIC_TEST|MRI examination|"The magnetic resonance imaging session will be performed in a clinical 3T MRI scanner (GE healthcare). A commercial human intent non-diagnostic RF coil (PulseTeq) will be used for 23Na MRI.~The scanner, coils and sequences are regularly used in research projects and validated for the same safety requirements as routinely used in the clinic. Nevertheless, the complete MRI session will be performed in research mode to use the advanced options (limits the usage to non-diagnostic purposes).~Participants will be placed in a supine position with coils covering the area of interest (AOF).~MRI examination will be performed by trained personnel."
224268123|NCT01487499|DRUG|Cisplatin|40 mg in 40 mL of normal saline for each of 4 bronchoscopies
224268124|NCT01006967|DEVICE|ActiveStep Treadmill|The ActiveStep treadmill is a device that trains patients to effectively react to simulated slips and trips while the patient is safely held in a harness.
224268125|NCT01006967|OTHER|Physical Therapy|Standard program of physical therapy for gait and balance
224268126|NCT02633241|DRUG|Dexmedetomidine bolus and high infusion-Propofol|First, the investigators will administer dexmedetomidine 1mcg/kg over 5 minutes. Next, the investigators will begin an infusion at 1mcg/kg/hour. At the 5 minute point, propofol will be given (2-3mg/kg bolus followed by 100mcg/kg/min infusion). The attending clinician will determine whether or not the child is in an adequate state to begin the MRI scan. If the sedative effect of the dexmedetomidine-propofol does not produce a sufficiently sedated state within 10 minutes, a repeat bolus of propofol 2mg/kg will be administered. The dose of Dexmedetomidine will not be changed. The dose will be repeated if the child is not adequately sedated in 2 more minutes. At this time infusion rate of propofol will be increased to 200 mcg/kg/minute. If the child is not sedated in 5 more minutes, the outcome will be recorded as a technique failure and sedation will continue at the discretion of the anesthesiologist.
223865691|NCT03753308|BIOLOGICAL|Liver biopsy|"The liver biopsy is part of the usual care and it follows the usual procedure of CHUGA:~The patient is placed in a supine position and received a transitory sedation, MEOPA gas (Kalinox®). Also, an ultrasound scan is performed. Local disinfection followed by local anesthesia with Xylocaine® are performed. The biopsy is performed with the Hepafix 17 gauge needle. 1 passage is carried out to obtain a biopsy fragment of at least 20 mm for the diagnosis (if the passage is unsuccessful, a second passage can be performed strictly as part of the usual care and not as part of research). If the biopsy is\> 20 mm, a fragment of the excess biopsy specimen (10% or 2 mm) will be cut and used for research in groups 1b and 2. This division is performed by the clinician directly on the fresh specimen"
223865692|NCT05279157|PROCEDURE|Implantation|Procedure: Implantation The ophthalmologist will carry out the implantation of the ADASCs cells with or without scaffold in the intrastromal cornea of the patient
223865693|NCT05279157|PROCEDURE|Lipoaspiration|"Procedure: Lipoaspiration The patient will have a liposuction surgery from which the autologous ADASCs implant in the cornea will be obtained.~Procedure: Implantation The ophthalmologist will carry out the implantation of the ADASCs with or without scaffold in the intrastromal cornea of the patient"
223865694|NCT01074788|BEHAVIORAL|mind body therapy|mind-body therapy includes guided imagery, relaxation techniques, mediation and touch therapy.
223865695|NCT00813657|BEHAVIORAL|Exercise|Women in the intervention group were enrolled in three sessions/week of individually supervised, resistance exercise training performed over the second and third trimester of pregnancy (in total 26 weeks, \~80 training sessions). Heart rate (HR) was carefully and individually controlled (≤80% of age-predicted maximum HR value, 220-age) through a heart rate monitor during the training sessions. In brief, each session consisted of 35-40 minutes of exercise divided in a light intensity (≤60% maximal heart rate) warm-up period (\~8 minutes), followed by toning and very light resistance exercises (\~20 minutes) and a light intensity cool-down (\~8 minutes) period. Resistance exercises were performed with barbells (≤3kg per exercise) or low-to-medium resistance bands (Therabands).
224268127|NCT02633241|DRUG|Dexmedetomidine bolus and low infusion-Propofol|First, the investigators will administer dexmedetomidine 1mcg/kg over 5 minutes. Next, the investigators will begin an infusion at 0.5mcg/kg/hour. At the 5 minute point, propofol will be given (2-3mg/kg bolus followed by 100mcg/kg/min infusion). The attending clinician will determine whether or not the child is in an adequate state to begin the MRI scan. If the sedative effect of the dexmedetomidine-propofol does not produce a sufficiently sedated state within 10 minutes, a repeat bolus of propofol 2mg/kg will be administered. The dose of Dexmedetomidine will not be changed. The dose will be repeated if the child is not adequately sedated in 2 more minutes. At this time infusion rate of propofol will be increased to 200 mcg/kg/minute. If the child is not sedated in 5 more minutes, the outcome will be recorded as a technique failure and sedation will continue at the discretion of the anesthesiologist.
224268128|NCT02633241|DRUG|Dexmedetomidine bolus only - Propofol|First, the investigators will begin by administering dexmedetomidine 1mcg/kg over 5 minutes. When this is completed, they will administer propofol 2-3mg/kg titrated bolus followed by 100mcg/kg/min infusion which can also be titrated up or down to a maximum of 300mcg/kg/min to keep the blood pressure and heart rate within 30% of baseline levels.
224268129|NCT06512519|OTHER|second allogeneic stem cell transplantation|"1. Change another donor if possible~2. Conditioning regimen: fludarabine (30mg/m2/day, days -6 to -2 ), cyclophosphamide (1g/m2/day, days -5 to -4)~3. GVHD prophylaxis: cyclosporine A (concentration 150-250ng/ml), mycophenolate mofetil (0.5g bid -3d to neutrophil engraftment)+anti CD25 monoAb (20mg -1d, +4d, +15d)"
224268130|NCT05453409|OTHER|No intervention|No intervention
224268131|NCT04485507|OTHER|Nature-VR|Viewing 360 degree nature pictures delivered by a virtual reality headset for 10 minutes/day, 5 days/week for 4 weeks (total of 200 minutes).
224268132|NCT04485507|OTHER|Urban-VR|Viewing 360 degree urban pictures delivered by a virtual reality headset for 10 minutes/day, 5 days/week for 4 weeks (total of 200 minutes).
224268133|NCT06126328|DEVICE|Materna Prep Device|Subjects are treated with Materna Prep Device prior to vaginal delivery
224268134|NCT04096651|OTHER|gait recordings|gait recordings
224268135|NCT04096651|OTHER|brain magnetic resonance imaging|brain magnetic resonance imaging
224268136|NCT04096651|OTHER|oculomotor movement recordings|oculomotor movement recordings
224268137|NCT06428851|OTHER|Laser therapy|Shoulder girdle muscles were lasered for 5 minutes a day, 3 days a week, total of 4 weeks.
224268138|NCT06428851|OTHER|Neuromuscular electrical nerve stimulation|Neuromuscular electrical nerve stimulation was applied to the shoulder flexor and abductor muscles for 20 minutes a day 5 days a week, total of 4 weeks.
224268139|NCT06428851|OTHER|Control|Classical physical therapy exercises were applied according to the patient's needs and neurologic level. These exercises are determined by the physiotherapist according to the functional status of the patient and consist of passive, passive assisted, active range of motion exercises, stretching and strengthening exercises, mobilization exercises 5 days a week for 1 hour, total of 4 weeks.
224268140|NCT03237117|BIOLOGICAL|Growth Hormone (GH)|to evaluate the effect of GH administration in the donated oocyte recipient program among women with RIF (repeated implantation failure)
224268141|NCT00001842|DRUG|Granulocyte colony-stimulating factor|
224268142|NCT00001842|DRUG|Dexamethasone|
224268143|NCT00003700|BIOLOGICAL|G-CSF|Courses I, II, IV, V: 5 ug/kg/d subQ injection Day 4 until ANC \> 5,000 uL after nadir: 7 day minimum for Courses I \& IV
224268144|NCT00003700|DRUG|asparaginase|6000 U/sq m subQ or IM injection 2X/wk for 6 doses starting on Day 5: Courses I \& IV
224268145|NCT00003700|DRUG|cyclophosphamide|1200 mg/sq m IV infusion over 15-30 min Day 1 Courses I \& IV (pts \< 60y/o) 1000 mg/sq m IV infusion over 15-30 min Day 1 Courses II \& V
224268146|NCT00003700|DRUG|cytarabine|2000 mg/sq m IV infusion over 3 hrs Days 1,2, \& 3: Courses II \& V
224268147|NCT00003700|DRUG|daunorubicin hydrochloride|80mg/sq m (pts\<60y/o)OR 60mg/sq m (pts =/\>60y/o) IV infusion over 5-10 min Days 1,2,\& 3: Courses I \& IV
224268148|NCT00003700|DRUG|leucovorin calcium|"Courses III \& VI:~25mg/sq m IV infusion Days 2, 9, and 16 5mg/sq m PO q 6 hr for 8 doses or until serum MTX \<0.05 uM after ea IV dose"
224268149|NCT00003700|DRUG|mercaptopurine|60mg/sq m/d PO every day Course VII
224268150|NCT00003700|DRUG|methotrexate|15mg intrathecal Day 1 Courses II \& V 1000mg/sq m IV infusion over 3 hrs Days 1, 8, \& 15 and 25mg/sq m PO q 6hr x 4 doses after ea IV dose: Courses III \& VI.
224268151|NCT00003700|DRUG|prednisone|60mg/sq m/day PO Days 1-21 (pts\<60y/o) OR Days 1-7 (pts \>/= 60y/o) Courses I \& IV and Days 1-5 of ea 4 cycle in Course VII
224268152|NCT00003700|DRUG|vincristine sulfate|2 mg total IV infusion Days 1,8,15,\& 22 Courses I \& IV and Days 1, 8, \& 15 Courses III \& VI, and Day 1 of ea 4 wk cycle in Course VII
224268153|NCT00003700|DRUG|Allopurinol|300mg PO q day Days 1-14 Course I
224268154|NCT01404962|BIOLOGICAL|Haemophilus influenza type b conjugate vaccine|Primary series is 3 doses given to infants beginning at 2 months of age with an interval of 2 months apart (i.e. 2, 4 and 6 months of age). Booster vaccination consists of 1 dose and is given to toddlers 16 to 20 months of age. In this study, subjects will receive vaccination from routine primary care.
224268155|NCT04043819|DRUG|PSC-01|PSC-01 is a form of autologous cellular therapy resulting from the enzymatic processing of lipoaspirate to yield adipose-derived stromal vascular fraction cells.
224268156|NCT02906813|DRUG|TAK-935 Tablets|Tablets
224268157|NCT02906813|DRUG|TAK-935 Oral Solution|Oral solution
224268158|NCT05735418|DIETARY_SUPPLEMENT|GI Biome #7|It comprises probiotics (Lactobacillus fermentum, Lactobacillus acidophilus, Lactobacillus plantarum, and Bifidobacterium animalis ssp. lactis) and prebiotics (vitamin B2., Korean red ginseng, and etc.). The administration dosage of probiotics is 5×10\^8 CFU/day.
224268159|NCT05735418|DIETARY_SUPPLEMENT|Placebo|The placebo consists of daily administration of the placebo pills made up of 100% maltodextrin for four weeks.
224268160|NCT00464113|DRUG|XL228|1-hour IV infusion
223865696|NCT05082636|OTHER|Observational Study ( Tissue Biopsy )|control study includes a total of 90 subjects. Of them 54 patients with early stage lung (stage I, II) cancer (Group 1) were selected from the Chest Department of Assiut University Hospital, besides 36 healthy controls; who were clinically suspicious with chest masses and proven histopathologically to be negative cancer (Group 2).obtained by fiberoptic bronchoscopy
223865697|NCT02437006|OTHER|exercise|cycle ergometry
223865698|NCT04833179|BIOLOGICAL|fecal transplant|"Healthy donors will be selected by the fecal transplant unit, in Tel-Aviv medical center. All donors will undergo a screening process that will include a detailed medical history, blood work and fecal tests. Only after passing the screening, the donor will be added to the groups of donors that will participant in this study.~The treatment will be givenin the form of fecal capsule. Each capsule will contain a double capsule with 2 layers to ensure that the fecal material will be contained. The treatments will include 30 capsules for the first treatment, that will be taken in two consecutive days, each day 15 capsules. The second, third and fourth treatments will all include 15 fecal capsules. There will be 2 weeks intervals between each treatment."
223865699|NCT04833179|OTHER|placebo|placebo
223865700|NCT05876949|BIOLOGICAL|AVT03|AVT03 will be given as 1 time subcutaneous injection
224268161|NCT03878264|DRUG|CORT118335 Oral|CORT118335 900 mg spray-dried dispersion in bottle and vehicle for oral administration
224268162|NCT03878264|DRUG|14C-CORT118335 intravenous|14C-CORT118335 solution for infusion 100 µg containing not more than 37 kiloBequerel (1 µCi) 14C
224268163|NCT03878264|DRUG|14C-CORT118335 oral|14C-CORT118335 oral solution 150 mg containing not more than 3.3 megaBequerel (90 µCi) 14C
224268164|NCT03495206|DRUG|Y-2(Edaravone And Borneol) Sublingual Tablet|Y-2 sublingual tablet at single ascending doses of one tablet , two tablets, three tablets, four tablets
224268165|NCT06200584|DRUG|Risperidone|Antipsychotic Agent
223865701|NCT05876949|BIOLOGICAL|Denosumab|Xgeva (denosumab) will be given as 1 time subcutaneous injection
223865702|NCT00746655|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|The first four patients will receive 50 Gy in 5 fractions (10 Gy /fx) over a 2 week period. The next four patients will be treated to a total dose of 60 Gy in 5 fractions (15 Gy/fx) over two weeks. The final four patients will receive 75 Gy in 5 fractions (15 Gy/fx) delivered over a 2-week period,
223865703|NCT00746655|PROCEDURE|Transcatheter Arterial Chemoembolization (TACE)|. Intra-arterial cisplatin treatment will be given at a dose of 125 mg/m2. After delivery of the drug(s) to the tumor, embolization will be accomplished with Embospheres (Biosphere Medical, Inc.,Rockland, MA, USA) until moderate to marked stasis of antegrade flow is seen in the artery.
223865704|NCT03644849|DEVICE|CO2RE® (Syneron Candela Corp, Wayland, MA)|The intervention will include a single treatment of a lower extremity wound with ablative fractional carbon dioxide laser after MMS surgery.
223865705|NCT03644849|OTHER|Sham laser treatment|A physician who is not blinded will perform a sham laser treatment on blinded subjects.
223865706|NCT03305536|DIETARY_SUPPLEMENT|Vitamin K2 (Menaquinone 7) + Vitamin D3|Vitamin K2 + Vitamin D3 arm will be compared with Vitamin D3 arm to slow of reverse the progression of the disease
223865707|NCT01346254|DRUG|Vildagliptin|50mg tablets once daily 20 min before breakfast for 3 months
223865708|NCT01346254|DRUG|Pioglitazone|30mg tablets once daily 20 min before breakfast for 3 months
223865709|NCT01346254|BEHAVIORAL|Life-Style Modification|All study participants were counselled regarding life-style modification including regular exercise, weight loss and diet.
223865710|NCT02460549|BEHAVIORAL|therapeutic education program|
223865711|NCT01109498|GENETIC|Alipogene Tiparvovec (AMT-011), Human LPL [S447X]|intra muscular, 1 x E12 gc per kg body weight, injected in a single series of intramuscular injections
223865712|NCT01109498|DRUG|Mycophenolate mofetil|oral, 2 g/day, day -3 till week 12
223865713|NCT01109498|GENETIC|Alipogene Tiparvovec (AMT-011), Human LPL [S447X]|intra muscular, 3 x E11 gc per kg body weight, injected in a single series of intramuscular injections
223865714|NCT01109498|DRUG|cyclosporine|oral, 3 mg/kg/day, day -3 till week 12
223865715|NCT02755805|BEHAVIORAL|CO-OP|
223865716|NCT02755805|BEHAVIORAL|Attention Control|
223865717|NCT04067219|PROCEDURE|DXA (dual-energy x-ray absorptiometric) measurement|DXA, evaluation of muscular function and muscle strength; neurocognitive tests; non invasive analysis of mechanical skin properties; food frequency questionnaire; laboratory assessment (25 hydroxy vitamin D, calcium/phosphate metabolism, bone remodelling markers, T cell activation).
223865718|NCT06160518|BEHAVIORAL|Virtual reality|artificial construction of 3D environment via mobile technology. It included a head-mounted device (HMD) with 3D-enabled goggles, sensory input devices and headphones, which together allow a multisensory experience to divert a child's attention.
223865719|NCT04043169|DIAGNOSTIC_TEST|Clearblue pregnancy test|Urine pregnancy test
224268166|NCT06200584|DRUG|Olanzapine|Antipsychotic Agent
224268167|NCT06200584|DRUG|Quetiapine|Antipsychotic Agent
224268168|NCT06200584|DRUG|Risperidone and Vitamin D and Vitamin E|vitamin
224268169|NCT06200584|DRUG|Olanzapine and Vitamin D and Vitamin E|vitamin and Antipsychotic agent
224268170|NCT06200584|DRUG|Quetiapine and Vitamin D and Vitamin E|Vitamin and Antipsychotic agents
224268171|NCT03102879|PROCEDURE|Regenerative Endodontic Procedure|Coronary access, conductometry, mechanized instrumentation, irrigation with sodium hypochlorite, intracanal calcium hydroxide medication and obturation with stem cells.
224268172|NCT03102879|PROCEDURE|Conventional Root Canal Treatment|Coronary access, conductometry, mechanized instrumentation, irrigation with sodium hypochlorite, intracanal calcium hydroxide medication and obturation with gutta-percha.
224268173|NCT00387608|DRUG|veliparib|
224268174|NCT00387608|OTHER|pharmacological study|
224268175|NCT00387608|PROCEDURE|biopsy|
224268176|NCT00508833|BIOLOGICAL|287615 containing HBsAg with adjuvants|
223865720|NCT03754036|BEHAVIORAL|Sleep manipulation|Participants will sleep their typical amount at home for 1 week and will then be randomized to either increase or decrease their time in bed by 1.5 hours per night for 1 week, completing the alternate schedule on the fourth week (washout period of 1 week between sleep conditions). This procedure will result in a targeted 3-hour time in bed difference between conditions. Sleep will be objectively measured using actigraphy (Actiwatch) and sleep schedule adherence will be promoted by providing fixed bedtimes and wake times during the experimental weeks, and will be monitored through phone calls to the research center.
223865721|NCT02334436|BIOLOGICAL|Botulinum toxin, Type A|Botulinum toxin, Type A
223865722|NCT02334436|OTHER|0.9% sterile, unpreserved saline|Placebo Comparator Arm
223865723|NCT03819166|DEVICE|with deep touch pressure application|The deep touch pressure is applied by the weight loading devices, including but not limited to, weight blanket and weight vest.
223865724|NCT03819166|DEVICE|without deep touch pressure application|The deep touch pressure will not be applied.
223865725|NCT01238874|DEVICE|Cardiac Resynchronization Therapy|All market-approved Medtronic CRT-D and CRT-P devices will be used in this study. All eligible devices are commercially released and will be used within their intended use per device labeling. The study may include future market-approved devices as they become commercially available. All market-approved leads may be used in the study. Epicardial leads may be used in the study.
223865726|NCT04380155|OTHER|Exercise|Moderate intensity cycling trials of different duration (30, 60 and 120 min)
223865727|NCT00483093|DRUG|NGR-hTNF|iv q3W escalating dose NGR-hTNF up to 1.6 mcg/sqm
223865728|NCT00483093|DRUG|Cisplatin|iv q3W 80 mg/sqm 30 minutes after NGR-hTNF infusion for a maximum of six cycles
223865729|NCT03045354|OTHER|Mashed potatoes|Isocaloric (450 kcal) breakfast treatments of eggs with a side of mashed potatoes
223865730|NCT03045354|OTHER|Traditional breakfast|Isocaloric (450 kcal) control breakfast treatments of cereal, milk, toast and jam
223865731|NCT03045354|OTHER|Breakfast skipping|No breakfast
223865732|NCT03045354|OTHER|French fries|Isocaloric (450 kcal) breakfast treatments of eggs with a side of French fries
223865733|NCT03045354|OTHER|Beans|Isocaloric (450 kcal) breakfast treatments of eggs with a side of beans
223865734|NCT04048668|DEVICE|Transcranial Direct Current Stimulation (tDCS)|tDCS is a non-invasive brain stimulation technique by which very small electrical currents (2 mA) are applied to the scalp.
224268177|NCT00754052|DRUG|Aricept (donepezil hydrochloride)|All participants will start with a dose of 2.5 mg/day (2.5 ml) donepezil ; dose escalation will occur every 2 weeks to a maximum of 5 mg/day (5 ml) donepezil. All doses will be administered orally.
224268178|NCT00754052|DRUG|Aricept (donepezil hydrochloride)|All participants will start with a dose of 2.5 mg/day (2.5 ml) donepezil ; dose escalations will occur every 2 weeks to a maximum of 10 mg/day (10 ml) donepezil. All doses will be administered orally.
224268179|NCT00754052|DRUG|Placebo|All participants will start with a dose of 2.5 mg/day (2.5 ml) placebo; dose escalations will occur every 2 weeks to a maximum of 10 mg/day (10 ml) placebo. All doses will be administered orally.
224268180|NCT04407832|DEVICE|heat probe or hemoclip|for hemostasis
224268181|NCT04407832|DEVICE|heat probe or hemoclip|for hemostasis
224268182|NCT03561987|PROCEDURE|Bariatric surgery|There are two components to the procedure. First, a small stomach pouch, approximately one ounce or 30 milliliters in volume, is created by dividing the top of the stomach from the rest of the stomach. Next, the first portion of the small intestine is divided, and the bottom end of the divided small intestine is brought up and connected to the newly created small stomach pouch. The procedure is completed by connecting the top portion of the divided small intestine to the small intestine further down so that the stomach acids and digestive enzymes from the bypassed stomach and first portion of small intestine will eventually mix with the food.
224268183|NCT01426087|DRUG|Somatostatin|giving stilamin 250ug/h after endoscopic therapy for 5 days
224268184|NCT01426087|PROCEDURE|endoscopic therapy|gastroscope plus EIS/EVL/HI
224268185|NCT03981978|BEHAVIORAL|Physical Activity|Self-report questionnaires assessing physical activity level.
224268186|NCT00909571|DRUG|FK506E (modified release tacrolimus)|oral
224268187|NCT00909571|DRUG|Prograf (tacrolimus)|injection
224268188|NCT01086228|DEVICE|XIENCE V / PROMUS stent|Patients receiving XIENCE V stent(s) or PROMUS stent(s) during their index procedure.
224268189|NCT02861651|OTHER|DNA sequencing|
224268190|NCT00316940|DRUG|bortezomib|
224268191|NCT00316940|RADIATION|samarium Sm 153 lexidronam pentasodium|
224268192|NCT02658019|DRUG|Pembrolizumab|Patients will be treated in three-week cycles, with intravenous (IV) administration of 200 mg of pembrolizumab on day 1 of each 3-week cycle.
224268193|NCT02751216|OTHER|EEG recording + pain protocol|
224268194|NCT04802213|OTHER|Rehabilitation exercise|Rehabilitation exercise use the methods that suggested by previous studies including finger wall climbing, pendulum exercise, and arms lifting.
224268195|NCT04802213|DEVICE|joint mobilization device treatment|The joint mobilization treatment used the mobilization device that developed in this research.It is a device developed by using the design of the vibration force generated by the vibration mechanism and the technologies to simulate the mobilization of the shoulder joint.When the subject uses the device, first sit on a seat that can be adjusted according to the user's body shape and buckle the shoulder fixation device. Then use the specially designed shoulder movement setting mechanism of the device to set the user's shoulder movement and movement angle.The next step is to set the direction and magnitude of the vibration force applied by the device to the shoulder joint in accordance with the joint mobilization technique (posterior, anterior, and inferior) that the therapist or user intends to perform to achieve the effect of simulating joint mobilization and increasing joint mobility.
224268196|NCT04802213|DEVICE|laser acupuncture device treatment|The laser acupuncture treatment use the laser acupuncture device that developed in this research. A gallium-aluminium-arsenide (GaAlAs, infrared laser) continuous wave diode laser device with a wavelength of 850nm (invisible), a power output of 100 mW, and a spot area of 0.07cm2 was used for laser acupuncture.When performing laser acupuncture treatment, the laser emitted by the device is irradiated on the selected acupuncture points .The acupuncture points (GB 21, LI 4, LI 11, LI 14, LI15, LI 16, SI 9, SI 10, SI 11, TE 14, and TE 15) were determined according to the literature regarding acupuncture application in shoulder pain based on traditional chinese acupuncture.
224268197|NCT03494686|PROCEDURE|LLETZ under local anaesthesia|Conization will be performed under local anaesthesia
224268198|NCT03494686|PROCEDURE|LLETZ under general anaesthesia|Conization will be performed under general anaesthesia
224268199|NCT00006434|BIOLOGICAL|tumor-pulsed dendritic cells|
224268200|NCT03145324|OTHER|Collection of vaccine histories|
224268201|NCT06285006|DRUG|Desmopressin|Desmopressin is a synthetic analogue of ADH released by the posterior pituitary gland that reduces urine production by increasing water reabsorption by the collecting tubules.
224268202|NCT01461291|DEVICE|iStent inject|Implantation of two GTS400 stents using G2-M-IS iStent inject
224268203|NCT01461291|PROCEDURE|Cataract surgery|Cataract surgery alone
224268204|NCT00697801|DRUG|MAP0010 low dose|a single dose of MAP0010 low dose delivered by nebulization twice daily for 6 weeks
224268205|NCT00697801|DRUG|MAP0010 high dose|a single dose of MAP0010 high dose delivered by nebulization twice daily for 6 weeks
224268206|NCT00697801|DRUG|Placebo|Placebo delivered by nebulization twice daily for 6 weeks
224268207|NCT04234555|DIAGNOSTIC_TEST|Corticomotor excitability to the pelvic floor muscles|Transcranial magenetic stimulation will be used to probe the excitability of cortical projections to the pelvic floor muscles. The outcomes of interest will include motor evoked potential amplitude and silent period.
223865735|NCT03050957|DIETARY_SUPPLEMENT|menthol|Alimentary bolus supplemented with menthol
223865736|NCT05254912|DRUG|6% Bemotrizinol in sunscreen formulation|6% Bemotrizinol (BEMT) in a basic sunscreen oil formulation (SU E 101413 85)
223865737|NCT05254912|DRUG|6% Bemotrizinol in petrolatum|6% Bemotrizinol (BEMT) as a dispersion in petrolatum (SU-E-101413-82)
223865738|NCT05254912|OTHER|Vehicle|Sunscreen oil vehicle with 10% ethanol as penetration enhancer without BEMT (SU E 101413 91)
223865739|NCT02252042|BIOLOGICAL|Pembrolizumab|200 mg intravenous (IV) on Day 1 of each 3-week cycle.
223865740|NCT02252042|DRUG|Methotrexate|40 mg/m\^2 IV (may be escalated to 60 mg/m\^2 maximum dose) on Days 1, 8, and 15 of each 3-week cycle
223865741|NCT02252042|DRUG|Docetaxel|75 mg/m\^2 IV on Day 1 of each 3- week cycle
223865742|NCT02252042|BIOLOGICAL|Cetuximab|400 mg/m\^2 IV loading dose on Day 1 and 250 mg/m\^2 IV on Days 8 and 15 of Cycle 1, followed by 250 mg/m\^2 on Days 1, 8, and 15 of each subsequent 3-week cycle.
223865743|NCT02189772|DRUG|Metadoxine extended release|MG01CI
223865744|NCT02189772|DRUG|Placebo|Inactive drug
223865745|NCT02273999|DEVICE|RecoveryRx™|Appliance of the device after surgery
223865746|NCT04942184|BEHAVIORAL|Memory strategies in Arm 1|Memory strategies will consist of daily at-home exercises lasting between 20 minutes to 1 hour depending on the memory tasks assigned to each participant. At the start of week 1 participants will be taught the memory strategies to use while completing the daily memory tasks. In week 1 and 2, subjects will be reminded daily to use the memory strategies. At the start of week 3, subjects will be advised to use the memory strategies however they will not be given daily reminders.
223865747|NCT04942184|DEVICE|Electroencephalogram (EEG) headset in Arm 1|A cap that measures brain activity using a 16-sensor wireless dry (no gel applied) EEG device designed by BrainWaveBank Ltd., that uses Bluetooth technology to securely transmit EEG signals to an Android tablet. The cap will be used during week 1,2,3 and 4.
224268208|NCT04234555|DIAGNOSTIC_TEST|Pelvic floor muscle response to pressure applied at the vulvar vestibule|Electromyography will be used to determine whether the pelvic floor muscles (PFMs) respond to pressure applied to the vulvar vestibule as anticipatory (i.e. PFMs are active before the pressure is applied) and as behavioural (i.e. PFMs are active after the pressure is applied) responses. The amplitude of the EMG responses will also be recorded.
224268209|NCT04234555|DIAGNOSTIC_TEST|Pressure pain threshold (PPS)|A custom vulvalgesiometer will be used to determine the mean pressure at which participants first report pain at the posterior vaginal fourchette.
224268210|NCT04234555|DIAGNOSTIC_TEST|Temporal summation of pain|A custom vulvalgesiometer will be used to apply the same pressure (rated as 4/10 duiring PPS testing as described above) to the vulvar vestibule across 10 repetitions. The difference in pain rated on the tenth application and that rated on the first application will be the outcome.
224268211|NCT04234555|DIAGNOSTIC_TEST|Tonic, phasic and reflex activation of the pelvic floor muscles (PFMs)|Electromyography will be used to measure the mean smoothed, rectified activation amplitude across 1 second of complete rest, across three maximal effort PFM contractions, and across three attempts at a bearing down maneuver.
224268212|NCT03816436|OTHER|Follow- up (FU) assessment|Follow- up (FU) assessment (clinical examination and patient questionnaires) at least 24 months after surgery (clavicular midshaft and lateral non- union treated by plate and iliac crest bone grafting)
224268213|NCT01518335|PROCEDURE|Platelet rich plasma injection|50ml of blood drawn into a 60cc with 10cc of anticoagulant is processed using MAGELLAN® Autologous Platelet (Arteriocyte Medical Systems, Cleveland Ohio)to separate out approximately 3-6 cc of platelet rich plasma, which is mixed with 1 cc of 1 % Lidocaine (xylocaine) and 1 cc of 0.25 % Marcaine (bupivacaine) and injected into the site of injury under USG guidance.
224268214|NCT01518335|PROCEDURE|Placebo Comparator: Placebo/Standard of Care|50ml of blood is drawn into a 60cc with 10cc of anticoagulant and is then discarded. 4 cc of saline solution is mixed with 1 cc of 1 % Lidocaine (xylocaine) and 1 cc of 0.25 % Marcaine (bupivacaine) and injected into the site of injury under USG guidance.
224268215|NCT00428818|DRUG|trimethoprim-sulfamethoxazole or doxycycline|
224268216|NCT04364854|BEHAVIORAL|SET (Speech Entrainment Therapy) 3 weeks|3 weeks of SET which consists of practicing fluent speech in real time with an audio-visual computer program
224268217|NCT04364854|BEHAVIORAL|SET (Speech Entrainment Therapy) 4.5 weeks|4.5 weeks of SET which consists of practicing fluent speech in real time with an audio-visual computer program
224268218|NCT04364854|BEHAVIORAL|SET (Speech Entrainment Therapy) 6 weeks|6 weeks of SET which consists of practicing fluent speech in real time with an audio-visual computer program
224268219|NCT04364854|OTHER|No Therapy 6 Weeks|Participants will not be getting any SET for 6 weeks
224268220|NCT01422928|PROCEDURE|Medical Acupuncture|"Subjects will be asked to report symptom concerns. Subjects are requested to wear loose clothing as most acupoints lie at or distal to the elbow and knee.~Sterile single use steel needles (ITO Adiquip 0.25 x 4.0 cm) will be inserted to a depth of 1 - 2 cm at acupoints thought to impact positively on the immune system. An ITO ES-160 Electrostimulator will be used to mimic the pecking technique of manual stimulation. Following needle insertion by the acupuncturist, a nurse or acupuncture student may assist by attaching electrodes to provide electrical stimulation. A 0.3 ms duration, 4 HZ, alternating current will be delivered with voltage set just below the pain threshold of the patient. After 20 minutes, the needles will be removed. Acupoints will include:~* GV.14~* LI.11 (bilateral)~* SP.6 (bilateral)~* SP.10 (bilateral)~* ST.36 (bilateral)~Additional points may be added based on the symptom concerns reported."
224268221|NCT00781430|DRUG|Neratinib (HKI-272)|Neratinib 40-mg oral tablets. SINGLE DOSE of 120-mg (3 x 40-mg tablets)
224268222|NCT05692882|DEVICE|Drug-Eluting Stents|The NOVA stent is a sirolimus-eluting stent system designed for intracranial artery stenosis with a rapid exchangeable balloon
224268223|NCT03993535|DRUG|selective serotonin reuptake inhibitor|open treatment based on patient preference and treatment availability
224268224|NCT06149767|DRUG|Adebrelimab|"The medication regimen for all enrolled patients is as follows, and the dose can be adjusted during treatment due to adverse reactions and other circumstances:~Adebrelimab : 20 mg/kg, D1, intravenously, 30-60 min, Q3w. Paclitaxel for Injection: 150 mg/m2, D1 Cisplatin: 50 mg/m2, IV, D1, Q3w. Radiotherapy: pelvic dose: 6MV-X, 180cGy/ times 27 times; Brachydose: 192Ir, 700cGy/ time 4 times.~First of all, after 2 cycles of concurrent chemoradiotherapy, the sequential chemotherapy combined with adbalizumab for 2-4 cycles, and the subsequent investigators selected Adbalizumab or other drugs to maintain the treatment according to the patient's situation or the patient's own will until the disease progressed or intolerable toxicity occurred or the subjects voluntarily withdrew from the study.adebrelimab until disease progression or intolerable toxicity or the subject voluntarily withdrew from the study。"
224268225|NCT01135784|DIETARY_SUPPLEMENT|MIGRA-ZEN RELIEF PLUS|one 2-capsule dose per 24hrs for a total of 180 caps over 90 days
223865748|NCT04942184|OTHER|Tablet in Arm 1|A computer tablet will be provided to each participant that will have daily reminders about the memory strategies during week 1 and 2, while no reminders will be present in week 3 and 4. The tablet software includes a user-friendly interface that provides feedback and instructions that help the participant properly wear the EEG headset. At the end of each session the tablet stores behavioral and EEG data on a secured server accessible by the research staff.
223865749|NCT04942184|BEHAVIORAL|Memory strategies in Arm 2|Memory strategies will consist of daily at home exercises lasting between 20 minutes to 1 hour depending on the memory tasks assigned to each participant. During weeks 1 and 2, participants will be completing the memory tasks without being instructed to use any specific strategy. At the end of week 2 subjects will be taught the memory strategies and during week 3 and 4, they will be reminded daily to use the memory strategies while completing the memory tasks.
223865750|NCT04942184|DEVICE|Electroencephalogram (EEG) headset in Arm 2|A cap that measures brain activity using a 16-sensor wireless dry (no gel applied) EEG device designed by BrainWaveBank Ltd., that uses Bluetooth technology to securely transmit EEG signals to an Android tablet. The cap will be used during week 1,2,3 and 4.
223865751|NCT04942184|OTHER|Tablet in Arm 2|A computer tablet will be provided to each participant. During week 3 and 4, the tablet will present daily reminders to use memory strategies while completing the memory tasks. The tablet software includes a user-friendly interface that provides feedback and instructions that help the participant properly wear the EEG headset. At the end of each session the tablet stores behavioral and EEG data on a secured server accessible by the research staff.
223865752|NCT02593149|DEVICE|ClearGuard HD End Cap|The ClearGuard HD end cap elutes chlorhexidine acetate into the hemodialysis hub
223865753|NCT01988649|DRUG|Intranasal Oxytocin|Administration of intranasal Oxytocin
223865754|NCT01988649|DRUG|Placebo (saline)|Administration of normal saline intranasally.
223865755|NCT00989469|DRUG|Nexavar (Sorafenib) and irinotecan (Campto)|Sorafenib administrated continuously orally 400 mg twice daily (a daily total dose of 800 mg). Irinotecan 180 mg/m² will be administered IV for 90 minutes every 2 weeks. The first dose of sorafenib will be administered after the first perfusion of irinotecan 180 mg/m² at the first infusion
224268226|NCT01135784|DIETARY_SUPPLEMENT|Placebo for Migrazen relief plus|2 capsule dose per 24 hours for 90 days
224268227|NCT05779527|BEHAVIORAL|Mindful Parenting Programme|Online Mindful Parenting Programme with group support sessions
223865756|NCT00043966|DRUG|Lopinavir/ritonavir|
223865757|NCT00043966|DRUG|Tenofovir DF|
223865758|NCT00043966|DRUG|Emtricitabine|
223865759|NCT02345174|DRUG|GSK2849330|GSK2849330 solution (100 mg/mL) for infusion diluted in 0.9% sodium chloride to the appropriate concentration for the dose.
224268228|NCT03814850|DEVICE|Standard Manual Aneroid Sphygmomanometer|Use of a standard manual blood pressure cuff and manometer for the conditioning intervention.
224268229|NCT02777307|OTHER|Hemopatch Sealing Hemostat|Place of Hemopatch Sealing Hemostat after laparoscopic cholecistectomy
223865760|NCT02345174|DRUG|89Zr-GSK2849330|89Zr-GSK2849330 solution for intravenous administration diluted with GSK2849330 Solution for Infusion (unlabelled GSK2849330) with a target radioactivity of 37MBq and a total antibody concentration of 0.4 mg/mL or 1.2 mg/mL.
223865761|NCT02474238|DEVICE|The sequential technique|By using 'the double frequency YAG laser' to make the initial bore and 'the Nd:YAG laser' to complete the perforation on iris.
223865762|NCT02474238|DEVICE|The pure Nd:YAG laser technique|By using 'the pure Nd:YAG laser' to make a complete perforation on iris.
223865763|NCT01571557|DRUG|dexamethasone 700 ug intravitreal implant|dexamethasone 700 ug intravitreal implant administered according to standard of care.
223865764|NCT02379715|DRUG|Remifentanil|
223865765|NCT02379715|DRUG|Desflurane|
223865766|NCT06267131|DEVICE|Brain Pulse Oximeter|Sensor is placed on the right and/or left forehead and maintained with an elasticized headband. The duration of monitoring will last for approximately 60 minutes per monitoring session to obtain sufficient data. Serial monitoring will occur on three consecutive days.
223865767|NCT05919368|DIETARY_SUPPLEMENT|Yam pill|It consists of sweet potato, white art and ginseng
224268230|NCT05920395|OTHER|Electro-acupuncture|Patients lie supine on the treatment bed, and after routine disinfection, a 0.30×60mm or 0.30×40mm disposable sterile acupuncture needle is inserted directly into the acupoint. Once obtaining qi, the needle is manipulated with even reinforcing and reducing techniques to maintain needle sensation. Acupoints selected include Zhongwan, Zusanli, Neiguan, and Tianshu, connected to the 6805-All electro-acupuncture therapy device. Zhongtuo and Tianshu acupoints are connected to a set of electrodes, with the positive pole connected to Zhongtuo and the negative pole connected to one side of Tianshu. The stimulation uses sparse and dense wave pulses with a frequency of 2Hz/100Hz, with the stimulation intensity determined based on individual patient tolerance. Each session lasts for 30 minutes, with a treatment frequency of once every other day, for a total of 4 weeks.
224268231|NCT05920395|OTHER|Sham electro-acupuncture group|Shallow acupuncture needles are used and then disconnected from the electrode. They are tied with black tape and connected to the sham electrode. The device is not powered on, and the rest of the treatment is the same as the electro-acupuncture group.
224268232|NCT00301886|DRUG|ibandronate|
224268233|NCT00301886|DRUG|zoledronate|
224268234|NCT00301886|PROCEDURE|quality-of-life assessment|
224268235|NCT02041013|OTHER|Taking Card|Recordable greeting card-style discharge instruction card
224268236|NCT02973906|OTHER|ADAPT Self Directed web|In the self-directed web-only ADAPT condition, participants have access to the full ADAPT website (10 modules, online discussion forum
224268237|NCT02973906|OTHER|ADAPT individualized web-facilitated|This condition comprises access to the full ADAPT web program as described above, with augmentation of individual facilitator web support (i.e. the facilitator connects via Google Hangout). Facilitators meet with families at a mutually convenient time weekly (10-14 weeks, approximately 3 sessions per month).
224268238|NCT02973906|OTHER|Group-based ADAPT|Groups will meet weekly for 120 minutes, at a time convenient to participants (usually early evening). Groups cover core ADAPT/PMTO topics:
224268239|NCT00258687|BIOLOGICAL|GVAX|4 vaccines every two weeks
224268240|NCT00504062|DRUG|budesonide|
224268241|NCT00504062|DRUG|fluticasone|
224268242|NCT02435433|DRUG|Ramucirumab|Administered IV
224268243|NCT02435433|DRUG|Placebo|Administered IV
224268244|NCT02599662|RADIATION|10 Gy Low-KV IORT|: intraoperative low-kV IORT will be delivered as a single dose of 10 Gy at 2 millimeter depth. Doses will be escalated in increments of 5 Gy until completion of 20 Gy dose level or the DLT is reached and MTD is realized.
224268245|NCT02599662|RADIATION|15 Gy Low-KV IORT|intraoperative low-kV IORT will be delivered as a single dose of 15 Gy at 2 millimeter depth. Doses will be escalated in increments of 5 Gy until completion of 20 Gy dose level or the DLT is reached and MTD is realized.
224268246|NCT02599662|RADIATION|20 GY Low-KV IORT|intraoperative low-kV IORT will be delivered as a single dose of 20 Gy at 2 millimeter depth. Patients will be accrued to this group until the DLT is reached and MTD is realized.
224268247|NCT00757705|DRUG|Paliperidone ER|Participants will receive paliperidone ER tablet in dose range of 3 to12 milligram (mg) per day orally once daily for 24 weeks as per Investigator's discretion based on the individual participant's clinical response to and tolerability of the study drug.
224268248|NCT04483349|OTHER|Survey Administration|Complete survey
224268249|NCT04346680|PROCEDURE|ADSC administration|The treated nerve will be identified and released. Scar tissue will be removed, and nerve fibers will be exposed. Prepared solutions of ADSC will be administered via microinjection with a 30-G needle along the released nerve fascicles, above and below the reconstructed area and around the adjacent tissue, which stayed in contact with the nerves.
224268250|NCT03242980|BEHAVIORAL|Structured adherence counseling|"Patients will undergo one standardized enhanced adherence counselling session. Counselling guidelines and a brochure were specifically developed to guide the adherence counselling for individuals with unsuppressed VL. All nurses at the health centres will be trained on the counselling prior to the cross-over to the intervention. The brochure was developed by culturally adapted by social scientists and contains only 3 key messages. The brochure will be given to the patient to take home.~Four weeks after the adherence counselling session, a SMS will be sent to the patient reminding them to take their ART. The content of the text message will be anonymous to protect disclosure and discussed/agreed upon with the patient during the adherence counselling."
224268251|NCT03400774|OTHER|Stair-climbing|Short bouts of moderate intensity stair-climbing
224268252|NCT04537520|DEVICE|Kerecis Omega3 Wound|Treatment of the wound with Kerecis Omega3 Wounds matrices
224268253|NCT05039541|DEVICE|Alio Device|Subjects will wear the Alio device over their vasculature.
223865768|NCT06107959|OTHER|Pre-surgical nutrition, hydration, RMR, and body composition assessments|Urine sample, InBody device platform, Metabolic cart with hood to collect RMR.
223865769|NCT06107959|OTHER|Post-surgical nutrition, hydration, RMR and body composition assessments|Same as pre-surgical tests at 1 week, 3 weeks, 6 weeks, and 12 weeks follow up time points.
223865770|NCT05048251|DEVICE|cTBS|continuous theta burst stimulation
223865771|NCT05048251|DEVICE|iTBS|intermittent theta burst stimulation
223865772|NCT05048251|DEVICE|sham|sham stimulation
223865773|NCT01057758|DRUG|SIMVASTATIN|Patients will receive 60 mg of study drug daily by mouth or feeding tube for 28 days or until discharged from the study ICU.
223865774|NCT01057758|DRUG|PLACEBO|Patients will receive one placebo by mouth or feeding tube daily for 28 days or until discharged form study ICU
223865775|NCT01269749|RADIATION|RAI treatment|Characteristics of study population. We will recruit a total of 150 patients diagnosed with GD younger than 18 years of age. All subjects are to be treated with 131I. In this trial, children will not be randomized to treatment, but will be treated per physician prescribed care. To ensure an equal distribution of age and gender between the two groups of children, we stratify enrollment by gender (male vs. female) and age (5-10 yrs, 10-15 yrs, 15-18 yrs).
224268254|NCT05493358|PROCEDURE|Laparoscopic distal gastrectomy|Distal gastrectomy and standard D2 lymphadenectomy
224268255|NCT01389713|DRUG|Clomifene Citrate|3x50 mg die for 5 days from day 3 to day 7 of the menstrual cycle
224268256|NCT01389713|DRUG|GnRH analog and recombinant human FSH|daily subcutaneous 0.1 mg decapeptyl from day 1-2 of the menstrual cycle and recombinant human FSH 450 IU/die from day 3.
224268257|NCT00659815|DEVICE|Bausch & Lomb ReNu MultiPlus Multi-Purpose Solution Packaged in the Currently Marketed Resin Bottle.|Daily care for contact lenses.
224268258|NCT00659815|DEVICE|Bausch & Lomb ReNu MultiPlus Multi-Purpose Solution Packaged in a Clear Resin Bottle.|Daily care for contact lenses
224268259|NCT02783287|BEHAVIORAL|Text message reminder for medication adherence|Patients randomized to this arm receive one text message per day (at the scheduled time) reminding them to take their medication.
224268260|NCT02783287|BEHAVIORAL|Text message reminder for exercise regimen|Patients randomized to this arm receive 4 daily text messages reminding them to exercise for 30 minutes per day.
224268261|NCT01710358|DRUG|Adalimumab|Administered SC
224268262|NCT01710358|DRUG|Baricitinib|Administered orally
224268263|NCT01710358|DRUG|Methotrexate|Administered orally
224268264|NCT01710358|DRUG|Adalimumab Placebo|Adalimumab placebo administered SC.
224268265|NCT01710358|DRUG|Baricitinib Placebo|Baricitinib placebo administered orally.
224268266|NCT03563794|DRUG|CSII+Vildagliptin|Vildagliptin(50mg b.i.d po.) will be added to Continuous Subcutaneous Insulin Infusion(insulin Lispro) treatment in T2DM. Doses of insulin Lispro will be instructed on a titration schedule, adjusted every 2 days.
224268267|NCT03563794|DRUG|CSII(insulin Lispro)|T2DM patients will receive Continuous Subcutaneous Insulin Infusion(insulin Lispro) treatment. Doses of insulin Lispro will be instructed on a titration schedule, adjusted every 2 days.
224268268|NCT06038318|BEHAVIORAL|PRISM Program Video Coach|A 6-session, skills-based, manualized resilience education program delivered via video coaching by trained English or Spanish speaking PRISM coaches. Participants will have complete access to the PRISM Program mobile app. Sessions will be delivered by a HIPAA compliant videoconferencing platform, Zoom, approximately every 1-2 weeks based on participant preference. For participants who do not have smartphones, temporary equipment will be provided.
224268269|NCT06038318|BEHAVIORAL|PRISM Program Text Coach|A 6-session, skills-based, manualized, resilience education program delivered via text coaching by trained English or Spanish speaking PRISM coaches. Participants will have complete access to the PRISM Program mobile app. Sessions will be delivered by HIPAA compliant SMS text-messaging service, Zoom, approximately every other week. For participants who do not have smartphones, temporary equipment will be provided.
224268270|NCT06038318|BEHAVIORAL|mPRISM Program App|6 static modules to practice skills-based, manualized, resilience education program delivered via PRISM Program mobile app. For participants who do not have smartphones, temporary equipment will be provided.
224268271|NCT06204939|PROCEDURE|Randomizing for EPGB procedure|"Classic gastric bypass with 2 anastomoses but with an extended pouch of 12-15cm and a biliary limb of 150cm.~Patients will be single blinded randomized for one of the two procedures. 125 patients will undergo EPGB and 125 patients will undergo OAGB.~Pre-operatively, 6 months post-op and yearly post-op we will collect: weight, complications, revisions, comorbidities, blood samples and questionnaires."
224268272|NCT06204939|PROCEDURE|Randomizing for OAGB procedure|"Gastric bypass with 1 anastomosis and an extended pouch of 12-15cm and a biliary limb of 150cm.~Patients will be single blinded randomized for one of the two procedures. 125 patients will undergo EPGB and 125 patients will undergo OAGB.~Pre-operatively, 6 months post-op and yearly post-op we will collect: weight, complications, revisions, comorbidities, blood samples and questionnaires."
224268273|NCT05740748|DRUG|Tezepelumab|tezepelumab 210 mg sc q4wks for 20 weeks
224268274|NCT05740748|DRUG|Placebo|placebo sc q4wks for 20 weeks
224268275|NCT04707846|DEVICE|Bright Blue Light Commercial AYO Light Therapy Device|"AYO light therapy glasses are a commercially available device which have 4 Light-emitting diodes (LEDs) with a dominant wavelength of approximately 470nm ± 2nm and typical irradiance (100% intensity) of approximately 250 µW/cm². AYO bright light glasses are classified as exempt for photo-biological risk based on the international standard and conformity assessment for photo-biological safety of lamps (IEC 62471)."
224268276|NCT04707846|DEVICE|Dim Blue Light Commercial AYO Light Therapy Device|"AYO light therapy glasses were made available to the research team by the vendor. The device has 4 Light-emitting diodes (LEDs) with a dominant wavelength of approximately 470nm ± 2nm and reduced irradiance (1% intensity) of approximately 250 µW/cm². AYO dim light glasses are classified as exempt for photo-biological risk based on the international standard and conformity assessment for photo-biological safety of lamps (IEC 62471)."
224268277|NCT01272024|BEHAVIORAL|Symptom Education|Participants are given a Symptom Education Toolkit at baseline and at each visit thereafter (1 month and 3 month) are encouraged to use the Toolkit for symptoms they are experiencing. They are also encouraged to use resources available to them.
223865776|NCT01269749|DRUG|ATD Group|Characteristics of study population. We will recruit a total of 150 patients diagnosed with GD younger than 18 years of age. All subjects are to be treated with antithyroid drugs (ATDs). In this trial, children will not be randomized to treatment, but will be treated per physician prescribed care. To ensure an equal distribution of age and gender between the two groups of children, we stratify enrollment by gender (male vs. female) and age (5-10 yrs, 10-15 yrs, 15-18 yrs).
223865777|NCT02671344|OTHER|Determination of gene profiles using arrays semen|Determination of gene profiles characterizing the set of mRNA and functional interpretation of the resulting list of genes.
223865778|NCT04889131|BEHAVIORAL|Yoga Program Immediately|free 12 week yoga program, twice a week for 75 minutes each
223865779|NCT04889131|BEHAVIORAL|Wait-Listed Control|assigned to take the Yoga Program in 12-weeks
224268278|NCT01272024|BEHAVIORAL|Intervention|Participants are visited/contacted by an intervention nurse ten times over a 12-week period for the purpose of helping them to manage uncertainty and distress,to boost their problem-solving skills, and to transition to treatment.
223865780|NCT04889131|OTHER|Activity Monitor|Garmin VivoSmart activity monitor throughout study
223865781|NCT02462369|DRUG|Saxagliptin|
223865782|NCT02462369|DRUG|glimepiride|
223865783|NCT02100371|DRUG|BMS-833923|BMS-833923, by mouth, at the dose and schedule administered while enrolled in CA194002.
223865784|NCT03547479|BEHAVIORAL|VDOT|In VDOT, reminder notifications are sent x minutes prior to the scheduled pill time, and continue every y minutes until the user sends a video of themselves taking their pill via the app. Instructions will be provided in Khmer. The web system has an administrator component whereby a healthcare provider can log in via the Internet to monitor and validate all the videos received that day, and reasons for non-submission.
223865785|NCT03547479|BEHAVIORAL|VDOT + mobile money|The VDOT intervention above will be paired with financial incentives in the form of mobile payments in one of the experimental arms.
224268279|NCT04697316|DEVICE|Transcranial Direct Current Stimulation|To stimulate the left DLPFC, the anode electrode will be placed over F3 and the cathode will be placed over F4. Each stimulation will be applied for 20 min at 2mA intensity.
224268280|NCT04697316|DEVICE|Sham|For the sham treatment, stimulation will be stopped after 30 seconds. Current will be renewed five times throughout the session for 2 seconds each time, to mimic the tDCS stimulation.
223865786|NCT02353988|DRUG|Bicalutamide|"Patients in experimental group are designated to take bicalutamide orally, 150mg on a continuous schedule. The investigator should pay attention to the patients' adverse event. Every month, the patients will be evaluated for the adverse event by the criterion National Cancer Institute Common Toxicity Criteria (NCI-CTC) version 3.0. Every 2 months, the patients will be evaluated for the clinical effects. If disease progressed, the patients would be ruled out.~Treatment continued until disease progression, unacceptable toxic effects, patient or physician request to discontinue, or serious protocol non-compliance. A maximum of 2 dose reductions for grade \>= 3 toxicity were allowed (100 and 50 mg). A maximum of 2 weeks was permitted for treatment delays due to toxicity."
223865787|NCT02353988|OTHER|Physician's Choice|"The comparator group, treatment of physician's choice (TPC), represented a mix of agents (both approved and non-approved for metastatic breast cancer) to mirror clinical practice at the time in this setting.~The 60 patients are enrolled in the study, before randomized to the two arms, each of them will be assessed for eligibility and then their proposed TPC.~Treatment continued until disease progression, unacceptable toxic effects, patient or physician request to discontinue, or serious protocol non-compliance."
223865788|NCT02658240|DRUG|Ropivacaine|Ropivacaine 300 mg and 0.5 mg epinephrine diluted to 60 mL
223865789|NCT02658240|DRUG|Epinephrine|0.5 mg epinephrine
224268281|NCT06086314|DEVICE|reactive exercise training with ''FitPodz Light Trainer'' device in addition to a neurorehabilitation program|Attending the neurorehabilitation program that includes scapula mobilization, trunk elongation training in sitting, and training lumbar stabilizers with bridge activity. Reaching forward and touching the sensor when the red light sensor is on, and withdrawing his/her hand as soon as the sensor goes out.
223865790|NCT03691428|BEHAVIORAL|Wish Outcome Obstacle Plan|"1\. Wish or goal: A wish (e.g. responding calmly when the partner asks a question repeatedly). 2. Outcome: The most positive outcome of realizing the wish or goal (e.g. both partners feel respected and happy). Then the participant vividly imagines the outcome. 3. Obstacle: The most critical internal, controllable, obstacle (e.g., feeling impatient). Then the participant vividly imagines the internal obstacle occurring. 4. Plan: The participant answers the following question: What action can I take or what thought can I think to overcome the obstacle (e.g., take a deep breath, take my partner's perspective, and answer the question calmly); then he or she forms an if \[specified obstacle - when I feel impatient\], then I will \[specified action or thought to overcome obstacle - take a deep breath, take my partner's perspective, and answer the question calmly\] plan."
223865791|NCT02527148|DEVICE|OtisMed® ShapeMatch® Technology|The appropriate Stryker ShapeMatch® Cutting Guides will be used to guide the surgeons bone resections. The surgeon will implant the knee prostheses following the surgical protocol for Triathlon® Knee System with OtisMed® ShapeMatch® Technology
223865792|NCT02527148|DEVICE|Stryker Precision Knee Navigation|Stryker PrecisioN Knee (4.0) Navigation System, comprising of computer hardware and software and associated instrumentation, will be used for intra-operative alignment and orientation of implant. Navigation trackers will be secured to the femur and tibia and registration of the limb will be undertaken according to the PrecisioN Knee System surgical technique.Femoral and tibial resections, followed by device implantation, will be performed according to the Triathlon Knee System Surgical Protocol.
223865793|NCT02527148|PROCEDURE|Total Knee Replacement|
223865794|NCT02527148|DEVICE|Stryker Triathlon® Total Knee System|"Prosthetic components to be implanted including~* Triathlon® Cruciate Retaining (CR) Total Knee System (cemented), including Femoral Component and Primary Tibial Baseplate;~* Triathlon® Cruciate Substituting (CS) X3® polyethylene insert;~* Triathlon® X3 Patella (asymmetric) - treated selectively by surgeon."
223865795|NCT04805996|BEHAVIORAL|Diabetes remission using total diet replacement and eHealth contact with the healthcare provider|Participants will replace usual foods with the commercially available total diet replacement Modifast (Impolin AB), which is delivered to them during the study period without any cost. Participants will be supplied with a scale, a finger-stick blood glucose meter and a blood pressure monitor and will be advised to measure body weight, fasting blood glucose and blood pressure every morning. The results are registered in the mobile phone application Telia Health Monitoring (Telia Sweden AB) and are wirelessly transmitted to the study team.
223865796|NCT01881386|DEVICE|Magnetic Resonance Imaging (MRI)|Magnetic Resonance Spectroscopy
223865797|NCT06357819|DEVICE|INSTI HCV Self Test|Each participant was provided with contrived INSTI membrane units by the study observer, in random order, and was asked to interpret the results using the INSTI HCV ST Instructions for Use.
223865798|NCT06554860|OTHER|scapular Blackburn stabilization plus exercise|scapular Blackburn stabilization
223865799|NCT06554860|OTHER|PNF plus Exercise|PNF plus Exercise
223865800|NCT06554860|OTHER|exercise only|Exercise only
224268282|NCT06086314|DEVICE|reactive exercise training with co-contraction with ''FitPodz Light Trainer'' device in addition to a neurorehabilitation program.|Attending the neurorehabilitation program that includes scapula mobilization, trunk elongation training in sitting, and training lumbar stabilizers with bridge activity. Reaching forward and touching the sensor when the green light sensor is on, and holding his/her hand on the sensor for 5 seconds and then withdrawing it.
224268283|NCT06086314|OTHER|neurorehabilitation program with functional reaching training without device.|Attending the neurorehabilitation program that includes scapula mobilization, trunk elongation training in sitting, and training lumbar stabilizers with bridge activity. Doing functional stretching to the anterior, right and left while standing.
224268284|NCT00002923|DRUG|KRN5500|
224268285|NCT01013818|DRUG|HGS1029|HGS1029 will be given as a 15-minute IV infusion (in the vein) once weekly for 3 consecutive weeks, followed by 1 week off.
224268286|NCT02297230|RADIATION|Radiation Therapy (RT)|Concurrent RT (to start within one week from first dose of Paclitaxel/Trastuzumab) to breast, supraclavicular, axillary fields, 45 Gy @ 1.8 Gy/fraction, + 14 Gy @ 2 Gy/fraction to the primary tumor. At the end of chemo-radiation, Trastuzumab will be continued weekly until surgery and as per standard of care after surgery for up to 1 year total.
224268287|NCT02297230|DRUG|Capecitabine|Capecitabine (Xeloda®) 750 mg/m2 twice/daily given orally. Treatment should begin on day 1 of radiation therapy. The two doses should be taken about 30 minutes after eating (eg. after breakfast and after dinner). Treatment will be given for 10 weeks (for 6 weeks during radiation and for 4 weeks after radiation).
224268288|NCT02297230|DRUG|Trastuzumab|Trastuzumab (Herceptin®) treatment will be administered weekly, together with one of the two weekly doses of Paclitaxel. The first dose will be 4mg/kg given IV over 90 minutes. Subsequent weekly doses will be given at a dose of 2 mg/kg/week IV over 30 minutes. The treatment with Trastuzumab will continue weekly after the completion of the radiation treatment until surgery and thereafter as per standard of care up to 1 year post surgery.
224268289|NCT02297230|DRUG|Paclitaxel|Paclitaxel 30 mg/m2 twice per week given IV over 1 hour. Treatment will be administered on a Monday/Thursday or Tuesday/Friday schedule.The radiation treatment will start within 1 week from the first dose of paclitaxel and trastuzumab. Pre-meds for paclitaxel should be based on the institutional standards; it is suggested that dexamethasone (Decadron®), 20 mg IV, be given with the first paclitaxel dose. If the patient tolerates the treatment, the dexamethasone may be tapered and/or discontinued for subsequent doses. Treatment will be given for 10 weeks (for 6 weeks during radiation and for 4 weeks following radiation).
224268290|NCT04172324|DEVICE|HIBBOT|Hibbot is an assistive mechanical device, lightweight and portable. The mechanism of the Hibbot manages to control all degrees of freedom (3x rotation and 3x translation) at the level of the pelvis and lower trunk. The goal is to maximize a child's own muscle activity and postural control while giving as minimal support as needed.
224268291|NCT04172324|OTHER|Standard Care|Standard care involves the standard physiotherapy the child would get during clinical care.
224268292|NCT05308823|PROCEDURE|Stent|The patients in this group will receive traditional treatment of IIH for 3 months in addition to venus sinus stent
224268293|NCT03546049|PROCEDURE|US-guided percutaneous biliary drainage|"Device: metal stent. The self-expandable metal stent is implanted percutaneously by a transhepatic access route.~The metal stent is partially covered or non-covered (in cases in which the gallbladder is not removed).~Length: 6-10 cm. Diameter: 8-10 mm."
224268294|NCT03546049|PROCEDURE|EUS-guided biliary drainage|"Device: metal stent. The transluminal (transgastric, transduodenal or transenteric) implanted self-expandable metal stent is released via echoendoscope.~The metal stent is partially covered or non-covered (in cases in which the gallbladder is not removed) or mixed covered (one half covered, one half non-covered). The mixed covered stent is used for the transhepatic access.~Length: 6-10 cm. Diameter: 8-10 mm."
224268295|NCT03063372|DIETARY_SUPPLEMENT|Pomella pomegranate extract|Participants will take a 500 mg capsule of pomegranate extract twice daily for 28 days.
224268296|NCT03063372|OTHER|Placebo|Participants will take a gelatin placebo twice daily for 28 days.
224268297|NCT04943107|OTHER|no intervention|no intervention, only measurement of blood pressure, intraocular pressure, hypertensive history questionnaire, retinal imaging, optical coherence tomography examination etc..
224268298|NCT03155893|DRUG|ODV Placebo (Matching 25 mg ODV)|Participants will receive ODV placebo (matching 25 \[mg\] ODV \[1\*25 mg tablet\]) once daily in Treatment A and B from Day 1 to 16 and Treatment C on Day 1.
224268299|NCT03155893|DRUG|ODV Placebo (Matching 200 mg ODV)|Participants will receive ODV placebo (matching 200 mg ODV \[4\*50 mg tablets\]) on Days 1 and 2 in Treatment E.
224268300|NCT03155893|DRUG|ODV Placebo (Matching 125 mg ODV)|Participants will receive ODV placebo (matching 125 mg ODV \[2\*50 mg tablets + 1\*25 mg tablets\]) orally once daily on Days 3 to 7 in Treatment E.
224268301|NCT03155893|DRUG|ODV Placebo (Matching 100 mg ODV)|Participants will receive ODV placebo (matching 100 mg ODV \[2\*50 mg tablets\] orally once daily on Days 8 to 14 in Treatment E.
224268302|NCT03155893|DRUG|SMV Placebo (Matching 150 mg SMV)|Participants will receive SMV Placebo (matching 150 mg SMV \[2\*75 mg capsules\]) orally once daily administered from Day 1 to 16 in Treatment A, B and on Day 1 in Treatment C.
224268303|NCT03155893|DRUG|AL-335 Placebo (matching 1200 mg AL-335)|Participants will receive a single dose of AL-335 placebo (matching 1200 mg AL-335 \[3\*400 mg tablets\]) administered orally on Day 15 in Treatment A and B.
223865801|NCT02561949|BEHAVIORAL|YRI|Youth Readiness Intervention (YRI) is an innovative, evidence-based mental health intervention to address co-morbid difficulties with externalizing problems (anger/emotion dysregulation) and internalizing problems (hopelessness/anxiety) among violence-affected youth. YRI methodology draws on evidence-based treatment elements commonly used in both cognitive-behavioral intervention and group interpersonal therapy. YRI has cross-cutting efficacy across a range of mental health conditions common in violence-affected youth. YRI will be delivered in 12 sessions over the course of 3 months.
223865802|NCT02561949|OTHER|Income generating activity program|Income generating activity programming will be carried out by GOAL in partnership with St. George's foundation through use of their current funding. GOAL focuses on supporting people in need by providing healthcare resources, advocating and advancing child protection practices and policies, and administering livelihood programs to empower them improve their lives in a sustainable manner. The St. George's Foundation's addresses child welfare concerns by actively reaching out to homeless and orphaned children. The program is 4 months in length and consists of skills training, soft skills development (primarily in numeracy and literacy), and a cash transfer of $200.
223865803|NCT06405555|DRUG|Midodrine Oral Tablet|Exposure to up to 5 days of midodrine (or until hospital discharge) in hospital at escalating doses with the following protocol: 2.5 mg po TID x 1 day, 5.0 mg po TID x 1 day, 7.5 mg po TID x 1 day, 10 mg po TID x 2 days.
223865804|NCT03553212|RADIATION|tomotherapy|20-23 Gy in 2 fractions on the whole prostate gland +/- seminal vesicles and 24-27 Gy in 2 fractions as simultaneous integrated boost (SIB) on the dominant intraprostatic lesion (DIL) 2 weeks in all.
224268304|NCT03155893|DRUG|Moxifloxacin Placebo (matching 400 mg moxifloxacin)|Participants will receive a single dose of moxifloxacin placebo (matching 400 mg moxifloxacin \[1\*400 mg capsule\]) administered orally on Day 1, 15 and 16 in Treatment A, on Day 1, 2 and 15 in Treatment B and on Day 1, 2, 15 and 16 in Treatment C.
224268305|NCT03155893|DRUG|ODV 25 mg|Participants will receive ODV 25 mg orally once daily administered on Days 2 to 16 in Treatment C.
224268306|NCT03155893|DRUG|ODV 200 mg|Participants will receive ODV 200 mg (4\*50 mg tablets) orally once daily will be administered on Days 1 and 2 in Treatment F.
224268307|NCT03155893|DRUG|ODV 125 mg|Participants will receive ODV 125 mg (2\*50 mg tablets + 1\*25 mg tablets) once daily administered on Days 3 to 7 in Treatment F.
224268308|NCT03155893|DRUG|ODV 100 mg|Participants will receive ODV 100 mg (2\*50 mg tablets) orally once daily administered on Days 8 to 14 in Treatment F.
224268309|NCT03155893|DRUG|SMV 150 mg|Participants will receive SMV 150 mg (2\*75 mg capsules) orally once daily administered on Days 2 to 16 in Treatment C.
224268310|NCT03155893|DRUG|AL-335 1200 mg|Participants will receive a single oral dose of AL-335 1200 mg (3\*400 mg tablets) administered on Day 15 in Treatment C.
224268311|NCT00425009|DRUG|Berberine|
224268312|NCT00425009|DRUG|Metformin|
224268313|NCT03929328|PROCEDURE|High flow oxygen therapy in spontaneous breathing trial|Patients were randomized to undergo a spontaneous breathing trial with high flow oxygen therapy that is connected on endotracheal tube. Patients tolerating the spontaneous breathing trial underwent extubation.
224268314|NCT00030511|DRUG|fluorouracil|
224268315|NCT00030511|PROCEDURE|conventional surgery|
224268316|NCT00030511|RADIATION|radiation therapy|
224268317|NCT03132311|BIOLOGICAL|Yellow Fever vaccination (17 DD Biomanguinhos)|One intramuscular injection
224268318|NCT00640393|DRUG|Etanercept|Etanercept 50 mg, subcutaneous (SC) injection.
224268319|NCT00640393|DEVICE|nbUVB|
224268320|NCT04406194|DRUG|FAVICOVIR 200 mg Film Tablet|FAVICOVIR 200 MG FT is containing 200 mg favipiravir manufactured by Atabay, Turkey.
224268321|NCT04406194|DRUG|AVIGAN 200 mg Film Tablets|AVIGAN 200 mg FT is containing 200 mg favipiravir manufactured by Toyama, Japan.
224268322|NCT01956162|DEVICE|Orthèse Diabète|The device ensures the discharge of the wound by the excavation of the orthopedic insole facing the wound and the load distribution in the healthy areas.
224268323|NCT01956162|DEVICE|"Conventional Device"|Standard (e.g.: CHUT, BAROUK, Tera-Diab, Sanital, Teraheel, Aircast boots, Walker Stabil D, etc.), or customized (orthopedic insole, Ransart boot, D.T.A.C.P., etc.) removable off-loading systems
224268324|NCT05196789|DIAGNOSTIC_TEST|whole genome and transcriptome sequencing|To perform whole genome/transcriptome analysis of patients in a cohort of up to 350 Australian patients with IBMFS-RD
224268325|NCT01878435|OTHER|SMS reminder|
224268326|NCT01878435|OTHER|Travel subsidy|
224268327|NCT01878435|OTHER|Travel subsidy 2|
224268328|NCT02505035|BEHAVIORAL|Default ordering of palliative consult|
224268329|NCT04945096|DRUG|decitabine|Decitabine (20mg/m2 intravenously from day -10 to day -8 of conditional regimen)
224268330|NCT04945096|DRUG|Acetylcysteine|Acetylcysteine: 1.2g twice a day, oral administration, from day -10 to day 365 after HSCT.
224268331|NCT04945096|DRUG|Semustine|Semustine: 250 mg/m2/day on day -9.
224268332|NCT04945096|DRUG|Cytarabine|Cytarabine: 2 g/m2 every 12 hours on day -8.
224268333|NCT04945096|DRUG|Busulfan|Busulfan: 3.2mg/kg/day on day -7 to -5.
224268334|NCT04945096|DRUG|Cyclophosphamide|Cyclophosphamide: 1.8g/m2/day on day -4 to -3.
224268335|NCT04945096|DRUG|Cyclosporin A|Cyclosporin A: 3mg/kg/d from day -8.
224268336|NCT04945096|DRUG|Anti-thymocyte globulin|Anti-thymocyte globulin (2mg/kg/d on day -5 to day -2) will be added for transplants with unrelated donor or HLA mismatched donor.
224268337|NCT04945096|DRUG|Mycophenolate|Mycophenolate (500mg, oral, twice a day from day -8) will be added for transplants with unrelated donor or HLA mismatched donor.
224268338|NCT00214864|DRUG|docetaxel, capecitabine|cohort 1 = capecitabine 900mg/m2 BID POx14 days and docetaxel 36mg/m2 day1\&8 cohort 2 = capecitabine 650mg/m2 BID POx14 days and docetaxel 30mg/m2 day1\&8 cohort 3 = capecitabine 850mg/m2 BID POx14 days and docetaxel 30mg/m2 day1\&8
224268339|NCT02443285|DRUG|Cefotaxime|Cefotaxime 2 gram every12 hours for 5 days
224268340|NCT02443285|DRUG|ceftriaxone|Ceftriaxone 2 gm every 24 hours for 5 days
224268341|NCT05645315|DRUG|TQB2618 injection and TQB2450 injection|TQB2618 is a TIM-3 receptor monoclonal antibody; TQB2450 is a new sequence of innovative anti-PD-L1 fully humanized monoclonal antibody;
224268342|NCT03391050|DRUG|APR-246|Intravenous infusion
224268343|NCT03391050|DRUG|Dabrafenib|Oral administration
224268344|NCT01229800|DRUG|Polyethylene glycol|Group 1 (split-dose PEG regimen; Colyte, Taejoon Pharmaceuticals, Seoul, Korea; 236g PEG, 22.74g Na2SO4, 6.74g NaHCO3, 5.86g NaCl, and 2.97g KCl) ingested 2 liters of PEG at 6 PM on the day before the procedure and the remaining 2 liters in the early morning at least 2 hours prior to the procedure. Patients were instructed to take PEG 250 ml every ten minutes. Group 2 (NaP regimen; Solin Oral, Korea Pharma., Seoul, Korea; 48g NaH2PO4 monosodium phosphate, 18g Na2HPO4 disodium phosphate) ingested 45ml NaP solution at 6 PM on the day before the procedure and remaining 45ml of NaP solution, separated temporally by minimum of 10 to 12 hours, at least 2 hours prior to the colonoscopy on the day of the procedure.
224268345|NCT01229800|DRUG|Sodium phosphate(NaP) solution|Group 2 (NaP regimen; Solin Oral, Korea Pharma., Seoul, Korea; 48g NaH2PO4 monosodium phosphate, 18g Na2HPO4 disodium phosphate) ingested 45ml NaP solution at 6 PM on the day before the procedure and remaining 45ml of NaP solution, separated temporally by minimum of 10 to 12 hours, at least 2 hours prior to the colonoscopy on the day of the procedure. Patients taking NaP solution were instructed to drink a minimum 1L of clear liquids during the evening on the day before the procedure and were encouraged to consume additional clear liquids.
224268346|NCT00396162|DRUG|probiotic containing L.rhamnosus R0011 strain|500 million active cells of L rhamnosus R0011 strain per tablet bid for 4 weeks
224268347|NCT00396162|OTHER|Placebo|Placebo pill
224268348|NCT01677338|DRUG|13C-uracil|PO, the Semi-solid Test Meal containing 100 mg of 13C-uracil . Perform the Breath Test.
224268349|NCT01677338|DRUG|99mTc sulfur colloid|PO, the Solid Test Meal containing 500 uCi 99mTc sulfur colloid. Perform the Scintigraphy.
224268350|NCT03734354|DRUG|Brexpiprazole|Brexpiprazole , single/oral/with fasting
224268351|NCT06254560|DRUG|Rituximab|Rituximab is administered at a dose of 100mg per week, a total of 4 times. Cyclosporin is administered at a dose of 3-5mg/kg per day.
224268352|NCT00028613|RADIATION|iodine I 131 monoclonal antibody Lym-1|
224268353|NCT02854826|OTHER|SAFE Care model of care|"SAFE Care Model Site Intervention:~1. Endorse best practices for frail patients;~2. Identify frail patients promptly using multi-dimensional screening and assessments;~3. Employ interprofessional unit-based care team approach to frailty risk reduction during inpatient stay and create post-acute care transitions (PACT) plan recommendations;~4. Develop electronic health record templates for patient-centered interprofessional frailty notes;~5. Communicate PACT plans to primary care providers to promote safe transitions to the ambulatory setting and across the continuum of care.~6. Increase awareness, improve management of frailty, and improve overall health and well-being for adults who are frail or at risk of becoming frail."
224268354|NCT03086941|DEVICE|I-gel|To compare between use of I-gel as a conduit for blind intubation and as a conduit for fiberoptic guided intubation in children. We also aim to validate the use of I-gel as conduit for blind intubation in absence of fiberoptic or lack of experience of its use.
224268355|NCT06018116|DRUG|Bicalutamide 150 mg|nonsteroidal antiandrogen
224268356|NCT06018116|DRUG|Placebo|placebo
224268357|NCT02109458|DEVICE|Navigation guided bronchoscopy|Navigation guided transthoracic needle aspiration (N-TTNA) and navigation guided bronchoscopy (NB); guidance system is by Veran Medical Technologies, Inc.
224268358|NCT01567319|BIOLOGICAL|Skin Prick Test|Skin prick test of 4 concentrations of each allergenic source, together with a positive and negative control, using 10 mg/ml histamine dihydrochloride solution and a glycerinated phenol saline solution, respectively, will be tested in every patient in duplicate on the volar surface of the forearm. Assessment of the wheal size after 15 minutes.
224268359|NCT01567319|BIOLOGICAL|Skin Prick Test - Atopic Subjects|Skin prick test of 4 concentrations of each allergenic source,together with a positive and negative control, using 10 mg/ml histamine dihydrochloride solution and a glycerinated phenol saline solution, respectively, will be tested in every patient in duplicate on the volar surface of the forearm. Assessment of the wheal size after 15 minutes.
224268360|NCT01567319|BIOLOGICAL|Skin Prick Test - No Atopic Subjects|Skin prick test of 4 concentrations of each allergenic source, together with a positive and negative control, using 10 mg/ml histamine dihydrochloride solution and a glycerinated phenol saline solution, respectively, will be tested in every subjects in duplicate on the volar surface of the forearm. Assessment of the wheal size after 15 minutes.
224268361|NCT03852745|BEHAVIORAL|Cognitive Behavioral Therapy|cognitive behavioral therapy; focus on learning skills including acceptance and commitment
224268362|NCT00263458|OTHER|Integrated office-based buprenorphine treatment for opioid dependence in an HIV primary care setting|Eligible opioid-dependent HIV-infected patients are randomly assigned to receive buprenorphine opioid agonist treatment for 12 months either in an integrated HIV primary care setting (intervention group) versus a non-integrated substance use treatment clinic setting (comparison group).
224268363|NCT03276767|OTHER|Endre|"The online intervention, Endre, a digital smoking cessation counsellor that communicates with the user primarily through interactive web-sessions. Intervention content is tailored based on user input and individual usage pattern. Up to 14 unique sessions is assigned to the users during the study period, one each day. If a user does not start a session by noon on the second day a reminder will be sendt."
224268364|NCT01931449|PROCEDURE|Modified method of digestive tract reconstruction|
224268365|NCT01931449|PROCEDURE|Routine digestive tract reconstruction|
224268366|NCT03540160|DRUG|5 mg Serlopitant Tablets|Serlopitant Tablets
224268367|NCT02920476|DRUG|TAS-102|"Days 1 through 5: TAS-102 (35 mg/m2/dose) orally 2 times daily with the first dose administered in the morning of Day 1 of each cycle and the last dose administered in the evening of Day 5. TAS-102 is to be taken within 1 hour of completion of morning and evening meals.~Days 6 through 7: Rest~Days 8 through 12: TAS-102 (35 mg/m2/dose) orally 2 times daily with the first dose administered in the morning of Day 8 of each cycle and the last dose administered in the evening of Day 12.~Days 13 through 28: Rest"
224268368|NCT03820258|DRUG|SOF/VEL/VOX|Administered once daily with food.
224268369|NCT01664039|DRUG|Travoprost 0.004% ophthalmic solution|Ophthalmic solution without benzalkonium chloride (BAK), containing Polyquad® preservative
224268370|NCT01664039|DRUG|Bimatoprost 0.01% ophthalmic solution|Ophthalmic solution containing benzalkonium chloride (BAK)
224268371|NCT01310855|DRUG|cediranib maleate|
224268372|NCT01310855|DRUG|gefitinib|
224268373|NCT01310855|DRUG|Placebo|
224268374|NCT05734716|DRUG|Erythropoietin|use of erythropoietin to stimulate red blood cell development prior to ascent to altitude
224268375|NCT05734716|DRUG|Iron sucrose (Venofer)|use of iron sucrose to stimulate red blood cell development prior to ascent to altitude
224268376|NCT05734716|DRUG|Sterile Sodium Chloride|sham treatment with sterile saline
224268377|NCT01704534|DRUG|Ustekinumab|subcutaneous injections of 45 mg or 90 mg (if the participant weighs more than 100 kg) on weeks 0 - 4 - 16 - 28
224268378|NCT06218394|PROCEDURE|microneedling|The microneedling technique (Electric microneedle, F6, China Bohui Meicui Bioengineering Technology Guangzhou Co., LTD.) performed in the targeted areas using a sterile micro needles stamp. In this study, the needle length was adjusted to 0.7\~1 mm according to the grade of hair loss and the degree of tolerance of the patient. Before microneedling treatment, the scalp was disinfected with 75% alcohol, and then 1 ml of nutritional dressing for the scalp was applied externally, and the microneedle pen was gently touched to the scalp vertically for pricking. Patients are instructed to refrain from shampooing, warm baths, and strenuous exercise for 8 hours after treatment. Each patient was treated by microneedling once every 2 weeks for a total of 12 treatments.
223865805|NCT01071408|OTHER|Stroke prevention care program|Stroke prevention care program consists of group clinics, telephone coordination of care, and tracking of care through registries in the first 7 months after stroke or TIA presentation. A nurse practitioner will follow algorithms to adjust medications and to motivate patients to improve lifestyle habits.
223865806|NCT03091010|OTHER|Fecal Microbiota Transplantation|Fecal Microbiota Transplantation will be given 100mL of suspension. It will given for a period of 7 days
223865807|NCT03091010|DRUG|Steroids|Oral steroids 40 mg (prednisolone) will be given for a period of 7 days in hospital followed by 3 weeks on OPD basis
223865808|NCT04973735|DRUG|LY-CovMab|single IV infusion
223865809|NCT05489406|DRUG|DTG DT (6 x 5 mg)|DTG 5mg dispersible tablet
223865810|NCT05489406|DRUG|F/TAF TOS (3 x 60/7.5 mg)|60/7.5 mg TOS emtricitabine/TAF
223865811|NCT04097418|BEHAVIORAL|Aerobic training compared to conventional motor training|"Aerobic training: aerobic training by treadmill at moderate intensity. Each treatment will consists of 35 minutes of training, administered 3 times per week, for 8 weeks.~Conventional motor training: 15 minutes of passive mobilization of upper and lower limbs and spine, 5 minutes of stretching of the upper and the lower limbs and 10 minutes of balance training, administered 3 times per week, for 8 weeks."
223865812|NCT03009331|PROCEDURE|Lungrecruitment manoeuver in prone position.|Postoperative lungrecruitment in prone position, pressure-controlled ventilation peak inspiratory pressure 40 cm H2O combined with PEEP 20 cm H2O during 60 seconds.
223865813|NCT03009331|PROCEDURE|Lungrecruitment manoeuver in supine position.|Postoperative lungrecruitment in supine position, pressure-controlled ventilation peak inspiratory pressure 40 cm H2O combined with PEEP 20 cm H2O during 60 seconds.
223865814|NCT05888584|OTHER|Research readiness tool|Online/paper based tool for use by nurses to aid discussions with lung cancer patients about clinical trials opportunities.
223865815|NCT01292681|OTHER|Multi-modality imaging|Week -2-0 FDG-PET-CT,1H MRS, DCE-MRI, DWI Week 1 1H MRS, DCE-MRI, DWI, 19F MRS, FDG-PET-CT Week 9 FDG-PET-CT
223865816|NCT05033301|DEVICE|Nurse Ned Clinic|Participants enrolled in the Nurse-led Ned Clinic will receive virtual PCa survivorship follow-up care from both their specialist and an oncology nurse for one year.
223865817|NCT06241235|DRUG|ZG005 Powder for Injection|ZG005 for dose escalations are set as 10 mg/kg, 15 mg/kg and other doses after discussion, intravenous infusion(IV), once every 3 weeks (Q3W). ZG005 for dose-expansion stage will commence after the Recommended Phase 2 Dose (RP2D) is determined during the dose-escalation stage.
223865818|NCT06241235|DRUG|Paclitaxel|IV infusion
223865819|NCT06241235|BIOLOGICAL|Bevacizumab|IV infusion
223865820|NCT06241235|DRUG|Cisplatin|IV infusion
223865821|NCT06241235|DRUG|Carboplatin|IV infusion
223865822|NCT05752006|OTHER|Repeated trunk flexion|A 60-min intermittent trunk flexion protocol. Participants will sit on a standard height sit, with their knees bent at approximately 90° with their hands crossed on their chest. They will perform 40 sets of 60 s of maintaining a flexed position, interspersed with 30 s of rest. Participants will achieve the flexed position by tilting the pelvis posteriorly and leaning forward. During rest, participants will sit up straight without leaning on the support.
223865823|NCT00495417|BIOLOGICAL|AFFITOPE AD01|s.c. injection
223865824|NCT00495417|BIOLOGICAL|AFFITOPE AD01 adjuvanted|s.c. injection
223865825|NCT02455141|DRUG|Epirubicin plus Cyclophosphamide|Epirubicin 90mg/m2, d1, q3w\*4 Cyclophosphamide: 600mg/m2, d1, q3w\*4
223865826|NCT02455141|DRUG|Taxanes|Paclitaxel: 80mg/m2, d1, qw\*12 or Docetaxel: 80-100mg/m2,d1,q3w\*4
223865827|NCT02455141|DRUG|Taxanes plus Carboplatin|Paclitaxel: 80mg/m2, d1,d8,d15, q4w\*4 Carboplatin AUC=2, d1,d8,d15, q4w\*4 or Docetaxel: 75mg/m2,d1,q3w\*4 plus Carboplatin AUC=5-6, d1, q3w\*4
223865828|NCT04908371|PROCEDURE|Selective Trunk Block|"It is one type of peripheral nerve blocks for upper extremity surgery. Patients will have an ultrasound scan and nerve block with local anesthetic (LA) agent (a mixture of 2% Xylocaine with 1:200,000 adrenaline and 0.5% Chirocaine in a total of 20ml) injected at the trunks of the brachial plexus in order to produce the anesthesia of the whole upper extremity of the patients scheduled for upper limb surgery. SeTB will be performed as a two-injection technique. One at the side of the neck (interscalene groove) of the affected upper limb, injections will be made near the superior trunk (5mL) and follow by redirection of the needle under ultrasound guidance to inject the LA to middle trunk (5mL). Then the second skin puncture will be made near the upper part mid-collar bone (supraclavicular fossa) to inject the LA to the inferior trunk (10mL)."
223865829|NCT04908371|PROCEDURE|Interscalene-Supraclavicular Brachial Plexus Block (IS-SC BPB)|"It is another type of peripheral nerve blocks for upper extremity surgery. Patients will have an ultrasound scan and nerve block with local anesthetic (LA) agent (a mixture of 2% Xylocaine with 1:200,000 adrenaline and 0.5% Chirocaine in a total of 30ml) injected at the interscalene groove and supraclavicular fossa, so two-injection technique will be adopted. The first skin puncture will be near the side of the neck (interscalene groove) of the affected upper limb (15mL) and then the second skin puncture will also be made near the upper mid-collar bone (supraclavicular fossa) to inject 15mL of LA."
223865830|NCT01035658|DRUG|Pazopanib|All patients will begin treatment with a 7-day run in period of single-agent pazopanib. Patients will receive pazopanib orally days 1-28 of a 28 day cycle.
223865831|NCT01035658|DRUG|Doxil|Liposomal doxorubicin (Doxil) will be administered IV on day 1 of a 28-day treatment cycle
223865832|NCT00987961|BEHAVIORAL|Linkage|This intervention provides an outpatient appointment with a Suboxone provider for medically hospitalized opioid-dependent patients to attend post-discharge.
223865833|NCT04864925|DRUG|Colgate Total Clean Mint|2 minutes of whole mouth toothbrushing
223865834|NCT04864925|DRUG|Tom's Botanically Bright Peppermint|2 minutes of whole mouth toothbrushing
223865835|NCT05756010|DEVICE|EMG|The program consisted of two strengthening (deep cervical flexors and shoulder retractors) and two stretchings (cervical extensors and pectoral muscles) exercises
223865836|NCT06176716|DRUG|ET-26|The dose is 0.8 mg/kg, single dose, Infusion time was 60s ± 5s.
223865837|NCT02871999|DEVICE|Acupuncture therapy|
223865838|NCT02871999|PROCEDURE|Laparoscopic Surgery|
223865839|NCT02118077|BIOLOGICAL|G17DT|
223865840|NCT01581736|DRUG|U100 Humulin|Infused at a rate of 80/mU/m2 surface area per minute one time over 2 hours
223865841|NCT01581736|OTHER|Exercise|Single episode of exercise riding a stationary bike.
223865842|NCT06311799|BEHAVIORAL|WIC Referral|Clinical team will refer study participants to WIC
223865843|NCT06311799|BEHAVIORAL|RDN Referral|Clinical team will refer study participants to a RDN
223865844|NCT03802266|DEVICE|Electromagnetic Navigation guided transthoracic needle aspiration|Patients in this group will receive electromagnetic navigation guided transthoracic needle aspiration for the diagnosis of pulmonary peripheral nodule
223865845|NCT03802266|DEVICE|CT-guided Transthoracic Needle Aspiration|Patients in this group will receive CT guided transthoracic needle aspiration for the diagnosis of pulmonary peripheral nodule
223865846|NCT03160781|BIOLOGICAL|Platelet Rich Plasma|Combination of Intraosseous and Intraarticular Infiltration of Platelet Rich Plasma
223865847|NCT00810680|DRUG|Valproic acid|Tab. Valproic acid will be started at a dose of 10 mg per kg per day in two or three divided doses. If well tolerated the dose will be increased to a maximum of 20 mg per kg per day and continued for a period of 3 months. The drug will be continued for another 3 months for a maximum of 6 months in responding patients. The drug will be stopped in all those who develop intolerable side effects or develop disease progression during therapy.
223865848|NCT01282346|DEVICE|SOLX Gold Shunt|Single use implant
223865849|NCT00817830|DRUG|lodenafil carbonate|Patients will do a cardiopulmonary exercise test after placebo administration. Seven days later, a new cardiopulmonary test should be done using lodenafil carbonate, 80mg, orally.
223865850|NCT00206024|DRUG|Esomeprazole magnesium (Nexium)|
223865851|NCT01831791|DRUG|Dutasteride 0.5 mg|Dutasteride will be supplied as soft gelatin capsules, containing 0.5 mg of Dutasteride and it will be packaged in high-density polyethylene (HDPE) bottles with plastic child-resistant closures.
223865852|NCT03587168|OTHER|the timed 360° turn test|Turning ability is assessed by using the timed 360° turn test.
223865853|NCT03587168|OTHER|Berg Balance Scale|Functional balance is assessed by using the Berg Balance Scale.
223865854|NCT03587168|OTHER|Four Square Step Test|The Four Square Step Test measures dynamic balance.
223865855|NCT03587168|OTHER|Functional Reach Test|The Functional Reach Test assesses limits of stability.
223865856|NCT03587168|OTHER|Trunk Impairment Scale|Trunk performance is assessed by using the trunk impairment scale.
223865857|NCT03587168|OTHER|Timed Up and Go Test|Functional mobility is assessed by using the timed up and go test.
223865858|NCT03587168|OTHER|Hoehn and Yahr Scale|Disease stage is assessed by the Hoehn and Yahr Scale.
223865859|NCT03587168|OTHER|Unified Parkinson's Disease Rating Scale|The Unified Parkinson's Disease Rating Scale assesses disease severity.
223865860|NCT02847702|DRUG|VM902A 200-mg Capsules|Taken orally with food twice daily
223865861|NCT02847702|DRUG|VM902A 400-mg Capsules|Taken orally with food twice daily
223865862|NCT02847702|DRUG|Naproxen 500-mg Capsules|Taken orally with food twice daily
223865863|NCT02847702|DRUG|Placebo|Capsules to match VM902A and/or naproxen taken orally with food twice daily
223865864|NCT00494780|DRUG|Ofatumumab|ofatumumab 300mg, 500mg or 1000mg should be diluted into 1000mL pyrogen free saline and administered as an IV infusion.Duration of infusion will be approximately 4 hours.Infusions should be given every 3 weeks until a total of 6 infusions has been given
223865865|NCT00494780|DRUG|Cyclophosphamide|Cyclophosphamide 750 mg/m2 iv for 1 day, 24-48h post-ofatumumab infusion start
223865866|NCT00494780|DRUG|Doxorubicin|Doxorubicin : 50mg/m2 iv for 1 day, 24-48h post-ofatumumumab infusion start
223865867|NCT00494780|DRUG|Vincristine|Vincristine : 1.4mg/m2 iv for 1 day, 24-48h post-ofatumumab infusion start
223865868|NCT00494780|DRUG|Prednisolone, Prednisone or equivalent|100mg p.o daily for 5 days, 24-48h post-ofatumumab infusion start
223865869|NCT04932707|OTHER|sub-occipital muscle inhibition technique|this technique will be conducted from a supine lying position. The therapist stretches the suboccipital, placing the hands beneath the patient's head applying pressure up and backward, pressure was maintained till tissue relaxation occurred flexes the head of the patient to get the chin to the manibiurim sternm.
223865870|NCT04932707|OTHER|Neurodynamic mobilization|Patient in a comfortable short sitting position at the edge of the bed with the trunk in an military straight position then ask the patient to slump; flex her neck and street the knee joint in complete extension the at the end of the procedure do active dorsiflexion at the tested foot.
223865871|NCT04932707|OTHER|control (passive stretch exercises)|The patient in a comfortable supine lying position, the patient was asked to flex his hip joint with complete knee extension and ankle in neutral position. The therapist stretches the hamstring of the dominant side
223865872|NCT04520880|DIAGNOSTIC_TEST|Testing procedure for Binding antibodies|Levels of S-specific and N-specific binding antibodies will be measured by enzyme immune-sorbent assay (ELISA). Briefly, a purified, recombinant S or N proteins will be coated into 96-well plates and incubated for 1 hour at room temperature. The plates will be then washed with 1X PBS five times. The unbound regions of the coated S proteins are blocked by 5% non-fat dry milk. After overnight incubation at 4 C. The plates are washed several times with 5X PBS. Patients sera samples are added in duplicate and incubated for 1 hour at room temperature. After several washes. anti-human IgG HRP conjugate is added. After 1-hour incubation at room temperature, the plates are washed with 1X PBS five times 3,3', 5,5' tetramethylbenzidine (TMB) substrate is added to each wells and incubated for 5 minutes. The reaction will be then stopped with 0.2 M sulfuric acid and the absorbance is measured at 450nm.
223865873|NCT04520880|DIAGNOSTIC_TEST|Neutralizing antibodies|Neutralizing antibodies against the S protein of SARS-CoV-2 are measured by PV microneutralization assay. Briefly, individual plasmids expressing S.fl gene, luciferase genes, and reporter genes are co-transfected into 293T cells to produce luciferase-expressing pseudo-viruses. Then, pseudo-viruses are added at equal volume into 96 well plates and incubated at 37 for 1 hour. Then, the ACE2 expressing 293T cells are added into the 96well pates with 100 ul of patients' sera in duplicates. After, a single round of replication the cells are lysed with lysis buffer. Luciferase activity is measured by the luciferase assay kit. The activity of luciferases is proportional to the number of cells infected. Luciferase activity is then measured by the luminometer device and the neutralization rate is calculated.
223865874|NCT01948999|PROCEDURE|ECT|Electroconvulsive Therapy inclusive anesthesia and concomitant muscular paralysis
223865875|NCT01948999|PROCEDURE|SHAM ECT|Anesthesia and concomitant muscular paralysis
223865876|NCT01948999|DRUG|Anesthesia|Temporary induced state of analgesia
223865877|NCT03908671|BIOLOGICAL|Personalized mRNA Tumor Vaccine|subcutaneous injection with personalized mRNA tumor vaccine
223865878|NCT03280017|DRUG|Ketamine|intravenous ketamine 0.2 mg/kg/hr (concentration 1 mg/ml)
223865879|NCT03280017|DRUG|Normal saline|normal saline infusion
223865880|NCT03238326|DRUG|Brexpiprazole|Once daily, oral tablets
223865881|NCT05076435|DRUG|Isotonic crystalloids|"Types of fluids in both intervention groups:~* Fluids used for electrolyte disturbances: Fluids should be chosen to substitute the specific deficiency~* Fluids given to substitute overt loss: Isotonic crystalloids are to be used. If large amounts of ascites are tapped, then human albumin may be used.~* Blood products are only to be used on specific indications including severe bleeding, severe anaemia and prophylactic in case of severe coagulopathy."
223865882|NCT03078634|OTHER|Multi-disciplinary clinic model|Clinic model incorporating multiple disciplines for the treatment of functional gut disorders. Disciplines include: gastroenterologists, psychiatrists, psychologists, hypnotherapists, behavioural therapists and dieticians. End of clinic case conference involving clinical disciplines will also occur to coordinate care.
223865883|NCT03078634|OTHER|Standard outpatient care|Standard care provided in outpatient clinics staffed by GI doctors only
223865884|NCT03637231|DIAGNOSTIC_TEST|Ultra low-dose CTAC|All patients undergo two non-contrast enhanced CT scans with standard dose (i.e. 120 kVp), one with 80 kVp and one with 70 kVp.
223865885|NCT06327633|OTHER|Olfactory Training|The subjects repeatedly sniffed pleasant scents of rose, lemon, clove, eucalyptus, coffee and cinnamon twice a day, 6-min per time, with focus, until the completion of the study.
223865886|NCT05315180|DRUG|BPI-421286|Characterize the pharmacokinetics (PK)，safety，effcicay of BPI-421286 following administration as an oral Tablet formulation
223865887|NCT01254019|DRUG|GSK2402968 6mg/kg/week|subcutaneous
223865888|NCT05462561|OTHER|Quality-of-Life Assessment|Ancillary studies
223865889|NCT05462561|PROCEDURE|Robotic Vascularized Composite Bladder Allograft Transplantation|Undergo robotic VCBA transplantation.
223865890|NCT04867291|DIETARY_SUPPLEMENT|Pizza|Portion equivalent to 200 µg of iodine (half a pizza), consumed with \~450mL of water.
223865891|NCT04867291|DIETARY_SUPPLEMENT|Seaweed Sheets|Portion equivalent to 200 µg of iodine (\~10g), consumed with two slices of white bread and \~450mL of water.
223865892|NCT04867291|DIETARY_SUPPLEMENT|Seaweed Powder|Portion equivalent to 200 µg of iodine (1 capsule), consumed with two slices of white bread and \~450mL of water.
223865893|NCT04867291|DIETARY_SUPPLEMENT|Potassium iodide|Portion equivalent to 200 µg of iodine (1.3 tablets), consumed with two slices of white bread and \~450mL of water.
223865894|NCT03061474|DRUG|Nicotinamide|Niacinamide (nicotinamide; 99%) is produced in a 750 mg sustained release tablet.
223865895|NCT03061474|DRUG|Placebo Comparator|Oral Tablet
223865896|NCT01587755|OTHER|TTOP|Patient is taken care of in an intensified, optimised manner
223865897|NCT01587755|OTHER|non-TTOP|Standard medical care
223865898|NCT00001354|DRUG|Interleukin-2/Zidovudine (AZT)|
223865899|NCT02888080|DRUG|ACZ885|ACZ885 will be administered subcutaneously to assigned study subjects once monthly for 6 months.
223865900|NCT02888080|DRUG|Placebo|Placebo will be administered subcutaneously to assigned study subjects once monthly for 6 months.
223865901|NCT02599818|BEHAVIORAL|NavSTAR|Participants in the NavSTAR program will work with a team of case workers who will provide motivational intervention and proactive barrier resolution services using patient navigation
223865902|NCT05625282|PROCEDURE|Weil osteotomy|Open, oblique, distal osteotomy of the metatarsal bone, with screw fixation.
223865903|NCT05625282|PROCEDURE|Plantar plate repair|Plantar plate reconstruction at metatarsophalangeal area, using sutures.
223865904|NCT00845832|DRUG|Placebo|iv on days 1 and 15 (Parts 1 and 2)
223865905|NCT00845832|DRUG|rituximab [MabThera/Rituxan]|0.5g iv on days 1 and 15 (Parts 1 and 2)
223865906|NCT00845832|DRUG|tocilizumab [RoActemra/Actemra]|2mg/kg-8mg/kg iv in Part 1 and selected dose in Part 2, on weeks 4, 8 and 12---Arm 1\\n8mg/kg iv on weeks 4,8 and 12 (Parts 1 and 2)--- Arm 2
223865907|NCT00190619|DRUG|Duloxetine|
223865908|NCT00190619|DRUG|Placebo|
223865909|NCT01665092|DRUG|Levo-Carnitine|
223865910|NCT01665092|DRUG|placebo|
223865911|NCT00189202|DRUG|Sirolimus|Thymoglobulin induction, sirolimus and no maintenance corticosteroid
223865912|NCT03156712|DIETARY_SUPPLEMENT|Ferrous sulfate|The intervention is the ASP, a natural form of iron supplement and compared to a widely used dietary iron supplement ferrous sulfate in terms of serum iron response over a 4h period.
223865913|NCT03417492|DRUG|Sildenafil Citrate|Three 20 mg capsules for the single dose studies. For the 5-week treatment phase, subjects will be assigned to a titration of doses for the 5 week duration of the study. Subjects will be instructed to take 20mg twice per day for 3 days, then 40mg twice per day for 3 days, and then 80mg twice per day for 4 weeks.
223865914|NCT05657730|DIETARY_SUPPLEMENT|Water Kefir beverage|Participants will consume the water kefir beverage for two weeks.
223865915|NCT06204055|OTHER|Intramuscular Dry-Needling|It is a minimally invasive procedure where a solid filament needle is inserted deeply into a myofascial trigger point (MTrP) within a muscle in an attempt to abate it and illicit a desired treatment effect.
223865916|NCT00980330|DRUG|TMC435|One TMC435 100-mg capsule or two 75-mg capsules orally (by mouth) once daily for 12, 24, or 48 weeks.
223865917|NCT00980330|DRUG|Placebo|One or 2 capsules of placebo identical in appearance to TMC435 taken orally once daily for 24, 36, or 48 weeks.
223865918|NCT00980330|DRUG|Peg-IFN-alfa-2a (P)|180 micrograms taken as one 0.5 mL subcutaneous injection once weekly for 48 weeks.
223865919|NCT00980330|DRUG|Ribavirin (R)|1000 or 1200 mg/day (5 or 6 tablets) taken orally as a twice daily regimen taken for 48 weeks.
223865920|NCT03147391|DEVICE|LAA closure with LAmbre|Percutaneous Left Atrial Appendage Closure Using the LAmbre Device in Patients With Atrial Fibrillation
223865921|NCT02910388|DEVICE|LLETZ with colposcopy|Loop procedure using a colposcope in order to see and remove the abnormal cervical tissue
223865922|NCT02910388|OTHER|LLETZ without colposcopy|Loop procedure without using a colposcope
223865923|NCT05117372|OTHER|treatment with immunotherapy and diffuse infiltrative lung disease|Patients treated with with immunotherapy and developing diffuse infiltrative lung disease
223865924|NCT05117372|OTHER|Patients requiring carcinologic lobectomy|Patients requiring carcinologic lobectomy
223865925|NCT01145170|RADIATION|Radiotherapy|Radiotherapy will be given at the standard dose between 54 and 60 Gy for irradiation of tumors of the central nervous system.
223865926|NCT01145170|BIOLOGICAL|Nimotuzumab|The patients will receive the induction therapy for 12 weeks. If the patient reaches a complete, partial response (CR, PR) to the treatment or is at least evaluated as stable disease (SD) on week 12, the consolidation therapy should be initiated. The consolidation therapy will consist of the nimotuzumab administration, every 2 weeks.
223865927|NCT03860532|DRUG|HMPL-011 tablets|Eligible subjects will recieve 1200 mg HMPL-011 tablets under fed and diet circumstance.
223865928|NCT03860532|DRUG|HMPL-011 capsules|Eligible subjects will recieve 1200 mg HMPL-011 capsules under fed and diet circumstance.
223865929|NCT03103295|BIOLOGICAL|3D-Tissue Engineered Bone Equivalent|Administrated for operative delivery of 3D-Tissue Engineered Bone Equivalent
223865930|NCT00317902|DRUG|Epoetin alfa|
223865931|NCT00568854|BIOLOGICAL|BCG|Both arms: diabetics and nondiabetics will receive vaccination in the upper arm with a 0.1-mg intradermal dose of a single strain of BCG (Mycobax, Sanofi-Aventis), which is FDA approved for this indication.
223865932|NCT04337307|BIOLOGICAL|Skin sampling of the hands of the healthcare workers involved in the decontamination of incubators|"Each incubator will be sampled in 5 points before and after decontamination. The healthcare worker that will be involved in the decontamination will also be sampled (skin sample of the hand) before and after decontamination of the incubator.~All the samples will be analyzed for the presence of pathogenic bacteria, using an inoculation on selective agar then an identification of each bacterial colony."
223865933|NCT02700958|PROCEDURE|Remote ischemic preconditioning|Remote ischemic preconditioning is performed with standard blood pressure cuff on upper-arm. RIPC will be started just before the coronarography or angiography. Time between the last inflation cycle and the beginning of the procedure will be less than 60 minutes.
223865934|NCT02700958|PROCEDURE|SHAM Remote ischemic preconditioning|SHAM Remote ischemic preconditioning is performed with standard blood pressure cuff on upper-arm. RIPC-SHAM will be started just before the coronarography or angiography. Time between the last inflation cycle and the beginning of the procedure will be less than 60 minutes
223865935|NCT02129582|RADIATION|total marrow irradiation|Undergo TMI
223865936|NCT02129582|DRUG|fludarabine phosphate|Given IV
223865937|NCT02129582|DRUG|busulfan|Given IV or PO
223865938|NCT02129582|PROCEDURE|myeloid progenitor cell transplantation|Undergo allogeneic hematopoietic progenitor cell transplant
223865939|NCT02129582|BIOLOGICAL|anti-thymocyte globulin|Given IV
223865940|NCT02129582|DRUG|tacrolimus|Given IV or PO
223865941|NCT02129582|DRUG|methotrexate|Given IV
223865942|NCT02129582|OTHER|laboratory biomarker analysis|Correlative studies
223865943|NCT05360043|DEVICE|laser treatment|All subjects were treated with a 1565-nm NAFL on their left faces for one pass, A 34-40 mJ per microbeam laser was used, and density was 250-300 microbeam per cm2. Their right faces were treated with a 1064-nm LPNY for one pass. We used a spot size of 10 mm in diameter, an energy density of 45-50 J/cm2, pulse width of 300 microseconds, and a repetition rate of 2 Hz. 1064-nm LPNY was equipped with a dynamic cooling device (DCD), the parameter was set as 40/20/0 ms. A total of 5 treatments were carried out at 2-week intervals, and one follow-up session at two months after last treatment. Before each treatment, subjects were asked to wash their face with clean water, and no topical lotion was applied. For post-treatment care, all subjects were advised to use their own moisturizing cream and avoid sun exposure.
223865944|NCT00190931|DRUG|Atomoxetine Hydrochloride|
223865945|NCT00190931|DRUG|placebo|
223865946|NCT00103025|DRUG|Sodium Nitrite|
223865947|NCT00103025|DRUG|Sodium Nitrite Injection|
223865948|NCT03697616|DEVICE|Ridge augmentation with sticky bone and GBR|"* Autogenous particulate bone will be harvested and a mixture of autogenous particulate and anorganic bovine bone mineral will be prepared at a ratio of 1:1~* Venous blood will be drawn from patients' forearm and centrifuged at 2500 RPM/3 minutes and 4000 RPM/15 minutes to produce autologous fibrin glue and concentrated growth factors membrane, respectively~* Sticky bone will be prepared by adding autologous fibrin glue to the particulate mixture, placed onto the defect and covered by the prepared concentrated growth factors membrane~* For guided bone regeneration the particulate mixture will be placed onto the defect and covered by resorbable collagen membrane~* Periosteal releasing incision will be done to provide flap advancement for tension free closure~* Closure will be done using horizontal mattress and interrupted 4/0 polypropylene sutures"
223865949|NCT01630564|BIOLOGICAL|Aldesleukin|Undergo ex-vivo-expanded umbilical cord blood progenitor cell donor T-cell infusion with aldesleukin
223865950|NCT01630564|PROCEDURE|Ex Vivo-Expanded Cord Blood Progenitor Cell Infusion|Undergo ex-vivo-expanded umbilical cord blood progenitor cell donor T-cell infusion with aldesleukin
223865951|NCT01630564|BIOLOGICAL|Umbilical Cord Blood-Derived Lymphocyte Therapy|Undergo ex-vivo-expanded umbilical cord blood progenitor cell donor T-cell infusion with aldesleukin
223865952|NCT00666276|DRUG|linezolid (Zyvox)|"Zyvox Tablets 600mg, Zyvox Injection 600mg Dosage, Frequency: According to Japanese Package Insert, In adults, administer usually 600mg of linezolid twice daily (q 12 hours) for a total daily dose of 1200 mg.~Duration: According to the protocol of A5951142, the duration of the investigation for findings regarding safety and efficacy of a patient is from the first drug administration to the 8 weeks after the first administration."
223865953|NCT04749017|DIETARY_SUPPLEMENT|Experimental product consumption|Consumption of the experimental product 2 capsules daily, morning and evening (450 mg each capsule) for 60 days
223865954|NCT04749017|OTHER|Control product consumption|Consumption of control product of identical appearance 2 capsules daily for 60 days, morning and evening
223865955|NCT03853655|RADIATION|Post-operative adjuvant radiotherapy|"Conventional treatment planning, as well as intensity-modulated radiation therapy (IMRT) planning, would be allowed on the study with patients being stratified on the RT technique.~Treatment would be delivered on telecobalt unit (gamma-rays/linear accelerator (6MV photons). All fields would be treated daily.~Phase I: 46 Gray(Gy) in 23 fractions over 4.5 weeks Phase II: 14Gray in 7 fractions over 1.5 weeks~For IMRT, inverse planning would be done on a commercial TPS configured to deliver IMRT using 6MV photons. Patients shall be treated using the simultaneous integrated boost (SIB) technique with 5 fractions being delivered every week."
223865956|NCT05861063|DEVICE|Fractional CO2 laser|All patients were given oral administration of 0.5mg paronosetron hydrochloride and lidocaine cream 1 hour before surgery. After cleaning and disinfection, fractional CO2 laser treatment was given. Among them, the fractional CO2 laser laser (American Medical Laser company) selected relatively constant energy parameters in the treatment
223865957|NCT05861063|DRUG|Dezocine|Desocine injection was injected intravenously half an hour before surgery (10ml normal saline was added for more than 30 seconds)
223865958|NCT04617652|DRUG|Magnesium sulfate|Patients will receive 1 gm of magnesium in 10 ml over 5 minutes then infusion of 1 gm in 50 ml over one hour.
223865959|NCT04617652|DRUG|Normal saline|Patients will receive 10 ml of saline, then infusion of 50 ml of normal saline over one hour.
223865960|NCT00007956|BIOLOGICAL|monoclonal antibody mono-dgA-RFB4|
223865961|NCT00389246|BEHAVIORAL|Consultation without genetic information|
223865962|NCT00389246|BEHAVIORAL|Consultation with genetic information|
223865963|NCT02765438|DEVICE|BOBO|"Each subject will play four games with the BOBO system."
223865964|NCT05480358|DIETARY_SUPPLEMENT|Fasting-Mimicking Diet ProlonADTM|Prolon by L-Nutra is a medically-designed dietary kit providing the food to eat for five days. Day 1 of Prolon provides \~4600 kJ (11% protein, 46% fat, and 43% carbohydrate), whereas days 2-to-5 provide \~3000 kJ (9% protein, 44% fat, and 47% carbohydrate) per day.
223865965|NCT02778958|DRUG|paracetamol|"iv paracetamol flakon, 1 gram infusion at 30 min;~iv morphine with patient controlled analgesia (1 mg demand bolus dose, 20 min lockout time)"
223865966|NCT02778958|DRUG|ibuprofen|"iv ibuprofen flakon, 800 mg;~iv morphine with patient controlled analgesia (1 mg demand bolus dose, 20 min lockout time)"
223865967|NCT01065220|DRUG|Testolactone undecanoate|4ml i.m.
223865968|NCT01065220|DRUG|Lynestrenol|2/day
223865969|NCT01065220|DRUG|Cyproterone Acetate|50mg per day
223865970|NCT01065220|DRUG|Estradiol|100 microgram TTS twice a week
223865971|NCT01065220|DRUG|5-alpha reductase inhibitor|1mg daily
223865972|NCT05824442|BIOLOGICAL|Blood sample for multiplex QPCR technique|Blood sampling specifically for qPCR Echino at inclusion and one year after
223865973|NCT02582437|OTHER|History for opioid use|
223865974|NCT04153435|DRUG|Calcium Chloride|Calcium chloride 5 mmol
223865975|NCT04153435|DRUG|Sodium chloride 0.9%|Placebo
223865976|NCT01511172|DRUG|liraglutide|Individually adjusted dose, maximum 2.0 mg. Injected subcutaneously
223865977|NCT01511172|DRUG|metformin|1000 mg daily, administered orally
223865978|NCT01511172|DRUG|placebo|Metformin placebo administered orally. 1000 mg daily
223865979|NCT01511172|DRUG|placebo|NNC 90-1170 placebo. Individually adjusted dose, maximum 2.0 mg. Injected subcutaneously
223865980|NCT01511172|DRUG|glimepiride|Individually adjusted dose, administered orally
223865981|NCT06436144|DRUG|Osimertinib|Etoposide Soft Capsules Dosage：25mg/tablet, 2 tablets/time, taken continuously for 21 days, and stopped for one week. Osimertinib Dosage：80mg/tablet, 1 tablet/time, QD, taken for two cycles.
223865982|NCT04102462|DRUG|BI 764198|Capsules
223865983|NCT04102462|DRUG|Matching placebo|Capsules
223865984|NCT04091152|OTHER|usability assessment|"Usability of ardoiz will be assesse using a validated usability questionnary"
223865985|NCT06490991|DRUG|HRS-5965 tablets；HRS-5965 capsules|Medication regimen: 1 Drug: HRS-5965 tablets Medication regimen: 2 Drug: HRS-5965 capsules
223865986|NCT05238194|OTHER|The Psychological Effects of The Covid-19 Pandemic Process|Investigation of The Psychological Effects of The Covid-19 Pandemic Process on The Health Staff Workıng in The Filation Team
223865987|NCT01317719|PROCEDURE|Distal Biceps Re-Insertion Surgery|Surgical Repair of the Distal Biceps Tendon
223865988|NCT00915330|PROCEDURE|Rapid on-site cytopathologic evaluation (ROSE)|ROSE: examination in the endoscopy suite, by a pathologist, during the bronchoscopic procedure, of samples obtained with transbronchial needle aspiration.
223865989|NCT00915330|PROCEDURE|TBNA|transbronchial needle aspiration
223865990|NCT03264755|DEVICE|Repetitive transcranial magnetic stimulation|Repetitive transcranial magnetic stimulation for cortical excitability in smokers and non smokers
223865991|NCT00665444|DRUG|Aripiprazole|All subjects will be assessed at baseline and then switched from their current antimanic agent to aripiprazole. Arpipirazole will be titrated from a starting dose of 5 mg/day up to a target dose of 15 mg/day over a period of up to 2 months (approximately 8 weeks). Concomitant medication will not be changed unless medically necessary. If a subject is taking an antipsychotic in addition to divalproex, aripiprazole will replace the antipsychotic.
223865992|NCT03299816|BEHAVIORAL|Coaching DASH group (C-DASH)|Participants assigned to the C-DASH diet advice group will be provided $30/week worth of fruits, vegetables, nuts and beans ordered through the study coach and delivered to a community location to reach a certain goal of potassium intake (months 0-4). During phase 2 of the study (months 5-12), a study coach will continue telephonic contact with the participants to set goals for following a DASH-like diet without the weekly food allowance.
223865993|NCT03299816|BEHAVIORAL|Self-Shopping DASH group (S-DASH)|Participants will be given a brochure containing information about the DASH diet which will be reviewed with a study team member. In months 1-4, participants will receive a gift card equivalent to a weekly allowance of $30 to Klein's ShopRite stores of Maryland for purchases of food and beverages of their choice. During phase two (months 5-12), they will be asked to continue following a DASH-like diet but will not receive a gift card for purchases.
223865994|NCT00194623|DRUG|Botulinum Toxin A (Botox)|
223865995|NCT03520413|OTHER|PRACTICE-DM|Five-component diabetes intervention: 1) telemonitoring; 2) self-management support; 3) diet/activity support; 4) medication management; and 5) depression support.
223865996|NCT03520413|OTHER|Standard VA Home Telehealth|Standard VA HT care coordination and telemonitoring.
223865997|NCT02311907|DRUG|Carboplatin|Given IV, over 30 minutes per planned chemotherapy regimen
223865998|NCT02311907|DRUG|Glutathione|Given IV, over 15 minutes, immediately before chemotherapy administration
223865999|NCT02311907|OTHER|Laboratory Biomarker Analysis|Correlative studies
223866000|NCT02311907|DRUG|Paclitaxel|Given IV, over 1 or 3 hours, per planned chemotherapy regimen
223866001|NCT02311907|OTHER|Placebo|Given IV
223866002|NCT02311907|OTHER|Quality-of-Life Assessment|Ancillary studies
223866003|NCT00092105|DRUG|MK0476, montelukast sodium|
223866004|NCT00092105|DRUG|Comparator: placebo|
223866005|NCT02600052|OTHER|PNF|RESPIRATORY PATTERN PROPRIOCEPTIVE NEUROMUSCULAR FACILITATION
223866006|NCT02600052|DEVICE|treadmill|AEROBIC TRAINING
223866007|NCT01385891|DRUG|Clofarabine VP 16 ciclophospahamide|Clofarabine intravenously 2-hour infusion,dose 40 mg/m2, followed by Etoposide (VP 16)100 mg/m2 i.v. over 2 hours and Cyclophosphamide 440 mg/m2 i.v. over 1 hour
223866008|NCT00625937|DRUG|cisplatin|
223866009|NCT00625937|DRUG|docetaxel|
223866010|NCT00625937|DRUG|tegafur-gimeracil-oteracil potassium|
223866011|NCT00625937|RADIATION|radiation therapy|
223866012|NCT00338299|DRUG|Epoetin alfa|
223866013|NCT04433429|DIETARY_SUPPLEMENT|Liposcudil Plus|
223866014|NCT04825366|DEVICE|Continuous glucose monitoring device|Participants will have to wear their continuous glucose monitoring device throughout the study.
223866015|NCT04825366|OTHER|Gold method|The Gold method will be used to assess impaired awareness of hypoglycemia
223866016|NCT04825366|OTHER|Clarke questionnaire|The Clarke questionnaire will be used to assess impaired awarness of hypoglycemia
223866017|NCT04825366|OTHER|Edinburgh Hypoglycemia Symptom Scale|The Edinburgh Hypoglycemia Symptom Scale will be used to assess symptoms of hypoglycemia
223866018|NCT04825366|OTHER|BAPAD questionnaire|The BArriers to Physical Activity in type 1 Diabetes (BAPAD) questionnaire will be used to assess barriers of physical activity
223866019|NCT04825366|OTHER|Hypoglycemia Fear Survey II|The Hypoglycemia Fear Survey II will be used to assess fear of hypoglycemia
223866020|NCT04825366|OTHER|Physical activity questionnaire|The International Physical Activity Questionnaire will be used to assess physical activity practice
223866021|NCT04825366|OTHER|Well-being|The WHO-5 well-being index will be used to assess well-being.
223866022|NCT04825366|OTHER|Treatment satisfaction|The Diabetes Treatment Satisfaction Questionnaire will be used to assess treatment satisfaction.
223866023|NCT04825366|OTHER|Hypoglycemia diary|Participants will be asked to record in a diary treatments for hypoglycemic events
223866024|NCT04825366|DEVICE|Piezo RxD|Participants will be asked to wear a pedometer throughout the study
223866025|NCT04825366|DEVICE|Heart rate monitor|During training sessions, participants will be asked to wear a heart rate monitor
223866026|NCT04825366|OTHER|Exercise diary|Before each training session, participants will be asked to note in a diary their glucose levels, if they have taken a snack or not and if insulin was administered. After each training session, participants will be asked to note that same information. In addition, they will be asked to note their bedtime blood glucose, if they have taken a bedtime snack and if adjustment to insulin doses was made.
223866027|NCT00869323|BIOLOGICAL|rituximab|375 mg/m\^2 intravenously on Days 1,8, 15 and 22
223866028|NCT00869323|DRUG|bortezomib|1.3 mg/m\^2 intravenous bolus days 1, 8, 15 and 22
223866029|NCT00145743|BEHAVIORAL|physio,pain,psychotherapy;social,nutrit.counselling&sports|profile and treatment recommendations based on the profile vs. routine psychooncology
223866030|NCT01135511|DRUG|CP-690,550 Eye drops|Ophthalmic topical solution, low dose, dosed once/day, 8 weeks
223866031|NCT01135511|DRUG|CP-690,550 Eye drops|Ophthalmic topical solution, medium dose, dosed once/day, 8 weeks
223866032|NCT01135511|DRUG|CP-690,550 Eye drops|Ophthalmic topical solution, high dose, dosed once/day, 8 weeks
223866033|NCT01135511|DRUG|CP-690,550 Eye drops-vehicle|Ophthalmic topical solution, vehicle, dosed once/day, 8 weeks
223866034|NCT01135511|DRUG|Sodium Hyaluronate|Ophthalmic topical solution, dosed 6 times/day, 8 weeks
223866035|NCT01990924|RADIATION|15 FPS|X-ray pictures
223866036|NCT01990924|RADIATION|7.5 FPS|X-ray pictures
223866037|NCT01340079|BEHAVIORAL|virtual world|health education using virtual world Second Life
223866038|NCT01340079|BEHAVIORAL|face to face|health education delivered in face to face groups
223866039|NCT03312309|PROCEDURE|personal embryo transfer|"According to the histological dating of endometrium of natural/hormone replacement cycle in control group, to explore the effectiveness of intervention by advanced or delayed personal embryo transfer .~The establishment of standard control group: Frozen embryo transfer patients according to the inclusion and exclusion criteria were evaluated for histological dating by endometrial biopsy on 7 days after ovulation/P+7. After routine time transfer in the frozen embryo transfer cycle, the standard of histological dating were determined according to the pregnancy outcome of the FET cycle .~pET in RIF patients was delayed one(ovulation +4/P+4, OV/P+4) / two days(OV/P+3) or advanced one day(OV/P+9). Day 5 blastocysts were transferred with this strategy in natural cycles."
223866040|NCT04705376|DEVICE|Breg Polarcare|The Breg Polarcare device is a type of cryotherapy machine that circulates ice cold water into a patch that can be worn by the patient on their affected joint (e.g., shoulder, knee).
223866041|NCT04705376|DEVICE|Thermazone|ThermaZone is a compact device that uses thermoelectric technology to provide heating and cooling therapy without the use of ice.
223866042|NCT05249036|PROCEDURE|Ultrasound guided arterial cannulation|Arterial cannulation will be attempted at the site of the radial artery of the non-dominant hand, using real-time ultrasound guidance
223866043|NCT05249036|PROCEDURE|Palpation guided arterial cannulation|Arterial cannulation will be attempted at the site of the radial artery of the non-dominant hand, using palpation technique (standard-of-care)
223866044|NCT03768869|DRUG|Low Risk: Oupatient Management|Intravenous Levaquin initially, then oral dosing. Patient discharged to go home to finish medication cycle after initial 120 minutes observation. Patients will be evaluated daily in the clinic, and his or her temperature must be taken and recorded four times per day. Blood cultures will be drawn at clinic visits.
223866045|NCT03768869|DRUG|Low Risk: Inpatient Management|Broad spectrum intravenous antibiotics. Daily blood work will be drawn, and patients will be monitored for fever and neutropenia in hospital.
223866046|NCT03768869|DRUG|High Risk: Inpatient Management|Broad spectrum intravenous antibiotics. Daily blood work will be drawn, and patients will be monitored for fever and neutropenia in hospital.
223866047|NCT05204615|OTHER|Collection of clinical, psychometric and biometric data|Wearable devices and a mobile app will be used to collect real-time data for 4 weeks to detect physiological and psychological complications based on biometric and psychometric (patient-reported outcomes) information.
223866048|NCT01013246|OTHER|1-hour video game play|FIFA 2009, a football video game played on Xbox 360
223866049|NCT00891930|BIOLOGICAL|Panitumumab|Panitumumab 6 mg/kg administered via IV infusion over 60 minutes
223866050|NCT00891930|BIOLOGICAL|Ganitumab|AMG 479 12 mg/kg adminstered by IV infusion over 60 minutes
223866051|NCT00891930|DRUG|Irinotecan|Irinotecan starting dose of 180 mg/m² adminstered via IV infusion
223866052|NCT05486364|DIAGNOSTIC_TEST|Digital Monitoring|Subjects will perform self-measurements with a PPG based smartphone application (FibriCheck™) to monitor for AF recurrence after the PVI procedure. One-minute measurements will be performed twice daily starting one month before the PVI procedure and continue up to 12 months after the procedure.
223866053|NCT05486364|DIAGNOSTIC_TEST|Standard of care|Subjects will wear a 24-hour holter monitor at 3, 6 and 12 months after the PVI procedure. Additionally, outpatient cardiology clinic visits are organised at 6 weeks, 3 months and 12 months after the PVI procedure (including a 12-lead ECG and cardiologist consultation).
223866054|NCT03098810|DRUG|Zinc sulphate|Oral syrup zinc sulphate
223866055|NCT03098810|OTHER|Placebo|Oral syrup placebo
223866056|NCT00638963|DRUG|temozolomide|Capsules to equal 75 mg/m\^2, orally, daily for 6 weeks, in 3 eight-week cycles
223866057|NCT05473260|OTHER|Control|In-patient care.
223866058|NCT05473260|OTHER|Experimental|Early discharge and outpatient follow-up.
223866059|NCT04688268|DRUG|deep neuromuscular blockade|Train of Four=0/4, Post tetanic count 1-2
223866060|NCT02403596|DRUG|Exacyl®|
223866061|NCT02403596|OTHER|Placebo of Exacyl®|
223866062|NCT05398965|DRUG|Eucalyptus Oil|The Eucalyptus Oil pack contains Oleum Eucalyptus citriodora, Oleum Eucalyptus globulus, and Peppermint oil, given 4 times daily for 45 minutes each frequency, applied to the mask.
223866063|NCT05398965|DRUG|Standard COVID medication|This standard treatment is personalized according to the severity but is not limited to standard antiviral therapy, azithromycin 500 mg a day, vitamin C 500 mg 8 hourly a day, zinc 20 mg a day, tablet of complex vitamin B, and other symptomatic treatments.
223866064|NCT02038868|DRUG|ASP4901|oral
223866065|NCT02038868|DRUG|Tamsulosin|oral
223866066|NCT02038868|DRUG|Placebo|oral
223866067|NCT03040661|PROCEDURE|Ablation for atrial fibrillation.|Ablation for atrial fibrillation.
223866068|NCT00889499|DRUG|Tropisetron 2 mg|Antagonist of the 5HT3 receptor.
223866069|NCT00889499|DRUG|Tropisetron 5mg|Antagonist of the 5HT3 receptor.
223866070|NCT00889499|DRUG|Placebo|NHCL 0,9%
223866071|NCT03999866|DEVICE|airtraq|airtraq videolaryngoscope
223866072|NCT03999866|DEVICE|mcgrath mac x-blade|mcgarth mac videolaryngoscope
223866073|NCT03999866|DEVICE|storz c-mac|storz c-mac videolaryngoscope
223866074|NCT03999866|DEVICE|storz d-blade|storz d-blade video laryngoscope
223866075|NCT01778283|BIOLOGICAL|Acetate-free dialysis solution|the hemodialysis solution that does not contain acetate as buffer
223866076|NCT00187941|DRUG|Mycophenolate Mofetil|Targeted MPA exposure to 30-60 mg/L/h during the first month post-transplant.
223866077|NCT00210509|DRUG|almotriptan malate|
223866078|NCT01556971|DRUG|Botox|Appropriate patients will randomly receive 29 units of Botox or a saline solution injected in to the procerus and corrugator supercilii frown muscles.
223866079|NCT01556971|DRUG|Saline Solution|29 units of saline solution will be injected in to the procerus and corrugator supercilii frown muscles of randomly chosen study participants.
223866080|NCT00761709|DRUG|AL-39256 Ophthalmic Suspension, 1%|
223866081|NCT00761709|DRUG|Latanoprost Ophthalmic Solution, 0.005%|
223866082|NCT00761709|DRUG|Vehicle|Inactive ingredients used as a placebo comparator
223866083|NCT06363357|DEVICE|Shoulder orthosis|muscle-mimicking, fabric-type shoulder orthosis
223866084|NCT05262478|DEVICE|Alpha-D CDP|Alpha-D cervical disc prosthesis was developed jointly by the Spine Center of Koç University Faculty of Medicine and Toledo University Bioengineering Department. It was designed as a single unit to ensure user-friendly administration for surgeons, and it was designed and manufactured to reproduce the movements of the normal cervical movement segment.
223866085|NCT04679571|BIOLOGICAL|Albumin|Patients with serum albumin \<3 g/L with recurrent ascites - Will receive 20 % albumin at 60 grams/week until target serum albumin of 3.0 g/L is achieved following this patients would get 40 grams of albumin every week until ascites resolution or serum albumin \>3.5 g/L. Patients who achieve this target will continue with 20 gm/week until patient has complete resolution of ascites and serum albumin \>3.5 gm/L this patients would receive albumin 20 gms once every 2 weeks.
223866086|NCT04679571|DRUG|Standard Medical Treatment|"Standard Medical Treatment- Salt-restriction, diuretics with large volume paracentesis These patients will be put on low sodium diet (2 g/day) and will be given a combination of loop diuretic (furosemide 40-160 mg/day) and a distal acting diuretic (spironolactone 100-400 mg/day) with dose escalation by one step at a time with monitoring for side-effects. Large volume paracentesis (LVP) will be performed along with intravenous albumin (8 g/L ascites removed) as required with record of the frequency of taps.~Follow up: 2 week, 4 weeks then every 3 months for 1 year."
223866087|NCT04191265|DIAGNOSTIC_TEST|serum tropinin, serum CKmb|early detection of myocardial injury, allowing application of acute cardiac shock and cardiogenic shock
223866088|NCT05007665|BIOLOGICAL|SARS-COV-2 VACCINE|the antibody titer and adverse reactions were observed.
223866089|NCT04181463|DRUG|Isopropyl Alcohol|Given via nasal inhalation
223866090|NCT04181463|OTHER|Placebo|Given via nasal inhalation
223866091|NCT04181463|OTHER|Questionnaire Administration|Ancillary studies
223866092|NCT04813419|DEVICE|1927nm thulium laser|The right face of subjects were treated with fractional 2940nm Er:YAG laser(MCL 31 Asclepion Laser Technologies, Germany), N25 mode. Energy was adjusted from 12 to 27J according to the severity of scarring. The left face of subjects were treated with fractional 1927nm thulium laser(Lavieen, korea). Parameters were set as stamp mode, a spot size of 5\*5mm, a pulse time of 1000us, an energy intensity of 3645mJ/cm2 and a repetition of 1-3 times. All patients received 3 treatment sessions totally at an average interval of 4 to 6 weeks.
223866093|NCT04813419|DEVICE|2940nm Er:YAG laser|The right face of subjects were treated with fractional 2940nm Er:YAG laser(MCL 31 Asclepion Laser Technologies, Germany), N25 mode. Energy was adjusted from 12 to 27J according to the severity of scarring. All patients received 3 treatment sessions totally at an average interval of 4 to 6 weeks.
223866094|NCT01499771|DRUG|Atorvastatin|80 Mg tablets
223866095|NCT06333717|DIETARY_SUPPLEMENT|Whole grain bread|Consumption of high-fibre bread as a dietary supplementation
223866096|NCT06333717|DIETARY_SUPPLEMENT|Control bread|Consumption of control bread as a dietary supplementation
223866097|NCT01814033|OTHER|Experimental: LRU Pillow|Foam wedge with a trough for positioning of the lower leg in an elevated position.
223866098|NCT01814033|OTHER|Control Group|Standard bed pillows placed under the lower leg to facilitate elevation
223866099|NCT06167525|DEVICE|Real-time feedback through the device. Bio-feedback signals will be given once deviated from a neutral posture for >1 minute. Response of surgeons to bio-feedback signals will be recorded|"During the first stage of the study the device will be set to record cervical spine positioning without bio-feedback signals. This will be used to record duration of time surgeons held maladaptation postures.~The second stage will involve real-time feedback through the device. For surgeons who consent, bio-feedback signals will be given once deviated from a neutral posture for \>1 minute. Response of surgeons to bio-feedback signals will also be recorded.~The Neck Disability index score will be used to assess for neck pain and the functional implications in relation to reported neck pain. This will be completed following study completion."
223866100|NCT00971789|RADIATION|fludeoxyglucose F 18|Fludeoxyglucose is the radioactive material/compound used as an injection to have a PET scan performed.
223866101|NCT00971789|DRUG|sirolimus|sirolimus 6 mg by mouth loading dose and 2 mg by mouth daily in a 28 day treatment cycle. Patients who do not have cancer take the drug for a total of two cycles (56 days) unless they develop unacceptable side effects. Those who have cancer may continue sirolimus beyond cycle 2 until their disease worsens or they develop unacceptable side effects
223866102|NCT00971789|OTHER|Clinical Videography|This examination involves testing of cerebellar function that controls movement, balance, and coordination.
223866103|NCT06073860|DRUG|Luspatercept|According to the approved label
223866104|NCT04154241|DIAGNOSTIC_TEST|PET/MR scan|"The PET will be performed with (68Ga)-labeled somatostatin analogue since it was proven to be superior to other NET PET tracers in terms of lesion detection and sensitivity \[11\] \[12\]. The 3 tesla magnet of the MRI should allow acquisition of several contrasts within a reasonable time frame. The protocol will include T1 and T2-weighted images, diffusion-weighted images with multiple b values and apparent diffusion coefficient (ADC) maps.~All images will be analyzed with big data tools such as radiomics and texture analysis in order to integrate all image parameters and different contrasts into individual tumor status. Then, accuracy, sensitivity and specificity will be evaluated by correlation of this data collection and analysis method with histological biomarkers (for example, Ki67 level) and treatment results."
223866105|NCT00860717|PROCEDURE|Routine treatment|Subjects from the Control Group received routine treatment, including daily simple dressings with sterile gauze after wound cleaning with a 0.9% physiologic solution, use of 1% hydrophilic silver sulfadiazine cream (Prati Donaduzzi Laboratory, Toledo, Brazil) and orientation about the use of adapted footwear, self-care and the prevention of disabilities. Surgical debridement was done whenever indicated by nursing or orthopedic services from UREMC.
223866106|NCT00860717|RADIATION|Low level laser therapy (LLLT)|"The LLLT equipment was an indium-gallium-aluminnium-phosphide (InGaAlP) semiconductor laser with a maximum output power of 40 mW, continuous radiation emission of visible red light with 660 nm wavelength (+/- 10 nm) and a spot area of 0.04 cm². The energy density used was 4 J per point in the wound edges and 2 J/cm² in the wound bed with a power density of 1 W/cm2.~Wound beds were irradiated using a scanning technique with no direct contact."
223866107|NCT02245581|PROCEDURE|SVV-guided fluid management|
223866108|NCT02245581|PROCEDURE|CVP-guided fluid management|
223866109|NCT00823225|PROCEDURE|standard therapy|wound debridement, moist wound dressing
223866110|NCT00823225|DRUG|Urokinase|"Daily infusion up to 21 applications, dose dependent on fibrinogen level:~\> 2,5g/l 1 000 000 IU, \< 2,5g/l 500 000 IU"
223866111|NCT02434107|PROCEDURE|Completion Lymphadenectomy|
223866112|NCT02434107|PROCEDURE|Clinical Monitoring (Palpation and node ultrasound)|
223866113|NCT03393377|DRUG|fluvastatin 10 mg and valsartan 20 mg|
223866114|NCT03393377|DRUG|placebo|
223866115|NCT02014766|PROCEDURE|Interscalene block|Ultrasound-guided interscalene block is performed.
223866116|NCT02014766|PROCEDURE|Supraclavicular block|Ultrasound-guided supraclavicular block is performed
223866117|NCT04291729|DRUG|Ganovo+ritonavir+/-Interferon nebulization|Ganovo one tablet (100mg / tablet) at a time, twice a day, up to 14 days. Ritonavir one tablet(100mg / tablet) at a time, twice a day, up to 14 days.With or without spray inhalation of interferon, 50μg / time for adults, twice a day up to 14 days.
223866118|NCT00362869|DRUG|Levofloxacin|Administered at a dose of 500 mg once a day for 3 days
223866119|NCT00362869|DRUG|Placebo|Sodium bicarbonate solution
223866120|NCT00362869|BIOLOGICAL|Enteroaggregative E. coli (EAEC)|Dosages: 1X10\^9, 5X10\^9, 1X10\^10, and 5X10\^10 cfu; given in a sodium bicarbonate solution
223866121|NCT01833364|PROCEDURE|Implantation of the Peripheral Nerve Graft|"The preparatory surgery for harvesting the peripheral nerve graft will take place in the operating room at the time of the Stage I surgery for the DBS procedure. The nerve exposure and preparation will take approximately 15 minutes of operating time in addition to the DBS procedure which typically takes 75-90 minutes.~The implantation of the nerve graft will take place in the operating room at the end of the second stage surgery for DBS. The graft harvesting and implantation will take approximately 15 minutes in addition to the 4 hours that is needed for the DBS surgery. The subject's peripheral nerve graft will be implanted into the substantia nigra unilaterally. This is a single arm trial to assess safety and feasibility."
223866122|NCT05001945|DRUG|MLS-101 (Part I)|MLS-101 tablet(s) by mouth once or twice daily.
223866123|NCT05001945|OTHER|Placebo (Part I)|Placebo tablet(s) by mouth once or twice daily.
223866124|NCT05001945|OTHER|Placebo (Part II)|Placebo tablet(s) by mouth once daily.
223866125|NCT05001945|DRUG|MLS-101 (Part II)|MLS-101 tablet(s) by mouth once daily.
223866126|NCT04395235|OTHER|Survey|A multi-item survey was prepared to assess fellow's perception of residency training. The survey was utilized by our group, understanding of patient vascular anatomy, awareness of the changes based on variations, independent decision-making, differential diagnosis, plan on key surgical steps, and preparation for unexpected bleeding. The answers to the questions asked for each case were analyzed to include senior (3 years and over) - junior (1-2 years) residents.Assistants spend 45 minutes in the survey. Data are entered into SPSS 24.0 for statistical analysis. Wilcoxon Signed Ranks Test was used to determine any significant differences in the measurements between the original CT images, 3D rendered images, the 3D model and CT images of the 3D model. Statistical significance was defined as a p value of less than 0.05. Junior assistants stated that they perceived 2D image statistically better than 3D models compared to the senior assistants (Kruskal-Wallis Test).
223866127|NCT04010006|PROCEDURE|4K Laparoscopic Surgery|4K Laparoscopic Surgery will be performed for the treatment of patients assigned to this group.
223866128|NCT04010006|PROCEDURE|HD Laparoscopic Surgery|HD Laparoscopic Surgery will be performed for the treatment of patients assigned to this group.
223866129|NCT00365157|DRUG|Eribulin Mesylate|Given IV
223866130|NCT00365157|OTHER|Laboratory Biomarker Analysis|Correlative studies
223866131|NCT00365157|OTHER|Pharmacological Study|Correlative studies
223866132|NCT03989986|BEHAVIORAL|iPeer2Peer Mentorship|Mentors and participants can have up to ten Skype calls over the course of 15 weeks.
223866133|NCT02425111|DRUG|Vedolizumab|Vedolizumab intravenous injection
223866134|NCT01257555|DEVICE|Photopneumatic therapy|Use of intense pulsed light (photo) in combination with vacuum technology (pneumatic) to treat mild to moderate acne.
223866135|NCT00162292|DRUG|BMS-582949 and Methotrexate|
223866136|NCT04674371|OTHER|central venous catheter insertion|Every operator should perform the CVC Insertion Procedure according to his common clinical practice.
223866137|NCT06038916|DRUG|STSA-1002 Injection Placebo|Intravenous infusion
223866138|NCT06038916|DRUG|STSA-1002 Injection|Intravenous infusion
223866139|NCT00477035|DRUG|CIK cells|2x10e8 cells/kg
223866140|NCT00477035|DRUG|etoposide|60 mg/kg
223866141|NCT00477035|DRUG|bcnu|15 mg/kg
223866142|NCT00477035|DRUG|cyclophosphamide|100 mg/kg
223866143|NCT00477035|DRUG|gemcitabine|1250 mg/m2
223866144|NCT00477035|DRUG|vinorelbine|30 mg/m2
223866145|NCT00477035|DRUG|melphalan|200 mg/m2
223866146|NCT01613274|OTHER|gum chewing|gum chewing three times a day for up to 20 minutes
223866147|NCT01613274|OTHER|no gum chewing|no gum chewing
223866148|NCT06187246|BEHAVIORAL|Avatar-based intervention|"Intervention was aimed at improving sexual variables (sexual satisfaction, sexual function, and initiative and sexual communication), and variables that are known to affect orgasm consecution (sexual self-esteem, sex-guilt, and sexual anxiety). To achieve this objective, it focused on fostering participants' abilities to increase their levels of sexual stimulation, and the engagement in personal values, along with identifying and modifying dysfunctional thoughts about sexuality. The techniques used included psychosexual education, cognitive restructuring, virtual exposure, sexual stimulation, and engagement in personal values from the acceptance and commitment therapy (ACT) perspective.~It was delivered via a metaverse: Second Life."
223866149|NCT06187246|OTHER|Individual informative talks|Participants were provided with information about female orgasm (e.g., what is an orgasm, neuronal orgasm, factors that may influence consecution, sexual response), masturbatory techniques (e.g., key elements to achieve pleasure, anatomy of the female genitalia, pleasure areas) and techniques to focus attention on one's body (i.e., an important factor to pleasure). Participants received three individual sessions once a month, and had a duration of one hour.
223866150|NCT04260906|DEVICE|Vagus nerve stimulator|Vagus nerve stimulation is carried out with a TENS device, which has specially designed surface electrodes in the shape of earphones, the size of which can be selected according to ear size. Electrodes were placed to correspond with the inner and rear surfaces of the tragus and the concha for both ears (Figure 1). The application is carried out, for 30 minutes, using a biphasic, asymmetrical waveform with a pulse duration that is less than 500 microseconds and a frequency of 10 Hertz.
223866151|NCT04260906|OTHER|exercise|The exercise group was assigned a program, which consisted of strengthening, stretching, isometric and posture exercises, targeting the body and upper and lower extremities. That program was home-based and the program was requested to be completed. Patients were asked to attend weekly face to face sessions with a total of 4 of these sessions in the study duration.
223866152|NCT02806557|DEVICE|Home finger-prick capillary blood count monitoring|A nurse will visit the participant's home according to the test schedule (up to a maximum frequency of 21 visits in a 21-day cycle) and perform the finger-prick capillary blood test and measure the neutrophil count using the Hemocue® WBC DIFF device.
223866153|NCT01839981|DRUG|6,8-bis(benzylthio)octanoic acid|Given IV
223866154|NCT01493310|DRUG|mifepristone|"Given orally (by mouth)~Up to 4 doses of mifepristone will be studied (300 mg, 600 mg, 900 mg, 1200 mg)"
223866155|NCT01493310|DRUG|placebo|Given orally
223866156|NCT01493310|DRUG|nab-paclitaxel|"Given by intravenous infusion (IV)~Dose of 80 mg/m2"
223866157|NCT04691635|OTHER|evaluation of movements with sensors|evaluation of movements with sensors
223866158|NCT03009864|DRUG|Tangshen Prescription|The prescription contains granules of five Chinese herbal medicines, every bag weighs 4.87g, take it one bag each time, two times a day.
223866159|NCT03009864|DRUG|Placebos|Treatment with placebo corresponding to each dose of Tangshen Prescription , every bag weighs 4.87g, take it one bag each time, two times a day.
223866160|NCT04457752|BIOLOGICAL|Dual Layer Amniotic Membrane (DLAM). Artacent®|"Artacent® is a double layer of dehydrated amniotic membrane. The amnion is harvested from human placenta obtained during planned Caesarean sections. Tides Medical uses a proprietary process to clean and decellularize the amniotic membrane. The amnion is then folded into a bi-layer with the stromal sides facing outward. The dual layer is dried and cut into various sizes. In the final step the DLAM is terminally sterilized.~Atracent®, like all other placental-derived products, is FDA cleared for homologous use through the 361 pathway. It is indicated for non-healing ulcers applied to a debrided, clean and uninfected ulcers."
223866161|NCT00376363|DEVICE|Ahmed implant|placement of glaucoma drainage device to control intraocular pressure
223866162|NCT00376363|DEVICE|Baerveldt implant|placement of glaucoma drainage device to control intraocular press
223866163|NCT04377698|BIOLOGICAL|Platelet Rich Fibrin|regeneration, restoration or reconstitution of the lost periapical tissues of the tooth by using regenerative therapies that utilize growth factors and barrier membranes.
223866164|NCT04377698|BIOLOGICAL|FDBA|regeneration, restoration or reconstitution of the lost periapical tissues of the tooth by using regenerative therapies that utilize growth factors and barrier membranes.
223866165|NCT03434652|DEVICE|Percutaneous neurostimulation|Auricular percutaneous neurostimulation
223866166|NCT04456751|OTHER|Redo op|Patients with a redo operation
223866167|NCT01869946|DRUG|Ropivacaine|
223866168|NCT03127280|OTHER|Fast Track foley removal|Foley catheter is removed at 4 hours after surgery
223866169|NCT00648726|DRUG|cefuroxime plus erythromycin|intravenous cefuroxime 1.5 g twice daily for 4 +/-1 days, followed by oral cefuroxime 0.5 g twice daily for a total duration of 9 +/-1 days plus erythromycin ethylsuccinate 0.5 g twice daily, which was given for a total duration of 14 days for subjects with suspected pneumonia due to atypical pathogens
223866170|NCT00648726|DRUG|azithromycin (Zithromax)|intravenous azithromycin 500 mg once daily for 4 +/-1 days, followed by oral azithromycin 500 mg once daily for a total duration of 9 +/-1 days
223866171|NCT00648726|DRUG|cefuroxime|intravenous cefuroxime 1.5 g twice daily for 4 +/-1 days, followed by oral cefuroxime 0.5 g twice daily for a total duration of 9 +/-1 days
223866172|NCT06215053|OTHER|erector spine plane block|After anesthesia and surgical procedures, bilateral ESP block will be applied under ultrasonography guidance from the midline 3 cm lateral from the T10 level. After cleaning the area with povidone-iodine before the block, the T10 transverse protrusion will be determined using a linear ultrasound probe. Local anesthetic will be applied between the transverse process and the erector spinae muscle with the help of an insulated needle designed for peripheral block procedures. The location of the needle will be confirmed by hydrodissection with physiological saline without local anesthesia. After the location of the needle is confirmed, 20 ml of LA and saline mixture will be applied and the same process will be repeated in the contralateral side. Of the total 40 ml LA, 20 ml will consist of bupivacaine 0.5% (MARCAİNE), 10 ml will consist of lidocaine 2% (Aritmal), and 10 ml will consist of physiological saline.
223866173|NCT02060669|DRUG|Xeloda|Xeloda
223866174|NCT05692778|OTHER|Patients being foot examined by using an eHealth tool|Patients being foot examined by using an eHealth tool that has been developed, will be tested with the intention to implement the eHealth tool
223866175|NCT05692778|OTHER|Patients being foot examined in traditional manner|Patient are being foot examined in the way as health care professionals usually make the foot examination in patients with diabetes
223866176|NCT05179486|PROCEDURE|Biospecimen Collection|Undergo collection of tissue, and blood
223866177|NCT05179486|OTHER|Questionnaire Administration|Complete questionnaire
223866178|NCT05284435|BEHAVIORAL|Cognitive Behavioral Therapy-Email (iCBT-E)|"Participating families will receive an access to the website that contains treatment materials for both parent and child.~During each of the weekly emails, therapists will serve to provide encouragement and support as the parent works through the program independently."
223866179|NCT05284435|BEHAVIORAL|Cognitive Behavioral Therapy-Email and Videoconferencing (iCBT-EV)|"Participating families will receive an access to the website that contains treatment materials for both parent and child.~During each of the weekly emails and six videoconferencing sessions, therapists will serve to provide encouragement and support as the parent works through the program independently. Therapists will also assist the parent with any problem-solving as needed."
223866180|NCT00591708|DIETARY_SUPPLEMENT|Beverage containing calcium citrate malate|Beverages containing a lower amount of calcium (0-400 mg/d) will be supplemented to a basal diet containing 600 mg/d Ca. The controlled diet will be consumed for 21 consecutive days.
223866181|NCT00591708|DIETARY_SUPPLEMENT|Beverage fortified with calcium citrate malate|Beverages containing a higher amount of calcium (500-1300 mg/d) will be supplemented to a basal diet containing 600 mg/d Ca. The controlled diet will be consumed for 21 consecutive days.
223866182|NCT04630535|PROCEDURE|aorto-bifemoral bypass surgery|aorto-bifemoral bypass surgery (Leriche syndrom, elective AAA repair)
223866183|NCT00742300|PROCEDURE|Autologous hematopoietic stem cell transplantation|Transplantation of CD34-selected autologous hematopoietic stem cells after high-dose chemotherapy with cyclophosphamide (200mg/kg) and rabbit-antithymocyteglobulin (90mg/kg)
223866184|NCT02359188|DEVICE|Transcutaneous vagal nerve stimulation|4 hours of transcutaneous vagal nerve stimulation
223866185|NCT00002072|DRUG|Epoetin alfa|
223866186|NCT06328023|OTHER|SCOAT 6 to find association|we will use SCOAT 6 to find the association between concussion , sleep and physical performance
223866187|NCT01444417|DRUG|Romiplostim|The starting dose of romiplostim is 1 µg/kg administered weekly by subcutaneous injection. Participants will return to the clinic weekly to provide platelet counts and undergo dose titrations under the supervision of the treating physician. Weekly dose increases will continue in increments of 1 µg/kg up to a maximum dose of 10 µg/kg in an attempt to reach a target platelet count of ≥ 50 x 10\^9/L. Dose adjustment will be allowed during the treatment period to maintain a platelet count between ≥ 50 x 10\^9/L and ≤ 200 x 10\^9/L.
223866188|NCT01444417|DRUG|Placebo|Matching placebo administered by subcutaneous injection
223866189|NCT01686906|PROCEDURE|Bowman layer graft implantation|For patients with progressive advanced keratoconus, a mid-stromal manual dissection is made and a donor isolated Bowman layer is positioned into the stromal pocket.
223866190|NCT03370796|OTHER|Reminiscence Therapy Program|The Reminiscence Therapy program is composed of: (i) main strand lasting 7 weeks, with sessions twice a week (total of 14 sessions); (ii) maintenance strand, which runs for 7 weeks, once a week (total of 7 sessions). The duration for each session will be 60 minutes.
223866191|NCT02755116|DRUG|Olanzapine|10mg of olanzapine by mouth prior to anesthetic induction
223866192|NCT02755116|DRUG|Placebo|placebo by mouth prior to anesthetic induction
223866193|NCT00010738|PROCEDURE|Meditation|
223866194|NCT04239586|DRUG|Sulfonylurea|Starting treatment with sulfonylurea class of drug
223866195|NCT00362778|DRUG|Insulin|intravenous continuous insulin infusion for 48 hours
223866196|NCT00291824|BEHAVIORAL|Cardiovascular risk factors and willingness to change|
223866197|NCT02436213|OTHER|Cardiopulmonary exercise test|"On Day 1, subjects will have the test in the Exercise Suite of Hammersmith Hospital, London, UK. They will have painless skin probes placed on their fingers, chest, and legs to monitor heart rate, ECG, blood oxygen levels, and oxygen delivery during the test. Subjects will also be shown how to breathe through a mouthpiece with a nose clip on, and how to indicate on a sliding device whether they feel breathless. They will then start cycling against a very low resistance at a steady speed. As long as they feel comfortable, there will be a gradual increase in work load until they feel they cannot keep going at the same speed. They can also stop sooner for any reason. Afterwards, while they are cooling down (within the hour on Day 1), they will fill in a short questionnaire describing how they feel."
223866198|NCT02436213|PROCEDURE|Blood test|On same day (Day 1), the subject will have 20-30mls of blood (that is, 4-6 teaspoonful) taken for analysis.
223866199|NCT00120367|DRUG|Enfuvirtide|
223866200|NCT00120367|DRUG|Tenofovir-Emtricitabine|
223866201|NCT01832467|DRUG|cetuximab-containing chemotherapy|
223866202|NCT04363996|OTHER|New Bioactive Restorative Material|Filling material
223866203|NCT02710851|BIOLOGICAL|low dosage HPV Vaccine(1:1)|"Participants would intramuscularly receive low dosage HPV bivalent vaccine with virus-like particles type 6 and 11 at 1:1 ratio.~All participants would be invited to receive 3 doses vaccine at 0, 1, 6 month."
223866204|NCT02710851|BIOLOGICAL|low dosage HPV Vaccine(1:2)|"Participants would intramuscularly receive low dosage HPV bivalent vaccine with virus-like particles type 6 and 11 at 1:2 ratio.~All participants would be invited to receive 3 doses vaccine at 0, 1, 6 month."
223866205|NCT02710851|BIOLOGICAL|high dosage HPV Vaccine(1:1)|"Participants would intramuscularly receive high dosage HPV bivalent vaccine with virus-like particles type 6 and 11 at 1:1 ratio.~All participants would be invited to receive 3 doses vaccine at 0, 1, 6 month."
223866206|NCT02710851|BIOLOGICAL|Hepatitis E vaccine,Hecolin®|Participants would intramuscularly receive Hepatitis E vaccine for 3 doses at 0, 1, 6 month.
223866207|NCT01124734|DRUG|Interleukin-2|Participants will receive IL-2 up to a maximum of 14 doses at 600,000 IU/kg
223866208|NCT01124734|DRUG|Temozolomide|Participants receive temozolomide at 75 mg/m2 after completion of the second cycle of high dose IL-2. Participants take the medication at bedtime daily. Four weeks after Cycle 2 of a course, they would take it for 21 days.
223866209|NCT03948997|RADIATION|Pulsed dye laser (PDL)|Pulsed dye laser (PDL, 595nm) is effective for vasodilatory diseases, especially for the superficial to middle layers of the dermis
223866210|NCT03924882|DRUG|Anlotinib|Anlotinib QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
223866211|NCT04614636|DRUG|FT538|Experimental Interventional Therapy, Allogeneic Cell Therapy NK Cell
223866212|NCT04614636|DRUG|Cyclophosphamide|Lympho-conditioning Agent
223866213|NCT04614636|DRUG|Fludarabine|Lympho-conditioning Agent
223866214|NCT04614636|DRUG|Daratumumab|Monoclonal Antibody, CD38, Anti-CD38
223866215|NCT04614636|DRUG|Elotuzumab|Monoclonal Antibody
223866216|NCT04212195|GENETIC|Next generation sequencing|Saliva samples
223866217|NCT04212195|DIAGNOSTIC_TEST|Imaging and fluid biomarkers|Magnetic resonance imaging of the brain and urine, blood and cerebrospinal fluid sampling
223866218|NCT01711905|DIETARY_SUPPLEMENT|Vitamin D3|daily dosage of 20 µg Vitamin D3 for 12 weeks
223866219|NCT02034903|OTHER|Feedings warmed with commercial warmer|
223866220|NCT00667056|DRUG|tacrolimus ointment|topical
223866221|NCT00667056|DRUG|placebo ointment|topical
223866222|NCT03768310|BIOLOGICAL|CD19.CAR-multiVST for Group A|Patients will be evaluated in the clinic and a single dose of CD19.CAR-multiVSTs will be given by intravenous injection on or after 30 days of the transplant (between days 30 and 90). A time period of 6 weeks will constitute the time for clinical safety monitoring.
223866223|NCT03768310|BIOLOGICAL|CD19.CAR-multiVST for Group B|Patients will be evaluated in the clinic and a single dose of CD19.CAR-multiVSTs will be given by intravenous injection on or after 30 days of the bone marrow transplant. A time period of 6 weeks will constitute the time for clinical safety monitoring. If patients with relapse after transplant or those with evidence of disease before bone marrow transplant have at least a partial response to the treatment or have stable disease, they will be eligible to receive up to 6 additional doses of T cells separated by a minimum of four weeks. Patients are eligible to receive additional doses only after they have completed the initial 6-week clinical safety monitoring period.
223866224|NCT00592813|BEHAVIORAL|Enhanced Strong for Life|"The program contains 5 minutes of warm-up, 25 minutes of strengthening, and 5 minutes of cool-down exercises. The SFL program is contained on a 35 minute videotape. Subjects are instructed to increase resistance when they can perform 10 repetitions of a movement pattern without significant fatigue or loss of proper execution. Subjects are instructed to move within a comfortable range of motion.~Participants will be taught the SFL program during two home visits conducted by a physical therapist. On the first visit, the exercise techniques will be taught, modified as needed based on individual needs and practiced as necessary until proper technique is attained. Each participant will be given written guidelines for how to progress resistance of the program, how to modify the exercises and how to complete bimonthly exercise calendars."
223866225|NCT00592813|BEHAVIORAL|cardiovascular nutrition education|administered as an attention control intervention using home visits, phone calls and mail-outs of information
223866226|NCT05654467|BIOLOGICAL|Novel Live Attenuated Type 3 Oral Poliomyelitis Vaccine (nOPV3)|The nOPV3 vaccine containing approximately 10\^5.5, 10\^6.0, or 10\^6.5 CCID50 per dose.
223866227|NCT05654467|BIOLOGICAL|Sabin Monovalent Oral Poliomyelitis Vaccine Type 3 (mOPV3)|The Sabin Monovalent Oral Poliomyelitis Vaccine Type 3 control and challenge vaccine (mOPV3) containing ≥ 10\^5.8 CCID50 per dose.
223866228|NCT00917202|DRUG|Methylenblue|
223866229|NCT00181753|DRUG|standard vs. glutamine enteral or parenteral feeding.|Patient in each group will continue on the same diet for \> 3 days before we conduct stable isotope tracer measurements.
223866230|NCT00181753|DIETARY_SUPPLEMENT|Stable isotope tracer study|7 hours of primed constant infusion
223866231|NCT00181753|DIETARY_SUPPLEMENT|Stable isotope study|7 hours of primed constant infusion of stable isotope tracers.
223866232|NCT00181753|DIETARY_SUPPLEMENT|Stable isotope tracer study|7 hours of primed constant stable isotope tracer infusion.
223866233|NCT00181753|DIETARY_SUPPLEMENT|Stable isotope tracer study|7 hours primed constant infusion of stable isotope tracer study
223866234|NCT01063972|BEHAVIORAL|Centralized disease management (CDM)|Centralized Disease Management (CDM) arm will receive smoking cessation counseling with coordination of pharmacotherapy with their insurance coverage and their health care provider
223866235|NCT01063972|BEHAVIORAL|Counseling (C)|Counseling (C) arm will receive counseling without the care coordination services.
223866236|NCT04191486|DRUG|T-817MA|224mg T-817MA orally once daily for first 4 weeks, and then 448mg T-817MA orally once daily for the following weeks.
223866237|NCT04191486|DRUG|Placebo|Placebo once daily
223866238|NCT02962817|OTHER|Educational intervention|
223866239|NCT02962817|OTHER|Video explaining the clinical practice guidelines on low back pain|
223866240|NCT00634621|DRUG|Hexaminolevulinate (Hexvix)|Each patient enrolled into the study will be infused with 50 mL of a 2 mg/mL Hexvix solution in the bladder using a catheter. Subsequently, after fluid retention by the patient in the bladder for one hour, the bladder will be emptied.
223866241|NCT03427216|DRUG|Baclofen/diazepam|Vaginal suppository placed once daily, patients will record pelvic pain daily on a VAS scale, sexual satisfaction and quality of life on a standardized questionnaire weekly
223866242|NCT03427216|DRUG|Vaginal placebo|Vaginal suppository placed once daily, patient will record pelvic pain daily on a VAS scale, sexual satisfaction and quality of life on a standardized questionnaire weeky.
223866243|NCT06445699|OTHER|Photodynamic therapy|A number of studies have reported that PDT can accelerate wound healing by inactivating local bacterial infection and colonization of bacterial biofilm, promoting wound re-epithelialization.
223866244|NCT06445699|OTHER|Hydrogel dressing|Hydrogel dressing is widely applied in clinical practice to improve the regeneration ability of wound granulation tissue, promote the division and migration of epithelial cells, speed up wound healing and relieve the pain.
223866245|NCT00521131|DRUG|Levocetirizine dihydrochloride|
223866246|NCT01635712|DRUG|SNX-5422|Capsule dosed every other day for 21 days out of 28 day cycle. Dose escalation based on safety
223866247|NCT04410510|DRUG|P2Et (Caesalpinia spinosa extract)|P2Et active extract capsule equivalent to 250mg of P2Et every 12 hours for 14 days + Standard Care
223866248|NCT04410510|OTHER|Placebo|Placebo capsule equivalent to 250mg of excipients of P2Et every 12 hours for 14 days + Standard Care
223866249|NCT03631953|DRUG|Trametinib|Trametinib administered at a fixed dose (1.5 mg daily)
223866250|NCT03631953|DRUG|Alpelisib|A panel of 3 doses of ALPELISIB could be tested
223866251|NCT03631953|BIOLOGICAL|Blood sample|Therapeutic biomarkers
223866252|NCT03631953|DEVICE|MRI|A MRI with contrast will be performed before treatment start. Assessment of tumor growth.
223866253|NCT05973578|RADIATION|Stereotactic radiotherapy|Single-session high dose stereotactic radiotherapy
223866254|NCT02648503|DRUG|Deep neuromuscular block|Using rocuronium and reversal with sugammadex
223866255|NCT02648503|DRUG|Moderate neuromuscular block|Using rocuronium and reversal with neostigmine (1 to 2 mg) and atropine (0.5 to 1 mg)
223866256|NCT01747070|OTHER|tDCS and EAC sham|The tDCS apparatus is operated on battery power, will be used rubber electrodes soaked in saline solution. The anode is placed in M1 and the cathode in the supraorbital region.
223866257|NCT01747070|OTHER|tDCS sham and EAC sham|For the EAC sham we will use rubber electrodes. They will be applied in the same areas of active EAC. They are connected to the same electroacupuncture device, but without current passing for the patient. All subjects receive one 30min session.
223866258|NCT01747070|OTHER|tDCS sham and EAC|For the sham tDCS we will use the same apparatus in the same location, but the current is stopped after 30 seconds.
223866259|NCT01747070|OTHER|tDCS and EAC|For the acupuncture we will use needles with guide tubes that are 40 mm in length and 0.25 mm in diameter. The needling will be applied using an electro acupuncture device in the dermatomes, myotome, or sclerotome corresponding to the nerve roots involved in the knee (L1, L2, L3, L4, L5, S1, and S2). All patients received one 30min session using a frequency of 2 Hz.
223866260|NCT03475316|BEHAVIORAL|Social Dancing|90-min dance sessions twice weekly for 6-months. The session includes warm-up, dance and cool down.
223866261|NCT03475316|BEHAVIORAL|Treadmill Walking|Each session starts with 5-10 minutes of warm-up walking at comfortable speed. Speed is gradually increased to the level at which participants felt it is 'somewhat hard' for two 35 minute sessions with breaks in between followed by 5-10 minute cool down period (total 90 min to match dance group).
223866262|NCT02981888|RADIATION|X-Ray|X-ray of the abdomen will be performed to assess colonic transit
223866263|NCT05865145|DEVICE|Electronic Bicycle Ergometer|Electronic Bicycle equipped with electronic break, display screen, adjustable seat, handle bar and foot straps will be adjusted for High or Low interval intensity training.
223866264|NCT03189589|DRUG|GSK2269557 500 µg|GSK2269557 is a potent and highly selective inhaled Phosphoinositide 3 Kinase delta inhibitor. Single dose of GSK2269557 500 µg will be administered to randomized subjects via inhalation route using ELLIPTA DPI.
223866265|NCT03189589|DRUG|GSK2269557 750 µg|GSK2269557 is a potent and highly selective inhaled Phosphoinositide 3 Kinase delta inhibitor. Single dose of GSK2269557 750 µg will be administered to randomized subjects via inhalation route using ELLIPTA DPI.
223866266|NCT00092274|DRUG|HuMax-CD20|
223866267|NCT00003432|BIOLOGICAL|carcinoembryonic antigen RNA-pulsed DC cancer vaccine|Approximately 60-90 days after the peripheral blood stem cell transplant, patients receive CEA RNA pulsed dendritic cells IV every 3 weeks for a total of 4 doses.
223866268|NCT02697201|DRUG|Intralipid|0.55 ml/kg/h
223866269|NCT02697201|DRUG|Saline|0.55 ml/kg/h for
223866270|NCT02025257|OTHER|Exercise|Individually prescribed hospital based exercise in group two times a week, home-based exercise once a week. The exercise intervention consists of interval based aerobic exercise on a bicycle ergometer 30 minutes with intensity level at 13-17 at Borg scale, resistance exercises and balance exercises
223866271|NCT01204359|RADIATION|Iodine 131|iodine 131，185、370、555mBq，6 months
223866272|NCT03389191|DRUG|Acyclovir|
223866273|NCT05605535|BIOLOGICAL|Oregovomab|2 mg, dissolved in 2 mL of 0.9% Sodium Chloride Injection USP, then added to 50 mL of Sodium Chloride Injection USP infused over 20 ± 5 minutes
223866274|NCT05605535|DRUG|Paclitaxel|175 mg/m\^2, every 3 weeks
223866275|NCT05605535|DRUG|Carboplatin|AUC 5 or 6 IV Day 1 x 6 cycles (every 21 days)
223866276|NCT05605535|BIOLOGICAL|Placebo|2 mg, dissolved in 2 mL of 0.9% Sodium Chloride Injection USP, then added to 50 mL of Sodium Chloride Injection USP infused over 20 ± 5 minutes
223866277|NCT02492048|DEVICE|Cellutome Epidermal Harvesting System|Cellutome Epidermal Harvesting System
223866278|NCT02492048|PROCEDURE|Split Thickness Skin Graft|Split Thickness Skin Graft
223866279|NCT05992701|DEVICE|Directional deep brain stimualtion|Directional deep brain stimualtion in the treatment of Parkinson's disease using L305/L306 leads and G107R/G107 implanted pulse generators (Beijing Pins Medical Co.).
223866280|NCT05395546|OTHER|dCBT-I|"1. Complete the evaluation of various scales and record a 7-day sleep diary before entering the group~2. Receive a 6-week treatment after enrollment, insist on using the app every day (about 5-10 minutes), and receive regular follow-up from the project doctor~3. Scale assessment needs to be completed at the end of treatment~4. One month after the end of treatment, cooperate with relevant follow-up and complete the scale evaluation"
223866281|NCT00457743|DRUG|Sunitinib malate (SU011248)|SU011248
223866282|NCT00566527|BIOLOGICAL|ProQuad® manufactured with recombinant Human Albumin (rHA)|A 2-dose regimen of ProQuad® (0.5 mL per dose) given via subcutaneous injection into the deltoid muscle at a 3-month interval. Each dose contains measles virus Enders' Edmonston strain (live attenuated), mumps virus Jeryl Lynn™ (Level B) strain (live attenuated), rubella virus Wistar RA 27 or 3 strain (live attenuated), and varicella virus Oka or Merck strain (live attenuated).
223866283|NCT03910491|BEHAVIORAL|PriCARE|PriCARE is a group parent training program designed to improve child behavior, improve parent-child relationships, and decrease stress for parents. PriCARE emphasizes the 3 Ps (Praise, Paraphrase, and Point-out-Behavior). The training initially focuses on parenting skills including giving attention to the child's positive behaviors and ignoring minor misbehaviors. The second phase of training includes teaching techniques for giving children effective commands to set age-appropriate limits. The PriCARE curriculum also includes trauma and stress education components in order to contextualize the use of these skills with the types of behaviors and problems demonstrated by many children who have experienced psychosocial adversity and chronic familial stress. Throughout the curriculum, caregivers are encouraged to practice the skills. PriCARE has been evaluated in the primary care setting and has shown promise. There have been limited studies on PriCARE for foster caregivers.
223866284|NCT03293498|BIOLOGICAL|NanoFlu|Vaccine
223866285|NCT03293498|BIOLOGICAL|Fluzone HD - Day 0|Vaccine
223866286|NCT03293498|BIOLOGICAL|Fluzone HD - Day 21|Vaccine
223866287|NCT03293498|OTHER|Saline - Day 21|Placebo
223866288|NCT01917097|DRUG|Dexmedetomidine|
223866289|NCT06969534|DRUG|Pucotenlimab combined with GP regimen|A total of 33 cases are planned to be enrolled. All the subjects will receive Pucotenlimab (3mg/kg, on day 1, with a maximum dose not exceeding 200mg), administered once every 3 weeks (Q3W), and combined with the GP regimen. The chemotherapy is a fixed regimen, with Gemcitabine at a dose of 1g/m² on day 1 and day 8, and cisplatin at a dose of 80mg/m² on day 1. The chemotherapy will be given for 3 to 6 cycles, once every 3 weeks (Q3W).
223866290|NCT00305695|OTHER|Laboratory Biomarker Analysis|Correlative studies
223866291|NCT00305695|DRUG|Zoledronic Acid|Given IV
223866292|NCT05232630|DRUG|Fenfluramine|"Administration of fenfluramine. Fenfluramine treatment dose: Between 0.2 and 0.7 mg/kg/day if no concomitant Stiripentol (STP), maximum dose: 40 mg/day \[or 0.5 mg/kg/day, maximum 30 mg/day, for subjects taking concomitant STP\]. Dosing will be started with 0.1mg/day per one week, then 0.2mg/kg/day per one week, then as investigator clinical decision-making, up to 0.4, 0.6 or 0.7mg/kg/day, with a maximum of 0.2mg/kg/day escalation every week.~Visits: There will be four visits; (visit 1) screening; (visit 2) treatment initiation, +2 weeks; (visit 3, telematic) +8 weeks; (visit 4) +14 weeks."
223866293|NCT05482399|OTHER|Statin discontinuation|Statin therapy will be stopped. Additional lipid-lowering medication lowering LDL cholesterol will also be stopped.
223866294|NCT00206375|DRUG|Growth hormone|Growth hormone + Synthroid + Lupron
223866295|NCT00206375|DRUG|Growth hormone treatment and puberty|Lupron once a month and growth hormone daily
223866296|NCT04145492|DRUG|Vitamin K2|Patients will take 90 ug of vitamin K2
223866297|NCT04145492|DRUG|Cholecalciferol (inactive vitamin D)|Patients will take 10 ug of vitamin inactive vitamin D
223866298|NCT04145492|DRUG|Vitamin K2 and Cholecalciferol|Patients will take 90 ug of vitamin K2 (MK-7) in addition 10 ug of vitamin inactive vitamin D
223866299|NCT06238063|BEHAVIORAL|Nurse-led Advance Care Planning (ACP) Intervention|An ACP discussion between the participating resident, family members, and the trained nurse will be incorporated into the annual review. The proposed ACP intervention will be divided into three parts (three weekly sessions, 1.5 hours each): 1) preparatory, 2) discussion, and 3) follow-up sessions.
223866300|NCT00290849|DRUG|Bivalirudin|
224076491|NCT03912129|GENETIC|blood sample|"A first systematic approach by Targeted-Next Generation Sequencing will be used on the entire cohort of patients with pSE. This step will be performed on a sequencing chip specifically developed to detect anomalies in known genes involved in autoimmunity.~In patients for whom no mutations are identified, a whole exome sequencing (WES) approach will be applied to patients and their parents to seek to identify mutations in new genes that may be related to pSE.~In patients for whom this WES approach is unsuccessful, the search for somatic lymphocyte mutations, or copy number variants will be performed before considering a complete genome sequencing .~If several candidate genes are identified, the clinical data provided by the CEREVANCE and the phenotypic analyses carried out prior to genetic analyses by the CEDI laboratory will guide the choices to prioritize the study of the identified variants."
224076492|NCT01882283|DIETARY_SUPPLEMENT|Tea Treatment Group|This intervention was a crossover trial, during which each patient experienced both placebo and tea treatment arms
223866301|NCT01838824|BEHAVIORAL|Speed of Processing Training|SPT involves trainer-guided practice of computer-based exercises, including Target Detection (indicating presence or absence of targets, identifying targets, etc.) and Discrimination and Localization (performing same/ different discriminations of targets presented very quickly and followed by a masking pattern) 10, 19, 84. Display speed, ranging from 17 to 500 ms, is the primary manipulation during training, which increases task demands and thus demands on PS itself.
224076493|NCT01882283|DIETARY_SUPPLEMENT|Placebo|
223866302|NCT04628650|DEVICE|Digital Pain-Management Tool|Self management digital tool for chronic pain
223866303|NCT00775242|DRUG|Estradiol and Progesterone|Injectable suspension of three different dosages of estradiol and progesterone a) 0.5 mg E/15 mg P; b) 1 mg E/20 mg P; c) 1 mg E/30 mg P. Administered on a monthly basis during a six-month period.
224076494|NCT02062658|DRUG|Ketamine|0.5mg/kg IV
224076495|NCT02062658|BEHAVIORAL|Exposure and Response Prevention|A type of Cognitive Behavioral Therapy called Exposure and Response Prevention.
224076496|NCT01571583|DRUG|Telaprevir|Type=exact number, unit=mg, number=375, form=tablet, route=oral. Patients will receive 2 oral tablets (750 mg) every 8 hours for 12 weeks.
223866304|NCT00775242|DRUG|Estradiol and Progesterone|Injectable suspension of three different formulations of estradiol and progesterone a) 0.5 mg E/15 mg P; b) 1 mg E/20 mg P; c) 1 mg E/30 mg P. Each will be applied on a monthly basis during a six-month period
223866305|NCT06677528|OTHER|Questionnaire|Questionnaire on Aortic Valve Disease, HADS-D, SCL-27, MLHFQ
224076497|NCT01571583|DRUG|Pegylated interferon alfa-2a|Type=exact number, unit=µg, number=180, form=injection, route=subcutaneous. 180 microgram (µg) per week, subcutaneous injection, for 48 weeks.
224076498|NCT01571583|DRUG|Ribavirin|Type=exact number, unit=mg, number=200, form=tablet, route=oral. Starting from 600 mg (3 tablets) per day on Day 1. This dose will become higher or lower based on blood results and the investigators opinion (to a goal of 1000 to 1200 mg/day \[5 to 6 tablets\] based on subject weight), twice daily regimen, for 48 weeks.
224076499|NCT03567070|OTHER|qualitative study based on an individual clinical interview|qualitative study based on an individual clinical interview
224076500|NCT02642978|PROCEDURE|RSRCLM|The Da Vinci Surgical System may help to overcome some of the difficulties of laparoscopy for complicated abdominal surgery. The aim of this study was to present an innovative technique that is robot-assisted, simultaneous radical resection of both colorectal cancer and liver metastasis (RSRCLM).
224076501|NCT02642978|PROCEDURE|Open|Traditional open simultaneous radical resection of both colorectal cancer and liver metastasis
224076502|NCT05090293|BEHAVIORAL|Experimental: Lifestyle Intervention with Body Image Treatment (LIBI)|A body image protocol designed to improve outcomes in a group-delivered multidisciplinary weight loss program by addressing body acceptance within a context of positive behavior change and utilizing existing body discomfort and re-purposing it as an agent of motivation.
224076503|NCT05090293|BEHAVIORAL|Lifestyle Intervention (LI)|A multidisciplinary, group-delivered, multidisciplinary weight loss program addressing various lifestyle factors impacting weight loss.
224076504|NCT01625780|PROCEDURE|3-layer block|"0.3 mL/kg of 0.25% bupivacaine (one injection in each layer) will be delivered by the 3-layer method using a standard 20-gauge block needle."
223866306|NCT06676202|BEHAVIORAL|Progressive Relaxation Exercises|It combines the contraction and relaxation of large muscle groups such as the face, arms, legs, neck and back with deep breathing exercises. Before applying progressive relaxation exercises, the environment should be quiet, dimly lit, a comfortable chair or armchair should be sat or lying down, and clothing should be loose and comfortable, and it is recommended to apply it one hour after eating. In the application of progressive relaxation exercises, it is first asked to breathe regularly. After our breathing rhythm is regulated, the hands, arm muscles, shoulder and neck muscles, chest, abdominal and hip muscles, legs, feet and facial muscles are contracted with a 5-7 second breathing exercise and relaxed during exhalation. This is repeated with 4-5 breathing exercises for each muscle and the exercise is ended when the eyelids are opened.
223866307|NCT02163876|DRUG|HuCNS-SC cells|surgery arm
223866308|NCT04313868|DRUG|GEN2 (HSV-Thymidine Kinase-m2 and hGM-CSF Genes)|GEN2 is an investigational drug combining cytotoxic and immunotherapy.
224076505|NCT01625780|PROCEDURE|Single-shot block|0.3 mL/kg of 0.25% bupivacaine will be delivered by the standard, single-shot method using a 20-gauge block needle.
223866309|NCT06611982|OTHER|Unconditional cash transfer|$1000/month for 12 months
223866310|NCT06611982|OTHER|Contact information for social worker and financial counselor|Information on financial toxicity and contact information for social worker and financial counselor
223866311|NCT06109129|DEVICE|EXOPULSE Mollii Suit|EXOPULSE Mollii Suit is a personal assistive medical device which is used for low energy whole body transcutaneous electrical stimulation - 20 Volt and 20 Hz. It is composed of a control unit, a jacket and pants with 58 embedded electrodes in direct contact with the skin. EXOPULSE Mollii Suit is used for activation of muscles or relaxation of spastic muscles mediated by a physiological reflex mechanism referred to as reciprocal inhibition. By sending an electrical signal to an antagonistic muscle, the spastic muscle may subsequently relax.
223866312|NCT06328127|BEHAVIORAL|PATH|PATH, a phone-delivered positive psychology intervention for patients who have undergone HSCT, consists of three 3-week modules. The first module focuses on gratitude and physical activity goal setting. The second module focuses on personal strengths and resources to enhance daily physical activity. The third module focuses on meaning and assessing barriers to physical activity. The third week of each module is an integration exercise dedicated to help participants explore practical ways of incorporating the themes for the given module into daily life. A trained interventionist will guide participants to complete each 30-minute weekly session.
223866313|NCT07022340|BEHAVIORAL|Resistance Training Intervention|Participants will complete a brief aerobic warm-up and dynamic stretching prior to each strength training session. Participants will complete 9 exercises for all major muscle groups. Strength testing at the baseline study visit will be used to determine initial load. Participants will complete 1 set of moderate-intensity loads (\~50% maximum and \~12 repetitions) in week 1, 2 sets in week 2, and 3 sets in week 3. By week 4, participants will be completing 3 sets at 60% of maximum. Weight loads will be progressively increased so volitional fatigue is reached by 8-12 repetitions/set.
223866314|NCT06631222|BEHAVIORAL|cognitive behavioral therapy|The therapeutic patient education (TPE) program was based on a biobehavioral approach and was divided into the following three parts: cognitive, operant, and respondent. The purpose of the TPE program was to modify erroneous beliefs about pain and disability, as well as to provide coping strategies and improve patient self-efficacy through a graded activity.
223866315|NCT06631222|OTHER|sub-occipital inhibitory pressure|The suboccipital musculature will be palpated until contact is made with the posterior arch of the atlas, and progressive and deep gliding pressure was applied, pushing the atlas anteriorly. The occiput will be rested on the hands of the therapist while the atlas is supported by the fingertips. Finger pressure will be maintained for 10 minutes to produce the proposed therapeutic effect of inhibiting the suboccipital soft tissues.
223866316|NCT06631222|OTHER|deep friction massage|Friction massage is performed with the fingertips placed on the trigger points. Pressure was applied and the fingertips move in a circular manner, while the pressure is gradually increased. This massage will be applied until the patient report a reduction in pain at the trigger point
223866317|NCT06631222|OTHER|Spinal manipulation|This technique is performed along an imaginary vertical line passing through the odontoid process of the axis. No flexion or extension and very little lateral flexion will be used. Application will be bilateral. First, cephalic decompression will be performed lightly, followed by small circumductions. Selective tension will be applied to take up tissue slack and create a firm joint barrier. Manipulation is then performed with rotation towards the manipulated side in a helicoidal cranial movement. This technique will be applied with the aim of increasing occiput, atlas, and axis joint mobility.
223866318|NCT06631222|OTHER|Exercises for forward head posture|"Scapular stabilization exercises:~1. In quadruped position, the patient lift¬ up his arms alternatively with shoulder abduction and 120 ° flexion.~2. In sitting position, with 90° knee flexion on a stool or bed without backrest, patient hold a pair of dumb¬bells (2 kg) in each hand and lift them up laterally while maintaining scapulae's height below 80°. The patient was instructed to hold each stage for 10 seconds and then re-turn to the starting position and three sets of 10 repetitions with 30-second pause in between were completed.~3. As for the progression of scapular stability exercise, T to Y the patient was instructed to lie in prone lying position on Swiss ball with arms abducted to 90° (the letter T); then she asked to flex elbows to 90°, retract scapulae and externally ro¬tate arms while keeping arm in 90° abductions. While maintaining the retraction of scapula, the patient is asked to raise his arms above head and extend the elbow while his arm flexed and abducted to 120°"
223866319|NCT07023094|DRUG|Ropivacaine 0.2% for PENG Block|U-S guided PENG (0.4 mL/kg) with 0.2% ropivacaine
223866320|NCT07023094|DRUG|Ropivacaine 0.2% for LFCB|LFCB (0.1 mL/kg) with 0.2% ropivacaine
223866321|NCT07023094|DRUG|Ropivacaine 0.2% for L-ESPB|Lumbar ESPB (0.25ml/kg) with 0.2% ropivacaine
223866322|NCT07023094|DRUG|Ropivacaine 0.2% for S-ESPB|Sacral ESPB (0.25ml/kg) with 0.2% ropivacaine
223866323|NCT05669014|DRUG|Daxdilimab|Participants will be administered daxdilimab by subcutaneous (SC) injection.
223866324|NCT05669014|DRUG|Placebo|Participants will be administered identically matching placebo by SC injection.
223866325|NCT06689501|COMBINATION_PRODUCT|SPICE BLEND CAPSULE|The study product is a powder mix of L-carnitine tartrate yeast protein hydrolysate and dihydrocapsiate.in the format of hard vegetable green capsules. Participants will consume a total of 4 capsules a day split in two servings.
223866326|NCT06689501|OTHER|Placebo|The matching placebo is microcrystalline cellulose in the format of hard vegetable green capsules. Participants will consume a total of 4 capsules a day split in two servings.
223866327|NCT06720987|DRUG|KQB365|Intravenous KQB365
223866328|NCT06720987|DRUG|Cetuximab|Intravenous cetuximab
223866329|NCT07039539|BEHAVIORAL|Harm Reduction intervention|Care intervention guided by the harm reduction paradigm. Based on the acceptance of participants' needs as a starting point for constructing care responses. Guidance will be provided in collective meetings with information based on reliable scientific evidence and will support the construction of new knowledge and practices of mutual support.
223866330|NCT06705517|BEHAVIORAL|Mediterranean Diet|The MD emphasizes a plant-based approach, with a high consumption of vegetables, fruits, whole grains, legumes, and nuts, alongside moderate amounts of fish, seafood, and dairy, while limiting meat, particularly red and processed varieties. Olive oil serves as the main fat source in the diet. In the case of this study participants will also be instructed to limit dairy intake, that although traditionally part of the MD, might exacerbate disease symptomatology in PD patients, likely due to the urate lowering effect of dairy.
223866331|NCT06728644|DRUG|L-arginine intervention|L-arginine intervention for 3 months, 3 g per day.
223866332|NCT07052188|PROCEDURE|without any preoperative stenting|Patients will have RIRS without any preoperative stenting.
223866333|NCT07052188|PROCEDURE|(DJ) stent placed with sedation and undergo RIRS within 2-4 weeks|Patients will have a double-J (DJ) stent placed with sedation and undergo RIRS within 2-4 weeks.
223866334|NCT07052188|PROCEDURE|Patients will have a DJ stent placed with sedation and undergo RIRS within 4-6 weeks.|Patients will have a DJ stent placed with sedation and undergo RIRS within 4-6 weeks
223866335|NCT07053163|DRUG|Crystalloid and blood as resuscitation|Patients receive crystalloid and blood as resuscitation
223866336|NCT07053163|DRUG|crystalloid, blood and low dose of norepinephrine|Group 2: receive crystalloid, blood and low dose of norepinephrine
223866337|NCT07053410|DEVICE|Direct 3D-Printed Retainer|Orthodontic retainers fabricated using direct 3D printing technology from digital STL models. The retainers are printed with biocompatible clear resin using an additive manufacturing process.
223866338|NCT07053410|DEVICE|Single-Layer Thermoformed Retainer|Clear orthodontic retainers fabricated by thermoforming a single-layer thermoplastic sheet over a 3D printed dental model using a vacuum forming machine.
223866339|NCT07053410|DEVICE|Multi-Layer Thermoformed Retainer|Orthodontic retainers fabricated using a multi-layer thermoforming technique combining different thermoplastic materials to enhance durability and fit accuracy.
223866340|NCT07052877|DIAGNOSTIC_TEST|PSMA PET/CT scan|PSMA PET scan will be used to monitor changes in PSMA expression in response to bevacizumab.
223866341|NCT05844826|DEVICE|SIMBA Capsule|Participants will swallow capsule
223866342|NCT07054138|DRUG|Dexmedetomidine|Patients will be nebulized with dexmedetomidine 1 mcg/kg in 3 ml of 0.9 % saline 15 minutes before shifting the patients to the operating room with a face mask 6 L/min in a sitting position.
223866343|NCT07054138|DRUG|Normal Saline|Patients will be nebulized with 3 ml of 0.9% normal saline 15 minutes before shifting the patients to the operating room with a face mask, 6 L/min in a sitting position.
223866344|NCT07056179|BEHAVIORAL|Brief behavioural intervention|Participants will receive a brief behavioural intervention comprising a regularity-focused sleep diary, 10 tips for maintaining sleep regularity, and a sleep education information sheet. The regularity-focused sleep diary is designed to emphasize in-bed and out-of-bed times, drawing participants' attention to their sleep regularity. Participants will be provided with a yellow marker to highlight their sleep periods. The 10 tips for maintaining sleep regularity include establishing a consistent out-of-bed time, using natural light to regulate the circadian clock, adjusting mealtimes, etc. The sleep education sheet contains information on reducing caffeine intake in the afternoon, limiting screen time before bed, etc.
223866345|NCT07056179|BEHAVIORAL|Health education|Participants will receive general health information without specific emphasis on sleep, such as weight control, smoking cessation, etc.
223866346|NCT06299657|BEHAVIORAL|IMPROVE|"IMPROVE is an individual manualized intervention.~Session1 includes:~* psychoeducation focusing on anxiety, its role in contributing to substance use, and the maintaining role of fear of bodily sensations~* guided discussion of maladaptive thoughts about bodily sensations related to anxiety~* how to challenge bodily sensations cognitively~* generating three takeaways about the benign nature of anxiety~Session 2 includes:~* review of homework~* psychoeducation focusing on the role of uncertainty in anxiety and identifying how new information can inform beliefs about uncertainty.~* when to challenge thoughts related to uncertainty and when to use acceptance regarding uncertainty.~Session 3 includes:~* review interoceptive exposure (IE) and behavioral exercises (BE) for progress~* revisit beliefs related to cognitive biases~* discuss areas where skills can be used moving forward"
223866347|NCT06299657|BEHAVIORAL|PHET|"Clinicians will administer PHET using a Powerpoint presentation focused on healthy living habits, including healthy eating, water consumption, and sleep hygiene. Clinicians will guide participants through an exercise using the USDA food tracker to plan, record, and monitor nutritional information of meals. PHET also includes a digital program that will include EDUCATION, MY CURRENT MOOD, and BEHAVIORAL ACTIVITY tabs."
223866348|NCT07060157|DRUG|resveratrol 1 % gel|left side of face the patient will be given resveratrol 1 % gel once daily at night (Home use ).
223866349|NCT07060157|DRUG|TCA20%|left side of face the patient will be given resveratrol 1 % gel once daily at night (homThee use ).
223866350|NCT07060040|DIETARY_SUPPLEMENT|BOSCOGEN 18% Protein ONS: Energy 480 kcal, Protein 21.6 g, BCAA 6000 mg, Omega-3 fatty acid 1.8 g, fiber 5 g|Oral nutritional supplementation: Energy 480 kcal, Protein 21.6 g, BCAA 6000 mg, Omega-3 fatty acid 1.8 g, fiber 5 g
223866351|NCT07060040|DIETARY_SUPPLEMENT|Fresubin dialysis ONS (200 ml): Energy 300 kcal, Protein 20 g, BCAA - mg, Omega-3 fatty acid - g, fiber 0.2 g|Fresubin dialysis ONS (200 ml): Energy 300 kcal, Protein 20 g, BCAA - mg, Omega-3 fatty acid - g, fiber 0.2 g
223866352|NCT07060443|DRUG|Indocyanine green (ICG) injection for intraoperative lymph node imaging|Indocyanine Green (ICG) is used to guide the extent of D3 lymph node dissection during right hemicolectomy. After informed consent, participants randomized to the experimental group undergo bowel preparation and receive an endoscopic submucosal injection of ICG (0.25 mg/ml in saline) at two sites adjacent to the tumor one day prior to surgery. During surgery, near-infrared laparoscopic or robotic imaging systems detect the fluorescence emitted by ICG, guiding targeted D3 lymph node dissection at the origins of the ileocolic artery (ICA) and middle colic artery (MCA).
223866353|NCT07060443|OTHER|Standard Right Hemicolectomy (Non-ICG)|Participants in the control group undergo standard right hemicolectomy with D3 lymph node dissection without the use of Indocyanine Green (ICG) or fluorescence imaging. The extent of dissection is determined by conventional anatomical landmarks and the surgeon's clinical judgment.
223866354|NCT07061743|BEHAVIORAL|activity management training|In activity management training, first week awareness training, second week ergonomics training, third week activity stepping training, fourth week joint-energy conservation training, and fifth week relaxation training will be given.
223866355|NCT07059949|DRUG|CAPOX+ Camrelizumab+ Cetuximab|For advanced primary treatment of unresectable rectal cancer, primary radiation therapy DT 25Gy/5F, and rest for 1 week, followed by CAPOX chemotherapy + Camrelizumab + Bevacizumab or Cetuximab (KRAS, NRAS, and BRAF all wild-type Cetuximab, KRAS, NRAS, and BRAF variants selected Bevacizumab) for 4-6 months, after which Capecitabine + Camrelizumab + Bevacizumab or Cetuximab was maintained
223866356|NCT07059949|DRUG|CAPOX+ Camrelizumab+ Bevacizumab|For advanced primary treatment of unresectable rectal cancer, primary radiation therapy DT 25Gy/5F, and rest for 1 week, followed by CAPOX chemotherapy + Camrelizumab + Bevacizumab or Cetuximab (KRAS, NRAS, and BRAF all wild-type Cetuximab, KRAS, NRAS, and BRAF variants selected Bevacizumab) for 4-6 months, after which Capecitabine + Camrelizumab + Bevacizumab or Cetuximab was maintained
223866357|NCT07060144|BEHAVIORAL|Regular CPT|Standard-model Cognitive Processing Therapy (CPT) - one 60-min session per week for 12 weeks total
223866358|NCT07060144|BEHAVIORAL|Massed CPT|Massed CPT - two 60-min sessions each day for 5 consecutive days (10 sessions total)
223866359|NCT07060599|OTHER|INvasion Screening with Intelligent Guidance for Histopathology Triage (INSIGHT) Workflow|An AI-generated segmentation model are refined through a post-processing pipeline: retaining only invasive carcinoma (IC) regions, filtering detections \<500 µm², grouping adjacent IC areas, and generating per-cluster bounding boxes (red boxes). This converted raw segmentations into clinically actionable ROI proposals, balancing sensitivity and specificity for pathologist review in external testing and clinical validation. The INSIGHT workflow addresses key diagnostic challenges in EIC cases by pre-screening whole-slide images (WSIs) and intelligently marking potential IC regions. This guides pathologists to prioritize diagnostically critical areas across multiple slides or within extensive DCIS - a task particularly valuable when IC is multifocal or presents as subtle micro-invasive foci easily overlooked during routine manual examination.
223866360|NCT07061106|OTHER|Otago exercise program|Study will be conducted after the approval of Ethical review board. After the initial evaluation will be done on participants underlying eligibility criteria. Intervention Group A received Otago Exercise Program and will receive intervention of 45 minutes per session, 3 times a week, and for a total of 8 weeks (24 sessions). The Otago Exercise Program is a fall prevention well designed program for older adults. It includes 17 strength and balance exercises and a walking program, which are typically performed three times a week and helps to prevent falls in older adults by strengthening muscles and improving balance. In this study, modified form of Otago would be used that focuses on balance and strengthening exercises.
223866361|NCT07061106|OTHER|Kitchen Sink Balance Exercises|Study will be conducted after the approval of Ethical review board. After the initial evaluation will be done on participants underlying eligibility criteria. Intervention Group B received Kitchen Sink Balance Exercises and will receive intervention of 45 minutes per session, 3 times a week, and for a total of 8 weeks (24 sessions). Kitchen sink balance exercises are beneficial for improving overall Individual's stability, strength, and coordination. These exercises can be easily integrated into daily routine and it also providing a practical way to enhance balance and overall fitness.
223866362|NCT07059689|DEVICE|High Flow Nasal Cannula (HFNC)|Participants in this arm will receive High Flow Nasal Cannula therapy using the Airvo™3 Nasal High Flow System immediately after planned extubation following cardiac surgery
223866363|NCT07059689|DEVICE|Non-Invasive Ventilation (NIV)|Participants in this arm will receive Non-Invasive Ventilation (NIV) immediately after planned extubation following cardiac surgery. NIV will be delivered using standard ICU ventilator settings, with parameters tailored to each patient's clinical condition
223866364|NCT07061808|DIAGNOSTIC_TEST|Lipedema Screening Questionnaire|The Lipoedema screening questionnaire (LSQ) is a practical tool that can be applied quickly and easily and is used to identify patients with lipoedema during history taking and physical examination.
223866365|NCT07061314|DEVICE|Elastic Barbell|A flexible plastic barbell that creates top-down perturbations during movement. Participants perform single-leg deadlifts using this elastic bar at three different speeds: normal (2 sec), fast (1 sec), and power (as fast as possible). The bar is loaded to 30% of the participant's estimated 1RM.
223866366|NCT07061314|DEVICE|Inelastic Barbell|A standard rigid steel barbell with no elasticity. Participants perform single-leg deadlifts using this barbell under the same speed conditions and loading parameters as the elastic barbell.
223866367|NCT07061795|BEHAVIORAL|healthy living behaviors|Effect of prenatal care with home visits on healthy lifestyle behaviors during pregnancy
223866368|NCT07060404|DRUG|Daily primaquine (0.5 mg/kg per day) for 14 days given with food food and water|Women will receive daily doses of PQ (0.5 mg/kg per day) for 14 days at a total treatment dose of 7 mg/kg PQ. All doses will be to the nearest full tablet, with food and water to prevent gastrointestinal discomfort, as directly observed treatment. Women vomiting within 30 minutes of administration of any dose will be re-treated.
223866369|NCT07060404|DRUG|Daily primaquine 1 mg/kg per day for 7 days given with food and water|Women will receive daily doses of PQ (1 mg/kg per day) for 7 days at a total treatment dose of 7 mg/kg PQ. All doses will be to the nearest full tablet, with food and water to prevent gastrointestinal discomfort, as directly observed treatment. Women vomiting within 30 minutes of administration of any dose will be re-treated.
223866370|NCT07060404|DRUG|Single-dose tafenoquine given with food and water to prevent gastrointestinal discomfort|Women will receive a single dose of 300mg tafenoquine. Treatment will be given with food and water to prevent gastrointestinal discomfort, as directly observed treatment. Women vomiting within 30 minutes of administration of any dose will be re-treated.
223866371|NCT07060703|DIAGNOSTIC_TEST|Osteodensitometry|"exploration of long bones using non-invasive Guided Wave Velocity (GWV) technology.~comparison of ultrasound parameters (cortical thickness and porosity, among others) with BMD values (spine, right and left femoral necks) obtained by DXA.~\[Time Frame: 20 MIN\]"
223866372|NCT07060352|DIAGNOSTIC_TEST|Ankle Dorsiflexion Index (ADI) measurement|Ankle Dorsiflexion Index (ADI) measurement at D0 and W8
223866373|NCT07059559|OTHER|Rhythmic walking|Patients who consent to participate and pass the screening process were randomly assigned to groups based on the order of their participation (random by sequence): control group or rhythmic walking group.
223866374|NCT07061587|BEHAVIORAL|Gout action plan|Gout action plan (that we aim to develop and refine during the study based on traffic light color system which will be categorized into zone system- green zone (well controlled), yellow zone (mild symptoms), red zone (severe symptoms). It will outline how to manage gout, identifying triggers, recognizing symptoms, appropriate medication usage, and when to seek medical attention)
223866375|NCT07061600|BEHAVIORAL|"ich bin alles"|"The web-based information platform ich bin alles (www-ich-bin-alles.de) on depression and mental health in youth as well as its Social Media channels were developed by the Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy of the LMU Munich Hospital together with the Prof. Otto Beisheim Foundation. It is aimed at youth with depression, healthy youth, and their parents. The project focuses on education, prevention, low-threshold support, and destigmatisation through the transfer of evidence-based knowledge and hands-on supportive materials. Information material on Instagram is posted four times a week in the form of a post, a longer explanatory video and two reels (i.e. short videos with overlays of text and music). All content is evidence-based information created by the research team and is primarily based on the ich bin alles page."
223866376|NCT07061600|BEHAVIORAL|Instagram profile that provides educational content|The participants of the control group asked to follow an Instagram profile that provides educational content produced by a public broadcaster (https://www.instagram.com/terrax/) and is not dedicated to the topic of mental health. This channel also posts several times a week and provides educational or informational content.
223866377|NCT07060170|DEVICE|Augmented Reality Glasses|The child will wear the augmented reality glass, and a cartoon movie will be displayed during the injection of local anesthesia
223866378|NCT07060170|DEVICE|Virtual Reality Glasses|The child will wear the glass, and a cartoon movie will be displayed during the injection of local anesthesia.
223866379|NCT07061652|BEHAVIORAL|Survey|Participants will receive up to eight coaching sessions with a caregiver coach and resource materials and access to an online tool designed to help caregivers find resources.
223866380|NCT07061652|OTHER|the resource booklet from the American Cancer Society|The caregiver will receive the resource booklet from the American Cancer Society.
223866381|NCT07061171|DEVICE|Continuous Positive Airway Pressure|Using a ResMed S9 AutoSet-S device with a pressure range of 4-20 cmH2O. Used for 5-7 hours per night, at least 5 nights per week, for 3 months.
223866382|NCT07061171|DRUG|Herbal Decoction|A daily dose of a decoction containing Ban Xia, Ju Hong, Shi Chang Pu, Yu Jin, Lai Fu Zi, Fu Ling, Bai Zhi, Cang Er Zi, and Gan Cao, administered orally in two divided doses.
223866383|NCT07061171|PROCEDURE|Acupuncture|Daily sessions with needle retention for 30 minutes, 5 times per week. Acupoints included Anmian (EX-HN22), Lianquan (CV23), Shanzhong (CV17), Zhongwan (CV12), Kongzui (LU6), Pishu (BL20), Fenglong (ST40), Zusanli (ST36), Yinlingquan (SP9), and Zhaohai (KI6).
223866384|NCT07061171|PROCEDURE|Tuina Massage|Includes massage techniques applied to the head and occipital region to relax muscles and improve local circulation.
223866385|NCT07060885|BIOLOGICAL|HDM SLIT-tablet (12 SQ-HDM)|"For daily administration (1 tablet per day)~Other Names: Acarizax, Odactra"
223866386|NCT07060885|OTHER|Placebo|For daily administration (1 tablet per day)
223866387|NCT07061093|DRUG|Ethynyl estradiol and Drospirenone|Oral ethynyl estradiol (20 mcg) and 3 mg drospirenone for 24 days and 4 days free of hormones
223866388|NCT07061093|DRUG|Drospirenone|A drospirenone (4mg) only pill
223866389|NCT07061093|DRUG|Estetrol and Drospirenone|Oral estetrol (15 mg) and drospirenone (3 mg) for 24 days and 4 days of interval free of hormone
223866390|NCT07059832|DRUG|68Ga-NODAGA-SNA006|68Ga-NODAGA-SNA006 PET/CT: after intravenous injection of 0.05 mCi/kg body weight of quality-controlled 68Ga-NODAGA-SNA006, an integrated PET/CT scanner (Biograph mCT; Siemens, Germany) will be applied.
223866391|NCT07060794|DRUG|Tafenoquine|Tafenoquine in combination with DHA-piperaquine
223866392|NCT07060027|PROCEDURE|horizontal bone augmentation using single tenting screw|Patients in this group will undergo guided bone regeneration (GBR) using a single titanium bone screw placed in the crestal position to stabilize the graft material. The surgical procedure includes sulcular and vertical releasing incisions, elevation of full-thickness buccal and palatal/lingual flaps, and multiple cortical perforations to enhance angiogenesis. The defect will be filled with particulate allograft extended 10-12 mm apicocoronally and covered with a bovine pericardium membrane. A tension-free primary closure will be achieved using 5-0 polypropylene sutures. Bone screw removal and implant placement will occur 6 months postoperatively. This group is distinguished by the use of a single crestal screw for graft stabilization compared to dual-screw fixation in the control group.
223866393|NCT07060027|PROCEDURE|horizontal bone augmentation using Double tenting screw|Participants in this group will receive guided bone regeneration (GBR) with two titanium bone screws for enhanced graft stabilization. One screw will be placed at the crestal level, while a second screw will be inserted 5 mm apical to the first, providing vertical stabilization of the graft material. The procedure involves sulcular and vertical releasing incisions, full-thickness flap elevation on both buccal and palatal/lingual aspects, and multiple cortical perforations to stimulate vascularization. The defect will be filled with particulate allograft extending 10-12 mm apicocoronally and covered with a bovine pericardium membrane. Tension-free primary closure will be performed using 5-0 polypropylene sutures. At 6 months, screws will be removed and dental implants placed. This intervention is distinguished by the dual-screw fixation technique, designed to provide greater mechanical stability compared to the single-screw approach used in the comparator group.
223866394|NCT07061626|DRUG|Rhenium-186 Nanoliposome|Rhenium (186Re) Obisbemeda (Rhenium-186 NanoLiposome, 186RNL), BMEDA-chelated-186rhenium encapsulated within liposomes, allows the 186Re to be directly delivered to the site of the tumor through CED and maintain localization at the site of infusion.
223866395|NCT04854863|DIAGNOSTIC_TEST|Comprehensive assessment of respiratory muscle function.|Comprehensive assessment of respiratory muscle function to the point of its invasive assessment with recordings of twitch transdiaphragmatic pressure in response to magnetic phrenic nerve stimulation and stimulation of the lower thoracic nerve roots.
223866396|NCT01402479|DRUG|Ramipril|ramipril 2.5mg twice a day
223866397|NCT05012241|DIAGNOSTIC_TEST|Nine Hole Peg Test|At first, each patient will be asked to fill in the questionnaire. Then he/she will be tested by the Nine Hole Peg Test according to the new Czech version of extended manual for this test. Audio recording of verbal instructions will be used.
223866398|NCT02986412|OTHER|CG428|The experimental group will receive CG428. For each application, the patient should shake the bottle before spraying 10-12 times directly to the dry scalp whole area, with the nozzle, and then gently massage the whole scalp with fingertips in order to spread the lotion evenly until it has completely penetrated the scalp. Hairs should not be washed or shampooed within 1 hour following study treatment administration. Each dose should be spaced out by minimum 4 hours.
223866399|NCT03454646|DRUG|cholinesterase inhibitors (CI) (donepezil, galantamine or rivastigmine)|"The choice of the treatment will be done by the specialist according to his habits; the specialist will monitor the treatment as usual. All the recruited patients will be treated by CI according to the recommendations of the French HAS and the clinician's habits to choose the type of CI and adjust the dosage. After a 6-month period under CI treatment, patients will be classified according to the evolution of the Mini Mental State Examination (MMSE) as non-responders or responders.~Responders patients will continue their treatment according to the habits of the clinician. Non-responder patients will be included in the RCT, with individual randomization in two groups: one group who stops the CI, one group who continues the CI. All randomized patients will then be followed-up for two years with regular assessment of judgment criteria every 6 months."
223866400|NCT05661994|DIETARY_SUPPLEMENT|Omega-3 fatty acid supplementation|"Patients with CAD were divided into the Omega-3 Group (n:16) and Control Group (n:18) to evaluate the effects of omega-3 FA supplementation on biochemical parameters, especially serum fetuin-A, anthropometric measurements, and nutritional status. 1.560 mg/day omega-3 FA supplementation was applied for 8 weeks to 16 participants with CAD included in the omega-3 group."
223866401|NCT01355549|BIOLOGICAL|Platelet-rich plasma (PRP) therapy|Platelet rich plasma (PRP) describes a new technology in which platelets are isolated from a sample of a person's own blood using simple cell-separating systems such as centrifugation in order to obtain highly concentrated samples of platelets that can be re-injected into an injury site to promote healing.
223866402|NCT02369484|DRUG|Afatinib|40mg p.o./ day until documented progression or unacceptable toxicity
223866403|NCT00039000|DRUG|HSPPC-96 or Oncophage|
223866404|NCT05641506|DRUG|Yangzheng Xiaoji|Chinese patent medicine Yangzheng Xiaoji capsule， 0.36g\*4 tid，28 days as one cycle，up to 3 cycles.
223866405|NCT05641506|DRUG|Niraparib|"Niraparib 200 or 300mg\* QD PO continually;~\*The starting dose of niraparib was individualized based on patients' bodyweight and baseline platelet count; 200 mg QD for Patients with baseline body weight \<77 kg or platelets count \<150,000/μL;300 mg QD for Patients with baseline body weight ≥77 kg and platelets count ≥150,000/μL."
223866406|NCT02520349|DEVICE|MarkTen and e-Go e-cigarettes|
223866407|NCT01125254|DRUG|Amlodipine|5mg po for 12 months
223866408|NCT03590275|DRUG|FOLFIRINOX|Patients treated with first-line FOLFIRINOX (oxaliplatin + irinotecan + lederfolin + 5-fluorouracil) as per clinical practice were included in the study
223866409|NCT06510881|PROCEDURE|Rhinoplasty with or without cleft alveolus repair|"* Group (A) : Correction of nasal deformity will be carried out using costochondral cartilage strut for support of septum and lengthening of columella . A concomitant iliac bone graft is taken to reconstruct the alveolar bone . This group age will be above 8 years .~* Group (B) : Patients who present early before age of 8 years will have rhinoplasty session only . Another session will be prepared for cleft alveolus at age of 8 years ."
223866410|NCT01091649|DRUG|ABT-450|Low dose ABT-450 / ritonavir see Arm Description for more information
223866411|NCT01091649|DRUG|ritonavir|ritonavir see Arm Description for more information
223866412|NCT01091649|DRUG|ABT-450|High dose ABT-450 / ritonavir See Arm Description for more information
223866413|NCT00756405|BEHAVIORAL|Antioxidant diet|Participants were asked to increase antioxidant-rich food intake to approximately double their daily habitual intake and take a placebo pill.
223866414|NCT00756405|DIETARY_SUPPLEMENT|Antioxidant supplement|Participants were asked to consume their usual diet and take a supplement containing carotenoids, mixed tocopherols, vitamin C and selenium, designed to approximately double their daily habitual intake.
223866415|NCT00756405|DIETARY_SUPPLEMENT|Placebo|Participants were asked to consume their usual diet and take a placebo pill.
223866416|NCT03149302|OTHER|Local neck treatment (LNT)|The local neck treatment consists of cervical mobilization and specific therapeutic exercises (30 minutes). The participants will attend 12 individual treatment sessions (2 visits per week for 6 weeks).
223866417|NCT03149302|OTHER|LNT plus sensorimotor exercises|The local neck treatment (30 minutes) plus the sensorimotor exercise program (15 minutes). The sensorimotor exercises include cervical joint position sense and oculomotor training. The participants will attend 12 individual treatment sessions (2 visits per week for 6 weeks).
223866418|NCT03149302|OTHER|LNT plus balance exercises|The local neck treatment (30 minutes) plus the balance exercise program (15 minutes).The balance program includes with static balance and progress to dynamic balance and gait. The participants will attend 12 individual treatment sessions (2 visits per week for 6 weeks).
223866419|NCT03149302|OTHER|LNT plus sensorimotor/balance exercises|The local neck treatment (30 minutes) plus the sensorimotor exercise program (15 minutes) and the balance exercises (15 minutes). The participants will attend 12 individual treatment sessions (2 visits per week for 6 weeks).
223866420|NCT06145932|DEVICE|real rTMS|treated with 1HZ rTMS 1800 pulses / day,for 10 days
223866421|NCT06145932|DEVICE|sham rTMS|treated with sham rTMS 1800 pulses / day,for 10 days
223866422|NCT04669028|DRUG|NE3107|NE3107 is an investigational orally bioavailable, blood-brain barrier permeable anti-inflammatory agent with a new mechanism of action targeting multiple mechanisms of pathology in Alzheimer's disease.
223866423|NCT04669028|DRUG|Placebo|capsules that do not contain NE3107
223866424|NCT02021006|DRUG|nitrofurantoin|"antibiotic prophylaxis of urinary tract infections The antibiotic for prophylaxis will be chosen by Physicians according to the local resistance spectrum of bacteria responsible of UTIs~Physicians can chose one the following schedules:~* nitrofurantoin 1.5-2 mg/kg per day~* amoxicilline/clavulanic acid 15 mg/kg per day (dose expressed in units equivalent to amoxicilline)~* cefixime 2 mg/kg per day~* trimethoprim/sulfamethoxazole 2.5 mg/kg per day (dose expressed in units equivalent to trimethoprim)"
223866425|NCT02021006|OTHER|No prophylaxis|children will be followed, but no antibiotic prophylaxis will be administered
223866426|NCT02021006|DRUG|Amoxicillin-Potassium Clavulanate Combination|"antibiotic prophylaxis of urinary tract infections The antibiotic for prophylaxis will be chosen by Physicians according to the local resistance spectrum of bacteria responsible of UTIs~Physicians can chose one the following schedules:~* nitrofurantoin 1.5-2 mg/kg per day~* amoxicilline/clavulanic acid 15 mg/kg per day (dose expressed in units equivalent to amoxicilline)~* cefixime 2 mg/kg per day~* trimethoprim/sulfamethoxazole 2.5 mg/kg per day (dose expressed in units equivalent to trimethoprim)"
223866427|NCT02021006|DRUG|Trimethoprim/sulfamethoxazole|"antibiotic prophylaxis of urinary tract infections The antibiotic for prophylaxis will be chosen by Physicians according to the local resistance spectrum of bacteria responsible of UTIs~Physicians can chose one the following schedules:~* nitrofurantoin 1.5-2 mg/kg per day~* amoxicilline/clavulanic acid 15 mg/kg per day (dose expressed in units equivalent to amoxicilline)~* cefixime 2 mg/kg per day~* trimethoprim/sulfamethoxazole 2.5 mg/kg per day (dose expressed in units equivalent to trimethoprim)"
223866428|NCT02021006|DRUG|Cefixime|"antibiotic prophylaxis of urinary tract infections The antibiotic for prophylaxis will be chosen by Physicians according to the local resistance spectrum of bacteria responsible of UTIs~Physicians can chose one the following schedules:~* nitrofurantoin 1.5-2 mg/kg per day~* amoxicilline/clavulanic acid 15 mg/kg per day (dose expressed in units equivalent to amoxicilline)~* cefixime 2 mg/kg per day~* trimethoprim/sulfamethoxazole 2.5 mg/kg per day (dose expressed in units equivalent to trimethoprim)"
223866429|NCT02426996|PROCEDURE|Scan of shoulder|A scan (no injection) of the concerned shoulder will be performed at 3 months post-surgery. Cuts in three planes of space, including all of the glenoid. 3D reconstructions.
223866430|NCT02291094|DRUG|Lidocaine|Patients in intravenous lidocaine group received an intravenous bolus injection of 2 mg/kg lidocaine followed by a continuous lidocaine infusion of 3 mg/kg/hr.
223866431|NCT02291094|DRUG|Remifentanil|Patients in remifentanil group received an intravenous bolus injection of 2 mg/kg lidocaine followed by a continuous remifentanil infusion of 0,1 mcg/kg/min.
223866432|NCT05456334|DEVICE|Pulsed-dye laser|Comparance of pulsed-dye laser-mediated and conventional photodynamic therapy in a split-head design
223866433|NCT05456334|DEVICE|Fractional CO2-laser|Comparance of fractional CO2-laser-mediated or plain daylight photodynamic therapy in a split-head design
223866434|NCT05456334|DRUG|Metvix cream|Metvix-cream was used for photodynamic therapy in all experimental arms
223866435|NCT04820049|DRUG|F573|F573 for injection
223866436|NCT04820049|OTHER|Placebo|Water for injection
223866437|NCT04124185|DIAGNOSTIC_TEST|Ocular assessments|Complete ocular examination, Axial length and corneal curvature, Optical Coherence Tomography, Visual acuity, Contrast sensitivity
223866438|NCT00604955|DRUG|Paromomycin sulfate|Paromomycin will be administered intramuscularly at 11 mg/kg, once a day, for 21 consecutive days
223866439|NCT05247437|BEHAVIORAL|Digital Intensive Lifestyle Intervention|The FitD consists of 8 digital lessons on how to improve dietary and exercise habits using self-monitoring, goal-setting, cognitive restructuring, and other behavioral and cognitive strategies. The FitD app offers a virtual coach that guides the participant to complete the treatment.
223866440|NCT05247437|BEHAVIORAL|Digital Self-Help Control Condition|The digital self-help control condition consists of educational materials related to diet and exercise. The materials are open for access all at once. There is no guidance by a virtual coach or digital lessons.
223866441|NCT04620421|OTHER|Rhythm-based Multitask Training|Participants will be assigned to a weekly one-hour RYMA session for six months, followed by a six-month follow-up period without training. An experienced instructor will perform the RYMA sessions, which consists of a wide variety of rhythm-based multitask exercises performed to improvised piano music. The RYMA intervention is inspired by Dalcroze eurhythmics and exercises consists of components such as 1) coordination between hands and/or feet, 2) dissociation between hands and/or feet, 3) movements based on musical cues (e.g. follow the tempo), 4) movement inhibition based on musical cues, 5) handling of props (e.g. balls, scarfs, and plates), 6) pair or group-based coordination movements (e.g. clapping each other's hands and mirroring movements), 7) memorizing and repeating of rhythmic patterns, and 8) quick motoric responses to unexpected cues.
223866442|NCT05122468|PROCEDURE|Connective tissue Harvest and CAF|A connective tissue graft will be harvested from the palate as a free gingival graft, which will be de-epithelialized with a 15-c blade(Zucchelli et al. 2010) before opening of the opaque envelopes, which contains the allocation concealment. The dimensions of the graft achieve 3 to 5 mm mesial and distal from the lateral teeth with an ideal thickness about 1 to 1.5 mm. Donor tissue will be taken at premolar and molar level. In control sites, the graft will be adapted to cover each exposed root to the CEJ, and stabilized with either 6-0 resorbable sutures (with the knot placed under the papillary area) or a non-resorbable suture with the knot on the palatal side. For suturing of the graft, interrupted sutures or sling sutures (anchored to periosteum apical to the graft and hanging around the neck of the experimental teeth) may be used.
223866443|NCT05122468|PROCEDURE|Connective tissue Harvest and Tunnel|"A connective tissue graft will be harvested from the palate as a free gingival graft, which will be de-epithelialized with a 15-c blade(Zucchelli et al. 2010) before opening of the opaque envelopes, which contains the allocation concealment. The dimensions of the graft achieve 3 to 5 mm mesial and distal from the lateral teeth with an ideal thickness about 1 to 1.5 mm. Donor tissue will be taken at premolar and molar level.~In test sites, the graft should be slid through the tunnel. To accomplish the adequate position of the graft into the tunnel, 2 sutures are first placed, 1 at the most mesial and the other at the most distal aspect of the tunnel. The needles should pass underneath the tunnel and exit through the largest or most central gingival recession, the one through which the grafting tissue will be introduced. With these 2 sutures already inside the tunnel, the graft is bitten on both ends with vertical mattress sutures."
223866444|NCT04072328|DRUG|Propofol|Propofol will be given 0.5 mg/kg bolus initially, and can be administered additionally after a least 30 secs if necessary.
223866445|NCT04072328|DRUG|Midazolam|midazolam with propofol
223866446|NCT00979992|OTHER|Laboratory Biomarker Analysis|Correlative studies
223866447|NCT00979992|DRUG|Sunitinib Malate|Given PO
223866448|NCT06227637|OTHER|Local Muscle Vibration compared to Muscle energy technique in SIJD|Apply Local Muscle Vibration compared to Muscle energy technique on patients with sacroiliac joint dysfunction and note the effect on pain intensity, pain pressure threshold, functional disability, and innominate angle tilt in SIJD.
223866449|NCT03913715|OTHER|Ostomy Self-Management Training|Ostomy Self management Training group in which subject will learn using pouches and equipment, skincare, ostomy complications, nutritional needs, Impact on feelings, clothing changes, social relationships, being prepared for emergencies, Intimacy and sexuality, communication skills, tips for traveling and physical activity recommendations
223866450|NCT04807556|OTHER|Alusti Test|Physical and psychological functional conditions are key factors in the elderly population
223866451|NCT02740595|OTHER|one time exposure to e-cig with nicotine|one time exposure to e-cig vapor with nicotine
223866452|NCT02740595|OTHER|one time exposure to e-cig without nicotine|one time exposure to e-cig without nicotine
223866453|NCT02740595|OTHER|one time exposure to empty e-cig|one time exposure to empty e-cig (sham control
223866454|NCT02350842|DEVICE|triple-site biventricular pacing with peri-operative echo guidance|placement of the third lead by peri-operative echo guidance.
223866455|NCT02350842|DEVICE|standard biventricular pacing|standard biventricular pacing without optimization by echo guidance
223866456|NCT04468698|OTHER|Peritoneum insufflation|Before surgery pneumoperitoneum is established by insufflating gas into the abdomen. Intraabdominal pressure (IAP) is set to 15 mmHg for initial abdominal stretching and then decreased in a stepwise manner down until 8 mmHg.
223866457|NCT00947453|DRUG|montelukast|montelukast 10 mg once daily for 8 weeks
223866458|NCT04722237|BEHAVIORAL|Acceptance and Commitment Therapy|Acceptance and Commitment Therapy (ACT) is an evidence-based psychological therapy that has been used to improve physical and mental health among adults with health conditions, including cancer (Graham, Gouick, Krahe, \& Gillanders, 2016). It fosters engagement with, rather than avoidance of, painful experiences, to move towards acceptance of unchangeable difficulties alongside building a rich and meaningful life despite the presence of ongoing problems.
223866459|NCT02663297|DRUG|ATLCAR.CD30 cells|"Three dose levels will be evaluated:~Group One, 2x10\^7 cells/m\^2 (maximum dose 5x10\^7 cells)~Group Two, 1x10\^8 cells/m\^2 (maximum dose 2.5x10\^8 cells)~Group Three, 2x10\^8 cells/m\^2 (maximum dose 5x10\^8 cells)"
223866460|NCT04532528|DRUG|Dabigatran|Dabigatran
223866461|NCT00648349|DRUG|Rabeprazole Sodium Delayed-Release Tablets 20 mg|20mg, single dose fasting
223866462|NCT00648349|DRUG|Aciphex® Delayed-Release Tablets 20 mg|20mg, single dose fasting
223866463|NCT04425551|PROCEDURE|laser light|laser light destruction of telangiectatic vessels of lower eyelid margin via selective thermolysis
223866464|NCT06181916|BEHAVIORAL|Amp|Amp is a virtual support system mHealth app that provides information and social support to help young Black men who have sex with men (YBMSM) living with HIV achieve better HIV care continuum outcomes and overall well-being.
223866465|NCT01636687|DRUG|Placebo|2 injections of placebo to secukinumab 150mg per dose
223866466|NCT01636687|DRUG|Secukinumab 150mg|Secukinumab 150mg: 1 injection of 150 mg secukinumab and 1 injection of placebo to secukinumab 150mg per dose. After Week 52 database lock, study is open label so only 1 injection of secukinumab 150mg per dose were administered
223866467|NCT01636687|DRUG|Secukinumab 300mg|Secukinumab 300mg (2 injections of 150mg secukinumab per dose)
223866468|NCT06065332|OTHER|Velez Intense Hydration Mask® (biotech cellulose face mask)|Application to one randomized side half of a Velez Intense Hydration Mask® (biotech cellulose face mask)
223866469|NCT01824056|DRUG|18F-FDG|"During this study, subjects will receive a single i.v. administration of approximately 10 mCi 18F-FP-(+)-DTBZ immediately prior to imaging.~The proposed dose for this study is based on our phase I study. At the proposed human dose of 10 mCi, the whole body effective dose (ED) will be approximately 680 mrem. The estimated human ED is expected to be comparable to or below the range of other approved brain imaging agents, such as 18F-FDG."
223866470|NCT03924037|BEHAVIORAL|Intergenerational Knowledge Sharing group|Participants will attend a CBPR developed 12-session individual treatment for suicidal behavior. In addition to receiving the 12-session individual treatment, participants that are assigned to the Intergenerational Knowledge Sharing group will attend 12 weekly groups taught by tribal elders that focuses on sharing knowledge about the tribe.
223866471|NCT03924037|BEHAVIORAL|Support group|Participants will attend a CBPR developed 12-session individual treatment for suicidal behavior. In addition to receiving the 12-session individual treatment, participants that are assigned to the support group will attend 12 weekly support groups led by a behavioral health specialist that focuses on social support of the youth.
223866472|NCT02255877|DEVICE|Zip Surgical Skin Closure|Non invasive skin closure device for closure of the skin layer for surgical incisions or laceration repair.
223866473|NCT02255877|DEVICE|Steel Staples|Skin Closure device for the closure of the skin layer for surgical incisions.
223866474|NCT03001362|RADIATION|Radical external beam radiotherapy|pelvic radiotherapy to a dose of 45 Gy in 25 fractions with a tumor boost to a dose of 9 Gy in 5 fractions (thus total of 54 Gy/30 fractions to the primary tumor), combined with radio sensitizing chemotherapy.
223866475|NCT01203306|DRUG|bevacizumab + octreotide LAR + capecitabine|long acting octreotide acetate at a dose of 20 or 30 mg administered intramuscularly every 4 weeks; Bevacizumab at a dose of 5 mg/kg every 2 weeks; orally capecitabine administered at a dose of 2000 mg/daily
223866476|NCT00829348|OTHER|No intervention|60 patients post ACS receiving the study medication + doctor/pharmacist explanation at discharge - control group
223866477|NCT00829348|BEHAVIORAL|Short Message Service (SMS)|60 patients post ACS receiving the study medication + doctor/pharmacist explanation at discharge + daily SMS reminder service (8 PM) - study group
223866478|NCT04302805|DRUG|Privigen|Patients randomized to PE/rATG/IVIG group will receive IVIG 0.5g/kg infusions, on 1st, 3rd and 5th postoperative day.
223866479|NCT04302805|DRUG|Thymoglobulin|All patients will receive 1.5 mg/kg intraoperatively and 1 mg/kg when possible daily within first week up to cumulative dose 5-7 mg/kg.
223866480|NCT04302805|OTHER|Plasma Exchange|All patient will undergo Plasma Exchange before transplantation.
223866481|NCT02771899|DEVICE|spineEOS software|During a full-length exam from head to feet in the standing position, 3D reconstructions of the spine, the pelvis and lower extremities using spine workflow and global postural assessment workflow on spineEOS software will be performed.
223866482|NCT02771899|DEVICE|EOS|The system performs a full-length exam from head to feet in the standing position. 2D parameters will be obtained per standard of care.
223866483|NCT02949206|DRUG|JNJ-64179375|During part 1, participants will receive a single ascending Intravenous dose of JNJ-64179375 ranging from (0.03 mg/kg to 5.0 mg/kg). In Part 2, participants will receive a 2.5 mg/kg or highest tolerable dose if lower than 2.5 mg/kg of JNJ-64179375. In Part 3, participants will receive a Single Subcutaneous (SC) dose of 1.0 mg/kg or highest tolerable dose if less than 1.0 mg/kg of JNJ-64179375.
223866484|NCT02949206|DRUG|Placebo|Participants will randomly receive matching placebo in all 3 Parts on day 1 administered via IV Route (for Part 1 and 2) and SC route (for Part 3).
223866485|NCT02949206|DRUG|4 Factor Prothrombin Complex Concentrate (PCC)|Following a single dose of JNJ-64179375, participants will receive a single IV dose of 4 factor-PCC.
223866486|NCT05342818|DRUG|Neostigmine|will be given by infusion in 20 minutes once daily by a nurse blinded to the study drugs
223866487|NCT05342818|DRUG|Ondansetron 8mg|will be given by infusion in 20 minutes once daily by a nurse blinded to the study drugs
223866488|NCT05342818|DRUG|Metoclopramide Injection|will be given by infusion in 20 minutes once daily by a nurse blinded to the study drugs
223866489|NCT05342818|OTHER|Enteral feeding nutrition|The type and rate of enteral feeding nutrition will be the same for all patients (180ml/3h). All patients have a 30-degree head-up position
223866490|NCT05342818|OTHER|Sequential Organ Failure Assessment (SOFA) score|SOFA score will be performed on all patients before the beginning of the study
223866491|NCT00994097|DRUG|NGR-hTNF|NGR-hTNF: 0.8 mcg/m² as 60-minute intravenous infusion every 3 weeks until confirmed evidence of disease progression or unacceptable toxicity occurs
223866492|NCT00994097|DRUG|Cisplatin|Cisplatin: 80 mg/m² intravenous infusion on day 1 every 3 weeks for a maximum of 6 cycles
223866493|NCT00994097|DRUG|Gemcitabine|Gemcitabine: 1,250 mg/m² intravenous infusion on days 1 and 8 every 3 weeks for a maximum of 6 cycles
223866494|NCT00994097|DRUG|Pemetrexed|Pemetrexed: 500 mg/m² intravenous infusion on day 1 every 3 weeks for a maximum of 6 cycles
223866495|NCT04706078|DIAGNOSTIC_TEST|The biotype of gingival|The biotype of gingival was also determined by periodontal probe.
223866496|NCT03835819|DRUG|Pembrolizumab|Pembrolizumab is an immunotherapy that activates a patient's own immune system to recognize and kill tumor cells
223866497|NCT03835819|DRUG|IMGN853|Mirvetuximab soravtansine is an antibody-drug conjugate.
223866498|NCT01189513|DRUG|SCH 900105|10 mg/kg by vein every week on days 1, 8 and 15 of a 30 day cycle.
223866499|NCT03318484|DRUG|Optimal Medical Care|Aspirin 100mg once a day, Atorvastatin 20mg once a day and Antihypertensive Agents if necessary.
223866500|NCT03318484|COMBINATION_PRODUCT|Sonodynamic therapy|SDT treatment is the combination of sonosensitizer administration and target atherosclerotic lesions ultrasound exposure. Sinoporphyrin sodium (DVDMS) as sonosensitizer, is dissolved in 0.9% sodium solution for following skin test and intravenous injection. 0.01mg/ml DVDMS solution (0.1ml) is prepared for skin test followed by 0.04 mg/ml DVDMS solution intravenous injection (0.2mg/kg). The target atherosclerotic lesions are marked on the corresponding skin with ultrasound guidance and underwent ultrasound exposure after 4 hours incubation. The therapeutic ultrasonic transducer is fixed to the marked skin site for 15min of each lesion. Ultrasound parameters included intensity of 1.8W/cm2 for femoral lesions, resonance frequency: 1.0 MHz and duty factor: 30%.
223866501|NCT02229019|BEHAVIORAL|Volunteer mealtime assistance|
223866502|NCT01865253|DEVICE|Renal Denervation|Renal Denervation
223866503|NCT01231568|DRUG|Regimen A|Two gelatin capsules containing 75 mg GSK2118436A (dosed as the mesylate salt, micronized particles, equivalent to 150 mg free base), dosed fasted
223866504|NCT01231568|DRUG|Regimen B|Two gelatin capsules containing 75 mg GSK2118436A (dosed as the mesylate salt, larger, non-micronized particles, equivalent to 150 mg free base), dosed fasted
223866505|NCT01231568|DRUG|Regimen C|Two Hydroxy Propyl Methyl Cellulose (HPMC) capsules containing 75 mg GSK2118436A (dosed as the mesylate salt, micronized particles, equivalent to 150 mg free base), dosed fasted
223866506|NCT01231568|DRUG|Regimen D|Two HPMC capsules containing 75 mg GSK2118436A (dosed as the mesylate salt, micronized particles, equivalent to 150 mg free base), dosed with a high-fat meal
223866507|NCT03784378|DRUG|RXDX-105|RXDX-105 capsules will be administered orally on a continuous daily dosing regimen. Patients will be continue to be treated at the dose level they were previously treated on during participation on Study of RXDX-105.
223866508|NCT01321411|OTHER|Near Infrared Spectroscopy|"Healthy Volunteers:~Study #1 (Abnormal Pulmonary Resistance) subjects will breathe through a Starling resistor simulating abnormal pulmonary resistance. WOB and RMBF will be measured during resting breathing, as well as at 25%, 50% and 75% of MVV.~Study #2 (Abnormal Pulmonary Compliance) subjects will breathe while wearing a chest binder simulating abnormal pulmonary resistance. WOB and RMBF will be measured during resting breathing, as well as at 25%, 50% and 75% of MVV."
223866509|NCT01321411|OTHER|Near Infrared Spectroscopy|"Clinical Volunteers:~Study #3 (Abnormal Pulmonary Resistance) subjects recovering from COPD exacerbations will breathe through their ventilator circuit. PAV support will be altered to change the subjects' WOB. WOB and RMBF will be measured during resting breathing, as well as at 75%, 125% and 150% of baseline WOB.~Study #4 (Abnormal Pulmonary Compliance) subjects recovering from ARDS will breathe through their ventilator circuit. PAV support will be altered to change the subjects' WOB. WOB and RMBF will be measured during resting breathing, as well as at 75%, 125% and 150% of baseline WOB."
223866510|NCT03703518|OTHER|Mixed reality|"This group received 6 exercise sessions over 3 weeks, 2 days/week with an interval of 48 to 72 hours between sessions, using the Microsoft Hololens Roboraid game. The duration of the sessions will be 10 minutes."
223866511|NCT03703518|OTHER|Conventional exercise group|This group received 6 exercise sessions over 3 weeks, 2 days/week with an interval of 48 to 72 hours between sessions. This program will consist on stabilisation exercises of the cervical region, in neck deep flexors and neck deep extensors muscles to provide them with strength and resistance
223866512|NCT00115713|BEHAVIORAL|Aerobic Exercise Training|
223866513|NCT00115713|BEHAVIORAL|Resistance Exercise Training|
223866514|NCT00944372|DRUG|Indium In-111 pentetreotide|Single intravenous injection of 222MBq (6.0 mCi) Indium In-111 pentetreotide
223866515|NCT06450730|BEHAVIORAL|Cognitive-Behavioral Therapy: face-to-face + app|"This group will receive three 1-hour face-to-face CBT sessions (1,3,8). Participants will be involved in psychoeducation and practical activities related to psychological variables crucial for the adequate management of the disease (emotion regulation, self-efficacy, psychological flexibility, decision-making, etc.). These activities will include role-playing, discussions, and assignments to highlight the importance of emotions, thoughts, and healthy behaviors in managing diabetes and and their impact on the quality of life.~For the online sessions, an app will be developed to complement the face-to-face intervention. Participants will engage in 5-weeks of exercises with weekly activities related to the intervention content (2,5,6,7). The structure of the activities will mirror that of the face-to-face sessions and will include tasks, self-report instruments, reinforcement and activity monitoring. In addition, the app will incoportate multiple resources (texts, slides, videos)."
223866516|NCT01460290|DRUG|Asenapine|Asenapine will be administered open-label in pill form. Asenapine will be initiated at 5 mg twice a day and increased as tolerated to a maximum of 20 mg/day. It is anticipated that maximum stable dosing will be achieved by 4 weeks of treatment, although dosage may be reduced due to tolerability concerns at the discretion of the treating research psychiatrist.
223866517|NCT03663842|OTHER|Physical therapy treatment|All patients underwent the same techniques, and there was no modification of the intervention protocol during the study: (1) Myofascial release technique - piriformis muscle and biceps femoral muscle; (2) Hip joint mobilization; (3) Cross-fiber friction over the sacroiliac joints; (4) Neural mobilization to improve sciatic nerve excursion.
223866518|NCT00771160|DRUG|montelukast sodium|Arm 1: montelukast tablet 5 mg, QD. Treatment period is 12-weeks. Arm 2: montelukast tablet 10 mg, QD. Treatment period is 12-weeks.
223866519|NCT03166449|DIETARY_SUPPLEMENT|Neomune|Enteral feeding with Neomune was delivered within 24 to 48 h after admission or surgery according to Brain Trauma Foundation (BTF) Guidelines
223866520|NCT03166449|DIETARY_SUPPLEMENT|Fresubin® HP energy|Enteral feeding with Neomune was delivered within 24 to 48 h after admission or surgery according to Brain Trauma Foundation (BTF) Guidelines
223866521|NCT06386627|DIAGNOSTIC_TEST|Stimulus response task|Participants were tasked with performing a finger extension exercise that required pressing buttons in response to visual stimuli. In cases where physical movement was not possible, participants were instructed to imagine performing the task while focusing on their fingers.
223866522|NCT06386627|DIAGNOSTIC_TEST|Transcranial magnetic stimulation|Transcranial magnetic stimulation to assess the integrity of corticospinal connections
223866523|NCT05717751|PROCEDURE|surgical staging|para-aortic lymphadenectomy from the inferior mesenteric artery cranially to the aorta caudally via laparoscopy or laparotomy
223866524|NCT01442935|DRUG|Oxaliplatin|85mg/m² over 120 mn every 2 weeks up to progression or toxicity
223866525|NCT01442935|DRUG|Folinic Acid|400mg/m² over 120 mn every 2 weeks up to progression or toxicity
223866526|NCT01442935|DRUG|5-FU|400mg/m² in bolus, then 2400mg/m² over 46 h every 2 weeks up to progression or toxicity
223866527|NCT01442935|DRUG|Irinotecan|180mg/m² over 90 mn every 2 weeks up to progression or toxicity
223866528|NCT01442935|DRUG|Irinotecan|150mg/m² over 30-90 mn every 2 weeks up to progression or toxicity
223866529|NCT01442935|DRUG|Bevacizumab|5mg/kg over 90 mn every 2 weeks up to progression or toxicity
223866530|NCT01442935|DRUG|Cetuximab|500mg/m² over 90 mn every 2 weeks up to progression or toxicity
223866531|NCT06371196|DRUG|Babaodan Capsule|Babao Dan Capsule (State Drug License: Z10940006) is produced by Xiamen Traditional Chinese Medicine Factory Co., Ltd; Packing specification: 0.3g/capsule, 6 capsules/board×2 boards/small box; Ingredients are in vitro cultivated cowhide, snake gallbladder, antelope horn, pearl, panax ginseng, artificial musk, and so on. Intervention measures are really the original UDCA treatment program based on the addition of eight treasure Dan capsule, 2 capsules / times, tid, oral. Course of treatment: 3 months (based on 30 days/month).
223866532|NCT05317910|OTHER|MUSIC CARE|"Relaxation-type receptive musical intervention technique. The standardized 20-minute musical sequence is broken down into several phases that gradually lead the patient to relaxation using the new U-Mount technique \[1, 2\] (Figure 1). The effect works by reducing the musical rhythm, orchestral formation, frequencies and volume (the U descending phase). After a maximum relaxation phase (lower part of the U), a re-activating phase (ascending branch of the U) is followed."
223866533|NCT02874430|DRUG|Metformin Hydrochloride|Given orally
223866534|NCT02874430|DRUG|Doxycycline|Given orally
223866535|NCT05201976|OTHER|Virtually administered Cardiac Rehab program|Virtual cardiac rehab program delivered through the CardaHealth platform.
223866536|NCT05201976|OTHER|Standard of Care in person Cardiac Rehab Program|Clinically ordered standard of care cardiac rehab program (in-person).
223866537|NCT06466902|OTHER|Quality assessment of D2 lymphadenectomy using the PhotoNode Score|"During the surgical procedure, a set of 5 high quality laparoscopic intraoperative images of the surgical field will be put on record. Photographs will be taken at the end of the lymphadenectomy phase, before the reconstructive phase begins.~Three surgeons will review the images. Quality of D2 lymphadenectomy will be assessed independently rating eight node stations (1, 5, 6, 7, 8a, 9, 11p and 12a), based upon the evaluation of the 5 images. Each node station will be given a score from 0 to 3, corresponding to a judgment of Unevaluable (0), Poor (1), Doubtful (2) or Excellent (3) lymphadenectomy respectively, in that specific node station.~A total score for each patient will be independently obtained from each reviewer ranging from a minimum of 7 (poor lymphadenectomy) to a maximum of 24 (excellent lymphadenectomy). The PNS for each patient will originate from the average score among the three reviewers."
223866538|NCT01291615|DRUG|Gemcitabine|800mg/m2 - 1000mg/m2, day 1 every 3 weeks. day 1, 15 every 4 weeks. day 1, 8 every 3 weeks. day 1, 8, 15, every 4 weeks
223866539|NCT01291615|DRUG|S-1|S-1 40mg/day - 120mg/day (depend on body surface area) day 1-14, every 3 weeks day 1-28, every 6 weeks.
223866540|NCT05211544|OTHER|physical therapy modalities and exercise|30 patient with osteoartritis will do knee strengthening exercise for half an hour a day,3 days a week. This exercise program will continue for 4 weeks. Also they will receive physical therapy modalities during two weeks for ten times. physical therapy modalities include hotpack, tens, ultrasound.
223866541|NCT05211544|OTHER|kinesio taping and exercise|30 patient with osteoartritis will do knee strengthening exercise for half an hour a day,3 days a week. This exercise program will continue for 4 weeks. Also they will receive kinesio tape for their knee three times a week for two week
223866542|NCT05211544|OTHER|exercise|30 patient with osteoartritis will do knee strengthening exercise for half an hour a day,3 days a week. This exercise program will continue for 4 weeks.
223866543|NCT03050788|DEVICE|Smartphone confocal microscopy|Imaging of skin lesion using the smartphone confocal microscopy
223866544|NCT02466672|OTHER|none - observational only|
223866545|NCT01039688|DRUG|CP-690,550|Oral tablets administered at a dose of 5 mg BID for 24 months
223866546|NCT01039688|DRUG|CP-690,550|Oral tablets administered at a dose of 10 mg BID for 24 months
223866547|NCT01039688|DRUG|Disease-modifying antirheumatic drug|Oral capsules,administered as 10 mg per week for 4 weeks titrated to 15 mg per week for 4 weeks, then titrated to 20 mg week for 24 months
223866548|NCT05400707|DIAGNOSTIC_TEST|Assessment of vital signs|heart rate, blood pressure, body temperature, respiration rate, peripheral capillary haemoglobin oxygen saturation)
223866549|NCT05400707|DIAGNOSTIC_TEST|Assessment of patient mobility at presentation|Patients are asked how they assess their own mobility: - Stable walking without aids or limited mobility with aids (walking aid, wheelchair, lying down).
223866550|NCT05400707|DIAGNOSTIC_TEST|Assessment of level of consciousness by AVPUC scale|Assessment of level of consciousness by AVPUC scale (alert, new confusion, verbal, pain, unresponsive, new confusion)
223866551|NCT05400707|DIAGNOSTIC_TEST|Assessment of symptoms patients presenting when admitted to ED|Questionnaire with a predefined list of 37 symptoms
223866552|NCT05400707|DIAGNOSTIC_TEST|Assessment of what matters most in patients of 65 years and older|"Patients over the age of 65 are asked the following: generally asked: what matters most to you at the moment? and why is that important for you?."
223866553|NCT05400707|DIAGNOSTIC_TEST|Assessment of Decision-making in senior physicians|Questionnaire consisting of 10 questions about the decision-making processes in the emergency department and the factors that form the basis of their decisions regarding the diagnosis, treatment, and disposition of the patient.
223866554|NCT05400707|DIAGNOSTIC_TEST|Pain Numeric Rating Scale (NRS)|"The NRS is a segmented numeric version of the visual analog scale (VAS) in which a respondent selects a whole number (0-10 integers) that best reflects the intensity of his/her pain ('0' representing one pain extreme (e.g. no pain) to '10' representing the other pain extreme (e.g. pain as bad as you can imagine))"
223866555|NCT05400707|DIAGNOSTIC_TEST|Clinical Frailty Scale (CFS)|The CFS is a commonly used score to assess frailty. It was developed within the Canadian Study of Health and Aging and consists of a 9-level ordinal scale ranging from very fit (score 1) to living with very severe frailty (score 8), and score 9 reserved for those who are terminally ill.
223866556|NCT00668863|DRUG|FOLFIRI (The combination regimen of Irinotecan, l-Leucovorin and 5-Fluorouracil)|FOLFIRI treatment with Sunitinib on Day, Irinotecan 180M/M IV , l-Leucovorin 200M/M, 5FU 400M/M bolus and 2400M/M in 46-hour continuous infusion on Day1 each 42 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
223866557|NCT00668863|DRUG|Sunitinib|37.5mg daily P.O., 4 weeks On 2weeks Off each 42 day cycle. Number of cycles: until progression or unacceptable toxicity develops.
223866558|NCT02995655|DRUG|CX-01|CX-01 at a dose of 4mg/kg on Day 1 of each 28-day cycle, followed by a continuous intravenous infusion at a dose of 0.25 mg/kg/hour for Days 1 through 7 of each cycle.
223866559|NCT02995655|DRUG|Azacitidine|Azacitidine at a dose of 75mg/m\^2 on Days 1-7 of each 28-day cycle.
223866560|NCT02995655|PROCEDURE|Bone marrow biopsy|-Baseline, day 28 of even-numbered cycle through Cycle 6, and end of study
223866561|NCT02995655|PROCEDURE|Peripheral blood draw|-Day 1 of each cycle, day 3 of each cycle, day 7 of each cycle, day 28 of every even-numbered cycle through Cycle 6, and end of study
223866562|NCT02768571|DRUG|Cerebrolysin|Cerebrolysin- cerebrolysin 30 ml with 100 ml dilution/day \* 21 days with rehabilitation
223866563|NCT02768571|DRUG|Placebo|Placebo- saline 100 ml/day \* 21 days with rehabilitation
223866564|NCT01296191|DRUG|Moxifloxacin|One drop 4 times daily for 3 days and one drop the day of sample collection
223866565|NCT01296191|DRUG|besifloxacin|One drop 4 times daily for 3 days and one drop on day of sample collection
223866566|NCT04959136|DEVICE|Ambulatory Monitoring Solution|Aim is to evaluate PR; RR; NIBP, cNIBP, SpO2 and arterial blood pressure with investigational Ambulatory Monitoring Solution (AMS)
223866567|NCT01733238|DRUG|PNT2258|
223866568|NCT05311137|PROCEDURE|Radiofrequency ablation|Combined use of radiofrequency ablation, cryoablation, left bundle branch pacing, and left atrial appendage closure according to the actual situation of the patient.
223866569|NCT02599935|DIETARY_SUPPLEMENT|Hypercaloric beverages|Nutritional supplement: Hypercaloric beverages
223866570|NCT02599935|OTHER|standard treatment|No other than standard treatment
223866571|NCT02599935|OTHER|educational structured counseling|Nutritional counseling leaded to patient and caregivers
223866572|NCT01809392|DRUG|decitabine|36 mg/m2 on day 42 after transplantation and administered daily for 5 consecutive days every 28 days for up to a total of 10 cycles
223866573|NCT04370418|DRUG|short course chemo-radiation with 5-fluorouracil|neo-adjuvant short course chemo-radiation in locally advanced rectal cancer patients followed by delayed surgery
223866574|NCT00992173|DRUG|Ultratrace Iobenguane I 131|Subjects will receive an Imaging Dose of 0.1 mCi/kg \[3.7 MBq/kg\] (a minimum dose of 1.0 mCi \[37 MBq\] but not to exceed 5.0 mCi \[185 MBq\]) of Ultratrace iobenguane I 131 to have dosimetry performed and to confirm tumor uptake of the test article prior to receiving each of 2 planned Therapeutic Doses of Ultratrace iobeneguane I 131 . Within 28 days of screening, eligible subjects (as confirmed by the first Imaging dose study)will receive an Ultratrace iobenguane I 131 Therapeutic dose of of 15.0 - 18.0 mCi/kg (max. 666 MBq/kg) followed by imaging 7 days later or upon discharge from radiation isolation. A second Therapeutic Dose (preceded by a repeat Image Dose and dosimetry study)and imaging upon discharge from radiation isolation will be repeated approximately 8 weeks after the first dose.
223866575|NCT02969863|DEVICE|Bihormonal Bionic Pancreas|Participants will wear a Bionic Pancreas that uses glucagon and insulin (bihormonal) to automate their glucose control based on continuous glucose monitor readings.
223866576|NCT02969863|DEVICE|Insulin Only Bionic Pancreas|Participants will wear a Bionic Pancreas that uses just insulin (insulin-only) to automate their glucose control based on continuous glucose monitor readings.
223866577|NCT02969863|OTHER|Monitored for Hypoglycemia|During half of the study arms (one each bihormonal bionic pancreas, insulin-only bionic pancreas and usual care) the subjects will be remotely monitored for device connectivity and hypoglycemia, and will be notified by study staff any time their continuous glucose monitor reads less than 50 mg/dl for 15 mintues.
223866578|NCT02969863|OTHER|Not Monitored for Hypoglycemia|During half of the study arms (one each bihormonal bionic pancreas, insulin-only bionic pancreas and usual care) the subjects will be remotely monitored for device connectivity only, not hypoglycemia.
223866579|NCT04072653|PROCEDURE|SLNB is spared|SLNB is spared in patients with negative preoperative axillary assessment(including LymphPET and other imaging examinations)
223866580|NCT06518538|DRUG|CPI-613, modified Folfirinox|"* CPI-613, devimistat~* mFFX: Oxaliplatin, Folinic acid, Fluorouracil and Irinotecan"
223866581|NCT03737240|DRUG|IDegLira|Participants in this study arm will discontinue all other diabetes medications, except for metformin which will be continued at prescribed dose (unless contraindicated). IDegLira will be given once daily, at the same time of the day with or without food for 26 weeks. IDegLira will be titrated until the maximum dose is reached, up to the target fasting blood glucose of 70 to 100 milligrams per deciliter (mg/dL).
223866582|NCT03737240|DRUG|Insulin Degludec (U-100)|Participants in the basal-bolus insulin study arm will discontinue all other diabetes medications, except for metformin which will be continued at the prescribed dose (unless contraindicated). Insulin Degludec (U-100) will be given once daily at the same time for 26 weeks. The dose will be titrated up to the fasting blood glucose target of 70 to 100 mg/dL, with no maximum dose.
223866583|NCT03737240|DRUG|Insulin Aspart|Participants in the basal-bolus insulin study arm will discontinue all other diabetes medications, except for metformin which will be continued at the prescribed dose (unless contraindicated). Insulin aspart will be taken before meals with a titration schedule and dose adjustment protocol to target pre-meal blood glucose level of 70 to 100 mg/dL.
223866584|NCT04164056|DEVICE|deep brain stimulation|deep brain stimulation on the hippocampus or the anterior nucleus of the thalamus
223866585|NCT04155177|PROCEDURE|training for french ambulatory caesarean section|"The participant will be first invited to consult a theoretical support and a video treating on FAUCS.~After that, he will be asked to be the first assistant, in a FAUCS procedure with one of the two senior surgeons assigned for the study.~In a second step, the trainee will have to perform all the steps of the FAUCS, assisted by one of the two senior surgeons . During each surgery, Operative time will be measured, while an evaluation on four stages according to the Zwisch model of supervision will performed by the senior surgeons .~Once, the two seniors agree on the highest level assessment for the resident, he will be allowed to operate alone FAUCS procedures and will be evaluated by the measurement of operating times, the neonatal outcomes and the occurrence or not of complications.~finally, total number of FAUCS procedures required for each resident in order to master the technique will be determined."
223866586|NCT00080639|OTHER|physiologic testing|
223866587|NCT00080639|PROCEDURE|study of high risk factors|
223866588|NCT01434862|DRUG|Closed loop with pramlintide|Dose of pramlintide will be titrated based on subject's current prescribed dose. The target dose is 60 mcq three times daily.
223866589|NCT01434862|DEVICE|Closed loop without pramlintide|This visit will assess how well the closed loop system works without the pramlintide.
223866590|NCT01434862|DRUG|Open loop with pramlintide|Dose of pramlintide will be titrated based on subject's current prescribed dose. The target dose is 60 mcq three times daily.
223866591|NCT05172388|OTHER|Air purifier|Real purification and sham purification would be conducted in the dormintory rooms (about 25 in total) of the study subjects for 4 days, following a randomized crossover design, which means a real air purifier and a sham purifier would be placed in the same dormintory room with a wash-out interval (15 days).
223866592|NCT05176964|RADIATION|split-course HFRT|7Gy/F, d7, q3w, 5 cycles
223866593|NCT05176964|DRUG|CAPOX chemotherapy|CAPOX chemotherapy will commence on day 1 for each of six cycles: oxaliplatin 130 mg/m\^2 intravenous infusion on day 1,followed by capecitabine 1000 mg/m\^2 administered orally twice daily on day 1 to 14 of a 21-day cycle.
223866594|NCT05176964|DRUG|Tislelizumab|Tislelizumab 200 mg intravenous infusion on day 1 of each 21-day cycle for each of six cycles.
223866595|NCT01430858|DEVICE|Strain Gauge|The study participants will each undergo sterile surgical implantation of a tibial bone strain gauge in the right leg (dominance will recorded and determined by handedness). A single stacked, 45°, rosette strain gauge (FRA-2-11 Tokyo Sokki Kenkyujo Co., Japan) will be unilaterally bonded to the medial tibial cortex and carefully aligned with the long axis of the tibia. The gauge will be attached at the mid-shaft region, to determine the transmission of the vibrations through the bone and quantification of the microstructural effect.
223866596|NCT01430858|OTHER|Vibration therapy|"Galileo 900 platform. Study subjects will be asked to stand on the device for a series of 36 tests, with vibrations applied at various frequencies and amplitudes. A 20-second duration of videomotion \& strain gauge readings will be captured.~Juvent 1000 platform The volunteers will stand on the platform for one minute during which a 20-second duration of videomotion \& strain gauge readings will be captured.~Power Plate Pro5 Two amplitude settings will be tested, described as low \& high. The subject will stand on each platform test for up to 1 minute, during which a 20-second duration of videomotion \& strain gauge readings will be captured."
223866597|NCT04802369|DIAGNOSTIC_TEST|Diagnostic tests|Selected prognostic factors will be analyzed, among others: demographic data of the patient, physical examination, symptoms, etiology and history of arterial hypertension, co-morbidities, results of selected laboratory tests, selected electrocardiographic and echocardiographic data, patient's cooperation with the doctor, treatment applied, parameters in the spiroergometric study, non-invasive assessment for central arterial pressure waveform analysis and body mass analysis.
223866598|NCT00471627|PROCEDURE|Pancreaticojejunostomy without stiches through the pancreas|The pancreas is cut with knife, without electric cautery and without stay sutures. Bleeding is controlled with 2-3 exactly placed stiches. The pancreatic stump is sunk inside the jejunum, which is tightened around the pancreas with a purse string. A biodegradable stent is left into the pancreatic duct to prevent its occlusion when tightning the purse string.
223866599|NCT03443453|DRUG|MIV-711|MIV-711 administered as tablets and capsules at four occasions
223866600|NCT02831712|DIETARY_SUPPLEMENT|Ferrous Fumarate|One tablet of a commercial iron supplement (Ferrous Fumarate 200 mg, from Drug House of Australia) will be provided to participants after overnight fast. The intervention is only one time.
223866601|NCT04575740|DEVICE|PAP|Positive airway pressure to treat sleep apnea
223866602|NCT02658370|DEVICE|animated home-based exercises (Wii-fit)|
223866603|NCT02658370|PROCEDURE|conventional home-based exercise program|
223866604|NCT06108271|DEVICE|Triglotix®|The Triglotix® has a biocompatible self-expanding viscoelastic cuff that is located in the supraglottic, glottic and subglottic space. This cuff separates the endotracheal tube from the laryngeal vestibule in the supraglottic space and the vocal cords avoiding direct tissue damage from the plastic components of the tube. The viscoelastic cuff self-expands after the endotracheal tube is in adequate position in the airway. Then it adapts progressively and gradually to the shape of structures it comes in contact with, applying minimal pressure to the surrounding tissue. The ETT-T also has two wire reinforced segments: the first is located outside the mouth to prevent deformation related with kinking, while the second segment is positioned distally along the larynx. The primary purpose of this design is to mitigate torsional, rotational and lateralization forces that the tube may encounter while the patient is intubated.
223866605|NCT06108271|DEVICE|Conventional endotracheal tube|Conventional endotracheal tube that is currently used worldwide
223866606|NCT05878158|DRUG|Simvastatin|pulpotomy of immature permanent teeth
223866607|NCT02448446|DRUG|ranibizumab 0.3mg|intravitreally administered
223866608|NCT01742481|BEHAVIORAL|Education and empowerment|Three group sessions delivered once per week over three weeks. Education on late effects of treatment, survivorship care, how to request medical records, and role playing on how to talk to a provider about childhood cancer health risks
223866609|NCT00661648|DEVICE|the closed-loop STG-22 system (Nikkiso Inc, Tokyo, Japan)|artificial pancreas
223866610|NCT03802318|DRUG|Rabeprazole|Rabeprazole daily four time (Bid) or daily four times (Qid) Amoxicillin used daily two times (1000 mg bid) or daily four times (500 mg qid) apply in the first line or the second line H pylori eradication therapy
223866611|NCT03561064|BEHAVIORAL|CBT-I|Eligible participants will receive CBT-I by a licensed clinical psychologist.
223866612|NCT02070666|BEHAVIORAL|Protective mechanical ventilation|"Ventilation mode: volume control, pressure control, dual modes (It is allowed to change to a spontaneous mode; a minimum of 5 cmH2O level of support should be used; in case the resulting tidal volume exceeds 6 mL/kg PBW this is accepted. This is not a reason to use more sedation and/or muscle relaxants, or to switch the ventilator to a controlled mode of ventilation).~* Tidal volume: 6 mL/Kg PBW, decreasing 1 mL/kg PBW each step if necessary (steps of 5 minutes), to maintain plateau pressure \< 25 cmH2O until a minimum tidal volume of 4 mL/Kg PBW, unless the patient suffers from severe dyspnea or unacceptable acidosis.~* Fraction of inspired oxygen inspired oxygen fraction (FiO2) \> 0.21 to maintain oxygen saturation 90-92%.~* PEEP ≥ 5 cmH2O, and optimized to maintain Oxygen saturation (SpO2) 90-92% (left to the discretion of the attending physician).~* Plateau pressure ≤ 25 cmH2O"
223866613|NCT02070666|BEHAVIORAL|Control group|"Ventilation mode: volume control, pressure control, dual modes (It is allowed to change to a spontaneous mode, with the level of support adjusted to reach tidal volumes minimum of 8 mL/kg predicted body weight PBW; if it is not possible, the data collection should be continue and an intention-to-treat analysis will be done).~* Tidal volume: minimum 8 mL/kg PBW. It is possible to increase until 10 mL/kg PBW unless plateau pressure increases above 25 cmH2O.~  · FiO2 \> 0.21 to maintain oxygen saturation 90-92%.~* PEEP ≥ 5 cmH2O, and optimized to maintain SpO2 90-92% (left to the discretion of the attending physician).~* Plateau pressure ≤ 25 cm H2O."
223866614|NCT02070666|OTHER|Dead space|Volumetric capnography will be used. Dead space (Vd/Vt) measurements will be taken at baseline and daily after initiation of mechanical ventilation. Nursing and respiratory care activities (including changes to ventilator settings) will be suspended for at least 5 minutes prior to all Vd/Vt measurements.
223866615|NCT04496050|DRUG|Prostaglandin E1|The same drug will be used. In this study the same patients will be evaluated after the same dose of medication.
223866616|NCT00643071|DRUG|Tacrolimus|Oral
223866617|NCT01238744|DIETARY_SUPPLEMENT|Flaxseed drink|Drink containing flaxseed mucilage
223866618|NCT01238744|DIETARY_SUPPLEMENT|Flaxseed drink|Drink containing flaxseed mucilage
223866619|NCT01238744|DIETARY_SUPPLEMENT|Flaxseed tablet|Tablets containing flaxseed mucilage consumed with a control drink
223866620|NCT01238744|DIETARY_SUPPLEMENT|Control drink|Control drink
223866621|NCT01254188|DRUG|Nilotinib|This was an open-label, single-arm, prospective, multi-center, Phase IIIb clinical study with nilotinib 300 mg bid treatment in newly diagnosed CML-CP patients not previously treated with imatinib therapy and diagnosed within 6 months of study entry. For patients insufficiently responding to nilotinib 300 mg bid, the dose may have been increased to 400 mg bid. Among patients with adverse events who had dose reduction, this study also allowed a possible re-escalation to 300 mg bid.
223866622|NCT04929587|OTHER|This is a observational research, there is no intervention|This is a observational research, there is no intervention
223866623|NCT02384070|PROCEDURE|FFR|Fractional flow reserve tracings were calculated using a Volcano pressure wire intra-coronary system after ensuring proper calibration of the aortic pressure transducer and the guidewire, using 6 Fr-guide catheters. Before crossing the stenosis, baseline pressure was measured by the guide catheter and the pressure guidewire were equalized according to the manufacturer's specifications. After advancing the pressure sensor across the stenosis, coronary hyperemia was induced using intravenous adenosine (140μg/kg/min until a steady state was reached for at least 3 minutes). Fractional flow reserve was considered positive if it was less than 0.80.
223866624|NCT02384070|DRUG|Aspirin|All patients received a chewable aspirin of 325 mg at least 6 hours before the procedure
223866625|NCT02384070|DRUG|Clopidogrel|All patient receiving clopidogrel, were loaded with 600 mg at least 6 hours before the procedure
223866626|NCT02384070|DRUG|Bivalirudin|Dosed based on the weight at 0.75 mg/kg I.V. bolus dose followed by a 1.75 mg/kg/hr I.V. infusion for the duration of the procedure
223866627|NCT00622219|OTHER|Randomized Drug Testing Trial|Adolescents in the experimental condition will receive all of the services offered by the Adolescent Substance Abuse Program (including individual meetings, parent and adolescent group meetings, psychopharmacology as indicated)and will be enrolled in a random drug testing program (with an average of 12 requests for testing over a 12 week period).
223866628|NCT05706168|DEVICE|treadmill exercise|Treadmill exercise is a form of aerobic exercise training that involves the use of a treadmill machine in a structured exercise programs.
223866629|NCT05706168|DEVICE|Cycle ergometer exercise|Cycle ergometer exercise is a form of aerobic exercise training that involves the use of a stationery recumbent bike in a structured exercise programs.
223866630|NCT02539108|BIOLOGICAL|Fluzone® Quadrivalent Influenza Vaccine, No Preservative|0.25 mL, Intramuscular (Pediatric Dose, 2015 2016 formulation)
223866631|NCT02539108|BIOLOGICAL|Fluzone® Quadrivalent Influenza Vaccine, No Preservative|0.5 mL, Intramuscular (2015 2016 formulation)
223866632|NCT01981837|DRUG|ALN-TTRSC (revusiran) for subcutaneous administration|
223866633|NCT02861066|BEHAVIORAL|Mindfulness-based Intervention|MBI will be delivered in group format, 120 minutes per week, for 6 consecutive weeks with 10-20 participants per group.
223866634|NCT03410446|DRUG|Ketamine Hydrochloride|Ketamine is a N-methyl-D-aspartate (NMDA) antagonist.
223866635|NCT03264443|BEHAVIORAL|Health education|Weekly group lectures (1h each) giving information on patient's best practices to manage hypertension.
223866636|NCT03264443|BEHAVIORAL|Combined training|Combined training (aerobic and strength exercises), in moderate intensities (perceived exertion controlled) performed 3x/week (1h) duration with a education component (10') based on the contents of the health intervention.
223866637|NCT02561039|DRUG|Ibandronate|Participants will receive ibandronate, either as a 6-mg IV infusion every 3 to 4 weeks or a 50-mg tablet PO daily, for 4 months.
223866638|NCT04275245|DRUG|Meplazumab for Injection|humanized MAb against CD147
223866639|NCT00930098|DRUG|clofarabine|
223866640|NCT04896034|DEVICE|MILTA Device|Patients in MILTA Device group will each receive 2 sessions of PBM in this study, the first session within 24 hours of delivery, and the second session 24 hours after the first session.
223866641|NCT04896034|DEVICE|" control 1  fake MILTA device"|Patients in group control 1 will each receive 2 sessions of PBM in this study, the first session within 24 hours of delivery, and the second session 24 hours after the first session.
223866642|NCT03519737|DEVICE|tPA in combination with the Sonolysis Headframe (TUS)|tPA: 60 minutes per approved labeling TUS insonation via the Sonolysis Headframe: minimum 90 minutes - maximum 120 minutes
223866643|NCT03519737|DEVICE|tPA in combination with the Sonolysis Headframe (Sham TUS)|tPA per approved labeling Sham (inactive) TUS insonation via the Sonolysis Headframe: minimum 90 minutes - maximum 120 minutes
223866644|NCT01428297|DRUG|BPR277 ointment (controlled application)|
223866645|NCT01428297|DRUG|Placebo (Vehicle)|
223866646|NCT01428297|DRUG|BPR277 ointment|
223866647|NCT01428297|DRUG|Placebo (Vehicle)|
223866648|NCT01428297|DRUG|BPR277|
223866649|NCT01428297|DRUG|Placebo (Vehicle)|
223866650|NCT05025995|BEHAVIORAL|Serious health game|Serious health game
223866651|NCT00547469|DRUG|DDP733|
223866652|NCT01084031|DRUG|propofol|intravenous propofol with sevoflurane inhalation induction
223866653|NCT00906529|DRUG|Levemir (Detemir) and Novolog (Aspart) Insulin|Will use individualized doses of levemir (detemir) and novolog (aspart) insulin to reach blood glucose goal
223866654|NCT01755949|DRUG|Colchicine, 0.6 mg PO BID|Colchicine tablets will be over-encapsulated by the research pharmacy to be indistinguishable from placebo
223866655|NCT01755949|DRUG|Matching placebo|Matching placebo tablets will be encapsulated by the research pharmacy to be indistinguishable from active drug
223866656|NCT00436072|DRUG|ZD6474|Orally on a daily basis
223866657|NCT00436072|DRUG|Cetuximab|Infusion once weekly
223866658|NCT00436072|DRUG|Irinotecan|Infusion once the safe dose of ZD6474 and cetuximab is established
223866659|NCT04454151|DRUG|Azithromycin Tablets|given PO Azithromycin 250 mg X1 daily, for 4 months, followed by a non-treatment follow-up period of 12 month.
223866660|NCT06075069|DEVICE|Feeding appliance|A preliminary alginate impression was made using wax stock tray to get a preliminary cast and construct a self-cure acrylic custom-made tray. A Medium viscosity rubber base impression material was used for making final impression which in turn will be poured to obtain a master cast. On this master cast, a feeding appliance will be constructed. Readymade facebow with two straight side length of hard, rounded, of 2mm diameter, 15cm length Nickel-Chrome wire with omega loops (at the end of the wire) was used to form extra-oral wings to be used as a retentive aid to maintain the prosthesis in situ. The appliance was fabricated in clear acrylic resin then finished and polished. A small piece of cold cure acrylic resin was added and adapted to the omega loops and manipulated to follow the checks contour.
223866661|NCT00824135|DRUG|Clofarabine|"One dose intravenously every 24 hrs for five days total.~Dose level 1 Clofarabine 40 mg/m2/day intravenous Dose level 2 Clofarabine 45 mg/m2/day intravenous Dose Level 3 Clofarabine 50 mg/m2/day intravenous"
223866662|NCT00824135|PROCEDURE|Stem Cell Transplantation, Hematopoietic|Haploidentical Hematopoietic Stem Cell Transplantation (two infusions, one on day 0 and the other on day +1)
223866663|NCT00824135|OTHER|OKT3|"Start at 0.0125 mg/kg intravenous once a day, taper dose down incrementally and discontinue after 17 days total~Muromonab-CD3"
223866664|NCT00824135|DRUG|Thiotepa|5 mg/kg/day intravenous every 12 hours (2 doses total)
223866665|NCT00824135|DRUG|Melphalan|60mg/m2 intravenous every 12 hours for 2 doses total.
223866666|NCT00824135|DRUG|Mycophenolate mofetil|"Mycophenolate mofetil 600 mg/m2 intravenous two times a day~(continue for approximately 2 months or as clinically indicated)"
223866667|NCT00824135|DRUG|Rituximab|375 mg/m2 intravenous for 1 dose total
223866668|NCT00824135|OTHER|G-CSF|G-CSF 5 mcg/kg/day subcutaneous or intravenous until ANC greater than 2.000/mm3 for 2 consecutive days and then as clinically indicated.
223866669|NCT05468411|OTHER|Oral application of miracle fruit pill|Miracle fruit has a taste modifying function from sourness to sweetness when it is exposed to an acidic environment. To activate the miracle fruit's function, a miracle fruit pill should be orally administered to coat taste buds prior to eating sour food. Thus, participants are instructed to place a miracle fruit pill is on their tongue, and roll the pill around their mouth to allow full contact of the pill with the surface of the oral cavity without chewing until the pill completely dissolved. A miracle fruit pill is administered prior to eating.
223866670|NCT05468411|OTHER|Oral application of sugar candy|To simulate the miracle fruit's function as a placebo, a chewable sugar candy that has a similar appearance to miracle fruit pill is orally administered. The same protocol that is used in miracle fruit intervention is followed in this placebo intervention but with a chewable sugar candy. Participants are instructed to place a sugar candy is on their tongue, and roll the candy around their mouth to allow full contact of the candy with the surface of the oral cavity without chewing until the candy completely dissolved. A sugar candy is administered prior to eating.
223866671|NCT02122445|DEVICE|Cramer Sports Motion Tape|lower body exercises with and without Cramer Sports Motion tape applied to the hip
223866672|NCT02957136|DEVICE|Rapid respiratory pathogen nucleic acid amplification test|Patients randomized to the rapid respiratory pathogen nucleic acid amplification test (Film Array Respiratory Panel, BioFire Diagnostics), will receive usual physician-directed care plus results from a rapid diagnostic test for 20 common respiratory pathogens. Patients will have a nasopharyngeal swab sample collected and tested during the ED episode of care with results reported in the electronic medical record (EMR) within two hours of sample collection. ED physicians will receive education regarding the rapid respiratory pathogen test prior to commencing the study. During the study, ED physicians will be free to review and interpret the respiratory pathogen test results and make treatment decisions based on their individual clinical judgment without involvement of study personnel.
223866673|NCT02867670|DEVICE|Transcranial Magnetic Stimulation|TMS is a form of non-invasive brain stimulation which uses magnetic pulses to stimulate regions of the brain from outside the head, on the scalp. Specifically, TMS is performed with a copper-and-plastic coil that emits a magnetic field, which can affect brain cells in specific locations. In this study, researchers will also use a form of TMS called theta-burst stimulation (TBS), where TMS pulses are delivered rapidly over time.
223866674|NCT05689125|DEVICE|Railroaded bougie|Residents expose the glottis by a video laryngoscope and place the tip of bougie through the vocal cords. Then, an assistant loads an endotracheal tube on the free end of the bougie. Residents advance the endotracheal tube over the bougie and withdraw the bougie.
223866675|NCT05689125|DEVICE|Preloaded bougie|Residents expose the glottis by a video laryngoscope and perform the endotracheal intubation using a bougie with a preloaded endotracheal tube while an assistant secures the free end of the bougie. Residents withdraw the bougie when the endotracheal tube reaches an appropriate depth.
223866676|NCT05689125|DEVICE|Stylet|Residents expose the glottis by a video laryngoscope and perform the endotracheal intubation with the assistance of a stylet. An assistant withdraws the stylet when the tip of the endotracheal tube passes through the vocal cords. Then residents place the endotracheal tube to an appropriate depth.
223866677|NCT00119951|BEHAVIORAL|Participation on the ACOR Listserv|
223866678|NCT00345007|PROCEDURE|Scleral buckling|
223866679|NCT02200770|DRUG|Inebilizumab|Participants will receive IV inebilizumab 300 mg.
223866680|NCT02200770|OTHER|Placebo|Participants will receive IV placebo matched to inebilizumab.
223866681|NCT01909167|BEHAVIORAL|Online Cognitive Behavioral Therapy (CBT)|CBT treatment: Patients randomized to the online treatment will have, in total, 10 real time individual sessions of 40min each, starting at the 20-23rd gestational week and lasting until 6 weeks postpartum. The therapy will be delivered every two weeks, with a break from the 36th gestational week until the 4th week postpartum.
223866682|NCT01909167|OTHER|Treatment as usual|Patients randomized to the treatment as usual arm will be advised by their GP,perinatal psychiatric team or mental health midwife concerning treatment.
223866683|NCT04018924|DEVICE|Illumination with blue light (400-430nm) for 60 seconds with a power density of 120mW/sqcm (EmoLED device)|Debridement and Dressing or compressive dressing if needed
223866684|NCT03957798|BEHAVIORAL|RecoveryWarrior 2.0|"RecoveryWarrior 2.0 was developed for use with Microsoft Kinect running on a Windows personal computer. All games made use of whole-body motion detection and the same voice-recognition feature. Body motions included a variety of arm, leg, and whole-body movements to physically enact the motions of destroying or evading images of drugs and drug paraphernalia. Voice features consisted of recognition of the refusal phrase I'm Clean Players could say or shout I'm Clean in order to gain additional strength for their game play avatar. All game art was created in a hyperrealistic, idealized, heroic style."
223866685|NCT01647438|BEHAVIORAL|Lifestyle Intervention|Participants will enroll in heart disease prevention group sessions focusing on physical activity, diet, weight, and stress management. Each group will have 6 to 8 participants who will attend 6 weekly, 90 minute group education sessions at Metropolitan Asian Family Services. During each session, participants will watch videos on the day's topic followed by discussion, activities, and assistance in setting realistic goals with attention to physical activity, diet, weight, and stress management. Participants will receive telephone support after each session and up to 12 weeks after they have completed the classes to help reinforce learning objectives.
223866686|NCT01647438|OTHER|Print Health Education|Participants will receive primary care referrals and print health education material about heart disease prevention in the mail.
223866687|NCT05086159|BEHAVIORAL|Pain Neuroscience Education|"Weekly education sessions lasting approximately 30 minutes each, once a week for four weeks.~Session 1: the nervous system is like an alarm to protect.~Session 2: common ways the nervous system becomes sensitive.~Session 3: importance of gradual conditioning and neuroplasticity.~Session 4: common ways to decrease nervous system sensitivity."
223866688|NCT05086159|BEHAVIORAL|Exercise|"The exercise protocol for each group will be identical and modeled after the Back to Fitness program. This program will consist of a 5-10-minute cardiovascular warm-up of walking in place or riding an exercise bike. Next is a 15-minute circuit consisting of 10 different general exercises for 1-minute each. Finally, a 5-minute cool down will consist of light stretching and trunk range of motion exercises. Each exercise will be tailored as easy, medium, or hard depending on the individual patient's tolerance. This program has been shown to be equally as effective as motor control exercises for long-term outcomes in patients with non-specific LBP."
223866689|NCT05086159|BEHAVIORAL|Traditional Education|"Weekly education sessions lasting approximately 30 minutes each, once a week for four weeks.~Session 1 will include a basic overview of the anatomy of the spine.~Session 2 will discuss an overview of stress symptoms to include hypervigilance, avoidance, and re-experiencing.~Session 3 will cover common recommendations delivered in stress education: the do's and don'ts of stress management.~Session 4: review and mindfulness."
223866690|NCT05007678|DRUG|leflunomide|leflunomide administered orally; daily loading dose of 100mg for 3 days, followed by a daily maintenance dose 10-20mg daily, to a total course of 10 days
223866691|NCT02990546|DRUG|midodrine|Midodrine will be given to treatment arm as enteral medication
223866692|NCT02990546|OTHER|Standard of Care|Patients in the control arm will receive standard of care for septic shock
223866693|NCT01760564|DRUG|Miglustat|miglustat 200mg tid for adult. For children surface area correction will be made. A lower dose may be used initially to decrease side effect.
223866694|NCT00911521|DRUG|human papillomavirus vaccination (Gardasil)|3 doses of the human papillomavirus vaccines to be given at baseline, month 2 and month 6
223866695|NCT06519253|OTHER|Virtual reality (VR) music intervention|The VR music intervention consists of musical performance which were already recorded. This is accessible classic music. During the intervention, the participants will be able to see the musicians (and the stage, empty auditorium, etc.) and hear the music.
223866696|NCT06519253|OTHER|Music only control|The control group consists of the same musical performances, with the audio only
223866697|NCT06449170|OTHER|Mango Ataulfo|In this intervention, subjects consumed 150g of mango Ataulfo plus 150 ml of control beverage (Supportan® Drink Cappuccino). The addition of the control beverage has the purpose of providing energy intake and limiting the noise that the control beverage may contribute to the metabolomic profile in urine and serum.
223866698|NCT06449170|OTHER|Avocado Hass|In this intervention, subjects consumed 120g of avocado hass plus 150 ml of a control beverage (Supportan® Drink Cappuccino). The addition of the control beverage provides energy intake and limits the noise that the beverage may contribute to the metabolomic profile in urine and serum.
223866699|NCT06449170|OTHER|Nopal|In this intervention, subjects consumed 300g of cooked nopal and 150 ml of control beverage (Supportan® Drink Cappuccino). The addition of the control beverage provides energy intake and limits the noise that the beverage may contribute to the metabolic profile in urine and serum.
223866700|NCT06449170|OTHER|3 corn tortilla|In this intervention, subjects consumed 3 corn tortillas and 150 ml of control beverage (Supportan® Drink Cappuccino). The addition of the control beverage provides energy intake and limits the noise that the beverage may contribute to the metabolic profile in urine and serum.
223866701|NCT06449170|OTHER|Guava|In this intervention, subjects consumed 3 guavas and 150 ml of control beverage (Supportan® Drink Cappuccino). The addition of the control beverage provides energy intake and limits the noise that the beverage may contribute to the metabolic profile in urine and serum.
223866702|NCT06449170|OTHER|Amaranth|In this intervention, subjects consumed 1/2 cup of amaranth and 150 ml of control beverage (Supportan® Drink Cappuccino). The addition of the control beverage provides energy intake and limits the noise that the beverage may contribute to the metabolic profile in urine and serum.
223866703|NCT06449170|DIETARY_SUPPLEMENT|Control Beverage (Supportan Drink ® Capuccino)|In this intervention, subjects consumed 290ml of Supportan Drink ® Capuccino to act as a control for the metabolomic profiling in urine and serum.
223866704|NCT01214824|DEVICE|FreeStyle Navigator Continuous Glucose Monitoring System|Six x 5 day wears of the continuous glucose monitoring device. Two of the 6 wears will be using a masked device (1 at the start and 1 at the end of the study).
223866705|NCT04277221|BIOLOGICAL|Autologous Dendritic Cell/Tumor Antigen, ADCTA|ADCTA is an individualized cell immunotherapy co-culturing autologous dendritic cells derived from peripheral blood mononuclear cells (PBMNCs) with autologous tumor cell as antigen in order to evoke specific immune response.
223866706|NCT03899324|DRUG|Bumetanide white, oblong, scored tablet|Bumetanide with a titration period
223866707|NCT03899324|DRUG|Placebo white, oblong, scored tablet|placebo intake identically to group 1
223866708|NCT01128075|DEVICE|RebiSmart™|Electronic self-injection device (RebiSmart™) to inject Rebif®
223866709|NCT01128075|DEVICE|RebiSmart™|Electronic self-injection device (RebiSmart™) to inject Rebif®
223866710|NCT02779062|OTHER|Interview|Interview
223866711|NCT02287441|OTHER|Tomato|Tomato Products (tomato)
223866712|NCT02287441|OTHER|Raw|Vegetables Prepared Raw (raw).
223866713|NCT01860612|DEVICE|Artificial Iris (CustomFlex)|
223866714|NCT00946582|BEHAVIORAL|Barkley's parenting management program|It is a parent training group to teach behavior therapy techniques to parents of children with ADHD. The group will contain about 10 parents of children with ADHD. It will be conducted 1.5 hour per session, one session per week, and 11 sessions totally.
223866715|NCT01353001|BEHAVIORAL|Diet|Participants will be given a calorie and fat gram goal according to their initial bodyweight. The fat gram goals will be set at 20% to 30% of total caloric intake. Subject calorie and fat gram goals are as follows: Subjects weighing less than 175 pounds will receive a diet prescription of 1200 calories and 27 fat grams per day. Subjects weighing between 175 and 219 pounds will receive a diet prescription of 1500 calories and 33 fat grams per day. Subjects weighing between 220 and 249 pounds will receive a diet prescription of 1800 calories and 40 fat grams per day. Subjects weighing greater than 250 pounds will receive a diet prescription of 2100 calories and 47 fat grams per day.
223866716|NCT01353001|BEHAVIORAL|Diet Plus Aerobic Training|Participants will receive all of the components as described for the DIET group. Additionally, this group will participate in supervised progressive aerobic training 3 days per week. Participants will be required to attend 3 sessions per week where they will participate in supervised exercise sessions progressing from 60 to 180 minutes per week of moderate-intensity (3.0-6.0 METS) aerobic exercise. 180 minutes per week of exercise will meet the American College of Sports Medicine and the American Heart Association recommendations of 450-750 METS.min.wk-1.
223866717|NCT01353001|BEHAVIORAL|Diet plus Resistance Training|Participants will receive all of the components as the DIET group. Participants will also participate in supervised resistance training protocol 3 days per week in the form of an individual session. The protocol will start the participants at a low volume of exercise at an intensity of 50-55% of 1-repetition maximum, and oscillate in both volume and intensity during the intervention, with a general trend toward increases in intensity as outlined in the ACSM Position Stand.
223866718|NCT05976295|DRUG|Jianpi Qushi Huatan Decoction|The treatment group will receive the Jianpi Qushi Huatan Decoction (consisting of Radix astragali, Atractylodes Lancea, Dioscorea oppositifolia, Cyperus rotundus, Lindera aggregata, Aconitum gymnandrum and Ligusticum wallichii, among others). Subjects will take the medication from the first day of inclusion, dissolving and consuming one packet twice a day (morning and evening) for a total of three months.
223866719|NCT05976295|DRUG|Placebo|The control group will receive a placebo treatment.
223866720|NCT03433690|BEHAVIORAL|HIIT|High Intensity Interval Training for twelve weeks
223866721|NCT03433690|BEHAVIORAL|Moderate training|Moderate training for twelve weeks
223866722|NCT02214160|DRUG|UX007|Administered orally (PO) with food or by gastrostomy tube, at the target dose range of 25-35% of total calories.
223866723|NCT03380611|DIETARY_SUPPLEMENT|Wakame|Consumption of 4.8 grams wakame per day for 17 days
223866724|NCT03380611|DIETARY_SUPPLEMENT|Spirulina|Consumption of 4.8 grams spirulina per day for 17 days
223866725|NCT03380611|DIETARY_SUPPLEMENT|Control|Consumption of microcrystalline cellulose for 17 days
223866726|NCT04882553|PROCEDURE|Diaphragmatic echography|Echography of the diaphragm at the zone of apposition. End-inspiratory and/or end-expiratory thickness of the diaphragm will be measured in M-mode.
223866727|NCT04882553|PROCEDURE|Measurement of esophageal pressure|Pressure will be measured in the lower third of the esophagus using an esophageal balloon and pressure transducer.
223866728|NCT04882553|DIAGNOSTIC_TEST|Registration of respiratory mechanics|Pressures and volumes will be registered by the Fluxmed respiratory monitor (MBMED, Argentina)
223866729|NCT02423798|DEVICE|Glucose sensor (Enlite)|This is a postmarket, interventional, open-label, non-randomized, single center clinical research trial. The trial will adopt a prospective single-sample design using the Yellow Spring Instruments (YSI) plasma glucose reference sampling procedure in the clinic and selfmonitoring of blood glucose (SMBG) plasma glucose reference sampling procedure at home. The trial will consist of 6 visits to the investigational site: a visit for informed consent procedures (Visit 0), a screening visit (Visit 1), 3 study visits (Visit 2-4) and a final examination (Visit 5).
223866730|NCT04114786|DEVICE|3D-printed mask|After patient is enrolled to the study, patients will have CT Sim. MR Sim (used to create 3D printed mask for intervention arm only) CT sim repeat (for intervention arm only) before start of radiation Patients will be asked to fill out a questionnaire after each CT Scan, and during the first and last week of radiation treatment
223866731|NCT04114786|DEVICE|Thermoplastic mask|Patients will undergo standard of care simulation, planning and treatment with conventional workflow using thermoplastic mask.They will complete the tolerability questionnaire after CT-sim, and towards the end of the first and last week of treatment.
223866732|NCT04134273|DRUG|CLPG Topical Gel 1%|Clindamycin Phosphate Topical Gel 1% (Taro Pharmaceuticals U.S.A, Inc.)
223866733|NCT04134273|DRUG|Clindamycin|Clindamycin Phosphate topical gel 1%
223866734|NCT04134273|DRUG|Placebo|Placebo (vehicle of the test product) (Taro Pharmaceuticals Inc.)
223866735|NCT05920642|DRUG|Intrathecal morphine administration|Administration of morphine into the spinal canal.
223866736|NCT05920642|DRUG|Parenteral administration of analgesics|Standard postoperative pain management of analgesics using parenteral route of administration.
223866737|NCT02579031|DEVICE|Orsiro|Novel biodegradable-polymer sirolimus-eluting stent used during primary percutaneous coronary intervention
223866738|NCT02579031|DEVICE|Xience|Durable-polymer everolimus-eluting stent used during primary percutaneous coronary intervention
223866739|NCT04224792|OTHER|Center-based exercise program|A routine individualized exercise prescription and supervised exercise sessions at a minimum of once per week for 11 weeks with an exercise prescription updated monthly.
223866740|NCT04224792|OTHER|Home-based exercise program|A one-time supervised exercise session with Cardiac Rehabilitation staff and a routine individualized exercise prescription for exercises to do at home. Additionally, weekly telephone followup calls by a clinical exercise physiologist for 11 weeks consisting of an exercise tip.
223866741|NCT02742571|OTHER|non applicable|
223866742|NCT03284567|BEHAVIORAL|Football fitness|"The training will consist of 30 min of warm-up exercises (running, dribbling, passing, shooting, balance and muscle strength exercises), followed by 2 x 15 minutes of 4-7 a-side games.~Training will take place on a natural grass pitch. In adverse weather conditions (i.e., \< 5°C or heavy rain) training will be performed indoors"
223866743|NCT05877352|RADIATION|Intraoperative Electron Radiotherapy (IOERT)|IOERT can be defined as the direct application of high-energy electron beam irradiation to a tumour bed during an operative procedure. This approach permits precise delivery of a single large fraction of radiation directly and specifically to high recurrence risk anatomical target areas, which the treating clinicians (surgeon and attending clinical oncologist) predict will be a close or involved margin, while simultaneously displacing and shielding dose-limiting radiosensitive structures such as the small bowel or ureter or any anastomoses, if not involved by tumour.
223866744|NCT05877352|PROCEDURE|Extended Margin Surgery|Surgery intended to remove both a tumour and any metastases
223866745|NCT02191319|DRUG|Viramune®|
223866746|NCT04933890|DEVICE|Use of Eko DUO electronic stethoscope|Auscultation of heart sounds using electronic stethoscope
223866747|NCT02063425|DRUG|Fluoxetine|1 pill of 20mg / day, during 3 months
223866748|NCT02063425|DRUG|Placebo of fluoxetine|1 pill of 20mg/day, during 3 months
223866749|NCT00065832|BEHAVIORAL|Reading Instruction|
223866750|NCT00042848|DRUG|modafinil|
223866751|NCT00826475|BEHAVIORAL|Mindfulness Based Stress Reduction MBSR|Mindfulness Based Stress Reduction: 8 weeks behavioral structured group programme teaching mindfulness skills
223866752|NCT00826475|BEHAVIORAL|Psychoeducation|Psychoeducation on Migraine, Progressive Muscle Relaxation PMR, three group meetings within 8 weeks, daily home work
223866753|NCT01264679|DRUG|Ferumoxytol|IV Ferumoxytol
223866754|NCT04149808|DEVICE|Mepilex Ag (burn dressing)|Dressing for low to medium exuding burns and wounds.
223866755|NCT04149808|DEVICE|Xeroform Dressing|Standard of care dressing for low to medium exuding burns and wounds.
223866756|NCT04608305|BIOLOGICAL|IIBR-100, low dose (prime)|Single administration of IIBR-100 1\*10E5 pfu/ml
223866757|NCT04608305|BIOLOGICAL|IIBR-100 medium dose (prime)|Single administration of IIBR-100 1\*10E6 pfu/ml
223866758|NCT04608305|BIOLOGICAL|IIBR-100 high-dose (prime)|Single administration of IIBR-100 1\*10E7 pfu/ml
223866759|NCT04608305|BIOLOGICAL|IIBR-100 low-dose (prime-boost)|Two administrations of IIBR-100 1\*10E5 pfu/ml, 28 days apart
223866760|NCT04608305|OTHER|Saline Placebo (single)|Single administration of saline placebo
223866761|NCT04608305|OTHER|Saline Placebo (double)|Two administrations of saline placebo, 28 days apart
223866762|NCT04608305|BIOLOGICAL|IIBR-100 medium-dose (prime-boost)|Two administrations of IIBR-100 1\*10E6 pfu/ml, 28 days apart
223866763|NCT04608305|BIOLOGICAL|IIBR-100 high-dose (prime-boost)|Two administrations of IIBR-100 1\*10E7 pfu/ml, 28 days apart
223866764|NCT04608305|BIOLOGICAL|IIBR-100 top-dose (prime-boost)|Two administrations of IIBR-100 1\*10E8 pfu/ml, 28 days apart
223866765|NCT05425862|DRUG|Pidnarulex|Pidnarulex is a treatment that is designed to stop the action of a particular protein in the body called Polymerase I, that cancer cells rely on. Laboratory studies show that pidnarulex targets a process involving Polymerase I within cells, which can lead to a decrease in cancer growth. Pidnarulex has been shown to have some anticancer activity in ovarian cancer and haematological cancers.
223866766|NCT05425862|DRUG|Talazoparib|Talazoparib belongs to a class of drugs called PARP inhibitors, which is currently being used to treat various types of cancer. Talazoparib blocks the function of PARP, a protein that is involved in repairing DNA in cells. By stopping damaged DNA in cells from being repaired, this will lead to accumulation of DNA damage in the cancer cell and ultimately cancer cell death. Talazoparib has established anticancer activity in breast, ovarian and prostate cancers with underlying DNA repair defects. This class of drug have also been used in combination with other treatments such as radiation or chemotherapy to further increase cell death within the cancer.
223866767|NCT03131037|BIOLOGICAL|CAN-2409 + valacyclovir|CAN-2409 will be administered intratumorally followed by oral valacyclovir. Valacyclovir will be administered orally at a fixed dose for 14 days after each injection.
223866768|NCT00275392|BEHAVIORAL|Vestibular rehabilitation|vestibular adaptation and substitution exercises
223866769|NCT00275392|BEHAVIORAL|Placebo|placebo vestibular exercises
223866770|NCT03352024|OTHER|Relational care|Relational care is combined with a cutaneous anesthesia (Transcutaneous device(plan) of lidocaïne-pilocaïne (EMLA®))
223866771|NCT03352024|OTHER|Hypno-analgesia|Hypno-analgesia is combined with a cutaneous anesthesia (Transcutaneous device(plan) of lidocaïne-pilocaïne (EMLA®))
223866772|NCT04498663|BEHAVIORAL|Emotion- and Relationship-Focused Therapeutic Interview|In this study, the therapeutic interview will be one-session lasting 90 minutes. Participants will explore prior and ongoing stressful life experiences. Participants will be educated about the role of stress in pain and will be encouraged to identify links between stressors, psychological and emotional conflicts related to the stressors, and their pain symptoms. The interview will encourage the experience and expression of previously avoided emotions related to interpersonal stressors.
223866773|NCT01830738|PROCEDURE|Single-port, peri-umbilical hysterectomy|Patients in this arm have a hysterectomy via a single-port peri-umbilical laparoscopic surgical technique.
223866774|NCT01830738|PROCEDURE|Multi-port hysterectomy|Patients in this arm have a hysterectomy via a conventional multi-port laparoscopic surgical technique.
223866775|NCT05235698|PROCEDURE|Ophthalmological examinations|Visual acuity, slit lamp examination, eye pressure, retinophotography, indocyanine green retinal angiography, OCT-A( Optical Coherence Tomography- Angiography), adaptive optics, automated visual field
223866776|NCT05235698|PROCEDURE|GlycoCheck|"Evaluation of the glycocalyx of sublingual capillaries with the GlycoCheck :~A sidestream dark field camera, coupled with GlycoCheck™ software is used to visualize the patient's sublingual microvascularization"
223866777|NCT05865938|DEVICE|PASCAL vs. MitraClip|"transcatheter mitral valve repair of the mitral valve (M-TEER) using the Edwards PASCAL Transcatheter Valve Repair System or the Abbott MitraClip in patients with severe and symptomatic degenerative or functional mitral regurgitation (FMR).~The type of device system used was not randomized but was determined by the operational structuring of the mitral valve program such that patients were scheduled for the next available implantation date with weekly alternating time slots for MitraClip device and PASCAL device."
223866778|NCT03946046|PROCEDURE|Clinical targeting|The intervention consists of the injection of botulinum toxin A into muscles targeted by a clinical localization method (observation and palpation of target muscles)
223866779|NCT03946046|PROCEDURE|Ultrasonography targeting|The intervention consists of the injection of botulinum toxin A into muscles by ultrason-guided method
223866780|NCT05298020|DRUG|Envafolimab|400mg,sc,d1,Q4W
223866781|NCT05298020|DRUG|Endostar|210mg，CIV72h，d1-3，Q4W
223866782|NCT05298020|DRUG|Nab paclitaxel|125mg/m2,iv,d1,d8,Q4W
223866783|NCT05298020|DRUG|Gemcitabine|1000mg/m2, iv,d1,d8，Q4W
223866784|NCT05035303|PROCEDURE|Nor-Epinephrine injection versus saline during PCNL|The PCNL tract is infiltrated by Nor-Epinephrine or Normal Saline before its dilatation.
223866785|NCT02799134|DRUG|Dexamethasone|
223866786|NCT02799134|DRUG|Vitamin C|
223866787|NCT03877198|DEVICE|Automated oxygen control by the CLiO2 algorithm|Automated oxygen control for 24 hours by the CLiO2 algorithm, preceded by a 1 hour wash-out period
223866788|NCT03877198|DEVICE|Automated oxygen control by the Oxygenie algorithm|Automated oxygen control for 24 hours by the Oxygenie algorithm, in case of switch in ventilator preceded by a 1-hour wash-out period.
223866789|NCT01598870|OTHER|Diagnostic tests|Leukocyte count by automated counters; reagent strips for leukocyte esterase and for lactoferrin; ascitic fluid pH; leukocyte cytometry; bacterial DNA detection and quantification.
223866790|NCT04532450|DEVICE|Branched / fenestrated aortic stent graft|Endovascular repair of an aortic aneurysm with a branched/fenestrated stent graft to revascularise all visceral arteries together with exclusion of the aortic aneurysm.
223866791|NCT01226849|DRUG|bortezomib, rituximab, ifosphamide, etoposide, carboplatin|Rituximab 375mg/m2 day 1 Etoposide 100mg/m2 day 1-3 Carboplatin AUC (5) max 800 days 2 Ifosfamide continuous infusion + Mesna 5/m2/24hr day2 Bortezomib 1.3mg/m2 days 1,4,8,11 G-CSF (SC) recommended
223866792|NCT02555215|DRUG|dimethyl fumarate|administered orally
223866793|NCT05407571|BEHAVIORAL|Significance of Echogenic Amniotic Fluid on Perinatal Outcome|To estimate the nature of echogenic amniotic fluid.and To overcome unnecessary intervention due to turbid amniotic fluid, assess neonatal outcome and estimate gestational age at time of delivery in patients with echogenic amniotic fluid.
223866794|NCT01983371|DRUG|Ferumoxytol|All study patients will receive a dose of ferumoxytol for the MRI. Ferumoxytol will be administered intravenously at a dose of 6 mg/kg, for a maximum dose of 510 mg.
223866795|NCT01983371|OTHER|Magnetic Resonance Imaging|All study patients will undergo a ferumoxytol-enhanced MRI in addition to any other ongoing care for colorectal cancer. Histopathologic analysis of lymph nodes will be the gold standard for determining lymph node status.
223866796|NCT00468052|DRUG|dexmedetomidine|2 micrograms/kilogram as a bolus then 0.7 micrograms/kilogram infusion
223866797|NCT00468052|DRUG|fentanyl|1 microgram/kilogram as a bolus
223866798|NCT03702647|DRUG|Ropivacaine|30mL of 0.2% Ropivacaine placed in the POEM tunnel
223866799|NCT03702647|DRUG|Normal saline|30mL of normal saline placed in the POEM tunnel
223866800|NCT04892290|OTHER|Conservative Treatment for Postdural Puncture Headache|The patients in Group C were given continuous bed rest in the supine position, 3000 mL daily hydration, 6 mg kg-1 aminophylline , 2 g day-1 paracetamol and 65 mg day-1 caffeine as conservative treatment. Topical SGB was applied to patients in Group SGB in addition to conservative treatment.
223866801|NCT05221736|PROCEDURE|Ultrasound-Guided Ethanol Sclerotherapy (UGES)|Comparison between Ultrasound-Guided Ethanol Sclerotherapy (UGES) \& surgical excision in management of warthin tumor of parotid gland.
223866802|NCT03212079|BEHAVIORAL|Mycoach Smart Text|Personalized text messages to you cellphone to help you become more active
223866803|NCT03212079|BEHAVIORAL|MyCoach on Amazon Alexa|This is an intelligent voice that you can communicate with via Amazon echo speaker
223866804|NCT00709423|DRUG|Moxaverine|
223866805|NCT00709423|DRUG|Moxaverin 150mg|intravenous administration
223866806|NCT00709423|DRUG|NaCl|intravenous administration
223866807|NCT00718939|DEVICE|Rheos Baroreflex Activation Therapy System|The two (2) Rheos Carotid Sinus Leads conduct the activation energy from the Rheos Implantable Pulse Generator to the baroreceptors located on the left (Left Carotid Sinus Lead) and right (Right Carotid Sinus Lead) carotid sinus. This energy activates the baroreflex by inducing signals that the brain interprets as elevated blood pressure.
223866808|NCT00739739|DRUG|PD 0299685 at 15mg BID|5 mg Capsules, 3 to be taken in the morning and at bedtime for the duration of the study
223866809|NCT00739739|DRUG|PD 0299685 at 30mg BID|10mg Capsules, 3 to be taken in the morning and at bedtime for the duration of the study. Initial 2 week titration period at 15mg BID.
223866810|NCT00739739|DRUG|placebo for PD 0299685|Capsules identical in appearance to PD 0299685, 3 to be taken in the morning and at bedtime for the duration of the study
223866811|NCT06114615|DEVICE|LiveCare|Patient use LiveCare device to monitor their blood pressure and data is transmitted to dashboard.
223866812|NCT06114615|BEHAVIORAL|Text Messages|Patients also receive text messages after their PCI procedure for follow up appointment reminders, enrollment in cardiac rehab, and diet and exercise counseling.
223866813|NCT06114615|OTHER|Conventional Care|No digital monitoring with LiveCare device and no text messages.
223866814|NCT01784653|BEHAVIORAL|iMET|Self-completed, computerized motivational enhancement therapy
223866815|NCT01784653|BEHAVIORAL|MET|Clinician-delivered Motivational Enhancement Therapy
223866816|NCT05290168|DIAGNOSTIC_TEST|abdominal Doppler|"1. Inferior vena cava diameter and distensibility~2. Hepatic vein Doppler~3. Portal vein Doppler~4. Splenic artery and vein Doppler~5. Renal artery and vein Doppler"
223866817|NCT02866435|DRUG|Insulin|In each clamp, a small intravenous catheter is placed in participant's arm for infusion of insulin together with potassium phosphate and glucose. Insulin is a hormone that body makes naturally and it causes blood sugar to decrease. Insulin (and glucose) will be infused in calculated doses to maintain blood sugar level in the target range of 95 mg/dl or 50 mg/dl depending on the clamp.
223866818|NCT02866435|DRUG|Glucose|Glucose is administered together with insulin and potassium phosphate during each clamp via the intravenous catheter. Glucose is a sugar and it is used to carefully regulate blood sugar level.
223866819|NCT02866435|DRUG|Potassium phosphate|Potassium phosphate is administered together with glucose and insulin during each clamp via the intravenous catheter. Potassium is a salt-like substance that is present in the blood.
223866820|NCT00356265|DRUG|Procedure: Regional phenylephrine arterial infusion|
223866821|NCT03071653|PROCEDURE|Left Cardiac Sympathetic Denervation (LCSD)|The procedure involves the surgical removal of the lower half of the left stellate ganglion (T1) and thoracic ganglia (T2-T4), thereby removing the pro-arrhythmic noradrenergic input to the ventricles
223866822|NCT03071653|OTHER|Optimal Medical Therapy|"All eligible patients with heart failure and depressed left ventricular systolic function will receive guideline and evidence based optimal tolerated medical therapy. The level of risk associated with optimal medical therapy is considered very low. For the majority of patients with heart failure and depressed left ventricular systolic function this will include:~1. A renin angiotensin system blocker at highest tolerated doses (e.g., enalapril 10mg twice daily or equivalent)~2. A mineralocorticoid receptor antagonist (e.g., Spironolactone 25-50mg daily or equivalent)~3. A Beta-blocker (e.g., Carvedilol 25mg twice daily or equivalent)~4. The use of a loop diuretic and digitalis will be clinically driven and used at the discretion of the attending clinician"
223866823|NCT02154217|DRUG|Bimatoprost|
223866824|NCT02154217|DRUG|Latanoprost/Timolol|
223866825|NCT04479969|BEHAVIORAL|Video Chat|Video chat with health coach using a computer tablet.
223866826|NCT03929770|PROCEDURE|with pause|When the practitioner or expert investigator recognize that the tip of Swan-Ganz catheter arrive in the right ventricle, the practitioner pause the advancement for 10 sec. Next, the practitioner re-advance it to the pulmonary artery.
223866827|NCT03929770|PROCEDURE|without pause|When the practitioner or expert investigator recognize that the tip of Swan-Ganz catheter arrive in the right ventricle, the practitioner advance it continuously without pause to the pulmonary artery.
223866828|NCT05874830|OTHER|Fecal microbiota transplant or plasebo through endoscopy|Colonoscopy and gastroscopy
223866829|NCT06199323|BEHAVIORAL|Routine rehabilitation training|"1. Balance function training: Patients were instructed to achieve weight shift between the left and right sides of the balance bar in a standing position.~2. Walking function training: based on hip, knee, and ankle control training, patients were instructed to take steps training.~3. Core muscle strength training: Patients were instructed to maintain 3 minutes of training in Bridge-style movement.~4. Functional training of daily living: including training on dressing and undressing, independent eating, painting, and writing.~Routine rehabilitation training was performed 30-45 minutes/time, 1-2 times/day, 5-7 days/week."
223866830|NCT06199323|BEHAVIORAL|Swallowing rehabilitation training|"1. Swallowing-related organ training: including movement training of lip, mandibular muscle, cheek, tongue muscle, soft palate, as well as exercises of vocal cord closure, laryngeal lifting and pharyngeal muscle training. 5-15 minutes/time, 1-2 times/day, 5-7 days/week.~2. Sensory stimulation training: With the self-made popsicle, medical staff slowly and gently stimulated the patient's cheek, palatoquadrate, soft palate, posterior pharyngeal wall, tongue surface and sublingual area repeatedly. 5-25 minutes/time, 1-3 times/day, 3-7 days/week.~3. Direct training: When the patient's swallowing function improves to a certain extent of which the safety of oral intake can be basically ensured, oral feeding training (direct training) can be attempted gradually.~4. Mendelsohn maneuver: During the Mendelsohn maneuver, the patient consciously prolonged the duration of the muscle contraction in the throat during swallowing.15-30 minutes/time, once per day, 5 days/week."
223866831|NCT06199323|PROCEDURE|Acupuncture therapy|"The whole acupuncture therapy was performed once daily for 5 days per week, including acupuncture needle and tongue needle.~Acupuncture needle:~Main acupoints: Lianquan, Shanglianquan (depression between the hyoid bone and the lower border of the mandible), Yifeng; Auxiliary acupoints: Fengchi, Wangu, Fengfu, Yamen, Neidaying (depression of 1 inch below the anterior margin of the mandible).~Tongue needle (pricking):~Acupoints: Jinjin, Yuye, posterior pharyngeal wall (both sides of the uvula)."
223866832|NCT01512810|PROCEDURE|Lymphadenectomy|Lymphadenectomy recommended, including: obturator, iliac (internal, external, common) and aortic lymph nodes
223866833|NCT00981643|BEHAVIORAL|Meditation instruction and practice|Meditation techniques introduced and practiced, in a group setting, once weekly for 8 weeks
223866834|NCT03216538|DRUG|AS101 1% oral solution|0.4 ml daily p.o.
223866835|NCT03216538|DRUG|Placebo|0.4 ml daily p.o.
223866836|NCT00851708|DRUG|N-acetylcysteine|600 mg bid orally from day 1 to 7 postoperative
223866837|NCT06327386|DIAGNOSTIC_TEST|18F-FAPI#18F-FDG|FAPI and FDG combined with PET/MR imaging in patients with gastric cancer after neoadjuvant therapy
223866838|NCT02779998|OTHER|non invasive ventilation|non invasive ventilation is delivered by a specific respirator with inspiratory help mode. NIV mask and parameters are adapted to obtains a Tidal volume ≤ to 8 ml/kg/cycle (if possible ≤ 6 ml/kg/cycle) and a SpO2 superior of 94%.
223866839|NCT02779998|OTHER|Standard oxygen therapy with facial mask|
223866840|NCT05364632|BEHAVIORAL|Behavioral Intervention to Increase Physical Activity|The educational program will consist of 2 classes held once a week, each lasting 90 minutes. The classes will be based on an education videotape, presentations and group discussions. The first class will address the asthma education. The second class will be about the current international physical activity recommendations and the importance and benefits of being physically active. The behavioural intervention will be performed in 8 weekly goal-setting consultation, face-to-face, each lasting until 90 minutes. Patients will be offered a commercially-available activity tracker to wear during 3 days prior to each consultation. According to their own physical activity (PA) data and the behavioural change stage, an individual action plan will be established to increase physical activity. Each participant will receive individual counselling with the goal of increasing participation in PA and reducing their sedentary time.
223866841|NCT05364632|OTHER|Aerobic Training|The same initial educational program described for the Behavioral Intervention group will be delivered to this group. Each aerobic training session will consist of 45 minutes divided into 5 minutes of warm-up, 35 minutes of aerobic exercise and 5 minutes of cool-down. During physical training, heart rate and level of respiratory distress will be monitored. The intensity of aerobic physical training will be based on the heart rate (HR) corresponding to one third of the difference between the anaerobic threshold (LA) and the respiratory compensation point (CRP). The patient may interrupt physical exercise if he presents any clinical symptoms and/or respiratory discomfort, returning as soon as his respiratory condition improves.
223866842|NCT02074488|OTHER|Balancing Act exercise curriculum|"Balance improvement exercise curriculum titled Balancing Act"
223866843|NCT02074488|OTHER|Informational Brochure|Informational Brochure on falls prevention
223866844|NCT01837966|OTHER|Lavender oil|2 drops for aromatherapy
223866845|NCT01837966|OTHER|Placebo|2 drops unscented mineral oil for aromatherapy
223866846|NCT04421261|DEVICE|Air-Q Self Pressurized Airway Device with Blocker|used in low risk adult females undergoing elective surgeries
223866847|NCT04421261|DEVICE|Proseal Laryngeal Mask Airway|used in low risk adult female patients undergoing elective surgeries
223866848|NCT06168149|DIAGNOSTIC_TEST|fetal lung elastography measurement|"Elastography measurements are planned to be performed as in the studies Feasibility of two-dimensional ultrasound shear wave elastography of human fetal lungs and liver: A pilot study and Feasibility of 2-D ultrasound shear wave elastography of fetal lungs in case of threatened preterm labour: a study protocol in the literature examples section of the file."
223866849|NCT00981968|DRUG|Sitaxentan sodium/Placebo|100 mg and 200 mg, tablet, single and multiple oral doses for 7 days
223866850|NCT00981968|DRUG|Sitaxentan sodium/Placebo|100 mg and 200 mg, tablet, single oral dose
223866851|NCT02178423|PROCEDURE|Ultrasound for diagnosis of CVC position in children|Using the ultrasound for diagnosis of the correct position of a central venous catheter in children immediate after the puncture.
223866852|NCT01885793|DEVICE|Cuffed endotracheal tube|Intubation with a cuffed endotracheal tube (ETT).
223866853|NCT02983669|DIETARY_SUPPLEMENT|Thyme|Thyme capsule 350 mg twice daily
223866854|NCT02983669|OTHER|Placebo|Placebo capsule 350 mg twice daily
223866855|NCT00159783|DRUG|asenapine|Asenapine, 40 weeks
223866856|NCT00159783|DRUG|Olanzapine|Olanzapine, 40 weeks
223866857|NCT00592410|DRUG|human regular insulin|administration of a primed continuous infusion of human regular insulin at a rate of 2.0 mU/kg/min while maintaining the plasma glucose level at 100 mg/dl via adjusting a variable infusion of 50% dextrose (i.e., a hyperinsulinemic euglycemic blood glucose clamp); duration of 3 hours; performed concomitantly with amino acid supplementation
223866858|NCT02721901|BEHAVIORAL|iEAT Manual Intervention|The iEAT manual guides caretakers in increasing the volume of food consumed by the child. The manual involves a touch screen application that collects and stores data on key behaviors and provides the feeder with direction for structuring treatment meals. Sessions will be 45 minutes long and occur biweekly for 10 sessions over 5 months. Two meals each day will be completed at home as part of the treatment of the feeding problems.
223866859|NCT02721901|BEHAVIORAL|Control group|The psychoeducation condition will involve 6 appointments (once monthly for 5 months and 1 session during the post-treatment assessment). Each appointment will include curriculum related to feeding concerns such as the etiology of feeding problems, meal structure, appropriate food selection, mealtime problem behaviors, and generalization of appropriate feeding behaviors. Each session will last approximately 45 minutes.
223866860|NCT03700294|DRUG|ADCT-601|Intravenous (IV)
223866861|NCT03104387|OTHER|Electric train|Exposure to air with low level of ultrafine particles (Electric train)
223866862|NCT03104387|OTHER|Diesel train|Exposure to air with high level of ultrafine particles (Diesel train)
223866863|NCT06353165|DRUG|Stannous fluoride toothpaste|product containing 0.45% stannous fluoride
223866864|NCT06353165|DRUG|Colgate Dental Cream|product containing 0.76% sodium monofluorophosphate
223866865|NCT05536037|DRUG|Metformin|Given PO
223866866|NCT05536037|PROCEDURE|Biopsy|Undergo biopsy
223866867|NCT01510977|DRUG|polyethylene glycol, Bisacodyl|After failure of first colonoscopy, bowel preparation with polyethylene glycol and bisacodyl one week after
223866868|NCT01510977|DRUG|polyethylene glycol|Immediately after first colonoscopy failure, polyethylene glycol 2L addition
223866869|NCT04917224|RADIATION|Stereotactic Adaptive Ablative Radiotherapy at 50 Gy (Gray)|Cohort A will include 30 patients with central tumors; the dose regimen prescribed is 50 Gy (Gray) in 5 fractions with a 40 hour inter-fraction interval.
223866870|NCT04917224|RADIATION|Stereotactic Adaptive Ablative Radiotherapy at 60 Gy (Gray)|Cohort B will include 30 patients with ultra-central tumors; the dose regimen prescribed is 60 Gy (Gray) in 8 fractions on consecutive days.
223866871|NCT02012569|DRUG|TT-173|Bleeding of the lesion will be evaluated after each product application and will be recorded as bleeding vs. not bleeding. The product will be applied at 4 times for about 1 minute apart each application after skin graft obtention.
223866872|NCT02012569|DRUG|Placebo|
223866873|NCT01736514|DRUG|febuxostat|oral
223866874|NCT01736514|DRUG|Allopurinol|oral
223866875|NCT00026234|DRUG|floxuridine|Given intra-arterially
223866876|NCT00026234|DRUG|dexamethasone|Given intra-arterially
223866877|NCT00026234|DRUG|oxaliplatin|Given IV
223866878|NCT00026234|DRUG|capecitabine|Given orally
223866879|NCT03995082|OTHER|Patient Reported Outcome Measure Survey result feedback|Patients will receive a graph of their results from the PROM survey each time they complete a survey
223866880|NCT04046575|RADIATION|Intensity Modulated Radiation Therapy|-15 fractions of treatment
223866881|NCT04046575|DRUG|Carboplatin|Begins on day 1 of radiotherapy
223866882|NCT04046575|OTHER|MD Anderson Symptom Inventory (MDASI)-Plus module|The QOL questionnaires will be answered by the patients prior to the start of chemoradiation, on the last week of RT, and at 6-8 week follow-up, 3, 6, 9, and 12 months post completion of RT
223866883|NCT04046575|OTHER|EuroQol (EQ-5D)|The QOL questionnaires will be answered by the patients prior to the start of chemoradiation, on the last week of RT, and at 6-8 week follow-up, 3, 6, 9, and 12 months post completion of RT
223866884|NCT04046575|OTHER|SF-12|The QOL questionnaires will be answered by the patients prior to the start of chemoradiation, on the last week of RT, and at 6-8 week follow-up, 3, 6, 9, and 12 months post completion of RT
223866885|NCT04046575|OTHER|MOS Social Support Measure|The QOL questionnaires will be answered by the patients prior to the start of chemoradiation, on the last week of RT, and at 6-8 week follow-up, 3, 6, 9, and 12 months post completion of RT
223866886|NCT04046575|OTHER|CES-D|The QOL questionnaires will be answered by the patients prior to the start of chemoradiation, on the last week of RT, and at 6-8 week follow-up, 3, 6, 9, and 12 months post completion of RT
223866887|NCT04046575|PROCEDURE|Blood for ctDNA (optional)|-Collected at pre-treatment, every 2 weeks during chemoradiation, every 2-3 weeks during consolidation chemotherapy, completion of therapy, 6-8 week follow-up, 3 month follow-up, 6 month follow-up, and 12 month follow-up
223866888|NCT04046575|PROCEDURE|Blood for SCCA|-Collected at pre-treatment, completion of therapy, and 6 month follow-up
223866889|NCT04046575|DRUG|Paclitaxel|Begins on day 1 of radiotherapy
223866890|NCT01006824|OTHER|Capsule endoscopy|Capsule endoscopy
223866891|NCT01006824|OTHER|Dedicated small bowel contrast radiography|Dedicated small bowel contrast radiography
223866892|NCT02928224|DRUG|Encorafenib|Orally, once daily.
223866893|NCT02928224|DRUG|Binimetinib|Orally, twice daily.
223866894|NCT02928224|DRUG|Cetuximab|Standard of care.
223866895|NCT02928224|DRUG|Irinotecan|Standard of care.
223866896|NCT02928224|DRUG|Folinic Acid|Standard of care.
223866897|NCT02928224|DRUG|5-Fluorouracil|Standard of care.
223866898|NCT04993807|OTHER|Shared decision-making tool|Participants will use an interactive web page intended to aid patient decision-making (i.e., a decision aid) while undergoing consultation for atrial fibrillation ablation.
223866899|NCT02538107|DRUG|Methoxy-polyethyleneglycol epoetin beta|
223866900|NCT00818805|DRUG|Olopatadine 0.1%|one drop in one eye
223866901|NCT00818805|DRUG|Tranilast 0.5%|one drop in one eye
223866902|NCT00818805|DRUG|Placebo (Olopatadine)|one drop in contralateral eye
223866903|NCT00818805|DRUG|Placebo (Tranilast)|one drop in contralateral eye
223866904|NCT01278394|DRUG|AN2690 Solution, 5.0%|Once daily application for 360 days
223866905|NCT02961010|BEHAVIORAL|Keeping Safe|A whole school Preventative Education programme
223866906|NCT02232295|DEVICE|Recognise [TM]|Recognise accurately measures to identify left and right body parts and movements, and to train left/right discrimination as part of a comprehensive GMI rehabilitation process.
223866907|NCT02232295|DEVICE|Mirror Box|A resource used for many pain and disability states of the hands and feet.
223866908|NCT04565418|BEHAVIORAL|High-intensity interval training|3 times per week high-intensity interval training (HIIT) will be performed on a cycle ergometer for 12 weeks adding up to 36 HIIT sessions
223866909|NCT02197975|DRUG|PT010 Dose 1|PT010 Dose 1; Budesonide, Glycopyrrolate, and Formoterol Fumarate (BGF) Inhalation Aerosol. Administered as 2 inhalations.
223866910|NCT02197975|DRUG|PT010 Dose 2|PT010 Dose 2; Budesonide, Glycopyrrolate, and Formoterol Fumarate (BGF) Inhalation Aerosol. Administered as 2 inhalations.
223866911|NCT02197975|DRUG|Placebo MDI|Placebo MDI. Administered as 2 inhalations
223866912|NCT03009136|DRUG|SCRT|composed of eight herbs: Glycyrrhiza uralensis Fischer 1g Zingiber officinale Roscoe 0.5g Cinnamomum cassia Blume 0.2g, Ephedra sinica Stapf 0.5g, Pinellia ternata Breitenbach 2.67g, Paeonia lactiflora PALL 1g, Asiasarum sieboldi F. Maekawa 0.5g, Schisandra chinensis 2.67g (per 9g of granules)
223866913|NCT03009136|DRUG|Placebos|is made of lactose, corn starch and caramel coloring, and has appearance, shape, weight, taste, and color similar to SCRT
223866914|NCT01236560|BIOLOGICAL|Bevacizumab|Given IV
223866915|NCT01236560|DRUG|Temozolomide|Given PO
223866916|NCT01236560|DRUG|Vorinostat|Given PO
223866917|NCT02472275|DRUG|Antiandrogen Therapy|Undergo ADT with leuprolide acetate, goserelin acetate, or degarelix
223866918|NCT02472275|OTHER|Laboratory Biomarker Analysis|Correlative studies
223866919|NCT02472275|DRUG|Multitargeted Tyrosine Kinase Inhibitor PLX3397|Given PO
223866920|NCT02472275|RADIATION|Radiation Therapy|Undergo radiation therapy
223866921|NCT06028503|BEHAVIORAL|Acceptance and Commitment Therapy|"Approximately 3 hours of ACT will be administered based on Gregg et al.;s (2007) protocol:~1. What is ACT?~2. Coping and Stress Management~3. Acceptance and Action"
223866922|NCT06028503|DEVICE|Abbott FreeStyle® Libre® 3|The Abbott FreeStyle® Libre® 3 (FDA approved) consists of a single use disposable electrochemical sensing unit which is placed on the upper arm and an App for smart phones where the participant can view their glucose data, including their current glucose reading, their 'trend arrow' so participants can see how glucose is changing, and their glucose history. The FreeStyle system does not require user calibration. A sensor log will be maintained for accountability of all sensors received as well as used sensors (including the lot/serial number, expiration date, and the date). Sensors will be stored at manufacturers recommendations.
223866923|NCT06028503|OTHER|Generic Education|Participants will be given information about how lifestyle choices, including daily dietary choices, affect blood sugar for people with T2D, and best practices related to checking blood sugar and carbohydrate counting if participants are on insulin therapy. These sessions will also include education on diabetes nutrition guidelines and improving self-management through better food and lifestyle choices.
223866924|NCT06034028|DEVICE|J-Valve TF System|The J-Valve TF System is a transcatheter aortic valve replacement system that consists of the J-Valve TF Bioprosthesis, J-Valve TF Delivery Device, and Loading Accessories.
223866925|NCT00378222|PROCEDURE|Autologous Stem Cell Transplantation|
223866926|NCT04327167|BEHAVIORAL|Video and questionnaire|Potential donors would be shown a video and asked to complete a questionnaire to capture change in attitude towards donation.
223866927|NCT04525651|DEVICE|Digital Acupuncture Manipulation Therapeutic Instrument|The device is based on the characteristics of traditional acupuncture manipulation of Shanghai School of Traditional Chinese Medicine, and absorbs the information of the techniques of famous experts, modulates the stimulation waveform of the electroacupuncture device by modulating the signal, and realizes the digitization of acupuncture technique information.
223866928|NCT04525651|OTHER|Manual Acupuncture|Manual acupuncture to acheive de qi.
223866929|NCT04525651|OTHER|Sham Acupuncture|Sham acupuncture to avoid de qi.
223866930|NCT00125645|DRUG|Irbesartan Oral Tablet|
223866931|NCT02730923|DRUG|AZD2014|"Following inclusion, patients will be randomized (2:1) to receive Arm A : AZD2014 + anastrozole Arm B : anastrozole alone~Mode of Action Selective and specific mTOR kinase inhibitor targeting both mTORC1 and mTORC2 complexes.~Route of Administration Oral~Dosage regimen 125mg BID with intermittent schedule (2 days of treatment followed by 5 days off (500mg/week))~Duration of treatment Until the patient experiences unacceptable toxicity, disease progression and/or treatment is discontinued per patient or investigator request."
223866932|NCT02730923|DRUG|Anastrozole|"Therapeutic Class Aromatase inhibitor~Mode of Action Potent and highly selective non-steroidal aromatase inhibitor.~Route of Administration Oral~Dosage regimen~1 mg tablet once a day~Duration of treatment Patients may continue treatment with anastrozole until the patient experiences unacceptable toxicity, disease progression and/or treatment is discontinued per patient or investigator request."
223866933|NCT01337622|PROCEDURE|No check of gastric residuals for early enteral feeding advancement|Discontinuation of gastric feeding and its advancement will be based on clinical examination of the abdomen and gastric aspirates containing blood or significant vomiting.
223866934|NCT01337622|PROCEDURE|Routine check of gastric residuals for early enteral feeding advancement|Discontinuation of gastric feeding and its advancement will be based on current practice of clinical examination of the abdomen and checking residual before every feed. Volume and color of gastric residual will be considered according to the current guideline.
223866935|NCT01079065|DRUG|Famotidine|Tablets
223866936|NCT01813773|DRUG|Intravitreal Aflibercept Injection (IAI)|EYLEA (aflibercept) is a recombinant fusion protein consisting of portions of human VEGF receptors 1 and 2 extracellular domains fused to the Fc portion of human IgG1 formulated as an iso-osmotic solution for intravitreal administration. Aflibercept is a dimeric glycoprotein with a protein molecular weight of 97 kilodaltons (kDa) and contains glycosylation, constituting an additional 15% of the total molecular mass, resulting in a total molecular weight of 115 kDa. Aflibercept is produced in recombinant Chinese hamster ovary (CHO) cells.
223866937|NCT05467319|DRUG|Ferric Derisomaltose Injection|1000mg of ferric derisomaltose in 100mL of normal saline by intravenous infusion
223866938|NCT05467319|DRUG|Normal saline|100 mL of 0.9% normal saline (w/v) by intravenous infusion
223866939|NCT05981157|DRUG|Anrotinib plus Tirelizumab|Subjects receive Anrotinib, 10mg, QD and Tirelizumab, 200mg, D1, Q3W. Treatment was continued until confirmed disease progression, death, unacceptable toxicity, withdrawal of consent, or investigator decision.
223866940|NCT03107806|DEVICE|OptiScanner®|"1. Glucose monitoring by OptiScanner® for 48 h~2. Glucose lowering intervention (insulin) guided by OptiScanner®"
223866941|NCT03688360|BEHAVIORAL|Cognitive Behavioral Therapy|. Each intervention will contain a 60-minute psycho-education session (PE) and two 60-minute exposure sessions (EX), conducted by a mental health professional together with a master student in psychology, who are both weekly supervised by a CBT certified psychologist. In the first (PE) session, participants learn about anxiety, specific phobias and exposure. During this session they will create a fear hierarchy, formulate their cognition about the feared object or situation and determine what they want to achieve during treatment (e.g. goal situation). The next two sessions consist of exposure exercises.
223866942|NCT03281382|BIOLOGICAL|Ad5-yCD/mutTKSR39rep-hIL12|Oncolytic adenovirus expressing two suicide genes and human IL-12
223866943|NCT03516240|OTHER|Biofreeze|Following a procedure that induces muscle fatigue in the lower extremity, a topical cream will be applied over the quadriceps. The cream will be either a topical analgesic (Biofreeze) or a placebo cream. Evaluation of the movement kinematics and kinetics will be evaluated for each group.
223866944|NCT03516240|OTHER|Placebo|Following a procedure that induces muscle fatigue in the lower extremity, a topical cream will be applied over the quadriceps. The cream will be either a topical analgesic (Biofreeze) or a placebo cream. Evaluation of the movement kinematics and kinetics will be evaluated for each group. Placebo cream will be blinded to both the experimenter and study participant. It will look and smell the same and will be in the same packaging.
223866945|NCT02034773|DRUG|CC-220|CC-220 0.3mg will be administered once daily for 14 days
223866946|NCT02034773|DRUG|CC-220|CC-220 1mg will be administered once daily for 28 days + 1 dose of tetanus toxoid vaccination and 1 dose of pneumococcal vaccination
223866947|NCT02034773|DRUG|CC-220|CC-220 0.3mg will be administered once daily for 28 days
223866948|NCT02034773|DRUG|CC-220|CC-220 1mg will be administered once daily for 7 days on 2 separate occasions, with a 7-day washout in between, for a total of 14 days of dosing
223866949|NCT02034773|DRUG|Placebo|Placebo will be administered once daily for up to 28 days
223866950|NCT02034773|DRUG|CC-220|CC-220 0.3mg will be administered every 3 days for 14 days (5 total doses)
223866951|NCT02034773|DRUG|CC-220|CC-220 1mg (once every 7 days for 28 days)
223866952|NCT02034773|DRUG|CC-220|CC-220 1mg will be administered as a single dose in each of 2 study periods; once as a formulated capsule and once as two reference capsules
223866953|NCT03114410|BEHAVIORAL|Re:MIX, a multi-layer comprehensive teen pregnancy prevention intervention aimed at reducing pregnancy and STIs among youth ages 13-17|Re:MIX is a comprehensive in-school health curriculum and teen pregnancy prevention program for adolescents covering a broad range of topics related to sexual health and youth development, including healthy relationships, communication, gender, consent, reproductive anatomy, contraception, sexual decision making, clinics, parenthood, and life planning. Re:MIX also aims to connect students and young parent educators with community resources and service linkages. The Re:MIX curriculum teaches mixed-gender groups of students in grades 8 to 10 to delay sex and use protection if they have sex. A co-facilitation team of young parent educators delivered the information with professional health educators using non-traditional approaches, such as game-based tools, technology, and storytelling. Youth received roughly nine hours and 10 minutes of group sessions during the school day over one semester (55 minutes per week for 10 weeks).
223866954|NCT05600335|PROCEDURE|ERAS protocol|Patients with esophageal cancer have undergone RAME using ERAS protocol and conventional management strategy
223866955|NCT04415528|OTHER|Emotion-Focused Mindfulness Therapy|"EFMT is a group intervention of 8weekly meetings of 2.5 hours with 10 - 12 participants per group. Participants are provided instruction that encourages noting and experiencing bodily sensations and emotions during meditations. Meditations are conducted in silence for between 20 and 35 minutes. Participants are asked to journal their recollection of the meditation and experiences that arise for them as they journal. Each participant then describes their experience in meditation, with the facilitator offering empathic exploration to support transforming negative emotions into adaptive emotions.~The study will be conducted in an online PHIPPA protected platform and has been modified to accommodate electronic delivery. Maximum number of participants per group will be six, and each session will be 1.5 hours. Data will be collected at three points by a research assistant to evaluate the feasibility of EFMT for older adults and determine whether anxiety is influenced by the intervention."
223866956|NCT05915533|OTHER|Dance therapy|Before/after study to measure the effects of the dance therapy activity on the quality of life of the disabled adults housed in the establishments of UNIVI group.
223866957|NCT06630442|OTHER|Educational Intervention|Attend a food safety educational training program
223866958|NCT06630442|OTHER|Questionnaire Administration|Ancillary studies
223866959|NCT04593251|BIOLOGICAL|CALY-002|1-hour intravenous infusion
223866960|NCT04593251|BIOLOGICAL|Placebo|1-hour intravenous infusion
223866961|NCT06063733|OTHER|Digital pursed lip breathing intervention|"After registration, participants will watch an educational video on the developed software, covering the definition, benefits, and techniques of pursed lip breathing. Following this, participants will engage in pursed lip breathing interventions, guided by voice and animated instructions from the software. These sessions will occur three times daily (morning, afternoon, and night) for 10 minutes each, lasting for 8 weeks.~After each session, participants can choose to post texts on a peer social forum for peer support. Fellow participants can give 'comments' or 'likes'. The principal researcher will oversee texts, peer comments, removing information containing personal data, medical recommendations, and negative comments.~Additionally, participants can earn health points by performing specific actions (e.g., watching the educational video and practicing pursed lip breathing) on the software, encouraging their participation in related activities."
223866962|NCT01618643|PROCEDURE|Acetic acid chromoendoscopy|"Prospective observational pilot study.~We would examine patients with Barrett's epithelium that is either healthy or has suspected areas of neoplasia. We will apply acetic acid spray to areas of healthy Barrett's metaplasia and time how long it takes for the aceto whitening to disappear. We will repeat this in cases referred with SM invasive cancer, intramucosal cancer, suspected high grade dysplasia and possible low grade dysplasia. We will record how long it takes for the acetowhitening to disappear. We will biopsy these areas to confirm the diagnosis.~We will correlate the histology to the aceto-whitening time to see if there is a correlation between the degree of neoplasia and the aceto-whitening time after acetic acid dye spray."
223866963|NCT01497704|DRUG|YN968D1|Daily dosing of YN968D1 for treatment of solid tumors
223866964|NCT03665779|DRUG|isosorbide mononitrate|70 pregnant females, induction of labor will be done by Intra vaginal isosorbide mono nitrate (Effox 40 mg MINAPHARM) repeated every 4 hours maximum 4 times
223866965|NCT03665779|DRUG|Placebo|70 pregnant females, induction will be done by placebo (pyridoxine) administered in the posterior vaginal fornix.repeated every 4 hours maximum 4 times
223866966|NCT04356820|OTHER|acupressure|Data collection took about 10 to 15 minutes. Then the woman invited to the examination room was asked to pull one of the envelopes with the names of the groups. The women who pulled the acupressure envelope were given a semi-sitting position where the acupressure application can feel comfortable and the researcher can easily apply the acupressure points. Before the acupressure application, massage was applied for 30 seconds to ensure circulation. Afterwards, 90 seconds consecutive pressures were applied to the specified acupressure points in a certain order (SP 6, Li 4), taking into account the direction of the meridian. After the examination, the pain formed during the gynecological examination was evaluated by applying the Short Form-McGill Pain Questionnaire without leaving the examination room
223866967|NCT00468910|DRUG|acetylsalicylic acid|Given orally
223866968|NCT00468910|DRUG|placebo|Given orally
223866969|NCT00468910|OTHER|laboratory biomarker analysis|Correlative study
223866970|NCT00963625|PROCEDURE|Embryo cryopreservation|Cohort cryopreserved as bipronuclear (2pn) oocytes, then thawed and cultured to the blastocyst stage before transfer to the uterus.
223866971|NCT00963625|PROCEDURE|Fresh blastocyst transfer|Fresh blastocyst transfer following cycle of controlled ovarian stimulation.
223866972|NCT04531592|DRUG|Valproic acid|Valproate sodium in 5-ml single-dose vials containing 100 mg/ml of VPA. The appropriate dose of 140 mg/kg, based on the subject's weight at study entry, will be diluted in isotonic saline solution to a final volume of 300 ml for administration
223866973|NCT04531592|DRUG|Isotonic saline solution|Isotonic saline solution consisting of 0.9% sodium chloride in the volume of 300 ml for administration
223866974|NCT05028959|OTHER|Multidisciplinary monitoring of healthy women|Multidisciplinary monitoring
223866975|NCT04672018|OTHER|Houtou Jianweiling tablet|Houtou Jianweiling tablet (0.38 g), 4 tablets taken orally at a time, 3 times a day and Omeprazole Enteric-coated placebo tablet, taken 1 tablet orally once a day before breakfast.
223866976|NCT04672018|DRUG|Omeprazole Tablet|Omeprazole Enteric-coated tablet (20 mg), 1 tablet taken orally once a day before breakfast and Houtou Jianweiling placebo tablets, taken orally, 4 tablets at a time, 3 times a day.
223866977|NCT04367272|PROCEDURE|First Arthroplasty|First Knee
223866978|NCT04367272|PROCEDURE|Second Arthroplasty|Second Knee
223866979|NCT06198114|OTHER|Multi Sensory Therapy|This group will be treated with activity based training by place different( nuts, screws, bullets, coins, paper clips, coloring ,scissor cutting with different shapes , Simulated feeding (by collecting beans with a spoon and transferring them into a container),transfer light and heavy weight objects into empty box. 5 days in a week
223866980|NCT06198114|OTHER|Conventional Therapy|This group will be treated with traditional therapy in which Place toys/objects inside and encourage the student to reach in and pull them out as well as put them back in. Give the student objects that can be put together and pulled apart. Encourage the students to use two hands in an organized manner to manipulate objects (e.g., grasp/release, twist/turn, rotate and examine, open/close, stack, nest).5 days a week for an hour/daily.
223866981|NCT05066958|BIOLOGICAL|boost anti-viral immunity after T-cell depleted HSCT|"* Registration and informed consent sign~* Screening clinical and laboratory examination, assessment of compliance with inclusion criteria~* Survey of the recipient and potential donors~* Donor selection~* The study of the immune response to relevant antigens in the donor and recipient~* Pre-transplant conditioning~* Stimulation of the donor and apheresis of peripheral blood mononuclear cells~* Graft processing~* The manufacturing of cell product~* Transplant Infusion~* Antigen-primed memory DLI infusion~* Inpatient care until day +30~* Outpatient monitoring and screening"
223866982|NCT03663036|DIAGNOSTIC_TEST|Magnetic Resonance Imaging of the shoulder|Clinical and radiological assessments of the shoulders and the donor sites
223866983|NCT01290185|DEVICE|Placement of different catheters for continuous nerve block|Placement different catheters adjacent to the femoral
223866984|NCT03123809|DEVICE|Gastric Electrical Stimulation (GES) System|Implantable GES System will be turned ON as an active intervention providing electrical stimulation to the muscle of stomach for 6 months in patients from the first arm, versus 3 months only of active stimulation in patients who are randomized to be in the second arm of the study. GES works by utilizing following parameters: Current 5 mA; Pulse Width 330µsec; Rate 14 Hz; Time ON 0.1 sec; Time OFF 5.0 sec.
223866985|NCT06113146|OTHER|ultra-processed slow eating rate diet|Consuming ultra-processed slow eating rate meals (served ad libitum) and snacks. Eating rate is manipulated through food texture, for example foods with a hard texture that require a long chewing duration before a bite of food can be swallowed.
223866986|NCT06113146|OTHER|Ultra-processed fast eating rate diet|Consuming ultra-processed fast eating rate meals (served ad libitum) and snacks. Eating rate is manipulated through food texture, for example foods with a soft texture that require little chewing before a bite of food can be swallowed.
223866987|NCT02191098|DRUG|ALT-803|Interleukin 15 (IL-15) is a common γ-chain cytokine that is related to interleukin-2 (IL-2) and is a critical factor for the development, proliferation, and activation of effector natural killer (NK) and CD8+ memory T cells
223866988|NCT05320796|DIAGNOSTIC_TEST|upper endoscopy|A wireless BRAVO™ - pH monitoring device is placed and the participant is discharged with ongoing pH monitoring. The next day, the participant is randomized to either receive Esomeprazol MUT Sandoz® tablet 40mg or Esomeprazol MUT Sandoz® 40mg in solution. Serum concentration of Esomeprazol is measured at 0, 60 and 120 minutes and the patient is discharged after. After 48 hours of pH monitoring, the patient returns the BRAVO™ - recorder, adverse events are assessed and the study is terminated.
223866989|NCT06240351|DRUG|Baricitinib 4 MG Oral Tablet|Baricitinib is a Janus kinase (JAK) inhibitor
223866990|NCT06114745|DRUG|SHR-1707 injection|Drug: SHR-1707 SHR-1707 will be administered through IV infusion. Drug: Placebo Placebo will be administered through IV infusion
223866991|NCT06114745|DRUG|Placebo|Placebo will be administered through IV infusion
223866992|NCT05631938|DRUG|cytisinicline|film-coated oral tablets containing 3 mg cytisinicline
224076506|NCT04867798|DRUG|Lamivudine-Tenofovir 300 Mg-300 Mg Oral Tablet|PrEP eligible participants will be asked to follow up monthly for 12 months. PrEP will be prescribed for once-daily use and discontinued if HIV tests are positive. At quarterly visits, participants will receive Integrated Next Steps Counseling (iNSC) for PrEP adherence with point-of-care drug level feedback. Participants will receive iNSC Support Level 1 to address PrEP adherence and sexual health needs. Those with urine tenofovir levels \<1500 ng/mL will receive iNSC Support Level 2, in which participant responses to two 7-item questionnaires on PrEP adherence and sexual health will guide problem solving on improved dosing. Medication refills will consist of 3-month supplies.
224076507|NCT00450931|OTHER|counseling intervention|
224076508|NCT00450931|OTHER|educational intervention|
224076509|NCT03937856|BEHAVIORAL|Calm- Mindfulness Meditation smartphone application|Participants will be asked to register and download the Calm application on participants' phones or home computer. Daily use for a minimum of 5 minutes will be suggested and will be recorded at study end.
224076510|NCT02161562|DRUG|omalizumab|150mg omalizumab via sub-cutaneous injection once every 4 weeks
224076511|NCT02161562|DRUG|omalizumab|300mg omalizumab via sub-cutaneous injection once every 4 weeks
224076512|NCT04456439|BIOLOGICAL|Remestemcel-L|Participants may receive up to 2 infusions of 2 x 10\^6 remestemcel-L within a 5-day period.
223866993|NCT06029023|COMBINATION_PRODUCT|MTA Cement, propolis nano particle, curcumin nanoparticles|MTA or nano propolis or nano curcumin will then be placed over the remaining healthy pulp per the manufacturer's recommendation. The cavities will be lined with glass ionomer cement and a permanent composite restoration will be placed after 6 months. After treatment, a periapical radiograph and CBCT will be immediately taken with ultra-low dose The patients and their parents will be interviewed by telephone on day 1 and day 7 post-surgery about any pain or adverse reactions related to the treatment. Paracetamol will be prescribed if the patients had pain, however, no antibiotic will be used following the surgery. The patients will receive a 3-month follow-up clinical and periapical radiographic examination, together with 6 months clinical and CBCT examinations.
223866994|NCT02044523|DEVICE|Transient elastography, acoustic radiation force impulse, magnetic resonance elastography|Transient elastography (Fibroscan) Acoustic Radiation Force Impulse (ARFI) Magnetic Resonance Elastography (MRE)
223866995|NCT02530073|DEVICE|Fetoscopic Endoluminal Tracheal Occlusion (FETO)|This study will position and remove an endoluminal tracheal balloon in utero (FETO) to study the feasibility of implementing FETO therapy in the most severe group of fetuses with left CDH and observed/expected length head ratio \<25% (O/E LHR).
223866996|NCT06406816|COMBINATION_PRODUCT|Neoantigen Vaccine plus Capecitabine|"1. Capecitabine.Twice a day, 30 minutes after breakfast, swallow with water, continue for 2 weeks, then stop for 1 week, constitutes one cycle; three weeks make one cycle, lasting for 8 cycles.~2. Neoantigen Vaccine . Every 3 weeks, once every 21 days, for 4 to 8 cycles. The injection is administered on the first day after cessation of capecitabine. Treatment can last for up to 6 months without occurrences such as the researcher determining no further clinical benefit, intolerable toxic reactions, initiation of new anti-tumor treatment, withdrawal of informed consent, loss to follow-up, death, or other circumstances specified in the protocol that require treatment termination."
223866997|NCT01168154|DIETARY_SUPPLEMENT|Lactobacillus Reuterii|Lactobacillus Reuterii 10000000000 CFU per day
223866998|NCT01168154|DIETARY_SUPPLEMENT|placebo|placebo
223866999|NCT00521833|PROCEDURE|phacoemulsification and intraocular lens implantation|clear cornea phacoemulsification and intraocular lens implantation using temporal or nasal incisions respectively
223867000|NCT06201819|DRUG|Liraglutide injection|Liraglutide (GLP-1 analog) injection during 3 months
223867001|NCT02748590|DEVICE|InterStim II Neurostimulator Model 3058|The neuromodulation will be carried out according to the usual protocol: Hospitalization for the establishment of percutaneous electrode in the operating room under general anesthesia with fluoroscopic control. The pacemaker startup will be performed within 12h after surgery
223867002|NCT00664430|DRUG|Calcitriol|Initial doses determined according to the National Kidney Foundation's Kidney Disease Outcomes Quality Initiative (KDOQI) guideline (Am J Kidney Dis 2003;42(4)Suppl 3:S1-S201). During therapy, calcitriol dose may be modified by 0.5 - 1 mcg at 2- to 4-week intervals.
223867003|NCT00664430|DRUG|Paricalcitol|Dose calculated by 0.04 to 0.1 microgram per kilogram (mcg/kg). Paricalcitol will be administered intravenously after the participants' dialysis. The paricalcitol dose will be titrated every 2 weeks until iPTH presents a reduction or up to 4 months, after which it will be adjusted monthly based on serum PTH, calcium, phosphorus and albumin measurements. Dosing may be modified by 2-4 mcg increments at 2- to 4-week intervals.
223867004|NCT03538912|OTHER|Biomarker strategy|EAT duration is determined by β-D-1,3-glucan and mannan serum assays, performed at day 0 (day of EAT initiation) and day 3.
223867005|NCT03538912|OTHER|Routine strategy|EAT duration is based on IDSA guidelines, which recommend 14 days of treatment for patients without subsequent proven ICI, and who improve under antifungal treatment, or less in other situations.
223867006|NCT04396730|DRUG|Cannabidiol Oil|400 mg Cannabidiol oil will be administered daily along with oral contraceptives daily for 24 days.
223867007|NCT04396730|DRUG|Placebo|Placebo will be administered daily along with oral contraceptives daily for 24 days.
223867008|NCT04396730|DRUG|Combined oral contraceptive pill|All participants will receive oral contraceptives
223867009|NCT00149864|DRUG|Mycophenolate sodium (enteric coated)|
223867010|NCT03404583|BEHAVIORAL|Person-centred care at distance through an eHealth platform|Person-centred care at distance through an eHealth platform, used by professionals, patients and relatives
224076513|NCT04456439|DRUG|Hydrocortisone|Participants who are not currently taking a corticosteroid will receive hydrocortisone, 0.5-1 milligram per kilogram (mg/kg), up to 50 mg IV, at least 30 minutes prior to the infusion of remestemcel-L.
224076514|NCT04456439|DRUG|Diphenhydramine|Participants will receive diphenhydramine, 0.5-1 mg/kg, up to 50 mg IV, at least 30 minutes prior to the infusion of remestemcel-L.
223867011|NCT02035969|BEHAVIORAL|Enhanced Treatment Support (ETS)|"Peer supporters, who are also caregivers of HIV-infected children, organize peer support group meetings. In the meetings one peer supporter discusses problems related to adherence with caretakers and provides them with information. Another supporter provides children above 3 years of age with age relevant information about their disease and treatment as well as games and play to enhance group bounds. The supporter will also have weekly telephone contact with all caretakers to assess the condition of the child.~For children with poor adherence individual support to caretakers and patients will be arranged to assess the child's condition and reason for poor adherence, in case of complications the supporter gives advice or refers the child for medical checkup."
223867012|NCT06088225|DEVICE|distance-image screen|Distance-image screen is a screen make each image at distance of 6-meters to reduce the accommodation and convergence for eyes during the reading and learning with screens.
223867013|NCT01576484|DRUG|Alirocumab|Alirocumab was supplied in a pre-filled syringe and administered subcutaneously (SC) in the abdomen, thigh, or outer upper arm; REGN727(SAR236553) is an anti-PCSK9 (proprotein convertase subtilisin/kexin type 9) antibody
223867014|NCT01576484|DRUG|Placebo Matched to Alirocumab|Placebo matched to alirocumab was supplied in a pre-filled syringe and administered subcutaneously (SC) in the abdomen, thigh, or outer upper arm; REGN727(SAR236553) is an anti-PCSK9 (proprotein convertase subtilisin/kexin type 9) antibody
223867015|NCT00581854|DRUG|modified Hyper-CVAD|rituximab and modified hyperfractionated cyclophosphamide, vincristine doxorubicin, dexamethasone (hyperCVAD) administered every 28 days for 4-6 cycles followed by rituximab maintenance therapy consisting of four weekly doses every six months for two years
223867016|NCT05286710|DEVICE|pharmacomechanical thrombectomy (PMT)|After randomization patients will be allocated to pharmacomechanical thrombectomy (PMT) via ipsilateral popliteal venous approach or to PMT via distal calf venous approach, bail-out contralateral femoral access can be used if puncture was failed in calf vein. After PMT treatment, residual thrombus was reevaluated by ascending venography. Catheter-directed thrombolysis (CDT) was conducted if there was residual thrombus. Stenosis of iliac vein was assessed by multiangle venography and intravascular ultrasound (IVUS) was used if necessary. Percutaneous balloon angioplasty (PTA) was conducted if there was \>50% stenosis of the diameter of the iliac vein. A stent was placed if the residual stenosis was \>50% after PTA treatment.
223867017|NCT00018785|PROCEDURE|donor bone marrow infusion|
223867018|NCT01217905|DRUG|AZD7687|Oral suspension
223867019|NCT05096663|DIETARY_SUPPLEMENT|Cobalamin|Given intramuscularly
223867020|NCT05096663|DRUG|Dexamethasone|Given orally (PO)
223867021|NCT05096663|DRUG|Docetaxel|Given IV
223867022|NCT05096663|DIETARY_SUPPLEMENT|Folic Acid|Given PO
223867023|NCT05096663|DRUG|Gemcitabine|Given IV
223867024|NCT05096663|DRUG|Nogapendekin Alfa|Given SC
223867025|NCT05096663|BIOLOGICAL|Pembrolizumab|Given IV
223867026|NCT05096663|DRUG|Pemetrexed|Given IV
223867027|NCT05096663|BIOLOGICAL|Ramucirumab|Given IV
223867028|NCT05001477|DEVICE|TULSA Procedure|Transurethral ultrasound ablation procedure
223867029|NCT02887625|DRUG|Pioglitazone plus exenatide|pioglitazone will be started at 30 mg/day and bydureon at 2 mg/week
223867030|NCT02887625|DRUG|insulin glargine and insulin aspart|the dose will be escalated to maintain HbA1c \<7.0%
223867031|NCT01806116|DRUG|decitabine|
223867032|NCT05763524|PROCEDURE|Adrenalectomy with or without lymphadenectomy|Regarding lymphadenectomy extent, it will be described as locoregional or systematic depending on availability of data in the Eurocrine database.
223867033|NCT02620813|DRUG|Tretinoin|Subjects will apply 0.5% tretinoin cream nightly to their face for a total of 12 weeks.
224268379|NCT06218394|PROCEDURE|Autologous Concentrated Growth Factor|"1. 27\~36ml of autologous venous blood is collected in a sterile Vacuette tube without anticoagulant solution, and centrifuged by Medifuge variable speed centrifuge (Silfradent company, Italy) for about 13min (accelerated for 30s; 2700 r/min, 2 min; 2400 r/min, 4min; 2700r/min, 4min; 3300r/min, 3 min; decelerated for 36s to stop). The lowest layer retains 2.5ml of CGF per 9ml of venous blood.~2. The scalp is cleaned, disinfected and anesthetized, CGF is extracted with a 2.5ml syringe, and the disposable sterile needle roller handle is slowly rolled in the hair loss area, and the CGF is applied to the corresponding scalp part for introduction treatment while rolling, and the force is uniform and stable, repeating back and forth several times, to the extent that the patient can tolerate and the skin in the treatment area is slightly red. The operation time is about 15\~20 minutes."
224268380|NCT06218394|DRUG|5% minoxidil|topical 5% minoxidil, 1 ml, once daily
224268381|NCT05216562|DRUG|Exosome-MSC Intravenous injection|Intravenous injection of Exosome-MSC
224268382|NCT05216562|DRUG|Placebo Intravenous Injection|Intravenous injection of Placebo
224268383|NCT05216562|DRUG|COVID-19 Standard Treatment|Specific drugs considered standard treatment for COVID-10 by each location may vary
224268384|NCT05900648|DRUG|Regorafenib|Given by PO
224268385|NCT05900648|DRUG|XmAb20717|Given by (IV) vein
223867034|NCT02620813|DRUG|Isotretinoin|Subjects will take isotretinoin as prescribed by their dermatologist.
223867035|NCT03378141|BEHAVIORAL|Maternal Nutrition Behavior change|Counseling and community mobilization
223867036|NCT01824485|DRUG|viscosupplementation 1+1+1|intra-articular injection with 1 ampoule per week for 3 weeks
223867037|NCT01824485|DRUG|viscosupplementation 3 at once|single intra-articular injection with 3 ampoules
223867038|NCT00158769|DRUG|Intravenous GR270773 - Phospholipid emulsion|GR270773 (lipid emulsion) is a sterile, white to off-white, semi-translucent liquid for intravenous injection.
223867039|NCT06969404|BIOLOGICAL|capillary blood sampling|capillary blood sampling during the hospital transfert
223867040|NCT01652417|DRUG|methylprednisolone bolus IV 15 mg/kg/d for 3 days.|methylprednisolone bolus IV 15 mg/kg/d for 3 days.
223867041|NCT06968221|DEVICE|Bioabsorbable Staple Line Reinforcemen|cingular Bioabsorbable Staple Line Reinforcement
223867042|NCT00390273|DRUG|Metformin|
223867043|NCT04578392|PROCEDURE|high ligation of ileocolic artery|Patients will be randomized according to post-operative recurrence risk to surgery to high ligation or mesenteric sparing
223867044|NCT04578392|PROCEDURE|mesenteric sparing|Patients will be randomized according to post-operative recurrence risk to surgery to high ligation or mesenteric sparing
224268386|NCT03480230|DRUG|Compound 121564|Compound 121564 10 mg/Kg administered over 60 minutes given intravenously every 2 weeks for 4 doses plus chemotherapy depending on tumor histology.
223867045|NCT06121349|DRUG|ocrelizumab|infusion therapy administered every six months
223867046|NCT06121349|DRUG|ofatumumab|self-injectable every month
223867047|NCT06409975|BEHAVIORAL|Mindful Self-Compassion (MSC)|MSC is an 8-week virtual intervention with weekly 2.5-hour sessions and a 4-hour retreat (between sessions 5 and 6) which will take place online via HIPAA-compliant Zoom. Each weekly session includes an opening meditation, reflection on weekly practice, short teaching, a weekly core meditation or informal practice discussion, short break, brief centering practice, weekly core reflective activity and discussion, and self compassion skill of the week practice. The 4-hour retreat is focused on engaging with the formal practices that have been taught in weeks 1-5.
223867048|NCT02672722|DRUG|Definity|During kidney ultrasound, Definity microbubbles will be injected into the vein to see how blood flows through the kidneys
223867049|NCT02672722|OTHER|Exercise|
223867050|NCT02672722|OTHER|Kidney Ultrasound|This done before and after exercise with the help of Definity to see changes in kidney blood flow
223867051|NCT03230942|OTHER|Pre-operative education|Verbal and booklet about symptoms and physical conditions pos knee replacement
223867052|NCT03230942|OTHER|Pos-operative rehabilitation|Physical therapy treatment
223867053|NCT04224142|DIETARY_SUPPLEMENT|PKU sphere|"PKU sphere is a Food for Special Medical Purposes (FSMP). This product is for use in the dietary management of phenylketonuria (PKU).~It is a powdered, low phenylalanine medical food containing a balanced mix of GMP, essential and non-essential amino acids, carbohydrate, fat, vitamins, minerals, and DHA.~It is available in 27g sachets providing 15g PE and contains 28mg Phe and 35g sachets providing 20g PE and contains 36mg Phe."
223867054|NCT05766189|BEHAVIORAL|Wastewater vaccine prompts|Social media communications showing levels of SARS-CoV-2 in wastewater
223867055|NCT05979870|PROCEDURE|Valvuloplasty,|Choice of type of intervention decided on a multidisciplinary conference
223867056|NCT04287478|BIOLOGICAL|Bacteriophage Therapy|Bacteriophage therapy will be personalized for each patient dependent on phage susceptibility testing
223867057|NCT02997280|DRUG|Ruxolitinib Oral Tablet|"Dose reduction criteria for acute GVHD: grade 4 neutropenia or grade 4 thrombocytopenia related to ruxolitinib administration based on the decision of attending physician.~Dose reduction criteria for chronic GVHD: grade 3 neutropenia, grade 3 thrombocytopenia or anemia requiring transfusion, related to ruxolitinib administration based on the decision of attending physician.~Reduced dose schedule: 5 mg bid for adults and children with body weight \> 40 kg, 0.08 mg/kg bid for children with body weight \< 40 kg.~Treatment discontinuation criteria: complete response; absence of response after 28 days or progressive disease after 7 days for acute GVHD; absence of response after 84 days or progressive disease after 28 days for chronic GVHD; life-threatening complications."
223867058|NCT03302741|DRUG|Botulinum neurotoxin (BTX)|Each patient will receive BTX injections in 2 sites. 100 units at double dilution will be injected at each site.
223867059|NCT03302741|OTHER|Physical Therapy|Standard physical therapy will be ordered to both groups as part of standard of care for patients after BTX injections to maximize the outcomes.
223867060|NCT03302741|DEVICE|Standard BTX injection (ultrasound guided)|For standard injection procedures, target muscles will be visualized under ultrasound imaging which is operated by an experienced and dedicated technician. Position of needle tip within the target muscle is visualized prior to injection. Ultrasound guidance can help ensure depth of needle tip location, i.e., to make sure the needle tip is within the muscle, but it is not able to tell where it is located with reference to the innervation zones (IZs) of the entire muscle.
223867061|NCT03302741|DEVICE|3-dimensional innervation zone (3DIZ) guided injection|Simultaneous surface EMG and intramuscular EMG measurements will be acquired from the spastic biceps of the patients. Patients will be seated comfortably on a height-adjustable chair. The arm to be tested will be secured firmly on a customized apparatus with the elbow joint at approximately 90° of flexion and the shoulder at approximately 45° of abduction and 30° of flexion. The 128-channel unipolar surface EMG signals will be recorded with 2 flexible 2-dimensional 64-channel surface electrode array. A coating fine wire electrode will be inserted into the mid-axial section of the biceps to record bipolar intramuscular EMG signals. Ultrasound scan will be performed on the biceps to identify the location of the inserted wire electrode. Patients will be asked to contract their impaired biceps to perform maximum voluntary contraction of elbow flexion against the vertical plates 3 times.
223867062|NCT02825485|PROCEDURE|Voiding cystourethrogram|
223867063|NCT03316521|DRUG|AMY-101|AMY-101 is a selective inhibitor of complement activation, which binds to the complement component C3.
223867064|NCT06164756|OTHER|Cognitive Behavior Therapy (CBT)|Participants will receive 10 weeks of CBT
223867065|NCT06164756|OTHER|Treatment As Usual (TAU)|Participants will receive standard of care treatment
223867066|NCT06453317|BIOLOGICAL|Infliximab|Infliximab 5 mg/kg i.v at Weeks 0, 2, 6 and then every 8 weeks for 52 weeks.
223867067|NCT06453317|BIOLOGICAL|Ustekinumab|Ustekinumab: first dose i.v. at Week 0 (Patients with body weight ≤55 kg - 260 mg, patients with body weight \>55-≤85 kg 390 mg, patients with body weight \>85 kg - 520 mg) then 90 mg s.c. every 8/12 weeks for 52 weeks.
223867068|NCT04489823|DEVICE|AVP III|Transcatheter closure of a paravalvular leak using AVP III
223867069|NCT05390567|BEHAVIORAL|Participant Choice of HPV Self-Test|Opportunity for participants to complete the HPV self-test in a non-clinical setting to be returned via a mailer or courier servie.
223867070|NCT05390567|BEHAVIORAL|Survey: Participant cancer history and cervical cancer prevention/screening knowledge|Asking women to respond to questions about their cancer history and knowledge of cervical cancer prevention and screening.
223867071|NCT05390567|BEHAVIORAL|Participant Choice of Standard of Care in-clinic Pap-test|Participant choice of cervical cancer screening method with either a SOC in-clinic pap test or HPV self-test
223867072|NCT05473364|DRUG|Acetazolamide|Diuretic and carbonic anhydrase inhibitor medication
223867073|NCT05545111|DRUG|NBI-1117568|Active treatment with orally administered NBI-1117568
223867074|NCT05545111|DRUG|Placebo|Placebo matching NBI-1117568
223867075|NCT06603090|BEHAVIORAL|Text message influenza vaccine reminders|Text message influenza vaccine reminders
224268387|NCT02818530|DEVICE|IOP by tonometer|Electronic tonometer will be used as gold standard for intraocular pressure measurement in supine position after induction of anaesthesia and every 2 hours intraoperatively and at end of surgery.
223867076|NCT06603090|BEHAVIORAL|Text message COVID-19 vaccine reminders|Text message COVID-19 vaccine reminders
223867077|NCT06603090|BEHAVIORAL|Text message influenza and COVID-19 vaccine reminders|Text message influenza and COVID-19 vaccine reminders
223867078|NCT06633614|DEVICE|Supervised prehabilitation programme|Participants will receive standard preoperative physiotherapy education along with a Fitbit Aspire 3 wearable device to track vital signs such as heart rate, physical activity, and sleep patterns. They will follow a personalized exercise program, supervised remotely by a physiotherapist via telemedicine twice a week. The program will include 20-minute sessions at least three times per week, focusing on strength training, aerobic exercises (at 40% of maximal heart rate), and flexibility exercises. Progress will be monitored through vital signs and workout data, with the physiotherapists adjusting the regimen as needed. Participants with low inspiratory pressure (MIP \&amp;lt;100 cmH₂O) will receive an Inspiratory Muscle Trainer (IMT). Additionally, some participants may be provided with a portable cycle pedometer featuring adjustable resistance. To ensure safety, both participants and caregivers will receive a safety briefing, and a 24-hour emergency hotline.
223867079|NCT05764187|OTHER|Orthodontic fixed appliance therapy|Follow up of white spot lesion development using quantitative light induced fluorescence in patients bonded with ceramic brackets versus patients bonded with conventional metal brackets
223867080|NCT06972524|DIETARY_SUPPLEMENT|a special probiotics from Mengniu Group, supplemented with milk powder|Sorbitol 、Xylitol 、Paracaseobacterium LC19 、Bifidobacterium lactis subsp. animalis MN-Gup 、Mulberry Leaf Extract 、Bitter Melon Powder 、Resistant Dextrin 、White Kidney Bean Extract 、Stachyose 、Galactooligosaccharides 、Food Flavoring、Mono- and Diglycerides of Fatty Acids 、Silicon Dioxide
223867081|NCT06972524|DIETARY_SUPPLEMENT|regular milk powder does not contain any additional supplementation, and the color, flavor, shape, taste, and weight are same with the probiotic milk powder|Sorbitol、Xylitol 、Food Flavoring 、Mono- and Diglycerides of Fatty Acids 、Silicon Dioxide、Maltodextrin
223867082|NCT06973850|BEHAVIORAL|The Self-Efficacy Building Nursing Program|"Intervention Description~The Self-Efficacy Building Nursing Program is a structured, theory-based educational intervention grounded in Bandura's Self-Efficacy Theory. It aims to enhance participants' confidence in their ability to perform daily foot self-care behaviors and perceive their risk of complications accurately. The content includes:~Educational modules on diabetes and foot health.~Training on daily foot inspection, hygiene, nail and skin care, and appropriate footwear.~Motivational strategies, goal setting, and problem-solving skills.~Video demonstrations, live discussions, and Q\&A sessions with a diabetes nurse educator.~The program will be delivered over four weekly virtual sessions, each lasting approximately 45-60 minutes, via a user-friendly telehealth platform (e.g., Zoom or WhatsApp Video). Follow-up support and reminders will be provided through weekly text messages and phone check-ins."
223867083|NCT06974136|DEVICE|transcranial electrical stimulation|Transcranial electrical stimulation (tES) is a non-invasive neuromodulation technique that applies low-intensity electrical currents to the scalp to modulate brain activity. It targets specific brain regions to influence neuronal excitability, connectivity, and plasticity, offering potential therapeutic benefits for neurological and psychiatric conditions. tES is portable, cost-effective, and generally well-tolerated, with minimal side effects such as mild tingling or itching at the stimulation site.
223867084|NCT04100109|DIETARY_SUPPLEMENT|Polylactose|Polylactose 15 g/day
223867085|NCT04100109|OTHER|Placebo|Cellulose 15 g/day
223867086|NCT03008018|DRUG|KA2507|KA2507, an orally-active new chemical entity, is a potent and selective inhibitor of the HDAC6 enzyme, with potential clinical utility in the treatment of melanoma and other solid tumors. KA2507 has been shown to display potent in vitro activity in a range of cancer cell lines, including melanoma cell lines. KA2507 exerts potent in vivo efficacy in a syngeneic model of B16 melanoma. Here, the combination of the agent's direct tumor growth inhibition and metastasis suppression, coupled with its immunotherapeutic activity - demonstrated by decreased expression of STAT-3 and PD-L1 and increased expression of acetylated tubulin, gp100 and MHC Class I in tumors - have been observed.
223867087|NCT05788146|OTHER|Cognitive Behavioural Therapy|A psychological intervention used to target depression
223867088|NCT01499654|DRUG|Half-dose of the Tc99-m sestamibi (Cardiolite)|Researchers will administer half of the radiotracer (Cardiolite), obtain resting images, administer the remainder of the radiotracer and obtain a second set of resting images. Subjects will be given the same amount of radioactive material that would normally be given for this test; however, it will be administered in two ½ doses.
223867089|NCT00786006|DRUG|FOLFIRI.3|FOLFIRI.3: Irinotecan 70 mg/m2 (over 60 min) on D1, LV 400 mg/m2 (over 2h) D1, 5-FU 2000 mg/m2 (over 46 hours) from D1, then irinotecan 70 mg/m2(over 60 min) at the end of the 5-FU infusion
223867090|NCT00786006|DRUG|FOLFOX|FOLFOX: oxaliplatin 85 mg/m2 (over 120 min) on D1, LV 400 mg/m2 (over 2hour) on D1, 5-FU 400 mg/m2 IVP on D1, 5-FU 2,000 mg/m2 (over 46 hours)
223867091|NCT06973447|PROCEDURE|Anterior suprascapular nerve block (ASSNB)|10 mL of 0.25% bupivacaine
223867092|NCT06973447|PROCEDURE|Infraclavicular Brachial Plexus Block (ICBPB)|15 mL of 0.25% bupivacaine
223867093|NCT06973447|PROCEDURE|Costoclavicular brachial plexus block (CCBPB)|15 mL of 0.25% bupivacaine
223867094|NCT00922649|DEVICE|Insulin Pump therapy|Initiation of Insulin pump therapy in patients on \>2 OAs (Cohort A), basal insulin ± OAs (Cohort B), or basal-bolus insulin ± OAs (Cohort C.
223867095|NCT05076058|DIETARY_SUPPLEMENT|Tablet of silybum marianum, Pueraria lobate and salvia miltiorrhiza|"Brand names: BY-HEALTH；~Main contents (per 100g): silibinin 2g, salvianolic acid B 0.72g，Puerarin 0.68g"
223867096|NCT05076058|OTHER|Placebo tablet|"Brand names: BY-HEALTH；~Main contents : starch"
223867097|NCT00005027|DRUG|becatecarin|
223867098|NCT03209037|DRUG|Peginterferon Alfa-2a|patients untreated in immune-active phase were given subcutaneous injection of Peginterferon Alfa-2a with starting dose of 180 mg/weekly in experiment group.
224268388|NCT02818530|DEVICE|Anterior chamber depth measurement by ultrasound|Anterior chamber depth will be measured by ultrasound in supine position after induction of anaesthesia and every 2 hours intraoperatively and at end of surgery.
224268389|NCT02125435|DRUG|ASP2408|intravenous
224268390|NCT02125435|DRUG|Placebo|intravenous
224268391|NCT02511535|BIOLOGICAL|TBE booster vaccination|
224268392|NCT04468282|DRUG|VGB-ST|Single oral administration of 500 mg VGB-ST
223867099|NCT01503749|DRUG|G-colony stimulating factor|G-colony stimulating factor (5ug/kg/day)will be administered subcutaneously to three patients with liver cirrhosis of this arm.
223867100|NCT01503749|OTHER|Infusion of the mobilized monocyte cells|G-colony stimulating factor (5ug/kg/day)will be administered twice subcutaneously for 3 days to three patients with liver cirrhosis of this arm. On the day 4th, leukapheresis will be done to collect peripheral blood mononucleated cells. And then we are going to infuse the collected peripheral blood mononucleated cells of their own through the portal vein of each patients under ultrasonographic guidance.
223867101|NCT04845685|DEVICE|Continuous Glucose Monitor (CGM)|A device that measures blood sugar levels every 1-5 minutes
223867102|NCT04090190|DRUG|Oxybutynin, Solifenacin, Tolterodine, Trospium, or Fesoterodine|Study participants will be evaluated for urgency urinary incontinence and will be offered treatment with a standard of care anticholinergic medication for 6 weeks. All study participants will fill out the UDI-6 and two day bladder diary at baseline before starting anticholinergic medication treatment. Participants will then provide a urine sample and blood draw to be assessed for urinary microbiome and inflammation. Anticholinergic medication will be taken daily for 6 weeks and the same procedures (UDI-6 questionnaire, bladder diary, urine sample except the blood draw for assessment) will be performed at the 6-week time period.
223867103|NCT00457691|DRUG|5 fluorouracil|400mg/m2 bolus injection day 1 followed by 2400mg/m2 continuous infusion for 46 hours every 14 days
223867104|NCT00457691|DRUG|irinotecan|180mg/m2 iv day 1 every 14 days
223867105|NCT00457691|DRUG|levo- leucovorin|200mg/m2 iv; day 1 every 14 days
223867106|NCT00457691|DRUG|sunitinib|37.5mg of blinded therapy every day for 28 days followed by 14 days of blinded therapy free period
223867107|NCT00457691|DRUG|5 fluorouracil|400mg/m2 bolus injection day 1 followed by 2400mg/m2 continuous infusion for 46 hours every 14 days
223867108|NCT00457691|DRUG|irinotecan|180mg/m2 iv day 1 every 14 days
223867109|NCT00457691|DRUG|levo- leucovorin|200mg/m2 iv; day 1 every 14 days
223867110|NCT00457691|DRUG|placebo|37.5mg of blinded placebo therapy every day for 28 days followed by 14 days of blinded therapy free period
223867111|NCT02644239|DIETARY_SUPPLEMENT|ketogenic diet|Ketogenic diet with high fat (90%)
223867112|NCT00009646|DRUG|indomethacin|Indocid P.D.A., Merck Frosst, Kirkland, Que., Canada, and Merck, West Point, Pa
223867113|NCT00009646|DRUG|Indomethacin|0.1 mg per kilogram of body weight
223867114|NCT00009646|DRUG|Placebo|0.1 mg per kilogram of body weight
223867115|NCT04689425|DRUG|Umbilical cord blood mononuclear cell gel（MNC）|Local wound treatment by combination of PRP and MNC, once;
223867116|NCT04689425|DRUG|The platelet rich plasma（PRP）|Local wound treatment by PRP alone, once.
223867117|NCT00582478|BEHAVIORAL|questionnaires|Participants will be followed regularly at 3, 6, 12, and 18-month intervals
223867118|NCT02079844|DRUG|Roflumilast|Roflumilast tablets
223867119|NCT02079844|DRUG|Placebo|Roflumilast placebo-matching tablets
223867120|NCT02079844|DRUG|Second generation antipsychotic|Second Generation Antipsychotic (SGA) medication for standard of care therapy will be sourced and managed locally by the site.
223867121|NCT04954196|DRUG|Amlodipine 5mg|"HRT administration: On Day 1 of the cycle, HRT is planned in accordance with the department's standard practice.~* The frozen embryo transfer will be performed 6 days after progesterone initiation.~* The HRT will be maintained until the pregnancy test is performed: If the test is positive,HRT will be continued for up to 12 weeks of amenorrhea at the same doses and then gradually stopped. If the test is negative,HRT will be stopped gradually~Amlodipine administration: On the day of the first monitoring Dm (corresponding to D13 D16 of the cycle), a single per os dose of amlodipine 5 mg is taken at night, neither the patient nor the investigator knows what drug is the patient getting. Monitoring is systematically performed the next morning.The treatment will be maintained until the pregnancy test is performed then if the test is positive, the treatment will be maintained for a total duration of 7 weeks."
223867122|NCT04954196|DRUG|Placebo|"HRT administration: On Day 1 of the cycle, HRT is planned in accordance with the department's standard practice.~* The frozen embryo transfer will be performed 6 days after progesterone initiation.~* The HRT will be maintained until the pregnancy test is performed: If the test is positive, HRT will be continued for up to 12 weeks of amenorrhea at the same doses and then gradually stopped. If the test is negative, HRT will be stopped gradually~Placebo administration:On the day of the first monitoring Dm (corresponding to D13-D16 of the cycle), a single per os dose of placebo (Microcrystalline cellulose) is taken at night, neither the patient nor the investigator knows what drug is the patient getting. Monitoring is systematically performed the next morning.. The treatment will be maintained until the pregnancy test is performed, then if the test is positive, the treatment will be maintained for a total duration of 7 weeks."
223867123|NCT06820879|DEVICE|Viscoelastic Tests (ROTEM)|Viscoelastic Tests (2-6 tests for the study over the first 24 hours)
223867124|NCT06044545|DIAGNOSTIC_TEST|Web Based Pregnancy Preparation Education Structured According to the Health Promotion Model Knowledge Attitude and Health Behaviors|"With this research, according to the health promotion model for the care that should be taken during the preconceptional period (pre-pregnancy) of women who are not yet pregnant, who will marry soon and who are considering pregnancy.~It is thought that they will gain knowledge, increase their awareness and develop positive health behaviors with the web-based pregnancy preparation training. In data collection; Introductory Characteristics Form, Preconceptional Knowledge and Attitudes Scale, Preconception Health Behaviours Scale will be used."
223867125|NCT03062137|DIAGNOSTIC_TEST|blood gas sampling|
223867126|NCT06660758|DEVICE|Feeding tube (Entarik)|Feeding tube placement will be verified using multiple methods in the duodenum and stomach.
223867127|NCT05719077|BEHAVIORAL|EDITH-HC|This study tests feasibility and acceptability of implementing a tool and training in a clinical practice and the preliminary efficacy of training materials to enhance hospice clinicians' knowledge of dementia-related caregiving issues at end of life and a tool for clinicians to use to address caregiving issues related to dementia at end of life.
223867128|NCT06034665|OTHER|Exercise|All patients will be included in the exercise program for their symptoms regarding knee osteoarthritis for 15 sessions.
223867129|NCT05977634|BEHAVIORAL|Bladder training|Bladder training has 4 components, educating the patient about anatomy, fluid intake control, pelvic floor muscle contractions and increasing the interval between visits to the bathroom
224076515|NCT02475655|DRUG|Ruxolitinib|10 mg orally twice daily for 5 weeks
223867130|NCT05977634|DEVICE|Transcutaneous tibial nerve stimulation|A combined electrotherapy device capable of applying transcutaneous electrical nerve stimulation will be used. Each session will take 30 minutes. Patient will visit the hospital twice a week for 6 weeks. An electrical current of 0-50 amperes with a frequency of 20 herz, and a duration of 200 micro seconds will be applied using 50x50 mm surface electordes. The aim is to create a tingling sensation without causing any pain on the tibial nerve, at the ankle level.
223867131|NCT06034678|BEHAVIORAL|Food Allergy Mastery Program|Food Allergy Mastery Program sessions will be delivered by masters-level counselors as 6 45-minute biweekly telehealth or in-person sessions over a period of 3 months. Session 1 will include both youth and caregiver, Session 2 will be a group session with 5-6 youth, Session 3 will include both youth and caregiver, Sessions 4-5 will be individual youth sessions, and Session 6 will include both youth and caregiver. Sessions will incorporate a variety of formats, each based on the needs of the session content.
223867132|NCT00928213|DRUG|Progesterone|40 units daily admission
223867133|NCT00928213|DRUG|Low molecular weight Heparin|40-80 mg/day
223867134|NCT00928213|DRUG|No Drug|no treatment
223867135|NCT06490003|DRUG|Fluoro Uracil|Esophageal cancer chemotherapy（First line treatment)
223867136|NCT03710343|DRUG|Metformin|Single case ABA study design. Phase B (intervention period) with metformin administered orally (or by gastrostomy tube) for 16 weeks.
223867137|NCT00039455|BIOLOGICAL|trastuzumab|Given IV
223867138|NCT00039455|DRUG|alvocidib|Given IV
223867139|NCT00039455|OTHER|laboratory biomarker analysis|Correlative studies
223867140|NCT00039455|OTHER|pharmacological study|Correlative studies
223867141|NCT06613204|BEHAVIORAL|STELLA-FTD Control|Participants receive information about FTD and support via weekly group video-conference-based meetings.
223867142|NCT06613204|BEHAVIORAL|STELLA-FTD Test|The test group receives a information and support, but with a focus that is different from the Control Group
223867143|NCT06673316|OTHER|Design thinking workshop|The workshop will cover the five stages of design thinking, allowing students to apply these principles to real-world healthcare challenges in their future practice.
223867144|NCT05909566|OTHER|Clinical Decision Support (CDS)|Education to front line clinicians and staff on standardized implementation and weaning of HHFNC and standardized assessments of patient work of breathing. HHFNC implementation and weaning strategies will be based on age-specific practices recommended by the American Academy of Pediatrics. Education will be undertaken by dedicated clinical educators.
223867145|NCT05909566|DEVICE|HHFNC Weaning|Wean patient off oxygen and flow as oxygenation and work of breathing improves.
223867146|NCT02487316|DRUG|crizotinib|crizotinib 250mg, oral, bid from day 1 to 18 weeks. cyclophosphamide, 750mg/m2,d1, vincristine, 1.4mg/m2, maximal dose is 2mg d1, doxorubicin, 50mg/m2d1, prednison, 100 mg d1-5) every 3 weeks for up to six cycles.
223867147|NCT00981630|BIOLOGICAL|Live attenuated Japanese encephalitis virus|0.5 mL,Subcutaneous
223867148|NCT00981630|BIOLOGICAL|Live attenuated Japanese encephalitis virus|0.5 mL, Subcutaneous
223867149|NCT00981630|BIOLOGICAL|Live attenuated Japanese encephalitis virus|0.5 mL, Subcutaneous
223867150|NCT00981630|BIOLOGICAL|ChimeriVax™ diluent (Placebo)|0.5 mL, Subcutaneous
223867151|NCT06677281|OTHER|Systematic Review of COVID-19's Impact on Pregnancy Outcomes|This study is a systematic review of existing literature that examines the effects of COVID-19 on pregnancy outcomes, including maternal health, neonatal health, and obstetric complications. It synthesizes data from various studies to provide an overview of the potential risks associated with COVID-19 infection during pregnancy. This intervention does not involve any new clinical trials or direct patient interaction.
223867152|NCT05836285|OTHER|ARRC|Eligible for ARRC and managed in ARRC unit
223867153|NCT05836285|OTHER|Usual Care|Eligible for ARRC but managed elsewhere as no ARRC bed available
223867154|NCT06092138|DEVICE|Wearable Device|Whether to use wearable devices.
223867155|NCT06864299|DEVICE|Trans-Carotid Artery Occlusion Shunt System Combined with Introducer Sets|To evaluate the Safety and Efficacy of the Trans-Carotid Artery Occlusion Shunt System Combined with Introducer Sets for Cerebral Protection During Carotid Angioplasty
223867156|NCT04848090|DIAGNOSTIC_TEST|Neonate WGS Testing|"Neonates will undergo whole genome sequencing, and analysis with a targeted panel of genes likely to cause genetic disorders in the first year of life. If no diagnosis is identified, sequenced data will be analyzed using a whole exome filter. Performed in a CLIA-certified lab. Pathogenic, likely pathogenic, and VUS in genes related to the phenotype will be returned to the care team and family.~Parents will be enrolled for the purpose of trio analysis with the child to assist in determining the pathogenicity of variants in genomic sequencing. Pathogenic and likely-pathogenic findings will be reported to the parents in the setting of genetic counseling.~Sibling will be enrolled and have samples collected for use in the genetic analysis only if deemed essential. Results will be reported to the parents in the setting of genetic counseling."
223867157|NCT07008898|PROCEDURE|Midurethral sling placed before robotic sacrocolpopexy|Sequence of midurethral sling placement (before or after suspension of the vaginal apex) during robotic sacrocolpopexy is largely surgeon-dependent and dictated by training and experience. This study will examine whether there are any differences in continence and patient satisfaction between patients in whom slings are placed prior to suspension of the vaginal apex during robotic sacrocolpopexy versus after.
223867158|NCT07008898|PROCEDURE|Midurethral sling placed after robotic sacrocolpopexy|Sequence of midurethral sling placement (before or after suspension of the vaginal apex) during robotic sacrocolpopexy is largely surgeon-dependent and dictated by training and experience. This study will examine whether there are any differences in continence and patient satisfaction between patients in whom slings are placed prior to suspension of the vaginal apex during robotic sacrocolpopexy versus after.
223867159|NCT05799963|DEVICE|BioMatrix Alpha|Patient will be treated with BioMatrix Alpha
224076516|NCT04293770|DEVICE|Indirect adhesive restoration of posterior teeth|Indirect restoration of significant loss of dental hard tissue
224076517|NCT03382847|COMBINATION_PRODUCT|Transplant with HCV positive donor, followed by surveillance and treatment of viremia|Heart transplant with HCV positive donor, followed by treatment for viremia if viremia occurs
224076518|NCT00643994|RADIATION|CyberKnife Stereotactic Radiosurgery|36.25 Gy delivered in 5 fractions of 7.25 Gy per fraction
223867160|NCT06676605|DIETARY_SUPPLEMENT|Withania somnifera|The experimental supplement administered to patients in this study was Withania somnifera, commonly known as ashwagandha. It is classified as a dietary supplement and is regulated similarly to pharmaceutical medications. The supplement has been authorized for commercialization and use by the Food and Drug Administration (FDA). Participants received the supplement in the form of 500 mg capsules, taken daily over a 40-day period, following the manufacturer's instructions. The range of the recommended daily dose is between 240 and 600 mg. The purpose of administering this supplement was to evaluate its impact on various health parameters, including serum lipid concentrations and body composition, in the study's participants.
223867161|NCT06676605|OTHER|Placebo Intervention|The product administered to the placebo group was designed to simulate the appearance and administration of the experimental supplement but without containing any active ingredients. Participants in the placebo group received capsules/tablets filled with starch rice. These capsules were taken daily over the same 40-day period as the experimental group, ensuring that the placebo group followed identical administration and monitoring procedures. The use of starch rice capsules aimed to serve as a neutral control, allowing for a comparison between the effects of the actual Withania somnifera supplement and the placebo.
223867162|NCT06677216|PROCEDURE|Botulinum Toxin, Type A|All participants will receive a solution of BTX-A (Xeomin, Merz Pharma GmbH, Frankfurt am Main, Germany) in the masseter and temporalis muscles (total of 100 units reconstituted with 4cc unpreserved 0.9% sodium chloride). The injection will be provided by the same maxillofacial surgeon. The participants are asked to clench their teeth to determine the site of the most intense muscle activity in the masseter and temporal muscles with palpation. Intramuscular BTX-A injections are administered on both sides at the location of the most intense muscle activity of the masseter (80 units) and temporalis (20 units).
223867163|NCT05251493|DRUG|Iron Isomaltoside 1000, ferric derisomaltose|iron isomaltoside 20 mg/mL
223867164|NCT05251493|DRUG|Iron sucrose|iron sucrose 100 mg/mL
223867165|NCT06676696|DRUG|Continue low dose calcineurin inhibitor (CNI)|CNI dose (tacrolimus or cyclosporine) will be adjusted to maintain low tacrolimus or cyclosporine whole blood trough levels from month 3 to month 24 or End of Study
223867166|NCT06676696|DRUG|Calcineurin inhibitor withdrawal at 6 months|CNI dose (tacrolimus or cyclosporine) will be reduced to one-half on month 3 visit and completely withdrawn on month 6 visit.
223867167|NCT06871774|DEVICE|Single Perclose Pro vascular closure device|Use of a single Perclose device for pre-closure of vascular access site after removal of TAVR sheath.
223867168|NCT06871774|DEVICE|Dual Perclose vascular closure device|Use of two Perclose devices for pre-closure of vascular access site after removal of TAVR sheath.
223867169|NCT06630299|DRUG|ISL/LEN|Tablet administered orally
223867170|NCT06630299|DRUG|Antiretroviral Combinations|2 or 3 antiretrovirals (ARVs) administered as defined by the investigator, according to the prescribing information.
223867171|NCT07023107|DRUG|0.9% Sodium Chloride Injection|After spinal anesthesia, the ultrasound-guided PENG block will be performed with 20ml of 0.9% sodium chloride
223867172|NCT07023107|DRUG|Ropivacaine 0.2% Injectable Solution|After spinal anesthesia, the ultrasound-guided PENG block will be performed with 20 ml of 0.2% ropivacaine
223867173|NCT07023120|DRUG|Ropivacaine 0.2% Injectable Solution|20ml 0.2% Ropivacaine
223867174|NCT07023120|DRUG|Dexamethasone 4mg|perineural 4mg Dexamethasone
223867175|NCT07023120|DRUG|Ropivacaine 0.2% Injectable Solution|10ml 0.2% Ropivacaine
223867176|NCT07025304|DEVICE|REFLEX ULTRA 45|One time use for surgery
223867177|NCT06873763|DRUG|Nelmastobart 800 mg+Trifluridine/Tipiracil+ Bevacizumab|Trifluridine/tipiracil is dose-deescalated from 35 mg/m² to 30 mg/m² and 25 mg/m² to determine the RP2D, in combination with fixed doses of Nelmastobart and Bevacizumab, in patients with metastatic colorectal cancer who are refractory or intolerant to prior oxaliplatin- and irinotecan-based chemotherapy.
223867178|NCT06701201|DRUG|SynKIR-110|Autologous T cells Transduced with Mesothelin KIR-CAR
223867179|NCT06701201|DRUG|SynKIR-310|Autologous T Cells transduced with CD19 KIR-CAR
223867180|NCT07055529|DRUG|Group A recieving PUVA therapy|This group A will recieve PUVA therapy twice weekly for 6 months
223867181|NCT07055529|DRUG|Group B receiving Tablet Tofacitinib|This group will be given tablet Tofacitinib 5mg twice daily for 6 months
223867182|NCT07061236|OTHER|Elastomeric Pump Education|This intervention involves a 15-20 minute face-to-face training session about the use of the elastomeric pump with 5-FU, supported by visual materials and an educational booklet developed by the researchers based on current literature and expert opinion
223867183|NCT07061223|PROCEDURE|SFIB|The block technique is based on administration of a local anesthetic under the iliac fascia to block the femoral, lateral femoral cutaneous, and obturator nerves. It is assumed that further leakage of local anesthetic through the interfascial space leads to blocking of the branches of the lumbar plexus in the small pelvis.
224268393|NCT03671954|BEHAVIORAL|Home Strengthening Exercises|The intervention group will perform unsupervised home strengthening exercises for the hip abductors in addition to standard physical therapy, while the control group will receive standard physical therapy alone.
224268394|NCT03671954|OTHER|Standard Physical Therapy|Physician determined standard of care for individual TKA patients.
224268395|NCT03671954|OTHER|Preoperative Assessments|"Assessments will include:~* TUG (timed up and go test) \>12 sec indicates increased fall risk~* Tandem balance test \< 10 sec indicates increased fall risk~* Sit to Stand test (age based norms)~* Knee Range Of Motion (ROM)~* Quadriceps and hamstring strength (MMT or hand held dynamometer)~* Lower Extremity Functional Score (LEFS questionnaire)"
224268396|NCT05885412|GENETIC|RP-A601|RP-A601 is a recombinant viral vector composed of an AAV serotype rh.74 (AAVrh.74) capsid encapsulating the transgene, human plakophilin 2 (PKP2), transcript variant 2a (PKP2a)
224268397|NCT03589430|OTHER|Laboratory investigations ( protein C, protein S , antithrombin III)|laboratory investigations ( protein C , protein S , antithrombin)
224268398|NCT04155450|OTHER|Extension Biased External Limb Loading Exercises|"Begin in the quadruped position and progress the intensity by~1. Flexing one upper extremity~2. Extending one lower extremity with a leg slide~3. Extending one lower extremity by lifting it off the mat~4. Flexing one upper extremity while extending contralateral lower extremity and then alternate to opposite extremities.~   Progress to prone position:~5. Extending one lower extremity~6. Extending both lower extremity"
223867184|NCT07061223|PROCEDURE|PENG block|The hip capsule is the main source of pain because the innervation of the joint capsule is a developed network of articular branches of the femoral, sciatic and obturator nerves. The main idea of this technique is to block these branches at the point of common passage between the tendon of the lumbar muscle and the crest of the pubic bone. The block technique is based on administration of a local anesthetic under the ileo-lumbar tendon. Anesthetic spreads through the hip joint capsule and blocks small sensitive branches of the femoral and obturator nerves.
223867185|NCT07061223|PROCEDURE|Patient control analgesia|In the postoperative period, if pain occurs, the patient will be offered the opportunity to use 20 ug Fentanyl solution bolus according to the patient control analgesia (PCA) without a basic infusion.
223867186|NCT07061223|PROCEDURE|General inhalation anaesthesia|General inhalation anesthesia will be performed in all groups, Desflurane with a minimal alveolar concentration (MAC) of 0.6-0.8 will be used for maintenance
223867187|NCT07061210|DRUG|HRS-2189|HRS-2189
223867188|NCT07061210|DRUG|Adebrelimab|Adebrelimab
223867189|NCT07061210|DRUG|BP102|BP102
223867190|NCT07061756|PROCEDURE|SRP|Full-mouth scaling and root planing (SRP) was performed using an ultrasonic scaler (EMS AIR-FLOW MASTER PIEZON®) supplemented by Gracey curettes for subgingival instrumentation. All procedures were conducted under local anesthesia by a calibrated periodontist, with each quadrant treated for a minimum of 30 minutes. Patients received standardized oral hygiene instructions and were scheduled for a 3-month postoperative follow-up.
223867191|NCT07061756|PROCEDURE|ND|"In addition to the identical SRP protocol described above, adjunctive Nd:YAG laser therapy (Wiser Waterlase MD, Vista Dental) was applied immediately post-SRP. Laser parameters were set at 150 mJ/pulse, 20 Hz frequency with water (level 1) and air (level 3) coolant. The fiber optic tip (300 μm diameter) was moved in a continuous Zig-zag pattern along the root surface and pocket epithelium, maintaining 2-second irradiation per site at a 30° angle to the tooth axis. Standardized oral hygiene instructions and 3-month follow-up were similarly provided."
223867192|NCT07059871|DIETARY_SUPPLEMENT|Silkworm pupa powder|Silkworm pupa powder, 2 times a day, two packets (12\*2 g) each time, take with warm water, before meals, for three months
223867193|NCT07059871|DIETARY_SUPPLEMENT|Placebo|Placebo, 2 sachets (12\*2 g) twice a day, with warm water, before meals, for three months
223867194|NCT07061015|PROCEDURE|osseodenification with osseodensifying burs|different osseodensification techniques to be studied
223867195|NCT07061015|PROCEDURE|reverse drilling|using the conventional drills in reverse mode
223867196|NCT07061015|PROCEDURE|rotary expanders|expanders in clockwise direction
223867197|NCT07061249|BEHAVIORAL|Waltz Dance|Participants in this arm will receive a structured Waltz dance intervention as moderate-intensity aerobic exercise. The program consists of 3 supervised sessions per week for 12 weeks, each lasting 105 minutes. Each session includes a 5-minute warm-up, 50 minutes of solo and partner Waltz practice, a 5-minute rest, 40 minutes of choreographed combinations, and a 5-minute cool-down. The dance routines are progressive and designed to improve cardiovascular fitness, coordination, and balance. Exercise intensity is maintained at 50-70% of estimated maximum heart rate, with music tempo and movement complexity adjusted as needed. Physical activity is monitored using accelerometers to ensure target intensity is achieved.
223867198|NCT07060053|OTHER|sesame oil|15min of oil pulling with 15ml sesame-based oil for 8 weeks
223867199|NCT07060053|OTHER|distilled water|15min rinsing with 15ml distilled water for 8 weeks
223867200|NCT04453020|DEVICE|DBS of the LHA|Deep Brain Stimulation of the Lateral Hypothalamic Area
223867201|NCT03101917|DEVICE|The Microtable® Stereotactic System|x
223867202|NCT04765111|DRUG|Acalabrutinib|Given PO
223867203|NCT04765111|BIOLOGICAL|Rituximab|Given IV
223867204|NCT04586270|DRUG|TAS0612|oral tablets
223867205|NCT04094038|DRUG|Olimel N12|A mixture of glucose, lipids, amino acids.
223867206|NCT04094038|DRUG|Glucose IV|Glucose 5%
223867207|NCT05966831|BEHAVIORAL|Metacognitive Self-Control Training (MCT)|"Metacognitive Self-Control Training (MCT) was originally developed by the Michigan Skills Project for students in middle/high school. The MCT training intervention has been updated to be suitable for adults. MCT is a lecture style intervention that encompasses 13 modules (over the course of 4 weeks) on improving self-control that is to be delivered in a community setting. Across the training, participants will learn new tools for improving self-control."
223867208|NCT05966831|BEHAVIORAL|Virtual Reality Job Interview Training (VR-JIT)|VR-JIT provides trainees with an opportunity to repeatedly practice interviewing for a job at fictional company 'Wondersmart'. Prior to interviewing, trainees review self-guided e-learning materials on how to find, prepare for, succeed in, and follow-up on job interviews that includes the review of 10 job interview skills. Trainees also complete an online job application for one of 14 jobs (e.g., cashier, clerical, customer service, food services, inventory, janitorial, web developer) that informs the virtual interview experience.
223867209|NCT06434402|BEHAVIORAL|Behavioral Intervention|Write about cancer experiences
223867210|NCT05065450|DEVICE|Intracranial Stimulation|Electrodes localized to the BLA will be stimulated with either active-BLAES (0.5-3.5 mA, theta-modulated gamma burst) electrical stimulation for a 1-sec duration immediately following item image presentation or sham-BLAES (zero-amplitude). At later stages of the project, stimulation parameters and timing will be varied and triggered not at random, but by real-time closed-loop analysis of memory biomarkers in the medial temporal lobe.
223867211|NCT06374836|DRUG|Phenylephrine|"At the OR, the patient will be sedated and have a transoesophageal echo (TEE) catether inserted, which is part of standard clinical care. When a patient becomes hypotensive and the attending anesthesiologist decides to infuse any of the following drugs (phenylephrine, ephedrine, norepinephrine, nitroprusside, or nicardipine), before infusion, the anesthesiolgist will acquire with TEE 10 beats of the thoracic ascending and descending aorta respectively. This is defined as one measurement. Five minutes after infusion the same measurement is repeated. A maximum of 10 measurements (5 before and 5 after infusion of a drug) per patient will be performed.~We want to explicitly mention that for study purposes the surgery or anesthesia will never be prolonged or modified, nor will any drugs be give for study purposes."
223867212|NCT03714997|PROCEDURE|Walking training|Practice of walking training in variable contexts, including multiple tasks and environments specific to the patients' deficits and community walking goals.
223867213|NCT05869890|DEVICE|MOSES laser system|A holmium laser technology widely used as the gold standard for laser lithotripsy for ureteroscopy treatment of renal calculi,
223867214|NCT04548024|DEVICE|Short term monitoring|By using the Biobeat monitoring device, we will monitor CHF patients during an outpatient visit and during treatment with diuretics.
223867215|NCT00304031|DRUG|Concurrent temozolomide|Daily oral temozolomide (75 mg/m2) up to 49 doses.
223867216|NCT00304031|RADIATION|Concurrent radiation therapy|60 Gy in 2 Gy fractions
223867217|NCT00304031|DRUG|100mg/m2 adjuvant temozolomide days 1 to 5 of 28 day cycle|Oral temozolomide on days 1-5 of a 28-day cycle. Dose starts at 150mg/m2 for first cycle, increases to 200mg/m2 for subsequent cycles if no unacceptable toxicity. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients with responding disease may receive up to 6 more courses of temozolomide.
223867218|NCT00304031|DRUG|75mg/m2 adjuvant temozolomide days 1-21 of 28 day cycle|Oral temozolomide on days 1-21 of a 28-day cycle. Dose starts at 75mg/m2 for first cycle, increases to 100mg/m2 for subsequent cycles if no unacceptable toxicity. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients with responding disease may receive up to 6 more courses of temozolomide.
223867219|NCT06530758|OTHER|Altered ASRS format, without shading and with grouping|Participants will be asked to complete the ASRS form without shading and with grouping.
223867220|NCT06530758|OTHER|Altered ASRS format, with shading and without grouping|Participants will be asked to complete the ASRS form with shading and without grouping.
223867221|NCT06530758|OTHER|Altered ASRS format, without shading and without grouping|Participants will be asked to complete the ASRS form without shading and without grouping.
223867222|NCT06222567|DEVICE|15 minutes pumping with INITIATE program|15 minutes pumping with INITIATE program
223867223|NCT06222567|DEVICE|5 minutes extra pumping with MAINTAIN program|Additional 5 minutes extra pumping with MAINTAIN program
223867224|NCT05733442|OTHER|Treatment as usual (TAU)|TAU entails medication to support patients' recovery (i.e., the partial opioid agonist, buprenorophine + naloxone/ Suboxone gel films), in-person case management and behavioral health intervention (i.e., in-person group and individual counseling), and referrals to other health care and behavioral health services.
223867225|NCT05733442|OTHER|CHaRRM-CN|The CHaRRM-CN intervention includes changes and additions to TAU to make MAT more culturally aligned (i.e., offering regular community-based, cultural programming; offering culturally aligned healing groups in the MAT program, such as Talking Circles and beading group) as well as lower barrier and incentivized (i.e., offering medication and behavioral health appointments via in-person, videoconference or telephone; offering harm-reduction groups in addition to abstinence-based groups; providing mailed and in-person pick-up options for buprenorphine prescriptions; conducting weekly chart reviews to ensure prescriptions and basic needs are continuously met; bimonthly, automated text outreach; contingency management supporting attendance at in-person or telehealth appointments).
223867226|NCT03048279|BEHAVIORAL|Questionnaires|"Multiple Endocrine Neoplasia Syndromes: MEN1/MEN2 Group: Participants interviewed by phone and/or mail to obtain medical history specific to their diagnosis of either MEN1 or MEN2.~Close Relatives of Registered MDACC MEN Patients Group: Participants asked to complete a health and family history questionnaire. This questionnaire process may be completed by phone or mail."
223867227|NCT04391101|DRUG|Convalescent plasma|400-500ml convalescent plasma
223867228|NCT01555099|DRUG|AZD5423|oral inhaled
223867229|NCT01555099|DRUG|Budesonide|oral inhaled
223867230|NCT01555099|DRUG|Placebo|oral inhaled
223867231|NCT04241354|BIOLOGICAL|Leukocyte-poor platelet rich plasma|Platelet rich plasma was prepared using PurePRP Supra Physiologic Protocol A preparation \[EmCyte Corp. Fort Myers FL\].
223867232|NCT05334004|DRUG|Lopinavir / Ritonavir|Human Immunodeficiency Virus (HIV) antiviral, given via suppository
223867233|NCT05563740|OTHER|Psychosocial|Daily telephone calls with two sessions of Brief Interventions for alcohol
223867234|NCT00897169|OTHER|Oral Glucose Tolerance Test (OGTT)|A 5-hour oral glucose tolerance test (OGTT) is performed at visit 2
223867235|NCT00897169|OTHER|Euglycaemic hyperinsulinaemic clamp|A 4-hour euglycaemic, hyperinsulinaemic clamp is performed at visit 3
223867236|NCT00027729|BIOLOGICAL|etaracizumab|
223867237|NCT03022994|OTHER|Duodenum and rectum examination|All subjects will undergo upper gastrointestinal endoscopy and proctoscopy. In addition, it will be also evaluated duodenal and rectal biopsies.
223867238|NCT03368768|OTHER|Obtain inform consent via questionnaire of Monkey Survey|This is an internet-based questionnaire study. Therefore, anyone in Thailand can access and answer the questionnaire.
223867239|NCT04565028|BEHAVIORAL|Contingency Management (CM)|Contingency management is an intensive behavioral therapy in which participants are paid to reduce substance use.
223867240|NCT03694691|DIAGNOSTIC_TEST|Liver Biopsy|For measurement of tissue co-factor levels, we will take needle biopsies of transplanted livers immediately after procurement, immediately prior to implantation (at the end of preservation), 30 minutes after portal vein reperfusion, and 30 minutes after hepatic artery reperfusion. For those livers that have more than 60 minutes between portal vein and hepatic artery reperfusion, an additional biopsy will be performed at 60 minutes after portal vein reperfusion. Post-procurement biopsies will be collected regardless of where the liver was obtained.
223867241|NCT05049434|DEVICE|Medicurtain®|Medicurtain® 5ml prefilled syringe
223867242|NCT05049434|DEVICE|GUARDIX-SG®|GUARDIX-SG® 5ml prefilled syringe
223867243|NCT02198469|DRUG|Er:YAG AFL-PDT|Er:YAG AFL was performed with 350 µm ablation depth, level 1 coagulation, 22% treatment density, and a single pulse. MAL cream was then applied under occlusion for 3 hrs and illuminated with a red light-emitting diode light at 37 J/cm2.
223867244|NCT02198469|DRUG|MAL-PDT|a 1-mm thick layer of MAL (16% Metvix® cream, PhotoCure ASA, Oslo, Norway) was applied to the lesion and to 5 mm of surrounding healthy tissue. The area was covered with an occlusive dressing (Tegaderm, 3M, Saint Paul, MN, US) for 3 hours, after which the remaining cream was removed with saline gauze, and the red fluorescence of porphyrins was visualized with Wood's light. Each treatment area was then separately illuminated with red light-emitting diode (LED) lamps (Aktilite CL128; Galderma, Bruchsal, Germany) with peak emission at 632 nm and total light dose of 37 J cm-2. Areas scheduled to receive MAL-PDT received the second treatment 7 days later.
223867245|NCT00683696|DEVICE|Implantable Cardioverter Defibrillator with Cardiac Resynchronization Therapy (BIOTRONIK Lumax HF-T CRT-D)|All patients will receive a commercially available BIOTRONIK Lumax HF-T CRT-D system with ICD back-up enabled. Patients will be randomized to CRT=ON or CRT=OFF.
223867246|NCT02396316|DRUG|Aflibercept (Eylea, BAY 86-5321)|After the first aflibercept IVT injection on Day 1, subjects may receive sham injection at Week 1, and aflibercept injection at Week 5 and/or Week 9 if the re-treatment criteria are met.
223867247|NCT02396316|DRUG|Sham Injection|After the first sham injection on Day 1, subjects may receive aflibercept IVT injection at Week 1, Week 5 and/or Week 9 if re-treatment criteria are met.
223867248|NCT00412308|PROCEDURE|Tidal volume used in mechanical ventilation|
223867249|NCT01823536|BIOLOGICAL|Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine|Subjects received at day 1 a single dose of Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine.
223867250|NCT05636332|DIAGNOSTIC_TEST|12 lead Electrocardiogram|12 lead Electrocardiogram
223867251|NCT03648762|BEHAVIORAL|Aerobic Exercise Intervention|Aerobic Exercise Intervention - 12 weeks of a minimum of 3 days a week for 60 minutes of aerobic exercise
223867252|NCT03648762|BEHAVIORAL|Combined Aerobic and Strength Exercise Intervention|Combined Aerobic and Strength Exercise Intervention- 12 weeks of a minimum of 3 days a week for 60 minutes of Combined Aerobic and Strength Exercise
223867253|NCT03648762|BEHAVIORAL|Inspiratory Muscle Training Exercise Intervention|Inspiratory Muscle Training Exercise Intervention- 12 weeks of a minimum of 3 days a week for 60 minutes of Inspiratory Muscle Training Exercise
223867254|NCT03791892|OTHER|Shoulder mobilization Group|Suprascapular nerve block administered every week to both groups. Joint mobilization (3 sets / 40 seconds hold / 30 seconds interval) Stretching exercises (3 sets / 30 seconds hold / 10 seconds interval) Strengthening exercises ( 3 sets / 15 reps)
223867255|NCT03791892|OTHER|Conventional Treatment Group|Suprascapular nerve block administered every week to both groups. Daily Stretching exercises (3 sets / 30 seconds hold / 10 seconds interval) Daily Strengthening exercises ( 3 sets / 15 reps)
223867256|NCT05886218|DEVICE|Quantitative Neuromuscular Function Monitoring|Quantitative electromyographic (EMG) monitoring
223867257|NCT02135679|RADIATION|Radiotherapy|
223867258|NCT00835952|DRUG|ATX-101|ATX-101 single doses
223867259|NCT01186159|DRUG|Parecoxib Sodium|40 mg Parecoxib Sodium is give to the patients intravenously (diluted with 5 ml normal saline) at 30 minutes before surgery, 20 mg Parecoxib Sodium (diluted with 5 ml normal saline) at 8 hours,20 hours,32 hours,44 hours,56 hours after surgery respectively.
223867260|NCT01782170|DRUG|Iocide Oral Rinse|
223867261|NCT01782170|DRUG|Placebo|
223867262|NCT05607186|RADIATION|neoadjuvant long course chemoradiotherapy|neoadjuvant long course chemoradiotherapy consist of radiosensitizing 5FU or capecitabine and 50.4 Gy in 28 fractions over 5 weeks
223867263|NCT05551065|DEVICE|Point-of-care ultrasound (POCUS)|Point-of-care ultrasound (POCUS) using a hand-held ultrasound (Vscan, GE Healthcare)
223867264|NCT03265886|DRUG|Warm bupivacaine at (37°c)|Bupivacaine 0.5%, 30 mL, warmed to 37◦C for 20 minutes. The empty syringes and needles, in their packaging, will be held at the same temperature before initiating the block.
223867265|NCT03265886|DRUG|Bupivacaine at operating room temperature (23°c)|Bupivacaine 0.5%, 30 ml held in crash shelf of the operating room temperature at 23◦C. The empty syringes and needles will be held in the same temperature before use.
223867266|NCT04934904|DRUG|Ropivacaine injection|On the first day of inclusion, performed T8 bilateral ultrasound-guided erector spinae plane block and indwelling tube will be left + 0.375% ropivacaine 20ml to both sides. Patients will be given injections every 12 h for 7 days.
223867267|NCT01731041|DRUG|Ticagrelor 180mg|Patients will receive 180 mg of ticagrelor
223867268|NCT01731041|DRUG|Ticagrelor 90mg|Patients will receive 90 mg of ticagrelor
223867269|NCT03555214|OTHER|Manual Therapy based on soft tissues|"Manual Therapy:~1. Technique of suboccipital inhibition.~2. Cranial frontal technique.~3. Cranial sphenoid technique.~4. Cranial fourth ventricle technique.~5. Antero-posterior abdominal-sacral technique."
223867270|NCT03555214|OTHER|Control group|"Placebo treatment:~The patient remains supine and the therapist sits on a stool at the bedside with the forearms resting on the couch. Both hands are placed on the posterolateral part of the patient's head and the position is maintained for 10 minutes without exerting any force or movement."
223867271|NCT03555214|OTHER|Manual Therapy based on structural techniques|"Manual Therapy:~1. Technique of manipulation of the occipito-atlanto-axoidea joint (OAA).~2. Articulation technique of the high cervical spine (C0-C1).~3. Postero-anterior articular technique of C2-C7 in supine position.~4. Postero-anterior articular technique of C2-C7 in prone position.~5. Manipulative technique of the flapper C7-T1.~6. Dorsal spinal manipulative technique (T1-T8).~7. Lumbosacral global manipulative technique."
223867272|NCT03555214|OTHER|Manual Therapy based on soft tissues and structural techniques|"Manual Therapy:~1. Technique of suboccipital inhibition.~2. Cranial frontal technique.~3. Cranial sphenoid technique.~4. Cranial fourth ventricle technique.~5. Antero-posterior abdominal-sacral technique.~6. Technique of manipulation of the occipito-atlanto-axoidea joint (OAA).~7. Articulation technique of the high cervical spine (C0-C1).~8. Postero-anterior articular technique of C2-C7 in supine position.~9. Postero-anterior articular technique of C2-C7 in prone position.~10. Manipulative technique of the flapper C7-T1.~11. Dorsal spinal manipulative technique (T1-T8).~12. Lumbosacral global manipulative technique."
223867273|NCT02731755|OTHER|Oat|The study oat intervention products will consist of 67.7g oatflake and 22.5g oatbran concentrate.
223867274|NCT02731755|OTHER|Control|60g cream of rice
223867275|NCT01951508|DRUG|Methylphenidate|60mg per os, single dose
223867276|NCT01951508|DRUG|Modafinil|600mg per os, single dose
223867277|NCT01951508|DRUG|MDMA|125mg per os, single dose
224268399|NCT04155450|OTHER|McKenzie Extension Exercise Protocol|"Static:~1. Lying Prone~2. Lying prone in extension~3. Sustained extension~4. Posture correction~   Dynamic:~5. Extension in lying~6. Extension in lying with clinician overpressure~7. Extension mobilization~8. Extension in standing"
223867278|NCT01951508|DRUG|Placebo|per os
223867279|NCT00166283|BEHAVIORAL|memory retraining exercises|Memory retraining exercises will be administered on a laptop computer twice a week for five weeks (10 training sessions).
223867280|NCT00166283|BEHAVIORAL|placebo control memory exercises|Placebo control memory exercises will be administered on a laptop computer twice a week for five weeks (10 training sessions).
223867281|NCT05103423|DRUG|BDB-001 Injection|Multiple IV infusions of BDB-001 Injection diluted in sodium chloride
223867282|NCT05103423|DRUG|Placebo|Multiple IV infusions of Placebo Injection diluted in sodium chloride
223867283|NCT05103423|DRUG|Placebo|Multiple IV infusions of Placebo Injection diluted in sodium chloride
223867284|NCT02819414|DRUG|Paracetamol drops|15 mg/kg/dose x 4/day diluted 1:15 yielding dose of 2.25 ml/kg/dose to be given for three days
223867285|NCT02819414|OTHER|Placebo|2.25 ml/kg/dose x 4/day of sterile water to be given for three days
223867286|NCT05573334|DEVICE|BioNourish|"BioNourish is a 510k-cleared class II medical device that has been on the market for over two years. It is a vaginal moisturizing gel that is designed with pH, osmolality, and lactic acid levels that match those observed in healthy vaginas. It does not have an active ingredient, but only provides moisture in a formula that is matched for physicochemical characteristics to healthy vaginal fluid."
223867287|NCT04730362|DEVICE|guedel airway|"Anesthesia will be conducted by induction with 1-2~• Mg/kg of an IV propofol bolus and then anesthesia is maintained with an inhalational anesthesia with sevoflurane 2%-4%. The goal is to maintain the patient spontaneous ventilation throughout the procedure. Monitoring of the patients is done by MRI compatible pulse oximetry for heart rate and oxygen saturation which is connected to MRI control room."
223867288|NCT04730362|DEVICE|supraglottic airway|supraglottic airway
223867289|NCT04730362|DRUG|propofol bolus and then anesthesia sevoflurane|Mg/kg of an IV propofol bolus and then anesthesia is maintained with an inhalational anesthesia with sevoflurane 2%-4%
223867290|NCT00002842|DRUG|floxuridine|Starting dose of 0.2 mg/kg/day for 14 consecutive days.
223867291|NCT00002842|DRUG|fluorouracil|300 mg/m2/day by intravenous bolus 24 hours apart for 5 consecutive days.
223867292|NCT00002842|DRUG|leucovorin calcium|500 mg/m2/day by continuous intravenous infusion beginning 24 hours prior to the first dose of 5-FU and continuing until 12 hours following the last dose of 5-FU.
223867293|NCT00002842|PROCEDURE|adjuvant therapy|Chemotherapy given after hepatic resection
223867294|NCT00002842|PROCEDURE|conventional surgery|Hepatic resection
223867295|NCT01599104|DRUG|LCZ696|200 mg (one tablet) or 400 mg (2 tablets of 200mg) once daily
223867296|NCT01599104|DRUG|Olmesartan|Olmesartan 20 mg capsule one daily
223867297|NCT01599104|DRUG|Placebo|Placebo to LCZ696 or Olmesartan
223867298|NCT04479865|DRUG|Aricept 5mg Tablet|1 tablet once daily
223867299|NCT04479865|DRUG|Aricept 10mg Tablet|1 tablet once daily
223867300|NCT04479865|DRUG|DA-5207 150mg|1 patch once weekly
223867301|NCT04479865|DRUG|DA-5207 170mg|1 patch once weekly
223867302|NCT00073684|BEHAVIORAL|Trauma focused cognitive behavioral therapy (TF-CBT)|This study aims to: (1) examine the differential effects of CBT with and without trauma narrative interventions; (2) examine the comparative efficacy of brief and extended (8 vs. 16 sessions) individual CBT; (3) make developmental comparisons between 4-7 year olds and 8-11 year olds as to the appropriateness and therapeutic necessity of exposure interventions and longer treatment; and (4) identify child and parent factors that may significantly mediate the relationships between treatment conditions and outcomes. The findings of this study will help establish clinical as well as developmental markers for the early identification of sexually abused children who may require more focused (i.e., including trauma narrative) and/or longer treatment to achieve optimal outcomes.
223867303|NCT00073684|BEHAVIORAL|Brief abuse-focused treatment|Participants will receive 8 sessions of TF-CBT with abuse-focused treatment.
223867304|NCT00073684|BEHAVIORAL|Brief coping skills treatment|Participants will receive 8 sessions of TF-CBT with brief coping skills treatment.
223867305|NCT00073684|BEHAVIORAL|Extended abuse-focused treatment|Participants will receive 16 sessions of TF-CBT with extended abuse-focused treatment.
223867306|NCT00073684|BEHAVIORAL|Extended coping skills treatment|Participants will receive 16 sessions of TF-CBT with extended coping skills treatment.
223867307|NCT02461264|DRUG|Single red blood packed cells Transfusion|
223867308|NCT02461264|DRUG|Two packed red blood cells Transfusion|
223867309|NCT00091650|DRUG|Olanzapine|
223867310|NCT00091650|DRUG|placebo|
223867311|NCT00269789|DRUG|Ritalin|
223867312|NCT00269789|DRUG|OROS Methylphenidate HCl|
223867313|NCT00269789|DRUG|Placebo|
223867314|NCT02780440|BEHAVIORAL|Traditional Home Based Exercise Program|Subjects in the control group will receive a traditional home Occupational Training exercise program as per conventional OT guidelines with the same home program duration.
223867315|NCT02780440|BEHAVIORAL|Unimanual Home Based Mirror Therapy Program|The affected hand will remain still in the mirror box, the unaffected hand will perform the exercises while the subject watches the mirror reflection.
223867316|NCT02780440|BEHAVIORAL|Bimanual Home Based Mirror Therapy Program|The affected hand in the mirror box will best mimic the unaffected hand, while also watching the mirror reflection.
223867317|NCT06435637|DIETARY_SUPPLEMENT|Collagen protein|Ingestion of 40, 20, 20 and 20 gram of collagen protein right after and every 2 hours after a bout of exercise
223867318|NCT06435637|BEHAVIORAL|Resistance exercise|A single resistance exercise session of the leg press and leg extension exercise
223867319|NCT02467946|DRUG|Adcetris-Levact|Association of Adcetris (1.2 mg/kg intravenously every 3 weeks) with Levact (90 mg/m2/day intravenously for 2 days every 3 weeks) during at least 6 cycles.
223867320|NCT01853410|DEVICE|gekoTM|
223867321|NCT05662449|DEVICE|Syndesmosis fixation using Activascrew|as described prior
223867322|NCT00773370|BEHAVIORAL|APA-Stroke|Exercise program design specifically for individuals with residual hemiparetic gait deficits due to stroke. Exercises are progressive, beginning with a 5 minute walk at the beginning and end of each class and gradually progressing to a 15 minute walk at the beginning and end of each class. Exercises focus on walking and are designed to improve walking ability and balance. Program includes a homework component.
223867323|NCT00773370|BEHAVIORAL|Sittercise|Not stroke specific. This less vigorous exercise program consists of seated exercise focusing on stretching to improve general range of movement and weight exercises to strengthen the trunk, arms, and legs. There is no assigned exercise homework.
223867324|NCT01801514|DEVICE|Computed Tomography scan|Routine Computed Tomography scan
223867325|NCT04996680|DEVICE|Blood Flow Restriction (by using smart-cuff pro devices, acting as pressurized tourniquet) combined low load strengh training|This group will undergo standard, traditional low load strength training consisting of calf, thigh, glute and core exercises, combined with optimal pressurized blood flow restriction
223867326|NCT04996680|OTHER|Standardised low load strength training|This group will undergo standard, traditional low load strength training consisting of calf, thigh, glute and core exercises
223867327|NCT04996680|DEVICE|Sham-BFR (by using smart-cuff pro devices, acting as pressurized tourniquet) combined with low load strength training|This group will undergo standard, traditional low load strength training consisting of calf, thigh, glute and core exercises, combined with blood flow restriction, but pressurized so the occlusion cuff has no significant effect on the lower limb blood flow.
223867328|NCT06155877|BEHAVIORAL|Activité Vaccins et Vaccination - LAMAP|Two activities created by the La Main a la Pate foundation
223867329|NCT06155877|BEHAVIORAL|Kidivax Chatbot|A chatbot created by our team to answer the most common questions about vaccination, based on a literature review and on focus groups.
223867330|NCT00693121|DRUG|Amantadine hydrochloride|100mg administered orally twice daily x 14 days
223867331|NCT00693121|DRUG|Placebo capsule|capsule, identical to amantadine hydrochloride capsule, administered twice daily x 14 days
223867332|NCT05284565|DEVICE|Reading of the skin prick allergy test|"A double reading of the forearm will be performed with the Nexkin DSPT device. Also, two healthcare professionals will perform, consecutively, the manual reading according to their usual practice. Nexkin DSPT device provides a semi-automatic wheal detection, presenting the user an initial set of potential wheals and information about them (as their measure).~Healthcare professional can then discard, add and/or confirm wheals by visual validation, and add/edit wheal information. The device automates the test reading process, digitises the results, and quantifies."
223867333|NCT01914913|BIOLOGICAL|BMMNCs|Intervention therapy , Total 3 doses ,in 30 days ,in 7days interval ,transfer of Autologous Bone Marrow derived Mono Nuclear Stem Cell (BMMNCs)
223867334|NCT02271854|DRUG|Diclofenac sodium gel 1%|Diclofenac sodium gel 1% four times daily (This study is a within-subject design i.e. active drug applied to one leg and placebo to the other leg at the same time. Therefore the study design is not a cross-over).
223867335|NCT02271854|DRUG|Placebo|Placebo gel four times daily (This study is a within-subject design i.e. active drug applied to one leg and placebo to the other leg at the same time. Therefore the study design is not a cross-over).
223867336|NCT06100458|OTHER|Skin and leakage protocol|The skin and leakage protocol have been developed by the sponsor with the aim to offer a tool that can aid care providers in identifying problems in continence care and follow up the effect of any care interventions to remedy these problems. The protocol is a digital diary tool that tracks both the instances of urine leaking out of an absorbing incontinence product onto clothes and bedsheets, and any apparent skin changes in the area covered by the product. The protocol is in clinical use at the care homes were the subjects are residing.
223867337|NCT01549756|BEHAVIORAL|bulletin board and teleophone depth interview|qualitative based research
223867338|NCT03677349|PROCEDURE|neurorrhaphy|"During the surgery, the flap is removed from its donor site, placed on the recipient site (instead of carcinological excision) and its survival is ensured by arterial and venous anastomosis (to the artery and facial vein or to the external carotid artery and thyro-linguofacial veinous trunk).~We then propose a reconstruction complement: nerve anastomosis (neurorrhaphy) to the lingual nerve for the antebrachioradial and anterolateral thigh flaps, and to the lower alveolar nerve for the fibular bone flaps. This supplement is performed during microsurgical time by a suture for the patient in group 1."
223867339|NCT04544904|DEVICE|PAARx|Prescription Physical Activity Programming Application
223867340|NCT04544904|DEVICE|JM|Joint Management (JM) web-based joint management resource.
223867341|NCT04760938|BEHAVIORAL|Outdoor Behavioral Healthcare (OBH)|Participants in this intervention will participate in one of 7 programs that have been accredited by the Outdoor Behavioral Healthcare Council that specializes in 13-17 year old adolescents experiencing behavioral healthcare issues. Each program works in a unique wilderness setting in various United States National Forests and Parks (e.g., Washington, Oregon, New Mexico, Wisconsin, Utah). The average length of stay in an OBH wilderness program is 90 days, which is a total standard care time of 1,056 hours. All of the OBH programs have been accredited by the Association for Experiential Education Accreditation for Outdoor Behavioral Healthcare programs.
223867342|NCT04760938|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|The 12-week treatment period will consist of 15 90-minute sessions that will be administered individually. Homework (including reading assignments) are given to encourage your child to practice the techniques learned during the weekly sessions. The total standard of care time for CBT is 22.5 hours of direct treatment hours not including time spent on homework over these twelve weeks. Those therapists that are selected to deliver treatment for the CBT group will be certified by a nationally recognized CBT organization and licensed to work as a therapist in the state where they are providing treatment. Therapy will be delivered in an outpatient setting or through Telehealth.
223867343|NCT06361953|DEVICE|EEG Neurofeedback|neurofeedback training over five weeks, comprising 15 sessions. Each neurofeedback training session lasted 30 minutes.
223867344|NCT03200626|PROCEDURE|Autologous hematopoietic cell transplant|Autologous hematopoietic cell transplant
223867345|NCT02823938|OTHER|existing database on data collection.|This is an observational study on an existing database.
223867346|NCT00493350|PROCEDURE|Blood Sample|1x4 ml (Serum Tube); 2x10 ml (CellSave Tube); 1x10 ml EDTA (Selected Centers)
223867347|NCT00929760|BEHAVIORAL|specialised renal care|"* Combined management PCP - nephrologists (at least 4 nephrology visits/year). Agreement of the PCP is required for this combined management.~* Management by PCPs only, with the help of written instructions from our nephrology unit based on EBPG. Requested Email or over the phone advices to PCPs will be provided by the nephrology division of HUG."
223867348|NCT03595852|DRUG|Cefazolin|Cefazolin will be given to patients in the experimental arm prophylactically prior to surgery
223867349|NCT03595852|DRUG|Placebos|IV normal saline will be given to patients 30-60 minutes prior to incision
223867350|NCT06349655|DRUG|Azvudine|Antiviral drug
223867351|NCT06349655|DRUG|Paxlovid|Antiviral drug
223867352|NCT01263613|PROCEDURE|tumor biopsy and blood draw|tumor biopsy and blood draw during and after chemotherapy
223867353|NCT01153880|DRUG|Retapamulin|Prescription sales claim of retapamulin
223867354|NCT01153880|DRUG|Co-prescription of retapamulin and topical mupirocin|Same day prescription sales claims for retapamulin and topical mupirocin
223867355|NCT04108923|DEVICE|Ligasure|the vessel sealing device ( ligasure covidien ) which seals vessels by fusing the inner layers of the vessel wall
223867356|NCT04108923|PROCEDURE|Conventional vessel ligation|Conventional vessel ligation either tying and /or clipping of blood vessels
223867357|NCT05481242|OTHER|retrospective observational study|retrospective observational study
223867358|NCT05863481|PROCEDURE|Laparoscopic cerclage placement|The surgical method of the laparoscopic cerclage procedure at Aarhus University Hospital previous described in a paper by Riiskjaer et al (DOI: 10.1111/aogs.12001)
223867359|NCT01437605|DRUG|MAGE-A3 ASCI injections without Poly IC:LC|MAGE-A3 ASCI injections without Poly IC:LC as outlined in Detailed Description
223867360|NCT01437605|DRUG|MAGE-A3 ASCI injections with Poly IC:LC|MAGE-A3 ASCI injections with Poly IC:LC as outlined in Detailed Description
223867361|NCT06518876|BIOLOGICAL|KQ-2003 CAR T-cells|KQ-2003 CAR T-cell therapy involves autologous chimeric antigen receptor T-cells, capable of targeting both human B cell maturation antigen (anti-BCMA CAR) and CD19 antigen molecules (anti-CD19 CAR) simultaneously as a cellular therapy.
223867362|NCT01112670|DRUG|Sitagliptin|sitagliptin 100 mg x 1 dose
223867363|NCT01112670|DRUG|atorvastatin|atorvastatin 40 mg x 5 doses
223867364|NCT02213744|DRUG|MM-302|
223867365|NCT02213744|DRUG|Gemcitabine|
223867366|NCT02213744|DRUG|Capecitabine|
223867367|NCT02213744|DRUG|Vinorelbine|
223867368|NCT02213744|DRUG|Trastuzumab|
223867369|NCT03973892|DIAGNOSTIC_TEST|Cere|Magnetic Rseonance imaging for brain tumour follow-up
223867370|NCT03895346|BEHAVIORAL|Mindfulness|Mindfulness meditation is a technique of sustained attention and focus, involving preventing the mind from wandering from the meditative object (i.e. breath or body sensations)
223867371|NCT03895346|BEHAVIORAL|Brain Games and Puzzles|Intervention will include the instruction and practice of puzzles such as word searches, crossword puzzles, Sudoku, and KenKen.
223867372|NCT02120430|OTHER|Video|"The video was developed by a multidisciplinary team (psychologists, paediatricians, filmmaker). It was conceived as an aid to parenting in the first year of life, providing opportunities for parents to look at their own experiences. The video lasts 24 minutes and describes the birth of a new relationship between primary caregivers and their babies, in chronological order, starting from late pregnancy to the end of the first year. Caregiver-child interactions are shown from early contact after delivery to common care practices, with an emphasis on four specific activities, which are believed to improve child development and caregiver-child interaction: reading aloud to the baby, exposure to songs, rhymes and music, promotion of early socialization for parents and for children."
223867373|NCT02825368|BIOLOGICAL|MMR|0.5 mL, subcutaneous
223867374|NCT02825368|BIOLOGICAL|Tdap|0.5 mL, intramuscular
223867375|NCT02825368|OTHER|Diphtherinum®|
223867376|NCT02825368|OTHER|Pertussinum®|
223867377|NCT02825368|OTHER|Tetanotxicum®|
223867378|NCT02825368|OTHER|Morbilinum®|
223867379|NCT02825368|OTHER|Ourlianum®|
223867380|NCT02825368|OTHER|Sterile saline|0.5 mL, intramuscular
223867381|NCT02825368|OTHER|Sugar pellets|
223867382|NCT06414850|BEHAVIORAL|Animal Assisted Therapy (AAT)|A structured AAT program and pharmacological treatment in Experimental group. The same structured program without therapy dog and pharmacological treatment in Control group.
223867383|NCT00557024|PROCEDURE|RFA|radiofrequency ablation
223867384|NCT00557024|PROCEDURE|radiotherapy after RFA|radiotherapy after RFA
223867385|NCT03454529|OTHER|Laboratory Biomarker Analysis|Correlative studies
223867386|NCT03454529|DRUG|Simvastatin|Given PO
223867387|NCT02909413|DRUG|Desﬂurane|Anesthesia maintenance: After endotracheal intubation, half of the patients will be randomized into Desﬂurane Group. The gas flow rate of Desflurane group is 2 L/min, include 50％ O2 and 4～5％ Desflurane.
223867388|NCT02909413|DRUG|sevoﬂurane|Anesthesia maintenance: After endotracheal intubation, half of the patients will be randomized into Sevoﬂurane Group. The gas flow rate of Desflurane group is 2 L/min, 50％O2 and 1.7-2.0% Sevoflurane.
223867389|NCT03828240|OTHER|HIP fracture REhabilitation Programme for the elderly with hip fractures|Eight-week activity-based intervention for elderly with hip fractures; one intervention during the hospital stay, four interventions at the elderly's municipality.
223867390|NCT02282267|DRUG|Gefitinib|Iressa 250mg oral daily
223867391|NCT05016830|DEVICE|Bilateral transcranial direct current stimulation|A direct current is applied with two electrodes (cathode and anode) in specific parts of the skull. In this case the anode was over the occipital area to target the amblyopic cortex, while the cathode was over the contralateral side, targeting the fellow cortex.
223867392|NCT03606915|BEHAVIORAL|pain evaluation|collect CSF during spinal anesthesia
223867393|NCT01820780|OTHER|Natriuretic peptides levels to J7 and J14|
223867394|NCT01820780|OTHER|Consultations specialized to J7 and J14|Optimization of treatments Education on the signs of alert of the disease and on the medicines Reduction of the rate of BNP or NTproBNP = 30 % between the exit of the hospitalization and the second consultation Planning of an adapted coverage
223867395|NCT01820780|OTHER|Phone calls in 6 months and 12 months|
223867396|NCT01820780|OTHER|Natriuretic peptides levels at 6 months|
223867397|NCT01820780|OTHER|Consultation with the general doctor or the cardiologist to J30 with blood results|
223867398|NCT02931214|DRUG|GMI-1359|
223867399|NCT02931214|DRUG|Placebo|
223867400|NCT05677061|DEVICE|Dynamic Hip Screw with HA-coating (Hiploc)|During surgery for pertrochanteric hip fracture a lag screw with hydroxyapatite coating on the screw thread was used to fix the fracture
223867401|NCT05677061|DEVICE|Dynamic Hip Screw without coating (Hiploc)|During surgery for pertrochanteric hip fracture a lag screw with no coating on the screw thread was used to fix the fracture
223867402|NCT04134611|DEVICE|Hyaluronic acid injection|Injection of Hyaluronic acid in knees of those who has degenerative changes after arthroscopic treatment of lateral patellar compression syndrome
223867403|NCT04134611|DEVICE|No injection of Hyaluronic acid|No injection of Hyaluronic acid was done
223867404|NCT04734132|DIETARY_SUPPLEMENT|Moringa|Leaves of Moringa oleifera from an organic Iberian peninsula cultivar. A single lot was prepared from the same crop. Leaves were dried and ground and encapsulated as a organic dietary supplement. No other changes in diet or physical activity were included although a general healthy lifestyle pattern was recommended.
224268400|NCT04155450|OTHER|Moist Heat|Moist Heating for 10 minutes at lumbar spine in prone position using moist heat packs, heated via hydro-collator.
223867405|NCT04734132|DIETARY_SUPPLEMENT|Placebo|Placebo capsules were indistinguishable from the experimental capsules in material and color (opaque white). Same number of capsules were consumed as in the experimental arm and no other changes in diet or physical activity were included although a general healthy lifestyle pattern was recommended.
223867406|NCT03813433|OTHER|Revascularization|a procedure used to regenerate pulp dentin complex that restores the functional properties of this immature anterior teeth, prevent and resolves apical periodontitis
223867407|NCT01593319|DRUG|Ropivacaine|Local injection (fascia iliaca block) using 150 mg ropivacaine
223867408|NCT01593319|DRUG|Natrium chloride|Placebo injection of Natrium chloride solution
223867409|NCT00320762|DEVICE|OculusGen Biodegradable Collagen Matrix Implant|
223867410|NCT02768545|DRUG|Ezetimibe|Ezetimibe 10 mg per day before and after transplant
223867411|NCT05119764|PROCEDURE|Manual Lymphatic Drainage|"Manual Lymphatic Drainage is a form of physical therapy with the primary goal of accelerating lymphatic drainage.~In this study, the manual lymphatic drainage is applied by experienced physical therapists 5 days in a row for 30 minutes each; after and/or before the surgery."
223867412|NCT04033107|DRUG|Vitamin C|Participants will receive intravenous Vitamin C injection (dose: 1.5g/kg, D1-3, every 2 weeks), treatment termination when the disease progress is confirmed.
223867413|NCT04033107|DRUG|Metformin|Participants will orally take metformin 4g daily.
223867414|NCT06419569|OTHER|high power laser|Sessions will performed with scanning in longitudinal and perpendicular direction on the medial and lateral sides of the knee with Laser scanner machine. handpiece was positioned in contact and perpendicularly while the patient in a supine lying position with the knee flexed at 30° to open the joint surfaces to the laser beam (optical windows). The scanning was performed transversely and longitudinally in the anterior, medial, and lateral aspects of the knee joint with emphasis on the application on the joint line between the tibial and femoral epicondyles. The total energy delivered to the patient during one session was 1,250 J through three phases of treatment. The initial phase is performed with fast manual scanning with a total of 500 J. In the initial phase, the laser fluency is set to two successive subphases of 710 and 810 mJ/cm2 for a total of 500 J.
223867415|NCT06419569|OTHER|low level laser|patients will receive laser with 0.5 W to gain energy density of 6 J/cm2, and total energy of 240 J during one session. LASER apparatus that will be used is Chattanoga Intelect Laser with 850nm wavelength and 200mW power Lasers. Same three phases like HPL with different energy dose. First phase: Fast manual scan 100 J. Second 10 point joint line phase with evey point 14 seconds and 4J to deliver a total of 40 J in this phase. Third phase: Slow manual scan 100 J.
223867416|NCT06419569|OTHER|conventional physical therapy|the patients will receive conventiobal physical therapy in the form of Exercise therapy program (1) Warm-up exercises: Walking at the usual speed on a flat surface for 10 min with hamstring and calf gentle stretches.(2) Major exercises for knee OA: Straight leg raise, quadriceps setting, heel raise, one leg balance, step ups, and quadriceps strengthening exercises. The US protocol consists of continuous ultrasonic waves of 1 MHz frequency and 1 W/cm2 intensity applied with a 5-cm diameter applicator. The patients will be placed in a supine position, and the US applied to the medial and lateral parts (5 min on each side) of the knee in circular movements with the probe at right angles to ensure maximum absorption of the energy.
223867417|NCT01405807|DRUG|Alemtuzumab|Alemtuzumab will be administered on Day 1 and Day 2 at 0 and 6 months
223867418|NCT04290572|DRUG|Isotretinoin capsules|Jelly capsules of isotretinoin
223867419|NCT03465527|DRUG|PrednisoLONE 50 MG|Prednisolone 50mg bid po or iv (equivalent dose of other steroid) for 5 days ± 2 days
223867420|NCT03259516|DRUG|Nivolumab|1 mg/kg by vein on Days 1 and 15 of a 28 day cycle
223867421|NCT03259516|DRUG|Azacitidine|75 mg/m2 subcutaneously on Days 1-7 of a 28 day cycle
223867422|NCT03259516|DRUG|Fludarabine|25 mg/m2 by vein on Days 1, 2 and 3 of a 28 day cycle. Dose reduction to 15 mg/m2 is permitted in cases of grade 4 hematological toxicity after first cycle.
223867423|NCT03259516|DRUG|Cyclophosphamide|300 mg/m2 by vein on Days 1, 2 and 3 of a 28 day cycle.
223867424|NCT03259516|DRUG|Cytarabine|10 mg/m2 subcutaneously two times a day on Days 1-10 of a 28 day cycle
223867425|NCT03259516|DRUG|all trans retinoic acid|45 mg/m2 per os daily during the whole course of treatment
223867426|NCT03259516|DRUG|Sildenafil|20 mg per os three times a day during the whole course of treatment
223867427|NCT03259516|DRUG|Melphalan|2 mg per os daily during the whole course of treatment
223867428|NCT04504786|OTHER|Vitality acupunch (VA) exercise program|The VA had three phases and took 40 minutes to complete.
223867429|NCT04504786|OTHER|Control|Participants maintained their daily activities.
223867430|NCT00779870|OTHER|bronchoscopy|bronchoscopy under local anaesthetic and sedation to obtain endobronchial biopsies
223867431|NCT02206750|OTHER|Clean Air|Each subject will be exposed to clean air for 2 hours. Subjects will exercise on a bike or treadmill. Each exercise session will consist of a 15 minute exercise interval at a level of up to 25 L/min/m2BSA followed by a 15 minute rest period.
223867432|NCT02206750|OTHER|Ozone|Each subject will be exposed up to 0.3ppm ozone for 2 hours. Subjects will exercise on a bike or treadmill. Each exercise session will consist of a 15 minute exercise interval at a level of up to 25 L/min/m2BSA followed by a 15 minute rest period.
223867433|NCT03976570|BEHAVIORAL|Occupational Therapy|Occupational therapy to children with subthreshold attention deficit hyperactivity disorder
223867434|NCT02285413|BIOLOGICAL|DC vaccination|DC vaccination without cisplatinum
223867435|NCT02285413|BIOLOGICAL|DC vaccination with cisplatinum|DC vaccination with cisplatinum
223867436|NCT00240149|DRUG|Regular Insulin via Insulin-Glucose Algorithm|
223867437|NCT00421070|PROCEDURE|Massage therapy|A qualified massage therapist will administer a 20-minute standard massage procedure with the client sitting fully clothed in a special massage chair. The massage therapy session will consist of ; 1) long, broad stroking with light-moderate pressure to the back, compression to the back (parallel to spine) from the shoulders to base of spine, trapezius squeeze, finger pressure on the shoulder; 2) arms dropped to the side with arms kneaded from shoulder to lower arm and pressing down on upper and lower arms; 3) entire hands massaged and pulling of fingers, light kneading to area of cervical vertebrae, pressing down on trapezius with finger pressure and squeezing continuing down the arms.
223867438|NCT01582100|DEVICE|Reletex|Neuromodulation device worn on the wrist
224268401|NCT00174421|DRUG|Treatment with Genotropin in different dosages|
223867439|NCT00130156|DRUG|Bunazosin|Patients will be randomized to the add-on treatment with Bunazosin (Detantol-R) 3 mg once-daily after breakfast for a total of eight weeks.
223867440|NCT00130156|DRUG|Doxazosin|Patients will be randomized to the add-on treatment with Doxazosin (Doxaben XL) 4 mg once-daily after breakfast for a total of eight weeks.
223867441|NCT00130156|DRUG|Valsartin|After wash-out period, the eligible subjects will be treated with Valsartin (Diovan) 80 mg as the mono therapy for 5 weeks. If the blood pressures are inadequately responded, then the patients will be randomized to either Bunazosin (Detantol-R) or Doxazosin (Doxaben XL) along with Valsartin as the add-on treatment for 8 weeks.
223867442|NCT03415360|PROCEDURE|cryoablation|cryoablation of nerve responsible for phantom limb pain
223867443|NCT04592575|OTHER|Vestibular Evaluation|Each patient will have a full vestibular evaluation by a physical therapist
223867444|NCT00654316|BIOLOGICAL|BCG|intradermal injection of 0.1ml BCG over the deltoid muscle
223867445|NCT02652091|DRUG|Interferon beta-1b (Betaseron, BAY86-5046)|Applied via the BETACONNECT device. Dose as prescribed by physician.
223867446|NCT02652091|DEVICE|BETACONNECT device|Used to apply Betaseron.
223867447|NCT02564744|DRUG|Debio 1562|Administered as IV Infusion.
223867448|NCT02564744|DRUG|Rituximab|Administered as IV Infusion.
223867449|NCT03572257|DRUG|Quetiapine|Patients randomized to the study treatment group will received quetiapine at 0.5 mg/kg, three times a day for 10 days. Doses can be increased up to a maximum of 6 mg/kg/day, in increments of 0.5 mg/kg, based on the subject's clinical delirium symptoms. PRN doses of 0.5 mg/kg can be given up to three times a day based on the clinical judgement of the subject's ICU care team.
223867450|NCT03572257|OTHER|Placebo|Patients randomized to the placebo group will be given an equivalent volume of sterile liquid or sugar pill, based on the individual subjects dosing preference or ability. Dosing will be done on the same schedule as the quetiapine group
223867451|NCT00002900|PROCEDURE|management of therapy complications|
223867452|NCT04781790|OTHER|Bone Marrow Failure|without interventional intervention . biological collection in the routine care Standard of care of patients with bone marrow failure.
223867453|NCT00491959|PROCEDURE|Cultured oral mucosa cell sheet transplantation|Cultivated oral mucosal cell sheets will be transplanted on the denuded corneal surface or the scleral surface of the symblepharon area. Therapeutic contact lenses will be applied after surgery.
223867454|NCT00508924|DRUG|Argatroban|
223867455|NCT00508924|DRUG|Argatroban|
223867456|NCT00508924|DRUG|Argatroban|
223867457|NCT00508924|DRUG|Heparin|
223867458|NCT04695483|DRUG|Corifollitropin alfa|Controlled ovarian stimulation long-acting protocol
223867459|NCT04695483|DRUG|Follitropin Beta|Daily controlled ovarian stimulation protocol
223867460|NCT03466931|OTHER|Milk|Meals containing Milk and Milk
223867461|NCT02178241|DRUG|Eribulin Mesylate|Given IV
223867462|NCT02178241|DRUG|Gemcitabine Hydrochloride|Given IV
223867463|NCT00329264|DRUG|Quetiapine fumarate|
223867464|NCT00706875|BEHAVIORAL|questionnaire|"A patient questionnaire, which includes validated instruments. Data collection methods are as follows:~* In person at the medical appointment~* Over the telephone~* Mailed with self-addressed return envelope and prepaid postage~* E-mailed and returned by e-mail, fax or self-addressed envelope and pre-paid postage"
223867465|NCT00706875|BEHAVIORAL|questionnaire|"A patient questionnaire, which includes validated instruments. Data collection methods are as follows:~* In person at the medical appointment~* Over the telephone~* Mailed with self-addressed return envelope and prepaid postage~* E-mailed and returned by e-mail, fax or self-addressed envelope and pre-paid postage"
223867466|NCT04816175|BEHAVIORAL|Acquire Therapy|This intervention is an operant conditioning based neurorehabilitation protocol for the promotion of psychomotor function
223867467|NCT00769353|BEHAVIORAL|Primary and Secondary Coping Enhancement Training|A cognitive behavioral therapy designed to help individuals cope with physical illness.
223867468|NCT00769353|BEHAVIORAL|Supportive Non-directive Therapy|A non-structured therapy designed to provide a supportive atmosphere in which individuals may discuss concerns and process events in their lives
223867469|NCT03809936|DEVICE|real tDCS|Direct current was applied by a battery-driven constant current stimulator using saline-soaked surface sponge electrodes (7 3 5 cm) with the anode positioned over the left dorsolateral prefrontal cortex (F3 according to the 10-20 international system for EEG placement) and the cathode placed over the right supraorbital region. During real tDCS, the current was increased to 2 mA from the onset of stimulation and applied for 20 minutes.
223867470|NCT03809936|DEVICE|sham tDCS|For the sham condition(sham tDCS), the same electrode placement was used as in the stimulation condition, but the current was applied for only 5 seconds, and was then ramped down.
223867471|NCT00567333|OTHER|Chiropractic care|A combination of professional therapies with the scope of practice, including spinal manipulation therapy, spinal mobilization, stretching and strengthening exercises, and self-care education.
223867472|NCT00567333|OTHER|Multidisciplinary, integrative care|A combination of therapies which may include acupuncture/Oriental medicine, chiropractic, cognitive behavioral therapy, exercise therapy, medicine, self-care information, and massage therapy.
223867473|NCT03522454|DIETARY_SUPPLEMENT|Protein-rich oral nutritional supplement|Ready-to-drink beverage containing 20 g protein and 1.5 g hydroxymethylbutyrate (HMB) per serving, consumed twice daily.
223867474|NCT03522454|BEHAVIORAL|Home-based supervised exercise program|WEBB (Weight-bearing Exercise for Better Balance) program combining walking and weight-bearing exercises to build strength and balance, administered by a trained therapist at the participant's home.
223867475|NCT05089097|OTHER|evaluation of delirium with CAM-ICU Score|the CAM-ICU score is an evaluation tool to verify the presence or absence of delirium in a subject
223867476|NCT00681525|DRUG|ABT-335|One ABT-335 135 mg capsule QD for 10 days
223867477|NCT00681525|DRUG|Atorvastatin|One 80 mg tablet of atorvastatin QD for 10 days
223867478|NCT00681525|DRUG|Ezetimibe|One ezetimibe 10 mg tablet QD for 10 days
223867479|NCT04333589|DRUG|Favipiravir|On the 1st day, 1600mg each time, twice a day; from the 2nd to the 7th day, 600mg each time, twice a day. Oral administration, the maximum number of days taken is not more than 14 days.
223867480|NCT00470938|DEVICE|SpineForce Reactive Neuromuscular Trainer|
223867481|NCT03593213|DRUG|Cariprazine|Cariprazine capsules, oral administration, once daily.
223867482|NCT03593213|DRUG|Placebo|Matching placebo capsules, oral administration, once daily.
223867483|NCT03204396|DRUG|Dulaglutide|Application of Dulaglutide (Trulicity®) 1.5 mg s.c. once weekly for 12 weeks.
223867484|NCT03204396|DRUG|0.5 ml normal saline (0.9% sodium chloride [0.9% NaCl])|Application of 0.5 ml normal saline (0.9% sodium chloride \[0.9% NaCl\]) once weekly for 12 weeks
223867485|NCT04589689|BEHAVIORAL|Insul-In This Together|Session 1: Introduction to Parental Monitoring Session 2: Advanced Parental Monitoring Session 3: Introduction to Parental Involvement Session 4: Advanced Parental Involvement Session 5: Introduction to Parent-Teen Conflict Management Session 6: Advanced Parent-Teen Conflict Management
223867486|NCT03109795|DRUG|Clonidine Pill|sympathetic nerve activity blockade
223867487|NCT03109795|DRUG|Hydrochlorothiazide|Blood pressure-lowering control condition
223867488|NCT04277715|BEHAVIORAL|Parent training|Parents will learn evidence-based techniques for increasing support and decreasing accommodation of children's chronic symptoms.
223867489|NCT03753841|OTHER|Adjustment of oral diet|Adjustment of oral diet based on findings in fiberendoscopic evaluation of swallowing (FEES)
223867490|NCT01694446|OTHER|Intraduodenal glucose or fructose|
223867491|NCT02954016|DEVICE|ePass|Subject is implanted with the device for up to 3 years.
223867492|NCT02378337|OTHER|Image quantify|Will be observed all patients who perform PET / CT examinations, independent of clinical indication, in nuclear medicine at Hospital Sao Rafael. Those who show interest in participating in the study, will be provided free and informed consent form (ICF) for your appreciation. This evaluation will serve for analysis and quantification of PET-CT images.
223867493|NCT00643929|DRUG|Eltrombopag|Subjects participated in a prior eltrombopag study, having received either eltrombopag or placebo
223867494|NCT02641990|DRUG|ITCA 650 20/60 mcg/day, ITCA placebo|ITCA 650 osmotic mini pump delivering exenatide 20/60 mcg/day and Levora® for 28 days, followed by ITCA osmotic mini pump delivering placebo and Levora® for 28 days
223867495|NCT02641990|DRUG|ITCA placebo, ITCA 650 20/60 mcg/day|ITCA osmotic mini pump delivering placebo and Levora® for 28 days, followed by Levora® and ITCA 650 osmotic mini pump delivering exenatide 20/60 mcg/day and Levora® for 28 days
223867496|NCT05093218|DIETARY_SUPPLEMENT|branch chain amino acid|• Branch chain amino acid at a dose of approxiametely 0.35g/kg will be supplemented in two divided doses group for a period of 12 weeks.For the sake of administration, it will be prescribed as per the following weight band categories: \<5kg 2 gm 5-10kg 4 gm 10-20kg 8 gm 20-40kg 12 gm 40-60kg 24 gm
223867497|NCT05093218|OTHER|placebo|Placebo will have the similar colour, taste and consistency. Both groups will be given the same dose.
223867498|NCT02594735|DRUG|Abatacept|Study participation will consist of a screening visit and 5 protocol visits over six months (week 0, week 6, week 12, week 18, and week 24) for each subject, and phone follow-up (week 2, week 4, week 8, week 10, week 14, week 16, week 20, and week 22). At Visit 1, which will be treatment initiation, eligible subjects will be instructed on the use and side effects of subcutaneous abatacept and will be started on the study drug (abatacept 125 mg SQ weekly for subjects with body weight ≥ 50 KG or abatacept 87.5mg SQ for subjects with body weight \< 50 KG).
223867499|NCT06046404|PROCEDURE|closed reduction|the intervention of closed fracture reduction widely known and part of daily practice. we test the eficacy of this intervention by not performing it in our test group.
223867500|NCT06046404|PROCEDURE|no closed reduction|no reduction will be performed
223867501|NCT04201249|DRUG|Piroxicam, lidocaine|Patients will be randomized to 2 groups group A - mesotherapy with piroxicam (20mg/ml, 1ml) and lidocaine (1%, 1.5ml) (treatment arm); group group B - mesotherapy without piroxicam
223867502|NCT04201249|DEVICE|Mesotherapy without drug administration|Patients will be randomized to 2 groups group A - mesotherapy with piroxicam (20mg/ml, 1ml) and lidocaine (1%, 1.5ml) (treatment arm); group group B - mesotherapy without piroxicam
223867503|NCT02962791|PROCEDURE|Cardiac resynchronization therapy implantation|Cardiac resynchronization therapy implantation will be done for patient with symptomatic heart failure
223867504|NCT02962791|DEVICE|Stimulation of 3 ventricular sites|Cardiac resynchronization therapy with stimulation of 3 ventricular sites
223867505|NCT02962791|DEVICE|Stimulation of 2 ventricular sites|Cardiac resynchronization therapy with stimulation of 2 ventricular sites
223867506|NCT02962791|DEVICE|Echocardiography|Standard Echocardiography will de bone for patient
223867507|NCT01883908|DEVICE|Acupuncture with Seirin® needles|Participants will be randomized to receive either usual medical care or acupuncture treatment plus usual medical care once a week for 8 weeks coinciding with their chemoradiation treatments. The length of the study will be 16 weeks: 8 weeks of treatment and two follow up visits at 4 weeks and 8 weeks after radiation (weeks 12 and 16).
223867508|NCT01883908|OTHER|Usual medical care|usual medical care such as viscous Lidocaine for relief of pain
223867509|NCT04567407|DRUG|Bilateral erector spinae blocks using ropivacaine|Bilateral chest wall nerve blocks using ropivacaine.
223867510|NCT01283750|BEHAVIORAL|care coordination|dementia-related care coordination
223867511|NCT03844269|DEVICE|AKL-T01|"AKL-T01 digital treatment is a state-of-the-art mobile video game-like platform, which deploys modern videogame graphics, engaging reward loops, and real-time adaptive mechanics to dynamically personalize difficulty based on the user's ability. AKL-T01 multitasking treatment employs perceptual discrimination attention/memory task as well as a continuous motor driving task. Performance on these tasks are assessed in isolation and when performed together to calculate a performance index for each individual user. A personalized multitask treatment regimen is automatically configured and delivered to the user and is optimized adaptively to increase multitask performance. As players proceed through the treatment periodic recalibration occurs to maintain an optimal difficulty level."
223867512|NCT05652933|DIAGNOSTIC_TEST|Software for identifying vessel occlusion, infarct volume and penumbra|Assessment of the AI tool software
223867513|NCT02540746|BEHAVIORAL|ERG Skills Training|Group-based Dialectical Behavior Therapy Skills Training for 12 weeks
223867514|NCT02540746|BEHAVIORAL|Motivational Enhancement|Three week Motivational Enhancement group
223867515|NCT02540746|BEHAVIORAL|Family Skills Training|12-week group-based family skills training using Family Connections model
223867516|NCT01932450|PROCEDURE|renal sympathetic denervation|One-time standard Catheter-based renal sympathetic denervation will be performed in both renal arteries by radiofrequency ablation.
223867517|NCT01932450|DRUG|antihypertensive drugs|antihypertensive drugs have been used from baseline in patients, and will be modified by patient's blood pressure.
223867518|NCT00864786|DRUG|PF03635659|Inhaled doses of 200 mcgQD
223867519|NCT00864786|DRUG|PF03635659|Inhaled doses of 600 mcg QD
223867520|NCT00864786|DRUG|PF03635659|Inhaled doses of 1000 mcg QD
223867521|NCT00864786|DRUG|PF03635659|Inhaled dose to be decided based on all available data from previous cohorts. It will run if maximum tolerated dose is not identified from previous cohorts or if a lower dose is required to be investigated.
223867522|NCT00864786|DRUG|PF03635659|Inhaled dose to be decided based on all available data from previous cohorts. It will run if maximum tolerated dose is not identified from previous cohorts or if a lower dose is required to be investigated.
223867523|NCT00475319|DRUG|placebo|comparison of different dosages of drug
223867524|NCT00475319|DRUG|1% OPC-12759 ophthalmic suspension|comparison of different dosages of drug
223867525|NCT00475319|DRUG|2% OPC-12759 ophthalmic suspension|comparison of different dosages of drug
223867526|NCT01318655|DRUG|NKTR-118|Tablet, Oral, Once daily
223867527|NCT01318655|DRUG|Placebo|Tablet, Oral, Once daily
223867528|NCT00101010|BIOLOGICAL|Filgrastim|5 mcg/kg, SC daily, start 24 hours after chemotherapy
223867529|NCT00101010|BIOLOGICAL|Pegfilgrastim|6 mg SC one time (24 hours after chemotherapy)
223867530|NCT00101010|BIOLOGICAL|Rituximab|375 mg/m\^2 intravenous piggy back (IVPB) on day 1, administered 1st
223867531|NCT00101010|DRUG|Cyclophosphamide|750 mg/m\^2 IVPB on day 1
223867532|NCT00101010|DRUG|Pegylated liposomal doxorubicin hydrochloride|40 mg/m\^2 IV (maximum dose 90 mg) infusion over 1 hour on day 1
223867533|NCT00101010|DRUG|Prednisone|40 mg/m\^2 oral days 1 - 5.
223867534|NCT00101010|DRUG|Vincristine Sulfate|2 mg IV, day 1
223867535|NCT04969172|DRUG|Exosomes overexpressing CD24|The suggested therapeutic agent here is based on an existing therapeutic platform that uses exosomes that were engineered to overexpress CD24 that can directly suppress the cytokine storm. The exosomes will be isolated and purified from human embryonic kidney T-REx™-293 cells that constitutively express high levels of human CD24.
223867536|NCT03470142|PROCEDURE|traditional laparoscopy-assisted surgery|All surgical procedures will be performed by the surgery team ,which is leaded by professor Sun Dong-Hui and Wang Quan. The traditional laparoscopic operation undergo and then a small incision(5cm) is made in the middle of the lower abdominal wall to trim the mesangial membrane and remove the specimen. At last the anastomosis operation undergo by the laparoscopic operation.
223867537|NCT03470142|PROCEDURE|total laparoscopic surgery with no incision (natural orifice transluminal endoscopic surgery, NOSES)|All surgical procedures will be performed by the surgery team ,which is leaded by professor Sun Dong-Hui and Wang Quan. The whole procedures undergo by total laparoscopic surgery with no incision in the abdominal wall. The specimen then will be removed through natural orifice (anal).
223867538|NCT06250413|OTHER|FMT|Capsulated oral auto fecal microbiota transplant
223867539|NCT06250413|OTHER|Placebo|Capsulated hot chocolate powder
223867540|NCT06250413|DRUG|Amox Clav|5 day course of Amoxicillin Clavulanic acid given to all participants
223867541|NCT03511651|PROCEDURE|PEEP|Two PEEP levels will be used during mechanical ventilation.
223867542|NCT00886951|DRUG|I123MNI388/I123MNI390|Subjects will be dosed by intravenous injection up to 5 mCi and not to exceed 5.5 (not \>10% of 5 mCi limit) 123-I MNI-388 or 123-I MNI-390.
223867543|NCT00230399|DRUG|Celecoxib|
223867544|NCT00230399|DRUG|Capecitabine|
223867545|NCT00230399|DRUG|Irinotecan|
223867546|NCT04469855|DRUG|semaglutide|Patients will be treated with commercially available Ozempic® according to routine clinical practice at the discretion of the treating physician. The treating physician's decision to initiate treatment with Ozempic® is independent of the decision to include the patient in the study.
223867547|NCT02242695|DRUG|Fluomizin vaginal tablets|One vaginal tablet for 6 days and 1 placebo tablet on day 7
223867548|NCT02242695|DRUG|Canesten vaginal tablets|one vaginal tablet for 7 days
223867549|NCT02368171|OTHER|measure exhaled carbon monoxide and nitric oxide|
223867550|NCT03583125|DRUG|EOC317|tablet(s) PO
223867551|NCT00585533|DRUG|Erlotinib (Tarceva)|Erlotinib
223867552|NCT03003845|OTHER|Questionnaires|QOL and pain questionnaires will be given to patients at 3, 6, and 12 months post surgery
223867553|NCT03003845|OTHER|Collection of Blood samples|Blood for PBLs will be collected at 3, 6, and 12 months post surgery
223867554|NCT01368016|DRUG|Nicotine|A single 6 mg dose of an experimental Nicotine Replacement Therapy (NRT), with a 36-hour washout between visits
223867555|NCT01368016|DRUG|Nicotine|A single 4 mg dose of a marketed Nicotine Gum, with a 36-hour washout between visits
223867556|NCT05454163|OTHER|SNOT 22 questionnaire|22 items, score between 0 and 5; sum, minimum = 0, maximum = 110; higher score = higher impact on quality of life)
223867557|NCT01369498|DRUG|Simtuzumab|Simtuzumab administered intravenously over approximately 30 minutes every 2 weeks
223867558|NCT01369498|DRUG|Ruxolitinib|In Stage 2, participants will be on a stable dose of ruxolitinib
223867559|NCT00534300|DRUG|Omegaven|Lipid emulsion (omegaven) for intravenous use, 100 ml (25 mL/h)
223867560|NCT00534300|DRUG|Isotonic saline|Intravenous infusion, 100 mL, 25mL/h
223867561|NCT01394510|DRUG|N-acetylcysteine|600 mg N-acetylcysteine (NAC) twice daily by mouth for 2 weeks followed by 1200 mg NAC twice daily by mouth for 2 additional weeks.
223867562|NCT06549582|OTHER|Taohong Tongluo Xiaoban Prescription|"Chinese herbal medicine Taohong Tongluo Xiaoban prescription, which includes Pinelliae Rhizoma, Poria, Bambusae caulis in taenias, Aurantii Fructus Immaturus, Arisaema cum bile, Acori Tatarinowii Rhizoma, Persicae Semen, Carthami Flos, Chuanxiong Rhizoma and Paeoniae Radix Rubra as a once - daily dosage with one administration per dose"
223867563|NCT06549582|OTHER|Fundamental medical treatment|The specific methods were developed in accordance with the 2010 Chinese Guidelines for Secondary Prevention of Ischemic Stroke and Transient Ischemic Attack. It primarily involves managing risk factors such as hypertension, diabetes, abnormal lipid metabolism, etc., and implementing antithrombotic therapy including antiplatelet agents (aspirin, clopidogrel, dipyridamole, dipyridamole + aspirin, clopidogrel + aspirin, silostazole, triflurosal, etc). For the management of post-stroke mood disorders, cognitive impairments, and spastic paralysis, pharmacological interventions encompass oral administration of anxiolytic or antidepressant agents, anti-dementia medications, as well as muscle relaxants.
223867564|NCT01373697|DRUG|Ibuprofen|Apply the gel at the site of pain or injury, massaging gently to promote penetration of 8 in 8 hours for 5 days. Leave the gel on the premises at least 4 hours before removal
223867565|NCT01373697|DRUG|Profenid|Apply the gel on the spot of pain or injury, massaging slightly to facilitate the penetration of 8 in 8 hours during 5 days. Leave the gel on the the site at least 4 hours before removal
223867566|NCT02773303|DEVICE|Mente Autism™|A portable headband records EEG activity, and specialized algorithms convert the EEG activity into sonified binaural signals feeding them back to the user
223867567|NCT02773303|DEVICE|Sham|a device externally identical to Mente Autism™, providing binaural beats but not tailor-made neurofeedback binaural beats
223867568|NCT05985512|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|Cognitive Behavioral Therapy for Insomnia is the main therapy for the patients. Medications include sedative-hypnotics and antidepressants with a sedative effect.
223867569|NCT02455752|PROCEDURE|LE-TME|Retroperitoneal approach for total mesorectal excision
223867570|NCT05815797|DRUG|SDD formula|SDD formula consists of 23 herbal medicines
223867571|NCT05815797|DRUG|Placebo|Placebo
223867572|NCT01691690|DRUG|Acetaminophen (paracetamol)|Acetaminophen IV (15 mg/kg).
223867573|NCT01691690|DRUG|Normal Saline Flush|Saline placebo will be infused intraoperatively.
223867574|NCT01691690|DRUG|Midazolam|Midazolam (0.5mg/kg to maximum dose of 20mg) given 15-20 minutes before induction.
223867575|NCT01691690|DRUG|Sevoflurane|Sevoflurane for anesthesia induction.
223867576|NCT01691690|DRUG|Nitrous Oxide/Oxygen|Combination of NO2 \& O2 for anesthesia induction.
223867577|NCT01691690|DRUG|Propofol|Propofol 1-1.5 mg/kg to facilitate endotracheal intubation.
223867578|NCT01691690|DRUG|Morphine|Morphine 0.1 mg/kg given prior to intubation.
223867579|NCT01691690|DRUG|Ondansetron|Ondansetron (0.15 mg/kg, maximum dose of 4 mg) for postoperative nausea prophylaxis.
223867580|NCT01691690|DRUG|Dexamethasone|Dexamethasone (0.25 mg/kg, maximum dose of 20 mg) for postoperative nausea prophylaxis.
223867581|NCT04958343|PROCEDURE|pelvic reconstruction|After radical cystectomy, the pelvic reconstruction including the ligation of dorsal vascular complex and posterior reconstruction will be performed on patients.
223867582|NCT05164094|BIOLOGICAL|mRNA-1189|Sterile liquid for injection
223867583|NCT05164094|BIOLOGICAL|Placebo|0.9% sodium chloride (normal saline) injection
223867584|NCT03967626|DEVICE|external cooling with the xxxxx device|external cooling with the xxxxx device
223867585|NCT05082935|BEHAVIORAL|Phase II Promotores de Salud|Community partners (e.g., Mexican Consulate) select events for testing and use their usual outreach methods to attract participants to the site and their event. Then, at the community partner's event, the research team holds COVID-19 testing events and the Promotores de Salud health behavior intervention is delivered by bilingual research staff. The health behavior intervention includes: 1) psychoeducation to promote hand-washing, social distancing, mask wearing if unvaccinated, and continued testing to mitigate the spread of COVID-19 and psychoeducation to address vaccine hesitancy; 2) information support and service navigation to address logistical challenges associated with testing and vaccination (e.g., scheduling health care visits, transportation, language barriers); 3) motivational interviewing to explore personal, social, and behavioral barriers to testing and vaccination, and to discuss available resources.
223867586|NCT05082935|BEHAVIORAL|Phase I Promotores de Salud Outreach|Testing events re-occur every two weeks at the same location and time, based on census density on Latinx individuals for site selection. Outreach conducted by promotores occurs to increase attendance at the testing events. Outreach is culturally responsive (e.g., culturally tailored radio announcements, social media posts, community canvassing, referral by community leaders).
223867587|NCT02589340|DRUG|Buspirone|
223867588|NCT02589340|DRUG|Placebo|Sugar Pill
223867589|NCT00439569|DRUG|sodium phenylbutyrate|500 mg/kg/day, depending upon tolerability subsequent dosages may increase to 675, 900, or 1200 mg/kg/day to identify maximum tolerated dose (MTD) and then an additional 6 participants will enroll at the MTD
223867590|NCT03963336|DRUG|LMWH|Subcutaneous LMWH 1mg/kg/day for 2 weeks
223867591|NCT03963336|DRUG|acetazolamide|Carbonic anhydrase inhibitor 1-2g/day for 6 months
223867592|NCT04665440|OTHER|Voice alone|mother's voice without tactile stimuli
223867593|NCT04665440|OTHER|Voice + tactile stimuli|mother's voice with tactile stimuli
223867594|NCT00855686|DRUG|Memantine|20mg once daily oral dose
223867595|NCT00855686|DRUG|Placebo|Daily oral dose
223867596|NCT00107159|BIOLOGICAL|autologous dendritic cell-allogeneic melanoma tumor cell lysate vaccine|
223867597|NCT01579370|OTHER|Quaternary ammonium|"Rooms from which a patient with a target organisms has been discharged (ie, a seed room) will be cleaned using quaternary-ammonium containing solutions. Room cleaning will proceed following standard cleaning protocols established at each study hospital."
223867598|NCT01579370|OTHER|Bleach|"Rooms from which a patient with a target organisms has been discharged (ie, a seed room) will be cleaned using bleach containing solutions. Room cleaning will proceed following standard cleaning protocols established at each study hospital."
223867599|NCT01579370|OTHER|Quaternary ammonium and UV-C light|"Rooms from which a patient with a target organisms has been discharged (ie, a seed room) will be cleaned using quaternary-ammonium containing solutions. Room cleaning will proceed following standard cleaning protocols established at each study hospital. Then, the UV-C light-emitting device will be brought to the room to irradiate the room until 12,000 uWs/cm2 (for vegetative bacteria) or 22,000 uWs/cm2 (for C. difficile) has been delivered to entire room."
223867600|NCT01579370|OTHER|Bleach and UV-C light|"Rooms from which a patient with a target organisms has been discharged (ie, a seed room) will be cleaned using bleach containing solutions. Room cleaning will proceed following standard cleaning protocols established at each study hospital. Then, the UV-C light-emitting device will be brought to the room to irradiate the room until 12,000 uWs/cm2 (for vegetative bacteria) or 22,000 uWs/cm2 (for C. difficile) has been delivered to entire room."
223867601|NCT03873896|DIAGNOSTIC_TEST|Stimulated skin wrinkling test|Stimulated skin wrinkling induced by the application of EMLA (eutectic mixture of local anesthetic) cream to the finger pads of blocked and unblocked fingers of study volunteers (test applied to both study arms)
223867602|NCT03873896|PROCEDURE|Digital Nerve Block|A digital nerve block is performed by injecting a total of 3 millilitres of 2% Lidocaine at the base of the ring finger of randomized hand of the volunteer. The effect of the block is confirmed clinically before proceeding with the study data collection. Please see the description for more details on the procedure
223867603|NCT03482011|DRUG|Mirikizumab|Administered SC
223867604|NCT03482011|DRUG|Placebo|Administered SC
223867605|NCT04153747|OTHER|High-power and short-duration radiofrequency ablatio (70 W / 9-10 s)|Pulmonary veins electrical isolation: high-power and short-duration ablation
223867606|NCT04153747|OTHER|Low-power (25-40 W) radiofrequency ablation guided by lesion size index (LSI) and ablation index (AI) values|Pulmonary veins electrical isolation: low-power ablation.
223867607|NCT04153747|OTHER|Esophageal endoscopy|Esophageal endoscopy to detect postablation esophageal thermal lesions.
223867608|NCT04153747|DIAGNOSTIC_TEST|Daily 30-seconds ECG|Transtelephonic daily 30-seconds single lead electrocardiogram
223867609|NCT02455297|DRUG|Copanlisib (BAY80-6946)|Starting dose 60 mg (dose reduction due to toxicities to 45 mg allowed). Administered in slow IV bolus on days 1, 8 and 15 of each 28 day cycle until disease progression or until another criterion is met for withdrawal from study treatment.
223867610|NCT05878470|BEHAVIORAL|video|A brief (119 seconds) social contact-based video. The video presented a young Black man in his early twenties, a professional actor, sharing his scripted personal story of struggles with psychotic illness and raising themes of recovery and hope.
223867611|NCT00000223|DRUG|Buprenorphine|
223867612|NCT02476409|DRUG|tolvaptan|Study will test the addition of tolvaptan to augmentation of loop diuretic as standard of care for outpatients presenting with worsening heart failure.
223867613|NCT02476409|OTHER|Placebo|Placebo for tolvaptan
223867614|NCT03017625|OTHER|Blood is drawn|Blood analyses
223867615|NCT00142285|DRUG|Zinc sulphate (20 mg)|
223867616|NCT05142878|DEVICE|Ultracore Repose® mattress|Residents will be placed on the Ultracore Repose® mattress during 14 days
223867617|NCT03848572|DIAGNOSTIC_TEST|Repetitive assessment of PRECISE-DAPT score|The PRECISE-DAPT score, which takes into consideration age, creatinine clearance, haemoglobin, white blood-cell count and previous spontaneous bleeding, will be reassessed every 3 months during the 12-month follow-up period
223867618|NCT02779634|DRUG|ubiquinol|Ubiquinol three times daily
223867619|NCT02779634|DRUG|Placebo|Sugar pill three times daily
223867620|NCT04221828|DRUG|NanoPac (sterile nanoparticulate paclitaxel) Powder for Suspension|NanoPac is manufactured using a Precipitation with Compressed Antisolvent (PCA) technique that employs supercritical carbon dioxide and acetone to generate paclitaxel nanoparticles. For clinical administration, the NanoPac powder in vial is suspended with Sterile Reconstitution Solution (1% Polysorbate 80, NF in 0.9% Sodium Chloride for Injection, USP) and then further diluted with 0.9% Sodium Chloride for Injection, USP, to achieve the final clinical formulation.
223867621|NCT01595061|DRUG|Cisplatin|Given IV
223867622|NCT01595061|DRUG|Gemcitabine Hydrochloride|Given IV
223867623|NCT01595061|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
223867624|NCT01595061|PROCEDURE|Therapeutic Conventional Surgery|Undergo local core biopsy or surgical excision
223867625|NCT00529789|DRUG|duloxetine|20 - 120 milligrams (mg) every day, once-daily (QD), by mouth (PO) for 30 weeks; If patient is ≤40 kilograms (kg), initial dose is 20 mg, then titrated up. If patient is \>40 kg, initial dose is 30 mg, then titrated up.
223867626|NCT01430611|BIOLOGICAL|Meningococcal (Groups A and C) Polysaccharide Vaccine|0.5 mL, Subcutaneous
223867627|NCT01430611|BIOLOGICAL|Meningococcal (Groups A and C) Polysaccharide Vaccine|0.5 mL, Subcutaneous
223867628|NCT05297175|DEVICE|Trammpolin medial meniscus prosthesis|Implantation of the Trammpolin medial meniscus prosthesis in patients with a severe medial meniscus damage
223867629|NCT03741049|DEVICE|Scalpel Bougie technique (plastic laryngeal model)|ScalpelBougie Set
223867630|NCT03741049|DEVICE|Seldinger technique (plastic laryngeal model)|Melker Set
223867631|NCT03741049|DEVICE|Surgical technique (plastic laryngeal model)|Scalpel and speculum
223867632|NCT03741049|DEVICE|Scalpel Bougie technique (porcine laryngeal model)|ScalpelCric Set
223867633|NCT03741049|DEVICE|Surgical technique (porcine laryngeal model)|Scalpel and speculum
223867634|NCT01884441|DRUG|Bendamustine|"Schedule:~Day 2: Bendamustine 90mg/mq Day 3: Bendamustine 90mg/mq for a maximum of 4 cycles"
223867635|NCT01884441|DRUG|Gemcitabine|Day 1: Gemcitabine 800mg/mq, Day 4: Gemcitabine 800mg/mq for a maximum of 4 cycles
223867636|NCT01884441|DRUG|Vinorelbine|Day 1 Vinorelbine 20mg/mq for a maximum of 4 cycles
223867637|NCT06034886|DRUG|Troriluzole|BHV-4157 140mg, 200mg or 280mg once daily by mouth.
223867638|NCT01247831|PROCEDURE|Selective Laser Trabeculoplasty|100 spots with an energy of 0,8 mJ are applied over 360° of the trabecular meshwork of glaucoma patients with a Q-switched 532 nm frequency doubled neodymium YAG Laser.
223867639|NCT05459259|OTHER|Interviews and Delphi Survey|no intervention delivered
223867640|NCT00401206|DRUG|dexmedetomidine|
223867641|NCT05794568|DEVICE|OITcontrol app monitoring|App to monitor OIT patients
223867642|NCT03576833|DEVICE|Elipse Balloon system|intragastic balloon
223867643|NCT00960141|DRUG|montelukast sodium|montelukast 10 mg tablet, taken orally once daily at bed time for 2 weeks
223867644|NCT00960141|DRUG|Comparator: loratadine|loratadine 10 mg tablet, taken orally once daily at bed time for 2 weeks
223867645|NCT00960141|DRUG|Comparator: placebo|placebo tablet, taken orally once daily at bed time for 2 weeks
223867646|NCT00185549|BEHAVIORAL|CF. DOC|
223867647|NCT04470258|OTHER|ELMO PROJECT AT COVID-19: STUDY IN HUMANS|The Elmo system will be applied to 10 patients with hypoxemic respiratory failure by COVID-19 and its effectiveness will be assessed by analyzing the physiological variables and the patient's comfort, as well as their clinical outcomes (need for tracheal intubation) and recovery time. Hypoxemic respiratory failure and need for O2.
223867648|NCT04470258|DEVICE|ELMO PROJECT AT COVID-19: PROOF OF CONCEPT AND USABILITY|After testing for the following requirements: offering CPAP, ensuring the maintenance of alveolar ventilation without CO2 rebreathing, monitoring intra-ELMO pressure, minimizing adverse effects of the system such as noise, face temperature, airway dryness and comfort global; tests will be carried out on healthy volunteers using prototypes of the Elmo system and assessing whether their effectiveness in providing positive airway pressure and their usability from the perspective of their primary users (doctor, physiotherapist and nurses) and the volunteer's comfort . With this, realistic simulations will be carried out, centered on the evaluation based on heuristic principles.
223867649|NCT01323166|PROCEDURE|Excision of the levator muscle|Cylindrical perineal excision including the levator muscle
223867650|NCT05806476|DIETARY_SUPPLEMENT|caffeine|1.75mg / kg body mass of caffeine x 3 times a day during the run-in days and 3mg / body mass of caffeine once on the experimental days
223867651|NCT05806476|DIETARY_SUPPLEMENT|placebo|1.75mg / kg body mass of microcrystalline cellulose x 3 times a day during the run-in days and 3mg / body mass of microcrystalline cellulose once on the experimental days
223867652|NCT03411291|DEVICE|MRI, MR Spectroscopy, MR Perfusion|One brain MRI/MR Spectroscopy/MR Perfusion at baseline and one brain MR/MR Spectroscopy/MR Perfusion at 3 months.
223867653|NCT06413095|BIOLOGICAL|Pembrolizumab|Intratumoral microdose injection by the CIVO device.
223867654|NCT06413095|COMBINATION_PRODUCT|MK-0482 + Pembrolizumab|Intratumoral microdose injection by the CIVO device.
223867655|NCT06413095|COMBINATION_PRODUCT|MK-4830 + Pembrolizumab|Intratumoral microdose injection by the CIVO device.
223867656|NCT02577198|OTHER|Medilogy Decision Support System (MediDSS)|Italian translation of Evidence-Based Medicine electronic Decision Support (EBMeDS), a set of rules (scripts) based on Evidence Based Medicine guidelines and applied to structured health data. MediDSS further includes knowledge from Swedish, Finnish, INteraction X-referencing (SFINX), a drug-drug interaction database containing concise evidence-based information of about 18,000 drug interactions and adverse events. MediDSS is integrated with local reminders.
223867657|NCT02896699|BEHAVIORAL|PrEP Intervention Group|
223867658|NCT02896699|OTHER|Control Group|
223867659|NCT02444598|DEVICE|Vaccum Assisted Closure device|Negative-pressure wound therapy
223867660|NCT02444598|PROCEDURE|Conventional wound dressings|Conventional wound dressings
223867661|NCT04431375|BIOLOGICAL|Plasma Exchange|Plasma exchange 2 sessions alternate day followed by FMT for 7 days and Tenofovir \[antiviral\] 300mg PO once a day .
223867662|NCT04431375|DRUG|Tenofovir|Tenofovir \[antiviral\] 300mg PO once a day .
223867663|NCT04431375|OTHER|Fecal Mircobiota Transplantation|FMT for 7 days
223867664|NCT04216394|PROCEDURE|Emergency general surgery|multidisciplinary surgery performed for traumatic and non-traumatic acute conditions during the same admission in the hospital.
223867665|NCT01302236|DRUG|Eplerenone|50mg/day for all as initial dose, 100mg/day for the patients that still show hypertension(above 140/90mmHg)after one month 150mg treatment,oral,on 6 months
223867666|NCT01336543|DRUG|Chemotherapy following concurrent Chemoradiotherapy|"1. NSCLC (Non-Small Cell Lung Cancer)~2. PE (Cisplatin 50mg/m2 on days 1,8,29,36 Etoposide 80mg/m2 days 1-3 and 29-31)~3. Radiation 59.4 Gy with 2 cycles of PE~4. (Non-squamous histology) Pemetrexed consolidation 500mg/m2 every 21 days for 4 cycles~5. (Squamous histology) Gemcitabine consolidation 1000mg/m2 days 1,8, every 21 days for 4 cycles"
223867667|NCT03340714|DEVICE|Monitoring Device|Wear ADAMM
223867668|NCT04589208|DRUG|Ketamine Hydrochloride|We will assign ketamine doses in successive 10 subject cohorts. The ketamine dose for the 1st cohort will start at 0.08 mg/kg. For subsequent cohorts, the bolus will be successively reduced or increased by 0.02 mg/kg (n=10/dose) to determine the lowest dose of ketamine that still produces a robust phBOLD response
223867669|NCT03184038|PROCEDURE|Cognitive Assessment|Undergo assessment of neurocognitive function
223867670|NCT03184038|RADIATION|Stereotactic Radiosurgery|Undergo SRS
223867671|NCT03184038|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
223867672|NCT03184038|OTHER|Quality-of-Life Assessment|Ancillary studies
223867673|NCT03180502|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
223867674|NCT03180502|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
223867675|NCT03180502|OTHER|Laboratory Biomarker Analysis|Correlative studies
223867676|NCT03180502|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223867677|NCT03180502|RADIATION|Proton Beam Radiation Therapy|Undergo proton beam radiation therapy
223867678|NCT03180502|OTHER|Quality-of-Life Assessment|Ancillary studies
223867679|NCT03180502|OTHER|Questionnaire Administration|Ancillary studies
223867680|NCT03180502|DRUG|Temozolomide|Drug
223867681|NCT06804096|DRUG|Faropenem|Tab. Faropenem 200mg three times daily
223867682|NCT06804096|DRUG|Co-amoxiclav|Tab. Co-Amoxiclav 625mg three times daily
223867683|NCT06804096|DRUG|Clarithromycin 500 mg|Tab. Clarithromycin 500mg two times daily
223867684|NCT03217305|DEVICE|NAVA|Neurally Adjusted Ventilatory Assist is a fairly new ventilation mode
223867685|NCT05393726|PROCEDURE|Ultrasound-Guided Suprainguinal Fascia Iliaca Block Versus Lumbar Erector Spinae Plane Block|"Suprainguinal Fascia Iliaca Block group will receive ultrasound-guided suprainguinal fascia iliaca block injection 40 ml of bupivacaine 0.25% mixed with 2 ml of dexamethasone 4 mg/ml.~Lumbar Erector Spinae Plane Block group will receive ultrasound-guided lumber erector spinae plane block (L-ESPB) injection 40 ml bupivacaine 0.25% mixed with 2 ml of dexamethasone 4 mg/ml.~control group will underwent surgery under general anesthesia and receive the perioperative routine protocol of analgesia"
223867686|NCT05444244|OTHER|Relational Research Recruitment and Engagement Intervention|"* Specified recruiter/point of contact~* Flexibility in study time, place, method of recruitment (preferred participant email, phone), and follow-up (in registry, if participant calls back at all restart 3 failed phone contacts)~* Resource matching (financial, transportation constraints)"
223867687|NCT00296751|PROCEDURE|ECG recording|
223867688|NCT00296751|PROCEDURE|Epidural catheter insertion|
223867689|NCT00296751|DRUG|Intravenous meperidine injection|
223867690|NCT00296751|DRUG|Epidural Bupivacaine and fentanyl injection|
223867691|NCT06523374|PROCEDURE|Endoscopic brush cytology|A total of four brush samples will be taken during the endoscopy. Other minimally invasive interventions during this study are standard of care.
223867692|NCT06073769|DRUG|Oral azacitidine|Maintenance therapy according to the approved label
223867693|NCT05689307|DEVICE|SIVA-MVP|Participants receive a small, wearable data recorder, wear it during the day and charge it on the nightstand during sleep for 14x24 hours. The encrypted, recorded segments are uploaded to a server. The server provides a secure environment where the segments are decrypted after receiving the required keys from the patient's SIVA smartphone application. The decrypted segments are then classified as cough by a machine learning algorithm. Participants respond to questions on a smartphone once a day for additional context data. The audio data from the first 24 hours after the patient started wearing the device are used for the validation of the performance of the cough detection algorithm.
223867694|NCT04474301|OTHER|Survey Administration|Complete survey
223867695|NCT06326320|PROCEDURE|Combined SAPB|Combined Deep and Superficial Serratus Anterior Plane Block will be performed unilaterally, under US guidance, before the surgical operation, after the induction of anesthesia, when the patient is placed in the supine position. 40 ml of 0.25% bupivacaine will be used in applications.
223867696|NCT04275102|OTHER|SPARK|Prompt to complete symptom screening three times weekly via SPARK with corresponding feedback sent to healthcare providers with each completed assessment.
223867697|NCT05388110|BEHAVIORAL|SKY Breath Intervention|Sudarshan Kriya Yoga (SKY) is a breath-based meditative practice that entails a sequence of specific breathing techniques to help practitioners achieve a state of calm alertness. It has offered benefits as a therapeutic option for mild-to-moderate depression and anxiety disorders and as an adjunctive treatment in patients with major depressive disorder, but the neurological mechanism of SKY breath intervention is still not fully understood.
223867698|NCT00793754|DRUG|Aspirin|100 mg / day for 8 weeks
223867699|NCT00793754|DRUG|Atorvastatin|40 mg / day for 8 weeks
223867700|NCT00793754|DRUG|Aspirin + Atorvastatin|Aspirin 100 mg / day + Atorvastatin 40 mg / day for 8 weeks
223867701|NCT06534554|BEHAVIORAL|Patient Navigation|A lay patient navigator working will contact patients seen in the UAB ED via phone within \~72 hours following the ED visit. During this initial phone conversation, the navigators will: 1) conduct a baseline assessment to identify barriers to attending an outpatient visit for gout care and to adhering to gout treatment recommendations and 2) determine the level of support and assistance needed by the patient.
223867702|NCT06410885|DEVICE|Thermal Anisotropy Measurement Device|The study device is a non-invasive sensor that is placed on the study subject's skin overlying an existing implanted CSF shunt. It uses an integrated thermal actuator and temperature sensors to assess shunt flow.
223867703|NCT02995252|OTHER|Blood draws|
223867704|NCT02995252|DRUG|Tenofovir Alafenamide|25 mg tablet, once a day by mouth.
223867705|NCT02995252|OTHER|Knowledge Index Questionnaire|
223867706|NCT02995252|OTHER|Liver transient elastography (FibroScan)|Participants of the hepatitis B treatment sub-study may have FibroScans completed at baseline, during the study with liver enzyme normalization, and at the end of the study.
223867707|NCT02995252|PROCEDURE|Liver Biopsy|40 participants of the hepatitis B treatment sub-study will have liver biopsies prior to starting tenofovir alafenamide, and at years 1 and 2 of receiving treatment.
223867708|NCT06510348|DIETARY_SUPPLEMENT|Supplemental Parenteral Nutrition (SPN)|Nutritional targets are based on ESPEN guidelines recommendation (calories administration based on indirect calorimetry study, proteins 1.3 g/kg/day). From the first day of ICU admission indirect calorimetry will be performed daily in order to evaluate energy requirements. On the fourth day, the patient will undergo a gastric residual volume measurement and a paracetamol absorption test. If gastrointestinal dysfunction is detected, the patient will be assigned to a study group based on the randomization protocol. The SPN group will gradually initiate supplemental parenteral nutrition in order to achieve the target of 80% by the fifth day. Trophic feed will be administered to cover the remaining 20% of the targeted nutrition intake.
223867709|NCT01792830|DRUG|Metformin|"Metformin is an oral antidiabetic agent used to control high blood glucose levels and is given in divided doses with meals. During treatment initiation and dose titration, the patient's blood glucose levels will be used to determine the therapeutic response to metformin and identify the minimum effective dose for the patient.~Patients without a history of diabetes and admission HbA1c \< 7% requiring SC insulin therapy in the hospital will be discharged on metformin monotherapy.~Treatment naïve patients with an HbA1c between 7% and 9% prior to admission will be discharged on metformin monotherapy or a combination of metformin and a single dose of subcutaneous insulin."
223867710|NCT01792830|DRUG|Glargine insulin|"Glargine is a recombinant human insulin analog that exhibits a constant glucose-lowering profile over 24 hours and permits once-daily dosing. It is administered subcutaneously once a day at the same time every day.~Patients with an HbA1c between 7% and 9% requiring subcutaneous insulin therapy in the hospital will be discharged on oral metformin and a single dose of glargine insulin at 50% of total daily hospital dose.~Patients with an HbA1c \> 9% will be discharged on oral metformin and a single dose of glargine insulin at 80% of total daily hospital dose."
223867711|NCT01792830|DRUG|Glulisine|Glulisine is an injectable, recombinant insulin analog. The total daily dose varies between 0.5 to 1 unit/kg/day depending on the levels of blood glucose. Glulisine will be given within 15 minutes before a meal or within 20 minutes after starting a meal.
223867712|NCT06025357|DIETARY_SUPPLEMENT|L-Citrulline supplementation|4 weeks of L-Citrulline supplementation (10 grams/day).
223867713|NCT06025357|DIETARY_SUPPLEMENT|Placebo|4 weeks of microcrystalline Cellulose supplementation.
223867714|NCT04220827|DRUG|Paclitaxel|Given IP
223867715|NCT01630772|OTHER|Physical therapy|Physical therapy in women with preeclampsia during the hospitalization
223867716|NCT01630772|OTHER|No physical therapy|Comparison of maternal and fetal hemodynamics in women with preeclampsia who underwent physical therapy and who did not have physical therapy
223867717|NCT03568292|OTHER|Best Practice|Receive standard of care
223867718|NCT03568292|OTHER|Laboratory Biomarker Analysis|Correlative studies
223867719|NCT03568292|DEVICE|Oculus Rift Headset|Subject wears headset for virtual reality intervention during bone marrow biopsy or lumbar puncture procedure
223867720|NCT03568292|OTHER|Questionnaire Administration|Ancillary studies
223867721|NCT04585074|PROCEDURE|Robotic or endoscopic nipple sparing mastectomy|Cases or Patients who underwent robotic nipple-sparing mastectomy and immediate reconstruction are enrolled in this arm. Robotic nipple-sparing mastectomy should be performed using robotic surgical systems. Robotic surgical systems include da Vinci S,Si, X, Xi, and SP systems. Axillary or lateral incisions are used for this procedure. Immediate reconstruction includes tissue expander insertion, direct-to-implant, latissimus dorsi flap, transverse abdominis rectus muscle flap, or deep inferior epigastric perforators flap. Cases with robotic mastectomy without immediate reconstruction are excluded.
223867722|NCT04585074|PROCEDURE|Conventional mastectomy (including nipple sparing mastectomy, skin sparing mastectomy)|Cases or Patients who underwent conventional mastectomy and immediate reconstruction are enrolled in this arm. Conventional mastectomy should not be performed using robotic or endoscopic surgical systems. Any incisions can be performed for this procedure. Conventional mastectomy includes also Nipple-sparing mastectomy and Skin sparing mastectomy. Immediate reconstruction includes tissue expander insertion, direct-to-implant, latissimus dorsi flap, transverse abdominis rectus muscle flap, or deep inferior epigastric perforators flap. Cases without immediate reconstruction are excluded.
223867723|NCT01390818|DRUG|MSC1936369B (pimasertib)|MSC1936369B (pimasertib) single dose capsule was administered at dose of 15 milligram (mg), 30 mg, 60 mg, 90 mg orally in successive 21-day cycles.Dose escalation was proceeded until Maximum Tolerated Dose (MTD) was reached. Once the MTD was reached, enrollment began in four disease-specific expansion cohorts at either the MTD or a lower dose recommended by the Safety Monitoring Committee. The four expansion cohorts enrolled subjects with Breast Cancer, Non-Small Cell Lung Cancer (NSCLC), Melanoma, and Colorectal Cancer.
223867724|NCT01390818|DRUG|SAR245409 (PI3K and mTOR inhibitor)|SAR245409 (PI3K and mTOR inhibitor) capsule was administered orally at a dose of 30 mg, 50 mg, 70 mg and 90 mg in successive 21-day cycles. Dose escalation was proceeded until MTD was reached. Once the MTD was reached, enrollment began in four disease-specific expansion cohorts at either the MTD or a lower dose recommended by the Safety Monitoring Committee. The four expansion cohort enrolled subjects with Breast Cancer, NSCLC, Melanoma, and Colorectal Cancer.
223867725|NCT01390818|DRUG|MSC1936369B (pimasertib)|MSC1936369B (pimasertib) capsule was administered twice daily orally at a dose of 60 mg and 45 mg in successive 21-day cycles. Dose escalation proceeded until MTD was reached. The maximum tolerated dose of MSC1936369B (pimasertib) was combined with a lower dose of SAR245409 (PI3K and mTOR inhibitor).
223867726|NCT01390818|DRUG|SAR245409 (PI3K and mTOR inhibitor)|SAR245409 (PI3K and mTOR inhibitor) was administered twice daily orally at a dose of 30 mg and 50 mg in successive 21-day cycles. Dose escalation proceeded until MTD was reached. The maximum tolerated dose of SAR245409 (PI3K and mTOR inhibitor) was combined with a lower dose of MSC1936369B (pimasertib).
223867727|NCT01943799|BIOLOGICAL|GS-4774|Administered as a subcutaneous injection every 4 weeks for a total of 6 doses
223867728|NCT01943799|DRUG|OAV Regimen|Administered prior to study enrollment (tenofovir disoproxil fumarate, entecavir, adefovir, lamivudine, or telbivudine either as single agents or in combination)
223867729|NCT01865149|PROCEDURE|retrobulbar ultrasound|both optic nerve sheath diameter (the posterior 3mm of the papilla), 5 individual measurement
223867730|NCT05678972|OTHER|Self-help online mindfulness-based intervention|"This self-help online mindfulness-based intervention is comprised of four weekly modules on education about mindfulness, guided meditations (e.g., mindful breathing, mindful eating, mindful walking, body scan, acceptance, choiceless awareness and disengaging from thoughts exercise), and guidance on using informal mindfulness skills in day-to-day life. Readings, audio and videos are included to explain the concept of mindfulness and overcome common difficulties associated with mindfulness practice.~Participants will be asked to meditate daily and complete a daily log on their mindfulness practice during this 8-week period."
223867731|NCT00771446|BIOLOGICAL|ELAD plus standard of care treatment|ELAD is a liver assist system - Standard of care for acute liver failure patients including medications and treatments typically given to these patients (Pentoxifylline, corticosteroids, abdominal paracentesis, nutritional therapy, etc., if indicated)
223867732|NCT00771446|OTHER|Standard of care treatment|Standard of care for acute liver failure patients including medications and treatments typically given to these patients (Pentoxifylline, corticosteroids, abdominal paracentesis, nutritional therapy, etc., if indicated)
223867733|NCT05072743|DEVICE|Photobiomodulation Therapy|PBMT will be applied to the cervical spine using the BIOFLEX® DUO+ system that utilizes a Light Emitting Diode (LED) array pad followed by laser probes. Both delivery methods will be applied to the cervical spine and will entail the use of red light at 660 nm wavelength and near-infrared light at 830-840 nm wavelength. Treatment is provided twice per week for 6 weeks for a total of 12 treatments utilizing Health Canada approved device specific protocol guidelines for the treatment of the cervical spine soft tissue injuries.
223867734|NCT03220425|DRUG|Insulin detemir|
223867735|NCT03220425|DRUG|NPH insulin|
223867736|NCT01583712|PROCEDURE|Confocal laser endomicroscopy|Endomicroscopy of the upper gastrointestinal tract including endomicroscopic pictures taken every ten centimetres in the small bowel, gastric antrum, gastric corpus and esophagus.
223867737|NCT01583712|DEVICE|Confocal Laser Endomicroscope|Pentax EC-3870 CIFK with the ISC-1000 confocal endomicroscopy processor - Pentax, Tokyo, Japan and Optiscan Pty Ltd, Notting Hill, Victoria, Australia
223867738|NCT04826445|OTHER|Data collection|Imaging collection
223867739|NCT03087578|OTHER|electroacupncture|Patients will receive electroacupuncture treatment for 30 minutes per weekly session for 6 weeks.
223867740|NCT03087578|DRUG|Mirabegron 50 MG [Myrbetriq]|Patients will receive 50 mg of mirabegron daily for 6 weeks.
223867741|NCT00870207|BEHAVIORAL|Tu Salud Si Cuenta Worksite Intervention|The intervention will consist of providing TSSC newsletters to employees of the worksite. Additionally, informational sessions about physical activity and healthful food choice (consistent with the TSSC messages) during work hours will be implemented. Social support groups for the behavior changes will be established thru colleague networks. Individualized behavior change plans will be designed for enrolled participants. Additionally, environmental changes including a well equipped exercise facility on site and access to healthful foods in vending machines and work groups providing fruit and vegetable access in kitchen area will be implemented.
223867742|NCT03114267|OTHER|Comparison of the prevalences of the parvovirus genome|Comparison of the prevalences of the parvovirus genome between cases and controls and then of other viruses according to the results of parvoviruses and data from the literature
223867743|NCT05894005|OTHER|Immersive Virtual Reality (IVR)|Students will be first taken to the anesthesia lounge. Here the students will receive IVR instructions on how to navigate the route (i.e. they will watch a 360-degree video using Oculus VR headset). Then the students will be assessed with an observed walkthrough of the route.
223867744|NCT05894005|OTHER|Traditional 2-D Video|Students will be first taken to the anesthesia lounge. Students will receive 2D video instruction on how to navigate the route by watching a normal 2D video using a desktop computer screen. Then the students will be assessed with an observed walkthrough of the route.
223867745|NCT06028074|DRUG|GIM122|GIM-122 administered IV once every 3 weeks or every 2 weeks
223867746|NCT04956757|OTHER|Exercise Intervention|Scapula retraction exercises at varying shoulder abduction angles will be applied
223867747|NCT06140953|DRUG|Trimetazidine|trimetazidine at dose 20 mg three times daily to be taken by intervention group
223867748|NCT06140953|DRUG|Conventional therapy|conventional therapy
223867749|NCT06140953|DRUG|Placebo|placebo tablet (inert substance has the same shape and color of intervention) to be taken by control group only
223867750|NCT06971848|OTHER|Drug skin tests (investigating hypersensitivity to a biotherapy)|allergologic skin tests (prick tests and intradermal tests)
223867751|NCT06647017|DEVICE|Volta tAN System|Transcutaneous auricular neurostimulation (tAN)
223867752|NCT06647017|DEVICE|SHAM Volta tAN System|Participants randomized to the sham group will have an earpiece applied, but stimulation will not be turned on.
223867753|NCT06821399|DIAGNOSTIC_TEST|Fundus Examination|Performing fundus photography on patients to assess the progression of diabetic retinopathy (DR).
223867754|NCT06821399|DIAGNOSTIC_TEST|Metabolomics analysis|Conduct metabolomics testing at enrollment.
223867755|NCT04168541|OTHER|Oral Nutrition Supplement|Product intake of oral nutrition supplement provided
223867756|NCT06173765|OTHER|freeze-dried whole strawberry powder 36 g powder|"After day 1 measurements, subjects will be given their first intervention drink (powder plus water) according to their randomization to 3 cup FW equivalent of strawberries. The freeze-dried whole strawberry powder (36 g powder) requested from the California Strawberry Commission.~All drinks will be standardized to 41 g powder to match USDA Control arm."
223867757|NCT06173765|OTHER|freeze-dried whole strawberry powder 12 g|"After day 1 measurements, subjects will be given their first intervention drink (powder plus water) according to their randomization to 1 cup FW equivalent of strawberries. The freeze-dried whole strawberry powder (12 g powder) requested from the California Strawberry Commission.~All drinks will be standardized to 41 g powder to match USDA Control arm."
223867758|NCT06173765|OTHER|freeze-dried control powder 0 g strawberry|"After day 1 measurements, subjects will be given their first intervention drink (powder plus water) according to their randomization to 0 cup FW equivalent of strawberries. The freeze-dried powder is used as a control.~All drinks will be standardized to 41 g powder to match USDA Control arm."
223867759|NCT04930159|BEHAVIORAL|Facilitated group support|Weekly group gatherings where content will alternate between group conversation and focused topics (e.g., treatment side-effects, mental health, family dynamics, nutrition, financial hardship) with facilitated discussion by a trained professional in nutrition, psychotherapy, cognitive behavioral therapy, or medicine. Each group will cycle through the same order of topics.
223867760|NCT04930159|BEHAVIORAL|1:1 Peer Support|1:1 peer support via telephone or video either during or near a treatment visit. Call content will be focused on social support and driven by the needs of the participant.
223867761|NCT05530109|OTHER|Neuropsychological screening and high resolution EEG recording|Each participant will be assessed with a battery of neuropsychological tests including Epitrack, the Raven's progressive matrice, the MoCA, the D2-R test, the BDI-II test, the STAI and the Qolie-31. Then, a prolonged EEG recording at rest and during an attentional task (the ANT) will be realized
223867762|NCT06161454|DRUG|Baloxavir Marboxil|"Baloxavir marboxil will be administered as either a tablet or granules. Dose is based on body weight:~40 mg for a participants weighing 20-79 kg, or 80 mg for a patient weighing more than or equal to 80 kg"
223867763|NCT06016478|DIETARY_SUPPLEMENT|L-citrulline|4 weeks of L-citrulline (6 g/day) in 8 capsules. Supplementation will be ingested daily, half of the doses in the morning and half at night.
223867764|NCT06016478|DIETARY_SUPPLEMENT|Placebo|4 weeks of microcrystalline cellulose in 8 capsules. Supplementation will be ingested daily, half of the doses in the morning and half at night.
223867765|NCT04923724|DEVICE|tourniquet|tourniquet is a device used during total knee surgery.
223867766|NCT04923724|DEVICE|No tourniquet|tourniquet is a device used during total knee surgery, this group does not get one
223867767|NCT05790837|BEHAVIORAL|"Computer prompt Stand up for your Health®"|"The intervention group consists on the implementation of a desktop application Stand up for your Health® computer prompt following the model proposed by the Guide to Physical Activity at Work (34). This app works by showing reminders and asking users to pause their work activity and take an active break. Pauses can be customized and programmed according to the user's preference, allowing control of the time of each pause, between pauses, and the possibility of delaying or interrupting the pause. In this study, the Stand up for your Health® app will be scheduled to appear every 60 minutes on the workers' computers and each break will last for 2 minutes. During this resting period, the worker will see a notice or reminder on their screen with a countdown clock. The application allows you to postpone or interrupt directions."
223867768|NCT05378815|PROCEDURE|PRP injection|3 weekly intra-articular injections of 5mL PRP under ultrasound guidance
223867769|NCT05378815|PROCEDURE|Placebo injection|3 weekly intra-articular injections of 5mL NaCL under ultrasound guidance
223867770|NCT02265276|DRUG|Saroglitazar|Tab Saroglitazar 4 mg oral daily for 24 weeks
223867771|NCT02265276|DRUG|Pioglitazone|Tab Pioglitazone 30 mg oral daily for 24 weeks
223867772|NCT00958633|DRUG|Escitalopram|"Escitalopram will be prescribed in the dose range 10-30 mg daily.~In patients randomized to the 8-week group:~* escitalopram will be tapered, discontinued, and replaced with placebo over a period of 2 weeks, beginning at the week 6 study visit. The dose of escitalopram (or matching placebo) may be decreased in 10 mg increments only in the case of intolerable side effects. The dose must remain within the protocol-defined range of 10-30 mg daily at all time points.~Patients randomized to the 52 week arm will continue treatment with their antidepressant medication for 52 weeks, or until withdrawal from the study."
223867773|NCT00958633|DRUG|Bupropion XL|"Bupropion XL will be prescribed in the dosage range 150-450 mg daily.~In patients randomized to the 8-week group:~* bupropion XL will be tapered, discontinued, and replaced with placebo over a period of 2 weeks, beginning at the week 6 study visit. The dose of bupropion XL (or matching placebo) may be decreased in 150 mg increments only in the case of intolerable side effects. The dose must remain within the protocol-defined range of 150-450 mg daily at all time points.~Patients randomized to the 52 week arm will continue treatment with their antidepressant medication for 52 weeks, or until withdrawal from the study."
223867774|NCT03104439|DRUG|Nivolumab|The antibodies in nivolumab work by causing programmed cell death of the cancer cells
223867775|NCT03104439|DRUG|Ipilimumab|The antibodies in ipilimumab work by not allowing cancer cell growth
223867776|NCT03104439|RADIATION|Radiation Therapy|Radiation therapy is believed to increase the likelihood of response of immunotherapy
223867777|NCT06532435|DIETARY_SUPPLEMENT|DHA & ARA Candy|Parpicipants need to eat 1-2 candy daily, for 4 consective weeks
223867778|NCT04343885|DRUG|177Lu-PSMA-617|Patients will be given 7.5GBq of 177Lu-PSMA every 6 weeks for 2 cycles.
223867779|NCT04343885|DRUG|Docetaxel|Docetaxel 75 mg/m2 given every 3 weeks for 6 cycles
223867780|NCT06496230|BEHAVIORAL|Empowering Pregnant Women and People Receiving Medications for Opioid Use Disorder|Two-pronged intervention model: 1) behavioral intervention utilizing interoceptive exposures and cognitive behavioral therapy for insomnia and, 2) mobile application that facilitates medication adherence.
223867781|NCT00126997|BIOLOGICAL|Measles, Mumps, Rubella and Chickenpox (live vaccine)|
223867782|NCT06131268|DRUG|Venlafaxine|we will recruit a cohort of 10 MDD patients currently receiving evidence-based treatments for depression (including treatment with an antidepressant drug such as SSRIs/SNRIs) who will be switched to the antidepressant venlafaxine and followed along for 4 weeks (Group 1). The switch from the ongoing treatment to venlafaxine will must be required by therapeutical needs (null or partial response and/or poor tolerability or compliance to ongoing therapy) according to the indications of the principle clinical guidelines for the treatment of MDD and it is independent of the decision of including the patient in the study.
223867783|NCT00389012|PROCEDURE|exercise therapy|
223867784|NCT00389012|PROCEDURE|walking rehabilitation|
223867785|NCT01954407|BEHAVIORAL|Smoking-Related Messages|
223867786|NCT02728349|DRUG|Chlorogenic acid|Chlorogenic acid for injection is polyphenols, micromolecular and un-endogenous substance. It might play the role of cancer treatment via balancing tumor micro-environmental immune status according to the stability and rationality of immunodeficiency and endogenous immune material expression around the tumor. Chlorogenic acid for injection is made from chlorogenic acid (purity≥98%) which is extracted from folium cortex eucommiae.Chlorogenic acid and its preparations have not been reported as chemical drug and marketed around the world.
223867787|NCT05913869|BEHAVIORAL|Online Mindfulness Based Stress Reduction|Based on the UMASS curriculum developed by Dr. Jon Kabat-Zinn, it is an 8-week mindfulness stress reduction program. It is a skill-based psychoeducational program that meets 2 hours for 8 weeks to discuss stress, cognition and health. The weekly intervention includes didactic presentations, class dialogue and inquiry, formal (e.g., body scan, walking meditation) and informal (e.g., awareness of pleasant and unpleasant events, interpersonal communications, etc.) mindfulness practice.
223867788|NCT03994705|BIOLOGICAL|Descartes-11|CAR T-Cells
223867789|NCT03994705|DRUG|Fludarabine|Pre-conditioning chemotherapy
223867790|NCT03994705|DRUG|Cyclophosphamide|Pre-conditioning therapy
223867791|NCT06041516|DRUG|ADCT-701|ADCT-701 in 2microgram/kg-255microgram/kg (weight based dosing), IV over 30 minutes (+15 minutes)
223867792|NCT06973681|DRUG|BGM0504|Administered SC
223867793|NCT06973681|DRUG|BGM0504|Administered SC
223867794|NCT06973681|DRUG|BGM0504|Administered SC
223867795|NCT06973681|DRUG|Placebo|Administered SC
223867796|NCT06972940|DEVICE|Polycaprolactone (PCL) Based Facial Injectable|Polycaprolactone (PCL) Based Facial Injectable
223867797|NCT06973941|OTHER|Virtual reality relaxation|"10-minute VR relaxation application, part of the app Nature Treks VR by Greenergames (released on May 21, 2019), used with a Metaquest head-mounted display"
223867798|NCT06973941|OTHER|Guided imagery relaxation|10-minute guided imagery relaxation where an investigator reads a dream journey
223867799|NCT06972706|DIETARY_SUPPLEMENT|Shatavari|Shatavari is scientifically known as Asparagus racemosus. One capsule containing Shatavari 300mg should be taken once daily.
223867800|NCT06972706|DIETARY_SUPPLEMENT|Shatavari + Ashwagandha extract|Shatavari is scientifically known as Asparagus racemosus along with Ashwagandha root extract scientifically known as Withania somnifera. One capsule containing Shatavari 300mg + Ashwagandha root extract 250mg should be taken once daily.
223867801|NCT06972706|DIETARY_SUPPLEMENT|Placebo|Placebo (starch)
223867802|NCT06973421|DRUG|Utidelone Capsules|60 mg/m2 orally, days 1 to 5, per cycle
223867803|NCT06973421|DRUG|Fruquintinib Capsules|5 mg orally, days 1 to 14, per cycle
223867804|NCT06974084|DRUG|Maraviroc (MVC)|Maraviroc, 300mg per tablet. Atorvastatin, 10mg per tablet
223867805|NCT06974084|DRUG|Atorvastatin, 10mg, 20mg, 40mg|Atorvastatin, 10mg will be given twice daily oral along with Maraviroc, 300-mg
223867806|NCT06974084|DRUG|Placebo, Maraviroc|Placebo of Maraviroc, 300mg
223867807|NCT06974084|DRUG|Placebo, Atorvastatin|Placebo of Atorvastin, 10mg
223867808|NCT06973707|BEHAVIORAL|Passive Digital Tools|Dynamic organizational chart of care team members Guide to general medicine service Plan for the day
223867809|NCT06973707|BEHAVIORAL|Active Digital Tools|Guide: why patient engagement is important Sample questions with answers Ability to create, organize, and store questions to ask the medical team; reminder to ask them during rounds Electronic journal function with categories: symptoms, emotions, function, what I learned; reminder to share with medical team during rounds
223867810|NCT06972511|COMBINATION_PRODUCT|neoadjuvant apatamide plus ADT + radical resection of prostate cancer + extended lymph node dissection + radiotherapy of metastases|neoadjuvant apadamide plus ADT: apadamide 240 mg qd po + leuproprolirelin 3.75mg subcutaneous injection once every month. After 4 months of neoadjuvant therapy, radical prostate cancer + extended lymph node dissection, lymph node dissection to the level of bilateral common iliac arteries, and radiotherapy for metastases was completed within 3 months after surgery.Postoperative adjuvant ADT therapy, regular follow-up until progress to hormone-resistant prostate cancer (CRPC) and then change treatment regimen.
223867811|NCT06972511|DRUG|Standard ADT treatment|leuproprolirelin 3.75mg subcutaneous injection once every month, regular follow-up until progress to hormone-resistant prostate cancer (CRPC) and then change treatment regimen.
223867812|NCT06972693|GENETIC|BRCA testing|BRCA 1 and 2 testing
223867813|NCT06974071|OTHER|Local cold therapy.|It will be applied by means of a refrigerated unit based on gel pack, these units will be stored in the refrigerator of the Unit, which is kept between 2 - 6 degrees, the application protocol is described in Annex B, this was reviewed in conjunction with quality nurses of the Cardiovascular Unit, to avoid biases.
223867814|NCT06974071|OTHER|Lavender oil.|"Lavender essential oil will be used by applying 5 drops in a sterile dressing 15x15 which will be placed on the side of the patient's bedside at 10 cm from the patient.~To maintain the safety of the patients and ensure the quality of the products, two essential oils will be chosen, certified by the Institute of Public Health (ISP), the first one Lavender essential oil, body and aromatherapy use of the Weleda brand, with sanitary authorization N° 154C-15 and the essential oil Doterra, sanitary authorization N° 2832C-6/21, with authorization by the Food and Drugs Administration (FDA), in charge of ensuring the quality of substances that are marketed from the United States to the rest of the world.~These oils will be subjected to a characterization process, choosing the one with the highest quality and purity, through the protocol sent by the Scientific and Technological Nucleus in Bioresources (BioRen), which are specified in section 5.10."
223867815|NCT06974045|OTHER|Single-stage LC + LCBDE|Choledochotomy and transductal common bile duct exploration or transcystic choledochoscopy and common bile duct exploration
223867816|NCT06972433|PROCEDURE|single visit root canal treatment|Root canal procedure performed in a single visit using ProTaper file system, sodium hypochlorite irrigation, and lateral compaction with gutta-percha and sealer. Final restoration with GIC.
223867817|NCT06972433|PROCEDURE|Multiple visit root canal treatment|Root canal procedure performed over two or more visits using the same instrumentation and irrigation protocol. Canals are medicated between appointments before obturation and restoration.
223867818|NCT06973954|OTHER|Text Message Intervention|This intervention was prepared by the researcher with the support of artificial intelligence to increase the activation of diabetic individuals in the experimental group. It consists of short messages with the themes of gain, loss and motivation related to diabetes and self-management.
223867819|NCT06973733|BEHAVIORAL|Clinical data and biospecimen collection|"Clinical Data Collection: Case report forms were utilized to systematically capture multimodal clinical data, including: demographic characteristics, clinical symptoms and physical signs, laboratory test results, chest imaging data, organ support parameters, pharmacological interventions , complications and clinical outcomes.~Biospecimen Collection: ARDS patients underwent biospecimen collection at days 1, 4, and 7 post-diagnosis. High-risk ARDS cohorts provided specimens within 24 hours of ICU admission. Specimens included: peripheral blood, Sputum/BALF, stool and urine."
223867820|NCT06974227|DEVICE|Assistive Pulse Data Collection (APDC) Device|An Assistive Pulse Data Collection Device prototype has been designed and manufactured by the Logistics and Supply Chain MultiTech R\&D Centre, Hong Kong. The device comprises a pulse sensor to record the patient's pulse and digitalize the pulse feature into waveform data. The digitalized waveform data is then converted the electronic signal into mechanical vibration that responds to the patient's pulse.
223867821|NCT06973889|BIOLOGICAL|Helicobacter pylori eradication therapy|12 grams of egg yolk powder containing about 2 grams of antibody twice a day for 2 weeks along with usual antibiotic treatment including OAC or omeprazole (40 mg/day), clarithromycin (1000 mg/day) and amoxicillin (2000 mg/day).
223867822|NCT06972576|BIOLOGICAL|EphA2-targeted CAR-T Cells|Autologous T cells genetically modified to express a chimeric antigen receptor (CAR) targeting EphA2
223867823|NCT06972576|BIOLOGICAL|EphA2-targeted CAR-DCs|Autologous dendritic cells (DCs) genetically modified to express a chimeric antigen receptor (CAR) targeting EphA2
223867824|NCT06972680|DRUG|Bupivacaine Liposomes(BL)|Prior to surgery, an interscalene brachial plexus block was performed, injecting the preset volume of 0.5% bupivacaine liposomes according to the Bayesian optimal interval method.
223867825|NCT06972589|DEVICE|Investigational Mask|Wear mask to enable the delivery of noninvasive ventilation (CPAP or bilevel) therapy during sleep.
223867826|NCT06972589|DEVICE|Conventional mask|Wear mask to enable the delivery of noninvasive ventilation (CPAP or bilevel) therapy during sleep.
223867827|NCT06972329|OTHER|Cerebral Near infrared spectroscopy (NIRSc).|Continuous cerebral near-infrared spectroscopy (NIRSc) during resuscitation in a patient treated for out-of-hospital cardiac arrest (OHCA).
223867828|NCT06973980|OTHER|Exercise|The exercises will be applied only to the intervention group for 12 weeks and will be progressively intensified every 4 weeks.
223867829|NCT06972862|OTHER|Osteogenic Index Optimized Exercise Training Program|The OI- Optimized Training is 6 months of planned, non-linear periodized training on a leg press machine called the PPM (Athletic Republic, Salt Lake City, UT) with a maintenance program during the semester breaks, as necessary.
223867830|NCT06974266|DIETARY_SUPPLEMENT|Probiotic|Subjects receive AKM Lab-01 Enteric-coated once daily by oral, 34B TFU/day , within half an hour after breakfast for 3 months.
223867831|NCT06974266|DIETARY_SUPPLEMENT|Placebo|Subjects receive placebo once daily by oral, one capsule/day, within half an hour after breakfast for 3 months.
223867832|NCT06965634|DEVICE|Lung ultrasound|Lung ultrasonography ; lung ultrasonography will be applied in 4 quadrants according to the LUS protocol and LUS score will be created.
223867833|NCT06973343|DRUG|Group A|Sintilimab 200mg Bevacizumab 7.5mg/kg Oxaliplatin 130mg/m2 Capecitabine 1250mg/m2
223867834|NCT06973343|DRUG|Group B|Sintilimab 200mg Bevacizumab 7.5mg/kg Irinotecan 150mg/m2 Capecitabine 1250mg/m2
223867835|NCT06972836|PROCEDURE|modified pericardial window|(H) shaped lines done by diathemy hoke above phrenic nerve then the upper and lower pericardial flabs reflelected outward in upper and lower directions respectively then 3 large clips applied on each angle of the reflected pericardial anlgles then heavy non absorbable suture is taken from the centre of the free reflected edge to adjacent upper and lower pericardium
223867836|NCT06972836|PROCEDURE|traditional pericardial window|A portion of pericardium (2 cm diameter) was resected anterior to the phrenic nerve by diathermy hook
223867837|NCT06973759|DEVICE|Bright light therapy|Exposure to blue-enriched white light for 15-30 minutes a day for 8 weeks
223867838|NCT06973759|DEVICE|Dim red light|Exposure to dim red light for 15-30 minutes a day for 8 weeks.
223867839|NCT06973200|COMBINATION_PRODUCT|Dihydroartemisin-piperaquine|All children with S. mansoni and/or S. haematobium infections at enrolment will then be treated with dihydroartemisinin-piperaquine (DP) and followed up on days 1, 2, 3, 4, 28, and 42 to assess the efficacy and safety of DP.
223867840|NCT06973278|PROCEDURE|SMILE|Small Incision Lenticule Extraction
223867841|NCT06973278|PROCEDURE|SMILE Xtra|Small Incision Lenticule Extraction combined with Corneal Cross-linking (SMILE Xtra)
223867842|NCT06243796|PROCEDURE|Flap fixation technique|After complete the modified radical mastectomy procedure, the researcher will use absorbable sutures (vicryl), multiple alternating stitched 2.5 cm apart between the subcutaneous of the flap and underlying muscle
223867843|NCT05103527|DEVICE|Dorsal Root Ganglion Stimulation|Stimulation at L2, L3, L4 and S1 spinal levels
223867844|NCT03144674|DRUG|Parsaclisib|Parsaclisib at the protocol-defined dose.
223867845|NCT04169399|DRUG|Toripalimab|240mg intravenously every 3 weeks
223867846|NCT04169399|RADIATION|Stereotactic body radiotherapy|Radiotherapy dose was 36 \~ 54Gy, divided into 6 times of irradiation, and the radiation was performed within 2 weeks.
223867847|NCT05475106|BIOLOGICAL|Neoantigen Peptides|Patients will receive intradermal injection of individualized neoantigen peptides vaccine at a dose of \~500ug per peptide once a week for 4 weeks, and every month for 5 months after that.
223867848|NCT00597103|OTHER|Cognitive Function Testing-10 Tests|Trailmaking A, Trailmaking B, Rey Auditory Verbal Learning, Letter Number Sequencing, Digit Symbol Substitution, Grooved Pegboard, Controlled Oral Word Association, Beck Depression Index, Feeling Thermometer, Modified Mini-Mental Status
223867849|NCT00597103|OTHER|Sleep Assessment Testing|"Sleep Assessment will be performed using an Actiwatch with subjects wearing the watch for 72 hours continuously"
223867850|NCT00597103|OTHER|Periodic Leg Movement Syndrome Assessment|"Subjects will wear and Actiwatch on both legs for three consecutive nights."
223867851|NCT00995150|DRUG|LNG20|levonorgestrel-releasing intrauterine system for contraception
223867852|NCT00995150|DRUG|Mirena|Mirena intrauterine system
223867853|NCT02833272|BEHAVIORAL|EMPOWER Educational Brochure|The EMPOWER educational brochure explains the risk of benzodiazepine and non-benzodiazepine sedative use to patients with a current prescription. The brochure also provides a tapering schedule if the patient chooses to discontinue taking the drug.
223867854|NCT01463046|DRUG|Panobinostat|"Induction - 20-60 mg (1-3 20 mg capsules) PO on days 1,3,5 and 8~Second induction - 20-60 mg (1-3 20 mg capsules) PO days 1,3 and 5~Consolidation - 20-60 mg (1-3 20 mg capsules) PO on days 1,3,5 and 8"
223867855|NCT01463046|DRUG|Cytarabine|"Induction - 100 mg/m2 continuous IV daily for 7 doses on day 3-9.~Second induction - 100 mg/m2 continuous IV daily for 7 doses on day 3-7.~Dosing for consolidation - 100 mg/m2 continuous IV daily for 7 doses on day 3-9."
223867856|NCT01463046|DRUG|Daunorubicin|"Induction - 60 mg/m2 IV over 15-30 minutes daily for 3 doses on day 3-5.~Second induction - 60 mg/m2 IV over 15-30 minutes daily for 2 doses on day 3 and 4.~Dosing for consolidation - 60 mg/m2 IV over 15-30 minutes daily for 3 doses on day 3-5."
223867857|NCT05968833|BEHAVIORAL|iParent2Parent Program|iParent2Parent is an online peer support mentorship program that is based on the iPeer2Peer online peer support mentorship program, which has been established in multiple chronic disease populations as a self-management intervention, including in chronic pain and juvenile idiopathic arthritis populations. The iParent2Parent program connect parents one-to-one with other parents of pediatric kidney transplant recipients who are trained to offer vital peer support and mentorship.
223867858|NCT01373346|PROCEDURE|Long limb Roux-en Y reconstruction|After radical gastrectomy, the gastrointestinal tract was reconstructed by Roux-en-Y gastrojejunostomy or esophagojejunostomy. The jejunum was divided at approximately 100-120 cm distal to the ligament of Treitz and the distal limb of the jejunum was then anastomosed along the proximal gastric greater curvature or esophagus. The jejuno-jejunostomy was performed approximately 100 to 120 cm distal from the gastrojejunal or esophagojejunal anastomosis
223867859|NCT02964195|DRUG|Rifaximin|ALFA WASSERMANN S.p.A.
223867860|NCT05582694|BIOLOGICAL|UB-421|UB-421 is a genetically engineered IgG1/kappa humanized monoclonal antibody with binding specificity to the human CD4 receptor complex. The dose of UB-421 will be 5 mg/kg given by intravenous infusion every 1 weeks for a total of 26 doses.
223867861|NCT03934658|DEVICE|NightWare Therapeutic System|A wearable digital therapeutic system that will measure physiologic data when worn during sleep to deliver a mild vibration via the watch to elicit arousal thereby disrupting nightmares. This detection and stimulation sequence will be performed according to NightWare's proprietary algorithm.
223867862|NCT03934658|DEVICE|NightWare Therapeutic System in Sham Mode|A wearable digital therapeutic system that will measure physiologic data when worn during sleep that does not deliver interventions.
223867863|NCT01141010|OTHER|Language|Plain language without psychological intervention
223867864|NCT01141010|OTHER|Language|Psychological linguistic intervention will be given
223867865|NCT05576181|DRUG|ThisCART19A|ThisCART19A is a new type CAR-T therapy for patients with r/r B-ALL.
223867866|NCT05576181|DRUG|Fludarabine Oral Tablet|Fludarabine is used for lymphodepletion.
223867867|NCT05576181|DRUG|Cyclophosphamide|Cyclophosphamide is used for lymphodepletion.
223867868|NCT05576181|DRUG|VP-16|VP-16 is used for lymphodepletion.
223867869|NCT05576181|PROCEDURE|HSCT|Hematological stem cell transplantation
223867870|NCT04655131|DIETARY_SUPPLEMENT|Whey protein isolate|Commercially available, FDA approved whey protein isolate for dietary supplementation
223867871|NCT06225388|OTHER|Compression socks|A pair of socks corresponding to the intervention allocated will be given to the participant, by an investigator who will not participate in the evaluation, in a dark plastic bag to avoid any visual influence. We will adopt strategies to prevent information about the socks from influencing the participants' behaviour: (1) the compression and placebo socks will have the same colour, any visual detail and branding will be covered. Words or logos from the compression sock will be covered, so participants are unable to differentiate them. (2) After performing the running protocol, participants will remove their socks and return them to the investigator.
223867872|NCT06225388|OTHER|Placebo socks|The compression and placebo socks will have the same colour, any visual detail and branding will be covered. Words or logos from the compression sock will be covered, so participants are unable to differentiate them. (2) After performing the running protocol, participants will remove their socks and return them to the investigator.
223867873|NCT04148040|PROCEDURE|G-POEM|Per-oral pyloromyotomy (POP), also named as gastric per-oral endoscopic myotomy (G-POEM), for treating infantile hypertrophic pyloric stenosis (IHPS) has the following steps: mucosal incision, creation of submucosal tunnel, full-thickness pyloromyotomy, closure of the mucosal entry.
223867874|NCT04290117|BEHAVIORAL|Acceptance and Commitment Training|During the ACT-based intervention, participants will get 4 training sessions in groups, once a week for an hour. Additionally, participants will be asked to implement behavioural exercises such as mindfulness and value-based exercises into their daily schedule.
223867875|NCT04290117|BEHAVIORAL|Sleep Hygiene and bright light in the morning|During the chronobiological intervention, participants will get 4 training sessions in groups, one hour per week. Additionally, they will use a daylight lamp at home, for 30 minutes per day after waking up.
223867876|NCT03582410|PROCEDURE|laparoscopic sacral colpopexy with absorbable suture|laparoscopic sacral colpopexy to correct pelvic organ prolapse with anterior and posterior meshes with absorbable suture
223867877|NCT03582410|PROCEDURE|laparoscopic sacral colpopexy with non absorbable suture|laparoscopic sacral colpopexy to correct pelvic organ prolapse with anterior and posterior meshes with non absorbable suture
223867878|NCT03611205|PROCEDURE|Computed Tomography|Undergo dPET/CT
223867879|NCT03611205|PROCEDURE|Positron Emission Tomography|Undergo dPET/CT
223867880|NCT00971022|BEHAVIORAL|Survey|20 minute survey to determine the relationship between awareness of the discount generic prescription program and utilization of the program.
223867881|NCT00971022|BEHAVIORAL|Focus Group|5 - 8 focus groups of 6 - 10 people, lasting approximately 90 minutes
223867882|NCT00441636|DEVICE|continuous positive airway pressure (CPAP)|CPAP (Respironics: RemStar plus M-series) machines for treatment of obstructive sleep apnea training for participant required by registered sleep technologist
223867883|NCT00310154|DRUG|docetaxel|
223867884|NCT00310154|DRUG|gefitinib|
223867885|NCT00310154|OTHER|laboratory biomarker analysis|
223867886|NCT00310154|RADIATION|radiation therapy|
223867887|NCT05068362|DEVICE|Auricular reconstruction|Medpor implant for treatment of microtia
223867888|NCT03639350|BEHAVIORAL|IER+MED group|Follow a Mediterranean diet 5 days per week and follow intermittent energy restriction 2 days per week.
223867889|NCT03639350|BEHAVIORAL|DASH group|Follow the distribution of macronutrients and food groups prescribed by the DASH diet 7 days per week.
223867890|NCT00551980|BEHAVIORAL|Cognitive, Relaxation, Exercise Therapy|The intervention consists of brief shoulder and neck exercises to be performed several times a day, a relaxation exercise and instructions of how to reduce hyperfunction of the craniofacial and cervical muscles during the day
223867891|NCT05592925|DIAGNOSTIC_TEST|coagulation-related factors|We retrospectively evaluated the relationship between lymph node metastasis and coagulation-related factors in 516 patients with T4a stage gastric cancer.
223867892|NCT06491212|DIAGNOSTIC_TEST|Determination of Foot Deformity Level|One of the methods used in our study to determine the presence and degree of pes planus is the navicular drop test.
223867893|NCT06491212|DIAGNOSTIC_TEST|Foot Function Index|Evaluation of Foot Function
223867894|NCT06491212|DIAGNOSTIC_TEST|UFAA-International Physical Activity Questionnaire|To determination of physical activity level.
223867895|NCT06491212|DIAGNOSTIC_TEST|Diaphragm ultrasound measurements|Rehabilitative ultrasound imaging is a method frequently used by physiotherapists to assess muscle function.
223867896|NCT06491212|DIAGNOSTIC_TEST|NeuruCom Balance Master Balnce and Performans Test|Balance master will be used for postural stability, static and dynamic balance measurements.
223867897|NCT06491212|DIAGNOSTIC_TEST|Plantar Pressure Assessment|When assessing plantar pressure, postural control will be evaluated statically or dynamically, through examination of the behavior of the center of plantar pressure (COP).
223867898|NCT01198028|DRUG|Erlotinib|Given PO
223867899|NCT04540822|OTHER|peripheral venous catheter with compress under the catheter-extension tube junction|Placement of a BD Insyte® type catheter of 20 to 24 Gauge calibre on a peripheral vein located in the crease of the elbow or top of the hand or scalp or top of the foot. The catheter is placed while respecting the detersion and disinfection of the skin with the appropriate products and according to the procedure in force in the department. Once the venous return has been checked, a 10 cm extension with a BECTON-DIC® 3-way valve will be connected, which is previously purged with 0.9% Sodium Chloride. Under the catheter-extension tube junction will be inserted a sterile non-woven compress, cut sterilely (3.5x1.5 cm). The assembly will be held in place by a transparent sterile semi-permeable adhesive dressing such as Tegaderm® (5x7 cm). This area will be secured by placing a crepe bandage (crepe bandage 4 m x7 cm).
223867900|NCT04540822|OTHER|peripheral venous catheter without compress under the catheter-extension tube junction|Placement of a BD Insyte® type catheter of 20 to 24 Gauge calibre on a peripheral vein located in the crease of the elbow or top of the hand or scalp or top of the foot. The catheter is placed while respecting the detersion and disinfection of the skin with the appropriate products and according to the procedure in force in the department. Once the venous return has been checked, a 10 cm extension with a BECTON-DIC® 3-way valve will be connected, which is previously purged with 0.9% Sodium Chloride. No compresses will be inserted under the catheter-extension tube junction.The assembly will be held in place by a transparent sterile semi-permeable adhesive dressing such as Tegaderm® (5x7 cm). This area will be secured by placing a crepe bandage (crepe bandage 4 m x7 cm).
223867901|NCT03470662|OTHER|Care bundle|Care bundle
223867902|NCT02705183|RADIATION|Radiotherapy|Multifractionated post-operative radiotherapy, several weeks after surgery
223867903|NCT03624166|DRUG|Ketamine|patients will receive sub- anesthetic dose of ketamine 0.5 mg/kg in 3 ml of isotonic saline after spinal anesthesia
223867904|NCT03624166|DRUG|isotonic saline|patients will receive 3 ml of isotonic saline after spinal anesthesia
223867905|NCT01395758|DRUG|ARQ 197 plus erlotinib|Eligible subjects will be randomly assigned to receive erlotinib plus ARQ 197.
223867906|NCT01395758|DRUG|Pemetrexed, docetaxel or gemcitabine|Investigator's choice of a single agent chemotherapy (pemetrexed, docetaxel, or gemcitabine) administered according to the approved label.
223867907|NCT02906735|PROCEDURE|Surgery|Implantation of knee joint prosthesis or deviation osteotomies of the knee
223867908|NCT00433199|DRUG|Testosterone (T) Gel 1.62%|Testosterone gel 1.62% contains 1.62% testosterone gel as active ingredient.
223867909|NCT00433199|DRUG|Placebo|Placebo Control
223867910|NCT00893425|DRUG|ramipril|
223867911|NCT01576952|DRUG|ISV-303|Bromfenac in DuraSite
223867912|NCT01576952|OTHER|DuraSite Vehicle|DuraSite Vehicle
223867913|NCT01166152|BEHAVIORAL|social skills training|meeting once a week or biweekly to play together using toys, games, and physical exercises.
223867914|NCT06362278|OTHER|multi-omics studies|15cc peripheral venous blood will be collected for multi-omics studies, including whole-exome study, transcriptomics \& metabolomics studies.
223867915|NCT04488783|DIETARY_SUPPLEMENT|zinc and ascorbate|oral zinc and ascorbate
223867916|NCT04141865|DEVICE|Xen|Xen microstent implantation
223867917|NCT04141865|DEVICE|Aqueous shunt|Aqueous shunt implantation
223867918|NCT00705328|BEHAVIORAL|Primary Health Care Model (PRMHLTH)|Primary health care service delivery
223867919|NCT00705328|BEHAVIORAL|Recreation Coordination Model (REC)|Recreation coordination service delivery
223867920|NCT00705328|BEHAVIORAL|Comprehensive Model (COMP)|a comprehensive service delivery model consisting of PRMHLTH plus REC.
223867921|NCT00357097|DRUG|Ropinirole|
223867922|NCT00794118|OTHER|As per clinical practice|As per clinical practice
223867923|NCT06300424|DRUG|almonertinib|110mg qd
223867924|NCT06300424|DRUG|Carboplatin|AUC 5, d1 every 3 weeks
223867925|NCT06300424|DRUG|Nab paclitaxel|135 mg/m2, d1,d8 every 3 weeks
223867926|NCT00838253|DRUG|Istaroxime|Istaroxime 0.5 μg/kg/min (30 μg/kg/h) continuous i.v. infusion for 24 hours
223867927|NCT00838253|DRUG|Istaroxime|Istaroxime 1.0 μg/kg/min (60 μg/kg/h) continuous i.v. infusion for 24 hours
223867928|NCT00838253|DRUG|Istaroxime|Istaroxime 1.5 μg/kg/min (90 μg/kg/h) continuous i.v. infusion for 24 hours
223867929|NCT00838253|DRUG|Placebo|Placebo continuous i.v. infusion for 24 hours
223867930|NCT01460563|DRUG|Magnesium Sulfate|MgSO4 infusion: 50mg/kg bolus followed by continuous infusion
223867931|NCT01460563|DRUG|0.9% saline|0.9% saline as same dose as MgSO4 as placebo
223867932|NCT01460563|DRUG|0.9% saline|0.9% saline as same dose as MgSO4 as placebo
223867933|NCT06839144|DRUG|Propranolol (Beta-Blocker) and Etodolac (COX-2 Inhibitor)|"\- Intervention Arm: Propranolol (Beta-Blocker) and Etodolac (COX-2 Inhibitor). Name: Propranolol (slow-Release) and Etodolac.~Propranolol Dosage Schedule:~5 days pre-surgery: 20mg twice daily (BID), Day of surgery: 80mg BID,~1-week Post-surgery: 40mg BID, week 2-11 post-surgery: 20mg BID.~Etodolac Dosage Schedule:~5 days pre-surgery until 3 weeks post-surgery: 400mg BID.~Administration Route: Oral."
223867934|NCT06839144|DRUG|Placebo (Matching for Propranolol & Etodolac)|\- Placebo Arm: Placebo (Matching for Propranolol \& Etodolac). Inert placebo tablets matching propranolol and etodolac in appearance and dosing schedule. Administration Route: Oral.
223867935|NCT04305405|DRUG|Benralizumab|Dose will be stratified by body weight at screening: Patients will receive Dose 1 or Dose 2 of Benralizumab administered by SC injection at Day 0 and Weeks 4, 8, and 16, 24, 32, and 40.
223867936|NCT04470401|DRUG|AbobotulinumtoxinA|application of 1cc of placebo (saline) or 1cc of abobotulinumtoxinA in both subscapularis and pectoral major muscles
223867937|NCT04470401|DRUG|Saline|application of 1cc of placebo (saline) or 1cc of abobotulinumtoxinA in both subscapularis and pectoral major muscles
223867938|NCT03968354|BIOLOGICAL|"Collection of additional blood tubes; Biobanking (plasma, liver tissue)."|"* Preservation of liver tissue obtain by liver biopsy, constitution of a collection~* Sampling of additional blood tubes for a biological collection (serum): Serum biomarker research and genetic research"
223867939|NCT02647268|DRUG|Oxytocin|Oxytocin, 10-5M solution
223867940|NCT02647268|DRUG|Magnesium Sulphate|Magnesium sulphate, 3.5mM solution
223867941|NCT00371085|BEHAVIORAL|education|Video-based educational program for heart failure focus on daily weights, medication taking, and salt restriction
223867942|NCT00223587|OTHER|1 week of treatment discontinuation|1 week of treatment discontinuation during allergic rhinitis season
223867943|NCT04728724|DRUG|Sintilimab|"Neoadjuvant treatment stage: Sintilimab 200mg, q3w, i.v., 2-4 cycles, then receive chest CT evaluation.~Surgery stage: the patients will receive radical surgery after the neoadjuvant treatment.~Adjuvant treatment stage: according to the NCCN guidelines."
223867944|NCT04728724|DRUG|Chemotherapy|"Neoadjuvant treatment stage: Sintilimab 200mg, q3w, i.v., 2-4 cycles; platinum-based chemotherapy (Non-squamus: Carboplatin AUC 5 + Pemetrexed 500mg/m2; Squamous: Carboplatin AUC 5 + Gemcitabine 1000mg/m2 or Paclitaxel 200mg/m2) q3w, i.v., 2-4 cycles, then receive chest CT evaluation.~Surgery stage: the patients will receive radical surgery after the neoadjuvant treatment.~Adjuvant treatment stage: according to the NCCN guidelines."
223867945|NCT06235424|DRUG|Del Nido Cardioplegia Solution|The route of cardioplegia delivery differed according to surgeons' preferences. The total dosage of cardioplegia depends on the type of cardioplegia. The standard dose of del Nido cardioplegia in our institution is 1000 ml as an initial dose and is delivered with a system pressure of 90-150 mmHg. The solution is prepared by our hospital's pharmacy. At 60. minute of cross-clamp (XC) if XC time was expected to exceed 90 minutes another dose of solution would be delivered. The volume of an additional dose was 500 ml. The temperature of the delivered del Nido cardioplegia was 4\*C.
223867946|NCT06235424|DRUG|HTK solution|The route of cardioplegia delivery differed according to surgeons' preferences. The dose of the HTK cardioplegia is calculated with an application of 20 mL/kg rule. It is delivered with a system pressure of 90-150 mmHg. If the XC time exceeds 120 minutes additional dose is given (10 mL/kg rule). The temperature of the delivered crystalloid cardioplegia is 4\*C
223867947|NCT05560659|DRUG|177Lu-PSMA|Lutetium-177 (177Lu)-PSMA is a radiopharmaceutical comprised of a small molecule inhibitor of PSMA that binds with high affinity to PSMA, labelled with 177Lu. 177Lu has favourable characteristics for radionuclide therapy emitting both a short-range (1-2mm) cytotoxic beta-particle, minimising irradiation of non-targeted normal tissues, alongside gamma emission that allows imaging. Numerous retrospective series initially demonstrated high clinical activity and limited normal tissue toxicity using PSMA-617 and PSMA-I\&T, which are the most advanced small molecule inhibitors of PSMA, radiolabelled with 177Lu
223867948|NCT04512651|OTHER|Tibiotarsal Thrust Manipulation|The dancers were positioned in dorsal decubitus position with the heel outside the stretcher. The osteopath positioned in a lateral feint, inflected knees and forearms in the same plane as the participant's leg. With the internal hand slipped the pinky finger on the medial edge of the foot to the talus neck, the other fingers on the dorsum of the foot and the thumbs controlling the first metatarsus. The position of the talus in relation to the tibia was corrected, initially by placing the foot in eversion and then in dorsal flexion. The osteopath left the body weight behind, causing a traction in the joint. The thrust consisted of a impulse of high speed and low amplitude impulse in a caudal direction, closing the elbows20. The technique was performed until the obtainment (achieved) the joint noise only in the restricted foot, and only one service was performed. After one week, a reassessment of the painful sensation after the dance was performed.
223867949|NCT04512651|OTHER|Simulation Tibiotarsal Thrust Manipulation|Simulation of the technique Tibiotarsal Thrust Manipulation, with the participants and the osteopath positioned in the same way as the IG, however there was no reproduction of joint noise.
223867950|NCT00262730|DRUG|poly ICLC|20 mcg/kg 3x each week (Maintenance cycles)
223867951|NCT00262730|DRUG|temozolomide|daily 75mg/m2 6wks concomitant therapy Wk 1 - days 1-5 150-200 mg/m2 maintenance cycles (adjuvant)
223867952|NCT00262730|RADIATION|radiation therapy|RT: 60 Gy (6 weeks) concomitant therapy
223867953|NCT01170962|DRUG|BMS-790052|Film coated tablet, Oral, 20 mg, once daily, 24 weeks
223867954|NCT01170962|DRUG|BMS-790052|Film coated Tablet, Oral, 60 mg, once daily (divided dose taken BID), 48 weeks
223867955|NCT01170962|DRUG|Placebo|Film coated tablet, Oral, 0mg, Once daily, 24 weeks
223867956|NCT01170962|DRUG|peginterferon alfa-2a|Solution for injection, Subcutaneous injection, 180 µg, weekly, 24 or 48 weeks
223867957|NCT01170962|DRUG|ribavirin|Film coated tablet, Oral, 1,000 or 1,200 mg based on weight, divided dose taken twice a day (BID), 48 weeks
223867958|NCT03887650|DRUG|Liposomal Bupivicaine 1.3%|10mL Liposomal Bupivacaine 1.3% (133 mg) mixed with 10mL of 0.5% Bupivacaine (total volume 20mL) in single injection interscalene brachial plexus block
223867959|NCT03887650|DRUG|Bupivacaine 0.5%|20mL 0.5% Bupivacaine with 5 mg PF dexamethasone and 5 mcg epinephrine (total volume 20.5mL) in single injection interscalene brachial plexus block
223867960|NCT05454228|BEHAVIORAL|postoperative delirium|Postoperative delirium (POD) occurs within 1 week after surgery in patients, with obvious time characteristics, mainly occurring within 1-3 days after surgery. Postoperative delirium has adverse effects on the short and long term prognosis of patients. Patients with delirium have an increased risk of postoperative complications, perioperative death, longer hospital stay and increased medical costs during hospitalization.
223867961|NCT06328985|BEHAVIORAL|Rehabilitation therapy|Including:Acupuncture: Regular acupuncture treatment that can prevent muscle atrophy, improve circulation, and have a stimulating effect. Exercise therapy: Training that focused on limb movements or joint mobilization to prevent muscle contracture, reduce joint mobility, improve spasms, and promote blood circulation. Others: Regular turning, back patting, and position changes performed by caregivers.
223867962|NCT06328985|DEVICE|Intermittent Oro-esophageal Tube Feeding|Based on this, the patients in the observation group were given nutrition support with Intermittent Oro-esophageal Tube Feeding (Medical Device No. 20010234, developed by the Swallowing Disorders Research Institute of Zhengzhou University). The entire feeding process strictly followed the standard procedure of Intermittent Oro-esophageal Tube Feeding. During the feeding process, patients were maintained in a semi-recumbent position with their head elevated, facilitating the placement of the tube into the oral cavity along one side, with the chin brought close to the manubrium sterni.
223867963|NCT06328985|DEVICE|Nasogastric tube feeding|The patients in the control group were provided nutrition support with Nasogastric tube feeding, while the feeding process strictly followed the relevant guideline. During the treatment, the patients remained in a continuous state of tube indwelling, receiving feeding every 2-3 hours with a maximum feeding volume of 200ml, of which the contents were consistent with the observation group. The entire feeding process was conducted by trained nursing staff. Besides, the tube was replaced by a new one every 5-7 days.
223867964|NCT02601170|BIOLOGICAL|Platelet-Rich Plasma Intra-Articular Injection|
223867965|NCT02601170|DRUG|Hyaluronic Acid Viscosupplementation|
223867966|NCT06040697|DEVICE|Thermal Anisotropy|Usability assessment observation.
223867967|NCT06465979|BEHAVIORAL|Speech Manipulation|"The acoustic properties of speech sounds will be modified in two main ways. The first way is to introduce gradual changes to the perceived articulation of the target speech sound, such as changing from sh to s by various types of signal processing and filtering. The second type of change is to modify acoustic properties of the sounds that immediately precede the target speech sound, such as changing the speaking rate or its frequencies composition."
223867968|NCT05484297|BEHAVIORAL|Crisis Caring Contacts post cards|A series of post cards with Crisis Caring Contacts content sent over 10 months
223867969|NCT05484297|BEHAVIORAL|Control post cards|"A series of post cards intended to control for attention received but not including elements thought to be active ingredients in the intervention"
223867970|NCT06972745|PROCEDURE|Ultrabrief pulse electroconvulsive therapy|Therapeutic seizure induction with pulse unidirectional electric charge through the right hemisphere, using ultrabrief pulses (≤0.3 ms).
223867971|NCT06972745|PROCEDURE|Brief pulse Electroconvulsive therapy|Therapeutic seizure induction with pulse unidirectional electric charge through the temporal hemisferes, using brief pulses (≥0.5 ms).
223867972|NCT06974032|DRUG|Xylocaine jelly 2%|To determine if a 6cc of 2% lidocaine jelly decreases pain of paracervical block injection before IUD placement in nulliparous women
223867973|NCT06974032|DRUG|Surgilube|To determine if the placebo gel increases pain of paracervical block injection before IUD placement in nulliparous women
223867974|NCT03368664|DRUG|Alemtuzumab GZ402673|Pharmaceutical form: solution, Route of administration: IV
223867975|NCT03368664|DRUG|Glatiramer acetate|Pharmaceutical form: solution, Route of administration: subcutaneous (SC)
223867976|NCT03368664|DRUG|Beta-Interferon|Pharmaceutical form: solution, Route of administration: SC / intramuscular (IM)
223867977|NCT03368664|DRUG|Methylprednisolone|Pharmaceutical form: solution, Route of administration: IV
223867978|NCT03368664|DRUG|Ranitidine|Pharmaceutical form: tablet, Route of administration: oral
223867979|NCT03368664|DRUG|Ceterizine|Pharmaceutical form: tablet, Route of administration: oral
223867980|NCT03368664|DRUG|Dexchlorpheniramine|Pharmaceutical form: tablet, Route of administration: oral
223867981|NCT03368664|DRUG|Paracetamol|Pharmaceutical form: tablet, Route of administration: oral
223867982|NCT03368664|DRUG|Acyclovir|Pharmaceutical form: tablet, Route of administration: oral
223867983|NCT03368664|DRUG|Prednisolone|Pharmaceutical form: tablet, Route of administration: oral
223867984|NCT03368664|DRUG|Diphenydramine|Pharmaceutical form: solution, Route of administration: IV
223867985|NCT03368664|DRUG|Other H1 antagonist|Pharmaceutical form: solution, Route of administration: IV
223867986|NCT03368664|DRUG|Other H1 antagonist|Pharmaceutical form: tablet/pill, Route of administration: oral
223867987|NCT05132842|OTHER|Survey Administration|Complete a Survey
223867988|NCT00837616|DRUG|17 B estradiol orally|Group A will be given estrogen by mouth daily(0.5 mg or 1mg or 2 mg of 17B Estradiol. Doses will vary depending on the blood levels of estrogen starting with the lower doses and adjusting these doses up as needed to keep the levels in the normal range. The estrogen will be taken for 21 days. In order to have a menstrual cycle progesterone will be given for 7 days, starting from day 14 through day 21 of each cycle. Then both medications are stopped on day 21 for a total of 7 days. Labs will be obtained at baseline, 1,2,3,6,9 and 12 months. Dual-energy X-ray absorptiometry (DXA) scan and calorimetry will be done at baseline and at 6 and 12 month.
223867989|NCT00837616|DRUG|17 B estradiol|Group B will be given estrogen via a patch applied to the skin twice a week (0.375mg or 0.05mg or 0.075mg) Doses will vary depending on the blood levels of estrogen starting with the lower doses and adjusting these doses up as needed to keep the levels in the normal range. The estrogen will be taken for 21 days. In order to have a menstrual cycle progesterone will be given for 7 days, starting from day 14 through day 21 of each cycle. Then both medications are stopped on day 21 for a total of 7 days. Labs will be obtained at baseline, 1,2,3,6,9 and 12 months. Dual-energy X-ray absorptiometry (DXA) scan and calorimetry will be done at baseline and at 6 and 12 month.
223867990|NCT00562679|OTHER|There is no intervention|
223867991|NCT00956982|DRUG|Pegylated interferon alpha-2b plus ribavirin|All patients were treated with a weight-based, 1.5 μg/kg weekly dose of subcutaneous PEG-IFN alpha-2b (PegIntron A, Schering-Plough, Osaka, Japan), in combination with PEG-IFN alpha-2b, RBV (Rebetol; Schering-Plough), which was given orally at a daily dose of 600-1000mg based on bodyweight (600 mg for patients weighing \< 60 kg, 800 mg for those weighing 60-80 kg, and 1000 mg for those weighing 80 kg). The length of treatment was 48 weeks for patients with HCV of genotype 1and 24 weeks for patients with genotypes 2, respectively
223867992|NCT04448418|OTHER|web based survey|Assess specific health care needs for the transpopulation during the COVID-19 outbreack using a newly created questionnaire and some validated questionnaries (Impact of Event Scale-Revised, BECK Depression Inventory and the Self-rated Health SF-12)
223867993|NCT01145248|DEVICE|double-balloon enteroscopy forceps biopsy|An endoscopic retrograde cholangiography (ERC) with a duodenoscope Olympus TFJ 160-R (Olympus Corp., Tokyo, Japan) and endoscopic sphincterotomy with an Olympus papillotome (Olympus) is performed under analgosedation . Then, the cannulation of the bile duct is performed by a pusher using a guidewire/guiding catheter. Subsequently, 2 histology samples are taken via a double-balloon enteroscopy (DBE) forceps (BF1725DF, Fujinon GmbH, Willich, Germany), which is placed under the guidance of the pusher.
223867994|NCT01145248|DEVICE|Transpapillary brush cytology|An endoscopic retrograde cholangiography (ERC) with a duodenoscope Olympus TFJ 160-R (Olympus Corp., Tokyo, Japan) and endoscopic sphincterotomy with an Olympus papillotome (Olympus) is performed under analgosedation . The region of interest is then brushed five times in both directions to obtain cytology specimen.
223867995|NCT01010919|DIETARY_SUPPLEMENT|Chicory root extract|
223867996|NCT00295074|PROCEDURE|neuropsychologic testing|
223867997|NCT02214693|DRUG|DA-1229|
223867998|NCT00028093|DRUG|Peginterferon alfa-2a with Ribavirin|Eligible patients were given peginterferon alpha-2a, 180 ug subcutaneous once weekly and weight-based oral ribavirin (1000 mg daily for patients \<75 kg and 1200 mg daily for patients \>=75 kg) for 48 weeks
223867999|NCT00028093|DRUG|Peginterferon alfa-2a|Eligible patients were given peginterferon-alpha-2a, 180 ug subcutaneous once weekly for the first 4 weeks of therapy, after which peginterferon was continued at the same dose and weight-based oral ribavirin was added and continued for an additional 44 weeks.
223868000|NCT00042224|PROCEDURE|Electroconvulsive Therapy (ECT)|ECT will be used to augment clozapine in schizophrenic patients who continue to have psychotic symptoms despite optimal treatment with clozapine.
223868001|NCT00042224|DRUG|Clozapine|Patients with psychotic symptoms will receive clozapine
223868002|NCT00777816|DRUG|XOMA 052|A single dose of study drug on Day 0, administered either as an intravenous (IV) infusion or as a subcutaneous (SC) injection.
223868003|NCT00777816|DRUG|Placebo|A single dose of placebo on Day 0, administered either as an intravenous (IV) infusion or as a subcutaneous (SC) injection.
223868004|NCT05664100|DRUG|FX-345|Single intratympanic injection of FX-345
223868005|NCT05664100|DRUG|Placebo|Single intratympanic injection of placebo
223868006|NCT04998903|PROCEDURE|Fiberoptic Bronchoscopy|Fiberoptic bronchoscopy done under conscious sedation
223868007|NCT04407780|OTHER|No interventions are planned|Non applicable
223868008|NCT04645394|DIETARY_SUPPLEMENT|Aronia melanocarpa|Administered once (acute study)
223868009|NCT04645394|DIETARY_SUPPLEMENT|Fermented Aronia Melanocarpa high dose|Administered once (acute study)
223868010|NCT04645394|DIETARY_SUPPLEMENT|Fermented Aronia Melanocarpa low dose|Administered once (acute study)
223868011|NCT04645394|DIETARY_SUPPLEMENT|Placebo|Administered once (acute study)
223868012|NCT05744206|OTHER|Electrocardiogram measurements by holter device and patch-type electrocardiographic at the same time|The patient is measured electrocardiogram simultaneously through a holter device and patch-type electrocardiograph
223868013|NCT01456078|DRUG|177Lu-DOTA-TATE|"177Lu-DOTA-TATE given as intravenous infusion given during 3-5 treatments. Evaluation is performed after every single cycle. Further more, evaluation is made after last cycle, and delivered cumulative dose to kidneys should be 27 Gy.~Patients with stable disease or partial response, and without pronounced toxicity will continue treatment to a step 2, where additional 3-5 treatment cycles are given, with a cumulative dose to kidneys to 40 Gy."
223868014|NCT01526642|DEVICE|Non Invasive Ventilation|NIV during night
223868015|NCT03915613|DRUG|Humulin R|"The investigator and/or designee will instruct the study participant on how the intranasal insulin spray should be administered. Each study participant is to receive a single dose of Humulin R 160 U.~The nasal spray bottles provide a deliverable volume of 0.1 mL/spray. Humulin R insulin will be sourced as 100 units/mL in a vials of 10 mL from Eli Lilly. 16 sprays in alternating nostrils (8 per nostril) will be administered per dose."
223868016|NCT03915613|DRUG|Diluent|"The investigator and/or designee will instruct the study participant on how the intranasal placebo spray should be administered. Each study participant is to receive a single dose of placebo.~The nasal spray bottles provide a deliverable volume of 0.1 mL/spray. Diluent will be sourced as 10 mL/vial from Eli Lilly. 16 sprays in alternating nostrils (8 per nostril) will be administered per dose."
223868017|NCT01165658|RADIATION|Proton Therapy|The regimen of 45 Gy in 15 fractions will be delivered as a baseline, and then the fraction size will be escalated in two different intervals of 0.5 Gy each, with the ultimate dose being 60 Gy in 4 Gy fractions.
223868018|NCT01559519|DRUG|Albumin|albumin 20% 1 g/Kg body weight for the first two days after TIPS followed by 0,5 g/Kg body weight at day 4 and then 0,5 g/Kg body weight once a week for three weeks.
223868019|NCT01656096|DEVICE|Renal sympathetic denervation (Symplicity ablation catheter, Medtronic Inc. Minneapolis, Minnesota, USA)|
223868020|NCT01656096|OTHER|Sham procedure|
223868021|NCT01597258|DRUG|Crizotinib (Xalkori)|"XALKORI® Capsule 200 mg／XALKORI® Capsule 250 mg This surveillance is all cases surveillance based on Japanese regulation. Frequency and duration are according to Package Insert as follows.  The recommended dose schedule of crizotinib is 250 mg taken orally twice daily. Dosing interruption and/or dose reduction may be required based on patients' clinical status. "
223868022|NCT04210765|DRUG|Clomiphene Citrate|Clomiphene citrate used in incremental doses in nonresponsive cases.
223868023|NCT04114968|OTHER|GP-based screening or HPV self-sampling|Women in the intervention group will receive an invitation for HPV-based cervical cancer screening by either 1) scheduling an appointment for a cervical cytology by the GP or 2) collect a cervico-vaginal sample themselves in their own home using a self-sampling kit.
223868024|NCT03772379|DEVICE|tooth borne hyrax expander|ready made four stainless steel bands will be supported on the first premolars and first permanent molars and to which the palatal expander will be soldered to form the Hyrax,.The appliance will be activated one quarter turn per day untill reaching maximum amount of lateral expansion of the jack screw. the patients will be recalled twice per week to evaluate the progress of treatment.
223868025|NCT03772379|PROCEDURE|microosteoperforation|"ready made four stainless steel bands supported on the first premolars and first permanent molars and to which the palatal expander will be soldered to form the Hyrax.No activation will be provided to the hyrax expander before the micro-osteoperforation is performed.~Microosteoperforation will applied bilaterally on the buccal surface between the roots of teeth at the level of mucoginival junction, starting from the distal of canine till the distal of the first permanent molar using a small sized surgical bur mounted on a hand piece ."
223868026|NCT00001063|DRUG|Stavudine|
223868027|NCT00001063|DRUG|Zidovudine|
223868028|NCT00001063|DRUG|Didanosine|
223868029|NCT06028984|DEVICE|Intervention app|An app-based intervention for depression
223868030|NCT06028984|OTHER|Control app|An app with non-therapeutic content
223868031|NCT01470040|DRUG|discontinuation of aspirin therapy|discontinuation of aspirin therapy
223868032|NCT01470040|DRUG|continuation of aspirin therapy|continuation of pre-injury low dose aspirin therapy as per previous medical indication
223868033|NCT04425616|OTHER|Exercise|"At least one and up to three supervised sessions per week including:~* aerobic exercise at a rating of perceived exertion of 11-14 (6-20 scale) accumulating 20 minutes per session~* resistance exercise of 8-10 exercises for 2x 8-15 repetitions performed in a controlled manner and covering the whole body~* Range of motion exercise performed through pain free range of motion covering the whole body to be maintained in good alignment for 10-30 seconds, with some movements held for a second set of 10-30 seconds if stiff"
223868034|NCT04425616|BEHAVIORAL|Psychological and Behaviour Change Support|Instructors will be trained in Healthy Conversation Skills (HCS), Making Every Contact Count (MECC) or equivalent. This will enable them to deliver brief participant centred empowering interventions informed by social cognitive theory. This skill set will be used to support participants in adopting and maintaining the prescribed exercise and diet programme as well as adopting and practicing strategies to self-manage psychological well-being. Participants will be given the option to be provided with a SMARTER goal setting sheet to assist with goal planning. Applicable standardised psychological support resources will be made available to the participants though the Macmillan resource repository that they can access online or in alternative format as necessary, for example relaxation and mindfulness exercises
223868035|NCT04425616|OTHER|Nutrition|Instructors will receive training in generic nutritional principles in line with recommendations from World Cancer Research Fund (WCRF) and British Dietetic Association, and will work with participant to review own diet and eating habits against WCRF recommendations to enable goal setting and identify links to existing resources reputable websites, outputs and on-line forums. These would include: principles of healthy eating ('eat well' advice), weight management, symptom management, prehab advice before treatment starts, rehab advice during and after treatment. The participant will be asked if they are eating and drinking well or have any concerns at the beginning of each exercise session. Further support will be provided to instructors to address participant concerns or requests for additional information.
223868036|NCT06615869|DRUG|Molnupiravir|Oral Administration.
223868037|NCT04861532|DIAGNOSTIC_TEST|Imaging|MRI scanning using new protocols
223868038|NCT06859762|DRUG|YL217|Patients will be treated with YL217 intravenous(IV)infusion.
223868039|NCT06859762|DRUG|YL217|Patients will be treated with YL217 intravenous(IV)infusion.
223868040|NCT06859762|DRUG|YL217|Patients will be treated with YL217 intravenous(IV)infusion.
223868041|NCT06668467|BEHAVIORAL|Mindfulness-based Stress Reduction|An 4-week Mindfulness-based stress reduction training programme
223868042|NCT06615375|BIOLOGICAL|Shigella4V2|Shigella4V2 is a tetravalent bioconjugate vaccine
223868043|NCT06615375|BIOLOGICAL|Placebo|Phosphate-buffered saline
223868044|NCT06383442|OTHER|L-HIIT|the long-interval HIIT group (4 × 4 min Exercise/4 min Rest)
223868045|NCT06383442|OTHER|M-HIIT|the medium-interval HIIT group (8 × 2 min Exercise /2 min Rest)
223868046|NCT07019506|OTHER|Cardiac rehabilitation|Sessions are conducted individually in accordance with cardiac rehabilitation guidelines, with a frequency of 2-3 times per week, each lasting 1 hour. Intensity is progressively increased on a weekly basis, with adaptations made according to each patient's specific needs. A total of 20 sessions are delivered, focused on improving the patient's cardiovascular capacity
223868047|NCT06630390|DRUG|Daridorexant 50 mg|Administered consistent with labeling from the US Food and Drug Administration.
223868048|NCT06630390|OTHER|Placebo|Identical appearing to daridorexant
223868049|NCT06630546|DEVICE|first generation iStent (Glaukos, San Clemente, CA, USA) insertion|In glaucoma patient who needed to receive cataract surgery, a standard phacoemulsification procedure was performed, along with the implantation of a foldable posterior chamber intraocular lens (PCIOL). Then, in adequate patient who wish to receive iStent insertion, we further inserted a preloaded micro-bypass stent (model GTS100L) through the temporal corneal incision into the nasal Schlemm's canal and checked the position. Adequate intraocular pressure (IOP) was assessed by palpation at the end of the surgery.
223868050|NCT06630546|DEVICE|phacoemulsification|A standard phacoemulsification procedure was performed, along with the implantation of a foldable posterior chamber intraocular lens (PCIOL).
223868051|NCT05909722|DIAGNOSTIC_TEST|Gastrointestinal Dysfunction Score will be calculated|We collect routine daily data on GI signs and symptoms and calculate the score (GIDS). We collect serum phosphate values as measured in routine practice of participating sites.
223868052|NCT06302101|BEHAVIORAL|chair-based exercises|"Synchronous online telerehabilitation chair-based exercises will be performed under the supervision of a physiotherapist twice a week for 8 weeks for intervention group.~The control group will be given a brochure with explanations of the exercises."
223868053|NCT06302101|BEHAVIORAL|cognitive exercises|Cognitive exercises will be performed under the supervision of a physiotherapist 1 day a week for 8 weeks as online telerehabilitation for intervention group.
224076519|NCT01936532|DRUG|MLN9708|"Induction therapy Patients will receive 3 cycles of induction therapy with MLN9708 (4 mg) on Days 1, 8 and 15, plus Lenalidomide (25 mg) on Days 1 through 21 and Dexamethasone (40 mg) on Days 1, 8, 15 and 22 of a 28-day cycle.~Consolidation therapy~* Early consolidation (consolidation part 1) will comprise 2 cycles of MRD identical to induction therapy.~* Late consolidation (consolidation part 2) will consist in 6 additional cycles of MLN9708 (4 mg on Days 1, 8 and 15) plus lenalidomide (25 mg on Days 1 through 21) of a 28-day cycle.~Maintenance therapy MLN9708 monotherapy (4 mg/day), will be given on days 1, 8 and 15 of a 28 day cycle, during 12 months."
224076520|NCT01936532|DRUG|Lenalidomide|
223868054|NCT06126601|OTHER|Pancreatectomy|"Patients who underwent pancreatectomy will be enrolled. Serum amylase and lipase will be measured preoperatively. During surgery, blood samples will be taken after completing the pancreatic anastomosis and at the end of the operation during skin suture. Patients will be followed up during hospital stay, 3 and 6 months after discharge. The clinical outcome (complications, rescue pancreatectomy) will be recorded and analysed.~Postoperative blood samples, according to clinical standard, will be taken at the 1, 2, 3, 5 and 7 day postoperatively. In addition to amylase several more parameters will be examined intra- and postoperatively: leucocytes, lipase, CRP, bilirubin, transaminases, AP, GGT, creatinine, interleukin-6, PCT. Intraoperative 1-2ml of pancreas juice will be taken for the evaluation of amylase and lipase levels."
223868055|NCT06245954|OTHER|simulated training|Simulation training of bronchoscopists by means of simulators and extracorporeal lungs
223868056|NCT06245954|OTHER|traditional bedside teaching|TBLC training for bronchoscopists through traditional lectures, hands-on demonstrations
223868057|NCT02964611|BEHAVIORAL|Observational Study|This is an observational study.
223868058|NCT05054309|DIETARY_SUPPLEMENT|Bifidobacterium longum|A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Effects of Bifidobacterium Longum NCC3001 on Intestinal and Psychological Symptoms in Subjects With Irritable Bowel Syndrome
223868059|NCT04095221|DRUG|Prexasertib|"DOSE LEVELS FOR PATIENTS \> 21 YEARS OF AGE, Dose Level -1, prexasertib 105 mg/ m2 once every 14 days in 28 day cycles Dose Level 0, 60 mg/m2 prexasertib once every 21 days Dose Level 1, (STARTING) 80 mg/m2 prexasertib once every 21 days Dose Level 2, 105 mg/m2 prexasertib once every 21 days Dose Level 3, 105 mg/m2 prexasertib once every 21 days~DOSE LEVELS FOR PATIENTS ≤ 21 YEARS OF AGE Dose Level -1, prexasertib 150 mg/ m2 once every 14 days in 28 day cycles, Dose Level 0, 60 mg/m2 prexasertib once every 21 days, Dose Level 1, (STARTING) 80 mg/m2 prexasertib once every 21 days, Dose Level 2, 150 mg/m2 prexasertib once every 21 days, Dose Level 3, 150 mg/m2 prexasertib once every 21 days"
223868060|NCT04095221|DRUG|Irinotecan|15 mg/m2 IV daily x 10 days in 21 day cycles
223868061|NCT02582593|DEVICE|MedX 1116 Rehab Console|This intervention makes use of transcranially applied near infrared light using light emitting diodes. Near infrared light will be applied to the scalp for a period of 1 hour at each session. A total of six session will be held.
223868062|NCT02582593|DEVICE|Sham MedX 1116 Rehab Console|This intervention makes use of sham transcranially applied near infrared light using light emitting diodes. Light emitting diodes (but not near-infrared light) will be applied to the scalp for a period of 1 hour at each session. A total of six session will be held.
223868063|NCT04263792|DRUG|[18F]fluoropropyl-trimethoprim|\[18F\]Fluoropropyl-Trimethoprim, also known as \[18F\]F-TMP, is a radiolabeled imaging agent for positron emission tomography (PET/CT).The use most relevant to this protocol is for imaging bacterial infection in human subjects. The parent compound, trimethoprim (TMP) is a well-known, safe, broad-spectrum, synthetic, small molecule antibiotic that has been used clinically for over 50 years for the treatment of acute bacterial infection and has been combined with sulfa-based antibiotics (Bactrim/Septra) for bacterial infection prophylaxis especially in the lung and bladder. An immediate clinical use for TMP radiotracers is imaging of pathologic bacteria that are the cause of human infection.
223868064|NCT05363137|OTHER|Chatbot Assistant|The physiotherpy treatment will be supervised via chatbot
223868065|NCT05363137|OTHER|Standard care|The physiotherpy treatment will be standard care
223868066|NCT05051436|DRUG|Mirabegron 50 MG|Mirabegron 50 mg/day will be administered for 14 weeks.
223868067|NCT05051436|DRUG|Tadalafil 10 MG|Tadalafil 10 mg/day will be administered for 14 weeks after baseline procedures.
223868068|NCT05051436|DRUG|Placebo|Placebo will be administered for 14 weeks after baseline procedures.
223868069|NCT06126510|DRUG|Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell)|VG161:1.0×10\^8PFU/day, intratumoral injection administration for 3 consecutive days, 28 days as a cycle
223868070|NCT05700006|DRUG|Aromatase inhibitor|Standard of care anastrozole, exemestane, or letrozole
223868071|NCT05681884|DRUG|Faricimab|Faricimab is a humanized bispecific antibody binding to human Ang-2 and VEGF. For Phase III studies, the Ro 686-7461 drug product is provided in single-dose 2-mL glass vials (6 mg/0.05 mL) with L-histidine/acetate buffered solution (approximately pH 5.5) containing sodium chloride, sucrose, L-methionine, polysorbate 20, and water for injection.
223868072|NCT06833203|DRUG|Amantadine+ Pregabalin|Two hours preoperative, patient will receive two capsules, one of them is Amantadine (Amantadine Hydrochloride) 100 mg and the other is Pregabalin (Lyrica) 75 mg and continued on both of them twice daily for 5 days postoperative.
223868073|NCT06833203|DRUG|Pregabalin|Two hours preoperative, the patient will receive two capsules, one of them is pregabalin 75 mg, and the other is a placebo capsule similar to the amantadine capsule and continued on both of them twice daily for 5 days postoperative.
223868074|NCT06833411|DRUG|Prednisone|Participant randomization to receive shortened (8 weeks) glucocorticoid taper upon initiation of a glucocorticoid-sparing agent.
223868075|NCT06833411|DRUG|Prednisone|Participant randomization to receive standard (26 weeks) glucocorticoid taper upon initiation of a glucocorticoid-sparing agent.
224076521|NCT01936532|DRUG|Dexamethasone|
224076522|NCT06463067|BEHAVIORAL|playing mobile game|Changes in anxiety levels were measured by playing a mobile game to children before dental examination.
224076523|NCT06463067|BEHAVIORAL|reading book|Changes in anxiety levels were measured by reading books to children before dental examination.
224076524|NCT06463067|BEHAVIORAL|watching video|Changes in anxiety levels were measured by showing a video to children before dental examination.
224076525|NCT06463067|BEHAVIORAL|tell-show-do group|Before the dental examination, the tell-show-do technique was applied to the children and the changes in their anxiety levels were measured.
224076526|NCT01573273|DRUG|Oxytocin|intranasal administration, 40 IUs
224076527|NCT01573273|DRUG|Saline|intranasal administration, 40 IUs
223868076|NCT06732778|OTHER|Pain Neuroscience Education (PNE)|"PNE was planned online for clients 1 week before menstruation in the form of speaking sessions in a presentation format. The training will be conveyed in relation to pain during menstruation. Visual aids, examples and metaphors will be used to improve patient understanding in the training. Ankle sprain picture, speeding bus picture, action potential picture, picture showing membrane resting potential, rusty nail picture, whole body nervous system picture, neuromatrix picture, lion and lion cub picture that helps explain stress responses, curious neighbors picture etc. will be used. The training session is planned to last between 2 and 4 hours.~The distribution of pain neuroscience training topics will be implemented in the order given below, with 10 main headings.~* Pain and the Biopsychosocial Model~* Injury and pain are not equivalent, pain is a brain output rather than an input~* Action potential, normal electrical activity of nerves and conduction~* Biological process of ion chann"
223868077|NCT06732778|OTHER|Control Group (CG)|The control group will not receive any training or practice.
223868078|NCT06499324|DRUG|BTA group|It consists of a blind injection of 288 IU (/144mL) of BTA (XEOMIN®) into the lateral muscles (18 injection sites, 16UI/8mL/injection site), 4 to 6 weeks before the treatment of a large anterior IH (width ≥ 10 cm) with open non absorbable mesh repair. The injection of BTA (XEOMIN®) will be done during an outpatient hospitalization, in each of the 3 lateral muscles of the abdomen on each side. To do this in the BTA group, 3 vials of 100 equivalent IU of BTA (XEOMIN® 100U), diluted to 2 IU/mL with 0.9% saline will be distributed in 3 syringes of 50 mL equipped with a 21G needle. A total of 72 mL of BTA solution (144 IU) will be injected on each side, at 3 injection points between the costal rim and iliac crest, under ultrasound control.
223868079|NCT06499324|DRUG|Placebo group|It consists of a blind injection of placebo of BTA (XEOMIN® 100U matching placebo) into the lateral muscles (18 injection sites, 8mL/injection site), 4 to 6 weeks before the treatment of a large IH (width \>= 10 cm) with open non absorbable mesh repair. The injection of placebo of BTA (XEOMIN® 100U matching placebo) will be done during an outpatient hospitalization, in each of the 3 lateral muscles of the abdomen on each side. To do this in the control group, 3 vials of placebo of BTA (XEOMIN® 100U matching placebo), diluted with 0.9% saline will be distributed in 3 syringes of 50 mL equipped with a 21G needle. A total of 72 mL of placebo of BTA solution will be injected on each side, at 3 injection points between the costal rim and iliac crest, under ultrasound control.
223868080|NCT06832761|BEHAVIORAL|Personalized lifestyle intervention|The lifestyle intervention in Group A comprises three parts (1) three individual consultations with a trained lifestyle coach, (2) a voucher program to encourage brain healthy activities, and (3) access to an online self-management tool for dementia risk reduction (www.breinzorg.nl).
223868081|NCT06831253|OTHER|injections of Platelet-Rich Plasma in lacrimal gland|injections of Platelet-Rich Plasma in lacrimal gland
223868082|NCT04897880|DRUG|Panobinostat|Panobinostat capsules, 10mg, starting at a de-escalated dose of 8mg/m2 per day
223868083|NCT04084223|OTHER|Ultrasound|"An Ultrasound exam (not performed in routine care) will be performed at Baseline, 1, 3 and 6 months for protocol.~All patients will also have CRP dosage (for DAS28 assessment), RAPID-3 and PROs (performed in routine care but analyzed for the study)."
223868084|NCT05250310|BEHAVIORAL|Chair Yoga|Yoga poses performed in a chair
223868085|NCT05252884|DIAGNOSTIC_TEST|calcium correction according to PTH levels|A PTH blood test will be performed 4 hours post-thyroidectomy. If the PTH result is \>15 pg/mL, the patient will be discharged without calcium intake; if PTH \< 15 pg/mL, start a dose of 1200 mg Calcium carbonate every 8 hours + 0.25 mcg of calcitriol every 12 hours orally for 15 days
223868086|NCT05252884|DRUG|routine postoperative calcium and calcitriol|The patient will receive a dose of 1,200 mg Calcium carbonate every 8 hours + 0.25 mcg of calcitriol every 12 hours orally for 15 days, starting on the same day as the intervention.
223868087|NCT05465187|OTHER|Non applicable|Non applicable
223868088|NCT03400085|OTHER|mHealth application|The intervention is an mHealth smartphone application designed for living kidney donors to complete their required 2-year follow-up. It allows the donor to input the answers to the clinical survey responses, as well as upload a picture of their lab values.
223868089|NCT05240586|PROCEDURE|pharmacopuncture therapy|This is a pragmatic RCT, so the physicians will choose the type and volume of pharmacopuncture according to participants' conditions.
223868090|NCT05240586|PROCEDURE|acupuncture therapy|This is a pragmatic RCT, so the physicians will choose the type and number of acupuncture therapy according to participants' conditions.
223868091|NCT05240586|PROCEDURE|physical therapy, medication(prn)|This is a pragmatic RCT, so the physicians will choose the type and time of physical therapy according to participants' conditions. According to clinical judgment, clinicians can prescribe analgesics and muscle relaxants if necessary.
223868092|NCT06232304|BEHAVIORAL|TEACH|TEACH is a cognitive behavioral coping skills program. It consists of six one-hour weekly sessions that are conducted either in-person or remotely.
223868093|NCT03215095|DRUG|Durvalumab (Medi4736)|durvalumab 1500 mg IV every 4 weeks
224076528|NCT03973281|DEVICE|Materna Prep Device|Materna Prep Device
223868094|NCT03215095|RADIATION|Radioiodine (RAI)|100 mCi (+/- 10 mCi) of 131I will be administered a day after Thyrogen injections have been administered for two consecutive calendar days.
223868095|NCT03927027|DRUG|Isosulfan Blue|Given SC
223868096|NCT03927027|PROCEDURE|Axillary Lymph Node Dissection|Undergo ALND
223868097|NCT03927027|PROCEDURE|Mapping|Undergo ARM
223868098|NCT03927027|OTHER|Quality-of-Life Assessment|Ancillary studies
223868099|NCT03927027|OTHER|Questionnaire Administration|Ancillary studies
223868100|NCT06409299|DRUG|Azithromycin 40 MG/ML|Maintenance Antibiotic treatment
223868101|NCT06409299|OTHER|Placebo|Placebo
223868102|NCT00925899|DRUG|Melatonin|20 mg melatonin orally every evening about 1 hour before bedtime for one week. After having participated in the cross-over part of the trial (one week of melatonin followed by one week of placebo, or the other way around), the participant may receive melatonin for 6 weeks.
223868103|NCT00925899|DRUG|Placebo|Placebo tablet orally every evening about one hour before bedtime for one week. After having participated in the cross-over part of the trial (one week of placebo followed by one week of melatonin, or the other way around), the participant may receive melatonin for 6 weeks.
223868104|NCT05627336|DIAGNOSTIC_TEST|pregnant women in the 3rd trimester|Pregnant women who are in their third trimester and will give birth in the clinic will form the study group. These pregnant women will be measured by applying a set of questionnaires to measure their fear of childbirth.
223868105|NCT01234363|DEVICE|Magnetic Resonance Elastography, and Supersonic Shear Imaging|Magnetic Resonance Elastography, and Supersonic Shear Imaging
223868106|NCT01875848|DRUG|buprenorphine/naloxone|partial opioid agonist
223868107|NCT01875848|DRUG|opioid dose escalation|up to 25% increase in patient's current opioid dose
223868108|NCT00030238|DRUG|Calcium supplement|Calcium Carbonate capsules prepared by NIH PDS
223868109|NCT00030238|DRUG|Placebo|Placebo capsules prepared by the NIH PDS to be identical to Calcium Carbonate capsules
223868110|NCT03724578|DRUG|Grape Seed Extract mouth wash|participants will use grape seeds extract mouth wash in addition to standard preventive measures
223868111|NCT03724578|DRUG|standard preventive measures|twice daily brushing with fluoride tooth pate and daily flossing
223868112|NCT03724578|DRUG|antimicrobial and fluoride mouth wash|using chlorhexidine and fluoride containing mouth wash
223868113|NCT04581733|DRUG|MT1621|All patients will receive MT1621 up to a target dose of 400 mg/kg/day each dC and dT, as tolerated.
223868114|NCT05099549|DRUG|AFM24|Tetravalent, bispecific EGFR- and CD16A-binding innate cell engager.
223868115|NCT05099549|BIOLOGICAL|SNK01|Patient-specific ex-vivo expanded autologous natural killer cells.
223868116|NCT02189252|DRUG|Epanova|
223868117|NCT02189252|DRUG|Lovaza|
223868118|NCT03941119|OTHER|VR-therapy|Wearing a Virtual Reality head mounted device allows the user to become immersed in a virtual environment. We have assembled a library of 3-10 minute 360-degree films from a variety of nature settings. The VR films were intentionally chosen to be calming in distinctive ways, as supported by the literature around nature visualization and wellbeing. By varying 1) the lengths of the films (3, 5, and 10 minutes), 2) the types of natural elements (greenery, earth, sky, water), 3) distance of view (close-ups, vistas), 4) motion (flowing water, wind in trees), 5) sound, and 6) presence of different elements (humans/animals, scenery, urban sites, etc.), the content provides a wide range of attributes that can be collaboratively selected by the individual, caregiver, or health care provider for each individual. We will display these films on commercially available VR equipment and will provide audio matching the film using commercially available headphones.
223868119|NCT06278870|DRUG|disitamab vedotin|disitamab vedotin 2mg/kg iv q2w
223868120|NCT06278870|DRUG|Pyrotinib|pyrotinib 400mg po q28d
223868121|NCT06278870|DRUG|trastuzumab|trastuzumab 8mg/kg for the first cycle, 6mg/kg for subsequent treatments iv q21d
223868122|NCT06278870|DRUG|Pertuzumab|pertuzumab 840mg for the first cycle, 420mg for subsequent treatments iv q21d
223868123|NCT06278870|DRUG|taxane drug|Docetaxel/paclitaxel/albumin paclitaxel/liposomal paclitaxel, dosage and administration are determined according to the latest version of the NCCN and CSCO breast cancer guideline recommendations
223868124|NCT00840177|DRUG|cytarabine|1.5 g/m2/day given by continuous IV on days 4-7
223868125|NCT00840177|DRUG|idarubicin|12 mg/m2/day given intravenously over 10-15 minutes on days 4-6
223868126|NCT00840177|DRUG|pravastatin sodium|1,280 mg/day given orally on days 1-8
223868127|NCT01391832|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|For the sham rTMS with CPT group, the rTMS coil will be placed over the right prefrontal scalp region with the MagStim Rapid Stimulator set to the sham mode so that all conditions are similar to the active delivery mode except that transcranial magnetic stimulation is not administered to the scalp and does not down modulate the right frontal lobe.
223868128|NCT01391832|BEHAVIORAL|Cognitive Processing Therapy|Cognitive Processing Therapy (CPT) is a 12 session evidenced based, trauma-focused treatment for PTSD. CPT is a cognitive therapy based on information processing theory and includes components which help the client to (a) access her or his memory of the event, (b) identify and experience her or his emotions until they have been extinguished, and (c) identify and challenge beliefs about the event itself and beliefs about self and the world which have been altered because of the combat related trauma.
223868129|NCT01391832|DEVICE|Repetitive Transcranial Magnet Stimulation (rTMS)|For the active rTMS with CPT group, the rTMS coil will be placed over the right prefrontal scalp region with the MagStim Rapid Stimulator set to the active mode. After motor threshold determination, the stimulator coil is positioned over the dorsolateral prefrontal cortex - DLPFC (Brodmann Area 9/46). The right frontal rTMS will safely, reversibly, and temporarily down modulate the right frontal lobe. The conducting coil is placed over the scalp while electrical current pulses pass through the coil. This alternating current turned on and off rapidly produces magnetic pulses (1.5-2.0 Tesla strength) that last for 100 - 300 microseconds. The time-varying magnetic pulses induce an electrical field that will result in current flow in neural tissue, thereby activating or deactivating cortex subjacent to the coil.
223868130|NCT01510236|BEHAVIORAL|Self-help program|The program is available via an internet platform (www.carebase.se) and consists of two steps: interactive support (Step 1) and cognitive behavioral therapy (CBT) delivered via internet (2). Step 1 provides information about the cancer experience and psychoeducation about frequent reactions and distress and how to manage this. The information and education is provided via texts, audio files, and video-interviews with persons who have survived cancer during adolescence. Step 1 also capitalizes on interaction between participants via chat and forum. There is also a possibility to ask questions to an expert via the website. Twenty-eight weeks after start of Step 1 participants are offered access to Step 2 which lasts ten weeks and consists of a self-help CBT material consisting of modules and weekly contact with a psychologist. Each module is focused on one problem area, e.g. worry or depressive symptoms. Step 1 is available during Step 2. The whole program lasts for 34 weeks.
223868131|NCT04925336|OTHER|Nociceptive stimulation|"These investigations in healthy volunteers will study the association between cerebral and neurovegetative (sympathetic and parasympathetic) electrophysiological responses in response to a controlled and tolerable pain stimulus, determined for each individual. The pain stimulus will be delivered using an electrically conductive glove used in clinical practice for transcutaneous therapeutic stimulation.~The thresholds of nociception and tolerance will be determined in each healthy volunteer."
223868132|NCT03618524|OTHER|Lower limb hot water immersion|Participants will undergo two interventions in separate visits: lower limb hot water (42 deg C) immersion up to the (1) ankles or (2) knees.
223868133|NCT04787653|DEVICE|Otoband|Participants with Tinnitus will wear the Otoband set at an effective power level during a 30 minute time frame and outcome measurements will be recorded in a Google Form.
223868134|NCT04787653|DEVICE|Placebo|Participants with Tinnitus will wear the Otoband set at a non-effective power level during a 30 minute time frame and outcome measurements will be recorded in a Google Form.
223868135|NCT05052450|OTHER|Observational|Patients data were collected throughout the following time
223868136|NCT01154985|DRUG|Placebo capsule|3x Placebo capsules three times a day (TID) for 365 days
223868137|NCT01154985|DRUG|EPA-E 300 mg capsule|2x 300 mg capsules + placebo capsule TID for 365 days
223868138|NCT01154985|DRUG|EPA-E 300 mg capsule|3x 300 mg capsules TID for 365 days
223868139|NCT04949503|DRUG|nimotuzumab|Patients in the study group were received nimotuzumab on the basis of chemoradiotherapy (control group).
223868140|NCT04803409|DEVICE|Splenic Ultrasound|Splenic Ultrasound: Daily ultrasound application to the spleen of approximately 18 minutes for up to 7 days, in addition to standard clinical care
223868141|NCT00589277|BEHAVIORAL|Gain-Framed counseling & Gain-framed materials|Novel messages for quitting smoking
223868142|NCT00589277|BEHAVIORAL|Standard care counseling + standard materials|Standard messages for quitting smoking
223868143|NCT03815136|OTHER|Chewing Gum|Patients of CG group chewed one piece of sugarless gum for approximately 15 min every 30 min at the first hour of the examination.
223868144|NCT03815136|OTHER|Control|The control group will not chew chewing gum while undergoing capsule endoscopy
223868145|NCT04117789|BEHAVIORAL|Therapist-guided internet-delivered cognitive behavior therapy for depression in adolescents|Participants will be assigned to a 10 weeks internet-delivered cognitive behavior therapy program with therapist support via an internet platform.
223868146|NCT04117789|BEHAVIORAL|Self-guided internet-delivered cognitive behavior therapy for depression in adolescents|Participants will be assigned to a 10 weeks internet-delivered cognitive behavior therapy program without therapist support via an internet platform.
223868147|NCT04117789|OTHER|Treatment as usual|Participants randomized to TAU, will be referred to the local CAMH's or primary care unit for children and youths and will be free to receive any treatment, either psychosocial, medical or the combination of both.
224076529|NCT03973281|OTHER|Standard of Care (SOC)|Standard of Care (SOC)
223868148|NCT03762434|OTHER|mobile application|"Mobile app: The participants can view the Life style modification program by using the app. In addition, a membership area of the app provides individual support of self- health monitoring, goal setting of exercise plan and exercise record. A user guide of the MetS app will be provided to the participants to take home after the briefing.~Booklet : The booklet content covers 26 pages about the metabolic syndrome and risk factors, suggested life style modification tips in terms of exercise, diet, smoking, mediation and stress management."
223868149|NCT02711436|DEVICE|Computed Tomography Scan|
223868150|NCT02711436|DEVICE|Fast Magnetic Resonance Imaging|
223868151|NCT03345901|DRUG|Pemafibrate|0.2 mg orally BID - twice daily
223868152|NCT03345901|DRUG|Placebo|orally BID - twice daily
223868153|NCT03825978|BEHAVIORAL|Prenatal Genetic Counseling|In this study prenatal genetic screening counseling was provided from the begining of the pregnancy, different from the other studies in the literature. In the literature, most of the study evaluated pregnant women's anxiety, information status about the test and decisional conflicts, only prenatal screening process or prenatal diagnosis process. In this study pregnant women were evaluated both in prenatal screening test and prenatal diagnosis procedures.
223868154|NCT04295915|DEVICE|Specimens that meet inclusion criteria|Specimens that have been de-identified and considered remnant by the laboratory (fresh specimens) or were contrived by the laboratory (using bacterial isolates with no identifying information) can be enrolled into the study.
223868155|NCT01485653|DRUG|Mepivacaine|Group 1) 20mL 1.5% mepivacaine, one dose Group 2) 30mL 1.5% mepivacaine, one dose
223868156|NCT00566735|DRUG|Razadyne|The starting dose of study medication is 4 mg twice a day
223868157|NCT00566735|DRUG|Placebo|4 mg, 2 times a day
223868158|NCT01696916|PROCEDURE|6-minute walking test|submaximum exercise test
223868159|NCT05986734|DRUG|Cutaquig|Subcutaneous immunoglobulin products are administered at the same monthly dose (0.4-0.8 g/kg), evenly divided into 3-5 administrations per month, subject to monitoring of the pre transfusion IgG level with target IgG values of at least 7 g/L.
223868160|NCT00722046|BIOLOGICAL|PF-04360365 0.1 mg/kg|0.1 mg/kg every 60 days (10 doses total)
223868161|NCT00722046|BIOLOGICAL|PF-04360365 0.5 mg/kg|0.5 mg/kg every 60 days (10 doses total)
223868162|NCT00722046|BIOLOGICAL|PF-04360365 1 mg/kg|1 mg/kg every 60 days (10 doses total)
223868163|NCT00722046|DRUG|Placebo|Placebo every 60 days (10 doses total)
223868164|NCT00722046|BIOLOGICAL|PF-04360365 3 mg/kg|3 mg/kg every 60 days (10 doses total)
223868165|NCT00722046|BIOLOGICAL|PF-04360365 8.5 mg/kg|8.5 mg/kg every 60 days (10 doses total)
223868166|NCT00402896|DRUG|ZD6474|300 mg/day orally for 10 weeks.
223868167|NCT00654589|DRUG|Deferasirox|
223868168|NCT05107024|DEVICE|RFR-guided step by step balloon dilation|The mean value of the minimum ratio of distal mean pressure to aortic mean pressure (Pd/Pa) in five consecutive complete cardiac cycles was obtained by scanning the diastolic and systolic stages at rest.
223868169|NCT05107024|DEVICE|Traditional balloon dilation|The surgeon determines the optimal size of the semi-compliant balloon based on angiography (balloon to vessel ratio 1.0) and performs adequate predilation to achieve residual stenosis. 30% of vascular anatomy criteria
223868170|NCT05514275|DRUG|Endostatin and Capecitabine|Patients received radiotherapy Combined With Endostatin(37.5mg/m2, continuous intravenous infusion for 120h, D-7, D8, D22, D36) and Capecitabine( 650 mg/m2 bid, orally, d1-21, every 3 weeks as a cycle for 17 cycles)
223868171|NCT00925587|DRUG|darbepoetin alfa|Drug administered either Q2W or QM using a prefilled syringe. Allowable doses of: 10, 20, 30, 40, 50, 60, 80, 100, 130, 150, 200, 300, 400 or 600 mcg.
223868172|NCT00274417|DRUG|dutasteride|
223868173|NCT03822520|DRUG|Celecoxib|Celecoxib 400mg capsule
223868174|NCT03822520|DRUG|Moxifloxacin|Moxifloxacin 400mg tablet
223868175|NCT03822520|OTHER|Water|Pure water 150ml
223868176|NCT05602285|DEVICE|Dislodgement device|Breakaway device that prevents IV dislodgement
223868177|NCT06524973|OTHER|Telemedicine|Attend telehealth self-management coaching sessions
223868178|NCT06524973|OTHER|Counseling|Attend telehealth self-management coaching sessions
223868179|NCT06524973|OTHER|Best Practice|Receive standard of care
223868180|NCT06524973|OTHER|Questionnaire Administration|Ancillary studies
223868181|NCT06524973|OTHER|Inrweview|Ancillary studies
223868182|NCT04897945|BEHAVIORAL|Shared decision-making for diabetes prevention|Pharmacists and/or nurses will engage patients with history of gestational diabetes mellitus using Healthwise (TM) Decision Tool to help match their personal preferences and values with treatment options, specifically lifestyle change will be referred to a CDC (Center for Disease Control and Prevention) recognized diabetes prevention program (DPP), and pharmacists will coordinate with primary care providers to prescribe metformin for patients interested in this treatment.
223868183|NCT01175317|PROCEDURE|Goal-directed fluid optimization|Fluid administration and optimization based on cardiac output findings during surgery and during the first 8 hours of the postoperative phase.
223868184|NCT01175317|OTHER|Regimen based on expertise anaesthesist|Fluid regimen based on expertise anaesthesist
223868185|NCT00445952|OTHER|clinical observation|
223868186|NCT00445952|PROCEDURE|management of therapy complications|
223868187|NCT06553053|OTHER|"Harmonizing Shaoyang, nourishing spleen and kidney with warmth Acupuncture Group"|Patients receiving acupuncture and mild moxibustion, whom were treated 2 times per week for 12 weeks and followed up for 40 weeks. The first group of acupoints is that CV4 and Bilateral ST37, SP6, SP4, KI3, LI11, SJ4 and GB26 were selected for acupuncture and CV12 and bilateral ST36 and GB41 were selected for moxibustion. The second group of acupoints is that CV12 and Bilateral ST36, GB41, SP4, KI3, LI11, SJ4 and GB26 were selected for acupuncture and CV4 and bilateral SP6 and GB34 were selected for moxibustion. These two groups are alternate. After deqi sensation was even reinforcing and reducing. The surface temperature of acupoints was maintained at 43℃± 1℃ for moxibustion. During each treatment, acupuncture and mild moxibustion are performed simultaneously, both lasting for 30 minutes.
224076530|NCT03545906|OTHER|TEAM-UP Intervention Group|Children randomly assigned to TEAM-UP will have a telemedicine assisted specialist visit scheduled after 4 weeks of initiating DOT at school, as well as 2 subsequent follow-up visits. The visits will be performed by a specialist in pediatric asthma, to implement guideline-based care. Prescriptions for asthma medications will be prescribed to be delivered as directly observed therapy in school.
223868188|NCT06553053|OTHER|"Nourishing spleen and kidney with warmth Acupuncture Group"|Patients receiving acupuncture and mild moxibustion, whom were treated 2 times per week for 12 weeks and followed up for 40 weeks. The first group of acupoints is that CV4 and Bilateral ST37, SP6, SP4, KI3 and LI11 were selected for acupuncture and CV12 and bilateral ST36 were selected for moxibustion. The second group of acupoints is that CV12 and Bilateral ST36, SP4, KI3 and LI11 were selected for acupuncture and CV4 and bilateral SP6 were selected for moxibustion. These two groups are alternate. After deqi sensation was even reinforcing and reducing. The surface temperature of acupoints was maintained at 43℃± 1℃ for moxibustion. During each treatment, acupuncture and mild moxibustion are performed simultaneously, both lasting for 30 minutes.
223868189|NCT02368626|DEVICE|EndyMed Pro™ RF Micro-Needles|RF Micro-needles ablation treatments
223868190|NCT02089763|BIOLOGICAL|pegylated recombinant human arginase|
223868191|NCT02164240|DRUG|Sunitinib|Intervention Description: 3 days of once daily sunitinib alternating with 4 days of once daily regorafenib throughout each 28 day cycle. The starting dose level (level 1) is sunitinib 37.5 mg/d and regorafenib 120 mg/d, and doses will be escalated in subsequent cohorts following a classical 3+3 design up to sunitinib 50 mg/d and regorafenib 160 mg/d or until maximum tolerable dosage (MTD) and recommended phase II dose (RP2D) is determined. Number of Cycles: until progression or unacceptable toxicity develops.
223868192|NCT02164240|DRUG|Regorafenib|Intervention Description: 3 days of once daily sunitinib alternating with 4 days of once daily regorafenib throughout each 28 day cycle. The starting dose level (level 1) is sunitinib 37.5 mg/d and regorafenib 120 mg/d, and doses will be escalated in subsequent cohorts following a classical 3+3 design up to sunitinib 50 mg/d and regorafenib 160 mg/d or until maximum tolerable dosage (MTD) and recommended phase II dose (RP2D) is determined. Number of Cycles: until progression or unacceptable toxicity develops.
223868193|NCT04938752|DRUG|DA-2811|single dose administration (one tablet once a day)
223868194|NCT04938752|DRUG|DA-2811-R|single dose administration (one tablet once a day)
223868195|NCT03348722|OTHER|Active surveillance|PSA testing (every 3 months, then every 6 after 30 months), clinical visit and DRE every 6 months, prostate biopsy after 1, 4 and 7 years
223868196|NCT03348722|PROCEDURE|Radical prostatectomy|Radical prostatectomy (open, laparoscopic or robotic)
223868197|NCT03348722|RADIATION|Radiotherapy|External radical radiotherapy or brachitherapy
223868198|NCT03348722|PROCEDURE|Other radical treatments|High intensity focal ultrasound, cryotherapy, others
223868199|NCT05959590|DRUG|Ferumoxides 11.2Mg Solution for Injection|the drug will be injected at a single dose of up to 7 mg/Kg and MRI will be performed after 24 hrs.
223868200|NCT05132816|DIAGNOSTIC_TEST|high-resolution manometry|"High-resolution manometry is an outpatient examination and part of our routine diagnostic or pre-operative evaluation in GERD.~A thin catheter is placed through the nose into the esophagus, local anaesthesia can be used if the patient experiences a discomfort. Once the tip of the manometry catheter is placed below the esophagogastric junction, the patient is asked to take in water and bread. In rest and during deglutition, pressure measurements are registered with the manometry catheter, allowing the investigator to detect IEM. The examination takes about 1.5 hours. The manometry is a standard and routine intervention being performed for over 30 years with minimal risks.~The GSRS questionnaire pre- and postoperatively is part of our standard workup, no additional assessment for this study is needed."
223868201|NCT00490802|DRUG|Oxytocin|Intranasal Oxytocin
223868202|NCT00490802|DRUG|Placebo|Placebo Comparator
223868203|NCT05455424|DRUG|Niraparib Oral Product|Niraparib (\[3S\]-3-\[4-\[7-(aminocarbonyl)-2H-indazol-2-yl\] phenyl\] piperidine \[tosylate monohydrate salt\]) is an orally available, potent, and highly selective PARP1 and PARP2 inhibitor. The excipients for niraparib are lactose monohydrate and magnesium stearate. Niraparib will be supplied in bottles containing 72 capsules of 100 mg. The capsules should be swallowed whole with water. The capsules should not be chewed or crushed and can be taken without regard to meals.
223868204|NCT05455424|OTHER|Active Symptom Control|ASC could involve regular specialist follow up; structured assessment of physical, psychological, and social problems; and appropriate treatment, including palliative radiotherapy and steroids.
223868205|NCT06338241|COMBINATION_PRODUCT|Biphasic bioceramic of tricalcium phosphate and hydroxyapatite with simvastatin|The intervention description for Galibone+ in the study involves the application of this substance to promote bone regeneration following the extraction of impacted mandibular third molars. Galibone is indicated to treat segmental and cavity bone loss, aesthetic repairs and bone augmentations (such as inlay or onlay grafts); to fill dental alveolar bone; for the placement of dental implants; for the stabilization of osteotomies and prostheses in dentistry.
223868206|NCT06338241|OTHER|Bovine Hydroxyapatite|The intervention description for Bio-Oss in the study involves the application of this standard material to promote bone regeneration following the extraction of impacted mandibular third molars. Bio-Oss is a commonly used xenograft material known for its osteoconductive properties.
223868207|NCT04979299|OTHER|Wheelchair|Patient will be asked to sit in a wheelchair, and a 5-minute video recording of spontaneous speech capturing the semi-structured iCGI interview is made.
223868208|NCT02843217|BEHAVIORAL|Lifestyle, screening|
223868209|NCT05519813|DRUG|Metformin|Use Metformin for 3 months to treat PCOS
223868210|NCT05519813|DRUG|Pioglitazone Hydrochloride And Metformin Hydrochloride Tablets|Use Pioglitazone Hydrochloride And Metformin Hydrochloride Tablets for 3 months to treat PCOS
223868211|NCT01519752|DRUG|Oxiconazole Nitrate Cream 1%|Oxiconazole Nitrate Cream 1% applied to affected area once a day for 28 days
223868212|NCT01519752|DRUG|Oxiconazole Nitrate Cream 1% (Oxistat®)|Oxiconazole Nitrate Cream 1%(Oxistat®)applied to affected area once a day for 28 days
223868213|NCT01519752|DRUG|Placebo|Placebo applied to affected area once a day for 28 days
223868214|NCT03737591|DIAGNOSTIC_TEST|Next-generation sequencing (NGS)|NGS test for colorectal tumor-specific plasma ctDNA methylation markers prior to endoscopy
223868215|NCT02961569|PROCEDURE|sputum collection for acid fast bacilli|spontaneous or post fiberoptic bronchoscopy sputa
223868216|NCT00686855|DRUG|Tacrolimus|Tacrolimus elixir taken as an oral rinse four times a day for 4 weeks
223868217|NCT00686855|DRUG|Dexamethasone|Dexamethasone elixir taken as an oral rinse 4 times a day for 4 weeks
223868218|NCT04773327|OTHER|Mecapegfilgrastim Injection|24-48h after the end of antitumor drug administration in each chemotherapy cycle, Mecapegfilgrastim was injected subcutaneously, 6mg/ time, once/cycle
223868219|NCT00085436|BIOLOGICAL|Aldesleukin,|Recombinant human interleukin-2 (Proleukin, Chiron Therapeutics) will be administered as a five day (120 hr) continuous intravenous infusion at a dose of 18x106 IU per square meter of body surface area per day as per the Negrier regimen (21). The treatment schedule consists of two induction cycles and three maintenance cycles. Each induction cycle consists of two five-day courses of interleukin-2 infusion separated by a nine-day break. Each maintenance cycle consists of a five-day infusion followed by 23-day rest period of no therapy.
223868220|NCT00085436|BIOLOGICAL|autologous tumor cell vaccine|we will administer 1 X 107 DC cells. The autologous tumor cell vaccine (1 X 107 cells/1cc) in lactated ringers solution and injected into one (or two if clinically necessary) inguinal lymph nodes under ultrasound guidance. Each cycle of DC vaccine will be administered alternately in the right and left inguinal lymph nodes.
223868221|NCT00085436|BIOLOGICAL|recombinant interferon alfa|Recombinant human interferon alfa-2a (Roferon, Roche), at a dose of 6 million IU per day three times a week subcutaneously will be given during the two interleukin-2 induction cycles and during each interleukin-2 maintenance cycle
223868222|NCT06124066|DRUG|Mirabegron 50 MG|The participants were given mirabegron 50 mg or tamsulosin 0.4 mg and filled in the Ureteral Stent Symptom Questionnaire (USSQ), filled in directly when the patient arrived or by telephone.
223868223|NCT04038814|PROCEDURE|Routine prevention of VAP|Enhanced hand hygiene protocol, tube cuff pressure monitoring ( set on 25-30 mm Hg) every 12 hours and every time when we suspected under or over distention, fast withdrawal of sedation, moderate supportive mechanical ventilation ( tidal volume (VT) 5-8 ml/kg ideal body weight (IBW), positive end expiratory pressure (PEEP) 3-5 cmH2O, Plateau pressure (Ppl) \< 25 cm H2O, normocapnia ), Proton Pump Inhibitors (PPIs) reduction, Selective oral decontamination (SOD) every 8 hours - 0,2% chlorhexidine digluconate mouthwash, Closed Tracheal Suction System (CTSS) - changed every 7 day, 30-45% lifting of the thorax
223868224|NCT04038814|PROCEDURE|Modified prevention of VAP|"3 modifications of the routine bundle in the prevention of VAP:~* Endotracheal tube ( Shiley Evac Endotracheal tube with TaperGuard Cuff) and tracheostomy tubes (Tracheostomy Tube Cuffed Seal Guard) instead of regular tubes,~* Automatic, continuous tube cuff pressure monitoring ( Covidien Shiley M Pressure Control Automatic Cuff Controller ( 25-30 mmHg),~* Automatic continuous subglottic secretion drainage"
223868225|NCT05340114|DEVICE|CEREBO®|Near-infrared based point-of-care portable intracranial hematoma detector
223868226|NCT01668940|OTHER|Lillipops Iced Soothies (4 flavours)|Lillipops Iced Soothies are naturally flavoured freezies developed in the United Kingdom for women with morning sickness. They are available in 5 different flavours: grapefruit and tangerine, lemon and mint, chamomile and orange, lime and vanilla, and ginger. The flavours are derived from steam distillation of the peels (grapefruit, tangerine, lemon, orange, lime), mint leaves, and chamomile flowers to release and collect their essential oils. Vanilla pods and ginger are macerated and their resin is used. These flavours were chosen because they may provide relief of symptoms as they are either traditional remedies for NVP, such as ginger, or soothing and refreshing flavours, such as chamomile, vanilla and citrus.
223868227|NCT01668940|OTHER|Mr. Freeze Freezies|There are other commercially available freezies, such as Mr. Freeze. Mr. Freeze freezies contain simulated flavours of watermelon, cherry, blue raspberry and cream soda. However, there have been no reports, studies or claims that they are effective as a remedy for the treatment of NVP.
223868228|NCT01668940|OTHER|Lillipop Iced Soothies (Ginger flavour)|Lillipops Iced Soothies are naturally flavoured freezies developed in the United Kingdom for women with morning sickness. They are available in 5 different flavours: grapefruit and tangerine, lemon and mint, chamomile and orange, lime and vanilla, and ginger.The flavours are derived from steam distillation of the peels (grapefruit, tangerine, lemon, orange, lime), mint leaves, and chamomile flowers to release and collect their essential oils. Vanilla pods and ginger are macerated and their resin is used. These flavours were chosen because they may provide relief of symptoms as they are either traditional remedies for NVP, such as ginger, or soothing and refreshing flavours, such as chamomile, vanilla and citrus.
223868229|NCT03698396|BIOLOGICAL|Allogenic Islet Cell Transplantation|Transplantation of allogenic islet cells will be given to eligible patients, up to three times during the study, using cell quantities based on body weight.
223868230|NCT02250235|OTHER|Health risk information|
223868231|NCT06320912|DEVICE|The intraparenchymal portal vein covered stent|The intraparenchymal portal vein covered stent, produced by Shanghai Shenqi Medical Technology Co., Ltd., is used for a transjugular approach. It establishes an artificial shunt between the hepatic vein and the main branches of the portal vein within the liver. This helps in reducing portal venous pressure and alleviating or improving the symptoms of portal hypertension and its complications, such as variceal bleeding, gastropathy, refractory ascites, and/or hepatic hydrothorax.
223868232|NCT06320912|DEVICE|TIPS Covered Stent System GORE|The GORE® VIATORR® Transjugular Intrahepatic Portosystemic Shunt (TIPS) Covered Stent consists of an implantable covered stent and a percutaneous delivery catheter.
223868233|NCT03508518|OTHER|Shared care device in psychiatry (DSPP)|The GPs of the intervention group will be able to refer their patients to the DSPP or to the routine care. The patient has a nursing telephone interview prior to one or few more psychiatric consultations. The time to obtain the psychiatric consultation is measured into the 2 groups. In both groups, questionnaires will be sent to the patient and their medico-administrative data will be collected passively over a period of 6 months after inclusion
223868234|NCT03508518|OTHER|Usual Care|psychiatric care available in the Haute Garonne: psychiatric consultation by a liberal psychiatrist or by a psychiatrist working in public health center.
223868235|NCT01039948|BIOLOGICAL|AV-299 + gefitinib|AV-299 is a humanized anti-HGF IgG1 monoclonal antibody directed against free HGF, ligand for c-Met tyrosine kinase receptor.
223868236|NCT01039948|DRUG|Gefitinib|Gefitinib is a small molecule (drug) which selectively inhibits epidermal growth factor receptor's (EGFR) tyrosine kinase domain.
223868237|NCT02672930|DEVICE|Electrocardiogram (ECG)|ECG and vital parameters were obtained before and after recommended standard calcium gluconate therapy for hyperkalemia
223868238|NCT01460446|DEVICE|Aviva Expert blood glucose meter|
223868239|NCT01460446|DEVICE|Aviva Nano blood glucose meter|
223868240|NCT02231983|GENETIC|gene sequencing|Amplify and identify exons from gene IL-2RG by PCR and agarose gel electrophoresis, and then followed by gene sequencing.
223868241|NCT03019614|DRUG|Hydrocortisone|Generic hydrocortisone
223868242|NCT03019614|DRUG|Chronocort|Modified formulation of hydrocortisone
223868243|NCT06445257|DRUG|zanubrutinib 160 mg BID orally|The ZRMT induction and maintenance regimen
223868244|NCT04616963|DRUG|Emtricitabine / Tenofovir Disoproxil Oral Tablet 200/300 mg|Following Phase I lead-in, all participants will continue PrEP with fixed dose combination daily oral F/TAF substituting for F/TDF in Phase II. Participants will continue to receive PrEP in accordance with standardized comprehensive methods of prescribing, which includes risk reduction counseling, adherence counseling, and clinical assessments with safety monitoring, as well as HIV and STI screening. Participants will receive daily adherence-supporting text message reminders through 12 weeks after F/TAF initiation.
223868245|NCT04616963|DRUG|Emtricitabine Tenofovir Alafenamide 200/25 mg|Following Phase I lead-in, all participants will continue PrEP with fixed dose combination daily oral F/TAF substituting for F/TDF in Phase II. Participants will continue to receive PrEP in accordance with standardized comprehensive methods of prescribing, which includes risk reduction counseling, adherence counseling, and clinical assessments with safety monitoring, as well as HIV and STI screening. Participants will receive daily adherence-supporting text message reminders through 12 weeks after F/TAF initiation
223868246|NCT03157401|DRUG|intravenous infusion group|In the tranexamic acid intravenous infusion group (n = 30), 15 mg/kg tranexamic acid diluted in 100 mL physiological saline was intravenously infused at the beginning of the surgery. After suturing deep fascia, 20 mL of physiological saline was intra-articularly injected.
223868247|NCT03157401|DRUG|intra-articular injection group|In the tranexamic acid intra-articular injection group (n = 30), 100 mL of physiological saline was intravenously infused at the beginning of the surgery. After suturing deep fascia, the mixture of 1.5 g tranexamic acid and 20 mL physiological saline was intra-articularly injected.
223868248|NCT03157401|DRUG|control group|In the control group (n = 30), 100 mL of physiological saline was intravenously infused at the beginning of the surgery. After suturing deep fascia, 20 mL of physiological saline was intra-articularly injected.
223868249|NCT03356223|DRUG|Abemaciclib|"400mg/day with 2 doses of 200mg 12-hour apart For each 28-day cycle, a total of 56 doses of study drug will be dispensed.~Route of administration : oral~Duration of treatment until the patient experiences an unacceptable toxicity or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status or withdrawal of consent."
223868250|NCT04801563|OTHER|MDS and AlloHSCT|Allogeneic stem cell transplantation, based on TMLI and followed by infusion of donor regulatory T cells and conventional T cells and purified donor CD34+ hematopoietic stem cells
223868251|NCT04218110|DRUG|Isopropyl alcohol & Chlorhexidine Gluconate Antiseptic|Application of antiseptic drug to the inguinal area of the subjects
223868252|NCT04218110|DRUG|Isopropyl alcohol & Chlorhexidine Gluconate Antiseptic|Application of antiseptic drug to the inguinal area of the subjects
223868253|NCT04218110|DRUG|Isopropyl alcohol & Chlorhexidine Gluconate Antiseptic|Application of antiseptic drug to the inguinal area of the subjects
223868254|NCT04218110|DRUG|Prevantics 3.15 % / 70 % Swabstick|Application of antiseptic drug to the inguinal area of the subjects
223868255|NCT05346523|DEVICE|Isabel Pro - The DDx generator (CDDS)|Isabel Pro - the DDx generator is a software developped for health professionals with the intention to support them in broadening their differential diagnoses. After the first patient examination, the resident is asked to enter patient symptoms into Isabel Pro, which returns a list of possible diagnoses from its underlying database that matches the entered data. The diagnosing resident physicians will be asked to consult Isabel Pro at least once within the first hour after the first patient assessement. After entering patient symptoms into the software, Isabel Pro will itself return a list with possible diagnoses derived from their underlying database. It is then free to the physician to decide whether one or more of the suggested DDx should be considered for further diagnostic or treatment procedure based on clinical judgement.
223868256|NCT05447975|OTHER|Tai Chi training|"As for Tai Chi training, standardized Tai Chi was taught by professional Tai Chi coaches from Sino Taiji of Fuxing International in classes: Qishi (Starting Posture), Shangsanbu (Twist Step), Yema Fenzong(Part the Wild Horse's Mane on Both Side), Jingang Daozhui (Buddha's warrior attendant pounds mortar), Shoushi (Closing Posture). Patients participated in this class were trained, twice a week, 60 min per time. PD patients whose attendance rate less than 75% were excluded."
223868257|NCT04574349|PROCEDURE|Decompressive craniectomy|Removing part of the skull (bone flap) to lower intracranial pressure
223868258|NCT04178239|DIAGNOSTIC_TEST|fMRI, questionnaires, pneumologic diagnostics|fMRI neuropsychological questionnaires pneumologic diagnostics: blood samples, whole body plethysmography, walking test
223868259|NCT04521530|OTHER|immediate functional implant loading|Patients will undergo implant placement and a minimum of 35 Ncm reading with the graded torque wrench. Temporary crowns in functional occlusion were cemented.
224076531|NCT03545906|OTHER|Enhanced Care Comparison|Similar to the TEAM-UP group, children in the Enhanced Care group will receive a symptom assessment and asthma education materials at baseline, and we will contact the PCP by facsimile or email and will recommend DOT of preventive asthma medication through school as well as a referral to specialist. However specialist visits will not be facilitated via telemedicine.
224076532|NCT01017107|DRUG|Activated protein C|24 micrograms/kg/hour intravenously for 96 hours
224076533|NCT05625776|PROCEDURE|pain delivery with capsaicin and heat|Experimental pain paradigm delivered (capsaicin cream combined with heat) that is short-term and painful but not harmful
224076534|NCT05625776|PROCEDURE|distractor delivery with sensory TENS|Distractor stimulus delivered (sensory TENS electrical stimulation) that is short-term and attention-demanding but not painful
224076535|NCT05201755|DEVICE|CPAP|Application of PEEP (positive end-expiratory pressure) through a CPAP Helmet with a set PEEP of 10 cmH2O. It is a very well tolerated and noninvasive device commonly used for ventilatory support.
223868260|NCT04521530|OTHER|immediate non functional implant loading|implant will be placed into the site following the manufacturer's protocol making sure to have a minimum of 35 Newton centimeter reading with the degraded torque wrench. Non-functional temporary crowns were cemented.
223868261|NCT01267383|DRUG|Sertraline|Sertraline Hydrochloride Tablets 100 mg
223868262|NCT03960606|COMBINATION_PRODUCT|PUR1900|PUR1900 contains itraconazole as the active ingredient, and it is formulated as a dry powder for oral inhalation.
223868263|NCT03960606|COMBINATION_PRODUCT|Placebo|PUR1900 placebo
223868264|NCT02520908|PROCEDURE|HSCT|Hematopoietic stem cell transplantation
223868265|NCT02520908|OTHER|Standard Care|
223868266|NCT01888848|DIETARY_SUPPLEMENT|Freeze-dried Blueberry|12g freeze-dried blueberry (powder), twice daily with water, for 90 days
223868267|NCT01888848|DIETARY_SUPPLEMENT|Blueberry Placebo|12g blue, blueberry-flavored powder, twice daily with water, for 90 days
223868268|NCT01507038|DRUG|YH14617|1mg once weekly
223868269|NCT01507038|DRUG|YH14617|1.6mg once weekly
223868270|NCT01507038|DRUG|YH14617|2mg once biweekly
223868271|NCT01507038|DRUG|Placebo|Once weekly
223868272|NCT06006949|DRUG|Roxadustat|Roxadustat (150 mgqod)
223868273|NCT06006949|DRUG|Luspatercept|Luspatercept (1.0 mg/kg, subcutaneously injection every 3 weeks, adjusted according to blood pattern, up to 1.75mg/kg)
223868274|NCT03875040|BEHAVIORAL|kinesiophobia|patients who have a high-level or low-level kinesiophobia have been evaluated.
223868275|NCT04414995|DRUG|Paracetamol injection and Ibuprofen injection|Use of combination acetaminophen and ibuprofen to reduce morphine requirement inpatient after Total knee arthroplasty
223868276|NCT04414995|DRUG|Paracetamol injection and normal saline|Use of paracetamol and normal saline to reduce morphine requirement inpatient after Total knee arthroplasty
223868277|NCT04414995|DRUG|Ibuprofen Injection and normal saline|Use of ibuprofen and normal saline to reduce morphine requirement inpatient after Total knee arthroplasty
223868278|NCT00373386|DRUG|growth hormone|Growth Hormone treatment
223868279|NCT00799396|DRUG|Clopidogrel|300 mg on first day, then 75 mg per day for the next 6 days
223868280|NCT00799396|DRUG|Aspirin|Single dose of 324 mg on the last day of clopidogrel treatment
223868281|NCT01867216|DRUG|Placebo|Administered orally as capsules
223868282|NCT01867216|DRUG|LY2922470|Administered orally as capsules
223868283|NCT01556724|DRUG|0.1% or 0.2% ropivacaine nerve blocks|Either 0.1% or 0.2% ropivacaine will be infused at 7 mL/hr through lumbar plexus nerve block catheter based upon randomization, and can then receive a 6 ml bolus of either 0.1% or 0.2% ropivacaine. Additional pain relief will be available by nurse administered boluses of additional local anesthetic (from their randomized infusion) with a maximum dose of an extra 3 ml per bolus and limited to one bolus per hour. This bolus of their randomized local anesthetic will remain available until the nerve catheters are removed. Nerve block infusion rates may be increased to 9 ml/h for patients with increased pain without increased motor blockade as determined by the acute interventional perioperative pain service (AIPPS) or decreased to 5 ml/h for patients with increased motor blockade or weakness from the peripheral nerve block as determined by the AIPPS .All continuous lumbar plexus catheters will be removed on post operative day (POD) 2.
223868284|NCT02190097|OTHER|Paleolithic diet|see procedures section for more details
223868285|NCT02190097|OTHER|American Diabetes Association diet|see procedures section
223868286|NCT01318382|DEVICE|TOF-Watch SX® Monitoring of NMB|Participants will have the extent of NMB monitored by a TOF-Watch SX®.
223868287|NCT05512182|DRUG|Chemotherapy|Pembrolizumab : 200mg/Q3W/IV infusion/Day 1of each 3-week cycle Neratinib : Week 1: 120 mg, Week 2: 160 mg, Week 3 and onwards: 240 mg/QD/Oral/Once daily Paclitaxel : 175mg/m2 /Q3W/IV infusion/Day 1of each 3-week cycle
223868288|NCT02639091|DRUG|BAY 94-9343|"In Part 1 of the study, anetumab ravtansine (BAY 94-9343) will be administered by 1-hour IV infusion with a starting dose of 5.5mg/kg(BW) on Day 1 of every treatment cycle (Q3W).~In Part 2 of the study, anetumab ravtansine (BAY 94-9343) will be administered on Day 2 of Cycle 1 and then on Day 1 of Cycle 2 and all subsequent cycles (Q3W)"
223868289|NCT02639091|DRUG|Pemetrexed|Administered at the dose of 500 mg/m2 body surface area (BSA) by 10-minute IV infusion on Day 1 of every treatment cycle (Q3W) in both parts of the study
223868290|NCT02639091|DRUG|Cisplatin|Administered at the dose of 75 mg/m2 (BSA) by 2-hour IV infusion on Day 1 of every treatment cycle (Q3W) in both parts of the study
223868291|NCT02772263|OTHER|CHAP-EMS|The CHAP-EMS program is a low cost community program that is designed to assess community dwelling seniors for lifestyle risk factors that may impact their health and well-being and to provide targeted education to address the pertinent risk factors. Each participant is guided through a structured health-risk assessment focused on diabetes, cardiovascular disease and other potential health issues. The assessment is conducted by a trained paramedic in a common area within the community housing building. Data gathered are used to develop individualized action plans concerning health-risk reduction, to direct participants to local health activities or resources, educate on promoting health and to transmit this information to a participants' family physician.
223868292|NCT03396146|OTHER|12 ml total blood tubes volume|12 ml total blood tubes at 0, +60, + 90, + 120 minutes before and after a mixed meal
223868293|NCT03396146|OTHER|Fecal sample|Fecal sample at inclusion
223868294|NCT01317446|DRUG|amine fluoride/stannous fluoride|10 ml qd, oral, topical, 6 months duration
223868295|NCT00714714|DRUG|Adapalene Gel|adapalene gel 0.3% topically applied daily in a split-face model for two weeks
223868296|NCT00714714|DRUG|Tretinoin Gel|Tretinoin 0.1% topically applied daily in a split face model for two weeks
223868297|NCT00019747|DRUG|thalidomide|oral thalidomide 100 mg at bedtime once daily for 4 weeks, then progresses to 200 mg at bedtime for 4 weeks, then progresses to 300 mg at bedtime (maintenance dose).
223868298|NCT00019747|PROCEDURE|adjuvant therapy|Initial dose: 100 mg by mouth (po) every bedtime ( Q hs) for four weeks, then progress to 200 mg po Q hs for four weeks, then progress to maintenance dose: 300 mg po Q hs.
223868299|NCT00019747|OTHER|Placebo|oral placebo once daily
223868300|NCT02313363|DEVICE|patient-centered smartphone-based diabetes care system|patient-centered smartphone-based diabetes care system (PSDCS) is composed of 4 modules such as glucose module, diet module, physical activity module, and SNS module. Participants were instructed to use the PSDCS and to measure blood glucose levels with a Bluetooth glucometer, input daily food intake, and wear an activity tracker.
223868301|NCT02713906|DEVICE|X-Ray Knee Guide group|
223868302|NCT04701879|OTHER|Spine decompression with core stability exercises|"* 50 minutes per session~* Decompression with core stability on alternate days for 8 visits."
223868303|NCT04701879|OTHER|Spine decompression|"40 minutes per session~-Decompression therapy on alternate days for 8 visits."
223868304|NCT01925469|DRUG|Benzocaine|
223868305|NCT01925469|DRUG|Saline spray|A saline spray will be used in the placebo group
223868306|NCT02377726|BEHAVIORAL|Alkoholhjälpen counselor support|Users will have access to counselor support through secure comments at the end of every module they complete in the self help program.
223868307|NCT02377726|BEHAVIORAL|eChange Alkoholhjälpen|An internet based intervention program (iCBT) consisting of 5 modules. Fully automated self-help
223868308|NCT02377726|BEHAVIORAL|Alkoholhjälpen|A swedish, open access website that includes information on alcohol, on how to find treatment and an internet discussion forum
223868309|NCT04933526|DRUG|Flumatinib|Flumatinib 600mg QD orally form 1 to 12 months
223868310|NCT04933526|DRUG|Dasatinib|Dasatinib 100mg QD orally form 1 to 12 months
223868311|NCT02382328|DRUG|alpha lipoic acid|comparison of 600mg/24h oral, alpha lipoid acid, 28 days before and 120 days after surgery (carpal tunnel release) versus placebo in carpal tunnel syndrome patients.
223868312|NCT02382328|DRUG|Placebo|Placebo oral pills, 28 days before and 120 days after surgery (carpal tunnel release) versus placebo in carpal tunnel syndrome patients.
223868313|NCT03797924|DRUG|Receive ICBN with ropivacaine|ICBN block will be performed using US guidance depositing 10 ml of 0.5% ropivacaine in the plane between pectoralis minor and serratus anterior over the 2nd and 3rd intercostal space.
223868314|NCT03797924|BEHAVIORAL|No ICBN block|The site of injection will be prepped with tinted chlorhexidine
223868315|NCT00226772|DRUG|OMS103HP|Maximum of 39 liters of OMS103HP irrigation solution over a maximum of 2 hours
223868316|NCT00226772|DRUG|Vehicle|Maximum of 39 liters of vehicle irrigation solution over a maximum of 2 hours
223868317|NCT00947635|DIETARY_SUPPLEMENT|Dietary intervention - supplements|Supplement bar \& spread formulated with key nutrients (fish oil, phytosterols, almonds, soy protein) shown to help in reducing blood lipid levels
223868318|NCT06408493|BEHAVIORAL|MYCardio-PEER|MYCardio-PEER participants will attend an 8-weeks intervention program delivered over the social networking application. Bite-sized videos and infographic posters on healthy diet and lifestyle for primary prevention of CVD will be delivered weekly, supplemented by interactive peer-group activities to encourage behavior change.
223868319|NCT02450344|BEHAVIORAL|Interactive health promotion|An Internet quiz game competition utilising quiz questions related to alcohol
223868320|NCT02450344|BEHAVIORAL|Passive health promotion|An electronic package of information related to alcohol
223868321|NCT03573518|DRUG|BTX 1503|BTX 1503 Dose 1 liquid formulation, or BTX 1503 Dose 2 liquid formulation
223868322|NCT03573518|DRUG|Vehicle|Placebo
223868323|NCT03884296|BIOLOGICAL|FluMist|Quadrivalent, live, attenuated influenza vaccine, intranasal spray
223868324|NCT03780686|DRUG|Norepinephrine, dopamine|drugs to decrease bleeding
223868325|NCT01308567|DRUG|Cabazitaxel (XRP6258)|Pharmaceutical form: Solution for injection; Route of administration: Intravenous
223868326|NCT01308567|DRUG|Docetaxel (XRP6976)|Pharmaceutical form: Solution for injection'; Route of administration: Intravenous
223868327|NCT01308567|DRUG|Prednisone|Pharmaceutical form: Tablet; Route of administration: Oral
223868328|NCT04135040|DIETARY_SUPPLEMENT|L-Amino Acid|8 different lysine intakes (L-Amino Acid and food) will be tested for 8 hours each.
223868329|NCT06103149|BEHAVIORAL|Mindfulness Intervention for Emotional Distress(MIED)|The MIED program integrates the rationales and practices from the Unified Protocol for Treatment of Emotional Disorders (UP) and Mindfulness based Interventions. Formal mindfulness exercises (e.g., body scan, mindful breathing, and mindful stretching) and informal mindfulness practices (e.g., mindful tooth brushing) were adapted from Mindfulness based intervention (MBIs). The offline received the 8-week (2.5-h per week) sessions.The online MIED program was delivered by a Chat Mini Program and lasted for 49 days. Each day, participants received different materials including (a) an audio recording of mindfulness meditation guidance; (b) learning materials in text or audio; and (c) assignments (for example, informal mindfulness practice, emotion journal, and challenging tasks). In total, it took about 30 min per day to finish all the tasks.
223868330|NCT00977158|PROCEDURE|Throat Swab|Swabs will be moistened in sterile 0.9% sodium chloride solution and rotated in the throat and processed for bacterial cultures and for bacterial DNA extraction.
223868331|NCT05956613|PROCEDURE|Partial pulpotomy|Use of newly introduced bioceramic putty in partial pulpotomy
223868332|NCT03462823|DEVICE|Osteoconductive scaffold-hamstring tendon composite repair|The device under study is a composite bone substitute composed of a natural mineral matrix of bovine origin, reinforced with biodegradable synthetic polymers and natural collagen derivatives of bovine origin (smartbone, IBI S.A., Switzerland).
223868333|NCT03462823|DEVICE|Hamstring tendon-only repair|ACL-reconstruction using hamstring autograft with hybrid fixation in accordance with in-house standard of care.
223868334|NCT00542789|DRUG|Esomeprazole|20mg once daily oral
223868335|NCT00542789|DRUG|Placebo|once daily oral
223868336|NCT00382681|DEVICE|FID 107027 Multi-Purpose Disinfecting Solution|Investigational, multi-purpose disinfecting solution intended for use in cleaning, rinsing, conditioning, disinfecting, and storing soft contact lenses.
223868337|NCT00382681|DEVICE|ReNu MultiPlus Multi-Purpose Solution No Rub Formula|Commercially marketed product indicated for cleaning, rinsing, disinfecting, and storing soft contact lenses.
223868338|NCT05391464|PROCEDURE|Peripheral Nerve Block|Utilized preoperatively with sedation during surgery, or postoperatively for additional anesthesia after GA.
223868339|NCT01714492|DEVICE|Sigma Posterior Stabilizing Rotating Platform TKA Beaded Poly|Sigma PS RP TKA including a polyethylene insert with 4 beads
223868340|NCT01101594|DRUG|hLL1-DOX (the doxorubicin conjugate of milatuzumab)|hLL1-DOX will be administered intravenously (through a vein) on days 1, 4, 8 \& 11 every 21 days for up to 8 treatment cycles. 4 different dose levels of hLL1-DOX will be studied for safety and tolerability.
223868341|NCT04700189|DEVICE|ab interno canaloplasty|A modification of traditional canaloplasty procedure. Can be combined with or done without cataract surgery.
223868342|NCT01733095|DRUG|ambrisentan|Ambrisentan (Volibris 5 mg film-coated tablets, Glaxo Smith-Kline) will be started at 5 mg every other day and increased to 5 mg daily after 4 weeks if tolerated well.
223868343|NCT02259543|OTHER|Root conditioning with citric acid+tetracycline solution|Application of a citric acid + tetracycline gel solution (1:1) for decontamination of root surfaces during the treatment of recession defects by subepithelial connective tissue graft
223868344|NCT04676334|DRUG|Rucaparib|Rucaparib will be administered daily.
223868345|NCT00404573|DRUG|RGH-188|
223868346|NCT02624258|BIOLOGICAL|CD19 RNA redirected autologous T-cells (RNA CART19 cells)|Subjects will be treated with IV administration of RNA anti-CD19 CAR T cells for a total of six doses over 3 weeks. The first dose will be administered 1-4 days after infusion of cyclophosphamide 30mg/kg.
223868347|NCT01426698|PROCEDURE|delayed cord clamping|at birth, the obstetrical provider delays the cord clamping for 45 seconds while lowering the infant. At 45 seconds the cord is milked once and then clamped and cut.
223868348|NCT01040689|DRUG|Olodaterol (BI1744) Low|Low dose inhaled orally once daily from Respimat inhaler
223868349|NCT01040689|DRUG|Placebo (for olodaterol BI1744)|Placebo (olodaterol low and high dose)delivered by Respimat
223868350|NCT01040689|DRUG|Placebo (for Tiotropium)|Placebo (Tiotropium 18 mcg) delivered by HandiHaler
223868351|NCT01040689|DRUG|Olodaterol (BI1744) High|High dose inhaled orally once daily from Respimat inhaler
223868352|NCT01040689|DRUG|Tiotropium 18 mcg|18mcg inhaled once daily from Handihaler
223868353|NCT01812096|OTHER|Subcutaneous bortezomib|
223868354|NCT01812096|OTHER|Intravenous bortezomib|
223868355|NCT04174768|PROCEDURE|Bariatric surgery|Bariatric surgery including sleeve gastrectomy and Roux-en-Y gastric bypass
223868356|NCT00158782|DRUG|GW786034|GW786034 (Pazopanib) is an orally active, potent, reversible, small molecule tyrosine kinase inhibitor of vascular endothelial growth factor receptor 1 (VEGFR-1), VEGFR-2, VEGFR-3, platelet-derived growth factor receptor-alpha (PDGFR-alpha), PDGFR-beta, and c-Kit.
223868357|NCT00158782|DRUG|lapatinib|Lapatinib is an oral, reversible, tyrosine kinase inhibitor of both epidermal growth factor receptor-1 (ErbB1) and ErbB2.
223868358|NCT01185561|BEHAVIORAL|Psychoeducational intervention|The intervention is group therapy for depression treatment based on cognitive behavioral therapy principles developed for women with type 2 diabetes. Specifically, the intervention comprises activities including (1) Education about how dysphoric symptoms (i.e., depressive symptoms, anxiety, and anger) affect glycemic control; (2) Recognition of dysphoric symptoms; and (3) Management of dysphoric symptoms using cognitive-behavioral skills.
223868359|NCT04447482|DEVICE|ENB with image-guided lung biopsy|Electromagnetic navigational bronchoscopy system with tip tracked instruments.
223868360|NCT04447482|PROCEDURE|Conventional Bronchoscopy guided by Fluoroscopy|Bronchoscopic lung biopsy with fluoroscopy.
223868361|NCT00105807|BEHAVIORAL|participation in low intensity exercise|
223868362|NCT00105807|BEHAVIORAL|participation in art and music activities|
223868363|NCT01824420|DRUG|Detrusitol 4mg QD and Oxybutynin ER 5mg QD|Study group
223868364|NCT01824420|DRUG|Detrusitol 4mg QD|Control group
223868365|NCT02432950|DIETARY_SUPPLEMENT|Dietary Intervention|Participate in the PNP
223868366|NCT02432950|OTHER|Educational Intervention|Participate in the PNP
223868367|NCT02432950|OTHER|Laboratory Biomarker Analysis|Correlative studies
223868368|NCT02432950|OTHER|Quality-of-Life Assessment|Ancillary studies
223868369|NCT03032913|PROCEDURE|Blood samples|Blood samples for both group
223868370|NCT03032913|PROCEDURE|Portal vein blood sample|Portal vein blood sample during surgery procedure for the Pancreatic Ductal Adenocarcinoma group
223868371|NCT03917303|DRUG|Adalimumab|episodic treatment with subcutaneous adalimumab for 6 months
223868372|NCT03917303|DRUG|standard step-up care|conventional step-up care starting with corticosteroids
223868373|NCT01631851|BEHAVIORAL|Cognitive-Behavioral Therapy (CBT) for Irritability|CBT is an individually administered behavioral interventions aimed at reducing irritability and disruptive behavior. There are 10 to 12 weekly sessions that are conducted with the child and the parent. During these sessions children are taught to recognize antecedents and consequences of problem behavior and to use emotion regulation and problem-solving skills to reduce irritability, aggression and noncompliance.
223868374|NCT02616900|DEVICE|eSight Eyewear|primary intervention
223868375|NCT01488734|DIETARY_SUPPLEMENT|Mushroom with 600 IU vitamin D2|Subjects in this group will eat daily meals containing mushrooms fortified with 600 IU of Vitamin D2. These subjects will also take one placebo tablet per day.
223868376|NCT01488734|DIETARY_SUPPLEMENT|Mushroom with 4000 IU Vitamin D2|Subjects in this group will eat daily meals containing mushrooms fortified with 4000 IU of Vitamin D2. These subjects will also take one placebo tablet per day.
223868377|NCT01488734|DIETARY_SUPPLEMENT|600 IU Vitamin D3 and untreated mushroom|Subjects in this group will take one commercially available tablet of 600 IU of Vitamin D3. These subjects will also eat one meal per day with untreated (inactive) mushrooms.
223868378|NCT01488734|DIETARY_SUPPLEMENT|4000 IU Vitamin D3 and untreated mushroom|Subjects in this group will take one commercially available tablet of 4000 IU of Vitamin D3. These subjects will also eat one meal per day with untreated (inactive) mushrooms.
223868379|NCT01488734|DRUG|Placebo|Placebo for the fortified mushroom arms
223868380|NCT00338650|DRUG|adalimumab|
223868381|NCT02075736|PROCEDURE|KTP laser|
223868382|NCT02075736|PROCEDURE|TUR-P|device
223868383|NCT02813369|DRUG|naloxegol|non-interventional study where patients are exposed to naloxegol during normal clinical practice
223868384|NCT02813369|DRUG|non-PAMORA laxative|non-interventional study where patients are exposed to non-peripherally acting mu-opioid receptor antagonist (PAMORA) laxative
223868385|NCT02499159|DRUG|Liposomal Bupivicaine|266 mg, 20 mL total, diluted at surgeon's discretion, delivered by 22 gauge needle.
223868386|NCT02499159|DRUG|0.25% standard bupivicaine|standard 0.25% bupivacaine, 20 mL total, delivered by 22 gauge needle.
223868387|NCT00002287|DRUG|Zidovudine|
223868388|NCT00002036|DRUG|Anti-HIV Immune Serum Globulin (Human)|
223868389|NCT00036244|DRUG|RG1068 (Synthetic Human Secretin)|
224076536|NCT01460823|PROCEDURE|Percutaneous Cochlear Implantation using image guided surgical techniques|Percutaneous Cochlear Implantation using image guided surgical techniques.
224076537|NCT00353418|DRUG|Peginterferon alfa-2a|180 µg subcutaneously weekly for 48 weeks
223868390|NCT00710775|PROCEDURE|surgical replacement of the aortic stenotic valve|Prior to surgical removal of the aortic valve, the native valve will be dilated under direct vision of the surgeon using a standard valve dilation balloon. The HLT valve will be loaded into a short version of the delivery catheter system and the catheter will be passed across the native valve.Measurements will be taken of the device relative to the anatomic structures of the heart. Once complete, the implant is removed from the native valve and the surgical valve replacement procedure is completed.
223868391|NCT05384366|DRUG|Neoadjuvant chemotherapy|doublet of taxane and carboplatin
223868392|NCT01477255|BEHAVIORAL|iPad|The proposed investigation is a prospective case-control pilot study. The major goal of this pilot study is to assess the feasibility of a daily diary methodology for monitoring the experiences of recently diagnosed pediatric cancer patients and healthy-matched peers. The investigation will also examine the relationships among individual and contextual factors that influence the daily psychosocial functioning of youth with cancer in comparison to youth without cancer.
223868393|NCT04079244|BEHAVIORAL|Video game|"Children receive a tablet with a video game at their arrival on the unit until the introduction of the anesthesia mask.~The video game used is Le Héros C'est Toi, a game specially developed for the unit. The game recreates the hospital environment and includes mini-games geared to children."
223868394|NCT04079244|BEHAVIORAL|Animated cartoon|"Children receive a tablet with an animated cartoon at their arrival on the unit until the introduction of the anesthesia mask.~The cartoon used is L'âge de glace, an animated cartoon geared to children."
223868395|NCT04373434|BEHAVIORAL|Health Homes/Healthy Families (HH/HF) Intervention|The HH/HF Intervention involves coaching calls, text messages and intervention materials that are designed to increase behavioral capability, self-efficacy and behavioral intention to improve the home food environment for healthy eating and weight gain prevention. The intervention is delivered over a 12 week period.
223868396|NCT04373434|BEHAVIORAL|Control|"Participants in the control condition will receive two mailings on healthy eating, the first from the Dietary Guidelines For Americans 2015-2020, 8th Edition and the second from Choose MyPlate. Additionally, both mailings will include a food diary from the Centers for Disease Control and Prevention. Mailings will be sent to participants one and six-weeks post-baseline. These materials focus on the same dietary outcomes being targeted in the HH/HF intervention, but without the home environment emphasis. Control group participants will receive their home environment profile with a list of healthy actions upon completion of the study."
223868397|NCT03903614|BEHAVIORAL|SML|SML consists of supervised handwriting practice, fitness exercises, and fine motor speed drills that preferentially belabor a participant's right eye, ear, hand and leg during therapy.
223868398|NCT03903614|BEHAVIORAL|CON|CON consists of supervised handwriting practice, fitness exercises, and fine motor speed drills on the participant's dominant hand.
223868399|NCT00752713|PROCEDURE|cardiac MRI|cardiac MRI at one time point for group 1 after intervention for group 2 at any time point
223868400|NCT00133458|DRUG|Albendazole|
223868401|NCT06025318|DRUG|PanCytoVir™|PanCytoVir™ 100 mg/mL oral suspension
223868402|NCT03976557|DEVICE|BIP CVC|Central venous access with noble metal coated CVC
223868403|NCT03976557|DEVICE|Standard CVC|Central venous access with standard uncoated CVC
223868404|NCT04294862|DRUG|TNP-2092|TNP-2092 for injection 100mg/vial
223868405|NCT06232889|DIAGNOSTIC_TEST|Deuterium Glucose Metabolic Imaging with MRI spectroscopy|MRI spectroscopy of the liver, following ingestion of 20 mg deuterium glucose p.o., prior to and after radioembolization treatment for mCRC
223868406|NCT01190007|DRUG|Caduet|One Caduet tablet will be administered once daily after breakfast, in principle, for 52 weeks
223868407|NCT02076451|DRUG|DS-8273a|DS-8273a will be administered as an intravenous (IV) solution. Subjects will receive DS-8273a on Day 1 of a 21 day cycle (once every 3 weeks
223868408|NCT02621632|DEVICE|(Socknleg)To done of a novel compression system|To done a novel compression system.
223868409|NCT03301025|DRUG|Pregabalin|Pregabalin 150 mg capsule, one h preinduction of general anesthesia
223868410|NCT03301025|DRUG|placebo|given a placebo identical capsule once one hour before anesthesia
223868411|NCT02080650|DEVICE|Mesenchymal-marker based ferrofluid (c-MET)|
223868412|NCT02080650|DEVICE|Epithelial cell adhesion molecule (EpCAM) ferrofluid|
223868413|NCT00413257|DRUG|Nefopam|0,3mg/kg IV bolus preoperative and 65 µg/kg/h during H48 postoperative
223868414|NCT00413257|DRUG|néfopam|bolus Néfopam (0,3mg/kg) during 10 min at the end of surgery and 65 µg/kg/h during postoperative H48
223868415|NCT00413257|DRUG|Placebo comparator|bolus NaCl during 10 min at the end of surgery and during postoperative H48
223868416|NCT04877834|DRUG|Dexlansoprazole|Dexlansoprazole capsule prepared by SAMI Pharmaceuticals will be administered to this arm.
223868417|NCT04877834|DRUG|Dexlansoprazole|Dexlansoprazole capsule prepared by Takeda Pharmaceutical Company will be administered to this arm.
223868418|NCT02600520|DRUG|SRP with RSV gel LDD|After SRP, 1.2% Rosuvastatin (RSV) gel was delivered subgingivally into the pocket
223868419|NCT02600520|DRUG|SRP with ATV gel LDD|After SRP, 1.2% Atorvastatin (ATV) gel was delivered subgingivally into the pocket
223868420|NCT02600520|DRUG|SRP with placebo gel LDD|After SRP, placebo gel was delivered subgingivally into the pocket
223868421|NCT04075942|PROCEDURE|Atrophic Anterior Maxillary Ridges|Use of modified cortical shell technique grafted with customized Xenograft bone shell
223868422|NCT00364013|DRUG|Panitumumab|Panitumumab 6 mg/kg over on Day 1 of each 14-day cycle, just prior to the administration of chemotherapy.
223868423|NCT00364013|DRUG|FOLFOX regimen|The FOLFOX regimen consisted of oxaliplatin 85 mg/m\^2 intravenous (IV) infusion on Day 1, leucovorin, 200 mg/m\^2 (racemate) on Days 1 and 2 and 5-fluorouracil 400 mg/m\^2 IV bolus followed by 600 mg/m\^2 IV infusion over 22 hours on Days 1 and 2. Each cycle was 14 days.
223868424|NCT00006224|DRUG|gemcitabine hydrochloride|
224076538|NCT00353418|DRUG|Ribavirin|800 mg orally daily for 48 weeks
224076539|NCT00353418|DRUG|Ribavirin|1000 mg or 1200 mg (based on patient weight of \< 75 kg or ≥ 75 kg, respectively) orally daily for 48 weeks
223868425|NCT06259474|COMBINATION_PRODUCT|Hypopressive Exercises and (heat therapy, medication, and progressive strength training)|20 subjects combined HE with traditional treatments for LBP (heat therapy, medication, and progressive strength training). Each session consisted of 5 to 10 HEs. Participants were instructed not to hold their breath or perform PFMS contractions during the HEs. Traditional treatment for low back pain typically involved using medications like acetaminophen (0.5-1 g three times daily) and heat therapy, which consisted of using a continuous heat wrap for 2 hours, 3 times per week at 40 °C, one hour before and after the session
223868426|NCT03586817|DRUG|Palonosetron|75 mcg during the anesthesia
223868427|NCT03586817|DRUG|Fosaprepitant|150 mg during the anesthesia
223868428|NCT00011531|PROCEDURE|Prevention of Pressure Ulcers|
223868429|NCT01591239|BEHAVIORAL|Home-Based Intervention|Parents will be trained through a 3 1/2-hour series on providing a 3-session drug and alcohol intervention program to their adolescent. The parent-led intervention will require parents to meet with their adolescent and work together to help strengthen family cohesiveness, enhance communication, and promote healthy life choices.
223868430|NCT01591239|BEHAVIORAL|Educational Group|Printed fact sheets will be delivered to parents in a single two-hour session. These fact sheets will provide general drug-related information from the public domain (e.g., substance use trends and well-known dangers of substance involvement), and focus on communication approaches and talking points when discussing substance use with their adolescent (e.g., why adolescents use; how the media may influence attitudes about substances).
223868431|NCT03068078|DIETARY_SUPPLEMENT|Low carbohydrate diet high in monounsaturated fats|Participants will have to change their diet during 6 months
223868432|NCT01591304|DEVICE|Ulthera System Treatment|Focused ultrasound energy delivered below the surface of the skin.
223868433|NCT04339855|OTHER|CAD with LCI for colorectal polyp detection|Polyps within fully recorded endoscopy videos with LCI mode, covering the whole spectrum of adenomatous histology, are used to evaluate the efficacy of CAD with LCI for polyp detection.
223868434|NCT06277401|OTHER|Neuromuscular training for the knee|The exercise programme includes exercises identified in literature to target muscles around the knee.
223868435|NCT06277401|OTHER|High-load strength training for the knee|The exercise programme includes exercises identified in literature to target muscles around the knee.
223868436|NCT05124847|BEHAVIORAL|Standard Care|Participants will receive nutritional education sessions and will be instructed to maintain an intake window of at least 13 hours a day, preferably every day of the week and in any case at least 6 days a week.
223868437|NCT05124847|BEHAVIORAL|Time restricted eating|A personalized progression will be established to progressively reduce the intake window during the first 10 days of intervention. After these first 10 days, the participants will be prescribed to limit food intake to a maximum of 10 hours a day, at least 5 days a week. Participant can freely select the time of day to place the intake window. However, it will be recommended to avoid making the last intake in the 3 hours before going to bed. After 4 weeks of intervention, the dietitian will invite them to reduce the intake window to 9 or 8 hours, if they consider it feasible, maintaining this new intake window during the last 4 weeks of intervention. The intake window can be maintained at 10 hours until the end of the study.
223868438|NCT05544643|DEVICE|Medtronic Extended Mio 30 Infusion Set|Safety and Efficacy of Medtronic Extended Mio 30 Infusion Set
223868439|NCT00396513|DRUG|Simvastatin|
223868440|NCT00396513|DRUG|Simvastatin and Metformin|
223868441|NCT00396513|DRUG|Metformin|
223868442|NCT00199966|DRUG|Divalproex sodium extended release|
223868443|NCT03174171|DRUG|Everolimus 0.75 mg|Everolimus 0.75 mg b.i.d. orally for 14 days.
223868444|NCT02272452|DEVICE|High-Resolution Magic-Angle Spinning Nuclear Magnetic Resonance spectroscopy|
223868445|NCT04655859|DIAGNOSTIC_TEST|saliva cotton swab|evaluate the role of thiol/disulfide homeostasis and oxidative stress in the saliva of children with severe early childhood caries and healthy group
223868446|NCT02947958|OTHER|Teleconsultation|Teleconsultation - the teleconsultation usage in chronic diseases, such as benign hyperplasia, seems to be a promising scenario. Once the patient symptoms are evaluated and diagnosed as a stable disease he is able to keep his treatment annually. In a way to do not overload de tertiary system, such monitoring could be done under a teleconsultation with a urological supervision in the primary care.
223868447|NCT02947958|OTHER|Hospital (control)|The patient will keep his usual care at the tertiary care.
223868448|NCT05997966|OTHER|Progresive Resistance Exercises|At the beginning of the study, there will be a home visit (week 0) where the exercises will be taught. Exercise brochures explaining the exercises in written and visual form will also be given to each participant during the first and subsequent home visits. After the first home visit, individuals will be asked to keep an exercise diary prepared by the physiotherapist in order to control the exercises, the occurrence of side effects and dependence on the treatment, and information will be obtained from the individuals by phone calls every week. Two more home visits will take place in weeks 5 and 9 to further the IDE program. Apart from these visits and phone calls, the participant will be allowed to call the physiotherapist if needed. In the exercise group, the 12-week home-based IDE program will be applied 2 sets/day for 3 days/week (on non-consecutive days).
223868449|NCT05997966|OTHER|No intervation|After a general education about osteoarthritis in the control group, 30 minutes of walking will be requested twice a week, and no other intervention will be made.
223868450|NCT03691922|PROCEDURE|Erector Spinae Plane (ESP) Block|"1. Preoperative US guided ESP blockade using 30 mL of 0.25% bupivacaine with 5 mcg/mL of epinephrine, injected in 5-mL aliquots through the needle (maximum of 3 mg/kg)~2. PAI of 30 mL of saline at the end of the surgical procedure on the operated side rotator cuff, injected in 5-mL aliquots through the needle"
223868451|NCT03691922|PROCEDURE|Periarticular Infiltration (PAI)|"1. Preoperative US guided ESP blockade using 30 mL of saline, injected in 5-mL aliquots through the needle~2. PAI of 30 mL of 0.25% bupivacaine with 5 mcg/mL of epinephrine at the end of the surgical procedure on the operated side rotator cuff, injected in 5-mL aliquots through the needle"
223868452|NCT01449422|DEVICE|Dressing|the dressing should be changed on average every 1 to 2 days, then as often as required (up to 7 days) depending on the exudate volume and the clinical condition of the wound (evaluated by the investigating doctor).
223868453|NCT01449422|DEVICE|Dressing|the hydrofibre dressing should be changed when it is saturated, or depending on the clinical appreciation of the situation. The dressing can remain in place for up to 7 days.
223868454|NCT02045459|BEHAVIORAL|Exercise Program|Subject will be exercising on a treadmill 3x/week. Subjects progress will dictate increases/decreases in time of exercise and pace.
223868455|NCT02710708|DRUG|EE20/DRSP (YAZ, BAY86-5300)|YAZ (DRSP 3 mg/EE 20 µg), oral route, 6 cycles of 28 days per cycle, each cycle comprising 24 days of active tablets followed by 4 days of placebo tablets
223868456|NCT01973816|DRUG|Triptoreline 11.25 i.v.; Estradiol 0.5% percutaneous gel;|Triptoreline 11.25 administered for 3 months, two consecutive cures Estradiol administered daily for 6 months
223868457|NCT01973816|PROCEDURE|rectal shaving; rectal disc excision; colorectal resection|
223868458|NCT01973816|DRUG|Cyproterone acetate 50 mg; estradiol 0.5% percutaneous|Daily intake for 18 months
223868459|NCT01973816|DRUG|Estradiol 0.5% percutaneous gel; Cyproterone acetate 50 mg oral|Daily intake during 24 months
223868460|NCT00435578|DRUG|Glufosfamide|
223868461|NCT03596853|OTHER|Progressive mobilization|"Will be applied once a day, 5x/ week, performed into 4 levels: N1 (bridge and rolling for both sides); N2 (transfer training from lying down to sitting on both sides); N3 (sit and stand up from a chair); N4 (running training). According to their functional level, patients will perform, once a day, 8 sets of each movement, alternating 20 seconds of execution with 10 seconds of rest. Patients will be stimulated constantly to perform the movements with the highest possible speed.~If the patient performs adequately within of your level functional level, can will progress in level, if can not progress, there will be an increase in training volume within the level itself. Adequate performance within the functional level means that the patient is able to complete more than eight sets of exercise and does not present increased sensation of pain, present sensation of perceived exertion within the safety limit of the protocol (Borg ≤ 6)."
223868462|NCT03596853|OTHER|Usual Care|This group will receive standard usual, which will be monitored, but not protocolised.
223868463|NCT04113096|DRUG|Dibenzyl trisulphide capsules|20 mg once daily for 6 months
223868464|NCT04113096|DRUG|Dibenzyl trisulphide capsules|20 mg once daily for 6 months
223868465|NCT04113096|DRUG|Dibenzyl trisulphide capsules|20 mg once daily for 6 months
223868466|NCT04113096|DRUG|Dibenzyl trisulphide capsules|20 mg once daily for 6 months
223868467|NCT04113096|DRUG|Stage IV Breast Cancer Placebo|20 mg once daily for 6 months
223868468|NCT04113096|DRUG|Stage IV: Colon Cancer Placebo|20 mg once daily for 6 months
223868469|NCT04113096|DRUG|Cervical Cancer Stage IV Placebo|20 mg once daily for 6 months
223868470|NCT04113096|DRUG|Cancer of the Prostate Placebo|20 mg once daily for 6 months
223868471|NCT04719858|BEHAVIORAL|#LIFEGOALS|"Digital health behaviour change intervention including:~1. self-regulation component with Fitbit: goal setting, monitoring, feedback;~2. narrative component: every week participants receive a new episode (2-5 minutes) of a youth series modeling the target behaviours;~3. chatbot component: automated virtual coach that will send encouraging messages and give an automated answer to user questions.~Participants install the #LIFEGOALS app on their own mobile phone and are asked to use the app during 12 consecutive weeks. Three times per week a notification will be sent to encourage engagement with the intervention."
223868472|NCT03668197|BIOLOGICAL|microbiological analysis|microbiological analysis of the peritoneal fluid
223868473|NCT01338675|DRUG|Busulfan|First dose: busulfan (120 mg/m2 ivs once daily) (if age\<1 yr: 80 mg/ m2) Second to forth dose: according to the daily pharmacokinetic study
223868474|NCT04328155|PROCEDURE|Hotpack Group|Hotpack Group received 20 minutes hotpack to hamstring muscles region at prone position and participants stretched the hamstring muscles at supine position.Self stretching hamstring exercise was done by straight leg lifting using a band three times for 15 seconds .
223868475|NCT04328155|PROCEDURE|Infrared Group|Infrared Group received 20 minutes infrared to hamstring muscles region at prone position and participants stretchted the hamstring muscles at supine position.Self stretching hamstring exercise was done by straight leg lifting using a band three times for 15. seconds .
223868476|NCT04328155|PROCEDURE|Ultrasound Group|Ultrasound Group received 5 minutes 1 M-Hz, 1,5 watt/cm2 ultrasound therapy to hamstring muscles region at prone position and participants stretched the hamstring muscles at supine position.Self stretching hamstring exercise was done by straight leg lifting using a band three times for 15 seconds .
223868477|NCT04328155|PROCEDURE|Control|Control Group participants stretched the hamstring muscles at supine position.Self stretching hamstring exercise was done by straight leg lifting using a band three times for 15 seconds .
223868478|NCT01510717|DEVICE|AcrySof® IQ ReSTOR® +2.5 D Multifocal IOL Model SN6AD2 [SV25T0]|Multifocal IOL with extended secondary focal point implanted for long-term use over the lifetime of the cataract patient
223868479|NCT01510717|DEVICE|AcrySof® IQ Monofocal IOL Model SN60WF|Monofocal IOL implanted for long-term use over the lifetime of the cataract patient
223868480|NCT04692909|DEVICE|dTMS with mPFC stimulation|dTMS with Brainsway's H7 device, stimulating the mPFC.
223868481|NCT05146271|PROCEDURE|Complete mouth rehabilitation under general anesthesia in a group of Egyptian children with Down syndrome|Complete mouth rehabilitation under general anesthesia in a group of Egyptian children with Down syndrome
223868482|NCT02204982|DRUG|Duvelisib|PI3K Inhibitor
223868483|NCT02204982|DRUG|Placebo|Matching Placebo (25 mg BID) administered orally in 28-day continuous treatment cycles.
223868484|NCT02204982|DRUG|Rituximab|IV infusion of rituximab (375 mg/m2) once weekly for 4 weeks during Cycle 1, then once on Day 1 of Cycles 4, 6, 8, and 10.
223868485|NCT03164408|PROCEDURE|Orthopaedic Implant Removal|
223868486|NCT03794635|BEHAVIORAL|Weekly 45 minute Sessions|"The current intervention consists of seven, weekly,45-minute sessions conducted over the telephone using the TAC manual workbook. MSK-approved platforms (such as Webex or Cisco Jabber) can be used for telephone calls in this study. There will be two versions of the intervention used for this study:~1. A culturally tailored version for Latinx participants refined during Phase 1 of this study (available in English and Spanish)~2. A version of the intervention that was not culturally tailored for Latinx patients and caregivers developed in previous work. The two interventions differ in minor content areas. The culturally tailored intervention for Latinx participants and the non-tailored intervention for non-Latinx participants will be used. Interventions will occur weekly with a plus three-week window.~Characteristics of prognostic discussions between patients and caregivers and health providers will be assessed at baseline and post-intervention."
223868487|NCT00210691|DRUG|Risperidone|
223868488|NCT00382850|PROCEDURE|Nissen fundoplication|
223868489|NCT03646279|DEVICE|Calibrace|The CALIBRACE is a new product designed to improve posture using a front-to-back tensioning system that lifts shoulders up and back.
223868490|NCT03381053|DRUG|Imatinib 400mg|The NIH assessment of patients with surgical excision of GIST with moderate to high risk of recurrence was recommended imatinib 400mg treatment.
223868491|NCT04871750|DIETARY_SUPPLEMENT|Soy protein|Daily consumption for 24 weeks
223868492|NCT04871750|DIETARY_SUPPLEMENT|Casein protein|Daily consumption for 24 weeks
223868493|NCT05274217|BEHAVIORAL|Journey of Transformation-Native Youth Health Leadership Program curriculum|Curriculum activities will include traditional storytelling and other Native American cultural arts activities (i.e., drum making, film making), as well as Traditional Ecological Knowledge (TEK) activities and field trips. Curriculum content explains leadership skills and promotes healthy decision-making around substance use and sexual health.
223868494|NCT04594759|DRUG|Isotretinoin|Participants will be getting isotretinoin (1-1.5 mg/kg/week)
223868495|NCT01691326|BIOLOGICAL|Fluzone®: Influenza Virus Vaccine, No Preservative: Pediatric Dose|0.25 mL dose, Intramuscular
223868496|NCT01691326|BIOLOGICAL|Fluzone®; Influenza Virus Vaccine, No Preservative|0.5 mL dose, Intramuscular
223868497|NCT03559348|DRUG|chemotherapy: TS-1, Leucovorin and Gemcitabine|Gemcitabine 800 mg/m2 , on day 1 S-1 80, 100 or 120 mg/d, orally twice daily on day 1 - 7; Leucovorin 60 mg/d, orally twice daily on day 1 - 7; Every 14 days as one cycle.
223868498|NCT06497894|BEHAVIORAL|Cognitive Behavioural Therapy for Insomnia (CBT-I)|CBT-I is conducted in an individual setting according to the manual used in McCurry (1). Factors at the level of behavior, cognitions, and physiology that perpetuate sleep onset and sleep maintenance disorders are addressed. In addition, psychoeducation on sleep and sleep hygiene, stimulus control, sleep restriction, relaxation, structured worry time, cognitive restructuring, and relapse prevention are part of the training. Each session will include homework.
223868499|NCT06497894|DRUG|Hormone Replacement Therapy (HRT)|Standard-dose continuously-combined bio-identical HRT containing transdermal estradiol 1.5 mg/d (= 2 strokes of Oestrogel® Dispenser) and oral micronized progesterone (= 1 capsule of Utrogestan® 200). This combination is the most popular HRT regimen, as it has a neutral effect on lipids, glucose, haemostasis. Participants will receive a conventional prescription for the 2 products that are covered by all health insurances in Switzerland.
223868500|NCT06497894|BEHAVIORAL|Sleep Hygiene|Sleep hygiene refers to healthy sleep habits, e.g. food and drink choices, a regular sleep schedule, evening routine. Although being widely used in daily practice, sleep hygiene shows no significant effect as monotherapy in patients with an established insomnia. The sleep hygiene condition in this study is matched to CBT-I in frequency and intensity of contact.
223868501|NCT04696575|BIOLOGICAL|Atezolizumab|Given IV
223868502|NCT04696575|DRUG|Carboplatin|Given IV
223868503|NCT04696575|DRUG|Etoposide|Given IV
223868504|NCT04696575|DRUG|Lamivudine|Given PO
223868505|NCT06014424|DRUG|CBD|Participants in this arm will receive CBD for 8 weeks during the first treatment period. They will then receive a two-week single-blind placebo washout before moving into the second 8-week treatment period, during which they will receive the opposite study treatment than the one given in the first treatment period.
223868506|NCT06014424|OTHER|Placebo|Participants in this arm will receive placebo for 8 weeks during the first treatment period. They will then receive a two-week single-blind placebo washout before moving into the second 8-week treatment period, during which they will receive the opposite study treatment than the one given in the first treatment period.
223868507|NCT02261467|BIOLOGICAL|OnabotulinumtoxinA|OnabotulinumtoxinA injected into the protocol-specified areas. Subjects will receive at least 1 and up to 3 treatments.
223868508|NCT02261467|DRUG|Normal Saline|Placebo (normal saline) injected into the protocol-specified areas on Day 1.
223868509|NCT01919645|OTHER|Combined Training ( Strength + Aerobics)|Strength training performed using workout devices and aerobic training performed using stationary bicycle.
223868510|NCT03213327|DEVICE|StayOk web application|Patients fill in the questionnaires of the web application and receive an analyzed profile of their psychosocial condition and health-promoting advices
223868511|NCT06973122|PROCEDURE|combined paragastric autonomic neural blockade and laparoscopic assisted transversus abdominis plane block|paragastric autonomic neural blockade and laparoscopic assisted transversus abdominis plane block
223868512|NCT06973122|PROCEDURE|laparoscopic assisted transversus abdominis plane block|laparoscopic assisted transversus abdominis plane block
223868513|NCT06974123|DRUG|A Phase I/II Clinical Study to Evaluate the Safety and Efficacy of Oral Tesilanbaiju in Patients with Radiation Proctitis|"Patients clinically diagnosed with radiation proctitis of CTCAE grade I-II will receive oral administration. Three dose groups of Teslanbai bacteria are tentatively planned, formulated as capsules with viable bacterial counts per capsule of ≥1107 CFU, 1108 CFU, and 1\*109 CFU, respectively. A 3+3 dose-escalation design will be adopted. Each dose group will enroll 3 subjects. If 1 subject experiences a grade ≥3 adverse reaction, 3 additional patients will be added. If 2 subjects exhibit adverse reactions, enrollment into higher dose groups will be discontinued. The final dosage for subsequent use of Teslanbai bacteria will be determined based on efficacy and safety data.~Approximately 9 subjects are planned for enrollment. After determining the optimal dosage, investigators and sponsors will decide whether to proceed to Phase II based on the study results and external data."
223868514|NCT06974123|DRUG|Teslanbai oral therapy|A Phase I/II Clinical Study to Evaluate the Safety and Efficacy of Oral Tesilanbaiju in Patients with Radiation Proctitis
223868515|NCT06973824|OTHER|Frequency of disease recurrence|To collect data of pituitary disease recurrence
223868516|NCT06974149|OTHER|Neurofunctional Rehabilitation|Neurofunctional Rehabilitation Protocol will consist of balance, motor coordination and gait exercises for 40 minutes and associated with tdcs
223868517|NCT06974149|DEVICE|transcranial direct current stimulation|Transcranial direct current stimulation will be applied for 20 minutes at an intensity of 2 mA. The anode will be placed on the scalp over the cerebellar area (2 cm below the inion); the cathode, in turn, will be placed on the spinal column in the lumbar enlargement (2 cm below T11)
223868518|NCT06974149|OTHER|Neurofunctional Rehabilitation|Neurofunctional Rehabilitation Protocol will consist of balance, motor coordination and gait exercises for 40 minutes and associated with tdcs
223868519|NCT06974149|DEVICE|transcranial direct current stimulation|Transcranial direct current stimulation will be applied for 30 seconds at an intensity of 2 mA. The anode will be placed on the scalp over the cerebellar area (2 cm below the inion); the cathode, in turn, will be placed on the spinal column in the lumbar enlargement (2 cm below T11). However the electrodes will be kept for 20 minutes to mask the stimulation
223868520|NCT06973590|DEVICE|Blood flow restriction (BFR)|BFR implementation involves an automated restriction band (SmartCuffs 4.0) positioned at the proximal region of the affected lower extremity, calibrated to 50% of the individual's lower limb occlusion pressure (LOP). The pressure system remains inflated throughout active training phases and is systematically deflated during inter-exercise intervals.
223868521|NCT06973590|DEVICE|Transcutaneous electrical nerve stimulation (TENS)|TENS will be delivered to the anterior thigh region of the paretic leg using a 120z Dual-Channel TENS Unit (ITO Physiotherapy \& Rehabilittaion, Co, Ltd, Tokyo, Japan). The TENS stimulation will be at 100 Hz, with 0.2 ms square pulses at an intensity of twice the sensory threshold (defined as the minimum intensity at which subject reported feeling a tingling sensation and below the motor threshold as indicated by the absence of muscle twitching.
223868522|NCT06973590|DEVICE|Sham blood flow restriction (Sham-BFR)|Sham BFR implementation involves an automated restriction band (SmartCuffs 4.0) positioned at the proximal region of the affected lower extremity, calibrated to 50% of the individual's lower limb occlusion pressure (LOP). But the pressure system remains deflated throughout active training and resting phases.
223868523|NCT06973590|DEVICE|Sham transcutaneous electrical nerve stimulation (Sham-TENS)|Sham TENS will be delivered to the anterior thigh region of the paretic leg using a 120z Dual-Channel TENS Unit (ITO Physiotherapy \& Rehabilittaion, Co, Ltd, Tokyo, Japan). The TENS stimulation will be at 100 Hz, with 0.2 ms square pulses at an intensity of twice the sensory threshold (defined as the minimum intensity at which subject reported feeling a tingling sensation and below the motor threshold as indicated by the absence of muscle twitching. But the stimulator will only be applied for the first and last 30 seconds.
223868524|NCT06973590|BEHAVIORAL|Low-intensity resistance training (LIRT)|The LIRT protocol utilizes 20% of one-repetition maximum (1-RM) as the standardized training load. LIRT including leg extensions, leg presses, and load-bearing squats focused on the affected limb. Each resistance exercise consists of 3 sets of 20 repetitions with rest intervals.
223868525|NCT06972602|DRUG|Topotecan|Intravitreal injection of topotecan at a dosage of 100μg was performed at week 1.Then based on the tumor response and vitreous seeding, it will be decided whether to continue the injection by ophthalmologists.
223868526|NCT06972602|OTHER|Collection of aqueous humor|Patients' aqueous humor samples will be collected for Inflammatory factor testing and IOP control every 4 weeks.
223868527|NCT06972602|OTHER|Electroretinogram|Electroretinogram was performed every 4 weeks.
223868528|NCT06974370|RADIATION|Active Surveillance|Following systemic therapy, participants will undergo active surveillance with brain MRI every 3 months. Radiation therapy will only be initiated if disease progression is observed on imaging, at the discretion of the treating physician.
223868529|NCT06973499|DIAGNOSTIC_TEST|Microbiome Profiling and Symptom Assessment|"GERD symptom assessment: Standardized GERD-Q questionnaire to evaluate reflux symptoms (heartburn, acid regurgitation) and high-risk behaviors.~Microbiome analysis: 16S rDNA sequencing of upper gastrointestinal and intratumoral microbiota."
223868530|NCT06972628|DRUG|Administering Lutetium-177-PSMA-617 (PLUVICTO)|The study begins with a first cohort of three participants, each receiving a dose of 100 millicuries (mCi). After administration, participants are monitored for any dose-limiting toxicities (DLTs) during a predefined observation window. If fewer than two participants experience a DLT in a given cohort, the dose will be escalated for the next group. The dose escalation schedule is structured as follows: the second cohort receives 130 mCi (a 30% increase), the third cohort receives 162.5 mCi (a 25% increase), and the fourth cohort receives 200 mCi, a dose that is already FDA-approved and clinically accepted for mCRPC. This stepwise escalation continues until the 200 mCi dose is reached, or until two or more DLTs are observed in any cohort. If that occurs, escalation stops immediately, and the maximum tolerated dose is considered to be the previous lower dose. This becomes the optimal tolerated dose (OTD). After identifying the OTD, additional participants will be enrolled for treatment.
223868531|NCT06973174|BIOLOGICAL|Premature neonates with invasive infection caused by Bacillus cereus|The whole genome sequencing of the bacterial strains was performed by using both Illumina and Nanopore technologies, allowing us to obatin high quality and complete circular genomes.
223868532|NCT06974422|BEHAVIORAL|Partial weight bearing during aerobic exercise training|Partial weight bearing (25% weight support) during the moderate intensity aerobic exercise training on the antigravity treadmill
223868533|NCT06974422|BEHAVIORAL|Full weight bearing during aerobic exercise training|Full weight bearing (100% weight loading, 0% weight support) during moderate intensity aerobic exercise training on the antigravity treadmill.
223868534|NCT06974422|DRUG|Regular oral anti-diabetic medications.|Participants in the control group (group C) received regular oral anti-diabetic medications.
223868535|NCT06973564|DRUG|JAB-23E73|Oral administration
223868536|NCT06973564|DRUG|JAB-23E73|Oral administration
223868537|NCT06973564|DRUG|JAB-23E73|Oral administration
223868538|NCT06973018|BEHAVIORAL|eRehabCog|eRehabCog is a manualised internet delivered compensatory cognitive rehabilitation program (10 weeks, 1 hour per week, 10 hours in total). It is designed to improve patient self efficacy and participation in everyday life activities through compensatory strategy learning
223868539|NCT06973018|BEHAVIORAL|CogMed QM|CogMed QM is an internet delivered training program (5 weeks, 2 hours per week, 10 hours in total) designed to improve patients working memory
223868540|NCT06973915|OTHER|AI model for movement and pain assessment in low back pain|This intervention involves developing an artificial intelligence (AI) model to objectively assess four physical parameters relevant to low back pain (LBP): 1) sit-to-stand performance, 2) trunk range of motion, 3) gait pattern, and 4) facial expression-based pain levels during movement. The AI model processes video recordings of participants performing these tasks to extract movement and facial data, providing standardized measurements. The tool is designed to assist physiotherapists in clinical decision-making by offering consistent and accurate assessments compared to traditional observational methods.
223868541|NCT06972537|DRUG|Increase the frequency and extended infusion time of Piperacillin Sodium and Tazobactam Sodium for Injection (Bonda) 4.5g|Piperacillin Sodium and Tazobactam Sodium for Injection (Bonda) 4.5g administered four times a day (QID), with each infusion lasting for 4 hours.
223868542|NCT06972537|DRUG|Extended Infusion Time of Piperacillin Sodium and Tazobactam Sodium for Injection (Bonda), 4.5g|Piperacillin Sodium and Tazobactam Sodium for Injection (Bonda), 4.5g administered three times a day (TID), with each infusion lasting for 3 hours.
223868543|NCT03739372|OTHER|Specialized tumor board recommendation|Based on the molecular profile, the specialized tumor board will determine an individualized treatment recommendation for each patient using up to four FDA approved drugs. In special circumstances, Investigational new drug (IND) study agents may be used.
223868544|NCT05026476|DIETARY_SUPPLEMENT|Resource Thicken up Junior|Each infant and child will be switch over to receive for a period of 7 days (new thickener)
223868545|NCT06368453|DEVICE|INSTI® HIV Self-Test|"Each participant will be provided with the INSTI® HIV Self-Test and asked to conduct self testing. The operator will observe the participant and record the subject's interpretation of the results. Subjects will perform the test without intervention from the operator.~The operator will then perform the comparator test and collect a fingerstick blood sample. In the event of a discrepant result between the INSTI® HIV ST and comparator test, an additional venous blood sample will be collected from the subject and sent for discrepancy testing."
223868546|NCT05831007|GENETIC|LX102-C01 Injection|Qualified subjects will receive a single unilateral intravitreal injection of LX102-C01 at Day 0 in the trial.
223868547|NCT02177318|DRUG|Spiriva (tiotropium bromide) inhalation capsules|Survey of patients with COPD using Spiriva (tiotropium bromide) inhalation capsules
223868548|NCT06325761|DRUG|SY-5007|SY-5007 160 mg, Tablets, 2 discrete single doses separated by 7-days
223868549|NCT06325761|DRUG|SY-5007|SY-5007 160 mg, Tablets, 2 discrete single doses separated by 7-days
223868550|NCT03366701|OTHER|Rehabilitation|The intervention (routine care) correspond to five weeks rehabilitation program
223868551|NCT02717117|OTHER|Soup meal|Soup meal as above
223868552|NCT06840574|DIETARY_SUPPLEMENT|Cyruta Plus: A Whole-Food Based Vitamin C supplement containing organic buckwheat (aerial parts) juice powder, organic buckwheat flour, bovine adrenal Cytosol™ extract, oat flour, honey, ascorbic acid|27 mg vitamin C, organic buckwheat (aerial parts) juice powder, organic buckwheat flour, bovine adrenal Cytosol™ extract, oat flour, honey, ascorbic acid, and calcium stearate
223868553|NCT06840574|DIETARY_SUPPLEMENT|Low Dose Vitamin C|27 mg ascorbic acid
223868554|NCT06840574|DIETARY_SUPPLEMENT|High Dose Vitamin C|500 mg ascorbic acid
223868555|NCT00529659|DRUG|Comparator: MK-0773|MK-0773 50 mg tablets twice daily, 6 month treatment period
223868556|NCT00529659|DRUG|Comparator: Placebo|Placebo tablets twice daily, 6 month treatment period
223868557|NCT06647628|DRUG|MK-1708|MK-1708 oral suspension
223868558|NCT06647628|DRUG|Placebo|Placebo oral suspension
223868559|NCT00064012|DRUG|bortezomib|
223868560|NCT00064012|DRUG|docetaxel|
223868561|NCT00095667|DRUG|lapatinib ditosylate|Given orally
223868562|NCT00095667|OTHER|laboratory biomarker analysis|Correlative studies
223868563|NCT01726842|DEVICE|Pediatric Vision Scanner|Subject is scanned with a 2.5 second pediatric vision scanner device test.
223868564|NCT06972316|OTHER|The Global postural reeducation|The Global postural reeducation (GPR) is a series of postures and gentle active movements are performed aimed at stretching shortened muscles, decompressing and aligning joints, with breath¬ing contro
223868565|NCT06972316|OTHER|Traditional treatments|Thermotherapy (hot packs) , Dynamic neck exercises, stretching exercise and posture advice
223868566|NCT06150079|PROCEDURE|Pes-Guided PEEP titration|Lung recruitment is performed at each time point, involving a switch from volume-controlled (VCV) mode to pressure-controlled (PCV) mode with a pressure setting of 20 cmH2O, RR of 15 bpm, I:E ratio of 1:1, FiO2 of 0.4, and PEEP of 5 cmH2O. During lung recruitment, PEEP is gradually increased in increments of 5 cmH2O, maintained for 5 respiratory cycles until PEEP reaches 20 cmH2O and airway pressure reaches 40 cmH2O, and then maintained for 10 respiratory cycles. After lung recruitment, ventilation is adjusted based on the target PEEP. Each PEEP titration should ensure adequate muscle relaxation, volume status, and hemodynamic stability. PEEP is chosen to maintain a positive transpulmonary pressure at end-expiration (PL = PEEP - Pes). Each PEEP titration should ensure adequate muscle relaxation, volume status, and hemodynamic stability.
223868567|NCT05102656|OTHER|Best Practice|Physician conversations occur in-person
223868568|NCT05102656|PROCEDURE|Discussion|Physician conversations occur via video call
223868569|NCT05102656|OTHER|Questionnaire Administration|Ancillary studies
223868570|NCT05854433|OTHER|Non-interventional study|No intervention will be administered as part of this study.
223868571|NCT05253118|DRUG|Tislelizumab|Tislelizumab (BGB-A317) 200mg will be administered on Day 1 of each 21-day cycle (once every 3 weeks) in combination with pemetrexed.
223868572|NCT05253118|DRUG|Pemetrexed|Pemetrexed 500 mg/m2 will be administered on Day 1 of each 21-day cycle (once every 3 weeks).
223868573|NCT06195475|OTHER|high vs low tidal volume|The clinical investigation aims to determine whether exposure to tidal volumes greater than 8 ml/kg of predicted body weight during the initial 72 hours of pressure support mode mechanical ventilation is associated with an increased risk of mortality in the intensive care unit when compared to individuals who maintain a tidal volume equal to or less than 8 ml/kg of predicted body weight.
223868574|NCT06306768|DEVICE|Activity Monitoring|Tracking participants step activity, workout frequency, minutes in target heart rate zone, and type of exercises completed over 1 year period. Goals will be set and customized by a research physical therapist to participants based on best practice recommendations.
223868575|NCT05714696|BEHAVIORAL|Weight discrimination experience|"In the experimental condition, participants will learn that their group members are biased against overweight people but not elderly or racial/ethnic minority individuals, as indicated by the getting to know you summary ratings handout. Participants will also receive negative feedback about their personal attributes by being labeled with negative weight-based stereotypes. Although some ratings will be positive (e.g., they will receive high ratings on being friendly and kind), participants will be rated poorly on attributes viewed as necessary to develop a strong marketing campaign (i.e., motivation to work hard, possessing self-discipline to persist at the task, and competence). After (ostensibly) assembling the group's preferences, the experimenter will inform participants that no one selected them to be their partner, thus they will perform the next few tasks alone. This manipulation has been shown to prompt feelings of social exclusion."
223868576|NCT05714696|BEHAVIORAL|Control experience|"In the control condition, participants will learn that their group members have positive attitudes toward people with higher body weight, as well as elderly and racial/ethnic minority individuals, as indicated by the getting to know you summary ratings handout. Participants will also receive positive feedback about their personal attributes, as indicated by the summary ratings averaged across the three members. Finally, participants in the control condition will be told that one of their group members had to leave unexpectedly for a family emergency, so pairs cannot be assembled as usual, thus they will perform the next few tasks alone. This manipulation should not prompt feelings of social exclusion."
223868577|NCT01872026|DRUG|ASP7991|oral
223868578|NCT03445598|BEHAVIORAL|Interactive and personalized CCBT|Participants will go through an automated program. Participants will learn and practice the techniques of CBT through multimedia elements along with personalized content and interactive features in the program
223868579|NCT03445598|BEHAVIORAL|Feature-limited CCBT|Participants will be going through an automated program. Participants will learn and practice the techniques of CBT in a plain-text format with reduced features.
223868580|NCT03445598|OTHER|Waitlist control|Participants will be put on a waitlist for a period of 6 weeks.
223868581|NCT00074633|BEHAVIORAL|Health at Every Size (HAES)|
223868582|NCT00074633|BEHAVIORAL|Diet (Traditional, moderate energy restriction)|
223868583|NCT00704626|OTHER|Blood Draw|A 5cc sample of serum will be drawn from each subject. Only one blood draw is required, but up to 8 additional blood draws can be obtained.
223868584|NCT00704626|OTHER|Cheek swab|A swab will be swished around the inside of the mouth to collect mouth (buccal) cells. This will be done with each blood draw.
223868585|NCT04890821|DEVICE|CI Percutaneous Ring Annuloplasty System|Percutaneous transcatheter implant and adjustment of the CI ring annuloplasty system.
223868586|NCT02824159|OTHER|Blood samples for pharmacokinetics exploration|6 blood sample at regular intervals
223868587|NCT02824159|OTHER|Imagery|Efficacity will be assessed with 3 sessions of resonance magnetic imaging or positron emission tomography scan
223868588|NCT02824159|OTHER|Quality of life scale|Quality of life will be evaluated with questionaries 5 times during the study
223868589|NCT02824159|OTHER|Detection of adverse events|The detection will be assessed using the AMA (assistance des malades ambulatoires) system
223868590|NCT02824159|GENETIC|Saliva samples|Saliva samples will be collected to explore genetic characteristics of germinal DNA (genes involved in drug pharmacokinetic)
223868591|NCT02824159|GENETIC|Blood sample|A unique blood sample will be performed in order to determine characteristics of tumoral DNA (resistance to treatment mutation)
223868592|NCT02824159|OTHER|Biological statement|"The following parameters will be assessed :~* Complete blood count~* Hemoglobin~* Hepatic enzymes~* Creatinine clearance~* Lactate dehydrogenase rate~* Total bilirubin rate~* Cluster of differentiation 4 T lymphocytes rate~* Total gamma-globulins rate"
223868593|NCT02824159|OTHER|Clinical examination|"The clinical examination are composed by :~* Weigh, Height and body mass index measurement~* Clinical state of patient during examination~* Stage of the disease (OMS grade, binet classification, Ahn Arbor classification)~* Presence of B symptomatology~* Prognostic factors (Genetic, Mantle Cell Lymphoma International Prognostic Index, Follicular Lymphoma International Prognostic Index, presence of lymph nodes, other target organs ...)"
223868594|NCT03589651|DRUG|Retifanlimab|"Part 1: INCMGA00012 at the protocol-defined starting dose administered intravenously every 4 weeks, with dose escalation to determine the maximum tolerated dose.~Part 2: INCMGA00012 at the recommended dose from Part 1."
223868595|NCT03589651|DRUG|Epacadostat|"Part 1: Epacadostat at the protocol-defined starting dose administered orally twice daily, with dose escalation to determine the maximum tolerated dose.~Part 2: Epacadostat at the recommended dose from Part 1."
223868596|NCT03589651|DRUG|INCB050465|Part 1: INCB050465 at the protocol-defined starting dose administered orally once daily, with dose escalation to determine the maximum tolerated dose. Part 2: INCB050465 at the recommended dose from Part 1.
223868597|NCT05566587|OTHER|Mediteranean to Western to Mediteranean Diet|week 2-3 : Switching between Mediterranean diet and Western diet week 4-5 : Switching between Western diet and Mediterranean diet week 6-7 : Switching between Mediterranean diet and Western diet
223868598|NCT05566587|OTHER|Western to Mediteranean to Western Diet|week 2-3 : Switching between Western diet and Mediterranean diet week 4-5 : Switching between Mediterranean diet and Western diet week 6-7 : Switching between Western diet and Mediterranean diet
223868599|NCT02576340|DRUG|otilonium bromide|otilonium bromide was administered before the procedure
223868600|NCT00553189|DRUG|ABT-888|
223868601|NCT00553189|DRUG|Topotecan|
223868602|NCT04139538|PROCEDURE|orthodontic treatment|Malocclusion will be treated with orthodontic appliances (fixed or removable)
223868603|NCT00301990|BIOLOGICAL|aldesleukin|
223868604|NCT00301990|BIOLOGICAL|bevacizumab|
223868605|NCT01406028|BEHAVIORAL|Phone calls|Phone calls to offer emotional support
223868606|NCT00415389|BEHAVIORAL|interactive educational program|2-session interactive stroke educational program
223868607|NCT00415389|BEHAVIORAL|usual medical care|standard educational materials and usual care
223868608|NCT02961179|BEHAVIORAL|Increased dairy product|
223868609|NCT02961179|BEHAVIORAL|Dietary counselling|
223868610|NCT00059241|BEHAVIORAL|Parent-child communication education|
223868611|NCT00059241|BEHAVIORAL|Service learning|
223868612|NCT00059241|BEHAVIORAL|Classroom health curriculum|
223868613|NCT05663918|BEHAVIORAL|Self- determined Intensity Interval Training|Individuals will participate in 3 sessions of Self Determined Intensity Interval training, using a cycle ergometer, for 4 weeks.Ratings of Perceived exertion (RPE) will be measured using a Borg's 6-20 scale. (44). Users will be asked to exercise on a stationary bike at an intensity whereby there RPE is challenging. The cycling protocol includes five, 1-minute cycling intervals, interspersed with 1.5 minutes of recovery (cycling at a slow pace to bring the individuals heart rate down). Participants will also perform a 3-minute warm-up and a 2-minute cool-down for a total exercise duration of 17.5 minutes
223868614|NCT01830946|OTHER|Whey Protein|Whey protein will be consumed every night of the week as the last food or caloric beverage prior to sleep in the evening at least two hours after dinner but no more than 30 minutes before bed.
223868615|NCT01830946|OTHER|Combined Resistance and High-Intensity Interval training|Completed 3 d/wk for 4 wks (2 d of Resistance Training (RT) and 1 d of High-Intensity Interval Training (HITT)). RT exercises were chest press, seated row,leg press, shoulder press, leg extension, and leg curl (3 total sets: 2 sets of 10 repetitions and a 3rd set to muscular exhaustion with a load equaling 75-85% of 1-Repetition Maximum(RM)). All exercises and sets were separated by 90-120 sec of rest. HIIT training was completed on commerical cardiovascular equipment and requires subjects to rate their perceived exertion on a scale from 1 to 10 (1= resting quietly, 5= a warm-up level, 10= an all-out exertion). Subjects warmed-up for 2 min at level 5 and increased their exertion each min for 3 min until level 9 is perceived and then recover at level 6 for 1 min. This pattern was repeated 4 times, where the 4th cycle subjects increased their last min of exertion to level 10, followed by 1-min recovery at the initial warm-up level 5.
223868616|NCT01830946|OTHER|Casein Protein|Casein protein will be consumed every night of the week as the last food or caloric beverage prior to sleep in the evening at least two hours after dinner but no more than 30 minutes before bed.
223868617|NCT00829751|DEVICE|PureVision lenses soaked in ReNu Multiplus|Purevision silicone hydrogel lenses
223868618|NCT00829751|DEVICE|PureVision lenses soaked in OptiFree RePlenish|Purevision silicone hydrogel lenses soaked in OptiFree RePlenish
223868619|NCT03393117|DRUG|Liposomal Bupivacaine|20mL vial of Liposomal Bupivacaine (266 mg). The infiltration technique for Liposomal Bupivacaine will be 80mL injected into either hemi-abdomen as a transversus abdominous plane (TAP) block via ultrasound guidance. The other 80mL will be utilized in the operative breast for the field blocks (20mL), pectoralis 1 (20mL), pectoralis 2 (20mL) and serratus anterior (20mL) blocks.
223868620|NCT03393117|DRUG|Bupivacaine|20mL vial of 0.25% Bupivacaine. The field blocks (20mL), pectoralis 1 (20mL), pectoralis 2 (20mL) and serratus anterior (20mL) blocks will be performed with 0.25% Bupivacaine.
223868621|NCT03393117|DRUG|Patient-Controlled Analgesia Pump|The patient-controlled anesthesia will be filled with morphine or hydromorphone. Pumps will be programmed be on demand only with no basal rate.
223868622|NCT03393117|DRUG|Oral Narcotic|Oral narcotics will be offered when the patient's diet is advanced as tolerated, typically post-operative day 1.
223868623|NCT01514734|DRUG|Brinzolamide/timolol maleate fixed combination|Commercially marketed topical ocular agent for the treatment of open-angle glaucoma (OAG) or ocular hypertension.
223868624|NCT04861012|DEVICE|Ultrasound|All subjects initially will be subjected to abdominal ultrasound, and if fatty liver is detected fibroscan will be done
223868625|NCT00696618|DRUG|Fleet Enema|hyper-osmolar preparation
223868626|NCT00696618|DRUG|tap water enema|hypo-osmolar preparation
223868627|NCT00696618|DRUG|Normosol-R enema|iso-osmolar preparation
223868628|NCT02674750|DRUG|CUDC-907|
223868629|NCT03400969|DEVICE|Glycerol 17%|Glycerol will be applied, using gauze on a lockable tweezer, at the end of the oral care procedure performed by a dentist.
223868630|NCT03400969|DEVICE|Aequasyal (OGT)|Aequasyl (OGT) will be sprayed on the mucosa, at the end of the oral care procedure, preformed by a dentist.
223868631|NCT03400969|DEVICE|Salient (new product)|Salient (new Product) will be applied/given on a spoon, at the end of the oral care procedure, preformed by a dentist.
223868632|NCT02747602|DRUG|AC-1204|40 g (120 mL) AC-1204 administered 30 minutes after the start of a standard breakfast.
223868633|NCT02747602|DRUG|caprylic triglyceride oil (standard breakfast)|20 g CT oil (21 mL) administered 30 minutes after the start of a standard breakfast.
223868634|NCT02747602|DRUG|caprylic triglyceride oil (high fat breakfast)|20 g CT oil (21 mL) administered 30 minutes after the start of a high fat breakfast.
223868635|NCT00138619|DRUG|vildagliptin|
223868636|NCT03319706|DRUG|Torrent's Olmesartan Medoxomil Tablets 40 mg|
223868637|NCT03319706|DRUG|Daiichi Sankyo Inc's Benicar Tablets 40 mg|
223868638|NCT01039142|DRUG|Acitretin|capsule acitretin in dose of 25 mg, 35 mg or 50 mg/ day for 12 weeks or reduction in PASI score by 75% whichever is earlier
223868639|NCT01607372|DRUG|GSK2245035|GSK2245035 nasal spray solution. A solution formulation in saline, preserved with Benzalkonium Chloride and Disodium Edetate
223868640|NCT01607372|DEVICE|Type 1 amber glass bottle|fitted with a metered Valios VP7 pump
223868641|NCT01607372|OTHER|Placebo|As for GSK2245035 nasal spray solution except for omission of the active ingredient
223868642|NCT00551876|DRUG|MK0653, ezetimibe / Duration of Treatment: 30 Weeks|
223868643|NCT00551876|DRUG|Comparator : ezetimibe (+) simvastatin / Duration of Treatment: 30 Weeks|
223868644|NCT01199705|BIOLOGICAL|Immune Globulin Subcutaneous (Human) (SCIG)|IgPro20 is a 20% (weight per volume \[w/v\]) liquid formulation of human SCIG. Subjects will receive weekly infusions of IgPro20 at a weekly dosage calculated based on previous IVIG treatment.
223868645|NCT03150238|OTHER|observation of prognostic factors for relapse|The identification of the most relevant prognostic factors and the definition of their weight in predict the risk of re-intervention will be the basis for the definition of a combined score
223868646|NCT02336776|OTHER|Functional electrical stimulation|"Functional electrical stimulation will be applied through self adhesive electrodes on the quadriceps muscle of both thighs, and these will be positioned at 60° of flexion and contained by a band for that exercise happen isometric form.~Parameter settings in the electrical stimulator are as follows: 80 Hz frequency, 0.4 ms pulse, 10 s time on, 50-20 s time off, intensity according to the patient's tolerance but enough to cause visible muscle contraction. The total time of each session starts at twenty minutes and is increased every week a total thirty-four minutes at the end of the eighth week. Intervention will be held three times a week for eight weeks and during hemodialysis session."
223868647|NCT04666857|OTHER|early motor intervention|infants with CHD after open heart surgery will receive early intervention
223868648|NCT00758433|DRUG|Zucapsaicin|Civamide patch 0.0075% q.d. 24 hours for 7 days
223868649|NCT00758433|DRUG|Zucapsaicin|Civamide patch 0.0150% q.d. 24 hours for 7 days
223868650|NCT00758433|DRUG|Placebo patch|Placebo patch q.d. 24 hours for 7 days
223868651|NCT01964937|BIOLOGICAL|DNA-HIV-PT123|The DNA-HIV-PT123 (containing clade C ZM96 gag and gp140 along with CN54 pol-nef) will be administered at a dose of 4 mg IM.
223868652|NCT01964937|BIOLOGICAL|NYVAC-HIV-PT1|The NYVAC-HIV-PT1 vaccine (containing clade C ZM96 gp140) will be administered at a dose of greater than or equal to 5×10\^6 plaque-forming units (PFU)IM, for a planned maximum dose of 1.2×10\^8 PFU.
223868653|NCT01964937|BIOLOGICAL|NYVAC-HIV-PT4|The NYVAC-HIV-PT4 vaccine (containing ZM96 gag-CN54 pol-nef) will be administered at a dose of greater than or equal to 5×10\^6 PFU IM, for a planned maximum dose of 1.1×10\^7 PFU.
223868654|NCT01964937|BIOLOGICAL|AIDSVAX B/E®|The AIDSVAX B/E ® vaccine will be administered as a 1 mL/600 mcg dose IM.
223868655|NCT01964937|BIOLOGICAL|Placebo vaccine|The placebo vaccine contains sodium chloride for injection USP, 0.9% and will be administered as a 1 mL injection IM.
223868656|NCT06392633|PROCEDURE|spastic hand sugery|Deformity correction can be performed with single event multilevel surgery, using a combination of soft tissue releases and lengthening, tendon transfers and joint stabilization procedures. In addition, selective and supraselective neurectomies can also be performed.
223868657|NCT06392633|DRUG|Botulinum Toxin A|Treatment consists of periodic injections of the toxin into the spastic muscles. It causes reversible chemical denervation by preventing the release of acetylcholine vesicles at the neuromuscular junctions of the affected muscles.
223868658|NCT03942835|OTHER|experience 1 : Competitive attention test in healthy participants|Comparison of behavioral measures (reaction times and percentage of correct responses) obtained twice with the CAT test in healthy participants (2 to 6 weeks apart).
223868659|NCT03942835|OTHER|experience 2 : Competitive attention test in patients with ADHD with no treatment|Behavioral (reaction times and percentage of correct responses) and Electroencephalography (EEG) measures obtained with the CAT test in patients with ADHD with no treatment.
223868660|NCT03942835|OTHER|experience 3 :Competitive attention test in patients with ADHD with psychostimulant treatment|Behavioral (reaction times and percentage of correct responses) and EEG measures obtained with the CAT test in patients with ADHD before and after psychostimulant treatment.
223868661|NCT01779999|OTHER|PICC-carrying patients|Echographic monitoring of patients carrying a peripherally inserted central catheter
223868662|NCT05135013|DRUG|Dydrogesterone Tablets, Norethisterone acetate, Ethinyl estradiol, Drospirenone and ethinyl estradiol|"History of hormonal use as follows:~1. Reason for hormonal use: contraception, fertility promotion, Polycystic ovary syndrome (PCOS)~2. Duration of hormonal use~3. Type of hormonal drug used: dose, hormone type, route of administration"
223868663|NCT00297674|DRUG|Intravenous Clarithromycin|
223868664|NCT00035841|DRUG|TLK286|
223868665|NCT01415349|DRUG|SSP-002358|1 mg, oral, once
223868666|NCT01415349|DRUG|SSP-002358 + omeprazole|SSP-002358 (1 mg) + omeprazole (40 mg) given orally, once
223868667|NCT02032069|OTHER|no intervention|
223868668|NCT00739518|PROCEDURE|MRI|Neurological MRI with new technology evaluation. The new technology may involve software or MRI scanning sequences. This is a long term research study that focuses on new technology that is constantly being created.
223868669|NCT04257136|DRUG|VBI-S|VBI-S is made of small particles of specific lipid called micelles and liposomes for the treatment of hypotension.
223868670|NCT03473340|DRUG|Pirfenidone Capsule|"Dosing:~Days 1 through 7, 267 mg three times daily; Days 8 through 14, 534 mg three times daily; Days 15 through end of treatment (24 weeks), 801 mg three times daily duration: 24 weeks"
223868671|NCT03473340|DRUG|Placebo Capsule|"Dosing:~* Days 1 through 7, 267 mg three times daily;~* Days 8 through 14, 534 mg three times daily;~* Days 15 through end of treatment (24 weeks), 801 mg three times daily duration: 24 weeks"
223868672|NCT05362110|DRUG|HCP1803-3|Take it once daily for 8 weeks orally.
223868673|NCT05362110|DRUG|RLD2002|Take it once daily for 8 weeks orally.
223868674|NCT05362110|DRUG|HPP2003-3|Placebo drug. Take it once daily for 8 weeks orally.
223868675|NCT05362110|DRUG|HPP2004|Placebo drug. Take it once daily for 8 weeks orally.
223868676|NCT03185650|DEVICE|tPAD Device|A novel, transnasal aerosol generator
223868677|NCT03185650|DEVICE|PARI LC Star Nebulizer|Standard oral nebulizer
223868678|NCT02163252|BEHAVIORAL|Standard|
223868679|NCT02163252|BEHAVIORAL|Early Intervention|
223868680|NCT03322124|DRUG|Octenidinedihydrochlorid|Mouth rinsing of the oral cavity with Octenidinehydrochlorid vs.Placebo over a period of 5 days
223868681|NCT03322124|OTHER|Placebo|Mouth rinsing of the oral cavity with Octenidinehydrochlorid vs.Placebo over a period of 5 days
223868682|NCT01105169|DIETARY_SUPPLEMENT|Magnesium glycinate|Oral administration of magnesium glycinate daily for 12 weeks
223868683|NCT01105169|DIETARY_SUPPLEMENT|Placebo|Oral administration of identical-appearing placebo daily for 12 weeks
223868684|NCT01495624|OTHER|ropivacaine plus dexamethasone anesthetic|Subjects will receive interscalen block comprised of 30 ml 0.5% ropivacaine plus dexamethasone 8 mg (2 ml) mixed with the local anesthetic with 2 ml normal saline given intravenously (systemic placebo);
223868685|NCT01495624|OTHER|ropivacaine plus saline plus dexamethasone anesthetic|Subjects will receive interscalen block with 30 ml 0.5% ropivacaine for interscalene block mixed with 2 ml normal saline (perineural placebo) plus dexamethasone 8 mg (2 ml) administered systemically.
223868686|NCT06331494|DRUG|Butylphthalide|Butylphthalide Sodium Chloride injection for 10±3 days, oral Butylphthalide soft capsules for day 11±3 to day 180.
223868687|NCT06331494|DRUG|Placebo|Butylphthalide Placebo injection for 10±3 days, oral Butylphthalide Placebo soft capsules for day 11±3 to day 180.
223868688|NCT06521541|BEHAVIORAL|Multimodal prehabilitation program|Patients adopted planned, structural, repetitive and purposeful approach that includes elements of exercise, nutritional and psychological.Patients were evaluated for changes during neoadjuvant therapy and postoperative recovery
223868689|NCT06521541|BEHAVIORAL|ERAS program|The core content is to adopt a series of optimized measures performed during the perioperative period on the basis of evidence-based medical findings to reduce the physiological and psychological stress of patients and to accelerate their recovery.
223868690|NCT01616459|BIOLOGICAL|Pneumococcal conjugate vaccine GSK2830929A|Intramuscular injection
223868691|NCT01616459|BIOLOGICAL|Pneumococcal conjugate vaccine GSK2830930A|Intramuscular injection
223868692|NCT01616459|BIOLOGICAL|Synflorix™|Intramuscular injection
223868693|NCT01616459|BIOLOGICAL|Prevnar 13™|Intramuscular injection
223868694|NCT01616459|BIOLOGICAL|Infanrix hexa™|Intramuscular injection
223868695|NCT01957124|PROCEDURE|PRF (Platelet-Rich Fibrin)|
223868696|NCT02901197|BEHAVIORAL|Education and Reminder Posters|See arm description
223868697|NCT02901197|OTHER|Policy Change|See arm description
223868698|NCT05239650|DRUG|HLX07|1000mg
223868699|NCT05239650|DRUG|HLX10|200mg
223868700|NCT05239650|DRUG|mFOLFOX6|OXA：85 mg/m2;LV:400 mg/m2；5-FU：400 mg/m2
223868701|NCT02245555|DRUG|Tamsulosin|
223868702|NCT00225004|PROCEDURE|DEXA scan|orto
223868703|NCT03953859|GENETIC|double strand break|an induction of a double strand break will be made in the embryos generated for this research and the repair mechanism observed
223868704|NCT00040313|DRUG|pegaptanib sodium (Macugen)|
223868705|NCT03133234|DRUG|osimertinib|Oral dose of 80mg once daily
223868706|NCT05707624|OTHER|video education|In the study, there are 2 groups in total: the intervention group (n=50) which videos of approaching the febrile child was watched once a week and 2 videos, and the control group (n=49) which no other application is made except for the routine procedure of the hospital
223868707|NCT05707624|OTHER|the routine procedure|the routine procedure
223868708|NCT01401023|DRUG|Tigecycline|: Standard treatment doses of oral antibiotics (vancomycin or metronidazole) for CDAD along with IV tigecycline (100 milligram loading dose followed by 50 milligrams every 12 hours) will be given to patients during their hospitalization (usually 7-14 days). Patients well enough to go home will receive only oral therapy.
223868709|NCT05493449|COMBINATION_PRODUCT|UHT Milk|In this group of participants, UHT milk, 180 mL was provided and results were compared with control and flavored milk group
223868710|NCT05493449|COMBINATION_PRODUCT|Flavored Milk|In this group of participants, flavored milk, 180 mL was provided and results were compared with control and UHT group
223868711|NCT06192043|BEHAVIORAL|Behavioral Psychoeducational Intervention|Psychoeducational Program would be used as an intervention strategy for individuals with smoking cessation to provide understanding and insight to the participants about the problem. Furthermore, this program would deal with interventions like motivation, cognitive conceptualization, coping skills and training, craving management, and relapse prevention among individuals with smoking cessation
223868712|NCT03394885|DRUG|Atezolizumab|1200mg IV q3weeks
223868713|NCT03394885|DRUG|Carboplatin|5-6mg/ML IV q3 weeks
223868714|NCT03394885|DRUG|Paclitaxel|70-80 mg/m2 IV q1 week
223868715|NCT03394885|DRUG|Bevacizumab|15 mg/kg IV q3 weeks
223868716|NCT05100784|BIOLOGICAL|HSSA test|Human Sperm Survival Assay testing performed on different batches of different types of IVF consumables. In practice, 3 consumables from the same batch will be tested with 3 different sperms to ensure the repeatability of the result / test.
223868717|NCT02515305|DRUG|Clindamycin and Benzoyl Peroxide Gel (combination)|
223868718|NCT02515305|DRUG|Clindamycin and Benzoyl Peroxide Gel (Reference) (combination)|
223868719|NCT02515305|DRUG|Placebo gel (combination)|
223868720|NCT04580420|DRUG|DCR-PHXC|Monthly dosing throughout study period
223868721|NCT05674149|DEVICE|camera|photographs using multi-spectral camera
223868722|NCT04654598|OTHER|BPA levels|BPA (bisphenol A) in urine, blood and follicle fluid samples
223868723|NCT03310866|DEVICE|fiberoptic, airway|classic fiberoptic bronchoscope, fenstrated airway
223868724|NCT03310866|DEVICE|fiberoptic, Machintosh|oral fiberoptic brochoscopic, Machintosh laryngoscope
223868725|NCT01925365|DIETARY_SUPPLEMENT|wholegrain cereals oats (WGO)|Volunteers had to consume wholegrain cereals oats (WGO)(45g/day) for six weeks followed by a four week wash out period
223868726|NCT01925365|DIETARY_SUPPLEMENT|Non wholegrain cereals|Volunteers had to consume non wholegrain cereals (NWG)(45g/day) for six weeks followed by a four week wash out period.
223868727|NCT05688592|PROCEDURE|PET-CT|"This is a before-and-after study (not a clinical trial)~* in the case of fungemia, 2 weeks after the initial staging 18F-FDG PET-CT.~* in the case of focal IFIs, 2-4 and 12 weeks after the initial staging 18F-FDG PET-CT"
223868728|NCT03089866|DRUG|Midazolam (0.02mg/kg)|Quantify the effects of sedation with midazolam on auditory activation and cognitive performance (mini Mental State exam and complex reaction time).
223868729|NCT04980755|OTHER|Body Reprogramming|An educational intervention originally designed for patients with fibromyalgia.
223868730|NCT00376519|DRUG|cyclophosphamide|Cyclophosphamide 60 mg/kg/day will be administered as a 2 hour intravenous infusion with a high volume fluid flush and mesna (MT(S)9006) on day -8 and -7 one hour after fludarabine infusion.
223868731|NCT00376519|DRUG|cyclosporine|Will be administered beginning on day -3 and adjusted to maintain a level of \>200. For adults the initial dose will be 2.5 mg/kg intravenously (IV) over 2 hours every 12 hours.
223868732|NCT00376519|DRUG|fludarabine phosphate|Fludarabine 25 mg/m\^2/day will be administered as a 1 hour intravenous infusion on days -9 through -7.
223868733|NCT00376519|DRUG|mycophenolate mofetil|All patients will begin mycophenolate mofetil (MMF) on day -3, at the dose of 3 grams/day divided into 2 or 3 doses (every 12 or 8 hours).
223868734|NCT00376519|PROCEDURE|Treg cell infusion|On day -1 prior to UCB transplantation, Treg cells will be infused IV without in-line filtration. A semi-log dose escalation of CD4+CD25+ Treg cells is scheduled with 3 patients at each step. Doses will be 0.1 x 10\^6/kg, 0.3 x 10\^6/kg, 1 x 10\^6/kg and 3 x 10\^6/kg weight (determined on the day prior to administration of the preparative therapy).
223868735|NCT00376519|PROCEDURE|umbilical cord blood transplantation|Following the administration of the preparative therapy, all subjects will undergo UCB transplantation. The UCB will be administrated by IV infusion without in-line filtration.
223868736|NCT00376519|RADIATION|total-body irradiation|Radiotherapy: 165 cGy will be administered on day -5 through -2 two fractions each day.
223868737|NCT05498363|BIOLOGICAL|Bacteriophage therapy|Difficult-to-treat bacterial infections were treated with bacteriophages (selected from a collection of 25 individual bacteriophages and 6 bacteriophage cocktails), which were shown to target the patient's infecting bacterial strain (in vitro)
223868738|NCT05849233|OTHER|no intervention|no intervention
223868739|NCT00414999|DRUG|TG100801|
223868740|NCT06375668|DIETARY_SUPPLEMENT|Probiotic|The patients who give their consent to take part in this study, will receive one time per day for a period of 12 month a capsule containing ten billions of Lactobacillus plantarum (LP 140 NORDBIOTIC™) and Lactobacillus paracasei (LPC 100 NORDBIOTIC™).
223868741|NCT06375668|OTHER|Placebo|The patients who give their consent to take part in this study, will receive one time per day for a period of 12 months a capsule containing maltodextrin.
223868742|NCT03949335|DEVICE|IOL Model ZFR00V|Bilateral implantation with Investigational IOL Model ZFR00V
223868743|NCT03949335|DEVICE|IOL Model ZCB00|Bilateral Implantation with control IOL Model ZCB00
223868744|NCT00118066|DIETARY_SUPPLEMENT|calcitriol|Given orally
223868745|NCT00118066|PROCEDURE|observation|No initial intervention
223868746|NCT05006092|DEVICE|ENDOMIND|CADe system for Polyp detection
223868747|NCT05727397|DRUG|RC28-E|Ophthalmic solution for intravitreal injection administered as a 2.0mg/50 µL dose.
223868748|NCT05727397|DRUG|Aflibercept|Ophthalmic solution for intravitreal injection administered as a 2.0mg/50 µL dose.
223868749|NCT04926571|DRUG|Dexamethasone Oral|New users of Dexamethasone
223868750|NCT01926977|DRUG|Ranibizumab 0.5mg|Patient will receive intravitreal injection of Ranibizumab 0.5mg.
223868751|NCT01926977|DRUG|Aflibercept 2.0mg|Patients will receive intravitreal injection of Aflibercept 2.0mg.
223868752|NCT04744402|DRUG|Autologous Chondrocyte Implantation (CartiLife®)|CartiLife consists of small beads (1 mm in diameter) in suspension, developed from pellet culture of autologous costal chondrocytes after multiplication. The beads are implanted in an injective manner with fibrin glue through minimal arthrotomy. The dose depends on the size (volume) of the defect, recommended dose is 480 pellets/cm\^3 defect
223868753|NCT03484611|DRUG|GnRH antagonist|0,25mg s.c, cetrotide, serono laboratories, Aubonne Switzerland) is given using flexible protocol, it is given when at least one follicle reaches size 14 mm to prevent premature lutenization ,until the day of hCG administration
223868754|NCT03484611|DRUG|Gonadotropins|started on day 2 of the menstrual cycle until the day of HCG administration(choriomon,IBSA10000IU)with starting dose 300IU to 450IU
223868755|NCT03484611|DRUG|Human chorionic gonadotropin|10000 IU is given to induce final oocytes maturation when at least 2 follicles reached 14 mm or more
223868756|NCT03484611|PROCEDURE|Embryo transfer|0ne to three grade 1 or 2 embryos were transferred on day 3 after oocyte retrieval. Embryo transfer was performed with a Wallace catheter (Smith Medical International Ltd, Hythe, Kent, UK)
223868757|NCT03484611|DRUG|Progesterone|vaginal prontogest 400 mg twice daily
223868758|NCT05375344|BEHAVIORAL|Exercise Group|Home-based exercise group intervention
223868759|NCT05148897|OTHER|Questionnaire|a self-administered questionnaire. Based on extensive literature review no questionnaire was found that specifically related to knowledge evaluation. The basic theme of the questionnaire was taken from Diabetes Knowledge Questionnaire (DKN), a well validated tool for knowledge assessment among type 1 and type 2 diabetes mellitus patients. Some modifications were made and new questions particularly related to GDM were included.
223868760|NCT06552533|OTHER|Resistance Exercises with Plyometric exercises|"We will apply protocol for 8 weeks 24 Sessions (3 sessions in a week) and 10 sec rest between each segment, 3 sets of 10 repetitions.~Resistive training will start in the form of manual resistive exercise for dorsiflexion, plantar flexion, eversion and inversion (manual resistance was applied for 3 to 5 seconds for ten repetitions in each cardinal plane).After resistance training the athletes will go for plyometric exercises and will follow the following guidelines.Tubing Exercises,Plyometric Ankle Jumps Ankle Circles"
223868761|NCT06552533|OTHER|Resistance Exercises without Plyometric exercises|We will apply protocol for 8 weeks 24 Sessions (3 sessions in a week) and 10 sec rest between each segment, 3 sets of 10 repetitions. Resistive training will start in the form of manual resistive exercise for dorsiflexion, plantar flexion, eversion and inversion (manual resistance was applied for 3 to 5 seconds for ten repetitions in each cardinal plane). While controlling the time that a maximal contraction will be maintained, the therapist will assure that the targeted musculature will being maximally loaded
223868762|NCT00801983|DEVICE|Alternative Keyboard|Subjects use either a typical or alternative keyboard
223868763|NCT05594576|PROCEDURE|GI GENIUS™ artificial intelligence system|Device used during coloscopy for detection of colonic adenoma
223868764|NCT05594576|PROCEDURE|ENDOCUFF VISION® endoscopic cap|Device used during coloscopy for detection of colonic adenoma
223868765|NCT06655792|OTHER|Educational Program on Mental Illness Stigma Reduction|The intervention consists of an 8-session educational program designed to reduce stigma towards mental illness among primary healthcare providers. The program includes lectures and multimedia presentations on mental health, stigma, and its effects. It engages participants in role-playing exercises to simulate the experience of stigma and improve communication skills. Group discussions allow participants to reflect on personal beliefs and attitudes, and case studies provide real-world examples of stigma and intervention strategies. The program spans four days, with two sessions per day, each lasting 50-60 minutes.
223868766|NCT04287114|BEHAVIORAL|Acute exercise|Acute exercise with different exercise intensities
223868767|NCT05924958|DRUG|Eprolidone|This study assessed the effect of eplerenone on circulating Treg cells in patients with chronic heart failure by detecting the level of aldosterone in venous blood and the activity of Treg cells and the level of inflammatory factors related to it after taking drugs.
223868768|NCT06051175|OTHER|Bitter taste perception|"Participants will perform a bitter taste perception analysis. During the analysis of sensory attributes, participants will pass the solutions through the various regions of the tongue, and at the end, throw the contents away, not ingesting the solution. Between analyzing the various solutions, participants will rinse their mouth with water.~Simultaneously with the analysis of sensory attributes, each participant will be subjected to an assessment of brain activity and physiological activity through the following non-invasive methods: electroencephalography technique; electrocardiography technique; monitoring cardiac electrical activity; facial mimicry activity via video analysis and eye tracking; and electrodermal activity using galvanic skin response."
223868769|NCT06051175|OTHER|Salty taste perception|"Participants will perform a salty taste perception analysis. During the analysis of sensory attributes, participants will pass the solutions through the various regions of the tongue, and at the end, throw the contents away, not ingesting the solution. Between analyzing the various solutions, participants will rinse their mouth with water.~Simultaneously with the analysis of sensory attributes, each participant will be subjected to an assessment of brain activity and physiological activity through the following non-invasive methods: electroencephalography technique; electrocardiography technique; monitoring cardiac electrical activity; facial mimicry activity via video analysis and eye tracking; and electrodermal activity using galvanic skin response."
223868770|NCT06051175|OTHER|Sweet taste perception|"Participants will perform a sweet taste perception analysis. During the analysis of sensory attributes, participants will pass the solutions through the various regions of the tongue, and at the end, throw the contents away, not ingesting the solution. Between analyzing the various solutions, participants will rinse their mouth with water.~Simultaneously with the analysis of sensory attributes, each participant will be subjected to an assessment of brain activity and physiological activity through the following non-invasive methods: electroencephalography technique; electrocardiography technique; monitoring cardiac electrical activity; facial mimicry activity via video analysis and eye tracking; and electrodermal activity using galvanic skin response."
223868771|NCT06051175|OTHER|Acid taste perception|"Participants will perform a acid taste perception analysis. During the analysis of sensory attributes, participants will pass the solutions through the various regions of the tongue, and at the end, throw the contents away, not ingesting the solution. Between analyzing the various solutions, participants will rinse their mouth with water.~Simultaneously with the analysis of sensory attributes, each participant will be subjected to an assessment of brain activity and physiological activity through the following non-invasive methods: electroencephalography technique; electrocardiography technique; monitoring cardiac electrical activity; facial mimicry activity via video analysis and eye tracking; and electrodermal activity using galvanic skin response."
223868772|NCT06051175|OTHER|Umami taste perception|"Participants will perform a umami taste perception analysis. During the analysis of sensory attributes, participants will pass the solutions through the various regions of the tongue, and at the end, throw the contents away, not ingesting the solution. Between analyzing the various solutions, participants will rinse their mouth with water.~Simultaneously with the analysis of sensory attributes, each participant will be subjected to an assessment of brain activity and physiological activity through the following non-invasive methods: electroencephalography technique; electrocardiography technique; monitoring cardiac electrical activity; facial mimicry activity via video analysis and eye tracking; and electrodermal activity using galvanic skin response."
223868773|NCT06280105|DRUG|Cadonilimab+regorafenib|cadonilimab: 6mg/kg iv D1 Q2W; regorafenib: 80mg QD oral; Eligible patients will receive cadonilimab combined with regorafenib, until disease progression or intolerable toxicity or death or withdrawal of informed consent, whichever occurred first
223868774|NCT02422095|PROCEDURE|Endoscopy-based (EUS-guided) interventions for pancreatic fluid collections|Data included are patient demographics, symptoms, disease severity, procedural indications, details of the pancreatic fluid collection on cross-sectional imaging/EUS, review of laboratory results/imaging, details of interventions, clinical response to intervention, adverse events from interventions and pancreatitis/pancreatic fluid collections, response to treatment including any recurrent hospital admissions, recurrence of pancreatic fluid collections, need for repeat interventions, details of pancreatic duct integrity (e.g. presence of disconnected pancreatic duct syndrome), and clinical status at follow-up.
223868775|NCT02422095|PROCEDURE|EUS of pancreatic cysts|Data included are patient demographics (age, gender, race), symptoms at presentation, imaging modality performed to detect the cyst, cyst features on EUS, technical details of EUS-guided sampling, results of cyst fluid analysis, final diagnosis, any follow up and repeat examinations and details of any treatment performed.
223868776|NCT02270645|DEVICE|595/1064 multiplex laser|595/1064 multiplex laser will be used 3 times spaced by a four week interval (+/- 3 days), it will be administered in an outpatient clinic setting.
223868777|NCT02043054|DRUG|Liraglutide|"Liraglutide (Victoza®, Novo Nordisk) is a stable analogue of the natural hormone glucagon-like peptide-1 (GLP-1). Liraglutide is licensed for use within the United Kingdom and recommended by NICE in combination with metformin, and/or sulphonylurea and/or thiazolidinedione if the following conditions are satisfied.~* BMI ≥ 35 kg/m2 in those of European descent (with appropriate adjustment for other ethnic groups) and specific psychological or medical problems associated with high body weight, or~* BMI \< 35 kg/m2, and therapy with insulin would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities."
223868778|NCT02043054|DRUG|Sitagliptin|Sitagliptin (Januvia®, Merck \& Co) is an enzyme-inhibiting drug used to inhibit the natural enzyme dipeptidyl peptidase-4 (DPP-4). It is an oral antihyperglycaemic agent used in the treatment of T2DM. Sitagliptin is licensed to be used either alone or in combination with other oral antihyperglycemic agents (such as metformin or a sulphonylurea) and is recommended by NICE as a second line therapy.
223868779|NCT03542630|DIAGNOSTIC_TEST|salivary MMP8 test|All female participants will make salivary MMP8 test and certain blood parameters to determine systemic inflammatory response
223868780|NCT03542630|OTHER|periodontal examination|Periodontal examination by a specialist of periodontology will be made to all female participants, using periodontal probe and dental mirror.
223868781|NCT03542630|OTHER|blood tests|All female participants who do not have recent blood tests will make new blood tests to determine certain blood parameters.
223868782|NCT04257435|BEHAVIORAL|Positive Psychological Group Treatment|Positive psychological group treatment will involve engagement in traditional behavioral health treatment, as well as a group treatment focusing on previously researched exercises that have been demonstrated to relate to reduced depression and increased positive emotionality (Seligman, Rashid, Parks, et al., 2005; Seligman, Rashid, \& Parks, 2006; Rashid, 2015).
223868783|NCT04257435|BEHAVIORAL|Traditional Behavioral Health Treatment|Treatment will include traditional individual behavioral health treatment, involving CBT-based therapeutic interventions for presenting diagnoses (typically depression, anxiety, or PTSD-related symptomatology).
223868784|NCT03680703|BEHAVIORAL|Guided Self-Help Behavioral Weight Loss|Participants will be provided with patient-focused materials and worksheets that contain all the necessary information, procedures, and techniques of the behavioral weight loss program. For 12 weeks, treatment will be provided over the internet. This therapy focuses on making gradual and modest lifestyle changes with goals of normalizing eating patterns, decreasing caloric intake, building coping skills, and increasing physical activity.
223868785|NCT02449070|DRUG|Nicorandil|4 mg iv after randomization, 2 mg ic just before ballooning, 2 mg ic just before stenting
223868786|NCT00492271|DRUG|Friulimicin B|Intravenous, once daily, single dose
223868787|NCT03149991|DRUG|Brexpiprazole|Administration of up to 3mg brexpiprazole
223868788|NCT03149991|DRUG|Ketamine|administration 6 times over two weeks of inhaled ketamine
223868789|NCT03149991|DRUG|Placebo|Administration of placebo which matches brexpiprazole in size and number of tablets per dose
223868790|NCT06602973|BEHAVIORAL|Rest|Participants will eat breakfast but abstain from exercise
223868791|NCT06602973|BEHAVIORAL|Fed Exercise|Participants will eat breakfast and engage in 30 minutes of physical activity at 75% of their personal V02max.
223868792|NCT06602973|BEHAVIORAL|Fasted Exercise|Participants will engage in 30 minutes of physical activity at their personal 75% V02max after abstaining from breakfast.
223868793|NCT06501612|OTHER|Continuous Glucose Monitor and Undermyfork App|Participants will be provided two Dexcom G7 sensors to wear during the 20-day intervention period (two 10-day devices). Participants will also be instructed to download and use Undermyfork mobile application where they will have access to their history of their blood glucose responses to their meals in Undermyfork. A randomly selected number of participants in this group will be requested to complete a semi-structured qualitative interview to assess satisfaction with using Undermyfork application immediately following the intervention.
223868794|NCT06501612|OTHER|Continuous Glucose Monitor|Participants will be provided two Dexcom G7 sensors to wear during the 20-day intervention period (two 10-day devices).
223868795|NCT05724472|DRUG|rVSV∆G-SEBOV-GP Vaccine or Placebo|rVSV∆G-SEBOV-GP Vaccine or Placebo
223868796|NCT05332054|BIOLOGICAL|Caribou-sponsored investigational therapy|N/A this is an observational study
223868797|NCT02427633|OTHER|Educational Intervention UKRC 1997|Educational poster intervention indicating the modified UKRC 1997 recovery position
223868798|NCT02427633|OTHER|Educational Intervention UKRC 2010|Educational poster intervention indicating the modified UKRC 2010 recovery position
223868799|NCT02744859|OTHER|Label Condition|Labels will be presented in front of drinks. We will vary the messaging presented to the consumer.
223868800|NCT06312683|DRUG|Rifaximin 550 MG Oral Tablet [XIFAXAN]|Rifaximin 550 MG Oral Tablet \[XIFAXAN\] Taken twice a day for up to 365 days
223868801|NCT06162858|OTHER|IMU (Inertial Measurement Devices)|Functional placing and reaching of objects of different weights on different heights
223868802|NCT01786525|BEHAVIORAL|House Calls|60-minute home based educational intervention which will be administered by a health educator
223868803|NCT01786525|BEHAVIORAL|Web-Based Patient-Centered Decision Support Intervention|Patients will be provided with access to the study website which will allow them to learn and receive LDKT support in a way the best meets their personal values and preferences
223868804|NCT03032224|PROCEDURE|Resection of the esophagus and the gastroesophageal junction|
223868805|NCT01856335|OTHER|Patient Education|
223868806|NCT01856335|OTHER|exercise: increase physical activity/goal setting|
223868807|NCT05264844|OTHER|Masking tape|IV catheters will be fixed with masking tape
223868808|NCT06661590|OTHER|Nutritional Messaging|Dieticians will evaluate nutritional messages created by LLM and Human Experts.
223868809|NCT01278433|BIOLOGICAL|IMOVAX Polio™: Inactivated Poliomyelitis Vaccine|0.5 mL, Intramuscular
223868810|NCT00087880|DRUG|Bupropion and NRT|All participants receive standard 12 week treatment of NRT, bupropion and five group counseling sessions. At week 11, subjects are randomly assigned to one of five treatment groups (1) Bupropion/Low Contact; (2) Placebo/Low Contact; (3) Bupropion/Relapse Prevention; (4) Placebo/Relapse Prevention; (5) No Further Treatment. Data is collected at Week 0, and at weeks 12, 24, 52, 64, and 104.
223868811|NCT04375813|DRUG|eRapa|0.5mg eRapa (encapsulated rapamycin) oral capsules
223868812|NCT04375813|DRUG|Placebos|placebo capsules visually identical to eRapa oral capsules
223868813|NCT06589830|DRUG|TL938 Capsules|Oral administration
223868814|NCT06589830|DRUG|Trastuzumab|Intravenous (IV) infusion
223868815|NCT03817060|PROCEDURE|cryopreservation of embryos at cleavage stage|cryopreservation of embryos at cleavage stage (day 3) of embryo development
223868816|NCT03817060|PROCEDURE|cryopreservation of embryos at blastocyst stage|cryopreservation of embryos at blastocyst stage (day 5 or 6) of embryo development
223868817|NCT06677268|PROCEDURE|rehabilitation|Patients will undergo a respiratory rehabilitation program (24 exercise sessions of 90 minutes each, three times a week for 8 weeks and up to 9 therapeutic education workshops of 1 hour of the patient\&#39;s choice)
223868818|NCT06676124|DIETARY_SUPPLEMENT|Piper crocatum Extract Cookie|Participants in the intervention group will receive cookies containing a standardized 10% ethyl acetate extract of Piper crocatum, known for its antioxidant and anti-inflammatory properties. These cookies will be consumed twice daily for 12 weeks. The intervention aims to assess the effects of Piper crocatum on renal biomarkers, such as MMP-9 and NGAL, in diabetic patients with early renal dysfunction
223868819|NCT06676124|DIETARY_SUPPLEMENT|Placebo Comparator|Participants in the placebo group will receive cookies that are identical in appearance, taste, and texture to the active Piper crocatum cookies but do not contain the Piper crocatum extract. These cookies will be consumed twice daily for 12 weeks, serving as a control to assess the effects of the active intervention on renal biomarkers associated with diabetic nephropathy.
223868820|NCT06676397|PROCEDURE|Blood Punction|venous blood sampling
223868821|NCT06676930|DEVICE|Colonoscopy With Computer-Aided Detection|Use of Computer-Aided Detection During Colonoscopy
223868822|NCT06676930|PROCEDURE|Colonoscopy without Computer-Aided Detection|Colonoscopy without Computer-Aided Detection (AI)
223868823|NCT07048743|DRUG|Psilocybin|Single high-dose (25mg) capsule of psilocybin taken orally in the context of Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) therapy
223868824|NCT05135000|DRUG|LTP001|LTP001, 6 mg, was administered orally once daily in the morning
223868825|NCT05135000|DRUG|Placebo|Placebo to LTP001 was administered once daily in the morning
223868826|NCT06526299|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223868827|NCT06526299|PROCEDURE|Bone Scan|Undergo bone scan
223868828|NCT06526299|PROCEDURE|Computed Tomography|Undergo SPECT/CT and CT
223868829|NCT06526299|DRUG|Lutetium Lu 177 Vipivotide Tetraxetan|Given IV
223868830|NCT06526299|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223868831|NCT06526299|PROCEDURE|PSMA PET-CT Scan|Undergo PSMA PET/CT
223868832|NCT06526299|OTHER|Questionnaire Administration|Ancillary studies
223868833|NCT06526299|PROCEDURE|Single Photon Emission Computed Tomography|Undergo SPECT/CT
223868834|NCT05741827|BEHAVIORAL|Lifestyle intervention|Lifestyle intervention focusing on diet and physical activity
223868835|NCT06893211|DRUG|Tirzepatide|Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. It will be administered via subcutaneous injection once weekly in a dose-titration scheme: starting at 2.5 mg, and increased every 4 weeks by 2.5 mg up to a maximum of 15 mg, based on tolerability. The medication will be supplied in prefilled pens identical in appearance to placebo pens.
223868836|NCT06893211|DRUG|Placebo|Placebo will be administered via subcutaneous injection once weekly using pens that are visually indistinguishable from those used for tirzepatide. Dose escalation will follow the same schedule (2.5 mg-equivalent increments every 4 weeks) to preserve blinding integrity.
223868837|NCT03129555|DRUG|Dabigatran Etexilate Oral Capsule|After cluster randomization, the cluster will use dabigatran to all their patients with venous thromboembolism when possible for six months. Hereafter the cluster will use the other three NOACs for six months one at the time. It is the clusters and not the patient that are randomized.
223868838|NCT03129555|DRUG|Rivaroxaban Oral Tablet|After cluster randomization, the cluster will use rivaroxaban to all their patients with venous thromboembolism when possible for six months. Hereafter the cluster will use the other three NOACs for six months one at the time. It is the clusters and not the patient that are randomized.
223868839|NCT03129555|DRUG|Edoxaban Oral Tablet|After cluster randomization, the cluster will use edoxaban to all their patients with venous thromboembolism when possible for six months. Hereafter the cluster will use the other three NOACs for six months one at the time. It is the clusters and not the patient that are randomized.
223868840|NCT03129555|DRUG|Apixaban Oral Tablet|After cluster randomization, the cluster will use apixaban to all their patients with venous thromboembolism when possible for six months. Hereafter the cluster will use the other three NOACs for six months one at the time. It is the clusters and not the patient that are randomized.
223868841|NCT06724640|DRUG|VH4011499 Injection|VH4011499 Injection will be administered either subcutaneously or intramuscularly.
223868842|NCT06724640|DRUG|Placebo for VH4011499 Injection|Placebo for VH4011499 Injection will be administered either subcutaneously or intramuscularly.
223868843|NCT07060417|DRUG|Empagliflozin|Empagliflozin 10 mg, encapsulated to match the placebo, will be used.
223868844|NCT07060417|DRUG|Placebo|Matching placebo will be used.
223868845|NCT07060287|PROCEDURE|Clock-Guided Minimally Invasive Surgery|All participants underwent video-assisted thoracoscopic surgery (VATS) for pulmonary nodule resection. Nodule localization was performed using a clock-guided anatomical positioning technique with a 3D reconstruction system. The surgical procedure included wedge resection, segmentectomy, or lobectomy based on clinical judgment.
223868846|NCT07061769|DEVICE|SHIFT|SHIFT is a low intensity PEMF cranial device. It has been designated as a Non-Significant Risk device by the FDA.
223868847|NCT07059988|OTHER|Stable isotope tracers|Deuterium-labelled non-radioactive stable isotopes of glucose, phenylalanine and glycerol.
223868848|NCT07059988|DIETARY_SUPPLEMENT|Parenteral nutrition|Parenteral nutrition infused a rate corresponding to 100% of measured energy expenditure, started after blood sampling during a baseline fasting period.
223868849|NCT07060911|DEVICE|Lung monitoring with the Neola device|Lung monitoring with the Neola device
223868850|NCT07060014|DRUG|Patients will be treated with NALIRIFOX (liposomal irinotecan 50 mg/m2 + 5-FU 2400 mg/m2 + LV 400 mg/m2 + oxaliplatin 60 mg/m2, IV) every 2 weeks for 12 months|The study drugs will be administered per the regimen defined in the NAPOLI-3 clinical trial. Patients will be treated with NALIRIFOX (liposomal irinotecan 50 mg/m2 + 5-FU 2400 mg/m2 + LV 400 mg/m2 + oxaliplatin 60 mg/m2, IV) every 2 weeks for 12 months.
223868851|NCT06898346|BEHAVIORAL|Nutrition Education|The treatment group will receive nutrition education (NE) and counseling 6 times. The 1st and 6th counselling sessions will be administered by a Registerd Dietitan in a health facility (weeks 21-22 and weeks 31-32). Four (4) bi-weekly follow-ups between these 2 sessions will be administered by Field Assistants (weeks 23, 25, 27 and 29) at the participant's home. NE will focus on dietary diversity and minimum meal frequency (Daniel et al, 2016; Gyimah et al., 2021), protein and energy intakes (Ota et al, 2015), intake of iron-rich foods (Otoo and Adam, 2016), guidelines for pregnancy with an emphasis on appropriate weight gain (Abubakar et al, 2016), and appropriate ingredients and food preparation methods required to optimize nutrition.
223868852|NCT06842966|DRUG|4-MUST|128 mg of trimebutine 4-methylumbelliferyl sulfate tablet.
223868853|NCT06842966|DRUG|Placebo|Placebo tablet.
223868854|NCT06843330|DEVICE|blood glucose meter; blood lactate meter|Blood lactate level measured by finger-stick with over the counter meter. Blood glucose level measured by finger-stick.
223868855|NCT06498518|DRUG|IMM-101, Pembrolizumab, Gemcitabine|Patients will receive IMM-101, Pembrolizumab, Gemcitabine on a 3 week cycle
223868856|NCT07061119|OTHER|Conventional treatment|"Trampolinejumping:5times. Gym ball exercise:5reps'Sensory diet:- Joint compressions: 1 set x 10reps on limbs, neck, and head region.~Deeppressure:1 setx10reps. Balance board exercises."
223868857|NCT07061119|OTHER|cawthorne cooksey exercises|"Cawthorne Cooksey exercises~* Start with low to moderate intensity.~* Gradually increase range, speed, and Complexity over time~* Trampoline jumping- Gym ball exercise- Sensory diet~* Cawthorne Cooksey exer cise Training~Phase1-In bed exerercises:- Eye movements:~1)Up and down 2)Side to side 3)Moving finger away from face~* Phase2-Sitting: Eye movements as above. Head movements at firsts low, then quick later with eyes closed~* bending forward and backward~* turning from side to side.~  --Shoulder shrugging and circling~* Bending forward and picking up objects from the ground~* Phase 3 - Standing:~* Eye, Head, Shoulder movements~* Throwing ball from hand to hand, hand under knee~* Switch to sitting to standing and turning around in between.~* Phase 4 - Walk: with eyes closed and open:~* Across room~* Slope and Stairs"
223868858|NCT06756477|BEHAVIORAL|mindfulness group|Online training will be implemented 2 times a week for 8 sessions. A 30-45 minute reminder training will be given 1 month after the training. Mindfulness-Based Healthy Living Behaviors Education (MTSYDE) booklet will be sent online to guide students' home practices. Taking into account the possibility of forgetting and demotivation in students, audio recordings will be used, reminder messages will be sent and counseling will be given regarding the program. A post-test will be administered 1 month after the reminder training.
223868859|NCT06756477|OTHER|control group|Menstruation-specific Healthy Living Behaviors training of 30-45 minutes in 8 sessions 2 times a week will be provided online. A standard training booklet will be sent 1 month after the training as a reminder. Standard reminder messages will be sent considering the possibility of forgetting and demotivation in students. A post-test will be administered 1 month after the reminder training.
223868860|NCT06770998|DEVICE|EEG-neurofeedback training|15 training sessions (twice/week) plus two booster training sessions added to treatment as usual.
223868861|NCT06770998|DEVICE|Sham training|15 sham sessions (twice/week) plus two sham booster sessions added to treatment as usual.
223868862|NCT07061405|OTHER|Multidisciplinary management associated with mobile application Doado|multidisciplinary program including physiotherapists, rheumatologists, physical medicine and rehabilitation specialists, occupational physicians, psychologists, etc., associated with Doado mobile application
223868863|NCT07061405|OTHER|Physiotherapy management alone associated with mobile application Doado|monodisciplinary physiotherapy rehabilitation program consisting of active treatment with a physiotherapist associated with Doado mobile application
223868864|NCT07061132|OTHER|AI-Based Interview Simulation|The intervention group participated in a structured, text-based job interview simulation supported by ChatGPT-4o, using nine standardized prompts based on ICN (2008) and ICM (2024) core competencies. Developed by experts in simulation and nursing education, the intervention aimed to enhance self-efficacy and reduce interview-related anxiety. Each session lasted 15-20 minutes and concluded with structured feedback provided by ChatGPT. Participants were also offered an optional preparation guide with 40 reflective questions across themes such as communication, anxiety, and self-awareness. This preparation was not mandatory and not included in the simulation time.
223868865|NCT06337227|DIAGNOSTIC_TEST|lncRNA signature analyses|Specific validation experiments will be performed by Real-Time PCR (C-reactive protein), Western Blot, flow cytometry and microscopy
223868866|NCT05299762|DEVICE|INFUSE™ Bone Graft|Ministry of Food and Drug Safety (MFDS) has approved the INFUSE™ Bone Graft for anterior (ALIF) or oblique (OLIF) lumbar interbody spine fusion as a substitute for autogenous bone graft for patients with degenerative disc disease (DDD) who have had at least 6 months of non-operative treatment for this condition.
223868867|NCT05199571|BIOLOGICAL|Ofatumumab|Solution for injection in an autoinjector (pre-filled pen) containing 20 mg ofatumumab
223868868|NCT04492033|DRUG|CTX-009 (ABL001)|CTX-009 (ABL001) will be administered biweekly.
223868869|NCT04492033|DRUG|Paclitaxel|Paclitaxel will be administered weekly.
223868870|NCT04492033|DRUG|Irinotecan|Irinotecan will be administered biweekly.
223868871|NCT06346834|BIOLOGICAL|sIPV|One dose of the experimental/control vaccine will be administered to 4-month-old infants who have already received two doses of sIPV from Beijing Institute of Biological Products Co., LTD.
223868872|NCT03215927|DRUG|Abatacept|Abatacept 125mg subcutaneous weekly
223868873|NCT03215927|OTHER|Placebo|Placebo
223868874|NCT05344599|DIAGNOSTIC_TEST|Autonomic Function Testing|Autonomic function test (orthostatic blood pressure and heart rate response to tilt, heart rate response to deep breathing, the Valsalva ratio, and beat-to-beat blood pressure measurements during phases II and IV of the Valsalva maneuver, tilt, and deep breathing). These combined tests provide a measurement of adrenergic, cardiovagal responses.
223868875|NCT05344599|DIAGNOSTIC_TEST|Genetic Testing|Genetic testing: for Acute hepatic porphyria panel - with intent to use Saliva kit
223868876|NCT05344599|DIAGNOSTIC_TEST|Urine Testing|Urine PBG, ALA and porphyrins in a spot urine sample with results normalized to urine creatinine
223868877|NCT05344599|DIAGNOSTIC_TEST|Blood laboratory Testing|"To determine the following laboratory analyses:~CBC, CMP, Iron studies (Ferritin and iron studies)"
223868878|NCT04163614|OTHER|IBPS-Guided Ultrafiltration|Each month, the study investigator will review the average intradialytic blood pressure slope from the prior two weeks. A prespecified algorithm will be used to prescribe additional fluid removal/weight reduction based on this slope.
223868879|NCT06515925|BEHAVIORAL|Our Whole Lives (OWL)|"OWL is a nine-session, web-accessible, self-paced mindfulness curriculum that has interactive components of self-monitoring and social support (online community). Our Whole Lives (OWL) online curriculum of self-management topics such as mindfulness, mind-body practices, education about chronic pain therapies, stress reduction, sleep, and nutrition.~Once a week for 9 weeks participants will attend a 1.5 -2-hour online group session via Zoom or Google Meets, accessing it through GEMINI platform."
223868880|NCT06515925|BEHAVIORAL|Low Dose Mindfulness Training|The GEMINI platform will facilitate the delivery of a low-dose version of Our Whole Lives program. OWL in this arm is a nine-session, web-accessible, self-paced curriculum, self-monitoring. Participants will interface with the GEMINI platform's static content.
223868881|NCT06780189|PROCEDURE|Tooth Extraction and Post-Procedure Monitoring Under Sedation in Children Exposed to Passive Smoking|This study is designed to evaluate the relationship between passive smoking and the vital parameters of children undergoing deep sedation. Additionally, the study aims to comprehensively assess and document the entire treatment process from start to finish by using the RASS, MASS, and PAED scales for postoperative evaluation.
223868882|NCT06780189|PROCEDURE|Tooth Extraction and Post-Procedure Monitoring Under Sedation in Children Not Exposed to Passive Smoking|This study is designed to measure the differences in vital parameters of children undergoing deep sedation who are not exposed to passive cigarette smoke at home. Furthermore, the study aims to comprehensively evaluate and document the entire treatment process from start to finish using the RASS, MASS, and PAED scales for postoperative assessment.
223868883|NCT04522271|OTHER|Resistant Starch|7.5 g resistant starch/m2 oral consumption
223868884|NCT04522271|OTHER|Placebo|Placebo oral consumption of food-grade cornstarch
223868885|NCT05436561|DRUG|MBF-RIC|Reduced intensity conditioning regimen with fludarabine, busulfan and melphalan
223868886|NCT03382145|OTHER|No intervention|No intervention
223868887|NCT05937750|DRUG|Imlifidase administered in the 20-HMedIdeS-19 (PAES) study|Imlifidase is an immunoglobulin G (IgG)-degrading enzyme of Streptococcus pyogenes that is highly selective towards IgG. The cleavage of IgG generates one F(ab')2- and one homodimeric Fc-fragment and efficiently neutralizes Fc-mediated activities of IgG.
223868888|NCT05937750|OTHER|Best available treatment administered in the 20-HMedIdeS-19 (PAES) study|Normal transplantation routine Transplantation and pre- and post-transplantation therapies in accordance with the clinic's normal transplantation routine.
223868889|NCT04469699|DRUG|Stereotactic biopsy followed by stereotactical photodynamic therapy with 5-aminolevulinic acid|5-ALA HCl orally (20 mg/kg bw) 3,5-4,5 hours prior to induction of anaesthesia for stereotactic biopsy followed by stereotactical photodynamic therapy. All patients will receive further treatment of recurrent glioblastoma at the investigator´s discretion (best possible care).
223868890|NCT04469699|PROCEDURE|Stereotactic biopsy|Stereotactic biopsy. All patients will receive further treatment of recurrent glioblastoma at the investigator´s discretion (best possible care).
223868891|NCT01000623|DRUG|venlafaxine|Given orally
223868892|NCT01000623|DRUG|placebo|Given orally
223868893|NCT01000623|PROCEDURE|hypnotherapy|Practice hypnosis
223868894|NCT01000623|PROCEDURE|mind-body intervention procedure|Practice focused attention
223868895|NCT06276465|DRUG|Darolutamide 300 mg|2 tablets of 300 mg twice daily (=1200 mg/day) up to 5 years from randomisation
223868896|NCT06276465|RADIATION|Stereotactic body radiation therapy|Over one week,30 Gy in 3 fractions of 10 Gy
223868897|NCT06276465|DRUG|Androgen deprivation therapy|Continuous ADT during the study course. The choice of ADT is left to the discretion of the investigator.
223868898|NCT06522061|DEVICE|Stream™ Platform|Stream™ Platform consists of 5 main components: Origin™, Delta™ Monitor, Stream™ Application, Accessory Calibration Syringe(s), and Stream™ Cart. Origin™ is an inline biosensor system that can be attached between an off-the-shelf drainage catheter and evacuator bag/bulb system and is designed to monitor real-time changes in drained effluent characteristics (specifically pH and electrical conductivity (EC)) for the early identification of postoperative complications. Origin™ requires daily calibration (via Accessory Calibration Syringe(s)) for optimal performance and accuracy of its sensors. The Stream Application is a mobile application for displaying and analyzing data collected continuously via Origin™. Stream™ Application is pre-installed on Android mobile devices (called Delta™ Monitor) that are supplied by FluidAI. Origin connects to Stream Application via Bluetooth. Mobile carts/mounts, denoted Stream™ Carts/Delta Mounts, will be used to house the Delta™ Monitor.
223868899|NCT05430997|DEVICE|IOB Warming Unit (WU505) + Inflatable Warming Blanket|The inflatable warming method (Inflatable Warming Unit (IOB Warming Unit, WU505) + Inflatable Warming Blanket (IOB Warming Blanket)) is a common clinical warming technique in anesthesiology, which is well tolerated by patients and safe and effective. The anesthesiology department has established standard operating procedures for the above-mentioned non-invasive operations.
223868900|NCT05430997|DEVICE|cover with a quilt from the neck to both feet|The patient was covered with a quilt from the neck to both feet after entering the operating room.
223868901|NCT03073941|DEVICE|Persona total knee system|314 participants with knee osteoarthritis set to receive primary total knee arthroplasty will receive either Persona knee or the Nexgen
223868902|NCT03073941|DEVICE|Nexgen total knee system|314 participants with knee osteoarthritis set to receive primary total knee arthroplasty will receive either Persona knee or the Nexgen
223868903|NCT03712813|DEVICE|Macrodyne LivMD plate|Synchronous (applied to both feet) low intensity vibration for 10 minutes, twice daily for 12 months.
223868904|NCT05361369|DRUG|EVEGYN 600 mg/1000 mg/100 mg Vaginal Ovule|Fixed dose combination of 600 mg fenticonazole nitrate + 1000 mg tinidazole + 100 mg lidocaine
223868905|NCT06814288|DRUG|Botulinum toxin A|Twenty keloid patients will be injected botulinum toxin A intralesional every 4 weeks.
223868906|NCT06814288|DRUG|Triamcinolone Acetonide|Twenty keloid patients will be injected triamcinolone acetonide intralesional every 4 weeks.
223868907|NCT05684432|OTHER|No intervention|No intervention
223868908|NCT04617314|DRUG|RC108|RC108 for injection is a novel antibody-drug conjugate, with a c-Met-targeting antibody and a microtube inhibitor.
223868909|NCT01758328|DRUG|busulfan|
223868910|NCT01758328|DRUG|melphalan|
223868911|NCT01758328|DRUG|fludarabine|
223868912|NCT01758328|BIOLOGICAL|anti-thymocyte globulin (ATG)|
223868913|NCT01758328|PROCEDURE|a T cell depleted stem cell transplant|
223868914|NCT06548607|DRUG|RD06-04 or RD06-05 CART Cell Injection|CAR T-cell therapy administered intravenously after a lymphodepleting therapy regimen consisting of fludarabine and cyclophosphamide.
223868915|NCT06439017|OTHER|Questionaire|The study will involve completing the Mind Excessively Wandering Scale (MEWS) and World Health Organization Disability Assessment Schedule 2.0 (WHODAS 2.0), a 36-item self-administered questionnaire.
223868916|NCT06455826|DRUG|VP-001|A Phase 1 Open-Label, Multiple Ascending Dose Study of VP-001 in Participants with Confirmed PRPF31 Mutation- Associated Retinal Dystrophy
223868917|NCT04250883|OTHER|Low intra-abdominal pressure|8 mmHg
223868918|NCT04250883|OTHER|Deep neuromuscular blockade (NMB)|Deep NMB (PTC1-2)
223868919|NCT04250883|OTHER|Standard intra-abdominal pressure|14 mmHg
223868920|NCT04250883|OTHER|Moderate neuromuscular blockade (NMB)|Moderate NMB (TOF 1-2)
223868921|NCT05969574|DIAGNOSTIC_TEST|Transvaginal ultrasound|Transvaginal ultrasound for antral follicle count (AFC) performed on the day of first consultation
223868922|NCT05969574|DIAGNOSTIC_TEST|Blood test AMH|Measurement of AMH performed on the day of first consultation
223868923|NCT03624712|DIAGNOSTIC_TEST|uterine neoplasms|Analysis of circulating (CTC) and disseminating tumor cells (DTC), determination of Human Papilloma Virus (HPV), Douglas cytology, DNA analysis in blood, proteome analysis, sentinel lymph node detection
223868924|NCT02398825|DRUG|Ponatinib|Ponatinib is given orally 30 mg daily, with dose adjustment to 15 mg daily once a BCR-ABL1 level minor or equal to 0.1% (MMR) has been achieved and confirmed in the next test, 4 weeks apart. A return to prior, 30 mg, dose is due in case of return of BCR-ABL1 transcripts level to \> 1%. Dose adjustments for toxicity are detailed in the protocol.
223868925|NCT04926181|DRUG|Apalutamide|240 mg once daily, for a 28 day cycle
223868926|NCT04926181|BIOLOGICAL|Cetrelimab|480 mg given through intravenous infusion (IV) on day 1 of every 28-day treatment cycle and administered over a 60-minute infusion
223868927|NCT04701307|BIOLOGICAL|Dostarlimab|Given IV
223868928|NCT04701307|DRUG|Niraparib|Given PO
223868929|NCT03710798|DIETARY_SUPPLEMENT|Low carbohydrate high fat diet|Energy balanced low carbohydrate high fat diet during 6 weeks. Then 6-week reintroduction of a healthy normal diet
223868930|NCT01643499|DRUG|oxaliplatin|Given IV
223868931|NCT01643499|DRUG|irinotecan hydrochloride|Given IV
223868932|NCT01643499|DRUG|leucovorin calcium|Given IV
223868933|NCT01643499|DRUG|fluorouracil|Given IV
223868934|NCT01643499|OTHER|laboratory biomarker analysis|Correlative studies
223868935|NCT04505371|BEHAVIORAL|Wellness Intervention for Smokers with HIV|"WISH is delivered remotely by mobile phone (voice and text message). WISH addresses both smoking and a number of other personally relevant health behaviors (such as treatment engagement, medication adherence, stress and mood management, social support, alcohol use, etc.), making it relevant and engaging to all, not just those ready to stop smoking. For those not yet ready to quit, WISH is designed to build and strengthen motivation and self-confidence for quitting, while smokers also work on other personal health goals.~Once ready to quit smoking, participants receive evidence-based cognitive-behavioral counseling and encouragement to access nicotine replacement therapy (NRT) or other appropriate pharmacotherapy through usual care VA procedures. Medications will not be prescribed or dispensed by the study."
223868936|NCT06506045|DEVICE|FlowSense|This study compares the performance of two generations of non-invasive cerebrospinal fluid (CSF) shunt flow assessment devices. Measurements of known non-functional and functional implanted shunts will assess the diagnostic non-inferiority of the second-generation device to the first-generation device.
223868937|NCT04527822|OTHER|Nurse led discharge planning program|a discharge planning program. It is a modified discharge planning program depends basically on the Re-Engineered Discharge program which is a program developed by Boston Medical Center in collaboration with AHRQ , 2013. The intervention consists of several components. The program components include making appointments for follow-up care (e.g., medical appointments and post discharge tests/labs). Plan for the follow-up of results from tests or labs that are pending at discharge. Identify the correct medicines and a plan for the patient to obtain them. Teach a written discharge plan the patient can understand. Educate the patient about his or her diagnosis and medicines. Review with the patient what to do if a problem arises. Assess the degree of the patient's understanding of the discharge plan and provide a telephone reinforcement of the discharge plan
223868938|NCT02803801|BEHAVIORAL|Build Your Parenting Toolkit Program|Ten session program, with a mix of parents-only lectures and parent and child Cooking Clubs.
223868939|NCT04846127|DEVICE|CanGaroo Envelope|Utilization of a CanGaroo envelope with the CIED during the participant's CIED implant procedure.
223868940|NCT01188655|DRUG|Enbrel|"The patients will be treated in accordance with the requirements of the labeling of Enbrel® in Austria. The dosage and duration of therapy is to be determined by the physician to meet the patients' individual needs for treatment.~To record complete dosing information, initial dose will be documented at baseline and any change will be documented with date, dose and reason at the subsequent visits."
223868941|NCT04425668|BEHAVIORAL|Academic detailing (AD)|In addition to continuing educational (CE) videos this group will receive up to two personalized, one-on-one, education sessions from an academic detailer. The sessions will last between 15-30 minutes. Each AD visit will consist of: an introduction, a brief needs assessment, key educational messages, a discussion of challenges the provider faces, and giving the provider leave-behind educational materials. The AD visit key educational messages are specific recommendations for opioid-prescribing practice change. When appropriate the detailer will suggest a phone call with Dr. Romesh Nalliah to discuss specific dentistry questions. There may also be a second AD visit if agreed upon by the dentist.
223868942|NCT04425668|OTHER|Continuing educational|"Dentists enrolled in the CE program will serve as the control group. They will have access to the 3 hours of CE content online similar to the AD group; however, they will not receive academic detailing or the opportunity to connect via phone with Dr. Nalliah.~In this group, if the dentists have content-specific questions after participating in the CE program, they may contact MichiganOPENdental@umich.edu for responses appropriately directed to Dr. Nalliah."
223868943|NCT05721105|OTHER|Quality of life assessment using questionnaires|Several quality of life questionnaires will be submitted to the patients and their parents. The questionnaires will be adapted to the age of the patients.
223868944|NCT04894565|PROCEDURE|rehabilitation|physical therapy 24 hrs after surgery
223868945|NCT02326987|DRUG|Pregabalin 150mg|GLA5PR GLARS-NF1 tablet 150mg/day(Pregabalin 150mg once a day)
223868946|NCT02326987|DRUG|Pregabalin 75mg|Lyrica Capsule 150mg/day(Pregabalin 75mg twice a day)
223868947|NCT01277250|BEHAVIORAL|Web-based smoking cessation program|"Web-based smoking cessation program that includes a transition coach to hospitalized patients who will assist them in quitting as they are discharged from the hospital. Intervention arm participants will have access to a tailored web-based intervention that will include e-messages and activities that are tailored to their recent hospital stay."
223868948|NCT02703246|PROCEDURE|abdominal morcellation|patients will be randomized to receive abdominal morcellation
223868949|NCT02703246|PROCEDURE|vaginal morcellation|patients will be randomized to receive vaginal morcellation
223868950|NCT03059394|DEVICE|Non intervention study|Test - Retest of measurements
223868951|NCT05869123|RADIATION|Online adaptive radiotherapy|PTV with 5 margins covers CTV
223868952|NCT05915546|DRUG|Emraclidine|Tablets
223868953|NCT00798642|BEHAVIORAL|Hypnotherapy|8 weeks of gut-directed hypnotherapy
223868954|NCT00798642|BEHAVIORAL|Standard care|8 weeks of standard of care
223868955|NCT00798642|BEHAVIORAL|Mind Body Therapy|8 weeks of mind-body therapy
223868956|NCT05083728|DIAGNOSTIC_TEST|CT|Clinicians are free to choose the adult subjects in whom a non-contrast calibrated CT-scan will be performed as a part of routine clinical care. The decision to order a noncontrast CT-scan of the shoulder must be made prior to, and independently from, the decision to enroll the patient.
223868957|NCT04780035|BIOLOGICAL|EpiVacCorona (EpiVacCorona vaccine based on peptide antigens for the prevention of COVID-19)|"The EpiVacCorona vaccine is intended to prevent COVID-19. The vaccine relies on chemically synthesized peptide antigens of SARS-CoV-2 proteins conjugated to a carrier protein and adsorbed on an aluminum-containing adjuvant (aluminum hydroxide).~The vaccine induces the specific immunity against the SARS-CoV-2 coronavirus following two intramuscular injections spaced 21 to 28 days apart.~The EpiVacCorona vaccine contributes to the development of protective immunity against SARS-CoV-2 coronavirus following two intramuscular administrations given 21 to 28 days apart."
223868958|NCT04780035|OTHER|Placebo (sodium chloride, a 0.9% solution for the preparation of dosage forms for injections)|The use of placebo: intramuscularly twice, given 21 to 28 days apart at a dose of 0.5 ml
223868959|NCT00089544|DRUG|Dacarbazine|Given IV
223868960|NCT00089544|DRUG|Doxorubicin Hydrochloride|Given IV
223868961|NCT00089544|BIOLOGICAL|Filgrastim|Given subcutaneously
223868962|NCT00089544|DRUG|Ifosfamide|Given IV
223868963|NCT00089544|OTHER|Laboratory Biomarker Analysis|Correlative studies
223868964|NCT00089544|RADIATION|Radiation Therapy|Undergo radiotherapy
223868965|NCT00089544|DRUG|Thalidomide|Given orally
223868966|NCT00089544|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgical resection
223868967|NCT03807908|OTHER|Tape|"The patient will be placed into maximal flexion of the lumbar spine prior to the tape being applied. The vertical strips will be applied on either side of spine, on the erector muscle group; from the lower PSIS with and end around the twelfth rib. The third strip of tape will be applied horizontally to superior to the posterior superior iliac spines (PSIS) and extend over the 2 vertical strips of tape. The tape will be gently rubbed to activate the adhesive.~Five to 7 days later, one of the investigators will follow up with the subjects over the phone and administer a questionnaire that will assess their experience with the tape as well as the outcome measures (numeric rating scale and Oswestry Disability Index)."
223868968|NCT03807908|OTHER|Sham Tape|"One strip of tape will be applied horizontally to the thoracolumbar junction (at the level of the lower rib cage over the T12-L1 spinous processes) with no tape-tension. The tape will be gently rubbed to activate the adhesive.~Five to 7 days later, one of the investigators will follow up with the subjects over the phone and administer a questionnaire that will assess their experience with the tape as well as the outcome measures (numeric rating scale and Oswestry Disability Index)."
223868969|NCT00014040|DRUG|Nitric Oxide and INOpulse Delivery System|
223868970|NCT00227994|DRUG|Galantamine|Participants assigned to receive galantamine will receive 4 mg twice a day for 4 weeks, 8 mg twice a day for the next 4 weeks, and 12 mg twice a day for the remainder of the study.
223868971|NCT00227994|DRUG|Donepezil|Participants assigned to receive donepezil will receive 5 mg twice a day for 6 weeks, and then 10 mg twice a day for the next 6 weeks.
223868972|NCT05726604|OTHER|Respiratory gating|10 minutes breathing motion monitoring during an additional CT scan to establish a more accurate cardiac and LAD dosimetry compared to reality
223868973|NCT05680389|DRUG|Minocycline|100 mg twice daily for 3 months
223868974|NCT05680389|DRUG|Placebo|twice daily for 3 months
223868975|NCT00000994|DRUG|Zidovudine|
223868976|NCT04044807|DIAGNOSTIC_TEST|Modified National Institutes of Health Stroke Scale|Clinical tool used in the diagnosis of acute stroke developed by the National Institutes of Health, and modified for simplicity.
223868977|NCT02582736|DRUG|Olanzapine|Exposure to olanzapine (ATC N05AH03) will be defined as a prescription for olanzapine on the date of cohort entry.
223868978|NCT02582736|DRUG|Risperidone|Exposure to risperidone (ATC N05AX08) will be defined will be defined as a prescription for risperidone on the date of cohort entry.
223868979|NCT02582736|DRUG|atypical antipsychotics (other)|Exposure to other atypitical antipsychotics (ATC N05AH02, N05AH04, N05AE04, N05AX13, N05AX12) will be defined will be defined as a prescription for an atypical antipsychotic other than olanzapine on the date of cohort entry.
223868980|NCT02582736|DRUG|typical antipsychotics|Exposure to typical antipsychotics (M03BB02, N05AA01, N05AF03, N05AF01, N05AB02, N05AG01, N05AD01, N05AA02, N05AH01, N05AC03, N05AB03, N05AG02, N05AC04, N07XX06, N05AB05, N05AB08, N05AC02, N05AF04, N05AB06, N05AF05) will be defined as a prescription for a typical antipsychotic on the date of cohort entry.
223868981|NCT00477308|PROCEDURE|salvage therapy|
223868982|NCT05670834|GENETIC|genotyping assay by real-time PCR|genotyping assay of MMP-2 gene with the real-time polymerase chain reaction
223868983|NCT05670834|DIAGNOSTIC_TEST|ELISA|. IL-6 level in serum will be analyzed by ELISA assay kit.
223868984|NCT06357559|DEVICE|OCTA|Optical Coherence Tomography Angiography
223868985|NCT04861233|OTHER|No Intervention|This is a non-interventional study.
223868986|NCT03097770|BIOLOGICAL|anti-CD19/20-CAR vector-transduced T cells|genetically engineered lymphocyte therapy
223868987|NCT00338442|DRUG|VariZIG™|Biological / Vaccine
223868988|NCT00326144|DRUG|Quetiapine fumarate|
223868989|NCT04112069|DEVICE|iLet Bionic Pancreas insulin-only configuration with Humalog or Novolog|iLet Bionic Pancreas insulin-only configuration with Humalog or Novolog
223868990|NCT04112069|OTHER|Usual Care|Usual care
223868991|NCT01745016|DIETARY_SUPPLEMENT|Placebo|
223868992|NCT01745016|DIETARY_SUPPLEMENT|Beta-alanine|
223868993|NCT00306397|DRUG|Rapamycin|Sirolimus perorally following kidney transplantation, randomisation after protocol biopsy at months three to a) Sirolimus - MF- or b) low dose tacrolimus - sirolimus -MMF -
223868994|NCT06285149|DRUG|Icaritin|This product is suitable for patients with unresectable hepatocellular carcinoma who are not suitable for or refuse to receive standard treatment and have not received systemic treatment in the past, and the peripheral blood compound markers of patients meet at least two of the following detection indicatorsItem: AFP\>400 ng/mL; TNF-a\<2.5 pg/mL; IFN-y\>7.0 pg/mL.The conditional approval is based on data from an interim analysis of an enriched population in a randomized controlled Phase 11 clinical trial, and full approval for this indication will be subject to confirmation of the clinical benefit of the product in planned confirmatory trials.
223868995|NCT00006368|RADIATION|yttrium Y 90-edotreotide|
223868996|NCT00973115|DRUG|Simvastatin CR|
223868997|NCT00864552|DRUG|Kogenate (BAY14-2222)|Patients with severe haemophilia A (\<2% FVIII:C baseline level) treated with Kogenate Bayer as their only source of recombinant FVIII
223868998|NCT02872480|OTHER|ACTIVE Training|Participants will be asked to complete aerobic exercise on a stationary bike during 30-minute sessions. Intensity will progress under a standard procedure for healthy participants (60-80% of VO2max) and as tolerated by concussed participants (starting at 60% of symptom exacerbation).
223868999|NCT05100589|DIETARY_SUPPLEMENT|PeakATP|Powder - 400mg Peak ATP, maltodextrin, silica-colloidal anhydrous, citric acid anhydrous, sucralose, guar gum
223869000|NCT05100589|DIETARY_SUPPLEMENT|Placebo|Powder - maltodextrin, silica-colloidal anhydrous, citric acid anhydrous, sucralose, guar gum
223869001|NCT00526006|DRUG|esomeprazole|40 mg od for 8 wks
223869002|NCT05324878|OTHER|Training|Social workers/nurses participants are agreeing to participating in the training program (3 sessions of 2 hours over a period of six weeks - one session every 2 weeks), follow up training sessions (occurring monthly), mentorship calls with social worker faculty on the project team, recording one conversation between social worker and a patient for quality improvement purposes, and completing evaluation of the project interventions (5-minute questionnaire after each education session, 15-minute questionnaire at end of participation in project).
223869003|NCT03612375|OTHER|ENDS (vaporizer/e-cig) and smoking cessation counseling|Participants in the intervention group will receive an ENDS and nicotine-containing e-liquids, which they will be allowed to use ad libitum. Additionally, they will receive smoking cessation counseling. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 24-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6, 12 and 24 months, participants will be asked to come to a clinical visit.
223869004|NCT03612375|OTHER|smoking cessation counseling|Participants in the control group will receive smoking cessation counseling only. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 24-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6, 12 and 24 months, participants will be asked to come to a clinical visit.
223869005|NCT00484055|DRUG|Local application of collagen-gentamicin|Application of 2 sponges (5 x 20 cm) of collagen-gentamicin between the sternal halves immediately before sternal closure
223869006|NCT00484055|PROCEDURE|Fixation of the sternotomy with more than six wires|At least 7 (or more) sternal fixation wires (preferaby put as separate single wires) used for fixation of the sternum at wound closure
223869007|NCT04351386|DEVICE|AF Detection|Recording PPG and single-lead ECG signals with the Withings HWA09 and ECG signal for the reference 12-lead ECG
223869008|NCT01892683|DRUG|General anesthesia with propofol|Study subjects will undergo general anesthesia with propofol according to the clinical standard protocol practiced at the hospital of the University of Munich.
223869009|NCT04296019|DRUG|Fruquintinib|Maintenance therapy with fruquintinib ( 5 mg qd for 3 consecutive weeks, followed by discontinuation for 1 week).
223869010|NCT03891927|DIETARY_SUPPLEMENT|extra virgin olive oil|During the experimental period (3 months ), participants will be requested to consume daily dose of 30 mL (3 tablespoons) of HP-EVOO
223869011|NCT00200213|BEHAVIORAL|portion or unportioned food|
223869012|NCT04423146|OTHER|The evocation of reproducible motor evoked potential according to the different BIS levels|The evocation of reproducible motor evoked potential and the actual value of amplitude and latency at different BIS levels (40 - 60) will be monitored.
223869013|NCT06147167|DEVICE|individualized intermittent theta burst sitmulation (iTBS)|Participants undergo daily sessions of individualized intermittent theta-burst stimulation (iTBS) administered with the MagStim stimulator (Rapid2, MagStim, Whiteland, United States). The intervention spans five days a week and extends over a three-week period. In this group, participants receive a personalized iTBS protocol comprising three pulses of stimulation delivered at 50 Hz, repeated every 200 ms. The stimulation frequency is tailored based on the electroencephalogram (EEG) results and is administered every 10 seconds, with a total duration of 190 seconds. The treatment is administered once a day for five days a week and continues for three weeks, with an immediate cessation in case of any discomfort. This study design ensures a meticulous and tailored approach to iTBS administration.
223869014|NCT06147167|DEVICE|standard iTBS|The MagStim stimulator (Rapid2, MagStim, Whiteland, United States) was employed in the current study. The intermittent theta-burst stimulation (iTBS) protocol utilized three pulses of stimulation delivered at a frequency of 50 Hz, with a repetition rate of every 200 ms. These pulses were organized into 2-second trains, repeated every 10 seconds, resulting in a cumulative duration of 190 seconds (equivalent to a total of 600 pulses). Notably, the administration of the treatment ceased promptly in the event of any participant discomfort.
223869015|NCT06147167|DEVICE|sham stimulation|The device and protocol are identical to the standard iTBS, with the only difference being the orientation of the coil, which is perpendicular to the scalp.
223869016|NCT03400254|DRUG|Hydroxychloroquine (HCQ)|All patients will receive HCQ at a dose of 600 mg orally twice daily. This dose is the same in both phase Ib and phase II portions of the protocol. Capsules of HCQ are available in 200 mg strength, thus patients will initially start with 3 capsules twice daily for a total of 6 capsules per day. HCQ will be administered in divided doses (BID). When taking HCQ twice daily, the two daily doses should be taken 12 hours apart as close to 9am and 9pm as possible. Patients receiving antacids, sucralfate, cholestyramine, and/or bicarbonate should have the HCQ drug dose administered at least 1 hour before or 2 hours after these medications. Hydroxychloroquine will be obtained from the UPENN Investigational Drug Service (IDS).
223869017|NCT03400254|DRUG|Gedatolisib|"Gedatolisib will be administered intravenously on a weekly dosing schedule at 150 mg IV.~Within 3 days prior to GED dosing the patient must have an ANC \>1.0 x 109/L and platelet count \> 75 x 109/L. If hematologic toxicity persists, treatment should be delayed by one week and the complete blood cell count with differential and platelet count repeated. Treatment may be delayed for up to 4 consecutive weeks (28 days). If after 28 days of delay all hematologic toxicity has still not resolved to normal and non-hematologic toxicity has not resolved to \<grade 1 then any further treatment with GED should be stopped."
223869018|NCT03260010|DRUG|Fosfomycin|Infectofos 5 g
223869019|NCT00908505|PROCEDURE|physiotherapy|physiotherapy either by biphasic cuirass ventilator or physiotherapist
223869020|NCT03017183|PROCEDURE|EBUS-TBNA|Endobronchial ultrasound guided transbronchial needle aspiration
223869021|NCT03017183|PROCEDURE|Endobronchial forceps biopsy|Conventional endobronchial forceps biopsy
223869022|NCT04645147|BIOLOGICAL|EBV gp350-Ferritin Vaccine|A 50 micrograms dose of EBV gp350-Ferritin vaccine will be administered intramuscularly for each vaccination at Days 0, 30, and 180 to all participants.
223869023|NCT04645147|OTHER|Matrix-M1|Each vaccine dose will consist of 50 micrograms of EBV gp350-Ferritin combined with 49 micrograms of Matrix-M1.
223869024|NCT05849311|DRUG|Envafolimab with new manufacturing process|"Dosage form:~Envafolimab is a monoclonal antibody drug administered subcutaneously in a minimum packaging unit of 1.0 ml solution in a single-use glass vial containing a total of 200 mg of Envafolimab.~Treatment method:~Envafolimab, single dose, 1 mg/kg, subcutaneously."
223869025|NCT05849311|DRUG|Envafolimab with old manufacturing process|"Dosage form:~Envafolimab is a monoclonal antibody drug administered subcutaneously in a minimum packaging unit of 1.0 ml solution in a single-use glass vial containing a total of 200 mg of Envafolimab.~Treatment method:~Envafolimab, single dose, 1 mg/kg, subcutaneously."
223869026|NCT02655588|BEHAVIORAL|Interactive Media-Based Problems Solving Treatment|
223869027|NCT04425629|DRUG|casirivimab+imdevimab combination therapy|Administered intravenously (IV) single dose
223869028|NCT02726828|DRUG|intrathecal morphine|patients received 10 mg of hyperbaric bupivacaine 0.5% in 2 ml volume and 0.3 mg intrathecal morphine1 ml volume.
223869029|NCT02726828|DRUG|intrathecal ketamine|patients received 10 mg of hyperbaric bupivacaine 0.5% in 2 ml volume and 0.1 mg/kg intrathecal ketamine in 1ml volume.
223869030|NCT02726828|DRUG|intrathecal morphine + ketamine|patients received 10 mg of hyperbaric bupivacaine 0.5% in 2 ml volume and intrathecal morphine + ketamine 0.3 mg and 0.1 mg/kg respectively in 1 ml volume.
223869031|NCT05806255|DEVICE|The RELIEF App|"RELIEF is a virtual app designed for the remote self-reporting of symptoms in patients with palliative care needs. The patient/caregiver securely logs into the site and self-reports symptoms, distress, and pain using the validated clinical tools ESAS-r, Distress Thermometer (DT), and Brief Pain Inventory (BPI) currently in daily use by healthcare providers across Canada.~This data is reported to the healthcare providers via RELIEF. Any increases in symptom burden, distress, or pain are flagged for clinical review as RELIEF alerts. Healthcare providers received alerts via secure email for any sudden changes in symptom status, or if the patient's symptoms, distress, or pain severity increases by set amounts over a period of time. Following review of the RELIEF alert by the healthcare providers, patients receive (1) earlier intervention; (2) mobilization of auxiliary services; and (3) recommendation for urgent clinic/home visit or emergency department visit."
223869032|NCT03113617|PROCEDURE|Computed Tomography|Undergo PET/CT
223869033|NCT03113617|DRUG|Gallium Ga 68-labeled GRPR Antagonist BAY86-7548|Given IV
223869034|NCT03113617|OTHER|Laboratory Biomarker Analysis|Correlative studies
223869035|NCT03113617|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
223869036|NCT05810194|DEVICE|StrataXRT|StrataXRT® is a TGA-approved silicone-based topical preparation. StrataXRT is a self-drying, non-sticky, transparent, silicone gel formulation and when used as directed, dries to form an inert, thin, flexible wound dressing with a protective layer that is gas permeable and waterproof. It is the only self-drying topical silicone gel indicated for the use on radiation dermatitis, which hydrates and protects compromised skin areas and open wounds from chemical and microbial invasion. StrataXRT helps create an optimal wound healing environment which leads to faster re-epithelialization and a reduced inflammatory response. The product can be applied to fresh incisions and excisions, open wounds and compromised skin surfaces.
223869037|NCT05810194|DRUG|Calendula|Calendula creams are over-the-counter (OTC) skin care ointments that are non-greasy, non-sticky, and quickly absorbed by the skin. Calendula is a topical agent derived from a plant of the marigold family Calendula Officinalis and is used in cuts, scrapes, chafing and minor burns. Containing numerous polyphenolic antioxidants, calendula has been studied in both the laboratory and clinical setting for the use in treating and preventing radiation induced skin toxicity.
223869038|NCT05810194|DRUG|Aquaphor|Aquaphor, containing 41 percent petrolatum (or petroleum jelly), temporarily protects minor cuts, scrapes, and burns; Aquaphor protects and helps relieve chapped or cracked skin and lips, as well as helps protecting from the drying effects of wind and cold weather.
223869039|NCT03262623|OTHER|Radial nerve block|A nerve stimulator will be used to localize the radial nerve. Then radial block will be performed. At this point 3-5 ml of the anesthetic mixture is injected. Each 10 ml of the anesthetic mixture contained: 3ml lidocaine 2%, 3ml lidocaine 2% with epinephrine, 1:2000,000, 3ml bupivicaine 0.5% and 1ml clonidine 150 µg/ml.
223869040|NCT03262623|OTHER|Placebo|A nerve stimulator will be used to localize the radial nerve. Then radial block will be performed containing normal saline
223869041|NCT01958866|DRUG|Tinospora Crispa-extract Product|
223869042|NCT01958866|DRUG|Acetaminophen|
223869043|NCT01958866|OTHER|Placebo|
223869044|NCT02474394|DEVICE|Mcgrath|The patient will be intubated using McGrath series 5 video laryngoscope and the intraocular pressure of the patient will be evaluated with Tonopen XL tonometer
223869045|NCT02474394|DEVICE|Macintosh|The patient will be intubated using Macintosh laryngoscope and the intraocular pressure of the patient will be evaluated with Tonopen XL tonometer
223869046|NCT03209778|OTHER|Patients with Schizophrenia|Patients with schizophrenia or schizoaffective disorder according to DSM-V criteria
223869047|NCT01279798|BIOLOGICAL|Lucanix® (belagenpumatucel-L)|Subjects will receive up to 12 monthly (28-35 day interval) Lucanix injections at a dose of 2.5 × 10e7 cells per injection.
223869048|NCT05263336|DRUG|Verdye Green|intraoperative iv application of indocyanic green for visualisation of blood supply to the anastomosis after rectal cancer recection
223869049|NCT02925351|PROCEDURE|Computed Tomography|Undergo PET/CT scan
223869050|NCT02925351|RADIATION|Fluorine F 18 Clofarabine|Given IV
223869051|NCT02925351|PROCEDURE|Positron Emission Tomography|Undergo PET/CT scan
223869052|NCT05355623|PROCEDURE|Vaginal Repair|Vaginal Repair will be done either by application of sterilized (gamma irradiated) amniotic membrane or by Classical repair
223869053|NCT02205853|OTHER|The patient-directed (PD) strategy|The patient-directed strategy will be designed to embed the success of implementation of PCRPs by influencing the patients.
223869054|NCT02205853|OTHER|The multi-faceted (MF) strategy|The multi-faceted strategy will be designed to embed the success by not only influencing the patients, but also professionals and organizational aspects.
223869055|NCT02653508|BEHAVIORAL|Diet and Activity|During all the following meetings, before the initiation of the training sessions, 10 to 15 minutes were devoted to an interactive discussion with participants on food pyramid, food choices, food labels, food preparation and cooking, eating habits, regular meals, controlling environments that stimulate overeating. All adolescents participated in a three-day per week training programme (45 minutes per training session). Many activities were delivered as games in order to encourage enthusiasm and participation. Endurance type activities accounted for most of the time spent in training (about 50% team sports and 50% running games), with attention to coordination and flexibility skills.
223869056|NCT02653508|BEHAVIORAL|Activity|All adolescents participated in a three-day per week training programme (45 minutes per training session). Training was directed by a professional teacher of physical education in a public training centre. The training program was designed according to the type and intensity of exercise that school children normally perform. Many activities were delivered as games in order to encourage enthusiasm and participation. Endurance type activities accounted for most of the time spent in training (about 50% team sports and 50% running games), with attention to coordination and flexibility skills. In order to encourage adolescents' behaviour change, they were instructed to add an extra 30-45 minutes of walking or other sport activity of their preference at least once a week and to reduce inactivity
223869057|NCT04586309|BEHAVIORAL|Transcendental meditation|"Instruction in the TM technique is taught over five sessions.~1. Introductory session-Review of previous scientific research on the TM program and a vision of possible benefits; Preparation- discussion of the mechanics and origin of the TM technique After the introductory session, a Personal Interview is conducted telephonically-with a teacher of the TM program.~2. Personal Instruction-individual one-on-one instruction in the TM technique. The student learns the mechanics of the TM technique. At the conclusion of this class the student is able to meditate properly.~3. First Day of Verification of Correct Practice and Further Instruction.~4. Second Day of Verification of Correct Practice-understanding the mechanics of the TM technique from personal experiences.~5. Third Day of Verification of Correct Practice-understanding the mechanics of the development of higher human potential and wellness."
223869058|NCT06290882|PROCEDURE|Robotic Heller Myotomy|Use five trocar technique with patient in the French position. Establish 12-15 mm Hg pneumoperitoneum. Divide phrenoesophageal ligament starting on the right and mobilize distal esophagus on the lateral and anterior side. Identify and spare anterior vagal nerve. Perform myotomy by dividing both muscle-layers extending at least 7 cm above gastroesophageal junction and 2 cm inferiorly over stomach. Measure myotomy length. Perform anterior fundoplication without mobilizeng fundus of the stomach by dividing short gastric vessels if not necessary. Suture fundus to both cut edges of myotomy, using non-resorbable material.
223869059|NCT06290882|PROCEDURE|Peroral Endoscopic Myotomy|After lavage, measure gastro-esophageal junction (GEJ) in cm from mouth piece. Determine entry point 12-14cm above GEJ at the lesser curvature site, inject 10ml coloured saline, create entry point. Advance endoscope into the submucosa, dissect the submucosal tunnel up to 2-3cm into the cardia. Dissect the submucosa close to the muscularis and check endoluminally for the direction of the lesser curvature, sufficient extension onto the cardia and mucosal integrity. After tunnel completion flush with gentamycin and saline. Start myotomy from proximally to distally starting 4-5cm below the mucosal entry site; the inner circular muscle layer should be fully dissected especially at the cardia for good symptomatic results. It is vital that the mucosa of the tubular esophagus remains intact. Extend myotomy at least 2cm onto the cardia. After completion check for mucosal integrity and opening of the distal esophageal sphincter. Close the entry point with clips from distal to proximal.
223869060|NCT03388281|OTHER|No intervention, retrospective analysis only.|No intervention, retrospective analysis only.
223869061|NCT02489695|DRUG|Axitinib|axitinib 10mg twice a day
223869062|NCT03999671|OTHER|Educational|Traditional method of nursing care with what is done every day, with the method through the nursing process using nursing language as a nursing diagnosis, classification of nursing interventions, and nursing outcomes.
223869063|NCT03999671|OTHER|Maneuver control|Verify that the control and intervention group developed the assigned activities in each case.
223869064|NCT02628171|OTHER|Base Diet|Participants will receive a controlled diet with 0 g/d of cashew nuts. Meals will be prepared using traditional American foods with a macronutrient composition representative of a typical American diet.
223869065|NCT02628171|OTHER|Base Diet with Cashew Nuts|Participants will receive a controlled diet with 42 g/d of cashew nuts. Meals will be prepared using traditional American foods with a macronutrient composition representative of a typical American diet.
223869066|NCT04085094|DIETARY_SUPPLEMENT|high-salt diet (V1) and low salt diet (V2)|Before the first visit, the participant will follow a five-day high salt diet (addition of 6g/day of salt to their regular diet followed at home). Before the second visit (V2), the participant will follow for five days a low-salt diet, according to dietary instructions followed provided during the screening visit.
223869067|NCT04085094|DIAGNOSTIC_TEST|Contrast-enhanced ultrasound (CEUS)|Renal ultrasound with use of a contrast product (SonoVue®), perfusion rate 0.015ml/kg/min. Four destruction-reperfusion sequences are performed in order to measure the Perfusion Index (PI) of the renal cortex.
223869068|NCT04085094|DIAGNOSTIC_TEST|functional MRI|Measurement of renal oxygenation with the Blood Oxygenation Level Dependant-MRI technique (BOLD-MRI) on Siemens Prisma 3T scanner before and 15minutes after 0.03mg/kg of IV furosemide. Assessment of the amount of salt stored in the skin and muscles with the 23Na MRI technique.
223869069|NCT04085094|OTHER|Pilocarpine test|Assessment of sweat salt and potassium concentrations in healthy volunteers according to slat intake. Two electrodes are placed on the forearm. The electric current between the two electrodes will induce perspiration which will be collected with the Macroduct system.
223869070|NCT03658408|DRUG|4-aminopyridine|Oral tablet of 2.5 mg given 4 times a day
223869071|NCT03658408|DRUG|placebo|2.5 mg sugar pill given orally 4 times a day
223869072|NCT03524534|OTHER|Telephone Call|A phone call will take place within 7 days of discharge by a Kaiser Permanente Heart Failure Care Manager from the Kaiser Permanente Heart Failure Chronic Care Management Program.
223869073|NCT03524534|OTHER|In-Person Primary Care Clinical Follow-Up Visit|This will be a standard in-person clinic visit with the subject's primary care physician within 7 days of discharge, with no structured heart failure protocol.
223869074|NCT00973986|DRUG|Atorvastatin|The subjects will receive atorvastatin (20 mg single dose) orally with approximately 240 ml of water. Blood samples(4 mL) will be taken prior to dosing and at 0.33, 0.66, 1, 1.5, 2, 2.5, 3, 4, 6, 9, 12, 24 and 48 h after drug administration.
223869075|NCT01808768|DRUG|Alcaftadine|Alcaftadine 0.25% one dorp each eye daily for 1-2 weeks.
223869076|NCT01149707|DRUG|PUR 0110 Rectal Enema 250 mg|PUR 0110 Rectal Enema 250 mg, once-daily, intrarectally
223869077|NCT01149707|DRUG|PUR 0110 Rectal Enema 500 mg|PUR 0110 Rectal Enema 500 mg, once-daily, intrarectally
223869078|NCT01149707|DRUG|PUR 0110 Rectal Enema 1000 mg|PUR 0110 Rectal Enema 1000 mg, once-daily, intrarectally
223869079|NCT01149707|DRUG|Placebo Enema|Placebo Enema, once-daily, intrarectally
223869080|NCT00610649|DRUG|MK-8777|Orally administered capsules containing either 50 mg or 100 mg MK-8777.
223869081|NCT00610649|DRUG|Placebo|Orally administered matching placebo capsules.
223869082|NCT02250430|DRUG|SB204|Applied topically twice a day on days 1, 2 and 3 to left and right cheeks
223869083|NCT02582086|OTHER|BOR15001L7|Active cream with 5% 15019L0
223869084|NCT02582086|OTHER|Placebo|Placebo Cream with 0% 15019L0
223869085|NCT02236793|DRUG|BioChaperone PDGF-BB|
223869086|NCT02236793|OTHER|Standard of Care|
223869087|NCT01292252|BIOLOGICAL|teriparatide|Teriparatide 20 ug subcutaneous injection daily for 12 weeks
223869088|NCT01292252|BIOLOGICAL|Placebo|Saline solution
223869089|NCT04252586|DRUG|GWP42003-P|GWP42003-P presented as an oral solution containing cannabidiol in the excipients sesame oil with anhydrous ethanol, sweetener (sucralose), and strawberry flavoring
223869090|NCT05517616|DRUG|[14C ]APG-2575|orally, single dose of 400 mg / 200 μCi \[14C\] APG-2575
223869091|NCT04517136|BEHAVIORAL|Assessment of work-related stress|Assessment of burnout, mindfulness, interoceptive awareness, anxiety, post-traumatic stress disorder, coping flexibility and sleep through questionnaires.
223869092|NCT04517136|BIOLOGICAL|Saliva sample collection|Saliva sample is collected before and after emotional stimulation in order to measure resting-state allostatic load biomarkers: Dehydroepiandrosterone (DHEA), cortisol and chromogranin A levels
223869093|NCT04517136|DEVICE|Cardiac and electrodermal recordings|Electrocardiogram and electrodermal activity (tonic and phasic) is collected at rest and after emotional stimulation.
223869094|NCT04517136|BEHAVIORAL|Assessment of behavioral response to emotional stimulation|"Emotional stimulation involves asking the participants to remember a recent event related to the COVID-19 crisis that has been emotionally difficult for them.~Perceived stress, situational awareness and emotions is assessed after emotional stimulation through questionnaires."
223869095|NCT01449123|DRUG|Mannitol challenge test & reversibility test|"Patients perform an asthma control test (ACT) to establish if they are well controlled or symptomatic. All patients will perform then perform the mannitol challenge test. Aridol™ is an indirect osmotic bronchial challenge test which can be used to identify bronchial hyperresponsiveness"
223869096|NCT03346616|OTHER|Texting Group|See above in arm/group description
223869097|NCT03346616|OTHER|Non Texting Group|See above in arm/group description
223869098|NCT02071836|BEHAVIORAL|Right Turns web application|
223869099|NCT02071836|BEHAVIORAL|Treatment as usual|
223869100|NCT05762159|OTHER|data collected|"data collected:~* Morphological data of the patients~* Data of the erector block realization~* Pupillometric data :the variation of the pupil size on stimulation (in percentage of the base diameter)"
223869101|NCT06044467|DRUG|Anti-human CCL24 monoclonal antibody (CM-101) - Part One|Anti-human CCL24 monoclonal antibody (CM-101) - Part One
223869102|NCT06044467|DRUG|Anti-human CCL24 monoclonal antibody (CM-101) - Part Two|Anti-human CCL24 monoclonal antibody (CM-101) - Part Two
223869103|NCT06044467|DRUG|Placebo - Study Part One|Placebo Comparator
223869104|NCT06044467|DRUG|Placebo - Study Part Two|Placebo Comparator
223869105|NCT05346978|DIETARY_SUPPLEMENT|Nasturtium (Tropaeolum majus)|Freeze dried nasturtium (Edible flower)
223869106|NCT05346978|DIETARY_SUPPLEMENT|Placebo|collagen colored with green pigment used in the food industry
223869107|NCT00414544|DEVICE|CosmetaLife|Dermal filler
223869108|NCT00414544|DEVICE|Restylane|Dermal filler
223869109|NCT00580112|DRUG|Dexamethasone|Dexamethasone 4 mg orally 24 hrs and 12 hrs before study drug infusion on Day -1, followed by dexamethasone 20 mg intravenously 30 minutes before study drug infusion on Day 1, followed by dexamethasone 4 mg orally 24, 36, 48, 60 and 72 hrs after the start of study drug infusion on Day 1 to 3.
223869110|NCT00580112|DRUG|Trabectedin|Trabectedin 1.3 mg/m\^2 intravenous infusion over 3-hrs every 3 weeks, on Day 1 of each cycle. Each cycle length will be 3 weeks.
223869111|NCT04728906|DEVICE|Heart patch seeded with autologous cardiomyocytes and amnion epithelial stem cells|heart patch is seeded with patient's cardiomyocytes (taken from patient's heart waste tissue when undergoing bypass surgery) and stock amnion epithelial stem cells (HLA-DR negative to eliminate risk of rejection)
223869112|NCT00310726|OTHER|abrupt weaning at 4 months|abrupt weaning at 4 months
223869113|NCT00310726|OTHER|Continued exclusive breastfeeding|Continued exclusive breastfeeding
223869114|NCT00386958|DRUG|Povidone-Iodine|
223869115|NCT00825084|DRUG|Dimebon|dose escalation of single oral doses of 5, 10 and 20 mg
223869116|NCT00825084|DRUG|Dimebon|dose escalation of single oral doses of 5, 10 and 20 mg
223869117|NCT00825084|DRUG|Dimebon|10 mg TID of Dimebon for 7 days followed by 20 mg TID of Dimebon for 7 days
223869118|NCT00825084|DRUG|Dimebon|10 mg TID of Dimebon for 7 days followed by 20 mg TID of Dimebon for 7 days
223869119|NCT00194974|DRUG|methyldopa|
223869120|NCT00194974|DRUG|labetalol|
223869121|NCT00194974|DRUG|nifedipine|
223869122|NCT00194974|DRUG|clonidine|
223869123|NCT03452189|DRUG|Vancomycin|Oral vancomycin 250mg capsules
223869124|NCT03452189|OTHER|Placebo|"Placebo Pills distributed by Research Pharmacy labeled placebo."
223869125|NCT00768235|OTHER|yoga practice|The yoga program comprised 70 min sessions, 3 times/week during 12 weeks
223869126|NCT03664401|DEVICE|Kerecis Oral™|
223869127|NCT03664401|OTHER|Free Gingival Graft|A free gingival autograft from patient palate placed and secured on wound bed
223869128|NCT02003469|DEVICE|Ambulatory Blood Pressure Monitoring|All enrolled patients have an ambulatory blood pressure monitor placed, pre-transplant/donation, again at 3 months and finally at 12 months post-transplant/donation to measure blood pressure and blood pressure patterns
223869129|NCT03510676|DEVICE|NiTiDES|
223869130|NCT00281554|DRUG|RSD1235|IV
223869131|NCT00223067|DRUG|TAIZ|
223869132|NCT00450359|PROCEDURE|breast imaging study|
223869133|NCT00450359|PROCEDURE|comparison of screening methods|
223869134|NCT00450359|PROCEDURE|radiomammography|
223869135|NCT01557855|DIAGNOSTIC_TEST|Corus CAD (ASGES)|Age/Sex/Gene Expression Score - ASGES
223869136|NCT01218698|DRUG|Losartan Potassium Tablets|
223869137|NCT01149369|DRUG|Aprepitant|Aprepitant, 125 mg, 1 capsule, q.d. (everyday) with lunch for 4 weeks
223869138|NCT01149369|DRUG|Placebo|Aprepitant-placebo, 125 mg, 1 capsule, q.d. (everyday) with lunch for 4 weeks
223869139|NCT04511767|OTHER|Do not take any interventions|Do not take any interventions
223869140|NCT01294215|DRUG|Nifedipine (Adalat, BAYA1040)|Nifedipine (Adalat, BAYA1040) 40mg twice a day (BID)
223869141|NCT05531708|BIOLOGICAL|Anti-mesothelin CAR-T cells|D0: Anti-mesothelin CAR-T cells are autologous genetically modified T cells. Cells will be infused intravenously.
223869142|NCT05531708|DRUG|Fludarabine|D-7 to D-3: Fludarabine (25 mg/m\^2/day) will be administered intravenously for 5 days.
223869143|NCT05531708|DRUG|Cyclophosphamide|D-7 and D-6: Cyclophosphamide (60 mg/kg/day) will be administered intravenously for 2 days.
223869144|NCT00083902|DRUG|Thalidomide|
223869145|NCT00083902|DRUG|Dexamethasone|
223869146|NCT01178034|GENETIC|Calculate warfarin dose using demographic/genetic algorithm|Age, body weight and genetic to calculate warfarin dosage
223869147|NCT00448734|DRUG|Picoplatin|"The treatment regimen will be the assigned dose of picoplatin plus docetaxel, 60 mg/m2 or 75 mg/m2, once every three weeks, plus prednisone (or prednisolone, if prednisone is not available), 5 mg orally twice daily beginning on day 1 and continuing daily until therapy is discontinued.~Docetaxel will be given intravenously over 60 minutes, followed 30 minutes later by picoplatin as a 1-2 hour intravenous infusion."
223869148|NCT00448734|DRUG|docetaxel|"The treatment regimen will be the assigned dose of picoplatin plus docetaxel, 60 mg/m2 or 75 mg/m2, once every three weeks, plus prednisone (or prednisolone, if prednisone is not available), 5 mg orally twice daily beginning on day 1 and continuing daily until therapy is discontinued.~Docetaxel will be given intravenously over 60 minutes, followed 30 minutes later by picoplatin as a 1-2 hour intravenous infusion."
223869149|NCT02106182|DRUG|Silodosin|
223869150|NCT02106182|OTHER|Laboratory tests|"Subject's overall health state will be evaluated by clinical laboratory tests.~Serum chemistry test: Creatinine, Blood Urea Nitrogen(BUN), Aspartate aminotransferase(AST), Alanine aminotransferase(ALT) Urinalysis: Urine Specific Gravity, Urine pH, Urine Protein, Urine Glucose, Urine Ketone, Urine Bilirubin, Urine Urobilinogen, Urine Nitrite, Urine Occult Blood(OB), Urine Red Blood Cell(RBC), Urine White Blood Cell(WBC) Immunoassay: Prostate Specific Antigen(PSA)"
223869151|NCT02106182|OTHER|3-days voiding diary|3-day voiding diaries will be distributed on Visits 1, 2 and 3. Subjects will record incidence of nocturia during 3 days on the diaries within 7 days of Visits 2 (baseline), 3 and 4. The average will be used to confirm the change in incidence of nocturia (at baseline, results from within 1 week from screening may be used but will be excluded for subjects needing wash-out period).
223869152|NCT02106182|OTHER|12 weeks|
223869153|NCT03795194|DRUG|ampicillin/clavulanate|FDA-approved antibiotic
223869154|NCT03567252|BEHAVIORAL|Walking Group|Participants will walk 1 kilometer to a Farmer's Market.
223869155|NCT01429805|DEVICE|HipJack Balloon Spacer|Use of the HipJack Kit to maintain distraction of the joint during hip arthroscopy.
223869156|NCT04981158|PROCEDURE|(Epidural /GA using tolerable endotracheal tube (TET) group, group II|patients will undergo a single shot epidural bupivacaine (15 ml with 0.25% concentration) followed by a standard general anesthetic technique in which the trachea was intubated using TET, through its side port 2mg/kg , lidocaine 2% will be sprayed immediately after intubation when the patient is in flat supine position then the same dose of lidocaine will be repeated 10 minutes before anesthetic discontinuation.
223869157|NCT04981158|PROCEDURE|standard general anesthetic technique, control group, group I|patients will undergo standard general anesthesia with classic endotracheal tube
223869158|NCT04837976|OTHER|Semi-structured interviews and a consensus workshops using nominal group techniques.|Stage 1 of the study includes individual remote semi-structured interviews (one per participant). Stage 2 involves taking part in a consensus workshop with around 7 other Parkinson's experts, consisting of patients, supportive individuals and healthcare professionals.
223869159|NCT06214442|OTHER|Evaluations of the mechanical properties of the achilles tendon in different phases of the menstrual cycle|Monitoring assessments to verify the effect of different phases of the menstrual cycle on the neuromechanical properties of the Achilles tendon.
223869160|NCT03570437|DRUG|Paclitaxel|80 mg/m2 on three days in a 28 day cycle (with 6 cycles)
223869161|NCT03570437|DRUG|Cediranib|20 mg per day
223869162|NCT03570437|DRUG|Olaparib|Olaparib tablets, 300 mg twice-daily
223869163|NCT01058785|BIOLOGICAL|Lucanix|Monthly intradermal injections of four irradiated allogeneic TGF-beta2 antisense gene modified NSCLC cell lines. Patients are randomized to receive either 12,500,000, 25,000,000 or 50,000,000 cells per injection for up to 16 injections.
223869164|NCT02403297|DEVICE|Quik Check PD|The device is not an intervention. It is a device to determine if MMP-8 is present in a subjects saliva.
223869165|NCT04085874|BEHAVIORAL|Promotion of Food-based recommendations|Prolonged contact through weekly home visits and monthly group meeting for 12 weeks
223869166|NCT04085874|BEHAVIORAL|Nutrition counseling from standard health services care|once nutrition counselling from health services
223869167|NCT03592602|PROCEDURE|arm abduction and adduction|All PICC lines will be placed under the guidance of intravascular ECG. Before the PICC placement procedure, basal ECG will be examed. During the procedure, intravascular ECG data will be collected with the punctured arm adduction and abduction while the catheter advances to the cavoatrial junction. After the procedure, chest X-ray radiographs will be taken with arms 90° abducted and adducted (i.e., 0°abducted) in a supine position.
223869168|NCT01332045|PROCEDURE|continuous saphenous nerve block|Postoperative intermittent boluses of 15 Ml Ropivacaine 7,5 mg/Ml every 12 hours for three days
223869169|NCT01332045|PROCEDURE|Saline boluses in nerve catheter|A nerve catheter will be placed in the adductor canal using saline instead of Ropivacaine for intermittent boluses.
223869170|NCT02242487|DRUG|CVT-301|
223869171|NCT00629096|PROCEDURE|Intracoronary infusion of autologous bone marrow cells|Autologous mononuclear bone marrow cells will be administered by intracoronary infusion via a percutaneous catheter
223869172|NCT03216213|OTHER|Frame|Vignette is framed in a way that nudges participant to leave a legacy
223869173|NCT03216213|OTHER|Norms|Vignette informs the participant that most people choose an option to try to nudge participant into choosing that option as well
223869174|NCT03112135|DRUG|Tranexamic Acid|TXA of 10-15 mg i.v over 30 min. followed by infusion in adose of 1 mg / kg /hr
223869175|NCT03112135|DRUG|Tranexamic Acid|Topical TXA 1 gm diluted in 200 ml saline
223869176|NCT03112135|DRUG|Adrenalin|Topical adrenaline 1 mg diluted on 200 ml saline
223869177|NCT01599793|DRUG|cabozantinib|Given PO
223869178|NCT01599793|OTHER|laboratory biomarker analysis|Correlative studies
223869179|NCT01599793|PROCEDURE|magnetic resonance imaging|Undergo MRI
223869180|NCT05150912|OTHER|Manual therapy|strching neck
223869181|NCT04370314|OTHER|Dental prosthetics|Implant-supported crowns
223869182|NCT04235738|OTHER|Observational|"ER2 is a simple and standardized clinical tool. The results of the questionnaires performed in ER2 study will be used. The assessment component of ER2 consists of 6 very simple closed-ended format questions (i.e., yes versus no) which are: Age category (≥ 85), male, polypharmacy (≥ 5 different medications per day), use of formal (health care or social professional) and/or informal (family and/or friend) home support, use of a walking aid regardless of its type, and temporal disorientation (inability to give the current month and/or year). A score of five points is assigned to the items use of walking aid and temporal disorientation, whereas, for the other items, the assigned score is one point. The weighting of points for ER2 items is based on the results of our previous studies. Scores range from 0 (lowest risk) to 14 (highest risk). ER2 scores stratify the risk for short-term ED adverse events into three levels: low, moderate and high."
223869183|NCT04522466|DRUG|Hydroxychloroquine (HCQ)|"Hydroxychloroquine (HCQ) will be administered as usual practice: dosage is adjusted to maintain a concentration between 1 and 2 mg/L.~Measure pharmacokinetics and pharmacodynamics of Hydroxychloroquine (HCQ)."
223869184|NCT05369936|OTHER|Aromatherapy|Lavender will be inhaled through three phases
223869185|NCT05369936|OTHER|Placebo|Vapors of the distal water will be inhaled through three phases
223869186|NCT04400136|DRUG|Lansoprazole oral tablets 30 mg|Post operative prescription
223869187|NCT01794858|OTHER|Therapeutic Hypothermia|Will receive medically-necessitated ventilator support under ICU monitoring with core temperatures ≥36°C and severe acute pancreatitis defined as either a Ranson Score ≥7, a CT indicating ≥50% pancreatic necrosis, or a significant deterioration in clinical status including dysfunction of two or more organ systems. All patients will receive current standard management for severe acute pancreatitis and a standardized protocol for application of therapeutic hypothermia and rewarming. Our primary endpoints are organ-specific cardiovascular, respiratory, hematological, renal, and metabolic dysfunction as measured at 28 days. Logistic Organ Dysfunction Scores will be compared before and after therapeutic hypothermia, establishing day 4 versus day 1 changes in LOD.
223869188|NCT01296815|DRUG|Bevacizumab|Intralesional bevacizumab, dosis of 5mg/cm2, injections every 2 weeks, total number of injections: 3
223869189|NCT02115828|DRUG|Vismodegib|
223869190|NCT05294393|DRUG|Placebo Comparator: N/S 0.9%|12 ml N/S 0.9% at the end of surgery
223869191|NCT05294393|DRUG|Ropivacaine 10%|12 ml solution of 100mg ropivacaine at the end of surgery
223869192|NCT05294393|DRUG|Ropivacaine 10% plus magnesium sulphate 10mg/kg|12 ml solution of 100mg ropivacaine plus magnesium sulphate 10mg/kg at the end of surgery
223869193|NCT00204672|DRUG|Achipex|
223869194|NCT03003624|DEVICE|Colorado® microdissection needle|The primary feature of the Colorado® microdissection needle is the ultra-sharp tungsten tip that delivers the wave-form from the electrosurgery generator to a very small spot. This allows the use of extremely low wattages, resulting in less tissue necrosis, precision cutting and cautery, and less post-operative pain.
223869195|NCT03003624|DEVICE|Cautery tip|Studies have shown that, heat generated by electrosurgical devices are influenced by factors like duration of contact between tissue and electrode tip, current intensity, electro section waveform and the electrode tip size. A larger tip causes more tissue damage, increased operating power and more amount of lateral heat production. This led to the development of microdissection needle with fine electrode tip and efficient power usage. The use of microdissection needles does not have any significant difference in wound healing or pain when compared with scalpel.
223869196|NCT03003624|DEVICE|BP blade|Studies have shown that, heat generated by electrosurgical devices are influenced by factors like duration of contact between tissue and electrode tip, current intensity, electro section waveform and the electrode tip size. A larger tip causes more tissue damage, increased operating power and more amount of lateral heat production. This led to the development of microdissection needle with fine electrode tip and efficient power usage. The use of microdissection needles does not have any significant difference in wound healing or pain when compared with scalpel.
223869197|NCT02129595|DIETARY_SUPPLEMENT|placebo|A placebo will given for 30 days or 34 days (if included in brown adipose tissue measurement), twice daily. One pill will be provided with lunch, and the other pill will be provided with dinner.
223869198|NCT02129595|DIETARY_SUPPLEMENT|resveratrol|resveratrol will be given for 30 days or 34 days (if included in brown adipose tissue measurement), twice daily. One pill, which contains 75 mg of resveratrol, will be provided with lunch, and the other pill, also containing 75 mg will be given with dinner. So in total a dose of 150 mg/day will be given.
223869199|NCT03434496|DEVICE|Gait Trainer 3|With the BIODEX Gait Trainer 3, patients acquire a smooth gait pattern. In addition, balance, coordination, endurance and the cardiovascular system are trained. Work on the treadmill strengthens the leg muscles. On the screen or via an audio message, the patients and therapists receive direct feedback on the smoothness of the gait pattern. The therapists can then make corrective interventions if necessary and the patients are motivated.
223869200|NCT02930954|DRUG|Gefitinib|Patients received Gefitinib 250mg Qd orally until disease progression, intolerable toxicity or death.
223869201|NCT02930954|DRUG|pemetrexed or gemcitabine plus carboplatin,|doublet chemotherapy with pemetrexed or gemcitabine plus carboplatin per 3 weeks
223869202|NCT02930954|DRUG|bevacizumab|bevacizumab 7.5mg/kg intravenously per 3 weeks
223869203|NCT03769870|DRUG|Teneligliptin 20mg/day|cross-over
223869204|NCT03769870|DRUG|Atorvastatin 40mg/Day|cross-over
223869205|NCT03769870|DRUG|Teneligliptin 20mg/day + Atorvastatin 40mg/day|cross-over
223869206|NCT04436900|PROCEDURE|Panretinal Photocoagulation (PRP)|PRP with ARC with a spot number of 1,200 to 1,500 per eye and spot size 500 micron with a duration of 200 ms.
223869207|NCT00995696|BEHAVIORAL|PhaST IVR Calls|Participants in this condition receive 7 computer automated IVR calls.
223869208|NCT04761016|OTHER|Usual Care|The current I-POP health model includes: 1) BSW HWC primary care medical home (for uninsured or Medicare patients), 2)BSW HWC providing diabetes prevention, nutrition education, weight loss, farm stands, physical activity programming (in collaboration with its onsite City of Dallas Park and Recreation Center), 3) BSW HWC programming at community sites in 75210, 4) Referrals to Parkland Hatcher Station clinic that provides health care to Medicaid patients, 5) Referrals between Parkland Hatcher Station and BSW HWC programming, 6) Community improvement in collaboration with Frazier Revitalization Inc. Individuals will have access to resources within our current, ongoing I-POP Health model, but without CHW navigation between BSW HWC and local service providers. Participants will complete follow-up visits for collection of study measures with study personnel at 6- and 10- months. At the end of the 10-month follow-up period, participants receive an assigned CHW and CHW-navigation.
223869209|NCT04761016|OTHER|I-POP + CHW navigation|Individuals randomized to this condition will be paired with a CHW to assist with navigation of I-POP Health resources at BSW HWC and entities in local zip codes. CHW navigation will occur through monthly one-on-one follow-up visits for a period of 10-months. Participants will complete study visits for collection of data measures at baseline, 6- and 10- month timepoints. Study participation ends with completion of 10-months data measures.
223869210|NCT01245400|DEVICE|Z-Lig|ACL replacement
223869211|NCT01245400|DEVICE|allograft|ACL replacement
223869212|NCT03810859|BIOLOGICAL|Blood sample|Adults : 7 to 10 mL Childs : 2 to 4 mL
223869213|NCT02799875|OTHER|Higher permissive hypercapnia|"* pCO2 ≥ 60mmHg with an upper limit ≤ 75mmHg;~* pH ≥ 7.20 from a capillary or arterial blood sample;"
223869214|NCT02799875|OTHER|Lower Permissive Hypercapnia|"* pCO2 ≥ 40mmHg with an upper limit ≤ 55mmHg;~* pH ≥ 7.25 from a capillary or arterial blood sample;"
223869215|NCT03122236|BEHAVIORAL|Neurorehabilitation of Standard Walking|Neurorehabilitation is a behavioral therapeutic approach for enhancing the neural control of task performance by: Restoration of function, specificity of training, Sensory input to the nervous system, Intensity, Repetition and Progression of training. Neurorehabilitation of standard walking will focus on the use of typical steady state walking.
223869216|NCT03122236|BEHAVIORAL|Neurorehabilitation of Complex Walking|Neurorehabilitation is a behavioral therapeutic approach for enhancing the neural control of task performance by: Restoration of function, specificity of training, Sensory input to the nervous system, Intensity, Repetition and Progression of training. Neurorehabilitation of complex walking will focus on the use of walking tasks that require increased attention and executive functions. The following walking tasks will be used: over obstacles, navigating around obstacles, changing speeds, on soft surfaces (exercise mat), in dim lighting, while conversing with the therapist, up/down ramps and climbing/descending stairs.
223869217|NCT03122236|DEVICE|Sham Transcranial Direct Current Stimulation (Sham tDCS)|"tDCS will be used to induce positive neuromodulation of frontal/executive circuits to make them more amenable to the activity-dependent neuroplasticity that is known to occur with behavioral neurorehabilitation. Specifically, tDCS may facilitate the efficacy of our walking neurorehabilitation intervention by strengthening the synaptic connections within the recruited circuits."
223869218|NCT03122236|DEVICE|Active Transcranial Direct Current Stimulation (Active tDCS)|"tDCS will be used to induce positive neuromodulation of frontal/executive circuits to make them more amenable to the activity-dependent neuroplasticity that is known to occur with behavioral neurorehabilitation. Specifically, tDCS may facilitate the efficacy of our walking neurorehabilitation intervention by strengthening the synaptic connections within the recruited circuits."
223869219|NCT00012805|PROCEDURE|Telephone Monitoring|
223869220|NCT03447236|BEHAVIORAL|Feuerstein Program|Mediated learning cognitive enhancement program
223869221|NCT01715636|DRUG|Eviplera = emtricitabine 200mg, rilpivirine 25mg, tenofovir 245mg|
223869222|NCT02381470|DRUG|Faropenem|Faropenem 600mg
223869223|NCT02381470|DRUG|Amoxicillin/clavulanic acid|Amoxicillin 500mg/ clavulanic acid 125mg
223869224|NCT02381470|DRUG|Cefadroxil|Cefadroxil 1g
223869225|NCT02381470|DRUG|Rifampicin|Rifampicin 10mg/kg
223869226|NCT01514149|DRUG|CJC-1134-PC Injection|CJC-1134-PC administered weekly by subcutaneous injection
223869227|NCT01514149|DRUG|Weekly placebo for CJC-1134-PC Injection|Weekly placebo for CJC-1134-PC administered weekly by subcutaneous injection
223869228|NCT04653506|DRUG|Paracetamol 1000 mg|Women participating in the study will receive postpartum analgesia immediately while reporting pain requiring analgesia, by envelope contains paracetamol 1000 mg or ibuprofen 400 mg
223869229|NCT04653506|DRUG|Ibuprofen 400 mg|Women participating in the study will receive postpartum analgesia immediately while reporting pain requiring analgesia, by envelope contains paracetamol 1000 mg or ibuprofen 400 mg
223869230|NCT04977700|BEHAVIORAL|Intervention Group|Test the developed algorithm that delivers location-based, tailored sun safety advice to Strava users through Strava comments for acceptability, ways of interacting with it, and barriers/willingness to allowing access.
223869231|NCT03610594|OTHER|Kalaripayattu|Combination of Exercise, breathing, meditation, combat practices
223869232|NCT04962750|DEVICE|Low level laser therapy|Low level laser therapy from suitable machine
223869233|NCT04962750|OTHER|Sham device|The device wasn't working
223869234|NCT01057459|OTHER|laboratory biomarker analysis|Correlative studies
223869235|NCT00391898|DRUG|Levodopa/carbidopa/entacapone|Patients were instructed to take the study medication at the same hours and the same levodopa dose they were taking prior to enrollment in this study. Levodopa/carbidopa/entacapone was available in 2 oral dosage forms: 100/25/200 or 150/37.5/200 mg encapsulated tablets.
223869236|NCT00391898|DRUG|Levodopa/carbidopa|Patients were instructed to take the study medication at the same hours and the same levodopa dose they were taking prior to enrollment in this study. Levodopa/carbidopa was available in 2 oral dosage forms: One or one and one-half 100/25 mg encapsulated tablets.
223869237|NCT05561452|OTHER|Single PRP Injection|"In single-PRP injection group, 10 ml of venous blood taken from the patients will be put into the T-LAB® PRP kit (T-Biotechnology Laboratory, İstanbul, Turkey) and will then be centrifuged at 3850 rpm for 8 minutes. Approximately 4 ml of the PRP obtained will be injected into the subacromial space using the lateral subacromial injection method under ultrasound guidance. All injections will be performed in the sagittal axis with the long axis in-plane technique, using the ultrasound device (Esaote My Lab 70 XVision 6-18 Mhz linear probe).~A physical therapy program including Codman pendulum exercises, shoulder range of motion, stretching and strengthening exercises will be given and be performed at least for 20 minutes daily."
223869238|NCT05561452|OTHER|Multiple PRP Injections|"In multiple-PRP injection group, two PRP injections will be performed with an interval of 3 weeks. 10 ml of venous blood taken from the patients will be put into the T-LAB® PRP kit (T-Biotechnology Laboratory, İstanbul, Turkey) and will then be centrifuged at 3850 rpm for 8 minutes. Approximately 4 ml of the PRP obtained is planned to be injected into the subacromial space using the lateral subacromial injection method under ultrasound guidance. All injections will be performed in the sagittal axis with the long axis in-plane technique, using the ultrasound device (Esaote My Lab 70 XVision 6-18 Mhz linear probe).~A physical therapy program including Codman pendulum exercises, shoulder range of motion, stretching and strengthening exercises will be given and be performed at least for 20 minutes daily."
223869239|NCT05561452|OTHER|Placebo Injection|"In placebo-injection group,10 ml of venous blood will be taken and after the same waiting time 4 ml of 0.9% saline will be injected into the subacromial space using the lateral subacromial injection method under ultrasound guidance. All injections will be performed in the sagittal axis with the long axis in-plane technique, using the ultrasound device (Esaote My Lab 70 XVision 6-18 Mhz linear probe).~A physical therapy program including Codman pendulum exercises, shoulder range of motion, stretching and strengthening exercises will be given and be performed at least for 20 minutes daily."
223869240|NCT00143234|DRUG|Amlodipine/atorvastatin single pill|
223869241|NCT00749749|DRUG|Bupivacaine Collagen Sponge (CollaRx Bupivacaine Implant)|The bupivacaine collagen sponge contains 70mg Type I bovine collagen and 50mg bupivacaine hydrochloride
223869242|NCT00749749|DRUG|ON-Q PainBuster Post-op Pain relief System|5 mL/hr per catheter of 0.25% bupivacaine (12.5 mg) for 72 hours(total dose 360 mL \[900 mg\])
223869243|NCT04834219|PROCEDURE|On-Pump CABG|Patients who have undergone on-pump Coronary artery bypass grafting (CABG) surgery are planned by the Department of Cardiovascular Surgery.
223869244|NCT04834219|PROCEDURE|Off-Pump CABG|Patients who have undergone off-pump Coronary artery bypass grafting (CABG) surgery are planned by the Department of Cardiovascular Surgery.
223869245|NCT00000493|DRUG|propranolol|
223869246|NCT00000493|DRUG|hyaluronidase|
223869247|NCT01178632|DRUG|Passiflora|01 tablet Passiflora p.o., b.i.d.
223869248|NCT01178632|DRUG|Valeriana officinalis|Active Comparator group will receive 01 tablet of Valeriana officinalis, p.o., b.i.d.
223869249|NCT04045886|BEHAVIORAL|Online Educational Modules (Videos)|5 educational online modules (videos) about DNR/goals of care discussions that the participant will watch as part of the intervention. This is the only intervention.
223869250|NCT04194749|OTHER|Digital Media Based Physical Therapy|This intervention is a modified post immobilization protocol. This will include giving the patients a USB drive loaded with a 12 week therapy protocol presented in digital form with videos and graphical representations of exercises to be done. They will also have access to the videos and multimedia on the Oregon Health \& Science University website.
223869251|NCT04194749|OTHER|Traditional Physical Therapy|This intervention is a 12 week therapist supervised clinic-based therapy protocol.
223869252|NCT02918279|DRUG|Liraglutide|Administered once daily subcutaneously (s.c., under the skin)
223869253|NCT02918279|DRUG|Placebo|Administered once daily subcutaneously (s.c., under the skin)
223869254|NCT00329251|BIOLOGICAL|Hepatitis A|
223869255|NCT00329251|BIOLOGICAL|Hepatitis B|
223869256|NCT00329251|BIOLOGICAL|Influenza|
223869257|NCT00329251|BIOLOGICAL|Pneumococcal|
223869258|NCT00329251|BIOLOGICAL|Tetanus-diphteria|
223869259|NCT00329251|BIOLOGICAL|Varicella|
223869260|NCT00329251|BIOLOGICAL|Measles-Mumps-Rubella|
223869261|NCT04466904|DRUG|IBI362|Administrated by subcutaneous injection
223869262|NCT04466904|DRUG|Placebo|Administrated by subcutaneous injection
223869263|NCT04466904|DRUG|Dulaglutide|Administrated by subcutaneous injection
223869264|NCT00309907|BIOLOGICAL|etanercept|Given IV and subcutaneously
223869265|NCT00309907|DRUG|methylprednisolone|Given IV and orally
223869266|NCT04378361|DEVICE|endovascular repair|Endovascular repair of complicated acute, subacute or chronic type B aortic dissection with double lumen
223869267|NCT00631579|DRUG|Rasburicase (SR29142)|
223869268|NCT05064930|DIETARY_SUPPLEMENT|Probiotic Bifidobacterium lactis|The probiotic will be administered orally over a period of 12 weeks.
223869269|NCT05064930|DIETARY_SUPPLEMENT|Probiotic Bacillus coagulans|The probiotic will be administered orally over a period of 12 weeks.
223869270|NCT05064930|DIETARY_SUPPLEMENT|Placebo|Maltodextrin as a placebo will be administered orally over a period of 12 weeks. The taste and appearance of the placebo will be similar to those of the probiotic formulation.
223869271|NCT02397317|RADIATION|Multi-fraction SABR|All participants will receive Multi-Fraction SABR; 36.25 Gy (PTV D95) in 5 Fractions within 2-5 weeks
223869272|NCT04129658|BEHAVIORAL|Educational outreach visit|Two-four hours of discussion between a cardiologist and the primary care physicians at the PHCC encompassing evidence-based treatment guidelines and counseling upon specific patient cases and their diagnose and treatment for congestive heart failure.
223869273|NCT00117702|DRUG|Tacrolimus|day 0-100, then taper
223869274|NCT00117702|DRUG|Everolimus|day 0-56
223869275|NCT00869258|DRUG|Gemcitabine, docetaxel, and capecitabine|Day 1-14: Capecitabine 1500 mg/m2/day (+/- 2days) Day 4 and 11: Gemcitabine 750 mg/m2/day (+/- 2days) Day 4 and 11: Docetaxel 30 mg/m2/day (+/- 2 days) Two week treatment regimen is followed by one week off, repeated for a total of 3 cycles
223869276|NCT00869258|RADIATION|Radiation therapy with gemzar|Starting on week 12 +/- 5 days radiation therapy will be given in the standard manner over 5 weeks with daily radiation fractions Monday through Friday. Once a week gemcitabine will be given IV over 30 minutes at 250-300 mg/m2
223869277|NCT00636207|DRUG|Montelukast|Montelukast dry powder inhaler, 0.1 mg, 0.3 mg, 1 mg, 3 mg or 10 mg
223869278|NCT00636207|DRUG|Placebo|Placebo dry powder inhaler
223869279|NCT04040413|PROCEDURE|bariatric surgery|All bariatric procedures
223869280|NCT01641198|DEVICE|Configuration 1|B placed at sites 2 and 5, SW placed at sites 1 and 4, SC placed at site 3
223869281|NCT01641198|DEVICE|Configuration 2|B placed at site 3, SW placed at sites 2 and 5, SC placed at sites 1 and 4
223869282|NCT01641198|DEVICE|Configuration 3|B placed at sites 1 and 4, SW placed at site 3, SC placed at sites 2 and 5
223869283|NCT04193410|BEHAVIORAL|Various health-promoting initiatives|No intervention is allocated in this study other than activities planned by childcare centres in accordance with wishes and needs of childcare centre staff and parents.
223869284|NCT02390544|DRUG|Melphalan|Melphalan is a bifunctional alkylating agent that inhibits DNA and RNA synthesis, cross-links strands of DNA and acts on both resting and rapidly dividing cells including tumor cells. It is administered intravenously.
223869285|NCT01396837|DEVICE|RedDress Wound Care System (RD1)|Weekly application. A blood based wound care treatment
223869286|NCT00316836|PROCEDURE|mammography|
223869287|NCT02473419|DRUG|Vayarin|
223869288|NCT02473419|DRUG|Placebo|
223869289|NCT02529995|DRUG|AZD9291 40 mg|This is a two parts (Part A and Part B) study to determine the pharmacokinetics of AZD9291 administered orally at two dose levels (40 mg Cohort 1 and 80 mg Cohort 2) in patients with locally advanced or metastatic NSCLC who have progressed following prior therapy with an EGFR TKI agent (+/- additional chemotherapy regimens).
223869290|NCT02529995|DRUG|AZD9291 80 mg|This is a two parts (Part A and Part B) study to determine the pharmacokinetics of AZD9291 administered orally at two dose levels (40 mg Cohort 1 and 80 mg Cohort 2) in patients with locally advanced or metastatic NSCLC who have progressed following prior therapy with an EGFR TKI agent (+/- additional chemotherapy regimens).
223869291|NCT01316263|BIOLOGICAL|Olaratumab|Administered IV
223869292|NCT05957900|BEHAVIORAL|Multisensory stimulation module|"* Tactile Stimulation; Gentle stroking massage with moderate pressure, with warm palms for 3 min in a sequence of chest, upper limbs, and lower limbs in supine position.~* Visual Stimulation; Black and white visual stimulation card hung at 8-10 in. from the neonate for 3 min.~* Vestibular Stimulation; neonates placed in a hammock for 3 min.~* Kinesthetic stimulation: It consist of passive exercises (flexion and extension) of upper and lower limbs; one of the hands support the stimulated limb, whereas the other hand will perform the movements for 3 min. in supine position.~* Oral stimulation: the perioral structures will stroke by gently tapping the cheeks, lips and jaw by the index and middle finger for 2 min and stroking the intraoral structures by rubbing the gum and applying downward pressure of the tongue for 2 min. Non-nutritive sucking for 8 minutes.~* Olfactory Stimulation for 3 min. using mother's milk.~* Auditory Stimulation listening to mother's heart beats for 3 min."
223869293|NCT01885806|DEVICE|Magnetic Stimulator Magstim Rapid 2|All procedures will use the Magnetic Stimulator Magstim Rapid 2. Total of session: 10 rTMS protocol: Freqüency: 10 Hz Intensity: 90% limiar motor Session duration: 16 minutes (20 TMS sequences of 6 second with intervals of 30 seconds between each sequence) Location: Left dorsolateral pre-frontal cortex
223869294|NCT01885806|DEVICE|Sham Magnetic Stimulator|"This intervention will follow the same protocol of the rTMS except that subjects will not receive magnetic stimulation of the brain.~Total of session: 10"
223869295|NCT02928874|BEHAVIORAL|% COMPX (low ED vs. high ED preload)|
223869296|NCT02928874|BEHAVIORAL|EAH (low ED vs. high ED snacks)|
223869297|NCT03823196|DIETARY_SUPPLEMENT|Verum900|Sinetrol® Xpur is a blend of polyphenol-rich extracts from grapefruit, guarana seed, sweet orange and blood orange. Daily dosage is 900 mg for 16 weeks
223869298|NCT03823196|DIETARY_SUPPLEMENT|Verum1800|Sinetrol® Xpur is a blend of polyphenol-rich extracts from grapefruit, guarana seed, sweet orange and blood orange. Daily dosage is 1800 mg for 16 weeks
223869299|NCT02472782|DRUG|Teriparatide|The study will include patients from pre-defined groups of individuals (postmenopausal, male, and steroid-induced osteoporosis) who would any way receive teriparatide for their condition according to standard medical practice and Greek treatment guidelines
223869300|NCT01222910|DRUG|Valacyclovir hydrochloride|
223869301|NCT01075217|DRUG|iopamidol|Participants received at least one intraarterial injection in one of the following 3 locations: aortic bifurcation (total volume 15-20 mL), iliac arteries (total volume 10-12 mL), or superficial femoral artery (total volume 8-12 mL to view only thigh, 10-15 mL to view calf as well, 20 mL for full runoff to foot).
223869302|NCT01075217|DRUG|iodixanol|Participants received at least one intraarterial injection in one of the following 3 locations: aortic bifurcation (total volume 15-20 mL), iliac arteries (total volume 10-12 mL), or superficial femoral artery (total volume 8-12 mL to view only thigh, 10-15 mL to view calf as well, 20 mL for full runoff to foot).
223869303|NCT06148727|DEVICE|Dental implant placement|Procedure/ surgery: Surgical placement of dental implants, four interforaminal dental implants were placed
223869304|NCT06148727|DEVICE|Bar attachment|Device: attachment, implants were connected to each others by 3 implant assembly in a trapezoidal design implants were loaded after 3 months of osseo-integration Control Group: patients received coventionally constructed heat cured overdenture Study Group: patients received 3d printed overdenture
223869305|NCT06555718|BEHAVIORAL|The Peer Support Program|Implementation of the research; Peer support programme for the intervention group will be carried out for 10 weeks in accordance with the peer guide-client implementation plan. Standard follow-up and training programme will be applied to the control group in accordance with the procedures of the institution.
223869306|NCT06555718|BEHAVIORAL|Standart care|The standard care provided by the institution will continue.
223869307|NCT05702658|BEHAVIORAL|CAPS|Community Autism Peer Support is a one-to-one autistic-delivered peer support, community-based intervention focused on independent living and participation.
223869308|NCT01032798|DRUG|mepivacaine|One intra-oral injection at four different sessions, of the following formulations: 2% mepivacaine with 1:100,000 epinephrine, 3% mepivacaine, 2% and 3% liposome-encapsulated mepivacaine.
223869309|NCT03615417|DEVICE|High Flow Nasal Cannula (HFNC)|"Preoxygenation trough High Flow Nasal Cannula (HFNC) at 100% FiO2, 50 liters/min and closed mouth.~After Rapid Sequence Induction (RSI), maintenance of apnea with HFNC at 100% FiO2, 70 liters/min and jaw thrust.~At time of peripheral oxygen saturations (SpO2) decreases by 2% or after 10 minutes of apnea, the participant is intubated."
223869310|NCT03615417|DEVICE|Standard anesthesia FaceMask (FM)|"Preoxygenation trough standard anesthesia FaceMask (FM) at 100% FiO2, 12 liters/min, CPAP 7 cmH2O.~After Rapid Sequence Induction (RSI), maintenance of apnea without mask. At time of peripheral oxygen saturations (SpO2) decreases by 2% or after 10 minutes of apnea, the participant is intubated."
223869311|NCT04722588|OTHER|Introducing clinical pharmacists to the interdisciplinary ED team.|There will be two shifts, one shift from 08.00 - 15.00 and one from 12.00 - 19.00. Consequently, the hours of the day when the majority of patients arrives, are covered and the pharmacist capacity is doubled during the busiest time of the day. Early mornings are normally relatively slowed paced and the pharmacist may use this time to follow up on patients admitted during the night (from 19.00 - 08.00), in particularly those who have been admitted to wards without an assigned pharmacist.
223869312|NCT01431586|DRUG|JDtic|"The planned JDTic dose levels to be evaluated are 1 mg, 3 mg, and 10 mg; however, the actual dose levels evaluated may be different, and/or additional dose levels may be added by protocol amendment, depending on the safety and PK results of the lower doses.~Subjects will be admitted to the clinic the day before dosing and will be confined to the clinic for 6 nights, with safety and PK evaluations and assessments lasting approximately 125 hours following administration of study drug."
223869313|NCT01068743|DRUG|saxagliptin|Tablets, Oral, 2.5 mg, once daily, single dose
223869314|NCT01068743|DRUG|metformin|Tablets, Oral, 850 mg, once daily, single dose
223869315|NCT01068743|DRUG|saxagliptin + metformin (FDC tablet)|Tablet, oral, (saxagliptin 2.5 mg) (metformin 850 mg), once daily, single dose
223869316|NCT03634280|OTHER|Kinesio taping|In patients in the splint group, 16-18 layers of cotton gauze (15-cm cast gauze) were applied from the tip of the toes to the beginning of the fibula. Following the gauze application, short leg splint application was performed in a neutral ankle position.
223869317|NCT05744193|OTHER|Exempt Infant Formula|Liquid human milk fortifier to be added to human milk daily
223869318|NCT03221478|OTHER|Kinesio Taping placebo and exercises|Kinesio Taping placebo and exercises
223869319|NCT03221478|OTHER|Kinesio Taping with tension and exercises|Kinesio Taping with tension and exercises
223869320|NCT03221478|OTHER|Kinesio Taping with tension|Kinesio Taping with tension
223869321|NCT00464399|DRUG|everolimus|
223869322|NCT05090930|DEVICE|HA330 - Jafron Biomedical Co., Ltd., China - extracorporeal hemocorrection|HA330 - Jafron Biomedical Co., Ltd., China - extracorporeal hemocorrection, which is based on the removal of cytokines from whole blood by sorption on a special hemoadsorbent due to the peculiarities of its porous structure and inner surface, which is indicated in conditions where cytokine levels are extremely elevated
223869323|NCT05090930|DEVICE|CytoSorb (CytoSorbents Corp., USA) - an extracorporeal cytokine adsorber|CytoSorb (CytoSorbents Corp., USA) - an extracorporeal cytokine adsorber is a biocompatible polymer with high adsorption capacity, which is indicated in conditions where cytokine levels are extremely elevated
223869324|NCT01599117|DRUG|Placebo|Capsule, appears identical with udenafil, will be provided by Dong-A pharmaceutical company. Patients will receive 50 mg of placebo drug two times a day for 4 weeks, and then the dosage will be escalated to 100 mg two times a day for next 8 weeks.
223869325|NCT01599117|DRUG|Udenafil (Zydena)|Udenafil (Zydena), a newly developed PDE-5 inhibitor by Dong-A pharmaceutical company, will be administered to patients in this group, 50 mg two times a day for 4 weeks, and then the dosage will be escalated to 100 mg two times a day for next 8 weeks.
223869326|NCT01962844|DIETARY_SUPPLEMENT|Coconut Oil|Patients were followed for 6 months with dietary treatment. Beginning supplementation with coconut oil extra virgin from the third month of intervention nutrition. Coconut oil was consumed neat or added to fruit.
223869327|NCT01962844|BEHAVIORAL|Diet|Patients were instructed to follow the dietary treatment for 6 months
223869328|NCT06488079|OTHER|Summary Label|The Nutri-Score Front-of-Pack nutritional label
223869329|NCT06488079|OTHER|Nutrient-specific label|The NutrInform Battery Front-of-Pack nutritional label
223869330|NCT06488079|OTHER|No label|Conventional food educational flyer
223869331|NCT05549869|DIAGNOSTIC_TEST|serum leptin|Evaluation of serum leptin in vitiligo patients and control Assessing its correlation to the body mass index leptin is supposed to contribute to vitiligo pathogenesis through promoting the release of pro-inflammatory mediators
223869332|NCT05628493|BEHAVIORAL|Gut microbiota Analysis|fecal samples were collected per patient on days 1,3 and 7 after ICU admission. All eligible patients were given antibiotics therapy, actively control infection source by puncture drainage or surgery if necessary, as well as other supportive therapy to maintain organ function.
223869333|NCT05700630|BIOLOGICAL|FT538|FT538 is an investigational off-the-shelf cryopreserved NK cell product derived from an iPSC that contains three functional modifications: 1) a novel high affinity, non-cleavable CD16 (Fc receptor) that maintains CD16 on the cell surface and remains fully functional after NK cell activation, thus augmenting ADCC; 2) an IL-15 receptor fusion that promotes NK cell activity and enhances cell persistence; and 3) the knock-out of CD38 expression prevent anti-CD38 antibody-induced fratricide.
223869334|NCT05700630|DRUG|Vorinostat|Vorinostat is a histone deacetylase inhibitor (HDACi) that is FDA approved for the treatment of cutaneous T-cell lymphoma and, under investigation in HIV as disruptor of HIV latency.
223869335|NCT01998711|BEHAVIORAL|Memory group|Five 1-1.5 hour weekly session of memory training
223869336|NCT03202199|DEVICE|PET/MRI|2 PET/MRI examinations
223869337|NCT02916758|OTHER|Let's Go Community Mobility Program|Four week multi-modal education and experiential program to improve community mobilty
223869338|NCT01077934|DEVICE|near-infrared spectroscopy|Non-invasive monitoring device applied on the surface of the skin that emits harmless red light to measure tissue perfusion.
223869339|NCT04928248|OTHER|Diabetes Dashboard integrated with Disease Manager App|The Diabetes Dashboard is available as a tab in the electronic health record (EHR) system and enables clinicians to confirm relevant patient parameters, select treatment goals, and review likely outcomes from alternative treatment strategies through an interactive graphical user interface. The Diabetes Dashboard is integrated within the diabetes module of the EHR-integrated Disease Manager App, which uses key information from the Diabetes Dashboard and provides a link to the Diabetes Dashboard.
223869340|NCT04356430|DRUG|Abiraterone Acetate|1000 mg orally daily for 24 weeks before robotic assisted radical prostatectomy
223869341|NCT04356430|DRUG|Prednisone|5 mg oral low dose prednisone, once daily
223869342|NCT04356430|DRUG|Goserelin 10.8 mg|10.8 mg goserelin hypodermic once per 12 weeks
223869343|NCT03996278|OTHER|Grafalon|None interventional study but there are two groups
223869344|NCT01032486|DRUG|Rasagiline mesylate|Azilect® tablets (0.5mg or 1.0 mg) administered orally once daily
223869345|NCT00137371|DRUG|PVC (daily for 21 days, 7 days off)|
223869346|NCT00137371|DRUG|PVC (twice weekly)|
223869347|NCT06108778|DEVICE|MRI|Investigations as CT,MRI.serum ammonia and lactate
223869348|NCT03696966|DIETARY_SUPPLEMENT|Portion-Controlled Meals|Increase dietary structure using portion-controlled meals (PCM)
223869349|NCT03696966|BEHAVIORAL|Low-Calorie Diet|Restrict calorie intake daily
223869350|NCT03696966|BEHAVIORAL|Intermittent Very-Low Calorie Diet|Severely restrict calorie intake intermittently
223869351|NCT05323266|DEVICE|Nasal Continuous Positive Airway Pressure (nCPAP)|The two main interventions in this study were Nasal continuous positive airway pressure (nCPAP) and high-flow nasal cannula (HFNC) in patients with acute stroke. Nasal continuous positive airway pressure (nCPAP) is a way of ventilation completed in a non-invasive ventilator. In this study, the nasal mask is mainly used to replace the traditional oral and nasal mask.
223869352|NCT05323266|DEVICE|High-Flow Nasal Cannula (HFNC)|The high-flow nasal cannula (HFNC), as another oxygen therapy, is also used as an intervention in this study to study the effect of early prognosis in patients with acute ischemic stroke.
223869353|NCT05688644|DEVICE|InterStim II|Sacral neuromodulation
223869354|NCT00523237|DRUG|Raltegravir|400 mg Twice daily for 24 weeks
223869355|NCT01090544|DEVICE|Nasal Insufflation|Breathing therapy
223869356|NCT05081570|DEVICE|telecare consultation|Two tertiary stroke care consultations will be provided by stroke nurses via telecare in 2 months. Consultation content includes provide education on modifying stroke-specific risk factors, disseminate self-management knowledge, reinforce the importance of medication compliance, revise the blood and investigation results, and co-design and follow-up on mutually agreed rehabilitation goals with the subjects. When necessary, the nurse will also refer the stroke survivors to multidisciplinary team members according to the referral guidelines. The nurse will also encourage the patients' family and/or informal caregivers to participate in the consultations.
223869357|NCT04352283|DEVICE|Preprocedural ultrasound exam of lumbar spine|Preprocedural ultrasound exam of lumbar spine used to determinate needle puncture site
223869358|NCT00620997|DRUG|Proparacaine drops 0.05%|topical, 0.05% drops, PRN continuously for up to 7 days
223869359|NCT00620997|DRUG|saline drops|saline drops continuously PRN for up to 7 days
223869360|NCT00139672|DRUG|PD-217,014|
223869361|NCT05032794|OTHER|Unrestricted diet before colonoscopy|Free diet, without restrictions
223869362|NCT05032794|OTHER|1-day low residue diet|To follow a diet low in residues / fiber. the day before the colonoscopy.
223869363|NCT05032794|DRUG|Bisacodyl 5 MG|If the participant is at risk of inadequate bowel cleansing, defined by a score of Dik et al ≥ 2 it will be given Bisacodyl 5 milgrams bid for 3 days.
223869364|NCT01698125|PROCEDURE|Abdominal surgery|Patients 65 years or older scheduled for abdominal surgery at Oslo University Hospital
223869365|NCT04395378|DEVICE|Continuous Glucose monitoring DEXCOM G6|Continuous glucose monitoring during flight and normal living life
223869366|NCT00851669|BEHAVIORAL|Interpersonal Psychotherapy for Co-occurring Alcohol Dependence and Major Depression (IPT-ADMD)|Interpersonal Psychotherapy for Co-occurring Alcohol Dependence and Major Depression (IPT-ADMD) is Interpersonal Psychotherapy with modifications specifically designed for the treatment of patients with co-occurring alcohol dependence and major depression
223869367|NCT00851669|BEHAVIORAL|Treatment as Usual|Individual psychotherapy following usual care practice in a chemical dependency treatment program.
223869368|NCT00171184|DRUG|Darifenacin|Darifenacin 7,5 mg tablets once daily with the possibility to up-titrate to 15 mg once daily
223869369|NCT00171184|DRUG|Placebo|Placebo tablet once daily with sham titration
223869370|NCT01472146|DRUG|Zo-Nantax|"Experimental:~AC,Docetaxel,Trastuzumab,Zolendronate~Drug: AC Adriamycin 60mg/m2 IV plus cyclophosphamide 600mg/m2 every 21 days for 4 cycles~Drug: Docetaxel~Docetaxel 100 mg/m2 every 21 days for 4 cycles.~Drug: Trastuzumab~Trastuzumab 8mg/kg \[loading dose\] once then 6mg/kg IV every 21 days for 3 cycles plus docetaxel.~Drug: zolendronic acid~Zolendronic acid 4mg IV every 21 days for 8 cycles combine with chemotherapy"
223869371|NCT00819325|DRUG|pioglitazone|pioglitazone 30mg p.o. once a day for 6 months
223869372|NCT00819325|DRUG|oral hypoglycemic agents|sulfonylurea or metformin
223869373|NCT03474822|BIOLOGICAL|Blood-stage infection of P.vivax|The P. vivax infected blood will be confirmed to follow the national standard of blood donation to ensure that only P. vivax is included, excluding the presence of P. falciparum. Exclude other infectious diseases according to the test of national standard of blood donation.
223869374|NCT02627183|PROCEDURE|Catheter ablation|Subjects undergoing catheter ablation for the first time for atrial fibrillation as part of their regular care (regardless of involvement in this study).
223869375|NCT02627183|BEHAVIORAL|Exercise training|Subjects participating in supervised exercise classes for up to 60 minutes in length 2 times/week as part of their involvement in another study (NCT02602457).
223869376|NCT01845532|DRUG|TPI|Trigger point injection with 25G needle on the shoulder before surgery(0.5% procaine, 0.25\~0.5% lidocaine, 0.125% bupivacaine)
223869377|NCT01845532|DRUG|EMLA cream|EMLA cream with occluding dressing on the shoulder before surgery(5% of eutectic mixture with 2.5% lidocaine and 2.5% prilocaine)
223869378|NCT00233337|DRUG|Co-artemether|
223869379|NCT03484065|OTHER|Questionnaire quality of life|
223869380|NCT00623792|BEHAVIORAL|Preoperative lifestyle Intervention|"6 month individual intervention consisting of weekly face-to-face and telephone sessions addressing diet, activity and preparation for surgery, followed by 3 booster telephone calls after surgery"
223869381|NCT04034771|DRUG|Melatonin 10 MG Oral Tablet|Melatonin tablets
223869382|NCT04034771|DRUG|Propofol|propofol amp
223869383|NCT04034771|DRUG|Placebo oral tablet|sugar pill manufactured to mimic melatonin tablets
223869384|NCT05035966|OTHER|Plasma β-amyloid 40 and 42 concentration|Plasma β-amyloid 40 and 42 concentrations were simultaneously measured by validated assay platforms from Meso Scale Discovery (MSD; Rockville, MD, USA).
223869385|NCT00214266|DRUG|Campath 1H®, Rituximab, mycophenolate mofetil|Induction therapy with Campath 30mg IV x 2 doses, Rituximab 375mg/m2 x 1, corticosteroids, and mycophenolate 1000mg bid
223869386|NCT03300492|OTHER|NK-DLI|"Application of three infusions of ex vivo expanded NK cells on days~+10, +15 and +20 with increasing NK cell doses (1x107/kg, 1x108/kg and the remaining cells up to 1x109/kg) following haplo-HSCT. Maximal cumulative T-cell dose is fixed at \<1x105/kg."
223869387|NCT03855397|OTHER|Microneedle|A microneedle patch (no drug) was applied in the following oral cavity sites: lip, buccal, tongue, palatal and gingival mucosa to access pain, discomfort and safety.
223869388|NCT03855397|OTHER|Hypodermic needle|30 gauge hypodermic needle was inserted in the following oral cavity sites: lip, buccal, tongue, palatal and gingival mucosa.
223869389|NCT03855397|OTHER|Flat patch|A flat patch was applied in the following oral cavity sites: lip, buccal, tongue, palatal and gingival mucosa.
223869390|NCT04008550|PROCEDURE|Right Heart Catheterization|A right heart catheterization will be done in patients with PAH before TAVI (3 months after TAVI)
223869391|NCT04459897|OTHER|Evaluation of epithelioid and gigantocellular granulomas within the hepatic parenchyma by histopathology approach.|: Retrospective histopathology review done by an expert of histopathology analysis (DAPI cell labeling). Analysis of the percentage of epithelioid cells and the percentage of gigantocellular granulomas in hepatic parenchyma of patient diagnosed for Hepatitis Granulomatous
223869392|NCT04291092|DRUG|Immunotherapy|Immunotherapy for brain metastasis
223869393|NCT04291092|RADIATION|WBRT|local therapy for brain metastasis
223869394|NCT04291092|DRUG|Chemotherapy|Chemotherapy for brain metastasis
223869395|NCT00621569|BEHAVIORAL|Dietary Approaches to Stop Hypertension-The DASH diet|The purpose of this study is to create a culturally appropriate diet to test the effectiveness of the intervention to lower blood pressure in a grou pof African American individuals at risk for developing hypertension (pre-hypertension) and those with mild hypertension (stage I).
223869396|NCT00621569|BEHAVIORAL|Intervention with no dietary component - information regarding useful life skills|Participants receive information regarding useful life skills in a group setting
223869397|NCT05083702|PROCEDURE|Fluoroscopy-guided superior hypogastric plexus block transdiscal approach|Patient lies prone, L5-S1 interspace identified under fluoroscopy, the skin is prepared and sterile drapes are placed after local anesthetic infiltration of the skin the subcutaneous tissue with 2% lidocaine a 20 guage, 15 cm needle with short bevel is inserted at the center of L5- S1 interlaminar space under anteroposterior fluoroscopic vision. The needle is then advanced toward the intervertebral disc. After confirmation, the needle is advanced through the intervertebral disc until it exists at its anterior surface confirmed by administration of 4 ml of soluble contrast media in both lateral and anteroposterior fluoroscopic view. Neurolysis is performed with 8 ml 8 % phenol solution. After neurolysis, 0.5 ml of saline is given to avoid the deposition of phenol within the intervertebral disc material. While withdrawing, the needle cephazoline 50 mg in 1 ml is injected into the disc.
223869398|NCT05083702|PROCEDURE|ultrasound-guided superior hypogastric plexus block|Patients are placed in the supine position and after sterilization, the low-frequency curved probe is used in the longitudinal axis to visualize the aortic bifurcation and is identified using a longitudinal Ultra-Sound (Phillips Healthcare, Andover, Massachusetts, US). Next, the probe is placed deeply transverse till aorta end and bifurcation seen of iliac vessels once seen we enter out of plane and inject.as it lies in front the vertebral body of the L5 vertebra. Local infiltration with 1% lidocaine is obtained at port of entry 1-1.5 inches below the umbilicus. A 15-cm, 22-G Chiba needle is inserted (out-of-plane) and advanced by avoiding vascular structures until contact with the L5-body. The needle will be withdrawan the 1-2 mm and inject 8 ml 8% phenol in saline. Finally, 0.5 ml of lidocaine is injected during Chiba needle removal
223869399|NCT05157724|PROCEDURE|PLASMA|"The aim is to remove the prostatic adenoma by enucleation, i.e. to pass through the plane between the adenoma and the prostatic capsule, as opposed to resection, which also consists of removing the adenoma, but by making small cuts in the prostatic tissue, without necessarily reaching this anatomical plane between the adenoma and the capsule. This means removing less adenoma and therefore increasing the risk of adenomatous regrowth in the long term or obtaining worse results than enucleation in the short to medium term.~The other advantage of using this approach is that it reduces intra- and post-operative bleeding and does not require the systematic discontinuation of anti-aggregating or anticoagulant treatments prior to the operation. The field of indications is thus potentially enlarged."
223869400|NCT02444416|PROCEDURE|blood sample|
223869401|NCT03941067|OTHER|Pre-event massage|Five minutes massage, combining superficial and high-frequency techniques of massage applied with the therapist hands
223869402|NCT02829931|RADIATION|Hypofractionated Stereotactic Irradiation|Hypofractionated Stereotactic Irradiation (HFSRT) prior to nivolumab.
223869403|NCT02829931|DRUG|Nivolumab|Nivolumab intravenously (IV): 240 mg every (q) 3 weeks x 4 months followed by 480 mg X 4 months.
223869404|NCT02829931|DRUG|Bevacizumab|Bevacizumab intervenously (IV): 15 mg/kg every (q) 3 weeks when given with Ipilumumab and Nivolumab combination. Dose changed to 10mg/kg every 2 weeks when given with Nivolumab only.
223869405|NCT02829931|DRUG|Ipilimumab|Ipilimumab 1mg/kg intervenously (IV) 200 mg (5 mg/mL) every (q) 3 weeks for 4 months.
223869406|NCT04160429|PROCEDURE|Biospecimen Collection|Undergo collection of sweat, saliva, and blood samples
223869407|NCT04160429|OTHER|Medical Chart Review|Review of medical chart
223869408|NCT04160429|OTHER|Questionnaire Administration|Complete questionnaire
223869409|NCT04126707|DRUG|[14C] HQP1351|Orally, single dose of 30mg
223869410|NCT01130194|OTHER|Combination of treatment modalities|"Intravenous cyclophosphamide, rituximab, and vincristine day 1 and 8 of 28 day cycles for 6 cycles total.~Oral prednisone and procarbazine day 1-14 of every 28 day cycle. Yttrium ibritumomab tiuxetan intravenous injection. Autologous stem cell transplant with intravenous BEAM (BCNU or carmustine, etoposide, ara-C or cytarabine, melphalan) chemotherapy conditioning."
223869411|NCT01997944|BIOLOGICAL|Human Serum ALbumin/interferon alpha2a|600,750 or 900 mcg dosing every 2 weeks
223869412|NCT01997944|BIOLOGICAL|Pegasys|180 mcg dosing every week
223869413|NCT00882934|OTHER|Induction to efficient treatment|Informative letters.
223869414|NCT00882934|OTHER|Doubt to the efficacy of treatment|Informative letters.
223869415|NCT00882934|OTHER|Induction to ineffective treatment|Informative letters
223869416|NCT01837940|DIETARY_SUPPLEMENT|Placebo|Galactooligosaccharide (GOS) and rhamnose in a powder formulation
223869417|NCT01837940|DIETARY_SUPPLEMENT|Lactobacillus reuteri DSM 17938|Lactobacillus reuteri DSM17938, Galactooligosaccharide (GOS), rhamnose in a powder formulation
223869418|NCT01943916|DEVICE|Imagio OA/US (US and OA/US)|opto-acoustic plus gray scale ultrasound
223869419|NCT01943916|DEVICE|Imagio gray scale ultrasound|gray scale ultrasound alone
223869420|NCT05676450|DIAGNOSTIC_TEST|cell-free DNA|Given by IV (vein)
223869421|NCT06145568|OTHER|Pregnant Women|We want to quantify Minority Americans at risk of pregnancy complications
223869422|NCT05254535|OTHER|I-SITE|I-SITE includes coaching facilitation, technical assistance, and an online toolkit to allow primary care clinics to tailor the integration of teleophthalmology into their daily workflows based on each clinic's unique needs and resources. The program includes a series of coaching sessions between a skilled practice facilitator and clinical personnel at each health system.
223869423|NCT06571747|BEHAVIORAL|Cardiovascular-Focused Nudge Communication|Intervention arms will receive a behavioral economic rooted nudge communication highlighting the potential cardiovascular benefits of vaccination.
223869424|NCT04592250|OTHER|Survey Administration|Complete survey
223869425|NCT04565925|DRUG|Sildenafil Citrate|Sildenafil 20mg TID for 4 weeks
223869426|NCT04565925|DRUG|Placebo|Placebo (Lactose) TID for 4 weeks
223869427|NCT06777498|OTHER|Whole Grain Intervention then fruits and vegetables|"TREATMENT 1: Participants will eat whole grains that add up to the required daily fiber needs. Investigators will provide participants with these products. Participants will follow this intervention for a set period of time. The beginning of the intervention will include a ramp up phase when they eat half of the daily fiber needs to prevent any gastrointestinal distress from suddenly consuming a higher fiber diet than usual.~TREATMENT 2: Participants will eat fruits and vegetables that add up to the required daily fiber needs. Investigators will provide participants with these products. Participants will follow this intervention for a set period of time. The beginning of the intervention will include a ramp up phase when participants eat half of the daily fiber needs to prevent any gastrointestinal distress from suddenly consuming a higher fiber diet than usual."
223869428|NCT06777498|OTHER|Fruit and Vegetable Intervention and then whole grains|"TREATMENT 1: Participants will eat fruits and vegetables that add up to the required daily fiber needs. Investigators will provide participants with these products. Participants will follow this intervention for a set period of time. The beginning of the intervention will include a ramp up phase when participants eat half of the daily fiber needs to prevent any gastrointestinal distress from suddenly consuming a higher fiber diet than usual.~TREATMENT 2: Participants will eat whole grains that add up to the required daily fiber needs. Investigators will provide participants with these products. Participants will follow this intervention for a set period of time. The beginning of the intervention will include a ramp up phase when they eat half of the daily fiber needs to prevent any gastrointestinal distress from suddenly consuming a higher fiber diet than usual."
223869429|NCT02245100|OTHER|Cytology specimen|Correlative studies
223869430|NCT02245100|OTHER|Laboratory biomarker analysis|Correlative studies
223869431|NCT01366664|DRUG|Treatment sequence 2|Treatment Period 1 (stable dose of terazosin \[2, 5, or 10 mg\] + placebo administered orally once daily for 5 days) followed up to 14 days later by Treatment Period 2 (stable dose of terazosin \[2, 5, or 10 mg\] + dapoxetine 60 mg administered orally once daily for 5 days)
223869432|NCT01366664|DRUG|Treatment sequence 1|Treatment Period 1 (stable dose of terazosin \[2, 5, or 10 mg\] + dapoxetine 60 mg administered orally once daily for 5 days) followed up to 14 days later by Treatment Period 2 (stable dose of terazosin \[2, 5, or 10 mg\] + placebo administered orally once daily for 5 days)
223869433|NCT00372450|PROCEDURE|management of therapy complications|
223869434|NCT00372450|PROCEDURE|quality-of-life assessment|
223869435|NCT03532711|DRUG|fluorouracil|chemotherapy treated patients
223869436|NCT03811574|DRUG|Semaglutide|Semaglutide injections will be administered once-weekly by a pre-filled pen-injector at the same day of the week (to the extent possible). Injections may be administered in the thigh, abdomen or upper arm, at any time of day irrespective of meals.
223869437|NCT03811574|DRUG|Placebo (semaglutide)|Placebo (semaglutide) injections will be administered once-weekly by a pre-filled pen-injector at the same day of the week (to the extent possible). Injections may be administered in the thigh, abdomen or upper arm, at any time of day irrespective of meals.
223869438|NCT01832480|DRUG|MTZ 500 mg twice daily x 7 days|MTZ 500 mg twice daily x 7 days
223869439|NCT01832480|DRUG|MTZ 2 g|MTZ 2 g
223869440|NCT03802149|DRUG|Ulipristal Acetate|90mg Ulipristal Acetate 18-24-hours prior to dilation and evacuation
223869441|NCT02990949|OTHER|Timing of trigger|
223869442|NCT05609032|BEHAVIORAL|Sense2Quit App|Participants in the intervention arm will receive access to Sense2Quit, a smartphone app that links to a smartwatch.
223869443|NCT01243619|DRUG|3'-deoxy-3'-(18) F-fluorothymidine|Radio-tracer for tumor imaging
223869444|NCT03819816|OTHER|DEA-App|"The intervention (DEA) group will receive the newly developed app. DEA will consist of three simultaneous modules that provide multidimensional support for informal caregivers aiming to reduce the caregiver burden:~1. Information module~   The information module consists of general information on the disease and the care of people suffering from dementia.~2. Activity module~   The activity module suggests individualized activities and physical fitness exercises by a self-learning algorithm, which supports the caregiver to deliver more targeted and easier care.~3. Communication module~If two or more persons are caring for one person with dementia, the communication module provides a networking possibility."
223869445|NCT03819816|OTHER|Standard Information group|The control group will receive a leaflet on some general principles for promoting health and well-being in older adults with dementia.
223869446|NCT04287894|DRUG|Durvalumab|The IP will be given to the patient as long as there is a clinical benefit, in invertigator's judgment. Per day, 1500 mg
223869447|NCT04287894|DRUG|Tremelimumab|Per day 75mg
223869448|NCT04287894|DRUG|Pemetrexed|500 mg/m2 on day 1 every 3 weeks for 2 cycles
223869449|NCT04287894|DRUG|Cisplatin|6 mg / m2 on day 1 every 3 weeks for 2 cycles
223869450|NCT04287894|RADIATION|chemo radiotherapy|Once-daily fraction, 2 Gy per fraction. Total dose is 60 Gy.
223869451|NCT04287894|PROCEDURE|Resection|After CIT-CRT
223869452|NCT06973369|OTHER|LEININGER THEORY BASED CREATIVE DRAMA EDUCATION METHOD|The effects of Leininger theory-based creative drama training given to nursing students for five weeks on the students' cultural sensitivity and effectiveness levels will be determined.
223869453|NCT06973369|OTHER|TRADITIONAL EDUCATION METHOD|Leininger theory training will be given to nursing students for five weeks and its effects on the students' cultural sensitivity and effectiveness levels will be determined.
223869454|NCT06974240|OTHER|Experimental Group|The training sessions were carried out following a strict order. The first phase was dedicated to improving group social skills. The beginning of the session was dedicated to greetings between participants and questions of social interest. During the second phase, videos were shown and participants answered targeted questions asked by the Nao Robot to understand if the child had correctly interpreted the general meaning of the story and to determine the degree of awareness that the expression should be understood in a non-literal sense. In the third phase, a role play was performed among the participants, which re-enacted the situations seen in the videos, involving all the members of the group in turn. During the last phase, participants were asked to share experiences in their lives in which they had used or could have used the pragmatic skill just analyzed. The protocol included 15 phases over 31 sessions, each lasting 45 minutes, twice a week.
224076540|NCT01347034|PROCEDURE|External Beam Radiation Therapy (RT)|"Day 1: Start external beam RT, 25 fractions from days 1-33 administered Monday through Friday only (no conventional external beam RT on days 6, 7, 13, 14, 20, 21, 27, or 28~Days 57-70: Surgery will occur 3-5 weeks after the final dose of external beam RT.~Day 78-91: First post-operative visit~Days 91-365: Clinical follow-up~Beyond day 365, follow-up will be conducted using the standard of care approach applicable to these patients for the determination of disease recurrence, progression and survival."
223869455|NCT06974240|OTHER|control group|The entire intervention was carried out in a group entirely mediated by an operator without the use of a social robot. The first phase is dedicated to improving group social skills. The beginning of the session was dedicated to greetings between participants and questions of social interest. During the second phase, stories were read and participants answered target questions to understand if the child had correctly interpreted the general meaning of the story and to determine the degree of awareness that the expression should be understood in a non-literal sense. In the third phase, a role play was performed among the participants, in which all members of the group participated in turn, recalling the situations seen in the videos. During the last phase, participants were asked to share experiences from their lives in which they used or could use the pragmatic skill just analyzed. The protocol included 15 phases over 31 sessions, each lasting 45 minutes, twice a week.
223869456|NCT06973772|BIOLOGICAL|DENGUE: Dengue 1,2,3,4 (attenuated) vaccine CHIKUNGUNYA: Chikungunya (CHIKV) live attenuated vaccine (VLA1555)|DENGUE: Dose 10\^2.5-4.1 PFU per virus (1,2,3,4) Route: Subcutaneous CHIKUNGUNYA: Dose \>= 3.0 log TCID50 per 0.5 mL Route: Intramuscular
223869457|NCT06973772|BIOLOGICAL|DENGUE: Dengue 1,2,3,4 (attenuated) vaccine|DENGUE: Dose 10\^2.5-4.1 PFU per virus (1,2,3,4) Route: Subcutaneous
223869458|NCT06973772|BIOLOGICAL|Chikungunya (CHIKV) live attenuated vaccine (VLA1555)|CHIKUNGUNYA: Dose \>= 3.0 log TCID50 per 0.5 mL Route: Intramuscular
223869459|NCT06974344|DRUG|Octreotide (drug)|Continuous intravenous octreotide acetate infusion initiated at hepatic reperfusion during living donor liver transplantation (LDLT). The initial dose is 1 mcg/kg/hr, titrated intraoperatively based on portal venous flow (PVF) and hepatic artery flow / resistive index (RI) measurements. The infusion continues postoperatively in the ICU until stable graft hemodynamics are achieved (target PVF \<5 mL/min/g and presence of diastolic hepatic arterial flow). Dose adjustments are permitted for efficacy or safety concerns, with all modifications documented. The intervention is administered via central venous access using standard infusion protocols
223869460|NCT06974344|PROCEDURE|Splenic Artery Ligation (SAL)|Intraoperative ligation of the splenic artery performed during living donor liver transplantation (LDLT) using non-absorbable suture material (e.g., polypropylene). The ligation is typically placed near the splenic artery origin for maximal portal flow modulation, with exact positioning determined by surgeon assessment of vascular anatomy and intraoperative hemodynamics (targeting portal venous flow \<5 mL/min/g). The procedure is performed under direct visualization during the transplant operation, with post-ligation Doppler ultrasound confirmation of hemodynamic response within 60 minutes of biliary anastomosis.
223869461|NCT06973044|DEVICE|Checkpoint Cardio wireless continuous monitoring device|Continuous monitoring of respiratory rate and heart rate
223869462|NCT06973967|BEHAVIORAL|delirium|Postoperatively, patients were monitored for delirium for seven days.
223869463|NCT06974214|OTHER|FAM-ICU|This multi-component intervention comprises several concrete and manageable components and operationalizing patient- and family-centered care principles in clinical practice.
223869464|NCT06973213|OTHER|core exercises|the intervention group underwent approximately 45 minutes of core stabilization exercises daily.
223869465|NCT06973109|DRUG|Romosozumab|Monthly subcutaneous injection (210 mg total dose) administered as two separate 105 mg injections, one per arm. Administered for 12 months to female patients ≥65 years undergoing spine surgery.
223869466|NCT06973109|DRUG|Alendronate (Fosamax)|Weekly oral dose (70 mg) administered for 12 months. Used as active comparator in control arm of study.
223869467|NCT06973109|DRUG|Placebo Romosozumab|Monthly subcutaneous injections mimicking romosozumab in appearance and administration schedule. Administered to control group.
223869468|NCT06973109|DRUG|Placebo Alendronate|Weekly oral placebo pill mimicking alendronate. Administered to treatment group.
223869469|NCT06967220|OTHER|Single leg training|All subjects will train one leg twice daily.
223869470|NCT06973694|DEVICE|Bulbicam|"The multi-test device, BulbiCam (BCAM), is a combined eye tracking; pupil metric; video graphic dual device which include the following 10 tests under development and ready for validation:~26 grids glaucoma screening perimetry 64 grids full perimetry (NeuroField64) Pupil and Relative Afferent Pupil Defect (RAPD) assessment Semi-automatic ptosis (droopy eyelid) grading Video-based nystagmus test Dynamic acuity and contrast sensitivity test Dark adaptation test Smooth pursuit eye movements Saccade movements Eye fixation stability BCAM is connected to the BulbiHub software where measured data is stored and presented in numbers, diagrams, and graphs."
223869471|NCT06973382|BEHAVIORAL|Comprehensive Pulmonary Rehabilitation Program|"Combined Aerobic + Resistance Training Program Mode: Cycle ergometry (stationary bicycle) Frequency: 3-5 sessions per week Program Duration: 12 weeks~Session Structure:~* 5-minute warm-up~* Continuous or interval training (15-30 minutes)~* 5-minute cool-downesistance Exercise Component~Mode: Dumbbell exercises + cycle ergometry~Frequency: 3 sessions per week~Program Duration: 12 weeks~Session Structure:~* 5-minute warm-up~* Training session (10-20 minutes)~* 5-minute cool-down"
223869472|NCT06973382|BEHAVIORAL|Standard Pulmonary Rehabilitation|"xercise Components:~Aerobic Exercise~Mode: Walking or jogging~Resistance Exercise~Mode: Elastic bands or dumbbells~Training Parameters:~Session Duration: ≥35 minutes (combined aerobic + resistance)~Frequency: 3-5 sessions per week~Program Duration: 12 weeks"
223869473|NCT06692283|DRUG|denifanstat|Tablet
223869474|NCT06692283|DRUG|Placebo|Matching tablet
223869475|NCT06073093|DRUG|SAR441566|Tablet
223869476|NCT06073093|DRUG|Placebo|Tablet
223869477|NCT06042166|BEHAVIORAL|Connecting and Reflecting Experience (CARE) Program|The intervention consists of a 12-session mentalizing-focused parenting group, which will involve weekly one-hour telehealth therapy sessions with up to 7 postpartum parents per group and 1 to 2 facilitators. CARE is a therapy focused on parents' reflective capacity, or the ability to consider how our own and our children's thoughts, feelings, intentions, and other mental states shape behavior and parent-child relationships.
223869478|NCT01192633|DRUG|GVP|"Drug: gemcitabine, vincristine,cisplatin~cisplatin 25mg/m2，ivgtt，D1, 2, 3 gemcitabine 1000mg/m2，ivgtt，30'，D1, 8 vincristine 1.4mg/m2(less than 2 mg), iv, D1 repeat every 3 weeks"
223869479|NCT00148434|BEHAVIORAL|Patient-held guideline for hypertension|
223869480|NCT00590551|OTHER|sling or no sling|Groups will be assigned as follows: 1-supine and with sling, 2-30o HOB elevation without leg elevation and with sling, 3-30o HOB elevation with 10o leg elevation and with sling, 4-supine and without sling, 5-30o HOB elevation without leg elevation and without sling, and 6-30o HOB elevation with 10o leg elevation and without sling
223869481|NCT06409286|DEVICE|Thermal Anisotropy Measurement Device|A wireless device for non-invasively assessing CSF shunt flow
223869482|NCT03914859|BIOLOGICAL|IN VITRO FERTILIZATION|Using exposure biomarker as a reliable means of evaluating gamete quality to estimate the chances of success in in vitro fertilization.
223869483|NCT02781766|OTHER|Thrombin generation measurement.|
223869484|NCT02998450|DRUG|IMR-687|1 of 6 possible single doses administered orally following overnight fast
223869485|NCT02998450|DRUG|Placebo Oral Capsule|Placebo oral capsule with 50 mg microcrystalline cellulose in capsules identical to those used for the active pharmaceutical ingredient.
223869486|NCT06972758|DRUG|Certirobell®|Patients enrolled in the study will initiate oral administration of Certirobell® between 4 to 6 weeks after hepatic resection. The medication will be taken for a duration of 92 weeks, twice daily at approximately 12-hour intervals. The initial dosage is 1.0 mg per dose (twice daily). For patients with a Child-Pugh score of 6, the starting dose will be reduced to 0.75 mg per dose (twice daily). At each visit, the blood concentration of Certirovel will be measured, and the investigator will adjust the dosage as needed to maintain levels within the target range of 3-8 ng/mL. If HCC recurrence is confirmed during treatment, the administration of the drug will be discontinued.
223869487|NCT06974331|BEHAVIORAL|Multimedia Protocol about Asthma Control|Addressing this multifaceted problem is essential for the well-being of individuals and communities worldwide. Therefore, this study aims to evaluate the effect of multimedia protocol about asthma control on asthmatic children's adaptation in the era of climate.
223869488|NCT00815750|OTHER|Information Gathering|An information gathering phase leading to development of a new decision aid.
223869489|NCT00815750|OTHER|Decision Aid|To test the newly developed decision aid.
223869490|NCT02095899|DRUG|Rufinamide|2x200mg up to max 2x800mg a day Titration over 20days
223869491|NCT01685606|BIOLOGICAL|cellular immunotherapy|A minimum of 1x108 CD3+ cells and maximum of 2x108 CD3+ cells/kg from a haploidentical donor irrespective of the number of CD34+ cells will be infused.
223869492|NCT01156935|OTHER|Laugh Yoga|1 hour including laugh, respiratory exercises and guided imagination by a group instructor specialized in laugh yoga
223869493|NCT01535833|PROCEDURE|Device- Robotic sacral colpopexy|To assess robotic sacral colpopexy for female patients with stage 2 pelvic organ prolapse
223869494|NCT02852681|DRUG|15 mg E4/3 mg DRSP|All subjects received both Treatment A and Treatment B either at the first treatment period (Period 1) or the second treatment period (Period 2). Approximately half of the subjects was randomized to receive either Treatment A followed by Treatment B (Sequence AB), or Treatment B followed by Treatment A (Sequence BA)
223869495|NCT01787760|DEVICE|Test Soft Contact Lens B|Test lenses to be worn in daily wear modality
223869496|NCT01787760|DEVICE|Test Soft Contact Lens C|Test lenses to be worn in a daily wear modality
223869497|NCT01787760|DEVICE|Active Comparator|Control spectacle lenses to be worn in a daily wear modality
223869498|NCT03512756|DRUG|SM-88 used with MPS (methoxsalen, phenytoin, sirolimus)|Daily oral therapy for cancer
223869499|NCT03512756|DRUG|Capecitabine, Gemcitabine, and 5-FU|"Investigator choice of the following therapies:~Capecitabine, Gemcitabine, and 5-FU"
223869500|NCT01029717|DEVICE|Standard polyurethane Central Venous Catheter|Standard polyurethane Central Venous Catheter, All CVCs used in the trial are CE marked medical devices used for their intended purpose.
223869501|NCT01029717|DEVICE|Antibiotic impregnated polyurethane CVC (minocycline and rifampicin)|Antibiotic impregnated polyurethane CVC (minocycline and rifampicin. All CVCs used in the trial are CE marked medical devices used for their intended purpose.
223869502|NCT01029717|DEVICE|Heparin bonded polyurethane CVC|Heparin bonded polyurethane CVC. All CVCs used in the trial are CE marked medical devices used for their intended purpose.
223869503|NCT04291586|OTHER|Virtual reality|Virtual Reality Intervention of 30 minutes, 3 times a week until reaching 24 sessions.
223869504|NCT04291586|OTHER|Paper and Pencil|Paper and Pencil Intervention of 30 minutes, 3 times a week until reaching 24 sessions.
223869505|NCT05803850|DRUG|HNC1058 Capsules|HNC1058 Capsules/Placebos, single dose, PO, starting dose of 10 mg escalating up to 80 mg；HNC1058 Capsules/Placebos, 50 mg, single dose, FED.
223869506|NCT02726490|DRUG|Glyburide|glyburide 2.5milligrams (mg) at bedtime (qhs) increased as needed to a maximum of 20mg/day usually taken twice a day (BID)
223869507|NCT02726490|DRUG|Glucovance|glucovance (2.5/500) 1 taken orally (PO) at bed time (QHS) increased as needed to a maximum dose of (20/2000)/day usually taken twice a day (BID)
223869508|NCT00060099|BIOLOGICAL|HspE7|
223869509|NCT00736853|DRUG|Tramadol Hydrochloride Plus Acetaminophen (Open-Label)|Fixed dose combination of tramadol 37.5 milligram (mg)/acetaminophen 325 mg, 1 or 2 tablets 4 times daily will be given for one week; dose level will be fixed for each participant during the second week based on analgesic efficacy and tolerability (maximum daily dose will be 8 tablets).
223869510|NCT00736853|DRUG|Tramadol Hydrochloride Plus Acetaminophen (Double-Blind)|Fixed dose combination of tramadol 37.5 mg/acetaminophen 325 mg, 1 or 2 tablets (same dose \[number of tablets\] as that for the second week in the open-label period) will be given 4 times daily up to 4 weeks.
223869511|NCT00736853|DRUG|Placebo (Double-Blind)|Matching placebo will be given up to 4 weeks.
223869512|NCT03419325|GENETIC|CYP2C19 test|Patients will be categorized into 4 groups based on the results of their genetic test for CYP2C19 as well as the residual platelet reactivity test (P2RY12 assay=PRU units) and DAPT treatments options will be recommended accordingly (i.e., through a Clinical Decision Support (CDS) tool that is based on a pharmacogenetic-driven algorithm and the PRU result).
223869513|NCT03419325|DIAGNOSTIC_TEST|P2RY12 assay|Patients will be categorized into 4 groups based on the results of their genetic test for CYP2C19 as well as the residual platelet reactivity test (P2RY12 assay=PRU units) and DAPT treatments options will be recommended accordingly (i.e., through a Clinical Decision Support (CDS) tool that is based on a pharmacogenetic-driven algorithm and the PRU result).
223869514|NCT03477149|DEVICE|Easyx|Embolization will be done with Easyx liquid agent.
223869515|NCT01815450|DRUG|BLI1100|BLI1100 topical cream
223869516|NCT01815450|DRUG|BLI1100 - modified formulation|BLI1100 topical cream
223869517|NCT01815450|DRUG|Placebo|Placebo topical cream
223869518|NCT03413748|PROCEDURE|Elective Cesarean Section|lower segment cesarean section
223869519|NCT03413748|OTHER|Peritoneal irrigation|Irrigation of peritoneal cavity with 500 - 1000 ml of warm normal saline
223869520|NCT03566186|OTHER|Phototherapy|Photobiomodulation or photobiostimulation, this technique is the application of monochromatic light that can influence cellular activity through inhibition or stimulation of chemical and biological functions.
223869521|NCT03566186|OTHER|Placebo|The same procedures as in the active phototherapy group was applied to the placebo group; however, the emitter was disabled. The device was emit the same sounds regardless of the programmed mode (active phototherapy).
223869522|NCT03566186|OTHER|Passive recovery|Participants was remain sat for passive recovery supervised by an independent therapist during the period when the other groups are received recovery strategies.
223869523|NCT01209039|DRUG|GSK1144814|Multiple daily doses of GSK1144814 for 28 days
223869524|NCT01209039|DRUG|GSK1144814|Multiple daily doses of GSK1144814 for 14 days
223869525|NCT01209039|DRUG|GSK1144814|Multiple daily doses of GSK1144814 for 7 days (or until steady state is reached)
223869526|NCT00092937|DRUG|Busulfan|
223869527|NCT00917241|DRUG|MMI combined with IID|MMI titration regimen for 18 months,initial dosage of MMI was 20 mg/d,which combined with IID for 3 months.Dexamethasone was injected into the two side of thyroid, the dose of dexamethasone was 5 mg by every side, twice a week. The treatment strategy was changed to once a week at the second month and twice a month at the third month, the dose of dexamethasone was the same as the first month.
223869528|NCT00917241|DRUG|MMI|MMI treatment with titration regimen for 18 months, initial dosage was 20 mg/d.
223869529|NCT02590952|DRUG|Epitinib|The starting daily dose is 20 mg. Dose escalation will follow daily dose of 40 mg,80 mg, 120 mg, 160 mg, 200 mg, and 250 mg. A 3+3 design applies to this study. Patients will continue taking Epitinib until they experience intolerable adverse events or their diseases are confirmed to be progressed.
223869530|NCT04586686|PROCEDURE|Ovarian biopsy via laparoscopy|A laparoscopy will be performed to achieve an ovarian cortical biopsy of one of both ovaries. Approximately twenty % of the ovarian volume as initially measured on the baseline ultrasound at the first visit will be removed to be processed in the lab for cortex freezing. The laparoscopic procedure in order to take the ovarian cortex biopsy will be standardised as much as possible. The technique developed by ProFam will be followed and adapted if needed by the surgeon's discretion. A three to four port laparoscopy will be used. The ovarian cortex biopsy will be taken using a curved scissor. Bipolar or unipolar cauterisation will be avoided as much as possible. If necessary for approximation or for hemostatic reasons, the ovarian edges can be stitched or Surgicel ® Absorbable Hemostat can be used.
223869531|NCT04586686|PROCEDURE|Transvaginal oocyte retrieval|After ovarian stimulation, a transvaginal oocyte retrieval will be performed either under local or general anaesthetics (patient's choice). The oocyte yield between the biopsied and non-biopsied ovary will be evaluated.
223869532|NCT02994173|DRUG|Oxycodone|Current clinical practice, used as a control in this study
223869533|NCT02994173|DRUG|S-Ketamine 0.25|dosage
223869534|NCT02994173|DRUG|S-Ketamine 0.5|dosage
223869535|NCT02994173|DRUG|S-Ketamine 0.75|dosage
223869536|NCT01441934|DRUG|Sildenafil citrate|sildenafil 20 mg t.i.d. compared to placebo 20 mg t.i.d - 16 weeks treatment
223869537|NCT01441934|DRUG|Sugar pills|placebo t.i.d.
223869538|NCT02298751|BEHAVIORAL|Cue Exposure Treatment|
223869539|NCT02439827|BEHAVIORAL|"Fortaleça sua Saúde program"|The program duration was of one academic semester (approximately four months) in 2014. The intervention strategies focus on teachers' training and activities on health in curriculum (including a specific training to Physical Education teachers), active opportunities in the school environment (availability of spaces and materials for PA) and health education (production and exhibition of health material at school, and distributing pamphlets to students and parents).
223869540|NCT04759066|DEVICE|HEALiX|HEALiX is a non-restraint patient safety device
223869541|NCT00222326|BEHAVIORAL|Pelvic floor muscle training and lifestyle modification|
223869542|NCT00933400|DIAGNOSTIC_TEST|CT Coronary Angiography (CTCA)|CT coronary angiography will be performed without and with contrast in participants randomized to receive imaging as well as traditional care. (For applicable purposes, the decision to perform contrast-enhanced imaging in the presence of a large amount of calcium should be made according to procedures at each individual site.) The imaging test will be considered positive if the participant has a greater than 50% stenosis of the right coronary, left main, left anterior descending, or circumflex arteries or of their branches in contrast-enhanced CT coronary angiography. Results will be communicated to the responsible ED and treating staff immediately upon interpretation; ED staff will determine appropriate course of management. Negative results will result in patient discharge.
223869543|NCT00933400|PROCEDURE|Traditional Strategy|Participants randomized to traditional care will be assessed and discharged/treated according to routine standard-of-care procedures in the institution's emergency department.
223869544|NCT01970891|DEVICE|neuromuscular stimulation device|Effect of neuromuscular stimulation device at specific muscle sites will be examined for freezing of gait amelioration.
223869545|NCT01892553|DEVICE|tDCS|"Procedure : 3 different sessions of tDCS (listed below) presented in random order, each applied at a different study visit~* Anodal tDCS: Intensity of 1.25 milliAmperes (mA) during 15 min~* Cathodal tDCS: Intensity of 1.25 mA during 15 min~* Sham tDCS (placebo) (1.25 mA maintained only during the first 30 sec of the 15 minutes application)"
223869546|NCT00010309|BIOLOGICAL|MART-1 antigen|
223869547|NCT00010309|BIOLOGICAL|gp100 antigen|
223869548|NCT04618614|DEVICE|HD-tDCS 1 mA to S1|Anodal high definition transcranial direct current stimulation of the right primary somatosensory cortex with an intensity of 1 mA
223869549|NCT04618614|DEVICE|HD-tDCS 1 mA to M1|Anodal high definition transcranial direct current stimulation of the right primary motor cortex with an intensity of 1 mA
223869550|NCT04618614|DEVICE|Sham control|Sham stimulation of the right primary somatosensory cortex
223869551|NCT00030888|DRUG|7-hydroxystaurosporine|
223869552|NCT00570219|DRUG|valproate|Valproate 20 mg/kg per day for 2 weeks, reduction during week 3. Conversion of benzodiazepines to an equivalent dose of diazepam (maximum 80 mg per day). Dosage reduced 10 mg daily until 40 mg per day. Reduction then continued 5 mg daily.
223869553|NCT00461747|DRUG|VBMCP/VBAD/Velcade|"VBMCP: Vincristine, 0,03 mg/Kg (iv) day 1, BCNU, 0,5 mg/Kg iv day 1, Cyclophosphamide, 10 mg/Kg iv day 1, Melfalan, 0,25 mg/Kg oral days 1 to 4 Prednisone, 1 mg/Kg oral days 1 to 4; 0,5 mg/Kg oral days 5 to 8 and 0,25 mg/Kg oral days 9 to 12.~VBAD : Vincristine, 1mg via iv day 1, BCNU, 30 mg/m2 iv day 1, Adriamycine, 40mg/m2 iv day 1 Dexamethasone, 40 mg oral days 1 to 4, 9 to 12 and 17 to 20."
223869554|NCT00461747|DRUG|Thalidomide/Dexamethasone|"Thalidomide day 1, cycle 1 (50 mg/day v.o). If toxicity \< grade 2, dose will be 100 mg/day on day 15, cycle 1 and 200 mg/day on day 1, cycle 2.~Dexamethasone:40 mg/day v.o.days 1 to 4 and 9 to 12, with a period without treatment of 16 days"
223869555|NCT00461747|DRUG|Velcade/Thalidomide/Dexamethasone|"Thalidomide: day 1 cycle 1 (50 mg/day).If toxicity is \< grade 2, the dose increased (100 mg/day) at day 15 cycle 1 and (200 mg de Thalidomide) at day 1 cycle 2.~Dexamethasone: 40 mg/day v.o days 1 to 4 and 8 to 11, with a period without treatment of 17 days.~Velcade: 1,3 mg/m2 iv twice a week (days 1, 4, 8 and 11) with a period without treatment of 17 days"
223869556|NCT04301635|PROCEDURE|Maxillo-mandibular Advancement + Counterclockwise rotation|Maxilla: Lefort I osteotomy Mandible: Obwegeser-Dal-Pont osteotomy Movements: Advance and counterclockwise rotation
223869557|NCT05082714|DRUG|Tocilizumab|tocilizumab 8mg/kg single infusion (a second infusion within 48 hours can be applied upon clinician's discretion)
223869558|NCT05082714|DRUG|Baricitinib|The baricitinib intervention consists of baricitinib at a dose of 4 mg/day (given daily for up to 14 days or until discharge from hospital, whichever occurred first); however, 2 mg/day will be given if the patient has a baseline eGFR of 30 to less than 60 mL/min/1·73 m2
223869559|NCT04653935|BEHAVIORAL|Self-management app with all intervention components|A behavioural self-management app, containing multiple cognitive- and behavioural self-management techniques for those living with Sjögren's syndrome. The intervention is comprised of several components and modules that holistically target several key symptoms: fatigue, sleep disturbances, chronic pain, and dryness. The app has been developed using user-centred methods, and is theory- and evidence-based.
223869560|NCT04653935|BEHAVIORAL|Self-management app with Information component only|self-management app for those with Sjögren's syndrome, includes Symptom and Lifestyle Information, only.
223869561|NCT05729672|BEHAVIORAL|Received the Nightingale in Gen-sEx course|The experimental group (n=75) will participate in the SPOC- based education program, consisting of five online teaching and learning modules over the span of 3 months and two hours of offline classroom.
223869562|NCT01041417|DRUG|Granulocyte-Macrophage Stimulating Factor (GM-CSF)|500 micrograms of GM-CSF
223869563|NCT01041417|DRUG|Placebo|Saline injection
223869564|NCT02113072|DRUG|Beclomethasone|The wheezing infants will be using the inhaled corticosteroid beclomethasone 50mcg - 02 jets per day (100mcg/dia).
223869565|NCT02113072|DRUG|Probiotics|Lyophilized form, each sachet containing 1 g of the probiotic, to be used in addition to milk, juice or yoghurt in the first morning meal once daily for 60 days.
223869566|NCT02113072|DRUG|Placebo|The placebo will be supplied in the same way with the same organoleptic characteristics of formula with probiotics, 1 g sachet for 60 days, in the juice, milk or yoghurt.
223869567|NCT00976625|PROCEDURE|Aortic Valve Replacement|Surgical valve replacement of the aorta
223869568|NCT03226899|DRUG|Lesinurad|200 mg oral tablet
223869569|NCT03226899|DRUG|XOI|All participants must be on a stable, medically appropriate dose of XOI as their sole urate-lowering therapy (ULT) indicated for the treatment of gout for at least 4 weeks prior to Screening and throughout the Screening Period. This stable dose of XOI will be maintained throughout the study period.
223869570|NCT03226899|DRUG|Placebo|matching placebo oral tablet
223869571|NCT03226899|DRUG|colchicine|Gout flare prophylaxis: commercially available colchicine is provided through the Month 6 study visit. Actual colchicine dose (0.5 or 0.6 mg qd) and frequency were adjusted based on the local label, subject medical history, and clinical judgement.
223869572|NCT03226899|DRUG|corticosteroids|Gout flare prophylaxis: Participants unable to take colchicine are permitted to take a short course of low-dose oral corticosteroids up to the Month 3 study visit
223869573|NCT02299375|DRUG|Losmapimod tablets|Losmapimod tablets will be provided as 15 mg strength in a formulation containing lactose. Administered orally, twice daily approximately 12 hours apart and with food and water for the duration of the treatment period. Participants will be instructed to take their medication with a full glass of water twice-daily within 30 minutes after meals for the duration of their treatment period.
223869574|NCT02299375|DRUG|Placebo tablets|Placebo tablets will be provided in a formulation containing lactose and visually matching the losmapimod tablets. Administered orally, twice daily approximately 12 hours apart and with food and water for the duration of the treatment period. Participants will be instructed to take their medication with a full glass of water twice-daily within 30 minutes after meals for the duration of their treatment period
223869575|NCT02299375|DRUG|Salbutamol MDI|Salbutamol MDI will be provided as a rescue medication.
223869576|NCT02047981|DRUG|Azithromycin|Children aged 1 month to 60 months per community will be offered weight or height-based, directly observed, oral azithromycin suspension every 6 months for 2 years. In Niger during year 3, all communities will be offered azithroymcin.
223869577|NCT02047981|DRUG|Placebo|Children aged 1 month to 60 months per community will be offered weight or height-based, directly observed, oral placebo every 6 months for 2 years. In Niger during year 3, all communities will be offered azithroymcin.
223869578|NCT02108236|DEVICE|acupuncture|Zhong-wan (RN12), Liang-men (ST21), Shui-fen (RN9) and Qi-hai (RN6) and bilateral acupuncture points Dai-mai (GB26), Tian-shu (ST25), Zu-sanli (ST36), Feng-long(ST40) and Liang-qiu(ST34) will be applied through the skin by acupuncture for 30 minutes every time. Electro-acupuncture apparatus will be connected to both Dai-mai, Zu-sanli and Feng-long, Zhong-wan and Qi-hai for 30 minutes with interrupted waves (2/100HZ).
223869579|NCT03618134|BIOLOGICAL|Durvalumab|Given IV
223869580|NCT03618134|PROCEDURE|Modified Radical Neck Dissection|Undergo modified radical neck dissection
223869581|NCT03618134|OTHER|Quality-of-Life Assessment|Ancillary studies
223869582|NCT03618134|OTHER|Questionnaire Administration|Ancillary studies
223869583|NCT03618134|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
223869584|NCT03618134|PROCEDURE|Transoral Robotic Surgery|Undergo TORS
223869585|NCT03618134|BIOLOGICAL|Tremelimumab|Given IV
223869586|NCT03760627|BEHAVIORAL|Refugees Mindfulness Resiliency Training|The intervention consists of meditation, guided imagery, yoga and exercise, biofeedback; self-expression in words, drawings, and movement; and small group support to demonstrate to participants techniques that they can use to self-manage their own stress and trauma.
223869587|NCT03760627|BEHAVIORAL|Mindfulness Resiliency Training|The intervention consists of meditation, guided imagery, yoga and exercise, biofeedback; self-expression in words, drawings, and movement; and small group support to demonstrate to participants techniques that they can use to self-manage their own stress and trauma.
223869588|NCT05184946|DRUG|Camrelizumab Combined with SOX|Administer camrelizumab and SOX regimen in the adjuvant treatment of advanced gastric adenocarcinoma or gastric esophageal junction adenocarcinoma
223869589|NCT03093298|OTHER|Enteroscopy with biopsy sampling and mixed meal test|Enteroscopies with biopsy retrieval and mixed meal tests with blood sampling before and after Roux-en-Y gastric bypass surgery
223869590|NCT06193005|OTHER|no intervention|no intervention
223869591|NCT02840006|PROCEDURE|General anesthesia only|Induction drugs: Citrate of fentanyl, atracurium, etomidate
223869592|NCT02840006|PROCEDURE|General anesthesia and Spinal anesthesia|Induction drugs: Citrate of fentanyl, atracurium, etomidate Spinal anesthesia: Bupivacaine hyperbaric, Morphine
223869593|NCT00866203|DRUG|HDS vs ProMECE/CytaBOM|
223869594|NCT00704184|DRUG|Comparator: Vaniprevir|Vaniprevir 300 mg b.i.d., 600 mg b.i.d., 600 mg q.d., or 800 mg q.d.; duration of treatment: 28 days
223869595|NCT00704184|DRUG|Comparator: Pegylated-Interferon (Peg-IFN)|Peg-IFN 180 mcg once-weekly subcutaneous injection; duration of treatment: 48 weeks
224076541|NCT01347034|BIOLOGICAL|Autologous Dendritic Cells|"Prior to each injection on Arm B, patients may receive prophylactic doses of a first generation cephalosporin antibiotic per physician discretion.~Following each DC injection, Arm B patients will assess procedure-associated pain on a scale of 0-10. The next Monday following each DC injection, the patient will be called and questioned about such procedure associated toxicities."
223869596|NCT00704184|DRUG|Comparator: Ribavirin|Ribavirin 200 mg tablet b.i.d. (dose based on body weight); duration of treatment: 48 weeks
223869597|NCT00704184|DRUG|Comparator: placebo|Matching placebo to vaniprevir; duration of treatment: 28 days
223869598|NCT00666068|OTHER|corticotropin releasing hormone (CRH)|50 µg injected at 2200, 2300, 0000, and 0100
223869599|NCT00666068|OTHER|Placebo|injected at 2200, 2300, 0000, and 0100
223869600|NCT00666068|OTHER|Placebo|injected at 2200, 2300, 0000, and 0100
223869601|NCT00328835|PROCEDURE|Brief Elevation of IOP|
223869602|NCT04781439|PROCEDURE|IV-to-PO conversion of antibiotics|IV-to-PO switching of antibiotics treatment
224076542|NCT03535623|OTHER|remote ischemic preconditioning (RIPC)|RIPC consists of 4 cycles of 5-min ischemia using pneumatic cuff pressure of 200 mmHg and 5-min reperfusion.
224076543|NCT03535623|OTHER|Sham-RIPC|Sham-RIPC consists of 4 cycles of 5-min ischemia using pneumatic cuff pressure of \< 10 mmHg and 5-min reperfusion.
224076544|NCT00257010|DRUG|Almotriptan Malate|Patients will take one 12.5 mg almotriptan malate tablet by mouth after the onset of migraine headache pain
223869603|NCT06212141|DEVICE|VisCalor Bulk,VOCO,Germany|"It was placed class II restorations.Before applying it, a 37% orthophosphoric acid will be injected into the cavity for 30 sec. on the enamel and 15 sec. on the dentin. Then, cavity will be rinsed with pressurized air and water for 15 sec. and Futura Bond U adhesive agent will be applied to the enamel and dentin surfaces using a disposable applicator for 20 sec. Then light air pressure will be applied for 5 sec., and then polymerization will be carried out for 10 sec. using LED light.~When it comes to the application of VisCalor , the VisCalor Gun , heating device will be used. A disposable composite capsule will be placed into the device, and it will be heated by selecting program 1 (65°C) for 30 sec. The material will remain hot for 2.5 min.~The nozzle of the capsule on the gun will be directly applied to the deepest part of the cavity, ensuring that the material is placed from bottom to top without exceeding 4 mm. Polymerization will be carried out with LED for 10 sec."
223869604|NCT06212141|DEVICE|Admira Fusion x-tra,VOCO,Germany|"Admira Fusion x-tra composite resin was placed class II restorations. Before applying it an orthophosphoric acid with a concentration of 37% will be injected into the cavity for 30 sec. on the enamel and 15 sec. on the dentin. Then, cavity will be rinsed with pressurized air and water for 20 sec. And Futura Bond U adhesive agent will be applied to the enamel and dentin surfaces using a disposable applicator for 20 sec. Following the manufacturer's recommendations, light air pressure will be applied for 5 sec, and then polymerization will be carried out for 10 sec. using LED light with a power of 1200 mW/cm².~Afterwards bulk-fill composite will be placed in the cavity, ensuring that each layer does not exceed 4 mm, and appropriate occlusal shaping will be performed. Polymerization will be carried out with LED light for 20 seconds."
223869605|NCT06212141|DEVICE|Filtek One Bulk,3M,Germany|"Filtek One Bulk composite resin was placed class II restorations. Before applyingthe material, a 37% orthophosphoric acid will be injected into the cavity for 30 sec. on the enamel and 15 sec. on the dentin, followed by rinsing the cavity with pressurized air and water for 20 sec.Then , adhesive agent will be applied to the enamel and dentin surfaces using a disposable applicator for 20 sec. Following the manufacturer's recommendations, light air pressure will be applied for 5 sec, and then polymerization will be carried out for 10 sec using LED light .~Afterwards, bulk-fill composite will be placed in the cavity, ensuring that each layer does not exceed 4 mm, and appropriate occlusal shaping will be performed. Polymerization will be carried out with LED light at a power of 1200 mW/cm² for 10 sec from all directions, following the manufacturer's recommendations."
223869606|NCT02378155|DEVICE|SenSmart Model X-100, Nonin Medical|Device to measure cerebral tissue oxygen saturation
223869607|NCT04658914|BIOLOGICAL|Rotarix|Live-attenuated oral human rotavirus vaccine (Rotarix) manufactured by GlaxoSmithKline containing at least 10\^6 CCID50(median cell culture infective doses) of G1P\[8\] rotavirus, RIX4414 strain produced in Vero cells. This vaccine is an oral suspension with a single dose (1.5ml) administered using an oral applicator.
223869608|NCT04658914|BIOLOGICAL|Trivalent P2-VP8|Trivalent P2-VP8 subunit vaccine manufactured by SK Chemicals containing 90ug of each VP8 antigen derived from P\[4\] (DS-1), P\[6\] (1076), and P\[8\] (Wa) rotavirus strains fused to the P2 epitope from tetanus toxoid and adsorbed to aluminium hydroxide. A single dose (0.5ml) of this vaccine is administered intramuscularly through injection.
223869609|NCT00716859|DRUG|Timolol|Timolol 0.5% dosed twice-daily
223869610|NCT00716859|DRUG|latanoprost|Latanoprost 0.005% ophthalmic solution dosed once-daily
223869611|NCT01764464|DRUG|Gralise®|14 day titration (days 1-7 at 600 mg daily Gralise®; days 8-14 at 1200 mg daily Gralise®). 28 day maintenance (1800 mg daily Gralise®). 7 day taper (days 1-4 at 1200 mg daily Gralise®; days 5-7 at 600 mg daily Gralise®).
223869612|NCT01764464|DRUG|Placebo|14 day titration (days 1-7 at 600 mg daily placebo; days 8-14 at 1200 mg daily placebo). 28 day maintenance (1800 mg daily placebo). 7 day taper (days 1-4 at 1200 mg daily placebo; days 5-7 at 600 mg daily placebo).
223869613|NCT00096915|DRUG|Darbepoetin Alfa|"QM administration for 32 weeks, allowable doses:~15, 20, 30, 40, 50, 60, 80, 100, 150, 200, 300, 400, 500, 600 and 800 mcg"
223869614|NCT02299752|PROCEDURE|single-gloving system|single-gloving system was used during Catheterization
223869615|NCT02299752|PROCEDURE|double-gloving system|double-gloving system was used during Catheterization. inner and outer gloves were the same size
223869616|NCT04250935|DIAGNOSTIC_TEST|Patients with cognitive dysfunction|Mini Mental Test Those with a score below 21 points
223869617|NCT03969524|DEVICE|MRI|Patients will undergo magnetic resonance imaging (MRI) at baseline (T0) (before NAC) and after the 2nd cycle of neoadjuvant chemotherapy(T2). Histopathological examination (gold standard) of the surgical specimen will be done for each patient and Compared to the results of MRI.
223869618|NCT04644341|COMBINATION_PRODUCT|cardiovascular and respiratory systems monitoring|only one group of individuals to observe the impact of COVID-19 on their cardiovascular and respiratory systems in long term.
223869619|NCT03649113|PROCEDURE|sclerotherapy arm|The liver mass will be punctured under guidance of ultrasonography with a 20- or 22-gauge Chiba needle. Contrast medium will be injected under fluoroscopy guidance to assess any possible communication with the biliary tree and to evaluate the amount of sclerosing agent which could be safely injected. Then, the mixture of Bleomycin (Bleocin-S; Korea United Pharm Inc., South Korea) and Lipiodol (Ultra-Fluid, Guerbet, France) will be slowly injected under continuous guidance of fluoroscopy. No more than 45 units of Bleomycin and 15 cc of Lipiodol will be injected in a single session.
223869620|NCT04080141|DIAGNOSTIC_TEST|Multiple psychometric questionnaire|At the time of first contact (T0) only women were subjected to Hamilton's rating scale for depression (HRSD or HAM-D), Hamilton's rating scale for anxiety (HRSA or HAM-A), Beck Depression Inventory (BDI-II). At the follow up after 1 year from the first examination (T1) they were subjected to a questionnaire with multiple psychometric tests for mother and her partner. The female version included Post-traumatic stress disorder checklist (PCL-5), Iowa Personality Disorder Screen (IPDS), Beck Depression Inventory (BDI-II), Connor-Davidson Resilience Scale 10 (CD-RISC 10) and Short-Form Questionnaire on childhood trauma (CTQ-SF). The male version included Post-traumatic stress disorder checklist (PCL-5), Iowa Personality Disorder Screen (IPDS), Connor-Davidson Resilience Scale 10 (CD-RISC 10) and Short-Form Questionnaire on childhood trauma (CTQ-SF).
223869621|NCT04080141|PROCEDURE|Clinical psychiatric examination|At the time of first contact (T0) only women were subjected to psychiatric clinical examination
223869622|NCT06972342|BEHAVIORAL|education|Participants will be intervened after the baseline measurements, including two training classes.
223869623|NCT01351272|DRUG|Methylphenidate, non-retard|Medication (methylphenidate, non-retard) will be titrated to optimal response within 6 weeks, with a maximum of 10 mg/day in week 1, 20 mg/day in week 2, 30 mg/day in week 3, 40 mg/day in week 4, 50 mg/day in week 5, and 60 mg/day in week 6, unless adverse effects emerged. After successful adjustment, medication will be maintained until week 6. Dosing will be based on at least two-weekly evaluations by a psychiatrist, including an interview with a review of symptoms and side effects, completion of the Clinical Global Impression (CGI) scale and completion of a standardised Side Effects Rating Scale for psychostimulants (SERS). The maximal daily dosage of MPH is 60 mg. Within this double blind study the same procedure is applied for the placebo condition.
223869624|NCT01351272|DRUG|Placebo|
223869625|NCT03813706|PROCEDURE|lymph node dissection|The right cervical central compartment VI is subdivided into right cervical central VI-1 subzone and VI-2 subzone. Right central VI-1 subzone lies anterior to the RLN bounded by the hyoid bone superiorly, the suprasternal notch inferiorly, the inner edge of the common carotid artery laterally, and the midline of the trachea medially. Right central VI-2 subzone lies posterior to the right RLN. The superior, inferior, lateral, and medial borders are the laryngeal entry points of RLN, the intersection of the RLN with the innominate artery (near the right apical pleura), the inner edge of the common carotid artery, and esophagus, respectively. The floor of right central VI-2 is the prevertebral fascia.
223869626|NCT03843021|OTHER|VAD Infection Prevention Survey|Healthcare providers caring for VAD Therapy recipients will answer questions regarding processes of care at their institutions.
223869627|NCT01897272|BEHAVIORAL|Splinting|One group will have their wrist splinted after their carpal tunnel release surgery.
223869628|NCT02531152|DRUG|Latanoprost|
223869629|NCT02531152|DRUG|SAR366234|
223869630|NCT02447874|DRUG|Arginine|"Arginine will be dispensed intravenously (in the vein) in the standard dose of arginine as 100 mg/kg three times a day for seven days or until discharge.~* Loading dose: 200 mg/kg once~* Continuous IV: 300 mg/kg/24 hours"
223869631|NCT02447874|DRUG|Arginine (Loading)|Arginine will be dispensed intravenously (in the vein) as an initial bolus (loading) at each specified group dose once, followed by a standard dose of 100mg/kg every 8 hours until discharge or for a total of 21 doses of arginine, whichever comes first.
223869632|NCT02447874|DRUG|Arginine (Continuous)|Arginine will be dispensed intravenously (in the vein) as a continuous IV infusion of 300 mg/kg/24hr
223869633|NCT05668403|DRUG|B007|Drug: B007 injection Drug: Placebo injection
223869634|NCT05668403|DRUG|B007|Drug: B007 injection Drug: Placebo injection
223869635|NCT05668403|DRUG|B007|Drug: B007 injection Drug: Placebo injection
223869636|NCT03602911|DRUG|The isotope 68Ga, NETSPOT and 18F-FDG-PET/CT|All patients will undergo 18F-FDG-PET/CT per established protocol. Following 18F-FDG-PET/CT, the patient will undergo NETSPOT imaging
223869637|NCT04725890|DEVICE|The DyaMX Device|The DyaMX device is designed to induce duodenal mucosal regeneration using pulsed electric field. The DyaMX procedure is a non-surgical, endoscopic procedure.
223869638|NCT04356976|DEVICE|Ventralex|Repair of hernia using Ventralex patch in sublay position
223869639|NCT04356976|OTHER|Stratafix|Repair of hernia without mesh. Defect closed with Stratafix suture.
223869640|NCT01170026|BEHAVIORAL|Family Check-up/ Individual MI|The 2-session intervention protocol consists of an individual motivational interview plus the Family Check-Up (Dishion \& Kavanagh, 2003), a family based motivational interview. The experimental protocol provides a thorough assessment of both individual and family strengths and weaknesses with respect to substance use prevention and school attendance/performance.
223869641|NCT01170026|BEHAVIORAL|Individual and family psychoeducation|Families in PE will return for the same number of visits as the IMI and FCU sessions of the IMI/FCU condition. An interventionist will review a set of educational materials with the parents regarding teen SU use, truancy and risk behaviors and parenting a teenager. A similar set of materials will be reviewed with the adolescent
223869642|NCT06756646|BEHAVIORAL|Aerobic exercise intervention|The aerobic exercise intervention will utilize an ergometer. The program will be conducted 2-3 times per week over a 3-month period.
223869643|NCT06756646|BEHAVIORAL|Disease and exercise suggestion|The participants will be provided by educational program about COPD self-care and home-based exercise approach.
223869644|NCT06756646|BEHAVIORAL|Blood flow restriction (BFR) intervention|Blood flow restriction (BFR) intervention will combine aerobic exercise on the ergometer with BFR training. The program will be conducted 2-3 times per week over a 3-month period.
223869645|NCT04246372|DRUG|Tofacitinib|Treatment with oral Tofacitinib for immune mediated skin conditions in adults with Down syndrome
223869646|NCT04514107|OTHER|Brazilian National Dengue Control Program|This program has 4 basic principles: 1) Adequate case finding, classification and treatment; 2) Epidemiological surveillance and reporting of all cases; 3) Mobilization and communication of risks to the public; 4) mosquito monitoring and control which consists fundamentally of detection of larva using a rapid larval index (LIRAa) followed by removal of breeding sites and local spraying.
223869647|NCT04514107|OTHER|Wolbachia-infected Aedes aegypti|Brazilian strain of Aedes aegypti infected with Wolbachia pipientis released into geographic clusters.
223869648|NCT03414775|OTHER|Nourish|The effects of Nourish on the gastrointestinal microbiome will be compared to the the effects of Pediasure on the gastrointestinal microbiome
223869649|NCT03414775|OTHER|Pediasure|The effects of Nourish on the gastrointestinal microbiome will be compared to the the effects of Pediasure on the gastrointestinal microbiome
223869650|NCT06758440|DRUG|chitosan|Evaluate Effectiveness of hydroxyapatite reinforced chitosan hydrogel in modulation of osseintegration round immediate dental implant in a Randomized single blind control study
223869651|NCT04623008|BEHAVIORAL|Goal-Oriented Episodic Future Thinking|Individuals in the intervention group will receive a 20-week web-based intervention and individual health coaching focused on stress management, healthy eating and physical activity.
224076545|NCT03739073|OTHER|OCTA (angiography by tomography in optical coherence)|The study concerns patients with intermediate stenosis of the left anterior descending artery (LDA). A fundus oculi and an OCTA (angiography by tomography in optical coherence) examination will be performed; it's a non-invasive imaging test. OCT uses light waves to take cross-section pictures of your retina and then ophthalmological examination data will correlate with coronary angiography.
224076546|NCT03618108|DRUG|Doxycycline Capsule|doxycycline capsule
223869652|NCT03554382|OTHER|system to support self-management of hypertension|The patients are provided with a home BP monitor. Thereafter they will be asked to use the self-management support system and self-report, once daily in the evening, via their own mobile phone during eight weeks. At each occasion, the patients first answer the questions on wellbeing, symptoms, lifestyle, medication intake and side effects and then measure their BP and pulse, and when these data (mean of three readings) are input into the mobile phone, they automatically register in the database. During intervention the paient has regular access to self-reported data via graphs
223869653|NCT06162013|DIETARY_SUPPLEMENT|Nicotinamide Riboside|Nicotinamide Riboside 3000mg/day
223869654|NCT06162013|OTHER|Placebo|Placebo. Identical in taste and appearance as the intervention.
223869655|NCT04781335|DRUG|Dexycu|"This is a contra-lateral randomized study, meaning that in clinic after a patient is identified as a candidate we will flip a coin for selection of the eye that is going to receive the Dexycu™ implant (the implant will be placed intracapsularly at the optic haptic junction of the IOL). The patients will receive the SAME topical regimen (Eye with Dexycu™: no steroid, Eye without Dexycu™: steroid will be used). The Dexycu™, topical NSAID, and antibiotic regimen will be provided to all patients in the study, at no cost, in order to avoid difficulties with compliance, insurance, and follow up."
224076547|NCT03618108|DRUG|Azithromycin Capsule|azithromycin capsule
224076548|NCT03618108|DRUG|Rifabutin Oral Capsule|rifabutin capsule
224076549|NCT03618108|DRUG|Placebo oral capsule|Placebo oral capsule identical in size and form to doxycycline
224076550|NCT03618108|DRUG|Placebo Oral Tablet|Placebo oral capsule identical in size and form to azithromcyin
224076551|NCT03618108|DRUG|Placebo oral capsule|Placebo oral capsule identical in size and form to rifabutin
224076552|NCT03362775|DRUG|Propofol|Target-controlled infusion of propofol with an effect-site concentration of 0.0 µL/mL; 0.5 µL/mL and 1.0 µL/mL.
224076553|NCT03622697|BEHAVIORAL|Mindfulness Meditation Phone Application|Mindfulness meditation intervention: patients will be asked to complete a guided mindfulness meditation intervention using a phone application for at least 4 weeks with periodic survey assessments using validated psychometric tools.
224076554|NCT06156085|DRUG|Vonoprazan and Amoxicillin|vonoprazan 20 mg and amoxicillin 1000 mg b.i.d. PC for 14days
224076555|NCT06156085|DRUG|Lansoprazole, Amoxicillin, Clarithromycin and Metronidazole|lansoprazole 30 mg + amoxicillin 1000 mg b.i.d. AC for 7 days, followed by the same PPI + clarithromycin 500 mg + metronidazole 500 mg b.i.d. AC for 7 days
224076556|NCT01238939|DRUG|NK012 and 5-FU|NK012 infusion on Day 1 of each 28 day cycle 5-FU continuous infusion on Days 1 and 15 of each 28 day cycle
224076557|NCT00197054|BIOLOGICAL|RTS, S/AS01B|0.5mL dose; 50ug RTS, S antigen, 50ug QS21 and liposomes in phosphate-buffered saline administered intramuscular deltoid of non-dominant arm at 0, 1 and 2 months.
224076558|NCT00197054|BIOLOGICAL|RTS, S/AS02A|0.5mL dose; 50ug RTS, S antigen, 50ug QS21 and proprietary oil-water emulsion in phosphate-buffered saline administered intramuscular deltoid of non-dominant arm at 0, 1 and 2 months.
223869656|NCT04781335|DRUG|Standard of Care post operative eye drops (steroid, antibiotic, NSAID)|"This is a contra-lateral randomized study, meaning that in clinic after a patient is identified as a candidate we will flip a coin for selection of the eye that is going to receive the Dexycu™ implant (the implant will be placed intracapsularly at the optic haptic junction of the IOL). The patients will receive the SAME topical regimen (Eye with Dexycu™: no steroid, Eye without Dexycu™: steroid will be used). The Dexycu™, topical NSAID, and antibiotic regimen will be provided to all patients in the study, at no cost, in order to avoid difficulties with compliance, insurance, and follow up."
223869657|NCT02098343|DRUG|APR-246|Intravenous infusion.
223869658|NCT02098343|DRUG|Carboplatin and Pegylated Liposomal Doxorubicin Hydrochloride (PLD)|Intravenous infusion.
224076559|NCT00197054|BIOLOGICAL|Rabipur (Rabies) Vaccine|1.0mL dose administered intramuscular deltoid of non-dominant arm at 0, 1 and 2 months
224076560|NCT00323557|DRUG|Sargramostim (GM-CSF)|Starting with 3 doses of 250 micrograms subcutaneously, either pre or post vaccine. For pre vaccine, GM-CSF on days -7 (+ 1 day) and -3 (+ 1 day), in the week prior to vaccination for pre-vaccination immune priming; 3rd dose on the day of vaccination (day 0); and for post-vaccine GM-CSF given simultaneously on day of vaccination (day 0) and 2 more doses Day +3 and Day +7 after pneumococcal vaccine.
224076561|NCT00323557|BIOLOGICAL|Pneumococcal Vaccine|Subcutaneously on Day 0
223869659|NCT05314634|BEHAVIORAL|concurrent exercise|Participants conduct warm up for 5-min, aerobic exercise for 12-min, resistance exercise for 13-min, and 5-min cool down.
223869660|NCT05314634|BEHAVIORAL|aerobic exercise|Participants conduct warm up for 5-min, resistance training for 25-min, and 5-min cool down.
223869661|NCT06069115|RADIATION|Radiation therapy protocol for Breast cancer|Conformal 3D radiation therapy will be performed 4-12 weeks after surgical treatment of breast cancer on Electa Axesse linear gas pedal with 6 MeV energy in traditional fractionation mode. Different RT schemes will be used depending on the stage of the disease, type of surgical treatment, and morphological variant of the tumor. In organ-preserving surgeries the remaining breast will be irradiated with a single focal dose (FD) of 2 Gy, up to the total focal dose (TFD) of 50 Gy. In the presence of risk factors, irradiation of lymphatic outflow pathways will be performed: axillary, sub/adclavicular and parasternal lymph nodes areas (FD 2 Gy, up to TFD 44-46 Gy). In radical breast resection we'll use irradiation of the anterior chest wall in 2 Gy FD, up to 50 Gy FD, irradiation of lymphatic outflow pathways: axillary, sub/adclavicular and parasternal lymph nodes (2 Gy FD, up to 44-46 Gy FD).
223869662|NCT06069115|DIAGNOSTIC_TEST|Spirography and assessment of pulmonary diffusion capacity|Using the Master Screen Body device you will be asked to take two series of breaths through a special tube for 2-3 minutes. Usually the procedure does not cause any discomfort
223869663|NCT06069115|DIAGNOSTIC_TEST|Cardiopulmonary stress test|The exercise test is performed on a bicycle ergometer Oxycon Pro. Prior to the test, special sensors for recording the electrocardiogram, a sensor to determine blood saturation, and a cuff to measure blood pressure will be glued on the body. Breathing during the test takes place through a face mask with a built-in gas analyzer sensor. The stress test is conducted up to an individual maximum (according to the age, sex, height and weight of the patient), followed by a recovery period. There is some temporary discomfort associated with performing physical activity. Dyspnea, leg fatigue, and dizziness may occur. Observation continues until full recovery of hemodynamic and gas exchange parameters, in case of appearance of unfavorable symptoms - until their disappearance.
224076562|NCT01175044|PROCEDURE|Betadine Lavage|Following revision knee surgery, a dilute betadine lavage prior to surgical closure for 3 minutes followed by 2000 ml of sterile saline irrigation
224076563|NCT01175044|PROCEDURE|Saline Lavage|Following revision knee surgery, 2000ml sterile saline lavage prior to closure
223869664|NCT06069115|DIAGNOSTIC_TEST|Computed tomography of the chest organs|"CT is a method of examination based on X-rays, but unlike conventional X-rays, it gives the most complete picture of the body structure, with less radiation.~Tomography usually does not cause any unpleasant feelings and is performed in a specialized department."
223869665|NCT06069115|DIAGNOSTIC_TEST|SF-36 Quality of Life Questionnaire|Standard questionnaire for assessment quality of patient's life https://clinmedjournals.org/articles/jmdt/jmdt-2-023-figure-1.pdf
223869666|NCT06069115|DIAGNOSTIC_TEST|Demographic and anthropometric measures|Age, sex, height. weight, body mass index (BMI)
223869667|NCT06069115|OTHER|Indicators characterizing the severity of the underlying disease|Severity of underlying disease (mMRC, BODE, SMRT-CO Respiratory Support Need Scale), and comorbidities (cardiovascular disease, diabetes mellitus, chronic obstructive pulmonary disease, chronic kidney disease) Medications taken.
223869668|NCT05132205|PROCEDURE|Radiofrequency Ablation|Radiofrequency Ablation using RFMedical device.
223869669|NCT06551987|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|6 weekly, 50-minute sessions delivered individually using in-person or telehealth format by a trained behavioral health provider.
223869670|NCT06551987|BEHAVIORAL|Brief Behavioral Therapy for Insomnia|4 weekly, 30-minute sessions delivered individually using in-person or telehealth format by a trained behavioral health provider.
223869671|NCT05679271|DEVICE|Venous stenting|venous stenting associated to antiaggregation protocol
223869672|NCT05679271|OTHER|Standard of care|observation: no treatment
223869673|NCT04987476|BIOLOGICAL|analyzes in singles cells|genome expression analyzes in single cells
224076564|NCT06403085|OTHER|Study group|Rhythmic Stabilization, Limb Matching, Double and Single Arm Balance, Balance with Ball and Weight Transfer will be performed for 8 weeks.
224076565|NCT02494531|RADIATION|Fluorodeoxyglucose-PET|Fluorodeoxyglucose-PET performed within 2 months
224076566|NCT02494531|RADIATION|florbetapir F 18-PET|florbetapir F 18-PET performed within 2 months
224076567|NCT01743638|PROCEDURE|MR-Guided Laser Ablation|
224076568|NCT03529877|BIOLOGICAL|allo-APZ2-EB|intravenous infusion of allo-APZ2-EB
223869674|NCT04729816|OTHER|Controlled, high fat/low fiber diet background diet, sequentially supplemented with an escalating dose of a fiber-blend snack food.|"Phase 1: Participants will be provided with a high fat/low fiber diet in the form of packed out meals and snacks for 10 days in total (days 2-11 and days 54-63)~Phase 2: Participants will be provided with the high fat/low fiber diet, plus 1 daily fiber-blend snack serving from days 12-25~Phase 3: Participants will receive 2 daily fiber-blend snack servings to supplement the high fat/low-fiber diet from days 26-39.~Phase 4: Participants will receive 3 daily fiber-blend snack servings to supplement the high fat/low-fiber diet from days 40-53.~Phase 5: Participants will return to the unsupplemented high fat/low fiber diet for days 54-63"
223869675|NCT04973566|DRUG|Nipocalimab|Nipocalimab will be administered as an IV infusion.
223869676|NCT04973566|DRUG|Etanercept|Etanercept will be administered subcutaneously.
223869677|NCT04973566|DRUG|Hydroxychloroquine|HCQ will be administered orally.
223869678|NCT03785782|DEVICE|Ultrasound|Breast ultrasound
223869679|NCT05219058|PROCEDURE|Biological mesh reconstruction|Patients receiving biological mesh of any kind or position as part of their reconstruction during surgery.
223869680|NCT05219058|PROCEDURE|Myocutaneous flap reconstruction|Patients receiving a myocutaneous flap of any kind as part of their reconstruction during surgery.
223869681|NCT05219058|PROCEDURE|Primary closure reconstruction|Patients receiving primary closure only using any suture material or technique as part of their reconstruction during surgery.
223869682|NCT04851509|PROCEDURE|Dynamic Rotational Locking|Performed, as per the Synthes technique guide, using the 5mm hex flexible set screwdriver and then loosening the set screw by one-half turn of the screwdriver.
223869683|NCT04851509|PROCEDURE|Static Locking|Performed by using the torque-limiting set screwdriver and locking the set screw down onto the helical screw to prevent dynamic sliding of the screw within the nail.
223869684|NCT03779048|BEHAVIORAL|Behavioral Treatment|Behavioral treatment (BT) for weight loss includes diet and physical activity recommendations and behavior therapy strategies. All participants will complete an initial 4-week BT run-in, delivered in individual, 20-30 minute weekly sessions. After the end of the run-in, participants will be offered an additional 24 weeks of 20-30 minute individual BT sessions, occurring weekly for the first 12 weeks and every other week for the last 12 weeks (total of 18 visits).
223869685|NCT03779048|DRUG|Placebo|The study medication (placebo or phentermine 15.0 mg) is a once-daily self-administered pill.
223869686|NCT03779048|DRUG|Phentermine 15 MG|The study medication (placebo or phentermine 15.0 mg) is a once-daily self-administered pill.
223869687|NCT06189131|DEVICE|Ventriject|Ventriject is a non-exercise method for estimating V02Max
223869688|NCT06245525|OTHER|This is not an interventional study|This is not an interventional study
223869689|NCT05164536|DRUG|Amyvid|All participants will undergo a single β-amyloid PET scan with Amyvid.
223869690|NCT03224949|OTHER|Blood draw|Patients will have a one time blood draw
223869691|NCT03889925|DRUG|Hyaluronan|Patients will receive 2 intra-articular injections of autologous conditioned plasma and hyaluronic acid once a week for 2 weeks and a third injection on the third week of ACP.
223869692|NCT03889925|BIOLOGICAL|Autologous conditioned plasma|Patients will receive 3 intra-articular injections of autologous conditioned plasma dosed at once a week for 3 weeks.
223869693|NCT05777785|DEVICE|VIZO Glasses|Eyeglasses with personalized peripheral retinal stimuli
223869694|NCT05116085|DRUG|Tislelizumab|Administered intravenously
223869695|NCT05376878|OTHER|Copper Cu 64-DOTA-Trastuzumab|Given IV
223869696|NCT05376878|PROCEDURE|Magnetic Resonance Imaging|Undergo PET/MRI
223869697|NCT05376878|DEVICE|Positron Emission Tomography|Undergo PET/MRI
223869698|NCT05376878|BIOLOGICAL|Trastuzumab|Given IV
223869699|NCT05376878|BIOLOGICAL|Trastuzumab Deruxtecan|Given IV
223869700|NCT06834516|DEVICE|ClearSight baby cuff|Noninvasive device for continuous blood pressure monitoring
223869701|NCT06829797|DRUG|Neoadjuvant Therapy(QL1706+SOX Chemotherapy)|Preoperative QL1706 combined with SOX regimen (4 cycles) → Radical surgery (D2) → Postoperative QL1706 combined with SOX regimen (4 cycles). QL1706 (50mg/2mL) , at a dose of 5mg/kg, the desired volume of drug is withdrawn and slowly infused into an IV bag of 0.9% NaCl, prepared as a diluent with a final concentration of 1-10mg/mL, mixed, and infused intravenously, Q3W, administered on the first day of each cycle.
223869702|NCT06829797|DRUG|Neoadjuvant Therapy(SOX Chemotherapy)|Preoperative SOX regimen (4 cycles) → radical surgery (D2) → postoperative SOX regimen (4 cycles).
223869703|NCT06829797|PROCEDURE|Radical surgery (D2)|Surgical treatment is completed within 3-5 weeks after the end of neoadjuvant therapy.
223869704|NCT06829797|DRUG|Drug: Adjuvant therapy(QL1706+SOX chemotherapy)|Postoperative adjuvant therapy is 4 cycles of QL1706+SOX chemotherapy.
223869705|NCT06829797|DRUG|Drug: Adjuvant therapy(SOX chemotherapy)|Postoperative adjuvant therapy is 4 cycles of SOX chemotherapy.
223869706|NCT03856632|DRUG|Liraglutide|Liraglutide will be administered with a starting dose of 0.6 mg once daily and subsequent increments to 1.2 mg once daily (after at least one week) and to 1.8 mg once daily (after at least a week on 1.2 mg). This will be taken for 3 consecutive months in conjunction with RFM program prior to catheter ablation. Treatment will resume post ablation and will be continue for 6 months.
224268402|NCT03577938|DRUG|Chinese herbal medicine|One dosage of CHM includes Artemisiacapillaris Thunb (30g), Salvia miltiorrhiza Bge (30g), Rhizoma Atractylodis Macroce- phalae (30g), Rubia cordifolia L (30g), Sieyesbeckiaorientalis L (30g). Paeoniae Radix Rubra (60g), Gardenia jasminoides Ellis (9g), Hedyotis diffusa Willd (30g) and Bletilla striata (15g) are involved for excess syndrome, and Astragalus membranaceus (30g), Radix Pseudostellariae (15g), Radix Aconiti Lateralis Praeparata (10g), Galli Gigeriae Endothelium Corneum (20g), Polygonum cuspidatum Sieb.et Zucc (15g) are involved for deficiency syndrome.
224268403|NCT03577938|OTHER|Control (blank)|SMT therapy includes a high-calorie diet; nucleoside analogues for HBV DNA-positive patients; sodium restriction, diuretics and paracentesis combined with albumin infusion for ascites; lactulose and L-ornithine aspartate and lactulose for HE and hyper-ammonia; hemostatic treatment for gastrointestinal hemorrhage; antibiotics for infections and renal replacement for HRS and uremic symptoms.
224268404|NCT03560843|BEHAVIORAL|MBSR|Mindfulness Based Stress Reduction
224268405|NCT03358147|DRUG|GP MDI 28.8 μg|GP MDI (PT001)14.4 μg per actuation taken as 2 inhalations BID
224268406|NCT03358147|DRUG|GP MDI 14.4 μg|GP MDI (PT001) 7.2 μg per actuation taken as 2 inhalations BID
224268407|NCT03358147|DRUG|GP MDI 7.2 μg|GP MDI (PT001) 3.6 μg per actuation taken as 2 inhalations BID
224268408|NCT03358147|DRUG|Placebo MDI|Placebo taken as 2 inhalations BID
224268409|NCT03358147|DRUG|Spiriva Respimat 2.5 μg|Spiriva Respimat 2.5 μg QD (open-label)
224268410|NCT03997019|PROCEDURE|opioid analgesia|opioid analgesia will be used with general anaesthesia
224268411|NCT03997019|PROCEDURE|ESP block|ultrasound guided ESP Block before anaesthesia induction
224268412|NCT05109377|DIAGNOSTIC_TEST|Endocan|Endocan will measured before and after treatment
224268413|NCT05109377|DRUG|tadalafil|tadalafil
224268414|NCT06558955|BEHAVIORAL|Technology-enabled anticipatory guidance and peer support|The intervention includes 4 online sessions led by an oral health therapist (OHT) or dentist, as well as push notifications and information delivered to participants via a mobile/web app.
224268415|NCT06558955|BEHAVIORAL|Conventional health education|Participants on this arm will receive conventional child oral health education materials at 4 time points.
224268416|NCT02524691|DEVICE|Use of Rapid Immunoassay Tests for the Detection of PROM|Patient will undergo both rapid immunoassay tests for the detection of PROM and the standard of care for the diagnosis of PROM using a sterile speculum (SSE). Women who cannot be confirmed clinically by the SSE will undergo an ultrasound evaluation to determine the amniotic fluid index. The patient will be treated according to the results of the SSE and ultrasound, not the results of rapid immunoassay tests. The provider conducting the SSE will be blinded to the results of the rapid immunoassay tests.
223869707|NCT03856632|OTHER|RFM|The program involves weight management and exercise regimen (30 minutes for 2 to 4 times a week), hyperlipidemia management (lifestyle measure changes and initiation of statins and fibrates if necessary), management of obstructive sleep apnea (initiation of Continuous Positive Airway Pressure (CPAP) if necessary), management of hypertension (reduction of salt intake, initiation of Angiotensin Converting Enzyme Inhibitor (ACEI) or Angiotensin II Receptor blockers (ARB) medications if necessary), diabetes management (lifestyle measure changes, endocrine review and initiation of metformin if necessary) and smoking cessation and alcohol abstinence or reduction. This program will be performed at start of study participation all throughout the follow up period.
223869708|NCT03856632|DRUG|Anti Arrhythmics|The choice of antiarrhythmic drug will be at the discretion of the managing physician, but will generally include either a class IC or class III antiarrhythmic drug. If necessary, and clinically indicated, amiodarone may be used. Therapy will be initiated at the start of study participation and will be discontinued 6-12 weeks after the ablation, as deemed clinically appropriate by the managing electrophysiologist.
223869709|NCT03856632|PROCEDURE|Afib Catheter Ablation|The procedure will be performed according to usual clinical practice. The primary approach will be antral pulmonary vein isolation (PVI), preferably performed by cryoballoon ablation, though radiofrequency may be used as deemed necessary by the operator for clinical reasons. This will be performed after 3 months of RFM or RFM + Liraglutide program.
223869710|NCT01868490|DRUG|cytokine induced killer cells|at least 10\*9 CIK cells, IV on day 0, 14, 28
223869711|NCT06786117|OTHER|SLP swallowing exercises|Clinical speech language pathologists will provide standard exercises based on the abnormalities seen on the modified barium swallow. Exercises are expected to include the effortful swallow, the Mendelsohn maneuver, expiratory muscle strength training with the EMST-150, supraglottic swallow, super supraglottic swallow, chin tuck against resistance isokinetic exercise, chin tuck against resistance isometric exercise, Masako maneuver, Shaker isometric head lift exercise, Shaker isokinetic head lift exercise, Falsetto high pitch glide exercise, tongue press exercise
223869712|NCT06786117|OTHER|myofunctional exercises|Participants will get a variety of exercises aimed at improving bolus formation, strengthening the seal of the soft palate with the tongue, and habituating nasal breathing. There will also be exercises aimed at stabilizing the epiglottis and strengthening the muscles supporting the lateral pharyngeal walls. Expiratory muscle strength training with the EMST-150 will also be done.
223869713|NCT06785311|BEHAVIORAL|Native Spirit After-School Program|Native Spirit is a culturally-grounded after-school program that is community-specific. The program is 10-sessions/weeks long and each session is 1.5-2 hours in duration. Each session is guided by a local cultural knowledge holder and is focused on a different cultural value and accompanying cultural practice. Native Spirit aims to promote self-esteem, cultural efficacy, awareness of cultural connectedness, and resilience while preventing and/or slow down the initiation of substance use.
223869714|NCT05457972|DRUG|Estradiol|Imvexxy is an FDA-approved drug produced by TherapeuticsMD.
223869715|NCT05457972|DEVICE|Vaginal Moisturizer|Ingredients include hydrogenated coconut and palm oils and natural-source vitamin E (d-alpha tocopheryl acetate and tocopherols).
223869716|NCT05143632|DEVICE|ClearSight|The primary hypothesis is that continuous non-invasive monitoring using ClearSight reduces the incidence of intraoperative hypotensive events (defined by mean arterial pressure below a value of 65 mmHg for more than 1 minute) and the duration of the events themselves, leading to an improvement in patients' outcomes.
223869717|NCT05988749|OTHER|Biofourmis Digital Platform|The intervention is a combination of the American Heart Association's Digital Heart Failure CarePlans and Education Content, delivered through and combined with the Biofourmis Platform. Patients enrolled in this arm will wear the device for 90 days and provide data to the participant's care team.
223869718|NCT06302660|DIAGNOSTIC_TEST|Breath test|Participants will attend an outpatient clinic, fasted for at least 4 hours for collection of breath.
223869719|NCT06302660|DIAGNOSTIC_TEST|Saliva sample|Participants will attend an outpatient clinic, fasted for at least 4 hours for collection of saliva.
223869720|NCT06302660|DIAGNOSTIC_TEST|Blood sample|Participants will attend an outpatient clinic, fasted for at least 4 hours for collection of blood.
223869721|NCT06302660|DIAGNOSTIC_TEST|Urine sample|Participants will attend an outpatient clinic, fasted for at least 4 hours for collection of urine.
223869722|NCT06302660|DIAGNOSTIC_TEST|Stool sample|Participants will attend an outpatient clinic, fasted for at least 4 hours for collection of stool.
223869723|NCT06302660|DIAGNOSTIC_TEST|Health-related Quality of life questionnaires|Participants will attend an outpatient clinic and complete validated healthy-related quality-of-life questionnaires.
223869724|NCT06164613|DRUG|Cinnamomum Verum oil extract|one capsule of 1000 mg orally of Cinnamomum Verum oil extract per day for 21-28 days
223869725|NCT06164613|DRUG|Placebo|400 mg PO Canola oil soft gel capsule
223869726|NCT05649930|OTHER|Functional power training|The training consists of weighted running and walking exercises performed at high-velocity and is given three times a week for 12 weeks.
223869727|NCT04709601|DRUG|Hiprex|Patients with negative urine culture will be prescribed Hiprex 1 g PO BID x 1 yr and patients with a positive urine culture will be prescribed antibiotics.
223869728|NCT05021328|DRUG|Toripalimab|Toripalimab 240mg, ivgtt, d1, q3w.
223869729|NCT05021328|DRUG|Anlotinib|Anlotinib 12 mg/d, d1-14, q3w.
223869730|NCT05021328|DRUG|SBRT 7Gy✖️5 QD|SBRT 7Gy✖️5 QD
223869731|NCT05470868|DRUG|Naphazoline / Hypromellose Ophthalmic|Naphazoline 0.03% / Hypromellose 0.2%
223869732|NCT03755102|DRUG|Dacomitinib|"Cohort 1 Dacomitinib Dosing:~Dose level 1: Dacomitinib 45mg daily Dose level -1: Dacomitinib 30mg daily Dose level -2: Dacomitinib 15mg daily~Cohort 2 Dacomitinib Dosing:~Dose level 1: Dacomitinib 30 mg daily Dose level -1: Dacomitinib 15 mg daily"
223869733|NCT03755102|DRUG|Osimertinib|"In cohort 2, participants will begin on dacomitinib orally daily in combination with Osimertinib~Dose level Osimertinib Dosing:~Dose level 1: Osimertinib 80 mg daily Dose level -1: Osimertinib 40 mg daily"
223869734|NCT00682032|DIETARY_SUPPLEMENT|beta-glucan|AIM 2: regimen to begin after baseline blood draw; AIM 3: regimen to begin after baseline blood draw and to be completed prior to surgery
223869735|NCT04922268|OTHER|Internal focus of attention feedback|Participants will complete 12 sessions over a 3-week period of functional movement retraining while receiving mirror feedback. Participants will be instructed to perform each functional task in a manner that keeps their knee in line with their toes.
223869736|NCT04922268|OTHER|External focus of attention feedback|Participants will complete 12 sessions over a 3-week period of functional movement retraining while receiving visual feedback via laser. Participants will be instructed to perform each functional task in a manner that does causes the laser to move up and down but not side-to-side.
223869737|NCT04588259|DRUG|Faster aspart|Administered s.c. (subcutaneously, under the skin) for 16 weeks
223869738|NCT04588259|DRUG|Insulin aspart|Administered s.c. (subcutaneously, under the skin) for 16 weeks
223869739|NCT04588259|DRUG|Insulin degludec|Administered s.c. (subcutaneously, under the skin) for 16 weeks
223869740|NCT06104332|DEVICE|ProRhinel Naturel spray nasal/ Allergic rhinitis|ProRhinel Naturel spray nasal: 21 days; 1 spray per nostril; 3 to 6 times per day
223869741|NCT06104332|DEVICE|ProRhinel EXTRA Eucalyptus spray nasal|ProRhinel EXTRA Eucalyptus spray nasal: until resolution of symptoms (period of 14 days maximum) ; 2 to 3 sprays per nostril; 6 times per day maximum
223869742|NCT06104332|DEVICE|RESPIMER Enfant|RESPIMER Enfant: until resolution of symptoms (period of 14 days maximum) ; 1 spray per nostril; 4 times per day maximum
223869743|NCT06104332|DEVICE|Phytosun Aroms spray nasal MAX|Phytosun Aroms spray nasal MAX: until resolution of symptoms (period of 14 days maximum) ; 1 spray per nostril; up to 4-6 times per day
223869744|NCT06104332|DEVICE|PHYSIOMER RHUME TRIPLE ACTION|PHYSIOMER RHUME TRIPLE ACTION: until resolution of symptoms (period of 14 days maximum) ; 1 spray per nostril; up to 4-6 times per day
223869745|NCT06104332|DEVICE|Phytosun Aroms spray nasal decongestionnant|Phytosun Aroms spray nasal decongestionnant : until resolution of symptoms (period of 14 days maximum) ; 1 spray per nostril; 6 times per day maximum
223869746|NCT06104332|DEVICE|ProRhinel Naturel spray nasal/ URTI|ProRhinel Naturel spray nasal: until resolution of symptoms (period of 14 days maximum) ; 1 spray per nostril; 3 to 6 times per day
223869747|NCT04951310|BEHAVIORAL|Philly Vax Sweepstakes|"The Philly Vax Sweepstakes is a citywide sweepstakes designed to motivate Philadelphians to get vaccinated against COVID-19. A total of 36 vaccinated Philadelphians will win among three cash prize packages, distributed from the total cash pool. These 36 will be chosen over three drawings, with 12 residents chosen in each drawing."
223869748|NCT06961929|OTHER|Control Trial|All participants will be exposed to a period of hyperthermia (hot and dry). In this condition, participants will not be given an experimental cooling modality.
223869749|NCT06961929|OTHER|Cool water limb immersion|All participants will be exposed to a period of hyperthermia (hot and dry). In this condition, participants will also immerse their hands and forearms in cool water.
223869750|NCT06961929|OTHER|Skin-Wetting Trial|All participants will be exposed to a period of hyperthermia (hot and dry). In this condition, participants will also be sprayed with water periodically.
223869751|NCT06963814|DRUG|HC006|Specified dose on specified days
223869752|NCT06963814|DRUG|KEYTRUDA ®( Pembrolizumab)|Specified dose on specified days
223869753|NCT06134089|BEHAVIORAL|Perceived Effectiveness Prompt|"Participants will assess pairs of messages with the prompt, Which of the messages below is more likely to make you want to get screened for colorectal cancer?~Participants will also be able to provide their own idea for a message rather than selecting a message from the pairs presented."
223869754|NCT06134089|BEHAVIORAL|Perceived Shareability Prompt|"Participants will assess pairs of messages with the prompt, Which of the messages below would you be more likely to share with your friends or family?~Participants will also be able to provide their own idea for a message rather than selecting a message from the pairs presented."
223869755|NCT02846506|DRUG|Canagliflozin and Metformin Extended Release (XR) Fixed Dose Combination [FDC]|Participants will receive 1 XR FDC tablet containing canagliflozin 150 mg and metformin 500 mg orally under fed (Treatment B)or fasted condition (Treatment D) in a given treatment period as per treatment sequence.
223869756|NCT02846506|DRUG|Canagliflozin 50 mg|Participants will receive canagliflozin 50 mg oral tablet under fed (part of Treatment A) or fasted condition (part of Treatment C) in a given treatment period as per treatment sequence.
223869757|NCT02846506|DRUG|Canagliflozin 100 mg|Participants will receive canagliflozin 100 mg oral tablet under fed (part of Treatment A) or fasted condition (part of Treatment C) in a given treatment period as per treatment sequence.
223869758|NCT02846506|DRUG|Metformin Extended Release (XR)|Participants will receive metformin XR 500 mg tablet orally under fed (part of Treatment A) or fasted condition (part of Treatment C) in a given treatment period as per treatment sequence.
223869759|NCT04948866|BEHAVIORAL|ADRD-PC Program|Included in arm/group descriptions
223869760|NCT05341739|OTHER|Pre-operative Stereotactic Radiosurgery|Pre-operative SRS will be performed prior to the surgical resection of the brain metastases.
223869761|NCT05894798|OTHER|Acupuncture|Acupuncture at point LI 4 in the thumb grip on the upper side of the hand, bilaterally, with a sterile disposable needle of dimension 0.20 x 13 mm. The stitch is approximately three mm deep. The needle is allowed to remain in place for about 30 seconds
223869762|NCT05419076|RADIATION|Stereotactic Radiosurgery|All participants will undergo MSK standard SRS. A CT simulation will be performed per institutional standards, typically with contrast unless a contraindication exists. A contrast-enhanced MRI with 1mm slices will be fused to the CT simulation scan for the purposes of SRS planning. The SRS GTV will be considered the visible tumor on MRI and CT contrast enhanced studies. An expansion of 1-2mm will be used to create the PTV. Radiation dose may be between 16Gy and 30Gy in 1 to 5 fractions, per the discretion of the treating radiation oncologist. Participants with multiple lesions may receive different doses to each lesion per the discretion of the treating radiation oncologist. Concurrent treatment to other body sites is permitted.
223869763|NCT05419076|PROCEDURE|Cerebrospinal fluid collection|All participants will undergo lumbar puncture for CSF collection at study enrollment.. Lumbar punctures will be performed by clinical staff in neurology or neuroradiology, per the discretion of the treating radiation oncologist, as dictated by scheduling limitations and expected clinical difficulty in obtaining a sample (e.g. requiring fluoroscopic guidance), with input from the PI, neurology, and/or neuroradiology as necessary. Participants will be encouraged to undergo repeat lumbar puncture for CSF collection at 3 months (+/- 4 weeks), and at the time of CNS disease progression, though these latter timepoints are not required. CSF cytology will be evaluated.
223869764|NCT06738251|DRUG|SHR-A2102 for Injection|SHR-A2102 for Injection.
223869765|NCT06738251|DRUG|Docetaxel Injection|Docetaxel Injection.
223869766|NCT06738251|DRUG|Paclitaxel Injection|Paclitaxel Injection.
223869767|NCT06738251|DRUG|Gemcitabine Hydrochloride for Injection|Gemcitabine Hydrochloride for Injection.
223869768|NCT06738251|DRUG|Pemetrexed Disodium for Injection|Pemetrexed Disodium for Injection.
223869769|NCT02763319|DRUG|Rituximab (RTX)|Rituximab: Dose: 375 mg/m2 IV
223869770|NCT02763319|DRUG|Tafasitamab|Tafasitamab: Tafasitamab dose: 12 mg/kg intravenously (IV)
223869771|NCT02763319|DRUG|Bendamustine (BEN)|
223869772|NCT06450301|PROCEDURE|Endometrial Biopsy|"An endometrial biopsy is the removal of a small piece of tissue from the endometrium, which is the lining of the uterus. Endometrial biopsies are commonly done to check for the window of implantation, to determine ovulation or for enhancing implantation (procedure called endometrial scratching). For this purpose, we will use a Pipelle catheter. This procedure is very common in gynecologic practice and~generally considered safe. In most of the cases this procedure is indicated for evaluation of irregular vaginal bleeding, vaginal bleeding in post-menopausal women and for infertility related problems (recurrent implantation failures for example)."
224268417|NCT05406050|DRUG|reference eldecalcitol soft capsule|0.75 μg, produced by Chugai Pharmaceutical Co., Ltd. Japan
224268418|NCT05406050|DRUG|test eldecalcitol soft capsule|0.75 μg, produced by Wenzhou Haihe Pharmaceutical Co., Ltd. China
224268419|NCT03061591|DIETARY_SUPPLEMENT|Wholistic Turmeric capsules|Oral capsules of wholistic Turmeric capsules (Pukka herbs) curcumin (each capsule 0.5100 m gr curcumin) for a total of 4 gr/d divided twice daily.
224268420|NCT03061591|OTHER|Placebo|Placebo capsules
224268421|NCT02704091|DRUG|Smecta|
224268422|NCT02704091|DRUG|Smecta placebo|
224268423|NCT00503789|PROCEDURE|fecal bacteria analysis|ad lib feeding
224268424|NCT00298961|DEVICE|Videoconference equipment FALCON/IP|
224268425|NCT06253260|DRUG|Analgesic Efficacy of Sequential Rapid Intrathecal Injection Of Dexmedetomidine Followed by Slow Injection of Hyperbaric Bupivacaine Injection in Patients Undergoing Unilateral Inguinal Hernia Repair|Analgesic Efficacy of Sequential Rapid Intrathecal Injection Of Dexmedetomidine Followed by Slow Injection of Hyperbaric Bupivacaine Injection in Patients Undergoing Unilateral Inguinal Hernia Repair Surgery
223869773|NCT05056493|OTHER|Caremap app|The Caremap app is intended for organizing and tracking patient-reported health insights over time and sharing those trends and patient-centered goals with their providers, not for urgent/emergent clinical communication. Information shared with providers through the app will be used for clinical care at the discretion of their provider. Use of the app to share information and health insights will not replace usual, existing channels for patient-provider communication (e.g., MyChart, phone calls, email, pager, etc.).
223869774|NCT05980052|BEHAVIORAL|Physical Activity|Theory-driven behavioral physical activity promotion intervention.
223869775|NCT05222139|BIOLOGICAL|COVID-19 vaccination|Monitoring COVID-19 vaccination
223869776|NCT06781957|DRUG|Gonadotropins Subcutaneos|Gonadotropins s.c. single dose
223869777|NCT04869020|DEVICE|Otoband|Participants with vertigo will wear the Otoband set at their chosen power level when experiencing symptoms.
223869778|NCT04869020|DEVICE|Sham A|Sham Device A is an OtoBand in which the transducer is modified so that the vibrations are not targeted at the vestibular system.
223869779|NCT04869020|DEVICE|Sham B|Sham Device B is an OtoBand that operates at power settings found to be nontherapeutic against vertigo associated with virtual reality.
223869780|NCT02682485|DRUG|Cipro, metronidazole, neomycin combo|During endoscopies after imaging, the anastomosis will be lavaged with an antibiotic solution composed of metronidazole, ciprofloxacin and neomycin
223869781|NCT02682485|PROCEDURE|Serial Endoscopic Surveillance|Patients will undergo serial endoscopic surveillance consisting of three endoscopies: one intra-operative endoscopy (POD0) and two post-operative endoscopies (POD3-7, POD12-28). During endoscopies, the anastomosis will be lavaged with saline, the fluid will be collected by suction and images will be taken.
223869782|NCT02682485|DRUG|Saline|During endoscopies after imaging, the anastomosis will be lavaged with a placebo direct topical saline solution
223869783|NCT05878288|DRUG|Cemiplimab|Cemiplimab 50 mg/mL supplied as a sterile liquid in single-use glass vials.
223869784|NCT02740283|BEHAVIORAL|glycemic monitoring|
223869785|NCT02740283|DIETARY_SUPPLEMENT|dietary guide|
223869786|NCT00761553|OTHER|Dietary supplements with exercise|Resistive exercise along with consuming two dietary supplements every day during both 8 week intervention periods, for a total of 16 weeks.
223869787|NCT00761553|DIETARY_SUPPLEMENT|Dietary supplement without exercise|Consuming two dietary supplements every day during both 8 week intervention periods, for a total of 16 weeks.
223869788|NCT02871206|BIOLOGICAL|Fluad|
223869789|NCT02871206|BIOLOGICAL|Fluzone|
223869790|NCT06795386|PROCEDURE|Bariatric Surgery|Participants will include people with chronic widespread pain who will undergo bariatric surgery. All participants will receive this intervention and will not be randomized to this or other interventions.
223869791|NCT05912738|OTHER|Interventional therapy|Interventional therapy for postherpetic neuralgia includes nerve blocks, pulsed radiofrequency therapy, etc
223869792|NCT03788590|DEVICE|Jenscare TAVI|Jenscare TAVI and delivery system will implant a percutaneous bioprosthesis value, which is positioned in the native aortic valve, plays a role to control blood flow, and help your heart to work better. It may also shorten your recovery time to getting back to everyday activities.
223869793|NCT03643939|DEVICE|High Flow Nasal Catheter|"HFNC will deliver through AIRVO2. FiO2 from 21 to 100% and heated humidified gas flow up to 60 l / min with temperature of the circuit maintained at 37 degrees.~Oxygen flow will be offered through a humidified nasal catheter. Flow and FiO2 will be titrated according to the protocol to maximize patient´s comfort and SpO2."
223869794|NCT03643939|DEVICE|Noninvasive ventilation|NIPPV will be performed using a facial mask (either oronasal or full face). NIPPV will deliver pressures and FiO2 tailored to specific ARF subgroups, according to the protocol. Adjustments of the inspiratory pressure (IPAP) and expiratory pressure (EPAP) and FiO2 according to protocol
223869795|NCT01168544|DIETARY_SUPPLEMENT|loading dose Vitamin D and 50.000 IU vit D3/month|loading dose based on body weight and baseline serum 25(OH)D level + 50.000 IU vit D3/month consolidation therapy
223869796|NCT01168544|DIETARY_SUPPLEMENT|loading dose and 25.000 IU vit D3/month|loading dose based on body weight and baseline serum 25(OH)D level + 25.000 IU vit D3/month consolidation therapy
223869797|NCT01168544|DIETARY_SUPPLEMENT|Vitamin D 800 IU /day|800 IU vit D3/day
223869798|NCT01331044|DIETARY_SUPPLEMENT|Plumpy Nut|to RUTF will receive commercially available RUTF (Plumpy nut) in a total of 200 kcal/kg.day in a sequential manner (Plumpy nut will be offered \~ 125 kcal/kg in 1st 24 hours, \~ 150 kcal/kg in 2nd 24 hours, then\~200k cal/kg by the third day).
223869799|NCT01331044|DIETARY_SUPPLEMENT|Khichuri and Halwa|"Day 1: Milk suji, 10ml/kg/ feed for 11 feed \& halwa 10gm/kg; 2 feed per day 125kcal/kg.day~Day 2: Milk suji, 10ml/kg/ feed for 11 feed \& halwa 10gm/kg; 2 feed per day \& khichuri 10gm/kg; 2 feed per day 150kcal/kg.day~Day 3: Milk suji 100, 10ml/kg/ feed for 11 feed \& halwa 10gm/kg; 2 feed per day \& khichuri 10gm/kg; 2 feed per day 175kcal/kg.day~Day 4: Milk suji 100, 10ml/kg/ feed for 11 feed \& halwa 10gm/kg; 3 feed per day \& khichuri 10gm/kg; 3 feed per day 200kcal/kg.day~Day 5 onward: Milk suji 100, 10ml/kg/ feed 6 hourly (4 feed per day) \& halwa 20gm/kg; 3 feed per day \& khichuri 20gm/kg; 3 feed per day 200kcal/kg.day"
223869800|NCT01150383|OTHER|Physical exercise training with supplemental oxygen|"Prior to the exercise training, an intervention-free control period with usual care is planned.~Intervention group with oxygen supplementation: Endurance training (performed within 70-80% of the heart rate at the anaerobic threshold) as well as strength training will be performed with oxygen supplementation.~After 6 weeks of intervention with oxygen supplementation, second intervention period will start with room air instead of oxygen supplementation (as described above)."
223869801|NCT01150383|OTHER|"Physical exercise training with room air supplementation"|"Prior to the exercise training, an intervention-free control period with usual care is planned.~Intervention group with room air supplementation: Endurance training (performed within 70-80% of the heart rate at the anaerobic threshold) as well as strength training will be performed under normoxic conditions.~After 6 weeks of intervention with room air, second intervention period will start with oxygen supplementation instead of room air (as described above)."
223869802|NCT03500393|BEHAVIORAL|Remotely Supervised Exercise (REM)|REM is designed to follow in the tradition of stepped care behavioral interventions. As such, participants who are successfully engaging in the prescribed exercise are provided minimal and automated encouragement and praise. Participants who demonstrate less adherence are given interventions that are tailored in content and intensity, depending on the level of success and the nature of the barriers to success
224268426|NCT06253260|DRUG|Analgesic Efficacy of Sequential Slow Intrathecal Injection Of Dexmedetomidine Followed by Slow Injection of Hyperbaric Bupivacaine in Patients Undergoing Unilateral Inguinal Hernia Repair Surgery|Analgesic Efficacy of Sequential Slow Intrathecal Injection Of Dexmedetomidine Followed by Slow Injection of Hyperbaric Bupivacaine in Patients Undergoing Unilateral Inguinal Hernia Repair Surgery
224268427|NCT04552665|DEVICE|KODEX-EPD system|To evaluate the performance of the KODEX-EPD system and collect procedural data and medical images for Philips' internal research and development activities (R\&D)
224268428|NCT00726830|DRUG|methadone hydrochloride|Given orally
224268429|NCT00726830|DRUG|morphine sulfate|Given orally
224268430|NCT00726830|DRUG|oxycodone hydrochloride|Given orally
224268431|NCT05235568|DEVICE|VALVOSFT intervention|Treatment of the calcific aorta valve by non-invasive ultrasound therapy
224268432|NCT00245739|DRUG|TMC-114|600/100 mg tablets of TMC114/rtv BID until commercial available to the subject
224268433|NCT00963495|DRUG|Clioquinol|Patients will take Clioquniol at escalating doses depending on when they enter into the trial.
224268434|NCT03577535|DIETARY_SUPPLEMENT|Oncoxin®|Chemo-, radiotherapy or their combination + standard oral mucositis treatment + ONCOXIN 25 ml twice daily for 20 days;
224268435|NCT04114890|DRUG|Tenofovir Disoproxil Fumarate|Tenofovir Disoproxil Fumarate 300 mg once daily and will continue until one month after delivery
224268436|NCT01860638|DRUG|Bevacizumab|Bevacizumab will be administered at a dose of 10 milligrams per kilogram (mg/kg) intravenous (IV) every 2 weeks (Q2W) throughout the study, with the exception of bevacizumab monotherapy prior to PD1, which will be given as 15 mg/kg IV every 3 weeks (Q3W).
224268437|NCT01860638|DRUG|Lomustine|Lomustine will be administered at a dose of 90 milligrams per square meter (mg/m\^2) orally (PO) every 6 weeks (Q6W), with a cap of 160 milligrams (mg) per dose. In the absence of hematologic toxicity following the first dose, the second and subsequent doses may be increased to 110 mg/m\^2 PO Q6W, with a cap of 200 mg per dose.
224268438|NCT01860638|DRUG|Placebo|Placebo will be administered via IV infusion, in a formulation matched to bevacizumab, Q2W after randomization.
224268439|NCT01860638|RADIATION|Radiotherapy|Radiotherapy will be administered for a total dose of 60 Gray (Gy), administered in 2-Gy fractions, 5 days per week for 6 weeks during first-line treatment.
224268440|NCT01860638|DRUG|Temozolomide|Temozolomide will be administered orally (PO) as 75 mg/m\^2 per day for the first 6 weeks of first-line treatment (concurrent treatment), followed by 6 cycles (28 days each) as follows: 150 mg/m\^2 per day for the first 5 days of Cycle 1, then 200 mg/m\^2 per day (if permitted by the participant's hematological and non-hematological toxicity profile) for the first 5 days of Cycles 2-6.
224268441|NCT01860638|DRUG|SOC Agent|The choice of SOC agent will be at the discretion of investigator. The SOC agent will be administered during third-line treatment and subsequent lines, as per standard practice.
224268442|NCT02241577|PROCEDURE|Surgical treatment|Flap surgery around dental implant for scaling and disinfection of the titanium surface under local anesthesia
224268443|NCT02241577|PROCEDURE|Non-surgical treatment|Non-surgical subgingival scaling and disinfection of the titanium surface of dental implant under local anesthesia
224268444|NCT03073798|DRUG|Roflumilast|500 mcg of Roflumilast which is a prescription medicine used in adults with severe COPD to decrease the number of flare-ups or the worsening of COPD symptoms
224268445|NCT03073798|DRUG|Placebo|500 mcg of placebo is used
224268446|NCT01250730|DRUG|PF-02341066|Cohort 1: a 150 mg single dose of PF-02341066 administered as 1 x 50 mg IRT and 1 x 100 mg IRT.
224268447|NCT01250730|DRUG|PF-02341066|Cohort 2: a 250 mg single dose of PF-02341066 administered as 1 x 50 mg IRT and 2 x 100 mg IRTs.
224268448|NCT01250730|DRUG|PF-02341066|Cohort 3: a 400 mg single dose of PF-02341066 administered as 4 x 100 mg IRTs.
224268449|NCT04738019|DIAGNOSTIC_TEST|Medical examination or treatment.|Medical examination or treatment when delayed on-set nodule or other side effects occur due to Y-Solution filler injection.
224268450|NCT00728351|DRUG|vildagliptin + metformin|
224268451|NCT00728351|DRUG|metformin|1000 bid metformin
223869803|NCT03500393|BEHAVIORAL|Unsupervised Exercise (UNSUP)|The control condition represents a minimalist intervention that could occur in any setting: (1) enthusiastic provision on an exercise prescription and (2) provision of a fitness device (i.e., the Garmin VivioActive) that can help participants track their exercise engagement. Participants are instructed in how to use the device to track their adherence to the exercise prescription.
223869804|NCT03821246|DRUG|Atezolizumab|Given IV
223869805|NCT03821246|DRUG|Tocilizumab|Given IV
223869806|NCT03821246|DRUG|Etrumadenant|Given Orally
223869807|NCT03803605|BIOLOGICAL|VRC07-523LS|VRC07-523LS 40 mg/kg administered intravenously per series (total of 2 infusions administered)
223869808|NCT03803605|DRUG|Vorinostat (VOR)|Vorinostat 400 mg administered orally every 72 hours for 10 doses per series (A total of 20 400-mg doses administered)
223869809|NCT03046810|DEVICE|Wellness toileting system|This group will use the wash, dry, cleanse, and apply zinc oxide barrier spray routinely for all toileting.
223869810|NCT05150106|OTHER|Clinical assessments of laryngeal function|Participants will undergo acoustic, aerodynamic, respiratory kinematic, nasoendoscopic, and laryngeal EMG recordings, as well as real-time MRI of the upper airway for comprehensive characterization of shared and distinct features of laryngeal dystonia and voice tremor.
223869811|NCT00945607|OTHER|GRT (Guided Relaxation Training)|Weekly on-site GRT sessions at the center in combination with twice daily independent GRT sessions at home.
223869812|NCT00233090|DRUG|Modafinil|single dose of 200 mg. a day of modafinil for four weeks
223869813|NCT00233090|DRUG|Placebo|daily dose of placebo for four weeks.
223869814|NCT01186549|DRUG|Ephedrine 30microgram/kg|"Patients were randomly allocated to one of 5~groups (33 patients per group): lidocaine 0.5 mg/kg(L) ,ephedrine 30micrograms/kg (E30)ephedrine 70micrograms/kg(E70),lidocaine0.5mg/kg -ephedrine30 micrograms/kg(LE) or 2ml saline (S)intravenously.participants in each group receive a single dose of the intervention treatment only.After one minute propofol 2 mg/kg into a dorsal hand vein was injected"
223869815|NCT01186549|DRUG|lidocaine0.5mg/kg -ephedrine30 micrograms/kg|"Patients were randomly allocated to one of 5~groups (33 patients per group): lidocaine 0.5 mg/kg(L) ,ephedrine 30micrograms/kg (E30)ephedrine 70micrograms/kg(E70),lidocaine0.5mg/kg -ephedrine30 micrograms/kg(LE) or 2ml saline (S)intravenously.participants in each group receive a single dose of the intervention treatment only.After one minute propofol 2 mg/kg into a dorsal hand vein was injected"
223869816|NCT01186549|DRUG|ephedrine 70 microgram/kg|"Patients were randomly allocated to one of 5~groups (33 patients per group): lidocaine 0.5 mg/kg(L) ,ephedrine 30micrograms/kg (E30)ephedrine 70micrograms/kg(E70),lidocaine0.5mg/kg -ephedrine30 micrograms/kg(LE) or 2ml saline (S)intravenously.participants in each group receive a single dose of the intervention treatment only.After one minute propofol 2 mg/kg into a dorsal hand vein was injected"
223869817|NCT01186549|DRUG|lidocaine 0.5mg/kg|"Patients were randomly allocated to one of 5~groups (33 patients per group): lidocaine 0.5 mg/kg(L) ,ephedrine 30micrograms/kg (E30)ephedrine 70micrograms/kg(E70),lidocaine0.5mg/kg -ephedrine30 micrograms/kg(LE) or 2ml saline (S)intravenously.participants in each group receive a single dose of the intervention treatment only.After one minute propofol 2 mg/kg into a dorsal hand vein was injected"
223869818|NCT01186549|DRUG|normal saline 2ml|"Patients were randomly allocated to one of 5~groups (33 patients per group): lidocaine 0.5 mg/kg(L) ,ephedrine 30micrograms/kg (E30)ephedrine 70micrograms/kg(E70),lidocaine0.5mg/kg -ephedrine30 micrograms/kg(LE) or 2ml saline (S)intravenously.participants in each group receive a single dose of the intervention treatment only.After one minute propofol 2 mg/kg into a dorsal hand vein was injected"
223869819|NCT05639777|DRUG|Dexmedetomidine group|That will receive intranasal dexmedetomidine (1.5mcg/kg)
223869820|NCT05639777|OTHER|control group|That will receive the same volume of 2 ml of intranasal normal saline
223869821|NCT02424318|DRUG|Topiramate|topiramate 25mg twice 1 week -\> topiramate 50mg twice 7 weeks
223869822|NCT01222039|OTHER|Conventional treatment plus intravenous infusion of allogenic mesenchymal stem cells from adipose tissue.|"Conventional treatment plus intravenous infusion of allogenic mesenchymal stem cells from adipose tissue. Low dose: 1 x10e6 / Kg.~Conventional treatment:Gradually descending dosage of prednisone and cyclosporin or tacrolimus for at least 46 weeks. Starting dose: 1 mg/Kg/24 h prednisone and 3 mg/Kg/12 h cyclosporin."
223869823|NCT01222039|OTHER|Conventional treatment plus intravenous infusion of allogenic mesenchymal stem cells from adipose tissue.|"Conventional treatment plus intravenous infusion of allogenic mesenchymal stem cells from adipose tissue. High dose: 3 x10e6/Kg.~Conventional treatment:Gradually descending dosage of prednisone and cyclosporin or tacrolimus for at least 46 weeks. Starting dose: 1 mg/Kg/24 h prednisone and 3 mg/Kg/12 h cyclosporin."
223869824|NCT05661578|DRUG|Tiragolumab and Atezolizumab IV FDC|Intravenous fixed dose combination (IV FDC) of tiragolumab 600 mg and atezolizumab 1200 mg once every 3 weeks (Q3W).
223869825|NCT01323686|OTHER|Imaging guided optimal LV lead placement|"LV lead placement guided by cardiac imaging using echocardiography, single-photon emission computed tomography, and CT to target a cardiac vein at the site of latest mechanical activation without scar tissue.~Visualization of cardiac venous anatomy is performed using cardiac CT if not contraindicated by depressed renal function (estimated glomerular filtration rate \<30 ml/min) or allergy to contrast media. In that case, a coronary venogram is used."
223869826|NCT01016522|DIETARY_SUPPLEMENT|KetoCal|Ketogenic Diet food via gastrostomy tube - 80% fat, 17% protein, 3% carbohydrates
223869827|NCT02290470|DRUG|Olanzapine|"* Drug: Olanzapine 10 mg oral~* Drug: Chemotherapy (carboplatin and paclitaxel). Patients will receive carboplatin and paclitaxel.~* Drug: Anti-emetic treatment (palonosetron; plus dexamethasone). Palonosetron (0.25 mg IV) on the day of chemotherapy plus dexamethasone (16 mg IV on the day of chemotherapy and 8 or 4 mg (depending on the experimental arm) oral on days 2 and 3 post-chemotherapy)."
223869828|NCT02290470|DRUG|Palonosetron, Dexamethasone, Carboplatin, Paclitaxel, Olanzapine|all patients enrolled in the study will receive Palonosetron, Dexamethasone, Carboplatin, Paclitaxel and olanzapine On day 1
223869829|NCT00424086|BIOLOGICAL|Inactivated seasonal influenza vaccine (split virus, vero cell derived)|
223869830|NCT00424086|BIOLOGICAL|Inactivated seasonal influenza vaccine (split virus, egg derived) [licensed control vaccine]|
223869831|NCT05001529|BIOLOGICAL|anti IL5 receptor antibodies|Subjects with severe uncontrolled asthma will be assigned to treatment with Omalizumab (anti Ig E antibodies) or Mepolizumab (anti IL-5 antibodies) according to medical advice and standardized protocols for asthma treatment.
223869832|NCT04257071|BEHAVIORAL|Usual Care|The usual care for MS involves standard patient neurology visits and encounters with pharmacists, financial counselors and social workers if patients need any financial assistance with medication or other expenses.
223869833|NCT04257071|BEHAVIORAL|OOP Cost Communication and Optimization|OOP Cost Communication and Optimization includes personalized discussion of OOP cost estimates for treatment plan obtained through an online price transparency tool, personalized analysis of patients' expenses by financial counselor, and patient enrollment in any cost optimization opportunities for which patient is eligible using a comprehensive financial navigation program.
223869834|NCT05831969|DRUG|Lenalidomide|Lenalidomide: 10mg/d, 1-21d/28d orally; until disease progression or intolerable adverse reactions.
223869835|NCT00232180|DRUG|Eplerenone|Eplerenone administered on top of background standard heart failure therapy
223869836|NCT01295697|DRUG|EZN-2208|Experimental
223869837|NCT02486835|DEVICE|Cough syrup for adults and children|Dosage is 5 ml three times a day for 4 nights, 3 days
223869838|NCT02486835|DEVICE|Placebo|Dosage is 5 ml three times a day for 4 nights, 3 days
223869839|NCT02271789|OTHER|problematic tooth|problematic tooth
224268452|NCT01813864|BEHAVIORAL|CASPAR/Treatment Planning|All counselors in the study will receive additional training in treatment planning and the CASPAR Resource Guide software to easily identify and link patients to services not available at substance abuse treatment centers such as General Educational Development (GED) training, dental clinics, job training, etc.
224268453|NCT02827045|DEVICE|Vestibular test|
224268454|NCT01186458|DRUG|Fludarabine|Fludarabine 25 mg/m2 IV over 30 minutes on days 1, 2, 4. Cycle = 28 days; maximum of 6 cycles of therapy.
224268455|NCT01186458|DRUG|Velcade|Velcade (given after fludarabine)1.3 mg/m2 IV push over 3 to 5 seconds on days 1, 4, 8, 11. Cycle = 28 days; maximum of 6 cycles of therapy.
224268456|NCT01186458|DRUG|Rituximab|Rituximab given after Velcade) 375 mg/m2 IV piggyback on day 1. Cycle = 28 days; maximum of 6 cycles of therapy.
224268457|NCT04182126|OTHER|Regular long-lasting insecticidal nets|Olyset nets: containing 2% permethrin or PermaNet 2.0 containing 1.8 and 1.4 g/kg, respectively, for 75 and 100 denier yarn
224268458|NCT04182126|OTHER|LLIN plus Piperonyl butoxide-treated LLIN|Olyset Plus: containing 2% permethrin and 1% PBO
224268459|NCT04182126|OTHER|Long-lasting microbial larvicide|Semi-permanent and permanent habitats will be treated with FourStar® 180-day Briquets using the recommended dosage of 100 ft2 water surface per briquet
224268460|NCT04182126|OTHER|Indoor residual spraying with micro-encapsulated pirimiphos-methyl or other insecticides|Each dwelling's interior walls and ceilings will be sprayed with micro-encapsulated pirimiphos-methyl at the recommended dosage of 1g/m² and at the recommended frequency of once a year or twice a year. Other insecticides may be used to replace the Actellic 300 CS depends on Kenya government policy, current policy requires rotating different insecticides annually.
224268461|NCT04626440|PROCEDURE|Diagnostic stage or the Clinical outcome|After enrollment, individual subject will be assigned into one of the four groups according to the medical management received, the diagnostic stage of breast cancer (BC), or the clinical outcome of BC at enrollment.
224268462|NCT03090022|PROCEDURE|Strattice|Intra-abdominally Fixation
224268463|NCT03090022|PROCEDURE|Single running suture of abdominal fascia|Intra-abdominal suture
224268464|NCT01637480|OTHER|Lumbopelvic manipulation|High-velocity-low-amplitude thrust manipulation of the lumbopelvic region
224268465|NCT02640235|DEVICE|CELSTAT|
224268466|NCT02640235|DEVICE|Surgicel Original|
224268467|NCT00694408|DRUG|methyl prednisolone, hydrocortisone, prednisolone|Will be specific dependant on weight of patients
224268468|NCT00694408|OTHER|No steroids|Children undergoing primary liver transplant will receive monoclonal antibodies and tacrolimus as per protocol
224268469|NCT01674387|DEVICE|acupuncture|56 patients (the EA group) receive the acupuncture treatment at nine acupuncture points: Dazhui (GV14), bilateral Jianzhongshu (SI15), bilateral Jingbailao (EX HN15), bilateral Jiaji (EX-B2) of cervical positive reaction plane (taking two pairs). Besides, bilateral Jianzhongshu (SI15) and bilateral Jiaji (EX-B2) receive the electro acupuncture treatment, with dilatational wave. All the needles retained for 20 minutes, one treatment every other day, 10 times a course, and the treatment assessed after a course.
224268470|NCT01674387|OTHER|comprehensive treatment|Other 56 patients (the matched group) receive the comprehensive treatment, including traction and TENS therapy. Each treatment 20 minutes, one treatment every other day, 10 times a course, and the treatment assessed after a course.
224268471|NCT05812638|OTHER|Mental imagery technique|Warm up Period Mental Imagery (Sit-stand task Static stance (30 seconds) Indoor walk on a leveled surface Walk indoor towards target Forward / Side Stepping) Walk outdoors
224268472|NCT05812638|OTHER|Virtual Reality technique|Virtual reality training (River rush, 20000 water leaks, reflex ridge.)
224268473|NCT05697679|BEHAVIORAL|Treatment group|WeChat groups will be set up, and once a week on Monday, articles on physical exercise and once a week on Wednesday, 3-minute films about health education will be shared. For the duration of the 3-month intervention period, the following technologies will be used to deliver the GAT-pap: (1) Short Messaging Service (SMS) text (batch messaging); (2) WeChat (e.g., physical activity guidelines, group chats); and (3) monthly face-to-face interviews (behaviour change promotion, risk factor management). Although not essential, participants will be urged to register their daily exercise in the group chat. In order to determine if they are accomplishing their goals and what objectives they should be pursuing, the researchers will develop customised training regimens for each participant.
224268474|NCT05697679|BEHAVIORAL|Contral group|One or two times each week, participants in the control group will get general lifestyle advice through SMS. They will not participate in the intervention's fitness routines, online classes, group chats, or films with health educators. Individual workout regimens, goals, or comments are not given by researchers. Participants in the control group's complaints or questions will always be answered with basic health information and suggestions. Researchers won't ask for individual advice or comments from other professionals.
224268475|NCT05247567|BIOLOGICAL|serum punction|A blood sample inclusion and at the end of study visit
223869840|NCT04030624|DEVICE|Remote Electronic Patient Monitoring|The Remote Patient Monitoring intervention is a remote monitoring system intended for use by healthcare professionals for the collection of physiological data in home and healthcare settings. Patient information is displayed on a computer located at the medical institution. Throughout the day, patient data from the remote monitoring system are presented on the clinician user interface (e.g., temperature, blood pressure, heart rate, respiration rate). Data are transmitted from sensors to the patient's smart phone.
223869841|NCT00140790|DRUG|valsartan|valsartan 40 or 160 (80) mg per day
223869842|NCT00991497|DEVICE|Compression bandaging|Cotton wool padding will then be placed over the treated vein and secured in place by crepe bandaging. An above-knee TED stocking will be applied on top of this.
223869843|NCT03344536|DRUG|Fulvestrant|Fulvestrant will be administered according to its approved dose of 500 mg intramuscularly on days 1, 15, 29 and then every 28 days (+/-3 days) thereafter.
223869844|NCT03344536|DRUG|Debio 1347|Debio 1347 will be administered orally daily (1 cycle is 28 days) and the dose of Debio 1347 could be deescalated.
223869845|NCT01571596|DRUG|KRN23|Subjects will receive escalating doses of KRN23 administered by SC injection every 28-days (up to 12 doses) based on a dosing algorithm and discretion of Investigator and Sponsor.
223869846|NCT01873313|DRUG|Ropivacaine|
223869847|NCT04954638|OTHER|endodontic desinfection|"* outcome assessment of the retreatment of endodontically treated teeth presenting chronic apical periodontitis~* effectiveness of hyperpure chlorine dioxide compared with sodium hypochloride~* using microbiological methods~* outcome assessed by radiological method and clinical evaluation"
223869848|NCT06324903|OTHER|echocardiography and percutaneous cardiac catheterization|pre- cardiac catheterization, intraprocedural and post-catheterization echocardiography.
223869849|NCT03926936|DRUG|Fulvestrant|intramuscular injection (2x 250mg), once every 2 weeks for the first month, and then monthly until completion of the study
223869850|NCT06545565|DRUG|sodium acetate group will receive sodium acetate in the neonatal PN.|This group will receive sterile sodium acetate daily in the neonatal PN for the duration the patient will receive parenteral nutrition, a maximum of 28 days of life.
224268476|NCT05247567|BIOLOGICAL|skin swab in elbow folds|passage of a cotton swab in the crease of the elbow at the inclusion
224268477|NCT02120872|DRUG|Platelet rich fibrin and simvastatin|Three wall intrabony defect sites treated with Open Flap Debridement. 0.1 mL prepared SMV gel (1.2 mg/0.1 mL) was mixed with PRF. The PRF - SMV mixture was delivered to the defect.
224268478|NCT02120872|BIOLOGICAL|Platelet rich fibrin|Three wall intrabony defect sites treated with Open Flap Debridement. PRF was placed into the intrabony defect.
224268479|NCT02120872|PROCEDURE|Open Flap Debridement alone|Three wall intrabony defect sites treated with Open Flap Debridement only. No PRF or SMV was delivered to the defect.
224268480|NCT03487939|DRUG|FOLFOXIRI|IRINOTECAN 150 mg/m\^2 IV over 1-h, day 1 + OXALIPLATIN 85 mg/m\^2 IV over 2-h, day 1 + L-LEUCOVORIN 200 mg/m\^2 IV over 2-h, day 1 + 5-FLUOROURACIL 2800 mg/m\^2 IV 48-h continuous infusion, starting on day 1 administered every two weeks for 4 cycles (2 months).
224268481|NCT00803816|DRUG|everolimus|everolimus 1.0 - 2.5mg oral daily dosage
224268482|NCT04419935|PROCEDURE|lymphadenectomy|Lymphadenctomy according with ESTS guidelines
224268483|NCT04436419|DIETARY_SUPPLEMENT|Alpha lipoic acid (plus full hospitalization)|"Women are included in an 8-weeks randomized double-blind against placebo supplementation study with ALA (eight per group) according to the following criteria:~Inclusion criteria: BMI\> 30; aged between 18 and 75 years. Non-inclusion criteria: HLA-DRB1\*04-03/06 polymorphisms; recent hospitalization (\<1 month); food supplement based on antioxidant; medicated in fibrate / telmisartan (modulator of PPARs); patients presenting an acute inflammatory state.~Exclusion criteria: Pregnant and/or lactating women; not affiliated with social security; not mutual health insurance; person deprived of liberty; participation in clinical research in the last 6 months.~Patients included in this clinical trial benefited from a complete hospitalization including dietary monitoring with a personalized food plan and an adapted physical activity program. α-LA (2x300mg/day of R-ALA) was administered double-blinded in the form of 2 capsules apart from meals."
224268484|NCT04436419|DIETARY_SUPPLEMENT|Placebo (full hospitalization: dietary monitoring with an adapted physical activity program)|Women are included in an 8-weeks randomized in placebo group. Patients included in this clinical trial benefited from a complete hospitalization including dietary monitoring with a personalized food plan and an adapted physical activity program. Placebo (2x300mg/day) was administered double-blinded in the form of 2 capsules apart from meals.
224268485|NCT00272441|DRUG|inhaled corticosteroids|
224268486|NCT00301964|BIOLOGICAL|bevacizumab|Given IV
224268487|NCT00301964|OTHER|laboratory biomarker analysis|Correlative studies
224268488|NCT03053856|DRUG|Pembrolizumab|Adjuvant pembrolizumab 200 mg every 3 weeks for up to 24 months. (treated with neoadjuvant concurrent chemoradiotherapy followed by curative resection)
224268489|NCT03053856|PROCEDURE|Curative resection|Neoadjuvant concurrent chemoradiotherapy followed by curative resection
224268490|NCT03053856|PROCEDURE|Neoadjuvant concurrent chemoradiotherapy|RT 44 Gy/22 Fractions for 5 weeks With Chemotherapy (Cisplatin 25mg/m2 once weekly, Paclitaxel 50mg/m2 once weekly)
224268491|NCT03053856|DRUG|Cisplatin|25mg/m2 once weekly
224268492|NCT03053856|DRUG|Paclitaxel|50mg/m2 once weekly
224268493|NCT01437761|DEVICE|2008 Sorbent System|2008 Sorbent System with dialysate flow rates (Qd) of 400 and 500 ml/min while maintaining a constant blood flow rate (Qb) and constant dialyzer (KoA).
224268494|NCT04129177|OTHER|Implementation of a bundle of surgical infection preventive measures|A bundle of six preventative measures is recommended to the VINCat hospitals. Bundle measures were: systemic and oral antibiotic prophylaxis, mechanical bowel preparation (MBP), laparoscopic surgery, maintenance of normothermia, and the use of a double-ring wound retractor.
224268495|NCT01959828|DRUG|IK-3001|
224268496|NCT05435196|OTHER|Therapeutic exercise|"The control group and the experimental group will receive the training with high-intensity interval exercise. For a period of 12 weeks both groups will participate in their exercise program, which will be supervised by the physiotherapist in charge of the study; different from the one who will carry out the randomization and the one who will perform the evaluations. Women will attend 3 times a week for an hour to the Hospital de especialidades to receive their exercise program in which they participated. Both groups will receive therapeutic education to encourage adherence and self-management, which include aspects such as flexibility, musculoskeletal pain, physical performance, quality of life focused on physical and mental health, etc."
224268497|NCT00473954|GENETIC|EGEN-001 (phIL-12-005/PPC)|"In stage 1, patients will receive standard doses of IV carboplatin and docetaxel for 2 treatment cycles with a 3 week interval. Patients will also receive 4 IP infusions of EGEN-001 at 12mg/m2 EGEN-001, 18mg/m2, or 24mg/m2, 10-11 days apart.~Stage 2 of the study will involve cycle escalation at the highest EGEN-001 dose identified from Stage 1. All patients will receive up to 8 doses of EGEN-001, 10-11 days apart plus up to 4 IV carboplatin and docetaxel cycles with 3 week intervals. After receiving the assigned number of treatments of EGEN-001, carboplatin, and docetaxel, patients may continue to receive up to 4 additional infusions of EGEN-001 and 2 IV carboplatin and docetaxel cycles with 3 week intervals."
223869851|NCT06545565|DRUG|sodium chloride group will receive sodium chloride in the neonatal PN.|This group will receive sterile sodium chloride daily in the neonatal PN for the duration the patient will receive parenteral nutrition, a maximum of 28 days of life.
223869852|NCT06282822|OTHER|Transthoracic echocardiography|All enrolled patients underwent noninvasive transthoracic echocardiography.
223869853|NCT03266081|DRUG|0.75% bupivacaine|topical anesthetic
223869854|NCT03450200|OTHER|exercises for diabetic peripheral neuropathy|Hands, fingers, and foot exercises for diabetic peripheral neuropathy to improve activities of daily living, and decreases the signs and symptoms of DPN
223869855|NCT03450200|OTHER|Health education for diabetic foot care|Health education for daily diabetic foot care to prevent diabetic foot ulcer was provided.
223869856|NCT04743440|DEVICE|Bronchoscopic endotracheal intubation through a supraglottic airway device|Prior to trial commencement, participants will be asked to watch a video demonstrating preparation and conduction of the procedure (bronchoscopic endotracheal intubation through a supraglottic airway device) in a patient not involved in the project. Afterwards they will submit an online test, examining knowledge of the procedure relating to the procedure checklist. After participants have watched the demonstration video and submitted the online test, trial investigator will demonstrate the procedure in the manikin; subsequently, they have the opportunity to train the procedure in the manikin with both Igel and Auragain - training estimated to take less than 30 minutes. Afterwards, they will have the opportunity to train the procedure on manikins, on their own discretion, as per usual standards for maintaining airway competence at the Anaesthesiology Department.
223869857|NCT05146375|BIOLOGICAL|TGFBR2|"TGFBR2 mutation correlation with severity of the aortic disease. Blood sampling. Serum will be analysed by DNA sequencing to detect specific mutations involved in aneurysms.~Cutaneous biopsy. Fibroblast culture will be done to assess the transcriptome analysis."
223869858|NCT00681213|DRUG|Tacrolimus/Sirolimus|
223869859|NCT00681213|DRUG|Tacrolimus/MMF|
223869860|NCT00681213|DRUG|Neoral/Sirolimus|
223869861|NCT06033118|DRUG|gemcitabine ,oxaliplatin,anlotinib,Sintilimab|Gemox chemotherapy（gemcitabine 1g/m2 ivgtt d1,d8 +oxaliplatin 85g/m2 ivgtt d1，q3w，anlotinib (8mg po d1-14 q3w )and Sintilimab (200mg ivgtt d1 q3w)
223869862|NCT01933802|BIOLOGICAL|intrathecal administration of autologous MSC-NP|Autologous MSC-NPs administered intrathecally at a dose between 2 and 10 million cells, depending on ex vivo expansion characteristics. Three doses will be administered at 3 month intervals.
223869863|NCT05445440|DRUG|Methotrexate|Specified dose on specified days
223869864|NCT05445440|DRUG|Leucovorin|Specified dose on specified days
223869865|NCT05445440|DRUG|BMS-986371|Specified dose on specified days
223869866|NCT05445440|DRUG|Sulfasalazine|Specified dose on specified days
224268498|NCT04573569|BEHAVIORAL|Behavioral testing|Patients recruited for this study have already undergone surgical implantation of invasive electrodes for purpose of localizing and characterizing electrographic seizures as part of the second phase of surgical epilepsy evaluation. Patients who consent and complete enrollment will then be asked to complete cognitive and behavioral tasks on a portable computer or tablet PC while the invasive electrodes remain implanted. Tasks typically require the patient to think or act and then respond by interacting minimally with the portable computer. These tasks are performed at the will of each patient during their stay in the intensive care unit while surgical electrodes remain.
224268499|NCT01459380|BIOLOGICAL|Bevacizumab|Given IV
224268500|NCT01459380|DRUG|Carboplatin|Given IV
224268501|NCT01459380|OTHER|Laboratory Biomarker Analysis|Correlative studies
223869867|NCT03298724|BEHAVIORAL|Teachers and Parents as Partners|A family-school partnership intervention to improve the home-school connection, parenting and teaching strategies, and child behavior outcomes.
223869868|NCT03068624|BIOLOGICAL|Aldesleukin|Given SC
223869869|NCT03068624|BIOLOGICAL|Autologous CD8+ SLC45A2-specific T Lymphocytes|Given via hepatic arterial infusion via central catheter
223869870|NCT03068624|DRUG|Cyclophosphamide|Given IV
223869871|NCT03068624|BIOLOGICAL|Ipilimumab|Given IV
223869872|NCT06371170|DRUG|Rivaroxaban|Oral anticoagulation
223869873|NCT01807481|DRUG|Mircera|Once Monthly Mircera
223869874|NCT01647581|DEVICE|Hemoclip Placement|Placement of hemoclip at polypectomy site for polyps at least 1cm in size
223869875|NCT01647581|DEVICE|NO hemoclip placement|No hemoclip placement (placebo / sham)
223869876|NCT04512482|DRUG|Bromelain|The subjects were randomized to either receive the bromelain pre-rinse or the powdered sugar placebo pre-rinse. Subjects then had a 5-9 day washout period and was then exposed to the other intervention.
223869877|NCT04512482|OTHER|Powdered sugar|The subjects were randomized to either receive the bromelain pre-rinse or the powdered sugar placebo pre-rinse. Subjects then had a 5-9 day washout period and was then exposed to the other intervention.
223869878|NCT02395744|OTHER|Paclitaxel administration using the OPC|
223869879|NCT05792293|DRUG|Atorvastatin 40 Mg Oral Tablet|40 mg oral dose of atorvastatin , lipid lowering drug with other pleotropic effects
223869880|NCT05792293|OTHER|Placebo|Placebo
223869881|NCT05752175|DRUG|WPV01|WPV01 tablets
223869882|NCT05752175|DRUG|Placebo|Placebo tablets
223869883|NCT06092255|RADIATION|Postoperative radiotherapy for SVZ|GBM patients who met the inclusion criteria received radiotherapy range and dose based on the EORTC outline principles. The ipsilateral and contralateral SVZ areas received 56Gy and 40Gy respectively, with a fractionated dose of 2Gy. Concurrent chemotherapy with temozolomide and six cycles of adjuvant temozolomide chemotherapy were performed at the same time as radiotherapy.
223869884|NCT06266936|OTHER|No intervention|The study involves longitudinal monitoring of the state of health of the specific population of students in care courses, from their entry into university studies (first year) until their final year of study, i.e. from 5 to 13 years depending on the course and the different universities.
223869885|NCT00446459|DRUG|mycophenolate mofetil (CellCept)|500mg - 1,000mg, taken PO, twice daily.
223869886|NCT02330458|PROCEDURE|Small bowel ultrasound|Small Bowel Ultrasound will be performed by a single radiologist using an Acuson S2000 machine with 6 MHz convex and 9 MHz linear array transducers (Siemens, Germany). Participants will be asked to not eat for at least 8 hours prior to the ultrasound, and to drink 500ml of a fluid of their choice just prior to the SBUS, for bowel distension and better visualization. Bowel wall thickness (BWT), the length of any segment of thickened bowel wall \>3mm, hyperemia using doppler, and the presence of free fluid, stricture, intestinal dilation, or enlarged lymph nodes will be documented
223869887|NCT04999917|DIAGNOSTIC_TEST|high-resolution PET-CT specimen imaging.|"A single intravenous injection of 18F-FDG (0.80 MBq/kg) is given between 30 minutes and 3 hours before tumor resection.~Surgical resection of the breast tumor (= main specimen) under general anesthesia.~The main specimen is imaged using the Aura 10 PET-CT Specimen Imager (XEOS Medical, Ghent, Belgium). In case of positive margins, the surgeon will perform oriented cavity shaving. The cavity shaves and lymph nodes (if any) are also imaged using the Aura 10 PET-CT Specimen Imager (for scientific purposes only).~The main specimen and if applicable the cavity shaves and lymph node(s) are processed following standard-of-care routine: from tissue samples to HE-stained and IHC-stained sections. The histopathological margin status shall be reported according to the ASCO-CAP guidelines, and shall be compared to the PET-CT images of the resected specimens."
223869888|NCT05779215|OTHER|Visit at D90|Visits at 90±7 days after stroke onset were conducted by trained and blinded investigators, with face-to-face, telephone call or Internet access.
223869889|NCT03791593|DRUG|Evolocumab|Evolocumab is a human IgG2 monoclonal antibody, it will add to patient treatment during 12 months.
224268502|NCT01459380|DRUG|Pegylated Liposomal Doxorubicin Hydrochloride|Given IV
224268503|NCT01459380|DRUG|Veliparib|Given PO
224268504|NCT05711901|DEVICE|Efferon LPS|Hemoperfusion using continuous extracorporeal LPS adsorption with Efferon LPS therapeutic device during a period of 12h immediately following admission to the intensive care unit
224268505|NCT03785262|DEVICE|Uroshield|The Uroshield device sends out low-frequency ultrasound waves which run along the surface of the catheter.
224268506|NCT03785262|DEVICE|Sham Uroshield|The sham Uroshield device is identical to the active machine, but it does not send out low-frequency ultrasound waves along the surface of the catheter.
224268507|NCT04789434|DRUG|PD-1 Inhibitor Tislelizumab maintenance therapy|PD-1 Inhibitor Tislelizumab maintenance therapy, 200mg, every 2 months, 12 times
224268508|NCT06289296|OTHER|Fatty acid intake in lean and obese males|Acute and chronic intake of MCT and LCT
224268509|NCT00270634|DRUG|Voclosporin|voclosporin 0.4, 0.6, 0.8 mg/kg po BID
224268510|NCT00270634|DRUG|tacrolimus|tacrolimus 0.05 mg/kg po BID
224268511|NCT05709496|RADIATION|De-escalated radiotherapy to be delivered on the Elekta Unity Unity MR-linac|30 Gy in 5 fractions to the whole prostate with 45 Gy in 5 fractions to the dominant lesion
224268512|NCT01968551|DRUG|E/C/F/TAF|150/150/200/10 mg FDC tablet administered orally once daily
224268513|NCT01968551|DRUG|DRV|800 mg tablet administered orally once daily
224268514|NCT01968551|DRUG|Baseline DRV- containing ARV regimen|Participants will take their baseline DRV- containing ARV regimen as prescribed.
224268515|NCT00167453|PROCEDURE|Exercise, Education|
224268516|NCT01181635|BEHAVIORAL|Psychotherapy|Standard psychotherapy for psychiatric disorders.
224268517|NCT00819169|BIOLOGICAL|AMG 479|AMG 479 is an investigational, fully human, monoclonal antibody that binds with Insulin-like growth factor receptor type 1.
224268518|NCT00819169|BIOLOGICAL|AMG 655|AMG 655 is an investigational, fully human, monoclonal antibody that binds with TNF-related apoptosis-inducing ligand, DR 5.
224268519|NCT04260373|DRUG|[14C]SHR4640|Patients will receive single dose of orally \[14C\]SHR4640 on Day 1.
223869890|NCT00639795|PROCEDURE|Thoracic Paravertebral Nerve Block|One Single-injection, thoracic peripheral nerve blockade performed intraoperatively following patient induction with general endotracheal anesthesia
223869891|NCT00639795|PROCEDURE|Thoracic Paravertebral Nerve Block|Sham single-injection thoracic peripheral nerve blockade following patient induction with general endotracheal anesthesia
223869892|NCT03296540|DRUG|Prasugrel (Crushed tablets)|loading dose of 6 crushed tablets 10mg Prasugrel
223869893|NCT03296540|DRUG|Prasugrel (Integral tablets)|loading dose of 6 integral tablets of 10mg Prasugrel
223869894|NCT00137722|BEHAVIORAL|Education of providers and their staff|
223869895|NCT00137722|BEHAVIORAL|Case management|
223869896|NCT00137722|BEHAVIORAL|Payment for desired behaviors|
223869897|NCT03311893|PROCEDURE|natural orifice surgery|evaluation of the awareness of the use of transvaginal, transoral and transcranial approach in surgical excision and the difference between the health staff and the pathology
223869898|NCT00079846|DRUG|Implitapide|
223869899|NCT04788212|BEHAVIORAL|Group Behavioral Activation Therapy for Autism Spectrum Disorder|This will be a modification of the Group Behavioral Activation Therapy program (Chu et al., 2009) for treatment of depression, anxiety and/or anger in autistic adults.
223869900|NCT03556449|DIAGNOSTIC_TEST|High resolution ultrasound|Using a high-frequency linear array transducer (18L6 HD)
223869901|NCT05591872|DRUG|LD+I+TRB|Same as in the arm description
223869902|NCT00634075|DRUG|omega-3-fatty acids (Omegaven)|The enrolled patients will be randomized to receive either supplementation of fish oil-based lipid emulsion (10 % Omegaven) as group 1 or placebo (0.9% Normal Saline) as group 2 via a central venous catheter within 24 hours after ICU admission, 100 ml daily for 5 days, respectively.
223869903|NCT00634075|DRUG|placebo|The enrolled patients will be randomized to receive either supplementation of fish oil-based lipid emulsion (10 % Omegaven) as group 1 or placebo (0.9% Normal Saline) as group 2 via a central venous catheter within 24 hours after ICU admission, 100 ml daily for 5 days, respectively.
223869904|NCT00809068|DRUG|fenofibrate and tibolone|fenofibrate 160mg daily 8 weeks tibolone 2.5mg daily 23 weeks
223869905|NCT00809068|DRUG|tibolone|tibolone 2.5 mg daily 23 weeks
223869906|NCT00397475|DRUG|Colecalciferol|
223869907|NCT02040831|BIOLOGICAL|RSV LID ΔM2-2 Vaccine|10\^5.0 plaque forming units (PFU); 0.5 mL dose delivered as nose drops (approximately 0.25 mL per nostril)
223869908|NCT02040831|BIOLOGICAL|Placebo Vaccine|0.5 mL dose delivered as nose drops (approximately 0.25 mL per nostril)
223869909|NCT00004149|DRUG|arsenic trioxide|
223869910|NCT00687856|PROCEDURE|Echocardiogram (echo)|Participants will undergo a series of echoes to determine if they are eligible to be weaned from LVAD support. Each echo exam will involve the use of an ultrasound probe on the chest of participants to assess the pumping ability of their hearts.
223869911|NCT05546710|DEVICE|miraDry treatment|The miraDry device is non-invasive and uses microwave energy, focused at the dermal/hypodermal interface, to thermally impact the sweat glands. The treatment area is identified (hair bearing area of the axilla) and high-volume anesthesia is delivered. The miraDry template is selected based upon the size of the treatment area and temporarily applied to the patient's skin. A new miraDry bioTip is attached to the miraDry Handpiece for each treatment session. The Handpiece is then placed on the surface of the skin in the area to be treated. The treatment cycle is activated by a button on the Handpiece. Multiple placements of the Handpiece are required to treat a full axilla in one treatment session.
223869912|NCT01311622|DRUG|warfarin|2 single 25 mg doses of Warfarin (5 x 5 mg tablets) administered 14 days apart
223869913|NCT01311622|DRUG|fostamatinib|2 x 50 mg Fostamatinib tablets (100 mg) twice daily for 13 days
223869914|NCT01644032|OTHER|Teleconsultation|Teleconsultation between paramedics and an EMS physician
223869915|NCT05985590|DRUG|BMS-986278|Specified dose on specified days
223869916|NCT05985590|DRUG|Drospirenone/Ethinyl Estradiol|Specified dose on specified days
223869917|NCT00829036|DEVICE|Wayfinding Prototype|A Wayfinding Prototype is used by subjects to determine any advantages over current standard of rehabilitation.
223869918|NCT04530149|DRUG|Acetaminophen|receive ketamine 0.15 mg/kg IV in 100 mL normal saline over 30 minutes for pain
223869919|NCT04530149|DRUG|Bupivacain|The injection of bupivicaine into the chest muscle is performed with an ultrasound machine which can see the needle as it enters the muscle.
223869920|NCT04530149|DRUG|Saline|The injection of saline into the chest muscle is performed with an ultrasound machine which can see the needle as it enters the muscle.
223869921|NCT05900505|OTHER|Social Navigator|The social navigator will assess patient/family needs and help them to access community resources (specific to their community) to address these, while promoting their engagement and self-efficacy.
223869922|NCT00244673|BIOLOGICAL|DTP3/4+OPV+MV versus OPV+MV or DTP4+OPV4 versus OPV4|Trial of not providing 3. and/or 4. DTP together with or after MV at 9 to 18 month of age.
223869923|NCT00808405|DRUG|acyclovir|400mg taken orally three times daily for 5 days
223869924|NCT00808405|DRUG|matching placebo|matching placebo taken orally three times daily for 5 days.
223869925|NCT02809794|DEVICE|Fisher & Paykel Healthcare CPAP Device|Fisher \& Paykel Healthcare CPAP Device
223869926|NCT01962090|OTHER|Thoracic Spine Thrust in Seated Position|The thoracic spine manipulation used here is a manipulation technique that involves positioning the patient so that a small amplitude quick stretch can be applied to the least mobile area of the thoracic spine as identified by the licensed physical therapist during spinal segmental mobility testing.
223869927|NCT01962090|OTHER|Thoracic Spine Thrust in Supine Position|The thoracic spine manipulation used here is a manipulation technique that involves positioning the patient so that a small amplitude quick stretch can be applied to the least mobile area of the thoracic spine as identified by the licensed physical therapist during spinal segmental mobility testing.
223869928|NCT03229044|GENETIC|Tetranectin|Adipose tissues were obtained from the breast of breast cancer patients with 0 to 1 progression stage. The subjects were 33-51 y of age (mean = 43.6, SD = 6.2) with a BMI of 16-33 kg/m2 (mean = 21.5, SD = 4.5). Blood samples were collected after an overnight fasting. Serum was separated by centrifugation and stored at -80 ℃ until analysis. Plasma Tetranectin,triglyceride (TG), high density lipoprotein (HDL), low density lipoprotein (LDL), cholesterol, glucose and insulin were measured. And the tetranectin mRNA and protein level was measure in adipose tissue
223869929|NCT05765370|PROCEDURE|Achieving a Target LDL-C level of 25mg/dL≤ LDL-C<70mg/dL|"Investigators initiated or adjusted lipid-lowering agents (drug and dosage) to achieve the target of 25mg/dL≤ LDL-C\<70mg/dL. The protocol encouraged, but did not mandate, the initiation of moderate-intensity statin therapy for secondary prevention with the evaluation of the potential for ASCVD risk reduction, adverse effects, and drug-drug interactions, as well as patient frailty and patient preferences. Statin monotherapy or in combination with ezetimibe, PCSK9 inhibitor or other drugs were adjusted on the basis of LDL-C levels.~At each follow-up visit, the investigators should verify whether the target LDL-C has been obtained. If the target level of LDL cholesterol was achieved, it is reasonable to continue to monitor adherence to lifestyle modiﬁcations, medication, and ongoing LDL-C response to therapy. If the target level of LDL cholesterol was not achieved, adjustment of the type and dose regimen of statin, or the additional of a nonstatin agent should be considered."
223869930|NCT05765370|PROCEDURE|Achieving a Target LDL-C level of 70mg/dL≤ LDL-C<100mg/dL|"Investigators initiated or adjusted lipid-lowering agents (drug and dosage) to achieve the target of 70mg/dL≤ LDL-C\<100mg/dL. The protocol encouraged, but did not mandate, the initiation of moderate-intensity statin therapy for secondary prevention with the evaluation of the potential for ASCVD risk reduction, adverse effects, and drug-drug interactions, as well as patient frailty and patient preferences. Statin monotherapy or in combination with ezetimibe, PCSK9 inhibitor or other drugs were adjusted on the basis of LDL-C levels.~At each follow-up visit, the investigators should verify whether the target LDL-C has been obtained. If the target level of LDL cholesterol was achieved, it is reasonable to continue to monitor adherence to lifestyle modiﬁcations, medication, and ongoing LDL-C response to therapy. If the target level of LDL cholesterol was not achieved, adjustment of the type and dose regimen of statin, or the additional of a nonstatin agent should be considered."
223869931|NCT03410966|PROCEDURE|trans cateheter ablation|All AF patients will receive trans catheter ablation by radiofrequency, to destroy arrhythmic atrial cells, and to isolate arrhythmic atrial firing around pulmonary veins' ostia.
223869932|NCT04326192|DEVICE|Research electrode|A second electrode will be placed percutaneously by Tuohy needle in the epidural space at the same time as the SCS trial implant; at lateral T1-2 area randomly assigned to the left or right side of the lateral epidural space, at the time of the procedure. Placement of electrodes is not experimental, but the placement of a second electrode is a research-driven procedure.
223869933|NCT01120418|DRUG|Besifloxacin Ophthalmic Suspension 0.6%|administered 3 times a day for 5 days to one eye.
223869934|NCT01236001|DRUG|Lacosamide|
223869935|NCT03933605|DRUG|midazolam and palonosetron group|intravenous midazolam and palonosetron administraion as prevention of postoperative nausea and vomiting
223869936|NCT03933605|DRUG|palonosetron group|intravenous palonosetron administraion as prevention of postoperative nausea and vomiting
223869937|NCT02882035|OTHER|OFA|
223869938|NCT04910555|OTHER|strong desire to void - cognitive task|Strong desire to void - cognitive task (verbal fluency)
224268520|NCT03045458|DEVICE|tissue level dental implant|After local anesthesia, full thickness flaps were reflected, and osteotomies were prepared in the first mandibular molar sites. In these surgical operations, 20 tissue-level implants 12 mm in length and 4.8 mm in diameter were inserted in Group I. Cover screw was removed and replaced with healing abutments.
224268521|NCT03045458|DEVICE|Bone level dental implant|After local anesthesia, full thickness flaps were reflected, and osteotomies were prepared in the first mandibular molar sites. In these surgical operations, 20 bone-level dental implants 12 mm in length and 4.8 mm in diameter were inserted inGroup II. Three months later, second-stage surgery was performed and implant exposed into the oral cavity. Cover screw was removed and replaced with healing abutments. Three months waited for second surgery in bone level implants.
224268522|NCT00431041|DRUG|solifenacin|Oral
224268523|NCT00431041|DRUG|oxybutynin immediate release|Oral
224268524|NCT00573313|DRUG|S-adenosylmethionine|Alcoholic liver disease patients received drug at dose of 400 mg three times daily for 24 weeks.
224268525|NCT00573313|DRUG|Placebo|Alcoholic liver disease patients received identical size and shape sugar pill placebo three times daily for 24 weeks.
224268526|NCT02318420|OTHER|The PartoMa intervention|WHO partogram, locally developed and achievable labour management guidelines (PartoMa guidelines), continual in-house training
224268527|NCT04434716|DEVICE|Feasibility of wearing a Readiband to monitor Sleep and Fatigue|On day one of the study participants will complete a demographic survey. On day one, every seventh day and at the end of the study each participant will complete all the scales; The Minnesota Living with Heart Failure Questionnaire (MLHFQ) and Self-Care of Heart Failure Index will be completed on day one and day 60. At the end of the intervention an Interview will be conducted to assess participants experiences using the Readiband: On a scale of 0-10, how would you rate your digital literacy? 2) Why that number? 3) Tell me about a day using the readiband? 4) Were there any challenges to wearing the band, forgetting to wear it, level of comfort wearing the band? Anything else etc..? 5) How did the digital tools enhance your health? 6) Did the use of digital tools cause you to take a proactive approach rather than a reactive approach to your health? 7) As I use the readiband in a next study, what suggestions do you have for me?
224268528|NCT03640741|PROCEDURE|Laparoscopy|The studies are carried out on patients who undergoes gynecological procedure that involves laparoscopy.
224268529|NCT03300011|DEVICE|stent|PTCA or PCI
223869939|NCT05944003|PROCEDURE|Resuscitative thoracotomies|Resuscitative thoracotomies is an effective life saving measure in appropriate populations \[1-8\]. Unfortunately, when used outside of these populations the mortality rate is typically more than 90% \[1-8\]. Western Trauma Association and Eastern Association for the Surgery of Trauma have provided guidelines for which trauma patients are a candidate for RT \[1-
223869940|NCT02840422|DEVICE|ARTHRUM H 2%|ARTHRUM H 2%
223869941|NCT00253110|DRUG|risperidone|
223869942|NCT00253110|DRUG|haloperidol|
224268530|NCT05509023|DRUG|ADX-914|Subcutaneous administration of ADX-914
224268531|NCT05509023|DRUG|Placebo|Subcutaneous administration of Placebo
224268532|NCT06626802|PROCEDURE|Balloon Dilation + Topical Mitomycin|Patients with recurrent esophageal strictures in Group A will undergo endoscopy and balloon dilation with a CRE balloon, followed by injection Mitomycin applied topically at stricture site (post dilation)
224268533|NCT06626802|PROCEDURE|Balloon Dilation + Injection Triamcinolone|Patients with recurrent esophageal strictures in Group B will undergo endoscopy and balloon dilation with a CRE balloon, followed by injection Triamcinolone, injected with a sclerotherapy injector, at stricture site (post dilation)
224268534|NCT03805633|DIAGNOSTIC_TEST|Venous blood sample|Venous blood samples will be obtained for hemoglobin A1c, C peptide, insulin level, and 2-hour fasting glucose tolerance test.
224268535|NCT03805633|DIAGNOSTIC_TEST|Ultrasound of pancreas|Ultrasound of pancreas will be obtained on all study participants.
224268536|NCT01839539|BIOLOGICAL|dendritic and cytokine-induced killer cells|
224268537|NCT00891787|DIETARY_SUPPLEMENT|Probiotic Supplement|
224268538|NCT03431558|COMBINATION_PRODUCT|bLF (Bovine lactoferrin)|BLF administration in two different strengths (150 \& 300mg) will be given on the third day of life with a single daily dose mixed with milk for 1 month.
224268539|NCT03431558|DRUG|Glucon-D 99.4% (Placebo)|This group will be given 100mg Glucon-D (99.4% glucose) placebo which will be similar in shape, color to the bLF.
224268540|NCT01927380|OTHER|steep trendelenburg position with pneumoperitoneum|ANS activity and baroreflex modulation is assessed at (i) baseline; (ii) after induction of general anesthesia; (iii) after steep trendelenburg position (head down at 25 degrees); (iv) after induction of pneumoperitoneum and (v) after removal of trendelenburg and pneumoperitoneum
224268541|NCT05346172|DEVICE|PanOptix or PanOptix Toric IOL|Patients who previously underwent cataract surgery with the PanOptix or PanOptix Toric IOL in both eyes.
224268542|NCT06466317|BEHAVIORAL|Honey intake with walking exercise|20 Children with metabolic syndrome will receive free walking continuous exercise (thirty minutes daily in nearby sport club in the presence of their parents and walking will supervised by authors via Videoconferencing Imo Program) and this group also will healthy diet guidelines in addition to consuming natural honey (2ml/kg honey will be taken.. This dose will be divided into two halves, the first half will be taken at 7 am and the other half will be taken at 7 pm for 12 weeks)
224268543|NCT06466317|BEHAVIORAL|Walking exercise|20 Children with metabolic syndrome will receive free walking continuous exercise (thirty minutes daily in nearby sport club in the presence of their parents and walking will supervised by authors via Videoconferencing Imo Program) and this group also will healthy diet guidelines for 12 weeks)
223869943|NCT03926039|BEHAVIORAL|sharing decision-making program|Sharing decision-making talks and decision-making assistance tools used in the process
223869944|NCT00117936|COMBINATION_PRODUCT|Human Recombinant Fibroblast Growth Factor-1 (FGF 1-141) - low dose|Up to ten intramyocardial injections of low dose FGF 1-141, via a NOGA Injection Catheter, single cath lab session
223869945|NCT00117936|COMBINATION_PRODUCT|Human Recombinant Fibroblast Growth Factor-1 (FGF1-141) - high dose|Up to ten intramyocardial injections of high dose group (FGF-1-141), via a NOGA Injection Catheter, single cath lab session
223869946|NCT00117936|COMBINATION_PRODUCT|Placebo|Up to ten intramyocardial injections of placebo via a NOGA Injection Catheter, single cath lab session
223869947|NCT01406223|DRUG|Varenicline|
223869948|NCT01406223|DRUG|Bupropion|
223869949|NCT01406223|DRUG|Nicotine patches|
223869950|NCT01406223|OTHER|Placebo varenicline|
223869951|NCT01406223|OTHER|Placebo bupropion|
223869952|NCT01406223|OTHER|Placebo patch|
223869953|NCT01667302|DRUG|Radiotherapy followed by chemotherapy|Radiotherapy Technique: IMRT Total dose: 50 Gy Per fraction: 2 Gy Chemotherapy: q3w Dexamethasone 40 mg d1-4 Ifosfamide 1200mg/m2 d1-4 Etoposide 60 mg/m2 d1-4 Cisplatin 20mg/m2 d1-4 Peg-asparaginase 2000 IU/m2 d1
223869954|NCT00479635|DRUG|TPI 287|160 mg/m2 every three weeks for six cycles
223869955|NCT00479635|DRUG|TPI 287|160 mg/m2 intravenously over 60 minutes every three weeks until toxicity or progression of disease.
223869956|NCT02514278|DRUG|Neoadjuvant chemotherapy Folfirinox, 4 cycles|"* oxaliplatin: 85 mg/m2~* irinotecan: 180 mg/m²~* folinic acid: 400 mg/m2 (DL form) or 200 mg/m2 (L form)~* 5FU: 2400 mg/m2"
223869957|NCT02514278|RADIATION|50 Gy, 2 Gy/session; 25 fractions|Radiochemotherapy 5 weeks
223869958|NCT02514278|PROCEDURE|Local excision in good responders|"If local excision:~* Surveillance if ypT0-1 or ypT2Nx/cN0 (no lymph node at baseline imaging)~* Complementary rectal excision if ypT2Nx/cN1, ypT3 or R1."
223869959|NCT02514278|PROCEDURE|Rectal excision in bad responders|
223869960|NCT02514278|DRUG|Capecitabine|1600 mg/m2 daily 5 days/7
223869961|NCT00067353|DRUG|Fluoride varnish|
223869962|NCT05765019|OTHER|Spinal mobilization|Spinal mobilization and core stabilization exercise
223869963|NCT05765019|OTHER|Core stabilization exercise|Stabilization exercises for the spine
223869964|NCT01371968|DRUG|alfentanil|Alfentanil is administered intravenously at the end of surgery.
223869965|NCT02869334|DEVICE|Active Transcranial direct current stimulation (tDCS)|Active tDCS, where an extremely weak electric current passes through the brain
223869966|NCT02869334|DEVICE|Sham Transcranial direct current stimulation (tDCS)|Sham (inactive or placebo) tDCS
223869967|NCT02869334|BEHAVIORAL|Auditory Remediation|Computer program designed to improve discrimination between sounds
223869968|NCT02869334|BEHAVIORAL|Control computer activities|Computer program (e.g. games), which are not designed to improve discrimination between sounds
223869969|NCT04272645|DRUG|Abemaciclib 200 MG|200 MG orally BID Days 1-21
223869970|NCT04272645|DRUG|Atezolizumab 1200 MG in 20 ML Injection|1200 mg IV on Day 1 of 21-day cycle
223869971|NCT04272645|DRUG|Abemaciclib 150 MG|150 MG orally BID Days 1-21
223869972|NCT02986269|PROCEDURE|general anesthesia across LMA|general anesthesia across LMA
223869973|NCT02986269|PROCEDURE|Spontaneous breathing(SB)|general anesthesia across LMA under SB without PSV
223869974|NCT02986269|PROCEDURE|Pressure Support Ventilation|general anesthesia across LMA under SB with PSV
223869975|NCT05652244|DEVICE|Mini-implants|En masse retraction of upper anterior teeth will be applied where mini-implants will be used as an anchor unit. Anterior teeth retraction will be initiated after completion of the leveling and alignment phase via closed nickel-titanium coil springs applying 150 g of force per side.
224268544|NCT01640743|DRUG|Tacrolimus + Methylprednisolone|"Induction therapy:~Methylprednisolone (500 mg), thymoglobulins (1.5 mg/Kg/die, beginning 1 hour before transplantation) and 1 mg/Kg/die during the following 3 days.~Maintenance therapy:~Tacrolimus dosage will be 0.2 mg/kg of body weight and will be administered approximately 12 hours after chirurgical intervention twice a day (mornings and evenings). Dosage will be adapted on individual basis in order to gain pre-dose blood dosages according to indicated plasmatic levels"
223869976|NCT05652244|DEVICE|Transpalatal arche (TPA)|Two-step retraction of upper anterior teeth will be applied where transpalatal arches (TPAs) will be used as an anchor unit. Teeth retraction will be initiated after completion of the leveling and alignment phase via closed nickel-titanium coil springs applying 150 g of force per side.
223869977|NCT01674699|DEVICE|EXCOR Pediatric|Ventricular Assist Device
223869978|NCT01836133|DRUG|Erlotinib 150 mg|
224268545|NCT01640743|DRUG|Tacrolimus + Everolimus + Methylprednisolone|"Induction therapy:~Methylprednisolone (500 mg), thymoglobulins (2.5 mg/Kg/die, beginning 1 hour before transplant) and Mycophenolate mofetil (1000 mg) and no immunosuppressive therapy for the following 3 days (WOFIE hypothesis), and for day 4-5-6 thymoglobulins (1.0 mg/Kg/die).~Maintenance therapy:~Tacrolimus dosage will be 0.1 mg/kg of body weight and will be administered approximately 12 hours after chirurgical intervention twice a day (mornings and evenings). Dosage will be adapted on individual basis in order to gain pre-dose blood dosages according to indicated plasmatic levels"
224268546|NCT00748696|DIETARY_SUPPLEMENT|Fortimel Extra®|260kcal and 20g protein per day
224268547|NCT00748696|OTHER|resistance training|3 sessions of resistance training per week
224268548|NCT00748696|OTHER|combined treatment|260kcal and 20g protein per day 3 sessions of resistance training per week
224268549|NCT00796913|OTHER|Stop medication|Stop medication Stop medication + se supplement
224268550|NCT02959619|DRUG|Ensartinib|Oral ensartinib was given daily at escalating doses in a 28-day cycle
224268551|NCT01398085|RADIATION|I131 1.1 GBq|Radio-iodine
224268552|NCT06627660|PROCEDURE|Valsalva maneuver|Closure of the nose and mouth during expiration for 20 sec
224268553|NCT02873182|DEVICE|Autonomic nervous system monitoring|Two intracorporal electrode needles will be inserted beneath the skin of the genitalia. After insertion, the electrodes will be secured and connected by leads to two standard neurophysiological devices for differential amplification, display, and storage. Smooth muscle free-running (continuous) and stimulated EMG will be recorded.
224268554|NCT05822726|DIAGNOSTIC_TEST|Prostate biopsy|"Targeted guided puncture biopsy guided by B-ultrasound will be performed (in addition to 12-needle system biopsy, if PSMA-PET/MRI or mpMRI indicates a positive lesion, puncture biopsy should be added at the lesion displayed on image, the 12-needle system biopsy+X scheme)."
223869979|NCT04348617|OTHER|Moderate exercise|50 minutes of moderate exercise on treadmill
223869980|NCT04348617|OTHER|Rest|50 minutes of rest or sedentary activity
223869981|NCT05282472|DIAGNOSTIC_TEST|CPET without mask|Regular cardiopulmonary exercise tests were applied to all participants in phase 1.
223869982|NCT05282472|DIAGNOSTIC_TEST|CPET with mask|A 3-layer surgical mask was placed on CPET device's mask and was fixed with a CPET tribune. In phase 2, as using this combined (surgical mask and device's mask) masks, CPETs were performed in all participants again, after 48 hours.
223869983|NCT00024063|DRUG|orantinib|
224268555|NCT01807026|DRUG|LY2886721|
224268556|NCT01807026|DRUG|Placebo|
223869984|NCT04478851|BEHAVIORAL|Group Exercise Classes|The exercise program to be implemented for rural cancer survivors will combine aerobic, resistance, balance, and flexibility exercises delivered in a circuit-type class setting or group personal training format, twice weekly for a 12-week period. If public health restrictions require closure of fitness facilities due to COVID-19, the program will be delivered online. If facilities are open, the sessions will be integrated in the community, delivered in-person. Whether delivered in-class or remotely, the program follows exercise progression principles (ie, frequency, intensity, time, type, overload and progression) over the 12-weeks, with tailoring of any exercise to meet individual participant needs as required, in order to promote fitness and wellness benefits. The exercise intervention is based on the Alberta Cancer Exercise (ACE) program.
223869985|NCT04377815|OTHER|General Public cohort|No intervention is being tested
223869986|NCT02883660|GENETIC|Genocept Assay|battery of pharmacogenetic tests relevant to psychiatry
223869987|NCT01003405|DRUG|KUC-7483|
223869988|NCT05376436|DIAGNOSTIC_TEST|Exercise challenge test (ECT)|Baseline demographic, clinical and rest lung functions were recorded. ECT was performed on treadmill according to fixed protocol. Clinical data during ECT was recorded. (visit 1- performed with nose clip, visit 2- performed without nose clip). Lung function were measured and recorded at fixed time after ECT and after bronchodilator administration.
223869989|NCT05877469|OTHER|Mat pilates Training|In this group 22 patients will perform mat pilates training. Patients will be asked to stay comfortable while performing mat pilates exercies that involve different types of movements of whole body like leg lifts, toe taps, Single leg stretch, one leg circle, side bend preparation, side kicks, side leg lifts, roll down and crisscross to improve the core strength. Treatments will be provided in 30 mins, three sessions per week for 8 consecutive weeks.
223869990|NCT05877469|OTHER|Functional Training|In this group 22 patients will perform functional training. Patients will be instructed to perform their daily living movements like squatting, reaching, or even carrying a heavy object. These exercises typically use the whole body and emphasize core strength and stability. Functional training typically uses weight-bearing activities that work the core muscles in the torso. the functional movements include involve glute bridge, squats, pushups, lateral lunge, step up to shoulder press, goblet and squats. Treatments will be provided in 30 mins, three sessions per week for 8 consecutive weeks.
223869991|NCT04303325|DRUG|Esketamine|All depression patients undergoing breast cancer operation will be to the treatment intervention with general anesthesia as an adjunct to esketamine 0.2mg/kg.
223869992|NCT04303325|DRUG|Saline Solution|All depression patients undergoing breast cancer operation will be to the treatment intervention with general anesthesia as an adjunct to saline.
223869993|NCT00078624|OTHER|Traditional exercise therapy for knee osteoarthritis|Exercises include stretching, strengthening, and aerobic exercise
223869994|NCT00078624|OTHER|Knee stability training|The addition of agility and perturbation training techniques to the traditional exercise program
223869995|NCT01831700|DRUG|Lisinopril and Hydrochlorothiazide Tablets (20+25) mg|Lisinopril and Hydrochlorothiazide (20+25) mg Tablets once a day
223869996|NCT01831700|DRUG|Zestoretic® 20/25 lisinopril/hydrochlorothiazide Tablets|Zestoretic® 20/25 lisinopril/hydrochlorothiazide Tablets once a day
223869997|NCT02219724|DRUG|MOXR0916|MOXR0916 will be administered as intravenous infusion on Day 1 of each 21-day cycle.
223869998|NCT02200094|DRUG|Low dose of Telmisartan, once daily|
223869999|NCT02200094|DRUG|High dose of Telmisartan, once daily|
223870000|NCT01869543|OTHER|Stand Alone Air Cleaner|This is an environmental intervention using a stand alone air cleaner designed to reduce the air pollution levels in the home.
223870001|NCT01869543|OTHER|HVAC Modification|This is an environmental intervention that modifies the home HVAC system to include high efficiency air filtration designed to reduce the air pollution levels in the home.
223870002|NCT02416115|DRUG|Ramosetron|Ramosetron was given iv.
223870003|NCT02416115|DRUG|Naloxone|Naloxone added to PCA was given iv.
223870004|NCT02416115|DRUG|saline|Saline was given iv.
223870005|NCT02416115|DRUG|Morphine|Morphine in the PCA was given iv.
223870006|NCT00664690|DRUG|celebrex|400 mg celebrex given 1 hour preop and celebrex 200 mg BID postop
223870007|NCT00664690|DRUG|placebo|placebo given preop and BID postop
223870008|NCT00003834|DRUG|fluorouracil|
223870009|NCT00003834|DRUG|leucovorin calcium|
223870010|NCT00003834|DRUG|oxaliplatin|
223870011|NCT02928354|DRUG|Treatment A - AZD7594|Particle size Large as a single inhaled dose of 440 µg (nominal dose), administered via DPI
223870012|NCT02928354|DRUG|Treatment B - AZD7594|Particle size Medium as a single inhaled dose of 440 µg (nominal dose), administered via DPI
223870013|NCT02928354|DRUG|Treatment C - AZD7594|Particle size Small as a single inhaled dose of 440 µg (nominal dose), administered via DPI
223870014|NCT06451016|DIETARY_SUPPLEMENT|Vitamin D supplements|70 mcg/day (equal to 2800 IU) of cholecalciferol
223870015|NCT06451016|DIETARY_SUPPLEMENT|Placebo|Matching Placebo
223870016|NCT01717820|DIETARY_SUPPLEMENT|Freeze-dried whole-grape powder|Participants are provided the equivalent of two servings per day of freeze-dried grape powder in a double-blind, placebo controlled, randomized design to determine the impact of the phytochemical, resveratrol, on biomarkers of adipose metabolism and bone metabolism.
223870017|NCT01891084|DRUG|Paracetamol|Paracetamol 1 tablet (500mg) four times daily. For a maximum period of 5 days if the patient is still having fever. When required, participants may take up to 2 tablets (1gm) in each dose.
223870018|NCT01891084|DRUG|Placebo|(Identical-looking) Placebo 1 tablet four times daily. For a maximum period of 5 days if the patient is still having fever. When required, participants may take up to 2 tablets in each dose.
223870019|NCT01891084|DRUG|Backup NSAID ibuprofen|Backup NSAID ibuprofen 200mg orally every 8 hourly will also be provided to all participants, which can be taken when necessary (PRN) if the participant finds the fever intolerable.
223870020|NCT03437369|DRUG|Ivabradine Oral Tablet|The target dose is 10 to 15 mg / day, administered orally in two doses
223870021|NCT03437369|OTHER|Standard of Care treatment|The study drug will be compared with the standard of Care treatment
223870022|NCT04217850|OTHER|250 kcal Dietary Energy Restriction|The nutrition intervention will be individualized and implemented as a free-living energy-restricted eating plan where energy intake will be based on a mild restriction (approx. 250 kcal/day).
223870023|NCT04217850|OTHER|Aerobic Exercise|Supervised aerobic exercise will be combined with the energy restriction. Individuals will perform aerobic exercise (treadmill, cycle, or rower or combination) 4-5 days per week for 12 weeks. At each session they will expend 250 or more calories to further meet or exceed the 500 kcal energy deficit.
223870024|NCT05845528|DEVICE|s-tDCS|\- Intervention: tDCS is a therapeutic method that modulates the membrane potential, where anodic stimuli induce cortical excitability and cathodic stimuli reduce it
223870025|NCT05845528|DEVICE|a- tDCS|\- Intervention: tDCS is a therapeutic method that modulates the membrane potential, where anodic stimuli induce cortical excitability and cathodic stimuli reduce it
223870026|NCT01924676|DRUG|Oxycodone|One capsule of 40 mg PF-00345439 Formulation X, single dose, under fasting conditions
223870027|NCT01924676|DRUG|Oxycodone|One capsule of 40 mg PF-00345439 Formulation K, single dose, under fasting conditions
223870028|NCT01924676|DRUG|Oxycodone|One capsule of 40 mg PF-00345439 Formulation K, single dose, under fed conditions
223870029|NCT02881203|DEVICE|Breathe Well|Breathe Well is an audiovisual biofeedback device used to assist patients to regulate their breathing whilst undergoing radiation treatment.
223870030|NCT02881203|DEVICE|RPM|Varian Real-time Position Management (RPM) system
223870031|NCT05475041|PROCEDURE|Major liver resection|Major liver resection (3 or more contiguous segments)
223870032|NCT05475041|PROCEDURE|Technically major liver resection|Minor liver resection (\<3 contiguous segments) in the posterosuperior segments (segment 1,4a,7,8)
223870033|NCT04002622|DRUG|TQB2450|TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.
223870034|NCT04202393|BEHAVIORAL|Integrated Treatment Adherence Program (ITAP)|Psychosocial support and treatment to improve treatment adherence, symptoms, and functioning.
223870035|NCT04202393|BEHAVIORAL|Safety Assessment and Follow-up Evaluation (SAFE)|Enhanced assessment and evaluation with clinician feedback.
223870036|NCT04589520|BEHAVIORAL|HeartBot App|HeartBot is an app designed to enable people 14 years and older to use relaxation tools offered by Heartfulness to deal with daily stress and anxiety in a healthy, productive manner.
223870037|NCT03419013|OTHER|New adhesive strip|This strip is made of a newly developed adhesive
223870038|NCT04168801|DIETARY_SUPPLEMENT|early oral refeeding|Once the patient had a score of 1-3 of the analogue numerical scale (ENA), he was interrogated about symptoms such as nausea or vomiting, receives diet indicated between 16 and 24 hours after admission.
223870039|NCT00134446|DEVICE|transcranial magnetic stimulation|
223870040|NCT04661410|BEHAVIORAL|Reward Re-Training|A brief, 10-session group-based behavioral treatment that is designed to indirectly change binge eating by directly focusing on building a more rewarding life. RRT hypothesizes that reductions in binge eating will occur as life becomes more rewarding because individuals will no longer need to rely on binge eating as a primary source of momentary reward. RRT notes that in order to live a satisfying life, individuals need to experience an adequate amount of reward in two overlapping yet distinguishable domains: momentary reward (i.e., the active experience of pleasure in the moment) and sustained reward (i.e., a deeper and more long-lasting sense of fulfillment and meaning that arises from building a personally valued life). A key aspect of RRT is an emphasize on building lasting and meaningful social relationships given the clear evidence that social connectedness can enhance both momentary reward and sustained reward.
223870041|NCT04661410|BEHAVIORAL|Supportive Therapy|A brief, 10-session group-based treatment that is designed to instill hope and optimism and to increase social connection and support through a non-directive group leader that allows the patients to determine the focus of each session. The group leader will act as an empathetic provider by using reflective listening, eliciting and validating affect, and offering empathic comments.
223870042|NCT02689180|DRUG|Placebo|Replacement of furosemide by placebo
223870043|NCT02689180|DRUG|Furosemide|Maintenance of furosemide on usual doses
223870044|NCT03995992|BEHAVIORAL|sport|10 days of sport (diving or multisport), once training per day
223870045|NCT00731185|DRUG|Mometasone Furoate Nasal Spray|MFNS 200 mcg (2 sprays of 50 mcg in each nostril) once daily in the morning for up to 24 weeks or until relapse
223870046|NCT00731185|DRUG|Placebo|
223870047|NCT04718688|OTHER|CO-OP rehabilitation|"The intervention was included within the child's conventional rehabilitation program.~In the CO-OP original protocol, the child sets 3 goals. Here, we concentrated on two rather than three goals, as addressing three occupations per session seemed too ambitious given the children's cognitive profile (the third goal served as control goal).~We chose to increase the number of sessions to 14 (two sessions per week for seven weeks, vs ten in the original protocol).~The global strategy was taught to the child at the first session. The following sessions consisted of an iterative process of implementation of the global strategy in the context of guided discovery to identify domain specific strategies to overcome performance ''breakdowns the children were experiencing when performing the self-selected tasks. In addition, homework was assigned to encourage the application and practice. Parents were invited to attend the sessions if it was possible for them."
223870048|NCT00465192|DRUG|estradiol, 10 mcg|
223870049|NCT00465192|DRUG|estradiol, 25 mcg|
223870050|NCT00465192|DRUG|placebo|
223870051|NCT01186198|DEVICE|MINI TREK RX 1.20 mm Coronary Dilatation Catheter|Enlarging coronary luminal diameter during percutaneous coronary intervention (PCI) procedures in subjects with ischemic heart disease due to stenotic lesions
223870052|NCT02665988|DEVICE|tDCS|Prior to initiating the real tDCS trial and to reduce the likelihood of irritation associated with electrical stimulation, a low dose (1/8 of an inch) topical lidocaine (4%) cream will be applied to the skin where the tDCS the sponge-coated, surface electrodes soaked in saline solution will be placed. Neurotargeting tDCS-explorer software, Version 2.3 will be used to locate the left and right DLPFC, where anodal stimulation of the left DLPFC and cathodal stimulation of the right DLPFC will be received. Real tDCS will be applied during 20-minute periods over the course of 10 sessions. After each session, vitamin-E will be applied to the skin where the electrodes had been placed to reduce likelihood of skin irritation.
223870053|NCT02665988|DEVICE|Sham tDCS|Participants randomized to sham tDCS will undergo the same procedures as those in the real tDCS sample, including the same pre-treatment lidocaine 4% cream, localization of electrode placement, actual placement of electrodes, turning on the tDCS device in sham setting but will not receive actual stimulation during the 20 minutes of each session, as well as post-treatment vitamin E.
223870054|NCT03861364|DRUG|Propofol|2,4 mg/kg
223870055|NCT03861364|DRUG|Propofol|1,4 mg/kg
223870056|NCT03751943|DEVICE|NanoFUSE® Bioactive Matrix (75%) w/autograft (25%)|NanoFUSE® Bioactive Matrix (75%) w/autograft (25%)within one posterolateral gutter
223870057|NCT01359436|DEVICE|Electrosensing antibody probing system (e- Ab sensing)|Electrosensing antibody probing system (e- Ab sensing), which was developed for the rapid and sensitive detection of hapten, proteins or viral antigen in medical samples, will be used for analyzing the interaction kinetics between mutation-specific anti-EGFR and its antigen mutant EGFR present in NSCLC. The system incorporates the use of engineered semiconductive antibodies or virus in vertical and lateral chip (eAbchip) or lateral flow through (eAbsignal) formats. In electrosensing antibody probing, semiconductive antibodies are bound as a suitable electrosensing probe which specifically and selectively binds mutant EGFR polypeptide target molecules in the test specimen.
223870058|NCT00430872|BEHAVIORAL|Survey|Survey about the severity of certain symptoms lasting 10-15 minutes.
223870059|NCT01041612|DEVICE|PTFE Covered ComVi [full covered] Biliary Stent|The stent is made of Nitinol wire. It is a flexible, fine mesh tubular prosthesis and it has 10 radiopaque markers; 4 in each end and 2 in the center.
223870060|NCT01041612|DEVICE|PTFE Covered ComVi [full covered] Biliary Stent|The stent is made of Nitinol wire. It is a flexible, fine mesh tubular prosthesis and it has 10 radiopaque markers; 4 in each end and 2 in the center.
223870061|NCT02095184|DRUG|Anastrozole|1 mg daily
223870062|NCT02095184|DRUG|Letrozole|2.5 mg daily
223870063|NCT02725762|DEVICE|LT-300 Active (PBM)|
223870064|NCT02725762|DEVICE|LT-300 Inactive (Sham)|
223870065|NCT03238391|PROCEDURE|Ischemic preconditioning|It is mentioned before in arm/group descriptions
223870066|NCT01759771|DRUG|Vitamin D3|4,000 IU of VD3 for at least one year
223870067|NCT01759771|DRUG|Placebo|Placebo for at least one year
223870068|NCT02541188|GENETIC|Genetic analysis|
223870069|NCT03560934|DRUG|Dronabinol|Single dose oral administration of 10-60mg dronabinol prior to night 2 or 3 sleep in the clinical laboratory.
223870070|NCT06553261|PROCEDURE|suturing of leak, lavage, drainage|Operative suturing of the leak, lavage, drainage within a revision surgery.
223870071|NCT06553261|PROCEDURE|Formation of a new anasthomosis|Operative resection of the old leaking anastomosis and formation of a new one.
223870072|NCT06553261|PROCEDURE|Fecal diversion|Formation of a deviating stoma.
223870073|NCT06553911|OTHER|Artificial Intelligence-based medical imaging interpretation|In the AI interpretation group, using clinical information, imaging data, and corresponding etiological results of the study participants, an AI diagnostic tool is established to specifically recognize patients' chest medical imaging and construct corresponding diagnostic conclusions.
223870074|NCT06499246|PROCEDURE|Donor Parathyroid|Once a potential donor becomes available, the transplant team will assess if the donor is a match for our study participant using standardized transplantation protocols that include serology blood tests completed in the pre-operative setting. If the donor is a match, the procurement team will procure all parathyroid tissue using standard surgical techniques. The specimen will be kept in organ preservation solution for transport and transported to the operating room. The recipient (study participant) will be admitted to the hospital under and taken to the operating room for the surgical procedure. Once the procurement team arrives with the parathyroid tissue the procedure will be performed under local anesthesia using a well-established technique, for parathyroid auto transplant, of implanting parathyroid tissue in the non-dominant brachioradialis muscle. Immunosuppression medication protocols will be initiated.
223870075|NCT02528188|DRUG|NSAID|Orally administered NSAID (naproxen 500 mg, celecoxib 100 mg or diclofenac 75 mg) twice daily for 56 weeks
223870076|NCT02528188|BIOLOGICAL|Tanezumab 2.5 mg|Subcutaneous injection of tanezumab 2.5 mg every 8 weeks for 56 weeks
223870077|NCT02528188|BIOLOGICAL|Tanezumab 5 mg|Subcutaneous injection of tanezumab 5 mg every 8 weeks for 56 weeks
223870078|NCT05861193|PROCEDURE|Treatment of the abfraction with BOPT technique|"The steps to follow for the treatment of abfraction using composite resin and the B.O.P.T. technique will consist of:~* Selection of the color of the composite, placement of the retraction cord and chamfering of the coronal margin of the lesion;~* Application of 37% phosphoric acid etching and adhesive in 3 steps; placement of the composite by layers, following the conventional obturation technique.~* Execution of an overfilling with the composite at the level of the cervical emergence profile of the tooth, with the aim of emphasizing said anatomical particularity.~* Removal of the retraction cord.~* Diamond milling with red rim flame diamond bur and contra-angle, positioned from the most apical point of the restoration at an angle of 45º without touching the restored dental portion, with the aim of performing a level rotary gingival curettage from the margin of the restoration.~* Polishing with a fine-grain flame bur, and polishing discs of decreasing granulometry."
223870079|NCT00204646|DRUG|Adriamycin|
223870080|NCT00204646|DRUG|Ifosfamide|
223870081|NCT00204646|DRUG|Etoposide|
223870082|NCT00204646|DRUG|Carboplatin|
223870083|NCT00505791|DRUG|Nesiritide|Study drug will be administered for 24 hours. Study drug will be initiated with a 2-µg/kg loading bolus followed by .01-µg/kg/min infusion. This may be increased at a rate of .005-µg/kg/min. every 3 hours until maximum dose of .03-µg/kg/min. Any increase in the infusion rate will be preceded by a 1-µg/kg bolus and increases in infusion rates will be permitted only in patients who have a systolic blood pressure \> 100 mmHg.
223870084|NCT02083575|DRUG|Vitamin C, Defriprone, deferisarox|adjuvant vitamin c with iron chelator.
223870085|NCT02083575|DRUG|deferiprone , deferesarox|iron chelator
223870086|NCT00060684|DRUG|Pixantrone (BBR 2778)|
224268557|NCT03732144|BEHAVIORAL|Connect Staff-based PA intervention|After school program sites receiving the Connect intervention will receive a 16 week program that includes three related components - a staff health promotion initiative that helps staff pursue personally-tailored health goals and involves weekly 'check-ins', a tailored social PA curriculum to implement within the program's enrichment hour at least 3 times per week, and a comprehensive staff training program that provides strategies and tools for improving social connections within the program and guided support for implementing the social PA curriculum. Compared to control ASPs, ASPs receiving the 'Connect' program are expected to show greater improvements from baseline to post- and 6 mo follow-up in PA-related social mechanisms, youth PA, and staff PA.
223870087|NCT00060684|DRUG|fludarabine|
223870088|NCT00060684|DRUG|dexamethasone|
223870089|NCT00060684|DRUG|rituximab|
223870090|NCT02616068|DRUG|Transdermal Patch|Transdermal patch 100 mg once a day for 7 days
223870091|NCT02616068|DRUG|Loxoprofen sodium|Loxoprofen sodium 60 mg per tablet by mouth, every 8 hours for 7 days
223870092|NCT02616068|DRUG|Placebo (for loxoprofen sodium)|Placebo (for loxoprofen sodium 60 mg per tablet) by mouth, every 8 hours for 7 days
223870093|NCT02616068|DRUG|Placebo (for transdermal patch)|Placebo (for transdermal patch 100 mg) once a day for 7 days
223870094|NCT03035994|OTHER|Real-Time Biofeedback|A custom written MatLab script will sample bilateral peak vertical ground reaction forces and display the magnitude in real time on a screen placed in front of the participant. A target line will be placed in the middle of the screen which corresponds to one of the three loading conditions. Participants will be instructed to alter their movement in an attempt to match each limb's vertical ground reaction force to the target line.
223870095|NCT03480451|OTHER|Multi-Disciplinary Patient Centered Rehab and Education|"This project is being withdrawn. No revisions to Intervention is available.~Patients will undergo consultation and education by members of a pre-determined multi-disciplinary team that aims to bring a predetermined set of services to the patient in a coordinated and scheduled manner in order to facilitate a comprehensive and through approach to the patient's entire well being"
223870096|NCT04581850|BEHAVIORAL|Sleep recording|Sleep is recorded at home during 7 nights in a row using a connected headband. The participant also has to fill in a sleep agenda every day.
223870097|NCT04581850|BEHAVIORAL|Cognitive tasks|Working memory and inhibition capacity is assessed during computer-based tasks (2-back and Go/No-Go tasks) at enrollment and 1 month after enrollment.
223870098|NCT04581850|OTHER|Questionnaires|"The participant has to fill in several questionnaires at enrollment and 1 month after enrollment in order to assess:~* PTSD severity~* chronotype~* Sleep quality~* Daytime sleepiness~* Mood state~* Depression~* Mental disorders and their consequences"
223870099|NCT04294173|BEHAVIORAL|video education|tracheostomy care will be given to student nurses with video training
223870100|NCT06647641|OTHER|Whole genome sequencing will be performed at the NIH|All samples will undergo non-CLIA approved whole genome sequencing on a research basis in collaboration with Sonja Scholz, MD, PhD at the Neurodegenerative Diseases Research Unit of the National Institutes of Health (Bethesda, MD). This sequencing method allows for the identification of not only variants known to be associated with these disorders but also potentially novel variants.
223870101|NCT03108703|RADIATION|SBRT|35-40 Gy delivered in 5 fractions
223870102|NCT02575560|OTHER|history data|history data of PFS after 1st line or second line theray
223870103|NCT04843475|DIAGNOSTIC_TEST|Echocardiography|Trans-thoracic Echocardiography
223870104|NCT03098368|DRUG|Rotigotine|
223870105|NCT03098368|DRUG|Placebo|Placebo of rotigotine patch
223870106|NCT01605773|DRUG|repaglinide|Dose individually adjusted and conducted according to labeling
223870107|NCT01605773|DRUG|glyburide|Dose individually adjusted and conducted according to labeling
224268558|NCT03732144|OTHER|Connect Health Curriculum Control|After school program sites receiving the general ASP health curriculum control will address the prevention of several negative health behaviors (e.g., substance use, stress, etc) and also involve three related components- a comprehensive health program curriculum that includes activities that are interactive and fun and where students will learn about a variety of health behaviors (nutrition, stress reduction, etc.) and life skills through group activities, a staff training program that provides strategies and tools for implementing program curriculum, and on-going support from the Connect staff. This arm will serve as the comparison group to the Connect Staff-based PA intervention
224268559|NCT00396929|DRUG|local intracoronary dosis of Paclitaxel|
224268560|NCT05718180|OTHER|Transperineal imaging|To measure the difference between ultrasound parameters based on maternal position: to measure the variation of AoP (Angle of progression), MLA (Midline Angle), PAA(pubic arch angle expressed in grades) HSD (head-symphysis distance) HPD(head perineum distance) expressed in millimeters, in the supine position and kneeling squat position in the same woman during the expulsion phase, in the resting step and during the push.
224268561|NCT03069976|DRUG|Metronidazole|Flagyl x 14 days.
224268562|NCT05963464|DEVICE|SCOUT® Radar occult breast lesion Localization|The SCOUT® Radar occult breast lesion Localization (SRL) uses non-radioactive micro-impulses to guide surgical excision in real time.
224268563|NCT03909633|BEHAVIORAL|a series of tests|all patients in every group will do a series of tests,including DSST、DST、MoCA、WCST、HADS
224268564|NCT05757830|DEVICE|UANGO suite exoskeleton|"Each subject will perform 3 experimental conditions (Condition 1: Walking without exoskeleton; Condition 2: Walking with exoskeleton; Condition 3: Walking with exoskeleton and walker).~Each condition includes 5 triasl (Trial 1 - Sitting: 5 minutes, sitting at rest in comfortable position; Trial 2 - Standing: 5 minutes, with assistance; Trial 3 - Comfortable speed Walking (100% assisted): 4 min during back-and-forth locomotion on a 20-m length linear flat path; Trial 4 - Comfortable speed Walking (75% assistance): 4 min during back-and-forth locomotion on a 20-m length linear flat path, Trial 4 is not available in condition 1; Trial 5 - 1 minute Sit to stand test). Nasa TLX and RPE will be requested at the end of each trial. Usability questionnaires will be fullfilled at the end of condition 2 and condition 3."
224268565|NCT04090658|BIOLOGICAL|RSV_PreF3 Vaccine (GSK3844766A) adjuvanted with AS01B|Subjects aged 60 to 80 years received 2 doses of the investigational adjuvanted RSV\_PreF3 vaccine (GSK3844766A), at Day 1 and Day 61, by intramuscular (IM) injection into the deltoid region of the non-dominant arm preferably.
224268566|NCT04090658|DRUG|Placebo|Subjects aged 60 to 80 years received 2 doses of placebo as control, at Day 1 and Day 61, by IM injection into the deltoid region of the non-dominant arm preferably.
224268567|NCT01476501|DRUG|Vitamin D3|Randomized into 1 of 2 oral vitamin D3 softgel capsule supplementation strategies: 1) 2,000 IU/day (2 x 1,000IU/capsule each day) or 2) 40,000 IU/month (4 x 10,000IU/capsule last day of each month), for 6 months each.
224268568|NCT05956717|DEVICE|Orthokeratology|The experimental group wore orthokeratology lenses
224268569|NCT03019016|PROCEDURE|Right Colectomy|Robotic-assisted or laparoscopic right colectomy with intracorporeal or extracorporeal anastomosis either on or proximal to midtransverse colon.
224268570|NCT01937234|DRUG|Metoclopramide|"Intravenous injection of 10mg metoclopramide, at enrollment, then every 2 hours.~Maximum of 3 doses."
224268571|NCT01937234|DRUG|Placebo|"Intravenous injection of 0.9% sodium chloride, at enrollment, then every 2 hours.~Maximum of 3 doses."
224268572|NCT00467597|DRUG|Levodopa (delivered intravenously)|"IV Levodopa is given from 09:00 to 11:00 am during the testing phase of the study. The IV Levodopa allows the researchers to watch one full on and off levodopa cycle while in the inpatient unit."
224268573|NCT03756233|DRUG|Remifentanil|Remifentanil is a potent, short-acting synthetic opioid analgesic drug. It is given to patients during surgery to relieve pain and as an adjunct to an anesthetic.
224268574|NCT00634205|DRUG|Valproate plus doxorubicin|Valproate 20-30 mg/kg orally (in order to obtain serum concentration between 50-100 mcg/ml) Doxorubicin 60 mg/m² intravenously every 3 weeks
224268575|NCT02722798|DRUG|KRN23|Doses may be titrated to achieve the target peak serum phosphorus range
224268576|NCT02096705|DRUG|Dapagliflozin|Tablet
224268577|NCT02096705|DRUG|Dapagliflozin Placebo|Tablet
224268578|NCT00417677|DRUG|Combination of Temsirolimus and Sunitinib|
223870108|NCT01316731|OTHER|Single legged exercise|A single exercise bout that consists of one hour one-legged cycling on a adapted recumbent cycle ergometer at a submaximal rate. The non-exercising leg will serve as control for the exercising leg.
223870109|NCT05403567|OTHER|Bootle Blast Home Intervention|Children will play BB at home for 8 continuous weeks. Participants will be asked to stop playing at the end of week 8 and the game will be programmatically locked to prevent further play until the post-intervention interviews and assessments are complete.
223870110|NCT04092231|BEHAVIORAL|Early speech perception test|The early speech test is one of the closed-set response speech discrimination tests,using object identification technique.It was carefully designed for estimation of speech perception abilities in very young children who have extremely low verbal abilities
223870111|NCT01844492|BEHAVIORAL|The PARTNER Intervention|The PARTNER intervention (PAiring Re-engineered ICU Teams with Nurse-driven Emotional Support and Relationship-building) consists of: 1) institution of a clinical pathway for family support overseen by ICU staff nurses; 2) advanced communication skills training for ICU staff nurses; 3) a multifaceted strategy to support implementation of the clinical pathway for family support.
223870112|NCT01844492|OTHER|ICU Usual Care Control|The control group will receive usual care, in which the frequency and content of clinician-family communication is determined by the clinical team according to their usual practice. No study ICU has a protocolized approach to family communication and instead clinicians determine the timing and frequency of communication with families. All sites have palliative care services.
223870113|NCT03272399|OTHER|Diet/nutrition intervention|The intervention will be administered through food products rather than dietary supplements
224268579|NCT06122805|DEVICE|Toothbrush|We will test three toothbrushes in patients undergoing surgery and a control no surgery group. These toothbrushes are manual toothbrushes, sonic toothbrushes, and sonic and dual light toothbrushes.
224268580|NCT04163094|DRUG|W_ova1 Vaccine|Patients will be treated with a W\_ova1 vaccine that includes 3 OC TAA RNA-LPX products.
224268581|NCT03669731|OTHER|food diary|This food diary is to be completed by the patient in the 3rd trimester of pregnancy, on 3 consecutive days and if possible including a weekend day. Finally, the investigator also prescribes a biological analysis: a urinary urea from a 24h diuresis to be collected in the 3rd trimester in a dedicated collector and given that same day.
224268582|NCT02472834|DIETARY_SUPPLEMENT|Amino acid supplementation NephrAmine®|Dialysis patients will be randomized to receive either 250 mL of NephrAmine® (5.4% amino acids for injection; B. Braun Medical, Inc) containing \~14 grams of essential amino acids during each dialysis session (3 times weekly for 8 weeks) or no treatment (standard-of-care)
224268583|NCT00476034|DRUG|lumiracoxib|
224268584|NCT01963455|BIOLOGICAL|paraurethral injection of MDCs|MDCs transplantation by paraurethral injection .
224268585|NCT03404921|PROCEDURE|ESTD|During the ESTD procedure,after marking and submucosal injection, incisions were made at both the anal and oral sides of the lesion, and the submucosa under the lesion was then dissected to create a tunnel between the distal and proximal incisions. When the endscope reached the lower incision, the distal end of the esophageal lumen could be visualized , then two lateral mucosal incisions were made, thus completing the ESD procedure.
224268586|NCT03404921|PROCEDURE|ESD|The ESD procedure involved marking,injection,circumferential cutting, submucosal dissection.
224268587|NCT02238587|OTHER|Control group|In control group, only placebos are given for 6 weeks. The patients who are in control groups are switched to receive Ganoderma Spores Powder Capsules for 6 weeks.
224268588|NCT02238587|DIETARY_SUPPLEMENT|Ganoderma Spores Powder Capsules|In experimental group, Ganoderma Spores Powder Capsules for 12 weeks.
224268589|NCT02235870|DEVICE|Obalon Intragastric Balloons|Intragastric Balloon System to aid in portion control.
224268590|NCT02235870|DEVICE|Sham Device|Sham Intragastric Balloon
224268591|NCT02235870|BEHAVIORAL|Nutrition and Lifestyle Program|Nutrition and lifestyle program reviewed with subjects every 3 weeks for 6 months.
224268592|NCT03234309|DRUG|Ferumoxytol|Given IV
224268593|NCT03234309|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
224268594|NCT02763345|OTHER|Supporting LIFE electronic Community Case Management|The SL eCCM App is smartphone application developed to run on Android operating systems 3.0 Honeycomb and above. The SL eCCM App represents an electronic format of the WHO and UNICEFs paper-based CCM clinical decision rule, currently adopted as national policy in Malawi for assessing children presenting to village clinics with acute illness.The App includes a tap-sensitive breath counter for measuring breathing rate.
224268595|NCT02763345|OTHER|Standard care|
224268596|NCT06348576|DRUG|AD-209|PO, Once daily(QD), 8weeks
224268597|NCT06348576|DRUG|AD-2091|PO, Once daily(QD), 8weeks
224268598|NCT06348576|DRUG|AD-209 Placebo|PO, Once daily(QD), 8weeks
224268599|NCT06348576|DRUG|AD-2091 Placebo|PO, Once daily(QD), 8weeks
224268600|NCT02956681|BEHAVIORAL|Intervention Group|Callers to California's toll-free breast/cervical screening phone service were screened for family history. Callers identified as high risk will be told that a genetic counselor will call them back to offer them a free genetic counseling appointment and that a brochure will be sent. A UCSF/SFGH genetic counseling assistant will call them back within a few days to offer them a free genetic counseling appointment at SFGH.
224268601|NCT02956681|BEHAVIORAL|Delayed Intervention Group|This is a randomized delayed intervention control trial in which eligible callers to California's toll-free breast/cervical screening phone service were screened for family history. Callers identified as high risk will be told that they are eligible to speak to a genetic counselor who is available at no charge at SFGH and that they will be sent a brochure with information on where to call.
224268602|NCT00532012|DRUG|RhuDex®|
224268603|NCT02166606|DEVICE|ImageReady MR Conditional Pacing System Implant|Implant according to standard-of-care. No study-specific interventions in that registry.
224268604|NCT04980170|DRUG|Clindamycin 300 mg|patients will be given clindamycin 300 mg twice daily for 5 days after dental implant
224268605|NCT04980170|DRUG|Amoxicillin with Clavulanic Acid 635mg|patients will be given Amoxicillin with Clavulanic Acid 635mg, three times daily for 5 days after dental implant
224268606|NCT01940159|DRUG|SEP-363856|SEP-36385625 as a single oral dose of 25, 50, 100, and 150 mcg
224268607|NCT01940159|DRUG|Placebo|single oral dose placebo
224268608|NCT02520193|PROCEDURE|Protocolized early mobilization in ICU|
224268609|NCT00000698|DRUG|Ganciclovir|
224268610|NCT02036398|DEVICE|Double J stent without nephrostomy|Double J stent only left at the end of the procedure without placement of a nephrostomy tube
224268611|NCT02036398|DEVICE|nephrostomy tube and double J stent|Double J stent and nephrostomy tube left at end of procedure
224268612|NCT04431973|DEVICE|Medacta Shoulder System|Surgical placement of the Medacta Shoulder System prothesis on patients with pathologies requiring the insertion of a total reverse shoulder prothesis for primary omarthrosis, cuff tear arthropathy, massive cuff rupture or post instability arthropathy
224268613|NCT05125276|DRUG|No aspirin|No aspirin
224268614|NCT05125276|DRUG|Aspirin|75-100 mg once daily
224268615|NCT01724762|OTHER|Nursing Orientation|"* Control group: patients who did not read the informative manual concerning bed bath and received only the unit's routine information~* Intervention group: patients who received nursing orientation and read the informative manual concerning bed bath"
224268616|NCT00290927|DRUG|insulin glulisine|
224268617|NCT03113227|DIAGNOSTIC_TEST|Transvaginal ultrasound|Transvaginal ultrasound will be made for assessment of posterior cervical angle and cervical length
224268618|NCT03113227|DIAGNOSTIC_TEST|Vaginal examination|Vaginal examination will be done for assessment of Bishop score
224268619|NCT00144222|DRUG|Telmisartan 40 mg/HCTZ 12.5 mg|
223870114|NCT04992364|OTHER|Burnout and Clinical performances questionnaires|Subjects were given questionnaires to assess burnout score and clinical performances
223870115|NCT04775992|OTHER|gabapentoids|Preemptive analgesia
223870116|NCT00581035|BIOLOGICAL|Prevenar and Meningitec|1 dose of Prevenar at 2,3.5,6 and 12 months and 1 dose of Meningitec at 2,6 and 12 months
223870117|NCT00581035|BIOLOGICAL|Prevenar|1 dose at 2,3.5,6 and 12 months
223870118|NCT00581035|BIOLOGICAL|Meningitec|1 dose at 2,6 and 12 months
223870119|NCT03872635|OTHER|oral carbohydrate liquid|patients undergoing neoadjuvant chemotherapy and radical hysterectomy with bilateral pelvic lymph node dissection were randomized to receive 300mL of an oral carbohydrate liquid supplement 2 hour before surgery
223870120|NCT02918591|DRUG|Empagliflozine|All 6type 2 diabetic participant will receive treatment with Empagliflozine during 2 month
223870121|NCT06389266|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|rTMS is a technique of TMS that allows the selective external manipulation of neural activity in a non-invasive manner. During TMS, a rapidly changing current is passed through an insulated coil placed against the scalp. This generates a temporary magnetic field that in turn induces electrical current in neurons and allows the modulation of neural circuitry. The combination of rTMS with functional magnetic resonance imaging allows the selective targeting and modulation of brain networks. The repeated application of rTMS can cause long term changes in behavior and task performance that is reflected in altered brain network connectivity.
223870122|NCT05720078|RADIATION|Adaptive, two-phase RT|Participants in this arm will be treated with an adaptive, two-phase radiation therapy approach
223870123|NCT06972654|PROCEDURE|Group Nalupnine|Patients will receive a unilateral ultrasound-guided pericapsular nerve group (PENG) block with a combination of 20 mL of bupivacaine 0.25%- and 2 ml nalbuphine (20 mg), with total volume 22ml.
223870124|NCT06972654|PROCEDURE|Group Dexamethasone|Patients will receive a unilateral ultrasound-guided PENG block with a combination of 20 mL of bupivacaine 0.25%- and 2 ml dexamethasone (8 mg), with total volume 22ml.
223870125|NCT03343197|DRUG|AG-120|Prior to surgery subjects will receive AG-120 administered continuously as a single agent dosed orally on Days 1 to 28 of a 28-day cycle. Subjects without residual disease following surgery will have the option to receive treatment for up to a year, until disease progression or unacceptable toxicity, whichever occurs first. Subjects with residual disease following surgery will have the option to receive treatment, until disease progression or unacceptable toxicity.
223870126|NCT03343197|DRUG|AG881|Prior to surgery subjects will receive AG-881 administered continuously as a single agent dosed orally on Days 1 to 28 of a 28-day cycle. Subjects without residual disease following surgery will have the option to receive treatment for up to a year, until disease progression or unacceptable toxicity, whichever occurs first. Subjects with residual disease following surgery will have the option to receive treatment, until disease progression or unacceptable toxicity.
223870127|NCT02592954|DRUG|Jojoba oil with broccoli sprout extract|500nmol of broccoli sprout extract in 1ml of jojoba oil will be applied to the same arm every night under saran wrap for 1 week
223870128|NCT02592954|DRUG|Jojoba oil (placebo)|1ml of jojoba oil will be applied to the same arm every night under saran wrap for 1 week
223870129|NCT00603356|DRUG|OSI-930 and erlotinib|OSI-930 administered daily in combination with Erlotinib at increasing doses until disease progression or unacceptable toxicity
223870130|NCT03140735|OTHER|Study the relationship between the arterial rigidity of large vessels and the presence and severity of degenerative aortic constriction|Study the relationship between the arterial rigidity of large vessels and the presence and severity of degenerative aortic constriction
223870131|NCT03140735|OTHER|Control group without heart disease|Control group without heart disease
223870132|NCT04333329|DEVICE|NEUROLITH|transcranial pulse stimulation (TPS)
223870133|NCT04441593|BEHAVIORAL|Motivational and Cognitive-Behavioral Management for Alcohol and Pain (MCBMAP)|Videoconferencing intervention to reduce alcohol use and chronic pain interference and severity
224268620|NCT00144222|DRUG|Telmisartan 40 mg|
224268621|NCT03010605|DEVICE|Measuring Every Day Device|
224268622|NCT03010605|OTHER|Physical Therapy|
224268623|NCT03981731|OTHER|Cardiac coherence|"An initiation session to cardiac coherence will take place between D-10 and D-7 before the operation (during the anaesthesia consultation) in order to obtain a breathing rate of 6 cycles/min via a free application (Respirelax) with listening to an audio tape.~3 cardiac coherence sessions per day of 5 min (before meals) during the 7 days preceding the operation.~\- The anaesthetic induction will be done with a session of cardiac coherence associated with listening to the audio tape."
224268624|NCT00951535|OTHER|questionnaire administration|
224268625|NCT00951535|PROCEDURE|quality-of-life assessment|
224268626|NCT00951535|RADIATION|image-guided radiation therapy|
224268627|NCT00951535|RADIATION|intensity-modulated radiation therapy|
224268628|NCT00951535|RADIATION|radiation therapy treatment planning/simulation|
224268629|NCT02248714|DIETARY_SUPPLEMENT|Glucerna SR|Glucerna SR (Abbott Laboratories, Columbus, USA) is a nutritional product with lower glycemic response.
224268630|NCT02942810|DRUG|WCK 5222|IV infusion over a period of 60 minutes
224268631|NCT01832922|DRUG|Bendamustine|
224268632|NCT01832922|DRUG|Rituximab|
224268633|NCT03600753|OTHER|culturomic|Culturomic is a high-throughput culture strategy based on the multiplication of culture conditions coupled with the rapid identification of bacteria by MALDI-TOF (Matrix-Assisted Laser Desorption / Ionization-Time-Of-Flight) mass spectrometry
224268634|NCT03600753|OTHER|Metagenomic|Metagenomics is an high throughput sequencing and will be performed using Miseq ( Illumina technology) targeting the V3-V4 hypervariable regions of the 16S RNA gene.
224268635|NCT04711057|OTHER|Community-based PA program|After completing the PR program, the experimental group (EG) will enroll in a 6-month personalized community-based PA program, which should be attended twice-weekly, minimum. During the first month the physiotherapist will guide patients through all available physical activities; afterwards, patients will be asked to choose one or two activities, according to their preference, which they'll attend for five more months. Physiotherapists' support will gradually decrease over time.
224268636|NCT04711057|OTHER|Pulmonary Rehabilitation|Exercise training, twice a week, and education and psychosocial support once every other week during 12 weeks.
223870134|NCT04441593|BEHAVIORAL|Treatment as Usual|Psychoeducation and Information about Treatment Resources
224076569|NCT06300853|OTHER|Analisys of cellular response and humoral response to SARS-CoV-2 vaccine booster doses|"Whole blood and serum samples will be longitudinally collected at the moment of the administration of the booster doses (T0) and three weeks after the booster doses (T1). Possible further time points will be collected within 2 years, based on the National recommended future vaccination regimens.~Biological samples will be used for the following exams:~* Cellular immunity characterization~  * T- and B-cells Immunophenotype.~ * Specific T-cell response.~ * In vitro specific B-cells characterization.~ * Antibody-dependent cellular cytotoxicity.~* Humoral response characterization~  * Serology assays.~ * Avidity assay.~ * Neutralization assays with different SARS-CoV-2 variants.~ * Presence of specific or cross-reactive antibodies for common hCoV.~* Genetic and epigenetic analysis"
223870135|NCT04021381|DIETARY_SUPPLEMENT|Potassium and magnesium citrate|Patients are treated with potassium and magnesium citrate 5.2 grams daily during 3 months, following flexible ureterorenoscopy for inferior calyx urolithiasis.
223870136|NCT04021381|DIETARY_SUPPLEMENT|Placebo|Patient are treated with placebo 5.2 grams daily during 3 months, following flexible ureterorenoscopy for inferior calyx urolithiasis.
223870137|NCT01850017|DRUG|Dexmedetomidine|In the intervention arm dexmedetomidine at a dose of 1 mcg/kg over 20 mins followed by an infusion of 0.5 mcg/kg/h for the duration of the surgery.
223870138|NCT05576844|BEHAVIORAL|8-week interpersonal and social rhythm intervention|The development of the intervention strategies are based on social rhythm theory, interpersonal and social rhythm therapy, and previous research results, and the intervention aims to improve sleep by stabilizing participants' social rhythm and increasing the amount of interpersonal communication.
223870139|NCT05576844|OTHER|Usual care|Control group participants received usual care, including daily disease management and routine drug guidance.
223870140|NCT03942042|DRUG|Ixekizumab|Administered SC
223870141|NCT00092027|DRUG|MK0217, alendronate sodium/Duration of Treatment: 6 months|
223870142|NCT00092027|DRUG|Comparator: placebo / Duration of Treatment: 6 months|
223870143|NCT04821336|OTHER|Metabolites dosage|"On samples investigators will quantify cholesterol metabolite and dendrogenin A (DDA) and 6-oxo-cholestane-3β,5α-diol (ou OCDO) metabolites in malignant tissue sample on one hand, and in sane samples on other hand.~The investigators will compare the rate of deregulation between sane and malignant ones."
223870144|NCT00563537|RADIATION|18F-X PET SCAN|18F-X PET Scan : Injection of 7.8 mSv for 370 MBq of dose (0.021 mSv / MBq)
223870145|NCT02399943|DRUG|Trametinib|
223870146|NCT02399943|DRUG|Panitumumab|
223870147|NCT03848234|DRUG|Estradiol|2 trans dermal patches to be changed twice a week for the duration of 8 weeks.
223870148|NCT03848234|DEVICE|Placebo|2 trans dermal patches to be changed twice a week for the duration of 8 weeks.
223870149|NCT02240550|DEVICE|ProFlor Hernia Repair System|The 3-D hernia mesh will be used in the repair of your inguinal hernia.
223870150|NCT02240550|DEVICE|Lichtenstein hernia repair|The standard Lichtenstein hernia repair with flat mesh will be used in the treatment of your inguinal hernia.
223870151|NCT00923871|PROCEDURE|Cone Beam CT|Patients will also have a CBCT scan when they are having their first IMRT treatment.
223870152|NCT06248788|DEVICE|PoC Device|PoC Device for Testing Salivary IgA
223870153|NCT02779517|OTHER|Mobile Service Robot Survey|The goal is to build a low-cost mobile service robot that will focus on the simple, but key, repetitive, data-driven tasks that robots do well. Rather than attempt to create a robot helper that mimics humans, the goal is to free human caregivers from the time-consuming tasks that robots can accomplish with facility, thereby allowing humans to focus on tasks that humans do best (i.e. human contact).
223870154|NCT02779517|OTHER|Mobile Service Robot Survey for Patients|The goal is to build a low-cost mobile service robot that will focus on the simple, but key, repetitive, data-driven tasks that robots do well. Rather than attempt to create a robot helper that mimics humans, the goal is to free human caregivers from the time-consuming tasks that robots can accomplish with facility, thereby allowing humans to focus on tasks that humans do best (i.e. human contact). This survey differs in terms of design questions.
223870155|NCT02202395|DRUG|LTS 0.25mg|use LTS 0.25mg/d
223870156|NCT02202395|DRUG|LTS 0.5mg|use LTS 0.5mg/d
223870157|NCT02202395|DRUG|LTS 1.0mg|use LTS 1.0mg/d
223870158|NCT02202395|DRUG|Placebo|use placebo once daily
223870159|NCT03998280|DEVICE|Assessment|Neck proprioception and postural stability
223870160|NCT00993369|OTHER|Holter monitor|Record heart rate for 2 to 6 hours on day of life 1 or 2.
223870161|NCT06051786|DRUG|azelastine/fluticasone 137/50 mcg nasal spray|AFC is a fixed-dose combination product of Azelastine hydrochloride (137mcg), a selective H1-receptor antagonist and, Fluticasone propionate (50mcg), a corticosteroid. AFC is administered intranasally and is used to treat Allergic Rhinitis (AR).
223870162|NCT06051786|DRUG|Dymista™|Dymista™ is a fixed-dose combination product of Azelastine hydrochloride (137mcg), a selective H1-receptor antagonist and, Fluticasone propionate (50mcg), a corticosteroid. Dymista™ is administered intranasally and is used to treat Allergic Rhinitis (AR).
223870163|NCT03599453|PROCEDURE|Biopsy|Undergo Biopsy
223870164|NCT03599453|PROCEDURE|Chemokine Modulation Therapy|Undergo chemokine modulation therapy
223870165|NCT03599453|DRUG|Celecoxib|Given by mouth
223870166|NCT03599453|BIOLOGICAL|Recombinant Interferon Alfa-2b|Given intravenously
223870167|NCT03599453|DRUG|Rintatolimod|Given intravenously
223870168|NCT03599453|BIOLOGICAL|Pembrolizumab|Given intravenously
223870169|NCT00901069|DRUG|Azacitidine with rituximab, vincristine, and cyclophosphamide|Azacitidine cycle days 1-5 Cyclophosphamide cycle days 6-9 Vincristine cycle day 8 Rituximab cycle day 8 Rituximab is only for those patients with CD20+ lymphoma. Azacitidine 25 mg/m2\^ Azacitidine 50 mg/m2\^ Azacitidine 75 mg/m2\^ Azacitidine 100 mg/m2\^
223870170|NCT01100125|DRUG|sitagliptin|sitagliptin 100mg once daily, orally, for 24 weeks.
223870171|NCT01100125|DRUG|insulin dose increase|insulin dose increase
223870172|NCT05273242|DRUG|Artesunate Injection|"* Artesunate: 2.4 mg/kg/dose at 0 hours, 12 hours, and 24 hours and thereafter every 24 hours; IV injection; duration of treatment 7 days. This is the standard dose recommended for the treatment of severe malaria.~* Infliximab: 5 mg/kg/dose (once only), single IV infusion over 2 hours. This is the standard dose that is given repeatedly for the treatment of psoriasis.~* Imatinib: 400 mg/dose; orally once daily; duration of treatment 14 days. This is the standard maintenance dose which is at the lower end of that used for several years in the treatment of hematological malignancies."
223870173|NCT02910635|DRUG|Volanesorsen|ISIS 304801 is supplied as 200mg of volanesorsen with 1.0mL of solution per vial
223870174|NCT02910635|DRUG|Moxifloxacin|Moxifloxacin Hydrochloride 400 mg tablet administered orally, Single Dose
223870175|NCT02910635|DRUG|Placebo|
223870176|NCT04120597|DRUG|Zishen Qingre Lishi Huayu Granules|The treatment group used Zishen Qingre Lishi Huayu Granules, including Zhimu（Anemarrhena asphodeloides Bge.）, Shengdi（Rehmannia glutinosa Libosch.）, Maidong（Ophio pogon japonicus (L.f) KerGawl.） , Bixie（Dioscorea septemloma Thunb.）, Huanglian（Coptis chinensis Franch.）, Zhuling（Polyporus umbellatus（Pers.）Fries）, Xuanshen（Scrophularia ningpoensis Hemsl.）, Zelan（Lycopus lucidus Turcz. Var. Hirtus Regel）, Danshen（Salvia miltiorrhiza Beg.）， Gancao（Glycyrrhiza uralensis Fisch.）. Subjects take the drug from the first day of inclusion. Take 1 pack each time, bid, for 3 months.
223870177|NCT04120597|DRUG|Placebo|"The treatment group used Caramel pigment、 Ku Ding Cha Extracts、Maltodextrin、Starch and 5% Zishen Qingre Lishi Huayu Granules .~Subjects take the drug from the first day of inclusion. Take 1 pack each time, bid, for 3 months."
223870178|NCT00179335|PROCEDURE|Blood drawing to determine drug levels|
223870179|NCT01638039|OTHER|Laboratory Tests|Stool, blood, urine and saliva samples
223870180|NCT06058104|DEVICE|Charades based mobile digital therapeutic|The mobile app is a charades style game and app that engages parent and child in fluid social interaction where the parent must guess what the child is acting out based on the prompt shown on the phone screen. Participants will use their own personal phone to download the study app. Parents are asked to play with their child 15 minutes 3-4 times per week for 8 weeks.
223870181|NCT04237155|OTHER|Questionnaire|Subjects will complete a verbal material scoring questionnaire
223870182|NCT04237155|OTHER|Cognitive tests|Subjects will complete two source-monitoring tasks: the source-monitoring task which will be created from step 1 as well as the task of reference
223870183|NCT03009994|PROCEDURE|Repair of uterine incision|
223870184|NCT03009994|PROCEDURE|Exteriorization of the uterus|
223870185|NCT03009994|PROCEDURE|Non exteriorization of the uterus|
223870186|NCT03798080|DRUG|Insulin glargine/Lixisenatide (HOE901/AVE0010)|"Pharmaceutical form: solution~Route of administration: subcutaneous"
223870187|NCT03798080|DRUG|Insulin glargine (HOE901)|"Pharmaceutical form: solution~Route of administration: subcutaneous"
223870188|NCT03798080|DRUG|Metformin|"Pharmaceutical form: tablet~Route of administration: oral"
223870189|NCT02569866|DRUG|Cephalexin|Capsules containing cephalexin/500mg
223870190|NCT02569866|DRUG|Placebo|Capsules containing placebo/500mg
223870191|NCT03339258|DRUG|Doxazosin Mesylate, Extended Release|Doxazosin is FDA-approved for the treatment of hypertension and urinary outflow problems associated with benign prostatic hyperplasia. The immediate-release formulation is approved for use from 1mg up to 16mg. Based on drug company information and Micromedex, the SFVA pharmacy on-line reference resource for drug information, the only contraindication to use of doxazosin is hypersensitivity to doxazosin, its contents, or other quinazolines (e.g. prazosin, terazosin).
223870192|NCT03339258|DRUG|Placebo|Placebo, or inactive pill.
223870193|NCT04631003|DIAGNOSTIC_TEST|dynamic functional testing|First, with an arthroCT of the wrist by intraarticular injection of contrast agent, a possible scaphulonary band lesion is detected. The surgeon does not yet know the findings of the possible ligament injury at this time, but he can assess the fracture in the CT. Subsequently, a dynamic functional test of the scapholunary distance is carried out intraoperatively under investigation with the modified Watson test before and after performing the osteosynthesis. For this purpose, the wrist is intraoperatively brought under pull on the thumb from a radial abduction into an ulnarabduction. In the presence of a scapholunary instability, a change in the distance of the scapholunary joint gap is shown here under illumination. Now the surgeon receives the finding of the Arthro-CT regarding an existing ligament injury. If necessary, this is treated in the same anaesthetic with a band seam and ossary transfixation.
223870194|NCT02457845|BIOLOGICAL|G207|Single dose of HSV-1 (G207) infused through catheters into region(s) of tumor defined by MRI
223870195|NCT03995446|DEVICE|low-level laser|low level laser emission on specific acupuncture points
223870196|NCT03995446|DEVICE|Sham laser|Sham laser
223870197|NCT00592241|DEVICE|"Adi Insulin Pump Usability"|no intervention
223870198|NCT01843101|DEVICE|Optical Coherence Tomography|Imaging of the cornea using ultrahigh resolution Spectral Domain OCT
223870199|NCT03661957|PROCEDURE|Non grafted maxillary sinus floor elevation with simultaneous implant placement|lateral window for sinus elevation ,membrane elevation ,implant placement , membrane for window closure
223870200|NCT03661957|PROCEDURE|using short dental implants for posterior atrophic maxilla|placement of short dental implant with bone height below 8mm
223870201|NCT03995498|OTHER|Physical activity|Participants will engage in team sports exercise twice a day: from 9h:30 to 10h:30 and from 11h:00 to 12h:00.
223870202|NCT03995498|OTHER|FreeStyle Libre|Glucose levels will be measured by the FreeStyle Libre
223870203|NCT03995498|OTHER|SenseWear Armband|Energy expenditure during physical activity sessions will be measured with the SenseWear Armband.
223870204|NCT05862610|DRUG|Trilaciclib plus chemotherapy|Trilaciclib: 240mg/m2 IV d1,within 4h before chemotherapy epirubicin: 100mg/m2 IV d1,Q2W/Q3W (decided by researchers),4 cycles cyclophosphamide:600mg/m2 IV d1,Q2W/Q3W (decided by researchers),4 cycles albumin-bound paclitaxel:100mg/m2 IV d1,8,15,Q3W,4cycles
223870205|NCT05862610|DRUG|Chemotherapy|epirubicin: 100mg/m2 IV d1,Q2W/Q3W (decided by researchers),4 cycles cyclophosphamide:600mg/m2 IV d1,Q2W/Q3W (decided by researchers),4 cycles albumin-bound paclitaxel:100mg/m2 IV d1,8,15,Q3W,4cycles
223870206|NCT03394976|DIAGNOSTIC_TEST|No intervention|No intervention
223870207|NCT01388881|OTHER|Music Education|"The intervention - music classes - will be methodologically and educationally based on the National Curriculum Parameters that were developed in Brazilian in the 80s; the focus here is centered on a modern approach to music education where the traditional process of musical learning is not restricted to the domain of the musical reading (sheet music), but also includes musical improvisation, composition and interpretation. Children will be encouraged to create their own music; perception and identification of the elements of musical language in production activities will be explained to them by means of voice, body, sound materials and tools available. Song lyrics, rhymes and rap will be created using elements of musical language not focused purely on the classical elements/music."
223870208|NCT06323902|PROCEDURE|Pars plana vitrectomy, with or without epiretinal membrane peeling, plus PRGF membrane implantation|In the operating room through pars plana vitrectomy after having completed the complete air exchange, with the help of a Backwash Charles cannula, the PRGF membrane is placed in the macular hole and C3F8 gas is left in the posterior chamber, the first hour in the recumbent position. supine and subsequently face down during the first postoperative week.
223870209|NCT03039361|BEHAVIORAL|Equine Assisted Psychotherapy|Therapist will use Equine Assisted Growth and Learning Association (EAGALA) modeled Equine Assisted Psychotherapy.
224268637|NCT01624272|DEVICE|Threshold® Inspiratory Muscle Trainer (Respironics® Health Scan Inc. Cedar Grove, NJ, USA).|Interval-based program consisting of seven cycles of 2-minutes work and 1-minute rest. The sessions took place 5 times per week over a six-week period for a total of 30 sessions. All participants were familiarized with the breathing exercises over a two-day familiarization period at the beginning of the protocol.
224268638|NCT01624272|OTHER|Yoga Pranayama breathing exercises|Interval-based program. The sessions took place 5 times per week over a six-week period for a total of 30 sessions. All participants were familiarized with the breathing exercises over a two-day familiarization period at the beginning of the protocol.
224268639|NCT02702895|BEHAVIORAL|In-depth Interview (IDIs) or Focus Group Discussion (FGD)|
224268640|NCT00052949|DRUG|imatinib mesylate|Given orally
224268641|NCT00052949|OTHER|laboratory biomarker analysis|Correlative studies
224268642|NCT00088608|DRUG|SOM230 s.c.|
224268643|NCT03300687|DRUG|FX-322|intratympanic injection
224268644|NCT03300687|DRUG|Placebo|intratympanic injection
223870210|NCT00700336|DRUG|pemetrexed, cisplatin and CBP501|"CBP501 25 mg/m2, Pemetrexed 500 mg/m2, cisplatin 75 mg/m2 CBP501 for injection is provided in single dose vials (20 mg) containing a sterile lyophilized powder comprising CBP501 peptide acetate salt (peptide base units). For administration, vial contents are reconstituted in 5% Dextrose Injection, USP, and added to a 100 mL IV bag of 5% Dextrose Injection, USP.~Pemetrexed: A commercial formulation of pemetrexed will be used, with reconstitution in 20mL 0.9% sodium chloride solution for injection, then dilution to 100mL.~Cisplatin: A commercial formulation will be used and will be diluted in 250 mL of normal saline for administration."
223870211|NCT00700336|DRUG|pemetrexed and cisplatin|"Pemetrexed 500 mg/m2, cisplatin 75 mg/m2 Pemetrexed: A commercial formulation of pemetrexed will be used, with reconstitution in 20mL 0.9% sodium chloride solution for injection, then dilution to 100mL.~Cisplatin: A commercial formulation will be used and will be diluted in 250 mL of normal saline for administration."
223870212|NCT00700336|DRUG|pemetrexed, cisplatin and CBP501, dose finding|"Dose level 1: CBP501 16 mg/m2, Pemetrexed 500 mg/m2, cisplatin 75 mg/m2 Dose level 2: CBP501 25 mg/m2, Pemetrexed 500 mg/m2, cisplatin 75 mg/m2 CBP501 for injection is provided in single dose vials (20 mg) containing a sterile lyophilized powder comprising CBP501 peptide acetate salt (peptide base units). For administration, vial contents are reconstituted in 5% Dextrose Injection, USP, and added to a 100 mL IV bag of 5% Dextrose Injection, USP.~Pemetrexed: A commercial formulation of pemetrexed will be used, with reconstitution in 20mL 0.9% sodium chloride solution for injection, then dilution to 100mL.~Cisplatin: A commercial formulation will be used and will be diluted in 250 mL of normal saline for administration."
223870213|NCT00970658|DRUG|Salonsip plaster|The plaster should be applied at the site of injury, which must be clean and dry and changed every 8 hours for a period of 48 hours of treatment (2 days).
223870214|NCT00970658|DRUG|Sabia plaster|The plaster should be applied at the site of injury, which must be clean and dry and changed every 8 hours for a period of 48 hours of treatment (2 days).
223870215|NCT02701257|DEVICE|iPhone bionic pancreas|An experimental device composed of three parts: a continuous glucose monitor, control algorithms running on an iPhone, and drug delivery using Tandem insulin pumps
223870216|NCT02701257|DEVICE|iLet bionic pancreas|An experimental device that combines the functions of the iPhone-based bionic pancreas into one device.
223870217|NCT02701257|DRUG|Xeris Xerisol glucagon|A stabilized formulation of human glucagon in a solvent based primarily composed of dimethyl sulfoxide (DMSO) that has prolonged stability and can be used for multiple days in a pump
223870218|NCT02701257|DRUG|Lilly glucagon|An aqueous formulation of human glucagon with limited stability that must be changed daily
223870219|NCT02701257|DEVICE|iLet infusion set|The infusion set sub-study will be studying the experimental iLet infusion set in a cross-over with the Contact Detach infusion set. These visits will be conducted separately from the iPhone and iLet BP visits.
223870220|NCT02701257|DEVICE|Contact Detach infusion set|The infusion set sub-study will be studying the experimental iLet infusion set in a cross-over with the Contact Detach infusion set. These visits will be conducted separately from the iPhone and iLet BP visits.
223870221|NCT04294329|PROCEDURE|US-guided Quadratus lumborum block.|Performance of quadratus lumborum block using ultrasound machine to relieve pain after bariatric surgery
223870222|NCT04294329|DRUG|Bupivacaine|Bupivacaine
223870223|NCT04294329|DRUG|Saline|normal saline
223870224|NCT04701866|OTHER|Music|Music will be provided via headphones during all 6 ketamine treatments, beginning at the commencement of each infusion and ending 55 minutes later. On the day of each infusion, before the treatment begins, clinicians will discuss music choices with participants in order to select amongst one of several options that have been designed for this purpose (length, genre, intensity, etc.).
223870225|NCT03762213|DEVICE|Oculus GO VR HMD, application Happy Place (© Mimerse)|The Entertainment Software Rating Board (ESRB) has rated Happy Place as 'E' ('Everyone' or content suitable for all ages).
223870226|NCT03762213|DEVICE|iPad, application Happy Place (© Mimerse)|The Entertainment Software Rating Board (ESRB) has rated Happy Place as 'E' ('Everyone' or content suitable for all ages).
224268645|NCT05232487|OTHER|Swiss low back acupuncture (SLBA)|"Participants are placed in the prone position (if required with a pillow under the abdomen). Then acupuncture is applied to the back of the body. The treatment takes place for the duration of 9 weeks (2x per week from week 1 to 6 and 1x a week from week 7 to 9). One treatment session lasts about 50-60 minutes.~Swiss low back pain acupuncture The SLBA method is a further developed method from the Jiu Gong acupuncture technique, also known as the Nine Palace-Points on the spine. The following acupuncture points will be used: LV3/ LV5, Tai Xi (Kl 3), Fe Yang (BL 58), Tai Chong (LR 3), Guang Ming (GB 37), Tai Xi (Kl 3) and Fe Yang (BL 58)."
223870227|NCT03366636|BEHAVIORAL|Project Legacy|"Project Legacy - Project Legacy is a 5-week, twice a week, 10 sessions small group intervention that encourages homeless and at-risk of homeless youth ages 14-19 to imagine a positive future and discuss how current risk behaviors can be a barrier to a successful adulthood. The program includes thinking about the future, the importance of positive social supports, short and long-term goal planning, and decision making. The program also includes life skills building, addressing past and current risk behaviors, linking to resources and navigating service systems, information on contraception and condoms, a healthy life plan and self-sufficiency. The 5 content core elements are the following:~* 1\. Thinking about the future~* 2\. Present actions to achieve future success~* 3\. Safeguarding one's future~* 4\. Creating a Healthy Life Plan~* 5\. Navigating service systems"
223870228|NCT02118675|OTHER|Body Measurements|A series of body measurements will be taken by trained staff. These measurements include height and weight. These measurements will be completed twice during this time. You will wear a hospital gown and bathing suit for these measurements. Your BMI will be calculated from these measurements.
224268646|NCT05232487|OTHER|Standard acupuncture (SA)|Participants are placed in the prone position (if required with a pillow under the abdomen). Then acupuncture is applied to the back of the body. The treatment takes place for the duration of 9 weeks (2x per week from week 1 to 6 and 1x a week from week 7 to 9). One treatment session lasts about 50-60 minutes. The SA method is described in the acupuncture textbook for TCM in China and all acupuncture points are selected based on TCM principles, international literature, and the opinion of national and international TCM experts. The following points have been selected: Ming Men (GV 4), Zhi Shi (BL 52), Tai Xi (KI 3) Yao Guan (GV 3), Guan Yuan Shu (BL 26), Ge Shu (BL 17), Ci Liao (BL 32), Wei Zhong (BL 40), Ji Zhong (GV 6), Yao Yang Guan (GV 3), Shen Shu (BL 23), Da Chang Shu (BL 25) and A-Shi points.
223870229|NCT02118675|OTHER|Body Composition and Circumference measurements|This test is to measure the amount of water in your body. After a fasting urine sample is collected, you will drink a glass of water that has been enriched with an atom called a stable isotope (deuterium). After you drink this non-radioactive heavy water, you will provide urine samples several times over the next 4 hours.
224268647|NCT01533038|DEVICE|UroLift System|The NeoTract UroLift System is a medical device approved for sale in the European Union, Australia, New Zealand, Canada, Serbia, and Turkey. It was developed for the intended use of soft tissue approximation and for the treatment of lower urinary tract symptoms (LUTS) associated with Benign Prostatic Hyperplasia (BPH). During the procedure, an implant is delivered into the prostatic lobe obstructing the urethra and restricting urine flow. The distal end of the device is used to compress the lobe then the implant is delivered to retain the lobe in position, thereby increasing the urethral opening and reducing the fluid obstruction through the prostatic urethra.
224268648|NCT01533038|PROCEDURE|Transurethral Resection of the Prostate|Transurethral Resection of the Prostate (TURP) is a surgical procedure which removes prostatic tissue by electrocautery dissection. During the procedure the tissue at the bladder neck and the adjacent adenoma are resected in quadrants. Resection continues into the midportion of the gland and concludes at the apex. Any remaining residual tissue is cleared, leaving a void from verumontanum to bladder neck.
223870230|NCT02118675|OTHER|Whole Body DXA scan|This scan measures the amount of bone, muscle, and fat in your body. The scan will be performed using a whole-body scanner. You will be required to wear a hospital gown, to remove all metal-containing objects from your body, and to lie down on the table. You will be carefully positioned on the table, and your legs will be placed together using two Velcro straps. A scanner emitting low energy X-rays and a detector will pass along your body. You will be asked to remain completely still while the scan is in progress. The scan takes approximately ten minutes.
223870231|NCT02118675|OTHER|Bioelectrical Impedance Analysis (BIA)|These tests will measure the amount of fat in your body. You will be asked to change into a hospital gown and to remove all footwear and socks/stockings. Once changed and barefoot, you will be asked to stand on a scale (similar to a large gym scale) and to hold on to hand electrodes on each side of the scale. You will be asked to step off of the scale once the measurement is complete (less than one minute). You will repeat this procedure on three different BIA systems.
223870232|NCT02118675|OTHER|BodPod|This test will estimate the amount of fat mass and fat free mass in your body. You will be required to change into a swimsuit and swim cap that we will provide for this procedure. If your swimsuit meets the necessary criteria, you can bring and wear it for the procedure, or PBRC will provide one for you. You will step onto a scale for a quick weight measurement. Next, you will sit inside of the system like you are sitting in a chair. The door of the system will be closed, but you will have a window so that you can see outside of the system while the measurements are completed. The test will be completed in about 15 minutes.
223870233|NCT02118675|OTHER|Circumferences|This test will measure the circumferences of your waist, hip, neck, arms, and legs and the lengths of your forearm, upper arm, thigh, and lower leg. The circumference measurements will be made by a trained observer using a calibrated tape measure and an automated circumference measurement device (KX-16). These measurements will be made in about 30 minutes.
224268649|NCT06292364|OTHER|immediate orthodontic retainer delivery|post orthodontic treatment patients will be given orthodontic retainer immediately after debonding
224268650|NCT06292364|OTHER|delayed orthodontic retainer delivery|post orthodontic treatment patients will be given orthodontic retainer after 7 days of debonding
224268651|NCT00770952|DRUG|Pioglitazone and Glimepiride|"Pioglitazone 30 mg, tablets, orally, once daily and Glimepiride 2 mg, tablets, orally once daily for two weeks; increased to:~Pioglitazone 30 mg, tablets, orally, once daily and Glimepiride 4 mg, tablets, orally, once daily for two weeks; increased to:~Pioglitazone 45 mg, tablets, orally, once daily and Glimepiride 4 mg, orally, once daily for up to 20 weeks."
224268652|NCT00770952|DRUG|Glimepiride|"Pioglitazone placebo-matching tablets, orally, once daily and Glimepiride 4 mg, tablets, orally once daily for two weeks; increased to:~Pioglitazone placebo-matching tablets, orally, once daily and Glimepiride 5 mg, tablets, orally once daily for two weeks; increased to:~Pioglitazone placebo-matching tablets, orally, once daily and Glimepiride 6 mg, tablets, orally once daily for up to 20 weeks."
224268653|NCT00635687|DEVICE|Fibroscan|transient elastography measure - Liver stiffness
224268654|NCT03369132|DEVICE|Angiflash|throat spray (20 ml) containing hypertonic seawater, vegetable glycerin, natural mint, acacia honey, propolis extract, essential oils of thyme linalool, ravintsara and wintergreen, natural lemon flavor.
224268655|NCT03369132|DEVICE|Placebo|water based throat spray matching Angiflash for posology, dispensed volume, shape and size.
224268656|NCT05563207|OTHER|traditional Chinese medicine health education standard path|Both groups of patients were given routine treatment, and were intervened by the same batch of nursing staff.During chemotherapy, the patient's condition was closely observed, patiently listened to the patient's chief complaint, answered their questions, and instructed the patient to follow the doctor's instructions to prevent complications such as infection and bleeding.
224268657|NCT05563207|OTHER|The contents of the health intervention mainly included:Graphic and text education|When the patient was admitted to the hospital, the responsible nurse had a comprehensive understanding of the patient's disease cognition and psychological state, and based on this, an individualized intervention plan was formulated. With the help of publicity boards, brochures and other forms of pictures and texts, to popularize the knowledge and precautions of disease treatment for patients
223870234|NCT02118675|OTHER|Ultrasound|An ultrasound is a procedure that uses sound waves to create a picture of an organ or soft tissue. This test measures the size of your tissue thicknesses for fat and skeletal muscle. For this procedure, you will be asked to raise your shirt, disrobe from the waist up, or change into a hospital gown and lie flat on your back on an examination table, or sit on a chair, or stand for measuring your leg dimensions. A gel will be spread on the ultrasound probe, and the probe will be applied directly to the skin on your arms, legs, and abdomen. You will feel slight pressure when the probe is applied. The entire procedure will take approximately 30 minutes.
223870235|NCT02190578|DEVICE|Reveal G4|All subjects tested with the investigational device, Reveal G4, plus with an algorithm of approved assays for HIV.
223870236|NCT02487927|BEHAVIORAL|weaning|T piece
223870237|NCT02147054|DRUG|Rocuronium|
223870238|NCT02147054|DRUG|Sugammadex|Effect of Rocuronium will be reversed at the appropriate time using Sugammadex 16mg/kg as a single dose which may be repeated once.
223870239|NCT00765271|DRUG|Abacavir|"Group 1 will be instructed to take • Abacavir 600 mg once daily (two 300 mg tablets once daily) as part of regular treatment throughout the whole study~Group 2 will be instructed to take~• Abacavir 600 mg once daily (two 300 mg tablets once daily) as part of regular treatment throughout the whole study"
224268658|NCT05563207|OTHER|The contents of the health intervention mainly included:Language education|adopt one-to-one method to inform patients of the principles, effects and precautions of chemotherapy, eliminate patients' misunderstandings, and repeat language education for many times during the treatment process to strengthen patients' memory
224268659|NCT05563207|OTHER|The contents of the health intervention mainly included:Psychological education|guide patients to express their own emotions, according to the patient's personality, cultural background, etc., after communicating with family members and negotiating, selectively inform the patient's actual condition
224268660|NCT05563207|OTHER|The contents of the health intervention mainly included:Dietary education|instruct patients to follow the principles of light, easy to digest and balanced nutrition
224268661|NCT05563207|OTHER|The contents of the health intervention mainly included:Complication education|Actively inform patients about complications in advance, and guide their prevention methods, such as increasing water intake, avoiding activities of affected limbs after chemotherapy, etc. Patients with vomiting, hair loss and other adverse reactions are prone to negative emotions such as anxiety and depression , timely take corresponding measures and appease the patient, inform them that it is a normal phenomenon, and guide them to maintain a good attitude.
224268662|NCT03324815|DRUG|Morphine|Pain Treatment
224268663|NCT03324815|DRUG|Methadone|Pain Treatment
224268664|NCT05118607|DEVICE|IG1|application of low intensity transcutaneous penile electrical stimulation for 45 minutes using frequency.
224268665|NCT02119637|DEVICE|Transcranial magnetic stimulation (TMS)|1 Hz rTMS for 20 minutes. TMS sessions were separated by at least 24 hours.
224268666|NCT02119637|DEVICE|MRI|Anatomical MRI, resting state MRI and functional MRI using gentle brushing and finger movement
224268667|NCT03576053|DRUG|Lidocaine|Lidocaine intradermal injection
224268668|NCT03576053|OTHER|Histamine|Skin Prick Test with Histamine
224268669|NCT03576053|OTHER|Cowhage|Manually skin insertion of cowhage spicules
224268670|NCT03576053|OTHER|Heat stimulation|Short heat stimulation
224268671|NCT03576053|OTHER|Pre-heating|Mild skin pre-heating
224268672|NCT03576053|OTHER|Serotonin|Serotonin electrophoresis
224268673|NCT00051805|BEHAVIORAL|Promotion of adherence to ARV medications|
224268674|NCT04020445|OTHER|de-escalation of complex insulin regimens|complex insulin regimens are switched to fix ratio combinations consisting of of a basal insulin and a GLP-1 (glucagon-like peptide-1) receptor agonist
224268675|NCT04507698|OTHER|Intensive Exercise Intervention|INTense Exercise foR surVivAL among Men with Metastatic Castrate-Resistant Prostate Cancer (INTERVAL - MCRPC), randomised to either the supervised exercise arm or the self-directed exercise arm.
224268676|NCT00537095|DRUG|Vandetanib|300 mg oral once daily oral dose
224268677|NCT00537095|OTHER|Placebo|
224268678|NCT00349765|BEHAVIORAL|higher fat, high polyunsaturated fat diet|
224268679|NCT00349765|BEHAVIORAL|higher fat, high saturated and trans fat diet|
224268680|NCT00349765|BEHAVIORAL|lower fat diet|
224268681|NCT03201276|DRUG|Glucosamine Sulfate|Patients taking glucosamine sulfate 1500mg every day for at least four days.
224268682|NCT00822887|DRUG|Vandetanib|Dose level 1:100 mg qd Dose level 2:200 mg qd Dose level 3:300 mg qd
224268683|NCT00822887|RADIATION|Fractionated Stereotactic Radiotherapy|All patients will receive 36 Gy of radiation in three fractions, given in three consecutive days.
224268684|NCT00566722|BIOLOGICAL|adalimumab|Participants received an 80 mg adalimumab loading dose by subcutaneous injection at Baseline (Week 0). From Week 1 to Week 15, participants received 40 mg adalimumab by subcutaneous injection every other week.
224268685|NCT01875107|DRUG|insulin pre-treatment|insulin pre-treatment of pregnant diabetic patients who receive betamethasone
224268686|NCT00799162|OTHER|Psychophysical testing, questionnaires, and genetics|pre-operative psychophysical testing of endogenous pain modulation, pre-operative questionnaires, peri- and post-operative data collection, long term follow-up assessing chronic pain, SNP association analysis, and whole genome scanning association studies
224268687|NCT02010034|DRUG|Omegaven|Omegaven will be used in place of soy oil Intralipid
224268688|NCT00380796|DRUG|Collection of safety data for Cohort 1|Twice-yearly collection of information about cancer incidence and cause of death among patients who participated in clinical trials of infliximab in the treatment of COPD. The follow-up period is 5 years.
224268689|NCT02246296|DIETARY_SUPPLEMENT|Standard F75 Milk|This is the standard F75 milk used worldwide (Control group)
224268690|NCT02246296|DIETARY_SUPPLEMENT|Modified F75 Milk|This is the experimental group
224268691|NCT03667963|OTHER|Glucose|50g glucose dissolved in 250ml water
224268692|NCT03667963|OTHER|Glucose plus lactulose|50g glucose plus 10g lactulose dissolved in 250ml water
224268693|NCT03667963|OTHER|Hot Rice|Freshly cooked polished rice containing 50g available carbohydrate (approximately 2/3 cup cooked rice) and consumed hot.
224268694|NCT03667963|OTHER|Cold Rice|Cooked polished rice containing 50g available carbohydrate (approximately 2/3 cup cooked rice) cooled overnight in a refrigerator and consumed cold.
223870240|NCT00765271|DRUG|Darunavir/ritonavir|"Group 1 will be instructed to take~• Three 300mg Darunavir tablets and one 100mg ritonavir tablet once a day for 14 days (on days 2 - 15)"
223870241|NCT00765271|DRUG|Raltegravir|"Group 1 will be instructed to take • Two 200mg Raltegravir tablets twice daily for 14 days (on 16 - 29)~Group 2 will be instructed to take~• Two 200mg Raltegravir tablets twice daily for 14 days (on days 2-15)"
224268695|NCT03545334|DIAGNOSTIC_TEST|Visionsense™ VS3 - Stereoscopic High Definition Visualisation System (VS3-3DHD)|Injection of ICG intradermally around the scar of the primary excision of the tumour and transcutaneous assessment of fluorescence with the VS3-3DHD camera (Visionsense™ VS3 - Stereoscopic High Definition Visualisation System ).
224268696|NCT04350697|PROCEDURE|Aortic Surgery|Surgery for aortic and/or aortic valve diseases
224268697|NCT00838188|OTHER|Way of Feeding - Breast feeding vs. Bottle feeding|Each infant was evaluated twice, once after breastfeeding and once after bottle feeding of breast. Computer-generated random numbers in sealed opaque envelopes to assign the breast/bottle sequence
224268698|NCT04674072|OTHER|Reverse Nordic curl exercise|The reverse Nordic curl is a body-weight exercise which mainly works the quadriceps and hip flexors. It has a large eccentric component, meaning the muscles are working whilst lengthening.
224268699|NCT04674072|OTHER|Usual warm up|Usual warm up is defined as any basic exercises performed before a performance or practice to prepare the muscles for vigorous actions.
224268700|NCT02611323|DRUG|Obinutuzumab|Participants will receive a fixed dose of obinutuzumab, 1000 milligrams (mg) via intravenous (IV) infusion to be given on Days 1, 8 and 15 of Cycle 1 and on Day 1 of Cycles 2 to 6. Cycle length will be 21 days. For eligible participants, post-induction treatment may be given at a dose of 1000 mg via IV infusion on Day 1 of every other month (starting from Month 2) for up to 24 months, until disease progression or unacceptable toxicity.
224268701|NCT02611323|DRUG|Rituximab|Participants will receive a fixed dose of rituximab, 375 milligrams per square meter (mg/m\^2) via IV infusion to be given on Day 1 of Cycles 1 to 6. Cycle length will be 21 days. For eligible participants, post-induction treatment may be given at a dose of 375 mg/m\^2 via IV infusion on Day 1 of every other month (starting from Month 2) for up to 8 months, until disease progression or unacceptable toxicity.
224268702|NCT02611323|DRUG|Polatuzumab Vedotin|Participants will receive polatuzumab vedotin via IV infusion at doses of 1.4 or 1.8 milligrams per kilogram (mg/kg) (for FL), and 1.8 mg/kg (for DLBCL) on Day 1 of each 21-day cycle for up to 18 weeks during induction treatment. Polatuzumab vedotin will not be given during the post-induction period.
224268703|NCT02611323|DRUG|Venetoclax|Participants will receive venetoclax film-coated tablets at doses of 200, 400, 600, or 800 mg (for FL), and 400, 600, or 800 mg (for DLBCL) on Days 1 to 21 of each 21-day cycle. Post-induction venetoclax may continue for up to 8 months, until disease progression or unacceptable toxicity.
224268704|NCT01158313|DIETARY_SUPPLEMENT|Thickened supplement|New thickener to be mixed to liquid to obtain different viscosities such as nectar viscosity, honey viscosity, conservative spoon-thick viscosity (CST) and extreme spoon-thick viscosity (EST
224268705|NCT03676790|OTHER|Group I|"Group I In the first month, continuous ultrasound was applied three times a week. In the second month, patients performed only exercise sessions three times a week. In the ultrasound treatment, the following parameters were used: frequency of 1 MHz, intensity of 1.5 W/cm2 (temporal and spatial mean SATA), duty cycle of 100%, with application time of 5 minutes on the medial side and 5 minutes on lateral side of knee.~Exercises~The intervention was divided into three phases: P-1, P-2 and P-3 during eight weeks with three sessions a week. Each session lasted 45 minutes:~* 10 minutes warming-up (treadmill, ergometer bike or rowing machine);~* 30 minutes 2-3 sets with P-1, P-2 or P-3;~* 5 minutes stretching (hamstrings, quadriceps, adductors, and gastrocmenius)."
224268706|NCT03676790|OTHER|Group II|"Group II In the first month, pulsed ultrasound was applied three times a week. In the second month, patients performed only exercise sessions three times a week. In the treatment with the US, the following parameters were used: 1 MHz frequency, 2.5 w / cm2 intensity (temporal and spatial mean SATA), pulsed mode (25%), 5 minutes on the medial side and 5 minutes on the lateral side of the knee.~Exercises~The intervention was divided into three phases: P-1, P-2 and P-3 during eight weeks with three sessions a week. Each session lasted 45 minutes:~* 10 minutes warming-up (treadmill, ergometer bike or rowing machine);~* 30 minutes 2-3 sets with P-1, P-2 or P-3;~* 5 minutes stretching (hamstrings, quadriceps, adductors, and gastrocmenius)."
224268707|NCT03676790|OTHER|Group III|"Group III In the first month, the continuous ultrasound was applied 3 times a week. In the second month, 3 times a week, the continuous ultrasound was applied associated with exercises. The parameters were used: frequency of 1 MHz, intensity of 1.5 w / cm2 (temporal and spatial mean SATA), continuous mode (100%), with application time of 5 minutes on the medial side and 5 minutes on lateral side of knee.~Exercises~The intervention was divided into three phases: P-1, P-2 and P-3 during eight weeks with three sessions a week. Each session lasted 45 minutes:~* 10 minutes warming-up (treadmill, ergometer bike or rowing machine);~* 30 minutes 2-3 sets with P-1, P-2 or P-3;~* 5 minutes stretching (hamstrings, quadriceps, adductors, and gastrocmenius)."
224268708|NCT03676790|OTHER|Group IV|"Group IV In the first month, the pulsed ultrasound was applied three times a week. In the second month, three times a week, the pulsed ultrasound associated with exercises was applied. In the treatment with the US, the following parameters were used: 1 MHz frequency, 2.5 w / cm2 intensity (temporal and spatial mean SATA), pulsed mode (25%), 5 minutes on the medial side and 5 Minutes on the lateral side of the knee.~Exercises~The intervention was divided into three phases: P-1, P-2 and P-3 during eight weeks with three sessions a week. Each session lasted 45 minutes:~* 10 minutes warming-up (treadmill, ergometer bike or rowing machine);~* 30 minutes 2-3 sets with P-1, P-2 or P-3;~* 5 minutes stretching (hamstrings, quadriceps, adductors, and gastrocmenius)."
224268709|NCT03676790|OTHER|Group V|"Group V Patients received only exercise sessions three times a week for two months.~Exercises~The intervention was divided into three phases: P-1, P-2 and P-3 during eight weeks with three sessions a week. Each session lasted 45 minutes:~* 10 minutes warming-up (treadmill, ergometer bike or rowing machine);~* 30 minutes 2-3 sets with P-1, P-2 or P-3;~* 5 minutes stretching (hamstrings, quadriceps, adductors, and gastrocmenius)."
224268710|NCT03853187|RADIATION|Zr-89 labelled durvalumab PET/CT|Patients will undergo a Zr-89 labelled durvalumab (MEDI4736) PET/CT and dedicated perfusion-CT prior to treatment with durvalumab (MEDI4736) and in- and ex-vivo In-111-oxine or in-vivo \[89zr\]-Df-crefmirlimab labelled CD8+ T-cells after two courses of treatment, prior to surgery.
223870242|NCT01735019|DRUG|Administration of remifentanil with TCI system|A given effect site concentration of remifentanil would be administered to subjects using TCI system. According to biased coin design, the given concentration of remifentanil is determined according to success or failure of just previously enrolled patient. If the former patient did not cough during anesthetic emergence at a given concentration (success), the next patient will be randomly allocated into the same concentration of remifentanil with 18/19 of probability or the lower concentration of remifentanil by 0.4 ng/ml with 1/19 of probability. If the former patient coughed during anesthetic emergence (failure), the next will be automatically allocated into the higher concentration of remifentanil by 0.4 ng/ml.
223870243|NCT01047852|PROCEDURE|Noninvasive ventilation|NIV will be delivered using a sequential mode (a minimum of 1 hour every 3 hours) immediately after extubation for a schedule period of 48 h after extubation. In between NIV courses ((NIV-free periods) O2 will be administered through nasal cannula in order to obtain a SaO2 ≥ 90%. Afterward, NIV will be withdraw and oxygen will be administered by nasal cannula
223870244|NCT02024685|BEHAVIORAL|Personalized Treatment Recommendations|This is a psychosocial/behavioral study. It will use a randomized trial to test the hypothesis that a decision analysis model that provides individualized estimates of quality-adjusted disease-free survival for each of the treatment options for clinically localized prostate cancer will lead to higher quality treatment decisions congruent with a patient's values leading to improved decisional regret and treatment satisfaction. In this trial, all patients would be evaluated at baseline for their utilities for various clinically important health states. The primary endpoint of this study will be regret-free survival at 2 years after treatment. There will be a 1:1 randomization. A random permuted design will be used to assure approximate balanced number of patients in the two groups over time.
223870245|NCT02024685|BEHAVIORAL|Standard patient-physician counseling interaction|Both patients and physicians will be unaware of the decision analysis recommendation and the patients will receive standard treatment counseling alone. After the patient has made a treatment decision he will be given a short questionnaire to assess decisional conflict. If after one month no treatment decision information is available, a letter and form requesting treatment information along with the decisional conflict questionnaire will be sent to patients.
223870246|NCT03187860|PROCEDURE|Bronchial Biopsy|Bronchial biopsies will be performed on all subjects.
223870247|NCT03187860|OTHER|ALI culture|Air-liquid-interface cell cultures will be derived from bronchial biopsy specimens. We are expecting several replicate cell lines from each biopsy specimen.
223870248|NCT01524952|DEVICE|combined thermal and electrical muscle stimulation (cTEMS)|cTEMS in three 60-minute sessions per week for 8 weeks
223870249|NCT02738320|OTHER|NHCPlus|A decision-aid tool that will interface with Nursing Home Compare and improve consumers' ability to assimilate and incorporate the information into their process of choosing a nursing home.
223870250|NCT04578496|DRUG|Afamelanotide|
223870251|NCT04600440|BIOLOGICAL|Convalescent plasma|Plasma donated from patients recovered from Covid-19 and having high titres of antibodies
223870252|NCT06027489|BEHAVIORAL|Music|In the second and third months, participants listened to a song that lasted 29 minutes and 32 seconds for four days (three days before menstruation and the first day of menstruation). The song to be played was determined by examining the literature, the song was composed by researcher Juan Sebastian Martin-Saavedra and was named Occasio Adolore (Music Piece No. 5-559-355 and Phonogram No. 12-105-295) by the author copyright institution of Colombia. registered under. While the researcher is composing the song, it is to create a piece of music that will reduce the pain felt, activate positive emotions and relax the person. The composed song is available online within the scope of the published article (https://soundcloud.com/jss-martin/occasio-adolore).
224268711|NCT03853187|DRUG|Durvalumab (MEDI4736)|Patients will receive two courses of durvalumab (MEDI4736)at a fixed dose of 750mg Q2W intravenously, prior to scheduled resection of NSCLC.
224268712|NCT00748787|DRUG|Ispaghula husk|1 sachet of effervescent powder containing 5 gr of product (3.5 g of Ispaghula husk), b.i.d. during 16 weeks. Oral route.
224268713|NCT00748787|DRUG|Placebo|1 sachet of effervescent powder b.i.d. during 16 weeks, oral route.
224268714|NCT05119049|OTHER|Exercise guideline|The experimental group underwent 20 sessions with an aquatic exercise plan in the pool at the rehabilitation department. The control group did the same exercises in one of the rooms in the rehabilitation department, with the same number of sessions. Both groups were guided by a physiotherapist. The main outcome variables were assessed at the start of the study, at the end of the 20 sessions, and at 3 months after completing the sessions.
224268715|NCT02597049|DRUG|Dulaglutide|Administered SC
224268716|NCT02597049|DRUG|Placebo|Administered SC
224268717|NCT02597049|DRUG|SGLT2 inhibitor|Administered orally as standard of care for type 2 diabetes
224268718|NCT02597049|DRUG|Metformin|Administered orally as standard of care for type 2 diabetes
224268719|NCT04305470|DRUG|Gleolan (Aminolevulinic Acid Hydrochloride/ALA/ALA-HCI)|One time oral dose on day of surgery (20 mg/kg bodyweight)
224268720|NCT01613937|BEHAVIORAL|Dulce Mother lifestyle training program|12 once weekly culturally tailored lifestyle management sessions
224268721|NCT04021407|DEVICE|LMA group|patients were ventilated with LMA
224268722|NCT04021407|DEVICE|AirQ group|patients were ventilated with AirQ airway
224268723|NCT02463487|DEVICE|Cardinal Pro +Simultaneous Irrigation (NPWTi)|NPWT with low volume irrigation (15 cc/hr) with 1% polyhexanide biguanide (PHMB), Prontosan®
224268724|NCT02463487|DEVICE|Cardinal Pro (NPWT) Therapy|NPWT 125 mm Hg continuous pressure with foam interface
224268725|NCT00243347|DRUG|AZD2171|oral tablet
224268726|NCT03124758|DEVICE|Hemoglobin Sensor ((Rainbow Reusable DCI, DCIP))|Measurement of Noninvasive Hemoglobin (SpHb)
224268727|NCT02709057|BEHAVIORAL|Lifestyle intervention|Life-style intervention includes 7-9 group sessions (two additional group sessions for participants whose body mass index exceeds 28 kg/m2) on diet (healthy diet according to Nordic and Finnish nutrition recommendations emphasizing appropriate energy intake, meal frequency, consumption of fruits, vegetables and berries, quality of dietary fat and carbohydrates, including sugar and fiber intake) and physical exercise (brisk walking a minimum of 30 minutes per day at least five days a week or other types of exercise, e.g. cycling, cross-country skiing, housework such as leafs raking, resistance training).
224268728|NCT01167335|DRUG|BGG492|
224268729|NCT01167335|DRUG|Placebo|
224268730|NCT02671058|DRUG|Cortenema|Hydrocortisone Administered as a Liquid Enema
224268731|NCT02671058|DRUG|Hydrocortisone Acetate|Hydrocortisone Acetate Administered as a Suppository with the Sephure® Rectal Suppository Applicator
224268732|NCT02193022|DRUG|Miltefosine|
224268733|NCT04738864|DIAGNOSTIC_TEST|ultrasound|extracranial and intracranial ultrasound assessment
224268734|NCT01939535|OTHER|No intervention|Evaluation of an imaging technique ic MRI
224268735|NCT03649763|DRUG|Lidocaine|lidocaine 1%, distal ( ulnar and medial nerve): 6ml/nerve , 12m total
224268736|NCT03649763|DRUG|Bupivacaine|Bupivacaine 0.5%,distal ( ulnar and medial nerve): 6ml/nerve , 12m total
224268737|NCT03649763|DRUG|Lidocaine|lidocaine 1%, distal and proximal ( ulnar and medial nerve): 3ml/nerve , 12m total
224268738|NCT03329209|DRUG|Vedolizumab|Vedolizumab intravenous infusion.
224268739|NCT01899053|DRUG|TAK-228|TAK-228 Capsules
224268740|NCT01899053|DRUG|TAK-117|TAK-117 Capsules
224268741|NCT00471094|DRUG|Ilaprazole|Ilaprazole 5 mg, capsules, orally, once daily for up to 8 weeks.
224268742|NCT00471094|DRUG|Ilaprazole|Ilaprazole 20 mg, capsules, orally, once daily for up to 8 weeks.
224268743|NCT00471094|DRUG|Ilaprazole|Ilaprazole 40 mg, capsules, orally, once daily for up to 8 weeks.
224268744|NCT00471094|DRUG|Lansoprazole|Lansoprazole 30 mg, capsules, orally, once daily for up to 8 weeks.
224268745|NCT03105297|DEVICE|Prototype nasal dilator strip|External Prototype Nasal Dilator strip. GSK prototype nasal dilator AB 2R11. All the participants used nasal dilator strip throughout the active phase of the study (Day 1 to Day 28). Followed by that all the participants used the nasal strip on Day 29 or 30 in Nasal resistance phase of the study as per their randomization sequence.
224268746|NCT03105297|OTHER|No strip|
224268747|NCT04139941|DIAGNOSTIC_TEST|Test for HCV antibodies with an RDT|Fingerstick whole blood, plasma and serum of each participant is tested with three investigational HCV RDTs and one reference HCV RDT. Plasma is also used for testing with the composite reference standard, HCV viral load and genotyping. All participants are also tested for HIV with an HIV RDT.
224268748|NCT06678386|BEHAVIORAL|50% sugar reduction|Participants were advised by a dietitian to reduce their daily caloric intake from sugars by 50% for 12 weeks.
223870253|NCT06027489|BEHAVIORAL|Drawing Group|: In the second and third months, the participants will be asked to paint for 29 minutes and 32 seconds (the duration of the intervention was determined in parallel with the music group in order not to create variability between the groups) for four days (three days before menstruation and the first day of menstruation). The type of paint to be used in the drawn picture (dry pen, crayon or watercolor) is left to the availability of the participants, and it will be stated that they prefer colors and drawings that will raise their emotions, focus their drawings and feed positive emotions in the picture to be drawn.
223870254|NCT05357469|DEVICE|Immediate St (Scrambler Therapy)|Participant will receive Scrambler Therapy one (1) time a day, Monday through Friday, for up to 2 weeks (a total of 10 ST treatments).
223870255|NCT05357469|DEVICE|Waitlist ST (Scrambler Therapy)|Participant will receive Scrambler Therapy one (1) time a day, Monday through Friday, for up to 2 weeks (a total of 10 ST treatments).
223870256|NCT03244046|BEHAVIORAL|Psychotherapy|The SE intervention followed the nine-step model as outlined by Peter Levine (2010) and involved gradually eliciting awareness of body sensations associated with the traumatic event. By the process of 'titration', patients were gradually encouraged to access somatic activation, feelings and body sensations as means to restore equilibrium to the autonomic nervous system and thereby alleviate hyperarousal, re-experiencing and avoidance of trauma-related experiences and thoughts.
224268749|NCT02976064|BEHAVIORAL|PreHabilitation|"1. Case identification: Candidates fulfilling the inclusion criteria will be identified by the anesthesiologist.~2. Case evaluation: Candidates will be assessed to identify the overall needs and perform a baseline evaluation.~3. Personalized Work plan definition: Personalization of the plan involves a calendar and planning of face to face visits and remote contacts; intensity of the supervised exercise training program; threshold of steps per day; nutritional intervention; psychological intervention; and integration of the intervention into the overall work plan.~4. Work plan execution \& 5-Follow-up+event handling: Involve the follow-up tasks, including non-scheduled interactions through the personal health folder (PHF)~6-Discharge: Patient will be discharged from prehabilitation and moved to rehabilitation."
223870257|NCT03244046|BEHAVIORAL|Physiotherapy|This treatment consisted of supervised exercises for low back pain delivered in 12 sessions and performed by physiotherapists in the center according to the European guidelines for the management of chronic low back pain (Airaksinen, et al., 2006).
223870258|NCT00150241|DRUG|CP-526,555 (varenicline)|
224268750|NCT02976064|BEHAVIORAL|Rehabilitation in chronic stable patients in primary care|"1. Case identification: Candidates fulfilling the inclusion criteria will be identified by the general practitioner.~2. Case evaluation: The primary care team will characterize the candidates, covering: i) patient requirements defining the work plan; ii) aerobic capacity and physical activity; iii) identification of factors modulating adherence.~3. Personalized work plan definition: The community-based intervention will include reassessment of the patient's work plan aiming at optimization of both pharmacological and non-pharmacological therapies. Consist of a motivational interview and a physical activity (PA) intervention (6-month duration) based on supervised endurance training, promotion of PA and empowerment for self-management using the PHF.~4. Work plan execution \& 5-Follow-up+event handling: The ICT-support will facilitate the program follow up.~6-Discharge: The patient will be discharged or moved to the PA service addressed to citizens at risk \& patients with mild disease."
224268751|NCT02976064|BEHAVIORAL|Rehabilitation in mild chronic patients and citizens at risk|"1. Case identification: Candidates fulfilling the inclusion criteria will be identified by the GP.~2. Case evaluation: i) patient requirements defining the work plan; ii) aerobic capacity and PA; iii) identification of factors modulating adherence.~3. Personalized work plan definition: i) motivational interview; ii) training for the use of the PHF for self-management; and iii) assign one case manager for off-line remote surveillance. The following optional modules are envisaged: i) basic service (above); ii) endurance training programs; iii) community physical activity group sessions; and/or, iv) upgraded PA program including sensors and close off-line supervision.~4. Work plan execution \& 5-Follow-up+event handling: The ICT-support will facilitate the program follow up.~6-Discharge: The basic version of the promotion of PA program is conceived for a timeless duration. However, the different modules included in the service portfolio will have specific agendas and associated costs."
224268752|NCT00842816|DRUG|ST101|10 mg; administered once/day
224268753|NCT00842816|DRUG|ST101|60 mg; administered once/day
224268754|NCT00842816|DRUG|ST101|120 mg; administered once/day
224268755|NCT00842816|DRUG|Placebo|placebo tablets to match ST101 tablets
224268756|NCT03968016|DEVICE|SYSMEX HLSCL|Diagnostic device
224268757|NCT01390948|DRUG|Bevacizumab|10 milligrams per kilogram every 2 weeks during the study for up to 12 cycles, each cycle length of 28 days
224268758|NCT01390948|RADIATION|Radiotherapy|Total dose of 54 Grey (Gy) units delivered in 30 daily fractions of 1.8 Gy over 6 weeks during the chemoradiation phase.
224268759|NCT01390948|DRUG|Temozolomide (TMZ)|75 milligrams per square meter (mg/m\^2) daily continuous starting concomitantly with the first radiation fraction and ending with the last radiation fraction for a maximum number of treatment days = 49 days. During the TMZ adjuvant treatment phase and for participants from YPC: TMZ (150 to 200 mg/m\^2/day) x 12 cycles, 1st cycle 150 mg/m\^2/days 1-5, escalated to 200 mg/m\^2 on Days 1-5 from Cycle 2 onwards depending on the tolerance during the 1st cycle. Cycle length = 28 days.
224268760|NCT01910831|DRUG|DerMend Moisturizing Bruise Formula|DerMend Moisturizing Bruise Formula, a skin care cream containing a proprietary blend of retinol, ceramides, arnica oil, and alpha hydroxy acids and other ingredients.
224268761|NCT01910831|DRUG|Non-active placebo control|Non-active placebo control
224268762|NCT02979041|BEHAVIORAL|Interactive virtual reality training|"The proposed VR intervention program will provide active training to be performed individually 4 times a week for 20 minutes a session.~The intervention program will be supervised by qualified, experienced physiotherapists, and will include individual training and two follow up meetings during the study period. The intervention program will include strengthening and endurance exercises for the cervical and shoulder girdle muscles. Training will include sensorimotor control and functional, quick, accurate, neck motion, using interactive VR training systems. This type of advanced training is very relevant to the pilots function in the cockpit as it includes interactive tasks aimed to increase range, speed, smoothness, accuracy, and control of cervical motion."
224268763|NCT02979041|OTHER|Standard Care|physiotherapy and medical care as provided currently
224268764|NCT01007019|DRUG|YH4808 30mg|YH4808 30mg (single dose)
224268765|NCT01007019|DRUG|YH4808 50mg|YH4808 50mg (single dose)
224268766|NCT01007019|DRUG|YH4808 100mg|YH4808 100mg (single dose)
224268767|NCT01007019|DRUG|YH4808 200mg|YH4808 200mg (single dose)
224268768|NCT01007019|DRUG|YH4808|YH4808 400mg (single dose)
224268769|NCT01007019|DRUG|YH4808 100mg (repeat dose)|YH4808 100mg (repeat dose)
224268770|NCT01007019|DRUG|YH4808 200mg (repeat dose)|YH4808 200mg (repeat dose)
224268771|NCT01007019|DRUG|YH4808 600mg|YH4808 600mg
224268772|NCT01007019|DRUG|YH4808 800mg (single dose)|YH4808 800mg (single dose)
224268773|NCT01007019|DRUG|YH4808 400 mg (repeat doses)|YH4808 400 mg (repeat doses)
224268774|NCT01007019|DRUG|Placebo|10 volunteers will be administered matched placebo.
224268775|NCT01007019|DRUG|Esomeprazole 40mg|24 volunteers will be administered Esomeprazole 40mg
224268776|NCT06346106|GENETIC|Male Rett|This study does not have an intervention. Participants of this study must be parents or caregivers to boys with Rett syndrome.
224268777|NCT03935737|DIAGNOSTIC_TEST|Full Dose Chest X-Ray|Full dose X ray at Day 1
224268778|NCT03935737|DIAGNOSTIC_TEST|Low Dose Chest X-Ray|Low dose X ray within 3 months from full dose
224268779|NCT02117505|DRUG|Formulation 2|Single-dose of JNJ-54781532 formulation 2 will be administered as 150 milligram (mg) oral tablet in one of the treatment periods.
224268780|NCT02117505|DRUG|Formulation 1|Single-dose of JNJ-54781532 formulation 1 will be administered as 150 milligram (mg) oral tablet (5\*30 mg tablet=150 mg) in one of the treatment periods.
224268781|NCT01487629|DRUG|Bevacizumab|Bevacizumab, 1.5 mg, intravitreal, throughout the study
224268782|NCT01487629|DRUG|Ranibizumab|Ranibizumab, 0.5 mg, intravitreal, throughout the study
223870259|NCT02918071|BIOLOGICAL|Benralizumab|Benralizumab administered subcutaneously every 4 weeks
223870260|NCT00174434|DRUG|SU011248|SU011248 provided as capsules. The starting dose is 25 mg orally, daily in a continuous regimen beginning on day 2. Dose rest for 1 week is allowed. Dose escalation to 37.5 mg po OD is allowed within the constraints of acceptable toxicity parameters. Dosing will continue for 1 year or until disease progression or unacceptable toxicity, whichever comes first.
223870261|NCT00174434|DRUG|Paclitaxel|Paclitaxel is provided as an intravenous infusion for 1 hour weekly for 3 weeks followed by a 1-week rest. The starting dose is 90 mg/m2. The weekly dose may be decreased to 65 mg/m2 in subsequent cycles based on tolerability. Dosing will continue for 1 year or until maximum benefit, disease progression or unacceptable toxicity, whichever comes first.
223870262|NCT00253734|BIOLOGICAL|Fluzone® (IM)|15, 9, 6, or 3 mcg of standard trivalent inactivated influenza vaccine (TIV) administered by the standard intramuscular route.
223870263|NCT00253734|BIOLOGICAL|Fluzone®|9, 6, or 3 mcg of standard trivalent inactivated influenza vaccine (TIV) administered by intradermal route (Mantoux technique).
223870264|NCT06075212|DRUG|blinatumomab|The dose of one course was as follows: day 1-2: 8ug/day, continuous intravenous drip for 24 hours, day 3-7: 16ug/day, continuous intravenous drip for 24 hours. Treatment with blinatumomab was initiated within 60 to 90 days after transplantation and was administered bimonthly until 1 year after transplantation. Dexamethasone 20mg was administered 1 hour before administration on days 1 and 3 to prevent adverse events.
223870265|NCT02834598|DEVICE|high-density electroencephalography|Cerebral measurements from high-density electroencephalography while standard and deviant sounds are presented to the participant.
223870266|NCT04916145|DEVICE|SAT-008|SAT-008 is a digital device containing several types of activities related to the immune function of adults.
223870267|NCT02094807|DRUG|NSAID|Will be used if other drugs are not tolerated.
223870268|NCT02094807|PROCEDURE|thoracic epidural anesthesia|Continous epidural anesthesia will be introduced by specialists in Anesthesia and Intensive care.
223870269|NCT02094807|DRUG|opioids|During firs 24 hours i.v will be used. Then slow releas tabletts will be preferred.
223870270|NCT02094807|DRUG|paracetamol|100mg x 4 i.v. during the first 24 hours. Then orally 100mg x 4.
223870271|NCT02094807|PROCEDURE|operative fixation of rib fractures|Fractures will be stabilized on the outside of of the ribs.
223870272|NCT02697877|DRUG|Regadenoson|
223870273|NCT04255290|OTHER|Leg Squat Lounge|The players assigned to the experimental group will receive an intervention through plyometric and eccentric hamstring exercises
223870274|NCT04255290|OTHER|Control group|The subjects included in the control group will perform an eccentric work protocol
223870275|NCT01550549|DRUG|florbetapir F 18|No study drug will be administered in this study - scans previously acquired in in Study A05(NCT00702143) and A07(NCT00857415) will be read
223870276|NCT06366984|OTHER|plastibell|plastibell used for circumcision
223870277|NCT06366984|OTHER|open method|open method used for circumcision
223870278|NCT05308056|DEVICE|Depth of anesthesia monitor, SedLine® (Masimo, Irvine, CA, USA)|The device monitors the patient's electroencephalogram using electrodes applied to the forehead.
223870279|NCT00203411|DRUG|Capecitabine (Xeloda)|1000mg/m\^2 administered orally twice daily for two weeks followed by one week rest period
223870280|NCT00203411|DRUG|Bevacizumab|7.5 mg/kg IV will be administered every 3 weeks
223870281|NCT01212991|DRUG|Enzalutamide|Participants received enzalutamide 160 mg, administered as four 40-mg capsules, once per day by mouth. Study drug treatment continued until disease progression (evidence of radiographic progression, a skeletal-related event, or clinical progression) and the initiation of a cytotoxic chemotherapy or an investigational agent, unacceptable toxicity, or withdrawal.
223870282|NCT01212991|DRUG|Placebo|Participants received placebo, administered as four capsules, once per day by mouth. Study drug treatment continued until disease progression (evidence of radiographic progression, a skeletal-related event, or clinical progression) and the initiation of a cytotoxic chemotherapy or an investigational agent, unacceptable toxicity, or withdrawal.
223870283|NCT04616911|PROCEDURE|Rerouting seton|Excision of superficial fistula tract and placment of seton with rerouting of the fistula tract around the internal anal sphincter
223870284|NCT04616911|PROCEDURE|LIFT|Ligation of the intersphincteric fistula tract
223870285|NCT05319522|BEHAVIORAL|Acute Exercise|Participants with and without SCI will complete an arm ergometer, high-intensity interval exercise bout. The exercise bout will be performed at a relative intensity based on previously determined peak power output during an arm ergometer graded exercise test.
223870286|NCT05850026|PROCEDURE|Septal myectomy and mitral valve repair with edge-to-edge technique|Resection of the obstructing part of the interventricular septum and mitral repair using the edge-to-edge technique (suture of leaflets free margins in the regurgitation spot)
223870287|NCT00086775|BIOLOGICAL|alemtuzumab|
223870288|NCT00086775|BIOLOGICAL|rituximab|
223870289|NCT00086775|DRUG|fludarabine phosphate|
223870290|NCT03163212|DIETARY_SUPPLEMENT|Lactoferrin/FOS|Bovine Lactoferrin/FOS 100mg/ml dissolved in sterile water
223870291|NCT04134078|DRUG|inhaled nitric oxide|Inhaled nitric oxide at 40 ppm will be administered upto 24 hours post ROSC in patient who developed in hospital cardiac arrest
223870292|NCT04942249|OTHER|No intervention|No intervention
223870293|NCT03546608|DRUG|Tepotinib|Participants received a single oral dose of tepotinib in Part 1.
223870294|NCT05633628|BEHAVIORAL|Periodic CGM group with data analysis report- Intervention group|The patients are also instructed to continue to perform SMBG by finger prick if they experience symptoms of hypo- or hyperglycemia. During visit 0 (baseline) the patients is also instructed about how they can log in to the National Diabetes Register (NDR) to access their own NDR's recorded data and use the diabetes questionnaire.
223870295|NCT06588530|BIOLOGICAL|TENIVAC|TENIVAC (Tetanus and Diphtheria Toxoids Adsorbed) is an active immunization for the prevention of tetanus and diphtheria in persons 7 years of age and older.
223870296|NCT06024291|OTHER|8-week HIIT programme|See arm description
223870297|NCT06024291|OTHER|Physical activity recommendation|See arm description
223870298|NCT01037634|DRUG|Oseltamivir|3 mg/kg given orally for 5 days for seasonal influenza, 7 days for 2009 H1N1 influenza (in Vietnam only), or 10 days for avian influenza, for children whose renal function is greater than or equal to 30 mL/min/1.73m2
223870299|NCT04190316|OTHER|Evaluation of fecal RA and environmental contamination of ESBL-PE carrier in ICU|ESBL-PE carriers included in the study will be sampled for evaluation of their fecal RA of ESBL-PE on day 0, 3, 5, 7, 10, 14 and weekly till day 30 or their discharge from ICU. Urine and respiratory samples will be collected on the same day to identify multiple-site colonization with ESBL-PE. Seven samples of patient care environment will be performed 2-times a week till day 30 or discharge of the patient from the ICU.
223870300|NCT03856099|DRUG|TTAC-0001|"* Investigational product (IP): TTAC-0001~* Treatment groups: 3 dose groups~  * Dose group A : TTAC-0001 16 mg/kg on D1 and D15~ * Dose group B : TTAC-0001 20 mg/kg on D1 and D15~ * Dose group C : TTAC-0001 24 mg/kg on D1 and D15~* Cycle: 4 weeks (28 days per cycle)"
223870301|NCT05053113|DEVICE|Activity Monitor|Monitor physical activity with FitBit
223870302|NCT05053113|DEVICE|Activity Monitor|Wear accelerometer
223870303|NCT05053113|OTHER|Educational Intervention|Receive educational newsletter
223870304|NCT05053113|OTHER|Survey Administration|Ancillary studies
223870305|NCT05053113|BEHAVIORAL|Telephone-Based Intervention|Receive phone call from health coach
223870306|NCT06859164|PROCEDURE|Genicular Artery Embolization|Embolization of genicular arteries that demonstrate neoangiogenesis or blush on angiogram.
223870307|NCT06859164|DEVICE|Lipiodol|3:1 emulsion of Lipiodol to Optiray
223870308|NCT06859164|PROCEDURE|Simple angiogram|Simple angiogram of the genicular arteries
223870309|NCT02971943|PROCEDURE|internal fixation for ankle fractures|The patients with ankle injury underwent internal fixation for ankle fractures and ligament repair. Ankle was observed with X-ray and magnetic resonance imaging.
223870310|NCT06677437|OTHER|This is an observational and retrospective study|"It concerns all patients with chronic renal failure awaiting a kidney transplant, and presenting a contraindication to the transplant due to their anatomical constraints: major arterial calcifications, iliac dissections, iliac stenoses. They can only receive the kidney transplant after arterial preparation. These patients will be included and will benefit from endovascular preparation for the kidney transplant using a tailor-made arterial stent.~Imaging examinations and follow-up clinical data will be analyzed. Reinterventions and causes of death will be analyzed.~An information sheet will be given to patients; if the patient refuses the use of their data, it will not be collected.~Data collection will be carried out by ARCs or PIs of the centers from medical records. The data will be pseudo-anonymized, entered into a REDCAP database shared between each center."
223870311|NCT06680752|BIOLOGICAL|ARD103|ARD103 autologous CAR-T cell therapy targeting CLL-1, single iv. infusion
223870312|NCT06680752|DRUG|Cyclophosphamide|iv administration for lymphodepletion
223870313|NCT06680752|DRUG|Fludarabine|iv administration for lymphodepletion
223870314|NCT06625346|DRUG|Fixed-Dose Combination of Amlodipine/Valsartan|Amlodipine and valsartan are two of the most commonly prescribed medications for the treatment of hypertension (high blood pressure). Amlodipine is a calcium channel blocker that works by relaxing the blood vessels, while valsartan is an angiotensin receptor blocker that works by blocking the effects of the hormone angiotensin II, which causes blood vessels to constrict. The combination of amlodipine and valsartan in a single pill has been shown to be more effective in lowering blood pressure than either medication alone. This is because the two medications have different mechanisms of action and work together to provide a more comprehensive approach to blood pressure control.
223870315|NCT06874192|DRUG|Low-dose colchicine at 0.5mg daily|LODOCO is low-dose colchicine at 0.5mg daily, ii is an FDA approved anti-inflammatory drug, to prevent cardiovascular events in patients with coronary artery disease. LODOCO works by inhibiting microtubule formation and reducing the activity of neutrophils, which play a key role in inflammation.
223870316|NCT06874192|OTHER|Placebo|Matching placebo
223870317|NCT00806611|PROCEDURE|Alcohol Block|Operating surgeon by injecting 20 ml of either 50% ethanol or saline on each side of the aorta at the level of the celiac axis with a 20 or 22 gauge spinal needle
223870318|NCT06703944|OTHER|risk model in diagnosis and prognosis|"In this study, we construct and evaluate the bone marrow cytology-based AI model for detection and prognosis of NB.~1. For the diagnostic model, we use AUC metrics to evaluate the model in terms of sensitivity, specificity, accuracy, positive predictive value and negative predictive value at different classification thresholds.~2. For the prognostic model, we use AUC as the performance metric and calculating sensitivity and specificity. Survival curves were constructed according to the Kaplan-Meier method."
223870319|NCT06706752|DIETARY_SUPPLEMENT|Shengbai Oral Formula|Shengbai Oral Formula contains 11 herbs: Folium Epimedii, Fructus Lycii, Radix Astragali, Caulis Spatholobi, Radix Rubiae, Rhizoma Phragmitis, Fructus Psoraleae, Radix Angelicae Sinensis, Radix Ophiopogonis,, Radix et Rhizoma Glycyrrhizae, Radix Aconiti Lateralis Preparata (Processed). It is taken by mouth three times per day for 14 days.
223870320|NCT06706752|OTHER|Inactive Placebo|Inactive placebo will be taken by mouth three times per day for 14 days.
223870321|NCT06708169|BEHAVIORAL|preemptive education provided by anesthesiologists|A preemptive education about 4 stages (prepare, anethesia, surgery, and recovery) by anesthesiologists within 15 minute.
223870322|NCT06882005|BEHAVIORAL|Rested & Ready to Learn|The intervention targets improving young children's sleep by providing parents with sleep education and activities to do at home with their child. Classroom teachers will also deliver a brief lesson aligned with intervention topics to reinforce key messaging in the classroom. The sleep intervention will focus on the benefits of sleep (physical health, social-emotional health, classroom participation/learning), creating and sticking to a bedtime routine, screen use before bed, and developmentally appropriate sleep behavior.
223870323|NCT00050375|DRUG|oregovomab|
223870324|NCT06722716|OTHER|Swab collection|Nasopharyngeal swab
223870325|NCT06725823|PROCEDURE|suprascapular nerve block group|A volume of (10 ml) of 2% lidocaine (7ml), 3% Mepivacaine (2ml), 1 ml methyl-prednisolone acetate (40 mg) will be injected to both groups.
223870326|NCT06725823|PROCEDURE|shoulder anterior capsular block group|A volume of (10ml) of 2% lidocaine (7ml), 3% Mepivacaine (2ml), 1 ml methyl-prednisolone acetate (40mg) will be injected to both groups.
223870327|NCT07044102|OTHER|Patients Undergoing Low Tidal Volume Ventilation During CABG|Postoperative Evaluation of Renal Resistive Index Using Doppler Ultrasound After Cardiopulmonary Bypass
223870328|NCT07044102|OTHER|Patients Undergoing Apneic Ventilation During CABG|"Postoperative Evaluation of Renal Resistive Index Using Doppler Ultrasound After Cardiopulmonary Bypass"
223870329|NCT06890065|DRUG|JY231 Injection|This is an open-label, single-arm study to evaluate the efficacy and safety of in vivo Chimeric Antigen Receptor T-Cell (CAR-T) therapy in patients with relapsed refractory B-cell lymphoma/ leukemia. Upon enrollment, subjects will receive an intravenous infusion of the JY231 preparation. Following the infusion, subjects will be hospitalized for one month for observation, and subjects will be evaluated for safety and efficacy. Subjects will be followed for up to 2 years to determine if the disease is under control.
223870330|NCT06925217|DEVICE|CamAPS HX|The CamAPS HX fully closed-loop system consists of an insulin pump, a continuous glucose monitoring (CGM) sensor, as well as the CamAPS HX app, which resides on a smartphone and communicates wirelessly with the insulin pump.
223870331|NCT06925217|DEVICE|Standard insulin therapy with CGM|Participants will continue their standard insulin therapy with a Freestyle Libre 3 CGM
223870332|NCT06721962|BIOLOGICAL|TRX103|TRX103 is an investigational research product that may treat and provide long term relief to individuals suffering from Crohn's Disease.
223870333|NCT06721962|DRUG|Cyclophosphamide|Low dose cyclophosphamide conditioning.
223870334|NCT06888115|DRUG|CS0159|Single oral dose of CS0159 4mg
223870335|NCT06886451|OTHER|ML-based intervention|For each patient, a ML model will predict the risk of vomiting within the next 96 hours. Patients will then receive care pathway-consistent interventions based on the ML model predictions.
223870336|NCT06740890|DRUG|Olanzapine-samidorphan + exercise|8 weeks of open label Olanzapine-samidorphan + 4 weeks of aerobic exercise
223870337|NCT07053657|DRUG|Dietary Supplement: Vitamin D3|2000 IU per day for 6 weeks (two capsules of 800 IU plus one capsule of 400 IU), followed by 800 IU (one capsule of 800 IU) per day for 6 weeks.
223870338|NCT07053657|DRUG|Dietary Supplement: Vitamin D3 placebo|Three capsules for 6 weeks, followed by one capsule for 6 weeks.
223870339|NCT07054892|BEHAVIORAL|FAAM - Activities of Daily Living (ADL) Subscale|The FAAM score is scientifically validated and allows for the assessment of foot and ankle functional ability
223870340|NCT07053358|GENETIC|LX111 Injection|Qualified subjects will receive a single unilateral intravitreal injection of LX111 at Day 0.
223870341|NCT07053306|DRUG|Empagliflozin 25 MG|A medication used in the management and treatment of type 2 diabetes mellitus. It is in the sodium-glucose co-transporter (SGLT-2) class of medications.
223870342|NCT07054099|BIOLOGICAL|MG1111 (Barycela inj.)|MG1111 (Barycela inj.)
223870343|NCT07054099|BIOLOGICAL|VARIVAX™|Varivax™
223870344|NCT07054840|BEHAVIORAL|Capsaicin 0.1% cream combined with a heat pack and applied to the lower leg|Capsaicin is applied to the skin of one of the lower legs, then covered with a heat pack that is secured to the leg with self-adhesive wrap.
223870345|NCT07053293|DRUG|Empagliflozin 25 MG|A medication used in the management and treatment of type 2 diabetes mellitus. It is in the sodium-glucose co-transporter (SGLT-2) class of medications.
223870346|NCT07056192|OTHER|Structured education group|Structured education group
223870347|NCT06887660|OTHER|Orthodontic diagnosis|"Initial Assessment Orthodontic residents assessed each patient based on their existing knowledge of speech therapy. They rated the necessity for a speech therapy consultation on a scale from 1 to 10, with 1 indicating not necessary and 10 indicating absolutely necessary.~Protocol-Guided Assessment The same residents then reassessed the same patients using the Interdisciplinary Orofacial Evaluation Protocol. After this evaluation, they again rated the necessity for a speech therapy consultation using the same 1 to 10 scale.~Speech-therapist Evaluation Subsequently, a speech therapy specialist independently evaluated each patient using the same protocol and provided their rating for the necessity of a speech therapy consultation on the same scale."
223870348|NCT06741085|DRUG|osimertinib|oral EGFR-TKI
223870349|NCT06741085|RADIATION|stereotactic radiosurgery (SRS)|"0-20mm-18Gy x 1, 21Gy x 1 ,9Gy x 3~20mm or larger- 9Gy x 3, 6Gy x 5, 5Gy x 5"
223870350|NCT07060001|DIAGNOSTIC_TEST|5hmC Biomarker|The 5hmC marker will be used to determine treatment modality post-induction therapy. After Week 4 of standard-of-care therapy (either HMA-based treatment or intensive induction chemotherapy), 5hmC biomarker testing will be performed. If MRD is positive, patients will continue the same standard-of-care treatment or crossover to the other arm of the study. If MRD is negative, patients will proceed with consolidation (either HSCT or continue on same treatment). For patients receiving HMA-based treatment, blood samples will be collected ± 5 days before and after 4 and 12 weeks of therapy. For patients receiving intensive chemotherapy blood samples will be collected ± 5 days before and after 4 and 12 weeks of therapy.
223870351|NCT07060001|DRUG|Venetoclax|Venetoclax is a BCL-2 inhibitor FDA Approved for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adults who are age 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy, in combination with azacitidine, decitabine or low-dose cytarabine.
223870352|NCT07060001|DRUG|Decitabine 20 mg/m²/day for 5 days|Decitabine is a nucleoside metabolic inhibitor that is administered as an intravenous infusion over a 1-3 hours.
223870353|NCT07060001|DRUG|Azacitidine (AZA)|Azacitidine can be given as a sub-cutaneous injection or intravenously.
223870354|NCT07060001|DRUG|Cytarabine (Ara-C)|Cytarabine is FDA approved chemotherapy (pyrimidine analog) infusion that is frequently used with other drug such as anthracycline to treat acute myeloid leukemia, acute lymphoblastic leukemia. Common side effects include low counts, immune suppression, nausea, neutropenic fever.
223870355|NCT07060001|DRUG|Anthracycline|Anthracyclines are chemotherapy infusions which topoisomerase II inhibition. Other than having side effects similar to cytarabine, it may cause weakening of heart pumping function few years later. Both of these medications may cause a temporary loss of hair in some people. After treatment with cytarabine has ended, normal hair growth should return.
223870356|NCT07061717|DRUG|Palbociclib 125mg qd (3 weeks of treatment followed by 1 week off) + Anastrozole 1mg qd / Letrozole 2.5mg qd / Exemestane 25mg qd|Standard-Dose Palbociclib + Endocrine therapy
223870357|NCT07061717|DRUG|Palbociclib 125mg qd (3 weeks of treatment followed by 1 week off) + Anastrozole 1mg qd / Letrozole 2.5mg qd / Exemestane 25mg qd + Hydroxychloroquine 600mg bid|Standard-Dose Palbociclib + Endocrine Therapy + Hydroxychloroquine
223870358|NCT07061717|DRUG|Palbociclib 200mg qd (3 weeks of treatment followed by 1 week off) + Anastrozole 1mg qd / Letrozole 2.5mg qd / Exemestane 25mg qd + Hydroxychloroquine 600mg bid|High-Dose Palbociclib + Endocrine Therapy + Hydroxychloroquine
224268783|NCT03694236|DRUG|durvalumab|"Neo-adjuvant chemoradiation period The treatment consisted of paclitaxel, carboplatin, duvalumab and radiation. The radiation treatment comprises 45Gy (total 25Fr) and that will be about 5 weeks. Intensity modulated RT (IMRT) or 3D CRT (three-dimensional conformal radiotherapy) will be allowed.~Surgery Chest CT and/or PET CT with appropriate other diagnostic method (ex. Bronchoscopy) will be performed before surgery and type of surgery Follow-up period There is every 4 month visit with chest CT and abdominal CT is done at 1,2,5 post-op year. Other diagnostic method can be performed if indicated."
224268784|NCT01602328|BIOLOGICAL|AC607|AC607 will be a single administration at a target dose of 2 x 10E6 hMSC/kg body weight
224268785|NCT01602328|BIOLOGICAL|Vehicle Only|The dose will be calculated and recorded in the same way as for AC607.
223870359|NCT07060378|DEVICE|Contrast-enhanced endobronchial ultrasound|Using CE-EBUS to observe pulmonary lesions and abnormal enlarged intrathoracic lymph nodes, the enhancement characteristics of benign and malignant lesions under CE-EBUS were extracted for both conditions.
223870360|NCT07055464|PROCEDURE|eTEP-RS Hernia Repair|Laparoscopic retromuscular mesh repair using the enhanced view totally extraperitoneal (eTEP-RS) technique for ventral or incisional hernia.
223870361|NCT07055464|PROCEDURE|IPOM Plus Hernia Repair|Intraperitoneal onlay mesh (IPOM Plus) repair involving laparoscopic fascial defect closure and mesh placement for abdominal wall hernias.
223870362|NCT07061704|BIOLOGICAL|Oncolytic Virus: Administered via intratumoral injection once every 3 weeks, for a total of two doses.|Oncolytic Virus: Administered via intratumoral injection once every 3 weeks, for a total of two doses, or until disease progression, the occurrence of unacceptable toxicity, or death from any cause, whichever occurs first. Chemotherapy + Immune Checkpoint Inhibitor (ICI): Administered via intravenous infusion once every 3 weeks.
223870363|NCT07060586|PROCEDURE|Sphenopalatine Ganglion Block|A bilateral transnasal sphenopalatine ganglion block with cotton tips soaked in a mixture of 0.5 mL lidocaine 4% and 0.5 mL ropivacaine 0.5% plus injection through the cotton tips of an additional 1 mL of the mixture. The Danish Medicines Agency waived need for approval as this procedure is not considered a pharmaceutical intervention.
223870364|NCT07060586|PROCEDURE|Sham Block|A sham block with two bilaterally inserted cotton tips not reaching the posterior part of the nasopharyngeal making not contact with the ganglion. Cotton tips are soaked in 1 mL placebo (saline) and have a total of 1 mL saline injected through the cotton tips. The Danish Medicines Agency waived need for approval as this procedure is not considered a pharmaceutical intervention.
224268786|NCT05016986|OTHER|Standard clinical management|outcomes in GSW cardiac injuries
224268787|NCT05920486|DEVICE|High-Intensity Laser Therapy (HILT)|High-Intensity Laser Therapy (HILT) is a non-invasive treatment that utilizes high-powered lasers to deliver therapeutic doses of energy to damaged tissue. In this study, HILT will be used to treat sacroiliitis, a condition that affects the sacroiliac joint in the lower back and pelvis. HILT will be administered using a Class IV laser with a wavelength of 980 nm, power output of 10 W, spot size of 0.5 cm, and a dose of 60 J/cm2 per session. The laser will be applied to the affected area of the sacroiliac joint, with the aim of achieving a sensation of warmth in the region. The treatment sessions will be delivered for 10 minutes per session, with a total of 12 sessions over 8 weeks. The aim of HILT is to promote cellular repair and regeneration, reduce pain, and improve function in patients with sacroiliitis. Participants in the HILT group will receive HILT treatment as the primary intervention in this study.
224268788|NCT05920486|DEVICE|Sham High-Intensity Laser Therapy (HILT)|Sham HILT is a non-invasive treatment that mimics the appearance and sensation of HILT but does not deliver any laser energy to the affected tissue. In this study, Sham HILT will be used as a control intervention for the treatment of sacroiliitis. The device used for Sham HILT will look and feel the same as the HILT device, but will not emit any laser energy. The device will be applied to the affected area of the sacroiliac joint, with the aim of achieving a sensation of warmth in the region. The treatment sessions will be delivered for 10 minutes per session, with a total of 12 sessions over 8 weeks. The aim of Sham HILT is to provide a credible control intervention that does not have any specific therapeutic effect on the sacroiliac joint. Participants in the Sham HILT group will receive Sham HILT treatment as the primary intervention in this study.
224268789|NCT04613167|DRUG|Alirocumab|The first group will receive alirocumab. Blood samples from all patients will be drawn for laboratory measurements and genetics determination. Ultrasound measurement of endothelium-dependent dilatation of the brachial artery, intima media thickness of carotid arteries and pulse wave will be measured.
223870365|NCT07061431|DIETARY_SUPPLEMENT|High Dose of Vitamin C with ir without 50 mg of flavonoids|The anti-inflammatory and anti-platelet efficacy and synergy of a supplement containing high dose (1 g) of vitamin C and a low dose (50 mg) citrus and rose bioflavonoids (VCF), was assessed in platelets of blood samples collected from healthy subjects, prior the oral administration (t=0 days) and just after this administration for 1 month (VCF Group), VERSUS the findings from the same procedure contacted for a supplement containing only high dose (1 g) of vitamin C (VC Group)
223870366|NCT07061262|PROCEDURE|External Oblique Intercostal Plane Block|Right after general anaesthesia induction and patient intubation, the patient will be placed in a supine position. Following sterile skin preparation, an external oblique plane block will be performed by the same anesthesiologist under ultrasound guidance, using an external oblique muscle approach. A 22-gauge, 50-mm insulated stimulating needle will be used to administer 20 mL of anaesthetic solution (0.25% bupivacaine, 20 mL). Finally, 20 mL of local anaesthetic solution (0.25% bupivacaine anaesthetic solution) will be administered to disperse within the external oblique space.
223870367|NCT07061262|PROCEDURE|Subcostal TAP block and spinal anesthesia group (STAP)|Right after general anaesthesia induction and patient intubation, the patient will be placed in a supine position. Following sterile skin preparation, a subcostal block will be performed by the same anaesthesiologist under ultrasound guidance with a subcostal approach. A 22-gauge, 50-mm insulated stimulating needle will be used to administer 20 mL of anaesthetic solution (0.25% bupivacaine, 20 mL). Finally, 20 mL of local anaesthetic solution (0.25% bupivacaine anaesthetic solution) will be administered to disperse within the subcostal space.
223870368|NCT07060092|BEHAVIORAL|Trail Making Task|Participants will perform a modified, life-size version of the Trail Making Test (TMT) while standing upright, either on a stable (force plates) or unstable (balance board) surface. The task involves visually searching for and tracing a sequential path through spatially randomized numerical targets projected onto a large screen using a laser pointer. This dual-task condition simultaneously engages cognitive, visual, and motor planning systems while requiring continuous postural control. The task is designed to elicit suprapostural coordination, capturing the dynamic interplay between postural stability and goal-directed behavior.
223870369|NCT07060092|BEHAVIORAL|Balance board|Participants will maintain an upright stance on a commercially available balance board positioned atop dual force plates. The unstable surface introduces controlled postural instability, requiring continuous sensorimotor adaptation to preserve balance without external support. This condition is administered alone and in combination with the Trail Making Task to simulate dual-task challenges that more closely resemble real-world balance demands.
223870370|NCT04873102|DRUG|Danazol Pill|"Danazol is a synthetic steroid derived from ethisterone, It suppresses the pituitary-ovarian axis by inhibiting the pituitary output of gonadotropins. The pituitary-suppressive action of danazol is reversible. Danazol has been approved in treating endometriosis, fibrocystic breast disease, hereditary angioedema, thrombocytopenic purpura, and other conditions. It is metabolized and eliminated by renal and fecal pathways. The mean half-life of danazol in healthy males is 9.7 hours. After 6 months of 200 mg three times a day dosing in endometriosis patients, the half-life of danazol was reported as 23.7 hours.~Adverse reactions from danazol include androgen like effects (i.e. weight gain, acne, mild hirsutism, edema, hair loss, voice change) and menstrual disturbances. The use of danazol in pregnancy is contraindicated. Other side effects include elevations in liver-enzyme levels and lipid abnormalities."
223870371|NCT05091970|PROCEDURE|Manualized cognitive rehabilitation for mild traumatic brain injury (mTBI)|Three 60-minute sessions per week with a minimum of 6 sessions and a maximum of 10 sessions. This intervention is to be delivered by trained Occupational Therapists (OTs) and Speech-Language Pathologists (SLPs), and includes training in compensatory strategies, direct training of cognitive subskills (e.g., attention training), and assigned homework to practice skills learned in treatment.
223870372|NCT07059884|OTHER|Exercise intervention|Complete supervised TH progressive resistance exercise sessions
223870373|NCT07059884|OTHER|Telemedicine|Complete supervised TH progressive resistance exercise sessions
223870374|NCT07059884|OTHER|Aerobic Exercise Intervention|Complete unsupervised aerobic exercise sessions
224268790|NCT04613167|DRUG|Evolocumab|The second group will receive evolocumab. Blood samples from all patients will be drawn for laboratory measurements and genetics determination. Ultrasound measurement of endothelium-dependent dilatation of the brachial artery, intima media thickness of carotid arteries and pulse wave will be measured.
224268791|NCT04613167|DRUG|Control group|The third group will receive only optimal guidelines-based secondary preventive treatment. Blood samples from all patients will be drawn for laboratory measurements and genetics determination. Ultrasound measurement of endothelium-dependent dilatation of the brachial artery, intima media thickness of carotid arteries and pulse wave will be measured.
224268792|NCT00983996|DRUG|Alendronate Sodium Tablets, 10 mg|10 mg, single-dose fasting
224268793|NCT00983996|DRUG|Fosamax Tablets, 10 mg|10 mg, single-dose fasting
224268794|NCT05315713|DRUG|Mosunetuzumab SC|Participants will receive SC mosunetuzumab for up to 17 treatment cycles (cycle length = 21 days)
223870375|NCT07059884|OTHER|Dumbbell Exercise Intervention|Receive adjustable-weight dumbbells
223870376|NCT07059884|PROCEDURE|Accelerometry|Wear accelerometer
223870377|NCT07059884|OTHER|Questionnaire Administration|Ancillary studies
223870378|NCT07059884|OTHER|Interview|Ancillary studies
223870379|NCT07059884|OTHER|Electronic Health Record Review|Ancillary studies
223870380|NCT07060521|OTHER|soft tissue mobilization|massage
223870381|NCT07060521|OTHER|Self Stretching|self stretching
223870382|NCT07060131|DEVICE|Far Infrared Eye Masks|Using far-infrared eye masks on the acupoints around the eyes, including Jingming, Taiyang, Sibai, Tongziliao, and Si Zhu Kong to assess whether there is an improvement in the symptomatic indicators of dry eye disease.
224268795|NCT05315713|DRUG|Tiragolumab|Participants will receive IV tiragolumab every 3 weeks (Q3W) for up to 17 treatment cycles (cycle length = 21 days)
224268796|NCT05315713|DRUG|Atezolizumab|Participants will receive IV atezolizumab Q3W for up to 17 treatment cycles (cycle length = 21 days)
224268797|NCT05315713|OTHER|Tocilizumab|Participants will receive IV tocilizumab as needed to manage cytokine release syndrome (CRS) events
224268798|NCT05779358|OTHER|Expectancy and gluten|Effect of expectancy to receive gluten and/or actual gluten intake
224268799|NCT02795572|DIETARY_SUPPLEMENT|Vitamin D|Vitamin D 2000 IU oral once daily
224268800|NCT02795572|DIETARY_SUPPLEMENT|Vitamin B6|Vitamin B6 100 mg oral once daily
223870383|NCT07061197|OTHER|Patient leaflet with the EMA's proposed key information section including qualitative statements.|The standard patient leaflet supplemented with a key information section. This section included qualitative descriptions of the goal of treatment, the main benefits, contraindications, and the most serious side effects. The content was designed to reflect the EMA's proposed format for improving the patient information leaflet.
223870384|NCT07061197|OTHER|Control (standard patient leaflet)|The standard patient information leaflet for a recently approved cancer drug, tivozanib (Fotivda), obtained electronically from the EMA website. The standard patient information does not contain structured benefit information.
223870385|NCT07061197|OTHER|Patient leaflet with a key information section providing both qualitative and quantitative information on drug benefits and harms.|The standard patient leaflet, supplemented with a key information section including quantitative data on the drug's main benefits and side effects, presented in a summary table format. This section provided structured information about the indication and goal of treatment, how the drug was studied (the comparator treatment and number of patients enrolled in the clinical trial that supported the drug's approval), and data on the drug's benefits and side effects.
223870386|NCT07061041|OTHER|Strength training|"The group will perform one workout per week consisting of 3 series of the Romanian deadlift exercise of 10 repetitions. Each repetition will be performed at a specific pace - 3s in eccentric contraction and 1s in concentric contraction. The aforementioned exercise, the Romanian deadlift, will be performed by the subjects on a platform (elevation) in order to achieve maximum range of motion."
223870387|NCT07061041|OTHER|Streching group|The group performed one training session per week consisting of 2 sets of 60 seconds of static stretching
223870388|NCT07060105|OTHER|Hypertonic Saline ( 3% Sodium Chloride Saline)|The intervention group (n=37) will receive 5ml/kg of 3% hypertonic saline, and the control group (n=37) will receive 5ml/kg of 0.9% normal saline. There is a maximum volume of 500ml for both fluids.
223870389|NCT07060105|OTHER|Normal Saline (0.9% NaCl)|The intervention group (n=37) will receive 5ml/kg of 3% hypertonic saline, and the control group (n=37) will receive 5ml/kg of 0.9% normal saline. There is a maximum volume of 500ml for both fluids.
223870390|NCT07059897|BEHAVIORAL|Animation video and mobile phone application|"An animation video scenario and MEKTUP mobile phone application were prepared by the researchers in light of the literature, in line with the National Breast Cancer Screening Program and by taking expert opinions."
223870391|NCT06892379|DRUG|HS-20110 (Phase Ia：Dose escalation )|HS-20110 for IV infusion of various dose strengths administered in 21 day dosing cycles
223870392|NCT06892379|DRUG|HS-20110 (Phase Ib:Dose expansion )|The recommended dose from the dose-escalation stage and other potential doses will be further explored
223870393|NCT07059845|DRUG|Mirvetuximab Soravtansine|Intravenous (IV) infusion
223870394|NCT07059845|DRUG|Bevacizumab|IV Infusion
223870395|NCT07059845|DRUG|Carboplatin|IV Infusion
223870396|NCT07059702|OTHER|There will be no intervention.|There will be no intervention. This is an observational study that uses EEG and FDG-PET results as parameters. These investigations will b e performed on a clinical basis.
223870397|NCT07060326|OTHER|Survey using a questionnaire.|REDCap Survey
223870398|NCT05710172|DEVICE|Auditory Mirror Therapy|21 days, up to 3 hours per day intervention
223870399|NCT04930289|DEVICE|LungGuard|The LUNGguard is an FDA cleared and is a CE-marked medical device intended to be used for the static hypothermic preservation of lungs during transportation and eventual transplantation into a recipient using cold storage solutions indicated for use with the lungs. The intended organ storage time for the LUNGguard is up to 8 hours.
223870400|NCT04930289|DEVICE|BAROGuard|"The BAROguard (the System) is ultraportable hypothermic preservation and transport system intended for use with donor lungs. BAROguard is a legally marketed, FDA cleared medical device in the United States. The intended organ storage time for BAROguard™ is up to 8 hours."
223870401|NCT06838806|DIAGNOSTIC_TEST|blood draw|Plasma samples will be collected in NTU Hospital or NTUCC. ChLIA kits and all other reagents will be provided by Volition. ChLIA analysis of samples will be performed by a Volition designated laboratory in Taiwan( NTU Centres of Genomic and Precision Medicine).
223870402|NCT07061834|DEVICE|Biofeedback training|The intervention consists of biofeedback training using the Nexus 10 device, which provides real-time feedback on physiological signals including galvanic skin response and peripheral temperature. Participants undergo sessions where they learn to consciously regulate their autonomic nervous system activity by observing and modifying these signals. This training aims to improve stress regulation and enhance physiological self-control. Unlike other biofeedback interventions, this protocol focuses on combined skin conductance and temperature measures delivered through the Nexus 10 system over multiple sessions.
223870403|NCT07061834|OTHER|control group|The control group received no intervention.
224268801|NCT02795572|DIETARY_SUPPLEMENT|Vitamin B12|Vitamin B12 100 mcg oral once daily
224268802|NCT02795572|DIETARY_SUPPLEMENT|Omega-3 Fatty Acids|Omega-3 Fatty Acids 900 mg oral three times a day (600 mg EPA, 300 mg DHA)
224268803|NCT04548258|DEVICE|electric intraoral weilding|weilding metal framework to the implants in completely edentulous maxilla using electric weilding device intraorally
224268804|NCT04548258|DEVICE|casting|casting metal framework
224268805|NCT04206267|DEVICE|Acceledent|Device for accelerating tooth movement
224268806|NCT01261767|DRUG|anti-IL-20|Anti-IL-20 in 100mg/vial for subcutaneous (under the skin) injection
224268807|NCT01261767|DRUG|placebo|Placebo for subcutaneous (under the skin) injection
224268808|NCT02721563|DRUG|Sodium Glycididazole|Sodium Glycididazole 700mg/m2.Three times a week (once every other one day),before radiation therapy, total 6 weeks.
224268809|NCT02721563|DRUG|Placebo|Placebo:three times a week (once every other one day),before radiation therapy, total 6 weeks.
224268810|NCT05940233|DRUG|Letrozole|In the experimental group, we give the Letrozole 10 mg PO daily on the 4th day before Misoprostol 800 mcg SL on the 4th day. In the control group, we give Misoprostol 800 mcg SL on the 4th day.
224268811|NCT05203146|DEVICE|PIMPmyHospital (mobile health tool)|Each participant will first be asked to retrieve a factious patient's laboratory results on the app when randomly made available, and then reach a colleague (role played by a study investigator) when asked to do so by a text message on the app.
223870404|NCT05051657|DIETARY_SUPPLEMENT|PKU express plus|PKU express plus is a powdered protein substitute for the dietary management of PKU. It is formulated in a variety of flavours to provide a convenient, low volume, lower calorie, pre-measured protein substitute, containing a full micronutrient profile.
223870405|NCT06813430|DEVICE|Non-contact Low Frequency Ultrasound|NCLF-US therapy involves delivering low-frequency (40 kHz), low-intensity (0.1-0.8 W/cm2) ultrasound energy via sterile water mist.
223870406|NCT06813430|OTHER|Lalonde Protocol (standard of care)|Standard of care local wound therapy using the Lalonde protocol - rinsing the site with clean water, applying a grease layer, wrapping with a one-inch gauze wrap, and securing with Coban tape.
223870407|NCT02788773|DRUG|Durvalumab|
223870408|NCT02788773|DRUG|Tremelimumab|
223870409|NCT03005678|DRUG|Denosumab|active treatment group
223870410|NCT03005678|DRUG|Alendronate|comparator
223870411|NCT06085755|DRUG|Trastuzumab deruxtecan|Trastuzumab deruxtecan will be administered 6.4mg/kg or 5.4mg/kg iv infusion q 3weeks as one cycle.
223870412|NCT06085755|DRUG|Afatinib|Afatinib will be administered orally 20mg \~40mg once a day or three times a week(Monday, Wednesday, Friday \[MWF\]) or twice weekly (Monday, Thursday \[MT\]) for 3weeks as one cycle.
223870413|NCT04415879|OTHER|N-95 Respirator|N-95 mask will be worn as personal protective equipment during a graded exercise test
223870414|NCT04415879|OTHER|Cloth Face Mask|A cloth mask will be worn as personal protective equipment during a graded exercise test
223870415|NCT06908226|DRUG|LP352|LP352 will be administered orally or through G-tube/ percutaneous endoscopic gastrostomy (PEG) tube.
223870416|NCT06924450|DEVICE|1.2 cm Mesh TOT|Patients in this group will undergo transobturator tape (TOT) surgery using a 1.2 cm monofilament polypropylene mesh. The modified mesh width is being evaluated for its effect on surgical success, symptom improvement, and postoperative complications.
223870417|NCT06924450|DEVICE|1.0 cm Mesh TOT|Patients in this group will undergo transobturator tape (TOT) surgery using a 1.0 cm monofilament polypropylene mesh, which is the standard procedure. This group serves as a comparator to assess the impact of the modified mesh width.
223870418|NCT04086446|DEVICE|high-definition transcranial direct current stimulation|The tDCS device will deliver a direct current of 1.5mA during 20 minutes. Cathode electrode will be localized in front of the right OFC on the Fp2 point according to the EEG international reference. Four anode electrodes will be placed around FP2 (i.e. Fpz, AFz, AF4, AF8)
223870419|NCT04086446|DEVICE|Sham tDCS|The same procedure will be applied except that the tDCS device will only deliver a current stimulation for the first and last 15 seconds.
223870420|NCT06941155|BEHAVIORAL|Gamified-Combined Cognitive Bias Modification|A gamified version of the combined cognitive bias modification (CBM-C) intervention, which includes both attention and interpretation bias modification tasks. The attention component is a modified dot-probe task, and the interpretation component consists of OCD-related scenarios with word-completion exercises. Gamification elements such as feedback and visual rewards are embedded to enhance motivation and engagement. The presentation order of the two intervention components will be counterbalanced: half of the participants will receive the attention bias task first followed by the interpretation task; the other half will receive the interpretation task first followed by the attention bias task. The intervention is delivered via mobile phone in eight sessions over four weeks (two sessions per week).
223870421|NCT06941155|BEHAVIORAL|Standard Combined Cognitive Bias Modification|A standard version of the combined cognitive bias modification (CBM-C) intervention, consisting of attention and interpretation bias tasks without gamification features. The attention task is a modified dot-probe paradigm, and the interpretation task involves OCD-related scenarios followed by word-completion exercises. The presentation order of the two intervention components will be counterbalanced: half of the participants will receive the attention bias task first followed by the interpretation task; the other half will receive the interpretation task first followed by the attention bias task. The intervention is delivered via mobile phone in eight sessions over four weeks (two sessions per week).
223870422|NCT06941155|BEHAVIORAL|Placebo|A placebo version of the standard CBM-C intervention that retains the same structure and timing but omits all active bias modification elements. The attention task (modified dot-probe) presents probes equally behind threat and neutral stimuli, and the interpretation task includes OCD-related scenarios with word-completion items that lead to neutral outcomes. No manipulations are applied to shift cognitive bias. The presentation order of the two intervention components will be counterbalanced: half of the participants will receive the attention bias task first followed by the interpretation task; the other half will receive the interpretation task first followed by the attention bias task. The intervention is delivered via mobile phone in eight sessions over four weeks (two sessions per week).
223870423|NCT04268550|DRUG|Selpercatinib|Given PO
223870424|NCT06937853|DRUG|Ibuprofen 600 mg|A single oral dose of 600 mg ibuprofen will be administered prior to the endodontic procedure to evaluate its preemptive analgesic effect on postoperative dental pain.
223870425|NCT06937853|DRUG|diclofenac sodium|A single oral dose of 100 mg diclofenac sodium will be administered to participants in the Diclofenac Sodium Group prior to the endodontic procedure. This intervention is designed to assess the preemptive analgesic efficacy of diclofenac sodium in the control of postoperative dental pain.
223870426|NCT06937853|DRUG|Placebo|A single oral dose of a placebo tablet, identical in appearance to the active drugs, will be administered to participants in the Placebo Group prior to the endodontic procedure. This group serves as the control to evaluate the true analgesic efficacy of the active interventions.
223870427|NCT06949566|OTHER|100 Hz Local Vibration|Participants in this group will receive 100 Hz local vibration along the flexor carpi ulnaris muscle for a duration of 10 minutes.
223870428|NCT06949566|OTHER|50 Hz Local Vibration|Participants in this group will receive 50 Hz local vibration along the flexor carpi ulnaris muscle for a duration of 10 minutes.
223870429|NCT06949566|OTHER|Sham Local Vibration|Participants in this group will receive sham vibration following the muscle fatigue protocol. The vibration device will be turned on but held near the muscle without making contact for 10 minutes. Participants will be informed that they are being treated with an electromagnetic vibration device.
223870430|NCT06951815|DEVICE|Hearing aids programmed to each participant's hearing loss.|This study is not investigating the efficacy of hearing aids, rather it is investigating the effect of adjusting hearing on cognitive resources, listening effort, and fatigue.
223870431|NCT04756323|BIOLOGICAL|medium dosage inactivated SARS-CoV-2 vaccine|medium dosage
223870432|NCT04756323|BIOLOGICAL|high dosage inactivated SARS-CoV-2 vaccine|high dosage
223870433|NCT04756323|BIOLOGICAL|Placebo|placebo
223870434|NCT01109745|OTHER|PELICAN Primary Care|The intervention is the integration of the output of the Pelican instrument in daily care to guide disease management for children with asthma treated in primary care. The general practitioner can integrate the information of the Pelican instrument in their consultation and disease management decisions. The general practitioner will be trained and supported to negotiate the child's, and physicians' agendas based on the outcome of the instrument, and discuss possible interventions. All participating children of a GP will be allocated to the same treatment group (i.e., hierarchical or nested design).
223870435|NCT01109745|OTHER|PELICAN Secondary Care|The intervention is the integration of the output of the Pelican instrument in daily care to guide disease management for children with asthma treated in secondary care. The nurse can integrate the information of the Pelican instrument in their consultation and disease management decisions. The paediatricians will be trained and supported to negotiate the child's, and nurses' agendas based on the outcome of the instrument, and discuss possible interventions.
223870436|NCT06238752|DRUG|Apatinib Combined With Tislelizumab and Chemotherapy|apatinib (250 mg, qd, d1-14), tislelizumab(200 mg d1), and oxaliplatin (130 mg/m2, d1) plus oral capecitabine (1000 mg/m2, bid, d1-14) every 3 weeks
223870437|NCT06233565|DRUG|0.9%sodium chloride|administration of 0.5ml/kg of 0,2% ropivacaine + 0.01ml/kg 0.9% sodium chloride for the popliteal nerve block
223870438|NCT06233565|DRUG|Dexamethasone|administration of 0.5ml/kg of 0.2% ropivacaine with 0.1mg/kg Dexamethasone for the popliteal nerve block
223870439|NCT06233565|DRUG|Dexmedetomidine|administration of 0.5ml/kg of 0.2% ropivacaine with 0.1ug/kg Dexmedetomidine for the popliteal nerve block
223870440|NCT06415591|DEVICE|Percutaneous electrical nerve field stimulation|FDA-approved acupuncture-like therapy applied to the external ear targeting several cranial nerve branches including the auricular branch of the vagus nerve to improve pain, physical function, and reduce symptoms of opioid withdrawal.
223870441|NCT04225598|DRUG|CAM2038|Patients will receive a 24 mg dose of injectable CAM2038 in the ED on Day 0.
223870442|NCT04225598|DRUG|Buprenorphine Sublingual Product|"COWS ≥ 8: Patients will receive 4mg of SL-BUP for a COWS score of 8-12 (mild withdrawal). After 30-45 minutes if tolerated and no unanticipated adverse reactions, an additional 4mg can be administered for a total of 8mg in the ED. Patients presenting with moderate-severe withdrawal (COWS \>≥ 13) will receive an initial dose of 8mg SL-BUP. All patients will receive a buprenorphine prescription and instructions for additional BUP doses to allow for up to a dose of 12mg if needed, and for 16mg each subsequent day until their scheduled follow up appointment for ongoing MOUD (medications for opioid use disorder).~COWS 4-7: Patients will be provided with a uniform set of instructions to guide unobserved (home) induction. They will be prescribed doses of SL-BUP to allow them to take dose up to 12mg in the 24 hours after discharge. All patients will also receive a buprenorphine prescription for 16mg each subsequent day until their scheduled follow up appointment for ongoing MOUD."
223870443|NCT04043442|DEVICE|Magventure MagProX100 with MagOption stimulator and Magpro Cool Coil B65 A/P|rTMS device
223870444|NCT03870230|DEVICE|Fourier Domain Doppler Optical Coherence Tomography (FDOCT)|Retinal blood flow will be assessed using FDOCT
223870445|NCT03870230|DEVICE|Dynamic Vessel Analyzer (DVA)|Retinal vessel diameters and oxygen saturation will be measured with the DVA device
223870446|NCT03870230|DEVICE|Pattern Electroretinography (pERG)|to assess the neuronal function of the retina, pattern ERG will be performed
223870447|NCT03870230|DEVICE|Optical coherence tomography (OCT)|to assess the morphology of the retina, OCT will be performed
223870448|NCT03870230|DEVICE|Laser Speckle Flowgraphy (LSFG)|to assess retinal blood flow, LSFG will be performed
223870449|NCT06444958|DIAGNOSTIC_TEST|observational study without any intervention component.|"extracting and analyzing the following data:~Outpatient department records: Diagnoses, treatments, patient demographics Inpatient admission records: Admission diagnoses, treatments, patient outcomes (discharged, transferred, died) Mortality records: Causes of death for pediatric patients"
223870450|NCT04073199|PROCEDURE|Long Lever Group|"the physiotherapist wears the limb passively towards flexion, external rotation and abduction until the physiotherapist has perception of stretch of the tissues (sensation terminal elastic firm according to the concept of Orthopaedic Manual Therapy for the soft tissue treatment) The patient's own weight stabilizes the proximal segment, in case that the scapula is not stable, the physiotherapist fixes with his free hand the scapula.~The technique will be performed two days a week, at intervals of 20 seconds of technique and 20 rest periods for ten reps (estimated time per session is 7 minutes approximate)."
224268812|NCT05203146|OTHER|Conventional method|Each participant will first be asked to retrieve a factious patient's laboratory results from the emergency department's computerized patient data system when randomly made available, and then contact a colleague (role played by a study investigator) when asked to do so (request made by a second study investigator).
224268813|NCT03385863|DRUG|Surfactant, Pulmonary，Curosurf|All NRDS were given an early endotracheal infusion of Curosuf, with an initial dose of 200mg/kg, and if the condition needed to be repeated. Compare the therapeutic effect of pulmonary surfactant of infants at different gestational ages and to investigate whether exogenous surfactant replacement therapy is effective for all newborns with RDS.
224268814|NCT03385863|OTHER|Perinatal risk factors of NRDS|Compare the perinatal risk factors that were closely related to NRDS between early preterm infants with RDS and near term/term infants with RDS.
224268815|NCT06319482|DEVICE|Proactive CPAP Therapy|CPAP machine uses Artificial Intelligence to make predictions and preventions of future apneic events to auto-adjust pressure.
224268816|NCT06319482|DEVICE|Conventional APAP Therapy|CPAP machine relies on the detection of respiratory events to determine how to react and auto-adjust pressure.
223870451|NCT04073199|PROCEDURE|Short Lever Group|"It consists of a stretch made by the physiotherapist, with the patient in supine position, with the extremity to be treated in a submaximal position of flexion and external rotation (fixed by the arm and body of the physiotherapist) and realizing the stretch a through the scapula in the medial and caudal dorsal direction.~The technique will be performed two days per week, at intervals of 20 seconds of technique and 20 rest periods for ten reps (estimated time per session is 7 minutes approximate)"
223870452|NCT00063713|DRUG|VELCADE TM (bortezomib) for Injection|
223870453|NCT00737035|BEHAVIORAL|Interactive Healthcare Communication Application|"The IHCA is an Internet-based tool that integrates multiple resources for guardians of survivors of interparental homicide. The IHCA will have six components: (1) an instant library of articles on topics of interest; (2) a resource directory of both national and local support and service organizations; (3) access to a peer communication system; (4) a Frequently Asked Questions section, updated with responses to user generated questions; (5) an Ask an Expert system staffed by researchers; and (6) personal stories of others dealing with IPH."
223870454|NCT00737035|BEHAVIORAL|Control Web sites|Only publicly available Web sites on parenting, child development, and trauma will be used.
223870455|NCT03049319|DEVICE|Psoriashield in the presence of a non-UV absorbing block.|The psoriashield will be applied to patient's back in the presence of a non-UV absorbing block.
223870456|NCT03049319|DEVICE|Psoriashield in the presence of a UV absorbing block.|The psoriashield will be applied to patient's back in the presence of a UV absorbing block.
223870457|NCT03049319|DEVICE|Psoriashield|The psoriashield will be applied to patient's back.
223870458|NCT03049319|DEVICE|Xtrac laser in the presence of a non-UV absorbing block.|The Xtrac laser will be applied to patient's back in the presence of a UV absorbing block.
223870459|NCT03049319|DEVICE|Xtrac in the presence of a UV absorbing block.|The Xtrac laser will be applied to patient's back in the presence of a non-UV absorbing block.
223870460|NCT03049319|DEVICE|Xtrac laser|The Xtrac laser will be applied to patient's back.
223870461|NCT00507338|PROCEDURE|PCI|early PCI for NSTEMI; primary PCI for STEMI
223870462|NCT05886634|DRUG|Etrumadenant|Will be administered PO daily for 24 weeks
223870463|NCT05886634|DRUG|Zimberelimab|Will be administered IV every 2 weeks for 24 weeks
223870464|NCT01622868|OTHER|Laboratory Biomarker Analysis|Correlative studies
223870465|NCT01622868|DRUG|Lapatinib Ditosylate|Given PO
223870466|NCT01622868|RADIATION|Stereotactic Radiosurgery|Undergo SRS
223870467|NCT01622868|RADIATION|Whole-Brain Radiotherapy|Undergo WBRT
223870468|NCT01010685|PROCEDURE|Recovery of gallbladder via gastrotomy instead of via the skin|The gallbladder is dissected as for a standard laparoscopic cholecystectomy but is then recovered via a hole in the stomach created and closed endoscopically rather than through the skin as in the standard fashion
223870469|NCT03359317|BEHAVIORAL|jogging|Jogging as instructed for 1 year
223870470|NCT03039244|OTHER|Photodynamic therapy|After Scaling and root planing, periodontal pockets will receive the antimicrobial (aPDT) photodynamic therapy. Shortly phenothiazine hydrochloride photosensitizing is applied at a concentration of 10mg/mL from the pocket bottom to the gingival margin. After 1 minute, irrigation is performed from periodontal pockets with distilled water to remove excess dye. The stained area is then irradiated with a diode laser with 660 nm of wavelength and maximum power of 60 mW/cm², through a fiber-optic probe of 0.6 mm diameter. Exposure to radiation will occur at six sites per tooth under treatment, making the total time of 1 minute per element, or the equivalent of 10 seconds per site. The aPDT applications will be repeated in the same way until the second week in the days 2, 7 and 14.
223870471|NCT03039244|OTHER|Control Group|A sham procedure will be held simultaneously in pairs of contralateral teeth selected that will not receive the aPDT (control group).
223870472|NCT03039244|DEVICE|Diode Laser|
224268817|NCT05050851|DIETARY_SUPPLEMENT|Measurement of nutritional parameters in children with pneumonia|measurement of Body Mass Index, head circumference, weight, length
224268818|NCT05336097|OTHER|Pathways to Empowerment|Pathways to Empowerment (PTE) is a program for person-centered intervention. PTE is rooted in the Strengths Model by Rapp and Goscha (2011), and in the Social Quality Approach as described by Van der Maesen and Walker (2005). The general aim of PTE is to improve the quality of the daily lives of persons who experience loss of control in their lives by focusing on their strengths and stimulating their personal agency, participation in society, and self-direction in life. The main task of professionals is to help create the conditions in which growth and recovery are likely to occur.
223870473|NCT06553768|DRUG|Maralixibat|Maralixibat will be provided as an oral solution along with 0.5-, 1.0-, and 3.0-mL sized dosing dispensers. During the double-blind dose escalation period (4 weeks), the study drug (maralixibat) will be administered once daily for 1 week and then twice daily (BID; morning and evening). During the double-blind stable dosing period (16 weeks), participants will be treated with 300 μg/kg BID or the maximum tolerated dose (determined during the double-blind dose-escalation period) of maralixibat. During the open-label dose escalation period (4 weeks), all participants will receive maralixibat treatment once daily for 1 week and then twice daily (BID; morning and evening). During the open-label stable dosing period (at least 16 weeks), participants will be treated with 300 μg/kg BID or the maximum tolerated dose (determined during the open-label dose-escalation period) of maralixibat.
223870474|NCT06553768|OTHER|Placebo|Placebo matched to maralixibat will be provided as an oral solution along with 0.5-, 1.0-, and 3.0-mL sized dosing dispensers. During the double-blind dose escalation period (4 weeks), study drug will be administered once daily for 1 week and then twice daily (BID; morning and evening). During the double-blind stable dosing period (16 weeks), participants will be treated with 300 μg/kg BID or the maximum tolerated dose (determined during the double-blind dose-escalation period) of study drug. During the open-label dose escalation period (4 weeks), all participants will receive maralixibat treatment once daily for 1 week and then twice daily (BID; morning and evening). During the open-label stable dosing period (16 weeks), participants will be treated with 300 μg/kg BID or the maximum tolerated dose (determined during the open-label dose-escalation period) of maralixibat.
223870475|NCT01285986|PROCEDURE|Vein collar at the distal anastomosis|Vein collar interposed at the distal anastomosis or No vein collar interposed at the distal anastomosis
223870476|NCT03990285|DRUG|Axumin, Intravenous Solution|To compare 18F-fluciclovine PET uptake measures in glioblastoma patients with tumor progression versus pseudoprogression
223870477|NCT05806060|DRUG|VEGFR and nab-paclitaxel, with maintenance of VEGFR and capecitabine|VEGFR bevacizumab 10mg/kg d1,15 ivgtt + nab-paclitaxel 100mg/m2 d1,8,15 ivgtt, 4 weeks as a cycle. Capecitabine with bevacizumab maintenance if intolerable toxicity was observed with no progression. Capecitabine maintenance 1000mg/m2 po bid d1-d14 every 3 weeks and bevacizumab 10mg/kg d1,15 ivgtt every 4 weeks.
223870478|NCT05806060|DRUG|nab-paclitaxel, with maintenance of capecitabine|Nab-paclitaxel 100mg/m2 d1,8,15 ivgtt, 4 weeks as a cycle. Capecitabine maintenance if intolerable toxicity was observed with no progression. Capecitabine maintenance 1000mg/m2 po bid d1-d14 every 3 weeks.
223870479|NCT05806060|DRUG|Eribulin Mesylate/Vinorelbine/Capecitabine/Carboplatin/UTD1|TPC
223870480|NCT05806060|DRUG|VEGFR and TPC|VEGFR bevacizumab and TPC
223870481|NCT06009120|OTHER|Education|The education program emphasized the characteristics of the oral stage, positive traits that can be acquired when the baby's needs are met during this stage, negative traits that may develop in the baby when their needs are not met, and the relationship between the oral stage and breastfeeding.
223870482|NCT04339348|DRUG|vaginal misoprostol|vaginal misoprostol 200 mcg will be given 3 hours before LNG-IUD insertion plus inert placebo cream vaginally at the time of LNG-IUD insertion
223870483|NCT04339348|DRUG|Lidocaine-Prilocaine Topical cream|Lidocaine-Prilocaine cream will be applied on the cervix at the time of LNG-IUD insertion plus vaginal placebo tablet 3 hours before LNG-IUD insertion
223870484|NCT04339348|DRUG|placebo|inert placebo cream will be applied on the cervix at the time of LNG-IUD insertion plus vaginal placebo tablet 3 hours before LNG-IUD insertion
223870485|NCT04151082|DRUG|Methylprednisolone|Given IV
223870486|NCT04151082|DRUG|Prednisone|Given PO
223870487|NCT04151082|OTHER|Quality-of-Life Assessment|Ancillary studies
223870488|NCT04151082|OTHER|Questionnaire Administration|Ancillary studies
223870489|NCT03117023|DRUG|dexmedetomidine|sufentanil 0.05ug/kh/h + dexmedetomidine 0.1ug/kg/h for 48h after surgery
223870490|NCT04261465|DRUG|Olaparib|PARP INHIBITOR
223870491|NCT04261465|DRUG|Paclitaxel|Chemotherapy
223870492|NCT04261465|DRUG|Carboplatin|Chemotherapy
223870493|NCT01164098|DRUG|Rituximab|Induction therapy
223870494|NCT03364595|PROCEDURE|plate fixation|ORIF of the radial head fracture
223870495|NCT03364595|PROCEDURE|replacement|replacement of the radial head fracture
223870496|NCT02761239|DEVICE|The NIM 3.0 Nerve Monitoring System|Electromyography recordings were accomplished with a pair of needle electrodes inserted through the CP muscle, which were plugged into the third and fourth channels of interface-connector box.The recurrent laryngeal nerve(RLN), vagus nerve, external branch of the superior laryngeal nerve(EBSLN) and pharyngeal plexus were stimulated with a current of 1 mA and a frequency of 4 MHz and the event threshold at 100 microV.
223870497|NCT04125433|BEHAVIORAL|Peer Integrated Care Services|The project employs a two level intervention to include Peer Support Specialist (PSS) and Community Health Advocate (CHA). Contact and engagement with participating members will be through both direct intervention in the emergency department as well as in the community for prevention visits and follow up. Peers and Community Health Advocates will address Behavioral and Social Determinants of Health (SDoH) concerns through a coordinated intervention supported by a common IT Medicaid member tracking platform. This research project will determine the feasibility of deploying a single shared IT platform that will include referral, appointment completion, and intervention outcome data. Project staff will develop a relationship with the members improving member access and engagement with community-based services. The project will determine the impact on total cost of care through redirecting study participants to community resources rather than return visits to the emergency department.
223870498|NCT03221023|DRUG|Vancomycin Hydrochloride|Individuals in the experimental arm will receive intrawound Vancomycin-saline + IV antibiotics
223870499|NCT03221023|DRUG|Saline Solution|Individuals in the control arm will receive intrawound saline solution
223870500|NCT04192305|PROCEDURE|LPV|LPV means tidal volume of 6 ml/kg, inspiratory-expiratory (I/E) ratio of 1/1, positive end expiratory pressure (PEEP) minimum 5 cmH20 and higher during laparoscopy in obese patients, Inspiratory oxygen concentration (FIO2) 40 % during maintenance and extubation while also giving CPAP. Lung recruitment maneuver (LRM) when lung compliance decreases below 40 ml/cmH2O.
223870501|NCT04192305|PROCEDURE|routine LV|Give volume en frequency as required by end tidal carbon dioxide, PEEP and LRM only when saturation drops intra operative, no requirement to use low FIO2 and CPAP during extubation.
223870502|NCT03419299|OTHER|Tube Feeding Application|A smart device application was developed and used to help residents determine the best enteral nutrition prescription for patients admitted to the ICU
223870503|NCT02767765|DRUG|r-HuEPO|All participants will receive r-HuEPO for 4 weeks, at a dose of 10000 international units per day (IU/day) according to 6 days/week schedule for first 2 weeks and at a dose of 10000 IU/day according to 3 days/week schedule (participants with response to treatment at end of Week 2) or according to 6 days/week schedule (participants without response to treatment at end of Week 2) for next 2 weeks.
223870504|NCT01951170|DRUG|Tocilizumab|162 milligrams (mg) tocilizumab was administered subcutaneously once weekly for 24 weeks
223870505|NCT01318967|DRUG|Furosemide|Renal blood flow is measured after the administration of 20 mg of furosemide during MRI scan only.
223870506|NCT01318967|OTHER|Placebo|
223870507|NCT03015311|DRUG|Intensive BP control|For all participants, Olmesartan Medoxomil tablets or Amlodipine Besylate tablets will be used as an initial therapy. Other drugs, including hydrochlorothiazide and β-blockers, are allowed, in order to achieve the SBP target. If the target BP level is not achieved during the Follow-up periods, adjustment of drug type and dosage will be carried out according to procedures defined in the protocol.
223870508|NCT03015311|DRUG|Standard BP control|For all participants, Olmesartan Medoxomil tablets or Amlodipine Besylate tablets will be used as an initial therapy. Other drugs, including hydrochlorothiazide and β-blockers, are allowed, in order to achieve the SBP target. If the target BP level is not achieved during the Follow-up periods, adjustment of drug type and dosage will be carried out according to procedures defined in the protocol.
223870509|NCT04980274|OTHER|Intervention focused on identified organ dysfunction(s)|Intervention focused on identified organ dysfunction(s)
223870510|NCT01305252|DRUG|treprostinil inhalations|Treprostinil inhalation QID starting at 3 breaths per inhalation \& gradually increasing to 9 breaths. Each breath provides approximately 6mcg of treprostinil.
223870511|NCT01305252|DRUG|tadalafil|tadalafil 20mg QD PO increasing to 40mg QD as tolerated
223870512|NCT00700986|DRUG|AZD9056|Oral tablet, 800mg, one single administration
223870513|NCT00700986|DRUG|Placebo|Single dose
223870514|NCT03020979|DRUG|Apatinib|Patients will take 500mg apatinib daily orally.
223870515|NCT02275377|OTHER|Inspiratory muscle training (IMT)|Participants will receive IMT for 30 min, 7 times per week for 8 weeks using Inspiratory muscle trainer device (PowerBreathe). During training, participants will be instructed to maintain diaphragmatic breathing with a breathing rate of 15-20 cycles/min. Inspiratory load will be set at 40% of maximum static inspiratory pressure, and weekly training loads will be adjusted to maintain 40% of MIP. Each week, six training sessions will be held at home and a training session will be supervised in the research center.
223870516|NCT02275377|OTHER|Sham IMT|Participants will receive IMT for 30 min, 7 times per week for 8 weeks using Inspiratory muscle trainer device (PowerBreathe). During training, participants will be instructed to maintain diaphragmatic breathing with a breathing rate of 15-20 cycles/min, but without a load generating resistance. Each week, six training sessions will be held at home and a training session will be supervised in the research center.
223870517|NCT00774904|DRUG|Losartan|Angiotensin II Type 1 Receptor Blockers
223870518|NCT00181311|PROCEDURE|hysterectomy|
223870519|NCT01105117|DRUG|ACT-385781A (Actelion Epoprostenol)|per Prescribing Information
223870520|NCT01105117|DRUG|Flolan®|per Prescribing Information
223870521|NCT03631433|DRUG|Ibuprofen 600 mg|identical appearing tablets containing 600 mg of ibuprofen
223870522|NCT03631433|DRUG|ibuprofen 600 mg and acetaminophen 650 mg|identical appearing tablets of the combination of ibuprofen and acetaminophen
223870523|NCT03999034|DIAGNOSTIC_TEST|questionnaire completion|Every patient (140) and healthy control (400) will fill in all the tests and questionnaires, except FSS, in a random order during a single appointment. The FSS will be fill in by patients only. All 400 healthy controls will be divided in 20 groups of 20 people, according to gender, age (5 classes: 18-33, 34-43, 44-54, 55-64, and more than 65 years old), and level of education (graduated or not). 60 of them will pass the XO test at the beginning and again at the end of the consult to investigate the test-retest effect.
223870524|NCT04894851|BEHAVIORAL|Contingency Management|Participants in the current study will receive contingencies for improvement in clutter, as measured by a trained, independent in-home rater. Ratings will be completed by after study consent, and once every month thereafter, being conducted at weeks 0, 4, 8, 12, and 16 of treatment. Participants will be reimbursed for each new 1-point reduction in CIR score, a set dollar amount per month for each CIR point reduction they maintain from baseline. Therefore, a perfectly performing patient would earn reimbursement (A CIR reduction of 8 points made in the first month and maintained throughout treatment. If a CIR score is higher than the prior month, the reinforcement schedule will reset to zero.
223870527|NCT05277441|DIAGNOSTIC_TEST|Novel severity grading system of unexpected events in pediatric surgery|Classification of unexpected events according to the Clavien-Madadi classification for pediatric surgical patients and simultaneously the non-modified Clavien-Dindo classification in more than 10.000 patients who have been treated at a single center from 2017 to 2022.
223870528|NCT05397262|OTHER|Hyperthermia|Deep Regional Hyperthermia (RHT) 1-2/week up to 10 sessions a type of cancer treatment in which body tissue is exposed to high temperatures (up to 113°F).
223870529|NCT05397262|RADIATION|Radiotherapy|50,4 Gy (28 x 1,8 Gy) plus Boost: If R0: 5,4 Gy; If R1/2: 9 Gy
223870530|NCT05397262|DRUG|Chemotherapy 5-Fluorouracil|600 mg/m\^2 civ 120h; d 1-5, 29-33
223870531|NCT05397262|DRUG|Chemotherapy Cisplatin|20 mg/m\^2; d1-5, 29-33
223870532|NCT00077675|DRUG|Telavancin|Telavancin 7.5 mg/kg/day, amended to 10 mg/kg/day, IV (intravenously) for up to 14 days
223870533|NCT00077675|DRUG|vancomycin or antistaphylococcal penicillin|Vancomycin 1 Gram IV (intravenously) every 12 hrs or nafcillin 2 Grams, oxacillin 2 Grams, or (in South Africa) cloxacillin 0.5 - 1 Gram, IV (intravenously) every 6 hrs for up to 14 days.
223870534|NCT03036176|BEHAVIORAL|Play-based family centered stimulation|Children in the intervention group received routine medical treatment and nutritional rehabilitation services in hospital; their primary caregivers were given basic orientations on child care, feeding and nutrition. Children attended play-based stimulation sessions in which trained nurses demonstrated caregivers on how to stimulate the SAM child using play materials and facilities at playroom and playground of the hospital. After discharge from hospital, they were followed up at home and visited three times over a period of six months. During the visits, new play materials were provided and caregivers were shown how to use them to stimulate the SAM child.
223870535|NCT03036176|OTHER|no intervention|On the other hand, the control SAM group did not receive the guided psychomotor/psychosocial stimulation services although they had access to the playground facilities. Both the intervention and the control groups received all the routine medical care and dietary rehabilitation services at the hospital.
223870536|NCT00081601|DRUG|CEP-701|
223870537|NCT00244855|OTHER|pharmacological study|Correlative studies
223870538|NCT00244855|BIOLOGICAL|rituximab|Given IV
223870539|NCT00244855|DRUG|dexamethasone|Given IV
223870540|NCT00244855|OTHER|laboratory biomarker analysis|Correlative studies
223870541|NCT04816487|DRUG|Potassium Iodide or Glutathione|Patient will receive either Glutathione or Potassium iodide
223870542|NCT05608343|DRUG|Difamilast|Off-white ointment containing active ingredient, petrolatum and other ingredients
223870543|NCT05608343|DRUG|Placebo|Matching Difamilast (Study drug) ointment without active ingradient
223870544|NCT00599716|DRUG|sodium hyaluronate|a sterile, unpreserved eye drop containing sodium hyaluronate in a proprietary formulation to be administered by ocular instillation
223870545|NCT00599716|DRUG|vehicle|identical to proprietary formulation of active eye drop but without active ingredient, sodium hyaluronate
223870546|NCT02957981|BEHAVIORAL|Web-based Counseling|The web-based genetic counseling and education intervention will include standard information typically provided in individual genetic counseling. the intervention will be individually tailored based upon key clinical and demographic characteristics of the participant.
223870547|NCT02957981|BEHAVIORAL|Standard Care|Standard care includes access to resource list for men from hereditary cancer families plus access to standard clinical genetic counseling
223870548|NCT00660439|BEHAVIORAL|Narrative Exposure Therapy|"Psychological treatment, with narration of positive and traumatic events in patients history, including in vivo exposure of traumatic events. The narrative is written down by the therapist."
223870549|NCT06110416|OTHER|nausea relief inhaler|Aromatherapy and essential oils are an alternative method to controlling post-operative nausea and vomiting after post-surgical intervention.
223870550|NCT01895023|DRUG|Dexmedetomidine|The dexmedetomidine group received intranasal dexmedetomidine 2mcg/kg premedication 45 min before induction of anaesthesia.
223870551|NCT01895023|DRUG|Midazolam|The midazolam group oral midazolam 0.5 mg/kg 30 min before induction of anaesthesia.
223870552|NCT01895023|DRUG|Saline|The Placebo group received intranasal saline premedication 45 min and oral saline 30 min before induction of anaesthesia
223870553|NCT03966508|PROCEDURE|High-frequency electrical stimulation|High-frequency stimulation will be applied on the volar forearm (6-10 cm distal to the cubital fossa). To avoid any confounding effect of handedness, the arm onto which HFS will be applied twice (dominant vs nondominant) will be counterbalanced across participants. HFS will consist of 12 trains of 42 Hz electrical pulses lasting 1 s each. The time interval between each train will be 10 s. The intensity of stimulation will be 5mA. Electrical pulses will be delivered to the skin using a specifically-designed electrode designed: the cathode consists of 16 blunt stainless-steel pins with a diameter of 0.2 mm protruding 1 mm from the base. The 16 pins are placed in a circle with a diameter of 10 mm. The anode consists of a surrounding stainless-steel ring having an inner diameter of 22 mm and an outer diameter of 40 mm. This procedure induces secondary pinprick hyperalgesia (an increase in pinprick sensitivity in a large area of the skin).
223870554|NCT01093430|PROCEDURE|Anterior superior iliac spine|The position of the right and left laparoscopic port sites will be determined by palpation of the nearby anterior superior iliac spine of the pelvic bone.
223870555|NCT01093430|PROCEDURE|Control|The position of the right and left laparoscopic port sites will be determined by visual inspection of the anterior abdominal wall.
223870556|NCT06214117|DRUG|Remimazolam|Anesthesia induction:intravenous Fentanyl 2-3 μg/kg, remimazolam 0.3-0.5 mg/kg and Rocuronium 0.6mg/kg; Maintenance of anesthesia:Remimazolam will infuse initially at a rate of 2 mg/kg/h (1-3 mg/kg/h), and remifentanil will administer at an initial infusion rate of 0.25 μg/kg/min (0.1-0.5 μg/kg/min).
223870557|NCT06214117|DRUG|Sevoflurane|Anesthesia induction: Anesthesia will induce with 8% sevoflurane in 100% oxygen at flow rate of 6 L/min, and then intravenous fentanyl (2-3 μg/kg) and rocuronium (0.6 mg/kg); Maintenance of anaesthesia: Anesthesia depth will maintain at 1-1.5 minimum alveolar concentration (MAC), and remifentanil was infuse at an initial rate of 0.25 μg/kg/min (0.1-0.5 μg/kg/min).
223870558|NCT00727922|DRUG|Mangafodipir|Mangafodipir (0.5 ml/kg) is administered as a 30 minutes infusion just after each administration of oxaliplatin. The oxaliplatin dose (85 to 100 mg/m²) and the length of the infusion (2 hours) are the same that before the inclusion and modifications are not authorized during all the study participation. During 4 months (8 administrations).
223870559|NCT03101410|BEHAVIORAL|Gluten|Selected participants will be randomly allocated to treatment group (gluten or gluten free).
223870560|NCT03101410|BEHAVIORAL|Gluten free|Selected participants will be randomly allocated to treatment group (gluten or gluten free).
223870561|NCT00428519|DRUG|Placebo|Placebo for 14 days
223870562|NCT00428519|DRUG|Aprepitant|Aprepitant at a dose of 125 mg daily for 14 days
223870563|NCT00428519|DRUG|Aprepitant|Aprepitant at a dose of 250 mg daily for 14 days
223870564|NCT01760109|DRUG|Piperacillin Sodium and Sulbactam Sodium|1.5-3.0g,iv,bid 7-14 days serious infections 6.0-12.0g,iv,tid for 7-14 days
223870565|NCT03953222|DEVICE|Wearable real-time feedback device|The proposed wearable device can provide real-time feedback of primary gait and posture measures through auditory feedback. The feasibility of people with Parkinson's disease (PD) to utilize to feedback to modulate and improve their gait and posture will be investigated. Two types of feedback will be studied: (a) continuous feedback involving sonification of movements to facilitate learning proper movements (such as to take big steps, swing arms, rhythmic walking, maintain upright posture, etc.) and (b) on-demand feedback where the feedback is provided only if necessary to reduce overload of information and prevent developing dependency on the system.
223870566|NCT04853602|BIOLOGICAL|IFx-Hu2.0|"The investigational drug product IFx-Hu2.0 is composed of the drug substance pAc/emm55 (pDNA) complexed with the two excipients in vivo-jetPEI® (linear polyethylenimine), a transfection reagent, and dextrose, a pDNA/polyethylenimine complex stabilizer.~Therapeutic Classification:~* Immunomodulatory Agent~Route of Administration:~* Intralesional (i.e. injection of cutaneous, subcutaneous or nodal lesions)~Mechanism of Action:~* Injection of IFx-Hu2.0 into the lesion facilitates the expression of the immunogenic Emm55 protein by the tumor cells.~Physiological Effect:~* Expression of the emm55 gene by the tumor cells triggers immune recognition of tumor-specific and -associated antigens which leads to innate and adaptive immune responses. In addition to priming anti-tumor immunity in immune checkpoint inhibitor (ICI)-naïve patients, this could re-sensitize patients with primary or secondary ICI clinical resistance."
223870567|NCT05173324|BIOLOGICAL|HPV vaccine|Licensed HPV vaccines (bivalent, quadrivalent, or nonvalent) available in the country of the study site
223870568|NCT05173324|DIAGNOSTIC_TEST|HPV testing|HPV testing with partial genotyping of HPV16/18 (and/or 45) to be used as a primary cervical screening test for all participants regardless of the study arm
223870569|NCT05173324|BIOLOGICAL|HAV vaccine|Hepatitis A virus (HAV) vaccine to be offered as a placebo
223870570|NCT06131892|OTHER|Defibrillation|Defibrillation
223870571|NCT01061203|DRUG|Grazax|Treatment with 75.000 SQ-T once daily
223870572|NCT01061203|DRUG|Placebo|Tablet with no active grass component.
223870573|NCT03653169|DEVICE|Transcranial Magnetic Stimulation|TMS is a form of noninvasive brain stimulation. An external electromagnetic coil is placed on the head, and a large current is passed through an insulated wire coil held flat on the surface of a subject's scalp in a fraction of a millisecond. This pulse of current induces a weak electrical current within the surface brain cortex. Repetitive trains of TMS pulses (repetitive TMS or rTMS) can transiently modulate corticospinal excitability following the rTMS train. When current is delivered at high frequency (10 Hz), it may simultaneously increase the activity of the brain at this site. In this study, individuals will receive 10 treatments with intermittent theta burst stimulation (twice daily for 5 days).
223870574|NCT05622396|PROCEDURE|Mindfulness Based Stress Reduction|Inspired by the standard Mindfulness Based Stress Reductio program, the study MAdaPARK is a 8 week program with weekly sessions of 2h30 and a full day of practice designed from the analysis of the post-program interviews carried out as part of the M-PARK study,as well as the reflections of the working group specially set up for this purpose. Several areas of adaptation have been identified: shorter mediations, a break time during the sessions, more times for exchanges, a more developed practice in movement, and finally, more important work based on self-esteem and self-compassion.
223870575|NCT04306718|PROCEDURE|membrane peeling|ERM and ILM are peeled routinely during surgery
223870576|NCT00098553|DRUG|everolimus|
223870577|NCT02838199|DEVICE|SAPIEN 3|
223870578|NCT02838199|PROCEDURE|SAVR|
223870579|NCT02050763|BEHAVIORAL|The SHARE Project|"SHARE aimed to reduce IPV and used methodologies from two proven successful violence prevention frameworks: Stepping Stones (Welbourn, 1995) and the Resource Guide for Mobilizing Communities to Prevent Domestic Violence (Michau \& Naker, 2003). SHARE promoted a process of social change based on the Transtheoretical Model's Stages of Change Theory (Prochaska \& DiClemente, 1983; Prochaska \& Velicer, 1997) which posits that although people realize they need to make changes in their life, they do it in stages instead of one major life change. There are five main stages of change: (1) pre-contemplation, (2) contemplation, (3) preparation for action, (4) action and (5) maintenance.~We hypothesized that repeated exposure to the ideas included in SHARE would encourage men and women to begin a process of change that results in preventive behavior."
223870580|NCT01336439|DRUG|Botulinum toxin type A (Meditoxin®)|"In this study, the botulinum toxin type A (Meditoxin®)was supplied as a freeze-dried powder of 200U, and was reconstituted with 4ml of sterile saline to a concentration of 5U/0.1ml.~After pre-injection polysomnography, botulinum toxin type A was injected into each side bilaterally using a 1ml-syringe with a 29-gauge, and a 1/2-inch needle. The M group had an injection in masseter muscle. The MT group had an injection in masseter and temporal muscle. A total of 25U of botulinum toxin type A was injected into each site.~After 4 weeks, the subjects had a post-injection polysomnography."
223870581|NCT00534183|DRUG|Olanzapine|Olanzapine in dose range of 10-20mg
223870582|NCT00534183|DRUG|Risperidone|Risperidone 1-6mg
223870583|NCT00534183|DRUG|Haloperidol|Haloperidol 10-20mg
223870584|NCT05898152|OTHER|Data collection|A collection about patient's data demographic, neurologic and gynecologic follow-up and satisfaction will be review by questionnaire. And a calendar of epileptic seizures will be completed by patients on 4 months
223870585|NCT02957006|DEVICE|Loop Recorder|Observation of Loop Recorder implanted for clinical reasons
223870586|NCT05996588|DRUG|Propofol 1 % Injectable Suspension|Propofol 1 % Injectable Suspension at a rate of 50 microgram/kg/min intravenously
223870587|NCT05996588|DRUG|Sevoflurane|Sevoflurane inhalation anaesthetic at a concentration of 4-5% to achieve a MAC of 0.25
223870588|NCT02928757|OTHER|Complex care clinic as part of the CCKO initiative|"The CCKO intervention involves intensive care coordination, defined as: deliberate organization of patient care activities between two or more participants (including the patient) involved in a patient's care to facilitate the appropriate delivery of health care services. Organizing care involves marshaling of personnel and other resources needed to carry out all required patient care activities and is often managed by the exchange of information among participants responsible for different aspects of care. Within CCKO, intensive care coordination will specifically include: 1) the tailored, family/health care provider co-creation and regular updating of care coordination plans for each child which will be 2) facilitated and accounted for by key workers partnering with families."
223870589|NCT00767013|OTHER|DSCT, TTE|One assessment each
223870590|NCT04861324|BEHAVIORAL|Dietary Intervention|Increasing fruit and vegetable by two servings a day and at least 30 min a day of postprandial physical activity
223870591|NCT00214591|DRUG|GALIDA|
223870592|NCT00875160|DRUG|AT2101|225mg (nine 25mg capsules total dose) to be taken by mouth every day for 9 days (Study Days 1, 3-10)
223870593|NCT02706717|DRUG|Visbiome Extra Strength|From week 2 to 4, participant will receive one sachet orally daily. From week 4 to 26, participant will receive one sachet orally twice daily.
223870594|NCT02706717|DRUG|Placebo|From week 2 to 4, participant will receive one sachet orally daily. From week 4 to 26, participant will receive one sachet orally twice daily.
223870595|NCT01977638|DRUG|CXD101|Capsules, administered orally
223870596|NCT03420209|BEHAVIORAL|Group applying PNF technique|
223870597|NCT01911169|DRUG|Cholecalciferol|5,000 International units versus 400 international units as an active comparator
223870598|NCT04122937|PROCEDURE|Cytoreductive surgery|Partial removal of peritoneal tissue involved by neoplastic invasion
223870599|NCT00293293|OTHER|healing touch|The practitioner performed a structured interview with the patient both a verbal assessment and an energy/physical assessment using pendulum and hand scan techniques. The practitioner will then provide the intervention which will consist of: chakra connection, magnetic passes (hands still and in motion), magnetic clearing.
223870600|NCT00293293|OTHER|massage therapy|Standard massage techniques will be employed over the head, neck, shoulders, back, hands, and/or feet areas. The intensity and rapidity of massage movements will be individualized to the patient's comfort level.
223870601|NCT00293293|OTHER|hypnosis|Steps: 1) begins with a progressive relaxation induction; 2) suggestions for deepening are then provided; 3) offered suggestions to increase comfort with medical procedures; 4) suggestion for enhanced capacity for coping will be given as an ego strengthening suggestion, with a post-hypnotic suggestion for increasing comfort/success in coping each time.
223870602|NCT00293293|DRUG|Standard chemotherapy|Patients will receive 6 cycles of taxane and platinum therapy as prescribed by their treating physician. Chemotherapy treatment is not part of this study.
223870603|NCT04446078|DEVICE|PEEK- acrylic resin prosthesis supported by 4 dental implants|Patients rehabilitated for edentulism of one or both arches through an implant supported fixed prosthesis
223870604|NCT03873337|BEHAVIORAL|Persistence Targeted Smoking Cessation in SMI (PTSC-S)|All participants will receive 8 weeks of persistence focused smoking cessation counseling delivered via telehealth
223870605|NCT03873337|DRUG|Nicotine patch|All participants will receive 10 weeks of nicotine patch
223870606|NCT02328768|DRUG|Omegaven|
223870607|NCT02512965|RADIATION|20 Gy in 5 fractions|
223870608|NCT02512965|RADIATION|Conventional SBRT: 24 Gy in 2 fractions|
223870609|NCT00835770|DRUG|dimethyl fumarate|BG00012 capsules
223870610|NCT00835770|DRUG|Placebo|Capsules taken to maintain the blind in the 240 mg BID treatment group.
223870611|NCT02888808|OTHER|Gastroscopy|Upper gastrointestinal endoscopy procedure
223870612|NCT00226538|DRUG|Phenytoin|
223870613|NCT00226538|DRUG|Rifampicin|
223870614|NCT00226538|DRUG|Diclophenac|
223870615|NCT00226538|DRUG|Fluconazole|
223870616|NCT01185782|DRUG|Gonalef® (Follitropin alfa)|Subcutaneous administration of follitropin alfa at a dose of 75 IU/day was started on dosing Day 1 and the same daily dose was maintained for the first 7 days of the treatment period. Dose increment by 37.5 IU was permitted on dosing Day 8, Day 15 and Day 22 if the dosage increase criterion was met.
223870617|NCT01185782|DRUG|Purified pituitary gonadotropin (Fertinorm-P®)|Subcutaneous administration of purified pituitary gonadotropin at a dose of 75 IU/day was started on dosing Day 1 and the same daily dose was maintained for the first 7 days of the treatment period. Dose increment by 37.5 IU was permitted on dosing Day 8, Day 15 and Day 22 if the dosage increase criterion was met.
223870618|NCT05076799|DRUG|100 ml lactulose combined with 1 L PEG|the participants were instructed to consume 100 ml lactulose combined with 1000 mL of PEG solution
223870619|NCT05076799|DRUG|100 ml lactulose combined with 2 L PEG|the participants were instructed to consume 100 ml lactulose combined with 2000 mL of PEG solution
223870620|NCT05076799|DRUG|200 ml lactulose|the participants were instructed to consume 200 ml lactulose alone
223870621|NCT05076799|DRUG|3 L Polyethylene glycol solution|the participants were instructed to consume 3000 mL of PEG solution
223870622|NCT03222323|DRUG|Dexmedetomidine perineurally|Dexmedetomidine is added perineurally on one side and will influence the nerve block perineurally on this side. Dexmedetomidine is also absorbed and redistributed systemically and will influence the opposite ulnar nerve block systemically.
223870623|NCT03222323|DRUG|Ropivacaine 5mg/ml|Ropivacaine is used in 5mg/ml in the perineural, systemic and placebo nerve blocks.
223870624|NCT03222323|DRUG|Ropivacaine 7.5mg/ml|In the high dose ropivacaine group a ropivacaine concentration of 7.5mg/ml is used.
223870625|NCT03222323|DRUG|Dexmedetomidine systemically|Dexmedetomidine administered perineurally on one side is absorbed and redistributed systemically and will influence the opposite ulnar nerve block systemically.
223870626|NCT03222323|DRUG|Isotonic saline|placebo (saline) is administered perineurally in all but the perineural group.
223870627|NCT00705588|DRUG|Tadalafil|Orally, titrated to maximum 20mg od
223870628|NCT00705588|DRUG|Vardenafil|Orally, titrated to 10 mg bid
223870629|NCT05278871|DEVICE|Constructive Shearwave Interference (CSI)|handheld ultrasound
223870630|NCT03480854|OTHER|Quality Improvement|Randomly selected sites will receive one of two system level improvement approaches; 1) patient centered specialty medical home certification 2) IHI Breakthrough Series improvement approach with professional improvement coaching.
223870631|NCT02006940|DEVICE|miniprobe Alveoflex|Alveoflex uses 488nm laser, generating real time moving images with an optical area of 600μm at a video frame rate of 12 images per second and a focus depth of 50μm
223870632|NCT06383117|DIETARY_SUPPLEMENT|Calcium carbonate|2 capsules containing 600 mg of calcium carbonate each
223870633|NCT06383117|DIETARY_SUPPLEMENT|Placebo Control|2 capsules containing methylcellulose
223870634|NCT03352778|RADIATION|IMRT|66Gy by intensity-modulated radiotherapy
223870635|NCT03352778|RADIATION|2DRT|66Gy by 2-dimensional radiotherapy
223870636|NCT04232371|PROCEDURE|New Ablation Technique|Patient will undergo ablation using voltage mapping and triangle of Koch propagation wave collision mapping. Ablation will be performed at or slightly above the site of wave front collision.
223870637|NCT04232371|PROCEDURE|Standard Ablation Technique|Ablation performed using the traditional anatomical / electrogram guided ablation approach.
223870638|NCT04141150|DRUG|[18F]APN-1607|In this study, all patients will receive one injection of \[18F\]APN-1607, a PET radiopharmaceutical selective for fibrillar tau. For the injection, subjects will receive a target dose of 7 mCi IV as a bolus injection. \[18F\]APN-1607 injection will be followed by a 10 ml saline flush.
223870639|NCT02347436|PROCEDURE|24-hr ambulatory blood pressure measurement|
223870640|NCT00149838|PROCEDURE|Prefrontal rTMS|Participants receive 120% motor threshold (MT) over left and right prefrontal cortex. Treatments will be administered daily for 3 weeks. Participants who show signs of improvement may continue Phase I for up to 3 additional weeks.
223870641|NCT00149838|DRUG|Antidepressant Regimen|Particpants who acheive remission with rTMS may start antidepressant medication in phase III.
223870642|NCT00149838|PROCEDURE|Sham Stimulation|The sham stimulation will mimic the sensation of rTMS but will not induce an intracerebral current. Treatments will be administered daily for 3 weeks.
223870643|NCT01684150|DRUG|EPZ-5676|MLL-r and MLL-PTD 28-day continuous IV infusion of each 28-day cycle. Number of cycles: until disease progression or unacceptable toxicity develops.
223870644|NCT02944188|PROCEDURE|Laparoscopic right hemicolectomy plus ERAS|patients treated with Laparoscopic right hemicolectomy plus enhanced recovery after surgery (ERAS) programs
223870645|NCT02944188|PROCEDURE|Open right hemicolectomy plus ERAS|patients treated Open right hemicolectomy plus enhanced recovery after surgery (ERAS) programs
223870646|NCT04217512|DRUG|Pantoprazole low dose|Pantoprazole 0.6 mg/kg
223870647|NCT04217512|DRUG|Pantoprazole high dose|Pantoprazole 1.6 mg\\kg
223870648|NCT04217512|OTHER|Standard hydration|Standard hydration alone
223870649|NCT04217512|DRUG|Cisplatin|Cisplatin
223870650|NCT02999022|DRUG|Lithium Carbonate|Intervention begins 14 days after injury for non-surgical participants and 2 weeks after surgery for participants who have surgical treatment of their fractures.
223870651|NCT02999022|DRUG|Lactose Placebo|Intervention begins 14 days after injury for non-surgical participants and 2 weeks after surgery for participants who have surgical treatment of their fractures.
223870652|NCT01117519|DRUG|Infusion Therapy|Based on changes of stroke volume measured by transoesophageal doppler patients during elective hip surgery will achieve either a unbalanced infusion solution, maximum dose of 100 ml/kg BW, or a compound of balanced infusion solution including 50% crystalloid and 50% colloid, each: maximum dose of 50 ml/kg BW. The study medication will be administered only during surgery.
223870653|NCT04434586|DEVICE|femoropopliteal revascularization for TASC C or TASC D lesion|Femoropopliteal revascularization: ATL or ATL/stenting for TASC C/D lesions. Control group: only angiography 2D final control. Experimental group: angiography + OCT control
223870654|NCT03950778|DRUG|Human albumin|Patients are divided into 2 groups by envelope randomization. In the treated group, albumin supplementation occurs up to a target of 30 g / l at the end of the test period at a maximum dose of 3 x 100 ml, and no albumin is added above the control value of 20 g / l. Patients with albumin below 20 g / l in the control group are excluded from the study and albumin supplemented. Blood samples are taken directly at the intensive care class, and at the same time on the following days. Urine was collected for 24 hours. The kinetics of the parameters are examined for five days.
223870655|NCT03324945|BEHAVIORAL|Neurocognitive assessments|Baseline and post-chemotherapy neurocognitive testing. A sequentially-assigned subset of participants also receive baseline and post-chemotherapy neuroimaging (FMRI)
223870656|NCT05660993|DRUG|Nivolumab|"Drug: Nivolumab Schedule: Nivolumab 3 mg/kg on day 0 of the Nivo-BeGEV or a maximum of 4 cycles Drug: Bendamustine~Schedule:~Day 2: Bendamustine 90mg/mq Day 3: Bendamustine 90mg/mq for a maximum of 4 cycles Other Name: Ribomustin~Drug: Gemcitabine Day 1: Gemcitabine 800mg/mq, Day 4: Gemcitabine 800mg/mq for a maximum of 4 cycles Other Name: Gemzar~Drug: Vinorelbine Day 1 Vinorelbine 20mg/mq for a maximum of 4 cycles Other Name: Navelbine"
223870657|NCT02147678|DRUG|Etomidate|
223870658|NCT02147678|DRUG|Propofol|
223870659|NCT02147678|DRUG|Remifentanil|During anesthesia maintenance, all patients will be given remifentanil at the speed of 0.2\~0.4 μg/kg/min.
223870660|NCT02147678|DRUG|Anesthesia induction|For all patients, the induction protocol is midazolam 0.1 mg/kg, sufentanil 0.3 μg/kg, cisatracurium 0.15 mg/kg.
223870661|NCT01232712|BIOLOGICAL|ImMucin, hGM-CSF|"* Six biweekly Intradermal or subcutaneous injections of 100 micrograms ImMucin~* After six injections, if response will not be observed, or if response will not be sufficient, Immucin dose will be escalated to 250 micrograms for six additional injections.~* In addition, each immunization, hGM-CSF with a total dose of 250 microgram will be injected."
223870662|NCT00144144|DRUG|Angiotensin II receptor antagonists, Calcium channel blocker|
223870663|NCT00338624|DRUG|oxybutynin chloride extended release|
223870664|NCT04577612|DRUG|CHI-554|hemp-derived CBD in MCT oil
223870665|NCT02988817|BIOLOGICAL|Enapotamab vedotin (HuMax-AXL-ADC)|Enapotamab vedotin (HuMax-AXL-ADC) will be administered intravenously.
223870666|NCT02906891|DEVICE|Vigilant Diabetes Management Application|The Vigilant Diabetes Management Companion by InSpark Technologies was developed to assist in the prevention of hypoglycemia by providing the individual with an unobtrusive analysis of their blood glucose values and notifying them about periods of upcoming risk for low and high blood glucose; and in particular periods of risk for severe hypoglycemia. This allows the individual to take preventive corrective action. Subjects will download the Vigilant DiabetesManagement Application and use it in conjunction with a study supplied wireless blood glucose meter. They will check blood glucose values at least three times a day and receive summaries and notifications from Vigilant regarding periods of risk and blood glucose patterns.
223870667|NCT04597658|BEHAVIORAL|Bodyweight supported treadmill training (BWSTT)|In the BWSTT group, walking training will be given by asking the patients to walk on the treadmill as fast as they can, without exceeding the medium intensity according to the Borg scale. Bodyweight support will be gradually reduced according to the patient's tolerance.
223870668|NCT04597658|BEHAVIORAL|Conventional rehabilitation|The conventional rehabilitation program includes posture and breathing exercises, lower extremity stretching, active-assistive range of motion and strengthening, balance-coordination exercises, and walking with a physiotherapist on a smooth surface.
223870669|NCT05369169|BEHAVIORAL|Resonance breathing|Participants will synchronize their breathing with a visual pacer (E-Z Air, Thought Technology, Ltd., Plattsburgh, NY) that moves up (inhale) and down (exhale) at the rate of 0.1 Hz (6 breaths per min)
223870670|NCT05369169|BEHAVIORAL|Low demand cognitive task|Different colored rectangles are presented for 10 sec each, and participants are instructed to silently count the number of blue rectangles
223870671|NCT05187975|PROCEDURE|Acupuncture|"Acupuncture:~Scalp acupuncture includes middle line of forehead (MS1), a front line by the forehead (MS2), and middle line of vertex (MS5), these acupoints are needled for 1 inch with the direction with scalp tilted 15-30 degrees.~Body acupuncture includes Yintang (DU29), Taichong (LR3), Shenmen (HT7), Neiguan (PC6), Danzhong (RN17), Qimen (LR14), Taixi (KI3).~Traditional Chinese medicine:~Chaihushugan Power: Chaihu 12g, Chenpi 12g, Chuanxiong 9g, vinegar Xiangfu 9g, Zhike 9g, Shaoyao 9g, roasted Gancao 3g.~Repetitive transcranial magnetic stimulation:~The CCY-I magnetic field stimulator from Wuhan Irid Medical Equipment New Technology Co is used, with a frequency of 10Hz.~Standard care:~The same as the standard care group."
223870672|NCT02634970|DRUG|Ranibizumab|0.5 mg, intravitreal injection
223870673|NCT05881317|DEVICE|ArtiAid® Plus Intra-articular Injection|Inject ArtiAid® Plus in the affected joint at weekly interval for 3 weeks
223870674|NCT01206504|BIOLOGICAL|MGAWN1|Humanized monoclonal to West Nile virus. Dose=30mg/kg
223870675|NCT00869011|OTHER|Endurance exercise|Endurance exercise, 3 times weekly for 35-45 minutes, 12 weeks.
223870676|NCT06498336|DIAGNOSTIC_TEST|Laboratory examination to determine the presence of sepsis|Standard laboratory biochemical methods will be used to determine sepsis diagnosis accord-ing to SEPSIS 3 (1). Blood samples for obtaining serum/plasma of the patients will be taken on the 1st and 4th day of sepsis diagnosis.
223870677|NCT06498336|DIAGNOSTIC_TEST|Laboratory examination to determine the presence of sepsis and acute kidney injury|Standard laboratory biochemical methods will be used to determine sepsis diagnosis according to SEPSIS 3 and acute kidney injury according to Guidelines Kidney Disease Improving Global Outcomes (KDIGO) 2012 (2). Blood samples for obtaining serum/plasma of the patients will be taken on the 1st and 4th day of sepsis diagnosis.
223870678|NCT06498336|DIAGNOSTIC_TEST|Laboratory examination to determine miRNA and biochemical parameters|Laboratory examination will be performed to determine miRNA and biochemical parameters.
223870679|NCT04967742|BIOLOGICAL|UB-612|UB-612 includes a designer S1-RBD-sFc fusion protein formulated with designer Th and CTL epitope peptides selected from immunodominant M, S2 and N regions known to bind to human MHC I and II.
223870680|NCT01336946|BEHAVIORAL|Psycho educational and behavioural group sessions|10 psycho educational and behavioural group sessions on topics like the Food Triangle, healthy eating, the importance of physical activity, healthy eating on a limited budget, implementing physical activity into the daily life, the influence of advertisements...
223870681|NCT01336946|BEHAVIORAL|Walking session|A weekly supervised walking session (30 minutes) in a 10-week period.
223870682|NCT00873405|PROCEDURE|Silastic® ring sleeve gastrectomy|SRSG group: ligation of the vessels of the greater curvature of the body and fundus of stomach; resection of the fundus and part of the body of stomach using a linear stapler (80 mm, Tyco®) and a 32-Fr tube to calibrate the remaining stomach; placement of a 6.2 cm Silastic® ring around the stomach, 5.0 cm below the esophagogastric junction.
223870683|NCT00873405|PROCEDURE|Silastic® ring gastric bypass|SRGB group: creation of a small, proximal gastric pouch using a linear stapler (80 mm, Tyco®) and a 32-Fr tube to calibrate the gastric pouch; creation of an intestinal loop of 150 cm and a biliopancreatic loop of 40 cm; placement of a 6.2 cm Silastic® ring around the stomach, 5.0 cm below the esophagogastric junction.
223870684|NCT05512858|BEHAVIORAL|sensory room|the room has dimmed lighting, sensing games, essential oils, picture books and cookbooks, two heavy blankets (weighing 9 kg and 11 kg), a rocking chair, and a vestibular plate. The occupational therapist will accompany the first entry into the room to create a sensory profile, adjust and instruct on the means, and write a treatment card. The treatment card will record the patient's choices and instructions for arranging the room, and it will be used by the staff members who will admit the patient as needed. Each patient will be able to stay in the room for self-treatment according to the individual treatment card prepared at the first sensory room treatment, up to half an hour.
223870685|NCT02722473|BIOLOGICAL|"NSE dosage hypothermia arm"|There 3 dosage of NSE per patient included: day 1, day 2 and day 3 during targeted temperature management between 33° and 37°C.
223870686|NCT02722473|BIOLOGICAL|"NSE dosage normothermia arm"|There 3 dosage of NSE per patient included: day 1, day 2 and day 3 during targeted temperature management at 37°C.
223870687|NCT03551535|BEHAVIORAL|Monitored, At-Home Exercise Intervention|Patients will be enrolled in the BurnAlong program as well as receive FitBit heart rate + activity monitors to track adherence rates to the prescribed exercise regimen on BurnAlong, with subsequent motivational interventions triggered if compliance varies from prescription
223870688|NCT06196788|DRUG|Gemcitabine|1000 mg per square meter
223870689|NCT06196788|DRUG|Nab paclitaxel|120 mg per square meter of body-surface area
223870690|NCT04065802|RADIATION|Stereotactic Radioablation|External, non-invasive radiation delivery to scar regions of heart to treat ventricular arrhythmias
223870691|NCT04725305|DEVICE|BiZact|It has been described as describes a bipolar device that continuously measures impedance of clamped tissue, adjusting energy levels in real time and automatically stopping energy delivery when a seal is established. Their literature suggests the device permanently seals vessels up to 3mm with less thermal damage, resulting in less intraoperative blood loss, more efficient procedures, and possibly less pain
223870692|NCT04725305|PROCEDURE|Standard of care|This method would involve removal of tonsils using electrocautery technique
223870693|NCT02559362|BEHAVIORAL|Survey|
223870694|NCT03319797|DRUG|NOVOCART® Inject plus|Treatment with NOVOCART® Inject plus (Autologous chondrocyte implantation)
223870695|NCT03833661|DRUG|M7824|Participants received an intravenous infusion of 1200 milligrams (mg) M7824 once every 2 weeks until confirmed disease progression, death, unacceptable toxicity or study withdrawal.
223870696|NCT06109220|BEHAVIORAL|Stromal vascular fraction,SVF|SVF was injected into the knee cavity
223870697|NCT06383793|PROCEDURE|overlap|Π
223870698|NCT01937507|DRUG|HAI with FOLFOX|HAI with FOLFOX q 3 weeks
223870699|NCT01248260|DIETARY_SUPPLEMENT|Folic Acid|4mg of higher strength folic acid once a day until delivery
223870700|NCT05193695|OTHER|Treadmill exercise|the patients walked on a treadmill for 20 minutes after dry needling, with an inclination of 5 degrees and at a speed at which the perceived exertion was 5 according to the Borg CR10 scale (Chen et al., 2002)
223870701|NCT00721565|BEHAVIORAL|Exercise Behavior Change|attend 12 supervised exercise sessions, attend 6 group sessions with psychologist, attend 3 counseling sessions with exercise specialist
223870702|NCT04238793|DRUG|KLS-2031|KLS-2031 administered by transforaminal epidural injection
223870703|NCT04238793|OTHER|Placebo|Normal Saline (0.9%) administered by transforaminal epidural injection
223870704|NCT03430258|DEVICE|high-flow nasal cannula|high flow of air with supplemental oxygen was delivered by an Optiflow cannula interface using an AIRVO 2 blower humidifier
223870705|NCT03430258|DEVICE|Conventional oxygen therapy|Conventional oxygen therapy
223870706|NCT05199142|DRUG|SDI-118|SDI-118 Powder in Capsules (PiC) are presented as Drug Substance in white, size 3, hydroxypropylmethylcellulose (HPMC) capsules. No excipients are added.
223870707|NCT05199142|DRUG|Placebo|The Matching Placebo for SDI-118 PiC is equivalent dose of mannitol (an inert excipient) in white, size 3, hydroxypropylmethylcellulose (HPMC) capsules.
223870708|NCT00946842|DRUG|Treatment A|Participants will receive phase II clinical study tablet formulation of TMC207 100 mg as a single oral dose with food on Day 1, Day 30 and Day 58.
223870709|NCT00946842|DRUG|Treatment B|Participants will receive newly developed tablet formulation with fine particle size distribution of TMC207 100 mg as a single oral dose with food on Day 1, Day 30 and Day 58.
223870710|NCT00946842|DRUG|Treatment C|Participants will receive newly developed tablet formulation with coarse particle size distribution of TMC207 100 mg as a single oral dose with food on Day 1, Day 30 and Day 58.
223870711|NCT00946842|DRUG|Treatment D|Participants will receive phase II clinical study tablet formulation of TMC207 100 mg as a single oral dose without food on Day 1, Day 30 and Day 58.
223870712|NCT00946842|DRUG|Treatment E|Participants will receive newly developed tablet formulation with fine particle size distribution of TMC207 100 mg as a single oral dose without food on Day 1, Day 30 and Day 58.
223870713|NCT00946842|DRUG|Treatment F|Participants will receive newly developed tablet formulation with coarse particle size distribution of TMC207 100 mg as a single oral dose without food on Day 1, Day 30 and Day 58
223870714|NCT00757133|PROCEDURE|Conventional laparotomy closure|Recommended technique: The laparotomy is closed with a slowly resorbable running suture (f.e. PDS) in a single layer. The length of the suture should approximately be four (4) times the length of the fascial incision. The skin is closed with the usual technique of the department
223870715|NCT00757133|PROCEDURE|Laparotomy closure with mesh augmentation|"Recommended technique: Mesh augmentation can be done in a retromuscular or a prefascial position. By consensus of the initial primary investigators a retromuscular (sublay) position of the mesh was chosen and as a mesh a light weight polypropylene mesh will be used. Retromuscular (sublay): (see reference no. 11: Rogers et al.) At the end of the vascular procedure the plane behind the rectus muscles (retromuscular-preperitoneal) is dissected as in a Stoppa repair for incisional hernias"
224268819|NCT05295524|OTHER|Kaftrio utilization in real life|daily utilization of PHEAL-CR-K application at home and VOC (volatile organic compound) measure of exhaled air for a group of the patients
224268820|NCT02271035|DRUG|Deflux|Deflux will be injected through the working channel of the cystoscope using a special needle into the submucosal space of the ureteral orifice (Deflux to one ureteral orifice and Vantris to the other side). The technique that will be used is HIT (Hydrodistention Implantation Technique)+ STING
224268821|NCT02271035|DRUG|Vantris|vantris will be injected through the working channel of the cystoscope using a special needle into the submucosal space of the ureteral orifice (Deflux to one Vantris to the other side). The technique that will be used is HIT (Hydrodistention Implantation Technique)+ STING
224268822|NCT03581630|DRUG|naltrexone/bupropion|Naltrexone hydrochloride (HCl) 8 mg/Bupropion hydrochloride (HCl) 90 mg extended release (ER) combination tablets, orally, one tablet, in the morning, daily, for 1 week, followed by Naltrexone HCl 8 mg/Bupropion HCl 90 mg ER combination tablets, orally, one tablet in the morning and one in the evening, daily, for 7 weeks.
224268823|NCT03581630|BEHAVIORAL|Mediterranean Diet|Diet instruction and menu samples from the dietitian on following the Mediterranean Diet.
223870716|NCT04530747|DRUG|Metformin + PAP|"Subjects randomized to this arm will receive 500 mg capsules containing metformin extended release (XR). Metformin XR dosing will be 500 mg (1 x 500 mg) every evening (qPM) during Week 1, 1000 mg (2 x 500 mg) qPM during Week 2, 1500 mg (3 x 500 mg) qPM during Week 3, and 2000 mg (4 x 500 mg) qPM from Week 4 onwards.~Subjects will also be provided PAP (positive airway pressure) device for standard management of obstructive sleep apnea."
223870717|NCT04530747|DRUG|Placebo oral capsule + PAP|"Subjects randomized to this arm will receive 500 mg capsules containing placebo. Placebo dosing will be 500 mg (1 x 500 mg) qPM during Week 1, 1000 mg (2 x 500 mg) qPM during Week 2, 1500 mg (3 x 500 mg) qPM during Week 3, and 2000 mg (4 x 500 mg) qPM from Week 4 onwards.~Subjects will also be provided PAP (positive airway pressure) device for standard management of obstructive sleep apnea."
223870718|NCT03292913|BEHAVIORAL|Positive Health Check|Positive Health Check (PHC) is an online intervention that delivers tailored evidence-based prevention messages to human immunodeficiency virus (HIV) positive patients through a series of brief interactive videos designed to simulate a conversation with an human immunodeficiency virus (HIV) primary care provider.
223870719|NCT03292913|BEHAVIORAL|Standard of Care|Standard of care for patients with human immunodeficiency virus (HIV) (this includes standard of care practices around antiretroviral therapy (ART) initiation, adherence and retention)
223870720|NCT03950622|BIOLOGICAL|V114|15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F in each 0.5 mL dose.
223870721|NCT03950622|BIOLOGICAL|Prevnar 13®|13-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F in each 0.5 mL dose.
223870722|NCT00296868|DRUG|ascorbic acid (vitamin C) versus placebo|
223870723|NCT05101954|PROCEDURE|Concentrated Growth Factors (CGF)|Concentrated Growth Factors membrane will be laid in the implant cavity. Bone graft material will be applied to fill the empty parts of the socket.
223870724|NCT05101954|PROCEDURE|Platelet-Rich Fibrin (PRF)|Platelet-Rich Fibrin (PRF) membrane will be laid in the implant cavity. Bone graft material will be applied to fill the empty parts of the socket.
223870725|NCT03689920|DEVICE|Boston Scientific Spectra WaveWriter™ Spinal Cord Stimulation (SCS) System|The Spectra WaveWriter Spinal Cord Stimulator (SCS) System is indicated as an aid in the management of chronic intractable pain of the trunk and/or limbs, including unilateral or bilateral pain associated with the following: failed back surgery syndrome, Complex Regional Pain Syndrome (CRPS) Types I and II, intractable low back pain and leg pain.
223870726|NCT00137995|DRUG|Rituximab|375 mg/m² D-2/D1
223870727|NCT00137995|DRUG|Etoposide|100 mg/m² D1-D2-D3
223870728|NCT00137995|DRUG|Carboplatine|max 800mg D2
223870729|NCT00137995|DRUG|Ifosfamide + Mesna|5 g/m² from D2 to D13
223870730|NCT00137995|DRUG|Cisplatine|100 mg/m² from D1 to D13
223870731|NCT00137995|DRUG|Cytosine Arabinoside|2000 mg/m²/12 h D2 D3
223870732|NCT00137995|DRUG|Dexamethasone|40 mg From D1 to D4
223870733|NCT00137995|PROCEDURE|Autologous Stem Cell Transplantation|
223870734|NCT00137995|DRUG|BCNU|300mg/m² on D-6
223870735|NCT00137995|DRUG|Etoposide|200 mg/m² from D-6 to D-3
223870736|NCT00137995|DRUG|Cytarabine|100 mg/m² from D-6 to D-3
223870737|NCT00137995|DRUG|Melphalan|140 mg/m² on D-2
223870738|NCT03272087|DEVICE|Thoracoscopy|50 % of patients will have performed af medical thoracoscopy (pleuroscopy)
223870739|NCT03272087|DEVICE|VATS (thoracoscopy)|50 % of patients will have performed a VATS (video-assisted thoracic surgery) thoracoscopy
223870740|NCT03980496|DRUG|Omeprazole|
223870741|NCT01284075|BEHAVIORAL|Guided imagery and music therapy|Participants will undergo a standardized regimen of peri-operative guided imagery and music therapy guided by CDs (compact disc). The peri-operative regimen will include: listening to the CD while in the pre-operative holding area, listening to the CD during the procedure; listening to the CD after the procedure beginning on the evening of post-operative day (POD)#0 and continuing twice a day until POD#3.
223870742|NCT01284075|BEHAVIORAL|White Noise|Control group (WN) will listen to a CD with white noise. Participants' regimen will include: listening to the CD while in the pre-operative holding area, listening to the CD during the procedure; listening to the CD after the procedure beginning on the evening of post-operative day (POD)#0 and continuing twice a day until POD#3.
223870743|NCT01284075|OTHER|No intervention|Control group (CP) will have no intervention at all and will follow our current peri-operative procedures.
223870744|NCT03753984|OTHER|Low-level laser therapy|In both arms will be applied Low-level laser therapy and induced muscle fatigue.
223870745|NCT05176054|OTHER|Health service program|The program will be implemented into the experimental group, the program has been designed as a three-stage model including hospital management, transition care, and post-acute stage care.
223870746|NCT02459015|DEVICE|Implantation|A peripheral nerve defect up to 26 mm in the finger will be repaired by implantation of either a Reaxon® Nerve Guide or an autologous nerve graft (depending on the randomization group) on day 0.
223870747|NCT05700487|OTHER|PELVIC FLOOR EXERCISES|Regular Pelvic floor exercises was performed three times a day for six months in the postoperative period
223870748|NCT05705856|DRUG|Ustekinumab|Patients will receive an intravenous induction (adjusted 6 mg/kg dose) followed by subcutaneous 90 mg every 12 or 8 weeks, and will receive dose escalation when response is not effective enough.
223870749|NCT02419703|DEVICE|STAR™ Tumor Ablation System|Targeted Radiofrequency ablation of painful metastatic tumor in the vertebral body.
223870750|NCT01995903|DIAGNOSTIC_TEST|MRI(magnetic resonance imaging)|Subjects with amyotrophic lateral sclerosis and lower neuron motor skills and healthy subjects will undergo an MRI(magnetic resonance imaging)scans of the brain to assess neurologic condition. The brain scans will take approximately 60 minutes to complete.
223870751|NCT02108210|DRUG|Anakinra|
223870752|NCT02108210|DRUG|Placebo|
223870753|NCT01546753|DRUG|Walnut Protein Powder|Blinded study product dosing begins with a 1-day oral desensitization protocol to walnut for subjects in the active arm. Starting at 0.1 mg protein and increasing to a maximum of 6 mg or until allergic symptoms develop. Subjects continue daily dosing of blinded OIT (walnut) with build-up every 2 weeks to a maximum daily dose of 1500mg at week 34, followed by 4 weeks of daily maintenance dosing. OFC to walnut and second tree nut occurs at week 38 then treatment is unblinded and open-label maintenance dosing occurs.
223870754|NCT01546753|DRUG|Oat Powder (placebo)|Blinded study product dosing begins with a one-day oral desensitization protocol with placebo (oat) powder. Subjects in the placebo group will undergo the same protocol as those in the active group with placebo OIT dosing. Unblinding to treatment assignment will occur after the 38 week oral food challenge. Placebo subjects will cross-over to active, open-label treatment with walnut powder after the 38 week oral food challenge. beginning with initial escalation day, through build-up and maintenance dosing per the same protocol sequence as noted for active, walnut powder. Subjects will complete an oral food challenge to walnut and the second tree nut at week 38 then will continue on long-term, open-label maintenance dosing until the end of study using same protocol design.
223870755|NCT01546753|DRUG|Open-label Walnut Protein Powder|Open-label treatment phase begins after the 38 week oral food challenge with unblinding of treatment assignment. For those on active treatment, daily maintenance dosing occurs for up to a total of 298 weeks. For those on placebo treatment, cross-over to active, open-label treatment occurs using the same active treatment protocol. Placebo-crossover subjects will complete an oral food challenge to walnut and the second tree nut at week 38 of active therapy then continue on long-term, open-label maintenance dosing until the end of study using same protocol design. All subjects may reach a qualifying IgE to walnut/second tree nut early and will undergo an OFCs on and 4 weeks off OIT. All subjects will have OFCs on and 4 weeks off OIT at week 142 and at week 298, unless both walnut/second tree nut OFCs are passed at previous OFC prompting addition of these foods into the diet.
223870756|NCT02652806|DRUG|FG-4592|
223870757|NCT02652806|DRUG|Epoetin Alfa|
223870758|NCT03125863|DEVICE|AquaBeam System|The AquaBeam system delivers a high-velocity saline stream under precise electromechanical control and live ultrasound guidance to ablate prostatic glandular tissue without the production of heat. The physician uses ultrasound imaging to plan the treatment contour and depth to define the treatment region. The AquaBeam ablates the target tissue, adhering to the pre-defined treatment zone.
223870759|NCT06136351|DRUG|Zanubrutinib|160 mg bid po, until disease progression, intolerance of drug toxicity or death, otherwise maintaining during the 2 years of follow-up
223870760|NCT06136351|DRUG|Rituximab|375 mg/m\^2 ivgtt, D0 of each 28-day cycle
223870761|NCT06136351|DRUG|Bendamustin|90mg/m\^2 ivgtt, D0 of each 28-day cycle
223870762|NCT05451095|DRUG|BI 474121|BI 474121
223870763|NCT05451095|DRUG|Placebo|Placebo
223870764|NCT05451095|DRUG|Ketamine hydrochloride|Ketamine hydrochloride
224268824|NCT02247687|DRUG|Protease inhibitor|"Modification in the antiretroviral treatment~•Switch arm for protease inhibitor : intervention switch of current boosted protease inhibitor for Prezista® (darunavir)/ Norvir® (ritonavir) (switch for a drug with a higher genetic barrier) 600/100 mg two times a day (BID) with counseling."
223870765|NCT02853565|DRUG|CAN008|The dose escalation in the phase I study including 200mg in the first cohort and 400mg in the second cohort to Recommended for Phase 2 Dose (RP2D)
223870766|NCT02413866|BEHAVIORAL|Calorie restriction only|Participants randomly assigned to this group will be instructed to reduce their daily energy intake to 95% of their resting metabolic rate.
223870767|NCT02413866|BEHAVIORAL|Sleep & calorie restriction|Participants randomly assigned to this group will be instructed to reduce their total time in bed by 90 minutes 5 days a week, in addition to restricting their dietary intake to approximately 95% of their resting metabolic rate.
223870768|NCT01790672|DIETARY_SUPPLEMENT|Ethanol|Vodka Absolut
223870769|NCT01790672|OTHER|Water|Lemon-flavored water
224268825|NCT02247687|DRUG|Isentress® (raltegravir)|• Addition of Isentress® (raltegravir) arm :Isentress® (raltegravir) 400 mg two times a day (BID) added to current antiretroviral treatment with counseling
224268826|NCT02247687|OTHER|Counseling arm|No change of antiretroviral treatment but only counseling
224268827|NCT03250117|DRUG|Ropinirole oral product|oral immediate-release ropinirole
224268828|NCT03250117|DRUG|Ropinirole Implant|ropinirole hydrochloride/ethylene vinyl acetate
224268829|NCT03694535|DRUG|bladder wall thermotherapy with Mitomycin-c|application of intravesical mitomycin-C with hyperthermia
223870770|NCT01790672|DIETARY_SUPPLEMENT|Alcoholized wine|Wine 13º or wine 8º
223870771|NCT01790672|DIETARY_SUPPLEMENT|De-alcoholized wine|Wine 0º
223870772|NCT00939510|BIOLOGICAL|sargramostim|All patients will receive GM-CSF at a dose of 250 mcg subcutaneously on Mondays, Wednesdays and Fridays every week. No dose escalation or de-escalations will be made to GM-CSF.
223870773|NCT00939510|DRUG|lenalidomide|Lenalidomide will be administered at 25 mg/day orally on days 1-21 of a 28-day cycle. Initially 6 patients will be entered at the 25 mg/day level. If 0 or 1 patients have a dose limiting toxicity, then the 25 mg lenalidomide + GM-CSF 250 mcg subcutaneously on Mondays, Wednesdays and Fridays every week will be accepted as the phase II dose.
223870774|NCT00939510|OTHER|laboratory biomarker analysis|Prior to the initiation of each cycle of therapy for the first 3 cycles, and at discontinuation from study blood will be collected for assessments of a prostate cancer specific immune response.
223870775|NCT05834270|DRUG|Single dose tamsulosin 0.4mg|Single dose tamsulosin 0.4mg
223870776|NCT05834270|DRUG|Double dose tamsulosin 0.4mg|Double dose tamsulosin 0.4mg
223870777|NCT04133337|DRUG|Apatinib|Apatinib Mesylate Tablets
223870778|NCT04133337|DRUG|SHR-1210|Camrelizumab for Injection
223870779|NCT01402830|OTHER|Visual analogue scales (EVAs)|This scale measures the pain intensity.
224268830|NCT00108030|PROCEDURE|Partial Body-weight supported Treadmill Training|
224268831|NCT00108030|PROCEDURE|PBWST + Power training|
224268832|NCT00108030|PROCEDURE|"Usual physiotherapy care"|
224268833|NCT01731977|BEHAVIORAL|Strengths-based family psychoeducation|Family psychoeducation in a group setting is performed every two weeks for eight weeks.
223870780|NCT01612169|BEHAVIORAL|Patient Navigation (PN) Group|The patient navigator approach includes five functions: 1) establishing an effective working relationship; 2) encouraging identification and use of strengths, abilities and assets; 3) supporting client control over goal setting and the search for needed resources; 4) viewing the community as a resource and identifying informal sources of support; and 5) conducting case management as an active community based activity.
223870781|NCT01612169|BEHAVIORAL|Patient Navigator Plus Contingency Management (PN+CM) Group|Study participants randomized to this group will receive the patient navigation (PN) intervention as outlined above combined with contingency management (CM).
223870782|NCT03546998|DIAGNOSTIC_TEST|Clinical instrumental examinations|Achalasia patients were periodically submitted to clinical assessment, barium swallow (esophageal diameter and residual barium column were measured), endoscopy. Mucosal esophageal biopsies were taken in order to diagnose dysplasia or epidermoid carcinoma.
223870783|NCT02933944|BIOLOGICAL|TG02-treatment|
223870784|NCT02933944|DRUG|Pembrolizumab|
223870785|NCT01558986|PROCEDURE|Cefazolin|Patients received intravenous cefazolin 1 gram within 30 minutes prior to skin incision;
223870786|NCT01558986|PROCEDURE|Sterile water|Patients received sterile water only within 30 minutes prior to skin incision
223870787|NCT03278587|OTHER|Community-based screening program|In communities randomized to receive the screening program, all adults aged 50 and older will be eligible to receive screening for ocular disease. Screening assessments include visual acuity, refraction, intra-ocular pressure, fundus photography, and anterior segment photography. Participants meeting criteria for referral based on screening assessments will be referred to the nearest eye care center or eye hospital for further evaluation.
223870788|NCT03278587|OTHER|Cataract camp program|In communities randomized to receive the cataract camp program, all adults aged 50 and older will be eligible to participate in a routine cataract camp run by Bharatpur Eye Hospital. Trained ophthalmic personnel and assistants will perform case detection for cataract via visual acuity, pen light exam, and indirect ophthalmoscope exam per Bharatpur Eye Hospital's standard cataract camp program. Participants with cataracts will be referred to the nearest eye care center or eye hospital for further evaluation.
223870789|NCT03278587|OTHER|Community health worker program|In communities randomized to receive the community health worker program, all adults aged 50 and older will be eligible to participate. Existing community health workers will be trained to perform case detection for cataract via visual acuity assessment. Participants with cataracts will be referred to the nearest eye care center or eye hospital for further evaluation.
223870790|NCT04731948|DIETARY_SUPPLEMENT|Folic Acid|400µg Folic Acid per day for 16 weeks
223870791|NCT04731948|DIETARY_SUPPLEMENT|2 µg Vitamin B12|2 µg Vitamin B12 per day for 16 weeks
223870792|NCT04731948|DIETARY_SUPPLEMENT|10 µg Vitamin B12|10 µg Vitamin B12 per day for 16 weeks
223870793|NCT04731948|DIETARY_SUPPLEMENT|50 µg Vitamin B12|50 µg Vitamin B12 per day for 16 weeks
223870794|NCT05089526|DRUG|ketamine-lidocaine-dexmedetomidine|"In the KLD group, patients will be administered 0,25 mcg/kg Dexmedetomidine in 100 mL of normal saline within 10 minutes. Followingly, they will receive 1mL/10 kg of the solution containing ketamine, lidocaine and dexmedetomidine at predefined concentrations. As maintenance, they will be receiving~1mL/10kg/h of the aforementioned solution."
223870795|NCT05089526|DRUG|fentanyl|In the fentanyl group, patients will be administered 2 mcg/kg fentanyl in 100 mL of normal saline within 10 minutes. Followingly, they will receive 1mL/10 kg of normal saline solution 0.9%. As maintenance, they will be receiving 1mL/10kg/h of normal saline solution 0.9%.
223870796|NCT06176391|DEVICE|Spinal Cord Stimulation|Single lead placement in the posterior thoracic epidural space (T1-T4) connected to a subcutaneous battery
223870797|NCT05496842|BEHAVIORAL|Multimodal pulmonary rehabilitation|The rehabilitation is based on the biopsychosocial ICF model of the WHO. Taking into account the physical and psychological condition of the patients, an individual therapy plan is created that is tailored to the needs of the patients.
223870798|NCT06258824|DIAGNOSTIC_TEST|Small RNA Sequencing and Validation of candidate miRNAs|Samples were prepared for small RNA sequencing using Qiagen's QIAseq small RNA Library Prep kit, quality controlled using an Agilent Bioanalyzer 2100 and sequenced on an NextSeq 500 system (Illumina, San Diego, USA) using the default single-end 75 base pair protocol to include integrated unique molecular indices (UMIs). Validation was undertaken using Quantitative Reverse Transcription Polymerase Chain Reaction (qRT-PCR) either using target-specific stem-loop primer assays (TaqMan) or universal reverse transcription (RT) and locked nucleic acid (LNA) enhanced specific primers with SYBR green I assay detection
223870799|NCT02083692|DRUG|Metformin|
223870800|NCT00263952|BIOLOGICAL|bee venom|
223870801|NCT03113266|BIOLOGICAL|humanized anti-PD-1 monoclonal antibody toripalimab|humanized anti-PD-1 monoclonal antibody (JS001) is a programmed death-1 (PD-1) immune checkpoint inhibitor antibody, which selectively interferes with the combination of PD-1 with its ligands, PD-L1 and PD-L2, resulting in the activation of lymphocytes and elimination of malignancy theoretically.
223870802|NCT00799552|DRUG|RX-10045|RX-10045 eye drop
223870803|NCT00799552|DRUG|Placebo|Placebo eye drop
223870804|NCT04247074|BIOLOGICAL|botulinum toxin neuromodulator|QM1114-DP will be injected into either the LCL, GL, or both the LCL and GL
223870805|NCT04247074|BIOLOGICAL|Placebo|Placebo will be injected into either the LCL, GL, or both the LCL and GL
224268834|NCT06322251|BEHAVIORAL|Use of instrument to identify exposure to violence in close relationships|Use of instrument to identify exposure to violence in close relationships
224268835|NCT02186353|BEHAVIORAL|Partial feeding study|Provision of all grain foods where only the processing of kernels used to produce the grain foods will differ among test diets. Each participant will be assigned to complete the three 4-week test diets in random sequence.
224268836|NCT04007835|DRUG|Anlotinib Hydrochloride|anlotinib (12 mg orally daily for 14 days every 21 days cycle) combined with one of EGFR-TKIs
224268837|NCT03142620|DRUG|Esomeprazole|40mg twice daily
224268838|NCT03142620|DRUG|Amoxicillin-Potassium Clavulanate Combination|1000mg twice daily
224268839|NCT03142620|DRUG|Clarithromycin|500mg twice daily
224268840|NCT03142620|DRUG|Vitamin D3|5000IU
224268841|NCT01687335|OTHER|answering questionnare in differents time of the treatment|
224268842|NCT01390051|DRUG|Innohep (Tinzaparin)|Dose: 4,500 IU daily in half of the study populationrandomised to treatment
223870806|NCT04193969|DIAGNOSTIC_TEST|Pressure pain assessment using computer controlled cuff algometry|Pressure pain sensitivity is assessed. The pressure is gradually increased and pain is rated by the participant on an electronic visual analogue pain rating scale (VAS) which is connected to the equipment. The assessment is performed on the lower leg and the upper arm. The pain free leg and the left upper arm is used in the patient group. The leg used in the control group will be chosen in a balanced manner meaning that half will receive pressure on the left leg and the other half on the right leg. The pain detection threshold (PDT), pain pressure tolerance threshold (PPT) and pressure pain intensity perceived as 6 on the VAS (VAS6) at the leg site is registered. The PDT and PPT on the arm site is registered.
223870807|NCT04193969|DIAGNOSTIC_TEST|Temporal summation (TS)|10 repeated inflations on the lower leg with a 1 sec interval. The pressure used at each pressure is equivalent the PPT measured at baseline. Each inflation is rated on the VAS. TS is registered as the increase pain intensity.
223870808|NCT04193969|DIAGNOSTIC_TEST|Conditioned pain modulation (CPM)|The cuff on the upper arm is inflated until 70% of the PPT is reached. While the pressure on the arm is kept constant the cuff on the leg is inflated. PDT, PPT and VAS6 pressure at the leg site is registered during the tonic stimulation (pressure on the left arm). The procedure on the leg is repeated within 30 seconds after the pressure is released on the arm site.
223870809|NCT04193969|DIAGNOSTIC_TEST|Low back pain rating scale (LBPRS-pain)|A questionnaire measuring the intensities of low back pain and leg pain currently, on average the last two weeks and the worst pain within the same period.
223870810|NCT04193969|DIAGNOSTIC_TEST|Oswestry Disability Index|A questionnaire measuring the disability in relation to low back pain and leg pain.
223870811|NCT01895699|OTHER|Contrast agent|
223870812|NCT02720965|OTHER|Remote-controlled perineural local anesthetics delivery|Remote-controlled perineural local anesthetics delivery
223870813|NCT00006517|DEVICE|bright light box|10,000 lux bright light therapy
223870814|NCT00006517|DEVICE|dawn simulator|gradual rise in bedroom illumination prior to wake-up
223870815|NCT00006517|DEVICE|high-output negative ion generator|automated air ion delivery in bedroom prior to wake-up
223870816|NCT00006517|DEVICE|low-output negative ion generator|automated air ion delivery in bedroom prior to wake-up
223870817|NCT00006517|DEVICE|dawn light pulse|rectangular light pulse matched for lux.time of dawn simulation delivered prior towake-up
223870818|NCT00995904|DRUG|84ug MAP0020|84ug of unit dose budesonide inhalation suspension delivered by Aeroneb® Go (MAP0020) as per protocol
223870819|NCT00995904|DRUG|42ug MAP0020|42ug of unit dose budesonide inhalation suspension delivered by Aeroneb® Go (MAP0020) as per protocol
223870820|NCT00995904|DRUG|21ug MAP0020|21ug of unit dose budesonide inhalation suspension delivered by Aeroneb® Go (MAP0020) as per protocol
223870821|NCT02490254|OTHER|Surveillance card|
223870822|NCT01622400|OTHER|Therapeutic education HTA Vasc|The intervention program takes place in 3 phases. First, the education team realizes an individual educational diagnosis to define the objectives of the intervention according to each patient's needs. Secondly, patients assist to 3 to 5 group sessions lasting 2 hours with a dedicated nurse focusing on medical therapy explanation and blood pressure self measurement education - and with a dedicated nutritionist focusing on stress management and nutrition program. Patients can also have individual consultations with the dedicated nutritionist. Finally, an individual assessment permits to evaluate the benefits of the program for each patient and to define new objectives.
223870823|NCT03569982|OTHER|Integrative medicine care|Including acupuncture, relaxation/breathing, and manual/touch modalities
223870824|NCT05702775|PROCEDURE|Endoscopic treatment group (EUS-GBD group|The placement of a endoscopic drain performed using a linear echoendoscope that allows the gallbladder to be punctured from the gastric antrum or the duodenal bulb to generate a cholecystogastrostomy or a cholecystoduodenostomy, respectively. Transmural gallbladder drainage will be performed by placing a metal apposition stent (LAMS) with the 15x15mm Hot AXIOS device (Boston Scientific) in the case of cholecystogastrostomy or 15x10 or 10x10mm in the case of cholecystoduodenostomy. Subsequently, the interior of the gallbladder will be irrigated with saline solution until the vesicular content comes out.
223870825|NCT04762875|BIOLOGICAL|MGTA-145|MGTA-145 will be be administered as an IV infusion
223870826|NCT04762875|BIOLOGICAL|Plerixafor|240 µg/kg subcutaneously
223870827|NCT05857267|DRUG|Dorzolamide / Timolol Ophthalmic Solution|Dorzolamide-timolol fixed combination in a preservative-free multidose device
223870828|NCT05857267|DRUG|dorzolamide/timolol|Dorzolamide-timolol BAK-preserved fixed combination
223870829|NCT05444517|PROCEDURE|Interscalene Block|"Ultrasound-guided brachial plexus block injecting 20 ml of bupivacaine 0.5% plus epinephrine 5 micrograms per ml in the Interscalene groove.~Patients will receive dexamethasone 4 mg intravenously and an ultrasound-guided intermediate cervical plexus block (5 ml of bupivacaine 0.5% plus epinephrine 5 micrograms per ml)."
223870830|NCT05444517|PROCEDURE|Infraclavicular - Anterior Supraescapular Nerve Blocks|"Ultrasound-guided combined infraclavicular-anterior suprascapular block of the brachial plexus, injecting 20 ml of bupivacaine 0.5% plus epinephrine 5 micrograms per ml dorsal to the axillary artery in the infraclavicular fossa plus an ultrasound-guided injection of 3 ml of bupivacaine 0.5% plus epinephrine 5 micrograms per ml under the omohyoid muscle. If the anterior suprascapular nerve could not be identified after five minutes of insonation time, an upper trunk block will be carried out with the same amount of local anesthetic.~Patients will receive dexamethasone 4 mg intravenously and an ultrasound-guided intermediate cervical plexus block (5 ml of bupivacaine 0.5% plus epinephrine 5 micrograms per ml)."
223870831|NCT03630055|DRUG|Rivaroxaban 15 MG Oral Tablet [Xarelto]|Patients will receive rivaroxaban 15mg orally daily for 7 days following transradial access.
223870832|NCT06647784|OTHER|pulmonary aeration in supine and ventral decubitus|The addition of repeated periods of 30 minutes of lateralization of 30° amplitude in dorsal decubitus and in ventral decubitus in patients with moderate to severe ARDS. Included patients will benefit from sessions of lateral decubitus for 30 minutes on each side (with an inclination of 30°) with alternation right/left (total one hour). During this period, the upper part of the bed will be inclined by 30°. Patients will then be positioned in strict prone position for a period of 6 hours after which, the same pattern of alternating lateral decubitus will be applied for 12 hours while the patient is still in the prone position. After reversal in supine position, an observation period of 1 hour will be respected before carrying out the last measurements. The total duration of the intervention will be 20 hours.
223870833|NCT02943590|DRUG|Placebo|A pill taken once a day
223870834|NCT02943590|DRUG|Atorvastatin|A pill taken once a day
223870835|NCT05782231|BEHAVIORAL|GetActive+|10-week group mind body program focused on improving self-report, performance-based and ambulatory step count by combining mind body skills tailored for individuals with chronic pain, with gradual increased in walking using quota-based pacing and goal setting, adapted specifically for older adults from a medically underserved location.
223870836|NCT04104776|DRUG|Tulmimetostat|Tulmimetostat dosed once per day orally in 28 day cycles
223870837|NCT04104776|DRUG|Enzalutamide|Enzalutamide dosed once per day orally in 28 day cycles
223870838|NCT05885022|DEVICE|Calibreye System|Implantation of a glaucoma device to reduce intraocular pressure
223870839|NCT03337399|OTHER|Stepped PC|"Palliative Care is involvement of a team of clinicians that specialize in lessening (or palliating) many of these distressing physical and emotional symptoms and in helping patients and their family cope with a serious illness improves patients' and their loved ones' experience with their cancer"
223870840|NCT03337399|OTHER|Early Integrated PC|"Palliative Care is involvement of a team of clinicians that specialize in lessening (or palliating) many of these distressing physical and emotional symptoms and in helping patients and their family cope with a serious illness improves patients' and their loved ones' experience with their cancer"
223870841|NCT04535882|DIAGNOSTIC_TEST|serum leucine-rich alpha-2 glycoprotein (LRG) levels|Patients who were diagnosed with possible UC or Crohn disease according to endoscopic, radiological, histological, and clinical criteria were enrolled. Serum samples were collected from patients, and scores for clinical and endoscopic activity of disease were obtained by reviewing the clinical records of patients. Serum sampling and colonoscopy were performed within 7 days.
223870842|NCT05733364|DIETARY_SUPPLEMENT|Capsules with B vitamins & taurine|Administered orally in a span of 28 days between mealtimes
223870843|NCT05733364|OTHER|Microcrystalline cellulose placebo|Administered orally in a span of 28 days between mealtimes
223870844|NCT05105646|PROCEDURE|Knee Arthroplasty, knee revision arthoplasty|Primary knee arthroplasty (e.g., total, unicondylar and patellofemoral)
223870845|NCT04831190|BEHAVIORAL|Tailored Exercise Intervention|The exercise program to be implemented for neuro-oncology patients will combine aerobic, resistance, balance, and flexibility exercises delivered in one-to-one setting (i.e., personal training) twice per week, for 12 weeks. Based on needs and preferences, participants will have the option to join a circuit-type group class once per week in place of one of their personal training sessions. During COVID-19, all sessions will be delivered remotely. If facilities are open and deemed safe for cancer patients, participants will have the option to attend an in-person session, integrated in the community. Whether delivered in-class or remotely, the intervention will follow exercise progression principles (i.e., frequency, intensity, time, type, overload, and progression) over the 12-weeks, with tailoring of any exercise to meet individual participant needs, with aims of promoting wellness and physical function. The exercise intervention is based on the Alberta Cancer Exercise (ACE) program.
223870846|NCT00311363|DRUG|GEn (XP13512)|1200 mg GEn (XP13512) orally, once daily for 24 weeks followed by either 1200 mg GEn (XP13512) or placebo, orally, once daily for an additional 12 weeks
223870847|NCT00311363|DRUG|GEn (XP13512)|1200 mg GEn (XP13512), orally, once daily for 24 weeks followed by either 1200 mg GEn (XP13512) or placebo, orally, once daily for an additional 12 weeks
223870848|NCT00311363|DRUG|Placebo|Placebo, orally, once daily for 12 weeks following single blind 24-week phase
223870849|NCT03830866|BIOLOGICAL|Durvalumab|IV infusion every 4 weeks
223870850|NCT03830866|DRUG|Cisplatin|Platinum based Standard of Care Chemotherapy administered concurrent with radiation therapy
223870851|NCT03830866|DRUG|Carboplatin|For patients enrolled under CSP v2 and prior - platinum based Standard of Care Chemotherapy administered concurrent with radiation therapy
223870852|NCT03830866|RADIATION|external beam radiation therapy (EBRT) + brachytherapy|Radiation therapy per standard of care
223870853|NCT03557411|DRUG|SHR-1210|SHR-1210 （an Anti-PD-1 Inhibitor） Simultaneously Combined with Hypofraction Radiotherapy
223870854|NCT02034968|DRUG|Nimotuzumab|Nimotuzumab: 200mg,IV once a week during chemotherapy.
223870855|NCT03316482|DRUG|Leuplin DPS 11.25mg|Leuplin DPS 11.25mg s.c. every 12 weeks
223870856|NCT02685189|OTHER|Previous exposure to stannsoporfin|No intervention in this protocol
223870857|NCT04213053|PROCEDURE|strabismus surgery|Lees screen before and after concomitant strabismus surgery
223870858|NCT02537483|DRUG|IDP-120 Gel|Investigational Product: IDP-120 Gel
223870859|NCT02537483|DRUG|IDP-120 Component A|Comparator Product: IDP-120 Component A
223870860|NCT02537483|DRUG|IDP-120 Component B|Comparator Product: IDP-120 Component B
223870861|NCT02537483|DRUG|IDP-120 Vehicle Gel|Comparator Product: IDP-120 Vehicle Lotion
223870862|NCT03588715|DRUG|Pegylated Interferon alpha 2b (peg-IFN-α2b)|Pegylated Interferon alpha 2b (peg-IFN-α2b) will be administered weekly via subcutaneous route.
223870863|NCT03588715|DRUG|3BNC117 + 10-1074|Broadly Neutralizing Antibodies - Sequential, separate IV infusions of 3NBC117 + 10-1074.
223870864|NCT03083197|DRUG|Doxycycline 7 days|loading dose 200mg PO, then 100mg PO every 12 hours for 7 days
223870865|NCT03083197|DRUG|Doxycycline 3 days|loading dose 200mg PO, then 100mg PO every 12 hours for 3 days
223870866|NCT03083197|DRUG|Azithromycin 3 days|loading dose 1000mg PO on day 1, then 500mg PO every 24 hours on days 2 and 3
223870867|NCT03615495|DEVICE|Flourish Pediatric Esphogeal Atresia device|The Flourish Pediatric Esophageal Atresia device consists of an esophageal catheter and a gastric catheter. Both catheters are equipped with an inner magnet catheter. When the esophageal and gastric catheters are aligned tip to tip, the magnets attract.
223870868|NCT03049969|DEVICE|tDCS stimulation|up to 4.0 mA, dorsolateral prefrontal cortex (montage dependent on specific area of deficit) while completing cognitive training tasks
223870869|NCT04567043|BEHAVIORAL|MORE+JITAI|Mindfulness-Oriented Recovery Enhancement (MORE) is a group behavioral intervention that unites mindfulness training, cognitive reappraisal, and positive psychological principles into an integrative intervention strategy targeting mechanisms of pain and opioid misuse. JITAI involves stress-triggered reminders to practice mindfulness skills.
223870870|NCT04567043|BEHAVIORAL|Supporive Psychotherapy|A supportive psychotherapy group will allow participants to express emotions, share experiences, and receive social support under the guidance of a skilled therapist.
224268843|NCT01390051|DRUG|tinzaparin|Dose 4,500 IE daily
223870871|NCT00879463|PROCEDURE|Brain tissue oxygen saturation monitoring|Brain tissue oxygen saturation monitoring with infrared spectrophotoscopy
223870872|NCT00879463|PROCEDURE|Transfusion according to the anesthesiologist's judgement|Transfusion if hemoglobin is between 5.5-7 mg/dl
223870873|NCT00510887|DRUG|Bortezomib|Bortezomib 1.6 mg/m2 on days 1 and 8 of each 28-day cycle
223870874|NCT00510887|DRUG|Rituximab|Rituximab 375 mg/m2 IV on day 1
223870875|NCT00510887|DRUG|Fludarabine|Fludarabine 25 mg/m2 IV on days 1,2,3
223870876|NCT00510887|DRUG|Mitoxantrone|Mitoxantrone 10 mg/m2 IV on day 2
223870877|NCT00510887|DRUG|Dexamethasone|Dexamethasone 20 mg orally on days 1,2,3,4,5
223870878|NCT06473090|OTHER|Video group|"Participants will watch a 15-minute educational video at the beginning of the session before their involvement in the 2 high-fidelity simulation scenarios.~The educational video used was developed by experts (in Human Factors and Obstetric Anesthesia) and validated by SFAR and CARO. It depicts poor use of NTS (including CLC) during a maternal cardiac arrest anesthesia scenario and then proper use of NTS during the same scenario."
223870879|NCT06473090|OTHER|Text group|"Participants will read a text-type educational support for 15 minutes at the beginning of the session before their involvement in 2 high-fidelity crisis simulation scenarios.~The text-type educational support, written in French by the same team of experts, covers all the NTS mentioned in the video and has already been used in a previous study"
223870880|NCT03071081|DRUG|TOP1288|Oral TOP1288
223870881|NCT03071081|DRUG|Placebo to TOP1288|Oral placebo to TOP1288
223870882|NCT02882698|BEHAVIORAL|Down Syndrome Group 1|Acquisition and retention phase on maze A, transfer on maze B and C.
223870883|NCT02882698|BEHAVIORAL|Down Syndrome Group 2|Acquisition and retention phase on maze C, transfer on maze A and B.
223870884|NCT02882698|BEHAVIORAL|Typical Development Group 1|Control group. Acquisition and retention phase on maze A, transfer on maze B and C.
223870885|NCT02882698|BEHAVIORAL|Typical Development Group 2|Control group. Acquisition and retention phase on maze C, transfer on maze A and B.
223870886|NCT01628419|BEHAVIORAL|Health intervention|"physical activity program at the workplace - once a week with a certified trainer. (The program will include: aerobic exercises as well as resistance exercises). The employees will encourage to perform two additional workouts during the week.~Nutritional counseling for the kitchen staff Lectures - lectures will be given at each worksite on different topics: physical activity, nutrition, sleeping behaviour, mental aspects."
223870887|NCT01542229|BEHAVIORAL|Prolonged Exposure for PTSD (PE) + Treatment as Usual (TAU)|12 weekly sessions of Prolonged Exposure in addition to Treatment As Usual
223870888|NCT01542229|BEHAVIORAL|Treatment As Usual (TAU)|Treatment as usual (TAU) will receive support services through the VA potentially inclusive of case management, psychotropic medication management, and/or supportive counseling
223870889|NCT00971906|BIOLOGICAL|Monovalent A/H1N1 influenza vaccine|This trial will be performed at multiple study sites in a population of healthy adults and elderly. Subjects will be randomized to receive two IM injections of low dose of antigen \& adjuvant,or high dose of antigen \& adjuvant, or high dose of antigen, according to the study groups
223870890|NCT00254657|DRUG|Levetiracetam|Started with one 500 mg tablet/day and titrated upward as tolerated over 6 weeks by 500 mg/week to a maximum dose of 3000 mg/day.
223870891|NCT00254657|DRUG|Placebo|
223870892|NCT03038217|DRUG|Capecitabine +/- Oxaliplatin|Patients in ACT group will undergo postoperative adjuvant chemotherapy with single agent Capecitabine regimen or combined Capecitabine +Oxaliplatin regimen.
223870893|NCT03038217|PROCEDURE|local resection|Patients in the LR group will undergo local resection of the T1-2N0 rectal carcinoma
223870894|NCT03038217|PROCEDURE|radical resection|Patients in the RR group will undergo radical resection of the T1-2N0 rectal carcinoma
223870895|NCT03038217|OTHER|No adjuvant chemotherapy|Patients in Non-ACT group will not undergo postoperative adjuvant chemotherapy.
223870896|NCT04794959|DIAGNOSTIC_TEST|Dual-energy CT|CMI patients planned for endovascular stent placement will be contacted and informed about this study prior to their procedure. If they wish to take part in the study, then a date for a pre-operative DECT scan will be arranged. Before scanning the patient will be given a standardized calorie dense drink (Nutridrink). This will take place one week prior to their surgical procedure. Following the surgical procedure, the patient will undergo another DECT scan before discharge.
223870897|NCT02904759|DRUG|Desmopressin|
223870898|NCT02904759|DRUG|Placebo|
223870899|NCT04111328|DRUG|intravenous sufentanil|The PCA pumps contain sufentanil . And the pump is connected to participants intravenously .
223870900|NCT04111328|DRUG|subcutaneous sufentanil|The PCA pumps contain sufentanil. And the pump is connected to participants subcutaneously.
223870901|NCT04111328|DRUG|intravenous hydromorphone|The PCA pumps contain hydromorphone. And the pump is connected to participants intravenously .
223870902|NCT04111328|DRUG|subcutaneous hydromorphone|The PCA pumps contain hydromorphone. And the pump is connected to participants subcutaneously.
223870903|NCT04111328|DRUG|intravenous sufentanil and dexmedetomidine|The PCA pumps contain sufentanil and dexmedetomidine. And the pump is connected to participants intravenously .
223870904|NCT04111328|DRUG|subcutaneous sufentanil and dexmedetomidine|The PCA pumps contain sufentanil and dexmedetomidine. And the pump is connected to participants subcutaneously.
223870905|NCT04111328|DRUG|intravenous hydromorphone and dexmedetomidine|The PCA pumps contain hydromorphone and dexmedetomidine. And the pump is connected to participants intravenously.
223870906|NCT04111328|DRUG|subcutaneous hydromorphone and dexmedetomidine|The PCA pumps contain hydromorphone and dexmedetomidine. And the pump is connected to participants subcutaneously
223870907|NCT03639558|DRUG|Haloperidol + Promethazine + Chlorpromazine|This is the usual treatment given by this hospital during an aggressive psychiatric episode.
223870908|NCT03639558|DRUG|Haloperidol + Promethazine|This is the second most used psycho-pharmacological combination used in this hospital during an aggressive psychiatric episode.
223870909|NCT00943358|BIOLOGICAL|MF59 H1N1 vaccine|3.75-7.5ug dose
223870910|NCT00943358|BIOLOGICAL|Plain H1N1 vaccine|7.5-15ug
223870911|NCT01897155|OTHER|SBP 20-30% over baseline|Patients were assigned to receive a phenylephrine infusion in order to maintain systolic blood pressure (SBP) 20% to 30% over the baseline. The upper limit of systolic blood pressure is 165 mmHg.
224268844|NCT02957578|DEVICE|Solo TTD|Placement of tympanostomy tube with Solo TTD
224268845|NCT00084097|DRUG|Omalizumab|
223870912|NCT01897155|OTHER|SBP 20-30% under baseline|Patients were assigned to receive a phenylephrine infusion in order to maintain systolic blood pressure (SBP) 20% to 30% below the baseline. The lower limit of systolic blood pressure is 75 mmHg
223870913|NCT03416712|OTHER|Screening survey and accompanying handout for resources|Intervention group will be completing a survey of social determinants of health and providing resources based on caregiver responses.
223870914|NCT01981174|PROCEDURE|30-gauge needle|
223870915|NCT01981174|PROCEDURE|32-gauge needle|
223870916|NCT01130246|DRUG|A-002, varespladib methyl|A-002 administered once daily in addition to atorvastatin and standard of care
223870917|NCT01130246|DRUG|Placebo|Placebo administered once daily in addition to atorvastatin and standard of care
223870918|NCT05950542|DRUG|Baricitinib|JAK inhibit0rs
223870919|NCT00094822|OTHER|PI Discretion|PI Discretion
223870920|NCT01897870|BEHAVIORAL|HomeCoMe-program|A home visit by patients own community pharmacist within seven days after hospital discharge. The community pharmacist will perform a semi-structured interview on (1) use of the prescribed medication, (2) ADEs, (3) adherence issues, by (A) assessing patient's needs and concerns around his pharmacotherapy, (B) identifying and solving obstacles for medicines intake, (C) checking on the need for a compliance aid, (D) collecting spare medication and finally (4) knowledge on medication use, when to take which medicine and why, and medication changes made during the hospitalisation.
223870921|NCT03485950|DRUG|Cefepime|Given IV
223870922|NCT03485950|DRUG|Ceftolozane|Given IV
223870923|NCT03485950|OTHER|Laboratory Biomarker Analysis|Correlative studies
223870924|NCT03485950|DRUG|Meropenem|Given IV
223870925|NCT03485950|DRUG|Piperacillin-Tazobactam|Given IV
223870926|NCT03485950|DRUG|Tazobactam|Given IV
223870927|NCT00103324|DRUG|lapatinib ditosylate|Given orally
223870928|NCT00103324|OTHER|laboratory biomarker analysis|Correlative studies
223870929|NCT02929147|DRUG|Morphine|In the Group 1 the PCA will set to administer a bolus dose of 1 mg morphine on demand with a lockout period of 10 minutes and maximum 20 mg for 4 hours. In the Group 2 the PCA set to administer a bolus dose of 0.5 mg morphine on demand with a lockout period of 10 minutes and maximum 20 mg for 4 hours.
223870930|NCT02929147|DRUG|Dexketoprofen|The Group 3 will take 50 mg dexketoprofen in the recovery room. Intra venous injections of dexketoprofen will repeat every 8 hours.
223870931|NCT02929147|DRUG|Placebo|In the Group 3 the PCA will contain placebo.
223870932|NCT03532243|PROCEDURE|incremental inspiratory load|inspiratory load ranges between 10 and 40 cm water column (cmH2O)or intolerable to the patient, each load increment for 5cm water column.
223870933|NCT05360901|BEHAVIORAL|IntelliCare with automated motivational messaging|Digital mental health intervention with automated motivational messaging
223870934|NCT04619290|DRUG|Sublingual Methylene blue|Patients will be received the treatment as follow: it will be placed Low Level Light Therapy (LLLT) NocUlite on the ventral side of the wrist on full power. Draw out 1ml of diluted Prexablu into a syringe. Activate this syringe LLLT device for 10 minutes. Then place 1ml of this activated solution of Prexablu sublingually. Patients must keep the solution under the tongue for 10 minutes before swallowing. Keep wrist pads on patients for 50 minutes.
223870935|NCT04619290|OTHER|Control patients|Control patients will be received the conventional treatment that may include analgesic, anti-inflammatory, antibiotic, steroid, antiplatelet, and anticoagulant.
223870936|NCT06004505|OTHER|Vestibular Rehabilitation|The patients received vestibular rehabilitation treatment in 4 sessions at 15-day intervals and applied the given exercise programs as home exercise in the form of 10 repetitions, 3 times a day. The exercises were performed sitting, standing and walking, respectively. Balance exercises were developed by changing the support area, support surface and arm positions. When they come to each session, the exercise programs are according to the patient's condition; alternating standing and walking forward, backward, tandem and semitandem positions.
223870937|NCT00988858|DRUG|LY2603618|150 milligram per square meter (mg/m\^2) intravenously on Day 2 of each 21 day cycle repeating every 21 days for a minimum of 2 cycles continuing until disease progression
223870938|NCT00988858|DRUG|Pemetrexed|500 mg/m\^2 intravenously on Day 1 of each 21 Day cycle repeating every 21 days for a minimum of 2 cycles or until disease progression
223870939|NCT04286113|BEHAVIORAL|control group|will receive standard medical care where research assistant will give pamphlets, with one size fits all recommendations for diet/nutrition, physical activity and sleep, to 10 subjects with comorbid HTN and T2D.
223870940|NCT04286113|BEHAVIORAL|Lifestyle management|Will use passive ubiquitous sensing through FitBit to 1)learn behavioral profiles of subjects who have pre-HTN/HTN and/or pre-diabetes /Diabetes 2) provide personalized recommendations through mobile based messaging app that will increase the likelihood of engaging in health diet/nutrition, physical activity and sleep practices
223870941|NCT04432389|BIOLOGICAL|ALLOB|After thawing, ALLOB® is a ready-to-use product for local administration at fracture site.
223870942|NCT04432389|OTHER|placebo|Placebo injected is a saline solution injectable grade (4 mL of 0.9% NaCl) filled in single-dose vial
223870943|NCT03562884|DRUG|BLI800|Two bottles of BLI800 are needed for appropriate cleansing of the bowel. Prior to administration, the content of each bottle must be diluted in water, using the cup provided, to a total volume of approximately 0.5 L, and must be followed by the ingestion of 1 additional litre of water.
223870944|NCT03562884|DRUG|Fortrans®|Fortrans® (Powder for Oral Solution) will be given according to Chinese approved Summary of Product Characteristics (SmPC). Fortrans® is provided as a powder for Polyethylene Glycol (PEG) based solution available in sachets containing a white powder readily miscible with water. The dosing for Fortrans® administration will be adapted to subjects' body weight as following: 1 L of solution for 15 to 20 kg, an average of 3 to 4 L (maximum 4 L).
223870945|NCT04368663|DRUG|Japanese traditional medicine group|TJ-134 (7.5g/day) or lactomin (3g/day) is administered for 8 weeks.
223870946|NCT02182336|DRUG|BI 201335 NA|"1. 480 mg BI 201335 NA in the morning, 240 mg BI 201335 NA in the evening of day 10~2. 240 mg BI 201335 NA bid from day 11 to 23"
223870947|NCT02182336|DRUG|Caffeine|days 1, 10 and 19
223870948|NCT02182336|DRUG|Warfarin sodium|days 1, 10 and 19
223870949|NCT02182336|DRUG|Vitamin K|days 1, 10 and 19
223870950|NCT02182336|DRUG|Omeprazole|days 1, 10 and 19
223870951|NCT02182336|DRUG|Dextromethorphan hydrobromide|days 1, 10 and 19
223870952|NCT02182336|DRUG|Midazolam HCl solution|Days 3 and 21
223870953|NCT02182336|DRUG|Midazolam HCl oral syrup|days 1, 10 and 19
223870954|NCT02182336|DRUG|Digoxin|Days 2 and 20
223870955|NCT00925210|PROCEDURE|Sequential pEBUS - ENB|"Subject will undergo bronchoscopy with peripheral endobronchial ultrasonography to identify the peripheral lung nodule. If the lesion is identified with pEBUS, samples will be collected.~If the lesion is not found by pEBUS, the electromagnetic navigation system will be deployed and directed to the lesion of interest, once again using pEBUS to confirm final location before samples are collected."
223870956|NCT05528380|BEHAVIORAL|LPA + Fitbit Intervention|Participants will receive a Fitbit to track activity levels and participate in a 6-session lifestyle physical activity intervention over the course of 12 weeks. The intervention consists of 20-25 minute phone or video-delivered session to: (a) review PA progress and re-evaluate current step-count goals, (b) problem-solve barriers to incorporating PA into their daily lives, (c) address difficulties utilizing the Fitbit, (d) encourage the use of bouts of PA as a coping strategy, and e) engage the participant in brief discussions focused on increasing and maintaining PA.
223870957|NCT05528380|BEHAVIORAL|Fitbit Only|Participants will receive a Fitbit to track activity levels and participate in 6 brief check-ins to assess any issues with the Fitbit device or app.
223870958|NCT06970847|DRUG|64Cu-SAR-bisPSMA|All Patients will receive a single administration, a bolus injection of 200MBq 64Cu-SAR-bisPSMA
223870959|NCT06645665|BIOLOGICAL|Bivalent RSV Vaccine (IN006)|Formulation for injection
223870960|NCT06645665|BIOLOGICAL|Placebo|0.9% sodium chloride (normal saline) injection
223870961|NCT04110743|DEVICE|EXPLORER PET/CT|Intervention: PET/CT using different protocols
223870962|NCT06086561|DEVICE|Thermal Anisotropy Measurement Device|The study device is a non-invasive sensor that is placed on the study subject's skin overlying an existing implanted CSF shunt. It uses an integrated thermal actuator and temperature sensors to assess shunt flow.
223870963|NCT05629793|OTHER|Experimental tests|Walking for 6 minutes, sitting down and getting up from a chair for 1 minute and finally the cold test (Cold pressor) where the hand is introduced for 1 minute in water at 4ºC. The patient will be monitored by means of a Polar H10 chest strap, as used in sports, continuously and 02 saturation, TA and voice (exhalation while saying /a/ and dry cough) will be collected before and after the tests. Finally, skin conductance will be monitored by performing baseline tracing and then control while performing the cold test.
223870964|NCT03380234|OTHER|Worksheets|Worksheets will be distributed to students for them and their parents to complete together. During the first 3 months, the teachers will distribute 1 worksheet every two weeks to the intervention grades, and 1 worksheet in the 4th and 5th months as boosters. The worksheets will deliver information about tobacco smoke, SHS and THS, inviting students and their family members to complete other interesting tasks together.
223870965|NCT03380234|OTHER|Whatsapp messages|A mobile phone number of this study is also provided on the worksheets, through which participants can receive WhatsApp/WeChat/instant messages (1-2 times every week) designed to encourage behavioural change \[15\]. They can then forward selected messages to other members of their household, especially smokers.
223870966|NCT03380234|OTHER|Online quizzes|At the end of each worksheet, a QR code is inserted. By scanning this code, students or parents will be invited to answer 2-3 simple quizzes which allow us to assess students' knowledge obtained from the intervention materials and their avoidance of environmental tobacco smoke.
223870967|NCT03380234|OTHER|Leaflet|A leaflet on smoking and SHS published by the Department of Health will be mailed to the control grades.
223870968|NCT00744224|DRUG|Placebo|Single dose of placebo with saline infusion
223870969|NCT00744224|DRUG|Prednisolone|Single dose of 80 mg prednisolone with saline infusion
223870970|NCT00744224|DRUG|Prednisolone and Exenatide|Prednisolone 80 mg single dose Exenatide infusion 20 mg/min
223870971|NCT04176380|BIOLOGICAL|RAPA-201 Autologous T cells|Autologous rapamycin resistant Th1/Tc1 cells
223870972|NCT05113771|DRUG|Liafensine|Liafensine
223870973|NCT05113771|DRUG|Placebo|Placebo
223870974|NCT04191434|DRUG|Flamboyant 125/12|Flamboyant 125/12 capsule
223870975|NCT04191434|DRUG|Budesonide/formoterol 200/6|Budesonid/formoterol 200/6 capsule
223870976|NCT04191434|OTHER|Flamboyant 125/12 Placebo|Flamboyant 125/12 Placebo capsule
223870977|NCT04191434|OTHER|Budesonide/formoterol 200/6 placebo|Budesonid/formoterol 200/6 Placebo capsule
223870978|NCT03085498|OTHER|No intervention|no intervention
223870979|NCT04821219|OTHER|Treatment prediction PDT platform|PDT will be generated and response to various chemotherapies and radiation will be investigated. Actionable targets will be identified and response to the target drug will be assessed and compared to the conventional treatment options.
223870980|NCT01063140|BIOLOGICAL|Rabies Vaccine (RabAvert)|The initial booster immunization is given on Day 1; subsequent booster immunizations will be administered if the donor's titers fall below 10 IU/mL. A maximum of 4 booster immunizations may be administered over the 2 year study period.
223870981|NCT01063140|BIOLOGICAL|Rabies Vaccine (Imovax)|The initial booster immunization is given on Day 1; subsequent booster immunizations will be administered if the donor's titers fall below 10 IU/mL. A maximum of 4 booster immunizations may be administered over the 2 year study period.
223870982|NCT05993351|DIAGNOSTIC_TEST|Magnetic resonance imaging (MRI)|All participants will have 3 MRI scanning sessions to track brain health over time following the same protocol each time. The MRI sessions will occur acutely (\<2 weeks post-concussion), 3-months and 6-months post-concussion. A series of MRI scans will be acquired including T1, T2, T2-FLAIR, SWI, ASL, rsfMRI, and DTI scans to characterize structural, microstructural, functional and tissue perfusion changes within the brain over time.
223870983|NCT05993351|DIAGNOSTIC_TEST|Urine and saliva samples|At each study visit all participants will be asked to provide small urine and saliva samples for a metabolomic analysis using a high throughput multi-segment injection-capillary electrophoresis-mass spectrometry technology. This will allow for rapid non-targeted analysis of polar/hydrophilic metabolites, as well as non-polar/ionic lipids with stringent quality control.
223870984|NCT05993351|BEHAVIORAL|Questionnaires|The Post-Concussion Symptom Scale (PCSS) and the Depression Anxiety Stress Scale (DASS-42) will be used to assess the self-reported presence and severity of known concussion-related symptoms.
223870985|NCT05156892|DRUG|SUBA-itraconazole|150 mg BD
223870986|NCT05156892|DRUG|Tamoxifen|"Dose Escalation:~Cohort 1: 20 mg OD Cohort 2: 40 mg OD Cohort 3: 60 mg OD~Dose-Expansion: Recommended dose from dose-escalation phase of study"
223870987|NCT04357951|DRUG|d-cycloserine|D-cycloserine is an FDA-approved antibiotic medication that has been shown to enhance extinction learning in several studies. It will be paired with 4 sessions of behavior therapy.
223870988|NCT04357951|DRUG|Placebo pill|A pill placebo serves as an active comparator. It will be paired with 4 sessions of behavior therapy.
223870989|NCT04357951|BEHAVIORAL|Behavior Therapy|All participants will receive 4 sessions of behavior therapy for tics (e.g., habit reversal training, comprehensive behavioral intervention for tics).
223870990|NCT02827474|OTHER|Patient Interview|Patient intervention includes a 30 minute interview prior to their abortion procedure and a follow up phone-interview that will be 10-minutes and held 24-72 hours from the procedure.
223870991|NCT02827474|OTHER|Provider Interview|For physician participants, providers will be interviewed after completion of the patient's visit and this will be 10-15 minutes.
223870992|NCT05912088|BEHAVIORAL|Intervention Group|Subjects will participate in groups of about 14 to implement the program.
223870993|NCT05912088|BEHAVIORAL|Control Group|Subjects will receive the usual care advice
223870994|NCT06091865|DRUG|Odronextamab|Odronextamab will be administered by intravenous (IV) infusion
223870995|NCT06091865|DRUG|Rituximab|Rituximab will be administered IV, or subcutaneously (SC)
223870996|NCT06091865|DRUG|Cyclophosphamide|Cyclophosphamide will be administered IV as part of chemotherapy
223870997|NCT06091865|DRUG|Doxorubicin|Doxorubicin will be administered IV as part of chemotherapy
223870998|NCT06091865|DRUG|Vincristine|Vincristine will be administered IV as part of chemotherapy
223870999|NCT06091865|DRUG|Prednisone/Prednisolone|Prednisone or prednisolone will be administered orally (PO) as part of chemotherapy
223871000|NCT06972368|DEVICE|tDCS|"Description:~Participants randomized to this arm will receive 14 sessions of home-based transcranial Direct Current Stimulation (tDCS), administered twice daily for 30 minutes over 7 consecutive days. Each session will use a 2mA current with a SNAPstrap™ montage targeting the left dorsolateral prefrontal cortex (F3) with the anode and the right DLPFC (F4) with the cathode. Sessions include a 30-second ramp-up and ramp-down. The total delivered charge will be 48 coulombs.~Enhancement component:~Each session will be paired with cognitive and emotional enhancement strategies:~Emotion regulation script (DBT-inspired, personalized and pre-written based on a moderately dysregulated situation).~Cognitive training via Lumosity, targeting executive functions and memory."
223871001|NCT06972368|PROCEDURE|Treatment as Usual (TAU)|"Description:~Throughout the study, participants are required to maintain stable pharmacological and psychotherapeutic regimens, defined as:~No changes in medications or therapy for at least 6 weeks after tDCS initiation.~TAU is provided by participants' regular treating physician or mental health professional, independent of the study team.~TAU includes psychotropic medication, psychotherapy, and case management, as clinically indicated."
223871002|NCT06972368|PROCEDURE|Psychoeducation|"All participants receive access to a structured online psychoeducation program before randomization.~This includes:~* Short videos (8-14 minutes each) covering BPD, depression, neuromodulation, therapeutic success factors, and tDCS.~* Multiple-choice quizzes (MCQs) to ensure comprehension.~* Delivered in French with English subtitles. Designed to improve understanding of BPD and associated treatments, including the rationale for tDCS."
223871003|NCT06972368|DEVICE|Sham-tDCS|"Description:~Participants randomized to this arm will receive 14 sessions of sham tDCS, with identical scheduling and device setup as the active condition. The session mimics real tDCS (same SNAPstrap montage, ramp-up and ramp-down of 30 seconds), but no current is delivered after the initial 30 seconds.~Enhancement component:~Participants follow the same emotional regulation script and Lumosity cognitive training during"
223871004|NCT06972667|OTHER|Video to promote colonoscopy|This video contains elements designed to engage and persuade people who tend to avoid colorectal cancer information to have a colonoscopy. Psychological elements include self-efficacy boosting, humor, and calming affect induction.
223871005|NCT06972667|OTHER|Video to promote screening for colorectal cancer with home tests|This video contains elements designed to engage and persuade people who tend to avoid colorectal cancer information to screen for colorectal cancer with a home test. Psychological elements include self-efficacy boosting, humor, and calming affect induction.
223871006|NCT06973538|OTHER|Music-based Calisthenic Exercise|Participants in this group will perform 8 weeks of calisthenic exercises with background music. Each session includes a 10-minute warm-up, 30 minutes of music-based exercises (e.g., seated leg lifts, chair squats, arm curls), and a 10-minute cool-down. Elastic resistance bands will be introduced from week 5 to increase intensity. Music tracks are selected to enhance motivation and engagement.
224268846|NCT05942976|OTHER|ULTRASOUND|10 enthesis areas will be evaluated in 20 minutes with ultrasound.
223871007|NCT06972498|DRUG|Patients will receive ivosimab combined with the XELOX/FOLFOX regimen, followed by radical surgery 4-6 weeks after the last dose; adjuvant chemotherapy will continue for 3 months postoperatively.|Patients will receive ivosimab combined with the XELOX/FOLFOX regimen, followed by radical surgery 4-6 weeks after the last dose; adjuvant chemotherapy will continue for 3 months postoperatively.
223871008|NCT06974162|DIAGNOSTIC_TEST|Metagenomic sequencing of aqueous humor|Metagenomic Sequencing on aqueous humor surplus to diagnostic requirements
223871009|NCT06974162|DIAGNOSTIC_TEST|Ocular Imaging|Ocular imaging with anterior segment OCT, laser flare photometry, confocal microscopy and colour fundus photography.
223871010|NCT06973057|PROCEDURE|Pulpotomy|The entire coronal pulp will be amputated to the level of canal orifices, after hemostasis, NeoMTA will be placed, then tooth will be restored with glass ionomer cement, and the tooth will be subsequently restored with a crown.
223871011|NCT06973057|PROCEDURE|Direct pulp capping (DPC)|At the exposure site hemostasis will be achieved, neo MTA will be placed, then tooth will be restored with glass ionomer cement, and the tooth will be subsequently restored with a crown.
223871012|NCT06972849|DRUG|Caffeine citrate|Clinically indicated for apnea of prematurity.
223871013|NCT05510245|DRUG|PF-07081532|One PF-07081532 20 mg tablet, administered orally
223871014|NCT05180591|BIOLOGICAL|Bacillus Calmette-Guérin|2 BCG vaccinations spaced 4 weeks apart at the beginning of the trial
223871015|NCT05180591|BIOLOGICAL|Saline Injection|2 BCG vaccinations spaced 4 weeks apart at the beginning of the trial
223871016|NCT05851391|DRUG|Burst Suppression EEG Target Intravenous Anesthesia|The objective of the burst suppression EEG target is to stop seizures by titrating the anesthetic infusion to suppress most of the EEG background (\>50% suppressed/attenuated). After this 24-hour period, this target would be continued for 24 hours. The anesthetic will then be tapered under EEG monitoring. In case of PCARSE recurrence, the intervention with the same target will be re-initiated for another cycle of 24 hours.
223871017|NCT05851391|DRUG|Seizure Suppression EEG Target Intravenous Anesthesia|is to stop seizures by titrating the anesthetic infusion without suppressing most of the EEG background. This target would be continued for 24 hours. After this 24-hours period, this target would be continued for 24 hours. The anesthetic will then be tapered under EEG monitoring. In case of PCARSE recurrence, the intervention with the same target will be re-initiated for another cycle of 24 hours.
223871018|NCT02414204|DRUG|Sildenafil|Sildenafil, a phosphodiesterase 5 inhibitor that enhances the effects of nitric oxide (NO), has been shown in experimental and clinical studies in cardiovascular disease to improve endothelial function and decrease vascular stenosis.
223871019|NCT02414204|OTHER|Placebo|Placebo will be over encapsulated to identical to drug comparison
223871020|NCT00586586|BEHAVIORAL|Cognitive behavioural therapy|The FRIENDS program developed by Paula Barrett, 10 weekly sessions of 60-90 minutes, with two additional parent meetings, and booster sessions 4 and 12 weeks after treatment.
223871021|NCT01834703|PROCEDURE|UAE|The patient will be admitted into hospital for UAE. UAE was performed with patients under local anesthesia. Embosphere particles (BioSphere Medical) with a size of 500 - 700µm were used in all procedures. Embospheres were mixed with contrast material and saline and injected into each uterine artery until either parenchyma filling of the fibroids had stopped (target embolization) or the main uterine artery was blocked with stasis of contrast material (selective embolization). After the procedure, women were admitted to the gynecology ward for postprocedural care. All patients were advised to stay in the hospital for at least 1 night.
223871022|NCT01834703|PROCEDURE|HIFU|Treatment will be given to the patient in one or more sessions on an outpatient basis. The uterine fibroid will be identified and located with ultrasonography and ablated with HIFU. For lesion beyond 6 cm distance from skin, HIFU is given at a power of 1200-1500 watt for 1500 - 2000 times at each spot, for 50 milli-second each time, at an interval of 100 milli-second, at a spot distance of 1.5cm, a line distance of 1.5cm, and a plane distance of 1.0 -1.5cm; for lesion within 6 cm distance from skin, HIFU is given at a power of 1300±15% Watt for 40 times at each spot, for120 milli-second each time, at an interval of 100 milli-second, at a spot distance of 0.3cm, a line distance of 0.3cm, and a plane distance of 0.8cm.
223871023|NCT01788930|DEVICE|CPAP|
223871024|NCT00303836|DRUG|cyclophosphamide|Given IV
223871025|NCT00303836|DRUG|fludarabine phosphate|Given IV
223871026|NCT00303836|BIOLOGICAL|therapeutic autologous lymphocytes|Given IV
223871027|NCT00303836|PROCEDURE|in vitro-treated peripheral blood stem cell transplantation|Undergo in vitro-treated peripheral blood stem cell transplantation
223871028|NCT00303836|BIOLOGICAL|gp100 antigen|Given SC
223871029|NCT00303836|BIOLOGICAL|MART-1 antigen|Given SC
223871030|NCT00303836|BIOLOGICAL|incomplete Freund's adjuvant|Given SC
223871031|NCT00303836|BIOLOGICAL|filgrastim|Given SC
223871032|NCT00303836|BIOLOGICAL|aldesleukin|Given IV
223871033|NCT00158028|DRUG|Risperidone|The dosage of risperidone was titrated upward in a stepwise design, beginning with 0.25 mg/d for the first week, 0.5 mg/d for weeks 2 and 3, 1.0 mg/d for weeks 4 and 5, 1.5 mg/d for weeks 6 and 7, and 2.0 mg/d for the remaining weeks.
223871034|NCT00158028|DRUG|Placebo|placebo match in identical tablets
223871035|NCT03302819|DIAGNOSTIC_TEST|MARIA scan|The patient will have an additional MARIA scan along with conventional imaging, pathology and surgical procedures.
223871036|NCT03534869|PROCEDURE|Ear acupuncture|French auriculotherapy guidelines - internal genital area, external genital area and Shen Men point.
223871037|NCT03534869|DRUG|Analgesics|Oral ibuprofen was given as first line therapy, while oral paracetamol was given as second line therapy.
223871038|NCT05908942|DEVICE|Nerve ablation|radiofrequency and phenol ablation of the genicular nerves will be performed
223871039|NCT06397144|DRUG|Paxlovid|Reference 1
223871040|NCT06397144|DRUG|Paxlovid|Reference 2
223871041|NCT06397144|DRUG|Nirmatrelvir/ritonavir|Test 1
223871042|NCT06397144|DRUG|Nirmatrelvir/ritonavir|Test 2
223871043|NCT03104036|OTHER|Faecal bacterial transplantation|Enema prepared from 50 g of stool of examined donor dissolved in 150 ml of normal saline
223871044|NCT03104036|DRUG|Mesalazine 4G Enema|Standard mesalazine enema
223871045|NCT03621917|DEVICE|Near-infrared spectroscopy reading|Non-invasive readings will be taken from forehead with near-infrared spectroscopy
223871046|NCT03014973|BIOLOGICAL|intra-prostatic concentration of sexual steroids|
223871047|NCT03014973|PROCEDURE|Trans-rectal biopsy|
223871048|NCT02088424|OTHER|insulin resistance(fasting glucose/fasting insulin)|insulin resistance(fasting glucose/fasting insulin )
223871049|NCT03294499|OTHER|Questionnaire|Patients will be asked to complete one off questionnaire.
223871050|NCT02400099|DIETARY_SUPPLEMENT|High-protein low calorie diet|
223871051|NCT02400099|DIETARY_SUPPLEMENT|Control low calorie diet|
223871052|NCT02400099|OTHER|Anthropometrical measurements|
223871053|NCT02400099|OTHER|Body composition|
223871054|NCT02400099|OTHER|8-h metabolic profile|
223871055|NCT02400099|OTHER|Liver biopsy|
223871056|NCT04125810|BIOLOGICAL|Probiotic|Probiotic
223871057|NCT04125810|OTHER|Placebo|Placebo
223871058|NCT04093908|OTHER|Prediction of motor outcome after STN DBS based on preoperative variables|Generating individual probabilities for motor response based on preoperative variables
223871059|NCT01347125|DEVICE|ImCardia Device|The device operates by harnessing energy expended by the left ventricle (LV) during Systole and returning it to the heart during Diastole thereby making it available to augment diastolic performance
223871060|NCT04747743|OTHER|a self structured questionnaire|A self structured questionnaire to assess knowledge of skeletal muscle use in dental practice
223871061|NCT01530698|BIOLOGICAL|autologous dendritic cell vaccine|Autologous monocyte-derived dendritic cells electroporated with mRNA encoding gp100 and tyrosinase (for antigen loading), active TLR4 and CD70 (for activation). Dendritic cells are vaccinated intranodally 3 times with biweekly intervals every 6 months, if no signs of progression, for a total of 9 vaccinations
223871062|NCT01530698|BIOLOGICAL|autologous dendritic cell vaccine|Autologous monocyte-derived dendritic cells electroporated with mRNA encoding gp100 and tyrosinase and matured with either cytokines or TLR ligands. Dendritic cells are vaccinated intranodally 3 times with biweekly intervals every 6 months, if no signs of progression, for a total of 9 vaccinations
223871063|NCT05833906|DRUG|CKR-051 Dose 1|Subjects will be administered 5 g of CKR-051.
223871064|NCT05833906|DRUG|CKR-051 Dose 2|Subjects will be administered 10 g of CKR-051.
223871065|NCT05833906|DRUG|CKR-051 Dose 3|Subjects will be administered 10 g of CKR-051.
223871066|NCT05833906|DRUG|CKR-051 Dose 4|Subjects will be administered 10 g of CKR-051.
223871067|NCT05833906|DRUG|Placebo|Placebo comparator.
223871068|NCT05515900|DIETARY_SUPPLEMENT|Sodium|Daily sodium supplementation of 2000 mg.
223871069|NCT05515900|DIETARY_SUPPLEMENT|HMB|Daily HMB supplementation of 3 g.
223871070|NCT05515900|OTHER|Placebo|Placebo pills that will be identical to sodium or HMB supplementations
223871071|NCT03336515|DEVICE|Group C-Postural device activated|General recommendation not sleeping in supine position and the postural device activated (intervention group).
223871072|NCT03336515|DEVICE|Group B-Postural device no activated|General recommendation not sleeping in supine position and the postural device without any activation (placebo)
223871073|NCT03336515|BEHAVIORAL|Group A-General Recommendation|General recommendation not sleeping in supine position
223871074|NCT06112977|PROCEDURE|Prepectoral implant-based immediate breast reconstruction|Prepectoral implant based breast reconstruction is an immediate breast reconstruction whereby a fixed volume implant or expander is placed on top of the chest wall muscle (Pectoralis Major) to reconstruct the breast after mastectomy.
223871075|NCT03131869|OTHER|Thickened Beverages Nectar|Thickened beverages in nectar consistency
223871076|NCT03131869|OTHER|Thickened Beverage Honey|Thickened beverages in honey consistency
223871077|NCT01115959|DRUG|valproic acid|treatment of 1 month dosage of 400 mg BID
223871078|NCT01115959|DRUG|placebo bid|
223871079|NCT05401474|DEVICE|High Flow Nasal Cannula at 30L/min|Flow will be set at 30L/min, FiO2 will be adjusted manually to maintain SpO2within the target range
223871080|NCT05401474|DEVICE|High Flow Nasal Cannula at 45L/min|Flow will be set at 45L/min, FiO2 will be adjusted manually to maintain SpO2within the target range
223871081|NCT05401474|DEVICE|High Flow Nasal Cannula at 60L/min|Flow will be set at 60L/min, FiO2 will be adjusted manually to maintain SpO2within the target range
223871082|NCT02708927|OTHER|Clinical evaluation|• Clinical assessment : Expanded Disability Status Scale (EDSS), ambulation test. Medications will be recorded.
223871083|NCT02708927|OTHER|Cognitive evaluation|• Neuropsychological, psychological, social and social cognitive evaluation
223871084|NCT02509637|DEVICE|Flutter|Flutter is a small device, simple, like a plastic pipe with a mouthpiece at one end and a perforated cover on the other, containing a steel ball resting in a plastic cone inside. When the patient exhales through the flutter expiratory flow causes movement of the ball, creating an oscillatory positive pressure.
223871085|NCT02509637|OTHER|Chest Compression|Manual chest compression is based on the application of forces resulting from the action of respiratory muscles or physiotherapist manual action in order to increase the alveolar pressure creating a pressure gradient to promote change in pulmonary flow and volume.It consists of vigorous compression of the chest at the beginning of expiration or during expiration.
223871086|NCT02509637|OTHER|Control|
223871087|NCT02509637|OTHER|Impulse Oscillometric|"For this measure will be used IOS Jaeger (Jaeger, Wurzburg, Germany). to minimize the effect of the bad positioning of the tongue will use a mouth free-flow, which contains a depressant for keeping the tongue in the mouth soil, stabilizing it and reducing oral resistance. Volunteers will support hands firmly on the cheeks to reduce the effect of oscillation thereof. The measures will be carried out with the volunteer sitting, using nasal, relaxed and your head in neutral clip, breathing normally through the mouthpiece to his lips tightly sealed to prevent air leaks."
223871088|NCT02509637|OTHER|Dyspnea scale|Dyspnea will be evaluated across the range Medical Research Council (MRC) for use in patients with chronic obstructive pulmonary disease in Brazil.
223871089|NCT02509637|OTHER|Acceptability and tolerance|patients will complete scales 1-7, 1: extremely and 7: none) on usefulness, ease to understand the instructions, easy to perform the exercises, degree of fatigue and discomfort
223871090|NCT02509637|DEVICE|Pulse oximetry|During therapy the patient will remain monitored with digital oximeter and the information will be recorded before and after the procedures
223871091|NCT02509637|OTHER|Difficulty sputum|Patients inform the ease or difficulty sputum according to a scale of 1 to 5, where 1 = no difficulty and 5 = extremely difficult.
223871092|NCT02309034|BEHAVIORAL|Jump exercise|Land Group / Jump (LG): Will hold weekly classes of nutritional guidance and three weekly sessions of jump, for 12 weeks, divided into warm up, main aerobics and relaxation.
223871093|NCT02309034|BEHAVIORAL|Aquatic exercise|Group Water / Water aerobics (WG): Will hold weekly classes of nutritional guidance and three weekly sessions of water, for 12 weeks, divided into warm up, main aerobics and relaxation.
223871094|NCT02309034|OTHER|Nutritional guidance|Control Group (CG): take part only of weekly classes of nutritional guidance, in addition to a closed group on Facebook in order to encourage them and increase attention to the group.
223871095|NCT00915564|DRUG|TMC435|Participants will receive 150 mg dose of TMC435 orally (by mouth) once daily for 7 days of treatment (from Day 1 to Day 7).
223871096|NCT00915564|OTHER|Methadone|Participants will receive supervised individualized methadone dose (dose of methadone will be adjusted for each participant between a range of 30 and 150 mg daily \[extremes included\]) from Day -14 untill Day 8. Participants will continue to receive individualized methadone during follow up of 30 to 32 days.
223871097|NCT03876210|COMBINATION_PRODUCT|PK101|PK101-001 + PK101-002 (combination)
223871098|NCT03876210|DRUG|PK101-001, PK101-002|coadministration
223871099|NCT01901081|DEVICE|IMES|"Once subjects recover from surgical implantation of IMES (approximately two weeks), they will practice IMES control using a bench-top IMES trainer for approximately a month. As soon as the subject's custom-fit IMES Prosthesis is available, it will be fitted and programmed. Subjects will then begin six months of prosthetic training. Month 1 training entails sessions with an Occupational Therapists 4-5 times per week. Months 2-6 Training entail meeting with an Occupational Therapist twice a month. During training, subject will learn how to contract residual musculature in the amputated limb to control movements of an electromechanical wrist and hand. The therapeutic goal is to develop skills needed to perform Activities of Daily Living using the IMES prosthesis.~After completing six months of training, subjects will be given the option to continue using their IMES Prosthesis for another sixteen months."
223871100|NCT00411216|OTHER|Control exercises|saccadic eye movements against a plain background; no head movements
223871101|NCT00411216|OTHER|gaze stabilization exercises|adaptation and substitutin exercises encorporating retinal lsip and head movements
223871102|NCT00417950|DRUG|Acarbose|
223871103|NCT02376842|BEHAVIORAL|Severe sepsis early warning best practice alert|
223871104|NCT02376842|BEHAVIORAL|Standard care|
223871105|NCT02828943|BEHAVIORAL|IMT with High Resistance EMT|
223871106|NCT02828943|BEHAVIORAL|IMT with Low Resistance EMT|
223871107|NCT01291381|DRUG|Dermatophagoides pteronyssinus|Children undergoing subcutaneous immunotherapy were given Dermatophagoides pteronyssinus extract (Alutard SQ, ALK-Abello, Hørsholm, Denmark) according to a cluster protocol
223871108|NCT01291381|DRUG|Pharmacotherapy|For patients randomized to non-SIT group, persistent rhinitis was managed with pharmacotherapy including intranasal steroids and oral antihistamines. Intranasal steroids were kept at the same dose during the study and antihistamines were used as required.
223871109|NCT00217841|DRUG|Aurograb|
223871110|NCT00967434|DRUG|Atorvastatin|atorvastatin 80 mg daily for at least 7 preoperative days atorvastatin 80 mg on day of surgery atorvastatin 80 mg daily for up to 7 postoperative days
223871111|NCT00967434|DRUG|Atorvastatin|Daily placebo on the preoperative days atorvastatin 80 mg on day of surgery atorvastatin 80 mg daily for up to 7 postoperative days
223871112|NCT00967434|DRUG|Placebo|Daily placebo in preoperative period Placebo on day of surgery Daily placebo for up to 7 postoperative days
223871113|NCT06150508|BEHAVIORAL|O2O digital healthcare service|The O2O service includes a mobile app and web-based portal that allows patients to monitor their blood glucose levels, track their medication use and physical activity, receive personalized feedback and education, and communicate with healthcare providers. The treatment group will receive a blood sugar checker and blood pressure checker that send the records automatically to the application through Bluetooth.
223871114|NCT04044651|DRUG|Lenvatinib|lenvatinib 12 mg (or 8 mg) by mouth (Po) once daily
223871115|NCT04044651|DRUG|Nivolumab|nivolumab 480 mg IV infusions for 30 minutes q4w
223871116|NCT05003778|OTHER|Traditional equipment resistance training|Participants will undergo 6 weeks of traditional equipment resistance training
223871117|NCT05003778|OTHER|Minimal equipment resistance training|Participants will undergo 6 weeks of minimal equipment resistance training
223871118|NCT05003778|OTHER|Blood flow restriction training|Participants will undergo 6 weeks of blood flow restriction training
223871119|NCT03809312|DRUG|Amoxicillin / Clavulanic acid 875mg / 125mg|Amoxicillin / Clavulanic acid 875 mg / 125 mg BID x 10 days
223871120|NCT03809312|DRUG|Placebos|Placebos BID x 10 days
223871121|NCT06113770|OTHER|preparation of the tooth to receive ready made zirconia crown|"Occlusal reduction 1 to 2 mm using flame bur . Open the interproximal contacts. The tooth should be reduced circumferentially by approximately 0.5-1.5mm . The preparation margin should be carefully extended and refined to a feather-edge approximately 1-2mm subgingivally .~Crown size will be determined using try in kit ."
223871122|NCT06113770|OTHER|preparation of the tooth to receive CAD CAM PMMA custom made crown|"* Open the interproximal contacts .~* The tooth should be reduced circumferentially by approximately 0.5-1mm .~* The preparation margin should be carefully extended and refined to a feather- edge approximately 1-2mm subgingivally .~* Rubber base impression will be taken by BMS additional silicone kit to the prepared tooth and will be sent to the laboratory to be scanned and to design the crown .~* The final crown will be cemented using glass ionomer cement ."
223871123|NCT06005857|OTHER|Standard hand therapy + home digital application-based exercises|Standard post-operative hand rehabilitation and home digital application-based exercises
223871124|NCT06005857|OTHER|standard hand therapy + home paper-based exercises|Standard post-operative hand rehabilitation and home paper-based exercises
223871125|NCT01348217|RADIATION|"Conformal 3D Radiotherapy with  ENI -type prophylactic irradiation of the lymph node"|40 Gy in 20 fractions / 5 weeks, PTV (1cm in every direction)
223871126|NCT01348217|RADIATION|Boost|Boost 10 Gy in 5 fr, PTV = +1cm.
223871127|NCT01348217|RADIATION|Boost|Boost 26 Gy in 13 fr, PTV = +1cm.
223871128|NCT01348217|DRUG|chemotherapy: FOLFOX 4|6 treatments with 4 courses concomitant to radiotherapy (D1, D15, D29, D43) arm B or 3 courses concomitant to radiotherapy (D1, D15, D29) arm A.
223871129|NCT01282840|DRUG|Tolterodine SR|Tolterodine SR 4 mg qd
223871130|NCT02052219|DRUG|Blisibimod|Blisibimod administered subcutaneously
223871131|NCT02052219|DRUG|Placebo|Placebo administered subcutaneously
223871132|NCT00511160|PROCEDURE|Myocardial biopsies with TRU CUT 14 Gauge needle|Myocardial needle biopsy and right atrial appendectomy
223871133|NCT00511160|PROCEDURE|Endomyocardial biopsies|The control arm C consists of routine-workup of patients with suspected myocarditis, independent of the study arm C, but with analogous screening methods and comparable biopsy sampling
223871134|NCT02694666|OTHER|Controlled whole-body vibration training|The intervention is an 8-week program
223871135|NCT02721134|OTHER|additional blood tubes|four whole blood tubes 5 ml (2 + EDTA tubes separating gel and dry tubes 2 + separating gel ) will be taken in order to assay more bacterial biomarkers on day 0 , J1, J2, J3 and J5
223871136|NCT02912208|DRUG|Eltrombopag/Revolade|Eltrombopag 50 mg once daily has been selected as the starting dose for this study. Thereafter, dependent on platelet response the dose of study medication can be increased by 50 mg every 2 weeks, up to a maximum dose of 300 mg once daily (150 mg in subjects of East Asian ethnicity).
223871137|NCT02912208|OTHER|Placebo|The administration is the same of eltrombopag
223871138|NCT04423016|DEVICE|Near Infrared Spectroscopy monitoring|Non-invasive continuous monitoring of cerebral oxygenation
223871139|NCT04423016|DEVICE|Electrical velocimetry and pulse oximetry|Non-invasive continuous monitoring of cerebral oxygenation
223871140|NCT04706052|OTHER|Superficial Parotidectomy|Classical procedure for pleomorphic adenoma of the parotid gland is superficial parotidectomy around the world. This study only observed the outcome with reference to facial nerve morbidity
223871141|NCT00237991|BIOLOGICAL|Hepatitis A|
223871142|NCT03250052|DRUG|(fimasartan or linagliptin) x 7days|Part A: fimasartan, Part B: linagliptin
223871143|NCT03250052|DRUG|(fimasartan and linagliptin) x 7days|Part A \& Part B: Co-administration of fimasartan and linagliptin
223871144|NCT04855903|DEVICE|Covirtua Cognition software|Cognitive training with Covirtua Cognition software
223871145|NCT05106270|DIAGNOSTIC_TEST|Atrial pressure measurement using transseptal puncture sheath|both left and right atrial pressure was measured using transseptal puncture sheath before and after combined procedure
223871146|NCT06223048|DRUG|AMDX-2011P|AMDX-2011P single bolus injection intravenous for diagnostic review
223871147|NCT06299228|OTHER|Experimental Group|Sensorimotor intervention, active range of motion, active assisted range of motion, strengthening
223871148|NCT06299228|OTHER|Control Group|Active range of motion, active assisted range of motion and strengthening
223871149|NCT04135885|DRUG|Folic Acid|The patient was continuously taking 7 ml of a brown sugar aqueous solution containing a certain amount of folic acid for 7 days before surgery (0.3 mg/d for children with 1-3 years old and 0.4 mg/d for children aged 4 to 5, once a day). After the operation, the PAED scores were performed every 10 minutes during the recovery of the child, at the time of extubation, and within 30 minutes after extubation. The PAED scores of all the children were performed by the same measurer. (The total score is 0\~20 points, and the score ≥10 points is defined as the recovery period).
223871150|NCT04135885|DRUG|Placebos|Patients in the placebo group received 20 ml of an aqueous solution of brown sugar with the same concentration as the intervention group on the 7th day before surgery. After the operation, the PAED scores were performed every 10 minutes during the recovery of the child, at the time of extubation, and within 30 minutes after extubation. The PAED scores of all the children were performed by the same measurer. (The total score is 0\~20 points, and the score ≥10 points is defined as the recovery period).
223871151|NCT05519202|DRUG|S-1,Oxaliplatin, Penpulimab|S-1 ( 40 mg/m2 bid po d1-14) and Penpulimab (200mg ivgtt d1) and Oxaliplatin ( 130 mg/m2 (d1)
223871152|NCT02740400|PROCEDURE|EBUS-GS|The equipment for EBUS-GS includes super-thin bronchoscope BF-P260F, endobronchial ultrasonic system EU-M30S, ultrasonic probe UM-S20-17S, and guided sheath kit K201. All facilities are provided by Olympus Co. The EBUS-GS procedure was performed by thoracic surgeons. The patient was in supine position, under general anesthesia, and provided ventilatation through laryngeal mask. First, the operator placed super-thin bronchoscope into the bronchus of interest, inserted the probe covered with GS through a work channel. Later, adjusted the bronchoscope and probe to obtain classical ultrasonic graphs. The assistant fixed the bronchoscope, pulled the probe out, and placed the brush and biopsy forceps, respectively, through the GS. This process was assisted using x-ray fluoroscope or not.
223871153|NCT02740400|PROCEDURE|CT-TTNB|The devices for CT-TTNB includes Lightspeed VCT spiral CT(GE co.) and Quickcore(COOK Co.) biopsy kit. The kit includes a sheath(5cm in length and 16G in outer diameter) and a automatic biopsy needle(15cm in length and 18G in outer diameter). The patient stays in supine, prone or lateral position according to the lesion's location. The first chest CT scan is performed to confirm the location of the lesion and make an optimal entry point. Then, after sterilization and 2% lidocaine local anesthesia, the sheath is stabbed into chest wall through the entry point. The second CT scan is performed to make sure that the sheath stays in proper angle and depth. The operator places the needle through the sheath and enter the lesion. Then fire the biopsy needle and repeat the procedure twice or third time. The last CT scan is conducted to determine whether pneumothorax or hemorrhage occurred.
223871154|NCT03855007|DRUG|Iguratimod|Iguratimod tablet，25mg, po, twice per day (Bid) prescribed at the beginning and adjusted due to patient response. Then may titer down until the endpoint.
223871155|NCT03855007|DRUG|MTX|MTX，7.5mg to 15mg, po, once per week (Qw) prescribed if needed and adjusted due to patient response or unacceptable toxicity develops.
223871156|NCT03855007|DRUG|HCQ|HCQ，200mg, po, twice per day (Bid) prescribed if needed and adjusted due to patient response.
223871157|NCT03855007|DRUG|Pred|Pred, 5-15mg, po, once per day (Qd) prescribed if needed and adjusted due to patient response
223871158|NCT04877652|OTHER|Standard of care|Standard medical treatment of ADHF patients deemed to have insufficient diuretic response.
223871159|NCT01003834|BEHAVIORAL|Computerized brief intervention|Intervention based on Motivational Interviewing technique
223871160|NCT01003834|BEHAVIORAL|Computerized health screening|Behavioral intervention
223871161|NCT01003834|BEHAVIORAL|Computerized assessment|Behavioral intervention
223871162|NCT01003834|BEHAVIORAL|Therapist-delivered motivational intervention|Behavioral intervention
223871163|NCT03116620|OTHER|Chewing evaluation|Children with neuromuscular disorders (NMD) will be participated. Children will be asked to chew a standardized biscuit while video recording. Two physical therapists will assess all video recordings independently and score each video according to the KCPS. The correlation between the KCPS scores of two therapists will be used for interobserver reliability. One therapist will rescore the recordings after an interval of 2 weeks for intraobserver reliability.
223871164|NCT01646749|DIETARY_SUPPLEMENT|Differences in protein content (En%) of meals|The three applied conditions will differ in the relative protein content of the meals, including 5 En%, 15 En% and 30 En% from protein. Beef protein will be used as main meat protein source in the 15 En% and 30 En% protein conditions. The resulting macronutrient compositions of the diets will be En% Protein/Carbohydrate/Fat; 5/60/35, 15/50/35, and 30/35/35. All meals (breakfast, lunch, dinner) within each condition will have the same macronutrient composition. All food items, and the energy density, weight and volume of the meals will be the same between conditions. All snack items will be very low in protein content.
223871165|NCT01029587|DRUG|Eculizumab|Eculizumab will be administered by intravenous infusion. Eculizumab will be administered at a dose of 1200mg by intravenous (IV) infusion on the day of or on the day prior to kidney transplantation, and at a dose of 900mg IV on post-operative day 1. Subsequently, the post-operative dosing regimen would be comprised of an induction phase of weekly doses of 900mg IV per dose followed by a maintenance phase of every other week dosing of 1200mg IV per dose. The weekly induction dosing regimen would begin on postoperative day 8, and would continue for three doses (specifically, doses of 900mg IV would be given on postoperative days 8, 15, and 22). The maintenance phase of dosing would begin with a dose of 1200mg on postoperative day 29, and would continue for a total of 5 doses (specifically, doses of 1200mg IV would be given on postoperative days 29, 43, 47, 72, and 85). In most cases, eculizumab would be discontinued after the 5th maintenance dose.
223871166|NCT05900921|DRUG|Trilaciclib|IV infusion, d1
223871167|NCT05900921|DRUG|Carboplatin|IV infusion, d1
223871168|NCT05900921|DRUG|Paclitaxel|IV infusion, d1
223871169|NCT05900921|DRUG|Tislelizumab|IV infusion, d1
223871170|NCT01608347|DRUG|LMWH+Folic acid|Patients will receive a fixed dose of 40 mg of enoxaparin subcutaneous daily. Treatment will start once positive pregnancy test and will be continued until abortion or delivery (if premature), or 37 weeks of pregnancy. Additionally, 500 micrograms Folic acid tablet once daily will be started once positive pregnancy test and continues until 13 weeks' of gestation.
223871171|NCT01608347|DRUG|Folic Acid|Folic acid 500 micrograms daily once positive pregnancy test until the 13th week of pregnancy or abortion
223871172|NCT04773678|DRUG|CBP-201|CBP-201 subcutaneous (SC) injection.
223871173|NCT04773678|DRUG|Placebo|Placebo subcutaneous (SC) injection.
223871174|NCT00391196|DRUG|Placebo|Subjects receive placebo plus non-pharmacological weight loss program.
223871175|NCT00391196|DRUG|CP-945,598|Subjects receive CP-945,598 plus non-pharmacological weight loss program.
223871176|NCT00391196|DRUG|CP-945,598 Treatment B|Subjects receive CP-945,598 plus non-pharmacological weight loss program.
223871177|NCT01761487|DEVICE|Gentamicin and polymyxin E|
224268847|NCT03983135|OTHER|Laparoscopic mini gastric by-pass|Adhesions will separated along the left edge of the stomach and the left lobe of the liver. The remnant stomach will transected at the incisura angularis level with 60 mm Endo-GIA stapler(ATW 35, EthiconEndo-SurgeryInc., Cincinnati, OH, USA). Later ante-cholic distal of the Treitz ligament hadgastro-jejunal anastomosisof nearly 150 cm jejunal loop performed with 44 mm Endo-GIA stapler. Routinely, the omentum will be divided in two and omentopexy will be performed around the anastomosis. The stapler line will supported by absorbable stitches.
224268848|NCT03983135|OTHER|LaparoscopicRe-sleeve gastrectomy|Adhesions will be separated with blunt and sharp dissections, then the remnant stomach will completely freed. Due to dilated antral pouch or fundus, the remnant stomach will resect as a tube stomach between the pillory and left crus with 60 mm Endo-GIA stapler accompanied by 36F bougie.
224268849|NCT03983135|OTHER|Laparoscopic Roux-en-Ygastric bypass|all adhesions will separated then after the stomach pouch will formed by the linear stapler, 100 cm of jejunum will transected from the Treitz ligament. Side-to-side gastrojejunostomy will performed for the distal jejunum with the linear stapler. The anterior face of the anastomosis will manually sutured. Proximal jejunum end hadside-to-side jejuno-jejunostomy performed 150 cm distal of the gastrojejunostomy anastomosis with linear stapler on the posterior wall and manual suturing of the anterior wall.
223871178|NCT03608995|DIAGNOSTIC_TEST|Premaquick (Diagnostic test)|"PREMAQUICK® is a rapid multiparametric test which aim to detect the presence of IGFBP-1 (Insulin-like Growth Factor-Binding Protein 1), fragmented IGFBP-1 and IL-6 (Interleukin 6) in vaginal secretions. By combining biomarkers of myometrial activation, cervical maturity and inflammation / infection, PREMAQUICK® integrates the main pathogenic mechanisms responsible for premature delivery, which makes it possible to predict or, on the contrary, rule out the risk of childbirth within 7 to 14 days. This test is intended for in vitro diagnostic use.~Vaginal secretions are collected under speculum with a swab (10 seconds of impregnation of the swab). The swab is immersed in a tube containing an extraction buffer for 10 seconds. The tube is mixed and then 3 drops are deposited in each wells of the test device for 10 minutes. Visual reading should be done between 10 and 15 minutes."
223871179|NCT03608995|DIAGNOSTIC_TEST|Quikcheck fFN ™|\- The Hologic QuikCheck fFN test is intended to be used for the qualitative detection of fetal fibronectin in cervicovaginal secretions. The presence of fetal fibronectin in cervicovaginal secretions between 22 weeks, 0 days and 34 weeks, 6 days of gestation is associated with elevated risk of preterm delivery. Quick Check fFN test® is a 10 min, one-step, visual test consists of a sterile polyester-tipped applicator, fetal fibronectin test strip, and sample extraction buffer. The QuikCheck fFN is a solid-phase immunogold assay which aim to detect fetal fibronectin. A positive specimen will result in two visible lines and a negative specimen will result in one visible line (control).
223871180|NCT05736094|DEVICE|SURF|Dual-frequency ultrasound
223871181|NCT06972303|BEHAVIORAL|Instructed bedtime app-guided mindfulness meditation|All participants will access the a smartphone app, and the mindfulness meditation practice may involve techniques such as breathing exercise, imagery, body scan, and relaxation. The investigators will provide instructions for participants who are assigned to practice at bedtime.
223871182|NCT06972303|BEHAVIORAL|Uninstructed app-guided mindfulness meditation|The guided mindfulness meditation practice will also be based on the same app. The investigators will not provide instructions for participants, and they have complete freedom to use the app as real-world users.
223871183|NCT06972303|BEHAVIORAL|Sleep hygiene education|Sleep hygiene education will be based on recognized, general, non-personalized sleep hygiene advice, for example, recommendations about bedtime routines and use of alcohol and caffeine, tips on creating a sleep-conducive bedroom environment.
223871184|NCT01086982|DRUG|Octreotide acetate LAR|30 mg, single dose
223871185|NCT01086982|DRUG|Sandostatin LAR ® (octreotide acetate LAR) 30 MG|30 mg, single dose
223871186|NCT06973408|BEHAVIORAL|Behavioral Treatment|Behavioral support is designed to help participants adhere to the dietary recommendations through personalized coaching and motivational strategies. Participants engage in weekly or bi-weekly coaching sessions, either online or in person, where they receive guidance on overcoming challenges and maintaining dietary changes. The coaching incorporates evidence-based behavior change techniques, such as goal setting, self-monitoring, feedback on performance, problem-solving, and stimulus control. To further support behavior change, participants receive practical tools, including visual aids, educational videos, and structured meal planning resources. The overall goal of behavioral support is to encourage sustainable dietary habits by providing continuous encouragement and individualized strategies.
223871187|NCT06973408|BEHAVIORAL|Food support|Food support, which is provided exclusively to participants in the Optimized Lifestyle Intervention Group, ensures that they have access to key foods required to meet dietary targets. These foods include whole grains such as whole grain bread, oats, and pasta; vegetables in both fresh and frozen forms; fruits and berries, including apples, pears, and frozen berries; legumes such as lentils, beans, and chickpeas; and seafood, including fatty fish, lean fish, and mussels. To facilitate adherence, participants also receive recipes and meal plans that incorporate these foods. Some fresh food items are made available at supermarkets near participants' residences to improve accessibility and convenience. Food support aims to reduce barriers to dietary change by ensuring that participants have the necessary ingredients to follow the SWITCH diet effectively.
223871188|NCT06973408|BEHAVIORAL|Dietary Advice|Dietary advice consists of a simple document outlining the SWITCH diet, which is based on European and Nordic dietary guidelines. Participants receive this information in written form without any additional guidance, counseling, or support. The SWITCH diet emphasizes increased consumption of whole grains, vegetables, fruits, legumes, and seafood while limiting processed foods, added sugars, and excessive salt.
223871189|NCT05755100|BEHAVIORAL|I MOVE!+UP|An individual psychotherapy that integrates behavioral weight management with evidence-based psychotherapy for PTSD (Cognitive Processing Therapy) for up to 6 months, augmented with evidence-based psychiatric and weight management medication management.
223871190|NCT04773639|BEHAVIORAL|Multi-Modal Palliative Care Intervention|An innovative muli-modal palliative care intervention that addresses the lack of advance care planning and unmet psychosocial needs commonly experienced by patients with metastatic cancer.
223871191|NCT04773639|BEHAVIORAL|Usual Care Control Condition|The control condition includes usual care (UC) at the collaborating clinics, consisting of access to a clinical social worker and nurse practitioners for advance care planning and supportive visits at patient request.
223871192|NCT06570213|BEHAVIORAL|Cognitive Processing Therapy|Cognitive Processing Therapy is a first-line, gold-standard psychotherapy intervention for the treatment of PTSD.
223871193|NCT06570213|DRUG|Stellate Ganglion Block|Stellate Ganglion Blocks are an injection of local anesthetic into the stellate ganglion, a collection of nerves in the side of the neck.
223871194|NCT04410055|BEHAVIORAL|Sitting|We proposed a dynamic standing approach (working while standing accompanied by small periodic stepping movements) as a more tolerable and thereby more applicative lifestyle modification. To evaluate this form on healthy subjects, three different conditions were applied: 3 hours of sitting, static standing and dynamic standing. Both standing conditions were done with height-adjustable table which was developed at the University of Michigan (Ann Arbor, Michigan, USA)
224268850|NCT02291796|DRUG|Bezafibrate|Patients with ST elevation acute myocardial infarction (STEAMI) and with fibrinogen concentration \>500 mg/dl at 72 h of evolution, were randomly assigned to bezafibrate 400 mg/day or just conventional therapy
224268851|NCT05025163|DRUG|1.23% fluoride foam application|topical application of fluoride foam every 6 months
224268852|NCT05025163|DRUG|2.26% fluoride varnish application|topical application of fluoride varnish every 6 months
224268853|NCT05370807|DRUG|Regorafenib 40 MG Oral Tablet|Patients take 2 regorafenib oral tablets of 40 mg daily
224268854|NCT05370807|DRUG|Triplet therapy|Regorafenib in combination with BRAF- / MEK- inhibitors
223871195|NCT04410055|BEHAVIORAL|Static standing|We proposed a dynamic standing approach (working while standing accompanied by small periodic stepping movements) as a more tolerable and thereby more applicative lifestyle modification. To evaluate this form on healthy subjects, three different conditions were applied: 3 hours of sitting, static standing and dynamic standing. Both standing conditions were done with height-adjustable table which was developed at the University of Michigan (Ann Arbor, Michigan, USA)
223871196|NCT04410055|BEHAVIORAL|Dynamic standing|We proposed a dynamic standing approach (working while standing accompanied by small periodic stepping movements) as a more tolerable and thereby more applicative lifestyle modification. To evaluate this form on healthy subjects, three different conditions were applied: 3 hours of sitting, static standing and dynamic standing. Both standing conditions were done with height-adjustable table which was developed at the University of Michigan (Ann Arbor, Michigan, USA)
223871197|NCT00590369|DEVICE|KCI -VAC|Negative pressure wound therapy device
223871198|NCT00590369|DEVICE|Versatile One (EZCare)|Negative pressure wound therapy device
223871199|NCT03182010|DEVICE|Cesarean section incision closure using barbed sutures|Cesarean section incision will be closed using a 24-cm × 24-cm 0 polydioxanone double-armed suture on a 26-mm half-circle reverse cutting needle( STRATAFIX™ Spiral PDO Knotless Tissue Control Device, Ethicon Inc , Somerville, NJ, USA ).Ultrasound examination will be performed 6 months after the operation to measure the residual myometrial thickness and the scar depth.
223871200|NCT03182010|DEVICE|Cesarean section incision closure using conventional sutures|Cesarean section incision will be closed using 1-0 polyglactin 910 suture(VICRYL™.; Ethicon Inc, Sommerville, NJ) .Ultrasound examination will be performed 6 months after the operation to measure the residual myometrial thickness and the scar depth.
223871201|NCT00002632|DRUG|paclitaxel|
223871202|NCT02634541|DRUG|Adalimumab|Biologic drug
223871203|NCT02634541|OTHER|PET/CT imaging|PET/CT imaging
223871204|NCT06974019|DRUG|Buffered Lidocaine|To determine if a 20 cc buffered (2 cc of sodium bicarbonate, 18 cc of 1% lidocaine) lidocaine paracervical block decreases pain with IUD placement in nulliparous women
223871205|NCT06974019|DRUG|Lidocaine 1% Injectable Solution|To determine if the unbuffered 1% lidocaine paracervical block offers any less pain control with IUD placement for nulliparous women
223871206|NCT06973798|DIAGNOSTIC_TEST|GFR will be measured using three methods at two weeks before surgery and four ± one week after surgery|GFR will be measured using three methods at two weeks before surgery and four ± one week after surgery
223871207|NCT06973798|DIAGNOSTIC_TEST|GFR will be measured using three methods: [68Ga]Ga-HBED-CC-DiAsp PET/CT, the Gates method, and the dual plasma sampling method with 99mTc-DTPA.|GFR will be measured using three methods: \[68Ga\]Ga-HBED-CC-DiAsp PET/CT, the Gates method, and the dual plasma sampling method with 99mTc-DTPA.
223871208|NCT06972615|DRUG|intravesical Chemotherapy docetaxel/gemcitabine|intravesical quimiotherapy plus intravenous immunotherapy
223871209|NCT06974253|PROCEDURE|Nasopalatine Implants, Trans-Sinus Implants, and Trans-Nasal Implants for Full-Arch Rehabilitation|"Pre-surgery (Implant Placement):~Clinical examination, panoramic radiography, film guide creation, and CBCT imaging will be performed. Based on CBCT data and the film guide, bone measurements will be taken, and a treatment plan with virtual implants will be developed. 4-6 pilot holes will be made, adjusting for critical structures like the maxillary sinus, inferior alveolar nerve, and planned implant sites. Full blood count and coagulation tests will be done.~During Surgery:~Implant surgery will be performed under local anesthesia/sedation. Incision and mucosal flap reflection will expose the implant site. A clip will be fixed to the anterior maxilla with screws, connected to the monitoring device. The dynamic navigation system will guide the placement of nasopalatine, trans-sinus, and trans-nasal implants, ensuring optimal placement.~Post-surgery:~Post-operative CBCT will be performed to check the implant positions, confirming the accuracy of the implant placement."
223871210|NCT03031561|DEVICE|Ultrasound|Undergo standard ultrasound
223871211|NCT03031561|DEVICE|MicoPure ultrasound|Undergo MicoPure ultrasound
223871212|NCT03031561|PROCEDURE|Biopsy of Breast|Undergo breast biopsy or surgical resection
223871213|NCT06049732|DEVICE|PainChek®|Both PainChek® and the Abbey Pain Scale are observational pain assessment tools which have been designed to assist healthcare professionals and profession caregivers assess pain in people who cannot self-report their pain
223871214|NCT02711293|OTHER|ART home delivery|Community health workers visit participants who are clinically stable on antiretroviral therapy (ART) at home (maintaining patients' prior clinic visit frequency) to deliver ART. Clinically stable on ART was defined as 1) taking ART for at least six months, 2) having had a CD4-cell count \>350 cells/μL or a suppressed viral load at six or more months after ART initiation, and 3) the patient's most current CD4-cell count must have been \>350 cells/μL or the most current viral load must have shown viral suppression, with the last measurement not taken more than 12 months ago.
223871215|NCT02711293|OTHER|Enhanced nutrition counseling|Community health workers visit participants at home to provide standard counseling (focusing on family planning, prevention of HIV transmission, and ART adherence) plus enhanced nutrition counseling (covering food production and dietary advice). In addition, participants who state that they have access to a plot of land or garden to grow vegetables receive a pack of seeds (amaranth, cowpea, or pumpkin) at enrolment.
223871216|NCT01251354|DRUG|BN83495|1 tablet of 40 mg, oral, daily until progression or death or unacceptable toxicity develops
223871217|NCT05210257|OTHER|Conventional physiotherapy|Group 1 was given conventinal physiotherapy Physiotherapy agents; 5 min ultrasound 1.5 watts/cm2 20 min conventional TENS 20 min heat agent application (hot pack) Exercise program; Stretching and relaxation exercises, Neck strengthening exercises that include concentric and isometric contractions Posture exercises 3 sets per day, 1 in the hospital with 10 repetitions
223871218|NCT05210257|OTHER|Neuroscience education|"Conventional physiotherapy program and The neuroscience education trainings will be conducted in the form of face-to-face interviews and 45-50 minute one-to-one sessions.~In sessions ; neurons and nerve conduction in the session, the formation process of pain, peripheral neuropathic pain, pain spread during the session, neuroplasticity, peripheral and central sensitization, hyperalgesia and allodynia, acute-chronic pain, The effects of stress, fear, anxiety, false thoughts and beliefs about pain and other psychosocial factors on the pain process and determining possible psychosocial factors in the patient during the session, Strategies for controlling the pain process and coping with psychosocial factors in the session will be completed by explaining the effect mechanisms of exercise on pain."
223871219|NCT03731377|DRUG|Crystalloid Solutions|Mini-fluid challenge with crystalloid 250 ml will be given to patients first. After observation of hemodynamic parameters, further fluid challenge will be given for response observation.
223871220|NCT06594523|DRUG|Denifanstat|Tablet
223871221|NCT06594523|DRUG|Placebo|Matching Tablet
223871222|NCT04543201|BEHAVIORAL|Early START visit using checklist over telephone or zoom|"Prior to visit subject receives pre-visit educational guide and copy of advance directive form~Follow up surveys:~Immediate: provider feedback survey~2-4 weeks after visit: subject feedback survey and caregiver/family feedback survey~After subject death: caregiver/family survey"
223871223|NCT01939171|DRUG|Thymoglobulin|
223871224|NCT06555159|BEHAVIORAL|Physical exercise prescription: Continuous aerobic training (jogging, swimming, static cycling)|Aerobic physical exercise (APE) program involving jogging, swimming, and static cycling, with a progressive intensity, which will start at 57%-63% of the maximum heart rate. (HRmax) in the first 4 weeks of the study, and will increase to 64% -76% in the final four weeks, fulfilling the principle of progressive overload
223871225|NCT06555159|BEHAVIORAL|Control group: Continuous aerobic physical exercise|Control group -A-, will perform aerobic physical exercise, which will be walking at 57% to 76% of HRmax, keeping this intensity for the 8 week intervention period.
223871226|NCT06671561|DEVICE|Observational data collection from patients with chronic rhinosinusitis (CRS) receiving PROPEL sinus implant(s) following functional endoscopic sinus surgery (FESS)|Observational data collection
223871227|NCT04022239|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo stem cell transplantation
223871228|NCT04022239|DRUG|Bendamustine|Given IV
223871229|NCT04022239|DRUG|Cyclophosphamide|Given IV
223871230|NCT04022239|BIOLOGICAL|Filgrastim-sndz|Given SC
223871231|NCT04022239|DRUG|Fludarabine|Given IV
223871232|NCT04022239|DRUG|Melphalan|Given IV
223871233|NCT04022239|DRUG|Mycophenolate Mofetil|Given PO
223871234|NCT04022239|BIOLOGICAL|Rituximab|Given IV
223871235|NCT04022239|DRUG|Tacrolimus|Given IV and PO
223871236|NCT04022239|RADIATION|Total-Body Irradiation|Undergo TBI
223871237|NCT06860633|DRUG|Efgartigimod|Dose of 10 mg/kg for IV infusion on days 1, 4, 11 and 18
223871238|NCT03807778|DRUG|Mobocertinib|Mobocertinib capsule.
223871239|NCT06496958|DEVICE|CO2 insufflation with an abdominal compression device|For participants randomized to the intervention group, the back brace support belt, Maxbelt (me3 type, Nippon Sigmax Co., Tokyo, Japan), will be applied around the circumference of the lower abdomen. Five sizes of Maxbelt will be employed in this study. According to the manufacturer, the ultra small-size (XS-size) belt will be used in those patients with an abdominal circumference of 55 cm-65 cm, the small-size (S-size) belt will be used in those patients with an abdominal circumference of 65 cm-75 cm, the medium-size (M-size) belt will be used for a circumference of 75 cm-85 cm, the large-size (L-size) belt will be used for a circumference of 85 cm-95 cm, and the ultra large-size (XL-size) will be used for a circumference of 95 cm-105 cm. Once applied, participants will be asked to assess and confirm that the belt is fastened tightly but not uncomfortably.
223871240|NCT06496958|DEVICE|CO2 insufflation with a sham abdominal compression device|The study coordinator will fit the sham device in a private bay alone with the patient. For participants randomized to the sham control group, a larger-sized Maxbelt with loose fitting will be used as a sham device. The L-size Maxbelt will be used in those patients with an abdominal circumference of 55 cm-71 cm, the XL-size Maxbelt will be used in in those patients with an abdominal circumference of 72 cm-88 cm, and the 2 XL-size Maxbelt will be used in in those patients with abdominal circumference 89 cm-105 cm.
223871241|NCT06496958|DEVICE|Water exchange colonoscopy|In those patients assigned to the water exchange (WE) group, the air pump will be turned off during the insertion phase of colonoscopy, while the colon is irrigated with warm-to-touch distilled water or half normal saline using a flushing pump. The WE approach involves the simultaneous infusion of water to facilitate luminal expansion and suction of unclean water during insertion. Any encountered air pockets will be aspirated to ensure optimal WE maneuvers in salvage cleaning.
223871242|NCT06677125|PROCEDURE|Electrical Mallet|The osteotome will be directly attached and pushed by magnetic mallet and a shock wave will be pushed on their tip. The electrical mallet will be imparted to osteotomes a longitudinal movement along a central axis moving up and down toward pilot bone hole providing a driving mechanism of longitudinal movements. Then the sinus lift instruments (Sweden and Martina) will be used to slowly lift the sinus. After that implant will be placed with the help of implant drilling device.
223871243|NCT06677125|PROCEDURE|Densah bur|The implant motor will be adjusted on reverse-densifying mode with 800 to 1200 rpm. According to the desired implant dimension, it will be started with the smallest densah bur. The first densah bur will advanced in densifying mode with bouncing motion in and out movement with copious irrigation until.
223871244|NCT05685316|DEVICE|COPLA® cartilage implant|In the investigation, the subjects will receive COPLA® device during normal clinical practice for cartilage repair surgery of the knee with bone marrow stimulation.
223871245|NCT06691919|DEVICE|Direct Endoscopic Necrosectomy with Powered Endoscopic Debridement|Patients will first undergo endoscopic ultrasound-guided cystgastrostomy using an electrocautery-enhanced lumen apposing metallic stent to gain access to the necrosum. Direct Endoscopic Necrosectomy will be performed using the EndoRotor® NecroMax 6.0 PED Catheter which has an outer diameter of 5.1 mm and is compatible with endoscopes that have a working channel of ≥6.0 mm.
224268855|NCT06601894|DIAGNOSTIC_TEST|Platelets count|the study include will take medical investigation data for all sickle cell patients.
224268856|NCT06595342|OTHER|No intervention|no intervention
224268857|NCT02243579|OTHER|Laboratory Biomarker Analysis|Correlative studies
224268858|NCT02243579|BIOLOGICAL|Pembrolizumab|Given IV
224268859|NCT03748381|PROCEDURE|Cataract surgery|During cataract surgery patients will be implanted with the AT Zeiss Lisa tri in one eye and the Rayner trifocal in the contralateral eye
224268860|NCT00348296|DRUG|High-dose intravenous immunoglobulin (Venoglobulin-IH)|
224268861|NCT04792723|DRUG|Sublingual aspirin|Vita Green Health Products sublingual aspirin 80 mg tablet
224268862|NCT04792723|DRUG|Oral aspirin|Synco (HK) oral aspirin 80mg tablet
223871246|NCT06691919|PROCEDURE|Transgastric Surgical Necrosectomy|Patients randomized to the surgical arm will undergo open or minimally invasive (laparoscopic) transgastric SN with the aim of creating an ample size cystgastrostomy to perform a complete debridement. In either approach, the peritoneal cavity is entered to identify the stomach through which an anterior gastrotomy is made. The retrogastric necrosum is identified either using a finder needle or ultrasound and accessed through a posterior cystgastrostomy. Transgastric SN is then manually performed, and any cyst fluid fully evacuated. The anterior gastrotomy is then closed allowing any residual necrosis or pancreatic enzyme to efflux into the stomach and enter the upper GI tract. As with endoscopy, patients with retrogastric collections are observed for a sufficient period to ensure full maturation of the necrosum.
223871247|NCT06702059|DIAGNOSTIC_TEST|Cardiopulmonary exercise testing|Subjects will undergo pre-operative cardiopulmonary exercise testing.
223871248|NCT05600556|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223871249|NCT05600556|PROCEDURE|Computed Tomography|Undergo CT
223871250|NCT05600556|OTHER|Best Practice|Review imaging on standard computer screen
223871251|NCT05600556|OTHER|Questionnaire Administration|Complete questionnaire
223871252|NCT05600556|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223871253|NCT05600556|PROCEDURE|Computed Tomography|Undergo CT
223871254|NCT05600556|OTHER|Virtual Technology Intervention|Review virtual reality images
223871255|NCT05600556|OTHER|Questionnaire Administration|Complete questionnaire
223871256|NCT04024293|DEVICE|Goldfish (GF)|The GF lens (SCL) will be place on participant's eye for a 24h IOP recording session
223871257|NCT06883123|DRUG|Simbrinza 0.2%-1% Ophthalmic Suspension|brinzolamide and brimonidine tartrate
223871258|NCT06883123|DRUG|Rocklatan 0.02%-0.005% Ophthalmic Solution|netarsudil and latanoprost
223871259|NCT06883123|DRUG|Cosopt PF 2%-0.5% Ophthalmic Solution|dorzolamide hydrochloride and timolol maleate
223871260|NCT06883123|DRUG|Latanoprost 0.005% Ophthalmic Solution|Latanoprost
223871261|NCT06750302|DRUG|Methoxyflurane - Penthrox|3ml
223871262|NCT06750302|OTHER|Placebo|saline + one drop of methoxyflurane
223871263|NCT06083181|DEVICE|Perf-Fix Otologic Gel Patch|Gel patch application
223871264|NCT07059754|DEVICE|Topical Ophthalmic Cooling|Targeted topical ophthalmic cooling treatment using the ETX-4143 cooling device
223871265|NCT06648031|DRUG|Arm 1 - DehydraTECH-CBD alone|Dose: 250 mg CBD twice daily (500 mg/day) for 12 weeks. Route of administration: Oral Dosage form: Capsule
223871266|NCT06648031|DRUG|Arm 2 - DehydraTECH-semaglutide alone|Dose: 3.5 mg once daily for 4 weeks, ascending to 7 mg once daily for the remaining 8 weeks. Route of administration: Oral Dosage form: Capsule
223871267|NCT06648031|DRUG|Arm 3 - DehydraTECH-CBD in combination with DehydraTECH-semaglutide|"DehydraTECH-CBD dosing = 250 mg twice daily for 12 weeks.~\- DehydraTECH-semaglutide = 3.5 mg once daily for 12 weeks Route of administration: Oral Dosage form: Capsule"
223871268|NCT06648031|DRUG|Arm 4 - Rybelsus medication (semaglutide) alone|Normal clinical dose of 3.0 mg once daily for 4 weeks, ascending to 7.0 mg once daily for the remaining 8 weeks. Route of administration: Oral Dosage form: Capsule
223871269|NCT06648031|DRUG|Arm 5- Tirzepatide|Tirzepatide arm - 20mg for 4 weeks and then 40mg for 8 weeks
223871270|NCT00130117|DRUG|r-metHuLeptin|Starting dose: 0.08mg/kg once daily Subcutaneous injection.
223871271|NCT00130117|DRUG|Oral Contraceptive Pills (OCPs)|Sprintec taken orally once daily.
223871272|NCT00130117|OTHER|Placebo|placebo (no active medication)
223871273|NCT06385340|OTHER|Lipikar Baume AP+M|• Lipikar Baume AP+M Application of Lipikar Baume AP+M at least twice daily for 4 weeks on one of the two arms according to a randomization scheme
223871274|NCT06913010|OTHER|No interventions.|This is an observational study with no interventions.
223871275|NCT02021799|DIETARY_SUPPLEMENT|Moringa and Lactobacillus rhamnosus GR-1|
223871276|NCT06890728|BEHAVIORAL|Culinary focused nutrition education|Culinary focused nutrition education based on MyPlate with an emphasis on taste and enjoyment of healthy foods.
223871277|NCT06890728|BEHAVIORAL|Standard low intensity nutrition education|Provided by a written MyPlate resource
223871278|NCT04449679|OTHER|Patient Monitoring System|Receive RT-CAMSS
223871279|NCT04449679|OTHER|Questionnaire Administration|Complete questionnaires
223871280|NCT04449679|OTHER|Consultation|Receive tailored feedback, including consultation with nurse
223871281|NCT06914648|PROCEDURE|Portal Vein Embolization|Description: Portal Vein embolization with Glue by a transhepatic approach
223871282|NCT06914648|PROCEDURE|Hepatic Vein Embolization|Hepatic Vein Embolization with Vascular plugs via a transjugular or transfemoral approach in the same session as the PVE procedure
223871283|NCT05094141|OTHER|Virtual reality|Virtual reality game played during port needle access.
223871284|NCT05682924|DIAGNOSTIC_TEST|taking blood for the study of biochemical parameters and the study of microcirculation using the method of laser Doppler flowmetry|In the study, blood will be taken from patients with chronic myelogenous leukemia in the chronic phase to determine biochemical parameters (endothelin-1, homocysteine, VEGF (vascular endothelial growth factor)), as well as a study of microcirculation in these groups of patients using the method of laser Doppler flowmetry, to study the function of the endothelium.
223871285|NCT04411056|OTHER|Barrier box|Placement of barrier box ( a plastic box for shielding)
223871286|NCT05463003|DIETARY_SUPPLEMENT|Berberine|A single dose of 1000 mg berberine in two capsules will be administered with 250 ml of still water in the overnight fasting condition. A total of 12 blood samples will be taken at defined time points (baseline, 1; 1.5; 2; 3; 4; 5; 6; 8; 10; 24; 48 h). At each time point, blood will be collected in 2x 7.5 ml tubes for collecting serum and plasma samples to determine berberine, its metabolites and biomarkers of OCT1 transport and CYP2D6 enzymatic activity
223871287|NCT03716557|DEVICE|Spinal Cord Stimulation 4000Hz|Differential programming of the Boston Scientific Precision™ Plus Spinal Cord Stimulator System
223871288|NCT03716557|DEVICE|Spinal Cord Stimulation 10000Hz|Differential programming of the Boston Scientific Precision™ Plus Spinal Cord Stimulator System
223871289|NCT03716557|DEVICE|Spinal Cord Stimulation 40Hz|Differential programming of the Boston Scientific Precision™ Plus Spinal Cord Stimulator System
223871290|NCT03838926|DRUG|Trichostatin A|Intravenous Infusion
223871291|NCT05601505|OTHER|circulating tumor DNA|This study will further testify the prognostic value of ctDNA in the treatment term of locally advanced rectal cancer, the higher the VAF value, the higher the risk of recurrence and metastasis.
223871292|NCT04786457|BIOLOGICAL|Dengue 1 Live Virus Human Challenge (DENV-1-LVHC)|one subcutaneous injection of Dengue 1 Live Virus Human Challenge (DENV-1-LVHC) at 0.5 mL of 6.5 x 10\^3 PFU/mL
223871293|NCT06319365|BEHAVIORAL|yoga|the yoga practice of the group should completed at the end of 12 weeks
223871294|NCT04956133|BEHAVIORAL|Physical Activity|Participants will receive the IMPACT program, which includes a combination of aerobic, resistance, balance, and flexibility exercises conducted 1:1 and delivered online by a physical activity specialist via Zoom. The IMPACT program follows basic physical activity progression principles (i.e., principles of frequency, intensity, time, type, overload and progression). Tailoring will be used to promote fitness and wellness benefits, while ensuring safety. In addition, prominent behaviour change techniques will be provided by physical activity specialists within each 1:1 session. Discussions and worksheets will be provided, depending on participants needs.
223871295|NCT06757959|COMBINATION_PRODUCT|Wet Needling|This involve the use of needles to inject a local anesthetics into trigger points or areas of muscle tightness around the knee particularly in the quadriceps surrounding soft tissue implicated in patellofemoral pain syndrome .To reduce localized pain, release muscle tension and improve tissue function.
223871296|NCT06757959|DIAGNOSTIC_TEST|Kinesiotaping|Application of kinesiotape around knee joint or quadricep following a specific technique aimed at reducing pain and improving joint stability . The tape is typically applied to encourge proper movement patterns , reducing swelling and provide sensory feedback to brain. Strengthening exercises : To strenghthen the quadriceps , gluteal muscles and other key stabilizing muscles of lower limbs. This is aimed at reducing the mechanical stress on the joint and improve overall function.
223871297|NCT02936388|PROCEDURE|SIRT|catheter-based application of radioactive microspheres into the hepatic artery
223871298|NCT02936388|PROCEDURE|DSM-TACE|catheter-based application of chemotherapy and degradable starch microspheres into the hepatic artery
223871299|NCT04239040|PROCEDURE|Tissue collection|Collection of cancerous tissue to create GVAX vaccine or irradiated GMCSF-secreting autologous neuroblastoma cell vaccine at time of clinically indicated surgical procedure
223871300|NCT04239040|BIOLOGICAL|GVAX vaccine|Vaccine injected weekly over initial 21 day cycle, biweekly for cycles 2-4 of 21 day cycle duration and cycles 5 and subsequent of 28 day cycle duration until vaccine supply is exhausted.
223871301|NCT04239040|DRUG|Nivolumab|"Intravenous infusion of nivolumab every 3 weeks, for cycles 1-4. Cycles 1-4 are 21 days~Intravenous infusion of nivolumab biweekly for cycle 5 and subsequent of 28 day cycle duration. Subsequent 28 day cycles will last up to 2 years."
223871302|NCT04239040|DRUG|Ipilimumab|Intravenous infusion of ipilimumab every 3 weeks, for cycles 1-4. Cycles 1-4 are 21 days
223871303|NCT05415800|BEHAVIORAL|Quality Improvement Practice Facilitation Intervention|"The practice facilitation intervention (implementation strategy package) consists of QI projects designed for primary care providers with external practice facilitation and technical support provided by a QI Coach and Data Coach on our team.~The QI projects focus on the implementation of cancer prevention and early detection guidelines in primary care settings, specifically one QI project for each of the following clinical guidelines: colorectal cancer screening, lung cancer screening, and tobacco treatment. The study participants are the healthcare providers and staff, not the patients, since the goal of the practice facilitation intervention (implementation strategy package) is to improve the implementation of existing standard of care."
223871304|NCT06044857|DRUG|68-Ga PSMA11|Will be injected/assessed in line with its FDA label.
223871305|NCT06352775|DIETARY_SUPPLEMENT|Calcium Carbonate|We will be using it in routes and doses consistent with its approved uses. Per the drug label information for Calcium Carbonate USP 500 mg found in the US National Library of Medicine, adults may take 2-4 tablets as symptoms occur and if pregnant to not exceed 10 tablets in 24 hours. Therefore, using a dosing of 500mg every 4 hours will be well below that guidance. When both cervical ripening has been completed and the oxytocin administration begins, the calcium carbonate treatment group will be given calcium carbonate 500mg every 4 hours (not to exceed 10 tablets in 24 hours) until they deliver.
223871306|NCT02160756|DRUG|JNJ-56021927 Softgel Capsule|Single oral dose of JNJ-56021927 240 mg softgel capsule on Day 1.
223871307|NCT02160756|DRUG|JNJ-56021927 Tablet Formulation 1|Single oral dose of JNJ-56021927 240 mg Tablet Formulation 1 on Day 1.
223871308|NCT02160756|DRUG|JNJ-56021927 Tablet Formulation 2|Single oral dose of JNJ-56021927 240 mg Tablet Formulation 2 on Day 1.
223871309|NCT02160756|DRUG|JNJ-56021927 Tablet Formulation 3|Single oral dose of JNJ-56021927 240 mg Tablet Formulation 3 on Day 1.
223871310|NCT05515562|DRUG|Omadacycline Injection|All participants will receive Intravenous (IV) omadacycline
223871311|NCT04198623|DRUG|Montelukast 10 Mg Oral Tablet|Montelukast(Singulair) 10mg to be taken at least 2 hours prior to initiation of monoclonal antibody infusion addition to institutional protocol premedication regiment
223871312|NCT05920382|PROCEDURE|Radiofrequency ablation of peripheral nerves.|Randomized double-blind clinical trial where we will apply thermal radiofrequency to the sensory terminal branches of the femoral nerve in the knee, including the vasto medial nerve, vasto lateral nerve, vasto intermedio nerves, and the infrapatellar branch of the saphenous nerve.
223871313|NCT06423677|PROCEDURE|Serratus Posterior Superior Intercostal Plane Block|The Serratus Posterior Superior Intercostal Plane Block will be performed under ultrasound guidance. During the block, a linear ultrasound probe will be placed parallel to the spine of the scapula on the surgical side and then slid medially. The block needle will be advanced under ultrasound guidance over the 3rd rib. After the needle touches the rib, it will be withdrawn by 1mm, and the block site will be confirmed by injecting sterile 0.9% NaCl. Subsequently, patients will be administered 50mg of bupivacaine and 100mg of lidocaine in a controlled manner.
223871314|NCT06423677|DEVICE|patient controlled analgesia|intravenous patient-controlled analgesia (PCA) with 4mg/ml Tramadol HCl in 100ml NaCl. There will be no basal infusion, with bolus doses of 20mg and a lockout period of 20 minutes, and a total dose limitation of 200mg over 4 hours
223871315|NCT04339140|DRUG|Zafirlukast|Oral tablets, 2x daily for 28 day cycle up to 1 year
223871316|NCT06775912|DRUG|RD06-05 CART Cell Injection|CAR T-cell therapy administered intravenously after a lymphodepleting therapy regimen consisting of fludarabine and cyclophosphamide
223871317|NCT06777069|PROCEDURE|Leucocyte and platelet rich fibrin membrane application|Leukocyte and platelet rich membrane, obtained by centrifuging 10 ml of venous blood collected from the patient's antecubital vein, was sutured to the donor sites.
223871318|NCT06777108|DIETARY_SUPPLEMENT|Inorganic Nitrate|The intervention evaluates the single and 1/2-dose pharmacokinetics of a plant-based bioequivalent inorganic nitrate (NO3-) complex with vitamins, antioxidantsand phytophenol rich food extracts.
223871319|NCT05459142|DRUG|Medical Abortion|Medical Abortion
223871320|NCT05328375|BEHAVIORAL|Telehealth-enhanced Hybrid CR|Participants in this group attend a total of 24 CR sessions (5 clinic-based + 19 home-based) over a 12-week period. Clinic-based sessions occur during the first week of the program and at the end of each month. Home-based sessions take place remotely once or twice per week via telehealth, depending on the week of the program. Patients are provided with onboarding sessions, remote patient monitoring devices (tablet, pulse oximeter, blood pressure monitor and cuff) and home-based exercise equipment (e.g., stationary bike and weights). Each CR session (clinic and home) is 60 minutes in duration and includes aerobic and resistance exercise training. Patients will also be asked to complete educational videos, as well as document their physical activity, dietary intake, medication management and homework sessions via surveys. Patients will be encouraged (but not required) to achieve ≥30 minutes of moderate aerobic activity, such as brisk walking, on ≥5 days per week.
223871321|NCT05328375|BEHAVIORAL|Traditional CR|Participants in this group attend a total of 24 clinic-based CR sessions according to standard of care protocols over a 12-week period. Each CR session is 60 minutes in duration and includes aerobic and resistance exercise training. In addition to scheduled sessions, patients will be asked to complete educational videos, as well as document their physical activity, dietary intake, medication management and homework sessions via surveys. Patients will be encouraged (but not required) to achieve ≥30 minutes of moderate aerobic activity, such as brisk walking, on ≥5 days per week.
223871322|NCT05491616|DRUG|Nivolumab|In this SANO-3 study, patients will receive Nivolumab at 480mg Q4W starting 10-14 weeks after nCRT (i.e., when cCR has been established) until disease progression or unacceptable toxicity, for a maximum duration of 1 year.
223871323|NCT06334575|DRUG|Budesonide|receive, on top of their usual treatment Budesonide dry powder inhaler, 400 mcg/12 hours for 8 weeks
223871324|NCT06474169|OTHER|1 blood sample for each participant|"Blood sample for cohort n°1 and n°2 (collection during a peripheral venous blood sample, part of the standard of care for this disease) :~1 blood sample for each patient 28mL of blood (4 tubes, 7mL per tube)~Blood samples for cohort n°3 (collection during blood donation at Etablissement Français du Sang) :~1 blood sample for each healthy donor 14mL of blood (2 tubes, 7mL per tube)"
223871325|NCT06209047|DRUG|Local instillation of gentamicin and Budesonide|Bronchoscopic local instillation of gentamicin and Budesonide
223871326|NCT06209047|DRUG|Local instillation of Levofloxacin and Budesonide|Bronchoscopic local instillation of Levofloxacin and Budesonide
223871327|NCT06209047|PROCEDURE|Bronchoscopic mechanical secretion suction and lavage|Bronchoscopic mechanical secretion suction and lavage
223871328|NCT06209047|PROCEDURE|Sham Bronchoscopy|Bronchoscopy for airway visualization only, no lavage or drug instillation (sham procedure).
223871329|NCT04219826|DRUG|CK-3773274 (5 - 15 mg)|CK-3773274 tablets administered orally
223871330|NCT04219826|DRUG|CK-3773274 (10 - 30 mg)|CK-3773274 tablets administered orally
223871331|NCT04219826|DRUG|Placebo for CK-3773274|Placebo administered orally
223871332|NCT06021314|OTHER|Brace|Cheneau type scoliosis brace due to brace indication for adolecant idiopatic scoliosis
223871333|NCT05215132|RADIATION|MRI|1.5T or 3T MRI scanner (Siemens Medical Systems)
223871334|NCT05215132|DRUG|Gadavist 2Ml Solution for Injection|Arm 1 and Arm 3 subjects will undergo this intervention (Gadavist 2Ml solution)
223871335|NCT06025942|BEHAVIORAL|Purrble intervention|"When the Purrble is picked up, it emits a frantic heartbeat that slows down if the person uses calm stroking movements. If the Purrble is soothed for long enough, it transitions into a purring vibration indicating a calm, content state.~Logic model underlying the intervention:~Level 1: in-the-moment soothing support to young people in emotional moments when they would attempt to utilise emotion regulation (ER) strategies to calm down.~Level 2: mechanisms that facilitate long-term engagement with the intervention, building on positive subjective experience of Level 1.~Level 3: shift in young peoples' ER practices and implicit beliefs about emotion, after repeated experience of Levels 1-2.~* see JMIR Res Protoc 2021;10(11):e28914 (doi: 10.2196/28914)"
223871336|NCT05996497|BEHAVIORAL|behavioral measures|behavioral measures
223871337|NCT05996497|OTHER|Electrophysiological measures|Electrophysiological measures
223871338|NCT05996497|OTHER|Training 1|Training 1
223871339|NCT05996497|OTHER|Training 2|Training 2
223871340|NCT03122886|DIETARY_SUPPLEMENT|Fat Emulsion|Given IV
223871341|NCT03122886|OTHER|Placebo|Given IV
224268863|NCT05451264|DIAGNOSTIC_TEST|blood pressure measurement|Completion of the physical activity and quality of life questionnaire (PedSQL adapted to the age of the child), measurement of weight and height; Measurement of VOP (Pulse wave velocity), AI (increase index) and ECG (electro cardiogram) collection at rest lying down; Stimulation test by slow breathing at 6 cycles/min for three minutes; Continuation of the measurements in a standing position for 5 minutes; Installation of blood pressure holter (MAPA) which will be kept for 24 hours and then returned by post.
224268864|NCT00556673|DRUG|indacaterol maleate/mometasone furoate|Indacaterol maleate 250 μg / mometasone furoate 200 μg delivered via the Twisthaler device.
223871342|NCT05356234|BEHAVIORAL|Treatment Intervention: Responsible Parenting, Relationships, and Employment Services|The Intervention group will be assigned a Case Manager and placed in the next available On My Shoulders (OMS) curriculum that offers strategies to help individuals develop a strong and healthy self in the service of making current and/or future relationships of all forms (parent-child, romantic, family, work) successful and satisfying. This curriculum is intended to equip men (and, where applicable, women) with the skills they need to build and nurture healthy relationships. This curriculum should help participants improve family functioning. Additionally, Transforming Impossible into Possible (TIP) financial literacy curriculum will be utilized to help participants increase job retention for those currently employed, improve wages through additional educational and training opportunities, and learn skills to better manage family finances. This curriculum should help participants increase economic stability and mobility.
223871346|NCT05808608|DRUG|AK104|Anti-PD-1/CTLA-4 bi-specific antibody drug; RP2D intravenously (IV)
223871347|NCT05808608|DRUG|Axitinib|An oral, small molecule, TKI selective for VEGFRs; 5mg bid orally
223871348|NCT05588479|DIETARY_SUPPLEMENT|Pomegranate extract|Two capsules of pomegranate extract (740 mg) will be taken daily at any time of the day for a period of 12 weeks.
223871349|NCT05588479|DIETARY_SUPPLEMENT|Control|One capsule of containing no pomegranate extract will be taken daily at any time of the day for a period of 12 weeks.
223871350|NCT03422276|OTHER|Rehabilitation Discharge Plan|"CARF standards for discharge following an inpatient rehabilitation stay for a traumatic brain injury. This approach may include the following:~1. patient and family education about TBI, both general and individualized to each person's symptoms and level of function, as well as education on medications and symptoms to monitor following discharge;~2. written discharge care instructions, including recommended appointments with primary care, rehabilitation medicine and outpatient therapies, and medication list which are reviewed with the patient and family prior to discharge; and~3. a phone call from an inpatient care provider within a few days of discharge to address any immediate problems and ensure that equipment has arrived, medications are being taken, etc."
223871351|NCT03422276|OTHER|Rehabilitation Transition Plan|"Participants and their caregivers (if applicable) randomized to the Rehabilitation Transition Plan group will receive up to 12 scheduled contacts 6 months post-discharge from a TBI care manager familiar with the care and resource networks at the respective sites. The contacts will at minimum be by telephone, although a HIPAA-compliant video conferencing option will also be available.~The content of these contacts will include:~1. Particularly in the first few calls, review of discharge plans and assistance and/or directive problem-solving around any obstacles to following discharge plans;~2. Assessment of unmet needs, developed into a standard checklist of areas of need that are relevant to TBI, culled from literature on need fulfillment in this population."
223871352|NCT05722522|DRUG|Secukinumab|The participants will receive Secukinumab 300 mg s.c. at randomization (Baseline visit), Week 1, 2, 3, 4, 8, and 12
223871353|NCT05722522|DRUG|Placebo|The participants will receive placebo s.c. at randomization (Baseline visit), Week 1, 2, 3, 4, 8, and 12
223871354|NCT05302817|COMBINATION_PRODUCT|Hyperpolarized xenon MRI|Patients with non-small cell lung cancer scheduled for radiation therapy willing to take part in this study will undergo hyperpolarized xenon MRI at several time points prior and post RT. Images will be used to determine maps for functional lung avoidance and post-RT changes in the lung function and compared to standard-of-care assessment methods.
223871355|NCT05985044|OTHER|Care cO-ORDInatioN And sympTom managEment (CO-ORDINATE) Intervention|The intervention consists of the following four components: i) needs assessment; ii) question prompt list; iii) goals discussion and; iv) symptom assessment and tracking. The intervention will start with the enrolment of a patient living with multimorbidity. The intervention consists of one in-person pre-discharge visit by the study team and four follow-up telephone calls (at 48 hours, 1 week, 4 weeks, and 6 weeks post-discharge).
223871356|NCT00248456|DRUG|Calcipotriol plus betamethasone dipropionate ointment|
223871357|NCT05499676|DEVICE|SilverCloud Health Mobile Intervention|SilverCloud Health is a mobile mental health platform offering cognitive-behavioral therapy-based guided self-help programs, including one for anorexia nervosa developed by our team. Participants in this arm will receive the support of a coach to guide them through the program. Participants will be able to communicate with their coach within the program.
223871358|NCT05499676|DEVICE|Social Networking Intervention: Facebook|Facebook is a social networking site that will offer participants the opportunity to interact with study team posts, post themselves, and connect with others in the study experiencing similar struggles in a private group
223871359|NCT06548282|OTHER|Acceptance and commitment therapy|"Introduction: Build rapport and complete pre-assessment questionnaires.~First Session:~Introduce therapist, ACT principles, and MI complications. Provide psychoeducation and assign homework.~Second Session:~Review feedback and encourage change. Assign homework.~Third Session:~Discuss acceptance and coping strategies. Assign homework.~Fourth Session:~Discuss cognitive diffusion and unhelpful thoughts. Assign homework.~Fifth Session:~Explore self-concept and mindfulness. Assign homework.~Sixth Session:~Identify and elaborate on values. Assign homework.~Seventh Session:~Discuss values, goals, and barriers. Assign homework.~Eighth Session:~Discuss commitment to action and relapse prevention. Administer post-test and express gratitude."
223871360|NCT06326645|DRUG|Crofelemer Oral Product|Crofelemer powder for solution (50g and 100g) or Crofelemer Powder for Oral Solution (100 mg/mL or 30 mg/mL vials for reconstitution and oral dosing)
223871361|NCT00987025|BEHAVIORAL|Telehealth|Use of telehealth blood pressure station every week
223871362|NCT00987025|BEHAVIORAL|Educational materials|Control
223871363|NCT05537207|DEVICE|low level laser therapy|low level laser therapy (LLLT) on the acupuncture points. inadition to non-steroidal anti-inflammatory drugs.The parameters of the laser device are wave length of 904 nm, maximum average power of 5 milli Watts, a maximum repetition rate of 5 kHz, energy of up to 30 J/cm², and energy density of 2 J/cm2
223871364|NCT05537207|OTHER|non-steroidal drugs|All women will receive non-steroidal anti-inflammatory drugs in the form of Brufen (Ibuprofen), 400 mg, 3 times per day after meals, for 6 weeks, as described by their gynecologist.
223871365|NCT05774782|DEVICE|Cerebral flow diverter|The surface-modified flow diverter is an intracranial implant designed to be placed in a parent artery so as to divert blood flow away from an aneurysm.
223871366|NCT05578898|BEHAVIORAL|CLEAR Care Companion (CC) application|The CLEAR CC application is an EPIC-based, electronic application, downloaded to the patient's Smartphone or Tablet. The CLEAR CC leverages patient-reported symptoms assessment vis-a-vis push notifications to complete clinically meaningful questions and validated questionnaires pertaining to symptoms that serve as early indicators of readmission. The CLEAR CC application will send notifications beginning two days prior to surgery and continue until the 6 week post operative appointment.
223871367|NCT05331521|DRUG|CETEG|At progression, patients without prior radiotherapy will undergo radiotherapy and PCV as an adjunct chemotherapy if bone marrow reserve allows in the experimental arm.
223871368|NCT05331521|DRUG|PCV|In the comparator arm there is the option for second radiotherapy or even reuse of the full radiochemotherapy regimen as it had been given at diagnosis (BIC).
223871369|NCT05331521|RADIATION|RT|Radiotherapy at 50.4/54 Gy in 1.8 Gy fractions for grade 2 and 59.4 Gy in 1.8 Gy fractions for grade 3 gliomas
223871370|NCT06566638|DEVICE|NucleoCapture device|100ml NucleoCapture selective DNA adsorber.
223871371|NCT04955210|OTHER|Not applicable（Cohort study）|This is a prospective observational study and does not include interventions.
223871372|NCT06307964|PROCEDURE|Biological sampling|"* A fragment of the diagnostic transjugular liver biopsy (D0)~* Plasma samples at D0, and at 1 and 6 months after liver biopsy if possible~* Fecal samples at D0, and at 1 and 6 months after liver biopsy if possible"
223871373|NCT04163328|DRUG|HydroEye®|This is an omega-3 fatty acids supplement.
223871374|NCT02279095|DRUG|Palovarotene dose level 1|Palovarotene was taken orally once daily at approximately the same time each day.
223871375|NCT02279095|DRUG|Palovarotene dose level 2|Palovarotene will be taken orally once daily at approximately the same time each day.
223871376|NCT02279095|DRUG|Palovarotene dose level 3|Palovarotene will be taken orally once daily at approximately the same time each day.
223871377|NCT02279095|DRUG|Palovarotene dose level 4|Palovarotene will be taken orally once daily at approximately the same time each day.
223871378|NCT05938413|DEVICE|Wise App with medication adherence reminders|The Intervention group will receive the Wise App that delivers medication adherence reminders.
223871379|NCT05938413|BEHAVIORAL|CHW Sessions|The Intervention group will complete sessions with a community health worker (CHW).
223871380|NCT05432206|DRUG|Cannabis Sativa Oil|Cannabis Sativa oil standardized: 11 mg THC/g and 22 mg CBD/g.
223871381|NCT05432206|DRUG|Placebo|Hemp virgin seed oil
223871382|NCT05577624|DRUG|AMG 510|Oral tablet
223871383|NCT05577624|DRUG|Rifampin|Oral capsule
223871384|NCT04805437|DEVICE|3D TLSO|Brace treatment with Boston 3D 20 hours a day until skeletal maturity.
223871385|NCT04805437|DEVICE|Standard TLSO|Brace treatment with standard Boston brace 20 hours a day until skeletal maturity.
223871386|NCT05681702|DRUG|aspirin plus clopidogrel|After at least 30 days of DAPT \[with aspirin 81-mg od and a potent P2Y12 inhibitor (prasugrel 10 mg od or ticagrelor 90-mg BID)\] in chronic coronary syndrome or after at least 90 days of DAPT in acute coronary syndromes; patients will continue aspirin and switch to clopidogrel 75-mg.
223871387|NCT05681702|DRUG|prasugrel or ticagrelor|After at least 30 days of DAPT \[with aspirin 81-mg od and a potent P2Y12 inhibitor (prasugrel 10 mg od or ticagrelor 90-mg BID)\] in chronic coronary syndrome or after at least 90 days of DAPT in acute coronary syndromes; patients will drop aspirin and continue prasugrel or ticagrelor.
223871388|NCT05550129|DRUG|AMG 510|Oral tablet
223871389|NCT05550129|DRUG|Metformin|Oral tablet
223871390|NCT05969704|PROCEDURE|MRI fusion targeted prostatic biopsy|combines the pictures from an MRI and an ultrasound to create a detailed 3-D image of the prostate. This procedure makes it easier to see an abnormal lesion of prostate in order to guide the biopsy needle into the abnormal lesion
223871391|NCT05969704|PROCEDURE|MRI cognitive targeted prostatic biopsy|the biopsy operator reviews the MR images and creates a mental three-dimensional representation of the prostate and of the lesion within it to take a biopsy from the lesion
223871392|NCT05460377|BIOLOGICAL|Full dose Sabin Inactivated Poliovirus Vaccine produced by IMBCAMS|The Sabin antigen content is 30, 32 and 45 D-antigen units (DU) for types 1, 2 and 3, respectively and will be delivered intramuscularly by needle and syringe.
223871393|NCT05460377|BIOLOGICAL|Fractional (1/5) Dose Sabin Inactivated Poliovirus Vaccine produced by IMBCAMS|The Sabin antigen content is 30, 32 and 45 D-antigen units (DU) for types 1, 2 and 3, respectively and will be delivered intradermally by needle and syringe.
224268865|NCT00556673|DRUG|placebo to indacaterol maleate/mometasone furoate|Placebo to indacaterol maleate/mometasone furoate delivered via the Twisthaler device.
224268866|NCT00556673|DRUG|fluticasone proprionate / salmeterol xinafoate|Fluticasone proprionate 250 μg / salmeterol xinafoate 50 μg delivered via the Accuhaler® device.
223871394|NCT05460377|BIOLOGICAL|Full dose Sabin Inactivated Poliovirus Vaccine produced by BIBP|The Sabin antigen content is 15 DU, 45 DU, 45 DU for types 1, 2, and 3, respectively and will be delivered intramuscularly by needle and syringe
223871395|NCT05460377|BIOLOGICAL|Fractional (1/5) dose Sabin Inactivated Poliovirus Vaccine produced by BIBP|The Sabin antigen content is 15 DU, 45 DU, 45 DU for types 1, 2, and 3, respectively and will be delivered intradermally by needle and syringe
223871396|NCT04099290|OTHER|Blood and tumor samples|Blood samples to be obtained at consent, post-operatively, post-adjuvant treatment, and at follow-up or recurrence. Tumor samples to be obtained at surgery and at time of recurrence or post-treatment biopsy, if applicable.
223871397|NCT02918331|DRUG|Daratumumab (16 mg/kg)|Daratumumab (16 mg/kg) will be administered by IV infusion to all participants once every week for 8 weeks; then once every other week for 16 weeks; thereafter once every 4 weeks until documented progression, unacceptable toxicity or study end.
223871398|NCT02918331|DRUG|Lenalidomide|Participants will receive lenalidomide 25 mg orally on Days 1 through 21 of each 28 day cycle. Participants with creatinine clearance (CrCl) between 30 and 60 milliLitre (mL)/minute (min) will receive lenalidomide 10 mg every 24 hours.
223871399|NCT02918331|DRUG|Dexamethasone|Participants will receive dexamethasone 40 mg weekly, at day 1, 8, 15, 22 of each cycle.
223871400|NCT06535308|DRUG|BnH-015B 5 mg|Korean / 3 on BnH-015B, 1 on placebo
223871401|NCT06535308|DRUG|BnH-015B 10 mg|Korean / 6 on BnH-015B, 2 on placebo
223871402|NCT06535308|DRUG|BnH-015B 20 mg|Korean / 6 on BnH-015B, 2 on placebo
223871403|NCT06535308|DRUG|BnH-015B 40 mg (Dietary impact)|Korean / 6 on BnH-015B, 2 on placebo
223871404|NCT06535308|DRUG|BnH-015B 40 mg|Caucasian / 6 on BnH-015B, 2 on placebo
223871405|NCT06535308|DRUG|BnH-015B 80 mg|Korean / 6 on BnH-015B, 2 on placebo
223871406|NCT06535308|DRUG|BnH-015B 160 mg|Korean / 6 on BnH-015B, 2 on placebo
223871407|NCT06535308|DRUG|BnH-015B 40 mg (MAD)|Korean / 6 on BnH-015B, 2 on placebo
223871408|NCT06535308|DRUG|BnH-015B 80 mg (MAD)|Korean / 6 on BnH-015B, 2 on placebo
223871409|NCT06535308|DRUG|BnH-015B 40 mg (Part II)|Korean / 9 subjects
223871410|NCT06535308|DRUG|BnH-015B 80 mg (Part II)|Korean / 9 subjects
223871411|NCT06535308|DRUG|BnH-015B Placebo (Part II)|Korean / 6 subjects
223871412|NCT05274048|DRUG|Neratinib Pill|Patients will be enrolled in cohorts of 3 at each dose level of Neratinib (120 mg, 160 mg, 200 mg) daily (days 1 through 21)
223871413|NCT05274048|DRUG|Fam-Trastuzumab Deruxtecan-Nxki (TDxD)|standard dosing of TDxD (5.4mg/m2) on day 1of a 21 day treatment cycle
223871414|NCT05411848|DIETARY_SUPPLEMENT|2kcal HP PlantBased|Patients will receive a minimum of 1 bottle per day of either (or both of) 2kcal HP PlantBased and/or 2kcal HP PlantBased MultiFibre Tube Feeds for a minimum of 7 days and a maximum of 28 days. During the 12-month follow-up, patients will have access to the same trial prescription as per the 28-day intervention period.
223871415|NCT05971303|OTHER|Questionnaire|Questionnaires will be given to patients, interpreters and cancer car professionals with aims of delineating the attitudes and experiences of patients, interpreters and cancer care professionals involved in the care of oncology patients with gynecologic malignancies
223871416|NCT02397083|DRUG|Everolimus|Given PO
223871417|NCT02397083|OTHER|Laboratory Biomarker Analysis|Correlative studies
223871418|NCT02397083|DEVICE|Levonorgestrel-Releasing Intrauterine System|Placed in the uterus
223871419|NCT03646045|OTHER|Transpyloric feeding|Preterm infant feeding using transpyloric feeding tube (nasoduodenal tube)
223871420|NCT06781840|BEHAVIORAL|Playing Playfully to Overcome Adversity|The intervention will consist of two parts: (a) five 45-minute-long parent group online sessions; and (b) one 30-minute long online guided play session with OTS/OT.The training will consist of asynchronous module and PowerPoint presentations followed by role play and discussions.
223871421|NCT06834399|DRUG|KN046 （PD-L1/CTLA4 BsAb）|KN046 is administered every 21 days until disease progression, unacceptable toxicity, withdrawal of consent, loss to follow-up, death, study end, or other discontinuation criteria are met.
223871422|NCT06834399|PROCEDURE|TATE：Intra-arterial Administration of Tirapazamine followed by Transarterial Embolization|TATE treatment is given every 21 days. Patients receive two initial cycles. Whether to continue TATE treatment from the third cycle onward is decided by the investigator based on tumor necrosis. If a patient experiences intrahepatic tumor progression (recurrence or new tumors) during follow-up after the third cycle and still meets the treatment criteria, additional TATE treatment may be given.
223871423|NCT06434506|OTHER|no intervention|No intervention
223871424|NCT06834919|OTHER|Observational|Psychometric properties will be assessed by administering the questionnaire online to approximately 200 participants. Reliability will be estimated by assessing stability and homogeneity.
223871425|NCT06782425|DRUG|XKDCT225|Autologous targeted claudin18.2 chimeric antigen receptor T cell injection
223871426|NCT06780163|DRUG|17β-estradiol 10 mcg|17β-estradiol 10 mcg will be given to all participants. The participants will be asked to use 1 tab daily for 2 weeks vaginally before bed, then 1 tab twice a week vaginally before bed until 12 weeks
223871427|NCT06780358|DEVICE|AI supported detection of bladder cancer|AI-model-supported detection of bladder cancer during white light cystoscopy
223871428|NCT04183426|DIAGNOSTIC_TEST|Carotid Artery Reactivity test (CAR test)|The CAR test will be applied to stimulate the sympathetic nervous system. This thermal stimulus is known to elevate blood pressure via sympathetic pathways, so it can be used to study the vascular response to sympathetic activation. The participant will submerge their left hand in a bucket of ice water (approximately 4 degrees celcius) for 3 minutes, which is reported to be sufficient to induce a maximal dilation in the common carotid artery. At baseline and every minute after the hand is submerged in ice water, the blood pressure will be measured to check whether a sympathetic stimulation is achieved.
224268867|NCT03012451|BEHAVIORAL|Advancing Adolescents|"The Advancing Adolescents programme is a structured 8-week psychosocial intervention for adolescents in humanitarian crises, based on profound stress attunement processes. It features three elements that are widely viewed as important to support youth adjustment in contexts of complex emergencies: (i) safety: establishment of a 'safe space' within the community as a base for activities and site of protection; (ii) support: facilitation of social support and self-expression; and (iii) structured activities: access to scheduled group activities."
223871429|NCT04183426|DIAGNOSTIC_TEST|Arterial Stiffness|"The SphygmoCor device will be used to non-invasively measure arterial stiffness parameters using applanation tonometry. For Pulse Wave Analyses (PWA), the radial waveform will be recorded. Approximately 10 waveforms are averaged, resulting in several non-invasive parameters:~* Peripheral pressure parameters~* Central and abdominal aneurysm pressure parameters (derived using a transfer function)~* Cardiac output parameters (sub-endocardial viability ratio (SEVR), Ejection Duration (ED))~Pulse wave velocity will be performed by recording the waveforms of the carotid and femoral artery sequentially. The travelled distance will be measured according to the current guidelines and entered in the program. The program will calculate the PWV based on 10 ECG triggered waveform of each artery."
223871430|NCT06781736|BEHAVIORAL|Talking Circle intervention|Talking Circle intervention
223871431|NCT05702060|PROCEDURE|Radial Artery Puncture Method for Coronary Angiography and Intervention|Radial Artery Puncture Method for Coronary Angiography and Intervention
223871432|NCT06700590|BEHAVIORAL|Intensive Treatment|"Participants engage in two preparatory sessions once weekly, lasting 50 minutes each, which focus on psychoeducation and case conceptualization. The core treatment consists of five days of twice-daily sessions delivered over one or two weeks. The first session of the day consists of prolonged exposure (PE). The second session consists of eye movement desensitization and reprocessing (EMDR). Both treatments are performed in strict adherence to their respective manualized protocol. Two closing sessions focus on lessons learned, integration and a prevention plan. The treatment in total lasts 6 weeks and contains 800 minutes of treatment.~To enhance practicality, treatment rotation is allowed and encouraged. Rigorous checks on treatment adhenrence will be implemented."
223871433|NCT06700590|BEHAVIORAL|Treatment as usual|Spaced/weekly treatment consists of a treatment-as-usual condition, increasing the representativeness of the control condition. Treatment duration is 800 minutes, either 13 weeks of 60 minutes (with the last sessions being 80 minutes), or 16 weeks of 50 minutes. All evidence-based treatment modalities of the Dutch guidelines are allowed: PE, EMDR, brief eclectic psychotherapy for PTSD (BEPP), narrative exposure therapy (NET), and imaginary rescripting (ImRs). All have common elements of psychoeducation, imaginal exposure, emotional processing, cognitive restructuring and/or meaning making. Treatment adherence will be monitored throughout the intervention. Therapist rotation is not performed
223871434|NCT06265961|OTHER|Education|"In line with the Papadopoulos Tilki Taylor cultural competence development model used in the research, a training presentation titled overview and basic concepts of intercultural nursing will be held at the beginning of the intervention in order to increase the cultural knowledge levels of nurses. In order to test the effectiveness of the bibliotherapy method, training will be given online via Google Meet to both groups (both study and control) at the beginning of the research."
223871435|NCT06265961|OTHER|Bibliotherapy|"The intervention consists of 1 online intercultural nursing training, 2 book and 2 short story reading activities and 1 film evaluation to be carried out over a 3-month period.~After the training, the nurses in the study group will be asked to read the introductions of the books on the reading list and choose 2 books that they feel close to and that they have not read before. Participants will complete readings and assignments (evaluation form, reflective thought essay) asynchronously in time periods convenient to them.~In addition to books, a supporting film will be used to raise awareness. At the end of the movie, they will be asked to write on their notes how they can relate to intercultural nursing, how they can behave when faced with similar situations, and what differences there are between their ideas about intercultural nursing before and after the movie."
223871436|NCT04498052|OTHER|EHR-integrated Shared Decision Making Tool and Clinical Decision Support for Lung Cancer Screening|"The intervention will consist of the following core items:~In period 1:~* An EHR-integrated shared decision making (SDM) tool for providing information on the risks and benefits of lung cancer screening through low-dose computed tomography (LDCT) testing. This intervention is referred to as Decision Precision+.~* Suggestions in the EHR to offer SDM for LDCT for patients eligible for lung cancer screening according to USPSTF guidelines. These suggestions include those provided by the EHR's Health Maintenance module as well as an EHR-integrated Disease Manager system for disease management and health maintenance.~In period 2:~\- Same as period 1 + simple patient reminders in the patient portal.~Following roll-out, clinic leaders may also receive periodic feedback on use of the intervention and LDCT screening rates, as well as advice on how to improve intervention adoption."
223871437|NCT06292533|DEVICE|Er:YAG laser|Ultrapulse is a is a laser beauty device using erbium-doped yttrium aluminium garnet laser (er:YAG). Er:YAG laser is a laser with wavelength of 2940nm which is able to penetrate into the dermis to a depth of 3-4 mm, and energy absorption occurs in the area of the dermal papilla, resulting in an increase in blood circulation of the papilla and activation of metabolism in the hair follicle.
223871438|NCT06453057|BIOLOGICAL|GT307 injection|GT307 injection to treat solid tumours
223871439|NCT06534125|PROCEDURE|Acupressure Therapy|Undergo self-administered acupressure therapy to planned pressure points
223871440|NCT06534125|DEVICE|Acupuncture Therapy|Undergo acupuncture therapy with acupuncture needles applied to planned pressure points
223871441|NCT06534125|DRUG|Aromatase Inhibition Therapy|Receive SOC AI therapy
223871442|NCT06534125|OTHER|Discussion|Ancillary studies
223871443|NCT06534125|OTHER|Survey Administration|Ancillary studies
223871444|NCT03568994|DRUG|Atovaquone|"Patients will receive standard of care MRC based Induction chemotherapy (such as ADE 10+3+5 with daily atovaquone dosing starting on day 6. In order to accommodate potential drug shortages modifications to ADE 10+3+5 that retain the MRC based induction backbone regimen of DA are allowed (see second Arm). These include but are not limited to substitution of etopophos for etoposide, exclusion of etoposide, use of CPX-351 (VYXEOS (daunorubicin and cytarabine) liposome) only, and daunorubicin and cytarabine (DA) + gemtuzumab ozogamicin (GO).~Patients will be monitored for adherence to and tolerance of daily dosing of atovaquone. Peripheral blood (PB) and bone marrow plasma samples will be obtained to measure atovaquone concentrations."
223871445|NCT03568994|DRUG|Cytarabine|As part of routine Induction 1 chemotherapy (ADE 10+3+5)
223871446|NCT03568994|DRUG|Daunorubicin|As part of routine Induction 1 chemotherapy (ADE 10+3+5)
223871447|NCT03568994|DRUG|Etoposide|As part of routine Induction 1 chemotherapy (ADE 10+3+5)
223871448|NCT03568994|DRUG|Gemtuzumab Ozogamicin|As part of routine Induction 1 chemotherapy(DA 3+10 + GO)
223871449|NCT02576574|DRUG|Avelumab|Participants received Avelumab at a dose of 10 milligrams per kilogram (mg/kg) as a 1-hour (-10/+20 minutes) intravenous (IV) infusion once every 2 weeks until disease progression or unacceptable toxicities.
223871450|NCT02576574|DRUG|Pemetrexed|Participants received Pemetrexed 500 milligrams per square meter (mg/m\^2) by IV infusion on Day 1 of 3-Week cycle up to a maximum of 6 cycles of IV injection until disease progression or unacceptable toxicities.
223871451|NCT02576574|DRUG|Paclitaxel|Participants received Paclitaxel 200 mg/m\^2 by IV infusion on Day 1 of 3-Week cycle up to a maximum of 6 cycles of IV injection until disease progression or unacceptable toxicities.
223871452|NCT02576574|DRUG|Gemcitabine|Participants received Gemcitabine 1250 mg/m\^2 on Day 1 and Day 8 by IV infusion in 3-Week cycle up to a maximum of 6 cycles when combined with cisplatin of IV injection until disease progression or unacceptable toxicities.
223871453|NCT02576574|DRUG|Gemcitabine|Participants received Gemcitabine 1000 mg/m\^2 on Day 1 and Day 8 by IV infusion in 3-Week cycle up to a maximum of 6 cycles of IV injection when combined with carboplatin until disease progression or unacceptable toxicities.
223871454|NCT02576574|DRUG|Carboplatin|Participants received Carboplatin area under concentration curve (AUC) 5 mg/mL\*min in 3-Week cycle up to a maximum of 6 cycles of IV injection when combined with gemcitabine until disease progression or unacceptable toxicities.
223871455|NCT02576574|DRUG|Cisplatin|Participants received Cisplatin 75 mg/m\^2 by IV infusion in 3-Week cycle up to a maximum of 6 cycles of IV injection until disease progression or unacceptable toxicities.
223871456|NCT02576574|DRUG|Carboplatin|Carboplatin AUC 6 mg/mL\*min by IV infusion in 3-Week cycle up to a maximum of 6 cycles of IV injection when combined with pemetrexed, or paclitaxel until disease progression or unacceptable toxicities.
223871457|NCT02576574|DRUG|Avelumab Weekly|Participants received Avelumab at a dose of 10 mg/kg as a 1-hour (-10/+20 minutes) IV infusion every week for 12 consecutive weeks.
223871458|NCT06469749|BEHAVIORAL|Theory-based and peer-led intervention on Instagram|"A pilot randomized controlled trial of the 12-weeks social media intervention for non-medical use of prescription opioids (NMUPO) among young adults will be developed upon the formative research (Aim 1) grounded in the information-motivation-behavioral-skills (IMB) model. Intervention will be delivered by peer leaders, who are well-trained recovery coaches, via private groups on Instagram. Intervention contents will be tailored to psychosocial factors contributing to NMUPO.~Intervention components. Incorporating Instagram functions, the intervention is planned to include four intervention modules: (1) NMUPO knowledge module, (2) self-care module, (3) virtual goal setting/monitoring module, (4) peer support module. Intervention will be delivered by peer leaders (assisted by clinical psychology trainees a) via private groups operated by their Instagram accounts. The process will be overseen by certificated experts in clinical psychology and addiction treatment."
223871459|NCT06345976|OTHER|questionnaire|On-line self-questionnaire, in the form of an 18-question form, the link to which is sent by e-mail to patients with albinism who have agreed to take part in the study.
223871460|NCT06083298|PROCEDURE|control group|patients will be operated under general anesthesia
223871461|NCT06083298|PROCEDURE|MCP group|patients will receive ultrasound-guided MCP block with 15 ml of bupivacaine 0.25% on each side followed by general anesthesia.
223871462|NCT06083298|PROCEDURE|ISP group|patients will receive ultrasound-guided ISP block with 15 ml of bupivacaine 0.25% on each side followed by general anesthesia.
223871463|NCT05716477|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223871464|NCT05716477|OTHER|Survey Administration|Complete survey
223871465|NCT06296147|OTHER|Virtual Reality Headset|The interventions are for supportive care ONLY.
223871466|NCT06296147|OTHER|Aromatherapy Patch|The interventions are for supportive care ONLY.
223871467|NCT06296147|OTHER|Standard of Care|Participant will undergo a transperineal prostate biopsy.
223871468|NCT05044637|DRUG|Primaquine|7 days of unsupervised primaquine (3.5 mg/kg total dose) administered once per day (0.5 mg/kg OD).
223871469|NCT05044637|DRUG|Primaquine|7 days of unsupervised primaquine (7.0 mg/kg total dose) administered once per day (1.0 mg/kg OD).
223871470|NCT05044637|DRUG|Primaquine|14 days of unsupervised primaquine (7mg/kg total dose) administered once per day (0.5 mg/kg).
223871471|NCT00274105|DRUG|telmisartan|
223871472|NCT00274105|DRUG|Placebo|
223871473|NCT04969471|DEVICE|enVast stent|In addition to conventional treatment, the treating physician will deploy as the first measure to obtain reperfusion, a enVast stent at the occlusion site in order to withdraw the clot.
223871474|NCT04969471|PROCEDURE|conventional treatment|Treatment strategies may include balloon angioplasty, manual aspiration thrombectomy and/or coronary stenting.
223871475|NCT06749977|DRUG|Remineralization with SAP11-4|The WSL were treated with SAP11-4 according to the manufacturer's instruction
223871476|NCT06749977|DRUG|Remineralization with sodium fluoride varnish|The WSL were treated with sodium fluoride varnish according to the manufacturer's instruction
224268868|NCT03183622|BIOLOGICAL|ALLO-ASC-DFU|"ALLO-ASC-DFU is a hydrogel sheet containing allogenic adipose-derived mesenchymal stem cells. Adipose-derived stem cells have anti-inflammatory effect and release growth factors such as vascular endothelial growth factor(VEGF) and hepatocyte growth factor (HGF), which can enhance wound healing and regeneration of new tissue, finally may provide a new option in treating a burn.~This tudy is a follow-up study without intervention.~Other Names:~Allogenic adipose-derived mesenchymal stem cells"
223871477|NCT04879524|PROCEDURE|Percutaneous infracoccygeal Botulinum toxin injection to puborectalis|"The intervention is an injection of 200 units of Botulinum toxin type A in to the puborectalis muscle under ultrasound guidance.~In the prone position, the puborectalis muscle will be identified below the coccyx using ultrasound. After skin preparation using 70% Isopropyl Alcohol Pad, and up to 5ml of local anaesthetic (1% lidocaine), an electromyography (EMG) needle will be inserted and the puborectalis muscle stimulated using a current to confirm correct needle position. 200 units of BTXA (Botox, Allergan, Ireland) prepared in 2 ml of saline solution and drawn up using a 2ml syringe. 1ml (100 units) of BTXA solution is injected through the EMG needle into the puborectalis muscle to each side of the midline, achieving a total of 200 units. The needle is withdrawn, and the procedure is complete."
223871478|NCT05907980|DRUG|ROSE12|ROSE12 as a IV infusion
223871479|NCT05907980|DRUG|Atezolizumab|Atezolizumab as a IV infusion
223871480|NCT05566938|OTHER|Tailored nutritional recommendations for each metabotype|Tailored nutritional recommendations for each metabotype detected (at the group level), that will be delivered through a mobile application. Moreover, each volunteer will recieve individualized nutritional recommendations.
223871481|NCT03256240|OTHER|side-to-side functional end anastomosis|type of anastomosis
223871482|NCT03256240|OTHER|Kono-S analstomosis|antimesenteric anastomosis
223871483|NCT03952507|DRUG|JNJ-64417184 600 (Oral Tablet Formulation)|Participants will receive 600 mg of JNJ-64417184 as oral tablet.
223871484|NCT03952507|DRUG|JNJ-64417184 (Oral Suspension Formulation)|Participants will also receive JNJ-64417184 600 mg as oral suspension.
223871485|NCT05632913|DEVICE|Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)|An intratumoral insertion of radioactive sources \[Ra-224 containing stainless-steel 316LVM tubes- (Alpha DaRT seeds)\]. The seeds release by recoil into the tumor short-lived alpha-emitting atoms
223871486|NCT01162109|DIETARY_SUPPLEMENT|Zinc sulfate|"A group of 10 mechanically ventilated patients with severe sepsis will be randomized to receive 500mcg/kg IBW elemental zinc (IV) or placebo. The dose will be escalated by 250mcg/kg IBW every 10 subjects to ceiling dose of 1250 mcg/kg IBW or until toxicity develops.~A group of healthy volunteers will also receive IV zinc (as a single dose) and the PK will be compared to that in patients with sepsis."
223871487|NCT06114602|BEHAVIORAL|E-Mail Reminder|Patients who have an appointment (either face-to-face or teleconsultation) scheduled with a doctor at the Hospital receive an e-mail at the time of their request as well as 14 days and 48 hours prior to the appointment, reminding them of the appointment time and the place where they have to go. In addition, a button has been added to the e-mail so that the patient can click on it and cancel it directly in a simple way.
223871488|NCT02529839|PROCEDURE|Autologous bone marrow transplantation|IMMUNOABLATIVE NONMYELOABLATIVE AUTOLOGOUS BONE MARROW TRANSPLANTATION on Day 0
223871489|NCT02529839|DRUG|Fludarabine|30mg/m2 on days -6 through -3
223871490|NCT02529839|DRUG|Cyclophosphamide|50mg/kg on days -5 through -4
223871491|NCT02529839|DRUG|Alemtuzumab|3mg on day -3, 9mg on day -2, 12 mg on day -1
223871492|NCT06772753|DRUG|Placebo|inactive substance
223871493|NCT06772753|DRUG|Psilocybin|active comparator for psychedelic effects
223871494|NCT06772753|DRUG|Ketamine|psychoactive substance
223871495|NCT06772753|DRUG|Dextromethorphan (DXM)|psychoactive substance
223871496|NCT06772753|DRUG|Dimethyltryptamine (DMT)|psychoactive substance
223871497|NCT06772753|DRUG|Methylenedioxymethamphetamine (MDMA)|psychoactive substance
223871498|NCT06772753|DRUG|Tetrahydrocannabinol (THC)|psychoactive substance
223871499|NCT05727657|DRUG|Satralizumab|120mg subcutaneous Day 0 and Day 14
223871500|NCT05254678|BEHAVIORAL|general exercise|A 10-week integrated physiotherapy and general exercise intervention compared to a general exercise intervention alone.
223871501|NCT06373380|DRUG|HB-200|HB-200 arm will receive HB-202 and HB-201 (HB-202: 1 x 10 \^7 RCV FFU and HB201: 5 x 106 RCV FFU) in an alternating fashion every (21 days) intravenously for 4 doses (2 doses each of HB-202 and HB-201 alternating).
224268869|NCT06331572|DIAGNOSTIC_TEST|17-HAMD|Patients were interviewed in a semi-structured manner and assessed using the 17-item Hamilton Depression Scale and the Hamilton Anxiety Scale
223871502|NCT01969981|PROCEDURE|PICC placement with Sherlock 3CG|
223871503|NCT06199973|DRUG|SHR-A1811|SHR-A1811(4.8 mg/kg) was administered intravenously on the first day of each cycle, once every 3 weeks (Q3W)
223871504|NCT06199973|DRUG|TAS-102, Regorafenib , Fruquintinib|physician choiced treatment,include: TAS-102(35 mg/m2, maximum 80 mg per dose), twice daily (BID) , once every 4 weeks (Q4W) , up to 3 years; or Regorafenib 160mg, once daily (QD) , once every 4 weeks (Q4W) , up to 3 years; or Fruquintinib 5mg once daily (QD) , once every 4 weeks (Q4W) , up to 3 years.
223871505|NCT00731497|DEVICE|Solar Water Disinfection (SODIS)|Intervention group has SODIS implemented at the household level as a way to disinfect drinking water
223871506|NCT03273777|PROCEDURE|Drawing of an incision line|Drawing of an incision line prior to skin incision at cesarean section
223871507|NCT00296361|DRUG|Tacrolimus|immunosuppression
223871508|NCT03390296|BIOLOGICAL|Anti-OX40 Agonist Monoclonal Antibody PF-04518600|Given IV
223871509|NCT03390296|DRUG|Avelumab|Given IV
223871510|NCT03390296|DRUG|Azacitidine|Given IV or SC
223871511|NCT03390296|DRUG|Gemtuzumab Ozogamicin|Given IV
223871512|NCT03390296|DRUG|Glasdegib|Given PO
223871513|NCT03390296|DRUG|Glasdegib Maleate|Given PO
223871514|NCT03390296|DRUG|Venetoclax|Given PO
223871515|NCT03390296|DRUG|Azacitidine|Given IV or SC
223871516|NCT06326931|DEVICE|thermal pulsation|Single, in-office bilateral treatment with Systane iLux thermal pulsation
223871517|NCT06326931|OTHER|warm compress|Twice daily, 10-minute at-home treatment with Bruder warm compress mask for 8 weeks
224268870|NCT03401281|OTHER|Coconut oil|50g extra virgin coconut oil daily for four weeks
224268871|NCT03401281|OTHER|Butter|50g butter daily for four weeks
224268872|NCT03401281|OTHER|Olive oil|50g extra virgin olive oil daily for four weeks
224268873|NCT05402046|OTHER|"Mobile phone application ProRodinki"|"Patient were underwent photography using mobile phone and tested application ProRodinkijust before preplanned excisional or incisional biopsy.~Application AI result than will be compared with pathology report by independent investigator"
224268874|NCT02228486|DEVICE|tDCS|2 mA (verum group) over the left dorsolateral prefrontal cortex (F3, anodal), 15 min; 10 seconds ramp in verum and sham group (see also above)
223871518|NCT00175292|DRUG|Probiotic - VSL#3|
223871519|NCT00891332|DRUG|S-1 plus LV (The combination therapy of S-1 and Leucovorin)|S-1 40-60 mg bid day 1～day 7 LV 25 mg bid day 1～day 7
223871520|NCT03577223|OTHER|Whole Eggs|3 whole eggs per day for 4 weeks
223871521|NCT03577223|OTHER|Egg White-Based Egg Substitute|3-egg equivalent of egg white-based egg substitute per day for 4 weeks
223871522|NCT06009536|OTHER|Achilles Tendon Loading Exercise Protocol According to Silbernagel|It is a 12-week Silbernagel ankle dorsiflexion resistance training protocol. It is a series of exercises with a gradual progression of load according to defined criteria, which the patient practices every day.
223871523|NCT02548806|DRUG|Clonidine MBT 50µg|Clonidine MBT 50µg, single dose
223871524|NCT02548806|DRUG|Clonidine MBT 100µg|Clonidine MBT 100µg, single dose
223871525|NCT02548806|DRUG|Catapres 100μg|Catapres tablet 100μg, single dose
223871526|NCT01950780|DRUG|Ruxolitinib|A fixed dose of ruxolitinib (20mg) will be self-administered orally twice daily for 12 to 24 weeks. Dosing may be decreased or held if needed due to adverse effects.
223871527|NCT00257998|PROCEDURE|Mobilization|manualtherapy techniques
223871528|NCT04010435|DEVICE|repetitive transcranial magnetic stimulation|high frequency (10 HZ) rTMS pulses are applied to the dorsolateral prefrontal cortex of the dominant hemisphere.
223871529|NCT04010435|DEVICE|Galvanic stimulation|galvanic stimulation of the vestibular apparatus
223871530|NCT00262782|DRUG|Fludarabine|Fludarabine i.v. (25 mg/m2/d, d1-5) q28d; max 6 cycles
223871531|NCT04929067|DRUG|immunotherapy combined with neoadjuvant chemotherapy in patients with locally advanced HPV (-) head and neck squamous cell carcinoma|immunotherapy combined with neoadjuvant chemotherapy in patients with locally advanced HPV (-) head and neck squamous cell carcinoma
223871532|NCT00687713|DRUG|Bupropion|150mg for the first 3 days of dosing. Increased to 150 mg b.i.d until taper.
223871533|NCT00687713|OTHER|Placebo|Placebo
223871534|NCT01557335|DRUG|Plavix® and PA32540|one Plavix® 300 mg loading dose in the PM of Day 1 one Plavix® 75 mg maintenance dose in the PM of Days 2-7 PA32540(delayed release aspirin 325 mg plus immediate release omeprazole 40 mg)
223871535|NCT01557335|DRUG|EC aspirin (Bayer®) ,EC omeprazole (Prilosec®) , Clopidogrel (Plavix®)|One EC aspirin (Bayer®) 81 mg tablet plus one EC omeprazole (Prilosec®) 40 mg capsule plus one Clopidogrel (Plavix®) tablet of 300 mg (loading dose) all One EC aspirin (Bayer®) 81 mg tablet plus one EC omeprazole (Prilosec®) 40 mg capsule plus one Clopidogrel (Plavix®) tablet of 75 mg (maintenance dose) all taken concomitantly in the AM of Days 2-7
223871536|NCT03561519|OTHER|Fecal Microbiota Transplantation (FMT)|Fecal suspension administered in colonoscopy into the cecum of the patient.
223871537|NCT03561519|OTHER|Placebo|As a placebo a fecal suspension made of patients own feces is administered into the cecum of the patient in colonoscopy.
223871538|NCT05594511|PROCEDURE|Muscle-energy mandibular technique|A single session will be used with the mandibular musculoenergy technique. It will last approximately 2-3 minutes and will be performed by a physiotherapist.
223871539|NCT05594511|PROCEDURE|Sham technique|A single session with a sham technique simulating the suboccipital muscle inhibition technique will be used. It will last approximately 2-3 minutes and will be performed by a physiotherapist.
223871540|NCT05223517|DEVICE|Acupuncture|"Hwato brand disposable acupuncture needles (size 0.30 × 40 mm and 0.30 × 75 mm) and adhesive pads will be used. Acupoints of Ciliao, Huiyang, Shenshu, Guanyuan, Shuidao, Sanyinjiao, Zusanli, Taixi, Hegu, and Taichong will be used for every participants. Those with sleep or mood disorders will also use acupoints of Shangyintang, Shenmen and Neiguan. Those with tenderness points on the abdominal wall will also use Ashi points no more than five.~The needles will be inserted to 60-70mm in Ciliao and Huiyang, 6-10 mm in Shenmen and 10-20mm in other acupoints through adhesive pads. Needles will be lifted, thrusted and twirled gently for 3 times (except for Ciliao) to achieve deqi sensation and manipulated every ten minutes during 20-minute maintenance in prone and supine position respectively.~Participants receive acupuncture treatment three times a week in the first four weeks and twice a week in the last four weeks."
224268875|NCT02228486|BEHAVIORAL|Cue Exposure Therapy|5 weeks (9 sessions) of cue-exposure therapy with preferred alcoholic beverage (see also above)
224268876|NCT00869193|DIETARY_SUPPLEMENT|Grape seed extract|Subjects will daily consume one capsule with grape seed extract for 8 weeks.
223871541|NCT05223517|DEVICE|Sham Acupuncture|"Hwato brand disposable placebo needles (with the handle identical to the needles in the acupuncture group and the body at a size 0.30 × 25 mm) and adhesive pads will be used. Acupoints of Ciliao, Huiyang, Shenshu, Guanyuan, Shuidao, Sanyinjiao, Zusanli, Taixi, Hegu, and Taichong will be used for every participants. Those with sleep or mood disorders will also use acupoints of Shangyintang, Shenmen and Neiguan. Those with tenderness points on the abdominal wall will also use Ashi points no more than five.~The needles will be inserted into adhesive pads without skin penetration. Needles will be lifted, thrusted and twirled gently for 3 times to mimic real acupuncture. No manipulation will be conducted during 20-minute maintenance in prone and supine position respectively.~Participants receive sham acupuncture treatment three times a week in the first four weeks and twice a week in the last four weeks."
223871542|NCT05191810|BEHAVIORAL|Educational information|Educational information about non-pharmacological supporting treatment of functional constipation, involving recommendation of adequate for age fluid intake
223871543|NCT03425552|DRUG|Paliperidone|Paliperidone Palmitate extended-release injectable suspension 156 mg (100 mg of Paliperidone)
224268877|NCT00869193|DIETARY_SUPPLEMENT|Microcrystalline cellulose (placebo)|Subjects will daily consume one capsule with microcrystalline cellulose for 8 weeks.
224268878|NCT01574027|DRUG|Vitamin D3 (cholecalciferol)|One capsule per day for six months
224268879|NCT01574027|DRUG|Placebo|One capsule per day for six months
224268880|NCT03555695|BEHAVIORAL|Karate Classes|Eligible subjects will engage in twice-weekly karate classes for 10 weeks, specifically designed for individuals with early to middle stage PD, focused on incorporating upper and lower limb movements in multiple directions, increasing awareness throughout the body, shifting body weight and rotation, relaxation of the muscles, improving reaction time, using complex repetitive actions to improve coordination, footwork training and centered weight shifts to help with fall prevention, and striking shields for self-defense and stress relief.
223871544|NCT03425552|DRUG|Paliperidone|Paliperidone Palmitate 156 mg (equivalent to Paliperiodne 100 mg) extended release injectable suspension
223871545|NCT02390570|OTHER|Patient Capacity Assessment Instrument|The Patient Capacity Assessment instrument is a conversational tool designed to help patients and clinicians discuss capacity in clinicial conversations of primary care.
223871546|NCT00872872|DRUG|AZT/3TC 2 weeks after delivery|AZT/3TC 300/150mg will be given every 12 hours for 1 week after NVP discontinuation in arm 1 and for 2 weeks after NVP discontinuation in arm 2.
223871547|NCT01761201|DRUG|Levofloxacin|Levofloxacin
223871548|NCT01761201|DRUG|Isoniazid|"300 mg/day for 9 months beginning after transplantation, when the liver function is stable and not before 3 months nor after 6 months."
223871549|NCT00238797|DRUG|Gefitinib|
223871550|NCT03772015|DIAGNOSTIC_TEST|Magnetic resonance imaging|MRI will be performed using a standard body spiral in the supine position with 5 mm section thickness, on the axial, coronal and sagittal planes and the diffusion weighted images acquired will be evaluated by a specialised radiologist who will be blind to the participants.
223871551|NCT06340100|OTHER|find association between vestibular impairment , cognitive fiunction with concussin|SCOAT 6 is a standardized tool used for evaluating athletes suspected of having a concussion. It includes a variety of components such as symptom evaluation, cognitive assessment, balance evaluation, and a neck examination. it helps in assessing the severity of the injury, tracking recovery, and making return-to-play decisions. Dr. Robert Cantu, a prominent figure in sports concussion research, has proposed guidelines for the management of concussions. These guidelines typically involve recommendations for the evaluation, treatment, and return-to-play decisions for athletes who have sustained concussions
223871552|NCT03470376|DIETARY_SUPPLEMENT|Nutraceutical combination (NC)|An oral NC (red yeast rice-derived monacolin K 3 mg, berberine 500 mg, policosanol 10 mg, astaxanthin 0.5 mg, folic acid 0.2 mg and coenzyme Q10 2 mg) one pill/day was administered for 3 months along with prosecution of standardized diet regimen
223871553|NCT03470376|BEHAVIORAL|No nutraceutical combination (noNC)|Prosecution of standardized diet regimen for 3 months
223871554|NCT02088372|DEVICE|Vanguard with E1 PS Bearing|Evaluate Clinical Performance of Vanguard Knee with E1 Bearing in Korean Patient Population
223871555|NCT00067496|DRUG|Modafinil|
223871556|NCT00253890|DRUG|Trazodone|50 mg 1-3 capsules at bedtime for 3 months
223871557|NCT00253890|DRUG|Placebo|1-3 at bedtime
223871558|NCT02675244|PROCEDURE|TV Annuloplasty|TV Annuloplasty will be performed using standard surgical techniques
223871559|NCT02675244|PROCEDURE|MVS|MVS will be performed using standard surgical techniques
223871560|NCT01126918|BEHAVIORAL|Body Project|Participants in this intervention attend four 1-hour group meetings (one per week for four consecutive weeks) in which they complete a series of written and verbal exercises intended to increase body satisfaction.
223871561|NCT05945017|DIETARY_SUPPLEMENT|Infloran® -Berne, Switzerland- (Bifidobacterium bifidum NCDO 2203 and Lactobacillus acidophilus NCDO 1748|
223871562|NCT02422784|DIETARY_SUPPLEMENT|Rooibos Iced-Tea (Control)|Participants will consume 240 mL of Rooibos iced-tea daily for 6 weeks. The iced-tea beverage will not contain any added sugar or artificial sweeteners. Beverages will be prepared fresh weekly and picked up by participants during their weekly study visits.
223871563|NCT02422784|DIETARY_SUPPLEMENT|Rooibos Tea - Vitamin D3|Participants will consume 240 mL of Rooibos iced-tea fortified with 1000 IU of water soluable Vitamin D3 daily for 6 weeks. The iced-tea beverage will not contain any added sugar or artificial sweeteners. Beverages will be prepared fresh weekly and picked up by participants during their weekly study visits.
223871564|NCT02422784|DIETARY_SUPPLEMENT|Rooibos Tea- Vitamin D3 & Calcium|Participants will consume 240 mL of Rooibos iced-tea fortified with 1000 IU of water soluable Vitamin D3 and 360 mg of Calicum daily for 6 weeks. The iced-tea beverage will not contain any added sugar or artificial sweeteners. Beverages will be prepared fresh weekly and picked up by participants during their weekly study visits.
223871565|NCT02344641|DRUG|Exenatide|
223871566|NCT04792905|DEVICE|Cardiologs|Two Apple Watch recordings (one recording with the watch on the wrist and one on the left side of the abdomen) interpreted by Cardiologs AI done simultaneously with each 12-lead ECG
223871567|NCT00940524|DRUG|Dasatinib, Mitoxantrone, Cytarabine|"INDUCTION- Dasatinib† (dose levels 1-3) \*continuously Cytarabine 3 g/m2 IV over 3 hours Mitoxantrone 80 mg/m2 IV Myeloid growth factor on day 7 until ANC \> 1,000/μl x 2 days Allopurinol 300 mg BID-TID x 7 days (starting 6-12 hours prior to chemotherapy) Dexamethasone 0.1% eye drops q6h while on cytarabine (start prior to the first dose of cytarabine and continuing at least 24 hours after the last dose) IT Methotrexate 12 mg days 2 and 4~CONSOLIDATION A-Dasatinib† (dose levels 1-3) \*continuously Vincristine 2 mg IV Dexamethasone 10 mg/m2/d days 2 to 29, then taper over 10 days Sulfamethoxazole/Trimethoprim 1 DS BID three times weekly days 2 to 29, then BID daily days 30 to 45 IT Methotrexate 12 mg days 8, 15, 22 and 29"
223871568|NCT04460313|OTHER|nasopharyngeal sample|Nasopharyngeal swabs from children with acute otitis media aged 6 to 24 months. The swabs were analyzed by the French National Reference Centre for Pneumococci.
223871569|NCT04460313|OTHER|Stools collection or anorectal swab samples|For a subgroup of children stools samples or anorectal swab samples were collected for assessment of E. coli (ESBL) resistance
223871570|NCT00181740|DRUG|atomoxetine (Strattera)|
223871571|NCT06051955|OTHER|oral sodium sulfate|All participants enrolled in this study will use Oral Sodium Sulfate as their bowel cleansing agent.
223871572|NCT01902784|BEHAVIORAL|Storytelling Interview|
223871573|NCT06148831|DEVICE|Infant Carrier|"The assigned home visitor will provide a participant with an infant carrier and will watch a short training video on how to use the carrier, including a demonstration of safe and ergonomic use. The home visitor will support the client to practice using the carrier and will provide materials to support continued learning.~All home visitors participated in an infant carrier training developed by Nurturely, centered on carrying as a cultural practice, utilizing culturally relevant visuals as well as easy-to-remember acronyms to promote safe and ergonomic use (i.e., the STOP acronym developed by Nurturely, signifying that all knots are Secure, infant is attached high enough to kiss the top of their head and Tight to the caregiver's body, nose and mouth are visible and airway is Open, and hips are Positioned in an ergonomic spread squat)."
223871574|NCT00110864|DRUG|PN2034|
223871575|NCT00110864|DRUG|Insulin|
223871576|NCT02772471|DEVICE|HS-1000|
223871577|NCT01001936|DRUG|SKI-606|
223871578|NCT03817476|DRUG|BI 425809 (Treatment T1)|Intended commercial formulation tablet from batch 1 (iCF1)
223871579|NCT03817476|DRUG|BI 425809 (Treatment T2)|Intended commercial formulation tablet from batch 2 (iCF2)
223871580|NCT03817476|DRUG|BI 425809 (Treatment R)|Trial formulation 2 tablet (TF2)
223871581|NCT02479217|DRUG|Docetaxel|
223871582|NCT02479217|DRUG|Xeloda|
223871583|NCT04169698|DRUG|Denosumab 60 mg/ml [Prolia]|full length human monoclonal antibody against the receptor activator of nuclear factor kappa-B ligand
223871584|NCT04169698|DRUG|Alendronate 70Mg Tab|Bisphosphonates
223871585|NCT01839331|BIOLOGICAL|4 mL injection of Ampion|4 mL Injection of Ampion
223871586|NCT01839331|BIOLOGICAL|10 mL Injection of Ampion|10 mL Injection of Ampion
223871587|NCT01839331|DRUG|4 mL Injection of Placebo|4 mL Injection of Placebo
223871588|NCT01839331|DRUG|10 mL Injection of Placebo|10 mL Injection of Placebo
223871589|NCT03752151|DEVICE|MARVEL 2 Algorithm Monitor Mode then Adaptive Mode|Software download into implanted Micra device and programmed to MARVEL 2 Monitor Mode then MARVEL 2 Adaptive Mode
223871590|NCT02304055|DRUG|Carbetocin|100 women with atonic PPH will receive Carbetocin 100 µgm slowly iv.
223871591|NCT02304055|DRUG|Oxytocin|100 women with atonic PPH will receive Oxytocin 5IU slowly iv.
223871592|NCT00529516|BIOLOGICAL|Fluarix|Single dose, Intramuscular injection
223871593|NCT00529516|BIOLOGICAL|GSK Biologicals Influenza Vaccine GSK576389A|Single dose, Intramuscular injection
223871594|NCT02850744|DRUG|PQR309|80mg capsules p.o. once daily and possibly Standard Treatment with temozolomide
223871595|NCT04056624|DIETARY_SUPPLEMENT|High carotenoid juice|Juice with high carotenoids
223871596|NCT04056624|DIETARY_SUPPLEMENT|Placebo control - Apple juice|Juice with negligible carotenoids
223871597|NCT03195608|DEVICE|Lane change assistance system|This study will investigate the feasibility and preliminary efficacy of a 6-session lane change ADAS-intervention on the simulated driving performance of individuals with mild to moderate PD. We anticipate that the use of lane change assist technology will decrease the number of driving errors in individuals with PD. As this is a feasibility study, we will evaluate: -recruitment capability and sample characteristics - data collection methods, procedures, and outcome measures - acceptability and suitability of the lane change assist technology intervention - preliminary efficacy The outcomes of this study will inform the design of a larger study, should such large-scale study be warranted.
223871598|NCT03195608|BEHAVIORAL|Active Control|Participants will practice their driving on a driving simulator with feedback form a trained interventionist.
223871599|NCT00548418|DRUG|Topotecan|
223871600|NCT00548418|DRUG|Cisplatin|
223871601|NCT00548418|DRUG|Bevacizumab|
223871602|NCT01404598|DRUG|naproxcinod 750 bid|naproxcinod 750 bid
223871603|NCT01404598|DRUG|naproxcinod 3000 mg od|naproxcinod 3000 mg od
223871604|NCT01404598|DRUG|naproxen 500 mg bid|naproxen 500 mg bid
223871605|NCT05951140|OTHER|Usage of the PROTEIN-Application|Participants were randomly distributed into 2 groups: (1) Start-Group used the developed Application and wereables to investigate the effect of this support. Participants used the devices and the App for 3 Months followed by a 6-Weeks time of only using wereables and no app, to be able to compare the effects of the Application. (2) The Wait-Group used wereables for 6 Weeks before adding the Protein-App for also 3 Months.
223871606|NCT06015399|PROCEDURE|Implementation of closed insufflation technique during segmentectomy|After the identification the targeted segmental bronchus during the operation,ligating the proximal end of the targeted bronchus. Put the vessel separation forceps in the distal bronchial space to avoid the accidental damage of the vessels. Use a 50ml syringe to inject air into the distal bronchus (about 100ml is expected) until the intersegmental plane is satisfactory. Divide the target bronchus using the cutting and closing device.
223871607|NCT06015399|PROCEDURE|Implementation of dilatation and collapse technique during segmentectomy|Divide the target bronchus using the cutting and closing device. Ask the anesthesiologist to inflate the lung completely from pure oxygen to the affected side and then change to single lung ventilation. Wait for the intersegmental plane to appear(usually about 15 minutes).
223871608|NCT03977935|DEVICE|the second-generation MCCG|Patients in the experimental group swallowed the second-generation MCCG (Ankon Navicam-2).
223871609|NCT03544736|DRUG|Nivolumab|Experimental: Nivolumab
223871610|NCT03544736|RADIATION|Radiotherapy|Radiotherapy
223871611|NCT03544736|DRUG|Chemotherapy|Chemotherapy
223871612|NCT03544736|PROCEDURE|Surgery|Surgery
223871613|NCT03565055|BEHAVIORAL|IPCST|"Integrative Psychosocial \& Community Skills Training (IPCST) programme~The IPCST programme includes:~1. psychoeducation, internalized stigma reduction, \& strength and coping enhancement~2. motivational interviewing skills~3. Neurocognitive and social cognitive training (Au, Tsang, So, Bell, Cheung, et al., 2015)~4. augmented supported employment with social skills training (Tsang, Fung, Li, Leung \& Cheung, 2010) and~5. family and patient involvement in care"
223871614|NCT03565055|BEHAVIORAL|E.A.S.Y|"The E.A.S.Y. (Early Assessment Service for Young People with Early Psychosis) Programme is a service programme for people suffering from early psychosis.~The E.A.S.Y programme includes:~1. Extensive public education~2. Early referral and assessment~3. Ongoing treatment services"
223871615|NCT04968756|DEVICE|Selective retina therapy SPECTRALIS CENTAURUS device|Microsecond laser microsurgery by using the SPECTRALIS CENTAURUS device
223871616|NCT00175864|DRUG|Seletracetam (ucb 44212)|
223871617|NCT06037993|DIETARY_SUPPLEMENT|Ultra-micronized Palmitoylethanolamide (PEA)|"Palmitoylethanolamide (PEA) is an N-acylethanolamine (AE), produced on demand by different cell types as a response to actual or potential damage, proven to down-regulate central and peripheral activity of mast cells and non-neuronal cells (e.g., astrocytes, microglia) and to exert protective functions against glutamate neuro-toxicity, accounting for its naturally-occurring anti-inflammatory, analgesic, and anticonvulsant properties. Due to the shared pharmacodynamic properties, PEA is considered as the endogenous equivalent of Cannabidiol (CBD). A growing body of literature has confirmed the role of PEA in most neurobiological mechanisms underpinning several neuropsychiatric conditions both in clinical and preclinical settings. The effect of PEA over neuroinflammation and glutamate signaling may represent a promising biobehavioral mechanism underlying the clinical utility of its oral supplementation in CHR state."
223871618|NCT03639896|DRUG|Dexmedetomidine|0.5μg/kg Dexmedetomidine as initial loading dose is given for 15 minutes before induction of anesthesia, followed by a maintenance infusion of 0.4μg/kg/h and stopped 30 minutes before the surgery over.
223871619|NCT03639896|DRUG|Saline|0.5μg/kg saline as initial loading dose is given for 15 minutes before induction of anesthesia, followed by a maintenance infusion of 0.4μg/kg/h and stopped 30 minutes before the surgery over.
223871620|NCT03107117|BEHAVIORAL|Computer Counseling|two computer counseling online programs for a teen and a parent
223871621|NCT03107117|BEHAVIORAL|Standard Care|A referral for substance use counseling
223871622|NCT03241017|DRUG|Durvalumab|Immunotherapy with Durvalumab after ASCT
223871623|NCT03029598|DRUG|Carboplatin|Given IV
223871624|NCT03029598|OTHER|Laboratory Biomarker Analysis|Correlative studies
223871625|NCT03029598|BIOLOGICAL|Pembrolizumab|Given IV
223871626|NCT03051165|DEVICE|Hypoglossal Nerve Stimulation Treatment Withdrawal|After 90 days of hypoglossal nerve stimulation (HGNS), therapy will be discontinued for 30 days before being reactivated.
223871627|NCT00052364|DRUG|oxaliplatin|Given IV
223871628|NCT00052364|OTHER|laboratory biomarker analysis|Correlative studies
223871629|NCT01047241|DRUG|Intranasal sufentanil/ketamine|Nasal spray sufentanil+ketamine, 0,5 microg/kg sufentanil+0,5 mg/kg ketamine, single dose
223871630|NCT03554460|DEVICE|dual-limb NIV|dual-limb NIV was served with servo i ventilator
223871631|NCT03922061|BIOLOGICAL|dmLT|double mutant \[LT(R192G/L211A)\] Enterotoxigenic Escherichia coli heat labile toxin (dmLT)
223871632|NCT03922061|BIOLOGICAL|fIPV|fractional-dose inactived polio vaccine
223871633|NCT04805216|PROCEDURE|Blood test|"Participants will have blood tests at baseline (nearest 30 day incremental time point after 2nd dose of Covid-19 vaccine, +/- 7 days):~* T, B \& NK cells~* Full Blood Count and differential~* Serum Immunoglobulins~* Antibodies against VZV, CMV, Rubella~* Quantiferon assay (T-Cell response)~* Covid antibody assay (LIAISON® SARS-CoV-2 S1/S2 IgG quantitative assay)~Participants will have blood tests during follow up (after second dose of Covid-19 vaccine) with a window of +/- 7 days:~* Blood test 2 - performed at the next 30 day time point (Covid antibody assay)~* Blood test 3 - performed at the next 30 day time point (Covid antibody assay and quantiferon\* if final blood test)~* Blood test 4 (optional) - performed at the next 30 day time point (Covid antibody assay)~* Blood test 5 (optional) - performed at the next 30 day time point (Covid antibody assay and quantiferon\* if final blood test)~  * Quantiferon assay will be only be performed where possible."
223871634|NCT03681522|PROCEDURE|Pelvic plexus block|Injections of 2.5 mL of 2% lidocaine were made to the pelvic neurovascular plexus located at the end of the seminal vesicle under Doppler US guidance on each side
223871635|NCT03681522|PROCEDURE|Periprostatic nerve block|Injections of 2.5 mL of 2% lidocaine were made to the neurovascular bundles at the junction of the prostate-bladder-seminal vesicle on each side.
223871636|NCT04978233|OTHER|sociodemographic and health, daily self-assessment, and feasibility of using the Opal app for COVID|The intervention consists of having confirmed COVID-19 infected participants register for the Opal app and complete a daily questionnaire on symptoms related to their physical and mental health as well as on certain key vital signs (e.g., oxygen saturation, heart rate, temperature). A nurse will check the questionnaire results each day and determine the need for a teleconsultation with an infectious disease physician. Participants will be followed up for a minimum of 14 days, depending on their symptoms.
223871637|NCT02092116|DRUG|Romidepsin|Latency reversing agent
223871638|NCT02092116|BIOLOGICAL|Vacc-4x|Vacc-4x is a peptide-based HIV immunotherapy administered intradermally. Vacc-4x peptides are reconstituted in sterile water.
223871639|NCT02092116|BIOLOGICAL|rhuGM-CSF|Granulocyte macrophage colony stimulating factor as a local adjuvant
223871640|NCT06154876|DEVICE|Cough assist device|"Cough assist device Cough Assist clears secretions from the lungs by gradually applying positive air pressure to the airway and then rapidly shifting to negative air pressure . The resulting high expiratory flow simulates a deep, natural cough.~Designed chest physical therapy Percussion, vibration, end expiratory pressure and bed mobility exercise."
223871641|NCT03531840|DRUG|Olaparib|All subjects will take olaparib by mouth twice per day until disease progression or unacceptable toxicity
223871642|NCT03531840|DEVICE|ClinOmics|Non-significant risk (NSR) device
223871643|NCT05235906|DRUG|Surufatinib+Sintilimab|Surufatinib at a dose of 250mg Qd, with humanized anti-PD-1 monoclonal antibody Sintilimab injected intravenously 200mg per 3 weeks until disease progresses or unacceptable tolerability occurs.
223871644|NCT04137497|DIAGNOSTIC_TEST|The Coma Recovery Scale-Revised and the Nociception Coma Scale-Revised (NCS-R)|All enrolled DOC patients were evaluated at least five times over one week by two trained professionals using the Chinese version of the CRS-R. During the evaluation of the patient's consciousness level, the NCS-R was used to evaluate the pain response of all patients in random order at least once, and the best behavioral response (i.e., the highest score) of each subscale was recorded during resting, noxious, and physiotherapy conditions, respectively, according to the NCS-R guidelines.
223871645|NCT01471756|PROCEDURE|Standard of Care Procedure as described in ARM|Standard of Care Procedure as described in ARM
223871646|NCT00770757|DRUG|CC-4047|
223871647|NCT00681603|DRUG|subconjunctival injection of bevacizumab ( 1.25 to 2.50 mg)|subconjunctival injection of bevacizumab ( 1.25 to 2.50mg) according to the clinical judgment. Once per months for three times then reevaluate the drug effect, if the response was adequate, stop the trial; if no improvement, another three month intervention would be performed.
223871648|NCT02545634|DIETARY_SUPPLEMENT|L. helveticus R0052 and B. longum R0175|See arm descriptions for intervention description.
223871649|NCT02545634|OTHER|Placebo|
223871650|NCT03427632|DRUG|Bone Cements|patents in PVP group will get injected with bone cement inside the collapsed malignant vertebra
223871651|NCT00105092|DRUG|Enzastaurin HCL|
223871652|NCT06145867|OTHER|Photobiomodulation therapy|deep red light therapy (670nm)
223871653|NCT04593056|DRUG|Warfarin|Warfarin dispensing claim is used as the reference
223871654|NCT04593056|DRUG|Rivaroxaban|Rivaroxaban dispensing claim is used as the exposure
223871655|NCT06159569|DEVICE|LACRIACT|"LACRIACT is is a preservative free ophthalmic sterile medical device solution. The solution is packaged in closable vials of inert material that does not affect the contents (clear low-density polyethylene), each vial contains 0.5 ml of solution.~Eligible patients will start the treatment. Patients will receive the box of eye drops, and will be instructed on how to self-administer 1 drop in each eye 4 times a day for 30 days starting from the day following the visit."
223871656|NCT01796067|BEHAVIORAL|Motivational and Family Weight Loss|This group will receive the comprehensive motivational and family weight loss intervention.
223871657|NCT01796067|BEHAVIORAL|Basic Health Education|This group will receive the comprehensive basic health education intervention.
223871658|NCT01796067|BEHAVIORAL|Online Intervention|Participants will receive the online tailored weight loss intervention program after they have either received the motivational plus family weight loss program or basic health face-to-face program.
223871659|NCT01796067|BEHAVIORAL|Online Control|Participants will receive the online control program after they have either received the motivational plus family weight loss program or the basic health education program.
223871660|NCT00319293|DRUG|Metformin|
223871661|NCT00744913|DRUG|Nicoderm patches|Women in this group will receive standard counselling and NRT (Nicoderm patches) starting with a dose of 14 mg/day that can be increased to 21 mg/day based on response (smoking cessation) and potential side effects
223871662|NCT00744913|OTHER|Counselling|Women in this arm of the study will receive standard counseling only.
223871663|NCT00761605|DRUG|Paliperidone|Paliperidone oral tablet will be administered once daily at a dose of 6 milligram (mg) for 24 weeks, wherein dose range was 3 to 12 mg per day.
223871664|NCT02361918|PROCEDURE|Colon surgery|
223871665|NCT01152398|BIOLOGICAL|MVA-BN-HER2|experimental vaccine, subcutaneous injection q4weeks x6
223871666|NCT06433102|OTHER|Visual perceptual training based on the lateral masking paradigm|Visual perceptual training is a novel rehabilitation approach aimed at enhancing visual performance through practice of visual tasks. Patients received visual perceptual training based on the lateral masking paradigm every other day. Each training session consisted of 9 stages, totaling 900 trials, lasting 35 to 45 minutes. The stimuli consisted of a central Gabor patch with relatively low contrast positioned in the central fixation area, along with co-linear high-contrast Gabor patches distributed above and below the central stimulus. These stimuli were presented on a Liquid Crystal Display (LCD) monitor, with a training distance of 150 cm.
223871667|NCT00025610|DRUG|carboplatin|
223871668|NCT00025610|DRUG|cyclophosphamide|
223871669|NCT00025610|DRUG|doxorubicin hydrochloride|
223871670|NCT00025610|DRUG|etoposide|
223871671|NCT00025610|DRUG|vincristine sulfate|
223871672|NCT04887675|DIAGNOSTIC_TEST|MRI|Both groups with undergo neuroimaging on 3T magnetic resonance unit (Trio Tim, Siemens, Erlangen, Germany) in the Center for Diagnostic Imaging, Oncology Institute of Vojvodina, Serbia. Multivoxel MRS will be performed in the supratentorial cerebral parenchyma, covering white matter of frontal and parietal lobes, as well as cortical grey matter in frontal and parietal lobes and the whole cingulate gyrus.
223871673|NCT00273624|DRUG|Olanzapine|10 mg Olanzapin concurrent to antidepressive medication
223871674|NCT00273624|DRUG|Placebo|placebo
223871675|NCT02267824|DEVICE|Extraoral OrthoPulse® PBM|Patients carry out daily extraoral OrthoPulse® PBM treatments at home.
223871676|NCT02267824|OTHER|Fixed Orthodontic Appliance Treatment|Patients are treated for full mouth fixed orthodontic appliance treatment by the qualified Principal Investigator (PI). Orthodontic treatment procedures carried out per the traditional practices of the PI and dental office.
223871677|NCT04065958|BEHAVIORAL|Yoga-mindfulness|Body-mind therapy
223871678|NCT04065958|BEHAVIORAL|Patient education and physiotherapy|Lectures and physiotherapy
223871679|NCT01504659|DRUG|Ketamine hydrochloride injection|Separate dosing regimens will be applied depending on the weight of the child. Group A with minimum-maximum weight of 20 kg-40 kg will receive a fixed initial dose of 10 mg ketamine(0.25-0.5mg/kg)and will not exceed a maximum dose of 40 mg ketamine. Group B with minimum - maximum weight of 40.01kg-100kg will get a fixed initial dose of 20 mg ketamine(0.20-0.5mg/kg) and will not exceed a maximum dose of 120mg. ketamine. There will be 4 administrations of the drug at three day intervals. Titration upward will depend upon degree of side effects, improvement from baseline on primary measures, subjective opinion. Doses will be held constant as long as a therapuetic response, as measure of 80% improvement on YBOCS and YMRS, is reached.
223871680|NCT01504659|DRUG|Flat tonic water (e.g., Canada Dry Tonic Water)|Separate dosing regimens will be applied depending on the weight of the child. Group A with minimum-maximum weight of 20 kg-40 kg will receive a fixed initial dose of 0.1cc placebo and not exceed a maximum dose of 0.4cc placebo. Group B with minimum - maximum weight of 40.01kg-100kg will get a fixed initial dose of 0.2cc placebo and will not exceed a maximum dose of 1.2cc. placebo. There will be 4 administrations of the placebo at three day intervals. Titration upward will depend upon degree of side effects, improvement from baseline on primary measures, and subjective opinion. Doses will be held constant as long as a therapuetic response, as a measure of 80% improvement on YBOCS and YMRS, is reached.
223871681|NCT00867256|DEVICE|Large Diameter Metal on Metal|
223871682|NCT06294275|BIOLOGICAL|LP-001 Dose 1 (Single)|A single dose of LP-001 (Dose 1) was administered subcutaneously.
223871683|NCT06294275|BIOLOGICAL|LP-001 Dose 2 (Single)|A single dose of LP-001 (Dose 2) was administered subcutaneously.
223871684|NCT06294275|BIOLOGICAL|LP-001 Dose 3 (Single)|A single dose of LP-001 (Dose 3) was administered subcutaneously.
223871685|NCT06294275|BIOLOGICAL|LP-001 Dose 4 (Single)|A single dose of LP-001 (Dose 4) was administered subcutaneously.
223871686|NCT06294275|BIOLOGICAL|LP-001 Dose 5 (Single)|A single dose of LP-001 (Dose 5) was administered subcutaneously.
223871687|NCT06294275|BIOLOGICAL|LP-001 Dose 6 (Single)|A single dose of LP-001 (Dose 6) was administered subcutaneously.
223871688|NCT06294275|BIOLOGICAL|Placebo (Single)|A single dose of placebo was administered subcutaneously.
223871689|NCT06294275|BIOLOGICAL|LP-001 Dose 7 (Multiple)|LP-001 (Dose 7) was administered multiple times subcutaneously.
223871690|NCT06294275|BIOLOGICAL|LP-001 Dose 8 (Multiple)|LP-001 (Dose 8) was administered multiple times subcutaneously.
223871691|NCT06294275|BIOLOGICAL|Placebo (Multiple)|Placebo was administered multiple times subcutaneously.
223871692|NCT00016341|BIOLOGICAL|filgrastim|
223871693|NCT00016341|DRUG|cisplatin|
223871694|NCT00016341|DRUG|doxorubicin hydrochloride|
223871695|NCT00016341|DRUG|megestrol acetate|
223871696|NCT00016341|DRUG|paclitaxel|
223871697|NCT00016341|DRUG|tamoxifen citrate|
223871698|NCT01088659|DRUG|peginterferon alfa-2a [Pegasys]|180mcg sc weekly, 96 weeks
223871699|NCT01088659|DRUG|placebo|orally daily, 96 weeks
223871700|NCT01088659|DRUG|tenofovir|245mg po daily, 96 weeks
223871701|NCT06059560|DIETARY_SUPPLEMENT|Nutritional therapy|Intensive nutritional therapy based on real world therapy
223871702|NCT06499558|OTHER|Classical Training|Students in the education group will practice family planning education skills in the professional skills laboratory.
223871703|NCT06499558|OTHER|Standard Patient Interviews|Students in the standardized patient education group will receive training involving a family planning counseling scenario with standardized patients.
223871704|NCT02578836|PROCEDURE|Fogel Gastroplasty|The subject will be placed under general anesthesia. The procedure will last approximately 1-2 hours. CO2 will be used rather than air for the insufflation that is required during the procedure to minimize abdominal distention. The physician will place an interrupted suture pattern in a manner which partitions the greater curvature of the stomach from the Angle of His to the level of the incisura, creating a tube-like passage for gastric volume reduction. Afterwards, the remaining gastric volume will be reduced using a circumferential running stitch.The device that will be used to place the stitches is the OverStitch system FDA approved for tissue apposition
223871705|NCT02904642|BEHAVIORAL|SMS reminder|Caregivers will receive two text message reminders for their child's measles immunization scheduled for 9 months of age
223871706|NCT02904642|BEHAVIORAL|Unconditional Incentive|A mobile-money incentive in the amount of 150 Kenyan Shillings will be transferred to the enrolled caregiver's mobile phone when the child reaches nine months of age
223871707|NCT03206684|DRUG|PEG-rhG-CSF|PEG-rhG-CSF single-dose was administered subcutaneously 48h after chemotherapy，weight ≥ 45kg were given 6mg once per chemotherapy cycle, weight \<45kg were given 3mg once per chemotherapy cycle.
223871708|NCT03206684|DRUG|rhG-CSF|rhG-CSF was administered subcutaneously 48h after chemotherapy，weight≥45kg were given 300μg/d, weight\<45kg were given 150μg/d,continuous injection for 3-5 days until the absolute neutrophils count≥2×10\^9/L.
223871709|NCT00978172|DRUG|artesunate and mefloquine|artesunate (50 mg/day) and mefloquine (125 mg/day) fixed dose formulation (stick pack) once daily for 3 consecutive days, orally
223871710|NCT03792620|COMBINATION_PRODUCT|Cyclo Thal Dex Daratumumab|Cyclo Thal Dex Daratumumab
223871711|NCT03085394|DRUG|tranexamic acid|Preoperative intravenous administration of 2 grams tranexamic acid in 10 ml saline
223871712|NCT03085394|DRUG|Placebo|Preoperative intravenous administration of 10 ml saline
223871713|NCT00915239|DRUG|Pantoprazole|40 mg pantoprazole once daily for 28 days
223871714|NCT00915239|DRUG|Placebo|identical placebo once daily for 28 days
223871715|NCT03074331|DRUG|SOF/VEL|400/100 mg FDC tablet(s) administered orally once daily
223871716|NCT05228054|PROCEDURE|laser procedure|In modified litothomy position patients with hemorrhoidal deasease will be treated with transcutaneous laser 1940nm 3watt in impulse regimen
223871717|NCT05228054|PROCEDURE|sclerotherapy|In modified litothomy position patients with hemorrhoidal deasease will be treated with sclerotherapy with Aethoxysklerol
223871718|NCT00035828|DRUG|ABX-IL8|
223871719|NCT00741455|PROCEDURE|Stem Cell Transplant|"Donor: Prior to mobilization, leukapheresis to collect CD3+ cells. The donor will then receive G-CSF (10 mcg/kg/day) with leukapheresis collection of peripheral blood stem cells on days 5, 6 and 7 as needed. Goal of leukapheresis will be \> 5 x 106 CD34+cells/kg of recipient.~Patient: Peripheral Blood Stem Cell (PBSC) Transplant. Fludarabine 25mg/m2/d IV over 30 minutes on days -6 to -2, followed by cyclophosphamide 1g/m2/d IV on days -3 and -2. This will be followed by allogeneic stem cell infusion 48 hours later.~Donor Lymphocyte Infusion (DLI) and Adjustment of Immunosuppression: Cyclosporine (CSA) and methotrexate (MTX) will be used for GvHD prophylaxis with target CSA levels of 200-400 ng/ml."
223871720|NCT00741455|DRUG|G-CSF|10 mcg/kg/day on days 5, 6, and 7
223871721|NCT00741455|DRUG|Fludarabine|25 mg/m2/d IV over 30 minutes on days -6 to -2
223871722|NCT00741455|DRUG|cyclophosphamide|1 g/m2/d IV on days -3 and -2
223871723|NCT00741455|DRUG|Cyclosporine|used for GvHD prophylaxis with target CSA levels of 200-400 ng/ml
223871724|NCT00741455|DRUG|Methotrexate|used for GvHD prophylaxis with target CSA levels of 200-400 ng/ml
223871725|NCT03257644|DRUG|Ruxolitinib phosphate cream|Ruxolitinib phosphate cream at the protocol-defined dose strength based on cohort assignment.
223871726|NCT03014375|DRUG|BIA-5-453|Each subject will receive a single oral dose of 100 μCi/ 3.7 MBq 14C labeled BIA 5-453 (600 mg).
223871727|NCT00788034|DRUG|Lu AA21004|5 or 10 mg/day
223871728|NCT00788034|DRUG|Placebo|Once daily
223871729|NCT00843687|DRUG|Risperidone long-acting injectable|
223871730|NCT05733507|PROCEDURE|IVT with tenecteplase or alteplase|Patients received intravenous tenecteplase 0.25mg/kg (maximum dose: 25mg), administered as a bolus over 5 to 10 seconds or intravenous alteplase 0.9 mg/kg (maximum dose: 90mg), 10% as bolus and the remainder as continuous perfusion over 1 hour.
223871731|NCT05733507|PROCEDURE|Intervention Name : Tirofiban and IVT with tenecteplase or alteplase|IVT with tenecteplase or alteplase with continuous infusion of tirofiban 0.4µg/kg/min continued for 24 to 48 hours.
223871732|NCT05494294|PROCEDURE|Intraorally de-epithelialization|In this group, the grafts were de-epithelialized at the donor site before harvesting. The calibrated surgeon removed the epithelium with a sharp Kirkland knife under magnification. To be sure of the elimination whole epithelial layer, bleeding was observed. Recipient site was prepared as follows; A after sulculer incision had done (blade 15c) two vertical incions were made from the gingival margin to 3 mm beyond the mucogingival junction A partial-thickness flap was elevated under the recession area and full thickness flap elevated adjacent flap portions. then relasing incisions were made apically from the mucogingival junction. After the preparation of the recipient site, obtained graft was sutured 1 mm apically to the cemento-enamel junction. Finally flap was positioned without tension and stabilized at least 2mm coronally from the cemento-enamel margin with the single interrupted sutures.
223871733|NCT05494294|PROCEDURE|Extraorally de-epithelialization|In this group, the grafts were de-epithelialized after graft harvesting. The calibrated surgeon removed the epithelium with 15 c knife under magnification. all remnants were removed under magnification. Same recipient site procedure was conducted in this group.
223871734|NCT03469596|DIAGNOSTIC_TEST|MRI sequence|several MRI sequence before and after contrast product injection.
223871735|NCT05519670|DRUG|Niraparib Oral Product|Niraparib + capecitabine treatment
223871736|NCT00077493|DRUG|BL22 immunotoxin|BL22 immunotoxin IV over 30 minutes on days 1, 3, and 5 OR on days 1, 3, 5, 7, 9, and 11. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients who achieve a complete response (CR) or unconfirmed CR (CRu) receive 2 additional courses beyond CR or CRu for a maximum of 6 courses.
223871737|NCT00077493|PROCEDURE|antibody-drug conjugate therapy|CD22 antibody, RFB4 on day 7
223871738|NCT00077493|PROCEDURE|immunotoxin therapy|tested for immunogenicity to CAT-8015 before each cycle and at end of study.
223871739|NCT00077493|PROCEDURE|monoclonal antibody therapy|administered intravenously over 30 minutes.
223871740|NCT03451721|DEVICE|ImageReady™ MR Conditional Defibrillation System|Subject will receive an ICD or CRT-D pulse generator in the left or right pectoral region ICD
223871741|NCT01319617|DEVICE|SENSIMED Triggerfish|Soft contact lens-based device intended for continuous recording of relative changes in IOP
223871742|NCT06282107|PROCEDURE|BiSAAE|SAAE is a catheter-based percutaneous transluminal procedure which selectively injects ethanol into bilateral adrenal artery to ablate part of the adrenal gland for suppression of excessive aldosterone and catecholamines
223871743|NCT06282107|PROCEDURE|traditional triple antihypertensive treatment|traditional triple antihypertensive treatment
223871744|NCT05877807|DRUG|Baclofen|Daily doses will be adapted to daily MDRD creatinine clearance from 150 to 50mg. On the day of randomisation, the patient will receive the full daily dose in a one-shot administration. Then daily doses will be divided into 3 intakes on the following days. During the mechanical ventilation period, the treatment will be administered via the nasogastric feeding tube. After extubation, the treatment will be administered either via the nasogastric tube or the oral route.
223871745|NCT05877807|OTHER|Placebo|Daily doses will be adapted to daily MDRD creatinine clearance from 150 to 50mg. On the day of randomisation, the patient will receive the full daily dose in a one-shot administration. Then daily doses will be divided into 3 intakes on the following days. During the mechanical ventilation period, the placebo will be administered via the nasogastric feeding tube. After extubation, the placebo will be administered either via the nasogastric tube or the oral route.
223871746|NCT03697707|BIOLOGICAL|DCP-001|allogeneic dendritic cell vaccine
223871747|NCT01592448|BEHAVIORAL|Active Ingredient Icon|"Enhanced bottles will have a symbol, or icon, designed to draw attention to active ingredient information. The icon is a black hexagon containing two letters denoting the active ingredient of the medication (i.e. Ac for acetaminophen). Over-the-counter bottles will have the icon placed on the front of the bottle next to active ingredient information and on the back of the bottle in the drug facts to the left of the active ingredient information. Prescription bottles will have the icon placed below the directions for how to take the medication and will be accompanied by a brief statement indicating the medicine contains acetaminophen."
223871748|NCT03750214|DEVICE|Biop Colposcopy System|"The procedure stages:~1. Scanning of the cervix - the cervix is scanned using the micro colposcope probe unit, to produce a total of 51 micro-images and one macro image from the panoramic camera.~2. Colposcopy exam - during the standard colposcopy exam, the doctor acquires a panoramic image of the cervix with the digital colposcope.~3. A questionnaire completed by the subject after the Biop procedure, with regards to any unusual sensations or events experienced during the procedure.~4. A questionnaire completed by the user after the Biop procedure, with regards to system usage~5. Image Registration analysis"
223871749|NCT05955989|OTHER|soft lining of complete denture processed by 3 different techniques.|soft lining for complete denture
223871750|NCT02337036|OTHER|Pharmacokinetic|Taking blood samples for an Pharmacokinetic of tacrolimus in Paediatric Liver Transplant Patients treated with tacrolimus
223871751|NCT02337036|OTHER|Pharmacogenetic|Pharmacogenetic study
223871752|NCT02337036|DRUG|Tacrolimus|These Patients are treated with tacrolimus after the Liver Transplantation
223871753|NCT03918967|DRUG|CT-G11|oral tablet of CT-G11 Experimental Drug
223871754|NCT03918967|DRUG|CT-G20|oral tablet of CT-G20 Experimental Drug
223871755|NCT03918967|DRUG|CT-G11 Placebo|oral tablet of Placebo
223871756|NCT03918967|DRUG|CT-G20 Placebo|oral tablet of Placebo
223871757|NCT03991754|PROCEDURE|transcatheter aortic valve implantation|transcatheter aortic valve implantation
223871758|NCT04768712|BEHAVIORAL|Weight bearing aerobic exercise|Weight bearing aerobic exercise three times per week.
223871759|NCT04011813|OTHER|Hypotaurine : antioxidant and osmoregulator|"Hypotaurine has protective effects on sperm motility, capacitation and acrosome reaction and reduces apoptotic markers.~Hypotaurine (50mM) was added in density gradient centrifugation, washing and cryopreservation media washing and cryopreservation media before spermatozoa freezing"
223871760|NCT03488745|BEHAVIORAL|IntelliCare + Phone Coaching|IntelliCare is composed of 13 separate, native apps. Each app targets a specific aspect of mental health (e.g., reducing worry, increasing social support, tracking negative thoughts). The apps are available to the public in both Android and iPhone stores. Participants will be asked to try two new IntelliCare apps every week, for 7 weeks. Phone coaching will occur at Day 0, before using any of the apps, and the third week of app usage.
223871761|NCT05915715|OTHER|McGill stabilization exercise|"McGill Curl Up Lie down on your back.~The Side Bridge Lie on your side.~The Bird Dog."
223871762|NCT05915715|OTHER|Proprioceptive neuromuscular facilitation technique|. The patient is in sitting position and faces the physical therapist. The RST program consisted of alternating (trunk flexion-extension) isometric contractions against resistance for 10 seconds, with no motion intended. Subjects performed 3 sets of 15 repetitions at maximal resistance provided by the same physical therapist. Rest intervals of 30 seconds and 60 seconds were provided after the completion of 15 repetitions for each pattern and between sets, respectively.
223871763|NCT01985334|DRUG|Glycopyrronium|Glycopyrronium 50 µg capsule for inhalation via SDDPI once per day
223871764|NCT01985334|DRUG|SABA|Short-acting β2-adrenergic agonist (SABA) as per approved by each country and as prescribed for each patient, used as background therapy
223871765|NCT01985334|DRUG|LABA|Long Acting Beta Agonist (LABA) as per approved by each country and as prescribed for each patient, used as background therapy
223871766|NCT01985334|DRUG|Indacaterol maleate and glycopyrronium bromide|Indacaterol maleate and glycopyrronium bromide fixed dose combination (110/50 µg) capsule for inhalation via SDDPI, once a day
223871767|NCT01985334|DRUG|LAMA|Long Acting Muscarinic Antagonist (LAMA) as per approved by each country and as prescribed for each patient, used as background therapy
223871768|NCT01985334|DRUG|SAMA|Short-acting muscarinic antagonist (SAMA) as per approved by each country and as prescribed for each patient, used as background therapy
223871769|NCT01985334|DRUG|ICS|Inhaled corticosteroid (ICS) as per approved by each country and as prescribed for each patient, used as background therapy
223871770|NCT01747707|DRUG|Docetaxel|
223871771|NCT01747707|DRUG|Cisplatin|
223871772|NCT01747707|DRUG|S-1|
223871773|NCT04657887|BIOLOGICAL|Voncento®|Solution for injection
223871774|NCT01831284|PROCEDURE|Sigmoidoscopy with biopsy|Sigmoidoscopy with biopsy
223871775|NCT04350541|OTHER|High-intensity interval training|Exercise with high-intensity intervals followed by active rest
224268881|NCT03555695|BEHAVIORAL|Pre-Intervention Focus Group|At the pre-intervention focus group, the study logistics will be reviewed, informed consent process will occur, the subject will complete a brief, individual pre-intervention assessment focused on overall mobility, gait, balance, mood, neurological status, and quality of life, and the subjects will be prompted to share aloud their thoughts on exercise, balance, and mindfulness practices in general and in PD specifically, and any expectations or preconceptions that they have regarding karate classes for PD.
224268882|NCT03555695|BEHAVIORAL|Post-Intervention Focus Group|At the post-intervention focus group, the pre-intervention assessments will be readministered, along with an assessment of the subject's global impression of change. Subjects will be prompted to share their thoughts on how the intervention impacted their overall wellbeing, balance, and mindfulness; whether the intervention achieved their expectations; and they will be asked to provide feedback for improvements.
224268883|NCT05226702|BIOLOGICAL|COVAC-2|Intramuscular vaccine against SARS-CoV-2
223871776|NCT04350541|OTHER|Continuous aerobic training|Interval Moderate-intensity aerobic training without intervals
223871777|NCT01483066|DEVICE|ShapeMatch Technology|ShapeMatch Technology places a plastic cutting guide on the end of the femur and tibia, so that cuts that do not automatically default to the mechanical axis, but rather attempt to recreate the patient's anatomic alignment.
223871778|NCT04691024|OTHER|Exercise|Spinal stabilization exercises
223871779|NCT05412199|DEVICE|Percussion Massage Therapy|Individuals in the percussion massage therapy group will get 3 minutes of percussion massage therapy on the hamstring and gastrocnemius muscles along the origo-insertion in the mid-frequency range.
223871780|NCT05412199|DEVICE|Graston|Instrument-assisted soft tissue mobilization will be used on the hamstring and gastrocnemius muscles along the 5-minute origo insertion line in the Graston group.
223871781|NCT05412199|OTHER|Dynamic Stretching|Dynamic stretching exercises for the hamstring and gastrocnemius muscles will be performed in the dynamic stretching exercise group.
223871782|NCT04329130|DRUG|Chidamide, Lenalidomide|All patients enrolled in the study will accept Chidamide combination with lenalidomide regimen.
223871783|NCT03777696|DRUG|Misoprostol|400 μg of buccal misoprostol
223871784|NCT03777696|DRUG|TA|1 gm of tranexamic acid in 100 ml saline iv
223871785|NCT03777696|DRUG|placebo to misoprostol|placebo tablets to misoprostol buccal
223871786|NCT03777696|DRUG|placebo to TA|110 ml saline iv
223871787|NCT05619952|DIETARY_SUPPLEMENT|Mushroom Powder|Ground shiitake mushrooms or ground white button mushrooms
223871788|NCT00879749|BIOLOGICAL|9 micrograms Nexvax2|9 micrograms, weekly intra-dermal injection, 3 week duration
223871789|NCT00879749|BIOLOGICAL|30 micrograms Nexvax2|30 micrograms, weekly intra-dermal injection, 3 week duration
223871790|NCT00879749|BIOLOGICAL|90 micrograms Nexvax2|90 micrograms, weekly intra-dermal injection, 3 week duration
223871791|NCT00879749|BIOLOGICAL|60 micrograms Nexvax2|60 micrograms, weekly intra-dermal injection, 3 week duration
223871792|NCT00879749|BIOLOGICAL|Up to 900 micrograms Nexvax2|Up to 900 micrograms, weekly intra-dermal injection, 3 week duration
223871793|NCT00879749|OTHER|Placebo|100 microlitres 0.9% sterile sodium chloride for injection
223871794|NCT04086966|DRUG|[68Ga]PSMA-PET/MRI or PET/CT|\[68Ga\]PSMA-PET/MRI or PET/CT
223871795|NCT03110965|BEHAVIORAL|Yoga poses|Patients are asked to perform one or two yoga poses daily for 4-10 months
223871796|NCT06478238|DRUG|calcium folinate|Intravenous infusion and/or oral therapy
223871797|NCT03830086|DRUG|Midazolam|Used for general anesthesia for gynecological laparoscopic procedures, together with Propofol, Sufentanil, Rocuronium, Sevoflurane
223871798|NCT03830086|DRUG|Sufentanil|Used for regional anesthesia (spinal or combined spinal-epidural anesthesia) for gynecological laparoscopic procedures together with Bupivacaine; and for general anesthesia for gynecological laparoscopic procedures, together with following drugs: Midazolam, Propofol, Rocuronium, Sevoflurane
223871799|NCT03830086|DRUG|Propofol|Used for general anesthesia for gynecological laparoscopic procedures, together with the following drugs: Midazolam, Sufentanil, Rocuronium, Sevoflurane
223871800|NCT03830086|DRUG|Rocuronium|Used for general anesthesia for gynecological laparoscopic procedures, together with the following drugs: Midazolam, Propofol, Sufentanil, Sevoflurane
223871801|NCT03830086|DRUG|Sevoflurane|Used for general anesthesia for gynecological laparoscopic procedures, together with the following drugs: Midazolam, Propofol, Sufentanil, Rocuronium
223871802|NCT03830086|DRUG|Bupivacaine|Used for regional anesthesia (spinal or combined spinal-epidural anesthesia) for gynecological laparoscopic procedures, together with Sufentanil
223871803|NCT03487172|DEVICE|poly-L-lactic acid to right knee|Subjects will receive PLLA injections to the right knee and bacteriostatic water to the left.
223871804|NCT03487172|DEVICE|poly-L-lactic acid to left knee|Subjects will receive PLLA injections to the left knee and bacteriostatic water to the right.
223871805|NCT02424071|DRUG|Melatonin|
223871806|NCT02424071|DRUG|placebo|
223871807|NCT04431297|OTHER|Mindfulness Rounds|Virtually delivered mindfulness education sessions of 15-30 minutes, two times/week, for four weeks
223871808|NCT04410458|BEHAVIORAL|blood donation SMS|The literature shows that the information extraction and processing in emergency is different from the normal situation. To find the most effective emergency recruitment method during an outbreak, we intervened with a well-balanced group of donors by presenting different emergency recruitment text messages.
223871809|NCT00000834|DRUG|Lamivudine|
223871810|NCT00000834|DRUG|Methotrexate|
224268884|NCT05226702|BIOLOGICAL|Saline Placebo|Intramuscular injection of saline placebo
224268885|NCT06106490|OTHER|the effect of adding pulsed radiofrequency (PRF) modality to suprascapular nerve injection with ultrasound glenohumeral steroid in chronic shoulder pain patients|"Suprascapular nerve block group: Patients will receive ultrasound guided intra articular Gleno-humeral steroid injection of Diprofos® (betamethasone 14 mg/ 2ml) and ultrasound guided suprascapular nerve block US SSN with 10mL of 0.25% preservative-free bupivacaine~Pulsed radiofrequency group: Patients will receive ultrasound guided intra articular Gleno-humeral steroid injection of Diprofos® (betamethasone 14 mg/ 2ml) and ultrasound guided suprascapular nerve block US SSN with 10mL of 0.25% preservative-free bupivacaine with application of pulse PRF at 42 Celsius of suprascapular nerve for 480 seconds."
224268886|NCT04889014|GENETIC|Personal genomic educational testing (PGET)|PGET consisted of a panel of pharmacogenomic variants
223871811|NCT00000834|DRUG|Zidovudine|
223871812|NCT00544752|OTHER|16|indoor temperature of 16 degrees celcius
223871813|NCT00544752|OTHER|indoor temperature of 20 degrees celcius|indoor temperature of 20 degrees celcius
223871814|NCT00544752|OTHER|indoor temperature of 24 degrees celcius|indoor temperature of 24 degrees celcius
223871815|NCT02698228|DRUG|Bupivacaine (femoral nerve block)|0.5% bupivacaine
223871816|NCT02698228|DRUG|Morphine|Intravenous injection of 0.1mg/kg of morphine
223871817|NCT02698228|DEVICE|Ultrasound|
223871818|NCT05045534|DRUG|Comparison of TB-840 treatment with Placebo|Single dose or Multiple Dose of TB-840 treatment
223871819|NCT06070337|DEVICE|H-Guard|A novel Haemodialyser primer used for one treatment only
223871820|NCT02059382|BEHAVIORAL|ChiRunning training|
223871821|NCT02059382|BEHAVIORAL|unblinded accelerometer|
223871822|NCT02059382|BEHAVIORAL|participation in online social network|
223871823|NCT02059382|BEHAVIORAL|participation in study website|
223871824|NCT02059382|BEHAVIORAL|Technology support for behavior change|
223871825|NCT01855334|DRUG|Spironolactone|
223871826|NCT01855334|DIETARY_SUPPLEMENT|L-arginine|
223871827|NCT01855334|DRUG|Placebo|
223871828|NCT03674034|OTHER|CTscan and MRI images|CTscan and MRI images segmented according to procedures previously developed by GRAMFC
223871829|NCT02725294|OTHER|This is an observational study without an intervention|Not applicable. This is an observational study without an intervention.
223871830|NCT03903822|DRUG|PF-06700841|PF-06700841 topical cream
223871831|NCT03903822|DRUG|Vehicle (Placebo)|Vehicle topical cream
223871832|NCT00000338|DRUG|Lisuride|
223871833|NCT02752230|PROCEDURE|Laparoscopic Roux en Y gastric bypass|Laparoscopic Roux en Y gastric bypass
223871834|NCT02752230|PROCEDURE|Laparoscopic Sleeve Gastrectomy|Laparoscopic Sleeve Gastrectomy
223871835|NCT01706354|PROCEDURE|Local Anaesthetic|Infiltration of local anaesthetic into the surgical site by the surgeon using a combination of 0.5% L-bupivicaine prior to incision and 1% lignocaine topically after the wound is opened. Maximum dose limits of 2mg/kg for bupivicaine, and 3mg/kg for lignocaine will be observed, recognising that these are additive.
223871836|NCT01706354|PROCEDURE|Regional anaesthetic|Ultrasound guided brachial plexus block. Supraclavicular will be the block performed unless there is a contraindication in which case axillary block may be used. A 1:1 mixture of 0.5% L-bupivicaine and 1.5% lignocaine with adrenaline (1 in 200,000) will be injected, up to a volume of 40ml but using a minimum of 25ml. Maximum dose limits of 2mg for bupivicaine and 7mg/kg for lignocaine with adrenaline will be observed, recognising that these are additive.
223871837|NCT05705505|DRUG|Narazaciclib|Orange tablets, each containing 40 mg or 120 mg of narazaciclib as narazaciclib monolactate
223871838|NCT05705505|DRUG|Letrozole 2.5mg|Tablet
223871839|NCT01796236|DEVICE|Minimally invasive surgery and BA400|The Cochlear Baha BA400 Abutment has been designed with a concave shape at the lower aspect of the abutment. The abutment is made of commercially pure titanium and is coated with a hydroxyapatite layer on the entire soft tissue-contacting surface of the abutment up to 3 mm below the top surface (2 mm below the top surface on 6 mm abutments).
223871840|NCT01796236|DEVICE|Traditional surgery and BA300|The BA300 abutment is made of commercially pure titanium and is available in two different lengths (6 mm and 9 mm).
223871841|NCT05801198|DIETARY_SUPPLEMENT|Artemisia afra or Annua 10g oral infusion/tea per day for 14 days|Participants will be recruited after completing standard malaria treatment, and those who have a positive qRT-PCR for plasmodium gametocyte reservoirs will be randomly assigned to either artemisia afra tea, or artemisia annua tea or into the control group with no intervention
223871842|NCT00145314|DRUG|FLOX (5-fluorouracil/folinic acid/oxaliplatin)|FLOX every 2nd week
223871843|NCT00145314|DRUG|FLOX (5-fluorouracil/folinic acid/oxaliplatin) and Cetuximab|FLOX every 2nd week Cetuximab weekly
223871844|NCT00145314|DRUG|FLOX (5-fluorouracil and folinic acid and oxaliplatin) intermittently and maintenance cetuximab|"FLOX every 2nd week for 8 cycles. Stop of FLOX until progression then FLOX is reintroduced.~Cetuximab weekly."
223871845|NCT01255501|DRUG|NI-0701|
224268887|NCT04889014|GENETIC|No personal genomic educational testing (NPGET)|Lack of pharmacogenomic testing
224268888|NCT04636034|PROCEDURE|Sphenopalatine Ganglion Block with Local Anesthetic|Block performed with bilaterally inserted q-tips with 1:1 mixture of lidocaine 40mg/ml and ropivacaine 5mg/mL
223871846|NCT01255501|DRUG|Placebo|
223871847|NCT05848531|DRUG|Clonidine|Comparing Clonidine with Morphine PCIA for the treatment of Vaso-Occlusive crisis in Sickle Cell disease patient
223871848|NCT00546754|DRUG|losartan potassium (+) hydrochlorothiazide|losartan potassium 50 mg/12.5 Hydrochlorothiazide (HCTZ) titrated as needed to losartan potassium 100 mg/25 mg Hydrochlorothiazide
223871849|NCT00546754|DRUG|Comparator: Valsartan (+) Hydrochlorothiazide|Valsartan 80 mg/ Hydrochlorothiazide 12.5 mg/day titrated as needed to valsartan 160 mg/25 mg Hydrochlorothiazide
223871850|NCT06079931|DRUG|Babaodan Capsule|The patient received 66-66Gy/30-33F radiation therapy. During radiation therapy, concurrent chemotherapy includes receiving 45mg/m2 paclitaxel and carboplatin (AUC 2) once a week; From the start of radiation therapy to 2 months after the completion of CCRT, the patient takes 2 capsules of Babaodan orally every day, tid (1.8 g/day), and systemic corticosteroids can be used for acute radiation pneumonia patients with G ≥ 2.
223871851|NCT03375151|DEVICE|EEG based feedback|Participants will participate in cognitive training sessions. The therapist will use feedback from the EEG analyzed data to direct the cognitive therapy based on the therapist's guidance to maximize the intensity and duration of the patient's high brain engagement Index (BEI) during exercise.
223871852|NCT03375151|BEHAVIORAL|Standard practice based feedback|Participants will participate in cognitive training sessions. The therapist will give feedback to the participants during the exercise based on their performance only according to the his therapist standard practice.
223871853|NCT03375151|BEHAVIORAL|No feedback|Participants will participate in cognitive training sessions. The therapist will not guide them during the sessions.
223871854|NCT04877496|DRUG|History of exposure to anti-CD20 treatment since 01/01/2010|Intravenous treatment history of anti-CD20 treatment since 01/01/2010
223871855|NCT04877496|BIOLOGICAL|Completion of COVID19 vaccine at least 4 weeks ago|Completion of COVID19 vaccination course at least 4 weeks ago.
223871856|NCT06169501|BEHAVIORAL|App-based Mindfulness Intervention|Participants in the trial will engage in a 30-day app-based mindfulness program called Unwinding Anxiety that they can complete over a maximum of 60 days. During this time, they will practice short daily mindfulness lessons and respond to a set of brief questions regarding their anxiety levels. Ultimately, we want to assess whether this intervention helps these caregivers feel less stressed and anxious.
223871857|NCT01818713|DRUG|2B3-101|50 mg/m2 2B3-101 intravenous 3-weekly administration
223871858|NCT03733119|DRUG|Akt/ERK Inhibitor ONC201|Given PO
223871859|NCT03733119|DIETARY_SUPPLEMENT|Methionine-Restricted Diet|Given PO
223871860|NCT01781585|PROCEDURE|hemodialysis|Patients were randomized to receive CVVH or SLED and the next day on the other.
224268889|NCT04636034|PROCEDURE|Sphenopalatine Ganglion Block with Placebo (Isotone NaCl)|Block performed with bilaterally inserted q-tips with isotone NaCl
223871861|NCT04702256|DRUG|Obinutuzumab administration|"Obinutuzumab administration by intravenous infusion (IV), IV of methylprednisolone, oral mycophenolate mofetil, no prednisone (or if required for extrarenal manifestation(s): less than 10mg/day at any time, less than 7.5mg/day after 6 months and less than 5mg/day after 9 months).~Hydroxychloroquine will be strongly recommended for all the patients."
223871862|NCT04702256|DRUG|Administration of Methylprednisolone + Prednisone + Mycophenolate mofetil|"IV of methylprednisolone, oral prednisone (according to the PNDS), and oral mycophenolate mofetil.~Hydroxychloroquine will be strongly recommended for all the patients."
223871863|NCT04702256|DRUG|Administration of methylprednisolone, paracetamol and dexchlorpheniramine|Prior to infusion of obinutuzumab, patients receiving obinutuzumab will receive premedication including 100 mg of methylprednisolone, paracetamol and dexchlorpheniramine.
223871864|NCT02253537|DEVICE|CST001|
223871865|NCT00192946|PROCEDURE|Temporary cardiac resynchronization therapy|
223871866|NCT04791592|PROCEDURE|Single-injection, ultrasound-guided bilateral PIF block.|"PIF block bilaterally (20 ml, 0.25% bupivacaine + 1:400.000 adrenaline). In addition, LA infiltration (10 ml, 0.25% bupivacaine) will be performed by the surgeon around the chest tube in all patients.~Intraoperative analgesia: At the end of the surgery, all patients will be given 0.05 mg/kg morphine IV.~Postoperative analgesia: Paracetamol 1 gr IV (every 6 hours) and IV PCA of 0.5 mg/ml morphine (demand dose 20µg/kg; lock out interval 6-10 min.; the 4-hour limit will be 80% of the total calculated dose).~In cases where rescue analgesia is required (NRS score ≥4) tramadol 100 mg IV will be infused within 30 minutes (max. 300 mg / day).~For postoperative nausea and vomiting prophylaxis, patients will be routinely administered ondansetron 4 mg IV 20 minutes before extubation in the intensive care unit."
223871867|NCT04791592|PROCEDURE|Single-injection, ultrasound-guided bilateral TTMP block.|"TTMP block bilaterally (20 ml, 0.25% bupivacaine + 1:400.000 adrenaline). In addition, LA infiltration (10 ml, 0.25% bupivacaine) will be performed by the surgeon around the chest tube in all patients.~Intraoperative analgesia: At the end of the surgery, all patients will be given 0.05 mg/kg morphine IV.~Postoperative analgesia: Paracetamol 1 gr IV (every 6 hours) and IV PCA of 0.5 mg/ml morphine (demand dose 20µg/kg; lock out interval 6-10 min.; the 4-hour limit will be 80% of the total calculated dose).~In cases where rescue analgesia is required (NRS score ≥4) tramadol 100 mg IV will be infused within 30 minutes (max. 300 mg / day).~For postoperative nausea and vomiting prophylaxis, patients will be routinely administered ondansetron 4 mg IV 20 minutes before extubation in the intensive care unit."
223871868|NCT02545036|OTHER|Traditional Chinese Medicine (TCM) daycare model|Traditional Chinese Medical (TCM) daycare model provides multiple approaches of traditional Chinese medical treatment, including 5 tones of Chinese music, massage for meridians and collaterals, acupuncture, and patient education. The treatment course is one time a week, for 12 weeks (12 treatments in total).
223871869|NCT05957016|PROCEDURE|CIETAI-R|"1. phase I: (1) Chemo-Immulo-embolization via Tumor Arterial, CIETAI: DSA guided tumor artery infusion of oxaliplatin 130 mg/m2+PD-1 inhibitor (Tirelizumab) 200mg, followed by gelatin sponge particles (350-560um) embolization~2. phase II: Chemoradiotherapy: IMRT：45Gy/25f/5w+capecitabine 1000，po. Bid d1-14, q3w Tirelizumab)200mg ivggt, d1, q3w"
223871870|NCT04960098|PROCEDURE|arthroplasty|patient with hip and knee osteoarthritis underwent hip and knee arthroplasty
223871871|NCT02678936|BIOLOGICAL|PRP|Application of platelet-rich plasma during surgery
223871872|NCT02618486|PROCEDURE|Non surgical periodontal therapy|NSPT includes oral hygiene education, scaling root planing and mouth wash
223871873|NCT04750044|OTHER|early refeeding|In the early refeeding group, oral diet is started 24 hours after PEP is confirmed. The oral diet starts with SOW (Sips of water) and builds up sequentially in the order of clear liquid diet-soft diet, considering patient tolerability.
223871874|NCT04750044|OTHER|delayed refeeding|In the delayed refeeding group, oral diet is started after confirmation of restoring of normal bowel sound, pain decreasing below VAS 2. The oral diet starts with SOW (Sips of water) and builds up sequentially in the order of clear liquid diet-soft diet, considering patient tolerability.
223871875|NCT01839526|DRUG|Iohexol|Evaluations of renal and cardiac function are standard-of-care in young patients with Fabry disease. This study uses the more precise iGFR measurement of renal function. No investigational drug will be administered in this study for the treatment of Fabry disease.
223871876|NCT02387242|DRUG|Rifampicin|Single oral dose of rifampicin
223871877|NCT00661869|OTHER|Wellness Program|36 weeks of educational and supportive interventions
223871878|NCT04445870|OTHER|data record|Data record on registers without medical files
223871879|NCT04629625|BIOLOGICAL|End-range mobilization|End-range mobilization performed in end-range of the tibiofemoral joints' flexion and extension
223871880|NCT04629625|BIOLOGICAL|Non end-range mobilization|Non end-range mobilization performed in tibiofemoral joints' loose position
223871881|NCT04629625|BIOLOGICAL|Placebo|Hands-on technique performed in end-range of the tibiofemoral joints' flexion and extension
223871882|NCT00244959|DRUG|anastrozole|1 mg orally daily for 12 months
223871883|NCT00244959|PROCEDURE|adjuvant therapy|treatment received after breast cancer surgery
223871884|NCT00903851|DRUG|Lidoderm|Patients participated in an 8-week treatment period; patients at one site were to continue treatment for the entire 8 weeks while patients at two sites were to terminate treatment after 3 weeks. Commercially available Lidoderm® (lidocaine patch 5%) was provided to each patient with up to four patches applied topically 18 hours on, 6 hours off per day to the area of maximal peripheral neuropathic pain.
223871885|NCT02148185|DRUG|MT-1303|
223871886|NCT02773524|DRUG|Regorafenib|Regorafenib is the experimental intervention in this study. Regorafenib will be self-administered by participants at 160mg (4 x 40mg tablets) orally once daily on days 1-21 of each 28 day cycle plus best supportive care until progression or prohibitive toxicity as defined by the protocol.
223871887|NCT02773524|OTHER|Placebo|Placebo (matching in appearance to regorafenib) made of microcrystalline cellulose, will be self-administered by participants at 160mg (4 x 40mg tablets) orally once daily on days 1-21 of each 28 day cycle plus best supportive care until progression or prohibitive toxicity as defined by the protocol.
223871888|NCT05096559|DEVICE|Microcirculation cytocam|Visualization of tongue microcirculation
223871889|NCT04907513|OTHER|Assessment of the Motivational State|A motivational interviewing algorithm developed in Rothschild Hospital for this study will be used. The results range between 0% (worst motivational state) to 100% (best motivational state).
223871890|NCT02318407|DRUG|AMG 403|AMG 403 for the treatment of subjects with osteoarthritis
223871891|NCT02318407|DRUG|Placebo|contains no active drug
223871892|NCT05457049|DIAGNOSTIC_TEST|Molecular residual disease test|OncoMRD Lung
223871893|NCT01634516|BEHAVIORAL|Dietary support|Face to face intervention plus subsequent telephone support
223871894|NCT01634516|BEHAVIORAL|No dietary support|No face to face intervention or subsequent telephone support
223871895|NCT02894658|DEVICE|LipiFlow system|LipiFlow System is an in-office FDA approved treatment that relieves meibomian gland obstruction through the use of heat and pulsatile pressure.
223871896|NCT02894658|PROCEDURE|Warm compresses|"Warm compresses will be applied to fellow eye and that eye will undergo daily treatment with eyelid scrubs using a warm wash cloth and no tears baby shampoo every morning and warm compresses on the eyelids for 5-10 minutes twice a day. Patients will be instructed on how to perform proper lid hygiene at the initial visit."
223871897|NCT03231358|BEHAVIORAL|Our Family Our Future|Our Family Our Future is a 'selective' behavioral prevention program, designed to address HIV/STI acquisition, sexual risk behavior, and depression among adolescents (ages 14-16) in communities with high HIV prevalence and from families where adolescents and parents already exhibit mild, potentially troublesome, depressive symptoms but do not reach the threshold for further screening for a significant clinical depressive disorder. Participants receive the intervention in a community setting, in a facilitated group format. The intervention is comprised of 3-hour sessions, held weekly for 3 consecutive weeks with an individual family meeting in the third or fourth week depending on family desires.
223871898|NCT02804425|OTHER|actor-spectator|"actor-spectator group : actor at least once during the simulation session"
223871899|NCT02972944|PROCEDURE|Laparoscopic cholecystectomy|
223871900|NCT02972944|PROCEDURE|Non-operative treatment|
223871901|NCT00255359|DRUG|XTL-2125|
223871902|NCT04625231|BEHAVIORAL|Educational Shared-Decision Making Tool|Patients received a short video presentation on pain management, use of over the counter medication, side effects of opioids and over-the-counter medications and ability to choose the amount of opioid pills up to the standard care amount.
223871903|NCT05712993|PROCEDURE|V2 thermal radio frequency|V2 targeted thermal radio frequency safely without sustained V3 stimulation
223871904|NCT00575614|DRUG|prucalopride|1 mg o.d.
223871905|NCT00575614|DRUG|placebo|o.d.
223871906|NCT05316246|DRUG|Brentuximab Vedotin in Combination with Tislelizumab|Brentuximab vedotin will be administered after diluted with 100 ml normal saline as an IV infusion over approximately 30 minutes on Day 1 of each 21-day cycle at a dose of 1.8 mg/kg. Tislelizumab will be administered after diluted with 100 ml normal saline as an IV infusion over approximately 30 minutes on Day 1 of each 21-day cycle at a fixed dose of 200 mg. The rationale of fixed dose of Tislelizumab is according to the drug description, which is based on previous I/II phase clinical trial results of Tislelizumab. The time interval between administration of tislelizumab and brentuximab vedotin should be not less than 2 hours, and thereafter, the dosing cycle of tislelizumab is synchronized with that of brentuximab vedotin.
223871907|NCT00156741|DEVICE|Vitatron C50 D Model C50A2 of Vitatron C60 DR model C60A2|
223871908|NCT00156741|PROCEDURE|Required pacemaker setting|
223871909|NCT02240446|DEVICE|Active tDCS|2mA stimulation for 20 minutes twice a day for five consecutive days
223871910|NCT02240446|DEVICE|Sham tDCS|2mA for 30 seconds twice a day for five consecutive days
223871911|NCT05238480|DEVICE|XC mouthguard|Use of a Xtreme Conventional custom-made mouthguard while playing rugby
223871912|NCT05238480|DEVICE|XP mouthguard|Use of a Xtreme Pro custom-made mouthguard while playing rugby
223871913|NCT02615769|BEHAVIORAL|focused information of spirometry in the invitation|Focused information of spirometry in the invitation to the preventive health check compose the intervention in this trial.
223871914|NCT02615769|BEHAVIORAL|standard invitation|The active comparator will receive a standard invitation to the preventive health checks. The preventive health checks in the active comparator group and the intervention group are identical.
223871915|NCT03532906|DRUG|TAP Block|Injection of Bupivacaine 0.5% 20 ml into the thickness of the right abdominal wall and of Bupivacaine 0.5% 10 ml into the surgical wounds.
223871916|NCT03532906|DRUG|Control|Injection of Bupivacaine 0.5% 10 ml into the surgical wounds
223871917|NCT04974450|DIETARY_SUPPLEMENT|Trigona honey|composition : vitamin C 0.15%, Protein 1.32%, lipid 0.23%, carbohydrate 64.12%, beta carotene 10.61 ppm, Calcium 273,23, magnesium 338.94, zinc 12.49 ppm, and acidity 5.76. Total polyphenol 133.52 ppm, total flavonoid 159.62 ppm. This liquid has a sour profile
223871918|NCT04974450|DIETARY_SUPPLEMENT|control|Artificial honey with fructose, Glucose, pure honey (2,271%), citric acid, and lime extract (0,076%).
223871919|NCT03011489|DEVICE|Vacuum formed aligners|Infants will receive this appliance which is a maxillary plate with nasal stent in addition to taping on the upper lip (taping is a modified step in Figueroa's technique.
223871920|NCT05208125|BIOLOGICAL|ChAdOx1.HTI at week 0, ConM SOSIP.v7 at weeks 4, 12 and 28, and MVA.HTI at week 22 (CSSMS).|Intramuscular administration of 1 x ChAdOx1.HTI (5x1010 Vp), 3 x ConM SOSIP.v7 (100μg) adjuvanted with MPLA liposomes (500μg), and 1 x MVA.HTI (2x108pfu)
223871921|NCT05208125|OTHER|Normal saline solution|Intramuscular administration of normal saline solution
223871922|NCT03433586|DRUG|Aspirin 81 mg|81mg of aspirin to be taken daily for 10-14 days
223871923|NCT03433586|DRUG|Placebo|Placebo pill (visually identical to aspirin pill) to be taken daily for 10-14 days
223871924|NCT03764475|DRUG|Roflumilast|Roflumilast cream 0.3% for topical application
223871925|NCT00936507|OTHER|Energy Density/Portion Size|
223871926|NCT06973135|PROCEDURE|Bioceramic sealer root canal obturation|Mandibular molars root canal obturation with bioceramic sealer after non surgical endodontic retreatment and then immediate periapical radiograph will be done to record PAI
223871927|NCT06973135|PROCEDURE|resin sealer root canal obturation|non surgical root canal retreatment of mandibular molar teeth will be done using resin based sealer in obturation and periapical radiograph will be taken immediately to record PAI
223871928|NCT00979537|DRUG|Nisoldipine Extended-release Tablets, 40 mg|
223871929|NCT00979537|DRUG|Sular Tablets, 40 mg|
223871930|NCT00390299|BIOLOGICAL|Carcinoembryonic Antigen-Expressing Measles Virus|Given via injection into resection cavity or around tumor bed and/or IT
223871931|NCT00390299|OTHER|Laboratory Biomarker Analysis|Correlative studies
223871932|NCT00390299|PROCEDURE|Therapeutic Conventional Surgery|Undergo en bloc resection
223871933|NCT02751138|PROCEDURE|Surgery|Tumor resection
223871934|NCT01898741|RADIATION|24 Gy in 3 fractions|
223871935|NCT05887180|OTHER|PräVaNet-Intervention|interdisciplinary and digitally supported prevention concept
223871936|NCT02517450|BEHAVIORAL|an adventure-based training programme|The programme consisted of five education sessions (around 75 minutes each) and a day's adventure-based training camp at the end of the academic year
223871937|NCT02517450|OTHER|a placebo control programme|Subjects in the control group were invited to attend five 75-minute sessions of leisure activities, organised by a community centre, which included a cartoon film show, handicraft workshops, a health talk on the prevention of influenza and age-appropriate physical leisure activities, such as table tennis, badminton, chess and Chinese billiards. Additionally, they were invited to join a day visit to Hong Kong Ocean Park at the end of the academic year.
223871938|NCT03592069|DRUG|10 day concomitant regimen|10 Day Concomitant Hp therapy Concomitant for 10 days, including 40 mg of esomeprazole bid, amoxicillin 1g bid, clarithromycin 500mg bid and metronidazole 500mg bid
223871939|NCT03592069|DRUG|14 day hybrid regimen|14 Day Hybrid Hp therapy Hybrid for 14 days, including 40 mg of esomeprazole bid and amoxicillin 1g bid, for the first 7 days followed by esomeprazole 40mg bid, amoxicillin 1g bid, clarithromycin 500mg bid and metronidazole 500mg bid, for another 7 days.
223871940|NCT02512341|DEVICE|Computer Aided Auscultation (CAA)|
223871941|NCT04481672|DRUG|Magnesium Sulfate|Intravenous infusion of magnesium sulfate prior to intraoperative chemotherapy with cisplatin.
223871942|NCT05075941|OTHER|Vaccination coverage|proportion of people declaring to have received at least one dose of vaccination against COVID-19 among target population
223871943|NCT05517564|DRUG|GM-60106|The participants will receive a single oral dose between 2.5 to 100 mg for Part A (SAD), Part B (MAD) once daily for 14 days, and for Part C (MAD) once daily for 28 days.
223871944|NCT05517564|OTHER|Placebo|Placebo-to-match GM-60106 capsules
223871945|NCT00970359|BIOLOGICAL|AZD6244|"Within 1 week of starting the study: Low iodine diet~The patient will receive three bottles of capsules containing the drug AZD6244. Each capsule contains 25 milligrams of AZD6244. They will take 3 capsules orally, by mouth twice a day for 4 weeks. AZD6244 should be taken on an empty stomach (either one hour before or 2 hours after meals). AZD6244 capsules should be taken with water only. Lesional dosimetry with iodine-124 PET will be done twice, at the beginning and at the end of the study. This is done the same way that a radioactive iodine scan is done and is spread out over 5 days. It requires injection with human recombinant TSH (Thyrogen) on day 1 and 2, as well as blood tests on day 1 and day 5. On day 3, you will receive the iodine-124 in form of an oral drink, and the PET scan will be obtained on day 5. You will need to follow a low iodine diet starting 5 days before and throughout the process."
223871946|NCT04572191|DIAGNOSTIC_TEST|CERAMIDE LEVEL IN BLOOD|BY ELISA ASSAY TO DETECT CERAMIDE LEVEL IN BLOOD IN ANTERIOR STEMI PATIENTS
223871947|NCT01565148|DRUG|iCo-007 350 mcg|iCo-007 (350 μg) as an intravitreal injection at baseline followed by another iCo-007 dose (350 μg) at month 4
223871948|NCT01565148|DRUG|iCo-007 700 mcg|iCo-007 (700 μg) as an intravitreal injection at baseline followed by another iCo-007 dose (700 μg) at month 4
223871949|NCT01565148|DRUG|iCo-007 350 mcg and Laser|iCo-007 (350 μg) as an intravitreal injection at baseline followed 7 days later by laser photocoagulation. At M4, intravitreal injection of iCo-007 (350 μg) will be given as mandatory treatment. If the eye also meets retreatment criteria, it will also receive the second laser photocoagulation
223871950|NCT01565148|DRUG|Ranibizumab and iCo-007 350 mcg|Ranibizumab (0.5 mg) intravitreal injection at baseline followed by iCo-007 (350 μg) intravitreal injection 2 weeks later; re-treatment with ranibizumab (0.5 mg) mandatory at M4 followed by iCo-007 (350 μg) 2 weeks later
223871951|NCT03832894|DRUG|Estradiol Valerate|Oestradiol supplementation starting from day of trigger through out the luteal phase
223871952|NCT03920566|OTHER|Anti-Xa level|Anti-Xa level taken before commencing enzalutamide and repeated after 4 weeks of treatment
223871953|NCT04329364|COMBINATION_PRODUCT|Laser Haemorrhoidoplasty (LAH)|Using a laser diode to cause coagulative necrosis to the haemorrhoidal cushion
223871954|NCT04329364|PROCEDURE|Open milligan-morgan conventional haemorrhoidectomy|conventional excisional haemorrhoidectomy
223871955|NCT05464316|DEVICE|Adjustable Transobturator Male System|The ATOMS sling was developed in 2008 by Agency for Medical Innovations GmbH in Austria. It is a self-anchoring adjustable system which supports the bulbar urethra dorsally and uses the trans obturator approach. This device gained its fame in the male sling scene by being adjustable, which theoretically makes it more efficacious than its competitors.
224268890|NCT04636034|PROCEDURE|"Sham-block with Placebo (Isotone NaCl)"|Block performed with bilaterally inserted q-tips with isotone NaCl. The q-tips are inserted a maximum of 3 cm into the nasopharynx thus not reaching the mucus above the ganglion.
224268891|NCT04538677|DEVICE|Video consultation|A two-way audio and visual connection between patients and surgeons
224268892|NCT03420053|BIOLOGICAL|PfSPZ Vaccine|Aseptic, purified, metabolically active, non-replicating, radiation-attenuated, cryopreserved Pf sporozoites.
224268893|NCT03420053|OTHER|Normal Saline Placebo|0.9% sodium chloride solution
224268894|NCT03420053|BIOLOGICAL|PfSPZ Challenge|Aseptic, purified, live, infectious, cryopreserved Pf sporozoites.
224268895|NCT00099151|BEHAVIORAL|Caloric Restriction (CR)|
223871956|NCT05464316|DEVICE|Artificial Urinary Sphincter|"The AMS800™, which is by far the most frequently implanted AUS, was first marketed in 1983 and was developed by America Medical Holdings in Minnesota. Today, the AUS has been given the title gold standard for surgical treatment for PPI. This device is an inflatable cuff which wraps around the urethra to supply circumferential pressure. It has a control pump, which is found in the scrotum and is operated by the patient. The patient can void simply by squeezing the pump, which brings the fluid from the cuff to a reservoir and release the pressure around the urethra. The cuff is then automatically refilled with fluid within a couple of minutes to close back the sphincter."
223871957|NCT01061671|DRUG|simvastatin|40 mgms of simvastatin daily
223871958|NCT01061671|DRUG|Placebo|Matched placebo pill daily
223871959|NCT06403956|OTHER|Training with video|The hand washing skills of the students in the three groups were evaluated by a researcher by observing the hand washing of the students in the sink with the Hand Washing Skills Checklist. After the students were given theoretical information about hand hygiene, including the importance of hand washing, the situations in which hands should be washed, and the steps of hand washing skills, the laboratory practice was started immediately afterwards. In the laboratory, hand washing training was given to the video group with the hand washing video developed by the researchers within the scope of the course. Afterwards, the same researcher who made the first observation re-evaluated the handwashing skills of all students in the sink by filling out the Handwashing Skill Checklist.
223871960|NCT06403956|OTHER|Training with paint|The hand washing skills of the students in the three groups were evaluated by a researcher by observing the hand washing of the students in the sink with the Hand Washing Skills Checklist. After the students were given theoretical information about hand hygiene, including the importance of hand washing, the situations in which hands should be washed, and the steps of hand washing skills, the laboratory practice was started immediately afterwards. In the laboratory, hand washing training was given to the paint group with the demonstration method using acrylic paint instead of soap. Afterwards, the same researcher who made the first observation re-evaluated the handwashing skills of all students in the sink by filling out the Handwashing Skill Checklist.
223871961|NCT05368831|DRUG|NST-1024|Drug Drug interactions between NST-1024 and caffeine (and paraxanthine), flurbiprofen, omeprazole, metoprolol, and midazolam
223871962|NCT05110534|BEHAVIORAL|additional oral hygiene appointments|Two additional preventive sessions including oral hygiene instructions one week before the date of the general anaesthesia treatment and at the control visit about a week after the general anaesthesia.
223871963|NCT05326607|DEVICE|Prototype of adaptive eyeglasses|The tested investigational medical device is a prototype of semi-integrated eyeglasses.
223871964|NCT05326607|DEVICE|Comparator|The comparator is either a pair of progressive lenses that provide clear vision at both distance and near vision, either, for wearers who have rejected progressive glasses, an alternative solution providing clear vision at both distance and near vision which can consist of bifocal glasses, multifocal or monovision lenses, multiple pairs of glasses or one pair for cases of emmetropia.
224268896|NCT00099151|BEHAVIORAL|Exercise|
224268897|NCT01726933|DRUG|LAS41008|gastric resistant tablet, weekly up-titration up to maximal tolerated dosage
224268898|NCT01726933|DRUG|LASW1835|gastric resistant tablet, weekly up-titration up to maximal tolerated dosage
224268899|NCT01726933|DRUG|Placebo|gastric resistant tablet, weekly up-titration up to maximal tolerated dosage
224268900|NCT01076491|DRUG|mannitol|inhaled mannitol - single doses of either 70 mg or 90 mg
224268901|NCT02955628|DRUG|Ibrutinib-RICE|Ibrutinib will be added to RICE regimen for patients not achieving a complete remission at interim PET-2. Ibrutinib will be continued for up to 1 year after autologous transplantation.
224268902|NCT02665962|OTHER|Perioperative Caloric Restriction Program|
224268903|NCT03152162|DEVICE|iTotal PS KRS|Total knee arthroplasty for treatment of osteoarthritis
224268904|NCT04671147|PROCEDURE|Preoperative traction|Compare two methods of preoperative traction (Cotrel traction exercises and skull tongs femoral traction)
224268905|NCT05055713|PROCEDURE|Endoscopic therapy+ beta blockers|Endoscopic variceal ligation (EVL) is for the secondary prophylaxis of esophageal variceal hemorrhage,and Cyanoacrylate injection is for gastric varices (GV).A standard dose of NSBB (carvedilol) was applied to patients according to the Baveno VI recommendations if there were no contraindications.
224268906|NCT05055713|PROCEDURE|Endoscopic therapy+ PSE+beta blockers|Endoscopic variceal ligation (EVL) is for the secondary prophylaxis of esophageal variceal hemorrhage,and Cyanoacrylate injection is for gastric varices (GV).A standard dose of NSBB (carvedilol) was applied to patients according to the Baveno VI recommendations if there were no contraindications.Partial splenic embolization (PSE) is one of the intra-arterial therapeutic approaches to embolize 60-80% splenic blood flow.
224268907|NCT05055713|PROCEDURE|Endoscopic therapy|Endoscopic variceal ligation (EVL) is for the secondary prophylaxis of esophageal variceal hemorrhage,and Cyanoacrylate injection is for gastric varices (GV).
224268908|NCT05055713|PROCEDURE|Endoscopic therapy+ PSE|Endoscopic variceal ligation (EVL) is for the secondary prophylaxis of esophageal variceal hemorrhage,and Cyanoacrylate injection is for gastric varices (GV).Partial splenic embolization (PSE) is one of the intra-arterial therapeutic approaches to embolize 60-80% splenic blood flow.
224268909|NCT05055713|PROCEDURE|Endoscopic therapy+Somatostatin|The first dose of 250 was injected intravenously, followed by a continuous iv infusion of 250 for 3-5 days. Endoscopic variceal ligation (EVL) is for the acute bleeding of esophageal variceal hemorrhage,and Cyanoacrylate injection is for gastric varices (GV).
224268910|NCT05055713|PROCEDURE|Endoscopic therapy+PSE+Somatostatin|The first dose of 250 was injected intravenously, followed by a continuous iv infusion of 250 for 3-5 days. Endoscopic variceal ligation (EVL) is for the acute bleeding of esophageal variceal hemorrhage,and Cyanoacrylate injection is for gastric varices (GV).Partial splenic embolization (PSE) is one of the intra-arterial therapeutic approaches to embolize 60-80% splenic blood flow.
224268911|NCT05502055|OTHER|Individual interviews|One on One interviews by Zoom video conferencing, \< 2 hours in duration
224268912|NCT05502055|OTHER|Focus Groups|Focus Groups discussions by Zoom video conferencing, \< 2 hours in duration
224268913|NCT05502055|OTHER|National Survey|Survey conducted online and distributed nationally
224268914|NCT02621190|DRUG|cabazitaxel|25mg/m2 q3w
224268915|NCT00453258|OTHER|Eye Examination|Subjects receiving eye examination
223871965|NCT06079515|PROCEDURE|Suprascapular Nerve Block|SSNB group: The patients were asked to sit comfortably in the chair, and the transducer was placed on the spine of the scapula in the coronal plane and moved laterally to observe the supraspinatus notch and the suprascapular nerve. The injection mixture was applied in-plane with a 22-gauge, 90-mm needle on the suprascapular nerve, under the fascia of the supraspinatus muscle.
223871966|NCT06079515|PROCEDURE|Intraarticular Shoulder Injection|IAI group: The patients were asked to sit on the chair with their hands facing the opposite shoulder, and the transducer was placed slightly below the spina scapula. The humeral head was observed by moving laterally. The injection mixture was applied in-plane with a 22-gauge, 90-mm needle entering the skin at a 45-degree angle and applied to the joint space
223871967|NCT03217669|DRUG|Epacadostat|Epacadostat tablet: 100mg or 300mg
223871968|NCT03217669|DRUG|sirolimus|Sirolimus tablet: 1mg, 2mg, 3mg, or 6mg
223871969|NCT06973616|PROCEDURE|Zirconia crown|A zirconia esthetic crown will be randomly placed on one side of the jaw
223871970|NCT06973616|PROCEDURE|Bioflx crown|A Bioflx esthetic crown will be randomly placed on one side of the jaw
223871971|NCT05431114|DIAGNOSTIC_TEST|MRI|Images of the injured shoulder will then be taken with magnetic resonance (MR) scanner. MRIs of each participant's shoulder will be acquired before and after completion of an exercise protocol.
223871972|NCT06321458|BEHAVIORAL|Intensive weight loss intervention|Intensive weight loss intervention, incl. total meal replacements, behavioural support, and weight loss medication.
223871973|NCT06321458|BEHAVIORAL|Usual care|Usual care
223871974|NCT01834248|BIOLOGICAL|DEC-205/NY-ESO-1 Fusion Protein CDX-1401|Given SC and ID
223871975|NCT01834248|DRUG|Decitabine|Given IV
223871976|NCT01834248|OTHER|Laboratory Biomarker Analysis|Correlative studies
223871977|NCT01834248|DRUG|Poly ICLC|Given SC
223871978|NCT02101190|DRUG|BIA 9-1067|Opicapone, OPC
224268916|NCT02763696|OTHER|Composition of Viginal flora of Child-Bearing women|Use high-throughput sequencing technology to exam Composition of Viginal flora of Child-Bearing women in different menstrual cycle and type of Vaginitis
224268917|NCT04194151|DRUG|Propofol Injection|1, 1.5 or 2 mg/kg of propofol according to the subgroup
224268918|NCT06687330|DEVICE|Tracking Mobility and Health Data with a Smartwatch in Discharged Oncology Patients to Predict Rehospitalization: A Prospective Study|The intervention involves daily monitoring of discharged oncology patients using a smartwatch (Huawei Watch Fit 2) to track physical activity (step count), heart rate, and sleep duration. Data is collected remotely via a smartphone app, allowing real-time tracking of health metrics post-discharge. This intervention is distinct in its focus on correlating mobility and physiological data with the risk of rehospitalization within a 30-90 day period. Patients will also receive recommendations to maintain daily walking routines as part of their post-discharge care. Additionally, quality of life and sleep quality assessments are conducted before discharge and at follow-up visits to provide a comprehensive overview of each patient's post-hospital recovery.
223871979|NCT04141943|OTHER|Virtual reality|The patients who are allocated to the VR arm will receive information about radiotherapy via virtual reality.
223871980|NCT03963128|DIETARY_SUPPLEMENT|Supplementation Vitamin D3|Supplementation of vitamin D3 at a dose of 50.000 IU administered every two months (equivalent of 800 IU per day)
223871981|NCT03963128|DIETARY_SUPPLEMENT|Placebo|Placebo administred every two months
223871982|NCT05640791|DRUG|Cisplatin|25mg/m2；d1, 8, 21 d cycle
223871983|NCT05640791|DRUG|Gemcitabine|1000mg/m2；d1, 8, 21 d cycle
223871984|NCT05640791|DRUG|Nab-paclitaxel|100mg/m2；d1, 8, 21 d cycle
223871985|NCT05640791|DRUG|Durvalumab|1000mg；d1, 21 d cycle
223871986|NCT04720014|BEHAVIORAL|SMART-3RP Group Intervention|"Nine 1.5 hour group sessions focusing on developing:~1. an understanding of stress physiology and the physiology of the relaxation response;~2. a regular practice of eliciting the relaxation response; and~3. cognitive behavioral and positive psychology/resilience skills.~Participants receive a copy of the SMART-3RP session manual and audio recorded guided meditations for independent relaxation practice. Participants are encouraged to practice eliciting the relaxation response daily throughout the study, using the audio recordings or other mind body techniques. Participants will use a practice log to track their practice."
223871987|NCT04835870|DRUG|Zanubrutinib|Zanubrutinib-160mg bid PO d0-d20(1-21d)
223871988|NCT04835870|DRUG|Rituximab|Rituximab-375 mg/m2 i.v d0 (/21d)
223871989|NCT04835870|DRUG|Cyclophosphamide|Cyclophosphamide-750 mg/m2 i.v d1 (/21d)
223871990|NCT04835870|DRUG|Doxorubicin|Doxorubicin-50 mg/m2 i.v d1 (/21d)
223871991|NCT04835870|DRUG|Vincristine|Vincristine-1.4 mg/m2 i.v d1 (/21d)(2 mg max)
223871992|NCT04835870|DRUG|Prednisone|Prednisone-100 mg p.o d1-d5 (/21d)
223871993|NCT02808585|DRUG|PB1046 Injection|Four weekly subcutaneous injections of PB1046.
223871994|NCT02808585|DRUG|Placebo Injection|Four weekly subcutaneous injections of placebo.
223871995|NCT01353170|OTHER|Dialysate calcium concentration|Calcium dialysate concentrations: 1.25, 1.35 and 1.5 mmol/l
223871996|NCT00493402|PROCEDURE|Transarterial chemoembolization (TACE)|drugs and dosage: chemotherapy with lipiodol mixed with EADM 50mg, lobaplatin 50mg, and MMC 6mg, plus particle embolization.
223871997|NCT00493402|PROCEDURE|Transarterial chemoembolization (TACE)|drugs and dosage: chemotherapy with lipiodol mixed with EADM 50mg, lobaplatin 50mg, and MMC 6mg.
223871998|NCT00493402|PROCEDURE|Transarterial chemoembolization (TACE)|Drugs and dosage:chemotherapy with lipiodol mixed with EADM 50mg, plus particle embolization.
223871999|NCT05921708|OTHER|Assessment1|International Physical Activity Questionnaire (IPAQ) (Short)
223872000|NCT05921708|OTHER|Assesment2|Physical Appearance Comparison Scale-Revised (PACS-R)
223872001|NCT05921708|OTHER|Assessment3|Sociocultural Attitudes Towards Appearance Questionnaire -4-Revised (SATAQ-4R)
223872002|NCT05921708|OTHER|Assessment4|Body-Cathexis Scale (BCS)
223872003|NCT05921708|OTHER|Assessment5|Mobile Health, Exercise Preferences and Social Media Questionnaire
223872004|NCT00092664|DRUG|MK0653A, ezetimibe (+) simvastatin / Duration of Treatment: 14 weeks|
223872005|NCT06238869|BEHAVIORAL|Computerized Cognitive Behavioral Therapy|CCBT (Computerized Cognitive Behavioral Therapy) is a unique approach to improving mental well-being. It utilizes computer-based cognitive and behavioral techniques to induce relaxation and regulate emotional responses by targeting specific brain regions. CCBT offers interactive and personalized interventions, empowering individuals to address mental health challenges like depression and anxiety. Its convenience and accessibility through digital platforms make it a practical choice for enhancing emotional well-being.
223872006|NCT06238869|BEHAVIORAL|Music Therapy|Music Therapy can make peoples gradually relax via relaxing and soothing music, and regulate individual psychological emotions through the influence of music on individuals' cerebral cortex, hypothalamus and limbic system, further improve the mood of daily tension and anxiety.
223872007|NCT06238869|BEHAVIORAL|Health education|Health education focuses on providing insights into adolescent mental health, offering practical coping strategies and behavior patterns. It emphasizes the crucial link between parental guidance and the well-being of adolescents. By fostering healthier psychological interactions, it cultivates an environment supportive of adolescent mental health, strengthens family support, and promotes comprehensive development in physical, mental, and cognitive aspects.
223872008|NCT00395603|DRUG|MK0653A, ezetimibe (+) simvastatin / Duration of Treatment: 6 Weeks|
223872009|NCT00395603|DRUG|Comparator: atorvastatin / Duration of Treatment: 6 Weeks|
223872010|NCT05567822|DRUG|Esmolol Hydrochloride|In the esmolol group, patients will receive a bolus dose of esmolol followed by a continuous infusion of esmolol intraoperatively
223872011|NCT05567822|DRUG|normal saline|In the placebo group, patients will receive a bolus dose of normal saline followed by a continuous infusion of normal saline intraoperatively
223872012|NCT01692730|BEHAVIORAL|Enhanced Web Assisted Tobacco Intervention|Subjects at community college campuses will be directed to a cessation website with current Public Health Service Guideline information and effective smoking cessation strategies, and some combination of novel interactive and social network features, including a variety of better-practice features recommended recent literature, and technologically advanced proactive features (e-mails, SMS texting, and social networking).
223872013|NCT01692730|BEHAVIORAL|Basic Web Assisted Tobacco Intervention|Subjects at community college campuses will be directed to a cessation website with current Public Health Service Guideline information and effective smoking cessation strategies, and with minimal interactive web-based features.
223872014|NCT03668288|OTHER|Data record and questionnaires passation|Data record and questionnaires passation (SF36)
223872015|NCT02081274|PROCEDURE|Surgery for congenital heart disease|
223872016|NCT00955695|DRUG|erlotinib hydrochloride|
223872017|NCT00955695|DRUG|gefitinib|
223872018|NCT00955695|OTHER|questionnaire administration|
223872019|NCT00955695|PROCEDURE|quality-of-life assessment|
223872020|NCT00955695|RADIATION|whole-brain radiation therapy|
223872021|NCT03143348|PROCEDURE|Single blood draw|One blood draw of 0.5 ml volume prior to discharge
223872022|NCT03143348|PROCEDURE|Multiple blood draws|Blood draw at 6 peri-operative time points.
223872023|NCT03143348|PROCEDURE|Multiple blood draws|Blood draw at 7 peri-operative time points
223872024|NCT01199575|DRUG|Revlimid|
223872025|NCT01199575|DRUG|Rituximab|
223872026|NCT01849055|DRUG|Placebo|Administered orally
223872027|NCT01849055|DRUG|LY3023703|Administered orally
223872028|NCT01849055|DRUG|Celecoxib|Administered orally
223872029|NCT00223795|DEVICE|Single point cane|Participants with symptomatic knee osteoarthritis will undergo gait evaluation with and without a single point cane.
223872030|NCT01239316|OTHER|Laboratory Biomarker Analysis|Correlative studies
223872031|NCT01239316|OTHER|Pharmacological Study|Correlative studies
223872032|NCT01239316|DRUG|Vismodegib|Given PO
223872033|NCT00475501|DRUG|Testosterone Enanthate|125 mg, i.m. injection, once/week, for 52 weeks
223872034|NCT00475501|DRUG|Finasteride|5 mg, oral, once/day, for 52 weeks
223872035|NCT00475501|OTHER|Placebo|Placebo
223872036|NCT02139943|DRUG|Canagliflozin 100 mg|Canagliflozin capsule of 100 mg dose will be taken orally, before the first meal of the day.
223872037|NCT02139943|DRUG|Canagliflozin 300 mg|Canagliflozin capsule of 300 mg dose will be taken orally, before the first meal of the day.
223872038|NCT02139943|DRUG|Placebo|Matching placebo capsule will be taken orally, before the first meal of the day.
223872039|NCT06193850|OTHER|Observation during time|Evaluation through clinical investigation and questionnaires useful for evaluating the patient's psycho-physical conditions
223872040|NCT05167656|OTHER|Intraoral manual therapy|Six intraoral manual therapy sessions based on ischemic compression and pain pressure release of the temporomandibular region muscles, applied bilateral.
223872041|NCT05167656|OTHER|Extraoral manual therapy|Six extraoral manual therapy sessions based on ischemic compression, pain pressure release and pressure sliding of the temporomandibular region muscles, applied bilateral.
223872042|NCT05167656|OTHER|Exercise and counselling|"Information about etiology, contributing and related factors, natural history and prognostic of the pathology of temporomandibular disorders.~Counselling based on: diet, habits like tabacism, stress and anxiety control, physical activity and awareness of dental clenching.~Exercise daily program based on active and passive mobility of the temporomandibular joint, stretching exercises and self massage."
223872043|NCT05684094|BEHAVIORAL|Sleep extension and advance|"Participants in the sleep extension and advance condition will maintain a stable sleep schedule that extends sleep duration and advances bedtime by 90 min relative to weekday bedtime. This chronotherapeutic manipulation will include blocking phase-delaying light in the evening using goggles with orange lenses (blue blockers) beginning 2 h prior to bedtime, and 30 min of 506 lux blue-green light exposure in the morning beginning at rise time using bright light goggles (ReTimer Pty Ltd., Australia). Schedule and chronotherapy adherence will be reinforced using motivational techniques (e.g., securing motivation, preplanning, problem-solving), requiring participants to text the study coordinator and complete morning assessments at rise time, and monetary incentives."
223872044|NCT05684094|BEHAVIORAL|Regular sleep duration and timing|Participants in the regular sleep duration and timing condition will keep a stable sleep schedule that matches their typical weekday sleep opportunity and timing. Schedule adherence will be reinforced using motivational techniques (e.g., securing motivation, preplanning, problem-solving), requiring participants to text the study coordinator and complete morning assessments at rise time, and monetary incentives.
223872045|NCT05498818|DIETARY_SUPPLEMENT|Synaquell|7.9 grams (1 scoop) of Synaquell powder mixed with 12 ounces of water two times per day for the duration of the sport season. The daily amount taken by each participant is (15.8 grams).
223872046|NCT05498818|DIETARY_SUPPLEMENT|Placebo|7.9 grams (1 scoop) of placebo powder mixed with 12 ounces of water two times per day for the duration of the sport season. The daily amount taken by each participant is (15.8 grams). The placebo looks, smells, and tastes like Synaquell but does not contain active ingredient.
223872047|NCT03268577|OTHER|Internet-Based Intervention|Complete ASA24
223872048|NCT03268577|OTHER|Internet-Based Intervention|Complete ACT24 reporting
223872049|NCT03268577|DEVICE|Monitoring Device|Wear accelerometer and inclinometer physical activity monitors
223872050|NCT03268577|OTHER|Questionnaire Administration|Ancillary studies
223872051|NCT05202912|DRUG|IDX-1197(After a meal)|randomized, open-label, single-dose, 2-period, 2-sequence crossover study in healthy male Korean and Caucasian volunteers
223872052|NCT05202912|DRUG|IDX-1197(fasting)|open-label, single-dose study in Chinese male volunteers
223872053|NCT01429350|DRUG|intravenous (IV) recombinant human tissue plasminogen activator (rtPA)|0.9mg/kg to a maximum of 90mg
223872054|NCT01429350|DEVICE|Penumbra System|The Penumbra System is an aspiration based mechanical thrombectomy device
223872055|NCT04526834|DRUG|CD30.CAR-T|"Bendamustine and Fludarabine (3 days)~Dose level 1: 2 x 108 cell/m2 CD30.CAR-T (Day 0)~Dose level 2: 4 x 108 cell/m2 CD30.CAR-T (Day 0)~Dose level 3: 6 x 108 cell/m2 CD30.CAR-T (Day 0)"
223872056|NCT00288392|DRUG|Soluble beta-1,3/1,6-glucan|
223872057|NCT00694447|PROCEDURE|Acupuncture|
223872058|NCT02990117|OTHER|No Intervention|No Intervention
223872059|NCT05817097|DRUG|Dipeptidyl peptidase-4 inhibitor|The definition of antidiabetic drug use is defined as a case in which an antidiabetic drug was prescribed for at least 2 months before stroke and the duration of treatment for stroke coincided with the prescribed duration of the drug.
223872060|NCT03750968|DRUG|Carotenoid Group|Softgel active ingredients: Lutein 10 mg and Zeaxanthin 2 mg in safflower oil
223872061|NCT03750968|DIETARY_SUPPLEMENT|Control Group|Placebo ingredients: Safflower oil
223872062|NCT03161327|DEVICE|ABI using QuantaFlo™|"Perform Digital ABI:~* Will be performed by the nurse/medical assistant with training to perform this test~* The patient will be placed in the supine position, with the arms and legs at the same level as the heart, for a minimum of 5 minutes before measurement.~* The optical sensor (similar to a pulse oximeter) will be placed sequentially in the fingers of the hands and feet: Right and left hand fingers and then right and left feet toes.~* Usually each digit takes about 15 seconds to obtain a waveform~* At the end of 60 seconds, an automated digital ABI will be generated.~Clinical course: If based on Screening questionnaire and digital ABI, I. Patient is diagnosed with PAD- the referring physician and patient will receive a phone call about the same. He/ she will then be advised any further testing/ referral to IR clinic.~II. There is no evidence of PAD- no further action will be taken. The patient will be informed of the same."
223872063|NCT02699385|OTHER|Oral Rehydration Therapy|Each participants will initiate ORT in the physician's office on Day 1.
223872064|NCT02699385|DRUG|Domperidone|Each participants will receive Domperidone 0.25 milligram per killogram (mg/kg) of body weight of oral suspension thrice daily for up to 7 days.
223872065|NCT02699385|DRUG|Placebo|Each participants will receive placebo oral suspension thrice daily for up to 7 days.
223872066|NCT00088413|BIOLOGICAL|PANVAC-V|Patients receive 2 x 10(8) pfu PANVAC-V (vaccinia) subcutaneously on Day 1.
223872067|NCT00088413|BIOLOGICAL|PANVAC-F|Patients receive 1 x 10(9) pfu PANVAC-F (fowlpox) or about days 15, 29, and 43 then every month for 12 doses then every 3 months until disease progression or toxicity.
223872068|NCT00088413|DRUG|Sargramostim (GM-CSF, Leukine)|100g sargramostim will be given subcutaneously at the site of the vaccination on each vaccination day and for three consecutive days thereafter.
223872069|NCT06369701|DEVICE|Compressive tissue floss band|Compressive tissue flossing (CTF) is a compressive technique that uses a latex elastic band to compress the tissues and restrict the circulation of fluids in the targeted area for a short time. CTF acts on the mechanoreceptors in the underlying fascial layers, causing blood reperfusion of the compressed tissue, and/or causing fascial shearing and the sliding potential of the fascia to be restored (Starrett \& Cordoza, 2015). Proposed benefits from references include improving joint mobility in the joints of the limbs (Starrett \& Cordoza, 2015), improving muscular power, and decreasing pain with motion (Angelopoulos et al., 2021) (Cage et al., 2022) (Jianhong et al., 2021).
223872070|NCT00922220|OTHER|stationary bike|Participants rode a stationary bike for five minutes
224268919|NCT06685900|DEVICE|digital therapeutics|Early intervention group will undergo app usage training, disease education, blood pressure measurements, orthostatic blood pressure measurements, and postprandial blood pressure measurements up to the third week of participation. From the fourth week onward, for a duration of 12 weeks, non-pharmacological treatment education will be provided through a digital therapeutic, and blood pressure will be measured according to a specified schedule.
223872071|NCT00922220|OTHER|lumbar extension exercise|Participants performed four sets of fifteen lumbar extension exercises over fifteen minutes
223872072|NCT00922220|OTHER|spinal manipulative therapy|participants received spinal manipulative therapy to the low back
223872073|NCT01094613|DRUG|Delayed Release 6 mercaptopurine|"Delayed Release oral tablet for ileal drug delivery, 80 mg, once nightly before bedtime, for 12 weeks.~Since the study drug must be blinded, patients randomized to this arm will receive the following: 80 mg DR-6MP: 2 active 40 mg DR-6MP tablets."
224268920|NCT06685900|DEVICE|digital therapeutics|Late intervention group will undergo app usage training, disease education, blood pressure measurements, orthostatic blood pressure measurements, and postprandial blood pressure measurements up to the ninth week of participation. From the tenth week onward, for a duration of 6 weeks, non-pharmacological treatment education will be provided through a digital therapeutic, and blood pressure will be measured according to a specified schedule.
223872074|NCT01094613|DRUG|6 Mercaptopurine|Oral tablet(s) to be administered once daily in the AM, for 12 weeks.Purinethol is available only as a 50 mg tablet; patients randomized to this arm will receive varying doses (dependent on baseline body weight and AE profile) throughout the study;and study drug to be blinded. Therefore, patients randomized to this arm to receive combination active Purinethol/comparable placebo. For ex: 50 mg Purinethol= 1 active 50 mg tablet, 2 comparable placebo tablets; 100 mg Purinethol = 2 active 50 mg tablets, 1 placebo tablet; 150 mg Purinethol = 3 active 50 mg tablets. Patients receiving 75 mg or 125 mg will receive alternating daily doses of 50 and 100 mg, or 100 and 150 mg, respectively, to arrive at a weekly average dose of 75 mg or 125 mg.
223872075|NCT01663584|PROCEDURE|Blood draw|
223872076|NCT04951362|DRUG|intranasal spray ivermectin|intranasal spray of saline
223872077|NCT00716924|DRUG|Clopidogrel|300 mg
223872078|NCT00716924|DRUG|Clopidogrel|600 mg
223872079|NCT04177459|BEHAVIORAL|Health promoting dialogue|Health promoting dialogues based on the salutogenic theory, focusing on resources within and around the individual, and on coping strategies. Seven individual dialogues for each participant, individually adapted due to the fatigue. The intervention is offered in the participants home or at the local hospital, dependent on the participants fatigue and what is preferred.
223872080|NCT04177459|OTHER|standard treatment / treatment as usual|Follow-up from primary and secondary health care, and from schools.
223872081|NCT02617069|BIOLOGICAL|botulinum toxin injection|
223872082|NCT02617069|BIOLOGICAL|0.9% normal saline injection|
223872083|NCT02617069|DEVICE|Implantable loop recorder|
223872084|NCT01692483|DRUG|Abiraterone acetate|Abiraterone 1000 mg (4 x 250 mg tablets) taken orally once daily
223872085|NCT01692483|DRUG|Prednisone|Prednisone or prednisolone 5 mg tablet taken orally twice daily
223872086|NCT03399669|DRUG|gefitinib|Patients will be treated 250 mg/day of gefitinib orally (1 cycle for 28 days). Cycles were repeated until disease progression, unacceptable toxicity, or until the patient or the investigator requested therapy discontinuation.
223872087|NCT01850511|PROCEDURE|Vibrissae trimming|Patients will have oxymetazoline administered prior to assessment of outcome measures to ensure minimal impact of erectile mucosal tissue on measurement.
223872088|NCT01850511|DRUG|Application of oxymetazoline|Afrin will be administered to minimize the impact of erectile mucosal tissue on obstruction.
223872089|NCT00418613|DRUG|MK633|MK0633 100mg capsules qd for a 12-wk treatment period.
223872090|NCT00418613|DRUG|Comparator: Placebo (unspecified)|MK0633 100mg Pbo capsules for a 12-wk treatment period
223872091|NCT02332512|DRUG|Apatinib|
223872092|NCT02332512|DRUG|Placebo|
223872093|NCT03074617|OTHER|LTE field|electromagnetic field of the latest standard in mobile communication (long term evolution, LTE)
223872094|NCT03074617|OTHER|sham field|no electromagnetic field
223872095|NCT00124878|PROCEDURE|Male circumcision|Sleeve circumcision
223872096|NCT06446076|BEHAVIORAL|Gamification (Gain/Loss framing)|"Participants will take part in a 6-week game-based program designed to help them reach their daily step goals. They are encouraged to maintain their daily step counts to achieve their daily step target over the 6-week intervention period. The gamification design incorporates two theoretically effective behavioral economics principles, Fresh Start and Loss Aversion. All participants start from the Silver rank (middle rank), and their rank changes based on each final point of the week. The ranks are set from top to bottom as Platinum, Gold, Silver, Bronze, and Blue. In loss framing, if the daily step target is 6000 steps, maintaining 70 points for achieving 6000 steps on day 1, and a deduction of 10 points for not achieving it. In gain framing, achieving 6000 steps on day 1 results in an addition of 10 points, with no increase for not achieving it. After one week, ranks increase if the points at midnight on Sunday are 40 or above, and decrease if below this threshold."
223872097|NCT06446076|BEHAVIORAL|Social support|Participants in this group are asked to designate a family member or friend to provide social support. This supporter is encouraged to check the participant's progress and provide support during the interventional period. The supporter will also receive weekly emails throughout the period, informing them about the participant's daily step counts, achievement status, points, levels, and other relevant information.
223872098|NCT01923012|DRUG|Vitamin K2 (Menaquinone)|
223872099|NCT00295724|DRUG|Bicifadine|
223872100|NCT01177696|BEHAVIORAL|Psychotherapeutic intervention|A psychotherapeutic intervention will be 8 sessions of 90 minutes in a pilot study groups. This intervention has been initially developed for family caregivers of patients with dementia.
223872101|NCT04928703|DRUG|Ketamine|Ketamine IV administration
223872102|NCT00939978|DRUG|rhEPO|recombinant human erythropoietin(rhEPO)
223872103|NCT00632424|DRUG|Ixabepilone (oral formulation)|Capsules, Oral, Dose escalating (Phase 1), 3 doses on 1 day every 3 weeks, until disease progression or unacceptable toxicity
223872104|NCT02531113|DRUG|RPC1063|
223872105|NCT00002049|DRUG|Thymopentin|
223872106|NCT03680417|BIOLOGICAL|Measles-Rubella (MR) Vaccine|Measles and Rubella Vaccine, live attenuated (Serum Institute of India) Form : Freeze dried Dose : 1 dose 0.5 ml contains not less than 1000 CCID50 of measles virus and 1000 CCID50 of rubella virus.
223872107|NCT02398617|OTHER|Decision Making Intervention|At their regularly scheduled admission follow-up visit with seven days of discharge, participants will be asked to bring their medical decision maker and participate in a semi-structured supplemental palliative care/education session facilitated by a heart failure nurse practitioner trained in palliative care discussions. Domains included in the intervention will include disease literacy and understanding, goals of care, legal issues for patients with terminal illness, symptom management, health-related quality of life, caregiver burden, patient autonomy, healthcare utilization, and establishment of end-of-life plans.
223872108|NCT06972823|DEVICE|3D printed custom-made mouthguards|Participants in the first group will receive 3D printed custom-made mouthguards
223872109|NCT06972823|DEVICE|Traditional custom-made mouthguards|Participants in the active comparator arm will receive traditional custom-made mouthguards as an intervention
223872110|NCT06972550|PROCEDURE|pronator quadratus sparing|the pronator quadratus was spared when doing orif and the plare was slided beneath it
224268921|NCT05513196|PROCEDURE|Erector spinae plane block (ESPB)|Bilateral erector spinae plane block will be performed with 20 mL, 0.25% bupivacaine at T9 level preoperatively.
224268922|NCT00240032|DRUG|glatiramer acetate injection with oral cetirizine hydrochloride|Copaxone® injection 20 mg, Oral Zyrtec® 10 mg tablet
223872111|NCT06087133|BEHAVIORAL|StEP:Prenatal|StEP is a health care-based intervention based on elements of Social Cognitive Theory, in which registered dietitians with additional certified lactation counselor training (RD/CLC) provide individual and group-based support for healthy diet, physical activity, other lifestyle behaviors, stress reduction, and healthy gestational weight gain. StEP:Prenatal will be delivered remotely. There are up to 8 sessions scheduled around the routine prenatal care visits and designed to be offered from the first trimester of pregnancy through delivery.
223872112|NCT06087133|OTHER|Routine Care|Routine care includes routine prenatal and post-partum primary care visits, on-site WIC services and referrals for additional services as needed (e.g., women with poor weight gain, obesity, or diabetes may be offered additional nutrition visits).
223872113|NCT06728059|DEVICE|Automated Insulin Delivery Adaptive NETwork (AIDANET)|Group A participants will use the AIDANET system at home for 7 days/6 nights. They will continue use of AIDANET system for 18 hours during the hotel session and then use AIDANET+BPS\_RL for 18 hours during the hotel session.
223872114|NCT06728059|DEVICE|AIDANET+ BPS_RL→AIDANET|Group B participant will use the AIDANET+BPS\_RL system for 18 hours during the hotel session and will then use AIDANET system for 18 hours during the hotel session. They will continue to use AIDANET+BPS\_RL system at home for 7 days/6 night and then use the AIDANET system at home for 7 days/6 nights.
223872115|NCT06215183|OTHER|Music therapy|Women applying for IUD application will receive music therapy for 5 minutes before the procedure, during the IUD application, and for 5 minutes after the procedure.
223872116|NCT06903234|DRUG|Iptacopan|Adult patients with PNH treated with iptacopan
223872117|NCT03554876|DEVICE|Multi-Im Machined transepithelial component.|Once the implant is placed, the implant loading protocol will be decided following the clinical criteria. When implant loading is to be done, then the Multi-IM machined transepithelial component is connected to the implant.
223872118|NCT03554876|DEVICE|Multi-Im Nanogolden transepithelial component|Once the implant is placed, the implant loading protocol will be decided following the clinical criteria. When implant loading is to be done, then the Multi-IM Nanogolden transepithelial component is connected to the implant.
223872119|NCT03554876|DEVICE|Multi-Im Ti-Golden transepithelial component|Once the implant is placed, the implant loading protocol will be decided following the clinical criteria. When implant loading is to be done, then the Multi-IM Ti-Golden transepithelial component is connected to the implant.
223872120|NCT05775055|OTHER|Composition of oral rehydration solutions|Investigate the efficacy of an amino acid-based oral rehydration solution compared to two current commercially available glucose-based oral rehydration solutions.
223872121|NCT05970991|BEHAVIORAL|Brief Online Training (BOLT) for measurement-based care (MBC)|Brief Online Training (BOLT) for measurement-based care (MBC) is a series of 4 interactive, self-paced, online training modules that takes approximately 75 - 120 minutes to complete. Clinicians are trained on the core functions, procedures, and best practice approaches for delivering MBC in the school mental health setting. MBC is the systematic collection of patient-reported data to support collaborative clinical decision-making from intake to termination.
223872122|NCT05970991|BEHAVIORAL|Virtual Implicit Bias Reduction and Neutralization Training (VIBRANT)|The Virtual Implicit Bias Reduction and Neutralization Training (VIBRANT) is a brief (45-minute), self-paced, interactive online training module designed to help school-based mental health clinicians understand and manage their implicit bias in clinical interactions.
223872123|NCT05970991|BEHAVIORAL|Live Post-Training Consultation|Two 1-hour long small group consultation sessions with an expert consultant designed as additional opportunities to support knowledge elaboration and skills generalization.
223872124|NCT05970991|BEHAVIORAL|Asynchronous Discussion Board|An expert facilitated online Discussion Board for additional opportunities of knowledge clarification, practice reinforcement, and community building to support implementation sustainment.
223872125|NCT04079348|DEVICE|Oasis ECM|The patient will undergo harvesting of a split-thickness skin graft using a dermatome set at standard depth with the subsequent application of Oasis Extracellular Matrix to their donor site wound.
223872126|NCT04079348|OTHER|standard wound care|The patient will undergo harvesting of a split-thickness skin graft using a dermatome set at standard depth with the subsequent application of standard wound care to their donor site wound.
223872127|NCT04147338|DRUG|Guselkumab|Guselkumab will be administered subcutaneously.
223872128|NCT05590923|DRUG|OLA group: Olanzapine|"OLA group: olanzapine 10 mg oral each night on days 1-4 after HEC (or days 1-3 after MEC).~DEX group: dexamethasone (Decadron) 8 mg oral daily on days 2-4 after HEC (or days 2-3 after MEC)."
223872129|NCT05590923|DRUG|DEX group: Dexamethasone|"DEX group: dexamethasone (Decadron) 8 mg oral daily on days 2-4 after HEC (or days 2-3 after MEC)..~OLA group: olanzapine 10 mg oral each night on days 1-4 after HEC (or days 1-3 after MEC)."
223872130|NCT03809637|DRUG|Pemetrexed, cisplatin|Pemetrexed 500mg/m2, Intravenous, Q 3weeks. Cisplatin 75mg/m2, Intravenous, Q 3weeks. Combination administration : up to 6cycles After 6 cycle, pemetrexed alone is administered.
223872131|NCT05263284|DRUG|8-Chloroadenosine|Given IV
223872132|NCT05263284|DRUG|Venetoclax|Given PO
223872133|NCT05333445|BEHAVIORAL|educational program|"Education for the management of AF is carried out in a structured way, following the Bowyer model using the following pre-specified subtitles: How the heart works; Causes and risk factors of AF; Symptoms of AF; Goals of treatment in atrial fibrillation ; ''preparation for the ablation procedure''; and Lifestyle Modification. The technique consists of discussing the main subtitles and adapting the visit line to the needs of each patient"
223872134|NCT05333445|BEHAVIORAL|risk factors management|identify risk factors and offer guidance based on management strategies for the specific risk factor in each case
224268923|NCT00240032|DRUG|glatiramer acetate with placebo|Copaxone® injection 20 mg, oral placebo
224268924|NCT00874276|DRUG|Dichloroacetate (DCA)|Dichloroacetate 2.5.ug/kg will be administered for five days in the clinical research center. On day 5 with the dose of DCA a pharmacokinetics test will be performed for 24 hours. 30 days later the individuals will return to the clinic and receive Dichloroacetate 25mg/kg (clinical dose) for five days. On day 1 and day 5 Pharmacokinetics will be performed to determine the relationship between DCA metabolism and haplotype.
224268925|NCT00874276|GENETIC|Genetic Marker on Chromosome 14q24.3|Individuals were genotyped at the beginning of the study and their haplotypes were defined. The study is looking at individuals with genetic markers on Chromosome 14q24.3 to determine if there will be a difference in how the DCA will be metabolized.
223872135|NCT05333445|BEHAVIORAL|telephone and e-mail contact|patients will also be provided with a phone number and email to contact the nurse for any concerns outside the designated times within the twelve-month follow-up.
223872136|NCT05333445|OTHER|usual care|standard care
223872137|NCT06422702|OTHER|Psychosomatic Symptoms Intervention|Psychosomatic symptoms included intervention of negative psychological symptoms and intervention of physical discomfort symptoms.
223872138|NCT06422702|OTHER|Extended supportive care|The control group implemented continuity of supportive care based on primary care
223872139|NCT06780904|PROCEDURE|Dry Needling|"Treatment protocol:~1. Dry needling: Prone position, identify trigger points in upper trapezius, use Hong technique with 50mm/0.25 gauge needle, eliciting local twitch response.~2. Passive stretching: Supine position, cervical spine stretched just short of restriction, hold for 30s with 20s rest, repeat 3 times.~3. Muscle Energy Technique: Supine position, identify restriction barrier, move spine away from barrier, instruct patient to isometrically contract opposing movement (25% strength), hold for 7-10s, then stretch towards new barrier for 30s, repeat 3 times."
223872140|NCT06780865|DRUG|Antihypertensive treatment with Arotinolol or Amlodipine or Clonidine|Participants will receive Almar 10 mg orally once daily between 8:00 PM and midnight. At the subsequent visit, if nocturnal blood pressure remains above the target of \<120/70 mmHg, Amlodipine Besylate will be added at a dose of 2.5 mg to 5 mg orally once daily. Should nocturnal blood pressure still not achieve the target at the following visit, Clonidine Hydrochloride 75 µg will be added to the regimen. The target for nocturnal blood pressure control is set at \<120/70 mmHg. For participants whose clinic blood pressure exceeds 140/90 mmHg, an unscheduled visit will be arranged within one month. If elevated clinic blood pressure persists during this visit, a 24-hour Ambulatory Blood Pressure Monitoring (ABPM) will be conducted. If the ABPM results indicate daytime blood pressure ≥135/85 mmHg, open-label add-on antihypertensive therapy will be initiated, prioritizing the use of antihypertensive medications outside of the study drugs to achieve blood pressure control.
223872141|NCT06780865|DRUG|Placebo-controlled group|Participants are treated with corresponding placebo
223872142|NCT02188420|DEVICE|"Transcranial Magnetic Stimulation will be applied to the primary motor cortex at the interstimulus interval of (Latency - 3ms)"|"Transcranial Magnetic Stimulation will be applied to the primary motor cortex at the interstimulus interval of (Latency - 3ms) where latency refers to the amount of time for the arrival of a sensory evoked potential as determined by EEG."
223872143|NCT02188420|DEVICE|"Transcranial Magnetic Stimulation will be applied to the primary motor cortex at the interstimulus interval of (Latency - 5ms)"|Transcranial Magnetic Stimulation 5ms
223872144|NCT02188420|DEVICE|"ranscranial Magnetic Stimulation will be applied to the primary motor cortex at the interstimulus interval of (Latency - 7ms)"|Transcranial Magnetic Stimulation 7ms
223872145|NCT02188420|DEVICE|Transcranial Magnetic Stimulation Time 100ms|Active Compator
223872146|NCT06781996|OTHER|multimodal Resilience© digital companion|"Resilience© is a multi-component, multi-level interventional mobile application that will offer: (a) supportive educational care information (b) self-symptom management resources with availability of a remote health-care provider evaluation that addresses patient-specific needs in survivorship care and recommends personalized digital self-management resources at onboarding and if needed in case of low engagement in the mobile app.~Intervention duration : 3 weeks"
223872147|NCT06781996|OTHER|Standard supportive care|standard of care provided by the oncologist and supportive care team at the patient local cancer center including referrals for local supportive care programs. Local supportive care programs may also include the use of already deployed remote patient monitoring and solutions, digital and in person education.
223872148|NCT05644444|DEVICE|Lubricant A (sensate water-based personal lubricant) and Comparator A (non-sensate water-based lubricant)|"In the tolerance phase, a pea-sized lubricant will be considered a single application for oral assessment and approximately 3g of lubricant will be considered a single application for vaginal assessment.~In the treatment phase, approximately 3g of lubricant will be considered a single application."
223872149|NCT05644444|DEVICE|Lubricant B (sensate silicone-based personal lubricant) and Comparator B (non-sensate silicone-based personal lubricant)|"In the tolerance phase, a pea-sized lubricant will be considered a single application for oral assessment and approximately 3g of lubricant will be considered a single application for vaginal assessment.~In the treatment phase, approximately 3g of lubricant will be considered a single application."
223872150|NCT05676203|DRUG|Standard ADT (androgen deprivation therapy)|as prescribed by the treating physician.
223872151|NCT05676203|DRUG|Standard Darolutamide|2x600 mg/d as prescribed by the treating physician
223872152|NCT05676203|DRUG|Docetaxel|Docetaxel
223872153|NCT04817670|DRUG|VIT-2763 120 mg|"Participants receive 2 capsules of VIT-2763 30 mg in the morning and in the evening, for 8 weeks.~Capsules are to be taken orally."
223872154|NCT04817670|DRUG|VIT-2763 360 mg|"Participants receive 2 capsules of VIT-2763 60 mg in the morning, in the afternoon and in the evening for 8 weeks.~Capsules are to be taken orally."
223872155|NCT04817670|DRUG|VIT-2763 240 mg|"Participants receive 2 capsules of VIT-2763 60 mg in the morning and in the evening, for 8 weeks.~Capsules are to be taken orally."
223872156|NCT04817670|DRUG|Placebo BID|"Participants receive 2 capsules of placebo in the morning and in the evening, for 8 weeks.~Capsules are to be taken orally."
223872157|NCT04817670|DRUG|Placebo TID|"Participants receive 2 capsules of Placebo in the morning, in the afternoon and in the evening, for 8 weeks.~Capsules are to be taken orally."
223872158|NCT03312907|DRUG|Belimumab|Belimumab will be administered as SC injection once weekly via autoinjector in thigh or abdomen
223872159|NCT03312907|DRUG|Rituximab|Rituximab will be administered as IV infusion of 1000mg at Week 4 and Week 6
223872160|NCT03312907|DRUG|Rituximab-placebo|Saline will be administered as IV infusions at Week 4 and Week 6
223872161|NCT03312907|DRUG|Standard therapy (Including Immunosuppressants)|Standard therapy will contain stable SLE medications including immunosuppressant to be administered from baseline through Week 104.
223872162|NCT03312907|DRUG|Standard therapy (Excluding Immunosuppressants)|Standard therapy excluding Immunosuppressant will contain anti-malarials, NSAIDs, and/or corticosteroids with prednisone dose equivalent to \<= 5 mg/day will administered through Week 104.
223872163|NCT03312907|DRUG|Steroid Taper|Steroid taper will include prednisone doses equivalent to =\< 5 mg/day in all Arms through Week 104.
223872164|NCT05434156|DRUG|ELE-101|ELE-101 solution for intravenous infusion
223872165|NCT05434156|DRUG|ELE-101 Placebo|ELE-101 placebo matching solution for intravenous infusion
223872166|NCT06270615|OTHER|Ambispective validation of machine learning-based predictive model|Retrospective and prospective validation of a machine learning model to predict major haemorrhage in trauma patients compared to clinician prediction
223872167|NCT06830278|BEHAVIORAL|The SUN Program|"The SUN Program is a manualized bystander program for high-school adolescents. The program includes ten 50-to-60 minute weekly sessions. The central contents of the program include sexual and reproductive rights, sexual violence throughout the lifespan in different contexts, bystander attitudes and behaviors, and empathy. Every session includes psychoeducation components as well as skills-training moments. The sessions must be delivered by two psychologists with supervision.~Session contents are divided as following:~Session 1: Introduction to sexual violence and sexual rights; Session 2: Sexual violence: behaviors and contexts, Session 3: Sexual consent; Session 4: Sexual violence myths; Session 5: Sexual violence in intimate relationships; Session 6: The role of the bystanders; Session 7: The bystander effect; Session 8: Bystander intervention; Session 9: Empathy; Session 10: Summary"
223872168|NCT06192693|DRUG|Capsulized fecal microbiota transfer containing the healthy feces + stool dilution solution|"1 FMT=30 capsulized FMT given during 2 days in several intakes per day (3 intakes per day).~FMT will be performed at baseline after randomization. Further treatment(s) will be given again at 6 and 12 weeks if we do not observe a change of Hba1c of at least -0.15% in patients who have Hba1c at inclusion \<7%; of at least -0.4% in patients who have Hba1c at inclusion ≤8% and of at least -0.7% in patients who have Hba1c at inclusion \>8%."
223872169|NCT06192693|DRUG|Capsulized placebo transfer containing dilution solution|"1 Placebo of FMT=30 capsulized given during 2 days in several intakes per day (3 intakes per day).~Placebo of FMT will be performed at baseline after randomization. Further treatment(s) will be given again at 6 and 12 weeks if we do not observe a change of Hba1c of at least -0.15% in patients who have Hba1c at inclusion \<7%; of at least -0.4% in patients who have Hba1c at inclusion ≤8% and of at least -0.7% in patients who have Hba1c at inclusion \>8%."
223872170|NCT06821893|DEVICE|Vibrational stimulation|"The auricular stimulation device produces continuous vibrational stimulation directly to the conchae of the auricle. It is designed to stimulate the vagus nerve for neuromodulation to treat a variety of clinical indications. The system includes a pulse generator and an ear electrode device. Participants will use a vibration motor in a custom-created soft plastic clip for the left ear.~Each participant will receive their own device by mail, which they will wear during the the 30 minutes mindfulness exercise portion of the 2-hour MBSR group sessions. Additionally, they will wear the devices during the 20-minute at-home MBSR activities for the remaining six days of the week, totaling 120 minutes. The total expected duration of device usage per week will be 2.5 hours or 150 minutes."
223872171|NCT06821893|DEVICE|Sham|"The sham device looks and is used identically to the auricular stimulation device, but does not produce vibrational stimulation. There will be no difference in the usage directions of the sham device compared to the stimulation device.~Each participant will receive their own device by mail, which they will wear during the 30 minutes mindfulness exercise portion of the 2-hour MBSR group sessions. Additionally, they will wear the devices during the 20-minute at-home MBSR activities for the remaining six days of the week, totaling 120 minutes. The total expected duration of device usage per week will be 2.5 hours or 150 minutes."
223872172|NCT06833905|BEHAVIORAL|Virtual reality: Beach|Session 1 or 2 (counterbalanced): Exposure to a beach landscape
223872173|NCT06833905|BEHAVIORAL|Virtual Reality: Forest|Session 1 or 2 (counterbalanced): Exposure to a forest landscape
223872174|NCT06833905|BEHAVIORAL|Hypnosis: Magic Hand|Session 3 or 4 (counterbalanced): Exposure to a hypnosis technique: the magic hand
223872175|NCT06833905|BEHAVIORAL|Hypnosis: Pain Manipulation|Session 3 or 4 (counterbalanced): Exposure to a hypnosis technique: manipulating the pain
223872176|NCT06833905|BEHAVIORAL|Session 1bis - 1 week|Repetition of the Session 1 one week after Session 4
223872177|NCT06833905|BEHAVIORAL|Follow-up|Repetition of the Session 1 three weeks after Session 4
223872178|NCT05948709|OTHER|Incentives for Physical Activity|Participants earn a meal donation and monetary incentives for each day that they reach 7,500 steps. Meals are donated by the investigators on behalf of participants.
223872179|NCT03150433|BEHAVIORAL|Behavioral symptom management|Individual sessions focused on behavioral and cognitive strategies for managing sleep disturbance, pain, and other symptoms of sickle cell disease
223872180|NCT03150433|OTHER|Sickle cell disease management|Individual sessions focused on understanding and managing sickle cell disease
223872181|NCT04614311|DRUG|Triamcinolone Hexacetonide 20 MG/ML|JIA patients (age 1-18 years) starting TNFi treatment randomised to intervention will receive treatment with intra articular glucocorticoids (triamcinolone hexacetonide) injections in inflamed joints
223872182|NCT03851445|DRUG|Screening Platform|The screening study tests patient specimens to determine eligibility for participation in the biomarker-driven and non-matched sub-studies included within the Lung-MAP umbrella protocol.
223872183|NCT06832345|OTHER|Experimental group|Web-based training will be shared with patient relatives before the patient is discharged. A home visit will be made 2-3 days after the patient is discharged. Data collection forms will be collected by the researcher at each home visit. A total of four home visits and eight telephone follow-ups will be made within two months.
223872184|NCT03439891|BIOLOGICAL|Nivolumab|Given IV
223872185|NCT03439891|DRUG|Sorafenib|Given PO
223872186|NCT05972473|DRUG|Aflibercept Ophthalmic|2mg Aflibercept will be administered by intravitreal injection into the study eye once every 4 weeks for 3 consecutive monthes, folloesd by once every 8 weeks(Q8W).
223872187|NCT05972473|BIOLOGICAL|IBI302|8 mg IBI302 will be administered by intraitreal injection into the study eye at intervals as specified in the study protocol.
223872188|NCT06788743|DRUG|TIVA ( anesthesia with propofol and remifentanil)|Participants assigned to the TIVA group will receive propofol combined with remifentanil for anesthesia maintenance during the surgery
223872189|NCT06788743|DRUG|VA（anesthesia with sevoflurane and remifentanil）|Participants assigned to the VA group will receive sevoflurane combined with remifentanil for anesthesia maintenance during the surgery.
223872190|NCT04649021|BIOLOGICAL|BNT162b2|Intramuscular injection
223872191|NCT04649021|OTHER|Placebo|Intramuscular injection
223872192|NCT03112174|DRUG|Ibrutinib|Administered orally once daily
223872193|NCT03112174|DRUG|Venetoclax|Administered orally once daily
223872194|NCT03112174|DRUG|Placebo Oral tablet to match Venetoclax|Administered orally once daily
223872195|NCT04619524|DIAGNOSTIC_TEST|Cervical mucus will be collected from patients undergoing IVF|Patients undergoing hormonal stimulation for IVF will be sampled for cervical mucus.
223872196|NCT04619524|DIAGNOSTIC_TEST|Cervical mucus will be collected from patients undergoing transfer of cryopreserved embryos|Patients undergoing hormonal substitution for transfer of cryopreserved embryos will be sampled for cervical mucus.
223872197|NCT04501744|DRUG|Cohort 1 of M701|Patients in Cohort 1 will receive 4 escalating doses (2, 5, 10 and 25 μg) of M701 on Days 1, 8, 15 and 22. The maintenance dose during extended treatment period is 25 μg.
223872198|NCT04501744|DRUG|Cohort 2 of M701|Patients in Cohort 2 will receive a starting dose on Day 1 and three infusions at a higher maintenance dose level on Days 8, 15 and 22. The starting dose is 25 μg, and the maintenance dose during core treatment period and extended treatment period is 50 μg.
223872199|NCT04501744|DRUG|Cohort 3 of M701|Patients in Cohort 3 will receive a starting dose on Day 1 and three infusions at a higher maintenance dose level on Days 8, 15 and 22. The starting dose is 50 μg, and the maintenance dose during core treatment period and extended treatment period is 100 μg.
223872200|NCT04501744|DRUG|Cohort 4 of M701|Patients in Cohort 4 will receive a starting dose on Day 1 and three infusions at a higher maintenance dose level on Days 8, 15 and 22. The starting dose is 100 μg, and the maintenance dose during core treatment period and extended treatment period is 200 μg.
223872201|NCT04501744|DRUG|Cohort 5 of M701|Patients in Cohort 5 will receive a starting dose on Day 1 and three infusions at a higher maintenance dose level on Days 8, 15 and 22. The starting dose is 150 μg, and the maintenance dose during core treatment period and extended treatment period is 300 μg.
223872202|NCT04501744|DRUG|Cohort 6 of M701|Patients in Cohort 6 will receive a starting dose on Day 1 and three infusions at a higher maintenance dose level on Days 8, 15 and 22. The starting dose is 200 μg, and the maintenance dose during core treatment period and extended treatment period is 400 μg.
223872203|NCT04501744|DRUG|Cohort 7 of M701|Patients in Cohort 7 will receive a starting doseon Day 1 and three infusions at a higher maintenance dose level on Days 8, 15 and 22. The starting dose is 250 μg, and the maintenance dose during core treatment period and extended treatment period is 500 μg.
223872204|NCT03966846|DIETARY_SUPPLEMENT|Kefir|
223872205|NCT03966846|DIETARY_SUPPLEMENT|Milk|
223872206|NCT00687167|DRUG|Zonisamide 100 mg Capsule|100 mg capsule administered 30 minutes after initiation of standardized, high-fat breakfast.
223872207|NCT00687167|DRUG|Zonisamide (Zonegran®) 100 mg Capsule|100 mg capsule administered 30 minutes after initiation of standardized, high-fat breakfast.
223872208|NCT04259450|DRUG|14 mg AFM24|14 milligram AFM24 weekly on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.
223872209|NCT04259450|DRUG|40 mg AFM24|40 milligram AFM24 weekly on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.
223872210|NCT04259450|DRUG|80 mg AFM24|80 milligram AFM24 weekly on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.
223872211|NCT04259450|DRUG|160 mg AFM24|160 milligram AFM24 weekly on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.
223872212|NCT04259450|DRUG|320 mg AFM24|320 milligram AFM24 weekly on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.
223872213|NCT04259450|DRUG|480 mg AFM24|480 milligram AFM24 weekly on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.
223872214|NCT04259450|DRUG|720 mg AFM24|720 milligram AFM24 weekly on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.
223872215|NCT06267690|PROCEDURE|surgery|Patients with suspected pancreatic cancer who underwent contrast-enhanced CT and pathological examinations after the surgery.
223872216|NCT02186769|DRUG|Risperdal® Consta®|
223872217|NCT02186769|DRUG|LY03004|
223872218|NCT01534494|DRUG|Psilocybin|two doses of 0.3 mg/kg PO and 0.4 mg/kg PO, separated by 4 weeks in combination with 12 weeks of manualized outpatient psychosocial treatment including preparation, debriefing, and motivational enhancement therapy.
223872219|NCT00075933|DRUG|ARQ 501|
223872220|NCT05356689|OTHER|mechanical traction|Group A: This group will get 3-dimensional lumbar traction on multi-dimensional traction bed spine MT. Group B: This group will get 2-dimensional lumbar traction on 2-dimensional traction bed. Common Treatment: Hot pack (for 10 minutes), and US 1mhz for 7 minutes, Mackenzie exercises and cold pack will applied for 15 minutes after traction.
223872221|NCT00010777|PROCEDURE|Multiple Component Mind/Body therapy|
223872222|NCT02724592|DEVICE|self assembling peptide P11-4 (Curodont™ Repair)|Applying of self assembling peptide P11-4 (Curodont™ Repair) on teeth with initial caries lesions
223872223|NCT02724592|DEVICE|fluoride varnish (Duraphat®)|Applying fluoride varnish (Duraphat®) on teeth with initial caries lesions
223872224|NCT04336059|PROCEDURE|pericapsular nerve group block|"The regional block will be performed with the patient in the supine position under complete sterile technique. A low frequency curvilinear ultrasound probe will be initially placed in a transverse plane over the anterior inferior iliacspine (AIIS) and then aligned with the pubic ramus by rotating the probe counterclockwise approximately 45 degrees. In this view, the iliopubic eminance(IPE), the iliopsoas muscle and tendon, the femoral artery, and pectineus muscle will observed.~A 22-gauge, 80-mm needle will be inserted from lateral to medial in an in-plane approach to place the tip in the musculofascial plane between the psoas tendon anteriorly and the pubic ramus posteriorly after local infiltration of the site of the block with 3 ml lidocaine 2%. Following negative aspiration,the normal saline solution will injected in 5-mL increments while observing for adequate fluid spread in this plane."
224268926|NCT06559280|DRUG|esketamine|During the operation, 0.25mg/kg esketamine was induced, and 1mg/kg esketamine was added to the postoperative analgesia pump
224268927|NCT03967262|BEHAVIORAL|Brief Motivational Intervention|The objective of motivational intervention is to make the patient aware of the relationship between the consumption of alcohol and other drugs and the accident, and induce them to carry out a change in habits.
224268928|NCT05201339|PROCEDURE|Standard method|Insert I-gel™ according to the manufacturer's instruction. Take the sniffing position and gently move the i-gel™ along the hard palate to the soft palate and the posterior oropharynx.
223872225|NCT03872310|DEVICE|STARSTIM|Right DLPC was located as F4 according to the international 10-20 EEG system. Anodal tDCS was delivered with the anodal pole on the right DLPFCand the cathodal pole on the left cheek of the participant to avoid contaminating other brain regions during electrical stimulation via a pair of rubber electrodes housed in saline-soaked sponge coverings (5x5 cm\^2). The direct current was applied with 1.5 mA for 15 min which can facilitate visual short-term memory and create an excitatory effect for up to 90 min. The anodal tDCS stimulated the right DLPC for 15 min with 1.5 mA in active tDCS condition. The sham tDCS condition followed identical tDCS protocol and same 15-min duration except the stimulation time only lasted for the initial 30s so that the participants felt the same initial tingling sensation (if any, only in some participants) but without the actual stimulation. The investigators will perform assessments of adverse effects after each session by a standardized questionnaire.
223872226|NCT02584829|DRUG|Avelumab|Given IV
223872227|NCT02584829|OTHER|Laboratory Biomarker Analysis|Correlative studies
223872228|NCT02584829|BIOLOGICAL|MCPyV TAg-specific Polyclonal Autologous CD8-positive T Cells|Given IV
223872229|NCT02584829|RADIATION|Radiation Therapy|Undergo radiation therapy
223872230|NCT02584829|BIOLOGICAL|Recombinant Interferon Beta|Given via intra-tumor injection
223872231|NCT04997616|DIETARY_SUPPLEMENT|Happy Lane Hemp Extract/CBD soft gels (25 mg/capsule)|Half of the study participants (5 women and 5 men) will be taking one gel capsule per day (25 mg/day dose), while the other half (5 women and 5 men) will be taking 2 gel capsules per day (50 mg/day dose). Study participants will be taking gel capsules for 10 consecutive days. At the end of this 10-day regimen, study participant will return to the TRI where blood specimen (up to 15 mL) will be collected within 2 to 6 hours after the last dose. Major plant cannabinoids and cannabinoid metabolites in each blood specimen will be determined using liquid chromatography-mass spectrometry.
223872232|NCT03669913|OTHER|Lessons on comprehensive sexuality education|Provision of 11 standardized lessons on comprehensive sexuality education based on international guidance on sexuality education by UNESCO
223872233|NCT00002270|DRUG|Interferon alfa-2b|
223872234|NCT00002270|DRUG|Zidovudine|
223872235|NCT00825630|DRUG|Lansoprazole (Lanton)|Oral administration of Lanzoprazole for 14 days in 25 patients with H.pylori infection
223872236|NCT00825630|DRUG|Omeprezole (Losec)|Oral administration of Omeprazole for 14 days in 25 patients with H.pylori infection
223872237|NCT00825630|DRUG|Pantoprazole(Controloc)|Oral administration of Pantoprazole for 14 days in 25 patients with H.pylori infection
223872238|NCT00825630|DRUG|Esomeprazole (Nexium)|Oral administration of Esomeprazole for 14 days in 25 patients with H.pylori infection
223872239|NCT01991301|DRUG|carfilzumib|carfilzumib will be added to the standard regimen of drugs for prevention of graft-versus-host disease.
223872240|NCT03118323|OTHER|Questionnaire|Patients are given a questionnaire with items related to personality and their willingness-to-pay for different treatment options.
223872241|NCT02851667|BEHAVIORAL|Resident training programs|A total of 24 resident training programs such as talks, day camp and thematic activities were delivered in the intervention estate by CFSC from June to November 2011. Each program included an introduction to the concepts of Learning Family and family 3Hs as well as how to promote family 3Hs through learning and communicating with family, delivered by interactive games and workshops.
223872242|NCT02880137|DRUG|Perflutren Lipid Microsphere|Definity (injectible suspension ultrasound contrast agent) will be diluted with saline for both Pediatric and Adult subjects. For pediatric subjects under 60kg (kilogram), the dose will be 20 MicroL/kg (MicroLiter/kilogram) diluted to the same concentration used in the adult dosing. Hand Injections will be performed at baseline, Pre-peak, and peak perfusion stages.
223872243|NCT02880137|PROCEDURE|RTMPE|Utilizes intravenous administration of biologically-inert microbubbles to assess myocardial perfusion and has demonstrated utility for identifying small vessel coronary artery disease.
223872244|NCT06229301|PROCEDURE|AI-predicted Nomogram|
223872245|NCT02617771|DRUG|Vitamin D3|from October to March, a Vitamin D oral supplementation (400 UI/die up to 12 month or 600 UI/die beyond 1 year
223872246|NCT00434304|DRUG|Ropinirole prolonged release/extended release(PR/XR)|Subjects will take the investigational drug once daily at the same time each day, it is recommended that this is in the morning for optimal benefit. Investigational drug is taken for 52 weeks, starting on the next day of the Week 0 visit. One tablet of ropinirole PR/XR 2 mg tablets will be orally dosed as the initial dose. The dose will be titrated weekly by 2 mg/day, and increased to 8 mg/day in Week 4. From Week 5 up to 16, the dose will be increased at minimum intervals of one week between titration steps until sufficient efficacy is obtained, according to individual clinical response and tolerability (the dose may be titrated up to 16 mg/day). In Week 16 and further, treatment dose at Week 16 will be continuously administered up to Week 52. If insufficient efficacy is judged in a subject during treatment, or unable to maintain the dose due to adverse event, the treatment dose may be changed. The dose is down tapered according to the maintenance dose at Week 52 (or withdrawal).
223872247|NCT05262738|DRUG|50 Micrograms Vaginal Misoprostol (Intervention)|Subjects will undergo cervical ripening with 50 micrograms of vaginal misoprostol every 4 hours.
223872248|NCT05262738|DRUG|25 Micrograms Vaginal Misoprostol (Control)|Subjects will undergo cervical ripening with 25 micrograms of vaginal misoprostol every 4 hours.
223872249|NCT02374463|BEHAVIORAL|MMBI|Multimodality Balance Intervention (MMBI): Our MMBI will be held 3-times a week for an hour and will consist of a group dynamic balance class (30 minutes), a supervised obstacle course (10 minutes), and lower extremity and core strengthening (20 minutes). The group exercise classes will focus on dynamic weight shifts with an emphasis on the lateral and diagonal directions. Over the 6 months of class, the exercises will gradually increase in difficulty to challenge balance. A skilled instructor will lead each class and 1-2 assistants will be present to assist with fall risk prevention. The supervised obstacle course will focus on obstacle negotiation, gait over challenging surfaces, and moving in lateral, diagonal, and backward directions. Finally, strength training of the lower extremities and core will focus on strengthening major muscles of the lower extremity and core utilizing commonly available gym equipment, ankle weights and body weight.
223872250|NCT02374463|BEHAVIORAL|Tai Chi|Tai Chi Intervention: The supervised Tai Chi class will be held 3-times a week for one hour. All Tai Chi classes will be taught in a group setting by an experienced instructor. The emphasis during the class will be on standing movements, body alignment, weight shift and changes of direction. Movements will be adapted as the class progresses to increase the difficulty of weight shift and change in direction over time so that participants balance is continually challenged throughout the 6 months. Chairs or hand rails will be available for the participants to use as needed for balance recovery.
223872251|NCT05365191|PROCEDURE|Near infrared fluorescence navigated sentinel lymph node mapping|Participants undergo sentinel lymph node biopsy for breast cancer, and use blue dye/Tc99m radioisotope as primary tracer. Indocyanine green near infrared fluorescence as secondary tracer for mapping.
223872252|NCT00920738|OTHER|metabolic assessment|Physical examination, medical history, blood pressure, anthropometrics, laboratory studies and other procedures (body composition, bone density, growth hormone, vascular, functional mobility, body fat assessments, etc).
223872253|NCT00920738|OTHER|questionnaire administration|Dietary habits will be evaluated using the Youth/ Adolescent Questionnaire (YAQ)and the Modifiable Activity Questionnaire for Adolescents (MAQA) will be used to assess participation in leisure time and competitive activities during the past year will be administered on Day 2.
223872254|NCT02538653|OTHER|Sandwich biscuit high in SDS|Consumption of the high SDS product (50g) alone with a glass of water
223872255|NCT02538653|OTHER|Co-extruded cereal low in SDS|Consumption of the low SDS product (48.3 g) alone with a glass of water
223872256|NCT04334746|OTHER|Balance measurement tools|Timed Up and Go Test Functional Reach Test One-leg Stance Test Berg Balance Scale
223872257|NCT01183936|PROCEDURE|2-cm margin|Patients with CMM treated with a surgical safety margin of 2-cm in the surrounding skin and down to the fascia.
223872258|NCT01183936|PROCEDURE|4-cm margin|Patients with CMM treated with a surgical safety margin of 4-cm in the surrounding skin and down to the fascia.
223872259|NCT06516315|PROCEDURE|Preoperative ultrasound examination.|Preoperative ultrasound examination performed the day before or the day of surgery.
223872260|NCT06516315|PROCEDURE|Peroperatoire angiography procedure and QFR analysis|Intraoperative angiography will be performed immediately prior to revascularization. Quantitative analysis of angiography images will be performed post-procedure using Medis QFR®2.2 software.
223872261|NCT01586936|DRUG|eptacog alfa (activated)|Prescription of eptacog alpha at the discretion of the physician
223872262|NCT02894879|DEVICE|BreatheMAX®|"Modify chest physical therapy~* oscillated incentive spirometry (OIS) with inspiratory load of 5-8 cm H2O 30 times/set~* oscillated positive expiratory pressure (OPEP) with expiratory load of 5-8 cm H2O 30 times/set~* Coughing with splinting 3 times/set~* Chest mobilization with overhead both arms rises 10 times/set total 5 set/day"
223872263|NCT02894879|OTHER|Routine treatment|"Routine chest physical therapy~* Deep breathing exercise (upper and lower costal and diaphragmatic breathing exercise) as deep as possible for 10 times/set/level~* Coughing with splinting 3 times/set~* Chest mobilization with overhead both arms raised 10 times/set total 5 set/day"
223872264|NCT00637585|DRUG|Fexofenadine|
223872265|NCT04045782|DRUG|single arm|switch from originator (Humira) to biosimilar (Imraldi)
223872266|NCT00348322|DRUG|Systane Free Lubricant Eye Drops|
223872267|NCT01091740|DEVICE|ZES resolute (Endeavor Resolute)|2nd generation drug eluting stent, which is coated with zotarolimus
223872268|NCT01091740|DEVICE|EES (Xience)|2nd generation drug eluting stent, which is coated with everolimus
223872269|NCT00804648|DRUG|Timolol Maleate in Sorbate|0.5%
223872270|NCT00804648|DRUG|Timolol hemihydrate|0.5%
223872271|NCT00804648|DRUG|Timolol maleate gel forming solution|0.5%
223872272|NCT00485459|DRUG|Atomoxetine Hydrochloride|
223872273|NCT00485459|DRUG|Placebo|
223872274|NCT05255835|DEVICE|Semiconductor Knee Sleeves|semiconductor elements germanium and carbon within the cotton fabric
223872275|NCT05255835|DEVICE|Cotton Knee Sleeves (Placebo)|cotton fabric knee sleeves
223872276|NCT05076942|RADIATION|Radiotherapy combined with cisplatin|Inguinofemoral radiotherapy combined with weekly cisplatin
223872277|NCT05076942|DRUG|Cisplatin|Inguinofemoral radiotherapy combined with weekly cisplatin
223872278|NCT03210896|DIETARY_SUPPLEMENT|Orange juice|Sub group I will drink Orange juice and have repeat measures.
223872279|NCT01939899|DRUG|IXAZOMIB|Each 28-day treatment cycle will include oral administration of IXAZOMIB on Days 1, 8, and 15 followed by a rest period of 13 days.
223872280|NCT05576857|OTHER|Doppler ultrasonography|All volunteers will be monitored with cerebral oximeter, asked to answer the Montreal cognitive assessment test and cervical blood flow values and optic nerve sheath diameter will be determined with Doppler ultrasonography.
223872281|NCT04458454|DIAGNOSTIC_TEST|Relaxin ELISA Kit|Ovarian stimulation was carried out from day 3 of the menstrual cycle using a fixed protocol, with recombinant (Gonal-F, Pergoveris) or human menopausal gonadotropins (Meriofert), GnRH antagonist (ganirelix 0.25 mg). A recombinant human chorionic gonadotropin Ovitrel 250 μg or a GnRH agonist, Diferelin 0.2 mg, was used as an ovulation trigger.
223872282|NCT06298305|DEVICE|Quantib prostate (Quantib B.V. Rotterdam, The Netherlands) software|Quantib Prostate is an AI-driven solution that provides an intuitive workflow for assessment of prostate MRI. The product integrates essential prostate MRI reading features into one workflow making it easy for the user to read, assess and report each patient case from within the same software interface. With automatic forwarding in place, the software preprocesses the MRI right after scanning. This allows the user to access calculations and analysis immediately when they open the software interface. Thanks to these features, the professional may experience an accelerated workflow, making it easier to manage their heavier workload.
223872283|NCT05018013|DRUG|Ammoxetine hydrochloride enteric-coated tablets|Ammoxetine hydrochloride enteric-coated tablets
223872284|NCT05018013|DRUG|Duloxetine hydrochloride enteric-coated capsules|Duloxetine hydrochloride enteric-coated capsules
223872285|NCT05018013|DRUG|Placebo to Ammoxetine|Placebo to Ammoxetine
223872286|NCT05018013|DRUG|Placebo to Duloxetine|Placebo to Duloxetine
223872287|NCT02061501|OTHER|Optometric therapy during 6 months|Optometric therapy during 6 months, once a week
223872288|NCT02061501|OTHER|Optometric therapy during 12 months|Optometric therapy once a week, during 12 months
223872289|NCT05674669|DRUG|Lysergic Acid Diethylamide (LSD) 50µg|
223872290|NCT05674669|DRUG|Lysergic Acid Diethylamide (LSD) 75µg|
223872291|NCT05674669|DRUG|Lysergic Acid Diethylamide (LSD) 100µg|
223872292|NCT05674669|DRUG|Placebo/Lysergic Acid Diethylamide (LSD) 75µg|
223872293|NCT05674669|DRUG|Lysergic Acid Diethylamide (LSD) 50µg/75µg|
223872294|NCT01043601|DRUG|Inhaled PT005|inhaled, twice daily for 1 week duration
223872295|NCT01043601|DRUG|Inhaled Placebo|inhaled, twice daily for 1 week duration
223872296|NCT01043601|DRUG|Formoterol Fumarate 12 µg (Foradil Aerolizer)|inhaled, twice daily for 1 week duration
223872297|NCT00162344|DRUG|Technetium Tc99m Sestamibi|
223872298|NCT04704258|PROCEDURE|TAVI (Transcatheter Aortic Valve Implant)|Placement of a filter to capture and remove emboli or debris detached during any transcatheter heart procedures
223872299|NCT04704258|DEVICE|FLOWer Embolic Protection System|FLOWer Embolic Protection System
223872300|NCT05766540|DRUG|Aripiprazole 10 MG|Aripiprazole hroup will receive Aripiprazole 10 mg/day along with Clozapine and Metformin
223872301|NCT02955407|OTHER|no intervention|observational case-control study
223872302|NCT02111889|OTHER|[11C] kinase inhibitor PET [15O]water PET and tumor biopsies.|\[11C\] kinase inhibitor PET (i.e. sorafenib and erlotinib in this study, with the aim to investigate others in future studies) and \[15O\]water PET will be performed before and after 2 weeks of treatment. Tumor biopsies will be performed before and after 2 weeks of therapy.
223872303|NCT03000842|DEVICE|transcutaneous vagal nerve stimulation on|electrical current on positioned in the ear to estimate vagal branch of auricular nerve
223872304|NCT03000842|DEVICE|transcutaneous vagal nerve stimulation off|an electrical current off positioned in the ear to estimate vagal branch of auricular nerve
223872305|NCT00585052|DRUG|Paclitaxel|Paclitaxel will be given at 80 mg/m2 IV over 1 hour on day 1 and repeated weekly
223872306|NCT00585052|DRUG|Lovastatin|Lovastatin, 80 mg, po, daily will be self-administered by the subject.
223872307|NCT05772923|RADIATION|Contact x-ray brachytherapy|With contact x-ray brachytherapy an intraluminal radiation boost up to 90 Gy is applied to the primary rectal tumour, with minimal collateral damage to the surrounding normal tissues due to minimal penetration of the 50 kVolt therapy.
223872308|NCT05772923|PROCEDURE|Local excision|Local excision will basically be performed by the TAMIS-procedure (transanal minimally invasive surgery).
223872309|NCT04910698|DRUG|Antibiotic|Antibiotic duration of treatment defined if the patient belonged to long course or short course group.
223872310|NCT02545920|OTHER|no intervention|observational study
223872311|NCT06516328|OTHER|Observational|GCF and saliva samples obtained.
223872312|NCT00123903|DRUG|metoprolol xl|
223872313|NCT00123903|DRUG|carvedilol MR|
223872314|NCT00123903|DRUG|lisinopril|
223872315|NCT05326971|PROCEDURE|gastroscopy|Gastroscopy to evaluate the effect of long term exposure of TDF or TAF on enterocytes
223872316|NCT05443542|DEVICE|Virtual Reality|Game to be played is a commercially available VR game
223872317|NCT05443542|OTHER|Control intervention|Sodoku, crossword puzzles
223872318|NCT02551536|DRUG|Montelukast|
223872319|NCT02551536|DRUG|Fexofenadine|group B received FDC tablet of montelukast 10mg and fexofenadine 120 mg O.D
223872320|NCT02551536|DRUG|Levocetrizine|group A recieved FDC tablet of montelukast 10 mg and levocetrizine 5mg O.D
223872321|NCT05000424|OTHER|Clary Sage Massage Oil|This massage oil contains clary sage oil. Five drops will be used daily.
223872322|NCT05000424|OTHER|Inert Massage Oil|This massage oil consists entirely of plant based oils. Five drops will be used daily.
223872323|NCT04723394|DRUG|AZD7442|Single dose (× 2 separate IM injections) of 600 mg of AZD7442 or saline placebo on Day 1.
223872324|NCT04723394|DRUG|Placebo|Single dose (× 2 separate IM injections) of 600 mg of AZD7442 or saline placebo on Day 1.
223872325|NCT00006017|DRUG|becatecarin|Arm I: Patients receive rebeccamycin analogue IV over 1 hour on day 1. Arm II: Patients receive rebeccamycin analogue IV over 1 hour on days 1-5. Treatment for both arms repeats every 3 weeks for 6-8 courses in the absence of disease progression or unacceptable toxicity.
223872326|NCT00044863|BIOLOGICAL|Erbitux (Cetuximab)|400 mg/m2 initial dose, 250 mg/m2 weekly
223872327|NCT01006434|OTHER|Recording of body weight estimations, approximations and tPA dose|Body weight estimation, patients are weighed, actual tPA dose is recorded
223872328|NCT00797017|DRUG|fentanyl|Infection, starting with 12mcg/h (flexible dose)
223872329|NCT00797017|DRUG|fentanyl|(CRPS) Complex Regional Pain Syndrome, starting with 12mcg/h (flexible dose)
223872330|NCT00797017|DRUG|fentanyl|Bone Fracture, starting with 12mcg/h (flexible dose)
223872331|NCT00797017|DRUG|fentanyl|(FBSS) Failed Back Surgery Syndrome, starting with 12mcg/h (flexible dose)
223872332|NCT00797017|DRUG|fentanyl|Other Deformity, starting with 12mcg/h (flexible dose)
223872333|NCT00797017|DRUG|fentanyl|(LDK) Lumbar Degenerative Kyphosis, starting with 12mcg/h (flexible dose)
223872334|NCT00797017|DRUG|fentanyl|Degenerative Spine Disorder, starting with 12mcg/h (flexible dose)
223872335|NCT03290859|PROCEDURE|Titrate propofol monotherapy infusion to effect|Train anesthesia providers in a standardized protocol for titrating propofol infusion to effect.
223872336|NCT01913691|DRUG|Ipilimumab|Ipilimumab is a recombinant, human monoclonal antibody that binds to CTLA-4. It is commercially available under the brand name Yervoy . The use of ipilimumab for MCC is investigational: a study-specific supply of medication will be provided by Bristol-Myers Squibb.
223872337|NCT03041584|PROCEDURE|Guided placement|implant placement with use of guide
223872338|NCT03041584|PROCEDURE|Non-guided placement|conventional implant placement
223872339|NCT03041584|DEVICE|Astra Tech TX implant|
223872340|NCT04682418|DEVICE|xvision Spine sytem|pedicle screw placement will be performed using the XVS navigation system
223872341|NCT02492516|BIOLOGICAL|mesenchymal stem cells|mesenchymal stem cells injection via peripheral vein.
223872342|NCT00007163|DRUG|J695|
223872343|NCT01970813|DEVICE|acupuncture and bee venom acupuncture point injection|acupuncture and bee venom acupuncture point injection at 10 acupuncture points twice a week for 12 weeks. This intervention is added on to the conventional antiparkinsonian drugs.
223872344|NCT01970813|DEVICE|sham acupuncture and normal saline injections|sham acupuncture and normal saline injections at 10 sham acupuncture points twice a week for 12 weeks. This intervention is added on to the conventional antiparkinsonian drugs.
223872345|NCT03002428|DRUG|Teriparatide (PF708)|Subcutaneous injection
223872346|NCT03002428|DRUG|Teriparatide (Forteo)|Subcutaneous injection
223872347|NCT04884295|DRUG|XVR011|Single dose of XVR011 via intravenous (IV) infusion
223872348|NCT00774397|DRUG|BI 201335 NA 240 mg QD / LI|240mg BI 201335 NA (Faldaprevir) once daily with a 3 days lead-in phase of PegIFN/RB, 24 weeks
223872349|NCT00774397|DRUG|PegIFN/RBV|PegIFN (180 µg/wk) and RBV (1000/1200mg/d), 24 or 48 weeks
223872350|NCT00774397|DRUG|BI 201335 NA 120mg QD / LI|120mg BI 201335 NA (Faldaprevir) once daily, for 24 weeks
223872351|NCT00774397|DRUG|PegIFN/RBV|PegIFN (180 µg/wk) and RBV (1000/1200mg/d),48 weeks
223872352|NCT00774397|DRUG|BI 201335 NA 240 mg QD|240mg BI 201335 NA (Faldaprevir) once daily, 24 weeks
223872353|NCT00774397|DRUG|PegIFN/RBV|PegIFN (180 µg/wk) and RBV (1000/1200mg/d),48 weeks
223872354|NCT00774397|DRUG|BI 201335 NA 240 mg QD|240mg BI 201335 NA (Faldaprevir) once daily, 24 weeks
223872355|NCT00774397|DRUG|PegIFN/RBV|PegIFN (180 µg/wk) and RBV (1000/1200mg/d), 24 or 48 weeks
223872356|NCT00774397|DRUG|BI 201335 NA 240 mg BID|240mg BI 201335 NA (Faldaprevir) twice, 24 weeks
223872357|NCT00774397|DRUG|PegIFN/RBV|PegIFN (180 µg/wk) and RBV (1000/1200mg/d),48 weeks
223872358|NCT00774397|DRUG|PegIFN/RBV|PegIFN (180 µg/wk) and RBV (1000/1200mg/d),48 weeks
223872359|NCT00774397|DRUG|BI 201335 NA 240 mg QD|240mg BI 201335 NA (Faldaprevir) once daily, 24 weeks
223872360|NCT00774397|DRUG|PegIFN/RBV|PegIFN (180 µg/wk) and RBV (1000/1200mg/d), 24 or 48 weeks
223872361|NCT00774397|DRUG|Placebo|Placebo
223872362|NCT00006349|DIETARY_SUPPLEMENT|vitamin E|
223872363|NCT00006349|DRUG|donepezil hydrochloride|
223872364|NCT00006349|OTHER|placebo|
223872365|NCT05436119|DIETARY_SUPPLEMENT|GrowBaby|Virtual group educational visits will cluster women in the same trimester of pregnancy teaching trimester-specific diet and lifestyle modification, further customized to the individual using limited micronutrient and gene variant analysis. Each woman will receive base multi-nutrient and probiotic supplementation with customization if identified needs cannot be met with diet and lifestyle modification alone.
223872366|NCT02675829|DRUG|ado-trastuzumab emtansine|Ado-trastuzumab emtansine is administered intravenously at 3.6 mg/kg every 21 days (unless dose reduction and/or dose delays are required) until disease progression or unacceptable toxicity.
223872367|NCT02944760|OTHER|Low-Level Light Therapy|The application of laser therapy will take place 30 minutes before the start of dialysis. The application will take place with the Chattanooga device, with the laser diode cluster probe from the same manufacturer consisting of five diodes 850 nm and power output of 200 mW. It is irradiated 6 points in quadriceps and 4 points in gastrocnemius, bilaterally by 30 seconds. The patient will be supine on a stretcher to the implementation of the intervention.
223872368|NCT00810849|DRUG|Prednisolone|Prednisolone and placebo will be supplied as 5 mg identical tablets and given at a dosage of 120 mg/day in the first week, followed by 90 mg/day in the second week, 60 mg/day in the third week, 30 mg/day in the fourth week, 15 mg/day in the fifth week, and 5 mg/day in the sixth week.
223872369|NCT00810849|BIOLOGICAL|Mycobacterium w immunotherapy|Patients enrolled in the Mycobacterium w experimental arm will receive 5 doses of 0.1 ml of the vaccine intradermally (on enrolment, at 2 weeks, 4 weeks, 6 weeks, and 3 months). Patients in the control arm of the Mycobacterium w comparison will receive a similar regime of placebo injections of normal saline in identically-packaged vials.
223872370|NCT02186743|OTHER|Personalized Dietary Advice|Personalized dietary advice based on a commercially available blood test. Participants will be instructed to avoid eating selected foods for the duration of the intervention period (4 weeks). Some foods will be acceptable to consume every four days in rotation diet fashion.
223872371|NCT02010944|DRUG|solifenacin succinate|oral
223872372|NCT02010944|DRUG|mirabegron|oral
223872373|NCT02010944|DRUG|mirabegron/solifenacin succinate|oral
223872374|NCT04971070|OTHER|Observation and follow-up|Observation and follow-up study
223872375|NCT01965665|DEVICE|MediHoney HCS dressing|
223872376|NCT05121467|OTHER|Pain Assessment|Visual Analogue Scale (VAS) were included in the study
223872377|NCT05121467|OTHER|Assessment of Muscular Endurance|The endurance of the 9 muscles/muscle groups including cervical flexor, extensor, deep flexor muscles, trunk flexor, extensor, lateral flexor, and stabilizer muscles, upper extremity, and scapular muscles (mm. serratus anterior and trapezius) were evaluated based on the assessment instructions given in the studies of Edmonston et al., Grimmer et al., Evans et al., Reece et al., ACSM guideline
223872378|NCT05121467|OTHER|Assessment of Neck Awareness|The Turkish version of the Fremantle Neck Awareness Questionnaire (FreNAQ) which was developed by Wand et al. to assess neck awareness in patients with chronic neck pain was used in this study
223872379|NCT05121467|OTHER|Assessment of Fear of Movement|The fear of movement was assessed by the Turkish version of the Tampa Scale of Kinesiophobia which originally developed by Kori et al.
223872380|NCT00858117|BIOLOGICAL|Alemtuzumab|Alemtuzumab administered subcutaneously 30mg per day, 3 days per week for 18 weeks
223872381|NCT00858117|BIOLOGICAL|Rituximab|Rituximab administered intravenously at 375mg/m2 every 2 weeks for 18 weeks
223872382|NCT02538458|DRUG|3 % hypertonic saline up to 72H|Treatment by inhalation of 3 % hypertonic saline, up to 72H. Test group.
223872383|NCT02538458|DRUG|3 % hypertonic saline up to 24H|"* Treatment by inhalation of 3 % hypertonic saline, up to 24H.~* followed by 48h of placebo : isotonic saline inhalation. Placebo control group."
223872384|NCT03466242|DRUG|Dexmedetomidine|Evaluate sedative and analgesic effects of Intranasal Dexmedetomidine
223872385|NCT03466242|DRUG|Ketamine|Evaluate sedative and analgesic effects of Intravenous Ketamine
223872386|NCT03308292|OTHER|Exercise|Aerobic exercise program
223872387|NCT02810236|PROCEDURE|Ultrasound|Ultrasound will be performed.
223872388|NCT02810236|BEHAVIORAL|Discussion|Radiologist will discuss with the patient the findings on mammogram.
223872389|NCT02798367|BEHAVIORAL|CBT-I plus placebo|Behavioral techniques of Sleep Hygiene and Stimulus Control standardized in clinical protocol plus placebo (01 tablet, orally, always at night one hour before bedtime) for 21(±2) days)
223872390|NCT02798367|DRUG|CBT-I plus Melatonin 3 mg|Behavioral techniques of Sleep Hygiene and Stimulus Control standardized in clinical protocol plus Melatonin 3 mg (01 tablet, orally, always at night one hour before bedtime) for 21(±2) days.
223872391|NCT02798367|DRUG|CBT-I plus Melatonin 5 mg|Behavioral techniques of Sleep Hygiene and Stimulus Control standardized in clinical protocol plus Melatonin 5 mg (01 tablet, orally, always at night one hour before bedtime) for 21(±2) days.
223872392|NCT03584659|DEVICE|Electronic patient-reported outcomes|Weekly reporting of patient-reported outcomes for closer contact between patient and clinic between treatment cycles.
223872393|NCT00225797|DRUG|Oxymorphone Extended Release|
223872394|NCT02355236|DRUG|Naproxen/Esomeprazol 500/20mg|Tablet, b.i.d.
223872395|NCT02355236|DRUG|Celecoxib 200mg|Capsule, o.d.
223872396|NCT02355236|DRUG|Naxozol-Placebo|Tablet (which is identical to Naxozol), b.i.d.
223872397|NCT02355236|DRUG|Comparator-Placebo|Capsule (which is identical to Celebrex), o.d.
223872398|NCT02259049|DIETARY_SUPPLEMENT|L-tyrosine|Each subject will receive 2,000 mg of L-tyrosine BID for 24 hours.
223872399|NCT02259049|DIETARY_SUPPLEMENT|Sugar Pill|Each subject will receive a sugar pill BID for 24 hours.
223872400|NCT01863485|DRUG|CM082 Tablet|CM082 tablets taken orally once a day on 28-day cycles
223872401|NCT03787966|OTHER|ATOPE-B|Patients will perform therapeutic exercise before medical treatment and will follow the usual care after medical treatment.
223872402|NCT03787966|OTHER|ATOPE-I|Patients will follow usual care before medical treatment and will perform therapeutic exercise after medical treatment.
223872403|NCT05965141|DRUG|Aribulin;carboplatin;bevacizumab|Aribulin combined with carboplatin and bevacizumab in first-line treatment of platinum-sensitive recurrent ovarian cancer.
223872404|NCT00083551|DRUG|Thalidomide|All patients will be randomly assigned to receive thalidomide 400 mg as an oral, once daily dose throughout induction and 100mg between transplants after platelets are greater than 50,000μl and 200 mg post transplant consolidation, and a reduced dose of 100 mg on alternating days during the first year of maintenance and 50 mg qod thereafter versus no thalidomide. Thalidomide will be held during conditioning, transplant procedure, and recovery following transplant. It may be resumed once plateletrecovery is complete after each transplant
223872405|NCT00083551|DRUG|Ara-C|"Cytarabine (Ara-C) 400 mg/m2 in 250 ml D5W over one hour daily for four days (on days -5, -4, -3, -2).~Start infusion 30 minutes after completion of BCNU on day -5."
223872406|NCT00083551|DRUG|BCNU|Carmustine (BCNU) 300 mg/m2 in 1 liter of D5W in glass bottle (protect from light) to infuse over 2 hours on day -5. Check blood pressure every 15 minutes during infusion and 30 minutes after completion
223872407|NCT00083551|DRUG|Cisplatin|"Cisplatin\* 15 mg/m2/day Continuous infusion 1-4 (DCEP CYCLE 2) Cisplatin\* 7.5 mg/m2 Continuous infusion 1-4 (DPACE cycle)~\*Cisplatin doses will be modified for renal insufficiency as follows: Cisplatin dose Creatinine 15 mg/m2 (full dose) \< 1.5 mg/dl 10 mg/m2 1.6 - 2.0 mg/dl 7.5 mg/m2 2.1 - 3.0 mg/dl 0 mg (hold Cisplatin) \> 3.0 mg/dl"
223872408|NCT00083551|DRUG|Cytoxan|Cycle 2 - DCEP Cyclophosphamide 400 mg/m2/day Continuous infusion 1-4 Cycle 3 - CAD and PBSC Collection #1 Cyclophosphamide 750 mg/m2/day Continuous infusion 1-4 Cycle 4 - DCEP Cyclophosphamide 400 mg/m2/day Continuous infusion 1-4 Cytoxan/VP-16 and PBSC Collection-Cyclophosphamide 2 grams/m2 (Total dose 4 gm/m2) IV by CI 1 and 2 Post-Transplant Consolidation-Cyclophosphamide 300 mg/m2 Continuous infusion 1-4
223872409|NCT00083551|DRUG|Dexamethasone|Induction cycle 1 VAD Dexamethasone 40 mg/day PO 1-4, 9-12, 17-20 Cycle 2 - DCEP Dexamethasone 40 mg/day PO 1-4 Cycle 3 - CAD and PBSC Collection #1 Dexamethasone 40 mg/day PO 1-4 Cycle 4 - DCEP and PBSC Collection #2 Dexamethasone 40 mg/day PO 1-4 Post-Transplant Consolidation Dexamethasone 40 mg PO 1-4 Dexamethasone Consolidation Patients that do not achieve adequate platelet recovery (defined as \< 80,000/μl) will receive consolidation with Dexamethasone 40 mg x 4 days every 28 days for 1 year Maintenance year one Dexamethasone 40 mg PO q 3 months, day 1-4, 9-12, 17-20
223872410|NCT00083551|DRUG|Doxorubicin|Doxorubicin may be further diluted in 5% dextrose or sodium chloride injection and should be administered slowly into tubing of a freely flowing intravenous infusion with great care taken to avoid extravasation.
223872411|NCT00083551|DRUG|Etoposide|Etoposide (VP16) 200 mg/m2 in 500 ml D5W over one hour daily for four days (on days -5, -4, -3, -2). Start infusion 30 minutes after completion of BCNU on day -5. Start infusion at completion of cytarabine on following three days
223872412|NCT00083551|DRUG|Filgrastim|G-CSF will be administered at a dose of 10mcg/kg or GM-CSF at a dose of 10 mcg/kg. G-CSF or GM-CSF will begin one day after completion of chemotherapy and continued during repeated apheresis and discontinued upon completion of apheresis.
223872413|NCT00083551|DRUG|Recombinant GM-CSF|GM-CSF at a dose of 10 μg/kg SC, divided in 2 doses each day, will begin one day after completion of chemotherapy and continued during repeated apheresis and discontinued upon completion of apheresis.
223872414|NCT00083551|DRUG|Interferon-alpha-2b|AGENT DOSE ROUTE DAYS Intron-A 3 million units/m2 SQ TIW Thalidomide (for those randomized at initial registration) 50 mg QOD PO Every other day (qod
223872415|NCT00083551|DRUG|Melphalan|Etoposide (VP16) 200 mg/m2 in 500 ml D5W over one hour daily for four days (on days -5, -4, -3, -2). Start infusion 30 minutes after completion of BCNU on day -5. Start infusion at completion of cytarabine on following three days
223872416|NCT00083551|DRUG|Vincristine|Formulation: 1 mg/1 ml, 2 mg/2 ml, and 5 mg/ 5 ml vials. Vincristine should be administered intravenously through a freely-running IV. If it extravasates, it produces a severe local reaction with skin slough. FATAL IF GIVEN INTRATHECALLY, FOR INTRAVENOUS USE ONLY.
223872417|NCT05379075|OTHER|26 styles of Chen Taichi training based on Relaxation guidelines|The arms and legs and the spine should rotate follow the arrow tips in order to cause a stretch reflex slightly. And then, the exerciser should use relaxation skills to eliminate the stretch reflex, such as exhaling, drop the control of body
223872418|NCT05379075|OTHER|26 styles of Chen Taichi training based on Coordination guidelines|"When the posture needs to open the arms should accompany with inhale and when the posture needs to close the arms should accompany with exhale. Similarly, if the arm is lifting should accompany with inhale, and the put down should accompany with exhale."
223872419|NCT02765100|DRUG|Minocycline|Minocycline 100 mg twice a day
223872420|NCT00961831|DRUG|F-18 (BAY85-8050)|Cancer patients, injection of BAY 85-8050, PET/CT
223872421|NCT00961831|DRUG|F-18 (BAY85-8050)|Healthy volunteers, injection of BAY 85-8050, whole body PET/CT for determination of effective dose, kinetics of BAY 85-8050 in blood
223872422|NCT00162422|DRUG|albuterol|
223872423|NCT02652442|BEHAVIORAL|Centrifugation Distance|To determine optimal distance off-axis, participants were rotated in a darkened rotary chair booth with 1 ear positioned 3.5 cm off-axis and the other ear positioned on-axis for 1 minute. Participants received 5 sessions in a 1-week period. Following a 2-week washout period, participants were rotated in a darkened rotary chair booth with 1 ear positioned 7.0 cm off-axis and the other ear positioned on-axis for 1 minute. Participants received 5 sessions in a 1-week period.
223872424|NCT02652442|BEHAVIORAL|Centrifugation Duration|To determine optimal duration, after a two week washout period, participants were rotated off-axis at 3.5 cm (determined to be optimal in Exp 1) for 3 minutes. Participants received 5 sessions in a 1-week period.
223872425|NCT02652442|BEHAVIORAL|Centrifugation Schedule|To determine optimal schedule, after a two week washout period, participants were rotated off-axis at 3.5 cm (determined to be optimal in Exp 1) for 3 minutes (determined to be optimal in Exp 2). Participants received biweekly sessions for a total of 5 sessions.
223872426|NCT04003259|BEHAVIORAL|Lifestyle management programme|The programme consisted of 1) the initiation phase (1-3 months), 2) the establishment phase (3-6 months), and 3) the maintenance phase (7-12 months). Guidance was given altogether on 25 separate occasions with special emphasis on the motivation and education. The goal for weight loss was 5-10 %. The programme included four visits by medical doctor, an educational lecture by medical doctor and personal trainer, five sessions by registered dietician, two cooking classes by professional chef, two group discussions, and exercise as follows: personalized exercise program tailored by personal trainer, one-year gym access with four guided group sessions, and two guided group Nordic walking sessions, and three individual exercise sessions by personal trainer.
223872427|NCT01065506|BEHAVIORAL|Cognitive Behavioral Treatment|Cognitive Behavioral Treatment
223872428|NCT01065506|DRUG|Nicotine Patch|Nicotine Patch
223872429|NCT01065506|BEHAVIORAL|Wellness Program|Wellness Program
223872430|NCT01065506|BEHAVIORAL|Aerobic Exercise|Aerobic Exercise
224268929|NCT05201339|PROCEDURE|Hean and Neck Rotation|After rotating the patient's head and neck to the left maximally, insert the i-gel™ from the right side of the tongue to the midline. When the tip reaches the soft palate and oropharynx positions, turn the head and neck back to the neutral position.
223872431|NCT06097390|DRUG|Semaglutide|Oral administration
223872432|NCT05012072|BEHAVIORAL|The Mastery Lifestyle Intervention|Combination cognitive behavioral intervention of phase 3 CBT using ACT and PST
223872433|NCT02949583|DRUG|Punica granatum Linn.|Mouthwash (6,25% of Punica granatum Linn) 10mL per day during 14 days
224268930|NCT03221530|BEHAVIORAL|Early Intervention for Suicide Risk Among Immigrant Youth|The EISR-I intervention includes family treatment engagement, shared problem definition, and sessions designed to address family cohesion, communication, and conflict resolution.
224268931|NCT03221530|BEHAVIORAL|Enhanced usual care|This intervention includes a session with the family to engage in safety planning and provide feedback on their baseline assessment data.
224268932|NCT00840840|DRUG|600 mg Amoxicillin/42.9 mg Clavulanate Postassium /5 mL|1 x 600 mg/42.9 mg/5 mL, single-dose fasting
224268933|NCT00840840|DRUG|Augmentin ES-600™|1 x 600 mg/42.9 mg/5 mL, single-dose fasting
223872434|NCT02949583|DRUG|chlorhexidine|standard anti-bacterial mouthwash Mouthwash (0,12% chlorhexidine) 10mL per day during 14 days
223872435|NCT03931265|DIAGNOSTIC_TEST|ketohexokinase|Check the isoforms of ketohexokinase in the specimen of endometrial cancer
223872436|NCT03152344|PROCEDURE|Timed Up and Go|It's a functional test evaluating the time to rise from a chair, walk 3 meters, turn around, walk back to the chair and sit down (abnormal cut-off value \>12 seconds).
223872437|NCT05741996|BEHAVIORAL|Taping|Taping types and brace acute effects for knee osteoartritis
223872438|NCT02860910|BEHAVIORAL|Cognitive Behavioral Group Therapy|
223872439|NCT05384210|DRUG|Milnacipran|Milnacipran will be administered according to the treatment recommendations for fibromyalgia, starting with 50 mg once daily for 1 week then increasing to reach 100 mg daily (50 mg twice daily) based on efficacy and tolerability for 3 months.
223872440|NCT05384210|DRUG|Gabapentin|Patients will receive gabapentin (1200 mg twice daily) as a monotherapy. Gabapentin will be administered according to the treatment recommendations for FM patients starting with 400 mg 3 times per day, then increasing the dose to 800 mg 3 times per day with a maximum dose of 2400 mg per day according to efficacy and tolerability for 3 months
223872441|NCT05384210|DRUG|Combined gabapentin/milnacipran|Patients will receive combined gabapentin as group B and MLN as group A
223872442|NCT03401190|DRUG|CM4620 Injectable Emulsion (Low Dose)|CM4620-IE 1.0 mg/kg on Day 1 and then 1.4 mg/kg on Days 2-4, during the first phase of the study (Cohorts 1 and 2). All doses of CM4620-IE will be administered intravenously (IV) over 4 hours.
223872443|NCT03401190|DRUG|CM4620 Injectable Emulsion (High Dose)|CM4620-IE 2.08 mg/kg on Days 1 and 2 and then 1.6 mg/kg on Days 3 and 4, during the second phase of the study (Cohorts 3 and 4). All doses of CM4620-IE will be administered intravenously (IV) over 4 hours.
223872444|NCT05434624|DRUG|Midazolam|Before the procedure, all patients were given i.v. 0:02 - 0:04 mg / kg midazolam (zolamide 15 mg / 3 mL, and medications, Turkey) will be administered.
223872445|NCT05434624|DRUG|Propofol|Propofol 0.5 mg/kg bolus dose will be administered to Group II. Maintenance will be provided with 60 mcg/kg/min propofol infusion, and the propofol infusion dose will be increased by 10 mcg/kg/min by titration until the BIS value is 40-60 during the procedure.
223872446|NCT02943629|DEVICE|Apneic oxygenation: Eight minute|A Pentax AWSTM video laryngoscope with attached P blade will be placed and then 10 l/minute flow of oxygen will be administered through the P blade (apneic oxygenation) for eight minutes, or less if SpO2 falls to ≤ 95%. The trachea will then be intubated and the ventilation of the lungs will commence using 100% oxygen until SpO2 ≥ 98%.
223872447|NCT02943629|DEVICE|Without apneic oxygenation|A Pentax AWSTM video laryngoscope with attached P blade will be placed for eight minutes, or less if SpO2 falls to ≤ 95%. The trachea will then be intubated and the ventilation of the lungs will commence using 100% oxygen until SpO2 ≥ 98%.
223872448|NCT02943629|DEVICE|Apneic oxygenation: five minutes|A Pentax AWSTM video laryngoscope with attached P blade will be placed and then 10 l/minute flow of oxygen will be administered through the P blade (apneic oxygenation) for five minutes, or less if SpO2 falls to ≤ 95%. The trachea will then be intubated and the ventilation of the lungs will commence using 100% oxygen until SpO2 ≥ 98%.
223872449|NCT02570568|DEVICE|Veinlite|Veinlite is a device that emits red light. It provides a non-invasive technique of inserting intra-venous cannula. Placing it onto the skin will cause the outlines of the veins to show up.
223872450|NCT02570568|DEVICE|Pen-torch Transillumination|Pen-torch Transillumination is a non-invasive technique that utilizes 2 pen-torches to provide illumination.The tips of the pen torches are pressed onto the skin, causing the silhouette of the vein to show up
223872451|NCT02570568|PROCEDURE|Conventional Venepuncture|This involves the conventional method of identifying veins suitable for venepuncture, which involves visualization and palpation.
223872452|NCT02500264|DEVICE|TENS|
223872453|NCT03705442|DIETARY_SUPPLEMENT|Omni-Biotic 10|All patients will have at their disposal current medications for diarrhea based on guidelines, and education regarding side effects and dietary recommendations will be undertaken. One cohort will also ingest a probiotic (OMNi-BiOTiC® 10AAD), while other cohort will take a placebo, same in colour, shape, taste and smell; both medications will be taken 2 per day, every 12 hours, over 84 days (6 chemotherapy cycles every 14 days).
223872454|NCT03705442|DRUG|"loperamide (Seldiar)"|All the patients will have access to standard drugs for diarrhoea
223872455|NCT03419442|DRUG|Xofigo|Radium-223, 55kBq (1.49 microcurie) per kg body weight given at 4 week intervals for 6 injection
223872456|NCT03419442|DRUG|Taxotere|Docetaxel injection 75mg/m2 every 3 weeks
223872457|NCT03419442|DRUG|Jevtana|Cabazitaxel injection 25mg/m2 intravenously once every 3 weeks
223872458|NCT03022812|OTHER|Neck-specific exercise|Neck-specific exercise
223872459|NCT05579054|DIAGNOSTIC_TEST|Foot Posture Index (FPI-6)|FPI-6 is a valid and reliable assessment tool for pediatrics in which 6 items are scored separately for the right and left feet while the patient was in an upright position in a relaxed posture with their body-weight evenly distributed on the both feet. Each item is scored as -2, -1, 0, 1, 2 and the assessment categorized as follows: 0 to +5 normal; +6 to +9 pronated; 10+ higly pronated; -1 to -4 supianted; and -5 to -12 higly supinated.
223872460|NCT00861029|DRUG|Pazopanib|Subjects treated with pazopanib
223872461|NCT00861029|OTHER|Placebo for pazopanib|Control for comparison with pazopanib
223872462|NCT00861029|DRUG|Moxifloxacin|Comparator for pazopanib
223872463|NCT00861029|OTHER|Placebo for moxifloxacin|Placebo for moxifloxacin
223872464|NCT05386498|PROCEDURE|precured composite insert technique|After curing of bonding agent a 2mm increment of composite will be placed on the gingival floor of the cavity and cured. a measured volume of composite(3mm height and 2mm width) will be cured outside the oral cavity on a flat plastic instrument for 40 seconds. a second increment of composite will be placed on the cavity and the precured composite will be pressed in the uncured increment and pressed outward against the matrix band and light cured for 20 seconds the rest of the cavity will be filled using the oblique layering technique.
223872465|NCT05386498|PROCEDURE|Contact making instrument|"a 1-2mm increment of the composite will be placed in the gingival floor of the proxial box.~a contact forming instrument will be placed in this uncured increment and an outward force will be applied using the instrument from the inside of the matrix band. The composite will then be cured for 20 seconds to achieve a tight contact."
223872466|NCT05386498|PROCEDURE|Incremental composite layering technique|Increments will be placed in 1-2mm increments in oblique layering manner by a flat plastic instrument and condenser .Each increment will be cured for 20 seconds till the cavity is slightly overfilled.
223872467|NCT00106080|BEHAVIORAL|Audit and Feedback|Intervention patients and clinicians received a one-page patient-specific individualized summary, based on questionnaire responses, to stimulate conversations.
223872468|NCT03740009|DRUG|Bazedoxifene/Conjugated Estrogen|20 mg bazedoxifene/0.45mg conjugated estrogens tablets
223872469|NCT01061151|DRUG|Zidovudine (ZDV)|300 mg twice daily
223872470|NCT01061151|DRUG|Nevirapine (NVP): Antepartum Mothers|200 mg at onset of labor
223872471|NCT01061151|DRUG|Emtricitabine-tenofovir disoproxil fumarate (Truvada [TRV]) tail|200 mg/300 mg x 2 tablets at onset of labor or as soon as possible thereafter; 200 mg/300 mg orally each day after delivery for 7 days or the date of the Week 1 visit (up to 14 days), whichever is later.
223872472|NCT01061151|DRUG|Lamivudine-Zidovudine (3TC-ZDV)|150 mg/300 mg twice daily
223872473|NCT01061151|DRUG|Lopinavir-ritonavir (LPV-RTV)|400 mg/100 mg twice daily beginning at \>= 14 weeks gestation; 600 mg/150 mg twice daily beginning at \>= 28 weeks gestation or at next visit (during third trimester) through delivery; 400 mg/100 mg twice daily after delivery up to 14 days postpartum.
223872474|NCT01061151|DRUG|Emtricitabine-tenofovir disoproxil fumarate (Truvada [TRV])|200 mg/300 mg
223872475|NCT01061151|DRUG|Nevirapine (NVP): Infant short-course|Oral suspension (dosing according to birth weight) once a day through 42 days of age or through the week 6 visit, whichever is later.
223872476|NCT01061151|DRUG|Nevirapine (NVP): Infant extended|Oral suspension (dosing according to birth weight) once a day from 6 (up to 14) days of age until there was no longer any risk of MTCT or until the end of follow-up (104 weeks), whichever came first.
223872477|NCT01061151|OTHER|No Intervention|"Women registered before/during labor received the full Antepartum Arm A regimen.~Women registered after labor, and who received nevirapine outside of the study, received the Emtricitabine-tenofovir disoproxil fumarate (Truvada \[TRV\]) tail."
223872478|NCT01061151|OTHER|Discontinue triple ARVs|ARVs were discontinued. When protocol specified criteria were met, mothers could be prescribed any licensed antiretroviral medication, as long as the treatment met the definition of HAART (three ARV drugs from two or more drug classes).
223872479|NCT01061151|OTHER|Continue triple ARVs|Mothers could be prescribed any licensed antiretroviral medication, as long as the treatment met the definition of HAART (three ARV drugs from two or more drug classes).
223872480|NCT03813498|BEHAVIORAL|HCV articles|The intervention group receive a targeted short article on HCV from WeChat weekly.
223872481|NCT03813498|BEHAVIORAL|general health articles|The control group receive a general health article with no mention of HCV from WeChat weekly.
223872482|NCT04811950|DEVICE|Emerald|Complete blood countdevice
223872483|NCT05032638|BEHAVIORAL|Therapist guided training|Therapist guided period delivered virtually (WebEx/Zoom). Participants will be patients associated with NYULH and will have access to Zoom. Each session will last 45 min, and will completed 3x/week by research therapists, who are part of the study.
223872484|NCT05032638|BEHAVIORAL|Upper extremity (UE) Training|The 4-week UE training is completed in the participants home on their own and communication with study staff is virtual. Participants will receive daily communication through the Expiwell app to answer survey questions related to adherence, and safety/adverse events. Participants will also complete weekly check-ins with their research therapist over Zoom to answer questions about difficulties related to UE training activities, refinement of training goals, and to receive feedback on their training performance. Each weekly check-in will be approximately 45 minutes.
223872485|NCT03535558|DRUG|Fluoroquinolone (FQ)|Participants exposed to an oral FQ will be observed. The oral FQ included are Levofloxacin, Ciprofloxacin, Moxifloxacin, Ofloxacin, Gemifloxacin. Participants will not receive any intervention as a part of this study.
223872486|NCT03535558|DRUG|Azithromycin (AZ)|Participants exposed to an oral AZ will be observed. Participants will not receive any intervention as a part of this study.
223872487|NCT03535558|DRUG|Sulfamethoxazole/Trimethoprim (ST) Fixed Dose Combination|Participants exposed to an oral ST will be observed. Participants will not receive any intervention as a part of this study.
223872488|NCT03264846|DIAGNOSTIC_TEST|Collection of Serum and Saliva Samples|Whole saliva samples were obtained via expectorating into polypropylene tubes venous blood were obtained from the antecubital vein via the standard venipuncture method.
223872489|NCT04135989|DEVICE|Percutaneous coronary intervention with implantation of amphilimus-eluting stents for coronary artery disease.|Implantation of polymer-free, amphilimus-eluting, drug-eluting stents
223872490|NCT04135989|DEVICE|Percutaneous coronary intervention with implantation of everolimus-eluting stents for coronary artery disease.|Implantation of biodegradable-polymer, everolimus-eluting, drug-eluting stents
223872491|NCT04135989|DRUG|Personalized DAPT duration|Duration of dual antiplatelet therapy according to DAPT score for 3- or 6- months in patients with low DAPT score (stable CAD or ACS, respectively) or for 24-months in patients with high DAPT score
223872492|NCT04135989|DRUG|Standard DAPT duration|Duration of dual antiplatelet therapy for 12 months.
223872493|NCT04114422|OTHER|Seven-day preoperative exercise training program|The preoperative exercise training program will be supervised by a physiotherapist and will comprise aerobic exercise on a treadmill as well as strengthening exercises for the upper and lower limbs. The protocol will include 7 daily sessions of 60 minutes in duration. The treadmill exercise will start with a 5-minute warm-up and will progress to 30 minutes of exercise with a speed corresponding to 70% of the maximum speed reached in the incremental shuttle walk test. It will finish with a 5-minute cool down period. Participants will also perform three strengthening exercises for the lower limbs (hip flexion, knee flexion and extension) and three for the upper limbs (shoulder flexion, elbow flexion and extension). The initial strengthening exercises intensity will be set at 60% of 1RM and will be progressively increased. Patients will perform 3 sets of 8 to 12 repetitions for each exercise.
223872494|NCT01852071|GENETIC|Infusion of autologous EFS-ADA LV CD34+ (OTL-101)|autologous EFS-ADA LV CD34+ cells (OTL-101) are infused intravenously
223872495|NCT01852071|DRUG|busulfan|Busulfan is used for non-myeloablative conditioning
223872496|NCT01852071|DRUG|PEG-ADA ERT|PEG-ADA ERT is discontinued at Day +30 (-3/+15 days) after successful engraftment
223872497|NCT02082548|OTHER|Educational Intervention|This intervention will contain educational materials for both patients and providers that are specific to the needs in each participating country
223872498|NCT01432613|PROCEDURE|MRI-oriented muscle biopsy|Orientation of muscle biopsy according to the MRI results
223872499|NCT00459745|DRUG|Pravafen|
223872500|NCT00459745|DRUG|Pravastatin|
223872501|NCT00459745|DRUG|Fenofibrate|
223872502|NCT01075113|DRUG|sorafenib tosylate|Given orally
223872503|NCT01075113|DRUG|vorinostat|Given orally
223872504|NCT01935544|DEVICE|Botulinum toxin injection|
223872505|NCT05384691|DRUG|Luspatercept Injection|"All formally included patients will receive 1.75 mg/kg luspatercept administered subcutaneously every three weeks (on day 1 of each 21-day cycle) for a duration of 24 weeks.~Responders at the response assessment (according to HI-E) in week 25 will be further treated with 1.75 mg/kg luspatercept until loss of response for an expected maximum of 18 months."
223872506|NCT00586222|DIETARY_SUPPLEMENT|Omega-3 Fatty Acid|600 mg of eicosapentaenoic acid, 340 g of docosahexanoic acid, and 96 mg gama-linoleic acid for 12 weeks.
223872507|NCT00586222|OTHER|Placebo|placebo pill of the same size, color, and shape as the dietary supplement.
223872508|NCT00855400|PROCEDURE|Laminectomy and bone marrow stem cells transplantation|T3-T4 laminectomy and bone marrow ficoll separated mononuclear autologous cells intraspinal transplantation
223872509|NCT00855400|PROCEDURE|Autologous bone marrow cells collection|Autologous bone marrow cells collection under sedation. Sixty mL are obtained and processed through a ficoll gradient.
223872510|NCT03289468|DIAGNOSTIC_TEST|Voluson E8 (GE Medical Systems, USA), Minimally Invasive Endometrium Sampler|The endometrial thickness, basic characteristics information and endometrial blood flow energy index, endometrial vascularization index, blood flow index are detected by color power Doppler and the energy histogram of endometrium is obtained using a Voluson E8 (GE Medical Systems, USA) ultrasound system. The specimen of uterine cytology and endometrial tissue are obtained through minimally invasive endometrium sampler, which are diagnosed by pathology.
223872511|NCT04759482|DIAGNOSTIC_TEST|polysomnography|Polysomnography consisted in recording sleep parameters during one night, using a non-invasive multi-channels device, including respiratory sensors, electrocardiogram and electroencephalogram
223872512|NCT04727840|DRUG|Sodium Zirconium Cyclosilicate Oral Product|"Sodium zirconium cyclosilicate (SZC), a non-absorbed cation exchanger, selectively binds potassium in the intestine. SZC is in a powder form and will be provided to patients in packets containing 5g or 10gm of the medication. Participants will mix the contents of one packet with water (about 45mL). The drink should be stirred and drank immediately. If powder remains in the glass, then water should be added and the remainder of the drink should be consumed. Other medications should be taken 2 hours before or after SZC.~At Day 0 and Day 1, participants will be taking SZC at 10gm three times a day. A serum potassium will be checked on Day 2; if serum potassium is \<5.1mEq/L, then the dose will be decreased to the maintenance dose of 5gm per day. At each serum potassium checks, the medication dosage will be adjusted accordingly."
223872513|NCT05419570|OTHER|Fluid Loading|Hemodynamic and ventilatory parameters will be recorded at five time points (T1 - T5). After baseline meausrements (T1), additional 5 cmH2O PEEP will be applied to patients for 30 seconds (short time low peep challenge, SLPC). Prior to PEEP lowering T2 measurement will be performed. T3 measurement will be performed one minute after PEEP is decreased to its initial value and will be recorded as the second baseline. Thereafter, 100 ml isotonic saline will be infused over one minute (MFC). T4 measurement will be performed one minute after MFC is completed,. Lastly, T5 measurement will be performed three minutes after additional 400 ml of isotonic saline is infused within 10 minutes to complete 500 ml of fluid loading.
223872514|NCT05103358|DRUG|nab-sirolimus|Prospective phase 2, open-label, multi-institutional basket trial to determine the efficacy and safety of nab-sirolimus administered by IV infusion to patients
223872515|NCT02310113|OTHER|NIRS|Measurment of skeletal muscle oxygenation by near-infrared spectroscopy
223872516|NCT02866968|PROCEDURE|FLAPS|Surgical procedures will involve 1) excision of pterygium tissue from cornea and conjunctiva, 2) resection of residual Tenon and coagulation to stop any bleeding 3) preparation of a 8x8 mm conjunctiva autograft in the superior bulbar conjunctiva with the femtosecond laser (12 o´clock position) and 4) fixation of the graft with fibrin glue to the resection site.
223872517|NCT00151567|DRUG|Tamsulosin|Oral tamsulosin once a day until stone elimination or the end of the follow-up (42 days)
223872518|NCT00151567|DRUG|Placebo|Oral placebo of tamsulosin once a day until stone elimination or the end of the follow-up (42 days)
223872519|NCT03947346|OTHER|Urine sample|The urine collected from the first morning void will be used to assess urine creatinine and microalbumin. The fresh urine specimen will be analyzed for novel urinary biomarkers of (urinary NGAL, TGF-β1, IL-18 and KIM-1). Serum BUN, creatinine, and cystatin-C will be assessed using serum samples drawn for routine clinical care.
223872520|NCT02639910|BIOLOGICAL|Tafasitamab|tafasitamab (MOR208) dose: 12 mg/kg intravenous infusion
223872521|NCT02639910|DRUG|Idelalisib|idelalisib dose: 150 mg twice daily orally
223872522|NCT02639910|DRUG|Venetoclax|venetoclax dose: 400 mg once daily orally
223872523|NCT00108823|DRUG|Roflumilast|
223872524|NCT01671449|DRUG|S-1|S-1 : 40 mg/m2, twice daily, Day 1-14
223872525|NCT01671449|DRUG|Cisplatin|60 mg/m2/day Day 1
223872526|NCT01671449|DRUG|Oxaliplatin|130 mg/m2/day Day 1
223872527|NCT00377182|DRUG|Copegus|1000/1200mg po daily for 4 weeks
223872528|NCT00377182|DRUG|PEGASYS|180 micrograms sc weekly for 4 weeks
223872529|NCT00377182|DRUG|RO5024048 1500mg|1500mg po bid for 4 weeks
223872530|NCT00377182|DRUG|RO5024048 3000mg|3000mg po bid for 4 weeks
223872531|NCT05328271|DIETARY_SUPPLEMENT|Beta-Aminoisobutyric Acid|All supplements provided to all research participants containing BAIBA, L-Valine or placebo will be procured and prepared in a similar manner. Briefly, beta-amino isobutyric acid (BAIBA), L-Valine (an amino acid), and a resistant starch commonly consumed in various foods will be used as test agents for this study protcol. All supplements (both BAIBA and Valine) as well as placebo are produced and provided by NNB Nutrition. A certificate of analysis is provided in the attachments for the BAIBA. All supplements (BAIBA, L-Valine, and placebo) will be administered in gelatin capsules and consumed with a specified amount of cold tap water. The same number of capsules will be administered each time. All doses will be capsulated by manufacturer prior to use in the study protocol.
223872532|NCT00055705|BIOLOGICAL|PV701|
223872533|NCT04146519|BIOLOGICAL|Autologous mesenchymal stem cells|Autologous mesenchymal stem cells
223872534|NCT04146519|OTHER|Placebo|Saline solution
223872535|NCT02007590|DEVICE|Aerosure 25 Hz|Active Aerosure device
223872536|NCT02007590|DEVICE|Aerosure Sham|Device designed to appear identical to active device but with HFAO mechanism disabled
223872537|NCT01290341|DRUG|NAFT-600 (naftin 2 % gel)|Topical; applied once daily for two weeks
223872538|NCT01290341|DRUG|Placebo|Topical; applied once daily for two weeks.
223872539|NCT02059538|OTHER|Adipose tissue biopsies (omental and subcutaneous) liver|
223872540|NCT02059538|RADIATION|CT-scan|
223872541|NCT02059538|OTHER|Stools sampling|
223872542|NCT02059538|OTHER|DNA sampling|
223872543|NCT02059538|OTHER|Blood sampling|
223872544|NCT02059538|OTHER|Urine sampling|
223872545|NCT02059538|RADIATION|Dual energy X-ray absorptiometry-scan (DEXA-scan)|
223872546|NCT01450163|DRUG|Pregabalin, Oxaliplatin|Oxaliplatin will be infused according to the FLOX treatment strategy, as a regular six-month-long adjuvant treatment to colorectal cancer. Pregabalin will be administered P.O. three days before and three days after each of the nine Ox infusions. The dose will be titrated during the first Ox infusion to the highest level tolerated by the patient. The dose used in this first session will be used in the eight following sessions.
223872547|NCT01450163|DRUG|Placebo , Oxaliplatin|Oxaliplatin will be infused according to the FLOX treatment strategy, as a regular six-month-long adjuvant treatment to colorectal cancer. Placebo will be administered P.O. three days before and three days after each of the nine Ox infusions. The dose will be titrated during the first Ox infusion to the highest level tolerated by the patient. The dose used in this first session will be used in the eight following sessions.
223872548|NCT01755936|OTHER|Cardiac Magnetic Resonance Imaging|For the evaluation of left ventricular volumes, function and mass. Also for the assessment of myocardial fibrosis based on the presence of delayed enhancement. Novel application of T1 mapping techniques will be evaluated.
223872549|NCT01755936|OTHER|Echocardiography|Assessment of aortic stenosis severity. Also evaluate diastolic and systolic function.
223872550|NCT01755936|OTHER|72 hour Holter Monitor|This will enable us to detect abnormal heart rhythms which may be associated with myocardial fibrosis
223872551|NCT05820594|BIOLOGICAL|Intradermal BCG (bacillus calmette-guerin) vaccine AJV|Participants will receive a one off dose of BCG (bacillus calmette-guerin) Vaccine AJV which contains the Danish Strain of Mycobacterium bovis BCG at a dose of 6 - 24 x 105 CFU (three times the standard dose). This will be injected intradermally into the upper deltoid region.
223872552|NCT00245791|DRUG|Levofloxacin|
223872553|NCT02352909|OTHER|Education|Education on running training modifications depending on symptoms (decrease running speed, spread running volume throughout the week, run/walk intervals, avoid downhill and stairs running). Education about symptoms will also be provided.
223872554|NCT02352909|OTHER|Exercise program|A home-based program including strengthening and motor control exercises will be prescribed. The program will include 4 different phases of 2 weeks.
223872555|NCT02352909|OTHER|Gait retraining|Running gait will be modified to reduce knee loading while running (step frequency, impact, foot strike pattern).
223872556|NCT01919450|DRUG|Regadenoson|Subjects will undergo a rest/Lexiscan (regadenoson) stress myocardial perfusion PET study.
223872557|NCT01919450|RADIATION|Rubidium-82|Subjects undergo a rest/Lexiscan (regadenoson) stress myocardial perfusion PET study.
223872558|NCT03230903|OTHER|Home telerehabilitation|Patients will receive an individualized exercise plan sent to a computer at their home. Patients will have daily access to a physical therapist and exercise physiologist.
223872559|NCT03230903|OTHER|Usual Care|Patients will receive a written individualized exercise plan during their baseline visit on top of their usual disease care.
223872560|NCT03377205|DEVICE|Compression screws and neutralization plate|Open reduction and internal fixation with screws and plate
223872561|NCT03377205|DEVICE|Acumed Fibular Rod System|intramedullary nailing of fibula
223872562|NCT04055246|DIETARY_SUPPLEMENT|Inulin|9 grams of food grade inulin added to custom made fiber bars.
223872563|NCT04055246|DIETARY_SUPPLEMENT|Placebo (maltodextrin)|9 grams of food grade maltodextrin - replaces inulin in fiber bars.
223872564|NCT00373373|DRUG|Sorafenib|2 x 400 mg/d
223872565|NCT00373373|DRUG|Placebo|Chemotherapy + Placebo
223872566|NCT04436614|DIETARY_SUPPLEMENT|Dietary Supplement:Aloe Vera with Crocus (saffron)|Dietary Supplement:Aloe Vera with Crocus (saffron) with 1L of Aloe Vera with Crocus (saffron) 1 glass bottle per 15 days
223872567|NCT04436614|DIETARY_SUPPLEMENT|Dietary Supplement:Aloe Vera (simple)|Dietary Supplement:Aloe Vera (simple)with 1L of Aloe Vera 1 glass bottle per 15 days
223872568|NCT04436614|DIETARY_SUPPLEMENT|Dietary Supplement:Mediterranean Diet|Dietary Supplement:Mediterranean dietary protocol Intervention:mediterranean diet
223872569|NCT02931175|DRUG|ACTH gel|Starting at month 6, retreatment will be offered to study subjects who have demonstrated any level of response during the first 6 months and who meet any of these Retreatment Criteria listed below. Patients receiving retreatment will receive the dose that was assigned to them at randomization.
223872570|NCT01620034|RADIATION|Stereotactic Body Radiotherapy|Patients on the 11 day arm receive 4 fractions of SBRT every 3rd day. Patients on the 4 day arm receive 4 fractions of SBRT every day.
223872571|NCT00094016|DRUG|beclomethasone dipropionate|
223872572|NCT06251570|OTHER|Evaluation of Dual Task Performance|"The Montreal Cognitive Evaluation Scale will be used to evaluate the cognitive functions of the participants.~Evaluation of Physical Activity Level: The Turkish validity and reliability of the International Physical Activity Questionnaire Short Form made by Sağlam et al. will be used.~Evaluation of Quality of Life: It will be evaluated by the European Organization for Cancer Research and Treatments QLQ-C30 questionnaire.~Fatigue Evaluation: A fatigue severity scale consisting of 9 items will be used.~Dyspnea Assessment: The Modified Medical Research Council Dyspnea Scale will be used.~Respiratory Muscle Endurance: Evaluation will be done by respiratory muscle endurance test at constant threshold load with a Power Breathe device and according to the metronome warning and a MOXY monitor will be used. In evaluation of dual-task performance, an auditory task test will be performed while walking on the treadmill."
223872573|NCT01102231|DRUG|Chemotherapy|Pemetrexed 500 mg/m², D1 (D1=D22, 4 cycles) Cisplatin 75 mg/m², D1 (D1=D22, 4 cycles)
223872574|NCT01102231|DRUG|ERBITUX|The initial dose of cetuximab (ERBITUX) is 400 mg/m² intravenously administered over 120 minutes, followed by 11 weekly infusions at 250 mg/m² IV over 60 minutes
223872575|NCT01102231|RADIATION|Radiotherapy|66 Gy (2 Gy by fraction, 5 fractions by week)
223872576|NCT04319432|BEHAVIORAL|Voice rest|The first days will take place in hospitalization to assess patient complience to voice rest. Patients will be instructed to continue voice rest at home up to 7 days accourding to group allocation in the study. The confirmation of voice rest will relay on patient report (telephonic approval), after the voice rest period will end.
223872577|NCT01370343|DRUG|PF-04991532 alone|a single dose of 150 mg PF-04991532, fasted
223872578|NCT01370343|DRUG|PF-04991532 + cyclosporine|a single dose of 150 mg PF-04991532 + a single dose of 600 mg cyclosporine, fasted
223872579|NCT04261231|PROCEDURE|Surgery and anesthesia|Elective surgery in adults
223872580|NCT01957969|DEVICE|Sacral Nerve Stimulation|
223872581|NCT00233038|PROCEDURE|Ethanol injection into a cyst|
223872582|NCT05820269|BEHAVIORAL|parents-child psychotherapy|filling out questionnaires during psychotherapy consultations
223872583|NCT03167736|OTHER|electric dry needling, manipulation|HVLA thrust manipulation to lumbar spine. Dry needling to lumbar/sacral paraspinal muscles and gluteus medium/minimus muscles. Treatment may include dry needling of the piriformis muscle, quadrates lumborum muscle and perineurial needling of sciatic/tibial nerve. Up to 12 treatment sessions over 6 weeks.
223872584|NCT03167736|OTHER|conventional physical therapy|Impairment-based manual therapy, stretching, strengthening and electrothermal modalities targeting the lumbar/sacral spine and hips. Up to 12 treatment sessions over 6 weeks.
223872585|NCT01244672|PROCEDURE|Ferguson|This is a modification of the Milligan-Morgan technique, whereby the incisions are totally or partially closed with absorbable running suture. A retractor is used to expose the hemorrhoidal tissue, which is then removed surgically. The remaining tissue is either sutured or is sealed through the coagulation effects of a surgical device.
223872586|NCT01244672|PROCEDURE|THD|Transanal hemorrhoidal dearterialization will be performed using an endoscopic ultrasonic probe. Approximately 7-8 hemorrhoidal arteries will be ligated at 1, 3, 5, 7, 9, 11 o'clock position as previously described in the literature. The ligation will be performed using a vicryl suture. The ultrasonic probe locates the arterial signal.
223872587|NCT00047931|DRUG|VRC-HIVDNA009-00-VP|
223872588|NCT01000831|BIOLOGICAL|adjuvanted Arepanrix|Two doses of adjuvanted Arepanrix vaccine given 3 weeks apart
223872589|NCT00533910|DRUG|Rifaximin|550mg BID rifaximin for 8 weeks
223872590|NCT00533910|DRUG|placebo|same as the experimental arm
223872591|NCT04139434|DRUG|LP-108|For the dose escalation phase, LP-108 will be given once daily at the following dose levels: 100 mg QD, 200 mg QD, 400 mg QD, 600 mg QD, 800 mg QD, 1000 mg QD.
223872592|NCT04139434|DRUG|LP-108 and azacitidine|For the dose escalation phase, LP-108 will be given once daily at the following dose levels: 100 mg QD, 200 mg QD, 400 mg QD, 600 mg QD, 800 mg QD, 1000 mg QD, with azacitidine at the standard dose of 75 mg/m2 on Day 1 - Day 7 of each 28-day cycle (weekly schedule) or on Days 1-5, 8, 9 of each 28-day cycle (5-2-2 schedule), according to institutional guidelines.
223872593|NCT03877250|DIAGNOSTIC_TEST|Pre-Treatment Biopsy|Participants screened for participation will include those with a diagnosis of advanced NSCLC who have undergone a pre-treatment biopsy prior to start of therapy with a PD-(L)1 inhibitor or who are medically able to undergo a biopsy if (1) no pre-treatment biopsy has been obtained and (2) no PD-(L)1 inhibitor has been started.
223872594|NCT03877250|DIAGNOSTIC_TEST|On-Treatment Biopsy|All participants who receive at least 1 dose of PD-(L)1 inhibitor will be referred for a biopsy. The biopsy should be obtained within 4 weeks of first on-treatment imaging (usually performed \~6-9 weeks after beginning therapy) and will be performed in participants regardless of radiologic response.
223872595|NCT03877250|DIAGNOSTIC_TEST|Biopsy at Disease Progression|All participants who develop disease progression after initial response to PD-(L)1 blockade will be considered for an additional, optional biopsy. Biopsies at disease progression are often obtained per standard of care within 4 weeks of documented progression on imaging and prior to the initiation of further systemic therapy.
223872596|NCT03877250|DIAGNOSTIC_TEST|Peripheral Blood-Based Studies|All participants will have peripheral blood obtained on Day 1 of cycles 1-4 (0, 3, 6, and 9 weeks). At each time point, peripheral blood sample will be collected pre-treatment and used for analysis of T cell subsets and TCR sequencing.
223872597|NCT06408662|OTHER|mindfulness-based intervention for tics (MBIT)|Psychological intervention that focuses on cultivating awareness of urges to tic and developing a different relationship to those urges through meditation and other mindfulness practice
223872598|NCT06408662|OTHER|psychoeducation with relaxation and supportive therapy (PRST)|Psychological Intervention that focuses on learning more about tics, practicing a range of strategies for coping with tics (e.g., relaxation, effective communication), and discussing challenges commonly experienced by individuals with tics.
223872599|NCT05390866|OTHER|HIIT|A single HIIT on a bicycle ergometer
223872600|NCT01721343|BEHAVIORAL|telephone-based intervention|Undergo telephonic monitoring
223872601|NCT01721343|OTHER|case management|Participate in an individualized conditioning program with an RCM
223872602|NCT01721343|PROCEDURE|management of therapy complications|Undergo enhanced usual care with an RCM and PCM
223872603|NCT01721343|PROCEDURE|physical therapy|Participate in an individualized conditioning program with an RCM
223872604|NCT01721343|OTHER|questionnaire administration|Ancillary studies
223872605|NCT01721343|PROCEDURE|quality-of-life assessment|Ancillary studies
223872606|NCT01721343|PROCEDURE|management of therapy complications|Undergo enhanced usual care
223872607|NCT01721343|PROCEDURE|assessment of therapy complications|Undergo enhanced usual care
223872608|NCT01721343|OTHER|educational intervention|Participate in an individualized conditioning program with an RCM
223872609|NCT01721343|PROCEDURE|management of therapy complications|Undergo enhanced usual care with an RCM
223872610|NCT01721343|PROCEDURE|assessment of therapy complications|Undergo enhanced usual care with an RCM
223872611|NCT01721343|PROCEDURE|assessment of therapy complications|Undergo enhanced usual care with an RCM and PCM
223872612|NCT03443661|DRUG|FOLFOXIRI|oxaliplatin 85 mg/m2 irinotecan 150 mg/m2, 5FU 2,400 mg/m2 by 46 h infusion repeated at 2week intervals
223872613|NCT03767907|BEHAVIORAL|Computer-based Training for Cognitive Behavioural Therapy|Interactive content organized into seven modules, illustrating real-life scenarios associated with common risky situations, which illustrate the application of targeted skills and strategies
223872614|NCT03767907|BEHAVIORAL|Treatment As Usual|Treatment as usual will include standard psychosocial care determined to be appropriate or necessary, on an individual patient basis.
223872615|NCT03522337|OTHER|Visual pedagogy (social stories)|Oral health instruction, tooth-brushing training (toothbrushes and fluoridated toothpastes provided)
223872616|NCT03522337|OTHER|Conventional leaflets|Oral health instruction, tooth-brushing training (toothbrushes and fluoridated toothpastes provided)
223872617|NCT03185338|BEHAVIORAL|Active commuting to/from school|Active transport to/from school on foot or by bike will be promoted
223872618|NCT03185338|BEHAVIORAL|Active Physical Education lessons|Specific lessons designed for increasing moderate to vigorous physical activity in Physical Education will be applied
223872619|NCT03185338|BEHAVIORAL|Active school recess|Teachers will design games and activities and will encourage children for being active
223872620|NCT03185338|BEHAVIORAL|Sleep health promotion|This intervention will aim to raise the awareness of the importance of having a good quality sleep at night and to teach healthy sleep behaviours that will contribute to improving sleep hygiene
223872621|NCT03185338|BEHAVIORAL|School global intervention|A simultaneous implementation of all four interventions (see the others arms) will be examined in one of the intervention schools.
223872622|NCT05188430|DEVICE|Medical Device (Kaptufat®)|"140 mg chitosan, 460 mg cellulose and 35.384 mg ascorbic acid for 1 tablet~Oral administration: 3 tablets twice a day before the main meals"
223872623|NCT05188430|OTHER|Placebo|Oral administration: 3 tablets twice a day before the main meals
223872624|NCT04802148|PROCEDURE|membrane guided regeneration|after tooth extraction, the socket was filled with membrane and graft (FDBA)
223872625|NCT04802148|PROCEDURE|collagen plug|after tooth extraction, the socket was filled with collagen plug
223872626|NCT02568683|DRUG|Entospletinib|ENTO spray dried dispersion tablets administered orally twice daily while in a fasted state
223872627|NCT02568683|DRUG|Vincristine|VCR administered intravenously
223872628|NCT05155917|DRUG|Insulin Glargine 300 UNT/ML [Toujeo]|insulin glargine sc (0.25 U/kg body weight)
223872629|NCT01828775|OTHER|palliative care|Receive early PCI
223872630|NCT01828775|OTHER|palliative care|Receive delayed PCI
223872631|NCT01828775|PROCEDURE|quality-of-life assessment|Ancillary studies
223872632|NCT01828775|OTHER|survey administration|Ancillary studies
223872633|NCT04783012|PROCEDURE|Catheter removal|Catheter management strategy after surgery
223872634|NCT05010655|DEVICE|Use of Eko DUO Electronic Stethoscope|Auscultation of heart sounds using electronic stethoscope
223872635|NCT03100513|DRUG|Lactulose|(lactulose) (20 to 30 g administered orally or by nasogastric tube (3 or more doses within 24 hours) or 200 g by rectal tube if oral intake was not possible or inadequate
223872636|NCT03100513|DRUG|Polyethylene Glycol|PEG as single dose of (3sachets if patient \<75Kg over 3 hours or 4 sachets if patient \>75Kg over 4 hours) dministered orally or via a nasogastric tube (each sachet 64g/25Kg must be dissolved in one liter of water).
223872637|NCT03381781|DRUG|Decitabine|20mg/m\^2,d1-5,ivgtt,28days as a duration
223872638|NCT03381781|DRUG|Arsenic Trioxide|0.16mg/kg,d1-5,ivgtt,28days as a duration
223872639|NCT03381781|DRUG|Cytarabine|15mg/m\^2,hypodermic injection,q12h,d1-7
223872640|NCT02190643|BEHAVIORAL|Cessation counseling with adherence focus|
223872641|NCT02190643|BEHAVIORAL|Cessation counseling without adherence focus|
223872642|NCT00220272|DRUG|SR57667B|
223872643|NCT04711213|DRUG|Dexamethasone Dose 1|Dexamethasone ophthalmic suspension dose 1
223872644|NCT04711213|DRUG|Dexamethasone Dose 2|Dexamethasone ophthalmic suspension dose 2
223872645|NCT04711213|DRUG|Placebo Dose 1|Placebo suspension dose 1
223872646|NCT04711213|DRUG|Placebo Dose 2|Placebo suspension dose 2
223872647|NCT02214550|DRUG|cyclic microgestin 1/20|Cyclic OC Use - Participants will ingest pills containing active hormones for 21 days followed by 7 days of no pills, and then the cycle will repeat
223872648|NCT02214550|DRUG|continuous microgestin 1/20|Continuous OC use - Pills containing hormones will be taken every day for 1 year
223872649|NCT02241538|DEVICE|Pilates 1|Combination of an educational booklet with exercises of the Pilates method. Patients will receive 6 sessions of treatment over a period of 6 weeks (1 session/week). The exercises of the Pilates method will be individualized to each patient´s needs (pragmatic treatment).
223872650|NCT02241538|DEVICE|Pilates 2|Combination of an educational booklet with exercises of the Pilates method. Patients will receive 12 sessions of treatment over a period of 6 weeks (2 sessions/week). The exercises of the Pilates method will be individualized to each patient´s needs (pragmatic treatment).
223872651|NCT02241538|DEVICE|Pilates 3|Combination of an educational booklet with exercises of the Pilates method. Patients will receive 18 sessions of treatment over a period of 6 weeks (3 sessions/week). The exercises of the Pilates method will be individualized to each patient´s needs (pragmatic treatment).
223872652|NCT02241538|DEVICE|Control|Patients will receive an educational booklet containing information about the anatomy of the spine and pelvis and the low back pain and recommendations regarding posture and movements involved in activities of daily living. The participants in this group did not receive additional exercise.
223872653|NCT03876249|OTHER|exposure to RSV|No intervention will be given, children naturally exposed to RSV in their early life
223872654|NCT00370019|DRUG|Estradiol/Medroxyprogesterone acetate|
223872655|NCT01581372|OTHER|Pharmacist care|Pharmacist prescribing, education, drug management
223872656|NCT01840826|OTHER|RED-D Care Management|The Case Management intervention will continue for 12 weeks post-discharge (from the index admission).
223872657|NCT00194896|DRUG|rosiglitazone|Tablet taken orally at a dosage of 4 mg once per day and increase to twice per day if adequate glycemic control was not achieved. Study drug was taken up to 3 years.
223872658|NCT00194896|DRUG|glyburide|Tablet taken orally, initially 2.5 mg in the morning or dose subject received prior to starting the study. Dosage was increased by 2.5 mg in the evening up to a maximum of 10 mg twice a day if necessary to achieve desired glycemic control. Study drug was taken up to 3 years.
223872659|NCT02652689|RADIATION|Diagnostic ultrasound radiation|Recording Doppler ultrasound signals from the right chest wall
223872660|NCT00367159|PROCEDURE|endoscopic treatment of vesico-renal reflux|Autologous Adipocytes Graft (lipostructure)
223872661|NCT01369004|BEHAVIORAL|Daily Self-weighing + weekly feedback+ weekly lessons|Daily self-weighing as a form of self-monitoring of body weight using a smart scale that sends their weights directly to a website (www.bodytrace.com) via the cellular network. They will be able to review weight trends overtime on this website via a graph showing both changes in weight and BMI. They will also receive weekly emailed feedback on their weight loss progress and compliance to the daily self-weighing prescription from a registered dietitian, as well as weekly emailed lessons with content related to behavioral weight control (e.g, how to control portion sizes, how to develop and exercise routine).
223872662|NCT06243094|DRUG|Antibiotic|All antibiotic therapy characteristics are monitored.
223872663|NCT02142751|DRUG|Fosfomycin sodium intravenous|4g every 6 hours iv (60 min infusion)
223872664|NCT02142751|DRUG|Meropenem intravenous|1g every 8 hours (15-30 min infusion) It depends on strain sensitivity: Strain with resistance to cephalosporins
223872665|NCT02142751|DRUG|Ceftriaxone intravenous|1g every 24 hours iv (2-4 min infusion) It depends on strain sensitivity: Strain with resistance to quinolone but sensitivity to cephalosporins
223872666|NCT05770427|BEHAVIORAL|Make the Connection® Online Program|"Make the Connection® (MTC) is an evidence-based parenting program offered by Strong Minds Strong Kids, Psychology Canada. Recently, the MTC program has been adapted to an online platform to help increase scalability and accessibility across Canada. The online modality is self-administered by parents and consist of 8 weekly, 15-minute modules.~MTC is an attachment-focused, evidence-informed, parent training program that is designed to support the development of positive parent-child relationships by teaching parents to understand their infant's cues. The overarching goal of the program is to enhance parental attitudes and cognitions towards their infants, which have been shown to be associated with sensitive parenting behaviour, and in turn, secure child attachment. Ultimately, by improving parenting skills and attitudes, the program seeks to support secure infant attachment."
223872667|NCT04350567|OTHER|Sleep Deprivation|On the first night, the participant sleeps normally as we assess their melatonin through blood work. On the second night, the participant has 3 PET/MRI scans. On the third night, the participant undergoes sleep deprivation. On the fourth night, the participant sleeps normally and we assess their melatonin again through blood work. Depression scores are taken before and after the intervention.
223872668|NCT05304377|DRUG|ELVN-001|orally once or twice daily
223872669|NCT06130020|BEHAVIORAL|Expressive Writing: Self|This intervention consists of a daily expressive writing exercise carried out for 14 consecutive days, for 15 minutes each day. Expressive writing involves asking participants to write about their deepest thoughts and feelings surrounding an emotional event. Participants in this condition will write as if they are writing to themselves.
223872670|NCT06130020|BEHAVIORAL|Expressive Writing: Other|This intervention consists of a daily expressive writing exercise carried out for 14 consecutive days, for 15 minutes each day. Expressive writing involves asking participants to write about their deepest thoughts and feelings surrounding an emotional event. Participants in this condition will write as if they are writing/talking to someone they're close to.
223872671|NCT06130020|BEHAVIORAL|Factual Writing|This intervention consists of a daily factual writing exercise carried out for 14 consecutive days, for 15 minutes each day. Participants are asked to give a factual description of their day. This is a standard control for Expressive writing studies. Participants in this condition will be asked to direct their writing to themselves.
223872672|NCT04764006|DRUG|Surufatinib|Surufatinib(250mg ,qd,po)+Sintilimab(200mg,q3w,iv),21 days for a cycle.The curative effect was evaluated every 8 weeks.
223872673|NCT04474379|BEHAVIORAL|Strategy Training (Time- and Event- Based)|In time-based training, strategic clock-checking behavior is taught by requiring participants to click a button to reveal the virtual time of day. Event-based training involves implementation intention methods.
223872674|NCT02133404|DRUG|ASP7991|oral
223872675|NCT02133404|DRUG|Cinacalcet|oral
223872676|NCT02133404|DRUG|Placebo|oral
223872677|NCT00235508|DRUG|Eszopiclone (Lunesta)|Escitalopram oxalate 10 mg at bedtime; Eszopiclone 3 mg at bedtime
223872678|NCT00180258|DEVICE|Cardiac Resynchronization Therapy with & without defibrillator|
223872679|NCT05305846|DEVICE|TENA-PROTO2|During urodynamics, the TENA-PROTO2 will be positioned onto the lower abdomen of patients to collect raw data for the continuous development of the future ultrasound bladder sensor.
223872680|NCT02748486|BEHAVIORAL|Metacognitive Training Jumping to Conclusion|Therapeutical intervention based on cognitive-behavioural therapy paradigm. Addresses cognitive bias of schizophrenia patients - jumping to conclusion.
223872681|NCT02748486|BEHAVIORAL|Group discussion|Group discussion of current events
223872682|NCT02748486|BEHAVIORAL|Metacognitive Training To Empathize|Therapeutical intervention based on cognitive-behavioural therapy paradigm. Addresses cognitive bias of schizophrenia patients - Theory of Mind deficits.
223872683|NCT01763970|RADIATION|SBRT|
223872684|NCT01595334|DRUG|Cetrorelix|Cetrorelix 0.25 mg/d would be administered by subcutaneous injection to women when the plasma LH is higher (\>4.5 mIU/ml) in the study arm
223872685|NCT01595334|DRUG|Luprolide Acetate|Women in the control arm would receive Luprolide acetate 1 mg/day by subcutaneous injection
223872686|NCT01297101|DRUG|Erlotinib|150mg/qd, on day 15-28 of each 28 day cycle.
223872687|NCT02359370|DRUG|Lidocaine|Lidocaine 2 mg/kg was administered through continuous infusion, immediately before induction of anesthesia
223872688|NCT02359370|DRUG|Magnesium Sulphate|Magnesium Sulphate 30 mg/kg was administered through continuous infusion, immediately before induction of anesthesia
223872689|NCT00049790|DRUG|recombinant human Angiostatin protein|
223872690|NCT00049790|DRUG|paclitaxel|
223872691|NCT00049790|DRUG|carboplatin|
223872692|NCT06150287|OTHER|Florajen Digestion|Florajen Digestion is a probiotics. One probiotics capsule contains 15 billion Colony Forming Unit (CFU) of live microorganisms. No live microorganisms are present in the placebo capsules.
223872693|NCT05521061|DIETARY_SUPPLEMENT|2-fucosyllactose|Volunteers will be visited to provide the investigational product/placebo to the diets of the patients included in the study for 3 months, and the use of the investigational product/placebo will be monitored. Parents will be trained by their fellows to provide synthetic breast milk oligosaccharides/placebo, the products to be used in the study will be provided by the scholars on a weekly basis, and their daily intake and possible problems will be monitored through weekly interviews. In this study, it is planned to supplement the diet of the placebo group with 1.5 g/day maltodextrins to approximately half of the diet and to supplement the other half with 3 g/day maltodextrins, after the group was randomized within itself. Effects of these doses on metabolic control are not expected. Maltodextrine is in powder form, its dosage of up to 3 g/day has a negligible effect on blood glucose, it has a neutral taste, it is cheap and easy to find, and it is safe and ineffective.
223872694|NCT03635151|BEHAVIORAL|Telephone Assessment and Skill-Building Kit (TASK III) Group|The TASK III group will receive a TASK III Resource Guide that we developed and 8 weekly calls from a nurse. The nurse will call again a month later. The TASK III nurse will help you assess your needs and concerns, build your skills as a caregiver, and refer you to community resources.
223872695|NCT03635151|BEHAVIORAL|Information Support and Referral (ISR) Group|The ISR group will receive an American Heart Association brochure and 8 weekly calls from a nurse. The nurse will call again a month later. The ISR nurse will provide information, support, and referral to community resources.
223872696|NCT05176106|BEHAVIORAL|CHW Incentives Intervention|The intervention comprises of an incentives package provided to VHTs who are active in the intervention-randomized parishes. It will comprise of items that will motivate them and support their work as VHTs in the community.
223872697|NCT01294033|OTHER|Fractional inspired oxygen (FiO2) 0.21|
223872698|NCT01294033|OTHER|Fractional inspired oxygen 0.28|Supplemental oxygen
223872699|NCT00886756|DRUG|AZD8529|Oral
223872700|NCT00886756|DRUG|Placebo|Oral
223872701|NCT03014947|DRUG|MSB11022|Subjects will receive single dose of 40 milligram (mg) MSB11022 as a subcutaneous injection in the lower abdomen on Day 1.
223872702|NCT03014947|DRUG|US-licensed Humira|Subject will receive single dose of 40 mg US-licensed Humira as a subcutaneous injection in the lower abdomen on Day 1.
223872703|NCT03014947|DRUG|EU-approved Humira|Subject will receive single dose of 40 mg EU-approved Humira as a subcutaneous injection in the lower abdomen on Day 1.
223872704|NCT02409667|BIOLOGICAL|Secukinumab|Secukinumab for s.c. injection was supplied in single boxes each containing 2 pre-filled syringes (PFS) of 150 mg secukinumab in a 1 mL liquid formulation. Each 300 mg dose was administered as 2 PFS injections of 150 mg secukinumab.
223872705|NCT04638322|OTHER|HIFT Group|An experimental group (EG) that after an initial evaluation will be subjected to a physical training program based on the HIFT method, for 12 weeks with 2 weekly sessions (Tuesday and Thursday), with a duration of 45 min per session. Once the intervention is finished, you will undergo a final evaluation to see if there is a difference or not with the results obtained at the beginning.
223872706|NCT06514222|DRUG|Paracetamol and Ibuprofen. The combination of the Paracetamol and Ibuprofen will be given together every 8 hours|Group 1- The patient will receive 400mg ibuprofen plus 1000mg Paracetamol simultaneously every 8 hours for two days.
223872707|NCT06514222|DRUG|Paracetamol and Ibuprofen. The combination of the Paracetamol and Ibuprofen will be given alternatively every four hours|Group 2- The patient will receive 400mg ibuprofen and 1000mg Paracetamol at 4 hours in intervals for two days. With a total of 3 doses of ibuprofen and 3 doses of paracetamol per day
223872708|NCT02280148|PROCEDURE|Endoscopy of Intravenous Anesthesia|The dose of intravenous anesthesia drug and time was controlled by the anesthesiologist,endoscopists were responsible for gastroscopy or colonoscopy , nurses assisted endoscopists with biopsy.Each subject's initial dose of propofol were set at 2mg / kg, and were added properly by anesthesiologists additional according to the subjects' intraoperative sedation or surgical time.
223872709|NCT02280148|DEVICE|Driving Simulator|
223872710|NCT02280148|DRUG|Propofol|2mg / kg
223872711|NCT02378896|BEHAVIORAL|Personalized Computer Program|Training with a personalized computerized inhibitory training program
223872712|NCT02378896|BEHAVIORAL|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy (CBT), consisting of Exposure and Ritual Prevention Therapy
223872713|NCT04764994|DEVICE|Armeo®Spring ((Task-oriented upper extremity rehabilitation system)|Armeo®Spring is a functional upper extremity rehabilitation device to provide specific therapy with augmented feedback. The Armeo Spring instrument facilitates intensive task-oriented upper extremity therapy after stroke, traumatic brain injury or other neurological diseases and injuries. It combines an adjustable arm support, with augmented feedback and a large 3D workspace that allows functional therapy exercises in a virtual reality environment.
223872714|NCT04764994|OTHER|Conventional Physical Therapy Program|This intervention t will include: muscle facilitation exercises, proprioceptive neuromuscular facilitation exercises, strengthening activities, stretching exercises and postural reactions exercises.
223872715|NCT01042197|RADIATION|Broadband UVB|UVB dose: 0.75 SED. Four UVB sessions with 2 days in between.
223872716|NCT01042197|RADIATION|Broadband UVB|UVB dose: 0.75 SED. Four UVB sessions with 2 days in between.
223872717|NCT01042197|RADIATION|Broadband UVB|UVB dose: 0.75 SED. Four UVB sessions with 2 days in between.
223872718|NCT01042197|RADIATION|Broadband UVB|UVB dose: 1.5 SED. Four UVB sessions with 2 days in between.
223872719|NCT01042197|RADIATION|Broadband UVB|UVB dose: 1.5 SED. Four UVB sessions with 2 days in between.
223872720|NCT01042197|RADIATION|Broadband UVB|UVB dose: 1.5 SED. Four UVB sessions with 2 days in between.
223872721|NCT01042197|RADIATION|Broadband UVB|UVB dose: 3.0 SED. Four UVB sessions with 2 days in between.
223872722|NCT01042197|RADIATION|Broadband UVB|UVB dose: 3.0 SED. Four UVB sessions with 2 days in between.
223872723|NCT01042197|RADIATION|Broadband UVB|UVB dose: 3.0 SED. Four UVB sessions with 2 days in between.
223872724|NCT03348917|DRUG|7.5% Povidone-Iodine [PVP-I]|Betadine® 7.5% skin cleanser (PVP-I 7.5%)
223872725|NCT03348917|DRUG|4% chlorhexidine skin cleanser|Unity antiseptic hand wash (no alcohol)
223872726|NCT03348917|DRUG|Plain non antibacterial soap|Guardian gel hand wash (not medicated),
223872727|NCT00044057|DRUG|YM872 (zonampanel), t-PA (alteplase)|
223872728|NCT04545918|DEVICE|Follicle Clarity|Mask Region-based Convolutional Neural Network in Ultrasound Follicle Identification
223872729|NCT06465446|BIOLOGICAL|Tislelizumab|IV infusion
223872730|NCT06465446|BIOLOGICAL|IMM01|2.0mg/kg, IV infusion
223872731|NCT06465446|DRUG|Bendamustine|IV infusion
223872732|NCT06465446|DRUG|Gemcitabine|IV infusion
223872733|NCT04045938|OTHER|Low Glycemic Index or Glycemic Load|Dietary pattern focused on low glycemic index foods or on a low glycemic load
223872734|NCT03427346|PROCEDURE|Endoscopic mucosal resection|Endoscopic resection is carried out using a double-channel scope. The lesion borders are marked with a coagulator. Saline liquid and sometimes epinephrine are injected into the submucosal layer to swell the area containing the lesion and elucidate the markings. The resected mucosa is lifted, then trapped and strangulated with a snare, and subsequently resected by electrocautery. Another method of EMR employs the use of a clear cap and prelooped snare inside the cap. After insertion, the cap is placed on the lesion and the mucosa containing the lesion is drawn up inside the cap by aspiration. The mucosa is caught by the snare and strangulated, and finally resected by electrocautery.
223872735|NCT03427346|PROCEDURE|Endoscopic submucosal dissection|After circumferential cutting of the surrounding mucosa of the lesion, fluid is injected into the submucosa to elevate the lesion from the muscle layer, and the connective tissue of the submucosa beneath the lesion is dissected subsequently.
223872736|NCT06103916|OTHER|Observational study. Prospective registration of ultrasound data in patients with ovarian tumors for which an ultrasound in according with the IOTA definitions is performed.|From all included patients, prospective data will be collected of the ultrasound(s) performed, the performed treatment and in case of surgery also the final pathological diagnosis. Participating patients will not be subjected to acts or additional procedures or examinations in this study, nor will rules of conduct be imposed.
223872737|NCT03657030|DRUG|CVN424|SAD / MAD
223872738|NCT03657030|DRUG|Placebo|Placebo
223872739|NCT01896349|OTHER|IPT+ antidepressant drugs|16 sessions of interpersonal psychotherapy plus antidepressant drugs.
223872740|NCT01896349|DRUG|fluoxetine|Antidepressant drugs, clinician´s free choice oriented by guidelines. Monotherapy or combinations are allowed
223872741|NCT01896349|DRUG|sertraline|
223872742|NCT01896349|DRUG|paroxetine|
223872743|NCT01896349|DRUG|Citalopram|
223872744|NCT01896349|DRUG|escitalopram|
223872745|NCT01896349|DRUG|fluvoxamine|
223872746|NCT01896349|DRUG|Venlafaxine|
223872747|NCT01896349|DRUG|Duloxetine|
223872748|NCT01896349|DRUG|Bupropion|
223872749|NCT01896349|DRUG|Lithium|
223872750|NCT01896349|DRUG|Risperidone|
223872751|NCT01896349|DRUG|tranylcypromine|
223872752|NCT01896349|DRUG|Imipramine|
223872753|NCT01896349|DRUG|amitriptyline|
223872754|NCT01896349|DRUG|Clomipramine|
223872755|NCT01896349|DRUG|nortriptyline|
223872756|NCT01896349|DRUG|trazodone|
223872757|NCT01896349|DRUG|Mirtazapine|
223872758|NCT01896349|DRUG|sulpiride|
223872759|NCT04083664|DIAGNOSTIC_TEST|NGAL and Hepcidin|Both NGAL and hepcidin are elevated inchronic kidney disease,not only through iron metabolism, but both are also associated with inflammationand may be related to anemia
223872760|NCT06013072|DIETARY_SUPPLEMENT|Dietary Supplement: Experimental|Combination of pre-probiotic
223872761|NCT06013072|DIETARY_SUPPLEMENT|Dietary Supplement: Placebo|Inert compound
223872762|NCT05239013|DRUG|Nitroglycerin ointment|2 cm (30mg) of 2% nitroglycerin applied 2 cm from the styloid process of the anterior forearm
223872763|NCT04580316|BEHAVIORAL|Parental active presence|The parents were allowed to stand close to their children, do handholding, eye contacting and help in explaining the dentist's instructions.
223872764|NCT04580316|BEHAVIORAL|Parent passive presence|Parents were instructed to sit silently in the dental clinic behind the patient with no eye contact, and without a spoken word only to reassure their children
223872765|NCT04877340|DEVICE|needle punction|EUS-guided sampling of pancreatic solid lesions obtained with the 22-gauge
223872766|NCT06093204|OTHER|Dietary evaluation|Comparative evaluation of the dietary consumption of ultraprocessed foods and ultraprocessed foods-derived compounds
223872767|NCT02703558|DRUG|Phenazopyridine|
223872768|NCT02703558|DRUG|Fluorescein|
223872769|NCT01616472|DRUG|Cumulative corticosteroid exposure|Cumulative steroid exposure will be modeled as cumulative dose (prednisone equivalent mg), cumulative days of exposure at any dose, cumulative days of exposure to doses ≥7.5mg and cumulative days of exposure to doses ≥20mg.
223872770|NCT01893970|BEHAVIORAL|SWIFT|Participants will receive: 1) acute social work intervention for adults with mTBI, including early education, reassurance, resources and brief alcohol intervention in the ED (SWIFT-Acute) and 2) follow up telephone counseling, needs assessment and case management referral to necessary services (SWIFT).
223872771|NCT01893970|BEHAVIORAL|SWIFT-Acute|acute social work intervention for adults with mTBI, including early education, reassurance, resources and brief alcohol intervention in the ED (SWIFT-Acute)
223872772|NCT04325048|DEVICE|Cordio App|Adult patients positive to COVID-19 virus will record several predefined sentences via a smartphone / tablet and will answer questions via the app
223872773|NCT03421678|DIAGNOSTIC_TEST|Urine Sample|One to two home visits where tobacco use and medical history and biological samples will be collected including blood, buccal cells and urine
223872774|NCT05301543|BEHAVIORAL|Experimental: Behavioral approach 1|Includes changing sleep habits and cognitions around sleep from a mental level
223872775|NCT05301543|BEHAVIORAL|Comparator: Behavioral approach 2|Includes changing sleep habits and awarenes of sleep from a perception level
223872776|NCT06119048|DIETARY_SUPPLEMENT|L-Phenylalanine|100 mg/kg
223872777|NCT03013504|DRUG|HD201|Loading dose of 8mg/kg in Cycle 1 and 6mg/kg in subsequent cycles.
223872778|NCT03013504|DRUG|Herceptin|Loading dose of 8mg/kg in Cycle 1 and 6mg/kg in subsequent cycles.
223872779|NCT03013504|DRUG|Docetaxel|75mg/m2 via i.v. infusion during cycles 1 to 4.
223872780|NCT03013504|DRUG|Epirubicin|75 mg/m2 via i.v. infusion during cycles 5-8.
223872781|NCT03013504|DRUG|Cyclophosphamide|500 mg/m2 via i.v. infusion during cycles 5-8.
223872782|NCT06643507|OTHER|Connective tissue graft|regenerative properties
223872783|NCT06643507|BIOLOGICAL|ALB-PRF|regenerative properties
223872784|NCT03350542|DEVICE|SYNERGY 48 mm|A drug eluting coronary stent system
223872785|NCT05005728|COMBINATION_PRODUCT|vudalimab + carboplatin + cabazitaxel|Vudalimab IV, carboplatin IV, cabazitaxel IV
223872786|NCT05005728|COMBINATION_PRODUCT|vudalimab + olaparib|Vudalimab IV, olaparib oral
223872787|NCT05005728|BIOLOGICAL|vudalimab monotherapy|Vudalimab IV
223872788|NCT05005728|COMBINATION_PRODUCT|vudalimab + docetaxel|Vudalimab IV, docetaxel IV
223872789|NCT05005728|COMBINATION_PRODUCT|vudalimab + cabazitaxel or docetaxel|Vudalimab IV, cabazitaxel or docetaxel IV
223872790|NCT04873245|BEHAVIORAL|Intensive Behavioral Program|Participants randomized to this group will receive intensive behavioral therapy.
223872791|NCT04873245|DRUG|Semaglutide and Behavioral Program|Participants randomized to this group will receive semaglutide and behavioral therapy.
223872792|NCT00774852|DRUG|abatacept|Intravenous infusion (500-1000 mg, dep on weight) at weeks 0, 2, and 4, then every 4 weeks until week 24; continue to week 48 only if partial response at 24 weeks
223872793|NCT00774852|DRUG|cyclophosphamide|500 mg intravenous infusion every 2 weeks for 12 weeks
223872794|NCT00774852|DRUG|azathioprine|2 mg/kg/day orally from weeks 12-28; continue until week 52 if only partial response observed at week 24
223872795|NCT00774852|DRUG|prednisone|60 mg/day for 2 weeks, then taper to 10 mg/day by 12 weeks, then continue on stable dose
223872796|NCT00774852|DRUG|abatacept placebo|Intravenous infusion at weeks 0, 2, and 4, then every 4 weeks until week 24; continue to week 48 only if partial response at 24 weeks
223872797|NCT00774852|DRUG|azathioprine placebo|Oral capsule, daily from weeks 28 to 52, only if complete response observed at week 24
223872798|NCT01842945|BEHAVIORAL|Internet-based cognitive behavioural therapy (iCBT) without therapist contact.|The iCBT consists of our structured self-help program lasting a total of eight active treatment weeks and does not include a therapist contact.
223872799|NCT01842945|BEHAVIORAL|Internet-based cognitive behavioural therapy (iCBT) with therapist contact.|The iCBT consists of our structured self-help program lasting a total of eight active treatment weeks and includes a therapist contact.
223872800|NCT04026594|OTHER|Mindfulness Based Stress Reduction|"MBSR teaches mindfulness meditation and mindful yoga exercises to develop non-judgmental awareness of moment-to-moment experience. The intervention duration is 8 weeks, with weekly two and half hours sessions. It will be delivered according to the fundamental concepts and specific techniques provided in the MBSR manualized protocol by Kabat-Zinn. The program also includes 30-min daily homework exercises.~MBSR teaches four main mindfulness practices: (1) body scan, a process of moving attention through the body; (2) mindful movement, consisting of gentle yoga stretches to develop awareness of body in movement; (3) sitting meditation; and (4) walking meditation. Inquiry and didactic teaching is also a part of MBSR and allows for some detailed exploration of participants' experiences."
223872801|NCT04026594|OTHER|Relaxation group|control group
223872802|NCT04999826|PROCEDURE|Biospecimen Collection|Undergo biospecimen collection
223872803|NCT04999826|OTHER|Quality-of-Life Assessment|Ancillary studies
223872804|NCT04999826|OTHER|Questionnaire Administration|Complete questionnaires
223872805|NCT06986161|OTHER|Mango|Mango beverage
223872806|NCT06986161|OTHER|Control Beverage|Italian Ice beverage
223872807|NCT03206554|DRUG|Ropivacaine|Large volume local anaesthetic intraarticularly
223872808|NCT03206554|OTHER|Saline|sham injection
223872809|NCT00899899|GENETIC|microarray analysis|
223872810|NCT00899899|GENETIC|reverse transcriptase-polymerase chain reaction|
223872811|NCT00899899|OTHER|laboratory biomarker analysis|
223872812|NCT03997916|DEVICE|Belun Ring|All patients scheduled for attended overnight in-lab polysomnography (PSG) in our 2 sleep labs will undergo PSG testing. On the same night of the PSG testing, these same patients will also wear the Belun Ring device. After the study, we will compare results of the Belun Ring device vis-à-vis with the results of the PSG on the same patient.
223872813|NCT03997916|DIAGNOSTIC_TEST|PSG|All patients scheduled for attended overnight in-lab polysomnography (PSG) in our 2 sleep labs will undergo PSG testing. On the same night of the PSG testing, these same patients will also wear the Belun Ring device. After the study, we will compare results of the Belun Ring device vis-à-vis with the results of the PSG on the same patient.
223872814|NCT05936411|DEVICE|Siemens Quadra PET/CT and [18F]FDG|The Siemens Quadra PET/CT, a clinically approved imaging device, is utilized in conjunction with the radiopharmaceutical tracer \[18F\]FDG in this study. The device allows for the acquisition of emission data across an extended axial field of view (axFOV) of 106 cm, covering an imaging range from the head to the thighs. The device's capabilities are leveraged to perform quantitative functional examinations of an extended axFOV. Subjects are scanned twice within a month for reproducibility standards. Each time, they are injected with 100MBq \[18F\]FDG and examined for 60 minutes in a dynamic scan. The tracer is used to build an atlas of normative glycolytic activities for most organs, excluding the brain. The glycolytic activities are measured as organ-based standardized uptake values. An ultra-low-dose CT scan is acquired to estimate mandatory attenuation correction factors.
223872815|NCT05936411|DEVICE|Apple i-Watch|The Apple i-Watch, a wearable smart device, is used to continuously monitor physiological signals from the subjects. These signals include heart rate, steps and distance, calories burned, sleep tracking, blood oxygen saturation (SpO2), electrocardiogram (ECG), and workout tracking. Subjects are required to wear the Apple i-Watch for three months prior to the first PET scan and up to three months after the second PET scan. The data collected from the Apple i-Watch is paired with the FDG-PET image readouts to identify relationships between lifestyle and glucose uptakes during the scan.
223872816|NCT04310358|OTHER|4 short PLMs group 1|Participants will take the 4 short PLMs on the visual estimation of LVEF. They will also take a pretest, an immediate post-test and a remote post-test at 1 month. Test 1 (pre-test), Test 2 (immediate post-test), Test 1 (remote post-test)
223872817|NCT04310358|OTHER|4 short PLMs group 2|Participants will take the 4 short PLMs on the visual estimation of LVEF. They will also take a pretest, an immediate post-test and a remote post-test at 1 month. Test 2 (pre-test), Test 1 (immediate post-test), Test 2 (remote post-test)
223872818|NCT01761552|DRUG|Sugammadex Reversal|
223872819|NCT01761552|DRUG|Atropine/Neostigmine|
223872820|NCT06216860|BEHAVIORAL|Laughter Yoga|In Laughter Yoga Practice; each session will last approximately 30 - 45 minutes and will consist of four parts. These parts are: warm-up exercises, deep breathing exercises, childlike games and laughter exercises.
223872821|NCT04193579|BEHAVIORAL|Language Treatment|Recording of a mother's voice reading a children's storybook.
223872822|NCT04193579|BEHAVIORAL|Control Treatment|Standard of Care
223872823|NCT04754425|PROCEDURE|Biopsy|Undergo biopsy
223872824|NCT04754425|PROCEDURE|Biospecimen Collection|Undergo collection of blood and bone marrow
223872825|NCT04754425|DRUG|Erdafitinib|Given PO
223872826|NCT06168474|OTHER|Simplified layered consent form|The simplified consent form includes all essential elements of trial consent including an explanation of the trial procedures, data and sample collection, and follow-up information. The form also outlines important ethical considerations for patients, such as confidentiality, regulatory and safety requirements, the ability to drop out, and the necessary process and contact numbers for grievances or feedback. In addition to the text, the form includes links to additional written information and videos that can be accessed on top of the simplified informed consent form (i.e., the additional layers in the layered consent process). These materials are hosted on the main SNAP trial website (https://www.snaptrial.com.au/patients) and are available in English and French. Participants will be able to access these directly through embedded hyperlinks using provided electronic tablets.
223872827|NCT06168474|OTHER|Full-length consent form|The full-length informed consent form contains all information upfront. Links to additional information will not be provided on the form but are freely available on the Internet should the participant wish to access them.
223872828|NCT05750901|DEVICE|Fractional ablative laser|Fractional ablative laser used for treatment for skin laxity and tightening
223872829|NCT00000919|DRUG|Indinavir sulfate|
223872830|NCT00000919|DRUG|Lamivudine/Zidovudine|
223872831|NCT00000919|DRUG|Ritonavir|
223872832|NCT00000919|DRUG|Hydroxyurea|
223872833|NCT00000919|DRUG|Abacavir sulfate|
223872834|NCT00000919|DRUG|Amprenavir|
223872835|NCT00000919|DRUG|Nelfinavir mesylate|
223872836|NCT00000919|DRUG|Efavirenz|
223872837|NCT00000919|DRUG|Lamivudine|
223872838|NCT00000919|DRUG|Stavudine|
223872839|NCT00000919|DRUG|Zidovudine|
223872840|NCT00000919|DRUG|Didanosine|
223872841|NCT02858882|OTHER|Screening|Screening of elite swimmers
223872842|NCT01275105|DRUG|Vehicle|one drop in each eye at designated visits
223872843|NCT01275105|DRUG|Brimonidine Tartrate 0.01%|one drop in each eye at designated visits
223872844|NCT01275105|DRUG|Brimonidine Tartrate 0.025%|one drop in each eye at designated visits
223872845|NCT01275105|DRUG|Oxymetazoline HCl 0.025%|one drop in each eye at designated visits
223872846|NCT01339234|OTHER|Body-weight supported treadmill training|Patients will undergo training using the Woodway Loco-system which consists of a treadmill with an overhead pulley system connected to a support harness. BWSTT allows patients with limited mobility to safely walk upright on a treadmill with a portion of their body weight counter balanced. Three trainers will be required to assist with the BWSTT program. Two trainers will be positioned at the lower limbs to manually guide the participant through a proper gait motion and provided lower limb control. A third trainer will stand behind the participant to provide trunk support and assist with weight shifting.
223872847|NCT04562844|OTHER|sociale cognition|several social cognition test
223872848|NCT05919446|BEHAVIORAL|Acceptance and commitment therapy (ACT)|Each session in the ACT group will include the first hour of ACT intervention followed by 1 hour of back exercise class. The ACT group will be led by a trained ACT counsellor and a trained exercise trainer.
223872849|NCT05919446|BEHAVIORAL|back exercise|The control group will undergo 1 hour of back exercise class, while the control group will be led by a trained exercise trainer.
223872850|NCT05256290|DRUG|silevertinib (BDTX-1535) monotherapy|Silevertinib (BDTX-1535) is a 4th generation irreversible brain penetrant EGFR MasterKey inhibitor, which targets a family of oncogenic EGFR classical and non-classical driver and resistance mutations in NSCLC.
223872851|NCT05352958|PROCEDURE|Diaphragmatic ultrasound|duration 15 minutes, performed at M0, M3, M6 and M9
223872852|NCT05352958|OTHER|Electro-physiological exploration of the diaphragm|duration between 30 and 60 minutes performed at M0
223872853|NCT06363253|OTHER|No specific intervention|"Patient will undergo their routine clinical treatment for their related clinical condition (eg. anti-obesity or bariatric intervention for obese group; muscle strengthening interventions or necessary treatment for their concomitant medical condition for the sarcopenia group).~Follow-up testing will include repeat assessment of the subjects metagenome and metabolome over time, and after intervention~Control subjects will have no interventions performed as well."
223872854|NCT06666972|DIAGNOSTIC_TEST|PCR MTB/NTM|• The Polymerase chain reaction (PCR) MTB/NTM MDR-TB test is an innovative technology that offers a cutting-edge approach to the precise diagnosis of tuberculosis and nontuberculous mycobacterial infections (NTM).
223872855|NCT06667466|DEVICE|Super Pulsed Thulium Fiber Laser (sTFL) + Flexible Negative Pressure Ureteral Access Sheath (UAS) Intervention|The intervention combines a Super Pulsed Thulium Fiber Laser (sTFL) with a power setting of 0.8J and a frequency of 12 - 20Hz for stone fragmentation and a Flexible Negative Pressure Ureteral Access Sheath (UAS) that allows access to the stone site and enables negative pressure suction for stone removal.
223872856|NCT06667466|DEVICE|Super Pulsed Thulium Fiber Laser (sTFL) + Conventional Ureteral Access Sheath (UAS) Intervention|The intervention combines a Super Pulsed Thulium Fiber Laser (sTFL) with a power setting of 0.8J and a frequency of 12 - 20Hz for stone fragmentation and a Conventional Ureteral Access Sheath (UAS) used for access to the upper ureter or ureteropelvic junction for stone treatment.
223872857|NCT05158153|OTHER|ORKID Bundled Intervention|During the 90-day study period, participants will be prescribed outpatient hemodialysis with cooled dialysate (35-36°C), high sodium dialysate (145 mmol/L), a high ultrafiltration hold threshold (systolic blood pressure \> 110 mmHg; ultrafiltration hold threshold will not be applied in participants with baseline systolic blood pressure \< 120 mmHg), and high dose diuretics (160 mg oral furosemide twice daily) to be taken every day at home will also be prescribed. Dialysis will be weaned according to an active weaning protocol.
223872858|NCT05158153|DRUG|Furosemide|160 mg oral furosemide twice daily to be taken every day at home
223872859|NCT00648011|DRUG|Quinapril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg|20/25mg, single dose fed
223872860|NCT00648011|DRUG|Accuretic™ Tablets 20 mg/25 mg|20/25mg, single dose fed
223872861|NCT03833648|OTHER|UControl Pain App with Education|The intervention will include educational information on pain management, e.g., using acetaminophen and NSAIDs to manage pain, as well as information on addiction and safe storage of medications.
223872862|NCT00481182|DRUG|fosamprenavir + ritonavir + methadone|
223872863|NCT05763277|DIAGNOSTIC_TEST|Early response evaluation|Atezolizumab and bevacizumab are administered every three weeks, and before to the second treatment cycle, blood tests and imaging tests are conducted (week 5). This precedes the standard response evaluation (week 9-12).
223872864|NCT06290609|DEVICE|Vibrotactile Coordinated Reset|The experimental device, the Stanford CR Glove, is designed to deliver vibratory stimulation to the fingertips of each hand according to a specific pattern, known as vibrotactile Coordinated Reset, which theoretically disrupts abnormal neuronal synchrony and is expected to restore function.
223872865|NCT03840668|DEVICE|USB Eye Mask|To evaluate the acceptance of the USB eye mask via questionnaire and also to monitor the use of USB eye mask over a period of 2 months.
223872866|NCT06616272|OTHER|Cervical rehabilitation|"* Manual joint mobilization (Grades I-V) of painful and restricted cervical spine segments.~* Supine manual cervical traction to stretch and mobilize the cervical spinal tissues.~* Manual soft tissue mobilization of the cervical, upper thoracic and/or shoulder muscles.~* Passive stretching of hypertonic muscles and active strengthening of hypotonic muscles.~* Motor-control and isometric exercises to activate the deep neck flexors."
223872867|NCT06616272|OTHER|Standard Concussion Care|"Standard Concussion Care interventions are individualized to each patient and their adjudicated profile(s)/moderating factor(s) and may include any/all of the following:~* Behavioral regulation~* Vestibular rehabilitation~* Oculomotor rehabilitation~* Exertion rehabilitation~* Pharmacological management~* Behavioral sleep intervention~* \*Cervical spine rehabilitation (the variable of interest in this study)~* Psychotherapy"
223872868|NCT06140615|DEVICE|Ultrasound|Ultrasound of lungs
223872869|NCT05983575|DEVICE|LIPUS-Brain|Transcranial low-power pulsed-wave ultrasound device
223872870|NCT05983575|DEVICE|Placebo|Placebo
223872871|NCT06336031|OTHER|blood-injection-injury (BII) phobia stimuli|498 seconds of BII phobia-related images and videos will begin two-minutes prior to head-up tilt test, while in supine.
223872872|NCT06336031|OTHER|neutral stimuli|498 seconds of neutral images and videos will begin two-minutes prior to head-up tilt test, while in supine.
223872873|NCT06280157|BIOLOGICAL|GBS-NN/NN2|GBS-NN/NN2 containing 50 μg of GBS-NN and 50 μg of GBS/NN2
223872874|NCT03697876|DRUG|PRO-165|PRO-165 Chondroitin sulfate 0.18% / sodium hyaluronate 0.2%, ophthalmic gel. Prepared by Sophia Laboratories, S.A. of C.V., Zapopan, Jalisco, Mexico.
223872875|NCT03697876|DRUG|Artelac|Artelac® Nightime Gel. 0.2% Carbomer, ophthalmic gel. Made in Germany by: Dr. Gerhard Mann Chem Pharm. Imported and marketed by: Bausch \& Lomb México, S.A. de C.V.
223872876|NCT06376383|PROCEDURE|Tonsillectomy|Standard tonsillectomy
223872877|NCT06376383|PROCEDURE|Tonsillotomy|Tonsillotomy
223872878|NCT05015010|DRUG|Alectinib|600 mg p.o. (four 150 mg capsules) twice daily with food (within 30 minutes after a meal, in the morning and evening).
223872879|NCT05518396|DIAGNOSTIC_TEST|CoDE-HF decision support tool|We will assess the diagnostic performance of the CoDE-HF decision support tool
223872880|NCT06677372|DIAGNOSTIC_TEST|Body temperature measurement|Comparative analysis of temperature between esophageal temperature and skin temperature
223872881|NCT06675968|PROCEDURE|Direct Suture|A capsular closure will be performed, closure of the gluteus medius with a direct tendon and absorbable suture. Addittionally, the iliotibial band, subcutaneous and skin suture closure will be performed.
223872882|NCT06675968|PROCEDURE|Transosseus Suture|A capsular closure will be performed, transosseous suture with a non-absorbable suture. Addittionally, the iliotibial band, subcutaneous and skin suture closure will be performed.
223872883|NCT06676644|DRUG|adjuvanted|adjuvanted (aIIV4) influenza vaccine in the Taiwanses elderly with chronic medical conditions
223872884|NCT06676644|DRUG|non-adjuvanted|non-adjuvanted (IIV4) influenza vaccine in the Taiwanses elderly with chronic medical conditions
223872885|NCT06676007|OTHER|Gd-IgA1 test|collect and test Gd-IgA1 test in enrolled subjects
223872886|NCT06677294|PROCEDURE|Placenta remove|This is an observational study. No intervention was performed
223872887|NCT06676761|PROCEDURE|nipple sparing mastectomy without reconstruction|nipple sparing mastectomy was conventionally performed with reconstruction. we aim to study the outcomes in the group of patients with Minimal scar mastectomy (MSM) who have nipple sparing mastectomy without reconstruction
223872888|NCT06677034|OTHER|Exercise|Mobile Game-Based Exercise Training
223872889|NCT06676553|DEVICE|Radiofrequency ablation alone, re-denervation to main and/or branch renal artery|Re-denervation according to the site where renal artery stimulation can induce systolic blood pressure rise of \>= 20 mmHg. Main renal artery denervation if proximal main renal artery stimulation positive, while branch renal artery denervation if distal main renal artery stimulation positive.
223872890|NCT06676553|PROCEDURE|Radiofrequency ablation alone, no further renal denervation|No further renal denervation after standard renal denervation even renal artery stimulation-induced systolic blood pressure rise \>= 20 mmHg
223872891|NCT06677008|DEVICE|Disposable endoscopic linear cutter stapler|Investigational devices of all the models of the staplers and its cartridge listed in Study Plan(Plan number: CAK-PMCF)
223872892|NCT06677073|BEHAVIORAL|High-intensity interval training|High-intensity interval training
223872893|NCT06677073|BEHAVIORAL|Maximal fat oxidation exercise|Maximal fat oxidation exercise
223872894|NCT06676527|OTHER|Follow-up study of the treated cohort|For those patients who have reached the end point of the study, survival data during treatment with vorolanib is obtained for retrospective analysis. The patients who are still on treatment with vorolanib are followed up closely and survival data is obtained for prospective analysis. After summarizing the results of retrospective and prospective studies, relevant efficacy and safety conclusions will be drawn.
223872895|NCT06677463|DEVICE|Virtual Reality|Studying the effect of virtual reality glasses on women during pregnancy, for the first time, it is also used to facilitate the birth process
223872896|NCT06677476|OTHER|mobile application training|Researchers compiled literature information and used their expertise to create mobile application content. This content will be downloaded to mobile phones via mobile application software and participants will be trained.
223872897|NCT06676410|OTHER|ICF|Application of Informed Consent Form.
223872898|NCT06676410|BEHAVIORAL|Eligibility Assessment|Assessment of inclusion, exclusion and discontinuation criteria.
223872899|NCT06676410|OTHER|Demographic data|Collection of demographic data.
223872900|NCT06676410|DIAGNOSTIC_TEST|Weight, height and BMI|Weight and height measurement and body mass index calculation.
223872901|NCT06676410|OTHER|Vital Signs|HR, BP and FR and T°, in addition to oximetry.
223872902|NCT06676410|DIAGNOSTIC_TEST|Medical evaluation|Medical history and physical examination at screening. In other consultations, the medical evaluation is focused on viral load, CD4+ and new complaints.
223872903|NCT06676410|DIAGNOSTIC_TEST|Safety exam|Blood collection for safety laboratory exams. Blood count, Na, K, U, C, amylase, total cholesterol and fractions, triglycerides, coagulation tests (TTTP, TT, platelets), TGO, TGP, AP, GGT, glycated hemoglobin, total bilirubin and fractions, creatine kinase and CKmB and urine I.
223872904|NCT06676410|DIAGNOSTIC_TEST|Pregnancy test|β-HCG in urine in non-sterile women
223872905|NCT06676410|DIAGNOSTIC_TEST|Serology|HBV (HBsAg, Anti-HBc) and HCV (anti-HCV-Ab).
223872906|NCT06676410|OTHER|Randomization|Assignment to the Standard Antiretroviral Treatment + Codivir® group or the Standard Antiretroviral Treatment only group
223872907|NCT06676410|DIAGNOSTIC_TEST|Apoptosis markers|Caspases and Annexin V.
223872908|NCT06676410|DIAGNOSTIC_TEST|Cell activation markers|PBMCs will be isolated by density gradient centrifugation. The cells will then be tested for CD4+, CD8+, CD38 and HLA DR
223872909|NCT06676410|DIAGNOSTIC_TEST|Inflammation markers|ultrasensitive CRP, D-dimer.
223872910|NCT06676410|DIAGNOSTIC_TEST|Proviral DNA:|Total HIV DNA will be measured to estimate the size of the viral reservoir throughout the preparation.
223872911|NCT06676410|DIAGNOSTIC_TEST|HIV-specific antibodies|Anti-HIV-1 specific antibody titers in plasma.
223872912|NCT06676410|DIAGNOSTIC_TEST|HIV viral load (RNA)|Performed on plasma.
223872913|NCT06676410|BEHAVIORAL|Codivir® Training|The participant is trained to self-inject Codivir®
223872914|NCT06676410|DRUG|Dispensing Codivir®|the participant receives Codivir®
223872915|NCT06676410|OTHER|Codivir® Accounting|The Codivir® used since the last visit is accounted for
223872916|NCT06676410|OTHER|Concomitant medication|Record of concomitant medications used.
223872917|NCT06676410|OTHER|Adverse events|Collection and recording of adverse events.
223872918|NCT06676410|DRUG|Antiretrovirals|"Tenofovir - inhibits HIV-1 reverse transcriptase activity by competing with the natural substrate, deoxyadenosine 5'-triphosphate and, upon incorporation into DNA, causes DNA chain termination.~* Lamivudine - potent selective inhibitor of HIV-1 and HIV-2 replication in vitro.~* Darunavir - prevents the formation of mature infective viral particles, indicated for the treatment of the human immunodeficiency virus (HIV), which causes AIDS.~* Ritonavir: antiretroviral protease inhibitor, widely used in combination with other protease inhibitors in the therapy and prevention of HIV infection, which causes the syndrome acquired immunodeficiency (AIDS).~* Single solid formulation (in 1 tablet) 1x/day with:~* Tenofovir (TDF) 300 mg~* Lamivudine (3TC) 300 mg~* Darunavir (DRV) 800 mg, 1x/day~* Ritonavir (RTV) 100 mg, 1x/day"
223872919|NCT06676865|DIAGNOSTIC_TEST|the palm print test|"The patient's dominant hand was pressed firmly against a blue ink pad, then onto a white sheet of paper without applying body weight. The palm prints were scored as follows:~* Grade 0: All phalangeal areas visible~* Grade 1: Deficiency in the interphalangeal areas of the 4th and 5th digits~* Grade 2: Deficiency in the interphalangeal areas of the 2nd to 5th digits~* Grade 3: Only the tips of the digits visible The palm print test was scored from 0 to 3. Grades 2 and 3 were considered indicators of difficult intubation."
223872920|NCT06676800|DRUG|Yiqi Gubiao pill|Take 10 pills orally each time, three times a day, after meals, for a continuous period of 12 weeks. Receiving basic treatment: standardized quadruple anti-tuberculosis therapy is administered, with Rifampicin, Isoniazid, Ethambutol, and Pyrazinamide used for the first 2 months, followed by Rifampicin and Isoniazid for the next 4 months.
223872921|NCT06676800|DRUG|Yiqi Gubiao Pill placebo|The placebo's appearance and content color are similar to that of Yiqi Gubiao Pill, with the main ingredients being starch and caramel. Take 10 pills orally each time, three times a day, after meals, for a continuous period of 12 weeks. Receiving basic treatment: standardized quadruple anti-tuberculosis therapy is administered, with Rifampicin, Isoniazid, Ethambutol, and Pyrazinamide used for the first 2 months, followed by Rifampicin and Isoniazid for the next 4 months.
223872922|NCT05756699|DIAGNOSTIC_TEST|multiple reaction monitoring (MRM)-based multimarker panel|multiple reaction monitoring (MRM)-based multimarker panel test to detect hepatocellular carcinoma
223872923|NCT06214897|DIETARY_SUPPLEMENT|C-RUSF (Ready-to-use Supplemental Food with added Choline)|Ready-to-use Supplemental Food with added Choline
223872924|NCT06214897|DIETARY_SUPPLEMENT|S-RUSF (Ready-to-use Supplemental Food without added Choline)|Standard Ready-to-use Supplemental Food
223872925|NCT06679530|OTHER|Mindful Music Listening (MML)|Self-guided mindful music listening intervention comprised of 1-hour daily music listening during inpatient hospitalization.
223872926|NCT04924218|PROCEDURE|endoscopic surgical intervention|The researchers investigated whether endoscopic surgical procedures performed due to various indications (hematuria, urinary tract stone, suspected bladder mass) in the patient group who had undergone radical prostatectomy, caused a change in urinary incontinence level. The researchers divided the endoscopic instruments used into 3 groups and evaluated whether there was a difference in urinary incontinence level between rigid cystoscope, flexible cystoscope and ureterorenoscope groups.
223872927|NCT05843903|BEHAVIORAL|#BabyLetsMove|The #BabyLetsMove digital health intervention uses a multi-level, systems-change approach. At the systems-level, racially concordant young adult WIC moms will be trained as health coaches. At the person level, adolescent WIC clients will be given empirically supported behavior goals, self-monitoring text messages with automated feedback, tailored skills training materials, a FitBit device, and tailored peer coaching support. The #BabyLetsMove intervention design is based on formative Teen Mom Study findings to build social cognition, affect, and skills to modify 3 concrete, achievable, and easily monitored behavioral targets: (1) Limit television viewing time to less than 2 hours per day; (2) Walk at least 10,000 steps per day; and (3) Do 20 minutes or more of exercise per day.
223872928|NCT05396794|BEHAVIORAL|Standard weight loss education|Participants will be randomized and given the standard weight loss education by the Gynecologic Oncology provider.
223872929|NCT05396794|BEHAVIORAL|Standard weight loss education + Educational Video|Participants will be randomized and given the standard weight loss education by the Gynecologic Oncology provider followed by a 15-minute educational video detailing the benefits of weight loss.
223872930|NCT06870682|BEHAVIORAL|ROBUST|During a 4-week intervention, participants get 48 hours additional sensorimotor upper limb training. They will come 3 times per week to Leuven for a therapy session of two hours. During these therapy sessions, they receive one hour robot-based therapy and one hour transfer package training with a therapist. Additionally, they follow 6 times a week a 1-hour home program. This intervention can be distinguished from others since it integrates both motor and sensory function, with focus on sensory processing. It combines robot-based therapy, a transfer package to daily activities, and a home program.
223872931|NCT06676787|OTHER|Transportation Voucher, Comunity engagement and microplannnig support|Transportation vouchers will be provided to caregivers of eligible children after vaccination at designated routine immunisation health facilities. This is in addition to support for microplaning (technical assistance) for these routine immunisation health facilities and comunity engagement at their catchment areas.
223872932|NCT06676787|OTHER|Direct Facility Funding, Community Engagement, and Microplaning Support|Direct funding will be provided to designated routine immunisation health facilities monthly, in addition to weekly performance monitoring and quarterly financial capacity building. Also, there will be support for microplaning (technical assistance) for these routine immunisation health facilities and comunity engagement at their catchment areas.
223872933|NCT06676787|OTHER|Transportation Voucher, Direct Facility Funding, Community engagement and Microplanning support|Transportation vouchers will be provided to caregivers of eligible children after vaccination at designated routine immunisation health facilities. Direct funding will be provided to designated routine immunisation health facilities monthly, in addition to weekly oerformance monitoring and quarterly financial capacity building. Also, there will be support for microplaning (technical assistance) for these routine immunisation health facilities and comunity engagement at their catchment areas.
223872934|NCT02474147|OTHER|Processed meat hamburger|MacMuffin Fresh 300 ml Cafe Latte + 21 g sugar Energy: 513.6 kcal Carbohydrates 55g (44.8%) Proteins 20.5g (16.7%) Lipids 22 g (38.6%)
223872935|NCT02474147|OTHER|Vegan sandwich|Burger with tofu + 300 ml green tea Energy 514.9 kcal Carbohydrates 54.2 g (44%) Proteins 19.9 g (16.2%) Lipids 22.8 g (39.8%)
223872936|NCT06057480|DEVICE|APM|Investigational programming software module, the Assisted Programming Module (APM)
223872937|NCT01827787|DRUG|Eribulin|
223872938|NCT06607588|OTHER|Not applicable- observational study|Not applicable- observational study
223872939|NCT06618664|DRUG|SHR-8068|SHR-8068: injection, 50 mg/10 mL, intravenous infusion
223872940|NCT06618664|DRUG|Adebrelimab|Adebrelimab: injection, 600 mg/12 mL, intravenous infusion
223872941|NCT06618664|DRUG|Bevacizumab|Bevacizumab: injection, 100 mg/4 mL, intravenous infusion
223872942|NCT06618664|DRUG|Sintilimab|Sintilimab: injection, 100 mg/10 mL, intravenous infusion
223872943|NCT03482635|DRUG|Spesolimab|Solution for infusion
223872944|NCT03482635|DRUG|Placebo|Solution for infusion
223872945|NCT03472755|OTHER|The posterolateral approach|The posterolateral approach was used for implantation among patients in lateral position. This approach goes through the gluteus maximus, the piriformis and superior gemeli muscles are detached and later reattached to bone
223872946|NCT03472755|OTHER|Direct anterior technique|patients were fixed in a supine position, a small entry incision was made in the vessel free interval between the tensor fasciae latae and the sartorius muscles and the prosthesis socket were put in place. Via a second dorsal incision, after releasing the external rotators, the prosthesis stem and ball were implanted and the two parts of the prosthesis were attached
223872947|NCT06625931|DRUG|NTCB01-1|3 Days infusion
223872948|NCT06625931|DRUG|NTCB-P|3 Days infusion
223872949|NCT06629155|DIAGNOSTIC_TEST|Infrared oculography|Eye movements will be captured through infrared oculography and processed via in-house algorithms.
223872950|NCT01116180|DRUG|Angiotensin II receptor antagonists (Candesartan)|Seven days of treatment with Candesartan 32 mg, capsules.
223872951|NCT01116180|DRUG|Placebo|Placebo Capsule matching the active comparator. Given for 7 days once daily.
223872952|NCT06699953|OTHER|Observational study in patients receiving fentanyl for surgery|"This observational study enrolls patients receiving fentanyl, a drug routinely administered during surgery under general anesthesia. The primary difference in the investigators' research protocol is the inclusion of a 5-minute interval between fentanyl administration and the induction of general anesthesia. Fentanyl will be given in two boluses of 2 mcg/kg (ideal body weight), spaced 2 minutes apart, totaling 4 mcg/kg. If the participant remains conscious, an additional 2 mcg/kg bolus will be administered after 2 minutes. Additionally, participants will complete a drug-liking questionnaire before the first bolus and every 30 seconds until anesthesia induction, rating how much they liked the drug on a 0-100 scale."
223872953|NCT06708754|DEVICE|Photobiomodulation (PBM) Therapy|"PBM is a low-intensity form of light therapy and employs visible or near-infrared (NIR) light generated from a laser or Light Emitting Diode (LED).~In this study, PBM will be delivered using an LED device emitting 660 and 850nm with the purpose of research. The output power typically ranges from 5 to 200 mW with wavelengths ranging 600-1,000nm."
223872954|NCT06708754|DEVICE|Sham PBM|Sham PBM will be delivered using a matching shame device that emits no output power.
223872955|NCT06728579|BEHAVIORAL|Mindfulness Oriented Recovery Enhancement (MORE)|eight weekly two-hour MORE sessions
223872956|NCT06728579|OTHER|Questionnaires|filled out up to 24 weeks
223872957|NCT06728579|BEHAVIORAL|Supportive Psychotherapy (SG)|eight weekly two-hour SG sessions
223872958|NCT06889688|DRUG|Camrelizumab+Apatinib+Eribulin|Camrelizumab (200 mg, IV, Day 1) + Apatinib (250 mg, PO, QD) + Eribulin (1.4 mg/m², IV, Day 1 and Day 8) administered in 21-day cycles.
223872959|NCT06889688|DRUG|Physician's choice chemotherapy|Physician's Choice Chemotherapy
223872960|NCT06720142|DEVICE|Mg OSTEOCRETE as a bone void filler|Patients will be treated with Mg OSTEOCRETE as per standard clinical care to fill defects in bone left by bone tumor resection
223872961|NCT06720142|DEVICE|Mg OSTEOCRETE as a bone void filler|Patients will be treated with Mg OSTEOCRETE as per standard clinical care to fill defects in bone left by aseptic loosening of orthopaedic hardware
223872962|NCT06720142|DEVICE|Mg OSTEOCRETE as a bone void filler|Patients will be treated with Mg OSTEOCRETE as per standard clinical care to fill defects in bone left by trauma-related conditions
223872963|NCT06597994|DEVICE|Amber UI system|Upgrade of Amber UI system recharge accessories and system firmware
223872964|NCT04223297|PROCEDURE|lung ultrasound|"The lung ultrasound will be performed by following the  Blue protocol "
223872965|NCT06754137|DIAGNOSTIC_TEST|AI-Assisted Fracture Detection System|The intervention involves the use of an AI-assisted fracture detection system (Aidoc or Gleamer BoneView), which is integrated into the hospital's Picture Archiving and Communication System (PACS). These AI tools analyze X-ray images in real time, highlighting potential fracture sites for physician review. The AI output serves as an additional aid, while the final diagnosis remains the responsibility of the physician.
223872966|NCT06754137|DIAGNOSTIC_TEST|Standard Physician-Interpreted Fracture Detection|Physicians interpret X-ray images using their standard diagnostic practices without any assistance from AI. This represents the traditional approach to diagnosing fractures.
223872967|NCT06761534|OTHER|Screening of comprehensive geriatic assessment.|The participants are screened before anti-tumor therapy with a comprehensive assessment screening tool developed for elderly cancer patients, which is more suitable for individualized decision-making in anti-tumor treatment.
223872968|NCT06761534|OTHER|the G8 assessment|The G8 is a rapid geriatric screening test that takes only a few minutes to complete. It is used as a calibration standard to validate the novel screening tool in this study.
223872969|NCT06761534|OTHER|Comprehensive Geriatric Assessment (CGA)|The participants screened as a high frailty risk will undergo CGA to determine the most appropriate treatment plan.
223872970|NCT04242940|DEVICE|Fitting of Ponto 4|Bone-anchored hearing systems (BAHS) use the body's natural ability to transfer sound through bone conduction. The sound processor picks up sound and converts it into vibrations that are transferred through the skull bone to the inner ear (cochlea). Thus, for patients with conductive or mixed hearing losses, patients with lasting hearing loss following a middle ear disease or malformations (such as microtia), the vibrations are bypassing the conductive problem in the ear canal or middle ear. The intervention in this study is audiologically fitting one/two bone-anchored sound processors (Ponto 4) to patients that are already implanted with abutments.
223872971|NCT04777851|DRUG|Regorafenib in combination with pembrolizumab|Randomized patients will receive regorafenib at a dose of 90 mg per day by mouth on days 1 to 21 of a 28-day cycle, in combination with pembrolizumab 400 mg using a 30-minute intravenous infusion, on day 1 (D1) of a 6-week cycle.
223872972|NCT04777851|PROCEDURE|Loco-regional therapy|"Patients will be treated with TACE or TARE on-demand according to site's standard of practice."
223872973|NCT04240808|BIOLOGICAL|UCD19 CAR T Cells|Lymphodepleting chemotherapy followed by infusion of UCD19 CAR T Cells (Lentiviral Vector \[LV\] Transduced Autologous Peripheral Blood Lymphocytes)
223872974|NCT04655365|DRUG|Enzalutamide capsule|160 mg po id
223872975|NCT06735950|BEHAVIORAL|Volunteering in Place Program|Implementation of the VIP Program consists of 4 steps guided by the Social Ecological Model (SEM) with Interpersonal interventions guided by Social Cognitive Theory (SCT), and will be implemented over a 6-month period by research supported Volunteer Coordinators. The four steps of the VIP Program are: Step 1: Stakeholder Team, Staff and Family Education; Step 2: Assessment of AL Environment and Residents Abilities and Interests; Step 3: Ongoing Implementation of the Volunteer Plan; and Step 4: Reassessment of the Volunteer Activity. Participants will volunteer three time per week for approximately 30 minutes.
223872976|NCT06735950|BEHAVIORAL|Recreational activity|The Recreational Activities group intervention will consist of similar staff education regarding the benefits of engaging residents in meaningful activities as described in Step 1 above, without other steps associated with the VIP Program. The Recreational Activities group will be exposed to a research team RA coordinator who will provide a current events activity (reviewing the daily newspaper) for the participants in the RA group three times per week for approximately 30 minutes as an attention control.
223872977|NCT05579392|DEVICE|Bright Light Therapy|Device: Bright Light Therapy Retimer
223872978|NCT05579392|DEVICE|Placebo Retimer Device|Device: Placebo Retimer Device with no bright light therapy
223872979|NCT06897514|DIAGNOSTIC_TEST|Prediction algorithm for intraoperative hypotension|All participants will receive five non-invasive monitoring during their surgery. Data from these monitoring device will be put into the prediction algorithm.
223872980|NCT06555757|OTHER|Height, weight, and BMI|Height, weight measurement and BMI calculation
223872981|NCT06555757|OTHER|Medical history|Brief medical history including medications/allergies and heart failure related healthcare utilisation over previous 12 months
223872982|NCT06555757|OTHER|Physical examination|Brief physical examination
223872983|NCT06555757|DIAGNOSTIC_TEST|Venous blood samples|Venous blood samples, to include WCC, HB, CRP and NTproBNP
223872984|NCT06555757|OTHER|Resting vital signs|HR, BP, RR, oxygen saturations on air)
223872985|NCT06555757|DIAGNOSTIC_TEST|Transthoracic echocardiogram|LVEF, IVC collapsibility, LV filling pressure, PA pressure
223872986|NCT06555757|OTHER|Sound recordings|Sound recordings (voice/cough/chest) recorded with the in-built microphone in a smartphone
223872987|NCT06555757|DIAGNOSTIC_TEST|Lung ultrasound|Lung ultrasound
223872988|NCT06555757|OTHER|KCCQ questionnaire|Kansas City Cardiomyopathy Questionnaire
223872989|NCT06555757|OTHER|ASCEND-HF score|An in-hospital congestion score which risk stratifies patients admitted with worsening heart failure, developed for the Acute study of clinical effectiveness of Nesiritide in decompensated heart failure trial
223872990|NCT06555757|OTHER|Composite Everest congestion score|A shortened version of the original 18-point score from the EVEREST trial
223872991|NCT06555757|DIAGNOSTIC_TEST|Bio impedance and total body water measurement|Bio impedance and total body water measurement using TANITA device
223872992|NCT06754163|DRUG|Semaglutide in combination with a healthy lifestyle intervention (diet and exercise)|"Wegovy (semaglutide) will be provided as an induction dose of 0.25 mg, titrated up every 4 weeks to 0.5 mg, 1.0 mg, 1.7 mg and 2.4 mg, will be given, with a maintenance dose of 2.4 mg or to the maximum tolerated dose.~To reduce the likelihood of gastrointestinal symptoms, the dose should be escalated over a 16-week period to a maintenance dose of 2.4 mg once weekly. The semaglutide injection will be administered once weekly on the same day of the week throughout the study period. Injections will be administered in the thigh, abdomen or upper arm at any time of the day. As part of the multi-disciplinary approach taken in the STEP trials of Wegovy, patients willl be encouraged to~* Increase their physical activity~* Reduce their daily calorie intake~* Record their physical activity and dietary intake on their Food/Activity/Sleep (FAS) Diary Sheets A secondary goal is to achieve sustained improvements in participants' activity levels and awareness of a healthy diet."
223872993|NCT06055465|DRUG|Sacituzumab Govitecan|"* 4 cycles, each cycle lasting for 3 weeks~* 10mg/kg given every day 1 and day 8 each cycle~* IV infusion"
223872994|NCT06055465|DRUG|Pembrolizumab|"* 4 cycles, each cycle lasting for 3 weeks in Neoadjuvant phase; after surgery, 13 cycles, each cycle lasting for 3 weeks in Maintenance phase.~* 200mg fixed dose every day 1 each cycle~* IV infusion"
223872995|NCT05598723|DRUG|IncobotulinumtoxinA (XEOMIN®)|IncobotulinumtoxinA (XEOMIN®) is injected into specific targets at two different time points. Changes in chronic migraine frequency and duration are recorded and compared.
223872996|NCT05598723|DRUG|OnabotulinumtoxinA (BOTOX®)|OnabotulinumtoxinA (BOTOX®) is injected into specific targets at two different time points. Changes in chronic migraine frequency and duration are recorded and compared.
223872997|NCT03918694|DIETARY_SUPPLEMENT|Vitamin C|Daily use of Vit C tablets
223872998|NCT03918694|DIETARY_SUPPLEMENT|Placebo|Daily use of placebo tablets
223872999|NCT04898829|DIETARY_SUPPLEMENT|PKU explore|"For 28 consecutive days, participants will take their usual restricted therapeutic diet, either:~\- Replacing their usual second stage concentrated protein substitute with PKU explore~OR~\- Commencing PKU explore and gradually reducing their Phe-free formula for infants."
223873000|NCT03801499|DRUG|Lenvatinib|12 mg (or 8 mg) once daily (QD) oral dosing.
223873001|NCT05062317|DRUG|Leucovorin|Given by PO
223873002|NCT05062317|DRUG|5-FLUOROURACIL|Given by IV
223873003|NCT05062317|DRUG|Oxaliplatin|Given by PO
223873004|NCT05062317|DRUG|Irinotecan|Given by IV
223873005|NCT05062317|DRUG|Capecitabine|Given by IV
223873006|NCT05062317|DRUG|Bevacizumab|Given by IV
223873007|NCT00025324|BIOLOGICAL|filgrastim|
223873008|NCT00025324|DRUG|carboplatin|
223873009|NCT00025324|DRUG|cyclophosphamide|
223873010|NCT00025324|DRUG|etoposide|
223873011|NCT00025324|DRUG|thiotepa|
223873012|NCT00025324|PROCEDURE|autologous bone marrow transplantation|
223873013|NCT00025324|PROCEDURE|bone marrow ablation with stem cell support|
223873014|NCT00025324|PROCEDURE|conventional surgery|
223873015|NCT00025324|PROCEDURE|peripheral blood stem cell transplantation|
223873016|NCT00025324|RADIATION|radiation therapy|
223873017|NCT06922786|DEVICE|Hemadsorption filter|"Plasma titers neurodepressing drug:~* At admission to the hospital (standard of care)~* 2 hours after admission (+/- 15 minutes)~* 4 hours after admission (+/- 15 minutes)~* 6 hours after admission (+/- 15 minutes)~* 8 hours after admission (+/- 15 minutes)~* Just before start hemadsorption~Hemadsorption via dialysis catheter in patients still fulfilling inclusion criteria 8 hours after admission.~Subsequent plasma titers pre- and post-hemadosorption filter:~* 15 minutes after start of hemadsorption (+ 15 minutes)~* 4 hours after start of hemadsorption (+/- 15 minutes)~* 8 hours after start of hemadsorption (+/- 15 minutes)~* 12 hours after start of hemadsorption (+/- 15 minutes)~* 16 hours after start of hemadsorption (+/- 15 minutes)~* 20 hours after start of hemadsorption (+/- 15 minutes)~* 24 hours after start of hemadsorption (+/- 15 minutes)~* Every other 24 hours until cessation of hemadsorption or normalization of the plasma titer (+/- 15 minutes)"
223873018|NCT02678572|COMBINATION_PRODUCT|Melphalan/HDS|Melphalan (3 mg/kg IBW) with Hepatic Device System (HDS)
223873019|NCT00431704|DRUG|vinorelbine|25 mg/m2 days 1 and 8 every 3 weeks for 6 cycles, or up to 9 cycles for responding patients
223873020|NCT00431704|DRUG|carboplatin|AUC 5 intravenously every 3 weeks for 6 cycles, up to 9 cycles for responding patients
223873021|NCT00431704|DRUG|trastuzumab|8 mg/kg IV day 1, then 6 mg/kg IV every 3 weeks until disease progression
223873022|NCT06925724|DRUG|Ivonescimab|Ivonescimab will be administered as 20 mg/kg IV (a fixed dose of 3200 mg for ivonescimab should be used for patients ≥ 160 kg), Q3W administered for 60 minutes (± 10 minutes)
223873023|NCT04474314|DRUG|IMR-687|Oral administration of once daily IMR-687
223873024|NCT04474314|DRUG|Placebo|Oral administration of once daily Placebo
223873025|NCT05742204|OTHER|Plasma protein biomarker analysis|Plasma samples from lung cancer patients were collected at the time of their diagnosis, prior to the initiation of treatment.We will use TMT-based proteomics approaches to analyze more than 2000 proteins in plasma samples from lung cancer patients .
223873026|NCT05742204|OTHER|Plasma protein biomarker analysis|Plasma samples of control subjects were collected.
223873027|NCT06935019|GENETIC|Genome sequencing pre-geneticist evaluation|The intervention is receiving immediate clinical routine GS, prior to evaluation by a medical geneticist. Pre-test counselling will be done by a research genetic counsellor. Results of GS will be returned during the participant's first visit to Genetics Clinic by their clinical team. Subsequent clinical care (including any other clinically indicated genetic testing or workup) will be arranged by the medical geneticist in clinic.
223873028|NCT06937073|BEHAVIORAL|dietary intake guidance and exercise guidance|"In the Fugu Medical WeChat mini program, the intervention plan for the intervention group included: (1) dietary intake guidance and (2) exercise guidance.~1. Dietary intake guidance: The dietary guidance was mainly based on the general dietary guidelines for the elderly issued by the Chinese Nutrition Society.~2. Exercise guidance Exercise guidance included resistance training and balance training."
223873029|NCT06937073|BEHAVIORAL|Control|Participants in the control group only received rehabilitation program articles in the form of images and text through the mobile application. These materials also included dietary intake guidance and exercise instructions. The frequency and intensity of the exercise instructions were sent to the patients at the same time. However, their daily adherence, including whether the training was completed or whether the dietary intake was appropriate, was not checked, verified, or followed up.
223873030|NCT06936449|DEVICE|CI632D|CI632 cochlear implant with Slim Modiolar electrode including dexamethasone in the electrode within wells
223873031|NCT06936449|DEVICE|CI632|CI632 cochlear implant with Slim Modiolar electrode with market approval and does not include dexamethasone
224076570|NCT04232735|OTHER|Tool and training|"The Source tool aims to assist health care providers with giving evidence based information about treatment outcomes by providing visualizations of personalized predictions of treatment outcomes for different treatments of oesophageal and gastric cancer. These predictions result from recently designed and updated prediction models on the survival, toxicity, complications and health related quality of life of oesophageal and gastric cancer patients.~The training aims to teach participants to inform patients about outcomes of treatment. The training is placed in the context of shared decision making (SDM), following the 4-step model by Stiggelbout et al., 2015.8 The training is provided in small groups (3-6 participants) by an experienced trainer and supported by professional actors. The training aims to address knowledge, attitude and skills."
223873032|NCT06932926|DRUG|Egg shell hydrogel|"I. Nano-eggshell powder preparation: After cleaning, A small crack will be made in each eggshell to split it into two halves to evacuate the content. The eggshells will be disinfected in a hot water at 100°C for 10 minutes to facilitate the detachment of the inner membrane. They will be exposed to steam sterilization. Then they will be crushed using a sterile mortar and pestle. The crushed particles will be milled using a zirconia ball-milling machine at 200 rpm . This will result in a nano-sized eggshell powder to incorporate them into a gel form.~II. Preparation of eggshell hydrogel formulations: through dispersing a suitable concentration of egg shell powder in distilled water, followed by dissolving the gelling agent; sodium carboxymethyl cellulose at a concentration of 5-10% under continuous stirring. The formed hydrogel will be kept at 8°C for a period of 24 hours before further use. This will produce a paste of consistency that is appropriate for handling and application."
223873033|NCT06932926|DRUG|Fluoride varnish|five percent sodium fluoride varnish (Charm varnish -Dentkist- Korea).
223873034|NCT06935253|OTHER|Large Language Model|The intervention is a Large Language Model.
223873035|NCT05678088|BEHAVIORAL|Oropharyngeal Exercises|The participant will practice exercises designed to strengthen the tongue and pharyngeal muscles
223873036|NCT05678088|BEHAVIORAL|Sham Exercises|The participant will practice exercises that have no impact on oropharyngeal (e.g., base of the tongue) muscle strength.
223873037|NCT06107894|BIOLOGICAL|Tumor-infiltrating lymphocytes|After NMA Lymphodepletion, autologous TILs will be intravenous infused into patients.
223873038|NCT06107894|DRUG|IL-2|IL-2 will be subcutaneous administrated for 14 days following TILs infusion.
223873039|NCT01523158|BIOLOGICAL|Allergovit grass or birch|subcutaneous injection of immunotherapy once weekly for 7 weeks prior to birch pollen season.
223873040|NCT05335798|DEVICE|Bodyweight augment system|Motorized cables will be providing downward force on the participant's pelvis
223873041|NCT05335798|DEVICE|Smart insole|Insole provided auditory feedback when heel strike or toe-off events happen
223873042|NCT01304277|BIOLOGICAL|agalsidase alfa|
223873043|NCT03971448|DEVICE|LPWB|The LPWB will be placed by clinical staff who will have been trained on the proper application of this device at the initial ED visit. At ED discharge, both populations will receive identical documentation on recommendations for weight bearing, type and frequency of analgesics, reasons to return for medical attention. The only difference will be care instructions related to the specific immobilization device. Specifically, the experimental group will be permitted to remove the LPWB as early as one week post ED visit as tolerated by the patient's symptoms.
223873044|NCT03971448|DEVICE|AKWC|If the patient is randomised to AKWC, it will be apply by a cast technician. Children with AKWC immobilization will be provided with up to two appointments in the orthopedic clinic. In case the AKWC could not been placed at initial visit, the first will be within 72 hours of the ED visit to have the fiberglass AKWC placed. The second appointment will be for cast removal.
223873045|NCT06335628|DEVICE|Geistlich Fibro-Gide®|Geistlich Fibro-Gide® is intended to be used as an implantable device for regeneration and augmentation of soft tissue in oral and maxillofacial surgery.
223873046|NCT05640154|BEHAVIORAL|educational program|The nursing educational program will be implemented in small groups from (5-7) in outpatient clinics. It includes nutrition, exercise, control hypertension , engage in weight control measures, smoking cessation, stress management, breathing exercise, appropriate treatment of diseases, control of diabetes, control of cholesterol in blood and routine follow up).
223873047|NCT04708509|DEVICE|Extubation Advisor|Participants undergoing a Spontaneous Breathing Trial (SBT) to assess readiness for extubation will be connected to a portable monitor displaying ECG, capnography, and other waveforms. This monitor will also be connected to a laptop containing the Extubation Advisor (EA) software. During the SBT, relevant patient information will be entered into the EA application and the EA application will record waveform data. When the SBT is complete, the EA application will analyze the waveform and patient data to generate a score summarizing the risk of extubation failure. A report will be generated and provided to the respiratory therapist and attending physician to help determine whether to proceed with extubation or not. Patients will be followed for 72 hours after extubation, when the clinical outcome case report form will be completed.
223873048|NCT04870645|PROCEDURE|Advanced Magnetic Resonance Imaging|Undergo advanced MRI
223873049|NCT04870645|PROCEDURE|Conventional Magnetic Resonance Imaging|Undergo conventional MRI
223873050|NCT04870645|DRUG|Gadolinium-Chelate|Contrast agent
223873051|NCT04870645|DRUG|Iopamidol|Contrast agent
223873052|NCT04888169|DEVICE|SMART Mobile App - Attention Bias Modification|ABM involves placing the probe behind the neutral stimulus on 100% of the trials.
223873053|NCT04888169|DEVICE|SMART Mobile App - Attention Control Training|ACT involves placing the probe behind the neutral stimulus on 50% of trials, and behind the threat stimulus on 50% of trials.
223873054|NCT04888169|DEVICE|SMART Mobile App - Placebo Training|Placebo training only includes neutral stimuli.
223873055|NCT04888169|DEVICE|SMART Mobile App - Control|Participants will only answer questions.
223873056|NCT04046224|BIOLOGICAL|ST-920|Single dose of investigational product ST-920
223873057|NCT04650386|BEHAVIORAL|Psychosocial support determined by adaptive treatment algorithm|Participants assigned to the adaptive intervention condition will be scheduled for buprenorphine medication management appointments according to the clinic protocol described above for TAU. The adjunctive psychosocial treatment that participants in this condition receive are (1) CBT delivered by behavioral health specialists and/or (2) peer support delivered by certified recovery specialist. The active intervention period will span 3 months post-study entry. Participants will continue to receive TAU following the active intervention period.
223873058|NCT05720884|DEVICE|acupuncture|Acupuncture of a disposable, sterilized, stainless steel needle of 0.20 mm \* 30 mm size (Dongbang medical, Boryeong, Rep of Korea) will be used.
223873059|NCT05720884|DEVICE|placebo acupuncture|Acupuncture of a disposable, sterilized, stainless steel needle of 0.20 mm \* 30 mm size (Dongbang medical, Boryeong, Rep of Korea) will be used but in differene location.
223873060|NCT05736159|DIAGNOSTIC_TEST|Method of assessment of school maturity|Psychophysiological examination of the functional readiness of the child for admission to school.
223873061|NCT05736159|DIAGNOSTIC_TEST|Assessment of school adaptation|Psychophysiological examination of the success of school education of first graders.
223873062|NCT06290427|DEVICE|DaVinci RAPN|Robot-assisted Partial Nephrectomy with DaVinci® Surgical System
223873063|NCT06290427|DEVICE|Hugo RAS RAPN|Robot-assisted Partial Nephrectomy with Hugo™ RAS System
223873064|NCT04086771|BEHAVIORAL|Navigation|Weekly phone-calls, personal messages, and American Cancer Society Pap test and mammography test reminder post card
223873065|NCT04086771|OTHER|Information only|American Cancer Society breast and cervical cancer screening information and Pap test and mammography test reminder post card
223873066|NCT03702842|DEVICE|Soterix Medical tsDCS stimulator|tsDCS will be delivered to the lumbar region of the spinal cord with electrodes placed over the low back and abdomen. The electrodes will be secured with a large elastic bandage so that stimulation can be applied for up to 30 minutes during locomotor training with a harness attached to the ceiling for safety. A physical therapist will supervise the session.
223873067|NCT03702842|OTHER|Locomotor training|Participants will complete 16 sessions of locomotor training (4 times per week for 4 weeks). This involves walking on a treadmill for up to 30 minutes with a harness attached to the ceiling for safety, followed by 10 minutes of overground walking training; with physical assistance as needed.
223873068|NCT05142904|DEVICE|Radiofrequency ablation|Ultrasound-guided radiofrequency ablation of the solitary autonomous thyroid nodule.
223873069|NCT05142904|DRUG|Radioactive iodine|I-131 according to standardized doses-calculation.
223873070|NCT05142904|DRUG|Radioactive iodine|I-131 according to local standard.
223873071|NCT04086017|OTHER|Reiki therapy|Reiki is a complementary health approach where trained providers place their hands lightly on or just above a person, in discrete positions, with the goal of facilitating the person's own healing response. A Reiki practitioner will perform the initial teaching and instruct the caregivers how to perform a simple 10-minute Reiki and self-Reiki session.
223873072|NCT06260878|OTHER|Intravenous Ringer's lactate|Intravenous Ringer's lactate
223873073|NCT05284227|OTHER|Electronic Clinical Decision Support Application|Preoperative anaesthesiological assessment and risk evaluation using a clinical decision support application, that calculates perioperative risks for the patient and informs the anaesthesiologist on indicated diagnostics and procedures according to clinical guidelines in real-time.
223873074|NCT05284227|OTHER|Standard procedures of the hospital and Sham Clinical Decision Support Application|Preoperative anaesthesiological assessment using standard procedures of the hospital. In addition a sham clinical decision support application will be used. Information on perioperative risks and indicated diagnostic procedures according to clinical guidelines is not given to the physician.
223873075|NCT05407545|DEVICE|Current prosthesis|A unilateral transfemoral amputee will conduct experiments with the current prosthesis
223873076|NCT05407545|DEVICE|Active Prosthesis (PowerKnee)|A unilateral transfemoral amputee will conduct experiments with the Power Knee. The PowerKnee is an active prosthesis developed by Össur.
223873077|NCT03867747|RADIATION|Cardiac Radiosurgery|Image-guided stereotactic body radiation therapy
223873078|NCT05242497|PROCEDURE|pharmacopuncture|This is a pragmatic randomized controlled trials, so the physicians will choose pharmacopuncture treatment, including the type and doses, according to each participant's conditions. The researcher will record the specific intervention precisely and concurrently.
223873079|NCT05242497|PROCEDURE|conservative treatments (including physiotherapy)|This is a pragmatic randomized controlled trials, so the physicians will choose conservative treatment, including physiotherapy and pharmacological treatment, according to each participant's conditions. The researcher will record the specific intervention precisely and concurrently.
223873080|NCT02460900|DRUG|Varenicline|
223873081|NCT02460900|BEHAVIORAL|Positively Smoke Free|
223873082|NCT02460900|DRUG|Placebo|
223873083|NCT02460900|BEHAVIORAL|Standard of Care|
223873084|NCT04485026|RADIATION|Local consolidative radiation therapy|All local consolidative radiation therapy should be delivered using hypofractionated local consolidative radiation therapy (\>2 Gy per fraction). Exceptions may be approved on a case by case basis by the trial principal investigator. Three-dimensional conformal radiotherapy (3D-CRT), intensity modulated radiation therapy (IMRT), volumetric modulated arc therapy (VMAT), stereotactic body radiotherapy (SBRT), stereotactic radiosurgery (SRS), and proton beam therapy (PBT) are all acceptable.
223873085|NCT04485026|DRUG|Standard of care radiation therapy|Standard of care palliative radiotherapy to symptomatic lesions is permissible. The dose to symptomatic lesions should not exceed 30 Gy in 10 fractions. Brain metastases will be treated with standard of care CNS therapy throughout the study. This may include (but is not limited to) stereotactic radiosurgery, neurosurgical intervention, whole brain radiotherapy
223873086|NCT04527887|DRUG|Dextenza (IDI) (Sustained Release Dexamethasone), (0.4 mg)|Intracanalicular dexamethasone insert contains 0.4 mg dexamethasone and is designed to provide a sustained and tapered release of therapeutic levels of dexamethasone to the ocular surface for up to 30 days for the reduction of postsurgical inflammation and pain associated with ocular surgery.
223873087|NCT04527887|OTHER|ProLong™ collagen plugs|The long term synthetic punctal plug is composed of an absorbable copolymer material and measures 0.4mm in diameter and 2.0mm in length.
223873088|NCT05165485|DRUG|Revefenacin|Revefenacin 175 mcg administered once daily for 84 days via nebulization
223873089|NCT05165485|DRUG|Tiotropium|Tiotropium 18 mcg administered once daily for 84 days via Spiriva HandiHaler®
223873090|NCT05165485|DRUG|Revefenacin Placebo|Placebo for Revefenacin administered once daily for 84 days via nebulization
223873091|NCT05165485|DRUG|Tiotropium Placebo|Placebo for Tiotropium administered once daily for 84 days via Spiriva HandiHaler®
223873092|NCT04888637|DIAGNOSTIC_TEST|Baseline MEG Test|Each subject will have one MEG session with the recordings of baseline resting state, language and memory protocols. Subjects will have a break period between the language and memory tasks. MEG recordings will be acquired for approximately 35 minutes. The subject will be allowed to practice the language and memory tasks before the MEG recording to feel familiar with them. This practice phase will be a short version of the task administered by a computer and will take approximately 6 minutes.
223873093|NCT04888637|BEHAVIORAL|Receptive Language Task|"The subject will perform a practice session where they will be instructed to try to remember a set of ﬁve audibly spoken English words, deemed targets (jump, little, please, drink, and good). Depending on the subject's overall verbal memory capacity, the target words will be presented once or twice during the practice phase. Subsequently, during the MEG recording, the ﬁve target words will repeat in a different random order, mixed with a different set of 40 distractors (non-repeating words) in each of three blocks of stimuli. The subject's task will be to listen to the words and lift their index finger of the dominant hand whenever they hear a repeated target word (one of the five). After the language task, the subject will be given a break."
223873094|NCT04888637|BEHAVIORAL|Memory Task|"The subject will be tasked with indicating whether the encoding stimulus matched the retrieval stimulus using two buttons; one for congruent and the other for incongruent response. Button type will be counterbalanced among subjects. The task will take around 16 minutes. The visual stimuli will be projected through an LCD projector onto a white screen located about 0.5 m in front of the subject and subtending 1.0-4.0 and 0.5 degrees of horizontal and vertical visual angle, respectively. A MEG compatible keyboard will be used to measure the subject's responses for congruent and incongruent. The subject will practice the memory task before going to the MEG system using a computer from MEG laboratory. This practice phase will consist of a short version of the memory task with duration of approximately 4 minutes."
223873095|NCT06832943|PROCEDURE|Unicorn system|Patients with airway stenosis undergo stent placement with the help of RBS.
223873096|NCT06831656|OTHER|Placebo-Pre|No dietary supplementation prior to undergoing the placebo supplement
223873097|NCT06831656|DIETARY_SUPPLEMENT|Placebo-Post|14 days of supplementation with 25 mg/day hemicellulose crystalline
223873098|NCT06831656|OTHER|Tetraselmis chuii-Pre|No dietary supplementation prior to undergoing the tetraselmis chuii supplement
223873099|NCT06831656|DIETARY_SUPPLEMENT|Tetraselmis chuii-Post|14 days of supplementation with 25 mg/day tetraselmis chuii
223873100|NCT05741879|BEHAVIORAL|Gamified exercise training|"Participants will complete a 2-days-a-week online training routine with their families: Each session will include a Warm-Up/Activation phase (3 minutes: light intensity continuous training), a Training phase (10-26 minutes: 6-12 repetitions, 20-40 of work, 10-20 recovery), and a Cool Down phase (3 minutes: static and dynamic exercises). The exercises will be different each week and will increase in length and intensity accordingly. The sessions will be supervised by the participants parent(s) and/or guardian(s)."
223873101|NCT05741879|BEHAVIORAL|Standard Care|This group will be allocated to standard care and therefore no gamified online exercise training will be provided. They will continue to perform their daily routine/activities including their basic motor skills classes at school and their extracurricular sports and/or cultural activities.
223873102|NCT03237481|DRUG|HTX-011|HTX 011 (bupivacaine/meloxicam), 300 mg/9 mg by instillation
223873103|NCT03237481|DRUG|Bupivacaine HCl|Bupivacaine HCl without epinephrine, 75 mg by injection
223873104|NCT03237481|DRUG|Saline placebo|Saline placebo by instillation
223873105|NCT03237481|DEVICE|Luer-lock applicator|Applicator for instillation
223873106|NCT03237481|DEVICE|Vial access device|Device for withdrawal of drug product
223873107|NCT03501719|DRUG|Number of drugs in the ART regimen|Triple therapy vs. dual therapy vs. monotherapy
223873108|NCT05501756|DRUG|Alemtuzumab|Alemtuzumab (Campath®) is a recombinant DNA-derived humanized monoclonal antibody directed against CD52. Alemtuzumab is produced in mammalian cell (Chinese hamster ovary) suspension culture in a medium containing neomycin. Neomycin is not detectable in the final product. Alemtuzumab is a sterile, clear, colorless, isotonic pH 6.8-7.4 solution for injection. Alemtuzumab is supplied in single-use clear glass ampules containing 30 mg of Alemtuzumab in 3 mL of solution. A single use vial of alemtuzumab contains 30 mg alemtuzumab, 8 mg sodium chloride, 1.44 mg dibasic sodium phosphate, 0.2 mg potassium chloride, 0.2 mg monobasic potassium phosphate, 0.1 mg polysorbate 80, and 0.0187 mg disodium edetate dihydrate.
223873109|NCT04543773|DEVICE|rTMS|rTMS will be delivered to the fMRI-determined DLPFC hotspot according to conventional parameters for clinical treatment (e.g., excitatory: 75 trains of 40 pulses, 10Hz, up to 3000 pulses). Magnetic field strength will be up to 120% of resting motor threshold. Ramp up of magnetic field strength may be utilized in the first week for tolerability. Side effects will be monitored and coil angle adjusted to improve tolerability if necessary.
223873110|NCT05786248|OTHER|Impedancemetry|the impedance measurement electrodes are placed on the lower limbs and neck. After the first measurement, the patients are invited to lie down. A new series of measurements will be performed at 30 (T30), 90 minutes (T90) and in the morning.
223873111|NCT06273605|OTHER|Egg Ladder|12 month protocol of graded and gradual egg introduction
223873112|NCT04950868|DRUG|Quetiapine|They will initially be given 25 mg of quetiapine per day. The dose may be increased by 25-50 mg per week, to a maximum dose of 150 mg per day by week 6 of the study.
223873113|NCT05178745|DRUG|Fluorouracil|Pharmaceutical Form: solution for injection Route of Administration: intravenous (IV), intravenous or intra-arterial infusion
223873114|NCT05178745|DRUG|Aflibercept|Pharmaceutical Form: concentrate solution for infusion Route of Administration: IV infusion
223873115|NCT05178745|DRUG|Irinotecan|Pharmaceutical Form: solution for injection Route of Administration: IV infusion
223873116|NCT01067287|DRUG|CT-011|Infusions starting one to three months following autologous transplant at 6 week intervals for a total of 3 doses
223873117|NCT01067287|BIOLOGICAL|Dendritic Cell Fusion Vaccine|One week following each infusion of CT-011
223873118|NCT06493032|DEVICE|Gastric Alimetry System|medical device that uses a large sheet of electrodes to assess gastric motility
223873119|NCT05646563|DRUG|NM8074|NM8074 is an anti-Factor Bb humanized monoclonal antibody that will be administered as an intravenous infusion. Doses will be administered over a treatment period of 13 weeks.
223873120|NCT05646563|DRUG|Soliris|Complement C5 blocker administered intravenously
223873121|NCT04068844|BEHAVIORAL|Exercise training|Exercise training, either whole body or isolated single leg
223873122|NCT05941637|DRUG|Axitinib 5 MG|Patients will receive Axitinib (AG 013736) is a multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ, and c-Kit - 5mg daily
223873123|NCT06260865|DEVICE|MORA Cure|MORA Cure (ETH-01K), developed by EverEx, Inc., is a digital therapeutics (S/W medical device) designed to provide multidisciplinary rehabilitation treatment, a combination of graded exercise therapy and cognitive behavioural therapy for patients with patellofemoral pain syndrome.
223873124|NCT06260865|OTHER|Treatment as Usual|In the control group, education is delivered and self-exercise is recommended.
223873125|NCT06219187|OTHER|Questionnaire completion|"To meet the study's objective, patients will be asked to complete a questionnaire characterizing their environmental and psychosocial context.~The questionnaire is to be completed by the patients themselves, or by their trusted support person as recorded in their medical records (in the particular case of a deceased patient).~It is estimated that the questionnaire will take around 30 minutes to complete.~Data will also be collected from the medical records of included patients:~* Demographics~* Disease data"
223873126|NCT06640972|DRUG|RDX-002|Gut-specific microsomal triglyceride transfer protein (MTP) inhibitor
223873127|NCT06640972|DRUG|Placebo|Matching placebo
223873128|NCT05396872|OTHER|Participant Surveys|Online surveys administered post appointment
223873129|NCT05396872|OTHER|Mobile app|Mobile application installed on mobile device
223873130|NCT02665195|OTHER|saliva specimen|
223873131|NCT02665195|BEHAVIORAL|questionnaire|
223873132|NCT06558006|DRUG|Predimenol tablet|2 tablets of Predimenol (400 mg Predimenol) will be taken with 220 mL of water (one glass of water).
223873133|NCT06558006|DRUG|Predimenol tablet + Placebo tablet of Predimenol|1 tablet of Predimenol (200 mg Predimenol) + 1 tablet of placebo will be taken with 220 mL of water (one glass of water).
223873134|NCT06558006|DRUG|Placebo tablet of Predimenol|2 tablets of placebo tablet of Predimenol will be taken with 220 mL of water (one glass of water).
223873135|NCT03309748|PROCEDURE|Dental prophylaxis|American Dental Association, Code on Dental Procedures and Nomenclature (CDT) CDT code D1110
223873136|NCT03309748|DEVICE|Dental prophylaxis + antimicrobial photodynamic therapy|Dental prophylaxis using American Dental Association, Code on Dental Procedures and Nomenclature (CDT) CDT code D1110 followed by two 8-minute irradiation cycles using GLO Brilliant home use whitening device (GLO ™ Science LLC, New York, USA).
223873137|NCT06235242|BIOLOGICAL|GT201 injection in combination with teraplizumab injection|GT201 injection in combination with teraplizumab injection for treatment of patients with non-small cell lung cancer
223873138|NCT06307782|DIETARY_SUPPLEMENT|whey protein intake before surgery|Total Hip Arthroplasty whey protein intake,Total Hip Arthroplasty, whey protein intake,CRP,cortisol insulin resistance
223873139|NCT06307782|DIETARY_SUPPLEMENT|Water before surgery|Total Hip Arthroplasty water before surgery,Total Hip Arthroplasty, water intake,CRP,cortisol insulin resistance
223873140|NCT04733040|DRUG|MOR202|MOR202 will be administered as an intravenous infusion
223873141|NCT00658827|OTHER|No intervention|This is an observational study. Patients receiving infliximab or anti-TNF as per the prescribing information will be observed.
223873142|NCT06589466|OTHER|Surgery|this study in observational study, no intervention.
223873143|NCT06471257|COMBINATION_PRODUCT|Budesonide/Albuterol metered dose inhaler, MDI|Combination Product (Drug + Device)
223873144|NCT06471257|COMBINATION_PRODUCT|Albuterol sulfate metered dose inhaler, MDI|Combination Product (Drug + Device)
223873145|NCT04981730|BEHAVIORAL|Web-based intervention|The web-based intervention participants will follow the website's orientation, the curriculum of modules, and professional feedback to complete the intervention.
223873146|NCT05384249|DRUG|Izokibep|"Biologic: IL-17A inhibitor~Form: Solution for injection~Route of administration: Subcutaneous (SC)"
223873147|NCT05384249|DRUG|Placebo|"Form: Solution for injection~Route of administration: Subcutaneous (SC)"
223873148|NCT06084455|OTHER|Aerobic exercise|30 minutes of aerobic exercise on a stationary bike
223873149|NCT06681090|DRUG|"0.1% topical triamcinolone Acetonide preparation Kenacourt-A Orabase"|The patients were administered topical corticosteroids in the form of a 0.1% triamcinolone acetonide preparation (Kenacort TM 0.1% Abbott). The medication was to be used 3 times every day for 4 weeks or until the lesion has healed, whichever occurs first. After applying the gel, the patients were instructed not to consume any fluids or food for at least 1 hour. In addition, a topical antifungal treatment consisting of Miconazole oral gel at a concentration of 2% should be applied once a day for 4 weeks
223873150|NCT06681090|DEVICE|980 nm diode laser|First group (Group A) underwent PBM therapy using a 980 nm diode laser (elexxion nano dental laser with a flat top handpiece). The therapy included 8 sessions for 4 weeks, with 2 sessions conducted per week, all administered by the same operator. The energy was evenly distributed across all the mucosal lesions and the surrounding tissues within a 0.5 cm range using a spot-technique method with little overlap.
223873151|NCT06360432|BEHAVIORAL|Dietary modification program|Participants will receive an 8-week program consisting of personalized dietary modification program. The dietary modification program is composed of a total of 8 personalized, one-hour face-to-face sessions. Participants will be encouraged to take on a moderate hypocaloric plan that cuts daily energy expenditure to encourage steady weight loss while preserving muscle mass. A protein intake of 1.5 g/kg of body weight per day is recommended. To optimize protein uptake, it's suggested that protein be distributed evenly across meals, aiming for 25-30 g per meal, inclusive of 2.5-2.8 g of leucine. Participants will also receive a guidebook, crafted through the Delphi method, to facilitate the adoption of these dietary modifications in their daily routines.
223873152|NCT06360432|BEHAVIORAL|Exercise training|Participants will receive an 8-week program consisting of exercise training. It entails weekly group sessions, with each lasting an hour for 8 weeks. These sessions, designed for groups of approximately 10, will blend resistance and aerobic workouts to enhance muscle mass and strength while reducing fat in individuals with SO. Each session includes a 10-minute warm-up and cool-down, 20 minutes of resistance training using elastic bands, followed by a 20-minute brisk walking segment. Participants will also receive a YouTube link and a pamphlet describing the exercises, encouraging them to maintain at least 30 minutes of exercise five times a week during and beyond the supervised programme.
223873153|NCT06360432|BEHAVIORAL|The EatWellLog App|Only participants in the M-health group will be instructed to use the EatWellLog app for daily diet self-management. This App supports participants with SO by providing a structured approach to managing a diet that encourages steady weight loss while maintaining muscle mass, in line with current nutritional recommendations for this demographic. The EatWellLog App has the following features: i) tracking participants' dietary habits by logging meals and snacks from a food list, ii) personalized online coaching and reminders by a multidisciplinary healthcare team, iii) participation of family caregivers through an interactive messaging function, iv) accessing health information via multiple channels, including animations, an at-a-glance display, and a reminder, and v) utilization of game elements, such as educational animations and video games to disseminate health and nutritional information related to SO.
223873154|NCT06421051|DEVICE|Transauricular Vagal Nerve Stimulation|Transauricular vagal nerve stimulation
223873155|NCT06750263|OTHER|Balance exercise with clamshell|balance was assessed by the Berg's Balance Scale exercise. Participants were instructed to walk (step) from one end of the mat to the other according to the step pattern provided. When reached the end of the mat, instructed to return to their starting position by walking normally off the mat and starting the next stepping. repeat every sequence five times and then started a new pattern. Duration would be 30 min. clamshell exercises a Participants were instructed to lie on their side with the weaker limb facing upwards. Both hips were flexed at 45 degrees, knees flexed at 90 degrees, and neither the feet nor the back were in contact with the wall. While keeping both heels and the first metatarsal head together, participants were instructed to separate their knees and rotate the weaker limb upward. They were advised not to tilt the limb backwards and to maintain a neutral pelvic position 3,5 sets for 10 repetations twice a week for 12 weeks
223873156|NCT06750263|OTHER|Balance exercise|Participants were instructed to lie on their side with the weaker limb facing upwards. Both hips were flexed at 45 degrees, the knees were flexed at 90 degrees, and neither the feet nor the back were in contact with the wall. While keeping both heels and the first metatarsal head together, participants were instructed to separate their knees and rotate the weaker limb upward. They were advised not to tilt the limb backwards and to maintain a neutral pelvic position 3,5 sets for 10 repetations twice a week for 12 weeks
223873157|NCT06343636|DRUG|VG-3927|Dose Escalation
223873158|NCT06343636|DRUG|Placebo|Dose Escalation
223873159|NCT06343636|DRUG|VG-3927|One Dose Level
223873160|NCT06142890|OTHER|No cooling (control)|Participants are exposed to 31°C, 45% relative humidity for 8 hours without cooling intervention (control condition). Drinking water is available ad libitum. Participants remain in supine position with slight (\~20°) chest and head elevation (low-Fowlers position) throughout the duration of bed-rest exposure.
223873161|NCT06142890|OTHER|Cooling with ceiling fan|Participants are exposed to 31°C, 45% relative humidity for 8 hours. Drinking water is available ad libitum. Participants remain in supine position with slight (\~20°) chest and head elevation (low-Fowlers position) throughout the duration of bed-rest exposure. Participants will remain under a commercially available ceiling fan generating a standard air flow throughout the duration of exposure.
223873162|NCT03535922|OTHER|PROMs Assessment|Routine measurement and reporting of disease-specific PROMs, generic PROMs, or combination of both
223873163|NCT06761638|COMBINATION_PRODUCT|Rhythmic Auditory Stimulation Therapy|Rhythmic auditory stimulation (RAS) is a therapeutic technique that uses rhythmic auditory cues, like a metronome or music, to improve motor control and coordination. It is often used in rehabilitation for conditions such as stroke, Parkinson's disease, and other movement disorders to enhance gait and other motor functions through the synchronization of movements to auditory rhythms.
223873164|NCT06761638|COMBINATION_PRODUCT|Task-Specific Training|Task-specific training is a rehabilitation approach that involves practicing specific tasks or activities to improve the performance of those tasks. It is based on the principle that repetitive practice of functional tasks enhances neuroplasticity, leading to better motor skills and functional recovery, especially in stroke and neurological rehabilitation.
223873165|NCT05896683|DRUG|Lazertinib|Lazertinib will be administered orally.
223873166|NCT03974854|DRUG|XELOXIRI-3|chemotherapy with XELOXIRI-3 regimen
223873167|NCT03974854|DRUG|Gemcitabine|chemotherapy with Gemcitabine regimen
223873168|NCT06815250|BEHAVIORAL|Influenza and Tdap Vaccination Educational and Learning Module|Influenza and Tdap learning and educational module delivered via website. The module will cover importance of vaccination for both pregnant women and infant, safety and efficacy of the influenza and TdaP vaccines, timing of vaccination, and addressing common concerns and misconceptions.
223873169|NCT02746081|DRUG|BAY1436032|The selected starting dose of BAY1436032 is 300 mg/day (150 mg BID) to be administered orally continuously in tablet form in 21-day cycles. Adjustments to this schedule may be made if warranted by information collected during the course of the study. The maximum feasible dose of BAY1436032 is expected to be 3000 mg/day.
223873170|NCT04907474|DRUG|tropicamide-phenylephrine fixed combination ophthalmic solution|Tropicamide-phenylephrine fixed combination ophthalmic solution is a tropical drug solution for mydriasis
223873171|NCT06835491|DRUG|Amiodarone|Initial loading dose of 300mg over 30 minutes in 250ml of glucose 5% solution. Continuous amiodarone infusion will be administered for 72 hours at a dose of 10 mg/kg without exceeding 900 mg/24h.
223873172|NCT06789835|DEVICE|Fluorescence imaging of disclosed and undisclosed plaque|Teeth are imaged using a fluorescence camera/an intraoral scanner before and after plaque disclosure.
223873173|NCT05613673|OTHER|No intervention - observational study only|No intervention - observational study only
223873174|NCT04077073|DEVICE|ReIn-Hand|ReIn-Hand assists the hand opening
223873175|NCT04077073|DEVICE|Robot|Robot supports the shoulder load
223873176|NCT05830058|PROCEDURE|Biospecimen Collection|Undergo blood collection
223873177|NCT05830058|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
223873178|NCT05830058|PROCEDURE|Positron Emission Tomography|Undergo PET
223873179|NCT05830058|OTHER|Questionnaire Administration|Ancillary studies
223873180|NCT05830058|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
223873181|NCT04661982|OTHER|Long-term Follow-up|Undergo long term follow-up
223873182|NCT04661982|OTHER|Questionnaire Administration|Ancillary studies
223873183|NCT04661982|OTHER|Quality-of-Life Assessment|Ancillary studies
223873184|NCT04677920|OTHER|High Linoleic Acid Healthy Cookies|High Linoleic Acid Healthy Cookies (containing about 10g of grapeseed oil) 1 per day for 2 weeks
223873185|NCT06785623|DIETARY_SUPPLEMENT|Gastrodia elata Blume water extract|Subjects in the experimental group will consume Gastrodia elata Blume water extract daily. The extract is prepared from dried Gastrodia elata Blume, which is processed into a water-soluble form. This dosage is administered orally for a duration of a week. The intervention is designed to evaluate the potential effects of Gastrodia elata Blume on alleviating depressive symptoms, improving autonomic nervous system function, and enhancing overall quality of life in terminal cancer patients.
223873186|NCT06784323|BEHAVIORAL|Catered diet|For a period of 8 weeks the participant will receive catered food, the study team will provide the participants breakfast, lunch and dinner. Participants will receive catered food for 3 daily meals, and record daily food intake. Catered diet will be sent to participants' homes on a weekly basis. The diet will consist of primarily whole foods with few additives, with a focus on Hispanic cultural foods.
223873187|NCT06784323|BEHAVIORAL|Diet guidance sessions|Participants will receive virtual weekly diet guidance with a dietitian regarding food safety preparation methods and cooking practices. Patients will receive weekly gift cards for grocery stipend. On average, initial counseling session with dietitian will last 30 minutes, and 7 follow-up sessions will last 20 minutes.
223873188|NCT06784323|BEHAVIORAL|Dietary counseling|Participants will receive dietary counseling weekly on Zoom for up to 30 minutes. Dietitian will meet with participants to explain benefits of adhering to diet therapy.
223873189|NCT06784323|BEHAVIORAL|Feedback sessions|Participants will be involved in one-time 50-minute feedback session over Zoom with dietitian and principal investigator. During the session, participants will discuss preferred foods/recipes during active disease, likeability of recipes, ease of recipe preparation, dietary adherence, and healthy food affordability.
223873190|NCT04301089|DEVICE|Pico G2 4K Headset with Applied VR software|headset worn at time points defined in study
223873191|NCT06830148|OTHER|Post-frenotomy manual manipulation|Parents assigned to the treatment group will be instructed to perform post-frenotomy stretches and exercises four times daily, after every other feed, until the time of their postoperative visit 2-3 weeks later.
223873192|NCT05925881|PROCEDURE|Surgical Repair of Large to Massive Rotator Cuff Tears|Surgical procedure to reconstruct the rotator cuff
223873193|NCT06549634|DRUG|Daratumumab|Daratumumab is not being administered as part of the study. Patients will receive daratumumab as part of their clinical care, and blood and urine will be collected in order to measure biomarkers pre- and post-daratumumab administration
223873194|NCT05281510|DRUG|Vesatolimod|Administered orally
223873195|NCT05281510|BIOLOGICAL|VRC07523LS|Administered intravenously
223873196|NCT05281510|BIOLOGICAL|CAP256V2LS|Administered intravenously
223873197|NCT05423379|DEVICE|XIENCE Skypoint Large Vessel Everolimus Eluting Coronary Stent System (EECSS)|XIENCE Skypoint Large Vessel EECSS is composed of a L-605 CoCr stent and coated with poly (n-butyl methacrylate) (PBMA) primer and a drug coating formulation of polymer of vinylidene fluoride and hexafluoropropylene (PVDF-HFP)/everolimus pre-mounted on a balloon catheter delivery system.
223873198|NCT06366672|BIOLOGICAL|JYNNEOS (Smallpox and Monkeypox Vaccine, Live, Nonreplicating) suspension for subcutaneous injection|live, nonreplicating vaccine delivered according to the FDA approved package insert
223873199|NCT06366672|PROCEDURE|Phlebotomy|Research blood draw
223873200|NCT06366672|PROCEDURE|Research bronchoscopy|Outpatient research bronchoscopy with bronchoalveolar lavage and endobronchial biopsy performed with conscious sedation.
223873201|NCT06366672|PROCEDURE|Skin punch biopsy|Skin punch biopsy performed with topical anesthesia.
223873202|NCT06366672|PROCEDURE|Bone marrow aspiration|Bone marrow aspiration performed with local anesthesia.
223873203|NCT03873779|DEVICE|The ZELTIQ System|Participants received cryolipolysis treatment in submental and submandibular areas using the CoolSculpting System and CoolMini applicator for fat layer reduction on Day 0, which was followed with a radiofrequency treatment performed 12 weeks after CoolSculpting.
223873204|NCT05436834|BIOLOGICAL|mRNA-1273.214|Sterile liquid for injection
223873205|NCT05436834|BIOLOGICAL|mRNA-1273.815|Sterile liquid for injection
223873206|NCT05271435|DEVICE|PAMSys Activity Monitoring System|This system is composed of a Study Tablet running custom fall detection and reporting software and PAMSys sensors. PAMSys provides clinical-grade physical activity monitoring, storing the raw accelerometer data that can be used for analyzing activity parameters such as those listed in Table 3. Sensor data will be downloaded manually upon receipt of the study device by Biosensics, the study sponsor. Sensors can be worn during all activities including while showering and sleeping. The rated battery life is 3-6 months for the fall sensor, and 4 weeks for the activity sensors. This system is not classified as a medical device. Reports of sensor use, step number, battery level, and memory availability are sent hourly to a secured and HIPAA compliant back-end server provided by BioSensics. The Study Tablet also contains modules for performing speech, handwriting, and pattern tracing tasks.
223873207|NCT05271435|BEHAVIORAL|Motor, Speech, and Handwriting Assessment|"These assessments occur at each study visit. After equipping the subject with 3 activity sensors (1 on pendant around neck and 2 on wrists).~* 10-meter walk task (5 minutes) - The subject starts from a standing position and walks a length of 10 meters. The best time of three trials is used.~* Timed Up and Go (TUG) test (5 minutes) - Subjects stand, walk to a marker on the floor 3 meters ahead, turn around the marker, walk back to the chair, and sit. The best time of three trials is used.~* Handwriting Assessment Battery (HAB) (15 minutes) \[Faddy2008\] - The subject is seated at a table with a pencil and paper and performs a series of writing tasks.~* Speech Assessment Battery (SAB)(10 minutes) - The participant will perform a set of audio recordings using the study tablet while sitting in a quiet room."
223873208|NCT05381987|DEVICE|Radial shockwave therapy|Shockwave Storz Medical device, Doulith SD1, Tower (BT)
223873209|NCT04761939|COMBINATION_PRODUCT|EluNIR Ridaforolimus Eluting Coronary Stent System|"The EluNIR Ridaforolimus Eluting Coronary Stent System is a single use device/drug combination product comprising of:~* Stent - a pre-mounted Cobalt Chromium (CoCr) alloy based stent - 2.25 mm Diameter and 8mm, 12mm, 15mm, 17mm, 20mm, 24mm, 28mm and 33mm length~* Delivery System - Rapid Exchange (RX) Coronary System~* Polymer matrix coating - Poly n-butyl methacrylate (PBMA) and CarboSil®~* Ridaforolimus drug - CAS Registry Number: 572924-54-0"
223873210|NCT05284240|DEVICE|Auryon Laser System|"The Auryon BTK Study is a prospective, single arm multicenter study evaluating the safety and procedural effectiveness of the Auryon laser in treating infrapopliteal disease in patients with critical limb ischemia and claudication.~The primary exposure of interest for this study is the use of the AURYON system for atherectomy."
223873211|NCT06782048|DRUG|Placebo|Participants will receive placebo by mouth once each day for a total of 14 days.
223873212|NCT06782048|DRUG|Pyrvinium|Participants will receive pyrvinium (2 mg/kg/day) by mouth once each day for a total of 14 days.
223873213|NCT06782048|PROCEDURE|Blood biomarkers analyses|Up to 20ml of blood will be drawn from each participant at each study visit, with a total of 4 study visits for molecular analyses.
223873214|NCT06782048|PROCEDURE|Oesophagogastroduodenoscopy (OGD) and biopsy|Study participant will undergo OGD with collection of gastric mucosal biopsies at the baseline visit to ascertain IM status and for molecular analyses. Study participant will undergo follow-up gastroscopy with collection of gastric mucosal biopsies at day 7 of treatment, 6 weeks post-treatment and 1 year post-treatment to assess if endpoint is reached and for molecular analyses. Gastric juice samples will be collected during each OGD.
223873215|NCT06782048|OTHER|Gastric juice, saliva and stool collection and analyses|Gastric juice will be taken, and gastric pH will be measured at each research endoscopy. Saliva and stool will also be obtained from participants at research endoscopy for microbiome studies at the following timepoints: baseline, 6 weeks post-treatment, and 1 year post-treatment.
223873216|NCT06782074|OTHER|emotional and neuropsychological assessment|The tests for evaluating emotional-behavioral functioning and quality of life will be self-administered by the patient/caregiver during regular follow-up visits. The cognitive assessment will be conducted by the clinician using standardized tests.
223873217|NCT05688436|DRUG|Diroximel Fumarate|Administered as specified in the treatment arm.
223873218|NCT05688436|BIOLOGICAL|Alemtuzumab|Administered as specified in the treatment arm.
223873219|NCT05688436|DRUG|Fingolimod|Administered as specified in the treatment arm.
223873220|NCT05688436|DRUG|Glatiramer acetate|Administered as specified in the treatment arm.
223873221|NCT05688436|BIOLOGICAL|Interferon beta|Administered as specified in the treatment arm.
223873222|NCT05688436|BIOLOGICAL|Natalizumab|Administered as specified in the treatment arm.
223873223|NCT05688436|BIOLOGICAL|Ocrelizumab|Administered as specified in the treatment arm.
223873224|NCT05688436|BIOLOGICAL|Ofatumumab|Administered as specified in the treatment arm.
223873225|NCT05688436|DRUG|Ozanimod|Administered as specified in the treatment arm.
223873226|NCT05688436|BIOLOGICAL|Peginterferon beta-1a|Administered as specified in the treatment arm.
223873227|NCT05688436|DRUG|Ponesimod|Administered as specified in the treatment arm.
223873228|NCT05688436|DRUG|Siponimod|Administered as specified in the treatment arm.
223873229|NCT02987192|DEVICE|pen type 27 gauge needles|minimally invasive group patients will receive pen type 27 gauge needles.
223873230|NCT02987192|DEVICE|cutting type 22 gauge needles|traditional group patients will receive cutting type 22 gauge needles.
223873231|NCT03936660|OTHER|Intense Education Intervention|Clinics provided with existing clinical care guidelines as well as a multifaceted educational intervention to support development of an integrated, multi-disciplinary care pathway for patients with T2DM and CVD.
223873232|NCT06119711|OTHER|No intervention|No intervention
223873233|NCT05836116|OTHER|Evaluation of Muscle Activation|"Evaluation of Muscle Activation The sEMG device, which is a surface EMG system (Myomonitor, Delsys Inc, Boston, MA), was used to measure the lateral and medial muscle activation levels of the latissimus dorsi.~Electrode placement was determined according to SENIAM (Surface Electromyography for Non-Invasive Evaluation of Muscles) criteria.~Evaluation of the Gibbosity Trunk rotation (gibbosity) assessments were performed using Adam's test and using a scoliometer . The bending test (Adam's test) is performed in both standing and forward bending positions. The standing version was used in our study.Each measurement equal to 0° on the scoliometer was defined as symmetry at the measured level of the trunk. All other scoliometer values were defined as asymmetry.~Evaluation of the Cobb Angle Cobb angles of the curves of the individuals participating in the study were measured with the MicroDicom application."
223873234|NCT00214240|DRUG|CMV Immune globulin|CMV IvIg 150mg/kg x 6 doses
223873235|NCT04757155|BEHAVIORAL|Internet Adaptation of Managing Cancer and Living Meaningfully (iCALM)|A online psychotherapy designed for patients with advanced and metastatic cancer.
223873236|NCT06215547|DEVICE|Enterra HDE|"Instructions for use Implanting physicians should have experience in the surgical and/or implantation techniques for the Enterra II system, operational and functional characteristics of the Enterra II system, 12 English 37800 2014-03 and experience in the continued management of patients by stimulation parameter adjustment. Physicians may contact Medtronic before prescribing or implanting an Enterra II system for the first time, and request a referral to a physician experienced in the use of the Enterra II system. Implanting physicians should be thoroughly familiar with all product labeling.~Cautions:~* When using sharp instruments near the neurostimulator, be extremely careful to avoid nicking or damaging the case, the insulation, or the connector block. Damaging the neurostimulator may require surgical replacement.~* Do not use saline or other ionic fluids at connections, which could result in a short circuit"
223873237|NCT01819571|DRUG|Fluid loading (Voluven)|HES 130/0.4 (VoluvenⓇ, Fresenius Kabi, Graz, Austria) 8ml / kg loading during 15 minutes after induction of anesthesia on both groups
223873238|NCT00803387|DRUG|Travaprost without BAC (Travatan Z)|A double blind comparison was used to assess whether Xalatan or TrvatanZ affects the tear breakup times, corneal staining, and baseline tear secretion tests in patients that are already taking latanoprost regularly with complaints of dryness and irritation. Patients included in the study will be given two bottles, one labeled for their right eye and the other for their left eye. Each pair of bottles will be identical in appearance and randomized with either latanoprost or travoprost and each pair will be assigned a number to aid in future analysis of the final results. One Drop from both bottles will be dispensed in the respective eye once a day.
223873239|NCT05242562|DRUG|Plenvu|a recently developed 1 liter bowel preparation fluid that is often used in clinical practice. Patients will receive a split dose protocol, low-residue diet 2 days before colonoscopy, and clear liquid diet 1 day before colonoscopy.
223873240|NCT05242562|DRUG|Moviprep|a 2 liter widely established 2 liter bowel preparation fluid that is commonly used in clinical practice. Patients will receive a split dose protocol, low-residue diet 2 days before colonoscopy, and clear liquid diet 1 day before colonoscopy.
223873241|NCT01526954|DEVICE|TissuGlu Surgical Adhesive|TissuGlu Surgical Adhesive to be used prior to closure of the large tissue flap in abdominoplasty cases.
223873242|NCT02343913|DEVICE|PAC checklist|
223873243|NCT02594631|PROCEDURE|ESWL|Patients in this arm will receive ESWL for treatment of acute calcular urinary retention
223873244|NCT02594631|PROCEDURE|Endoscopic treatment|Patients in this arm will receive endoscopic treatment of acute calcular urinary retention
223873245|NCT01941758|BIOLOGICAL|trivalent influenza vaccine|
223873246|NCT01941758|OTHER|laboratory biomarker analysis|Correlative studies
223873247|NCT05958836|DEVICE|pacemaker|Micra TPS or traditional PM group
223873248|NCT01240434|PROCEDURE|Trocar site closure|The study has 2 arms: one in which all the ST orifices are closed by suturing the external fascia of the abdominal wall with a number 1 monofilament absorbable suture (Polydioxanone) (Group A), and another in which all the orifices of the ST are left open, closing only the skin (Group B).
223873249|NCT04623567|DRUG|Jiangtang Tiaozhi recipe|The Jiangtang Tiaozhi recipe is a combination of several Chinese herbs, which has been granted a patent (No. ZL 2013 1 0373659.7)
223873250|NCT04623567|DRUG|Metformin|The metformin tablets (500mg) will be administrated.
223873251|NCT03002675|DRUG|Bydureon|exenatide (Bydureon) 2mg s.c. 1x/wk
223873252|NCT06358534|BEHAVIORAL|psychoeducation based on acceptance and commitment therapy|psychoeducation based on acceptance and commitment therapy prepared by the researchers was applied individually to the patients
223873253|NCT02355275|PROCEDURE|Home Exercise Program|All patients will be provided with a Thera-Band® Loop and Band and handout describing home exercises to be performed 3 times a week for 4 weeks.
223873254|NCT04425863|DRUG|Ivermectin 5 MG/ML oral solution, Aspirin 250 mg tablets|24 mg oral Ivermectin on days 0 and 7 and 1 Aspirin tablet daily for 30 days. Outpatient treatment.
223873255|NCT04425863|OTHER|Ivermectin 5 mg/mL oral solution, Dexamethasone 4-mg injection, Aspirin 250 mg tablets|36 mg oral Ivermectin on days 0 and 7; 1 daily injection of 4-mg Dexamethasone until discharge, 1 Aspirin tablet daily for 30 days. Inpatient treatment in ward care, including Low flow washed oxygen or oxygen concentrator
223873256|NCT04425863|OTHER|Ivermectin 5 MG/ML oral solution, Dexamethasone 4-mg injection, Enoxaparin injection. Inpatient treatment with mechanical ventilation in ICU.|48 mg oral Ivermectin on days 0 and 7; 1 daily injection of 4-mg Dexamethasone until discharge, Enoxaparin 100 IU/kg (ca. 1 mg/kg) daily until transfer to ward care. Then continue with inpatient treatment in ward care.
223873257|NCT03323775|DIAGNOSTIC_TEST|Suprathreshold stimulation|Intraoperatively, radiofrequency needles will be placed on specific nerves targeted using parallel needle placement technique under image guidance. These nerves will have identified by the diagnostic injections carried out previously. The nerves will be located using 50 Hz sensory stimulation. The targeted medial branches (dorsal ramus in the case of L5) will be stimulated using suprathreshold stimulation (up to three times the sensory detection threshold) to identify the pain referral area. Motor stimulation of 2 Hz will be used to identify the multifidus muscle as well as to evaluate the close proximity to major spinal nerve to improve the safety of the procedure.
223873258|NCT01462149|DRUG|Neoadjuvant chemotherapy|Docetaxel 75mg/m2BAS, q 3 weeks, 3 cycles
223873259|NCT01462149|DRUG|Carboplatin|Carboplatin AUC 5, q 3 weeks, 3 cycles
223873260|NCT04677192|COMBINATION_PRODUCT|Microwave Ablation combination with chemotherapy|Microwave Ablation combination with chemotherapy. Maximum tumor diameter ≤ 3cm, single microwave needle, maximum tumor diameter\> 3cm, double ablation needle, the ablation range completely covers the lesion ≥ 0.5cm in order to obtain a satisfactory ablation margin. After the operation, contrast ultrasound is performed again to confirm the ablation edge. Enhanced MRI or CT to evaluate the ablation effect 4 weeks after surgery. Selection of chemotherapy regimen refers to the 2020 NCCN Guidelines for Pancreatic Cancer. First-line chemotherapy regimen: gemcitabine combined with albumin-bound paclitaxel or FOLFIRINOX; second-line chemotherapy regimen: If first-line chemotherapy based on gemcitabine, 5-FU-based regimen for second-line, If 5-FU-based regimen for first-line, gemcitabine for second-line.
223873261|NCT06450496|BEHAVIORAL|Positive parenting on-line program|Positive parenting on-line program focused on parenting and personal competences relevant for parents with adolescents exhibiting mental health problems
223873262|NCT02233595|RADIATION|Chemoradiation|
223873263|NCT01902147|OTHER|Postoperative Quality Recovery Scale (PQRS)|The PQRS is completed prior to surgery to provide baseline values, and then repeated at different intervals: 15 minutes, 40 minutes, 1 and 3 days, and 4-8 weeks after the completion of surgery. Recovery is broadly defined as return to baseline or better.
223873264|NCT03285542|DEVICE|DERMABOND|DERMABOND PRINEO (Ethicon, Johnson and Johnson, Somerville, New Jersey)
223873265|NCT03285542|DEVICE|Staples|staples for skin closure
223873266|NCT04961021|PROCEDURE|Strabismus surgery|Strengthening of medial rectus muscle or strengthening of medial rectus muscle with weakening of the lateral rectus muscle
223873267|NCT00329862|PROCEDURE|Laparoscopic Truncal Vagotomy|
223873268|NCT01534741|OTHER|dialyzer comparison|Each patient will be treated by post-dilution online hemodiafiltration once with each dialyzer type (FX CorDiax 60or FX 60 ) The order of dialyzers used will be randomly assigned to the patient at the time of randomisation by lot. Every subject will be treated one time with each dialyzer. In order to achieve controlled conditions, the mid- or end-week session data will be used, only.
223873269|NCT01534741|DEVICE|Dialyzer|Comparison Dialyzer FX60 versus Cordiax60
223873270|NCT05469841|OTHER|Systemic pain assessment|Pain will be evaluated via i) pupillometry with 3 successive measurements ii) Behaviour Pain Scale (BPS) and Critical Care Pain Observation Tool (CPOT) score evaluated by an investigator (physician) iii) evolution of physiological parameters (ie heart rate, blood pressure, respiratory rate) iv) Nociception Level Index (NOL) index.
223873271|NCT01797354|BEHAVIORAL|Cognitive-behavioral therapy and hypnosis group|
223873272|NCT01797354|BEHAVIORAL|Support group|
223873273|NCT02966275|DEVICE|Glucagon-only bionic pancreas - glucagon|A computer algorithm will automatically deliver glucagon based on the signal from a minimally invasive continuous glucose monitor.
223873274|NCT02966275|DEVICE|Glucagon-only bionic pancreas - placebo|A computer algorithm will automatically deliver placebo based on the signal from a minimally invasive continuous glucose monitor.
223873275|NCT05079126|DRUG|Trans Sodium Crocetinate|Single IV Bolus
223873276|NCT05079126|DRUG|Placebo|Single IV Bolus
223873277|NCT02080754|OTHER|effective sellick maneuver|Sellick maneuver is applied, as originally described by Sellick et al .
223873278|NCT02080754|OTHER|sham sellick maneuver|The operator who applied the maneuver is the only person who knows the arm inclusion of the patient. Thus, he sets his fingers as described in Sellick arms without exerting pressure on the cricoid cartilage.
223873279|NCT03392038|PROCEDURE|Thin ADM|Use of soft tissue allograft for root coverage
223873280|NCT03392038|PROCEDURE|Thick ADM|Periodontal surgical procedure to coronally position the tissue over the ADM allograft
223873281|NCT03072316|OTHER|3D surface imaging|3D photography
223873282|NCT03072316|OTHER|semi-structured interview|qualitative analysis using semi structured interview
223873283|NCT03072316|OTHER|applanation tonometry|measurement of breast compressibility
223873284|NCT05848817|DEVICE|Contoura LASIK|Subjects receiving Phorcides Planned Contoura LASIK
223873285|NCT04014179|DIAGNOSTIC_TEST|Xpert HCV Viral Load Fingerstick|The Cepheid Xpert HCV Viral Load (VL) Fingerstick assay is an in vitro nucleic acid amplification test designed for the quantitation of Hepatitis C Virus (HCV) DNA in human whole blood using the automated GeneXpert Systems. The HCV RNA result from the Xpert test will be used to initiate HCV treatment.
223873286|NCT04014179|DIAGNOSTIC_TEST|Aptima HCV Quant DX Assay|"The Aptima HCV Quant Dx assay is a real-time transcription-mediated amplification test.~The assay is used for both detection and quantitation of hepatitis C virus (HCV) RNA in fresh and frozen human serum and plasma from HCV-infected individuals, and in this study from dried blood spots. The HCV RNA result from the Aptima assay will be used to initiate HCV treatment."
223873287|NCT02808351|DRUG|Berberine|
223873288|NCT00277355|DRUG|minocycline|Minocycline: Oral; minocycline 100 mg capsules administered twice a day with the morning and evening meal (\~ 8 hours apart)
223873289|NCT00277355|DRUG|Matching placebo|Matching placebo 1 capsule twice daily, 18 months treatment duration.
223873290|NCT02097394|DRUG|Combizym|Combizym( 1 tablet, po, tid)
223873291|NCT02097394|DRUG|Bifidobacteri|Bifidobacteri (2 tablet, po, tid)
223873292|NCT02097394|DRUG|Combizym + Bifidobacteri|Combizym( 1 tablet, po, tid) + Bifidobacteri (2 tablet, po, tid)
223873293|NCT00538759|DEVICE|External beam radiation therapy|Experimental beam radiation therapy to the aortic valve after successful balloon aortic valvuloplasty
223873294|NCT00538759|OTHER|Sham Control|
223873295|NCT00006241|BIOLOGICAL|filgrastim|
223873296|NCT00006241|DRUG|chemotherapy|
223873297|NCT00006241|PROCEDURE|in vitro-treated peripheral blood stem cell transplantation|
223873298|NCT00006241|PROCEDURE|peripheral blood stem cell transplantation|
223873299|NCT00006241|RADIATION|radiation therapy|
223873300|NCT05680649|OTHER|Breathing exercise|Diaphragmatic breathing exercises were taught to the individuals by the researcher and they were asked to start breathing exercises before starting PIVC. While the PIVC was being placed, the individuals continued the breathing exercise and the breathing exercise was terminated at the end of the application.
223873301|NCT00735852|DRUG|Decapeptyl SR 11.25mg|11.25 mgs, Intra muscular (IM) every 3 months for 2 years
223873302|NCT05953675|DRUG|Ethanol 70%|Once a week, the catheter will be closed with 3 mL ethanol 70% lock-solution after a completed hemodialysis. The fluid will stay in the catheter until next hemodialysis (ca. 48 hours). The fluid will be aspirated before the hemodialysis. Standard lock-solution of isotonic saline with heparin will be used for the remaining two hemodialysis procedures of the week.
223873303|NCT05953675|DRUG|Isotonic saline with heparin|Standard procedure of isotonic saline used as lock-fluid after completed hemodialysis.
223873304|NCT03096236|DEVICE|EFTR|EFTR with the FTRD developed for gastric resection (gFTRD).
223873305|NCT05530161|OTHER|hypocalcemia|hypocalcemia or normocalcemia
223873306|NCT05073224|DIAGNOSTIC_TEST|Active Straight Leg Raise Test|The ASLR test is a well-established clinical test that assesses stability of the lumbar spine/pelvis, posterior pelvic pain severity, and ability to activate the abdominal muscles. It is performed in supine. Participants are instructed to raise one leg, with the knee straight, to a heel height of 20 cm. The leg is held at the top for 5 seconds, then slowly lowered to the ground. The participant is asked to report perceived difficulty to raise the leg on a 0 to 5 scale (0=not at all difficult; 5=unable to lift leg) and pain on a 0 to 10 scale (0=no pain; 10=worst possible pain). If difficulty or pain are rated at a 1 or higher, the test is repeated with the researcher providing external compression of the pelvis. If perceived difficulty or reported pain are lower with compression, the test is considered positive for lumbopelvic instability. The test is then repeated on the opposite limb.
223873307|NCT05073224|OTHER|Active Straight Leg Raise Fatigue Task|The protocol is similar to the ASLR test, except that the participant is instructed to maintain the elevated leg off the ground for as long as possible. A biofeedback air cuff will be placed under the participant's lumbopelvic region to assess movement of the spine/pelvis. The cuff will be inflated to 40 mm Hg, and the participant instructed to keep the needle as close to 40 mm Hg as possible throughout the test; no information will be provided on how to affect cuff pressure, but visual feedback of cuff pressure will be provided throughout the task. Ratings of perceived exertion (RPE) and pain will be obtained from participants every 30-60 seconds. Task failure will be defined as a heel height ≤10 cm or a change in cuff pressure ≥20 mm Hg. Both limbs will be tested, but in different sessions. The order of limb testing (dominant vs non-dominant) will be randomized and counter-balanced. Limb dominance will be self-reported.
223873308|NCT05073224|OTHER|Lower Extremity Strength Testing|"A straight leg raise maximal voluntary contraction (MVC) of each lower extremity an MVC of the hip extensors of the grounded limb will be performed in supine before and within 2 minutes of completing the ASLR fatigue task. The straight leg raise MVC will be performed with a custom-made load cell instrumented strength testing device, which consists of a rigid platform on which the participant will lie. At the foot of the device is a tower that houses 2 load cells connected to a lightly padded push plate.~The hip extension MVC will be performed on a force plate. Before the ASLR fatigue task, a minimum of 3 MVC trials will be performed for each muscle group, with a minimum of 1 minute rest between trials; the highest peak force will be considered the MVC. Only 1 MVC trial per muscle group will be performed following the ASLR Fatigue Task."
223873309|NCT05073224|DIAGNOSTIC_TEST|Ultrasound imaging of abdominal wall|Real time ultrasound will be used to assess inter-recti distance above and below the umbilicus. Participants will be assessed with B Mode images in supine at rest, in supine while lifting their head, and in supine while performing a straight leg raise. The Principle Investigator has training and experience in musculoskeletal ultrasound.
223873310|NCT05447936|DIETARY_SUPPLEMENT|Jarlsberg cheese|Jarlsberg cheese is a regular cheese for free sale in grocery stores. The allotted amount of cheese was taken orally each day
223873311|NCT04733833|DRUG|VB-201 + Standard of care|Daily oral administration of VB-201- 160 mg (80 mg BID) with standard of care
223873312|NCT04733833|DRUG|Standard of care|Standard of care
223873313|NCT05656664|DIETARY_SUPPLEMENT|Folic Acid|Folic acid supplementation to assess for increased arsenic metabolite excretion
223873314|NCT05656664|OTHER|Placebo|Placebo group to assess arsenic metabolite excretion
223873315|NCT01900249|DRUG|R348 Ophthalmic Solution, 0.2%|R348 Ophthalmic Solution, 0.2% 1 drop per eye twice a day for 12 weeks.
223873316|NCT01900249|DRUG|R348 Ophthalmic Solution, 0.5%|R348 Ophthalmic Solution, 0.5% 1 drop per eye twice a day for 12 weeks.
223873317|NCT01900249|DRUG|Placebo|Placebo Ophthalmic Solution 1 drop per eye twice a day for 12 weeks.
223873318|NCT00642850|DRUG|methoxy polyethylene glycol-epoetin beta [Mircera]|120, 200 or 360 micrograms iv monthly (starting dose)
223873319|NCT06509243|BIOLOGICAL|tablets Acarizax|sublingual immunotherapy to house dust mites
223873320|NCT06509243|BIOLOGICAL|dupilumab|dupilumab - biologic therapy for atopic dermatitis
223873321|NCT06509243|DRUG|cyclosporine|cyclosporine used in atopic dermatitis
223873322|NCT04040296|OTHER|Kidney Action Team Recommendations|Upon review of the patient's medical information, the Kidney Action Team will create personalized recommendations that will be delivered to the patient's primary care team via a specialized note in the electronic medical record system within 2 hours of AKI detection. The attending of record will be identified as a cosigner to ensure that a member of the care team is made aware of the note's presence.
223873323|NCT02387645|PROCEDURE|Lavage of the Uterus|The lavage will be performed in the operating theatre under general anesthesia. The ALPINE technique includes the following steps. A three way catheter (catheter for uterine and tubal lavage) is inserted into the cervical canal and a balloon is inflated to seal the cervical canal. The patient is put into anti-Trendellenburg positioning. Normal saline is slowly flushed into the uterine cavity and proximal tubes. After the lavage is finished, the balloon is deflated and the catheter is removed. A cap is put on the collection syringe and the syringe is sent to the laboratory.
223873324|NCT01690572|DEVICE|Paclitaxel coated balloon catheter|Dilatation of the target lesion
223873325|NCT01690572|DEVICE|"uncoated balloon catheter sprinter legend"|Dilatation of the target lesion
223873326|NCT05298397|OTHER|EAT-PTSD adapted for youth for anxiety|"This is an eight session (90 minute sessions) weekly experiential group treatment. The first session includes psychoeducation, orientation to treatment, a barn tour, and ends with meeting the horses. Subsequent sessions involve increasingly complex encounters and interactions with horses accompanied by feedback and direction from the treatment. Early phase treatment exercises acquaint patients with the horse, with grooming exercises, leading with a rope or a wand, and directing the horse. The middle phase furthers patients' mastery and comfort with the horse in individual and teamwork exercises. The final session includes a graduation ceremony. All intervention sessions begin with Opening Circle and end with Closing Circle. Opening Circle incorporates a grounding exercise and is orients participants to the session to check in regarding thoughts and feelings. Closing Circle reviews lessons learned during the session, eliciting participant feedback and facilitating discussion."
223873327|NCT03960398|DRUG|Iatrogenic disease impact on emergency consultations|Determination of the proportion of emergency consultations linked to iatrogenic diseases
223873328|NCT02984332|OTHER|Lower limb immobilisation (leg brace)|
223873329|NCT00219791|DRUG|glucarpidase (50 Units/kg)|
223873330|NCT03978728|DEVICE|Extra-corporeal membrane oxygenation|Cardiovascular shock patients received extra-corporeal membrane oxygenation suppot.
223873331|NCT00223600|BEHAVIORAL|Nutritional and life style counseling|
223873332|NCT06111638|GENETIC|Single dose intravenous injection of BBM-H803|Single dose intravenous infusion of BBM-H803, an adeno-associated viral (AAV) vector derived from recombinant DNA techniques to contain an expression cassette of the human factor VIII transgene in liver. The dose of BBM-H803 will be calculated according to participant's weight.
223873333|NCT02837796|PROCEDURE|transobturator tape|
223873334|NCT04807790|OTHER|Telerehabilitation based structured home program applications|"The structured home program will consist of activities determined by the family members according to the functional level of the child and the activities he / she can not do, and which are determined according to the goals specific to the child. In order to ensure that the structured home program created can be implemented by the family, a 1 hour family training will be provided.~After the structured home program training, a 45-minute video interview will be held with one of the family members (mother-father-caregiver) once a week, in order to check by the physiotherapist whether the home program is implemented correctly. Video interviews will be the telerehabilitation part of the study."
223873335|NCT03929432|DEVICE|Active Transcranial Direct Current Stimulation with SLT|"Soterix Medical 1×1 transcranial Direct Current Stimulator for Clinical Trials (1x1 tDCS-CT).~Excitatory stimulation to the left hemisphere will be achieved through a 1x1 montage utilizing two carbon-rubber electrodes and 5x7 EASY pad sponges (A-tDCS \[excitatory\]left target; C-tDCS \[inhibitory\]right hemisphere). Each PWA will have a unique 5-digit tDCS program code for each treatment phase. One code will instruct the 1x1 tDCS-CT to administer active stimulation as describe above (i.e., 1.5 mA for 20 min). The other will administer 1.5 mA for only a few seconds to simulate active stimulation. SLT will consist of Semantic Feature Analysis, Phonological Component Analysis, and Verb Network Strengthening Treatment"
223873336|NCT03929432|DEVICE|Sham Transcranial Direct Current Stimulation with SLT|Control condition in which only SLT is administered.Participant receives 1.5 mA for only a few seconds to simulate active stimulation, then the stimulation will cease. SLT will consist of Semantic Feature Analysis, Phonological Component Analysis, and Verb Network Strengthening Treatment
223873337|NCT02926794|BEHAVIORAL|SA and II|Self affirmation intervention where participants rank 11 values, then write about why their top ranked value is important AND Implementation intentions intervention where participants form two implementation intentions (If/then) statements regarding drinking behavior and write why these are important
223873338|NCT02926794|BEHAVIORAL|SA and No II|Self affirmation intervention where participants rank 11 values, then write about why their top ranked value is important AND No implementation intentions intervention where participants write why selected health strategies are important (and do nothing else)
223873339|NCT02926794|BEHAVIORAL|No SA and II|Control writing intervention where participants rank 11 values, then write about why their 10th ranked value is important to someone else AND Implementation intentions intervention where participants form two implementation intentions (If/then) statements regarding drinking behavior and write why these are important
223873340|NCT02926794|BEHAVIORAL|No SA and No II|Control writing intervention where participants rank 11 values, then write about why their 10th ranked value is important to someone else AND No implementation intentions intervention where participants write why selected health strategies are important (and do nothing else)
223873341|NCT06831474|DRUG|Rivaroxaban 10 MG Oral Tablet|10mg rivaroxaban daily
223873342|NCT06831474|DRUG|Rivaroxaban 20 MG Oral Tablet|20mg rivaroxaban daily
223873343|NCT05038618|BIOLOGICAL|MVC-COV1901(S protein with adjuvant)|Approximately 400 participants will receive 2 doses of MVC-COV1901(S-2P protein with adjuvant) at Day 1 and Day 29 via intramuscular (IM) injection in the deltoid region
223873344|NCT05500326|DRUG|Ivermectin Tablets|"ITCHY Study:~All participants will receive one dose of oral ivermectin 3mg on day 0 and have two blood samples taken to determine the serum ivermectin concentrations after the dose. Timing of blood samples will vary depending on the allocated group.~ITCHY2 Study:~Participants will receive one age-specific dose of oral ivermectin on day 0 and have two blood samples taken to determine the serum ivermectin concentrations after the dose. Timing of blood samples will vary depending on the allocated group.~Age specific ivermectin dose:~* 0.75mg of ivermectin will be given to participants aged 3 to 7 months~* 1.5mg of ivermectin will be given to participants aged 8 to 12 months~* 3mg of ivermectin will be given to participants aged 13 to 24 months"
223873345|NCT05662917|BEHAVIORAL|Individual semi-structured interviews|After information and written consent, the investigator will interview the participants through a semi-structured individual interview (conducted by an interview guide). The interview is expected to last 45 minutes (variable depending on the subject). It will be recorded by dictaphone, respecting the anonymity of the participant throughout the interview. The subject's participation will end after the interview.
223873346|NCT02748954|BEHAVIORAL|Thoughts|"Thoughts. Increasing helpful thoughts consisted of two psychoeducational segments (i.e., thoughts affect emotions, and how to manage harmful thoughts), and a list of helpful thoughts that participants could choose to use to increase their mood for the next week."
223873347|NCT02748954|BEHAVIORAL|Activities.|"Increasing activity level included a brief description of how activities affect mood. Participants were then asked to choose the activities they could use to improve their mood from an available list of helpful activities; users were also able to generate their own helpful activities. Participants were also presented with examples of unhelpful activities such as staying in bed and being isolated"
223873348|NCT02748954|BEHAVIORAL|Assertiveness.|Increasing assertiveness, consisting of tips for communicating assertively, and an example of an assertive statement. Participants were asked to describe a recent conflict and apply the intervention's assertiveness techniques to address the conflict.
223873349|NCT02748954|BEHAVIORAL|Sleep hygiene|"Increasing sleep hygiene included a description on how sleep can affect mood. Participants were also asked to select from a list of helpful sleep hygiene suggestions to be practiced within the next week such as, Don't take naps during the day and Use the bed/bedroom for sleep or sex only."
223873350|NCT02748954|BEHAVIORAL|Own Methods|wherein participants were asked to identify four of their own personal strategies that have helped them improve their mood in the past.
223873351|NCT05188781|DRUG|Pembrolizumab combined Anlotinib|Pembrolizumab 200 mg every 3 weeks, Anlotinib 12 mg/day, orally;2weeks treatment followed by 1week off
223873352|NCT00609310|DIETARY_SUPPLEMENT|Flavonoids|Nutritional Supplement: flavonoid mixture with 20 mg apigenin and 20 mg epigallocathechin gallate as tablets per day
223873353|NCT05489484|DEVICE|MD-Shoulder Collagen Medical Device|"Only one experimental group is scheduled by the Investigation Plan to be treated with 2-mL volume ultrasound-guided infiltrations of MD-Shoulder Collagen Medical Device (GUNA, Milan-Italy).~Subjects will be treated with number one ultrasound-guided infiltration at the time of enrollment, 2 weeks after enrollment, and 4 weeks after enrollment.~Intra-articular infiltrations will be performed with 5cc syringes and 22-gauge needles.~MD-Shoulder Collagen Medical Device will be infiltrated within the scapulohumeral joint under conditions of complete asepsis."
223873354|NCT05650567|DRUG|M5049 high dose|Participants will receive film-coated tablets of M5049 at a high dose orally, twice daily up to 24 weeks.
223873355|NCT05650567|DRUG|Placebo|Participants will receive placebo matched to M5049 orally, twice daily up to 24 weeks.
223873356|NCT02156050|DEVICE|two sessions of 4 hours Phototherapy treatment|two sessions of 4 hours Phototherapy treatment
223873357|NCT04152421|OTHER|Software use|"The patient will connect to a computerized platform to access the program. The program consists of 5 modules (lessons), each lasting approximately 40 minutes. Each module or lesson includes pedagogical assessments and explanations of the problem(s) in question, illustrations, testimonies, tips, exercises and recommended activities."
223873358|NCT03429998|DRUG|evolocumab|evolocumab 140 mg/biweekly
223873359|NCT03429998|DRUG|evolocumab and LDL apheresis|evolocumab 140 mg/biweekly LDL-apheresis monthly
223873360|NCT03429998|PROCEDURE|LDL apheresis|LDL apheresis biweekly
223873361|NCT01537419|BEHAVIORAL|Attachment-Based Family Therapy|Although ABFT therapists implement behavior focused and psychoeducational interventions, the model is primarily a process oriented, emotion focused treatment guided by a semi-structured treatment protocol. ABFT aims to improve the family's capacity for problem solving, affect regulation, and organization. This strengthens family cohesion which can buffer against depression, suicidal thinking, and risk behaviors.
223873362|NCT01537419|BEHAVIORAL|Family-Enhanced Non-directive Supportive Therapy|Family-Enhanced Non-directive Supportive Therapy (FE-NST) is a 16 week therapy designed to control for the non-specific effects of psychotherapy with suicidal youth. FE-NST aims toward relief or reduction of symptoms without expectation of change in the basic personality structure. We have added a parent component to: a) control for parent involvement and b) improve the generalizability and safety of the FE-NST treatment. This enhancement consists of 5 potential parent sessions beginning with a family safety plan in the initial treatment session that will be monitored regularly throughout the treatment. The remaining 4 parent psycho-education sessions offer parents knowledge, skills and support to improve management of the suicidal teen.
223873363|NCT04004819|DRUG|Rituximab|A lower dosage of rituximab for HTLV-1-associated myelopathy
223873364|NCT00420901|DRUG|sildenafil|
223873365|NCT05822063|DRUG|Lidocaine topical|lidocaine spray
223873366|NCT05822063|OTHER|cold packs|ice packs
223873367|NCT05822063|DEVICE|flash lights|flash lights by camera
223873368|NCT02519517|PROCEDURE|Permissive hypercapnia|During one lung ventilation, right ventricular function was assessed by transesophageal echocardiography (TEE) and the effect of increased carbon dioxide pressure was evaluated
223873369|NCT06223113|DEVICE|EyenableTM PA60AS1 IOL|Subjects will undergo surgery to remove cataract (the cloudy lenses) via phacoemulsification, and implant the Eyedeal® EyenableTM PA60AS1 IOL in the eye capsule.
223873370|NCT05126121|DRUG|three kinds of antibiotics including amoxicillin，tetracycline, furazolidone, levofloxacin,clarithromycin,levofloxacin,tinidazole,metronidazol|Three kinds of antibiotics including amoxicillin，tetracycline, furazolidone, levofloxacin,clarithromycin,tinidazole,metronidazol
223873371|NCT01351493|DRUG|Nitric Oxide|Nitric Oxide Gel, once or twice per day, 12weeks
223873372|NCT01351493|DRUG|placebo|placebo Gel, once or twice per day, 12weeks
223873373|NCT06149819|OTHER|Diagnostic and safety of a nursing pathway for the management of non-traumatic chest pain|trained nurses will take in charge non-traumatic chest pain patient according to the standardized algorithm based on the recommendations .
223873374|NCT02620410|DEVICE|Axonics Sacral Neuromodulation (SNM) System|The implantable components of the Axonics Sacral Neuromodulation (SNM) System consist of an IPG and tined lead. Additional components include a clinician programmer, surgical tool kit, recharging kit, and patient remote control.
223873375|NCT03678558|OTHER|Cytochalasin B supplemented vitrification medium|Vitrification of human oocyte in medium supplemented with Cytochalasin B
223873376|NCT05993507|BEHAVIORAL|Problem Management Plus (PM+)|Problem Management Plus (PM+) is a brief, scalable intervention that is developed by World Health Organization for communities exposed to adversity. PM+ consists of five weekly in-person sessions of 90 minutes. The intervention integrates four evidence-based behavioural strategies: arousal reduction using a slow breathing exercise (session 1), problem-solving (session 2), behavioural activation by re-engaging with pleasant and task-oriented activities (session 3) and accessing social support (session 4). Homework practice is scheduled following each session and discussed in the next session. Psychoeducation is delivered in session 1 and relapse prevention is discussed in session 5. Facilitators will receive weekly supervisions by PM+ supervisors.
223873377|NCT00444600|DRUG|Triamcinolone Acetonide + laser|4 mg intravitreal triamcinolone at randomization plus focal photocoagulation 1 week post-injection, repeated every 16 weeks with sham injections at 4-week intervals in-between. Retreatment starting at 16 weeks depends on visual acuity and OCT.
223873378|NCT00444600|DRUG|Ranibizumab + laser|0.5 mg intravitreal ranibizumab at randomization plus focal photocoagulation 1 week post-injection. Injections are repeated every 4 weeks with focal photocoagulation given post-injection every 16 weeks. Retreatment starting at 16 weeks depends on visual acuity and OCT.
223873379|NCT00444600|DRUG|Sham injection + laser|Sham injection at randomization plus focal photocoagulation 1 week post-injection. Injections are repeated every 4 weeks with focal photocoagulation given post-injection every 16 weeks. Retreatment starting at 16 weeks depends on visual acuity and OCT.
223873380|NCT00444600|DRUG|Ranibizumab + deferred laser|0.5 mg intravitreal ranibizumab at randomization, repeated every 4 weeks. Retreatment starting at 16 weeks depends on visual acuity and OCT. If improvement has not occured from injections alone, laser can be given starting at the 24 week visit.
223873381|NCT00481390|PROCEDURE|Cheek cells sample|Cheek cells sample
223873382|NCT00481390|PROCEDURE|Blood sample|Blood sample
223873383|NCT05132478|OTHER|Emotionally Supportive Video|The video is approximately 6 1/2 minutes in length and portrays an emotionally supportive conversation between a patient and surgeon during which the surgeon discusses: the diagnosis, prognosis, available treatment options, benefits and harms of the options, and need for decision making. The surgeon speaks for the majority of the simulated visit and discusses total and hemi-thyroidectomy with the addition of emotionally supportive statements and gestures.
223873384|NCT05132478|OTHER|Standard Video|The video is approximately 5 minutes in length and portrays a standard conversation between a patient and surgeon during which the surgeon discusses: the diagnosis, prognosis, available treatment options, benefits and harms of the options, and need for decision making. The surgeon speaks for the majority of the simulated visit and discusses total and hemi-thyroidectomy.
223873385|NCT00865436|DRUG|Glyburide and Metformin Hydrochloride Tablets 5 mg/500 mg|A: Experimental Subjects received Alpharma formulated products under fasting conditions
223873386|NCT00865436|DRUG|CLUCOVANCE® 5 mg/500 mg Tablets, single dose|B: Active comparator Subjects received Bristol-Myers Squibb Company formulated products under fasting conditions
223873387|NCT06335472|PROCEDURE|3 nerves pulsed radiofrequency with hydrodissection|"Patient will be in a sitting position, targeting the SSN, needle will be pushed towards floor of the suprascapular fossa, SSN is just adjacent to the suprascapular artery.~The axillary nerve, between the deltoid muscle posteriorly, triceps muscle caudally and humerus anteriorly, axillary nerve appears as hyperechoic round in relation to posterior circumflex humeral artery.~Lateral pectoral nerve, middle of coracoid process should be targeted, lie within hyperechoic fascial plane between pectoralis major and pectoralis minor muscle.~hydrodissection, US transducer will be positioned inferior to scapular line , landmarks are contours of glenoid rim and humeral head, needle will be advanced until enter the GHJ capsule.~A solution composed of 3 mL of lidocaine 1%, 3 mL of bupivacaine 0.25%, and 1 mL of dexamethasone 40 mg, followed by infusion of up to 40 mL of normal saline, until capsule is adequately distended and resistance felt"
223873388|NCT06335472|PROCEDURE|suprascapular nerve pulsed radiofrequency with hydrodissection|"The patient will be positioned in a sitting position, PRF needle will be pushed forward towards the floor of the suprascapular fossa the SSN will be visualized just adjacent to the suprascapular artery.~hydrodissection will be done under all aseptic measures ,the US transducer will be positioned just inferior to the scapular line , landmarks are contours of posterior glenoid rim and humeral head, needle will be advanced until the needle tip will enter the GHJ capsule.~A solution composed of 3 mL of lidocaine 1%, 3 mL of bupivacaine 0.25%, and 1 mL of dexamethasone 40 mg, followed by an infusion of up to 40 mL of normal saline , until the capsule is adequately distended and resistance will be felt."
223873389|NCT06090786|DIAGNOSTIC_TEST|MRD assessment|Bone marrow withdrawal for MRD quantification
223873390|NCT02549170|BIOLOGICAL|HYQVIA|Participants will receive HYQVIA/HyQvia SC which contains both Immune Globulin Infusion 10% (Human) (IGI, 10%) and recombinant human hyaluronidase (rHuPH20).
223873391|NCT02549170|BIOLOGICAL|0.25% albumin placebo solution with rHuPH20|Participants will receive placebo solution (0.25% human albumin in Lactated Ringer's solution) and rHuPH20.
223873392|NCT02549170|BIOLOGICAL|IGIV GAMMAGARD LIQUID/KIOVIG|Participants will receive GAMMAGARD LIQUID/KIOVIG
223873393|NCT02549170|BIOLOGICAL|IGIV GAMUNEX®-C|Participants will receive GAMUNEX®-C
223873394|NCT03418805|DRUG|Advil Ibuprofen table 200 mg|"Administration of the comparator drug:~Three tablets (dosing at a 4-hour interval, q4h) of reference ibuprofen standard products, followed by 24 hours after the first dose administration."
223873395|NCT03418805|DRUG|Motrin IB Ibuprofen Tablets 200 mg|"Administration of the comparator drug:~Three tablets (dosing at a 4-hour interval, q4h) of reference ibuprofen standard products, followed by 24 hours after the first dose administration."
223873396|NCT03418805|DRUG|Ibuprofen CR Tablets 600 mg|"Administration of the investigational product:~Single oral dose of IBUCR, followed by 28 and 32 hours after the dose administration for fasted and fed studies, respectively"
223873397|NCT02235272|DRUG|XG-102|Comparison of XG-102 versus placebo sub-conjunctival injection efficacy
223873398|NCT02235272|DRUG|Placebo|comparison of XG-102 versus placebo sub-conjunctival injection efficacy
223873399|NCT00827346|DRUG|Clopidogrel|600 mg now
223873400|NCT00827346|DRUG|Clopidogrel|600 mg now and 600 mg in 3 hours
223873401|NCT00827346|DRUG|Clopidogrel|900 mg now
223873402|NCT00827346|DRUG|Clopidogrel|600 mg now and 300 mg in 3 hours
223873403|NCT00004243|DRUG|docetaxel|
223873404|NCT00004243|DRUG|oxaliplatin|
223873405|NCT01538914|PROCEDURE|paravertebral block|Postoperative pain is controlled with local analgesics via PVB.
223873406|NCT01538914|PROCEDURE|PCA|Postoperative pain is controlled with intravenous PCA.
223873407|NCT00898846|DRUG|UFT adjuvant chemotherapy|UFT is given at a dose of 500-600 mg/day as tegafur in 2 divided doses after meals for 5 days, followed by a 2-day rest. This one-week cycle is repeated for one year.
223873408|NCT02979808|DEVICE|Navina Smart|Subjects treatment-naïve to transanal irrigation (TAI). Frequency of TAI will be tailored to each subject.
223873409|NCT06152939|OTHER|Primary percutaneous coronary intervention or thrombolytic therapy|Primary percutaneous coronary intervention or thrombolytic therapy
223873410|NCT02396602|BEHAVIORAL|miPlan intervention|miPlan mobile contraceptive counseling waiting room app intervention
223873411|NCT01843569|BIOLOGICAL|In Vitro maturation|
223873412|NCT05106946|BIOLOGICAL|ThisCART22 cells|0.2-60 x 10\^6 CAR T cells per kg body weight
223873413|NCT06220097|DRUG|Mitoxantrone hydrochloride liposome Injection-based bridging therapy+ Fludarabine-based chemotherapy +CD19 CAR-T Cells|Bridging therapies from enrollment before CD19 CAR-T infusion. A treatment regimen containing mitoxantrone hydrochloride liposome injection, including but not limited to the following recommended regimens: R-MINE regimen (rituximab + ifosfamide + mitoxantrone hydrochloride liposome + etoposide) G-MINE regimen (obinutuzumab + ifosfamide + mitoxantrone hydrochloride liposome + etoposide) MAE regimen (mitoxantrone liposome hydrochloride + cytarabine + etoposide) . The recommended dose of mitoxantrone liposome hydrochloride is not limited. For patients who achieve SD or better after one cycle of bridging treatment, it is up to the investigator to decide whether to receive CAR-T therapy. Fludarabine-based lymphodepletion chemotherapy was followed by CD19 CAR-T cells (relma-cel, axi-cel or humanized CAR19). Relma-cel and axi-cel will be infused according to the instructions. CART19 infusion is conducted at a dose of 1x10\^6/kg on day 0 and day 1 respectively.
223873414|NCT05973812|DIETARY_SUPPLEMENT|Infant formula supplemented with Bifidobacterium breve PS1|Feeding with an infant formula containing 7 log10 cfu of the strain per gram of formula.
223873415|NCT05973812|DIETARY_SUPPLEMENT|Infant formula NOT supplemented with Bifidobacterium breve PS1|Feeding with the same infant formula but without supplementation with the B. breve strain
223873416|NCT01448317|DRUG|Alirocumab (Solution)|"Pharmaceutical form: solution~Route of administration: subcutaneous"
223873417|NCT01448317|DRUG|Alirocumab (Lyophilized formulation)|"Pharmaceutical form: lyophilized formulation~Route of administration: subcutaneous"
223873418|NCT01448317|DRUG|Placebo (Solution)|"Pharmaceutical form: solution~Route of administration: subcutaneous"
223873419|NCT01448317|DRUG|Placebo (Lyophilized formulation)|"Pharmaceutical form: lyophilized formulation~Route of administration: Subcutaneous"
223873420|NCT03107546|DEVICE|Hyalomatrix|We are comparing two techniques for covering the open area of the finger at the end of syndactyly release surgery. We would like to compare the current technique, a skin graft, with a new technique called Hyalomatrix.
223873421|NCT03107546|OTHER|Skin graft|We are comparing two techniques for covering the open area of the finger at the end of syndactyly release surgery. We would like to compare the current technique, a skin graft, with a new technique called Hyalomatrix.
223873422|NCT04804046|DIETARY_SUPPLEMENT|Synbiotic|Eighteen participants with Crohn's disease that are undergoing an ileocecal resection will supplement their normal diet with three Bifidobacterium spp. (3x10\^9 CFU) plus three dietary fibers (24 g fiber) daily for six months.
223873423|NCT04804046|OTHER|Digestible Maltodextrin|Eighteen participants with Crohn's disease that are undergoing an ileocecal resection will supplement their normal diet with Maltodextrin daily for six months.
223873424|NCT03701386|PROCEDURE|cesarean hysterectomy|Elective cesarean hysterectomy will be planned at 37-38 weeks of gestation. An adequate amount of blood products was prepared to be available for transfusion. Delivery will be performed by the same multidisciplinary team, including two expert obstetricians, an assistant, an expert anesthesiologist, and a pediatrician.
223873425|NCT03701386|PROCEDURE|N&H sandwich technique|In the N\&H group, after acceptable control of bleeding from the placental bed, the internal os of the cervix was identified a double uterine compression suture at the lower uterine segment with inflated Foley's catheter balloon tamponade will be performed
223873426|NCT01414738|RADIATION|Radiotherapy|Hippocampal-Avoiding Whole Brain Irradiation with Simultaneous Integrated Boost
223873427|NCT04204993|DEVICE|Lumee Oxygen Platform|Two sensors will be inserted (one in the skin fo the upper arm and one on the side of the chest). A wireless patch reader is placed on top of the skin over the area where the sensor has been placed to measure local oxygen content.
223873428|NCT03200808|DRUG|mixed methylene blue compound injection|Every patient received intradermal mixed methylene blue compound injection twice.
223873429|NCT05150067|OTHER|A Blended Learning Programme|A blended learning programme with face-to-face training and an online module on handover practice
223873430|NCT05150067|OTHER|Waitlist control group|The participants in the waitlist control group received the same face-to-face training workshop as the experimental group. However, these participants were invited to access the online module only after data collection was completed
223873431|NCT01116596|DRUG|Paracetamol|determine, in subjects aged over 70 years, the blood concentration of glutathione (GSH) and urinary loss of cysteine in the detoxification of paracetamol, when taking paracetamol treatment repeated.
223873432|NCT05435313|PROCEDURE|HAIC|After successful percutaneous hepatic artery cannulation, superior mesenteric arteriogram and hepatic arteriogram were performed, and after confirming that the subjects were eligible for enrollment according to the results, the hepatic artery was cannulated to the predetermined position. The catheter was connected to a syringe pump in the ward for continuous pumping of drugs.
223873433|NCT05435313|DRUG|Fruquintinib|3mg, qd, po, 21 days for a cycle, Suspend medication on the day of HAIC
223873434|NCT05435313|DRUG|Tislelizumab|200mg, ivgtt, d1, 21 days for a cycle
223873435|NCT05435313|DRUG|Raltitrexed|2 mg/m2, hepatic artery infusion for 15 min, d1, 4-6 Cycles
223873436|NCT05435313|DRUG|Oxaliplatin|85 mg/m2, hepatic artery infusion for 2 h, d1, 4-6 Cycles
223873437|NCT05435313|DRUG|Irinotecan|120mg/m2, hepatic artery perfusion for 30-90min, d1, 4-6 Cycles
223873438|NCT02065024|DIETARY_SUPPLEMENT|b-cryptoxanthin plus phytosterols|
223873439|NCT02379819|DEVICE|Nucleus Hybrid L24 Implant|
223873440|NCT03062813|DRUG|Tacrolimus &entecavir|HBV-GN patients with nephrotic syndrome were randomly givenTacrolimus (0.05-0.1 mg/kg/day) combined with entecavir. Tacrolimus was divided into two daily doses at 12-hour intervals. Subsequent doses were adjusted to achieve a whole blood 12-hour trough level between 5 and 10 ng/ml.All patients will receive entecavir antiviral therapy(0.5mg/d), entecavir was taken once a day. All of HBV-GN patients were followed up to 25week.
223873441|NCT03062813|DRUG|placebo & entecavir|HBV-GN patients with nephrotic syndrome were randomly givenTacrolimus placebo (0.05-0.1 mg/kg/day) combined with entecavir.Tacrolimus placebo was divided into two daily doses at 12-hour intervals. All patients will receive entecavir antiviral therapy(0.5mg/d), entecavir was taken once a day. All of HBV-GN patients were followed up to 25week.
223873442|NCT02118064|BIOLOGICAL|G17DT-Irinotecan|500µg dose of G17DT intramuscular injection in combination with 125 mg/m\^2 intravenous infusion of Irinotecan over 90 minutes.
223873443|NCT04263519|DRUG|Tacrolimus|Oral Immunosuppressant
223873444|NCT04215172|DRUG|Macrolides|administration of azithromycin three times weekly for six months
223873445|NCT03449173|DRUG|Sunitinib|small-molecule, multi-targeted receptor tyrosine kinase (RTK) inhibitor
223873446|NCT05204394|DRUG|VM-1500A-LAI|Injectable nanoformulation of depulfavirine (parent drug of elsulfavirine)
223873447|NCT05204394|OTHER|Standard of Care|Any oral 1st line approved HIV treatment regimen
223873448|NCT03224390|OTHER|digital family planning screening and referral service|Clients text the service and receive a free call back to complete an automated family planning counseling session that results in a set of recommended methods that fit the client's preferences. The client is matched to family planning providers that offer these methods, and the service sends a referral code that the client can redeem at a facility. When someone receives a referral code, the service tracks them through their encounter with a provider to learn about their experience with the service, the provider, and their choice in contraception. The service also follows-up with clients who do not act on referrals to better understand their reasons and tries different behavioral nudges to promote uptake of contraception. The service does not pay costs the client may incur at a facility.
223873449|NCT00243529|BIOLOGICAL|autologous dendritic cell vaccine|
223873450|NCT04728568|DRUG|Sintilimab|Sintilimab binds to PD-1, an inhibitory signaling receptor expressed on the surface of activated T cells, and blocks the binding to and activation of PD-1 by its ligands, which results in the activation of T-cell-mediated immune responses against tumor cells
223873451|NCT00703820|DRUG|Cytarabine|See Detailed Description
223873452|NCT00703820|DRUG|Daunorubicin|See Detailed Description
223873453|NCT00703820|DRUG|Etoposide|See Detailed Description
223873454|NCT00703820|DRUG|Clofarabine|See Detailed Description
223873455|NCT00703820|DEVICE|CliniMACS|The mechanism of action of the CliniMACS Cell Selection System is based on magnetic-activated cell sorting (MACS). The CliniMACS device is a powerful tool for the isolation of many cell types from heterogeneous cell mixtures, (e.g. apheresis products). These can then be separated in a magnetic field using an immunomagnetic label specific for the cell type of interest, such as CD3+ human T cells.
223873456|NCT03440034|DRUG|Pioglitazone|Pioglitazone comes as a tablet to take by mouth and can be taken with or without food.
223873457|NCT03803748|DEVICE|Eyestil Plus®|• To demonstrate the non-inferiority of Eyestil Plus® compared to Vismed Multi® in terms of clinical performance as detected by a reduction of keratitis lesions objectified by staining tests after 1 month of treatment, in patients with moderate to severe dry eye syndrome with keratoconjunctivitis
223873458|NCT01522573|PROCEDURE|EUS guided ERCP|Endoscopic ultrasound guided (EUS) endoscopic retrograde cholangiopancreatography (ERCP)
223873459|NCT05951309|DRUG|inofolic combi|The patients in this group were given inofolic combi once a day for 12-16 weeks
223873460|NCT05951309|DRUG|Glucophage 500Mg Tablet|The patients in this group were given glucophage three times a day for 12-16 weeks
223873461|NCT03062332|GENETIC|Faecal genome|Sequencing faecal genome is not the intervention measure.It is the Observational method to detect the component of faecal microbiota.
223873462|NCT02796586|OTHER|Counseling|Participants will be randomly assigned to group versus individual contraceptive counseling
223873463|NCT01625104|OTHER|Non Intervention|Business as usual
223873464|NCT01625104|OTHER|Agressive Intervention Process Improvement Strategies|
223873465|NCT01730352|DRUG|H. pylori triple therapy|Children up to 5 years: clarithromycin 15mg/kg, amoxicillin 50mg/kg, and/or furazolidone 7mg/kg Children above 8 years: doxycycline 4,4mg/kg if necessary Children able to swallow tablets or capsules, above 30kg: clarithromycin 500mg, amoxicillin 500mg, furazolidone 200mg, and/ or doxycycline 100mg, all 2 times per day, for 14 days.
223873466|NCT02586597|DEVICE|Transcranial magnetic stimulation & median nerve stimulation|"Paired associative stimulation (PAS) is a new technique where one pairs a peripheral stimulation with centrally applied transcranial magnetic stimulation (TMS), and produces plasticity, as measured by TMS MEP's. Currently PAS is performed with median nerve stimulation.~PA25: The interval between median nerve stimulation and TMS was chosen to be 25 ms, which is called PAS25. 240 paired TMS and median nerve stimulation at a frequency of 0.2 Hz over 20 min.~PAS10: 240 paired TMS and median nerve stimulation with interval of 10 min second at a frequency of 0.2 Hz over 20 min.~PAS100: 240 paired TMS and median nerve stimulation with interval of 100 min second at a frequency of 0.2 Hz over 20 min."
223873467|NCT03065569|DRUG|Bupivacaine|16 mL of 0.125% bupivacaine
223873468|NCT00541268|DEVICE|ICD|Intracardioverter defibrillators from 2 different manufacturers
223873469|NCT00541268|OTHER|Optimal medical treatment|ACEi or angiotensin receptor blockers Betablockers Aldosterone blockers
223873470|NCT06427863|DRUG|Ornidazole|Patients will receive three consecutive enemas of ornidazole 0.5g+50ml saline through the TET tube, followed by WMT treatment once daily for a duration of 3 days
223873471|NCT06427863|DRUG|Placebo|Patients will receive three consecutive enemas of placebo of equal volume through the TET tube, followed by WMT treatment once daily for a duration of 3 days
223873472|NCT04698655|OTHER|Information on treatment options|"Asked to read two A4 pages of information on treatment options (osteoarthritis treatment options)"
223873473|NCT04698655|OTHER|Recommendation from general practitioner|Receive a hypothetical general practitioner recommendation for exercise
223873474|NCT04698655|OTHER|Information on osteoarthritis|Asked to read 1 A4 page of brief information on osteoarthritis
223873475|NCT01477268|DRUG|Zoloft (antidepressant)|Zoloft 50-200 mg po od x 12 weeks
223873476|NCT04834648|BEHAVIORAL|Structured Counseling|"Structured Counseling, which includes A. Counseling is done by a trained counselor~B. Telephonic Follow up:~C. Development of Fast Track system at the Base Hospital. D. Provide Health Education Material to all Diabetic Patients. E. Referral communication and feedback between referring and referral facility."
223873477|NCT01845844|DRUG|Ranibizumab 0.3mg/0.05cc|"Group A (Arm A) will receive monthly 0.3mg/0.05cc intravitreal injections for 12 consecutive months.~Group B (Arm B) will receive monthly 0.3mg/0.05cc intravitreal injections for the first six months and then PRN for the remaining 6 months per protocol specified criteria."
223873478|NCT05110105|BEHAVIORAL|Interactive board game health education|The interactive board game includes risk factors, symptoms, and acute management of stroke. It's a card game combined with (1) addition and subtraction game (risk factors). (2) gestures game (symptoms) (3) matching game (acute management), but in traditional Chinese. The game was implemented in a group (2\~6 individuals) for 40 minutes.
223873479|NCT05110105|BEHAVIORAL|Conventional health education|The health education flier was made refer to medical institutions, e.g., hospitals or clinics, the stroke prevention video was collected from the internet. Participants were assigned to read the health education flier for 20 minutes. Then watch the stroke prevention video for 20 minutes.
223873480|NCT00452270|DRUG|Xylometazoline|
223873481|NCT00204113|DEVICE|Multi-purpose rehabilitation frame|
223873482|NCT00204113|DEVICE|Surface Functional Electrical Stimulation|
223873483|NCT03021369|DEVICE|Pleural drainage system|Pleural drainage system is connected to the chest tubes after surgery.
223873484|NCT01604161|DRUG|somatropin|Collection of safety and efficacy data in connection with use of somatropin (Norditropin®) in daily clinical practice.
223873485|NCT02153541|DRUG|Antipyrine-benzocaine otic solution|Participants receiving antipyrine-benzocaine otic solution are expected to decrease usage of rescue inhalers.
223873486|NCT02153541|OTHER|Glycerin with Oxyquinoline Sulfate|50% of participants will receive the glycerin with oxyquinoline sulfate. These participants will be randomly selected and unaware that they are receiving the placebo and are expected to have no change in usage of rescue inhalers.
223873487|NCT02073578|PROCEDURE|Peroral Endoscopic Myotomy (POEM)|Endoscopy myotomy for treatment of achalasia
223873488|NCT00098319|DRUG|Folic acid (0.4mg vs. 4.0mg)|
223873489|NCT04549831|GENETIC|Massive parallel sequencing of host genome|Massive parallel sequencing and genotyping of host genome of individuals infected with SARS-CoV-2 and showing different clinical outcomes from asymptomatic to severely affected patients in order to identify the genetic determinants of severe COVID-19 and the genetic protective factors.
223873490|NCT01074567|DRUG|DMSO cocktail|intra-vesical: DMSO 50% in 50 cc water for injection 10 cc heparin 5000 IU hydrocortisone 100 mg bupivacaine 0.125%
223873491|NCT04314765|PROCEDURE|lower third molar extraction|the extraction is performed with one of the two type of flap based non randomization.
223873492|NCT00775294|DRUG|Maraviroc|Healthy male volunteers will take maraviroc 300 mg orally twice daily for 15 doses (8 days)
223873493|NCT00350792|DRUG|pemetrexed|500 milligrams per square meter (mg/m\^2), intravenous (IV), every 21 days x 6 cycles
223873494|NCT00350792|DRUG|carboplatin|Area Under the Curve (AUC) 5, intravenous (IV), every 21 days x 6 cycles
223873495|NCT03054415|PROCEDURE|endoscopy|colonic biopsies during endoscopy and anal manometry with barostat and anal endoflip
223873496|NCT06001190|DIETARY_SUPPLEMENT|probiotic:Lactobacillus crispatus|We seek to observe that probiotic supplement(arm A) can improve vagina microbiome distribution by comapred to placebo group(arm B) in our study.
223873497|NCT00623987|DRUG|warfarin accordingly INR value|warfarin accordingly to INR value between 2.0-3.0
223873498|NCT03262831|OTHER|Yoga|The yoga practice, Gentle Hatha and Restorative Yoga, will be based on protocols that have been found to decease fatigue and weight gain by helping the participant gain insight in recognizing stress responses and ways to relax
223873499|NCT03262831|PROCEDURE|Blood draw|"* Baseline and end of treatment~* To evaluate change in inflammatory markers (CRP, IL-6, and TNF)"
223873500|NCT03262831|BEHAVIORAL|FACT-G questionnaire|"* 7 statements that other people with breast cancer have said are important, the patient is to circle or mark one number per line to indicate the response as it applies in the last 7 days~* Answers range from 0=not at all to 4=very much"
223873501|NCT03262831|PROCEDURE|Weight measurement|-Weight will be taken at baseline, on day 1 of each cycle, and the end of treatment
223873502|NCT03262831|BEHAVIORAL|Recent Physical Activity Questionnaire|-To assess physical activity, the RPAQ will be completed at baseline and at the end of treatment.
223873503|NCT03262831|BEHAVIORAL|NHANES Food Questionnaire|-To assess diet, the NHANES Food Questionnaire will be completed at baseline and at the end of treatment.
223873504|NCT00914589|DRUG|catridecacog|Single dose via slow intravenous (i.v.) push at a rate not exceeding two mL per minute
223873505|NCT00914589|DRUG|catridecacog|Single dose via slow intravenous (i.v.) push at a rate not exceeding two mL per minute
223873506|NCT00914589|DRUG|placebo|Single dose via slow intravenous (i.v.) push at a rate not exceeding two mL per minute
223873507|NCT00257049|DRUG|levofloxacin|
223873508|NCT05048680|PROCEDURE|Hypoxia and/or Exercise|Hypoxia at rest versus normoxia at rest; Hypoxia during exercise versus Normoxia during exercise.
223873509|NCT04153058|PROCEDURE|Robotic Assisted AEG Radical Gastrectomy|Robotic Assisted Radical Gastrectomy for Advanced Siewert II/III Esophagogastric Junction Adenocarcinoma
223873510|NCT04153058|PROCEDURE|Laparoscopic Assisted AEG Radical Gastrectomy|Laparoscopic Assisted Radical Gastrectomy for Advanced Siewert II/III Esophagogastric Junction Adenocarcinoma
223873511|NCT03820050|DEVICE|Freestyle LIbre Flash Glucose Monitoring System|System Performance will be characterized with respect to YSI reference venous plasma measurements
223873512|NCT05125874|BIOLOGICAL|Recombinant SARS-CoV-2 Fusion Protein Vaccine|The product should be a milky-white suspension for injection. For prevention of SARS-CoV-2 infection.
223873513|NCT02315456|PROCEDURE|capsulorhexis|
223873514|NCT00139984|DEVICE|24 hour blood pressure measurement|
223873515|NCT05397275|OTHER|progressive muscle relaxation+breathe exercises|progressive muscle relaxation+breathe exercises
223873516|NCT05397275|OTHER|breathe exercises|breathe exercises
223873517|NCT04324099|OTHER|neuroimaging session (with simultaneously acquired eye-tracking)|neuroimaging session, including two functional neuroimaging paradigms (ca. 15-20 minutes each) and a short structural image acquisition (mprage) for coregistration. Functional Magnetic Brain Imaging (fMRI) and simultaneous eye-tracking data will be collected during the paradigms: 1) an emotion processing paradigm (adapted from Passamonti et al., 2010); and 2) an emotional Go/noGo paradigm (adapted from Hare et al., 2008).
223873518|NCT04324099|OTHER|Questionnaire (for children) assessing traumatic experiences (Childhood trauma questionnaire (CTQ))|The Childhood Trauma Questionnaire is a brief survey of six early traumatic experiences (death, divorce, violence, sexual abuse, illness or other), and assesses individual's understanding of their childhood trauma.
223873519|NCT04324099|OTHER|Social and Health Assessment (SAHA) questionnaire (for children)|Self reported survey assessing social and mental health with four aspects of parenting determined (parental involvement, parental warmth, parental control, and inconsistency of parenting).
223873520|NCT04324099|OTHER|Massachusetts Youth Screening Instrument (MAYSI-2) (for children)|"The Massachusetts Youth Screening Instrument (MAYSI-2) is a screening instrument developed for detecting mental health needs in youth aged 12-17. Designed as a low-cost, easily administered tool, it screens for multiple issues and can be administered in 10-15 minutes. It is divided into seven scales composed of 52 questions that are designed to detect alcohol/drug use, angryirritable behavior, depression-anxiety, somatic complaints, suicide ideation, thought disturbance, and traumatic experience. Youths answer YES or NO concerning whether each item has been true for them within the past few months."
223873521|NCT04324099|OTHER|Interpersonal Reactivity Index (IRI) (for children)|The Interpersonal Reactivity Index is a measure of dispositional empathy that takes as its starting point the notion that empathy consists of a set of separate but related constructs. The instrument contains four seven-item subscales (seven Likert items each), each tapping a separate facet of empathy (Empathic Concern, Perspective Taking, Personal Distress, and Fantasy). The 28-item IRI contains four subscales
223873522|NCT04324099|OTHER|Youth Psychopathic Traits Inventory (YPI) (for children)|self-report screening measures to assess psychopathic traits in youth assessing 10 core personality traits associated with the construct (grandiosity, lying, manipulation, callousness, unemotionality, impulsivity, irresponsibility, dishonest charm, remorselessness, and thrill seeking). Each item is scored on an ordinal 4-point Likert scale (1 = Does not apply at all, to 4 = Applies very well). Higher scores reflect an increased presence of psychopathic traits.
223873523|NCT04324099|OTHER|Reactive Proactive Questionnaire (RPQ) (for children)|The Reactive-Proactive Questionnaire (RPQ) scores (0 (never), 1 sometimes, 2 (often)) for proactive aggression items and reactive items. Proactive and reactive scale scores are summated to obtain total aggression scores.
223873524|NCT04324099|OTHER|Emotion Regulation Questionnaire (for children)|10-item scale designed to measure respondents' tendency to regulate their emotions in two ways: (1) Cognitive Reappraisal and (2) Expressive Suppression. Respondents answer each item on a 7-point Likert-type scale ranging from 1 (strongly disagree) to 7 (strongly agree)
223873525|NCT04324099|OTHER|Basic Empathy Scale (BES) (for children)|The Basic Empathy Scale (BES) measures 20 items (affective and cognitive empathy) on a Five-point Likert-type scale.
223873526|NCT04324099|OTHER|Pubertal Development Scale (PDS) (for children)|self-report measure of physical development which has been shown to be correlated with measures of pubertal development derived from physical examination. Responses are coded on 4-point scales (1 = no development and 4 = completed development). For girls, a yes-no question about onset of menarche is weighted more heavily (1 = no and 4 = yes). For both genders, ratings are then averaged to create an overall score for physical maturation.
223873527|NCT04324099|OTHER|Alabama Parenting Questionnaire (APQ) (for parents)|The APQ measures five dimensions of parenting that are relevant to the etiology and treatment of child externalizing problems: (1) positive involvement with children, (2) supervision and monitoring, (3) use of positive discipline techniques, (4) consistency in the use of such discipline and (5) use of corporal punishment (42 self-reported responses, rated on a 5-point Likert scale- 1 (never) to 5 (always) for both child and parent forms)
223873528|NCT04324099|OTHER|Inventory of Callous Unemotional Traits (ICU) (for parents)|24-item questionnaire designed to provide a comprehensive assessment of callous and unemotional traits.The ICU has three subscales: Callousness, Uncaring, and Unemotional. The ICU is made up of statements with a 4-point Likert scale, ranging from 0 (Not at all true) to 3 (Definitely True), with higher scores indicating greater CU traits.
223873529|NCT04324099|OTHER|Child Behavior Checklist (CBCL) (for parents)|"The eight empirically-based syndrome scales are:~1. Aggressive Behavior~2. Anxious/Depressed~3. Attention Problems~4. Rule-Breaking Behavior~5. Somatic Complaints~6. Social Problems~7. Thought Problems~8. Withdrawn/Depressed. Higher scores indicate greater Problems."
223873530|NCT04324099|OTHER|Griffith Empathy Measure (GEM) (for parents)|self-report 23-item measure of empathy in which the respondent answers each item on a nine-point Likert scale from strongly disagree to strongly agree
223873531|NCT04324099|OTHER|Social Responsiveness Scale (SRS) (for parents)|Social Responsiveness Scale (SRS) measures social ability of children from 4 years to 18 years old. It is used primarily with individuals with Autism Spectrum Disorder (ASD), family members of individuals with ASD, and others who have social impairments. Parent or teacher questionnaire (65 items on a 4-point Likert scale). High scores are associated with more severe social impairments.
223873532|NCT05528549|OTHER|Exercise|The investigators are looking at how blood flow and blood pressure are regulated in individuals with Down syndrome, who have a reduced ability to do work. This study will compare individuals with Down syndrome to a control group without Down syndrome.
223873533|NCT03279861|DRUG|Entresto|First line therapy in Entresto arm
223873534|NCT03279861|DRUG|Valsartan|"First line therapy in usual meds arm"
223873535|NCT03925558|DIETARY_SUPPLEMENT|Probiotics|
223873536|NCT03925558|DIETARY_SUPPLEMENT|Placebo|
223873537|NCT04688866|OTHER|Sequencing|This is an observational study, since the assignment of the medical intervention (e.g. cerclage or pessary) is not at the discretion of the investigator. However, cervical samples collected from both groups are subjected to amplicon sequencing for taxonomic classification of microorganisms.
223873538|NCT01675258|OTHER|Salivary samples|Each participant will give a sample of saliva through spitting for 10 minutes in a sterile tube.
223873539|NCT03145155|BEHAVIORAL|Integrating services for noncommunicable diseases in continuum of care for mothers and children|The intervention package will comprise of two components, (1) utilization of CoC card and (2) health education on CoC in maternal, newborn and child health (MNCH), NCD and nutrition. The CoC card will be distributed to mothers by midwives at the time of receiving ANC. The CoC card includes CoC services from first antenatal care(ANC) to last postnatal care(PNC) including four ANC, skilled birth attendance (SBA) and four PNC and essential services. Pregnant women will get stickers if they receive above services. Health education will be given by Public Health Supervisors 2 at the health facilities. Health education will be given three times during pregnancy and one time during postpartum period with pamphlets and posters.
223873540|NCT03145155|BEHAVIORAL|Ordinary health education for pregnant women|The ordinary health education intervention will cover schedule for ANC, delivery and PNC; danger signs; birth preparedness and nutrition. Health education will be given three times during pregnancy and one time during postpartum period with pamphlets and posters.
223873541|NCT03988023|BIOLOGICAL|Ampion|4 mL injection of Ampion
223873542|NCT03988023|DRUG|Saline|Saline solution, 4 mL, single intra-articular injection
223873543|NCT02125695|PROCEDURE|Skin Taping|Skin taping from affected and unaffected sites (4 tape harvestings/area plus photograph of taping site)
223873544|NCT02125695|PROCEDURE|Blood Sampling|Sampling for biomarker and basic research in CLE and AD
223873545|NCT02125695|PROCEDURE|Skin Biopsy|As described in the treatment arm
223873546|NCT03036813|DRUG|voxelotor|
223873547|NCT03036813|OTHER|Placebo|
223873548|NCT00182975|DRUG|DHEA replacement|
223873549|NCT03993704|DRUG|LHF-535|Oral suspension administered once daily for 14 days
223873550|NCT03339115|DEVICE|Cardiovalve Transfemoral Mitral Valve|The Cardiovalve Transfemoral Mitral Valve System is intended for use symptomatic patients with severe mitral regurgitation who are at elevated risk for surgical mitral valve repair or replacement and who are anatomically eligible for transfemoral mitral valve replacement with transseptal access to the left atrium.
223873551|NCT02462616|OTHER|not intervention|This is a cross-sectional study, no intervention was performed.
223873552|NCT02546999|DRUG|botox|The agent will be given only once at point zero in the time scheme for the project.
223873553|NCT02546999|DRUG|placebo|The agent will be given only once at point zero in the time scheme for the project.
223873554|NCT01251224|OTHER|Integrated Pest Management|The IPM intervention will include professional mouse abatement, two HEPA filters, targeted cleaning, education about IPM, and allergen-proof mattress and pillow encasements. The intervention will be delivered at baseline to the IPM Group, and then repeated if recurrent or persistent mouse infestation is present.
223873555|NCT01251224|OTHER|Education|This group will receive education about mouse IPM.
223873556|NCT00785512|DRUG|Nebivolol|Nebivolol 10 mg, 10-mg Nebivolol nontrade tablets , oral administration Nebivolol 20 mg, 20-mg Nebivolol nontrade tablets , oral administration Nebivolol 40 mg, two 20-mg Nebivolol nontrade tablets , oral administration
223873557|NCT00785512|DRUG|Placebo|Matching placebo tablets, oral administration
223873558|NCT00194714|BIOLOGICAL|HER-2/neu Peptide Vaccine|Given ID
223873559|NCT00194714|OTHER|Laboratory Biomarker Analysis|Correlative studies
223873560|NCT00899015|OTHER|pharmacological study|
223873561|NCT05760235|PROCEDURE|Endoscopic sleeve gastroplasty (ESG)|ESG will be performed under general anaesthesia with orotracheal intubation. The Endomina® suturing system (EndoTools Therapeutics S.A., Gosselies, Belgium) mounted on a single channel endoscope will be used. This system allows to obtain full thickness gastric sutures through the gastric wall of the gastric body, leaving the antrum and the gastric fundus free15. The procedure will be performed with the patient in supine position. Carbon dioxide will be blown to stretch the gastric lumen. An initial endoscopic evaluation will be performed immediately to confirm the absence of any contraindication to ESG before suturing. The ESG starts with the reduction of the gastric body, suturing from distal to proximal and starting from the notch of the angulus and ending at the level of the fundus. 4-8 full thickness stitches will be placed, with 2 passes per stitch.
223873562|NCT02677129|OTHER|home-based exercise intervention|Endurance training (moderate intensity; walking), 3-5 times per week Patients will receive exercise counselling how to realize the planned intervention home-based. Further, they will be asked to fill out an exercise log. The study team will periodically review adherence to the intervention and identify problems.
223873563|NCT02502344|BEHAVIORAL|healthy lifestyle|food control and intensive exercise to lose weight
223873564|NCT02502344|DRUG|Metformin|use metformin to reduce insulin resistance
223873565|NCT01195883|DRUG|Crystalloid|For goal directed volume management we use corrected aortic flow time (FTc) and stroke volume derived from esophageal Doppler as in previous studies. In case of hypovolemia, detected by esophageal Doppler monitoring (CardioQ, Deltex Medical Group PLC, Chichester, UK) according to a previously published algorithm, an additional fluid bolus of 250 ml of LR will be given over a period of 5 minutes.
223873566|NCT01195883|DRUG|Colloid|For goal directed volume management we use corrected aortic flow time (FTc) and stroke volume derived from esophageal Doppler as in previous studies. In case of hypovolemia, detected by esophageal Doppler monitoring (CardioQ, Deltex Medical Group PLC, Chichester, UK) according to a previously published algorithm, an additional fluid bolus of 250 ml of Hydroxyethylstarch 6% 130/0.4 (Voluven®Fresenius-Kabi, Bad Homburg, Germany) will be given over a period of 5 minutes.
223873567|NCT03017469|OTHER|ARISE|"1. Full day (7.5 hours) workshop consisting of a resilience-focused seminar facilitated by our Employee Assistance Provider (EAP) \[Shepell\], an introduction to hospital based resources including EAP and health and wellness offerings, and an introduction to self-care and self-care techniques including yoga and stretches, stress relief using the senses and mindfulness~2. Half day (3.75 hours) workshop focusing on the following self-care techniques: mindfulness, yoga and stretching, and creative and reflective reading and writing~3. Peer support through social media engagement (closed Facebook group) for 3 months post-intervention participation~4. Five online, instructor-guided mindfulness sessions (Zoom)"
223873568|NCT01070940|DRUG|NG-monomethyl-L-arginine (L-NMMA)|3 mg/kg IV priming dose + 2 mg/kg/hr IV infusion for 1 hour
223873569|NCT01070940|DRUG|NG-monomethyl-L-arginine (L-NMMA)|6 mg/kg IV priming dose + 4 mg/kg/hr IV infusion for 1 hour
223873570|NCT01070940|DRUG|NG-monomethyl-L-arginine (L-NMMA)|4.5 mg/kg IV priming dose + 3 mg/kg/hr IV infusion for 1 hour
223873571|NCT01070940|DRUG|Placebo|Isotonic saline solution IV priming dose + IV infusion for 1 hour
223873572|NCT02059616|DRUG|Amlodipine 5mg|Daily oral administration for 8 weeks
223873573|NCT02059616|DRUG|Amlodipine 10mg|Daily oral administration for 8 weeks
223873574|NCT02059616|DRUG|Candesartan Cilexetil 8mg|Daily oral administration for 8 weeks
223873575|NCT02059616|DRUG|Candesartan cilexetil 16mg|Daily oral administration for 8 weeks
223873576|NCT00529100|DRUG|Pemetrexed Phase 1|300 mg/m\^2 IV, Days 1 and 22; intermediate dose escalation level of 400 mg/m\^2 IV; then 500 mg/m\^2 IV, repeated every 21 days (q 21 days) x 2 cycles
223873577|NCT00529100|DRUG|Cisplatin Phase 1|"Cohorts 1-3: 25 mg/m\^2 IV, Days 1-3 and 22-24 then 75 mg/m\^2 IV, q21 days x 2 cycles~Cohort 4 carried into Phase 2: 20 mg/m\^2 IV, Days 1-5 and 22-26 then 75 mg/m\^2 IV, q21 days x 2 cycles."
223873578|NCT00529100|PROCEDURE|Radiation Therapy|Phases 1 and 2: 61-65 Gy in 33-35 fractions
223873579|NCT00529100|DRUG|Pemetrexed Phase 2|Concurrent phase pemetrexed IV bolus as determined by Phase 1 trial to be 500 mg/m\^2 IV on Days 1 and 22.
223873580|NCT00529100|DRUG|Cisplatin Phase 2|Phase 2 (Cohort 4 carried over from Phase 1): 20 mg/m\^2 IV, Days 1-5 and 22-26 then 75 mg/m\^2 IV, q21 days x 2 cycles.
223873581|NCT01471145|DRUG|Naltrexone|naltrexone for extended-release injectable suspension, 380 mg/vial, every 4 weeks or once a month
223873582|NCT00003017|BIOLOGICAL|recombinant interleukin-12|
223873583|NCT00295464|DRUG|Betamethasone sodium phos (drug)|
223873584|NCT01407458|OTHER|Upper Limb Exercises|Upper limb exercises
223873585|NCT01407458|OTHER|Normal physical exercises|Exercises usually done by children in physical education classes
223873586|NCT04245644|BEHAVIORAL|use of targeted drugs such as aspirin, B-Blockers, Metformin, ACE-inhibitors, Statins|enrolled patients will be asked details regarding their daily drug use, before and after diagnosis of pancreatic cancer
223873587|NCT00780351|DEVICE|sustained low efficiency daily hemodiafiltration (SLEDD-f)|vancomycin 15mg/kg IV infusion on day 1 from 6PM to 8PM. Start SLEDD-f on day 2 from 9AM to 5PM.
223873588|NCT03822234|PROCEDURE|Modified ileal conduit|Modified ileal conduit (Extraperitonealization)
223873589|NCT03631238|DIAGNOSTIC_TEST|Blood sampling for total cholesterol and homocysteine and cognitive assessment by psychometric tests.|"all participant are subjected to cognitive assessment by psychometric tests by using the arabic version of Mini Mental State Exam (MMSE) and Memory Assessment Scale (MAS).~Blood samples were collected in the morning using 10 mL yellow top (plain) Vacutainer tubes.~Lipid profile (triglycerides, low-density lipoprotein (LDL), and high-density lipoprotein (HDL)) were measured by Assiut university labs using Cholesterol Kits and analyzed by COBAS Integra analyzer.~Total cholesterol levels were calculated using the sum of the LDL and HDL plus one-fifth of triglyceride levels.~Samples of serum homocysteine are collected, centrifuged to separate plasma within 30 minutes after venipuncture and stored in specialized container in the Department of Clinical Pathology at (-20◦C) temperature.~Total homocysteine was measured by ELISA technique, Sinogen kits (Research Use Only) and Statfax-2100 microplate analyzer."
223873590|NCT01393067|DEVICE|Non-expandable plastic stent (plastic endoprosthesis)|plastic stent (plastic endoprosthesis)
223873591|NCT01393067|DEVICE|Covered self-expandable metal stent (cSEMS)|Removable, covered self-expandable metal stent (cSEMS)
223873592|NCT05621499|DRUG|HAIC|Oxaliplatin 85 mg/m2, LV 400 mg/ m2, 5-FU 400 mg/m2 bolus and then 2400 mg/m2 as 46h continuous infusion，Q3W，a total of 2 cycles
223873593|NCT05621499|DRUG|Sintilimab|200mg，iv，d1，q3w，a total of 3 cycles
223873594|NCT05621499|DRUG|Lenvatinib|12 or 8mg/kg，po，qd，a total of 3 cycles
223873595|NCT03580135|DRUG|Propolis|One and half gram of Standardized Propolis Extract powder (Y.S. Eco Bee Farms Propolis Powder) at 100% was mixed with 1.75 mL of polyethylene glycol (Continental Chemicals, New Delhi, India) to form a thick consistency on a clean dry glass slab with a metal spatula. The paste was carried to the pulp stumps with a metal carrier and then condensed lightly to a thickness of 2 - 3 mm followed by placement of thick mix of GIC to seal the cavity and covered by st.st crown.
223873596|NCT03580135|DRUG|Mineral Trioxide Aggregate|MTA paste will be prepared as per the manufacturers' instructions to obtain a putty-like consistency. The mixture will be delivered to the pulp stumps and condensed lightly with a moistened sterile cotton pellet to ensure a thickness of 2 to 3 mm. A thick mix of glass ionomer cement (GIC) will applied over the MTA and covered by st.st crown.
223873597|NCT04577924|OTHER|Interview|"Trained research assistants would abstract the data as per a preset proforma. The data would be collected from the patient (if coherent), pre-hospital care provider or primary care provider.~Data would was also obtained from patient records and the proforma filled by the attending doctors on duty.~Follow up of cases would be done until discharge from the hospital."
223873598|NCT00004440|DRUG|ibuprofen|
223873599|NCT00585624|DIETARY_SUPPLEMENT|Impact Advanced Recovery|Nutritional supplement
223873600|NCT00585624|DIETARY_SUPPLEMENT|No supplement|No supplement
223873601|NCT00530569|PROCEDURE|Blood Test|CBC and HER2 level at baseline, prior to each chemo and/or herceptin cycle, one month after chemo and/or herceptin completion, quarterly up to 12 months or a maximum of 20 blood draws.
223873602|NCT02009228|PROCEDURE|Ovarian cystectomy|
223873603|NCT05618132|DIAGNOSTIC_TEST|Acetylcholine rechallenge|"STEP 1 consists of verapamil 1mg IC. Angiography after 60 seconds, if spasm persists, NTG 200µg IC is given (step 2). If verapamil suppresses spasm, ACH rechallenge (ACHR) is performed after 3 minutes.~In STEP 2, patients with persistent spasm after verapamil or with spasm after ACHR receive NTG 200µg IC. Angiography after 60 seconds, if spasm persists, NTG 200µg IC is delivered again. If refractory spasm occurs, atropine 1mg IV is given. Coronary spasm is considered suppressed once ACHR can no longer provoke spasm. NTG 200µg IC is given as final drug regardless of spasm.~ACHR consists of ACH 100 or 200µg IC depending on the dose that previously provoked the coronary artery spasm (both microvascular and epicardial spasm)."
223873604|NCT03210454|OTHER|Smallholder Marketing|The smallholder marketing intervention involves product purchasing (e.g., bananas, beans, goats, eggs) from smallholder farmers' associations through WFP's large procurement procedures. WFP is will also provide technical training on topics such as sustainable farming practices, quality control, and business practices.
223873605|NCT03210454|OTHER|Intimate Partner Violence (IPV) Prevention Training|IPV prevention training involves 24 hours of gender training (gender equality and rights, economic empowerment, gender-based violence prevention), and 8 hours of nutrition and food security training (with a focus on gender).
223873606|NCT06342154|BEHAVIORAL|Endorphin Massage|The person who will perform the endorphin massage opens his hands with his palms facing himself and draws a semicircle with the nails of his middle, ring and little fingers touching the sacrum. Then, a semicircle is drawn with the fingertips from each side of the spine, starting from the sacrum to the shoulder area, towards the waist area, As a result of this process, a palm shape is drawn on the back. Effleurage is applied from the shoulders to the arms up to the elbows. Effleurage is applied towards the shoulders by pressing from the elbows upwards with the back of the thumb. Effleurage is applied up to the sacrum by pressing circular movements with two thumbs on both sides of the spine. Effleurage is applied from the sacrum to the neck by pressing with two thumbs in a circular motion on both sides of the spine (approximately 1.5 cm apart). Lastly, effleurage is applied to the neck area and scalp, then petrissage (rubbing) is applied and the massage is completed.
223873607|NCT00527540|DRUG|Pegylated Interferon alpha 2a + Ribavirin|Pegaferon: Ampule, 180 microgram per week Ribaverin: Tablet, 10-15 mg/kg per day
223873608|NCT06028282|RADIATION|SPECT|SPECT of thyroid traced with I-131
223873609|NCT04226664|PROCEDURE|Bariatric surgery|Although there may be slight variation by centre, Gastric Bypass generally involves creation of a 30-50 cc stomach pouch, which is anastamosed with a Roux limb of jejunum 75-100 cm in length and a biliary limb of 20-30 cm in length. The operation creates a small gastric pouch, with nutrients bypassing the duodenum and proximal jejunum. Sleeve Gastrectomy involves decreasing the size of the stomach to approximately 15% of its original size by resecting a large portion of the stomach along the greater curvature.
223873610|NCT00241241|DRUG|pegylated interferon-alfa 2a|
223873611|NCT06143371|BIOLOGICAL|CAN10|Single dose intravenous or Multiple doses subcutaneously
223873612|NCT06143371|BIOLOGICAL|CAN10 - Placebo|Single dose intravenous or Multiple doses subcutaneously
223873613|NCT05209581|DIAGNOSTIC_TEST|Distance Visual Acuity Examination|Best spectacle-corrected distance visual acuity of refugees/immigrants will be examined via a web-based digital visual acuity chart
223873614|NCT04470375|BEHAVIORAL|Virtual Reality Pain Neuroscience Education|Use of virtual reality media to provide pain neuroscience education
223873615|NCT06154746|DIAGNOSTIC_TEST|slit lamb & OCT|"1. The Slit lamb is a biomicroscope. It emits a beam of light that can be varied in height and width. It allows visualization of the anterior segment of the eye. With auxiliary lenses, the examiner can also view the posterior segment. These lenses are simple, affordable, and portable. Although high-end devices like fundus cameras and optical coherence tomography have revolutionized how practitioners detect eye diseases, they can never replace these handheld lenses.~2. OCT is a noninvasive method that yields a cross-section image of the retina by exposing the eye to near-infrared light. Specifically, an emitted light beam is scattered and reflected back by the retinal surface as well as its different layers."
223873616|NCT01064336|DRUG|Eltrombopag|Eltrombopag is an orally bioavailable, small molecule thrombopoietin receptor (TPO-R) agonist for the treatment of idiopathic thrombocytopenic purpura
223873617|NCT02239913|DRUG|Cocaine|The pharmacodynamic effects of cocaine will be determined during maintenance on placebo and topiramate.
223873618|NCT02239913|DRUG|Placebo|The pharmacodynamic effects of placebo will be determined during maintenance on placebo and topiramate.
223873619|NCT02239913|DRUG|Phentermine|The pharmacodynamic effects of phentermine maintenance will be determined during maintenance on placebo and topiramate.
223873620|NCT02239913|DRUG|Topiramate|The pharmacodynamic effects of chronic topiramate will be determined.
223873621|NCT02376244|OTHER|High intensity interval training (HIIT)|Standard care cardiac rehabilitation classes, delivered at a higher exercise intensity
223873622|NCT02376244|OTHER|Standard care|Standard care cardiac rehabilitation according to current guidelines
223873623|NCT03888768|DRUG|MonoFer|Administration of IV Monofer will be given according to body weight as recommended by the drug manufacturer.
223873624|NCT00807937|DRUG|AZD7325|4 tablets and 1 capsule taken twice a day for 28 days
223873625|NCT00807937|DRUG|AZD7325|4 tablets and 1 capsule taken twice a day for 28 days
223873626|NCT00807937|DRUG|Lorazepam|4 tablets and 1 capsule taken twice a day for 28 days
223873627|NCT00807937|DRUG|Placebo|4 tablets and 1 capsule taken twice a day for 28 days
223873628|NCT03611972|DIETARY_SUPPLEMENT|Sugar-sweetened beverage|Sugar-sweetened koolaid-flavored water.
223873629|NCT04629950|DRUG|Rimegepant|Active Agent
223873630|NCT04629950|DRUG|Placebo|Placebo Comparator
223873631|NCT05976581|BEHAVIORAL|Electronic alert|An alert will appear in the electronic health record that provides options for diagnostic testing based on low, medium, or high probability of bacterial pneumonia.
223873632|NCT05976581|BEHAVIORAL|Structured communication of test results|A clinical research team member will send an electronic message to the primary care team on behalf of the antimicrobial stewardship program with structured guidance to stop or de-escalate antibiotics and document these recommendations in the patient's chart.
223873633|NCT02088853|DIETARY_SUPPLEMENT|high fat diet (hfd), then high carbohydrate diet|Sixty % of the energy content is based on fat, then sixty % of the energy content is based on carbohydrates
223873634|NCT02088853|DIETARY_SUPPLEMENT|high carbohydrate diet, then high fat diet|Sixty % of the energy content is based on carbohydrates, then sixty % of the energy content is based on fat
223873635|NCT02508038|PROCEDURE|TCRαβ+/CD19+ depleted Haploidentical HSCT|Patients with high-risk leukemia will receive myeloablative conditioning. All other patients will undergo a reduced-intensity conditioning with ATG, Fludarabine, Thiotepa and Melphalan followed by transplant with a KIR/KIR (Killer cell immunoglobulin-like recetptor) ligand mismatched haploidentical donor peripheral blood stem cell graft depleted of TCRab+ cells and CD19+ cells using the CliniMACS System.
223873636|NCT02508038|DRUG|Zoledronate|Given IV. Patients will receive five doses of Zoledronate (each 1.25 mg/m2 at a 28 day interval) following transplant.
223873637|NCT05315258|DRUG|Tebentafusp|Tebentafusp supplied as concentrate for solution for infusion and diluted prior to administration. 0.2 mg/mL drug product will be provided as a sterile, refrigerated solution in glass vials.
223873638|NCT05189223|BEHAVIORAL|Brief, values based intervention for early buprenorphine treatment|The initial intervention structure consists of four weekly sessions. Session one focuses on values clarification using an empirically validated clinical exercise. The second session will include a discussion of the connection between values, addiction treatment engagement, and the challenges associated with discomfort (i.e., withdrawal and cravings) in early treatment. The third session will focus on barriers and goal setting to enhance self-efficacy for committed action. The final session will review progress made and focus on the Veterans' recovery plan moving forward. The initial study intervention will be refined iteratively using Phase 1 stakeholder and Phase 2 open trial participant feedback.
223873639|NCT05189223|BEHAVIORAL|Treatment as Usual|Veterans will be recruited from an intensive treatment phase where all Veterans receive case management and regular group therapy in addition to appointments with their buprenorphine, methadone, or naltrexone prescriber. After the first two weeks, they have the option to continue with a less intensive group schedule and case management support through an Aftercare program.
223873640|NCT05768802|DEVICE|Myoelectric Implantable Recording Array (MIRA)|The Myoelectric Implantable Recording Array (MIRA) will use electromyography to detect the electrical activity of forearm muscles and transmit that information to an externally-powered prosthetic limb. The MIRA is implanted under the skin.
223873641|NCT06535789|DRUG|Inhaled Technosphere Insulin|Patients will receive TI (Afrezza) to be compared to RAA following a breakfast meal
223873642|NCT03896724|BIOLOGICAL|R21 adjuvanted with 25mcg Matrix-M|Vaccine
223873643|NCT03896724|BIOLOGICAL|Rabies Vaccine|Vaccine
223873644|NCT03896724|BIOLOGICAL|R21 adjuvanted with 50mcg Matrix-M|vaccine
223873645|NCT05474105|DIETARY_SUPPLEMENT|Oral nutritional supplement|Daily drink 125 ml together with meal
223873646|NCT06127147|DEVICE|IMT|The IMT protocol will consist of high-intensity daily training - 2 sets of 30 breaths with a 1-minute rest between sets, twice a day for 4 weeks using an IMT Threshold device (Threshold IMT Philips® Respironics, Inc). The intensity of the training will be set to 60% of each patient's maximal inspiratory pressure.
223873647|NCT06127147|DEVICE|Sham-IMT|The sham IMT protocol will consist of high-intensity daily training - 2 sets of 30 breaths with a 1-minute rest between sets, twice a day for 4 weeks using an IMT Threshold device (Threshold IMT Philips® Respironics, Inc) without intensity.
223873648|NCT06964035|PROCEDURE|Aortic valve replacement|"All operations were performed through median longitudinal sternotomy or mini-sternotomy.~8 Intraoperative transesophageal echocardiography (TOE) was used in all patients. Arterial cannulation was central and venous cannulation was achieved with a common two-stage cannula in the right atrium. Left ventricle was vented through the right superior pulmonary vein. In minimally invasive procedures, venous cannulation was achieved percutaneously. Myocardial protection was achieved by administration of cold crystalloid or blood cardioplegia at the surgeon's discretion in an antegrade (indirect or selective) or retrograde fashion. The removal of the calcified cusps and the decalcification of the annulus was performed according to traditional techniques. All the prosthesis were be implanted with supranular technique and 2-0 U-shaped pledgeted sutures."
223873649|NCT05896774|DRUG|Maplirpacept|Study drug will be administered intravenously with adjustment for body weight weekly over 28-day cycles.
223873650|NCT06013423|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223873651|NCT06013423|PROCEDURE|Bone Marrow Aspirate|Undergo bone marrow aspirate
223873652|NCT06013423|DRUG|Cyclophosphamide|Receive IV
223873653|NCT06013423|DRUG|Cyclosporine|Receive IV or PO
223873654|NCT06013423|PROCEDURE|Diagnostic Imaging|Undergo diagnostic imaging
223873655|NCT06013423|PROCEDURE|Echocardiography|Undergo ECHO
223873656|NCT06013423|DRUG|Fludarabine Phosphate|Receive IV
223873657|NCT06013423|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
223873658|NCT06013423|DRUG|Mycophenolate Mofetil|Receive IV
223873659|NCT06013423|OTHER|Survey Administration|Ancillary studies
223873660|NCT06013423|DRUG|Thiotepa|Receive IV
223873661|NCT06013423|RADIATION|Total-Body Irradiation|Undergo high-dose or middle-intensity TBI
223873662|NCT06013423|PROCEDURE|Umbilical Cord Blood Transplantation|Undergo UCBT
223873663|NCT01306864|DEVICE|Hemospray Kit|Hemostasis of Arterial GI Bleeding
223873664|NCT00126308|DEVICE|poly-L-lactic acid|immediate injections poly-L-lactic acid (4 bilateral treatments - 8 vials)
223873665|NCT00126308|DEVICE|poly-L-lactic acid|delayed (24 weeks) poly-L-lactic acid injections (4 bilateral treatment - 8 vials)
223873666|NCT03324035|DRUG|Amitriptyline|Administer amitriptyline on flexible doses variating from 25mg to 75mg, with backup of tramadol, and evaluate the reduction of the pain based on the Brief Pain Inventory Questionnaire.
223873667|NCT03324035|DRUG|Placebo oral capsule|Administer amitriptyline on flexible doses variating from 1 to 3 capsules, with backup of tramadol, and evaluate the reduction of the pain based on the Brief Pain Inventory Questionnaire.
223873668|NCT03324035|DRUG|Tramadol|"Administer to both arms on as needed scheme, to a maximum of 150mg/day."
223873669|NCT00396084|DRUG|Gatifloxacin|Gatifloxacin 400 mg/day x 7 days.
223873670|NCT00396084|DRUG|Isoniazid|Isoniazid 300 mg/day x 7 days.
223873671|NCT00396084|DRUG|Levofloxacin|Levofloxacin 1000 mg/day x 7 days.
223873672|NCT00396084|DRUG|Linezolid|Linezolid 600 mg/day x 7 days; Linezolid 600 mg every 12 hours x 7 days.
223873673|NCT00396084|DRUG|Moxifloxacin|Moxifloxacin 400 mg/day x 7 days.
223873674|NCT01502969|BIOLOGICAL|Rotavin-M1|liquid, 10e6ffu/dose, 2 doses, 2 month interval
223873675|NCT01502969|BIOLOGICAL|cell culture medium in absence of virus|Placebo
223873676|NCT01274299|PROCEDURE|Digital camera picture|A digital camera will be used to take a 3D picture the face of each infant. Off line measurements of landmarks on the face will be marked and dimensions will be calculated using a special analysis software.
223873677|NCT02502708|DRUG|Indoximod|Indoximod will be administered orally twice daily.
223873678|NCT02502708|DRUG|Temozolomide|Temozolomide will be administered on days 1-5 of every 28 day cycle.
223873679|NCT02502708|RADIATION|Conformal Radiation|Conformal radiation will be administered on days 3-7 of induction cycle.
223873680|NCT02502708|DRUG|Cyclophosphamide|Cyclophosphamide will be administered orally daily.
223873681|NCT02502708|DRUG|Etoposide|Etoposide will be administered orally daily.
223873682|NCT00035971|DRUG|raloxifene HCI and alendronate Na|
223873683|NCT05086354|BEHAVIORAL|JUMP|Warm-up, stretching, jumping rope, cool-down
223873684|NCT02708108|BEHAVIORAL|Dietary Intervention|Beginning at time of diagnosis, the dietary component of the intervention uses a personalized menu to implement high protein, moderate fat, and low glycemic index/high fiber diet to achieve a minimum net -10% daily caloric deficit during the induction phase of chemotherapy.
223873685|NCT02708108|BEHAVIORAL|Activity and Exercise Intervention|"Beginning at the time of diagnosis, the exercise and activity component uses an activity menu to implement a target level of 200 minutes per week of moderate exercise activity (as estimated by metabolic equivalents) during the induction phase of chemotherapy."
223873686|NCT03882502|OTHER|anodal transcranial direct current stimulation (tDCS)- accompanied naming therapy or sham stimulation|anodal tDCS or sham stimulation will be combined with an intensive naming training and the number of items that could be named will be assessed immediately after the intervention.
223873687|NCT03540381|OTHER|neoatherosclerosis|
223873688|NCT01703897|DEVICE|Manometry and Impedance analysis|
223873689|NCT00891436|DRUG|Fluticasone furoate nasal spray|2 sprays each nostril every morning for 2 weeks
223873690|NCT00891436|DRUG|Placebo nasal spray|2 sprays each nostril every morning for 2 weeks
223873691|NCT01697969|DRUG|Olopatadine hydrochloride ophthalmic solution, 0.2%|
223873692|NCT00386516|DRUG|GM-CT-01|GM-CT-01 at 280 mg/m2 given IV for 4 consecutive days in 28 days cycle until disease progression
223873693|NCT00386516|DRUG|5-Fluorouracil|5-FU given IV by infusion for 30, at 600 mg/m2 in combination with GM-CT-01 for 4 consecutive days in 28 days cycle until disease progression
223873694|NCT00081250|DIETARY_SUPPLEMENT|creatine monohydrate|Given orally
223873695|NCT00081250|OTHER|placebo|Given orally
223873696|NCT02655458|DRUG|Elotuzumab|"The following must also be administered before any elotuzumab:~Dexamethasone 8 mg IV (on the day of elotuzumab infusion 45-90 mins prior to the start of infusion), the following 30 - 90 minutes prior to start of infusion: H1 blocker: diphenhydramine (25 - 50 mg po or IV) or equivalent, H2 blocker: ranitidine (50 mg IV) or equivalent (adjusted for renal failure as indicated), acetaminophen (650 - 1000 mg po)."
223873697|NCT02655458|DRUG|Lenalidomide|On the days of elotuzumab administration, the dose of lenalidomide is to be administered at least 2 hours after completion of elotuzumab dosing. Aspirin 81 mg PO daily will also be prescribed for DVT prophylaxis.
223873698|NCT02655458|OTHER|autologous PBMC reconstitution|Autologous peripheral blood mononuclear cell collection and reconstitution. PBMC will be collected from patients by standard apheresis procedures. Up to 25 ml of autologous plasma will also be recovered for dilution of cryopreserved products (if necessary). For reconstitution, Patients will be pre-medicated as per each institution's standard protocols prior to reinfusion of PBMC products. Patient ID will be checked and verified by nursing staff and the products will be re-infused by continuous intravenous infusion pump. Patient vital signs will be monitored every 15 minutes for the duration of the procedure as per standard reinfusion protocol.
223873699|NCT02655458|OTHER|ASCT|"Autologous peripheral blood stem cell transplantation. (stem cells from the patient's own marrow are harvested, stored and then returned to the body (engrafted). To be done as part of standard of care."
223873700|NCT01561989|DIETARY_SUPPLEMENT|cholecalciferol|Given PO
223873701|NCT01561989|OTHER|questionnaire administration|Ancillary studies
223873702|NCT01561989|BIOLOGICAL|trivalent influenza vaccine|Given IM
223873703|NCT03135184|DEVICE|HDL Therapeutics PDS-2 System|Delipidation of plasma HDL to reduce coronary atheroma
223873704|NCT04304924|OTHER|The personalized telephone based intervention|"The personalized telephone based intervention:~1. Provide Behavioral support to facilitate lifestyle change by a weight loss coach located at a centralized call center. Participants will be paired with an individual coach who will work with the participant through all phases of the 1-year weight loss program. The behavior change program will be based on Social Cognitive Theory, which hypothesizes that the interactions between environmental, personal and behavioral elements determine behavioral change (Bandura 1989);~2. Utilize a toolbox approach that will allow for tailoring the intervention to the individual participant. Examples of possible Toolbox solutions include: alternative dietary approaches, instructions for strength-training exercises."
223873705|NCT02195297|OTHER|ANTICELLULITE GMG GIULIANI Cream and SOMATOLINE Cream|Products application: mono-laterally, once a day at evening (4 doses from each dispenser for the first 2 day-treatment and 2 doses for the following days)
223873706|NCT02346526|PROCEDURE|Blood Tests|Blood will be drawn for standard and nonstandard testing on day one, day 4, and weeks 5, 9, 13, 17, 21, 25, 37, and 93.
223873707|NCT02346526|PROCEDURE|CT scan|Standard CT scans will be carried out prior to treatment, week 9, and week 25.
223873708|NCT02346526|PROCEDURE|FACBC PET/MRI in a subset of participants|Approximately half of the study patients (n=10) will undergo experimental FACBC PET/MRI testing at 2 time points each: (1) prior to therapy, and (2) week 9.
223873709|NCT02346526|DRUG|Radium-223 dichloride|Ra-223- Each treatment cycle lasts 4 weeks during which the patient receives Ra-223 at a dose of 50 kBq/kg body weight by intravenous infusion on day 1 only. Treatments are given every 4 weeks for a total of 6 treatments.
223873710|NCT02346526|PROCEDURE|bone scan|Standard bone scans will be carried out prior to treatment, week 9, and week 25.
223873711|NCT01381406|DRUG|TIO|Patients receiving tiotropium bromide at index within the study period.
223873712|NCT01381406|DRUG|TIO+FSC|Patients receiving tiotropium bromide plus fluticasone propionate-salmeterol xinafoate combination at time of index within the study period.
223873713|NCT05575622|DEVICE|CTC PD-L1, exosomal PD-L1, and exosomal LAG-3 detection|Collect peripheral blood sample of 200 HCC patients at treatment baseline, every time point response till disease progression.Blood samples will be transferred to central lab to detect CTC PD-L1, exosomal PD-L1, and exosomal LAG-3 by microfluidic chip.Tumor response evaluation will be performed after two cycles of therapy by CT/MRI based on RECIST.Clinical data, including tumor stage,metastatic organ ,regimen, objective response, progression free survival, overall survival, etc, will be collected according to study protocol.
223873714|NCT03447249|DRUG|VX-659/TEZ/IVA|Participants received VX-659/TEZ/IVA orally once daily in the morning.
223873715|NCT03447249|DRUG|IVA|Participants received IVA orally once daily in the evening.
223873716|NCT03447249|DRUG|Placebo|Participants received placebo matched VX-659/TEZ/IVA orally once daily in the morning and placebo matched to IVA orally once daily in the evening.
223873717|NCT02818335|DRUG|LY3023414 Reference Fasted|Administered Orally
223873718|NCT02818335|DRUG|LY3023414 Test Fasted|Administered Orally
223873719|NCT02818335|DRUG|LY3023414 Test Fed|Administered Orally
223873720|NCT02405013|DRUG|Sofosbuvir|Sofosbuvir 400mg QD (Sovaldi®) in treatment-naïve patients infected with HCV genotype 2 (12-week course)
223873721|NCT02405013|DRUG|Ribavirin|Ribavirin weight-adjusted dosing (1000mg BID in patients \< 75kg and 1200mg BID in patients ≥ 75kg) in treatment-naïve patients infected with HCV genotype 2 (12-week course)
223873722|NCT02405013|DRUG|Sofosbuvir|Sofosbuvir/Ledipasvir 400mg/90mg (Harvoni®) in treatment-naïve patients infected with HCV genotype 1 or genotype 4 (12-week course)
223873723|NCT02405013|DRUG|Ledipasvir|Sofosbuvir/Ledipasvir 400mg/90mg (Harvoni®) in treatment-naïve patients infected with HCV genotype 1 or genotype 4 (12-week course)
223873724|NCT01006577|PROCEDURE|side-to-end anastomosis|Low anterior resection for rectal cancer \< 12 cm from the anal verge with total mesorectal excision (TME), ligation of the inferior mesenteric artery close to the aorta, mobilization of the splenic flexure, radical lymph node dissection and side-to-end colorectal/ coloanal anastomosis (STE). The blind end of the descending colon (3-5 cm long) is closed with a linear stapler. Stapling of the anastomosis is done by introducing the stapler from the anus by the assistant surgeon while the surgeon is holding the descending colon in the correct position. The anastomosis is performed on the antimesenteric aspect of the descending colon. The length of the blind end is measured and the integrity of the anastomosis is tested intraoperatively. The intended minimal distal clearance margin from the tumor is 2 cm. A protective loop ileostomy will be performed regularly which is intended to be closed 3 months postoperatively.
223873725|NCT01006577|PROCEDURE|colon j pouch|Low anterior resection for rectal cancer with total mesorectal excision (TME), ligation of the inferior mesenteric artery close to the aorta, mobilization of the splenic flexure, radical lymph node dissection and colon J pouch rectal/colon J pouch anal anastomosis (CJP). The colon J Pouch is formed by the descending colon by stapling with a defined pouch limb length of 5-6 cm, which is measured intraoperatively. The stapling is done by introducing the stapler from the anus by the assistant surgeon while the surgeon is holding the descending colon in the correct position. The integrity of the anastomosis is tested intraoperatively. The intended minimal distal clearance margin from the tumor is 2 cm. A protective loop ileostomy will be performed regularly which is intended to be closed 3 months postoperatively.
223873726|NCT01248936|DRUG|RO5185426|
223873727|NCT00663624|DRUG|aspart insulin|subcutaneous aspart insulin every 2 hours
223873728|NCT00663624|DRUG|Usual care as prescribed by the ED physicians.|Usual care can be oral anti-diabetic agents, subcutaneous insulin therapy or a combination of both. Subcutaneous insulin used for usual care could include NPH, 70/30 insulin, aspart insulin, regular insulin or insulin glargine
223873729|NCT05933213|DRUG|Mescaline sodium enteric-coated tablets|Induction period: orally, twice a day, at 720-1440 mg/d； Maintenance period: orally, twice a day, 360-540mg/d
223873730|NCT05933213|DRUG|Morte-mescaline|Induction period: orally, twice a day, 1-2 g/d; Maintenance period: orally, twice a day, 0.5-0.75 g/d
223873731|NCT05933213|DRUG|Glucocorticoids|glucocorticoids
223873732|NCT06514937|BEHAVIORAL|Emotional Training|Emotional Training Therapy following the programme in the computer
223873733|NCT04854772|BEHAVIORAL|Mind Body Syndrome Therapy for Long Covid|The intervention consists of a mind-body based intervention for the COVID long haul syndrome. The components of the intervention include knowledge therapy, desensitization, emotional expression, and stress reduction techniques.
223873734|NCT04556981|BIOLOGICAL|M72/AS01E Mycobacterium tuberculosis vaccine|Participants will receive an intramuscular dose of M72 (10 micrograms of recombinant fusion protein) reconstituted with AS01E (an adjuvant system), on Day 1 and Day 29
223873735|NCT04556981|BIOLOGICAL|Placebo|Participants will receive an intramuscular dose of saline (0.9% NaCl), on Day 1 and Day 29
223873736|NCT00144066|DRUG|platinum-based chemotherapy alone (up to six cycles)|
223873737|NCT00144066|DRUG|platinum-based chemotherapy followed by maintenance therapy with gefitinib|
223873738|NCT03079817|OTHER|Yoga Meditation|Yoga meditation using motor imagery to perceive movement patterns
223873739|NCT03079817|OTHER|Proprioceptive Drills|Active balance and proprioception drills
223873740|NCT05712694|DRUG|ADI PEG20|Treatment for advanced or metastatic uterine/non-uterine leiomyosarcoma (LMS)
223873741|NCT05712694|OTHER|Placebo|Treatment for advanced or metastatic uterine/non-uterine leiomyosarcoma (LMS)
223873742|NCT01750866|DRUG|Cabazitaxel|Cabazitaxel 25 mg/m2 will be administered by intravenous infusion over 1 hour on Day 1 of every 21-day cycle.
223873743|NCT01750866|DRUG|Prednisone|Prednisone 10 mg on Day 1 of the first cycle and continue taking 10 mg po daily for the entire cycle.
223873744|NCT01750866|DRUG|Granulocyte colony-stimulating factor (G-CSF)|Granulocyte colony stimulating factor (Neulasta 6 mg sc) with each cycle, starting with the first cycle, to minimize the risk of complications from neutropenia.
223873745|NCT01388361|DRUG|insulin degludec|Injected s.c. (under the skin) once daily. The doses will be individually adjusted
223873746|NCT01388361|DRUG|insulin aspart|Injected s.c. (under the skin) once daily. The doses will be individually adjusted.
223873747|NCT01388361|DRUG|liraglutide|Injected s.c. (under the skin) once daily. The doses will be individually adjusted.
223873748|NCT05320666|BEHAVIORAL|Yes You Can…Make Smart Choices! (YYC…MSC!) program|The YYC…MSC! is an 11-lesson curriculum that will be delivered to 9th graders in Newark, New Jersey public schools during 40-minute health classes. The curriculum will be delivered in-person over approximately 2 weeks by NJPAG educators. The goal of the program is to prevent teen pregnancy and enhance character development in youth. Each time an NJPAG educator is in the classroom, they will deliver a single lesson of the curriculum. All NJPAG educators have received internal training for the program. The intervention addresses the following adult preparation subjects: parent-child communication, healthy relationships, healthy life skills, adolescent development, and financial literacy.
223873749|NCT01803139|DEVICE|Adjuvant breast radiotherapy|Adjuvant radiotherapy delivering 50 Gy in 25 treatments, with an additional boost dose of 16 Gy at the discretion of the radiation oncologist.
223873750|NCT03571711|DRUG|Meropenem Injection|Meropenem is administered as prescribed by treating physician
223873751|NCT04835181|BEHAVIORAL|Electroacupuncture combined with umbilical moxibustion|"①Umbilical moxibustion intervention: point selection: Shenque point Operation: Place the aconite cake on the Shenque point, place the Aizhu in the middle of the aconite cake, ignite the Aizhu and apply moxibustion to make the local warm sensation without burning pain, until the skin is flushed.~②Electro-acupuncture intervention: Acupoint selection: Tianshu, Zusanli, Zhongwan, Moisture, Daheng, Vein, Waterway, Huaroumen, Abdominal Knot.~Operation: supine position, routine skin disinfection. After routine acupuncture at the acupoints, apply the technique of flattening, replenishing, relieving, and relieving qi. Tianshu and Daheng points, respectively, were horizontally connected to the electrodes of the electroacupuncture instrument on the needle handles of the bilateral Tianshu and Daheng points.~Electroacupuncture parameters: density wave, current intensity 1-5mA, electroacupuncture intensity is subject to patient tolerance."
223873752|NCT04835181|BEHAVIORAL|Electroacupuncture|"②Electro-acupuncture intervention: Acupoint selection: Tianshu, Zusanli, Zhongwan, Moisture, Daheng, Vein, Waterway, Huaroumen, Abdominal Knot.~Operation: supine position, routine skin disinfection. After routine acupuncture at the acupoints, apply the technique of flattening, replenishing, relieving, and relieving qi. Tianshu and Daheng points, respectively, were horizontally connected to the electrodes of the electroacupuncture instrument on the needle handles of the bilateral Tianshu and Daheng points.~Electroacupuncture parameters: density wave, current intensity 1-5mA, electroacupuncture intensity is subject to patient tolerance."
223873753|NCT06057116|OTHER|massage|Massage and acupressure were applied when cervical dilatation was 3-4, 5-7 and 8-10 cm in latent active and transitional phases.
223873754|NCT03481608|OTHER|Lauric acid (coconut oil)|A breakfast shake made from a complete meal shake will be prepared with water and supplemented with 2 tablespoons of coconut oil.
223873755|NCT03481608|OTHER|No Lauric acid (olive oil)|A breakfast shake made from a complete meal shake will be prepared with water and supplemented with 2 tablespoons of olive oil.
223873756|NCT00355095|DRUG|Erythropoietin|intravenous daily 3.3 \*10\^4 Units, duration 3 days
223873757|NCT01061034|DRUG|aspirin and omeprazole|aspirin 100 mg, once daily aspirin 100 mg and omeprazole 20 mg both once daily.
223873758|NCT00068601|DRUG|cyclophosphamide|Part of planned chemotherapy regimen
223873759|NCT00068601|DRUG|goserelin acetate|Given subcutaneously
223873760|NCT00519389|BIOLOGICAL|H5N1 VLP Vaccine|Two doses - Day 0 \& Day 28
223873761|NCT00519389|BIOLOGICAL|Placebo|Two doses - Day 0 \& Day 28
223873762|NCT06301204|DRUG|Tranexamic acid injection|tranexamic acid administration 250mg or 500 mg
223873763|NCT06301204|DRUG|Saline|onyl ıv saline (NaCl 0.09%)
223873764|NCT03429972|DEVICE|Elasto-Gel™|Elasto-Gel™ hypothermia mitts and slippers contain glycerine, which has thermal properties, allowing use for cold therapies.
223873765|NCT03429972|DRUG|Paclitaxel|80mg/m\^2 of Paclitaxel is administered by infusion for 60 mins once a week, for a total of 12 cycles
223873766|NCT00440011|DRUG|bimatoprost 0.03% eye drops|bimatoprost 0.03% 1 drop nightly for 3 months
223873767|NCT00440011|DRUG|travoprost 0.004% eye drops|travoprost 0.004% 1 drop nightly for 3 months
223873768|NCT05487118|DEVICE|Placebo PBMT + MCE|Placebo PBMT will be irradiated at 4 sites in the lumbar region and 6 sites in the patient's abdominal region, without any emission of therapeutic dose. After, the patient will be submitted to a MCE protocol consisting on stabilization exercises and isometric abdominal training. The treatment will be performed twice a week (on non-consecutive days), for 6 weeks, yielding 12 treatment sessions.
223873769|NCT05487118|DEVICE|Active PBMT + MCE|Active PBMT will be irradiated at 4 sites in the lumbar region and 6 sites in the patient's abdominal region, with a dose of 30 J per site. After, the patient will be submitted to a MCE protocol consisting on stabilization exercises and isometric abdominal training. The treatment will be performed twice a week (on non-consecutive days), for 6 weeks, yielding 12 treatment sessions.
223873770|NCT03741517|RADIATION|18F-FDG-PET|Fludeoxyglucose F18
223873771|NCT03741517|RADIATION|68Ga-DOTATOC-PET|DOTA-tyr3-Octreotide Ga68
223873772|NCT03741517|RADIATION|Computed tomography|Computed tomography of thorax and abdomen with 3-phase contrast
223873773|NCT03741517|OTHER|Core needle biopsy|Core needle biopsy of metastatic lesions
223873774|NCT03741517|OTHER|Phlebotomy|Phlebotomy from peripheral vein
223873775|NCT02035670|OTHER|Two-step diagnostic strategy|"The first step is to differentiate FUO according to the onset of disease and invasive pathogens. Apart from collecting detailed present medical history and careful physical examination, it focuses on seeking the clues of bacterial invasion two weeks before the fever onset from five aspects.To finish this part, the doctor needs to ask for informations following a list we already made, which covers more than forty definite items. If some of these items were proved existed, result of first step would be positive.~The second step is calculating the integral score of inflammatory biomarkers and vital diagnostic clues, WBC\& N, ESR, CRP, LDH, SF, ANCA, ANA, RF, PCT and T-Spot, as well as the clinical findings were included in this integrating system.The results of these items will be recorded and calculated with certain interval of time. If the score were more than nine, this part would be considered. positive."
223873776|NCT01506934|DRUG|linifanib|"Single Dose on Day 1 of Periods 1, 2 and 3 (Bioavailability Portion)~Single Dose on Day 1 of Periods 1 and 2 (Food Effect Portion)"
223873777|NCT03208491|OTHER|serious games use|This program has enabled several SGs to be developed that allow physical and cognitive workouts to be carried out with a therapist
223873778|NCT03208491|OTHER|usual care|usual care of patient
223873779|NCT00004387|PROCEDURE|fetal nigral transplantation|
223873780|NCT05207241|OTHER|provides guidance on gravitationally assisted breastfeeding|Prior to the first breastfeeding after delivery, the guidance of gravitationally assisted breastfeeding will be provided. The primary breastfeeding position is advised to be the sitting position, supplemented by the lateral position with a time ratio of 4:1. The following guidance will also be given: (1) participating women breastfeed individually without using a breast pump; (2) massage their breasts 4 times a day for 15 minutes each time; (3) breastfeeding time is scientifically matched with infant's schedule; (4) alternative breastfeed, ensuring emptying one breast within 24 hours. Doctors follow up once a month via WeChat. Participants complete the questionnaires. A breast ultrasound will be performed every three months. The infant weight will be measured and recorded 6 months after breastfeeding.
223873781|NCT02837497|OTHER|ICU-RESUS CPR Improvement Bundle|"1. Point-of-care CPR training~2. Post-cardiac arrest educational debriefings"
223873782|NCT05272046|PROCEDURE|Per-oral Endoscopic Myotomy|Therapeutic endoscopy procedure by means of electrocautery surgical tools for treatment of various esophageal conditions such as achalasia or spastic esophageal disorders.
223873783|NCT05272046|DEVICE|Speedboat (Bipolar electrocautery knife)|Use of Creo Medical's Speedboat RS2 knife and generator in performing the POEM procedure for patients presenting with an esophageal motility disorder.
223873784|NCT04507945|DRUG|Nutritional Therapy, Metabolic Disorder, Regular|According to the result reported by Byrne, Wilmore, etc. in 1992 \~ 1995, the use of growth hormone, glutamine, modified diet and other measures proposed intestinal rehabilitation treatment. Then, check the patient's quality of life survey, nutritional status, inflammation indicators and other changes every three months, and use metabolomics and microbiomic tools to detect changes in the patient's nutritional metabolism, intestinal microecology, etc., and adjust the patient's nutritional treatment and microecological treatment based on the results Program.
223873785|NCT02845050|DRUG|Vinflunine|"One cycle is defined as a period of 3 weeks of treatment:~Vinflunine (280 mg/m²) on Day 1, every 21 days as a 20 minute IV infusion~Cisplatin (70 mg/m²) on Day 2, every 21 days~4 cycles of neo-adjuvant chemotherapy prior to radical cystectomy"
223873786|NCT02845050|DRUG|Cisplatin|"One cycle is defined as a period of 3 weeks of treatment:~Vinflunine (280 mg/m²) on Day 1, every 21 days as a 20 minute IV infusion~Cisplatin (70 mg/m²) on Day 2, every 21 days~4 cycles of neo-adjuvant chemotherapy prior to radical cystectomy"
223873787|NCT02845050|PROCEDURE|Radical cystectomy|max. 4 weeks after 4 cycles of neo-adjuvant treatment radical cystectomy will be performed
223873788|NCT04465734|DRUG|HLX10|HLX10 is an innovative monoclonal antibody targeting PD-1，developed by Shanghai Henlius Biotech, Inc.
223873789|NCT04465734|DRUG|HLX04|HLX04 is an recombinant anti-VEGF humanized monoclonal antibody ，developed by Shanghai Henlius Biotech, Inc.
223873790|NCT04465734|DRUG|Sorafenib|Sorafenib is a multi-target, multi-kinase inhibitor capable.The standard treatment of HCC.
223873791|NCT02615210|DEVICE|SOC-directed biopsies using the SpyGlass System|The cholangioscopy procedure with the SpyGlass System is performed by a single operator with the SpyScope Access and Delivery Catheter positioned just below the operating channel of the duodenoscope. SpyBite Biopsy Forceps guided by the SpyScope Catheter are introduced and endoscopic-guided biopsy is taken at the level of the stricture. Target lesions will be identified under direct visualization using the SOC system, and 6-8 bites will be performed with the SpyBite forceps. Once SOC-directed biopsies are obtained, the SOC system will be withdrawn into the working channel of the duodenoscope and removed Patient will be contacted monthly to determine if they have undergone any additional procedures and to record potential adverse events.
223873792|NCT05904925|OTHER|Pilates exercises|Sessions will last 60 minutes: five minutes for warming up, 50 minutes for the practice of Pilates exercises, and five minutes for relaxing with the Swiss ball. The exercise protocol will be divided into three gestational phases, covering the entire gestational period, with different and specific objectives for each phase. In all phases, the exercises will be classified into three levels of difficulty: basic, intermediate, and advanced, according to the evolution of each pregnant woman throughout the practice of Pilates. Modifications will be allowed to facilitate or hinder the execution of the movement. The exercises will be performed in one or two sets of seven to 10 repetitions. The number of series, repetitions and exercises and interval time between them, as well as the level of difficulty of the exercises, will be gradually adjusted. The intensity of the exercises will vary between light and moderate and will be controlled by the Borg scale.
223873793|NCT03359889|DRUG|PraxbindTM|Drug
223873794|NCT03837431|DIAGNOSTIC_TEST|Skin slit|Skin slit microscopy, RDT and PCR
223873795|NCT03837431|DIAGNOSTIC_TEST|Dental broach|Dental broach RDT and PCR
223873796|NCT03837431|DIAGNOSTIC_TEST|Tape disc|Tape disc PCR
223873797|NCT05593159|OTHER|Dentin Conditioning|After washing and drying -but not desiccating- Dentin Conditioner 20% (GC, Japan) will be applied using a cotton pellet for 20 seconds then rinsed thoroughly and gently dried
223873798|NCT05593159|OTHER|RM-GIC|RM-GIC (Fuji II LC) will be applied in \<2mm incremental layers afterword light-cured for 10 sec (1,000 mW/cm2) per increment to fill the cavity.
223873799|NCT05593159|OTHER|1-step adhesive|A universal adhesive system (Tetric® N-Bond Universal) will be applied on both enamel and dentin and gently scraped for 20 sec, then dispersed with oil-free gentle air stream, then light-cured for 10 sec (1,000 mW/cm2).
223873800|NCT05593159|OTHER|Cention N|The cavity will be restored using cention N followed by light curing for 10sec (1,000 mW/cm2)
223873801|NCT05593159|OTHER|Dentin roughness|Using a round carbide bur size 14/16, (H1SEM.204.014 VPE5 or H1SEM.204.016 VPE 5, Komet Dental, Lemgo, Germany) on a low-speed handpiece. (No bevel preparation will be made)
223873802|NCT05593159|OTHER|Gingival retentive groove preparation|Using size-010 round carbide bur (H1SEM.205.010 VPE 5, Komet Dental, Lemgo, Germany) on a low-speed handpiece.
223873803|NCT00344994|DRUG|pramipexole|PO, 0.25mg, 0.50mg, or 0.75mg QHS
223873804|NCT05486897|OTHER|None, pure observational study|None, pure observational study
223873805|NCT05345951|BEHAVIORAL|e-PBI+|The e-PBI+ is a preventive parent-based intervention emphasizing parent-teen communication on drinking/risks of alcohol abuse, with the addition of data-driven cannabis content to guide parent communications with their students (e.g., cannabis content focusing on the endocannabinoid system; acute and chronic cannabis use effects on the brain, cognition, and development; THC potency in present-day cannabis; cannabis use effects on mental and physical health, including psychosis, depression, and anxiety; respiratory/cardiovascular/sleep problems; cannabidiol (CBD) content, myths; and cannabis effects on psychosocial function). Together the goals are to reduce alcohol and cannabis use in college students.
223873806|NCT05345951|BEHAVIORAL|e-PBI|"The e-PBI is currently a model prevention resource at NIAAA's College Alcohol Intervention Matrix and the research was discussed in the most recent Surgeon General's Report as one of two prevention approaches that met the rigorous criteria to be considered efficacious. The first section of the e-PBI provides an introduction to the problem of substance use. The second section focuses on specific skill building strategies that parents can use to improve communication channels with their teen. Third is a section that addresses peer influence and provides strategies for developing assertiveness. The fourth section is an in-depth discussion of underage drinking, physiological and psychological effects, mixing alcohol with other drugs, motives for why students drink and don't drink, warning signs, risky binge-type drinking, impaired driving, riding with impaired drivers, alcohol and sexual assault, and how to communicate about parents' experiences when they were young."
223873807|NCT03435770|DEVICE|EUSRA RFA needle|A 19-gauge RFA electrode and a RF generator with a electrode that is needle-shaped and echogenic that allows EUS guided puncture of the target lesion. The active electrode tip is 1 cm in length. During ablation, the RF electrode is cooled and perfused internally with circulating chilled saline solution (0°C) delivered via a pump to maintain a constant temperature. A setting of 50W energy would be used for RFA and the duration of application is 10 seconds. Sequential applications of up to 7 times per session are allowed for complete ablation of the lesions.
223873808|NCT02336386|DRUG|CDD|Chemotherapy
223873809|NCT02336386|DRUG|CDD Plus Bortezomib|Chemotherapy plus Proteasome Inhibitors
223873810|NCT00969137|DRUG|saline|intravenous saline
223873811|NCT00969137|DRUG|Nicotine|Intravenous nicotine
223873812|NCT01323231|BEHAVIORAL|XY-Zone|"The XY-Zone works to empower students to decrease risk factors and increase protective factors through three linear treatment steps. The first step is driven by guiding principles known as the five R's: respect, responsibility, relationship, role modeling, and reaching out. Through these principles, the participant explores healthy psychosocial behaviors and thoughts in a structured 10 session group setting. The leadership step builds upon the guiding principles and employs activities exploring true leadership through 10 sessions. During the leadership step, participants organize and carry out a service learning projects in their community. The third and final step is ambassador. Those in the ambassador step become a mentor to those in step one and are expected to explore the principles of leadership and the five R's, and determine their personal relevance to their lives as young men (Allen, 2009, p. i)."
223873813|NCT01361945|DRUG|AUY922|AUY 922 is given intravenously weekly; letrozole and lapatinib are given orally
223873814|NCT04985136|DRUG|camrelizumab；Rivoceranib|Camrelizumab at 200 mg via intravenous administration (IV), once every 2 weeks (Q2W), in combination with 250 mg of rivoceranib mesylate, oral administration, once a day (QD)
223873815|NCT04985136|DRUG|Rivoceranib|Rivoceranib mesylate (750 mg, QD, po)
223873816|NCT04985136|DRUG|Sorafenib|Sorafenib tosylate (400 mg, twice a day (BID), po)
223873817|NCT04985136|DRUG|Regorafenib|Regorafenib (160 mg, administer for 21 days then stop for 7 days, po)
223873818|NCT03641703|BIOLOGICAL|FLT180a|FLT180a is a replication-incompetent adeno-associated viral vector. The vector is composed of a DNA vector genome encapsidated in an adeno-associated virus derived protein capsid. The expression cassette contains DNA encoding Factor IX.
223873819|NCT04585412|DRUG|Palonosetron|Pharmacokinetic study under fasting conditions
223873820|NCT04292132|PROCEDURE|Implant placement|interforaminal placement of 2 implants
223873821|NCT04292132|PROCEDURE|immediate loading|immediate loading with a locator retained mandibular overdenture
223873822|NCT04292132|PROCEDURE|conventional loading|conventional loading with a locator retained mandibular overdenture 3 months postoperatively
223873823|NCT00616668|DEVICE|Air- Limb|
223873824|NCT04380467|DIETARY_SUPPLEMENT|Vitamin D (cholecalciferol)|(aviticol) 5x 20,000unit capsules administered monthly over 20 weeks
223873825|NCT01000597|DRUG|fluticasone furoate|"Seven inhaled doses of 200mcg FF given once daily in the morning (Part A; Days 1-7) followed by seven inhaled doses of 800mcg FF given once daily in the morning (Part B; Day 1 and Days 3-8, i.e. no dose on Day 2).~A single intravenous dose of 250mcg FF given over 20 minutes (Day 1)."
223873826|NCT04820361|DRUG|Cannabis sativa L., folium cum flore|Muscle Relaxation
223873827|NCT04820361|DRUG|Placebo|Muscle Relaxation
223873828|NCT02283242|DRUG|Galantamine|Oral use for 12 weeks
223873829|NCT02283242|DRUG|Placebo (for galantamine)|Oral use for 12 weeks
223873830|NCT00160914|BEHAVIORAL|Identification/management of childhood obesity (behavior)|In this project, we plan to conduct a national survey of pediatricians to assess common strategies for identification and management of childhood obesity, along with pediatricians' attitudes and beliefs about childhood obesity.
223873831|NCT01803555|DRUG|Budesonide/Formoterol SPIROMAX®|BF Spiromax will be administered per dose and schedule specified in the arm.
223873832|NCT01803555|DRUG|SYMBICORT® TURBOHALER®|Symbicort Turbohaler will be administered per dose and schedule specified in the arm.
223873833|NCT01803555|DRUG|SYMBICORT placebo|SYMBICORT placebo multi-dose dry powder inhaler (DPI) identical in appearance to SYMBICORT TURBOHALER will be administered per dose and schedule specified in the arm.
223873834|NCT01803555|DRUG|SPIROMAX Placebo|SPIROMAX Placebo multi-dose dry powder inhaler (DPI) identical in appearance to BF SPIROMAX will be administered per dose and schedule specified in the arm.
223873835|NCT01457612|DIETARY_SUPPLEMENT|Strawberry|20g twice per day (BID) in beverage
223873836|NCT01457612|DIETARY_SUPPLEMENT|Placebo1|Placebo Beverage 1 without fiber
223873837|NCT01457612|DIETARY_SUPPLEMENT|Placebo2|Placebo Beverage 2 with Fiber
223873838|NCT04912791|PROCEDURE|Obstetric anesthesia and analgesia|All anesthesia procedures during labor: labor analgesia, anesthesia for Cesarean section, anesthesia for procedures in third stage of labor
223873839|NCT05485389|OTHER|simulation based learning|An educational methodology that aims to improve participants' attitudes towards the elderly and their perception of individualized care.
223873840|NCT05684354|OTHER|Patient Reported Outcomes (PROs)|"The day before or the morning before surgery, the patient filled the first QoR-15 scale alone or could be helped by one of the investigators in case of questions or difficulties.~The second QoR-15 scale was distributed the day before or the day of discharge from the hospital"
223873841|NCT01551355|BEHAVIORAL|Children-Multicomponent intervention|"The intervened children were provided classroom educational and playful activities during 5 months, which included Sesame Workshop Healthy Habits storybooks, posters, videos, games, and songs (1 hour daily); a Healthy family day workshop (1 hour); and weekly health notes. Parents participated in 3 workshops and weekly notes containing positive health messages about nutrition and active lifestyles to share with their children. Teachers also participated in 3 centralized training sessions, plus personalized working sessions with a research supervisor (2 hours every 15 days), and received a teacher's guide."
223873842|NCT01925339|DEVICE|Test (immediate restoration)|Test (immediate restoration)
223873843|NCT01925339|DEVICE|Control: delayed restoration|Control: delayed restoration
223873844|NCT05957653|DRUG|lidocaine and sufentanil|A total of 20ml of 2% lidocaine and 1μg/ml sufentanil was injected into the bladder through the catheter.
223873845|NCT05957653|DRUG|Saline|A total of 20ml normal saline was injected into the bladder through the catheter.
223873846|NCT01538719|DRUG|Rilonacept|Patients randomized to active study drug will receive Rilonacept 320 mg subcutaneously (SQ) on day 0 and 160 mg SQ each week for 5 additional weeks
223873847|NCT01538719|OTHER|Placebo|Patients randomized to placebo will receive saline subcutaneously (SQ) on day 0 and each week for 5 additional weeks
223873848|NCT05623553|DEVICE|Picterus Jaundice Pro|Use Picterus Jaundice Pro, a smartphone app that is used to take photo of the newborns skin, where the Picterus calibration card is place.
223873849|NCT06014216|OTHER|Flavoured ice lollies (popsicles)|Blackcurrant flavoured ice popsicles, 105ml volume.
223873850|NCT06014216|OTHER|Water|Water from tap, one cup given by recovery nurses.
223873851|NCT00645034|DRUG|placebo|placebo by mouth as a single dose
223873852|NCT00645034|DRUG|sildenafil|sildenafil 100 mg by mouth as a single dose
223873853|NCT01030107|BEHAVIORAL|Increase Sleep|Children are asked to increase their sleep by approximately 1 1/2 hours/night for 1 week.
223873854|NCT01030107|BEHAVIORAL|Decrease Sleep|Children are asked to decrease their sleep by approximately 1 1/2 hours/night.
223873855|NCT03664960|DRUG|AK002|AK002 is a humanized non-fucosylated immunoglobulin G1 (IgG1) monoclonal antibody directed against Siglec-8.
223873856|NCT06394375|DRUG|Dexmedetomidine|OFA
223873857|NCT06394375|DRUG|Fentanyl|Given as analgesia in opioid balanced anesthesia (control) group
223873858|NCT04761536|OTHER|Rectal cancer case centralization|In November 2016, the decision to centralize rectal cancer patients to only one surgical unit was taken, with only two surgeons performing the procedures. Furthermore, a close collaboration with local Gastroenterology Units and General Practiotioners was started in order to increase colorectal cancer case referral to our unit. At the same time, we decided to promote the use of laparoscopy and to implement ERAS protocol in our colorectal surgery practice.
223873859|NCT05729997|OTHER|Listening to live classical music|The group of musicians perform music in the hemodialysis room while patients receive treatment.
223873860|NCT03401138|OTHER|Preoperative Stroke Volume(SV)-guided fluid optimization|"Preoperative SV-guided hemodynamic optimization will be commenced with patients receiving 250ml fluid challenges over five minutes aiming to maximize SV. Maximal SV is defined as absence of a sustained rise in SV by at least 10% in response to a fluid challenge.~PPI will be obtained from the Masimo Radical 7 (Masimo, Irvine, CA, USA) and NIRS from Invos 5100C (Medtronic, Minneapolis, MN, USA).~BV measurements will use pulse dye densitometry (PDD) with Indocyanine Green (ICG). We will use the Dye Densitogram 3300 analyser Nihon Kohden (Tokyo, Japan) for registration of the spectrophotometrical absorption of ICG and calculation of BV."
223873861|NCT01616888|DEVICE|PTA with drug eluting balloon with paclitaxel|Angioplasty with drug eluting balloon with paclitaxel on femoropopliteal arteries
223873862|NCT05054920|OTHER|concentric exercises|concentric exercises for rotator cuff. internal rotators, external rotators and abductors Patient will do 3 sets of 10 repetitions resistance will be personalized to each patients
223873863|NCT05054920|OTHER|eccentric exercises|Eccentric exercises exercises for rotator cuff internal rotators, external rotators and abductors Patient will do 3 sets of 10 repetitions resistance will be personalized to each patients
223873864|NCT05054920|OTHER|Stretching|stretching exercise for posterior capsule and pectoralis minor each stretch will be done for 30 seconds and repeated 3 times
223873865|NCT03151655|BEHAVIORAL|MATTeRS Video|Narrative-based video intervention and accompanying workbook
223873866|NCT03151655|BEHAVIORAL|Didactic Video|Education only video
223873867|NCT05527717|PROCEDURE|Culprit lesion only PCI|"Randomization will be done after coronary angiography before or during primary PCI for IRA. Patients will be randomized to either immediate multi-vesesl PCI group or culprit-lesion only PCI group with 1:1 ratio.~This group will be taken culprit-lesion only PCI during primary PCI."
223873868|NCT05527717|PROCEDURE|Immediate multi-vessel PCI|"Randomization will be done after coronary angiography before or during primary PCI for IRA. Patients will be randomized to either immediate multi-vesesl PCI group or culprit-lesion only PCI group with 1:1 ratio.~This group will be taken immediate multi-vesesl PCI during primary PCI."
223873869|NCT03647423|BIOLOGICAL|Aldoxorubicin Hydrochloride|Aldoxorubicin Hydrochloride HCI
223873870|NCT03647423|BIOLOGICAL|ALT-803|Recombinant human super agonist interleukin-15 (IL-15) complex
223873871|NCT03647423|BIOLOGICAL|ETBX-051|Ad5 \[E1-, E2b-\]-Brachyury
223873872|NCT03647423|BIOLOGICAL|ETBX-061|Ad5 \[E1-, E2b-\]-mucin 1 \[MUC1\]
223873873|NCT03647423|BIOLOGICAL|GI-6301|Brachyury yeast
223873874|NCT03647423|BIOLOGICAL|haNK|haNK™, NK-92 \[CD16.158V, ER IL-2\]
223873875|NCT03647423|DRUG|Avelumab|injection
223873876|NCT03647423|DRUG|Cetuximab|Injection
223873877|NCT03647423|DRUG|Cyclophosphamide|Capsules
223873878|NCT03647423|RADIATION|SBRT|Stereotactic body radiation therapy
223873879|NCT05436639|DRUG|SPI-62 dose|SPI-62 is an 11β hydroxysteroid dehydrogenase type 1 (HSD-1) inhibitor, supplied as oral tablets for dose 2 of drug (2mg).
223873880|NCT03479515|DEVICE|Ultrasound|Ultrasound, ADP, bioimpedance measurements
223873881|NCT06254040|DIETARY_SUPPLEMENT|Placebo|Each participant will consume 1 dissolving powder pack per day diluted in water, with breakfast, without any restriction in the diet or in their life habits.
223873882|NCT06254040|DIETARY_SUPPLEMENT|mixture of extracts and DHA|Each participant will consume 1 dissolving powder pack per day diluted in water, with breakfast, without any restriction in the diet or in their life habits.
223873883|NCT06513338|DRUG|Eculizumab|eculizumab 900mg iv. per week for 4 weeks, then 1200mg every two weeks for week 5 to. week 11
223873884|NCT04610853|DIAGNOSTIC_TEST|rotational thromboelastometry|ROTEM will be conducted and DIC score calculated within 24 hours after the diagnosis of Sepsis as well as on day 3 and 5 of ICU stay
223873885|NCT05000021|BEHAVIORAL|Cognitive Behavioral Therapy for Diabetes Distress (CBT-DD) with Continuous Glucose Monitoring|CBT-DD consists of approximately 10 individual sessions of CBT delivered virtually by trained protocol therapists, conducted over the course of approximately 12 weeks. The CBT-DD consists of 5 core modules targeting negative emotionality and aversive reactions to emotional experiences. These modules are preceded by an introductory session that reviews the patient's presenting symptoms and provides a therapeutic rationale, as well as a module on motivational enhancement. The final module consists of relapse prevention. CBT-DD sessions will integrate a review of Continuous Glucose Monitoring (CGM) data and feedback will be provided by the therapist.
223873886|NCT05000021|DEVICE|Continuous Glucose Monitoring (CGM)|Use of commercially available, FDA-approved continuous glucose monitoring (CGM) for 6 months post-randomization. Usual diabetes care will continue and participants can initiate a CGM review from their healthcare providers, as desired. In addition, a nurse practitioner with expertise in CGM will train each participant via video recordings in the proper placement of the device, and technical issues, and provide basic teaching at the beginning of the trial on interpretation of CGM data and self-titration of insulin/self-management. Written materials and online resources for recognizing and managing diabetes distress, along with self-management information and treatment options to discuss with providers will also be provided.
223873887|NCT04385940|DIETARY_SUPPLEMENT|Ddrops® products, 50,000 IU, Oral|Vitamin D3
223873888|NCT04385940|DIETARY_SUPPLEMENT|Vitamin D3|Vitamin D3 1000IU
223873889|NCT05588414|PROCEDURE|Standardization of the sentinel node detection procedure|All patients included in the study underwent the same pre- and intra-operative procedure, consisting of a double systematic sentinel node detection, using sequential ICG and isotopic technique. The patient is his own control for the analysis of the performance of the ICG technique alone compared to the combined ICG and isotopic technique.
223873890|NCT06282770|DEVICE|Laser Diode Brace|The device is a brace with laser diodes. The braces light up and the red light has therapeutic abilities.
223873891|NCT06282770|DEVICE|Sham Laser Diode Brace|The Sham brace has no therapeutic ability and will act as a placebo.
223873892|NCT03207594|OTHER|Survey|Subjects will be asked to complete a survey asking questions about his/her current health, well-being and quality of life.
223873893|NCT03207594|OTHER|Saliva sample|Subjects will have saliva collected by a member of the study team using a cotton swab.
223873894|NCT03207594|OTHER|Smoking Status questions|Subjects will be asked to complete an assessment asking questions about his/her current smoking status
223873895|NCT03716830|DEVICE|verum acupuncture|Participants will receive real acupuncture treatment.
223873896|NCT03716830|DEVICE|sham acupuncture|Participants will receive sham acupuncture treatment.
223873897|NCT03716830|DEVICE|real tDCS|Participants will receive real transcranial direct current stimulation.
223873898|NCT03716830|DEVICE|sham tDCS|Participants will receive sham transcranial direct current stimulation.
223873899|NCT02992015|DRUG|Gemcitabine|Participants receive a one time IV dose of gemcitabine prior to having standard of care surgery.
223873900|NCT04246203|OTHER|Liquid Biopsy|17-20 ml of blood will be collected prior of surgery and within 14 days before start of adjuvant chemotherapy.
223873901|NCT04922021|DRUG|LEO 138559|LEO 138559 is an antibody given by injection just under the skin.
223873902|NCT04922021|DRUG|LEO 138559 placebo|LEO 138559 placebo is given by injection just under the skin. LEO 138559 placebo contains the same excipients in the same concentration as LEO 138559, except for the medical ingredient LEO 138559.
223873903|NCT06835517|BEHAVIORAL|Theory of Dissonance|The design of this intervention will consist of presenting information that generates dissonance with the subjects' attitudes and beliefs about clinical errors. Dissonance will be intensified by experiential experiences through simulations that provide compelling information that supports the idea of accepting honest errors as learning opportunities within the framework of a Just Culture.
223873904|NCT06835517|BEHAVIORAL|Theory of Reasoned Action|"The intervention will consist of the presentation, to the different groups, of testimonies, narratives, statements and analysis of everyday clinical practice situations that promote a change in the so-called subjective norms (a person's beliefs about whether significant people in his or her life approve or disapprove of a specific behavior) in relation to the acceptance of honest mistakes (including learning and improving health care from error)."
223873905|NCT06835790|DIAGNOSTIC_TEST|Ph-measurement|Ph measurement before and after the surgery
223873906|NCT06835790|OTHER|Questionnaires|GERD-HRQL Reflux symptom index scale before and after surgery
223873907|NCT06835790|DIAGNOSTIC_TEST|gastroduodenal transit|Imaging test that uses the properties of X-rays - after the administration of a radiopaque contrast agent (usually barium) - to visualize the upper digestive tract: the esophagus, stomach, and duodenum (the upper segment of the small intestine).
223873908|NCT06782438|OTHER|artificial intelligence algorithm|to apply an artificial intelligence algorithm to treat the imaging
223873909|NCT06790901|PROCEDURE|LUNG ULTRASOUND|Determination of atelectsis By Lung Ultrasound Score
223873910|NCT06792162|DRUG|Carilizumab and Apatinib|After every 2 cycles of meparticipants. Apatinib was discontinued for one cycle and an additional course of Carilizumab was administered in preparation for surgery. The time between the last dose and surgery was 3-6 weeks, with a maximum of 6 weeks. Both surgical and non-surgical participants will continue to receive treatment with the original regimen of Carilizumab combined with Apatinib after surgery until disease progression, recurrence, or death, for a maximum of 2 years.
223873911|NCT06783127|DRUG|Olaparib|Olaparib given according the clinical practice to BRCA positive mCRPC patients
223873912|NCT06833684|DEVICE|ICE Treatment|Each patient in the Experimental ICE Group will receive one Intermittent Colonic Exoperistalsis (ICE) treatment session lasting 20 minutes. These sessions will be conducted at least once per day, every day at the same hour, for a total duration of 12 weeks. The ICE treatment involves using the MOWOOT medical device designed to alleviate chronic constipation by stimulating colonic peristalsis.
223873913|NCT06833684|PROCEDURE|TAI Standard-of-Care Treatment|Each patient in the Control TAI Group will follow the usual Trans-Anal Irrigation (TAI) standard-of-care treatment. This involves the regular use of TAI procedures as prescribed by healthcare professionals for the intervention period of 12 weeks. The TAI treatment is a well-established method for managing chronic constipation by mechanically clearing the bowel.
223873914|NCT04906343|PROCEDURE|Colonoscopy|Colonoscopy surveillance in SPS patient after 3 years of the last colonoscopy.
223873915|NCT06783530|BEHAVIORAL|Splint Therapy with Enhanced Doctor-Patient Communication|A structured communication protocol aimed at improving doctor-patient interaction and treatment adherence.
223873916|NCT06783530|DEVICE|Splint Therapy|A custom-fitted occlusal splint designed to alleviate symptoms of temporomandibular disorders (TMD).
223873917|NCT06835179|RADIATION|SBRT|SBRT short course radiotherapy (total dose 30-60 Gy, completed in 3-5 sessions)
223873918|NCT06835179|DRUG|PD-1 Inhibitors|Tislelizumab (200mg on day 1)
223873919|NCT06835179|DRUG|CapeOX + bevacizumab|intravenous administration of bevacizumab (7.5mg/kg on day 1), oxaliplatin (135mg/m² on day 1), as well as oral capecitabine (1g/m² twice daily from day 1 to day 14)
223873920|NCT03817684|DRUG|BPN14770|Drug BPN14770
223873921|NCT03817684|DRUG|Placebo|Placebo
223873922|NCT04626479|BIOLOGICAL|Pembrolizumab|Administered via IV infusion at a dose of 400 mg Q6W
223873923|NCT04626479|BIOLOGICAL|Favezelimab/Pembrolizumab|Administered via IV infusion at a dose of 800 mg/200 mg Q3W
223873924|NCT04626479|DRUG|Belzutifan|Administered via oral tablet at a dose of 120 mg QD
223873925|NCT04626479|DRUG|Lenvatinib|Administered via oral capsule at a dose of 20 mg QD
223873926|NCT04626479|BIOLOGICAL|Pembrolizumab/Quavonlimab|Administered via IV infusion at a dose of 400 mg/25 mg Q6W
223873927|NCT04626479|DRUG|Vibostolimab/Pembrolizumab|Administered via IV infusion at a dose of 200 mg/200 mg Q6W
223873928|NCT05588700|BEHAVIORAL|Physical activity recommendations|At the baseline, all participants will receive the international recommendations in terms of physical activity for promoting health in the general population.
223873929|NCT05588700|BEHAVIORAL|Connected activity tracker|At baseline, all participants will receive a connected activity tracker to wear 24 hours a day during one year. Patients will be asked to download an application, dedicated to the study so that the physical activity data (ie. number of steps per day) will be synchronized in the application.
224076571|NCT04389242|OTHER|REST Online（Reduce Stress Tour Online）|Different cognitive behavioral skills are introduced and practiced in a 8 weekly online program, which includes animation briefing and debriefing, case demonstration video, exercise, forum, internal messaging, online assessment and reminder. One face-to-face session and one telephone follow-up provided by an experienced CBT therapist are also provided to clients.
223873930|NCT05588700|BEHAVIORAL|Physical Activity (PA) Intervention|"The intervention will last 1 year and will have 2 phases. Phase 1: At each cycle of chemotherapy, patients will be proposed to perform 2-4 sessions per week. This program will be individual, supervised, performed at a moderate intensity. Between cycles, patients will be asked to perform 1-2 supervised collective live online physical activity sessions per week, proposed by a partner specialized in online PA.~Phase 2: After chemotherapy, patients will be asked to perform 2-3 PA sessions per week at a moderate intensity. Patients will be offered 2 options of PA practice: in the supervised collective live online PA session (as already performed in the phase 1), and/or in a fitness center (this practice will take place in a classic environment with a 9-month free access for patients thanks to a partnership).~In addition, patients will benefit from 4 individual motivational interviews, conducted by videoconference and/or by phone call with a professional."
223873931|NCT06832800|COMBINATION_PRODUCT|MDT|"（actually not combination product, but have to select that option in order to delete warning in study desine）MDT method for sNH with the description as follow： 1. diagnosis of neonatal hemolysis：~The neonatal subjects with symptom of hyperbilirubinemia are diagnosed as hemolysis if they met one criterion from Category A or two criteria from Category B:~Category A:~1. Positive DAT~2. Significantly elevated ETCOc;~3. Significant morphological abnormalities~Category B:~1. Positive release test;~2. Elevated ETCOc;~3. COHb \> 1.2%;~4. Hb \< 140 g/L or Hct) \< 40%;~5. Ret \> 6%. 2.Exchange transfusion (ET) therapy for sNH： any of the following criteria are met:~(1) TSB ≥ the current ET threshold; (2) TSB \> (ET - 2) mg/dL or the increase of TSB \> 0.5 mg/dL/h, accompanied by abnormal aEEG findings; (3) TSB \> (ET - 2) mg/dL or \> 0.5 mg/dL/h, accompanied by a BIND score of 4-6; (4) Presence of clinical manifestations of acute ABE; (5) BIND score of 7-9."
223873932|NCT06832800|OTHER|control (current management)|"Control (current) method for sNH (severe neonatal hemolysis) with the description as follow：~1. Diagnosis of neonatal hemolysis： The neonatal subjects with symptom of hyperbilirubinemia are diagnosed as hemolysis if they have positive Direct Antiglobulin Test (DAT) or positive release test result.~2. Exchange transfusion (ET) therapy for sNH： The neonatal subjects with symptom of hyperbilirubinemia are treated with ET therapy if their Total serum bilirubin (TSB) reaches or exceeds the current exchange transfusion threshold;"
223873933|NCT06418737|BEHAVIORAL|Sleep HygieneTraining|"Training Content~* Importance of Sleep: The vital importance of sleep for physical and mental health.~* Benefits of Adequate and Quality Sleep: The numerous benefits of sufficient and good quality sleep.~* Sleep Stages: The different stages of sleep and their characteristics.~* Sleep Hygiene: The concept of sleep hygiene and its importance for improving sleep quality.~* What to Do?~* What to Avoid for Better Sleep?"
223873934|NCT03035500|OTHER|Educational Intervention|Receive health education
223873935|NCT03035500|OTHER|Laboratory Biomarker Analysis|Correlative studies
223873936|NCT03035500|OTHER|Long-term Follow-up|Undergo long-term follow-up using survivorship care plan
223873937|NCT03035500|OTHER|Quality-of-Life Assessment|Ancillary studies
223873938|NCT03035500|OTHER|Questionnaire Administration|Ancillary studies
223873939|NCT06834256|BEHAVIORAL|intermittent fasting|Group A participants followed the IF diet for 6 weeks . intermittent fasting , specifically time-restricted feeding (TRF), involves consuming all of one's energy requirements inside an 8-h.The fasting interval was designated as 16 h, and the other 8-h was the eating period . During the 8-h eating window, the patient consumes a well-balanced meal consisting of 55%-65% carbs, 7%-20% protein, and 15%-30% fat .
223873940|NCT06834256|BEHAVIORAL|low volume high intensity interval training|. Group B engaged in low-volume HIIT exercise (aerobic activity) three times weekly for six weeks. The exercise routine consisted of a 5-min warm-up phase at 70% of MHR, followed by four intervals of 2-min maximum effort cycling sessions (4 × 2 HIIT) compared to a sub-maximal workload at 85%-90% of MHR. The participants engaged in four work bouts, with each bout lasting around 4 min and followed by a 4-min rest period. During the workouts, the participants maintained an HR of 60%-70% of their MHR. This resulted in 8 min of intense physical activity during each training session. Additionally, there was a 5-min cooling down phase at 70% of the MHR. The treatment's intensity was adapted based on the modified Bruce protocol.
223873941|NCT06830356|RADIATION|Dose escalation of radiation therapy, based on somatostatin receptor PET imaging|Radiation treatment with higher doses than the standard and defined using PET imaging
223873942|NCT04577911|OTHER|Basic Science Experiment|participants complete cognitive tasks while undergoing functional magnetic resonance imaging (fMRI)
223873943|NCT06628193|DEVICE|Low intensity focused ultrasound|low-intensity focused ultrasound for neuromodulation applied to the head.
223873944|NCT06628193|DEVICE|Sham (No Treatment)|Sham LIFU application
223873945|NCT06557161|RADIATION|TBI|The total dose of TBI is 12 Gy, administered on days -7, -6, and -5, with 2 Gy per fraction, twice daily, for a total of 6 fractions.
223873946|NCT06557161|RADIATION|TMLI|The total dose of TMLI is 12 Gy, administered on days -7, -6, and -5, with 2 Gy per fraction, twice daily, for a total of 6 fractions.
223873947|NCT06557161|DRUG|Cyclophosphamide|The total dose of cyclophosphamide is 120 mg/kg, administered over 2 days on days -4 and -3.
223873948|NCT03133182|DRUG|Polypharmacy|Patients who are taking \>=5 unique prescription drugs in the 3 months prior to surgery
223873949|NCT03314753|OTHER|No interventions - retrospective data collection|No new patients will be enrolled within this project; only retrospective data will be collected on performed re-ablations within the FIRE AND ICE Trial
223873950|NCT01285999|DEVICE|PROMUS Element Coronary Stent System|Everolimus-eluting Coronary Stent Drug-eluting Stent (DES) implantation
223873951|NCT01285999|DEVICE|TAXUS Liberté Coronary Stent System|Paclitaxel-eluting Coronary Stent Drug-eluting Stent (DES) implantation
223873952|NCT05861076|OTHER|Moringa Powder - Low Dose|1 teaspoon Moringa leaf powder to be consumed with usual food and/or drinks daily for 7 days
223873953|NCT05861076|OTHER|Moringa Powder - Medium Dose|2 teaspoons Moringa leaf powder to be consumed with usual food and/or drinks daily for 7 days
223873954|NCT05861076|OTHER|Moringa Powder - High Dose|3 teaspoons Moringa leaf powder to be consumed with usual food and/or drinks daily for 7 days
223873955|NCT06829407|OTHER|injection time|give an injection
223873956|NCT06829407|OTHER|palm stimulator|give an injection
223873957|NCT06829407|OTHER|injection time and palm stimulator|give an injection
224076572|NCT03728946|DRUG|Liposomal Bupivacaine|Addition of 15mL of liposomal bupivacaine to 15mL of standard nerve block anesthetic solution containing 0.5% bupivacaine and 4mg of decadron
223873958|NCT06832228|DRUG|Pomalidomide Combination With Rituximab and Anti-PD-1 Antibody （PPR）|"All patients will receive the PPR regimen (a total of 4-6 cycles, 28 days for each cycle):~* pomalidomide: 4 mg, orally, once daily from Day 1 to Day 21.~* Rituximab: 375 mg/m², administered on Day 1.~* PD-1: 200 mg, administered on Days 1."
223873959|NCT06284408|OTHER|Centralized Screening Unit Implementation|The CSU provides a proactive and comprehensive population health approach to screening. This includes core functions of a) patient identification, b) contact, c) engagement, education and support, d) referral and navigation to LDCT screening, e) post screening follow-up, and f) retention
223873960|NCT03999333|DEVICE|Virtual Reality (Oculus Go)|Participants will self-administer virtual reality intervention, in addition to standard of care treatment for pain. There will be 6 weeks of weeks of monitoring period (2 weeks before, 4 weeks during, and 2 weeks after the virtual reality intervention).
223873961|NCT06829433|OTHER|No intervention|Observational cross-sectional study
223873962|NCT03726554|DEVICE|Comprehensive Reverse Porous Augmented Glenoid|Three glenoid baseplate options designed for various severities of glenoid erosion and deformity, the device promotes bony ingrowth while restoring natural human anatomy.
223873963|NCT03726554|DEVICE|Comprehensive Mini Humeral Tray|The mini humeral tray offers additional sizing options to the Comprehensive Shoulder line. The mini tray is designed to fit smaller anatomies.
223873964|NCT06507787|DIAGNOSTIC_TEST|EDIT-B test|"EDIT-B® is the first blood test for the differential diagnosis of bipolar disorder (BD) and major depression. It consists of a biological analysis (including targeted RNA sequencing) followed by a software interpretation thanks to an algorithm developed with AI. The test is CE marked, clinically validated on two independent cohorts and shows an excellent performance with a sensitivity and specificity of more than 80%.~For performing the test, a blood sample of 2.5 ml will be drawn using PAXgene™ Blood RNA tubes (Becton Dickinson, UK) according to the manufacturer's instructions.~The objective of EDIT-B® is to reduce the time to diagnosis of BD, which is currently 7 years on average. This will improve the patient pathway, thanks to faster access to appropriate care - whether for unipolar or bipolar patients - with a major medical, social and financial impact."
223873965|NCT06507787|DIAGNOSTIC_TEST|EDIT-B test (without giving result)|"EDIT-B® is the first blood test for the differential diagnosis of bipolar disorder (BD) and major depression. It consists of a biological analysis (including targeted RNA sequencing) followed by a software interpretation thanks to an algorithm developed with AI. The test is CE marked, clinically validated on two independent cohorts and shows an excellent performance with a sensitivity and specificity of more than 80%.~For performing the test, a blood sample of 2.5 ml will be drawn using PAXgene™ Blood RNA tubes (Becton Dickinson, UK) according to the manufacturer's instructions. THE RESULT OF THE TEST WILL NOT BE GIVEN TO THE PARTICIPANT BEFORE THE END OF THE STUDY.~The objective of EDIT-B® is to reduce the time to diagnosis of BD, which is currently 7 years on average. This will improve the patient pathway, thanks to faster access to appropriate care - whether for unipolar or bipolar patients - with a major medical, social and financial impact."
223873966|NCT06784271|DIETARY_SUPPLEMENT|Phenylcapsaicin|2.5mg of Phenylcapsaicin
223873967|NCT06784271|DIETARY_SUPPLEMENT|Placebo|Placebo
223873968|NCT06788977|DEVICE|external Trigeminal Nerve Stimulation|"External trigeminal nerve stimulation (e-TNS) is a non-invasive, nondrug option for the acute and preventative treatment of migraine. The device is marketed under the trade name CEFALY and has received clearance from the US Food and Drug Administration (FDA) for the acute and preventative treatment of migraine.~The CEFALY device provides transcutaneous stimulation of the supraorbital and supratrochlear branches of the ophthalmic division of the Trigeminal nerve. Patients apply a self-adhesive electrode pad to their forehead, then place the CEFALY generator over the electrodes, resulting in a magnetic connection. The user then selects a treatment program for acute or preventative therapy, which lasts for 60 or 20 minutes."
223873969|NCT04843332|BEHAVIORAL|Community Health Worker Support|For those in the experimental group, a community health worker will provide health education and support as described in the Community Health Worker Intervention arm.
223873970|NCT02544074|BEHAVIORAL|neuropsychological testing|standard neuropsychological testing including brief standardized assessments
223873971|NCT02544074|BEHAVIORAL|eSAGE testing|Neuropsychological testing including the eSAGE tablet and eSAGE smartphone
223873972|NCT04408625|BIOLOGICAL|LY3884963|Participants will receive a single dose of LY3884963, administered intra cisterna magna
223873973|NCT04408625|DRUG|Methylprednisolone|IV pulses every 2 weeks in the first 3 months.
223873974|NCT04408625|DRUG|Optional Sirolimus|At the investigators discretion following steroid tolerability issues, patients may receive a loading dose, followed by maintenance dose, followed by dose tapering; administered as concomitant medication
223873975|NCT04408625|DRUG|Optional Prednisone|If needed and at the investigator discretion, Oral Prednisone may be added to the immunosuppression regimen
223873976|NCT03742245|DRUG|Olaparib|PARP inhibitor
223873977|NCT03742245|DRUG|Vorinostat|HDAC inhibitor
223873978|NCT06549946|BIOLOGICAL|Ixovex-1|Ixovex-1 is a novel oncolytic human adenovirus serotype 5.
223873979|NCT06549946|BIOLOGICAL|Pembrolizumab|Humanised antibody
223873980|NCT06262529|OTHER|Cerebral MRI|Cerebral MRI at 72h / 3 months / 12 months
223873981|NCT05630053|DEVICE|Cementless Persona Knee System|The Persona Keel Knee system is a total knee system used in the replacement of the knee joint.
223873982|NCT05630053|DEVICE|Cemented Persona Knee System|The Persona Keel Knee system is a total knee system used in the replacement of the knee joint.
223873983|NCT04497168|DRUG|Citalopram 20mg|20mg daily
223873984|NCT04497168|DRUG|Placebo|matching placebo pills
223873985|NCT06117020|DRUG|MTR-601|Safety and tolerability of oral MTR-601, a highly selective fast twitch myosin 2 ATPase inhibitor in normal healthy volunteers
223873986|NCT06389539|OTHER|SBD111 medical food|SBD111 medical food is a defined microbial assemblage (DMA) consisting of oligofructose and dried berry powder (prebiotics), a Pseudomonas fluorescens, a Lactobacillus brevis, a Leuconostoc mesenteroides, a Lactobacillus plantarum, and a Pichia kudriavzevii (yeast).
223873987|NCT06389539|OTHER|Placebo|Placebo
223873988|NCT05469815|BEHAVIORAL|Lost Children Society Game|36 online therapeutic role-playing sessions spread over 36 weeks, one session per week
223873989|NCT05558527|BEHAVIORAL|social support|social support is provided in the form of social touch (hand holding)
223873990|NCT03731455|DEVICE|WISE Cortical Strip|The WISE Cortical Strip is a medical device composed by a strip and by a cable.
223873991|NCT04933903|DRUG|Ipilimumab|1mg/kg IV on day 1 (1 dose total)
223873992|NCT04933903|DRUG|Nivolumab|3mg/kg (to a maximum of 240mg) IV on days 1, 15, 29 (+/- 3 days) (3 doses total)
223873993|NCT04933903|RADIATION|SBRT|1 fraction or 2 fractions delivered to the gross primary tumor and nodal disease, following the first treatment with ipilimumab + nivolumab on days 1-3.
223873994|NCT03970057|BEHAVIORAL|Internet-based Cognitive Behavioural Therapy|"MoodUP is an iCBT intervention that is tailored to perinatal women. The core content is presented via different types of devices, such as smartphones, tablets, laptops, or desktops, connected to the internet. The program is designed as an integration of online sessions, self-monitoring, homework, peer support, and therapist support.~MoodUP consists of six online sessions focused on CBT skills for improving stress, anxiety, and depressive symptoms among at-risk antenatal women; each session takes between 30 and 40 minutes to complete. The content of the sessions will be as follows: Session 1: Managing mood, Session 2: Psychoeducation, Session 3: Cognitive restructuring, Session 4: Behavioural activation, Session5: Lifestyle modification, Session 6: Problem-solving."
223873995|NCT03970057|OTHER|Usual Care|Participants will receive a series of six, weekly online sessions comprising general antenatal education. The content of the sessions will be as follows: Session 1: Parenthood; Session 2: Diet; Session 3: Exercise; Session 4: Breastfeeding; Session 5: Rest and sleep and Session 6: Common pregnancy problems.
223873996|NCT06360705|DEVICE|StrataMGT|StrataMGT® is a semi-permeable, non-resorbable and self-drying gel. StrataMGT® contains no steroids, hormones, alcohol, parabens or fragrances. StrataMGT® gel is bacteriostatic, inert, and is manufactured in compliance with good manufacturing practices (GMPs), 21CFR210 and 211.
223873997|NCT06720298|DRUG|18F-FDG|All study participants will undergo one 18F-FDG PET/ CT scan.
223873998|NCT06433297|PROCEDURE|INDIRECT AND DIRECT PULP CAPPING AFTER PARTIAL OR COMPLETE CARIES REMOVAL IN DEEPLY CARIOUS MATURE PERMANENT MANDIBULAR MOLARS WITH MODERATE PULPITIS|"After partial caries removal the cavity is disinfected, dried, and capped with a 2-3mm layer of MTA followed by a light-cured resin layer. The tooth is then definitively restored with composite.~Following complete caries removal, any bleeding pulp will be controlled with sodium hypochlorite for up to 5 minutes. Exposed pulp will then be directly capped with a 2-3mm layer of MTA, followed by a light-cured resin layer and definitive composite restoration using an etch-and-rinse technique."
223873999|NCT02993315|BIOLOGICAL|nDC vaccination|
223874000|NCT02993315|BIOLOGICAL|placebo injection|
223874001|NCT04483089|DEVICE|Transcatheter heart valve procedure|Transcatheter treatment of TR with Abbott TriClip™.
223874002|NCT02437123|BEHAVIORAL|The Cedar Project mHealth intervention|
223874003|NCT04302259|DEVICE|Intelligent Spine Interface|"ISI-C is a bi-directional, two anatomical location Epidural Electrical Stimulation (EES) system to bridge the lesion core in patients with chronic complete and incomplete spinal cord injury (SCI). This Intelligent Spine Interface, or ISI will interpret recorded neural information from above a spinal cord lesion and transfer that information, via deep neural network-based interpreters (i.e. models), to stimulation sites (electrodes) below the lesion with the aim of restoring volitional control of the lower limb."
223874004|NCT04139668|DRUG|Naltrexone 380 MG [Vivitrol]|Three 4ml intramuscular injections of naltrexone 380mg (Vivitrol) administered over 12 weeks (one injection every 4 weeks)
223874005|NCT04139668|BEHAVIORAL|Motivational Enhancement Therapy and Cognitive Behavioral Therapy|Weekly Motivational Enhancement Therapy and Cognitive Behavioral Therapy (MET/CBT), based upon the Brief Counselling for Marijuana Dependence Manual published by the Substance Abuse and Mental Health Services Administration (SAMHSA), for 12 weeks
223874006|NCT06527066|COMBINATION_PRODUCT|Geranium (Pelargonium graveolens) essential oil (EO) diluted to 1% in All.me Beauty® Gel Sérum Biocompatível|"Volunteers must use a total of one gram of the formulation on their face, twice a day, in the morning and at night. The total duration of the protocol will be 12 weeks, with assessment of the participants' skin conditions, in relation to the item Instrumental Facial Assessment, before treatment and after four, eight and 12 weeks."
223874007|NCT06527066|OTHER|Gel Sérum Biocompatível All.me Beauty®|"Volunteers must use a total of one gram of the formulation on their face, twice a day, in the morning and at night. The total duration of the protocol will be 12 weeks, with assessment of the participants' skin conditions, in relation to the item Instrumental Facial Assessment, before treatment and after four, eight and 12 weeks."
223874008|NCT03746327|DRUG|Sivextro 200 milligrams Oral Tablet|200 mg milligram per day during 4 weeks
223874009|NCT03718065|DRUG|Lofexidine|Lofexidine, sold under the brand name Lucemyra among others, is a medication historically used to treat high blood pressure, but more commonly used to help with the physical symptoms of opioid withdrawal. It is taken by mouth. It is an α2A adrenergic receptor agonist.
223874010|NCT03718065|DRUG|Placebo|Placebo comparator.
223874011|NCT06190392|OTHER|MODS Modified simplified diagnostic strategy|"The intervention will be the patient's management with a simplified global strategy. Whether PE is the most likely diagnostic will be assessed by the unstructured implicit clinician's estimation.~In patient with a clinical suspicion of pulmonary embolism: DDimer testing will be performed.~If the likelihood of PE is low (PE is not the most likely diagnosis), then threshold for DDimer testing will be 1000 ng/ml. If the likelihood of PE is high (PE is the most likely diagnosis), then the age-adjusted DDimer threshold will be applied."
224076573|NCT03244033|OTHER|Contextual clinical decision support|Incorporation of contextual data into EHR clinical decision support alerts
224076574|NCT03244033|BEHAVIORAL|Contextual survey|Patients complete a survey asking about red flags that could signal contextual factors relevant to their care
224076575|NCT02450578|DRUG|DSM265 400mg|DSM265 400mg, single oral administration in a fed state
224076576|NCT02450578|DRUG|Placebo to DSM265 400 mg|Placebo to DSM265 400mg, single oral administration in a fed state
224076577|NCT02450578|BIOLOGICAL|Plasmodium falciparum sporozoite challenge|IV Plasmodium falciparum sporozoites (3200) by direct venous inoculation
224076578|NCT02450578|DRUG|Malarone|250 mg atovaquone, 100 mg proguanil hydrochloride
223874012|NCT05154448|DEVICE|Non-Invasive Thermal Ablation of the Medial Branch Nerves (Neurolyser XR)|Thermal ablation of the medial nerve branch using High Intensity Focused Ultrasound
223874013|NCT05154448|OTHER|Sham procedure|Sham procedure done in an identical manner to the treatment arm, but without deploying acoustical energy
223874014|NCT02581215|DRUG|mFOLFIRINOX|"mFOLFIRINOX:~* Oxaliplatin 85 mg/m2 over 2-4 hours~* Irinotecan 165 mg/m2 over 90 minutes~* 5-FU 2,400 mg/m2 as a 46-hour continuous infusion without the 5-FU bolus to decrease the risk of neutropenia."
223874015|NCT02581215|DRUG|Ramucirumab|Ramucirumab administered as an intravenous infusion over 60 minutes (infusion rate should not exceed 25 mg/min), at a fixed dose of 8 mg/kg every 2 weeks.
223874016|NCT02581215|OTHER|Placebo|Placebo infusion with volume calculated as if it were ramucirumab every 2 weeks.
223874017|NCT03860272|DRUG|Botensilimab|An Fc-engineered anti-CTLA-4 monoclonal antibody
223874018|NCT03860272|DRUG|Balstilimab|A fully human monoclonal anti-PD-1 antibody
223874019|NCT00766584|OTHER|Sleep apnea/hypopnea detection|Simultaneous 24-hour ambulatory electrocardiogram and polygraphic recordings performed at home during a night.
223874020|NCT06084221|BEHAVIORAL|Data-Driven Decision Making (DDDM)|The intervention consists of providing real-time data on overdose touchpoints to OFRs and training in DDDM for continuous quality improvement cycles, leading to improved OFR recommendations and implementation of overdose prevention strategies.
223874021|NCT06084221|BEHAVIORAL|Overdose-prevention strategies inventory|A list of overdose prevention and harm reduction strategies will be provided to OFRs for possible implementation, depending on local needs and final dashboard development.
223874022|NCT04009967|DRUG|Pembrolizumab|Pembrolizumab 200 mg every three weeks for 3 cycles only
223874023|NCT04567121|BEHAVIORAL|Intensive intervention group|Establish a team of chronic disease prevention managers (5 people), with each educator responsible for the intervention of 200 people. For sub-health population and chronic disease patients, there would be conducted health education interview twice, 4 calls, online communication 50 times once a year, controlling risk factors and making treatment plan.
223874024|NCT04567121|BEHAVIORAL|standard intervention group|Conduct general health education without active management
223874025|NCT05144321|OTHER|Impact of environment upon obstetrical|Impact of environment upon obstetrical
223874026|NCT05144321|OTHER|neonatal and maternal adverse outcome|neonatal and maternal adverse outcome
223874027|NCT04270526|DRUG|Bicarbonate protocol|Intradetrussor treatment with 50 mL 1% lidocaine + 45ml of 0.9% normal saline + 5 mL 8.4% sodium bicarbonate
223874028|NCT04270526|DRUG|Standard protocol|Intradetrussor treatment with 50 mL 1% lidocaine + 50ml of 0.9% normal saline
223874029|NCT04279574|DEVICE|Lithium disilicate onlays (IPS emaxCAD/Ivoclar)|Restoration of posterior teeth
223874030|NCT04279574|DEVICE|Chairside zirconia crowns (3M)|Restoration of posterior teeth
223874031|NCT04188379|BIOLOGICAL|efgartigimod|Intravenous infusion of efgartigimod
223874032|NCT04188379|OTHER|Placebo|Intravenous infusion of placebo
223874033|NCT06780735|PROCEDURE|The margin-positive rate using the localization technique|Localization of breast cancer using indocyanine green fluorescence (ICG-F)
223874034|NCT03043599|RADIATION|Thoracic Radiation Therapy|All participants will receive radiation therapy (3Gy x 10 fractions) to the chest for 10 days (Monday through Friday for 2 weeks).
223874035|NCT03043599|DRUG|Ipilimumab|Ipilimumab 3 mg/kg (90 minute IV infusion) will be administered every 3 weeks for 4 doses.
223874036|NCT03043599|DRUG|Nivolumab|Nivolumab 1 mg/kg (30 minute IV infusion) will be administered every 3 weeks for 4 doses, followed by nivolumab 480 mg every 4 weeks.
223874037|NCT06234943|OTHER|Chlamydia trachomatis and Neisseria gonorrhea self-swab(s) and/or urine collection. Clinical assessment and prescribing of treatment for participants with positive test results|Participants will be tested by self-swab sample (pharyngeal, vaginal or rectal) and/or urine sample (urogenital) for Chlamydia trachomatis and Neisseria gonorrhea. Selection of swab(s) or urine-based testing will be determined by the individual's sexual risk factors. Participants who have positive CT and/or NG test results will undergo clinical assessment of the CT and/or NG infection by the pharmacist and a prescription will be issued for treatment as appropriate.
223874038|NCT06789614|DRUG|intravenous CYCLIZINE ,Metaclopromide|US giuded measure of GRV in bariatrics surgery upon recieving drugs of study
223874039|NCT05704283|DEVICE|Ultrasound Imaging|Undergo 3D-US
223874040|NCT05428033|DRUG|centanafadine capsule|capsule
223874041|NCT05428033|OTHER|placebo capsule|capsule
223874042|NCT06004167|RADIATION|Adaptive Bridging Radiation Therapy (ABRT)|Radiation Therapy
223874043|NCT02740491|OTHER|Remission Consultation|"At the end of adjuvant treatment (adjuvant chemotherapy and / or radiotherapy), the patient is seen by a referent oncologist and included in the study. A Remission consultation with a psychotherapist is then proposed and its purpose explained to the patient. The patient agrees or refuses take advantage of the Remission consultation; in case of refusal, the reasons are documented and further information is provided, thus giving the opportunity for the patient to benefit from further psychological counseling if desired.~If approval is given, the patient will be scheduled for the Remission consultation (duration 1 hour) . The latter includes a first phase evaluating the mental state of the patient, and then a proposal of individualized care if necessary and according to several methods, depending on the choice of the patient."
223874044|NCT05793593|OTHER|FITx3 intervention and CRC education|Provide CRC education, SN education, handouts and text message/social media posts example library. Monthly Telephone Support Provide any additional support to index participants for peer FIT testing, assist in completion of peer outreach tracker. Biweekly Text Messages. Follow-up Assessment (month 8 after intervention) Complete follow-up form and assist in completion of peer outreach tracker Provide reminders to encourage participants to encourage peers to get FIT tested.
223874045|NCT05793593|OTHER|Colorectal Cancer (CRC) education alone|CRC education alone.
223874046|NCT05780528|OTHER|mulligan mobilization|The patients will receive mobilization with movement technique of lateral glide. the patients will be in supine subject and pronate forearm, during the application of the lateral glide by the physiotherapist, each patient was asked to perform the closure of the fist (provocative but painless gesture in the execution of the technique) for 3 sets of 10 repetitions.
224076579|NCT00859703|DRUG|Risedronate|35mg oral risedronate once per week for 24 months
224076580|NCT00859703|DRUG|Placebo|Placebo 35 mg once a week for 24 months
223874047|NCT05780528|OTHER|instrumented assisted soft tissue mobilization|the participant will receive instrumented assisted soft tissue mobilization. The participant's elbow will rest on a table. A lubricant (Vaseline) will be applied to the skin around the elbow prior to treatment and the blade will be cleaned with an alcohol pad. First, the blade will be used to find the exact areas of restriction in the common extensor origin. Then the M2T blade will be used in the treatment planes 1, 2, and 3, to apply slow strokes along the muscle, without causing any discomfort or pain, from the muscle origin to its insertion (sweeping technique)
223874048|NCT05780528|OTHER|conventional treatment|the patients will receive conventional treatment in the form of Ultrasound therapy, conventional transcutaneous electrical nerve stimulation (TENS) - hot pack - stretching and strengthening exercises and wrist rest splints
223874049|NCT06099249|DEVICE|ASUS ECG App|The procedure will commence with instructing the participants to become acquainted with the ASUS ECG App. Following this introduction, participants will be asked to sit quietly for a 5-minute resting period before undergoing a 12-lead ECG recording, which will last for approximately 30 seconds. The participant will be guided to simultaneously record a separate single-lead ECG using the ASUS ECG App. Both data streams will be synced together by the Study Staff. Each participant will undergo a total of three trials involving the simultaneous recording of a 12-lead ECG and a single-lead ECG using the ASUS ECG App.
223874050|NCT06958159|PROCEDURE|Endoscopic Stricturotomy|"Endoscopic stricturotomy is performed using either a needle knife or an insulated-tip (IT) knife (Olympus, Tokyo, Japan), selected based on the location and morphology of the stricture. Electrosurgical cutting is delivered using the Endo Cut I mode on an ERBE VIO 300D or VIO 3 electrosurgical unit (Erbe Elektromedizin, Germany), with standardized settings: Effect 3, Cut Duration 1, Cut Interval 3.~Radial incisions are initially made across the stricture, followed by circumferential cutting in non-ulcerated areas to relieve luminal narrowing. The goal is to achieve adequate stricture opening while minimizing the risk of perforation."
223874051|NCT06958159|PROCEDURE|Endoscopic Balloon Dilation|"Endoscopic balloon dilation is performed using a Controlled Radial Expansion (CRE) balloon (Boston Scientific, USA). The size of the balloon is selected based on the estimated diameter of the stricture, presence or absence of ulceration, and the anatomical location.~The balloon is gradually inflated under endoscopic visualization to a maximum diameter of 12-20 mm, tailored to the baseline luminal narrowing. The balloon is maintained at full inflation for 60 seconds to achieve controlled and uniform dilation of the stricture."
223874052|NCT03827304|DEVICE|Virtual Reality Distraction for Burns patients|Patients wore a VR headset while undergoing a burns dressing change
223874053|NCT03295747|DRUG|Peppermint oil|Three doses of peppermint oil will be investigated: 180, 360, 540 mg; i.e. three arms.
223874054|NCT02541565|DRUG|Cyclophosphamide|Given IV
223874055|NCT02541565|DRUG|Doxorubicin Hydrochloride|Given IV
223874056|NCT02541565|OTHER|Laboratory Biomarker Analysis|Correlative studies
223874057|NCT02541565|BIOLOGICAL|Pembrolizumab|Given IV
223874058|NCT02541565|DRUG|Prednisone|Given PO
223874059|NCT02541565|BIOLOGICAL|Rituximab|Given IV
223874060|NCT02541565|DRUG|Vincristine Sulfate|Given IV
223874061|NCT06958198|BIOLOGICAL|R21|A protein particle comprising recombinant HBsAg fused to the central repeat and the C-terminus of the circumsporozoite protein
223874062|NCT06958198|BIOLOGICAL|RH5.1|A soluble protein vaccine against the RH5 antigen
223874063|NCT06958198|BIOLOGICAL|R78C|A soluble RIPR EGF-CyRPA fusion protein vaccine
223874064|NCT06958198|BIOLOGICAL|Matrix-M™|A saponin-based vaccine adjuvant
223874065|NCT05406258|DEVICE|Modified Self-Catheterization Mirror|Following training, participants will have a modified mirror for self-catheterization. They will record the mirror used, position, and time for self-catheterization. They will also complete the System Usability Scale for each mirror related to self-operation and user satisfaction.
223874066|NCT05406258|DEVICE|Standard Self-Catheterization Mirror|Following training, participants will have a standard, hospital-provided mirror for self-catheterization. They will record the mirror used, position, and time for self-catheterization. They will also complete the System Usability Scale for each mirror related to self-operation and user satisfaction.
223874067|NCT02229812|DRUG|alteplase|
223874068|NCT00290069|DRUG|Tacrolimus|
223874069|NCT00290069|DRUG|Rapamycin|
223874070|NCT01837238|DIETARY_SUPPLEMENT|HMB|Following this initial round of testing,participant will be assigned to daily HMB supplementation for 6 months. You will be asked to consume a 1000mg HMB capsule 3 times per day, 7 days per week, for 6 months.
223874071|NCT01837238|DIETARY_SUPPLEMENT|placebo|The placebo group will consume non-nutritive placebo pills daily for 6 months.
223874072|NCT02002845|DEVICE|robotic surgery using the da Vinci Surgical System|
223874073|NCT02566902|DEVICE|T-Piece Nebulizer|Albuterol treatment administered with Hudson RCI® Micro Mist® nebulizer (Teleflex Medical®, Research Triangle Park, NJ)
223874074|NCT02566902|DEVICE|Breath-Enhanced Nebulizer|Albuterol treatment administered with NebuTech® HDN®, Breath-Enhanced High Density Jet Nebulizer (Salter Labs®, Arvin, CA)
223874075|NCT02566902|DRUG|Albuterol|One time 5mg nebulized albuterol treatment given with one of two devices over 10 minutes.
223874076|NCT02566902|PROCEDURE|Pre-Treatment Spirometry Measurement|Bedside spirometry measurements taken prior to albuterol therapy using ndd® EasyOne Plus® spirometer.
223874077|NCT02566902|PROCEDURE|Post-Treatment Spirometry Measurement|Bedside spirometry measurements taken after albuterol therapy using ndd® EasyOne Plus® spirometer.
223874078|NCT04138316|DRUG|Candesartan|Treatment with Candesartan
223874079|NCT00321867|PROCEDURE|Graft augmented posterior repair|Posterior repair with graft
223874080|NCT00321867|PROCEDURE|Control|Native tissue repair
223874081|NCT05488080|BEHAVIORAL|Department-level audit and feedback and electronic health record-embedded clinical decision support|This intervention will provide clinicians with Equity Report Cards and clinician decision support on mitigating disparities in quality of care.
223874082|NCT06360458|DRUG|Methylprednisolone sodium succinate|Intravenous injection of methylprednisolone sodium succinate (Chongqing Lummy Pharmaceutical Co., Ltd., 40mg/bottle) with a dose of 2mg/kg (maximum dose of 160mg), once daily, for three consecutive days. The initial study drug will be administered as soon as possible after randomization. It is recommended that the initial study drug administrated before arterial access closure, but it should not be delayed more than 2 hours after arterial access closure.
223874083|NCT06360458|DRUG|Placebo (normal saline)|Intravenous injection of placebo (normal saline) (Chongqing Lummy Pharmaceutical Co., Ltd., 40mg/bottle) with a dose of 2mg/kg (maximum dose of 160mg), once daily, for three consecutive days. The initial study drug will be administered as soon as possible after randomization. It is recommended that the initial study drug administrated before arterial access closure, but it should not be delayed more than 2 hours after arterial access closure.
223874084|NCT06122298|OTHER|fMRI|A brain imaging technique that measures in vivo the activity of brain areas by detecting local changes in blood flow.
223874085|NCT06122298|OTHER|Ecological Momentary Assessment|studies people's thoughts and behaviour in their daily lives by repeatedly collecting data in an individual's normal environment, at or close to the time they carry out that behaviour
223874086|NCT05938426|DEVICE|ET-101|Patients have training sessions twice a day. Each training session takes about 10\~25 minutes. Cognitive training programs include meditation, cognitive training, and cognitive testing.
223874087|NCT05938426|DEVICE|Sham Device|Sham device has only cognitive function test excluding training programs.
223874088|NCT02411084|BIOLOGICAL|Begelomab|BEGEDINA® (Begelomab) is a murine immunoglobulin G (IgG) 2b monoclonal antibody against CD26 (dipeptidyl peptidase-4; DPP4) and is produced by biotechnological means.
223874089|NCT02411084|BIOLOGICAL|Conventional Second-line Treatment|"There are no approved second-line treatments for aGvHD and due to the life-threatening nature of the disease it was agreed with the FDA and EMA that BEGEDINA® would be compared with best conventional second-line treatments which will be chosen by each center, based on the clinical conditions of the individual subject and according to the standard practice at the study center and which may vary between centers. Treatments are generally biological products and could include anti-thymocyte globulin, monoclonal antibodies, such as anti-CD147, basiliximab, daclizumab and alemtuzumab; mycophenolate mofetil; anti-TNF-alpha; pentostatin; dinileukin diftitox; N-acetyl-cysteine; sirolimus; and visulizumab."
223874090|NCT03825575|DEVICE|Low level laser therapy (LLLT)|A 3 week treatment period with a total of 8 treatments of 1 hour over the sacral spinal cord
223874091|NCT01238042|DRUG|HPPH|3mg/m2 or 4 mg/m2 at light doses of 150, 175 and 200 joules/cm
223874092|NCT00199407|DRUG|Istradefylline (KW-6002)|
223874093|NCT05883696|OTHER|Swedish Palliative Care Guide (S-PCG)|"S-PCG is a care guide that aim to inform best practice and to meet palliative care needs of patients and their families throughout all the time with palliative care needs. The S-PCG support palliative care for adult patients regardless of diagnosis, place of care and if it is early och late palliative care.~The S-PCG includes three parts~1. Assessments of palliative care needs~2. Initiating palliative care 2D. End of life care.~3. After death. In this study only the first part of the S-PCG will be used."
223874094|NCT02663778|BEHAVIORAL|Strength training|weight lifting to increase muscle strength
223874095|NCT02663778|BEHAVIORAL|Endurance training|treadmill walking to increase endurance
223874096|NCT02663778|BEHAVIORAL|Flexibility training|stretches to improve flexibility
223874097|NCT02663778|BEHAVIORAL|Task Specific timing and coordination training|stepping and walking patterns to improve timing and coordination of gait
223874098|NCT02663778|BEHAVIORAL|Physical activity behavioral intervention|Intervention to encourage participants to be more physically active
223874099|NCT05990452|DRUG|9MW2921|All subjects will receive 9MW2921 by intravenous (IV) every 3 weeks.
223874100|NCT00459212|DRUG|GTI-2040|Given IV
223874101|NCT00459212|PROCEDURE|pharmacological study|Correlative study
223874102|NCT00459212|PROCEDURE|laboratory biomarker analysis|Correlative study
223874103|NCT01108003|DRUG|broccoli sprout extract|Given orally
223874104|NCT01108003|OTHER|laboratory biomarker analysis|Correlative studies
223874105|NCT01108003|OTHER|Mango Juice|given orally
223874106|NCT04879368|DRUG|Regorafenib|Oral multi-targeted tyrosine kinase inhibitor (TKI) which targets angiogenic (VEGF, TIE-2), stromal (PDGF-β), and oncogenic (RAF, RET and KIT) receptor tyrosine kinases
223874107|NCT04879368|BIOLOGICAL|Nivolumab|human IgG4 monoclonal antibody inhibitor of PD-1
223874108|NCT04879368|DRUG|Docetaxel|"Docetaxel is taxane-derivative chemotherapy drug, used in the treatment of early, locally advanced and metastatic breast cancer. It is an anti-microtubule agent. Other uses are in the treatment of non-small cell lung cancer, advanced stomach cancer, head and neck cancers, soft tissue sarcoma, ovarian cancer, metastatic prostate cancer, etc.~microtubules, and simultaneously promotes assembly and inhibits disassembly of them"
223874109|NCT04879368|DRUG|Paclitaxel|Paclitaxel is one of several cytoskeletal drugs that target tubulin. Paclitaxel-treated cells have defects in mitotic spindle assembly, chromosome segregation, and cell division. Unlike other tubulin-targeting drugs, such as colchicine, that inhibit microtubule assembly, paclitaxel stabilizes the microtubule polymer and protects it from disassembly. Chromosomes are thus unable to achieve a metaphase spindle configuration. This blocks the progression of mitosis and prolonged activation of the mitotic checkpoint triggers apoptosis or reversion to the G0-phase of the cell cycle without cell division
223874110|NCT04879368|DRUG|Irinotecan|Camptothecin, one of the four major structural classifications of plant-derived anti-cancerous compounds, is a cytotoxic alkaloid which consists of a pentacyclic ring structure containing a pyrrole (3, 4 β) quinoline moiety, an S-configured lactone form, and a carboxylate form. Irinotecan is activated by hydrolysis to SN-38, an inhibitor of topoisomerase I. This is then inactivated by glucuronidation by uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1). The inhibition of topoisomerase I by the active metabolite SN-38 eventually leads to inhibition of both DNA replication and transcription.
223874111|NCT04879368|DRUG|Trifluridine/Tipracil|The drug consists of the cytotoxin trifluridine and the thymidine phosphorylase inhibitor (TPI) tipiracil. Trifluridine is incorporated into DNA during DNA synthesis and inhibits tumor cell growth. Trifluridine (TFT) is incorporated into DNA by phosphorylation by thymidylate kinase (TK) to TF-TMP; TF-TMP then covalently binds to tyrosine 146 of the active site of thymidylate synthase (TS) inhibiting the enzyme's activity. TS is vital to the synthesis of DNA because it is an enzyme involved in the synthesis of the deoxynucleotide, thymidine triphosphate (dTTP). Inhibition of TS depletes the cell of dTTP and causes accumulation of deoxyuridine monophosphate (dUMP), which increases the likelihood that uracil gets misincorporated into the DNA.
223874112|NCT02652585|DRUG|Naltrexone|
223874113|NCT02652585|DRUG|Placebo|capsule filled with micro crystalline cellulose, manufactured to mimic naltrexone capsule
224076581|NCT00662792|DRUG|Tiotropium (Tio18GEL)|18 µg Tiotropium (Tio18GEL) inhalation powder
223874114|NCT04291638|BEHAVIORAL|Remote Caregiver Training|The remote caregiver training is a 5-hour videoconferencing-based training program that focuses on teaching cognitive behavioral therapy skills to the caregivers of children with selective mutism in a group format across 3 sessions.
223874115|NCT04291638|BEHAVIORAL|Remote Intensive Group Behavioral Treatment (IGBT)|The remote IGBT is a 5-day videoconferencing-based treatment program that delivers cognitive behavioral therapy to children and their caregivers in a group format across 2-3 hours per day.
223874116|NCT03000595|DRUG|SAN007 Cream|A cream containing 5% East Indian sandalwood oil (EISO).
223874117|NCT03000595|DRUG|Placebo|The vehicle cream
223874118|NCT04209712|BIOLOGICAL|haploid allogeneic NK cell therapy|NK cells will be intravenously infused to the patient for 2 days, with following subcutaneously injection of Interleukin-2.
223874119|NCT03941665|DEVICE|Gelronate|Gel for topical use
223874120|NCT03941665|OTHER|Aloevera|Gel for topical use
223874121|NCT05412017|DIAGNOSTIC_TEST|Hepatitis C Point of Care Testing and Treatment|Pharmacy led hepatitis C point of care testing
223874122|NCT05239156|DEVICE|Janesse|"Device: Janesse® is a sterile, injectable, non-pyrogenic, re-absorbable medical product made of reticulated hyaluronic acid of non-animal origin, produced via bacterial fermentation.~The subjects will receive at baseline the first investigational medical device by the Investigator in accordance with the clinical investigation plan."
223874123|NCT03676413|DRUG|Fluticasone Propionate 100 mcg and Salmeterol 50 mcg inhalation Powder/Respirent Pharmaceuticals|new generic product of Fluticasone Propionate 100 mcg and Salmeterol 50 mcg Inhalation Powder twice daily inhalation throughout the study
223874124|NCT03676413|DRUG|ADVAIR DISKUS® 100/50 mcg inhalation powder pre-dispensed/GSK|twice daily inhalation throughout the study
223874125|NCT03676413|DRUG|Placebo|twice daily inhalation throughout the study
223874126|NCT05688423|BEHAVIORAL|SIRI Team|"Participants randomized to the intervention will receive integrated ID and SUD care (SIRI Team) both during the hospitalization and after hospital discharge for 4 months post-randomization. The intervention is based upon six general principles for treating PWID with infectious complications and is informed by harm reduction.~1. Medications for SUD as integral to management of infectious complications~2. Integration of ID and SUD care~3. Longitudinal care with familiar providers~4. Multidisciplinary care and care coordination~5. Tailored antibiotic options and care settings~6. Harm reduction"
223874127|NCT05688423|BEHAVIORAL|Treatment as Usual|Participants assigned to the TAU group will receive the standard treatment for their severe injection-related infection and substance use disorder at each hospital. While TAU may differ between sites, it is typically comprised of a patient being cared for primarily by a hospital medicine physician (hospitalist) with consultation by infectious diseases (ID) and either psychiatry or addiction medicine physician. If the ID or addiction teams believe post-hospitalization follow up is indicated, each service will follow local protocols for arranging post-discharge continuation of care.
223874128|NCT03951142|DRUG|Losartan|This trial is open-label; therefore, the participant, the trial site personnel, the Sponsor and/or designee are not blinded to treatment. Drug identity (name, strength) is included in the label text. Storage, handling and preparation requirements will be handled in concordance with the Pharmacy Manual for losartan.
223874129|NCT01778907|OTHER|Genotype information accompanied by a drug dosing advice|Dosing advices for deviating genotypes (Poor Metabolizer, Intermediate Metabolizer, Ultrarapid Metabolizer)based on the guidelines of the Royal Dutch Pharmacists Association (KNMP).
223874130|NCT05185245|PROCEDURE|Liver Transplantation|Liver Transplantation for Non-Resectable Colorectal Liver Metastasis
223874131|NCT03435367|DEVICE|Virtual Reality Program|VR with head mounted display (HMD) and headphones.
223874132|NCT03435367|DEVICE|iPad Tablet|iPad with headphones
223874133|NCT04846959|DRUG|Risankizumab|Subcutaneous Injection
223874134|NCT04846959|DRUG|Comparator|Subcutaneous or Intravenous Injection
223874135|NCT04880876|DRUG|25mg Eluxadoline|Oral Tablets
223874136|NCT04880876|DRUG|100mg Eluxadoline|Oral Tablets
223874137|NCT06134882|BEHAVIORAL|Contingency management|Monetary incentives are delivered via reloadable debit card based on verified engagement in target behaviors, including drug abstinence, appointment attendance, and completion of self-paced cognitive behavior therapy modules.
223874138|NCT06134882|BEHAVIORAL|Cognitive-Behavior Therapy Modules|Self-paced cognitive-behavior therapy modules delivered via smartphone.
223874139|NCT06134882|BEHAVIORAL|Peer Contingency Management (CM) Guide|Peer supports delivered via telehealth. Support is informed by the community reinforcement approach and includes motivational interviewing
223874140|NCT06134882|BEHAVIORAL|Drug testing|Self-performed salivary drug testing with incentives contingent upon proper completion of test procedures as confirmed by video.
223874141|NCT06134882|BEHAVIORAL|Wellness modules|Basic health and wellness information delivered via self-paced learning modules.
223874142|NCT06134882|BEHAVIORAL|Peer technical support|Peer support for promoting engagement and addressing technical issues delivered via a mobile digital platform.
223874143|NCT03303651|PROCEDURE|Opioid administration in intervention groups|Elective surgery in radical open abdominal prostatectomy. Opioid titration is guided by analgesia indices during general anesthesia in the experimental arms.
223874144|NCT03303651|PROCEDURE|Opioid administration in control group|Elective surgery in radical open abdominal prostatectomy. Opioid titration is guided by clinical signs in the control group.
223874145|NCT06441136|OTHER|PhoRTE Program|Speech therapy program guided by a speech language pathologist. This program includes in person or virtual visits and at home exercises.
223874146|NCT06441136|OTHER|University of California Los Angeles (UCLA) Loneliness Scale|A questionnaire measuring levels of loneliness.
224076582|NCT00662792|DRUG|Salmeterol MDPI (Salm50DPI)|50 µg Salmeterol MDPI (Salm50DPI) twice daily (BID)
223874147|NCT06441136|OTHER|Social Disconnectedness Scale|A questionnaire that asks about social network size and the frequency of social activities attended.
223874148|NCT06441136|OTHER|Patient Health Questionnaire 9|A questionnaire measuring levels of depression.
223874149|NCT06441136|OTHER|Aging Voice Index|A questionnaire of patient-reported voice outcome measures designed to capture the quality of life impact of dysphonia in older adults.
223874150|NCT06441136|OTHER|The Edmonton Frail Scale|A questionnaire that measures frailty levels.
223874151|NCT06441136|OTHER|Vocal Effort Scale|A picture based questionnaire scale that asks the subject to rate their perceived effort when using their voice.
223874152|NCT06441136|OTHER|Montreal Cognitive Assessment|A screening tool used to test for cognitive impairment.
223874153|NCT06441136|OTHER|Voice Handicap Index-10|A questionnaire used to measure quality of life impact of dysphonia.
223874154|NCT06441136|OTHER|Voice Problem Impact Scales|A 4 question survey that captures impact of voice on four domains - work/daily activities, social life, home, and overall quality of life.
223874155|NCT06441136|OTHER|Cough Severity Index|A 10 question survey asking to rate severity of cough.
223874156|NCT06441136|PROCEDURE|Laryngoscopy|Nose is anesthetized and a flexible endoscope is passed to visualize the larynx at rest and during sustained vowel production (/i/) for 3-5 seconds. This will be used to measure bowing index and normalized glottal gap of the vocal folds.
223874157|NCT06441136|OTHER|Acoustic, perceptual, and aerodynamic assessments|Participants will complete voice recording tasks including sustained vowel production, six standard sentences, and 20 seconds of natural conversational speech. This will be used to measure CAPE-V rating, Cepstral peak prominence, fundamental frequency, signal-to-noise ratio, voice type components, mean flow rate, subglottal pressure, and vocal efficiency.
223874158|NCT03340857|OTHER|Intelligent electric bicycle (VELIS) sessions|Oncology patients will participate in intelligent electric bicycle (VELIS) sessions twice a week for 6 weeks after their release from a rehabilitation and recuperative care facility
223874159|NCT00476346|DIETARY_SUPPLEMENT|Calcium & Vitamin D|Calcium 2000mg / daily Vitamin D 800IU / daily
223874160|NCT02657733|DEVICE|Radical-7|"Comparison between 3 different monitors that measure respiratory rate. The participant is connected to 3 monitors at the same time.~Radical-7- measures respiratory rate according to acoustic respiratory rate (RRa)."
223874161|NCT02657733|DEVICE|Nellcor™ Bedside Respiratory Patient Monitoring System|"Comparison between 3 different monitors that measure repiratory rate. The participant is connected to 3 monitors at the same time.~Nellcor™ Bedside Respiratory Patient Monitoring System - measures respiratory rate according to oximetry respiration rate (RRoxi)."
223874162|NCT02657733|DEVICE|Capnostream 20p|Comparison between 3 different monitors that measure respiratory rate. The participant is connected to 3 monitors at the same time. Capnostream 20p- measures respiratory rate according to Capnography (RRetco2).
223874163|NCT02036424|DRUG|Ozurdex|intravitreal steroid
223874164|NCT02036424|DRUG|Bevacizumab|antiVEGF
223874165|NCT01365598|DRUG|Primaquine|Single dose of oral primaquine phosphate. Comparator dose is 0.75mg/kg primaquine base. Each experimental arm is a different (reduced) dose of primaquine phosphate. Placebo contains no primaquine phosphate (non-active ingredients only).
223874166|NCT05773313|BEHAVIORAL|The Open Table|An organization that connects community volunteers to individuals in need to help overcome life's challenges.
223874167|NCT01905462|OTHER|Data Collection|Analyses of data collected within the CPRD GOLD database.
223874168|NCT01905462|BIOLOGICAL|Cervarix|Women with last menstrual period (LMP) between 30 days before and 45 days after, or 30 days before and 90 days after any dose of Cervarix and women with LMP between 120 days and 18 months after the last Cervarix dose.
223874169|NCT02748317|DRUG|Lactobacillus rhamnosus GG|For the intravesicular Lactobacillus instillation, participants will be instructed to mix the contents of 1 Lactobacillus capsule into 45 cc sterile 0.9% saline.5,6 After mixing, participants will draw up the 45 cc of the liquid Lactobacillus mixture into a 60cc catheter tip syringe and instill via the intermittent catheter after the last catheterization prior to going to bed. Participants will receive 10 Lactobacillus GG tabs at the beginning of treatment phase. At the end of each month, the coordinator or RA will ask how many remaining tablets the participant has, and if needed dispense the next supply of 10 tablets Participants will be instructed to complete the USQ-NB weekly.
223874170|NCT01131780|DRUG|Ibuprofen + Pseudoephedrine Hydrochloride|Ibuprofen 200 mg + Pseudoephedrine Hydrochloride 30 mg Tablets
223874171|NCT05381233|OTHER|Gross motor function classification System (GMFCS)|assessment
223874172|NCT05381233|OTHER|Arabic Version of Zarit burden Inventory measure|assessment
223874173|NCT05381233|OTHER|Arabic Version of Chalder Fatigue Scale (CFQ version 11)|assessment
223874174|NCT04987021|DEVICE|Cochlear Implant (CI)-CI500 series, CI600 series or Freedom series cochlear implants|The Remote Assist (RA) System is intended to support clinicians to conduct a remote programming session with their CI recipients.
223874175|NCT04421924|PROCEDURE|thrombelastogram|Patients in the TEG group will receive prothrombin complex concentrates (PCC) at a dose of 10 IE/kg of ideal body weight, when R-time was greater than 40 minutes (2400 sec) and they will receive platelet transfusion in the amount of 1 apheresis unit when MA was below 30 mm
223874176|NCT04421924|PROCEDURE|standard of care|2\) In the SOC group, patients will receive PCC at the dose of 10 IE /kg of ideal body weight when the PT is below 50% and/or INR\>1.8 and/or received platelet transfusion in the amount of 1 apheresis when platelet count is below 50 G/L
223874177|NCT04847414|DIAGNOSTIC_TEST|HbA1C, other investigations|we will do some necessary investigations for prospective group
223874178|NCT04050644|DRUG|Preservative Free drop treatment|Patients will use the preservative-free dexamethasone 0.1% 4 times a day in the first week after cataract surgery, 3 times a day in the second week, twice daily in the third week and once daily in the fourth week and diclofenac 0.1% eye drops 3 times daily for 1 day preoperatively and every 15 minutes in the hour before surgery and then 3 times a day for four weeks.
223874179|NCT04050644|DRUG|Preserved drop treatment|Patients will use the preserved dexamethasone 0.1% 4 times a day in the first week after cataract surgery, 3 times a day in the second week, twice daily in the third week and once daily in the fourth week and diclofenac 0.1% eye drops 3 times daily for 1 day preoperatively and every 15 minutes in the hour before surgery and then 3 times a day for four weeks.
223874180|NCT01634893|DRUG|Sorafenib combined with Hydroxychloroquine|"dose escalation of sorafenib combined with hydroxychloroquine (HCQ) to a maximum of sorafenib 400 mg PO BID plus HCQ 400 mg PO QD.~Drugs are given on an intermittent schedule of days 1-5/week in a 28-day cycle.~Sorafenib alone is given in cycle 1, and HCQ is added in cycle 2."
223874181|NCT00989183|OTHER|Women undergoing a bilateral or unilateral oophorectomy at OU Medical Center, Oklahoma City, Oklahoma|Women undergoing an elective bilateral or unilateral oophorectomy at OU Medical Center, Oklahoma City, Oklahoma Age range 21-55 years old
223874182|NCT00332241|DRUG|Aripiprazole|Tablets, Oral, 5, 10, or 15 mg, once daily, 8 weeks
223874183|NCT00332241|DRUG|Placebo|Tablets, Oral, once daily, 8 weeks
223874184|NCT01335828|DEVICE|Medical ultrasound device (ShearWave system)|"Echography (all modes) and elastography ShearWave system"
223874185|NCT03319680|OTHER|Citrate dialysate|Compare the effect of citrate dialysate with acetate dialysate
223874186|NCT04667780|DRUG|Colchicine|Colchicine tablet 0.5 mg
223874187|NCT04667780|DRUG|Standard COVID-19 care|As per the hospital guidelines
223874188|NCT00924807|DRUG|Leuprolide acetate, Bicalutamide, Sorafenib|Leuprolide acetate - depot, Bicalutamide 50 mg, Sorafenib 400mg
223874189|NCT03984357|DRUG|PD-1 blocking antibody|"1. Whole-course concurrent PD-1 blocking antibody: every 3 weeks × 6 cycles; 360 mg, day 1; start on day 1 of the first cycle IC and continue every 3 weeks for 6 cycles till the end of IMRT, involving the whole-course of IC + IMRT alone.~2. Adjuvant PD-1 blocking antibody: every 4 weeks × 6 cycles; 480 mg, day 1"
223874190|NCT03984357|DRUG|Gemcitabine|Gemcitabine as induction chemotherapy, 1000 mg/m2 day 1, 8 per cycle, every 3 weeks for 3 cycles
223874191|NCT03984357|DRUG|Cisplatin|Cisplatin as induction chemotherapy, 80 mg/m2 day 1 per cycle, every 3 weeks for 3 cycles
223874192|NCT03984357|RADIATION|Intensity-modulated radiotherapy|Definitive IMRT of 70 Gy, 33 fractions, 5 fractions/week, 1 fraction/day
223874193|NCT03647969|DRUG|Nivolumab|"Nivolumab 240mg Flatdose i.v. d1 over 30 minutes every 2 weeks"
223874194|NCT03647969|DRUG|Ipilimumab|1mg/kg i.v. d1 over 30 minutes every 6 weeks
223874195|NCT03647969|DRUG|mFOLFOX|Oxaliplatin at a dose of 85 mg/m² iv over two hours (day 1), Leucovorin at a dose of 400 mg/m2 iv over two hours (day 1), Fluorouracil at a dose of 400 mg/m² iv bolus (day 1), and Fluorouracil at a dose of 2400 mg/m² iv continuous infusion over 44 hours (day 1+2) every 2 weeks
223874196|NCT03647969|DRUG|FLOT|"Docetaxel at a dose of 50 mg/m² iv over one hour (day 1), Oxaliplatin at a dose of 85 mg/m² iv over two hours (day 1), Leucovorin\* at a dose of 200 mg/m² iv over one hour (day 1), Fluorouracil at a dose of 2600 mg/m² iv over 24 hours (day 1) every 2 weeks~\* Note: Leucovorin can be replaced by sodium folinate that is given according to local guideline."
223874197|NCT00131638|DRUG|Placebo|Single IV dose of placebo at 120 μg/kg, 3 days before the start of Radiotherapy, plus 6 once weekly placebo doses at the same dose during a 6-week radiotherapy / chemotherapy course.
223874198|NCT00131638|DRUG|Palifermin|Single IV dose of palifermin at 120 μg/kg, 3 days before the start of radiotherapy plus 6 once weekly palifermin doses at the same dose level during a 6-week Radiotherapy / chemotherapy course
223874199|NCT04601974|GENETIC|lentiviral gene therapy|lentiviral gene therapy to treat drug resistant epilepsy
223874200|NCT02378597|BEHAVIORAL|Behavioral: Resiliency Intervention|4 hour behavioral session including education in the relaxation response, education about stress and allostatic load, cognitive skills building, review of difficult encounters with patients.
223874201|NCT00802464|BIOLOGICAL|Herpes zoster vaccine GSK1437173A|2 vaccinations at Months 0 and 2 with GSK1437173A (different formulations)
223874202|NCT00802464|BIOLOGICAL|Placebo|2 vaccinations at Months 0 and 2 with placebo
223874203|NCT01871324|BEHAVIORAL|Lifestyle counseling|group therapy
223874204|NCT00468806|DRUG|GSK598809, using [11C]-(+)-PHNO|
223874205|NCT02797444|OTHER|semi-structured interviews|
223874206|NCT05669170|BEHAVIORAL|Psychosocial intervention|"The counseling session, in which a trained study clinician will counsel the primary caregiver, will take place at each study visit and after the randomization visit. It will last approximately 20-30 minutes. Each counseling session will consist of the following elements:~* Review and adjustment of the patient and caregiver supportive care plans~* Emotional support and the opportunity to ventilate feelings~* Counseling regarding specific caregiving skills~* Assistance with problem-solving of specific issues that the caregiver brings to the sessions~* Answers to questions regarding the educational materials The educational materials will consist of a copy of the book The 36-Hour Day by Nancy L. Mace and Peter V. Rabins. The caregiver also will be provided with 24-hour phone access to the study nurse or physician for assistance with crises that may arise after hours."
223874207|NCT05669170|DRUG|Methylphenidate|norepinephrine and dopamine reuptake inhibitor
223874208|NCT00402246|OTHER|Remote Management|"The Remote Management method of treating patients consists of 3 components:~CareAlerts: Device alerts that are triggered by either device integrity issues or arrhythmic issues with the patient (e.g. multiple shocks delivered for a ventricular arrhythmia, more than 12 hours of atrial arrhythmias occurring in a day)~Conexus: the device feature which allows the device to wirelessly transmit information (possibly triggered by a CareAlert) to a patient monitor that is hooked up a patient's phone line~CareLink: the Medtronic system which allows device data to be transmitted from a patient's monitor through the phone line to ultimately be displayed on a secure website for viewing by the patient's physician.~The combination of these 3 components allow the patient's device to transmit information relating to either a device issue or patient issue to be viewed by a clinician without the patient having to take direct action."
223874209|NCT00402246|OTHER|In-Office Care|Routine in-office care
223874210|NCT00739531|DEVICE|Exhaled nitric oxide (eNO)|Subjects will perform a controlled breath maneuver using both the Apieron and NIOX devices. The devices will measure nitric oxide in the subjects' exhaled breath.
223874211|NCT02133820|DRUG|4 mg 12 hourly capsule - strong pain killer fasted|
223874212|NCT02133820|DRUG|4 mg 12 hourly capsule - strong pain killer fed|
223874213|NCT02133820|DRUG|12 hourly capsule strong painkiller with antagonist fasted)|
223874214|NCT02133820|DRUG|4 mg 12 hourly capsule strong painkiller with antagonist fed|
223874215|NCT04965415|BEHAVIORAL|Health Links + Leadership Training|Help businesses undergo transactional (i.e., business management practices) and transformational (i.e., business leadership and culture) change. Transactional change component: Health Links is an existing community-based intervention that seeks to help businesses - especially small and medium-sized businesses - incorporate Total Worker Health (TWH) programming into their business practices through assessment, advising, and certification. There is evidence that this consultation intervention is effective at helping businesses develop and implement policies and programs.Transformational change component: The experimental arm includes TWH leadership training for small business owners and other senior leaders. This is a three-month training that includes assessments, in-person training, and virtual training transfer activities. The goal is to help the leader understand their organization's current approach to TWH, identify areas for improvement, and to take action.
223874216|NCT04965415|BEHAVIORAL|Health Links|Health Links is an existing community-based intervention that seeks to help businesses - especially small and medium-sized businesses - create a culture of both safety and health. Health Links does this by helping businesses incorporate Total Worker Health (TWH) programming into their business practices through assessment, advising, and certification. There is evidence that this consultation intervention is effective at helping businesses develop and implement policies and programs.
223874217|NCT04140331|DEVICE|Accelerometer|Patient will wear the accelerometer for 7 consecutive days to measure the level of physical activity.
223874218|NCT05872724|DRUG|Chemoradiotherapy + Adjuvant chemotherapy and Zimberelimab|"* Radiation therapy:~  1\. Irradiation mode and dose: 6MV-X-ray (6Megavoltage-X-ray), IMRT or RapidArc-IMRT were used for external radiotherapy. External radiotherapy dose: PTV (Planning Target Volume) 45-50Gy/25 times.~* Chemotherapy:~  1. Concurrent chemotherapy: Cisplatin monotherapy: DDP 75 mg/m2 for 3 days, q3w. Carboplatin or nedaplatin may be used in patients that cannot tolerate cisplatin.~ 2. Adjuvant chemotherapy: After the concurrent chemoradiotherapy, 4 cycles of consolidation chemotherapy plus immunotherapy are recommended for patients with high risk or MRDc0 (+). Recommended chemotherapy regimen: liposome paclitaxel 135mg/m2 d1 +DDP 25 mg/m2 D1-3, Q21.~* Zimberelimab injection:~  240 mg, IV, q3w. Start the drug one day before the start of postoperative radiotherapy."
223874219|NCT05872724|DRUG|Chemoradiotherapy (small pelvic) + Zimberelimab|"Radiation therapy:~1\. Target volume of radiotherapy for small pelvis: CTVp includes tumor bed area, paracentral area and part of vagina; CTVn includes bilateral internal iliac, external iliac and obturator lymphatic drainage areas. Upper boundary to sacroiliac joint level, lower boundary to 2cm below vaginal stump.~Chemotherapy:~Concurrent chemotherapy: Cisplatin monotherapy: DDP 75 mg/m2 for 3 days, q3w. Carboplatin or nedaplatin may be used in patients that cannot tolerate cisplatin.~Adjuvant chemotherapy: After the concurrent chemoradiotherapy, 4 cycles of adjuvant immunotherapy are recommended for patients in good general condition (ECOG: 0-1) with medium risk and MRDc0 (-).~Zimberelimab injection: 240 mg, IV, q3w. Start the drug one day before the start of posterior radiotherapy."
223874220|NCT02553161|DRUG|Escitalopram|Youth in the MED condition will be given the USFDA approved antidepressant, escitalopram for the treatment of depression or anxiety in youth and follow a standard dose titration schedule of 5 mg/day for 1 week, 10mg/day for 1 week, then with a target dose of 20-30 mg/day by 4 weeks. Titration will be no faster than 5mg/week. This titration guideline was drawn from the escitalopram package insert for pediatric dosing, which states that target doses may be achieved by 4 weeks.
223874221|NCT02553161|BEHAVIORAL|Cognitive behavioral Psychotherapy|All participants (No MED and MED) will be assigned a study-trained therapist who will provide hour-long weekly individual cognitive behavioral psychotherapy (CBT) based on current evidence-based practices for the treatment of anxiety and depressive symptoms for youth.
223874222|NCT01111513|DRUG|48-hour ropivacaine infusions|Patients receive 20 ml of ropivacaine 0.5 % pre-operation through femoral block catheter, followed by ropivacaine infusions from 0.1 % to 0.1 ml/kg/hour for 48 hours.
223874223|NCT01111513|DRUG|Single dose ropivacaine|Patients receive 20 ml of ropivacaine 0.5% pre-operation
223874224|NCT01111513|DRUG|Patient controlled analgesics|Patient controlled analgesics alone, no femoral block
223874225|NCT02125110|DEVICE|MRI|
223874226|NCT02125110|OTHER|neuropsychological assessment|
223874227|NCT05114967|OTHER|mPAS questionnaire|The modified Preoperative Anxiety Scale (mPAS) questionnaire as given in the article by Viola et al will be used after permission from the authors
223874228|NCT05984212|DRUG|Ultrasound guided rectus sheath block with dexmedetomidine|Intervention Group: Ultrasound guided rectus sheath block with 0.5% ropivacaine 20ml at each side (bilateral)
223874229|NCT05984212|DRUG|Ultrasound guided rectus sheath block with normal saline|Control Group: Ultrasound guided rectus sheath block with 0.9% normal saline 20ml at each side (bilateral)
223874230|NCT00639860|DEVICE|OSSIX-Plus|resorbable collagen membrane
223874231|NCT01804387|DRUG|telbivudine plus adefovir|telbivudine 600 mg qd plus adefovir 10 mg qd
223874232|NCT01804387|DRUG|lamivudine plus adefovir|lamivudine 100 mg qd plus adefovir 10mg qd
223874233|NCT04418973|OTHER|VOCs analysis in exhaled air|using an electronic nose and a mass spectrometry
223874234|NCT02356341|DEVICE|NovaTears® Eye Drops|Topical eye drops for lubrication of the ocular surface
223874235|NCT04372316|DRUG|methylcobalamin|methylcobamin injection 8 weeks or tablet 8 weeks， followed by 24 weeks methylcobamin tablet until 32 weeks
223874236|NCT03504423|DRUG|CPI 613, mFolfirinox|CPI-613: 500mg/m2, IV infusion at a rate of 4mL/min via a central venous port. mFolfirinox: given immediately after CPI-613 administration
223874237|NCT03504423|DRUG|Folfirinox|Folfirinox
223874238|NCT03122158|DRUG|Escitalopram|Escitalopram treatment will be given to the arms with a starting dose of 2.5 mg day. The treatment dose will be gradually increased up to 20 mg day (if necessary) and the maximal treatment dose was determined as 30 mg day in each group.
224076583|NCT00662792|DRUG|Tiotropium (T18GEL) + Salmeterol MDPI (S_DPI)|18 µg Tiotropium (T18GEL) inhalation powder plus 50 µg Salmeterol MDPI (S\_DPI) twice daily (BID)
224076584|NCT00662792|DRUG|Tiotropium/Salmeterol (T+S_PE)|Fixed-dose combination of 7.5 µg/ 25 µg Tiotropium/Salmeterol (T+S\_PE) inhalation powder
224076585|NCT05499962|BEHAVIORAL|Social Networking Strategies|Assess whether PrEP-using Black SMM can serve as an Interventionist to get their social and sexual network members to uptake and adhere to PrEP
224076586|NCT02272686|DRUG|Ibrutinib|560 mg by mouth daily.
223874239|NCT02837211|BEHAVIORAL|Tapered Low Calorie Diet|"All participants will start with a 3 week run-in period during which they are fed a diet at 1.4 x their resting metabolic rate (kcal). Participants who are weight stable at the end of run in and are randomized to the Tapered Diet Arm will undergo the following 24 week feeding study intervention.~The difference between a participant's run-in period energy intake and low-calorie prescribed energy intake (1000 kcal for women; 1200kcal for men) will be divided by six. At weekly intervals from weeks 1-6, daily caloric intake will be decreased by this fixed amount, reaching the final daily caloric goal (1000 kcals for women and 1200 kcals for men) by the end of the 6th week. Participants will present twice per week during weeks 1-6 to receive food that sums to that week's prescribed calorie level.~From weeks 7-24, these participants will then follow a traditional low-calorie diet, still presenting for food pickups twice per week at a stable caloric level during this period."
223874240|NCT02837211|BEHAVIORAL|Traditional Low-Calorie Diet|"All participants will start with a 3 week run-in period during which they are fed a diet at 1.4 x their resting metabolic rate (kcal). Participants who are weight stable at the end of run in and are randomized to the Traditional Diet Arm will undergo the following 24 week feeding study intervention.~Immediately following run-in, these participants will start a low-calorie diet (1000 kcal per day for women; 1200kcal for men) Participants will present twice per week during weeks 1-24 to receive food that sums to that week's prescribed calorie level."
223874241|NCT03177044|BEHAVIORAL|Behavioural treatment|2 to 6 sessions of behavioural training with a pelvic floor physiotherapist
223874242|NCT03079700|BIOLOGICAL|Trichuris suis eggs|Live eggs from swine whipworm, Trichuris suis
223874243|NCT01814839|DRUG|ALN-TTRSC (revusiran)|Ascending doses of ALN-TTRSC (revusiran) by subcutaneous (SC) injection
223874244|NCT01814839|DRUG|Sterile Normal Saline (0.9% NaCl)|Calculated volume to match active comparator
223874245|NCT01471691|DRUG|ranibizumab 0.5mg|Standard dose
223874246|NCT01471691|DRUG|ranibizumab 1.0mg|High dose
223874247|NCT01808339|DRUG|Fluticasone Furoate (FF)|Inhalation powder 100 microgram per blister strip to be administered via dry powder inhaler either in the morning (AM dose with FF and PM dose with +/-2 days).
223874248|NCT01808339|DRUG|Placebo|Placebo in single strip to be administered via dry powder inhaler in the morning and evening for 14 days (+/- 2 days).
223874249|NCT05212181|DEVICE|H-Man|H-Man device will be deployed to patients for onboarding and home-based training.
223874250|NCT03586258|BEHAVIORAL|Neuropsychological testing|Experimental test about cognitive deficit of interest and standard neuropsychological tests
223874251|NCT03586258|OTHER|Brain Imaging|Anatomical, diffusion, and/or functional MRI
223874252|NCT03586258|OTHER|Galvanic Vestibular Stimulation (GVS)|Stimulation versus Sham
223874253|NCT02298452|DEVICE|Hearing aid.|The hearing aid will be fitted to the individual hearing loss of the subject.
223874254|NCT03311737|COMBINATION_PRODUCT|general anesthesia|The investigators used general anesthesia preoperatively in uniportal VATS lung surgery
223874255|NCT03311737|COMBINATION_PRODUCT|epidural anesthesia|The investigators used general anesthesia combined with epidural anesthesia preoperatively in uniportal VATS lung surgery
223874256|NCT02622568|DRUG|Veregen only|Topical application of Veregen 15% ointment on affected areas twice daily
223874257|NCT02622568|PROCEDURE|Cryotherapy and Veregen|Cryotherapy followed by topical application of Veregen 15% ointment on affected areas twice daily
223874258|NCT01643616|DRUG|midazolam|Prior to performing the regional anesthesia the investigators administered midazolam as a premedication by mouth (3,75-7,5mg) or intravenously (2-3mg).
223874259|NCT01643616|DRUG|Prilocaine 1%|20ml Prilocaine 1% for distal sciatic nerve block (30ml Prilocaine 1% in outpatients)
223874260|NCT01643616|DRUG|Ropivacaine 0.75%|10ml Ropivacaine 0.75% for distal sciatic nerve block (not in outpatients)
223874261|NCT01643616|DRUG|Prilocaine 1%|10ml Prilocaine 1% for saphenous nerve block
223874262|NCT01643616|DEVICE|ultrasound guidance|In group US the sciatic nerve localization and needle guidance is realized using ultrasound.
223874263|NCT01643616|DEVICE|nerve stimulation technique|In the group NS sciatic nerve localization and needle guidance is realized using nerve stimulation technique. However, ultrasound is used observing (Observer) the procedure, but blinded for the physician (Anesthetist) performing the block.
223874264|NCT01116635|DRUG|doxorubicin, superabsorbent polymer microspheres, embolotherapy|varying doses of doxorubicin loaded onto SAP during embolization procedure. Pharmacokinetic analysis of elution profile through serum concentrations over 1 month period embolization of surgically resectable HCC with superabsorbent polymer microspheres loaded with doxorubicin from a single treatment. Phase I will follow a modified Fibonacci sequence (with pharmacokinetic analysis of serum doxorubicin) to determine mean tolerated dose (MTD), severe adverse reaction (SAE) and dose limiting toxicities (DLT) when microspheres are loaded with 25mg, 50mg, or 75mg of doxorubicin. Phase II will continue enrollment with the two highest tolerated doses. At least one month after treatment, all patients will undergo imaging and surgical resection of reference tumor, with assessment of degree of necrosis, microsphere distribution, and correlation with concentration of doxorubicin loaded onto microsphere.
223874265|NCT06322446|OTHER|Exercise|16-week exercise intervention: At the beginning of the intervention, we will conduct a face-to-face familiarisation session with the exercises of the training programme. The intervention will consist of 2 sessions/week for 16 weeks. Each session consists of three stages: (i) Warm-up: 10 min of joint mobility and low intensity exercises involving the musculature to be worked in that session; (ii) Main part: circuit training mainly composed of strength exercises targeting the different muscle groups of the body and playing activities (iii) Cool down: 10 min with guided breathing work and stretching of the main muscle groups worked
223874266|NCT00710567|DEVICE|DuraHeart Left Ventricular Assist System (LVAS)|The DuraHeart LVAS is implanted in using open heart surgery
223874267|NCT02262767|DRUG|PF-06649751|Experimental Pfizer compound.
223874268|NCT02262767|DRUG|Trimethobenzamide Hydrochloride|Trimethobenzamide Hydrochloride is indicated for the treatment of postoperative nausea and vomiting and for nausea associated with gastroenteritis.
223874269|NCT04644679|DIAGNOSTIC_TEST|7-day electrocardiographic monitoring|7-day external electrocardiographic monitoring
223874270|NCT04644679|DIAGNOSTIC_TEST|48-hr electrocardiographic monitoring|48-hr external electrocardiographic monitoring
223874271|NCT06523205|DIAGNOSTIC_TEST|Clinical Measurements and Saliva Sample Collection|"Saliva samples will be collected from all patients. Clinical parameters will also be recorded. Plaque index (PI) and gingival index (GI) will be recorded at four sites per tooth. Full-mouth probing depth (PD) and clinical attachment level (CAL) will be detailed per tooth at six sites, and the percentage of bleeding areas will be recorded as present or absent within 20 seconds after probing using a binary scoring system. A calibrated periodontologist will record all clinical parameters using manual probing.~Following sampling, saliva samples will be stored at -80°C until analysis. Concentrations of Tenascin-C, IL-4, IL-6, and IL-1beta will be analyzed by specific enzyme-linked immunosorbent assay (ELISA) kits in saliva samples."
223874272|NCT00031785|DRUG|megestrol acetate|
223874273|NCT00031785|RADIATION|radiation therapy|
223874274|NCT03847259|DIAGNOSTIC_TEST|mechanical posture changes|evaluated by Posture screen mobile, (BackPEI) questionnaire , VISUAL ANALOG SCALE (VAS), Depression Anxiety Stress Scales-21(DASS-21).
223874275|NCT04576975|DRUG|Ketamine|compare the use of ketamine versus dexmedetomidine when used as perioperative infusion in obese patients undergoing laparoscopic bariatric surgery regarding their analgesic efficacy as well as any side effects or drawbacks (PONV and effects on consciousness) that might associate with their use.
223874276|NCT04576975|DRUG|Dexmedetomidine|compare the use of ketamine versus dexmedetomidine when used as perioperative infusion in obese patients undergoing laparoscopic bariatric surgery regarding their analgesic efficacy as well as any side effects or drawbacks (PONV and effects on consciousness) that might associate with their use.
223874277|NCT04576975|DRUG|Normal Saline 0.9%|compare the use of ketamine versus dexmedetomidine when used as perioperative infusion in obese patients undergoing laparoscopic bariatric surgery regarding their analgesic efficacy as well as any side effects or drawbacks (PONV and effects on consciousness) that might associate with their use.
223874278|NCT04613700|DRUG|Secretin|Native hormone
223874279|NCT04613700|OTHER|Placebo|Saline
223874280|NCT03513367|OTHER|Duchenne Muscular Dystrophy of the PedsQL ™ 3.0 scale|"Scaling in multidisciplinary consultations in the form of a self-administered questionnaire with the help of a third party (psychologist). The child and his / her parent complete the questionnaire independently. The result of the questionnaire will then be scored.~To validate the French translation of the pediatric module of Duchenne Muscular Dystrophy of the PedsQL ™ 3.0 scale. The validation process is confirmatory, the scale being widely used in English. The scale will measure the quality of life of the child using two independent assessments : children and their parents."
223874281|NCT03513367|OTHER|The following data of motor function|In parallel, the following data are collected on the day of the consultation: assessment of motor function (MFM, use of a wheelchair, age of loss of walking); assessment of respiratory function (EFR, FVC, respiratory assistance, type of respiratory aid); evaluation of cardiac function (FE); assessment of nutritional status (weight, height, BMI, nutritional support by gastrostomy), school status; ongoing drug treatments (corticosteroids, IEC).
223874282|NCT00532142|DRUG|Intravitreal Triamcinolone|
223874283|NCT00532142|PROCEDURE|Radial Optic Neurotomy|
223874284|NCT00532142|OTHER|Placebo - Sham Intravitreal Injection|
223874285|NCT05286489|COMBINATION_PRODUCT|Qigong exercise|The qigong style they learned is known as 18 Forms Tai Chi Internal Qigong. It is a kind of physical and mental exercise (internal qigong) that focuses on relaxation, deep breathing, and slow and coordinated movements and uses the mind to guide these movements. There are a total of 18 upper and lower body movements, and all of the techniques are performed while either standing or semi squatting. qigong practice session was initiated immediately and continued for about 6 minutes. Each participant in the qigong group performed 18 Forms Tai Chi Internal Qigong once and was assessed immediately afterward in sitting (to measure the vascular outcomes) and lying (to measure the upper limb circumference) positions. The control participants were given no specific exercise instruction after the baseline assessment. Instead, they were asked to rest (sit quietly in the laboratory) for 6 minutes and then participated in the postassessment directly
223874286|NCT00374192|DRUG|Eszopiclone|3 mg per day
223874287|NCT00374192|DRUG|Placebo|Placebo
223874288|NCT06514417|OTHER|US-guided external oblique intercostal block|"After induction of general anesthesia, external oblique intercostal block will be performed (8) under ultrasonographic guidance with transportable ultrasound device ( Sonosite ,superficial probe ,14-15 MHz).~the patient will be positioned supine, and a linear ultrasound transducer will be placed in the sagittal plane between the midclavicular and anterior axillary lines at the level of sixth rib. 20 ml of bupivacaine 0.25% will be injected between the plane of the external oblique and the intercostal muscles. The drug will be injected after a negative aspiration.~The contralateral side block will be performed in a same manner."
223874289|NCT00861770|OTHER|Ultrafiltration|Ultrafiltration based on standard of care.
223874290|NCT00861770|OTHER|Ultrafiltration using BVM|Ultrafiltration will be guided by blood volume measurement results.
223874291|NCT04038736|DEVICE|C-Scan System|During C-Scan procedure the subject swallows the C-Scan cap. The capsule travels painlessly through the gastrointestinal tract, seeking polyps, the precursors of colorectal cancer. It is essential to increase the stool's contrast by ingesting radio-opaque material. During the passage of the capsule in the gastrointestinal tract, it transmits information to a recorder attached to the back. In order to collect data about the instantaneous localization of the capsule traveling in the colon additional sensors are embedded in the recorder on the back side. After the capsule is expelled, the data from the recorder is downloaded to an acquisition workstation. Later, the data is transferred to a processing workstation where dedicated software visualizes and analyses the data.
223874292|NCT01727375|OTHER|Circadian light|"Artificial ceiling lighting throughout the day will be provided by the Philips HealWell system, CE marked, which is able to deliver varying light levels and warmer or cooler light according to the time of the day (circadian light). Emergency or examination lighting can be set on demand as circumstances require.~Lighting conditions at the patients bedside will be characterized by transformations on the time-series of light levels as measured by a luxmeter. The following metrics will be used for lighting characterization in a period of 24h: mean levels of bright and dark periods, contrast between bright and dark periods, clustering of bright and dark periods, and circadian variation."
223874293|NCT01714960|DRUG|MRZ-99030 eye drops 5mg/mL|
223874294|NCT01714960|DRUG|MRZ-99030 eye drops 20mg/mL|
223874295|NCT01714960|DRUG|Placebo to MRZ-99030 eye drops|
223874296|NCT04741113|OTHER|An online 15-minute educational module|"An online 15-minute educational module with four sections: a) Knowledge about obesity; b) Weight bias definition and impact; c) Strategies to reduce weight bias; d) A short quiz.~The module will be based on relevant literature and expert opinion"
223874297|NCT05296213|DRUG|Silver diamine fluoride- potassium iodide|SDF-KI (riva star, SDI.Ltd )was applied ( as a professional application) by micro brush over the early enamel lesions on the buccal surface of molar teeth
223874298|NCT05296213|DRUG|Casein phosphopeptide amorphous calcium phosphate|CPP-ACP (tooth mousse, GC, Matraville Sydney, Australia) was applied by using micro brush over the early enamel lesions on the buccal surface of the molar teeth twice daily. the patients were instructed to leave it for about 3minutes before rinsing
223874299|NCT05296213|DRUG|experimental tricalcium silicate|prepared tricalcium silicate paste was applied by using micro brush over the early enamel lesions on the buccal surface of the molar teeth twice daily. the patients were instructed to leave it for about 3minutes before rinsing
223874300|NCT05043272|BIOLOGICAL|SARS-COV-2 VACCINE|The antibody titer and adverse reactions were observed.
223874301|NCT00371787|DEVICE|Soft contact lens|Soft contact lens
223874302|NCT05178459|DIAGNOSTIC_TEST|Neuropathy measurement|Patient will step on Withings WBS08 and on the Sudoscan to get their sudomotor dysfunction caused by the neuropathy evaluated.
223874303|NCT02415088|PROCEDURE|Interscalene block|block of the plexus brachialis in the interscalene region with local anaesthetics
223874304|NCT02415088|PROCEDURE|Selective shoulder block|selective block of the suprascapular nerve and the axillary nerve with local anaesthetics
223874305|NCT04718909|DRUG|Regorafenib + sintilimab|"Regorafenib: 160 mg p.o. qd for 3 weeks of every 4 week cycle (i.e. 3 weeks on, 1 week off).~Sintilimab: 200mg i.v. q3w."
223874306|NCT04718909|DRUG|Regorafenib|160 mg p.o. qd for 3 weeks of every 4 week cycle.
223874307|NCT03277534|OTHER|Electrical stimulation|sensory electrical stimulation was applied prior to upper limb functional training
223874308|NCT03277534|OTHER|Sham electrical stimulation|electrodes were placed on the same location as the Electrical stimulation condition, but no electric current was applied
223874309|NCT04460807|DRUG|Exemestane|Exemestane in addition to standard therapy, in Experimental arm.
223874310|NCT04460807|OTHER|Placebo oral tablet|Placebo in addition to standard therapy, in Control arm.
223874311|NCT04860401|DEVICE|Measurement of tissue oxygenation with novel diagnostic near-infrared spectroscopy device (OxyPrem) (no clinical decisions based on oxygenation levels)|The precision of OxyPrem is assessed by repeated measurements of tissue oxygenation and hemoglobin concentration. The accuracy of OxyPrem is assessed by comparing the measurement data to those acquired simultaneously by established NIRS devices and standard clinical monitoring devices. In substudy 1, healthy adult subjects are enrolled, in substudy 2, measurements are conducted on preterm neonates.
223874312|NCT03955575|DRUG|Liraglutide 6 MG/ML|Liraglutide as injections.
223874313|NCT03955575|DRUG|Colesevelam|3 x 625 miligram 2 times a day.
223874314|NCT05801367|DRUG|Formocresol|Formocresol will be used as non-vital pulpotomy medicament (which is gold standard)
223874315|NCT05801367|DRUG|Allium Sativum Oil|Allium sativum oil will be used as non-vital pulpotomy medicament compared with Formocresol (which is gold standard)
223874316|NCT02987816|DEVICE|Sham tDCS|NeuroConn Direct-Current Stimulator. Sham tDCS: 45 second ramp up to 1milliamp, 60 second current hold at 1milliamp, 45 second ramp down to 0milliamp. Anode positioned over the left primary motor cortex, and the cathode over the contralateral supraorbital area.
223874317|NCT02987816|DEVICE|Anodal tDCS|NeuroConn Direct-Current Stimulator. Sham tDCS: 45 second ramp up to 1milliamp, 20 minute current hold at 1milliamp, 45 second ramp down to 0milliamp. Anode positioned over the left primary motor cortex, and the cathode over the contralateral supraorbital area.
223874318|NCT04218890|DIAGNOSTIC_TEST|Urinary tissue factor (TF), tissue factor pathway inhibitor (TFPI) and plasmin|urinary sample
223874319|NCT05398224|DRUG|Zanubrutinib, high-dose methotrexate (HD-MTX), rituximab|"Induction therapy: Zanubrutinib will be given as 160mg bid orally between days 1 and 14 of each 14-day cycle; rituximab will be given at 375mg/m2 intravenously on day 1 of each cycle; methotrexate at 3.5g/m2 for patients ≤65 or 1.5g/m2 for patients \>65 (standard hydration/leucovorin support) will be given intravenously on day 2 of each 14-day cycle; for 6 cycles.~Consolidation therapy: For patients ≤65, autologous hematopoietic stem cell transplantation (ASCT with a conditioning regimen of thiotepa/carmustine) will be given as consolidation treatment after induction therapy.~Maintenance therapy:Drug: zanubrutinib. Zanubrutinib will be given as 160mg bid orally continuously until progression of the disease (PD), intolerable toxicity, death, or patient/investigator discretion."
223874320|NCT01816672|DEVICE|AutoloGel|Treatment with Autologel and standard of care twice a week for the first two weeks and once a week thereafter
223874321|NCT01816672|OTHER|Usual and Customary Care|Standard of care treatment twice weekly for 2 weeks then weekly
223874322|NCT01854385|DRUG|Sumatriptan 100 mg|This is a single-arm, unblinded study of treatment for post-traumatic headache with the open label medication sumatriptan and is being undertaken to test necessary study instruments and procedures, establish feasibility and determine side effects in a population with complicated mild, moderate and severe TBI.
223874323|NCT01472900|DEVICE|2940 nm Er:YAG laser (DualisXS M002-2A, Fotona®, Fotona d.d, Ljubljana, Slovenia)|2 passes of 2940nm Er:YAG laser
223874324|NCT01472900|DRUG|Benzoyl Peroxide gel|2.5% benzoyl peroxide gel apply twice daily on inflammatory acne on the control side of face
223874325|NCT02722551|DEVICE|Transcatheter Mitral Valve Re-placement (TMVR) with the CardiAQ-Edwards™ Transcatheter Mitral Valve|Replacement of the mitral valve through a transcatheter approach
223874326|NCT00960024|BEHAVIORAL|Individual Placement and Support-vocational rehabilitation|Individual contact with an employment specialist, who works according to 7 core principles according to SE/IPS. 1) competitive employment as primary goal, 2) rapid job search, 3) eligibility based on client choice, 4) job search based on to client preferences, 5) integration with the mental health care team, 6) availability of time unlimited support at work 7) benefits counseling.
223874327|NCT00960024|BEHAVIORAL|Vocational rehabilitation available|The participants are offered vocational rehabilitation available at site
223874328|NCT01062087|DRUG|Bupivacaine, Lidocaine|Injection at surgical port site of 0.25% Bupivicaine, 2.5 mg/mL NaCl solution and/or application of Lidocaine HCl jelly 2% aqueous, up to 5 mL
223874329|NCT01266122|BEHAVIORAL|Behavioral intervention|The behavioral intervention will consist of 4 group sessions and 4 individual sessions over 3 months. The overall focus is on psychosocial concerns and HIV risk.
223874330|NCT03756571|OTHER|Ankle Foot Orthoses-Footwear Combination|This is a solid AFO with angle of ankle in AFO and shoe modifications per algorithm based on physical exam and visual observation of lower extremity kinematics through stance phase of walking.
223874331|NCT03756571|OTHER|Traditional Solid Ankle AFO (TSAFO)|This is a solid ankle AFO with angle of ankle in AFO at 90 degrees or neutral dorsiflexion/plantarflexion.
223874332|NCT00421889|DRUG|belinostat|
223874333|NCT00421889|DRUG|Paclitaxel|
223874334|NCT00421889|DRUG|Carboplatin|
223874335|NCT04244500|PROCEDURE|swab sampling|Multiplex polymerase chain reaction assay for organisms of upper respiratory tract infections
223874336|NCT00978042|DEVICE|Juvéderm® VOLUMA XC|Treating Investigator determines the appropriate volume of VOLUMA XC to be injected up to a maximum total of 12 mL for initial and touch-up treatment. One repeat treatment with up to 12 mL may be performed at the Subject's option after study completion.
223874337|NCT02917343|BEHAVIORAL|mirror therapy and repetitive task training|
223874338|NCT04597684|PROCEDURE|Cementless Total Knee Arthroplasty|Total Knee Arthroplasty (TKA) with cementless knees
223874339|NCT04597684|PROCEDURE|Cemented Total Knee Arthroplasty|Total Knee Arthroplasty (TKA) with cemented knees
223874340|NCT04966416|DIETARY_SUPPLEMENT|Pyrophosphate|50 mg/kg bwt once daily in gelatine capsules.
223874341|NCT04966416|DIETARY_SUPPLEMENT|Placebo|Glucose in gelatine capsules.
223874342|NCT00520546|OTHER|18F-Ethylcholine Positron Emission Tomography (FEC-PET)|"PET scans were performed on a LSO scanner (ECAT ACCEL, Siemens, Erlangen, Germany) by using a multiphase protocol starting with a cold transmission scan of the lower pelvis. This was followed by a list mode emission scan with 10 frames à 1 minute starting immediately after the administration of 3.3MBq \[18F\]Fluoroethylcholine chloride (FEC; Eckert \& Ziegler EURO-PET Berlin GmbH) as a bolus through the cubital vein. After a short gap due to computer processing time the whole body scan was performed starting at the upper thoracic aperture down to the proximal femur. Acquisition parameters were 3 minutes emission scan and 2 minutes transmission scan for each bed position. Therefore the prostate region was scanned again at 45 minutes p.i. (post injection) A delayed local acquisition at 65 minutes over the lower pelvis with 6 minutes emission and 2 minutes transmission finished the diagnostic acquisition procedure."
223874343|NCT00520546|OTHER|Endorectal Magnetic Resonance Imaging (1.5Tesla) (eMRI)|The MRI examination was performed on a 1.5Tesla MRI system (Gyroscan ACS-NT, Philips, Hamburg, Germany) with combined QBody and endorectal coil. Pelvic assessment and lymph node staging was effected with 5mm T2 weighted (T2w) turbo spin echo (TSE) transversal and a coronal short-tau inversion recovery (STIR) sequence. For prostate assessment, 3mm endorectal T2w spin echo (SE) sagittal, transversal and coronal sequences were acquired.
223874344|NCT02613546|BEHAVIORAL|Cognitive behavioral therapy (CBT)|"The study group will undergo 10 sessions of guidelines and cognitive behavioral therapy (CBT) about an hour long, once a week. Of these:~1. evaluation session;~2. sessions of psychoeducation about the CBT model~5 sessions of cognitive restructuring 2 sessions of preventing relapse"
223874345|NCT02613546|BEHAVIORAL|Control therapy|The control group will be subjected to 10 weekly sessions (1 time per week) approximately one hour guidelines.
223874346|NCT04167020|DEVICE|High definition surface electromyography (HD-sEMG)|HD-sEMG data will be collected by Mobita 32® (TMSi) device
223874347|NCT05027607|PROCEDURE|Bascom's pit-pick|Pit-pick procedure of simple pilonidal sinus disease in the natal cleft in a day-surgery setting.
223874348|NCT04446598|DEVICE|non-ablative SMOOTH mode Erbium YAG laser|Erbium:YAG (Er:YAG) laser with non-ablative SMOOTH™ mode
223874349|NCT04446598|DRUG|Tadalafil 5mg|oral tadalafil 5 mg was administered daily over a period of two months
223874350|NCT03401372|DRUG|Doxycycline|Oral doxycycline 100mg twice daily
223874351|NCT03401372|DRUG|Bortezomib|1.3mg/m2 of bortezomib on days 1, 8, 15 and 22 of a 35-day cycle
223874352|NCT03401372|DRUG|Cyclophosphamide|300mg/m2 cyclophosphamide on days 1, 8, 15 and 22 of a 35-day cycle
223874353|NCT03401372|DRUG|Dexamethasone|40mg of dexamethasone on days 1, 8, 15 and 22 of a 35-day cycle
223874354|NCT03769571|BEHAVIORAL|Parental coaching program at ESDM (P-ESDM)|It will have a duration of 7 months (with an inclusion period of 1 year). Parents will come to the hospital with their child once every 15 days for one-hour parental coaching sessions on the ESDM method. Home video sessions will also be performed by parents once every 15 days. Each parent will have a Certified therapist referral to the practice of ESDM and the program is framed by a certified therapist and trained in ESDM parental coaching.
223874355|NCT00595790|BIOLOGICAL|IC51|
223874356|NCT02101281|DRUG|rhNGF 20 µg/mL|1 drop for each eye, twice daily for 28 day
223874357|NCT02101281|DRUG|rhNGF 4 µg/mL|1 drop each eye, twice daily for 28 day
223874358|NCT04626011|PROCEDURE|Tooth extractions|After blood collection tests, Periodontal analysis, Orthopantomography and Anamnestic record each group will receive a full mouth disinfection and needed extractions.
223874359|NCT04992585|DEVICE|Percutaneous transhepatic implantation of self-expandable metal stent|A self-expandable metal stent is inserted into the extrahepatic bile duct which is obstructed by malignant disease
223874360|NCT05372146|PROCEDURE|GSV radiofrequency ablation with concomitant phlebectomy|Radiofrequency ablation with concomitant phlebectomy
224076587|NCT04464213|OTHER|Single dose experiments|In single dose experiments, after clean the diabetic foot ulcer, paint the Human placental mesenchymal stem cells gel on the wound, each patient only receive treatment once time.
223874361|NCT01969461|BEHAVIORAL|Motivational Enhancement Therapy (MET)|The 4-session MET intervention will address alcohol use and HIV medication (ART) adherence. Sessions will be delivered in the clinic or the home by a CHW (outreach worker, etc) already providing services in the clinic. In sessions 1 and 2 (each behavior will get its own session), CHW will elicit the client's view of the problem using MI techniques, building motivation for change by eliciting and reinforcing change talk. The CHW will deliver feedback and discuss the consideration of a behavior change plan option, and the client sets the change plan goal and consolidates commitment. In the last two sessions, the CHW will review the change plan, continue to elicit and reinforce change talk, problem-solve barriers, consolidate commitment, and consider strategies to maintain behavior change.
223874362|NCT01671267|BEHAVIORAL|Strength training|
223874363|NCT01671267|BEHAVIORAL|Ergonomic|
223874364|NCT06350812|DRUG|PB-119|Administered subcutaneously once a week
223874365|NCT06350812|DRUG|Placebo|Administered subcutaneously once a week
223874366|NCT01699152|DRUG|TG02 citrate|TG02 citrate capsules
223874367|NCT00180505|DEVICE|ABSOLUTE™: Self-Expandable Peripheral Nitinol Stent|A prospective, non-randomized, multi-center study to investigate the performance of the ABSOLUTE™ .035 Peripheral Self-Expanding Stent System (ABSOLUTE™ Stent) in preventing restenosis of occluded or stenotic superficial femoral or proximal popliteal arteries. Follow up at 30, 180, 270, 365 days and 2 years.
223874368|NCT00002755|BIOLOGICAL|filgrastim|
223874369|NCT00002755|DRUG|CMF regimen|
223874370|NCT00002755|DRUG|cyclophosphamide|
223874371|NCT00002755|DRUG|doxorubicin hydrochloride|
223874372|NCT00002755|DRUG|fluorouracil|
223874373|NCT00002755|DRUG|methotrexate|
223874374|NCT00002755|DRUG|tamoxifen citrate|
223874375|NCT00002755|DRUG|thiotepa|
223874376|NCT00002755|PROCEDURE|autologous bone marrow transplantation|
223874377|NCT00002755|PROCEDURE|peripheral blood stem cell transplantation|
223874378|NCT00002755|RADIATION|low-LET cobalt-60 gamma ray therapy|
223874379|NCT00002755|RADIATION|low-LET electron therapy|
223874380|NCT00002755|RADIATION|low-LET photon therapy|
223874381|NCT05724420|BEHAVIORAL|STRIVE course delivery|STRIVE is adapted from the Road to Mental Readiness curriculum, developed by the Department of National Defence in Canada. It is comprised of a 4-hour formal education session where participants are provided knowledge, skills and resources specific to self-assessment for mental wellness and effective mindfulness strategies. High fidelity simulation sessions are then utilized to reinforce and apply mindfulness techniques learned in the formal session..
223874382|NCT04153110|DEVICE|Anodal cerebellar and cathodal spinal tDCS|10 sessions of anodal cerebellar and cathodal spinal transcranial direct current stimulation (5 days/week for 2 weeks)
223874383|NCT04153110|DEVICE|Sham cerebellar and sham spinal tDCS|10 sessions of sham cerebellar and sham spinal transcranial direct current stimulation (5 days/week for 2 weeks)
223874384|NCT04641741|DRUG|Mepolizumab 100 MG|Discovery of predictive/prognostic biomarkers of response to mepolizumab using flow cytometry, transcriptomic, and proteomic technologies.
223874385|NCT04175899|OTHER|Pharmacist-led Oral Chemo Care Program (POCCP)|"Structured intensified pharmaceutical care program for patients ongoing oral chemotherapy treatment.~Led by oncology experienced clinical pharmacist and run alongside oncologist patient review at the clinic or daycare.~It utilizes structured educational material (for patients) and monitoring guideline or checklists (for pharmacists) during provision of service at each clinic visit such as patient education, pre-treatment review, medication reconciliation, prescription screening (dose, regime, supportive meds), adherence, adverse drug event monitoring and treatment recommendations on basis of agreed protocols.~Pharmacist scheduled additional review within 1-week interval of start of oral chemotherapy at clinic or via phone call (according to patient's preference) will also be conducted to review patients taking their oral medications at home, assess adherence and symptom experienced to provide individualized recommendations or support to patients."
223874386|NCT04223388|DIETARY_SUPPLEMENT|Lactobacillus plantarum 276|5 Billion CFU/dose, serving size = 1 capsule/day
223874387|NCT04223388|OTHER|Placebo|Placebo product, serving size = 1 capsule/day
223874388|NCT05537675|OTHER|To evaluate the SUVmean (Standard Uptake Value) as a predictive factor of the tumor absorbed dose compared to the SUVmax|Measure SUVmean (Standard Uptake Value) and SUVmax on PET exams
223874389|NCT06375603|OTHER|Ultrasound scans|Clinical experts will conduct non-invasive ultrasound scans from the specified nerve or plane block views and record the acquired data.
223874390|NCT01611246|DEVICE|Iontophoresis System With Earset|iontophoresis of lidocaine-based solution for numbing tympanic membrane
223874391|NCT03949101|DRUG|Atropine Sulfate 1 % Ophthalmic Ointment and Atropine Sulfate 0.01% Eye Drop|use one drop into subconjunctiva
223874392|NCT03949101|DRUG|atropine 0.01% eye drop|use one drop into subconjunctiva
223874393|NCT00296036|DIETARY_SUPPLEMENT|pyridoxine hydrochloride|Given orally
223874394|NCT00296036|DRUG|urea/lactic acid-based topical cream|Applied topically
223874395|NCT00296036|OTHER|placebo|Given orally or applied topically
223874396|NCT01482975|OTHER|Tailored computer based intervention|Best practices for TTM tailored communication with two types of feedback: normative - compared to peer and ipsative - self compared to previous assessment.
223874397|NCT01482975|OTHER|Tailored computer intervention|Best practices for TTM tailored communication with two types of feedback: normative - compared to peer and ipsative - self compared to previous assessment
224076588|NCT04464213|OTHER|Multi-dose experiments|In multi-dose experiments, after clean the diabetic foot ulcer, paint the Human placental mesenchymal stem cells gel on the wound, each patient receive treatment on six consecutive days.
223874398|NCT02716246|BIOLOGICAL|UX111|Self-complementary adeno-associated virus serotype 9 carrying the human SGSH gene under the control of a U1a promoter (scAAV9.U1a.hSGSH) will be delivered one time through a venous catheter inserted into a peripheral limb vein.
223874399|NCT02716246|DRUG|Prophylactic Immunomodulatory (IM) Therapy|
223874400|NCT02716246|DRUG|Optimized Prophylactic IM Therapy|
223874401|NCT02716246|DRUG|Adjuvant IM Therapy|The Principal Investigator and/or caregiver, in consultation with the medical monitor, will determine whether to initiate adjuvant IM therapy. Not all participants may receive adjuvant IM therapy.
223874402|NCT03067116|DIAGNOSTIC_TEST|Posturography Evaluation|Posturography testing using the modified Clinical Testing of Sensory Integration in Balance (mCTSIB) protocol: the subjects will be required to stand on a hard or compliant surface in a comfortable posture, with eyes open or closed
223874403|NCT03067116|DIAGNOSTIC_TEST|Anthropometrics|measurement of height, minimum stance width (feet together or as close as they can be), circumference of the torso at the breast level, of the abdomen, of the hip, and of each thigh, and supine fundal height
223874404|NCT03067116|DIAGNOSTIC_TEST|Vitals|measurement (bilateral and seated/standing if applicable) of temperature, respiration rate, heart rate, blood pressure, pulse oxygenation and heart rate variability
223874405|NCT03067116|OTHER|Health and daily activity questionnaires|one time general health questionnaire as well as session questionnaires asking the subjects if they have fallen since their last testing session and how comfortable they are in doing daily activities
223874406|NCT04857294|PROCEDURE|TMJ unilateral discectomy|All patients underwent general anesthesia with nasotracheal intubation, managed in most cases with intravenous anesthesia protocol, usually with remifentanil infusion. Intraoperative steroids, usually dexamethasone, were administered primarily to minimize postoperative swelling. A classic preauricular incision or a root of helix inter tragus notch incision (RHITNI) was used in most cases, as previously described. No bandage or special care was performed after the surgery. No air washing restrictions were recommended.
223874407|NCT03113630|DEVICE|Acquisition on TouchScreen|Participants performed acquisition and retention on TouchScreen, transfer 1 on Kinect and transfer 2 on LeapMotion.
223874408|NCT03113630|DEVICE|Acquisition on Kinect|Participants performed acquisition and retention on Kinect, transfer 1 on TouchScreen and transfer 2 on LeapMotion.
223874409|NCT03113630|DEVICE|Acquisition on LeapMotion|Participants performed acquisition and retention on LeapMotion, transfer 1 on TouchScreen and transfer 2 on Kinect.
223874410|NCT03113630|DEVICE|Acquisition on TouchScreen Control Group|Participants performed acquisition and retention on TouchScreen, transfer 1 on Kinect and transfer 2 on LeapMotion.
223874411|NCT03113630|DEVICE|Acquisition on Kinect Control Group|Participants performed acquisition and retention on Kinect, transfer 1 on TouchScreen and transfer 2 on LeapMotion.
223874412|NCT03113630|DEVICE|Acquisition on LeapMotion Control Group|Participants performed acquisition and retention on LeapMotion, transfer 1 on TouchScreen and transfer 2 on Kinect.
223874413|NCT03818893|DRUG|Combination of GEN0101 and Pembrolizmub|New Combination immunotherapy GEN0101 and Pembrolizmub
223874414|NCT01723631|DEVICE|Trap Myelin Test|
223874415|NCT05246124|OTHER|Zumba dance exercise|The intervention was Zumba dance done 3 times a week during the 2-week self-isolation period, with each session lasting for 50 minutes. The participants did exercise by following instructions from Zumba video shown
223874416|NCT01014273|PROCEDURE|Percutaneous Coronary Intervention|
223874417|NCT01858831|DRUG|Atovaquone/proguanil HCL|Atovaquone/proguanil HCL
223874418|NCT01858831|DRUG|Atovaquone|Atovaquone
223874419|NCT03013452|DEVICE|oPEP|Daily chest clearance (chest physiotherapy) using an oPEP (Aerobika) device.
223874420|NCT03013452|BEHAVIORAL|Autogenic drainage|Daily chest clearance (chest physiotherapy) by Autogenic Drainage method.
223874421|NCT00895531|DRUG|Depodur|7.5 mg Depodur via the epidural catheter
223874422|NCT00895531|PROCEDURE|sciatic nerve block|The sciatic nerve will be identified at the subgluteal level with ultrasound. A point 3 cm lateral and 4 cm caudad will be marked. Patients will be placed in the lateral position. A 18 G Tuohy needle will be inserted at a 45° angle until a peroneal or tibial twitch is obtained at 1.5 mA. Once the current can be reduced to obtain a twitch less than 0.5 mA, a catheter will be inserted and placed perineurally. If placed preoperatively, the catheter will be flushed with normal saline or 5% dextrose and will not be dosed until after surgery. After the patient is in the PACU and the surgeons have verified the sciatic nerve function, the sciatic catheter will be dosed with 35 mL 0.25% ropivacaine.
223874423|NCT06803407|OTHER|Home exercise|The study group will be given exercises that include temporomandibular joint and neck as a home exercise program.
223874424|NCT06803407|OTHER|Patient education|Information about the disease and symptoms, chewing recommendations, dietary changes, parafunctional habits, activities to avoid, posture training
223874425|NCT01596933|DIETARY_SUPPLEMENT|BioMega SDA®|Echium oil, 15ml/day, 2 times per oral 7.5ml sachet/day, during 7-week radio(chemo)therapy
223874426|NCT01596933|DIETARY_SUPPLEMENT|Sunflower oil high oleic|Sunflower oil high oleic, 15ml/day, 2 times per oral 7.5ml sachet/day, during 7-week radio(chemo)therapy
223874427|NCT03819829|OTHER|Blood sample|Blood sample
223874428|NCT03403413|DEVICE|muscle vibration during walking|Baseline assessment of gait followed by 12 sessions (3/week for a month) of gait training with cyclic muscle vibration during walking emulating normal muscle activity of lower extremities in treatment group. Gait assessment both with and without muscle vibration were collected at follow-up after 12 sessions of gait training with muscle vibration.
223874429|NCT01019213|OTHER|Septal pacing|Septal lead activated
223874430|NCT01019213|OTHER|His lead activated|His lead will be activated 80 ms before septal lead
223874431|NCT00682708|DIETARY_SUPPLEMENT|PlumpyNut|
223874432|NCT00682708|DIETARY_SUPPLEMENT|PlumpyDoz|
223874433|NCT03119558|DRUG|18F-Florbetaben (Neuraceq®) PET/MRI|Administration of 8.0 mCi 18F-Florbetaben (Neuraceq®) IV followed by simultaneous acquisition PET emission and cardiac MRI sequence scan 45-60 minutes post-injection.
223874434|NCT05463549|OTHER|Informative video|An informative instructional film regarding the amniocentesis procedure including answers to frequently asked questions.
223874435|NCT00925977|DRUG|insulin Glargine + Insulin Apidra|12 wees treatment with Insulin Glargine + Insulin Apidra
223874436|NCT00925977|DRUG|Insulin NPH + Insulin Apidra: Active Comparator|Insulin NPH + Insulin Apidra: Active Comparator
223874437|NCT03238313|BEHAVIORAL|Plan A|
223874438|NCT03238313|BEHAVIORAL|Toxic Life Cycle of a Cigarette|Video
223874439|NCT05738707|BIOLOGICAL|Recombinant protein vaccine and adenovirus vector vaccine|Administer recombinant protein vaccine and adenovirus vector vaccine
223874440|NCT04452318|DRUG|REGN10933 + REGN10987|Subcutaneous (SC) or Intramuscular (IM) injections
223874441|NCT04452318|DRUG|Placebo|SC or IM injections
223874442|NCT00595413|DRUG|Placebo matched to atacicept|Placebo matched to atacicept will be administered subcutaneously twice a week for initial 4 weeks, followed by once a week for subsequent 21 weeks.
223874443|NCT00595413|DRUG|Atacicept: with loading dose|Atacicept will be administered subcutaneously at a dose of 150 milligram (mg) twice a week for initial 4 weeks as loading dose, followed by 150 mg once a week for subsequent 21 weeks.
223874444|NCT00595413|DRUG|Atacicept|Atacicept will be administered subcutaneously at a dose of 150 mg once a week for 25 weeks.
223874445|NCT00595413|BIOLOGICAL|Adalimumab|Adalimumab (Humira®) will be administered subcutaneously at a dose of 40 mg every other week for 25 weeks.
223874446|NCT00215397|DRUG|Formoterol Fumarate|
223874447|NCT04149002|BEHAVIORAL|Intervention Arm Weekly IP3 text messages|Subjects will be provided with a pre and post intervention survey, in addition to a narrated Powerpoint presentation focusing on the logistics of their IP3. Subjects will also receive weekly automated text messages to encourage adherence to the need for their IP3.
223874448|NCT04149002|OTHER|Active Control Arm General pregnancy text messages|Subjects will be given pre and post pre questionnaires, in addition to a narrated Powerpoint presentation about the Clinic. Subjects will also be sent weekly text messages with general pregnancy information.
223874449|NCT05537935|DRUG|Low Dose Naltrexone|Participants will start with 3mg LDN orally administered daily for one week, with a planned increase to 4 mg/day beginning week two, if tolerated. They will be provided with a 4-week supply of study medication. The most common side effects are difficulty sleeping and vivid dreams, which are seen more frequently with nighttime dosing, so LDN will be given as a daytime dose.
223874450|NCT03908060|DRUG|Methadone|One intravenous administration of methadone (0.2 mg/kg ideal body weight)
223874451|NCT03908060|DRUG|Morphine|One intravenous administration of morphine (0.2 mg/kg ideal body weight)
223874452|NCT03440346|OTHER|Few-foods diet|The few-foods diet (FFD) is followed for 5-weeks preceded by a 1-week transition period during which the child's eating pattern will be gradually adjusted. The diet consists of rice, meat (turkey and lamb), a range of vegetables, pear, rice milk with added calcium and water, and is complemented with foods such as potatoes, fruits, corn, some sweets and wheat, which are allowed in small quantities only. Normal quantities of vegetables, rice and meat are allowed every day. If necessary the diet will be adjusted to avoid foods that the child dislikes or has cravings for. If the child does not respond to the initial FFD, i.e. no change in behaviour after the first two weeks, interim adjustments to the FFD will be made in consultation with the parents.
223874453|NCT03427021|DRUG|Oxaliplatin|Infusion
223874454|NCT01327664|BIOLOGICAL|AIN457|
223874455|NCT05363436|DRUG|Oxycodone|Providers had to prescribe 15 oxycodone pills to each patient discharge
223874456|NCT06171412|BEHAVIORAL|Glu-COACH|peer-mentoring support from a peer of the same cultural identity and access to a private social media group for all Black and Latinx teens
223874458|NCT04111471|DIETARY_SUPPLEMENT|Prebiotics|Enrolled patients will receive 10 grams of inulin daily for 21 days
223874459|NCT04111471|DIETARY_SUPPLEMENT|Placebos|Enrolled patients will receive 5.6 grams of placebo powder daily for 21 days
223874460|NCT03233633|DRUG|Medical Marijuana|oral capsule, high ratio CBD:THC
223874461|NCT05257395|DRUG|XZP-3287+ Letrozole/Anastrozole|XZP-3287 360 mg orally after meals Twice daily of every 28-day cycle; Letrozole tablets 2.5mg orally once daily of every 28-day cycle or Anastrozole tablets 1mg orally once daily of every 28-day cycle
223874462|NCT05257395|DRUG|Placebo + Letrozole/Anastrozole|Placebo 360 mg orally after meals Twice daily of every 28-day cycle; Letrozole tablets 2.5mg orally once daily of every 28-day cycle or Anastrozole tablets 1mg orally once daily of every 28-day cycle
223874463|NCT05949190|DIETARY_SUPPLEMENT|M-RUSF+ (Maternal Ready-to-Use Supplementary Food + DHA/EPA/choline)|Balanced energy protein supplement with added DHA/EPA/choline, micronutrients
223874464|NCT05949190|DIETARY_SUPPLEMENT|M-RUSF (Maternal Ready-to-Use Supplementary Food)|Balanced energy protein supplement with added micronutrients
223874465|NCT05949190|DRUG|Azithromycin|1g dose
223874466|NCT05949190|DRUG|Albendazole|400mg dose
223874467|NCT05949190|DRUG|Sulfadoxine pyrimethamine|Monthly, 1,500/75mg dose
223874468|NCT05949190|BEHAVIORAL|Cognitive behavioral therapy|Novel program developed for illiterate end-users
223874469|NCT05949190|OTHER|Insecticide-treated mosquito net|Bed net to prevent malaria
223874470|NCT02131597|DRUG|Guadecitabine|Given SC
223874471|NCT04818138|DEVICE|Narrowband UVB phototherapy|Narrowband UVB phototherapy (full body) administered three times weekly according to individual clinical protocols.
223874472|NCT04818138|DEVICE|Broadband UVB phototherapy|Broadband UVB phototherapy (full body) administered three times weekly according to individual clinical protocols.
223874473|NCT05682872|BEHAVIORAL|Physical exercise program (VIVIFRAIL) supervised by a physiotherapist|Promotion of physical exercise program for frailty and falls prevention in elderly. Muscular strength training, cardiovascular resistance, balance and gait. Initially guided and supervised every 3 months by a physiotherapist.
223874474|NCT05682872|BEHAVIORAL|Adequacy of the environment|A home study and the environment will be made to diagnose fall risks. Guided and supervised by a occupational therapist during a home visit.
223874475|NCT05682872|BEHAVIORAL|Polypharmacy review|Assessment of the medication that patients receives related to fall risks proposing its adjustment. Revised by a primary care doctor different from care routine.
223874476|NCT05682872|BEHAVIORAL|Health education related to falls prevention (4 sessions)|"SESSION 1: Fall Risk factors. Pharmacology. Nutrition and falls (Primary Care Doctor and Primary Care Nurse)~SESSION 2: Accident prevention through environmental modification (Occupational Therapist)~SESSION 3: Importance of physical exercise to prevent falls (Physiotherapist)~SESSION 4: Footwear and foot care. How to react to a fall?: what to do and how to get up? (Primary Care Nurse)"
223874477|NCT05682872|BEHAVIORAL|General Assement|General assessment (feet, footwear, nutrition, cognitive/psychological, social of risk factors) carried out by Primary Care Doctor and Primary Care Nurse
223874478|NCT05682872|BEHAVIORAL|Evaluation of patients by an expert group|Evaluation of the patient by an expert group (Primary care doctor, primary care nurse, polypharmacy review doctor, occupational therapist, frailty group) and decision-making for correction of fall risk factors.
223874479|NCT05682872|BEHAVIORAL|Information brochures on the importance of physical exercise|Integrated Assistance Process for prevention falls in elderly. Benefits of physical exercise and fall prevention at home. Prepared by the Junta de Comunidades de Castilla-La Mancha and Servicio de Salud de Castilla-La Mancha.
223874480|NCT05682872|BEHAVIORAL|Physical exercise program (VIVIFRAIL) supervised by a primary care doctor or primary care nurse|Promotion of physical exercise program for frailty and falls prevention in elderly. Muscular strength training, cardiovascular resistance, balance and gait. Supervised by primary care doctor o primary care nurse according to passport recommendations.
223874481|NCT05682872|BEHAVIORAL|Regular assessment and follow-up by primary care doctor and primary care nurse|General assessment related to falls with the established protocols at primary care routine.
223874482|NCT05682872|BEHAVIORAL|Health education related to falls prevention (1 session)|There will be a single session. The session will cover the following topics: Fall Risk factors. Pharmacology. Nutrition and falls. Accident prevention through environmental modification. Importance of physical exercise to prevent falls. Footwear and foot care. How to react to a fall?: what to do and how to get up?
223874483|NCT04583423|DRUG|MK-3655|MK-3655 50, 100 or 300 dose for injection
223874484|NCT04583423|DRUG|Placebo|Matching placebo to MK-3655
223874485|NCT02462460|DEVICE|MRI|
223874486|NCT02462460|BEHAVIORAL|Optional Screening Questionnaire|
223874487|NCT05509855|GENETIC|Genetic: WU-CART-007|No study drug is administered in this study. Patients who have received WU-CART-007 will be enrolled in this study for Long Term Safety and Efficacy
223874488|NCT04472793|DIAGNOSTIC_TEST|SARS-CoV-2|"1. Testing weekly samples from nasal swabs to promptly diagnose acute COVID-19 infection.~2. Testing monthly serum samples to document post-viral infection."
223874489|NCT05094609|BIOLOGICAL|Ad5-triCoV/Mac|Ad5-triCoV/Mac is a recombinant type 5 human adenovirus vector which has been engineered to express our trivalent SARS-CoV-2 transgene cassette under the control of an MCMV promoter, and is followed by an SV40 polyA signal. The adenovirus construct is E1 and E3 deleted.This trivalent transgene cassette consists of the S1 region of SARS-CoV-2 spike protein (aa 47-716), full-length SARS-CoV-2 nucleoprotein (N) fused to a highly conserved portion of the SARS-CoV-2 polymerase (RdRp or POL).
223874490|NCT05094609|BIOLOGICAL|ChAd-triCoV/Mac|ChAd-triCoV/Mac is an E1 and E3 deleted chimpanzee adenovirus serotype 68 where the trivalent SARS-CoV-2 transgene cassette is under the control of an HCMV promoter and is followed by an SV40 polyA signal. The trivalent transgene cassette consists of the S1 region of SARS-CoV-2 spike protein (aa 47-716), full-length SARS-CoV-2 nucleoprotein (N) fused to a highly conserved portion of the SARS-CoV-2 polymerase (RdRp or POL).
223874491|NCT05917509|DRUG|DTG/3TC|DTG/3TC FDC will be administered as an oral once daily tablet.
223874492|NCT05917509|DRUG|Cabotegravir (CAB) LA|CAB LA will be administered as a gluteal intramuscular injection once every 2 months in combination with RPV LA.
223874493|NCT05917509|DRUG|Rilpivirine (RPV) LA|RPV LA will be administered as a gluteal intramuscular injection once every 2 months in combination with CAB LA.
223874494|NCT05635123|OTHER|No intervention|This is a prospective observational study with no intervention.
223874495|NCT01198145|DRUG|sulfasalazine|Given orally
223874496|NCT01198145|OTHER|placebo|Given orally
223874497|NCT05946551|DRUG|Cetirizine|Cetirizine will be dispensed as a 10mg capsule with instructions for patients to take one capsule daily by mouth, preferably at bedtime.
223874498|NCT05946551|DRUG|Famotidine|Famotidine will be dispensed in 20mg capsules with instructions for patients to take one capsule twice daily, as close to the same times every day as possible.
223874499|NCT05946551|DRUG|Cetirizine Placebo|The cetirizine placebo will be designed as a capsule of an inert substance and will match the morphology of the cetirizine treatment capsule. Administration instructions to match that of cetirizine.
223874500|NCT05946551|DRUG|Famotidine Placebo|The famotidine placebo will be designed as a capsule of an inert substance and will match the morphology of the famotidine treatment capsule. Administration instructions to match that of famotidine.
223874501|NCT05460793|DEVICE|Minimally invasive endoscopy-guided surgery|The devices allowed into the trial, are minimally invasive neuronavigation integrated endoscopy-guided devices that are CE approved and admissible by the steering committee. Currently, only the Artemis Neuro Evacuation Device (Penumbra Inc, Alameda, California, USA) is available and CE approved.
223874502|NCT06536530|BEHAVIORAL|Exergame-Based Training|40-50 min sessions, two sessions per week, for a total of eight weeks.
223874503|NCT06536530|BEHAVIORAL|Cognitive-Based Training|40-50 min sessions, two sessions per week, for a total of eight weeks.
223874504|NCT06536530|BEHAVIORAL|Wait-List|Participants will not train with any program and they will not assist to any specific session or intervention
223874505|NCT00127049|DRUG|gemcitabine, ifosfamide, cisplatin, G-CSF|
223874506|NCT02639975|DRUG|PBF-677|once daily oral administration
223874507|NCT02639975|DRUG|Placebo|once daily oral administration
223874508|NCT00603954|DRUG|Conditioning regimen: TBI + Fludarabine|2 Gy TBI, Fludarabine 90 mg/m²
223874509|NCT00603954|DRUG|Conditioning regimen:TLI (8 Gy) + ATG|TLI 8 Gy + ATG (Thymoglobulin) 7.5 mg/kg
223874510|NCT03477695|DEVICE|ambulatory use of the Upright device|Patients will wear the UpRight for a period of two month
223874511|NCT04528472|OTHER|Acupuncture Treatment|stimulate acupoints to accelerate recovery
223874512|NCT04528472|OTHER|Regular Treatment|Oral Medicine and Rehabilitation Treatment
223874513|NCT03757572|OTHER|Alginate dressings|"The pilonidal cyst will be resected, with the use of a scalpel and then haemostasis will be performed with diathermy. Alginate dressings with silver and high-G cellulose will be applied to the wound. The size of the dressings will be 3cm X 45cm and 1 cm cord will be used for filling the wound cavity. Dressings with perimetric adhesive layer from natural materials, will be also placed.~During wound care the wound will be irrigated with normal saline and betadine solution and finally without pressure the trauma will be dried."
223874514|NCT03757572|OTHER|Simple gauze dressings|"The pilonidal cyst will be resected, with the use of a scalpel and then haemostasis will be performed with diathermy. Simple gauze dressings will be applied to the wound.~During wound care the wound will be irrigated with normal saline and betadine solution and finally without pressure the trauma will be dried."
223874515|NCT04434677|RADIATION|Hypofractionation|3D conformal Radiotherapy whole breast irradiation +- Supraclavicular fossa using Linear Machine (6-15 MV energy) 40.05 Gray (2.67 Gy/ fx) over 15 fractions with or without boost over 3 weeks
223874516|NCT04434677|RADIATION|ultraHypofractionation|3D conformal Radiotherapy whole breast irradiation +- Supraclavicular fossa using Linear Machine (6-15 MV energy) 26 Gray (5.2 Gy/fx) over 5 fractions over 1.5 weeks
223874517|NCT02768467|PROCEDURE|Tissue Matrix Graft Placement|Subject will receive a covering for the wound post buccal mucosa removal.
223874518|NCT02768467|PROCEDURE|No Stitches|Subject will not receive stitches post buccal mucosa removal.
223874519|NCT00314860|DRUG|ropinirole Extended Release (XR)|
223874520|NCT00484913|PROCEDURE|abdominal hot compress|
223874521|NCT06497374|DRUG|Efgartigimod Alfa Injection|Efgartigimod+IVMP; IVMP; Efgartigimod
223874522|NCT06497374|DRUG|High-dose intravenous methylprednisolone|Efgartigimod+IVMP; IVMP; Efgartigimod
223874523|NCT01548170|DRUG|Sunitinib|One capsule of sunitinib 50 mg orally. Single dose
223874524|NCT01548170|DRUG|Sunitinib and Ketoconazol|Sunitinib capsule 37.5mg. Single dose Ketoconazol 2 tablets of 200mg administered daily during 6 days.
223874525|NCT01548170|DRUG|Sunitiinb and Ketoconazol|Sunitinib capsule 37.5mg. Single dose Ketoconazol 1 tablet of 200mg administered daily during 6 days.
223874526|NCT01548170|DRUG|Sunitinib and Ketoconazol|Sunitinib capsule 25mg. Single dose Ketoconazol 1 tablet of 200mg administered daily during 6 days.
223874527|NCT01548170|DRUG|Sunitinib and Ketoconazol|Sunitinib capsule 25mg. Single dose Ketoconazol 2 tablets of 200mg administered daily during 6 days.
223874528|NCT04564196|PROCEDURE|Breath Sample|breathe 2 tidal volume breaths into a single breath collection bag. The breath collection bag will be closed between each breath. The combined 2 tidal volume breaths will count as a single sample.
223874529|NCT01736215|DRUG|Erythropoietin: Observational study|This is an observational study. Participants receiving erythropoietin (dosage and regimen will comply with Thai Food and Drug Administration approval package insert) will be observed.
223874530|NCT01024881|PROCEDURE|neutral shoulder position|neutral shoulder position during infraclavicular subclavian catheterization
223874531|NCT01024881|PROCEDURE|lowered shoulder position|lowered shoulder position during infraclavicular subclavian catheterization
223874532|NCT03010813|PROCEDURE|Robotic single port surgery and NOTES|Robotic single port colorectal surgery; Robotic transanal surgery; Robotic single port urologic surgery; Transoral robotic surgery
223874533|NCT05291104|DIETARY_SUPPLEMENT|Folic acid, choline chloride|In this study, we divide intervention group into two groups which received folic acid (FA) or choline chloride (CC) supplement. Each subgroups contain 20 subjects, including 10 men and women. According to Recommended Daily Nutrient Allowance, FA recommended intake is 400 ug / day and choline recommended intake in men and women is 450 and 390 mg / day. From phase 1 to phase 3 stage, for every 10 days, subjects are given 2-fold, 4-fold and 8-fold recommended intake dose of FA or CC. All supplement solve in 240 ml cranberry juice.
223874534|NCT02778828|DRUG|Linezolid|adjustment of Linezolid of based on the AUC/MIC and % T\> MIC for each patient to confirm the appropriateness, in light of the peak and residual, and the interest of the split doses more frequently performed in case of too low residual or toxicity.
223874535|NCT01598259|DRUG|Melatonin|po 1 hour before bedtime
223874536|NCT01598259|OTHER|placebo|po, 1 hour before bed
223874537|NCT00697489|PROCEDURE|correction of POP plus preventive continence procedure|
223874538|NCT00697489|PROCEDURE|POP surgery followed by eventual incontinence procedure|
223874539|NCT04340479|DIAGNOSTIC_TEST|Ultrasound lung imaging as part of FAST+ evaluation|"FAST+ evaluations will expand on the traditional FAST exam to systematically survey bilateral lung fields. Traditional FAST evaluation will survey the perihepatic, perisplenic, pelvic, and pericardial areas. Representative images will be saved by the performing provider for further evaluation. Up to sixteen areas in total will be included in FAST+ evaluation:~1. Anterior midclavicular right and left (apical, medial, basal)~2. Posterior paraspinal right and left\* (apical, medial, basal)~   \*Posterior lung evaluation will be omitted if patients are at risk for further traumatic injury from repeated side rolling.~3. Lateral axillary medial right and left (apical and basal)~Specifically, we will document the presence or absence of bilateral, diffuse pleural line abnormalities, subpleural consolidations, white lung areas and thick, irregular vertical artifacts in these lung fields by ultrasound and will record these findings."
224076589|NCT05340985|DIETARY_SUPPLEMENT|25(OH)D3|calcifediol
223874540|NCT05221281|BEHAVIORAL|Multimodal intervention consisting of four core components|"Core Component 1: Individualized Assessment: Each participant will undergo individualized assessment of their biopsychosocial risk profile (PIBD INTERMED), self-efficacy (IBD-SES-A), function (IBD-DI), transition readiness (TRAQ) and IBD knowledge (IBD-KID2), and depression, anxiety and activation.~Core Component 2: Transition Navigator: Participants will be assigned a transition navigators, who will have knowledge of IBD, an understanding of the care pathway involved in transitioning IBD patients, and the skills and ability to provide psychosocial support.~Core Component 3: Participant Skills-building: Skills-building materials delivered virtually. Navigators will also be trained as motivational coaches and will lead separate personalized virtual sessions targeting individual skills that have been identified as deficient during the assessment phase.~Core Component 4: eLearning Curriculum: Organized online eLearning modules with reinforcement of knowledge by the navigators."
223874541|NCT05221281|BEHAVIORAL|Standard of care|"The control group will be provided a standardized version of routine care for transition. In addition to recruiting centers' standard of care, all participating centers will implement the following transition interventions:~1. A written letter explaining the goals of transition to the patient and family.~2. Completion of age-appropriate checklists to ensure adolescents are meeting milestones of transition (developed by the TRACC Network).51~3. Annual online live educational webinars on transition and adolescent issues (hosted by the CIDsCaNN Education Committee).~4. Completion of the Pediatric INTERMED,52 with appropriate biopsychosocial intervention.~5. Completion of a transfer-of-care summary letter sent to the receiving adult gastroenterologist using a standardized letter template.53~The Control Group may also receive any interventions currently in place in their participating care center, but will not receive the formal 4-component intervention described below."
223874542|NCT06020313|DIETARY_SUPPLEMENT|Resveratrol Experimental|The amount of 500mg per day will be offered for seven days distributed in doses of 100mg per schedule (7am, 10am, 1pm, 4pm and 7pm).
223874543|NCT02209415|BEHAVIORAL|standard follow-up|Outpatient clinic visits
223874544|NCT02209415|PROCEDURE|PET/CT and EUS|PET/CT and EUS
223874545|NCT04760834|OTHER|Questionnaire|Complete a questionnaire to look for signs of concussion in the past. The questions also seek to collect data on participants' knowledge, concussion management and potential confounding factors
223874546|NCT05424796|COMBINATION_PRODUCT|Physiological saline|Pulpotomy is a vital pulp treatment in which the vital coronal pulp tissue is surgically removed and the remaining radicular dental pulp is covered with an appropriate material. In this group, hemostasis was achieved by checking the saline soaked cotton pellet.
223874547|NCT05424796|COMBINATION_PRODUCT|Hemostasis and cavity disinfection with NaOCl|Pulpotomy is a vital pulp treatment in which the vital coronal pulp tissue is surgically removed and the remaining radicular dental pulp is covered with an appropriate material. In this group, 2.5% NaOCl soaked cotton pellets were placed over canal orifices.
223874548|NCT05424796|DEVICE|Hemostasis and cavity disinfection with KTP laser|Pulpotomy is a vital pulp treatment in which the vital coronal pulp tissue is surgically removed and the remaining radicular dental pulp is covered with an appropriate material. In this group, complete hemostasis and cavity disinfection were achieved using a KTP laser (SMARLITE D, Deka, Calenzano FI, Italy).
223874549|NCT05293431|OTHER|Transcranial Alternate Current Stimulation|tACS utilizes low-amplitude alternating currents to modulate brain activity and entrain specific brain oscillations depending on the applied stimulation frequency
223874550|NCT05293431|OTHER|Sham stimulation|Sham stimulation will simulated the real tACS stimulation
223874551|NCT06967051|DRUG|Tetrahydrocannabinol (10 mg)|10 mg of Tetrahydrocannabinol (THC) provided as a softgel capsule
223874552|NCT06967051|DRUG|Tetrahydrocannabinol (25 mg)|25 mg of THC provided as a softgel capsule.
223874553|NCT06967051|DIAGNOSTIC_TEST|Pupillary Light Reflex (PLR) Test|SOBEREYE OPTOVERA is a portable, non-invasive test that measures the Pupillary Light Reflex (PLR)
223874554|NCT06967051|DIAGNOSTIC_TEST|Pupillometer|NeuroLight is an automated pupillometer that generates a flash of light and measures the photomotor reflex very accurately.
223874555|NCT00258297|DRUG|gefitinib|
223874556|NCT00258297|PROCEDURE|conventional surgery|
223874557|NCT00258297|PROCEDURE|enzyme inhibitor therapy|
223874558|NCT00258297|PROCEDURE|neoadjuvant therapy|
223874559|NCT00258297|PROCEDURE|protein tyrosine kinase inhibitor therapy|
223874560|NCT00258297|PROCEDURE|surgery|
223874561|NCT06518070|DIAGNOSTIC_TEST|Cerviray AI|Patient was screened using Cerviray AI, Cerviray AI evaluation by expert anc compared to VIA test in the same day.
223874562|NCT06565065|PROCEDURE|Osteopathic Manipulative Treatment (OMT)|A full standardized lymphatic protocol will be performed, including thoracic inlet left and right, thoracoabdominal release, pelvic diaphragm release, pedal pump, splenic pump, and abdominal lymphatic pump. This treatment will be done by systematically working down and back up. The protocol will last a total of 12 minutes for each participant
223874563|NCT06565065|OTHER|Sham Light Touch|A full standardized 12-minute session in which treaters will mimic various osteopathic manipulative techniques at specific anatomical locations without applying pressure or manipulation.
224076590|NCT05340985|DIETARY_SUPPLEMENT|vitamin D3|Cholecalciferol
224076591|NCT01699087|PROCEDURE|Photorefractive keratectomy (PRK)|In this corneal surgical procedure, the outer corneal epithelial layer will be removed, after which the corneal stroma will be reshaped by excimer laser ablation to reduce or eliminate refractive errors.
224076592|NCT01699087|DEVICE|ALLEGRETTO WAVE EYE-Q excimer laser system|The ALLEGRETTO WAVE EYE-Q excimer laser system is used for corneal stroma reshaping during PRK surgery
223874564|NCT06565065|OTHER|Exercise Protocol|A full standardized moderate-intensity physical activity as defined by the Centers for Disease Control (CDC). Target heart rate for moderate-intensity exercise should be between 64 and 76% of maximum heart rate. To estimate age-related heart rate, subjects' age will be subtracted from 220. Then, that number will be multiplied by 75%, which will be standardized across all subjects in the study. Heart rate will be monitored with the use of an attached pulse-ox monitor. Treadmill speed will be adjusted accordingly so that each subject maintains a heart rate of 75% of their maximum heart rate. A brisk walk will be done on a flat treadmill and no incline will be utilized. Subjects will be allowed a minute of warm-up to get to the appropriate pace/target heart rate.
223874565|NCT05742815|OTHER|No intervention|This is an observational collection of data from purchased donor milk samples
223874566|NCT02414412|DIETARY_SUPPLEMENT|Ulmus macrocarpa water extract|
223874567|NCT00422006|PROCEDURE|biopsy of muscle, of liver, and of adipose tissue|biopsy of muscle, of liver, and of adipose tissue
223874568|NCT00422006|PROCEDURE|clamp euglycemic - hyperglycemic|clamp euglycemic-hyperglycemic
223874569|NCT00422006|BEHAVIORAL|diet|diet
223874570|NCT00422006|OTHER|biopsies for biological and genetic analyses|biopsies for biological and genetic analyses
223874571|NCT02000349|OTHER|PGD|PGD using Next generation sequencing
223874572|NCT01691846|DRUG|aleglitazar+metformin|150 mcg aleglitazar given orally once a day for 26 weeks. Patients will continue on their existing dose and regimen of metformin (≥ 1500 mg/day or individual maximally tolerated dose)
223874573|NCT01691846|DRUG|placebo+metformin|Oral doses of matching placebo once a day for 26 weeks. Patients will continue on their existing dose and regimen of metformin (≥ 1500 mg/day or individual maximally tolerated dose)
223874574|NCT01514344|DRUG|intralesional rituximab|10-20 mg (1-2 ml) rituximab once a week for 4 weeks; followed by 10-20 mg (1-2 ml) rituximab monthly per six months
223874575|NCT01514344|BIOLOGICAL|supplemental autologous serum|patients in PD or SD during or after administration of 6 doses monthly rituximab will be administered the same dose of intralesional rituximab supplemented by autologous serum
223874576|NCT05033938|PROCEDURE|Early Mobilization Protocol|Subjects will be placed in a bulky soft dressing immediately after surgery. They will be made non-weight bearing, but active and passive motion of digits, forearm, elbow, and shoulder will be allowed with light functional tasks permitted as tolerated. Wrist motion within the soft dressing will be permitted as tolerated by patient. On postoperative day 3, patients will be advised to remove the dressing at home and begin home hand/wrist therapy. They will use a removable Velcro wrist splint for nighttime wear and strenuous activity. This splint can be removed during normal activities of daily living and therapy.
223874577|NCT05033938|PROCEDURE|Late Mobilization Protocol|Subjects will be placed in a plaster volar resting splint. They will be made non-weight bearing, with use of digits for light functional tasks permitted. They will be given home exercises for their fingers but will not yet resume wrist motion
223874578|NCT02093312|DIETARY_SUPPLEMENT|Home food-delivery service|A home food-delivery service is offered the intervention group of cancer patients
223874579|NCT01070069|DEVICE|PEVAR (ProGlide closure)|Percutaneous EVAR facilitated by the ProGlide closure device
223874580|NCT01070069|DEVICE|SEVAR (IntuiTrak)|Standard vascular exposure for access prior to EVAR
223874581|NCT01070069|DEVICE|PEVAR (Prostar XL closure)|Percutaneous EVAR facilitated by the Prostar XL closure device
223874582|NCT04643899|DEVICE|Muscle Electrostimulation|"* Scheduled sessions of 20 minutes per day; 5 days a week~* In physiotherapy or in their room for the most dependent patients~* Installation and monitoring by a physiotherapist or by the trained clinical research nurse~* Modalities:~  * Device program n ° 1: 20mn (2mn of warm-up, 15mn of work at 75hz, then 3mn of recovery)~ * 4 electrodes (2 per thigh): large model (5 \* 10 cm) for better comfort - Dura-Stick Plus model (reference 42200)~ * Gradual auto-increase of the intensity to the highest possible value tolerated, nevertheless allowing a contraction"
223874583|NCT05876143|DEVICE|Unicompartmental knee arthroplasty|"Knee joint could be subject to natural or pathological wear or shocks (primary or secondary evolutive or traumatic osteoarthritis) which cause pain and reduced mobility of the knee.~When only one lateral or medial compartment of the femoro-tibial knee joint is affected, the treatment of unicompartmental femoro-tibial osteoarthritis of the knee is generally carried out by the implantation of a so-called unicondylar knee prosthesis (UKP), in order to reduce pain and improve joint mobility of the knee compared to the preoperative state."
223874584|NCT05386953|DRUG|Normal saline|Patients received normal saline as a maintenance crystalloid during liver transplantation surgery.
223874585|NCT05386953|DRUG|Balanced crystalloid solution|Patients received balanced crystalloids such as lactated Ringer's solution or Plasma solution as a maintenance crystalloid during liver transplantation surgery.
223874586|NCT02668250|PROCEDURE|OPTI-AGED|OPTI-AGED is composed of a multi-parametric optimization strategy.
223874587|NCT02668250|PROCEDURE|Usual Care|Patients receive the usual care.
223874588|NCT02434744|DRUG|KD026|Dosed in combination
223874589|NCT02434744|DRUG|Placebo|Dosed in combination
223874590|NCT02434744|DRUG|Metformin|Drug prescribed by each subject's prescribing physician
223874591|NCT03742050|PROCEDURE|Percutaneous coronary intervention|Percutaneous coronary intervention with drug-eluting stents aiming to achieve complete revascularisation
223874592|NCT00971724|DRUG|Placebo|Oral administration, once daily, for 15 days
223874593|NCT00971724|DRUG|Prednisolone|Oral administration
223874594|NCT04948801|DRUG|Epclusa (sofosbuvir and velpatasvir)|Epclusa (sofosbuvir and velpatasvir) is a nucleotide analog polymerase inhibitor and pan-genotypic NS5A inhibitor fixed-dose combination for the treatment of chronic genotype 1-6 hepatitis C virus (HCV) infection.
223874595|NCT04290013|DRUG|norethisterone acetate|norethisterone acetate 15 mg daily from day 5 of the cycle to day 26.
223874596|NCT04290013|DRUG|tranexamic acid tablets|tranexemic acid 1 gm three times daily from the first day of the menstrual cycle up to 5 days .The dose can be increased but not exceeding 4 gm per day.
224076593|NCT06455514|DRUG|Magnesium Sulfate|4 g of magnesium sulfate intravenously within 2 hours of Return of Spontaneous Circulation (ROSC), followed by a continuous drip (16 g) over 24 hours
224076594|NCT06455514|DRUG|Saline|Control subjects will receive an equivalent volume of normal saline intravenously.
224076595|NCT02582957|OTHER|Sigh breaths|Sigh breaths delivered once every 6 minutes, as part of usual invasive mechanical ventilation.
223874597|NCT05330234|DEVICE|OnTrack Tools|"The intervention is the OnTrack Tools system consisting of a graphical user interface (GUI) used to manage patients who are users of the OnTrack rehabilitation system. Participants will be asked to complete clinical and non-clinical tasks in simulation using OnTrack Tools. The themes for the scenarios of use presented in each of the three phases are summarised below:~Phase 1 - Account creation, system onboarding and general system navigation. Phase 2 - Individual patient management. Phase 3 - Content and data management."
223874598|NCT05848609|DIAGNOSTIC_TEST|Geriatric Assessment|Geriatric assessment to evaluate cognitive function, functional status and quality of life before and after surgery
223874599|NCT01823133|DRUG|gemigliptin only|gemigliptin 50mg qd on day 1\~7
223874600|NCT01823133|DRUG|rosuvastatin only|rosuvastatin 20mg qd on day 1\~7
223874601|NCT01823133|DRUG|gemigliptin and rosuvastatin|gemigliptin 50mg, rosuvastatin 20mg qd on day 1\~7
223874602|NCT03314675|DEVICE|BIOTRONIK CRT-D|Pre-specified follow-up and measurements
223874603|NCT02541461|PROCEDURE|Laparoscopic gastrectomy|(1) Wedge resection, subtotal or total gastrectomy with or without lymph node dissection; (2) R0 resection; (3) Laparoscopic gastrectomy; (4) Gastroduodenal anastomosis or duodenal bypass, including Roux-en-Y or gastrojejunostomy
223874604|NCT01306786|DRUG|Quadruple therapy|"First line: 5 days esomeprazole 20mg b.d., bismuth subcitrate 120mg q.i.d., tetracycline 250mg q.i.d. and metronidazole 250mg q.i.d.~Cross over second line for those who failed first line: 7 days esomeprazole 20mg b.d., amoxicillin 1g b.d. and clarithromycin 500mg b.d"
223874605|NCT01306786|DRUG|Triple therapy|First line: 7 days esomeprazole 20mg b.d., amoxicillin 1g b.d. and clarithromycin 500mg b.d Second line cross over if failed first line: 7 days quadruple therapy: esomeprazole 20mg b.d., bismuth subcitrate 120mg q.i.d., tetracycline 250mg q.i.d. and metronidazole 250mg q.i.d.)
223874606|NCT01877343|DEVICE|CVInsight(TM)|Patient will be placed on a tilt table and pulse oximetry (Nonin Medical) and blood pressure will be measured at different table positions (different angles). Four positions will be explored. A hemodynamic monitor called CVInsight(TM) will be used to monitor the pulse oximeter readings.
223874607|NCT01137708|DRUG|ethinyloestradiol (EE) and levonorgestrel (LN), CP-690,550 + ethinyloestradiol (EE) and levonorgestrel (LN)|Period 1: 30 mcg ethinyloestradiol and 150 mcg levonorgestrel alone Period 2: 30 mcg ethinyloestradiol and 150 mcg levonorgestrel plus 30 mg CP-690,550 after 9 days of CP-690,550 at 30 mg BID
223874608|NCT01137708|DRUG|CP-690,550 + ethinyloestradiol (EE) and levonorgestrel (LN), ethinyloestradiol (EE) and levonorgestrel (LN)|Period 1: 30 mcg ethinyloestradiol and 150 mcg levonorgestrel plus 30 mg CP-690,550 after 9 days of CP-690,550 at 30 mg BID Period 2: 30 mcg ethinyloestradiol and 150 mcg levonorgestrel alone
223874609|NCT02820116|DRUG|Icotinib|In the neoadjuvant treatment phase, eligible patients will receive 125mg of Icotinib three times per day for 8 weeks (56 days). In the post-surgery phase, Icotinib 125mg/three tims/day taken orally for 2 years or till disease progression or unacceptable toxicity.
223874610|NCT05592028|DEVICE|transcranial magnetic resonance-guided focused ultrasound pallidothalamic tractotomy|XDP patients will receive unilateral or bilateral transcranial magnetic resonance-guided focused ultrasound pallidothalamic tractotomy.
223874611|NCT01837472|DRUG|Probiotic|Patients in the probiotic group received the probiotic compound Balance® (Protexin Co., Somerset, UK) or similar placebo, twice daily after meal for 14 consecutive days. Balance® capsules contains seven bacteria species including Lactobacillus strains (L. casei, L. rhamnosus, L. acidophilus, and L. bulgaricus), Bifidobacterium strains (B. breve and B. longum), and Streptococcus thermophiles. Total viable count (TVC) is 1 x 108 CFU/per capsule. Other Ingredients are Fructo-oligosaccharide as prebiotic, magnesium stearate, and hydroxypropyl methyl cellulose.
223874612|NCT01837472|DRUG|Placebo|Patients in the placebo group received the placebo capsule twice daily after meal for 14 consecutive days.
223874613|NCT00822367|DIETARY_SUPPLEMENT|Glucerna; Ensure; SlimFast|Each participant will consume all three nutritional supplements randomly assigned by computer program to drink one of the three products in one week intervals. Each product will contain 50 grams of carbohydrate but differs in volume, fat, protein, and fiber composition. BG will be tested by finger sticks before (fasting) and at 15, 30, 60, 90, 120, 150 and 180 minutes after drinking the supplement. The participants will have 8 finger stick blood sugar measurements over about 3 hours on each of the 3 testing days.
223874614|NCT03609008|DRUG|Levcromakalim|Intravenous administration of levcromakalim or placebo for 20 minutes. To investigate the role of levcromakalim/placebo on cerebral hemodynamic in healthy volunteers.
223874615|NCT03609008|DRUG|Saline|Intravenous administration of levcromakalim or placebo for 20 minutes. To investigate the role of levcromakalim/placebo on cerebral hemodynamic in healthy volunteers.
223874616|NCT04095715|OTHER|Haemostasis consultation|Haemostasis consultation
223874617|NCT04095715|BIOLOGICAL|Standard management of patients suspected of thrombopathy|Standard management of patients suspected of thrombopathy
223874618|NCT01193894|OTHER|Profermin|Medical Food (food for special medical purposes)
223874619|NCT01193894|OTHER|Fresubin|Medical food (food for special medical purposes)
223874620|NCT03373708|DRUG|Epirubicin|100mg/m2
223874621|NCT03373708|DRUG|Cyclophosphamide|600mg/m2
223874622|NCT03373708|DRUG|Docetaxel|75mg/m2(TC), 100mg/m2(EC-T)
223874623|NCT03373708|DRUG|Goserelin acetate|3.6mg every month
223874624|NCT03373708|DRUG|Tamoxifen|10mg twice daily oral
223874625|NCT03373708|DRUG|Letrozole|2.5mg every daily oral
223874626|NCT03760354|DRUG|Methylprednisolone|Dose: 500mg/day for the first two days then 2mg/kg per day for three days. Dilution in 0.9% NaCl, 100 ml as a single slow intravenous administration over 60 minutes Total processing time of 5 days
223874627|NCT03760354|OTHER|Placebo|NaCl 0.9%, 100ml per day as a single slow intravenous administration over 60 minutes for a total treatment duration of 5 days
223874628|NCT00419341|BIOLOGICAL|Human Normal Immunoglobulin for Subcutaneous Administration|
223874629|NCT00168753|DRUG|Alefacept|IM
224076596|NCT04902365|OTHER|neurofeedback|(based on real-time functional magnetic resonance signals)
224076597|NCT01217541|OTHER|Education and Supervision|Implementation of Scales in the care of patients with dementia in nursing home units with focus on person-centred care. Supervision of caregivers on a regular basis.
224076598|NCT01217541|OTHER|Control|A control group of nursing home units that do not get any form of active intervention
223874630|NCT06971432|PROCEDURE|Group SAPB|Using ultrasound guidance, the needle is advanced in-plane at approximately 45° toward the fifth rib. For the superficial SAPB, the local anesthetic is injected anteriorly to the serratus anterior in the plane created with the latissimus dorsi muscle. The thoracodorsal artery runs in this plane, and while care should be taken not to puncture this vessel, the spread of the injectate around the vessel confirms the appropriate injection plane. For the deep SAPB, the local anesthetic is injected anteriorly to the rib and deep to the serratus anterior. Deep and superficial serratus anterior plane block (SAPB) will be performed at the level of the 5th rib. A total of 40 ml of 0.25% bupivacaine will be administered-20 ml into each compartment. All patients will routinely receive paracetamol 1 g four times daily. If the VAS score is 4 or higher, 100 mg of tramadol HCl will be administered.
223874631|NCT06971432|PROCEDURE|Group SAPB + LIA|"SAPB is applied similarly to the other group.Deep and superficial serratus anterior plane block (SAPB) will be performed at the level of the 5th rib. A total of 40 ml of 0.25% bupivacaine will be administered-20 ml into each compartment.At the end of the surgical procedure, while the incision line is still open, a catheter will be placed in the subcutaneous tissue, at the most lateral part of the incision. A 0.20% bupivacaine solution will be prepared and at the end of the operation, a 10 ml bolus will be administered, followed by a 2 ml/hour infusion for 48 hours.~All patients will routinely receive paracetamol 1 g four times daily. If the VAS score is 4 or higher, 100 mg of tramadol HCl will be administered."
223874632|NCT06342999|PROCEDURE|Fetal Aortic Valvuloplasty Procedure|Treatment given during pregnancy in which a balloon is used to increase the size of the baby's aortic valve in vitro.
223874633|NCT06342999|DEVICE|Emerge Monorail and Over-The-Wire PTCA Dilatation Catheter|Balloon Catheter
223874634|NCT06342999|DEVICE|Trek RX and Mini Trek RX Coronary Dilatation Catheter|Coronary Dilation Catheter
223874635|NCT02792374|OTHER|Psychological Measurement|Measurement of psychological status in three levels: discrete symptom level, dimensional level, global level as measured by the scale
223874636|NCT02072213|DRUG|GL2702 GLARS-NF1|0.4mg once a day
223874637|NCT02072213|DRUG|Omix Ocas|0.4mg once a day
223874638|NCT00014599|DRUG|paclitaxel|
223874639|NCT00687622|DRUG|GSK1120212|Part 1-dose-escalation Part 2 - Recommended Part 2 dose Part 3 - characterize the range of biologically effective doses
223874640|NCT01499199|DRUG|Dolutegravir|50mg Once Daily
223874641|NCT01673555|DRUG|GSK1278863|GSK1278863
223874642|NCT01673555|DRUG|Placebo|Placebo
223874643|NCT04234776|DRUG|Ketamine|(0,75 mg/kg) saline solution (15 mg) Escitalopram (5 mg) Aripiprazole
223874644|NCT04234776|DIAGNOSTIC_TEST|Cognition|Composite tools
223874645|NCT04234776|OTHER|Suicide risk|MADRS (10) and HAM-D (3)
223874646|NCT04234776|OTHER|Depression thoughts|EPD
223874647|NCT04234776|OTHER|Quality of life and disability|Quality of life and disability
223874648|NCT04234776|OTHER|Clinical and epidemiological factors|Variables and categories
223874649|NCT04234776|DEVICE|Safety of ketamine IM|Vital signs
223874650|NCT04234776|OTHER|Tolerability of ketamine IM|UKU-SERS, YOUNG, CADSS and BPRS-12.
223874651|NCT06012331|PROCEDURE|concentrated growth factors in open apex|"Dry canals with paper points. A 10 ml of venous blood will be collected and transferred to sterile tubes without anticoagulant solutions by a trained nurse. The tubes will be centrifuged machine using a one-step centrifugation protocol at variable rpm, after centrifugation, four layers will be obtained: the first layer at the top is serum, second layer is the fibrin buffy coat, the third layer is the liquid phase containing growth factors, The concentrated growth factor was separated from the red blood cells and serum using sterile scissors.~CGF will be packed into canal to the full working length using sterile pluggers.~The coronal level of the CGF gel is near the cervical area above cementoenamel junction and white MTA placed as capping material after CGF, then GIC and composite restoration"
223874652|NCT06012331|PROCEDURE|Blood Clot (BC)|"1. Create bleeding into the canal by over-instrumenting (induce by rotating a pre-curved K-file at 2 mm past the apical foramen with the goal of having the entire canal filled with blood to CEJ level)~2. Stop bleeding at a level that allows for 3-4 mm of restorative material.~3. Then white MTA as a coronal plug material be followed by GIC, then composite restoration."
223874653|NCT03617978|PROCEDURE|Hemodynamics parameters|real-time evaluation of cardiac output parameters using the ICON device
223874654|NCT00000699|DRUG|Inosine pranobex|
223874655|NCT00000699|DRUG|Ribavirin|
223874656|NCT01717677|PROCEDURE|radical prostatectomy|
223874657|NCT01717677|RADIATION|percutaneous radiation therapy|
223874658|NCT01717677|RADIATION|permanent seed implantation|
223874659|NCT01717677|PROCEDURE|Active Surveillance|
223874660|NCT01268813|OTHER|Breath analysis and blood analysis|Exhaled breath and blood samples will be collected and further tested using Gas Chromatography-Mass Spectroscopy system.
223874661|NCT04152694|OTHER|Ceftaroline levels in CRRT|Levels of ceftaroline measured in patients receiving CRRT
223874662|NCT05075213|BEHAVIORAL|contingency management (deposit contract)|Participants will deposit $30 of their own money to play QuitBet. Participants will submit a CO test once per day between the hours of noon and 11:59pm. Participants whose CO test is 6ppm or lower (indicating no smoking) on at least 24 of 26 days between day 3-28 of the game will be declared winners and split the pot of deposited money. Participants who submit at least 21 CO tests, regardless of the result, will be entered into a raffle to win a prize worth $75.
223874663|NCT05075213|BEHAVIORAL|leaderboard and social feed|Participants will have access to a discussion board on which participants can post and respond to messages to each other. Also, a game host will post educational information about smoking cessation and serve as a discussion moderator.
223874664|NCT05075213|BEHAVIORAL|smoking cessation resource list|Participants will have access to a list of smoking cessation resources
223874665|NCT03426839|DIAGNOSTIC_TEST|Coagulation tests|
223874666|NCT00513526|BIOLOGICAL|Gardasil|week 0, 8, 24, 128
223874667|NCT00711217|OTHER|Medical Food|twice daily
223874668|NCT00711217|OTHER|Drink mix calorically similar to experimental product|twice daily
223874669|NCT04152317|DRUG|Misoprostol 200mcg Tab|In the misoprostol 200mcg group there will be one tablet of 200mcg and three identical tablets in shape, size and color without pharmacological properties. These four tablets will be single dose administered via vaginal route for each participant.
223874670|NCT04152317|DRUG|Misoprostol 800mcg Tab|In the misoprostol 800mcg group there will be four tablets of 200mcg. These four tablets will be single dose administered via vaginal route for each participant.
223874671|NCT00995306|DRUG|Civamide (Zucapsaicin)|"Civamide Cream 0.075%, TID for 12 weeks~Civamide Cream 0.01%, TID for 12 weeks"
223874672|NCT02711059|PROCEDURE|parathyroidectomy|surgical treatment of hyperparathyroidism
223874673|NCT02020252|BEHAVIORAL|Testing an interactive technology in a diverse health literary population|Enrollment in therapeutic cancer trials remains low, and is especially challenging for patients with low health literacy. We tested an interactive technology designed for patients with diverse health literacy skills aimed at improving patient receptiveness, willingness, knowledge, self-efficacy and positive attitudes regarding clinical trials.
223874674|NCT02793154|DRUG|Exenatide|Supplied as SC injection containing 250 mcg/mL of exenatide, provided in the following dose regimens: Part A: 10 mcg taken twice daily for 5 days; Part B: 5 mcg twice daily taken for 4 weeks followed by uptitration to 10 mcg for 4 weeks In both parts, it will be administered within 60-minute period before morning and evening meals (or before 2 meals with approximate \>=6 hours apart)
223874675|NCT02793154|DRUG|Albiglutide|Part B: Albiglutide will be supplied as follows:30 mg SC injection pen containing 40.3 mg lyophilized albiglutide and 0.65 mL; 50 mg SC injection pen contains 67 mg lyophilized albiglutide and 0.65 mL water; Starting dose will be 30 mg weekly for 4 weeks and then uptitrated to 50 mg weekly for 4 weeks; Administered as a single SC injection once a week in the morning
223874676|NCT02738372|OTHER|Diagnosis/Prognosis|The present study will be a 24 months multi-center, triple-blind, prospective, cohort study which will be carried out between April 2016 and March 2018. Subjects diagnosed of rotator cuff (RC) tendinopathy, adhesive capsulitis (AC), glenohumeral instability, SLAP lesion, and/or acromioclavicular pathology and fulfill the inclusion criteria will be asked for participating in our study. Several questionnaires that will test the influence of different biopsychosocial factors and the presence of Central Sensitization will be administrated to these subjects. The outcomes will be assessed at baseline and 5 follow-ups (after 3, 6, 12, 18 and 24 months, t1-t6).
223874677|NCT04783246|BEHAVIORAL|Group Fitness|The group fitness intervention will involve streaming a group fitness class lead by a certified personal trainer. certified personal trainer and include variations of body-weight strength and aerobic exercise activities. Each work out session will be 30 minutes in duration and follow a structure of a warm-up period, alternating strength and aerobic exercises of varying intensity, and a cool-down period. The videos will be streamed to the group by a facilitator over Zoom video conferencing.
223874678|NCT04783246|OTHER|Nutrition education|The nutrition education intervention will involve 45-minute educational sessions involving didactic teaching, interactive goal setting, and a live cooking demonstration. Each session will be taught by a registered dietician who will also be responsible for designing the curriculum schedule.
223874679|NCT06215092|OTHER|Psychological assessment|Psychological assessment of cognitive and social-emotional functioning.
223874680|NCT04732338|OTHER|Osteopathic Manipulative Therapy|Osteopathic Manipulative Therapy (OMT) is a non-pharmacological, noninvasive form of manual medicine. Osteopathic practitioners use a wide variety of therapeutic manual techniques to improve physiological function and help restore homeostasis in the body. There is a structural assessment is to identify possible abnormalities of tissue texture. Areas of asymmetry and misalignment of bony landmarks are also evaluated, along with the quality of motion, balance, and organization. These asymmetries, also known as somatic dysfunctions, are then treated by a variety of manual treatments, administered by osteopaths.
223874681|NCT02703701|BEHAVIORAL|Physician at triage|A physician embedded at triage
223874682|NCT02703701|OTHER|Usual Care|No physician at triage
223874683|NCT06233500|PROCEDURE|pars plana vitrectomy|"All eyes in this study will be subjected to pars plana vitrectomy procedure with these main steps:~* 23 G trocar system will be used~* Posterior vitreous detachment will be induced with the aid of triamcinolone acetate injection, and core vitrectomy will be done~* Brilliant blue stain will be injected, and ILM forceps will be used for ILM peeling~Patients will be divided then into two groups:~Group A: Only wide ILM peeling up to the arcades well be done Group B: ILM peeling with flap well be done~* Shaving of the vitreous base, and then fluid air exchange~* SF 6 gas tamponade will be used"
223874684|NCT04426500|DRUG|Bupivacain|Direct injection of 0.25% bupivacaine into surgical wounds
223874685|NCT04426500|DRUG|Ultrasound-guided transversus abdominus plane block|bilateral TAP using ultrasound guidance in prostatectomies
223874686|NCT04426500|DRUG|Laparoscopic-guided transversus abdominus plane block|bilateral TAP using laparoscopic guidance in prostatectomies
223874687|NCT03276871|PROCEDURE|Telescopic Dissection|Creation of extraperitoneal space with blunt dissection using the laparoscopic probe
223874688|NCT03276871|DEVICE|Balloon Dissection|Creation of extraperitoneal space with aid of the disposable Spacemaker balloon dissector
223874689|NCT01811407|BEHAVIORAL|Precommitment announcement|
223874690|NCT01811407|BEHAVIORAL|Results announcement|
223874691|NCT01811407|BEHAVIORAL|Walking program|
223874692|NCT02897882|OTHER|Lung transplant|Pain evaluation
223874693|NCT03399916|BEHAVIORAL|Prompt sent|
223874694|NCT04113798|OTHER|Day 1 Assessments|Structured clinical interview to assess trauma history and mental health diagnoses, as well as a screening EKG to assess safety to engage in exercise testing (lasts 3-4 hours)
223874695|NCT04113798|OTHER|Day 2 Fear Learning|Participants undergo a standard fear conditioning procedure, in which they learn that one of two geometric shapes (circles or triangles) predict the occurrence of a noxious stimulus (mild electrotactile stimulation). Day 2 lasts about 1 hour.
223874696|NCT04113798|OTHER|Day 3 Fear Extinction|Participants undergo a fear extinction procedure, in which participants learn that the geometric shapes no longer predict a noxious stimulus (i.e., safety learning). Blood samples will be drawn immediately before exercise, and immediately following.
223874697|NCT04113798|BEHAVIORAL|Moderate Intensity Exercise|The moderate-intensity aerobic exercise session will consist of a 5 minute warm-up of light intensity activity (40-60% maximum heart rate; MHR) on a treadmill followed by walking or running at a moderate intensity (i.e., between 70-75% MHR) for 30 minutes on Day 3
223874698|NCT04113798|BEHAVIORAL|Low Intensity Exercise|Control participants will maintain light-intensity activity (i.e., walking at \~50% of MHR) for the full duration of 30 minutes.
223874699|NCT04113798|OTHER|Day 4 Recall of Fear Extinction|During Day 4, recall of the fear extinction memory is tested. Visits on Day 4 occur \~24 hours following Day 3, and lasts about 30 minutes.
223874700|NCT05936177|OTHER|Patient education|The intervention in this osteoporosis education research will consist of a concise and informative educational session delivered by a physiatrist, utilizing slides prepared based on information from reputable sources such as the International Osteoporosis Foundation website and the World Health Organization (WHO) health education booklet. The session will cover various topics including the definition of osteoporosis, its causes, risks, complications, dietary options, and specific exercise recommendations, with a focus on raising awareness and promoting informed decision-making regarding prevention and treatment options.
223874701|NCT06335446|OTHER|Novel mapping algorithm|Signals will be collected during the catheter ablation. These signals STAR maps will be created post procedure and these will be compared to the conventional maps used during the atrial tachycardia ablation. This will be used to validate the STAR maps created.
223874702|NCT03307278|BIOLOGICAL|House dust mite|As a stimulant to induce inflammasome activation
223874703|NCT02539225|DRUG|Ramucirumab|Administered IV
223874704|NCT02539225|DRUG|Placebo|Administered IV
223874705|NCT02539225|DRUG|S-1|Administered PO
223874706|NCT02539225|DRUG|Oxaliplatin|Administered IV
223874707|NCT02539225|DRUG|Paclitaxel|Administered IV
223874708|NCT00974831|OTHER|Amino Acid Drink Mixture|22 oz consumed in 7 oz, 8oz, 7 oz increments 5 minutes apart over 15 mins
223874709|NCT00974831|OTHER|Glucose drink|22 oz consumed in 7 oz, 8oz, 7 oz increments 5 minutes apart over 15 mins
223874710|NCT00212134|DEVICE|Contact lens correction of aphakia|optical correction of infant surgical aphakia with Contact lens
223874711|NCT00212134|DEVICE|Intraocular lens implantation|optical correction of surgical aphakia with intraocular lens
223874712|NCT04597203|DEVICE|755-nm picosecond alexandrite laser with topical 2% hydroquinone|treatment one side of the face with 755-nm picosecond alexandrite laser with topical 2% hydroquinone
223874713|NCT04597203|DRUG|topical 2% hydroquinone|treatment one side of the face with topical 2% hydroquinone
223874714|NCT02728765|DEVICE|Continuous positive airway pressure (CPAP)|Continuous positive airway pressure (CPAP) is the gold standard treatment for patients with obstructive sleep apnea (OSA). In a previous trials comparing therapeutic CPAP vs subtherapeutic CPAP, CPAP could reduce 24-hour mean blood pressure in mildly sleepy patients with OSA over 3 months whereas our one-year prospective study has shown that reduction of carotid artery intima-media thickness of OSA patients occurred mostly in the first 6 months and was sustained at 12 months in patients with CPAP compliance about 4.7 hours per night.
223874715|NCT05344924|DRUG|TACE+penpulimab+anlotinib vs. penpulimab+anlotinib|Patients will receive TACE as needed; penpulimab 200 mg i.v. every 3 weeks(Q3W); and anlotinib 12 mg orally before breakfast,everyday(QD); continue taking for 2 weeks and stop for 1 week, that is, 3 weeks (21 days) as a course of treatment.
223874716|NCT04784026|OTHER|Gait assessment (single)|The single walk will be evaluated with a 10-meter walking test and a G-Walk portable device.
223874717|NCT04784026|OTHER|Dual task gait assessment (motor+motor)|The dual task gait, 10-meter walking test and a motor (carrying a full water glass) will be combined with the task and evaluated with the G-Walk portable device.
223874718|NCT04784026|OTHER|Dual tak gait assessment (motor+cognitive)|The dual task gait will be combined with a 10-meter walking test and a cognitive (1-back test) task and evaluated with the G-Walk portable device.
223874719|NCT04804930|PROCEDURE|picture|We will perform a non-invasive assessment of the scalp with a dermoscope by taking two standardized pictures on the frontal area and the occipital area in order to a blinded analysis of trichoscopic patterns
223874720|NCT04766034|BEHAVIORAL|Simulated Grocery Shopping Exercise|Participants will click a link and simulate a shopping experience by selecting a week's worth of Supplemental Nutrition Assistance Program (SNAP)-eligible groceries for their household in a web-based supermarket platform
223874721|NCT01339130|BEHAVIORAL|Computerized tests and Electrophysiological measurements|"* Computerized tests: used to evaluate the empathy The participant observes a computer screen on which appears different types of images or words that can evoke an emotion. The participant responds by pressing the screen with his finger. This is a choice between several answers and respond as quickly as possible.~* Electrophysiological measurements: provide a measure of autonomic response to emotional stimuli: galvanic response (GSR) and electromyographic activity (EMG) of facial muscles (corrugator supercilii and zygomatic major).~* Neuropsychological assessment includes an assessment of intellectual efficiency, perceptual and visual-constructive abilities, memory, executive and an assessment of behavior and mood from questionnaires."
223874722|NCT03638440|DRUG|Naloxegol|Naloxegol is a PEGylated derivative of the μ-opioid receptor antagonist naloxone
223874723|NCT02971085|PROCEDURE|Active surveillance|Active surveillance cohorts are routinely performed the systematic biopsy ≥ 12 cores by TRUS-guided or MR-TRUS fusion according to the protocol based by time path as 1, 2, 4, 7, 10 years and subsequently every 5 years following initial TRUS biopsy.
223874724|NCT06540898|BEHAVIORAL|Mindfulness-Based Eating and Movement Program|"This intervention integrates mindful eating practices and mindful movement into physical education classes for a duration of 8 weeks.~Each session begins with a 10-minute mindful eating practice designed to enhance participants; awareness of hunger and fullness cues, the sensory experience of eating, and their emotional responses to food. The program is to address food literacy, physical literacy, and social-emotional learning. It applied the principles of various established mindfulness and cognitive behavioral therapies and the book The Joy of Half a Cookie: Using Mindfulness to Lose Weight and End the Struggle with Food . It is grounded in the components of Mindfulness-Based Eating Awareness Training. The movement practices include basic poses in pairs and groups, and breath awareness techniques to facilitate a mindful connection with physical sensations and mental states."
223874725|NCT06940492|OTHER|Dry needling|Dry needling is a force-based manipulation technique used by health care providers. Force-based manipulation describes when forces external to the body are passively applied to tissue with a therapeutic intent. During dry needling, a filiform needle (i.e., one without medication) is inserted into a muscle to target a trigger point, often times with the intent of eliciting a localized twitch response
224076599|NCT03021642|DRUG|Tepotinib test (Treatment Period 1)|Subjects will be administered a single oral dose of test treatment of film-coated tepotinib tablet (1 \* 500 mg tablet) in Treatment period 1 (Day 1)
223874726|NCT06298786|DIAGNOSTIC_TEST|Functional 6-minute mastication test|All participants will be evaluated in 3 different phases. First, they will respond to the online TMD screener questionnaire. Then, they will be presentally evaluated using the DC/TMD and finally they will undergo the functional 6-minute mastication test.
223874727|NCT05884775|OTHER|Mobile Health (mHealth) Patient-Reported Outcome (PRO) tool|Once the program begins, the AI chatbot sends daily text messages that include the PRO questions; a link to a library of educational resources tailored to their responses and personalized motivational messages with support. Participants will also be sent links to the interactive web-based dashboard that visualizes their daily PRO and HbA1c data. PCPs will be able to view reports of patients' PRO and home A1c data through the EHR interface, which can be reviewed during visits with the patient or asynchronously to track patient PROs between visits.
223874728|NCT04170062|DEVICE|Nasal Delivery of High-Flow Air and Oxygen Therapy|They will receive high-flow air and oxygen via a dual lumen nasal cannula at rest. Participants will be administered the high-flow air and then titrated with oxygen from 0 L/min until they reach and maintain a SpO2 level of 95% for 30 seconds. They will then remain on this setting for 3 additional minutes with continuous monitoring of SpO2 levels.
223874729|NCT04170062|DEVICE|Nasal Delivery of Oxygen Therapy|They will receive oxygen via a dual lumen nasal cannula at rest. Participants will be titrated with oxygen from 0 L/min until they reach and maintain a SpO2 level of 95% for 30 seconds. They will then remain on this setting for 3 additional minutes with continuous monitoring of SpO2 levels.
223874730|NCT05002257|OTHER|music therapy|Patients included in the intervention arm with music therapy will choose among 3 possible music: music from elsewhere, classical music, today's music. These 3 music thearpy will have an identical duration of 20 minutes.
223874731|NCT05002257|OTHER|No music therapy|Usual care
223874732|NCT05026749|DRUG|AZM Group|AZM at 20 mg/kg will be given intravenous daily for 3 days once patients are consented and enrolled into the study.
223874733|NCT05026749|OTHER|Control Group|Saline will be given intravenous daily for 3 days once patients are consented and enrolled into the study.
223874734|NCT06472492|BEHAVIORAL|Adjuvant yoga intervention|The yoga will include following asanas under the supervision of a yoga therapist. This will include Griva Shithilikarana, Skandha Sanchalana , Kati Sanchalana, Jaanu Sanchalana, Pada Sanchalana, Tadasana, Kati Sakti Vikasaka, Konasana,Marjari Asana, Vakrasana, Pascimottanasana, Matsyasana, Bhujangasana, Ardha Shalabhasana, Viparitakarani, Pavanamuktasana, Setubhandasana, Shavasana, Kapalabhati, Surya-anuloma pranayama, Chandraanuloma pranayama, Bhastrika, Bhramari Pranayama, Nadanusandhana.
223874735|NCT05146427|DEVICE|Slow-wave enhancement|A headband that measures slow-wave activity during sleep and uses auditory stimulation to enhance slow waves using closed-loop auditory stimulation.
223874736|NCT05146427|DEVICE|Sham device|A headband that measures slow-wave activity during sleep but has no auditory stimulation.
223874737|NCT04585191|BEHAVIORAL|Conversation Aid|"Intervention is a newly developed, 1-page conversation aid/communication tool entitled Talking to Your Doctor about Diabetes: Are My Current Medicines Still Right for Me? that patients receive prior to a scheduled appointment with their primary care physician (PCP). This document will provide brief education about changing risks and benefits of diabetes treatment as patients age, elicit values and preferences regarding treatment, and help direct next conversation steps."
223874738|NCT04585191|OTHER|Attention Control Educational Handout|Attention control is an existing health education handout that provides some general health advice geared towards older patients.
223874739|NCT04961164|DIETARY_SUPPLEMENT|Resistant Potato Starch, Corn Starch|Consume resistant potato starch at study period 1, then consume corn starch at study period 2.
223874740|NCT04961164|DIETARY_SUPPLEMENT|Corn Starch, Resistant Potato Starch|Consume corn starch at study period 1, then consume resistant starch at study period 2.
223874741|NCT06756282|PROCEDURE|Pacemaker and defibrillator|only patients with pacemaker implantation will be evaluated in the study
223874742|NCT05657119|BEHAVIORAL|MI FSN - Lethal Means Reduction|"Motivational Interviewing lethal means reduction, firearm storage supplies, Tailored text messages~* Participate in a 15-20-minute motivational interviewing (MI) session conducted by trained University of Michigan research staff focused on encouraging suicide lethal means~* Be offered to take home gun safety and lethal means reduction materials, including trigger locks, cable locks, ammo boxes, medication boxes and mental health resources~* Receive 4 weeks of tailored text message reminders and encouragement"
223874743|NCT05657119|BEHAVIORAL|Scripted FSN - Lethal Means Reduction|"Scripted lethal means reduction, firearm storage supplies, tailored text messages~* Participate in a 10-15-minute scripted session focused on gun safety and lethal means reduction~* Be offered to home gun safety and lethal means reduction materials, including trigger locks, cable locks, ammo boxes, medication boxes and mental health resources~* Receive 4 weeks of tailored text message reminders and encouragement"
223874744|NCT05657119|BEHAVIORAL|General Firearm Safety Intervention - General Firearm Safety|"General information on gun safety, firearm storage supplies, tailored text messages~* Participate in a 10-minute scripted conversation about safe gun storage practice~* Be offered to take home safe gun storage materials, including trigger locks, cable locks, and ammo boxes~* Receive 4 weeks of tailored text message reminders and encouragement"
223874745|NCT05657119|BEHAVIORAL|General Firearm Comparison - General Firearm Safety|"firearm storage supplies~\* Be offered to take home safe gun storage materials, including trigger locks, cable locks, and ammo boxes"
223874746|NCT01701986|PROCEDURE|Allogeneic Bone Marrow Transplantation|Undergo allogeneic BMT
223874747|NCT01701986|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic BMT or PBSCT
223874748|NCT01701986|BIOLOGICAL|Anti-Thymocyte Globulin|Given IV
223874749|NCT01701986|DRUG|Busulfan|Given IV
223874750|NCT01701986|DRUG|Clofarabine|Given IV
223874751|NCT01701986|DRUG|Gemcitabine Hydrochloride|Given IV
223874752|NCT01701986|DRUG|Mycophenolate Mofetil|Given IV then PO
223874753|NCT01701986|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo allogeneic PBSCT
223874754|NCT01701986|OTHER|Pharmacological Study|Correlative studies
223874755|NCT01701986|BIOLOGICAL|Rituximab|Given IV
223874756|NCT01701986|DRUG|Tacrolimus|Given IV then PO
223874757|NCT00777582|DRUG|AZD2281|Oral single dose formulation
223874758|NCT04295317|DRUG|PD-1 blocking antibody SHR-1210|PD1 antibody SHR-1210 D1 200 mg every three weeks; Three weeks is a course of treatment with a total of 8 courses, or the patient has tumor recurrence or metastasis (requires imaging to determine tumor recurrence or metastasis)
223874759|NCT04295317|DRUG|Capecitabine|Capecitabine 2500mg / m2/ d, 2 times/d for 2 weeks, followed by 1 week of stopping ,Three weeks is a course of treatment with a total of 8 courses, or the patient has tumor recurrence or metastasis (requires imaging to determine tumor recurrence or metastasis)
223874760|NCT04814186|DRUG|Tafamidis|61 mg, once daily, oral administration, for 12 months.
223874761|NCT06757231|BEHAVIORAL|Nurse Counseling Based on the Chronic Care Model (CCM)|"This intervention involves personalized nurse counseling for patients diagnosed with Inflammatory Bowel Disease (IBD) based on the Chronic Care Model. The intervention includes:~Biweekly phone consultations and weekly informational messages to provide education and support for symptom management, stress reduction, and quality-of-life improvement.~An educational booklet to aid self-management. Follow-ups to assess progress, address concerns, and provide guidance on IBD management strategies."
223874762|NCT04404569|DRUG|BXQ-350|BXQ-350 is a novel anti-neoplastic therapeutic agent configured from two components: Saposin C (SapC), an expressed (human) lysosomal protein, and the phospholipid dioleoylphosphatidyl-serine (DOPS), a phospholipid located on cell membranes (clinical formulation BXQ-350). BXQ-350 is administered by intravenous (IV) infusion in 28-day cycles
223874763|NCT01703078|DRUG|Ingenol once daily for two consecutive days|
223874764|NCT06694025|BIOLOGICAL|Efluelda Tetra Pre-filled syringe|Suspension for injection in a pre-filled syringe
223874765|NCT04917588|COMBINATION_PRODUCT|Saypha® FILLER Lidocaine (HQ)|Saypha® FILLER Lidocaine is administered by injection into the lips. The volume applied depends on the size of the area which requires correction and will be selected by the investigator. A maximum volume of 2 mL for both lips in total (i.e., for upper plus lower lip) including touch up might be needed per treatment but the treatment should not exceed 10 mL in total per treatment or 20 mL per year.
223874766|NCT04917588|COMBINATION_PRODUCT|Saypha® FILLER Lidocaine (C1)|Saypha® FILLER Lidocaine is administered by injection into the lips. The volume applied depends on the size of the area which requires correction and will be selected by the investigator. A maximum volume of 2 mL for both lips in total (i.e., for upper plus lower lip) including touch up might be needed per treatment but the treatment should not exceed 10 mL in total per treatment or 20 mL per year.
223874767|NCT06040190|DRUG|topical placebo tablet|Individuals will be instructed to dissolve half a tablet of placebo medication and hold the saliva near the painful oral sites without swallowing, for 3 minutes and then spit. Tablets will contain magnesium silicate, with the same color and flavor as the test medications. Researchers will provide a total of 32 tablets for each participant.
223874768|NCT06040190|DRUG|topical clonazepam tablet|Individuals will be instructed to dissolve half a tablet of clonazepam and hold the saliva near the painful oral sites without swallowing for 3 minutes and then spit. Researchers will provide a total of 32 tablets for each participant.
223874769|NCT06040190|DIETARY_SUPPLEMENT|oral alpha-lipoic acid capsule|Participants in this group will be instructed to take oral capsules containing alpha-lipoic acid.
223874770|NCT06040190|OTHER|topical phytotherapic capsaicin gel|Participants in this group will to apply the gel containing tocapsaicin on painful oral sites.
223874771|NCT06040190|RADIATION|local photobiomodulation|Photobiomodulation will be applied during 10 seconds per point at 56 points (three on the vestibular mucosa of the 4 quadrants, four on each labial mucosa, six on each of the two buccal mucosae, six on the hard palate, four on each lateral edge of the tongue, six on the dorsum of the tongue, and four sublingual points) with an intermediate distance of 2 mm. A dose of 12 J/cm² per session will be applied in continuous mode for 10 sessions. The 10 sessions will be applied twice a week for 5 consecutive weeks. The LASER will be applied perpendicularly in contact with the mucosa. All patients and the clinician will wear protective glasses.
223874772|NCT03495960|DRUG|Rituximab|"PART A - INDUCTION PHASE During the primary chemo-immunotherapy (PRIMAIN regimen, 2 courses; every 43 days) administered as induction in the PART A of the study, Rituximab is given 375 mg/m2 as standard infusion at days -6, 1, 15 \& 29. Rituximab on day -6 will be delivered only during the first course; it will be delivered between day -6 and day 0 according to clinical requirements and patient's conditions. Some patients would need for a fast chemotherapy starting.~PART B - INDUCTION PHASE Patients ineligible for high-dose methotrexate, will be assigned to receive concomitant whole brain radiotherapy-temozolomide-rituximab (Induction Part B). Rituximab is given 375 mg/m2 in 4 weekly doses, starting on day 2 of radiotherapy."
223874773|NCT03495960|DRUG|Methotrexate|During the primary chemo-immunotherapy (PRIMAIN regimen, 2 courses; every 43 days) administered as induction in the PART A of the study, Methotrexate is given 3 g/m2 as infusion (0.5 g/m2 in 15 min. + 2.5 g/m2 in 3-hr infusion) on days 2, 16 \& 30
223874774|NCT03495960|DRUG|Procarbazine|"PART A - INDUCTION PHASE During the primary chemo-immunotherapy (PRIMAIN regimen, 2 courses; every 43 days) administered as induction in the PART A of the study, Procarbazine is given oral 60 mg/m2/d from days 2 to 11~PART A - MANTEINANCE PHASE (control arm) Patients responsive or with stable disease after two courses of PRIMAIN regimen (the induction treatment) will be randomly allocated to receive two different maintenance therapies. Maintenance will start on day 60 of the 2nd PRIMAIN course.~Procarbazine represents the control arm and is given oral 100 mg/d from day 1 to 5 for 6 courses, every 4 weeks."
223874775|NCT03495960|DRUG|Lenalidomide|"Patients responsive or with stable disease after two courses of PRIMAIN regimen (the induction treatment) will be randomly allocated to receive two different maintenance therapies. Maintenance will start on day 60 of the 2nd PRIMAIN course.~Lenalidomide represents the experimental arm and is given oral 25 mg/d from day 1 to 21 for 24 courses; every 4 weeks."
223874776|NCT03495960|RADIATION|Radiotherapy|Patients ineligible for high-dose methotrexate, will be assigned to receive concomitant whole brain radiotherapy-temozolomide-rituximab (Induction Part B). Whole-brain will be irradiated by two opposite lateral fields including the first two cervical vertebras and the posterior two thirds of the eyes. Photons of 4 - 10 MeV, 180 - 200 cGy per day, 5 weekly fractions will be employed
224076600|NCT03021642|DRUG|Tepotinib reference (Treatment Period 2)|Followed by a 21-day washout after Treatment period 1 (Day 1), subjects will be administered a single oral dose of reference treatment of film-coated tepotinib tablet (5 \* 100 mg tablet) in Treatment period 2 (Day 22)
223874777|NCT03495960|DRUG|Temozolomide|"PART B - INDUCTION PHASE Patients ineligible for high-dose methotrexate, will be assigned to receive concomitant whole brain radiotherapy-temozolomide-rituximab (Induction Part B). Temoyolomide is given 75 mg/m2/d, every day for the whole duration of radiotherapy.~PART B - MAINTENANCE PHASE Temozolomide is also given as maintenance in Part B. The treatment consists of 12 courses where temozolomide is administered on days 1-5, every 4 weeks at a dose of 150 mg/m2/d at the first course, and of 200 mg/m2/d at the subsequent courses,"
223874778|NCT04919590|BEHAVIORAL|This is Quitting|Text message-based intervention for quit vaping support.
223874779|NCT04919590|OTHER|Assessment only control|Assessment only
223874780|NCT04919590|OTHER|Waitlist control|No contact until follow-up survey, waitlisted to receive intervention post study
223874781|NCT06417229|DRUG|BMS-986365|Specified dose on specified days
223874782|NCT06417229|DRUG|Rabeprazole|Specified dose on specified days
223874783|NCT05238142|DEVICE|MiniMed™ 780G Insulin Pump system|MiniMed 780G insulin pump with Guardian 4 sensor (phase 1) MiniMed™ 780G BLE 2.0 insulin pump used in combination with Disposable Sensor 5 (phase 2)
223874784|NCT03568422|DRUG|CFI-402257|Orally taken on intermittent schedule (days 1, 2, 8, 9, 15 \& 16
223874785|NCT03568422|DRUG|Paclitaxel|80 mg/m2 IV days 1, 8 \& 15 every 28 days
223874786|NCT06526741|OTHER|Longitudinal data collection|This is an observational ambispective non-interventional registry collecting longitudinal real-world data only. There is no intervention.
223874787|NCT05255146|DEVICE|Atricure Inc. Nitrous oxide Cryoprobe|Cryoanalgesia will be given by applying a nitrous oxide-cooled probe (AtriCure, Inc. 2000) locally to intercostal nerves in the 4th, 5th, and 6th rib spaces after completion of the surgical repair and before surgical closure. The probe will be cooled to -60°C and held on each location for 60 sec.
223874788|NCT02631603|DRUG|Placebo|Administer Placebo as anti-inflammatory
223874789|NCT02631603|DRUG|Prednisolone|Administer Prednisolone as anti-inflammatory
223874790|NCT03239626|RADIATION|POHIM-RT|postoperative adjuvant IMRT with hypofractionation (2.5 Gy/fraction, 16 fractions, once a day)
223874791|NCT06075446|BEHAVIORAL|ACT Raising Safe Kids|American Psychological Association ACT Raising Safe Kids
223874792|NCT06088888|DRUG|TGRX-678|Participants are given TGRX-678 tablets orally, once daily, at one of the dose levels as pre-determined for the dose escalation sequence or expansion cohorts.
223874793|NCT05229679|DIAGNOSTIC_TEST|HPV testing|All women age 23-29 resident in the pilot counties will be invited to HPV screening as of the study start date. The same invitation as currently used for women aged 30 and upwards will be used. This information clearly states that it is possible to opt out of the program and that data from the screening program will be collected to regional and national quality registers who will systematically evaluate the quality of the care. At the screening station, the samples are collected identically regardless of primary screening test used - there is no change in the procedures used neither for the woman or for the midwives taking the sample. HPV testing will be performed using the same purchased, CE-marked and accredited HPV screening platforms as currently used for women aged 30 and upwards. The cytology is according to the liquid-based cytology method.
223874794|NCT03632941|BIOLOGICAL|VRP-HER2|VRP (alphavirus-like replicon particles) containing self amplifying replicon RNA for HER2
223874795|NCT03632941|BIOLOGICAL|Pembrolizumab|A humanized antibody specific for the programmed cell death 1 (PD-1) receptor.
223874796|NCT05736432|DIETARY_SUPPLEMENT|Blueberries|Experimental condition
223874797|NCT05736432|DIETARY_SUPPLEMENT|Placebo|Placebo condition
223874798|NCT06083649|BEHAVIORAL|The AI-assisted tool used in this study was called Dental Monitoring (DM).|DM is the first APP system used in orthopedics patients in the world,it has been widely used in Asian countries (Taiwan, Hong Kong, Singapore, Japan,etc.) and has been used by 2140 patients so far. DM allows patients to take in-mouth photos at home, and uses AI as a background analysis to evaluate the patient's current oral condition (including oral hygiene and gum status) based on the photo.
223874799|NCT05115760|DIETARY_SUPPLEMENT|Dietary Supplement|Given Kate Farms pea protein oral nutrition supplement PO
223874800|NCT05115760|OTHER|Quality-of-Life Assessment|Ancillary studies
223874801|NCT05115760|OTHER|Questionnaire Administration|Ancillary studies
223874802|NCT02376049|DRUG|Pimecrolimus cream|
223874803|NCT02376049|DRUG|Betamethasone dipropionate cream|
223874804|NCT02376049|DRUG|Clobetasol propionate cream|
223874805|NCT02376049|DRUG|Glaxal Base cream vehicle|
223874806|NCT02237417|DRUG|Standard of Care Oral antipsychotics|A total of 15 to 20 subjects with schizophrenia will receive SOC oral antipsychotic medications (e.g., aripiprazole (Abilify®), risperidone (Risperdal®), lurasidone HCI (Latuda®), quetiapine fumarate (Seroquel®), olanzapine (Zyprexa®), and ziprasidone HCI(Geodon®)) or once monthly aripiprazole (Abilify®), PO daily, in accordance with their respective product labeling.
223874807|NCT02237417|DRUG|IM aripiprazole once monthly|A total of 30 to 40 subjects with schizophrenia will receive aripiprazole (Abilify®) monthly, at a starting dose of 400 mg IM or an approved dose based on the investigator's judgment and in accordance with product labeling.
223874808|NCT02237417|OTHER|No Treatment|A total of 15 healthy controls will participate in the study and will not receive medication
223874809|NCT06775938|OTHER|resident exam|Resident exam in May 2024.
223874810|NCT05374395|BEHAVIORAL|Peer Recovery Support-Delivered Dropout Prevention enhancement|Peer recovery supports will meet with emerging adults for four weekly sessions plus monthly check-ins during the next two months. Peer recovery supports will engage the emerging adults in motivational and skills-based strategies aimed at increasing adherence to services and attendance to treatment sessions.
223874811|NCT01143298|DRUG|LEO 27847 oral solution|
223874812|NCT04156581|DRUG|Bupivacaine|Bupivacaine is administered typically to reduce sensation in an area. It acts as a nerve block for surgical procedures.
223874813|NCT04156581|DRUG|Dexamethasone|Dexamethasone is a corticosteroid that reduces inflammation.
223874814|NCT04156581|OTHER|Saline|Saline is a mixture of NaCl and water that can be used as a placebo.
223874815|NCT03602612|DRUG|Cyclophosphamide|300 mg/m\^2 intravenous (IV) over 30 minutes on days -5, -4, and -3
223874816|NCT03602612|DRUG|Fludarabine|30 mg/m\^2 intravenous (IV) infusion over 30 minutes administered immediately following the cyclophosphamide on day -5, -4, -3
223874817|NCT03602612|BIOLOGICAL|Anti-B Cell Maturation Antigen (BCMA) chimeric antigen receptors (CARs) T cells|0.75x10\^6 - 12.0X10\^6 CAR+ T cells per kg of recipient bodyweight one time dose on day 0
223874818|NCT06336629|DRUG|Winlevi (clascoterone) 1% & Duac gel|Participants will use Winlevi (clascoterone) 1% and Duac gel as per label
223874819|NCT03960463|DEVICE|Transcu O2®|Participants randomized into study active group will be provided with a Transcu O2® at their surgical site and followed for 4 weeks.
223874820|NCT06126107|BEHAVIORAL|Brief Normative Feedback|Once a participant has completed the assessment of their drinking during the baseline battery, the participant will receive brief normative feedback about how their drinking compares to their peers.
223874821|NCT06126107|BEHAVIORAL|Loss-framed Text-messaging|Daily text-messages on the consequence of hazardous drinking.
223874822|NCT06126107|BEHAVIORAL|Gain-framed Text-messaging|Daily text messages on the benefits of reducing drinking to safe guidelines.
223874823|NCT05794581|DRUG|CT-868|CT-868
223874824|NCT05794581|DRUG|Placebo|Placebo as SC Injection
223874825|NCT05794581|DRUG|Victoza|Victoza as active comparator as SC Injection
223874826|NCT04043455|DRUG|Olorinab|Olorinab Dose 1 capsule or tablet by mouth, 3 times per day up to 12 weeks
223874827|NCT04043455|DRUG|Olorinab|Olorinab Dose 2 capsule or tablet by mouth, 3 times per day up to 12 weeks
223874828|NCT04043455|DRUG|Olorinab|Olorinab Dose 3 capsule or tablet by mouth, 3 times per day up to 12 weeks
223874829|NCT04043455|DRUG|Placebo|Olorinab matching placebo capsule or tablet by mouth, 3 times per day up to 12 weeks
223874830|NCT04043455|DRUG|Olorinab|Olorinab Dose 2 capsule or tablet by mouth, 3 times per day up to 52 weeks
223874831|NCT04043455|DRUG|Olorinab|Olorinab Dose 3 capsule or tablet by mouth, 3 times per day up to 52 weeks
223874832|NCT05769348|DEVICE|HD-tDCS Active Protocol|non-invasive brain stimulation (active protocol)
223874833|NCT05769348|DEVICE|HD-tDCS Sham Protocol|non-invasive brain stimulation (sham protocol)
223874834|NCT06187038|OTHER|Therapeutic exercises|The therapeutic exercise program will include warm-up, resistance, neuromuscular, mobility, and balance exercises. Over ten weeks, two sessions of the therapeutic exercise program will be carried out individually, lasting approximately 60 minutes each-a total of 20 therapeutic exercise sessions. Therapeutic exercise sessions will be carried out at least 24 hours between sessions. Therapeutic exercises will be performed in up to three sets of 8-12 repetitions or 30-60 seconds each, with rest intervals of 90 seconds between sets.
223874835|NCT06187038|OTHER|Therapeutic exercises + pain neuroscience education program|"In addition to the therapeutic exercise protocol previously reported in the control group, research participants allocated to the experimental group will undergo an education program in the neurosciences of chronic pain carried out one day a week between the two therapeutic exercise sessions lasting ten weeks.~The chronic pain neuroscience education program will be based on three domains. Making sense of pain, Exposure with control, and Lifestyle changes also urge modifications aimed at improving sleep, stress, and anxiety."
223874836|NCT03468530|PROCEDURE|Transurethral ablation|transurethral resection and/or coagulation with a bipolar loop under spinal or general anesthesia
223874837|NCT06375577|DIETARY_SUPPLEMENT|45 grams Voom Pocket Rocket Electro Energy|Participants will be required to consume 45 grams (in carbohydrates) of the Voom Pocket Rocket Electro Energy on one of the three experimental visits. Participants will have blood glucose, blood lactate, and insulin sampled throughout a 1-hour modified oral glucose tolerance test. Gas exchange will also be monitored throughout the 1-hour study visit.
223874838|NCT06375577|DIETARY_SUPPLEMENT|45 grams SIS Go Isotonic Energy Gel|Participants will be required to consume 45 grams (in carbohydrates) SIS Isotonic Energy Gel on one of the three experimental visits. Participants will have blood glucose, blood lactate, and insulin sampled throughout a 1-hour modified oral glucose tolerance test. Gas exchange will also be monitored throughout the 1-hour study visit.
223874839|NCT06375577|DIETARY_SUPPLEMENT|45 grams Maurten Gel 160|Participants will be required to consume 45 grams (in carbohydrates) Maurten Gel 160 on one of the three experimental visits. Participants will have blood glucose, blood lactate, and insulin sampled throughout a 1-hour modified oral glucose tolerance test. Gas exchange will also be monitored throughout the 1-hour study visit.
223874840|NCT04147585|OTHER|Intermittent Reduced Calorie Diet (IRCD)|Three cycles of a 5-day Intermittent Reduced Calorie Diet over three months.
223874841|NCT05137587|DEVICE|Integrated Pulmonary Index (IPI) monitoring|Integrated Pulmonary Index (IPI) monitor will be applied to the patients, to provide numerical data obtained from the measurements of end-tidal carbon dioxide, respiratory rate, oxygen saturation measured by pulse oximetry (SpO2), and pulse rate.
223874842|NCT05137587|DRUG|propofol|propofol
223874843|NCT05137587|DRUG|ketamine|ketamine
224076601|NCT03021642|DRUG|Tepotinib reference (Treatment Period 1)|Subjects will be administered a single oral dose of reference treatment of film-coated tepotinib tablet (5 \* 100 mg tablet) in Treatment period 1 (Day 1)
224076602|NCT03021642|DRUG|Tepotinib test (Treatment Period 2)|Followed by a 21-day washout after Treatment period 1 (Day 1), subjects will be administered a single oral dose of test treatment of film-coated tepotinib tablet (1 \* 500 mg tablet) in Treatment period 2 (Day 22)
224076603|NCT02639663|DEVICE|dental device|"Leboride~1. Post-partum primi and multiparous women whom are interested in breastfeeding and have not begun yet. This arm will be randomized into 2 groups~   1. Intervention group: participants will receive the dental device and be instructed to use it during breastfeeding.~  2. Control group: participants will not receive any device for breastfeeding pain control~2. Post-partum women that have already begun breast feeding, will receive the dental device and each woman will be serve as her own control (breastfeeding before and after the use of the dental device."
224076604|NCT00756938|DRUG|losartan potassium|losartan potassium, dry powder, to be suspended in liquid and given orally, once daily; doses will start at 0.1 mg/kg, 0.3 mg/kg, and 0.7 mg/kg, respectively, in the three study arms and can be escalated up to 1.4 mg/kg (maximum dose 100 mg) until target blood pressure is reached.
223874844|NCT05370105|OTHER|blood withdrawal|"10 ml of blood, two 5 ml tubes suitable for serum isolation. Given the nature and objectives of the study, there are no risks and / o inconveniences of particular importance for the patient since the blood samples will be performed according to the common procedure used in all analysis laboratories. At the end of the collection, in the area where the blood sample was taken, a small bruise may form which will disappear in the following hours, in any case during the collection particular attention will be paid to the subjects being treated with antiplatelet and anticoagulants.~The study does not include the execution of interventional treatments or therapies."
223874845|NCT05568615|DRUG|MT-1186|Suspension
223874846|NCT05629559|BIOLOGICAL|4D-310|Single IV administration of 4D-310
223874847|NCT03529110|DRUG|Trastuzumab deruxtecan (T-DXd)|T-DXd is sterile lyophilized powder reconstituted into a sterile aqueous solution (100 mg/5 mL) to be administered intravenously.
223874848|NCT03529110|DRUG|Ado-trastuzumab emtansine (T-DM1)|The treatment will be in accordance with the approved label.
223874849|NCT03947827|DRUG|Minocycline|Participants will be randomized to receive either Minocycline or placebo added to standard oral antidepressants.
223874850|NCT03447379|DRUG|P2Y12 antagonist monotherapy|P2Y12 inhibitor(Clopidogrel 75mg/day or Ticagrelor 180mg/day) for 9months after 3 months of DAPT(Aspirin 100mg/day + Clopidogrel 75mg/day or Aspirin 100mg/day + Ticagrelor 180mg/day)
223874851|NCT03447379|DRUG|Aspirin plus P2Y12 antagonist|DAPT(Aspirin 100mg/day + Clopidogrel 75mg/day or Aspirin 100mg/day + Ticagrelor 180mg/day) for a year
223874852|NCT05194917|OTHER|Older Smoker Motivational Intervention|OSMI identified in Aim 2 of the study, motivational interventions will be delivered via mailer with QR video code.
223874853|NCT05194917|OTHER|Control Motivational Message|"One control motivational message with a standard health- and EBST access-related content (i.e., Quitting smoking is the best thing you can do for your health. Call 1-800-QUIT-NOW for help.), motivational interventions will be delivered via mailer with QR video code."
223874854|NCT05844566|DEVICE|Decision Support System (DSS)|"This DSS will provide estimates of potential benefits in terms of ASCVD risk reduction (composite endpoint: combined non-fatal myocardial infarction, non-fatal ischaemic stroke and cardiovascular death) as a function of treatment duration and magnitude of LDL-C lowering.~The DSS does not recommend treatments but shows the expected ASCVD risk, absolute and relative ASCDV risk reductions and number needed to treat for the various treatments selected by the clinical user on the potential value of initiation of an add-on therapy for reducing the risk of recurrent Cardiovascular (CV) events. Implementing the patient-specific recommendation remains at the clinicians' discretion."
223874855|NCT06364059|PROCEDURE|Decompressive craniectomy with evacuation of subdural hematoma|Adult patients who underwent decompressive craniectomy with evacuation of subdural hematoma.
223874856|NCT06130163|PROCEDURE|endoscopic retrograde cholangiopancreatography|endoscopical clearance of the common bile duct
223874857|NCT06296173|OTHER|"Protective open-lung extubation"|Emergence using 50% FiO2, semi-sitting position with pressure support ventilation and preserved PEEP
223874858|NCT06296173|OTHER|Conventional extubation|Emergence using 100% FiO2, dorsal decubitus position with assistance or manual bag ventilation without PEEP
223874859|NCT05386134|DEVICE|Adaptive Optics Retinal Camera|The rtx1 is a non-invasive device functions without making contact with the eye. The fundus of the patient's eye is illuminated with the IR light emitted from the illumination optical system. The device is comprised of an optoelectronic sensor (OES) that measures the optical defects, software that calculates the necessary corrections and a deformable mirror (DM) that constantly adapts its shape to restore the image's clarity. The digital camera, which is built into the instrument, receives the images and then the images are recorded in the computer hard disk. The AO image software registers and averages the captured image series in order to reduce noise and produce a final enhanced image. The rtx1 integrates AO technology in a flood illumination imaging system and enables visualizing the retina with a high transverse optical resolution of 250 line-pairs per millimeter.
223874860|NCT04520061|BEHAVIORAL|Health Insurance Navigation Program|The program will be delivered via videoconferencing by a navigator over a 2-month period and will consist of 4 sessions. The navigation intervention sessions will be as follows: Session 1- Learning About Survivorship Healthcare Needs; Session 2- Learning About Your Plan in Relation to Policy; Session 3- Navigating One's Own Plan and Overcoming Obstacles; Session 4- Managing Care Costs.
223874861|NCT05436106|BEHAVIORAL|Adaptive Intervention Approach|"This is an adaptive intervention approach with 7 module-based sessions selected on the basis of post-session assessments of acceptability and satisfaction;~1. weekly group sessions will be co-led by a community member with expertise in working with transgender women and a public health nurse,~2. supplemental educational content will be available for individual consumption via an online portal or application (and tracked via participant click counts), and~3. additional social resources will be available through the online portal or app."
223874862|NCT05540678|DIETARY_SUPPLEMENT|FibreGum|To chew every day during a period of 6 months 3 chewing gums (morning, noon and evening) for at least 20 minutes each.
223874863|NCT05540678|DIETARY_SUPPLEMENT|Placebo|To chew every day during a period of 6 months 3 chewing gums (morning, noon and evening) for at least 20 minutes each.
223874864|NCT06554678|PROCEDURE|Transnasal humidified rapid insufflation ventilatory exchange（THRIVE）|Transnasal humidified rapid insufflation ventilatory exchange（THRIVE）
223874865|NCT06554678|PROCEDURE|conventional oxygen mask|conventional oxygen mask
223874866|NCT05124249|DIAGNOSTIC_TEST|Intravascular imaging (IVUS or OCT) or Invasive physiologic assessment|Intravascular imaging (IVUS or OCT) or Invasive physiologic assessment
223874867|NCT05124249|PROCEDURE|PCI|Patients who undergoing PCI
223874868|NCT06207396|DIAGNOSTIC_TEST|serum and urine analysis|Spiking will be analyzed by immunoassay testing and high-resolution screening
223874869|NCT04192747|DEVICE|Percutaneous Coronary Intervention|Percutaneous coronary intervention of de novo native coronary artery lesions
223874870|NCT00724334|DRUG|SAR302503 (TG101348)|orally administered, once a day
223874871|NCT05570006|DRUG|ABBV-668|Oral Capsule
223874872|NCT06780059|RADIATION|Adjuvant Radiotherapy|Postoperative Radiotherapy with 3D-CRT and IMRT Techniques Following R0 Resection in BoPT and MPT Patients
223874873|NCT06780059|PROCEDURE|R0 resection|Patients who received R0 resection (complete resection without tumor margin)
223874874|NCT06781528|OTHER|Ultrasound evaluation|All patients will undergo 2D and 3D transvaginal ultrasonography 6-12 months after delivery at the outpatient clinics of our center, as per normal care procedure. Ultrasonographic evaluation aims to detect alterations of the uterine ecostructure, particularly of the endometrial-myometrial junctional zone. The presence of typical signs of uterine adenomyosis, in its various forms (diffuse, focal or localized-adenomyoma) will be investigated.
223874875|NCT06834802|PROCEDURE|PRF|PRF membrane will be used for soft tissue grafting around implant
223874876|NCT06834802|PROCEDURE|Human amniotic membrane|Human amniotic membrane will be used for soft tissue grafting around implan
223874877|NCT06834802|PROCEDURE|No grafting|No soft tissue grafting around implant
223874878|NCT06779929|DRUG|Tirzepatide|Tirzepatide
223874879|NCT06779929|DRUG|Dulaglutide|Dulaglutide
223874880|NCT06783231|BEHAVIORAL|Identifying with the aggressor|The IWA lab task consists 10 min audio recorded story, portraying a romantic relationship between two women (Lori and Sophia), in which one of them (Lori - the perpetrator) is being aggressive towards the other (Sophia - the victim). The story was carefully designed to align with ethical considerations - it is non-graphic, contains no severe acts of violence, and mostly describes a romantic power dynamic which may be considered abusive or toxic. The three groups of participants will receive different instructions before listening to the audio recording. The 'identification with the aggressor' group will be asked to try to identify, understand and adopt the point of view of Lori (the perpetrator)
223874881|NCT06783231|BEHAVIORAL|Identifying with the victim|The IWA lab task consists 10 min audio recorded story, portraying a romantic relationship between two women (Lori and Sophia), in which one of them (Lori - the perpetrator) is being aggressive towards the other (Sophia - the victim). The story was carefully designed to align with ethical considerations - it is non-graphic, contains no severe acts of violence, and mostly describes a romantic power dynamic which may be considered abusive or toxic. The three groups of participants will receive different instructions before listening to the audio recording. The 'identification with the victim' group will be asked to try to identify, understand and adopt the point of view of Sophia (the victim)
223874882|NCT06783231|BEHAVIORAL|Neutral|The IWA lab task consists 10 min audio recorded story, portraying a romantic relationship between two women (Lori and Sophia), in which one of them (Lori - the perpetrator) is being aggressive towards the other (Sophia - the victim). The story was carefully designed to align with ethical considerations - it is non-graphic, contains no severe acts of violence, and mostly describes a romantic power dynamic which may be considered abusive or toxic. The three groups of participants will receive different instructions before listening to the audio recording. The control group will be asked to pay attention to the story's details and to try and remember as much details as they can.
223874883|NCT05086406|OTHER|Combination of Video and Virtual Pre-operative Counseling|Intervention will be a pre-operative counseling video followed by a virtual visit with a gynecologic surgery provider, using standard and secure communications.
223874884|NCT04968990|DEVICE|Proton Beam Radiation (PBRT)|The treatment approach with radiation therapy prescribed in this trial is designed to deliver highly conformal radiation therapy (proton beam radiation or intensity modulated photon radiation) to target volumes that are based on the burden of disease.
223874885|NCT04968990|DRUG|DD-4A Chemotherapy Regimen|Patients will receive standard of care chemotherapy based on diagnosis and stage.
223874886|NCT04968990|PROCEDURE|Complete Surgical Resection|Participants will undergo complete surgical resection at diagnosis or after 6-12 weeks of induction chemotherapy
223874887|NCT04968990|PROCEDURE|Surgical Resection|Participants will undergo surgical resection at diagnosis or after 6-12 weeks of induction chemotherapy.
223874888|NCT04968990|PROCEDURE|Partial Nephrectomy|Participants will undergo partial nephrectomy after 6-12 weeks of induction chemotherapy.
223874889|NCT05327543|BEHAVIORAL|Iyengar Yoga|Iyengar Yoga focuses on the correct alignment of the body while practicing the physical exercises of yoga. Props are used to support the body in finding the right alignment. Relaxation is also part of this intervention. Participiants receive 1x90 min guided yoga class per week for 8 weeks and are encouraged to continue their practice at home daily for at least 30 minutes.
223874890|NCT05327543|BEHAVIORAL|Meditative Yoga|Meditative Yoga in the context of this study means practicing the physical exercises of yoga as well as meditation. Additionally, each week one of the yamas/niyamas, which are ethical principles to live by in the Yoga philosophy, will be presented at the beginning of each class and will form the theme of the class. Participants receive 1x90 min guided yoga class per week for 8 weeks and are encouraged to continue their practice at home daily for at least 30 minutes.
223874891|NCT06783166|DRUG|Dapagliflozin 10mg|Dapagliflozin 10 mg is a medication classified as a sodium-glucose cotransporter-2 (SGLT-2) inhibitor.
223874892|NCT06783166|DRUG|Acetazolamide 500mg|Acetazolamide 500 mg is a medication classified as a carbonic anhydrase inhibitor.
224076605|NCT04438447|DIETARY_SUPPLEMENT|parenteral feeding|A 3-bag compartment peripheral parenteral solution (mOsm \< 800) containing carbohydrate, lipids and proteins will be infused to deliver 20/25 total Kcal/kg for a total of 5 days after the operation
223874893|NCT06792357|OTHER|Vagal Active Tone Application Procedure|"First section; A video will be created that includes pictures and visuals describing the vagus nerve, explaining its benefits, and providing information about its effects and usage during the birth process.~Second section; Deep breathing and focus exercises;~Feather Breath:~Candle Breath: The pregnant woman inhaled and exhaled as if she was trying to blow out a candle.~Relaxation Breath: Deep breath Third section; Body relaxation exercises; Fourth section; Facial muscle relaxation exercises; Fifth section; Neck and larynx muscle relaxation exercises;"
223874894|NCT06701903|DRUG|ITI-1284 10 mg|ITI-1284 10 mg tablet, taken once daily, sublingual administration.
223874895|NCT06701903|DRUG|ITI-1284 20 mg|ITI-1284 20 mg tablet, taken once daily, sublingual administration.
223874896|NCT06701903|DRUG|Placebo|Matching placebo tablet, taken once daily, sublingual administration
223874897|NCT06784622|DRUG|Treatment as usual|Well-Root PT is clinically used in many areas such as pulp capping, perforation and resorption repair, root tip filling and apexification. As Well-Root PT is available in pre-mixed capsule form, it can provide a consistent and adequate consistency and clinical convenience. Well-Root PT can be applied directly into the oral cavity by placing the capsule in a syringe. In addition, Well-Root PT has a shorter setting time than MTA.Despite these advantages, there is no study in the literature on the effect of Well-Root PT on postoperative pain and tooth vitality after pulpotomy in mature permanent molars
223874898|NCT06294912|OTHER|Plasmodium falciparum|Parasite inoculation administered by intravenous (IV) infusion as the challenge agent
223874899|NCT06294912|DRUG|MK-7602|Capsules to be administered orally.
223874900|NCT06294912|DRUG|Artemether/lumefantrine|Tablets to be administered orally as definitive antimalarial treatment.
223874901|NCT06294912|DRUG|Primaquine|Tablets to be administered orally as definitive antimalarial treatment.
223874902|NCT06294912|DRUG|Artesunate|Intravenous (IV) infusion to be administered as definitive antimalarial treatment.
223874903|NCT06294912|DRUG|Atovaquone/proguanil|Tablets to be administered orally as definitive antimalarial treatment.
223874904|NCT06831279|OTHER|EXERCISE|Conventional Physiotherapy + Dual-Task Approach During Walking and Balance Exercises:
223874905|NCT06832670|OTHER|intervention|Participants in the intervention group will receive vaccine education, video animation and game practice.
223874906|NCT06832670|OTHER|active comparator|There will be no intervention in this group. It will continue its active education.
223874907|NCT06090266|DRUG|OR502|IgG1 monoclonal antibody that binds specifically to the LILRB2 protein.
223874908|NCT06090266|DRUG|Cemiplimab|IgG4 mAb that binds to PD-1 and blocks its interaction with PD-L1 and PD-L2.
223874909|NCT03066843|DRUG|ALA (5-aminolevulinic acid)|ALA (5-aminolevulinic acid) will be applied to subjects' skin for either zero time incubation or one hour incubation
223874910|NCT03066843|DEVICE|Blue light therapy|Subjects will be exposed to blue light
223874911|NCT03271762|DEVICE|percutaneous mitral valve repair with MITRACLIP NT, MITRACLIP NTR/XTR, MITRACLIP G4NT/XT, MITRACLIP G4NTW/XTW|percutaneous mitral valve repair Percutaneous MitraClip Device Implantation
223874912|NCT03271762|PROCEDURE|cardiac surgery|mitral valve repair or mitral valve remplacement
223874913|NCT04703686|DRUG|Obinutuzumab|1000mg - prephase - one infusion at D-3
223874914|NCT04703686|DRUG|RO7082859|2.5 mg D1C1, 10 mg D3C1, then 30 mg D8C1 and D1 every 21 days (C2-C11, D1C2 starts 14 days after D1C1)
223874915|NCT05470595|DRUG|Atezolizumab|Atezolizumab (IMP) will be added to Platinum/Etoposide (Standard-of-Care). Four cycles of combined immunochemotherapy 3qw will be follows by maintenance with atezolizumab monotherapy until progression.
223874916|NCT04688450|DEVICE|VIGORIS Blood Pressure Management Clinical Decision Support System|Software system to optimize tight blood pressure management during vasopressor infusion
223874917|NCT06834061|PROCEDURE|Ultrasound|All patients underwent high-resolution real-time sonography of the carpal tunnel (both hands) using an Ultrasound (US) machine and a 12 MHz linear array transducer. US examination will be performed before and 3 months after surgery.
223874918|NCT06832605|BEHAVIORAL|MBCT group|"MBCT is a systematic training in mindfulness meditation techniques to teach participants skills to prevent relapse/recurrence of depression. Treatment includes weekly 2-hour classes over an 8-week period with home exercises, a full day of practice (6 hours long, adapted for online delivery), and 4 booster sessions offered every 3 months from the start of the programme.~Standard pharmacological treatment usually provided to patients suffering depression."
223874919|NCT06832605|BEHAVIORAL|MBCT self-help|"The 'MBCT self-help' is based on the book 'The Mindfulness Way: An 8-week plan to free yourself from depression and emotional stress'. The book presents the 8-week MBCT course as a self-help booklet. Participants are asked to guide themselves using the self-help book. The book provides elaborate and practical mindfulness guidelines that can be exercised each week, as well as questions to help with reflection, ways to check progress and valuable feedback from others who have undertaken this MBCT programme.~Standard pharmacological treatment usually provided to patients suffering depression."
223874920|NCT06832605|OTHER|Treatment as Usual (TAU)|Standard pharmacological treatment usually provided to patients suffering depression.
223874921|NCT06301477|OTHER|Resistant Starch|7.5g/m2 or 5.0g/m2 (body surface area) resistant starch oral consumption
223874922|NCT06301477|OTHER|Placebo|Placebo oral consumption of food-grade cornstarch
223874923|NCT06449053|PROCEDURE|ORGANIZATIONAL|A. a formalization of the recommendations to be applied to prevent DILH B. implemented and facilitated by an e-health application C. and will be based on adapting the hospital environment (connected mats, movement sensors, prescription assistance) D. and the dissemination of knowledge (production of summary and empowerment documents).
223874924|NCT06832553|OTHER|surgical incision drep|To compare the efficacy of surgical incision with silk plaster in ETT fixation.
223874925|NCT05777954|OTHER|Possible Klotho effects on SSc clinical conditions, namely skeletal, fibrotic and microangiopathic damage|"Female patients with a diagnosis of Systemic Sclerosis ( EULAR/ACR 2013 criteria ) attending the FPG Department of Rheumatology will be recruited after exclusion criteria are ruled out and informed consent is signed. DXA bone mineral density determination (Lunar Prodigy ) will be performed and bone metabolism parameters, according to routinary clinical practice, will be collected. Immunological and SSc-related disease features will also be recorded. Fibrosis will be determined by the extent of cutaneous involvement (limited or diffuse) and modified Rodnan Skin Score. Microangiopathy will be assessed by videocapillaroscopy and presence of acral ulcers or acrosteolysis; Presence of calcinosis will also be assessed .~Upon recruitment each SSc patient will undergo blood sampling, which will be centrifuged and stored at -80° until the day of the processing. Biomarkers (Klotho, OPG, DKK, and sclerostin) will be determined using commercial kit of the ELISA Immunoenzyme techniques"
223874926|NCT05777954|OTHER|Evalution in healthy patients of bone mineral density, Klotho level and key bone-related cytokines|Healthy female control patients undergoing bone mineral density determination will be recruited upon exclusion criteria are ruled out. A detailed clinical history will be assessed and blood sempling will be processed for detection of bone-related cytokines
223874927|NCT05593341|OTHER|Opioid education in person|"The presentation and handouts contain information regarding the following topics:~* Reviewing opioids and strategies for analgesia~  * Defining and identifying opioids~ * Goals for postoperative pain management and utilizing opioids to treat pain~ * Alternative modes of treating pain~ * Regional anesthesia/analgesia defined~* Side effects and risks of opioids~  * Common side effects of opioids~ * Risks of addiction, tolerance, dependence, opioid-induced hyperalgesia with long-term use~* Proper use and handling of opioids~  * Safe practices when taking opioids~ * Weaning off opioids~ * Safe storage and disposal of opioids"
223874928|NCT05593341|OTHER|Opioid education via video|"The video and handouts contain information regarding the following topics:~* Reviewing opioids and strategies for analgesia~  * Defining and identifying opioids~ * Goals for postoperative pain management and utilizing opioids to treat pain~ * Alternative modes of treating pain~ * Regional anesthesia/analgesia defined~* Side effects and risks of opioids~  * Common side effects of opioids~ * Risks of addiction, tolerance, dependence, opioid-induced hyperalgesia with long-term use~* Proper use and handling of opioids~  * Safe practices when taking opioids~ * Weaning off opioids~ * Safe storage and disposal of opioids"
223874929|NCT06782685|DRUG|Irinotecan liposoma|Exploration started with 50mg/m\^2 dose, preset 50mg/m\^2, 60mg/m\^2, 2 dose groups, IV infusion 90min, d1
223874930|NCT06782685|DRUG|oxaliplatin|Exploration started with 60mg/m\^2 dose, preset 60mg/m\^2, 85mg/m\^2, 2 dose groups, IV infusion, d1
223874931|NCT06782685|DRUG|bevacizumab|5mg/kg，i.v.，d1
223874932|NCT06782685|DRUG|5-FU|2400mg/m\^2, i.v.，46h
223874933|NCT06782685|DRUG|LV|400mg/m\^2, i.v.，d1
223874934|NCT06782685|DRUG|Irinotecan Liposomal|70mg/m\^2, i.v.，d1
223874935|NCT06782685|DRUG|Irinotecan Liposomal|Phase II recommended dose
223874936|NCT06782685|DRUG|Oxaliplatin|Phase II recommended dose
223874937|NCT06785909|BEHAVIORAL|Assessment of postural control, body perception, psychosocial factors and inflammation|Behavioral assessment of postural control, lumbar proprioceptive use during postural control, back-specific body perception, psychosocial factors (incl. fear of movement, pain catastrophizing, sense of coherence, fear-avoidance beliefs, (pregnancy-related) depression, anxiety and stress) and inflammatory mediators.
223874938|NCT06778499|OTHER|Plyometric training for experimental group|The experimental groups will undergo 3 interventions a week, with one session lasting 90 minutes. The experimental group will perform 15 minutes of dynamic stretching, 30 minutes of Latin dance-specific technique training, 30 minutes of plyometric training, and 15 minutes of relaxation stretching.
223874939|NCT06778499|OTHER|Traditional training for control group|The control group will perform 15 minutes of dynamic stretching, 30 minutes of Latin dance-specific technique training, 30 minutes of general training, and 15 minutes of relaxation stretching.
223874940|NCT05313243|DRUG|Brentuximab vedotin|Brentuximab vedotin is an antibody-drug conjugate medication used to treat relapsed or refractory Hodgkin lymphoma (HL) and systemic anaplastic large cell lymphoma (ALCL), a type of T cell non-Hodgkin lymphoma. It selectively targets tumor cells expressing the CD30 antigen, a defining marker of Hodgkin lymphoma and ALCL.
223874941|NCT05313243|DRUG|Pembrolizumab|Pembrolizumab is a humanized antibody used in cancer immunotherapy that treats melanoma, lung cancer, head and neck cancer, Hodgkin lymphoma, stomach cancer, cervical cancer, and certain types of breast cancer.
223874942|NCT03137095|OTHER|Cognitive testing|computerized and paper-based cognitive tests that assess memory, executive function, processing speed and concentration performed at Assessments 1, 3, 4.5 \& 5.
223874943|NCT03137095|OTHER|Research Brain MRI|Optional sub-study participation includes undergoing research brain MRI to obtain structural and functional brain images at Assessment 4.5 and 6.
223874944|NCT03646604|DRUG|Upadacitinib (ABT-494)|Upadacitinib will be administered orally.
223874945|NCT03442244|DRUG|LEO 90100 foam|Each subject has each of the 2 treatments applied at the same time on 2 different sites on the back
223874946|NCT03442244|DRUG|Vehicle of LEO 90100 foam|Each subject has each of the 2 treatments applied at the same time on 2 different sites on the back
223874947|NCT05782972|DRUG|dapagliflozin (Forxiga)|The participants received oral dapagliflozin (Forxiga) 10 mg/day for 24 weeks.
223874948|NCT05661942|DRUG|Calcium pre-treatment|The intervention is Calcium gluconate 1 gram/100ml 0.9% NaCl or 100ml 0.9% NaCl) over 5 minutes.
223874949|NCT05661942|OTHER|Placebo|Placebo/ no calcium pre-treatment.
223874950|NCT05532241|DEVICE|fixed metal orthodontic appliance|fixed metal orthodontic appliance (stainless steel brackets (Mini Master MBT 0.022'', American Orthodontics), nickel-titanium archwire (NiTi, American Orthodontics), elastomeric ligatures (Elastomerics, American Orthodontics))
223874951|NCT05532241|DEVICE|fixed non-metal orthodontic appliance|fixed non-metal orthodontic appliance (ceramic brackets (Radiance MBT 0.022'', American Orthodontics), polyamide thread, elastomeric ligatures (Elastomerics, American Orthodontics))
223874952|NCT05532241|PROCEDURE|oral hygiene|conducting regular oral hygiene, commonly recommended for orthodontic patients (toothbrush + toothpaste with a low fluoride concentration of 1450 ppm (Parodontax, GSK)
224076606|NCT00441545|DRUG|Fosrenol (Lanthanum Carbonate)|The starting dose is a total daily dose of 2250mg of Fosrenol (Lanthanum carbonate) to a maximum dose of 3000mg daily. Chewable tablets will be administered orally with meals in 750mg and 1000mg strength tablets.
224076607|NCT00441545|DRUG|Sevelamer hydrochloride|The starting dose is a total daily dose of 4800mg of sevelamer hydrochloride up to a maximum of 6400 mg daily. Sevelamer hydrochloride 800mg tablets, administered orally with meals.
224076608|NCT02347176|OTHER|Placebo|Subcutaneous injection with placebo
224076609|NCT02347176|BIOLOGICAL|Tralokinumab Dose 1|Subcutaneous injection with tralokinumab
224076610|NCT02347176|BIOLOGICAL|Tralokinumab Dose 2|Subcutaneous injection with tralokinumab
224076611|NCT02347176|BIOLOGICAL|Tralokinumab Dose 3|Subcutaneous injection with tralokinumab
224076612|NCT02213874|OTHER|Questionnaire|A questionnaire will be administered during the early stages of prenatal care \& again during the postpartum period. The initial questionnaire will assess trust in the health care system, locus of control, religiosity, health literacy \& collect information about demographics, contraceptive \& reproductive history, future pregnancy intentions, \& baseline knowledge about contraception. The postpartum questionnaire will repeat questions about future pregnancy \& contraception intentions, trust in the health care system, knowledge of contraception and collect new information about characteristics of antenatal contraceptive counseling received including whether a provider recommended a specific method of contraception, the amount of counseling received, \& the type of counseling received.
224076613|NCT01783119|DIETARY_SUPPLEMENT|Aloe Barbadensis Miller|
224076614|NCT01783119|DIETARY_SUPPLEMENT|placebo water|
224076615|NCT04628546|BEHAVIORAL|The Parenting Young Children Check-up Initial Check-up and Text Messages|Parents assigned to the intervention condition will go through the Initial Check-up, which is a brief intervention that uses motivational content to promote use of the Parenting Young Children Check-up parenting education website. They will also receive text messages and a brochure to connect them to the parenting education website.
224076616|NCT04628546|BEHAVIORAL|The Parenting Young Children Check-up Flier and Text Messages|Parents assigned to the control condition will not go through the Parenting Young Children Check-up Initial Check-up. They will only go through assessment and then see a brief flier about the Parenting Young Children. Like the intervention condition, they will also receive text messages and a brochure to connect them to the Parenting Young Children Check-up parenting education website.
224076617|NCT01442259|DRUG|AFQ056|
224076618|NCT00003100|DIETARY_SUPPLEMENT|soy isoflavones|
224076619|NCT02474082|BIOLOGICAL|Secukinumab|Secukinumab 150 mg, 1 ml liquid formulation in a pre-filled pen for s.c. injection
224076620|NCT02474082|DRUG|Fumaric acid|Fumaric acid initial therapy (tablet contains 30 mg dimethylfumarate, 67 mg ethylhydrogenfumarate calcium salt, 5 mg ethylhydrogenfumarate magnesium salt, 3 mg ethylhydrogenfumarate zinc salt) and Fumaric acid maintenance therapy (tablet contains 120 mg dimethylfumarate, 87 mg ethylhydrogenfumarate calcium salt, 5 mg ethylhydrogenfumarate magnesium salt, 3 mg ethylhydrogenfumarate zinc salt)
224076621|NCT03389282|DIAGNOSTIC_TEST|Tear Sampling|comprehensive eye exam, Schirmer test, break-up time, tear sampling
224076622|NCT01034046|OTHER|Low Carbohydrate Diet|Low carbohydrate diet (45% carbohydrate, 35% fat and 20% protein diet) administered utilizing meal replacements.
224076623|NCT01034046|OTHER|Low Fat Diet|Low fat diet (60% carbohydrate, 20% fat and 20% protein diet) administered utilizing meal replacements.
224076624|NCT00002147|DRUG|Doxorubicin hydrochloride (liposomal)|
224076625|NCT03452371|BEHAVIORAL|Patient Navigation|Navigators will also screen participants for barriers to smoking cessation. Patient navigation intervention calls will use motivational interviewing (MI) strategies to: (1) Assess stage of change; (2) Assess and reinforce any prior abstinence from smoking and/or any efforts made to reduce/quit smoking; (3) Explore motivation to quit smoking, drawing on recent illness, financial/family situations as appropriate; advise about the risks of smoking and benefits of quitting (4) Discuss past experience with utilizing cessation support; (5) Explore potential barriers to using smoking cessation medications; (6) Brainstorm strategies to address identified barriers; (7) Elicit commitment to accept another patient navigation counseling call, discuss timing.
223874953|NCT05532241|DRUG|Chlorhexidine mouthwash|conducting regular oral hygiene (Parodontay, GSK) + 0.12% chlorhexidine digluconate mouthwash (Curasept ADS 212, Curaden) daily during one month
224076626|NCT03452371|BEHAVIORAL|Enhanced Traditional Care|Enhanced traditional care will include a resource card with information on quitlines, Boston Medical Center's (BMC's) Tobacco Treatment Center Program number, and websites for smoking cessation.
224076627|NCT01792908|DEVICE|Kinesio tape|The KT used was Kinesiology Tape® of 5 cm and it was applied according to Kase protocol (Kase K). The first layer of tape consisted of a single strip placed over the anterior talofibular ligament from insertion to origin, with a 50% tension, except the two-centimetre proximal and distal ends, applied with no tension. The same procedure was repeated for the calcaneofibular ligament and posterior talofibular ligament
223874954|NCT04266041|DIAGNOSTIC_TEST|High-density electroencephalogram (HD-EEG)|This study will focus on obtaining a special type of high-density scalp electroencephalography (HD-EEG) recordings in patients with neurological disorders (i.e., epilepsy, brain tumor, stroke, etc.) and appropriately matched controls. HD-EEG is a scalp EEG which uses up to 256 channels compared to the standard 21 channels used for routine clinical applications. The reason for using more channels to record is for more precise localization of epileptogenic foci and/or more precise mapping of brain functions. This type of EEG requires the use of patient's own MRI scan to precisely localize activity. Therefore, all patients and controls getting an HD-EEG will require a structural MRI scan.
223874955|NCT04511455|DRUG|Cabozantinib|Cabozantinib 60 mg/day peroral
223874956|NCT04780568|DRUG|Osimertinib|Given PO
223874957|NCT04780568|DRUG|Tegavivint|Given IV
223874958|NCT05488496|BEHAVIORAL|Nature-based social intervention (NBSI), referred as Friends in Nature (FiN)|"The nature-based social prescribing is a multicomponent complex intervention applied by health or social care professionals as facilitators after a specific training.~It comprises: a psychosocial component and nature-based activities.~The psychosocial component is adapted from the group dynamic of Circle of Friends methodology focused on loneliness (Jansson A, Pitkälä KH, 2021) adapted to the cultural context of Barcelona and the target population of adults living in urban socio-economic vulnerable areas.~Nature-based activities are chosen by group participants through a co-created menu comprising all local resources in the area related to nature.~Specifically, participants start with an individual one-to-one session and then they meet once a week for two hours 10 weeks. Each week, participants decide the nature-based activity they wish to conduct."
223874959|NCT05488496|BEHAVIORAL|Usual care + menu with nature-based activities|Social prescribing as existing in usual care plus a written menu with the list of nature-based activities in the area.
223874960|NCT03915418|PROCEDURE|Connected tools|At home, parents will record their child's sleep for 1night Then, on the date scheduled for the inclusion of the children and after the recording of the 1 night at home, the child will spend a night in a hospital environment to carry out the recording by polysomnography and tools connected simultaneously.
223874961|NCT05526963|OTHER|Medication plan review|Intervention group patients will receive a revised medication plan by external pharmacologist based on the the STOPP/START criteria. The revised medication plan will be provided to the family physician who then will provide it to the patient. The revision comes along with evidence based information for the physician to prevent possible uncertainties by the physicians.
223874962|NCT05526963|BEHAVIORAL|Adherence support|Intervention group patients will receive a study nurse administered adherence support measure based on telephone-based motivational interviewing. The measure includes information on possible consequences of inadherence and signs of adverse drug reactions that is comprehensible for lay persons.
223874963|NCT02567201|OTHER|electrophysiological evaluation|electrophysiological assessment (experience 1 : passive ; experience 2 : active versus passive ; experience 3 : active, with feedback) Experience 1, 2, 3 : one session maximum by experience
223874964|NCT02567201|OTHER|electrophysiological evaluation of patients|electrophysiological assessment (experience 1 : passive ; experience 2 : active versus passive ; experience 3 : active, with feedback) Experience 1 : maximum one session by sensory modality of stimulation (auditory, tactile, or visual) Experience 2 : maximum one session by sensory modality of stimulation (auditory, tactile, or visual) Experience 3 : Stimulation = auditory or visual ; possibility of several sessions if the patient is tired.
223874965|NCT04306380|OTHER|no intervention, database study|data collection from EMR for database
223874966|NCT06497439|DRUG|Silfamin|2 tablets of Silfamin 150 mg twice daily
223874967|NCT06497439|DRUG|Placebo tablet of Silfamin|2 tablets of Silfamin Placebo twice daily
223874968|NCT04354636|DRUG|Silver modified atraumatic restorative treatment|Silver diamine fluoride that will be applied during atraumatic restorative treatment
223874969|NCT04354636|OTHER|Atraumatic restorative treatment|Using atraumatic restorative treatment without applying silver diamine fluoride
223874970|NCT05430373|BIOLOGICAL|GT101|Autologous tumor infiltrating lymphocyte injection
223874971|NCT05320614|OTHER|Web-Based Education|Web-Based Education Information about the operation that the child will undergo; animation films about the hospital, the operating room and the medical equipment to be used; training with presentation including methods of coping with anxiety, fear and pain, postoperative wound care, possible complications in nutrition and nursing care; educational games Education with Therapeutic Play Method Training with the therapeutic game method for 30-45 minutes in the game room in the service one day before the surgery
223874972|NCT05320614|OTHER|Routine maintenance Training|Explaining the routine care given to the child and parent in the control group by the pediatric surgery nurse in the service.
223874973|NCT04499690|BEHAVIORAL|Managing Cancer and Living Meaningfully|A brief, individual, manualized psychosocial intervention for patients with advanced and metastatic cancer
223874974|NCT05132114|DIAGNOSTIC_TEST|Lugol's iodine test|Intraoperative application of Lugol's iodine (i.e. staining of the cervix with Lugol's iodine solution)
223874975|NCT03189524|DRUG|Zanubrutinib|Zanubrutinib is a white to off-white solid that is slightly hygroscopic. The drug product was formulated as 20-mg (blue, size 3) and 80-mg (white, size 0) hard gelatin, opaque oral capsules. Zanubrutinib is classified as a Biopharmaceutics Classification System Class II compound.
223874976|NCT05800574|RADIATION|Radiation therapy (5 days for 7 weeks)|Mon-Fri (5 days for 7 weeks), total 35 fractions over 35 treatment days of radiation therapy (RT)
223874977|NCT05800574|RADIATION|Radiation therapy (5 days for 6 weeks)|Mon-Fri (5 days for 6 weeks), total 35 fractions over 30 treatment days of RT (two doses 6 hours apart except for the last 6th Friday of the 6 weeks )
223874978|NCT05800574|DRUG|Cisplatin|Cisplatin, 40mg/m2 (weekly for 7 weeks)
223874979|NCT05607719|DRUG|Bevespi|Two puffs twice a day
223874980|NCT05607719|DRUG|Bretzri|Two puffs twice a day
223874981|NCT02980276|DRUG|Metformin Hydrochloride|Women randomised to the metformin group will receive metformin 500mg once daily, with the dose titrated upwards every 2 days over 10 days increasing to a maximum of 2500mg Metformin daily (5 tablets) or maximum tolerated dose, in addition to usual care (exercise and MNT), and taken until delivery.
223874982|NCT02980276|OTHER|Placebo|Women randomised to the placebo group will receive 1 placebo tablet once daily, with the dose titrated upwards every 2 days over 10 days increasing to a maximum of five placebo tablets daily, in addition to usual care (exercise and MNT), and taken until delivery.
223874983|NCT06008912|OTHER|Calisthenic Exercises|Exercises for upper extremity, lower extremity and trunk which applying just patient's own body weight via using body mechanics. There is no need for any tools for exercises.
223874984|NCT06008912|OTHER|Aerobic Exercises|Exercises which loading cardiovascular, respiratory and muscular system at the same time. Treadmill training will apply in the study.
223874985|NCT06371833|DEVICE|Shoulder Arthroplasy with PRIMA humeral stem|Data collection of population that underwent a total shoulder arthroplasty with PRIMA humeral stem (anatomic configuration or reverse configuration)
223874986|NCT02124668|DRUG|Enzalutamide|oral
223874987|NCT04357288|OTHER|Patient Decision Aid|The Patient Decision Aid (PDA) is an interactive website designed for use by a participant without the need of their clinician present. It provides information about the atrial fibrillation diagnosis, possible treatments, the effect of this diagnosis on daily life, and how to prepare for a discussion about medications with a clinician. Participants may interact with the website by inputting their health information into the stroke risk calculator or answering questions about their values, goals, thoughts, etc. that they would like to discuss with their clinician.
223874988|NCT04357288|OTHER|Encounter Decision Aid|The Encounter Decision Aid (EDA) is an interactive website designed for use by a participant and their clinician together. Together, the clinician and participant can go through the website together and input the participant's health information into the same stroke risk calculator also in the PDA. The EDA also provides information about the diagnosis of AF, living with this diagnosis, and possible treatments, and prompts discussion of how a participant's values affects these aspects of AF.
223874989|NCT05894967|BEHAVIORAL|C1 - Standard Perceptual Learning (SPL)|Each trial starts with a fixation point (500ms) after which a Gabor (1° radius, at cut-off SF of 25% accuracy, estimated from Pre-Test CSF, at either 45° or 135°) appears for 128ms. The task is to indicate whether the Gabor was tilted left or right. Gabor contrast will be controlled by a 3/1 staircase (converging on approximately \~80% contrast threshold) across all training sessions.
223874990|NCT05894967|BEHAVIORAL|C2 - Long Training (LT)|Will be the same as the SPL with the exception that each session in LT will be twice as long as in SPL.
223874991|NCT05894967|BEHAVIORAL|C3 - Short Staircases (SS)|"Will be largely the same as SPL with the only difference being a change to the adaptive procedure. SS will use so-called short-staircases, which are initialized at 60% contrast with steps of .05 log units and employs a 3/1 staircase that after every 40 trials is reset (the short in short-staircases) back to 60% contrast."
223874992|NCT05894967|BEHAVIORAL|C4 - Mixed Difficulty (MD)|This condition will be identical to SPL with the exception that two staircases - one a 2/1 staircase producing difficulties centered around 60-70% accuracy, the other a 4/1 staircase producing difficulties centered around 85-95% accuracy - will be utilized to control the stimuli.
223874993|NCT05894967|BEHAVIORAL|C5 - Noise Training (NT)|The NT condition will be the same as SPL with the exception that contrast thresholds will be estimated in 5-different levels of external noise (10%, 15%, 20%, 25%, 30%).
223874994|NCT05894967|BEHAVIORAL|C6 - Training with Flankers (TWF)|TWF will be reasonably different from the standard SPL task. Here, on 50% of trials a target Gabor will be presented at either 45° or 135° (as in SPL) and will be flanked by two collinear Gabors. On the remaining 50% of trials, flankers will be present without a target. TWF is thus a yes/no detection task, which is necessary since the collinear flankers fully indicate the target orientation. In different 20-trial mini-blocks the flankers will appear either lambda, 1.5 lambda, or 2 lambda from the target (i.e., closer or further from the target) and target contrast will be controlled by a 3/1 staircase separately for each spacing.
223874995|NCT05894967|BEHAVIORAL|C7 - Parafoveal Training (PT)|The PT condition is the baseline for C8-C11 (all of which involve parafoveally presented targets). In PT, we utilize the same task as in SPL, however, in PT, in addition to central training, targets will also appear in one of two peripheral locations (5° eccentricity; angles = 135° and 270°). The location of targets will be randomized trial-wise so as to discourage eye-movements and independent 3/1 staircases will be run at each location. By training only 2 peripheral locations we can measure the extent to which training gives rise to location transfer (e.g., in transfer tasks examining performance at 8 different locations - 2 trained locations and 6 untrained locations). Furthermore, training at the central location facilitates comparisons between PT and SPL.
224076628|NCT02655081|DIETARY_SUPPLEMENT|high arginine nutritional supplement (Nestle's Impact AR)|Preoperative High-Arginine Nutritional Supplement Prior to Radical Cystectomy
224076629|NCT03355508|DEVICE|pucture in the arteriovenous fistula|"The compression time will be measured with a stopwatch so that it is objective and accurate, although the compression times range from minute to minute.~An initial 2-week observation phase (phase 1) will establish a reference time for each patient using the most common puncture technique in the department: bevel up.~We will evaluate the patient's reference time by counting the time of compression using a stopwatch for 2 weeks (ie 6 sessions) and we will take an average.~A draw will determine for each patient the order in which the direction of the needles will be used.~After this determination of the reference time, the patient will enter two successive phases where it will be punctured bevel up (phase 2) and then down (phase 3) or vice versa following the draw."
223874996|NCT05894967|BEHAVIORAL|C8 - Stimulus Variety (SV)|"The base task for SV is the PT condition. However, SV employ 20 trial mini-blocks of different SFs (.75, 1.5, 3, 6, 12, 24 cpd) and locations (45°, 135°, 225°, 315° - i.e., more locations than PT, but not the full set tested in the transfer battery) with separate staircases for each SF and location. Orientations will also be drawn from a larger set (22.5°, 45°, 67.5° - for which participants respond clockwise and 112.5°, 135°, 157.5° - for which participants respond counter-clockwise) and will vary on a trial-by-trial basis. This design holds-out 4 locations and 2 orientations to address transfer."
223874997|NCT05894967|BEHAVIORAL|C8a - Complex Features (CF)|This is the same as C8, however we will use band-pass filtered stimuli similar to what has been done by a number of groups including Hussein et al.
223874998|NCT05894967|BEHAVIORAL|C9 - Exogenous Attention Training (ExAT)|Stimuli will be presented in a similar manner as in PT. However, in ExAT, a 100% valid cue, a small black dot - 48ms duration with an 96ms SOA prior to stimulus onset - will appear above the target location on each trial.
223874999|NCT05894967|BEHAVIORAL|C10 - Endogenous Attention Training (EnAT)|Stimuli will be presented in a similar manner as in PT. However, in EnAT, a 100% valid cue (letter UL, LR; standing for upper left and lower right, respectively) - 150ms duration with an 500ms SOA prior to stimulus onset - will appear at the fixation point.
223875000|NCT05894967|BEHAVIORAL|C11 - Multisensory Facilitation (MF)|MF utilizes the same basic task structure as in ExEAT, however, rather than a visual cue, an auditory cue will be used (50ms, 1000hz tone with sound location determined by convolving sound with generic head-related transfer function, kemar large ears.
223875001|NCT05894967|BEHAVIORAL|No Contact Control|"While not a training condition one type of experience that could be part of a condition is a no contact control (i.e., where participants do no training activities over the same rough time span as for the other training tasks)."
223875002|NCT06071858|BEHAVIORAL|Care Coordination|"* The study staff clinician will review all medical issues for each patient and reach out to primary care providers (PCP), dieticians, and other medical providers as needed.~* The study staff clinician will serve as point person for communication with emergency departments and inpatient providers if the patient requires those levels of care.~* The clinician will communicate with outside providers to provide background and ensure health decision making by those providers, visit and support patients as appropriate, access outside records and share with rest of the care team, and most critically ensure that a proper discharge plan has been made for the patient including care appointments, access to prescriptions and any new referrals made during hospitalization."
223875003|NCT06071858|BEHAVIORAL|Individual Peer Support|• Patients will be offered weekly 1:1 sessions with a Peer Provider as part of routine care in a mixture of in-person and virtual formats as appropriate to support patients around treatment decisions, and recovery.
223875004|NCT06071858|BEHAVIORAL|Digital Outreach|• mindLAMP smartphone application for various kinds of outreach including but not limited to medication and/or appointment reminders, resources, and activities such as breathing and meditation exercises.
223875005|NCT06071858|BEHAVIORAL|Cognitive Remediation|"* For participants identified as needing and/or wanting support around cognition.~* The cognitive remediation program is available online or in-app and offers memory, attention, processing speed, executive functioning, and social cognition training activities."
223875006|NCT06071858|BEHAVIORAL|Multi-Family Group Therapy|"* Families whose loved ones are in CSC clinic will be offered weekly group sessions with a study staff clinician.~* Each group may include 5-8 families and include a mixture of in-person and virtual formats.~* These groups will be open-ended, including psychoeducation, and practical problem-solving discussions around care and other topics."
223875007|NCT05291286|DRUG|BXQ-350|BXQ-350 is a novel anti-neoplastic therapeutic agent configured from two components: Saposin C (SapC), an expressed (human) lysosomal protein, and the phospholipid dioleoylphosphatidyl-serine (DOPS), a phospholipid located on cell membranes (clinical formulation BXQ-350). BXQ-350 will be administered by intravenous (IV) infusion
223875008|NCT05291286|OTHER|Placebo|Placebo will be 0.9% normal saline of matching volume to BXQ-350 administered by intravenous (IV) infusion
223875009|NCT04384250|DIAGNOSTIC_TEST|Whole Exome Sequencing|Genetic study of patients
223875010|NCT04090528|BIOLOGICAL|pTVG-HP|pTVG-HP is a plasmid DNA, produced in E. coli, that encodes the complementary deoxyribonucleic acid (cDNA) for human prostatic acid phosphatase (PAP).
223875011|NCT04090528|BIOLOGICAL|pTVG-AR|pTVG-AR is a plasmid DNA
223875012|NCT04090528|DRUG|Pembrolizumab|Pembrolizumab is a human programmed death receptor-1 (PD-1)-blocking antibody indicated for the treatment of patients with multiple different types of cancer.
223875013|NCT04732117|DRUG|Secukinumab|Secukinumab 150 mg s.c. at BSL, Weeks 1, 2, and 3, followed by administration every 4 weeks starting at Week 4.
223875014|NCT04732117|DRUG|Placebo|Placebo 150 mg s.c.at BSL, Weeks 1, 2 and 3, followed by administration every 4 weeks starting at Week 4.
223875015|NCT04562688|OTHER|CICADAS only|Participants completed baseline assessments and neuroplasticity-based targeted cognitive training (NB-TCT) exercises on a digital device for up to 40 hours through BrainHQ (Posit Science Corporation, San Francisco). The CICADAS app captures user-specific sensory and cognitive processing metrics through 10 brief computerized assessments; these data are used to guide and personalize the delivery of 13 NB-TCT exercises. The NB-TCT exercises are adaptive with the task difficulty adjusting on a trial-to-trial and session-by-session basis to the abilities of each individual. A second set of computerized assessments was administered following the intervention period. Participants had to log in to access these assessments and exercises using a study provided username that contained no personally identifiable information.
224076630|NCT04044755|OTHER|Myopia prediction algorithm|Candidate predictors mainly includes age at examination, SER, and annual progression rate. Using these predictors, the algorithm will be used to predict SER at 3 years.
224076631|NCT04283903|DIAGNOSTIC_TEST|PICF|PICF collection from 4 sites
224076632|NCT00495651|DRUG|Antiretroviral medications|Antiretroviral medications initiation at any time during the trial if at least one WHO-recommended criterion for starting ART is observed.
224076633|NCT00495651|DRUG|Antiretroviral medications+Isoniazid prophylaxis|"* Antiretroviral initiation at any time during the trial if at least one 2009 WHO-recommended criterion for starting ART is observed.~* Isoniazid prophylaxis:300 mg of INH once a day before breakfast for six months, starting one month after study inclusion"
224076634|NCT00495651|DRUG|Antiretroviral medications|Early ART initiation on the day of inclusion, before reaching the current WHO criteria
223875016|NCT04562688|OTHER|PEERS + CICADAS and then no-contact|Participants will complete both PEERS and CICADAS study activities. Participants completed baseline assessments and neuroplasticity-based targeted cognitive training (NB-TCT) exercises on a digital device for up to 40 hours through BrainHQ (Posit Science Corporation, San Francisco). The CICADAS app captures user-specific sensory and cognitive processing metrics through 10 brief computerized assessments; these data are used to guide and personalize the delivery of 13 NB-TCT exercises. In addition, participants will be asked to attend weekly 1-hour group sessions led by a PEERS clinician. Each PEERS group session will consist of a minimum of 3 participants and will meet as a group using Zoom. PEERS teaches how to solve real-life social dilemmas, appraise affect and social contexts, and initiate and maintain conversations while receiving feedback from peers and clinicians. After 16 weeks, participant will crossover to No-Contact with no active intervention.
223875017|NCT04562688|OTHER|PEERS + Active Comparator and then no-contact|Participants will complete both PEERS and Active Comparator study activities. Participants will engage in computerized, casual video games for a total of 40 hours. Participants will also complete the 10 sensory processing abnormalities (SPA) computerized assessments. In addition, participants will be asked to attend weekly 1-hour group sessions led by a PEERS clinician. Each PEERS group session will consist of a minimum of 3 participants and will meet as a group using Zoom. PEERS teaches how to solve real-life social dilemmas, appraise affect and social contexts, and initiate and maintain conversations while receiving feedback from peers and clinicians. After 16 weeks, participant will crossover to No-Contact with no active intervention.
223875018|NCT02307812|DRUG|Ramucirumab|Administered intravenously (IV)
223875019|NCT02307812|DRUG|Paclitaxel|Administered IV
223875020|NCT03025789|DRUG|Fexinidazole|Tablets of 600 mg; Participants with a weight between 20 and 34 kg received 1200 mg (2 tablets) for 4 days, then 600 mg (1 tablet) for 6 days (with food); Participants with a weight of 35 kg and above received 1800 mg (3 tablets) for 4 days, then 1200 mg (2 tablets) for 6 days (with food)
223875021|NCT05286385|DEVICE|CP1150 Sound Processor|Speech perception tests whilst the subject is fitted with the CP1150 Sound Processor
223875022|NCT05286385|DEVICE|CP1150 NF|Speech perception tests whilst the subject is fitted with the CP1150 modified firmware (the addition of notch filters at 978Hz, 1956Hz, 2934Hz, 3912Hz).
223875023|NCT05286385|DEVICE|CP1150 + FF|Speech perception tests whilst the subject is fitted with the CP1150 Sound Processor with ForwardFocus.
223875024|NCT05286385|DEVICE|CP1110|Speech perception tests whilst the subject is fitted with the CP1110 Sound Processor.
223875025|NCT02789228|BIOLOGICAL|Tumor associated antigen lymphocytes (TAA-CTL)|"This protocol is designed as a phase I dose-escalation study. In each treatment group (A and B), patients will be enrolled to one of the following TAA-T dose levels:~Dose Level One: 1 x 107 cells/m2 Dose Level Two: 2 x 107 cells/m2 Dose Level Three: 4 x 107 cells/m2"
223875026|NCT06049589|DIETARY_SUPPLEMENT|Coconut Oil|Coconut oil rinsing
223875027|NCT06049589|DRUG|Chlorhexidine mouthwash|Chlorhexidine rinsing
223875028|NCT06049589|OTHER|Water mouthwash|Control with water rinsing
223875029|NCT06814678|BEHAVIORAL|Interactive Exergaming with Otago Exercise Program|Participants will receive a 12-week structured program combining interactive exergaming and Otago Exercise Program. Sessions include balance training, strength exercises, and functional mobility activities delivered through interactive gaming platforms, supervised by trained instructors.
223875030|NCT06814678|OTHER|Control Group with Usual Care|Participants will maintain their regular activities at community centers or facilities, including cognitive therapy, oral exercises, and upper limb training programs, during the 12-week study period
223875031|NCT02723955|DRUG|feladilimab (GSK3359609)|
223875032|NCT02723955|DRUG|GSK3174998|
223875033|NCT02723955|DRUG|Pembrolizumab|
223875034|NCT02723955|DRUG|Docetaxel|
223875035|NCT02723955|DRUG|Pemetrexed|
223875036|NCT02723955|DRUG|Paclitaxel plus Carboplatin|
223875037|NCT02723955|DRUG|Gemcitabine plus Carboplatin|
223875038|NCT02723955|DRUG|Fluorouracil (5-FU) plus carboplatin or cisplatin|
223875039|NCT02723955|DRUG|Dostarlimab|
223875040|NCT02723955|DRUG|Cobolimab|
223875041|NCT02723955|DRUG|Bintrafusp alfa|
223875042|NCT06757283|BIOLOGICAL|Purified Vi capsular polysaccharide of Salmonella typhi conjugated to tetanus toxoid as carrier protein (Typhoid Vi Conjugate Vaccine I.P.). Trade name: ZyVac® TCV|Purified Vi capsular polysaccharide of Salmonella typhi conjugated to tetanus toxoid as carrier protein (Typhoid Vi Conjugate Vaccine I.P.)
223875043|NCT06502145|DRUG|Azacitidine Level -1|Intravenous (IV) or subcutaneous (SC) 75 mg / m\^2 days 1-7 X 28 days.
223875044|NCT06502145|DRUG|Azacitidine Level 0|Intravenous (IV) or subcutaneous (SC) 75 mg / m\^2 days 1-7 X 28 days.
223875045|NCT06502145|DRUG|Azacitidine Level 1|Intravenous (IV) or subcutaneous (SC) 75 mg / m\^2 days 1-7 X 28 days.
223875046|NCT06502145|DRUG|Iadademstat Level -1|75 µg by mouth (PO) 5 days on, 2 days off for 2 weeks every 28 days.
223875047|NCT06502145|DRUG|Iadademstat Level 0|75 µg PO 5 days on, 2 days off for 3 weeks every 28 days.
223875048|NCT06502145|DRUG|Iadademstat Level 1|100 µg PO 5 days on, 2 days off for 3 weeks every 28 days.
223875049|NCT04300647|DRUG|Tiragolumab|Tiragolumab at a fixed dose of 600 milligrams (mg) will be administered by intravenous (IV) infusion every 3 weeks (Q3W) on Day 1 of each 21-day cycle.
223875050|NCT04300647|DRUG|Atezolizumab|Atezolizumab at a fixed dose of 1200 mg will be administered by IV infusion Q3W on Day 1 of each 21-day cycle.
223875051|NCT06815224|DEVICE|Sonar|Abdominal sonar
223875052|NCT03408613|PROCEDURE|Positive Airway Pressure|See arm/group description
223875053|NCT03408613|PROCEDURE|Supplemental Oxygen|See arm/group description
223875054|NCT03408613|PROCEDURE|Sham|See arm/group description
223875055|NCT03657212|DRUG|Zolpidem|The research involves oral administration of zolpidem (ZOL) or placebo during sleep with EEG recording. This study will employ a within-subject, crossover design, in which every subject experiences each of the following study conditions: Nap/5mg, Nap/placebo, plus an adaptation nap to be scheduled one week prior to the first experimental day. One condition will be tested per week, with condition order counterbalanced. Each subject will have 2 visits (plus an adaptation nap), each separated by 5-7 days (although this may be extended based on participant availability) to ensure that the drug is completely eliminated from the body. The order of drug conditions will be randomized and counterbalanced.
223875056|NCT04999085|OTHER|Supportive care interventions|Subjects will be referred to specialists and/or supportive care interventions based on issues/deficits identified on a baseline geriatric assessment. These interventions will be selected based on deficits or problems identified on baseline assessments. These include referral to physical/occupational therapy for those with physical deficits (Activities of Daily Living impairment, Instrumental Activities of Daily Living impairment, Timed Up and Go, or falls), to optometry/ophthalmology (for visual impairment), to audiology (for hearing impairment), to pharmacist (for polypharmacy), and to cancer center support program (for Mental Health Index 13 criteria).
223875057|NCT03532100|DEVICE|Torsionally adaptive prosthesis with 0:1 coupling ratio|The torsionally adaptive prosthesis can be programmed to couple the motion between the transverse- and sagittal-planes. A coupling ratio (transverse:sagittal) of 0:1 means there will be no coupling between the transverse- and sagittal-plane motion. That is, regardless of any motion in the sagittal plane, there will be zero motion in the transverse plane.
223875058|NCT03532100|DEVICE|Torsionally adaptive prosthesis with 1:6 coupling ratio|The torsionally adaptive prosthesis can be programmed to couple the motion between the transverse- and sagittal-planes. A coupling ratio (transverse:sagittal) of 1:6 means there will be one degree of motion in the transverse plane for every six degrees of motion in the sagittal plane.
223875059|NCT03532100|DEVICE|Torsionally adaptive prosthesis with 1:4 coupling ratio|The torsionally adaptive prosthesis can be programmed to couple the motion between the transverse- and sagittal-planes. A coupling ratio (transverse:sagittal) of 1:4 means there will be one degree of motion in the transverse plane for every four degrees of motion in the sagittal plane.
223875060|NCT03532100|DEVICE|Torsionally adaptive prosthesis with 1:3 coupling ratio|The torsionally adaptive prosthesis can be programmed to couple the motion between the transverse- and sagittal-planes. A coupling ratio (transverse:sagittal) of 1:3 means there will be one degree of motion in the transverse plane for every three degrees of motion in the sagittal plane.
223875061|NCT03532100|DEVICE|Torsionally adaptive prosthesis with 1:2 coupling ratio|The torsionally adaptive prosthesis can be programmed to couple the motion between the transverse- and sagittal-planes. A coupling ratio (transverse:sagittal) of 1:2 means there will be one degree of motion in the transverse plane for every two degrees of motion in the sagittal plane.
223875062|NCT06784479|DRUG|Remimazolam and Propofol|Application of Remimazolam and Propofol to induce sleep
223875063|NCT06784479|DRUG|Propofol|Application of Propofol to induce sleep
223875064|NCT06784479|DRUG|Midazolam and propofol|Application of Midazolam and Propofol to induce sleep
223875065|NCT05423483|BEHAVIORAL|Safe Home Text Message Reminders|Text messages sent 2x a week with reminders to keep lethal means restricted and surveys of lethal means practices that serve as a prompt to adhere to suggested restriction measures.
223875066|NCT02476695|DEVICE|FibroTouch Examination|Liver stiffness measurements are performed using FibroTouch and the procedure is non-invasive and painless.
223875067|NCT02476695|DEVICE|FibroScan Examination|Liver stiffness measurements are performed using another transient elastography, FibroScan, and the procedure is non-invasive and painless.
223875068|NCT02476695|DEVICE|Ultrasonic B Examination|The ultrasonic B examination is made at an empty stomach for ≥8h. The inner diameter of liver, spleen, gallbladder, portal vein and splenoportal vein is measured through the ordinary two-dimensional ultrasonic examination. The echo data of liver surface/edge/parenchyma and gallbladder wall is scored to evaluate the severity of fibrosis.
223875069|NCT05402280|BEHAVIORAL|Sleep protocol|To investigate the effect of a multicomponent sleep protocol on the quality of sleep hospitalized patients assessed both subjectively and objectively.
223875070|NCT06790628|PROCEDURE|Fibula free flap|"surgical technique used in reconstructive surgery where a segment of the fibula bone, along with its blood vessels, is taken from the lower leg and transplanted to reconstruct defects in the mandible due to its length, strength, and ability to support dental implants.~The blood vessels are connected to nearby vessels at the reconstruction site to ensure the bone's survival and integration.~The procedure is highly versatile and often referred to as the gold standard for mandibular reconstruction."
223875071|NCT04050176|BEHAVIORAL|Hypnotic Medication Open-Label Taper|Participants will have their soporific hypnotic medication dosage reduced by 25% every two weeks during a 10 week open-label tapering period.
223875072|NCT04050176|BEHAVIORAL|Hypnotic Medication Blinded Taper|Participants will have their soporific hypnotic medication dosage reduced by 25% every two weeks during a 10 week blinded tapering period.
223875073|NCT04120766|DRUG|Nicorandil|20 mg po qd
223875074|NCT04120766|DRUG|Placebo|Matching tablet
223875075|NCT06785220|OTHER|ORAL FACIAL FACILITATION|"A group will receive oral facial facilitation which included exercise for given,~1. Brushing~2. Vibration~3. Manipulation (stroking and tapping)~4. Oral motor sensory exercise (lip, tongue, swallowing exercises)"
223875076|NCT06785220|OTHER|ORAL MOTOR THERAPY|"B group will receive oral motor therapy which included exercise for given,~1. A volcano bubbles~2. Party blower target~3. Bubble blowing~4. Curly straws"
223875077|NCT06785220|OTHER|ORAL FACIAL FACILITATION WITH ORAL MOROR THERAY|"C group will receive oral facial facilitation and oral motor therapy which included exercise for given,~1. Brushing~2. Vibration~3. Manipulation (stroking and tapping)~4. Oral motor sensory exercise (lip, tongue, swallowing exercises)~5. A volcano bubbles~6. Party blower target~7. Bubble blowing~8. Curly straws"
223875078|NCT06285682|DIETARY_SUPPLEMENT|OliPhenolia®)|Olive derived hydroxytyrosol will be ingested via a commercially available olive fruit wastewater (OliPhenolia®) in a dose relative to participant body mass. Participants will consume three doses within the entire study, one dose per visit, separated by a ≥3 day wash out period.
223875079|NCT03346538|DRUG|Continuous infusion high-dose MCI-186|intravenous injection
223875080|NCT03346538|DRUG|Continuous infusion low-dose MCI-186|intravenous injection
223875081|NCT03346538|DRUG|Continuous infusion placebo|intravenous injection
223875082|NCT03346538|DRUG|Approved dosing regimen MCI-186|intravenous injection
223875083|NCT03346538|DRUG|Approved dosing regimen placebo|intravenous injection
223875084|NCT04930432|DRUG|MCLA-129|MCLA-129 will be administered by intravenous infusion on the 28-day treatment cycle.
223875085|NCT01353313|DRUG|Hydrocortisone|"Hydrocortisone sodium succinate for intravenous administration (unpreserved, Solu-Cortef plain, Pfizer®, reconstituted with unpreserved normal saline to avoid exposure to the benzyl alcohol contained in preserved diluents), to be administered either intravenously or orally if no intravenous line is available at the same dose, and tapered as follows:~4mg/kg/day ¸ q 6 hours x 2 days, then 2mg/kg/day ¸ q 6 hours x 3 days; then~1mg/kg/day ¸ q 12 hours x 3 days; then 0.5mg/kg/d as a single dose x 2 days"
224076635|NCT00495651|DRUG|Antiretroviral medications+Isoniazid prophylaxis|"* Early Antiretroviral medications initiation on the day of inclusion, before reaching the current WHO criteria~* Isoniazid prophylaxis: 300 mg of INH once a day before breakfast for six months, starting one month after study inclusion"
223875086|NCT01353313|DRUG|Placebo|"Saline placebo to be administered either intravenously or orally if no intravenous line is available, at the same dose, and tapered as follows:~4mg/kg/day ¸ q 6 hours x 2 days, then 2mg/kg/day ¸ q 6 hours x 3 days; then~1mg/kg/day ¸ q 12 hours x 3 days; then 0.5mg/kg/d as a single dose x 2 days"
223875087|NCT02879162|DRUG|Durvalumab|
223875088|NCT02879162|DRUG|Tremelimumab|
223875089|NCT02824029|DRUG|Ibrutinib|Given PO
223875090|NCT02824029|OTHER|Laboratory Biomarker Analysis|Correlative studies
223875091|NCT02824029|OTHER|Pharmacological Study|Correlative studies
223875092|NCT03806465|OTHER|Feasibility survey|A survey questionnaire will be administered at each household. At the baseline household survey, each child aged less than 5 years will be tested for malaria using a rapid malaria test.
223875093|NCT03806465|OTHER|Sentinel hospital surveillance|Cerebrospinal samples will be collected from all children hospitalised and suspected of having meningitis.
223875094|NCT03806465|OTHER|Community mortality surveillance|A verbal autopsy will be performed
224076636|NCT04031703|DRUG|Paclitaxel|Paclitaxel chemotherapy (injection)
224076637|NCT04031703|DRUG|Carboplatin|Carboplatin chemotherapy (injection)
224076638|NCT04031703|DRUG|Epirubicin|Epirubicin chemotherapy (injection)
224076639|NCT04031703|DRUG|Cyclophosphamide|Cyclophosphamide chemotherapy (injection)
224076640|NCT04031703|DRUG|5-fluorouracil|5-fluorouracil chemotherapy (injection)
224076641|NCT04031703|DRUG|Docetaxel|Docetaxel chemotherapy (injection)
223875095|NCT05997602|DRUG|FCN-159|5mg/m² (Maximum dose does not exceed 8mg, the recommended oral dose for adults), orally, once daily, continuously for 28 days per cycle.
223875096|NCT06790355|DEVICE|multi-cancer early detection|Blood collection for multi-cancer early detection（MCED）, followed by clinical diagnosis based on the results of MCED and standard-of-care screening
223875097|NCT06786481|BEHAVIORAL|Educational with milnacipran|"Before starting the foot massage, the client is informed about the number, duration and time of the session. The average interview time with the patients in the experimental group will be 15-20 minutes. The first interview with the women in the experimental group will be held at any time after the birth when the woman feels well. Before the application, the researcher washes and dries her hands and warms them appropriately by massaging with baby oil and facilitates the process. First, a three-minute general massage is performed to prepare the feet, and then the correct points for each foot are massaged for 10 minutes. 'Introductory Information Form', LATCH Breastfeeding Diagnostic Measurement Tool, Newborn Stress Scale and Pittsburgh Sleep Quality Index (PSQI) forms will be filled. The woman's address and telephone details will be taken to meet again."
223875098|NCT06786481|BEHAVIORAL|Locally Directed Therapy|"Before starting the foot massage, the client is informed about the number, duration and time of the session. The average interview time with the patients in the experimental group will be 15-20 minutes. The first interview with the women in the experimental group will be held at any time after the birth when the woman feels well. Before the application, the researcher washes and dries her hands and warms them appropriately by massaging with baby oil and facilitates the process. First, a three-minute general massage is performed to prepare the feet, and then the correct points for each foot are massaged for 10 minutes. 'Introductory Information Form', LATCH Breastfeeding Diagnostic Measurement Tool, Newborn Stress Scale and Pittsburgh Sleep Quality Index (PSQI) forms will be filled. The woman's address and telephone details will be taken to meet again."
223875099|NCT06828965|OTHER|Neutrophil creatinine index|Neutrophil creatinine index will be calculated
223875100|NCT06828965|OTHER|Neutrophil creatinine index|Neutrophi creatinine index will be calculated in all patients
223875101|NCT06782880|PROCEDURE|Fecal microbiota transplantation (FMT)|To assess if heterologous FMT is more effective than autologous FMT in reducing the rate of major infection episodes within 6-months after OLT.
223875102|NCT05149157|OTHER|Symptomatic malaria|This observational study will be recruiting patients who have symptomatic malaria (confirmed by presence of asexual stage parasitaemia of any Plasmodium species on blood film)
223875103|NCT04452955|BIOLOGICAL|PRL3-zumab|Starting dose of 6 mg/kg will be administered as IV infusion over 60 minutes every 2 weeks (±2 days)
223875104|NCT06726772|BEHAVIORAL|Group Psychotherapy|Group psychotherapy based on Cognitive Behavioral Therapy (CBT) and Acceptance and Commitment Therapy (ACT) elements
223875105|NCT03272438|DEVICE|Accelerometer|Participants use an accelerometer to monitor their steps activity
223875106|NCT03272438|BEHAVIORAL|Step goal|Participants are given a daily step goal to aim for
223875107|NCT03272438|BEHAVIORAL|Consistent contexts|Participants plan to take steps in contexts that are similar from day to day
223875108|NCT03272438|BEHAVIORAL|Inconsistent contexts|Participants plan to take steps in contexts that vary from day to day
223875109|NCT06834412|DIAGNOSTIC_TEST|68Ga-Pentixafor and 18F-FDG PET/CT Scan|The imaging agent 68Ga-Pentixafor and 18F-FDG used in this project is synthesized following the standards for radiopharmaceutical production, with reference to the Chinese Pharmacopoeia (quality standards for 18F-FDG). The pH value is about 4; the radiochemical purity is not less than 95%, and the bacterial endotoxin content in each milliliter of solution is less than 15EU; the radioactive concentration is not less than 37 MBq/mL; the solvent residues comply with the regulations. Specification: 185\~1850 MBq/ml Characteristics: Clear, colorless, no visible particles. Radioactive physical half-life: 68Ga is 68 minutes. Expiry: Calculated from the time of labeling, stable for 3 half-lives. Administration method: Intravenous injection. Dosage: 0.05-0.1mCi/kg, flush with 5 mL of saline after injection.
223875110|NCT06788678|BEHAVIORAL|MOVED|MOVED includes 8 self-guided, web-based sessions administered over 4 weeks. Web-based sessions include 3 core components: (1) elicit moral elevation, (2) engage in reflection about moral elevation response, and (3) set a behavioral goal that is inspired by the moral elevation exercise.
223875111|NCT06788678|OTHER|Supportive Care Control|A present-centered, nondirective intervention that aims to control for the nonspecific therapeutic effects of supportive care. In this case, the effects of engaging in regular web-based sessions that convey information about PTSD symptoms. Sessions will include psychoeducation materials about PTSD symptoms, functioning, and resources for dealing with related stressors. Key components of MOVED will be strictly excluded.
223875112|NCT06791005|DRUG|Preoperative Injection of Carbon Nanoparticles|1.Medication: Carbon nanoparticles, Chongqing Lemay Pharmaceutical Co. Ltd., production license, Food and Drug Administration Production License No. (China) 2007204, Registration No.: State prescription H20041829. The product is a stable suspension of carbon particles with a diameter of 150 nm.2. 2.Preoperative injection method: The preoperative subgroup was injected with carbon nanoparticles 2-6 hours before surgery, with the patient in the position of padded shoulder, and disinfection around the puncture point was prepared prior to the injection of carbon nanoparticles. Under ultrasound guidance, a fine needle was used to puncture the lower 1/3 of the ventral surface, and no blood was detected on aspiration, i.e., 0.1 mL of carbon nanoparticles was injected into each of the 2 sites of each gland, and the total volume of carbon nanoparticles injected was 0.4 mL, and the depth of injection was approximately within the upper third of the gland.
224076642|NCT05860062|DIETARY_SUPPLEMENT|Vitamin D|Patients with prophylactic treatment (amitriptyline, topiramate) + 0.266 mg of calcifediol (15,960 IU of vitamin D)
224076643|NCT05860062|OTHER|Calcium|3: Patients with prophylactic treatment (amitriptyline, topiramate) + and Calcium: 1 Tablet every 24 hours containing: Calcium Carbonate 300 mg + Calcium Lactate Gluconate 2.94 g (500 mg of calcium).
223875113|NCT06791005|DRUG|Intraoperative Injection of Carbon Nanoparticles|Intraoperative injection of carbon nanoparticles: After exposing the thyroid peritoneum, 0.1 mL of carbon nanoparticles was injected into both sides of normal thyroid tissue using a syringe (1 mL). Two spots were needed for each flap, and the total volume of injected carbon nanoparticles was 0.4 mL. Finally, the needle was gently backed up under negative pressure to prevent the leakage of carbon nanoparticles.
223875114|NCT02984124|BEHAVIORAL|Informed Assent Discussion|"Participants randomized to the intervention arm will participate in a discussion about CPR with a study doctor that follows these steps:~1. Patient's values and preferences for therapies and outcomes elicited from patient and family; overall therapeutic goals formulated~2. Description of CPR and dying process provided~3. Personalized explanation provided about probable lack of achieving any reasonable therapeutic goal with CPR (i.e. why s/he is a poor candidate for CPR due to underlying illness)~4. Patient and family informed that due to severe underlying illness and high likelihood that CPR will be burdensome/harmful and will not provide benefit, CPR will not be offered unless they disagree (except in rare circumstance where overall therapeutic goals from step 1 are to preserve life regardless of quality of that life) Assessment of patient's and family's understanding of issues discussed; patients may actively disagree and request CPR be performed, but CPR not explicitly offered"
223875115|NCT02984124|BEHAVIORAL|Usual Care with Attention Control|Participants who are randomized to the usual care arm will receive a friendly visit in the hospital from research personnel to ask if they have any questions or concerns. Follow up assessments and time windows will be explained. Importance of their participation in the study will be emphasized.
223875116|NCT06586216|DRUG|PF-07817883|Experimental
223875117|NCT06791590|PROCEDURE|intermittent oro-esophageal|A disposable gastric tube was used to perform enteral nutrition support therapy, and contraindications were evaluated again. Inform the patient and family members of the precautions for intermittent feeding through oral tube, and play the video of the operation process to make them actively cooperate with the operation.
223875118|NCT06791590|PROCEDURE|Naso-intestinal tube nutrition support|For patients at risk of repeated aspiration and regurgitation, and for patients with gastric nutritional intolerance that cannot be improved by gastrointestinal motivity drugs, indwelling intestinal tube and retropyloric feeding are given.
223875119|NCT06786143|BEHAVIORAL|Esmadem Education Model|"Application Application of the Research The implementation of the research was done in 3 steps.~Step 1: In the first stage of the research, after the risky pregnant women who come to the polyclinic are informed about the study, the participants who agree to participate and meet the criteria for inclusion in the research will be determined by randomization. After the pregnant women assigned to the training or control group sign the voluntary consent form and their consent is obtained, Personal InformationForm, Mishel Uncertainty in Illness Scale Depression-Anxiety-Stress Scale Depression-Anxiety-Stress Scale (DASÖ-21) scales will be applied. After the first interviews, the study group will be informed about the sessions and the training will start via zoom.~In educational sciences, since the number of groups is between 2-20 people in the acquisition of target behaviors at the conceptual level, two training groups will be created and 15 pregnant women will be in the first group, 15 preg"
223875120|NCT06835296|DRUG|YUQ-A1007 is a novel gut-enriched AhR agonist. This compound is undergoing preclinical development, and comprehensive nonclinical studies.|Dose: Ascending doses (SAD stage: 200, 800, 1600, or 3200 mg; MAD stage: two dosages will be determined based on the results from the SAD stage) Mode of administration: Oral, once daily.
223875121|NCT06575296|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223875122|NCT06575296|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
223875123|NCT06575296|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
223875124|NCT06575296|PROCEDURE|Echocardiography|Undergo ECHO
223875125|NCT06575296|OTHER|Electronic Health Record Review|Ancillary studies
223875126|NCT06575296|OTHER|Quality-of-Life Assessment|Ancillary studies
223875127|NCT06575296|OTHER|Questionnaire Administration|Ancillary studies
223875128|NCT06575296|DRUG|Revumenib|Given PO
223875129|NCT06835855|OTHER|Passive Viewing Task|Infants will complete a computer-based task in which they view facial displays of emotion (angry, happy, sad, neutral) while an eye tracker records their gaze.
223875130|NCT06835855|OTHER|Interaction Task|Mother and infants will also complete a standardized interaction task during which we assess infant gaze and psychophysiology. The task consists of three stages, each of which lasts three minutes. For the first stage (Free Play 1), infants sit in a highchair and mothers are asked to play with their baby as they normally would, without any toys or other objects. In the second stage (Sad), mothers are asked to think about times when they are sad or depressed and do not feel able to effectively play with their child. They are instructed to look at their child but speak in a monotone and minimize body movement or any physical contact with the infant. In the third stage (Free Play 2), mothers again interact with their infants normally for three minutes.
223875131|NCT06833814|DRUG|Prednisone|Either 150 mg over 3 days or 250 mg over 7 days or 350 mg over 10 days
223875132|NCT04524390|DRUG|Maralixibat|A small molecule inhibitor of the ileal bile acid transporter (IBAT)
223875133|NCT04524390|OTHER|Placebo|Identical to maralixibat except for the active drug substance
223875134|NCT05666362|DRUG|benoxinate hydrochloride 0.4% group|They will receive benoxinate hydrochloride 0.4% immediately before fundus
223875135|NCT05666362|DRUG|saline 0.9% .|They will receive saline 0.9% before fundus examination in each eye .
223875136|NCT06523088|DRUG|PN20|Six dose levels of PN20 will be evaluated
223875137|NCT06523088|DRUG|Placebo|Placebo of PN20
223875138|NCT06014775|DRUG|Anti-CD38 antibody Injection|"intravenous Anti-CD38 antibody administration~This study adopts a prospective, single arm, open design method. Ten subjects were enrolled in the study and were treated with Anti-CD38 antibody (16mg/kg/w) for 8 weeks.~The first stage is the main research stage (d1-w8), which is the core treatment period. The subjects will receive intravenous infusion of 16mg/kg Anti-CD38 antibody once a week for 8 weeks to observe the safety and efficacy during treatment.~The second stage (w9-w24) is the stage of withdrawal from the visit, mainly to observe the safety and continuous efficacy of Anti-CD38 antibody after treatment."
224076644|NCT03067272|DEVICE|FemBloc® Permanent Contraceptive System|The FemBloc Permanent Contraceptive System consists of treatment with a Delivery System and Biopolymer, and a confirmation test with the FemChec® Tubal Occlusion Confirmation device as part of a sonographic hysterosalpingogram (Sono HSG).
223875139|NCT04751526|DEVICE|BreEStim 240|240 BreEStim stimuli/visit will be applied for 10 sessions to test any accumulated analgesic effect.
223875140|NCT04751526|DEVICE|EStim 240|240 EStim stimuli/visit will be applied for 10 sessions to test any accumulated analgesic effect.
223875141|NCT05412615|PROCEDURE|Meniscus Allograft Transplantation with Proximal Row Carpectomy|Supplementing the wrist reconstruction with a meniscal allograft to improve wrist function and pain scores.
223875142|NCT05412615|PROCEDURE|Proximal Row Carpectomy|Standard proximal row carpectomy with no tissue or synthetic adjuncts
223875143|NCT02839070|OTHER|Sleep/Wake Schedule|Timing of sleep and wake
223875144|NCT01630850|BIOLOGICAL|Allogenic islet cells (human, U. Chicago)|Human allogenic islet cells. Immunosuppression may include remicade, thymoglobulin,prograf, solu-medrol, and cellcept. Dosage will vary per patient based on weight. Patients will receive immunosuppression medications while islet cells are functioning.
223875145|NCT01630850|PROCEDURE|Intraportal infusion of islet cells|Intraportal infusion of islet cell through the portal vein in the liver.
223875146|NCT01582893|DEVICE|HCO1100|Dialysis
223875147|NCT01582893|DEVICE|P210H|Dialysis
223875148|NCT04328038|OTHER|Survey|Patient fill out a survey containing: Demographic Information, medical history, several Questionnaires about Health Literacy, Well Being/HRQoL and Fatigue
223875149|NCT05930782|DRUG|Piperaquine Tetraphosphate uncoated tablets|Piperaquine tetraphosphate hard tablet 320 mg; single dose (320 mg) given orally with 240 ml of water
223875150|NCT05930782|DRUG|Piperaquine Tetraphosphate dispersible granules|Piperaquine tetraphosphate dispersible granules 320 mg dose equivalent dispersed in 25 ml of water; single dose (320 mg) given orally
223875151|NCT05949801|DRUG|Neucardin|10 days IV infusion of 0.6 ug/kg/day
223875152|NCT05949801|DRUG|Placebo|10 days IV infusion of 0 ug/kg/day
223875153|NCT06750341|DRUG|QLC7401|QLC7401 combined with lipid-lowering agents
223875154|NCT06750341|DRUG|Placebo|Placebo combined with lipid-lowering agents
223875155|NCT06788548|PROCEDURE|combined endoscopic-laparoscopic sentinel lymph node navigation surgery|"1. Determination of tumor location and sentinel lymph node: endoscopic staining (2mg indocyanine green, four-quadrant submucosal injection) was used to determine the location of the lesion during laparoscopic surgery combined with endoscopic localization to ensure effective and safe resection margins. The staining technique was used to identify the sentinel lymph nodes basin, and en bloc resection of the lymph node basin biopsy was performed.~2. Standard of lymph node basin dissection: All sentinel nodes are located within the lymphatic basin, which is considered the primary lymphatic drainage area for each patient. Follow the SENORITA trail criteria\[9\], lymphatic basin is delineated by the distribution of dye within the lymphatic channels, as seen in dye mapping. The proximal extent of the lymphatic basin is demarcated by the fatty tissue adjacent to the stomach wall, while the distal boundary is marked by the most distant stained node from the stomach."
223875156|NCT06788548|PROCEDURE|Laparoscopic D2 radical gastrectomy|Preparation: The patient is positioned supine with general anesthesia. An orogastric tube and Foley catheter are inserted. Antibiotics are administered, and sequential stockings are applied. Port Placement: Pneumoperitoneum is created via a Veress needle at the umbilicus. Working ports are placed in the upper quadrants, with a fifth port for liver retraction. Abdominal Exploration: The abdomen is inspected for metastases, and peritoneal cytology is performed. Dissection and Lymph Node Removal: The lesser omentum is divided near the liver, reaching the cardia and diaphragm. The gastrocolic ligament is divided along the transverse colon. Lymph node dissection begins along the splenic artery, then proceeds to the left gastric artery and celiac nodes. The left gastric vessels are controlled with endoclips.After lymph node dissection, distal subtotal gastrectomy is performed. Digestive tract reconstruction is typically done through a mini-laparotomy.
223875157|NCT06477042|OTHER|Kansas City Cardiomyopathy Questionnaire (KCCQ-12) score|Change in quality-of-life score assessed by the Kansas City Cardiomyopathy Questionnaire (KCCQ-12) between the 2-month early visit and inclusion in the poor-prognosis group.
224076645|NCT03828929|DRUG|Vitamin C|IV vitamin C, 1500mg in 50ml of normal saline every six hours, infused over one hour and IV Thiamine 200mg in 50ml of 5% dextrose every 12 hours, for 4 days or until discharge from the intensive care unit, whichever comes first.
223875158|NCT05871892|DIAGNOSTIC_TEST|18F-FDGal PET/CT or PET/MRI|All patients suspected of or diagnosed with HCC will be offered an initial 18F-FDGal PET/CT or PET/MRI scan. Moreover, patients who undergo loco-regional treatment (resection, ablation (radiation or microwave), chemo- or radio-embolization) are re-examined with 18F-FDGal. The scans will be performed 1-2 months and 3-5 months after the loco-regional treatment. The images will be analyzed by an experienced PET specialist and the CT or MR images by an experienced radiologist for focal lesions and compared to other imaging modalities. The investigators expect approximately 25 patients per year during a 5-year period and as such aim at a total of 125 patients
223875159|NCT05809271|DRUG|MDMA 120 mg + MDMA 60 mg|An oral dose of 120 mg racemic MDMA will be administered followed by a second dose of 60 mg racemic MDMA two hours later.
223875160|NCT05809271|DRUG|MDMA 120 mg + placebo|An oral dose of 120 mg racemic MDMA will be administered followed by a placebo two hours later.
223875161|NCT05809271|DRUG|Placebo|An oral placebo will be administered followed by a placebo two hours later.
223875162|NCT05693129|DRUG|Leniolisib|The doses selected will range from 10 to 50 mg twice daily (BID) (resulting in total daily doses ranging from 20 to 100 mg per day).
223875163|NCT00713063|BEHAVIORAL|aerobic exercise|12-week moderate intensity behavioral exercise intervention (MIBE) AND a 12-week standard smoking cessation program (including transdermal nicotine patch)
223875164|NCT00713063|BEHAVIORAL|Health Education Control|12-week health education control (HEC) AND a 12-week standard smoking cessation program (including transdermal nicotine patch).
223875165|NCT00711581|DEVICE|Gallbladder retraction|The gallbladder will be retracted using the Endograb retractor
223875166|NCT03921580|OTHER|Control Canned Tuna|210 g/day
223875167|NCT03921580|OTHER|Enriched Canned Tuna Variety 1|210 g/day
223875168|NCT03921580|OTHER|Enriched Canned Tuna Variety 2|210 g/day
223875169|NCT00174382|DRUG|Donepezil|donepezil 5mg/day for 6 weeks and then 5 to 10mg/day for 18 weeks
223875170|NCT04050969|PROCEDURE|Bariatric surgery|Participants will undergo either a laparoscopic sleeve gastrectomy or laparoscopic Roux-en-Y gastric bypass.
223875171|NCT04050969|PROCEDURE|Atrial Fibrillation (AF) Catheter Ablation|Participants will undergo catheter ablation using either radiofrequency or cryoablation of pulmonary veins. Participants with persistent AF may also undergo roof and/or floor linear ablation with or without ablation of extrapulmonary sites at the physician's discretion.
223875172|NCT03428620|OTHER|High Velocity Low Amplitude mobilization|Mobilizations will be performed one time at each joint, prior to completing the exercise protocol during the first three treatment sessions.
223875173|NCT03428620|OTHER|Exercise protocol|This exercise regimen is a modified version of the balance training program described by McKeon et al.
223875174|NCT06617702|BEHAVIORAL|A text message alcohol intervention focused on cognitive, behavioral, and peer influences|Each Thursday and Sunday ASPIRE will conduct brief text message communication aimed at modifying cognitive (e.g.desire to get drunk), behavioral (e.g.alcohol consumption), and peer influences (e.g.peer pressure and support).
223875175|NCT06617702|BEHAVIORAL|A text message alcohol intervention focused on cognitive and behavioral influences|Each Thursday and Sunday ASPIRE will conduct brief text message communication aimed at modifying cognitive (e.g. desire to get drunk) and behavioral (e.g. alcohol consumption) influences.
223875176|NCT03655262|BEHAVIORAL|Unconscious Neuro-reinforcement|Individuals will complete an implicit fmri neuro-reinforcement task where real-time brain activity is matched to a desired activation. Individuals will also receive financial reward for activating the desired activation. Visual feedback will be presented to indicate how well individuals' brain activity matches the desired activation. Individuals will complete x day(s) of neuro-reinforcement.
223875177|NCT03292120|OTHER|measure of the SOFA score|The Sequential Organ Failure Assessment (SOFA) Score predicts ICU mortality based on lab results and clinical data.
223875178|NCT01833923|DRUG|anlotinib|oral medicine.
223875179|NCT00830934|PROCEDURE|Individual care|The first treatment group (individual care group) will involve 3 sessions held weekly. Each session will last approximately 45 minutes.
223875180|NCT00830934|PROCEDURE|group care|The second treatment group (group care group) will be assigned to weekly group exercise classes, focusing on core stability and strengthening exercises. Classes will last one hour and will be conducted for 4 weeks. In both treatment groups pain scores will be followed up for 1 week post last treatment.
223875181|NCT05075083|BIOLOGICAL|Inactivated COVID-19 vaccine|receive two doses inactivated COVID-19 vaccine with the interval of 21 days
223875182|NCT04047719|DIAGNOSTIC_TEST|Karius Test|Karius Test for detection of microbial cell free DNA (mcfDNA) in plasma
223875183|NCT06093243|OTHER|data collection|data collection
223875184|NCT04456725|BEHAVIORAL|Intensive management|The intervention group will be assigned to a partnership of one nurse practitioner and one medical assistant who will manage them intensively, with the support of the study team.
223875185|NCT04456725|BEHAVIORAL|Control|Usual care
223875186|NCT02974465|PROCEDURE|Biofeedback Electromyography|protocol of sEMG-BFB that consisted of active movements in glenohumeral abduction guided by the visual signal of the register equipment. The protocol was the following: firstly proof active movements were requested in glenohumeral abduction without feeling any pain in order to teach the visual signal of their muscle activity. The therapist dedicated around 10 minutes in each session for subject learned to control the activation of both muscles in the limits that physical therapist marked with each individual in particular (controlling the activation in the upper trapezius). Once integrated information, shoulder abduction were requested following 4 main principles.
223875187|NCT02974465|PROCEDURE|Sham Biofeedback Electromyography|consisted of Sham-EMG biofeedback, in which the electrodes were placed as the same method as the EG (Fig. 2) but the screen emit no signal. The subject performed 3 sequences of 10 abduction contractions (first degrees) without pain feeling and with 5 minutes of rest between sequences.
223875188|NCT02974465|PROCEDURE|Conventional Physical Therapy Treatment|All participants received a conventional daily treatment of neurological physical therapy. Since no evidence has been found about a specific therapy that specially could benefit hemiparesis consequences, the common approach in this center consists of a combination of different specific concepts (Bobath, Brunnstrom, Rood, Johnstone, Propioceptive Neuromuscular Facilitation, Perfetti, Vojta, Motor Relearning Programme,…), exercise programs, electrotherapy, myofascial techniques, etc…
223875189|NCT04320771|DRUG|Neladenoson bialanate (BAY 1067197)|10 mg as a single IR tablet dose. Active metabolite: BAY 84-3174
223875190|NCT03572075|DIAGNOSTIC_TEST|assessment of symptoms at the first medical examination|assessment of endometriosis related symptoms using NRS (Numerical Rating Scale); intestinal, sexual and urinary functions are evaluated with validated questionnaires (Knowles-Eccersley-Scott-Symptom Questionnaire (KESS), Female Sexual Function Index (FSFI), Bristol Female Lower Urinary Tract Symptoms (BFLUTS)); pelvic floor morphometry at rest, during pelvic floor contraction and during Valsalva manoeuvre is evaluated using 3D/4D transperineal ultrasound through the assessment of the levator hiatus area (LHA) at the first medical examination
223875191|NCT03572075|PROCEDURE|pelvic floor physiotherapy|six individual sessions (weeks 1, 3 , 5, 8, 11 from the randomization) with pelvic floor consciousness exercises with mild contractions and relaxation (ex. 'kegel reverse' exercises); respiratory rate control exercises; extra exercises to perform at home are suggested.
223875192|NCT03572075|PROCEDURE|standard care protocol|the treatment is the same as usual in our center
223875193|NCT03572075|DIAGNOSTIC_TEST|assessment of symptoms after four months|assessment of endometriosis related symptoms using NRS (Numerical Rating Scale); intestinal, sexual and urinary functions are evaluated with validated questionnaires (Knowles-Eccersley-Scott-Symptom Questionnaire (KESS), Female Sexual Function Index (FSFI), Bristol Female Lower Urinary Tract Symptoms (BFLUTS)); pelvic floor morphometry at rest, during pelvic floor contraction and during Valsalva manoeuvre is evaluated using 3D/4D transperineal ultrasound through the assessment of the levator hiatus area (LHA) after four months from the randomization.
223875194|NCT02158819|DEVICE|Total knee arthroplasty with Visionaire|Patient Specific Instrumentation
223875195|NCT00002697|BIOLOGICAL|filgrastim|
223875196|NCT00002697|BIOLOGICAL|sargramostim|
223875197|NCT00002697|DRUG|carboplatin|
223875198|NCT00002697|DRUG|etoposide|
223875199|NCT00002697|DRUG|ifosfamide|
223875200|NCT00002697|PROCEDURE|autologous bone marrow transplantation|
223875201|NCT00002697|PROCEDURE|bone marrow ablation with stem cell support|
223875202|NCT00002697|PROCEDURE|peripheral blood stem cell transplantation|
223875203|NCT00002697|RADIATION|radiation therapy|
223875204|NCT05758012|DRUG|oxytocin|Participants will be randomized to receive Oxytocin after delivery of the baby's head and shoulders
223875205|NCT05758012|DRUG|Carbetocin|Participants will be randomized to receive Cabetocin after delivery of the baby's head and shoulders
223875206|NCT00665340|DRUG|Placebo|Matching placebo
223875207|NCT00665340|DRUG|Levitra (Vardenafil, BAY38-9456)|5m, 10 mg and 20 mg 1 h prior to sexual intercourse
223875208|NCT03632759|DRUG|Liraglutide|Participants will receive subcutaneous (SC) liraglutide for 8 weeks
223875209|NCT03632759|DRUG|Golimumab|Participants will receive subcutaneous (SC) golimumab for 8 weeks
223875210|NCT01828554|DRUG|Xeloda|"Cycle 1: Days 1-7 (21 day cycle): 1250 mg/m2 Xeloda orally twice a day using Ideal Body Weight to calculate dosage. Cycle 1, Day 8-No drug.~Cycle 1: Days 9-15 (21 day cycle): 1250 mg/m2 Xeloda orally twice a day using Actual Body Weight to calculate dosage. Days 16-21-No drug.~Cycle 2 and greater: Days 1-14 (21 day cycle): 1250 mg/m2 Xeloda orally twice a day using Actual Body Weight to calculate dosage."
223875211|NCT06449859|DRUG|TQC2938 Injection|TQC2938 injection is a humanized monoclonal antibody that interfering with the signal cascade.
223875212|NCT06449859|DRUG|TQC2938 Placebo|TQC2938 Placebo is a placebo comparator
223875213|NCT02753738|DRUG|Escitalopram|Tablet 10mg, 21 days
223875214|NCT02753738|DRUG|Placebo|Tablet, 21 days
223875215|NCT02753738|OTHER|3xMR scan (fMRI, DTI, strucutral MRI)|3 Tesla PRISMA MAGNETOM MR scanner; performed at baseline, after 21 days of performing learning paradigms and after 21 days of drug/placebo treatment and re-learning paradigms
223875216|NCT02753738|BEHAVIORAL|Association learning paradigm|21 daily internet-based sessions (20min) of learning associations (pairs) of stimuli
223875217|NCT02753738|BEHAVIORAL|Association re-learning paradigm|21 daily internet-based sessions (20min) of learning new associations (pairs) of stimuli performed during escitalopram/placebo treatment
223875218|NCT04646031|DRUG|T89 capsule|T89 capsule, an medicinal product for oral use under active INDs in the US is a botanical drug containing 75mg active substance of the water extract of Danshen and Sanqi.
223875219|NCT00543816|DRUG|MK0767|
223875220|NCT05899270|OTHER|3D reconstruction automatic matching system|it is an automatic comparison software for 3D reconstruction based on CT data (3DRACS). It reconstructs the trachea and bronchus and compares them with the DLT, predicting the most suitable size and depth of the DLT for lung isolation.
223875221|NCT05899270|OTHER|traditional method for selecting double lumen tube|In control group, the size of DLT is based on patient's sex and weight and the height is used to guide the depth of DLT insertion.
223875222|NCT04706624|BEHAVIORAL|High intensity contingency management|Participants receive 12 weeks of contingency management.
223875223|NCT04706624|BEHAVIORAL|Low intensity contingency management|Participants receive 6 weeks of contingency management and 6 weeks of group education.
223875224|NCT04706624|BEHAVIORAL|SMS reminders|Participants receive two daily SMS reminders plus one weekly self-monitoring assessment.
223875225|NCT04706624|BEHAVIORAL|Matrix only|Participants attend 12 weekly Matrix group counseling sessions.
223875226|NCT04706624|BEHAVIORAL|Matrix + Contingency management|Participants attend 12 weekly Matrix group counseling sessions plus 12 weeks of contingency management.
224076646|NCT03828929|DRUG|Normal saline|50ml of IV normal saline every six hours and 50ml of IV 5% dextrose every 12 hours, for 4 days or until discharge from the intensive care unit, whichever comes first.
223875227|NCT06135246|DEVICE|High Intensity Laser Therapy|Participants will receive high-intensity laser therapy using an 810nm continuous wave diode laser (Multiwave locked System (MlS) provided by aSa). The laser applicator has a flat top hat beam profile with a spot size of 1cm2. The laser will be delivered in direct contact mode perpendicularly to the ulcer surface. Each 1cm2 area of the venous ulcer and a 1cm margin of periwound skin will be treated sequentially using a overlapping grid pattern to cover the entire ulcer area, with a 1 second exposure time per point. This results in a laser energy density of 4J/cm2 delivered to each point.
223875228|NCT06135246|OTHER|Standard Care|Participants will receive standard compression bandaging and wound care as per institutional protocols, without any laser therapy. The compression bandaging protocol is based on recommendations from the American Venous Forum and American College of Phlebology guidelines (O'Donnell et al., 2014). Multi-layer compression bandages will be applied weekly by trained nurses, with layers including orthopedic padding, elastic bandages, and cohesive bandages. Bandages will be applied with high pressure at the ankle gradually decreasing up the leg, with an ankle pressure of approximately 40 mmHg (Mosti et al., 2015).
223875229|NCT06384820|DRUG|cemiplimab|Administered Intravenous (IV) infusion every three weeks (Q3W)
223875230|NCT06384820|DRUG|fianlimab|IV infusion Q3W
223875231|NCT03428698|DEVICE|Aminogam|A lower third molar was extracted. All the surgical tools and materials as well as the surgical field were sterile. A full-thickness flap was raised and, if necessary, osteotomy and tooth sectioning were performed using a straight handpiece with dedicated burs under copious irrigation with sterile saline solution. The extraction was completed with curved and straight extractors, the socket was closely inspected and the dental follicle was removed. Depending on the group to which the patient was assigned, one of the following procedures was carried out.
223875232|NCT03214185|PROCEDURE|IVF/ICSI|in vitro fertilization or intracytoplasmatic sperm injection
223875233|NCT03214185|GENETIC|PGS 2.0|Blastocysts are selected by PGS 2.0(NGS based) and only euploid embryos will be transferred.
223875234|NCT03214185|OTHER|Conventional embryo morphology evaluation|Blastocysts are selected by morphology criteria and only good-scored embryo will be transferred.
223875235|NCT05444075|OTHER|a method for communication|"the Arabic alphabet (arranged in the traditional order) printed on double-sided cardboard, with one copy facing the person and one facing the doctor.~The code will be in the case of a positive selection (the desired line or letter) by looking up or one blink, but in the case of a negative selection (not the desired line or letter), it will be by looking down or two blinks.~The person will choose the letters of each word and then choose the end of the word and after selecting all the words of the sentence choose the end of the sentence.~After the strategy has been taught to the subject, he or she will be asked to communicate with the physician using this way."
223875236|NCT04611932|DRUG|CKD-330 Tab. and D090 Tab.|1T
223875237|NCT04611932|DRUG|CKD-333 Tab.|1T
223875238|NCT05065203|PROCEDURE|planned or unplanned Cesarean, operative, or non operative delivery|All types of delivery
223875239|NCT05338307|DIETARY_SUPPLEMENT|R-1,3-Butanediol|Study participants will be taking 35mL of HVMN Ketone-IQ by mouth three times daily, with each dose containing 10 grams of R-1,3-Butanediol.
223875240|NCT03951805|DRUG|Insulin icodec|Administered subcutaneously SC once weekly. Starting dose will be 70U.
223875241|NCT03951805|DRUG|Insulin Glargine|Administered subcutaneously SC once daily.The starting dose will be 10U.
223875242|NCT01343459|RADIATION|HIOB|"IOERT single shot as a boost followed by hypofractionated WBRT (HIOB)~* IOERT is performed on mobile or fixed linacs~* Reference dose: 11 Gy specified as maximum dose, with a minimum target volume dose of 90% encompassing the PTV (i.e. 10 Gy).~WBRT~* must start within day 36- 56 postoperatively (week 6 - 8 p.o.) in case of adjuvant hormonal treatment (or no further tumor specific medication)~* In case of adjuvant chemotherapy, a time - gap between IOERT and WBRT up to 9 months is allowed.~* Single reference dose per fraction: 2,7 Gy (ICRU)~* Number of fractions: 15, Number of fractions per week: 5~* Total WBRT dose: 40,5 Gy"
223875243|NCT01154387|DRUG|Anti-Thymocyte Globulin|1.5mg/kg IV on Day of Transplant and 1.0-1.5 mg/kg IV once daily for a minimum of 4.5mg/kg and a maximum of 7.5mg/kg total cumulative dose
223875244|NCT01154387|DRUG|TOL101|Potential Therapeutic Dose (PTD)-A (0.28-56 mg to be determined in Phase 1/Part A ) IV once daily x 6-10 doses starting on Day of Transplant
223875245|NCT01154387|DRUG|TOL101|Potential Therapeutic Dose (PTD)-B (0.28-56 mg to be determined in Phase 1/Part A ) IV once daily x 6-10 doses starting on Day of Transplant
223875246|NCT01154387|DRUG|Steroids|IV methylprednisolone prior to first 3 doses of study drug; oral prednisone tapered to 5-10 mg over 6 months
223875247|NCT01154387|DRUG|Tacrolimus|Oral administration started by 6 days post-transplantation and continued for 6 months
223875248|NCT01154387|DRUG|Mycophenolate mofetil (MMF)|Oral administration started by Day 1 post-transplantation and continued for 6 months
223875249|NCT01765231|DRUG|Entecavir prophylaxis|Entecavir 0.5mg daily from day 1 of antitumor therapy to at least 6 months after completing antitumor therapy
223875250|NCT01765231|DRUG|Observation arm|Entecavir 0.5mg daily will be prescribed for patients with hepatitis B virus reactivation.
223875251|NCT05216770|OTHER|Brain imaging|Brain images will be conducted with function MRI, magnetoencephalography (MEG), and electroencephalography (EEG) to identify disorder-specific neural markers
223875252|NCT05216770|DRUG|Laryngeal sensory block with topical bupivacaine|Laryngeal sensory block with bupivacaine will be used to modulate sensory feedback from vocal fold mucosa and examine the impact of sensory feedback on abnormal neural activity in LD and VT
223875253|NCT03638674|OTHER|DXA + CT|Two dual-energy X-ray scans + CT scan
223875254|NCT03196882|DRUG|40mg/day of iron|Ferrimanitol ovalbumin granulated. Powder for oral solution. The doses of 40 mg per day of elemental iron correspond to 300 mg ferrimanitol ovoalbumin
223875255|NCT03196882|DRUG|20mg/day of iron|Ferrimanitol ovalbumin granulated Powder for oral solution. The doses of 20 mg per day of elemental iron correspond to 150 mg ferrimanitol ovoalbumin
223875256|NCT03196882|DRUG|80mg/day of iron|Ferrimanitol ovalbumin granulated. Powder for oral solution The doses of 80 mg per day of elemental iron correspond to 600 mg ferrimanitol ovoalbumin.
223875257|NCT03840122|OTHER|ACB + IPACK block with injection of local anesthetic|"ACB + IPACK block with injection of local anesthetic which is comprised of the following agents and amounts:~* Ropivacaine 5mg/ml (49.25ml)~* Epinephrine 1mg/ml (0.5ml)~* Ketorolac 30mg/ml (1ml)~* Clonidine 0.1mg/ml (0.8ml)~* Saline 48.45ml"
223875258|NCT03840122|OTHER|ACB + IPACK block without injection|ACB + IPACK block without an injection of local anesthetic
223875259|NCT00405054|DRUG|MK0457|IV infusion 32 mg/m2/hour; 5-day continuous infusion every 14 days
223875260|NCT04132141|OTHER|Virtual Reality Headset with curated content|clinicians will wear VR immersive headset for up to 15 minutes during their break
223875261|NCT01695954|DRUG|Pitavastatin|Pitavastatin 2 mg tablets taken at bedtime in Arm A and in the morning in Arm B.
223875262|NCT01695954|DRUG|Darunavir|Darunavir 400 mg tablets x 2 taken daily in Arm B
223875263|NCT01695954|DRUG|Ritonavir|Ritonavir 100 mg tablets taken daily in Arm B
223875264|NCT01695954|DRUG|Efavirenz|Efavirenz 600 mg tablets taken at bedtime in Arm A
223875265|NCT06407882|BEHAVIORAL|Conductive Exercises|Conductive education (CE) is a useful educational system for the management of motor disabled individuals whose disability and dysfunction was due to the damage to the central nervous system, mainly at the pre-, peri- or post-natal period of life. Conductive exercises basically include task-oriented learning within highly structured programs and conductors who are trained in special education and therapy administer the conductive education program
223875266|NCT06407882|BEHAVIORAL|Routine Physical Therapy|Group B will perform routine physical therapy (RPT) alone. Active and passive movements, Passive stretching, strengthening exercises, weight bearing exercises.
223875267|NCT03921866|DRUG|Palbociclib|Palbociclib
223875268|NCT02782507|BEHAVIORAL|CBT for Distressing visual hallucinations|"Eight to ten sessions of manualised CBT for distressing visual hallucinations based on existing treatment manuals (ie. Kingdon \& Turkington, 2004, Morrison et al., 2005), delivered over 8 to 12 weeks by CBT therapists.~Subjects will continue to receive treatment as usual throughout the therapy period and will receive appropriate prescription of medication if requested or clinically indicated."
223875269|NCT04328727|DRUG|eltrombopag|Tablet 25mg and 12.5mg
223875270|NCT04328727|DRUG|rabbit anti-thymocyte globulin (r-ATG)|r-ATG 25 mg sterile lyophilized powder in 10 mL vials for IV use
223875271|NCT04328727|DRUG|cyclosporine A (CsA)|CsA 25mg Capsule or CsA 5.0g/50mL solution for oral use
223875273|NCT06329973|DRUG|Fruquintinib in combination with Sintilimab and CAPEOX|Different doses of fruquintinib combined with sintilimab and CAPEOX
223875274|NCT04487431|DRUG|BAY1817080|Oral single dose
223875275|NCT04487431|DRUG|[14C]BAY1817080|Oral single dose
223875276|NCT00522782|DRUG|Nebulized Budesonide|Pulmicort Respules 0.5mg/2cc
223875277|NCT00522782|DEVICE|Nitric Oxide Analyzer|Niox NO analyzer
223875278|NCT03684044|DRUG|Baloxavir Marboxil|Baloxavir marboxil will be administered as a weight-based dose on Days 1 and 4. A third dose will be given on Day 7 for participants who have not improved according to protocol defined criteria on Day 5.
223875279|NCT03684044|OTHER|Placebo|Participants will receive matching placebo on Days 1, 4 and 7.
223875280|NCT00411034|DRUG|OROS Hydromorphone HCI|
223875281|NCT03703336|BIOLOGICAL|ROTAVIN (liquid formulation)|Live attenuated human rotavirus vaccine containing ≥ 2x10\^6 plaque forming units (PFU) of strain G1P\[8\] per dose of 2 mL.
223875282|NCT03703336|BIOLOGICAL|ROTAVIN-M1 (frozen formulation)|Live attenuated human rotavirus vaccine containing ≥ 2x10\^6 PFU of strain G1P\[8\] per dose of 2 mL.
223875283|NCT06045845|DIETARY_SUPPLEMENT|Beet Juice|70 milliliter (70mL) standard Beet Juice (Beet It Sport Shot) consumed 2.5 hours before exercise test
223875284|NCT06045845|DIETARY_SUPPLEMENT|Placebo|70mL placebo Beet Juice (Beet It Sport Shot with nitrate removed) consumed 2.5 hours before exercise test
223875285|NCT00418496|DRUG|Aldesleukin|600,000 IU/kg every 8 hours on days 1-5 (week 1) to a maximum of 12 doses. Another cycle of HD aldesleukin will be started on day 15 (week 3).
223875286|NCT00418496|DRUG|Sorafenib|To be initiated at a dose of 200 mg orally. Once it is determined that no further HD aldesleukin therapy will be given, sorafenib may be given daily at the FDA approved dose of 400 mg twice daily until there is lack of clinical benefit or intolerable side effects develop.
223875287|NCT05104294|DIAGNOSTIC_TEST|Optical Coherence Tomography- Angiography|Peripapillary retinal nerve fiber layer thickness, ganglion cell complex, superficial and deep capillary plexus vessel density were measured.
223875288|NCT05104294|DIAGNOSTIC_TEST|Photopic negative response|Both the implicit time and amplitude of PhNR were recorded.
223875289|NCT03498768|OTHER|Questionnaire Administration|Subjects will be invited to complete a detailed questionnaire regarding personal information, known risk factors for lung cancer and psychological status.
223875290|NCT05322252|DRUG|Mifepristone|200mg orally
223875291|NCT05322252|DRUG|Misoprostol|Per clinician
223875292|NCT05891366|DRUG|WAL0921|Investigational product WAL0921
223875293|NCT05891366|DRUG|Placebo|Placebo product
223875294|NCT02449863|OTHER|Lung ultrasound|Lung ultrasound performed to newborns with respiratory distress
223875295|NCT06006052|COMBINATION_PRODUCT|regeneration technique|clinical procedure of regenerative endodontic as AAE mentioned using different material in each group
223875296|NCT00737542|DRUG|lidocaine|
223875297|NCT00737542|DRUG|NACL 0.9%|
223875298|NCT05284136|DIETARY_SUPPLEMENT|Crohn's disease exclusion diet (CDED)|16-week course of CDED+Partial Enteral Nutrition. During the first 6 weeks (phase 1 of CDED), patients will be prescribed the CDED and oral Modulen 1 liter (1000kcal) daily. Between week 6 and 16 (phase 2 of CDED), patients will be prescribed CDED and oral Modulen (500 mL).
223875299|NCT05284136|DRUG|Oral prednisolone|oral prednisolone at an initial dose of 40 to 60 mg/day (or 1 mg/kg for those patients who weigh less than 40 kg), with a fixed, tapering regimen such that patients should be off steroids by the last day of week 12. Increases in steroid dose during tapering of corticosteroids is allowed but if the patient receives steroids (other than hydrocortisone for adrenal insufficiency) after week 12, he/she is in failure.
223875300|NCT03000049|OTHER|bedside blood culture|
223875301|NCT00006330|DRUG|Digoxin|
223875302|NCT00006330|DRUG|Hawthorn|
223875303|NCT03792204|DIAGNOSTIC_TEST|Wearing-off 9 questionnaire|The participants would receive appropriate anti-PD medical treatments according to the patients' need during the investigation.The anti -PD treatment would not be changed in the population of the participants.
223875304|NCT05952895|PROCEDURE|Conventional quadrant-wise scaling and root planing (SRP)|SRP was conducted at baseline, after saliva collection and periodontal assessment, starting with the upper right quadrant and continuing clockwise over four visits at weekly intervals. SRP was performed under local anesthesia by the same periodontist (B.A.) by use of ultrasonic instruments (Mini Piezon, EMS, Nyon, CH) and manual periodontal curettes (Gracey curets, scaler Hu-Friedy, Chicago, IL). All present teeth were instrumented until the root surface was visually and tactilely clean and smooth. Self-performed plaque control measures consisted of toothbrushing using the modified Bass technique with a medium toothbrush and a regular toothpaste with fluoride twice a day and interdental cleaning using dental floss and/or interdental brushes once a day.
223875305|NCT00392249|BEHAVIORAL|Supervised Treatment of Schizophrenia by a family member|
223875306|NCT05660941|DRUG|Lispro|Ultra rapid Lispro
223875307|NCT05660941|DRUG|Lispro|Conventional Lispro
223875308|NCT00971269|DEVICE|Solesta (Nasha/Dx)|Gel (hyaluronic acid/dextranomer) for intersphincteric injection 4x2 ml and retreatment 4x2 ml after 4 weeks
223875309|NCT04364451|OTHER|Correlation of Polymorphisms of Lipoprotein Lipase (LpL) and Apolipoprotein E (Apo E) With Lipid Profile of Children With Acute Lymphoblastic Leukaemia During Therapy With L - Asparaginase|Children that meet all the inclusion criteria for this study will be examined and undergo treatment with asparaginase (Experimental group) and will be compared to the corresponding teams of healthy children and children that have ailed and are off chemotherapy for at least 6 months (Control group).
223875310|NCT02628678|DIETARY_SUPPLEMENT|FOS|
223875311|NCT01066026|PROCEDURE|hyaluronic acid with metallic cannula or standard needle.|"The sides of injection were randomized and both the subject and the evaluator were blind to it. The injections were performed according through two different devices:~* In one of the sides, the hyaluronic acid (Restylane®) was injected in its conventional pharmaceutical presentation, with a standard needle which is part of the product's kit;~* In the other side, the hyaluronic acid (Restylane®) was injected through a metallic cannula, which replaced the needle of the product's kit.~Local analgesia was provided for both applications: topical analgesics 4% Lidocaine, for the application with the standard needle, and nerve block (Lidocaine 2%), where the application was performed with the metallic cannula."
223875312|NCT01066026|DRUG|Hyaluronic acid injected with the new tool.|hyaluronic acid with metallic cannula.
223875313|NCT05426317|OTHER|Blood sample|This study only involves the patient taking 5 additional blood tests (peripheral venipuncture) compared to his usual care, which will be taken when he comes to the hospital. Each sample only requires a blood volume of 5mL (one tube), or a total blood volume of 25mL for the study (one blood test every 3 months for one year).
223875314|NCT00677469|DRUG|Cholestyramine|2 grams BID
223875315|NCT00677469|DRUG|Cholestyramine|1 gram BID
223875316|NCT00677469|DRUG|Placebo powder|1 gram BID
223875317|NCT06966648|OTHER|Core stabilization on stable surfaces|Participants will perform a structured core stabilization training program on stable surfaces, such as the floor and rigid foam blocks. The program includes functional exercises targeting trunk control, postural alignment, and balance, delivered three times per week over a 7-week period.
223875318|NCT06966648|OTHER|Core stabilization on unstable surfaces|Participants will perform the same structured core stabilization training program as the stable surface group, but on unstable surfaces such as BOSU balls and wobble boards. The intervention is designed to challenge balance, proprioception, and core muscle activation. Sessions are conducted three times per week over a 7-week period.
223875319|NCT00885924|DRUG|Desmopressin|Desmopressin 0.3 microgram/kg as an intravenous infusion given during 20 min.
223875320|NCT00885924|DRUG|Placebo|NaCl 0.9%
223875321|NCT04164940|OTHER|Brief alcohol intervention|Brief alcohol intervention already implemented in daily routine by the individual hospitals.
223875322|NCT01086826|DRUG|RT+CDDP/5-FU|RT=70 Gy (2 Gy x1/day, 5 days per week for 7 weeks) CDDP: 20 mg/m2/day as 30 minutes IV infusion from day 1 to day 4 5-FU: 800 mg/m2/day for 4 days Both drugs will be administered during weeks 1 and 6 of irradiation, starting from day 1 of radiotherapy.
223875323|NCT01086826|DRUG|RT+CETUXIMAB|RT= 70 Gy (2 Gy x1/day, 5 days per week for 7 weeks) Cetuximab= 400 mg/m2 as first dose.Subsequent doses of 250 mg/ m2, weekly, for 7 times.
223875324|NCT01086826|DRUG|INDUCTION CTx(TPF)+(RT+CDDP/5-FU)|"INDUCTION CTx(TPF):docetaxel 75 mg/m² + CDDP 80mg/m² + 5-FU 800 mg/m²/day from day 1 to day 4 will begin after the end of cisplatin infusion on day 1.Every 3 weeks.~concomitant CTx= CDDP 20 mg/m2/day + 5-FU 800 mg/m2/day RT= 70 Gy(2 Gy x1/day, 5 days per week for 7 weeks)"
223875325|NCT01086826|DRUG|INDUCTION CTx(TPF)+(RT+CETUXIMAB)|"INDUCTION CTx(TPF):docetaxel 75 mg/m² + CDDP 80mg/m² + 5-FU 800 mg/m²/day from day 1 to day 4 will begin after the end of cisplatin infusion on day 1.Every 3 weeks.~RT= 70 Gy(2 Gy x1/day, 5 days per week for 7 weeks) CETUXIMAB= 400 mg/m2 as first dose. Subsequent doses of 250 mg/ m2, weekly, for 7 times."
223875326|NCT04042207|DEVICE|Low Glucose Predictive Suspend system|consists of sensor-augmented pump therapy (SAP) / Low Glucose Predictive Suspend system (with predictive low glucose management technology)
223875327|NCT04042207|DEVICE|DBLHU System|DBLHU system embeds a regulation algorithm to automatically regulate the patient's glycaemia. It takes as input glycaemia value received every 5 minutes from the CGM and patient inputs related to meals and physical activities and it calculates the amount of insulin to be delivered. It sends this information to the pump that automatically delivers this quantity.
223875328|NCT00310635|BIOLOGICAL|Meningococcal C conjugate vaccine|
223875329|NCT03727958|DIAGNOSTIC_TEST|Lung and coronary CT assessment|Subjects will undergo simultaneous coronary arteries and thoracic CT assessment
223875330|NCT03727958|DIAGNOSTIC_TEST|Coronary CT assessment|Subjects will undergo coronary arteries CT assessment only
223875331|NCT02641938|DRUG|Dexmedetomidine|Dexmedetomidine group :1ug/kg IV loading over 20 minutes followed by 0.5ug/kg/hr IV infusion after induction of anesthesia until the completion of the surgery
223875332|NCT02641938|DRUG|Normal Saline|Control group :IV loading and infusion of same volume of normal saline after induction of anesthesia until the completion of the surgery
223875333|NCT03930420|BEHAVIORAL|Connect to Wellness|The research team will train LHD staff and offer them technical assistance to work with small worksites. LHD staff will be trained to deliver the Connect to Wellness program to worksites. Connect to Wellness is a program to disseminate EBIs to small worksites. Worksites receive guidance about EBIs and ongoing implementation assistance from a trained interventionist. In this study, LHD staff will be the interventionists. Worksites participating in Connect to Wellness complete three phases of activities, Assessment, Recommendations, and Implementation. LHD staff will receive Connect to Wellness intervention materials, multiple webinars delivered in real-time, access to a comprehensive intervention and training platform with features that allow them to connect with each other and with research staff, and group technical assistance calls to support their ability to recruit worksites in their communities and deliver Connect to Wellness to these worksites.
223875334|NCT05984589|BEHAVIORAL|RISE Personalized Self-Management Training (PSMT)|Along with patient education and internalization of self-determination, the RISE intervention focuses on replacing unhealthy habits with health-promoting habits. Ongoing practice and guidance in generating and enacting SMART (specific, measurable, achievable, realistic, and time-bound) health goals is the centerpiece of the RISE intervention. Working one-on-one with the PI, participants will set goals and develop practical strategies to establish sustainable healthy behavior (HB) change. Motivational interviewing, cognitive behavioral therapy, and patient education will accompany intensive collaborative problem-solving and creation of accountability structures to create lasting change. The 6-week intervention includes 2 in-person visits and 4 videoconference sessions.
223875335|NCT05984589|BEHAVIORAL|Standardized Self-Management Training (SSMT)|Participants randomized to the control condition will receive 6 standardized sessions from one of the occupational therapy (OT) interveners, matched to the PSMT for setting. At these visits, participants will be presented with slides containing pre-specified, standardized didactic content about the World Cancer Research Fund/American Institute for Cancer Research (WCRF/AICR) healthy behavior recommendations (HBRs). We hypothesize that these visits will control for the effect of research participation and increased knowledge about HBRs, and that simply providing standardized didactic content as an intervention modality without any personalization will have negligible effects on participants' healthy behaviors (HBs), self-efficacy, or quality of life. Content will follow the WCRF/AICR HBRs. Weeks 1-2 will focus on physical activity; weeks 3-4 will focus on diet and alcohol, and weeks 5-6 will focus on weight management and generalized strategies for HB change.
223875336|NCT05814146|DRUG|Dialysate bicarbonate concentration|"Assess how a lower dialysate bicarbonate affects:~* QTc duration during and between hemodialysis sessions~* PVC burden during and between hemodialysis sessions~* Clinically significant arrhythmia during and between hemodialysis sessions~* Intradialytic hypotension~* Adverse symptoms during hemodialysis sessions"
223875337|NCT05814146|DEVICE|Dialysate bicarbonate concentration - telemetry monitoring|Patients will be monitored with telemetry on both arms of the trial.
223875338|NCT02480205|DEVICE|NeuroBox to deliver the NeuroPAP|"The patients will be studied during the following conditions:~* On conventional NIPPV device with the clinically prescribed settings (30 min)~* With NeuroPAP and no change of Pmin (=peep) (60 min)~* With NeuroPAP and adjusted Pmin (decreased by 2 cmH2O) (60 min)~* During CPAP delivered with NeuroPAP device (15 min)~* Again with original NIPPV device and settings for 30 minutes"
223875339|NCT00760136|PROCEDURE|Computed Tomography|CT imaging of bilateral knee
223875340|NCT04105712|BEHAVIORAL|Dietary Change (low in highly processed foods)|For post-dietary change, food is provided for 3 days (participants provide own food and do food journals the other 2 days to confirm adherence). University of Michigan's Nutrition Obesity Research Center (NORC)'s Metabolic Kitchen prepares the food. Low HP food diet is based on prior methods where participants are placed on an isocaloric diet composed of 5% or less of calories from added sugar and 10% or less of overall calories from total sugar. No foods that meet the criteria for a HP food (defined by Kant and colleagues) that corresponds to: sweeteners (sugar, candy, etc); carbonated and non-carbonated beverages (fruit drinks, sweetened / diet beverages, etc.); baked / dairy desserts (cookies, ice cream, etc.); salted snacks (potato chips, etc.) and fast foods (pizza, cheeseburgers, etc.) are included in diet portions. The overall macro nutrient composition of the diet will be approximately 20-25% of kcal from protein, 30-35% of kcal from fat, and 40-50% of kcal from carbohydrates.
223875341|NCT03408041|OTHER|Medical file data extraction|Medical file data extraction
223875342|NCT00580866|DEVICE|JAS Brace|For approximately 6 weeks after surgery, the brace will be utilized for a period of 30 minutes, 3 times per day. Participants will also receive physical therapy 3 times per week.
223875343|NCT04595305|DEVICE|Cardiac resynchronization therapy by CRT-P or CRT-D implantation|Clinically indicated implantation of a CRT-P or CRT-D device as per standard of care
223875344|NCT05188118|DRUG|Cabozantinib|60mg oral once daily for 12 weeks
223875345|NCT05188118|DRUG|Ipilimumab|1mg/kg intravenous once every 3 weeks over 12 weeks
223875346|NCT05188118|DRUG|Nivolumab|3mg/kg intravenous once every 3 weeks over 12 weeks, then 480mg once every 4 weeks after
223875347|NCT05188118|DRUG|Lenvatinib|18mg oral once daily for 12 weeks
223875348|NCT05188118|DRUG|Everolimus|5mg oral once daily for 12 weeks
223875349|NCT00609336|DRUG|gemcitabine hydrochloride|Given IV
223875350|NCT00609336|DRUG|docetaxel|Given IV
223875351|NCT00609336|DRUG|capecitabine|Given PO
223875352|NCT00609336|RADIATION|intensity-modulated radiation therapy|Undergo IMRT
223875353|NCT00609336|DRUG|oxaliplatin|Given IV
223875354|NCT00609336|PROCEDURE|pancreatic surgical procedure|Undergo pancreaticoduodenectomy
223875355|NCT00609336|PROCEDURE|therapeutic conventional surgery|Undergo therapeutic conventional surgery
223875356|NCT00609336|OTHER|laboratory biomarker analysis|Correlative studies
223875357|NCT02238483|DRUG|AZD7624 1.0 mg|Inhaled AZD7624 solution, 11 mg/mL
223875358|NCT02238483|DRUG|Placebo|Inhaled placebo solution
223875359|NCT00006446|PROCEDURE|Training in parenting skills and communication|
223875360|NCT02477605|DEVICE|CONSTELLATION® 27-gauge Combined Surgical Pak|Sterile single-use supplies necessary to perform 1 vitrectomy surgery: 1 ULTRAVIT® 27-gauge 7500 cuts per minute (cpm) vitrectomy probe and a 27-gauge EDGEPLUS® Valved Entry System comprised of 3 trocar/cannulas and related accessories.
223875361|NCT02477605|DEVICE|CONSTELLATION® 23-gauge Combined Surgical Pak|Sterile single-use supplies necessary to perform 1 vitrectomy surgery: 1 ULTRAVIT® 23-gauge 7500 cuts per minute (cpm) vitrectomy probe and a 23-gauge EDGEPLUS® trocar/cannula set comprising of 3 trocars/cannulas and related accessories.
223875362|NCT02477605|PROCEDURE|Vitrectomy surgery|Microincisional pars plana vitrectomy (PPV) surgery for the treatment of various vitreoretinal diseases ranging from simple to advanced cases
223875363|NCT02215707|BIOLOGICAL|PfSPZ Vaccine|Suspension of metabolically active, non-replicating (live), radiation-attenuated, purified, cryopreserved, aseptic Plasmodium falciparum (Pf) sporozoites (SPZ)
223875364|NCT06177444|DRUG|Antibiotic|Postoperative antibiotic treatment
223875365|NCT03476811|DRUG|0.25% Marcaine at 2ml/hr and pain medications|Subcutaneous pain control with OnQ Subcutaneous Drug pump
223875366|NCT03476811|DEVICE|Placement of OnQ Drug pump|Subcutaneous placement of OnQ drug pump with normal saline infusion
223875367|NCT02574455|DRUG|Sacituzumab govitecan|10 mg/kg administered as a slow intravenous (IV) infusion either by gravity or with an infusion pump. Infusion rate for the first 15 minutes will start with 50 mg/hour or less with a subsequent infusion of 100 to 200 mg/hour up to a maximum recommended rate (advanced every 15 to 30 minutes) of 500 mg/hour with a subsequent infusion of 1000 mg/hour.
223875368|NCT02574455|DRUG|Eribulin|Administered IV over 2 to 5 minutes at a dose 1.4 mg/m\^2 at North American sites and 1.23 mg/m\^2 at European sites on Days 1 and 8 of a 21-day cycle for up to 15.3 months. Lower doses will be administered on the same schedule to participants with moderate hepatic impairment (ie, Child-Pugh B; 0.7 mg/m\^2 and 0.67 mg/m\^2 for North American and European sites, respectively).
223875369|NCT02574455|DRUG|Capecitabine|1000 to 1250 mg/m\^2 will be administered in a 21-day cycle, with capecitabine administered orally twice daily for 2 weeks followed by 1-week rest period for up to 10.6 months.
223875370|NCT02574455|DRUG|Gemcitabine|800 to 1200 mg/m\^2 will be administered IV over 30 minutes on Days 1, 8, and 15 of a 28-day cycle for up to 8.1 months.
223875371|NCT02574455|DRUG|Vinorelbine|25 mg/m\^2 will be administered as a weekly IV injection over 6-10 minutes for up to 11.5 months. Vinorelbine will not be allowed as TPC for any participant with Grade 2 neuropathy.
223875372|NCT00198315|COMBINATION_PRODUCT|Medpulser electroporation with Bleomycin|Patients receive electroporation with injection of bleomycin sulfate at a concentration of 1 U/ml per cm3 of tumor treatment area.
223875373|NCT00198315|PROCEDURE|Tumor surgical excision|Patients have their tumor surgically removed.
223875374|NCT01322477|OTHER|F18-FDG PET/CT|
223875375|NCT03914664|DIAGNOSTIC_TEST|Electroencephalogram (EEG) testing procedure|EEG testing procedure, comprised of somatosensory and auditory event-related potential paradigms, as well as resting state EEG
223875376|NCT03914664|DIAGNOSTIC_TEST|Autonomic function testing procedure|Autonomic function testing procedure, comprised of electrodes to determine heart rate variability and electrodermal activity (EDA)
223875377|NCT02387866|DRUG|AG-221|
223875378|NCT06973655|OTHER|Social Work support|Participants enrolled during the treatment phase at their clinic will receive social work support for 6 months from the time of enrollment. They will have an intake appointment with the social worker before or during their initial fracture clinic visit to assess their needs, identify goals that they can address with the support of the social worker, and collaboratively formulate a personalized care plan tailored to their specific circumstances. The social worker will then implement the plan, which may involve educating participants and their support network, coordinating delivery of care and benefits, making referrals to community services, advocating for the participant, and providing emotional support and brief counselling. The social worker will be accessible to participants for 6 months post-enrollment, following up via telephone, telemedicine or in-person to evaluate the effectiveness of the care plan and offer sustained ongoing support.
223875379|NCT04804241|DRUG|Senicapoc|10 mg oral tablet
223875380|NCT04804241|OTHER|Placebo Tablet|Placebo Oral Tablet
223875381|NCT02677896|DRUG|Enzalutamide|Oral
223875382|NCT02677896|DRUG|Placebo|Oral
223875383|NCT06089057|BEHAVIORAL|Pro-social Power training Activity for Aging and Well-being with Chronic Kidney Disease|This is a 16-week power-training and physical activity-focused intervention that contains group in-center and individual at-home components and motivational coaching. Participants will meet 2-3 times per week for the in-center power training. Participants will also be asked to wear accelerometers at home in order for their physical activity frequency to be measured.
223875384|NCT06089057|BEHAVIORAL|Attention Control for Pro-social Power training Activity for Aging and Well-being with Chronic Kidney Disease|This will be the attention control arm that will involve receipt of a physical activity education booklet, use of an accelerometer, and weekly check-in calls. No power training or motivational coaching will be delivered.
223875385|NCT00567489|DRUG|Physioneal|Physioneal 40 or Physioneal 35
223875386|NCT00567489|DRUG|Dianeal|Dianeal 1.5% Dextrose (1.30% glucose), 2.5% Dextrose (2.27% glucose), 4.5% Dextrose (3.86% glucose)
223875387|NCT00567489|DRUG|Extraneal|7.5% Icodextrin
223875388|NCT00567489|DRUG|Nutrineal|Amino Acids 1.1%
223875389|NCT06490770|DIAGNOSTIC_TEST|Gait analysis, Magnetic Resonance Imaging|Gait analysis and Magnetic Resonance Imaging to investigate the functionality and the pathological condition of the knee, respectively
223875390|NCT06212271|DRUG|Colchicine|See arm description.
223875391|NCT06212271|DRUG|Placebo|See arm description.
223875392|NCT04557228|DIETARY_SUPPLEMENT|Placebo|4 weeks of placebo supplements
223875393|NCT04557228|DIETARY_SUPPLEMENT|Phosphatidylserine|4 weeks of phosphatidylserine supplements
223875394|NCT04724421|DRUG|Voxelotor|tablet or powder for oral suspension
223875395|NCT06560125|OTHER|Standard care|Treatment appropriate for wound condition
223875396|NCT04455841|DRUG|INCB000928|INCB000928 will be administered at protocol defined dose.
223875397|NCT04455841|DRUG|ruxolitinib|Ruxolitinib will be administered at protocol defined dose.
223875398|NCT01813812|DRUG|DA-6034|
223875399|NCT01813812|DRUG|Rebamipide 300mg|
223875400|NCT02390986|DRUG|LON002|Extension study to provide continuing access to LON002 medication.
223875401|NCT01666704|DRUG|BMS-823778|Capsules, Oral, 2mg, Once daily, 1 year
223875402|NCT01666704|DRUG|BMS-823778|Capsules, Oral, 15mg, Once daily, 1 year
223875403|NCT01666704|DRUG|Placebo matching with BMS-823778|Capsules, Oral, 0mg, Once daily, 1 year
223875404|NCT00593866|RADIATION|INTENSITY MODULATED RADIOTHERAPY|Five fractions weekly, fraction size determined by dose level
223875405|NCT00593866|DRUG|Gemcitabine|1000mg/m2 will be infused over 100 minutes on days 1, 8, 22 and 29 of the radiation treatment
223875406|NCT05447871|PROCEDURE|Ultrasound guided single injection modified 4 in 1 block technique|A high-frequency ultrasound probe is placed over the femoral condyle and vastus medialis muscle is identified. The probe is slid proximally till the superficial femoral artery appeared. The probe is slid proximally till the descending genicular artery branching from the superficial femoral artery. The point of interest is 8-10 cm above the femoral condyle. The needle is guided into the Vastus medialis muscle till the nerve to Vastus medialis. At this point, 5-7 mL of the local anaesthetic drug is injected. The needle is guided further in-plane from lateral to medial side to reach the perivascular region and after negative aspiration 25 ml local anaesthetic drug is injected.
223875407|NCT05447871|PROCEDURE|Ultrasound guided adductor canal block technique|The Adductor canal is identified in the middle of the thigh beneath the sartorius muscle using a high-frequency ultrasonic transducer. the probe is slid till the superficial femoral artery appeared in the adductor canal between vastus medialis and adductor longus muscle. A 22-gauge spinal needle is inserted in a lateral to medial plane to reach the perivascular region and after negative aspiration 20 ml local anaesthetic drug is injected, visualised to push the femoral artery.
223875408|NCT05447871|DRUG|Bupivacaine 0.25%|bupivacaine 0.25%
223875409|NCT01945125|OTHER|rhTSH Group|Patients receiving rhTSH for RIT stimulation
223875410|NCT02206269|DEVICE|Alair System|The Alair system is used for doing bronchial thermoplasty.
223875411|NCT06261606|OTHER|Hybrid strategy|"A hybrid strategy inclusive of:~1. A one-page flashcard describing the adverse cardiovascular effects of air pollution and individual-level strategies to mitigate these effects~2. Alerting patients on polluted days (defined as air quality index (AQI) ≥ 131 \[33\]) by sending cell phone text messages and recommending to not go outdoors or minimize outdoor activities (especially exercising) on those days. This will also be accompanied by periodic phone calls to ascertain that the patients receive the messages and are attentive to them.~3. Wearing KN-95 facemasks (provided by the investigators of this study) as a physical barrier against air pollution on highly polluted days (defined as AQI ≥ 131) in case the patient cannot avoid going outdoors~4. Dietary intervention by encouraging patients to consume citrus fruits during days with AQI ≥ 131"
223875412|NCT06307301|DRUG|Abatacept Injection [Orencia] and Proleukin (aldesleukin)|Abatacept (Orencia®) and recombinant human IL-2 (aldesleukin). Patients will receive a fixed dose of subcutaneous abatacept (125 mg/mL) at day 1. Two weeks later (day 15), patients will receive the second dose of subcutaneous abatacept (125 mg/mL). In addition, patients will receive subcutaneous IL-2 (1x106units /day) for 5 days (days 15-19). If this treatment regimen is tolerated, patients will receive 28 further similar treatment courses of abatacept and IL-2 every two weeks.
223875413|NCT00004104|BIOLOGICAL|liposomal interleukin-2|
223875414|NCT00004104|BIOLOGICAL|polyvalent melanoma vaccine|
223875415|NCT00004104|BIOLOGICAL|recombinant interferon alfa|
223875416|NCT03837886|DIETARY_SUPPLEMENT|Sodium bicarbonate|The subjects should ingest 0.3g.kg of sodium bicarbonate 90 minutes before the beginning of the protocol task.
223875417|NCT03837886|DIETARY_SUPPLEMENT|Calcium carbonate|The subjects should receive gelatinous capsules containing 0.3 g.kg -1 of Calcium Carbonate
223875418|NCT03320746|DEVICE|Polar Loop 2 activity tracker|"The participants were instructed to aim to reach the daily activity goal, initially set at stage 1 as per the goals set by the trackers' manufacturer. The daily activity goal was based on user's typical daily activities, gender and age. The stage 1 daily activity goal corresponded to \~1h/day of jogging or \~2h/day of walking or \~7h/day household activities or a combination of these activities. The tracker gave an inactivity alert as a vibration and text it's time to move on the screen of the tracker if the user has been still for 55 minutes."
223875419|NCT03991286|DIETARY_SUPPLEMENT|Astaxanthin 8 mg|experimental
223875420|NCT03991286|OTHER|placebo|Matching placebo pill
223875421|NCT04982536|DEVICE|VMCore Biopsy System|Prostate Examine
223875422|NCT04982536|DEVICE|Standard of Care Biopsy Needle|Prostate Examine
223875423|NCT05079646|OTHER|class 1 and class 2 cavity preparation and restored with contemporary materials|class 1 and class 2 cavities prepared in extracted teeth after endodontic procedure and then these cavities were filled with new contemporary core buildup materials.
223875424|NCT06411743|BIOLOGICAL|Recombinant Human Albumin Injection|Recombinant Human Albumin injection, strength: 10 g/vial (20%, 50 mL); storage conditions: 2-8°C, protected from light; manufactured and supplied by Tonghua Anrate Biopharmaceutical Co., Ltd.
223875425|NCT06411743|BIOLOGICAL|Human Albumin|Human Albumin (An Pu Lai Shi®), strength: 10 g/vial (protein concentration 20%, 50 mL/vial), storage conditions: 2-8°C, protected from light; manufactured by Shanghai RAAS Blood Products Co., Ltd.
223875426|NCT02120222|DRUG|selinexor|Given PO
223875427|NCT02120222|OTHER|Correlative studies|Blood will be collected for pK and pDn analysis pretreatment on day 1 and 8 hours after treatment, on day 1 of cycles 1 and 2.
223875428|NCT01350024|PROCEDURE|Frontal nerve block with 2% lidocaine with 1:100,000 dilution of epinephrine|Frontal Nerve Block 5 cc will be administered preoperatively once.
223875429|NCT01350024|PROCEDURE|Subconjunctival injection of 2% lidocaine with 1:100,000 dilution with epinephrine|Patients will receive a 1.5 cc dose of subconjunctival lidocaine as above
223875430|NCT06133049|DRUG|Ozanimod|Women with MS who were exposed to ozanimod during pregnancy
223875431|NCT06133049|DRUG|Select DMTs other than ozanimod|Women with MS exposed to select DMTs other than ozanimod during pregnancy
223875432|NCT06133049|DRUG|No DMTs|Women with MS not exposed to any DMTs during pregnancy
223875433|NCT01620203|OTHER|No intervention/treatment is given|
223875434|NCT00002542|DRUG|CMF regimen|
223875435|NCT00002542|DRUG|cyclophosphamide|
223875436|NCT00002542|DRUG|doxorubicin hydrochloride|
223875437|NCT00002542|DRUG|epirubicin hydrochloride|
223875438|NCT00002542|DRUG|fluorouracil|
223875439|NCT00002542|DRUG|methotrexate|
223875440|NCT00002542|DRUG|tamoxifen citrate|
223875441|NCT00002542|RADIATION|radiation therapy|
223875442|NCT04110223|GENETIC|next generation sequence|targeted NGS of patients' pretreatment tumor biopsy samples using a 474-gene panel, which covers cancer- and radio-sensitivity-related mutations and SNPs.
223875443|NCT06534216|DIAGNOSTIC_TEST|Intestinal ultrasound|This study employs intestinal ultrasound (IUS) to assess disease activity in Inflammatory Bowel Disease (IBD) patients. Ultrasound parameters include bowel wall thickness measurement, evaluation of vascularization via color Doppler, assessment of wall stratification, and identification of mesentery features and complications (e.g., strictures, fistulas, abscesses). For ulcerative colitis, disease activity is gauged using the Milan Ultrasound Criteria (MUC), where a score \>6.3 indicates active disease based on bowel wall thickness and vascularization. In Crohn's disease, the Bowel Ultrasound Score (BUSS) and International Bowel Ultrasound Segmental Activity Score (IBUS-SAS) assess bowel wall thickness, vascularization, stratification, and inflammatory fat, with scores \>3.52 (BUSS) and \>48.7 (IBUS-SAS) indicating active disease. IUS evaluations occur at baseline, 2-6 weeks, 12 weeks, and 6-12 months to track disease progression and treatment response.
223875444|NCT02942862|DRUG|Orcein staining|Prognostic value of venous emboli detected by orcein staining
223875445|NCT01464034|DRUG|Carfilzomib|IV over 30 minutes on Days 1,2,8,9,15, and 16 every 28 days
223875446|NCT01464034|DRUG|Pomalidomide|PO daily on Days 1-21, every 28 Days
223875447|NCT01464034|DRUG|Dexamethasone|40 mg weekly PO or IV on Days 1, 8, 15, and 22, every 28 days.
223875448|NCT02058875|DRUG|Myfortic®|
223875449|NCT02058875|DRUG|Neoral®|
223875450|NCT02058875|DRUG|Cellcept®|
223875451|NCT02058875|DRUG|Prednisone|
223875452|NCT01367405|PROCEDURE|Surgical decompression|Surgical decompression within 24 hour postinjury
223875453|NCT01367405|PROCEDURE|Conservative treatment|Usual conservative treatment without surgery
223875454|NCT06322316|PROCEDURE|The Ultrasound-guided Retrolaminar Block Group|"The ultrasound probe was placed on the back in a transverse orientation on the lateral side of the posterior median line to identify the lamina of the 5th vertebra, ESM, and transversospinalis muscles of the target segment.~A 38-mm 22-gauge regional block needle was advanced using an in-plane technique. When the puncture needle touched the lamina, 20 mL of 0.25% levobupivacaine was administered between the transversospinalis muscle and lamina. The LA diffusion between the lamina and the ESM indicated a successful puncture."
223875455|NCT06322316|PROCEDURE|The Ultrasound-guided Erector Spinae Plane Block Group|"The ultrasound probe was placed on the back in a transverse orientation to identify the tip of the T5 transverse process as flat, squared-off acoustic shadows with a faint image of the pleura visible. When the tip of the transverse process was centered on the ultrasound screen, the probe was rotated to a longitudinal orientation. In the parasagittal view, the following layers were visible superficial to the acoustic shadows of the transverse processes: skin and subcutaneous tissue, trapezius, ESM, and T5 transverse process.~The block needle was inserted in-plane in a cranial-to-caudal direction until contact was made with the T5 transverse process. The correct location of the needle tip in the fascial plane deep to the ESM was confirmed by injecting 0.5-1.0 ml of normal saline and seeing the fluid lifting the ESM off the transverse process without distending the muscle. Then 20 ml levobupivacaine 0.25% was injected."
223875456|NCT00991107|DRUG|HE3286|HE3286 20 mg (10 mg BID) for 28 days
223875457|NCT03631550|DEVICE|Relivion active|1 hour self-administered occipital and supraorbital transcutaneous nerve stimulation
223875458|NCT03631550|DEVICE|Relivion Sham|1 hour self-administered Sham occipital and supraorbital transcutaneous nerve stimulation
223875459|NCT01741441|PROCEDURE|laparoscopic total fundoplication|LTF was performed using a standard five-trocar technique in all cases and carried out by two expert surgeons who had previously performed more than 50 laparoscopic fundoplications. A floppy 360° total fundoplication of 2-2,5 cm was constructed after full esophageal mobilization and posterior crural repair with nonabsorbable sutures.
223875460|NCT02395913|DRUG|Surfolase capsule (100mg)|Surfolase capsule one capsule twice one days fasting administration
223875461|NCT02395913|DRUG|Surfolase CR (200mg, T1)|one tablet once one days fasting administration.
223875462|NCT02395913|DRUG|Surfolase CR (200mg, T3)|one tablet once one days fasting administration.
223875463|NCT02395913|DRUG|Surfolase CR (200mg, T4)|one tablet once one days fasting administration.
223875464|NCT02806934|PROCEDURE|biological and ultrasound test|biological and ultrasound test 20 days after implantation in order to see the implantation rate
223875465|NCT04739527|BIOLOGICAL|DCP-001|allogeneic dendritic cell vaccine
223875466|NCT03565315|BIOLOGICAL|VRC-HIVMAB095-00-AB (10E8VLS)|10E8VLS is an investigational Monoclonal Antibody targeted to the membrane proximal external region and proximal viral membrane lipid region of HIV-1.
223875467|NCT03565315|BIOLOGICAL|VRC-HIVMAB075-00-AB (VRC07-523LS)|VRC07-523LS is an investigational Monoclonal Antibody targeted to the CD4 binding site of HIV-1.
223875468|NCT04385056|BIOLOGICAL|MSCTC-0010|MSCTC-0010 is a suspension product for infusion. The active ingredient is the umbilical cord-derived allogeneic mesenchymal stem cells (US-MSCs).
223875469|NCT00462358|DRUG|ARRY-520, KSP(Eg5) inhibitor; intravenous|Part 1: multiple dose, escalating; Part 2: multiple dose, single schedule.
223875470|NCT00462358|DRUG|Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous|Part 1: standard of care; Part 2: standard of care.
223875471|NCT04381975|BEHAVIORAL|Move in Mind Program|Each of the six Move in Mind sessions will take place once a week for approximately 1.5 hours, with 12-17 individuals participating per class. The material and exercises taught will include physical floor exercises, breathing exercises, as well as awareness training.
223875472|NCT04381975|BEHAVIORAL|6 Week Waitlist Control|The waitlist control group will receive the Move in Mind program after 6 weeks.
223875473|NCT04162444|DIAGNOSTIC_TEST|Physical examination|A physical examination is a routine screening procedure used to investigate a patient's symptoms or complaints. It consists of a series of questions regarding patient medical history followed by an examination of the symptoms to determine the correct diagnosis and treatment plan.
223875474|NCT04162444|DIAGNOSTIC_TEST|The Ross Classification for Heart Failure in Children|The assessment is performed by pediatric cardiologist according to the classic Ross scale. One of the 4 classes of chronic heart failure is registered.
223875475|NCT04162444|DIAGNOSTIC_TEST|The Aristotle score|Surgical risks will be assessed by the ARISTOTLE score developed specially for the task. The calculation will be performed online, available from http://www.aristotleinstitute.org.
223875476|NCT04162444|OTHER|Assessment of administered specific therapy|"The data will be registered as groups of administered medicines:~* Antiplatelet agents~* Loop diuretics~* Potassium-sparing diuretics~* Angiotensin-converting enzyme inhibitors"
223875477|NCT04162444|DIAGNOSTIC_TEST|Multispiral computed tomography/3D echocardiography|"All patients enrolled in the study should be routinely examined with multispiral computed tomography (MS-CT) or 3D-echo before surgery and 3 years later. As a result, a 3D aortic root reconstruction will be made to assess its size and anatomy and subsequently build a 3D soft model for surgery imitation.~At the study onset, we plan to perform MS-CT, then 3D-echo. If the correlation resulting from 3D-echo and the actual sizes will be high, the isolated 3D-echo will be preferred in the future.~If none of the methods is available, the patients will not be enrolled in the study.~The following data will be registered for further analysis:~* Perimeter of the aortic valve~* Diameter of the aortic valve at sinuses level~* Height of the aortic sinuses~* Morphology of the aortic valve"
223875478|NCT04162444|DIAGNOSTIC_TEST|Transthoracic and transesophageal echocardiography|"Transthoracic echocardiography is carried out at baseline, at discharge and then annually. It is performed in order to assess the contractile function of the heart and hemodynamic characteristics of the aortic valve and its autopericardium graft.~Transesophageal echocardiography is carried out directly after the withdrawal of the artificial circulation when performing augmentation of the aortic valve with autopericardium in order to asses hemodynamic characteristics of the aortic neo-valve."
223875479|NCT04162444|DIAGNOSTIC_TEST|12-lead electrocardiogram|"Registering 12-lead electrocardiogram (ECG) is used as a tool for assessment of the regularity of the heart rhythm as well as screening and predictive tool for assessment of fibrosis and hypertrophy processes in the myocardium. The following data will be registered:~* Heart rate~* Sinus rhythm (yes/no)~* Positive R wave in leads V5-6~* Angle α less than 0~* Presence/absence of abnormal Q wave~* Presence/absence of ST-segment depression in precordial leads"
223875480|NCT00345150|DRUG|Ng-monomethyl-L-arginine (drug)|
223875481|NCT01625234|DRUG|Phase I: X-396 (ensartinib)|Oral, ALK inhibitor
223875482|NCT01625234|DRUG|Phase II: X-396 (ensartinib)|Expanded Cohort
223875483|NCT03761472|BIOLOGICAL|Hyaluronic acid injection|Hyaluronic acid 48 mg 2.0% in 2.4 ml solution
223875484|NCT03761472|BIOLOGICAL|Platelet-rich plasma injection|Platelet-rich plasma injection 5ml
223875485|NCT05769764|OTHER|Archival tissue specimen and immunohistochemistry staining|This is a non-interventional study and no intervention will be administered.
223875486|NCT05946421|DEVICE|exhaled breath analysis|non invasive technology to measure components of exhaled breath
223875487|NCT00871130|PROCEDURE|Bariatric surgery|gastric banding, gastric bypass or vertical gastroplasty either open or laparoscopic or a combination of any
223875488|NCT05572060|DRUG|Metformin|Patient screening will be done using SOFA scoring and NEWS Supplemental oxygen will be supplied. Intubation and mechanical ventilation may be required Venous access will be established.CBC, chemistries, liver function tests,coagulation studies ,Peripheral blood cultures, urinalysis, microbiological cultures from suspected sources (eg, sputum, urine,etc),(ABG) and serum lactate will be obtained Crystalloids will be given at 30 mL/kg, started by one hour and completed within three hours Empiric antibiotic therapy is targeted at the suspected organism(s) In patients with lactic acidosis and severe acidemia, Sodium bicarbonate will be used to maintain the arterial pH above 7.15 In patients having persistent hypoperfusion vasopressors will be added Evaluation of volume status will be done using straight leg raising test and ultrasound guided IVC collapsibility index Plasma rennin, serum lactate and IL6 concentrations will be measured on admission and at one week.
223875489|NCT05572060|OTHER|standardized protocol|standardized protocol
223875490|NCT05043805|DRUG|Dextromethorphan|add on therapy
223875491|NCT05043805|OTHER|placebo|add on therapy
223875492|NCT05798273|PROCEDURE|intra-arterial injection|"All patients will receive an intravenous injection of \[68Ga\]Ga-PSMA-11 (1.5 MBq/kg), followed by a synchronous PET/MRI scan (median duration approximately 50 min) at 45-60 min post-injection.~In case of a positive \[68Ga\]Ga-PSMA-PET signal at the tumor site, patients will return (in 2 weeks) for an intra-arterial injection (i.e., a neuro-interventional procedure) of 68Ga-PSMA-11 (1.5 MBq/kg), followed by a repeat synchronous PET/MRI scan (median duration 50 min) at 45-60 min post-injection."
223875493|NCT05798273|DEVICE|synchronous PET/MRI scan|Scan done at (median duration approximately 50 min) at 45-60 min post-injection.
223875494|NCT05798273|OTHER|Radiopharmacon Contrast agent|Type: \[68Ga\]Ga-PSMA-11 dosage: 1.5 MBq/kg
223875495|NCT01566968|OTHER|Cough challenge test|Cough challenge will be performed with Capsaicin, citric acid and prostaglandin E2.
223875496|NCT01566968|OTHER|24 hour ambulatory cough recording|Cough recording by using an ambulatory sound recording device.
223875497|NCT01566968|OTHER|Cough quality of life questionnaire|questionnaire designed to assess impact of cough on a person's life
223875498|NCT04353531|DEVICE|High-flow nasal cannula|High-flow nasal cannula is a modality of oxygen device that can provide gas flow meets or exceeds patient inspiratory flow demand (flow can be set at 10-60 L/min), it has been proven to improve oxygenation and reduce intubation rate in hypoxemic patients.
223875499|NCT04353531|DEVICE|Surgical mask|A procedure mask will be used to cover patient's face after HFNC is initiated.
223875500|NCT04353531|PROCEDURE|bronchoscopy examination|is a procedure that allows a doctor to examine the inside of the lungs, including the bronchi, which are the main pathways into the lungs. During a bronchoscopy, a doctor inserts a thin tube containing a light and camera into the lungs through the nose or mouth or via artificial airway such as intubation or tracheotomy tube
223875501|NCT04353531|PROCEDURE|intubation|Intubation is the process of inserting a tube, called an endotracheal tube (ET), through the mouth and then into the airway. This is done so that a patient can be placed on a ventilator to assist with breathing during anesthesia, sedation, or severe illness.
223875502|NCT04353531|PROCEDURE|tracheostomy|A tracheostomy is a medical procedure - either temporary or permanent - that involves creating an opening in the neck in order to place a tube into a person's windpipe. The tube is inserted through a cut in the neck below the vocal cords. This allows air to enter the lungs.
223875503|NCT04353531|DEVICE|nebulization|A nebulizer is a piece of medical equipment that a person with asthma or another respiratory condition can use to administer medication directly and quickly to the lungs
223875504|NCT04353531|DIAGNOSTIC_TEST|Pulmonary function test|Pulmonary function tests (PFTs) are noninvasive tests that show how well the lungs are working. The tests measure lung volume, capacity, rates of flow, and gas exchange.
223875505|NCT05180851|DRUG|Recombinant L-IFN adenovirus injection|Before use, dilute the product with normal saline according to the size of the tumor to an appropriate volume (10-30% of the total volume of the tumor), or adjust appropriately according to the specific tumor situation, inject directly into the tumor or inject under the guidance of B ultrasound /CT, inject the drug solution into the tumor edge and tumor evenly
223875506|NCT00051571|DRUG|SGN-15|
223875507|NCT00051571|DRUG|Docetaxel|
223875508|NCT01083316|DRUG|Bortezomib|"Induction:~Velcade 1.3 mg/m2/dose IV Days 1, 4, 8, 11 repeated every 21 days~Conditioning:~Bortezomib 1.0 mg/m2/dose will be administered on Days +6, -3, +1, + 4"
223875509|NCT01083316|DRUG|Dexamethasone|"Induction:~Dexamethasone 20 mg PO/IV Days 1, 4, 8, 11 repeated every 21 days"
223875510|NCT01083316|DRUG|Melphalan|"Conditioning:~Melphalan 70-100 mg/m2/day IV on days -2 and -1"
223875511|NCT00000936|DRUG|hOKT3|Administered both during and after transplantation in IV form. Dosage determined by individual weight and given for a maximum of 14 days.
223875512|NCT00000936|DRUG|Oral Cyclosporine|Administered orally as either sandimmune or neoral at a dose determined by weight. Patients 6 years of age and older begin at a dose of 15 mg/kg/day and patients under 6 years of age receive 500 mg/m2/day, for the duration of the study.
223875513|NCT00000936|DRUG|IV Cyclosporine|Administered intravenously (IV) both during and after transplantation at a dosage determined by individual age.
223875514|NCT06003517|PROCEDURE|Screening with PSI check list|Screening PSI with institutional check list
223875515|NCT00000587|PROCEDURE|erythropoietin, recombinant|
223875516|NCT00074919|BIOLOGICAL|alglucosidase alfa|20 mg/kg qow
223875517|NCT04141514|OTHER|therapeutic fasting|fasting limited to daily 250 kcal during 3 days (day before chemotherapy, the D day of the chemotherapy and the day after chemotherapy)
223875518|NCT04553770|DRUG|Anastrozole|Given PO
223875519|NCT04553770|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
223875520|NCT04553770|BIOLOGICAL|Trastuzumab Deruxtecan|Given IV
223875521|NCT04200365|DRUG|Itacitinib|Itacitinib will be administered orally once daily for up to 24 months.
223875522|NCT01544270|DIETARY_SUPPLEMENT|Yogurt-like snacks|twice a day 120 g for four weeks
223875523|NCT04222686|DRUG|Perindopril Arginine|10 mg Perindopril tablet / day will be added to the usual treatment for each patient for a period of 8 weeks.
223875524|NCT04222686|DRUG|Losartan Potassium|100 mg Losartan tablet will be added to the usual treatment for each patient for a period of 08 weeks.
223875525|NCT00282971|DRUG|Inhaled Insulin (Exubera)|Addition of inhaled insulin to pre-existing oral diabetes therapy.
223875526|NCT00282971|OTHER|Standard of Care|Standard of Care: All licensed diabetes drugs can be prescribed per discretion of investigators
223875527|NCT01281163|DRUG|Akt Inhibitor MK2206|Given PO
223875528|NCT01281163|OTHER|Laboratory Biomarker Analysis|Correlative studies
223875529|NCT01281163|DRUG|Lapatinib Ditosylate|Given PO
223875530|NCT01281163|OTHER|Pharmacogenomic Study|Correlative studies
223875531|NCT01281163|OTHER|Pharmacological Study|Correlative studies
223875532|NCT02725086|DRUG|Leucostim®|
223875533|NCT02725086|DRUG|Neupogen®|
223875534|NCT00533546|DRUG|Activated Protein C|Intravenous APC (10, 15, 22, 33, 50, and 75 mcg/kg) administered to patients with acute ischemic stroke within 0 - 9 hours of symptom onset
223875535|NCT03799783|DRUG|dexmedetomidine|To administer dexmedetomidine IV 2 μg/kg in 10 minutes (loading dose) followed by continuous infusion at a rate of 1 μg/kg/h until procedure was complete
223875536|NCT02945098|OTHER|Kinesio Taping|Kinesio Taping application with tension (Kinesio Tex Gold®, Japan) in the anterior region of the non-dominant arm.
223875537|NCT02945098|OTHER|Placebo Kinesio Taping|Kinesio Taping application without tension (Kinesio Tex Gold®, Japan) in the anterior region of the non-dominant arm.
223875538|NCT03435666|DRUG|Capecitabine|Single oral dose (1250mg/m2) Capecitabine or XELODA in each period.
223875539|NCT03435666|DRUG|XELODA|Single oral dose (1250mg/m2) Capecitabine or XELODA in each period.
223875540|NCT02441881|DEVICE|Venefit|Endovenous radiofrequency device
223875541|NCT02441881|DEVICE|Radiofrequency Induced Thermal Therapy|Endovenous radiofrequency device
223875542|NCT02441881|DEVICE|Endovenous Radiofrequency|Endovenous radiofrequency device
223875543|NCT03567798|DIETARY_SUPPLEMENT|UPLAT|Carica papaya leaf Extract + Tinospora cardifolia Extract
223875544|NCT03567798|OTHER|Placebo|Placebo
223875545|NCT00879060|DRUG|Spironolactone|spironolactone 50mg daily
223875546|NCT00879060|DRUG|Placebo|inactive placebo pill daily
223875547|NCT01563380|BIOLOGICAL|Platelet rich plasma|PRP ready to be injected was supplied in a syringe in a quantity of 8 ml for each knee. The entire procedure was done under complete aseptic precautions. The calcium chloride required for activation was given in a separate syringe in a ratio of 4:1. About 12-16 ml of platelet rich plasma was obtained by this method and it was used for application. To confirm sterility, culture and sensitivity of PRP was performed. Patient's peripheral blood platelet count and the prepared platelet concentrate's platelet count was performed and recorded. Number of tramadol injections given was also noted
223875548|NCT00485329|OTHER|Papain|15,000 USP U/ml
223875549|NCT00485329|OTHER|Papain|30,000 USP U/ml
223875550|NCT00485329|OTHER|Papain|60,000 USP U/ml
223875551|NCT04730713|DEVICE|The morphology and parameters of cranial ultrasound spectrum based on cerebral artery|Subjects who meet the standards will undergo a full-body examination and basic life after entering the ICU Sign evaluation and monitoring, mainly including nervous system specialist physical examination, multi-modal brain function testing, Respiratory system monitoring and management, hemodynamic monitoring, APACHE Ⅱ score, GCS score, and routine general circulation, respiratory management, sedation and analgesia management, temperature management, infiltration Pressure management, lumbar pressure measurement The included subjects were monitored for optic nerve sheath diameter, TCD/TCCD before and after lumbar puncture, and recorded spectrum morphology: normal, high resistance state, ischemic topic, congestion state, spasticity, nail wave/oscillating wave state, S1S2 fusion high point state, and recording at the same time Parameters: systolic flow rate (Vs) Shu Tensile blood flow velocity (Vd), average blood flow velocity (Vm), pulsatility index (PI), impedance Index (RI)
223875552|NCT05796323|OTHER|No intervention.|The subjects will complete a survey related to workplace violance.
223875553|NCT03858413|DIAGNOSTIC_TEST|No intervention|No intervention
223875554|NCT00211419|DRUG|Anecortave Acetate 15 mg|
223875555|NCT00211419|DRUG|Triamcinolone Acetate 4 mg|
223875556|NCT00211419|PROCEDURE|Photodynamic Therapy with Verteporfin|
223875557|NCT00211419|PROCEDURE|Thermal Laser|
223875558|NCT05911581|OTHER|intra-arterial flushing|"The catheter will be flushed to prevent occlusion after radial artery catheterization.~intra-arterial flushing with heparinized fluid kept in room air"
223875559|NCT05911581|OTHER|intra-arterial flushing|Intra-arterial flushing with heparinized fluid at patient body temperature
223875560|NCT02318134|PROCEDURE|Fecal Microbiota Transplantation|FMT via a nasoduodenal tube with fresh bacteria from healthy donor
223875561|NCT02318134|DRUG|normal saline|Normal saline via a nasoduodenal tube.
223875562|NCT04900766|DRUG|Mitoxantrone Hydrochloride Liposome Injection|20 mg/m2, IV, on day 1 of each 21-day cycle (q3w).
223875563|NCT01976312|OTHER|Sham injection|Sham injections referred to the imitation of an intravitreal injection using an injection syringe without needle.
223875564|NCT01976312|DRUG|Ranibizumab 0.5 mg|Ranibizumab solution for injection was supplied in vials. Each vial contained ranibizumab concentration of 10mg/mL labeled as 0.5 mg/0.5 mL, corresponding to a 0.5 mg dose level. Ranibizumab was formulated as a sterile solution aseptically filled in a sterile glass vial for single use only
223875565|NCT03010631|DRUG|Cohort 1: Lubiprostone Capsule, Fasted|Lubiprostone soft gelatin capsule administered under fasted conditions
223875566|NCT03010631|DRUG|Cohort 1: Lubiprostone Sprinkle Formulation, Fasted|Lubiprostone sprinkle formulation administered under fasted conditions
223875567|NCT03010631|DRUG|Cohort 2: Lubiprostone Sprinkle Formulation, Fed|Lubiprostone sprinkle formulation administered under fed conditions
223875568|NCT03010631|DRUG|Cohort 2: Lubiprostone Sprinkle Formulation, Fasted|Lubiprostone sprinkle formulation administered under fasted conditions
223875569|NCT04680520|OTHER|Experimental (Doublebase Gel® or Diprobase Cream®)|Emollient (Doublebase Gel® or Diprobase Cream®) use on the skin. The emollient should be applied at least once a day.
223875570|NCT04680520|OTHER|Best practice skin care advice booklet|This is a booklet containing advice on best practice skin care. This will contain information on avoiding soap etc.
223875571|NCT00293358|DRUG|carboplatin|
223875572|NCT00293358|DRUG|cisplatin|
223875573|NCT00293358|DRUG|etoposide phosphate|
223875574|NCT00293358|DRUG|ifosfamide|
223875575|NCT00293358|PROCEDURE|adjuvant therapy|
223875576|NCT00293358|PROCEDURE|conventional surgery|
223875577|NCT00293358|PROCEDURE|neoadjuvant therapy|
223875578|NCT00293358|RADIATION|radiation therapy|
223875579|NCT02497716|DRUG|Rivaroxaban (Xarelto, BAY59-7939|Single dose of reconstituted rivaroxaban granules
223875580|NCT04513314|DRUG|Valproate|Valproate sodium (enteral or intravenous) will be administered at a dosage of 10 to 15 mg/kg/day. The dosage may be increased by 5 to 10 mg/kg/week to achieve optimal clinical response. Ordinarily, optimal clinical response is achieved at daily doses below 60 mg/kg/day.
223875581|NCT04513314|DRUG|Quetiapine|Enteral quetiapine dosing on Day 3: 25 mg to 50 mg twice daily. Increase in increments of 50 mg/day to 100 mg/day divided two on Days 4 and 5 to range of 50-400 mg/day by Day 7. Further adjustments can be made in increments of 25-50 mg twice a day, in intervals of not less than 2 days. Recommended dose range is 150-750 mg/day.
223875582|NCT04513314|OTHER|Standard of Care|Standard of Care is a combination of IV dexmedetomidine (D), midazolam (M), ketamine (K) and propofol (P), at the discretion of treating physician.
223875583|NCT04827524|OTHER|Anthropometric measurement|The demographic information and birth histories of the subjects included in the study will be taken first. Anthropometric measurements of all subjects will be measured with the Star Scanner device. The Star Scanner 3 dimensional data collection system is a scanning system that enables the anthropometric head measurements of the baby to be taken in just 2 seconds. The advantages of this device is that it does not emit any harmful beams during evaluation, it does not have any harmful effects on health, and that it is an application that will not disturb babies.
223875584|NCT01985542|DRUG|birch pollen subcutaneous immunotherapy|birch pollen subcutaneous immunotherapy
223875585|NCT05949359|OTHER|Nintendo RingFit-augmented exercise program|"Participants in the NRE group received an 8-week exercise training program using the Nintendo RingFit (60 minutes for each session, two sessions a week). In each session, the participants first performed 5 minutes of walk-up exercises (i.e., simple jogging), followed by 50 minutes of Nintendo RingFit exercises and 5 minutes of cool down exercises.~The exercise intensity, in terms of repetitions, holding time of the exercise and advancement to difficult tasks, progressed gradually in 8 weeks."
223875586|NCT01609218|DRUG|LY2140023|
223875587|NCT01609218|DRUG|Aqueous activated charcoal|
223875588|NCT00199082|DRUG|Adriamycin|
223875589|NCT00199082|DRUG|Cyclophosphamide|
223875590|NCT00199082|DRUG|Cytarabine|
223875591|NCT00199082|DRUG|Dexamethasone/Prednisolone|
223875592|NCT00199082|DRUG|VP16|
223875593|NCT00199082|DRUG|Ifosfamide|
223875594|NCT00199082|DRUG|Methotrexate|
223875595|NCT00199082|DRUG|G-CSF|
223875596|NCT00199082|DRUG|Rituximab|
223875597|NCT00199082|DRUG|Vincristine/Vindesine|
223875598|NCT00199082|PROCEDURE|Irradiation (in specific conditions)|
223875599|NCT01996605|DRUG|Oxytocin 15 mcg|Oxytocin 15 mcg will be administered spinally
223875600|NCT01996605|DRUG|Oxytocin 150 mcg|Oxytocin 150 mcg will be administered spinally
223875601|NCT01996605|DRUG|Placebo|placebo will be administered spinally
223875602|NCT01472003|DRUG|ABT-806|ABT-806 will be administered by intravenous infusion.
223875603|NCT01472003|DRUG|ABT-806i|ABT-806i will be administered by intravenous infusion.
223875604|NCT06019923|OTHER|No intervention|No intervention
223875605|NCT04317794|DRUG|Nusinersen Sodium Injection|Administered as specified in the treatment arm.
223875606|NCT06859684|DRUG|Durvalumab|Durvalumab: During combination therapy: 1500 mg, Q3W, during combination therapy, on days 3-5 of each 3-week cycle (determined by the investigator); during maintenance therapy: 1500 mg Q4W
223875607|NCT06859684|DRUG|hepatic arterial infusion chemotherapy (HAIC)|hepatic arterial infusion chemotherapy (HAIC) : GemCis regimen was adopted, with the specific regimen as follows: cisplatin 60 mg/m2 on the first day, arterial infusion for half an hour, gemcitabine 1000 mg/m2 on the first day, arterial infusion for half an hour, repeated once every 3 weeks, and 4-6 cycles of treatment (the specific number of cycles was determined by the investigator according to the patient's condition).
223875608|NCT06859684|DRUG|Lenvatinib|Lenvatinib 8mg (weight \<60 kg) or 12mg (weight ≥60 kg) oral QD, during combination therapy, starting on day 3 of each 3-week cycle (determined by the investigator)
223875609|NCT04220229|DRUG|Cabozantinib S-malate|Given PO
223875610|NCT04220229|RADIATION|Radiation Therapy|Undergo standard of care radiation therapy
223875611|NCT02286154|DRUG|Hydroxyurea|For New Cohort participants, PK/PD data will be used to predict the most effective maximum tolerated dose. Old Cohort participants will receive hydroxyurea escalated to MTD as per local clinical guidelines.
223875612|NCT04428112|BEHAVIORAL|Building Better Caregivers Workshop|"Workshops consist of small group or about 20-25 persons. Two peer co-facilitators (caregiver themselves) will guide workshop activities. Participants will receive a workshop booklet. Each week, participants will log on at least 2-3 times for a total time of approximately two hours. Participants do not require real time attendance at pre-determined times."
223875613|NCT04428112|BEHAVIORAL|Attention Control|Participants will receive two brief 15-30 minutes phone calls by study staff, and will receive a handbook on dementia and caregiver resources while they wait for the workshop.
223875614|NCT05349331|PROCEDURE|Liver Resection|Surgical resection treatment: laparoscopic or open liver resection is performed, and targeted and immunotherapy are not continued after surgery.
223875615|NCT05925140|DRUG|Lopinavir / Ritonavir|"Kaletra is a medication that is produced by AbbVie, a pharmaceutical company based in the United States. It is FDA approved for the treatment of HIV-1 infection in adults and pediatric patients. Kaletra contains two active ingredients, lopinavir, and ritonavir, which work together to inhibit the replication of the HIV virus.~Administration dose and duration of treatment: Patients will receive a loading dose (800/200, daily) of lopinavir 400 mg plus ritonavir 100 mg orally every 12 h for 10 days or until discharge, if sooner."
223875616|NCT05925140|DRUG|Remdesivir (RDV)|"Remdesivir is provided by the United States as an FDA-approved drug, an antiviral medication developed by Gilead Sciences, and has been authorized for emergency use and approved for the treatment of COVID-19 in certain countries, including the United States.~Administration dose and duration of treatment: intravenously as a 200-mg loading dose on day 1, followed by a 100-mg once daily on days 2-10 or until hospital discharge or death. Duration is generally 5 days or until hospital discharge, whichever is first, but may extend to up to 10 days based on clinical response: For inpatients not requiring IMV and/or ECMO: 5 days; if clinical improvement is not demonstrated, treatment may be extended up to 10 days total. For inpatients requiring IMV and/or ECMO: 10 days."
223875617|NCT05925140|DRUG|Tocilizumab|"Actemra is an FDA-approved brand name for Tocilizumab, a monoclonal antibody that targets the interleukin-6 (IL-6) receptor, an immunosuppressive drug produced by Roche. It belongs to a class of medications known as IL-6 receptor antagonists and is designed to suppress the activity of the immune system. By blocking IL-6 receptor signaling, Actemra helps reduce inflammation and is used in the treatment of various autoimmune conditions and cytokine release syndrome.~Administration dose and duration of treatment: TCZ was administered 8 mg/kg intravenously (800 mg per infusion) as a single 60-minute intravenous infusion for 4 Weeks initially. The second infusion (400 mg) after 24 h may be administered based on clinical response in case of respiratory worsening, or 8 mg/kg at T0 followed by 8 mg/kg after 12 h."
223875618|NCT05925140|OTHER|Corticosteroid Therapy-enhanced Standard Care (CTSC)|(1) Methylprednisone (120mg/24h/IV) followed by 80mg/day (7days), and if necessary, continued with 40mg/day; or a pulse therapy (patient in critical state (360mg/day/IV) for 3 serial days, followed by 80mg/day (7days), and if necessary, continued with a dose of 40mg/day. (2) Standard Care: Normal Saline 0.9% (500cc/24h); vitamins \[D (Oravil, 100.000IU/2ml PO STAT), C (10g/250cc in normal saline, 60drops/min/day), B (BECOZYME, 6 ampoules IV STAT)\]; Omeprazole (RISEK, 40 mg/day IV); Paracetamol (PREFALGAN, 1g IV each 8h 3 times per day), Ketoprofen (PROFENID, 100mg/12h); Ceftriaxone (ROCEPHIN, 2g/day for 3 consecutive days), Doxycycline (VIBRAMYCIN, 100mg/12h PO for 8 days), Ivermectin (12mg/day for a period of 5 days); TOPLEXIL (Syrup, 10cc/each 8h) or SINECOD (Syrup, 15cc/each 8h); ATORVASTATIN (20mg/day); LOVENOX (40mg/12h if \<80kg, or 60mg/12h if \>80kg). Tranquillizers: NORMOCALM (400mg/night), XANAX (10mg/day), SEROQUEL (25mg/night), DEPIA (2mg/day), to be administered orally
223875619|NCT07007260|DIETARY_SUPPLEMENT|niacinamide supplementation|Patients will take niacinamide supplementation (500mg) every day for 1 year
223875620|NCT06315179|DIAGNOSTIC_TEST|Esophagogastroduodenoscopy (EGD) with biopsy|Esophagogastroduodenoscopy (EGD) is a test procedure to examine the lining of the esophagus, stomach, and first part of the small intestine.
223875621|NCT06315179|DIAGNOSTIC_TEST|Colonoscopy w/ biopsy|Colonoscopy is a test procedure to examine the lining of the different portions of the large intestine: cecum, colon, rectum, and anal canal.
223875622|NCT01207492|DRUG|nilotinib|Taken orally twice daily
223875623|NCT02769858|DEVICE|Light therapy|Light therapy glasses
223875624|NCT06693804|OTHER|Digital Otoscope and Ophthalmoscope|The otoscope and ophthalmoscope will be used by residents to examine the eyes and ears under illumination and magnification during physical examinations.
223875625|NCT06693804|OTHER|Conventional otoscope and ophthalmoscope|The otoscope and ophthalmoscope will be used by residents to examine the eyes and ears under illumination during physical examinations.
223875626|NCT07071103|RADIATION|Low-dose radiotherapy to the intestine (ILDR)|A single total dose of 1 Gy irradiation targeting the jejunum and ileum. Primary tumor or metastatic lesions that are within the irradiation field are irradiated concurrently.
223875627|NCT07071103|DRUG|PD-1/PD-L1 monoclonal antibodies|Pre-progression immunotherapy regimen continues or switches to an alternative PD-1/PD-L1 monoclonal antibody according to clinical guidelines.PD-1/PD-L1 monoclonal antibody will be given 1 day after ILDR at a 3-week interval.
223875628|NCT06182605|DEVICE|multifunctional instruments|Ophthalmic retractors can be used to lift the lens during surgery to assist in lens sucking or resection; Intraoperative injection of reagent, which has the advantage of retractable, micro-incision. Ophthalmic hooks can be used to secure support capsular bags; auxiliary cleavage; polishing capsule; Viscoelastic agent is injected as needed. The front end of the membranous cataract scissor is a capsular tearing forceps, and the capsule tearing and capsule scissors can be flexibly switched. All three instruments have the functions of two or three traditional instruments, which can be designed to reduce the number of times the instruments enter and exit the incision during surgery, improve surgical efficiency,
223875629|NCT06182605|DEVICE|traditional instruments|traditional Cataract-assisted instruments for cataract operation.Puncture knives, microscissors, microscopic forceps, nucleus hooks, lens graft forceps, are used to cut the cornea, assist in removing the cloudy lens, suturing wounds.
223875630|NCT04943562|DIAGNOSTIC_TEST|ACT+EEG|Combination of ACT+EEG. This is not an intervention, but rather a combination of devices to be tested regarding its diagnostic validity.
223875631|NCT01871675|DRUG|IPI-145|
223875632|NCT01871675|DRUG|Rituximab|
223875633|NCT01871675|DRUG|Bendamustine|
223875634|NCT00675246|DRUG|Betamethasone|IM administration of 12mg of betamethasone each 24 hours (total dose=24mg)
223875635|NCT06715306|OTHER|Oral treatment|Patients randomized to oral treatment will commence the oral treatment immediately. The oral treatment is based on specially developed treatment suggestions developed by microbiologists and specialists in infectious diseases from the participating regions, and in respect with local treatment guidelines (detailed described in the protocol).
223875636|NCT06780397|DIAGNOSTIC_TEST|Joint ultrasonography|"Patients will undergo rheumatologic visits at baseline and scheduled follow-ups.~Rheumatologic visit procedures:~* collection of patients' anamnesis of rheumatologic diaseases.~* identification of painful and/or swollen joints and enthesis.~* evaluation of joint and enthesis pain.~* joint ultrasonography and assessment of joint structures and enthesis."
223875637|NCT06780397|OTHER|European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 version 3.0|"Patients will undergo dermatologic visits at baseline and scheduled follow-ups.~Dermatologic visit procedures:~* collection of patients' oncologic anamnesis and general personal and lifestyle information.~* administration of the quality of life questionnaire (European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 version 3.0) to assess the impact of rheumatologic adverse events on patients' quality of life."
223875638|NCT06780202|DRUG|medrol dosepak|"Methylprednisolone is a corticosteroid with anti-inflammatory properties and immune suppression.~This study will utilize a 6-day Medrol Dosepak: a tapered low-dose corticosteroid course taken orally once a day. This includes 6 tablets on day 1 (24 mg), 5 tablets on day 2 (20 mg), 4 tablets on day 3 (16 mg), 3 tablets on day 4 (12 mg), 2 tablets on day 5 (8 mg) and 1 tablet on day 6 (4 mg)."
223875639|NCT06780202|DRUG|HYDROcodone Oral Tablet|This study will utilize a prescription of 20 pills of hydrocodone, 5mg each, to be taken as needed for pain, 1 every 6 hours.
223875640|NCT06145802|BIOLOGICAL|GT316|Autologous Tumor Infiltrating Lymphocyte Injection
223875641|NCT06834464|DRUG|Nanohydroxyapatite paste|nanohydroxyapatite paste will be applied with a brush on the surface of the teeth
223875642|NCT06834464|DRUG|HCl liquid|HCl liquid will be applied for 60 seconds prior to application of nanohydroxyapatite paste in certain groups
223875643|NCT06834464|DRUG|microabrasion|the material will be applied on the surface of teeth then microabrasion will be done with a rubber cup for 60 seconds
223875644|NCT05741034|DEVICE|JUVÉDERM® VOLITE™|Injection, subdermal and/or intradermal
223875645|NCT05741034|OTHER|Control|No-treatment control
223875646|NCT06786104|OTHER|VIDEO-PEDS|Following enrollment, parents will receive a link to view the refined video decision aid that is designed to prompt parents to think about their goals of care for their child with cancer, and then to react by engaging in communication with a trained member of the research team called the Navigator and eventually their clinical team over the course of the 9-month study duration.
223875647|NCT06786104|OTHER|VIDEO-PEDS pilot|This is the 3-month pilot version of the intervention, which will be further developed for the eventual RWCT.
223875648|NCT06786104|OTHER|Focus Group|Parents will view the Video aid and provide fascilitated feedback in an audio-recorded virtual group setting.
223875649|NCT06785844|DRUG|Botulinum Toxin A (Botox )|Botulinum Toxin injection
223875650|NCT05813730|OTHER|urinary creatinine excretion measurement|Urine samples will be collected up to 6 times a day from birth until discharge from the maternity hospital, to analyze the kinetics of creatinuria.
223875651|NCT06783894|BEHAVIORAL|exercise (elliptical training)|twenty irritable bowel syndrome men with sexual dysfunction ( weak erection of penis or erectile dysfunction) will perform ellpitical physical activity (40 minutes on elliptical trainer three times weekly. the duration of physical activity will be 12 weeks.
223875652|NCT06788860|PROCEDURE|Tri-directional Ultrasound-guided Needle Knife Release|"This procedure involves ultrasound-guided tri-directional needle knife release for the treatment of trigger finger. Local anesthesia using 3-5 ml of 1% lidocaine and 0.25% bupivacaine will be administered for patient comfort. It aims to ensure precise tissue dissection while minimizing risks and improving outcomes.~Device: Sonosite M-Turbo Ultrasound Machine with Linear Probe HFL38x (6-13 MHz) is used for real-time imaging during the procedure."
223875653|NCT05786391|OTHER|Flat position|Flat patient position during the cystoscopy
223875654|NCT05786391|OTHER|Trendelenburg position|Trendelenburg position (head down) during the cystoscopy
223875655|NCT05786391|DEVICE|Insufflation|Insufflation to 15 mm Hg
223875656|NCT06788574|DEVICE|TECAR device: MCRR. The sign producer is an INDIBA® 448 kHz RF device that has a vaginal/ or rectum electrode (made in Barcelona, Spain)|TECAR (Transfer Electrical, Capacitive, and Resistive) is originally used in Italy. TECAR therapy is a radiofrequency (RF) therapy, which produces high-frequency waves. RF can be capacitive or resistive The capacitive mode (CET) generates energy in electrolyte-rich soft tissues such as muscles and vascular or lymphatic tissues . The resistive mode (RET) directs energy to deeper tissues that contain more fat and fibers (such as bones, ligaments, and tendons;
223875657|NCT06788574|PROCEDURE|pelvic floor exercises|pelvic floor exercise will be performed with the perineometer twice a week for eight weeks (16 sessions), with five sets of 20 repetitions each
223875658|NCT06788574|DEVICE|Sham device|sham treatment by Tecar device for 15 min without producing any waves.
223875659|NCT06788665|DEVICE|Medical Device Dermalyser|Dermalyser is an Artificial Intelligence (AI) application (app) that allows medical professionals to take pictures of cutaneous lesions with the help of a smartphone camera. A dermatoscope is connected to the smartphone camera and is used to take the digital image of cutaneous lesions with suspicion of melanoma. Based on image processing algorithms, the app does a detailed analysis of the captured cutaneous lesion. In this clinical investigation, the objective is to test the device performance in a prospective setting in patients with a suspicion of primary cutaneous melanoma, to validate the added AI component. The intended purpose of the device is not to replace the physician's assessment, but rather to assist physicians in their assessment. Consequently, the final device should be regarded as a second opinion to augment clinical decision-making. The ultimate aim is to develop a tool that may augment clinical decision-making.
223875660|NCT06814184|BEHAVIORAL|app-based nurse-led virtual diabetes care|A nurse-led, app-based behavioral intervention consisting of (1) education via MyChart messaging, (2) problem solving with an action plan via phone, and (3) remote patient monitoring via mySugr app to identify the need to adjust treatment
223875661|NCT04105335|DRUG|MTL-CEBPA|Intravenous administration
223875662|NCT04105335|DRUG|Pembrolizumab|Intravenous administration
223875663|NCT03108443|DIAGNOSTIC_TEST|Optical Coherence tomography angiography|All subjects will have OCT angiography imaging performed
223875664|NCT00411905|DRUG|Bortezomib|
223875665|NCT04620187|DRUG|Ado-trastuzumab (T) emtansine (T-DM1)|Intravenous infusion ever 21 days (3weeks) for 1 year (52 weeks)
223875666|NCT04620187|RADIATION|Standard of Care Radiotherapy|Radiotherapy to shrink or kill tumors
223875667|NCT04620187|DRUG|Standard of Care Chemotherapy|Intravenous injection
223875668|NCT06535542|GENETIC|Whole Genome Sequencing|Participants in this arm will have their blood sample analyzed by whole-genome sequencing (WGS) and will be given access to Predictiv™ Deoxyribonucleic acid (DNA)-based digital twin platform, a web-based interactive application with WGS results. The platform will include positive monogenic and polygenic Familial Hypercholesterolemia results and pharmacogenomics results on statins and clopidogrel. A report of positive monogenic variants will be included in their medical record. This may also include genes on the American College of Medical Genetics and Genomics (ACMG) secondary findings (SF) version 3.2 list if the participant consents to receive these incidental findings. The report will only include pathogenic, likely pathogenic, and variant of uncertain significance (VUS) results.
223875669|NCT06679556|DRUG|Strength A Sublingual Minoxidil|One single dose of Strength A sublingual minoxidil
223875670|NCT06679556|DRUG|Strength B Sublingual Minoxidil|One single dose of Strength B sublingual minoxidil
223875671|NCT03713528|DRUG|Intraoperative Intraosseous Vancomycin|After debridement and irrigation the interventional group will receive intraosseous vancomycin 500mg in 150ml of normal saline. This solution will be prepared by the hospital pharmacy and administered via an EZ-IO intraosseous cannula. 75ccs of the vancomycin solution will be injected as a bolus. Subsequent to this the remaining 75ccs will be placed in the distal femur just proximal to the femoral component evenly split between the medial and lateral femoral condyles in knees.
223875672|NCT06832488|BEHAVIORAL|Diet|To compare the total food and energy intake of the diet with textures that require reduced oral processing versus the diet with textures that require increased oral processing by measuring weight before and after consumption of each meal and snack
223875673|NCT05367245|DRUG|Cal-Mag Butyrate|Supplements
223875674|NCT05367245|DRUG|Placebo|Only Cal-Mag but no Butyric acid
223875675|NCT06559345|RADIATION|TMLI|The total dose of TMLI is 12 Gy, administered on days -7, -6, and -5, with 2 Gy per fraction, twice daily, for a total of 6 fractions.
223875676|NCT06559345|RADIATION|TBI|The total dose of TBI is 12 Gy, administered on days -7, -6, and -5, with 2 Gy per fraction, twice daily, for a total of 6 fractions.
223875677|NCT06559345|DRUG|Cyclophosphamide|The total dose of cyclophosphamide is 120 mg/kg, administered over 2 days on days -4 and -3.
223875678|NCT06791616|PROCEDURE|Colonoscopy|Surveillance colonoscopy
223875679|NCT06786416|OTHER|PEQUOD|During cardiopulmonary bypass registration of the parameters of interest by the Livanova BE-CAPTA monitor. After surgery, registration of creatinine values up to 48 postoperative hours.
223875680|NCT03599843|BEHAVIORAL|Exercise|Participants will complete a 12 week exercise session that will be comprised of aerobic and/or resistance and/or flexibility training.
223875681|NCT06347393|DIAGNOSTIC_TEST|Mammography and Breast Ultrasound|Patients will be scanned using mammography and Breast Ultrasound for Breast Cancer Screening
223875682|NCT04578808|OTHER|Unruptured intracranial aneurysms|UIA of bifurcation between 3 and 7 mm for whom a clinical and imaging follow-up without occlusion treatment was scheduled by local multidisciplinary staff will be included. Extensive clinical, biological and imaging data will be recorded during a 3 years follow-up (visits at 1 and 3 years after inclusion).
223875683|NCT06778174|OTHER|observational study|"The interventions are not determined by the study, which is purely observational on real world data."
223875684|NCT00788684|DRUG|rituximab|IV infusion once weekly for four doses
223875685|NCT00788684|DRUG|ABT-263|ABT-263: oral solution or tablets, once daily dosing until disease progression
223875686|NCT03254589|DRUG|Methotrexate|See arm descriptions
223875687|NCT03254589|DRUG|Sulfasalazine|See arm description
223875688|NCT03254589|DRUG|Other DMARDs|See arm
223875689|NCT06173362|DRUG|Abiraterone|Given abiraterone
223875690|NCT06173362|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
223875691|NCT06173362|DRUG|Darolutamide|Given darolutamide
223875692|NCT06173362|DRUG|Prednisone|Given prednisone
223875693|NCT04529707|BEHAVIORAL|Transdiagnostic Behavioral Sleep Intervention|"The Transdiagnostic Sleep and Circadian Intervention for Youth (TranS-CY) uses a comprehensive sleep health framework along with robust evidence for promoting healthy sleep patterns in youth. The TranS-CY incorporates best practices from numerous efficacious behavioral sleep interventions including 1) cognitive behavioral therapy, 2) interpersonal and social rhythm therapy, and 3) behavioral treatment of circadian rhythm sleep-wake disorders. The traditional TranS-CY is clinician-led and provides a robust sleep treatment framework for youth with a wide range of disorders and sleep health concerns. For this study, investigators are using the basic framework of the TranS-CY, but clinicians will train parents to incorporate the intervention into the home for their young child with DMD. Trained clinicians will work with parents to ensure the basic components of the TranS-CY are incorporated into the home-based intervention."
223875694|NCT03121469|DEVICE|Papillon +TM|Technique of Per-Operative Radiotherapy (RPO) by Papillon +TM
223875695|NCT06389474|BIOLOGICAL|INM004|Two doses of Anti-Shiga Toxin Hyperimmune Equine Immunoglobulin F(ab´)2 fragments at a dosage of 4 mg/kg of body weight, 24 hours apart. Each vial contains 25 mg of protein/ml. Therefore, each subject must receive 0.16 ml/kg per dose. The vial volume will be reconstituted in a 100 ml (for subjects with a body weight of 20 kg or more) or 50 ml (for subjects under 20 kg of body weight) infusion bag. It will be administered as an intravenous infusion using an infusion pump over a period of 50 minutes. In subjects with a BMI over 30 kg/m2, infusion will be performed over a period of 100 minutes
223875696|NCT06389474|OTHER|Placebo|Two doses of placebo, 24 hours apart. The placebo solution has the same composition of excipients as INM004 without the active pharmaceutical ingredient, and its appearance is identical. Each subject must receive 0.16 ml/kg of placebo solution per dose. The vial volume will be reconstituted in a 100 ml (for subjects with a body weight of 20 kg or more) or 50 ml (for subjects under 20 kg of body weight) infusion bag. It will be administered as an intravenous infusion using an infusion pump over a period of 50 minutes. In subjects with a BMI over 30 kg/m2, infusion will be performed over a period of 100 minutes
223875697|NCT05396443|BEHAVIORAL|Black Girls for Wellness Telehealth|Weekly for 12 weeks, adolescent-caregiver dyads will attend 1) a live stream group Wellness (mindfulness, nutrition lesson, dance class, program reflection) session (90 min/wk) and 2) a home cooking experience using ingredients sent to participants' homes (60 min/wk) with their caregiver. Others in the home (e.g., siblings) will be encouraged to participate in activities as well.
223875698|NCT06365385|OTHER|Carbohydrate-last meal pattern|Skyr yoghurt, whey protein and almonds over \~5 min, immediately followed by white bread, strawberry jam, banana and pulp-free orange juice over \~10 min.
223875699|NCT06365385|OTHER|Carbohydrate-first meal pattern|White bread, strawberry jam, banana and pulp-free orange juice over \~10 min, immediately followed by skyr yoghurt, whey protein and almonds over \~5 min.
223875700|NCT04955821|DIAGNOSTIC_TEST|mNGS diagnose of VAP|This study is an observational study to evaluate the accuracy of pathogens in children with VAP tested by mNGS with no intervention. All patients from the cohort accept mNGS test and bacterial culture or virus PCR detection. A double sputum specimens are used for test.The reference standard is bacterial culture or virus PCR detection.
223875701|NCT03784924|DIAGNOSTIC_TEST|MRI prostate|MRI and laboratory biomarkers
223875702|NCT05464329|DRUG|Mosunetuzumab|Provided by Genentech.
223875703|NCT05464329|DRUG|DHAX|-Standard of care. Flexibility in administration is permitted at the discretion of the treating physician.
223875704|NCT05464329|DRUG|ICE|-Standard of care. Flexibility in administration is permitted at the discretion of the treating physician.
223875705|NCT06786806|OTHER|Gamified Infection Control Education Program|A four-week educational program integrating gamification techniques such as physical games, case studies, and escape rooms to teach infection control practices.Designed to enhance engagement, learning motivation, and cognitive achievement among nursing students.
223875706|NCT06786806|OTHER|Traditional Lecture-Based Instruction|Standard didactic teaching method focusing on infection control principles without incorporating gamification. Served as the comparator to evaluate the effectiveness of the gamified program.
223875707|NCT06791343|DIAGNOSTIC_TEST|AI-Based Diagnostic and Prognostic Model|This intervention involves an AI system that integrates multimodal data, including maternal health records, laboratory test results, and imaging data, to predict the risk of maternal and neonatal diseases. The system uses deep learning algorithms to provide real-time, accurate predictions, enabling early identification of health complications. By analyzing historical health data, the model aims to predict potential risks for both mothers and infants, improving early intervention and outcomes.
223875708|NCT06484478|OTHER|Wearable technology monitoring|Observational study (no intervention delivered)
223875709|NCT06464172|OTHER|Acute Oral gamma-aminobutyric acid (Natural Health Product in Canada)|1800 mg (3 capsules of 600mg) of GABA taken at the research center under the supervision of the research team.
223875710|NCT06464172|OTHER|Acute Placebo|A capsule filled with powdered sugar taken under the supervision of the research team.
223875711|NCT06790212|DRUG|Ivonescimab|20mg/kg Q3W，D1
223875712|NCT06790212|DRUG|Oxaliplatin|Oxaliplatin，130mg/m2，D1，Q3W；
223875713|NCT06790212|DRUG|Capecitabine|Capecitabine，1000mg/m2，po，BID，D1-D14，Q3W
223875714|NCT06525532|OTHER|follow up|performing a 3 Tesla MRI of the operated foot
223875715|NCT06785545|DIAGNOSTIC_TEST|CA19-9|All patients Ca19-9 levels calculated from their urinary samples
223875716|NCT04533503|DEVICE|HF-OCT Imaging with the Vis-Rx Micro-Imaging Catheter|Intracoronary HF-OCT imaging of the target lesion(s) during the procedure.
223875717|NCT06046443|DRUG|LB54640|Oral daily administration
223875718|NCT06046443|DRUG|Placebo|Placebo matched to LB54640
223875719|NCT06356662|DRUG|Tenofovir Disoproxil Fumarate|take tenofovir disoproxil fumarate 300mg/d
223875720|NCT04755660|BEHAVIORAL|Exercise behavior change for resistance exercise|The intervention includes motivational interviews and self-efficacy theory-based exercise behavior and home-based resistance exercise intervention (by Elastic Band or non- Elastic Band ), and 3 follow-up telephone calls. The usual care group will receive exercise counseling.
223875721|NCT03845829|PROCEDURE|In situ laser assisted fenestration|In situ laser assisted fenestration for the left subclavian artery during the procedure of TEVAR for type B aortic dissection
223875722|NCT06234033|BEHAVIORAL|Discrimination Acuity test|Estimating the just-noticeable difference of auditory loudness and vibrotactile displacement to fit a psychometric function for each modality with parameters: threshold, slope, sensitivity, and response criterion.
223875723|NCT06234033|DIAGNOSTIC_TEST|Transiently Evoked Otoacoustic Emission|Examination of integrity of outer hair cells in the inner ear; with and without contralateral suppression.
223875724|NCT06234033|OTHER|Questionnaires|Caregiver questionnaires send to parents online to acquire demographic information Autism Quotient (AQ), Child Behavior Checklist (CBCL6-16), Sensory Profile 2 (SP-2).
223875725|NCT06234033|BEHAVIORAL|Wechsler Intelligence Scale for Children, Fifth Edition (WISC-V)|Estimates intelligence quotient
223875726|NCT06234033|DIAGNOSTIC_TEST|Clinical tests of ASD|Autism Diagnostic Observation Schedule, 2nd edition (ADOS-2)
223875727|NCT06234033|OTHER|Electroencephalography (EEG) with auditory or vibrotactile stimuli|Two paradigms will be used: an auditory frequency tagging paradigm with interspersed pitch oddballs and a classical sensory gating paradigm with either vibrotactile stimuli or auditory clicks.
223875728|NCT06234033|DIAGNOSTIC_TEST|Clinical tests of ADHD|ADHD-Rating Scale (ADHD-RS)
223875729|NCT06652880|DEVICE|Digital technology|The digital app is a customized comprehensive self-management platform designed to provide recovery and parenting support for individuals with substance use disorders.
223875730|NCT06652880|OTHER|Bibliotherapy|Bibliotherapy control group will receive parenting book what to expect the first year.
223875731|NCT06783023|OTHER|validity and reliability study|In the study, which will include at least 24 individuals with CIED determined by power analysis, unassisted arm exercise capacity and arm function/endurance, maximum arm exercise capacity, double product, heart recovery, comorbidity level, hand grip strength, fear of movement, activities of daily living and quality of life will be evaluated.
223875732|NCT05062889|DRUG|5-Fluorouracil continuous infusion FOLFOXIRI schedule|3200 mg/sqm 48 h-continuous infusion, starting on day 1. To be repeated every two weeks for a maximum of 12 cycles.
223875733|NCT05062889|DRUG|5-Fluorouracil bolus FOLFOX schedule|400 mg/sqm iv bolus, day 1. To be repeated every two weeks for a maximum of 12 cycles.
223875734|NCT05062889|DRUG|5-Fluorouracil continuous infusion FOLFOX schedule|2400 mg/sqm 48 h-continuous infusion, starting on day 1. To be repeated every two weeks for a maximum of 12 cycles.
223875735|NCT05062889|DRUG|Oxaliplatin FOLFOX and FOLFOXIRI schedule|85 mg/sqm iv over 2 hours, day 1. To be repeated every two weeks for a maximum of 12 cycles.
223875736|NCT05062889|DRUG|Oxaliplatin CAPOX schedule|130 mg/sqm iv over 2 hours, day 1. To be repeated every three weeks for a maximum of 8 cycles.
223875737|NCT05062889|DRUG|L-Leucovorin|200 mg/sqm iv over 2 hours, day 1. To be repeated every two weeks for a maximum of 12 cycles.
223875738|NCT05062889|DRUG|Capecitabine|Capecitabine 1000 mg/sqm/bid per os from day 1 to day 14. To be repeated every 3 weeks until 8 cycles. Available as 500 and 150 mg tablets.
223875739|NCT05062889|DRUG|Irinotecan|165 mg/sqm iv over 60 minutes, day 1. To be repeated every two weeks for a maximum of 12 cycles.
223875740|NCT05062889|DRUG|Trifluridine/Tipiracil|35 mg/m2/bid per os days 1-5 and 8-12. To be repeated every 4 weeks until 6 cycles. Available as 20 and 15 mg tablets.
223875741|NCT05062889|DRUG|Trastuzumab|4 mg/kg iv over 30 minutes, day 1 (loading dose: 6 mg/kg iv over 90 minutes). To be repeated every two weeks for a maximum of 12 cycles.
223875742|NCT05062889|DRUG|Tucatinib|300 mg (two 150 mg tablets)/bid orally twice daily (approximately 8 to 12 hours between doses with or without a meal) for a maximum of 12 biweekly cycles.
223875743|NCT06502262|DRUG|Bupivacaine Hydrochloride|patient will be given 3ml (15mg) of 0.5% hyperbaric bupivacaine + 0.5 ml of normal saline intrathecally.
223875744|NCT06502262|DRUG|Fentanyl|patients will be given 3ml (15mg) of 0.5%hyperbaric bupivacaine +0.5ml (25 microgram) of fentanyl intrathecally
223875745|NCT06502262|DRUG|Dexmedetomidine|patient will receive 3ml (15mg) of .05 hyperbaric bupivacaine 0.5ml(5 microgram) of diluted dexmedetomidine intrathecally
223875746|NCT04358276|OTHER|Computer-Assisted Intervention|Complete online course
223875747|NCT04358276|DEVICE|Dermatoscope|Receive dermatoscope
223875748|NCT04358276|OTHER|Educational Intervention|Receive study packet
223875749|NCT04358276|OTHER|Educational Intervention (Physician)|Receive physician directed letter and educational package
223875750|NCT04358276|OTHER|Questionnaire Administration|Ancillary studies
223875751|NCT04358276|OTHER|Text Message|Receive text messages
223875752|NCT06789289|DRUG|TQC2938 injection|TQC2938 is a humanized monoclonal antibody that interfering with the signal cascade.
223875753|NCT06789289|DRUG|TQC2938 injection Placebo|TQC2938 is a humanized monoclonal antibody that interfering with the signal cascade.
223875754|NCT02865226|OTHER|paravertebral block by the anesthetist before incision (paravertebral block guided by ultrasound)|
223875755|NCT02865226|OTHER|paravertebral block by the thoracic surgeon at chest closure (paravertebral block visual).|
223875756|NCT06828757|DRUG|nanocrystalline megestrol oral suspension + PD-1/L1 inhibitor combined with chemotherapy|Oral suspension of nanocrystalline megestrol is taken orally once a day until disease progression or 12 weeks (maximum duration of 12 weeks) PD-1/L1 inhibitors combined with chemotherapy are given every 3 weeks for one dosing cycle.
223875757|NCT06828757|DRUG|PD-1/L1 inhibitor combined with chemotherapy|PD-1/L1 inhibitors combined with chemotherapy are given every 3 weeks for one dosing cycle.
223875758|NCT06689839|DEVICE|F2 Filter and Delivery System|Use of the F2 Filter and Delivery System in conjunction with a Transcatheter Aortic Valve Replacement (TAVR) procedure
223875759|NCT06689839|PROCEDURE|Transcatheter Aortic Valve Replacement (TAVR)|Transcatheter Aortic Valve Replacement (TAVR) with commercially available Transcatheter Aortic Valve Replacement (TAVR) device
223875760|NCT06828926|BEHAVIORAL|Tai Chi|The Tai Chi program content is based on the Harvard Medical School (HMS) Guide to Tai Chi, developed by clinical scientist Dr. Peter M. Wayne. Each participant will receive a workbook that describes the philosophy, evidence, and practice of Tai Chi, along with a video series for home practice that features the exercises from the HMS Guide to Tai Chi program. The in-person classes will be led by the PI and delivered weekly over 8 weeks, with 75-minute sessions. The in-person and video series will include an introduction to the principles of practice and tips on establishing and maintaining a practice, followed by a series of warm-up exercises, Tai Chi movements, and cool-down exercises. The Tin-person (and offer virtual live sessions for those who cannot attend in-person) over 8 weeks, accompanied by a workbook and video-recorded practices to promote self-management.
223875761|NCT05000528|OTHER|therapeutic education|In groups of 5-6, patients will have a one-day therapeutic training session comprising 4 workshops: how to create a sleep agenda; normal sleep; sleep hygiene; medical treatments.
223875762|NCT05000528|OTHER|Actimetry|once from inclusion for 2 weeks, second for 2 weeks starting 2 weeks after intervention
223875763|NCT05377840|BEHAVIORAL|Psychologist-administered Cognitive Behavioral Therapy|CBT is a combined psycho-social intervention that aims to improve overall mental health focusing on developing coping strategies. For psychologist-administered CBT: Participants will have individual weekly sessions (virtually) lasting 60 minutes each over an 8-week period with 1 follow-up maintenance session at week 12.
223875764|NCT05377840|BEHAVIORAL|Self-Administered Cognitive Behavioral Therapy|CBT is a combined psycho-social intervention that aims to improve overall mental health focusing on developing coping strategies. For self-administered CBT: Participants will be given a book written for patients on CBT for IBD with instructions on how to self-administer CBT.
223875765|NCT06788522|DRUG|Suvorexant|Suvorexant pills (10-20 mg)
223875766|NCT06788522|DRUG|Placebo|Matching placebo pills
223875767|NCT06828744|OTHER|Exercise|Participants in this group will follow an exercise and stretching program for five weeks, performed three times per week.
223875768|NCT06828744|OTHER|Exercise plus Joint Mobilization|Participants in this group will follow a five-week exercise and stretching program, performed three times per week, in combination with an ankle joint mobilization program.
223875769|NCT03789747|OTHER|As a observational study, there is no intervention.|As a observational study, there is no intervention.
223875770|NCT06792318|DIAGNOSTIC_TEST|FAPI PET-CT|"FAPI PET-CT imaging protocol:~Single dose 68Ga/18F-FAPI (2 MBq/kg)~Two imaging sessions:~First: 10 and 30 minutes post-injection Second: 60 and 80 minutes post-injection Ultra-low dose CT for attenuation correction and anatomical localization"
223875771|NCT05804708|DRUG|GH001|GH001 is administered via inhalation
223875772|NCT06784856|OTHER|PICC AR APP|"This study utilized Vuforia software and Unity 2022 LTS as the primary development platforms to create an AR-Enhanced and Game-Assisted Teaching curriculum. The designed PICC AR Exploration APP was developed for both iOS and Android platforms. The PICC-related content was based on the 8th Edition of the Infusion Therapy Standards of Practice published by the Infusion Nurses Society (INS) in 2021 and the 2022 Clinical Guidelines for Vascular Access Devices.~The required items for PICC care procedures were photographed and used to create 3D object elements and animations for developing AR scenarios and interactive gaming elements. The design and content of the PICC AR Exploration APP are described as follows:~Game Design Concept:~The PICC AR Exploration APP includes a learning unit system and a quiz unit system:~Learning Unit System Content:~Topic 1: Updates to guidelines and an introduction to clinical applications. Topic 2: PICC catheter care, dressing change steps, and techni"
223875773|NCT06784856|OTHER|Classroom Teaching and Case Sharing|"Introduction to Updated CVAD-PICC Guidelines and Clinical Applications~PICC Catheter Care Management of Common PICC-Related Complications Case Sharing on PICC Complication Management: Researchers"
223875774|NCT06829355|DRUG|Thymalfasin (Thymosin alpha 1, Ta1)|Thymalfasin: 4.8 mg, administered subcutaneously twice weekly.
223875775|NCT06829355|DRUG|Regorafenib (BAY 73-4506)|Regorafenib: Start at 80 mg once daily, orally, taken at a fixed time for 2 consecutive weeks and then stopped for 1 week. If the patient tolerates it well, increase to 120 mg/d in Cycle 2.
223875776|NCT06829355|DRUG|Tislelizumab (BGB-A317)|Tislelizumab: 200 mg, iv.gtt, single infusion, 21 days as a cycle, Day 1.
223875777|NCT06788171|RADIATION|Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy|PULSAR (SBRT): A targeted radiation therapy delivering 5-10 Gy/fraction every 3 weeks (q3w) to the gross tumor volume (GTV), for 3 times.
223875778|NCT06788171|DRUG|Bevacizumab|Bevacizumab: 5mg/kg, d1, q3w, 6 cycles.
223875779|NCT06788171|DRUG|Capecitabine|Capecitabine: 1000mg/m2, d1-14, bid, q3w, 6 cycles.
223875780|NCT06788171|DRUG|Oxaliplatin|Oxaliplatin: 130mg/m2, d1, q3w, 6 cycles.
223875781|NCT06788171|DRUG|Sintilimab|Sintilimab: 200mg, d1, q3w, 6 cycles.
223875782|NCT06834048|OTHER|observation alone|Psychometric properties will be assessed by administering the questionnaire online to approximately 200 participants. Reliability will be estimated by assessing stability and homogeneity.
223875783|NCT06791928|BEHAVIORAL|Peer distribution of self testking kits|Participants will be given a demonstration and instructions on how to use self-test kits (written and pictorial instructions in Luganda) and provided with ten serialized kits (five HIVST and five syphilis self-testing) to distribute to eligible social and sexual network members. Peers effective at reaching infrequent and non-testers will be asked to distribute an additional three to five test kits. Each peer will receive an IRB-approved $5 for each kit distributed and accounted for as in prior studies. (62). Respondents will be compensated for each successful recruitment, and SNS recruiting will continue until the sample size of 200 is attained. Each peer will receive a REC-approved transport facilitation of $30 per month since most MSM who have never tested are hard to trace. Control group peers will only distribute invitation letters for fast-track HIV/syphilis at the study clinic to minimize contamination (i.e., use of the intervention by control group participants).
223875784|NCT05306041|DRUG|Inavolisib|daily application of 9 mg (may be decreased to 6 mg and to 3 mg)
223875785|NCT05306041|DRUG|PHESGO|fixed-dose combination of pertuzumab and trastuzumab with hyaluronidase s.c. (PH-FDC SC) q3w beginning on day 1 of cycle 1 for 6 cycles (18 weeks)
223875786|NCT05306041|DRUG|Endocrine therapy|Endocrine therapy per physician´s choice with either tamoxifen 20mg or an aromatase inhibitor +/- GnRH analogue for premenopausal women and men
223875787|NCT06831617|OTHER|AI-based low dose CBCT reconstructed images system|Participants in the experimental group undergo AI-based low dose (radiation dose is 1/6th of the dose used in the clinic) CBCT reconstructed images guided lung puncture procedures.
223875788|NCT06831617|OTHER|Conventional CBCT images system|Participants in the experimental group undergo conventional CBCT images guided lung puncture procedures.
223875789|NCT06790277|DEVICE|Mepilex Border Sacrum dressings|Both types of intervention will be available in the operating room. Patient will be examined by head nurse of wound management team after the operation then at day 3- and 7-days post operation. The dressing should be removed after 7 days post operation or if there is any clinical indication for removal. If a patient is discharged before 7 days post operation for any reason the head nurse of wound management team will examine the patient before discharge. Follow up will be for maximum 7 days post operation for each subject. Any patient will be unable to continue the study because of death or change in the care setting will be excluded from the study.
223875790|NCT06790277|DEVICE|Polyurethane foams (Pink Pad)|Both types of intervention will be available in the operating room. Patient will be examined by head nurse of wound management team after the operation then at day 3- and 7-days post operation. The dressing should be removed after 7 days post operation or if there is any clinical indication for removal. If a patient is discharged before 7 days post operation for any reason the head nurse of wound management team will examine the patient before discharge. Follow up will be for maximum 7 days post operation for each subject. Any patient will be unable to continue the study because of death or change in the care setting will be excluded from the study.
223875791|NCT06833216|OTHER|Genetic variation|To observe and describe the clinical features, diagnosis and treatment plan and survival prognosis of familial hereditary breast cancer in China, and explore the main factors affecting prognosis.
223875792|NCT06783803|DIAGNOSTIC_TEST|Linkage Analysis|WES-Linkage analysis in families with FTAAD in follow-up in an Italian reference centre for genetic aorthopathies
223875793|NCT05840003|RADIATION|Ultra-Low-Dose thoraco-abdominopelvic scan|In addition to the usual management (i.e. standard dose Computed Tomography), an Ultra-Low-Dose thoraco-abdominopelvic scan will be routinely performed.
223875794|NCT04655235|GENETIC|Genotyping|Genotyping of glutamatergic, GABAergic, dopaminergic and other CNS-related genes
223875795|NCT05982132|OTHER|anthropometric measurement|Measurement of weight and other anthropometrics data
223875796|NCT03088813|DRUG|Irinotecan liposome injection|IV
223875797|NCT03088813|DRUG|Topotecan|IV
223875798|NCT06360640|DRUG|APC148 and Placebo|IV infusion
223875799|NCT06443684|DIAGNOSTIC_TEST|MRD|MRD（LC-10）include 10 lung cancer-related driver gene mutation site
223875800|NCT05820789|OTHER|Family support|Before the extubation procedure, the patient's relatives will be informed, and the patient will be allowed to enter the intensive care unit, and the patient will be able to express that he is with the patient by holding his hand and talking.
223875801|NCT05921032|OTHER|Exercise intervention|8 weeks of exercise with two session in a week
223875802|NCT05183542|DRUG|Bone scan|Persons to be operated on for lumbar arthrodesis by the neurosurgery team of the Nancy CHRU and respecting the eligibility criteria (including a score of neuropathique pain scale \< 4, see non-inclusion criteria), will be proposed to participate in the study neuropathic pain If they give their oral agreement to the neurosurgeon, a request for a bone scan will be sent to the nuclear medicine department of the Nancy-Brabois Hospital. The patients will fill pain scales before and after surgery (ODI and NS)
223875803|NCT05766657|DIETARY_SUPPLEMENT|Microbiome-targeted diet|The gut microbiota (on stool) and metabolic profile (on stool and urine) will be analyzed at time 0, and the dietary plan will contain specific directions aimed at restoring a proper metagenomic and metabolomic profile of the microbiota.
223875804|NCT05766657|DIETARY_SUPPLEMENT|Usual care diet|Subjects on the control group will receive general dietetic advice for Obesity or T1D
223875805|NCT06547905|DEVICE|Ostomy Leakage Detection System|A system that is used to detect ostomy leaks
223875806|NCT04689607|OTHER|Mulligan Traction Straight Leg Raise (TSLR)|The patient was in a supine position on a low bed and the therapist faced the limb of the patient that was to be treated. The therapist grasped the lower leg of the patient just near the ankle and raises the leg off the bed to a position just above the painful range. The therapist flexes the knees. Traction was retained as far as possible with a straight leg lift if there was no pain. The pain-free traction straight leg raise range was administered for 10 second and the procedure was repeated three times.
223875807|NCT04689607|OTHER|Post Isometric Relaxation technique (PIR):|The knee of the affected leg was extended, and the affected hip was flexed. Then the calf of the patient was placed on the shoulder of therapist. The therapist was standing on the side of the affected leg. The flexion of the hip was performed on the affected leg until resistance was felt. The patient was asked to gently push down on the therapist's shoulder with the leg. The therapist resisted hip extension to create an isometric contraction. The duration of the contraction was 10 seconds. Then the patient was instructed to relax and the therapist gently flexed the hip until the next barrier was felt. The technique was repeated three times.
223875808|NCT04605458|COMBINATION_PRODUCT|Contingency Management|Participants will receive 3-6 counseling sessions, nicotine patches \& lozenges, and monetary payment delivered contingent on abstinence verified by CO breath test.
223875809|NCT04605458|COMBINATION_PRODUCT|Standard Care|Participants will receive 3-6 counseling sessions, nicotine patches \& lozenges, and CO breath test monitoring.
223875810|NCT06029426|DRUG|NMRA-335140|Participants will receive NMRA-335140 at a dose of 80 mg QD, orally
223875811|NCT06029426|DRUG|Placebo|Placebo will be administered orally
223875812|NCT05910554|DRUG|Metformin|Patients randomized to metformin will be assigned the active arm.
223875813|NCT05910554|DRUG|Cellulose|Patients randomized to cellulose will be assigned the placebo arm.
223875814|NCT05423847|DIAGNOSTIC_TEST|POCUS|POCUS of lungs, pericardium and abdomen
223875815|NCT06085274|PROCEDURE|ICG guided sentinel lymph node biopsy|During sentinel lymph node biopsy the surgeon will inject a volume of 0.1ml divided into 2 doses (0.05ml each) of 2.5mg/mL ICG into the periareolar dermis of the involved breast. Technetium and blue dye will also be administered as per standard of care. The surgeon will assess the axilla with the the SPY-PHI near infrared imaging system to identify and remove ICG-fluorescent nodes; Any other sentinel lymph nodes identified will also be removed as per standard of care. If there is no progression of ICG towards the axilla, or if no ICG sentinel lymph node can be identified, an alternate injection technique involving peritumoural injection at 2-3 locations near the cancer site in the subcutaneous or dermal space of 0.05ml will be utilized.
223875816|NCT02949284|DRUG|Abiraterone Acetate|Given PO
223875817|NCT02949284|DRUG|Androgen Receptor Antagonist ARN-509|Given PO
223875818|NCT02949284|BIOLOGICAL|Gonadotropin-releasing Hormone Analog|Given SC
223875819|NCT02949284|DRUG|Prednisone|Given PO
223875820|NCT02949284|OTHER|Quality-of-Life Assessment|Ancillary studies
223875821|NCT02949284|OTHER|Questionnaire Administration|Ancillary studies
223875822|NCT02949284|PROCEDURE|Radical Prostatectomy|Undergo radical prostatectomy
223875823|NCT05587361|DRUG|Propranolol|Propranolol Capsule; 40 mg IR
223875824|NCT05587361|DRUG|Nicotine Patch|Nicotine Patch; 14 mg
223875825|NCT05587361|DRUG|Placebo Propranolol|Placebo Capsule, no active ingredients
223875826|NCT05587361|DRUG|Placebo Patch|Placebo Patch, no active ingredients
223875827|NCT05928169|DRUG|Topical and systemic drugs|Recruitment and follow-up will be independent on the type of treatment
223875828|NCT05398250|BEHAVIORAL|Safety Planning Intervention tailored for Autistic Individuals|To develop the SPI-A, clinicians work collaboratively with patients, and when indicated, their family members, to create a list of concrete coping mechanisms to be enacted leading up to or during a crisis. This list can be depicted in writing or pictorially, depending on patient preference. As part of the intervention, patients (and family members, when appropriate) also identify warning signs that signal the need to use the safety plan, as well as a detailed plan for reducing access to lethal means. SPI-A is a stand-alone intervention without a follow-up component.
223875829|NCT05398250|BEHAVIORAL|Safety Planning Intervention Tailored for Autistic Individuals Plus Structured Follow-Up Contacts|"SPI-A+ includes SPI-A plus a structured follow-up component. The structured follow-up component of SPI-A+ includes three elements:~1. A brief risk assessment and mood check~2. Review and, if needed, revision of SPI-A~3. Support related to outpatient mental health treatment initiation"
223875830|NCT04663399|OTHER|Prospective patient|The immuno-inflammatory and thrombo-inflammatory profiles will be evaluated at inclusion, and at 24 hours +/- 12 hours of the reperfusion treatment.
223875831|NCT03004664|BEHAVIORAL|Support Empowerment Model|The DSMS combines a series of clinically informed group didactic sessions that use a patient self-determination approach to empower patients to take control of their own diabetes health with follow-up supports to sustain self-management gains achieved during the sessions.
223875832|NCT03004664|BEHAVIORAL|The Chronic Care Model|the CCM focuses on addressing social determinants of health by meeting the medical, cultural, and linguistic needs of patients through integration of cultural norms and social relationships from the patient population into program design
223875833|NCT06306755|PROCEDURE|Risk Assessment and Individualized Surveillance|"1. An epidemiological questionnaire-based risk assessment for UGIC conducted prior to the endoscopic examination;~2. Individuals identified as high-risk receive the upper gastrointestinal endoscopic examination with Lugol's Iodine in the esophagus and indigo carmine staining in the stomach;~3. Individualized reexamination and surveillance strategy will be given to participants diagnosed with premalignant lesions, based on evaluation of risk progression using endoscopic characteristics, pathological diagnosis, and biomarkers."
223875834|NCT06306755|PROCEDURE|Universal screening|"1. A questionnaire investigation;~2. All participants undergo the upper gastrointestinal endoscopic examination with Lugol's Iodine in the esophagus and indigo carmine staining in the stomach;~3. Reexamination and surveillance will be performed according to the current guidelines for UGIC screening and clinical treatment."
223875835|NCT01903811|DRUG|Carfilzomib|Given IV
223875836|NCT01903811|DRUG|Dexamethasone|Given IV
223875837|NCT01903811|OTHER|Laboratory Biomarker Analysis|Correlative studies
223875838|NCT06170307|OTHER|two-dimensional speckle tracking echocardiography|The structural and functional parameters of the left atrial were obtained by conventional echocardiography, and the left atrial strain parameters were obtained by two-dimensional speckle tracking echocardiography.
223875839|NCT04540913|DEVICE|RHA 3|Investigational Product, RHA® 3 is a viscoelastic, sterile, non-pyrogenic, clear, colorless, homogenous, and biodegradable gel implant. It is formulated with sodium hyaluronic acid (NaHA) at a concentration of 23 mg/g obtained from bacterial fermentation using the Streptococcus equi bacterial strained, crosslinked with 1,4 butanediol diglycidyl ether (BDDE) and reconstituted in a physiological buffer (pH 7.3). RHA® 3 also contains 0.3% lidocaine hydrochloride to reduce pain on injection.
223875840|NCT04540913|DEVICE|Restylane-L|Comparator Product, Restylane-L is a gel of hyaluronic acid generated by Streptococcus species of bacteria, chemically crosslinked with BDDE, stabilized and suspended in phosphate buffered saline at pH=7 and concentration of 20 mg/mL with 0.3% lidocaine.
223875841|NCT03458429|DRUG|GMFFP|Granulocyte-Colony Stimulating Factor (G-CSF) Mobilized Fresh Frozen Plasma
223875842|NCT06478121|OTHER|Data and Blood collection|Data and Blood collection
223875843|NCT06478121|OTHER|MRI|MRI (optional)
223875844|NCT06820944|OTHER|dark chocolate|Consumption of 100 g/day of 72% dark chocolate bar for 14 days consecutively
223875845|NCT06820944|OTHER|white chocolate|Consumption of 80 g/day of white chocolate bar for 14 days consecutively
223875846|NCT06821230|BEHAVIORAL|Dyadic mindfulness|The dyadic mindfulness intervention group will receive 8 weekly 90-min sessions, with a total of 12 contact hours. The intervention will be delivered in a small group format with 6-8 dyads each and led by a certified yoga instructor with mindfulness qualifications. The program content mindfulness meditation, mindful breathing, and yoga sequences with warm-up and cool-down and each component is modified to pair-based practices.
223875847|NCT06699901|OTHER|Massive Transfusion Group|This group includes trauma patients who receive a massive transfusion, defined as the transfusion of at least 3 units of blood. Blood samples are collected at six specific timepoints following the administration of antibiotics to analyze plasma antibiotic concentrations. Existing clinical draws will be used whenever possible to minimize additional venipunctures, with a maximum of two dedicated research-only draws allowed if necessary. Data analysis will assess the impact of large blood transfusions on antibiotic pharmacokinetics over time, adjusting for factors such as kidney function.
223875848|NCT06699901|OTHER|Control Group|This group consists of trauma patients who receive minimal or no blood transfusions (up to 2 units of blood). Blood samples are also collected at six designated timepoints after antibiotic administration to measure plasma antibiotic concentrations. As with the massive transfusion group, clinical draws will be coordinated whenever possible to obtain research samples, with a maximum of two dedicated research-only draws if needed. Data analysis will compare antibiotic concentration trends in this group with those in the massive transfusion group to understand the effects of blood transfusion volume on antibiotic pharmacokinetics.
223875849|NCT05607030|COMBINATION_PRODUCT|VT-X7 Treatment System|Seven-day local antibiotic irrigation (alternating vancomycin hydrochloride and tobramycin sulfate) via the temporary VT-X7 Knee or Hip Spacer.
223875850|NCT05607030|PROCEDURE|Two-stage exchange arthroplasty|Stage 1 consists of surgical removal of the infected prosthesis, debridement, and implantation of a temporary spacer. Stage 2 surgery consists of explantation of the temporary spacer, debridement, and implantation of a permanent prosthesis.
223875851|NCT05607030|DRUG|SOC Antibiotics|Administration of at least 6 weeks of systemic antibiotics post-Stage 1 surgery followed by a 2-week antibiotic holiday before the Stage 2 surgery. After Stage 2 surgery, administration of at least 12 weeks of systemic antibiotics. Antibiotics will be selected by the treatment provider based on the infecting organism and administered per national and local treatment guidelines.
223875852|NCT05607030|DRUG|Experimental Antibiotics|After Stage 2 surgery, administration of at least 12 weeks of systemic antibiotics. Antibiotics will be selected by the treatment provider based on the infecting organism and administered per national and local treatment guidelines.
223875853|NCT03613740|DRUG|Fucoxanthin|Intervention will be administered 30 minutes before breakfast.
223875854|NCT03613740|DRUG|Placebo|Intervention will be administered 30 minutes before breakfast.
223875855|NCT06755099|DRUG|Botox|"The patient will be placed in gynecological position. Subsequently, the patient will be anesthetized with propofol bolus, a total of 270 mg IV sterilization of valval area with antiseptic solution then digital examination to assess the spasm of intriotus and vaginal walls under lowest possible doses then increasing the doses to allow for intra vaginal injection of Botox under full sedation. Pacik technique will be adopted for Botox Injection in the vagina .~. One vial of frozen Botox 100 U will be diluted with 2 mL saline, without foaming or shaking the vial, giving a concentration of 2.5 U/0.05 mL . Using a small sized speculum and after bending the needle to 30° to facilitate injection into sub mucosal area,1 mL (50 U) of Botox will be injected into the right bulbocavernosus then into the left side ."
223875856|NCT06755099|DEVICE|Radiofrequency|"Patients will be placed in prone position. After proper disinfection, the ischial spine (IS) and insertion point of the sacrospinous ligament will be identified using fluoroscopy medial to IS. 5 ml Lidocaine 2 % will be used to apply local anesthesia to the skin at the expected entry point for the radiofrequency cannula. Then a 20 G, 10 cm long and 1 cm active tip radiofrequency cannula will be introduced gradually utilizing 2 Hz motor stimulation until pudendal nerve is identified visually by the occurrence of contraction of the external anal sphincter muscle.~Subsequently, pulsed radiofrequency lesioning at temperature limit of 42 C will be applied bilaterally to the pudendal nerves for 240 s (2 cycles of 120 s) after applying local anesthesia using 2 cm 2% lidocaine in its vicinity."
223875857|NCT06764758|PROCEDURE|Endodontic treatment|Root-canal therapy applied in asymptomatic teeth with deep carious lesion required endodontic treatment.
223875858|NCT06764758|PROCEDURE|Restorative treatment|Composite resin restoration applied in teeth previously applied endodontic treatment.
223875859|NCT01722695|OTHER|Dialyzer comparison|"Each patient is treated by hemodialysis for one week (3 sessions) with each dialyzer type (Revaclear or FX).~The order of dialyzers used will be randomly assigned to the patient at randomization."
223875860|NCT06364358|BEHAVIORAL|Computerized CKD Education|The intervention is a culturally tailored computer-based adaptive program (developed during this intervention) to educate patients about kidney disease and renal replacement therapy options.
223875861|NCT06364358|BEHAVIORAL|Usual Hospital Care|Computer based patient education materials about general healthy lifestyle that will include information about the importance of a healthy diet, physical activity and medical adherence
223875862|NCT04928001|OTHER|internet based iCBT program, Youth Thrive|iCBT program is a skills program which teaches assertive communication, constructive thinking and rewarding activities
223875863|NCT01693120|DEVICE|Medtronic Phased RF Ablation System|Phased RF ablation
223875864|NCT05863598|BEHAVIORAL|Enhancing protective factors|Participants will watch some short movies and infographics, and will be asked to argue for the importance of body image flexibility, body functionality appreciation, etc.
223875865|NCT05863598|BEHAVIORAL|Expressive writing|Participants will reflect and write about any cognitions or emotions they can have in relation to their bodies.
223875866|NCT06436833|DRUG|2-Liter polyethylene glycol plus elobixibat|Take Elobixibat 10 mg, one day before colonoscopy at 8 a.m. Take Polyethylene glycol 1 Liter, one day before colonoscopy at 8 p.m. Take polyethylene glycol 1 Liter, at day of colonoscopy at 5 a.m.
223875867|NCT06436833|DRUG|4-Liter polyethylene glycol|Take Polyethylene glycol 2 Liter, one day before colonoscopy at 8 p.m. Take polyethylene glycol 2 Liter, at day of colonoscopy at 5 a.m.
223875868|NCT04097743|BEHAVIORAL|Coping Statement|Daily practice of coping statement
223875869|NCT06803940|PROCEDURE|clear aligner|closing of spacing in anterior teeth with clear aligner therapy
223875870|NCT06803940|PROCEDURE|orthodontic treatment|conventional fixed orthodontic appliance
223875871|NCT04654585|OTHER|The STOP intervention|The stop intervention is a heath professional (medical doctor) led intervention assisting smokers with low socioeconomic position in their smoking cessation attempt. It consists of routine care and adapted advice supplemented with a free delivery of any or several type(s) of nicotine replacement therapy (NRT) (patches, inhalers, gum, tablets, etc.) and/or an e-cigarette + e-liquid. The delivery of those smoking aids is based on the smokers' preference and choice.
223875872|NCT04654585|OTHER|Standard Care|"Participants randomised to the standard care group will be given standard care in assisting their smoking cessation attempt, but without free delivery of NRT or e-cigarettes.~Standard care includes motivational interviewing, advice to quit and prescription for NRTs. The number and online address of the French smoking cessation support helpline could also be provided. Health professionals will also be in position to prescribe NRT or other treatments (for example: Varenicline or Bupropion) which can help with smoking cessation, according to routine practice. The health professional could also give advice on e-cigarette use if he or she finds it suitable."
223875873|NCT06798740|DEVICE|Sugita Titanium Aneurysm Clip II|Aneurysm clipping is a surgical procedure used to treat brain aneurysms.
223875874|NCT04153565|DRUG|Pembrolizumab|Participants will receive Pembrolizumab 200 mg IV every 3 weeks (Q3W) until disease progression, or until participant has received 35 administrations of Pembrolizumab (approximately 2 years).
223875875|NCT04153565|DRUG|Pemetrexed|Participants will receive Pemetrexed 500 mg/m\^2 IV on Day 1 of each cycle up to 4-6 cycles where each cycle = 3 weeks
223875876|NCT04153565|DRUG|Cisplatin|Participants will receive Cisplatin 75 mg/m\^2 IV on Day 1 of each cycle up to 4-6 cycles where each cycle = 3 weeks
223875877|NCT05236296|BEHAVIORAL|EASE-CG|EASE-CG is an adapted brief psychotherapeutic intervention with relational support and trauma-based cognitive behavioral therapy (CBT) components.
223875878|NCT01741363|OTHER|FIT(Eiken OC-Sensor) Two-day sampling|Collect two stool samples in two separate days
223875879|NCT01741363|OTHER|FIT(Eiken OC-Sensor) One-year interval|Screening with one-year interval
223875880|NCT01741363|OTHER|FIT(Eiken OC-Sensor) One-day sampling|One-day sampling
223875881|NCT01741363|OTHER|FIT(Eiken OC-Sensor) Two-year interval|Screening with two-year interval
223875882|NCT01741363|OTHER|HpSA (Firstep Helicobacter pylori Antigen Rapid Test)|HpSA for detection of upper gastrointestinal diseases; screen and treat for H. pylori infection. Upper endoscopy for H. pylori carriers. HPSA+FIT compared with FIT alone.
223875883|NCT01741363|OTHER|FIT only|HPSA+FIT compared with FIT alone.
223875884|NCT06255262|DRUG|Surufatinib|"(1) Safety introduction phase (6 cases): 250mg, oral, QD,after one cycle of combined treatment, the occurrence of DLT was evaluated: 1) If ≤1person occurs, continue the dose expansion study at that dose level. 2)In the event of DLT\> 1, then the dose of surufatinib was adjusted to 200mg，oral，QD,until disease progression or intolerance of toxicity.~(2) Dose expansion phase (24 cases): RP2D, oral, QD,until disease progression or intolerance of toxicity."
223875885|NCT06255262|DRUG|Durvalumab|1500mg, Q4W.iv.every 28 days; until disease progression or intolerance of toxicity.
223875886|NCT01479647|DRUG|PH-797804|Tablet, 1 mg, single dose
223875887|NCT01479647|DRUG|PH-797804|Tablet, 1 mg, single dose
223875888|NCT01479647|DRUG|PH-797804|Tablet, 10 mg, single dose
223875889|NCT01479647|DRUG|PH-797804|Tablet, 10 mg, single dose
223875890|NCT01479647|DRUG|PH-797804|Tablet, 24 mg, single dose
223875891|NCT02802995|DRUG|PRP/thrombin mixture|Mixture of platelet rich plasma and thrombin applied topically on the wound surface
223875892|NCT05447507|DRUG|Remimazolam|0.075 mg/kg Remimazolam bolus infusion for 1 min, then 0.5\~1.0 mg/kg/h continuous infusion
223875893|NCT05447507|DRUG|Dexmedetomidine|1 mcg/kg Dexmedetomidine infusion for 10 min, then 0.2\~0.7 mcg/kg/h continuous infusion
223875894|NCT04853706|DIAGNOSTIC_TEST|3d cam|The 3D-CAM is a short interview that uses verbal responses and allows completion of the Confusion Assessment Method (CAM) diagnostic algorithm
223875895|NCT04853706|DIAGNOSTIC_TEST|DSM 5|The DSM-5 is the gold standard for diagnosing delirium. But proper use requires professional psychiatric background and training.
223875896|NCT04196504|DEVICE|Echocardiograghy, ECG|transthoracic echocariography, 12 lead ECG
223875897|NCT02333513|DRUG|Lomustine/Vincristine/Procarbazine|
223875898|NCT05304546|DRUG|Pembrolizumab|Solution for IV
223875899|NCT05304546|DRUG|Encorafenib|Oral QD
223875900|NCT05304546|DRUG|Binimetinib|Oral BID
223875901|NCT01443845|DRUG|Roflumilast|Roflumilast 500 µg, oral administration, once per day
223875902|NCT01443845|DRUG|Placebo|Dose-matched placebo, oral administration, once per day.
223875903|NCT02627469|BEHAVIORAL|Extended professional oral hygiene care|Weekly professional oral hygiene performed by dental hygienists
223875904|NCT02627469|DEVICE|Electric toothbrush (Oral-B Professional Care 7000)|Weekly professional oral hygiene performed by dental hygienists
223875905|NCT02627469|DEVICE|1100 ppm sodium fluoride dentifrice (Zendium Classic)|Weekly professional oral hygiene performed by dental hygienists
223875906|NCT00538122|DEVICE|24 Holter Monitor Recording|"All subjects will be fitted with a device to obtain 24-hour Holter EKG continuous recordings of bipolar leads C5C5R. They will also receive a standard 12-lead EKG recording prior to the placement of the Holter device. The subjects will be asked to keep a diary during the course of the 24 hours to record information such as wake and sleep times and symptoms such as shortness of breath, heart palpitations, lightheadedness, etc.~From each recording, 12 sets of 10 consecutive QRS epochs, plus QRS samplings obtained during sleep will be analyzed by a cardiologist blind to the medication status of subjects."
223875907|NCT05920746|OTHER|Kinesiotherapy with magnetotherapy|Individual kinesiotherapy. Parameters of magnetic field: 7 mT, f= 10-20 Hz, type of impulse: bipolar, rectangular pulse
223875908|NCT02146716|OTHER|Energetic Resonance by Cutaneous Stimulation|Energetic Resonance by Cutaneous Stimulation (RESC) is a non-invasive method based on energetic Chinese medicine principles and digital contact. RESC is characterized by echo phenomena between two stimulation points.
223875909|NCT02825641|DRUG|Oxytocin|"Labor induction and cervical ripening by oxytocin in women with premature rupture of membranes in 2 types of women:~1. Induction of labor on presentation at the delivery room.~2. Induction of labor after 24 hours of rupture of membranes."
223875910|NCT02825641|DRUG|Dinoprostone|"Labor induction and cervical ripening by dinoprostone in women with premature rupture of membranes in 2 types of women:~1. Induction of labor on presentation at the delivery room.~2. Induction of labor after 24 hours of rupture of membranes."
223875911|NCT01676558|DRUG|131I-rituximab|
223875912|NCT01515436|OTHER|Mozart alternating with Beethoven|Study participants will listen to Mozart's Sonata for Two Pianos in D Major, K. 448 alternating with Beethoven's Fur Elise.
223875913|NCT01515436|OTHER|Beethoven alternating with Mozart|Study participants will listen to Beethoven's Fur Elise alternating with Mozart's Sonata for Two Pianos in D Major, K. 448.
223875914|NCT05177939|DRUG|NPB-01|NPB-01 will be administered for the treatment of autoimmune encephalitis
223875915|NCT05177939|DRUG|NPB-01-ME|NPB-01-ME will be administered for the treatment of autoimmune encephalitis
223875916|NCT02060955|BIOLOGICAL|ALECSAT|The ALECSAT will be administered at week 4, 9, 14, 26 and week 46. Cells are re-suspended in a plasmalyte injection fluid up to a total volume of 20 ml. The 20 ml cell suspension will contain between 10 million and 1 billion cells. Each dose is supplied in a sterile 20 ml syringe and should be injected intravenously.
223875917|NCT02060955|DRUG|Bevacizumab/Irinotecan|Patients allocated to the Bevacizumab/Irinotecan (control group) will receive treatment according to standard praxis, i.e. up to 16 treatment cycles with 4 weeks duration. Each cycle consist of 2 dosing days; day 1 and day 15 in the cycle.
223875918|NCT00764335|PROCEDURE|total hip arthroplasty one side|unilateral total hip arthroplasty
223875919|NCT00764335|PROCEDURE|total hip arthroplasty both sides|bilateral total hip arthroplasty
223875920|NCT03172234|OTHER|oral amantadine sulfate|In amantadine group:the patients will receive100 mg oral amantadine sulfate 90 minute prior to the surgery
223875921|NCT03172234|DRUG|oral gabapentin|In gabapentin group: the patients will receive oral 800 mg gabapentin 90 minute prior to the surgery
223875922|NCT03172234|DRUG|Placebo Oral Tablet|in control group : the patients will receive Placebo Oral Tablet 90 minute prior to the surgery
223875923|NCT04771780|DRUG|KHK7791|oral administration
223875924|NCT03640195|OTHER|Device: Transcutaneous acupoint electrical stimulation and seeds for auricular acupressure|"Experimental group received Acupoint stimulation, Transcutaneous acupoint electrical stimulation20 minutes/weeks, once a week for six consecutive weeks.~The second part of The Experimental group received Auricular acupressure applied to four acupoints, including shenmen (TF2), mouth (IC6), subcortex (CW2), Occiput (AT3). each point is 1min, 5days/week, 3 times/day."
223875925|NCT01228669|DRUG|NNC 0172-0000-2021|Single dose injected i.v. (into a vein). Each treatment dose is assessed for safety before escalating to next dose
223875926|NCT01228669|DRUG|NNC 0172-0000-2021|Single dose injected s.c. (under the skin). Each treatment dose is assessed for safety before escalating to next dose.
223875927|NCT01228669|DRUG|placebo|Single dose injected i.v. and s.c. Each treatment dose is assessed for safety before escalating to next dose.
223875928|NCT03926442|OTHER|Italian Herb meal|Italian Herb in active breakfast meal
223875929|NCT03926442|OTHER|Cinnamon Meal|Cinnamon in active breakfast meal
223875930|NCT03926442|OTHER|Pumpkin Spice meal|Pumpkin Spice Mix in active breakfast meal
223875931|NCT03926442|OTHER|Placebo meal|Placebo in breakfast meal
223875932|NCT01499992|PROCEDURE|Standard physical therapy program PLUS aquatic physical therapy|2\. Standard physical therapy program PLUS aquatic physical therapy: The above PLUS a aquatic physical therapy program which will be conducted twice weekly for 10 weeks and will include a 40-50 minute hydrotherapy session emphasizing range of motion and light resistive exercises of the arm, primarily focusing on the shoulder. The program will start with general mobility of the other upper limb joints to allow time for preconditioning of the painful shoulder. Shoulder exercises will emphasize flexion, rotation and abduction and a slow transition from pain-free range to the restricted range of motion to maximize the effectiveness of the heat and buoyancy.
223875933|NCT01499992|OTHER|standard care|Total of 12 weeks; each exercise session will be 20 -30 minutes of direct contact and additional supervised exercise as defined by assignment and stage.
223875934|NCT03084549|DRUG|Administration of Ropivacaïne|Administration of Ropivacaïne in the margins of the episiotomy
223875935|NCT03084549|DRUG|Administration of placebo|Administration of placebo in the margins of the episiotomy
223875936|NCT02283749|BIOLOGICAL|Xofigo|This is a radio-isotope
223875937|NCT01574794|OTHER|Muscle strengthening exercises|The group will perform 8-week home based muscle strengthening exercises with 8 weekly supervised sessions which will be conducted by a rehabilitation specialist.
223875938|NCT01574794|OTHER|Muscle stretching exercise|The group will perform 8 week home based exercise intervention with 8 weekly supervised sessions which will be conducted by a rehabilitation specialist
223875939|NCT01753986|BEHAVIORAL|Brief Alcohol Intervention plus Standard Batterer Intervention|Brief Alcohol Intervention plus 40 hours or Standard Batterer Intervention
223875940|NCT01753986|BEHAVIORAL|General Health Improvement Intervention plus Standard Batterer Intervention|General Health Improvement Intervention plus 40 hours of Standard Batterer Intervention
223875941|NCT05264168|DRUG|Rivaroxaban|Any rivaroxaban dispensing claim is used as the reference group
223875942|NCT05264168|DRUG|Apixaban|Any apixaban dispensing claim is used as the exposure group
223875943|NCT03775785|DIETARY_SUPPLEMENT|Tailored enteral nutrition|"The mean of three measurements per batch (3 x 2-3ml) will be used to calculate the required amount of extra fat, protein, and carbohydrate for the following 3 days of fortification using a predefined Excel spread sheet (Microsoft Inc, Redmond, Washington).~The intervention will consist of adding fat, protein, and/or carbohydrate to achieve target levels of macronutrients.~The defined macronutrient concentration in breast milk is 4.4 g/100 mL of fat, 3 g/100 mL of protein, and 8.8 g/ 100 mL of carbohydrate to meet the European Society for Paediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN) guidelines (6.6 g/kg/d of fat, 4.5 g/kg/d of protein, and 13.2 g/kg/d of carbohydrate) assuming an intake of 150 mL/kg/d."
223875944|NCT02660970|OTHER|Acupressure|Children will have to wear a 'seasickness-band', which has the effect of acupressure
223875945|NCT02660970|OTHER|Placebo-band|Children will have to wear a 'placebo-wristband'
223875946|NCT02660970|DRUG|Iberogast|Children will have to take Iberogast drops
223875947|NCT02660970|OTHER|Placebo-drops|Children will have to take placebo-drops
223875948|NCT01610297|DRUG|ICL670|Oral dose of ICL670 at 10 mg/kg daily
223875949|NCT02014831|DRUG|Cetuximab|"Cetuximab treatment will be administered on specific days within a 21-days-cycle and for a maximum of 6 cycles as follow :~CETUXIMAB I.V infusion of 400 mg/m2 on cycle 1 Day 0 for 2 hours, then 250 mg/m2 for subsequent infusions for 1 hour on Day 8, Day 15 and next cycles Day1, Day8, Day15.~In case of documented toxicities, 2 drugs doses reductions are allowed according specific algorithms indicated in protocol"
223875950|NCT02014831|DRUG|TIP|"The TIP combination of treatments will be administered on specific days within a 21-days-cycle and for a maximum of 6 cycles as follow :~PACLITAXEL I.V infusion of 175 mg/m2, for 3 hours, on Day 1 of the cycle.~IFOSFAMIDE I.V infusion of 1200 mg/m2, for 2 hours, on Day 1, Day 2, Day 3 of the cycle.~CISPLATINE I.V infusion of 25 mg/m2, for 1 hour, on Day 1, Day 2, Day 3.~In case of documented toxicities, 2 drugs doses reductions are allowed according specific algorithms indicated in protocol"
223875951|NCT00002446|DRUG|Posaconazole|
223875952|NCT00002446|DRUG|Fluconazole|
223875953|NCT02847689|BEHAVIORAL|Language Treatment|Recording of a mother's voice reading a children's storybook.
223875954|NCT02847689|BEHAVIORAL|Control Treatment|Standard of Care
223875955|NCT05715437|DRUG|Bupivacaine plus Normal Saline|Effect of Bupivacain and ketamine and is superior to Bupivacaine and Normal Saline in terms of providing better pain control for 48 hours postoperatively after TKA.
223875956|NCT05715437|DRUG|Bupivacain and ketamine|Effect of Bupivacain and ketamine and is superior to Bupivacaine and Normal Saline in terms of providing better pain control for 48 hours postoperatively after TKA.
223875957|NCT03632616|OTHER|PANQOLI (quality of life instrument)|A quality of life instrument, the PANQOLI, will be administered prior to endoscopic intervention, and at 1,3, 6 and 12 months post-intervention.
223875958|NCT06516861|DRUG|Magnesium Sulfate 20 MG/ML|Administered intravenously with a dose of 30 mg/kg
223875959|NCT06516861|DRUG|Lidocaine IV|Administered intravenously with a dose of 1.5mg/Kg
223875960|NCT06516861|DRUG|saline solution|Administered intravenously with 20 ml
223875961|NCT01947634|OTHER|ResMed Apnea Link plus|Overnight respiratory polygraphy to detect sleep-related breathing disorders is performed in Fabry patients
223875962|NCT01007396|OTHER|1-step tuberculin skin test (TST) and blood sampling|In only new healthcare workers, the 1-step TST and quantiFERON-TB Gold In-Tube test were performed.
223875963|NCT01408524|DRUG|Diltiazem|2.5 mg iv q 2-5 min for keeping SBP below 140 mmHg during the emergence
223875964|NCT01408524|DRUG|Labetalol|2.5 mg iv q 2-5 min for keeping SBP below 140 mmHg during the emergence
223875965|NCT04878328|BEHAVIORAL|Onsite Point-of-care|Guided by Social Cognitive Theory, O-PoC will employ CHWs with lived experience of incarceration to provide: 1) COVID-19 education; 2) SARS-CoV-2 testing with Cepheid XpertXpress PCR tests at Fortune facilities; 3) Needs assessments and facilitated access to masks and hygiene supplies; 4) Navigation to vaccination sites (when available) and single-room housing at Fortune's supportive housing sites and partnering shelters, or alternative strategies that will maximize the ability to socially distance for those who test PCR positive; 5) Supportive counseling.
223875966|NCT01697059|DRUG|Piperacillin + Amoxicillin|
223875967|NCT05875987|DEVICE|Quantra System|Diagnostic device to monitor coagulation properties of a whole blood sample at the point-of-care.
223875968|NCT03283371|DRUG|Natalizumab|As specified in the treatment arm.
223875969|NCT03283371|OTHER|Placebo|As specified in treatment arms.
223875970|NCT00786513|OTHER|Conventional antimicrobial susceptibility testing|Subjects in this arm will be prescribed 14 days of an intravenous 2 drug antibiotic combination based on conventional planktonic antimicrobial susceptibility testing results.
223875971|NCT00786513|OTHER|Biofilm antimicrobial susceptibility testing|Subjects in this arm will be prescribed 14 days of an intravenous 2 drug antibiotic combination based on biofilm antimicrobial susceptibility testing results.
223875972|NCT01277614|BEHAVIORAL|Therapeutic lifestyle|This is a 6-month intervention in which participants with 2r more MS components are randomly assigned to intervention or control group. Intervention comprise individual diet counseling, an exercise plan and monthly lifestyle workshops. Controls receive printed material on healthy eating and lifestyle modification.
223875973|NCT06266845|BEHAVIORAL|In-person Escape Room|The in-person escape room will be conducted in the nursing laboratory of a Higher Education Institution (HEI), equipped with a high-fidelity mannequin to simulate a critical patient and create a realistic environment. Participants will be divided into groups, with one group entering at a time as requested. During the in-person escape room, participants will interact with the patient mannequin, hospital equipment and devices, as well as with objects and clues in the environment. The game duration will be 30 minutes to ensure equal conditions among participants and prevent time distortions. Interactions and participants' performance will be recorded by the facilitator, guiding the feedback.
223875974|NCT06266845|BEHAVIORAL|Virtual Escape-Room|The virtual escape room will be conducted in a classroom of an HEI, utilizing an online platform that allows the virtual reproduction of the game. Each group will have access to a tablet or computer to participate in the game provided by the researcher. During the game, participants will interact with the platform interface and solve challenges to escape the virtual room within 30 minutes. Thus, each group will have a maximum of 30 minutes to complete the escape room, ensuring equal conditions among participants. Records of interactions and participant performance will be logged for later analysis and feedback.
223875975|NCT04930718|OTHER|Thumb active Exercises|Active específico exercises; Reeducation program
223875976|NCT03386539|DRUG|Everolimus|Everolimus tablet
223875977|NCT03386539|DRUG|Tacrolimus|Tacrolimus capsule or liquid suspension
223875978|NCT03386539|DRUG|Mycophenolate Mofetil|Mycophenolate Mofetil capsule or liquid suspension
223875979|NCT00570700|DRUG|Dasatinib|150mg (3 pills) orally daily for as long as the drug benefits
223875980|NCT03076515|DEVICE|Nerivio Migra neurostimulation|transcutaneous electrical stimulation
223875981|NCT03076515|DEVICE|Sham Nerivio Migra|electrical stimulation- shame mode
223875982|NCT06067035|OTHER|Imaging|Imaging data from patients with small-vessel liver tumours will be compared with histological data.
223875983|NCT03080324|DRUG|Fentanyl sublingual|Fentanyl sublingual
223875984|NCT03080324|DRUG|Fentanyl ev|Fentanyl ev
223875985|NCT03080324|DRUG|Placebo sublingual|Placebo sublingual
223875986|NCT03080324|DRUG|Placebo ev|Saline
223875987|NCT00708188|DEVICE|Multidetector raw CT|Multidetector raw CT
223875988|NCT00521755|DEVICE|Seraffix LTB|laser soldering for soft tissue wounds
223875989|NCT02216552|DIETARY_SUPPLEMENT|Resveratrol|All adolescents will receive standardized lifestyle counselling at enrolment designed and disseminated by a registered dietitian as well as a licensed physiotherapist who both have experience working with overweight adolescents. The lifestyle component will be goal-based and tailored to each participant. The overall content and messaging will be consistent for all participants with nutritional recommendations based on Canada Food Guide and physical activity counselling aligning with the Healthy Active Living Recommendations of the Canadian Pediatric Society and Health Canada's Physical Activity Guidelines.
223875990|NCT02216552|DIETARY_SUPPLEMENT|Placebo|All adolescents will receive standardized lifestyle counselling at enrolment designed and disseminated by a registered dietitian as well as a licensed physiotherapist who both have experience working with overweight adolescents. The lifestyle component will be goal-based and tailored to each participant. The overall content and messaging will be consistent for all participants with nutritional recommendations based on Canada Food Guide and physical activity counselling aligning with the Healthy Active Living Recommendations of the Canadian Pediatric Society and Health Canada's Physical Activity Guidelines.
223875991|NCT02102841|PROCEDURE|Skin biopsy|
223875992|NCT02102841|PROCEDURE|Skin suction blister|
223875993|NCT02102841|BIOLOGICAL|Mantoux test|
223875994|NCT03245424|DRUG|ivosidenib (AG-120)|Patients will receive ivosidenib 500 mg by mouth once daily on 28-day cycles
223875995|NCT01189331|DEVICE|CT coronary angiography and computational fluid dynamics|Evaluate coronary blood flow dynamics by CT coronary angiography and computational fluid dynamics
223875996|NCT03315481|PROCEDURE|SAX catheter insertion|Suture-method catheter inserted in the short axis of the adductor canal
223875997|NCT03315481|PROCEDURE|LAX catheter insertion|Suture-method catheter inserted in the long axis of the adductor canal
223875998|NCT04192916|DRUG|DOACs|Direct Oral Anticoagulants
223875999|NCT02650544|DRUG|Mirtazapine|Patients in mirtazapine arm will be orally administered mirtazapine as an anti-depression therapy; along with palliative chemotherapy.
223876000|NCT02650544|DRUG|Placebo|Patients in placebo arm will be orally administered placebo; along with palliative chemotherapy.
223876001|NCT01777750|DEVICE|EMCOOLS flex pad; Philips Innercool RTx|Surface cooling with EMCOOLS flex pads (out-of-hospital); Infusion of 1000ml to 2000ml of cold saline (out-of-hospital); central-venous cooling (Philips Inntercool RTx)
223876002|NCT02309996|BEHAVIORAL|Supervisor Training Program|
223876003|NCT03201822|OTHER|100 mg of Cocoa Flavanols/70 kg BW|Fruit-flavored non-dairy drink containing 100 cocoa flavanols/70kg BW.
223876004|NCT03201822|OTHER|200 mg of Cocoa Flavanols/70 kg BW|Fruit-flavored non-dairy drink containing 200 cocoa flavanols/70kg BW.
223876005|NCT03201822|OTHER|400 mg of Cocoa Flavanols/70 kg BW|Fruit-flavored non-dairy drink containing 400 cocoa flavanols/70kg BW.
223876006|NCT03201822|OTHER|1000 mg of Cocoa Flavanols/70 kg BW|Fruit-flavored non-dairy drink containing 1000 cocoa flavanols/70kg BW.
223876007|NCT00996229|BEHAVIORAL|Caloric restriction|20-30% CR for 6 months
223876008|NCT00996229|DIETARY_SUPPLEMENT|Omega-3 (fish oil capsules)|2g/day DHA/EPA capsules for 6 months
223876009|NCT00996229|DIETARY_SUPPLEMENT|Placebo|Daily corn oil capsules for 6 months
223876010|NCT00996229|DIETARY_SUPPLEMENT|Resveratrol|daily resveratrol for 6 months
223876011|NCT01501604|DRUG|BKM120|100 MG PO QD in cycles of 28 days
223876012|NCT04081779|OTHER|Survivorship Care Plan|Receive patient-generated SCP
223876013|NCT04081779|OTHER|Educational Intervention|Receive telephone-based educational counseling session
223876014|NCT04081779|OTHER|Questionnaire Administration|Ancillary studies
223876015|NCT04081779|OTHER|Supportive Care|Receive generic information on survivorship care
223876016|NCT03966898|DRUG|SHR6390 Tablets|SHR6390 Tablets
223876017|NCT03966898|DRUG|Placebo Tablets|Placebo Tablets
223876018|NCT03966898|DRUG|Letrozole or Anastrozole Tablets|Letrozole or Anastrozole Tablets
223876019|NCT02505321|OTHER|Oral Triglyceride Tolerance Test (OTTT)|Participants consume a fatty drink. An intravenous catheter is inserted into the antecubital veins in one arm for intermittent sampling over the following 4 hours. The OTTT permits simple evaluation of postchallenge triglyceride levels and is acceptable to participants.
223876020|NCT02505321|PROCEDURE|Abdominal fat biopsy (optional)|A sample of abdominal fat will be obtained by firstly injecting some local anaesthetic into an accessible area of the abdomen. Using a scalpel, a small incision (approx 2-3 cm) will be made to a depth of approx 15mm and two small pea-sized samples of fat will be removed. The wound will be closed with simple sutures or steristrips.
223876021|NCT03501264|BEHAVIORAL|Online Game|LGBTQ Bullying game
223876022|NCT03501264|BEHAVIORAL|LGBTQ Resources|This group receives LGBTQ Resources
223876023|NCT05555719|DEVICE|Mandibular Protraction Appliance|Mandibular Protraction Appliance was installed on fixed orthodontic appliance
223876024|NCT05555719|DEVICE|PowerScope Appliance|PowerScope Appliance was installed on fixed orthodontic appliance
223876025|NCT01579968|DRUG|eptacog alfa (activated)|Safety and effectiveness data collection in connection with the use of eptacog alpha in daily clinical practice
223876026|NCT02076568|BEHAVIORAL|Education - Diabetes and Partnership|"Based on the treatment and education programme PRIMAS a problem-specific education module regarding Diabetes and Partnership was created. The module covers specific and detailed aspects of the topic partnership such as dealing with hypoglycemia, late complications, and talking about diabetes in a relationship. With this module, a more comprehensive education of patients with specific interest in these topics is possible."
223876027|NCT04748939|BIOLOGICAL|recombinant subunit herpes zoster vaccine|vaccine administration
223876028|NCT00780949|OTHER|intestinal biopsies|intestinal biopsies during routine endoscopy
223876029|NCT00903539|DEVICE|SecurAcath Securement System|Subcutaneous catheter securement system
223876030|NCT05953870|OTHER|Music Therapy|slower tempo music that can quiet mind and make patients feel soothed
223876031|NCT01672060|BEHAVIORAL|Nurse-Family Partnership (NFP)|Trained Public Health Nurses (PHNs) will deliver Nurse-Family Partnership (NFP) using specified pregnancy, infancy and toddler curricula. Following enrollment in the study, NFP PHNs will provide regular home visits to participants throughout the remainder of the participant's pregnancy, continuing through until the child's second birthday. In addition to offering standard care during each visit, PHNs will deliver NFP content using program materials relevant to the following domains: personal health, maternal role, environmental health, family and friends, life course development, and health and human services.
223876032|NCT01672060|BEHAVIORAL|Existing services|Participants allocated to the comparison group will receive all the usual perinatal programs and services offered within their Health Authority, including primary care and specialist physician services covered under BC's public healthcare system. These services vary across the province but may include: standard primary healthcare services; public health programs including prenatal classes, pregnancy outreach and home visiting by nurses or paraprofessionals; and a variety of targeted and universal parenting and early child development programs.
223876033|NCT03989024|DRUG|Gonadorelin|Drug: Gonadotropin-releasing Hormone. Generic name: Gonadorelin. Dosage form: 600ug. Dosage: 10ug/puls. Frequency: every 90 min. Duration: 3 months
223876034|NCT03989024|DRUG|Clomiphene|Drug: Clomiphene. Generic name: Clomiphene. Dosage form: 50mg. Dosage: 50mg. Frequency: once a day. Duration: 3 months
223876035|NCT06520332|PROCEDURE|Dental Implant Surgery - short implant group (less than or equal to 6mm)|"A mucoperiosteal flap will be raised in edentulous ridge. A short dental implant (experimental group) will be placed according to the standard protocol.~The platform of the implant will be placed 2 to 3 mm below CEJ of adjacent teeth.~The surgical wound closure will be coapted with mattress and single interrupted sutures"
223876036|NCT06520332|PROCEDURE|Dental Implant Surgery - Conventional implant group (greater than or equal to 10mm)|"A mucoperiosteal flap will be raised in edentulous ridge. A standard length implant ( comparative group) ( ≥10mm) will be placed according to the standard protocol in the augmented/native bone .~The platform of the implant will be placed 2 to 3 mm below CEJ of adjacent teeth.~The surgical wound closure will be coapted with mattress and single interrupted sutures"
223876037|NCT04666493|OTHER|Cognitive behavior therapy (CBT), specifically using the Facing Your Fears (FYF) curriculum|The Facing Your Fears program (FYF; Reaven et al. 2011) is a CBT-based group treatment program that has been adapted for the needs of children with high-functioning ASD. The current project will adapt the FYF program for virtual delivery and examine its effectiveness.
223876038|NCT02554786|DRUG|Indacaterol acetate/Mometasone furoate|
223876039|NCT02554786|DRUG|Mometasone furoate|
223876040|NCT02554786|DRUG|Salmeterol xinafoate/fluticasone propionate|
223876041|NCT04705675|BEHAVIORAL|Breastfeeding Education|The mothers were asked to remember the pseudonyms they used on the pretest and to use the same pseudonym on the posttest. Following the pretest, the mothers in the study group were taken into a separate room at the FHC and asked to breastfeed their infants. The mothers' breastfeeding behaviors were observed. After the breastfeeding, each mother was provided an average 30-minute session of individual education. All of the mothers in the study group received the education from the same researcher. Both audio and visual materials were used in the mothers' training.
223876042|NCT04965272|DRUG|Cariprazine 0.75 mg/day|Oral Capsule
223876043|NCT04965272|DRUG|Cariprazine 1.5 mg/day|Oral Capsule
223876044|NCT04965272|DRUG|Cariprazine 3.0 mg/day|Oral Capsule
223876045|NCT04965272|OTHER|Placebo|Oral Capsule
223876046|NCT05434273|BEHAVIORAL|HE programme|Participants will receive a 12-week integrated exercise and cardiovascular health education programme (HE programme) which is constructed based on self-efficacy theory. A booster intervention in the form of SMS messaging will be given from Week 1 to Week 12.
223876047|NCT05434273|BEHAVIORAL|Usual care|Participants will receive usual care which primarily includes an education talk on basic health issues. A governmental health education leaflet and a lecture video will be provided for reference.
223876048|NCT00774124|OTHER|telemonitoring|Women will transmit their blood glucose levels, fetal movement counts, and insulin doses via the Internet and/or IVR system at least three times per week
223876049|NCT00774124|OTHER|Standard of care|Health data (blood glucose levels and insulin doses) will be recorded in a paper log book which will be reviewed at prenatal visits.
223876050|NCT03434587|PROCEDURE|Syndactyly|Syndactyly
223876051|NCT03434587|PROCEDURE|Reduction and inmobilization|Closed reduction and inmobilization with splint
223876052|NCT02172872|DRUG|standard combination chemotherapy|"1. Cycle 1~   1. daunorubicin (60 mg/m²) infusion (15-30 min) for 3 days~  2. cytarabine (200 mg/m²) continuous infusion (24 hrs) for 7 days.~2. Cycle 2~   1. daunorubicin (45 mg/m²) infusion (15-30 min) for 3 days~  2. cytarabine (200 mg/m²) continuous infusion (24 hrs) for 7 days.~3. Cycle 3 (mini-ICE)~   1. idarubicin (8 mg/m²) infusion (15-30 min) for 3 days~  2. cytarabine (100 mg/m²) continuous infusion (24 hrs) for 5 days~  3. etoposide (100 mg/m²) infusion (1 hr) for 3 days~4. Cycle 4 (mini-ICE) (optional)~   1. idarubicin (8 mg/m²) infusion (15-30 min) for 3 days~  2. cytarabine (100 mg/m²) continuous infusion (24 hrs) for 5 days~  3. etoposide (100 mg/m²) infusion (1 hr) for 3 days"
223876053|NCT02172872|DRUG|decitabine|"1. Cycle 1: decitabine (20 mg/m²) infusion (1 hr) for 10 days~2. Cycle 2~   1. if bone marrow (BM) blasts \< 5%: decitabine (20 mg/m²) infusion (1 hr) for 5 days~  2. if BM blasts \>= 5%: decitabine (20 mg/m²) infusion (1 hr) for 10 days~3. Cycle 3~   1. if BM blasts \< 5%: decitabine (20 mg/m²) infusion (1 hr) for 5 days~  2. if BM blasts \>= 5%: decitabine (20 mg/m²) infusion (1 hr) for 10 days~4. Cycle 4-6: decitabine (20 mg/m²) infusion (1 hr) for 5 days~5. Continuation therapy from Cycle 7 and until 'progression or toxicity': decitabine (20 mg/m²) infusion (1 hr) for 5 days or 3 days~Note: All patients considered eligible for transplant should be consolidated with alloHCT once donor is available."
223876054|NCT01651767|DRUG|Placebo|Form=suspension, route=oral.
223876055|NCT01651767|DRUG|JNJ-47910382|Type=exact number, unit=mg, number=30, 90, 300, 400 or 450, form=suspension, route=oral. Study drug will be administered once or twice daily
223876056|NCT04797923|DRUG|1. Treatment: IP chemotherapy + Systemic chemotherapy|1\. Treatment: IP chemotherapy + Systemic chemotherapy Day1 + Day 8: IP Paclitaxel 40 mg/m2 every 3 weeks Day1: IV Oxaliplatin 100 mg/m2 every 3 weeks Day 1\~14: Capecitabine 1000 mg/m2 PO, BID every 3 weeks
223876057|NCT04797923|PROCEDURE|2. Response evaluation after 4 cycles of IP + systemic chemotherapy|"2\. Response evaluation after 4 cycles of IP + systemic chemotherapy~* Conversion surgery will be done following diagnostic laparoscopy after 4 cycles of IP + systemic chemotherapy. Additional 4 cycles of IP + systemic chemotherapy wille be done following surgery.~* If surgery is impossible after 4th cycle, four additional cycles of treatment will be done, and convertibility will be evaluated.~* IP chemotherapy should not exceed total of 8 cycles."
223876058|NCT02831361|DRUG|Gemigliptin|
223876059|NCT02831361|DRUG|Gemigliptin placebo|
223876060|NCT02831361|DRUG|Metformin|For patients who have been taking metformin, the patients who had taken at least 1000 mg of metformin daily and continue the same dosage and administration as before participant in the study
223876061|NCT02831361|PROCEDURE|Diet/exercise questionnaire|"doing exercise with about intermediate intensity(50\~70%) for ≥150minutes in total over at least 3 times(every other day) weekly should be recommended and regualr diet without greater changes in life style as much as possible during the whole study period.~the questionnaire regarding diet/exercise will be collected at -week2, week 1 week 7, week 13, week 19, week 25"
223876062|NCT02877797|DEVICE|Cap|cap assisted esophagogastroduodenoscopy
223876063|NCT05598554|OTHER|Telerehabilitation|Chair-based yoga with telerehabilitation was applied to the study group for 45 minutes a day, 2 days a week, for 6 weeks.
223876064|NCT05598554|OTHER|information|A one-session training was provided on the effects of exercise on quality of life.
223876065|NCT03221959|DEVICE|Medical Device Vittamed 205|Intracranial pressure measurement
223876066|NCT05866978|BEHAVIORAL|Integrated Approach to Health, Wellbeing, and Productivity at Work (ITASPA)|The intervention investigates the effect of the Australian WorkHealth Improvement Network (WIN) program and the Total Worker Health (TWH) concepts in a Danish context among blue-collar workers.
223876067|NCT03581357|BEHAVIORAL|Mobile Mindfulness Meditation|It is hypothesized that participants who are randomized in the app condition will have significantly less anxiety, pain, fatigue, and sleep disturbance than their counterparts in the control condition.
223876068|NCT03581357|BEHAVIORAL|Mindfulness Coach|It is hypothesized that participants who are randomized into treatment condition will have significantly less CIPN, anxiety, and fatigue, and improved anxiety, in comparison to their counterparts in the wait-list control condition.
223876069|NCT02698813|BIOLOGICAL|umbilical cord mesenchymal stem cells and hyaluronic acid|
223876070|NCT02698813|DRUG|hyaluronic acid|
223876071|NCT06288334|OTHER|1-3 Cetirizine Pharmacokinetic samples|Limited sampling strategy was used in this study. For each child, only 1\~3 blood samples were collected before and after cetirizine administration.
223876072|NCT01119313|DRUG|LAS 41002|LAS 41002, once daily
223876073|NCT01119313|DRUG|Active|Active, once daily
223876074|NCT04206813|DRUG|Gardasil 9 2 dose regimen|a 2-dose regimen of Gardasil 9 at 0 and 6 months
223876075|NCT04206813|DRUG|Gardasil 9 3 dose regimen|standard 3-dose regimen of Gardasil 9 at 0, 2, 6 months
223876076|NCT04206813|DRUG|Gardasil 9 rescue dose|A rescue dose of Gardasil 9 will be given at 12 months
223876077|NCT04704284|DIAGNOSTIC_TEST|Zero Echo Time Magnetic Resonance Imaging (ZTE MRI)|Magnetic Resonance Imaging (MRI) with zero echo-time (ZTE) that uses proton density differences rather than T2 relaxation time differences to achieve contrast.
223876078|NCT06434207|OTHER|Collecting discarded blood samples|Discarded blood samples will be collected from routine clinical labs collected before and after surgery.
223876079|NCT03425734|DRUG|Dexmedetomidine|The drug will be prepared in 50 ml saline 0.5 ml DEX (100mc/ml +49.5 cc saline 1ml=1mg), and the dose will be calculated according to body weight.
223876080|NCT04366908|DRUG|BAT + Calcifediol|"The subject will be treated with the best available therapy, which will include any combination of drugs included in the current protocol of the Ministry of Health and/or complementary notes issued by the Spanish Agency of Medicines and Health Products (AEMPS) plus Calcifediol caps. 266 µg. According to the pharmacokinetics of Calcifediol evaluated in an inflammatory model, the posology will be~Start: 2 capsules Days 3, 7, 14, 21, 28: 1 capsule"
223876081|NCT04366908|DRUG|BAT|The subject will be treated with the best available therapy, which will include any combination of drugs included in the current protocol of the Ministry of Health and/or complementary notes issued by the Spanish Agency of Medicines and Health Products (AEMPS).
223876082|NCT05859152|OTHER|Zona Pellucida-Bound Sperm Selection for ICSI|one half of the patients' oocytes will be inseminated via the ICSI procedure with sperm that was bound to the ZP of an immature oocyte.
223876083|NCT05859152|OTHER|Routine Embryologist Selected Sperm|one half of the patients' oocytes will be inseminated via the ICSI procedure with sperm that has been selected based on morphology and mobility characteristics by the embryologist per routine.
223876084|NCT05143996|DRUG|CLN-049|\[FLT3\] x \[CD3\] bispecific T cell engager
223876085|NCT00890305|DRUG|CT-011|
223876086|NCT00890305|DRUG|FOLFOX|"FOLFOX-4: each cycle consists of the following: oxaliplatin 85 mg/m2 on Day 1, leucovorin 200 mg/m2/day on Day 1 and Day 2 followed by 5-FU 400 mg/m2 bolus and a 22 hour infusion of 5-FU 600 mg/m2 for two consecutive days.~mFOLFOX-6: each cycle consists of the following: oxaliplatin 85 mg/m2 and leucovorin 400 mg/m2 on Day 1, followed by 5-FU 400 mg/m2 bolus, followed by 5-FU 1200 mg/m2/day for two consecutive days (total 2,400 mg/m2 over 46-48 hours)."
223876087|NCT00103363|OTHER|cytology specimen collection procedure|
223876088|NCT00103363|OTHER|physiologic testing|
223876089|NCT00103363|PROCEDURE|annual screening|
223876090|NCT00103363|PROCEDURE|study of high risk factors|
223876091|NCT01838343|OTHER|Ultrasound|Goal-directed ultrasound using a GE Vscan performed by a critical care fellow trained in ultrasonography.
223876092|NCT04163042|BEHAVIORAL|12-week videoconferencing behavioural support intervention to promote physical activity behaviour|Participants in Group A will receive six real-time, 1-on-1 60-minute sessions led by a physical activity counsellor over a 12-week period. Sessions will be delivered via videoconferencing and will aim to provide young adult cancer survivors with support as well as the knowledge, skills, and confidence to identify and overcome challenges to engaging in physical activity in order to increase physical activity behaviour and enhance patient-reported outcomes.
223876093|NCT03018561|OTHER|Exercise and Cognitive testing|Maximal cardiopulmonary test Rest cognitive testing
223876094|NCT04014634|DRUG|Methylprednisolone|Single GON injection with methylprednisolone
223876095|NCT04014634|OTHER|Placebo|Single GON-injection with NaCl
223876096|NCT02189915|DRUG|Creatine monohydrate|
223876097|NCT05261139|DRUG|nirmatrelvir|PF-07321332
223876098|NCT05261139|DRUG|ritonavir|ritonavir
223876099|NCT03429582|DEVICE|Standard C02 Cryotherapy|Standard therapy using carbon dioxide for freezing of tissue
223876100|NCT03429582|DEVICE|Single Tip Thermoablation|Thermoablator outfitted with a 19mm conical tip
223876101|NCT03429582|DEVICE|Multiple Tip Thermoablation|Thermoablator outfitted with detachable probes
223876102|NCT05647070|PROCEDURE|Autologous rectus Fascia TOT|"A sterile Foley catheter is placed to drain the bladder, following this, injectable normal saline is utilized using 10 cc syringe for hydro-distention of the anterior vaginal wall, and a midline incision is made based on the mid-urethra. Dissection is carried out bilaterally to the obturator Foramen on both sides.~Through Pfannestiel incision, \~1 cm× \~5 cm rectus fascia strip is isolated from the anterior rectus sheath. Two stay sutures are secured to the corner of the fascial segment on each side. Next, two separate trocar passages are performed on each side using a reusable C-shaped trocar, with care taken to ensure at least a 1 cm tissue bridge in the obturator membrane between the superior and inferior passes. Following this, the stay sutures are tied external to the obturator membrane on both sides, leaving the sling secured and flush with the mid-urethra. Sutures are also placed to secure the sling to the periurethral tissue to prevent rolling or migration"
223876103|NCT00726544|DRUG|ARC 1779 Placebo|ARC1779 Injection or placebo is administered intravenously to patients as an initial loading dose followed by continuous infusion of up to 14 days plus 2 day taper.
223876104|NCT00726544|DRUG|ARC1779 Injection|ARC1779 Injection or placebo is administered intravenously to patients as an initial loading dose followed by continuous infusion of up to 14 days plus 2 day taper. Treatment with ARC1779 Injection is to be given at low dosage that is intended to produce target steady-state ARC1779 plasma concentrations during infusion of 3μg/mL.
223876105|NCT00726544|DRUG|ARC1779 Injection|ARC1779 Injection or placebo is administered intravenously to patients as an initial loading dose followed by continuous infusion of up to 14 days plus 2 day taper. Treatment with ARC1779 Injection is to be given at low dosage that is intended to produce target steady-state ARC1779 plasma concentrations during infusion of 6μg/mL.
223876106|NCT00726544|DRUG|ARC1779 Injection|ARC1779 Injection or placebo is administered intravenously to patients as an initial loading dose followed by continuous infusion of up to 14 days plus 2 day taper. Treatment with ARC1779 Injection is to be given at low dosage that is intended to produce target steady-state ARC1779 plasma concentrations during infusion of 12μg/mL.
223876107|NCT00979563|DRUG|HM30181AK tablet + Irinotecan tablets|HM30181AK 60 mg tablet + Irinotecan 20mg, 5 mg or 2mg tablets
223876108|NCT02597751|BEHAVIORAL|Cognitive Orientation to Occupational Performance (CO-OP)|"CO-OP is a cognitive approach to solving functional motor problems (Polatajko et al., 2001b). Therapists teach children a global problem solving strategy (Goal-Plan-Do-Check) as a framework for developing specific strategies for overcoming motor problems; these strategies are determined after a dynamic performance analysis by the therapist to determine where the breakdown is in performing the task. Occupational therapists will see children once weekly for one hour over 10 weeks as per published protocol (Polatajko et al., 2001b), plus two assessment sessions. Children will select three functional motor goals to be addressed over the course of treatment, rating their performance and satisfaction of these goals pre- and post-intervention."
223876109|NCT00539734|DRUG|ranibizumab|A single dose of 0.5 mg ranibizumab injected intravitreally.
223876110|NCT02764242|OTHER|Skin prick test|Skin prick tests to local and imported insect sting allergen with different concentration are performed.
223876111|NCT02764242|OTHER|sIgE measurement|sIgE levels to stinging insect allergen and their recombinant venom allergen are measured
223876112|NCT03175861|OTHER|Stereotactic radiotherapy|"The patient will have an initial pre-therapeutic assessment in the 8 weeks before the start of radiotherapy Then, radiation therapy planning with 3 free breathing 4D (4 dimensions) scanners performed over 8 days without injection of iodinated contrast agent.~Then the patient will receive his treatment by conventional stereotactic radiotherapy"
223876113|NCT04346732|OTHER|Vapocoolant spray|Vapocoolant spray
223876114|NCT01952769|BIOLOGICAL|MDV9300|"The study will be done in the following manner:~1. Evaluation of MDV9300 and radiation-~   1. Cohort A-3 patients: first dose of MDV9300 3mg/m2 .If no toxicity over grade 2-second dose and on -6 mg/kg.~  2. Cohort B -3 patiens: if no toxicity \>grade 2 seen in cohort A- start dose will be 6 mg/kg If toxicity\> grade 2 in 2 patients or more on a dose of 3 mg/kg the dose in cohort B will be 1 mg/kg during irradiation If toxicity\> grade 2 in 2 patients or more on a dose of 1 mg/kg no further concurrent MDV9300 and radiation will be given~2. Evaluation of MDV9300 and cyclophosphamide~After completion of the first phase (6 patients) a cohort of 15 patients will be accrued. The treatment protocol of this cohort will be as follows:~Following radiation completion , and after recovery from treatment adverse events of grade 2 and higher, the patients will be started on concurrent biweekly MDV9300 and weekly cyclophosphamide 200mg/m2"
223876115|NCT00332813|BEHAVIORAL|HIV Risk Behavior Intervention|
223876116|NCT05378828|DEVICE|Using anti-collision Sensors on electric wheelchairs|use of anti-collision sensors on the electric wheelchair during 3 weeks
223876117|NCT05378828|OTHER|Use of an electric wheelchair without sensors|Use of an electric wheelchair without sensors for 3 weeks before using anti-collision sensors then during 3 weeks after using the anti-collision sensors.
223876118|NCT03877016|PROCEDURE|TENS|TENS Eco2 or actiTENS, both admitted and reimbursed in FRANCE according to regulation
223876119|NCT01340716|OTHER|Tai Chi Chuan exercise|patients in this group held three weekly classes of 60 minutes during 12 weeks of Tai Chi Chuan, Yang style. The exercises will be mild to moderate (HR 60 to 75% of HR Max). Slow movements combined with exercises and maintained using your own body weight.
223876120|NCT01340716|OTHER|stretching exercise|patients in this group held weekly classes of two stretching for 12 weeks.
223876121|NCT04775654|DIETARY_SUPPLEMENT|Blackcurrant|Two capsules containing 455mg of CurrantCraft 11% black currant extract.
223876122|NCT04775654|OTHER|Placebo|Two capsules containing an inert material.
223876123|NCT02704507|DRUG|Triamcinolone|topical application nightly to half the face for 4 weeks
223876124|NCT02704507|DRUG|Tretinoin|topical application nightly for 8 weeks
223876125|NCT02704507|DRUG|Emollient|topical application nightly to half the face for 4 weeks
223876126|NCT01576107|OTHER|Exercise counseling (behavior change techniques)|4-week exercise intervention for cancer patients of different entities and out-patient regimes.
223876127|NCT01576107|OTHER|Stress-management training|4-week stress-management-training for cancer patients of different entities and out-patient regimes.
223876128|NCT00566072|BEHAVIORAL|instructions and coaching|instructions and coaching or no intervention on the use and intake of ganciclovir
223876129|NCT02729506|PROCEDURE|Transarterial Radioembolization|Yttrium-90 radioembolization (90Y) is a relatively new technique involving the trans-arterial administration of glass or resin microspheres loaded with Yttrium-90, a β-emitting isotope, delivering selective internal radiation to the tumor.
223876130|NCT02729506|PROCEDURE|Transarterial Chemoembolization using drug-eluting beads|"TACE is a procedure in which a catheter is introduced into the branches of the hepatic artery supplying the tumor. Embolic material and chemotherapeutic agents are deployed through the catheter directly into the tumor vasculature. This technique potentially enhances the cytotoxic effect by inducing ischemia and retention of the therapeutic agent in the vicinity of the tumor.~The drug-eluting beads (DEBs) enable standardization of TACE since DEBs act as both an occluding agent as well as a drug-loaded carrier, achieving local ischemia and cytotoxic death of the tumor with one device."
223876131|NCT03372473|DRUG|Montelukast mixed with Loratadine|Montelukast 5mg mixed with Loratadine 5mg, one dose per day
223876132|NCT03372473|DRUG|Montelukast|Montelukast 5mg
223876133|NCT06409117|DEVICE|Percutaneous coronary intervention|Percutaneous coronary intervention with scaffold implantation in patients with NSTE/ACS
223876134|NCT00364702|DRUG|methylphenidate|
223876135|NCT05265481|DEVICE|Tourniquet|The investigators will apply a pressure cuff tourniquet inflated to 60 mmHg
223876136|NCT05265481|DEVICE|Manual Tapping|The investigators will apply tapping directly over the vein manually to increase the vein dimension.
223876137|NCT05265481|DEVICE|Device tapping|The investigators will apply tapping directly over the vein with a massage device to increase the vein dimension.
223876138|NCT05229835|OTHER|Time restricted eating and exercise|We apply time restricted eating, exercise alone and combined
223876139|NCT04515641|DRUG|Islatravir|Two ISL 30 mg capsules taken by mouth.
223876140|NCT02570191|DRUG|Peginterferon alfa-2a|180 uG in 0.5 mL solution administered once weekly for 48 weeks
223876141|NCT00542035|DRUG|ARRY-371797, p38 inhibitor; oral|dose 1, dose 2
223876142|NCT00542035|DRUG|Placebo; oral|dose 1, dose 2
223876143|NCT00542035|DRUG|Placebo; oral|dose 1
223876144|NCT00542035|DRUG|ARRY-371797, p38 inhibitor; oral|dose 2
223876145|NCT02692417|DEVICE|Transcutaneous Electrical Nerve Stimulation|Both arms will receive stimulation from the same TENS (transcutaneous electrical nerve stimulation) unit with identical stimulation frequency, but potentially different amplitudes depending on the subject's stimulation threshold.
223876146|NCT05369507|BEHAVIORAL|Virtual Care Coordination|Participants randomly assigned to the virtual care coordination group will use a mobile app to assist in HCV treatment care coordination.
223876147|NCT04115683|OTHER|Dual Task Training|45 minutes of dual task training consisting of motor activities (walking, balance... etc.) with combination of cognitive activities (spelling words, image description, nomination, word generation, counting... etc.) at sime time.
223876148|NCT04115683|OTHER|Single Task Training|45 minutes of single task training consisting of same motor activities (walking, balance... etc.)
223876149|NCT06188377|DEVICE|measured by a impedance analyzer|the healthy chinese neonates will be measured by a impedance analyzer, and will be compared with that of other ethnicity whose data have been reported by literatures.
223876150|NCT03365895|PROCEDURE|Diffusion Tensor Imaging|Undergo non-enhanced MRI using MRN and DTI
223876151|NCT03365895|OTHER|Laboratory Biomarker Analysis|Correlative studies
223876152|NCT03365895|PROCEDURE|Magnetic Resonance Imaging|Undergo non-enhanced MRI using MRN and DTI
223876153|NCT03365895|OTHER|Questionnaire Administration|Ancillary studies
223876154|NCT03628235|BEHAVIORAL|Online survey|Online survey to capture indirect and out of pocket costs of Huntington's Disease in HDGECs and companions
223876155|NCT02550691|PROCEDURE|blood sampling|A blood sample will be taken on subject carrying specific genotype
223876156|NCT00779636|DRUG|Desloratadine|Desloratadine 10 mg daily x 28 days
223876157|NCT00779636|DRUG|Placebo|Placebo daily x 28 days
223876158|NCT04713735|DIETARY_SUPPLEMENT|Control: Placebo|Placebo
223876159|NCT04713735|DIETARY_SUPPLEMENT|bovine lactoferrin supplement|600 mg
223876160|NCT00644475|DRUG|Imidapril|tablets; 5, 10, 15, 20 mg; od; 12 weeks
223876161|NCT00644475|DRUG|Candesartan|tablets; 8, 16, 24, and 32 mg; od; 12 weeks
223876162|NCT04695197|DRUG|Artemether-lumefantrine (AL)|Current first line treatment of malaria. Dose: Bodyweight (kg) Dose (mg) of artemether + lumefantrine given twice daily for 3 days (total, six doses) 5 to \< 15 20 + 120 15 to \< 25 40 + 240 25 to \< 35 60 + 360 \>=35 80 + 480; Twice daily for 3 days (total, six doses)
223876163|NCT04695197|DRUG|Pyronaridine-artesunate (PA)|Antimalarial; Dose: Body weight (kg) Dose (mg) of pyronaridine + aresunate given once daily for 3 days (total, three doses) 5 to \< 8 60 + 20 8 to \<15 120 + 40 15 to \<20 180 + 60 20 to \<24 kg 180 + 60 24 to \<45 360 + 120 45 to \<65 540 + 180 \>=65 720 + 240; Once-daily for 3 days (total, three doses).
223876164|NCT04404686|DRUG|Indomethacin|Per vagina administration of 100 mg followed by a second 100 mg dosage the following day
223876165|NCT04404686|DRUG|Nifedipine|Per os administration according to current protocol of 20mg each 20 minutes for 1 hour followed by 20 mg q8 for 48 hours.
223876166|NCT01215552|DRUG|HT-0712|A range of single oral dose levels will be explored, utilizing 5mg and 25mg strength capsules
223876167|NCT04987294|DRUG|ALLN-346|ALLN-346 (Engineered Urate Oxidase) is an orally administered, novel urate oxidase; provided as capsules for oral administration
223876168|NCT04987294|DRUG|Placebo|Matched placebo capsules are similar in weight and appearance to the ALLN-346 capsules
223876169|NCT06048172|BEHAVIORAL|Prolonged Exposure|In the intervention condition, patients are treated directly after the baseline measurement by Prolonged Exposure in 16 hours of individual therapy. The 16 individual therapy sessions will take place in 1 to 2 sessions per week over a period of 7 to 16 weeks. The individual therapy sessions are videotaped with camera focus on the therapist. Parts of the Prolonged Exposure process (the re-experiencing of the traumatic memory) are recorded on tape, so that the patient can listen to the recording as homework at home. Afterwards, the patients take part in a study diagnostic session.
223876170|NCT02372253|DRUG|Verapamil|
223876171|NCT02372253|DRUG|Placebo|
223876172|NCT05143658|PROCEDURE|LLS versus LP|Procedure: Laparoscopic repair of anterior and apical pelvic organ prolapse Surgical correction of anterior and apical pelvic organ prolapse by laparoscopy
223876173|NCT00925886|PROCEDURE|Acrysof Toric one-piece intraocular lens|Cataract Surgery with a intraocular lens implantation
223876174|NCT00247208|DEVICE|Taxus polymer-based paclitaxel-eluting stent|Two different types of stents (paclitaxel-eluting and a similar bare metal stent) are being compared in saphenous vein graft lesions.
223876175|NCT00247208|DEVICE|Express 2 bare metal stent|Two different types of stents (paclitaxel-eluting and a similar bare metal stent) are being compared in saphenous vein graft lesions.
223876176|NCT05300542|OTHER|Topical Placebo Cream|Application of test products before and after irradiation
223876177|NCT05300542|OTHER|Topical Cream with 0.5% Active|Application of test products before and after irradiation
223876178|NCT05300542|OTHER|Topical Cream with 1% Active|Application of test products before and after irradiation
223876179|NCT04127669|DRUG|OSU 6162|The active ingredient of OSU6162 is the S-enantiomer with the chemical name (S)-3-\[3-(methylsulfonyl)phenyl\]-1-propylpiperidine hydrochloride. The substance is a white powder with a melting point of 177-182°C. Solubility in water is \> 2000 mg/ml. Current laboratory code used is OSU6162-HCl. In trial protocol, OSU6162-HCl is shortened to OSU6162.
223876180|NCT04127669|DRUG|Placebo oral tablet|Circular coated tablet (with identical appearance to active treatment tablets 15 mg).
223876181|NCT05073562|DIETARY_SUPPLEMENT|Iron and folic acid (IFA) supplementation|Weekly IFA supplementation for duration of the study.
223876182|NCT05073562|BEHAVIORAL|Targeted nutrition education|Structured nutrition education package delivered at household level by trained Community Health Assistants (CHAs)
223876183|NCT05073562|DRUG|Mebendazole Pill|One-time deworming treatment with mebendazole.
223876184|NCT05073562|OTHER|Standard nutrition services|Basic nutrition services currently provided at the health facility and at community level in Liberia
223876185|NCT01846936|PROCEDURE|DLT with conventional technique|The double lumen tube is introduced into the glottis under direct laryngoscopy. After the bronchial cuff had passes the vocal cords, the tube is rotated counterclockwise 90° and advanced until a slight resistance was encountered.
223876186|NCT01846936|PROCEDURE|BB with conventional technique|"The brochial blocker (BB) is introduced through the endotracheal tube to the desired bronchus under FOB vision by turning the device's steering wheel.~The BB cuff is inflated with air under FOB vision with the volume necessary to seal the bronchus and initiate one lung ventilation."
223876187|NCT01846936|PROCEDURE|Disconnection technique|Disconnection technique 1) deflate of the blocker cuff, 2) turn-off the ventilator and opened the APL valve allowing both lungs to collapse, 3) after loss of carbon dioxide trace in the capnograph, reinflate blocker cuff with the same volume of air as during the initial insertion, 4) reconnect the tube to the ventilator allowing only dependent-lung reventilation with a 5 cmH2O positive end-expiratory pressure preceded by a single recruitment maneuver performed by elevating the airway pressure to 40 cmH2O for 7 seconds.
223876188|NCT05198531|DRUG|TQB2858 Injection|TQB2858 Injection, a bifunctional fusion protein against Programmed death ligand 1 (PD-LI) and transforming growth factor-β (TGF-β). TQB2858 Injection blocks the PD-1/PD-L1 pathway and neutralizes TGF-β in the tumor microenvironment.
223876189|NCT05198531|DRUG|Anlotinib Hydrochloride Capsule|Anlotinib hydrochloride is a muti-target tyrosine kinase inhibitor.
223876190|NCT05198531|DRUG|Gemcitabine hydrochloride injection|Gemcitabine hydrochloride, cell cycle-specific antimetabolites, mainly acting on tumor cells in the DNA synthesis phase (S phase cell). Under certain conditions, it can prevent the progression from G1 phase to S phase.
223876191|NCT05198531|DRUG|Cisplatin Injection|After cisplatin enters cells, it reacts with DNA to form cross-links between two points or two strands in DNA, thereby inhibiting DNA replication and transcription, resulting in DNA breaks and miscoding.
223876192|NCT03576742|DIAGNOSTIC_TEST|potential biomarkers|facs analysis, microbiome analysis
223876193|NCT05446363|DEVICE|Medimonitor|A digital solution consisting of web based portal gathering data from mobile fundus camera and intraocular tonometer provided to the physicians located remotely to the University hospital that provides consults and analyses of on-site gathered data.
223876194|NCT03718598|BEHAVIORAL|Tendon and Nerve Gliding Exercises|Tendon and Nerve Gliding Exercises: The tendon slip exercises used in this study were performed in five different positions, namely flexion, flat, hook, punch, table top and flat punch positions. Nerve-gliding exercises were performed by moving the fingers and wrists in six different positions, focusing on the median nerve consisting of all the disease grip, finger lengthening, wrist extension, thumb extension, forearm supination and gentle gentle gait. Instructions were given to make 10 sets of exercises in 3 sets, written and verbal, in order to have e exercises for all patient's tendons and nerves shifting exercises. Brochures were also provided explaining the exercises.
223876195|NCT03912961|OTHER|Picture of the retina with a handheld retinal camera|Patient with diabetes will have their undilated and dilated images taken, with the images being centered on the macula and on the optic disc.
223876196|NCT00242359|DRUG|omalizumab|
223876197|NCT01069471|BIOLOGICAL|Shigella vaccine|Two intramuscular injections of bioconjugate vaccine will be administrated at D0 and D60.
223876198|NCT03569072|RADIATION|Functionally adapted, dose escalated VMAT radiotherapy|Volumetric Modulated Arc Therapy planning and treatment delivery to treat primary and nodal planning target volume with 60 Gy in 30 fractions and a simultaneous integrated boost to the primary tumour to a total dose 69Gy in 30 fractions while avoiding organs at risk including functional lung, heart and oesophagus.
223876199|NCT02879760|BIOLOGICAL|Ad-MAGEA3|Intramuscular injection
223876200|NCT02879760|BIOLOGICAL|MG1-MAGEA3|Intravenous infusion
223876201|NCT02879760|BIOLOGICAL|Pembrolizumab|Intravenous infusion
223876202|NCT04962477|OTHER|Nasal brush sampling|Nasal brush samples will be collected from the inferior turbinate using standardized techniques after local anesthetic application. After clearing the mucus from the nasal cavity by asking the patient to blow their nostrils twice followed by local anesthetic spray application, nasal brush samples will be collected from the inferior turbinate of each nostril with dedicated soft cytology brushes and pooled together for molecular biological experiments. Simultaneously, 10 mL of peripheral blood will be collected for immunophenotyping.
223876203|NCT04767698|DRUG|Belimumab|200 mg SC weekly for 36 months
223876204|NCT04767698|DRUG|Short-course Ocrelizumab|300 mg, two infusions two weeks apart and then 600 mg as a single infusion after six months (only one time) (total of two courses of treatment)
223876205|NCT04767698|DRUG|Continued Ocrelizumab|300 mg, two infusions two weeks apart and then 600 mg as a single infusion every six months for a total of 36 months
223876206|NCT01381471|DRUG|fluticasone propionate/salmeterol xinafoate combination|fluticasone propionate/salmeterol xinafoate combination
223876207|NCT00715494|BEHAVIORAL|Cognitive, physical, and functional rehabilitation|A multicomponent program of cognitive, physical, and functional rehabilitation interventions will be delivered to patients in their home environments over a focused 12 week period with the aid of tele-technology to utilize the expertise of physical therapy, occupational therapy, and neuropsychology.
223876208|NCT06407258|BEHAVIORAL|SLEEPAC|"6x individual blended-care counselling sessions:~* 1 x face-to-face kick-off sessions at study site (45 min)~* 1 x try-out exercise sessions at study site (45 min)~* 4 x online face-to-face sessions via zoom (30 min)~* Both the intervention and the waitlist control condition will continue with TAU.~Component 1: CBT-I: Sleep restriction, and cognitive therapy strategies with education about sleep-wake regulation, sleep hygiene, and pre-bedtime counter arousal methods.~Component 2: Circadian treatment: Morning bright light therapy with a gradual advanced sleep schedule and timed morning exercise.~Component 3: Physical activity counselling involves providing personalized guidance and support to individuals to help them adopt and maintain a physically active lifestyle tailored to their preferences and needs."
223876209|NCT00780234|PROCEDURE|fluorescence bronchoscopy|examination of the central airways with a bronchoscope. Both white light and fluorescent light will be used.
223876210|NCT00780234|PROCEDURE|quantitative high resolution CT scan|High resolution CT scan of the chest
223876211|NCT00780234|DRUG|PIOGLITAZONE VS. PLACEBO 30 mg|"Patients will be randomized to receive either pioglitazone or placebo. Pioglitazone hydrochloride, a thiazolidinedione antidiabetic agent and a potent peroxisome proliferator-~activated receptor-gamma agonist. It is FDA approved for the treatment of Type II diabetes. It has been previously administered to non-diabetic subjects. The most common side effect of pioglitazone is fluid retention and modest weight gain. There is a potential risk that pioglitazone may cause an elevation in liver enzymes and more serious hepatotoxicity (rare). There is risk of edema and weight gain associated with pioglitazone therapy. 5% experienced peripheral edema in clinical trials. fluid retention may result in new onset heart failure or exacerbation of existing heart failure. Small risk of hypoglycemia, anemia, myalgia, bone fracture, headache, and macular retinal edema exists. There is insufficient information to confirm its safety in Pregnancy/Breastfeeding. Bladder cancer is more serious but rare."
223876212|NCT04746131|DRUG|IMM0306|IMM0306 is an bi-specific antibody
223876213|NCT02178098|DRUG|ETC-1002|ETC-1002 capsules taken once daily
223876214|NCT02178098|DRUG|Placebo|Placebo capsules taken once daily
223876215|NCT05161429|DRUG|DPP4|Dipeptidyl peptidase-4 inhibitors (DPP4) including alogliptin, linagliptin, sitagliptin, and saxagliptin
223876216|NCT05161429|DRUG|GLP-1 receptor agonist|Glucagon-like peptide-1 receptor agonists (GLP1-RA) including dulaglutide, exenatide, liraglutide and semaglutide
223876217|NCT05161429|DRUG|Basal Insulin|degludec, detemir, glargine and NPH
223876218|NCT05161429|DRUG|SLGT2|Sodium-glucose cotransporter-2 inhibitors (SLGT2) including canagliflozin, dapagliflozin, empagliflozin, and ertugliflozin
223876219|NCT05161429|DRUG|SU|Sulfonylurea (SU) including glimepiride, glipizide, and glyburide
223876220|NCT04997213|OTHER|Biofeedback exercises|Biofeedback system is a center of pressure-controlled video game-based exercise system designed for patients with neurological and orthopedic diseases and provides balance training using auditory, visual, and pressure biofeedback. The system contains several games, each designed to focus on a different component of balance. Biofeedback is provided by means of a monitor in front of the patient. The balance exercises program was involved a total of 18 sessions, each lasting 20 min, three times a week for six weeks, and was individually tailored based on the patient's tolerance and current motor and sensorial capacities. All patients performed conventional exercises.
223876221|NCT04997213|OTHER|Conventional Exercises|Classic balance exercises were performed (two-leg stance, semi-tandem stance, tandem stance, standing on one leg, tandem walking, turning completely around, heel-to-toe stance, and standing with the eyes closed). Patients with balance disorder first could be commenced balance training in a seated position before progressing to standing exercises, to the extent that these could be tolerable.
223876222|NCT03743506|DIAGNOSTIC_TEST|With feedback|To evaluate the displacement of the center of pressure on the disc during the equilibration with feedback.
223876223|NCT03743506|DIAGNOSTIC_TEST|Without feedback|To evaluate the displacement of the center of pressure on the disc during the equilibration without feedback.
223876224|NCT00957242|DRUG|warfarin|Oral warfarin (1mg or 2.5mg) titrated to an INR of 2-3.
223876225|NCT00957242|DRUG|placebo|Oral placebo (1mg or 2.5mg)
223876226|NCT05074069|PROCEDURE|Gynaecological reconstruction|Methods of vulvovaginal reconstruction, e.g. flap formation, neovagina formation
223876227|NCT02940951|OTHER|QPSS|Home care providers use the QPSS that includes standardized instruments for assessing patient and family caregiver quality of life in routine care. In addition to instant calculation of scores, the QPSS allows for tracking scores over time and sharing them with other registered users from that home care service.
223876228|NCT02940951|OTHER|Usual care|Home healthcare services provided by nurses and, where applicable, multi-professional teams.
223876229|NCT02265432|BEHAVIORAL|General physical activity educational materials|
223876230|NCT02265432|DEVICE|Wearable activity tracking devices (fitbit)|
223876231|NCT02265432|OTHER|online map|
223876232|NCT02265432|OTHER|Personalized text messages|
223876233|NCT01044303|DRUG|Myfortic Escalation|Dose increases of 180 mg every 3 months until DSA titer is zero or until maximum tolerable dose of EC-MPS is achieved. Maximum dose will not exceed 2160 mg daily.
223876234|NCT00301652|DRUG|mycophenolate mofetil|MMF,1.0g/d
223876235|NCT01603758|DRUG|Ezetimibe|Ezetimibe 10 mg/day or placebo will be given for 6 weeks
223876236|NCT03059212|DEVICE|rTMS|High frequency rTMS for 3 to 10 min to increase the excitability of cortex.
223876237|NCT03059212|BEHAVIORAL|Cognitive training program|A rehabilitation protocol that facilitates attention, memory, execution.
223876238|NCT05563168|DRUG|DILTIAZEM TEVA 60 mg or placebo|DILTIAZEM TEVA 60 mg 3 times a day during 7 days + standard of care Or placebo 3 times a day during 7 days + standard of care.
223876239|NCT01058499|BEHAVIORAL|Mindfulness Based Stress Reduction Program (MBSR)|Traditional eight-week MBSR Program.
223876240|NCT00551577|PROCEDURE|neoadjuvant chemotherapy (Carboplatin/Docetaxel)|3 cycles of Carboplatin/Docetaxel (3-weekly) preoperative and 3 cycles of Carboplatin/Docetaxel (3-weekly) postoperative
223876241|NCT00551577|PROCEDURE|neoadjuvant chemotherapy (Carboplatin/Docetaxel)|2 cycles of Carboplatin/Docetaxel (3-weekly) preoperative and 4 cycles of Carboplatin/Docetaxel (3-weekly) postoperative
223876242|NCT01109524|DRUG|Cetuximab|Vial, Intravenous, 400mg/m², week 1, then 250mg/m², Weekly, Until Progressive Disease (PD)/ Toxicity/Pt-PI Decision
223876243|NCT01109524|DRUG|Cisplatin|Vial, Intravenous, 80mg/m², Day 1 of each 21 day cycle, Maximum 6 cycles
223876244|NCT01109524|DRUG|Vinorelbine|Vial, Intravenous, 25 mg/m², Day 1 and 8 of each 21 day cycle, Maximum 6 cycles
223876245|NCT04385680|DRUG|Chlorhexidine Gluconate vaginal solution 0.05%|preoperative vaginal preparation
223876246|NCT02407834|OTHER|S1|Immersion in 0.25% sodium hypochlorite for 20 minutes, during 7 days.
223876247|NCT02407834|OTHER|S2|Immersion in 0.5% sodium hypochlorite for 20 minutes, during 7 days.
223876248|NCT02407834|OTHER|S3|Immersion in 10% Ricinus communis for 20 minutes, during 7 days.
223876249|NCT02407834|OTHER|S4|Immersion in Saline solution for 20 minutes, during 7 days.
223876250|NCT00003612|BIOLOGICAL|trastuzumab|
223876251|NCT00003612|DRUG|carboplatin|
223876252|NCT00003612|DRUG|paclitaxel|
223876253|NCT00111085|DRUG|Clazosentan 1 mg/h|Subjects receive intravenous clazosentan at a rate of 1 mg/h starting within 56 hours maximum after aneurysm rupture and continuing until Day 14 post-aneurysm rupture
223876254|NCT00111085|DRUG|Clazosentan 5 mg/h|Subjects receive intravenous clazosentan at a rate of 5 mg/h starting within 56 hours maximum after aneurysm rupture and continuing until Day 14 post-aneurysm rupture
223876255|NCT00111085|DRUG|Clazosentan 15 mg/h|Subjects receive intravenous clazosentan at a rate of 15 mg/h starting within 56 hours maximum after aneurysm rupture and continuing until Day 14 post-aneurysm rupture
223876256|NCT00111085|DRUG|Placebo|Subjects receive intravenous placebo starting within 56 hours maximum after aneurysm rupture and continuing until Day 14 post-aneurysm rupture
223876257|NCT01849978|BEHAVIORAL|Newsletter about physical activity and breast cancer survivors|Both groups will receive a newsletter that covers: 1) the recommendation to pursue at least 150 mins/week of moderate to strenuous intensity PA, 2) the benefits of PA specific to breast cancer survivors (e.g., reducing in death and breast cancer recurrence), and 3) their total minutes of moderate to strenuous intensity PA and how this compares to the recommendation.
223876258|NCT01849978|BEHAVIORAL|Changing your habits brochure|"Both groups will receive the brochure titled Changing Your Habits: Steps to Better Health, developed by the NIH, that describes, based a person's stage of change, the benefits of PA, how to overcome common barriers to PA, and if ready, how to plan for PA."
223876259|NCT01849978|BEHAVIORAL|Tips for making exercise enjoyable and personally-valued|Participants will get a list of potentially enjoyable activities and a space to list other activities after they consider aspects that can make events fun/interesting.13 Aspects to consider include: location (indoors vs. outdoors, the latter which may appeal to some), hobbies that can involve PA (e.g., sports, dancing), whether the activity is made more enjoyable by having it performed by oneself or with others (e.g., team activities vs. individual activities); what valued outcomes may be achieved (e.g., sense of competence, pride, better health, body image), accompanying activities that are pleasant (e.g., listening to music), etc.
223876260|NCT01849978|BEHAVIORAL|Testimonials from breast cancer survivors|Participants will get two to three testimonials of actual breast cancer survivors. These testimonials will include story-like details of what these survivors find enjoyable about exercising and what they have done to make exercise enjoyable.
223876261|NCT00847834|DRUG|Irbesartan 150mg / Hydrochlorothiazide 12.5mg|Once a day
223876262|NCT00847834|DRUG|Irbesartan 150mg|Once a day
223876263|NCT06516250|OTHER|Virtual serious game GEMAS|Implement and evaluate a virtual serious game designed to improve the learning and retention of clinical knowledge in medicine and nursing students and residents through the simulation of clinical cases in a hospital emergency environment.
223876264|NCT05900765|DRUG|Zimberelimab 240mg|"AVD regimen:~Doxorubicin 25mg/m2, d1, d15, IV; Vincristine 3mg/m2, d1, d15 IV; Dacarbazine 0.375mg/m2, d1, d15 IV"
223876265|NCT02903199|DIETARY_SUPPLEMENT|Whey Protein|Whey protein (18 g) administered immediately prior to breakfast and lunch meals.
223876266|NCT02903199|DIETARY_SUPPLEMENT|Hydrolysed Protein|Hydrolysed whey protein (19.1 g) administered immediately prior to breakfast and lunch meals.
223876267|NCT02903199|DIETARY_SUPPLEMENT|Placebo|Placebo intervention administered immediately prior to breakfast and lunch meals.
223876268|NCT01923480|DRUG|15% CLINISOL - Sulfite-free (Amino Acid) Injection|
223876269|NCT01923480|DRUG|15% CLINISOL - Sulfite-free (Amino Acid) Injection|
223876270|NCT01923480|DRUG|15% CLINISOL - Sulfite-free (Amino Acid) Injection|
223876271|NCT06514027|DRUG|BEBT-109 Capsules|BEBT-109 Capsules: Administration and Dosage: Oral administration, 120mg or 180mg; Frequency and Duration of Administration: Once a day or twice a day,and 21 days as a treatment cycle.
223876272|NCT06514027|DRUG|Pemetrexed Disodium for Injection|Pemetrexed Disodium for Injection: Administration and Dosage: Intravenous infusion, 500mg/m\^2; Frequency and Duration of Administration: On the first day of each cycle,and 21 days as a treatment cycle.
223876273|NCT06514027|DRUG|Carboplatin Injection|Carboplatin Injection: Administration and Dosage: Intravenous infusion, AUC=5 mg/ml.min, with a single dose not exceeding 800 mg; Frequency and Duration of Administration: On the first day of each cycle for the first four cycles, and 21 days as a treatment cycle, totaling four cycles.
223876274|NCT06514027|DRUG|Cisplatin Injection|Cisplatin Injection: Administration and Dosage: Intravenous infusion, 75 mg/m\^2; Frequency and Duration of Administration: On the first day of each cycle for the first four cycles, and 21 days as a treatment cycle, totaling four cycles.
223876275|NCT01553058|DRUG|Adalimumab (Humira)|Humira will be given at an initial dose of 80mg followed by 40 mg the second week, subsequent doses will be given at 40mg and follow FDA dosing schedule.
223876276|NCT01553058|DRUG|Placebo Injection|Placebo injection will be given according to the same dose and schedule as the active comparator.
223876277|NCT01553058|OTHER|NB-UVB phototherapy|Phototherapy will be given 3 times per week according to the Fitzpatrick scale for skin types.
223876278|NCT02650791|DRUG|Tranexamic Acid|
223876279|NCT03493724|OTHER|telemedecine|to evaluate the diagnostic performance of the photographs made by Smartphone, during requests for emergency dermatological advice
223876280|NCT00002383|DRUG|Saquinavir|
223876281|NCT00975039|DRUG|WST11|WST11-mediated VTP will consist of the combination of a single IV administration of WST11 at doses of 2.5 and 5 mg/kg, using 753nm laser light at a fixed power (150 mW/cm) and light energy (200 J/cm). Illumination in the bile duct is performed by inserting a diffusing fiber, with cylindrical uniform light distribution, in a transparent standard ERCP catheter and by positioning, under radioscopy, the illumination tip of the diffusing fiber in front of the lesion.
223876282|NCT00194610|DRUG|Botox|Botox 25 international units per injection injected in two places in the bladder neck, with option to inject two other tender points with 25 units each
223876283|NCT00194610|OTHER|normal saline|Normal saline injected into the bladder neck via the perineum, 1 cc each given at positions 3 o'clock and 9 o'clock
223876284|NCT02743195|DIETARY_SUPPLEMENT|Polyphenol/prebiotic blend|
223876285|NCT04854395|DRUG|Marcain 5 mg/ml|Total volumes of Marcain differs in each arm, depending on which nerve blocks the patients is randomized to receive. Sham block does not include injection of placebo saline, due to the risk of hydrodissection between the anatomical sections which may erase the isolation of the different nerve blocks. Instead the sham block include imitation of the real nerve block, including correct placement of the needle on the target for the block.
223876286|NCT02745340|OTHER|Acetate by Citrate substitution and vice versa|substitution of acetate by citrate in dialysis fluid
223876287|NCT05123742|DIAGNOSTIC_TEST|COVID-19 Testing|Testing for the SARS-CoV-2 virus
223876288|NCT00031694|DRUG|paclitaxel|Given IV
223876289|NCT00031694|DRUG|bryostatin 1|Given IV
223876290|NCT04307511|DRUG|Ticagrelor|60mg ticagrelor based DAPT vs 90mg ticagrelor based DAPT vs 90mg ticagrelor monotherapy
223876291|NCT04307511|DRUG|Aspirin|Aspirin
223876292|NCT03240978|BEHAVIORAL|exercise intervention|A period of 12-week exercise intervention under the supervision of exercise specialists will be conducted.
223876293|NCT04838496|DRUG|FOLFOXIRI Protocol|"FOLFOXIRI consists of oxaliplatin, irinotecan, leucovorin and 5-fluorouracil and is administered every 2 weeks:~Dosing:~* Day 1: irinotecan 165 mg/m2 body-surface area (BSA) intravenously (IV), followed by oxaliplatin 85mg/m2 BSA IV in combination with leucovorin 400mg/m2 BSA, followed by:~* Day 1-2: 3200 mg/m2 BSA of continuous 5-fluorouracil IV~* Day 3-14: rest days.~Both regimen are initially administered for four cycles. In case of responsive or stable disease, a 5th and 6th cycle of FOLFOXIRI will be administered.~In case of unacceptable toxicity, the aforementioned dosages can be reduced or one or more chemotherapeutical agents can be omitted at discretion of the medical oncologist and will be noted in the patient's medical file. At discretion of the medical oncologist, a start dosage of 75% of the advised dosage could be considered in patients above 70 years of age."
223876294|NCT03778242|DRUG|Topical tranexamic acid|temporary uterine packing with gauze of the dimensions soaked with 2 gm tranexamic diluted in 60ml saline acid
223876295|NCT03778242|DRUG|normal saline|2 placebo ampoules to TA in 100 ml saline by slow infusion
223876296|NCT00018603|DRUG|guanfacine|
223876297|NCT04834141|OTHER|FlexiCurve ruler method to assess thoracic kyphosis angle|The determination that the effect of thoracic kyphosis posture on trunk biomechanical alignment may be related to balance may contribute to new treatment recommendations in this area. The aim of this study is to investigate whether the thoracic kyphosis posture has an effect on static balance.
223876298|NCT05799742|PROCEDURE|Bilateral hernioplasty|
223876299|NCT03945123|DIETARY_SUPPLEMENT|Red ginseng|Red ginseng tablet 120g
223876300|NCT00746343|BEHAVIORAL|IRRI|Subjects will remain in their assigned treatment condition for 24 months. IRRI subjects will meet with the lifestyle coach 25-27 times throughout the duration of the study.
223876301|NCT00746343|BEHAVIORAL|PCCM|Subjects will remain in their assigned treatment condition for 24 months.
223876302|NCT00006431|BIOLOGICAL|DC RCC-RNA|
223876303|NCT02076659|DRUG|F8IL10|"Weekly administration of F8IL10 (from 6 to 600 μg/kg), starting from 6 μg/kg cohort 1. The cohort 10 represents the last dose-level of the study.~F8IL10 will be administered as subcutaneous (s.c.) injections. Patients will receive 4 cycles of treatment unless there is unacceptable toxicity or withdrawal of consent."
223876304|NCT02076659|DRUG|Methotrexate|"Methotrexate will be administered at a fixed dose of 10-15 mg on Day 1, orally (p.o.), subcutaneously (s.c.) or intramuscularly (i.m.).~Patients will receive 4 cycles of treatment unless there is unacceptable toxicity or withdrawal of consent."
223876305|NCT01286714|DEVICE|CLIP OST|
223876306|NCT03159273|DIETARY_SUPPLEMENT|Beetroot Juice Group|Beetroot juice drink- 7 daily doses (70 ml, containing 0.4-0.5 mg nitrate) taken over a week
223876307|NCT02009215|DRUG|Dihydroartemisinin-piperaquine (DP)|Intermittent preventive treatment (IPT) with dihyroartemisinin-piperaquine (DP) will be delivered to participating students monthly, for up to 6 rounds of treatment during one school year. DP will be given once a day for 3 days, using full strength tablets (40/320mg) according to weight-based guidelines. Treatment will be directly observed, and will not be blinded.
224076647|NCT03970187|OTHER|Exposure-based eye contact training in Virtual Reality (VR)|"The intervention is an App for virtual reality. The VR App provides three different virtual scenarios. Participants will be asked to stand in front of a virtual audience and to maintain eye contact with audience members. The advance to higher difficulty levels is according to a pre-defined exposure scheme. Participants will be given all instructions via the App.~There will be three sessions on one day (duration of 20 min each) in study phase 1. The indication is disproportionate fear of being evaluated by others and reduced eye contact as a typical avoidance strategy in individuals with fear of public speaking. In the study phase 2, there will be nine sessions spanning over two weeks (duration of 20 min each, with maximally one session per day). The indication is disproportionate fear of being evaluated by others and reduced eye contact as a typical avoidance strategy in individuals with fear of public speaking."
223876308|NCT04048382|BEHAVIORAL|Patient Navigation|Spanish-English bilingual peer lay navigators hired by Family Health Centers of San Diego will provide the PN intervention during the study, trained using manuals developed in formative research and via the Patient Navigation Research Program training approach. Services will generally focus on: 1) overcoming community, health system, interpersonal, and individual barriers to accessing PrEP-related healthcare; 2) increasing each patient's knowledge, attitudes, and self-efficacy for initiating and adhering to PrEP; 3) improving communication between the patient and healthcare team through appointment scheduling and reminders; and 4) sexual risk reduction counseling.
223876309|NCT04048382|OTHER|Usual Care|The booklet given is a 2-page booklet including the following information: 1) overview of PrEP; 2) eligibility for PrEP; 3) efficacy of PrEP; 4) safety of PrEP; and 5) obtaining, initiating, and adhering to PrEP. Participants will also be provided with both verbal and written information regarding available sexual health and HIV prevention services, including PrEP, at Family Health Centers of San Diego (FHCSD). Comprehensive HIV-prevention healthcare, including PrEP, is available to study participants at FHCSD at no or minimal cost. If a UC participant is diagnosed with a sexually transmitted infection, including HIV, treatment and follow-up will be coordinated by FHCSD staff as per usual care procedures.
223876310|NCT04131153|PROCEDURE|"three-step radiofrequency ablation"|"After destroying the main blood supply of the tumor, extracting the blood in the tumor, reducing the blood flow in the tumor and shrinking the tumor volume, the remaining tumor was then treated with radiofrequency ablation, namely the three-step radiofrequency ablation with one block, two inhalation and three damages."
223876311|NCT04131153|PROCEDURE|radiofrequency ablation|Conventional radiofrequency ablation
223876312|NCT00698919|OTHER|Observational study|"This is not an interventional studies. We will just compare two methods of bacterial diagnosis. Of note the physicians will care of their patients with the classic bacterial analysis tools; so there is no modification of the care.~The new techniques used (DNA detection) will done later on and thus won't modify their decision."
223876313|NCT03671252|DRUG|FOLFOXIRI|Irinotecan165 mg/m2、Oxaliplatin85 mg/m2、Left-calcium leucovorin 200mg/㎡，Intravenous infusion，first day. Then, 5-FU 1600 mg/m2/d×2 continuous intravenous infusion（total 3200 mg/m2，infusion 46 hours）in the next two days. Repeat every 14 days.
223876314|NCT03671252|DRUG|XELOX|XELOX consisting of 130 mg/m2 oxaliplatin administered intravenously on day 1 and 1,000 mg/m2 capecitabine administered orally twice daily on days 1-14 for a 3-week cycle.
223876315|NCT03671252|OTHER|Chemoradiotherapy|"Chemotherapy: oral capecitabine（1650 mg/m2）twice daily during radiotherapy without weekend breaks.~Radiation: Radiation therapy is administered via intensity-modulated radiation therapy (IMRT) with a linear accelerator, 6MV-X ray. The patients are scheduled to receive a GTV expanding 6mm to form PTV1 and CTV expanding 6mm to form PTV2. The dose of PTV1 is 50Gy/25 times for 35 days and the dose of PTV2 is 45Gy/25 times for 35 days. Patients were treated in consecutive days per week for a total of 5 weeks."
223876316|NCT03671252|PROCEDURE|TME operation|TME operation
223876317|NCT03671252|PROCEDURE|efficacy evaluation|chest/ abdominal CT、pelvic nuclear magnetic resonanceimaging、transrectal ultrasonography
223876318|NCT04426916|OTHER|Spondylolisthesis|Spondylolisthesis at a single level
223876319|NCT00490100|DRUG|Increlex|
223876320|NCT01657604|DRUG|Peginterferon α2b|Patients will receive nilotinib 300 mg BID given as two 150 mg capsules twice daily with at a starting target dose of 30μg/week. After confirmed MMR or at least 24 mo. after start of therapy, maintenance therapy (nilotinib will be discontinued) will start for a study duration of up to 5 years.
223876321|NCT01657604|DRUG|Nilotinib|Patients will receive nilotinib 300 mg BID given as two 150 mg capsules twice daily for a study duration of up to 5 years.
223876322|NCT05208242|DRUG|hyperoncotic human albumin solution|20% human albumin solution (presented in 100ml glass bottles)
223876323|NCT05208242|DRUG|Buffered crystalloid solutions|Buffered crystalloids solutions for all intravenous fluid therapy
223876324|NCT03807752|DIETARY_SUPPLEMENT|MPH_active|One daily intake at breakfast of supplementary marine protein hydrolysate (MPH), a dosage of X mg, duration 8 weeks. The form is powder, flavored with lemon, and to be mixed with 100 ml water. Random sequence of arms.
223876325|NCT03807752|DIETARY_SUPPLEMENT|MPH_placebo|One daily intake at breakfast of supplementary placebo, a dosage of X mg, duration 8 weeks. The form is powder, flavored with lemon, and to be mixed with 100 ml water.
223876326|NCT00212693|DRUG|ONO-2506PO|
223876327|NCT01139944|GENETIC|DNA methylation analysis|
223876328|NCT01139944|GENETIC|polymerase chain reaction|
223876329|NCT01139944|OTHER|laboratory biomarker analysis|
223876330|NCT02752503|DRUG|Nalmefene|
223876331|NCT01205048|DEVICE|Emervel Classic Lidocaine|20 mg/mL + 0.3% lidocaine
224076648|NCT02369276|OTHER|ultrasonography and elastography|Evaluate the soft tissue of shoulder girdle with musculoskeletal ultrasonography and elastography, compare the finding in each group and the range of motion of their shoulder, the severity of wing scapula, visual pain analog scale and the score of The Disability of Arm, Shoulder and Hand
224076649|NCT03783260|OTHER|Mediterranean diet|During both Mediterranean diet periods, participants will be provided with meals and snacks representative of the Mediterranean nutritional habits. Participants will be required to eat only the meals provided.
223876332|NCT01205048|DEVICE|Juvederm® Ultra|24mg/mL
224076650|NCT05315921|DRUG|OsrhAAT 1 mg/kg IV|"Drug: OsrhAAT 1 mg/kg IV A single dose of OsrhAAT 1 mg/kg IV infusion at a rate approximately 0.04 ml/min/kg.~Placebo: Normal Saline (0.9% Sodium Chloride)"
223876333|NCT03964870|DIAGNOSTIC_TEST|Diagnostic of polymorphisms in malignant hyperthermia|Identify and catalogue the variants or polymorphisms in the RYR1 and CACNA1S genes in the Spanish population.
223876334|NCT01255670|DRUG|penicillin and metronidazole in peritonsillar abscess|Peroral Penicillin: 1000 000 IU 3 times a day for 10 days Peroral metronidazole: 500 mg 3 times a day for 7 days
223876335|NCT01037985|DRUG|EXC 001|Multiple intradermal injections of EXC 001 and placebo
223876336|NCT01037985|DRUG|Placebo|Multiple intradermal injections of EXC 001 and placebo
223876337|NCT02269475|DRUG|MEDI3250|MEDI3250
223876338|NCT02269475|DRUG|Placebo|Placebo
223876339|NCT02730871|DRUG|Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension|
223876340|NCT02730871|DRUG|Brinzolamide/brimonidine vehicle|Inactive ingredients used as placebo comparator
223876341|NCT02730871|DRUG|Travoprost 0.004%/timolol 0.5% solution|1 drop instilled in the affected eye(s) daily in the morning (at 9:00) or in the evening (at 21:00) for up to 10 days during the Screening/Eligibility Phase and 42 days during the Treatment Phase
223876342|NCT03489187|DEVICE|Visualase Thermal Therapy System|Patients who have previously received treatment with VTTS when used as intended.
223876343|NCT01298934|DRUG|LBH589|Dose escalation study starting at 20mg by mouth three times a week, given weekly for 24 weeks in the phase I portion of the study.
223876344|NCT00823472|DRUG|Mild stimulation|Fixed daily dose of 150 IU rFSH start cycle day 5 or day 2 depending on the Arm
223876345|NCT06137105|DRUG|eltrombopag and romiplastim|"Group I: eltrombopag and romiplastim~Group II : recived corticosteroid."
223876346|NCT04649996|PROCEDURE|Appendectomy|comparison between operative and conservative treatment
223876347|NCT01754636|OTHER|No intervention|
223876348|NCT05908669|DIAGNOSTIC_TEST|Deuterium metabolic imaging|MRI after oral administration of 75g of \[6,6'-2H2\]glucose.
223876349|NCT03467529|OTHER|Non interventional study|Non interventional study
223876350|NCT03333018|DRUG|Aclidinium bromide|Administered as monotherapy, prescribed as recorded in the database.
223876351|NCT03333018|DRUG|Aclidinium bromide/formoterol|Administered in combination with formoterol fumarate (concomitant or as a fixed-dose combination), prescribed as recorded in the database.
223876352|NCT03333018|DRUG|Other COPD medication|"Other COPD medication including:~tiotropium; other long-acting anticholinergic (LAMAs; lycopyrronium bromide, umeclidinium); LABA (formoterol, salmeterol, indacaterol); LABA/ICS (formoterol/budesonide, formoterol/beclometasone, formoterol/mometasone, formoterol/fluticasone, salmeterol/fluticasone propionate, and vilanterol/fluticasone); LAMA/LABA (approved or under regulatory review or in development; glycopyrrolate/formoterol, glycopyrronium/indacaterol, tiotropium/olodaterol, umeclidinium/vilanterol), prescribed as recorded in the database."
223876353|NCT06652698|OTHER|Cow's milk formula [CMF]|At least 10 ml daily of cow's milk formula (Bebiko 1 NUTRIFlor Expert®, Nutricia; formula with galactooligosaccharides and without probiotics); and if additional supplementation will be needed (i.e., insufficient, partial, or discontinuation of breastfeeding), the randomly assigned nutritional intervention until the end of 4 months of age will be provided.
223876354|NCT06652698|OTHER|Amino-acid formula [AAF]|At least 10 ml daily of amino-acid formula (Nutramigen Pureamino®, Reckitt Benckiser Group PLC); and if additional supplementation will be needed (i.e., insufficient, partial, or discontinuation of breastfeeding), the randomly assigned nutritional intervention until the end of 4 months of age will be provided.
223876355|NCT06652698|OTHER|Donor human milk [DHM]|At least 10 ml daily of donor human milk; and if additional supplementation will be needed (i.e., insufficient, partial, or discontinuation of breastfeeding), the randomly assigned nutritional intervention until the end of 4 months of age will be provided.
223876356|NCT06652698|OTHER|"High-pressure processed pascalized donor human milk [DHM-P]"|"At least 10 ml daily of high-pressure processed pascalized donor human milk; and if additional supplementation will be needed (i.e., insufficient, partial, or discontinuation of breastfeeding), the randomly assigned nutritional intervention until the end of 4 months of age will be provided."
223876357|NCT05180344|BEHAVIORAL|Mobile Application to Prevent Suicide (MAPS)|Safety Planning Intervention, ecological momentary intervention smartphone app system, and bidirectional communication with study clinician.
223876358|NCT03035396|DEVICE|Diassess Influenza A and B Test|
223876359|NCT06025383|DIETARY_SUPPLEMENT|L-Citrulline|2 weeks of L-Citrulline supplementation (6 grams/day)
223876360|NCT06025383|DIETARY_SUPPLEMENT|Placebo|2 weeks of microcrystalline cellulose supplementation (8 capsules/day)
223876361|NCT06854471|OTHER|Placebo beverage, kiwi-strawberry flavor|9.3.oz 3 times for a total of 28 oz over a 35 min period followed by 25 min rest until Time 0 post-dose
223876362|NCT06854471|OTHER|Electrolyte solution without glycerol beverage 1|4 oz 3 times for a total of 12 oz over a 35 min period followed by 25 min rest until Time 0 post-dose. Beverage matched to placebo for color and flavor.
223876363|NCT06854471|OTHER|Electrolyte solution without glycerol beverage 2|6.7 oz 3 times for a total of 20 oz over a 35 min period followed by 25 min rest until Time 0 post-dose. Beverage matched to placebo for color and flavor.
223876364|NCT06854471|OTHER|Electrolyte solution without glycerol beverage 3|9.3.oz 3 times for a total of 28 oz over a 35 min period followed by 25 min rest until Time 0 post-dose. Beverage matched to placebo for color and flavor.
223876365|NCT06854471|OTHER|Electrolyte solution with glycerol beverage 1|4 oz 3 times for a total of 12 oz over a 35 min period followed by 25 min rest until Time 0 post-dose. Beverage matched to placebo for color and flavor.
223876366|NCT06854471|OTHER|Electrolyte solution with glycerol beverage 2|4 oz 3 times for a total of 12 oz over a 35 min period followed by 25 min rest until Time 0 post-dose. Beverage matched to placebo for color and flavor.
223876367|NCT06854471|OTHER|Electrolyte solution with glycerol beverage 3|9.3.oz 3 times for a total of 28 oz over a 35 min period followed by 25 min rest until Time 0 post-dose. Beverage matched to placebo for color and flavor.
223876368|NCT06854471|OTHER|Base with glycerol, no electrolytes beverage 1|4 oz 3 times for a total of 12 oz over a 35 min period followed by 25 min rest until Time 0 post-dose. Beverage matched to placebo for color and flavor.
223876369|NCT06854471|OTHER|Base with glycerol, no electrolytes beverage 2|6.7 oz 3 times for a total of 20 oz over a 35 min period followed by 25 min rest until Time 0 post-dose. Beverage matched to placebo for color and flavor.
224076651|NCT05315921|DRUG|OsrhAAT 3 mg/kg IV|"Drug: OsrhAAT 3 mg/kg IV A single dose of OsrhAAT 3 mg/kg IV infusion at a rate approximately 0.04 ml/min/kg.~Placebo: Normal Saline (0.9% Sodium Chloride)"
224076652|NCT05315921|DRUG|OsrhAAT 10 mg/kg IV|"Drug: : OsrhAAT 10 mg/kg IV A single dose of OsrhAAT 10 mg/kg IV infusion at a rate approximately 0.04 ml/min/kg.~Placebo: Normal Saline (0.9% Sodium Chloride)"
224076653|NCT05315921|DRUG|OsrhAAT 20 mg/kg IV|"Drug: OsrhAAT 20 mg/kg IV A single dose of OsrhAAT 20 mg/kg IV infusion at a rate approximately 0.04 ml/min/kg.~Placebo: Normal Saline (0.9% Sodium Chloride)"
223876370|NCT06854471|OTHER|Base with glycerol, no electrolytes beverage 3|9.3.oz 3 times for a total of 28 oz over a 35 min period followed by 25 min rest until Time 0 post-dose. Beverage matched to placebo for color and flavor.
223876371|NCT06187298|DIETARY_SUPPLEMENT|A combined supplement of Berberine and Curcumin (Enterophytol® PLUS) alongside standard of care|(Enterophytol® PLUS) alongside standard of care
223876372|NCT06815653|DRUG|Psilocybin 25mg|Psilocybin PEX010 is an investigational drug provided in capsule form, containing a 25 mg dose of synthetic psilocybin. The product is manufactured under Good Manufacturing Practice (GMP) standards to ensure purity, potency, and consistency. Each participant will receive a single oral dose of 25 mg psilocybin in a hydroxypropyl methylcellulose (HPMC) capsule. The intervention is administered once during the study session, with the effects expected to last approximately 4 to 6 hours.
223876373|NCT06684782|OTHER|Screening for symptoms of restless leg syndrome|The patients will be screened for restless leg syndrome by clinical questioning.
223876374|NCT03778424|DRUG|Rufinamide|Rufinamide up to 45 milligram per kilogram per day (mg/kg/day).
223876375|NCT03281694|DRUG|Placebo|placebo skin patch and placebo oral solution
223876376|NCT03281694|DRUG|Nicotine|nicotine skin patch (7 mg/24 hrs) and placebo oral solution
223876377|NCT03281694|DRUG|AVL-3288|placebo skin patch and AVL-3288 oral solution (3 mg)
223876378|NCT03281694|DRUG|Nicotine + AVL-3288|nicotine skin patch (7 mg/24 hrs) and AVL-3288 oral solution (3 mg)
223876379|NCT06859372|BEHAVIORAL|Nurturing Care Family Navigator|The Nurturing Care Family Navigator (NCFN) is a comprehensive barrier-focused and long-term family-centered intervention that will offer screenings for food insecurity, referrals to community resources, and follow-up with families experiencing very low or low food security in the past 12 months. The goal of the NCFN is to increase knowledge (cognitive factors) and self-efficacy (behavioral factors) to navigate barriers across the four pillars of food insecurity by securing enrollment and sustaining engagement with a set of community nurturing care services (environmental factors) to improve levels of food security, and ultimately maternal-child health and nutrition outcomes of low-income families during the postpartum phase.
223876380|NCT06864988|BIOLOGICAL|4D-150 IVT (3E10 vg/eye)|If randomized to the 4D-150 treatment arm, 4D-150 will be administered at the assigned dose level as a single dose IVT injection on Day 1
223876381|NCT06864988|BIOLOGICAL|EYLEA® (aflibercept) Injection 2 mg (0.05mL)|Eylea (aflibercept) will be administered at applicable visits
223876382|NCT04674293|DRUG|Revelisa|Thrombolytic therapy for patients with ischemic stroke
223876383|NCT07000552|OTHER|EFT intervention|The intervention groups will be followed up for 4 weeks and 4 EFT therapies will be applied, one session per week.
223876384|NCT06676852|BEHAVIORAL|Primary palliative care|Enrolled patient participants will receive Sentinel prior to and during their hospitalization for HCT. Prior to HCT, a transplant clinician (nurse practitioner - NP) will conduct a focused PC visit to build rapport, manage expectations regarding HCT, review anticipated symptoms, and discuss illness coping strategies. During the HCT hospitalization, HCT physicians and advanced practice providers will incorporate PC domains into their routine care of patients undergoing HCT.
223876385|NCT07004374|DEVICE|a percussion massage gun|Participants receive percussion massage therapy (33 Hz) applied to the quadriceps and gastrocnemius muscles using a handheld massage device for 5 minutes per muscle group.
223876386|NCT07004374|DEVICE|specially designed stainless-steel instruments|Participants receive instrument-assisted soft tissue mobilization (IASTM, Graston technique) applied to the quadriceps and gastrocnemius muscles using stainless steel tools with standardized techniques (Sweep, Fan, Brush) for 6 minutes.
223876387|NCT04992390|BEHAVIORAL|Brief digital imagery-competing task intervention|"First session guided by a researcher: A memory cue followed by playing the brief digital imagery-competing task with mental rotation instructions.~Option to engage in self-administered/guided sessions after the first session and record their intrusive memories (symptom monitoring)."
223876388|NCT01456013|DEVICE|RenalGuard Therapy|Induced Diuresis with matched replacement
223876389|NCT01456013|DRUG|Standard Therapy|Standard of care for patients at risk of CIN
223876390|NCT02792114|DRUG|Cyclophosphamide|
223876391|NCT02792114|BIOLOGICAL|Mesothelin-targeted T cells|
223876392|NCT02792114|DRUG|AP1903|
223876393|NCT02807779|DRUG|Dexamethasone infusion|Participants will receive dexamethasone infusion following plain balloon angioplasty
223876394|NCT02807779|DEVICE|Drug coated balloon|Participants will receive angioplasty with a drug-coated balloon following plain balloon angioplasty
223876395|NCT02807779|DEVICE|Plain balloon angioplasty|Participants will receive plain balloon angioplasty only
223876396|NCT05009862|DRUG|Rivaroxaban 2.5 Mg Oral Tablet|rivaroxaban 2.5 milligrams twice daily
223876397|NCT05009862|DRUG|Placebo|placebo
223876398|NCT05009862|DRUG|Aspirin 81Mg Ec Tab|aspirin 81 milligrams
223876399|NCT07021872|BEHAVIORAL|Tele-Positive Affect Intervention|A 4-week intervention consisting of eight skills aimed at enhancing positive affect, delivered via telephone by trained facilitators. Participants will learn skills such as gratitude, mindfulness, and positive reappraisal, with sessions held twice a week.
223876400|NCT07021872|BEHAVIORAL|Tele-Behavioral Activation Intervention|A 4-week intervention designed to promote engagement in meaningful activities, delivered through telephone by trained facilitators. The intervention will include behavior monitoring, activity planning, and social skills enhancement, with sessions held twice a week.
223876401|NCT07021872|BEHAVIORAL|Tele-Friendly Visit|An active control condition consisting of telephone-delivered friendly visits. Participants will engage in social conversation and activities to provide companionship without any specific skills training aimed at reducing loneliness. The intervention will be held within 4-week.
223876402|NCT07034092|DEVICE|ePATH System will be used to create an endoAVF|An endoAVF will be created in subjects that need fistulas for hemodialysis
223876403|NCT07041242|PROCEDURE|"ligament reconstruction using the single-bundle over-the-top technique"|"Patients who have undergone anterior cruciate ligament reconstruction using the single-bundle over-the-top technique with gracilis and semitendinosus tendons, combined with a lateral extra-articular tenodesis, will be enrolled"
223876404|NCT07043751|DRUG|TQB6411 injection|TQB6411 for injection is an antibody-conjugated drug (ADC) targeting EGFR/c-Met. After injecting intravenously, the antibody part of this product binds to the EGFR and c-Met on the surface of tumor cells to block the activation of EGFR and c-Met signaling pathways. The ADC is enrolled and transported to the lysosome through cells. The linker releases toxins after enzyme cleavage, resulting in DNA damage and cell death.
223876405|NCT06724809|DRUG|eculizumab|Participants will receive eculizumab by intravenous (IV) infusion for 52 weeks.
223876406|NCT01740531|BIOLOGICAL|S-303 Treated Red Blood Cells (RBCs)|
223876407|NCT01740531|BIOLOGICAL|Conventional, untreated Red Blood Cells|
223876408|NCT06738056|DEVICE|Nerivio|Remote electrical neuromodulation (REN) wearable device for the treatment of migraine. The device delivers electrical stimulation to the upper arm to induce conditioned pain modulation (CPM) that activates a descending endogenous analgesic mechanism. The treatment is self-administered and controlled by a smartphone application.
223876409|NCT07051980|DEVICE|Supraglottic Oxygen Delivery via an Endotracheal Tube|patients use the Supraglottic Oxygen Delivery via an Endotracheal Tube
223876410|NCT06846138|DIETARY_SUPPLEMENT|Polyherbal Formulation (PHF)|"Description: A polyherbal formulation with known beneficial effects on gut microbiota and metabolic regulation. The formulation contains selected plant extracts studied for their hypoglycemic, antioxidant, and gut microbiota-modulating properties.~Administration: Oral, daily dosage as per study protocol. Supplier: Arya Vaidya Pharmacy (AVP), Coimbatore, India (GMP-certified)."
223876411|NCT06846138|OTHER|Placebo|"Type: Placebo Comparator Description: A placebo formulation that matches PHF in appearance, texture, and administration schedule.~Administration: Oral, daily dosage as per study protocol."
223876412|NCT06846138|DRUG|Metformin (Standard Treatment for Type 2 Diabetes)|"Description: Metformin is an FDA and EMA-approved antihyperglycemic medication that improves glycemic control by reducing hepatic glucose production and enhancing insulin sensitivity.~Administration: Oral, per standard dosing guidelines. Availability: Provided to all participants per the national reimbursement scheme for T2D patients in Latvia."
223876413|NCT07070271|OTHER|Respiratory neurophysiological facilitation techniques|The respiratory neurophysiological facilitation techniques in form of (anterior basal lift, intercostal stretch, abdominal co-contraction) once a day for 5 days.
223876414|NCT07070271|OTHER|conventional chest physical therapy|conventional chest physical therapy program in form of (postural drainage, chest percussion, vibration and suction if needed) once a day for 5 days.
223876415|NCT06749028|DIETARY_SUPPLEMENT|Intervention Arm: Omega-3 + Phospholipids.|Intervention Arm: Omega-3 + Phospholipids.
223876416|NCT06749028|DIETARY_SUPPLEMENT|Comparator Arm: Omega-3 alone.|Comparator Arm: Omega-3 alone.
223876417|NCT07061067|PROCEDURE|Lumbar Spine Surgery|Patients undergoing lumbar spine surgery Presenting symptoms include lumbar back pain, lumbar radiculopathy, neurogenic claudication, lower-extremity weakness, bowel or bladder symptoms, and duration of symptoms.
223876418|NCT07058948|RADIATION|lattice radiation therapy|"Eligible patients will receive treatment using a medical linear accelerator. Within the largest tumor's gross tumor volume (GTV), spheres (0.5 - 3 cm in diameter) will be created as high - dose targets (LRT targets), spaced 2.0 - 5.0 cm apart. The LRT targets must be drawn within the GTV, avoiding blood vessels, with a margin of at least 1 cm from the GTV edge and a volume ratio of 1% - 10% of the GTV.~For a single lesion, the D95 of the GTV will be ≥1 Gy per fraction, and the D95 of the LRT target will be 8 - 12 Gy per fraction, while keeping the single - fraction dose to organs at risk as low as possible. All other irradiated metastases will receive low - dose radiotherapy at 100 - 300 cGy × 5 fractions. Brain and bone metastases will be treated with palliative radiotherapy as per clinical routine and are not included in the low - dose radiotherapy. Immunotherapy will be administered during or within one week after radiotherapy."
223876419|NCT07064694|PROCEDURE|Hybrid Parastomal Endoscopic Repair (HyPER)|Combined laparoscopic and open surgical approach involving adhesiolysis, hernia sac excision, intraperitoneal mesh fixation, and stoma revision or relocation as indicated. Standard mesh used was DynaMesh-IPST®; in selected cases, a cost-effective modification with macroporous polypropylene mesh and omental interposition was applied.
223876420|NCT06769997|DEVICE|Optilume® BPH Catheter System|The technology is based on a device/drug combination consisting of two catheters: the Optilume BPH Prostatic Pre-dilation Catheter which is a non-drug coated catheter used to start commissurotomy between the lateral lobes of the prostate and the Optilume BPH Prostatic Dilatation DCB Catheter which is a drug coated catheter used to complete the commissurotomy and transfers drug (paclitaxel) to the pre-dilated prostatic urethra and anterior commissure. Hence, the device applies a mechanical dilatation to open prostatic urethral lumen to increase urine flow, followed by the transfer of paclitaxel drug to inhibit cell proliferation and maintain this dilatation.
223876421|NCT06769997|DEVICE|Rezum Water Vapor Therapy|The Rezum system is minimally invasive therapy for LUTS secondary to BPH. The system injects water vapor at 103°C generated by radiofrequency to create thermal energy via a transurethral approach. The vapor disperses through the tissue interstices within the treatment zone (transition zone). The injection of vapor last for approximatively 9 seconds and the number of injections depends on the prostate volume and length of the prostatic urethra.
223876422|NCT07064551|BEHAVIORAL|Cognitive behavioural therapy-based stepped-care intervention|After initial clinical assessment, participants will be offered interventions based on their depressive symptom severity (Patient Health Questionnaire-9-item \[PHQ-9\]). Mild symptoms (PHQ-9=5-9): 6 weekly low intensity CBT-based group intervention sessions led by trained clinical social workers, with 2 booster sessions as necessary. Moderate symptoms (PHQ-9=10-14): 6 weekly high intensity CBT-based group intervention sessions led by trained clinical social workers, with 2 booster sessions as necessary. Moderately severe symptoms (PHQ-9≥15): high intensity individual or group CBT-based intervention. Trained peer supporters will be matched to participants to walk them through the process with regular follow-up.
223876423|NCT07064551|OTHER|Self-management booklet|The booklet incorporates components of behavioural activation, which encourages participants to engage in meaningful activities in daily life to change their mood. Trained research assistants will regularly check in with the participants to monitor their depressive symptoms.
223876424|NCT06774612|OTHER|ChatGPT-4o|OpenAI's ChatGPT-4o large language model with chat interface.
223876425|NCT07070882|DRUG|Methylprednisolone|Patients will receive a tapered dose of methylprednisolone with the standard of care pain management
223876426|NCT07069686|PROCEDURE|Ultrasound guided airway nerve block for Endotracheal intubation|Glossopharyngeal nerve block: 1.5 mL 2% lidocaine, ultrasound probe on lateral neck below mandible, landmark = hyoid bone, tilt cephalad to target pharyngeal wall near tonsil; right side needle inserted out-of-plane from superior probe edge to avoid artery. Bilateral superior laryngeal nerve blocks: out-of-plane at lateral thyroid cartilage, orient probe medially, inject 1 mL 2% lidocaine into thyrohyoid membrane between hyoid and thyroid cartilage using 25-G 25 mm needle. Bilateral recurrent laryngeal nerve blocks: translaryngeal out-of-plane, locate cricothyroid membrane below thyroid cartilage, insert 25-G 25 mm needle 1.5 cm, confirm air backflow, inject 2 mL 2% lidocaine.
223876427|NCT07069686|PROCEDURE|lidocaine topical anesthesia for Endotracheal intubation|will receive topical lidocaine 10% spray directly on the tongue and oropharynx without exceeding toxic doses.
223876428|NCT07070843|OTHER|Control Group: Standard Eye Care Group|There is no established protocol or guideline for eye care in the intensive care unit where the study will be conducted. Routine eye care involves the use of sterile gauze and sterile saline. During routine suctioning procedures, patients' eyes are not closed. If a patient is unable to achieve full eyelid closure, their eyes are covered with an eye patch or sterile gauze. The Schirmer test will be administered to both eyes on the first day (prior to the first eye care intervention), as well as on the fifth, seventh, and tenth days after eye care is performed. Signs and symptoms of eye infection and chemosis will be evaluated daily after the second eye care procedure. Data for this group will be collected, and the administration and documentation of eye care will be monitored.
223876429|NCT07070843|OTHER|Intervention Group 1: Eye Care Using an Eye Care Kit|Eye care will be performed using an eye care kit. All nursing staff in the intensive care unit will receive training regarding the contents and usage of the kit. Patients in this group will receive eye care solely using the kit, following a 4-times-daily care protocol. For patients with lagophthalmos, eyes will be covered using the eye closure pad provided in the kit. The Schirmer test will be performed on both eyes on the first day prior to the initial eye care intervention, and on the fifth, seventh, and tenth days following eye care, with results recorded. Signs of infection and chemosis will be assessed daily after the second eye care session. Data collection will be done using , and eye care administration will be tracked.
223876430|NCT07070843|OTHER|Intervention Group 2: Eye Care According to an Eye Care Protocol|"* All ICU nursing staff will be educated on the eye care protocol. A copy of the protocol will be posted on the doors of the rooms of patients receiving care under the protocol.~* Patients' ocular risk factors will be assessed daily, followed by eye care based on the protocol.~* Changes in ocular condition will be assessed and documented, and ICU physicians will be informed as necessary.~* In cases of incomplete eyelid closure, eyes will be covered upon physician notification.~* Patients will be assessed daily for signs of eye infection and conjunctival edema in accordance with the protocol. If signs of infection or complications occur during the day, they will be marked with a (+) symbol on the form.~* The Schirmer test will be applied on the first day (prior to the initial eye care session) and after eye care on days 5, 7, and 10, with results documented."
223876431|NCT07070843|OTHER|Intervention Group 3: Eye Care Using Both the Eye Care Protocol and the Eye Care Kit|"* ICU nursing staff will be educated on the eye care protocol. A copy of the protocol will be posted on the doors of the rooms of patients receiving this combined care.~* Eye care will be performed using the Eye Care Kit developed by the researchers in accordance with the protocol.~* Patients will be assessed for ocular risk factors daily, and eye care will be provided according to the management guidelines of the protocol.~* In cases of incomplete eyelid closure, the eyes will be covered with physician knowledge.~* Patients will be assessed daily for signs of infection and conjunctival edema as per the protocol. Any signs of infection or complications will be marked with a (+) on the form.~* The Schirmer test will be performed on both eyes before the first eye care session on day 1, and following eye care on days 5, 7, and 10, with results recorded."
223876432|NCT07070908|DEVICE|Antrum calibration|For antral calibration, a 50 cc balloon catheter was used to guide the staple line.
223876433|NCT07070908|PROCEDURE|Fudus calibration|"Fundus transection was performed 1 cm from the fat pad in calibrated cases (an anatomically constant area near the short gastric vessels that contains minimal fat and facilitates dissection toward the diaphragmatic crus)."
223876434|NCT07070908|PROCEDURE|No antrum calibration|In patients without antrum calibration, gastric transection was performed 5 cm from the pylorus.
223876435|NCT07070908|PROCEDURE|No fundus calibration|"Fundus transection was performed adjacent to the fat pad in no calibrated cases."
223876436|NCT07070102|OTHER|blood samples|2 blood samples of 1 mL
223876437|NCT07066735|DEVICE|ESWT|Transperineal Shockwaves that are applied once a week for 8 consecutive weeks with a protocol of 3000 pulses each; pressure: 1.8-2.0 bar and a frequency of 10 Hertz (Hz)
223876438|NCT07066735|DRUG|Phytotherapy that contains powder extract of (saw palmetto , tomato , uva ursi , pygeum and pumpkin|1capsule tob be taken twice daily for one month.
223876439|NCT07070739|DRUG|HSK44459 tablets|Orally, twice a day
223876440|NCT07070622|DRUG|patients were assigned to receive TNT or iTNT management|TNT or iTNT
223876441|NCT07070557|OTHER|neutrophil lymphocyte ratio and platelet lymphocyte ratio|explore the role of neutrophil-to-lymphocyte ratio ( NLR ) and platelet-to-lymphocyte ratio ( PLR ) in predicting mortality in hemodialysis (HD) patients
223876442|NCT07071571|DEVICE|neuromonitoring|new neuromonitorin device will use
224076654|NCT05315921|DRUG|OsrhAAT 40 mg/kg IV|"Drug: OsrhAAT 40 mg/kg IV A single dose of OsrhAAT 40 mg/kg IV infusion at a rate approximately 0.04 ml/min/kg.~Placebo: Normal Saline (0.9% Sodium Chloride)"
224076655|NCT05315921|DRUG|OsrhAAT 60 mg/kg IV|"Drug: OsrhAAT 60 mg/kg IV A single dose of OsrhAAT 60 mg/kg IV infusion at a rate approximately 0.04 ml/min/kg.~Placebo: Normal Saline (0.9% Sodium Chloride)"
224076656|NCT04138485|BIOLOGICAL|IgPro10|10% liquid formulation of human immunoglobulin for IVIG
224076657|NCT04138485|BIOLOGICAL|Placebo|0.5% human albumin solution stabilized with 250 mmol/L L-proline
224076658|NCT01899170|PROCEDURE|Deep brain stimulation|Implantation of a deep brain stimulation electrode into pain processing brain areas
224076659|NCT01899170|DEVICE|Cervel Neurotech, Multi-coil TMS|Non-invasive selective stimulation of deep brain areas using magnetic fields.
223876443|NCT07069634|OTHER|Individual training using the Teach Back Method|"Day 1 (Monday): Patients are introduced to the study; consent forms are signed, and initial forms are completed. An educational booklet is provided and explained. General information about hemodialysis and treatment is delivered using the Teach-Back Method.~Day 2 (Wednesday): Patients recall previous session topics; unclear points are clarified. Education focuses on fluid and dietary restrictions and the importance of adherence, using the Teach-Back Method.~Day 3 (Friday): Patients summarize previous content; the researcher reinforces unclear areas. Education covers medication adherence and lifestyle habits, again using the Teach-Back Method."
223876444|NCT07069998|OTHER|virtual assistant|Programming codes that interpret atrial fibrillation symptoms and design management plans based on algorithms that reflect the European Society of Cardiology (ESC) 2024 guidelines and the expertise of consultant cardiologists, finally checked and approved by a cardiologist.
223876445|NCT07069998|OTHER|Standard AF care|AF care provided via the National Health System (NHS) standard AF care system
223876446|NCT07070505|OTHER|Experimental|"* Before applying hand massage, the individual/patient's hand or arm will be evaluated for thrombus, phlebitis, ecchymosis, hematoma, deterioration in skin integrity and change in skin color in order to determine whether there is a risk.~* Hand massage application is a massage performed with western technique that includes five basic classical massage manipulations including efflorescence, petrissage, friction, tapotment and vibration.~* Massage should be performed in a way that creates light pressure on the individual, then the applied pressure should be gradually increased."
223876447|NCT07070011|COMBINATION_PRODUCT|EC/EP + ICIs|Collect blood samples from patients with small cell lung cancer before receiving immunotherapy combined with chemotherapy.
223876448|NCT07070583|PROCEDURE|Stent placement|Patients with an aorto-iliac occlusion will receive a stent, according to standard care
223876449|NCT07069842|DIAGNOSTIC_TEST|Multiplex Immunofluorescence Technology|Detect the levels of TILs (using Multiplex Immunofluorescence Technology) and H3K4me3 (using Co-Immunoprecipitation Technology) in fresh tissue samples of patients before and after immunotherapy combination treatment.Meanwhile, detect the expression of cytokines, NLR, PLR, SII, and tumor markers in peripheral blood.Immunohistochemical staining was used to detect the expression of Her-2, PD-L1, MMR (MLH1, PMS2, MSH2, MSH6), KMTs (MLL1, MLL2, SETD1A, SETD1B), specific subunits of the SET1/MLL complex (MEN1, CFP1, WDR5, RBBP5, ASH2L, DPY30), and KDMs (KDM5A, KDM5B) in patient tissue specimens.In situ hybridization with chromogenic detection was performed to assess the EBER status.
223876450|NCT07069842|DIAGNOSTIC_TEST|Co-Immunoprecipitation (Co-IP) Technology|Detect the levels of TILs (using Multiplex Immunofluorescence Technology) and H3K4me3 (using Co-Immunoprecipitation Technology) in fresh tissue samples of patients before and after immunotherapy combination treatment
223876451|NCT07069842|DIAGNOSTIC_TEST|Immunohistochemistry|Immunohistochemical staining was used to detect the expression of Her-2, PD-L1, MMR (MLH1, PMS2, MSH2, MSH6), KMTs (MLL1, MLL2, SETD1A, SETD1B), specific subunits of the SET1/MLL complex (MEN1, CFP1, WDR5, RBBP5, ASH2L, DPY30), and KDMs (KDM5A, KDM5B) in patient tissue specimens.
223876452|NCT07069842|DIAGNOSTIC_TEST|In situ hybridization with chromogenic detection|In situ hybridization with chromogenic detection was performed to assess the EBER status.
223876453|NCT07070466|DRUG|Ivonescimab|Humanized immunoglobulin G1 monoclonal antibody
223876454|NCT07070466|DRUG|5-Fluorouracil|Nucleoside metabolic inhibitor
223876455|NCT07070466|DRUG|Oxaliplatin|Platinum-based drug and organoplatinum complex
223876456|NCT07070466|DRUG|Leucovorin|5-formyl derivative of tetrahydrofolic acid
223876457|NCT07070414|BEHAVIORAL|Brief Negotiation Interview intervention (BNI) (adapted)|A brief motivational interview designed to increase motivation to reduce alcohol and/or cannabis use and engagement in treatment referral.
223876458|NCT07071038|DRUG|Switch|Participants in the switch arm will receive a new prescription for either anastrozole or exemestane at a dose of 1mg or 25mg daily, respectively. The choice of AI in the first line setting will be at the discretion of the treating oncologist. If side effects persist after the 1st line switch, the participant will have the option to switch to another AI not yet tried, or to tamoxifen at 20mg daily
223876459|NCT07071038|OTHER|Guideline Directed Intervention (GDI)|"Subjects in this group will receive a guideline-directed intervention GDI using medication and/or non-medication treatment options according to the National Comprehensive Cancer Network (NCCN) supportive care guidelines. A GDI Book was created for this trial that lists treatment options and resources for each of the common side effects of hormonal therapy and is available for providers and staff to help select treatment options. For less common side effects with limited evidence-based options, treatment will be determined in collaboration with the treating provider and PI, using best available evidence."
223876460|NCT03897127|DRUG|Cytarabine|"Induction therapy: 200 mg/m2 i.v. (continuously) d1-7~Consolidation therapy:~* Patients age 18-60 years~  o Intermediate-dose cytarabine 1500 mg/m2 i.v. q12h (3 hrs) d1-3~* Patients age \>60 years o Intermediate-dose cytarabine 1000 mg/m2 i.v. q12h (3 hrs) d1-3"
223876461|NCT03897127|DRUG|Daunorubicin|Induction therapy: 60 mg/m2 i.v. (1 hr) d1-3
223876462|NCT03897127|DRUG|CPX-351|"Induction 1:~o CPX-351 44 mg/m2 daunorubicin / 100 mg/m2 cytarabine \[100 U/m²\] i.v. (90 min) d1,3,5~Induction 2:~o CPX-351 44 mg/m2 daunorubicin / 100 mg/m2 cytarabine \[100 U/m²\] i.v. (90 min) d1,3~Consolidation therapy:~o CPX-351 29 mg/m2 daunorubicin / 65 mg/m2 cytarabine \[65 U/m²\] i.v. (90 min) d1,3"
224076660|NCT01899170|DRUG|11C-Carfentanil|PET-radioligand for functional brain imaging to assess opioid binding. The compound is a potent synthetic opioid.
224076661|NCT05810545|OTHER|Per- and polyfluoroalkyl substances (PFAS)|Assess the association between exposure to per- and polyfluoroalkyl substances (PFAS) via drinking water in pregnancy and birth outcomes (i.e. growth retardation, premature birth, and congenital developmental defects) and maternal morbidity (gestational hypertension, diabetes and preeclampsia) in a prospective population-wide register based cohort.
224076662|NCT03873155|BEHAVIORAL|Mindfulness Based Cognitive Therapy|Mindfulness based cognitive group therapy (MBCT) is a structured eight-week programme (although an extra introductory week will be added in the current study) that combines mindfulness-based exercises with cognitive therapy.
224076663|NCT03119519|RADIATION|Local Definitive Radiotherapy|three-dimensional conformal therapy or intensity modulated radiation therapy
223876463|NCT06932120|BEHAVIORAL|Internet-based treatment (GROw) combined with face-to-face videoconferencing sessions with a therapist in BF-GROw group|The treatment that will be applied is an internet-based treatment (GROw) (Tur et al., 2021, 2022)combined with face-to-face videoconferencing sessions with a therapist (blended) . This protocol has 8 weekly modules and lasts between 8 and 12 weeks. The modules included are: 1) Welcome (starting the program), 2) Understanding reactions to loss, 3) Coping with loss, 4) Loss integration and restoration (first steps), 5) Deeping integration and restoration of loss, 6) Consolidating loss integration and restoration, 7) Self-care, guilt, and forgiveness in the grieving process, and 8) Evaluating progress and looking to the future. BF-GROw group will receive a treatment module every 10-12 days. This protocol is available online: (https://psicologiaytecnologia.labpsitec.es).
223876464|NCT06932120|BEHAVIORAL|Internet-based treatment (GROw) supported by the App developed which contains the EMA and EMI tools in iGROw group.|The treatment that will be applied is an internet-based treatment (GROw) (Tur et al., 2021, 2022) supported by the App developed which contains the Ecological Momentary Assessment (EMA) and Ecological Momentary Intervention (EMI) tools . This protocol has 8 weekly modules and lasts between 8 and 12 weeks. The modules included are: 1) Welcome (starting the program), 2) Understanding reactions to loss, 3) Coping with loss, 4) Loss integration and restoration (first steps), 5) Deeping integration and restoration of loss, 6) Consolidating loss integration and restoration, 7) Self-care, guilt, and forgiveness in the grieving process, and 8) Evaluating progress and looking to the future. This protocol is available online: (https://psicologiaytecnologia.labpsitec.es).
223876465|NCT02181660|DRUG|Gilteritinib|oral
223876466|NCT03764787|COMBINATION_PRODUCT|Radiation+PD-1 Ab|combination of proton radiotherapy with PD-1 antibody
223876467|NCT01700296|BEHAVIORAL|Best care|"Best Care: subjects are randomly assigned to the Best care regardless MRC class and severity of symptoms through:~1. 10 weeks of rehabilitation (2 hours, 2 times a week) by Region Zealand's instructions on sundhed.dk. COPD rehabilitation includes physical exercise, smoking cessation, medication, nutrition education and psychosocial support and patient education. Rehabilitation provided by a multidisciplinary effort with lung nurse, dietician and physiotherapist according to national and international guidelines (1.5) (6) (24) (25)~2. Outpatient follow-up every 3 months, a total of 5 visits, and during these visits various subjective, clinical, paraclinical and invasive parameters."
223876468|NCT02051491|DEVICE|BP-NCPAP|Initial settings of BP-NCPAP will be a lower level PEEP of 5 cm H2O and a higher level PEEP of 8 cm H2O at a cycle rate of 20 per minute with 1 second at the higher PEEP per cycle. The settings can then be adjusted and titrated up to a maximum of 7 and 10 cm H2O for the lower and higher PEEPs respectively at a maximum rate of 30 cycles per second based on FiO2 requirements.
223876469|NCT02051491|DEVICE|NIHFV|The initial settings will be a MAP of 8 cm H2O, frequency of 10 Hz, and amplitude of 20 cm H2O. The maximum allowable MAP will be 10 cm of H2O. The range of frequency allowed will be 6 - 14 Hz. Both frequency and amplitude will be adjusted to try and achieve palpable/visible chest movement and to achieve target CO2 levels for the particular patient.
223876470|NCT06334666|OTHER|Encourage using pedometer|MASLD patient used pedometer recording actively with encourage by care provider or investigator
223876471|NCT05290597|BIOLOGICAL|IBI363|a mutated IL-2 cytokine fused to an anti-PD-1 antibody to combine IL-2 pathway stimulation with checkpoint blockade.
223876472|NCT06155708|DIETARY_SUPPLEMENT|Ketone|\- Ketone monoester supplement in the form of (R)-3-hydroxybutyl (R)-3-hydroxybutyrate based on participants' body weight (0.45ml/kg body weight) ingested with water and vanilla-flavored stevia in a total volume of 100 ml.
223876473|NCT06155708|DIETARY_SUPPLEMENT|Water|100 ml water combined with 10ml bitter flavor and vanilla-flavored stevia
223876474|NCT05655819|DRUG|Glutamine|5 gram powder, one rounded teaspoon, dissolved in 8 ounces of water or juice prior to drinking) taken orally three times per day
223876475|NCT05655819|DRUG|Placebo|Lactose powder dissolved in 8 ounces of water or juice prior to drinking, taken orally three times per day. Looks exactly like the study drug, but it contains no active ingredient.
223876476|NCT05941234|OTHER|Biological biomarker analysis|Collection of tumor and blood samples at T0 (surgery) and T1 (6 months follow-up) Tumor microenvironment and blood multi-omics analysis In-depth functional characterization of tumor microenvironment Cancer stem cells generation and drug testing Data integration by business intelligence and development of AI-based prognostic markers
223876477|NCT05786482|BEHAVIORAL|Online mind-body wellness program|Online program (mindful movement, meditation, breathwork, psychology-based coping skills program)
223876478|NCT05786482|BEHAVIORAL|Online mind-body wellness program + Weekly Check-ins|Online program (mindful movement, meditation, breathwork, psychology-based coping skills program) + brief weekly check-ins
223876479|NCT06530212|PROCEDURE|SGJIB|sleeve gastrectomy with jejunoileal bypass with anastomosis between the jejunum at about 100 cm from the duodeno-jejunal flexure and the ileum at 250 cm from the ileocaecal junction.
223876480|NCT06530212|PROCEDURE|SAS-JB|single anastomosis sleeve jejunal bypass (SAS-JB) with biliary limb equal one third of total intestinal length.
223876481|NCT06247371|BEHAVIORAL|Decision aid|The Singapore developed HF DA is a A3 sized one-page poster designed to convey information about HF medications options (ACEI and ARNI only) and their pros and cons. The DA contains informative attributes of both medications that are presented side by side for comparison. These attributes include subsidized cost, frequency of use, duration of use, route of administration, low blood pressure side effect rate and benefits such as non-hospitalization rate and survival rate.
223876482|NCT03783026|DRUG|Apremilast|Tablets for oral administration
223876483|NCT05413655|DRUG|EX039|The dosage form of EX039 is the capsule for oral use
223876484|NCT05413655|DRUG|Placebo|The dosage form of Placebo is the capsule for oral use
223876485|NCT06062069|DRUG|CT-868|CT-868 is an investigational medication administered subcutaneously via a pre-filled pen injector device.
223876486|NCT06062069|DEVICE|CT-868 Pen Injector|The CT-868 pen injector is a multi-dose, single-participant, disposable pen.
223876487|NCT06062069|DRUG|CT-868 Pen Injector, Placebo|The placebo pen injector is identical and contains the same ingredients except for CT-868.
223876488|NCT05391750|BIOLOGICAL|Tocilizumab|Given IV
223876489|NCT05391750|DRUG|Venetoclax|Given PO
223876490|NCT06429605|DRUG|duloxetine|In addition to our standard clinical protocol, study patients were administered 60 mg oral duloxetine 2 hours before surgery and 24 hours after surgery
223876491|NCT06060158|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|6 sessions
223876492|NCT05443594|DEVICE|Phase 1: FARAPULSE Ablation System|PHASE 1: Pulsed Field Ablation to isolate the Pulmonary Veins and Posterior Wall using the FARAPULSE Ablation System.
223876493|NCT05443594|DEVICE|Phase 2: FARAPULSE Ablation System|PHASE 2: Pulsed Field Ablation to isolate the Pulmonary Veins, Posterior Wall and Cavo-Tricuspid Isthmus using the FARAPULSE Ablation System.
223876494|NCT06464458|OTHER|management on hydroxyurea by therapeutic pharmacological monitoring|"HU dose adaptation according:~* HU AUC with a target AUC and subject to haematological tolerance.~* T2H (at V2, V3, V4), subject to haematological tolerance."
223876495|NCT06423183|BEHAVIORAL|A Mindful Approach to Building a Resilient Healthcare Workforce (RENEW)|Synchronous, 4-month intervention that teaches skills in mindfulness, stress management, and resilience as an individual and as a team. Sessions occur monthly and include a 1 hour in-person introductory session followed by 3 50-minute virtual sessions.
223876496|NCT05508334|DRUG|RC88|Every 2 weeks for a maximum of 2 years
223876497|NCT01853748|DRUG|Trastuzumab|
223876498|NCT01853748|DRUG|Paclitaxel|
223876499|NCT01853748|DRUG|Trastuzumab emtansine|
223876500|NCT05115968|PROCEDURE|Tonsillectomy|Subjects who are diagnosed to have OSA with adeontonsillar enlargement will undergo adenotonsillectomy if it is clinically indicated. Adenotonsillar tissue will be obtained for single cell sequencing. Controls will be non-OSA subjects (with PSG OAHI \<1/hour) who undergo adenotonsillectomy for other reasons such as recurrent tonsillitis.
223876501|NCT06191562|DEVICE|Tympanostomy tube|Participants will receive an ear tube in the usual location (anterior-inferior) in one ear and a new location (posterior-inferior) in the other ear during surgery.
223876502|NCT03575013|DRUG|Avelumab|Avelumab is a fully human anti-programmed death ligand 1 (PD-L1) IgG1 antibody
223876503|NCT03575013|DRUG|Docetaxel|Docetaxel is a antineoplastic agent belonging to the taxoid family
223876504|NCT05289310|OTHER|Normobaric hypoxia (NH)|Low oxygen exposure to mimic \~8500 feet elevation (experimental).
223876505|NCT05289310|OTHER|Normobaric normoxia (NN)|Normal oxygen exposure to mimic sea level conditions (sham comparator).
223876506|NCT06102070|OTHER|Blood samples drawing|10 ml of periferal blood
223876507|NCT06102070|OTHER|Skin biopsy|Skin biopsy only in some index cases depending of the pathology at the recruitment
223876508|NCT03342027|DRUG|Bupropion|medication for smoking cessation
223876509|NCT03342027|BEHAVIORAL|Positively smoke free|an 8 session, tailored behavioral intervention for treating tobacco dependence
223876510|NCT03342027|OTHER|Brief advice to quit smoking|Standardized brief advice to quit smoking (standard of care)
223876511|NCT05958719|DRUG|Chidamide|chidamide 30mg biw, p.o, 21 days for a cycle.
223876512|NCT05958719|DRUG|Azacitidine|75mg/m2, continuous i.h. on day 1-7，21 days for a cycle.
223876513|NCT05958719|DRUG|liposomal mitoxantrone|12mg/m2， d1,21 days for a cycle.
223876514|NCT05958719|DRUG|prednisone|60mg/m2，d1-5,21 days for a cycle.
223876515|NCT03566043|GENETIC|RGX-121|Recombinant adeno-associated virus serotype 9 capsid containing human iduronate-2-sulfatase expression cassette
223876516|NCT05583136|DEVICE|Parietal tACS combined with visuo-attentional training|Parietal tACS combined with visuo-attentional training
223876517|NCT05583136|DEVICE|Sham (placebo) tACS combined with visuo-attentional training|Sham (placebo) tACS combined with visuo-attentional training
223876518|NCT05583136|DEVICE|Sham (placebo) tACS combined with phonics training|Sham (placebo) tACS combined with phonics training
223876519|NCT06462118|DRUG|Astegolimab|Participants will receive one SC dose of astegolimab in the abdomen, upper arm, or thigh.
223876520|NCT03863288|PROCEDURE|Functional MRI (fMRI)|Functional MRI (fMRI) scan with affective/cognitive tasks
223876521|NCT03863288|DRUG|Oxytocin Intranasal Spray 8 International Unit (8IU)|Oxytocin intranasal spray liquid administration
223876522|NCT03863288|DRUG|Oxytocin intranasal spray 24 International Unit (24IU)|Oxytocin intranasal spray liquid administration
223876523|NCT03863288|DRUG|Oxytocin intranasal spray 48 International Unit (48IU)|Oxytocin intranasal spray liquid administration
223876524|NCT03863288|DRUG|Oxytocin intranasal spray 80 International Unit (80IU)|Oxytocin intranasal spray liquid administration
223876525|NCT03863288|DRUG|Placebo|Placebo intranasal spray liquid administration
223876526|NCT06199856|DIAGNOSTIC_TEST|ultrasound scan|ultrasound scan
223876527|NCT04680390|BEHAVIORAL|Standard of care engagement practices|The control arm will be standard-of-care, which is as-needed case management for justice-involved women. The goals of case management services are to reduce recidivism, mitigate behavioral challenges, strengthen public safety, and build self-sufficiency skills. Case managers refer clients to appropriate services in the community (e.g., housing, food).
224076664|NCT03119519|DRUG|No Local Definitive Radiotherapy|Standard platinum-based doublet chemotherapy or EGFR-TKI (Gefitinib or Erlotinib) alone, according to gene test.
223876528|NCT04680390|BEHAVIORAL|Peer Navigators Addressing INtersectional Stigma to Improve HIV Prevention Among Criminal-Justice Involved Women|kINSHIP is a peer-led navigator intervention to address intersectional stigma and improve PrEP treatment initiation and engagement for justice-involved women. The key components of the kINSHIP intervention are to: 1) increase social support; 2) increase self-efficacy in accessing PrEP services; 3) enhance access to healthcare services; 4) improve adaptive coping skills to manage experiences of intersectional stigma.
223876529|NCT06489262|BEHAVIORAL|"Healthy Together (Juntos)"|"Parent-adolescent dyads will log in to a secured website for six months. The intervention will be delivered primarily through smartphones and will include didactic content on healthy lifestyle behaviors (for parents/adolescents), family behavior change content for setting weekly goals and self-monitoring health behaviors (for parents/adolescents), and positive parenting content (for parents only), all of which were developed in accordance with participant feedback based on formative intervention development work. In addition, and to increase participant compliance/reduce attrition often observed in digital health interventions, human support (supportive accountability) will be provided. Specifically, each family will be assigned a coach who will use video conferencing software to engage in approximately weekly (during the first 3 months), and monthly (during the following 3 months) 20-30-minute sessions regarding the family's progress throughout the intervention period."
224076665|NCT05358847|DEVICE|Sofwave|The Sofwave System, comprised of an applicator and a console, generates high intensity, non-focused ultrasonic energy which can be delivered percutaneously to tissues.
223876530|NCT05642598|BEHAVIORAL|Pivot for Vape|"Pivot for Vape vaping cessation smartphone app and program"
223876531|NCT06026319|DRUG|CD79b-19 CAR T cells|Intravenous infusion
223876532|NCT06026319|DRUG|Cyclophosphamide|Intravenous infusion
223876533|NCT06026319|DRUG|Fludarabine|Intravenous infusion
223876534|NCT04940091|DRUG|Epidural analgesia|Epidural analgesia is performed with a mixture of local anesthetics (ropivacaine) and opioids (sufentanil).
223876535|NCT05348889|DRUG|1A46 Injection|Participants will receive IV 1A46 weekly for Cycles 1-8, then every 3 weeks (Q3W) for Cycles 9-16 (21 days/cycle).
223876536|NCT06312904|PROCEDURE|paravertebral block|After cardiac surgery, the anesthesiologist will use 3mg/kg of 0.375% ropivacaine to conduct paravertebral block.
223876537|NCT06312904|PROCEDURE|Local infiltration anesthesia|After cardiac surgery, the anesthesiologist will use 3mg/kg of 0.375% ropivacaine to conduct local infiltration anesthesia.
223876538|NCT06826742|DRUG|Intravenous line (IV) Methadone|"Subjects will receive standardized spinal anesthesia without intrathecal morphine (intrathecal 1.6-2 mL 0.75% bupivacaine + dextrose, 15 mcg fentanyl) and intravenous methadone (0.2mg/kg total body weight up to max dose of 20 mg, with saline added to make total volume 2 mL)~The Intravenous line (IV) methadone will be administered after cord clamping and administration of uterotonics with the dose of medication divided into 4 equal aliquots each administered 5 minutes apart."
223876539|NCT06826742|DRUG|Intrathecal Morphine|"Subjects will receive standardized spinal anesthesia with intrathecal morphine 150 micrograms and no methadone (2cc dose of IV normal saline)~The Intravenous line (IV) saline will be administered after cord clamping and administration of uterotonics with the dose of medication divided into 4 equal aliquots each administered 5 minutes apart."
223876540|NCT06780813|BEHAVIORAL|Supplemental oxygen therapy|In this grou participants will receive supplemental oxygen in the form of a Venturi mask upon low oxygen saturation in oximetry (SaO2\<95%) and a nasal oxygen mask in all other cases during the first 2 postoperative days
223876541|NCT06782529|DRUG|Triamcinolone Acetonide Low Dose|"Subjects will receive a reduced dose of 20mg of triamcinolone acetonide.~Total injection volume of 5ml, consisting of:~* 0.5ml triamcinolone acetonide (20mg)~* 4.5ml lidocaine (45mg)"
223876542|NCT06782529|DRUG|Triamcinolone Acetonide Standard Dose|"Subjects will receive the standard of care dose of 40mg triamcinolone acetonide~Total injection volume of 5ml, consisting of:~* 1ml triamcinolone acetonide (40mg)~* 4ml lidocaine (40mg)"
223876543|NCT05686408|DRUG|TNX-601 ER|Patients will take 1 tablet orally once daily for 6 weeks.
223876544|NCT05686408|DRUG|Placebo|Patients will take 1 tablet orally once daily for 6 weeks.
223876545|NCT05810259|DEVICE|Caravan Wellness app|Caravan Wellness is a digital platform that offers brief mindfulness and light to moderate physical activity modules, among many others (e.g., Pilates, Yoga, Barre, meditation, etc.), to enhance overall individual well-being.
223876546|NCT06247332|OTHER|Review of available clinical data sources related to use cases|There will be a review of available clinical data sources related to use cases. In addition, this information will be complemented by a cohort of anonymized retrospective data of 100 cases obtained from the clinical information resulting from the assistance to COVID-19 patients managed by the Primary Care Health District of Sevilla Norte and the Infectious Diseases Department of the Virgen Macarena University Hospital
223876547|NCT05029258|PROCEDURE|Biopsy of tumour|Cervical tumour biopsy during treatment. This will be used for gene expression (RNA) analysis against a hypoxia associated gene signature.
223876548|NCT05029258|DIAGNOSTIC_TEST|MRI scans|Multiple magnetic resonance imaging (MRI) scans before and during treatment using oxygen enhanced (OE) / tissues oxygen level dependent (TOLD) sequence
223876549|NCT02576509|DRUG|Nivolumab|Specified Dose on Specified Days
223876550|NCT02576509|DRUG|Sorafenib|Specified Dose on Specified Days
223876551|NCT06835361|DRUG|Clotrimazole+Lactulose.|Vaginal suppositories containing clotrimazole (100 mg) and lactulose (300 mg)
223876552|NCT06835361|DRUG|Canesten (Clotrimazole)|Vaginal tablets containing clotrimazole (100 mg)
223876553|NCT06835361|DRUG|Lactulose|Vaginal suppositories containing lactulose (300 mg)
223876554|NCT04645628|OTHER|MRI examination|All subjects (healthy subjects and patients) will have an MRI examination with optimized sequences
223876555|NCT06830083|RADIATION|Hypofractionated Radiation Therapy|Hypofractionation regimen: Total dose to the chest wall and the regional lymph nodes is 4050 cGy, and each fraction consists of 270 cGy per day(daily, Monday through Friday )
223876556|NCT06830083|RADIATION|Conventional fraction radiotherapy|Total dose of plan tumor volume is 5000 cGy，and each fraction will consist of 200 cGy per day. 25 fractions(daily, Monday through Friday) to the chest wall and to the supraclavicular (with or without axillary) lymph nodes.
223876557|NCT06832033|OTHER|Exercise|12 weeks of concurrent training, which is understood as a combination of strength and aerobic exercises, not necessarily in the same training session. The weekly frequency will be 3 times per week. The aerobic component of the session will last between 30 and 50 minutes (increasing as the weeks go by) and the strength work will be made up of 8 exercises (3 upper body and 5 lower body). The intensity of the training will be individualized and always moderate.
223876558|NCT02627508|DRUG|Pregnenolone|orally administered Pregnenolone capsules
223876559|NCT02627508|DRUG|Placebo|orally administered placebo capsules
223876560|NCT06685445|DRUG|Active Comparator: Continue Erector Spinae Plane Block|For the block, the ultrasound (USG)probe will be placed longitudinally 2-3 cm lateral to the transverse process of the T4-5 vertebra. The erector spinae muscle will be visualized above the hyperechoic transverse process. Using in plane technique, the block needle will be advanced in the cranio-caudal direction and 5 ml of saline will be injected under the erector spinae muscle to confirm the block site. After the block site is confirmed, 30 ml of 0.25% bupivacaine (Marcain 0.5%® AstraZeneca, England) will be administered. The block catheter (Perifix® Braun, Germany) will then be inserted to block area
224076666|NCT03838224|OTHER|dry needling|"Participants allocated in this group will receive a single session of dry needling of the obliquus capitis inferior. Prior to the intervention, participants will receive information about the procedure and will be free to withdraw. The needle was shown to the participant before the intervention. Participants will be requested to lie in prone on the plinth. Participants' skin will be sterilized with antiseptic spray for the skin. The therapist will clean his hands and use sterilized gloves. The needle will be moved up and down within the muscle, using a fast-in and fast-out technique. Needle insertions will be repeated 12 times."
223876561|NCT06685445|DRUG|Active Comparator: Continue Erector Spinae Plane Block + Serratus Anterior Plane Block|For ESPB, USG probe will be placed longitudinally 2-3 cm lateral to the transverse process of the T4-5 vertebra. The erector spinae muscle will be visualized above the hyperechoic transverse process. Using in plane technique, the block needle will be advanced in the cranio-caudal direction and 5 ml of saline will be injected under the erector spinae muscle to confirm the block site and 30 ml of 0.25% bupivacaine (Marcain®) will be administered. The block catheter (Perifix®) will be inserted. For SAPB, the USG probe will be placed parasagittal to the mid-axillary line at the 5th-6th rib level and the anechoic shadow of the costa together with the latissumus dorsi and serratus anterior muscles will be visualized. Then using in plane technique, the block needle will be advanced in the cranio-caudal direction and 5 ml of saline will be injected under the serratus anterior muscle and the block site will be confirmed and 30 ml of 0.25% bupivacaine will be administered.
223876562|NCT03746054|COMBINATION_PRODUCT|Optimal medical treatment|Life style modifications, Monitoring of the risk factors and Optimal medical treatment Lipid-lowering treatment, anti-platelet treatment and ACEi or AT2 antagonists treatment for a total duration of 24 months
223876563|NCT03746054|COMBINATION_PRODUCT|usual clinical practice|usual clinical practice in each center
223876564|NCT06790537|DRUG|Pregabalin 75 mg|75 mg of pregabalin will be given at night for the intervention group along with emollient local application
223876565|NCT06790537|OTHER|Placebo Oral Capsule|placebo capsule will be identical in appearance to the pregabalin capsule. it will be given at the same time of the day like pregabalin. same Emollient which is used in the Intervention arm will be applied locally on the areas of itching, morning after bathing .
223876566|NCT06788145|BEHAVIORAL|Social Support Single-Session Intervention|Single-session intervention to increase self-efficacy, social support, help-seeking, and recovery-oriented behaviors to address disordered eating.
223876567|NCT05873062|DRUG|AUT00201|Single oral dose
223876568|NCT05873062|DRUG|Placebo|Single oral dose
223876569|NCT06546657|OTHER|Breakfast|Breakfast meal
223876570|NCT02514525|DEVICE|CryoBalloon Ablation System|CryoBalloon Ablation System, a balloon-based cryotherapy device, provides controlled ablation for the treatment of BE. Deployed through the working channel of an endoscope, the Balloon is simultaneously inflated and cooled with an inert cryogen (nitrous oxide) delivered from the handle that ablates the BE cells upon contact with the esophagus.
223876571|NCT01999062|OTHER|IMRT + CT + MR scan|
223876572|NCT05589220|OTHER|Music Intervention|Music therapy carried out with MUSIC CARE©
223876573|NCT05589220|DRUG|Nicotine replacement|NRT: Nicotine Patch, Nicotine Gum
223876574|NCT03595059|DRUG|ABBV-155|Intravenous (IV) Infusion
223876575|NCT03595059|DRUG|Paclitaxel|Intravenous (IV) Infusion
223876576|NCT03595059|DRUG|Docetaxel|Intravenous (IV) Infusion
223876577|NCT06694857|DRUG|HA filler|patient will receive FDA approved dosages of filler to the lower face region to treat facial contour or asymmetry, as per FDA approved indications. Patients are limited to 20 mL of any JUVÉDERM® injectable gel per 60 kg (132 lbs) body mass per year. Prior to injection patients will be imaged with 3-dimensional photogrammetry. Subjects will return post-injection in 2 weeks, 1 month, and 3 months for re-imaging.
223876578|NCT06651255|PROCEDURE|Optimized management|systematic gastrointestinal and nasal endoscopic exploration, local endoscopic treatment whenever applicable,prophylaxis with stepwise dose escalation of VWF concentrate and use of antiangiogenic drugs in patients with severe GI angiodysplasia-related bleeding
223876579|NCT06651255|PROCEDURE|Standard of care management|Standard of care management
223876580|NCT04418271|BEHAVIORAL|Prehabilitation- new form of care|The participants in the intervention group take part in a shared decision-making (SDM) conference to plan the intervention. The therapeutic content of the prehabilitation is defined individually for each patient in the SDM conference. Prehabilitation will be a structured and individually tailored 3-week program.
223876581|NCT04847479|BEHAVIORAL|COVID-19 self-test|Up to 3 COVID-19 self-test kits will be given to individuals who have tested positive for COVID-19. Participants will be instructed to give test kits to close contacts who have been exposed to them.
223876582|NCT04847479|BEHAVIORAL|COVID-19 test referral|Text messages with testing information will be given to individuals who have tested positive for COVID-19. Participants will be instructed to share text messages with close contacts who have been exposed to them.
223876583|NCT05078528|DEVICE|Multimodal Mobile Colposcope (MMC)|Women referred for colposcopy due to abnormal cervical screening or follow-up for a history of dysplasia will be recruited into the experimental group of the study. Imaging of study participants will take place during the colposcopy examination.
223876584|NCT01285479|DRUG|Fingolimod|fingolimod 0.5 mg/day, including generic versions of fingolimod
223876585|NCT06703177|DRUG|SHR-1826|SHR-1826
223876586|NCT06703177|DRUG|SHR-4642|SHR-4642
223876587|NCT06703177|DRUG|SHR-9839|SHR-9839
223876588|NCT06703177|DRUG|SHR-8068|SHR-8068
223876589|NCT06703177|DRUG|Bevacizumab Injection|Bevacizumab Injection
223876590|NCT06703177|DRUG|Fluorouracil Injection|Fluorouracil Injection
223876591|NCT06703177|DRUG|Calcium Folinate Injection|Calcium Folinate Injection
223876592|NCT06703177|DRUG|Adebrelimab Injection|Adebrelimab Injection
223876593|NCT03725722|DRUG|Delgocitinib cream|Cream for topical application
223876594|NCT03725722|DRUG|Delgocitinib cream vehicle|The cream vehicle is similar to the delgocitinib cream except that it does not contain any active ingredient.
223876595|NCT05505045|BEHAVIORAL|CO-OP Procedures|CO-OP is a metacognitive strategy training intervention that will be used in this study. First, five functional, everyday life goals are identified collaboratively by the participant and interventionist. In the second meeting, we introduce the approach to the subject and teach the global cognitive strategy (i.e., GOAL-PLAN-DO-CHECK). In all subsequent sessions, this strategy is used as the main problem-solving framework to facilitate skill acquisition.The subject identifies a GOAL, and then is guided by the therapist to discover a PLAN to potentially achieve the goal. The subject is then asked to DO the plan (if feasible during the therapy session otherwise asked to complete at home prior to the next treatment session), and subsequently to CHECK to see if the plan worked, i.e. the goal was achieved. This process is repeated until satisfactory performance is met for each established goal.
223876596|NCT05505045|BEHAVIORAL|Attention Control Procedures|Individuals in the attention control group will have dose-equivalent, weekly virtual contact through the Zoom platform for 12-weeks with a a trained interventionist not involved in CO-OP treatment. The control group will control for interpersonal interaction, maturation effects, and testing effects. The focus of each session will include: (1) social interaction characterized by warmth/empathy and (2) provision of usual care CRCI educational resources (e.g. exercise, using memory aids, minimizing distractions) from MD Anderson Cancer Center. These recommendations will be provided without further instruction. Any questions that arise regarding CRCI the subject is experiencing will be answered. The therapist will debrief with the subject on any changes in CRCI symptoms. The content and duration of each call will be tracked. Each session will be recorded with two randomly selected and reviewed for fidelity.
223876597|NCT05678699|BEHAVIORAL|Medicaid healthcare quality interventions (equity payment and obstetric bundled payment)|"This study has two components, with the first component being examined in Aim 1 and the first and second components being examine in aim 2.~1\) health equity incentive payment program makes available $26 million annually in Medicaid managed care organization (MCO) payments to plans that improve access to timely prenatal care and well-child visits among Black beneficiaries. The equity-focused obstetric care bundled payment model provides incentives for clinicians to improve on a wide range of pregnancy health outcomes, and specifically incentivizes improvements among Black beneficiaries"
223876598|NCT05678699|BEHAVIORAL|Doula|"This study has two components, with the first component being examined in Aim 1 and the first and second components being examine in aim 2.~1. health equity incentive payment program makes available $26 million annually in Medicaid managed care organization (MCO) payments to plans that improve access to timely prenatal care and well-child visits among Black beneficiaries. The equity-focused obstetric care bundled payment model provides incentives for clinicians to improve on a wide range of pregnancy health outcomes, and specifically incentivizes improvements among Black beneficiaries.~2. care intervention by coverage of doula services for all Medicaid beneficiaries across Pennsylvania."
223876599|NCT05678699|BEHAVIORAL|Standard Care|Participants receive standard care without quality interventions or doula care
223876600|NCT05154825|OTHER|Imaging-Observational|Preoperative standing and supine, intraoperative pre- and post-correction, and postoperative standing imaging as well as imaging collected during follow-up exams for a year following surgery
223876601|NCT05663034|BEHAVIORAL|Mindfulness-based treatment for insomnia (MBTI)|A 6-week intervention that uses the principles and practices of mindfulness meditation along with behavioral strategies (stimulus control, sleep restriction therapy) to reduce symptoms of insomnia
223876602|NCT05663034|BEHAVIORAL|Cognitive behavioral therapy for insomnia (CBT-I)|Standard of care for adults with chronic insomnia. 6-week program that uses behavioral techniques to decrease psychophysiological arousal and increase sleep propensity to deepen and consolidate sleep.
223876603|NCT01495806|DRUG|Glucomannan|2 x 5g
223876604|NCT01495806|DRUG|placebo|glucose 5 g
223876605|NCT06103825|DRUG|Solriamfetol|solriamfetol : QD，PO，Day 1-Day 84；
223876606|NCT06103825|DRUG|Placebo|Placebo :QD，PO，Day 1-Day 84
223876607|NCT04122456|RADIATION|Ultraviolet B Radiation|One skin punch biopsy will be taken to the laboratory for exposure to ultraviolet B radiation. After 1-hour incubation, the biopsies will be bisected in half.
223876608|NCT04122456|OTHER|No Ultraviolet B Radiation|One skin punch biopsy will be taken to the laboratory and will be kept as a non-irradiated control.
223876609|NCT04354337|BEHAVIORAL|Sleep Innovations for Preschoolers with Arthritis (SIPA)|The SIPA intervention is interactive and personalized. Every week, parent will receive an email sent automatically through the system with instructions for this week's activity, designed to take about 30 minutes to complete. The SIPA weekly modules will begin with a learning module, then direct participants through goal setting, anticipated barriers, and problem solving. The intervention site will include fillable responses to queries, instructions, and assignments. Tasks for parents and their young children will use multimedia elements to enhance delivery of information, such as links to videos and pictures targeting self-efficacy, motivation, and patient activation. Submissions and progress will be monitored by the study team, who will send email, call or text with reminders (whichever the family prefers) and answer questions as needed, review progress, and help problem solve any technology issues or barriers to implementing skills.
223876610|NCT04507503|DRUG|TAS-120|Futibatinib 20mg QD orally on a 28 days cycle
223876611|NCT04925375|DRUG|Abatacept|Abatacept is a selective costimulation modulator, inhibiting T lymphocyte activation by binding to CD80 and CD86, thereby blocking interaction with CD28. Orencia solution supplied in a prefilled syringe should be refrigerated at 2C to 8C (36F to 46F). Orencia should not be used beyond the expiration date on the prefilled syringe. The product should be protected from light by storing in the original package until time of use. The prefilled syringe should not be frozen.
223876612|NCT04925375|OTHER|Placebo|The composition of the placebo for Orencia is the same as the active study drug without the abatacept. The placebo will be packaged and labeled as described above for the Orencia prefilled syringes. To maintain the blind, injection volumes will be the same as the active treatment.
223876613|NCT06582212|DEVICE|Mymovesmatter mobile application|Patients with Parkinson's disease will use a mobile application (Mymovesmatter) to evaluate changes in motor and non motor symptoms during their hormonal cycles.
223876614|NCT03397108|OTHER|The IBD group was divided into 2 subgroups: with or without anti-TNF antibody use|This observational study enrolled women with IBD, and some of them were receiving a treatment with anti-TNF monoclonal antibody, which was prescribed by their responsible prescribers at a standard dose and dosing interval.
223876615|NCT02097758|DEVICE|Transcatheter device closure|"Closure of atrial septal defect with device~* choosing device size with 3D image and the formula~* we do not use sizing balloon for choosing of the device size"
223876616|NCT05231421|BEHAVIORAL|Focus Group|Each focus group will consist of 5-10 participants. They will first introduce to each other and be asked to keep information shared during the session private. The moderator will initiate some questions for the group to discuss. Prompt and follow-up questions will be asked. There is no right or wrong answer for each question and no sensitive questions will be asked. The conversations during the focus group discussion will be recorded. The group will be debriefed about the purpose of the study and have a chance to ask any questions about the study if they have. The focus group discussion for each session will last about 60-90 minutes.
223876617|NCT04649008|DIAGNOSTIC_TEST|3T Magnetic Resonance Imaging|Magnetic resonance imaging acquired at a field strength of 3 Tesla.
223876618|NCT04649008|DIAGNOSTIC_TEST|Intracranial electroencephalography recordings|Epilepsy patients may undergo implantation of intracranial electroencephalography (iEEG) electrodes for localization of epileptogenic foci, which also provide a means to record localized brain activity during memory or other tasks for research purposes.
223876619|NCT04649008|DIAGNOSTIC_TEST|7T Magnetic Resonance Imaging|Magnetic resonance imaging acquired at a field strength of 7 Tesla.
223876620|NCT06007495|DEVICE|Investigational full-face mask with expiratory washout|With cross-over in randomized order, mask worn for 30 minutes with prescribed single-limb non-invasive ventilation
223876621|NCT06007495|DEVICE|Conventional full-face mask - single-limb|With cross-over in randomized order, conventional mask such as RT077, worn for 30 minutes with prescribed single-limb non-invasive ventilation
223876622|NCT06007495|DEVICE|Conventional full-face mask - dual-limb|With cross-over in randomized order, conventional mask such as RT076, worn for 30 minutes with prescribed dual-limb non-invasive ventilation
223876623|NCT06815042|BIOLOGICAL|Autologous Platelet-Rich Plasma (PRP) Injection|Participants will receive autologous PRP injections prepared from their own blood to treat elbow tendinopathy. PRP is a plasma product with a 3-5 times higher platelet concentration than normal blood, containing growth factors such as TGF-β, PDGF, IGF, and EGF, which are known to promote tissue repair and regeneration. The PRP will be injected directly into the affected tendon area to evaluate its clinical effectiveness and the relationship between platelet concentration, growth factors, and treatment outcomes.
223876624|NCT06581419|DRUG|IAP0971|Subjects receive IAP0971, which will be administered every 3 weeks in a 3-week cycle.
223876625|NCT03554265|DRUG|Somatropin|Genotropin given by injection
223876626|NCT05579743|OTHER|Remote wound monitoring technology|Healthy.io developed a professional-user wound management system that captures wound measurements and analyzes tissue distribution in real time through a smartphone application. Clinical oversight of the healing status of the wound via remote imaging and expert review allows for real time intervention when stagnation or worsening of a wound is detected. Patients with wounds on their legs will receive access to Healthy.io's mobile app and will be able to perform self-scans of their wound which will be automatically sent to the medical professionals, thus allowing them to assess the wound remotely.
223876627|NCT02574728|DRUG|Sirolimus|The starting dose for sirolimus is 2 mg/m2 once daily. The dose of sirolimus will be individually adjusted to achieve a target serum trough concentration in the range of 10-15 ng/ml. Sirolimus will be given by mouth every day for six weeks (every six weeks is called one cycle) for up to two years or 16 cycles.
223876628|NCT02574728|DRUG|Celecoxib|Celecoxib 100 mg will be given by mouth twice a day for six weeks (every six weeks is called one cycle) for up to two years or 16 cycles.
223876629|NCT02574728|DRUG|Etoposide|Etoposide 50 mg/m2 (maximum dose 100 mg) will be given daily by mouth for the first 3 weeks of a 6 week cycle. Six week cycles will be repeated for up to two years or 16 cycles.
223876630|NCT02574728|DRUG|Cyclophosphamide|Cyclophosphamide 2.5 mg/Kg (maximum dose 100 mg) will be given daily by mouth for the second 3 weeks of a 6 week cycle. Six week cycles will be repeated for up to two years or 16 cycles.
223876631|NCT02432963|OTHER|Laboratory Biomarker Analysis|Correlative studies
223876632|NCT02432963|BIOLOGICAL|Modified Vaccinia Virus Ankara Vaccine Expressing p53|Given SC
223876633|NCT02432963|BIOLOGICAL|Pembrolizumab|Given IV
223876634|NCT05235464|OTHER|Standard meal|Standard meal
223876635|NCT05235464|OTHER|High animal protein meal|Meal with high animal protein content
223876636|NCT05235464|OTHER|High plant protein meal|Meal with high plant protein content
223876637|NCT05235464|OTHER|High plant protein meal with additional leucine|Meal with high plant protein content and additional leucine
223876638|NCT04522154|DIAGNOSTIC_TEST|Magnet resonance imaging|Patients will receive a cardiac magnet resonance tomography before and 3-month after the procedure
223876639|NCT06786390|OTHER|Rehabilitation protocol: FES|Subjects diagnosed with CIP will follow the FES-based rehabilitation protocol
223876640|NCT06786390|OTHER|Rehabilitation protocol without FES|Subjects belonging to the control group will follow the rehabilitation protocol without FES
223876641|NCT06786390|OTHER|Rehabilitation protocol: FES|Subjects diagnosed with CIM will follow the FES-based rehabilitation protocol
223876642|NCT05663294|RADIATION|external beams radiotherapy|"External beam radiation therapy uses high doses of radiation to destroy cancer cells and shrink tumors. A large machine aims radiation at the cancer. The allowed schedules for external beams radiotherapy are:~* 40 Gy in 15 fractions;~* 30 Gy in 5 fractions;~* 40 Gy or 38.5 in 10 twice-daily fractions (each daily dose must be separated by at least 6 hours)."
223876643|NCT05663294|RADIATION|brachytherapy|"Brachytherapy is a form of radiation therapy where a sealed radiation source is placed inside or next to the area requiring treatment.~The schedule for brachytherapy are:~* 32 Gy in 8 twice-daily fractions for HDR;~* 30.3 Gy in 7 twice-daily fractions for HDR;~* 50Gy 0.60-0.80 Gy/hour (1 pulse/hour, 24 hours/day) for PDR."
223876644|NCT03328455|BEHAVIORAL|Inhibitory control training|Cognitive training is inhibitory task-related.
223876645|NCT03328455|BEHAVIORAL|Knowledge-based training|Training is not inhibitory task-related.
223876646|NCT05386238|BEHAVIORAL|Standard behavioral weight loss program|16 internet-delivered, group sessions over 6 months supported by digital handouts. The intervention will focus on changes to eating, physical activity, and self-monitoring.
223876647|NCT05386238|BEHAVIORAL|Tailored behavioral weight loss program|16 internet-delivered, group sessions over 6 months supported by digital handouts or videos tailored to men working in blue-collar occupations. The intervention will focus on changes to eating, physical activity, and self-monitoring.
223876648|NCT06109038|OTHER|Conventional PT + ITB release with graston technique|"An emollient will be applied to the leg from the lateral joint line along the tibial condyle to just below the iliac crest. The instrument GT-4 will be used for treatment. The tool was used to assess the soft tissue in three locations on the lateral leg: anterior to the ITB, over the ITB, and posterior to the ITB. Brushing and strumming strokes were performed to the tissue utilising the instrument's convex surface. Treatment time with the instrument is 8 -10 mins .~Conventional PT including Hot Pack for 5mins. Quadriceps setting exercises, short arc terminal knee extension, straight leg raise, ROM exercises, hamstring curls in prone lying position, quadriceps strengthening in high sitting position, gastrocnemius muscle stretching (10reps × 5sec × 2sets). Maitland mobilization (Grade 1, 2 and 3 for 10 repetitions)."
223876649|NCT06109038|OTHER|Conventional PT|Conventional PT including Hot Pack for 5mins. Quadriceps setting exercises, short arc terminal knee extension, straight leg raise, ROM exercises, hamstring curls in prone lying position, quadriceps strengthening in high sitting position, gastrocnemius muscle stretching (10reps × 5sec × 2sets). Maitland mobilization (Grade 1, 2 and 3 for 10 repetitions).
223876650|NCT05989347|DRUG|Dapagliflozin 10mg|10 mg tablets for oral administration daily throughout chemotherapy treatment
223876651|NCT06785922|PROCEDURE|Stomach biopsy for gastric microbiota|Stomach biopsy for gastric microbiota testing (16S RNA sequencing)
223876652|NCT06819280|BIOLOGICAL|GT307 injection|GT307 injection to treat Advanced Colorectal Cancer
223876653|NCT06395051|DIETARY_SUPPLEMENT|Ketone Monoester|Ketone monoester supplement (395 mg/kg body mass)
223876654|NCT06395051|DIETARY_SUPPLEMENT|Placebo|The placebo will be taste-matched to the active supplement for bitterness using denatonium benzoate and volume-matched with water
223876655|NCT06783608|BEHAVIORAL|Laughter yoga|Laughter yoga was applied to the experimental group for 4 weeks, 2 days a week, for 8 sessions (each session duration is 30-45 minutes on average). Patients were asked to measure and record their blood glucose value before breakfast. The yoga session was started 30 minutes after breakfast, and after the session was completed, they were asked to measure and record their blood glucose value again at 120 minutes after breakfast.
223876656|NCT05371327|BEHAVIORAL|Public deliberation|Public deliberation is a method for engaging the public in collective decision-making. Its goal is to facilitate debate and discussion that: 1) fosters the formation of reasonable and informed opinions, 2) permits participants to revise their perspectives and positions in light of new information and dialogue with others, and 3) encourages participants to consider not only their own preferences but also the greater goal of a policy or resolution that is justifiable for all persons affected by the issue under debate.
223876657|NCT06398340|OTHER|High Calorie Meal Intervention|Subjects will receive a unhealthy meal high in calorie, sugar and fat
223876658|NCT06398340|OTHER|Low Calorie Meal Intervention|Subjects will receive a healthy meal with balanced macronutrient, high in vegetables and dietary fibre
223876659|NCT06787950|DRUG|ASN-3186|ASN-3186 will be administered orally.
223876660|NCT06787950|DRUG|ASN-3186|ASN-3186 will be administered orally.
223876661|NCT06787950|DRUG|ASN-3186|ASN-3186 will be administered orally.
223876662|NCT05659030|OTHER|Education|In order to develop the training material, first of all, a literature review will be made and a training booklet will be prepared. The training booklet will be submitted to expert opinion and a pilot application will be made by giving its final form. The training content is based on Pender's Health Promotion Model, which consists of 3 components.
223876663|NCT05986526|PROCEDURE|Pulmonary vein isolation without posterior wall ablation|Pulmonary vein isolation with Pulsed field ablation without left atrial posterior wall ablation. At the end of the procedure, an implantable cardiac monitor will be implanted for the purpose of continuous arrhythmia monitoring
223876664|NCT05986526|PROCEDURE|Pulmonary vein isolation with posterior wall ablation|Pulmonary vein isolation with Pulsed field ablation with left atrial posterior wall ablation. At the end of the procedure, an implantable cardiac monitor will be implanted for the purpose of continuous arrhythmia monitoring
223876665|NCT06831539|DRUG|PEGLyte bowel preparation|"Volunteers will be administered 4L of PEG bowel preparation. The following instructions will be provided with the prescription:~1. Fill the supplied container containing the bowel cleanse powder with lukewarm water (to facilitate dissolution) to the 4-liter fill line. The solution is clear and colourless when reconstituted to a final volume of 4 liters.~2. After capping the container, shake vigorously several times to ensure that the ingredients are dissolved. The solution is more palatable if chilled prior to drinking. When reconstituted use within 48 hours.~3. Attempt to drink a maximum of 4 liters at a rate of 240 mL (8 oz.) every 10 minutes, until 4 liters has been consumed or the rectal effluent is clear. Rapid drinking of each portion is preferred to drinking small amounts continuously.~4. The first bowel movements should occur approximately one hour after the start of bowel cleanse administration. Continue drinking until the watery stool is clear and free of solid matter."
223876666|NCT06475352|DRUG|FOLFOX regimen|Oxaliplatin will be administered at a fixed dose of 85 mg/m² by 2h intravenous (IV) infusion concurrently with folinic acid 400 mg/m² (or 200 mg/m² if L-folinic acid) as a 2 h IV infusion on day 1 of each 14-day cycle followed by 5-fluorouracil (5-FU) 400 mg/m² IV bolus on day 1, then continuous IV infusion of 1,200 mg/m² /day × 2 days (total 2400 mg/m² for 46-48 hours)
223876667|NCT06475352|DRUG|CAPOX regimen|Oxaliplatin will be administered at a fixed dose of 130 mg/m² by 2h IV infusion on day 1 of each 21-day cycle followed by capecitabine (1000 mg/m²) twice a day (BID) during 2 weeks, every 3 weeks
223876668|NCT06791031|DRUG|inclisiran|"Patients randomized to the inclisiran early intensified therapy arm will receive initial treatment with inclisiran sodium 300 mg (equivalent to inclisiran 284 mg) on moderate-intensity statin therapy (i.e., atorvastatin: 20 mg; rosuvastatin: 10 mg) during hospitalization for the index ACS (administered within 24 hours after randomization), regardless of baseline LDL-C levels and whether on stable statin treatment or not. Subsequent doses will be administered by healthcare professionals at the month 3 and month 9 study visits and documented in the patient's medical history, without dose adjustment throughout the study. The study only provided inclisiran as PCSK9 inhibitors in the inclisiran early arm. The baseline types and regiments of lipid-lowering drugs other than PCSK9 inhibitors were maintained throughout the study period in both experimental and control group."
223876669|NCT06507579|DEVICE|Hydra transcatheter aortic valve (THV) series|The Hydra device consists of a self-expanding nitinol frame and three bovine pericardial leaflets in supra-annular position.
223876670|NCT06831604|DRUG|Superficial Cervical Plexus Block (SCPB) and Clavipectoral Fascial Plane Block (CPB)|Patients will receive Superficial Cervical Plexus Block (SCPB) and Clavipectoral Fascial Plane Block (CPB).
223876671|NCT06831604|DRUG|Superficial Cervical Plexus Block (SCPB) and Interscalene Brachial Block (ISBP)|Patients will receive Superficial Cervical Plexus Block (SCPB) and Interscalene Brachial Block (ISBP)
223876672|NCT05672667|DRUG|intravenous oxytocin|Oxytocin given by intravenous route
223876673|NCT05672667|DRUG|intranasal oxytocin|Oxytocin given by intranasal administration
223876674|NCT06784557|DRUG|Atorvastatin 40mg|High intensity HMG-CoA reductase inhibitor
223876675|NCT06784557|DRUG|Atorvastatin 20mg+Ezetimibe 10mg|Moderate intensity HMG-CoA reductase inhibitor plus NPC1L1 antagonist
223876676|NCT06830668|DRUG|Regimen：BIC+FTC+TAF|"Same-day restart of BIC+FTC+TAF among HIV patients who experienced discontinuation from previous NNRTI-based regimens"
223876677|NCT06816069|DEVICE|VOLNEWMER|Monopolar radiofrequency device
223876678|NCT03286868|PROCEDURE|Total Knee Arthroplasty|Total Knee Arthroplasty
223876679|NCT03286868|DEVICE|Total Knee Arthroplasty with Verasense sensor|Total Knee Arthroplasty with Verasense sensor
223876680|NCT04157322|DIAGNOSTIC_TEST|prospective single arm biomarker (plasma cell-free DNA hydroxymethylation) study|Blood draw
223876681|NCT02274805|PROCEDURE|Adults presenting for surgery in the neck area|
223876682|NCT05568082|DRUG|AMG 510|Oral tablet
223876683|NCT05568082|DRUG|Itraconazole|Oral capsule
223876684|NCT02217904|DRUG|1 mg islatravir|Single oral dose of 1 mg islatravir administered following ≥8 hour fast
223876685|NCT02217904|DRUG|2 mg islatravir|Single oral dose of 2 mg islatravir administered following ≥8 hour fast
223876686|NCT02217904|DRUG|10 mg islatravir|Single oral dose of 10 mg islatravir administered following ≥8 hour fast
223876687|NCT02217904|DRUG|30 mg islatravir|Single oral dose of 30 mg islatravir administered following ≥8 hour fast
223876688|NCT02217904|DRUG|0.5 mg islatravir|Single oral dose of 0.5 mg islatravir administered following ≥8 hour fast
223876689|NCT02217904|DRUG|0.25 mg islatravir|Single oral dose of 0.25 mg islatravir administered following ≥8 hour fast
223876690|NCT05534165|DRUG|Tecovirimat|600 mg po BID
223876691|NCT05534165|DRUG|Placebo|identical placebo 600 mg po BID
223876692|NCT03791112|DRUG|BPI-16350|BPI-16350 capsules administered orally
223876693|NCT03344276|DIAGNOSTIC_TEST|Neurocognitive Assessments|Patients will undergo carotid artery stenting for 50-70% carotid artery stenosis. Prior to surgery patients will undergo a battery of neurocogntive assessments 1 month and 2 months prior to surgery.
223876694|NCT03344276|DIAGNOSTIC_TEST|Measurements of inflammatory biomarkers|Patients will undergo carotid artery stenting for 50-70% carotid artery stenosis. After surgery, patients will undergo blood draws to measure for inflammatory biomarkers.
223876695|NCT03344276|PROCEDURE|Carotid Artery Stenting|Patients will undergo carotid artery stenting for 50-70% carotid artery stenosis.
223876696|NCT05600088|DEVICE|CryoTherapy System (CTS)|local cryotherapy of coronary high-risk plaque lesions using the CTS consisting of a semi-compliant balloon and a console controlling the temperature of cryotherapy
223876697|NCT06267768|DIAGNOSTIC_TEST|Various intensities of inspiratory muscle training|Each participant will be asked to perform the lung function test to measure the maximal inspiratory pressure (MIP) after including the study. After the baseline measurement, all participants will be requested to use a nose clip to hold the nose and breathe with the mouth through a pressure threshold inspiratory loading device (POWERbreathe, KH2, England). The inspiratory pressure will be set at 30%, 40%, 50%, 60%, 70%, or 80% of their MIP, in random order. Each MIP intensity protocol consists of 10 breaths. Resting will be allowed between different protocols of contraction intensity (% MIP). During the test, sternocleidomastoid muscle activity will be measured with surface electromyography (sEMG) and diaphragm thickness will be used to assessed with ultrasonography.
223876698|NCT06075771|DRUG|Carbidopa Levodopa|Patients will receive between one and three tablets per day of 150 mg L-DOPA (administered with 37.5 mg carbidopa) to achieve doses ranging from 150 to 450 mg/day.
223876699|NCT06075771|DRUG|Placebo|A placebo is a sugar pill that has no therapeutic effect and will be administered orally. Participants will receive between one and three placebo tablets per day matching the Carbidopa Levodopa tablet.
223876700|NCT06216509|DEVICE|Endoscopic ultrasound pressure measurement|all eligible patients from both groups will undergo Endoscopic ultrasound pressure measurement under sedation.
223876701|NCT05338970|DRUG|Patritumab Deruxtecan|Intravenous administration, 5.6 mg/kg every 3 weeks (q3W)
223876702|NCT05338970|DRUG|Platinum-based chemotherapy|Intravenous, pemetrexed 500 mg/m\^2 plus either cisplatin (75 mg/m\^2) or carboplatin (target area under the plasma concentration time curve of 5 \[AUC5\] by using the Calvert formula) q3W
223876703|NCT06803966|OTHER|Post Operative Analgesia|"Group A will receive local wound infiltration at port sites with inj bupivacaine (bupivacaine Hydrochloride) 0.5 %~Group B will receive Transversus Abdominal Plane Block on both sides by inj bupivacaine (bupivacaine Hydrochloride) 0.25%"
223876704|NCT06802666|RADIATION|short-course radiotherapy|Eligible subjects will receive short-course radiotherapy (SCRT). One week after the end of treatment, subjects continued to receive neoadjuvant chemotherapy combined with AK112 regimen for 6 cycles.
223876705|NCT06802666|DRUG|Ivonescimab|AK112 20 mg/kg, intravenous infusion every 3 weeks (Q3W)
223876706|NCT06802666|DRUG|capecitabine|1000mg/m2, bid, po, d1-14,q3w
223876707|NCT06802666|DRUG|oxaliplatin|130mg/m2, ivgtt, d1,q3w
223876708|NCT06802666|PROCEDURE|TME surgery|The surgery was performed 1 week after the end of neoadjuvant therapy.
223876709|NCT06133062|DRUG|Atezolizumab|Atezolizumab 1200 mg will be administered as an IV infusion on Day 1 of each cycle, with cycles occurring every 3 weeks. The initial dose will be delivered over 60 (± 15) minutes, and if well-tolerated, subsequent infusions may be given over 30 minutes. For patients who achieve a complete response (CR) within one year of treatment, atezolizumab should be continuously used for a year. For patients who experience a partial response (PR), atezolizumab should be continued until achieving CR or experiencing progressive disease (PD). Patients with stable disease should receive atezolizumab for 6 months. In the case of PD, atezolizumab should be discontinued at the time when PD is confirmed.
223876710|NCT06133062|DRUG|Bevacizumab|Bevacizumab 15 mg/kg will be administered as an IV infusion on Day 1 of each 3-week cycle. The initial dose will be delivered over 90 minutes (±15 minutes), and if well-tolerated, subsequent infusions may be given over 60 minutes. For patients who achieve a complete response (CR) within one year of treatment, bevacizumab should be continuously used for a year. In the case of patients experiencing a partial response (PR), bevacizumab should be continued until achieving CR or experiencing progressive disease (PD). Patients with stable disease should receive bevacizumab for 6 months. In the event of PD, bevacizumab should be discontinued when PD is confirmed. Temporary withholding or dose reduction of bevacizumab is permitted if patients experience adverse events such as bleeding episodes, severe hypertension, or proteinuria at the discretion of the treating physician.
223876711|NCT06133062|RADIATION|Proton radiotherapy|"* 72.6 CGE in 22 fractions for tumors ≤1 cm from the hepatic hilum, bowel, and heart.~* 66 CGE in 10 fractions for tumors \>1 cm from the hepatic hilum, bowel, and heart."
223876712|NCT06425796|DIETARY_SUPPLEMENT|Adiposity and Iron Requirements in Pregnancy (ADIPREG)|"Iron 25 arm will receive: two iron supplements containing 12.5 mg of elemental iron + 1 multivitamin supplement (they will receive a total of 3 supplements per day).~Iron 50 arm will receive: two 25 mg elemental iron supplements + 1 multivitamin supplement (they will receive a total of 3 supplements per day).~The multivitamin supplement will contain folic acid, vitamin B1, vitamin B2, vitamin B3, vitamin B5, vitamin B6, vitamin B12, vitamin C and vitamin D. In summary, each participant will receive 3 supplements per day and instructed to take the 3 supplements together, in the morning, with breakfast. Supplements will be given to the participants when they attend for their clinic appointment. The intervention will begin at 12 gestational weeks and continue until the baby is delivered."
223876713|NCT05142618|OTHER|Supervised Physical Therapy|The twice-per-week 8-week course of supervised physical therapy begins 2 weeks after surgery. It targets abdominal core function through progressive muscle retraining and strengthening, and patient-specific posture and body mechanics education.
223876714|NCT05142618|OTHER|Post-operative Precautions|This intervention includes standard of care post-operative instructions typically given to patients undergoing ventral hernia repair across the world. These include limiting strenuous physical activity and a lifting restriction of no more than 10 pounds for 6 weeks. Binder use is also encouraged for 4-6 weeks after the operation.
223876715|NCT03575052|DRUG|Pimavanserin|Pimavanserin 34 mg total daily dose, tablets, once daily by mouth (provided as two 17 mg NUPLAZID® tablets)
223876716|NCT03575052|DRUG|Placebo|Placebo, tablets, once daily by mouth (provided as two placebo tablets)
223876717|NCT06779760|PROCEDURE|parathyroidectomy|"The FLUOBEAM® LX apparatus consists of a camera with a built-in light emitter (750-800 nm) and detector (800-830 nm) connected to a processor with an indication-oriented software (Fluosoft®). The processor captures the emitted light, allowing display of PTG images in real time. The camera is placed in a sterile sheath and is held perpendicularly at 8 cm from the target tissue with operating lights, all background lights, and any ambient light being extinguished. The reported depth of tissue penetration of near-infrared light is limited to a maximum of 3 mm only with no observed differences between superior and inferior PTGs \[10\]. This highlights the importance of a major surgical technical point reaching the correct plane of dissection namely, the pre-vertebral fascia to maximize the chances of eliciting an adequate signal from parathyroid tissue. The correct application of the technology has demonstrated a success rate of signal elicitation of 90%-100% \[11\]. The ability of near-infr"
223876718|NCT06781073|DRUG|Nimotuzumab|Nimotuzumab in combined with chemotherapy period, 400mg, day1, administered intravenously before chemotherapy ,weekly, for 18 weeks; Maintenance period, 400mg, every two weeks until disease progression or intolerable toxicity , maximum duration is 60 weeks .
223876719|NCT06781073|DRUG|Paclitaxel|175mg/m\^2,for 3 hour,day1,21 days for a cycle ,until disease progression or toxicity，maximum duration is 6 cycles.
223876720|NCT06781073|DRUG|Cisplatin|50mg/m\^2,day1orday2，21 days for a cycle ,until disease progression or toxicity,maximum duration is 6 cycles.
223876721|NCT06781073|DRUG|Placebo|Placebo in combined with chemotherapy period, 400mg, day1, administered intravenously before chemotherapy ,weekly, for 18 weeks; Maintenance period, 400mg, every two weeks until disease progression or intolerable toxicity , maximum duration is 60 weeks .
223876722|NCT04998123|DEVICE|SeizureStop Device|Intersectional Short Pulse (ISP) Stimulation will be performed using SeizureStop Device. The ISP stimulation method proposed in this study is to increase the intensity of stimulation delivered to targeted brain regions, while minimizing the peripheral effects of stimulation. For sham stimulation, no settings will be modified.
223876723|NCT02204085|DRUG|GO-203-2c|
223876724|NCT02204085|DRUG|GO-203-2c + Decitabine|
223876725|NCT05444335|DEVICE|Wearable cardiac monitor -Zio patch|Women older than 70 years old will be asked to wear a cutaneous cardiac monitor for 2 weeks.
223876726|NCT04794608|DEVICE|HYPNO VR® device|"The HYPNO VR® device is a software application of medical hypnosis in the treatment of pain and anxiety. It is associated with equipment: a virtual reality headset and a headphone.~Before each session of hypnosis, the nursing staff offers patients the choices: visual universe, musical theme, male or female voice. The nursing staff selects the program, selects a duration of 20 minutes and presses start to start the medical hypnosis session in virtual reality.~After completing the hypnotic trance sequence, as in a classic session, the patient is brought back to the return and exit hypnosis phase under the supervision of the nursing staff."
223876727|NCT04200729|DRUG|Irrigation with PVI|The intervention will be irrigation with PVI, diluted to a concentration of 1% (containing 0.1% active iodine). After removal of the appendix from the patient's abdomen and attainment of hemostasis,10 mL/kg of 1% PVI solution will be used to irrigate the pelvis and right upper and lower quadrants. The solution will be left to dwell for 1 minute and then suctioned.
223876728|NCT04200729|PROCEDURE|Usual care|The control will be usual care, which is expected to vary between institutions. The only stipulation for usual care will be that surgeons do not change their usual practice during the baseline period. Some surgeons utilize intra-abdominal irrigation while others use only local irrigation. Intraabdominal irrigation is defined as intraoperative instillation of a large volume (\> 200 mL) of irrigation solution into all 4 quadrants of the abdomen. Local irrigation is defined as instillation of a small volume of liquid, typically \<50 mL, in the operative field. Intra-abdominal irrigation is utilized with the intention of preventing IAAs while local irrigation is often used to confirm hemostasis or assist with suctioning thick purulent fluid.
223876729|NCT03438188|OTHER|Practice Quit Attempt|Smokers will be studied under 2 conditions: smoking as usual and during a 4 day practice quit attempt.
223876730|NCT02476864|DRUG|Treatment A (adult formulation)|Single oral administration of one film-coated tablet containing 10 mg of macitentan as active substance and lactose, magnesium stearate, microcrystalline cellulose, povidone, sodium starch glycolate type A, polysorbate as inactive ingredients.The film coat contains titanium dioxide, talc, xanthan gum, polyvinyl alcohol, and soy lecithin.
223876731|NCT02476864|DRUG|Treatment B (pediatric formulation)|Single oral administration of two dispersible tablets, each containing 5 mg of macitentan as active ingredient and Mannitol delta polymorphic crystals, mannitol, isomalt, isomalt agglomerated, croscarmellose sodium, and magnesium stearate as inactive ingredients.
223876732|NCT06241703|PROCEDURE|ICCAUT|For patients in the ICCAUT group, intermittent catheter clamping will be initiated at 9:00 AM. The catheter will be clamped for 3 h, followed by a 5-minute release, which is one cycle. The next cycle will begin after the cycle was completed. Catheter training is to conclude at 10:00 PM on the first postoperative day, and the catheter is left open during the night. At 6:00 AM on the second postoperative day, another cycle of catheter training will be performed, with the catheter removed at 9:00 AM after the bladder is empty. During the training period, if the patient experiences a strong urge to urinate before the 3-hour clamping time is over, the clamping can be released in advance for 5 min, allowing the patient to proceed to the next cycle of bladder training. Each time the catheter is released, we will encourage the patients to actively initiate urination to facilitate complete bladder emptying.
223876733|NCT06241703|PROCEDURE|Free drainage|For patients in the free draining group, no intervention will be performed on the catheter during this period. The catheter will be removed at 9:00 AM on postoperative day two.
223876734|NCT06391931|DRUG|Cipepofol|0.6±0.2 mg/kg induce + 0.8 mg/kg/h maintain
223876735|NCT06391931|DRUG|Propofol|3.0 mg/kg induce + 5.0 mg/kg/h maintain
223876736|NCT05368662|OTHER|Quality of life and sleep questionnaire|Evaluation of quality of life and quality of sleep by questionnaires
223876737|NCT01141309|DRUG|sorafenib with everolimus|"Treatment will be with sorafenib 400 mg orally twice a day and everolimus 5 mg orally daily. Restage every 2 cycles \*Cycle = 4 weeks of treatment.~Subjects may consent to allowing blood to be drawn for DNA. Two blue top tubes will be required. Approximately 5-6 ml will be needed. This may be done at anytime, including before, during, or after treatment. This is not required to participate in the study."
223876738|NCT05227144|DRUG|ORIC-533|ORIC-533 once daily in consecutive 28-day cycles
223876739|NCT03578198|DRUG|Rituximab + MG4101|"1. Induction phase:~   * Rituximab (Truxima) 375mg/m2 IV Weekly (X4)~  * MG4101 3x107 cells/kg IV Weekly (X4)~2. Maintenance phase~   * Rituximab (Truxima) 375mg/m2 IV q 4 weeks (X4)~  * MG4101 3x107 cells/kg IV q 4 weeks (X4)"
223876740|NCT06787820|BEHAVIORAL|Music intervention|The musical intervention conducted at the senior home focused on the development of rhythmic and vocal skills, as well as the creation of educational experiences that promoted the acquisition of these competencies. To achieve this, both conventional percussion instruments, such as claves, tambourines, woodblocks, and triangles, and unconventional elements, such as buckets played with drumsticks, sheets of paper, spoons, ribbons, elastic bands, and a parachute, were used to mark the rhythm during the singing sessions. The selected songs were chosen based on the musical styles mentioned by the participants during the pre-intervention interview. Furthermore, participants were given the opportunity to showcase their progress at the end of the activity, with the aim of sharing these achievements with family and friends at the home.
223876741|NCT06787157|OTHER|Prediction Model Construction|
223876742|NCT06787534|OTHER|No Interventions|
223876743|NCT05929976|OTHER|No intervention|No intervention
223876744|NCT06163989|DRUG|TheaLoz Duo Eyedrop|TheaLoz Duo lubricating eyedrop contains 3.0% trehalose and 0.15% sodium hyaluronate as active ingredients and will be used by participants everyday to instill 1 drop, 4 times a day in both eyes.
223876745|NCT06789848|DRUG|Ligufalimab|Ligufalimab (AK117) 45 mg/kg IV over 120 minutes on Day 1 every 3 weeks
223876746|NCT06789848|DRUG|Cadonilimab|Cadonilimab (AK104) 10 mg/kg IV over 60 minuets at least 30 minutes after Ligufalimab on Day 1 every 3 weeks
223876747|NCT06789458|PROCEDURE|Professional mechanical plaque control|"thisThe first step in therapy is aimed at guiding behavior change by motivating the patient to undertake successful removal of supragingival dental biofilm and risk factor control and may include the following interventions:~* Interventions to improve the effectiveness of oral hygiene \[motivation, instructions (oral hygiene instructions, OHI)~* Professional mechanical plaque removal (PMPR), which includes the professional interventions aimed at removing supragingival plaque and calculus, as well as possible plaque-retentive factors that impair oral hygiene practices.~* Adjustment of faulty restoration and polishing~* The mechanical plaque control instructions for each patient include brushing and interdental cleaning techniques."
223876748|NCT06783049|BEHAVIORAL|Cerebrovascular Disease Secondary Prevention Smart Management System|The continuous post-discharge intervention for patients was conducted using the Cerebrovascular Disease Secondary Prevention Smart Management System. This system, integrated with a WeChat-based applet, records patients' basic information and connects with mobile IoT devices such as blood pressure monitors and glucose meters. This allows patients to self-monitor their risk factors post-discharge. Based on international guidelines, high-level evidence, and the clinical expertise of cerebrovascular specialists, a comprehensive clinical decision-making tree was developed. This serves as the foundation for an AI feedback system that provides intelligent feedback on risk factor control and predicts the risk of recurrence.
223876749|NCT04300231|DRUG|epidural bupivacaine 0.05%|Mix of epidural bupivacaine 0.05% and hydromorphone 0.05mg/ml will be given using PCEA.
223876750|NCT04300231|DRUG|Liposomal bupivacaine|20 ml
223876751|NCT04300231|DRUG|bupivacaine 0.125%|40 mL
223876752|NCT04300231|DRUG|bupivacaine 0.5%|60 mL
223876753|NCT04300231|DRUG|/hydromorphone 0.05mg/ml|Mix of epidural bupivacaine 0.05% and hydromorphone 0.05mg/ml will be given using PCEA.
223876754|NCT04300231|DRUG|injectable saline|40 mL
223876755|NCT04788914|DIETARY_SUPPLEMENT|Active bamboo charcoal± probiotics|Active bamboo charcoal 2g, TID probiotics 0.8g
223876756|NCT05273723|BEHAVIORAL|5 Behavioral Change Techniques|"1. Goal setting: set or agree on a goal defined in terms of behavior to be achieved. Example: Set the goal of walking 2,000 steps more per day.~2. Action planning: prompt detailed planning of performance of behavior (must include a setting \[walking to the mailbox\], frequency, duration, and intensity. Example: Develop a plan to walk today.~3. Self-Monitoring of behavior: establish a method for person to monitor and record their number of steps based on their Fitbit. Example: Did you check your Fitbit and record daily total number of steps?~4. Feedback on behavior: Monitor and provide informative or evaluative feedback on performance of the behavior (e.g. form, frequency, duration, intensity). Example: You walked 6,000 steps today.~5. Prompts/Cues: introduce or define environmental or social stimulus with the purpose of prompting or cueing the behavior. The prompt or cue would normally occur at the time or place of performance. Example: You planned to walk today in the park at 3pm."
223876757|NCT04959838|BEHAVIORAL|Impact of prolonged work|Evaluate the impact of prolonged work (up to 60 consecutive hours) on the surgical capacities evaluated on a simulator, as well as on stress markers (questionnaires, saliva assays, skin conductance, quality of sleep) compared to a standard day.
223876758|NCT05523882|DIAGNOSTIC_TEST|point-of-care ultrasound|"All participants will receive the same ultrasound education through attendance of the ultrasound course arranged by PLO-e. The educations intervention consists of three teaching seminars delivered over three months, a curriculum of 10 POCUS applications, an online learning platform providing educational support before, during, and after the teaching sessions (see Figure 2).~The online platform includes videos demonstrating the performance of POCUS, suggestions for additional literature, assignments to support the development of skills, self-quizzes to focus attention of learning outcomes and specific actioncards for each of the 10 POCUS applications framing the examinations in the clinical context. In addition, the online platform provides participants access to webinars and communication with other participants and teachers"
223876759|NCT06798961|PROCEDURE|Ablation|Patient treated with an ablation to eliminate the accessory conduction pathway in the heart.
223876760|NCT06798961|PROCEDURE|Standard of care without ablation|Patient diagnosed with accessory pathway but elected against cardiac ablation as a treatment option at the time of diagnosis.
223876761|NCT04997382|DRUG|Chemotherapy alone or Chemotherapy plus Immune Checkpoint Inhibitors with or without Bevacizumab|Immune Checkpoint Inhibitors, for pembrolizumab, 200mg ivgtt once,every 21 days; for Atezolizumab, 1200mg vgtt once,every 21 days.
223876762|NCT04997382|DRUG|Chemotherapy alone or Chemotherapy with or without Bevacizumab|Bevacizumab, 15mg/kg，every 21 day
223876763|NCT06775249|BEHAVIORAL|ICE Mindfulness Program|The ICE Mindfulness Program is a tailored, self-paced intervention designed for crew members in isolated and confined environments. It includes a three-week pre-departure online course with videos, audio, and cognitive exercises promoting mindfulness, flexibility, and creativity, requiring 15-30 minutes daily. Delivered via email, it blends elements from Mindfulness-Based Stress Reduction and the Langerian approach. Participants receive new content daily, focusing on stress reduction and adaptation in extreme settings. Pre-departure, the PI leads a 1.5-hour interactive session with group meditation. During the mission, bi-weekly booster sessions are conducted by the ESA MD, supplemented by ongoing access to training materials. Exercises include meditations, mindful discussions, and cognitive tasks, with flexibility to fit participant schedules. The program will be available in Italian, French, and English.
223876764|NCT04500301|OTHER|Preemptive Pharmacogenomic Testing|The use of a pharmacogenomic (PGx) testing to help manage drugs prescribed to subjects for pain and depression.
223876765|NCT06772259|DEVICE|Palm Stimulator|The apparatus is 1.6 cm in diameter and 4 cm long. It has a cylindrical, non-slippery and easy-to-grasp structure for maximum contact with the palm
223876766|NCT06772259|OTHER|Cartoon|The cartoon was projected on a blank wall in the intervention room with a projection device. The cartoon was played in preparation for the PIK procedure and children were allowed to watch it until the procedure was completed.
223876767|NCT06295289|DEVICE|Hybrid Closed-loop Insulin Delivery System|The Hybrid Closed-loop Insulin Delivery System system consisted of a Medtronic pump, a continuous glucose monitoring system（SIBIONICS®）and an open-source algorithm integrated into the phone. Insulin pump therapy group consisted of a Medtronic pump, and a continuous glucose monitoring system（SIBIONICS®). The difference between the two groups is that the artificial pancreas system automatically regulates the basal rate to maintain blood glucose in a target range.
223876768|NCT06295289|DEVICE|Insulin pump|Participants used conventional insulin pumps to control blood glucose, At the same time, a continuous glucose monitoring system was used to monitor glucose changes. Health care providers adjust the insulin dose of patients according to their blood glucose level.
223876769|NCT01218490|PROCEDURE|ovarian cancer surgery|
223876771|NCT04795856|DRUG|[11C] acetate|PET Tracer
223876772|NCT06191939|BEHAVIORAL|Mindful Self-Compassion for Lung Cancer (MSC-LC)|"The overall goal of this 10-week, group-based, virtually-delivered, psychosocial intervention is to enhance recognition and responsiveness to difficult thoughts and emotions and to build self-compassion skills that facilitate patients' ability to turn inward to those thoughts and feelings with mindfulness, connectedness, and self-kindness. Each weekly session is designed to be 90 minutes and follows an agenda with highly structured scripts covering self-compassion topics (e.g., pain of disconnection, listening with compassion), which are carefully organized to build upon one another. In each session, didactic topics (e.g., What is self-compassion?) taught by trained interventionists lead into guided experiential learning practices (e.g., guided meditation), which are then followed by inquiry into the participants' direct experiences of the practices. The treatment manual is adapted based on the Mindful Self-Compassion Teacher Guide (from the Center for Mindful Self-Compassion)."
223876773|NCT06191939|OTHER|Enhanced standard of care with waitlist|Participants in the enhanced standard of care control condition will be provided with an information sheet from the NCI about how to find helpful organizations and resources in their community. Self-report will be used to describe any supportive care services pursued by the participant. Additionally, control participants will be added to a waiting list for receiving the MSC-LC intervention program. After completing all questionnaire assessments (16 weeks following study entry), the study team will offer the MSC-LC intervention program to participants on the waiting list.
223876774|NCT02479906|DEVICE|Deep TMS System|Deep TMS treatments will be administered 3 times a week for 4 weeks and additional 2 booster treatments at the 5 and 9 week follow-up visits, for a total of 14 treatment sessions.
223876775|NCT02479906|DEVICE|Sham Treatment|Sham treatments will be administered 3 times a week for 4 weeks and additional 2 booster treatments at the 5 and 9 week follow-up visits, for a total of 14 treatment sessions
223876776|NCT06791135|OTHER|Health and Life in Balance|"Health and Life in Balance is an intervention for patients 65 years and older, with 2 or more chronic diseases, and an increased care need. It involved for the patient to meet with a district nurse during 1-2 meetings to set up a care plan and then have scheduled follow-ups during 6 months. During the 1-2 meetings they went through ICAN discussion aid to discuss aspects of capacity and workload in the patient's life and healthcare. The district nurse and the patient's GP had improved communication during the intervention period.~No use of drugs or devices was part of the intervention."
223876777|NCT06791135|OTHER|Care as usual|Care as usual
223876778|NCT06796374|DIETARY_SUPPLEMENT|Fisetin|"A single oral dose of 100 mg fisetin (as Novusetin®) will be administered as 1 capsule with 240 ml of still water in the overnight fasting condition:~A total of 18 blood samples will be taken at defined time points (baseline; 10; 20; 30; 40; 50; 60; 80; 100 min; 2.0; 2.5; 3.0; 4.0; 5.0; 6.0; 8.0; 10.0; 24.0 h). At each time point, blood will be collected (4.9 ml for separation of plasma) to determine fisetin, and fisetin metabolites. The total amount of blood collected for each participant and each arm is 90 ml at the kinetic visits and 12 ml at the screening visit. Urine will be collected during the first 10 hours after fisetin administration."
224076667|NCT03838224|OTHER|Sham needling|Sham needling has shown to be a valid control method in dry needling research. The procedure in the sham group will be the same as the experimental group to guarantee the participants' blinding. Prior to the intervention, participants will receive information about the procedure and will be free to withdraw. The sham needle (same appearance/material as the true needle) was shown to the participant before the intervention to guarantee the blinding.
224076668|NCT00289263|DRUG|Paclitaxel|
223876779|NCT06796374|DIETARY_SUPPLEMENT|Fisetin + Quercetin|"A single oral dose of 1000 mg fisetin + 200 mg quercetin will be administered as 2 softgel capsule with 240 ml of still water in the overnight fasting condition:~A total of 18 blood samples will be taken at defined time points (baseline; 10; 20; 30; 40; 50; 60; 80; 100 min; 2.0; 2.5; 3.0; 4.0; 5.0; 6.0; 8.0; 10.0; 24.0 h). At each time point, blood will be collected (4.9 ml for separation of plasma) to determine fisetin, fisetin metabolites, and quercetin. The total amount of blood collected for each participant and each arm is 90 ml at the kinetic visits and 12 ml at the screening visit. Urine will be collected during the first 10 hours after fisetin administration."
223876780|NCT05993416|DRUG|Nedosiran|In adults and in adolescents (aged 12-17 years) weighing greater than or equal to (\>=) 50 kilograms (kg), Nedosiran will be administered via subcutaneous (SC) injection once monthly at a dose of 170 milligrams (mg). In adults and adolescents weighing \< 50 kg, nedosiran will be administered once monthly at a dose of 136 mg. The dose for participants aged 6 to 11 years will be 3.5 mg/kg monthly, not to exceed 170 mg.
223876781|NCT04234217|DEVICE|Continuous positive airway pressure|Continuous positive airway pressure (CPAP) treatment of obstructive sleep apnea (OSA)
223876782|NCT04234217|OTHER|Niacin|Suppression of lipolysis by niacin infusion
223876783|NCT06841016|OTHER|Virtual Nephrologist|Quality improvement (QI) pilot of an interactive, conversational virtual healthcare agent to educate and engage patients with advanced CKD about transplantation
223876784|NCT05114720|DRUG|standard adjuvant chemotherapy plus moxifloxacin|docetaxel 75mg/m\^2, or nab-paclitaxel 260mg/m\^2, IV, days 1 cyclophosphamide 1000 mg/m\^2, IV, days 1, cycled every 21 days; or doxorubicin 60mg/m\^2, IV, days 1, cycled every 21 days cyclophosphamide 600 mg/m\^2, IV, days 1, cycled every 21 days docetaxel 100 mg/m\^2, IV, days 1, cycled every 21 days; plus Moxifloxacin 0.4 PO once daily days 1-5; cycled every 21 days
223876785|NCT05114720|DRUG|standard adjuvant chemotherapy plus placebo|docetaxel 75mg/m\^2, or nab-paclitaxel 260mg/m\^2, IV, days 1 cyclophosphamide 1000 mg/m\^2, IV, days 1, cycled every 21 days; or doxorubicin 60mg/m\^2, IV, days 1, cycled every 21 days cyclophosphamide 600 mg/m\^2, IV, days 1, cycled every 21 days docetaxel 100 mg/m\^2, IV, days 1, cycled every 21 days; plus Placebo 0.4 PO once daily days 1-5; cycled every 21 days
223876786|NCT05701709|DRUG|SHR-A2102|SHR-A2102 was given intravenously. Patients may continue to use SHR-A2102 until disease progression or unacceptable toxicity occurs.
223876787|NCT06471322|DEVICE|Continuous Glucose Monitoring (CGM)|Patients will wear a continuous glucose monitor upon discharge from the hospital for six months
223876788|NCT06471322|OTHER|Standard of Care|Standard of Care - retrospective review
223876789|NCT05234853|DRUG|PUR001|Monoclonal antibody
223876790|NCT05590169|OTHER|Exercise training|Group 1: Group exercises via Zoom application Group 2: Individual exercises via Zoom application Group 3: Routine treatment
223876791|NCT06840951|DEVICE|rTMS|rTMS is a non-invasive procedure that uses electromagnetic field pulses to stimulate regions of the brain. rTMS can induce excitatory and inhibitory neural activity in the neural circuits of the motor cortex.
223876792|NCT06840951|BEHAVIORAL|CBT|CBT for OCD is a structured, short-term, present-oriented therapy with an emphasis on problem-solving and the modification of dysfunctional thinking and behaviour. CBT will be conducted in a group setting according to a session-by-session treatment manual that incorporates Exposure and Response Prevention (ERP) in the early phases of treatment and then increases emphasis on cognitive approaches for obsessions and compulsions with step-by-step strategies.
223876793|NCT00670046|DRUG|valproic acid|given orally
223876794|NCT00670046|OTHER|standard of care follow-up|participant follow the standard of care for patient with metastatic prostate cancer
223876795|NCT06051032|DEVICE|Balloon thrombectomy|A specialized catheter with an inflatable balloon at the tip is inserted over a guidewire, previously inserted through the sheath, and advanced to the location of the clot within the blood vessel. The catheter is positioned precisely using fluoroscopic guidance or other imaging modalities. Once positioned, the balloon is inflated, creating pressure against the clot and effectively removing or dislodging it from the vessel walls.
223876796|NCT06051032|DEVICE|Thromboaspiration system|The thromboaspiration catheter is carefully guided to the site of the clot within the blood vessel. Once positioned, the suction mechanism is activated, creating a vacuum effect. The catheter gently aspirates or suctions the clot, gradually removing it from the vessel walls. The procedure is performed under fluoroscopic guidance or other imaging modalities to ensure accurate placement of the catheter and successful clot aspiration.
223876797|NCT02262468|RADIATION|x ray|
223876798|NCT06249412|DEVICE|MI-E with PEP function activated during the pause|PEP function will be activated during the pause when using the EOVE-70. The PEP function in cmH2O will start at 8 cmH2O; the PEP setting can be decreased or increased at the discretion of the practitioner to optimize. The other therapeutic settings (positive pressure, negative pressure, inspiratory time, expiratory time and pause time) will be set individually for each patient by an experienced physiotherapist in order to reach the best clinical efficacy (usual clinical care)
223876799|NCT06249412|DEVICE|MI-E without PEP function activated during the pause|The PEP function will not be activated during the pause when using the EOVE-70. The other therapeutic settings (positive pressure, negative pressure, inspiratory time, expiratory time and pause time) will be set individually for each patient by an experienced physiotherapist in order to reach the best clinical efficacy (usual clinical care)
223876800|NCT04194710|BIOLOGICAL|Autologous Cytokine Rich Serum|"Proteins, called cytokines, released from blood platelets and leukocytes, play an important role in the repair and regeneration of the injured tissue that causes lateral epicondylitis.~Autologous Cytokine Rich Serum is prepared by the medical devise Q-Cytokine (CE MED31489) from patient's blood. The company Tecnologia Regenerativa Qrem S.L., with licence number 7096-PS from Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), is the manufacturer of this product. Q-Cytokine is a lab-in-a-box devise, and consist of an automatic centrifuge and a sterile disposable kit. After 9 steps of centrifugation, that take place in 36 minutes, Cytokine Rich Serum is obtained. This Cytokine Rich Serum is then injected to the epicondyle.~Patients randomized to this treatment will receive 1 injections of Autologous Cytokine Rich Serum right after randomization and another one after 15 days.~This process will take place at outpatient clinics."
223876801|NCT04194710|PROCEDURE|Arthroscopic Resection|"Surgical treatment of resection by arthroscopy is the standard treatment for chronic epicondylitis. The surgery is performed in the operating room under local anesthesia and lasts approximately 30 minutes. During the surgery, the doctor accesses the tendon by arthroscopy to perform an exeresis of the degenerated tendon. After the operation, the patient is directed to the recovery room where the responsible doctor will perform a physical examination and examination before leaving the center.~This process will take place at the major ambulatory surgery center of the investigator's hospital."
223876802|NCT00003042|BIOLOGICAL|filgrastim|
223876803|NCT00003042|DRUG|cisplatin|
223876804|NCT00003042|DRUG|cyclophosphamide|
223876805|NCT00003042|DRUG|doxorubicin hydrochloride|
223876806|NCT00003042|DRUG|melphalan|
223876807|NCT00003042|DRUG|mesna|
223876808|NCT00003042|DRUG|paclitaxel|
223876809|NCT00003042|DRUG|tamoxifen citrate|
223876810|NCT00003042|PROCEDURE|bone marrow ablation with stem cell support|
223876811|NCT00003042|PROCEDURE|conventional surgery|
223876812|NCT00003042|PROCEDURE|peripheral blood stem cell transplantation|
223876813|NCT06397625|OTHER|Percutaneous electrical neurostimulation (Placebo)|"Group I (Control), will be operated with the same procedure but without electric current, and using placebo needles of the same size (Streitberger Placebo-Needle ® , Asiamed, Pullach, Germany)"
223876814|NCT06397625|OTHER|Percutaneous electrical neurostimulation|The Group II and III electrostimulation procedure is called peripheral nerve stimulation and is known as an echo-guided peripheral nerve stimulation technique using a blunt, dry needle (active electrode). The intervention will be performed on the pudendal nerve, in an area where there is no risk of perforating any vascular-nerve bundle. The invasive technique will be performed by a physiotherapist expert in musculoskeletal and peripheral nervous system ultrasound and specialized in invasive techniques, with two years of experience in the sector. The needle will be introduced through the anterior (perineum).
223876815|NCT05056402|BIOLOGICAL|3 doses of the Recombinant Human Papillomavirus Nonavalent (Types 6,11,16,18,31,33,45,52,58 )Vaccine(E.Coli)|Three doses administered intramuscularly at 0, 1 and 6 month.
223876816|NCT05056402|BIOLOGICAL|2 doses of theRecombinant Human Papillomavirus Nonavalent (Types 6,11,16,18,31,33,45,52,58 )Vaccine(E.Coli)|Two doses administered intramuscularly at 0 and 6 month.
223876817|NCT02300298|DRUG|Nintedanib|Nintedanib
223876818|NCT02300298|DRUG|Docetaxel|Docetaxel
223876819|NCT06844474|DRUG|SHR-1826；Adebrelimab；SHR-8068；Bevacizumab|"Drug:~Drug: SHR-1826 Administration by intravenous infusion for a cycle of 3 weeks.~Drug: Adebrelimab Administration by intravenous infusion for a cycle of 3 weeks.~Drug: SHR-8068 Administration by intravenous infusion for a cycle of 6 weeks.~Drug: Bevacizumab Administration by intravenous infusion for a cycle of 3 weeks."
223876820|NCT00560599|DRUG|mupirocin and chlorhexidine|"Mupirocin (Bactroban Nasal): twice a day for 7 days, apply one pea-sized amount of Bactroban Nasal ointment directly into one nostril and another pea-sized amount for the other nostril.~Chlorhexidine (Hibiclens): once a day for 14 days, rinse body with chlorhexidine."
223876821|NCT00560599|BEHAVIORAL|household cleaning and disinfection|Environmental cleaning with topical ethanol and laundering of clothes and linen.
223876822|NCT00560599|DRUG|mupirocin, chlorhexidine, & household cleaning/disinfection|"Mupirocin (Bactroban Nasal): twice a day for 7 days, apply one pea-sized amount of Bactroban Nasal ointment directly into one nostril and another pea-sized amount for the other nostril.~Chlorhexidine (Hibiclens): once a day for 14 days, rinse body with chlorhexidine.~Environmental cleaning with topical ethanol and laundering of clothes and linen."
223876823|NCT06793956|DRUG|Sintilimab and Linperlisib Combination Treatment|Sintilimab administered via intravenous infusion; Linperlisib administered orally.
223876824|NCT06848127|OTHER|Self-questionnaires|All subjects (healthy volunteers and all patients) will complete a battery of self-questionnaires, assessing emotional dysregulation, traumatic symptoms, alteration of the sense of self, sensitivity to social rejection, dissociative symptoms, child abuse, functional repercussions of the disorders, depressive and anxiety symptoms and Impulsivity.
223876825|NCT06848127|OTHER|Cognitive assessment|Completion of cognitive assessment, consisting of verbal fluency tasks , emotional Hayling, a dissociative associative memory retrieval task, a negative priming task and a heart rhythm detection task. The tasks of associative-dissociative memory retrieval, negative priming and heart rhythm detection will be coupled with a physiological recording, via a Biopac, to measure the change in skin conductance, body temperature and heart rate. The negative priming task will also be associated with the recording of eye movements allowing an indirect measurement of attentional orientation.
223876826|NCT06848127|OTHER|Momentary Ecological Assessment (EMA)|A momentary ecological evaluation protocol will be proposed (between visits V1 and V2 for all subjects and between V3 and V4 for the 4 groups of patients) in order to assess emotional and symptomatic dynamics in a daily life context through a connected wath. During 7 days, subjects will be invited, via their smartphone, to carry out daily semi-random readings (indicated by smartphone notifications) of their subjective emotional experiences (10 once/day), but also spontaneous (by reporting emotions deemed intense immediately afterwards that they take place).
224076669|NCT04567212|GENETIC|genetic evaluation|A sampe of blood (3 mL) and of oral mucosa will be take and analyzed using nCounter GX Human Inflammation Kit a comprehensive number of 8SNPs in 3 human genes known to be differentially expressed in allergic asthma.
224076670|NCT04567212|OTHER|MicroRNA evaluation|Using the sampe of blood (3 mL) using RT-PCR we will evaluate the expression of microRNA in enrolled patients
224076671|NCT00264706|DRUG|Nona-L-arginine|
224076672|NCT03524248|RADIATION|Image guided radiation therapy|Real-time 4D video imaging guidance with combination use of cone-beam computerized tomography (CBCT) useful for daily setup and target motion tracking in advanced image-guided radiotherapy (IGRT).
223876827|NCT06848127|OTHER|Semi-structured interviews ITI and DSCID-II|"ITI International Trauma Interview is a semi-structured interview consisting of one part allocated to the description of a traumatic event and two parts addressing the symptoms of PTSD (i.e. reliving, avoidance and alteration of wakefulness) and the symptoms of the disturbance of self-organization.~The SCID-II Structured Clinical Interview for DSM-IV Personality Disorder is a 90-item semi-structured interview, covering all 10 categories of personality disorder as described in the DSM-IV."
223876828|NCT04618133|BEHAVIORAL|Early time-restricted eating|Participants will be advised to eat only during a selected window of 8 hours over the 24-hour cycle, i.e. from 6am to 2pm, with a 1-hour allowance according to their daily routine
223876829|NCT04618133|BEHAVIORAL|Late time-restricted eating|Participants will be advised to eat only during a selected window of 8 hours over the 24-hour cycle, i.e. from noon to 8pm, with a 1-hour allowance according to their daily routine
223876830|NCT04618133|BEHAVIORAL|Active control|Participants will be advised to eat a minimum of 3 meals over the 24-hour cycle, i.e. breakfast from 6am to 9am, lunch from 11am to 2pm, dinner from 6pm to 10pm. Snacks will be allowed between meals
223876831|NCT02632071|DRUG|ACY-1215|An orally active, selective HDAC6 inhibitor. Assigned dosing 80 mg, 120 mg, 180 mg, 240 mg PO, once daily Days 1-21 in a 28-day cycle
223876832|NCT02632071|DRUG|Nab-paclitaxel|"Taxanes are among the most widely used chemotherapy agents in the treatment of breast cancer.~100 mg/m2 30 minute IV infusion Days 1, 8, and 15 in a 28-day cycle"
223876833|NCT00710294|DEVICE|CVRx Rheos Baroreflex Hypertension Therapy System|"The pulse generator, which is similar to a pacemaker, is typically implanted under the skin below the collarbone.~Two small leads from the device are wrapped around the carotid arteries on both sides of the neck and connected to the pulse generator."
223876834|NCT00280228|BEHAVIORAL|Adolescent Skills Parent Management Parent-Adol Negotiation|Acute treatment for 12 weeks followed by three monthly booster sessions.
223876835|NCT00280228|BEHAVIORAL|Treatment as Usual|Standard outpatient treatment for behavioral problems and substance use
223876836|NCT05209477|OTHER|lung ultrasound assessment|"In patients undergoing invasive mechanical ventilation with an arterial oxygen tension on inspired oxygen fraction ratio \< 200 mmHg requiring recruitment maneuver and prone positioning as a rescue therapy, lung aeration will be evaluated at:~1. baseline, in supine position under protective ventilation~2. after two minute of recruitment maneuver in pressure controlled ventilation~3. at 1 hour following prone positioning application"
223876837|NCT05171985|PROCEDURE|Dexmedetomidine sedation|72 cases sedated on Propofol infusion 50-200 mg/h + Fentanyl infusion 25-250 mcg/h guided by hemodynamics in addition to Dexmedetomidine infusion 0.2 - 1 mcg/kg/h, and also guided by hemodynamics.
223876838|NCT06093724|DIAGNOSTIC_TEST|Static and dynamic perineo-pelvic MRI|Static and dynamic perineo-pelvic MRI before surgery, and at 6 and 24 months after surgery.
223876839|NCT06521411|BEHAVIORAL|CSA model|Community-supported agriculture (CSA) involves a community of individuals who support a farm and in return receive distributions of the farm's produce throughout the growing season. Culturally appropriate produce will be provided in subsidized weekly boxes for 20 weeks to community members at Brooklyn Grange Farm in Sunset Park at a fee of $5, which was determined to be acceptable by community members. Participants that receive SNAP benefits can use their EBT card to cover their $5. Education will be offered in the form of nutrition education, cooking tutorials, and farming information provided by staff at Brooklyn Grange.
223876840|NCT01723267|OTHER|3D follicles assessment|3D ultrasound evaluation in IVF treatment (vs 2D ultrasound)
223876841|NCT01723267|OTHER|2D follicles assessment|2D ultrasound in IVF treatment (vs 3D ultrasound)
223876842|NCT06613906|DEVICE|Healsea Children nasal spray|dosage: 1 puff in each nostril twice daily during 3 treatment periods of 28 days interspersed by 2 wash-out periods of 10 days
223876843|NCT05029141|DRUG|CAHAG regimen|"Chidamide 30mg orally twice every week for 2 weeks on days 1, 4, 8, 11, azacytidine 75mg/m2 intravenously daily for 7 days (d3-d9) and HAG regimen (cytarabine, 10 mg/m2 subcutaneously every 12 h on days 3-16; homoharringtonine, 1mg/m2 intravenously every day on days 3-16; and concurrent granulocyte colony-stimulating factor, 200mg/m2/day subcutaneously daily from days 2 to neutral granulocyte recovery. (when WBC \> 20×10E9/L, G-CSF paused).~One treatment cycle for 28 days, a total of 2 cycles. If the bone marrow assessment is MLFS on the 28th day in the first cycle, the second cycle of treatment will be started after NE\<1.0×10E9/L; if the delay exceeds 2 weeks, the patient needs to withdraw from the trial."
223876844|NCT05029141|DRUG|Placebo regimen|"Chidamide 0mg orally twice every week for 2 weeks on days 1, 4, 8, 11, azacytidine 75mg/m2 intravenously daily for 7 days (d3-d9) and HAG regimen (cytarabine, 10 mg/m2 subcutaneously every 12 h on days 3-16; homoharringtonine, 1mg/m2 intravenously every day on days 3-16; and concurrent granulocyte colony-stimulating factor, 200mg/m2/day subcutaneously daily from days 2 to neutral granulocyte recovery. (when WBC \> 20×10E9/L, G-CSF paused).~One treatment cycle for 28 days, a total of 2 cycles. If the bone marrow assessment is MLFS on the 28th day in the first cycle, the second cycle of treatment will be started after NE\<1.0×10E9/L; if the delay exceeds 2 weeks, the patient needs to withdraw from the trial."
223876845|NCT01973322|OTHER|arm 1: DC Vaccine + RT|three daily doses of 8 Gy up to 12 Gy delivered to one non-index metastatic field between vaccine doses 1 and 2 (optional to one additional field between vaccine doses 7 and 8) utilizing IMRT-IMAT techniques
223876846|NCT01973322|OTHER|arm 2: DC Vaccine + IFN-alfa|daily 3 MU subcutaneous IFN-alfa for 7 days before leukapheresis (day -15 to -9, and for 7 days before any other additional leukapheresis)
223876847|NCT01973322|OTHER|arm 3: both arm 1 and 2 + RT|both 1 and 2 external immunostimulant conditions (Intradermal Autologous Dendritic Cell Vaccine + 3 single boosts of RT + IFN-alfa, 3 MU daily for 7 days before leukapheresis)
223876848|NCT01973322|BIOLOGICAL|arm 4: DC Vaccine|neither 1 or 2 external immunostimulant conditions (only Intradermal Autologous Dendritic Cell Vaccine)
223876849|NCT00790894|DRUG|ixabepilone|Arm A: ixabepilone will be given at a dose of 40 mg/m2 as a 3-hour intravenous infusion on Day 1 in a 21 days cycle.
223876850|NCT00790894|DRUG|ixabepilone|Arm B: ixabepilone will be given at a dose of 20 mg/m2 as a 3-hour intravenous infusion on Days 1, 8 and 15, then 1 week off in a 28-days cycle.
223876851|NCT00361205|DEVICE|Electronic Monitoring cap|
223876852|NCT03285763|DRUG|Atezolizumab|Participants will receive 1200 milligrams (mg) of atezolizumab administered by intravenous infusion on Day 1 of every 3-week cycle until Investigator-assessed loss of clinical benefit, unacceptable toxicity, investigator or participant's decision to withdraw from therapy, or death (whichever occurs first).
223876853|NCT03961451|DEVICE|Podometer|Patients will be equipped with pedometers for 8 weeks, all day and must complete the number of steps each day. They will have to complete online evaluation questionnaires regularly. The main objective is to correlate the level of physical activity with the level of fatigue, quality of life and well-being weekly during an anticancer treatment.
223876854|NCT03624972|BEHAVIORAL|Starting the Conversation Video|The Starting the Conversation program is designed to increase self-efficacy and outcome expectancies for communicating with providers about sexual health and related issues, reduce barriers to communication, and provide basic training in skills for communicating with providers about these topics, including prioritizing concerns, tips for effective communication, communication practice, and self-feedback.
223876855|NCT03624972|BEHAVIORAL|Sexual and Menopausal Health Resources|Patients will receive a resource list that includes both web-based resources on menopausal and sexual health and center-specific resources, such as contact information for a menopausal \& sexual health clinic.
223876856|NCT06146374|OTHER|Placebo for SLV213|Microcrystalline cellulose in a size 1 orange hard gelatin capsule.
223876857|NCT06146374|DRUG|SLV213|SLV213 drug substance (K777) is 4-methylpiperazine-1-carboxylic acid, a vinyl sulfone cysteine protease inhibitor for the treatment of subjects infected with SARS-CoV-2. SLV213 is a white powder substance without excipients or stabilizer that will be packed into gelatin capsules which has been demonstrated to exhibit broad inhibitory properties against host cathepsins (e.g., Cathepsin L).
223876858|NCT03593642|DRUG|Continuous infusion of ropivacain in ESP catheter|administration of ropivacaine in ESP catheter to provide regional analgesia after surgery
223876859|NCT03593642|DRUG|Continuous infusion of Iso Saline in ESP catheter|administration of Iso Saline in ESP catheter to be the control group
223876860|NCT04407975|OTHER|Betamethasone|A single injection will be administered to the patient at least 24 hours before undergoing C-section. This injection will be prepared in the hospital's pharmacy to contain betamethasone
223876861|NCT04407975|OTHER|Placebo|A single injection will be administered to the patient. This injection will be prepared in the hospital's pharmacy to contain normal saline.
223876862|NCT04148170|PROCEDURE|Endodiathermy Probe and Intubation Versus Intubation|children suffer from congenital nasolacrimal duct obstruction will have probing with endodiathermy probe and then intubation with bicanlicular silicon tube
223876863|NCT00086359|DRUG|Abacavir sulfate, lamivudine, and zidovudine|one pill twice daily
223876864|NCT00086359|DRUG|Lamivudine/zidovudine|one pill twice daily
223876865|NCT00086359|DRUG|Lopinavir/ritonavir|four pills twice daily
223876866|NCT05500859|OTHER|Data collection at Baseline, 3 months after baseline (BL), 1-year follow-up, Telephone follow-up and questionnaire 3 years and 5 years after BL|Data collection (Patient characteristics including medical history, current medication, cardiovascular risk factors, routine laboratory analysis (including lipids, Hb1c, NT-proBNP), clinical status, electrocardiogram, echocardiography data from latest echo, cardio pulmonary exercise testing (CPET), questions on general health behavior (diet, weekly exercise load), Quality of Life and questions on socio-economic parameters)
223876867|NCT06158204|BEHAVIORAL|Lifestyle Intervention|"Participants will receive guidance on when and what to eat and when to sleep and be physically active. Additionally, participants will be provided with whey protein isolate powder to be mixed with water and grain-based snack bars to be consumed primarily during work shifts. Lean body mass (kg) will be used to prescribe total caloric (\~30kcal/kg lean mass) and protein (2g/kg lean mass) needs and sleep/rest goals will be 6-8 hours per 24 hour day"
223876868|NCT05438160|DEVICE|Clinical Learning Study smartphone app (i.e., the study app)|The study app is designed to provide 7-weeks of the medication tracking and educational components in a clinical learning study version of CT-155. This design allows inferences to be made about the usability and acceptability of these components of CT-155. Eligible participants will be enrolled during an in-person clinic visit on Day 1. Participants will then be directed to access the study app and perform tasks each day for the 49-day engagement period.
223876869|NCT05193552|DRUG|Hizentra|subjects level of immunoglobulin replacement therapy will be adjusted for bioavailability as per manufacturer's instructions
223876870|NCT03456076|DRUG|Alectnib|Participants will receive alectinib 600 mg orally BID until completion of treatment period (24 months) or recurrence of disease , unacceptable toxicity, withdrawal of consent or death, whichever occurs first.
223876871|NCT03456076|DRUG|Cisplatin|"Participants will receive Cisplatin 75 milligrams per square meter (mg/m\^2) on Day 1 every 21 days IV intravenously (IV) until completion of treatment period (4 cycles), recurrence of disease, unacceptable toxicity, withdrawal of consent, or death, whichever occurs first."
223876872|NCT03456076|DRUG|Vinorelbine|Participants will receive Vinorelbine 25 mg/m\^2 IV on Days 1 and 8 Q21D until completion of treatment period (4 cycles), recurrence of disease, unacceptable toxicity, withdrawal of consent, or death, whichever occurs first.
223876873|NCT03456076|DRUG|Gemcitabine|Participants will receive Gemcitabine 1250 mg/m\^2 on Days 1 and 8 Q21D IV until completion of treatment period (4 cycles), recurrence of disease, unacceptable toxicity, withdrawal of consent, or death, whichever occurs first.
223876874|NCT03456076|DRUG|Pemetrexed|"Participants will receive 500 mg/m\^2 Day 1 Q21D until completion of treatment period (4 cycles), recurrence of disease, unacceptable toxicity, withdrawal of consent, or death, whichever occurs first."
223876875|NCT03456076|DRUG|Carboplatin|For participants who experience unacceptable toxicity with cisplatin, carboplatin can be used.
223876876|NCT06250283|DIETARY_SUPPLEMENT|Resveratrol|Resveratrol (500 mg)
223876877|NCT06250283|DIETARY_SUPPLEMENT|Placebo|Placebo (500 mg)
223876878|NCT06491017|DEVICE|MI-E Intervention protocol|"The endotracheal tube cuff will be inflated to 40 cmH2O and MI-E device will be used to deliver MI-E in automatic mode, with 4 sets of 5 respiratory cycles each and a 1-minute interval between each set.~Before initiation of the MI-E intervention protocol, the investigators will carry out a short-period test to find the appropriate MI-E settings to achieve inspiratory volumes of ≥1 liter and PEF ≥80 L/min. Concretely, inspiratory and expiratory time will always be set at 4 seconds and 2 seconds, respectively, and inspiratory flow will always be in slow mode. Once the appropriate inspiratory pressure will be found, the expiratory pressure will be initially set to exceed in 30 cmH2O the inspiratory pressure and, if required, this will be increased by 5 cmH2O until achieving a PEF ≥80 L/min with a maximum expiratory pressure of 70 cmH2O."
223876879|NCT06491017|DEVICE|Standard MI-E setting|"Cough Assist E70 device (Philips Respironics, USA, Andover, Massachusetts) will be used to deliver MI-E in automatic mode, with 4 sets of 5 respiratory cycles each and a 1-minute interval between each set. During the 1-minute pause between sets, the patient will be reconnected to the ventilator to avoid desaturation and de-recruitment during procedures. PEEP will remain stable during the protocol.~The standard MI-E setting will consist of in-expiratory pressures of +40/-40 cmH2O, medium inspiratory flow, with 3 seconds and 2 seconds of in-expiratory time, respectively, and 1-second pause."
223876880|NCT03230747|DEVICE|Edwards SAPIEN M3 System|SAPIEN M3 System includes the SAPIEN M3 valve and the SAPIEN M3 dock
223876881|NCT06476197|DEVICE|SAT-003|Device: SAT-003(Software) Using SAT-003 for 12 weeks
223876882|NCT06624371|DRUG|Atovaquone|"Atovaquone oral suspension (750 mg/5mL) will be administered with meals on an outpatient basis.~Patients 13 years and older will receive atovaquone 750 mg PO BID, the standard pediatric dosing for Pneumocystis Jirovecii Pneumonia (PJP) prevention and treatment.~For those aged 2-12 years, atovaquone will be dosed at 30mg/kg once daily. The maximum dose for children under 12 will be 1500 mg."
223876883|NCT06624371|RADIATION|Radiation Therapy|54-60 Gy in 1.8 Gy daily fractions of MRI-guided proton radiotherapy using intensity-modulated pencil-beam scanning technology to match the target will be used.
223876884|NCT04754022|OTHER|Restrictive Transfusion Strategy|Patients will receive a RBC transfusion if their Hb concentration is \<75 g/L (\<7.5 g/dL; \<4.7mmol/L) intraoperatively and/or postoperatively.
223876885|NCT04754022|OTHER|Liberal transfusion strategy|Patients will receive a RBC transfusion if their Hb concentration is \<95 g/L (\<9.5 g/dL; \<5.9mmol/L) intraoperatively, or postoperatively in the ICU; and/or \<85 g/L (\< 8.5 g/dL; \<5.3mmol/L) on the ward.
223876886|NCT05350592|DRUG|Tocilizumab|Single bolus
223876887|NCT05350592|DRUG|Dobutamine|Continous weight-adjusted infusion
223876888|NCT05350592|DRUG|NaCl 0.9%|Placebo comparator and diluent
223876889|NCT05261828|BEHAVIORAL|Education and rehabilitation associated with personalized follow-up|short multidisciplinary program including education and rehabilitation and a personalized follow-up for patients with subacute and chronic low back pain
223876890|NCT05261828|BEHAVIORAL|Reassuring messages and advices|Reassuring messages and advices in agreement with current recommendations
223876891|NCT05432830|OTHER|E-liquid Flavor 1|E-liquid containing 36mg/ml pronated nicotine will be administered with sweet e-cigarette flavor.
223876892|NCT05432830|OTHER|E-liquid Flavor 2|E-liquid containing 36mg/ml pronated nicotine will be administered with cooling e-cigarette flavor.
223876893|NCT05432830|OTHER|E-liquid Flavor 3|E-liquid containing 36mg/ml pronated nicotine will be administered with unflavored e-cigarette flavor.
223876894|NCT04136535|DRUG|Pemetrexed|Pemetrexed，500mg/m²，ivgtt ，d1，q3w
223876895|NCT04136535|DRUG|Carboplatin|Carboplatin，AUC 5.0，ivgtt，d1，q3w，
223876896|NCT04136535|DRUG|Anlotinib|Anlotinib ，12 mg，po，qd，d1-14，q3w；
223876897|NCT05909618|DRUG|Crizanlizumab-Tmca 10 MG/1 ML Intravenous Solution [ADAKVEO]|5 mg/kg solution for injection
223876898|NCT05909618|DRUG|Nivolumab 10 MG/1 ML Intravenous Solution [OPDIVO]|3 mg/mL solution for injection
223876899|NCT05698758|DRUG|Dextrometropine and 0.9% sodium chloride solution|Intranasal dexmedetomidine or 0.9% sodium chloride solution as a sedative premedication for patients undergoing cataract surgery
223876900|NCT06326125|BEHAVIORAL|TICK-B|TICK-B as art-based distraction
223876901|NCT06326125|DRUG|TKTX-Cream|TKTX-Cream as local anesthesia cream
223876902|NCT06326125|OTHER|TICK-B and TKTX-C|TICK-B and TkTx-C as combined intervention approche (pharmacology and non-pharmacology)
223876903|NCT03517917|OTHER|Tumour tissue collection|Collection of tumour tissue and blood
223876904|NCT05660603|OTHER|control|patients will receive standard general anesthesia
223876905|NCT05660603|PROCEDURE|LSP|patients will receive standard general anesthesia followed by ultrasound-guided combined lumbar and sacral plexus blocks with 40 ml of bupivacaine 0.25%.
223876906|NCT05660603|PROCEDURE|CP|patients will receive standard general anesthesia followed by ultrasound-guided circum-psoas blocks with 40 ml of bupivacaine 0.25%.
223876907|NCT05660603|DEVICE|Ultrasound|ultrasound
223876908|NCT03716336|OTHER|Resistance exercise|Resistance exercise were performed for all participants in group (A) only included 9 exercise for big muscles of upper limbs (shoulder flexors muscles, shoulder extensors and shoulder abductors), lower limbs (hip flexors, hip extensors and knee flexors and knee extensors) and abdominal muscle using moderate work load (60 - 75% of IRM) 1set of 10 repetitions, progressing to 2 sets of 10 repetitions after four weeks for 20 minutes
223876909|NCT03716336|OTHER|Aerobic exercise|aerobic exercise were performed on treadmill. For 20 minutes. All patients in both groups (A,B) had attended the program of a resistance exercises and followed by aerobic exercise for 8 weeks in form of 20 minutes walking on the treadmill without inclination.
223876910|NCT03716336|DIETARY_SUPPLEMENT|diet restriction|All participants in both groups (A,B) were instructed to follow a moderate restricted diet limited to (1800-2000) kcal/ day under supervision of a certified dietician. The diet contained: Protein and fibers: 20% carbohydrate: 50-60%, fat: low 20%.
223876911|NCT04042051|DRUG|Copanlisib|Copanlisib is supplied as lyophilized preparation in a 6mL injection vial. The total amount of copanlisib per vial is 60mg. The solution for IV infusions is obtained after reconstitution with normal saline solution. Copanlisib will be administered on Days 1 (and 8 and 15 \[according to the dose escalation scheme\]) of each 21-day cycle. Copanlisib will be administered first over 60 minutes followed by the infusion of trastuzumab emtansine.
223876912|NCT04042051|DRUG|Trastuzumab emtansine|Trastuzumab emtansine 3.6mg/kg IV infusion on Day 1 of each 21-day treatment cycle.
223876913|NCT03411356|BEHAVIORAL|Daily Caloric Restriction (DCR)|Participants in this group will be given a calorie goal designed to produce a 34.3% energy deficit from estimated baseline weight maintenance energy requirements. Participants in this group will also receive a 12 month comprehensive group-based behavioral weight loss program and will be instructed in specific strategies to support DCR. Randomized groups will meet separately. Participants in this group will also be asked to increase moderate intensity physical activity to a target of 300 minutes per week.
223876914|NCT03411356|BEHAVIORAL|Intermittent Fasting (IMF)|Participants in this group will be instructed to limit energy intake to 20% of estimated baseline energy requirements on three non-consecutive days per week, and to eat ad libitum the other 4 days per week. Participants in this group will also receive a 12 month comprehensive group based behavioral weight loss program and will be instructed in specific strategies to support IMF. Randomized groups will meet separately. Participants in this group will also be asked to increase moderate intensity physical activity to a target of 300 minutes per week.
223876915|NCT06088589|BEHAVIORAL|Mismatch negativity|"Event related potentials are compared between frequent and infrequent speech sounds (i.e., ba vs da)."
223876916|NCT03772652|OTHER|Observation|Soft tissue implant measurements
223876917|NCT04433078|DRUG|Doxycycline|100 MG Tablet
223876918|NCT04433078|DRUG|Placebo|Placebo Tablet
223876919|NCT05017129|BEHAVIORAL|Inmates Care|The single intervention is a computer-based learning program.
223876920|NCT06225895|PROCEDURE|general anesthesia|patients will receive general anesthesia.
223876921|NCT06225895|PROCEDURE|Erector spinae plane block|patients will receive Erector spinae plane block with 20 ml of bupivacaine 0.25% on each side followed by general anesthesia.
223876922|NCT06225895|PROCEDURE|a rhomboid intercostal nerve block|patients will receive a rhomboid intercostal nerve block with 20 ml of bupivacaine 0.25% on each side followed by general anesthesia.
223876923|NCT06225895|DRUG|Bupivacaine|20 ml of bupivacaine 0.25%
223876924|NCT05623163|DEVICE|EndoZip System|"The Nitinotes EndoZip system is designed to allow for the creation of multiple internal gastric segmentation (up to 5 sutures) in the stomach by using an endoscopic approach. The system allows the forming of wall-to-wall longitudinal attachments of the anterior and posterior stomach walls, creating multiple strictures within.~Creation of this segmentation may significantly reduce gastric volume, may affect gastric motility and consequently, reduce weight."
223876925|NCT03090763|GENETIC|PCR and sequencing|Blood will be subsequently added into a test tube containing RNA solution of a stabilizer, necessary for preservation of the circulating miRNAs. Subsequently, centrifugation will be performed in a cooled centrifuge and the material thus processed will be kept for the subsequent isolation. The isolation of miRNA will be performed using the High Pure miRNA Isolation Kit (Roche, Basel, CHE) according to the manufacturer's standardized procedure. Presence and quality of the miRNA isolated will be spectrophotometrically confirmed using the NanoDrop device (ThermoScientific, Wilmington, DE, USA). By means of the data available in the on-line gene data basis, primers that are necessary for amplification of miRNA through the RT-PCR method using fluorescent dyes will be suggested.
223876926|NCT04481074|OTHER|Inspiratory muscle training|Inspiratory muscle training will be performed using the tapered flow-resistive loading trainer (POWERbreathe®).
223876927|NCT06564753|DRUG|Drug: Placebo daily and orally|• Placebo comparator
223876928|NCT06564753|DRUG|NA-931, dose 1, daily and orally|"Drug: NA-931 dose 1, daily and orally~• NA-931 is a peptide quadruple GLP-1, IGF-1, GIP , Glucagon quadruple agonist"
223876929|NCT06564753|DRUG|NA-931, dose2, daily and orally|"Drug: NA-931 dose 2, daily and orally~• NA-931 is a peptide quadruple GLP-1, IGF-1, GIP , Glucagon quadruple agonist"
223876930|NCT06564753|DRUG|NA-931 dose 3, daily and orally|"Drug: NA-931 dose 3, daily and orally~• NA-931 is a peptide quadruple GLP-1, IGF-1, GIP , Glucagon quadruple agonist"
223876931|NCT06564753|DRUG|NA-931 dose 4, daily and orally|"Drug: NA-931 dose 4, daily and orally~• NA-931 is a peptide quadruple GLP-1, IGF-1, GIP , Glucagon quadruple agonist"
223876932|NCT05048914|DRUG|Ibuprofen|treatment of acute migraine attack
223876933|NCT03086863|DEVICE|electroacupuncture|All the patients in verum electroacupuncture group will receive acupuncture on the six adjacent acupoints (LI4, LI15, TE14, SI9, SI11, and GB21) in unilateral side. Acupuncture needles (stainless steel, 0.25 mm × 40 mm, Dong Bang Acupuncture Inc., Republic of Korea) will be inserted 10-15 mm in depth and de qi sensation will be elicited. Park sham guide tubes will be used in verum group, too. Low frequency stimulate (STN-111, Stratek, Republic of Korea) will be connected to the tips of needles to provide electrical stimulation at middle frequency (30 Hz). Needles with electrical stimulation will be retained for 20 minutes. Patients should take this procedure 3 times a week for 3 weeks (9 sessions in total).
223876934|NCT03086863|DEVICE|sham electroacupuncture|We selected a non-penetrating sham needling, i.e., Park sham device, which has been developed and validated in preceding studies as comparison. On the exactly same 6 acupoints as verum electroacupuncture group, needles will be installed with Park sham guide tubes and the same electrical stimulators will be connected the tips of needles. Since the needles do not penetrate the skin, the stimulation is not electrically conducted. To be sure of patient blinding, the low frequency stimulate will be turned on with the same frequency (30 Hz), which makes a fake noise, resulting in letting patients believe that they are taking real electroacupuncture therapy for 20 minutes. Sham group will also 9 session for 3 weeks (3 sessions a week).
223876935|NCT01285635|DRUG|AT-101|Pulse Dose: AT-101 dose of 40 mg b.i.d. on days 1-3 Metronomic Dose: AT-101, 20 mg daily, days 1-14
223876936|NCT01285635|DRUG|Docetaxel|Docetaxel 75 mg/m2 on Cycle Day 1
223876937|NCT01675999|OTHER|Perioperative simplified FOLFOX-4 chemotherapy|Preoperative chemotherapy
223876938|NCT01675999|OTHER|Perioperative FOLFOX4+Cetuximab chemotherapy|Preoperative chemotherapy
223876939|NCT01675999|OTHER|Surgery followed by FOLFOX4 chemotherapy|Preoperative chemotherapy
223876940|NCT03990649|DRUG|Soticlestat|Soticlestat tablets
223876941|NCT03990649|DRUG|Placebo|Soticlestat matching placebo tablets
223876942|NCT00088738|DRUG|[18F] SPA-RQ|
223876943|NCT04689685|OTHER|Wearing smartwatch and continous glucose sensor|Patients will be wearing a smartwatch and a continuous glucose meter (CGM) over a maximum duration of 3 months in an outpatient setting.
223876944|NCT01296646|DRUG|Naltrexone|50 mg oral naltrexone once/day
223876945|NCT01296646|BEHAVIORAL|Brenda Therapy Sessions|participants will meet with a trained therapist for nine 30-minute BRENDA therapy sessions Medical monitoring will also be conducted by study physicians and will consist of review of vital signs, concomitant medication use, and general inquiries into side effects.
223876946|NCT01296646|DRUG|Placebo|An inactive pill to control for non-pharmacological responses.
223876947|NCT05032534|DEVICE|Cone Small, Qufora A/S|Newly developed cone in a softer material and a design matching the use for transanal irrigation.
223876948|NCT05032534|DEVICE|Colotip, Coloplast A/S|Cone currently used for transanal irrigation at the Pediatric Ward, Aarhus University Hospital.
223876949|NCT04080336|DRUG|Dinoprostone|1 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia \& Upjohn, Puurs, Belgium) inserted by the study nurse 3hours before IUD insertion.
223876950|NCT04080336|DRUG|Misoprostol|1 vaginal tablet of misoprostol (200mcg) (Misotac®; Sigma Pharma, SAE, Egypt) inserted by the study nurse 3 hours before IUD insertion.
223876951|NCT04080336|DRUG|placebo|one tablet of placebo inserted by the study nurse 3 hours before IUD insertion.
223876952|NCT00209742|DRUG|UFT|P.O. everyday
223876953|NCT00209742|DRUG|USEL/Leucovorin|P.O. everyday
223876954|NCT00209742|DRUG|Krestin|P.O. everyday
223876955|NCT03496103|BIOLOGICAL|ragweed pollen|three hours ragweed pollen in a allergen exposure chamber
223876956|NCT03305146|GENETIC|Molecular biology analysis of pancreatic intra-cyst fluid|"The EUS FNA will be performed according to the Francophone Club of Echo Endoscopy recommendations.~For molecular biology technique, the samples will be processed within the UMR\_S910 unit. Nucleic acids will be extracted from the intra-cystic fluid or, for post-operative patients, from a resected specimen that will be collected into a tube containing a nucleic acid stabilization solution (Allprotect Tissue reagent, Qiagen).~The nucleic acids will be extracted and then sequenced. The sequencing technology chosen (HaloPlexHS, Agilent) allows a detection close to 1% in allelic frequency. This new technical approach that links high sensitivity and specificity is also suitable with degraded and/or low-volume ( \<50ng) DNA."
223876957|NCT03565523|OTHER|Beetroot|Containing 385 mg nitrate
223876958|NCT03565523|OTHER|Placebo beverage|\<0.1 mmol nitrate in sucrose solution with beet coloring
223876959|NCT05075694|BEHAVIORAL|Therapeutic Touch|Therapeutic Touch performed in line with the Therapeutic Touch Practice Procedure included the following steps: centering, assessing, rebalancing, reassessing, reexamining, grounding, and closure.
223876960|NCT05075694|OTHER|Sham Therapeutic Touch|The control group was administered STT instead of TT for 10 minutes for successive 5 days. The practice was implemented in line with STTPP. The practice was implemented by not centering or intending to help to heal, by moving at a longer distance, and by imitating the TT practice protocol visually.
223876961|NCT04454879|DRUG|Roxadustat|Patients in the standard dosage group will receive starting dosage of roxadustat 100 mg, three times per week for weight 45-60kg and 120 mg, three times per week for weight greater than 60kg. Patients in the lower dosage group will receive the starting dosage of roxadustat 50 mg, three times per week for weight lower than 50kg, 70 mg, three times per week for weight 50-70kg, 90 mg, three times per week for weight 70-90kg and 110 mg, three times per week for weight 90-110kg, respectively.
223876962|NCT01612312|PROCEDURE|Thrombectomy|Manual thrombectomy will be performed in the thrombus aspiration group using an aspiration catheter utilized in daily clinical routine (Eliminate, Terumo Europe, Leuven, Belgium). In the standard PCI group, patients will be treated by conventional PCI according to local practice without thrombectomy.
223876963|NCT01612312|PROCEDURE|Standard percutaneous coronary intervention|In the standard percutaneous coronary intervention (PCI) group, patients will be treated by conventional PCI according to local practice without thrombectomy.
223876964|NCT02612844|DRUG|NNC0143-0406|Subject will receive one single dose only Subcutanesously (s.c., under the skin)
223876965|NCT02612844|DRUG|insulin aspart|Subject will receive one single dose only. Subcutanesously (s.c., under the skin)
223876966|NCT02487069|PROCEDURE|HSCT from MSD|HSCT from MSD is the first choice for the patients who have HLA-matched sibling donors.
223876967|NCT02487069|PROCEDURE|HSCT from MUD|HSCT from MUD is the second choice for the patients who don't have HLA-matched sibling donors but have HLA-matched unrelated donors.
223876968|NCT02487069|PROCEDURE|HSCT from HRD|HSCT from HRD is the choice for the patients who have neither HLA-matched sibling donors nor HLA-matched unrelated donors.
223876969|NCT02487069|DRUG|Cyclosporin A|CsA is used in all the patients for GVHD prophylaxis.
223876970|NCT02487069|DRUG|Methotrexate|MTX is used in all the patients for GVHD prophylaxis.
223876971|NCT02487069|DRUG|Antithymocyte globulin|ATG is used in the patients receiving HSCT from MUD and HRD for GVHD prophylaxis.In MUD group,total ATG doses is 7 mg/kg;In HRD group,total ATG doses is 7.5 or 10 mg/kg.
223876972|NCT02487069|DRUG|Mycophenolate mofetil|MMF is used in the patients receiving HSCT from MSD and HRD for GVHD prophylaxis.
223876973|NCT02317874|DRUG|Carboplatin|Given IV
223876974|NCT02317874|DRUG|Paclitaxel|Given IV
223876975|NCT02317874|DRUG|Talazoparib|Given PO
223876976|NCT00580593|DEVICE|BiPAP® S/T System|The BiPAP® S/T System is a NIPPV device that provides intermittent ventilatory assistance to people with difficulty breathing secondary to respiratory muscle weakness.
223876977|NCT00580593|OTHER|sham-NIPPV|a sham-device
223876978|NCT05558423|BEHAVIORAL|Time Restricted Eating|Participants are asked to follow a Time Restricted Eating regimen with eating window of ≤10 hours.
223876979|NCT05101941|PROCEDURE|Immediate dental implants|Implants will be immediately placed in sockets associated with chronic periapical granuloma Extraction of non-restorable Teeth with periapical granuloma and socket debridement will be done then implants will be placed
223876980|NCT00321152|OTHER|6(S)-5-MTHF (a Medical Food)|The study consists of 8 visits over a period of 8 weeks or 60 days. Eligible participants will be randomized to double-blind treatment with placebo or Deplin (6(S)-5-MTHF). Participants will have a greater than 50% chance of receiving active medication (Deplin) at some point in the 8 week study. At the end of the double-blind phase, both responders and non-responders who have completed the 8 week study will have the option of receiving free, open-label adjunctive treatment with either 7.5 mg or 15 mg of 6(S)-5-MTHF for 12 months. Subjects who agree to receive open-label treatment with 6(S)-5-MTHF for 12 months will be assessed every three (3) months until the end of the follow-up phase.
223876981|NCT05589441|DRUG|salbutamol|10 mg salbutamol diluted to 2 ml with distilled water and inhaled as aerosolized for 15 min before the start of the hepatic-free phase.
223876982|NCT05589441|DRUG|Insulin|Intravenous injection of 8U of insulin complex 10% glucose solution 250 ml before the start of the hepatic phase was completed in 15 minutes.
223876983|NCT02134951|DRUG|Ketamine|intravenous infusion of saline solution with ketamine
223876984|NCT02134951|DRUG|Normal saline|Normal saline will be used for placebo in this group
223876985|NCT05927896|DIAGNOSTIC_TEST|6-item Carpal Tunnel Syndrome Symptoms Scale|6-item Carpal Tunnel Syndrome Symptoms Scale is a self-reported 6 item questionnaire.
223876986|NCT04015349|DIAGNOSTIC_TEST|Polysomnography|The polysomnography (referred to as type I) allows assessing several sleep physiologic parameters (eg, EEG, electrooculogram, electromyogram, electrocardiogram, airflow, respiratory effort, oxygen saturation), whereas audio-video recording enables documenting tooth-grinding sounds and distinguishing between rhythmic masticatory muscle activity (RMMA) and orofacial (eg, swallowing) and other muscular activity (eg, head movements) during sleep. Based on the RMMA index (number of episodes per hour of sleep), sleep bruxism is diagnosed when RMMA episodes are greater than or equal to 2 (low-frequency SB, mild bruxism) or RMMA episodes are greater than or equal to 4 (high-frequency SB, severe bruxism)
223876987|NCT02555475|OTHER|community based hepatitis C care and treatment|
223876988|NCT01535690|OTHER|photodynamic therapy and periodontal debridement|At least two teeth (one with PD ≥ 7 mm and another with PS ≥ 5 mm) were randomly assigned (by coin toss) to one of the treatments: with (test group) or without PDT (control group). After random allocation, all patients received full-mouth ultrasonic debridement using an ultrasonic scaler for 1 hour. Specific tips were used. PDT was performed on only one side of the mouth and the initial step was subgingival irrigation with 0.005% methylene blue dye. To avoid contamination of the control sites with the dye, the methylene blue was applied only inside the periodontal pockets and a high-powered suction device controlled the flow. Two minutes after applying the photosensitizer, the low power laser - AsGaAl was applied for 90 seconds.
223876989|NCT02773693|BEHAVIORAL|Cognitive Processing Therapy-Cognitive Only (CPT)|Twice weekly CPT over 6 weeks.
223876990|NCT02773693|BEHAVIORAL|Cognitive Behavioral Therapy of Insomnia and Nightmares (CBTin)|Cognitive behavioral therapy of insomnia and nightmares weekly over 6 weeks.
223876991|NCT02773693|BEHAVIORAL|Continuation Cognitive Processing Therapy-Cognitive Only (CPT)|Once weekly continuation CPT over 6 weeks.
223876992|NCT03039803|PROCEDURE|uterine closure during cesarean section|
223876993|NCT02005406|DEVICE|Experimental group and control groupl|JET
223876994|NCT01463176|BEHAVIORAL|Music Therapy|Live music therapy is interactive and incorporates behavioral cues for coping techniques during the procedure, using patient-preferred music.
223876995|NCT05882617|OTHER|implants supported overdentures|implant supported and retained with different number of implants retained by ball attachments
223876996|NCT00431834|DEVICE|Cardioblate System Surgical Ablation System|This investigation is a prospective, nonrandomized multicenter clinical trial evaluating the outcome of patients with AF requiring concomitant open heart surgery plus the Cardioblate Surgical Ablation System using the modified Maze III procedure. The trial population includes patients requiring valve replacements or repairs, atrial septal defect (ASD) repairs, patent foramen ovale (PFO) closure or coronary artery bypass grafts (CABG) procedures.
223876997|NCT00431834|PROCEDURE|Surgical RF Ablation|This investigation is a prospective, nonrandomized multicenter clinical trial evaluating the outcome of patients with AF requiring concomitant open heart surgery plus the Cardioblate Surgical Ablation System using the modified Maze III procedure. The trial population includes patients requiring valve replacements or repairs, atrial septal defect (ASD) repairs, patent foramen ovale (PFO) closure or coronary artery bypass grafts (CABG) procedures.
223876998|NCT05967429|DIAGNOSTIC_TEST|The neutrophil-to- lymphocyte ratio|It was calculated by dividing the neutrophil count by the lymphocyte count.
223876999|NCT05967429|DIAGNOSTIC_TEST|Prognostic nutrition index|It was calculated using the following formula: serum albumin (g/L) + 0.005 × total lymphocyte count/μL
223877000|NCT03312322|OTHER|High-frequency transcutaneous electrical nerve stimulation|"4 self adhesive surface electrodes are positioned by pair at the L3-L4 level, laterally.~Stimulation is setted at rest, 10min before constant workload testing. During this period, intensity is increased every 3minutes to the maximum tolerated by the patient (pain threshold). Thereafter, intensity is not increased anymore during the test.~It is explained to the patient that he might or no experience the electrical stimulation sensation.~Current characteristics : 100Hertz, 100ms, bidirectional. Constant workload testing : 60-70rpm ; 75% Wpic ; up to exhaustion or rpm \< 60 during more than 10s."
223877001|NCT03312322|OTHER|Low-frequency transcutaneous electrical nerve stimulation|"4 self adhesive surface electrodes are positioned by pair at the L3-L4 level, laterally.~Stimulation is setted at rest, 10min before constant workload testing. During this period, intensity is increased every 3minutes to the maximum tolerated by the patient (pain threshold). Thereafter, intensity is not increased anymore during the test.~It is explained to the patient that he might or no experience the electrical stimulation sensation.~Current characteristics : 4Hertz, 100ms, bidirectional. Constant workload testing : 60-70rpm ; 75% Wpic ; up to exhaustion or rpm \< 60 during more than 10s."
223877002|NCT03312322|OTHER|Sham transcutaneous electrical nerve stimulation|The procedure is the same as high-frequency transcutaneous electrical stimulation but intensity is progressively setted back to 1mA (over a 45sec period) after every increment so that constant workload testing is performed with 1mA.
223877003|NCT03532165|DIAGNOSTIC_TEST|Lower extremity Ultrasound|One group may forego a CT angiogram of the chest if they have a positive lower extremity ultrasound. The other group with a negative ultrasound may still require CT angiogram imaging.
223877004|NCT05408572|BIOLOGICAL|SON-1010 (IL12-FHAB)|SON-1010 is a single-chain human IL-12 cytokine linked to a single-chain variable region known as the FHAB.
223877005|NCT04066725|DRUG|Aspirin 81 mg|Participants will be given ASA 81 mg orally once daily for a total of 60 days
223877006|NCT04066725|DRUG|Aspirin 325mg|Participants will be given ASA 325 mg orally once daily for a total of 60 days
223877007|NCT04066725|DRUG|Placebo oral tablet|Participants will be given placebo orally once daily for a total of 60 days
223877008|NCT04071756|DRUG|Topical Tazarotene|This medicine works by making the skin less inflamed and reducing the thickness and pain from lesions of the skin
223877009|NCT04071756|OTHER|Placebo|A substance that has no therapeutic effect, used as a control in testing new drugs
223877010|NCT03628885|BEHAVIORAL|Top Concern Tailored Intervention|General Vaccine Information video plus a brief (\< 50 sec) animated video address the parent's top ranked question or concern from the provided list of possible concerns.
223877011|NCT03628885|BEHAVIORAL|All Concerns Tailored Intervention|General Vaccine Information video plus one or more brief (\< 50 sec) animated videos that address all of the parent's indicated question or concern from the provided list of possible concerns.
223877012|NCT05055752|DRUG|Pharmaceutical-lipid aspirin (PL-ASA)|Subjects receive the first drug, followed by a 7-day washout period, then receive the second drug.
223877013|NCT01422603|DRUG|Clofarabine|Clofarabine preconditioning (40mg/m2 daily for 5 days) prior to full intensity allogeneic stem cell transplant
223877014|NCT01422603|DRUG|Clofarabine|Clofarabine preconditioning (40mg/m2 daily for 5 days) prior to reduced intensity allogeneic stem cell transplant
223877015|NCT04508010|OTHER|IVR|Participants will receive an IVR survey
223877016|NCT04508010|OTHER|CATI|Participants will receive a CATI survey
223877017|NCT05715398|DRUG|BR790+anlotinib|BR790 will be administered orally, variable dose on Day 1 of each 21-day cycle， Anlotinib will be administered as PO fixed dose on Day1-14 of each 21-day cycle
223877018|NCT06222983|PROCEDURE|CEA or CAS|After the patient is admitted to the hospital, the supervising doctor comprehensively evaluates the patient's general condition and adopts CEA or CAS treatment. The researcher does not provide advice to the supervising doctor and only observes safety and effectiveness
223877019|NCT04710849|DIAGNOSTIC_TEST|Serum metabolic markers|Ultraperformance liquid chromatography / mass spectrometry (LC-MS) and gas chromatography / mass spectrometry (GC-MS) methods for analysis of the metabolites in AECOPD patients and compare the metabolites profiles between patients with systemic glucocorticoid treatment success and treatment failure.
223877020|NCT01066767|DRUG|Fexofenadine|Fexofenadine Hydrochloride 180 mg Tablets
223877021|NCT05310916|DRUG|Dapagliflozin 10mg Tab plus another oral hypoglycemic agent|Dapagliflozin is a member of Sodium-glucose co-transporter 2 inhibitors class which in addition to its glucose control effect, has reno-protective and cardioprotective effects, controls blood pressure and causes weight loss.
223877022|NCT05310916|DRUG|Two oral hypoglycemic agents other than dapagliflozin|Two oral anti-diabetic agents not including sodium-glucose co-transporter 2 inhibitors
223877023|NCT05634382|DRUG|Intravenous thrombolysis agents|Intravenous thrombolysis with recombinant tissue-type plasminogen activator (rt-PA，alteplase) or TNK-tPA (Tenecteplase，Metalyse)
223877024|NCT05634382|PROCEDURE|endovascular thrombectomy|endovascular mechanical thrombectomy with nonspecific device
223877025|NCT04556539|DRUG|SC10914|400mg TID, oral admination on fasting condition
223877026|NCT06302920|DEVICE|Kinesiotape|Lymphatic correction technique
223877027|NCT02461628|BEHAVIORAL|Malaria RDT & conditional voucher for ACT from retail sector|Trained community health volunteers will offer eligible household members free malaria rapid diagnostic tests and a voucher allowing the purchase of a qualified ACT at a reduced fixed price in the retail sector conditional on a positive test
223877028|NCT06107101|DRUG|Mepolizumab|100mg of mepolizumab every 4 weeks subcutaneously for 6 months
223877029|NCT01955226|OTHER|Tegaderm CHG clear dressing|Tegaderm CHG clear dressing will be used in central line care and will remain uniform as dictated by the central line maintenance bundle currently directing central line care in our children's hospital.
223877030|NCT01955226|OTHER|Standard clear Tegaderm dressing|Standard clear Tegaderm dressing will be used in central line care and will remain uniform as dictated by the central line maintenance bundle currently directing central line care in our children's hospital.
223877031|NCT02941484|PROCEDURE|early oral intake|early oral intake is started within 24 hours after pancreaticoduodenectomies following to the ERAS guideline
223877032|NCT02941484|PROCEDURE|jejunostomy tube feeding (JTF)|The jejunostomy tube was placed using the Flocare CH-10 tube with the longitudinal Witzel jejunostomy technique.nutrition is supplemented via JTF rather than early oral intake.Velocity is progressively increased by 20ml/hr until full nutritional goal (25Kcal/Kg)
223877033|NCT00000777|BIOLOGICAL|gp160 Vaccine (MicroGeneSys)|
223877034|NCT04106869|OTHER|Hyperventilation|"Ventilatory settings will be the following:~6-8 ml/kg and Respiratory rate adjusted to the required ETC02 (\<35 mmHg) PEEP in order to ensure a driving pressure (P plateau- PEEP) below 15 mmHg."
223877035|NCT04106869|OTHER|Hypoventilation|"Ventilatory settings will be the following:~6-8 ml/kg and Respiratory rate adjusted to the required ETC02 (40-45 mmHg) PEEP in order to ensure a driving pressure (P plateau- PEEP) below 15 mmHg."
223877036|NCT03217240|PROCEDURE|Cardiac Magnetic Resonance - MRI|All participants will have to undergo CMR which uses interaction of the magnetic properties of body tissues with strong magnetic fields to create images. Participants will be asked to lie on a narrow bed placed inside of a large magnet for about 1 hour. Several sets of images are needed. Participants are required to stay very still and follow the instruction of the MRI technologist who operates the machine from a room next door.
223877037|NCT03217240|OTHER|Cardiopulmonary Exercise Test|Participants will be asked to undergo a cardiopulmonary exercise test (CPET). Participants will need to wear a mask. Several electrodes will be placed on the chest to record heart activity during exercise. Participants will need to pedal for at least 8-12 minutes. Pedalling will be instructed to report any symptoms such as chest discomfort, shortness of breath, leg fatigue or dizziness. A small probe will be placed on participant's finger during the test to measure the oxygen content in the blood. Immediately after exercising, participants will rest for 5-10 minutes while the blood pressure and electrocardiogram are monitored. The results will be read by a cardiologist.
223877038|NCT03217240|OTHER|Blood Sampling for all participants|Serum samples will be obtained before CMR. The sample will be stored at -80 degree until assay. Investigators will perform various tests related to participants heart function
223877039|NCT02167958|DRUG|Fludarabine|"Fludarabine 30 mg/m2/day will be administered over 30-60 minutes intravenous infusion on Days -6 through -2. Fludarabine will be dosed according to the recipient's Adjusted Ideal Body Weight (AIBW) unless AIBW is less than Ideal Body Weight (IBW).~For decreased creatinine clearance (\< 61 mL/min) determined by the Cockcroft Formula:~Cockcroft-Gault CrCl = (140-age) \* (Wt in kg) \* (0.85 if female) / (72 \* Cr)~Fludarabine dosage should be reduced per standard of care."
223877040|NCT02167958|DRUG|Cyclophosphamide|"Pre-transplant~Cy 14.5 mg/kg/day will be administered as a 1-2 hour intravenous infusion with a high volume fluid flush on Days -6 and -5. Cy will be dosed according to the recipient's actual body weight unless the patient weighs more than 125% of IBW, in which case the drug will be dosed according to the adjusted IBW~Post-transplant~Hydration prior to cyclophosphamide may be given according to Standard Practice Guidelines.~Cyclophosphamide \[50mg/kg\] will be given on Day 3 post-transplant (between 60 and 72 hours after marrow infusion) and on Day 4 post-transplant (approximately 24 hours after Day 3 cyclophosphamide). Cy will be dosed according to the recipient's actual body weight unless the patient weighs more than 125% of IBW, in which case the drug will be dosed according to the adjusted IBW. Cyclophosphamide will be given as an IV infusion over 1-2 hours.~."
223877041|NCT02167958|DRUG|Mesna|"Pre-transplant~Mesna should be given in divided doses IV 30 min pre- and at 3, 6, and 8 hours post-cyclophosphamide. Mesna dose will be based on the cyclophosphamide dose being given. The total daily dose of mesna is equal to 100% of the total daily dose of cyclophosphamide.~Post-transplant~Mesna should be given in divided doses IV 30 min pre- and at 3, 6, and 8 hours post-cyclophosphamide. Mesna dose will be based on the cyclophosphamide dose being given. The total daily dose of mesna is equal to 100% of the total daily dose of cyclophosphamide."
223877042|NCT02167958|RADIATION|Total Body Irradiation|200 cGy will be administered in a single fraction on Day -1 via linear accelerator.
223877043|NCT02167958|OTHER|Hematopoietic stem cell infusion|Donors who consent to PBSC donation will receive 5 daily doses of G-CSF, 10 μg/kg/day by subcutaneous injection commencing on day -5. PBSC's will be collected in the afternoon of day -1, stored at 4C overnight, and infused as soon as possible on day 0. If the collection on day -1 contains less than 5.0 X 106 CD34+ cells per kg recipient weight, a second collection will be performed the following morning and infused on day 0. Quantitation of CD34 and CD3 cells will be performed by the Cellular Therapy Lab. For all patients, the target number of CD34 cells to be infused should be 5-6 X 106 cells per kg recipient weight. PBSC in excess of 6.0 x 106 CD34 cells/kg recipient weight may be cryopreserved.
223877044|NCT02167958|DRUG|Tacrolimus|Tacrolimus will be given at a dose of .03 mg/kg IV over 24 hours. Tacrolimus will be changed to a PO dosing schedule once a therapeutic level is achieved and the patient is tolerating PO. Whole bloodblood levels of tacrolimus will be measured around Day 7 and then should be checked at least weekly thereafter and the dose adjusted accordingly to maintain a level of 5-10 ng/mL. Tacrolimus will be discontinued after the last dose around Day 180, or may be continued if active GVHD is present. Cyclosporine (target concentration 200-400 ng/ml) may be substituted for tacrolimus if the patient is intolerant of tacrolimus.
223877045|NCT02167958|DRUG|Mycophenolate|Either the sodium salt of mycophenolate or mycophenolate mofetil (MMF) may be used as prophylaxis of GvHD and will be dosed by actual bodyweight. Only MMF is available as IV formulation. Sodium mycophenolate will be given at a dose of 10mg/kg PO TID rounded to the nearest number of 180mg tablets. MMF will be given at a dose of 15 mg/kg PO TID. The maximum total daily dose should not exceed 2160 mg (sodium salt) or 3 grams (mofetil). Mycophenolate prophylaxis will be discontinued after the last dose on Day 35, or may be continued if active GVHD is present.
223877046|NCT02167958|DRUG|G-CSF|G-CSF will be given beginning on Day 5 at a dose of 5 mcg/kg/day (rounding to the nearest vial dose is allowed), until the absolute neutrophil count (ANC) is \> 1,000/mm3 for three consecutive days.
223877047|NCT01522794|DRUG|NOX-H94|single i.v. infusion
223877048|NCT01522794|DRUG|Placebo solution|single i.v. infusion
223877049|NCT02515071|DIETARY_SUPPLEMENT|Dietary nitrate|140ml of nitrate rich beetroot juice provides 12.9mmol nitrate and will be consumed on a daily basis during the intervention by the study subjects.
223877050|NCT02515071|DIETARY_SUPPLEMENT|Placebo|140ml of nitrate depleted beetroot juice provides 0.5mmol nitrate and will be consumed on a daily basis during the intervention by the study subjects.
223877051|NCT06464224|BEHAVIORAL|low respiratory effort|patients under respiratory effort lower than -1,5 cmH2O (P0,1) and/or -7 cmH2O (Pocc)
223877052|NCT06464224|BEHAVIORAL|high respiratory effort|patients under respiratory effort higher than -3,5 cmH2O (P0,1) and/or -15 cmH2O (Pocc)
223877053|NCT02634892|DEVICE|PRO-TECT|Patient will be placed on ROHO SOFFLEX2 mattress with has been modified with gel cushions in the sacral region for heal dissipation by standard closed system cooling pad
223877054|NCT06451770|DRUG|VERVE-201|Intravenous (IV) infusion
223877055|NCT04282824|PROCEDURE|Biospecimen Collection|Undergo collection of saliva
223877056|NCT04282824|PROCEDURE|Computed Tomography|Undergo PET/CT
223877057|NCT04282824|DRUG|Gallium Ga 68-labeled PSMA-11|Given IV
223877058|NCT04282824|DIETARY_SUPPLEMENT|Monosodium Glutamate|Given PO
223877059|NCT04282824|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
223877060|NCT05835934|DRUG|[14C]HSK21542|A single intravenous dose of 2 μg/0.212 μCi/kg \[14C\]HSK21542 in boluses within 2 minute after fasting for at least 10 hours.
223877061|NCT04667858|DEVICE|Home Ovulation Test|Visual read home ovulation test
223877062|NCT04238858|BIOLOGICAL|Platelet rich plasma|blood is drawn from the patient's antecubital vein and inserted into four 3.0 ml vacutainer tubes that contain trisodium citrate. These four tubes were placed in a centrifuge machine, and centrifugation was carried out at 2500 rpm (580×g) for 8 min within a 30-min blood collection period. As a result of centrifugation, the plasma was separated in the vacutainer tubes from the remaining blood components. Three different layers formed in the tubes: red blood cells at the bottom, aPRP in the middle layer, and aPPP in the top layer. A total of 1.5 ml of the middle layer (which mainly contained platelets) was withdrawn by syringe, and it was immediately injected into the subtenon space of each eye.
223877063|NCT04014439|DIAGNOSTIC_TEST|Ratio of Neutrophil to Lymphocyte|Each patient was examined for a blood sample of 6 ml of venous blood taken from the cubital vein using a vacuum tube without anticoagulants. Blood samples were centrifuged at a speed of 3500 rpm for 20 minutes. Samples are processed with abbott® devices, to obtain neutrophil and serum lymphocyte levels. Plasma samples are stored in the refrigerator -20 C. The patient's diaphragm thickness was measured on days 0, 3, 5 and then the measurement was compared. Diaphragm thickness was measured in patients using mechanical ventilation in intensive care rooms.
223877064|NCT04014439|DIAGNOSTIC_TEST|Level of Prealbumin Serum|Each patient was examined for a blood sample of 6 ml of venous blood taken from the cubital vein using a vacuum tube without anticoagulants. Blood samples were centrifuged at a speed of 3500 rpm for 20 minutes. Samples are processed with abbott® devices, to obtain neutrophil and serum lymphocyte levels. Plasma samples are stored in the refrigerator -20 C. The patient's diaphragm thickness was measured on days 0, 3, 5 and then the measurement was compared. Diaphragm thickness was measured in patients using mechanical ventilation in intensive care rooms.
223877065|NCT00175812|DRUG|all-trans retinoic acid (ATRA)|All-trans retinoic acid 22.5 mg/square meter twice daily days 1-14
223877066|NCT00175812|DRUG|Valproic acid|Valproic acid, highest dose without side effects from day 3 until progression
223877067|NCT00175812|DRUG|Theophyllin|Theophyllin, targetted serum level 50-100 from day 3 until progression
223877068|NCT01073358|PROCEDURE|Routine hilar lymphadenectomy|Hilar lymphadenectomy is performed before actual resection of the colorectal liver metastases
223877069|NCT03304041|DIETARY_SUPPLEMENT|low-FODMAPs diet|"The low-FODMAPs diet(LFD) aims to keep oligosaccharides, fructose in excess of glucose, and polyol content at less than 0.5 g each per serving based on previously published data.~low-FODMAPs diet therapy for 3 weeks"
223877070|NCT03304041|DIETARY_SUPPLEMENT|Traditional dietary advice|"Traditional dietary advice(TDA) will focus more on how and when to eat rather than on what foods to ingest . Patients will be instructed to regularly eat, never too much or too little, never to be hungry or too full; to eat in peace and to chew thoroughly; reduce intake of fatty, spicy food, fiber, coffee and alcohol during the intervention period~traditional dietary advice for 3 weeks"
223877071|NCT02930200|BEHAVIORAL|Treatment as Usual|Tobacco Treatment Research Program (TTRP) or Treatment as Usual (TAU)
223877072|NCT02930200|BEHAVIORAL|QuitGuide|NCI QuitGuide Treatment App
223877073|NCT02930200|BEHAVIORAL|Smart-T|Smart-Treatment App
223877074|NCT03331575|RADIATION|Arm1 (Hypofractionated radiotherapy)|hypofractionated RT（PTV-G60.5Gy/22Fx, 2.75Gy/Fx; PTV-C 49.5Gy/22Fx, 2.25Gy/Fx）, with concurrent chemotherapy : Cisplatin(20 mg/m2 d1) Docetaxel (20 mg/m2 d1),weekly, 6 cycles )
223877075|NCT00324350|DRUG|hypoglycemic agents, hydroxymethylglutaryl-CoA Reductase inhibitors, hypertensive agents|type 2 diabetes treatments, per standard of care
223877076|NCT00439413|DRUG|Selegiline Transdermal Patch|Selegiline cm(2) via transdermal system
223877077|NCT00439413|DRUG|Placebo|Matching placebo via transdermal system
223877078|NCT00439413|BEHAVIORAL|Smoking Cessation Counseling|Subjects were provided with on-site, individual smoking cessation counseling sessions 1x per week for 9 weeks
223877079|NCT01310348|DEVICE|whole-body vibration (WBV)|The whole-body vibration (WBV) training group will be trained on a WBV platform (Power Plate) 5 times a week for 4 weeks period. Training volume and training intensity will be low at the beginning but progressed slowly according to the overload principle. The training volume will be increased systematically over the 4-week training period. The training intensity will be increased by increasing the amplitude (2-4 mm) and the frequency (40 Hz) of the vibration.
223877080|NCT01310348|DEVICE|WBV (Sham stimulation)|Sham stimulus will be performed by WBV platform 5 times a week for a 4 weeks period.
223877081|NCT04255706|DEVICE|biometric measurement IOLMaster 700|Three biometric measurements will be performed with 3 devices for all the patients included
223877082|NCT04255706|DEVICE|biometric measurement Lenstar LS 700|Three biometric measurements will be performed with 3 devices for all the patients included
223877083|NCT04255706|DEVICE|biometric measurement Anterion Heildelberg|Three biometric measurements will be performed with 3 devices for all the patients included
223877084|NCT05857930|DRUG|OM-85|OM-85 capsule (3.5mg) contents will be mixed with adequate quantity of water, fruit juice or milk/formula and orally administered once a day for 6 consecutive months.
223877085|NCT05857930|DRUG|Placebo|Placebo capsule contents will be mixed with adequate quantity of water, fruit juice or milk/formula and orally administered once a day for 6 consecutive months.
223877086|NCT03556085|DEVICE|Venous sinus stenting (Serenity River)|Patient is placed under general anesthesia. From femoral vein access, a standard guide-catheter is advanced in the internal jugular vein (on the side considered for stenting). The sigmoid then transverse sinus is catheterized with a microcatheter and guide-wire and an exchange guide-wire is placed in the superior sagittal sinus. The River stent delivery catheter is advanced over the exchange guide-wire in the sigmoid then transverse sinus up to the torcula. The River stent is deployed to cover the entire transverse sinus and the proximal half of the sigmoid sinus. The catheters are removed and hemostasis obtained by using a closure device or manual compression. The patient is kept overnight in the hospital for observation.
223877087|NCT00334776|BIOLOGICAL|MART-1 antigen|
223877088|NCT00334776|BIOLOGICAL|gp100:209-217(210M) peptide vaccine|
223877089|NCT00334776|BIOLOGICAL|therapeutic autologous dendritic cells|
223877090|NCT00334776|BIOLOGICAL|tyrosinase peptide|
223877091|NCT03614273|DRUG|Hypertonic saline|The nebulizations were administered via an oxygen run jet nebulizer, with a flow of 6-7 litres/min.
223877092|NCT03614273|DRUG|Adrenaline|The nebulizations were administered via an oxygen run jet nebulizer, with a flow of 6-7 litres/min.
223877093|NCT02647905|DEVICE|Continuous Glucose Monitoring System|Accuracy and safety assessment of a continuous glucose monitoring device
223877094|NCT00133250|DRUG|Abciximab|Abciximab bolus and infusion is given. Study medication includes 3 identical vials, each with 5 ml solution containing 10 mg abciximab. The bolus dose to be given should be rated at 0.125 ml/kg of patient's weight. After the bolus, a total dose of 0.045 ml/kg study substance (up to a maximal quantity of 3.6 ml) should be given over 12 hours.
223877095|NCT00133250|OTHER|Placebo Heparin Sodium|Placebo bolus plus infusion is given. Study medication includes 3 identical vials, each with 5 ml solution containing 3000 U Heparin. The bolus dose to be given should be rated at 0.125 ml/kg of patient's weight. After the bolus, a total dose of 0.045 ml/kg study substance (up to a maximal quantity of 3.6 ml) should be given over 12 hours.
223877096|NCT01762475|DRUG|Sildenafil|
223877097|NCT02015520|DRUG|Clazakizumab|
223877098|NCT02015520|DRUG|Placebo (Matching with Clazakizumab)|
223877099|NCT05387044|RADIATION|SBRT|Patients with oligoprogressive NSCLC after first line treatment with immune checkpoint inhibitors will be treated with SBRT for all progressing lesions.
223877100|NCT00415402|DRUG|Vitamin D3|
223877101|NCT02531737|DRUG|vargatef®|Patients will be treated to oral nintedanib (vargatef®) 400 mg/d on days 2 to 21 of a 3-week cycle
223877102|NCT02531737|DRUG|Docetaxel|Patients will be treated to IV docetaxel 75 mg/m² on day 1 of evry 3-week cycle
223877103|NCT00972075|DRUG|melatonin (Circadin)|2 mg prolonged release melatonin tablets once daily 2 hours before going to bed
223877104|NCT00972075|DRUG|placebo|one tablet per day 2 hours before going to bed
223877105|NCT00265200|DRUG|zoledronic acid|3.0-4.0 mg by IV (in the vein), once a month for 6 months
223877106|NCT01294956|OTHER|Lubricant Eye Drop|1 drop in each eye, four times a day for 42 days
223877107|NCT01294956|OTHER|Refresh Liquigel|1 drop in each eye, four times a day for 42 days
223877108|NCT02065193|BEHAVIORAL|ADOS/ADI-R/Clinical assessment|
223877109|NCT01746641|DRUG|Remifentanil|
223877110|NCT01746641|DRUG|Propofol|
223877111|NCT05119855|BIOLOGICAL|9vHPV Vaccine|9-valent human papillomavirus (Types 6, 11, 16, 18, 31, 33, 45, 52, 58) administered as a 0.5-mL intramuscular (IM) injection
223877112|NCT05119855|BIOLOGICAL|mRNA-1273 Vaccine|mRNA-1273 50 mcg dose administered as a 0.25-mL IM injection
223877113|NCT02932579|OTHER|Pharmacogenomic Testing|Saliva collection (5mL)
223877114|NCT02932579|DRUG|Ibuprofen|400 mg
223877115|NCT02932579|DRUG|hydroxycontin/acetominophen|hydroxycontin 2.5 mg, acetominophen 325 mg
223877116|NCT02932579|DRUG|acetominophen|650 mg
223877117|NCT02932579|DRUG|Oxycontin/acetominophen|5mg Oxycontin, 325 mg acetominophen. This will be a rescue medication is the other three pain medications do not work.
223877118|NCT00414024|DRUG|Tegaserod|
223877119|NCT01972724|DRUG|Pioglitazone|Pioglitazone tablets
223877120|NCT01972724|DRUG|Metformin|Metformin as prescribed in clinical practice
223877121|NCT01972724|DRUG|Sulfonylurea|Sulfonylurea as prescribed in clinical practice
223877122|NCT03791008|OTHER|Risk based screening|Breast cancer risk measurement, screening recommendations and shared decision making
223877123|NCT04542005|BEHAVIORAL|q3h albuterol|Using q3h albuterol as discharge criteria from hospital
223877124|NCT06191016|DEVICE|Vagal nerve stimulation|Experimental group will receive noninvasive vagal nerve stimulation (nVNS) in addition to prescribed medications
223877125|NCT06191016|DEVICE|Sham vagal nerve stimulation|control will receive sham stimulation to vagal nerve along with prescribed medications
223877126|NCT05188300|PROCEDURE|Freestyle pedicled perforators propellers flaps for meningomyelocele defects|Freestyle pedicled perforators propellers flaps for meningomyelocele defects reconstruction with sequential advance in perforators dissection, large number cases, and detailed successful technique.
223877127|NCT00054210|DRUG|carboplatin|
223877128|NCT00054210|DRUG|paclitaxel|
223877129|NCT00054210|DRUG|paclitaxel poliglumex|
223877130|NCT02846909|DRUG|Progesterone|400mg progesterone pessaries
223877131|NCT06392412|BEHAVIORAL|fi-VR Cognitive Training|All participants will 16 sessions over eight weeks, with two sessions per week, each lasting 70 minutes. Participants in the fi-VRCT will use the virtual reality system with head-mounted display and handheld controllers. The fi-VRCT will be administered by an experienced research assistant.
223877132|NCT06392412|BEHAVIORAL|Traditional Cognitive Training|All participants will 16 sessions over eight weeks, with two sessions per week, each lasting 70 minutes. The CT control program will include cognitive board games designed to improve various cognitive capacities. Certified community occupational therapists will lead the CT control group.
223877133|NCT06211972|BEHAVIORAL|OpiVenture|"OpiVenture, a targeted psychosocial intervention, complements opioid agonist therapy for opioid use disorder. Adapted from proven interventions like PreVenture, it unfolds over three sessions. Session one covers introductions, an ice-breaker, trait overview, strengths/limitations discussion, goal setting, and homework. Session two reviews homework, explores coping strategies, weighs alternatives, introduces hot thoughts, reviews trait-specific hot thoughts, and assigns homework. The concluding session involves reviewing homework, identifying personal hot thoughts, challenging them through a cognitive-behavioral exercise, applying insights to goal setting, and concluding with a wrap-up."
223877134|NCT00944593|DIETARY_SUPPLEMENT|Jejunal Feed|Liquid nutrient (Ensure 200ml (300kcal) over 60 minutes) will be delivered by naso-jejunal feeding tube (previously placed by endoscopy)
223877135|NCT00944593|DIETARY_SUPPLEMENT|Normal Saline|200ml Normal Saline 0.9%
223877136|NCT02168400|DEVICE|Transcranial Direct Current Stimulation (tDCS)|tDCS will be performed with Neuroelectrics Starstim Enobio 20, a non-invasive investigational device that has been labeled as a non-significant risk device by the FDA. This study is regulated by the FDA as an Abbreviated IDE. It has built-in safety mechanisms which allow for immediate cessation of stimulation if the subject becomes uncomfortable. The current will be administered via two electrode sponges for 25 mins with 1-2 milliamperes. These administration protocols are in line with protocols that have outlined safe administration (Nitsche 2007; 2008). No side-effects have been reported with the exception of slight itching under the electrode and occasional occurrence of headache, fatigue, or nausea (Poreisz 2007). Electrodes placement: dorsolateral prefrontal cortex (DLPFC); cathode on left DLPFC, anode on right DLPFC.
223877137|NCT06272058|DRUG|Avenciguat (BI 685509)|Avenciguat (BI 685509)
223877138|NCT06958666|DEVICE|Digital Inhaled Therapy Management|"The subjects will be trained on their inhalation techniques with the Digital Medication Administration Device consists of an inhalation device with a display and inhalation technique assessment module. The device will show a standardized video demonstration and will evaluate the subjects' inhalation technique. A printed report will be available afterwards.~A home-based inhalation management service package will be provided to the subjects including a digital sensor that records the time, frequency, and key inhalation technique parameters for each use of metered-dose inhalers or dry powder inhalers, and automatically synchronizes the data to the cloud. The data is then analyzed for adherence and technique performance. Based on the data, subjects will receive medication reminders and voice alerts for any technique errors on the app provided with the package. Visual charts of medication adherence and inhalation technique will be available to reinforce self-management."
223877139|NCT06958666|DEVICE|Inspiratory Muscle Training|The subjects will receive standardized verbal training and demonstration of inhalation techniques and any questions will be answered Inspiratory muscle training equipment, ancillary software, inspiratory muscle training plan, and equipment user guide will be sent home with the patient.
223877140|NCT06160791|DRUG|Ruxolitinib|Administered Orally (PO)
223877141|NCT06160791|DRUG|Etoposide|Administered IV
223877142|NCT06160791|DRUG|Dexamethasone|Administered PO or IV
223877143|NCT06160791|PROCEDURE|Non-interventional Imaging|Participants undergo abdominal ultrasound and/or magnetic resonance imaging (MRI)
223877144|NCT06160791|PROCEDURE|Research Biopsy|Bone marrow biopsy and lymph node biopsy will be obtained during screening and as clinically indicated throughout the trial.
223877145|NCT06160791|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223877146|NCT06517355|OTHER|In this research, the procedure under study is represented:|"* On the one hand, by carrying out sexology consultations which consist of individual interviews with a qualified sexologist nurse.~* Secondly, questionnaires to assess quality of life and sexual function, to be completed by patients during standard follow-up consultations; and a questionnaire on satisfaction with sexological follow-up, to be completed by patients and their partners (if applicable) during the last standard follow-up consultation."
223877147|NCT00335036|DEVICE|ICD lead implant|Randomization of ICD lead type at implant
223877148|NCT00335036|DEVICE|Thin leads|Thin (less than or equal to 7 French introducer) isodiametric ICD leads
223877149|NCT06347640|BIOLOGICAL|induced bleeding|revascularization of tooth is achieved by induced bleeding
223877150|NCT06347640|BIOLOGICAL|plasma rich fibrin|revascularization of tooth is achieved by plasma rich fibrin
223877151|NCT06299098|DRUG|Trevogrumab-Part A|Administered IV or SC in Part A
223877152|NCT06299098|DRUG|Trevogrumab-Part B and Part C|Administered SC in Part B, Part C
223877153|NCT06299098|DRUG|Garetosmab|Administered IV in Part B
223877154|NCT06299098|DRUG|Semaglutide|Administered SC in Part B and Part C
223877155|NCT06299098|DRUG|Matching Placebo-Part A|Administered IV or SC in Part A
223877156|NCT06299098|DRUG|Matching Placebo-Trevogrumab|Administered SC in Part B and Part C
223877157|NCT06299098|DRUG|Matching Placebo-Garetosmab|Administered IV in Part B
223877158|NCT04348123|OTHER|Survey|Survey questionnaire seeks to collect data relevant to mammogram completion, barriers, and facilitators
223877159|NCT04348123|BEHAVIORAL|Education Session|After the survey, clinic staff will conduct brief, culturally-appropriate educational session about breast health and mammography delivered by a female public health educator with experience in the underserved community. Educational session will explain screening options and address common barriers
223877160|NCT04086745|DRUG|Baricitinib|Administered orally.
223877161|NCT04086745|DRUG|TNF Inhibitor|Administered SC
223877162|NCT04174742|DRUG|pegfilgrastim|It works by increasing neutrophil migration to counteract cytotoxicity. It is commonly administered to patients receiving chemotherapy for breast cancer treatment. It has been shown to significantly reduce the incidence of neutropenic fever, although without statistically significant impact on overall survival.
223877163|NCT05608564|PROCEDURE|Piperacillin and Tazobactam in gel form|After non-surgical periodontal treatment, the test group will receive local antibiotics.
223877164|NCT05608564|PROCEDURE|Amoxicillin and Metronidazole|After non-surgical periodontal treatment, the control group will receive systemic antibiotics.
223877165|NCT04207294|OTHER|Pork arm|The effect of 1 portion of vitamin D-enriched pork on 25(OH)D concentration in comparison to a vitamin D supplement and control pork.
223877166|NCT04207294|OTHER|Chicken arm|The effect of 1 portion of vitamin D-enriched chicken on 25(OH)D concentration in comparison to control chicken.
223877167|NCT04995718|OTHER|Intelligent Physical Exercise Training (IPET)|Wind technicians performed 1-hour weekly individualized physical exercise training during working hours. The specific content of the exercise program was based on the specific job exposure profile, the physical capacity profile and the physical health profile of the employee.
223877168|NCT03898024|DRUG|SHR-1222|Pharmaceutical form: water injection; Route of administration: subcutaneous
223877169|NCT03898024|DRUG|Placebo|Pharmaceutical form: water injection; Route of administration: subcutaneous
223877170|NCT05901896|OTHER|there are no intervention|no intervention
223877171|NCT02872675|DIETARY_SUPPLEMENT|HOST-DM059|"Experimental Supplement: HOST-DM059.~Participants will be asked to orally consume one powdered sachet each day, at the same time in the morning, reconstituted in tea/coffee/fruit juice, or sprinkled over cereal etc. Whichever method of consumption is chosen, this must be kept consistent across both supplementation phases."
223877172|NCT02872675|DIETARY_SUPPLEMENT|Maltodextrin|Placebo Comparator: Maltodextrin.
223877173|NCT00111813|DRUG|vorinostat|Vorinostat capsules. Treatment in 21 day cycles (participants receive vorinostat for 14 days followed by a 7 day break).
223877174|NCT00111813|DRUG|bortezomib|Bortezomib injection. Given twice weekly for 2 weeks with a 1 week break. Treatment in 21 day cycles.
223877175|NCT02292329|DIETARY_SUPPLEMENT|Acai puree, frozen blended it with banana|150g of acai fruit, frozen blended it with banana.
223877176|NCT02292329|DIETARY_SUPPLEMENT|Control Macronutrient matched|Macronutrient matched control in water and also prepared with banana.
223877177|NCT02308319|DRUG|Tenofovir disoproxil fumarate|300mg q.d. per oral
223877178|NCT01159275|DRUG|Generic LPV/r and Aluvia (pharmacokinetics)|Generic LPV/r 200/50 mg BID 12 hr PK then cross over to Pediatric Aluvia 200/50 mg BID
223877179|NCT01159275|DRUG|Aluvia and Generic LPV/r (pharmacokinetics)|First Pediatric Aluvia® 200/50 mg BID, then cross over to Generic LPV/r 200/50 mg BID
223877180|NCT03698084|PROCEDURE|venepuncture|sample collection for analysis
223877181|NCT03698084|PROCEDURE|nasopharyngeal swab|sample collection for analysis
223877182|NCT05412316|OTHER|Intervention: Short-wave diathermy|The SWD will be applied using a CEC M-8 shortwave thermotherapy unit (CEC Electrónica S.R.L., Argentina) that emits RF at a frequency of 27.12 MHz. The device has two rectangular capacitive applicators (18 × 12 cm), which will be placed below and above the dominant shoulder. The coplanar application will be done using the continuous wave mode. The intensity of SWD will be gradually increased until the volunteer perceives a sensation of heat, and once familiar with this perception, the intensity will be increased until a sensation of constant but tolerable pain is evoked. This sensation will be maintained throughout the SWD application, and three repetitions will be performed. Healthy volunteers will be in a lateral supine position, and a cotton towel will be used to absorb perspiration and avoid unwanted heat effects.
223877183|NCT06083155|DIAGNOSTIC_TEST|Coronary Function Test|All participants are referred for a clinically indicated coronary function test
223877184|NCT06083155|OTHER|Patient questionnaires|All participants that consent will receive yearly followup questionnaires for 5 years after their initial consent
223877185|NCT03128359|DRUG|Busulfan|Given IV
223877186|NCT03128359|DRUG|Cyclophosphamide|Given IV
223877187|NCT03128359|DRUG|Fludarabine Phosphate|Given IV
223877188|NCT03128359|PROCEDURE|Hematopoietic Cell Transplantation|Undergo PBSC HCT
223877189|NCT03128359|OTHER|Laboratory Biomarker Analysis|Correlative studies
223877190|NCT03128359|DRUG|Melphalan Hydrochloride|Given IV
223877191|NCT03128359|DRUG|Mycophenolate Mofetil|Given IV or PO
223877192|NCT03128359|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo PBSC HCT
223877193|NCT03128359|OTHER|Quality-of-Life Assessment|Ancillary studies
223877194|NCT03128359|DRUG|Tacrolimus|Given IV
223877195|NCT03128359|RADIATION|Total-Body Irradiation|Undergo TBI
223877196|NCT02448576|RADIATION|prophylactic cranial irradiation|Prophylactic cranial irradiation in patients with advanced triple negative breast cancer who had a response to first line chemotherapy
223877197|NCT05015608|DRUG|Savolitinib + Osimertinib|Subjects will receive Savolitinib orally once per day (QD) + Osimertinib orally QD,21day cycles (every 3 weeks) until disease progression, death, adverse event (AE) leading to discontinuation or withdrawal of consent.
223877198|NCT05015608|DRUG|Pemetrexed + Cisplatin /Carboplatin|Pemetrexed combined with platinumon on Day 1 of 21day cycles (every 3 weeks)
223877199|NCT00171431|DRUG|Tegaserod|
223877200|NCT01777009|PROCEDURE|Primary Total Knee Replacement Surgery|Patients randomized to the eversion group had patellas everted during the flexion portions of the surgery. Patients randomized to the retraction group had patellas everted only for the patellar resurfacing portions of the surgery. Both groups were mobilized with anterior tibial translation. All other aspects of surgery including postoperative care, anticoagulation, pain control, and physical therapy were done as per standard arthroplasty protocols at our institution.
223877201|NCT02612142|BEHAVIORAL|physical exercise|endurance-training or stretching (sham exercise)
223877202|NCT04279366|BEHAVIORAL|Lifestyle intervention|The 14 week courses takes place at a Danish folk high school (Ubberup), specialized in lifestyle interventions targeting a 10% weight loss. Adult individuals with obesity sign up for the course. They stay at the School for the whole course period and the total cost amounts to 300-400 Euros per week plus loss of income.
223877203|NCT06339892|DIAGNOSTIC_TEST|Determination of HCMV DNA in plasma after DNAse digestion.|Plasma will be tested after DNAse digestion for quantification of virion-associated HCMV DNA (defined as true breakthrough HCMV productive infection).
223877204|NCT06339892|DIAGNOSTIC_TEST|Determination of HCMV DNA in blood or plasma.|HCMV DNA will be determined in blood or plasma without DNAse digestion, as per current clinical practice.
223877205|NCT05989932|OTHER|Upadacitinib|Real-world on the use of Upadacitinib
223877206|NCT01947790|DRUG|pioglitazone group|
223877207|NCT01947790|DRUG|Metformin group|
223877208|NCT05522868|DRUG|SB17170|SB17170 capsules, Oral administration 21days/cycle
223877209|NCT05172596|BIOLOGICAL|PHE885|Intravenous (IV) infusion
223877210|NCT00946413|BEHAVIORAL|CBT plus parent education|The 10-session group CBT with two-session parental education in our study was derived from the CWDA, with some modifications made based on cultural considerations. Skills taught and discussed included mood monitoring, improving social skills, increasing pleasant activities, decreasing anxiety, reducing depressogenic cognitions, improving communication, and conflict resolution. The issues taught and discussed included an introduction to adolescent depression and suicide, their etiology, symptoms, treatment, and prognosis, as well as stress management. A 1-year individual follow-up program was used to maintain the effect of the experimental intervention and to provide necessary individual interventions for students such as CBT, support, and counseling.
223877211|NCT00946413|BEHAVIORAL|CBT alone|The 10-session group CBT with two-session parental education in our study was derived from the CWDA, with some modifications made based on cultural considerations. Skills taught and discussed included mood monitoring, improving social skills, increasing pleasant activities, decreasing anxiety, reducing depressogenic cognitions, improving communication, and conflict resolution.A 1-year individual follow-up program was used to maintain the effect of the experimental intervention and to provide necessary individual interventions for students such as CBT, support, and counseling.
223877212|NCT05580380|OTHER|Limited Relationship|In this group, participants will share information regarding their low back pain history to a clinician who is not providing eye-contact, has farther physical distance, and is not directly facing the participant. The clinician will not provide verbal affirmations or ask clarifying questions about the patient's low back pain history. Instead, more time will be spent on completion of documentation.
223877213|NCT05580380|OTHER|Enhanced Relationship|A condition in which the clinician is providing enhanced relatedness with consistent eye contact, closer physical distance, facing the patient, and providing non-verbal affirmations (i.e. nodding, smiling), as the participant shares their low back pain history. The clinician will provide empathic verbal affirmations and will ask clarifying questions about the patient's low back pain history.
223877214|NCT05467904|OTHER|Xltranplus, Xltran|Xltranplus and Xltran are full hemp flower formulations
223877215|NCT03148496|DEVICE|Biologic Mesh|Biologic mesh placed during surgery
223877216|NCT03148496|PROCEDURE|Small Bites|0.5 cm x 0.5 cm sutures used
223877217|NCT03148496|PROCEDURE|Large Bites|1.0 x 1.0 sutures used
223877218|NCT01888744|DRUG|GnRH agonist|
223877219|NCT01888744|DRUG|GnRH antagonist|
223877220|NCT01888744|DRUG|hP-hMG|
223877221|NCT01888744|DRUG|Human chorionic gonadotropin|induction of final oocyte maturation
223877222|NCT01888744|DRUG|Progesterone|
223877223|NCT00222924|BEHAVIORAL|weight loss/ exercise|
223877224|NCT01637246|DRUG|Any Fixed Combination Therapy|Patients with POAG or OHT previously treated with monotherapy and currently treated with any fixed combination therapy. This was a retrospective chart review study, so no treatment was administered in this study.
223877225|NCT03201562|DRUG|Aceclidine+tropicamide combination|Ophthalmic Solution
223877226|NCT03201562|DRUG|Aceclidine|Ophthalmic Solution
223877227|NCT03201562|DRUG|Vehicle|Ophthalmic Solution
223877228|NCT00393484|DRUG|Entecavir|Tablets, Oral, 0.5 mg, once daily (0-96 weeks) and (96-240 weeks)
223877229|NCT00393484|DRUG|Lamivudine Placebo|Capsules, Oral, 0 mg, once daily (0-96 weeks)
223877230|NCT00393484|DRUG|Lamivudine|"Capsules, Oral, 100 mg, once daily (0-96 weeks)~Tablets, Oral, 100 mg, once daily (96-240 weeks)"
223877231|NCT00393484|DRUG|Entecavir Placebo|Tablets, Oral, 0 mg, once daily (0-96 weeks)
223877232|NCT00132964|DEVICE|Below knee walking cast|Not required
223877233|NCT00132964|DEVICE|Removable ankle brace|not required
223877234|NCT00826852|DRUG|docetaxel and carboplatin|weekly docetaxel 30mg/m2 and four weekly carboplatin AUC (Area under curve) 5
223877235|NCT04900636|DEVICE|Telemedicine Arm|Patients with DM1 ≥ 18 years of age, users of closed loop hybrid systems, assigned to a follow-up program using a telemedicine platform combined with face-to-face visits according to protocol.
223877236|NCT03237416|DRUG|Dabigatran etexilate|In Period 1, Day 1 a single dose of 75 mg will be administered after breakfast In Period 2, Day 3 a single dose of 75 mg will be administered prior to breakfast In Period 2, Day 9 a single dose of 75 mg will be administered after breakfast
223877237|NCT03237416|DRUG|Midazolam|In Period 1, Day 1 a single dose of 1 mg will be administered after breakfast In Period 2, Day 9 a single dose of 1 mg will be administered after breakfast
223877238|NCT03237416|DRUG|BAY1841788 (darolutamide)|In Period 2, Days 1-11 600 mg twice a day (as 2 x 300 mg tablets) will be administered after breakfast
223877239|NCT03019913|OTHER|Observational cohort|Evaluation of bedside methods to measure muscularity in critically ill patients
223877240|NCT00338572|BEHAVIORAL|Exercise Program|Participants in the exercise group will receive a 12-week membership to the YMCA and will meet with a personal trainer twice a week. They will be encouraged to exercise on their own for an additional 3 to 4 days per week. Participants will also be provided with a pedometer, which will track the number of steps they take each day.
223877241|NCT00338572|BEHAVIORAL|Combined Exercise and Diet Program|Participants in this group will receive a 12-week membership to the YMCA and will meet with a personal trainer twice a week. They will be encouraged to exercise on their own for an additional 3 to 4 days per week. Participants will also be provided with a pedometer, which will track the number of steps they take each day. They will meet with a dietician and will be encouraged to reduce their caloric intake by incorporating low-fat, high-fiber foods into their diet.
223877242|NCT02150967|DRUG|BGJ398 (infigratinib)|Capsule for oral use
223877243|NCT03359967|DRUG|Entresto tablet|Changes in intrathoracic impedance and other related parameters between before- and after Sacubitril/Valsartan treatment collected via previously implanted device algoritm. (OptiVol Fluid Index)
223877244|NCT02556138|DEVICE|ORBERA Intragastric Balloon|The ORBERA Intragastric Balloon will be placed in the stomach endoscopically through a catheter under conscious sedation. The procedure takes about 20 minutes to complete. The balloon will stay in place for 6 months and then it will be removed endoscopically.
223877245|NCT06860113|PROCEDURE|T-tilting of the patient during surgery|Patients will be placed at the T-Tilt position (15 degrees Trendelenburg and 15 degrees away from the surgical side kidney) during surgery.
223877246|NCT06860113|PROCEDURE|standard lithotomy position|Patients will be placed in regular lithotomy position with operating table at 0 degrees of tilting.
223877247|NCT06372067|DEVICE|Intramedullary screw|Intramedullary (IM) screw fixation is a minimally invasive technique that provides rigid fixation of fractures, acting as an internal splint and load-sharing device. IM screw fixation may allow for early mobilization without the operative site morbidity of open reduction and its associated complications.
223877248|NCT06372067|DEVICE|Kirschner wire|Kirschner wire (K-wire) fixation is a minimally invasive technique that provides non-rigid fixation of fractures. K-wires allow for fracture fixation with minimal soft tissue injury and preserved blood supply. However, patients require prolonged postoperative immobilization and are at risk of malunion and pin tract infection.
223877249|NCT06920693|DRUG|GB-7624|Study Drug GB-7624
223877250|NCT06920693|DRUG|Placebo|Placebo
223877251|NCT06867445|PROCEDURE|Minimally invasive pelvic exenteration|If all criteria are met, patients are registered. The patient is enrolled before the surgery, at the time of pelvic evaluation under anaesthesia. A diagnostic laparoscopic assessment can be performed before the operation to exclude peritoneal metastasis. The experimental procedure in this protocol involves the use of a minimally invasive approach (robot-assisted or laparoscopic) for performing pelvic exenteration.
223877252|NCT06891235|OTHER|Biologic testing for THC|Participants will be asked to complete at-home urine test(s) and a series of oral fluid tests.
223877253|NCT06893146|BEHAVIORAL|Reduction of Sedentary Behavior|The intervention group will receive an intervention that will include two group sessions, bimonthly phone calls and a face-to-face visit with the study nurse. Phone calls will be made every two months using motivational interviewing techniques with the aim of educating on habits and behaviors that reduce sedentary lifestyles, addressing needs and concerns on an individual basis, and enhancing patients motivation, well-being and quality of life. The same purpose is served by the face-to-face visit that will be conducted in the third month of the study. The study's interventions have a personalized approach, which considers individual preferences and needs to consolidate the new habits acquired in the long term. The active intervention has a duration of 6 months and will be carried out by nursing professionals.
223877254|NCT06893146|BEHAVIORAL|Educational support|Every two months, this group will receive detailed written information about healthy lifestyle habits via email, emphasizing the importance of maintaining an active lifestyle. Additionally, they will be provided with standard educational material on the management of type 2 diabetes.
223877255|NCT07057648|DEVICE|Shape-sensing Robotic-assisted Bronchoscopy (ssRAB)|"Diagnostic procedure using the ION endoluminal system (Intuitive Surgical, Sunnyvale, CA) for navigation and tissue sampling of peripheral pulmonary nodules. The procedure involves:~1. Pre-procedure 3D navigation planning using thin-section chest CT~2. Shape-sensing catheter navigation to target nodules~3. Real-time position monitoring with fiber optic sensors~4. Tissue sampling using various tools (biopsy needles, forceps, brush, or cryobiopsy)~5. Optional radial endobronchial ultrasound (rEBUS) confirmation~6. Fluoroscopic guidance when needed~The procedure is performed under deep sedation or general anesthesia through an endotracheal tube."
223877256|NCT06455215|BEHAVIORAL|Community garden activities|The gardens in the intervention group will receive an 8-week intervention that includes 1) educational materials, 2) healthy cooking demonstrations, food and transportation support and 3) garden social activities. The control group will be asked to abstain from intervention activities. The control group will receive the delayed 8-week intervention one month after the intervention group.
223877257|NCT07062393|BEHAVIORAL|Traditional Counseling → MAR Counseling|A single session begins with mobile augmented-reality counseling using interactive 3D models, followed by a standard verbal counseling with printed diagrams and CT images.
223877258|NCT07062393|BEHAVIORAL|MAR Counseling → Traditional Counseling|A single session begins with mobile augmented-reality counseling using interactive 3D models, followed by a standard verbal counseling with printed diagrams and CT images.
223877259|NCT07064512|OTHER|Endogenous heating|Exercise was used as the endogenous heating modality, the participant cycled at 60% of his VO2max until rectal temperature reached 39°C
223877260|NCT07064512|OTHER|Exogenous heating|Hot-water immersion was used as the exogenous heating modality, where the participants sat immersed in a water bath at 43.5 ± 0.5°C and remained submerged until rectal temperature reached 39°C.
223877261|NCT07063433|DRUG|Gluma Desensitizer|Each sensitive tooth will be cleaned with a polishing paste, rinsed with water and air dried. Two coats of Gluma Desensitizer will be applied using a disposable brush applicator following the manufacturer's instructions and left untouched for 30-60 minutes.
223877262|NCT07063433|DRUG|Bioactive glass|The NSK Prophymate Neo will be utilized to dispense Sylc dry powder, which comprises calcium sodium phosphosilicate, onto the sensitive areas. The air stream will be carefully adjusted to 40-46 psi in accordance with the manufacturer's instructions. The handpiece will be maintained at a constant distance of 3-4 mm from the tooth surface, positioned at 60-80 degrees on the buccal surfaces. The powder will be applied for 5-10 seconds per tooth, using a circular motion.
223877263|NCT07063433|DRUG|Fluoride varnish|The application of a single dose of Bifluorid 10 (by VOCO) will be carried out using a micro brush. A thin coat of varnish will be applied to the tooth surface, and it will be left in place for 10-20 seconds before being air-dried.
223877264|NCT07065084|PROCEDURE|Virtual Reality glasses|"In the study, the patients in the intervention group were fitted with VR goggles by the researcher immediately after the spinal anesthesia was administered by the researcher during the operation in hernia patients who received spinal anesthesia for the study, when the patient was placed on the operating table and given the operating position, just before the surgical incision started. The procedures were performed without interfering with anesthesia and general operating room functioning. When the surgical incision was to be made, videos were started to be watched from the VR glasses simultaneously. During the 20 minute procedure, the licensed product Relax with Nature with music background with virtual reality glasses (Bobo VR Z4 Binocular Glasses and 5.7 inch 1440x2560 pixel screen resolution display unit, China) was watched with virtual reality application. Patients were shown videos of lakes, forests, waterfalls, rivers and beaches. In the studies, it was stated that these videos"
223877265|NCT07071181|DIETARY_SUPPLEMENT|Original flavour kefir|"Participants will consume 250ml of original flavour kefir daily for 4 weeks. According to the manufacturer, packed with billions of live cultures to support Gut health."
223877266|NCT07071181|OTHER|Milk|Participants will consume 250 ml milk daily for 4 weeks. This milk will not contain any live cultures.
223877267|NCT07071857|DIAGNOSTIC_TEST|ECG CT angiography|Preoperative: electrocardiography-gated computed tomographic angiography.
223877268|NCT07071857|DIAGNOSTIC_TEST|TTFM|Intraoperative: TTFM after weaning from cardiopulmonary bypass and just before sternal closure.
223877269|NCT07071857|DIAGNOSTIC_TEST|computed tomography of the aorta and/or grafts|computed tomography of the aorta and/or grafts within 2 weeks after surgery.
223877270|NCT07071662|OTHER|delivery mode|To observe the different modes of delivery and evaluate the characteristics of the patients as well as maternal and fetal well being in the post partum period.
223877271|NCT07069920|DEVICE|BRDE33-100|BRDE33-100 will be injected once at Visit 2 (Baseline).
223877272|NCT07069920|DEVICE|Soonsoofill|Soonsoofill will be injected once at Visit 2 (Baseline).
223877273|NCT07070934|BIOLOGICAL|CAR-T|The T cells are genetically modified to expressa chimeric antigen receptor targeting BCMA andare infused after induction therapy at a target dose of ≥2.0×10\^6 cells/kg
223877274|NCT07070934|BIOLOGICAL|ASCT|Patients in this arm will receive autologous hematopoietic stem cell transplantation (ASCT).
223877275|NCT07069764|DEVICE|Doctor smile 635nm For Arm 1|Participants will receive low-level laser therapy using a diode laser with a wavelength of 635 nanometers. The treatment will be applied twice weekly for five weeks to the affected temporomandibular joint muscles to reduce myofascial pain and improve muscle function.
223877276|NCT07069764|DEVICE|Doctor smile 980 nm For Arm2|Participants will receive low-level laser therapy using a diode laser with a wavelength of 980 nanometers. The treatment will be applied twice weekly for five weeks to the affected temporomandibular joint muscles to reduce myofascial pain and improve muscle function.
223877277|NCT07071584|DEVICE|Cutaneous Prosthesis Control System|Prosthesis control system using a multi-electrode cutaneous sensor array
223877278|NCT07070531|BEHAVIORAL|Unified Protocol|The Unified Protocol (UP) is a transdiagnostic, emotion-focused cognitive-behavioral treatment designed to address a range of emotional disorders, including anxiety, depression, and related conditions. It targets core mechanisms such as emotional avoidance, cognitive rigidity, and maladaptive emotion regulation strategies. The UP consists of structured modules focused on increasing emotional awareness, cognitive flexibility, and exposure to emotionally evocative situations. By addressing common underlying processes across disorders, the UP enhances treatment efficiency and applicability in both individual and group formats. Its flexibility makes it suitable for diverse populations and settings, including community and clinical contexts.
223877279|NCT07071064|BEHAVIORAL|Food Box + Nutrition Classes|The Nutrition Security Intervention is a 12-month project enrolling 400 adults across four sites. Participants will receive the intervention for 6 months, with a 9-month and 12-month in person follow-up. Individuals receiving this intervention will receive bi-weekly food boxes, containing 15-20 pounds of fresh produce, grains, and legumes. They will also participate in a bi-weekly nutrition class, led by a Registered Dietician.
223877280|NCT07071064|BEHAVIORAL|Food Box Only|The intervention is a 12-month project enrolling 400 adults across four partner sites. Participants will receive the intervention for 6 months, with a 9-month and 12-month in person follow-up. In this intervention, participants will receive a bi-weekly food box only (no nutrition education) during the intervention period. They will have the opportunity to participate in the educational component after the completion of the intervention period.
223877281|NCT07070648|DRUG|POLA-R-CHP|Pola-R-CHP treatment for 6 cycles (IPI score 2-5)
223877282|NCT07070635|OTHER|Nutritional intervention with Fermented Seaweed Enriched English Breakfast Tea|Participants will consume 3 cups of tea per day - spread out during the day, for 8 weeks. For each cup, they will be asked to briefly stir one tea bag (3g tea + 1 g fermented seaweed) into 250mL boiling water and let it brew for 3minutes, before removing the tea bag without squeezing it.
223877283|NCT07070635|OTHER|Nutritional intervention with Control English Breakfast Tea|Participants will consume 3 cups of tea per day - spread out during the day, for 8 weeks. For each cup, they will be asked to briefly stir one tea bag (3g tea) into 250mL boiling water and let it brew for 3minutes, before removing the tea bag without squeezing it.
223877284|NCT07070453|PROCEDURE|Non-surgical periodontal treatment|Removal of deposits above and below the gum line using hand or ultrasonic tools and thorough smoothing of root surfaces to discourage re-accumulation of bacteria.
223877285|NCT07070453|PROCEDURE|Scaling and root planing + aPDT|Non-invasive treatment that uses a combination of a light-sensitive compound (photosensitizer), specific light, and oxygen to generate reactive oxygen species (ROS) that kill bacteria.
223877286|NCT07069933|DRUG|Standard care +itraconazole 200mg|Is an antifungal used to treat a variety of fungal infections. It belongs to a class of drugs known as azole antifungals.
223877287|NCT07069933|DRUG|Chemotherapy|Standard Care (in control arm)
223877288|NCT07071493|DEVICE|tPBM Group, taVNS Group, Combined Treatment Group: Stimulation Program (5 Weeks)|"Stimulation Program (5 Weeks) Each participant will follow one of the following programs, assigned randomly, five days a week for a total duration of five weeks.~tPBM Group: Participants will receive transcranial photobiomodulation (tPBM) for 15 minutes per day.~taVNS Group: Participants will receive transcutaneous auricular vagus nerve stimulation (taVNS) for 15 minutes per day.~Combined Treatment Group: Participants will simultaneously receive both tPBM and taVNS for 15 minutes per day."
223877289|NCT07070245|PROCEDURE|Instrument assisted soft tissue mobilization|The treatment protocol will be two sessions. given per week for 4 weeks.
223877290|NCT07070245|PROCEDURE|Positional release|The treatment protocol will be two sessions. given per week for 4 weeks.
223877291|NCT07070245|PROCEDURE|Exercises|The treatment protocol will be two sessions. given per week for 4 weeks.
223877292|NCT07078370|DEVICE|ATEV with ESS|Patients will be implanted with a single Acellular Tissue Engineered Vessel with External Support Structure bypass (single proximal and distal anastomoses) to the second or third coronary artery bypass target
223877293|NCT04939246|RADIATION|Stereotactic ablative body radiation therapy|Single-fraction of stereotactic ablative body radiation (SABR) therapy will be delivered with an integrated magnetic resonance imaging (MRI)-guided radiotherapy delivery system (ViewRay MRIdian Linac). The prescription dose is dependent on the anatomic location of the lesion and based on previously published safety data.
223877294|NCT04994509|DRUG|Oral Lenacapavir (LEN)|Tablets administered orally without regard to food
223877295|NCT04994509|DRUG|Subcutaneous (SC) Lenacapavir (LEN)|Administered via SC injections
223877296|NCT04994509|DRUG|F/TAF|Tablets administered orally
223877297|NCT04994509|DRUG|F/TDF|Tablets administered orally
223877298|NCT04994509|DRUG|Placebo SC LEN|Administered via SC injections
223877299|NCT04994509|DRUG|PTM Oral LEN|Tablets administered orally
223877300|NCT04994509|DRUG|PTM F/TAF|Tablets administered orally
223877301|NCT04994509|DRUG|PTM F/TDF|Tablets administered orally
223877302|NCT05020756|DIETARY_SUPPLEMENT|Isosource Junior Mix|Single arm study, collecting data on those who have been on Isosourcr Junior mix tube feed formula for 30 days
223877303|NCT06923267|DIAGNOSTIC_TEST|No Pressure Support No Positive End Expiratory Pressure Spontaneous Breathing Trial|The spontaneous breathing test is carried out with the patient connected to the ventilator, reducing both the positive end-expiratory pressure (PEEP) and the pressure support to 0 cmH2O, for 15 minutes.
223877304|NCT06923267|DIAGNOSTIC_TEST|Pressure Support Spontaneous Breathing trial|The spontaneous breathing test is carried out with the patient connected to the ventilator, reducing the positive end-expiratory pressure (PEEP) to 0 cmH2O and the pressure support to 7 cmH2O, for 15 minutes. A 10-minute washout period is left before the start of the next SBT modality.
223877305|NCT06923267|DIAGNOSTIC_TEST|Humidified High Flow Spontaneous Breathing Trial|The spontaneous breathing trial is carried out with humidified high flow ventilator mode set at 50 liters per minute for 15 minutes. The patient will be connected to the ventilator via a specific connector enabling the administration of humidified high flow. A 10-minute washout period is left before the start of the next SBT modality.
223877306|NCT06920498|DRUG|PF-07941944|Oral formulation
223877307|NCT06920498|DRUG|Placebo|Oral formulation
223877308|NCT06920498|DRUG|Midazolam|Oral formulation
223877309|NCT03411369|DIETARY_SUPPLEMENT|Creatine, D-Ribose, B1 Vitamin, and B6 vitamin|The treatment will consist of taking 2 sachets / day for the first two weeks, and then continuing with 1 sachet/day for the next month.
223877310|NCT03411369|OTHER|Placebo|Water-soluble powder in sachets of 4 grams containing inert product consisting of starch powder.
223877311|NCT03638427|DIAGNOSTIC_TEST|Menstrual Blood Analysis (Menstrual Blood Analysis)|We will be testing women's menstrual blood to investigate the feasibility and efficacy of assessing HR-HPV DNA and HPV E6/E7 mRNA via self-collected menstrual blood from a menstrual pad.
223877312|NCT06953284|OTHER|KINESOTAPING|Kinesio Taping (KT) is commonly used in sport injuries, in neurology and oncology patients following the surgical protocols, and for paediatric rehabilitation to reduce pain, facilitate or inhibit muscle activity, prevent injuries, reposition joints, aid the lymphatic system, support postural alignment, and improve proprioception.7-9 Although its mechanism of action has not been fully understood, it is believed that activation of the cutaneous receptors could influence neuromuscular functions.10 The cutaneous sensory system provides preliminary information about limb positions and muscle forces to the central nervous system for monitoring and controlling limb movements, planning actions, and providing fluent movement.11 Common causes of unilateral spastic CP are middle cerebral artery infarct, hemi-brain atrophy, periventricular lesions, and brain malformations that disturb the integrity of the motor areas. Middle cerebral artery infarctions can particularly impair the somatosensory sy
223877313|NCT06953284|OTHER|Functional Electrical Stimulation|This systematic review is the first to examine the effect of FES on activity in children with CP using only randomized trials.However, evidence was limited with only 5 trials being included. This limited evidence suggests that FES is effective, that is, it is better than no FES intervention, but that it is no more effective than activity training, that is, practicing the activity without FES will be just as effective. Furthermore, no evidence was found on whether any benefits are maintained beyond the intervention period because even though a follow-up measurement was reported for 2 studies, the authors failed to provide data. Even though the review was restricted to the highest standard of evidence, randomized trials, firm conclusions cannot be made. This is primarily because of the absence of group data (means and SD) in the papers, preventing a meta-analysis. This poor reporting is disappointing given that 3 of the 5 trials were published within the last 5 years. Therefore, we may b
223877314|NCT02089698|DEVICE|Mini-flared|Mini-flared Kelman tip
223877315|NCT02089698|DEVICE|Reversed tip|Reversed Kelman tip
223877316|NCT06946186|BEHAVIORAL|Virtual Senior Center - GrandPad|The Virtual Senior Center engages older adults in programs and services online with the help of a GrandPad.
223877317|NCT06946186|BEHAVIORAL|Virtual Senior Center - No GrandPad|Participants will be given information to access the website when they are able from their own phone, tablet, or computer.
223877318|NCT06955234|DIETARY_SUPPLEMENT|Berbevis supplement|This intervention consists of a standardized oral dietary supplement containing Berberis aristata extract formulated in phospholipids (Berbevis™). The supplement is formulated to support metabolic balance. It is administered twice daily for 8 weeks to evaluate safety, tolerability, and dose-response effects in healthy adult volunteers.
223877319|NCT03795220|DRUG|Lutinus + transfer day 6|Four parallel groups of patients undergoing fertility treatment (modified natural cycle frozen embryo transfer) will be compared using/not using vaginal progesterone (Lutinus) and subject to blastocyst warming and transfer 6/7 days after hCG trigger.
223877320|NCT03795220|DRUG|Lutinus + transfer day 7|Four parallel groups of patients undergoing fertility treatment (modified natural cycle frozen embryo transfer) will be compared using/not using vaginal progesterone (Lutinus) and subject to blastocyst warming and transfer 6/7 days after hCG trigger.
223877321|NCT03795220|DRUG|No Lutinus + transfer day 6|Four parallel groups of patients undergoing fertility treatment (modified natural cycle frozen embryo transfer) will be compared using/not using vaginal progesterone (Lutinus) and subject to blastocyst warming and transfer 6/7 days after hCG trigger.
223877322|NCT03795220|DRUG|No Lutinus + transfer day 7|Four parallel groups of patients undergoing fertility treatment (modified natural cycle frozen embryo transfer) will be compared using/not using vaginal progesterone (Lutinus) and subject to blastocyst warming and transfer 6/7 days after hCG trigger.
223877323|NCT03757949|OTHER|Laboratory Biomarker Analysis|Correlative studies
223877324|NCT03757949|DIETARY_SUPPLEMENT|Nutritional Intervention|Receive SIM PO
223877325|NCT03757949|OTHER|Placebo Administration|Given PO
223877326|NCT03757949|OTHER|Quality-of-Life Assessment|Ancillary studies
223877327|NCT03757949|OTHER|Questionnaire Administration|Ancillary studies
223877328|NCT04631406|BIOLOGICAL|Neural Stem Cells|NR1 is a human embryonic stem cell (hESC) derived product for the treatment of chronic ischemic subcortical stroke
223877329|NCT05225402|DRUG|Hemodynamic measurements during reduction in Norepinephrine and fluid boli.|"1. Extended monitoring equipment will be connected to the patient. Clinical and biochemical parameters will be collected for a baseline before the next step. A Safety check will be performed to ensure correct patient data, correct equipment function and safety measures are meet. A passive leg raise test will be performed to predict fluid responsiveness, in case of a positive test, a fluid challenge will be administered.~2. A stepwise reduction of the NE infusion rate from baseline while monitoring stroke volume (SV) to elucidate changes in SV and potential preloadresponsiveness. The reduction will occur in steps of 3-5 minute until either discontinuation of the norepinephrine infusion, a 50% reduction in SV or MAP\<40.~3. While maintaining the NE infusion rate from the previous step 2, a fluid challenge will be administrated, until additional fluid does not increase SV\>10%.~4. As in step 2, a stepwise increase in NE infusion rate to the baseline infusion level or the baseline BP."
223877330|NCT04272736|DIETARY_SUPPLEMENT|Low calorie protein substitute|The evaluated dietary supplement is a lower calorie amino acid based liquid protein substitute designed for patients with PKU.
223877331|NCT06062017|DIETARY_SUPPLEMENT|Water and Potassium supplementation|All Participants will be given cases of water and instructed to drink at least an extra 1L per day. Additionally, participants will be given 2000 mg of potassium via potassium chloride powder.
223877332|NCT05573048|DEVICE|Trans-Perineal Grid|A small square piece of plastic with many holes in it placed between the legs to help guide the path of the interventional instruments and to facilitate the prostate intervention. The guide grid will help with needle placement using the grid technology.
223877333|NCT04694339|OTHER|Survey|Survey
223877334|NCT05833360|DEVICE|Exai oncRNA blood test|A phlebotomist will collect approximately 40 ml (about 2-3 tablespoons) of blood from the subjects after consent. The Exai oncRNA blood test will be run on the blood samples.
223877335|NCT06094426|BIOLOGICAL|GT316|Autologous Tumor Infiltrating Lymphocyte Injection
223877336|NCT01643070|DRUG|Capecitabine, Oxaliplatin|Induction chemotherapy - Induction XELOX (Capecitabine 1250 mg/m2 PO twice daily on D1-14 and oxaliplatin 130 mg/m2 on D1, every 3 weeks for 2 cycles) Preoperative chemoradiotherapy - XELOX RT (Capecitabine 825 mg/m2 PO twice daily during radiotherapy and oxaliplatin 50 mg/m2/day on weekly.)
223877337|NCT01643070|RADIATION|Radiotherapy|Preoperative radiotherapy, 5040 cGy with 28 fractions
223877338|NCT04389372|BEHAVIORAL|Mindfulness|Mindfulness by smartphone combined to video calls for clinical evaluation in patients with chronic migraine and medication overuse after withdrawal program
223877339|NCT06113666|BEHAVIORAL|Digital Cognitive Behavioral Therapy for Insomnia (dCBT-I)|dCBT-I during 9 weeks. Multicomponent intervention that includes the following: psychoeducation about sleep, sleep hygiene, sleep restriction therapy, stimulus control and challenging beliefs and perception about sleep. The digital CBT-I that will be utilized in this study is named Sleep Healthy Using The internet (SHUTi). The intervention is fully automated with no contact with health care personnel, it is interactive and adapts to input from the users. It comprises of the same elements included in face-to-face CBT-I, but the user gains access to a new educational, behavioral or cognitive module each week only after completion of digital sleep diaries. dCBT-I can be accessed on computers or hand-held devices
223877340|NCT06113666|BEHAVIORAL|Digital patient education about insomnia (PE)|Control condition PE during 9 weeks. A digital patient education program that can be accessed on computers or hand-held devices. The information overlaps with that included in the dCBT-I intervention but it does not include any of the interactive features of the dCBT-I intervention and all the information is available from the moment the PE site is opened.
223877341|NCT03620786|DEVICE|Sonablate HIFU device|In this study, we will be using the Sonablate 450 HIFU System. The Sonablate HIFU device was approved by the U.S. FDA for prostate tissue ablation in October, 2015. HIFU is an example of focal therapy, where the intervention involves targeting diseased areas of prostate tissue, while preserving healthy prostate tissue and minimizing damage to surrounding structures.
223877342|NCT06118788|BIOLOGICAL|BG1805|A single infusion of BG1805 Injection administered intravenously.
223877343|NCT05885529|OTHER|UCH-L1 GFAP|measurment of UCH-L1 GFAP within 12 hours in adult patients after a mild traumatic brain injury
223877344|NCT01600014|DRUG|Ingenol mebutate gel, 0.015%|Topical field treatment once daily for 3 consecutive days within a 25 cm2 treatment area on the face or scalp of AKs present or emerging after an initial treatment with ingenol mebutate gel, 0.015%
223877345|NCT01600014|DRUG|Vehicle gel|Topical field treatment once daily for 3 consecutive days within a 25 cm2 treatment area on the face or scalp of AKs present or emerging after an initial treatment with ingenol mebutate gel, 0.015%
223877346|NCT04804358|BEHAVIORAL|Exposition Test|"During this test (7 minutes) participants will be exposed to photos evoking positive or negative emotions (anger, disgust, sadness and fear) interspersed with emotionally neutral photos.~The test sequence is composed of 3 blocks as follows:~* 12 photos evoking positive emotions (2 min)~* Pause of 30 seconds (white screen)~* 12 photos presenting a neutral emotional valence (2 min)~* Pause of 30 seconds (white screen)~* 12 photos evoking negative emotions (2min)~In each block, photos will be selected and presented to the participant in a randomized and sequential manner. In total, 30 photos will be presented in 7 minutes to each participant (10 seconds per photo).~The participant must be at rest in front of the computer screen during these 7 minutes with optimal visibility. The photos will be presented sequentially using software (E-Prime or Visual Basic 6.0). During this exposure test, a heart rate recording will be made using a BIOPAC MP160 recording system."
223877347|NCT03738553|DEVICE|MRI|Diffusion Weighted Imaging and Dynamic Contrast enhanced MRI
223877348|NCT03738553|DRUG|Trastuzumab|Single dose of Trastuzumab prior to surgery
223877349|NCT05759533|PROCEDURE|Corrected carotid flow time, IVC diameter|Corrected carotid flow time correction: is the carotid systole time, with heart rate correction applied IVC Collapsibility Index measurement is a reliable predictor of intraoperative hypotension within 30 minutes of spinal anesthetic administration
223877350|NCT01976247|DEVICE|High Intensity Focused Ultrasound Device|
223877351|NCT01976247|DEVICE|Noninvasive Cryolipolysis Device|
223877352|NCT06464055|DRUG|Dose Escalation|Drug: GQ1010
223877353|NCT06464055|DRUG|Dose Expansion1|Drug: GQ1010 dose 1
223877354|NCT06464055|DRUG|Dose Expansion2|Drug: GQ1010 dose 2
223877355|NCT06464055|DRUG|Dose Expansion3|Drug: GQ1010 dose 3
223877356|NCT06464055|DRUG|phase II|Drug: GQ1010 RP2D
223877357|NCT04510064|DRUG|Camrelizumab plus mFLOT regimen|Patients were treated with domestic PD-1 antibody (Camrelizumab for injection) commbined with mFLOT regimen immunotherapy every three weeks, and HER-2 positive patients were added with Herceptin therapy. Camrelizumab 200mg on day 1, albumin bound paclitaxol 125mg/m² on day 1,oxaliplatin 85 mg/m² on day 1, leucovorin 200 mg/m² on day 1, and 5-FU 2600 mg/m² as 24-h infusion on day 1.Herceptin 6mg/Kg at the first time, followed by 4mg/Kg if needed.
223877358|NCT04510064|PROCEDURE|R0 surgery|The efficacy of therapy was evaluated every 3 treatment cycles. If the tumor can be R0 resected after 6-9 cycles, then proceeded to surgery. After the operation, patients continued to receive the prior immunotherapy totally to 12 cycles or to the disease progressed or intolerable toxicity.
223877359|NCT04524273|DRUG|inebilizumab|Participants will receive IV inebilizumab
223877360|NCT04524273|DRUG|IV Placebo|Participants will receive IV placebo matched to inebilizumab
223877361|NCT06160882|OTHER|Powered Prosthesis Training and EMG data collection|"Participants are fit for a custom instrumented socket for collection of surface EMG signals and use with the powered lower limb prosthesis.~EMG control sites will be located using clinical best practices. Once socket fit is completed, the prosthetist will attach and align the powered prosthesis. The participant will be instructed to walk with the powered prosthesis for level ground walking, incline walking, stair climbing and non-weight bearing independence control activities. A non-weight bearing independent control system will be configured. These data are used to train a pattern recognition control system which can control the leg knee and ankle joints respectively, either in a virtual environment or with the physical prosthesis The participants will complete functional, biomechanical, metabolic, and patient reported outcome measures."
223877362|NCT06160882|PROCEDURE|Perform Osseointegration (OI) surgery and Targeted Muscle Reinnervation (TMR)|"Participants will undergo OI Surgery 1 +TMR and recovery. Following recovery, participants will receive OI surgery 2 where the abutment is connected to the fixture with in the femur. Participants will receive standard post-surgical care and participate in the OPRA rehab program through the Shirley Ryan AbilityLab. The participant uses their clinically prescribed prosthetic knee unit for training in the OPRA rehab program.~Post-Surgery Fitting and Powered Leg Prosthesis Training: EMG signals are measured using a custom fit electrode band on the residual limb that is tethered to the prosthesis. Participants are fit with the powered prosthesis using their OI interface and trained on its use. The participant will complete non-weight-bearing neural control tasks as done prior to surgery. The participants will complete functional, biomechanical, metabolic, and patient-reported outcome measures using the OI interface and the powered leg prosthesis."
223877363|NCT06780254|DRUG|MH-001|capsules
223877364|NCT06780254|DRUG|Placebo|capsules
223877365|NCT03398148|DRUG|risankizumab IV|risankizumab intravenous (IV) infusion
223877366|NCT03398148|DRUG|placebo for risankizumab|placebo for risankizumab
223877367|NCT03398148|DRUG|risankizumab SC|risankizumab subcutaneous (SC) injection
223877368|NCT04690322|DRUG|Eloctate|Eloctate is FDA-approved to treat patients with Hemophilia A. This drug will be used for extended half-life factor VIII-based replacement therapy.
223877369|NCT04690322|DRUG|Adynovate|Adynovate is FDA-approved to treat patients with Hemophilia A. This drug will be used for extended half-life factor VIII-based replacement therapy.
223877370|NCT04690322|DRUG|Emicizumab|Emicizumab is FDA-approved to treat patients with Hemophilia A. This drug will be used for non-factor VIII-based replacement therapy.
223877371|NCT05985902|OTHER|Core Stabilization Exercises|"Core stabilization training; exercises for 2 muscle systems that contribute to spinal stability are given. The first one is the local system muscles; multifidus, transversus abdominis, diaphragm and pelvic floor muscles. The second, the global system includes large superficial muscles, such as erector spines, rectus abdominis, internal and external obliques, quadratus lumborum, gluteus ma"
223877372|NCT05985902|OTHER|Schroth Exercises|In the Schroth exercise training, there are 3-dimensional exercises that include the principles of axial reach, deflection, derotation, rotational breathing and stabilization.
223877373|NCT06536192|OTHER|Model group|"1. Process: Theoretical knowledge will be given to students, and then different types of gynecological examinations will be explained practically on a model in the laboratory environment.~2. Process: The learner guide will be filled out.~3. Process: After 15 days, students will be taken back to the laboratory environment to fill out the learner guide again. In addition, SCS and SSSLS will be filled out for the last exam."
223877374|NCT04278586|BEHAVIORAL|Live-Online M-ROCC|"1. LDM (Low-Dose Mindfulness): A 4-wk intro mindfulness program for OUD, 50-60 min/week including explicit training in use of mobile mindfulness apps, with rolling admission and ascending practice dose ladder.~2. MTPC (Mindfulness Training for Primary Care): An eight-week intensive mindfulness group with ascending practice dose ladder and skill integration over 16 weeks with 60 minutes/wk.~3. MCS (Mindfulness Maintenance Check-in Support): Ongoing weekly mindfulness group with check-in and reminders, leveraging mobile mindfulness apps and motivational counseling for graduates of LDM for 50-60 mins/wk.~After completion of the LDM group, participation in various levels is fluid based on patient motivation, choice, and readiness."
223877375|NCT04278586|BEHAVIORAL|Live-Online Control|A time- and attention-matched live online control group. The manualized control intervention developed for the basic group-based opioid treatment group in primary care uses 16 core modules and 8 elective modules that are common to eclectic approach in treatment as usual addiction recovery groups (including engagement and group development activities with a mix of basic CBT skills, twelve-step facilitation, community reinforcement, and motivational interviewing). As an active group control, this method will help to isolate mindfulness as the putative mechanism of action by controlling for the therapeutic aspects of group without any reference to mindfulness.
223877376|NCT05583708|DRUG|Pembrolizumab|Pembrolizumab 400mg IV
223877377|NCT05583708|DRUG|Lutetium Lu 177 dotatate|7.4GBq (200 mCi) IV
223877378|NCT05403723|DRUG|Durvalumab 50 MG/1 ML Intravenous Solution|Durvalumab (1500 mg durvalumab via IV infusion) in combination with platinum doublet chemotherapy will be administered to patients once every 3 weeks for up to 4 cycles plus SBRT (platinum resistant group) or without SBRT (platinum sensitive group). Each 3-week of chemoimmunotherapy interval is considered a cycle. Patients with platinum sensitive disease will receive the combination of durvalumab and chemotherapy (total of four cycles) while those with platinum resistant SCLC will receive SBRT and continue to receive up to two additional cycles of treatment with durvalumab along with platinum/etoposide (not to exceed a total of four6 cycles of chemoimmunotherapy including 2 cycles obtained prior to SBRT). Following completion of 4-6 cycles of combination therapy, patients in both groups will continue with maintenance durvalumab (1500 mg) in q4w cycles until disease progression.
223877379|NCT05403723|DRUG|Etoposide Injection|A platinum/etoposide doublet will be administered according to institutional standards. Platinum-etoposide will consist of etoposide 80-100 mg/m2 on days 1-3 of each cycle along with a choice of either carboplatin area under the curve 5-6 mg/mL per min or cisplatin 75-80 mg/m2 (administered on day 1 of each cycle).
223877380|NCT05403723|DRUG|Cisplatin|A platinum/etoposide doublet will be administered according to institutional standards. Platinum-etoposide will consist of etoposide 80-100 mg/m2 on days 1-3 of each cycle along with a choice of either carboplatin area under the curve 5-6 mg/mL per min or cisplatin 75-80 mg/m2 (administered on day 1 of each cycle).
223877381|NCT05403723|DRUG|Carboplatin|A platinum/etoposide doublet will be administered according to institutional standards. Platinum-etoposide will consist of etoposide 80-100 mg/m2 on days 1-3 of each cycle along with a choice of either carboplatin area under the curve 5-6 mg/mL per min or cisplatin 75-80 mg/m2 (administered on day 1 of each cycle).
223877382|NCT05403723|DEVICE|Stereotactic Body Radiotherapy|Patients will receive palliative radiation to the primary tumor site up to 30 Gy for 1 week given as 5 daily fractions of 6 Gy each or 27 Gy as 3 fractions of 9 Gy administered every other day.
223877383|NCT05231655|DIAGNOSTIC_TEST|Functional drug screen|High-throughput ex-vivo drug screen of cells processed directly from solid tumours to determine sensitivity / resistance profiles
223877384|NCT06397547|OTHER|Flipped Learning|Materials for students' pre-class studies and for use by the instructor during class will be created by the researchers. For students in the experimental group to come prepared for class according to the flipped learning model, digital materials will be prepared by the researchers. The experimental group will receive digital materials prior to the topic. The links to these materials will be sent to the students, who can access them via their mobile phones and watch the explanatory and demonstration videos as many times as they wish. Subsequently, the topic will be presented to the students. They will summarize the information learned from the videos and engage in question-answer sessions and discussions using prepared digital resources to address any points they do not understand. To reinforce the practices in the experimental group, online word clouds and quizzes will be sent.
223877385|NCT05499741|DEVICE|Forehead Temperature-Regulating Therapy|A forehead thermal therapy device will be used nightly for the duration of each sleep period for four weeks. This device includes a bedside unit and a pump to transport thermal fluid to a bladder, affixed to the forehead with a headband. The bladder circulates fluid over the forehead at adjustable temperatures ranging from 57-61 °F.
223877386|NCT05923944|BEHAVIORAL|Eco-Rescue|Ecorescue is a gamified adaptation of the multiple object tracking task (MOT) combined with a detection task. It requires to track the spatial position of specific moving targets among visually similar moving distractors, while at the same time detecting briefly flashed events. It was designed to load on attentional control and visuo-spatial working memory. Additionally, targets may express various facial emotions (happy, angry or neutral) requiring some emotional control in addition to attentional control.
223877387|NCT05923944|BEHAVIORAL|Bejelewed 3|Bejeweled 3 is a commercially available puzzle video game developed and edited by PopCap Games. The main objective is to swap two adjacent gems of seven colors to create a line or row of 3 or more gems of the same type. When these gems are aligned, they disappear, and points are earned. The goal is to get as many points as possible until it is impossible to line up gems. Bejeweled 3 offers a variety of game modes that players can freely explore at their own pace, enhancing the overall enjoyment and providing increased variability during each gaming session. These game modes typically have shorter durations, with a single game usually lasting less than 5 minutes. Bejeweled 3 was chosen as it requires fewer attentional resources compared to Eco-Rescue and because it was reported to reduce stress and anxiety in adult samples (Russoniello et al. 2009, 2013).
223877388|NCT02791230|DRUG|Tafamidis|Soft gel capsules administered once a day for 60 months
223877389|NCT06439537|OTHER|Semi-structured questionnaire|All patients recruited to the study will undergo a semi-structured questionnaire within 36 hours of admission
223877390|NCT06439537|OTHER|Post-operative interview|All patients recruited to the study will undergo a semi-structured interview once they have reached post-operative day 7 or over
223877391|NCT06190899|DRUG|Gedatolisib|Gedatolisib is a potent reversible inhibitor that selectively targets all Class I PI3K isoforms and mTOR.
223877392|NCT06190899|DRUG|Darolutamide|Darolutamide is a novel androgen receptor inhibitor that has been studied and received approval for treatment of patients with nonmetastatic CRPC and in metastatic hormone-sensitive prostate cancer.
223877393|NCT05138393|OTHER|Active self-corrective exercises|Scoliosis specific exercises with an Active self-corrective approach. Non-specific physical activity 60 minutes per day.
223877394|NCT05138393|OTHER|Observation|Non-specific physical activity 60 minutes per day.
223877395|NCT05233098|DEVICE|Technetium-99m macroaggregated albumin (Tc-99m MAA)|Patients who are being evaluated for TheraSphere administration.
223877396|NCT05698329|DRUG|AIV007|Periocular injection
223877397|NCT04076293|DRUG|HM15912|The study will be conducted in approximately 5 sequential dosing cohorts, enrolling 8 subjects per cohort. Subjects will be randomized to HM15912 or placebo in a ratio of 6:2 (6 active, 2 placebo).
223877398|NCT04076293|DRUG|Placebo|The study will be conducted in approximately 5 sequential dosing cohorts, enrolling 8 subjects per cohort. Subjects will be randomized to HM15912 or placebo in a ratio of 6:2 (6 active, 2 placebo).
223877399|NCT04107948|OTHER|physical activity program|"Two weekly exercise sessions at the university hospital of St-Etienne for 1 month then relay outside in a sports association or club certified Sports Health in the Loire (42), Haute-Loire (43) or Ardèche (07) for 2 months."
223877400|NCT04107948|OTHER|Advice and recommendations of physical activity at home|Advice and recommendations of physical activity at home (= current clinical practice, from 1 to 3 sessions per week in autonomy).
223877401|NCT00263718|DRUG|Calcipotriol plus betamethasone dipropionate (LEO 80185) gel|
223877402|NCT05281718|DRUG|Factor IX|Factor IX is on of the substrates of emicizumab.
223877403|NCT05810051|BEHAVIORAL|Cardiac rehabilitation|"The patients in this arm will be trained for 1 hour, 2 or 3 times per week for 36 sessions. In addition to the training program, the patients also get access to the cardiovascular educational program.~The training (a 1h session) consists of 60% cardiovascular endurance training and 40% resistance training."
223877404|NCT05777759|DEVICE|Restylane Lyft with Lidocaine|hyaluronic acid
223877405|NCT05777759|DEVICE|Juvederm Voluma XC|hyaluronic acid
223877406|NCT05676645|DRUG|Artemether-lumefantrine|National policy recommendation for treatment of uncomplicated malaria in Uganda
223877407|NCT06381427|OTHER|Interdisciplinary decision-making for perioperative care|Interdisciplinary decision-making for perioperative care involving a cardiologist, anesthesiologist, and surgeon in collaboration with the primary care physician. Decisions include determining whether surgery is feasible or if patient optimization is necessary first. Subsequently, targeted postoperative visits by a heart failure nurse and appropriate postoperative care, also after discharge from the hospital, through the primary care physician.
223877408|NCT06014229|DEVICE|cryoablation|Single session with an argon-based cryoablation device; an specific applicator will be used for the treatments; gas release 100% for cryoablation; local anesthesia or moderate sedation or general anesthesia at discretion of the anesthesiology / interventional radiology team; benign thyroid nodules (two benign cytological examinations) measuring between 5 and 65 mL of volume and less than 40% of cystic component;
223877409|NCT06497712|OTHER|Hypnosis|Before the beginning of stitches, the patient will be offered a hypnotic induction. The hypnotic induction is the initial phase of the hypnosis process. Its goal is to bring the patient to a state of dissociation: the hypnotic trance. Induction is usually achieved through progressive relaxation, sensory focusing, and a process of confusion.
223877410|NCT04201834|DRUG|Risperidone|capsule or tablet, 0.5 mg
223877411|NCT04201834|DEVICE|BioStamp nPoint device|MC10 has developed the BioStamp nPointTM, a FDA 510(k) cleared medical device. This multimodal, reusable and rechargeable biosensor uses flexible and stretchable electronics to enable unobtrusive wear on the body and monitoring in the home. The sensors have accelerometry, gyroscopy, and ECG/EMG capabilities. A docking station enables wireless recharging and data collection.
223877412|NCT06241482|PROCEDURE|Enhanced recovery after surgery|"The technologies, processes and measures of enhanced recovery after surgery focus on the following aspects:~1. Early assessment and treatment~2. Optimized anesthetic protocol~3. Reducing surgical stress~4. Multi-modal comprehensive monitoring~5. Comprehensive diagnosis and treatment in neurosurgical intensive care~6. Intensive early rehabilitation treatment"
223877413|NCT06241482|PROCEDURE|Conventional therapy|Conventional therapy in neurocritical care.
223877414|NCT06536270|OTHER|A validation and reproducibility study with a cross-sectional component|The primary intervention in this study involves adapting and validating the eNutri web-based Food Frequency Questionnaire and Diet Quality Score for the Turkish population.
223877415|NCT04082637|BEHAVIORAL|Mindful Awareness in Body-oriented Therapy|A mind-body intervention designed to teach interoceptive awareness skills for emotion regulation and self-care. Delivered individually in 75 minute sessions once a week for 8 weeks.
223877416|NCT06545409|PROCEDURE|Ultrasound-guided Serratus Posterior Superior Intercostal Plane Block performed with 0.25% bupivacaine|While the patient is in the prone or the sitting position, a high-frequency linear transducer is placed transversely at the level of the scapular spine, visualizing the upper medial border of the scapula, trapezius muscle, rhomboid major, serratus posterior superior muscle, and the second and third ribs. Next, the transducer is rotated to obtain an oblique view, including the upper medial border of the scapula. The needle is then advanced immediately medial to the scapula, aiming for the area between the second and third ribs to reach the fascial plane between the serratus posterior superior muscle and intercostal muscles using the in-plane technique. Once the needle contacts the rib, 30 mL of 0.25% bupivacaine is administered superficially to the intercostal muscle.
223877417|NCT06545409|PROCEDURE|Ultrasound-guided Serratus Posterior Superior Intercostal Plane Block performed with a placebo solution (0.9% NaCl)|While the patient is in the prone or the sitting position, a high-frequency linear transducer is placed transversely at the level of the scapular spine, visualizing the upper medial border of the scapula, trapezius muscle, rhomboid major, serratus posterior superior muscle, and the second and third ribs. Next, the transducer is rotated to obtain an oblique view, including the upper medial border of the scapula. The needle is then advanced immediately medial to the scapula, aiming for the area between the second and third ribs to reach the fascial plane between the serratus posterior superior muscle and intercostal muscles using the in-plane technique. Once the needle contacts the rib, 30 mL of 0.9% NaCl is administered superficially to the intercostal muscle
223877418|NCT06402318|DEVICE|A&M Breathalyzer PROTECT Kiosk|The A\&M Breathalyzer PROTECT Kiosk will collect the mass spectrum breath readings from each participant, scan speed, and will autoanalyze noise and scan thresholds and sensitivity data.
223877419|NCT05624606|BIOLOGICAL|Quadrivalent Influenza mRNA Vaccine MRT5410|Pharmaceutical form: Liquid frozen solution for injection in a vial Route of administration: Intramuscular
223877420|NCT05624606|BIOLOGICAL|Quadrivalent Recombinant Influenza vaccine RIV4|Pharmaceutical form: Liquid suspension for injection in prefilled syringe Route of administration: Intramuscular
223877421|NCT05624606|BIOLOGICAL|Quadrivalent Inactivated Influenza Standard Dose QIV-SD|Pharmaceutical form: Liquid suspension for injection in prefilled syringe Route of administration: Intramuscular
223877422|NCT05624606|BIOLOGICAL|Quadrivalent Inactivated Influenza High Dose QIV-HD|Pharmaceutical form: Liquid suspension for injection in prefilled syringe Route of administration: Intramuscular
223877423|NCT06241794|PROCEDURE|Group M-TAPA|Aseptic conditions are ensured in the area where the block will be performed. Under ultrasound guidance, a linear probe at the sagittal plane and costochondral angle is used to identify the transversus abdominis, internal oblique, and external oblique muscles at the level of the 10th rib. To visualize the lower surface of the rib cartilage in the midline, a sagittal angle is applied with the probe in the direction of the costochondral angle at the edge of the 10th rib. Using a 22-G, 80-100 mm block needle with an in-plane technique, the needle is advanced cranially. The needle tip is directed towards the posterior surface of the 10th rib cartilage, underneath the condyle. Subsequently, 20 ml of 0.25% concentration bupivacaine is injected beneath the condyle. The same procedure will be applied to the opposite side using the same technique.
223877424|NCT06241794|PROCEDURE|Group Serratus Intercostal Plane Block and Rectus Sheath Block|"Serratus intercostal plane block:The serratus anterior muscle and intercostal muscles are identified at the level of 8th rib along the right mid-axillary line.Using block needle,20 ml of 0.25% Bupivacaine is injected into the interfascial plane between these muscles.The SIPB will be performed only on the right side.~Rectus sheath block:a linear probe is placed in a transverse position just above the umbilicus and slightly lateral to the midline.After visualizing the rectus abdominis muscle, posterior rectus sheath,and the hypoechoic space between them,block needle is advanced in-plane along the subcutaneous tissue.The needle is progressed until reaching the space between the epimysium of the muscle and the posterior rectus sheath, passing horizontally through the anterior rectus sheath of the rectus abdominis muscle.10 ml of 0.25% bupivacaine is injected.Adequate spread will lift the epimysium of rectus abdominis muscle while displacing the posterior fascia and peritoneum downward"
223877425|NCT04349826|DRUG|Azithromycin|Azithromycin 20 mg/kg/day for 7 days
223877426|NCT04349826|DRUG|Cefixime|cefixime 20-30 mg/kg/day for 7 days
223877427|NCT04349826|DRUG|Placebo|cefixime-matched placebo for 7 days
223877428|NCT05437380|DIAGNOSTIC_TEST|peritumoral microbubbles and contrast-enhanced ultrasonography|Inject 1ml microbubbles around the tumors. Then detect lymph vessel and lymph nodes under contrast-enhanced ultrasonography.
223877429|NCT05123365|DRUG|N-Acetylcysteine|Given PO
223877430|NCT05540535|OTHER|Gait assessment|The average speed of gait and spatiotemporal gait parameters would be calculated by the APDM, inertial motion units. Participants will walk in their normal speed for 1 minute along a corridor, back and forth, with or without performing a cognitive task (single or DT). The DT condition will include serial subtraction (counting backwards out loud) in jumps of 3 from a random three-digit number. Randomization of numbers will be done using the excel function generating random numbers (Excel RAND function). The numbers will be recorded for offline processing and the outcome will be the number of correct numbers. Each condition will be performed once, and all conditions will be randomized.
223877431|NCT05540535|OTHER|Cognitive assessment|Participants will complete a computerized cognitive battery (CNS vital sign; CNSVS)that will include verbal memory, visual memory, Stroop test, shifting attention and 4-part continuous performance (sustained attention and working memory). Moreover, performance on the single cognitive task (serial subtraction in jumps of 3; measuring working memory and executive function) will also be evaluated while sitting (cognitive single task). The numbers will be recorded for offline processing and the outcome will be the number of correct numbers. These tests do not require the ability to hear in order to pass successfully. Also, there is a need for investigation of cognitive domains such as attention, memory, executive function, and cognitive flexibility in people with HL.
223877432|NCT05947344|DRUG|STI-8591|Four dosing cohorts will be evaluated in the dose escalation phase: 20mg, 40mg, 60mg and 80mg. Expansion is planned in two dose groups of 40mg and 60mg.
223877433|NCT05629936|OTHER|Digital interdisciplinary intervention|Digital medication interview, comprehensive medication review, interdisciplinary patient-centred discussions, follow-ups
223877434|NCT04301726|DRUG|Deutetrabenazine Oral Tablet [Austedo]|The participants randomized to this group will receive oral deutetrabenazine for 8 weeks. Week 1: 6 mg tab once daily; Week 2: 6 mg tab (BID); Week 3: 9 mg tab (BID); Week 4: 12 mg tab (BID); Week 5: 15 mg (6 mg tab + 9 mg tab BID); Week 6: 18 mg (9 mg tab + 9 mg tab BID); Week 7: 21 mg (9 mg tab + 12 mg tab BID); Week 8: 24 mg (12 mg tab BID).
223877435|NCT04301726|DRUG|Placebo oral tablet|The participants randomized to this group will receive oral placebo for 8 weeks. Week 1: 6 mg tab once daily; Week 2: 6 mg tab (BID); Week 3: 9 mg tab (BID); Week 4: 12 mg tab (BID); Week 5: 15 mg (6 mg tab + 9 mg tab BID); Week 6: 18 mg (9 mg tab + 9 mg tab BID); Week 7: 21 mg (9 mg tab + 12 mg tab BID); Week 8: 24 mg (12 mg tab BID).
223877436|NCT01923506|RADIATION|stereotactic body radiation therapy|Undergo SBRT
223877437|NCT01923506|PROCEDURE|quality-of-life assessment|Ancillary studies
223877438|NCT01923506|OTHER|laboratory biomarker analysis|Correlative studies
223877439|NCT03089125|BEHAVIORAL|Dyspnea Intervention|"Dyspnea intervention will be administered over two sessions~Patients will receive:~* Psychoeducation~* Relaxation training for reducing physiological stress~* Behavioral techniques for managing acute breathlessness"
223877440|NCT03089125|OTHER|Usual Care|Patients will receive any usual care for their dyspnea as deemed appropriate by their clinicians
223877441|NCT06005740|DRUG|TORL-4-500|antibody drug conjugate
223877442|NCT04418115|OTHER|Acupuncture; based on Tradidtional Chinese Medicine|Acupuncture is a form of treatment that involves inserting very thin needles through a person's skin at specific points on the body, to various depths. Research suggests that it can help relieve pain, and it is used for a wide range of other complaints.
223877443|NCT06453005|PROCEDURE|SMART Hall Technique or procedure|"The SMART Hall technique, a minimally invasive approach in pediatric dentistry for managing caries in primary teeth, involves gentle cavity preparation using hand instruments and minimal local anesthesia. A glass ionomer cement is used for restoration, followed by crown adaptation and cementation. Postoperative care and follow-up assessments at 3 and 6 months are included.~The Stainless Steel Crown (SSC) technique for restoring extensively decayed primary molars involves tooth preparation, crown selection, adaptation, and cementation. Postoperative care and follow-up assessments at 3 and 6 months are also part of the procedure."
223877444|NCT04310735|BEHAVIORAL|Verbal smoking expectancy manipulation|Instructions regarding whether or not participants will have an opportunity to smoke during the experimental session.
223877445|NCT05994209|DEVICE|quitSTART Mobile Application|Mobile application with educational content, motivational messages, self-monitoring, and tips for managing cravings to support vaping cessation among young adults.
223877446|NCT05994209|BEHAVIORAL|Chatbot Feature in quitSTART Mobile Application|In-App chatbot feature emedded into quitSTART mobile application to motivate vaping cessation and support app navigation.
223877447|NCT04104321|DRUG|Aramchol free acid|Aramchol 300 mg BID
223877448|NCT04104321|DRUG|Placebo|Placebo BID
223877449|NCT03481777|DEVICE|Remote Ischemic Conditioning|RIC is commonly achieved by inflation of a blood pressure cuff to induce 5-minute cycles of limb ischemia alternating with 5 minutes of reperfusion.
223877450|NCT03481777|DEVICE|Sham Remote Ischemic Conditioning|Sham Comparator (Sham-RIC)
223877451|NCT05275959|OTHER|A cluster randomized trial of a comprehensive intervention nesting family and clinic into school centered implementation to reduce myopia and obesity among children and adolescents in Beijing, China|"Myopia and obesity in children and adolescents have become serious public health problems that endanger public health, especially in China. Unhealthy lifestyle behaviors are environmental drivers of both myopia and obesity. This protocol describes a study to evaluate the effectiveness of 22510SS, that is 2 h of daytime outdoor activities ('2'); Limit screen time to no more than 2 h per day ('2'); Consume at least 5 servings of fruits and vegetables daily ('5'); Attain 1 h of physical activity daily ('1'); Consume 0 sugar-sweetened beverages ('0'); Reasonable sleep duration ('S'); Regular supervision ('S'). A school-based, multifaceted intervention strategy for myopia and obesity prevention, and to assess and explore the implementation of 22510SS with regards to acceptability, feasibility, adoption, usage and maintenance."
223877452|NCT02977819|OTHER|Meditation practice|18 months
223877453|NCT02977819|OTHER|Learning English as a foreign language|18 months
223877454|NCT05840055|BEHAVIORAL|Acceptance and Commitment Therapy|"Acceptance and Commitment Therapy is one potential intervention for reducing internalizing symptoms, increasing purpose in life, and reducing avoidance-based coping among people with NMOSD and their caregiver loved ones. ACT is a third wave behavioral therapy which balances encouraging life changes in the service of one's values (purpose in life) with a strong acceptance component. This novel, experiential, contextual talk therapy is an empirically supported treatment for anxiety and depression, substance use, and has proven successful in managing chronic pain, somatic problems, HIV, Pancreatic Cancer and Cystic Fibrosis."
223877455|NCT03150914|DRUG|Sirolimus|mTOR inhibitor or placebo
223877456|NCT06471335|DIAGNOSTIC_TEST|Extraction of microRNAs extracted from plasma (4 ml recovered as part of treatment)|Comparison of these micro RNAs with the micro RNAs extracted from oral swabs (in Fetal Alcohol Spectrum Disorder group)
223877457|NCT06471335|DIAGNOSTIC_TEST|Extraction of microRNAs extracted from bucal swabs (act added for research).|Comparison of the microRNAs extracted from the oral swabs of the Fetal Alcohol Spectrum Disorder group with the microRNAs extracted from the oral swabs of the without Fetal Alcohol Spectrum Disorder group
223877458|NCT06380153|DRUG|Hemay005|15mg/tablet，Four tablets (60mg) each time. Participants will receive a single dose of Hemay005 tablet in Day1
223877459|NCT06515080|DIAGNOSTIC_TEST|Near Red Infrascopy|Monitor of regional cerebral oxygen saturation
223877460|NCT05696080|BIOLOGICAL|V116|Pneumococcal 21-valent conjugate vaccine with 4 μg of each of the following pneumococcal polysaccharides (PnPs) antigen: 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15C, 16F, 17F, 19A, 20, 22F, 23A, 23B, 24F, 31, 33F, and 35B in each 0.5 mL sterile solution
223877461|NCT05696080|BIOLOGICAL|Placebo|Saline in each 0.5 mL sterile solution
223877462|NCT05696080|BIOLOGICAL|PCV15|Pneumococcal 15-valent conjugate vaccine with 2 μg of each of the following PnPs antigen: 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F; and 4 μg of PnPs antigen 6B in each 0.5 mL sterile suspension
223877463|NCT05696080|BIOLOGICAL|PPSV23|Pneumococcal 23-valent polyvalent vaccine with 25 μg of each of the following PnPs antigen: 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F in each 0.5 mL sterile solution
223877464|NCT05152394|BIOLOGICAL|AlloEx|cultured allogeneic adult umbilical cord derived mesenchymal stem cell exosomes
223877465|NCT06472609|BEHAVIORAL|enhanced interactive education|The present study is a prospective randomized open-label study. Patients with diabetes mellitus who have HbA1c% more than 9% during the recent 1 year are enrolled. The intervention group receives, besides routine medical control of diabetes,enhanced interactive education program through weekly phone call for 12 weeks.
223877466|NCT05351281|DEVICE|CDSS-OPTIMED|The CDSS-OPTIMED is a software program that provides the physician with a personalized alert on whether to consider stopping or starting medication for a specific patient with a life expectancy of less than 3 months.
223877467|NCT02724228|DRUG|BMN 111|BMN 111 will be administered subcutaneously daily.
223877468|NCT05189418|DEVICE|Ambulatory blood pressure monitoring (ABPM)|Periodic (quarterly) 48h ABPM evaluation during follow-up
223877469|NCT05189418|DEVICE|Home blood pressure monitoring (HBPM)|Periodic (monthly) 7-day HBPM, both during awake and sleep spans, during follow-up
223877470|NCT05868330|PROCEDURE|Interscalene Catheter|Pre-operatively the patient will have a interscalene catheter placed by a regional skilled anesthesiologist. The initial block will be with 20 cc of 0.5% Bupivacaine and maintained on an infusion post-operatively at 8cc/hr of 0.2% ropivacaine as is our intuitions protocol
223877471|NCT05868330|PROCEDURE|Exparel Single Shot Interscalene Block|Pre-operatively the patient will have a interscalene single shot block with 133 mg Liposomal Bupivacaine and 10 ccs 0.5% Bupivacaine placed by a regional skilled anesthesiologist.
223877472|NCT05587530|BEHAVIORAL|Treatment engagement and retention intervention for suicidal clients|The manualized behavioral intervention for treatment engagement and retention of suicidal clients will be based on client and staff stakeholder preferences, informed by data from qualitative participatory interviews and secondary data analysis of administrative databases (conducted in phase 1). In addition to factors identified by stakeholders, if deemed feasible and acceptable during phase 1, the intervention will include structured phone outreach, shared decision-making, and peer support.
223877473|NCT05932212|DRUG|AK104|AK104 15mg/kg intravenously(IV) every 3 weeks (Q3W), until progressive disease, unacceptable toxicity, completion of 2 years treatment or withdrawal of consent.
223877474|NCT05932212|DRUG|AK104+ Paclitaxel+Cisplatin or Carboplatin|AK104 (10 mg/kg) + paclitaxel (175 mg/m2)+ cisplatin (50 mg/m2) or carboplatin (AUC 4-5) , IV, Q3W, for up to 6 cycles, followed by maintenance therapy of AK104 10 mg/kg Q3W until disease progression, intolerable toxicity, withdrawal of consent, or completion of 2 years treatment.
223877475|NCT05306080|DRUG|Tadekinig alfa (IL-18BP)|"Tadekinig alfa will be administered via subcutaneous injection. The site of subcutaneous injection should be rotated to avoid injection site reactions; e.g. the outside of the thighs, arms, and the various quadrants of the anterior abdominal wall.~* Injection #1/Day 1:~  o Loading dose of 4 mg/kg; Maximum dose of 350 mg.~* Repeat Injection(s): 2 mg/kg/injection; Maximum dose of 160 mg/injection. Missed doses will not be made up.~  * Injection #2/Day 3: Approximately 48 hours (+/- 5 hours) after receipt of the 1st injection.~ * Injection #3/Day 5: Approximately 48 hours (+/- 5 hours) after receipt of the 2nd injection.~ * Continued Dosing (Optional): Approximately q48-72 hours; If the subject is responsive to initial therapy, but has ongoing symptoms of CRS/CRHLS."
223877476|NCT06418321|DEVICE|Investigational device|The participants' hearing status will be evaluated using the investigational device.
223877477|NCT06418321|OTHER|Audiometer|Participants' hearing thresholds are tested with an audiogram.
223877478|NCT06418321|DEVICE|Otomicroscopy|The status of the participants' ear canals and tympanic membranes are checked.
223877479|NCT06418321|OTHER|REM (Real Ear Measurements)|The acoustic properties of the participants' ears will be measured during the interventions.
223877480|NCT05849012|OTHER|Low Sulfur Diet|"Subjects will be placed on a low sulfur diet for 8 weeks with the support of a nutritionist.~In addition, participants will be asked to complete: surveys, lactulose-mannitol test, glucose hydrogen breath test, blood samples, visceral sensation test, 24-hour urine sample for sulfate level, provide stool samples, optional colonoscopy."
223877481|NCT05849012|OTHER|Usual Diet|"Subjects will continue on their usual diet for 8 weeks. At the end of 8 weeks, if participants are interested, they will be offered treatment with low sulfur diet for 8 weeks with the support of a nutritionist.~In addition, participants will be asked to complete: surveys, lactulose-mannitol test, glucose hydrogen breath test, blood samples, visceral sensation test, 24-hour urine sample for sulfate level, provide stool samples, optional colonoscopy."
223877482|NCT06226220|PROCEDURE|Sacral neuromodulation|Sacral neuromodulation (SNM) is a minimally invasive procedure that provides low-amplitude electrical stimulation to the S3 nerve root to improve micturition and defecation. Patients who elect to proceed with SNM undergo a trial phase to determine therapeutic response prior to placement of a permanent implantable pulse generator (IPG). A trial phase can be performed in two ways: a percutaneous nerve evaluation (PNE) or staged implantation. PNE involves the placement of a temporary wire connected to an electrode using external stimulation. It is performed in the office using local anesthesia. If the patient displays adequate improvement in symptoms (defined as \>50% improvement of symptoms from baseline), a permanent lead and subcutaneous IPG are implanted in the operating room.
223877483|NCT06402942|OTHER|Gamified occupational therapy programme|Gamified occupational therapy program for the experimental group and classical occupational therapy program for the control group, which will be applied to both groups for eight weeks
223877484|NCT06402942|OTHER|Classic occupational therapy programme|Gamified occupational therapy program for the experimental group and classical occupational therapy program for the control group, which will be applied to both groups for eight weeks
223877485|NCT06810687|DRUG|Methenamine Hippurate 1g BD|Antibiotic prophylaxis
223877486|NCT06810687|OTHER|Antibiotic prophylaxis|Antibiotic prophylaxis
223877487|NCT06389188|PROCEDURE|RHB Group|The RHB-group were treated with passive manual therapy (P-MT) by soft tissue mobilization, massage and muscular stretching of the anterior and posterior cervical muscles; active therapeutic exercises (A-TE); and oculo-cervical exercises (OC-E). Patients received a total of 20 sessions of 30 minutes each during 4 weeks
223877488|NCT04063709|DIAGNOSTIC_TEST|Acoustic Radiation Force Impulse (ARFI) ultrasound|ARFI imaging is an ultrasound-based, noninvasive imaging method and will be used in accordance with approved labeling.
223877489|NCT04793906|OTHER|Iron supplement with a lunch meal containing beef|Participants will consume a lunch meal containing beef with an iron supplement for 8 weeks.
223877490|NCT04793906|OTHER|Iron supplement with a lunch meal containing plant-based alternative|Participants will consume a lunch meal containing plant-based alternative with an iron supplement for 8 weeks.
223877491|NCT05657743|DEVICE|Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)|An intratumoral insertion of radioactive sources \[Ra-224 containing stainless-steel 316LVM tubes- (Alpha DaRT seeds)\]. The seeds release by recoil into the tumor short-lived alpha-emitting atoms
223877492|NCT06748352|PROCEDURE|FASTER-assisted ESD|The patients who are randomly assigned to the FASTER-assisted ESD group will undergo the ESD procedure with the assistance of the FASTER system.
223877493|NCT06748352|PROCEDURE|Conventional ESD|The patients who are randomly assigned to the conventional ESD group will undergo the ESD following the clinically established pattern.
223877494|NCT06749652|DEVICE|firm silicone stent insertion|Insertion of firm silicon ureteral stent (Percuflex Plus)
223877495|NCT06749652|DEVICE|Soft silicone ureteral stent insertion|Soft silicone ureteral stent insertion
223877496|NCT05672615|OTHER|Questionnaires|Participants will be given the Zung Self-Rating Anxiety Scale and Zung Self-Rating Depression Scale to complete prior to each induction intravesical treatment and prior to 3-month follow-up appointments.
223877497|NCT05672615|OTHER|Daily Mood Diaries|Participants will be given daily mood diaries to complete during their 6-week induction intravesical treatment, 3-week maintenance treatment course, and between 3-month follow-up appointments.
223877498|NCT05672615|OTHER|Urine Specimen Collection|Urine collections from patients will occur prior to each induction intravesical treatment and at 3-month follow-up cystoscopy appointments. An at home urine collection may occur 6 hours post intravesical treatment.
223877499|NCT05672615|OTHER|Research Blood Draw|Blood collections will occur prior to first intravesical treatment, prior to fourth intravesical treatment, and each 3-month cystoscopy as indicated by the participant's treatment course.
223877500|NCT05672615|OTHER|Utilize excess tissue from a standard of care procedure|Participants may indicate permission to provide excess tissue from a clinically indicated procedure for research purposes.
223877501|NCT01489813|DRUG|Genistein|30 mg of genistein supplement by mouth three times daily (PO TID).
223877502|NCT01489813|DRUG|Sugar pill|Sugar pills will be taken by mouth three times daily (PO TID).
223877503|NCT06138093|DEVICE|Sealing device|Intratracheal tracheostomy sealing
223877504|NCT06138093|DEVICE|No device|Open tracheostomy wound
223877505|NCT02632760|DRUG|Ferric carboxymaltose|treatment for Iron deficient anaemia
223877506|NCT02632760|DRUG|Placebo|placebo - no active drug
223877507|NCT05621889|PROCEDURE|virtual group speech therapy intervention guided by a patient partner|virtual group speech therapy intervention guided by a patient partner
223877508|NCT06279650|OTHER|Self-hypnosis|The HYlaDo intervention comprises 8 90-minute sessions. Session 1 offers psycho-education on pain and medical hypnosis. Sessions 2 to 7 offer brief introductions followed by hypnosis induction, during which the CBT elements (exposure and cognitive restructuring) to be worked on during the session are introduced. The sessions are aimed at managing: 2- anxiety and mood; 3- pain dramatization; 4- and 5- pain perception; 6- kinesiophobia; 7- future projection and resource mobilization. Session 8 provides feedback and recommendations for independent practice. Each hypnosis follows the same pattern: induction, deepening, CBT-based hypnotic work, post-hypnotic suggestions and return to wakefulness, explanations of the exercise and recommendations for independent practice.
223877509|NCT06279650|OTHER|Psycho-education and cognitive Bahavioral therapy (CBT)|The psychoeducation-CBT intervention for pain and anxiety/depression consists of 8 90-minute sessions. It has already been implemented in HMR's pain clinic, and controls both the effects of time and repetition of measures, as well as non-specific factors including expectations associated with receiving active treatment, therapeutic relationship, frequency of encounters, and participation in a manualized intervention. It is designed to inform participants about pain, its costs, neurophysiology, nature and impact. It includes general information on pain, as well as information tailored to the participants' particular type of pain. The sessions are interactive, with the therapist stimulating discussion of the educational content and its relevance to the participants' lives.
223877510|NCT04392050|OTHER|Interview|Complete interview
223877511|NCT04392050|OTHER|Focus Group|Attend focus groups
223877512|NCT04392050|OTHER|Questionnaire Administration|Ancillary studies
223877513|NCT03433469|DRUG|Osimertinib|Given PO (orally)
223877514|NCT03433469|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
223877515|NCT04605198|BEHAVIORAL|Modified Mindfulness-based Stress Reduction|Participants will be trained in mindfulness meditation and the applicability of mindfulness practices to daily life. During MBSR programming, teachers will lecture about key topics in mindfulness and lead class discussions. Participants are given homework assignments, such as listening to guided meditations. Participants are given opportunities to ask the instructor questions and to share their experiences with each other. Each session focuses on a different key topic. Topics are: Session 1: Introduction; Session 2: Understanding Perceptions; Session 3: Hatha Yoga, Sitting Meditation, Walking Meditation; Session 4: Concentration \& Awareness; Session 5: Unhealthy Patterns \&Getting Unstuck; Session 6: Transformational Coping Strategies; Session 7: Mini-retreat; Session 8: Maintaining Discipline \& Flexibility; Session 9: Course Review.
223877516|NCT04605198|BEHAVIORAL|Health Promotion Wellness Classes|Sessions will cover the following general wellness topics: Session 1; Introduction; Session 2: Envisioning Health Through Art; Session 3: Chronic Disease 1 (Heart Health); Session 4: Chronic Disease II (Diabetes); Session 5: Nutrition and Hydration; Session 6: Infectious Disease Prevention; Session 7: Skin Care; Session 8: Oral Health; Session 9: Promoting Social Integration \& Course Graduation.
223877517|NCT06131541|PROCEDURE|autogenous tooth graft|undemineralized autogenous tooth graft will augment the gap between the splitted ridge and the simultaneously \[laced implant fixture
223877518|NCT06131541|PROCEDURE|autogenous bone graft|autogenous bone graft will augment the gap between the splitted ridge and the simultaneously \[laced implant fixture
223877519|NCT04038957|DRUG|SEP-363856|SEP-363856 50mg, 75mg flexable dosing, dosed once daily capsule
223877520|NCT00319267|DRUG|Bosentan|Pediatric oral formulation of bosentan, i.e., 32 mg dispersible and breakable tablets
223877521|NCT06748716|DEVICE|Blue-blocking glasses|The investigators hypothesize that blue-blocking glasses (intervention) is more effective than placebo.
223877522|NCT06748716|DEVICE|Clear glasses|Clear-lensed glasses are placebo
223877523|NCT03591770|BIOLOGICAL|SHINGRIX|"SHINGRIX is a vaccine indicated for prevention of herpes zoster (shingles) in adults aged 50 years and older.~SHINGRIX is a suspension for injection supplied as a single-dose vial of lyophilized gE antigen component to be reconstituted with the accompanying vial of AS01B adjuvant suspension component. A single dose after reconstitution is 0.5 mL.~Dose and Schedule: Two doses (0.5 mL each) administered intramuscularly according to the following schedule: A first dose at Month 0 followed by a second dose administered anytime between 2 and 6 months later."
223877524|NCT05777902|DRUG|Ozanimod Oral Capsule|We propose to integrate measurements obtained using multiple tools. Patients will undergo MRI and hdEEG procedures, and blood samples will be obtained for the immunological and biochemical studies on the same day. The study of the immune system's status will include an extensive immunophenotypic analysis, a functional characterization following ex vivo stimulation of innate immune cells, and the measurement of soluble products in the serum, such as cytokines. Cellular traits of interest include the absolute numbers and relative proportions of specific cell subsets, transcriptional states, secretory functions, proliferative capacity or cytolytic potential. Specifically, the following antibody combination will constitute the core of the immunophenotypic analysis: HLADR CD11c, CD38, CD14, CD123, lineage (CD3, CD56, CD19).
223877525|NCT03859830|DEVICE|Artis Dialysis System, ArtiSet PrePost and Ultra HDF Line|The HDF session will be performed in post-dilution volume-controlled mode, with a minimum target total convective volume (VCtot) of 16 L and blood flow rate (QB) set at 200-300 mL/min.
223877526|NCT03859830|DEVICE|AK200 Ultra S, extracorporeal circulation conduct of blood purification|The HDF session will be performed in post-dilution volume-controlled mode, with a minimum target total convective volume (VCtot) of 16 L and blood flow rate (QB) set at 200-300 mL/min.
223877527|NCT05091957|OTHER|Community Support Worker|structured review of participant income supports with a trained CSW, to identify financial needs and benefits for which the family is eligible, including assessment of income and food security, affordability of medications, housing and energy insecurity, and dental care. The visits will be conducted in person, by telephone or by videoconferencing, according to participant preference and to ensure adherence to COVID-19 pandemic-related criteria.
223877528|NCT05091957|OTHER|Usual Care|Participants in both groups will receive a written summary of available resources
223877529|NCT01998984|DRUG|ingenol mebutate|
223877530|NCT01998984|OTHER|Placebo|
223877531|NCT06306027|BEHAVIORAL|Web-based education|The patient discharged after knee arthroplasty surgery will attend a follow-up appointment 15 days later, and during this visit, they will be granted permission to resume work. The patient will receive detailed information about accessing, entering, and using the web-based training. Scales with pre-test data will be completed by the patient. They will be encouraged to log in at least twice a week, and the patient will be monitored for a total of 1 month (4 weeks). After one month, the patient will be asked to fill out the scales again.
223877532|NCT05649982|BEHAVIORAL|ALVA|Behavioural digital self-help intervention
223877533|NCT05939427|OTHER|NGAGE tool|Will have access to the NGAGE tool to learn about engaging in care and to request engagement activities.
223877534|NCT05874570|DRUG|Esomeprazole|Proton pump inhibitor
223877535|NCT05874570|DRUG|Bismuth Potassium Citrate|Gastric mucosal protective drug with anti-H. pylori effect
223877536|NCT05874570|DRUG|Tetracycline|Antibiotics for H. pylori eradication
223877537|NCT05874570|DRUG|Doxycycline|Antibiotics for H. pylori eradication
223877538|NCT05874570|DRUG|Metronidazole|Antibiotics for H. pylori eradication
223877539|NCT04009005|BEHAVIORAL|Therapeutic diet and lifestyle|Educational videos, 1 individual support call from RD follwed by monthly support group meetings conducted via an internet based audio/ video conference platform. Patients will be trained on a low lectin modified paleolithic elimination diet; breathing meditation practice, and walking sessions to increase daily moderate to vigorous physiscal activity
223877540|NCT06239155|DRUG|AST-3424|liquid formulation for Intravenous infusion
223877541|NCT05085990|BIOLOGICAL|TARA-002|Phase 1b, Dose Expansion Phase: All subjects will receive 6 weekly doses of TARA-002 at the recommended Phase 2 dose (R2PD)
223877542|NCT06282172|DEVICE|Treatment with BTL-785-7|Treatment with BTL-785-7 delivering simultaneously radiofrequency (RF) and HIFES energy on the submental area
223877543|NCT03532880|DRUG|Olaparib Pill 50 mg|"Olaparib dosing will be twice-daily (BID) dosing. Olaparib tablets should be taken at the same time each day, approximately 12 hours apart with one glass of water.~Drug administration at the dose level will occur on Day 1 (6 - 9 days prior to start of radiotherapy; for logistical considerations this may occur on the day of simulation for radiotherapy) and will continue concurrently with low dose consolidative thoracic radiotherapy until last day of radiotherapy (Day 20 - 23)"
223877544|NCT03532880|DRUG|Olaparib Pill 100 mg|"Olaparib dosing will be twice-daily (BID) dosing. Olaparib tablets should be taken at the same time each day, approximately 12 hours apart with one glass of water.~Drug administration at the dose level will occur on Day 1 (6 - 9 days prior to start of radiotherapy; for logistical considerations this may occur on the day of simulation for radiotherapy) and will continue concurrently with low dose consolidative thoracic radiotherapy until last day of radiotherapy (Day 20 - 23)"
223877545|NCT03532880|DRUG|Olaparib Pill 150 mg|"Olaparib dosing will be twice-daily (BID) dosing. Olaparib tablets should be taken at the same time each day, approximately 12 hours apart with one glass of water.~Drug administration at the dose level will occur on Day 1 (6 - 9 days prior to start of radiotherapy; for logistical considerations this may occur on the day of simulation for radiotherapy) and will continue concurrently with low dose consolidative thoracic radiotherapy until last day of radiotherapy (Day 20 - 23)"
223877546|NCT03532880|DRUG|Olaparib Pill 200 mg|"Olaparib dosing will be twice-daily (BID) dosing. Olaparib tablets should be taken at the same time each day, approximately 12 hours apart with one glass of water.~Drug administration at the dose level will occur on Day 1 (6 - 9 days prior to start of radiotherapy; for logistical considerations this may occur on the day of simulation for radiotherapy) and will continue concurrently with low dose consolidative thoracic radiotherapy until last day of radiotherapy (Day 20 - 23)"
223877547|NCT03532880|DRUG|Olaparib Pill 250 mg|"Olaparib dosing will be twice-daily (BID) dosing. Olaparib tablets should be taken at the same time each day, approximately 12 hours apart with one glass of water.~Drug administration at the dose level will occur on Day 1 (6 - 9 days prior to start of radiotherapy; for logistical considerations this may occur on the day of simulation for radiotherapy) and will continue concurrently with low dose consolidative thoracic radiotherapy until last day of radiotherapy (Day 20 - 23)"
223877548|NCT03532880|DRUG|Olaparib Pill 300 mg|"Olaparib dosing will be twice-daily (BID) dosing. Olaparib tablets should be taken at the same time each day, approximately 12 hours apart with one glass of water.~Drug administration at the dose level will occur on Day 1 (6 - 9 days prior to start of radiotherapy; for logistical considerations this may occur on the day of simulation for radiotherapy) and will continue concurrently with low dose consolidative thoracic radiotherapy until last day of radiotherapy (Day 20 - 23)"
223877549|NCT03532880|RADIATION|Radiotherapy|The total prescribed dose will be 30 Gy in ten daily fractions of 3 Gy each delivered during business days over 2 calendar weeks.
223877550|NCT01843374|DRUG|Tremelimumab|Tremelimumab is to be administered as an IV solution, followed by observation.
223877551|NCT01843374|DRUG|Placebo|Placebo is to be administered as an IV solution, followed by observation.
223877552|NCT06031649|DEVICE|MyotonPRO device|It is a valid and reliable device for measuring the muscular mechanical properties
223877553|NCT06814600|DIAGNOSTIC_TEST|Transient elastometry|"Controlled attenuation parameter (CAP) and liver stiffness measurement (LSM) will be measured by transient liver elastometry Fibroscan to evaluate hepatic steatosis and fibrosis in all patients at baseline. Absence of steatosis S0 is defined as CAP \<248 dB/m, mild steatosis S1 with CAP \< 268 dB/m, and moderate to severe steatosis ≥ S2 is defined as CAP \>280 dB/m. Liver fibrosis will be evaluated using the liver stiffness measurement (LSM) in kPa7."
223877554|NCT06406387|DIAGNOSTIC_TEST|ATRX/DAXX immunohistochemistry|Immunohistochemistry will be performed using an Autostainer Leica (Leica Biosystems) according to the manufacturer's instructions. Four μm formalin-fixed paraffin-embedded sections will be immunostained with antibodies for Cytokeratin AE1/AE3 (AE1-AE3, 1:100 dilution, Novocastra/United Kingdom) Chromogranin A (DAK-A3, 1:2500, Dako/Denmark), and Synaptophysin (27G12, 1:100, Novocastra), Ki67 (MIB1, 1:100, Dako/Denmark), ATRX (1:400, Sigma-Aldrich), DAXX (1:200, Sigma-Aldrich). After antigen retrieval, immunostaining will be performed in an automated Bond instrument (Vision-Biosystem, Leica, Milan, Italy) using a sensitive peroxidase-based 'Bond polymer Refine' detection system.
223877555|NCT05364944|DRUG|Debio 4126|Intramuscular (IM) injection
223877556|NCT05364944|DRUG|Sandostatin LAR|Sandostatin LAR will be administered as IM injection as pre-study treatment dose prior to Debio 4126 administration
223877557|NCT05364944|DRUG|Somatuline ATG|Somatulin ATG will be administered as deep subcutaneous (SC) injection as pre-study treatment dose prior to Debio 4126 administration
223877558|NCT02605837|DRUG|Oral Budesonide Suspension (OBS)|Oral Budesonide Suspension (OBS) 10 milliliter (ml) of 0.2 milligram per milliliter (mg/ml) twice daily up to 16 weeks.
223877559|NCT02605837|DRUG|Placebo|Oral dose of 10 ml of placebo matched with the experimental drug.
223877560|NCT05670002|DIETARY_SUPPLEMENT|Milk supplement|Children will take the milk supplement for a period of 6 months. During the intervention, anthropometry data, Zinc Protoporphyrin levels, dietary intake, any illness will be recorded.
223877561|NCT03573752|OTHER|outpatient management for promontofixation by laparoscopy|postoperative H8 exit after laparoscopic promontofixation
223877562|NCT03573752|OTHER|questionnaire|Each patient will complete a questionnaire on the experience of management, both in terms of pain management, anxiety and overall satisfaction.
223877563|NCT06434701|DIAGNOSTIC_TEST|Nasopharyngeal swab sampling for COVID-19|The healthcare provider will gently insert the swab a short distance (1-1.5 cm for young children) into one nostril, reaching the back of the nasal cavity. The swab will then be gently rotated and rubbed for a few seconds to collect a sample of mucus. The same process may be repeated in the other nostril.
223877564|NCT02652260|DRUG|Doravirine, Tenofovir, Lamivudine - Blinded|A single tablet FDC containing doravirine 100 mg, lamivudine (3TC) 300 mg and tenofovir disoproxil fumarate (TDF) 300 mg administered orally, once daily for 12 weeks during the Blinded period
223877565|NCT02652260|DRUG|Doravirine, Tenofovir, Lamivudine - Open-Label|A single-tablet FDC containing doravirine 100 mg, 3TC 300 mg and TDF 300 mg administered orally, once daily for either 12 or 24 weeks during the Open-Label Period; also an additional 96 weeks during the Open-Label extension period 1; a maximum total duration of treatment of 228 weeks during the Open-Label extension period 2; and a maximum total duration of treatment of 324 weeks during the Open-Label extension period 3.
223877566|NCT02652260|DRUG|ATRIPLA^TM|A single tablet FDC containing efavirenz (EFV) 600 mg, emtricitabine (FTC) 200 mg, and TDF 300 mg administered orally, once daily for 12 weeks during the Blinded period
223877567|NCT02652260|DRUG|Placebo to ATRIPLA™|A single placebo to ATRIPLA™ tablet administered orally, once daily for 12 weeks during the Blinded period
223877568|NCT02652260|DRUG|Placebo to Doravirine, Tenofovir, Lamivudine|A single placebo to doravirine, tenofovir, lamivudine tablet administered orally, once daily for 12 weeks during the Blinded period
223877569|NCT06667648|PROCEDURE|cupping session|Each cupping session takes about 30-40 min and can be conducted in five steps. The first step includes primary suction. In this phase, the therapist allocates specific points or areas for cupping and disinfects the area, which located at the upper back (opposite to C7), Para spinal and below scapula. A cup with a suitable size is placed on the selected site and sucked the air inside the cup by manual suction. Then the cup was applied to the skin and left for a period of 3 to 5 min. The second step is about puncturing. Puncturing with a needle to get out of blood the third step is about suction and bloodletting. The cup is placed back on the skin using the similar procedure described above for 3 to 5 min. The fourth step includes the removal of the cup, followed by the fifth step which includes dressing the area after cleaning and disinfecting with FDA-approved skin disinfectant.
223877570|NCT06072378|BEHAVIORAL|Value-manipulation|During the decision-making task, different choices are assigned different values probabilistically.
223877571|NCT06761755|OTHER|hot pack , K taping , Progressive muscle relaxation|"Group A has given the kinesiology taping on the lower abdomen and back for 1-3 days with progressive muscle relaxation technique for 10-20 minutes and a baseline treatment hot pack at a time twice a day from the start of menstruation~Group B has receive the kinesiology taping on the lower abdomen and baseline treatment hot pack without progressive muscle relaxation technique for 1-3 days"
223877572|NCT06760741|GENETIC|Multigene panel|"Germline Genetic Testing: Germline genetic testing will be performed on all patients with pancreatic cancer (PC) using a custom multigene panel. This panel includes 25 candidate genetic variants of interest and 13 clinically recognized genes associated with a higher risk of PC.~DNA Extraction: Germline DNA will be extracted from peripheral blood samples using the QIAamp DNA Blood Kit (Qiagen, Redwood City, CA, USA) following the manufacturer's instructions. The concentration of double-stranded DNA will be measured using a fluorometric method (Qubit, Thermo Fisher Scientific)."
223877573|NCT06760741|DIAGNOSTIC_TEST|Other|"1. Characterization of Suspected Pancreatic Cancer Lesions:~   Characterization of suspected pancreatic cancer (PC) lesions identified by endoscopic ultrasound (EUS) and/or magnetic resonance imaging (MRI) in patients undergoing screening since 2014. This includes lesion type (solid or cystic), rapid cyst growth exceeding 4 mm per year, location, size, potential assessment of resectability, lobulocentric parenchymal atrophy, and Wirsung duct dilation. Clinically relevant suspected lesions will be defined as solid lesions, intraductal papillary mucinous neoplasms (IPMN), cystic lesions ≥10 mm, and cystic lesions with mural nodules.~2. Determination of CA 19-9 and Glycated Hemoglobin:~Measurement of CA 19-9 levels and glycated hemoglobin (HbA1c) as part of the diagnostic and monitoring process."
223877574|NCT06760741|DIAGNOSTIC_TEST|miRNA measurement in blood|"Analysis of miRNA Expression in plasma:~The expression of circulating miRNAs (in plasma) will be analyzed using quantitative reverse transcription polymerase chain reaction (qRT-PCR). The signature includes two miRNAs (miR-33a-3p and miR-320a) combined with CA 19-9."
223877575|NCT06760741|GENETIC|Generation of 3D Pancreatic Organoids|"Generation of 3D Pancreatic Organoids for Complementary Analyses:~3D pancreatic organoids will be generated for complementary analyses involving in vitro functional studies to evaluate the pathogenicity of novel genes (selected based on the results of the multigene panel). These organoids will be developed from surgical samples obtained from five patients undergoing surgery as part of clinical care."
223877576|NCT06385119|DRUG|Plixorafenib|Oral Tablet
223877577|NCT06385119|DRUG|Cobicistat|Oral Tablet
223877578|NCT06068868|DRUG|ABBV-787|Intravenous (IV) Infusion
223877579|NCT05453565|OTHER|Vasopressors|A haemodynamic resuscitation strategy based upon the restriction of IV fluids (by either volume or rate of infusion) with initiation or change of rate of vasopressors if required to meet perfusion targets
223877580|NCT05453565|OTHER|Fluids|A strategy of resuscitation with intravenous fluids as the primary intervention to achieve perfusion targets with subsequent initiation or change of rate of vasopressors if required.
223877581|NCT06122844|BEHAVIORAL|Social, Emotional, and Ethical Development (SEED) curriculum|In response to fulfilling children's urgent psychosocial needs, the Bodhi Love Foundation (BLF) adapted the Kindness Curriculum for young children in Hong Kong by translating it from English to Chinese and adapting its length and content for implementation in the local kindergarten context. The adapted Kindness Curriculum, renamed as Social, Emotional, and Ethical Development curriculum (SEED), is a two-part program involving teacher training and delivery of SEED. The teacher training is consist of a 12-hour mindfulness course and a 1-day (6 hours) workshop to get familiarized with the understanding and practice of mindfulness, and the details of the SEED Curriculum. The SEED Curriculum involves 8 short sessions of basic techniques in mindfulness with 10 minutes each. In addition, it has 12 mindfulness-based lessons with specific themes for children in K2 and K3. Each lesson lasts for approximately 30-40 minutes.
223877582|NCT05322525|DRUG|ON101 Cream|"Test drug:~1. Name: ON101~2. Dosage form: Topical cream~3. Active ingredients: Extracts of Plectranthus amboinicus and Centella Asiatica~4. Dose(s): Apply 1 cc per 5 cm2 ulcer size (not exceeding 2 mm in thickness)~5. Dosing schedule: Apply once a day"
223877583|NCT05056246|DRUG|AMG 133|Solution for SC injection
223877584|NCT04997096|OTHER|Exercise|16-week, virtually supervised, technology-based, aerobic and resistance exercise program performed 3 days per week which starts at least 4 weeks after surgery
223877585|NCT04997096|OTHER|Attention Control|Home-based stretching program consisting of one set of 4 static stretching exercises held for 30 seconds and performed 3 days/week. Participants will be shown how to use the booklet and instructed on how to complete the stretching exercises by an exercise trainer.
223877586|NCT03894917|OTHER|Comprehensive Geriatric Assessment (CGA)|Assessments will be done for participants that are 65 years or older.
223877587|NCT04647435|DRUG|APSCTC|APSCTC + Toragesic® placebo + Tramal® placebo
223877588|NCT04647435|DRUG|Toragesic®|APSCTC placebo + Toragesic® + Tramal® placebo
223877589|NCT04647435|DRUG|Tramal®|APSCTC placebo + Toragesic® placebo + Tramal®
223877590|NCT06414317|PROCEDURE|Assessment of Distress|Undergo psychological distress screening
223877591|NCT06414317|OTHER|Consultation Visit|Attend consultations
223877592|NCT06414317|OTHER|Nutritional Assessment|Undergo malnutrition screening
223877593|NCT06414317|OTHER|Questionnaire Administration|Ancillary studies
223877594|NCT06414317|OTHER|Supportive Care|Receive access to bladder cancer ENST
223877595|NCT06414317|OTHER|Supportive Care|Attend virtual support group meetings
223877596|NCT06789926|OTHER|Intervention Group|Attending a 4-hour ACT workshop, and after attending participants will utilize the remaining course time to independently access the LINE platform. The platform will feature pre-recorded guided audio files for relaxation, emotional videos, and psychological cards.
223877597|NCT06783348|DRUG|177Lu-PSMA-617|Administeration by intravenous infusion or injection at an activity of 7.4 GBq every 6 weeks (±1 week) for up to a total of 6 doses, unless there is disease progression or unacceptable toxicity or until the occurrence of a withdrawal criterion. The first infusion should be administered within 3 weeks from enrolment. Patients in PR or SD after 4 cycles will receive an additional two doses.
223877598|NCT05055778|BEHAVIORAL|SmokefreeTXT|"The program is identical to the publicly available program available through the National Cancer Institute Smokefree.gov Initiative but has been set up to be delivered through a research account. The program will send 3-5 messages a day over 7 weeks, with one week to prepare for a quit attempt and 6 weeks of cessation support messages. Participants can get real time support for cravings, mood, and slips by texting keywords to the program. They keywords are CRAVE, MOOD, and SLIP. Participants can also re-set their quit date by texting NEW. The program asks questions each week to ask about smoking status and about mood and cravings."
223877599|NCT06784739|OTHER|Blood sampling|Venous blood sampling
223877600|NCT06784739|OTHER|Mucosal sampling|Saliva and nasal secretions
223877601|NCT06784739|DIAGNOSTIC_TEST|PCR-test|RT qPCR test to determine infection with SARS-CoV-2, Influenza A/B and/or RSV A/B.
223877602|NCT05729256|BEHAVIORAL|Self-Regulation Intervention|Single session motivational intervention on reducing heavy drinking and sexual risk behavior, encouraging consideration of pre-exposure prophylaxis (PrEP), followed by 4 weeks of text messages on content relevant to drinking goals and support for healthy sexual choices
223877603|NCT05729256|BEHAVIORAL|Brief Advice and Information|Psychoeducation about heavy drinking risks, discussion of barriers to safe sex, information about pre-exposure prophylaxis (PrEP)
223877604|NCT06783439|OTHER|Ultrasound|The ultrasound probe will be placed parallel to the body of the piriformis muscle on an imaginary line drawn from the sacrum to the greater trochanter of the femur. This area is also the sensitive area of the patients during the examination with pressure, and when the US probe is in this position, the subcutaneous fat tissue, gluteus maximus muscle, piriformis muscle, and the upper and lower borders of the sciatic nerve will be displayed in order from superficial to deep. First, the maximum thickness of the piriformis muscle body will be measured, then the thickness of the sciatic nerve will be measured, and the same measurements will be applied to the patient's asymptomatic hip, and the measurements will be recorded.
223877605|NCT04659408|DIETARY_SUPPLEMENT|Multistrain probiotic preparation|One sachet daily, containing 3 grams of the freeze-dried multispecies probiotic Bactosan for a period of four weeks. One sachet will be mixed with 50-100 ml water and taken daily before breakfast or dinner. Bactosan contains the following eight bacterial strains: Bifidobacterium lactis W51, Bifidobacterium lactis W52, Enterococcus faecium W54, Lactobacillus acidophilus W22, Lactobacillus paracasei W20, Lactobacillus plantarum W21, Lactobacillus salivarius W24 and Lactococcus lactis W19, with a total viable cell count of 1 × 109 cfu/gram, and therefore 3 × 109 cfu/daily dose.
223877606|NCT04659408|DIETARY_SUPPLEMENT|Oat Bran|5 grams (one teaspoon) daily of the oat bran together with a meal of preference. The oat bran can be added to the usual breakfast cereal, yoghurt, pancakes, juice, milk, salad sauce or in an omelette.
223877607|NCT04714320|DRUG|Placebo|ISIS 757456 matching placebo administered by SC injection.
223877608|NCT04714320|DRUG|IONIS-AGT-LRx|IONIS-AGT-LRx administered by SC injection.
223877609|NCT05057897|BIOLOGICAL|AZD1222|10 mM histidine, 7.5% (w/v) sucrose, 35 mM sodium chloride, 1 mM magnesium chloride, 0.1% (w/v) polysorbate 80, 0.1 mM edetate disodium, 0.5% (w/v) ethanol, at pH 6.6
223877610|NCT06322706|DRUG|ABSK021|ABSK021 oral
223877611|NCT06322706|DRUG|Omeprazole|Omeprazole oral
223877612|NCT05659459|DRUG|KIN001|Oral tablet
223877613|NCT05659459|DRUG|KIN001-Placebo|Comparator - Oral tablet with same appearance of KIN001
223877614|NCT06032208|DEVICE|Theranova Dialyzer|The Theranova dialyzer will be used for each of the hemodialysis treatments beginning week 5 and ending at the end of dialysis week 28. This will allow us to compare patient reported symptoms in weeks 1-4 on their usual dialyzer with with their symptoms on the Theranova dialyzer.
223877615|NCT05864118|DIAGNOSTIC_TEST|Respiratory pathogen panel PCR test|Respiratory pathogen panel PCR test and COVID-19 antibody test.
223877616|NCT05864118|DIAGNOSTIC_TEST|COVID-19 antibody test|COVID-19 antibody test
223877617|NCT03363854|DRUG|Tralokinumab|Tralokinumab is a human recombinant monoclonal antibody of the IgG4 subclass that specifically binds to human IL-13 and blocks interaction with the IL-13 receptors. It is presented as a liquid formulation for subcutaneous (SC) administration.
223877618|NCT03363854|DRUG|Placebo|Placebo contains the same excipients in the same concentration only lacking tralokinumab.
223877619|NCT06745856|DRUG|5-fluorouracil|Subconjunctival, peroperative, application of 50mg/ml concentration of 5-fluoruracil.
223877620|NCT06745856|DRUG|placebo|Subconjunctival, peroperative application of normal saline (NaCl 0.9%)
223877621|NCT06734923|OTHER|Questionnaire (28 questions)|demographic data, information-seeking behavior, platform use and online consultation habits, trust and impact, and interest in additional resources
223877622|NCT05600972|PROCEDURE|FSH priming|Patients who are randomized into the FSH priming arm will receive two days of FSH injections of 150 IU/day. Oocyte retrieval will be scheduled at 42 hours after the last FSH injection.
223877623|NCT06745154|PROCEDURE|Biospecimen Collection|Undergo nasal swab collection
223877624|NCT06745154|PROCEDURE|Cognitive Assessment|Undergo cognitive assessment
223877625|NCT06745154|OTHER|Interview|Ancillary studies
223877626|NCT06745154|DRUG|Nicotine Replacement|Given nicotine patches, gum, or lozenges
223877627|NCT06745154|BEHAVIORAL|Smoking Cessation Intervention|Receive access to the Ohio Tobacco Quit Line
223877628|NCT06745154|OTHER|Survey Administration|Ancillary studies
223877629|NCT06745154|OTHER|Tobacco Cessation Counseling|Participate in counseling sessions
223877630|NCT05651659|OTHER|TIME model in the prevention and treatment of crises in frail community-dwelling people|TIME is a manual-based, multicomponent programme that will include a rigorous assessment of the crises, one or more interdisciplinary case conferences and the testing and evaluation of customised treatment measures.This multicomponent interdisciplinary model consisting of three overlapping phases. First the assessment phase where the care staff and the physician collaborate in a comprehensive bio-psychosocial assessment. The second phase is the reflection phase with interdisciplinary case conferences based on principles from cognitive behavioural therapy and abc-method, where a customized treatment plan is developed. The abc-method from cognitive behavioural therapy is used as an analytic tool for the analyses of the complex challenges in the case conferences. In the third phase the treatment plan is implemented and evaluated systematically.
223877631|NCT04273555|DRUG|[18F]-FDG|\[18F\]-FDG will be injected prior to PET/MRI imaging up to three times over the course of six months.
223877632|NCT05982769|BEHAVIORAL|Endurance Training 3 times per week|endurance training will be performed from home 3 times per week under the supervision of the research team.
223877633|NCT05982769|BEHAVIORAL|Resistance Exercise|resistance training will be performed from home 2 times per week under the supervision of the research team.
223877634|NCT05982769|BEHAVIORAL|Standard of Care|continue usual activity
223877635|NCT05766878|DEVICE|implants placement|The intervention will consist of placement of two types of short implants (one with traditional machined collar and one with anodized collar). After their healing period, the prosthetic rehabilitation will be made.
223877636|NCT04731467|DRUG|CM-24 and Nivolumab - Dose Escalation|Dose escalation of CM24 with nivolumab in adult patients with selected recurrent or metastatic solid tumors
223877637|NCT04731467|DRUG|CM-24, Nivolumab, Nab paclitaxel and Gemcitabine - Expansion|Expansion cohort of CM24 in combination with nivolumab, nab-paclitaxel and gemcitabine in adult patients with advanced metastatic pancreatic cancer
223877638|NCT04731467|DRUG|CM-24, Nivolumab, and Nal-IRI/5-FU/LV - Expansion|Expansion cohort of CM24 in combination with nivolumab and Nal-IRI/5-FU/LV in adult patients with advanced metastatic pancreatic cancer
223877639|NCT04731467|DRUG|Nivolumab, Nab paclitaxel and Gemcitabine - Expansion|Expansion cohort of nivolumab in combination with nab-paclitaxel and gemcitabine in adult patients with advanced metastatic pancreatic cancer
223877640|NCT04731467|DRUG|Nivolumab and Nal-IRI/5-FU/LV - Expansion|Expansion cohort of nivolumab in combination with Nal-IRI/5-FU/LV in adult patients with advanced metastatic pancreatic cancer
223877641|NCT06475261|DEVICE|Tissue Oximetry with ForeSight|Evaluation of a correlation between average intraoperative muscle tissue oximetry and postoperative renal damage in patients undergoing cytoreductive surgery with HIPEC for ovarian cancer
223877642|NCT03612648|RADIATION|Three Fraction Accelerated Partial Breast Irradiation|"* TRI-APBI simulation must take place no more than 8 weeks from final definitive breast surgery~* Machines that could be used include: SAVI applicator, The ViewRay System for Radiation Therapy, The ViewRay (MRIdian) Linac System, Halcyon, True Beam, True Beam STx, Edge Radiotherapy Delivery System"
223877643|NCT03612648|PROCEDURE|Partial mastectomy|-Standard of Care
223877644|NCT06040892|DIAGNOSTIC_TEST|SPHERE protocol : Spatial hearing performances test|Participants will be instructed to localize a sound emitted in their environment using a virtual reality setup (SPHERE protocol).
223877645|NCT06040892|DIAGNOSTIC_TEST|FRASIMAT Test : audiology test of speech in noise perception|Intelligibility threshold is the signal-to-noise ratio (in decibels) for which the subject can repeat 50% of the words heard in a dichotic listening.
223877646|NCT06040892|DIAGNOSTIC_TEST|Kid SSQ questionnaire of life : The Speech, Spatial and Other Qualities of Hearing Scale|The SSQ questionnaire is a clinical subjective scale that allows evaluating of hearing performances in daily life. The questionnaire is divided into 3 main items (A: speech; B: spatial hearing; C: other qualities of hearing) comprising questions with rating scores out of ten.
223877647|NCT06040892|OTHER|spatial hearing rehabilitation program|The tool makes it possible to propose rehabilitation programs adapted to the performance and expectations of each child. This program will manipulate both the ambient sound with varying background noise to simulate daily life environments (i.e. making auditory detection more or less complex), and also manipulate virtual immersive environment (i.e. giving more or less relevant visual cues related to real sound location).
223877648|NCT06409897|OTHER|Sequencial increasing of head of the bed elevation and alveolar recruitment maneuver followed by a PEEP titration with 10° of head of the elevation|Patients will be sequentially positioned at 0, 10, 20, 30, and 40 degrees of head-of-bed elevation. An alveolar recruitment maneuver will be performed. For patients with body mass index ≤ 30 kg/m\^2, the maneuver will be conducted in pressure control mode, pressure control = 15 cmH2O, respiratory rate = 20 breaths per minute, and the PEEP will be increased in steps of 5 up to 30 cmH2O. For patients with body mass index \> 30, the PEEP will be increased up to 35. Then, a PEEP titration will be performed, tidal volume = 5 mL/Kg, respiratory rate = 25 breaths per minute, and the PEEP will be decreased from 24 down to 4 cmH2O in steps of 2 cmH2O with 30 seconds in each PEEP level. The PEEP titration software of Enlight 2100 will be used to determine the ideal PEEP, defined as the PEEP level with a collapse less than 5%. The alveolar recruitment maneuver will be performed again to reopen the lungs. Then, data will be collected, as with the 0 and 40-degree steps, with ideal PEEP.
223877649|NCT04419857|DIETARY_SUPPLEMENT|High-calorie formula|Infant randomly assigned to high-calorie formula for 14 days
223877650|NCT05506085|DEVICE|Deep Brain Stimulation|Deep Brain Stimulation of Globus Pallidus interna
223877651|NCT05685108|DEVICE|Ultrasound stimulation intensity|A clinical ultrasound transducer will be placed against the abdomen or neck of an individual in order to administer insonification to the splenic nerve.
223877652|NCT05685108|DEVICE|Ultrasound stimulation site|A clinical ultrasound transducer will be placed against the abdomen or neck of an individual in order to administer insonification to the splenic nerve and the cervical vagus nerve.
223877653|NCT05492266|DEVICE|Expiratory Muscle Strength Training|At visit 1, participants will be block randomized based on PWSS score (5-6 or 7+) to Expiratory Muscle Strength Training (EMST) for 6 to 8 weeks or no exercises. Participants in the EMST-150 group will perform 5 sets of 5 resistive expirations once a day with a 10-15 second rest between each repetition and a 1-2 minute rest between each set of 5 repetitions.
223877654|NCT05492266|DEVICE|Maintenance Training|"At visit 2, participants with improved (decreased) CAPS-A hypernasality rating of 1 or more points, for whom the family and/or surgeon is not currently considering surgical intervention for VPI, will be further randomized to continue maintenance EMST exercises or no exercises for 6 months. Participants in the maintenance group will complete 3-5 sessions exercise sessions each week (rather than daily training), with 2 sets of 5 resistive expirations (rather than 5 sets)"
223877655|NCT05163301|BEHAVIORAL|Relapse Prevention Intervention|2 session intervention to address relapse prevention among people with HIV who have an alcohol use disorder
223877656|NCT06533540|BIOLOGICAL|TPX-115(allogeneic fibroblasts)|Intradermal injection of TPX-115(allogeneic fibroblasts)
223877657|NCT03948867|DRUG|Hydroxyurea|Hydroxyurea treatment will be provided to reduce stroke risk. Hydroxyurea treatment will be started at a fixed dose of 20.0 ± 5.0 mg/kg/day, followed by escalation to maximum tolerated dose (MTD).
223877658|NCT03948867|DIAGNOSTIC_TEST|Elevated Arm TCD Examination|"TCD examination on children with SCA between ages 2 and 16 years of age will be completed to evaluate their risk of stroke.~For children with elevated velocities at initial screening or at 1 Year who receive hydroxyurea therapy, TCD examinations will occur every 6 ± 2 months."
223877659|NCT03948867|DIAGNOSTIC_TEST|Normal Arm TCD Examination|TCD examination on children with SCA between ages 2 and 16 years of age will be completed to evaluate their risk of stroke. TCD examination for all participants will occur at initial screening, at Year 1 (12 ± 3 months), and Year 2 (24 ± 3 months). Children with normal TCD velocities at initial screening will undergo repeat TCD 12 months after enrolment. If the TCD at 12 months has changed to an elevated velocity (conditional or abnormal), the child can begin study treatment (Hydroxyurea).
223877660|NCT05339113|DIAGNOSTIC_TEST|68Ga-FAPI-46 PET/CT|Patients are scanned 10 minute, 30 minute and 1 hour after 68Ga-FAPI-46 as well as one hour 18-FDG injection within 2-3 days interval.
223877661|NCT03576521|COMBINATION_PRODUCT|CT + Ocoxin-Viusid|"The included patients received the Ocoxin-Viusid nutritional supplement at a rate of 75 ml daily (25 ml in 3 doses every 8 hours) administered after main meals diluted in milk or juice. The treatment will start a week before, it will be maintained throughout the coventional chemotherapy treatment\* and up to three weeks after the end of the treatment.~\*All patients should receive the CT Adriamycin 60 mg per m2 of Body Surface (BS) and Cyclophosphamide Infusion intravenous every 21 days, up to a total of 4 to 6 cycles according to protocols provided in the center."
223877662|NCT03576521|COMBINATION_PRODUCT|CT + Placebo|"The included patients received the OV placebo in oral solution at a rate of 75 ml daily (25 ml in 3 doses every 8 hours), administered after main meals diluted in milk or juice. The treatment will start a week before, it will be maintained throughout the coventional chemotherapy treatment\* and up to three weeks after the end of the treatment.~\*All patients should receive the CT Adriamycin 60 mg per m2 of Body Surface (BS) and Cyclophosphamide Infusion intravenous every 21 days, up to a total of 4 to 6 cycles according to protocols provided in the center."
223877663|NCT00505934|DRUG|Levetiracetam|"Intravenous 100 mg/mL, twice a day, maximum of 4 days~Subjects on oral levetiracetam at study entry receive the same intravenous (IV) dosage (mg-for-mg) to their oral dose within the following dose range, calculated on the basis of their age and weight:.~* Ages ≥ 1 month to \< 6 months: 14 mg/kg/day (7 mg/kg twice daily) to 42 mg/kg/day (21 mg/kg/day twice daily);~* Ages ≥ 6 months to \< 4 years: 20 mg/kg/day (10 mg/kg twice daily) to 60 mg/kg/day (30 mg/kg/day twice daily).~For subjects not taking levetiracetam oral solution prior to entering the study, the intravenous (IV) dosage corresponded to their age and weight as follows:~* Ages ≥ 1 month to \< 6 months: 14 mg/kg/day (7 mg/kg twice daily).~* Ages ≥ 6 months to \< 4 years: 20 mg/kg/day (10 mg/kg twice daily)."
223877664|NCT03050814|DRUG|Avelumab|10 mg/kg intravenous (IV) over 30-60 min on Day 1
223877665|NCT03050814|BIOLOGICAL|Ad-CEA vaccine|Subcutaneous injection in the thigh prior to Avelumab on Day 1 of cycles 1, 2 3, 5, 7, 9; every 6 cycles thereafter.
223877666|NCT03050814|DRUG|Bevacizumab|5mg/kg intravenous (IV) over 30-90 min on day 1 (Arm A) or 2 (Arm B). Part of the standard of care therapy.
223877667|NCT03050814|DRUG|5-Fluorouracil (FU)|400mg/m\^2 (only Arm A) intravenous (IV) bolus on day 1. Part of the standard of care therapy.
223877668|NCT03050814|DRUG|Leucovorin|400mg/m\^2 intravenous (IV) over 2 hours on day 1 (Arm A) or Day 2 (Arm B). Part of the standard of care therapy.
223877669|NCT03050814|DRUG|Oxaliplatin|85mg/m\^2 (Arm A) or 68mg/m\^2 (Arm B) intravenous (IV) over 2 hours on day 1 (Arm A) or Day 2 (Arm B). Part of the standard of care therapy.
223877670|NCT03050814|DRUG|Capecitabine|625 mg/m\^2 twice a day by mouth. Part of the standard of care therapy.
223877671|NCT03050814|DRUG|5-Fluorouracil (FU)|2400 mg/m\^2 (Arm A and B) intravenous (IV) over 46 hours (+/-2 hours) to start on Day 1 (ARM A) or Day 2 (Arm B). Part of the standard of care therapy.
223877672|NCT02692469|PROCEDURE|Duodenal Switch|Bariatric procedure
223877673|NCT02692469|PROCEDURE|Duodenal-ileal Bypass with Sleeve Gastrectomy|Bariatric procedure
223877674|NCT02014129|DRUG|LY2835219|Administered orally
223877675|NCT03849352|BEHAVIORAL|Lifestyle changes with the support of health technology|Written instructions will be provided to participants, to include how to download supportive apps on smartphones. Participants will be asked to complete a 3 day food diary using an online platform (MyFood24) prior to attending a face to face consultation which will reinforce the participant's responsibilities. Participants will be assisted to set specific diet and lifestyle goals. 3 fortnightly follow ups will be arranged via 15 minute telephone consultations, three 24 hour dietary diaries will be completed via MyFood24 prior to each fortnightly digital consultation. Participants will be asked to measure their daily activity via a pedometer on their smart phones. Participants will be asked to complete the Godin leisure time questionnaire to assess changes in leisure time exercise.
223877676|NCT00164216|DRUG|mefloquine plus artesunate|
223877677|NCT03465813|BEHAVIORAL|CaringGuidance After Breast Cancer Diagnosis|CaringGuidance After Breast Cancer Diagnosis, psychoeducational, Internet-accessible program
223877678|NCT05137236|BIOLOGICAL|mRNA-1283|Sterile liquid for injection
223877679|NCT05137236|BIOLOGICAL|mRNA-1283.211|Sterile liquid for injection
223877680|NCT05137236|BIOLOGICAL|mRNA-1273|Sterile liquid for injection
223877681|NCT05137236|BIOLOGICAL|mRNA-1283.529|Sterile liquid for injection
223877682|NCT03244449|OTHER|No apply|
223877683|NCT02724956|DEVICE|Ambu AuraGain|Pre-curved, rigid airway tube, SGAD. Third generation Ambu laryngeal mask satisfying 3 fundamental airway management needs by integrating gastric access and intubation capability in an anatomically curved single-use device that facilitates rapid establishment of a safe airway. A SGAD used for ventilation, and a conduit for intubation. SGAD insertion followed by fiber-optic evaluation using Ambu aScope.
223877684|NCT02724956|DEVICE|Teleflex LMA Protector|Pre-curved, rigid airway tube, SGAD: A next-generation, single-use laryngeal mask with a dual gastric drainage channel and pharyngeal chamber. A SGAD used for ventilation, and a conduit for intubation. SGAD insertion followed by fiber-optic evaluation using Ambu aScope.
223877685|NCT02724956|DEVICE|Ambu aScope|Flexible scope which will be introduced into airway tube and guided through the SGAD until it will be possible to view the vocal cords. Description of the maximal optical view will be measured by the Percentage of Glottic Opening (POGO).
223877686|NCT05928637|DRUG|D745, D759, D150|QD, PO for 5 days
223877687|NCT03807661|PROCEDURE|Percutaneous deep vein arterialization|Creation of an arterio-venous fistula in the below-the-knee vasculature using the LimFlow System endovascular, minimally invasive approach
223877688|NCT03807661|DEVICE|LimFlow System|Creation of an arterio-venous fistula in the below-the-knee vasculature using the LimFlow System endovascular, minimally invasive approach
223877689|NCT02054923|PROCEDURE|Implementation of routine videorecording|All screening centres (clusters) assigned to the routine video recording group will receive an appropriate number of video recorders and DVDs for each colonoscopy room. Screening centre coordinators will be responsible for the implementation of routine video recording of all screening colonoscopies (only withdrawal) in the centres. Every three months screening centre coordinators will be asked to send back all recorded DVDs. All the recorded DVDs will be reviewed to verify ceacal intubation and withdrawal time by the PCSP team and then stored.
223877690|NCT02054923|BEHAVIORAL|No routine videorecording|Screening centres (clusters) assigned to the control group will not receive video recorders and DVDs but will be allowed to record colonoscopies on demand.
223877691|NCT00933712|DRUG|LACTIC ACID(ND)|Dermacyd Silver Floral (Lactic Acid) sample will be applied like a curative for 6 weeks.
223877692|NCT04059042|BEHAVIORAL|Music Listening|Participants will have pain threshold testing while listening to silence, music, or nature sounds.
223877693|NCT06221137|PROCEDURE|conventional circumferential supracrestal fiberotomy|"The amount of tooth that need to be extruded will be measured Bonding brackets slot 0,022x0.028 Roth prescription on piggyback for the tooth with (0.016. x 0.022 ) stainless steel main arch wire and 0.0014 nickel titanium auxiliary.~• Fiberotomy After 2 days of bonding, local anaesthetic solution will be administrated. The depth of the fibrotomy should be equal to the amount of tooth that need to be extruded.~supracrustal fibrotomy will be performed using 15 c blade (Carvalho, Bauer et al. 2006)"
223877694|NCT06221137|PROCEDURE|laser circumferential supracrestal fiberotomy|"* The amount of tooth that need to be extruded will be measured~* Bonding brackets slot 0,022x0.028 Roth prescription~* piggyback for the tooth with (0.016. x 0.022 ) stainless steel main arch wire and 0.0014 nickel titanium auxiliary.~  • Fiberotomy~* After 2 days of bonding, local anaesthetic solution will be administrated.~* The depth of the fibrotomy should be equal to the amount of tooth that need to be extruded.~* A diode laser of 980 nm wavelength will be used The laser tip will be inserted, and incision will be extended around tooth circumference with the system configured to a continuous wave with the movement of the laser tip in an up and down stroking movement The laser tip will be moved in a circumferential manner taking care that all the fibers are lysed."
223877695|NCT04264013|BEHAVIORAL|Exercise|Participants will exercise in a supervised facility twice weekly and consume their habitual diet.
223877696|NCT04264013|BEHAVIORAL|Exercise plus diet (egg)|Participants will exercise in a supervised facility twice weekly and consume an addiitonal 4 eggs per day.
223877697|NCT03733028|BEHAVIORAL|Mobile Intervention for Reducing Anger (MIRA)|This is a mobile intervention that uses interpretation bias modification (IBM) techniques to reduce the hostile interpretation bias. Participants will be given a mobile device with the MIRA app and instructed to complete 5 treatment sessions each week for a period of 4 weeks. Each session takes approximately 10 minutes. The app also includes a Nightly Diary to track symptoms, a calendar to program session reminders, and a My Progress feature to track use and performance.
223877698|NCT03733028|BEHAVIORAL|Mindfulness Intervention|"This is a mobile intervention that uses the Mindful Breathing and Body Scan exercises from the Mindfulness Coach app. These audio-guided exercises take approximately 10 minutes each. Participants will be given a mobile device with the Mindfulness app and instructed to complete 5 exercises (i.e., Body Scan or Mindful Breathing) each week for a period of 4 weeks. The app also includes a Nightly Diary to track symptoms, a calendar to program reminders, and a My Progress feature to track use and performance."
223877699|NCT06359379|DRUG|Ropidoxuridine|Ropidoxuridine is administered daily, 5 days a week, for 7 weeks, starting one week prior to radiotherapy, and then concurrently with a standard 60 Gy radiotherapy, followed by a 4-week rest period.
223877700|NCT06341088|PROCEDURE|unilateral suture sacro-hysteropexy|patients in this group will undergo unilateral sacrouterine ligament plication with nonabsorbable suture and unilaterally suspended to the anterior longitudinal ligament.
223877701|NCT06341088|PROCEDURE|bilateral suture sacro-hysteropexy|patients in this group will undergo bilateral sacrouterine ligament plication with nonabsorbable suture and bilaterally suspended to the anterior longitudinal ligament.
223877702|NCT06271356|BEHAVIORAL|BC-Navigate|BC-Navigate is a website/application to help guide women through care delivery during breast cancer treatment.
223877703|NCT03684980|DRUG|Methotrexate|(Cohort A) will receive MTX 3 g/m2 or (Cohort B) will receive MTX 8 g/m\^2 (Cohort E) will receive MTX ≤ 3.5 g/ m2
223877704|NCT03684980|DRUG|Rituximab|Patients will be treated with rituximab 500 mg/m\^2.
223877705|NCT03684980|DRUG|leucovorin|Patients will also receive standard of care leucovorin rescue starting at least 24 hours after MTX and 2 hours after Voraxaze. Cycles will be 14 days long.
223877706|NCT03684980|DRUG|Glucarpidase|Glucarpidase 2000 units. Arm E 1000 units.
223877707|NCT04415060|DRUG|Isoflurane Inhalant Product|Isoflurane will be administered using an inhalation device
223877708|NCT04415060|DRUG|Sevoflurane inhalant product|Sevoflurane will be administered using an inhalation device
223877709|NCT00473902|BEHAVIORAL|Training|
223877710|NCT00473902|DRUG|Creatine Monohydrate, Conjugated Linoleic Acid|
223877711|NCT06541561|DEVICE|transcutaneous electrical acupoint stimulation|Patients in the TEAS group, the acupoints are bilateral neiguan (PC6), Zusanli (ST 36), Hegu (L14) and Waiguan (SJ5) acupoints. The treatment will consist of two phases: a 30-minute stimulation administered 30 minutes before anesthesia induction, and a 30-minute stimulation session once daily on postoperative days 1, 2, and 3. The stimulation intensity will be adjusted in accordance with the maximal level tolerated by each patient. Patients in the sham group will receive electrode attachment but without stimulation.
223877712|NCT06541561|DEVICE|sham transcutaneous electrical acupoint stimulation|Patients in the sham group will receive electrode attachment but without stimulation.
223877713|NCT04239092|DRUG|9-ING-41|9-ING-41 will be administered by intravenous infusion twice weekly at an initial dose of 9.3 mg/kg. Cycle duration is 21 days.
223877714|NCT04239092|DRUG|Irinotecan|Irinotecan 50 mg/m2/day administered over 90 minutes IV on days 1-5 every 21 days.
223877715|NCT04239092|DRUG|Temozolomide|Temozolomide will be administered at a dose of 100 mg/m2/dose by mouth on Days 1 through 5 of a 21 day cycle.
223877716|NCT04239092|DRUG|Cyclophosphamide|Cyclophosphamide 400 mg/m2/dose administered intravenously over 30 min on Days 1 through 5 of a 21 day cycle.
223877717|NCT04239092|DRUG|Topotecan|Topotecan 1.2 mg/m2/dose administered intravenously over 30 min once on Days 1 through 5 of a 21 day cycle.
223877718|NCT05241041|BEHAVIORAL|group counseling|Group counseling with positive psychology and motivational interviewing was undertaken once per week for 6 weeks.
223877719|NCT05241041|DEVICE|auricular acupressure|Auricular acupressure using acupellets was performed for 6 weeks continuously.
223877720|NCT05241041|DEVICE|placebo acupressure|Placebo acupellets were prepared without metal projections, and placed on both sides in the same areas of the ear as the active condition.
223877721|NCT02942355|DRUG|anastrozole|Anastrozole by mouth daily
223877722|NCT02942355|DRUG|Palbociclib|Palbociclib by mouth daily days 1-21 every 28 days
223877723|NCT02244411|BEHAVIORAL|individual diet & physical activity counselor and website through Healthways at Hopkins|Phone and web-based weight loss intervention (via Healthways at Hopkins counselor and website) focused on increasing physical activity and adhering to a healthy diet. Participants will log diet, physical activity, and weight in web-hub. Counselors will have access to this information to direct participants to goals and achievements.
223877724|NCT02244411|BEHAVIORAL|self directed weight loss|Participants will be given information and links to CDC and American Cancer Society recommendations for healthy eating and physical activity.
223877725|NCT02244411|BEHAVIORAL|questionnaires|Participants will complete behavioral questionnaires as well as diet and physical activity assessments through CCSS-based study website as baseline, 12 and 24 months.
223877726|NCT02244411|OTHER|fasting blood draw, measurement of height, weight and waist circumference, and blood pressure|During three time periods, at baseline and at 12 and 24 months.
223877727|NCT06006611|DRUG|Azvudine|Received antiviral treatment with azvudine
223877728|NCT02709304|DRUG|Lidocaine gel|Gel used for insertion of urinary catheter containing local anesthetic to determine if patients have less discomfort postoperatively when this is used
223877729|NCT02709304|DRUG|standard gel|Standard gel that is used to insert a urinary catheter that does not contain local anesthetic
223877730|NCT01254006|DRUG|forskolin, rutin and vitamins B1 and B2|
223877731|NCT01739907|OTHER|Iron fortified flavoured skimmed milk with or without vitamin D in iron deficient women|
223877732|NCT00963404|RADIATION|Radiation boost|Radiation boost of the bladder-tumor: 10 Gy/5 fractions, 2 Gy per fraction.
223877733|NCT01602640|DRUG|Morphine infusion|Conventional dose
223877734|NCT01602640|DRUG|Fentanyl and Midazolam infusion|Conventional dose
223877735|NCT03268213|BIOLOGICAL|Fecal Microbial Transplantation|"Fecal microbial transplant is offered as treatment option to eligible patients. Donors selected by the patients will be screened by questionnaire and by blood and stool tests for potential transmissible pathogens.~The stool filtrate will be administered in the ileum and/or cecum via colonoscopy"
223877736|NCT00945789|DRUG|Human recombinant erythropoietin|Epo dse is 2500 IU/kg subcutaneous daily for 5 days.
223877737|NCT00945789|PROCEDURE|EEG and Brain MRI|EEG to be done twice in hte first 48 hours and at 2-3 weeks. MRI to be done at 3 weeks of age.
223877738|NCT00945789|BIOLOGICAL|Nitric oxide measurement in the blood|Concentration of nitric oxide is measured in the blood at enrollment. For the 2 groups with asphyxia, measurement to be repeated in 2 weeks.
223877739|NCT03649243|DRUG|Propolis spray|Propolis was added at the site of injury, 3 puff for any wound in the foot of patients. All the patients decide voluntary if they want to receive the propolis spray treatment or only receive they normal wound healing care.
223877740|NCT01020643|DRUG|controlled administration of propofol|comparison of propofol sedation
223877741|NCT03288753|OTHER|Satisfaction questionnaire|Participants have to complete a satisfaction questionnaire on the Neuro 1 or 2 processor.
223877742|NCT03288753|BEHAVIORAL|Speech intelligibility in quiet|The speech material corresponds to the lists of Lafon designed for cochlear implant patients. Each lists contains 17 monosyllabic words. Speech comprehension is evaluated by the percentage of correct words and the percentage of correct phonemes. Speech signals are presented at 65 dB SPL. 2 lists of 17 words are presented. At visit 1, the participants wear the sound processor Neuro 1. At visits 2 and 3, the participants wear the Neuro 2.
223877743|NCT03288753|BEHAVIORAL|Speech intelligibility in noise|The speech material corresponds to the lists of Lafon designed for cochlear implant patients. Each lists contains 17 monosyllabic words. Speech comprehension is evaluated by the percentage of correct words and the percentage of correct phonemes. Speech signals are presented at 65 dB SPL. 2 lists of 17 words are presented. The noise corresponds to a cocktail party presented at +10 dB SNR (Speech on Noise Ratio). At visit 1, the participants wear the sound processor Neuro 1. At visits 2 and 3, the participants wear the Neuro 2.
223877744|NCT03288753|BEHAVIORAL|VRB (Vocale Rapide dans le Bruit)|Speech intelligibility in noise measured with the test VRB (Vocale Rapide dans le Bruit, French version of the Quick Sin). This test measures the SNR (Signal to Noise Ratio) at which the listeners understand half of the words of a sentence correctly. The outcome measure is in dB. 3 lists are presented. Speech signals are presented at 60 dB SPL.
223877745|NCT02849054|DEVICE|Measurement of PTPdi|Insertion of pressure transducer catheter to measure gastic and oesophadgeal pressures for calculation of PTPdi
223877746|NCT02849054|DEVICE|TTV at 4ml/kg|Provision of targetted tidal volume of 4ml/kg
223877747|NCT02849054|DEVICE|TTV at 5ml/kg|Provision of targetted tidal volume of 5ml/kg
223877748|NCT02849054|DEVICE|TTV at 6ml/kg|Provision of targetted tidal volume of 6ml/kg
223877749|NCT01095822|DRUG|Aliskiren + Valsartan|Comparison of combination (aliskiren + valsartan) therapy versus valsartan alone on hemostatic indices
223877750|NCT04751838|OTHER|no intervention|no intervention
223877751|NCT04502901|DRUG|KX0826|investigational AR antagonist
223877752|NCT04502901|OTHER|Placebo|Placebo of KX-826
223877753|NCT01929759|DRUG|Stribild (elvitegravir, cobicistat, emtricitabine and tenofovir)|Switch from Atripla (efavirenz, emtricitabine and tenofovir) to Stribild (elvitegravir, cobicistat, emtricitabine and tenofovir)for total of 8 weeks
223877754|NCT05172323|DEVICE|3DCT-scan|A contrast CT-scan of the coronary arteries will be performed and 3D analyzed to determine the best angle for the C-arm during Percutaneous Coronary Intervention (PCI) for stent implantation. Furthermore determining the amount and localization of calcium in the right coronary artery (RCA) and diameter and length of RCA. The use of IVUS will be used to determine the degree of calcium.
223877755|NCT05172323|OTHER|Angiography guided PCI|Standard of care is angiography guided PCI of the ostium of the RCA. The use of IVUS will be used to determine the degree of calcium.
223877756|NCT01661569|OTHER|Headspace On-the-go app|Participants will be given access to a 45-day programme of mindfulness meditation, created and branded by Headspace. They will be encouraged to listen to one meditation podcast each day, or as frequently as possible over 8 weeks.
223877757|NCT00117026|DRUG|Placebo|Placebo for benfotiamine
223877758|NCT00117026|DRUG|Benfotiamine|300mg/day
223877759|NCT02848794|DRUG|Apatinib and Irinotecan|Patients were administered at apatinib (850mg po qd) and irinotecan(125mg/m2 d1,8) intravenously every three weeks for up to 6 cycles.Maintenance apatinib (500mg po qd) was administered until disease progression or unacceptable toxicity.
223877760|NCT00364117|BEHAVIORAL|Timely Discharge (Remote Presence Technology)|
223877761|NCT00574834|DRUG|Ramipril|Ramipril 20 mg once daily for 6 months
223877762|NCT00574834|DRUG|HCTZ-hydrochlorothiazide|HCTZ 25 mg once daily for 6 months
223877763|NCT00574834|DRUG|Ramipril+HCTZ|Ramipril 20 mg and HCTZ 25 mg, both once daily for 6 months
223877764|NCT02121002|DRUG|Diclofenac Sodium Topical Gel, 1%|Opaque, white gel
223877765|NCT02121002|DRUG|Voltaren Topical Gel, 1%|Opaque, white gel
223877766|NCT02121002|DRUG|Vehicle Diclofenac Sodium Topical Gel|Opaque, white gel
223877767|NCT00017472|BIOLOGICAL|apolizumab|Given IV
223877768|NCT00017472|OTHER|laboratory biomarker analysis|Correlative studies
223877769|NCT00017472|OTHER|pharmacological study|Correlative studies
223877770|NCT03647241|DEVICE|Self-Ligating Brackets|These brackets can be opened and closed through the use of a sliding cap embedded into the design of these brackets. There is no need to use elastic modules to ligate the arch.
223877771|NCT03647241|DEVICE|Traditionally-Ligated Brackets|These brackets are used in the conventional manner, where the orthodontist is obliged to use elastic modules to engage the arch into the slot of the bracket.
223877772|NCT03647241|PROCEDURE|Corticotomy|Corticotomy without flap elevations will be performed in order to induce acceleration in tooth movement during the orthodontic treatment in only one group.
223877773|NCT00937131|DRUG|Rituximab|Concentrate for solution for infusion, Intravenous use, 375mg/m2, Maximum 8 weekly infusions
223877774|NCT04553458|DEVICE|Radiofrequency ablation|Radiofrequency ablation of the tumour
223877775|NCT04553458|DRUG|Trance-arterial chemoembolization|Trance-arterial chemotherapy
223877776|NCT04553458|PROCEDURE|Liver resection|non-anatomical or anatomical liver resection
223877777|NCT04553458|COMBINATION_PRODUCT|Combined radiofrequency ablation + percutaneous ethanol injection|combined therapy
223877778|NCT04553458|DRUG|Percutaneous ethanol injection|Percutaneous ethanol injection of HCC
223877779|NCT04553458|DRUG|Systemic chemotherapy|Systemic chemotherapy
223877780|NCT04553458|DRUG|Sorafenib|Sorafenib
223877781|NCT04553458|DIETARY_SUPPLEMENT|Viscum|Viscum for HCC
223877782|NCT04553458|DRUG|Symptomatic treatment|Symptomatic treatment
223877783|NCT05565508|PROCEDURE|new laparoscopic access technique for group a|new laparoscopic access technique through the epigastric region
223877784|NCT05565508|PROCEDURE|Hasson's technique for laparoscopic access in group b|Hasson's technique for laparoscopic access in group b
223877785|NCT02590432|DRUG|Linaclotide|Linaclotide capsules, orally, once daily.
223877786|NCT04290819|DIETARY_SUPPLEMENT|Creatine Monohydrate|0.1g/kg of body weight (pre measured creatine) and 3mg/kg of body weight (pre measured micronized cellulose powder-caffeine placebo) self administered 1 hr prior to working out mixed in water.
223877787|NCT04290819|DIETARY_SUPPLEMENT|Creatine Monohydrate and Caffeine|0.1g/kg body weight (pre measured creatine) and 3mg/kg body weight (pre measured caffeine) self administered 1hr prior to working out mixed in water.
223877788|NCT04290819|DIETARY_SUPPLEMENT|Caffeine|3mg/kg of body weight (pre measured caffeine) and 0.1g/kg of bodyweight (pre measured maltodextrin- creatine placebo) self administered 1 hr prior to working out mixed in water.
223877789|NCT04290819|DIETARY_SUPPLEMENT|Placebo|0.1g/kg of body weight (pre measured maltodextrin) and 3mg/kg of body weight (pre measured micronized cellulose powder) self administered 1 hr prior to working out mixed in water.
223877790|NCT06107023|BEHAVIORAL|Action observation training|6 weeks, three days a week.
223877791|NCT06107023|BEHAVIORAL|sham action observation training|6 weeks, three days a week.
223877792|NCT01964534|DRUG|ABI-007|ABI-007 : 125 mg/m² IV /30min (day 1, day 8, day 15)
223877793|NCT01964534|DRUG|Gemcitabine|1000 mg/m² IV /30min (day 1, day 8, day 15)
223877794|NCT01964534|DRUG|simplified LV5FU2|Folinic acid: 400 mg/m² IV /2h (day 1, day 15) Bolus 5-FU: 400 mg/m² IV /15min (day 1, day 15) 5-FU infusion: 2400 mg/m² IV /46h (day 1-2, day 15-16)
223877795|NCT02006758|DEVICE|EnligHTN™ Renal Denervation System|The EnligHTN™ Renal Denervation System is designed to deliver radiofrequency (RF) energy to the renal nerves to achieve targeted denervation. The system consists of the EnligHTN™ RF Ablation Generator (generator), the EnligHTN™ Renal Artery Ablation Catheter (ablation catheter), and the EnligHTN™ Guiding Catheter (optional).
223877796|NCT02611609|BIOLOGICAL|MultiStem|
223877797|NCT02611609|BIOLOGICAL|MultiStem|
223877798|NCT02611609|BIOLOGICAL|Placebo|
223877799|NCT05243784|BEHAVIORAL|MOVI-HIIT intervention|"Each HIIT break will last approximately 5 minutes and will not require any specific materials. The structure of the HIIT-Rest will be as follows: 1' to describe the work to be done; 3' of work following the HIIT protocol: 6 repetitions of a functional movement such as squats, Jumping Jack or running on site for 20 at high intensity (85-90% of HR -heart rate- max) followed by 10 of recovery (65-75% of HR max); and 1' to perform a return to calm in order to lower the activation and prepare the student body to return to class activities."
223877800|NCT03405714|DRUG|Brivaracetam|"* Pharmaceutical form: Solution for iv injection~* Route of administration: intravenous use~* Concentration: 10 mg/ml"
223877801|NCT04788641|DRUG|Tacrolimus|Each subject in this cohort will receive a single dose of oral capsules of tacrolimus on 2 occasions, once alone and once in combination with oral suspension of SZC. Drug administrations will occur after a 12 hour overnight fast.
223877802|NCT04788641|DRUG|Cyclosporin|Each subject will receive a single dose of oral capsules of cyclosporin on 2 occasions, once alone and once in combination with oral suspension of SZC. Drug administrations will occur after a 12 hour overnight fast.
223877803|NCT04788641|DRUG|Sodium Zirconium Cyclosilicate|Each subject will receive single oral doses of SZC with tacrolimus (cohort 1) or cyclosporin (cohort 2) under fasted conditions. The doses will be administered after an overnight fast of at least 12 hours.
223877804|NCT04172207|OTHER|Sampling|After periodontal parameters measured, smear samples were obtained from the buccal mucosa and keratinized gingiva, and then a gingival biopsy was performed from the upper premolars.
223877805|NCT01291446|DIETARY_SUPPLEMENT|High flatulogenic diet|During 3-days subjects will consume a diet with high content of fermentable residues
223877806|NCT05459233|PROCEDURE|Doppler-echocardiography|The TAVR (valve-in-valve) procedure will be performed with the SAPIEN 3 Ultra valve, with valve sizing according to current manufacturer recommendations. Following valve implantation, further intervention will be based on Doppler-echocardiographic measurements. Balloon post-dilation with a non-compliant balloon will be performed in the presence of a residual mean gradient ≥20 mmHg as assessed by Doppler-echocardiography.
223877807|NCT05459233|PROCEDURE|Invasive hemodynamic measurements|The TAVR (valve-in-valve) procedure will be performed with the SAPIEN 3 Ultra valve, with valve sizing according to current manufacturer recommendations. Following valve implantation, further interventions will be based on invasive hemodynamic measurements (with simultaneous aortic and ventricular pressure recording). Balloon post-dilation will be performed with a non-compliant balloon in the presence of a mean residual gradient ≥20 mmHg as assessed by hemodynamic measurements.
223877808|NCT02530216|OTHER|AEGIS (Automated Evaluation of Gastrointestinal Symptoms)|"AEGIS (Automated Evaluation of Gastrointestinal Symptoms) guides patients through questionnaires to measure symptom attributes including the timing, severity, frequency, location, quality, and character of their gastrointestinal (GI) symptoms, along with relevant comorbidities, family history, and alarm features. This information is transformed into a history of present illness (HPI) written in language familiar to clinicians. AEGIS also supports both the clinician and patient with an individualized education prescription which guides the patient through a library of multi-media educational materials on GI symptoms, conditions, and treatments. The prescription is created by the portal based on each patient's unique AEGIS fingerprint."
223877809|NCT01250769|DEVICE|Manual Toothbrush|A standard size manual toothbrush to clean visible tooth surfaces
223877810|NCT01250769|DEVICE|Interproximal Cleaning Device|An electronic device that combines water and air to clean between the teeth
223877811|NCT06181695|DRUG|Sufentanil|Administration of intranasal sufentanil
223877812|NCT00335049|DEVICE|progressive addition spectacle lens (bifocal)|Progressive addition lenses (PAL) with a +2.00 D add.
223877813|NCT00335049|DEVICE|Single Vision Lenses (SVLs)|Single vision spectacle lenses.
223877814|NCT00038454|DRUG|Hemolink (hemoglobin raffimer IV solution)|
223877815|NCT01869179|BEHAVIORAL|Community of Voices choir program|Attend weekly choir sessions for 12 months at the Senior Center. All choir sessions will include activities that focus on cognitive, psychosocial, and physical engagement components Choir sessions will last 90 minutes each with a 10 minute break. Take part in 3-4 informal choir concerts.
223877816|NCT01869179|BEHAVIORAL|Wait-list control group|
223877817|NCT01596296|DEVICE|Transcervical foley catheter|16 French foley catheter insertion
223877818|NCT01596296|DRUG|Dinoprostone 10mg|Dinoprostone vaginal insertion
223877819|NCT05960994|OTHER|Intervention period|"During the intervention period, three interventions will be implemented through telemedicine.~1. A daily multidisciplinary round conducted by a physician specialized in intensive care medicine.~2. A intervention package administered by a specialized multidisciplinary team, consisting of nursing, physiotherapy, and clinical pharmacy.~3. A management intervention package will be implemented, with a specific focus on enhancing quality and safety."
223877820|NCT04351828|PROCEDURE|Blood draw once a time|Investigation of intestinal permeability by measuring serum zonulin levels in blood sample
223877821|NCT02740231|DRUG|JTA-004 intra-articular injection|Each patient will undergo a single injection of JTA-004 into the knee joint
223877822|NCT02740231|DEVICE|Reference product intra-articular injection|Each patient will undergo a single injection of Reference product into the knee joint
223877823|NCT02462759|DRUG|Nusinersen|Administered by intrathecal injection.
223877824|NCT02462759|PROCEDURE|Sham Procedure|Small needle prick on the lower back at the location where the IT injection is normally made.
223877825|NCT00243503|DRUG|SU011248/Trastuzumab|SU011248 will be administered orally, starting dose of 37.5 mg daily on a continuous regimen. Trastuzumab will be administered weekly (loading dose 4 mg/kg followed by weekly 2mg/kg) or every 3 weeks (loading dose 8 mg/kg followed by 6mg/kg q3w). Study treatment should continue until progression, withdrawal for other reasons, or for up to 18 months following which patients requiring continued access will be offered SU011248 on a separate protocol.
223877826|NCT01881412|DRUG|fluticasone|During discharge, the study MD/nurse informs the family that the child has been randomized to the inhaled corticosteroid (ICS) group, and will be prescribed fluticasone to help control the asthma. The families preferred pharmacy is determined and a prescription for a fluticasone multi-dose inhaler (MDI) provided. Dosing follows the NHLBI asthma guidelines for low dose ICS in this age group (88 mcg administered twice per day, dispense one inhaler, 3 refills). In addition to standard asthma discharge instructions, the family receives specific instructions for ICS administration, possible side effects of medication use, and distinction between controller and quick-relief rescue medications. Parents are instructed to discuss with their primary care provider the length of ICS use.
223877827|NCT01881412|OTHER|Standard Asthma Discharge Instructions|Study MD or nurse provides asthma discharge instructions using a standardized checklist. The topics covered include 1) description of asthma manifestations related to current visit, 2) signs of respiratory distress family should be looking for, 3) instructions to follow up with the child's primary care provider within one week, 4) provision and review of an asthma action plan, 5) provision of a spacer device to be used with inhalers (if family does not already possess), and 6) smoking cessation advice. (if indicated)
223877828|NCT04267458|OTHER|evaluation of sofuspovir containing DAA regien expected insult on kidney|to use different kidney biomarkers to evaluate acute kidney damage after using sofuspovir containing DAA regimen in treatment of HCV
223877829|NCT04704323|DRUG|CAP-100|CAP-100 (humanized antibody against C-C-chemokine receptor 7 \[CCR\]7)
223877830|NCT03048994|DIETARY_SUPPLEMENT|Glutamine|"* Patients randomised to receive glutamine supplementation will receive IV glutamine (0.5g/kg body weight/day) continuously over 24 hours.~* IV glutamine will be administered for 5 days or less if death ensues prior to 5 days or transferred to another hospital prior to 5 days. IV glutamine will be continued even if the patient is transferred outside the ICU but within the hospital.~* An intravenous saline solution that is identical in volume, color and consistency will be administered to the placebo group with the same dosing regimen and duration."
223877831|NCT03048994|DIETARY_SUPPLEMENT|Placebo|"* Nutritional support will be continued as per managing ICU team discretion.~* Management of severe sepsis will be continued as per managing ICU team discretion.~* Weaning patients from mechanical ventilation will be done as per managing ICU team discretion.~* To minimise differences between centers, active dissemination of practice guidelines for nutritional support, sepsis management and weaning will be carried out."
223877832|NCT05998330|BEHAVIORAL|LiverPAL|The intervention include integrating early palliative care with usual hepatology care to evaluate and treat patients' symptoms, enhance their illness and prognostic understanding, support their coping, and coordinate their serious illness, transitional, and end-of-life care.
223877833|NCT05307536|COMBINATION_PRODUCT|Autologous BMMNCs transplantation and educational intervention|"Biological/ Vaccine: Autologous bone marrow-derived mononuclear cell infusion (BM-MNCs) will be administrated at baseline, and the second infusion will be performed six months after the first administration. For each transplantation, the bone marrow will be harvested through an anterior iliac crest puncture under general anesthesia in the operating theatre. The volume collected depends on the patient's body weight based on our experience from a previous study as follows: 8 ml/kg for patients under 10 kg; \[80 ml + (body weight in kg - 10) x 7 ml\] for patients above 10 kg but no more than 250 ml in total.~Educational intervention: 6 months based on the Early Start Denver Model"
223877834|NCT05307536|COMBINATION_PRODUCT|Educational intervention|Educational intervention: 6 months based on the Early Start Denver Model
223877835|NCT03693937|RADIATION|SRT-100|The SRT-100™ is a simple painless non-invasive in-office procedure that is approved by the U.S. Food and Drug Administration (U.S. FDA) to treat keloids caused by surgery or injury by delivering a precise, calibrated dose of Superficial Radiation Therapy (SRT) that only goes skin deep.
223877836|NCT03821636|PROCEDURE|Standard Roux-en-Y gastric bypass|Standard Roux-en-Y gastric bypass is performed with a 30 ml gastric pouch, a stapled gastrojejunal anastomosis with an alimentary limb of 25 % of total length of the intestine (150 cm), connected to the biliary limb of 10 % of total length of the intestine (60 cm) below the duodeno-jejunal junction with a side-to-side jejuno-jejunal anastomosis and a common limb of 65 % of total length of the intestine (400 cm).
223877837|NCT03821636|PROCEDURE|Long alimentary limb Roux-en-Y gastric bypass|Long alimentary limb Roux-en-Y gastric bypass is performed with a 30 ml gastric pouch, a stapled gastrojejunal anastomosis with an alimentary limb of 45 % of total length of the intestine (280 cm), connected to the biliary limb of 10 % of total length of the intestine (60 cm) below the duodeno-jejunal junction with a side-to-side jejuno-jejunal anastomosis and a common limb of 45 % of total length of the intestine (280 cm
223877838|NCT01000480|DRUG|Pemetrexed|500 milligrams per square meter (mg/m²) intravenous infusion on Day 1 of a 21 day cycle for 2 cycles: with possibility of 2 additional cycles.
223877839|NCT01000480|DRUG|Cisplatin|75 mg/m² intravenous infusion on Day 1 of a 21 day cycle for 2 cycles; with the possibility of 2 additional cycles.
223877840|NCT01000480|RADIATION|Thoracic Radiotherapy|Administered at 2 gray (Gy)/fraction after completion of the pemetrexed and cisplatin infusions on Day 1 of Cycle 3 and will continue daily (5 days per week) until the total delivered dose reaches a therapeutic goal of 66 Gy, over approximately 7 weeks.
223877841|NCT03490045|OTHER|Diaper Incentive|A diaper incentive will be distributed to participants in the Intervention condition at 4-time points, which will coincide with the well-child visits that occur at 2-weeks, 2-months, 4-months, and 6-months. A follow-up assessment will also occur approximately 3 months after the family received their final distribution of diapers.
223877842|NCT03490045|OTHER|Conditional Cash Transfer Condition|Participants in the control condition will receive the cash equivalent value of the diapers distributed to the Experimental Condition for their participation at 4-time points, which will coincide with the well-child visits that occur at 2-weeks, 2-months, 4-months, and 6-months. A follow-up assessment will also occur approximately 3 months after the family received their final conditional cash transfer.
223877843|NCT06510595|OTHER|Active Treatment Arm|"Electrotherapy:~Transcutaneous Electrical Nerve Stimulation (TENS) will be placed across the fracture segments. The setting will be adjusted to 2±0.4 Hz sinusoidal wave, with a pulse width set between 50-200 microseconds, and each session will last between 20-30 minutes.~Active Elbow Flexion Exercise:~Following the electrotherapy session, the child will perform active assisted elbow flexion exercises with the forearm in a neutral position. This exercise will consist of 3 sets of 15 repetitions to enhance the role of the horizontal components of the brachioradialis muscle force."
223877844|NCT06510595|OTHER|Control Treatment Arm|The child will wear a brace as a conservative treatment method.
223877845|NCT05295342|BEHAVIORAL|No Means No intervention Girls' Curriculum|"The No Means No (NMN) Girls' Curriculum is a violence prevention program designed for adolescent girls and young women 10-20 years old. This curriculum has been designed specifically for safer implementation during the COVID-19 pandemic. NMN Girls' programming is deeply rooted in Empowerment Self-Defense, which is a uniquely holistic, survivor-centered, feminist approach to self-protection skills. Youth educators called Instructors deliver the curriculum to young people in schools. This 8-hour intervention is comprised of classes that teach young people mental, verbal and physical self-defense skills that can be used to prevent sexual assault and other forms of gender-based violence."
223877846|NCT05295342|BEHAVIORAL|No Means No intervention Boys' Curriculum|"The No Means No (NMN) Boys' Curriculum is a violence prevention curriculum that has been designed specifically for implementation during the COVID-19 pandemic. Designed for adolescent boys and young men age 10-20. Like the girls program it is delivered by youth educators called Instructors in schools. This 8-hour intervention is comprised of classes that teach young people gender equitable attitudes, skills to defend equality and how to avoid violence as a power paradigm."
223877847|NCT05295342|BEHAVIORAL|Active comparator: Life Orientation|The standard school-based Life Orientation curriculum
223877848|NCT03220100|OTHER|Stepped Palliative Care|Palliative care clinicians will develop a therapeutic relationship with participants and address their symptoms, coping, prognostic awareness and illness understanding, treatment decision-making, and end of life care needs and preferences.
223877849|NCT02561702|OTHER|Placebo|240 mg lactose powder in a size 3 capsule taken by mouth 3 times daily for 5-7 days
223877850|NCT02561702|DRUG|Mexiletine|150 mg Mexiletine taken by mouth in capsule form 3 times daily for 5-7 days
223877851|NCT00962702|DEVICE|LAAx TigerPaw System|Exclusion of Left Atrial Appendage
223877852|NCT02410018|DEVICE|OCL 503 (uterine artery embolization)|Transcatheter embolization of the uterine artery(ies) using an embolic agent.
223877853|NCT06438094|PROCEDURE|Root coverage surgery by means of a coronally advanced flap combined with a connective tissue graft|A root coverage surgery will be performed using Zucchelli et al.'s coronally advanced flap combined with a connective tissue graft from the palate.
223877854|NCT06438094|PROCEDURE|Reconstruction of the CEJ with a composite restoration followed by root coverage surgery by means of a coronally advanced flap combined with a connective tissue graft|Reconstruction of the CEJ with a composite restoration will be performed in B+ and B- defects prior to root coverage surgery. A root coverage surgery will be performed using Zucchelli et al.'s coronally advanced flap combined with a connective tissue graft from the palate.
223877855|NCT00829634|DRUG|l-methamphetamine|5mg of l-methamphetamine per day throughout the 2 week study
223877856|NCT00829634|DRUG|d-methamphetamine|15mg on Study Day 9, 30mg on Study Day 11, 45mg on Study Day 13
223877857|NCT04162457|DIETARY_SUPPLEMENT|Stevia|Participants will be administered one of the study beverages at each one of the 4 imaging sessions.
223877858|NCT04162457|DIETARY_SUPPLEMENT|Glucose|Participants will be administered one of the study beverages at each one of the 4 imaging sessions.
223877859|NCT04162457|DIETARY_SUPPLEMENT|Maltodextrin|Participants will be administered one of the study beverages at each one of the 4 imaging sessions.
223877860|NCT04162457|DIETARY_SUPPLEMENT|Water|Participants will be administered one of the study beverages at each one of the 4 imaging sessions.
223877861|NCT04600752|DRUG|Augmentin (ES)-600|Augmentin ES will be administered as reconstituted oral suspension containing Amoxicillin and Potassium Clavulanate 600 mg/42.9 mg per 5 milliliters.
223877862|NCT05398055|DRUG|Azithromycin + Doxycycline|azithromycin 500 mg orally every 24 hours for three dose plus doxycycline 100 mg orally every 12 hours for 7 days
223877863|NCT05398055|DRUG|Placebo + Doxycycline|doxycycline 100 mg orally every 12 hours for 7 days plus placebo 1 capsule every 24 hours, 3 doses
223877864|NCT00933426|DRUG|Lenalidomide|Lead-In beginning dose of 5 mg capsules by mouth once a day for 21 days in a row, followed by 7 days of rest (Days 22-28) for a 28 day cycle.
223877865|NCT00933426|DRUG|Paclitaxel|50 mg/m\^2 given by vein over 1 hour on Days 1, 8, and 15 of each 28 day cycle.
223877866|NCT03348371|OTHER|Ethanol|The intervention is two different administrationforms of ethanol, orally and i.v.
223877867|NCT01346982|DRUG|Silimarine|darunavir/ritonavir 600/100 mg + silimarine (150 mg every 8 hours)
223877868|NCT02301208|DRUG|Nedaplatin|Nedaplatin combine with IMRT
223877869|NCT02301208|DRUG|Cisplatin|Cisplatin combine with IMRT
223877870|NCT05004558|OTHER|Remote-based Resistance Exercise Training|All participants enrolled in the trial will receive supervised remote-based resistance exercise training. The exercises will be performed with the use of Therabands and will include 8-10 exercises performed for 1 set of 15 repetitions, performed 3 days per week for 24 weeks.
223877871|NCT05742126|DRUG|HSK36273|Multiple continuous IV infusion ascending doses for 5 days
223877872|NCT05742126|DRUG|Placebo|Matching placebo
223877873|NCT05742126|DRUG|Heparin sodium injection|Matching positive control
223877874|NCT06800040|BEHAVIORAL|Memory training|Memory training
223877875|NCT04626180|PROCEDURE|Extubation|Extubation is the removal of an endotracheal tube (ETT), which is the last step in liberating a patient from the mechanical ventilator.
223877876|NCT04626180|PROCEDURE|Manual Hyperinflation|Providing a larger tidal volume than baseline tidal volume to the patient and using a tidal volume which is 50% greater than that delivered by the ventilator
223877877|NCT04374916|DEVICE|Premaquick®|Vaginal secretions are collected prior to any vaginal or endovaginal ultrasound examination to avoid false positives, with the nylon swab provided with the test (placed in the posterior fornix of the vagina for 10 seconds).Then the samples are tested with the Premaquick test. Results are obtained in 10 minutes.
223877878|NCT04374916|DEVICE|PARTOSURE®|An immunochromatographic test wich determines the qualitative in vitro detection of placental alpha microglobulin-1 (PAMG-1) in cervico-vaginal secretions.
223877879|NCT01203995|BEHAVIORAL|Nutrition information|Brief nutrition education with take home reference materials and portion size tools
223877880|NCT01203995|BEHAVIORAL|Nutrition education and exercise training|Twice per week nutrition education and exercise class held either in-clinic or through vide-conference.
223877881|NCT05401513|OTHER|Pilates Group|The individuals of the Pilates group will perform specific exercises of the method, which will involve mobility, stability and muscular resistance. The exercises will progress according to the level of difficulty (basic, intermediate and advanced), load and repetition every three or four weeks.
223877882|NCT06477848|OTHER|Integrated Behavioral Health System with SUD Resources|This is a system-level intervention designed to improve collaboration among personnel from primary care clinics and SUD resources.
223877883|NCT04403789|OTHER|Exercise Time|Employees will be provided with exercise time of 2 hours per week. The 2 hours should be used in two days. The intervention duration is 12 weeks.
223877884|NCT04403789|BEHAVIORAL|Supervised Group Exercise|The intervention group will receive 2-hours of exercise sessions per week under the supervision of a certified trainer in the gym workplace. The intervention duration is 12 weeks.
223877885|NCT04622722|OTHER|Nutren Diabetes|Nutren Diabetes provides energy at 360 kcal per 360 ml
223877886|NCT04622722|OTHER|Isocaloric|Isocaloric diet One carton of soy milk (250 ml) and bologna sandwiches (two slices of bread) with mayonnaise
223877887|NCT02374307|OTHER|Exercise and education|Exercise according to the falls prevention programme. Information on motivation, the effectiveness of falls prevention and the importance of adherence.
223877888|NCT03722316|OTHER|Immersive Nature Video|"An approximately 15-minute digital nature experience using work by filmmaker Louie Schwartzberg-Visual Healing by Moving Art. Time-lapse, high-speed, and macro cinematography are incorporated within each video. Audiovisual content include vivid imagery of a variety of ecosystems and climates accompanied by calming instrumental music.~Both the MCI/Mild dementia arm and the healthy older adult arm will experience this intervention."
223877889|NCT03722316|OTHER|Neutral Video|"This video will include clips from relatively non-arousing educational documentaries. Fifteen minutes of documentary content will be selected from a longer video, ensuring that the content remains as neutral as possible. Video selections were modeled after the work from Eryilmaz, Van De Ville, Schwartz, and Vuilleumier (2011) who identified very brief movie clips (i.e., \<1 minute) that were rated as neutral as opposed to frightful or enjoyable.~Both the MCI/Mild dementia arm and the healthy older adult arm will experience this intervention."
223877890|NCT01188369|DRUG|levosimendan|Intravenous infusion, 0,1ug/kg/min, duration 4 hours prior to operation and until the end of operation.
223877891|NCT01188369|DRUG|placebo drug|Intravenous infusion, colour identical to levosimendan
223877892|NCT00198146|DRUG|Zenapax|
223877893|NCT05293548|BIOLOGICAL|Recombinant COVID-19 Vaccine (CHO cell，NVSI-06-09)|Intramuscular injection of Recombinant COVID-19 Vaccine (CHO cell，NVSI-06-09) in the deltoid muscle of the upper arm
223877894|NCT05293548|BIOLOGICAL|Inactivated COVID-19 vaccine (Vero cells)|Biological/Vaccine: Inactivated COVID-19 vaccine (Vero cells) Intramuscular injection of Inactivated COVID-19 vaccine (Vero cells) in the deltoid muscle of the upper arm
223877895|NCT02934789|PROCEDURE|Hysteroscopic myomectomy with Truclear|Hysteroscopic myomectomy with Truclear done on patients with abnormal uterine bleeding and submucosal fibroid(s).
223877896|NCT02934789|DRUG|Medical therapy|Medical therapy for patients with abnormal uterine bleeding/ heavy menses and submucosal fibroids.
223877897|NCT01571804|DRUG|Placebo|to receive two identical placebo capsules 1 hr before surgery
223877898|NCT01571804|DRUG|pregabalin|one capsule of pregabalin 150 mg and one placebo capsule 1 hr before surgery
223877899|NCT01571804|DRUG|pregabalin|two capsules of pregabalin 150 mg 1 hr before surgery
223877900|NCT04802382|DRUG|Placebo administration|patients will receive the placebo treatment in addition to Standard of Care
223877901|NCT04802382|DIAGNOSTIC_TEST|Confirm SARS-CoV-2 infection|patients will be tested for SARS-CoV-2 on days 1, 14 and 28
223877902|NCT04802382|PROCEDURE|Physical Examination|patients will undergo a physical examination on days 1-14 and day 28
223877903|NCT04802382|PROCEDURE|Vital Signs|patient's vital signs will be measured on days 1-14 and day 28
223877904|NCT04802382|DIAGNOSTIC_TEST|Hematology blood test|patients will provide a blood sample for a hematology blood test on days 1-14 and day 28
223877905|NCT04802382|DIAGNOSTIC_TEST|Biochemistry blood test|patients will provide a blood sample for a biochemistry blood test on days 1-14 and day 28
223877906|NCT04802382|OTHER|NEWS score|patient's NEWS score will be evaluated on days 1-14 and day 28
223877907|NCT04802382|DIAGNOSTIC_TEST|PK test|PK test will be performed on day 1 only (only in Brazil sites)
223877908|NCT04802382|DIAGNOSTIC_TEST|blood test for inflammatory markers|patients will provide a blood sample for an inflammatory markers blood test (IL-6, IL-1β, IL-12, TNF α, IFN-γ) on days 1-7, day 14, and day 28
223877909|NCT04802382|DIAGNOSTIC_TEST|D-dimer test|patients will provide a blood sample for D-dimer blood test on days 1, day 2, day 7, day 14, and day 28
223877910|NCT04802382|OTHER|VAS scale|patient's VAS scale will be evaluated on days 1-14, day 21, and day 28
223877911|NCT04802382|DIAGNOSTIC_TEST|Urine pregnancy test for women of childbearing potential|patients will provide a urine sample for a urine pregnancy test on days 1, and day 28
223877912|NCT04802382|PROCEDURE|ECG|patients will undergo an ECG examination on days 1, and day 28
223877913|NCT04802382|OTHER|COVID-19-Impact on Quality of Life Questionnaire|patients will answer the COVID-19-Impact on Quality of Life Questionnaire on days 1, 7,14,21 and 28
223877914|NCT04802382|DRUG|CimetrA-1|patients will receive the study treatment, CimetrA-1 treatment in addition to Standard of Care
223877915|NCT04802382|DRUG|CimetrA-2|patients will receive the study treatment, CimetrA-2 treatment in addition to Standard of Care
223877916|NCT02922088|DEVICE|DuraGraft|DuraGraft is a one-time intraoperative vascular graft treatment designed to prevent graft disease and failure and reduce the clinical complications associated with graft failure.
223877917|NCT01485406|BIOLOGICAL|Pneumococcal vaccine GSK2830930A|1 dose administered intramuscularly
223877918|NCT01485406|BIOLOGICAL|Synflorix™|1 dose administered intramuscularly
223877919|NCT04438343|OTHER|Impairment-specific and augmented intervention|Balance and lower extremities strength training
223877920|NCT04438343|OTHER|Conventional physical therapy|Trunk and upper extremity training
223877921|NCT01145729|BEHAVIORAL|Biomarker Feedback|Providing providers biomarker feedback on childhood secondhand smoke exposure
223877922|NCT06521944|BIOLOGICAL|RSV Vaccine|RSV Vaccine approved for administration to pregnant individuals between 32 weeks, 0 days and 36 weeks, 6 days of gestation
223877923|NCT06521944|OTHER|Non-exposure to RSV Vaccine|Pregnant individuals who are not exposed to the RSV vaccine
223877924|NCT04810767|OTHER|Questionnaire|Pain experienced assessed by questionnaire described by Nikolajsen et al, 2004
223877925|NCT06647082|DEVICE|Pediatric Knee Exoskeleton|The current knee exoskeleton is designed specifically for use in children. The device can be operated either bilaterally or unilaterally and is capable of providing 10- 17.4 Nm of torque assistance at the knee joint which is \~60% of the average biological joint torque for an American 15 year old child. It is adjustable in height such that the passive hip joint and powered knee joint can be placed at the correct anatomical location for each child. Thigh and calf cuffs are interchangeable to accommodate varying leg sizes. The device is autonomous, allowing a child to move freely and can even be used outdoors. The device can accommodate for varying lower limb alignment presentations, adjusting to accommodate for varying femoral rotations and varum and valgum alignments at the knee. The device can be worn independently of the visual biofeedback video game, but is intended for participants to use in conjunction with the knee exoskeleton.
223877926|NCT06220123|DRUG|SHR-2004|Investigational product arm: SHR-2004
223877927|NCT06220123|DRUG|Enoxaparin Sodium Injection; Rivaroxaban Tablets|Positive control arm: Enoxaparin Sodium Injection + Rivaroxaban Tablets
223877928|NCT00475930|DRUG|2% chlorhexidine gluconate (CHG) impregnated cloths|self applied three times per week
223877929|NCT00475930|DRUG|Comfort Bath cloths (placebo cloths)|self applied three times weekly
223877930|NCT06142786|BEHAVIORAL|Enhancing the individualized upper alpha frequency band and suppressing the lower alpha band.|Real time visual feedback will be given the participants, such that as the higher/lower alpha power increases (relative to the mean value in the pre-training resting state EEG recording) a plane on the screen will move horizontally (the movement is correspondent to the magnitude of upper/lower alpha ratio), and the animation will change based on EEG parameter every 2 seconds. EMG-based feedback is also provided, such that if the children's EMG level is too high the plane will drop (vertical movement). Participants are instructed to 'fly' the plane as far as possible.
223877931|NCT06142786|BEHAVIORAL|Sham neurofeedback|The sham neurofeedback protocol was identical to the verum neurofeedback protocol except that the animation (horizontal plane movement) was based on the EEG results of another participant. EMG-based feedback will still be provided for the sham condition
223877932|NCT01294020|DRUG|Tacrolimus|Oral capsule
223877933|NCT01294020|DRUG|Tacrolimus prolonged release|Oral capsule
223877934|NCT05902312|DEVICE|transcranial magnetic stimulation|Participants will receive either rTMS or dTMS
223877935|NCT06230744|BEHAVIORAL|Lifestyle|All participants will receive diet and exercise goals and coaching.
223877936|NCT06230744|BEHAVIORAL|Lifestyle II|All participants will receive diet and exercise goals and coaching.
223877937|NCT04448366|BEHAVIORAL|Cognitive behavioral therapy|Patients in the CBT group will receive usual care. In addition, they will undergo one pre-surgery and six post-surgery face-to-face sessions of CBT. In the pre-surgery session, management of expectations towards surgery will be addressed. In the six post-surgery sessions, attention will be paid to psycho-education concerning the biological link between endometriosis-related pain and stress, relaxation training, cognitive stress management, and management of anxiety, catastrophizing and hypervigilance. The CBT sessions will be coordinated by a registered psychotherapist who is experienced in CBT and has knowledge about endometriosis. All CBT will be individual sessions.
223877938|NCT05370820|DRUG|Tranexamic acid|Tranexamic Acid 1000 mg administered intravenously via infusion over 10 minutes.
223877939|NCT05370820|DRUG|Tranexamic acid|Tranexamic Acid 1000 mg administered intravenously via push over 2 minutes.
223877940|NCT05370820|DRUG|Tranexamic acid|Tranexamic Acid 1000 mg administered intramuscularly.
223877941|NCT05370820|OTHER|No intervention|Control group with no administration of Tranexamic Acid.
223877942|NCT04531475|DRUG|X842|X842 capsules
223877943|NCT04531475|DRUG|X842 Placebo|X842 placebo-matching capsules
223877944|NCT04531475|DRUG|Lansoprazole|Lansoprazole capsules
223877945|NCT04531475|DRUG|Lansoprazole Placebo|Lansoprazole placebo-matching capsules
223877946|NCT04779216|DRUG|Romosozumab Prefilled Syringe|Romosozumab 210mg Injection monthly for 12 months
223877947|NCT04779216|DRUG|Placebo|Placebo Injection monthly for 12 months
223877948|NCT04779216|DRUG|Alendronate 70Mg Tab|Alendronate 70mg PO weekly starting at 12 months through 24 months.
223877949|NCT06070428|OTHER|PAC provision at hospital discharge|Patients randomized to receive the intervention will receive two PACs fitted with True HEPA filters.
223877950|NCT06070428|OTHER|Control non-intervention; PAC without filter|Patients randomized to the control non-interventional arm will receive two PACs with no filters inserted.
223877951|NCT05593666|DRUG|LXE408|Film-coated tablets
223877952|NCT05593666|OTHER|Placebo|Placebo film-coated tablets
223877953|NCT05593666|DRUG|AmBisome®|Sterile lyophilised powder in a 15 mL sterile clear glass vial
223877954|NCT05797545|DIAGNOSTIC_TEST|Breast MRI for Breast Cancer Detection|Comparison of diagnostic results of abbreviated breast MRI and full protocol MRI for secondary breast cancer surveillance
223877955|NCT03351699|DRUG|MK-4250|MK-4250 tablets for oral administration
223877956|NCT05319353|DRUG|Maribavir|Participants will receive maribavir.
223877957|NCT02616562|DRUG|somapacitan|Administered subcutaneously (s.c., under the skin) once-weekly.
223877958|NCT02616562|DRUG|Norditropin® FlexPro® pen|Administered subcutaneously (s.c., under the skin) once daily.
223877959|NCT02616562|DRUG|NNC0195-0092|Administered subcutaneously (s.c., under the skin) once-weekly.
223877960|NCT05644730|DEVICE|Fusion closed loop glucose control system|The FUSION system will be used to control the subjects glucose to a range of 100-140 mg/dL. Data will be collected for up to 24 hours, or upon early termination of the study session.
223877961|NCT01051635|DRUG|LMP400|Indenoisoquinolines are non-camptothecin inhibitors of topoisomerase 1 with improved characteristics such as better chemical stability, producing stable DNA-top1 cleavage complexes, and exhibiting a preference for unique DNA cleavage sites compared with their camptothecin counterparts.
223877962|NCT01051635|DRUG|LMP776|Indenoisoquinolines are non-camptothecin inhibitors of topoisomerase 1 with improved characteristics such as better chemical stability, producing stable DNA-top1 cleavage complexes, and exhibiting a preference for unique DNA cleavage sites compared with their camptothecin counterparts.
223877963|NCT06406348|DRUG|ALIA-1758|Intravenous or subcutaneous doses
223877964|NCT06406348|OTHER|Placebo|Intravenous or subcutaneous doses
223877965|NCT06117306|DRUG|3,4 Methylenedioxymethamphetamine|1 MDMA session
223877966|NCT06117306|BEHAVIORAL|Prolonged Exposure|12 90-minute PE sessions; initial two sessions both occurring during the first treatment visit, third and fourth sessions occurring during the MDMA session, and the remaining sessions occurring daily or every other day
223877967|NCT05224765|OTHER|Fall prevention class|Participants attend fall prevention discharge class per hospital protocols
223877968|NCT06549192|OTHER|20 meter shuttle run test|20 Meter Shuttle Run Test: Subjects run distance of 20 meters round trip. Running speed is monitored at certain intervals with help of a tape recorder that gives a signal. Subjects start running when they hear first beep and must reach other line(one foot must cross the line) by second beep. When they hear second signal, they return to starting line. The speed, which is slow at beginning, gradually increases every 10 seconds. The subject adjusts his/her pace so that he/she is on the other line at the second signal. If subject misses one signal and catches second signal, test continues. If subject misses two signals in row and doesn't reach line at other signal, test is terminated. At end of test, aerobic power values are calculated from VO2max estimation table in ml/kg/min according to number of sit-ups run. At end of test, marks obtained by athlete are calculated and VO2max value of subject is calculated in ml/kg/min from evaluation table.
223877969|NCT05430334|COMBINATION_PRODUCT|e-liquid 1|30/70 PG/VG ratio with nicotine concentration 4mg/ml protonated
223877970|NCT05430334|COMBINATION_PRODUCT|e-liquid 2|30/70 PG/VG ratio with nicotine concentration 10mg/ml protonated
223877971|NCT05430334|COMBINATION_PRODUCT|e-liquid 3|30/70 PG/VG ratio with nicotine concentration 4mg/ml free base
223877972|NCT05430334|COMBINATION_PRODUCT|e-liquid 4|30/70 PG/VG ratio with nicotine concentration 10mg/ml freebase
223877973|NCT05430334|COMBINATION_PRODUCT|e-liquid 5|30/70 PG/VG ratio with nicotine concentration 0mg/ml (placebo)
223877974|NCT05430334|COMBINATION_PRODUCT|e-liquid 6|30/70 PG/VG ratio with nicotine concentration 0mg/ml
223877975|NCT05430334|COMBINATION_PRODUCT|e-liquid 7 and e-liquid 8|e-liquid 7: 30/70 PG/VG ratio with nicotine concentration 4mg/ml protonated e-liquid 8: 30/70 PG/VG ratio with nicotine concentration 8mg/ml protonated
223877976|NCT05430334|COMBINATION_PRODUCT|e-liquid 9 and e-liquid 10|e-liquid 9: 30/70 PG/VG ratio with nicotine concentration 4mg/ml protonated e-liquid 10: 70/30 PG/VG ratio with nicotine concentration 4mg/ml protonated
223877977|NCT04093986|OTHER|Chart Review|Medical records or data available from previous clinical care prior to June 20, 2019 about pregnancy and breastfeeding outcomes, both for babies with hydroxyurea exposure and other babies by these same women.
223877978|NCT04093986|OTHER|Survey|Women who choose to participate directly and provide information in survey format will receive a brief survey and the option to upload their medical records (if available) into Cincinnati Children's maintained REDCap database.
223877979|NCT03348150|PROCEDURE|Cytoreductive surgery + Gastrecomy|Complete cytoreduction followed by a (sub)total gastric resection with D2 lymphadenectomy.
223877980|NCT03348150|DRUG|Hyperthermic Intraperitoneal Chemotherapy (HIPEC)|HIPEC: perfusion with oxaliplatin (460mg/m2 ) (42 °C) followed by docetaxel (50mg/m2 ) (37°C)
223877981|NCT04895748|DRUG|DFF332|Hif2alpha inhibitor
223877982|NCT04895748|DRUG|RAD001|mTOR inhibitor
223877983|NCT04895748|DRUG|PDR001|anti-PD-1
223877984|NCT04895748|DRUG|NIR178|Adenosine A2A antagonist receptor
223877985|NCT01626612|PROCEDURE|continuation of the empirical antimicrobial therapy|ALL THE ANTIBACTERIAL IN WORN SYSTEMATIC
223877986|NCT01626612|PROCEDURE|streamlining of the empirical antimicrobial therapy|ALL THE ANTIBACTERIAL IN WORN SYSTEMATIC
223877987|NCT01542593|DEVICE|Ureteral catheterization - Cook Urological Inc. open end ureteral catheter 5FR|"During a planned procedure involving ureteroscopy or ureteral stenting, after retrograde pyelography and insertion of a safety wire, ureteral catheterization will be performed using Cook Urological Inc. open end ureteral catheter 5FR for the purpose of measuring exact ureteral length.~Measurement results will be compared to measurements performed on CT scan (obtained before surgery)."
223877988|NCT03366870|BEHAVIORAL|Computerized Cognitive Behavioral Therapy for Insomnia|A computerized insomnia intervention that employs the same behavioral, educational, and cognitive treatment components that underlie non-computerized CBT-I.
223877989|NCT03366870|BEHAVIORAL|Sleep Education|A web-based program will deliver components of sleep education via an Internet platform.
223877990|NCT06530056|OTHER|Costovertebral Mobilization+Conventional Therapy|"Patient would receive costovertebral mobilization in side lying position for left 10th to 6th, in sitting position for right 10th to 2nd rib and in supine lying position for 1st rib.~Conventional Therapy:~Hot pack 10 mints, Posture corrective exercises, Breathing exercises Frequency; 4 times/week for 3 weeks"
223877991|NCT06530056|OTHER|Conventional Therapy|"Electrotherapy:~• Hot Pack 10 minutes~Posture Corrective Exercises:~* Thoracic Rotation 10 rep/session~* Thoracic extension 10 rep/session~* Scapular retraction 5 rep/session~* Deep neck flexor Isometric 5 rep/session~Deep Breathing Exercises:~• Pursed lip breathing 10 repetition in one session"
223877992|NCT05499351|BIOLOGICAL|Adult group in immunogenicity and safety study of combined immunization|The COVID-19 vaccine was manufactured by Sinovac Research \& Development Co., Ltd,and the quadrivalent influenza vaccine and the 23-valent pneumococcal polysaccharide vaccine(PPV23) were manufactured by Sinovac Biotech Co.The COVID-19 vaccine:600SU inactivated virus in 0.5 mL of aluminium hydroxide solution per injection;The quadrivalent influenza vaccine:15ug hemagglutinin (HA) of each of the four influenza strains in 0.5 mL of sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate per injection;PPV23:capsular polysaccharides of 23 serotypes of pneumococcus in 0.5 mL of Sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate per injection.
223877993|NCT05499351|BIOLOGICAL|Elderly group in immunogenicity and safety study of combined immunization|The COVID-19 vaccine was manufactured by Sinovac Research \& Development Co., Ltd,and the quadrivalent influenza vaccine and the 23-valent pneumococcal polysaccharide vaccine(PPV23) were manufactured by Sinovac Biotech Co.The COVID-19 vaccine:600SU inactivated virus in 0.5 mL of aluminium hydroxide solution per injection;The quadrivalent influenza vaccine:15ug hemagglutinin (HA) of each of the four influenza strains in 0.5 mL of sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate per injection;PPV23:capsular polysaccharides of 23 serotypes of pneumococcus in 0.5 mL of Sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate per injection.
223877994|NCT05499351|BIOLOGICAL|Adult group in safety observation study of combined immunization|The COVID-19 vaccine was manufactured by Sinovac Research \& Development Co., Ltd,and the quadrivalent influenza vaccine and the 23-valent pneumococcal polysaccharide vaccine(PPV23) were manufactured by Sinovac Biotech Co.The COVID-19 vaccine:600SU inactivated virus in 0.5 mL of aluminium hydroxide solution per injection;The quadrivalent influenza vaccine:15ug hemagglutinin (HA) of each of the four influenza strains in 0.5 mL of sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate per injection;PPV23:capsular polysaccharides of 23 serotypes of pneumococcus in 0.5 mL of Sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate per injection.
223877995|NCT05499351|BIOLOGICAL|Elderly group in safety observation study of combined immunization|The COVID-19 vaccine was manufactured by Sinovac Research \& Development Co., Ltd,and the quadrivalent influenza vaccine and the 23-valent pneumococcal polysaccharide vaccine(PPV23) were manufactured by Sinovac Biotech Co.The COVID-19 vaccine:600SU inactivated virus in 0.5 mL of aluminium hydroxide solution per injection;The quadrivalent influenza vaccine:15ug hemagglutinin (HA) of each of the four influenza strains in 0.5 mL of sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate per injection;PPV23:capsular polysaccharides of 23 serotypes of pneumococcus in 0.5 mL of Sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate per injection.
223877996|NCT01922830|DIETARY_SUPPLEMENT|Bio-25 (Supherb)|The Bio-25 (Supherb) is a probiotic supplement consisting of 11 different species of patented probiotic bacteria and over 25 billion active bacteria in each capsule. The bacteria in the formula are patented bacteria that have undergone drying, freezing, and double coating which ensures their survival under stomach acidity conditions and their enrooting in the intestines.
223877997|NCT01922830|DIETARY_SUPPLEMENT|Placebo (for Bio-25, Supherb)|A pill manufactured to mimic Bio-25 (Supherb) pill
223877998|NCT05758597|DRUG|Remazolam besylate|Remazolam benzoate group was given 0.1-1mg/kg/h, and the target RASS score was maintained.
223877999|NCT05758597|DRUG|midazolam|Meanwhile the midazolam group was given 0.05-0.2 mg/kg/h midazolam, and the target RASS score was maintained.
223878000|NCT02847780|DEVICE|Active Comparator :C-Mac Videolaryngoscope|Real time assessment of Glottic aperture at the time of extubation by videolaryngoscope
223878001|NCT02847780|DEVICE|Experimental: Airway ultrasound,|Airway ultrasound using portable ultrasound machine to assess vocal cords movement.
223878002|NCT06417346|PROCEDURE|Laparoscopic TEP Repair|Laparoscopic TEP Repair performed
223878003|NCT06417346|PROCEDURE|Open Technique (Lichtenstein)|Open Technique (Lichtenstein) performed
223878004|NCT02962141|DEVICE|Paclitaxel Releasing Peripheral Balloon Dilatation Catheter|Treatment group
223878005|NCT02962141|DEVICE|Balloon Dilatation Catheter|Control group
223878006|NCT00001017|DRUG|Fluconazole|
223878007|NCT00001017|DRUG|Amphotericin B|
223878008|NCT02415140|OTHER|Rate of depression|
223878009|NCT00151424|DRUG|asenapine|Asenapine 5-10mgBID
223878010|NCT00151424|DRUG|Placebo|Matched against asenapine and olanzapine
223878011|NCT00151424|DRUG|Olanzapine|10-20 mg QD
223878012|NCT04165967|DRUG|Combination of TIL Transfer with anti-PD-1 Therapy and low dose IL-2|"The study uses a personalized IMP, i.e. TIL product and in combination with IL-2 treatment and nivolumab.~Day 0: Autologous TIL: (minimum 5 x 109 and up to a maximum of 2 x 1011 lymphocytes) administered intravenously over 20 to 30 minutes.~Day 0: Interleukin-2 (Proleukin): 125.000 IU/kg/day s.c. for maximum 12 days as inpatients with a 2 days break after the first 4-5 doses (maximum 10 days dosing). Actual body weight will be used in calculating the dose of interleukin-2.~Starting Day 14: Nivolumab application 240 mg i.v. over 30 minutes ever 2 weeks with a maximum to 2 years, or until disease progression or inacceptable toxicity."
223878013|NCT02633267|BEHAVIORAL|Vocational Services as usual plus Cognitive Behavioral Therapy (CBT)|Teaches thought restructuring and exposure therapy to socially anxious job seekers delivered by vocational service professionals
223878014|NCT02633267|BEHAVIORAL|Usual Vocational Services|Vocational services delivered by vocational professionals at vocational service center (e.g., resume assistance, job leads)
223878015|NCT04244318|BEHAVIORAL|Video-feedback ODISEA 3.0|Video-feedback intervention ODISEA 3.0 (Gómez \& Maureira, 2022), which incorporates an attachment theory framework. This intervention was constructed within the ODISEA's comprehensive and formative model of parenthood which was developed in Chile by Dr. Esteban Gómez Muzzio (Gómez, 2022).
223878016|NCT04244318|BEHAVIORAL|ODISEA-DTP: parental therapy|Parental Therapy (ODISEA-DTP, Gómez \& Maureira, 2022): is a parental therapy strategy that works over 5 sessions with the history of caregivers in a systematic way, allowing to explore their past, present and expected future concerning parenting, child rearing, attachment and child abuse, between other issues. The DTP is a protocolized model of parental therapy, each session is carefully designed to elicit memories, emotions and to stimulate reflective function (about the past and their own childhood) and parental reflective function (about the present with the child).
223878017|NCT04244318|BEHAVIORAL|Treatment as usual|"Psychosocial intervention (parental education, family counseling, home visits and school and Court coordination) for child abuse and neglect, implemented by six Family Therapeutic Programs (AFT) of the NGO Protectora de la Infancia"
223878018|NCT05628792|DIAGNOSTIC_TEST|CT|Ultra High Resolution CT scan
223878019|NCT05429307|OTHER|Population|Turkish Validity and Reliability of The Exercise Sensitivity Questionnair Scale to Turkish society and to make its validity and reliability in Turkish.
223878020|NCT01157663|OTHER|Adapted balance training|during 8 weeks
223878021|NCT01157663|OTHER|Balance Training|Balance training with unipedal standing during 8 weeks
223878022|NCT01827917|BIOLOGICAL|rabies vaccine|Injection on day 0、7、21
223878023|NCT00224510|DRUG|lamotrigine|
223878024|NCT00479700|DRUG|SAM-531|
223878025|NCT03206515|DEVICE|18F Peel-Way Sheath|Patients undergoing Mini Percutaneous Nephrolithotomy with The 18F peel-way sheath
223878026|NCT03206515|DEVICE|18F access sheath with a suction-evacuation function|Patients undergoing Mini Percutaneous Nephrolithotomy with The 18F access sheath with a suction-evacuation function
223878027|NCT05967065|DIAGNOSTIC_TEST|vibration induced nystagmus test|Vibration induced nystagmus test by bone transducer B250.
223878028|NCT01655888|DRUG|Tremelimumab|Tremelimumab is administered as endovenous infusion
223878029|NCT03086161|BEHAVIORAL|Interpersonal Psychotherapy|Six individual 1-hour sessions delivered over the course of pregnancy to address interpersonal problems areas that may lead to emotional eating, physical inactivity, and increased stress during pregnancy, which are drivers of excess weight gain in pregnancy
223878030|NCT03086161|BEHAVIORAL|Treatment-as-usual|Routine prenatal care as part of multidisciplinary adolescent pregnancy clinic, including medical (ob/gyn), nutrition, and social work
223878031|NCT05718089|OTHER|Continuous aerobic exercise|"The Continuous aerobic exercise session will be performed in total two times, as it will be repeated in sets on consecutive weeks (e.g. Two Tuesdays in a row) with a 1-week wash-out period. The  Continuous aerobic exercise intervention is matched to the other arms on the time spend for each bout equating a total of 50 minutes of exercise per session.~An oral glucose tolerance test will be performed 24 hours and 48 hours after the exercise bout."
223878032|NCT05718089|OTHER|High intensity interval training|"The High intensity interval training session will be performed in total two times, as it will be repeated in sets on consecutive weeks (e.g. Two Tuesdays in a row) with a 1-week wash-out period. The High intensity interval training intervention is matched to the other arms on the time spend for each bout equating a total of 50 minutes of exercise per session.~An oral glucose tolerance test will be performed 24 hours and 48 hours after the exercise bout."
223878033|NCT05718089|OTHER|Resistance training|"The Resistance training session will be performed in total two times, as it will be repeated in sets on consecutive weeks (e.g. Two Tuesdays in a row) with a 1-week wash-out period. The Resistance training intervention is matched to the other arms on the time spend for each bout equating a total of 50 minutes of exercise per session.~An oral glucose tolerance test will be performed 24 hours and 48 hours after the exercise bout."
223878034|NCT02570022|DRUG|Liposomal bupivacaine|Local infiltration of liposomal bupivacaine
223878035|NCT02570022|PROCEDURE|Inter-scalene nerve block|Pre-operative inter-scalene nerve block
223878036|NCT02570022|DRUG|Ropivacaine|Ropivicaine was used for the inter-scalene nerve block.
223878037|NCT00041938|DRUG|aspirin|325 mg per day
223878038|NCT00041938|DRUG|Warfarin|INR 2.5-3.0; target INR 2.75
223878039|NCT00496743|DEVICE|Low-dose total skin electron beam therapy (4 Gy)|
223878040|NCT05127681|RADIATION|HR-pQCT|Patients will have a unique HR-pQCT scanner imaging to study their bone microarchitecture
223878041|NCT05127681|BIOLOGICAL|Blood sample|Patients will have a unique blood sampling of 10 mL for the measurements of sera PINP, CTX-I, periostin levels
223878042|NCT05127681|RADIATION|Dual energy X-ray absorptiometry|A dual energy X-ray absorptiometry scan of lumbar spine, hip, distal radius and whole body, body composition, lateral spine will be performed.
223878043|NCT05127681|OTHER|medical data collection|Data of healthy men is already available
223878044|NCT01747486|BIOLOGICAL|CART-19|CART-19 cells (autologous T cells expressing CD19 chimeric antigen receptors expressing tandem TCR zeta and 4-1BB costimulatory domains)
223878045|NCT01771731|DRUG|Cannabis|
223878046|NCT00220519|DRUG|Lactobacillus GG|
223878047|NCT00010725|DRUG|MAK|
223878048|NCT00010725|DRUG|Vitamin Supplements|
223878049|NCT03251222|DRUG|Dexmedetomidine|Intranasal aplication of dexmedetomidine
223878050|NCT03251222|OTHER|Placebo - Concentrate|Intranasal aplication of 0.9% NaCl
223878051|NCT00087139|DRUG|ixabepilone|Given IV
223878052|NCT05821569|OTHER|Standard approach|Adoption of standard approach (derived by Unicef guidelines) to breastfeed
223878053|NCT05821569|OTHER|Biological nurturing|Adoption of biological nurturing approach to breastfeed
223878054|NCT00033098|DRUG|Metyrapone|
223878055|NCT01879189|BEHAVIORAL|Breast Cancer Screening Decision Aid|The intervention will include access to the personal decision aid tool for patients in the intervention arm of the study, determined by the randomized physician schedule and the patient's appointment time.
223878056|NCT05952258|DEVICE|Magnetic stimulation|The magnetic stimulation to the pelvic floor muscle will be provided by the Emsella® chair: which will be activated for 28 minutes at each treatment session. The treatment arm will receive up to 100% intensity at each treatment session.
223878057|NCT05952258|DEVICE|Sham Magnetic stimulation|The sham arm will receive up to 5% intensity at each treatment session
223878058|NCT04865939|PROCEDURE|sterile water irrigation|Continuous irrigation of bladder with sterile water during surgery (prior to entry into bladder).
223878059|NCT04865939|DRUG|Gemcitabine|Intravesical gemcitabine instilled into bladder during surgery (drained prior to entry into bladder).
223878060|NCT05434962|DEVICE|Cardiac resynchronization therapy|"Standard BiV-CRT The CRT-P/CRT-D device and leads should be implanted according to the physician's manual provided with the devices. Only locally approved Medtronic CRT-P/CRT-D generators will be used during the study. The LV lead should be implanted at a lateral or posterolateral CS branch in a basal or mid ventricular position confirmed by ortogonal fluoroscopic views (RAO and LAO 40º). Acceptable LV pacing threshold should be \<3V@0,5ms and phrenic nerve stimulation (PNS) margin should be \>1V with respect to the pacing threshold.~LBBAP-CRT The CRT-P/CRT-D device and leads should be implanted according to the physician's standard practice. Only locally approved Medtronic CRT-P/CRT-D generators will be used during the study. During the implant procedure lead impedances, pacing and sensing parameters will be measured using a pacing system analyzer (PSA). For LBBAP, the Medtronic 3830 lead will be used. Acceptable LBBAP threshold should be \<2,5V@0,5ms"
223878061|NCT00629850|DEVICE|Powerlung Performer|Inspiratory/Expiratory muscle trainer
223878062|NCT00001277|DRUG|68Ga-Dotatate|68Ga-Dotatate PET/CT will be administered prior to a PET/CT scan to detect known and occult primary and metastatic bronchial, gastrointestinal and pancreatic neuroendocrine tumors.
223878063|NCT00001277|DRUG|18F-DOPA|18F-DOPA PET/CT will be administered prior to a whole-body scan to detect known and occult primary and metastatic bronchial, gastrointestinal and pancreatic neuroendocrine tumors.
223878064|NCT00065260|DRUG|Campath-1H|Campath-1H IV 10 days. Adults:10mg/day (children:0.2mg/kg/day).
223878065|NCT00065260|DRUG|r-ATG|Rabbit ATG 3.5mg/kg/day for consecutive 5 days
223878066|NCT00065260|DRUG|CsA|CsA 10mg/kg/day orally twice daily for 6 months (15mg/kg/day for children under 12 yrs.
223878067|NCT01411592|OTHER|Multilink|After air-abrasion of the retainer wings (50 µm alumina particles at 0.25 MPa) and etching the enamel with 36% phosphoric acid for 30 sec, the RBFDPs were inserted using an adhesive bonding system with a phosphonic acid acrylate primer for the zirconia ceramic (Multilink-Automix bonding system with Metal/Zirconia primer)
223878068|NCT01411592|OTHER|Panavia 21 TC|After air-abrasion of the retainer wings (50 µm alumina particles at 0.25 MPa) and etching the enamel with 36% phosphoric acid for 30 sec, the RBFDPs were inserted using a phosphate monomer containing resin (Panavia 21 TC) without any primer
223878069|NCT04865146|DEVICE|TRIGEN™ INTERTAN™|Femoral fracture treated with INTERTAN 10S Nail
223878070|NCT01519037|DRUG|Cinacalcet 60 MG|one dose of oral cinacalcet, 60mg
223878071|NCT01519037|DRUG|Placebo oral tablet|one tablet of placebo
223878072|NCT06412770|BEHAVIORAL|Tai chi|Participants will be asked to do Tai Chi for 30 minutes three times a week
223878073|NCT06412770|BEHAVIORAL|Tai Chi imagery|Participants will be asked to do Tai Chi imagery for 30 minutes three times a week
223878074|NCT06412770|OTHER|no-intervention|The comparison group will be given usual care
223878075|NCT03101371|DRUG|Catheter insertion with Povidone Iodine|The catheter will be treated with Povidone Iodine prior to insertion.
223878076|NCT03101371|PROCEDURE|Standard of care catheter insertion|Catheter inserted right out of package.
223878077|NCT00110929|DRUG|AMG 073|
223878078|NCT02545738|DRUG|Liraglutide|active treatment
223878079|NCT02545738|DRUG|placebo|placebo
223878080|NCT04005287|DRUG|WST-057 (4% pirenzepine) Lose Dose 2mL|Topical Solution
223878081|NCT04005287|DRUG|WST-057 (4% pirenzepine) High Dose 4mL|Topical Solution
223878082|NCT04005287|DRUG|Placebo Low Dose|Topical Solution
223878083|NCT04005287|DRUG|Placebo High Dose|Topical Solution
223878084|NCT03498196|DRUG|Avelumab|avelumab 10 mg/kg intravenously every 2 weeks for 3 cycles or 42 days.
223878085|NCT04187599|DEVICE|Paragon CRT®100 Contact Lens|Paragon CRT® 100 Contact Lenses for Corneal Refractive Therapy are indicated for use in the reduction of myopic refractive error in nondiseased eyes.
223878086|NCT01989741|OTHER|Sleep restriction|4 hours sleep by night during one week
223878087|NCT03063866|DRUG|Propofol|Propofol 1 mg/kg i.v
223878088|NCT03063866|DRUG|Midazolam|Midazolam 3 mg i.v
223878089|NCT03063866|DRUG|Fentanyl|fentanyl 0.5 ug/kg
223878090|NCT02247817|DEVICE|Hybrid CRT-D/P implantation|
223878091|NCT00996749|DIETARY_SUPPLEMENT|omega-3 fatty acid|Given PO
223878092|NCT00996749|OTHER|bone scan|Correlative studies
223878093|NCT00996749|OTHER|dual x-ray absorptometry|Correlative studies
223878094|NCT00996749|OTHER|laboratory biomarker analysis|Correlative studies
223878095|NCT00996749|PROCEDURE|biopsy|Correlative studies
223878096|NCT04019444|BIOLOGICAL|ChAd155-RG|The ChAd155-RG Vaccine consists of a replication-defective group C ChAd, ChAd155, expressing RG under the control of the CMV promoter. The RG sequence cloned into the ChAd155 vector is a medoid, a natural viral strain with the highest average percent of amino acid identity among all RG sequences annotated in the NCBI database. The selected RG (NCBI strain AGN94271) shares an average 94% percent identity to the RGs in current vaccines.
223878097|NCT04019444|OTHER|Placebo|0.9% Sodium Chloride, USP injection.
223878098|NCT04019444|BIOLOGICAL|Rabies Vaccine|The RABAVERT Vaccine is an inactivated, purified chick embryo cell vaccine (PCECV). It consists of lyophilized rabies virus (strain Flury LEP) that has been propagated in chicken fibroblasts, inactivated with beta-propiolactone, and concentrated and purified by centrifugation
223878099|NCT05239182|DRUG|9-ING-41|9-ING-41 is a small molecule potent selective GSK-3β inhibitor
223878100|NCT05239182|DRUG|Retifanlimab|Humanized, hinge-stabilized, IgG4κ monoclonal antibody that recognizes human PD-1.
223878101|NCT05239182|DRUG|Gemcitabine|cytotoxic chemotherapy agent
223878102|NCT05239182|DRUG|Abraxane|cytotoxic chemotherapy agent
223878103|NCT00903162|DRUG|leuprolide|Given intramuscularly beginning on day 1 and then either 7.5 mg every month or 22.5 mg every 3 months for two years
223878104|NCT00903162|DRUG|letrozole|Taken orally once a day 6-8 weeks after initial leuprolide administration
223878105|NCT00903162|DRUG|zoledronic acid|If desired, given intravenously every 6 months for a total of 4 injections (optional)
223878106|NCT00047528|DRUG|Alcon Investigational Agent|
223878107|NCT00997490|DRUG|Neurapas® balance (Herbal combination out of hypericum, valerian, passionflower)|3 x 2 tablets/day over 6 weeks
223878108|NCT00997490|DRUG|film-coated sugar-pill|3 x 2 tablets / day over 6 weeks
223878109|NCT03776500|DRUG|PBTZ169|PBTZ169 crystalline supplied as powder for oral solution
223878110|NCT03776500|DRUG|Placebo|matching placebo supplied as powder for oral solution
223878111|NCT01865474|DRUG|DLBS1033|1 DLBS1033 tablet 490 mg thrice daily for 2 months
223878112|NCT01865474|DRUG|placebo tablet of DLBS1033|1 placebo tablet of DLBS1033 thrice daily for 2 months
223878113|NCT05161585|DIAGNOSTIC_TEST|ctDNA dynamic monitoring|ctDNA is detected before operation, before chemotherapy, and then every three months for 2 years, 10 times in total.
223878114|NCT05477316|RADIATION|Radiation treatment|Radiation treatment of IMRT to the cerebellum and SRS to the cerebrum
223878115|NCT02960204|DRUG|Emricasan|
223878116|NCT02960204|DRUG|Placebo|
223878117|NCT02134106|DRUG|Polymyxin B|Intravenous polymyxin B will be started on a standard dose of 25,000U/kg body weight, in 2 divided doses each day, infused over 2 hours. The duration of intravenous antibiotic treatment for subjects with either bacteremia or VAP or HAP will be at least 10 days. The duration of intravenous polymyxin B can be prolonged based on clinical indication, e.g., deep-seated source of infection, etc. For patients with VAP, nebulized colistin at the dose of 2 MU 8 hourly for 5 days will be prescribed.
223878118|NCT02134106|DRUG|Polymyxin B + Doripenem|Standard dose of intravenous polymyxin B at 25,000U/kg body weight will be given in 2 divided doses each day with each dose infused over 2 hours and intravenous doripenem 500mg, with each dose infused over 4 hours. For patients with VAP, nebulized colistin at the dose of 2 MU 8 hourly for 5 days will be prescribed.
223878119|NCT00475241|BEHAVIORAL|Prolonged Exposure therapy for PTSD|exposure-based treatment for PTSD
223878120|NCT00475241|BEHAVIORAL|Present centered therapy for PTSD|present focused coping and problem solving for PTSD
223878121|NCT02044809|DRUG|Cannabidiol|
223878122|NCT02044809|DRUG|Placebo|
223878123|NCT03933800|DEVICE|High flow nasal cannula|High flow nasal cannula therapy
223878124|NCT03933800|DEVICE|Continuous positive airway pressure|Continuous positive airway pressure therapy
223878125|NCT06374004|OTHER|Exercise Group|The exercises will be given as a home program and each exercise will be performed 2 times a day for a total of 12 weeks. Participants will perform the exercises 1 day a week under the supervision of a physiotherapist. The exercise program lasts approximately 30 minutes.
223878126|NCT06374004|OTHER|Thoracic Mobilization Group|The exercises will be given as a home program and each exercise will be performed 2 times a day for a total of 12 weeks. Participants will perform the exercises 1 day a week under the supervision of a physiotherapist. The exercise program lasts approximately 30 minutes. Thoracic mobilization will be applied to segments where passive accessory movement is insufficient or painful. 30 repetitions/4 sets will be applied to each determined segment. Thoracic mobilization will be performed with the patient lying prone position.
223878127|NCT05663502|PROCEDURE|Biospecimen Collection|Undergo blood and/or tumor tissue sample collection
223878128|NCT06488781|DRUG|Azithromycin|Azithromycin 500 milligrams intravenously once and cefazolin 2 grams intravenously every 8 hours for up to three doses
223878129|NCT06488781|DRUG|Placebo|Placebo given in place of other two active drugs
223878130|NCT01154439|DRUG|cytarabine|Remission induction therapy: by short i.v. infusion on days 1 and 7. Consolidation therapy: by continuous infusion on days 1-5.
223878131|NCT01154439|DRUG|etoposide|Remission induction therapy: by short i.v. infusion, on days 1-7. Consolidation therapy: by short i.v. infusion, on days 1-5.
223878132|NCT01154439|DRUG|everolimus|"Remission induction therapy: test dose once a day by mouth, on days 1-21 (21 days).~Consolidation therapy: dose as defined by the cohort once a day by mouth, on days 1-10."
223878133|NCT01154439|DRUG|idarubicin|Consolidation therapy: by short infusion i.c. on days 1, 3 and 5.
223878134|NCT01154439|DRUG|mitoxantrone hydrochloride|Remission induction therapy: by short i.v. infusion on days 1, 3 and 5
223878135|NCT05115058|OTHER|relex Smile module|
223878136|NCT00173524|BEHAVIORAL|PharmacoEconomic Assessment|Collecting PE data.
223878137|NCT03087708|DRUG|Naloxegol|Given PO
223878138|NCT03087708|OTHER|Placebo|Given PO
223878139|NCT03087708|OTHER|Laboratory Biomarker Analysis|Correlative studies
223878140|NCT03087708|OTHER|Quality-of-Life Assessment|Ancillary studies
223878141|NCT06978166|OTHER|Just-In-Time Adaptive Interventions (JITAIs)|JITAIs are digital interventions that aim to deliver support to a user when the person is most in need and receptive to the intervention. In this study, multiple JITAIs will be tested and refined through completion of an iterative series of randomized trials that are interspersed with qualitative participant interviews. The purpose of each JITAI under investigation is to improve engagement with the Wysa for Chronic Pain app.
223878142|NCT06978166|BEHAVIORAL|Wysa for Chronic Pain|Wysa for Chronic Pain is an app-based digital mental health intervention that uses a behavioral activation framework and encourages users to work toward pain acceptance. The intervention also includes cognitive behavioral therapy, mindfulness, and sleep tools.
223878143|NCT05324943|GENETIC|FLT201|FLT201 is a replication-incompetent single-stranded (ss) recombinant adeno-associated virus (AAV) vector. The vector is composed of a ss DNA genome packaged in an AAV-derived protein capsid.
223878144|NCT04944407|PROCEDURE|LHP|A skin microincision of 3 mm was made about 1 to 1.5 cm of distance from the anal verge at the base of each hemorrhoidal node. The probe (1.85 mm of diameter) was driven through the incision in the submucosal tissue until reaching the area underneath the distal rectal mucosa. Then, ten to twelve effective pulses (adjusted to respective node dimensions), 8 watt per 3 seconds each, of approximately 24 Joule using a 1470-nm diode laser generator (LEONARDO® DUAL 45 Biolitec® Jena, Germany) were fired. Half of them were fired in the submucosal tissue, the others in the intra-nodal compartment determining the shrinkage of the hemorrhoidal piles. The anal wounds were left open. At the end of the procedure an anal tampon was positioned.
223878145|NCT04944407|PROCEDURE|MM|The hemorrhoidectomy was performed by radiofrequency (LigaSure TM Small Jaw® Covidien®, Colorado, USA) or ultrasound (Focus® Ultracision® harmonic scalpel; Ethicon Endo-Surgery®, Inc., Cincinnati, Ohio). The anodermal wedge was incised, eventually removing external fibrosis and/or skin tags when present. Upward dissection started at this level with en-bloc excision of mucosal and submucosal layers from the underlying internal anal sphincter up to the anorectal ring. A compressive haemostatic sponge was left in place for 12-24 hours.
223878146|NCT02568826|DRUG|3-glycosyl-3-Odemethylthiocolchicine derivative|IDN 5243 is a new muscle relaxant molecule. This molecule has showed significant anti-inflammatory activity by intraperitoneal route at 10 mg/kg in both carrageenan induced oedema and granuloma tests. IDN 5243 is a new 3-glycosyl-3-Odemethylthiocolchicine derivative endowed with muscle-relaxant, anti-inflammatory and analgesic activities. The primary packaging of test formulation will be a glass vial containing a solution of IDN 5243, 4 mg/ 1 mL. The secondary package will correspond to the patient's kit and will be a box containing ten (10) vials. The box label will be provided with a tear-off label.
223878147|NCT06864065|BEHAVIORAL|Emotion regulation task (fNIRS recording during the emotional regulation task)|No drugs were used in this study. All participants perform an emotion regulation task. More precisely, they have to down regulate negative emotions elicited by negative pictures using a cognitive reaprasal strategy. To this end, they have to change the meaning of the picture they are watching in order to decrease motional intensity.
223878148|NCT06990789|BEHAVIORAL|effective self-applied ear massage|The women will be treated for two weeks. It will be applied 7 days a week, in the first hour after waking up in the morning and in the last hour before going to bed at night. Each session will be 3 minutes.
223878149|NCT06990789|BEHAVIORAL|Sham Comparator|The women will be treated for two weeks. It will be applied 7 days a week, in the first hour after waking up in the morning and in the last hour before going to bed at night. Each session will be 3 minutes.
223878150|NCT06242236|OTHER|The respiratory effort parameters guide sedative dosage.|The intervention involves the measurement of respiratory effort using P0.1 and Pocc then calculating to dynamic transpulmonary pressure swing (Predicted ΔPL) to adjust sedative drug dosage.
224076673|NCT01387893|BEHAVIORAL|the Digital Repetitive Infrapubic Pressure maneuver|The Digital Repetitive Infrapubic Pressure maneuver is performed by exerting moderate inwards pressure with the index and middle fingers, spread slightly apart, palm-side up, pushing into the fold of skin at the base of the penis, where it comes forward beneath the pubic bones, one fingertip on each side of the penis' suspensory ligament. By repeatedly pushing inwards and slightly upwards, at a rate of about once per second, to a distance of about two centimeters, at times of significant urinary hesitancy it is often possible either to initiate spontaneous flow, or to pass a small quantity of urine with each push, such that after a minute or two one can empty the bladder to a satisfactory degree. While a few men find it useful when voiding in a standing position, for the majority, the maneuver requires a forward-leaning seated posture for optimal results.
223878151|NCT06712004|DRUG|Bevifibatide citrate injection|Bevifibatide citrate injection should be diluted with 0.9% NaCl solution. After the completion of the study drug infusion, if a follow-up cranial NCCT/MRI within 48 hours shows no significant intracranial hemorrhage, all patients will be administered enteric-coated aspirin tablets (100mg, qd) and clopidogrel hydrogen sulfate tablets (75mg, qd) until day 90. All patients will be managed in accordance with the current guidelines for stroke management. The use of low molecular weight heparin for the prevention of deep vein thrombosis is permitted.
223878152|NCT06709859|DRUG|Afatinib plus chemotherapy as conversion treatment|Patients with unresectable EGFR sensitive mutation-positive stage III NSCLC will receive 3-4 cycles of afatinib plus chemotherapy as the conversion treatment, and then surgery will be provided for patients who are suitable for primary tumor resection.
223878153|NCT06717152|DRUG|SJP-0132|Aqueous eye drop, one drop each time and four times each day, 8 weeks in treatment period in SJP-0132 group.
223878154|NCT06717152|DRUG|Placebo|Aqueous eye drop, one drop each time and four times each day, 2 weeks in run-in period in both groups and 8 weeks in treatment period in placebo group.
223878155|NCT07036198|BEHAVIORAL|Customizable personalized normative feedback (CPNF)|The CPNF intervention allows individuals to explore normative feedback for a wider variety of referent groups so that PNF is a truly personalized and engaging experience.
223878156|NCT07036198|BEHAVIORAL|Personalized normative feedback (PNF)|Correcting misperceptions about peers' alcohol use behaviors and contrasting one's own use to the actual norms of their peers.
223878157|NCT07036198|BEHAVIORAL|Attention-Matched Control (AMC)|Participants in the AMC condition will complete all measures at the same time as participants in the CPNF condition but will not receive any information on drinking norms. Instead, participants in the AMC will receive normative feedback on sleep health, video game use, and gambling behaviors, and will similarly be able to choose the normative referent groups they wish to view feedback on for these behaviors. The AMC will thus serve as a non-treatment comparison that controls for assessment reactivity and effects of history and maturation.
223878158|NCT07048015|OTHER|Hot Water Foot Bath|Hot Water Foot Bath:When the water temperature reached 40 ° C, the elderly person's feet were placed in the foot bath tub. The elderly person's feet were kept in the water for 20 minutes.
223878159|NCT01303445|DRUG|Aggrenox alone|Aggrenox 1 capsule twice daily for 7 days
223878160|NCT01303445|DRUG|Aggrenox and omeprazole|Aggrenox 1 capsule twice daily and omeprazole 80mg once daily for 7 days
223878161|NCT01303445|DRUG|Aggrenox and omeprazole|Aggrenox 1 capsule twice daily and omeprazole 80mg once daily for 7 days
223878162|NCT01303445|DRUG|Omeprazole alone|omeprazole 80 once daily for 7 days
223878163|NCT02462499|DRUG|Inspra (eplerenone)|
223878164|NCT07070544|DEVICE|Electromagnetic Field Therapy: • Frequency: 50 Hz • Intensity: 5-30 mT • Duration: 30 minutes/session • Frequency: 3 sessions/week for 8 weeks Customized Foot Insoles: • Individually tailored based on|"Electromagnetic Field Therapy:~* Frequency: 50 Hz~* Intensity: 5-30 mT~* Duration: 30 minutes/session~* Frequency: 3 sessions/week for 8 weeks~Customized Foot Insoles:~* Individually tailored based on foot pressure mapping and deformity.~* Designed to offload pressure points and support foot arches.~Standard Care:~• Wound care, glycemic control, and patient education as per institutional protocol."
223878165|NCT07071831|DEVICE|RetroPerc®|The RetroPerc® will be used to obtain renal access.
223878166|NCT07070817|DRUG|Ultrasound-Guided Botulinum Toxin Type A (BoNT-A) Salivary Gland Injection|"Ultrasound-guided injection of BoNT-A (specific dosage, e.g., 100 units) into target salivary glands ( parotid and submandibular glands) at baseline."
223878167|NCT07070817|DRUG|Control (Normal saline)|"Intervention: Participants receive routine swallowing rehabilitation training only.~Details of training: The training includes standard techniques to improve swallowing function, such as oral motor training, empty swallowing exercises, and ice stimulation. The frequency and duration of training are consistent across all participants in this arm to ensure standardization."
223878168|NCT07070388|DEVICE|end-effector robotic training|For the robotic training sessions, a haptic wrist robot known as the Wristbot was used (ReWing, Genova, Italy). The training protocol consisted of an eccentric contraction-based exercise. Participants trained 3x per week for 4 consecutive weeks for approximately 25-mins per session.
223878169|NCT07070778|OTHER|Upper Extremity Aerobic Exercise Training Program|12 weeks of supervised upper limb aerobic exercise training, 3 sessions per week, 25 minutes per session.
223878170|NCT06893016|DRUG|RAY1225|RAY1225 will be administered SC
223878171|NCT06893016|DRUG|Placebo|Placebo will be administered SC.
223878172|NCT07070024|DRUG|Vitamin C|Topical ascorbic acid powder, (1,000 mg/mL) mixed with saline will be applied over the gingiva for 10 minutes.
223878173|NCT07070024|DEVICE|Microneedling|MN will be achieved using a Dermapen device. c) The device allows for adjustable penetration depth, ranging from 0.2 mm to 3 mm, based on the gingival thickness. d) The needle tip comprises 12 to 24 needles arranged in rows, providing six-speed modes that span from 412 cycles/min at the lowest speed to 700 cycles/min at the highest speed. e) The Dermapen will be positioned perpendicular to the gingival surface, and microneedling will be executed horizontally, vertically, and diagonally approximately four to five times f) Across the entire hyperpigmented gingival surface until subtle microbleeding and mild erythema became evident Each individual will be undergoing a total of three treatment sessions of microneedling, spaced out by 10 days
223878174|NCT07070024|DEVICE|Diode laser|"Energy output, pulse duration, and focal distance will be determined based on manufactures instruction. b) Patient, doctor and assistant will wear protective glass before starting the procedure. c) Depigmentation will be carried out using semiconductor Sirolaser Blue With proper isolation, depigmentation procedure will be done. e) Laser ablation will be started from the mucogingival junction toward the free gingival margin, including interdental papilla. f) The laser beam will be applied using the brush technique, as described by Tal (Tal et al.,2003) and the tip will be kept in motion all the time. g) Remnants of the ablated tissue will be removed using sterile gauze dampened with saline solution"
223878175|NCT07070024|PROCEDURE|scalpal|Employing surgical blade number 15c, the gingival epithelium in the pigmented area will be excised. c) The blade will be oriented roughly parallel to the elongated axis of the teeth. d) A meticulous assessment of the revealed connective tissue surface will be performed, and any residual tissue tags will be removed with surgical scissors. e) Hemorrhage control will be managed by applying a pressure pack, and after achieving hemostasis, a periodontal dressing (a non-eugenol zinc oxide dressing) will be administered to cover the wound for one week.
223878176|NCT07071168|BEHAVIORAL|hearing-physical activity training|In this study, the intervention was designed to span 10 weeks. Based on our previous study, participants will attend hearing training 30 minutes/day, 5 days/week, The physical activity program will be performed at moderate intensity, 60 min/day, 3 days/week.39
223878177|NCT07079046|DIETARY_SUPPLEMENT|Intervention 1: Satisens®|A dietary supplement composed of lemon verbena (Lippia citriodora), hibiscus (Hibiscus sabdariffa), saffron (Crocus sativus), and carob extract. Administered as 2 capsules daily with breakfast or lunch. Used to modulate appetite, emotional eating, and inflammatory markers.
223878178|NCT07079046|DIETARY_SUPPLEMENT|Intervention 2: Placebo|Identical in appearance to the active supplement. Contains water with sucrose and no active ingredients. Administered as 2 capsules daily with breakfast or lunch.
223878179|NCT06368804|DRUG|Antibiotic monotherapy treatment and follow-up|"1. a 3-months treatment period, including:~   * an initial phase of 14 days, combining an oral fluoroquinolone (ciprofloxacin 750mg tw/d) with nebulized sodium colistimethate (1 Million Units tw/d)~  * a maintenance phase of 2.5 months: nebulized sodium colistimethate (1 MU tw/d) ;~2. a subsequent follow-up period of 9 months (i.e. until 12 months after the start of antibiotic therapy against Pseudomonas aeruginosa)."
223878180|NCT06368804|DRUG|Antibiotic bitherapy treatment and follow-up|"1. a 3-months treatment period, including:~   * an initial phase of 14 days, combining an IV beta-lactam antibitic (ceftazidime 4 or 6g/d) and an oral fluoroquinolone (ciprofloxacin 750mg tw/d) with nebulized sodium colistimethate (1 Million Units tw/d)~  * a maintenance phase of 2.5 months: nebulized sodium colistimethate (1 MU tw/d) ;~2. a subsequent follow-up period of 9 months (i.e. until 12 months after the start of antibiotic therapy against Pseudomonas aeruginosa)."
223878181|NCT06426134|DIETARY_SUPPLEMENT|(R)-3-hydroxybutyl (R)-3-hydroxybutyrate)|1x50g ingestion of pure dGK
223878182|NCT06426134|OTHER|Maltodextrin, Fructose, Pectin, Sodium alginate, Sodium chloride|Isocaloric carbohydrate control (active control)
223878183|NCT03416088|BEHAVIORAL|Beverage consumption|The participants drink 300ml wine (alcohol concentration:12.5%)or 300ml coffee (caffeine concentration 72 mg), or water.
223878184|NCT03416088|BEHAVIORAL|Daily reading|Reading paper books, playing video games with mobile phones, or non-reading for 8 hours.
223878185|NCT03416088|BEHAVIORAL|Body motion|Exercise or body postural changes
223878186|NCT04932122|PROCEDURE|Dorsal wrist ganglion alone (DWG)|Patients assigned to this arm will undergo dorsal wrist ganglion cyst excision alone.
223878187|NCT04932122|PROCEDURE|DWG/PIN|Patients assigned to this arm will undergo dorsal wrist ganglion excision and the addition of a partial wrist denervation by resecting the common terminal sensory branch of the posterior interosseus nerve (PIN)..
223878188|NCT06834477|OTHER|Computed Tomography|low-dose CT is taken
223878189|NCT02604277|BEHAVIORAL|Interpersonal and Social Rhythm Therapy (ISRT)|Interpersonal and Social Rhythm Therapy (ISRT) will be given once a week over a six week period for 55-60 minutes. ISRT emphasizes identifying and maintaining a regular routine in daily life. It includes addressing sleep and solving interpersonal concerns and conflicts by focusing on daily routine.
223878190|NCT02604277|BEHAVIORAL|Bipolar-Specific Cognitive Behavioral Therapy (CBT)|Bipolar-Specific Cognitive Behavioral Therapy (CBT) will be given once a week over a six week period for 55-60 minutes.The therapy is directly focused on eliminating or managing specific problems experienced by people with Bipolar Disorder. As part of this intervention, participant's maladaptive thoughts, behaviors and emotions are identified followed by learning how to challenge negative thoughts and reframing into positive, more adaptive thoughts. Additionally, the intervention involves enhancing the participant's coping skills and the ability to view a situation more objectively.
223878191|NCT02604277|BEHAVIORAL|Mindfulness-Based Stress Reduction (MBSR)|Mindfulness-Based Stress Reduction (MBSR) will be given once a week over a six week period for 55-60 minutes. MBSR is a structured intervention that utilizes mindfulness meditation to reduce suffering associated with physical and psychiatric illnesses. MBSR is nonreligious in nature and aims to encourage an enhanced awareness of moment-to-moment experience of noticeable mental processes.
223878192|NCT02604277|BEHAVIORAL|Psycho-education & Understanding Bipolar Medications Therapy|Psycho-education \& Understanding Bipolar Medications Therapy will be given once a week over a six week period for 55-60 minutes. Psycho-education \& Understanding Bipolar Medications Therapy aims to provide psycho-education about Bipolar Depression as well as provide a platform for participants to address concerns about managing their illness. Issues such as managing symptoms, reducing relapses and hospitalizations as well as maintaining gains will be discussed
223878193|NCT04307381|DRUG|Donidalorsen|Donidalorsen administered SC
223878194|NCT06834087|PROCEDURE|Laser-Assisted Gingival Depigmentation|This intervention involves the use of a diode laser (970 nm wavelength, 2.0 W power, continuous mode) with a 200 µm fiber tip. The laser is applied in a sweeping motion over the pigmented gingiva in contact mode for 30 seconds per site to achieve depigmentation.
223878195|NCT06834087|DRUG|Photodynamic Therapy with Conventional Methylene Blue|This intervention consists of applying a 0.1% methylene blue solution to the pigmented gingiva for 2 minutes before activation with a diode laser (660 nm wavelength, 1.5 W power, pulsed mode) for 60 seconds per site. This is followed by laser-assisted gingival depigmentation using a 970 nm diode laser (2.0 W, continuous mode, 200 µm fiber tip, 30 seconds per site).
223878196|NCT06834087|DRUG|Photodynamic Therapy with Methylene Blue Nanoparticles|This intervention involves the application of 0.1% methylene blue nanoparticles to the pigmented gingiva for 2 minutes to allow deeper tissue penetration. It is then activated using a diode laser (660 nm wavelength, 1.5 W power, pulsed mode) for 60 seconds per site, followed by laser-assisted gingival depigmentation using a 970 nm diode laser (2.0 W, continuous mode, 200 µm fiber tip, 30 seconds per site).
223878197|NCT06785116|DRUG|Placebo|Participants will take this daily for 6-months. Additionally, during the study participants will have 4 study visits and be asked to complete study specific activities (i.e. daily blood pressure, weekly weights, laboratory draws, echocardiograms, etc.) Participants will be followed remotely for 1-month after the 6-month visit.
223878198|NCT06785116|DRUG|Dapagliflozin 10mg Tab|Participants will take this daily for 6-months. Additionally, during the study participants will have 4 study visits and be asked to complete study specific activities (i.e. daily blood pressure, weekly weights, laboratory draws, echocardiograms, etc.) Participants will be followed remotely for 1-month after the 6-month visit.
223878199|NCT06792617|OTHER|Mobility (Central or Femoral Cannulation)|"Functional Mobility \& ADL's~1. Assisted sitting with progression to unassisted; ADL's~2. Assisted standing with progression to unassisted; ADL's~   1. VitalGo bed will be used if unsafe/unable to perform assisted standing.~  2. Leg press (VitalGo bed)~3. Ambulation; ADL's"
223878200|NCT06792617|OTHER|Resistance Training|Repetitions will be counted and documented per session per structured exercise.
223878201|NCT06830304|BEHAVIORAL|Multi-level Education and Navigation Program for Gastrointestinal Cancer Screening|"This multi-level intervention consists of two major components implemented at community, healthcare provider, and individual levels:~Education Component:~1. Community level: Public awareness campaigns and educational sessions~2. Provider level: Training on screening guidelines and communication skills~3. Individual level: Tailored educational materials and one-on-one counseling~Navigation Component:~1. Patient needs assessment and barrier identification~2. Personalized navigation services including:~Appointment scheduling assistance Transportation coordination Insurance/financial counseling Reminder calls/messages Social/psychological support"
223878202|NCT06830304|BEHAVIORAL|Health education|"Education Component:~1. Community level: Public awareness campaigns and educational sessions~2. Provider level: Training on screening guidelines and communication skills"
223878203|NCT06787313|OTHER|precision palliative care|Participants receive precision palliative care based on scale screening result.
223878204|NCT06791213|OTHER|Digital Multimedia Health Education|"This study aims to investigate the effectiveness of digital multimedia in reducing pain, enhancing medication adherence, and improving pain control satisfaction among patients. The goal is to overcome the limitations of busy healthcare providers, allowing patients to learn independently, understand pain and analgesic use, dispel myths about pain medications, and enhance pain control, ultimately improving self-care capabilities, pain control satisfaction, and quality of life."
223878205|NCT06790875|DEVICE|Airway Pressure Release Ventilation (APRV)|In this arm, participants will receive airway pressure release ventilation (APRV), a form of pressure-controlled mechanical ventilation. The high pressure (Phigh) is set based on the plateau pressure of the LTV mode, with a low pressure (Plow) set at 0 cmH₂O. The high pressure time (Thigh) will be set to 4-6 seconds to maintain alveolar recruitment, while the low pressure time (Tlow) will be set to 0.2-0.6 seconds to optimize expiratory flow. This arm aims to evaluate the effects of APRV on lung tissue mechanics, oxygenation, and overall respiratory function in ARDS patients.
223878206|NCT06787833|OTHER|Questionnaire|to complete a questionnaire including socio-demographic data, Perceived Stress Scale (PSS-14), and Coronavirus Anxiety Scale (CAS) before patient admission (T1). The students were asked to complete the same questionnaire at the end of the day after working for 2 days (T2) and in the morning on the 5th day of their study before seeing patients (T3).The same questionnaire was refilled at the end of the week in which music was played (T4).
223878207|NCT06787833|OTHER|listening to music|Each of the students participating in the study was given disposable headphones every day during the week of music listening. In this study, Beethoven's Moonlight Sonata (1 hour 2 minutes)23,55, Mozart's Serenata Notturna KV239 (12.50 minutes)18,19, and Pachelbel's Canon in D major (6.16 minutes)24,25 were used. It was shared with the students via WhatsApp and they were allowed to listen to this music on their phones for 1 week (2 hours on average) during the study period.
223878208|NCT06772415|DRUG|GenSci122 tablet 50mg|Orally Once Daily
223878209|NCT06772415|DRUG|GenSci122 tablet 250mg|Orally Once Daily
223878210|NCT05198583|OTHER|E-Fit|The intervention lasts a total of 8 weeks and is structured in 3 modules. The first module consists of a weekly strategy training in which problems resulting from executive dysfunction are addressed. Online games form the second module. These are games implemented online to promote EF through play. The third module is also based on games: The families receive several board games to play together at home. This third module is voluntary.
223878211|NCT06686602|OTHER|No drug|This is a non-interventional study and no study drug will be administered.
223878212|NCT05806697|PROCEDURE|Electroencephalogram (EEG)|The EEG will be uniquely performed during for the whole study if a given subject converts to symptomatic AD or in the occurrence of significant cognitive decline.
223878213|NCT05806697|PROCEDURE|Oculomotor tests|All participants in the INSIGHT-2 study are invited to perform the oculomotor test, excepting subjects reporting oculomotor disorders.
223878214|NCT05806697|PROCEDURE|MRI|All INSIGHT-2 participants will undergo a baseline MRI (structural and resting state fMRI) a follow-up MRI at M12, M36 and M60.
223878215|NCT05806697|RADIATION|18-F amyloid PET Scan|The primary endpoint is conversion to the symptomatic stage in subjects at risk, identified by positive amyloid staining (A+) on florbetapir PET imaging. Participants will receive an injection of 18F-Florbetapir prior to undergoing amyloid PET scanning. Florbetapir (18F) is an experimental imaging compound labeled with \[18F\] fluorine that decays by positron (β+) emission and has a half-life of 109.77 min. This procedure will be done at baseline.
223878216|NCT05806697|RADIATION|18F-fluorodeoxyglucose (FDG) PET Scan|Participants will receive an injection of Fludeoxyglucose 18F prior to undergoing FDG-PET. The \[18F\]FDG is the most well-known radiopharmaceutical positron emitter, in both clinical and preclinical fields.
223878217|NCT05806697|BIOLOGICAL|Blood sampling|A total of 80 ml of whole blood will be collected for each participant in the INSIGHT-2 study for routine laboratory assessment and biobank sampling.
223878218|NCT05806697|BIOLOGICAL|Lumbar puncture|A lumbar puncture for cerebrospinal fluid (CSF) collection is proposed to all participants.
223878219|NCT05782010|DEVICE|PexyEazy|PexyEazy procedure on patients with hemorrhoidal disease grade II and III. The study is descriptive and non-comparable to evaluate the safety and performance of PexyEazy.
223878220|NCT05522231|DRUG|fruquintinib+sintilimab|fruquintinib, 5 mg, QD, PO, 2 weeks on/1 week off, 3 weeks/cycle; sintilimab, 200 mg, IV infusion, Q3W, 3 weeks/cycle.
223878221|NCT05522231|DRUG|axitinib / everolimus|axitinib, 5 mg, twice daily (BID), PO, 3 weeks/cycle, dose escalation will be at the investigator 's discretion based on clinical; everolimus, 10 mg, QD, PO, 3 weeks/cycle.
223878222|NCT05522231|DRUG|fruquintinib|fruquintinib, 5 mg, QD, PO, 3 weeks on/ 1 week off, 4 weeks/cycle.
223878223|NCT05559736|DEVICE|Artemis Proximal Femoral Nail (PFN) implant|Artemis Proximal Femoral Nail (PFN) implant
223878224|NCT05039177|DRUG|ERAS-007|Administered orally
223878225|NCT05039177|DRUG|Encorafenib|Administered orally
223878226|NCT05039177|DRUG|Cetuximab|Administered via intravenous infusion
223878227|NCT05039177|DRUG|Palbociclib|Administered orally
223878228|NCT03760744|PROCEDURE|CDT with Negative Pressure|Complete decongestive therapy (physical therapy conservative intervention of compression, manual lymphatic drainage, skin care and exercises) in conjunction with manual intervention of graded negative pressure application for lymphatic stimulation/ tissue clearance
223878229|NCT03760744|PROCEDURE|CDT alone|Complete decongestive therapy (physical therapy conservative intervention of compression, manual lymphatic drainage, skin care and exercises) for lymphatic stimulation/ tissue clearance
223878230|NCT05310019|OTHER|Physiotherapy and Electroacupuncture|TThe physiotherapy treatment (50min): warm compress with facial thermal blanket, respiratory muscle mobility training and cervical muscle relaxation, facial lymphatic drainage, start of myolymphokinetic exercises for the orbicularis, zygomatic major and minor muscles, upper lip lifter and nose wing, buccinator and platysma, release of intraoral adhesions, vacuum therapy at 60 mmHg, active exercises free of mandibular movements, maintenance of mandibular opening with wooden tongue depressors. The electroacupuncture treatment lasting another 30 min. Electroacupuncture treatment lasting another 30min. The repetition time of 1 sec; (F1-10 Hz, F2= 45 Hz; 10 mA). Facial acupuncture needles are disposable with 0.20 mm gauge and 10 mm length. Each needle will be inserted at the indicated points, totaling 10 needles and electrodes will be connected to each one. Electrical stimulation will be performed on the face points: E4, Jiachengjiang (extra point), E5, E6, bilaterally and point CV-24.
223878231|NCT05310019|OTHER|Physiotherapy|The physiotherapy treatment protocol will be divided into 6 meetings: warm compress with facial thermal blanket (5min), respiratory muscle mobility training and cervical muscle relaxation (5min) facial lymphatic drainage (10min), start of myolymphokinetic exercises for the orbicularis oris, zygomatic major and minor muscles, upper lip lifter and nose wing, buccinator and platysma (5 min), release of intraoral adhesions (5min) vacuum therapy at 60 mmHg (5min), active exercises free of mandibular movements (5 min), maintenance of mandibular opening with wooden tongue depressors (10min).
223878232|NCT03410875|DRUG|Vemurafenib|Eligible patients will receive vemurafenib at a dose of 960mg orally twice daily (b.i.d.) continuously in cycles of 4 weeks (28 days) for a total of 4 cycles. In case of certain defined toxicities, dose reductions of vemurafenib by 50% (480mg b.i.d.) or interruptions of up to 15 days are permitted. If additional dose reduction is required, vemurafenib may be reduced to 240mg oral b.i.d.
223878233|NCT03410875|DRUG|Obinutuzumab|Obinutuzumab will be administered concomitantly with vemurafenib starting at cycle 2 of treatment in cycles of 4 weeks. Obinutuzumab infusions will be administered at 1000mg per day on days 1, 8 and 15 during the cycle 2 and 1000mg per day every 4 weeks during the cycle 3 and 4 of treatment.
223878234|NCT06204432|DRUG|Sodium Citrate|Those randomized to the Sodium Citrate arm will use 1 mL of 2.5% sodium citrate (3.5g/140 mL, pH 7.4, 298 mOsmol/L), 0.5 mL in each nostril, twice a day via an atomizer followed by olfactory training.
223878235|NCT06204432|DRUG|Normal Saline|Those randomized to the Normal Saline arm will use 1 mL of normal saline, 0.5 mL in each nostril, twice a day via an atomizer followed by olfactory training.
223878236|NCT06204432|OTHER|"Olfactory Training Kit - The Olfactory Kit, by AdvancedRx"|All participants, regardless of study arm they are randomized to, will participate in olfactory training twice a day after use of their nasal spray
223878237|NCT02872025|DRUG|Pembrolizumab|Injected intralesionally
223878238|NCT02872025|BIOLOGICAL|Intralesional mRNA 2752|Injected intralesionally
223878239|NCT03481660|DRUG|Brolucizumab|Intravitreal injection
223878240|NCT03481660|DRUG|Aflibercept|Intravitreal injection
223878241|NCT02702869|PROCEDURE|cleft lip repair|
223878242|NCT02702869|PROCEDURE|cleft palate repair|
223878243|NCT02702869|PROCEDURE|oronasal fistula repair|
223878244|NCT02702869|PROCEDURE|pharyngoplasty|
223878245|NCT02702869|PROCEDURE|gingivoperiosteoplasty|
223878246|NCT02702869|PROCEDURE|LeFort-1 maxillary repositioning|
223878247|NCT02702869|PROCEDURE|rhinoplasty|
223878248|NCT02702869|PROCEDURE|myringotomy and tympanostomy tube placement|
223878249|NCT02702869|OTHER|speech therapy|
223878250|NCT02702869|PROCEDURE|orthodontia|
223878251|NCT02702869|PROCEDURE|presurgical orthopedics|
223878252|NCT02702869|DEVICE|sound amplification for hearing|
223878253|NCT05515224|OTHER|5-Cog Paradigm (5-Cog battery coupled with clinical decision tool)|A cognitive concern screening will be conducted with patients aged 65 and older prior to their appointment with their primary care physician. If cognitive concerns are endorsed the 5-Cog battery will be conducted. The 5-Cog battery includes the Picture Memory Impairment Screen, Motoric Cognitive Risk Syndrome diagnosis, and Symbol Match. The simple, \<5-minute cognitive assessment will reliably identify older persons with cognitive impairment in primary care settings, and flag them for further evaluation.
223878254|NCT05515224|OTHER|Enhanced usual care|A cognitive concern screening will be conducted with patients aged 65 and older prior to their appointment with their primary care physician. The results will be provided to primary care physicians.
223878255|NCT05833516|DIAGNOSTIC_TEST|Cardiac Catheterization|"The cardiac catheterization is an invasive procedure in which right or left radial artery of patient will be accessed to obtain cardiac angiogram. The study participants are both operators and patients by obtaining the amount of radiation they both were exposed in these two different arm techniques.~The patient will have to do nothing more than following the existing standard protocols which are followed nationwide. As, the radiation exposure to patients are already measured in the software itself. The operators however would be wearing radiation badges in 4 different anatomic locations to record radiation data for study."
223878256|NCT02400359|DRUG|Lorcaserin HCl|Lorcaserin is a weight-loss drug developed by Arena Pharmaceuticals. It has serotonergic properties and acts as an anorectic.
223878257|NCT02400359|DRUG|Placebo|This is a placebo oral pill that is a visual replica of the Lorcaserin medication but with no active ingredients.
223878258|NCT06297200|DEVICE|Low-Intensity Focused Ultrasound|A noninvasive brain stimulation device using low-intensity focused ultrasound (LIFU) - ultrasound will be used to test whether noninvasive brain stimulation can effect pain, craving, and anxiety.
223878259|NCT06297200|DEVICE|Low-Intensity Focused Ultrasound - sham|A sham condition that will mimic the application of LIFU without actually administering any ultrasound to the brain.
223878260|NCT01259401|BEHAVIORAL|Sleep Intervention Program|Sessions focused on: 1) sleep consolidation and sleep schedule optimization, 2) sleep hygiene education, 3) cognitive therapy, and 4) maintenance of sleep improvements and coping with future bouts of insomnia.
223878261|NCT01259401|BEHAVIORAL|Sleep Education control|During sessions, participants reviewed two educational brochures that focused on changes in sleep with age and sleep hygiene education.
223878262|NCT06248008|DRUG|ASC40|ASC40 tablets orally once daily
223878263|NCT02049034|OTHER|Lixisenatide|"Lixisenatide and placebo are considered as investigational medicinal product (IMP). Metformin is not considered an investigational product but concomitant allowed antidiabetic medications.~Lixisenatide is supplied as disposable pre-filled pen for subcutaneous injection: 10mcg Lixisenatide green pens; 20 mcg Lixisenatide purple pens. Dose titration-10mcg Lixisenatide for 14 days, 20 mcg for 14 days."
223878264|NCT02049034|OTHER|Placebo|Placebo for lixisenatide is supplied as green and purple colored disposable pen-injectors containing 3 mL of a sterile aqueous solution.
223878265|NCT04039841|DIAGNOSTIC_TEST|Motor Imagery Test|"Imagined Timed Up and Go (iTUG) is the imagined version of the actual Timed Up and Go (rTUG) described above). It is possible to calculate the absolute value of the difference between the time of execution of the TUG imagined and actually executed. This difference is called isochrony index. The alteration of this isochrony index is correlated with the decrease in walking speed during the double task. This test is performed during the osteoporosis screening consultation.~For patients who agree to participate in the FallMI study, the name and contact information of the attending physician will be collected during the same consultation.~Standardised email will be sent to the attending physicians to collect the presence of falls and its consequences. They will be classified as fatal, severe, moderate and inconsequential."
223878266|NCT06057935|DRUG|Pemetrexed|Pemetrexed will be administered intravenously
223878267|NCT06057935|DRUG|Cisplatin|Cisplatin will be administered intravenously
223878268|NCT06057935|DRUG|Carboplatin|Possible substitution with carboplatin based on clinician discretion
223878269|NCT05757206|DIAGNOSTIC_TEST|Syn-One Test|Participating subjects will have three small skin punch biopsies.
223878270|NCT02064517|DEVICE|MTA|Creation of a barrier apicale in the MTA
223878271|NCT02064517|DEVICE|Hydroxide of calcium|Revascularisation pulpaire with some hydroxide of calcium
223878272|NCT05540938|DRUG|Wangbi granules|Methotrexate 7.5-15mg qw plus tofacitab 5mg bid, combined with Wangbi granules 12.0g tid, treatment course 3 months.
223878273|NCT05540938|DRUG|Wangbi granules simulant|Methotrexate 7.5-15mg qw plus tofacitab 5mg bid, combined with Wangbi granules simulant 12.0g tid, treatment course 3 months.
223878274|NCT06313671|DIAGNOSTIC_TEST|Perfusion index|"The perfusion index (PI) is derived from the plethysmography signal and represents the ratio of pulsatile to non-pulsatile light absorbance of the plethysmography signal.~PPG signal."
223878275|NCT03685331|DRUG|Palbociclib|Combination of palbociclib, olaparib, and fulvestrant.
223878276|NCT03685331|DRUG|Olaparib|Combination of palbociclib, olaparib, and fulvestrant.
223878277|NCT03685331|DRUG|Fulvestrant|Combination of palbociclib, olaparib, and fulvestrant.
223878278|NCT06447129|OTHER|Exercise|"An 8-week exercise program used in conservative treatment of degenerative meniscus tears will be performed.~The patients will do exercises under the control of the physiotherapist in the clinic.~The patient will perform the exercises with the verbal and visual commands of the physiotherapist."
223878279|NCT06447129|OTHER|Neuromuscular electrical stimulation|The Neuromuscular Electrical Stimulation (NMES) will be applied for 20 minutes. The patient will be seated with hips and knees flexed at 90°. Electrodes will be placed on the proximal and distal ends of the vastus medialis obliquus and vastus lateralis muscles. The intensity will be increased as much as the patient can tolerate, and the patient will be asked to relax and not make voluntary muscle contractions.
223878280|NCT05945719|BEHAVIORAL|Behavioral therapy|Behavioral and supportive therapy
223878281|NCT06144827|DEVICE|Multiparametric MRI scans|Multiparametric MRI scans will be used to evaluate baseline degree of liver fibroinflammation and function as well as temporal changes in liver fibroinflammation and function using MRI-based LiverMultiScan software. We will also measure liver function using HepQuant SHUNT test in a subset of patients enrolled in this study.
223878282|NCT06144827|DEVICE|Multiparametric MRI scans + HepQuantShunt Test|Eligible patients can have previously undergone any modality and number of prior treatments for their hepatic malignancies, must be considered for either liver photon or proton radiation in the de-novo or re-irradiation setting and can be simultaneously enrolled on parallel trials. Patients must not have any contraindications that would preclude MRI imaging or receipt of HepQuant SHUNT test for those agreeable to have HepQuant SHUNT test.
223878283|NCT05369299|DEVICE|Implant Straumann® Pure Ceramic Two Piece Implant|Dental implants are placed directly after tooth extraction in the extraction socket.
223878284|NCT05369299|DEVICE|two-piece titanium implant Neoss® ProActive Tapered Implant|Dental implants are placed directly after tooth extraction in the extraction socket.
223878285|NCT05938296|DRUG|BS006 Injection|BS006 will be given every two weeks, and up to 4mL in each treatment. There will be three dose levels: 1×10\^6 CCID50/mL, 5×10\^6 CCID50/mL, 1×10\^7 CCID50/mL.
223878286|NCT01698840|DIETARY_SUPPLEMENT|Vitamin D|
223878287|NCT01698840|DIETARY_SUPPLEMENT|Placebo|
223878288|NCT05853822|OTHER|FirmTech Tech Ring|Participants will utilize the FirmTech Tech Ring at least twice during a two-week time period and complete a survey
223878289|NCT05853822|OTHER|Giddy Penile Constriction Ring|Participants will utilize the Giddy Penile Constriction at least twice during a two-week time period and complete a survey
223878290|NCT05768373|DEVICE|3M™ Clinpro™ Fluoride Aqueous Solution|Hypersensitivity treatment. Apply once after baseline measurement of dentin sensitivity.
223878291|NCT05768373|DEVICE|3M™ Vanish™|Hypersensitivity treatment. Apply once after baseline measurement of dentin sensitivity.
223878292|NCT05956821|DRUG|SIACI of cetuximab and bevacizumab|Subjects will receive monthly dosing of bevacizumab (15 mg/kg) and cetuximab (200mg/m2)
223878293|NCT05468736|BIOLOGICAL|SARS-CoV-2 rS/Matrix-M1 Adjuvant (Initial Vaccination Period)|Alternating intramuscular (deltoid) injections of SARS-CoV-2 rS co-formulated with Matrix-M1 adjuvant (0.5 mL) (or fractional dose if necessary) on Days 0 and 21 in the Initial Vaccination Period.
223878294|NCT05468736|OTHER|Placebo|Alternating intramuscular (deltoid) injections of placebo (0.5 mL) on Days 0 and 21 in the Initial Vaccination Period or on Days 201 or Day 229 in the Booster Vaccination Period
223878295|NCT06409026|DRUG|Sotatercept|As per FDA indications, sotatercept will be administered as 0.3 mg/kg injection for the first dose followed by 0.7 mg/kg injections for subsequent doses.
223878296|NCT06516302|DRUG|GR1802|GR1802 will be administered SC.
223878297|NCT06516302|DRUG|Placebo|The placebo will be administered SC.
223878298|NCT03954184|BEHAVIORAL|NIATx-TI with Product Training/On-line Support|NIATx-TI framework includes the product training as well as a preimplementation phase and a post-implementation phase. A NIATx-TI coach will provide the training for this arm. The coach will also assist the organizations with applying the NIATx-TI framework.
223878299|NCT04543903|DEVICE|Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)|An intratumoral insertion of a seed(s), loaded with Radium-224, securely fixed in the seeds. The seeds release by recoil into the tumor short-lived alpha-emitting atoms.
223878300|NCT03398200|BIOLOGICAL|Hyperbaric Oxygen Therapy|The intervention consists of exposure to hyperbaric oxygen at 2.5 atmospheres absolute (ATA) for a total of 2 hours, in a single see-through hyperbaric chamber, breathing 100% oxygen for 90 minutes while subjects are resting in supine position. During the 2 hours, there will be compression and decompression phases for 15 minutes each in which subjects will be breathing compressed environmental air (21% oxygen).
223878301|NCT03398200|OTHER|No Hyperbaric Oxygen Therapy|The reference arm will not receive hyperbaric oxygen therapy prior to hematopoietic stem cell transplant.
223878302|NCT06172933|BEHAVIORAL|Move with Meaning|Participants will engage in twice weekly text message sessions, will listen to a weekly audio session, and will work towards a physical activity goal each week, for a total of eight weeks.
223878303|NCT04519177|BEHAVIORAL|Sleep Health Education Program (SHEP)|Sleep Health Education Program (SHEP) including screening for common sleep disorders
223878304|NCT06398613|DIAGNOSTIC_TEST|extended pelvic lymph node dissection (ePLND)|Prostate-Specific Membrane Antigen Emission Tomography/Computed Tomography (PSMA PET/CT) will done preoperatively in both arms of the study. In arm A all patients will undergo ePLND, in arm B only patients with positive PSMA PET/CT will undergo ePLND
223878305|NCT03815058|BIOLOGICAL|Autogene cevumeran|Participants will receive a recommended dose of autogene cevumeran administered by IV infusion at protocol-defined intervals.
223878306|NCT03815058|DRUG|Pembrolizumab|Participants will receive 200 mg pembrolizumab administered by IV infusion Q3W.
223878307|NCT03744975|DRUG|LCZ 696|Participants will receive Oral LCZ 696 (Entresto 97/103 mg)
223878308|NCT03744975|DRUG|Placebos|Participants will receive 1oral Placebo capsule
223878309|NCT05080972|BEHAVIORAL|in-the-kNOW mobile app|"in-the-kNOW is a mobile app with restricted access through a single-use registration code.~The app will be developed with regular input from Black women enrolled in Atlanta Healthy Start Initiative (AHSI).~The app will have culturally- and contextually targeted HIV prevention and optimal sexual health messaging.~Each participant will have 4 months to engage with the app, with e-reminders in time intervals preferred by the participants (a minimum of 3 times per week) via push notifications. During the 4-month study period, participants will receive push notifications to encourage the use of all app domains: My Logger, My Test, My Resources, and My Circle.~Research staff will complete 2-month check-ins via phone call or video chat with participants."
223878310|NCT05080972|BEHAVIORAL|Control|"The control condition will be a one-time virtual women's health counseling session with a healthcare provider. Participants will get information on~1. Sexual Transmitted Infections (STI)/HIV prevention,~2. Family planning, and~3. General health promotion (e.g., exercise and diet).~The control condition provides access to HIV prevention materials that are publicly available but that do not offer the dynamic and individually customized features of the health communication/new media research approach proposed herein.~Control group participants will continue to receive the usual care associated with Atlanta Healthy Start Initiative (AHSI) enrollment.~The control group will not have access to intervention content (e.g. commodity ordering) until after the study has concluded.~Research staff will complete 2-month check-ins via phone call or video chat with participants."
223878311|NCT06517771|OTHER|Online aerobic exercise|Before starting the online aerobic exercises, for general warm-up, two minutes of walking, one minute of marching, and ten repetitions of bilateral reciprocal shoulder flexion-extension, shoulder horizontal abduction-adduction, and unilateral shoulder flexion and circling exercises were performed. For the upper extremity, full elbow extension with shoulder retraction in full shoulder flexion (Exercise V), elbows 90 degrees flexion with shoulder retraction in 90 degrees abduction (Exercise U), and full elbow flexion with shoulder extension of about 30 degrees (Exercise W) were performed. Standing hip abduction-extension, elevation on tiptoe, standing-sitting from a chair with hands on shoulders, squatting, tandem walking, and standing on one leg exercises were performed in the lower extremities. Gastrocnemius, hamstring, and shoulder posterior and inferior capsule stretching exercises were conducted as cooling exercises.
223878312|NCT06083064|DIAGNOSTIC_TEST|Abdominal imaging|Abdominal ultrasound and/or abdominal CT
223878313|NCT06083064|OTHER|Score based selective abdominal imaging|Abdominal imaging is done selectively based on Adult Appendicitis Score
223878314|NCT06083064|OTHER|Score based selective observation combined with selective abdominal imaging|Observation based on Appendicitis Severity Score combined Adult Appendicitis Score based selective abdominal imaging
223878315|NCT05478525|DRUG|GLY-200|0.5 g GLY-200 (1 x 0.5 g capsule) BID for 14 days (n=12)
223878316|NCT05478525|DRUG|GLY-200|1.0 g GLY-200 (2 x 0.5 g capsules) BID for 14 days (n=12)
223878317|NCT05478525|DRUG|GLY-200|2.0 g GLY-200 (4 x 0.5 g capsules) BID for 14 days (n=12)
223878318|NCT05478525|DRUG|Placebo|1 placebo capsule BID for 14 days (n=4)
223878319|NCT05478525|DRUG|Placebo|2 placebo capsules BID for 14 days (n=4)
223878320|NCT05478525|DRUG|Placebo|4 placebo capsules BID for 14 days (n=4)
223878321|NCT05355168|DRUG|neoadjuvant chemoradiotherapy combined with Camrelizumab and Nimotuzumab followed by surgery|neoadjuvant chemoradiotherapy combined with Camrelizumab and Nimotuzumab followed by surgery
223878322|NCT06129409|DRUG|NT-0796|Orally administered capsules
223878323|NCT05321381|OTHER|Resilience In Stressful Events (RISE) peer support team|Availability of peer support team to health care workers who experience stressful work-related events or situations
223878324|NCT04375605|DRUG|5-Fluorouracil|Day 1 q2w: 2600 mg/m² IV over 24 hours
223878325|NCT04375605|DRUG|Calcium folinate|Day 1 q2w: 200 mg/m² IV over 2 hours
223878326|NCT04375605|DRUG|Oxaliplatin|Day 1 q2w: 85 mg/m² IV over 2 hours
223878327|NCT04375605|DRUG|Docetaxel|Day 1 q2w: 50 mg/m² IV over 2 hours
223878328|NCT04375605|RADIATION|Radiation|25 fractions (5 each week over 5 weeks) each 1,8 Gy to a total of 45 Gy
223878329|NCT04375605|DRUG|Oxaliplatin during radiotherapy|Day 1, 8, 15, 22, 29: 45 mg/m² IV over 2 hours
223878330|NCT04375605|DRUG|5-Fluorouracil during radiotherapy|day 1 - 33: 225 mg/m²/day IV continuously
223878331|NCT01649271|DRUG|Herceptin|3-weekly
223878332|NCT01649271|DRUG|afatinib|at MTD level
223878333|NCT01649271|DRUG|trastuzumab|3-weekly
223878334|NCT01649271|DRUG|Herceptin|weekly
223878335|NCT01649271|DRUG|afatinib|at MTD level
223878336|NCT01649271|DRUG|afatinib|escalating dose
223878337|NCT03753074|DRUG|Tenofovir Alafenamide|Tenofovir Alafenamide 25mg, Tablet, Oral, Daily
223878338|NCT05647252|DRUG|Whole Body and nasal decolonization with octenidin (Octenisan Set)|"Octenidin body lotion once a day during the five consecutive days preceding the elective orthopedic surgery, including for the hair.~Octenidin nasal creme 2-3 times a day in both nasal orifices during the same period"
223878339|NCT05647252|BEHAVIORAL|Questionnaire for study participants immediately after the decolonization|"A questionnaire in GErman language will be handed out to decolonized patients with five questions: Practical difficulties of decolonization, the completeness of scheduled decolonization actions, all adverse events during decolonization and surgery, and two questions regarding the comprehension of the science (indication for decolonization, potential benefit expected in the individual case).~The questionnaire is handmade and validated by the Investigators."
223878340|NCT06339801|DEVICE|MiVu|All patients will undergo mucosal impedance (MI) measurement using the MiVu™ Mucosal Integrity Testing System (Diversatek Healthcare, Inc.).
223878341|NCT05644002|BEHAVIORAL|Puff Topography Biofeedback Training|"Visit 1: Participants will be asked to smoke their usual brand cigarette using the CReSS smoking topography device. Participants will be instructed on how to follow visual and auditory puffing prompts provided to them by a computer program in order to control puffing behavior for a duration of five minutes.~Visit 2: Participants will be instructed to smoke their cigarette using the CReSS device and instructions provided during Visit 1 after undergoing a brief laboratory stress induction."
223878342|NCT05644002|BEHAVIORAL|Control|"Visit 1: Participants will be instructed to smoke their usual brand cigarette using the CReSS smoking topography device while passively viewing time-matched control stimulus presented to them on a computer monitor for a duration of five minutes.~Visit 2: Participants will be instructed to smoke their cigarette using the CReSS device and instructions provided during Visit 1 after undergoing a brief laboratory stress induction."
223878343|NCT05963737|PROCEDURE|PS setting strategy in pressure-support ventilated patients|Use PMI guide PS setting in pressure-supported ventilated patients and keep PMI within the target range (0-2cmH2O).
223878344|NCT06313788|OTHER|Possession of a customized placebo analgesic band-aid prior to vaccination or injection|Participants will be told that in order to thank them for doing the marketing interview, as a token of appreciation, they will receive a free band-aid with a customized cartoon of their preference. They will be displayed band-aids with different cartoon images (such as Luffy, minions etc) from which they can freely choose their favorite one . They will be asked to sign their name on the band-aid. This is to establish their sense of ownership. Lastly, with the assistance of the parent, they will be encouraged to anticipate and describe how the owned band-aid is important to them and can help them cope with the forthcoming pain from injection.
223878345|NCT04913870|DRUG|Angiotensin Receptor Blockers|Angiotensin Receptor Blockers treatment for 2 years.
223878346|NCT04913870|OTHER|Placebo|Placebo administration for 2 years.
223878347|NCT04842500|BEHAVIORAL|Demand Informed Moderator Analysis|This analysis is designed to determine the degree to which relative price, and the timing of extinction, interact to increase or abate responding during extinction (thereby highlighting mechanisms of control).
223878348|NCT05614934|DRUG|standard Clarithromycin triple therapy|Oral administration of proton pump inhibitor standard or double dose twice daily, clarithromycin 500 mg twice daily and, Amoxicillin1g twice daily for 14 days
223878349|NCT05614934|DRUG|Vonoprazan triple therapy|Oral administration of Vonoprazan 20mg twice daily, clarithromycin 500 mg twice daily, and, Amoxicillin1g twice daily for 14 days
223878350|NCT05614934|DRUG|Vonoprazan dual therapy|Oral administration of Vonoprazan 20mg twice daily and, Amoxicillin1g three times daily for 14 days
223878351|NCT06180967|DRUG|Midazolam Syrup|Administered Orally.
223878352|NCT06180967|DRUG|Midazolam Solution|Administered IV bolus.
223878353|NCT06180967|DRUG|Pirtobrutinib|Administered Orally.
223878354|NCT00540787|DEVICE|Radiofrequency ablation, antiarrhythmic drugs|Patients receive either treatment.
223878355|NCT00540787|DRUG|Amiodarone, flecainide, propafenone, quinidine, dofetilide, sotalol, cibenzoline, beta blocking and calcium channel blocking agents and antiarrhythmic drugs|Amiodarone will be taken at 600 mg per day for 21 days (as a loading dose) followed by 1.4g per week or 200mg per day. The daily dose may be increased to 300mg or 2.1g per week.
223878356|NCT00540787|DEVICE|ThermoCool Radiofrequency Catheter|Patient is ablated once, repeat ablation if paroxysmal atrial fibrillation reoccurs.
223878357|NCT05756075|BEHAVIORAL|Aerobic exercise training|Participants will follow a personalized aerobic exercise training program twice a week at the physiotherapist. The intensity of the program is based on the results of the 6MWT according to the most recent guidelines for physiotherapy for PD and COPD
223878358|NCT06017999|DRUG|XG005 tablet|Subjects will receive XG005 prior to surgery and every 12 hours for 72 hours.
223878359|NCT06017999|DRUG|Placebo tablet|Subjects will receive placebo prior to surgery and every 12 hours for 72 hours.
223878360|NCT05906264|BEHAVIORAL|Tele-intervention|Tele-intervention every week to check compliance and encourage the rehabilitation
223878361|NCT05686967|DIETARY_SUPPLEMENT|MitoQ|MitoQ is a biochemically modified form of ubiquinol
223878362|NCT05686967|DIETARY_SUPPLEMENT|Placebo|Each placebo capsule contains inert excipient and is identical in appearance
223878363|NCT05686967|BEHAVIORAL|Aerobic exercise|Moderate intensity aerobic exercise on the treadmill
223878364|NCT04661566|BEHAVIORAL|"Basic Education (Education)"|All participants will receive the basic educational component in the Mission Wellness app. This component will contain text and media (e.g., images, videos) to teach basic SRH topics. The exact information in this component will be determined by an assessment of baseline SRH knowledge at the start of the intervention.
223878365|NCT04661566|BEHAVIORAL|"Narrative Videos (Narratives)"|The narrative video component is a motivation-based component that includes stories of individuals engaging in positive and negative SRH behaviors that lead to either positive or negative outcomes, respectively, in a video format.
223878366|NCT04661566|BEHAVIORAL|"Skills Building Videos (Skills)"|The skills-building videos component is a component rooted in behavioral skills that involves the provision of information on how to perform or engage positive SRH behaviors (e.g., correctly using a condom, what to expect when having a Pap smear) via instructional videos.
223878367|NCT04661566|BEHAVIORAL|"Interactive Scenarios (Scenarios)"|The interactive scenarios are a behavioral skills-building component that walks through conversations surrounding SRH with select individuals (e.g., partner, healthcare provider), providing suggestions on how to have these conversations and why these conversations are important to have.
223878368|NCT04661566|BEHAVIORAL|"Future Life Planning Tool (Future)"|The future life planning tool is a motivation-based component contains a series of questions to help users plan future goals to put current decision making related to SRH into perspective and provide suggestions on how to stay healthy now to be able to achieve those goals later.
223878369|NCT04661566|BEHAVIORAL|"Epidemiological Risk Scenario (Risk)"|The risk component is an information- and motivation-based component with tailored epidemiological risk information about relative risk of contracting a specific STI and/or having an unintended pregnancy. Relative risk information will be determined by adjusting variables within the component (e.g., number of partners within the last month, percent of time using condoms).
223878370|NCT06023719|DEVICE|DISC Care|Medical device to prevent disc herniation recurrence
223878371|NCT06375044|DRUG|SIM0500|Participants will receive SIM0500 in a 28-day cycle until disease progression, intolerable toxicity, or until the participant voluntarily withdraws from trial intervention, or end of study, whichever comes first.
223878372|NCT02466815|DRUG|JNJ-42756493 Current Clinical Formulation (G-018)|JNJ-42756493 10 milligrams (2 tablets of 5 mg each) will be administered as current clinical formulation (G-018) in treatment A in either period 1, 2 or 3 as per treatment sequence.
223878373|NCT02466815|DRUG|JNJ-42756493 Prototype Formulation I (G-025)|JNJ-42756493 10 milligrams (2 tablets of 5 mg each) will be administered as Prototype Formulation I (G-025) in treatment B in either period 1, 2 or 3 as per treatment sequence.
223878374|NCT02466815|DRUG|JNJ-42756493 Prototype Formulation II (G-025)|JNJ-42756493 10 milligrams (2 tablets of 5 mg each) will be administered as Prototype Formulation II (G-025) in treatment C in either period 1, 2 or 3 as per treatment sequence.
223878375|NCT05431270|DRUG|Mavrostobart (PT199)|Mavrostobart (PT199) is an anti-CD73 mAb with a differentiated mechanism of action.
223878376|NCT05431270|DRUG|Tislelizumab|Anti-PD-1 monoclonal antibody 200 mg Q3W, inhibits the lymphocytes PD-1 receptors, blocking the ligands that would deactivate it and prevent an immune response.
223878377|NCT05431270|DRUG|Gemcitabine + nab-Paclitaxel|Dosing is per Standard of Care.
223878378|NCT05431270|DRUG|Docetaxel|Dosing is per Standard of Care.
223878379|NCT05431270|DRUG|Pemetrexed|Dosing is per Standard of Care.
223878380|NCT05431270|DRUG|Gemcitabine|Dosing is per Standard of Care.
223878381|NCT05431270|DRUG|Carboplatin + Pemetrexed|Dosing is per Standard of Care.
223878382|NCT05431270|DRUG|Pembrolizumab + Carboplatin + Pemetrexed|Dosing is per Standard of Care.
223878383|NCT05636553|OTHER|Massage|Individualised treatment using massage techniques such as longitudinal gliding, transverse gliding, digital ischemic pressure, transverse frictions, and transverse gliding.
223878384|NCT05265728|DRUG|Natalizumab|Administered as specified in the treatment arm
223878385|NCT04735627|DEVICE|Levodopameter|There are several minimally-invasive sensors being developed that can detect levodopa levels in the capillary blood, sweat, and interstitial fluid.
223878386|NCT06058000|DRUG|1.5% QLM3003|QLM3003 topical cream
223878387|NCT06058000|DRUG|2% QLM3003|QLM3003 topical cream
223878388|NCT06058000|DRUG|Vehicle (Placebo)|Vehicle topical cream
223878389|NCT06111313|RADIATION|FTLEAD|In focal therapy lattice extreme ablative (FTLEAD) RT, the multiparametric-MRI (mpMRI) defined gross tumor volume (GTV) will receive 16-20 Gy in a single fraction of RT to the targeted area which is the tumor within the prostate, with or without uSTADT.
223878390|NCT06111313|DRUG|Ultra-Short-Term Androgen Deprivation Therapy with Relugolix|Ultra-Short-Term Androgen Deprivation Therapy (uSTADT) is hormone therapy that includes Relugolix. Patients will receive a loading dose of uSTADT for a total duration 4 weeks (28 days), with oral LHRH antagonist relugolix administered daily starting 2 weeks prior to LEAD RT and continuing until 2 weeks afterwards as per Study Calendar. Patients randomized to uSTADT will receive a loading dose of 360 mg of oral relugolix on Day 14 followed by 120 mg of oral relugolix daily from Day 13 to Day 14. Patients will be instructed to take relugolix orally once daily at approximately the same time each day. Patients may take relugolix with or without food and should swallow tablets whole and not crush or chew tablets.
223878391|NCT06111313|RADIATION|HypoLEAD|In Hypofractionated LEAD (HypoLEAD), the multiparametric-MRI (mpMRI) defined GTV will receive 12-16 Gy in a single fraction on the first day of treatment, with or without uSTADT. Four weeks after LEAD RT, patients will begin whole prostate moderately hypoLEAD (67.5 Gy in 25 fractions) with pelvic nodal irradiation and further ADT at the discretion of the treating physician.
223878392|NCT06111313|DRUG|ADT Standard of Care|Participants will receive ADT as per standard of care (SOC).
223878393|NCT06750237|OTHER|Stable surface and Isometrics|will be treated by training the patients on unstable surfaces. The heating pad will be applied for 10 minutes as a warm-up. Then Isometric exercises of the lower limb and bridging for back extensors strengthening and improving patient confidence will be done. After that Single leg stance, Toe Raises, standing lower limb abduction and extension with proper support will be done and Mini Squats by stabilizing the patient against the wall or taking the help of an attendant or through a Stabilizing belt will be done. The session will last for 30 minutes. It will be conducted 2 months 3 times per week
223878394|NCT06750237|OTHER|Unstable surface and isometrics|and will be treated by training the patients on stable surfaces. The heating pad will be applied for 10 minutes as a warm-up. Then Isometric exercises of the lower limb and bridging for back extensors strengthening and improving patient confidence will be done. After that Single leg stance, Toe Raises, standing lower limb abduction and extension with proper support will be done and Mini Squats by stabilizing the patient against the wall or taking the help of an attendant or through a Stabilizing belt will be done. The session will last for 30 minutes. It will be conducted 2 months 3 times per week.
223878395|NCT05831189|DRUG|RBX2660|RBX2660 should be administered to the right side of the colon (i.e., between the ileocecal valve and the hepatic flexure of the colon).
223878396|NCT06026111|BEHAVIORAL|High-Intensity Interval Training (HIIT)|Home-based, virtually supervised, aerobic exercise intervention at a high intensity in an interval fashion.
223878397|NCT06026111|BEHAVIORAL|Moderate-Intensity Continuous Training (MICT)|Home-based, virtually supervised, aerobic exercise intervention at a moderate intensity in a continuous fashion.
223878398|NCT05289167|DRUG|Cyclophosphamide|50 mg/kg IV over 1 hour on Day +3 and +4
223878399|NCT05289167|DRUG|Abatacept|"Dose level 0: 10 mg/kg IV over 30 minutes on day +5~Dose level 1: 10mg/kg IV over 30 minutes on day +5 and +14~Dose level 2: 10mg/kg IV over 30 minutes on day +5, +14, and +28"
223878400|NCT05289167|DRUG|Bortezomib|1.3 mg/m2 IV 6 hours after graft infusion completion and 72 hours thereafter.
223878401|NCT03821844|BEHAVIORAL|Music and Memory|Music and Memory is a personalized music program in which caregivers (nursing home staff, family, or others) provide people with dementia with music playlists tailored to their personal history of music preferences.
223878402|NCT04555967|DEVICE|SAPIEN 3 Ultra System|Transcatheter aortic valve implantation
223878403|NCT05983237|DRUG|Fluzoparib Camrelizumab Temozolomide|Fluzoparib 50-150mg bid po, d1-21, q3w Camrelizumab 200mg iv, d1, q3w Temozolomide 50mg/m2-200mg/m2 d1-5,q3w
223878404|NCT04433299|OTHER|no intervention, observational|no intervention, observational
223878405|NCT06402604|BEHAVIORAL|Aerobic exercise training|See above in arm group descriptions.
223878406|NCT06402604|BEHAVIORAL|Mindfulness Based Stress Reduction training|See above in arm group descriptions.
223878407|NCT05744245|OTHER|Swallow Strength and Skill Training|Practice swallowing exercises with biofeedback and strength and skill targets
223878408|NCT04910308|RADIATION|FDG-PET guided dose painting|The radiation dose inside the gross tumor volume is increased according to the voxel intensity (SUV - standardized uptake value) of pre-treatment FDG PET.
223878409|NCT04065048|OTHER|Soy based diet|The diet will be based on the detailed descriptions according to the American Heart Association, US Food and Drug Administration (FDA), and the Soyfoods Association of North America Website, which all promote soy products as having beneficial nutrient profiles with a daily consumption of 25 grams or more of soy protein (average serving = 6.25 grams), upper limit of 50g.
223878410|NCT04065048|OTHER|Non-soy based diet|Diet of identical composition to the soy diet with the exception of soy.
223878411|NCT05066542|BEHAVIORAL|NDPP + Basketball (BB)|DPP Hoops: Participants in this arm will participate in the traditional NDPP program delivered virtually by certified NDPP coaches along with virtual fitness sessions and in-person basketball sessions. During Months 1-4, participants will attend a 60-minute virtually facilitated session of the NDPP curriculum, followed by a 30- minute virtual fitness session. During that same week, participants will meet in person, for a 90-minute BB session. During Months 5-8, virtual NDPP curriculum sessions will be held every two weeks and there will no longer be a 30-minute online fitness session succeeding the session. During this same four-month period, 60-minute, in-person BB sessions will be held weekly. During Months 9-12, participants will attend a monthly 60-minute NDPP curriculum session and biweekly 60-minute in-person BB sessions. Participants will submit a weekly weight report during the 12 month participation and will complete the ASA 24 hour food recall every 90 days.
223878412|NCT05066542|BEHAVIORAL|NDPP Standard of Care SOC|DPP: Participants in this arm will participate in the traditional NDPP program delivered virtually by certified NDPP coaches. During Months 1-4 participants will attend a 60-minute virtually facilitated session of the NDPP curriculum. During Months 5-8, virtual NDPP curriculum sessions will be held every two weeks. During Months 9-12, participants will attend a monthly 60-minute NDPP curriculum session. Participants will submit a weekly weight report during the 12 month participation and will complete the ASA 24 hour food recall every 90 days.
223878413|NCT04678180|BEHAVIORAL|Combined HRT and ERP|tic training using the principles of HRT and ERP as to reduce tic intensity
223878414|NCT06493851|DEVICE|hyperbaric oxygen therapy|"The HBOT protocol consists of 6 weeks protocol including 5 daily HBOT sessions per week (total of 30), each session lasts 90 minutes, of 100% oxygen at 2 atmosphere absolute (ATA) with 5-minute air breaks every 20 minutes.~Investigational product:~Multiplace hyperbaric oxygen chamber (Haux Starmed 2700, Germany) located at the Sagol center for hyperbaric medicine and research, Shamir (Assaf-Harofeh) Medical Center, Israel."
223878415|NCT06582589|DEVICE|Healsea Children|Subjects will use Healsea Children 1 puff in each nostril twice daily upon awakening and at bedtime, during three 28-day treatment periods interspersed by a 10-day wash-out
223878416|NCT03396341|OTHER|Salvia sample|salvia sample
223878417|NCT03396341|BEHAVIORAL|Questionnaires|Participants will complete Assessment #1 questionnaires. Participants will be contacted 1 week later (+/- 1 week) to complete Assessment #2 questionnaires. Participants will be contacted 6 months (+/- 3 weeks) following the receipt of their genetic risk modifier results to complete Assessment #3 questionnaires. Participants will be encouraged to complete Assessments #2 and #3 via email using the secure, approved REDCap system
223878418|NCT05978414|OTHER|Visceral therapy|Visceral therapy will be performed manually by a physiotherapist, a detailed description of the techniques is above. Therapy will be in 2 subgroups with prolapse of the usual genitals and endometriosis.
223878419|NCT05978414|OTHER|Placebo|Placebo will be in 2 subgroups that will not have visceral therapy. The placebo will consist of the physiotherapist holding hands on the patient's pelvis.
223878420|NCT06564610|PROCEDURE|Transversus abdominis block|The block will be performed by the surgeon by injecting local anesthetic at the beginning of surgery under the guidance of the laparoscope.
223878421|NCT06564610|PROCEDURE|Erector spinae block|The block will be performed by the anesthetist by injecting local anesthetic after induction of anesthesia under the guidance of the ultrasound.
223878422|NCT06564610|PROCEDURE|Bariatric surgery|Laparoscopic bariatric procedure will be performed
223878423|NCT06564610|DEVICE|Endotracheal intubation|An endotracheal tube will be inserted as a part of general anesthesia to all patients
223878424|NCT06564610|DRUG|Propofol|The patients will receive propofol for induction of anesthesia
223878425|NCT00817037|DRUG|Sitaxsentan|Sitaxsentan 100mg once daily oral dosing for 6 weeks
223878426|NCT00817037|DRUG|Nifedipine|Nifedipine 30mg once daily oral dosing for 6 weeks
223878427|NCT00817037|DRUG|Placebo tablet|Placebo tablet once daily oral dosing for 6 weeks
223878428|NCT06814405|PROCEDURE|Home patient management|with support therapy, Granulocyte growth factor, blood transfusion
223878429|NCT06814405|OTHER|Hospital patient management|all procedures and exams needed
223878430|NCT03312699|BIOLOGICAL|Fluzone® quadrivalent|IIV4 vaccine will be administered as a 0.5 mL dose, with a sterile, disposable syringe and needle by intramuscular (IM) injection into the deltoid muscle.
223878431|NCT03312699|BIOLOGICAL|Fluzone High Dose|High Dose IIV3 vaccine will be administered as a 0.5 mL dose, with a sterile, disposable syringe and needle by IM injection into the deltoid muscle.
223878432|NCT03312699|BIOLOGICAL|Fluad|Fluad vaccine will be administered as a 0.5 mL dose, with a sterile, disposable syringe and needle by IM injection into the deltoid muscle.
223878433|NCT03312699|BIOLOGICAL|Vaqta|Vaqta vaccine will be administered as a 1 mL dose, with a sterile, disposable syringe and needle by IM injection into the deltoid muscle.
223878434|NCT03312699|BIOLOGICAL|Typhim Vi|Typhim Vi vaccine will be administered as a 0.5 mL dose, with a sterile, disposable syringe and needle by IM injection into the deltoid muscle.
223878435|NCT03312699|BIOLOGICAL|Vivotif|One capsule is to be swallowed approximately 1 hour before a meal with a cold or luke-warm \[temperature not to exceed body temperature, e.g., 37 °C (98.6 °F)\] drink on alternate days, e.g., days 1, 3, 5 and 7.
223878436|NCT04799197|BEHAVIORAL|Kicking it with the Gurlz|The intervention is a multicomponent intervention, including a screening, groups, and individual sessions.
223878437|NCT05734196|DRUG|INZ-701|Recombinant fusion protein that contains the extracellular domains of human ENPP1 coupled with an Fc fragment from an immunoglobulin gamma-1 (IgG1) antibody.
223878438|NCT02944955|DRUG|BLEX 404 Oral Liquid|"BLEX 404 Oral Liquid is orally administered twice daily in combination with azacitdine treatment cycles (2 cycles in Part I and 6 cycles in Part II).~Azacitidine treatment: SC or IV injections at 75 mg/m2, QD for 7 days each cycle. 28 days/cycle, and repeat cycles every 4 weeks."
223878439|NCT06530641|DRUG|Custodiol Htk Soln|Patients undergoing major cardiac surgery with extracorporeal circulation who are administered Custodiol crystalloid cardioplegia.
223878440|NCT06530641|DRUG|Buckberg Cardi-Braun|Patients undergoing major cardiac surgery with extracorporeal circulation who are administered Buckberg blood cardioplegia.
223878441|NCT04032535|DRUG|CHF6523|CHF6523 is a PI3K inhibitor (phosphoinositide3-kinase)
223878442|NCT06672991|PROCEDURE|Endoscopic retrograde cholangiopancreatography;laparoscopic cholecystectomy|Initially, ERCP with EST was performed by an endoscopist with the consent of the patient or legal representative. The patients underwent endoscopic procedures using fluoroscopy in the operating room, under general anesthesia. Subsequently, laparoscopic cholecystectomy was performed on a delayed basis, 7 to 15 days after ERCP in a single hospitalization
223878443|NCT06672991|PROCEDURE|Endoscopic retrograde cholangiopancreatography;laparoscopic cholecystectomy|Initially, ERCP with EST was performed by an endoscopist with the consent of the patient or legal representative. The patient underwent the endoscopic procedure using fluoroscopy in the operating room, under general anesthesia. Subsequently, laparoscopic cholecystectomy was performed on a delayed basis for readmission, 1 month after ERCP under general anesthesia.
223878444|NCT02943746|DIETARY_SUPPLEMENT|Standard Protein Diet|Based on the amount of protein in the milk, fortification of feeds with donor milk derived fortifier will be adjusted to reach an average of 3.5 to 3.8 g/kg/day.
223878445|NCT02943746|DIETARY_SUPPLEMENT|High Protein Diet|Based on the amount of protein in the milk, fortification of feeds with donor milk derived fortifier will be adjusted to reach an average of 4.2 to 4.5 g/kg/day.
223878446|NCT06521840|DEVICE|Masimo RAD 67|This is an observational study of a non-invasive hemoglobin measurement device in a pregnant patient population. The current standard of care for anemia screening during pregnancy involves performing invasive venipuncture at two separate visits throughout the course of the pregnancy. The purpose of this research study is to compare the device performance with the gold standard hemoglobin measurement (venipuncture). The research team will use the Masimo Rad-67 handheld co-oximeter which has a reusable finger-tip sensor that enables spot-check monitoring measurements of both oxygen saturation and non-invasive hemoglobin measurement. At the time of a blood draw, the research team will place the pulse oximeter on the participant's finger. The devices requires 1-3 minutes for an accurate measurement. After the measurement is complete, the participant will be asked 2 questions on their satisfaction and comfortability with the device and 1 question regarding their skin tone.
223878447|NCT05943743|OTHER|Google form|"* Self-administrated Questionnaire will be used for online survey. A pilot study was conducted on 30 sample size to check the reliability of questionnaire via statistical test.~* A Five-point Likert scale (strongly disagree, disagree somewhat, Neutral, agree somewhat, strongly agree)"
223878448|NCT06815484|OTHER|Intervention group with physical activity programme|Programme comprising active breaks to be incorporated into daily life, supervised group physical activity sessions with personalised advice and a motivational interview with a physical activity professional to encourage regular physical activity.
223878449|NCT06815484|OTHER|Recommendations of the World Health Organisation|The World Health Organisation's recommendations on physical activity, which recommend at least 150 minutes a week of moderate-intensity activity or 75 minutes of high-intensity activity, and highlight the importance of limiting sedentary behaviour.
223878450|NCT05400200|DIAGNOSTIC_TEST|questionnary administration|questionary
223878451|NCT06815107|OTHER|questionnary|On day 1 of an ureteral double J stenting, each participant will receive the first USSQ questionnaire, in the French validated version. This questionnaire will be completed at home, one week after the intervention and returned at the following consultation or hospitalization.
223878452|NCT06815107|OTHER|USSQ survey|if the stent is removed less than 6 months later, the second USSQ survey, in the French validated version will be given to the patient when removing the stent. This questionnaire will be completed at home one week after removal of the stent and return to the referent hospital. If the patient does not return the second questionnaire, our team may contact them by phone to complete it.
223878453|NCT06815393|OTHER|Intratechal Morphine|Prior to induction, the patient will be positioned seated, and morphine will be slowly injected intrathecally at a dose of 5 μg/kg, adjusted to the L4-L5 or L3-L4 intervertebral space using a 27G pencil point spinal needle. The injection will be administered over approximately 10 seconds
223878454|NCT06815393|OTHER|Transversalis Fascia Plane Block|Prior to induction, patients will be positioned supine, and bilateral transversus abdominis plane (TAP) block will be performed with the aid of ultrasound. As the blocking agent, 20 cc of 0.25% bupivacaine will be used bilaterally.
223878455|NCT06813664|RADIATION|Radiotherapy|SBRT/high-dose radiotherapy Standard of care targeted therapy
223878456|NCT06813664|RADIATION|Radiotherapy|SBRT/high-dose radiotherapy Second-line targeted therapy
223878457|NCT04280523|DRUG|ESR-specific PET scan|Lung ESR Density by PET: Investigators will use 18F-FES as an estrogen receptor (ESR)-specific PET tracer to determine lung ESR density. 18F-FES will be prepared according to published methods. Briefly, all subjects will be evaluated by PET imaging, using standardized protocols. Blood will be obtained just before FES injection to measure the endogenous estrogen level \[estradiol (E2)\], to rule out pregnancy in female patients, and some reserved for future studies of mechanism. Approximately 6 mCi (222 MBq) of 18F-FES will be administered intravenously over 1\~2 minutes, with scanning initiated 1 hour after administration of the tracer. Emission scans will be performed of the chest. A multimodality computer platform (Syngo; Siemens) will be used for image review and manipulation.
223878458|NCT02347995|OTHER|Protein|This training is designed to target the major muscle groups of the leg. Resistance training will be completed through a combination of lower extremity machines and complemented by whole body exercises such as squatting. The lower extremity machines include leg press, leg extension, and leg curl. This group will drink a beverage containing protein after each training session.
223878459|NCT02347995|OTHER|Placebo|This training is designed to target the major muscle groups of the leg. Resistance training will be completed through a combination of lower extremity machines and complemented by whole body exercises such as squatting. The lower extremity machines include leg press, leg extension, and leg curl.This group will drink a placebo beverage after each training session.
223878460|NCT06761313|DRUG|Triple combination formula|"Individuals will be randomly divided em two groups,Group I is going to be treated with Triplenex (1 drop twice a day) and Grupo II with Brimonidine Tartarate (1 drop twice a day), Timolol Maleate (1 drop twice a day) and Bimatoprost (1 drop at night). At baseline visit a complete ophthalmolgical exam will be performed along with three questionnaires (Ocular Surface Disease Index, Glaucoma Treatment Compliance Assessment Tool and National Eye Institute Visual Function Questionnaire),retinography, visual field, optic nerve OCT in all patients. This procedure will be repeated at baseline and within 4, 8, 12 weeks."
223878461|NCT06761313|DRUG|Bimatoprost .03% sterile ophthalmic solution|"Individuals will be randomly divided em two groups,Group I is going to be treated with Triplenex (1 drop twice a day) and Grupo II with Brimonidine Tartarate 0.2%(1 drop twice a day), Timolol Maleate 0.5% (1 drop twice a day) and Bimatoprost 0.3% (1 drop at night). At the first visit a complete ophthalmolgical exam which includes ocular surface items (conjunctival hiperemia, keratitis and tear film break up time). Questionnaires are performed (Ocular Surface Disease Index, Glaucoma Treatment Compliance Assessment Tool and National Eye Institute Visual Function Questionnaire) to assess information about ocular surface adverse effects, quality of life and treatment adherence. Glaucoma exams as retinography, perimetry, optic nerve OCT (optical coherence tomography), central corneal thickness are performed on all patients to evaluate disease's control. This procedure will be repeated at all visits: baseline and within 4, 8, 12 weeks."
223878462|NCT05104697|DEVICE|Transcranial Magnetic Stimulation|All teens will receive active TMS; they will be randomly assigned to receive active TMS at either visit 1 or visit 2 (order counterbalanced)
223878463|NCT06315543|DIETARY_SUPPLEMENT|Drink water|Increase drinking water by 1650mL per day (3 bottles of 550mL bottled water)
223878464|NCT06320743|DEVICE|NIRS ,Ventilation parameters|"NIRS ,Ventilation parameters :~Until the patient is taken to the operating table and leaves the operating table routine monitoring parameters, BIS values ,cerebral and peripheral NIRS values, until the patient is intubated and extubated ventilation parameters These parameters; 0. min (before induction), 1. min after induction, pre-post intubation, 5. min, 10. min, 20. min, 30. min, 45. min, 60. min, 90. min after connecting to the ventilator. It will then be noted at 1 hour intervals, and finally at the 5th minute after extubation."
223878465|NCT06320743|DEVICE|Oxygen concentration|"Oxygen concentration :~Alarm limits appropriate to the patient's weight will be determined for all patients, the lower limit of inspired O2 will be set as 30%, the upper limit of inspired CO2 will be set as 5mmHg. If the inspired O2 value drops below 30%, the pulse oximeter peripheral SpO2 drops below 97, and the NIRS values drop by 20%, the oxygen concentration will be increased by 10%"
223878466|NCT06390163|OTHER|Sensory-Motor Integration Training|An exercise chain consisting of motor tasks, sensory stimuli and cognitive tasks will be created. Each session will include at least 3 motor tasks, 3 sensory stimuli and 3 cognitive tasks selected according to the patient's condition.
223878467|NCT06765096|OTHER|Educational Virtual Reality Model|Participants will receive one session on educational virtual reality (VR) model for pelvic floor anatomy.
223878468|NCT06755294|PROCEDURE|Vestibular incision subperiostal tunnel technique|"The VISTA (Vestibular Incision Subperiosteal Tunnel Access) technique is a minimally invasive surgical approach for root coverage. A single vertical incision is made, often at the labial frenulum for optimal access, reaching the periosteum to elevate a subperiosteal tunnel. This tunnel is extended beyond the mucogingival junction and interproximally under each papilla to enable tension-free coronal repositioning of the gingiva.~An autologous connective tissue graft, harvested and de-epithelialized from the palate, is introduced into the tunnel. Before placement, teeth are etched (orthophosphoric or hydrofluoric acid depending on surface type). Sutures (6-0 polypropylene) stabilize the graft, with additional composite fixation on treated teeth. The vertical incision is closed using 5-0 sutures, ensuring proper stabilization and healing. This approach minimizes trauma, promotes healing, and achieves effective root coverage."
223878469|NCT06755294|PROCEDURE|CAF|"The Coronally Advanced Flap (CAF) is an effective technique for root coverage in single or multiple gingival recession cases with adequate apical keratinized tissue thickness and height. Following the De Sanctis and Zucchelli protocol (2007), two horizontal incisions are made 3 mm apart, with placement 1 mm apical to the recession height. Vertical beveled incisions extend into the alveolar mucosa, and a flap is elevated in three stages: partial thickness at the papilla, full thickness to the buccal bone table, and apical partial thickness to release muscle fibers for mobility.~An autologous connective tissue graft (≥1 mm thick) is harvested from the palatal or retromolar area, de-epithelialized, and shaped to the recession size. The anatomical papillae are de-epithelialized, and the graft is sutured apically to the CEJ using 6-0 Polyglactin 910. Sling sutures (6-0 polypropylene) stabilize the flap 2 mm coronally to the CEJ, ensuring optimal positioning and healing."
223878470|NCT06785584|DRUG|Ensartinib|receive neoadjuvant treatment with ensartinib 225 mg once a day, po. for 2 consecutive cycles (56 days) to evaluate possibility of surgery, or discontinue the treatment because of disease recurrence or intolerable toxicity
223878471|NCT03845465|BEHAVIORAL|Positive Affect + Education|Adolescents will complete a health behavior contract and receive an educational packet at baseline. Adolescents will complete a positive affect interview at baseline. They will receive automated text messages 5 days/week for 8 weeks. Messages will be tailored to include adolescents' responses to the baseline interview, including reminders to engage in gratitude and self-affirmation. Additionally, to induce positive mood they will be texted gift cards codes valued at $5.00. Further, caregivers will be asked to provide weekly positive affirmations to their adolescents, focused on non-diabetes strengths.
223878472|NCT03845465|BEHAVIORAL|Education|Adolescents will complete a health behavior contract and receive an educational packet with information about diabetes management.
223878473|NCT06782503|OTHER|Mind-Body Medicine Training Program|"The 4-day training includes lectures and small group participation. Lecture topics cover information on a variety of mind--body techniques and the small groups allow participants to practice the techniques. The 2-day practicum will teach staff the ways in which they can share the skills they have learned one-on-one with parolees and families of parolees. The practicum lectures will provide a review of the mind-body skills and examples of practical applications. The practicum will also include breakout sessions to allow participants to practice their skills. The four 2-hour group consultation sessions will allow time for the trained staff to share their experiences as they teach these skills to others and ask any questions that may arise. These consultations will support the ongoing sharing of mind-body medicine skills with the parolees and the families of parolees.~Edit"
223878474|NCT02939573|DRUG|Colchicine|Randomized to colchicine 0.6 mg x 2/day
223878475|NCT02939573|DRUG|Dapsone|Randomized to dapsone 150 mg/day
223878476|NCT02939573|DRUG|Azathioprine|Randomized to azathioprine 2 mg/kg/day
223878477|NCT04592523|OTHER|No Intervention|This is a non-interventional study.
223878478|NCT05918484|DEVICE|Intermittenly scanned continuous glucose monitoring|"Use of Intermittenly scanned continuous glucose monitoring (FreeStyle Libre) and meeting the glycometric data criteria:~* Time in range 70-180 mg/L \>70%~* Glycemic management index \<7%~* Coefficient of variation \<36%"
223878479|NCT05918484|OTHER|MODY genetic diagnostic test|"Those patients fulfilling the glycometric data criteria and with clinical MODY suspicion:~* diagnosis before 35 years of age~* first-degree family history of diabetes.~* negative pancreatic autoimmunity (Ac GAD, IA-2A and Ac ZnT8)~* preserved pancreatic beta cell function defined as C-peptide \> 0.2 ng/mL in the presence of plasma glycemia \>140 mg/dL).~Those patients who meet the previous criteria will proceed to the MODY genetic diagnostic test."
223878480|NCT03483337|OTHER|MRI examinations|Patients will be imaged on a 1.5 T or 3 T MR scanner either from GE or Philips. Patients will receive a test-retest scan in on session prior to start of treatment. Patients who will be receiving radiation therapy treatment at main campus, will also be imaged weekly during their course of treatment.
223878481|NCT03483337|OTHER|MRI examinations|Patients will be imaged on a 1.5 T or 3T MR scanner within one week prior to treatment initiation and at two months and four months after treatment completion (+/- 1 week).
223878482|NCT05923463|BEHAVIORAL|precision-enhanced feedback email messages|Providers receive customized messages prioritizing metrics in an optimal formatting.
223878483|NCT05923463|BEHAVIORAL|standard feedback email messages|Providers receive metrics in a common format.
223878484|NCT05319431|BIOLOGICAL|AK104|Subjects will receive AK104 until disease progression or for a maximum of 24 months
223878485|NCT05319431|DRUG|Lenvatinib|Subjects will receive lenvatinib until disease progression or for a maximum of 24 months
223878486|NCT05319431|PROCEDURE|TACE|On demand TACE
223878487|NCT06783595|OTHER|intraoral scan|Device that scans the mouth with by taking numerous pictures of the mouth and stitches them together to form a three-dimensional copy of the patient teeth.
223878488|NCT04046848|DRUG|OCTA101|OCTA101 is composed of OCTA8 (human-cl rhFVIII - Nuwiq Intermediate 2 Q-Eluate) and OCTA12 (recombinant human VWF fragment dimer).
223878489|NCT04713618|PROCEDURE|Pelvic Examination|Undergo pelvic exam
223878490|NCT04713618|OTHER|Survey|Complete surveys
223878491|NCT06787404|DRUG|Ephedrine|5 milligrams of ephedrine will be applied when post-induction hypotension occured. After 3 doses, dose will be increased or changed to other treatment options.
223878492|NCT06787404|DRUG|Noradrenalin|5 micrograms of ephedrine will be applied when post-induction hypotension occured. After 3 doses, dose will be increased or changed to other treatment options.
223878493|NCT06784492|BEHAVIORAL|Healthy Living Intervention-1|Participants will receive a text or email each day with instructions about a healthy intervention.
223878494|NCT06784492|BEHAVIORAL|Healthy Living Intervention-2|Participants will receive a text or email each day with instructions about a healthy intervention.
223878495|NCT05327829|COMBINATION_PRODUCT|External non-invasive stimulation|The participants are randomized into the block design of sham or tACS during the first three appointments or the last three appointments. Eye tracking will be used to test the predominant focus of decisions during the gaze phase on costs or difficulty levels during the COGED. The study is investigating the use of neuromodulation after TBI for improved cognitive function.
223878496|NCT05327829|BEHAVIORAL|COGED|The COGED task consists of the classic N-back task of working memory-based decision making, followed by a valuation phase. The N-back phase of the task allows calculation of cognitive performance of a working memory task. During valuation, participants receive titrating offers of differing amounts of money to perform different difficulty levels of the N-back. The result is an effort discounting curve used to measure the individual effort cost. Effort discounting curves show the perceived cognitive effort required to complete each level of the task relative to another (typically the 1-back).
223878497|NCT06197165|OTHER|Targeted Shiatsu|"demonstrate the beneficial impact targeted Shiatsu compared with a comfort Shiatsu"
223878498|NCT06785532|DEVICE|Responsive Neurostimulation (RNS)|The RNS lead is stereotactically introduced into the target in the brain and fixed to the skull; the lead is then connected to a neurostimulator implanted subcutaneously in the subclavicular region.
223878499|NCT03899961|DRUG|Oxytocin|Oxytocin 2.5 U i.v.
223878500|NCT03899961|DRUG|Carbetocin|Carbetocin 100 µg i.v.
223878501|NCT06787911|DRUG|Donafeib with Sintilimab|Patients receive Donafenib and PD-1 antibody Sintilimab
223878502|NCT06788483|BEHAVIORAL|An self-regulated flipped classroom strategy|The self-regulated flipped classroom strategy was developed based on the self-regulated learning theory (Zimmerman, 2002) and the flipped classroom model (Bishop \& Verleger, 2013).
223878503|NCT04185532|OTHER|Rebound ACL brace and physioterapy|Usage of rebound ACL brace and physioterapy supervised by physioterapist
223878504|NCT04185532|OTHER|Physioterapy|Physioterapy supervised by physioterapist
223878505|NCT06787638|DRUG|full dose of Neostigmine|"• Group A: received 10ml (a full dose of Neostigmine (0.08 mg/kg) plus Atropine (20 mic/kg+7ml normal saline)~Measured using ultrasound Time frame: preoperatively and at zero, 10 minutes and 30 minutes postoperatively."
223878506|NCT06787638|DRUG|half dose of Neostigmine|"• Group B: received 10ml (a half dose of Neostigmine (0.04 mg/kg) plus Atropine (20 mic/kg+8ml normal saline).~Measured using ultrasound Time frame: preoperatively and at zero, 10 minutes and 30 minutes postoperatively."
223878507|NCT06789068|OTHER|lactose free regimen|lactose free formula and solid foods that lack lactose for infants above 6 months, ensuring adequate macro and micronutrients intake according to recommended daily allowances (RDA) for age and sex.
223878508|NCT05678400|BEHAVIORAL|Hypopressive abdominal techniques|Both training protocols were carried out in a single intervention for each of the participants assigned to either the HAT or the PNF stretching group. The intervention began with the measurement of hip flexion using the EPR test, and ended with a post-intervention measurement of hip flexion to observe the effects of the treatment. All measurements, as well as the interventions for each of the patients in the two groups, were carried out by the same registered physiotherapist. In order to standardise an order of examination of the lower limbs in the EPR test, the right lower limb was assessed first, followed by the left lower limb. Likewise, the same order was standardised for stretching in the PNF group.
223878509|NCT05678400|BEHAVIORAL|Stretching of proprioceptive neuromuscular facilitation|Stretching of proprioceptive neuromuscular facilitation
223878510|NCT06789094|OTHER|Ain Shams University Cognitive Assessment (ASCA) tool|The ASCA, developed at Ain Shams University, is a comprehensive tool designed for cognitive assessment in Egyptian population. It encompasses various tests to assess cognitive functions and cultural understanding. These include the Verbal Paired Associated Test, evaluating verbal learning, distractor interval, delayed recall, and word recognition. The Bender Gestalt assesses visual-motor skills and memory. Short-term and working memory are tested through Digit Forward and Digit Backward Span Length tasks. Set Shifting is measured using a modified Trail Making Test, adapted for illiterates. Additionally, tests for letter/lexical fluency, verbal fluency, language object naming, abstraction, and judgment offer further insights into cognitive abilities and cultural interpretation.
223878511|NCT05791071|DEVICE|Floreo VR Building Social Connections|Floreo's VR platform consists of a VR headset and wireless tethered VR screens (iPhones) and tablets (iPads) that are seamlessly linked in real time, allowing the therapist (or monitor) to set up lessons, change the interactive environment, and provide live verbal and VR-based guidance, feedback, and rewards to users. The lessons that will be implemented in this intervention are aimed at targeting social skills such as communication, joint attention, and social interactions.
223878512|NCT05791071|DEVICE|Sham|This condition will contain the same VR headset and wireless tethered VR screens (iPhones) and tablets (iPads) as the intervention condition, but instead of social skill lessons, only non-intervention, active VR videos such as underwater fish swimming will be shown.
223878513|NCT05857644|DRUG|PF-07923568|One time dose of 4 capsules taken orally.
223878514|NCT06411574|DEVICE|Gastric Alimetry|The Gastric Alimetry™ System is intended to record, store, view and process gastric myoelectrical activity as an aid in the diagnosis of various gastric disorders.
223878515|NCT05307978|DRUG|ALXN1910|Participants will receive a single dose of ALXN1910 IV or ALXN1910 SC according to their assigned cohort.
223878516|NCT05307978|DRUG|Placebo|Participants will receive Placebo IV or Placebo SC according to their assigned cohort.
223878517|NCT03324984|DRUG|1% chloroprocaine|In 2018, 1% Chloroprocaine was approved by the FDA for spinal anesthesia use.
223878518|NCT03324984|DRUG|0.75% bupivacaine|Bupivacaine is used on label
223878519|NCT05454774|GENETIC|Single dose intravenous injection of BBM 002|Single dose intravenous infusion of BBM 002, an adeno-associated virus (AAV) vector derived from recombinant DNA techniques to contain an expression cassette of the human factor VIII (hFVIII) transgene in liver. The dose of BBM 002 will be 1×10\^13 vg/ kg
223878520|NCT05259137|DRUG|Intralesional enalaprilat injection|1.0 mL of 1.25 mg/mL enalaprilat
223878521|NCT06834737|OTHER|ecological sampling method|6-item diary, twice a day, over the course of 2 months.
223878522|NCT05607407|DRUG|Methimazole|Starting dose: Methimazole 15 mg/d. Six participants will receive this dose. If they achieve a 10% increase in peripheral blood H2S concentrations, an additional 13 participants will receive this dose to accrue a total of 19 participants for which a preliminary estimate of PFS6 can be calculated. If the first 6 participants do not achieve a 10% increase in peripheral blood H2S concentrations, the dose will be increased to the second and final dose level of 25 mg/d at which 19 participants will be treated.
223878523|NCT05607407|PROCEDURE|Recurrent Glioblastoma Surgical Resection|The purpose of resection is to remove as much tumor as possible to alleviate mass effect and to obtain brain tissue for experimental analysis.
223878524|NCT05607407|DIAGNOSTIC_TEST|Pharmacodynamic Assays|Pharmacodynamic assays are intended to investigate drug and downstream drug-induced effects.
223878525|NCT05057091|OTHER|Group 1 - Maitland's Posterior-Anterior Central Vertebral Manipulation|For the posterior-anterior unilateral vertebral manipulation, the therapist positioned both thumbs on top of each other on the spinous process of the vertebra and applied an average of 4 kg of discrete pressure
223878526|NCT05057091|OTHER|Group 2- Side-Lying Lumbar Spinal Manipulation|The therapist stood in front of the patient, who was instructed to lie on their side with the painful side facing upward.the therapist utilized their arm and body to apply the manipulation. A high-speed, low-amplitude thrust force was applied in opposite directions: anteriorly to the pelvis and posteriorly to the shoulder.
223878527|NCT06831578|PROCEDURE|seratuse anterior plane block|after patient consenting, induction of anathesia Under sterile conditions, and while the patients will be still on the lateral position with the diseased side up after induction of anesthesia, a linear ultrasound transducer (10-12 MHz) will be placed in a sagittal plane over the mid-clavicular region of the thoracic cage. Then counting down ribs till the seventh rib will be identified in the mid-axillar\]y line. The following muscles will be identified overlying the sixth rib: the latissimus dorsi (superficial and posterior), teres major (superior) and serratus muscle (deep and inferior). The needle (22-G, 50-mm Touhy needle) will be introduced in-plane with respect to the ultrasound probe targeting the plane deep to the serratus anterior muscle . Under continuous ultrasound guidance, 20 ml of 0.25% bupivacaine will be injected then a catheter will be threaded. A continuous infusion of 5 ml/hr of 0.125% bupivacaine will be then started through the catheter.
223878528|NCT06831578|PROCEDURE|paravertebral plane block|after concenting patient, induction of anathesia Paravertebral plan block will be performed while the patient is still in lateral position and a linear ultrasound transducer (10-12 MHz) will be used for ultrasound guidance. A sagittal or transverse image can be obtained at the appropriate vertebral level. After image optimization, the Tuohy needle is advanced in plane until the tip rests in the thoracic paravertebral space. Injection of small amounts of fluid (hydrodissection) will aid in needle tip location. Saline or local anesthetic is injected through the Tuohy needle. The endpoint for a successful block is anterior displacement of the pleura. 20 ml of 0.25% bupivacaine will be injected then a catheter will be threaded. A continuous infusion of 5 ml/hr of 0.125% bupivacaine will be then started through the catheter. The catheter is threaded through the Tuohy needle and its position is confirmed by injecting local anesthetic or small air bubbles. Pleural depression should agai
223878529|NCT06834711|DRUG|N-Acetyl Cysteine|The root canals were irrigated with 3 mL N-acetyl Cysteine (NAC)(200 mg/ml) in N-acetyl Cysteine group in the final irrigation.
223878530|NCT06834711|DRUG|Chlorhexidine|The root canals were irrigated with 3 ml %2 chlorhexidine in chlorhexidin group in the final irrigation.
223878531|NCT05656911|DRUG|Zabedosertib (BAY1834845)|Oral administration, two times a day
223878532|NCT05656911|DRUG|Placebo to zabedosertib (BAY1834845)|Oral administration, two times a day
223878533|NCT06788730|BEHAVIORAL|Transtheoretical Model Based Healthy Internet Use Programme Intervention Supported by Mindfulness Exercise Applied to Adolescents|Transtheoretical Model Based Healthy Internet Use Programme Supported by Mindfulness Exercise will be carried out as one session per week for 8 weeks. The training programme will be carried out by dividing the students into 2 groups (the first group is 18 and the second group is 19 people). The training programme will be applied to the groups two days in the same week at the times determined by the guidance teacher. Interventions will be applied to the intervention group with trainings, homework applications and interventions to increase healthy internet use.
223878534|NCT01229098|DRUG|LEO 80185 (Xamiol® gel/Taclonex® Scalp topical suspension)|LEO 80185 (Taclonex® Scalp topical suspension/Xamiol® gel) Topical suspension applied once daily for up to 8 weeks
223878535|NCT06214351|OTHER|Use of mobile midwifery application|Pregnant women in the experimental group will have a mobile midwifery application installed on their smartphones. The pregnant woman will be able to reach the research midwife 24/7. With the informative content and algorithm mechanism in the application, she will be able to provide individual care and detect early signs of danger, enabling her to seek medical attention.
223878536|NCT06792097|DIAGNOSTIC_TEST|Ga-68 Dolacga PET scan|"Contrast Name: Nuclear Medicine Dolacga (Lyophilized product for the preparation of gallium Ga68 Dolacga injection).~Active Ingredient, Dosage, Route: NOTA-Hexa lactoside (INER038), 40 micrograms, IV injection.~PET Imaging Schedule: Before radiofrequency ablation therapy, one month after ablation therapy, and follow-up every three months thereafter."
223878537|NCT05073302|PROCEDURE|Implantation of Nylon catheter (Device-less sentinel unit)|"Implantation of the Device-Less sentinel units. Ultrasound monitoring will be performed after Device-Less implantation. Standard Islet cell Transplantation: Will occur simultaneously Portal islet transplantation and subcutaneous islet transplantation in the Device-Less sentinel spaces.~Islets are maintained for a minimum of 6 hours up to 72 hours in supplemented CMRL1066-based media until the time of transplant.~Concomitant to portal vein infusion, islet transplantation will occur in all four (4) DL sentinel spaces.~To explant a unit, the Surgeon will make an incision and then carefully dissect the tissue engrafted around the transplant. The entire transplant site and any adherent tissue capsule can then be removed entirely from the pocket."
223878538|NCT06029179|DRUG|sodium zirconium cyclosilicate (SZC)|60 patients will receive sodium zirconium cyclosilicate (SZC) 5 g once daily on non-dialysis days (15 gm/week) for 8 weeks.
223878539|NCT06029179|DRUG|sodium polystyrene sulfonate|60 patients will receive sodium polystyrene sulfonate 15 g once daily on non-dialysis days (45 gm/week) for 8 weeks.
223878540|NCT05650554|BIOLOGICAL|Quadrivalent Influenza mRNA Vaccine MRT5413|"Pharmaceutical Form: Liquid frozen solution in a vial~Route of Administration: Intramuscular injection"
223878541|NCT05650554|BIOLOGICAL|Quadrivalent Recombinant Influenza Vaccine|"Pharmaceutical Form: Liquid frozen solution in a vial~Route of Administration: Intramuscular injection"
223878542|NCT05650554|BIOLOGICAL|Quadrivalent Influenza Standard Dose Vaccine|"Pharmaceutical Form: Liquid suspension for injection in pre-filled syringe~Route of Administration: Intramuscular injection"
223878543|NCT05650554|BIOLOGICAL|Quadrivalent Influenza High-Dose Vaccine|"Pharmaceutical Form: Liquid suspension for injection in pre-filled syringe~Route of Administration: Intramuscular injection"
223878544|NCT02611180|PROCEDURE|Skin punch biopsy|
223878545|NCT02611180|PROCEDURE|Peripheral blood draw|
223878546|NCT06334562|DRUG|SUGAMMADEX SODIUM 100 Mg in 1 mL|The dose of Sugammadex Sodium 100 Mg in 1 mL is 2mg/kg
223878547|NCT06334562|DRUG|Neostigmine|Neostigmine is 50 μg/kg
223878548|NCT05076448|PROCEDURE|Gonadal veins resection|"Gonadal veins resection (GVR) was performed open, transperitoneal and retroperitoneal endoscopic methods under general anesthesia.~Open GVR was performed in the Trendelenburg position, on the back with the operating table rotating 30° The retroperitoneal approach was employed in the left and/or right iliac region. The GV was mobilized for 10-12 cm and the vein was resected..~Transperitoneal GVR was performed with 3 ports were placed: one 10-mm port in the umbilical region, one 5-mm port in the left or right iliac region, and one 5-mm port 5 cm below the umbilicus. The GV was mobilized over a length of 10-12 cm and the vessel was resected.~Retroperitoneal GVR was performed with the patient in a lateral position and in the reverse Trendelenburg position. A 10-mm camera port was installed in the lumbar region between the posterior superior iliac spine and the lower edge of the XII rib. The GV was mobilized over a length of 10-12 cm and the vessel was resected."
223878549|NCT05076448|PROCEDURE|Gonadal vein embolization with coils|"Procedure was performed under local anesthesia with 5.0-10.0 mL of 0.5% lidocaine solution with a patient under intravenous sedation. For the left GV embolization, the transfemoral approach was used, while for the right or both GV embolization, the transjugular approach was used. The vein puncture was performed under ultrasound guidance. The 5F multipurpose angiographic catheters (Cordis; USA), standard 'moving core' J .035 guidewire, and an angled hydrophilic guidewire (Radiofocus; Terumo Corp., Japan) were used. For the GV occlusion, the pushable 0.035 standard stainless steel coils (Gianturco; William Cook, Bjæverskov, Denmark) and 0.035 coils made of Inconel with interwoven long collagen fibrils (MReye; Cook Medical Inc., Bloomington, USA) were used. The diameter of coils was 8-12 mm, and the length was 10-20 cm."
223878550|NCT05076448|PROCEDURE|Endovascular stenting of the common iliac vein (CIV)|"After providing local anesthesia, the left common femoral vein was punctured, a 0.035 guidewire was inserted into the inferior vena cava (IVC), and then a 10F introducer was installed. A balloon catheter was introduced over the guidewire in the left CIV (XXL balloon, Boston Scientific, diameter 14-18, length 40-60 mm), and double balloon dilation of the vessel was performed with a pressure of 6-8 atm. Then, a delivery system was advanced to the area of stenosis in the left CIV, and stent was deployed at the level of confluence of the left CIV and inferior vena cava (IVC) or with a protrusion in the IVC of no more than 1 cm. For better fixation of stent in the venous lumen and prevention of its displacements and migration, a balloon post-dilatation of the stented vessel was performed. In case of residual stenosis, the balloon angioplasty was performed."
223878551|NCT05075408|DRUG|Nemolizumab|Participants received a loading dose of 60 mg nemolizumab at Baseline followed by 2 Subcutaneous (SC) injections for a total dose of 30 mg nemolizumab once every 4 weeks i.e. at Week 4 and Week 8.
223878552|NCT05075408|DRUG|Nemolizumab|Participants received 2 SC injections of 30 mg nemolizumab once every 4 weeks i.e. at Week 4 and Week 8.
223878553|NCT05075408|DRUG|Placebo|Participants received 2 SC injections of 30 mg placebo-matched to nemolizumab once every 4 weeks i.e. at Week 4 and Week 8.
223878554|NCT04142476|OTHER|interview|interviews with patient's pharmacist to motivate in the hormonotherapy's compliance.
223878555|NCT06833827|DEVICE|Catheter-directed thrombectomy (CDT)|The intervention consists of immediate thrombectomy (thrombectomy with any approved device) without systemic/locally administered thrombolysis. Thrombectomy is performed via jugular or femoral venous access according to the instructions for use for the particular device. The catheter is advanced over a preplaced guidewire across the right heart into the pulmonary arteries to the location of proximal thrombus. Procedural therapeutic anticoagulation with heparin is administered. After removal of the dilator, the thrombus is extracted by controlled volume aspiration through an aspiration catheter using a syringe or dedicated aspiration system, with multiple aspirations performed as needed. Procedural objectives will be clearly stated prior to the intervention and patient's clinical and hemodynamic status and residual thrombus will guide the investigators to determine when to terminate the procedure. Treatment success is defined as clear evidence of right ventricular recompensation.
223878556|NCT06833827|DRUG|thrombolysis therapy|Standard reperfusion treatment for high-risk PE patients is thrombolytic therapy, typically consisting of Alteplase, Urokinase, or Tenecteplase, with the idea of accelerated fragmentation of the thrombus by lytic medication given systemically.
223878557|NCT06109766|BEHAVIORAL|Promoting First Relationships|"Promoting First Relationships ® is based on attachment theory and is strengths-based. The 10 week intervention is delivered in the home of the family or over Zoom. Each week has a theme for discussion, handouts, an activity, and time for joining - checking in with the parent, listening to their concerns, and establishing a positive, supportive relationship. The provider videotapes playtime between parent and child, and alternates weeks watching the video with the parent, reflecting about the needs of both parent and child (reflective observation). PFR consultation strategies include Joining, Positive Feedback, Instructive Feedback, Reflective Questions and Comments, and Instruction with Handouts. These core strategies enhance parents' sense of security and competency. The provider helps the parent develop greater empathy and understanding of the child's needs and feelings, and helps the parent to identify their own feelings and needs around parenting."
223878558|NCT06832176|OTHER|CMTS4520 (dietary fiber probiotics)|CMTS4520 is a synbiotic formulation containing a standardized ratio of plant-derived prebiotics and clinically validated probiotic strains. Participants will receive 4 weeks of CMTS4520 daily for chronic constipation.
223878559|NCT06832176|OTHER|Placebo|Capsules with matching volume and consistent appearance to CMTS4520.
223878560|NCT06822179|OTHER|Education for self-management|Education program performed online including information, recommendations and guidance for promoting self-management
223878561|NCT06822179|OTHER|Personalised exercise program|Individualized exercise that includes progressive load adapted to each patient. It includes making flexible adjustments to their exercise (up or down as needed) to help them gradually improve their physical abilities while staying within their energy limits
223878562|NCT06822179|OTHER|Usual Care|Usual care these patients may receive out from the clinical trial.
223878563|NCT06389201|DRUG|HCQ|HCQ, 400-600mg, oral tablet, once, one day before chemotherapy and radiotherapy. During therapy, HCQ maintenance dose is 200-400mg daily.
223878564|NCT06389201|OTHER|Placebo|Placebo, oral tablet, once, one day before chemotherapy and radiotherapy. During therapy, placebo maintenance oral tablet once daily.
223878565|NCT06829992|DEVICE|Kinesio Taping|"KT will be applied by a physiotherapist with experience in the Kinesio Taping method by Kenzo Kase. Three I-shaped Kinesio tapes will be used, 5 cm wide, covering the T-11 and T-12 dermatomes. The first tape will be applied vertically between the navel and pubis, with the participant in an orthostatic position with slight trunk extension.~The second tape, with the same length as the first, will be applied with its central region over the middle zone of the first, perpendicularly. The third tape will be applied horizontally to the lower back, covering the spines posterosuperior iliac muscles, with the participant in an orthostatic position, performing light trunk flexion."
223878566|NCT06829992|DEVICE|Placebo Group|The quantity of tapes, type, size and region of application will be the same as the group KT, however, in this group the tapes will be applied without tension and with procedure different from that recommended, first starting to adhere a side anchor into the skin, followed by the center and then the other side anchor.
223878567|NCT05247242|BEHAVIORAL|Lakeshore Online Fitness (Online)|Online physical activity program delivered to residents of Tarrant, AL via teleconferencing technology to a local community center. Instructors from Lakeshore will lead the physical activity program. This intervention will last six weeks.
223878568|NCT05247242|BEHAVIORAL|Get Active with Virtual Reality (VR)|Participants will utilize the Oculus Quest 2 virtual reality headset, which is a head-mounted display system where users can interact with a virtual environment in a gaming setting. The Oculus Quest 2 incorporates social features where participants can interact with other users. This VR intervention will include periods of gameplay where participants can play games in either competitive or cooperative settings. This intervention will last six weeks.
223878569|NCT06835504|DRUG|Ketamine hydrochloride|Sub-dissociative ketamine, IV
223878570|NCT06835504|DRUG|Morphine sulphate|Morphine, IV
223878571|NCT06784635|BEHAVIORAL|In person|Participant dyads will meet in person for a mock clinical interview, seated at a desk opposite their counterpart. They will be in an office setting. There will be a sham white noise and lamp device placed on the desk.
223878572|NCT06784635|BEHAVIORAL|Online interaction|Participant dyads will meet online in a mock clinical interview, via an encrypted video call, seated at a desk. They will be in an office setting. There will be a sham white noise and lamp device placed on the desk.
223878573|NCT05779228|BEHAVIORAL|Mode Switching Training|Wear of colored lenses for 1 hr, 5 times per day, for 5 days
223878574|NCT05340998|PROCEDURE|Transradial access for percutaneous coronary procedures|Transradial approach for percutaneous coronary procedures. The modality of radial puncture (needle vs cannula), the choice of radial sheath (long vs short; hydrophilic vs non hydrophilic), the type of catheters employed, the use of spasmolytic agents and the choice of secondary vascular access will be left to the operator discretion
223878575|NCT06788041|OTHER|Hamman experience|There will be a circuit in the Hammam Al Andalus baths with baths in all pools (warm, hot or cold water) and sauna for 30 minutes. The time in each pool will be determined by the sensation and tolerance of each participant. In addition, participants will receive foam with aromatic oils on the participant's body (arms, trunk and legs). This foam will be left for about 10 minutes on the participant's body, while a manual body therapy is performed. The force to be applied will be very weak, a superficial rubbing will be performed to prepare the tissue, followed by a maintained pressure and then sliding pressures are performed. The application time should not exceed 15 minutes.
223878576|NCT06788041|OTHER|Massage|Duration of 45 minutes. A complete dorsal and ventral body massage will be performed, with superficial maneuvers at a slow pace of traditional massage.
223878577|NCT06788041|OTHER|Placebo Comparator|The person will be instructed to stay for 45 minutes during which he/she will receive different electrotherapy techniques with the devices disconnected, a mobile device that simulates a beep will be placed so that the patient believes that the device is connected.
223878578|NCT06785649|OTHER|Lavender herbal tea|The participant will be allocated 14 pieces of lavender tea bags consisting of 2 grams and originating from Turkey. During 14 days, the participant will be advised to use 2 g of lavender herb brewed in 300 mL hot water for 10-15 minutes in the morning and evening. Participants will be able to use 1 lavender tea bag twice a day.
223878579|NCT06784206|DRUG|Adebrelimab Maintenance Therapy After Concurrent Chemoradiotherapy with Hyperfractionated Radiotherapy|"Chemotherapy:~Etoposide will be administered intravenously at a dose of 100 mg/m² on days 1 to 3 of each cycle. Cisplatin will be given at a dose of 75 mg/m² on day 1 of each cycle. The treatment will be repeated every 3 weeks for a total of 4 cycles.~Concurrent Radiotherapy:~Chest radiotherapy will be initiated concurrently with the first 3 cycles of chemotherapy. The total dose of radiotherapy will be 54 Gy, delivered in 30 fractions, with 2 fractions per day.~Prophylactic Cranial Irradiation (PCI):~For patients who achieve a partial response (PR) or complete response (CR) after chemoradiotherapy, PCI will be administered 3 to 4 weeks after the completion of chemoradiotherapy. The dose for PCI will be 25 Gy in 10 fractions.~Adebrelimab Maintenance Therapy:~Following PCI, patients will receive maintenance therapy with Adebrelimab. The dose will be 1200 mg administered intravenously on day 1 of each cycle. The treatment will be repeated every 3 weeks until disease progression, death"
223878580|NCT06785142|DIETARY_SUPPLEMENT|Functional Shot|60ml functional energy shot contained a proprietary blend of L-theanine, chamomile, lemon balm, ginseng and vitamins
223878581|NCT06785142|DIETARY_SUPPLEMENT|Placebo Shot|Placebo 60 ml Shot, matched in volume, taste and colour and but did not contain any active ingredients
223878582|NCT06397963|BIOLOGICAL|GT307 injection|GT307 injection to treat solid tumours
223878583|NCT06792370|DIETARY_SUPPLEMENT|ready-to-use therapeutic food (for children with MAM)|Each child with MAM will be supplemented with RUTF for a maximum of 12 weeks. He/she will be followed subsequently up to 24 weeks.
223878584|NCT06792370|DIETARY_SUPPLEMENT|Ready-to-use supplementary food|Each child with MAM will be supplemented with RUSF for a maximum of 12 weeks. He/she will be followed subsequently up to 24 weeks post recovery
223878585|NCT06792370|DIETARY_SUPPLEMENT|Ready to Use Therapeutic Food - Reduced dose 1|Each child with SAM will be treated with a reduced dose for a maximum of 12 weeks : dose of 150-185 kcal/kg/day of RUTF until programmatic recovery. He/she will be followed subsequently up to 24 weeks post recovery.
223878586|NCT06792370|DIETARY_SUPPLEMENT|Ready to Use Therapeutic Food - Standard dose|Each child with SAM will be treated with a standard dose (according to the national protocol for the integrated management of acute malnutrition in Burkina Faso) for a maximum of 12 weeks. He/she will be followed subsequently up to 24 weeks post recovery.
223878587|NCT06792370|DIETARY_SUPPLEMENT|Ready to Use Therapeutic Food - Reduced dose 2|Each child with SAM will be treated with a reduced dose for a maximum of 12 weeks : dose of 150-185 kcal/kg/day of RUTF until the child is no longer severely malnourished and does not have nutritional oedema then 100-130 kcal/kg/day of RUTF until programmatic recovery. He/she will be followed subsequently up to 24 weeks post recovery.
223878588|NCT06791642|DEVICE|Laparoscopic Parastomal Hernia Repair Using the Sandwich Technique|"The sandwich technique was performed laparoscopically according to minimally invasive principles. Pneumoperitoneum was typically established using a Veress needle if the subcostal region was free from previous surgical scarring. For patients with prior extensive abdominal surgeries, a small laparotomy was performed to place the first 10-mm trocar directly under vision, ensuring safe entry into the peritoneal cavity. A 30° laparoscope was used throughout the procedure for enhanced visualization of the operative field.~Trocar placement was designed to optimize access and ergonomics. The primary trocar was placed either in the periumbilical region or in the left or right flank, depending on the patient's anatomy and stoma location. Mesh used:1. Parietex™ Composite Mesh (Medtronic, USA): A multifilament polyester mesh with an anti-adhesive collagen barrier to minimize visceral adhesions."
223878589|NCT06791642|DEVICE|Laparoscopic Parastomal Hernia Repair Using the Sandwich Technique|"The sandwich technique was performed laparoscopically according to minimally invasive principles. Pneumoperitoneum was typically established using a Veress needle if the subcostal region was free from previous surgical scarring. For patients with prior extensive abdominal surgeries, a small laparotomy was performed to place the first 10-mm trocar directly under vision, ensuring safe entry into the peritoneal cavity. A 30° laparoscope was used throughout the procedure for enhanced visualization of the operative field.~Trocar placement was designed to optimize access and ergonomics. The primary trocar was placed either in the periumbilical region or in the left or right flank, depending on the patient's anatomy and stoma location. Mesh use Synecor™ Hybrid Mesh (BD, USA): A macroporous mesh combining polypropylene with a bioresorbable layer that degrades over time, leaving a durable support structure to promote tissue integration."
223878590|NCT06833658|OTHER|Experimental: Aromatherapy with essential oil intervention|Aromatherapy, customized to meet the psychological needs of pancreatic cancer patients, was employed as part of the intervention. A senior aromatherapist developed the protocol, selecting pleasant essential oils diluted at a ratio of 1-2 drops in 70ml of water. The aromatherapy was administered twice daily for one hour each session using an aromatherapy diffuser.During aromatherapy, nurses should inspect patients every 30 minutes to ensure comfort, and take immediate action if discomfort is reported.
223878591|NCT06833658|OTHER|Control Group 0.9% Isotonic Saline|1\. Pre - operation: Present pancreatic cancer knowledge, such as causes, common symptoms, treatment methods, and the need for surgery. Answer patients' queries promptly to reduce their fear of the disease and surgery. 2. Post - operation: Report the surgical outcome, explain common post - op complications and solutions to relieve negative emotions. 3. Post - operation: Intensify post - op education on drainage tube care, activity guidelines, disease knowledge, and diet advice. Strengthen mental health education, encourage family members to show more concern for patients, and enhance family support. 4. Pre - discharge: Provide discharge instructions to patients and their families. Guide patients who need tube removal and suture removal after discharge to make online appointments for outpatient follow - up.
223878592|NCT04747314|DRUG|Antidepressant|"The antidepressant treatment utilizes antidepressant medication to improve pain, function, and depression outcomes.~The Antidepressant Treatment History Form (ATHF) will be used to assess adequacy of any prior antidepressant medication treatment and to assist the decision regarding which antidepressant to start. A medication flowchart will help serve as a guideline throughout the drug selection and dosing determination. Weekly assessments completed by subjects will help determine response, tolerability, and necessity for dose adjustment or medication change."
223878593|NCT04747314|OTHER|Enhanced Fear Avoidance Rehabilitation|The EFAR treatment utilizes physical therapy, pain education, and motivational messaging to improve pain, function, and depression outcomes. Subjects will engage in gradual exposure to exercises and activities they are apprehensive about, such as standing to wash dishes.
223878594|NCT06833723|OTHER|Retrospective Data Collection and Analysis|This is a retrospective study involving the collection and analysis of existing clinical data from breast cancer patients who received immunotherapy or neoadjuvant immunotherapy between January 1, 2015, and September 30, 2023. No new interventions are administered as part of this study. The data includes diagnostic puncture tissue, residual tumor tissue post-surgery, blood samples, and imaging data. These samples are analyzed using multi-omics approaches (proteomics, transcriptomics, metabolomics) and advanced imaging techniques (imaging mass cytometry and spatial transcriptomics) to build a predictive model for immunotherapy efficacy.
223878595|NCT06830408|DRUG|radionuclide therapy with 177Lu-PSMA-I&T|Standard PSMA RLT with 7-8 GBq i.v. infusion of 177Lu-PSMA-I\&T performed every 6-8 weeks for 4-6 cycles, or until progression or complete response.
223878596|NCT06831955|OTHER|Exercise Therapy|The exercise regimen consists of a non-linear aerobic exercise program of 3-4 sessions per week. During days of FMD no exercise will be prescribed.
223878597|NCT06831955|DIETARY_SUPPLEMENT|Fasting-Mimicking Diet|The FMD is a plant-based, low-carbohydrate, low-caloric diet of 4 days , with the fourth day being the day of chemo/immunotherapy. A total of 6 FMD cycles will be administered over the treatment period of 20 weeks.
223878598|NCT06831955|DRUG|SOC|Four cycles of an intravenous infusion of pembrolizumab (200 mg) once every 3 weeks plus paclitaxel (80 mg per square meter of body-surface area once weekly) plus carboplatin (at a dose based on an area under the concentration-time curve of 1.5 mg per milliliter per minute) once weekly in the first 12 weeks, followed by four cycles of epirubicin (90 mg per square meter) plus cyclophosphamide (600 mg per square meter) once every 2 weeks plus pembrolizumab 400mg every 6 weeks or pembrolizumab 200mg every 3 weeks in the subsequent 8 weeks.
223878599|NCT06155292|BEHAVIORAL|Standard Communication Email|This is a standard quarterly email communication without personalized performance metrics.
223878600|NCT06155292|BEHAVIORAL|Personalized Report Card Email|This personalized information about physician performance replaces the standard communication email to provide personalized feedback to physicians.
223878601|NCT06155292|BEHAVIORAL|Bottom-Up Framing|"The bottom-up framing is added onto the personalized communication email to provide insight on how the PCCE program was informed by physician feedback.~The bottom-up framing is added onto the survey communication to provide insight on how the PCCE program was informed by physician feedback."
223878602|NCT06790433|DEVICE|Vibraject|The needle was advanced into the tissue until it was estimated to be over the root apex while remaining parallel to the tooth's long axis. The Vibraject was activated after aspiration to deposit the solution slowly at approximately 50 seconds. Following cartridge deposition, the operator adjusted the participant to an upright seated position
223878603|NCT06790433|DEVICE|Dentapen|The needle was advanced into the tissue until it was estimated to be over the root apex while remaining parallel to the tooth's long axis (needle placement). The Dentapen was activated after aspiration to deposit the solution at a medium rate (1 mL/60 s) using the ramp-up mode. Following cartridge deposition, the operator adjusted the participant to an upright seated position
223878604|NCT05860816|OTHER|Survey|Survey aimed at finding out the barriers and facilitators that Spanish primary care physiotherapists have to implement pain neuroscience-based education programmes in patients with chronic pain.
223878605|NCT06791824|BIOLOGICAL|CM313(SC) injection|Phase IB: CM313(SC) administered at low dose according to the protocol. Phase II: CM313(SC) administered at different doses based on Phase IB's results.
223878606|NCT06791824|BIOLOGICAL|CM313(SC) injection|Phase IB: CM313(SC) administered at medium dose according to the protocol. Phase II: CM313(SC) administered at different doses based on Phase IB's results.
223878607|NCT06791824|BIOLOGICAL|CM313(SC) injection|Phase IB: CM313(SC) administered at high dose according to the protocol. Phase II: CM313(SC) administered at different doses based on Phase IB's results.
223878608|NCT06783790|DRUG|Avapritinib, azacitidine, Venetoclax|"A: Induction therapy period: After patients were screened and enrolled, they began to receive 1-2 cycles of induction therapy, and the specific administration regimen was as follows: Avapritinib 100mg po qd D1-D14, azacitidine 35mg/m2 ih D1-D5, Venetoclax 100mg po qd D1-D14. The 28-day cycle was followed by curative effect evaluation at the end of each cycle. Patients who achieved complete remission entered the consolidation treatment stage.~B: Consolidation therapy period: Patients who achieved complete remission after 1-2 cycles of induction therapy continued to receive avapritinib 100mg/d po. monotherapy for consolidation therapy, with a cycle of 28 days and a total of 4 cycles"
223878609|NCT06792214|DRUG|Nirmatrelvir/ritonavir|Paxlovid PO BID for 5 days + standard of care
223878610|NCT06792214|DRUG|Remdesivir|Veklury IV daily for 5 days + standard of care
223878611|NCT06787014|OTHER|Histopathological review|Histopathological review
223878612|NCT06835114|PROCEDURE|CABG|CABG
223878613|NCT06835114|PROCEDURE|LIMA on lay patch|Left internal mammary artery harvesting with on lay patch on left anterior descending coronary artery
223878614|NCT06835114|PROCEDURE|Safenous vein patch|Safenous vein patch on left anterior descending artery
223878615|NCT05977712|OTHER|Questionnaire|The questionnaire includes information on socio-demographics (age, sex, education, occupation, marital status), behavioural (smoking, alcohol consumption, social functioning), and health-related factors (morbidities, treatment, sleep disturbance, eye diseases, frailty, falls).
223878616|NCT05977712|OTHER|Clinical examination|This includes earing test, cognitive tests (mini-mental status examination, MemScreen), body mass index, waist circumference, blood pressure and blood tests (biomarkers of Alzheimer's disease, neurodegeneration, and other dementias).
223878617|NCT05977712|OTHER|Accelerometer port|Participants will be wearing an accelerometer for 9 days.
223878618|NCT05977712|OTHER|Eye examination|Eye fundus photo, OCT and OCT-A exams
223878619|NCT05371587|OTHER|Autonomy and Perceptions Approach to Resistance Training (APART)|Alternative resistance training prescription based on trainees' autonomy and perceptions.
223878620|NCT05371587|OTHER|Standard prescription|Standard resistance training prescription, based on international organization's guidelines.
223878621|NCT02837510|BEHAVIORAL|Standard smoking cessation counseling|Participants will discuss reasons for quitting, the model of smoking as a learned habit, triggers for smoking, and trigger management; receive brief training in how to manage withdrawal symptoms and relapse prevention counseling and receive the NCI Clearing the Air self-help smoking cessation booklet. The target quit date (TQD) session will be scheduled to occur up to 2 weeks following the pre-quit session. Participants will then meet with a smoking cessation counselor for a 15 minute booster counseling session. During the first week following TQD there will be two monitoring visits to closely monitor abstinence. Weekly thereafter for four weeks, participants will attend a brief booster counseling session.
223878622|NCT03188796|DRUG|Cholecalciferol|oral/enteral loading dose of 37.5 ml MCT including 540,000 IU vitamin D3 followed by 10 drops daily (4000 IU) for 90 days
223878623|NCT03188796|DRUG|Placebo|oral/enteral loading dose of 37.5 ml MCT followed by 10 drops daily for 90 days
223878624|NCT06272435|DIETARY_SUPPLEMENT|Multiplier|Subjects will consume 1 Liter (2 servings) of commercially available Hydration Multiplier product at a rate of 250 milliliters per 7.5 minutes.
223878625|NCT06272435|DIETARY_SUPPLEMENT|Sugar Free|Subjects will consume 1 Liter (2 servings) of experimental Sugar Free Hydration Multiplier product at a rate of 250 milliliters per 7.5 minutes.
223878626|NCT06272435|DIETARY_SUPPLEMENT|Sugar Free with Amino Acids|Subjects will consume 1 Liter (2 servings) of commercially available Sugar Free Hydration Multiplier product that contains amino acids at a rate of 250 milliliters per 7.5 minutes.
223878627|NCT06272435|DIETARY_SUPPLEMENT|Water|Subjects will consume 1 Liter of water at a rate of 250 milliliters per 7.5 minutes.
223878628|NCT05849168|BEHAVIORAL|Exercise training|Participants will complete a 12-week exercise training program. The program consists of 3x/week HIIT sessions on an upright stationary bicycle (\~40 minutes each) and 3x/week home aerobic sessions (any type of aerobic exercise; 45 minutes each).
223878629|NCT04740775|DEVICE|LiquiBand Exceed|Cyanoacrylate glue for closure of surgical wounds
223878630|NCT04740775|DEVICE|LiquiBand Rapid|Cyanoacrylate glue for closure of surgical wounds
223878631|NCT04070560|PROCEDURE|Intact cord (≥ 180 seconds) resuscitation|Resuscitation performed in near proximity to the mother with umbilical cord uncut
223878632|NCT04070560|PROCEDURE|Early (≤ 60 seconds) cord clamping|Resuscitation performed at a designated area after umbilical cord is cut
223878633|NCT06292988|PROCEDURE|Total Thyroidectomy|Total thyroidectomy
223878634|NCT05411744|DRUG|1 month Rifapentine, Isoniazid and Vitamin B6|Participants will be treated with one month (4 weeks) of daily Isoniazid, Rifapentine and Vitamin B6.
223878635|NCT06393699|PROCEDURE|composite restoration|different types of resin composite restorations will be used to restore NCCL
223878636|NCT04345016|DEVICE|Once-daily remote foot temperature monitoring|Participants were provided a once-daily remote foot temperature monitoring mat (Podimetrics SmartMat; Podimetrics Inc., Somerville MA) which they used for one year or until dying, dropping out of the study, or disenrolling at a member of the health plan administering the study.
223878637|NCT05419505|DRUG|CCH-aaes|Administered by subcutaneous injection.
223878638|NCT05419505|DRUG|Antifibrinolytic Agent|Self-administered by participants enrolled in Cohort 7.
223878639|NCT05113264|DEVICE|'Penny' via Memora Platform|"The overall objective of this study is to evaluate the feasibility and safety of a novel SMS text- based intervention of an Algorithmically Driven Augmented Intelligence chatbot, Penny. This chat bot will walk patients through how and when to take their oral chemotherapies, as well as provide real-time management of side effects Grade II or less, and escalate to the clinical team side effects of Grade III or more, as based on the Common Terminology Criteria for Adverse Events (CTCAE), for patients that have a gastrointestinal (GI) cancer."
223878640|NCT06025994|OTHER|MULTI-DOMAIN LIFESTILE INTERVENTION|All participants in the multi-domain lifestyle group will receive five different kinds of intervention: i) strict management of CV and metabolic risk factors, ii) tailoring of medical therapy on the basis of the invasive assessment of CMD and coronary vasomotion, iii) exercise training iv) dietary counselling, v) psychological intervention.
223878641|NCT03172624|DRUG|Nivolumab|nivolumab 3 mg/kg every 2 weeks
223878642|NCT03172624|DRUG|Ipilimumab|ipilimumab 1 mg/kg every 6 weeks (1 cycle= 6 weeks)
223878643|NCT05683392|DEVICE|t:slim X2 insulin pump with Control-IQ technology 2.0|t:slim X2 insulin pump with Control-IQ technology 2.0, and wearing the Dexcom G6 sensor.
223878644|NCT03503344|DRUG|Apalutamide|Given PO, 240 mg per day (4 x 60mg tablets)
223878645|NCT03503344|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
223878646|NCT02780388|DRUG|VIB4920|Participants will receive a single IV dose of VIB4920 Q2W from Day 1 up to 12 weeks.
223878647|NCT02780388|OTHER|Placebo|Participants will receive a single IV dose of placebo matched to VIB4920 Q2W from Day 1 up to 12 weeks.
223878648|NCT02705287|OTHER|Vitamin D dynamics-pregnant|tracer dose of deuterated vitamin D3
223878649|NCT02705287|OTHER|Vitamin D dynamics-nonpregnant|tracer dose of deuterated vitamin D3
223878650|NCT05041556|OTHER|Case-control study of clinical outcomes|A case-control questionnaire will be administered at the home of cases and controls
223878651|NCT05041556|OTHER|Case-control study of mortality outcome|A case-control questionnaire will be administered at the home of cases and controls
223878652|NCT06818019|DRUG|Stopping dupilumab|Stopping dupilumab with no dose-reducing or interval of time-increasing strategy
223878653|NCT06846580|PROCEDURE|brachiobasilic AVF|perform 2 stage brachiobasilic AVF in hemodialysis patients with central venous stenosis
223878654|NCT04975087|OTHER|Patients group|Patients will complete the mentioned questionnaires.
223878656|NCT06440577|BEHAVIORAL|Audio-visual stimuli (Neutral-Relaxing)|Audio instruction for participant to allow themselves to experience their feelings followed by 3-min passive viewing of images of neutral everyday objects (e.g., tools, dirt) and their use (construction, gardening).
223878657|NCT06440577|BEHAVIORAL|Audio-visual stimuli (Drug)|Audio instruction for participant to allow themselves to experience their feelings followed by 3-min passive viewing of images of drug paraphernalia (e.g., syringe, tourniquet, heroin) and preparation.
223878658|NCT06440577|BEHAVIORAL|Audio-visual stimuli (Non-Food)|Audio instruction for participant to focus their attention on the experimenter followed by 3-min audio-guided viewing of the experimenter opening/unwrapping an everyday object (e.g., box of crayons) and taking out its contents.
223878659|NCT06440577|BEHAVIORAL|Audio-visual stimuli (Food)|Audio instruction for participant to focus their attention on the experimenter followed by 3-min audio-guided viewing of the experimenter opening/unwrapping a snack (e.g., chocolate bar, bag of chips) and taking out its contents.
223878660|NCT01615393|DRUG|ribavirin [Copegus]|Single oral dose of 400 mg tablets
223878661|NCT01615393|DRUG|ribavirin [Vilona]|Single oral dose of a 400 mg capsule
223878662|NCT03424499|PROCEDURE|Single-use catheter|Each urethral catheterization will be done with a new sterile catheter in a period of 8 weeks. Frequency of urethral catheterization will depend of the conditions of each patient (from 3-5 per day). Patients and parents were instructed to use clean technique by hand washing with water and soup, and penis/vulva cleansing with antiseptic wipes. Researchers reinforced the intermittent catheterization technique before the trial.
223878663|NCT03424499|PROCEDURE|Reused catheter|Each catheter is programmed to last 1 week. Evaluation will last a period of 8 weeks. Frequency of urethral catheterization will depend of the conditions of each patient (from 3-5 per day). after catheterization. Each catheter was programmed to last a week. Patients and parents were instructed to use clean technique by hand washing with water and soup, and penis/vulva cleansing with antiseptic wipes. Researchers reinforced the intermittent catheterization technique before the trial.
223878664|NCT03424499|DIAGNOSTIC_TEST|Urine culture|A midstream urine sample will be obtained using sterile catheterization for urine culture performed by health provider. Urine cultures will be done in days 0, 7, 14, 28, 42 and 56.
223878665|NCT04930406|OTHER|Physical therapy|Had to receive 10 or more visits of physical therapy during the cancer treatment period to qualify for intervention group.
223878666|NCT02058108|DRUG|Telbivudine|Patients of any age and weight\< 30kg: telbivudine oral solution (20 mg/mL): 20 mg/kg up to 600 mg q.d corresponding to weight (kg) x1mL, p.o. once daily Patients \< 12 years old and weight≥ 30kg: telbivudine oral solution (20mg/mL), 600 mg/day corresponding to 30 mL p.o. once daily Patients ≥ 12 years old and weight ≥ 30kg: telbivudine film-coated tablet, 600 mg/day, corresponding to 1 tablet p.o. once daily
223878667|NCT02058108|DRUG|Placebo|Patients of any age and weight \< 30kg: placebo oral solution corresponding to weight (kg) x1mL, p.o. once daily Patients \< 12 years old and weight ≥ 30kg: placebo oral solution corresponding to 30 mL p.o. once daily Patients ≥ 12 years old and weight ≥ 30kg: placebo tablet, corresponding to 1 tablet p.o. once daily
223878668|NCT01154192|DRUG|Dexamethasone|Each subject in each group will receive 1 mg of oral dexamethasone in the evening and return in the morning for an injection of 25ug of IV recombinant human chorionic gonadotropin. Subjects will also have blood drawn at times -0.5, 0, 0.5, and 24 hours after the injection of r-hCG for measurement of steroid hormones.
223878669|NCT01154192|DRUG|recombinant human chorionic gonadotropin (r-hCG)|Each subject in each group will receive 1 mg of oral dexamethasone in the evening and return in the morning for an injection of 25ug of IV recombinant human chorionic gonadotropin (r-hCG). Subjects will also have blood drawn at times -0.5, 0, 0.5, and 24 hours after the injection of r-hCG for measurement of steroid hormones.
223878670|NCT03746613|DEVICE|HEARO|Robotic system for otological procedures
223878671|NCT02380105|BEHAVIORAL|Counseling|Patients were informed of their condition and possible etiological factors contributing to the pathology. They were also educated about the postural rest position of the mandible and instructed to perform bilateral chewing and not overload the temporomandibular joint and masticatory muscles. Techniques to relieve pain and tension were taught to correct postural habits, food and sleep irregularities. The patients received written instructions for future reference, as a way of reinforcing the information provided during the initial consultation.
223878672|NCT02380105|DEVICE|Interocclusal Appliances|Patients were treated using interocclusal appliances
223878673|NCT04759833|DRUG|Prucalopride|Prucalopride oral solution or oral tablets.
223878674|NCT04759833|OTHER|Placebo|Prucalopride-matching placebo oral solution or oral tablets.
223878675|NCT05672095|PROCEDURE|Biopsy|Undergo needle or core biopsy
223878676|NCT05672095|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223878677|NCT05672095|DRUG|Niraparib|Given PO
223878678|NCT05672095|OTHER|Questionnaire Administration|Ancillary studies
223878679|NCT05672095|DIETARY_SUPPLEMENT|Selenium|Given IV
223878680|NCT04711135|DRUG|Lutetium [177Lu] oxodotreotide/dotatate|Radiopharmaceutical solution for infusion (7.4 GBq of Lutathera per 30 ml vial)
223878681|NCT06253858|DEVICE|Catheter Placement with Solopass System|This device is used as a guidance for placing a brain catheter to target the brain ventricles and decrease multiple brain passes, incorrect deployment and malfunctioning of the drain.
223878682|NCT02191085|PROCEDURE|Fast Track|"In the Fast Track arm, an ACP will perform the initial assessment and will determine the management plan with the patient. To ensure patient safety, the management plan will be discussed with a sleep respirologist, who will be designated as the patient's primary sleep physician. This sleep physician will be available at the FMC Sleep Centre during the Fast Track clinic to assist with the assessment of patients who appear unwell. As in the Standard Management arm, follow-up visits to review test results, discuss and initiate treatment, or to assess treatment response may occur with the ACP who performed the initial assessment or may be delegated to any other ACP."
223878683|NCT03708627|DRUG|Bimatoprost Ophthalmic|Bimatoprost, aka Lumigan, one drop in one eye nightly
223878684|NCT02686528|OTHER|Hip Precautions|Hip precautions are functional limitations of the hip replacement prescribed to patients for the first six weeks after surgery and are no hip flexion past 90º, no crossing the legs, and no twisting at the waist.
223878685|NCT02686528|OTHER|No Hip Precautions|Patients will not be prescribed hip precautions in the first 6 weeks after surgery. The hip precautions that will no longer be prescribed are: no hip flexion past 90º, no crossing the legs, and no twisting at the waist.
223878686|NCT05903495|DEVICE|Deep Brain Stimulation|randomized, sham-controlled, partial crossover study investigating DBS, targeting the nucleus accumbens (NAc) and ventral internal capsule (VC), for participants with severe, treatment refractory OUD.
223878687|NCT03594396|DRUG|Olaparib|Olaparib 300mg bid will be given on days 1-28 days without rest.
223878688|NCT03594396|DRUG|Durvalumab|A fixed dose of durvalumab 1500 mg is given via IV infusion on Day 15.
223878689|NCT01875744|DRUG|Polyethylene glycol 4000|
223878690|NCT03593733|OTHER|Photobiomodulation Therapy|Photobiomodulation Therapy
223878691|NCT03593733|OTHER|Cold Water Immersion|Cold Water Immersion
223878692|NCT01077986|DRUG|Capecitabine|Capecitabine will be administered for 14 days in a 3 weekly cycle, starting on day 8.
223878693|NCT01077986|DRUG|Cetuximab|Cetuximab will be administered weekly, starting at day 8.
223878694|NCT01077986|DRUG|Everolimus|Everolimus will be administered daily, starting on day 1.
223878695|NCT03953001|DEVICE|Adminstration Technique using Buzzy external distractor|External application of Buzzy distractor during administration of dental anesthetic
223878696|NCT03953001|DRUG|2% Lidocaine with 1:50,000 epinephrine|Local Dental anesthetic infiltration
223878697|NCT03953001|DRUG|Topical Anesthetic|20% Benzocaine gel was applied on the area of infiltration
223878698|NCT02621086|DIETARY_SUPPLEMENT|Cellodextrin|Gastrointestinal tolerability of single ascending doses of Cellodextrins
223878699|NCT00998881|DRUG|Teneligliptin 20 mg|
223878700|NCT00998881|DRUG|Placebo|
223878702|NCT05293808|DRUG|aspirin 100 mg bis in die|Patient will be randomized and after 10 days and 30 days we will measure platelets aggregation.
223878703|NCT05293808|DRUG|aspririn 200 mg once daily|Patient will be randomized and after 10 days and 30 days we will measure platelets aggregation.
223878704|NCT05293808|DRUG|aspirin 100 mg once daily|Patient will be randomized and after 10 days and 30 days we will measure platelets aggregation.
223878705|NCT00818246|DEVICE|Sham light|
223878706|NCT00818246|DEVICE|LumiPhase-R™, OPUSMED Inc. Montreal, Canada|660 nm wavelength delivered in a sequential pulsing mode
223878707|NCT01896310|DEVICE|probe-based confocal laser endomicroscopy|all patients will receive pCLE examination
223878708|NCT03083067|DRUG|Budesonide/formoterol|On the foundation of basic treatment strategies, inhaled budesonide/formoterol（160ug/4.5ug）will be used as an intervention drug for patients in PIC group. When air quality index (AQI) is above 200, they will temporary add one inhalation of budesonide/formoterol（160ug/4.5ug）twice a day until the third day after AQI drops below 200.
223878709|NCT03083067|DRUG|tiotropium bromide|Inhaled tiotropium bromide(18ug) will be used as routine medicine according to doctor's advice.
223878710|NCT03372070|DEVICE|cNEP|soft silicon collar applied to anterior neck with negative pressure
223878711|NCT01121991|DRUG|Recombinant Human-Luteinizing Hormone (Luveris)|Recombinant Human-Luteinizing Hormone (Luveris) was administered once daily subcutaneously at a starting dose of 150 IU per day beginning on stimulation Day 6.
223878712|NCT01104675|DRUG|ENMD-2076|275 mg (or 250 mg for BSA \< 1.65) per day in oral capsules in 28 day continuous cycles
223878713|NCT01629316|BEHAVIORAL|Text reminders, counseling, and link coordination|This is an intervention with text reminders, counseling that involves motivational interviewing, and link coordination
223878714|NCT01629316|BEHAVIORAL|Standard of care - control arm|The control arm is standard of care for each subject.
223878715|NCT05439395|DEVICE|Sternum Closure after Cardiac Surgery|Sternal closure using Steelex® Sternum Set after CABG or cardiac valve replacement / reconstruction.
223878716|NCT01409824|OTHER|CDSS|Clinical Decision Support System
223878717|NCT00692042|DRUG|AZD1704|One dose, by mouth
223878718|NCT04680767|DRUG|LY3502970|Administered orally.
223878719|NCT04680767|DRUG|[¹⁴C]-LY3502970|Administered orally.
223878720|NCT00409838|DRUG|Abatacept|Intravenous (IV) solution, - weight tiered (500 mg \<60 kg); (750 mg 60-100 kg); (1 gram \> 100 kg), Day 1, Day 15, Day 29; every 28 days thereafter, 6 months
223878721|NCT00409838|DRUG|Methotrexate|Tablets, Oral, ≥ 15 mg, weekly, 6 months
223878722|NCT00409838|DRUG|Placebo|IV solution, Intravenous, D5W, Day 1, Day 15, Day 29; every 28 days thereafter, 6 months
223878723|NCT00409838|DRUG|Abatacept|Solution, intravenous, 10 mg/kg, every 28 days
223878724|NCT00409838|DRUG|Methotrexate|Tablets, oral, 15 mg weekly to be adjusted according to patient condition
223878725|NCT04498234|PROCEDURE|ultrasound guided erector spinae plane block with bupivacaine 0.25% And ultrasound guided Paraveretebral block with bupivacaine 0.25 %|One groupvwill receive 0.25% bupivacaine (20 ml ) into interfascial plane below erector spinae muscle at level of T4 and the other group willreceive (0.3 ml /kg ) 0.25% bubivicaine divided equially at each level of T2 , T4 and T6 at thoracic paravertebral space .
223878726|NCT02847715|DEVICE|ePRIME|ePRIME is an remote monitoring pathway that includes an online system for patients to self-report symptoms and AE following cancer treatments. ePRIME allows AE reporting from home and enables patient reported data to be integrated into existing EPR to allow for the reports to be used in routine care. In addition the system is capable of generating alerts for serious symptoms to the relevant clinical team and providing patient advice on managing mild and moderate symptoms.
223878727|NCT01619410|BIOLOGICAL|Linezolid|Linezolid 600 mg every 12 hours for 7 days
223878728|NCT01619410|BIOLOGICAL|Clindamycin|Clindamycin 300 mg po every 6 hours for 7 days
223878729|NCT03399604|DRUG|LIQ861 Inhaled Treprostinil|LIQ861 bulk powder is generated from a treprostinil/excipient matrix from which particles of precise size and shape are created and filled into a hydroxypropyl methylcellulose (HPMC) capsule (size 3). LIQ861 capsules are provided in capsule strengths of 25 μg, 50 μg, 75 μg and 100 μg treprostinil.
223878730|NCT00143949|DRUG|enalapril|
223878731|NCT00143949|DRUG|losartan|
223878732|NCT05957731|OTHER|Routine physical therapy|Both groups received routine physical therapy, which encompasses various components such as electrotherapy, strength training for both lower and upper limbs, gait training, and occupational therapy.
223878733|NCT05957731|OTHER|antagonist contract relax|antagonist contraction i used to improve spasticity and range of motion in stroke patients
223878734|NCT05957731|OTHER|agonist contract relax|agonist contraction is used to improve spasticity and range of motion in stroke patients
223878735|NCT01864889|BIOLOGICAL|anti-CD19-CAR vector-transduced T cells|genetically engineered lymphocyte therapy
223878736|NCT04396782|OTHER|Physioterapy rehabilitation with IVR|This program includes: static bicycle with virtual reality glasses, analytical lower limb exercises, global lower limb exerciseswith virtual reality glasses and activities to be done at home.
223878737|NCT04396782|OTHER|standard physiotherapy rehabilitation|"static bicycle, analytical lower limb exercises, global lower limb exercises and activities to be done at home.~This group will perform only five minutes of virtual reality play, but will not use their lower limbs. This way, the results of rehabilitation will not be affected and therapists and patients will be blinded."
223878738|NCT02011854|DEVICE|rehabilitation|rehabilitation,To treat five times a week,Total course is eight weeks
223878739|NCT02011854|DEVICE|Acupuncture|
223878740|NCT06284642|DRUG|Urokinase|On the basis of standard treatment for severe neurological conditions, within 24 hours of aneurysm treatment, lumbar drainage combined with intrathecal urokinase injection was started. 30,000 IU urokinase dissolved in 3 ml normal saline was injected into the subarachnoid space, 3 ml normal saline was rinsed into the tube, and the tube was clamped for observation for 2 hours, once a day, for 3 consecutive days. Lumbar cisternae drainage Cerebrospinal fluid is slowly and steadily drained at a rate of less than 8ml/h per hour, the daily drainage volume is not more than 200 ml, and the drainage time of lumbar cisternae is controlled within 7 to 10 days, not more than 14 days.
223878741|NCT06284642|DRUG|Placebo|On the basis of standard treatment for severe neurological conditions, the treatment of lumbar drainage combined with intrathecal placebo saline injection was started within 24 hours after aneurysm treatment, 3 ml placebo was injected into the subarachnoid space, 3 ml normal saline was flushed into the tube, and the tube was observed for 2 hours, once a day for 3 consecutive days. Lumbar cisternae drainage Cerebrospinal fluid is slowly and steadily drained at a rate of less than 8ml/h per hour, the daily drainage volume is not more than 200 ml, and the drainage time of lumbar cisternae is controlled within 7 to 10 days, not more than 14 days.
223878742|NCT04140526|DRUG|ONC-392|ONC-392 will be given by intravenous infusion, once every 21 days (Q3W). In Part C Arm M and in Part D, ONC-392 will be given Q4W.
223878743|NCT04140526|DRUG|Pembrolizumab|Pembrolizumab will be given intravenous (IV) infusion at 200 mg/cycle, once every 21 days (Q3W).
223878744|NCT04140526|DRUG|Docetaxel|Docetaxel will be given intravenous (IV) infusion at 75 mg/m2, once every 21 days (Q3W).
223878745|NCT00999167|DRUG|HPN-100|Part B: 6 mL BID for 16 weeks.
223878746|NCT00999167|DRUG|Placebo|Part B: same as experimental arm
223878747|NCT02769819|DEVICE|Flexible fiberscope|"* Characteristics of patients will be assessed before induction of general anesthesia~* Glottic visualization will be evaluated by direct laryngoscopy.~* The endotracheal tube will be loaded onto the scope after silicon spray lubrication~* Intubation will be performed with the flexible fiberscope with the patient in supine position with head and neck in neutral position~* With the tip of the fiberscope in satisfactory position, the endotracheal tube will be advanced into the trachea. The scope will then be removed.~* Accurate positioning of the endotracheal tube will be confirmed by capnography and lung auscultation."
223878748|NCT02885636|DRUG|Albuterol|": Experimental: Inhaled albuterol~2.5 mg inhaled albuterol through a high efficiency nebulizer as a single dose"
223878749|NCT02885636|OTHER|Saline placebo|Saline inhaled through a nebulizer as a single dose
223878750|NCT04400734|OTHER|No intervention, observational study|no intervention
223878751|NCT05052996|DRUG|ISL|Capsules administered orally without regard to food
223878752|NCT05052996|DRUG|LEN|Tablets administered orally without regard to food
223878753|NCT05052996|DRUG|B/F/TAF|Tablets administered orally without regard to food
223878754|NCT05052996|DRUG|ISL/LEN FDC|Tablets administered orally without regard to food
223878755|NCT01763853|DRUG|4% albumin|
223878756|NCT01132560|GENETIC|RNA analysis|
223878757|NCT01132560|GENETIC|gene expression analysis|
223878758|NCT01132560|GENETIC|reverse transcriptase-polymerase chain reaction|
223878759|NCT01132560|OTHER|laboratory biomarker analysis|
223878760|NCT02902471|OTHER|Forced oscillations measure|
223878761|NCT04295993|DRUG|Methylene Blue|The patient will receive Methylene Blue bolus with a dose of 2 mg/kg over 10 minutes.
223878762|NCT04295993|DRUG|Norepinephrine infusion|The patient will receive norepinephrine infusion to maintain mean arterial pressure above 65 mmHg
223878763|NCT01340417|OTHER|Measurements of melatonin levels in urine, blood, milk.|Measurements of melatonin levels in urine, blood, milk.
223878764|NCT03704727|DIETARY_SUPPLEMENT|Probiotic|Probiotics (beneficial microorganisms) VSL#3 is a probiotic formula containing a mixture of 9x10\^10 CFU/g Lactobacilli strains (Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus casei, and Lactobacillus bulgaricus), 8x10\^10 CFU/g Bifidum strains (Bifidobacterium breve, Bifidobacterium longum, Bifidobacterium infantis) and 20x10\^10 CFU/g Streptococcus thermophilus
223878765|NCT04743362|DIAGNOSTIC_TEST|Dermoscopic imaging|The skin lesion will be imaged before application of alcohol (spray/wipe) and after application of alcohol (spray/wipe). The dermatoscope/camera with dermoscopy imaging capabilities, including but not limited to VEOS® SLR (Canfield Scientific, Inc.), will be placed on/near the area(s) of interest. Images will be captured in polarized and/or nonpolarized modes and contact and/or non-contact modes.
223878766|NCT04743362|DIAGNOSTIC_TEST|3-dimensional total body photography|Participants will stand in the center of an imaging station consisting of 92 high-resolution cameras. Image capture by all cameras will occur simultaneously, (approx. 3 milliseconds). Within a few minutes, specialized software will process and assemble the images into a 3D avatar - a digital model of the patient's skin - showing all his or her lesions.
223878767|NCT04743362|DIAGNOSTIC_TEST|Confocal microscopy|CM imaging (Vivascope®, Caliber Imaging and Diagnostics, Rochester, NY) will be performed using an arm-mounted CM device (Vivascope1500, Caliber I.D., Inc.) or using a handheld CM device (Vivascope3000, Caliber I.D., Inc.).
223878768|NCT04743362|DIAGNOSTIC_TEST|Optical Coherence Tomography imaging|OCT subsurface imaging shows structural-level morphology (epidermal and dermal layers) in skin down to the deeper reticular dermis.
223878769|NCT04743362|DIAGNOSTIC_TEST|Ultrasound|US imaging allows assessment of depth, Doppler vascular imaging, and elastography features of skin lesions.
223878770|NCT04743362|DIAGNOSTIC_TEST|Hyperspectral imaging|Hyperspectral imaging shows biochemical information regarding the distribution of skin melanin and hemoglobin50. SkinSpect™ is a form of a hyperspectral dermatoscope.
223878771|NCT04743362|DIAGNOSTIC_TEST|Electrical impedance spectroscopy|Electrical impedance spectroscopy (EIS) measures skin's resistance to the flow of alternating electric currents to differentiate benign and malignant lesions.
223878772|NCT04743362|DIAGNOSTIC_TEST|Patient self-imaging|Clinical and dermoscopy self-imaging by patients can be accomplished using mobile phone technology. In the case of dermoscopy, this requires a small dermatoscope attachment for the phone.
223878773|NCT01086813|DRUG|AZD3043|single dose/IV, bolus over 60secs - infusion over 30 mins
223878774|NCT04175405|PROCEDURE|Irradiation of implants with 635nm laser|Irradiation of implants with 635nm laser with a dose of 10J
223878775|NCT06492707|BIOLOGICAL|Decoy-resistant interleukin-18|Given SC
223878776|NCT06492707|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223878777|NCT06492707|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
223878778|NCT04616170|OTHER|Hip extension|Hips extended at the time of vaginal delivery
223878779|NCT04616170|OTHER|Usual Care|"Hips positioned in the usual care position per provider preference at the time of vaginal delivery"
223878780|NCT03306082|OTHER|Image-Guided Cochlear Implant Programming|Post Cochlear Implant surgery, participant will receive traditional activation and programming per routine. IGCIP will be used to offer alternative programming of the implant.
223878781|NCT01352429|RADIATION|Proton Therapy|
223878782|NCT01352429|RADIATION|IMRT|
223878783|NCT03568188|PROCEDURE|treatment with focal HIFU|HIFU treatment will be conducted with the Focal One® device. The treatment area will be defined using MRI data and 3D biopsies. A safety distance of at least 9 mm will be defined around the tumor. An intraoperative contrast echocardiographic control will be performed to evaluate the necrotic area. If necessary, additional HIFU lesions will be performed during the same session. In case of residual tumor demonstrated during control biopsies, additional treatment of this tumor with focal HIFU may be proposed.
223878784|NCT03568188|BIOLOGICAL|PSA dosage|PSA dosage will be regularly performed during patient follow up thanks to blood sampling.
223878785|NCT03568188|DEVICE|MRI|MRI exam will be regularly performed during patient follow up.
223878786|NCT03568188|OTHER|Questionnaires|Patients will have to complete five questionnaires during their follow up : QLQ-C30 (Quality of Life questionnaire), EPIC-26 (The Expanded Prostate Cancer Index Composite), IPSS (International Prostate Score Symptom), IIEF-5 (The International Index of Erectile Function).
223878787|NCT03568188|PROCEDURE|Prostatic biopsies|Prostatic biopsies will be regularly performed during patient follow up.
223878788|NCT03568188|BIOLOGICAL|blood test|if the patient decides to participate in the ancillary study, a blood test (for immunological analyzes and detection of CTC (circulating tumor cells)) will be performed during their follow up.
223878789|NCT03568188|BIOLOGICAL|urine test|if the patient decides to participate in the ancillary study, a urine test (for PCA3 test) will be performed during their follow up.
223878790|NCT04902391|OTHER|Health Services|The Acute Mental Health Care Bundle consists of 3 core elements, including: (1) ED triage, (2) ED assessment and care, and (3) follow-up care.
223878791|NCT06239701|BEHAVIORAL|LPA+Fitbit Intervention|"1. In-Person LPA+Fitbit Orientation. During an initial, orientation (45 minutes), a study interventionist will provide information regarding the acute and long-term psychological and physical benefits of increasing PA, including prenatally.~2. Telephone PA counseling sessions. A study interventionist will call participants at weeks 2, 4, 6, 8, and 10 of the intervention for a 20-min telephone session.~3. Fitbit activity tracker. With participant permission, a Fitbit account (on Fitbit.com) and study-generated password will be created. In doing so, investigators will have access to the participant activity data throughout the intervention. The Fitbit web-based and mobile apps facilitate goal-setting by allowing participants to easily set goals and change these goals at any point. We will customize each participant account to display daily steps and very active minutes, though they will be encouraged to adjust the display according to their preferences."
223878792|NCT06239701|BEHAVIORAL|Fitbit Only|"1. In-person Fitbit Orientation. Participants will be given information on the public health guidelines for PA during pregnancy, and as well as how to determine if their PA is moderate-intensity. In addition, interventionists will orient participants to the proper use of the Fitbit tracker and offer tips for self-monitoring step counts with the tracker and on the app.~2. Fitbit Activity Tracker. Participants will be given the same Fitbit as in the LPA condition. Participants will not be given any specific step count goals to achieve during the 12-week intervention.~3. Brief Telephone Check-ins. As with the LPA+Fitbit participants, those in the Fitbit Only condition will receive phone calls on weeks 2, 4, 6, 8, 10. These calls will last 5 minutes and be focused entirely on answering any problems related to the Fitbit such as syncing issues, charging the battery, and any other technical problems that may arise. No physical activity counseling will be delivered on these calls."
223878793|NCT06499051|OTHER|cognition, impulsivity, emotional regulation, sexuality, diagnosis, sexual violence, motivation, self-esteem, social desirability, and defense mechanisms|self-administered questionnaires
223878794|NCT05624554|DRUG|Nemtabrutinib|65 mg administered orally daily until disease progression, unacceptable toxicity, or discontinuation criteria met.
223878795|NCT05624554|DRUG|Fludarabine|25 mg/m\^2 administered via intravenous (IV) infusion on Days 1, 2, and 3 of each 28-day cycle up to 6 cycles.
223878796|NCT05624554|DRUG|Cyclophosphamide|250 mg/m\^2 administered via IV infusion on Days 1, 2, and 3 of each 28-day cycle up to 6 cycles.
223878797|NCT05624554|DRUG|Bendamustine|Administered via IV infusion on Days 1 and 2 of each 28-day cycle up to 6 cycles. The first dose is given as 70 to 90 mg/m\^2. Subsequent doses may be escalated up to 90 mg/m\^2, if applicable and as per local guidelines.
223878798|NCT05624554|BIOLOGICAL|Rituximab|Administered as an IV infusion on Day 1 of each 28-day cycle. The initial dose is 375 mg/m\^2 (cycle 1) followed by 500 mg/m\^2 for remaining cycles.
223878799|NCT05624554|BIOLOGICAL|Truxima|Administered as an IV infusion on Day 1 of each 28-day cycle. The initial dose is 375 mg/m\^2 (cycle 1) followed by 500 mg/m\^2 for remaining cycles.
223878800|NCT05624554|BIOLOGICAL|Ruxience|Administered as an IV infusion on Day 1 of each 28-day cycle. The initial dose is 375 mg/m\^2 (cycle 1) followed by 500 mg/m\^2 for remaining cycles.
223878801|NCT05624554|BIOLOGICAL|Riabni|Administered as an IV infusion on Day 1 of each 28-day cycle. The initial dose is 375 mg/m\^2 (cycle 1) followed by 500 mg/m\^2 for remaining cycles.
223878802|NCT01837875|BEHAVIORAL|Chronic Disease Self-Management Program (CDSMP)|The Chronic Disease Self-Management Program (CDSMP) is a 2.5 hour workshop given weekly for six weeks. People with different chronic health problems attend together and support one another in making positive changes in their health. Workshops are facilitated by two trained leaders, one or both of whom are non-health professionals with a chronic disease themselves. It is the process in which the program is taught that makes it effective. Classes are highly participative, and mutual support builds the participants' confidence in their ability to manage their health and maintain active and fulfilling lives.
223878803|NCT01837875|BEHAVIORAL|Mail-delivered arthritis kit|"The Arthritis Self-Management Tool Kit contains 1) a Self Test to help participants determine how arthritis affects their lives and self-tailor the use of the Tool Kit, including items related to pain, fatigue, physical limitations, and health worries; 2) information sheets: Working with Your Doctor and the Health Care System; Exercise; Medications; Healthy Eating; Fatigue and Pain Management; Finding Community Resources; and Dealing with One's Emotions; 3) information sheets on key process components of the ASMP: Action Planning, Problem Solving, Deciding What to Try, and Individualizing an Exercise Program; 4) The Arthritis Helpbook; 5) audio relaxation and exercise compact discs (CDs); and 6) an audio CD of all material printed on the information sheets."
223878804|NCT01837875|BEHAVIORAL|Support group|"Interested participants will be referred to the Lupus: Listening and Learning Group, a Charleston-based support group affiliated with the Lupus Foundation of America (LFA). One to two LFA-trained facilitators implement the group. The meeting format generally includes a specific discussion topic or an informative presentation such as by a medical or counseling professional, pharmacist, or lupus researcher. This program is followed by time within the group for further interaction and support among the attendees who wish to participate. The Lupus: Listening and Learning Group is open to all lupus patients, family members, friends and supporters, and there is no pre-registration or fee involved."
223878805|NCT01837875|BEHAVIORAL|Listserv|A project listserv will be established to link all intervention participants to facilitate exchange of coping strategies, pose questions, and share preferred educational resources or any other information relative to their everyday and disease-specific experiences and/or participation in the project. Participants will be provided with a URL, from which they will be able to subscribe to the listserv. Once subscribed, they will be able to post and receive messages, managed by a listserv moderator, who will be responsible for distribution to listserv members as appropriate. Participants will have the option to unsubscribe at any time.
223878806|NCT01083342|DRUG|MTX, MVD, VIA|MTX: Methotrexate,Leucovorin MVD: Methotrexate,Vincristine,Dexamethasone VIA: VP-16 (Etoposide),Ifosfamide,Mesna, Cytarabine (ara-C)
223878807|NCT04319874|DRUG|Ganoderma lucidum|Participants take ganoderma lucidum spore powder once a day, 1000mg
223878808|NCT04319874|DRUG|Chemotherapy|Subjects are treated with conventional chemotherapy
223878809|NCT04319874|DRUG|Placebos|Subjects are treated with conventional chemotherapy and Placebos once a day, 1000mg
223878810|NCT04159493|DRUG|Estriol|Vaginal Application
223878811|NCT04159493|DRUG|Placebo|Vaginal Application
223878812|NCT00522951|DRUG|Gadobutrol (Gadavist, Gadovist, BAY86-4875)|Gadobutrol enhanced MRI (first injection of gadobutrol 0.1 mmol/kg bw, corresponding to a dose of 0.1 mmol/kg bw)
223878813|NCT00522951|DRUG|Gadobutrol (Gadavist, Gadovist, BAY86-4875)|Gadobutrol enhanced MRI (second injection of gadobutrol 0.1 mmol/kg bw, corresponding to a total dose of 0.2 mmol/kg bw)
223878814|NCT00522951|DRUG|ProHance|ProHance enhanced MRI (two injections of gadoteridol 0.1 mmol/kg bw, corresponding to a total dose of 0.2 mmol/kg bw)
223878815|NCT01576029|DRUG|CABAZITAXEL (XRP6258)|Pharmaceutical form: solution Route of administration: intravenous
223878816|NCT01576029|DRUG|DOCETAXEL (XRP6976)|Pharmaceutical form: solution Route of administration: intravenous
223878817|NCT00547352|DRUG|tadalafil|20 mg tadalafil tablets taken by mouth, as needed, no more than once a day for 8 weeks.
223878818|NCT00547352|DRUG|sildenafil|Current users of sildenafil citrate for a minimum of 6 weeks prior to visit 1 will continue with an individual dosage to be taken no more than once a day for an additional 4 weeks.
223878819|NCT01571466|DRUG|Vaccination|"* Modified Pox virus, strain MVA clade -B (expressing HIV-1 Bx08gp120 and IIIB gagpolnef)~  -\~ 1 x 10e8 pfu/ml~* 3 immunisations at week 0, 4 and 16"
223878820|NCT01571466|DRUG|Placebo|3 immunisations at week 0, 4 and 16
223878821|NCT05003843|DEVICE|Indigo Aspiration System|Indigo Aspiration System
223878822|NCT03101930|DRUG|Liraglutide|subcutaneous liraglutide daily
223878823|NCT03101930|DRUG|Sitagliptin|oral sitagliptin daily
223878824|NCT03101930|OTHER|hypocaloric diet|Reduced calorie intake to achieve weight loss.
223878825|NCT03101930|DRUG|Placebos|Subjects in the liraglutide arm will receive a placebo for sitagliptin. Those in the sitagliptin arm will receive a placebo for liraglutide. All subjects will receive a placebo for Exendin 9-39.
223878826|NCT03101930|DRUG|Exendin (9-39)|All subjects will receive Exendin (9-39) or matching placebo in crossover fashion during study days on the first and third days of the second week after randomization and again on the 5th and 7th days of the 14th week of treatment.
223878827|NCT06648226|BEHAVIORAL|Health swaps|"Participants will view health grade labels on all products in the online grocery store indicating their healthfulness as estimated by United Kingdom Ofcom Nutrient Profiling Model scores. The health score labels will mimic Nutri-Score labels, a labeling system used in some European countries, showing a color-coded grade of A (green) through F (red) on each product. Products with A and B labels will meet the United Kingdom's cutoff for products that can be marketed to children and C, D and F labels products are less healthy than this cutoff (based on tertiles of Ofcom scores within each food group). When participants attempt to add a less healthy product to their cart (e.g., C, D or F health label), the store will automatically suggest a healthier product from the same category (e.g., with a A or B health label)."
223878828|NCT06648226|BEHAVIORAL|Climate swaps|"Participants will view climate grade labels on all products indicating their climate impact. The climate impact is calculated as the greenhouse gas emissions associated with producing the product in carbon dioxide equivalents (CO2-eq) per 100g (i.e., carbon footprint). Labels will be applied based on quintiles of carbon footprints in each food group. When participants attempt to add a high-climate-impact product to their cart (e.g., with a C, D, or F climate label), the store will automatically offer them swaps to more climate-friendly products (e.g., with a A or B climate label)."
223878829|NCT06648226|BEHAVIORAL|Combined health and climate swaps|"Participants will view both the health and climate grade labels on all products in the online grocery store. When participants attempt to select a product with a C, D, or F label on either dimension to their cart, the store will automatically offer them swaps to products that offer improvement over the original food on at least 1 dimension (health or climate-friendliness) and were at least as good or better on the other dimension, with the additional guardrail that the store never suggests products with a C, D or F label on either dimension."
223878830|NCT06648226|BEHAVIORAL|Control|Participants will not view any extra labels or be offered any swaps in the online grocery store.
223878831|NCT00767559|DRUG|warfarin|5 mg beginning the night before surgery, followed by 5 mg the PM of surgery\*, and then variable daily dose, until day 28 (+/-2 days) from day of surgery follow-up. (target INR 2.0 -2.5)
223878832|NCT00767559|DRUG|Fondaparinux:|2.5 mg daily starting more than 6 hours following surgery and no later than 6 AM the next day\*, or 6-8 hours after epidural catheter removal, and continued until follow up day 28 (+/-2 days) from day of surgery.
223878833|NCT00767559|DRUG|warfarin|"Fixed Low Dose warfarin~1 mg daily beginning 7 days preoperative, and continued at 1 mg daily until follow-up 28 day (+/- 2 days) from day of surgery."
223878834|NCT01448512|BEHAVIORAL|PartnerPlus Intervention|The intervention employs a closed, structured, group intervention limited to 10 participants (women or men). Four weekly, 11/2-2 hour sessions are led by a trained gender-congruent counselor and a peer facilitator and emphasize group participation, cognitive-behavioral skill building, sexual negotiation and experimentation with products.
223878835|NCT01448512|OTHER|Usual Care|4 time matched sessions focused on health education
223878836|NCT05744596|OTHER|Incisura biopsy analysis|a pathologist blinded to the other biopsies analyzes the biopsy from the incisura
223878837|NCT05237453|RADIATION|Photons|MR-guided adaptive radiotherapy
223878838|NCT02847013|DRUG|TAP block w Liposomal bupivacaine|TAP block w Liposomal bupivacaine diluted to 0.66% (20 mLs)
223878839|NCT02847013|PROCEDURE|TAP block w normal saline|TAP block w normal saline -preservative free 0.9% sodium chloride (20mLs)
223878840|NCT01230450|PROCEDURE|sub-urethral tape (TVT-O)|Tension free vaginal tape vs. single incision sub-urethral tension free vaginal tape
223878841|NCT01230450|OTHER|stand standard mid-urethral sling (TVT-O)|
223878842|NCT00704314|DRUG|Simvastatin|80 mg Simvastatin daily for 8 weeks
223878843|NCT00704314|DRUG|Placebo|The placebo was identical in appearance and was provided by the same manufacturer
223878844|NCT03066115|DRUG|L-NMMA|See arm description.
223878845|NCT03066115|DRUG|Ketorolac|See arm description.
223878846|NCT03066115|DRUG|Ascorbic Acid|See arm description.
223878847|NCT03066115|PROCEDURE|Intravenous Catheter|Two intravenous catheters will be placed for each study visit. One catheter will be used for the intravenous infusion of study drugs (L-NMMA, Ketorolac, and Ascorbic Acid). The second catheter will be used to draw intermittent blood samples at 8-specific time points throughout each study visit to ensure pharmaceutical efficacy and examine systemic physiologic blood variables of interest.
223878848|NCT03066115|PROCEDURE|Transcranial Doppler Ultrasound|MCAv will be measured via the transtemporal window while BAv will be measured through the transforaminal window with 2-MHz transcranial Doppler ultrasound probes (TCD, Neurovision model 500M, Multigon Industries, Inc.; Yonkers, NY, USA)
223878849|NCT00976495|DRUG|Dapagliflozin|Tablets, Oral, 10 mg, once daily, 12 weeks
223878850|NCT00976495|DRUG|Placebo|Tablets, Oral, 0 mg, once daily, 12 weeks
223878851|NCT00976495|DRUG|Hydrochlorothiazide|Tablets, Oral, 25 mg, once daily, 12 weeks
223878852|NCT05643456|PROCEDURE|surgery|"69 Patients with exotropia of (40-55) PD who are ≥ 5 years old. The 1st group 30 patients had two muscles surgery; bilateral lateral rectus recession.~The 2nd group 39 patients had three muscles surgery; bilateral lateral rectus recession and unilateral medial rectus tucking."
223878853|NCT02184806|PROCEDURE|orthotopic graft|(1) laparoscopy (2) ovarian fragments can be put back inside the pelvic cavity close to the natural location of the ovaries or
223878854|NCT02184806|PROCEDURE|heterotopic graft|"1. put under the skin~2. the ovarian fragments can be put under the skin of the abdomen"
223878855|NCT05364216|BEHAVIORAL|Measurement of cognitive function|Patients undergoing thoracoscopic surgery underwent general anesthesia.MMSE and MoCA were assessed at one day before surgery, one day after surgery, and three months after surgery
223878856|NCT05364216|PROCEDURE|Thoracic paravertebral block|"The patient was placed in lateral supine position, and the T5 spinous process was moved 2 to 3 cm laterally to the operative side as the puncture point, and the pleura and T5 transverse process were observed, and the paraspinal space was observed on the lower lateral side of the transverse process. Using in-plane technique, the needle position was adjusted under ultrasound visualization to reach the paraspinal space. 20ml 0.375% ropivacaine was injected into the suction syringe when there was no blood or gas, and the drug liquid could be seen spreading outside the pleura. Landscape sign appeared, indicating successful block"
223878857|NCT05364216|BEHAVIORAL|The assessment of cognitive function|Participants were assessed for MMSE and MoCA at the same period as the group C
223878858|NCT02809989|DRUG|Ovaleap®|"About 6-8 weeks of observation per patient from start of the stimulation therapy with Ovaleap® depending on the duration of the required stimulating therapy. Up to 10-11 months per patient for follow-up but only if in case of songraphically intact intrauterine pregnancy to determinate the Baby-Take-Home-Rate (live-births)."
223878859|NCT02538341|BIOLOGICAL|Herpes Zoster (HZ) Vaccine|
223878860|NCT02538341|DRUG|Placebo|
223878861|NCT04386772|PROCEDURE|PVE with coils plus TAGM|PVE with TAGM distally and coils proximally and subsequent scheduled major hepatectomy. Sequential transcatheter arterial chemoembolization and PVE for patients with HCC. Selective biliary drainage on future liver remnant (FLR) side for patients with pCCA when obstructive jaundice is present.
223878862|NCT04386772|PROCEDURE|PVE with multiple coils|Procedure: PVE with multiple coils PVE with multiple coils proximally and distally and subsequent scheduled major hepatectomy. Sequential transcatheter arterial chemoembolization and PVE for patients with HCC. Selective biliary drainage on FLR side for patients with pCCA when obstructive jaundice is present.
223878863|NCT00331136|DRUG|Pyronaridine-Artesunate|Once a day for 3 days
223878864|NCT05280275|DRUG|Belantamab Mafodotin-Blmf|"Blmf will be available as 100 mg/vial in single-use vial for reconstitution, supplied as lyophilized powder.~Blmf will be delivered as IV solution over at least 30 minutes."
223878865|NCT05280275|DRUG|Daratumumab|Daratumumab will be administered with subcutaneous injections. On days where Blmf is given together with daratumumab, daratumumab should be performed first.
223878866|NCT05280275|DRUG|Lenalidomide|Lenalidomide will be administered per os.
223878867|NCT05280275|DRUG|Dexamethasone|Dexamethasone will be administered intravenously or per os.
223878868|NCT04308083|PROCEDURE|dental implant placement|Implants will be placed according to the manufacturer recommendations. Implants will be placed at 1.5 to 2.0 mm from the adjacent natural tooth. However, these distances will be directed by the prosthetic crown needed and they will be recorded in the CRF.
223878869|NCT03548857|OTHER|Lung transplantation|Single or double lung transplantation in patients with COPD
223878870|NCT05452525|DRUG|CKD-379 I|1 tablet administration under fed condition
223878871|NCT05452525|DRUG|CKD-379 II|1 tablet administration under fed condition
223878872|NCT05452525|DRUG|D759+D745+D150|3 tablet coadministration under fed condition
223878873|NCT02860741|BEHAVIORAL|REJOICE|Small groups led by lay leaders undergo an 8-session faith-based behavioral activation protocol that provides individuals with education about: identifying depressive symptoms, identifying pleasurable activities, scheduling pleasurable activities, and identifying and addressing avoidant behaviors that act as barriers to completing pleasurable activities
223878874|NCT02860741|OTHER|Control|Churches in the control arm will receive an educational materials about identifying depressive symptoms and self-management options for addressing depressive symptoms.
223878875|NCT02681900|BEHAVIORAL|Self-affirmation manipulation task|Participants in the self-affirmation condition indicate their most important value, give three examples of why this value is important to them and one example of something they had done to demonstrate its importance.
223878876|NCT02681900|BEHAVIORAL|Control task|People in the control condition indicate their least important value, three examples of why that value could be important to someone else, and describe something that person could do to show its importance.
223878877|NCT01859559|PROCEDURE|Ultrasound-guided peripheral intravenous access line placement|The ED technician will use an ultrasound machine with a vascular probe to visualize the vein and guide the PIV line using a one-operator dynamic technique.
223878878|NCT01859559|PROCEDURE|Landmark Approach to peripheral intravenous access line placement|ED technician will use standard anatomical landmarks and palpation to puncture the skin and insert the peripheral intravenous access line in the upper extremity.
223878879|NCT06347185|PROCEDURE|Early palliative care, integrated with the standard oncologic care (proactive approach)|Besides the Oncology visit, patient will have the palliative care expert visit and follow up (proactive approach). The oncologist will define the therapeutic approach and the assessments requested, in terms of type of exams and timing. The palliative care clinician and the oncologist will judge the burden of symptoms and together they will propose the suggested interventions to relief the symptoms, with a particular attention to the Liverpool Head and Neck Patient Concern Inventory (PCI-H\&N) and patient priority questionnaire's results.
223878880|NCT06347185|PROCEDURE|Palliative care requested as needed, integrated with the standard oncologic care (reactive approach)|The oncologist will be the main referral of the patient, deciding the therapeutic approach, the assessments requested, in terms of type of exams and timing and the need of possible further support from other expertise (reactive approach). The oncologist will base the choices also upon the results of the PCI-H\&N and the patient's preferences. At the end of the first oncological visit, the physician will be asked to predict the survival of the patient.
223878881|NCT05783570|BIOLOGICAL|EU307 CAR-T Cell|"* Dose to be administered: a single dose~* IV administration~* Dosing rate: To be administrated at a rate of approximately 2 mL/min"
223878882|NCT02321514|DEVICE|Tendyne Mitral Valve System|Patients will undergo transcatheter mitral valve replacement using Tendyne Mitral Valve system
223878883|NCT02743910|OTHER|ptDNA|Pre-operative blood samples for ptDNA will be collected at the time of diagnosis/prior to NAT, post-cycle 1/pre-cycle 2 of NAT, after all NAT/immediately before surgery, and post-operatively at 6, 12, 24, and 36 months, and annually thereafter if funding allows.
223878884|NCT02743910|OTHER|Tissue sample|Representative tissue sample will be collected from the diagnostic biopsy (in all participants) and definitive surgery (if available)
223878885|NCT05336864|OTHER|Non-invasive cerebral oximetry monitoring|"Main study (all patients): Continuous bilateral frontal cerebral near-infrared spectroscopy (NIRS) monitoring will be performed in all patients for the duration of general anesthesia. Intraoperative parameters including NIRS and invasive blood pressure will be collected and recorded in real-time using the software ICM+.~Postoperative hemodynamics substudy (facultative): Cerebral NIRS monitoring will be continued postoperatively in a subset of patients being admitted to the ICU."
223878886|NCT05336864|OTHER|additional perioperative blood sampling|"Main study (all patients): Creatinine, high-sensitivity troponin (T hs-cTnT), Growth/Differentiation Factor-15 (GDF-15), Hemoglobin~Neurological injury substudy (facultative): Neurofilament Light Chain (NFL) and C-reactive protein (CRP)"
223878887|NCT05336864|OTHER|clinical & telephone assessments|Main study (all patients): Telephone follow-up (1-year outcomes).
223878888|NCT05336864|OTHER|Non-invasive somatic oximetry monitoring|Tissue perfusion substudy (facultative): Continuous somatic NIRS monitoring of an extremity (i.e. on skin of leg or arm) will be performed intraoperatively and postoperatively in a subset of patients being admitted postoperatively to the ICU.
223878889|NCT05336864|OTHER|Processed electroencephalogram (pEEG) monitoring|Processed EEG substudy to explore the relationship between processed EEG-derived depth of anesthesia metrics and cerebral autoregulatory function.
223878890|NCT05973461|DEVICE|Exercise and virtual reality|Riding a cycle ergometer while experiencing virtual reality
223878891|NCT05973461|OTHER|Riding a cycle ergometer|Riding on a cycle ergometer without experiencing virtual reality
223878892|NCT05394285|DRUG|Hetrombopag|"The first anti-tumor treatment cycle (multicenter, open label, randomized controlled):~When platelets were \<50\*109/L, oral hetrombopag 7.5 mg/day was started. When the platelet count is \>100\*109/L, the administration is suspended.~2nd anti-tumor treatment cycle (exploratory study): Prophylactic use (60 cases in the test group and the control group): oral hetrombopag 7.5 mg/day (initial dose) was started on d2 after anti-tumor treatment for 14 days."
223878893|NCT01038011|DRUG|drug treatment|
223878894|NCT00332917|DRUG|Pardoprunox|12-42 mg
223878895|NCT01859416|DIETARY_SUPPLEMENT|Oral nutritional supplement|
223878896|NCT02032849|PROCEDURE|Manual air-impingement operation|A method which we invented to clear subglottic secretion
223878897|NCT02032849|DEVICE|subglottic secretion drainage|The conventional method with a special tube to drainage subglottic secretion
223878898|NCT03396900|DRUG|RhBMP-2 Protein, Recombinant|Bone morphogenetic proteins (BMPs) are a category of proteins that are involved in bone formation and repair. Among these, BMP-2 is one of the most potent members of the BMP family and has been used for correcting intrabony, supraalveolar, furcation, and fenestration defects due to its osteoinductive property. BMP's are also essential for differentiation of osteoclasts, but their role in this process remains unclear. Treatment of osteoclasts with exogenous BMP-2 directly enhances RANKL-stimulated differentiation of osteoclast precursors in vitro and stimulates survival and resorptive activity of mature osteoclasts that accelerates the tooth movement.
223878899|NCT03396900|OTHER|Conventional Corticotomy|A conventional PAOO Surgical procedure will be performed for individuals in this arm
223878900|NCT05631210|OTHER|Privacy agreements with pictograms|The intervention consisted of a modified privacy agreement talking about health data. Instead of presenting all of that information through text, the investigators added pictograms that summarized the key points at the beginning.
223878901|NCT04448158|DIAGNOSTIC_TEST|Genotypic Resistance Test|"A Genotypic Resistance Test by Sanger sequencing will be done after the period of virological suppression.~* If M184V is still present no additional test will be performed.~* If M184V is absent, we will go back in the previous samples (one per year) to determine the time point where the mutation has been cleared by sanger and UDS sequencing."
223878902|NCT02662894|DRUG|Valsartan 160mg + Rosuvastatin 20mg|1 tablet, oral, a day
223878903|NCT02662894|DRUG|Valsartan 320mg + Rosuvastatin 20mg|1 tablet, oral, a day
223878904|NCT02662894|DRUG|Diovan® 160mg + Crestor® 20mg|Take together 1 tablet of Diovan (160mg) plus 1 tablet of Crestor (20mg), oral, once daily.
223878905|NCT02662894|DRUG|Diovan® 320mg + Crestor® 20mg|Take together 1 tablet of Diovan (320mg) plus 1 tablet of Crestor (20mg), oral, once daily.
223878906|NCT02258815|DRUG|ch14.18/CHO|"A six courses regimen consisting of a 8 hour infusion (ch14.18/CHOmAb 20 mg/m² ) for five consecutive days will be administered every 4 weeks.~Interleukin 2 will be added to cycles 4-6 at days 6,8,10 (1 x 106 IU/m²/d s.c.) Participants will be premedicated with an intravenous antihistamine and ranitidine within approximately 30 minutes prior and during the infusion of the study agent Pain as an anticipated side effect is managed by a standard pain prophylaxis with Morphium hydrochloride Disease status will be evaluated after 3 and 6 courses and after 1 year."
223878907|NCT02988037|BEHAVIORAL|A-DBT-A|Adapted Dialectical Behaviour Therapy for Adolescents
223878908|NCT06354140|DRUG|Tegafur|Tegafur (S-1) 80mg/100mg/120mg Q3W (discontinued at the third week) + tislelizumab 200 mg Q3W, treatment for 1 year. Tegafur: body surface area (BSA) \< 1.25m2, use 80mg; 1.25-1.5m2, use 100mg; \> 1.5m2, use 120mg. Treatment for 1 year
223878909|NCT00153569|BIOLOGICAL|Tyrosinase, MAGE-3, GnTV|
223878910|NCT03954210|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia (CBT-I)|CBT-I is an in-person, one-on-one program with a graduate psychology research assistant who is trained in providing a standardized CBT-I. Participants will maintain a sleep diary during the course of the program to aid in tailoring the program. Each session will begin with a summary and graphing of sleep diary data and will include an assessment of treatment gains and adherence.
223878911|NCT03954210|BEHAVIORAL|Sleep and Lifestyle Education|Participants in the sleep and lifestyle education group will attend six weekly, in-person, one-on-one, stretching, and thinking activity sessions with a graduate research assistant to control for socialization and contact with research personnel.
223878912|NCT00536341|DRUG|lenalidomide|2.5 mg orally (PO) daily, Days 8-28, Cycle 1; 5.0 mg PO daily, Days 8-28 Cycles 2-6
223878913|NCT00536341|DRUG|Rituximab|375 mg/m2 Cycle 1 (split over Day 1 \& Day 2); 500 mg/m2 Day 1 of Cycles 2-6
223878914|NCT00536341|DRUG|Fludarabine|25 mg/m2 on Days 1, 2, and 3
223878915|NCT03954301|DIAGNOSTIC_TEST|Anthropometric measures|Q, valgity angle, subtalar joint, medial longitudinal arch and hallux valgus angles were measured with a goniometer. The height from the ground of the navicula was calculated by caliper, using the Navicular drop test. Metatarsal width was also calculated with this device. Medial longitudinal arch angle, metatarsal width and nacivular drop tests were performed under weight-bearing and non-weight-bearing conditions.
223878916|NCT06554756|OTHER|Saliva, serum and GCF sampling|Saliva were collected to analyze the selected markers as unstimulated samples during the early hours of the day. The saliva was centrifuged and then transferred into Eppendorf tubes. Venous puncture was performed after saliva collection and 10 mL of blood samples were collected by qualified staff from each participant. Gingival crevicular fluid (GCF) samples were taken from the vestibular, mesial, and distal surfaces of a single-rooted tooth with standard paper strips (Periopaper, Oraflow Inc., Plainview, NY, USA). Saliva, GCF and serum were then stored at -80 °C until analysis.
223878917|NCT01231802|DRUG|Eniluracil|Eniluracil (40 mg) orally at 18:00 ± 1 hour (6:00 PM) on Days 1, 8, \& 15
223878918|NCT01231802|DRUG|5-Fluorouracil|5-FU (30 mg/m2) orally at 7:00 AM ± 1 hour on Days 2, 9, \& 16
223878919|NCT01231802|DRUG|Leucovorin|Leucovorin (30 mg) orally at 7:00 AM ± 2 hours on Days 2, 3, 9, 10, 16, \& 17
223878920|NCT01231802|DRUG|Capecitabine|Capecitabine (1000 mg/m2) twice daily (12 hr apart) for 14 consecutive days followed by 7 days off-treatment
223878921|NCT04652583|DEVICE|Earstim - Active Stimulation|Intramuscular stimulation
223878922|NCT04652583|DEVICE|Earstim - Sham Stimulation|Sham stimulation
223878923|NCT01215344|DRUG|VELCADE|1.3 mg/m2 by IV on days 1, 4, 8, 11 of each cycle
223878924|NCT01215344|DRUG|Lenalidomide|25 mg by mouth on days 1-4 of each cycle
223878925|NCT01215344|DRUG|Dexamethasone|20 mg the day before and the day after receiving VELCADE
223878926|NCT01215344|DRUG|DVT prophylaxis|At least one asprin 81 mg per day. Other option per physician's choice
223878927|NCT01215344|DRUG|Bisphosphonates|Zoledronic acid by IB or pamidronate by IV can be used as per standard of care.
223878928|NCT01215344|DRUG|Liposomal doxorubicin|30 mg/m2 on day 4 of each cycle
223878929|NCT01215344|DRUG|Dexamethasone|40 mg by mouth on days 1-4, 8-11, and 15-18 of cycle 1 and days 1-4 on cycle 2-4
223878930|NCT04077164|OTHER|No intervention, observational only.|No intervention, this study will use self-report information regarding health, social, and behavioral factors for each member of the couple.
223878931|NCT04372004|DIAGNOSTIC_TEST|diagnostic tests for COVID-19 infection|Compare the efficacy of diagnostic tests for COVID-19 infection in detecting antibodies and viral-RNA
223878932|NCT02058017|DRUG|OPB-51602|
223878933|NCT01130727|OTHER|green tea extract|1.21g of green tea extract (965 mg of flavonols)
223878934|NCT01130727|OTHER|cocoa extract rich in polyphenols|2.14 g of cocoa extract rich in polyphenols equivalent to 965 mg of polyphenols
223878935|NCT01130727|OTHER|placebo|placebo
223878936|NCT01130727|OTHER|low polyphenol cocoa extract|placebo
223878937|NCT05725135|DRUG|Propofol|Propofol total intravenous anesthesia (TIVA) will be used for induction and maintenance of anesthesia. Propofol will be delivered using automated closed-loop anesthesia delivery system.
223878938|NCT03608475|OTHER|Limited Ultrasound Imaging|Ultrasound imaging will not be performed at the 2, 5 and 8 week clinic visits
223878939|NCT03608475|OTHER|Standard Ultrasound Imaging|Ultrasound imaging will be performed at all clinic visits
223878940|NCT03600051|DEVICE|Automated Heart Murmur Detection AI|"Automated AI algorithm-based analysis of digital heart sound recordings to detect pathological heart murmurs. Heart sound recordings were fully blinded before undergoing one-time automated analysis. Algorithm results for each recording included: AHA classification (I pathologic versus III innocent/no murmur), murmur timing, murmur grade, heart rate and S1/S2 identification."
223878941|NCT04484935|DRUG|Nirsevimab|Single fixed IM dose of nirsevimab 50 mg if body weight \< 5 kg or 100 mg if body weight ≥ 5 kg, and subjects entering their second RSV season will receive a single fixed IM dose of nirsevimab 200 mg
223878942|NCT01216722|OTHER|Resistance Strengthening Exercise Program|Home exercise Program. 3-4 days a week. 30 minutes a session. 12 weeks
223878943|NCT03072914|PROCEDURE|RIPC with RIPostC|The sphygmomanometer is closed to the lower limb and the cuff is inflated and the pressure is increased by 30 mmHg higher than the systolic blood pressure of each patient for 5 minutes. The loss of the distal pulse is confirmed by Doppler in the dorsalis pedis pulse. If there is a pulse, increase the pressure until it disappears. After 5 minutes of ischemia time, the cuff is deflated to confirm that the pulse has returned and has a reperfusion time of 5 minutes. A total of 4 cycles of 5 cycles of ischemic time and 5 minutes of reperfusion time are performed. (Estimated total 40 minutes) When the skull is started to close, RIpc with RIPostC group performs RpostC and the method is the same as the above RIPC method. (Estimated total 40 minutes)
223878944|NCT02219568|PROCEDURE|CT enterography|CT enterography is performed using 64-channel multi-detector row CT scanners (Siemens Sensation 64, Siemens Medical solution, Forchiem, Germany). Prior to the scan, 1500 cc of a neutral oral-enteric contrast material, polyethylene glycol (NIFLEC) is taken by the patient. During the scan, 2cc/kg of intravenous contrast (iohexol, Ominipaque Amersham GE-Health care, Princeton, NJ) is injected at the velocity 5 cc/sec.
223878945|NCT02219568|DEVICE|video capsule endoscopy|Video capsule endoscopy is performed using PillCam SB (Given Imaging, Yokneam, Israel). Polyethylene glycol (NIFLEC) is used for bowel preparation.
223878946|NCT04806529|DRUG|Adjuvanted SARS-CoV-2 Subunit vaccine (aCoV2)|Biological/Vaccine: Investigational adjuvanted SARS-CoV-2 Subunit vaccine
223878947|NCT04806529|DRUG|Comparator|Biological/Vaccine: A dose of 0.5 mL saline for injection will be administrated to subjects randomized to receive the placebo
223878948|NCT04504708|DRUG|ZX-101A|Once daily, oral dosing of ZX-101A at the assigned dose level for 28 consecutive days in a 28-day cycle
223878949|NCT03437850|OTHER|Usual care|Care as usual, in terms of processes and outcomes, will be collected for all participants in both cohorts
223878950|NCT01387906|DRUG|topical bimatoprost|topical bimatoprost will be applied one drop to each eyebrow each night.
223878951|NCT02190981|DEVICE|Ultrasound for Small Bowel Obstruction|Point-of-care ultrasound to evaluate emergency department patients for suspected small bowel obstruction
223878952|NCT03432858|DRUG|Vancomycin|Vancomycin - 1-gram dosing
223878953|NCT03432858|DRUG|Cefazolin|2-gram dosing for patients \<120 kg 3-gram dosing for patients 120 kg or greater
223878954|NCT03432858|DRUG|Saline Solution|Placebo
223878955|NCT04011631|PROCEDURE|Internal defibrillation during cardiac surgery, using the iD-system|When ventricular fibrillation of ventricular tachycardia occurs during surgery, the iD-Paddle will be applied directly to the heart. A maximum of 4 shocks are delivered to the heart to restore normal sinus rhythm. If 4 shocks are not successful standard operating procedure will be enable conform hospital protocol.
223878956|NCT05231317|OTHER|Plant-based diet|16 days with all foods provided
223878957|NCT05231317|OTHER|Western diet|16 days with all foods provided
223878958|NCT05075486|BEHAVIORAL|Collaborative quality improvement|Hospitals will receive standardized center-specific ECLS data report with benchmarking to feedback on their performance. Evidence-based potential better practice list will be established as a reference for all hospitals. During the intervention period, the hospitals will receive training in collaborative quality improvement method and then develop, implement, and document evidence-based practice changes to reduce adverse outcomes of neonatal ECLS treatment. Compliance with practice changes and neonatal outcomes will be monitored. All hospitals will have access to implementation support and collaborative activities.
223878959|NCT03208881|DIETARY_SUPPLEMENT|Dietary Supplement: Intensive dietary intervention|Participants receive a hypo-caloric formula diet containing 800 to 1,000 kcal/day. The formula diet consists of ready-to-use meal bars and powders to mix with water to make shakes, soups, or porridge. The weight loss programme consists of an 8-week period with full meal replacement by a standard liquid energy intake protocol. To facilitate compliance with the programme, participants will be scheduled for weekly facility-based group sessions with 6-8 participants led by a dietician. The recommendations for daily nutrient intake will be met.
223878960|NCT02382744|DEVICE|Ultrasound Guidance|Ultrasound guidance will be used to place a saphenous nerve block
223878961|NCT02382744|DEVICE|Ultrasound guidance + nerve stimulation|Ultrasound guidance and nerve stimulation will be used to place a saphenous nerve block
223878962|NCT00584246|DRUG|Pregabalin (Lyrica)|50 - 150 mg po qhs for 2 months
223878963|NCT00584246|DRUG|Placebo|50 - 150 mg po qhs for 2 months
223878964|NCT00000924|DRUG|Ritonavir|
223878965|NCT00000924|DRUG|Nelfinavir mesylate|
223878966|NCT00000924|DRUG|Nevirapine|
223878967|NCT00000924|DRUG|Stavudine|
223878968|NCT00000924|DRUG|Didanosine|
223878969|NCT05264012|PROCEDURE|Neurosurgery|Neurosurgery
223878970|NCT04156789|DIAGNOSTIC_TEST|Home sleep apnea testing|Sarcoidosis patients and control subjects will undergo one night of home sleep apnea testing using ApnoeaLinkTM Plus device (ResMed Corporation, Poway, Calif). The device records the patient's nasal respiratory pressure signal as a surrogate of nasal flow, respiratory movements by a thoracic impedance belt, and finger pulse oximetry. The results of the sleep study will be scored automatically with dedicated software (ResMed Corporation, Poway, Calif), and manually reviewed to ensure data accuracy.
223878971|NCT00550823|DEVICE|Cardiac CT 0BRILLIANT 64|Cardiac CT
223878972|NCT01189942|DRUG|OMP-21M18|The first 6 participants will receive OMP21M18 2.5 mg/kg once every other week, the next 6 participants will receive 5 mg/kg once every other week, and the final 6 participants will receive 10 mg/kg once every other week. A Data Safety Monitoring Board (DSMB) will review the data for the 6 participants in each dose level after the last participant in that group has been treated for 56 days and decide whether it is safe to move up to the next highest dose level. After confirming the optimum dose, 14 additional participants will be treated at the highest dose level that the DSMB considers safe.
223878973|NCT01094184|DRUG|Bevacizumab|Bevacizumab will be administered at a dose of 10 mg/kg Q2W or 15 mg/kg Q3W as intravenous infusion.
223878974|NCT01094184|DRUG|Paclitaxel|Paclitaxel will be administered as intravenous infusion Q1W as per discretion of the treating physician.
223878975|NCT01094184|DRUG|Docetaxel|Docetaxel will be administered as intravenous infusion Q3W as per discretion of the treating physician. Protocol amendment 2 (dated 17-Feb-2011) removed the option to choose docetaxel.
223878976|NCT04355221|PROCEDURE|pulsed radiofrequency|Pulsed radiofrequency of the trigeminal nerve using NeuroTherm NT 1100 RF generator device
223878977|NCT06220149|DIAGNOSTIC_TEST|FIT (fecal immunochemical test)|A FIT (fecal immunochemical test) will be done daily for the 14 days following polypectomy.
223878978|NCT01093820|DRUG|methoxy-polyethyleneglycol epoetin beta|Mircera® 150μg i.v., before / during reperfusion of the infarct related coronary artery followed by Mircera® 30μg s.c. at 1 and 2 months post-MI
223878979|NCT06257680|BIOLOGICAL|ReT01 ACT|Patients were infused with ReT01 ACT injection after pretreatment, and subjects were closely observed for 24 hours after each infusion.
223878980|NCT05166070|DRUG|RD133|The enhanced MSLN-CAR-T cell design of this study is obtained by co-infecting T cells with two lentiviral vectors. One lentiviral vector expresses CD19-CAR and tEGFR molecular safety switch, and the other lentiviral vector expresses MSLN- CAR and dnTGFβRII receptors. dnTGFβRII receptor without intracellular signal is used to resist the inhibition of T cell function by the immune microenvironment of tumor tissue. In addition, for the safety of CAR-T cell application in vivo, tEGFR is used in the CAR design as a molecular safety switch for CAR-T cells.
223878981|NCT00868504|OTHER|no intervention|no intervention
223878982|NCT03892564|DRUG|MC2-01 Cream, irradiation|One application of MC2-01 Cream, followed by irradiation. Visual evaluation of application site using a visual scale that rated the degree of erythema, edema and other signs of cutaneous irritation
223878983|NCT03892564|DRUG|MC2-01 Cream, no irradiation|One application of MC2-01 Cream. Visual evaluation of application site using a visual scale that rated the degree of erythema, edema and other signs of cutaneous irritation
223878984|NCT03892564|DRUG|MC2-01 vehicle, irradiation|One application of MC2-01 vehicle, followed by irradiation. Visual evaluation of application site using a visual scale that rated the degree of erythema, edema and other signs of cutaneous irritation
223878985|NCT03892564|DRUG|MC2-01 vehicle, no irradiation|One application of MC2-01 vehicle. Visual evaluation of application site using a visual scale that rated the degree of erythema, edema and other signs of cutaneous irritation
223878986|NCT03892564|DRUG|Control, irradiation|Untreated, irradiated site. Visual evaluation of application site using a visual scale that rated the degree of erythema, edema and other signs of cutaneous irritation
223878987|NCT04659018|BIOLOGICAL|blood collection|A 5ml blood sample will be taken in a dry tube when the venous line necessary for the general anaesthesia for the colonoscopy is placed.
223878988|NCT06520306|DRUG|Ropivacaine combined with methylene blue for iliac fascia block|Ultrasound-guided fascia iliaca block using different concentrations of methylene blue combined with ropivacaine
223878989|NCT03197116|OTHER|Telephone reminder|Interactive telephone reminder by a trained layperson with a standard script to remind return to the center for taking fecal tubes for CRC screening
223878990|NCT03197116|OTHER|No other|No additional reminder will be offered
223878991|NCT06235541|DRUG|GENA-104A16|GENA-104A16 is administered as a 1 hour (h) \[-5 minutes and +60 minutes , i.e., 55-120 minutes as window time\] as intravenous (IV) infusion on q2w.
223878992|NCT00070694|DRUG|MDL100.907|
223878993|NCT04325685|DRUG|Control|Oropharyngeal decontamination with saline will be performing three time a day every 8 hours during mechanical ventilation
223878994|NCT04325685|DRUG|Antiseptic Solution|Oropharyngeal decontamination with antiseptic solution will be performing three time a day every 8 hours during mechanical ventilation
223878995|NCT04325685|DRUG|Bacteriophage|Oropharyngeal decontamination with bacteriophage will be performing three time a day every 8 hours during mechanical ventilation
223878996|NCT04144595|DIAGNOSTIC_TEST|2 hour 75 g Oral glucose tolerance test|In pregnant women between 24 and 34 weeks of gestational age, plasma glucose was recorded after an overnight fast. Following consumption of 75 g glucose in 200 mL water over 10 min, the equivalent 1 hour and 2 hour values was recorded
223878997|NCT06676215|DIETARY_SUPPLEMENT|IAA mix supplement|The intervention is a daily IAA dose that provides x1.5 the estimated average requirement (EAR) for a healthy child. This IAA dose will be mixed to the complementary food and will be taken once daily for 4 weeks (28 days) by the child in the intervention group.
223878998|NCT06676215|OTHER|Complementary food comprised of rice and legumes|Each study child will receive standard complementary food which he/she will take once daily for 4 weeks (28 days)
223878999|NCT06676683|DRUG|Usage of Statin in diabetic patients|The use of statin in diabetic patients not known to have Atherosclerotic cardiovascular disease in a low income community
223879000|NCT06677255|DRUG|VUM02 Injection (UC-MSCs)+BAT|"The dose-escalation phase (phase I):~Single dose escalation Phase 1a study: 3 dose levels of a single IV infusion; Multiple dose escalation Phase 1b study: 3 dose levels of twice weekly for 4 consecutive week.~The dose-expansion phase (phase II):~-Two dose groups will be selected by the investigator and the sponsor based on the results of the Phase 1b study, twice a week for 4 consecutive weeks for a total of 8 doses."
223879001|NCT06677255|OTHER|The control group with Best Available Therapy (BAT)|According to BAT scheme, the drug administration is determined by PI according to the condition of the patients.
223879002|NCT06716190|DRUG|BI 3731579|BI 3731579
223879003|NCT06716190|DRUG|Placebo matching BI 3731579|Placebo matching BI 3731579
223879004|NCT06716190|DRUG|Midazolam|Midazolam
223879005|NCT06717906|DIAGNOSTIC_TEST|Endoscopic Ultrasound|If sigmoidoscopy is warranted as per clinical indication, the consenting patients shall undergo endoscopic ultrasound (EUS) using a radial echo-endoscope during the same sitting of sigmoidoscopy without incurring any additional cost to the patient. Total rectal wall thickness in anterior and posterior wall shall be measured in upper, middle and lower rectum with assessment of vascularity (Modified Limberg scale). The maximal wall thickness including maximum mucosal and submucosal thickness shall be noted and compared to total wall thickness measured by transabdominal ultrasound (TAS) and Transperineal ultrasound (TPUS). On sigmoidoscopy, rectal inflammation shall be measured by ulcerative colitis endoscopic index of severity (UCEIS) in rectum. Biopsy seal be taken as standard protocol to document histologic inflammation (measured by Nancy histologic index) which is known to predict future risk of relapse.
223879006|NCT07037927|OTHER|RETAIN Program|Facilitates early intervention strategies to support workers in staying-at or returning-to-work (SAW/RTW) after injury or illness and preventing unnecessary disability. This is done by incorporating a Return-to-Work Case Manager as a member of the healthcare clinical team who acts as a liaison for the patient and assists in coordination of referrals between healthcare and Workforce Development services. Return-to-Work Case Managers will interact with treating providers of Minnesota RETAIN participants to ensure functionally based work restrictions are documented and shared with the patient's employer.
223879007|NCT07045142|DRUG|Atorvastatin|Participants will receive atorvastatin 20 mg daily.
223879008|NCT07045142|DRUG|Metformin|Participants will receive metformin 1000 mg daily.
223879009|NCT07045142|DRUG|Placebo|Participants will receive placebo 1000 mg daily, mimicking the appearance of metformin without containing active ingredients.
223879010|NCT06716112|DEVICE|Vagus Nerve Stimulation (VNS) Device|All patients will be implanted with the ReStore VNS device by an NYU neurosurgeon. During treatment sessions, study personnel will deliver a VNS burst at the completion of a training movement by pressing a button on a smart device, which wirelessly triggers active VNS stimulation.
223879011|NCT06716112|DEVICE|Sham VNS Device|All patients will be implanted with the ReStore VNS device by an NYU neurosurgeon. During treatment sessions, study personnel will deliver a VNS burst at the completion of a training movement by pressing a button on a smart device, which wirelessly triggers sham VNS stimulation.
223879012|NCT06716112|BEHAVIORAL|Upper Extremity Rehabilitation|"Rehabilitation training will be functional and activity-based, focusing on six task categories: reaching and grasping objects, gross movements with objects, flipping objects, inserting objects, self-feeding, and opening and closing containers.~Three 90-minute training sessions per week will be administered by a licensed occupational therapist, over two six-week treatment blocks. Sessions will be paired with either active or sham VNS administration."
223879013|NCT04320251|PROCEDURE|cochlear implant revision surgery|Observation during routine cochlear implant revision surgery
223879014|NCT07048795|OTHER|No Intervention: Observational Cohort|No intervention
223879015|NCT07063381|DEVICE|tVNS|tVNS will be performed daily after workouts for 60 minutes over a period of 6 months.
223879016|NCT07064486|DRUG|BGM0504|Administered SC
223879017|NCT07064486|DRUG|BGM0504|Administered SC
223879018|NCT07064486|DRUG|Semaglutide|Administered SC
223879019|NCT07071844|DRUG|Trifluridine/tipiracil|35 mg/m², orally
223879020|NCT07071844|DRUG|Bevacizumab|5 mg/kg, intravenous route
223879021|NCT07071740|DEVICE|ventral hernia repair|Robotic-assisted incisional or primary ventral hernia repair with the DEXTER robotic surgery system
223879022|NCT07066267|OTHER|Experimental|Autologous adipose stem cell mitochondrial transfer to mature oocytes along with intracytoplasmic sperm injection (ICSI). The intervention is also termed as Adipose Stem Cell ENergy Transfer (ASCENT).
223879023|NCT07064148|BEHAVIORAL|Self-Myofascial Release (SMR) Program|The intervention involves a structured 6-week Self-Myofascial Release (SMR) program using foam rollers and massage balls. Participants perform standardized SMR exercises targeting major muscle groups relevant to golf performance, including the calves, hamstrings, glutes, back, shoulders, and thoracic spine. The intervention is conducted three times per week, with each session lasting approximately 30 minutes. Exercises are demonstrated and monitored by certified instructors. The control group continues regular physical activities without SMR.
223879024|NCT07064148|BEHAVIORAL|Golf-Related Video Viewing (Attention Control)|Participants in the control group did not receive any self-myofascial release (SMR) intervention. They followed the same daily training schedule, accommodation, and meals as the SMR group. Instead of engaging in SMR exercises, participants in the control group engaged in supervised viewing of golf-related instructional videos or documentaries three times per week, approximately 30 minutes per session, after 7:00 PM in a designated classroom. This viewing schedule was matched in timing and frequency to the SMR group's intervention sessions. No flexibility, mobility, or soft tissue techniques were included in the control group's activities. The sessions were conducted collectively in the same setting and at the same time as the SMR group to control for attention and environmental bias. Attendance and compliance were closely monitored by supervisors to ensure adherence.
223879025|NCT07070687|DEVICE|Transcutaneous Electrical Nerve Stimulation (TENS)|Low-frequency electrical stimulation (800Hz) applied at CV2/S3 regions twice daily for 7 days using MMK520i device
223879026|NCT07071246|DRUG|Rituximab Injection|low dose of rituximab intravenously
223879027|NCT07071155|DRUG|Momelotinib|The investigators will randomize the first 10 patients to receive 200 mg momelotinib (MMB) monotherapy for first 3 cycles with addition of HMA starting cycle 4 (Arm A, n=5) versus starting with MMB-HMA combination both starting in cycle 1 (Arm B, n=5). The regimen used for the next 8 patients (Arm C- expansion) will be determined after an interim analysis of Arms A and B at week 12 after the first 10 participants have been randomized.
223879028|NCT07071155|DRUG|Azacitidine|75 mg/m2, days 1-5 in a 28-day cycle
223879029|NCT07071155|DRUG|Decitabine|20mg/m2, days 1-5 in a 28-day cycle
223879030|NCT07069790|OTHER|Test of neuromuscular fatigue and associated hemodynamic responses|Baseline measurements of neuromuscular function and hemodynamic responses will be performed. Baroreflex sensitivity will be assessed using a neck collar applying positive and negative pressures to stimulate the carotid baroreceptors, thereby modulating baroreflex activity in a dose-dependent manner. Mechanoreflex activation will then be evaluated using the passive leg movement (PLM) technique. After the PLM, participants will perform four fatigue tasks, each followed by 2 minutes of post-exercise circulatory occlusion (PECO). Tasks involve isometric quadriceps contractions at 20% of maximal voluntary contraction (MVC) during 1 min (block 1), 2 min (blocks 2 and 3) and until failure (block4). Neuromuscular function will be assessed through MVC changes and quadriceps twitch responses. Mean arterial pressure (MAP) will be recorded continuously. Metaboreflex activity will be determined by plotting post-PECO changes in peripheral fatigue against the change in MAP during PECO phases.
223879031|NCT07070297|DRUG|XKH001 Injection|Dosage: 600 mg Q4W (D1, D29 and D57) Method of administration: the drug will be administered by SC injection in an area 3 cm away from and within 5 cm around the umbilicus of the abdomen. Sites with skin damage, inflammation, ulceration, rash and scar should be avoided. Subjects should be closely observed for reactions within 4 h after dosing.
223879032|NCT07077564|DRUG|Sac-TMT|Sacituzumab govitecan 5 mg/kg every 2 weeks on Day 1 of each cycle（IV）
223879033|NCT07078110|PROCEDURE|Material: Filtek Z250 (3M ESPE, USA)|"Group I (Incremental Technique):~Material: Filtek Z250 (3M ESPE, USA) Applied in 2 mm incremental layers, light-cured for 40 seconds per increment."
223879034|NCT07078110|PROCEDURE|Material: Filtek Bulk-Fill Restorative (FBF), 3M ESPE, USA|"Group II (Bulk-Fill Technique):~Material: Filtek Bulk-Fill Restorative (FBF), 3M ESPE, USA Applied in a single increment (up to 4 mm) and light-cured for 40 seconds."
223879035|NCT07077759|OTHER|Online self-compassion intervention|Participants in the intervention group will receive five consecutive weekly sessions, with each session lasting 2 hours (totaling 10 hours). Each session will include an introduction, guided exercises, group discussions and home practice.
223879036|NCT07078318|OTHER|Pelvic floor rehabilitation|Participants in this group will receive standard pelvic floor rehabilitation. This includes education about pelvic floor anatomy and function, supervised pelvic floor muscle training (Kegel exercises), relaxation techniques, and manual release of trigger points if necessary. The aim is to improve muscle strength, coordination, and reduce pelvic floor hypertonicity contributing to dyspareunia.
223879037|NCT07078318|OTHER|Diaphragmatic Breathing Exercises|In addition to the standard pelvic floor rehabilitation, participants in this group will practice diaphragmatic breathing exercises. These exercises focus on deep, slow nasal inhalation using the diaphragm, encouraging abdominal expansion while minimizing chest movement. Sessions are performed twice daily for 10 minutes. This technique is aimed at promoting parasympathetic activation, reducing anxiety, and improving autonomic regulation.
223879038|NCT07078318|OTHER|Diaphragm Manual Therapy|an additional manual therapy intervention targeting the diaphragm. Diaphragm manual therapy involves hands-on techniques applied to the thoracic and abdominal regions to reduce fascial restrictions, improve diaphragmatic mobility, and support deeper, more effective breathing. The therapy is delivered for 15 minutes at the start of each weekly session by a trained physiotherapist.
223879039|NCT07078539|OTHER|Kaltenborn Mobilization Group|"Participants in this group will receive Kaltenborn mobilization techniques applied to the talocrural and subtalar joints. Mobilizations will be performed as Grade III passive accessory glides for 10 repetitions per joint, each sustained for 15 seconds with a 10-second rest interval~Conventional treatment includs therapeutic ultrasound (3 MHz, 1.5 W/cm², continuous mode for 5 minutes), plantar fascia and calf stretching (10 minutes, 1 set of 10 reps), intrinsic foot muscle strengthening exercises (toe curls and towel curls for 10 minutes, 2 sets of 10 reps), and cryotherapy at home for 10 minutes daily. The intervention will be delivered twice weekly for 3 weeks."
224076674|NCT05827029|PROCEDURE|Preopertive drink|"* Group C: will receive a carbohydrate drink of 400 ml (50 g of glucose prepared by nutrition division, same appearance and containing bottles of water)~* Group W: will receive water 400 ml (prepared by nutrition division, Songklanagarind hospital, same appearance and containing bottles of carbohydrate drink) In both groups, the received 400-mL drink was consumed within 5 minutes.~* Before drinking, baseline data (gastric residual volume, POCT glucose, degree of hunger, and thirst) will be evaluated.~* Gastric ultrasound will be performed by the same Radiologist on each participant at 0, 30, 60, 90, 120 minutes~* after drinking to evaluate the gastric residual volume and time to empty gastric antrum.~* POCT glucose and degree of hunger and thirst are also assessed again at 120 minutes after drinking.~* After completing one type of drinking, participants will be appointed again after 1 week later for doing the same protocol with another drinking."
224076675|NCT03403205|DRUG|ALXN1840|ALXN1840 administered orally in 15 mg tablets
223879040|NCT07078539|OTHER|Mulligan Mobilization Group|"Participants in this group will receive Mulligan mobilization with movement (MWM) techniques applied to the talocrural and subtalar joints. Mobilizations will be applied as 3 sets of 10 repetitions per joint with 1-minute rest between sets.~Conventional treatment includs therapeutic ultrasound (3 MHz, 1.5 W/cm², continuous mode for 5 minutes), plantar fascia and calf stretching (10 minutes, 1 set of 10 reps), intrinsic foot muscle strengthening exercises (toe curls and towel curls for 10 minutes, 2 sets of 10 reps), and cryotherapy at home for 10 minutes daily. The intervention will be delivered twice weekly for 3 weeks."
223879041|NCT07077538|DRUG|Amino acid peritoneal dialysis solution|After breakfast daily, use a bag of amino acid (15) peritoneal dialysis solution (2L), followed by treatment with glucose peritoneal dialysis solution (lactate).
223879042|NCT07078240|OTHER|Falls risk - Artificial Intelligence Recommender (FAIR)|"FAIR is an alert system built into the hospital's electronic medical record system. It is an adaptation of a machine learning model for fall risk calculation built in another hospital in Singapore. FAIR combines multiple patient-specific variables to identify if a patient is at increased risk of falling during their inpatient stay, marking them as a 'falls risk'.~Based on the 'flag' raised, the nurse will be instructed to prioritise her falls risk assessment of the patient (If deemed 'high risk') or to do so subsequently as a lower priority once other pressing patient care issues are resolved (if deemed 'low risk').~That way, it ensures the requirements of each patient receiving a falls risk assessment as scored through mWHeFRA are still met, with FAIR allowing nurses to better prioritise their focus and attention on the patient that most needs the assessment at point of admission,"
223879043|NCT07078240|OTHER|modified Western Health Falls Risk Assessment Tool (mWHeFRA)|The mWHeFRA is the hospital's standard falls risk assessment tool. All nurses are expected to be proficient in its use to guide their risk assessment of patients
223879044|NCT07076771|OTHER|Coronary Angiography|All angiographic procedures will be performed. Coronary artery disease will be defined as \>70% stenosis in at least one major epicardial artery or \>50% the left main coronary artery.
223879045|NCT07076771|OTHER|Syntax Score|The angiographic complexity of coronary artery disease (CAD) will be assessed using the SYNTAX score.
223879046|NCT07077161|DRUG|Cabozantinib|For patients using 40mg the experimental regimen consists of 60mg once daily for 2 days followed by 1 skipping day (60-60-0 mg). For patients using 20mg the experimental regimen consists of 60mg once daily for 1 day followed by 2 skipping days (60-0-0 mg).
223879047|NCT06894680|OTHER|Stepped care|"It is a systematic, staged approach to delivering care based on the severity of a condition and the patient's response to treatment. In this model, less intensive interventions are provided first, and only those who do not improve progress to more intensive treatments.~In clinical research, stepped-care is classified as an adaptive intervention, where treatment is adjusted based on pre-specified criteria, making it patient-centered and resource-efficient."
224076676|NCT03403205|DRUG|SoC Therapy|Depending on the site/region, participants randomized to receive SoC treatment will receive trientine, penicillamine, Zinc, or a combination of these medicines, administered according to standard regimens.
224076677|NCT06533475|DRUG|Minzasolmin tablet formulation under fasting condition|Drug: Minzasolmin Pharmaceutical form: Tablet formulation under fasting condition
224076678|NCT06533475|DRUG|Minzasolmin Granules in capsule under fasting condition|Drug: Minzasolmin Pharmaceutical form: Granules in capsule under fasting condition
224076679|NCT06533475|DRUG|Minzasolmin tablet formulation under fed condition|Drug: Minzasolmin Pharmaceutical form: Tablet formulation under fed condition
223879048|NCT06894680|OTHER|Treatment as usual|Clients that are considered to be depressed are offered counselling by the Nurses who are the first point of contact. Depending on the severity of symptoms the client are then referred to the medical officer at the HIV clinic for assessment and offered counselling services by the counsellors. if symptoms are severe and considered to need specialist care the medical officer will refer to a specialist(psychiatrist) outside the HIV care facility.
223879049|NCT07078851|DEVICE|Fractional Picosecond Laser Treatment|Compound lidocaine cream (Tongfang Pharmaceutical Group Co., Ltd., National Drug Approval Number: H20063466) was applied to the face. After 60 minutes, it was cleaned thoroughly in preparation for treatment. The subjects lay flat on the treatment bed, and the face was disinfected twice. Treatment was performed using the Picsure Focus Lens (Cynosure, USA, Registration Certificate Number: National Medical Device Import 20153242702) with the following parameters: 6mm spot size, focus filter, 755nm wavelength, energy of 6.0J/cm², and 2Hz frequency. The endpoint response was skin flushing and mild edema. Immediately after the operation, recombinant human epidermal growth factor (Kanghesu, 20000IU/4ml/vial, Shanghai Haohai Biological Technology Co., Ltd.) was applied externally, followed by wet compresses with saline gauze combined with cold spray for 30 minutes. The subjects were required to apply recombinant human epidermal growth factor to the entire facial skin twice a day (one vial each
223879050|NCT07078851|DEVICE|gold microneedle treatment|The face was topically anesthetized with compound lidocaine cream (Tongfang Pharmaceutical Group Co., Ltd., National Drug Approval No. H20063466). After 60 minutes, the cream was cleaned off thoroughly to prepare for treatment. The subject was positioned supine on the treatment bed, and the face was disinfected twice. Gold microneedle radiofrequency treatment was performed using the NDPRD00009-E 3DEEP Phased RF治疗仪 (Eedy Med, Israel). The gold microneedle handpiece was disinfected with 95% medical ethanol. Under sterile conditions, the microneedle tips were installed, and the treatment parameters were set as follows: Cheeks mode with Intensif method, microneedle length 0.8-2.0 mm (length \<1.5 mm for forehead, temporal region, and zygomatic bone prominences); RF output time 180 ms; RF power 6-16 W. The operator held the device vertically and applied it evenly across the treatment area in a grid pattern, ensuring gentle contact with the skin to avoid excessive pressure. Any untreated gaps
223879051|NCT07077551|DRUG|NALIRIFOX|A cycle will be repeated every 14 days. G-CSF prophylaxis will be allowed after each cycle. Patients will undergo re-staging studies every 8 weeks. Patients will receive up to 12 cycles during the study. Additional cycles will be determined per investigators' discretion.
224076680|NCT05018234|DEVICE|Noval Oral Appliance|A scan of the mouth will be performed to make the oral device. The device will be 3D printed with Asiga UV Max printer using FDA 510(k) cleared VeriSplint OS Resin.Subjects will be will be asked to wear the oral device at night for 3 nights and fill out a survey reviewing their experience wearing the device.
223879052|NCT07070947|DIAGNOSTIC_TEST|sEMG|The spectral characteristics in the amplitude domain will be recorded through the root mean square (RMS, unit: μV) or the mean power frequency (MPF, unit: Hz) of the musculature to be evaluated by means of EMGs, with the electrodes placed parallel to the muscle fibers of the temporal, masseter, and suprahyoid muscles. Standardized EMGs will be recorded and compared in resting position and during maximum voluntary clenching
223879053|NCT06164275|PROCEDURE|Biopsy|Undergo tumor biopsy
223879054|NCT06164275|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223879055|NCT06164275|PROCEDURE|Computed Tomography|Undergo CT scan
223879056|NCT06164275|DRUG|Dacarbazine|Given IV
223879057|NCT06164275|DRUG|Doxorubicin|Given IV
223879058|NCT06164275|PROCEDURE|Echocardiography|Undergo echocardiography
223879059|NCT06164275|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA scan
223879060|NCT06164275|BIOLOGICAL|Pembrolizumab|Given IV
223879061|NCT06164275|PROCEDURE|Positron Emission Tomography|Undergo PET scan
223879062|NCT06164275|DRUG|Vinblastine|Given IV
223879063|NCT06937814|DIETARY_SUPPLEMENT|Humiome ® Post LB|Participants will be instructed to take one capsule with a glass of water after the first meal of the day.
223879064|NCT06937814|OTHER|Placebo|Participants will be instructed to take one capsule with a glass of water after the first meal of the day.
223879065|NCT04680065|BIOLOGICAL|AAV2-GDNF gene therapy|Bilateral image-guided infusion of AAV2-GDNF into putamen, single dose
223879066|NCT04680065|PROCEDURE|Sham (Placebo) Surgery|Bilateral partial burr/twist holes without dural penetration
223879067|NCT04402294|DIAGNOSTIC_TEST|Functional Magnetic Resonance Imaging (fMRI)|Participants undergo resting-state and task-based fMRI to identify individualized transcranial magnetic stimulation (TMS) targets and determine optimal and sub-optimal stimulation frequencies. Additional fMRI scans are performed after each neuromodulation phase to assess changes following three days of stimulation at the optimal and sub-optimal frequencies.
223879068|NCT04402294|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|Participants first receive multiple rTMS frequencies during an fMRI scan to assess brain responses and determine individualized optimal and sub-optimal stimulation frequencies. They then complete two neuromodulation intervention periods, receiving rTMS at the identified optimal and sub-optimal frequencies. Each frequency is administered over three consecutive days, with the order of conditions randomized and counterbalanced.
223879069|NCT06948578|DEVICE|Thread embedding-acupuncture|TEA is performed once at bilateral ST36 (perpendicular insertion) and BL13 (oblique insertion toward EX-B1) using absorbable PDO thread (CARA® 30G × 38 mm). Standard aseptic procedures are followed. Bleeding is controlled, and insertion sites are covered. Participants continue their routine pharmacological COPD treatment.
223879070|NCT06948578|DEVICE|Sham thread-embedding acupuncture|Sham TEA involves taping needles onto the surface of bilateral ST36 and BL13 without skin penetration or thread insertion. The direction toward EX-B1 is mimicked without actual insertion. All procedures, including marking and aseptic preparation, are performed identically to maintain blinding. Participants continue their routine pharmacological COPD treatment.
223879071|NCT00012454|DRUG|E-Selectin nasal spray|
223879072|NCT06951594|DEVICE|Robotic|The iotaSOFT™ Insertion System is an FDA approved cochlear implant (CI) electrode array insertion tool. It provides surgeons with consistent insertion speed and force. The system consists of a drive unit connected to a touch screen control console and foot pedal interface. The surgeon secures the base to the skull with two pre-loaded self-drilling bone screws. The drive unit is placed into the base and the adjustable drive head is coupled to a CI electrode. Before insertion begins, the surgeon selects the desired speed of insertion. the surgeon controls the electrode insertion forward and reverse motion via foot pedal while guiding the electrode array into the cochlea with standard CI instrumentation. Upon the completion of electrode array insertion, the drive head and unit are uncoupled from the electrode lead and removed from the patient for disposal.
224076681|NCT02326415|OTHER|"Clinical Pathway with Fast-Track"|Care described in the critical pathway during postoperative like the moment when the patients can eat, can move or are discharged.
224076682|NCT02326415|OTHER|Postoperative Usual Protocol|Cares step by step as sugery responsable thinks are the best for patients until discharge.
223879073|NCT06785935|DEVICE|Needle knife|ultrasonography-guided percutaneous A1 pulley release using a needle knife
223879074|NCT06785935|DRUG|Corticosteroid: Betamethasone|ultrasonography-guided corticosteroid injection under the A1 pulley
223879075|NCT06834893|OTHER|Cool roof|Cool roofs are a heat-reflecting material that can be applied to existing household roofing in the form of a liquid-applied membrane. Cool roofs work by increasing solar reflectance (the ability to reflect the visible wavelengths of sunlight, reducing heat transfer to the surface) and thermal emittance (the ability to radiate absorbed solar energy) thereby reducing the amount of heat transferred into the home.
223879076|NCT04077086|DEVICE|Spectacles|Intervention group children in middle school Year 1 will receive spectacles in December 2024. Assuming that the relevant effects of treatment (glasses wear) on the main study outcome are complete once examinations determining high school attendance are finished at the end of Middle School Year 3, Intervention participants will have undergone 32 months (December 2024 - July 2027) of treatment by the endpoint of the trial.
223879077|NCT06830447|OTHER|low-frequency fatigue|Low frequency fatigue tested with myocene
223879078|NCT03181477|DEVICE|Radiotherapy|Radiotherapy of 80 GY + Chemotherapy (Temozolomide)
223879079|NCT06292208|BIOLOGICAL|IBD0333|This is a phase I/II, open, non-randomized, dose-escalation and expansion study designed to evaluate the safety, tolerability, pharmacokinetic (PK), immunogenicity, and preliminary efficacy of IBD0333 in patients with locally advanced/metastatic solid tumor or non-Hodgkin lymphoma in dose-escalation, dose-expansion, and clinical exploration phases.
223879080|NCT06829745|OTHER|Laughter Yoga|Laughter yoga is applied to the intervention group patient 2 hours after the burn dressing. It is applied every other day for 30 minutes after dressing for three weeks.
223879081|NCT06265597|OTHER|Healthy Nutrition and Yoga Program|"* Healthy Nutrition Program~  * At the beginning of the Healthy Nutrition and Yoga Program by the researcher give education to families and children in 3 sessions (Importance of Nutrition in School Age, Obesity in School Age, Nutrition Recommendations for Obese Children).~ * Providing individual counseling to children every 2 weeks from the start of the Healthy Nutrition Program, in cooperation with a nutritionist, in line with the basic healthy eating behavior goals.~ * After the 2nd session of the healthy nutrition education and from the beginning of the Yoga Program, in the 2nd, 4th, 6th, 8th and 10th weeks, children are asked to keep a food diary for 2 weekdays and 1 weekend (Thursday-Friday-Saturday) and planning is made according to reaching basic healthy nutrition behavior goals.~* Yoga Program \*Children's yoga is applied to each group twice a week for 12 weeks."
223879082|NCT04948489|DRUG|norethindrone acetate (NETA)|5mg of the NETA capsule by mouth daily for 12 months
223879083|NCT04948489|DRUG|Placebo|Placebo capsule everyday for 12 months
223879084|NCT03485430|BEHAVIORAL|Tapering|Tapering with follow up by nurse at weekly basis in beginning of tapering. Tapering in an outpatient setting. Follow-up to doctor after four months.
223879085|NCT01216176|DRUG|Anastrozole|
223879086|NCT01216176|DRUG|AZD0530 (saracatinib)|
223879087|NCT01216176|DRUG|Placebo|
223879088|NCT03231878|DRUG|MIN-102|MIN-102 treatment
223879089|NCT03231878|DRUG|Placebos|Placebo
223879090|NCT06702527|PROCEDURE|Mitral transcatheter edge-to-edge repair|Mitral transcatheter edge-to-edge repair with the PASCAL system
223879091|NCT05605548|DRUG|MitoQ|MitoQ is a mitochondrial targeted antioxidant that can be obtained over-the-counter.
223879092|NCT05605548|OTHER|Placebo|"A look-alike inactive substance, a sugar pill"
223879093|NCT06831877|DEVICE|active-dTMS|The dTMS using H-coil with 5Hz stimulate ACC. The sessions of dTMS will be conducted twice daily for 5 consecutive days, and twice sessions of a day will be separated by 3 hours at least.
223879094|NCT06831877|DEVICE|sham-dTMS|The sham-dTMS has the same appearance with the real stimulation coil, which can not generate magnetic field. A sound generator is built in the coil beat to simulate the sound of the real stimulation.
223879095|NCT02975505|OTHER|Strict blood pressure control|Systolic Blood Pressure Target \< 120 mm Hg (measured at home)
223879096|NCT06833398|PROCEDURE|Arthroscopic Simple Biceps Tenotomy:|"Arthroscopic Simple Biceps Tenotomy: This procedure involves an arthroscopic release of the LHB tendon from its attachment at the superior glenoid labrum. It is a quick and simple technique that does not require implants or extensive postoperative rehabilitation. The main drawback is the potential for developing a Popeye deformity, where the biceps muscle bulges due to distal migration, as well as occasional muscle cramps."
223879097|NCT06833398|PROCEDURE|Anchor Tenotomy Technique:|Anchor Tenotomy Technique: This is a novel arthroscopic method where, after releasing the LHB tendon, it is anchored in place to prevent distal migration. The goal of this technique is to avoid the Popeye deformity and improve cosmetic outcomes while maintaining functional integrity. This procedure is technically more challenging and may involve a longer operative time compared to simple tenotomy.
223879098|NCT04956341|DEVICE|Auricular acupuncture|Auricular acupuncture treatments will be utilizing ASP needles. The needles will stay in and fall out on their own (usually 3-10 days). For some patients who are acupuncture naïve, Seirin 15mm needles will be placed and allowed to remain for 45 minutes. This option will be provided to all subjects for their first treatment. Auricular acupuncture treatment possible locations will be as defined as: Master Cerebral/Prefrontal cortex, Amygdala, Hippocampus, Hypothalamus, Point Zero, Shen Men, Insomnia 1,Insomnia 2 OR Prefrontal Cortex, Reticular formation, Pineal gland, Hypothalamus, Point zero. In acupuncture parlance, the patient will be treated with ATP plus sleep I on first visit, then the acupuncturist will continue to use that treatment for each subsequent visit with the potential to add ATP plus sleep II. Both ears will be treated unless the patient requests that one be left open. The acupuncturist may use sleep I in one ear and sleep II in the other.
223879099|NCT04956341|OTHER|Standard treatment|Standard treatment from Primary Care Manager (PCM) or Mental Health or both
223879100|NCT06241664|DEVICE|AEYE-DS Software|An Artificial Intelligence (AI) software device to be used as a diagnostic tool to assist healthcare providers in screening for diabetic retinopathy (DR) using digital funduscopic images. The device automatically detects more than mild diabetic retinopathy (mtmDR) in adults diagnosed with diabetes who have not been previously diagnosed with DR.
223879101|NCT04927234|DEVICE|geko™ therapy|Neuro-muscular electrical stimulation of the peroneal nerve
223879102|NCT03388788|RADIATION|PET Imaging|Positron Emission Tomography (PET) imaging for research.
223879103|NCT03388788|BEHAVIORAL|Circadian Study Protocol|5-day circadian study schedule
223879104|NCT03388788|DRUG|11C-Meta-Hydroxyephedrine (mHED)|11C-meta-hydroxyephedrine will be used during PET imaging to measure cardiac presynaptic norepinephrine transporter function.
223879105|NCT03388788|DRUG|11C-CGP12177|Cardiac beta adrenergic receptor density will be measured via PET imaging with infusion of 11C-CGP12177.
223879106|NCT03388788|DRUG|O15-water|Blood flow will be measured via PET imaging with infusion of O15-water.
223879107|NCT05206747|DEVICE|Blue-blocking glasses|It will transmit 45% of visible light with the following light transmission profile.
223879108|NCT05206747|DEVICE|Lightly-tinted glasses|It will also filter short wavelength light but at a lower threshold with near identical transmission above this threshold. It will transmit 91% of visible light with the following light transmission profile.
223879109|NCT06113640|DRUG|levodopa-carbidopa|Carbidopa/levodopa, also known as levocarb and co-careldopa, is the combination of the two medications carbidopa and levodopa. It is primarily used to manage the symptoms of Parkinson's disease
223879110|NCT06113640|DRUG|Montelukast|Montelukast and other CysLT1 antagonists are currently used as an adjuvant therapy for children and adults suffering from asthma. Other indications have been proposed and most evidence exists for the use of montelukast to treat allergic rhinitis, but its use in other inflammatory conditions, such as atherosclerosis and chronic obstructive pulmonary disease, have also been suggested.
223879111|NCT00212355|DRUG|NPC-02|zinc acetate
223879112|NCT05769595|BIOLOGICAL|MK-2060|Lyophilized powder diluted in normal saline for IV infusion
223879113|NCT05769595|DRUG|Placebo|IV infusion
223879114|NCT03661359|OTHER|Social Determinants of Health Referrals|Patients who screen positive for any of the Social Determinants of Health will be given information for referral to any of the community resources that apply to their situation.
223879115|NCT06515418|DRUG|Oral Azelaprag (BGE-105)|Capsules
223879116|NCT06515418|DRUG|Oral Placebo for Azelaprag (BGE-105)|Capsules
223879117|NCT06515418|DRUG|Tirzepatide|Subcutaneous Injection
223879118|NCT06515418|DRUG|Tirzepatide Placebo|Subcutaneous Injection
223879119|NCT04175639|BEHAVIORAL|Mobile Health Pain Coping Skills Training (mPCST)|Participating in Mobile Health Pain Coping Skills Training will involve four 50-minute individual intervention sessions conducted over the course of 8 weeks with tele-video-conferencing at patient's community-based clinic. The therapist delivering the intervention will be at Duke University Medical Center, and patients will be at their community clinic.
223879120|NCT00186992|RADIATION|image-guided radiotherapy|Conformal limited image radiotherapy is radiation therapy that targets tumors with a prescribed dose of radiation which allows the surrounding normal tissues to remain basically untreated.
223879121|NCT00353483|PROCEDURE|Peripheral blood draw|
223879122|NCT00353483|PROCEDURE|Breast tissue collection|
223879123|NCT00353483|PROCEDURE|Bone marrow biopsy|
223879124|NCT03683069|DRUG|Eplerenone vs Amlodipine|We posit that decreases in striatin activity/levels increases aldosterone secretion resulting in hypertension and salt sensitive blood pressure. Thus, our mechanistic clinical study will assess whether hypertensive striatin risk allele carriers will show significantly greater reductions in blood pressure with a specific aldosterone mediated treatment approach (mineralocorticoid receptor blockade) than with a non-specific approach (amlodipine). To test this hypothesis, we will perform a randomized, double-blind, active controlled study in hypertensive carriers of the striatin risk allele using a novel two-limb, proof-of-principle study. Our primary outcome will be a liberal salt diet systolic blood pressure with a secondary outcome of salt sensitive blood pressure. Therefore, this mechanistic trial will provide support for using a genetic marker that identifies individuals who are uniquely responsive to mineralocorticoid receptor blockade--personalized, precision medicine.
223879125|NCT06106451|BEHAVIORAL|Standard of Care plus Enhanced Patient Education|Patients in this arm will receive a pamphlet explaining the benefits of cardiac rehabilitation. This pamphlet will be given in addition to standard of care patient education. The research team will also call the patient at four specified time points to provide additional information.
223879126|NCT06106451|BEHAVIORAL|Motivational Interviewing Intervention|Patients in this arm of the study will participate in a tailor-made motivational interviewing program. These motivational interviewing sessions will focus on enhancing communication with patients. Each motivational interviewing session will be approximately one hour long. There will be a total of 4-6 motivational interviewing sessions.
223879127|NCT06106451|BEHAVIORAL|Home-Based Activity Program plus Motivational Interviewing Intervention|Patients in this arm will be evaluated on postoperative day 1 by a physical therapist on the study team. After the evaluation, the physical therapist will use the information from the evaluation to make a tailored home-based physical activity program for the patient. The patient will begin the home-based physical activity program on the day of their 1-month post-operative cardiology clinic appointment. In addition to the home-based activity program, patients will participate in a tailor-made motivational interviewing program. These motivational interviewing sessions will focus on enhancing communication with patients. Each motivational interviewing session will be approximately one hour long. There will be a total of 4-6 motivational interviewing sessions.
223879128|NCT04343703|BEHAVIORAL|Telephone-based management|The intervention consists of a series of phone calls aimed at providing follow up care of individuals at risk. At each phone call the case manager collects information regarding the current treatment, adherence to mental health services, and current life stressors.
223879129|NCT04343703|BEHAVIORAL|iFightDepression for Suicide|The iFD-Survive is a cognitive-behavioral, internet-based self-management tool, developed by the European Alliance Against Depression (EAAD). The iFD is intended to address mild-to-moderate depressive symptoms. The iDF tool is structured in seven core modules focused on: behavioral activation, cognitive restructuring, sleep regulation, mood monitoring, and healthy lifestyle habits. The content of each module is intended to be followed over 1 week and consists of written information, tasks to do over the week and worksheets. All of these aims to consolidate learning and promote self-monitoring. For this study, an additional module (iFD-S) will be developed. The iFD-S also provides telephone guidance (2h per participant).
224076683|NCT01834729|DRUG|Alfuzosin|oral alfuzosin immediate release (IR) 2.5 mg (Part A) or oral alfuzosin extended release (ER) 10 mg (Part B)
224076684|NCT01834729|OTHER|Placebo|placebo capsule identical to the study drug
223879130|NCT04343703|BEHAVIORAL|Treatment as Usual|Treatment as Usual (TaU) will vary across sites, however it generally implies a combination of case management strategies (including telephone calls, visits by mental health services) and pharmacotherapy. For this study, any nonspecific intervention to address suicidal behavior or to prevent suicide will be considered as treatment as usual.
223879131|NCT04343703|BEHAVIORAL|Self Awareness of Mental Health|The SAM consist of five, face-to-face, individual sessions designed to raise awareness about depression, anxiety and suicidal behaviors as well as to enhancing skills to effectively cope with stressful life events and mood.
223879132|NCT03769168|DRUG|Secukinumab|Secukinumab solution for subcutaneous injections was provided in PFS. Initially, participants continued to receive secukinumab at either 75 mg (in 0.5mL) or 150 mg (in 1mL) every 4 weeks, consistent with their dosage at the Week 100 visit of the core study. The dose could be escalated from 75 mg to 150 mg for patients whose signs and symptoms were not fully controlled, as judged by the investigator, with the current 75 mg dose. Furthermore, the dose could also be escalated to 300 mg every 4 weeks for patients weighing 50kg and over who were currently on the 150 mg dose and whose signs and symptoms were not well-controlled, as judged by the investigator. The dose escalation from secukinumab 75 mg to 300 mg was to be implemented in two steps (first 150 mg and then 300 mg based on the investigator's judgment). At each study treatment time point, one or two subcutaneous injections in the form of PFS were administered.
223879133|NCT03117751|DRUG|Prednisone|Given orally (PO).
223879134|NCT03117751|DRUG|Vincristine|Given intravenously (IV).
223879135|NCT03117751|DRUG|Daunorubicin|Given IV.
223879136|NCT03117751|DRUG|Pegaspargase|Given IV or intramuscularly (IM) .
223879137|NCT03117751|DRUG|Erwinase®|To be used in case of hypersensitivity or intolerance to Pegaspargase or if Pegaspargase is not available. Given IV or intramuscularly (IM).
223879138|NCT03117751|DRUG|Cyclophosphamide|Given IV.
223879139|NCT03117751|DRUG|Cytarabine|Given IV or by subcutaneous injection (SQ).
223879140|NCT03117751|DRUG|Mercaptopurine|Given PO.
223879141|NCT03117751|DRUG|Dasatinib|Given PO.
223879142|NCT03117751|DRUG|Methotrexate|Given IV.
223879143|NCT03117751|DRUG|Blinatumomab|Given IV.
223879144|NCT03117751|DRUG|Ruxolitinib|Given PO.
223879145|NCT03117751|DRUG|Bortezomib|Given IV or subcutaneously (SQ).
223879146|NCT03117751|DRUG|Dexamethasone|Given PO.
223879147|NCT03117751|DRUG|Doxorubicin|Given IV.
223879148|NCT03117751|DRUG|Etoposide|Given IV.
223879149|NCT03117751|DRUG|Clofarabine|Given IV.
223879150|NCT03117751|DRUG|Vorinostat|Given PO.
223879151|NCT03117751|DRUG|Idarubicin|Given IV.
223879152|NCT03117751|DRUG|Nelarabine|Given IV.
223879153|NCT03117751|DRUG|Thioguanine|Participants with mercaptopurine-related pancreatitis. Given PO.
223879154|NCT03117751|DRUG|Asparaginase Erwinia chrysanthemi (recombinant)-rywn|To be used in case of hypersensitivity or intolerance to Pegaspargase or if Pegaspargase is not available. Given intramuscularly (IM).
223879155|NCT03117751|DRUG|Calaspargase Pegol|To be used in case of hypersensitivity or intolerance to Pegaspargase or if Pegaspargase is not available. Given IV.
223879156|NCT05093179|PROCEDURE|Deep tissue massage|Administered as a soft tissue mobilization performed by the therapist with fingertips, knuckles, elbows and/or fists on the tissues that manifest symptoms of fascial restrictions. The techniques were performed with individually adjusted force until the change (eg. increased mobility) in the tissue being treated was stated by the therapist.
223879157|NCT05093179|PROCEDURE|Classic massage|The subject was lying supine on the table, with a roller placed under the knee joints, the upper limbs along the body. The following sequence of techniques was used in the longitudinal and transverse strands and in the intercostal spaces (excluding the breast in women): effleurage, friction, petrissage, pressures, tapotement and vibrations.
223879158|NCT05383079|DRUG|Lutetium-177 PSMA-I&T|Patients will be given 7.4 GBq of 177Lu-PSMA every 6 weeks for up to 6 Cycles
223879159|NCT05383079|DRUG|Radium-223|During dose escalation, doses of Radium-223 that will be administered include 27.5 kBq/kg and 55 kBq/kg. The maximum tolerated dose of Radium-223 will be used during dose expansion. Radium-223 will be given once every 6 weeks for up to 6 doses between day 1-5 of each Cycle.
223879160|NCT04620239|DRUG|padeliporfin VTP|During treatment, placement at the target area of an optical light fiber, through the working channel of the ureteroscope. Intravenous administration of padeliporfin at the dose of 3.66 mg/kg infused over 10 minutes. Each target area will be illuminated for 10 minutes.
223879161|NCT05344378|BEHAVIORAL|ATTAIN NAV Technology-Enhanced Family Navigation Model|The purpose of ATTAIN NAV is to test the impact of family navigation in multiple primary care clinics in Southern California for children with autism who have additional mental health needs. Family navigation includes: screening and behavioral health referral, supporting access to behavioral health services, engaging in evidence-based treatment, monitoring to achieve family goals, family strengthening, and connecting to concrete resources.
223879162|NCT04941287|BIOLOGICAL|Atezolizumab|Given IV
223879163|NCT04941287|PROCEDURE|Biopsy|Undergo tumor biopsy
223879164|NCT04941287|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223879165|NCT04941287|DRUG|Cobimetinib|Given PO
223879166|NCT04941287|PROCEDURE|Computed Tomography|Undergo a CT scan
223879167|NCT04941287|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223879168|NCT04941287|DRUG|Varlilumab|Given IV
223879169|NCT04209985|BEHAVIORAL|Health coaching|Brief telephonic intervention consisting of up to five phone calls from a health coach
224076685|NCT02971670|BIOLOGICAL|rTSST-1 Variant Candidate Vaccine|Immunization either according to their former allocated dose (group 4: 3 µg of candidate vaccine or placebo, group 5: 10 µg of candidate vaccine or placebo, group 6: 30 µg of candidate vaccine or placebo) or 3 µg of candidate vaccine or placebo (groups 1 - 3) from Phase I.
224076686|NCT03664414|DRUG|pentoxifylline|Pentoxifylline or placebo will be prescribed three times a day with meals. All the participants will continue with the usual treatment. Time frame: two years
224076687|NCT03431987|DRUG|One day with a dose of placebo cannabis paired with alcohol|Vaporized placebo marijuana with little to no THC paired with drinking alcohol to BrAC of 0.05%
224076688|NCT03431987|DRUG|One day with a dose of active THC cannabis paired with alcohol|Vaporized marijuana with active THC paired with drinking alcohol to BrAC of 0.05%
223879170|NCT05641974|BEHAVIORAL|Helpers Stay Quit Training|"The Helpers Stay Quit training emphasizes a tobacco-user centered, non-confrontational approach to encouraging others to quit smoking. Helpers Stay Quit trainees learn how to offer a 4-step helping conversation. The four steps of a helping conversation parallel the 4 core training modules of Helpers Stay Quit (Awareness, Understanding, Helping, Relating). A key learning objective of Helpers Stay Quit, is for Helpers to learn how to manage their own expectations for the process and outcome of a helping conversation (e.g. Helpers are taught that they cannot make anyone quit, but they can offer non-judgmental support, and information about effective cessation aids). Consequently, Helpers are taught to manage their own behavior when helping others (e.g. avoiding nagging or pushing a tobacco-user to quit). The helping conversation focuses on encouraging behavior change that is aligned with the tobacco user's current willingness/readiness to take any action toward quitting."
223879171|NCT05532059|DRUG|Lenvatinib, tislelizumab, gemcitabine and cisplatin|Lenvatinib, tislelizumab, gemcitabine and cisplatin
223879172|NCT05532059|DRUG|gemcitabine and cisplatin|gemcitabine and cisplatin
223879173|NCT05904470|DRUG|Bemnifosbuvir|550 mg administered orally once a day (QD) for 8 weeks
223879174|NCT05904470|DRUG|Ruzasvir|180 mg administered orally once a day (QD) for 8 weeks
223879175|NCT04437498|DEVICE|sham stimulation|non invasive vagal nerve stimulation
223879176|NCT04437498|DEVICE|nVNS|active vns stimulation
223879177|NCT06230198|PROCEDURE|retrograde autologous priming (RAP)|sites follow an institutional policy of routine use of retrograde autologous priming (RAP) during cardiac surgery
223879178|NCT06230198|PROCEDURE|Crystalloid priming|sites implement crystalloid priming use during cardiac surgery
223879179|NCT03190174|DRUG|Nab-Rapamycin|Escalating doses of ABI-009 will be given IV over 30 min for 2 of every 3 weeks beginning Day 8 Cycle 2. Only nivolumab will be given in Cycle 1. At Dose Level 1, 3-6 patients will receive 56 mg/m\^2; at Dose Level 2, 3-6 six patients will receive 75 mg/m\^2; and at Dose Level 3, 3-6 patients will receive 100 mg/m\^2.
223879180|NCT03190174|BIOLOGICAL|Nivolumab|A defined dose of nivolumab, 3 mg/kg, will be given IV over 30 minutes q 3 weeks
223879181|NCT06791772|BIOLOGICAL|CM313 injection|CM313 600mg（4ml）/vial. Subcutaneous injection 600mg. The first 5 doses were administered weekly, followed by every two weeks, a total of 14 doses.
223879182|NCT06791772|BIOLOGICAL|CM313 injection|CM313 600mg（4ml）/vial. Subcutaneous injection 1200mg. The first 5 doses were administered weekly, followed by every two weeks, a total of 14 doses.
223879183|NCT06791772|DRUG|Placebo|Placebo 4 mL/vial. Subcutaneous injection 4 or 8 mL. The first 5 doses were administered weekly, followed by every two weeks, a total of 14 doses.
223879184|NCT06785376|BEHAVIORAL|DIY (Do It Yourself)|DIY is 3-session program that promotes empowerment, autonomy, stigma coping/resistance and social support to promote sexual health and pleasure and HIV prevention.
223879185|NCT06785376|BEHAVIORAL|TRUST|TRUST is a single-session HIV self-testing training with facilitator
223879186|NCT06785376|BEHAVIORAL|SOC|standard of care single-session, low threshold peer/near-peer navigation to PrEP.
223879187|NCT06459739|PROCEDURE|sacral ESPB|sacral ESPB
223879188|NCT04765865|OTHER|SHAKE Package|The SHAKE (Surveillance of salt intake, Harness industry, Adopt standards for labelling and marketing, Knowledge to empower consumers, and Environments to promote health eating) package is a WHO Best Buy and is recently implemented within Nigeria by the Nigerian Agency for Food and Drug Administration and Control (NAFDAC).
223879189|NCT06199700|DRUG|Esketamine hydrochloride|Intravenous infusion of Ketamine
223879190|NCT06787170|DIAGNOSTIC_TEST|MRI habitat imaging|Habitat imaging, a data-driven image processing technique that divides the entire lesion into multiple sub-regions without assuming anything prior, has capacity to noninvasively evaluate the intratumoral heterogeneity.
223879191|NCT06791785|OTHER|Before Application|All groups will be asked to fill out forms before the application (Westside test anxiety scale, burdon attention test, descriptive information form)
223879192|NCT06791785|OTHER|Before the 1st Written Exam|Fill out forms before the 1st written exam (Westside test anxiety scale, burdon attention test, descriptive information form)
223879193|NCT06791785|OTHER|End of Term|Fill out forms at the end of the term (Westside test anxiety scale, burdon attention test, descriptive information form)
223879194|NCT04661501|DEVICE|AlloDerm|Acellular Dermal Matrices (ADMs) are breast reconstruction material. They are donated cadaveric dermis that is aseptically processed or sterilized in order to remove cellular and immunogenic components to prevent host reactions.
223879195|NCT04661501|DEVICE|AlloMax|Acellular Dermal Matrices (ADMs) are breast reconstruction material. They are donated cadaveric dermis that is aseptically processed or sterilized in order to remove cellular and immunogenic components to prevent host reactions.
223879196|NCT04661501|DEVICE|DermACELL|Acellular Dermal Matrices (ADMs) are breast reconstruction material. They are donated cadaveric dermis that is aseptically processed or sterilized in order to remove cellular and immunogenic components to prevent host reactions.
223879197|NCT04661501|DEVICE|Flex HD|Acellular Dermal Matrices (ADMs) are breast reconstruction material. They are donated cadaveric dermis that is aseptically processed or sterilized in order to remove cellular and immunogenic components to prevent host reactions.
223879198|NCT06835426|OTHER|Single intravenous injection of the radiotracer|"* only in case of 18F-FDG as PET-tracer: blood glucose level is measured;~* single intravenous injection of the radiotracer between 30 minutes and 5 hours (ideally between 60 and 90 minutes) before the specimen is imaged. The type and dose of radiotracer depends on the patient group:~  * breast cancer group: 0.8 MBq/kg of 18F-FDG~ * prostate cancer group: 1 MBq/kg 18F-PSMA~ * thyroid cancer group: 1 MBq/kg of 18F-FDG~ * parathyroid adenoma group: 1 MBq/kg of 18F-Choline~ * head \& neck cancer group: 1 MBq/kg of 18F-FDG~ * skin cancer group: 4 MBq/kg of 18F-FDG~ * primary and secondary hepatobiliary tumors group: 1 MBq/kg of 18F-FDG~ * genitourinary malignancies group: 1 MBq/kg of 18F-FDG~ * metabolic active lesions undergoing biopsy: 1 MBq/kg of 18F-FDG~ * Neuro-endocrine malignancies group: 1 MBq/kg of 18F-FDG~ * Brain tumor group: 1 MBq/kg of 18F-FDG, 18F-Choline or 18F~ * Gastrointestinal group: 1 MBq/kg of 18F-FDG~ * Thoracovascular group: 1MBq/kg of 18F-FDG"
223879199|NCT06835426|DIAGNOSTIC_TEST|Imaging resected specimen using the high-resolution PET-CT specimen imager|"* the resected specimen is imaged in the operation theatre using the high-resolution PET-CT specimen imager (XEOS Aura; XEOS Medical, Ghent, Belgium); in principle no treatment decisions will be taken based on the images acquired by the specimen imager; however a decision to extend the resection can be taken at the discretion of the surgeon if there is clinical suspicion of a positive resection margin;~* additional resected tissue (e.g. lymph nodes, cavity shaves etc) could also be imaged by the high-resolution PET-CT specimen imager; no treatment decisions will be taken based on the images acquired by the specimen imager;"
223879200|NCT05205174|DEVICE|depth electrodes|The study will be conducted at a single center, in TBI patients requiring neurosurgical intervention in the form of EVD placement. During neurosurgical intervention at the bedside in the Intensive Care Unit (ICU), a single depth electrode will be placed in the brain adjacent to the EVD catheter in the same burr hole. After EVD and depth electrode placement, continuous recording of ECoG activity as well as relevant physiological parameters will be performed for the duration of clinically indicated invasive neuromonitoring in accordance with the standard of care for TBI patients. A single recording station is currently available for data collection, therefore, with an anticipated average recording period of 14 days, the study will take greater than 210 days to complete for a total of 15 patients.
223879201|NCT05236582|DRUG|Herombopag|The subjects will initiate treatment with 7.5 mg/d Herombopag. Platelet counts is obtained weekly and dose adjustment should be done according to platelet counts, and maximum dose should not exceed 7.5 mg daily. Subjects whose platelet count ≤100×109/L，the Herombopag dose will maintain. If platelet count \>100×109/L for 2 weeks, the subjects need to reduce the dose of Herombopag to the next lower dose or lower frequency. If subjects whose platelet count exceeds 100×109/L for 4 weeks，already have reduced the dose of Herombopag to 2.5mg once every other day or lower frequency during the treatment period, Herombopag can be stopped for observation, until platelet counts fall below 100×109/L. If the subjects do not need further chemotherapy or radiotherapy, the subjects can taper off Herombopag if the platelet is greater than 50×109/L.
223879202|NCT04527146|OTHER|IMAGINE-PD|The Interactive, Multimedia Approach to Genetic Counseling to INform and Educate in Parkinson's Disease (IMAGINE-PD) is a novel, interactive, web-based, audiovisual, self-guided, genetic counseling tool in the development phase. Essential genetic counseling themes, outlined by a senior certified clinical genetics counselor in accordance with national guidelines, are presented in a web-based format, utilizing videos, text, pictures, and audio. Participants can interact with IMAGINE-PD at their own pace, with the ability to move backward and forward, repeat sections, and have the ability to submit questions to the genetic counselor via e-mail.
223879203|NCT04527146|OTHER|Virtual genetic counseling|The virtual visits will be conducted by a certified genetic counselor to provide all counseling in accordance with guidelines set forth by the National Society of Genetic Counselors. The counseling visit will be conducted in real-time on an established and secure audiovisual conferencing telemedicine platform (BlueJeans) within the Penn Chart/Epic electronic medical record dashboard.
223879204|NCT04527146|OTHER|Telephone genetic counseling|The telephone counseling will be conducted by a certified genetic counselor to provide all counseling in accordance with guidelines set forth by the National Society of Genetic Counselors.
223879205|NCT05254509|OTHER|Occupational Therapy|Occupational therapy helps individuals with chronic pain to participate in daily activities in an adaptive way. The subjects will be provided with customized plans and objectives to address their self-care, vocational, and leisure goals. This includes education, home exercises, stress management, home safety, energy conservation, and work simplification - all of which promote a safe return to daily activities.
223879206|NCT05254509|OTHER|Occupational Therapy +Virtual Reality|The occupational therapy +VR utilizes the regular therapy sessions along with providing a Virtual reality headset to relieve pain. After each VR session, there will be a debriefing from the therapist.
223879207|NCT05107401|BEHAVIORAL|Digital Crowdsourced Intervention to Reduce HIV Stigma among Adolescents and Young Adults|Adolescents and young adults will participate in a crowdsourcing contest to create digital materials to reduce HIV stigma in order to increase HIV testing. Entries will be judged by a community judging panel and expert judging panel. Winning entries will be selected for the digital intervention and presented to participants in the intervention arm.
223879208|NCT06328751|DEVICE|Case group|Meditation will be taught through a video played on a Samsung® gear VR virtual reality glasses with monitoring of the patient's vital signs by the Samsung® smart watch to promote better quality of life and control cancer pain in patients treated at the Pain Therapy and Palliative Care Service.
223879209|NCT06328751|BEHAVIORAL|Active control group|Meditation will be taught through a video played on a Samsung® cell phone with monitoring of the patient's vital signs by the Samsung® smart watch to promote better quality of life and control cancer pain in patients treated at the Pain Therapy and Palliative Care Service.
223879210|NCT06328751|BEHAVIORAL|Passive control group|Meditation will be taught through a audio played on a Samsung® cell phone with monitoring of the patient's vital signs by the Samsung® smart watch to promote better quality of life and control cancer pain in patients treated at the Pain Therapy and Palliative Care Service.
223879211|NCT06707337|OTHER|Brief Self-compassion Program|Brief Self-compassion Program will be held in a face-to-face hospital environment for the patients with colorectal cancer in the experimental group. This training program has been developed based on the concepts of Mindfulness-Based Compassionate Living and Mindfulness-Based Stress Reduction Programs. The content and topics of the sessions in the program are arranged according to the conceptual structure and flow of the mindfulness-based model. The training program was created in a certain flow, based on the introduction to a short self-compassion program (1 sessions), the importance of self-compassion and self-care in the cancer experience (1 sessions), a self-compassionate approach to challenging emotions and situations (1 sessions). There are 3 sessions in the program and the frequency of sessions is 3 times a week, and each session lasts approximately 45 minutes. The training program will be applied to 33 patients with colorectal cancer in the experimental group.
224076689|NCT01258959|PROCEDURE|Ultrasound detection of local anesthetics spread|During the parabulbar injection the ultrasound operator experienced in ultrasound guided retrobulbar block will assess whether there is spread of local anaesthetic in the central cone just behind the sclera (yes or no). The anaesthesist performing the block will be blinded to the ultrasound visualized spread of local anaesthetic.
223879212|NCT02379520|GENETIC|HPV Specific T Cells|"Dose escalation study with 5 dose levels: DL1-1×10\^7 cells/m2, DL2-3×10\^7 cells/m2, and DL3-1×10\^8 cells/m2, DL4- 2 to 3×10\^8 cells/m2, DL5- 0.8 to 1×10\^9 cells/m2~Group A -HPVST cells Group B -lymphodepletion \& nivolumab \& HPVST cells.~First, treatment in Group A will be completed for DL1 and DL2. Only if DL2 in Group A proves safe, Group B will be treated on DL2, DL3, DL4, and DL5.~Group A will be treated at DL3, DL4, and DL5 only if there is excessive toxicity in cohorts treated with lymphodepletion.~HPVSTs will be given by IV injection over 1-10 minutes through a peripheral or a central line on day 0.~If patients have clinical benefit (as determined by symptoms, physical exam or radiological studies) \& no significant toxicities, they may get up to 5 repeat infusions (for max total of 6 infusions) of HPVSTs at or below the same dose level."
223879213|NCT02379520|DRUG|Cytoxan|500mg/m\^2/day x 3 days (on days -4, -3 and -2)
223879214|NCT02379520|DRUG|Fludarabine|30mg/m\^2/day x 3 days (on days -4, -3, and -2)
223879215|NCT02379520|BIOLOGICAL|Nivolumab|240mg every 2 weeks (+/- 3 days) starting on day -1
223879216|NCT06347211|DEVICE|Acumen IQ sensor with Hemosphere monitor incorporating the HPI algorithm|"Hemosphere monitoring and requires the use of a AcumenIQ sensor connected to an arterial line (Edwards Lifesciences Corp., Irvine, CA, USA). The sensor has a splitter which enables the splitting of the arterial blood pressure signal to facilitate a blood pressure signal on both the anesthesia machine monitor (standard care) and the HemoSphere monitor (study).~In the intervention arm we asked the anesthesiologist and anesthesia nurse to use the study treatment flowchart. If the HPI alarm goes off, which entails both a sound and a flickering light, we ask the anesthesiologist to act upon this alarm immediately. Use of the study treatment flowchart ensures that the anesthesiologist has to think about the underlying cause. The HemoSphere with HPI software has a second screen with variables that provide information about the underlying cause of the predicted hypotension."
223879217|NCT06133322|BEHAVIORAL|Behavioral: Evidence-based interventions recommended by the 2017 ACC/AHA hypertension clinical guideline|The recommended evidence-based interventions include therapeutic lifestyle change and medical treatment of hypertension
223879218|NCT01865110|DRUG|R-CHOP|R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) administered in 3 week cycles for 8 cycles
223879219|NCT01865110|DRUG|R-CHOP / R-HAD|R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) administered in 3 week cycles for 3 cycles R-HAD (rituximab, cytarabine, dexamethasone) administered in 3 week cycles for 4 cycles alternating
223879220|NCT01865110|DRUG|Rituximab|Rituximab SC 1400 mg every 8 weeks for 24 months
223879221|NCT01865110|DRUG|Lenalidomide|Lenalidomide 15 mg 3 weeks every 4 weeks for 24 months
223879222|NCT05856123|DEVICE|SimPull Lateral Transfer Device|Automated lateral transfer device
223879223|NCT04256798|DRUG|Chlorhexidine mouthwash|0.2% Chlorhexidine digluconate
223879224|NCT04256798|DRUG|Oxygen|Oxygen 80-100%
223879225|NCT04256798|DRUG|Oxygen|Oxygen 21-30 %
223879226|NCT04713982|DRUG|Deutetrabenazine|Maximum dose of 48mg/day or up to 36 mg/d if receiving a strong CYP2D6 inhibitor
223879227|NCT06212349|OTHER|therapeutic-educational physiotherapy and pain education program|The EG will carry out a total of 24 sessions, at a rate of 3 weekly sessions of 30 minutes each. The first session of each month will be in person and the rest will be done at home following video tutorials with an App (https://fisiotrack.com). The face-to-face sessions will be conducted by a women's health physiotherapist, and will consist on therapeutic exercises based on body awareness, motor control and respiratory awareness.They will also receive a pain education program with indications on pain education, as well as basic information and general advice on the positive effects of physical activity and a healthy lifestyle for endometriosis. In addition, biweekly supervision will be carried out via telephone or video conference by a specialized physiotherapist.
223879228|NCT06212349|OTHER|pain education program|They will receive instructions on pain education, as well as basic information and general advice about the positive effects of physical activity and a healthy lifestyle for your endometriosis, in writing via email. In addition, they will receive biweekly supervision via telephone or video conference by a specialized physical therapist.
223879229|NCT06486597|DIETARY_SUPPLEMENT|Meal|Liquid meal
223879230|NCT06274879|DRUG|Gemcitabin, Cisplatin and Durvalumab|CICI (Gemcitabin d1 \& d8 Cisplatin d1 \& d8, Durvalumab d1) are administered repeating every 21 days for a total of 8 cycles.
223879231|NCT06274879|PROCEDURE|Biliary Radiofrequency Ablation|Biliary Radiofrequency Ablation is applied at baseline, 6 and 12 weeks
223879232|NCT06274879|PROCEDURE|Endoscopic Retrograde Cholangio-Pancreatography with stenting|ERCP with stenting are applied at baseline and as clinically indicated
223879233|NCT06440057|BIOLOGICAL|ZG006|ZG006 will be administered as an intravenous (IV) infusion.
223879234|NCT03356990|DIETARY_SUPPLEMENT|Resistant Starch|"Dietary supplement will be taken every day for total of 2 weeks. Each participant will be take half the dose (one bag) of Hi-Maze 260 or High RS Gummy Chews in the morning and the other half dose (one bag) in the evening."
223879235|NCT05568069|DEVICE|Implantable Cardioverter-Defibrillator (ICD) or Cardiac Resynchronisation Therapy Defibrillator (CRTD)|An ICD is a device that is implanted under the skin under a local anesthetic. It has a battery/generator component and leads which are fixed into the heart chambers. It has the ability to detect dangerous heart rhythms if they occur, and deliver a shock to treat this to help prevent sudden cardiac death. A CRTD is a pacemaker with a defibrillator function.
223879236|NCT06009653|BEHAVIORAL|Standard Care|Participants will meet with community health workers to receive general health information through individual check-ins.
223879237|NCT06009653|BEHAVIORAL|Culturally-tailored dietary and behavioral intensive lifestyle intervention|Participants will meet with community health workers to receive information focused on healthy eating while still adhering to a culturally-tailored plant-forward diet.
223879238|NCT06009653|DRUG|Placebo|Participants will receive placebo subcutaneous injections.
223879239|NCT06009653|DRUG|Tirzepatide|Participants will receive subcutaneous injections of tirzepatide that gradually increase up to 15 mg per week.
224076690|NCT00288080|DRUG|Dexamethasone|Premedication of dexamethasone prior to docetaxel, per institutional standards.
223879240|NCT03206320|DRUG|Lidocaine Topical|Comparison of lidocaine topical gel with lidocaine infiltration and with no local anesthesia in reducing needle insertion and injection pain
223879241|NCT04184089|DEVICE|High flow nasal cannula (15 L/m)|nasal cannula at a flow rate of 15 l/min and FiO2 of 40%
223879242|NCT04184089|DEVICE|High flow nasal cannula (30 L/m)|nasal cannula at a flow rate of 30l/min and FiO2 of 40%
223879243|NCT04184089|DEVICE|High flow nasal cannula (60 L/m)|nasal cannula at flow rate of 60L/min. Oxygen supplementation will be at an FiO2 of 40%.
223879244|NCT04656925|BEHAVIORAL|Contingency management|Reinforcement, or incentives, in exchange for evidence of not drinking alcohol.
223879245|NCT04910776|DRUG|avalglucosidase alfa|Sterile lyophilized powder intravenous (IV) infusion
223879246|NCT00977691|PROCEDURE|PBSC Transplant|PBSC transplant
223879247|NCT00977691|DRUG|Alemtuzumab|alemtuzumab
223879248|NCT00977691|DRUG|Sirolimus|sirolimus
223879249|NCT00977691|DRUG|Cyclophosphamide|cyclophosphamide
223879250|NCT00977691|PROCEDURE|Low Dose Irradiation|low dose irradiation
223879251|NCT03513939|COMBINATION_PRODUCT|Sernova Cell Pouch|"The Sernova Cell Pouch will be implanted against the rectus abdominis. The patient will receive either an 8-plug or 10-plug Cell Pouch configuration depending on Cohort assignment. A minimum of three weeks after Cell Pouch implantation, immunosuppression will be initiated and optimized for another 3 weeks. This will allow for proper vascularization of the Cell Pouch chambers and the patient to be stabilized on immunosuppression prior to islet transplantation. A mass of highly purified islets will be transplanted in the Cell Pouch.~Patients who elect to retain the Cell Pouch after completion of the study will be asked to consent to long term safety follow-up, with data collected beyond the study scheduled visits every 3 months for up to 5 years until the last Cell Pouch explant (and then for a minimum of 3 months thereafter)."
223879252|NCT06231381|DRUG|HB0034|Anti-IL-36R antibody
223879253|NCT06231381|OTHER|Placebo|non-biologically active drug
223879254|NCT06331130|DIAGNOSTIC_TEST|Computed Tomography|Computed Tomography done according to Clinical Practice to assess mesenteric involvment
223879255|NCT05175352|DRUG|Cendakimab|Specified dose on specified days
223879256|NCT05175352|DRUG|CYP substrates|Specified dose on specified days
223879257|NCT06744998|DEVICE|Hemopatch® (Baxter)|HEMOPATCH® is an absorbable collagen pad intended for sealing and hemostasis
223879258|NCT05030831|DRUG|INZ-701|INZ-701 is a recombinant fusion protein that contains the extracellular domains of human ENPP1 coupled with an Fc fragment from an immunoglobulin gamma-1 (IgG1) antibody (rhENPP1-Fc).
223879259|NCT02645487|RADIATION|Stereotactic Radiosurgery|Radiation, Stereotactic Radiosurgery Size \<= 1cm: 24 Gray (Gy); + 3 Gy incremental escalation up to 30 Gy \>1-2cm: 21 Gy; + 3 Gy incremental escalation up to 27 Gy \>2-3cm: 18 Gy; + 3 Gy incremental escalation up to 24 Gy
223879260|NCT05687903|DRUG|TAK-861|TAK-861 oral tablets
223879261|NCT05687903|DRUG|Placebo|Placebo oral tablets matching TAK-861
223879262|NCT04468776|DRUG|Zolpidem|Zolpidem, as prescribed by physician
223879263|NCT04468776|BEHAVIORAL|Internet Cognitive Behavioral Therapy for Insomnia (CBT-I)|6-week internet CBT-I multi-component intervention (SHUTi) including sleep restriction, stimulus control, cognitive restructuring, sleep behaviors, and relapse prevention
223879264|NCT04468776|DRUG|Trazodone|Trazodone, as prescribed by physician
223879265|NCT04003948|DRUG|Ibogaine Hydrochloride|Fixed or ascending doses of ibogaine will be administered for the treatment of opioid withdrawal syndrome.
223879266|NCT06614907|DRUG|QL2108 injection|300mg/2.0mL; single dose; prefilled syringe; subcutaneous injection
223879267|NCT06614907|DRUG|Dupixent®|300mg/2.0mL; single dose; prefilled syringe; subcutaneous injection
223879268|NCT06424132|OTHER|Cold Vest Exposure Period|A cold vest will be placed on the participant which consists of a water-perfused wearable vest, size S-M or M-L with adjustable straps attached to a small 'cooler' reservoir to circulate cold water between the vest and the cooler (Polar Products, Stow, OH- Product link: www.polarproducts.com/polarshop/pc/CoolOR-13-Quart-System-with-Arctic-Chiller-p24757.htm) This product is safe and recommended by experimental guidelines for human BAT studies. Participants will be cold exposed for a period of 3 hours resting in a reclined position engaged in reading and/or digital entertainment of their choice.
223879269|NCT06424132|OTHER|Rewarming Exposure Period|Following cold exposure, the cold vests will be removed, and participants will be offered a warm blanket to ease the transition from cold back to warm temperatures. Participants will then be moved to an adjacent warm room maintained at 30 degrees celsius and asked to return to the resting position of their choice. Participants will then engage in reading and/or digital entertainment for a 3-hour warm exposure period.
224076691|NCT00288080|DRUG|Prednisone|10 mg orally per day until day 21 of the last cycle of docetaxel, beginning 28 days after the completion of RT.
223879270|NCT06424132|OTHER|Fasting|Participants will be requested to refrain from food and caloric drinks for 12 hours (starting at 8pm) prior to the study visit. Blood will then be drawn the following morning (between 8 and 9am) 30mins later following a breakfast meal (9:30am- 10am). Participants will be housed in a room with ambient temperature at 25 degrees celsius between the two blood draws.
223879271|NCT05613205|BIOLOGICAL|TYP04A Low Dose without Alum investigational vaccine|2 doses of TYP04A Low Dose without Alum investigational vaccine administered intramuscularly as a priming dose on Day 1 and a booster dose on Day 169.
223879272|NCT05613205|BIOLOGICAL|TYP04B Full Dose without Alum investigational vaccine|2 doses of TYP04B Full Dose without Alum investigational vaccine administered intramuscularly as a priming dose on Day 1 and a booster dose on Day 169.
223879273|NCT05613205|BIOLOGICAL|TYP03A Low Dose with Alum investigational vaccine|2 doses of TYP03A Low Dose with Alum investigational vaccine administered intramuscularly as a priming dose on Day 1 and a booster dose on Day 169.
223879274|NCT05613205|BIOLOGICAL|TYP03B Full Dose with Alum investigational vaccine|2 doses of TYP03B Full Dose with Alum investigational vaccine administered intramuscularly as a priming dose on Day 1 and a booster dose on Day 169.
223879275|NCT05613205|BIOLOGICAL|Sanofi Pasteur's Typhoid Vi polysaccharide vaccine|1 dose of Sanofi Pasteur's Typhoid Vi polysaccharide vaccine administered intramuscularly, at Day 1, to participants in the control group.
223879276|NCT05613205|BIOLOGICAL|GSK's Tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine|1 dose of GSK's Tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine administered intramuscularly, at Day 169, to participants in the control group.
223879277|NCT02690064|DIETARY_SUPPLEMENT|Acute Antioxidant|Flow-Mediated Dilation will be determined at baseline and 2 hours following acute antioxidant treatment
223879278|NCT02690064|DIETARY_SUPPLEMENT|Chronic Antioxidant|Flow-Mediated Dilation will be determined at baseline, week 4, week 8, and week 12.
223879279|NCT02690064|OTHER|Placebo|Flow-Mediated Dilation will be determined at baseline and 2 hours following acute antioxidant treatment
223879280|NCT03569176|DEVICE|Autism Glass|The intervention uses the outward-facing camera on the google glasses to read facial expressions and provides social cues within the child's natural environment during usual social interaction and during games accessed via the smartphone application. Participants who receive the Google Glass intervention will be asked to use it for around 20 minutes 3 times a week with their parents or during ABA therapy.
223879281|NCT05864248|DEVICE|Supira System|The Supira System is a temporary (≤ 4 hours) ventricular support device indicated for use during elective or urgent high-risk percutaneous coronary interventions (HRPCI) performed in hemodynamically stable patients with severe coronary artery disease when a heart team has determined HRPCI is the appropriate therapeutic option.
223879282|NCT04791228|DEVICE|Magnetic Resonance-Guided High Intensity Focused Ultrasound|"Magnetic resonance (MR)-guided high intensity focused ultrasound (HIFU) provides precise and controlled delivery of heat by focusing ultrasound energy inside a lesion using an external applicator without the need for a scalpel or needle.~Additional therapeutic advantages of this modality include its range of bioeffects, including both high temperature tumor ablation via coagulative necrosis, and effects of lower temperature, mild hyperthermia that can help to enhance local drug delivery to tumors. Both tumor ablation and hyperthermia may be employed to potentiate the effects of chemotherapy."
223879283|NCT04791228|DRUG|Lyso-thermosensitive Liposomal Doxorubicin|"LTLD combines doxorubicin with lyso-thermosensitive liposomes that can selectively deliver drug to tumors and when exposed to temperatures greater than 40°C, rapidly and locally releases doxorubicin in high concentrations from systemically administered LTLD.~If combined with hyperthermia, doxorubicin will be released in the heated tumor margins and in any areas within the tumor that were not completely ablated and increase the likelihood of complete tumor necrosis. LTLD will extend tumor cell death to the hyperthermic regions in the peri-ablation zones and minimize the possibility of incomplete ablation or tumor recurrence."
223879284|NCT04720456|DRUG|SHAPE measurement using the ultrasound contrast agent Sonazoid (perfluorobutane microbubbles)|The ultrasound contrast agent will be infused thorough an IV line and SHAPE ultrasound imaging and data acquisition will be performed with a Logiq E10 (GE Medical Systems, Waukesha, WI) ultrasound scanner.
223879285|NCT04720456|DRUG|SHAPE measurement using the ultrasound contrast agent Lumason (sulfur hexafluoride lipid-type A microspheres)|The ultrasound contrast agent will be infused thorough an IV line and SHAPE ultrasound imaging and data acquisition will be performed with a Logiq E10 (GE Medical Systems, Waukesha, WI) ultrasound scanner.
223879286|NCT04377932|GENETIC|AGAR T cells|"Four different dosing schedules will be evaluated. Three to six patients will be evaluated on each dosing schedule. The following dose levels will be evaluated:~DL1: 3x10\^7/m2 DL2: 1x10\^8/m2 DL3: 3x10\^8/m2 DL4: 1x10\^9/m2~The doses are calculated according to the actual number of GPC3-CAR transduced T cells."
223879287|NCT04656158|OTHER|Physical activity involving exposure to nature: Therapeutic horticulture|2 sessions of 90 minutes of therapeutic horticulture and 2 sessions of 90 minutes of handiwork
223879288|NCT02865668|DRUG|Canagliflozin and Metformin Extended Release (XR) Fixed Dose Combination [FDC]|Participants will receive 1 XR FDC tablet containing canagliflozin 50 mg and metformin 500 mg orally under fed (Treatment B) or fasted (Treatment D) condition in a given treatment period as per treatment sequence.
223879289|NCT02865668|DRUG|Canagliflozin|Participants will receive canagliflozin 50 mg oral tablet) under fed (part of treatment A) or fasted (part of treatment C) condition in a given treatment period as per treatment sequence.
223879290|NCT02865668|DRUG|Metformin Extended Release (XR)|Participants will receive 1 metformin XR tablet of 500 mg orally under fed (part of treatment A) or fasted (part of treatment C) condition in a given treatment period as per treatment sequence.
223879291|NCT05159791|DIAGNOSTIC_TEST|Invasive coronary blood flow assessment and simulations and fluid dynamic patient specific simulation|The coronary blood flow and its distribution between the anomalous and normal artery will be measured by invasive coronary catheterization. Coronary artery flow will be calculated based on intravascular ultrasound (IVUS) and pressure difference measurements. After the IVUS assessment, a pressure transducer (FFR/iFR probe) will be inserted in the coronary artery for pressure measurements. The measurements will be done in the anomalous and normal coronary arteries in each patient to determine coronary flow distribution. Patient's specific heart parameters will be retrieve from CT, MRI and other diagnostic tests and integrated in the simulation module.
223879292|NCT06309693|PROCEDURE|Quadratus Lumborum (QL) Block|The standard of care QL block will be performed by the regional anesthesia team according to their standard protocol with a uniform quantity and concentration of analgesic agent. Patients will subsequently be asked about their pain postoperatively and opioid medication administration will be quantified.
223879293|NCT06309693|PROCEDURE|Enhanced Recovery After Surgical (ERAS) Protocol|Subjects randomized to the ERAS arm will undergo the standard ERAS protocol of early postoperative ambulation, no bowel preparation, and the use of multimodal pain medications including acetaminophen and non-steroid anti-inflammatory drugs (NSAIDs). Patients will subsequently be asked about their pain postoperatively and opioid medication administration will be quantified.
223879294|NCT01689935|DRUG|20 % Aminolevulinic Acid|topical medication for ALA-PDT and i-PDT
223879295|NCT01689935|DEVICE|Red light only|Red Light therapy
223879296|NCT01689935|DEVICE|Blue light only|Blue light only
223879297|NCT05335421|BEHAVIORAL|Healthy Minds Program (HMP) App|The full HMP app includes 5 modules with practices designed to cultivate categories of mental and emotional skills linked to both hedonic and eudaimonic well-being. These include the cultivation of mindful attention (Awareness), positive relationships with self and others (Connection), insight into the nature of self and internal experience (Insight), and purpose, values, and meaning in life (Purpose), as well as an initial module which includes abbreviated introductions to the topics and lessons in all four areas (Foundations). For this study, the active intervention will include 4 weeks of training using the Foundations module followed by 4 weeks of training using the Awareness module.
223879298|NCT04460352|RADIATION|Neoadjuvant radiotherapy (arm A)|1.8 Gy fractions 5 days per week in 23 fractions to a total dose of 41.4 Gy.
223879299|NCT04460352|DRUG|Carboplatin, paclitaxel|Carboplatin AUC 2 + Paclitaxel 50mg/m2 weekly x 5 (day 1, 8, 15, 22, 29), starting same day as radiotherapy
223879300|NCT04460352|PROCEDURE|Esophagectomy|Esophagectomy performed within 8 weeks after termination of chemoradiotherapy
223879301|NCT04460352|RADIATION|Neoadjuvant radiotherapy (arm B)|"Two alternative schemes:~1. 1.8 Gy fractions five days per week in 28 fractions to a total dose of 50.4 Gy.~2. 2.0 Gy fractions five days per week in 25 fractions to a total dose of 50 Gy."
223879302|NCT04460352|DRUG|Carboplatin, paclitaxel|Carboplatin AUC 2 + Paclitaxel 50mg/m2 on day 1 weekly during the full course of radiotherapy (5 weeks or 6 weeks, depending on the radiotherapy regimen used).
223879303|NCT04460352|DRUG|Cisplatin, paclitaxel|Cisplatin 75mg/m2 on the first day of weeks 1 and 5 + 5-fluorouracil 1000 mg/m2/day by continuous infusion on the first four days of weeks 1 and 5.
223879304|NCT04460352|DRUG|Oxaliplatin, calcium folinate, 5-fluorouracil|FOLFOX: Oxaliplatin 85 mg/m2, calcium folinate 200 mg/m2 and 5-fluorouracil 400 mg/m2 on the first days of weeks 1, 3 and 5 + 5-fluorouracil 800 mg/m2 by continuous infusion on the first two days of weeks 1, 3 and 5.
223879305|NCT04460352|PROCEDURE|Esophagectomy|Esophagectomy only in case of residual or recurrent locoregional cancer.
223879306|NCT05769478|DRUG|Amifampridine|a single dose of amifampridine (20mg) will be orally administered
223879307|NCT06267183|DRUG|SV001|SV001 ： single-dose
223879308|NCT06267183|DRUG|Placebo|Placebo ： single-dose
223879309|NCT05551403|DEVICE|Eyes-closed rest-EEG registration|Recording of spontaneous brain activity while eyes are shut for the duration of 7 minutes using a tablet with instructions
223879310|NCT05551403|DEVICE|Transcranial Magnetic Stimulation during EEG and EMG registrations|Recording of TMS-evoked EEG and EMG responses according to various stimulation protocols
223879311|NCT05551403|DEVICE|Photic stimulation during eyes-closes EEG registration|Recording of visual evoked potentials in the EEG during flash stimulation by light-emitting diode (LED) goggles (while eyes are closed)
223879312|NCT05746871|DEVICE|Agilik|The Agilik is a powered orthosis system that can assist or resist motion independently in each gait phase. It is used as a pair of knee-ankle-foot orthosis (KAFO), one for each leg. The device applies up to 12 Nm across the knee in the direction of either flexion or extension. The system consists of an orthosis for each leg integrated with an electro-mechanical actuator, a battery, a carry pack, cabling and application software running on a computer. A foot pressure sensor is embedded in the footbed of the KAFO and connected to the actuator. The foot sensor and angular velocity are used to detect the gait phase of the patient and communicate with the motor controller to provide a unique torque for each gait phase. The torque ramp and intensity can be modified through the Agilik App to cater towards individual patients by assisting or resisting motion during their gait. This allows for the clinician working with the patient to adjust the settings of the device for the patient's needs.
223879313|NCT05746871|OTHER|standard care|Subjects will continue with their standard care for 5 weeks
223879314|NCT05328557|DRUG|CUG252|CUG252 will be administered by subcutaneous (SC) injection
223879315|NCT05328557|DRUG|Placebo|Placebo will be administered by subcutaneous (SC) injection
223879316|NCT04537247|PROCEDURE|partial nephrectomy for complex renal tumor|removal of tumor with sufficient safety margin with preservation of functioning renal unit (renal tissue with its collecting system, arterial supply and venous as well as lymphatic drainage).
223879317|NCT04335643|BEHAVIORAL|TEACH|TEACH is a remotely delivered psychological intervention. It consists of six one-hour weekly sessions that are HIPAA compliant and conducted over video conferencing.
223879318|NCT05874102|OTHER|Sidelying|Position sidelying then Upright
223879319|NCT05874102|OTHER|Upright|Position upright then sidelying
223879320|NCT04440176|BIOLOGICAL|MenABCWY|Neisseria meningitidis group A, B, C, W, and Y vaccine
223879321|NCT04440176|BIOLOGICAL|Saline|Placebo
223879322|NCT04637594|DRUG|Pembrolizumab|Given IV
223879323|NCT04637594|DRUG|Nivolumab|Given IV
223879324|NCT04637594|DRUG|Atezolizumab|Given IV
223879325|NCT04637594|DRUG|Durvalumab|Given IV
223879326|NCT04637594|DRUG|Avelumab|Given IV
223879327|NCT05124925|BIOLOGICAL|Ianalumab|Ianalumab VAY736 150mg/1ml Solution for injection
223879328|NCT04036188|DRUG|Triamcinolone|Triamcinolone 0.1% daily
223879329|NCT04036188|DIETARY_SUPPLEMENT|Vitamin D3|40,000 IU Vitamin D3 daily
223879330|NCT04036188|DRUG|Placebo|Placebo daily
224076692|NCT00288080|DRUG|docetaxel|75 mg/m2 i.v. over 1 hour (on day 1 of each cycle) every 21 days for 6 cycles, beginning 28 days after the completion of RT.
224076693|NCT00288080|DRUG|Oral antiandrogen|Oral antiandrogen of treating institution's choice to be given per package instructions for 8 weeks, then concurrent with radiation therapy. Treatment is discontinued at the end of radiation therapy.
223879331|NCT03079024|DEVICE|Targeted Cognitive Training|"1. Auditory Training Module (20 hours): exercises designed to improve speed and accuracy of auditory processing while engaging working memory and cognitive control. Exercises adjust difficulty level to maintain an \~80% correct performance. Exercises contain stimuli spanning the acoustic organization of speech. In the initial stages, stimuli exaggerate the rapid temporal transitions by increasing amplitude and stretching in time. The exaggeration is gradually removed so that by the end, all stimuli have characteristics representative of real-world speech.~2. Social Cognition Module (10 hours): exercises designed to improve core deficits of social cognition in psychosis. Exercises apply principles of implicit learning to restore capacity to process and utilize socially-relevant information, and includes training to improve perception of affect (visual/vocal) and social cues (faces, gazes, social situations), theory of mind, self-referential style, emotion labeling and working memory."
223879332|NCT03079024|DEVICE|General Cognitive Exercises|The GCE will focus on executive dysfunction, as this domain is a significant, functionally important area of deficit in schizophrenia and has been the target of many previous studies. We will train this domain using a suite of engaging, adaptive web-based exercises that target executive function, intelligence, and spatial navigation developed by Posit Science. The exercises will be provide engaging, adaptive training as described in the Targeted Cognitive Training.
223879333|NCT03079024|OTHER|Coordinated Specialty Care for First Episode Psychosis|Individuals in this study are receiving care from a coordinated specialty care clinic (CSC) for first episode psychosis. These clinics are following the NAVIGATE treatment model for early psychosis.
223879334|NCT04990349|DRUG|Oxygen gas|Targeted PO2 postoxygenator is obtained by modulating ECMO Membrane oxygen fraction.
223879335|NCT03494504|DRUG|Reproxalap Ophthalmic Solution (0.25%)|Reproxalap Ophthalmic Solution (0.25%) administered once.
223879336|NCT03494504|DRUG|Reproxalap Ophthalmic Solution (0.5%)|Reproxalap Ophthalmic Solution (0.5%) administered once.
223879337|NCT03494504|DRUG|Vehicle Ophthalmic Solution|Vehicle Ophthalmic Solution administered once.
223879338|NCT03719924|DRUG|Onivyde|onivyde will be administered first, followed by folinic acid or L-folinic acid and then 5-FU at D1 and D14.
223879339|NCT03719924|DRUG|Paclitaxel|Paclitaxel : 80 mg/m2 IV during 60 minutes at D1, D8 and D15
223879340|NCT05554692|DIAGNOSTIC_TEST|Diagnostic tests of cochlear implant function|Because the subjects in the study will use CI devices that they have already received as part of their standard-of-care treatment, the medical device itself is not an intervention for the purposes of this study. The intervention here will be to carry out diagnostic tests of CI function. This will include perceptual tests of temporal discrimination and speech understanding.
223879341|NCT05554692|DIAGNOSTIC_TEST|Diagnostic tests of auditory function|The intervention here will be to carry out diagnostic tests of hearing. This will include perceptual tests of temporal discrimination and speech understanding.
223879342|NCT05523635|DEVICE|Gamma4 Nailing System|The Gamma4 Nailing System is is indicated for the treatment of stable and unstable fractures as well as for stabilization of bones and correction of bone deformities in the intracapsular, trochanteric, subtrochanteric and shaft regions of the femur (including osteoporotic and osteopenic bone).
223879343|NCT06221930|BEHAVIORAL|attexis|Participants will receive access to the digital health intervention attexis in addition to TAU.
223879344|NCT05923125|BEHAVIORAL|Graded-Intensity Treadmill Exercise Protocol|The exercise protocol will be administered by the principal investigator or other trained study staff under the supervision of the PI in the stress testing laboratory of NYU Langone Health - Tisch Hospital. The exercise protocol duration will vary by participant, but is likely to be between 8 and 25 minutes in duration.
223879345|NCT04817462|PROCEDURE|Liver biopsy|The study population is patients with either haemophilia A or B who have previously been administered gene therapy treatment in one of three specific gene therapy clinical trials. In this study they will have a liver biopsy performed to take up to 3 samples for laboratory analysis.
223879346|NCT04640441|OTHER|Sit-to-stand care|"1. Passive range of motion(ROM) exercise of lower legs, active ROM exercise of lower legs, and sitting balance exercise, 20\~30 min, once daily.~2. Anti-gravity ROM exercise of lower leg, resistance exercise of low leg, and sitting balance exercise, 20\~30min, once daily.~3. Stepping exercise and sit-to-stand exercise, 20\~30min, once daily."
223879347|NCT05471908|BEHAVIORAL|As-needed follow up|At hospital discharge, participant receives a recommendation for PRN follow-up. Recommendation informs participant that scheduling a follow-up visit is not needed at discharge and suggests that participant follow symptoms after discharge to decide if a visit is ultimately needed or not.
223879348|NCT05471908|BEHAVIORAL|Automatic follow-up|At hospital discharge, participant receives a recommendation for automatic follow-up. Recommendation instructs participant to schedule a follow-up visit and attend the visit even if symptoms get better.
223879349|NCT05612789|BEHAVIORAL|Exercise Program (Cohort A Prehab)|Pre-frail and frail potential HCT recipients 60 years and older will participate in a supervised exercise program from the time of enrollment up until HCT admission. Exercise compliance will be measured in part through physical activity trackers.from time of discharge from HCT until day +100 post-HCT. All HCT recipients 60 years and older will participate in a supervised exercise program from the time of discharge from HCT admission until day +100 post-HCT. Exercise compliance will be measured in part through physical activity trackers.
223879350|NCT05612789|BEHAVIORAL|Exercise Program (Cohort B Rehab)|All HCT recipients 60 years and older will participate in a supervised exercise program from the time of discharge from HCT admission until day +100 post-HCT. Exercise compliance will be measured in part through physical activity trackers.
223879351|NCT06782763|DEVICE|Repetitive transcranial magnetic stimulation device|Activating neurons: rTMS can activate or inhibit neuronal activity in certain brain areas, changing the activity pattern of neural networks. Neuroplasticity: By changing the strength and connection mode of synapses, it promotes the plasticity of the nervous system, which helps treat neuropsychiatric diseases. Regulating neurotransmitters: rTMS can regulate the release of neurotransmitters, affect nerve conduction, and thus improve disease symptoms.
223879352|NCT05470205|DRUG|SHAPE measurement (Sonazoid ultrasoud contrast agent)|Three vials with 48 µl of Sonazoid (GE Healthcare, Oslo, Norway) microbubbles (6 ml) will be prepared and drawn into a 10 ml syringe, placed in a syringe pump. Sonazoid will be co-infused at a rate of 0.024 µl/kg body weight/minute (suspension infusion rate of 0.18 ml/kg/hour) together with a 0.9% NaCl solution infused at a rate of at least 2 ml/min.
223879353|NCT05470205|DRUG|SHAPE measurement (Definity ultrasoud contrast agent)|Two vials with 3 mL of Definity will be mixed and diluted in 50 mL of normal saline, yielding a concentration of 49.4 μL/mL, and infused at a rate of at least 4 ml/min.
223879354|NCT05176366|BIOLOGICAL|ExoFlo|Intravenous administration of bone marrow mesenchymal stem cell derived extracellular vesicles
223879355|NCT06819397|OTHER|post isometric relaxation|the athlete will be given instructions to perform a 7-second isometric contraction in the direction of horizontal abduction at about 25% of peak effort, while the examiner will apply an opposing force at the distal humerus.
223879356|NCT06819397|OTHER|cross friction soft tissue mobilization|by identifying the fascia restriction, patients in group B will be treated with the cross friction soft tissue mobilization approach, which comprised applying a low load and prolonged stretch through the knuckles or elbows to the constricted fascia. The therapist will then give the contralateral side of rotation resistance for ten seconds
223879357|NCT06819930|OTHER|Physical Assessments, Questionnaires, and Accelerometry for Fibromyalgia evaluation|This study involves a combination of functional tests, questionnaires, and activity measurement using accelerometers. The functional tests include the six-minute walk test (6MWT), handgrip strength dynamometry, and the 8-foot up \&amp; go test. Participants will also complete validated questionnaires assessing symptoms, quality of life, and psychosocial impact. Additionally, accelerometers will be used to objectively measure physical activity levels throughout the study period
224076694|NCT00288080|RADIATION|Radiation therapy|46.8 Gy, using either three-dimensional conformal radiotherapy (3DCRT) or intensity-modulated radiation therapy (IMRT), will be given to the regional lymphatics followed by a 25.2-28.8 Gy boost to the prostate, to bring the total dose to the prostate to 72.0-75.6 Gy. Daily prescription doses will be 1.8 Gy per day, 5 days per week x 8-8.5 weeks, beginning 8 weeks after the initiation of androgen suppression.
223879358|NCT06819605|DRUG|Dabrafenib and trametinib (combination)|"This clinical study investigates the combination of Dabrafenib (2 mg once daily for adults; 0.025 mg/kg/day for children ≥12 years, orally once daily) and Trametinib (2 mg once daily for adults; 0.025 mg/kg/day for children ≥12 years, orally once daily) as a treatment for \[specific condition\]. The treatment will be administered until disease progression or intolerable toxicities occur. Both medications should be taken at least 1 hour before or 2 hours after a meal, at the same time each day. If a dose is missed, it should be taken within 12 hours of the scheduled time. If less than 12 hours remain before the next dose, the missed dose should not be taken. Both medications should be taken in combination with the scheduled dose of Dabrafenib at either morning or evening and must not be chewed or crushed.~Each treatment cycle lasts 30 days. At the end of each cycle, follow-up assessments will include clinical examination, laboratory tests to evaluate drug safety, and imaging studies to a"
223879359|NCT06477900|OTHER|SMS reception|reception of 72 SMS encouraging physical activity and nutritional advice
224076695|NCT00288080|DRUG|LHRH agonist|LHRH agonist of treating institution's choice to be given per package instructions for 8 weeks, then concurrent with radiation therapy, and then until 24 months from initiation of any treatment has been reached.
223879360|NCT05954962|DRUG|Progesterone 200 MG|"The patients in the study group will administer oral natural micronized progesterone capsules from day 1 of ovarian stimulation instead of antagonist (ganirelix) subcutaneaous injections from day 5-6 of stimulation."
223879361|NCT05954962|DRUG|Ganirelix Acetate|The patients in the control group will administer subcutaneaous injections of ganirelix from day 5-6 of stimulation as per currently used protocol.
223879362|NCT06508801|OTHER|Blood flow restriction training|The BFR Intervention will consist of 75 repetitions; reps (set 1: 30 reps, sets 2 - 4: 15 reps with 30 s of rest between sets and 1 minute between exercises) at 20-30% of 10 repetition maximum (RM). BFR training will be performed during toe raises, lunges and single leg stance exercises on unstable surfaces (i.e., foam, Dyna disc, balance disc, and BOSU-ball®) as tolerated by the participant.
223879363|NCT06508801|OTHER|Instability Resistance Training|The following devices will be used for instability training: foam, dyna disc, balance disc and BOSU-ball®. Unstable devices will be changed during the six-week period from the least to the most unstable devices. Once a participant reduces the body sway on a device, the device will be progressed. Participants will perform IRT with or without blood flow restriction.
223879364|NCT05887700|DEVICE|CeraFlex™ Atrial Septal Defect (ASD) Closure System|The CeraFlex™ ASD Occluder have two types of occluders, CeraFlex™ ASD Occluder and CeraFlex™ Multi-fenestrated (Cribriform) ASD Occluder. The CeraFlex™ ASD Occluder is percutaneous, transcatheter closure devices for the non-surgical closure of atrial septal defects.
223879365|NCT04219696|OTHER|Reactive balance training|A research physiotherapist will oversee reactive balance training (RBT) to ensure consistent RBT delivery across participants. Training strategies will be individualized to each participant, based on their balance impairments and rehabilitation goals. The RBT program includes multi-directional 'internal' and 'external' balance perturbations. Internal perturbations are achieved by asking the participant to complete tasks that challenge balance control, such that they lose balance when attempting to perform the task (e.g., kicking a soccer ball). External perturbation are delivered manually using a push or pull from the physiotherapist. As participants improve their reactive balance control, difficulty will be increased by shifting task requirements along a continuum from stable to mobile, and from predictable to unpredictable, and by increasing perturbation magnitude or imposing sensory or environmental challenges.
223879366|NCT05605015|BEHAVIORAL|ACTIVE-CR|The ACTIVE-CR intervention comprises three key components: a wrist-worn physical activity monitor, a web-based platform providing physical activity feedback, and three autonomy supportive online trainer sessions. Each component is grounded by multiple established behaviour change techniques consistent with the behaviour change taxonomy developed by Michie et al. (2013). The barriers to physical activity were identified in our previous work and are consistent with previous literature
223879367|NCT04608045|DRUG|CPX-POM|CPX-POM
223879368|NCT05833789|DEVICE|Magnetic Flexible Endoscope (MFE)|After colonoscopy has been completed with the legacy colonoscope, the MFE will be introduced into the colon and traverse from the rectum to the cecum.
223879369|NCT01558804|OTHER|Identifying group A strep carriers|At study entry, at 14 days, and if follow up is positive, again in 14-21 days: Standard culture for GAS and analysis of mRNA.
223879370|NCT05863546|OTHER|Traditional treatment|The patients received traditional physical therapy treatment for carpal tunnel syndrome, in the form of hot packs, tendon and nerve glide exercises, and wrist splint for 4 weeks.
223879371|NCT05863546|DEVICE|Therapeutic ultrasound|US treatment sessions were performed for 6 min per session, once a day, three days a week, for a total of 4 weeks.
223879372|NCT05650411|DEVICE|LMCA PCI with Supraflex Cruz ultrathin-strut biodegradable polymer sirolimus-eluting stent (Sahajanand Medical Technologies Ltd., Surat, India).|Successful LMCA PCI with ≥1 Supraflex Cruz ultrathin-strut biodegradable polymer sirolimus-eluting stent (Sahajanand Medical Technologies Ltd., Surat, India).
223879373|NCT05650411|DRUG|P2Y12 inhibitor-based SAPT after short DAPT|Potent P2Y12 inhibitor-based SAPT (ticagrelor 90 mg bd, or prasugrel 5 or 10 mg od, at the discretion of the investigator) during 2 years. Aspirin stopped after LMCA or at latest at hospital discharge.
223879374|NCT05650411|DRUG|Conventional DAPT|6 to 12 months of DAPT combining aspirin (≥75 mg od) and a P2Y12 inhibitor (clopidogrel 75 mg od, ticagrelor 90 mg bd, prasugrel 5 or 10 mg od at the discretion of the investigator) followed by aspirin SAPT.
223879375|NCT05361447|DRUG|Diazepam|5 mg twice daily oral for 1 week and then increase to 10 mg twice daily oral
223879376|NCT05229900|DRUG|SGN-ALPV|Given into the vein (IV; intravenously)
224076696|NCT03437239|DEVICE|Delfi PTS II Portable Tourniquet System|This is a portable tourniquet system that allows for occlusion of venous outflow without inhibiting arterial blood flow. This portable tourniquet system allows for rapid cuff inflation and deflation with a battery. The Delfi PTS is a purpose-built system that allows for precise control of pressure throughout training, despite the natural changes in muscle shape and length. The device has advanced pressure leak detection that monitors the tourniquet cuff, tubing, and connectors for air leaks and safely alerts staff to hazards or follow-up actions required. The device has visual and audio alarms for over and under pressure and elapsed time as well as a large, easily visible display of tourniquet pressure and elapsed time. The Delfi PTS II calibrates and self-tests on startup. It has a safety interlock that limits the normal maximum pressure and integrated tourniquet cuff testing as recommended in current AORN Standards and Recommended Practices
224076697|NCT03166332|BEHAVIORAL|Mediterranean diet|Mediterranean diet supplemented with extra-virgin olive oil and nuts
224076698|NCT03166332|BEHAVIORAL|Mindfulness|Mindfulness-Based Stress Reduction program (MBSR)
223879377|NCT05369182|DIAGNOSTIC_TEST|Invasive physiologic assessment|"All coronary physiologic parameters are measured following diagnostic angiography. Resting pd/pa, FFR, CFR and IMR will be calculated using coronary physiologic parameters.~In patients treated by PCI, post-PCI physiologic assessment including CFR, IMR, and FFR will be performed."
223879378|NCT05369182|DIAGNOSTIC_TEST|Intravascular imaging|By the operator's discretion, stent-optimization will be performed under intravascular imaging devices (IVUS \[Boston Scientific, Natick, Massachusetts, USA\] or OCT \[Abbott Vascular\], St. Paul, MN, USA\]).
223879379|NCT04781959|DRUG|Filgrastim|Receive filgrastim subcutaneous injection once daily for five consecutive days starting 24-72 hours after chemotherapy
223879380|NCT04781959|DRUG|Pegfilgrastim|Receive pegfilgrastim as a single dose subcutaneous injection 24-72 hours after chemotherapy
223879381|NCT05307835|BIOLOGICAL|iNeo-Vac-P01|iNeo-Vac-P01 (peptides)： 4 x 300 mcg per peptide given on days 1, 4, 8, 15, 22, 52, and 82 for a total of 7 doses;
223879382|NCT05307835|BIOLOGICAL|GM-CSF|4 x 40 mcg (total dose 160 mcg) given on days 1, 4, 8, 15, 22, 52, and 82 for a total of 7 doses
223879383|NCT01822652|GENETIC|iC9-GD2 T Cells - frozen|"Subjects will receive the iC9-GD2 T cells through an IV over 5 to 10 minutes.~Subjects will receive one of the following dose levels (cells/m2):~* Dose Level 1 = 1 x 10\^7~* Dose Level 2 = 1 x 10\^8~* Dose Level 3 = 2 x 10\^8~Six weeks after the infusion, patients will have a disease re-evaluation. If the disease has not gotten worse AND they have not had a severe side effect caused by the infusion of the iC9-GD2 T cells, the subject may be eligible to receive up to 2 additional doses of T cells. Each dose will be at the same dose level as the first infusion, if available, and separated by at least 6 weeks."
223879384|NCT01822652|GENETIC|iC9-GD2 T Cells - fresh|"For subjects who will receive a fresh T cell product:~* Dose Level 1 = 1 x 10\^8~* Dose Level 2 = 1.5 x 10\^8~* Dose Level 3 = 2 x 10\^8~Six weeks after the infusion, patients will have a disease re-evaluation. If the disease has not gotten worse AND they have not had a severe side effect caused by the infusion of the iC9-GD2 T cells, the subject may be eligible to receive up to 2 additional doses of T cells. Each dose will be at the same dose level as the first infusion, if available, and separated by at least 6 weeks."
223879385|NCT01822652|DRUG|Cytoxan|Cyclophosphamide (500 mg/m2/day x 2 days, for patients \<12 kg = 16.7 mg/kg/day x 2 days)
223879386|NCT01822652|DRUG|Fludara|Fludarabine (30 mg/m2/day x 3 days, for patients \<12 kg = 1 mg/kg/day x 3 days)
223879387|NCT01822652|DRUG|Keytruda|Pembrolizumab (2 mg/kg on Day -1 and on Day 21).
223879388|NCT01822652|GENETIC|iC9-GD2 T cells|"For subjects who will receive a fresh T cell product:~* Dose Level 1 = 1.5 x 10\^8~* Dose Level 2 = 2 x 10\^8~Six weeks after the infusion, patients will have a disease re-evaluation. If the disease has not gotten worse AND they have not had a severe side effect caused by the infusion of the iC9-GD2 T cells, the subject may be eligible to receive up to 2 additional doses of T cells. Each dose will be at the same dose level as the first infusion, if available, and separated by at least 6 weeks."
223879389|NCT03171025|DRUG|Nivolumab|Nivolumab at a dose of 480 mg will be administered as an IV infusion over 60 minutes every 4 weeks until disease recurrence or discontinuation due to unacceptable toxicity for a maximum of 12 treatments over an expected duration of 1 year.
224076699|NCT05813509|DEVICE|Organoid culture|Tumor like organ is a kind of organ cultured from tissues of tumor patients, which is a small tumor growing in a culture dish. Compared with the traditional two-dimensional culture system, the most important feature of this technological innovation is that it can directly use the patient's own tissue to culture organ like cells. At the same time, these organ like cells can well replicate some key characteristics of the primary tumor and retain the pathological form and biological mechanism of the patient's tissue
224076700|NCT03524261|BIOLOGICAL|Activated CIK and CD3-MUC1 Bispecific Antibody in Treating Breast Cancer|CIK cells was activated by PD-1 inhibitor and bispecific antibody of anti-CD3/MUC1
224076701|NCT03524261|PROCEDURE|cryotherapy|the maximum tumor length≥2 cm，cool down the lesion,result in degeneration, necrosis or loss of the lesion.
223879390|NCT05831683|OTHER|Introduction of Standard Operating Procedure regarding lung protective ventilation during general anaesthesia.|The Standard Operating Procedure document will be introduced. The SOP document will cover the theoretical background, definition, and recommendations/criteria of LPV. The SOP document will reflect the most recent LPV guidelines.
223879391|NCT05788848|BEHAVIORAL|VRCT|The VRCT will focus primarily on skills that impact instrumental activities of daily living (e.g., taking medications, shopping). Thirty-six individuals with mild to moderate AD/ADRD will be enrolled and will utilize the VRCT over seven weeks within their home.
223879392|NCT02209350|PROCEDURE|Aorta-femoral bypass|"Access to the femoral artery is performed through a lateral incision from the inguinal ligament. Operations technique on the abdominal aorta.~Aorta-femoral bypass. Proximal anastomosis between the prosthesis and aorta is applied in the sort of end-to-side in the reconstruction by shunting.~After jaws prosthesis conduction on hip distal anastomosis is formed with twisting controlling. In a case of preserved antegrade blood flow the femoral artery anastomosis applied in the sort of end-to-side. If antegrade flow is absent, anastomosis is formed in the sort of end to end."
224076702|NCT04459455|BEHAVIORAL|Contain COVID Anxiety SSI|Participants first receive normalizing scientific information (including neuroscience findings) that help explain why increased anxiety during the COVID-19 is a typical response. They then read testimonials from three other people around the world who have applied a 3-step action plan for coping more effectively with their anxiety. The entire intervention takes approximately 8 minutes and is completely entirely within the Qualtrics survey platform.
224076703|NCT04459455|BEHAVIORAL|Remain COVID Free SSI|This placebo SSI was developed to mirror the structure of the Contain COVID Anxiety SSI, discuss COVID-19 related content, and do so without as many of the potential active ingredients of effective SSIs. Participants will receive scientific information about how soap kills the COVID-19 virus, but no neuroscience information related to behaviors or behavior change.
223879393|NCT02209350|PROCEDURE|Recanalization and stenting of aorta-iliac segment|"Standard endovascular access is performed under local anesthesia and affected arterial segment is visualized.~Stenosis or artery occlusion is passed with hydrophilic guide. In case of occlusion transluminal or subintimal (often mixed) artery recanalization is performed. To maximize the preservation of the affected artery initial patency, occlusion recanalization is performed by ante-and retrograde accesses. Then stenosis or occlusion predilation is performed with balloon catheter (balloon catheter diameter is smaller than the affected artery diameter for 1-2 mm). After control angiography stent is installed in the aorta-iliac area throughout the lesion (lesion diameter corresponds to the stenotic arteries diameter)."
223879394|NCT02209350|DRUG|Therapy: aspirin and clopidogrel|prescribed long-term aspirin (100 mg daily) and clopidogrel for 3 months (75 mg daily).
223879395|NCT06775535|DEVICE|ECAP-controlled, closed-loop SCS|Spinal cord stimulation that measures and records evoked compound action potentials (ECAPs) and automatically adjusts the stimulation current to maintain a consistent ECAP amplitude
223879396|NCT06753825|DEVICE|Radiofrequency|radiofrequency treatment
223879397|NCT06753825|DRUG|flunarizine|flunarizine oral treatment
223879398|NCT05103033|BEHAVIORAL|Systems Analysis and Improvement Approach for Mental Health (SAIA-MH)|The 5 steps of SAIA-MH include: (1) cascade analysis to visualize treatment cascade drop-offs and prioritize areas for system improvements; (2) process mapping to identify modifiable facility-level bottlenecks; (3) identification and implementation of modifications to improve system performance; (4) assessment of modification effects on the cascade; and (5) repeated analysis and improvement cycles.
223879399|NCT05103033|BEHAVIORAL|Attentional Placebo Control|Facilities randomized to attentional placebo control will attend a 1-week in-person training which will include the same minimum staff above for SAIA-MH. This training will focus on reviewing data collection tools, ethics, mental health stigma and burnout for mental health professionals. Following the 1-week in person training, attentional placebo control facilities will receive regular supervision following the same schedule as SAIA-MH focused on reviewing data collection tools.
223879400|NCT05872919|OTHER|SMS reminder massages about adherence|SMS three-times per week in the first six weeks and twice per week in the second six weeks reminding the patient about adherence to prescribed medication
223879401|NCT05631574|DRUG|BMF-219|BMF-219 is an orally bioavailable, covalent small-molecule menin inhibitor.
223879402|NCT01338389|DIETARY_SUPPLEMENT|CITICOLINE|"Oral administration of CITICOLINE:~Form: Powder for solution Dosage: 800mg per day duration: 5 years"
223879403|NCT01338389|DIETARY_SUPPLEMENT|PLACEBO|"Oral administration of placebo:~Form: Powder for solution duration: 5 years"
223879404|NCT05795634|BEHAVIORAL|Trier Social Stress Test|Acute psychosocial stress procedure; 5 minutes of public speaking and 5 minutes of mental arithmetic
223879405|NCT06419777|DRUG|Insulin|Insulin will be used in gestational diabetics to control blood glucose levels
223879406|NCT06273683|OTHER|Hand-held bipolar energy instrument|A bipolar energy instrument is used for complete salpingectomy at the time of cesarean delivery.
223879407|NCT06273683|OTHER|Traditional suture ligation|Traditional suture ligation technique is used for complete salpingectomy at the time of cesarean delivery.
223879408|NCT06775236|DRUG|SYS6010 jnjection|SYS6010 is an antibody conjugate drug (ADC), composed of one anti-EGFR monoclonal antibody coupled to one JS1 via an enzyme specific linker
223879409|NCT06775236|DRUG|monotherapy chemotherapy|Investigator's choice of monotherapy chemotherapy (Eribulin, Capecitabine, Gemcitabine, Vinorelbine, or Taxanes.)
223879410|NCT06775236|DRUG|SYH2051 tablets|SYH2051 is a Selective ATM protein kinase inhibitor
223879411|NCT06773663|COMBINATION_PRODUCT|Al18F-NOTA-Pentixafor PET/CT|"Participants will receive an intravenous injection of Al18F-NOTA-Pentixafor, prepared on-site and measured by qualified personnel using a dose calibrator, with readings and time recorded. The radiopharmaceutical will be slowly administered through a three-way stopcock, followed by a flush with 5 mL of normal saline.~The recommended dose is approximately 4.81 MBq/kg (0.13 mCi/kg) body weight, with variations depending on drug yield and clinical scheduling.~CT and PET imaging are planned 45-90 minutes after administration, with adjustments based on drug yield and equipment availability."
223879412|NCT06772519|DEVICE|green colored lens glasses|Researchers will compare the blue-lens glasses and green-lens glasses groups to the transparent (colorless) glasses group and the non-glasses group to see if the colored lenses have an effect on postoperative pain and nausea.
223879413|NCT06772519|DEVICE|blue colored lens glasses|Researchers will compare the blue-lens glasses and green-lens glasses groups to the transparent (colorless) glasses group and the non-glasses group to see if the colored lenses have an effect on postoperative pain and nausea.
223879414|NCT06772519|DEVICE|colorless (transparent) lens glasses|Researchers will compare the blue-lens glasses and green-lens glasses groups to the transparent (colorless) glasses group and the non-glasses group to see if the colored lenses have an effect on postoperative pain and nausea.
223879415|NCT03103321|OTHER|Internet-Based Intervention|"Receive Knowing your Options decision aid"
223879416|NCT03103321|OTHER|Internet-Based Intervention|"Receive Prostate Choice decision aid"
223879417|NCT03103321|OTHER|Best Practice|Undergo usual care
223879418|NCT03103321|OTHER|Quality-of-Life Assessment|Ancillary studies
223879419|NCT03103321|OTHER|Questionnaire Administration|Ancillary studies
223879420|NCT03103321|OTHER|Survey Administration|Ancillary studies
223879421|NCT03103321|OTHER|Laboratory Biomarker Analysis|Correlative studies
223879422|NCT06776627|OTHER|Adapted physical activity (APA)|Adapted program: aerobic capacity, strength, endurance, flexibility, balance and proprioception tests. APA sessions take place over 12 weeks. There will be 2 to 3 sessions per week. Course of a session: - Warm-up: 10-15min: cycling or walking. - Moderate-intensity endurance activity: cycling, walking or swimming: 10min, the duration will be increased gradually up to a minimum of 30min at the end of the program. - Muscle strengthening: with polyarticular or monoarticular exercises targeting the upper limbs or lower limbs in alternation and sheathing. At the beginning: 8 exercises per session and 8 repetitions, 1 time per week. Objective will be to increase the number of repetitions and then integrate other exercises to reach 10 exercises with 12 repetitions, 2 times per week. - Stretching and balance: learning to stretch the muscle groups worked and then working on proprioception (bipodal, monopodal station, then double task). - Quiet time: relaxation through breathing 5 min.
223879423|NCT06777160|PROCEDURE|Collecting data from patients who underwent arthroplasty and cement was used|Collecting data that may change in cement reaction before, during and after surgery from patients who underwent arthroplasty and cement use and taught it to artificial intelligence.
223879424|NCT05784935|DEVICE|Real time AI detection model|Bowel preparation will be conducted according to usual local practices. During colonoscopy, the colonoscope will be first advanced to the cecum in all patients as confirmed by identification of the appendicular orifice and ileocecal valve or by intubation of the ileum, as per the standard of care by experienced endoscopists. During the insertion, no action will be taken. After cecal intubation is performed, the colonoscope will be slowly withdrawn to the splenic flexure by the primary endoscopists. Real time AI detection model will be activated with the output displayed in real time on a separate monitor and will be only viewed by an independent investigator, who is an experienced endoscopists (or a person trained in polyp recognition). The primary endoscopists will be blinded to the AI real time detection result
223879425|NCT04247542|DRUG|Ibezapolstat|Investigational antibacterial agent
223879426|NCT04247542|DRUG|Vancomycin|Active comparator
223879427|NCT04517357|DRUG|Fluzoparib+Apatinib|Fluzoparib-Apatinib combination
223879428|NCT04517357|DRUG|Fluzoparib|Fluzoparib monotherapy
223879429|NCT04517357|DRUG|Fluzoparib+Apatinib|Fluzoparib-Apatinib combination
223879430|NCT06799130|OTHER|instrument-assisted soft tissue mobilization|instrument-assisted soft tissue mobilization
223879431|NCT06799130|OTHER|Muscle energy technique|Muscle energy technique
223879432|NCT04153162|DEVICE|Stereotactic body radiation therapy|Stereotactic body radiation therapy delivered to reduce LVOTO in patients with HCM
223879433|NCT05514002|BIOLOGICAL|Fluzone Quadrivalent|Intramuscular
223879434|NCT05514002|BIOLOGICAL|Flublok Quadrivalent|Intramuscular
223879435|NCT06781944|DRUG|Cyclophosphamide (CTX)|"Participants in the control arm will receive cyclical cyclophosphamide and glucocorticoids.~Oral cyclophosphamide will be given for 30 days in month 2, 4, 6.~The dosage is adjusted based on the age and renal function (rounded down to the nearest 25 mg, max 100 mg/day, Cyclophosphamide tablets should not be split; if necessary, alternating doses of 50 mg/day and 100 mg/day can be used):~* 2.0 mg/kg/d in patients \< 65 years with eGFR ≥60ml/min~* 1.5 mg/kg/d in patients \< 65 years with eGFR\<60ml/min~* 1.5 mg/kg/d in patients ≥ 65 years with eGFR ≥60ml/min~* 1.0 mg/kg/d in patients ≥ 65 years with eGFR\<60ml/min"
223879436|NCT06781944|DRUG|Glucocorticoids|"Participants in the control arm will receive cyclical cyclophosphamide and glucocorticoids.~Methylprednisolone 500 mg iv will be given for 3 consecutive days at the start of month 1,3,5 and followed by prednisone 0.5mg/kg/d (max 40mg/d) for 27 days."
223879437|NCT06779916|DIAGNOSTIC_TEST|Blood test|"16 blood samples (16 tubes, i.e. 55.3 ml) will be taken at inclusion. Pregnant women will be seen every month as part of their pregnancy follow-up, and blood (11 tubes, i.e. 35.5 ml) and urine samples will be taken at each follow-up visit.~At delivery, a systematic blood sample will be taken as part of the usual care, and an additional 11 tubes of blood (35.5 ml) will be taken."
223879438|NCT06779916|DIAGNOSTIC_TEST|Urine test|Urine samples will be taken at the inclusion visit and at each follow-up visit.
223879439|NCT06779786|OTHER|Group 1 (Aromatherapy Groups):|Self-administered by ICU nurses for four weeks, in the first week, every day in the morning and evening; In the second, third and fourth weeks, every day only in the morning, 2 ml of eucalyptus sttriodora (Group 1) oil, diluted with 3% sesame oil, is dropped into the palm of the hand, and after rubbing the hands together, rub the earlobe from top to bottom with the thumb and index finger for four minutes. Massage application together and again by dropping 2 ml of 3% eucalyptus sttriodora (Intervention 1) oil into the palm. These are groups that are given a gentle massage of the cervical muscles from top to bottom for four minutes after rubbing the hands mutually.
224076704|NCT00853697|OTHER|testosterone (AndroGel®) with the 5α-reductase inhibitor dutasteride|"Patients will be treated with dutasteride 3.5 mg once daily (oral administration). To avoid rapid conversion of testosterone to DHT in case 5α-reductase is not adequately inhibited during the first few days of concurrent treatment with dutasteride and testosterone, daily dutasteride treatment will be initiated 7 days prior to testosterone initiation.~Patients will receive AndroGel® at the dose of 15 g (3 times the standard replacement dose for hypogonadism) once daily (topical administration), starting on Day 8 and continuing for 12 weeks (or until disease progression or withdrawal from the study)."
224076705|NCT05275062|DRUG|IM92 CAR-T cells|2.5×10\^8 CAR-T cells
224076706|NCT02576743|DEVICE|7 Tesla MRI|MR imaging using a 7 Tesla MR system.
224076707|NCT04438174|DRUG|Processed Amniotic Fluid|Injection of 1 ml of processed amniotic fluid per 5 cm2 of wound area
223879440|NCT06779786|OTHER|Group 2 (Aromatherapy Groups):|Group 2(Aromatherapy Groups): Self-administered by ICU nurses for four weeks, in the first week, every day in the morning and evening; In the second, third and fourth weeks, every day only in the morning, 2 ml of medicanal lavandula (Group 2) oil, diluted with 3% sesame oil, is dropped into the palm of the hand, and after rubbing the hands together, rub the earlobe from top to bottom with the thumb and index finger for four minutes. Massage application together and again by dropping 2 ml of 3% medicanal lavandula (Intervention 1) oil into the palm. These are groups that are given a gentle massage of the cervical muscles from top to bottom for four minutes after rubbing the hands mutually.
224076708|NCT04438174|OTHER|Standard of Care Wound Treatment Regimen|ointment-based dressing and non-ointment-based dressings
224076709|NCT04347083|DIAGNOSTIC_TEST|Electrodiagnostic test|Muscle spindle- based reflex latency will be measured
224076710|NCT02844114|DRUG|Ganoderma lucidum spore|G 300mg, 5 tablets by mouth
224076711|NCT02844114|DRUG|Placebo|Sugar pill manufactured to mimic tramadol 1500mg tablet
223879441|NCT06779786|OTHER|Group 3 (Placebo Control Group)|Self-administered by ICU nurses for four weeks, in the first week, every day in the morning and evening; In the second, third and fourth weeks, every day only in the morning, 2 ml of sesame oil is dropped into the palm of the hand and after rubbing the hands mutually, massage the earlobe from top to bottom with the thumb and index finger for four minutes, and again apply 2 ml of sesame oil into the palm. The group was given a gentle massage of the cervical muscles from top to bottom for four minutes after rubbing the hands together with the drops.
224076712|NCT02844114|DRUG|Chemotherapy|iv.30 minutes
224076713|NCT05480813|DEVICE|Automated KINCISE™ impaction system versus handheld traditional mallet|The KINCISE™ Surgical Automated System (KINCISE) (DePuy Synthes Products, Inc, Warsaw, IN) was developed to replace the handheld mallet traditionally used in total hip arthroplasty (THA). The device is an FDA-approved medical instrument.
223879442|NCT04118452|BEHAVIORAL|Telephone-based early childhood developmental care coordination|The 211LA care coordinator will review developmental screening results and provide referral recommendations to the family and use 211LA's extensive resource directory and agency relationships to identify appropriate referrals. The 211LA care coordinator will provide a report to the clinical provider containing recommendations for follow-up and a care coordination plan. The report will be scanned into the EMR (Electronic Medical Record) by clinic staff and be available for provider review. The 211LA care coordinator will also make all recommended referrals and will call the family monthly until 1) children begin receiving services, 2) families refuse services, or 3) children are deemed ineligible by service providers.
223879443|NCT06803368|BIOLOGICAL|baseline anti-HBs titer|Patients with baseline anti-HBs titer\<100 mIU/ml were randomly divided into two groups, group B and group C. Group B did not intervene, while group C received hepatitis B vaccine intervention and observed its indicators.
223879444|NCT06803693|DRUG|Polatuzumab vedotin|Polatuzumab vedotin IV infusion will be administered as per the schedule specified in the respective arm.
223879445|NCT06803693|DRUG|Rituximab|Rituximab IV infusion will be administered as per the schedule specified in the respective arm.
223879446|NCT06803693|DRUG|Cyclophosphamide|Cyclophosphamide IV infusion will be administered as per the schedule specified in the respective arm.
223879447|NCT06803693|DRUG|Doxorubicin|Doxorubicin IV infusion will be administered as per the schedule specified in the respective arm.
223879448|NCT06803693|DRUG|Prednisone|Prednisone PO will be administered as per the schedule specified in the respective arm.
223879449|NCT06803693|DRUG|Zanubrutinib|Zanubrutinib PO will be administered as per the schedule specified in the respective arm.
223879450|NCT06803693|DRUG|Lenalidomide|Lenalidomide PO will be administered as per the schedule specified in the respective arm.
223879451|NCT06803693|DRUG|Decitabine|Decitabine IV infusion will be administered as per the schedule specified in the respective arm.
223879452|NCT04077567|DRUG|TS-152|30mg,80mg
223879453|NCT06368440|DRUG|AZD6793|Participants will receive AZD6793 single dose as oral suspension.
223879454|NCT06368440|DRUG|AZD6793|Participants will receive AZD6793 multiple doses daily as oral suspension.
223879455|NCT06368440|DRUG|Placebo|Participants will receive matching doses of placebo as oral suspension.
224076714|NCT05480813|OTHER|Efficiency and ergonomics analysis and physical assessments|Operational efficiency, ergonomic impaction, cognitive/physical/stress level evaluations,
224076715|NCT02949752|DRUG|Aripiprazole|Aripiprazole 5 mg every morning will be prescribed for 12 weeks
224076716|NCT01714271|BEHAVIORAL|Home environs-based lifestyle counseling|Social learning theory-based behavior modification embedded in a social ecological framework is used to shape both the home environment and the lifestyle choices of the study participants to optimize their adherence to the Dietary Guidelines for Americans and the Physical Activity Guidelines for Americans.
224076717|NCT01714271|BEHAVIORAL|Cancer early detection|Conventional health education is used to increase study participant knowledge of practical strategies for detecting and treating common cancers early, before cancers have metastasized. Additional instruction is devoted to the biology and physiology of the cancer process. Although some mention will be made of the importance of maintaining a healthy weight for minimizing lifetime risk of certain cancers, most of the focus will be on episodic cancer screening, e.g., mammograms, PAP smears, colonoscopies, etc. for prevention of death from cancer.
223879456|NCT05330130|DRUG|Follitropin beta injection 150 IU|"Participants commence ovarian stimulation on day 2 or 3 of their menstrual cycle with a daily dosage of 150 IU rec-FSH. The dosage will remain constant throughout the course of the stimulation. From the morning of the 5th stimulation day, GnRH-antagonist will be administered daily to prevent LH-rise. As soon as ≥ 3 follicle of a size of 17mm are seen, 0.3 mg GnRH-Agonist will be administered for final oocyte maturation. During ovarian stimulation, follicle puncture procedures with the aspiration of follicular fluid will be performed at the following time:~* one follicle on the morning of day 5, before the administration of the first GnRH-antagonist~* one follicle of the size of 12 to 14 mm, when at least 2 to 3 follicles have reached a size of 12 to 14 mm~* two follicles (= pre-ovulatory follicle) on the morning of the day of final oocyte maturation.~Oocyte retrieval of all other follicles will be carried out 36 hours after injection of the medication for final oocyte maturation."
224076718|NCT02387580|DRUG|OZ439 + TPGS|
224076719|NCT02387580|DRUG|OZ439 Prototype 1|
224076720|NCT02387580|DRUG|OZ439 Prototype 3|
224076721|NCT02387580|DRUG|PQP|
224076722|NCT03201185|DRUG|Ramipril|Initial dose: 2,5 mg. Up-titrated at one month to 5 mg and 10 mg at three months (following clinical practice recommendations for up-titration). Target dose: 10 mg (or maximum tolerated dose).
224076723|NCT03355989|OTHER|Conditional Cash Transfer|Conditional cash transfer provided via mobile airtime and easypaisa along with SMS reminders to increase immunization coverage and timeliness
223879457|NCT05330130|DRUG|Follitropin beta injection 300 IU|"Participants commence ovarian stimulation on day 2 or 3 of their menstrual cycle with a daily dosage of 300 IU rec-FSH. The dosage will remain constant throughout the course of the stimulation. From the morning of the 5th stimulation day, GnRH-antagonist will be administered daily to prevent LH-rise. As soon as ≥ 3 follicle of a size of 17mm are seen, 0.3 mg GnRH-Agonist will be administered for final oocyte maturation. During ovarian stimulation, follicle puncture procedures with the aspiration of follicular fluid will be performed at the following time:~* one follicle on the morning of day 5, before the administration of the first GnRH-antagonist~* one follicle of the size of 12 to 14 mm, when at least 2 to 3 follicles have reached a size of 12 to 14 mm~* two follicles (= pre-ovulatory follicle) on the morning of the day of final oocyte maturation.~Oocyte retrieval of all other follicles will be carried out 36 hours after injection of the medication for final oocyte maturation."
223879458|NCT04847999|DIETARY_SUPPLEMENT|Dark chocolate|Dark chocolate
223879459|NCT06358339|OTHER|TEEM|The TEEM app will provide four types of gamified intervention elements as Routine Tracker, Mind Care, Social Connectivity, and Achievement \& Rewards which providing services including brief contact intervention, mCBT, health education, venting space, mood sharing, etc. Only enrolled participants have access to log in and use the app.
224076724|NCT03355989|OTHER|SMS Reminder|Three SMS reminders for immunization provided before, at and after the due date respectively
223879460|NCT03217006|PROCEDURE|Single arterial graft|This interventions consists of patients receiving the left internal thoracic artery to the left anterior descending coronary artery of the heart. In addition to the left internal thoracic artery patients will receive venous grafts for all additional grafting.
223879461|NCT03217006|PROCEDURE|Multiple arterial grafting|This intervention consists of the patient receiving the left internal thoracic artery to the left anterior descending coronary artery of the heart. The second arterial graft (right internal thoracic artery or radial artery) will be directed to the major branch of the circumflex. Additional grafts will include saphenous veins or arterial conduits.
223879462|NCT02879448|DEVICE|Amulet Left Atrial Appendage Occluder|Transcatheter left atrial appendage closure
223879463|NCT02879448|DEVICE|WATCHMAN Left Atrial Appendage Closure|Transcatheter left atrial appendage closure
223879464|NCT04999202|DRUG|BAY2416964|Oral, twice or three times daily
223879465|NCT04999202|DRUG|BAY2416964|The highest dose determined safe in combination with pembrolizumab in the dose escalation part or a lower dose. More than one dose may be explored in the dose expansion.
223879466|NCT04999202|DRUG|Pembrolizumab|Administered as a dose of 200 mg using a 30-minute IV infusion every 3 weeks
223879467|NCT05778656|BEHAVIORAL|Cardiovascular Risk Prevention with a Mediterranean Dietary Pattern Reduced in Saturated Fat|Eight-week behavioral intervention consisting of a Mediterranean dietary pattern with elimination of red and processed meat
223879468|NCT05952076|DIETARY_SUPPLEMENT|B. infantis Bi-26|A once-daily oral dose of Bi-26 will be provided to infants for 28 days.
223879469|NCT05952076|DIETARY_SUPPLEMENT|Placebo|A once-daily oral dose of placebo maltodextrin will be provided to infants for 28 days
223879470|NCT02915575|OTHER|Risk guided follow-up|Participant will be stratified for risk of CKD in three groups: Low (\<1% risk of CKD), medium (1-10 % risk of CKD) and high (≥10 % risk of CKD). Specific follow-up will be guided by risk status
223879471|NCT02915575|OTHER|Usual Care|Participants will be discharged as per usual ward discharge protocols.
223879472|NCT06739824|DIAGNOSTIC_TEST|Conventional Treatment(CI)|Patients receive a corticosteroid injection followed by conventional treatment, such as standard physical therapy exercises focused on range of motion and strengthening, without the specific manual techniques of the Spencer method.
223879473|NCT06739824|COMBINATION_PRODUCT|Spencer Technique (CI)|Patients receive a corticosteroid injection followed by the Spencer technique, which involves a series of specific manual mobilization maneuvers aimed at improving shoulder mobility and reducing pain.
223879474|NCT06102460|DIETARY_SUPPLEMENT|Casein protein|40 grams of casein protein powder mixed with 8-10 fl. oz. of water.
223879475|NCT06102460|DIETARY_SUPPLEMENT|a-lactalbumin protein|40 grams of a-lactalbumin protein powder mixed with 8-10 fl. oz. of water.
223879476|NCT06102460|DIETARY_SUPPLEMENT|Carbohydrate|40 grams of a carbohydrate powder mixed with 8-10 fl. oz. of water.
223879477|NCT06102460|DIETARY_SUPPLEMENT|Placebo|Zero calorie, placebo powder mixed with 8-10 fl. oz. of water.
223879478|NCT05937425|OTHER|LungCaNN|The needs of the patients included in the study will be determined with the supportive care needs scale. A training booklet will be given to the patients in the intervention group and they will be informed about the existing or newly formed unsupported care needs, the evaluation of their frequency and severity, and the ability of the patients to call the navigator nurse 24/7 or send an SMS. For interventions that can be applied in line with evidence-based guidelines for unsupported care needs with patients included in the intervention group every week for 12 weeks, a face-to-face navigation will be made by the navigator nurse over the phone and once a month.
223879479|NCT05097599|DRUG|lorlatinib|This arm of the Strata PATH trial will assess the clinical benefit of Lorbrena® (lorlatinib) in ALK and ROS1 gene fusion positive solid tumors, as detected by Strata testing, with the exception of NSCLC.
223879480|NCT05097599|DRUG|encorafenib + binimetinib|This arm of the Strata PATH trial will assess the clinical benefit of Braftovi® (encorafenib) + Mektovi® (binimetinib) in BRAF p.v600X mutated solid tumors, as detected by Strata testing, with the exception of melanoma and colorectal cancer.
223879481|NCT05097599|DRUG|talazoparib|This arm of the Strata PATH trial will assess the clinical benefit of Talzenna® (talazoparib) in patients with advanced solid tumors harboring deep deletions or deleterious mutations with LOH in BRCA1/2 and PALB2, as detected by Strata testing, excluding HER2 negative breast cancer.
223879482|NCT05097599|DRUG|sacituzumab govitecan|This arm of the Strata PATH trial will assess the clinical benefit of Trodelvy® (sacituzumab govitecan) in patients with advanced solid tumors and are Trop2 Treatment Response Score High (Trop2 TRS-H), as detected by Strata testing, excluding triple negative breast cancer, hormone receptor positive/ human epidermal growth factor receptor 2 negative (HR+/HER2-) breast cancer, metastatic urothelial cancer, non-small cell lung (NSCLC) cancer, small cell lung cancer (SCLC), head and neck cancer, colorectal cancer (CRC), and endometrial cancer.
223879483|NCT05097599|DRUG|axitinib|This arm of the Strata PATH trial will assess the clinical benefit of Inlyta® (axitinib) in patients with advanced solid tumors and are Angiogensis Inhibitor Treatment Response Score High (Angio TRS-H), as detected by Strata testing, excluding renal cell carcinoma, alveolar soft part sarcoma, and solitary fibrous tumors.
223879484|NCT05097599|DRUG|Fam-Trastuzumab Deruxtecan-Nxki|This arm of the Strata PATH trial will assess the clinical benefit of Enhertu ® in patients with advanced solid tumors with Her2 overexpression
223879485|NCT05097599|DRUG|enfortumab vedotin|This arm of the Strata PATH trial will assess the clinical benefit of Padcev® in patients with advanced solid tumors with nectin-4 overexpression
223879486|NCT05998278|PROCEDURE|Personalized Optimization of Systematic Prostate Biopsy|Login the model based on our previous study (https://daringsky.shinyapps.io/prediction\_v2/) allows for input of age, BMI, serum PSA, size and location of suspicious lesions, PIRADS - V2 score, and prostate volume to generate an individualized needle distribution map,then targeted biopsy combined personalized optimization of systematic prostate biopsy was performed.
223879487|NCT06480981|DRUG|Noribogaine|Noribogaine capsules
223879488|NCT04123379|DRUG|Nivolumab|q4w, dosed twice before surgery and three times following recovery from surgery by injection
223879489|NCT04123379|DRUG|BMS-813160|300mg oral twice a day for 28 days
223879490|NCT04123379|DRUG|BMS-986253|2400mg once by injection
223879491|NCT06436157|OTHER|Enhanced education|"In addition to the education conducted as part of usual care, the nurse will: 1) provide basic education on GCT; and 2) if the patient is eligible and agreeable to GCT, place a referral to GCT (if not already ordered).~Patients will also be provided with written materials reinforcing the key messages of GCT education, designed to be understandable to individuals without a medical background. Nurses will also conduct a follow-up nudge by sending an in basket message via electronic medical record to ensure that the referrals are processed by the referral coordinators."
223879492|NCT06436157|OTHER|Usual care education|"A brief introduction to GCT will be provided in accordance with the information covered in the chemo education binder, which is the current standard of care at Enloe Regional Cancer Center. As per the usual care, referrals for genetic testing will be clinician-initiated without the proactive involvement of the RN."
223879493|NCT06170580|DIAGNOSTIC_TEST|Conventional duplex|Conventional carotid duplex measurement
223879494|NCT06170580|DIAGNOSTIC_TEST|Ultrasound-based flow imaging using plane wave imaging|Ultrasound-based flow imaging using plane wave imaging
223879495|NCT06170580|DIAGNOSTIC_TEST|Ultrasound-based flow imaging using cascaded wave imaging|Ultrasound-based flow imaging using cascaded wave imaging
223879496|NCT06799806|DEVICE|virtual reality device|20 minutes session with virtual reality device
223879497|NCT05288283|DRUG|GWP42003-P|oral solution
223879498|NCT05288283|DRUG|Placebo|oral solution
223879499|NCT04709380|OTHER|Radiotherapy plus Toripalimab|Intensity modulated radiotherapy has shown important role in the treatment of hepatocellular carcinoma (HCC), especially for advanced disease with portal vein tumor thrombosis (PVTT), or hepatic vein tumor thrombosis. Toripalimab is a recombinant, humanized programmed death receptor-1 (PD-1) monoclonal antibody that binds to PD-1 and prevents binding of PD-1 with programmed death ligands 1 (PD-L1) and 2 (PD-L2).
223879500|NCT04709380|DRUG|Sorafenib|Sorafenib is a multi-targeted oral drug for the treatment of cancer.Treatment of inoperable advanced renal cell carcinoma ,inoperable or distant metastatic primary hepatocellular carcinoma and so on.
223879501|NCT05002647|OTHER|NO intervention|There is no intervention
223879502|NCT03511118|DRUG|Tranexamic acid (TXA)|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
223879503|NCT03511118|DRUG|labetalol|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
223879504|NCT03511118|DRUG|metformin|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
223879505|NCT03511118|DRUG|nifedipine|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
223879506|NCT03511118|DRUG|clindamycin|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
223879507|NCT03511118|DRUG|oxycodone|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
223879508|NCT03511118|DRUG|azithromycin|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
223879509|NCT03511118|DRUG|escitalopram|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
223879510|NCT03511118|DRUG|sertraline|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
223879511|NCT03511118|DRUG|ondansetron|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
223879512|NCT03511118|DRUG|Ciprofloxacin|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
223879513|NCT03511118|DRUG|Doxycycline|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
223879514|NCT03511118|DRUG|Levofloxacin|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
223879515|NCT03511118|DRUG|Methylphenidate|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
223879516|NCT03511118|DRUG|Sumatriptan|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
223879517|NCT03511118|DRUG|Citalopram|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
223879518|NCT03511118|DRUG|Cyclobenzaprine|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
223879519|NCT03511118|DRUG|Furosemide|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
223879520|NCT03511118|DRUG|Gabapentin|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
223879521|NCT03511118|DRUG|Hydrochlorothiazide|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
223879522|NCT03511118|DRUG|Hydroxyurea|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
223879523|NCT03511118|DRUG|Rosuvastatin|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
223879524|NCT03511118|DRUG|Topiramate|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
223879525|NCT03511118|DRUG|Trazodone|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
223879526|NCT03511118|DRUG|Valganciclovir|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
223879527|NCT03511118|DRUG|Venlafaxine|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
223879528|NCT03511118|DRUG|Verapamil|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
223879529|NCT03511118|DRUG|Remdesivir|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
223879530|NCT03511118|DRUG|Anakinra|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
223879531|NCT03511118|DRUG|Tocilizumab|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
223879532|NCT03511118|DRUG|Fluvoxamine|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
223879533|NCT03511118|DRUG|Amoxicillin|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
223879534|NCT03511118|DRUG|Bupropion|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
223879535|NCT03511118|DRUG|Duloxetine|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
223879536|NCT03511118|DRUG|Hydrocodone|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
223879537|NCT03511118|DRUG|Levetiracetam|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
223879538|NCT03511118|DRUG|Paroxetine|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
223879539|NCT03511118|DRUG|Buprenorphine|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
223879540|NCT03388775|OTHER|deep venous thrombosis|Five-year prospective analysis of deep venous thrombosis performed by the RHEUNI group of five public schools in the State of São Paulo.
223879541|NCT05086744|DRUG|Iptacopan|Iptacopan 200 mg BID given orally (capsule)
223879542|NCT06785363|OTHER|pumped technique for ilio-lumbar ligament release|Patient position: the patient lying supine or side lying Therapist position: standing on one side of patient. Hand grip: one hand placed on posterior region of iliac crest (close to attachment of ilio-lumbar ligament) while other hand stabilize the medial part of thigh. Therapist force: therapist pulling patient's thigh posteriorly.
223879543|NCT06785363|OTHER|Hot Packs|postnatal women will be treated by hot packs for 20 minutes three times per week for 8 weeks.
223879544|NCT06785987|DRUG|Continuous Lidocaine Infusion|Maintained with sevoflurane and continuous lidocaine infusion under dosage: 1.5 mg/kg/hr
223879545|NCT06785987|DRUG|intermittent fentanyl infusion|Maintained with volatile anesthetic gas (sevoflurane) and intermittent fentanyl infusion.
223879546|NCT06785987|DRUG|Continuous remifentanil Infusion|Maintained with sevoflurane and continuous remifentanil infusion under dosage: 3-5μg /kg/hr
223879547|NCT06790654|BEHAVIORAL|Text-message based motivational interviewing|Participants will receive weekly text messages during the pilot study period, initiated and managed by MItrained interviewers. Each text message exchange will begin with a short, MI-consistent prompt developed with input from focus groups of mothers who have previously breastfed. These prompts will address common breastfeeding barriers. Following the initial prompt, MI-trained trainers will engage with participants through text exchanges that utilize the core MI OARS skills (open-ended questions, affirmations, reflections, or summaries) to facilitate change talk.
223879548|NCT03982082|PROCEDURE|Physical Therapy|Undergo physical therapy
223879549|NCT03982082|OTHER|Questionnaire Administration|Ancillary studies
223879550|NCT03982082|PROCEDURE|Ultrasound|Undergo ultrasound via MuscleSound technology
223879551|NCT06792058|DEVICE|"Mechanomiograph: The gold standard of quantitative monitoring"|"The gold standard of quantitative monitoring is mechanomyography (MMG), which measures the force of contraction of the adductor pollicis muscle following ulnar nerve stimulation. MMG responses are accurate and reproducible. However, the complex and bulky devices are only suitable for research use, are not suitable for clinical use and are not commercially available."
224076725|NCT05514964|BEHAVIORAL|Feasibility study|"Individuals interested to participate in this study were informed about the intervention via the project website and Facebook page of the project. Prior to the start of the study, participants were invited to read the Informed Consent and express their agreement to participate. Only after the Informed Consent was electronically signed, participants were able to complete the screening questionnaires online.~The intervention program (based on Acceptance and Commitment Therapy) consists of six treatment modules adapted to the online environment. Each module was structured like a therapy session and contained at least two or three homework assignments. Each participant was assigned to an online psychotherapist. At the end of the six modules, participants completed the post-intervention measures."
223879552|NCT06792058|DEVICE|Electromiograph|Another type of monitor is the electromyograph, which can be seen as an alternative to mechanomyography because of its accuracy. This technique measures muscle activity as a summation of the action potentials of muscle fibres. This activity is proportional to the strength of the muscle contraction. The most commonly innervated nerve is also the ulnar nerve, which innervates the abductor digiti minimi and the first dorsalis interosseus muscles. During the measurements, electrical signals from these muscles are detected. EMG has several advantages over other monitoring techniques. It does not require immobilisation of the hand, thumb immobility is not a problem, no preload is required, and hypothermia does not affect the hand as much as other neuromuscular monitors. The TetraGraph (Senzime AB, Sweden) is a portable EMG-based neuromuscular minitor for which the manufacturers received marketing approval from the U.S. Food and Drug Administration (FDA) in 2019.
223879553|NCT06100237|DRUG|Teclistamab|Teclistamab will be administered by subcutaneous (SC) injection per discretion of treating physician. Participants will receive the recommended dosage.
223879554|NCT06100237|DRUG|Talquetamab|Talquetamab will be administered per discretion of treating physician. Participants will receive the recommended dosage.
223879555|NCT06100237|DRUG|Daratumumab SC|Daratumumab SC will be administered by subcutaneous (SC) injection per discretion of treating physician. Participants will receive the recommended dosage.
223879556|NCT05254002|DRUG|Finerenone (BAY94-8862 ) 10 mg|oral administration, once daily if screening eGFR (Estimated glomerular filtration rate) results are: \<60 mL/min/1.73 m2
223879557|NCT05254002|DRUG|Empagliflozin|oral administration, once daily
223879558|NCT05254002|DRUG|Empagliflozin Placebo|Matching placebo to empagliflozin oral administration, once daily
223879559|NCT05254002|DRUG|Finerenone (BAY94-8862 ) 20 mg|oral administration, once daily if screening eGFR (Estimated glomerular filtration rate) results are: ≥60 mL/min/1.73 m2
223879560|NCT05254002|DRUG|Finerenone Placebo|Matching Placebo to Finerenone oral administration once daily
223879561|NCT04393532|DEVICE|Su2ura Approximation Device|the use of the study device during a laparoscopic surgery
223879562|NCT04393532|PROCEDURE|Laparoscopic hernia repair surgery|repairing primary umbilical hernia in a laparoscopic procedure using the study device.
223879563|NCT01704079|DRUG|CTAP101 30 μg capsules|CTAP101 30 μg capsule taken daily at bedtime
224076726|NCT04461470|GENETIC|epigenetic longitudinal waves|force - inducing energies using electromagnetic field(s)
223879564|NCT01704079|OTHER|Sugar pill to CTAP101 30 μg capsules|Sugar pill capsule (placebo to CTAP101 30 μg capsule) taken daily at bedtime.
223879565|NCT05422924|BEHAVIORAL|Web-based platform. (My Viva Plan)|Participants will use a web-based platform (i.e. My Viva Plan®) to improve physical function, nutrition and mindfulness.
223879566|NCT04763356|OTHER|Symptom Care at Home with NP follow up|In the SCH-NP group all participants will report their CIPN related symptoms daily via the app, website or phone tree. Any concerning symptoms will trigger a call back from a nurse practitioner who will use a consensus and evidence based algorithm to prescribe therapies for the CIPN symptoms.
224076727|NCT03170674|OTHER|FT21039|an electronic cigarette product
223879567|NCT03068663|OTHER|Sampling|Patients will receive their standard treatments, surgery with/without chemotherapy. A patient intervention consists in taking samples of blood, saliva, faeces, lung/tumour tissue, and bronchoalveolar lavage fluid.
223879568|NCT04965181|BEHAVIORAL|Mindfulness-Based Addiction Treatment|Mindfulness-based Addiction Treatment (MBAT) consists of 8 weekly virtual 2-hour sessions that teach mindfulness and cognitive-behavioral strategies for smoking cessation.
224076728|NCT03170674|OTHER|FT21092|an electronic cigarette product
224076729|NCT03170674|OTHER|FT21018|an electronic cigarette product
224076730|NCT06437938|DIETARY_SUPPLEMENT|Dietary supplement A: Wasabi leaf powder (product of BIOGENA GmbH & Co KG)|To be taken according to the information in the study protocol/patient information leaflet.
223879569|NCT04965181|DRUG|Nicotine Replacement Therapy|"Patch therapy (beginning quit day) for participants who smoke \>10 cigarettes/day will consist of 4 weeks of 21 mg patches, 2 week of 14 mg patches, and 2 week of 7 mg patches. Patch therapy for participants who smoke less than 10 cigarettes/day will consist of 4 weeks of 14 mg patches and 4 weeks of 7 mg patches.~Lozenge therapy (beginning quit day) for participants who smoke first cigarette within 30 minutes of waking up will consist of 8 weeks of 4mg lozenges. Lozenge therapy (beginning quit day) for participants who smoke first cigarette 30 minutes of more after they wake up will consist of 8 weeks of 2mg lozenges."
223879570|NCT04965181|BEHAVIORAL|Self-help materials|"Self-help materials for smoking cessation are based on the Treating Tobacco Use and Dependence Clinical Practice Guideline (Fiore et al., 2008) and include the Clearing the Air booklet developed by the National Cancer Institute (NCI) and a referral to the Tobacco Cessation Quitline (1-800-QUIT-NOW)."
223879571|NCT04965181|BEHAVIORAL|iQuit Mindfully|iQuit Mindfully involves text messages on each day between treatment sessions. The text messages provide mindfulness and cognitive-behavioral strategies and support for smoking cessation.
224076731|NCT06437938|DIETARY_SUPPLEMENT|Dietary supplement B: Berberin Phytoactive Gold (product of BIOGENA GmbH & Co KG)|To be taken according to the information in the study protocol/patient information leaflet.
223879572|NCT04827979|BIOLOGICAL|daratumumab|"Daratumumab is a CD38 (Cluster of Differentiation 38)-directed cytolytic monoclonal antibody indicated for the treatment of multiple myeloma. In this study, daratumumab will be used in highly sensitized subjects without myeloma who are awaiting a kidney transplant.~Definition of highly sensitized: Potential kidney transplant recipients with either:~* calculated panel reactive antibodies (cPRA) ≥99.9% awaiting deceased donor transplant, or~* cPRA \>98% (with \>5 years of waiting time) awaiting living donor transplant"
223879573|NCT04827979|BIOLOGICAL|belatacept|Belatacept, a monoclonal antibody, is indicated for the prophylaxis of organ rejection in adult patients receiving a kidney transplant. In this study, belatacept will be used in subjects who have not received a kidney transplant.
224076732|NCT06437938|DIETARY_SUPPLEMENT|Dietary supplement C: DiaPhyt® Formula 3.0 (product of BIOGENA GmbH & Co KG)|To be taken according to the information in the study protocol/patient information leaflet.
224076733|NCT06437938|OTHER|Placebo group 1: Placebo capsules corresponding to DiaPhyt® Formula 3.0/Berberin Phytoactive Gold|To be taken according to the information in the study protocol/patient information leaflet.
224076734|NCT06437938|OTHER|Placebo group 2: Placebo powder corresponding to Wasabi leaf powder|To be taken according to the information in the study protocol/patient information leaflet.
224076735|NCT01402297|DRUG|Apocynin and placebo nebulization|6 ml of apocynin of total dose 3 mg (0.5 mg/ml dissolved in sterile 0.9% NaCl as the study drug) and 0,9% NaCl as placebo, has been nebulized for 15-20 min through the mouthpiece with using of a nose clip. A nebulizer Pulmo Aide AP-50 (DeVilbiss; Richmond, VA) was used (mass median aerosol diameter 3.1 mm, output 0.3 ml/min.)
223879574|NCT04827979|PROCEDURE|Bone marrow aspiration|Subjects will undergo a bone marrow aspiration prior to starting the study regimen and at 12 weeks after starting the study regimen. In subjects who undergo a kidney transplant during the study, another bone marrow aspiration will be done if it has been \>4 weeks since the previous bone marrow aspiration.
223879575|NCT05986565|BEHAVIORAL|Families Moving Forward (FMF) Teacher adapted training|The FMF Connect Teacher Companion website is designed to offer teachers evidence-based education about FASD and strategies to support students with FASD. It is adapted from the FMF Program and FMF Connect, evidence based interventions to support caregivers of children with FASD. The FMF Program and FMF Connect aim to improve caregivers' efficacy and satisfaction as a parent, efficacy, attributions for their child's behavior, and the parent-child relationship.
224076736|NCT05953636|DIETARY_SUPPLEMENT|oral protein nutritional supplement (ONS) (Fresubin protein powder 25mg/5scoops per hemodialysis session)|oral protein nutritional supplement (ONS) (Fresubin protein powder 25mg/5scoops per hemodialysis session) given in group A (predialytic: 1 hour before the start of the session), in group B (intradialytic: 2 hours after the start of the session ), in group C (interdialytic: in non-dialysis days )
224076737|NCT04451629|BEHAVIORAL|pelvıc base exercıse, core exercise|Effectıveness of the pelvıc base exercıse on the paın and qualıty of lıfe ın dysmenoral youth 40 minutes exercise intervention 4 times a week for 8 weeks
224076738|NCT02340663|DEVICE|SOVA Bite Splint|Over-the-counter thermoplastic bite splint blank, heated, molded to fit.
224076739|NCT02340663|DEVICE|Michigan Bite Splint|Heat-cured acrylic bite splint fabricated by dentist/dental technician to fit
224076740|NCT02392182|OTHER|Fiberoptic bronchoscopy|All subjects will undergo a research fiberoptic bronchoscopy under moderate conscious sedation. There is no randomization
224076741|NCT05838638|BEHAVIORAL|eSSET-CINV|Participants in the intervention group will be asked to play the serious game on an iPad at their first chemotherapy treatment visit. The control group will be able to play at time 6.
224076742|NCT02979431|BIOLOGICAL|ALX-0171 3.0 mg/kg|
224076743|NCT02979431|BIOLOGICAL|ALX-0171 6.0 mg/kg|
224076744|NCT02979431|BIOLOGICAL|ALX-0171 9.0 mg/kg|
224076745|NCT02979431|OTHER|Placebo|
224076746|NCT00367042|DEVICE|Scalpel for tissue scoring|During Mohs surgery we will compare the outcomes of scarring, to determine whether a mark (with a pen) or a score with a scalpel will receive the best scar.
224076747|NCT00367042|DEVICE|Surgical marker for tissue marking|You will be asked to participate, examined, discuss participation have procedure and come in for follow up for photos and check up.
224076748|NCT05393609|PROCEDURE|Sigmoidectomy|Conventional laparoscopic resection of the sigmoid colon
224076749|NCT05393609|DIETARY_SUPPLEMENT|Conservative|According to current practice including advice on supplementary dietary fiber, analgetics, or laxatives when indicated.
224076750|NCT02676687|PROCEDURE|total resection|Removing the parenchyma until signal abnormalities on FLAIR-weighted MR / enhanced-weighted MR in adults with glioma
224076751|NCT02676687|PROCEDURE|supratotal resection|Extended removing the parenchyma at least 1cm beyond signal abnormalities on FLAIR-weighted MR / enhanced-weighted MR in adults with glioma
224076752|NCT01656434|DRUG|NOMAC-E2|NOMAC-E2 film-coated oral tablets containing 2.5 mg nomegestrol acetate and 1.5 mg 17ß-estradiol.
224076753|NCT01656434|DRUG|NETA-EE|NETA-EE film-coated oral tablets containing 1 mg norethisterone acetate and 10 μg ethinylestradiol.
224076754|NCT01656434|OTHER|Placebo|tablet
224076755|NCT01656434|DRUG|ethinylestradiol (EE)|EE 10 μg tablet
224076756|NCT01656434|DRUG|ferrous fumarate|ferrous fumarate 75 mg tablet
224076757|NCT01819779|DRUG|Exforge tab. 10/160mg|
224076758|NCT01819779|DRUG|Lodivixx tab. 5/160mg|
224076759|NCT03712579|DIETARY_SUPPLEMENT|SFA-Rich Meal|Saturated fatty acid-rich test meal, containing 75g test fat
224076760|NCT03712579|DIETARY_SUPPLEMENT|MUFA-Rich Meal|Monounsaturated fatty acid-rich test meal, containing 75g test fat
224076761|NCT04315896|DRUG|Hydroxychloroquine|hydroxychloroquine 400mg day for 10 days
224076762|NCT04315896|DRUG|Placebo oral tablet|Placebo oral tablet
224076763|NCT00615615|DRUG|Levetiracetam|"* high total tablet weight (HTTW) formulation in tablet strengths of 166.5 mg, 250 mg, and 500 mg was used for patients weighing at least 40.1 kg~* low total tablet weight (LTTW) formulation in tablet strengths of 166 mg and 250 mg was used for patients weighing 40 kg or less"
224076764|NCT00615615|DRUG|Placebo|Placebo tablets for oral administration that were identical in appearance to the respective formulations (LTTW and HTTW) were used as reference therapy
224076765|NCT04128540|DRUG|Fentanyl|fentanyl infusion at a dose of (1 μg/kg/hour) after induction of anesthesia and to be continued all through the whole operation.rescue analgesia by a bolus of (Fentanyl 1mcg/kg) will be given to the patients in either group, if either systolic blood pressure or heart rate increased more than 20% of the baseline readings.
224076766|NCT04128540|PROCEDURE|Erector spinae plane block|"ultrasound guided erector spinae plane block by injecting 0.4ml/kg (1:1 solution of bupivacaine 0.25% and lidocaine 1%). This will be performed at the same side of the planned thoracotomy under strict aseptic precautions.A high frequency 12 MHz linear ultrasound transducer will be placed in a longitudinal orientation 3 cm lateral to the T3 spinous process corresponding to the T2 transverse process.~Three muscles; trapezius, rhomboids major, and erector spinae will be identified superior to the hyperechoic transverse process.~Using in-plane approach a 25 G needle will be inserted in caudal-cephalic direction, until the tip is deep to erector spinae muscle.~Correct needle tip location will be confirmed by injecting 3 mL of normal saline and visualizing the linear LA spread in the fascial plane between the erector spinae muscle and the transverse process.."
224076767|NCT06201793|DRUG|Mesalazine|Mesalamine, also known as 5-aminosalicylic acid (5-ASA), is a medication used to treat ulcerative colitis. It is usually used to induce or maintain remission of mildly to moderately active ulcerative colitis
224076768|NCT06201793|DRUG|Minocycline|Minocycline is a tetracycline antibiotic medication used to treat a number of bacterial infections such as pneumonia. It is generally less preferred than the tetracycline doxycycline. Minocycline is also used for the treatment of acne and rheumatoid arthritis.
224076769|NCT00104546|PROCEDURE|Acupuncture point injection of vitamin K|
224076770|NCT03504592|BEHAVIORAL|Completion of Glucose logs|Glucose logs will be assessed by provider for completeness and accuracy
224076771|NCT01331304|DRUG|Lithium|600-900mg per day over 6 months
224076772|NCT01331304|DRUG|Quetiapine|100-800mg a day over 6 months
223879576|NCT06798311|BEHAVIORAL|SUPPORT workbook|"The SUPPORT workbook contains a template for how pelvic floor physical therapy is delivered in the typical in-person setting with a combination of education, bladder re-training exercises, pelvic floor stretching and core strengthening. To aid in the demonstration of physical therapy exercises, the workbook includes QR-coded links to videos of a physical therapist performing the exercises in an ideal form. The videos include audio instruction to ensure that patients can learn the concepts in either visual, auditory or written form. The cognitive behavioral therapy (CBT) portion of the workbook is adapted from the standardized CBT protocol and includes short introductions and exercises pertaining to cognitive flexibility, behavioral activation and social support. The total time commitment for the program is 2-hours per week.~Patients also will be given access to a custom programmed GPT trained on the SUPPORT workbook and given instructions on empathetic communication techniques."
223879577|NCT06754839|DEVICE|Percutaneous left ventricular assist device(Ventiflow LP)|The PCI will be completed with the support of percutaneous left ventricular assist device(Ventiflow LP).
223879578|NCT06754839|DEVICE|VA-ECMO|The PCI will be completed with the support of Veno-arterial extracorporeal membrane oxygenation (VA-ECMO).
224076773|NCT01580397|DRUG|INNO-206|INNO-206 at a total dose of 350 mg/m2 (260 mg/m2 doxorubicin equivalent) will be administered as a 30 minute IV infusion every 21 days.
224076774|NCT00481416|DEVICE|PillCam Eso|
224076775|NCT02004873|DEVICE|Micra Pacemaker Implant|
224076776|NCT06103032|PROCEDURE|Breast Conserving Surgery|Patients undergoing breast conserving surgery
224076777|NCT06103032|PROCEDURE|Mastectomy|Patients undergoing mastectomy
223879579|NCT05056545|BEHAVIORAL|C4 Intervention|"C4 Intervention, is an innovative form of Post Partum Family Planning (PPFP). PPFP methods include: the copper intrauterine device, hormonal implant, tubal ligation, and (after 6 weeks post-partum in breastfeeding women) Depo-Provera and oral contraceptive pills. These are provided as current, standard of care in Rwanda, are procured by the government, and administered by trained nurses and doctors.~The C4 training will occur at the 4 pilot facilities. Training will include a 2-day didactic session covering PPFP provision, follow-up, use of the C4 counseling flipchart; mock counseling sessions; and PPIUD and PP implant insertion and removal trainings. The study team will train government clinic staff in family planning, ANC, L\&D, and IV to promote C4 at the selected facilities. 'Happy Clients' will be recruited from women who received promotions and selected PPFP to join a clinic-based PPFP promotions team. Women interested in PPFP will be referred to the facility by their CHW."
223879580|NCT04164472|BEHAVIORAL|Friend to Friend (F2F) with Coaching|Friend to Friend (F2F) with Coaching has 14 small group sessions and 8 classroom sessions as led by school staff with coaching from the Children's Hospital of Philadelphia (CHOP) research team. The program aims to improve problem solving and prosocial behaviors, and decrease aggressive behaviors.
223879581|NCT06763133|OTHER|Cold Water Spray Application|Cold water spray application after endonasal endoscopic surgery.
223879582|NCT06763133|OTHER|Clinical routine practice|The process of giving 2 cc of water to patients with a syringe as a clinical routine practice.
223879583|NCT06444529|DRUG|Apraclonidine Hydrochloride Ophthalmic Solution|Investigational ophthalmic solution applied topically to the eye with a dropper bottle
223879584|NCT06444529|DRUG|Vehicle|Vehicle (inactive ingredients) applied topically to the eye with a dropper bottle
223879585|NCT04431050|DIAGNOSTIC_TEST|Point of care testing of respiratory viruses.|Single use point of care diagnostic device.
223879586|NCT04053842|DIAGNOSTIC_TEST|PET Scan|PET imaging uses small amounts of a radioactive substance called a tracer to look for disease in the body. The radioactive substance used in this study is \[18F\]PSMA-1007.
223879587|NCT04053842|DRUG|[18F]PSMA-1007 Injection|\[18F\]PSMA-1007 is given by intravenous (IV) injection into the arm. It travels through the blood stream where it is rapidly taken up by prostate cancer cells and emits tiny, positively charged particles (called positrons) that produce signals into the body. These signals are detected by the PET component of the PET/MRI scanner.
223879588|NCT04053842|DIAGNOSTIC_TEST|Sodium MRI|Sodium MRI uses magnetic waves and a specially-designed rectal probe to measure the sodium concentration (amount of salt) in the prostate. Previous research has shown that higher sodium concentrations in the prostate might be a sign of more aggressive cancer.
223879589|NCT04053842|DIAGNOSTIC_TEST|Multiparametric MRI|MRI is a common medical diagnostic tool that uses magnetic waves and a contrast agent (dye) called Gadovist to take pictures of body tissue.
223879590|NCT03215069|DRUG|Empagliflozin 10 MG|Empagliflozin 10 mg PO daily
223879591|NCT03215069|DRUG|Placebo oral capsule|Placebo PO daily
223879592|NCT06793553|DRUG|Induction therapy|2 cycles of PTX+ bevacizumab induction therapy followed by atezolizumab+nab-PTX
223879593|NCT06791980|OTHER|CM-TCM|To assess the long-term effects of integrated case management model involving traditional Chinese medicine (CM-TCM) model. The persons participating will be invited to enroll in this stage, and they will be assigned to receive either the usual care or a usual care plus integrated 3-month CM-TCM
223879594|NCT05882253|OTHER|Restricted Spectrum Imaging-Magnetic Resonance Imaging (RSI-MRI)|An advanced imaging software that supports improved prostate cancer detection and diagnosis
224076778|NCT00311467|DRUG|Capecitabine, Interferon, Interleukin|"Capecitabine orally from day 1 to 14 at a dose of 1000 mg/m2 twice daily every 21 days.~Interferon-alpha subcutaneously on days 1 + 3 + 5 weeks 1 + 2 +6 + 7,11+12 at a dose of 6 MIU/d.~Interleukin-2 subcutaneously on days 1 to 4 in weeks 3 + 4 +8 + 9,13+14 at a dose of 4.5 MIU/day.~Group B~Patients randomized to group B will receive treatment according to the same treatment schedule and at the same dosages without capecitabine.~Efficacy evaluations will be performed every 14 weeks of treatment in both groups"
223879595|NCT06959238|OTHER|Temel beden farkındalığı terapisi|Individuals in the TBFT group will receive a total of 16 exercise sessions, with individual exercises 2 days a week for the first 2 weeks and group exercises 2 days a week for the next 6 weeks. The purpose of the individual sessions is to aim for the participant to learn the TBFT exercises and to prepare the participant for the group sessions. In individual sessions, the person learns body scanning and develops awareness about their own body. The participant continues the exercises they learned in the individual session at home. At this stage, the participant is assigned a notebook and is asked to write down their experiences of the exercises they do at home in this notebook. The participant who completes the individual sessions continues with the group sessions. The purpose of the group sessions is to provide interaction within the group and to establish a bond of trust between the individuals in the group with the interaction obtained. The fact that the participants do exercises toge
223879596|NCT02991807|DRUG|RAD001|"RAD001 is formulated as tablets of 5.0 mg strength, blister-packed under aluminum foil in units of 10 tablets and dosed on a regular basis. RAD001 tablets should be opened only at the time of administration as drug is both hygroscopic and light-sensitive.~Patients will be instructed to take 4.5 mg/m2 of RAD001 orally with a glass of water at regular intervals at the same time (delete: each day) in the morning after a light, nonfat breakfast."
223879597|NCT02991807|DRUG|Placebo|"Matching placebo will be provided as a matching tablet and will also be blister packed under aluminum foil in units of 10. Matching placebo tablets should be opened only at the time of administration as drug is both hygroscopic and light-sensitive.~Patients will be instructed to take 4.5 mg/m2 of the matching placebo orally with a glass of water at regular intervals at the same time (delete: each day) in the morning after a light, nonfat breakfast."
223879598|NCT06430658|COMBINATION_PRODUCT|Tislelizumab (BGB-A317) with chemoradiotherapy|Different sequences and methods of treatment to convert surgery
223879599|NCT06834022|DEVICE|Transcranial direct current stimulation|tDCS will be used according to instructions for use in migraine headache (supraorbital and M1 stimulation), 1 mA, 20 min, 10 sessions
223879600|NCT06834022|PROCEDURE|Acupuncture|Acupuncture will be semistandardized, (every patient is stimulated over Li4, St36, Li3 + patient specific acu-points), 10 sessions
223879601|NCT06636500|DRUG|CG001419|Oral doses
223879602|NCT06636500|DRUG|Placebo|Oral doses
223879603|NCT04605913|COMBINATION_PRODUCT|Modified GCN+TTF treatment|The regimen will consist of gemcitabine (G) administered at a dose of 800 mg/m2, cisplatin (C) 30 mg/m2, and protein-bound paclitaxel (N) 150 mg/m2 administered on cycle 1 day 1 and every 2 weeks thereafter and TTF will be administered daily (150kHz 18 hours/day) starting with Cycle 1 Day 1 (dose level 1). One cycle consists of 28 days including 2 chemotherapy treatments (same regimen studied in the PAXG trial: Reni BJC 2016 without capecitabine). After completing 6 cycles, patients will then transition to a maintenance phase of G administered at a dose of 1000 mg/m2 every 2 weeks and daily TTF (150 KHZ 18 hours/day) until progression of disease (POD) per RECIST v1.1.
223879604|NCT06490809|OTHER|Physiotherapy|Parkinson\&#39;s upper extremity rehabilitation generally consists of stretching, strengthening, coordination, recreational activities and skill activities. Exercises will be prescribed by the clinical specialist physician and physiotherapist.
224076779|NCT04269109|OTHER|Multi-modal Opioid Sparing Pain Management Protocol|Incorporating multimodal opioid sparing ERAS techniques for cardiac surgery patients should show a decrease in the amount of opioids received, reduction in incidence of chronic pain, ileus, delirium, and potential for opioid addiction post-operatively. Between the dates of November 2018 through February 2019, a multi-modal, opioid sparing pain management protocol was evolving and a protocol was put into place. This study will compare outcomes before and after implementation of the protocol between the dates of September 1, 2018 - October 31, 2018 and March 1, 2019 - April 30, 2019.
223879605|NCT04279262|OTHER|attendance by community first responders for medical emergencies|The investigators will purposively sample patients, relatives, and ambulance staff identified from records of patients who have been attended by a CFR in a rural location in the previous six months. Where possible the investigators will interview patients, relatives, CFRs and ambulance staff attending the same event. GPs will be purposively sampled from rural areas of the ambulance services involved. Investigators will recruit a maximum variation sample of patients (according to age, sex, condition, and ethnicity), ambulance staff (sex, experience, ethnicity and role), CFR (sex, ethnicity, length of experience, skill level) and CFR scheme leads (independent charity and ambulance trust overseen schemes).
223879606|NCT06846944|OTHER|Breathing/relaxation intervention|"Ladybug TECHNIQUE is a breathing/relaxation intervention performed in children aged 5 to 10 years and consists of telling the story of a ladybug performing 4 moves and visualizing and performing breathing techniques independently. Afterwards, a drawing is invited.~SUNRISE TECHNIQUE is a breathing/relaxation intervention performed in children aged 10 to 15 years and consists of having the child imagine a favorite place. Then they are invited to reflect on the experience either verbally or through writing or drawing."
223879607|NCT01771484|DEVICE|External automated abdominal binder|Participants will wear the abdominal compression binder on day 4 or 5 of the study diet. Seated and standing vitals will be collected before and during application of binder.
223879608|NCT02845466|BIOLOGICAL|Becaplermin|0.25 cm of 100 µg/g Becaplermin gel topically per 1cm² of ulcer area applied 3 times per week for 6 weeks.
223879609|NCT02845466|DEVICE|Promagran Dressing|44% oxidized regenerated cellulose (ORC), 55% collagen and 1% silver-ORC wound dressing applied 3 times per week for 4 weeks.
223879610|NCT02845466|DEVICE|Placebo Dressing|Inactive wound dressing.
223879611|NCT03755141|DRUG|Herzuma|Herzuma + Treatment of Physician's Choice
223879612|NCT03399292|DRUG|Cationorm MD sine eye drops|studyparticipants receive lipidbased eye drops once only in the study eye
223879613|NCT05842057|BIOLOGICAL|BioDFence G3 Placental Tissue Membrane|The BioDFence G3 Placental Tissue Membrane is a three-layer tissue allograft consisting of amnion-chorion-amnion. Amniotic membranes will be placed over the neurovascular bundle after extirpative RARP. The membrane will be cut into two longitudinal pieces and placed over each neurovascular bundle separately.
223879614|NCT05842057|PROCEDURE|Robot-Assisted Radical Prostatectomy|Robot-assisted surgical removal of the prostate, administered standard of care.
223879615|NCT03812874|DRUG|PTX-9908 Injection|"Proposed dose cohorts:1 mg/kg, 2 mg/kg, 4 mg/kg, 8 mg/kg, and 16 mg/kg.~Frequency:~Phase I: one dose per day for 4 consecutive weeks (20 doses). Phase II (A)Daily Dose Regimen one dose per day for 12 consecutive weeks (60 doses). (B) Daily for first week, followed by weekly treatment Regimen One dose per day for 5 consecutive days in Week 1 (5 doses), and one dose per week till for 11 weeks (11 doses).~Duration: 4 weeks (Phase I) and 12 weeks (Phase II)."
223879616|NCT03812874|DRUG|Placebo|"water for injection~Phase II (A)Daily Dose Regimen one dose per day for 12 consecutive weeks (60 doses). (B) Daily for first week, followed by weekly treatment Regimen One dose per day for 5 consecutive days in Week 1 (5 doses), and one dose per week till for 11 weeks (11 doses).~Duration: 12 weeks (Phase II)"
223879617|NCT03206372|OTHER|Case group|Questionnaire to be completed, blood sample and possibly echo-doppler
223879618|NCT03206372|OTHER|Control group|Questionnaire to be completed, blood sample and possibly echo-doppler
224076780|NCT05358379|DRUG|CYC140|CYC140 is a highly selective, orally- and intravenously- available, ATP-competitive inhibitor of PLK1.
223879619|NCT05306509|BEHAVIORAL|NiCE|Participants will receive an initial conversation led by a trained senior nurse within eight weeks after initial oncologic diagnosis or relapse/recurrent disease diagnosis, with an introduction to the intervention and learning about the goals, values, hopes, and fears of each patient and family. The PPC team will then follow each patient by ongoing regular conversations (related to the child and family's conditions) led by the same nurse, every 4 weeks for six months, when symptom assessment and management, goal-directed supportive care, team collaboration, and care coordination will be delivered according to the family's needs. Increased PPC involvement, end-of-life care and bereavement care will be involved when necessary. If a participant feels any discomfort or distress during the intervention, a break will be taken until they feel better. If not, the central contact person will come and discussion about the participant's feeling and wiliness to continue the intervention.
223879620|NCT05306509|OTHER|Routine PPC|Participants will be scheduled to meet with the PPC team only when participants themselves, their families, or the attending oncologist requested an appointment.
223879621|NCT06395402|DRUG|Lutetium Lu 177 dotatate therapy|LUTATHERA is an FDA approved radiopharmaceutical therapy for gastroenteropancreatic neuroendocrine tumor (GEP-NET). This radiopharmaceutical binds to somatostatin receptors, which are overexpressed on GEP-NET cells, and subsequently delivers beta particle radiation to the tumor cells.
223879622|NCT00006786|BIOLOGICAL|bevacizumab|
223879623|NCT00006786|DRUG|fluorouracil|
223879624|NCT00006786|DRUG|irinotecan hydrochloride|
223879625|NCT00006786|DRUG|leucovorin calcium|
223879626|NCT02543125|DEVICE|NIPPV|"For infants in the NIPPV-group who failNIPPV (see definition below), need immediate intubation, a invasive Rescue-Treatment may be provided. The decision to attempt Rescue-Treatment, the mode of respiratory support and the ventilator settings used are at the discretion of the attending clinician."
223879627|NCT02543125|DEVICE|NHFOV|"For infants in the NHFOV-group who failNHFOV (see definition below), need immediate intubation, a invasive Rescue-Treatment may be provided. The decision to attempt Rescue-Treatment, the mode of respiratory support and the ventilator settings used are at the discretion of the attending clinician."
223879628|NCT05128968|PROCEDURE|endotracheal intubation|Endotracheal intubation is performed in simple head extension or sniffing position using a McGrath MAC videolaryngoscope.
223879629|NCT04164784|BEHAVIORAL|therapeutic monitoring|According to the glucose lever recorded by FreeStyle Libre H (Flash Continuous Glucose Monitoring System) ,the investigators give the intervention group instructions to adjust their diet and lifestyle to abtain a good glucose control.
223879630|NCT00621634|DIETARY_SUPPLEMENT|Omega-3 fish oil capsules (including DHA)|Fish oil capsules of 1000 mg ea., including DHA 460-540 mg/capsule 2 capsules TID daily at mealtime for 12 consecutive weeks
223879631|NCT00621634|DIETARY_SUPPLEMENT|Placebo|Corn/Soybean (1:1) placebo 1000 mg capsules 2 capsules TID daily at mealtime for 12 consecutive weeks
223879632|NCT05363449|DRUG|UHE-103 Cream|UHE-103 is an investigational combinational therapy containing keratolytic and antifungal
223879633|NCT05363449|DRUG|Naftin (naftifine hydrochloride) Cream|Naftin (naftifine hydrochloride) Cream, 2%. Topical cream containing active drug
224076781|NCT05416294|DEVICE|Primary Relief|The group will receive PENS treatment using Primary Relief in addition to the multimodal analgesia (morphine, ketorolac, methyl, prednisolone, adrenaline) including the periarticular infiltration of local anaesthetic and/or femoral or epidural catheter for postoperative pain management (bupivacaine, ropivacaine).
224076782|NCT05416294|DEVICE|Inactive Primary Relief|The group will receive a sham device with multimodal analgesia (morphine, ketorolac, methyl, prednisolone, adrenaline), including the periarticular infiltration of local anaesthetic and/or femoral or epidural catheter for postoperative pain management (bupivacaine, ropivacaine).
224076783|NCT00002655|PROCEDURE|cryosurgery|
223879634|NCT04687293|DEVICE|HUBER (LPG Systems, France)|The HUBER® device consists of an oval motorized platform, which performs rotating, oscillatory movements with a controlled amplitude and speed. It also comprises, two large handles with force sensors, mounted on a movable column. Its originality is based on its capacity to capture simultaneously the subjects' balance, core stability, core strength and total body strength; and adapt the training accordingly. Indeed, the platform interferes with the balance of the patient who must continually adjust his/her posture by exerting isometric pushing and pulling efforts with the arms. As a result, the device provides postural and muscle adaptation with visual feedback. Due to the constant adaptation of the device, it is thought to enhance muscular strength and improve neuromuscular coordination simultaneously.
223879635|NCT03636334|BEHAVIORAL|Computer-based decision support system|At intervention sites, physicians will receive training and support on use of the DSS, which will be installed on their local IT system. Individuals eligible for DSS at Intervention sites will be randomized or assigned to different drug sequence protocols for BP-lowering therapy using their current antihypertensive medications, co-morbidities, and intolerance to medications and according to the assignment plan in the Algorithm. If the protocol is not suitable for the patient because of new co-morbidities, medication intolerance or contraindication, the DSS will recommend switching to a new protocol.
223879636|NCT03069859|DRUG|TXA (1g)|1 gram of TXA (10 mL) diluted into 0.9% saline, 50 ml mini-bag (a total of 60 mL)
223879637|NCT03069859|DRUG|Placebo (0.9% saline)|0.9% saline (10 mL), diluted into 0.9% saline, 50 ml mini-bag (a total of 60 mL)
223879638|NCT00792636|DRUG|sumatriptan and naproxen sodium combination tablet|sumatriptan 85mg and naproxen sodium 500mg
223879639|NCT00792636|DRUG|sumatriptan tablet|sumatriptan 85mg
223879640|NCT00792636|DRUG|naproxen sodium tablet|Naproxen sodium 500mg
223879641|NCT01915459|BIOLOGICAL|Botulinum toxin type A(Botulax®)|IM, total dose of 360 Units at wrist flexor, elbow flexor, finger flexor, and thumb flexor based on muscle tone
223879642|NCT01915459|BIOLOGICAL|Botulinum toxin type A(Botox®)|
223879643|NCT01046136|DRUG|guaifenesin (Mucinex)|bid 7 days
223879644|NCT01046136|DRUG|placebo|bid 7 days
223879645|NCT06450366|DRUG|Enlicitide Decanoate|Administered orally.
223879646|NCT06450366|DRUG|Ezetimibe|Administered orally.
223879647|NCT06450366|DRUG|Bempedoic Acid|Administered orally.
223879648|NCT06450366|OTHER|Placebo for Enlicitide Decanoate|Administered orally.
223879649|NCT06450366|OTHER|Placebo for Ezetimibe|Administered orally.
223879650|NCT06450366|OTHER|Placebo for Bempedoic Acid|Administered orally.
223879651|NCT05660356|DRUG|Growth Hormone|Pfizer provided GH therapy
223879652|NCT05660356|DRUG|Placebo|Pfizer provided placebo
223879653|NCT04579250|BIOLOGICAL|VRC-FLUNPF0103-00-VP (H10ssF-6473)|The vaccine is composed of the haemagglutinin (HA) stem domain from A/Jiangxi/IPB13/2013 (H10N8) influenza genetically fused to the ferritin protein from H. pylori. Purified H10ssF-6473 displays eight well-formed HA trimers that antigenically resemble the native H10 stem viral spikes.
223879654|NCT03706521|DRUG|SM04690|Healthcare professional-administered intra-articular injection performed once on Day 1 of the study.
223879655|NCT02437422|BIOLOGICAL|SANGUINATE|Single two-hour infusion of SANGUINATE
223879656|NCT02109601|OTHER|Extensive bedside training for accessing patient portal|EXTENSIVE bedside training from a research assistant on how to access and effectively use their patient portal.
223879657|NCT02109601|OTHER|Limited bedside training on patient portal use.|EXTENSIVE bedside training from a research assistant on how to access and effectively use their patient portal.
223879658|NCT04602975|BIOLOGICAL|Injection SF2A-TT15 10 µg Adjuvanted|Intramuscular injection of experimental vaccine (adjuvanted 10 µg)
223879659|NCT04602975|BIOLOGICAL|Injection SF2A-TT15 10 µg|Intramuscular injection of experimental vaccine (not adjuvanted 10 µg)
223879660|NCT04602975|BIOLOGICAL|Injection Adjuvanted Placebo|Intramuscular injection of Placebo with alhydrogel
223879661|NCT04602975|BIOLOGICAL|Injection Placebo|Intramuscular injection of the not adjuvanted Placebo
223879662|NCT04602975|BIOLOGICAL|Injection SF2A-TT15 2 µg Adjuvanted|Intramuscular injection of experimental vaccine (adjuvanted 2 µg)
223879663|NCT04602975|BIOLOGICAL|Injection SF2A-TT15 2 µg|Intramuscular injection of experimental vaccine (not adjuvanted 2 µg)
223879664|NCT00727909|DEVICE|Hearing Aid Treatments|"Hearing aid treatments:~Traditional Custom (TC), Receiver-in-the Aid (RITA) and Receiver-in-the-Ear (RITE)"
223879665|NCT03446157|DRUG|Cetuximab|Loading dose on day 1 of week 1 of 400 mg/m2 via IV over 2 hours Subsequent doses of 250 mg/m2 via IV over 1 hour weekly for 4 weeks (28 days) in combination with palbociclib
223879666|NCT03446157|DRUG|Palbociclib|125 mg taken orally once daily on days 1-21, then 7 days off
223879667|NCT04587505|PROCEDURE|Epidural anesthesia with light general anesthesia|Epidural anaesthesia: mixture of ropivacaine 6.5 mg/ ml and fentanyl 8.3 μg/ml. Light general anesthesia: isoflurane in mixture of 50/50 of nitrous oxide and oxygen to achieve Minimum alveolar concentration between 0.6 and 0.8.
223879668|NCT04587505|DRUG|Postoperative epidural analgesia|Before the end of operation was given 4 ml of the mixture of ropivacaine 4.4 mg/ml and morphine 0.8mg/ ml. Epidural analgesia was continued for next 24 hours with a mixture of ropivacaine 2.2 mg/ml and morphine 0.4 mg/ml.
223879669|NCT04587505|PROCEDURE|General anesthesia|Maintaining general anesthesia: nitrous oxide and oxygen in mixture 50/50 and isoflurane to achieve minimum alveolar concentration between 0.8 and 1. Fentanyl loading dose: 6-8 μg/kg. Additional fentanyl doses were given incrementally.
223879670|NCT04587505|DRUG|Continuous intravenous analgesia|Tramadol 100 mg in the first hour followed by tramadol 300 mg continuously for the next 24 hours.
223879671|NCT00537212|OTHER|The South Beach Diet|"Subjects will receive dietary counselling aimed at reducing simple carbohydrates and increasing weight loss. Subjects also receive a copy of The South Beach Diet."
223879672|NCT00537212|OTHER|The Ornish Diet|"Subjects will receive dietary counselling aimed to reduce fat consumption and increase weight loss. Subjects also receive a copy of The Ornish Diet book."
223879673|NCT00537212|OTHER|Control Group|This group will receive phototherapy alone. They will not be counselled or give literature on a particular diet.
223879674|NCT01432106|DRUG|Aliskerin/Valsartan and Rampiril|"Patients will start on low dose Ramipril 10 mg or Valturna 150/160 at visit 2, and up-titrate to target dose of Ramipril 20 mg or Valturna 300/320 at visit 3. At visit 5, the addition of Hydrochlorothiazide (HCTZ) or amlodipine will be allowed to achieve the SBP target of \< 140 mmHg. High dose will then be maintained throughout the remainder of the study. In case of symptoms of low blood pressures, the study medication may be decreased to the low dose.~(However, all non-study medication will be manipulated, initially.)"
223879675|NCT05990738|DRUG|BI 764532|BI 764532
223879676|NCT05990738|DRUG|Topotecan|Topotecan
223879677|NCT05990738|DRUG|Single agent chemotherapy|single agent chemotherapy
223879678|NCT06122688|BEHAVIORAL|Navigator Plus App Intervention|Navigators will provide their usual care services and also be encouraged to use the Connected for Wellness (CFW) app during their usual activities with youth and caregivers at their site. The duration of this period (2, 3, or 4 years) will depend on the step period of the individual's site. All youth at the school or clinic site can use the CFW app on their own and through the app receive prevention strategies, psycho-education that destigmatizes mental health, encourages referrals to local resources as needed, and increases motivation to access care if needed.
223879679|NCT06050317|DRUG|Sintilimab Plus mFFN or NALIRIFOX and Radiation|Sintilimab Plus mFFN or NALIRIFOX and Radiation
223879680|NCT00411151|DRUG|Sunitinib-Malate|Capsules of 50, 25 or 12,5 mg. Dosage 50 mg, 37.5 mg or 25 mg once daily until progression of disease or untolerable side effects
223879681|NCT05683418|DRUG|TOS-358|Covalent Phosphoinositide-3-Kinase (PI3K)-alpha Inhibitor
223879682|NCT04192422|OTHER|no intervention|This is a cohort study no intervention
223879683|NCT05169229|DRUG|Vancomycin + Tobramycin|1 g vancomycin (powder) diluted in 8 ml tobramycin (40 -80mg/ml). Added to the prepared allograft before the allograft is used during the revision surgery.
223879684|NCT05169229|DRUG|Saline|As a placebo added to the allograft.
223879685|NCT05486052|OTHER|Evaluation of reliability, repeatability and validity of devices among healthy subjects|"Evaluation of reliability, reproducibility and validity of devices among healthy subjects Prior to the study among individuals with neurological disorders, an evaluation of the reliability, repeatability and credibility of the devices to be included in the biofeedback rehabilitation and optical oximetry measurements will be carried out.~The evaluation of the devices will be carried out by two independent researchers twice"
223879686|NCT05486052|OTHER|Biofeedback method and Health-resort based rehabilitation Health-resort based treatments supplemented with biofeedback training|"The rehabilitation programme will run for 3 weeks from Monday to Friday. Patients will receive: group and individual exercises (active and assisted exercises, manipulative exercises, PNF-based exercises, balance and breathing exercises), manual massages, physical treatments such as laser, whirlpool, mud packs, carbonic acid therapy , TENS therapy, BIO-V lamp, local cryotherapy.~Health-resort based rehabilitation The rehabilitation programme will last 3 weeks from Monday to Friday. Patients will receive: group and individual exercises (active and assisted exercises, manipulative exercises, PNF-based exercises, balance and breathing exercises), manual massage, physical treatments such as laser, whirlpool, peat wraps, carbonic acid therapy , TENS therapy, BIO-V lamp, local cryotherapy."
223879687|NCT05486052|OTHER|Health-resort based rehabilitation Control group - health-resort based treatments, without biofeedback training.|Health-resort based rehabilitation The rehabilitation programme will last 3 weeks from Monday to Friday. Patients will receive: group and individual exercises (active and assisted exercises, manipulative exercises, PNF-based exercises, balance and breathing exercises), manual massage, physical treatments such as laser, whirlpool, mud packs, carbonic acid therapy , TENS therapy, BIO-V lamp, local cryotherapy
223879688|NCT01370330|DRUG|Metaiodobenzylguanidine (MIBG)|131I-MIBG Therapeutic Administration. Therapeutic 131I-MIBG will be synthesized at Jubilant DraxImage (Quebec, Canada) with specific activities of 9-18 Ci/mmole, or at Progenics with specific activity of 2,500 mCi/mg. The therapeutic dose (8-18 mCi/kg at investigator's discretion; any dose greater than 12 requires stored stem cells) will be diluted in 25-50 ml of normal saline for either preparation, and will be infused intravenously through a patient's central line, if already present, or a peripheral IV if a central line is not present.If Azedra is used, the dose will be infused over 30-60 minutes; the low specific activity preparation from Draximage will be infused over 90-120 minutes. For patients with pheochromocytoma or paraganglioma, the recommended maximum dose is 500 mCI or 12 mCi/kg.
223879689|NCT03110549|DRUG|TMB-607|
223879690|NCT03110549|DRUG|Placebo|
223879691|NCT03276403|DEVICE|PiCCO Catheter|The PiCCO Catheter is an investigational device intended to measure lung water content in individuals requiring advanced haemodynamic monitoring. The device system is to be used only in accordance with the approved Investigational Plan on subjects who have signed an informed consent form. Device use is limited to the approved study investigators.
223879692|NCT02949375|DRUG|Placebo Comparator|Placebo gel capsule to be taken daily for 28 days
223879693|NCT02949375|DRUG|Active Comparator:4.5mg GRI-0621|4.5mg GRI-0621 gel capsule to be taken daily for 28 days
223879694|NCT02949375|DRUG|Active Comparator: 6.0mg GRI-0621|6.0mg GRI-0621 gel capsule to be taken daily for 28 days
223879695|NCT02954211|DEVICE|repetitive transcranial magnetic stimulation (rTMS)|"rTMS can be given to either the stroke or nonstroke hemisphere. For the nonstroke hemisphere, priming rTMS will be given to the optimal spot at an intensity of 90% of threshold at a frequency of 6 Hz for a 5-s ON period followed by 25-s OFF period. The ON-OFF cycling continues for 10 min. Principal rTMS follows priming and is applied at the same intensity at 1 Hz continuously for 10 minutes. The rationale for 6-Hz priming is to make the 1-Hz principal rTMS more effective. The after-effects of the principal rTMS are inhibition of the underlying neurons in the nonstroke hemisphere, which has a facilitating effect on the stroke hemisphere.~For the stroke hemisphere, rTMS will involve 6-Hz stimulation at the optimal spot at an intensity of 90% of threshold at a frequency of 6 Hz for a 5-s ON period followed by a 25-s OFF period. The ON-Off cycling continues for 10 minutes. With either form of rTMS, the desired effects of the rTMS are facilitation of the neurons in the stroke hemisphere."
223879696|NCT02954211|BEHAVIORAL|Physical therapy|Following the total rTMS treatment and a 3-minute break, physical therapy treatment will commence. The physical therapy treatment will consist of 15 minutes of finger movement tracking training followed by 15 minutes of virtual hand exercises. The tracking involves placing an small device on the weak hand that records finger motion and moving the index finger into finger extension and flexion to track a computer screen cursor as accurately as possible along a target track. The virtual hand exercises involve placing the weak hand in front of a computer with a program that will show a virtual hand and some blocks on a computer screen. The patient will attempt to stack the blocks by doing active hand movements that control the virtual hand. Another virtual hand exercise involves using the thumb and index finger to pluck petals from a virtual flower shown on the screen. There are further exercises like this.
223879697|NCT02612233|DRUG|Pregabalin or Duloxetine or Placebo|This is a randomized, double blind placebo controlled trial with a head-to-head comparison of duloxetine vs pregabalin vs placebo over-encapsulated to prevent unblinding of treatment arm
223879698|NCT03261908|GENETIC|detection of genotype|detection of genotype by next generation sequencing
223879699|NCT02320877|DEVICE|Mandibular Advancement Device (Somnomed Flex)|The SomnoDent Flex™ MAS is a custom-made, titratable MAS that is validated in randomized controlled trials described in literature
223879700|NCT05057936|BIOLOGICAL|COVID vaccine|The enrolled patients will received COVID-19 vaccine according to the vaccine protocol in Thailand ie The ChAdox-1 nCOV-19 vaccine (day 1, day 84, 12 weeks duration) or Corona vac 2 doses (day 2, day 21, 3 weeks duration) of the study. All the participants underwent blood drawn for antibody and cellular immunity measurement before the final dose of vaccination, with 7 days before first vaccine dose and eight weeks after the second doses
223879701|NCT01541436|DEVICE|Remote Ischemic Preconditioning, Capsaicin, UV-B|The participants will have one disposable tourniquet applied to the left mid thigh by research personnel. The participants will then be randomized to the treatment group or sham group. The treatment group will receive 3 cycles of RIPC to the left lower leg by occluding blood flow at the thigh with a pneumatic cuff. Each cycle will consist of 5 minutes of ischemia by inflating the cuff to 300 mmHg followed by 5 minutes of reperfusion. The sham group will have the cuff inflated to no more than 15mmHg for three cycles as described above. Areas of hypersensitivity and allodynia will be obtained every 40 min for 280 min following the end of capsaicin application.
223879702|NCT05358457|BEHAVIORAL|Familiar Metacognitive Training|The original metacognitive training program consist of 8 therapeutic units and 2 complementary. Seven of the therapeutic units address cognitive deviations and errors that are frequently seen in problem solving in schizophrenia, involved in the formation and maintenance of delusions. The other three units work with metacognition and the aims of the progra, as a psychoeducation session, so in total the MCTf will include 11 sessions.
223879703|NCT00643188|PROCEDURE|Radiofrequency ablation|Radiofrequency ablation of atrial fibrillation
223879704|NCT00643188|OTHER|Conventional treatment|The best medical treatment according to the ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult and the ACC/AHA/ESC 2006 Guidelines for Management of Patients with Atrial Fibrillation.
223879705|NCT05106075|PROCEDURE|blood sample or joint fluid or gingival exudate|blood sample collected by peripheral blood mobilization joint fluid collected by punction gingival exudate collected with paper strips
223879706|NCT00000749|BIOLOGICAL|rgp120/HIV-1 SF-2|
223879707|NCT00426829|DRUG|Bevacizumab|10 mg/kg by vein every 14 days +/- 2 days, starting on day 1.
223879708|NCT00426829|RADIATION|Proton Radiation Therapy|3 Gy dose/fraction x 20 fractions.
223879709|NCT03237975|BEHAVIORAL|Be the Expert for Your Own (BEYO)|"The BEYO program is structured adopting solution focused therapy (SFT). The basic principles for SFT are focusing on positive change and establishing groups driven by goals rather than problems. Solutions are generated through searching for strengths, skills, resources that working in clients' lives.~The common flow for structured sessions contains 7 steps: 1) Health education; 2) Discuss self-care experience and identify deficit; 3) Describe exceptions; 4) Identify the strengths; 5) Miracle question and scaling; 6) Establish the solution; 7) Action plan."
223879710|NCT03237975|OTHER|Routine health education|The control group will receive routine health education.
223879711|NCT05819242|DIAGNOSTIC_TEST|Angulus|Smartphone app
223879712|NCT02586090|BEHAVIORAL|Parents as Coaches|PAC (modeled after NIH-funded NOURISH) focuses on parenting strategies to support and facilitate their child's weight management via family-based change. Each visit includes group psychoeducation and discussion, focused on parenting strategies to facilitate healthy weight management in their child(ren). Topics include focus such as role modeling, strategies for healthy lifestyle changes, and how to be a coach to your teen.
223879713|NCT02586090|BEHAVIORAL|Parent Weight Loss|In PWL parents will be given a weight loss goal of 1-2 lbs/week, as well as specific calorie and fat prescriptions, PA goals, and instructions to self-monitor key information. Parents will receive training in core behavioral weight loss strategies (e.g., goal setting, stimulus control) and techniques to help them achieve these goals and will also receive personalized feedback throughout the program
223879714|NCT02755259|DRUG|Acetazolamide|
223879715|NCT02755259|DRUG|Placebo|
223879716|NCT01766154|DRUG|Tirofiban|A single high-dose bolus (3 min IV infusion) of tirofiban (25 µg/kg)
223879717|NCT04110054|DRUG|S-600918|Tablets for oral administration
223879718|NCT04110054|DRUG|Placebo to S-600918|Tablets for oral administration
223879719|NCT04363866|DRUG|Hydroxychloroquine|Hydroxychloroquine is more polar, less lipophilic, and has more difficulty diffusing across cell membranes than the parent compound, chloroquine. These characteristics result in hydroxychloroquine having a longer half-life, comparatively lower toxicity to chloroquine, as well as fewer concerns pertaining to drug-drug interactions
223879720|NCT04363866|DRUG|Placebo|A placebo is a pill that looks like the study drug but has no real medicine in it.
223879721|NCT05021341|DIETARY_SUPPLEMENT|Berberine|For each visit, all participants will report to the laboratory between 0600 - 1000 hours after observing an 8 - 10 hr fast. Participants will ingest the double-blinded supplement (500 mg of berberine) at specific times, the day before and morning of study visits 2 - 5. For each visit, participants will have their heart rate, blood pressure, body mass, and height measured. After final ingestion of their assigned supplementation dose, standard multiple sample phlebotomy approaches will be used to collect 10 mL of venous blood from a forearm vein at 0, 20, 40, 60, 90, and 120 minutes post-supplement ingestion. After donating baseline blood sample (0-min) a standard test meal, white bread, and glucose powder mixed in 250 mL of water. The complete nutritional breakdown of the test meal is anticipated to be 382 kcal, 3.2 grams of fat, 80.6 grams of carbohydrate, and 7.64 grams of protein.
223879722|NCT05021341|DIETARY_SUPPLEMENT|Dihydroberberine 200|For each visit, all participants will report to the laboratory between 0600 - 1000 hours after observing an 8 - 10 hr fast. Participants will ingest the double-blinded supplement (200 mg of dihydroberberine) at specific times, the day before and morning of study visits 2 - 5. For each visit, participants will have their heart rate, blood pressure, body mass, and height measured. After final ingestion of their assigned supplementation dose, standard multiple sample phlebotomy approaches will be used to collect 10 mL of venous blood from a forearm vein at 0, 20, 40, 60, 90, and 120 minutes post-supplement ingestion. After donating baseline blood sample (0-min) a standard test meal, white bread, and glucose powder mixed in 250 mL of water. The complete nutritional breakdown of the test meal is anticipated to be 382 kcal, 3.2 grams of fat, 80.6 grams of carbohydrate, and 7.64 grams of protein.
223879723|NCT05021341|DIETARY_SUPPLEMENT|Dihydroberberine 100|For each visit, all participants will report to the laboratory between 0600 - 1000 hours after observing an 8 - 10 hr fast. Participants will ingest the double-blinded supplement (100 mg of dihydroberberine) at specific times, the day before and morning of study visits 2 - 5. For each visit, participants will have their heart rate, blood pressure, body mass, and height measured. After final ingestion of their assigned supplementation dose, standard multiple sample phlebotomy approaches will be used to collect 10 mL of venous blood from a forearm vein at 0, 20, 40, 60, 90, and 120 minutes post-supplement ingestion. After donating baseline blood sample (0-min) a standard test meal, white bread and glucose powder mixed in 250 mL of water. The complete nutritional breakdown of the test meal is anticipated to be 382 kcal, 3.2 grams of fat, 80.6 grams of carbohydrate, and 7.64 grams of protein.
223879724|NCT05021341|DIETARY_SUPPLEMENT|Placebo|For each visit, all participants will report to the laboratory between 0600 - 1000 hours after observing an 8 - 10 hr fast. Participants will ingest the double-blinded supplement (Maltodextrin placebo) at specific times, the day before and morning of study visits 2 - 5. For each visit, participants will have their heart rate, blood pressure, body mass, and height measured. After final ingestion of their assigned supplementation dose, standard multiple sample phlebotomy approaches will be used to collect 10 mL of venous blood from a forearm vein at 0, 20, 40, 60, 90, and 120 minutes post-supplement ingestion. After donating baseline blood sample (0-min) a standard test meal, white bread, and glucose powder mixed in 250 mL of water. The complete nutritional breakdown of the test meal is anticipated to be 382 kcal, 3.2 grams of fat, 80.6 grams of carbohydrate, and 7.64 grams of protein.
223879725|NCT02711865|BIOLOGICAL|IGF1R antibody MK0646|
223879726|NCT02711865|OTHER|Saline solution|
223879727|NCT00093015|DRUG|Placebo|Volume and dose frequency changes resembling dosing in the active treatment group
223879728|NCT00093015|DRUG|darbepoetin alfa|Starting dose : 0.75 mcg/kg subcutaneous (SC) every two weeks (Q2W); subsequent doses titrated to achieve hemoglobin (Hb) target of 13.0 g/dL
223879729|NCT03836378|PROCEDURE|BioXclude™|The addition of BioXclude™ dehydrated human amnion-chorion membrane into deep pockets with scaling and root planing.
223879730|NCT06635902|DRUG|L-citrulline|Intravenous L-citrulline (50 mg/kg + 9mg/kg/hr.) for 16 hours
223879731|NCT06635902|OTHER|Placebo|Isotonic normal saline
223879732|NCT06635902|DRUG|L-citrulline|Intravenous L-citrulline (25 mg/kg + 9mg/kg/hr.) for 16 hours
223879733|NCT01261052|DEVICE|The Fading Memory Proportional Derivative/Adaptive Proportional Derivative Algorithm|"The APD algorithm is based largely on a program that employs the Fading Memory Proportional Derivative (FMPD) insulin and glucagon infusion algorithm. The FMPD algorithm determines insulin and glucagon delivery rates based on proportional error, defined as the difference between the current glucose level and the target level, and the derivative error, defined as the rate of change of the glucose. The fading memory designation refers to weighting recent errors more heavily than remote errors.~The APD algorithm, like the FMPD algorithm, will determine insulin and glucagon infusion rates based on sensed glucose values and utilizes the derivative and proportional glucose error to determine delivery rates of insulin. However, the APD algorithm has a model predictive element which also leads to frequent measurement of tissue sensitivity to insulin."
223879734|NCT01261052|DEVICE|The Adaptive Proportional Derivative Algorithm|"The APD algorithm is based largely on a program that employs the Fading Memory Proportional Derivative (FMPD) insulin and glucagon infusion algorithm. The FMPD algorithm determines insulin and glucagon delivery rates based on proportional error, defined as the difference between the current glucose level and the target level, and the derivative error, defined as the rate of change of the glucose. The fading memory designation refers to weighting recent errors more heavily than remote errors.~The APD algorithm, like the FMPD algorithm, will determine insulin and glucagon infusion rates based on sensed glucose values and utilizes the derivative and proportional glucose error to determine delivery rates of insulin. However, the APD algorithm has a model predictive element which also leads to frequent measurement of tissue sensitivity to insulin."
223879735|NCT06635564|DIAGNOSTIC_TEST|Viscoelastic testing|viscoelasting testing refers to a global hemostatic assay,that quantifies the viscoelastic properties of citrated whole blood
223879736|NCT06796543|RADIATION|Consolidative radiation therapy (cRT)|Treatment that is given after cancer has disappeared following the initial therapy. Consolidation therapy is used to kill any cancer cells that may be left in the body. It may include radiation therapy, a stem cell transplant, or treatment with drugs that kill cancer cells. Also called intensification therapy and postremission therapy.
223879737|NCT05673434|BIOLOGICAL|TM4SF1-positive chimeric antigen receptor T-cell therapy|"Specification: 50mL/bag. Storage: The prepared CAR T-cells are cryopreserved in a preserving medium . This product is manufactured under the current good manufacture practices (cGMP) conditions, with restrictions on chemical components, free from animal- or human-derived components and confirming to the United States Pharmacopeia (USP)\<71\> and \<85\> regulations.~Preservation: The frozen CAR T-cells are preserved in the liquid nitrogen transfer tank.~Usage: The frozen CAR T-cells are preserved at low temperature and transferred to the bedside. The cells are thawed by 36 degrees centigrade to 38 degrees centigrade. water bath. The frozen cells are gently massaged until complete thawing. Then they are transfused back to the patients intravenously. The transfusion will be finished within 10-20 min."
223879738|NCT06271616|PROCEDURE|Echocardiography Test|Undergo echocardiography
223879739|NCT06271616|DRUG|Ibrutinib|Given PO
223879740|NCT05493969|DRUG|Dolutegravir 50 MG plus lamivudine 300 MG； Dolutegravir/lamivudine (50 MG/300 MG)|Subjects will discontinue their TDF + 3TC/FTC-based regimen and will switch to DTG+3TC or fixed dose combination DTG/3TC.
223879741|NCT05493215|DRUG|Imatinib|Therapeutic drug level monitoring with plans to increase to adjust drug dosage based on levels and patient symptoms.
223879742|NCT01408849|DRUG|Maytenus ilicifolia leaves infusion|2 g of powdered leaves in 150 mL of boiling water, 3 times a day, for 8 weeks
223879743|NCT01408849|DRUG|Omeprazole|Standard therapy
223879744|NCT04183452|DRUG|17-Hydroxyprogesterone Caproate 250 mg IM Dose|17-Hydroxyprogesterone Caproate is a progestin indicated to reduce the risk of preterm birth in women with a singleton pregnancy who have a history of singleton spontaneous preterm birth.
223879745|NCT04183452|DRUG|17-Hydroxyprogesterone Caproate 275 mg SC Dose|17-Hydroxyprogesterone Caproate is a progestin indicated to reduce the risk of preterm birth in women with a singleton pregnancy who have a history of singleton spontaneous preterm birth
223879746|NCT04421469|DRUG|Triprilimab(JS001)|"1. JS001 240mg d1, gemcitabine(1g/m²),d1,8 + nedaplatin (80-100mg/m²),d2,q3w,6cycles.The curative effect was evaluated every 2 cycles.If the therapeutic evaluation was SD,the chemotherapy scheme was changed;~2. Local treatment of active lesions(including radiotherapy and/or radiofrequency ablation);~3. JS001 maintenance treatment."
223879747|NCT00632203|DRUG|Temozolomide|5-mg, 20-mg, and 100-mg gel capsules, 75 mg/m\^2 PO daily for 21 consecutive days, followed by a 7-day rest period, until progression or up to a maximum of 6 cycles, whichever occurs first.
223879748|NCT01411631|DIETARY_SUPPLEMENT|Grape juice polyphenols|Participants will consume grape juice polyphenols for 12 weeks and a control juice for 12 weeks.
223879749|NCT02641912|OTHER|Biotene mouthwash|During supervised product use: Participants will rinse with 15 mls of mouthwash for 30 seconds and spit out. No rinsing with water immediately after product usage is permitted. At Home use:Participants will rinse with 15 mls of mouthwash for 30 seconds and spit out. A maximum of two doses can be used per day.
223879750|NCT02641912|OTHER|Mineral Water|"During supervised product use:Participants will take a dose (drink) of one measured sip of 15mls of water.~At Home use: Participants can sip (drink) water as often as required. Participants will be consuming their own water for home use."
223879751|NCT05713526|BEHAVIORAL|Telehealth service|Researchers will send educational materials (video and e-brochures) about childhood vaccinations to the participants' mobile phones at regular intervals, answer their questions over the phone and send reminder messages before the vaccination appointment.
223879752|NCT03928522|DRUG|hand mixed vancomycin|hand mixed vancomycin powder into cement
223879753|NCT03928522|DRUG|hand mixed tobramycin|hand mixed tobramycin into cement
223879754|NCT03928522|DEVICE|pre-mixed tobramycin|this cement is already pre-mixed with tobramycin
223879755|NCT05350904|OTHER|Hybrid of telehealth and in-person physical therapy services|The experimental group will receive a hybrid of telehealth and in-person physical therapy services to address an in-home functional skill in children with moderate to severe disability.
223879756|NCT06464393|DRUG|ketamine-lidocaine-dexmedetomidine|Patients will be administered 0,8 mcg/kg Dexmedetomidine in 100 mL of normal saline within 10 minutes as premedication. Followingly, they will receive 1mL/10 kg of the solution containing ketamine, lidocaine and dexmedetomidine at predefined concentrations just before induction of anesthesia.
223879757|NCT06464393|DRUG|fentanyl|Patients will be administered 2 mcg/kg fentanyl in 100 mL of normal saline within 10 minutes as premedication. Followingly, they will receive 1mL/10 kg of normal saline solution 0.9% just before induction of anesthesia.
223879758|NCT01150916|PROCEDURE|BNP, SAAG, ascites total protein, echocardiography|diagnostic tests
223879759|NCT00448669|DRUG|Tenofovir Disoproxil Fumarate 300 mg + Emtricitabine 200 mg|
223879760|NCT00448669|DRUG|Placebo Oral Tablet|
223879761|NCT00039234|BIOLOGICAL|aldesleukin|
223879762|NCT00039234|DRUG|histamine dihydrochloride|
223879763|NCT04287985|DRUG|Dose-Placebo|Unit Dose Strength - 0.9%.
223879764|NCT04287985|DRUG|Low Dose-VIS649|Dose Level = Low
223879765|NCT04287985|DRUG|Medium Dose-VIS649|Dose Level = Medium
223879766|NCT04287985|DRUG|High Dose-VIS649|Dose Level = High
223879767|NCT01737489|BEHAVIORAL|LACE|commercially available LACE program which is administered by computer as daily lessons. The participants will do this program for one month
223879768|NCT01737489|BEHAVIORAL|NOOK|will use an electronic reader (Barnes and Noble - NOOK device) to do speech tracking.will do this activity for approximately one hour per day for five days out of seven for a total of four weeks. The speech tracking activity will involve reading approximately two books within the one month time frame. The participants will listen to the book while reading an unabridged book in printed form.
223879769|NCT04953273|OTHER|Vigitrauma|Case management algorithm using early phone contact
223879770|NCT05751785|OTHER|Physical Therapy|All participants may complete a PT program as standard of care (SOC) treatment addressing individual strength, mobility, and flexibility deficits in both proximal (e.g. spine and hip girdle) along with distal (thigh, leg, and foot/ankle) muscle groups. The provider may also use other modalities to address distal issues. To standardize the loading program, all participants will be given an at-home exercise program designed by Dr. Karin Sibernagel for progressive Achilles tendon loading. The participants will also follow the University of Delaware Return to Sport protocol for return to running. This will be completed alongside the standard of care PT participants will be receiving.
223879771|NCT05751785|DEVICE|Shockwave Therapy|A medical provider will conduct SWT on study participants using the OrthoPlus Ultra 100. This Extracorporeal Pressure Activation Treatment device will be used at a radial shockwave of 3000 counts treatment settings of 15 Hz minimum 2 bars with a focus applicator head at mid-portion of Achilles using clinical focusing technique, and 3000 counts at 15 Hz minimum 2.5 bars using broad oscillator to myotendinous region and over symptomatic areas of gastrocnemius and soleus, treatment will be applied distally to proximally to facilitate lymphatic return adjusting treatment air pressure and amount of force applied by applicator head by patient comfort. The maximum setting for each treatment applicator will be 4 bars of air pressure, and the first 500 counts using each applicator will be applied at 1.5 bars to help desensitize the tissue prior to increasing energy settings. The settings used for each participant will be recorded and followed in a similar approach to treatment.
223879772|NCT05751785|DEVICE|Photobiomodulation Therapy|PBMT is delivered with the LightForce® XPi 25W device through the Smart Hand Piece technology. The therapy is transmitted with a rolling glass massage ball at 10 Joules/cm\^2 that is applied in a serpentine manner over the site of injury.
223879773|NCT05205798|BEHAVIORAL|Food consumption using plates with a diameter of 23 cm.|In the experiment, individuals will consume the amount of pasta with sauce offered in the open buffet in the amount they will determine (ad libitum), using plates with a diameter of 23 cm.
223879774|NCT05205798|BEHAVIORAL|Washout period|No interventional food consumption for 1 week
223879775|NCT05205798|BEHAVIORAL|Food consumption using plates with a diameter of 31 cm.|In the experiment, individuals will consume the amount of pasta with sauce offered in the open buffet in the amount they will determine (ad libitum), using plates with a diameter of 31 cm.
223879776|NCT02988089|DRUG|Clarithromycin susceptibility dependant strategy|"Patients in this group will receive a 14-day bismuth-based quadruple regimen to eradicate H. pylori. Antimicrobial susceptibility testing (AST) will be used to test the susceptibility of clarithromycin.~If clarithromycin is susceptible, amoxicillin 1 g b.i.d and clarithromycin 500 mg b.i.d will be chosen; If clarithromycin is resistant, amoxicillin 1 g bid and furazolidone 100 mg b.i.d will be chosen."
223879777|NCT02988089|DRUG|2 susceptible antibiotics (amoxicillin, clarithromycin, metronidazole, tinidazole,levofloxacin, furazolidone and tetracycline )|Patients in this group will receive a a 14-day bismuth-based quadruple regimen to eradicate H. pylori. The regimen is consist of a PPI, Colloidal Bismuth Pectin and 2 susceptible antibiotics which are determined by AST. The susceptibility of amoxicillin, clarithromycin, metronidazole, tinidazole,levofloxacin, furazolidone and tetracycline will be evaluated.
223879778|NCT02988089|DRUG|proton pump inhibitor (PPI) and Colloidal Bismuth Pectin|all patients need these two drugs.
223879779|NCT02988089|DRUG|amoxicillin and clarithromycin or amoxicillin and furazolidone|patients in the 6 antibiotics dependant group will use these intervention.
223879780|NCT02988089|DRUG|amoxicillin and furazolidone or amoxicillin and tetracycline|salvage therapy for negative culture when the results of culture are negative
223879781|NCT02988089|DRUG|amoxicillin and furazolidone or amoxicillin and Tinidazole or amoxicillin and Levofloxacin|salvage therapy for failed eradication if failed with AST guided eradication therapy
223879782|NCT03248505|DEVICE|Conventional TENS|Transcutaneous Electrical Nerve Stimulation (frequency of 100 Hz, pulse duration of 100 micro-seconds and sensory-level amplitude) with two electrodes in each side of the lumbar spinal.
223879783|NCT03248505|DEVICE|Burst TENS|Burst-modulated TENS with carrier frequency of 100 Hz, burst-modulated at 4Hz, pulse duration of 200 micro-seconds and motor-level amplitude.
223879784|NCT03248505|OTHER|Cryotherapy|1,5 Kg of crushed ice pack on lumbar spine.
223879785|NCT03248505|DEVICE|Burst TENS + Cryotherapy|Burst-modulated TENS with carrier frequency of 100 Hz, burst-modulated at 4Hz, pulse duration of 200 micro-seconds and motor-level amplitude plus 1,5 Kg of crushed ice pack on lumbar spine.
223879786|NCT03248505|DEVICE|Conventional TENS + Cryotherapy|Transcutaneous Electrical Nerve Stimulation (frequency of 100 Hz, pulse duration of 100 micro-seconds and sensory-level amplitude) plus s 1,5 Kg of crushed ice pack on lumbar spine.
223879787|NCT03248505|OTHER|Placebo TENS|TENS device turned on, but with zero amplitude.
223879788|NCT05673746|PROCEDURE|Acupuncture|acupuncture administration
223879789|NCT05673746|DRUG|treatment of physician choice, according to the standard of care|treatment of physician choice, according to the standard of care for the treatment of chemotherapy-induced peripheral neuropathy, including neuropathic pain
223879790|NCT00920972|DRUG|Treatment Plan 1: Stratum 1|Day -50 to -21: Hydroxyurea 30mg/kg PO q day Day -22: Campath-1H 3 mg IV or SQ... Day -21: Campath-1H 10 mg IV or SQ... Day -20: Campath-1H 15 mg IV or SQ... Day -19: Campath-1H 20 mg IV or SQ... Day -8: Fludarabine 30mg/m2 IV... Day -7: Fludarabine 30mg/m2 IV... Day -6: Fludarabine 30mg/m2 IV... Day -5: Fludarabine 30mg/m2 IV... Day -4: Fludarabine 30mg/m2 IV... Day -3: Melphalan 140 mg/m2 IV... (dose modifications for patients \<10 kgs) Procedure/Surgery: Hematopoietic stem cell infusion on Day 0...
223879791|NCT00920972|DRUG|Treatment Plan 2: Strata 2, 3, or 4|Day -50 to -21: Hydroxyurea 30mg/kg PO q day… Day -22: Campath-1H 3 mg IV or SQ... Day -21: Campath-1H 10 mg IV or SQ... Day -20: Campath-1H 15 mg IV or SQ... Day -19: Campath-1H 20 mg IV or SQ... Day -8: Fludarabine 30mg/m2 IV... Day -7: Fludarabine 30mg/m2 IV... Day -6: Fludarabine 30mg/m2 IV... Day -5: Fludarabine 30mg/m2 IV... Day -4: Fludarabine 30mg/m2 IV... Day -4: Thiotepa 8mg/kg IV… Day -3: Melphalan 140 mg/m2 IV... (dose modifications for patients \<10 kgs) Procedure/Surgery: Hematopoietic stem cell infusion on day 0...
223879792|NCT00920972|DRUG|GVHD Regimen A: UCB Recipients|Day -3: Begin Tacrolimus or cyclosporine Begin MMF Day -1: Abatacept 10mg/kg IV Day +5: Abatacept 10mg/kg IV Day +14: Abatacept 10mg/kg IV Day +28: Abatacept 10mg/kg IV Day +60: Abatacept 10mg/kg IV Day +100: Abatacept 10mg/kg IV
223879793|NCT00920972|DRUG|GVHD Regimen B: BM Recipients|Day -3: Begin Tacrolimus or cyclosporine Begin MMF Day -1: Abatacept 10mg/kg IV Day +1: Methotrexate 7.5mg/m2 IV Day +3: Methotrexate 7.5mg/m2 IV Day +5: Abatacept 10mg/kg IV Day +6: Methotrexate 7.5mg/m2 IV Day +14: Abatacept 10mg/kg IV Day +28: Abatacept 10mg/kg IV Day +60: Abatacept 10mg/kg IV Day +100: Abatacept 10mg/kg IV Day +180: Abatacept 10mg/kg IV Day +270: Abatacept 10mg/kg IV Day +365: Abatacept 10mg/kg IV
223879794|NCT04762238|OTHER|Diacutaneous Fibrolysis|Diacutaneous Fibrolysis is a non invasive physiotherapeutic technique applied by means of a set of metallic hooks ending a spatula with bevelled edges that help to treat the muscles and conjunctive tissues and trying to improve mobility between mobility between muscle planes.
223879795|NCT06436326|DEVICE|Continuous glucose monitor|"Participants will receive a set of continuous glucose monitor (CGM) at 24-32 weeks of pregnancy (first set) and 33 weeks of pregnancy to before delivery (second set), respectively.~CGM wearing instruction will be provided before the first wearing at 24-32 weeks of pregnancy. After completing the first wearing (approximately 14 days after starting to wear), the investigators will provide a glucose monitor report. The second CGM was worn from the 33rd week of pregnancy to before delivery, and another glucose monitor report was given approximately 14 days after starting to wear."
223879796|NCT06436326|BEHAVIORAL|Perinatal nursing care for gestational diabetes|Individual nursing care and consultation for pregnant women with gestational diabetes mellitus, including glucose monitor suggestions, dietary suggestions, emotional support, breastfeeding support.
223879797|NCT06436326|OTHER|Blood glucose meters (BGM)|"Participants are required to use blood glucose meters (BGM) at 24-32 weeks of pregnancy and 33 weeks to before delivery. After 14 days of glucose monitoring at 24-32 weeks of pregnancy, a glucose monitor report will be given to the participants. After the 14 days of glucose monitoring at 33 weeks to before delivery , another glucose monitor report will be given to the participants."
223879798|NCT05165459|DEVICE|Venous leg ulcer treatment with adipous SVF|The Celution® System isolates approximately maximum 30 million SVF cells per 100 mL of adipose tissue to be processed. Approximately 1-3 million cells per injection (total 8-30) will be administered locally, in the target ulcer.
223879799|NCT02776475|PROCEDURE|Sacral neuromodulation device turned off|Each patient will be to have the sacral neuromodulation device turned off for four consecutive weeks.
223879800|NCT01340066|DRUG|UISH001|sublingual dosing, 1 drop 3 times a day
223879801|NCT01340066|DRUG|matching placebo|sublingual dosing,1 drop 3 times a day
223879802|NCT00578916|DRUG|EVRI (BMS-690514)|Oral Solution, Oral, 200 mg, single dose followed by 10-12 day inpatient stay
223879803|NCT02789020|DRUG|Rasagiline|Rasagiline will be taken for one year at the dose of 1mg a day. and subjects will undergo functional and structural brain imaging to determine if rasagiline is slowing the progression of Parkinson's Disease in the brain.
223879804|NCT02789020|OTHER|Placebo|A placebo tablet will be taken for one year, once a day, and at the same dose of 1mg. subjects will undergo functional and structural brain imaging to be compared with the group taking the rasagiline intervention.
223879805|NCT02789020|DEVICE|Magnetic Resonance Imaging|This test will be performed at baseline and one year.
223879806|NCT02789020|DEVICE|functional Magnetic Resonance Imaging|This test will be performed at baseline and one year.
223879807|NCT02789020|OTHER|Physical Function Performance Test|This test will be performed at baseline and one year.
223879808|NCT06530628|BEHAVIORAL|Adult patients resident in Pavillon C of the Pierre Garraud Hospital|"Adult patients resident in Pavillon C of the Pierre Garraud Hospital, aged over 70, polypathological, with or without undernutrition.~The intervention involves the diffusion of culinary odors using diffusers in the unit's hallways, 20 minutes before lunch, from Monday to Friday, for a period of three weeks.~This experiment will be repeated over 18 weeks (6 cycles), alternating meals without olfactory stimulation (cycles 1, 3 and 5) and meals with stimulation (cycles 2, 4 and 6).~The 3-week rhythm corresponds to the menu cycle proposed by the Unité Centrale de Production Alimentaire (UCPA). Thus, the menu will be the same whether or not it is associated with the diffusion of culinary scents."
223879809|NCT02614235|DEVICE|Pocket-ECG III system|Continuous cardiac telemetry until diagnosis or a maximum of two months
223879810|NCT04523688|BIOLOGICAL|Autologous Dendritic Cells (DC) vaccine|10×10exp6 autologous dendritic cells loaded with autologous tumour homogenate given by intradermal injection (day 1)
223879811|NCT04523688|DRUG|Temozolomide|Adjuvant temozolomide assumed orally from day 1 to 5 (start on week 5). Dosage: 150mg/m2/day for the first cycle and 200 mg/m2/day for subsequent cycles (q28).
223879812|NCT04317885|BIOLOGICAL|Prizloncabtagene Autoleucel|Autologous 2nd generation CD19/CD20-directed CAR-T cells, single infusion intravenously
223879813|NCT01363492|BIOLOGICAL|Replagal (agalsidase alfa)|0.2 mg/kg administered over 40 minutes every other week (EOW)
223879814|NCT00468702|DEVICE|CoaguChek S|
223879815|NCT05334199|DEVICE|Biodegradable stent|Bronchoscopic placement of biodegradable stent in patients with airway complications after lung transplant
223879816|NCT01691079|DRUG|ipratropium bromide|Inhaled ipratropium bromide administered before exercise.
223879817|NCT01691079|DRUG|Placebo|Inhaled placebo administered before exercise.
223879818|NCT02395978|DRUG|PDC-1421 Capsule|PDC-1421 Capsule is a botanical investigational new drug containing the extract of Radix Polygalae (Polygala tenuifolia Willd.) as active ingredient.
223879819|NCT02395978|DRUG|placebo|Placebo contained corn starch.
223879820|NCT03794024|DEVICE|The Nuvectra Algovita Dorsal Column Spinal Cord Stimulator|The Nuvectra Algovita Dorsal Column Spinal Cord Stimulator is indicated as an aid in the management of chronic intractable pain of the trunk and/or limbs, including unilateral or bilateral pain associated with failed back surgery syndrome, intractable low back pain and leg pain.
223879821|NCT03794024|DEVICE|The Axium Neurostimulator System|The Axium Neurostimulator System is indicated for spinal column stimulation via epidural and intra-spinal lead access to the dorsal root ganglion as an aid in the management of moderate to severe chronic intractable pain of the lower limbs in adult patients with Complex Regional Pain Syndrome Types I and II
223879822|NCT03771352|DEVICE|RxSight RxLAL|The patients will be assessed for 6 months
223879823|NCT00011986|DRUG|Paclitaxel|Given IV
223879824|NCT00011986|DRUG|Carboplatin|Given IV
223879825|NCT00011986|DRUG|Gemcitabine Hydrochloride|Given IV
223879826|NCT00011986|DRUG|Pegylated Liposomal Doxorubicin Hydrochloride|
223879827|NCT00011986|DRUG|Topotecan Hydrochloride|Given IV
223879828|NCT00011986|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
223879829|NCT06105125|DEVICE|Rigenera + bone substitute|Minimally invasive flap elevation and debridement of the intrabony defect with micro-curettes. A small punch of connective tissue will be harvested from the palate in the premolar region. Then the graft will be mechanically dissociated using the Rigenera Machine System rotating speed to 80 rpm, in 1.0 ml sterile physiologic solution. After dissociation, the cellular suspension will be passed through a disposable grid with 100 hexagonal blades filtering cells and components of extracellular matrix with a cut-off of 50 um in an average time of 90 s. Finally, part of the suspension containing AMGs will be seeded on the scaffold material and subsequently compacted within the defect. Flaps will be positioned at the pre-surgical level or slightly coronal without any tension.
223879830|NCT06105125|DEVICE|Bone substitute alone|Minimally invasive flap elevation and debridement of the intrabony defect with micro-curettes. The defect will be filled with the same bone substitute employed in the test group. Finally, flaps will be positioned at the pre-surgical level or slightly coronal without any tension.
223879831|NCT00806169|DRUG|triamcinolone and bevacizumab|
223879832|NCT03438903|DEVICE|Repeat exams of OCT device|All 2 consecutive OCT examinations were performed by 1 experienced technician, in the order of SD-OCT and SS-OCT. The interval was 10 minutes between examinations by each OCT devices
223879833|NCT02376530|BEHAVIORAL|Nutrient profiling|Nutrient profiling system will be present during shopping session.
223879834|NCT02376530|BEHAVIORAL|Price Changes|Price changes will be present during shopping session.
223879835|NCT03338816|DRUG|Givosiran|Givosiran by SC
223879836|NCT03338816|DRUG|Placebo|Matching placebo (normal saline \[0.9% NaCl\]) by SC
223879837|NCT00445315|DRUG|PF-00868554|300 mg BID
223879838|NCT00445315|DRUG|PF-00868554|450 mg BID
223879839|NCT00445315|DRUG|PF-00868554|100 mg BID
223879840|NCT00445315|DRUG|PF-00868554|300 mg TID
223879841|NCT00445315|DRUG|Placebo|Placebo
223879842|NCT02331745|DRUG|Granulocyte colony-stimulating factor|Granulocyte colony-stimulating factor(G-CSF) was given 5 ug/kg subcutaneously qd for 6 doses,then qod for other 6 doses(total 12 doses).
223879843|NCT02331745|DRUG|standard treatment|Standard treatment includes reduced glutathione, glycyrrhizin, ademetionine,polyene phosphatidylcholine, alprostadil, and human serum albumin) on the day of admission. HBV associated ACLF patients receive entecavir at the same time
223879844|NCT05327049|OTHER|no intervention|treatment of deep carious lesions
223879845|NCT05327049|DEVICE|diode laser|laser light for cavity disinfection
223879846|NCT05327049|DIETARY_SUPPLEMENT|Aloe Vera|herbal dietary supplement for treatment of deep carious lesions
223879847|NCT03285386|BEHAVIORAL|Priming exercise|"All participants will perform a bout of high-intensity priming exercise for 6 minutes, 10 minutes prior to undertaking an exhaustive exercise test on four separate occasions."
223879848|NCT03285386|BEHAVIORAL|Control Exercise|All participants will perform 3 minutes of baseline cycling prior to undertaking an exhaustive exercise test on four separate occasions.
223879849|NCT06010862|BIOLOGICAL|CEA CAR-T cells|After lymphodepletion with Fludarabine and Cyclophosphamide,CAR T cells were transfused intravenically
223879850|NCT06010862|BIOLOGICAL|CEA CAR-T cells|After lymphodepletion with Fludarabine and Cyclophosphamide,CAR T cells were injected intraperitoneally
223879851|NCT05588817|GENETIC|PCR polymorphism|PCR polymorphism in Rhomatoid arthritis patients in Egypt
223879852|NCT05990816|DIAGNOSTIC_TEST|Blood works for homocysteine levels|In a single patient group of 80 people, the natural course of homocysteine after total joint arthroplasty will be examined by blood work analyzes at the 1,2,3,4 and 6th weeks after operation
223879853|NCT05490524|DEVICE|GATEKEEPER|The GATEKEEPER is a digital platform that allows patients and caregivers to record their day-to-day symptoms and other parameters such as quality of life using means such as apps and wearable devices that record both self-report (quality of life, depression, anxiety) and physiological data (mobility, pain, sleep patterns, heart rate), and allows healthcare professionals to monitor these data and tailor healthcare so to prevent and intervene in symptoms that may be occurring.
223879854|NCT02129283|BEHAVIORAL|Simulation training|End-of-life simulation training. The simulation training will include training with standardized patients (actors) using 9 essential skills for communication and interpersonal relationships. The control group will have no training.
223879855|NCT02746549|OTHER|renal perfusion|measurement of renal perfusion with MRI arterial spin labelling technique
223879856|NCT02986984|OTHER|There is no intervention|There are no interventions
223879857|NCT06124911|OTHER|Leg Press Resistance Training (3x5)|Leg Press resistance training at 60% one-rep-max for three sets of five repetitions
223879858|NCT06124911|OTHER|Leg Press Resistance Training (5x5)|Leg Press resistance training at 60% one-rep-max for five sets of five repetitions
223879859|NCT05917275|DRUG|Amlodipine|4 weeks of Amlodipine
223879860|NCT05917275|DRUG|Olmesartan|4 weeks of Olmesartan
223879861|NCT05917275|DRUG|Hydrochlorothiazide|4 weeks of Hydrochlorothiazide
223879862|NCT05917275|DRUG|Amlodipine/Olmesartan|4 weeks of Amlodipine/Olmesartan
223879863|NCT04238247|BEHAVIORAL|Tiny Cargo, Big Deal/Abróchame Bien, Cuídame Bien (TCBD/ABCB) Basic Intervention|"A bilingual emergency department (ED)-based precision prevention intervention grounded in Self-Determination Theory. The Basic TCBD/ABCB intervention integrates one personalized counseling session based on principles of motivational interviewing (MI) and eHealth components including a tailored mobile-friendly educational website and short message service (SMS) text message communications with the goal of improving child passenger safety.~Participants receive monthly text message requests to submit photographs depicting the child as they usually travel. Feedback is provided via text message to correct any observed errors or misuse. Tailored informational and motivational text messages are sent twice each month."
223879864|NCT04238247|BEHAVIORAL|Tiny Cargo, Big Deal/Abróchame Bien, Cuídame Bien (TCBD/ABCB) Enhanced Intervention|The Enhanced TCBD/ABCB Intervention includes a second motivational interviewing session. Basic Intervention text messages continue with an additional 1-2 tailored text messages per month.
223879865|NCT05422742|PROCEDURE|SRP + MM|Subjects will be randomized into either SRP only or SRP +MM. Periodontal therapy will consist of one visit full-month SRP alone or in-combination with MM placed at all sites regardless of probing pocket depth. Each site will recieve 1mg of MM for a total of 6mg of MM per tooth.
223879866|NCT05422742|PROCEDURE|Scaling and Root Planing (SRP)|Procedure involving removal of dental plaque and calculus (scaling or debridement) and then smoothing, or planing, of the (exposed) surfaces of the roots, removing cementum or dentine that is impregnated with calculus, toxins, or microorganisms, the etiologic agents that cause inflammation.
223879867|NCT03092726|DRUG|ASP8062|ASP8062 30 mg was administered orally as a single daily dose, taken preferably in the morning with or without food.
223879868|NCT03092726|DRUG|Placebo|Placebo was administered orally as a single daily dose, taken preferably in the morning with or without food.
223879869|NCT04403711|OTHER|local anesthetic and dexmedetomidine|in patients allocated to the dexmedetomidine group, ultrasound-guided transversus abdominis plane block will be performed with the combination of local anesthetic and dexmedetomidine
223879870|NCT04403711|OTHER|local anesthetic and placebo|in patients allocated to the dexmedetomidine group, ultrasound-guided transversus abdominis plane block will be performed with the combination of local anesthetic and normal saline
223879871|NCT04718350|DRUG|levosimendan at a dose of 6 mcg/kg|levosimendan will be administered intravenously at a dose of 6 mcg/kg after anesthesia induction
223879872|NCT04718350|DRUG|milrinone at a dose of 50 mcg/kg|milrinone will be administered via inhalation at a dose of 50 mcg/kg after anesthesia induction
223879873|NCT05953623|BIOLOGICAL|Albumin|In the first phase of the study, a 3 + 3 dose-escalation study with 7 doses (0.25g/kg, 0.35g/kg, 0.40g/kg, 0.45g/kg, 0.5g/kg, 0.55g/kg, 0.60g/kg). Intra-arterial albumin infusion will be applied after successful recanalization of the culprit artery in the anterior circulation. In the second phase of the study, at the maximum safe dose determined in the first phase, an additional 15 to 20 patients will be enrolled for intra-arterial albumin infusion.
223879874|NCT04656210|RADIATION|MRI|Non conventional MRI (35 minutes)
223879875|NCT04656210|OTHER|neuropsychological tests|Standardized and quantified neuropsychological assessment
223879876|NCT06241456|DRUG|FT825|FT825 will be administered as an intravenous (IV) infusion at planned dose levels.
223879877|NCT06241456|DRUG|Fludarabine|Fludarabine will be administered as an IV infusion at planned dose levels.
223879878|NCT06241456|DRUG|Cyclophosphamide|Cyclophosphamide will be administered as an IV infusion at planned dose levels.
223879879|NCT06241456|DRUG|Bendamustine|Bendamustine will be administered as an IV infusion at planned dose levels.
223879880|NCT06241456|DRUG|Docetaxel|Docetaxel will be administered as an IV infusion at planned dose levels.
223879881|NCT06241456|DRUG|Cisplatin|Cisplatin will be administered as an IV infusion at planned dose levels.
223879882|NCT06241456|DRUG|Cetuximab|Cetuximab will be administered as an IV infusion at planned dose levels.
223879883|NCT02754115|OTHER|Hyperthermic intraperitoneal chemotherapy|Perioperative data of all the patients posted for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy will be collected prospectively
223879884|NCT05875974|DRUG|JZP258 (XYWAV)|"Narcolepsy Cohort: Initiate dosage per XYWAV label and titrate to effect.~IH Cohort: Initiate dosage per XYWAV label and titrate to effect.~Narcolepsy \>9-Gram Cohort: XYWAV titrated to a dosage of \>9 to 12 grams."
223879885|NCT06495723|DRUG|LIS1|The study intervention (LIS1) is a glyco-humanized polyclonal antibody drug which is formulated for IV administration.
223879886|NCT06413693|DRUG|PF-07293893|A single dose of PF-07293893 administered orally as tablets
223879887|NCT06413693|DRUG|Placebo|A single dose of Placebo administered orally as tablets that look the same as PF-07293893
223879888|NCT03999853|DRUG|BKR-017|BKR-017
223879889|NCT04950127|DRUG|Linerixibat|Participants will receive linerixibat.
223879890|NCT04950127|DRUG|Placebo|Participants will receive placebo.
223879891|NCT04094168|DRUG|DEL NIDO CARDIOPLEGIA|"Del Nido components: Plasmalyte 148 (1000 ml), NaHCO3 8.4% 1M (13 ml), MgSO4 0,5 M (16,5 ml), Mannitol 20% (16,3 ml), KCl 2 M (13 ml), Lidocaine 2% (6,5 ml).~Electrolytic composition (l000 ml): Na+ 153 mEq, K+ 31 mEq, Cl - 124 mEq, Mg2+ 19,5 mEq, NaHCO3 13 mEq, Acetate 27 mEq, Sulfate 16,5 mEq, Gluconate 23 mEq."
223879892|NCT04094168|DRUG|COLD BLOOD BASED CARDIOPLEGIA|Cardibraun components: Electrolytic composition (1000 ml): Na+ 185,8 mmol, K+ 24,1 mmol, Cl- 192,8 mmol, Acetate 23 mmol, Fosfate 0,97 mmol, Citrate 6,32 mmol.
223879893|NCT03032406|DRUG|Hydroxychloroquine|Hydroxychloroquine
223879894|NCT03032406|DRUG|Everolimus|Everolimus
223879895|NCT03833167|BIOLOGICAL|Pembrolizumab|400 mg IV infusion
223879896|NCT03833167|DRUG|Placebo|Placebo-matched IV infusion
223879897|NCT03997864|DRUG|Prazosin|"Starting dose: 2mg at HS. Maximum dose: 15 mg at HS. Dosage will be increased 1 mg every 3 days until sleep is improved, max dose is reached, or side effects are problematic.~Tapering Decrease prazosin 1 mg every 3 days or 3 mgs per week until off completely. Tapering will take approximately 2-3 weeks."
223879898|NCT03997864|DRUG|Placebos|Starting dose: 2mg at HS. Maximum dose: 15 mg at HS. Dosage will be increased 1 mg every 3 days until sleep is improved max dose is reached, or side effects are problematic.
223879899|NCT05187442|OTHER|questionnaire, interview|The first stage is an online questionnaire survey. A total of 321 TMs were recruited. The time of online questionnaire is about 10-15 minutes to get a preliminary understanding of the erotic and sexual risk experience of TM in Taiwan. In the second stage, focus groups and in-depth interviews will be conducted, 2 hours of each group and interview. A total of 29 transgender man and women, and non-binary participants were recruited.
223879900|NCT05854836|BEHAVIORAL|CHOICES-PLEAS (Pregnancy Liberated from Exposure to Alcohol and Substances)|CHOICES-PLEAS includes four manual-guided motivational interviewing sessions delivered by a trained counselor and one family planning counseling session delivered by a family planning clinician. The intervention is based on the Transtheoretical Model (TTM) of behavior change and motivational interviewing that includes a decisional balance exercise, goal self-selection, self-monitoring, self-generated plans, and importance and confidence scales. By using a patient-centered approach based on the TTM that meets patients where they are, counselors can have a more effective impact on patient behaviors. This adaptation from the original CHOICES intervention contains unique features focused on the incarcerated setting, illicit polysubstance use, and risky sexual behaviors most common among women with illicit polysubstance use.
223879901|NCT06501911|DRUG|Bicalutamide|Participants will receive daily oral bicalutamide for six (6) months. The dose will be determined by the cohort to which the participant is enrolled as well as the toxicities experienced by previously enrolled cohorts.
223879902|NCT06501911|RADIATION|Intensity-modulated radiation therapy (IMRT)|Participants will receive 35 Gy delivered in 10 fractions, administered once daily on weekdays.
223879903|NCT06040710|DEVICE|POSEIDON size estimation software with the EndoMind polyp detection system|Polyp size estimation using the POSEIDON software and bounding boxes of the EndoMind polyp detection system.
223879904|NCT03606837|DRUG|68Ga-PSMA-617 PET/CT|PET/CT Imaging with 68Ga-PSMA-617 injection
223879905|NCT03606837|DRUG|68Ga-RM2 PET/CT|PET/CT Imaging with 68Ga-RM2 injection
223879906|NCT06430281|OTHER|Manual therapy|A manual force will be applied to a manikin positioned on a chiropractic treatment table. The force exerted during the manual therapy must align with the trial label indicated on the Manual Therapy Force Perception \[MTFP\] scale.
223879907|NCT05261620|DIETARY_SUPPLEMENT|red wine|Subjects in the intervention arm (SoC+WISE) will be assigned to consume exclusively during meals one glass (around 150 ml at lunch and 150 ml at dinner) of red wine containing ethanol (˜13% EtOH v/v) with a high content of phenolic compounds (800 mg of Gallic acid equivalent) both for woman and men. Total polyphenolic contents and antioxidant activity (Folin-Ciocalteu method with calibration curve in gallic acid), antioxidant/radical scavenger capacity \[DPPH (2,2-diphenyl-1-picrylhydrazyl) test\] and phenolic profiles \[HPLC (High Performance Liquid Chromatography)/DAD (diode-array detector) /ESI-MS (Electrospray Ionisation Mass Spectrometry) analysis\] will be performed for wine selection for the clinical trial.
223879908|NCT01948661|DIETARY_SUPPLEMENT|Mirtoselect® + Meriva®|
223879909|NCT01948661|DIETARY_SUPPLEMENT|Placebo|
223879910|NCT03894566|OTHER|No intervention - birth cohort study|There are no interventions because it is a birth cohort study
223879911|NCT04471974|DRUG|BET Bromodomain Inhibitor ZEN-3694|Given PO
223879912|NCT04471974|DRUG|Enzalutamide|Given PO
223879913|NCT04471974|BIOLOGICAL|Pembrolizumab|Given IV
223879914|NCT06049459|DEVICE|Optical Correction|Optical correction (if needed)
223879915|NCT06049459|DEVICE|Therapeutic Dichoptic Virtual Reality Games|Virtual Reality Game play for amblyopia treatment
223879916|NCT03271489|DRUG|Elagolix|Film-coated 300 mg tablets
223879917|NCT03271489|DRUG|Estradiol /norethindrone acetate (E2/NETA)|Estradiol 1 mg/norethindrone acetate 0.5 mg capsules
223879918|NCT03271489|OTHER|E2/NETA Placebo|Placebo capsules
223879919|NCT03271489|OTHER|Elagolix Placebo|Film-coated placebo tablets
223879920|NCT05445466|DEVICE|High-Definition Transcranial Electrical-Current Stimulation|Non-frequency dependent transcranial electrical stimulation condition for 5 days of twice a day treatment
223879921|NCT05445466|DEVICE|High-Definition Transcranial Alternate-Current Stimulation|Active-control stimulation condition will target alpha (10 Hz) for 5 days of twice a day treatment
223879922|NCT05445466|DEVICE|High-Definition Personalized Beta-Gamma Electrical Stimulation|Personalized beta-gamma electrical stimulation for 5 days of twice a day treatment
223879923|NCT06288230|BIOLOGICAL|vesemnogene lantuparvovec|Exploratory study evaluating the safety and efficacy of vesemnogene lantuparvovec in patients with SMA.
223879924|NCT06148142|BEHAVIORAL|Pharmacy based health promotion|This project will consist of three phases: baseline survey with first time intervention implementation; second intervention at 6 months; third at 12 months and , end-line survey at 18 months. As part of the intervention within the randomized selected groups, the CP will conduct two 15-30 minute sessions throughout the intervention period, once at the baseline or first visit (T0) and once at the sixth month (T1). Patients will attend the two sessions at the pharmacies where they collect their prescription medication. Face-to-face counselling sessions will be held about hypertension and its management, including lifestyle changes and drug compliance.
223879925|NCT06779474|PROCEDURE|Laparoscopic ALPPS|Laparoscopic Associating Liver Partition With Portal Vein Ligation for Staged Hepatectomy
223879926|NCT06488261|BIOLOGICAL|AVR-RD-02|No study drug is administered in this study. Subjects who received AVR-RD-02 in a separate parent trial will be evaluated in this trial for long-term safety.
223879927|NCT06041802|BIOLOGICAL|Pembrolizumab (+) Berahyaluronidase alfa|Pembrolizumab (+) Berahyaluronidase alfa is a fixed-dose formulation of pembrolizumab and berahyaluronidase alfa for SC administration.
223879928|NCT03238755|OTHER|Cardiac MRI/MRS|whole blood, plasma, and serum
223879929|NCT06181617|OTHER|Quality of life assessment|Quality of life assessment
223879930|NCT06216535|DRUG|Escitalopram|Escitalopram is an FDA-approved SSRI antidepressant that is administered by mouth
223879931|NCT06216535|DRUG|Placebo|Inactive placebo comparator
223879932|NCT06010342|DRUG|TL118 Capsule|Oral administration
223879933|NCT03330795|BIOLOGICAL|CD3/CD19 neg allogeneic BMT|Negative selection for CD3/CD19 will be performed on a CliniMACS® depletion device within 36 hours of collection, and cryopreserved for later marrow transplantation. BMT conditioning and transplantation will start at least 8 weeks or more post lung transplant - once the participant is clinically judged suitable to undergo BMT conditioning and transplantion.
223879934|NCT06964256|BEHAVIORAL|Abdominal breathing exercises|"Control group: conventional rehabilitation treatment. Conventional rehabilitation treatment methods include intermittent catheterization and acupuncture. Intermittent catheterization is based on the results of urodynamic examination to develop a personalized drinking plan and the number of catheterization, and the number of catheterization is selected according to the amount of residual urine; Intermittent catheterization can reduce the rate of urinary tract infections, the incidence of urethral stones, and improve bladder capacity. Acupuncture treatment improves the patient's urinary function by acupuncture on the lower abdomen and lumbosacral acupoints once a day, 5 days a week, for a total of 3 weeks Experimental group: Conventional rehabilitation treatment sEMG monitoring of lower abdominal breathing training.~The conventional rehabilitation treatment method is the same as above; The specific operation of sEMG abdominal breathing training: ask the patient to empty the bladder befor"
223879935|NCT06964256|OTHER|Control group: intermittent catheterization|Intermittent catheterization is based on the results of urodynamic examination to develop a personalized drinking plan and the number of catheterization, and the number of catheterization is selected according to the amount of residual urine; Intermittent catheterization can reduce the rate of urinary tract infections, the incidence of urethral stones, and improve bladder capacity. Acupuncture treatment improves the patient's urinary function by acupuncture on the lower abdomen and lumbosacral acupoints once a day, 5 days a week, for a total of 3 weeks
223879936|NCT06964256|BEHAVIORAL|Experimental group: intermittent catheterization|Conventional rehabilitation treatment methods include intermittent catheterization and acupuncture. Intermittent catheterization is based on the results of urodynamic examination to develop a personalized drinking plan and the number of catheterization, and the number of catheterization is selected according to the amount of residual urine; Intermittent catheterization can reduce the rate of urinary tract infections, the incidence of urethral stones, and improve bladder capacity. Acupuncture treatment improves the patient's urinary function by acupuncture on the lower abdomen and lumbosacral acupoints once a day, 5 days a week, for a total of 3 weeks. The specific operation of sEMG abdominal breathing training: ask the patient to empty the bladder before training, the patient to take a supine position, hip and knee flexion 60 degrees (for those who cannot maintain hip and knee flexion in the lower limbs, family members can assist), at the same time, the electrodes are attached to both
223879937|NCT06964256|OTHER|Control group and experimental group: acupuncture treatment|Acupuncture treatment uses acupuncture to act on the acupuncture points in the lower abdomen and lumbosacral region to improve the patient's urination function
223879938|NCT06190197|DRUG|Prophylactic antibiotics postoperatively.|Prophylactic antibiotics postoperatively. All participants in this arm will receive nitrofurantoin 100 milligrams by mouth daily for either 10 or 21 days based on whether they had an ileal conduit or orthotopic neobladder, respectively, for the diversion. Participants will be instructed to swallow the capsule whole, preferably with food and at the same time each day. If a dose is forgotten, participants will be asked to take it when they remember and then take the next dose as usual. However, if they do not remember until the next dose, do not take extra capsules to make up the missed dose.
223879939|NCT04069013|PROCEDURE|PCNL|Patients receive standard of care treatment for their urolithiasis using one of two surgical procedures, either standard PCNL or Mini-PCNL
223879940|NCT03358693|DRUG|Anti-TNF|Subject receives anti-TNF antibodies open-label as per guidelines
223879941|NCT03358693|DRUG|Anti-IL12/23|Subject receives anti-IL12/23 antibodies open-label as per guidelines
223879942|NCT03358693|DRUG|Anti-IL17|Subject receives anti-IL17 antibodies open-label as per guidelines
223879943|NCT03358693|DRUG|Dupilumab|Subject receives Dupilumab open-label as per guidelines
223879944|NCT03358693|DRUG|Anti-IL23|Subject receives anti-IL23 antibodies open-label as per guidelines
223879945|NCT03358693|DRUG|Baricitinib|Subject receives Baricitinib open-label as per guidelines
223879946|NCT03358693|DRUG|Abrocitinib|Subject receives Abrocitinib open-label as per guidelines
223879947|NCT03358693|DRUG|Upadacitinib|Subject receives Upadacitinib open-label as per guidelines
223879948|NCT03358693|DRUG|Tralokinumab|Subject receives Tralokinumab open-label as per guidelines
223879949|NCT03358693|DRUG|Lebrikizumab|Subject receives Lebrikizumab open-label as per guidelines
223879950|NCT03358693|DRUG|Nemolizumab|Subject receives Nemolizumab open-label as per guidelines
223879951|NCT06049082|DRUG|KB408 (Nebulization)|Nebulized solution of KB408, a replication-defective HSV-1 vector expressing full length human SERPINA1
223879952|NCT06828705|OTHER|datscan scintigraphy|Semi-quantitative analysis on Datscan imaging scintigraphy
223879953|NCT05064735|DRUG|semaglutide 2.4 mg|semaglutide subcutaneous (s.c.) 2.4 mg once-weekly or semaglutide placebo once-weekly as adjunct to a reduced-calorie diet and increased physical activity
223879954|NCT05064735|DRUG|semaglutide 2.4 mg (placebo)|semaglutide subcutanous (s.c.) 2.4 mg once-weekly or semaglutide placebo once-weekly as adjunct to a reduced-calorie diet and increased physical activity
223879955|NCT06286774|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|Cognitive Behavioral Therapy for Insomnia (CBT-I). Participants assigned to the CBT-I condition will attend 1-hour individual sessions of CBT-I once a week for five weeks. Consistent with clinical guidelines (Schutte-Rodin, Broch, Buysse, Dorsey, \& Sateia, 2008), treatment will include stimulus control (e.g., limit use of bed to sleep or sexual activity, get out of bed if lying awake for more than 20 minutes), sleep restriction (limit time in bed to amount of time spent sleeping on a typical night), sleep hygiene (e.g., avoid exercise within 2 hours of bedtime, create cool and dark sleep environment), relaxation training, and cognitive restructuring.
223879956|NCT06782243|DRUG|Moderate-Intensity Statins|Participants will be administered statins based on moderate intensity. This group will receive oral tablets once daily for 3 months. The intervention includes Atorvastatin 20 mg and rosuvastatin 10 mg.
223879957|NCT06782243|DRUG|High-Intensity Statins|Participants will be administered statins based on high intensity. This group will receive oral tablets once daily for 3 months. The intervention includes Atorvastatin 40 mg and rosuvastatin 20 mg.
223879958|NCT05030272|DEVICE|"Quit on the Go App (formerly Learn to Quit  App)"|A smartphone app developed by the research team designed for people with serious mental illness, that provides Acceptance and Commitment Therapy skills to address (a) smoking cessation and (b) mental health symptoms.
223879959|NCT05030272|BEHAVIORAL|Brief advice|Brief Advice will consist of 20 minutes of guidance about the use of nicotine replacement therapy, and strategies to initiate and maintain a quit attempt.
223879960|NCT05030272|DRUG|Nicotine patch|All participants will receive an 8-week course of transdermal nicotine patches. The first 4 weeks of use will be 21mg/24 hours, followed by 2 weeks of 14mg/24 hours patches, and finally 2 weeks of 7mg/24 hours patches.
223879961|NCT05030272|BEHAVIORAL|Smartphone coaching|Participants randomized to the smartphone app intervention will receive 4 weeks of smartphone coaching given by research staff. The coaching is meant to be a time to address any issues that may rise with the participants' study smartphone or app.
223879962|NCT05030272|DRUG|Nicotine gum|Each participant enrolled will be given NRT gum (5-10week course) to be taken orally as nicotine cravings arise. Depending on participants' nicotine dependence, they will receive either the 2mg or 4mg (if they smoke within the first 30 minutes of waking) gum pieces per package instructions. We will direct subjects to use them for the first weeks following their quit date, using no more than one every 1-2 hours.
223879963|NCT05030272|DRUG|Nicotine Lozenges|In cases where participants are unable to chew nicotine gum, lozenges will be sent as a replacement of Nicotine gum. Depending on participants' nicotine dependence, they will receive either the 2mg or 4mg (if they smoke within the first 30 minutes of waking) lozenge pieces per package instructions. We will direct subjects to use them for the first weeks following their quit date, using no more than one every 1-2 hours.
223879964|NCT02886286|DRUG|Bupivacaine|Patient-activated intrathecal bolus for incident pain
223879965|NCT02886286|DRUG|Opioid|Patient-activated intrathecal bolus for incident pain
223879966|NCT00707772|DRUG|PEGASYS® (Peginterferon Alfa-2a (40KD)) Plus COPEGUS® (Ribavirin)|PEGASYS: 180 microgram per week (Injection) Plus Ribavirin: 800 milligram per day (PO)
223879967|NCT00707772|DRUG|PEGASYS® (Peginterferon Alfa-2a (40KD)) Plus COPEGUS® (Ribavirin)|PEGASYS: 180 microgram per week (Injection) Plus Ribavirin: \[=\<75 kg: 1000 mg; \>75 kg: 1200 mg per day (PO)\]
223879968|NCT01620684|DRUG|metyrapone|Overnight treatment (15 mg/kg at midnight and 15 mg/kg at 6 am)
223879969|NCT01620684|DRUG|placebo|placebo capsules
223879970|NCT06969105|OTHER|Music|Prior to randomization, all participants will pre-select their preferred music genre. If randomized to the music group, their preferred music genre will be played for a 10 minute duration.
223879971|NCT01362153|DRUG|Golimumab|SC injection of 100 mg every 4 weeks through Week 20
223879972|NCT01362153|DRUG|Golimumab|IV infusions of 2 mg/kg golimumab on Days 1 and 85.
223879973|NCT02941575|OTHER|Crystal Ultra|Crystal Ultra: is a resin nano-ceramic material, that combines both advantages of ceramics and composites.
223879974|NCT02941575|OTHER|All ceramic|IPS Emax: is an all ceramic crown that has proven superior aesthetics and strength properties.
223879975|NCT03891316|DIAGNOSTIC_TEST|HFIP and Sevoflurane are measured after 3 consecutive days of work.|Concentration of hexafluoroisopropanol and Sevoflurane are measured in urine by gas chromatography
223879976|NCT03895515|DRUG|Fiasp®|Participants receive treatment with Fiasp® according to routine clinical practice. All treatment decisions, including assignment of participants to Fiasp® treatment, were made independently of the study and prior to the participants' inclusion in the study.
223879977|NCT04368312|OTHER|No intervention|No intervention, just of questionnaire including validated tests
223879978|NCT05226780|DRUG|NBI-921352|Administered orally
223879979|NCT07071077|BEHAVIORAL|Web-Based Storytelling Intervention|The Web-based storytelling group will access stories and educational materials on the study website.
223879980|NCT07071077|BEHAVIORAL|Group-Based Storytelling Plus Intervention|The storytelling plus group will watch the stories in a group setting, share their experiences and have educational sessions led by a health coach.
223879981|NCT07071753|BEHAVIORAL|Video tutorial|At the onset of the intervention, all participants will receive tutorial videos via text, covering Instacart account setup, online item selection, and SNAP-eligible stores, aiming to improve digital literacy in grocery shopping. The video was developed by our team, reviewed by SNAP-Ed partners, and available in English and Spanish. Despite being considered helpful during the pilot, nearly half of the participants reported not receiving or watching the tutorial video. To address this, we will call all participants within the trial's first week to provide technical assistance, including step-by-step instructions on redemption of the free delivery membership. Phone follow-ups were well-received during the pilot. Also, an intervention package will be mailed to all participants as material to be referred to in the calls and throughout the intervention. Those receiving the grocery list component will receive shopping lists and recipes printed and via SMS, to aid online grocery ordering in si
223879982|NCT07071753|BEHAVIORAL|Delivery fee waiver|All participants will receive a 12-week Instacart+ Membership e-gift card, eliminating the online delivery fee for orders \>$35.
223879983|NCT07071753|BEHAVIORAL|Texting|Participants randomized to this component will receive 2 text messages weekly via EZ text to enhance their perception of behavioral control and trust in online grocery services. Text messages, deemed acceptable during our pilot, will be actionable, informed by constructs of the Theory of Planned Behavior, and tailored to assist shoppers using Instacart delivery services. We will deliver 24 short text messages (\<160 characters), on Friday afternoons and Mondays, each with one or more of the purposes rooted in behavior change techniques: increasing salience of the benefits of online grocery, modeling steps in behavior change, giving facts to address mistrust or improve control, asking questions to promote engagement, adding anonymized quotations from the pilot participants to reinforce social norms.
223879984|NCT07071753|BEHAVIORAL|Financial incentive|"Participants randomized to this component (alone or in combination with another experimental condition) will receive $1 for each dollar spent on fresh, frozen, or canned FVL loaded onto Instacart Fresh Funds, verified based on the submitted online grocery receipt or data from Instacart. The incentive applies to online purchases only and will not be earned for in-store transactions. A maximum weekly matched incentive will be set to $10, following the local FV incentive NYC (Get the Good Stuff). Fresh Funds earned, supported by Instacart Health, is an infrastructure integrated with retailer payment systems. Incentives will only be used for purchases of healthier foods (FVL) predetermined by the research team, as it has been used by FV prescription programs."
223879985|NCT07071753|BEHAVIORAL|Grocery list with instant shoppable SNAP-Ed recipes|Participants randomized to this component will receive weekly SNAP-Ed-based meal plans with instant shoppable grocery lists tailored to household size, dietary, and cultural preferences. All recipes will emphasize FVL-based eating patterns with Hispanic cuisine influences that have FVL as primary ingredients. Grocery lists organized by store department and recipe, will reflect the nearest available in-store unit. For example, if one recipe calls for 1 cup of flour, a small flour bag will be added to the list. Weekly meal plans will be shared via text as a photo and mailed as hard copies, with instant shoppable lists generated through Instacart's List feature as a hyperlink. Links to the instant shoppable list will be shared via text. Upon clicking, grocery items will be pre-filled automatically in the participant's online shopping cart. Participants can modify items and quantities before checking out.
223879986|NCT06917404|DRUG|Pentosan Polysulfate Sodium twice weekly|Subcutaneous injection, 2 mg/kg twice weekly for 6 weeks
223879987|NCT06917404|DRUG|Placebo|Placebo, subcutaneous injection, twice weekly for 6 weeks
223879988|NCT06929663|DRUG|AK146D1 for injection|AK146D1 for injection is an anti-Trop2/Nectin4 bispecific antibody-drug conjugate
223879989|NCT06937866|DRUG|Zanzalintinib|Three zanzalintinib doses of 40mg, 60mg or 100mg. The initial starting dose of zanzalintinib will be 40mg. The patients will receive zanzalintinib orally daily continuously for 28 day cycles.
223879990|NCT06937866|DRUG|Etoposide Capsule|Oral daily for 21 days of each 28 day cycle.
223879991|NCT03482245|OTHER|Blue Light|"Subjects that are to be exposed to blue light will be provided by the research personnel with a Day-Light Classic 10,000 lumen SAD light, a device that has been used in many of the previously listed published studies (Epilepsy Behav. 2012 Jul;24(3):359-64. doi: 10.1016/j.yebeh.2012.04.123. Epub 2012 May 30.) The light is small (4 X 16 X 21 inches) and weights less than a pound. It is UV filtered and glare free. There is a single On/Off switch. It will be attached to a rolling stand.~This light is fitted with a blue spectrum filter (peak 442 nm) such that it produces 1700 Lux of blue spectrum lighting when positioned at a distance of 12 inches from the subject. Those subjects assigned to blue light will be asked to shine this small portable blue enriched light on themselves from 0800 to 2000 for 3 days."
223879992|NCT05385484|BEHAVIORAL|Receives mobile banking account with incentives to save|Participants will receive assistance in opening and using a mobile savings account, will be given education emphasizing saving practices and will be told about lottery-based incentives opportunities.
223879993|NCT05755672|DRUG|Chemotherapy|Neo-adjuvant and adjuvant chemotherapy with curative intent, according to the current clinical practice guidelines
223879994|NCT05755672|PROCEDURE|Resection of the primary tumor|Surgical resection of the primary tumour, according to the current clinical practice guidelines
223879995|NCT05755672|PROCEDURE|Resection of tumour metastases|Surgical resection of tumour metastases, according to the current clinical practice guidelines
223879996|NCT05755672|PROCEDURE|Blood sampling during chemotherapy|Drawing of blood samples several times during patient visits for chemotherapy regimen
223879997|NCT00572169|DRUG|Velcade|Will be given in central venous catheter
223879998|NCT00572169|DRUG|Thalidomide|Capsule taken by mouth
223879999|NCT00572169|DRUG|Dexamethasone|A pill taken by mouth
223880000|NCT00572169|DRUG|Adriamycin|Given into the vein (IV) by a continuous infusion through a central catheter
223880001|NCT00572169|DRUG|Cisplatin|Given into the vein (IV) by a continuous infusion through a central catheter
223880002|NCT00572169|DRUG|Cyclophosphamide|Given into the vein (IV) by a continuous infusion through a central catheter
223880003|NCT00572169|DRUG|Etoposide|Given into the vein (IV) by a continuous infusion through a central catheter
223880004|NCT04927819|DEVICE|BTI Implant|BTI Dental implants are non-active medical device, single use, non resterilizable, biocompatible and sterile devices made of alloplastic materials (Titanium) intended to be surgically implanted into alveolar and/or basal bone of the mandible or maxilla to provide support and a means of retention for a dental prosthesis (e.g. bridge, single-tooth, overdenture).
223880005|NCT06222723|DRUG|Dexamethasone|Dexamethasone will be administered for 10 days. For the first 48 hours, dexamethasone will be given iv. After 48 hours, a switch to oral dexamethasone (same dosage) is permitted at the discretion of the study physician.
223880006|NCT06222723|DRUG|Ribavirin|Ribavirin treatment will be administered iv for 10 days, as recommended in the Nigeria Centre for Disease Control and Prevention National Guidelines for LF Case Management.
223880007|NCT05461352|DRUG|TS-142 5 mg|Participants received repeated doses of 5 mg of TS-142 (oral tablet)
223880008|NCT05461352|DRUG|TS-142 10 mg|Participants received repeated doses of 10 mg of TS-142 (oral tablet)
223880009|NCT04592198|DRUG|Palonosetron Hydrochloride Buccal Film 0.25 Mg|Dose equal to the iv control
223880010|NCT04592198|DRUG|Palonosetron Hydrochloride Buccal Film 0.5 Mg|Dose twice that of iv control
223880011|NCT04592198|DRUG|Palonosetron Hydrochloride, 0.25 Mg/5 mL Intravenous Solution|iv control
223880012|NCT05834920|DEVICE|Transcranial pulse stimulation (TPS)|Participants will be treated with the TPS device NEUROLITH (Storz Medical AG). Treatments will be administered for up to 12 sessions within 4 weeks, each session consisting of 6000 TPS pulses of 0.2 mJ/mm².
223880013|NCT05834920|DEVICE|Neurofeedback|Participants will engage in a neurofeedback game designed to increase the ratio of theta/beta frequency bands in electroencephalography measurement. This intervention will be delivered for up to 12 sessions within 4 weeks.
223880014|NCT06780696|DEVICE|SyMapCath I™ catheter and SYMPIONEER S1™ Stimulator/Generator|Radiofrequency ablation of renal arterial sympathetic nerves
223880015|NCT06475677|DEVICE|OrthoCor Advanced System|The OrthoCor Advanced System is a portable battery-operated non-invasive device that delivers Pulsed Electromagnetic Field (PEMF) plus heat therapy for general use pain relief. It utilizes a wrap that positions the device over painful areas and joint motion tracking recorded by a smart device application to monitor recovery metrics and therapy compliance.
223880016|NCT06789783|DRUG|Lithium Carbonate Capsule|10mg/Kg twice a day, 150mg or 300mg Lithium Carbonate
223880017|NCT02314481|DRUG|MPDL3280A|Intravenous (IV) infusion, as monotherapy of in combination with chemotherapy
223880018|NCT02314481|DRUG|Vemurafenib|Film coated tablet
223880019|NCT02314481|DRUG|Alectinib|capsule
223880020|NCT02314481|DRUG|Trastuzumab emtansine|Powder for concentrate for solution for infusion
223880021|NCT02950051|DRUG|Fludarabine|Fludarabine i.v.: cycles 1-6: 25 mg/m², d1-3, q28d
223880022|NCT02950051|DRUG|Cyclophosphamide|Cyclophosphamide i.v.: cycles 1-6: 250 mg/m², d1-3, q28d
223880023|NCT02950051|BIOLOGICAL|Rituximab|Rituximab i.v. (before chemotherapy): cycle 1: 375 mg/m², d0; cycles 2-6: 500 mg/m², d1; q28d
223880024|NCT02950051|DRUG|Bendamustine|Bendamustine i.v.: cycles 1-6: 90mg/m², d1-2, q28d
223880025|NCT02950051|DRUG|Venetoclax|"Venetoclax p.o. (ramp-up: dose escalation until final dose is reached)~cycle 1: 20 mg (2 tabl. at 10 mg), d22-28, q28d~cycle 2: 50 mg (1 tabl. at 50 mg), d1-7; 100 mg (1 tabl. at 100 mg), d8-14; 200 mg (2 tabl. at 100 mg), d15-21; 400 mg (4 tabl. at 100 mg), d22-28, q28d~cycles 3-12: 400 mg (4 tabl. at 100 mg), d1-28, q28d"
223880026|NCT02950051|BIOLOGICAL|Obinutuzumab|"Obinutuzumab i.v.~cycle 1: 100 mg, d1; 900 mg, d1(2); 1000 mg, d8+15, q28d~cycles 2-6: 1000 mg, d1, q28d"
223880027|NCT02950051|DRUG|Ibrutinib|"Ibrutinib p.o.~cycles 1-12: 420 mg, d1-28, q28d~cycles 13-36: 420 mg, d1-28, q28d"
223880028|NCT06395181|BEHAVIORAL|Whole Food Plant-Based Diet|A whole food, plant-based diet focuses on whole foods that are not processed. The diet places an emphasis on plant foods that are naturally lower in fat and includes eating a variety of plant foods (fruits, vegetables, beans and legumes, whole grains, nuts and seeds, spices and herbs).
223880029|NCT06257472|DEVICE|Virtual Reality Headset|Participants will be mailed a Meta Quest 2 Headset. Participants will be asked to wear and use the VR headset for around 20 minutes each day for 8 weeks.
223880030|NCT04767022|DEVICE|Paclitaxel Coated PTCA Balloon Catheter(Genoss® DCB)|Drug Coated Balloon
223880031|NCT04767022|DEVICE|Paclitaxel Coated PTCA Balloon Catheter(SeQuent® Please NEO)|Drug Coated Balloon
223880032|NCT05609552|COMBINATION_PRODUCT|18F-Pretomanid PET/CT|A bolus of less than or equal to 10 mCi (370 MBq) of 18F-pretomanid will be injected into the intravenous line by slow IV push. Immediately after administration of 18F-pretomanid, dynamic PET acquisition will take place.
223880033|NCT06472414|BEHAVIORAL|Individualized Counselling Sessions|Four counselling sessions led by an experienced exercise physiologist will be provided. At the first session, benefits of cardiovascular rehabilitation (CR), functioning of the CR program, barriers to attendance, strategies to overcome them will be explained and discussed, leading to the choice of the best suitable CR modality/schedule. Physical activity (PA) recommendations will be discussed and an action plan to increase/maintain PA levels and decrease sedentary behaviour will be given. WFG will receive access to an online platform where 4 pre-recorded different exercise sessions will be placed, and a booklet to register weekly PA. The second session will be to discuss barriers and facilitators. For the third session PA goals will be re-established, a new action plan constructed and strategies to overcome barriers given. For the final session, overall feedback, results of the intervention, satisfaction, doubts, knowledge acquired and recommendations for the future will be discussed.
223880034|NCT06472414|BEHAVIORAL|Educational Women-Focused Sessions|Five pre-recorded women-focused educational sessions will be placed in an online platform at the end of each month. There will be a first short session explaining the importance of cardiovascular rehabilitation, followed by four sessions regarding: women and cardiovascular disease, benefits of physical exercise in women, women and mental health and women and healthy eating. Each session will have a duration of 10/15 minutes and will be delivered by specialized professionals according to the theme (cardiologists, exercise physiologists, nutritionists, psychologists). After every session, a short Likert-type questionnaire will be applied to assess what they thought of the topic in terms of importance and what they have learned.
223880035|NCT06472414|BEHAVIORAL|Supervised Exercise Training Sessions|Participants will exercise 2-3 times/week (60 min/session), on non-consecutive days, for 6 months (weekly target of 10 kcal/kg). Blood pressure and heart rate (HR) will be measured before and after each session. During exercise, a HR chest strap (POLAR H10) will be used to monitor HR and control intensity. Aerobic prescription will be based on the baseline cardiopulmonary exercise test, each session will start with a 5'-10' minutes warm-up - low to moderate intensity \[\<40% of HR Reserve (HRR), 9-10 Rated Perceived Exertion Borg Scale (RPE)\], mobility and low impact exercises, followed by a 30'-45' minutes of combined training with an aerobic component - moderate intensity (40% to 59% of HRR; 12-14 RPE) using ergometers, aerobic exercises, walking/jogging; and a strength component - 8/10 exercises, 30-80% of 1-Repetition Maximum, 12-15 repetitions, 2 sets - ending with a 5'-10' minute cool down - static/dynamic stretching exercises for all major muscle groups.
223880036|NCT05215756|DEVICE|transcutaneous vagal nerve stimulation|The tVNS device will be attached to the left concha of the ear to stimulate the auricular branch of the vagal nerve. Each stimulation will last for 2 minutes.
223880037|NCT04921501|DEVICE|HD ECG|This experimental procedure is a passive, non-invasive, high-density surface ECG recording using 128 skin electrodes.The electrodes are positioned on strips of 10 electrodes to be prepared with adhesive tape and coated with conductive gel before installation on the patient. The total duration of the acquisition is 10 to 30 minutes.
223880038|NCT04921501|DEVICE|Conventional 12-lead ECG|This standard 12-lead ECG is defined on the HD ECG, from electrodes F13, G3, G14, H5, H15, H25 corresponding to the precordial electrodes. 4 limb electrodes will be added for the frontal leads. Thus, the HD and 12-lead ECGs will be obtained simultaneously.
223880039|NCT02204098|BIOLOGICAL|Mammaglobin-A DNA Vaccine|
223880040|NCT02204098|PROCEDURE|Optional biopsy|
223880041|NCT05423106|DRUG|JNJ-64457744|JNJ-64457744 will be administered as oral solution.
223880042|NCT05423106|DRUG|Placebo|Placebo will be administered as an oral formulation.
223880043|NCT05423106|DRUG|Tenofovir Disoproxil Fumarate (TDF)|TDF tablet will be administered orally
223880044|NCT05423106|DRUG|Tenofovir Alafenamide (TAF)|TAF tablet will be administered orally.
223880045|NCT05423106|DRUG|Entecavir (ETV)|ETV tablet will be administered orally.
223880046|NCT05423106|DRUG|JNJ-64457744|JNJ-64457744 will be administered as oral tablet.
223880047|NCT00643656|DRUG|Kalinox 170 bar|Flow of gas administrated to the patient between 4 and 15 litre/min and less than 1 hour
223880048|NCT00643656|DRUG|Mix of 50% oxygen and 50% nitrogen|Flow of gas administrated to the patient between 4 and 15 litre/min and less than 1 hour
223880049|NCT06783192|DRUG|MK-8527|MK-8527 capsule taken by mouth
223880050|NCT06783192|DRUG|LNG/EE|LNG/EE combination tablet taken by mouth.
223880051|NCT06286293|OTHER|Neuropsychological assessment, driving simulator task|Neuropsychological assessment consisting of test measuring general cognitive abilities and social cognition. Driving simulator task measuring risk-taking.
223880052|NCT06791447|OTHER|AI-assisted Predictive Model for Dialysis Outcomes|This study utilizes an AI-assisted predictive model that analyzes multimodal data from electronic health records, including medical history, laboratory results, dialysis treatment details, and clinical observations, to predict outcomes for dialysis patients. The model employs deep learning algorithms to predict mortality risk, intermediate outcomes such as anemia, blood pressure control, nutrition, and calcium-phosphate metabolism, and helps identify early signs of deterioration. The intervention is not a direct treatment or procedure but aims to develop a tool for predicting patient outcomes and optimizing treatment strategies to improve overall health and survival rates for dialysis patients.
223880053|NCT06785077|PROCEDURE|buccal cells|custom myeloid gene panel (Myelo-Panel) to identify germline mutations predisposing to cancer development (Thermo Fisher Scientific)
223880054|NCT06785077|PROCEDURE|bone marrow cells|"Bone marrow cells (optional, for comparison, only in a limited number of patients):~* morphological analysis~* immunophenotype~* cytogenetics/FISH~* analysis of CHIP by custom gene panel and high sensitivity NGS"
223880055|NCT06785077|PROCEDURE|peripheral blood cells|analysis of CHIP by custom gene panel and high sensitivity NGS
223880056|NCT06785077|PROCEDURE|bone marrow biopsy|"Bone marrow biopsy (optional, for comparison, only in a limited number of patients):~* histology~* immunohistochemistry"
223880057|NCT01885676|DEVICE|PRGF-Endoret|PRGF-Endoret mesotherapy micro injection.
223880058|NCT01885676|OTHER|Saline Solution|Saline Solution mesotherapy micro injection
223880059|NCT03102125|DRUG|Regadenoson|For use in stress myocardial perfusion imaging.
223880060|NCT05534581|DEVICE|PVI using the Arctic Front Cryoballoon (Medtronic)|Patients randomized to the Arctic Front cryoballoon group will undergo PVI using the Arctic Front Cryoballoon (Medtronic). At the end of the procedure, an implantable cardiac monitor will be implanted for the purpose of continuous arrhythmia monitoring.
223880061|NCT05534581|DEVICE|PVI using FARAPULSE Pulsed Field Ablation (Boston Scientific)|Patients randomized to the Pulsed Field Ablation group will undergo PVI using the FARAPULSE PFA system (Boston Scientific). At the end of the procedure, an implantable cardiac monitor will be implanted for the purpose of continuous arrhythmia monitoring.
223880062|NCT05096819|OTHER|Patients Using the 6MWT App in the Community|Patients under the care of the cardiovascular clinics in Oxford, who used the Timed Walk app to perform 6MWT in their community during the CODIV19 pandemic period
223880063|NCT05096819|OTHER|Volunteers for 6MWT distance comparison|Volunteers (cardiac patients and hospital staff) who performed 10 6MWT using the TimedWalk app and a trundle wheel simultaneously. Five tests were performed following instructions and 5 were performed introducing errors. Aim is to measure app accuracy under different circumstances.
223880064|NCT04661683|OTHER|Combustible Hookah Smoke|Exposure to combustible hookah smoke for a duration of 60 minutes.
223880065|NCT04661683|OTHER|Electronic Hookah Aerosol|Exposure to electronic hookah aerosol for a duration of 60 minutes.
223880066|NCT04661683|OTHER|Clean Room Air|Exposure to room air for a duration of 60 minutes.
223880067|NCT06382220|DRUG|Bupivacain|drug injection
223880068|NCT06461676|DRUG|Ventrix Bio Extracellular Matrix|VentriGel will be administered by injection into the right ventricle of the heart in the following defined doses per injection. There will be a total of 8 injections. The proposed dose of up to 0.6 mL is administered as up to 8 sequential injections of 4 injections of 0.1 mL each and 4 injections of 0.05 mL each.
223880069|NCT06785558|DRUG|Anticholinergic therapy|Overactive bladder group use anticholinergic drug and 1 month later their urinary atp levels calculated again
223880070|NCT06318507|COMBINATION_PRODUCT|Fecal microbial diversity|Fecal microbiome diversity via 16S rRNA and metagenomic sequencing
223880071|NCT05690386|BIOLOGICAL|Lonapegsomatropin|Once-weekly subcutaneous injection of Lonapegsomatropin
223880072|NCT05690386|DRUG|Somatropin|Once-daily subcutaneous injection of Somatropin
223880073|NCT06829511|OTHER|Questionnaire and Physical Exam|Cardiac Self-Efficacy Scale (CSES) 36-Item Short Form Survey (SF-36) Symptom Distress Scale (SDS)
223880074|NCT06373211|DRUG|Immunoglobulins IV (CLAYRIG)|"Patients will be treated with cycles of :~\- Intravenous (IV) immunoglobulins: 2 g/kg per cycle, over 3 to 5 days (D1 to D3 or D5).~Cycles will be administered every 4 weeks for a total of 3 first cycles"
223880075|NCT06373211|DRUG|Cyclophosphamide IV|"Patients will be treated with cycles of :~\- Cyclophosphamide IV: 1 g on the first day (D1). Cycles will be administered every 4 weeks for a total of 6 cycles"
223880076|NCT06373211|DRUG|Methylprednisolone IV|"Patients will be treated with cycles of :~Methylprednisolone IV: 1 g/day for 3 days (D1 to D3). Cycles will be administered every 4 weeks for a total of 6 cycles"
223880077|NCT04096014|DIETARY_SUPPLEMENT|Ensure Enlive|The subjects in the intervention group will receive two Ensure Enlive supplements per day for 180 days.
223880078|NCT04096014|OTHER|Standard Of Care|The subjects in the Standard of care group will continue to receive the standard clinical therapy.
223880079|NCT06782516|DEVICE|System of Care - combination of algorithm and Brief Contact Intervention|Case managers see the Native-RISE algorithm classification and Clinical Providers receive a risk notification. A resource card is provided to the participant.
223880080|NCT06782516|BEHAVIORAL|Active Comparator - Provider notification of risk status|Clinical Providers receive a risk notification and a resource card is provided to the participant.
223880081|NCT06558201|OTHER|Ketogenic diet|The ketogenic diet (KD) is a normo-caloric diet composed of high-fat, low carbohydrate, and adequate protein intake. The KD will consist of 3 meals a day plus snacks, targeting 75-80% fat, 13-18% protein, 7% carbohydrates.
223880082|NCT03547908|DRUG|B/F/TAF|50/200/25 mg B/F/TAF FDC tablet administered orally once daily, without regard to food
223880083|NCT03547908|DRUG|Placebo to match DTG|Tablet administered orally once daily, without regard to food
223880084|NCT03547908|DRUG|Placebo to match F/TDF|Tablet administered orally once daily, without regard to food
223880085|NCT03547908|DRUG|DTG|50 mg tablet administered orally once daily, without regard to food
223880086|NCT03547908|DRUG|F/TDF|200/300 mg tablet administered orally once daily, without regard to food
223880087|NCT03547908|DRUG|Placebo to match B/F/TAF|Tablet administered orally once daily, without regard to food
223880088|NCT06789575|DRUG|Bupivacaine|the patients will receive the content of a syringe (10 ml of bupivacaine 0.25%)
223880089|NCT06789575|DRUG|Adrenaline|the patients will receive the content of a syringe 15 μg adrenaline
223880090|NCT06789575|DRUG|Lidocaine (drug)|the patients will receive the content of a syringe 70 ml Lidocaine .
223880091|NCT06792032|OTHER|peer mentoring with mobile application|peer mentoring with mobile application
223880092|NCT05256862|OTHER|Data collection|"Data collection~* on the effect of a bundle of measures on the proportion of females being screened for cervical cancer in the Kilombero and Ulanga Antiretroviral Cohort (KIULARCO) comparing the time period before implementation (01/2017-01/2020) and after implementation (02/2020-06/2022)~* on the performance of three novel tests as triage tool in the screening algorithm, QG-MPH, Prevo-check® and PT Monitor®"
223880093|NCT05898620|GENETIC|NGN-401|NGN-401 is a non-replicating, recombinant AAV9 carrying a full length human MECP2 transgene.
223880094|NCT04533386|BEHAVIORAL|Multi-component intervention strategy|Multi-component intervention strategy using a peer change agent and mobile application to record and review sexual risk behaviors
223880095|NCT06787027|PROCEDURE|Manual Lymphatic Drainage technique|Following the morning surgery, manual lymphatic drainage therapy was administered in the afternoon of the same day by a professional physiotherapist.
223880096|NCT06787027|PROCEDURE|Conventional Treatment group|patients were prescribed antibiotics (amoxicillin with clavulanic acid, 1 g, twice daily), analgesics (paracetamol, 500 mg, twice daily), and mouthwash (chlorhexidine gluconate, three times daily) for five days. Cold application was recommended to all patients.
223880097|NCT06820840|OTHER|SHOFU Block HC Hard|Cementation of hybrid ceramic onlay (SHOFU Block HC Hard) on carious molars.
223880098|NCT06820840|OTHER|SHOFU Ceramage|Cementation of hybrid resin composite onlay (SHOFU Ceramage) on carious molars.
223880099|NCT06786741|BEHAVIORAL|AER for Stronger Communities|3 week rapid intervention aimed at reducing stress.
223880100|NCT06786741|OTHER|Placebo Comparator|3 week short video program (control)
223880101|NCT06831435|DEVICE|a digital product based on CBT|The digital cognitive behavioral therapy in this study is conducted based on a self-developed mobile applet. The therapy is developed by psychotherapists, which is conducted for a total of 8 weeks, with weekly sessions including Al-guided course work and homework.
223880102|NCT05997186|PROCEDURE|Surgical reconstruction|Surgical reconstruction with a free reinnervated profunda artery perforator flap
223880103|NCT06790888|COMBINATION_PRODUCT|Ripertamab/Eltrombopag|Ripertamab, a novel anti-CD20 monoclonal antibody, in combination with Eltrombopag . Ripertamab is administered intravenously at a dose of 375 mg/m² BSA on Day 1 . If the participant remains in remission at the 3-month mark, an additional intravenous dose of 375 mg/m² Ripertamab is administered. Eltrombopag are given orally at an initial dose of 2.5 mg once daily, with dosage adjustments made every two weeks based on platelet count response, for a total treatment duration of up to Day 28.
223880104|NCT06790888|DRUG|Eltrombopag|Eltrombopag as a single therapy. Eltrombopag is a thrombopoietin receptor agonist given orally at an initial dose of 2.5 mg once daily, with dosage adjustments made every two weeks based on platelet count response, for a total treatment duration of up to Day 28.
223880105|NCT05551117|BIOLOGICAL|vobramitamab duocarmazine 2.0 mg (Arm A)|2.0 mg/kg intravenous (IV) every 4 weeks
223880106|NCT05551117|BIOLOGICAL|vobramitamab duocarmazine 2.7 mg (Arm B)|2.7 mg.kg IV every 4 weeks
223880107|NCT05551117|BIOLOGICAL|vobramitamab duocarmazine|2.7 mg.kg IV every 4 weeks
223880108|NCT05551117|DRUG|Abiraterone|1000 mg once daily
223880109|NCT05551117|DRUG|Enzalutamide|160 mg daily
223880110|NCT06786169|OTHER|psychological stress status|The assessment of depressive and anxiety symptoms was conducted using Patient Health Questionnaire-9 (PHQ-9) and Generalized Anxiety Disorder Assessment 7 (GAD-7). Patients with a PHQ-9 score ≥ 5 or a GAD-7 score ≥ 5 were categorized as the stressed group.
223880111|NCT04701437|BEHAVIORAL|Peer mentor|Peer mentors will contact participants within 72 hours of enrollment to discuss the early release period, gauge their readiness for HCV treatment, and identify ancillary needs. They will also accompany the participant to their first medical appointment with an HCV provider and any future appointments if requested by the participant. Peer mentors will offer participants social support throughout the 6 months they are enrolled in the study.
223880112|NCT04701437|BEHAVIORAL|Standard of care|Passive referral to a HCV provider
223880113|NCT05155137|DRUG|Drug Capsule (Valsartan + Amlodipine + Rosuvastatin)|Polypill with 3 medications (Valsartan 80 mg + Amlodipine 5 mg + Rosuvastatin 10 mg)
223880114|NCT05155137|BEHAVIORAL|Stroke Riskometer|Participants will be randomized to use Stroke Riskometer App for lifestyle modifications
223880115|NCT01025089|DRUG|Cetuximab, Cisplatin, Doxorubicin & Cyclophosphamide|Patients will receive single agent cetuximab infusion starting with a 400mg/m2 IV loading dose on day 1 of week 1, followed by weekly infusions (250mg/m2) on day 1 of weeks 2 3, and 4. Patients will receive single agent cetuximab infusion starting with a 400mg/m2 IV loading dose on day 1 of week 1, followed by weekly infusions (250mg/m2) on day 1 of weeks 2 3, and 4. Patients who have completed the neo-adjuvant treatment regimen, who have no evidence of distant progression, and who are medically operable will proceed to surgical resection within 6 weeks of the last infusion.
223880116|NCT01727518|OTHER|As the LEAD study is an observational cohort study, there is no intervention to report.|As the LEAD study is an observational cohort study, there is no intervention to report.
223880117|NCT03570333|DIAGNOSTIC_TEST|progenitor potential of Gingival Mesenchymal cells|tissues collected from the molar and premolar sites will be sent to the lab for cell culturing. once in the lab, the tissues will be already separated and labeled (molar) and ( premolar) and then treated to extract the cells from them. then, these cells will be tested for their capacity to form different kinds of cells and tissues ( bone, cartilage, fibers for periodontal ligaments). After this test, results will be collected for how many cells were collected from each tissue sample.
223880118|NCT02152137|DRUG|efatutazone|Given PO
223880119|NCT02152137|DRUG|paclitaxel|Given IV
223880120|NCT03358875|DRUG|Tislelizumab|Tislelizumab administered by intravenous (IV) infusion
223880121|NCT03358875|DRUG|Docetaxel|Docetaxel administered as an IV infusion over 1 hour
223880122|NCT03599648|BEHAVIORAL|BPT-M|"Participants randomized to the BPT-M condition receive the Mindfulness-Based Stress Reduction (MBSR) intervention, followed by Behavioral Parent Training (BPT). The MBSR module includes six weekly 2.5 hour group sessions, 30-45 minutes of daily home practice guided by audio CDs, and an MBSR parent workbook. In the sessions, participants practice formal mindfulness exercises, and are provided instruction on stress physiology and using mindfulness for coping with stress in everyday life.~The BPT component of the intervention includes 10 weekly sessions lasting 2.5 hours. Each session is structured around videotape vignettes and uses discussion, role-playing, modeling, and feedback to foster mastery of the material. Parents are given weekly homework assignments and practice their skills."
223880123|NCT03599648|BEHAVIORAL|BPT-E|Participants randomized to the BPT-E condition will received 6 weeks of a psychoeducation program followed by 10 weeks of the Behavioral Parent Training (BPT) used in both conditions. The psychoeducation module consists of 6 weekly 2.5-hour sessions, daily homework that includes monitoring progress on goals identified at the end of each session, and a workbook for parents of children with special needs that provides parents with information regarding their child's development, disability, and associated considerations. Each of the 6 weekly sessions includes a general topic for discussion. These include preparing for IEP meetings, navigating the regional center and developmental service agencies, communicating with teachers, advocacy, sibling issues, and community resources.
223880124|NCT04422652|DRUG|Bupropion|Bupropion is an anti-depressant medication.
223880125|NCT04422652|BEHAVIORAL|Behavioral activation therapy|Brief behavioral activation treatments administered via video tele-conferencing.
223880126|NCT04422652|DRUG|Placebo|Double-blind placebo.
223880127|NCT04422652|OTHER|Clinical Management|Clinical management will serve as the attention control for the Behavioral Activation Therapy intervention.
223880128|NCT05169489|BIOLOGICAL|bbT369|bbT369 is a genetically modified autologous T cell immunotherapy product consisting of T cells that are transduced with a single lentiviral vector (LVV) to express anti-CD79a and anti-CD20 chimeric antigen receptors (CARs) and transfected with an mRNA encoding the CBLB-targeting megaTAL enzyme to edit the CBLB gene, suspended in a cryopreservative solution.
223880129|NCT04887259|BIOLOGICAL|LAVA-051|In part 1 and part 2, LAVA-051 will be administered via intravenous (IV) infusion
223880130|NCT04887259|BIOLOGICAL|Interleukin 2|In Part 1 and Part 2, a low dose of interleukin 2 will be given via subcutaneous injection with LAVA-051 in a selected group of patients
223880131|NCT05008926|DRUG|Naloxegol|Administration of Naloxegol 25 mg per day by nasogastric tube (SNG) or orogastric tube (SOG). The administration should be started within the first 24 hours after the patient is admitted to intensive care and continued for the duration of the administration of the morphine derivative and until 48 hours after its discontinuation.
223880132|NCT05008926|DRUG|Placebo|Administration of the placebo according to the same procedures as the experimental arm.
223880133|NCT05708911|DEVICE|Pharyngeal exerciser|Pharyngo-esophageal manometry during lateral fluoroscopy
223880134|NCT05626725|DEVICE|Automated insulin delivery system|This is an outpatient prospective observational study to evaluate the effect of DIY-AID use on maintaining glucose levels in physically active adult people living with T1D.
223880135|NCT02214381|DRUG|Myocet|
223880136|NCT02214381|DRUG|Cyclophosphamide|
223880137|NCT02214381|DRUG|Paclitaxel|
223880138|NCT05333978|DEVICE|MSOT Device|The MSOT Device will be used to take images of the areas of inflammation in patients with inflammatory diseases such as GVHD, Colitis, and IBD, prior to, and after 4 weeks of treatment.
223880139|NCT05333978|PROCEDURE|Temperature Measurement|The temperature of the skin will be measured prior to and after each instance of MSOT imaging.
223880140|NCT05792540|DRUG|Fluoxetine 20 mg|Fluoxetine is a type of antidepressant known as a selective serotonin reuptake inhibitor (SSRI). It's often used to treat depression, and sometimes obsessive-compulsive disorder and bulimia. It works by increasing the levels of serotonin in the brain
223880141|NCT05792540|DRUG|Dapagliflozin 10mg Tab|Dapagliflozin (DAPA), a sodium-glucose co-transporter 2 inhibitor (SGLT2-I), has proven to be an effective hyperglycemic suppressor due to its role in inhibiting the reabsorption of 30-50% of the glucose filtered by the kidney, besides its role in the improvement of insulin resistance
223880142|NCT05792540|DRUG|Atorvastatin 80mg|Atorvastatin is a synthetic and lipophilic statin, a class of drugs used in the treatment of hypercholesterolemia
223880143|NCT01293357|DRUG|LEO 90105|Ointment
223880144|NCT04975178|BIOLOGICAL|MTBVAC|MTBVAC is a novel TB vaccine candidate based on an attenuated M. tuberculosis clinical isolate of the Euro-American lineage. Attenuation is based on two independent, stable genetic deletions of the genes phoP and fadD26 coding for two major virulence factors, the transcription factor PhoP and the cell-wall lipids PDIM, respectively. We hypothesize that MTBVAC will provide improved protection, as individuals latently infected with live M.tuberculosis have an 80% lower chance of developing TB, and as MTBVAC contains most of the genes deleted from BCG and presents a wider collection of antigens to the host immune system. Preclinical studies in different animal models indicated that MTBVAC is safe and is able to induce an improved protection compared to BCG.
223880145|NCT04975178|BIOLOGICAL|BCG|BCG is a live attenuated M. bovis strain developed 100 years ago and is used as a preventive vaccine against tuberculosis. It is administered at birth.
223880146|NCT03429803|DRUG|DAY101|28 day cycle, oral, once per week
223880147|NCT06051305|BEHAVIORAL|Sensory Training|Participants will use gamified sensory training technology once daily for 8 weeks. This will involve participants completing a 15 minute sensory training session using the provided technology. The tool used in this study has two components. The first is a game that can be downloaded onto any smartphone device. The second component is two tactile devices that can be attached to the body.
223880148|NCT05461781|PROCEDURE|distal radial access|primary percutaneous coronary intervention via distal radial access
223880149|NCT05461781|PROCEDURE|conventional transradial access|primary percutaneous coronary intervention via conventional transradial access
223880150|NCT05152784|DEVICE|Octaray catheter|A high density diagnostic catheter used for substrate and activation mapping.
223880151|NCT05152784|DEVICE|Standard of care|VT ablation guided by substrate-mapping alone.
223880152|NCT05808504|OTHER|Neuropsychological assessment|interview with a neuropsychologist and carrying out tests measuring overall cognitive abilities, depression, apathy and anxiety (respectively using the MOCA, MADRS, LARS, STAI scales)
223880153|NCT05808504|OTHER|Neurological assessment|Only for patients with Parkinson disease. Evaluation consisting in a disease severity assessment using the Hoehn and Yahr and Schwab and England scales, as a well as a measure of levodopa equivalent daily dose.
223880154|NCT05808504|OTHER|Cognitive task|"The task consists in pressing a left or right button as fast and as accurately as possible according to the direction of an arrow displayed at the center of a screen. On 25 % of the trials, a stop signal will occur right after the stimulus, indicating the participant to stop his impending button press. The delay between the presentation of the arrow stimulus and the stop signal will be adjusted to ensure a final 50% accuracy (decreased following an accurate response and increased after an error), which is necessary to comply with the assumptions for a robust calculation of the stop signal reaction time (SSRT)."
223880155|NCT05808504|PROCEDURE|EEG|A high-resolution (256 channels) electroencephalographic recording will be done at rest and during the Stop task, before and after each real or sham stimulation.
223880156|NCT05808504|PROCEDURE|tACS (real or sham)|Real or sham tACS will be applied with the same equipment (StarStim, Neuroelectrics). The stimulation will consist in applying a current (max 2 mA) at frontal sites (F8 and Cz according to standard EEG position, and defined based on dosimetry analyses on averaged head models) for 12-15 minutes during the task. A 10 s ramp (fade-in/fade-out) will be used to avoid current perception of the stimulation and optimize blinding. Sham stimulation will be done using the same protocol, but with no stimulation in between onset and offset.
223880157|NCT05294809|BEHAVIORAL|PsyPills|Prescribing personalized rational thinking strategies to change levels of dysfunctional emotionality.
223880158|NCT05294809|BEHAVIORAL|Online-Contingent Attention Training, OCAT|Facilitating the disengagement from negative content and engagement of positive one of personally relevant information by providing instruction and feedback on performance.
223880159|NCT05294809|BEHAVIORAL|shamOCAT|"The active control group, which consists of the fake version of the OCAT intervention, by offering the same attentional training, without training and feedback on performance."
223880160|NCT05666167|BEHAVIORAL|Group Telehealth Exercise Sessions with text messaging plus booster sessions|Participants receive 3 months of group telehealth exercise initiation plus text messaging followed by 6 months of text messaging plus monthly group telehealth exercise booster sessions.
223880161|NCT06522022|BEHAVIORAL|Culturally Responsive SBIRT for OB|"SBIRT is a well-established enhanced screening preventive intervention model that is feasible and acceptable for use with trauma-exposed patients and in minoritized communities and can be delivered in the OB clinic during a prenatal care visit. The elements include:~1. standardized screening for PTSD and depression using the Primary Care Post Traumatic Stress Disorder Screen (PC-PTSD-5) and the Edinburgh Postnatal Depression Screening (EPDS) that will mirror brief screening practice;~2. explicit focus on concerns regarding mistrust,~3. psychoeducation on PTSD, depression, and the effects of trauma including medical trauma and traumatic loss on health/functioning,~4. motivational interviewing strategy components to promote awareness of psychological symptoms and engagement in culturally relevant resources including support/resources related to relevant social determinants of health,~5. teaching coping skills with culturally responsive technology tools"
223880162|NCT06522022|BEHAVIORAL|Brief Screening for PTSD|This well-established 5-minute in-clinic interview includes administration of the PC-PTSD-5, a 5-item PTSD screening tool by trained medical staff (nurse, physician's assistant). Providers receive approximately one hour of training in trauma-informed care and how to administer the screening protocol. This method is regularly used in primary care clinic settings with trauma-exposed veterans and is validated for use in civilian samples, including low-income Black adults utilizing urban safety net hospital medical clinics.
223880163|NCT05322590|DRUG|BXQ-350|BXQ-350 is a novel anti-neoplastic therapeutic agent configured from two components: Saposin C (SapC), an expressed (human) lysosomal protein, and the phospholipid dioleoylphosphatidyl-serine (DOPS), a phospholipid located on cell membranes (clinical formulation BXQ-350). BXQ-350 will be administered by intravenous (IV) infusion over six months and continued for an additional 20 months for participants who remain eligible.
223880164|NCT05322590|OTHER|Placebo|Placebo will be 0.9% normal saline of matching volume to BXQ-350 administered by intravenous (IV) infusion over six months and continued for an additional 20 months for participants who remain eligible (Stage 2 only)
223880165|NCT05720338|DEVICE|19 French Blake Drain|19 French Blake Intraperitoneal Drain will be placed near the pancreatic resection margin
223880166|NCT04759443|OTHER|Image processing of skin|Image processing will be used to extract skin features that correlate with loss of small skin fibers.
223880167|NCT04609553|BEHAVIORAL|Usual care including ROR|Usual care which includes ROR.
223880168|NCT04609553|BEHAVIORAL|Text messages|3 text messages per week and one interactive text per month.
223880169|NCT04609553|BEHAVIORAL|Connection to community resources|Referral to a non-profit that connects families with community resources and provides families with case management.
223880170|NCT03587688|PROCEDURE|mitral valve surgery|pre-, intra- and postoperative data on patients undergoing mitral valve surgery at the Department for Cardiac Surgery of Universitätsspital Basel/ Switzerland since 2009
223880171|NCT05945537|DRUG|INI-822 (A)|Different dose levels of INI-822
223880172|NCT05945537|OTHER|Placebo (B)|Matching placebo to INI-822
223880173|NCT03837977|DRUG|Liposomal Irinotecan|Arm I
223880174|NCT03837977|DRUG|Fluorouracil|Arm I
223880175|NCT03837977|DRUG|Folinic Acid|Arm I
223880176|NCT03837977|DRUG|Docetaxel|Arm II
223880177|NCT06194214|DRUG|Pirtobrutinib|Administered Orally.
223880178|NCT06194214|DRUG|Digoxin|Administered Orally.
223880179|NCT04642599|DEVICE|Bimanual motor skill learning with the REAplan® rehabilitation robot|REAplan® rehabilitation robot: training to perform complex, coordinated, bimanual movements
223880180|NCT05754034|DEVICE|High flow oxygen|humidified and heated oxygen delivered at high flow rates via nasal cannula, with protocol to target SpO2 90-94%
223880181|NCT05754034|OTHER|Standard flow oxygen|oxygen delivered at standard flow rates via nasal cannula, facemask, or nonrebreather mask, with protocol to target SpO2 90-94%
223880182|NCT02945904|PROCEDURE|adrenalectomy|Unilateral adrenalectomy for Conn's adenoma
223880183|NCT04615819|OTHER|Kidney Transplant Fast Track (KTFT)|Streamlined KT evaluation involving completion of most or all testing on the same day a patient arrives for their first pre-transplant clinic appointment. Or, a transplant clinic scheduler secures testing within a 4 week period.
223880184|NCT04615819|OTHER|Peer Navigation (PN)|Uses trained, previous KT recipients who meet weekly to monthly with patient participants to provide tailored information and assistance in completing the necessary steps to proceed to transplant.
223880185|NCT04047810|BIOLOGICAL|Mesenchymal Stem Cells|0.5- 2 million cells/kg, intravenously once
223880186|NCT06319144|OTHER|5% glucose|Patients in the experimental group were infused intravenously with 5% dextrose (500 ml/h) in the PACU.
223880187|NCT06319144|OTHER|0.9% sodium chloride solution|Patients in the control group were infused intravenously with 0.9% sodium chloride solution in the PACU.
223880188|NCT04468399|OTHER|Routine medical record data collection|The study will collect routine medical record data from the electronic medical record system, other electronic databases, and paper charts.
223880189|NCT04468399|OTHER|Interviews with service providers|Clinicians and lay staff will be interviewed regarding the ART initiation process.
223880190|NCT02281097|OTHER|Stimulation|Application of current to skin above auricular branch of vagal nerve to modulate heart rate and symptoms
223880191|NCT02281097|OTHER|Placebo|Application of low intensive current or frequency to skin above auricular branch of vagal nerve as sham intervention
223880192|NCT06161753|BEHAVIORAL|Cognitive Functional Therapy|"CFT is an individualised, combined physical and behavioural approach specifically developed to target the multidimensional complexity of persistent LBP. CFT utilises a multidimensional clinical reasoning framework that enables the clinician to identify both modifiable and non-modifiable biopsychosocial factors (i.e. physical, cognitive, emotional, social, lifestyle and health comorbidities) underlying an individual's LBP. CFT targets these factors by: (1) helping the patient 'make sense of their pain' from a biopsychosocial perspective, (2) build confidence to engage in valued activities through functional movement training and (3) adopt positive lifestyle behaviours (O'Sullivan et al., 2018).~Participants will receive approximately 7 treatment sessions over a 13-week period, although this will vary depending on participant needs, in line with the individualised nature of the intervention. Participants will be provided a booster session at 26 weeks to reinforce self-management."
223880193|NCT06781567|DRUG|HG146|HG146 is available as Capsule at a unit dose strength of 5 mg and 10 mg.
223880194|NCT04247165|DRUG|Gemcitabine|800 mg/m2 Day 1, 8, 15: Q4W IV Infusion
223880195|NCT04247165|DRUG|Nab-paclitaxel|100 mg/m2 Day 1, 8, 15: Q4W IV Infusion
223880196|NCT04247165|DRUG|Nivolumab|3 mg/kg Day 1, Q4W IV Infusion
223880197|NCT04247165|DRUG|Ipilimumab|1 mg/kg Day 1 Cycle 1 IV Infusion
223880198|NCT04247165|RADIATION|SBRT|"Patients will be planned and treated with SBRT on a MRidian MR guided Linac.~Prescription dose shall be according to the following specifications:~* Prescription dose shall be according to the following specifications:~* A total dose of 24 Gy in 3 fractions (3 fractions/week) are prescribed as the mean dose to the PTV.~* Pauses are accepted but the treatment should be delivered within 10 calendar days.~* PTV should be covered by 95% isodose (PTV D99% \>95%)."
223880199|NCT03067467|DRUG|Hyperpolarized 13C-Pyruvate|Hyperpolarized 13C-pyruvate IV bolus followed by brain MRSI.
223880200|NCT03067467|DRUG|Gadolinium|Brain MRI performed with and without gadolinium-based contrast.
223880201|NCT06763042|DEVICE|Mindfulness-based Life Management Social Robots|Mindfulness-based life management contents for pediatric patients operated by Social Robots
223880202|NCT06763770|BEHAVIORAL|Managing Your Health (MYH)|The Managing Your Health intervention consists of six weekly videoconference calls with a peer mentor and five self-management educational modules within a mobile application. The first call is to get to know each other, share survivorship stories, identify self-management strengths and weaknesses, and select goals for participation in the intervention. The remaining five weekly calls cover a self-management topic each week, including understanding your survivorship care plan, navigating the healthcare system and insurance, managing the emotional aspects of survivorship, negotiating family and significant other involvement in care, and engaging in healthy lifestyle behaviors.
223880203|NCT06763770|BEHAVIORAL|The Usual Care + Educational Control|The Usual Care + Educational Control group will receive weekly emails with links to the Health Links developed by the Children's Oncology Group for use in survivorship care. Access to these Health Links reflects the current state of clinical care available to survivors. These Health Links were developed as patient education materials to cover relevant self-management and survivorship care topics. The weekly messages will align with the content of the modules from Managing Your Health to provide similar information, including Introduction to Long-Term Follow-Up (Module 1), Finding and Paying for Healthcare (Module 2), Emotional Issues (Modules 3 and 4), Educational Issues, Diet and Physical Activity, Skin Health, Reducing the Risk of Second Cancers, and Male/Female Health Issues (Module 5).
223880204|NCT06763211|PROCEDURE|Chlorhexidine Hair Bath|Intervention group 1 will have a hair bath with 5 ml of chlorhexidine gluconate solution 2 times consecutively. Intervention group 2 will first be given a hair bath using the patient's soap or shampoo. Afterwards, the hair will be bathed 2 times consecutively with 5 ml chlorhexidine gluconate solution. Hair bath will be given to the control group using the patient's own soap or shampoo. Surgical site infection follow-up form, laboratory findings form, vital signs form, culture follow-up form will be filled out before and after banyadon. Additionally, cultures will be taken from the surgical area with hair immediately after bathing, on the 2nd post-operative day, and on the day the stitches are removed.
223880205|NCT06826287|OTHER|7T MR exam|a 7 Tesla MRI scan, with a functional and anatomical dedicated protocol
223880206|NCT06826287|OTHER|clinical assessment|A comprehensive clinical assessment before the MRI exam.
223880207|NCT04256707|DRUG|Selinexor 100 mg|"100-mg 2 formulations:~* 5 × 20-mg tablets (Tablet A)~* 1 × 100-mg tablet (Tablet B)"
223880208|NCT04256707|DRUG|Docetaxel|75 mg/m\^2 IV
223880209|NCT04256707|DRUG|Pembrolizumab|200 mg IV
223880210|NCT04256707|DRUG|FOLFIRI|"FOLFIRI:~* Irinotecan 180 mg/m\^2~* Leucovorin 400 mg/m\^2~* 5-FU 400 mg/m\^2 bolus~* 5-FU 2400 mg/m\^2 IV"
223880211|NCT04256707|DRUG|Selinexor 40 mg|\- 2 × 20-mg tablets (Tablet A)
223880212|NCT04256707|DRUG|Selinexor 80 mg|\- 4 × 20-mg tablets (Tablet A)
223880213|NCT04256707|DRUG|Selinexor 60 mg|\- 3× 20-mg tablets (Tablet A)
223880214|NCT06098677|DIETARY_SUPPLEMENT|Carotenoids supplementation|Daily oral supplementation of a soft gel capsule containing 10mg lutein (L), 10mg meso-zeaxanthin (MZ) and 2mg zeaxanthin (Z).
223880215|NCT06098677|DIETARY_SUPPLEMENT|Placebo|Daily oral supplementation of a soft gel capsule containing only placebo oil
223880216|NCT06789536|OTHER|training nurses to prescribe nicotine substitutes, to adapt doses and to transmit to the outpatient physician and/or nurse nurse to facilitate the continuation of treatment|Nurses will undergo training sessions provided by the smoking cessation team to learn how to prescribe nicotine replacement therapy, adjust dosages, and forward a referral letter to the patient's primary care physician and/or community nurse for continuity of care. They will receive a dosage adjustment guide to share with patients. Upon completing the training, nurses will be authorized to prescribe nicotine replacement therapy using the hospital's prescription software.
223880217|NCT05236595|OTHER|Individualized drug matching per genetic disease|Patient phenotype and samples will be evaluated for individualized therapeutic drug development
223880218|NCT02707120|DRUG|PRGF-Endoret|Active treatment will be PRP eye drops obtained by the PRGF-Endoret system.
223880219|NCT02707120|DRUG|Artificial tears eye-drops|Artificial tear moisturizing eyedrops (Hidrathea®, Nacl 0.9 % solution without preservatives).
223880220|NCT05587036|DRUG|Rifaximin|Rifaximin oral tablet, 550 mg, twice daily, two-weeks
223880221|NCT05587036|DIETARY_SUPPLEMENT|Placebo|Placebo oral tablet, twice daily, two-weeks
223880222|NCT03433339|DEVICE|Active transcutaneous spinal direct current stimulation|Active anode electrodes placed at Thoracic 10 level, Cathode electrode placed on right shoulder.
223880223|NCT03433339|DEVICE|Sham transcutaneous spinal direct current stimulation|Sham anode electrodes placed at Thoracic 10 level, Cathode electrode placed on right shoulder.
223880224|NCT06223659|DRUG|Eutectic Mixture of Local Anesthetics|Apply topically to skin
223880225|NCT06223659|DRUG|Placebo Administration|Apply topically to skin
223880226|NCT06223659|OTHER|Questionnaire Administration|Ancillary studies
223880227|NCT06267586|DIETARY_SUPPLEMENT|PeptiSleep|Plant protein hydrolysate
223880228|NCT06267586|DIETARY_SUPPLEMENT|Placebo MCC micro-crystalline cellulose|Placebo MCC micro-crystalline cellulose
223880229|NCT04570735|DIAGNOSTIC_TEST|MRI|MRI
223880230|NCT06456866|OTHER|interpretation|interpretation of blood gases samples
223880231|NCT03525288|RADIATION|PSMA -PET/CT simulation|"* PET/CT simulation.~* If no additional lesions detected: RT as planned per standard care.~* If PSMA-PET/CT imaging consistent with oligometastases (1-5 lesions): all lesions must be treated with definitive RT.~* If PSMA-PET/CT imaging consistent with widely metastatic disease (\>5 lesions): treatment of all detected disease with RT is not recommended, but treatment of the primary site as initially planned is encouraged."
223880232|NCT03525288|RADIATION|Standard-care simulation|No PSMA-PET/CT as part of RT treatment planning.
223880233|NCT05332340|DRUG|BZ371A|Single dose topical administration of 1.5 mL with a concentration of 5 mg/mL of BZ371A.
223880234|NCT06739070|OTHER|Plyometric|Session will start with 9 minutes of warm up which includes 4 minutes of jogging and moderate intensity dynamic stretching for 5 minutes.. And 9 minutes cool down period. Following Plyometrics would be performed:1 medicine ball squats 2.ABC pushups 3.Medicine ball chest press 4.standing jump reach for star 5.SINGLE leg hops 6.Pushup on knees 7.zig zag double jump
223880235|NCT06739070|OTHER|Calisthenics|Session will start with 9 minutes of warm up which includes 4 minutes of jogging and moderate intensity dynamic stretching for 5 minutes.. And 9 minutes cool down period. Following Plyometrics would be performed:1 medicine ball squats 2.ABC pushups 3.Medicine ball chest press 4.standing jump reach for star 5.SINGLE leg hops 6.Pushup on knees 7.zig zag double jump
223880236|NCT06739070|OTHER|Control group (no intervention)|In control group no intervention would be given. Initial test would be performed at 4th and 8th week and then results would be compared with experimental group.
223880237|NCT06737406|DRUG|Topical 5% fluorouracil cream|Topical 5% fluorouracil cream twice daily for 21 days on the affected area (palmoplantar)
223880238|NCT06737406|DRUG|Topical 0.005% calcipotriol ointment|Topical 0.005% calcipotriol ointment twice daily for 21 days on the affected area (palmoplatar)
223880239|NCT06737406|DRUG|Placebo|A placebo ointment in identical tubes in terms of color and scent and with identical usage instructions to calcipotriol.
223880240|NCT06737406|DRUG|Placebo|A placebo cream in identical tubes in terms of color and scent and with identical usage instructions to fluorouracil.
223880241|NCT06328504|COMBINATION_PRODUCT|Cashew immunotherapy|Following the building-up phase (up to 60 weeks), patients will receive a daily low dose of cashew flour (1200 mg cashew protein) mixed with well-tolerated fruit mousse for 3 months (12 +/- 3 weeks).
223880242|NCT06738381|BEHAVIORAL|Digital intervention and motivational counselling|A single sesstion of motivational interviewing and access to a digital plattform for a six months period
223880243|NCT06736652|OTHER|Parabolic flight|Preflight each individual was exposed to the 3 Other Interventions and monitored for changes in behavioral performance and neurophysiological responses. In-flight the same monitoring was conducted during partial-gravity (0.25, 0.5. 0.75g) and microgravity (\~0g).
223880244|NCT03717415|DRUG|Rebastinib|Administered orally
223880245|NCT03717415|DRUG|Carboplatin|Administered by IV infusion
223880246|NCT04670081|DRUG|Psilocybin|25 mg, p.o.
223880247|NCT04670081|DRUG|Psilocybin|5 mg, p.o.
223880248|NCT04670081|DRUG|Nicotinamide|100 mg, p.o.
223880249|NCT03137771|RADIATION|3-Dimensional Conformal Radiation Therapy (3D-CRT)|Undergo 3DCRT
223880250|NCT03137771|DRUG|Docetaxel|Given IV
223880251|NCT03137771|DRUG|Gemcitabine|Given IV
223880252|NCT03137771|RADIATION|Intensity-Modulated Radiation Therapy (IMRT)|Undergo IMRT
223880253|NCT03137771|DRUG|Pemetrexed Disodium|Given IV
223880254|NCT03137771|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|Undergo SBRT
223880255|NCT03137771|DRUG|Erlotinib Hydrochloride|Given PO
223880256|NCT03137771|DRUG|Pembrolizumab|Given IV
223880257|NCT06740123|PROCEDURE|Nonsurgical periodontal treatment and application of H42® hydrogel to the peri-implant pocket|Firstly, after appropriate oral hygiene training, full mouth supragingival scaling will be performed using an ultrasonic device (EMS Piezon ultrasonic system, EMS Electro Medical Systems, Switzerland). Non-surgical periodontal treatment will be completed after subgingival curettage of peri-implant pocket areas between 5-8 mm in the contralateral quadrant. The tested site will be partially isolated and then air-dried. A bent, blunt-tipped needle syringe will be used to inject the H42® hydrogel into the pocket, ensuring that the tip reaches the deepest point of the pocket. Once the gel is visible at the gingival margin, the needle will be gently removed from the pocket. After approximately 0.1 mL of gel has been applied, excess gel will be removed with a sterile gauze swab to prevent any spreading effect or possible systemic effect. After application of the H42 hydrogel, the area will be kept dry for 5 minutes to ensure optimum adhesion of H42 to the pocket tissue.
223880258|NCT06740123|PROCEDURE|Nonsurgical periodontal treatment of periodontal pocket|Systemic and dental anamnesis will be taken from all patients. Firstly, after appropriate oral hygiene education, full mouth supragingival scaling will be performed using an ultrasonic device (EMS Piezon ultrasonic system, EMS Electro Medical Systems, Switzerland). Non-surgical periodontal treatment will be completed after subgingival curettage of periodontal pocket areas between 5-8 mm in the contralateral quadrant.
223880259|NCT06740123|PROCEDURE|Non-surgical periodontal treatment and application of H42® hydrogel to the periodontal pocket|Firstly, after appropriate oral hygiene training, full mouth supragingival scaling will be performed using an ultrasonic device (EMS Piezon ultrasonic system, EMS Electro Medical Systems, Switzerland). Non-surgical periodontal treatment will be completed after subgingival curettage of periodontal pocket areas between 5-8 mm in the contralateral quadrant. The tested site will be partially isolated and then air-dried. A bent, blunt-tipped needle syringe will be used to inject the H42® hydrogel into the pocket, ensuring that the tip reaches the deepest point of the pocket. Once the gel is visible at the gingival margin, the needle will be gently removed from the pocket. After approximately 0.1 mL of gel has been applied, excess gel will be removed with a sterile gauze swab to prevent any spreading effect or possible systemic effect. After application of the H42 hydrogel, the area will be kept dry for 5 minutes to ensure optimum adhesion of H42 to the pocket tissue.
223880260|NCT06740123|PROCEDURE|Nonsurgical periodontal treatment of peri-implant pocket|Systemic and dental anamnesis will be taken from all patients. Firstly, after appropriate oral hygiene education, full mouth supragingival scaling will be performed using an ultrasonic device (EMS Piezon ultrasonic system, EMS Electro Medical Systems, Switzerland). Non-surgical periodontal treatment will be completed after subgingival curettage of peri-implant pocket areas between 5-8 mm in the contralateral quadrant.
223880261|NCT06739928|DRUG|Irinotecan liposome (II) combined with adebrelimab and carboplatin|Irinotecan liposome (II) + adebrelimab + carboplatin
223880262|NCT06739928|DRUG|etoposide combined with adebrelimab and carboplatin|etoposide + adebrelimab + carboplatin
223880263|NCT06738615|DIAGNOSTIC_TEST|Pressure volume loop evaluation|During the left heart catheterization there are catheters which are introduced into the left ventricle to measure left ventricular pressures and into the coronary arteries to assess their patency. This study will require the placement of an additional specialized catheter made into the left ventricle to measure the change of pressure and volume during the cardiac cycle. This will allow the measurement of heart muscle stiffness.
223880264|NCT06738615|DIAGNOSTIC_TEST|cardiovascular magnetic resonance imaging|Patients will undergo standard cardiovascular magnetic resonance imaging of their heart to measure their heart size, heart function, and severity of mitral regurgitation. In addition, contrast will be administered and heart tissue will be assessed for scarring or fibrosis.
223880265|NCT06738615|DIAGNOSTIC_TEST|Cardiopulmonary exercise testing (CPET)|A CPET will be performed to objectively measure a patient ability to perform exercise.
223880266|NCT06738615|DIAGNOSTIC_TEST|Kansas City Cardiomyopathy Questionairre|This is a short questionnaire which objectively quantifies symptom burden
223880267|NCT03401853|OTHER|Laboratory Biomarker Analysis|Correlative studies
223880268|NCT03401853|BIOLOGICAL|Pembrolizumab|Given IV
223880269|NCT03401853|BIOLOGICAL|Rituximab|Given IV
223880270|NCT03401853|BIOLOGICAL|Obinutuzumab|Given IV
223880271|NCT06782204|DRUG|Paracetamol|At visit 2, complying subjects will receive a tablet containing 1 gram of paracetamol and have blood and urine samples collected 2 hours after administration.
223880272|NCT06478030|DIAGNOSTIC_TEST|questionnaire, Helicobacter pylori (H. pylori) test, fecal immunochemical test (FIT)|The questionnaire covers nine aspects: basic information of the participants, symptoms and previous examinations, medical history and surgical history, medication history, smoking history, alcohol consumption history, dietary habits, physical exercise, and family history.
223880273|NCT01898494|PROCEDURE|Transoral surgery|Undergo transoral surgical resection
223880274|NCT01898494|RADIATION|intensity-modulated radiation therapy|Undergo standard-dose or low-dose IMRT
223880275|NCT01898494|DRUG|cisplatin|Given IV
223880276|NCT01898494|DRUG|carboplatin|Given IV
223880277|NCT06091215|DEVICE|Sciton Joule System|Sciton Joule System
223880278|NCT05540002|DEVICE|High Intensity Quell|Participants will receive 1 hour of continuous stimulation during each therapy session. Subjects are asked to complete a minimum of 3 sessions per day.
223880279|NCT05540002|DEVICE|Low Intensity Quell|Participants will receive only three 2-minute periods of stimulation (at 0, 28, 58 minutes) during each 60-minute therapeutic session. Subjects are asked to complete a minimum of 3 sessions per day.
223880280|NCT06780657|BEHAVIORAL|Online hypopressive exercise training program|The hypopressive exercises were based on recommendations from the literature and consultation with an expert in the field. Each session will be held twice a week for 20-25 minutes. Participants will perform each exercise 10 times during these sessions.
223880281|NCT03289039|DRUG|Neratinib|Neratinib is a recently discovered oral drug that may stop breast cancer cells from growing abnormally by inhibiting (or blocking) members of a family of proteins that include Human Epidermal Growth Factor Receptor 2 (HER2)
223880282|NCT03289039|DRUG|Fulvestrant|Fulvestrant, works in treating breast cancer that has spread to other parts of the body
223880283|NCT02961660|DRUG|Odalasvir|Participants will receive odalasvir 25 mg tablet, orally.
223880284|NCT04621357|RADIATION|Brain MRI|Brain MRI will include differents sequences.
223880285|NCT04621357|BIOLOGICAL|Biological biomarkers|Biological biomarkers will include a set of systemic inflammatory markers
223880286|NCT05739175|DEVICE|Mobile Application with Interactive Nurse Support|"A mobile application containing an interactive nurse support program will be applied to the patients in the experimental group and its effect on patient outcomes will be evaluated through scales.~The mobile application consists of three modules. The first part is a learning module with videos on Covid 19, breast cancer and chemotherapy related side effects management. Second part is ask the nurse/doctor. Third part is patient experiences module.~After the participants download the mobile application to their phones, they can log in to the application with a valid e-mail address and password."
223880287|NCT06798285|PROCEDURE|Pars Plana Vitrectomy Standard|Group I: PPV with endoillumination set at 3.2 Lm.
223880288|NCT06798285|PROCEDURE|Pars Plana Vitrectomy 3D|Group II: PPV with endoillumination set at 0.5 Lm.
223880289|NCT04732494|BIOLOGICAL|Tislelizumab|Tislelizumab is a monoclonal antibody formulated for intravenous injection.
223880290|NCT04732494|BIOLOGICAL|Ociperlimab|Ociperlimab is a monoclonal antibody formulated for intravenous injection.
223880291|NCT04732494|DRUG|Placebo|Ociperlimab placebo injection is a sterile, preservative-free solution for infusion formulated in the same buffer as ociperlimab active drug.
223880292|NCT06795061|BEHAVIORAL|Peer-Supported Exercise with Professional Guidance|Participants will engage in small, peer-supported exercise groups (4-6 individuals) to coordinate weekly sessions (e.g., running, cycling, yoga). A professional coach provides knowledge-based guidance remotely, focusing on safe exercise techniques, injury prevention, basic nutrition, and motivation strategies, but does not conduct in-person training sessions. The aim is to improve adherence to physical activity and enhance mental well-being through peer accountability and evidence-informed coaching.
223880293|NCT04456478|PROCEDURE|pH at 7.38 ± 0.02|In the 3 centers of the study, IVF-ICSI will be performed according to the usual procedure: ovarian stimulation, oocyte retrieval, sperm microinjection by ICSI, embryo culture in Global® Total HSA medium, embryo selection and transfer at day 3. The day of the oocyte puncture, the embryologist will proceed to the 1: 1 randomization: culture of the embryos in a medium with a pH at 7.38 ± 0.02. We have chosen to study specifically the early stages of fertilization and embryo development (until day 3), stages for which extracellular pH control is more critical because the intracellular pH regulatory mechanisms are somewhat limited and could be exceeded.
223880294|NCT04456478|PROCEDURE|pH at 7.22 ± 0.02|In the 3 centers of the study, IVF-ICSI will be performed according to the usual procedure: ovarian stimulation, oocyte retrieval, sperm microinjection by ICSI, embryo culture in Global® Total HSA medium, embryo selection and transfer at day 3. The day of the oocyte puncture, the embryologist will proceed to the 1: 1 randomization: culture of the embryos in a medium with a pH at 7.22 ± 0.02. We have chosen to study specifically the early stages of fertilization and embryo development (until day 3), stages for which extracellular pH control is more critical because the intracellular pH regulatory mechanisms are somewhat limited and could be exceeded.
223880295|NCT05744960|BEHAVIORAL|Communication training|Clinics will host an Announcement Approach Training (AAT) workshop. A trained facilitator will use a standard script and slides to deliver workshop in-person or over Zoom; clinical staff who are unavailable will take the workshop later on their own.
223880296|NCT05744960|BEHAVIORAL|financial Incentive|Clinics will host an AAT workshop, as in the other trial arm. Clinics in the intervention arm will then receive a 12-month clinic-level financial incentive program with predetermined targets for HPV vaccine initiation rates (5%, 10%, and 30% increases from baseline). Clinics will be notified of their HPV vaccination rates though a monthly, automated report. Clinic achievement will be assessed and incentives will be paid out to clinics monthly. Incentives will be tiered based on target and sized based on the number of clinic providers. For reaching the highest tier of 30%, clinics will receive an aggregate of $1000 per provider.
223880297|NCT06583135|OTHER|Sleep hygiene education and motivational interviewing|The intervention group, will receive face-to-face sleep hygiene training and then 4 online motivational interviews will be held within 6 weeks. The online motivational interviews will be implemented in the 1st week (interview 1), 2nd week (interview 2), 4th week (interview 3), and 6th week (interview 4).
223880298|NCT06583135|OTHER|face-to-face sleep hygiene training|The control group receive face-to-face sleep hygiene training
223880299|NCT06495190|DIETARY_SUPPLEMENT|Blueberry|50 g/d blueberry powder supplement
223880300|NCT06495190|BEHAVIORAL|Walking|Five 45-min walking sessions per week
223880301|NCT06495190|DIETARY_SUPPLEMENT|Placebo|50 g/d placebo powder supplement
223880302|NCT06495190|BEHAVIORAL|Stretching|Five 45-min stretching sessions per week
223880303|NCT04073290|DRUG|Rifaximin 550 milligram Oral Tablet [XIFAXAN]|Rifaximin 550 milligram b.i.d. 72 hours before TIPS placement till 3 months post-TIPS
223880304|NCT04073290|DRUG|Placebo oral tablet|Placebo b.i.d. 72 hours before TIPS placement till 3 months post-TIPS
223880305|NCT04073290|DRUG|Lactulose 667 milligram/milliliter Oral Solution|Lactulose based on soft stool frequency, 72 hours before TIPS placement till 3 months post-TIPS
223880306|NCT06453824|DRUG|MDI-2517|study drug
223880307|NCT06453824|OTHER|Placebo|matching placebo
223880308|NCT05869656|BEHAVIORAL|Fluid restriction|Oral fluid restriction of 1000ml per day
223880309|NCT05869656|BEHAVIORAL|Free fluids|Continue care without any oral fluid restriction
223880310|NCT05792137|OTHER|High saturated fat challenge meal|High saturated fat challenge meal made with palm oil
223880311|NCT05792137|OTHER|High mono unsaturated fat challenge meal|High mono unsaturated fat challenge meal made with olive oil
223880312|NCT05504226|DRUG|Teneligliptin (as Teneligliptin Hydrobromide) 20 Mg Oral Tablet|To be orally administered once daily for 52 weeks.
223880313|NCT05504226|DRUG|Teneligliptin Placebo Oral Tablet|To be orally administered once daily for 52 weeks. This arm will be switched to teneligliptin from week 24.
223880314|NCT05765344|DRUG|Bulevirtide|Administered via subcutaneous injections.
223880315|NCT06799884|DRUG|Ethinyl Estradiol / Levonorgestrel Oral Tablet|Coated tablet of 20 µg ethinyl estradiol and 100 µg levonorgestrel
223880316|NCT06799884|DRUG|Aprocitentan|Film-coated tablet of aprocitentan 25 mg
223880317|NCT06479590|DEVICE|tDCS|The DCS electrode sheaths of 7x5 cm will be soaked with standard saline solution(NaCl 9%) and fixed by elastic bands. tDCS will deliver 20 min of anodal stimulation (1-2mA, fade in/out 8 sec)
223880318|NCT06479590|OTHER|Sham tDCS|sham-tDCS will be applied for 30 s to make it difficult for the individual to distinguish the placebo from a real tDCS application
223880319|NCT06310200|DRUG|Lidocaine Topical 4% Topical Solution|Intranasal administration
223880320|NCT06310200|DRUG|Bitrex|Bittering agent
223880321|NCT06310200|DRUG|normal saline|Placebo
223880322|NCT05946109|BEHAVIORAL|ACTIVE-AGE@home|"functional, homebased training program offering basic functional exercises connected to meaningful activities, lifestyle coaching and motivational interviewing; derived from evidence-based training principles . Through a precise application of the FITT-VP\* guidelines, a progressive and balanced program was designed and piloted in different proof-of-concept studies. The uniqueness of the program lies in the multi-component approach which brings together functional exercises for (1) muscle strength/muscle endurance, (2) aerobic endurance, (3) flexibility, motor ability and balance and (4) meaningful daily activities, in a home-based environment.~The frail participants are visited three times a week during 24 weeks with in total 72 sessions. Each session is 1 hour in duration. Thus they receive 72 training hours.~\*(Frequency, Intensity, Time, Type of exercises, Volume and Progression)"
223880323|NCT05178810|DRUG|FAB122|Daily dose 100 mg
223880324|NCT05178810|DRUG|Placebo|Daily dose
223880325|NCT04423250|OTHER|impact of the intervention of a clinical pharmacist with expertise in sterile medical devices on non-compliances related to the use of sterile medical devices|\- Failure to trace, Lack of product information, absence of product in the operating room
223880326|NCT05151315|DEVICE|Total Knee Arthroplasty with Evolution® NitrX™ Knee System|Patients will receive cemented Evolution knee system with NitrX coating for their total knee arthroplasty.
223880327|NCT05151315|DEVICE|Total Knee Arthroplasty with Evolution Knee System|Patients will receive cemented Evolution knee system without NitrX coating for their total knee arthroplasty.
223880328|NCT04080128|DEVICE|Contact lenses|Depending on the results of the BLINK Study either a single vision spherical contact lens or a multifocal contact lens.
223880329|NCT05136404|DRUG|Selpercatinib|Administered orally
223880330|NCT06149598|BEHAVIORAL|Coughing at the time of biopsy|Patients are asked to cough or not to cough during cervical biopsy.
223880331|NCT04906200|OTHER|Best Practice|Receive usual care
223880332|NCT04906200|OTHER|Internet-Based Intervention|Receive access to YES portal
223880333|NCT04906200|OTHER|Survey Administration|Complete survey
223880334|NCT05798585|PROCEDURE|ESP block|US guided ESP infiltration (saline solution vs Ropivacaine 0.375% according to randomization): unilateral injection of 0,4 ml kg -1 (ideal weight)2 under US guidance between the deep fascia of erector spinae muscle and the two transverse processes at the level of the 5th thoracic vertebrae. Duration approximately 10-15 minutes
223880335|NCT00448240|DRUG|Erlotinib|loading dose of 300 mg on Day 2 followed by 150 mg daily Days 3 - 17 of each cycle of paclitaxel and cisplatin/carboplatin
223880336|NCT04187040|PROCEDURE|Study intervention: 3-step hand hygiene technique|"3-step hand hygiene technique:~1. Covering all surfaces of the hands (based on own judgement)~2. Rotational rubbing of fingertips in the palm of the alternate hand~3. Rotational rubbing of both thumbs"
223880337|NCT04187040|PROCEDURE|Control intervention: 6-step hand hygiene technique|"6-step hand hygiene technique (according to the WHO Guidelines on Hand Hygiene in Health Care, First Global Patient Safety Challenge):~1. Rubbing hands palm to palm~2. Palm to palm with fingers interlaced~3. Right palm over left dorsum with interlaced fingers and vice versa~4. Back of fingers to opposing palms with fingers interlocked~5. Rotational rubbing of left thumb clasped in right palm and vice versa~6. Rotational rubbing backwards and forwards with clasped fingers of right hand in left palm and vice versa"
223880338|NCT06030609|DRUG|Ringer's Lactate Crystalloid Solutions|The patient will receive RLS as a replacement fluid for urine output (mL per mL) until the patient have sufficient oral intake and fluid can be removed.
223880339|NCT06030609|DRUG|Normal saline|The patient will receive NSS with D5W as a replacement fluid for urine output (mL per mL) until the patient have sufficient oral intake and fluid can be removed.
223880340|NCT05253833|DRUG|AR882 Dose 1|Solid Oral Capsule
223880341|NCT05253833|DRUG|AR882 Dose 2|Solid Oral Capsule
223880342|NCT05253833|DRUG|Allopurinol Tablet|Solid tablet
223880343|NCT05769660|DRUG|BEY1107|Administer twice daily, PO, 4-week continuous dose.
223880344|NCT05769660|COMBINATION_PRODUCT|Temozolomide|Administer once daily, PO, 5-day continuous dose, followed by 23-day rest period.
223880345|NCT03148743|BIOLOGICAL|Fecal microbiota|fecal microbiota transplantation
223880346|NCT05512962|DRUG|Triamcinolone Acetonide|Single suprachoroidal Administration of Triamcinolone acetonide
223880347|NCT05512962|DEVICE|Semi-automated Suprachoroidal Microcatheter|Ophthalmic Adminstration Device
223880348|NCT02860130|DRUG|Prismocitrate 18|Modality of CVVHDF
223880349|NCT02860130|OTHER|No Anticoagulation|Modality of CVVHDF
223880350|NCT06484595|OTHER|Best Practice|Receive SOC supportive care services
223880351|NCT06484595|BEHAVIORAL|Patient Navigation|Receive clinical trial navigator guide services
223880352|NCT03915964|DRUG|Baricitinib|Administered orally.
223880353|NCT03915964|DRUG|TNF Inhibitor|Administered SC
223880354|NCT03772561|DRUG|AZD5363+Olaparib+Durvalumab|Patients will receive AZD5363 orally twice a day 4 days-on/ 3 days-off starting 14 days prior to cycle 1 day 1 (C1D1). Olaparib continuously twice a day at 300mg and Durvalumab intravenously at 1500mg once every 4 weeks will commence at C1D1. Treatment will continue until disease progression or the development of unacceptable toxicities.
223880355|NCT06456242|BEHAVIORAL|CounsCM+MedCM (Health Rewards)|Small financial incentives for completing quitline calls (CounsCM) plus small financial incentives for taking varenicline (MedCM).
223880356|NCT06062966|DRUG|Anakinra|Anakinra 100 mg SC daily will be administered to sujects on chronic inotrope treatment who are not candidates for transplantation or left ventricular assist device (LVAD).
223880357|NCT03954678|BEHAVIORAL|Exercise Group|For the first two days after their pre-operative visit, participants will be asked to continue their present level of exercise and activity, which will be monitored by pedometer. Participants will begin the activity intervention on study Day 3. Participants will be instructed to take 10,000 steps per day, recording their daily steps with a pedometer. Participants also will be provided with resistance bands and instructed on how to safely perform 10 whole-body strength training exercises. They will be instructed to perform the exercises once per day, three days a week. Participants will complete the exercise intervention until they have surgery, which is typically 12 to 48 days after the pre-operative visit.
223880358|NCT03954678|DIETARY_SUPPLEMENT|Nutrition Group|Participants in the nutrition group will be provided with a liquid over-the-counter nutrition supplement (i.e. Boost or Ensure) to consume. Participants will be instructed to consume 1 bottle, 2 times per day, beginning 5 days before surgery and continuing 5 days post-operatively.
223880359|NCT05575076|DRUG|Simufilam|simufilam 100 mg oral tablet, twice daily
223880360|NCT06965712|DEVICE|Point-of-Care Ultrasound (POCUS)|Participants assigned to this group will receive Point-of-Care Ultrasound (POCUS) evaluations of the lungs and inferior vena cava (IVC) during their hospital stay. The ultrasound will be performed twice: once within 24 hours of hospital admission and once prior to hospital discharge. The POCUS findings will be used to guide clinical management decisions regarding fluid status and decongestion therapy in patients with decompensated heart failure. The procedure is non-invasive, radiation-free, and performed at the bedside.
223880361|NCT03459677|BEHAVIORAL|Back2School|Modular Trans-diagnostic Cognitive Behavioral Therapy treating school absenteeism in youths
223880362|NCT03459677|OTHER|Treatment As Usual|Aarhus municipality's treatment as usual for youths presenting school absenteeism
223880363|NCT04164459|DRUG|Xalost S|One drop one times a day in study eye
223880364|NCT04164459|DRUG|Xalatan|One drop one times a day in study eye
223880365|NCT04164459|DRUG|Taflotan-S|One drop one times a day in study eye
223880366|NCT01127373|RADIATION|Multi-Beam Intensity-Modulated Radiation Therapy|IMRT with multiple beams will be utilized to treat the breast or chest wall and axillary, supraclavicular and internal mammary lymph nodes. Treatment will be delivered once a day, 5 days a week for approximately 5 weeks. All missed radiation treatment visits will be made up. Daily set-up error will be checked prior to the delivery of every treatment.
223880367|NCT01127373|BEHAVIORAL|BreastQ questionnaire-|MSKCC Department of Surgery. For patients who received a mastectomy with or without reconstruction, the questionnaire will be administered at baseline and 5-7 months after treatment.
223880368|NCT05722158|DIETARY_SUPPLEMENT|Dietary supplementation with placebo.|Volunteers will be provided with the placebo. For each volunteer, a blood sample from digital puncture will be obtained, and collagen-derived amino acids, di-peptides and tri-peptides will be quantified by LC-MS.
223880369|NCT05722158|DIETARY_SUPPLEMENT|Dietary supplementation with the collagen-based product CP1.|Volunteers will be provided with the collagen-derived product CP1. For each volunteer, a blood sample from digital puncture will be obtained, and collagen-derived amino acids, di-peptides and tri-peptides will be quantified by LC-MS.
223880370|NCT05722158|DIETARY_SUPPLEMENT|Dietary supplementation with the collagen-based product CP2.|Volunteers will be provided with the collagen-derived product CP2. For each volunteer, a blood sample from digital puncture will be obtained, and collagen-derived amino acids, di-peptides and tri-peptides will be quantified by LC-MS.
223880371|NCT05722158|DIETARY_SUPPLEMENT|Dietary supplementation with the collagen-based product CP3.|Volunteers will be provided with the collagen-derived product CP3. For each volunteer, a blood sample from digital puncture will be obtained, and collagen-derived amino acids, di-peptides and tri-peptides will be quantified by LC-MS.
223880372|NCT05722158|DIETARY_SUPPLEMENT|Dietary supplementation with the collagen-based product CP4.|Volunteers will be provided with the collagen-derived product CP4. For each volunteer, a blood sample from digital puncture will be obtained, and collagen-derived amino acids, di-peptides and tri-peptides will be quantified by LC-MS.
223880373|NCT02009813|PROCEDURE|Hyperbaric Oxygen Therapy|Participants will undergo 2 treatments of hyperbaric oxygen. Each treatment consists of 90 minutes compression at 2 atmospheres of pressure, with 30 minutes decompression back to 1 atmosphere. During this time, patients will be treated with 100% oxygen delivered via a hood system.
223880374|NCT02218060|PROCEDURE|Coronary CT angiography on SOMATOM Force|Coronary CT angiography using iodinated contrast; metoprolol and/or nitroglycerin may also be administered on a per-patient basis
223880375|NCT02218060|PROCEDURE|Previous coronary CT angiography on 2nd generation CT scanner|Clinically indicated coronary CT angiography previously performed on a 2nd generation CT scanner
223880376|NCT05097417|COMBINATION_PRODUCT|traditional Chinese medicine and ablation in the primary tumor sites|Patients will be treated with traditional Chinese medicine and ablation in the primary tumor sites
223880377|NCT05097417|PROCEDURE|ablation|Patients will be treated with ablation in the primary tumor sites
223880378|NCT02290613|DRUG|Ambrisentan|"Titration:~As common practice of the clinic, the patient will adapt the dose from 5 mg to 10 mg after 1 to 4 weeks according to tolerability and after consultation (by phone or personally) with one of the investigators.~Additionally, at each study visit the investigator needs to decide, based on the patient's well-being, patients´ assessment, safety parameters, and tolerance of ambrisentan, if the study medication should be modified. The respective decision (increase, maintain or decrease dose) must be documented.~Maximum dose allowed: not to exceed 10 mg/day.~Administration:~Ambrisentan and placebo will be administered orally with or without food intake."
223880379|NCT02290613|DRUG|Placebo|Placebo tablet (one to two tablets corresponding to one to two verum tablets)
223880380|NCT02713126|DRUG|Placebo|administered orally or inhaled, taken every 4 hours or 3 times per day during waking hours for 12 weeks
223880381|NCT02713126|DRUG|Sodium Nitrite|administered orally or inhaled, 40 mg, taken every 4 hours or 3 times per day during waking hours for 12 weeks
223880382|NCT02713126|DEVICE|Accelerometer|External triaxial accelerometer is worn externally at the hip during exercise training sessions, and day/night to continuously measure activity levels, removed for bathing only.
223880383|NCT02713126|OTHER|Cardiac Exercise Training|Cardiac rehabilitation exercise training consisting of supervised endurance and strength exercise training of approximately one hour, 3 times per week for 12 weeks.
223880384|NCT03750539|RADIATION|Standard radiotherapy|External Bean Pelvic Radiation: 50 Gy in 15 fractions, with weekly cisplatin.
223880385|NCT03750539|RADIATION|hypofractionated radiotherapy|External Bean Pelvic Radiation: 37.5 Gy in 15 fractions, with weekly cisplatin.
223880386|NCT03750539|PROCEDURE|Radical hysterectomy|Radical hysterectomy and pelvic and paraaortic lymph node resection
223880387|NCT00100698|DRUG|recombinant human growth hormone|growth hormone dosed by weight and IGF-1 level,subcutaneously once a day, 18 months
223880388|NCT00100698|DRUG|placebo|placebo subcutaneously once a day, 18 months
223880389|NCT02909192|DEVICE|Light Therapy Device|
223880390|NCT00374959|DRUG|ceftriaxone|
223880391|NCT00374959|DEVICE|Endotracheal tube for aspiration of subglottic secretions.|
223880392|NCT05950867|DIAGNOSTIC_TEST|ECG + echocardiography|Electrocardiogram and echocardiography
223880393|NCT05950867|OTHER|Answering questionnaires|Answering questionnaires about polyneuropathy symptoms (NTSS -6, COMPASS31, NIS, mPND) and also cardialogical symptoms (KCCQ-12).
223880394|NCT02035904|DRUG|Levobupivacaine PCIA (Patient Controlled Intrawound Analgesia)|patient controlled infusion from the 2nd day after surgery
223880395|NCT02035904|DRUG|saline|patient controlled infusion from the 2nd day after surgery
223880396|NCT02035904|DRUG|Levobupivacaine continuous infusion|Continuous infusion Levobupivacaine 0,25% 5ml/h for 24 hs in all patients
223880397|NCT02035904|DEVICE|intrawound infusion catheter|placed by surgeon at the end surgery in all patients
223880398|NCT02035904|DRUG|morphine|PCA with morphine: 0,5 mg/ml bolus 1 mg lock-out 5 min max 20 mg in 4 hs - for the first 24 hs as rescue analgesia
223880399|NCT02035904|DRUG|Patrol|tramadol-paracetamol 37,5/325 mg oral fix combination-rescue analgesia from 2nd day (after morphine PCA removal)
223880400|NCT02376790|DRUG|Etanercept|Etanercept was administered by subcutaneous injection once a week
223880401|NCT02376790|DRUG|Methotrexate|Methotrexate capsules taken orally once a week. Dosing was initiated at 10 mg weekly and titrated up to a final dose of 20 mg weekly over a 4-week period.
223880402|NCT02376790|DRUG|Placebo to Etanercept|Placebo to etanercept was administered by subcutaneous injection once a week.
223880403|NCT02376790|DRUG|Placebo to Methotrexate|Placebo to methotrexate capsules taken orally once a week.
223880404|NCT00044564|DRUG|Bay 59-8862|75 mg/m2 of BAY 59-8862 intravenously over one hour. Treatment will be repeated once every 3 weeks and tumor measurements will be made every 2 cycles till progression, unacceptable toxicity or consent withdrawal
223880405|NCT00831688|DEVICE|Meniett(C) device by MedTronic|pulsed pressure application, up to 12 cm H20 column, 3 times daily for 5 minutes, generated by Meniett device and conducted to middle ear cavity via tympanostomy tube
223880406|NCT00831688|DEVICE|placebo treatment|device seemingly identical to active device, manufactured by Medtronic. 3 times daily for 5 minutes.Produces similar sound effect, but without pulsed pressure elevation.
223880407|NCT05450458|DRUG|KNEE JOINT INFILTRATION WITH HYALURONIC ACID WITH SORBITOL SYNOLIS VA|KNEE INFILTRATION WITH HYALURONIC ACID WITH SORBITOL IN SPORTSMEN
223880408|NCT04974567|OTHER|Schirmer Strip|A tear-based screening assay for breast cancer developed and validated by Namida Lab, Inc., a high complexity CLIA certified lab. It consists of two parts: tear sample collection using a Schirmer Strip and a clinical lab-developed test that measures protein biomarkers for breast cancer screening.
223880409|NCT05607199|DRUG|AUR103|Twice Daily
223880410|NCT04452201|BEHAVIORAL|Guided Participation|GP couples' participation together in development of communication competencies in the context of infant care will be supported by a handbook and telephone guidance structured for collaboration with the nurse/research assistant beginning at approximately 2 weeks of age. Two face-to-face sessions are expected prior to hospital discharge, followed by 5 or 6 monthly phone sessions. If the baby is inpatient at the time an intervention session is to take place, the session may be done face-to-face, if more convenient than a phone session for the parents.
223880411|NCT03205436|OTHER|Affinity human amniotic membrane|fresh hypothermically stored human amniotic membrane
223880412|NCT06376058|DRUG|Chloroprocaine 1% Injectable Solution|• in parturients allocated to the chloroprocaine group, a fixed dose of chloroprocaine 1% will be administered intrathecally
223880413|NCT06376058|DRUG|Ropivacaine 0.75% Injectable Solution|• in parturients allocated to the ropivacaine group, a fixed dose of ropivacaine 0.75% will be administered intrathecally
223880414|NCT04552509|RADIATION|Stereotactic Body Radiotherapy|Treatment of prostate cancer with stereotactic body radiation therapy (SBRT)
223880415|NCT05046171|OTHER|Pharmacist-led deprescribing|A pharmacist recruited onto the study will review the patient's current medication list and develop a list of targeted recommendations for deprescribing using the 3-step potentially inappropriate medications identification method.
223880416|NCT05046171|OTHER|Patient education|Subjects receive a written pamphlet about deprescribing.
223880417|NCT05633719|OTHER|Chemotherapy involving cisplatin or carboplatin|Chemotherapy
223880418|NCT03865056|DEVICE|Optiflow (High-flow Nasal Cannula)|Optiflow will be applied for 20 minutes
223880419|NCT03865056|DEVICE|Non-invasive Ventilation|non-invasive ventilation will be applied for 20 minutes
223880420|NCT05069974|DRUG|Linezolid 600 mg|After randomized to the experimental arm, the patient will take 1 tablet of Linezolid every 12hours during 10 days or 1 tablet of of Linezolid every 24hours during 5 days.
223880421|NCT05069974|DRUG|Benzathine Penicilllin G|After randomized to the control arm, the patient will receive a single dose of intramuscular BPG.
223880422|NCT05056077|OTHER|Counseling|Receive support person coaching
223880423|NCT05056077|OTHER|Educational Intervention|Receive personal report and booklet on nutrition and physical activity for patients with a history of cancer
223880424|NCT05056077|BEHAVIORAL|Health Education|Receive health coaching
223880425|NCT05056077|OTHER|Health Promotion and Education - Direct Text Messaging|Receive text messages
223880426|NCT05056077|OTHER|Health Promotion and Education - Digital health tool kit|Receive digital health tool kit
223880427|NCT05056077|OTHER|Questionnaires|Quality of Life and Behavioral Questionnaires
223880428|NCT02794480|DEVICE|ELLIPTA DPI|It is the inhaler with two blister strips containing white coloured powder, one placebo strip containing lactose monohydrate and a second placebo strip containing lactose monohydrate blended with magnesium stearate. It is given as oral inhalation (Inhalation powder)
223880429|NCT02794480|DEVICE|GSK MDI|It is the placebo inhaler with clear liquid containing propellant (1,1,1, 2- Tetrafluoroethane). It is given as oral inhalation (Inhalation Aerosol).
223880430|NCT02794480|DEVICE|AZ MDI|It is the placebo inhaler with clear liquid. It is given as oral inhalation (Inhalation Aerosol).
223880431|NCT03818100|RADIATION|Intensity modulated radiotherapy (IMRT)|Simultaneous integrated boost technique using IMRT: 48 Gray (Gy) and 40 Gy will treat tumour and breast tissue respectively, in 15 fractions over 3 weeks.
223880432|NCT03818100|DRUG|Endocrine therapy|Endocrine therapy will commence following completion of radiotherapy, and will continue for 20 weeks.
223880433|NCT03818100|PROCEDURE|Breast conserving surgery|Surgery carried out using local protocol following completion of endocrine therapy.
223880434|NCT03037892|DRUG|Midazolam, Fentanyl|Two minutes before the colonoscopy procedure, a bolus of midazolam 0.03mg/Kg and 1.5microgram/Kg fentanyl will be given intravenously over 60 sec in group 1. 0.5 mg of midazolam intravenously can be given every two minutes till the patient is sufficiently sedated (sleeping but arousable on calling). The colonoscopy can start at this end point. Increments of 0.5mcg/Kg of fentanyl will be given if patient complains of pain, which can be repeated every 5 minutes if there is persistent pain.
223880435|NCT03037892|DRUG|Midazolam, Remifentanil|The patient in group 2 Target controlled infusion of Remifentanil to 3.0 ng/ml will be started 2 minutes before procedure. The patient will then be given same doses of midazolam in 0.5 mg increments till sedated sufficiently (sleeping but arousable on verbal command). During Colonoscopy the dose of Remifentanil could be increased by 0.5ng/ml if patient complained of pain upto 4.0ng/ml.
223880436|NCT03037892|DRUG|Remifentanil|The group 3 patient will receive only Remifentanil in the same doses as given in group
223880437|NCT00262301|DRUG|recombinant human C1 inhibitor|IV
223880438|NCT00262301|DRUG|Placebo|IV
223880439|NCT02023710|DRUG|Paclitaxel|175 mg/m\^2 by IV infusion on the first day of each 4-week cycle (dose was based on patient's weight and could be adjusted for weight change)
223880440|NCT02023710|DRUG|Carboplatin|Dose based on patients' creatinine clearance (Calvert formula) and administered by intravenous (IV) infusion on the first day of each 4-week cycle
223880441|NCT02023710|DRUG|Bevacizumab|5mg/kg by intravenous (IV) infusion every two weeks of each 4-week cycle (dose was based on patient's weight at screening and remained the same throughout study)
223880442|NCT00015067|DRUG|Methylphenidate|
223880443|NCT04251013|DEVICE|Biliary brushing with the RX Cytology brush, Boston Scientific|"Biliary brushing during ERCP:~* Performing a dozen back and forth movements in the stenosis~* Bile aspiration if possible, by the catheter of the brush for cytological analysis~* The contents of the brush will be spread over 3 blades (numbered) then sectioned and placed in cytolit with the contents of the tubing of the brush flushed with a few cc of cytolit. Each brush in a numbered pot. Blades 1,2 and 3 +/- bile 1 joined to pot n ° 1; blades 4,5 and 6 +/- bile 2 joined to pot 2~  * In the event of technical failure (impossibility of accessing the stenosis with the first or second brush, impossibility of removing the brush), the patient will be considered to have failed for this brush (absence of pathological material brought back)"
223880444|NCT04251013|DEVICE|Biliary brushing with the Infinity® brush, US Endoscopy|"Biliary brushing during ERCP:~* Performing a dozen back and forth movements in the stenosis~* Bile aspiration if possible, by the catheter of the brush for cytological analysis~* The contents of the brush will be spread over 3 blades (numbered) then sectioned and placed in cytolit with the contents of the tubing of the brush flushed with a few cc of cytolit. Each brush in a numbered pot. Blades 1,2 and 3 +/- bile 1 joined to pot n ° 1; blades 4,5 and 6 +/- bile 2 joined to pot 2~  * In the event of technical failure (impossibility of accessing the stenosis with the first or second brush, impossibility of removing the brush), the patient will be considered to have failed for this brush (absence of pathological material brought back)"
223880445|NCT04770649|BIOLOGICAL|COVID-19 vaccine|Any vaccine for COVID-19
223880446|NCT01017146|DRUG|Tazarotene foam|Tazarotene foam once a day application to the face
223880447|NCT01017146|DRUG|Vehicle Foam|Vehicle Foam once a day application to the face
223880448|NCT02241070|BEHAVIORAL|mindulness-based intervention|"A number of mindfulness techniques, including both formal and informal practices with integration in the context of Mind/Body meditation, were explored in order to cultivate moment-by-moment present awareness with non-judgmental acceptance."
223880449|NCT01084707|DRUG|Oral Nicotine|Oral Nicotine either self-administered or provided by study personnel within 12 hours
223880450|NCT01084707|DRUG|Nicotine Lozenge|Nicotine lozenge marketed as NiQuitin™ 4 mg hourly within 12 hours
223880451|NCT01084707|DRUG|Nicotine gum|Nicotine gum marketed as Nicorette® 4 mg hourly within 12 hours
223880452|NCT04850586|OTHER|Education Group|The patients in the training group were given structured training by a multidisciplinary team. After the content of the structured education was prepared, three experts were consulted for their opinions in terms of the scope and content. Necessary adjustments were made in line with their recommendations. Patients in this group were visited in their rooms at least 12 hours before undergoing surgery by a multidisciplinary team consisting of a surgeon, an anesthesiologist, and a nurse. The multidisciplinary team visited the patients at the same time and provided their education after introducing the team. Structured verbal education and written documents were given to the patients for 30 minutes on preoperative preparation, anesthesia, intubation, mobilization, deep breathing and coughing exercises, nutrition and fluid management, the postoperative recovery process, clinical practice guideline and operating room protocols.
223880453|NCT00901901|DRUG|Sorafenib (Nexavar, BAY43-9006)|Sorafenib 400 mg twice daily
223880454|NCT00901901|DRUG|Erlotinib (Tarceva)|Erlotinib 150 mg once daily
223880455|NCT00901901|DRUG|Placebo|Matching erlotinib placebo 150 mg once daily
223880456|NCT02035631|BEHAVIORAL|Diet|The dietary component, aimed to reduce calorie intake according to individual requirements, will be structured in 1-hour weekly sessions led by trained nutritionists. Sessions will concentrate on teaching participants about food groups, the food pyramid and Mediterranean diet, how to chose, prepare and cook hypo-caloric meals.
223880457|NCT02035631|BEHAVIORAL|Physical activity|The physical activity component will include two sessions per week led by trained physical activity monitors including aerobic exercise of high/moderate intensity, and instruction about the at-home exercise activities (3 more sessions).
223880458|NCT02035631|BEHAVIORAL|Minimal diet intervention|Some basic diet recommendations
223880459|NCT02035631|BEHAVIORAL|Minimal physical activity intervention|Some basic recommendations on physical activity
223880460|NCT01347892|OTHER|DeNovo NT Natural Tissue Graft|DeNovo NT is a juvenile cartilagenous tissue graft, inclusive of a viable human cartilage cells. It is provided as particulated tissue pieces of approximately 1mm3 each
223880461|NCT01886729|OTHER|transcranial direct current stimulation (tDCS)|
223880462|NCT00662519|DRUG|Neulasta (Pegylated)|Subjects will receive 6mg/dose given every 2 weeks for 12 weeks. Subjects less than 45kg will receive 100mcg/kg/dose every 2 weeks for 12 weeks.
223880463|NCT00662519|DRUG|Placebo|Placebo injections will be given in identical volumes in identical syringes in the identical subcutaneous manner. 6mg/dose given every 2 weeks for 12 weeks. Subjects less than 45kg will receive 100mcg/kg/dose every 2 weeks for 12 weeks.
223880464|NCT00662519|DIETARY_SUPPLEMENT|Mixed Meal Tolerance Test (MMTT)|This is a 2 hour test to find out how much C-peptide is being produced. C-peptide is used to measure the insulin being made by the cells of the pancreas. Both groups will have this test performed.
223880465|NCT00662519|OTHER|Blood test|HbA1c is a blood test that measures the average blood sugar control and will be performed in both groups.
223880466|NCT00662519|OTHER|DNA Test|The HLA test looks at the different chromosomes (DNA) for diabetes and will be performed in both groups.
223880467|NCT01942018|PROCEDURE|POEM|Patients will receive Per oral endoscopic myotomy (POEM) for symptomatic gastroesophageal junction outflow obstruction (EGOO)
223880468|NCT01172418|DRUG|Alemtuzumab|Alemtuzumab used as part of combined Induction.
223880469|NCT01172418|DRUG|Daclizumab|Daclizumab used as part of combined induction.
223880470|NCT01172418|DRUG|Thymoglobulin|Thymoglobulin used as part of combined induction.
223880471|NCT01739270|PROCEDURE|supraclavicular brachial plexus block|
223880472|NCT03052335|DEVICE|Pillcam® COLON 2 Capsule|The second generation of PillCam colon capsule endoscopy (CCE-2) is 11.6 mm × 31.5 mm in size and has two imagers, that each have a 172° angle of view, allowing for almost 360° visual coverage of the colon. CCE-2 has an adaptive frame rate from 4 to 35 images per second. This means that the camera is able to capture up to 35 pictures while in motion whereas 4 images per second are captured when it is virtually stationary. During the examination the patient wears a sensor array which is attached to the abdomen and a data recorder for storage of the information generated by the ingested capsule. After the examination the data are downloaded into the workstation and a video is generated.
223880473|NCT03052335|PROCEDURE|Colonoscopy|Optical colonoscopy is the standard method for evaluating the colon
223880474|NCT02272816|DRUG|Carboplatin AUC-10|Carboplatin AUC-10 according to the Calvert formula \[10 x (glomerular filtration rate (ml/min) + 25)\]mg given in 5% glucose over 1 hour every 21 days for 3 or 4 cycles.
223880475|NCT05171777|DRUG|Atezolizumab|Atezolizumab will be administered on Day 1 of each 21-day cycle. Participants will receive atezolizumab according to their assigned route of administration (i.e., SC or IV) for the first three treatment cycles. At Cycle 4, participants will cross-over and receive atezolizumab administered according to the alternative route of administration for Cycles 4-6. This period of 3+3 cycles in both treatment arms constitutes the study Treatment Cross-over Period. After Cycle 6, participants will select how they would like atezolizumab to be administered (SC or IV) for the Treatment Continuation Period. The Treatment Continuation Period will continue until Cycle 16 for participants with early-stage NSCLC or until loss of clinical benefit, as determined by the investigator according to local standard of care, for patients with advanced NSCLC.
223880476|NCT06045208|OTHER|Foot exercise|This group will engage in an 8-week foot intrinsic strengthening training
223880477|NCT06045208|OTHER|Lower Extremity Exercise|This group will engage in an 8-week lower extremity strengthening training
223880478|NCT05344807|DIAGNOSTIC_TEST|Renal DMSA Scintigraphy|patient injected with Tc99mDMSA then imaged after 2-4 hours by gamma camera
223880479|NCT02522312|OTHER|No Intervention|No drug is administered in this study
223880480|NCT01306500|PROCEDURE|Gastric lavage|8 Fr feeding tube was inserted orally with length equal to distance from the bridge of the nose to the earlobe and from the earlobe to a point halfway between the xiphoid process and the umbilicus. 20ml normal saline was used for gastric lavage. It was ensured that entire amount of normal saline used was removed from stomach.
223880481|NCT04405921|DRUG|Hydroxychloroquine 200 Mg Oral Tablet|orally or via gastric tube
223880482|NCT04405921|DRUG|Azithromycin 250 MG|orally or via gastric tube
223880483|NCT04434742|OTHER|Complex interventions|An advanced practice nurse (APN) from a hospital discharge team visited them to familiarize him/herself with their condition and prepare a discharge plan. A face-to-face or telephone call handover between the APN and the project nurse case manager (NCM) was performed before the client was discharged. The past and current medical conditions, medical and nursing management, and follow-up appointments were discussed. After discharge home, the NCM, functioning as the leader of health-social care team, conducted the initial assessment in the first home visit to identify the client's health and social problems within one week of discharge. Community workers, supervised by both the nurse case manager and social worker, provided telephone follow-up and subsequent home visits to monitor the client's progress and provide support when necessary.
223880484|NCT04434742|OTHER|Usual care|Social call was given to this group.
223880485|NCT00715884|DEVICE|CYPHER® ELITE™ Sirolimus-Eluting Stent System|Drug eluting stent
223880486|NCT00715884|DEVICE|CYPHER® Bx VELOCITY® Sirolimus-eluting Stent System|Drug eluting stent
223880487|NCT06440642|DEVICE|tonopen|Intraoculer pressure will be measured in the supine position after intubation (T1), during pneumoperitoneum (T2), when placed in steep trendelenburg posıtıon (T3), at the end of the operation when pneumoperitoneum is terminated (T4), after being placed back in the supine position (T5), and 10 minutes after being placed back in the supine position (T6).
223880488|NCT00632749|DRUG|BI 811283 (d 1 and 15)|BI 811283 (24 hours i.v.c.i.) on day 1 and 15 of a 4-week treatment cycle
223880489|NCT00632749|DRUG|Cytarabine|Cytarabine 2 x 20 mg/d s.c. on days 1-10 of a 4-week treatment cycle
223880490|NCT00632749|DRUG|BI 811283 (d1)|BI 811283 (24 hours i.v.c.i.) on day 1 of a 4-week treatment cycle
223880491|NCT00632749|DRUG|Cytarabine|Cytarabine 2 x 20 mg/d s.c. on days 1-10 of a 4-week treatment cycle
223880492|NCT01645033|OTHER|computerized Cognitive Behavioral Therapy (CBT)|Standard treatment (as described in TAU) plus a short session using a computer program containing CBT to understand risks related to sexual and other behaviors and how those risks relate to spread of infections.
223880493|NCT01645033|OTHER|Treatment as Usual (TAU)|"This is the infectious disease orientation that would normally be received at this clinic to address risky behavior. This orientation generally includes individual and group therapy sessions that discuss behaviors and the resulting risk of sexually or drug-related infections (for example: use of a condom). Sessions will generally include items such as:~* Teaching about the treatment program~* Teaching important ideas about sexual behaviors risks~* Increasing knowledge about specific sexually transmitted diseases~* Discussions of ways to reduce or minimize spread of diseases related to drug use \[for example, Hepatitis and Human Immunodeficiency virus (HIV, the virus responsible for causing AIDS)\]"
223880494|NCT00339131|DRUG|Ultratrace iobenguane I 131|
223880495|NCT04870749|DIAGNOSTIC_TEST|IPP,IPSS,VPSS|Prostate volume, IPSS, VPSS and IPP were determined after urological examinations of the patients.
223880496|NCT03373448|DEVICE|Labrida BioClean|The implant pockets will be debrided with the BioClean™ biodegradable brush for 2 minutes and with the brush seated in an oscillating dental handpiece (NSK ESQ10 TEQ) and thereafter irrigated with sterile saline or commercially available and area-specific titanium curettes (Langer and Langer, Rønvig) for 2 minutes and thereafter irrigated with sterile saline. The treatment will be repeated every three months until the terminal examination after 24 months. Debridement is performed with local anaesthesia as needed. Healthy sites will not be retreated.
223880497|NCT03373448|OTHER|Titanium curettes|Peri-implant pockets will be debrided using titanium curettes.
223880498|NCT04386356|DEVICE|Orotracheal intubation with either Macintosh laryngoscope versus Airtraq video laryngoscope|Tracheal intubation will be performed by first year anaesthesia trainee using either Macintosh laryngoscope or Airtraq video laryngoscope according to the randomization sequence supervised by an experienced anaesthesiologist and data recorded by an independent observer on one group of patients.
223880499|NCT03624335|PROCEDURE|ECC|Early clamping of the umbilical cord
223880500|NCT03624335|PROCEDURE|DCC|Delayed clamping of the umbilical cord
223880501|NCT03624335|PROCEDURE|Blood Test 6hours|Blood Test 6hours
223880502|NCT03624335|PROCEDURE|Blood Test 24hours|Blood Test 24hours
223880503|NCT03624335|PROCEDURE|Blood Test 48hours|Blood Test 48hours
223880504|NCT03624335|PROCEDURE|Blood Test 28days|Blood Test 28days
223880505|NCT02671435|DRUG|Monalizumab|Participants will receive IV infusion of monalizumab as stated in arm description.
223880506|NCT02671435|DRUG|Durvalumab|Participants will receive IV infusion of durvalumab as stated in arm description.
223880507|NCT02671435|DRUG|Cetuximab|Participants will receive IV infusion of cetuximab as stated in arm description.
223880508|NCT02671435|DRUG|mFOLFOX6|Participants will receive IV infusion of mFOLFOX as stated in arm description.
223880509|NCT02671435|DRUG|Bevacizumab|Participants will receive IV infusion of bevacizumab as stated in arm description.
223880510|NCT06364683|OTHER|Survey study|The data collection tools to be used in the study will be filled. It does not include any invasive or non-invasive intervention.
223880511|NCT06286085|OTHER|Lung function tests|Pulmonary function tests
223880512|NCT06000813|BEHAVIORAL|REACH-Es|REACH-Español is a mobile health platform adapted from the original REACH intervention to a Latino population with type 2 diabetes. The goal of REACH-Español is to improve diabetes medication adherence and glycemic management in this population.
223880513|NCT06000813|BEHAVIORAL|ETAU|Participants will maintain care as usual (medication treatment and physician monitoring) in addition to a welcome SMS following enrollment, a SMS each time an HbA1c is collected with a link to a secure website that displays the result, and bi-monthly information on diabetes self-care education.
223880514|NCT06334107|BEHAVIORAL|Exercise|Participants will be asked to follow a moderate-intensity aerobic exercise training program for 4-5 days per week for 40-60 minutes each session.
223880515|NCT01136876|DRUG|Iopamidol|Iopamidol 370, one time administration for percutaneous coronary intervention
223880516|NCT01136876|DRUG|Iodixanol-320|Iodixanol-320 single administration for percutaneous coronary intervention procedure
223880517|NCT05383859|BEHAVIORAL|Intervention|"1. Dietary and/ or physical activity: face to face plus written material (at baseline)~2. 3 months later: motivational phone call."
223880518|NCT03281616|BEHAVIORAL|Diet|Individually tailored diets; 30% caloric reduction according to daily energy requirements measured by indirect calorimetry
223880519|NCT05192980|OTHER|No Intervention NA|Additional blood sampling (not mandatory)
223880520|NCT01241916|DEVICE|Static-Progressive Splint|Static progressive splinting is a well-established adjunct for restoring elbow motion. Such splints apply a static stress relaxation force to the elbow tissues, which is sequentially increased, as motion is achieved.
223880521|NCT01241916|DEVICE|Dynamic Splint|Dynamic splints are a popular alternative, and apply a constant prolonged force to the tissues as additional motion is achieved.
223880522|NCT02412748|BEHAVIORAL|BBTF Intervention|The Building Bridges to Fatherhood (BBTF) intervention consists of 9 group sessions and 1 booster session as described in the arm/group descriptions.
223880523|NCT02412748|BEHAVIORAL|Financial Literacy Program|The Financial Literacy Program (FLP) attention control condition consists of 9 group sessions and 1 booster session as described in the arm/group descriptions.
223880524|NCT01320657|DEVICE|Conventional orthodontic bracket, passive self-ligating brackets and active self-ligating bracket|"Subjects randomized to treatment with one of three fixed orthodontic appliances: Damon Q, InOvation C and Ovation brackets. A pre-determined archwire sequence will be used involving round nickel titanium, rectangular nickel titanium progressing to 0.019 X 0.025 inch stainless steel; specific archwire sequences and appointment intervals will be based on the manufacturer's guidelines. All erupted teeth will have attachments placed from the outset.~Treated for a minimum of 8 months with the 0.019 X 0.025 inch stainless steel archwire in place for at least 8 weeks."
223880525|NCT04128319|DRUG|T-Guard|Patients will receive 4 doses of T-Guard treatment, administered intravenously as four 4-hour infusions at least two calendar days (no less than 40 hours) apart. Each dose consists of 4 mg/m\^2 Body Surface Area (BSA).
223880526|NCT00251576|DRUG|A-Phase: tirofiban; Z-Phase simvastatin|
223880527|NCT00251576|DRUG|Duration of Treatment: A-Phase: minimum suggested 48 hours, maximum suggested 108 hours. Z-Phase: 2 years|
223880528|NCT00251576|DRUG|Comparator: A-Phase: low molecular weight heparin, unfractionated heparin|
223880529|NCT00251576|DRUG|Duration of Treatment: A-Phase: low molecular weight heparin, 2 to 8 days; unfractionated heparin, minium suggested 48 hours, maximum 108 hours|
223880530|NCT00251576|DRUG|Duration of Treatment: Z-Phase, 2 years.|
223880531|NCT05466955|DEVICE|Free eye glasses for un or under-corrected myopia|All participants randomised to the intervention group will be provided with free eye glasses
223880532|NCT04065113|PROCEDURE|Middle Meningeal Artery Embolization with polyvinyl alcohol particles (PVA)|Seal off blood supply to the middle meningeal artery to prevent growth of subdural hematoma
223880533|NCT04065113|PROCEDURE|Drainage of Subdural Hematoma|Drainage of subdural hematoma via burrhole or craniotomy
223880534|NCT00573482|BEHAVIORAL|REDE|"The intervention group received the education in REDE techniques.~The intervention in this study comprised four components:~* Four group education sessions to introduce the REDE principles of eating;~* Approximately 10 new lower energy-dense foods were introduced in the employee cafeteria daily at lunchtime;~* Food labels for all foods sold in the employee cafeteria at lunch time, which provided the energy density, calories, and macronutrient content of the prepared cafeteria foods. Prior to the intervention almost no foods had food labels.~* Price reductions for lower energy density items. Both groups were exposed to the food labels and the new lower ED foods, but only the intervention group received the education sessions about how to take advantage of the new labels and cafeteria foods and only they were eligible for the price reductions."
223880535|NCT00573482|BEHAVIORAL|control|The control group received no REDE intervention at all. Both groups were exposed to the food labels and the new lower ED foods, but the control group did not receive the education sessions.
223880536|NCT00839241|DEVICE|Bellovac ABT|Bellovac ABT (autologous blood)
223880537|NCT00839241|PROCEDURE|Allogenic Blood Transfusion|"Transfusion of allogenic (bank) blood."
223880538|NCT00976937|DRUG|Lixisenatide (AVE0010)|Self-administered by subcutaneous injections once daily within the hour preceding breakfast.
223880539|NCT00976937|DRUG|Lixisenatide Placebo|Self-administered by subcutaneous injections once daily within the hour preceding breakfast.
223880540|NCT00976937|DEVICE|Pen auto-injector|
223880541|NCT00976937|DRUG|Sitagliptin|Administered orally once a day in the morning with or without food at approximately the same time each day.
223880542|NCT00976937|DRUG|Sitagliptin Placebo|Administered orally once a day in the morning with or without food at approximately the same time each day.
223880543|NCT00976937|DRUG|Metformin|Metformin to be continued at stable dose (at least 1.5 gram per day) up to Week 24.
223880544|NCT02317965|OTHER|Maternal Blood Draw|Maternal Blood Draw
223880545|NCT03069313|DIETARY_SUPPLEMENT|Vitamin B12|Vitamin B12 2500 micrograms sublingually per day over the course of 90 days (+/- 10 days)
223880546|NCT05506436|DEVICE|Evident 3|It consists of brief 5-minute counselling on general physical activity recommendations and explaining the plate method for a balanced diet. Also, it includes the Evident 3 application, which is a daily dietary log that provides information on calories and diet composition and shows a reminder of the 10000 steps/day.
223880547|NCT05506436|OTHER|Implementation strategy|"Four sessions have been designed to obtain the implementation strategy:~First session: Presentation of the Evident 3 application and its results in clinical trials. Training in the use of the application and identification of possible areas for improvement.~Second session: Presentation of evidence-based practices on the management of obesity in Primary Care. Consensus selection of those related to health promotion and mHealth. Sharing of possible lines of improvement of the care offered in the practice.~Third session (optional): Intervention on those components (coherence, cognitive participation, collective action and reflective follow-up) of the NOMAD questionnaire, if very low scores are obtained.~Fourth session: Brainstorming on possible strategies for the implementation of the Evident 3 intervention. Analysis and evaluation of these strategies and determination of a common strategy for their implementation."
223880548|NCT06211556|BEHAVIORAL|Very-low calorie diet|\~800 kcal/day delivered via commercially available diet plan (NUPO).
223880549|NCT01551953|BEHAVIORAL|Tai chi|12 week tai chi class
223880550|NCT01551953|BEHAVIORAL|Mind-body breathing|12 week breathing class
223880551|NCT01551953|BEHAVIORAL|Education|12 week education class
223880552|NCT00854191|DEVICE|simulator training|4 half-day of simulator ERCP practice as endoscopist and/or assistant followed by usual training
223880553|NCT00686504|DRUG|AZD2066|single dose of oral dose, 3 times per subject
223880554|NCT00686504|DRUG|radioligand [11C] AZ12713580|single dose of iv administered 4 times per subject (3 times together with AZD2066)
223880555|NCT05925920|DRUG|ENT-03|single dose of active drug
223880556|NCT05925920|DRUG|Placebo|single dose of placebo comparator
223880557|NCT05297851|DRUG|Cytoflavin (succinic acid + inosine + nicotinamide + riboflavin)|10 ml diluted to 100-200 ml of 5-10% dextroseor 0.9% sodium chloride solution. The rate of administration is 3-4 ml / min. The drug is administered in a volume of 10 ml per injection with an interval of 8-12 hours for 10 days. In severe cases of the disease, a single dose is increased to 20 ml.
223880558|NCT05297851|DRUG|Control|Standard treatment accordind to the routine clinical practice
223880559|NCT00268671|DRUG|Docetaxel|
223880560|NCT05508243|OTHER|Hyaluronic Nasal Spray|Health care product - nasal application
223880561|NCT03407846|PROCEDURE|Hystrectomy|Total laparscopic hystrectomy versus total abdominal hystrectomy
223880562|NCT05998252|DEVICE|Alveo HP Balloon Dilatation Catheter|Alveo HP Balloon is intended for dilatation of stenosis in the coronary artery.
223880563|NCT05640180|DRUG|Finerenone (Kerendia, BAY94-8862)|Retrospective cohort analysis using randomized clinical trials data.
223880564|NCT05640180|DRUG|Sodium-glucose cotransporter-2 inhibitors (SGLT2i)|Retrospective cohort analysis using United States Optum Electronic Health Records data.
223880565|NCT04856826|DEVICE|ultrasound guidance and therapeutic communication|insertion of a peripheral venous catheter with ultrasound guidance and therapeutic communication
223880566|NCT03067142|OTHER|Observational|Not an interventional study. Analyses of previously collected urine specimens and data on estimated kidney filtering function.
223880567|NCT02351310|DRUG|Betamethasone|Course of ACS given intramuscularly (2 doses of 12 mg, 24 hours apart)
223880568|NCT02351310|GENETIC|Placebo|Course of placebo drug given intramuscularly (2 doses of normal saline (of equal quantity) 24 hours apart).
223880569|NCT00826657|DIETARY_SUPPLEMENT|Vitamin B12|500 microgram daily supplement of vitamin B12 1000 mg injection vitamin B12 given at the start of the study
223880570|NCT00826657|DIETARY_SUPPLEMENT|placebo|placebo given as a daily supplement 1000 mg injection of vitamin B12 given at the end of the study
223880571|NCT01011946|DEVICE|Positron Emission Mammography|Patients will receive bilateral (both sides) breast and axillary PEM scans, bilateral mammography, DCE-MRI, US of the breast and axilla (the side of the affected breast), and ultrasound guided biopsy of axillary lymph node if suspicious. Various PEM views will be performed on both your breast and axilla (underarm).
223880572|NCT01404182|BIOLOGICAL|Vaccination with Fluval AB influenza vaccine|Vaccination with a single dose of Fluval AB influenza vaccine (trivalent, seasonal, active ingredient content: 15 μg HA/0.5mL of seasonal H1N1, H3N2 and B influenza antigens each) and aluminium phosphate gel adjuvant.
223880573|NCT05004597|OTHER|three dimensional photography using a 3dMDHead System (3dMD, Atlanta, GA, USA)|A series of 3D craniofacial photos were captured using a 3dMDHead System (3dMD, Atlanta, GA, USA) within 7 days before or after the age of 1, 2, 4, 6, 9, and 12 months.
223880574|NCT03427034|DEVICE|BladderLight®|Using a cell collection device to look for the presence of bladder cancer cells
223880575|NCT01203813|OTHER|Electronic Decision Support|"Physicians randomized to the intervention will receive:~1. Electronic alerts during office visits for patients with chronic kidney disease~2. Opportunity to enroll their patients with chronic kidney disease in a self management support outreach program"
223880576|NCT01644916|PROCEDURE|Integrated care|Integrated care will be provided with management of multifaceted group including, nurse educators, doctors, case manager and psychologists.
223880577|NCT01644916|PROCEDURE|Usual control|Usual control group will be provided with usual standard procedures for management of COPD and psychiatric comorbidities.
223880578|NCT04818931|DRUG|Cefazolin Injection|cefazolin 2 g or clindamycin 900 mg in case of penicillin allergy
223880579|NCT00003542|BIOLOGICAL|pegylated interferon alfa|
223880580|NCT04705311|OTHER|Pain neuroscience education|Neurophysiological education of pain allows patients to explore a wider contribution to pain through the knowledge that pain is often an unreliable indicator of the extent or extent of tissue damage. This aims at reconceptualization from biomedical or structural models to actual biological psychosocial pain models.
223880581|NCT04705311|BEHAVIORAL|Rotator cuff repair rehabilitation|Postoperative rehabilitation programs include thermal therapy, electrical therapy, manual therapy, and therapeutic exercise.
223880582|NCT04820686|DRUG|VBR|VBR is an HBV core protein inhibitor. Participants will receive VBR 300 mg tablets orally once daily (QD).
223880583|NCT04820686|DRUG|AB-729|AB-729 is a small interfering ribonucleic acid (siRNA) inhibitor of HBV. Participants will receive a 60-mg subcutaneous injection of AB-729 once every 8 weeks.
223880584|NCT04820686|DRUG|SOC NrtI|Participants will receive their SOC NrtI (ETV, TDF or TAF) tablet orally as per approved package insert.
223880585|NCT01872078|DRUG|AZD4901 (oral)|Patients randomized to 1 of 4 treatment groups: AZD4901 20 mg once a day, AZD4901 20 mg twice a day, AZD4901 40 mg twice a day or placebo
223880586|NCT01872078|DRUG|Placebo to match AZD4901|Patients randomized to 1 of 4 treatment groups: AZD4901 20 mg once a day, AZD4901 20 mg twice a day, AZD4901 40 mg twice a day or placebo
223880587|NCT05278533|DIETARY_SUPPLEMENT|BioPlete™ Advanced Formula|2 capsules, twice a day for a total of 4 capsules daily, preferably with a meal
223880588|NCT05278533|DIETARY_SUPPLEMENT|Placebo|2 capsules, twice a day for a total of 4 capsules daily, preferably with a meal
223880589|NCT01424670|DRUG|Delamanid + OBR|The assigned doses of delamanid were administered with an OBR. The selection and administration of the OBR were based on WHO's guidelines for the programmatic management of drug-resistant TB, in conjunction with national TB program guidelines in each country.
223880590|NCT01424670|DRUG|Placebo + OBR|Matching placebo was administered with an OBR. The selection and administration of the OBR were based on WHO's guidelines for the programmatic management of drug-resistant TB, in conjunction with national TB program guidelines in each country.
223880591|NCT00761189|DRUG|Paliperidone|Paliperidone extended-release (ER) tablet will be administered orally in dose range of 3 to 12 milligram (mg) per day for 12 weeks as per Investigator's discretion.
223880592|NCT04156204|OTHER|Medication Event Monitoring System (MEMS)|AYA kidney recipients will receive a Medication Event Monitoring System (MEMS) via medication bottle and cap system
223880593|NCT04156204|DRUG|Once-Daily Tacrolimus extended release|AYA kidney recipients will receive once daily tacrolimus XR 1-10mg daily
223880594|NCT03169894|DRUG|MDGN-002|MDGN-002 is a fully human IgG4 monoclonal antibody specific to human LIGHT.
223880595|NCT01392638|OTHER|sugar pill|Sugar pills: 37.5, 50.0, and 100.0 mg each 30 minutes.
223880596|NCT01392638|DRUG|sildenafil|Sildenafil pills: 37.5, 50.0, and 100.0 mg each 30 minutes.
223880597|NCT00498511|PROCEDURE|upper gastrointestinal endoscopy, colonoscopy|
223880598|NCT02789215|BEHAVIORAL|Proposed Meal Changes for CACFP: Impact on Child Food Intake and Costs|
223880599|NCT02332577|DRUG|PRISTINAMYCIN XRP7263|Pharmaceutical form:tablet 500 mg Route of administration: oral
223880600|NCT02332577|DRUG|Amoxicillin|Pharmaceutical form:capsule 500 mg Route of administration: oral
223880601|NCT02332577|DRUG|Amoxicillin Placebo|Pharmaceutical form: capsule Route of administration: oral
223880602|NCT02332577|DRUG|PRISTINAMYCIN Placebo|Pharmaceutical form:Tablet Route of administration: Oral
223880603|NCT03988842|DRUG|Alteplase|Lyophilized powder for reconstitution in 50mg vials
223880604|NCT03988842|DRUG|Unfractionated heparin|Heparin sodium in 0.45% sodium chloride injection for intravenous use
223880605|NCT03988842|DRUG|Placebo|Saline solution reconstituted to mimic Alteplase 50mg vial
223880606|NCT03988842|DRUG|Apixaban|Apixaban tablet
223880607|NCT00972439|DRUG|Oral Contraceptive: Ortho-Novum® 1/35|
223880608|NCT00972439|DRUG|Oral Contraceptive: Ovcon Fe®|
223880609|NCT05136157|DRUG|Rapid-Acting Insulin|50 IU of rapid acting insulin taken by a 100 units (1ml) insulin syringe will be added to a 50 ml syringe containing normal saline (NS) to have a total volume of 50 ml with a concentration of 1 IU of insulin per 1 ml of NS
223880610|NCT03055689|BEHAVIORAL|Educational telephone intervention|Subjects will receive a nurse-led educational telephone intervention for bowel preparation 24-48 hours before the colonoscopy
223880611|NCT03055689|BEHAVIORAL|Standard education for colonoscopy|Standard education for bowel preparation at the time of colonoscopy scheduling
223880612|NCT05527912|DRUG|Rituximab, Chidamide, Zanubrutinib-induced and CHOP Therapy|"All subjects received two courses of the following treatment:~Rituximab ，375mg/m²， D1； Chidamiade ，20mg ，biw， d1-14； Zanubrutinib ，160mg， bid， d1-21；~three weeks for a period of treatment, all subjects complete tumor assessment after two courses of treatment, patients which achieve complete remission continue for up to 8 sessions, patients achieve partial response and stable disease combined use of the following CHOP threapy to 6 courses, Patients with progressive disease dropped out of this research.~CHOP Therapy:~Cyclophosphamide， 750mg/m² ，D1； Vincristine， 1.4mg/m² ，D1 (maximum：2mg)； Doxorubicin or pirarubicin， 50mg/m²， D1； Prednisone ，30mg ，tid， D1-5."
223880613|NCT01460667|DRUG|IV acetaminophen|IV acetaminophen 1000 mg (100 mL) every 6 hours over 30 hours
223880614|NCT01460667|DRUG|IV normal saline|0.9% normal saline IV, every 6 hours over 30 hours.
223880615|NCT00580918|OTHER|functional magnetic resonance imaging fMRI|functional magnetic resonance imaging fMRI
223880616|NCT03306368|BEHAVIORAL|Youth Opioid Recovery Support|"The components of the Youth Opioid Recovery Support intervention are:~XR-NTX, home delivery of XR-NTX, the family framework approach engages and empowers families, assertive continuing care incorporates outreach, home delivery of XR-NTX, contingency management."
223880617|NCT00753480|DRUG|D4064A|
223880618|NCT00563446|DRUG|Darbepoetin alfa|
223880619|NCT01541631|DRUG|Praziquantel and Albendazole|Praziquantel Tablet - 40mg/kgBWT given once Albendazole Tablet - 400mg once
223880620|NCT01541631|DRUG|Praziquantel and Albendazole|Praziquantel- 40mg/kgBWT Albendazole - 400mg once
223880621|NCT01541631|DRUG|Praziquantel and Albendazole|Praziquantel- 40MG/KG ONCE Albendazole - 400mg once
223880622|NCT00352976|DRUG|Cyclophosphamide|Day -5 through Day -2, subjects will receive chemotherapy of Cyclophosphamide via central line (i.e. Hickman or Broviac),10 mg/kg intravenously (IV)
223880623|NCT00352976|DRUG|Fludarabine|Day -5 through Day -2 prior to transplant; subjects will receive chemotherapy of Fludarabine via central line (i.e. Hickman or Broviac),35 mg/m\^2 intravenous (IV)
223880624|NCT00352976|PROCEDURE|Total Body Irradiation|total body irradiation (300 cGy) with thymic shielding will be given six days before the stem cells are given (day -6). Thymic shielding is done by placing a piece of lead on the chest during the irradiation treatment so that the irradiation beams do not go to the thymus.
223880625|NCT00352976|PROCEDURE|Bone Marrow Transplantation|A target of 5 \* 10\^6/kg and a minimum of 4 \* 10\^6 CD34+ cell/kg recipient weight will be collected by apheresis and used for transplant. In most cases this dose will be recovered in a single apheresis; however, a second or rarely third apheresis performed on the following days may be required to achieve the minimum dose.
223880626|NCT00352976|DRUG|Mycophenolate Mofetil|Patients will receive MMF therapy beginning on day -3 through day +30 or for 7 days after engraftment, whichever day is later, if no acute graft-versus-host disease (GVHD). Engraftment is defined as 1st day of 3 consecutive days of absolute neutrophil count \[ANC\] \> 0.5 \* 10\^9/L. MMF will be given at a dose of 15 mg/kg/dose every 8 hours by mouth(to a maximum dose of 1 gram).
223880627|NCT00352976|DRUG|Sirolimus|Sirolimus will be administered starting at day -3 with 8mg-12mg mg oral loading dose followed by single dose 4 mg/day with a target serum concentration of 3 to 12 mg/mL by high-performance liquid chromatography (HPLC). Levels are to be monitored 3 times/week in the first 2 weeks, weekly until day +60, and as clinically indicated until day +100 post-transplantation. In the absence of acute GVHD sirolimus may be tapered starting at day +100 and eliminated by day +180 post-transplantation.
223880628|NCT05708144|DIAGNOSTIC_TEST|ICG-SG incubation solution|The fresh excision breast cancer tissues were completely soaked in the incubation solution and performed fluorescence imaging.
223880629|NCT00709098|DRUG|iloprost|Iloprost 5 mcg delivered by I-neb(R) adaptive aerosol delivery (AAD)(R) System power disc-6 administered 6 to 9 times per day for 12 weeks. If patient enters open label follow-up period, iloprost 5 mcg delivered by I-neb(R)AAD(R) System power disc-15 administered 6 to 9 times per day until the end of study.
223880630|NCT00709098|DRUG|iloprost|Iloprost 5 mcg delivered by I-neb(R)AAD(R) System power disc-15 administered 6 to 9 times per day for 12 weeks. If patient enters open label follow-up period, iloprost 5 mcg delivered by I-neb(R)AAD(R) System power disc-15 administered 6 to 9 times per day until the end of study.
223880631|NCT01227265|DRUG|Preladenant|Preladenant 2 mg or 5 mg oral tablet taken twice daily
223880632|NCT01227265|DRUG|Placebo|Preladenant-matching placebo oral tablet taken twice daily
223880633|NCT01967836|DEVICE|Glad Press 'n Seal|Application of Glad Press n' Seal product as an IV site dressing protection during subject showering
223880634|NCT04497766|DRUG|Nebulized Magnesium sulfate|MgSO4 100mg in 20 ml normal saline will be given via ultrasonic nebulizer over 10 minutes,and PAS score will be assessed at 30,60,120,240,360 minutes
223880635|NCT04497766|DRUG|Intravenous magnesium sulphate|pts age 2 to 12 years will receive intravenous magnesium sulphate 50 mg/kg over half hour
223880636|NCT03452982|OTHER|sentinel node technique|Injection of a tracer in the stump of the infundibulo-pelvic ligament and uterus-ovary for sentinel node detection.
223880637|NCT03481816|BIOLOGICAL|ETBX-071; adenoviral PSA vaccine|5 x 10 to the eleventh power VP (standard dose), 1 x 10 to the eleventh power VP (DL-1), or 5 x 10 to the tenth power VP (DL-2) subcutaneous injection every 3 weeks for 3 immunizations.
223880638|NCT03481816|BIOLOGICAL|ETBX-061; adenoviral MUC1 vaccine|5 x 10 to the eleventh power VP (standard dose), 1 x 10 to the eleventh power VP (DL-1), or 5 x 10 to the tenth power VP (DL-2) subcutaneous injection every 3 weeks for 3 immunizations.
223880639|NCT03481816|BIOLOGICAL|ETBX-051; adenoviral brachyury vaccine|5 x 10 to the eleventh power VP (standard dose), 1 x 10 to the eleventh power VP (DL-1), or 5 x 10 to the tenth power VP (DL-2) subcutaneous injection every 3 weeks for 3 immunizations.
223880640|NCT04758416|PROCEDURE|biopsy or surgical pathology in metastases|biopsy or surgical pathology in extrahepatic/liver/brain metastases
223880641|NCT04758416|DRUG|68Ga-HER2 affibody,18F-FDG, 18F-FES|68Ga-NOTA-MAL-MZHER2 (68Ga-HER2) affibody is an investigational Positron Emission Tomography (PET)/ Computed Tomography (CT) radiopharmaceutical.
223880642|NCT01449617|DRUG|Aspirin plus clopidogrel|"Clopidogrel, will be started 48 hours before the procedure with a loading dose of of 300mg and continued at 75mg/day.~Aspirin will be given at the dose of 100-325mg/day."
223880643|NCT01704196|DRUG|Nepicastat|120 mg of active drug and 100mg of riboflavin daily for 11 weeks or matching placebo containing 100mg of riboflavin daily for 11 weeks.
223880644|NCT01704196|DRUG|Placebo|
223880645|NCT04223258|DEVICE|Automatic Oxygen control|The CLiO device is integral to the Avea infant ventilator and allows automated OXYGEN adjustment aiming to maintain SpO2 within assigned target range using neonatal pulse oximeter. When first started it adopts the FiO2 previously set by the clinician as the initial 'Baseline FiO2' level. Thereafter, the changes to the FiO2 and their frequency depend on whether SpO2 is below, above or within the target range, the trend in SpO2 and all changes are proportionate to the 'Baseline FiO2' level.
223880646|NCT04223258|OTHER|Manual Oxygen Control|In the manual arm the oxygen is adjusted manually by the clinical team.
223880647|NCT04943419|DIAGNOSTIC_TEST|Level of Myeloid-Derived Suppressor Cells|Establishing of levels of all MDSC, PMNMDSC, MMDSC, EMDSC, M/PMN MDSC ratio on the day before operation.
223880648|NCT00752453|PROCEDURE|Dialysis during 4 hours|Blood and dialysate sampling
223880649|NCT00752453|PROCEDURE|Dialysis during 6 hours|Blood and dialysate sampling
223880650|NCT00752453|PROCEDURE|Dialysis during 8 hours|Blood and dialysate sampling
223880651|NCT01811394|RADIATION|protons|Treatment is performed using 16 x 4 GyE protons
223880652|NCT01811394|RADIATION|carbon ions|Treatment is performed using 16 x 4 GyE carbon ions
223880653|NCT04393389|DEVICE|"AcoArt Orchid (0.035), AcoArt Tulip (0.018) and AcoArt Litos (0.014) percutaneous transluminal angioplasty (PTA) paclitaxel drug coated balloon catheter manufactured by Acotec Scientific Co., Ltd."|All comers Post Market Clinical Follow-up to continue the surveillance of the Acotec Drug Coated PTA Catheter AcoArt Orchid, AcoArt Tulip and AcoArt Litos in lower limb treatment
223880654|NCT03060317|BEHAVIORAL|Examination with neurological scales.|Coma Recovery Scale, Glasgo Coma Scale, FOUR scale
223880655|NCT02362867|DEVICE|Balanced Knee System|A multi-compartmental total knee replacement providing a system of components for primary posterior cruciate ligament substituting procedures. The system consists of femoral, tibial, and patellar components that allow the surgeon to select the most appropriate component combination to meet specific patient needs.
223880656|NCT04185636|DEVICE|MolecuLight i:X imaging|The MolecuLight i:X Imaging Device will be used to take standard (ST) and fluorescent (FL) images of each graft site. The MolecuLight i:X will also be used to take measurements of the wound using the measurement feature of the device.
223880657|NCT01279668|DRUG|Montelukast|10mg tablets, once per day for 28 days.
223880658|NCT01279668|DRUG|Placebo|tablets, once per day for 28 days.
223880659|NCT06528925|OTHER|Virtual reality goggles|Patients in the study group will be shown a video with virtual reality glasses during the procedure. Patients will be asked to wear a virtual reality goggle (VR Box Virtual Reality Headset 3D Vr Glasses V2.0 2020 model) that is compatible with a mobile phone (Xiaomi Redmi Note 8 Pro 2019 model) with android operating system and minimizes sound loss in the supine position. With the virtual reality glasses, nature landscapes with relaxing music background will be watched by adjusting the volume at the level desired by the patient. Virtual reality goggles will be applied during the urodynamic procedure.
223880660|NCT03640949|DRUG|Vasopressin, Arginine|20 IE of vasopressin per dose for a maximum of four doses (80 IU)
223880661|NCT03640949|DRUG|Methylprednisolone|40 mg methylprednisolone once
223880662|NCT03640949|DRUG|NaCl|Placebo
223880663|NCT04668638|OTHER|Respiratory rehabilitation|Respiratory rehabilitation includes education, hypoventilation exercises, diaphragmatic breathing exercises, relaxation, retraining, others.
223880664|NCT06696716|DRUG|ONO-4059|Tirabrutinib is a Bruton's Tyrosine Kinase Inhibitor. Tirabrutinib will be administered orally at a dose of 80 mg once daily after a meal (breakfast, lunch, or dinner).
223880665|NCT06696716|DRUG|ONO-4059 placebo|Placebo will be administered orally once daily after a meal (breakfast, lunch, or dinner).
223880666|NCT01448681|OTHER|No Interventions|
223880667|NCT01627652|OTHER|altitude|the subjects will live one month at 3450 m altitude in the Jungfraujoch Research Station
223880668|NCT02778659|DRUG|Zolpidem|The hypnotic will be administrated orally at 22:00 in the evening before a sleep recording and an early wake-up at 01:00 for cognitive and motor assessment.
223880669|NCT02778659|DRUG|Placebo|The placebo will be administrated orally at 22:00 in the evening before a sleep recording and an early wake-up at 01:00 for cognitive and motor assessment.
223880670|NCT06345404|DRUG|Soquelitinib|Tablets
223880671|NCT06345404|DRUG|Placebo|Soquelitinib matching placebo tablets
223880672|NCT04873869|DRUG|NBI-921352|Administered orally
223880673|NCT04873869|DRUG|Placebo|Administered orally
223880674|NCT05375162|BEHAVIORAL|Core Intervention|"All participants will receive a low-resource self-monitoring intervention consisting of the Fitbit Alta HR (or similar) and the Opt2Move self-monitoring app.~Participants will be provided with the Fitbit Alta HR. They will be asked to download the Fitbit app and wear the Fitbit 24/7 throughout the 24-week study period. The Fitbit measures PA intensity, steps, and heart rate, and it syncs directly with the Ftibit app on the smartphone which will ill automatically sync with the Opt2Move study app and provide Fitbit data to the study team in real-time.~The core Opt2Move study app will support YACS to increase their MVPA. The app will also contain educational information on MVPA and effective behavior change strategies for building self-efficacy, overcoming barriers, enhancing facilitators, setting realistic outcome expectations, and self-regulatory skill-building (i.e., reviewing progress, goal setting, action-planning and coping with disruptions)."
223880675|NCT05375162|BEHAVIORAL|E-Coach|Participants assigned to this condition will receive a weekly scheduled text message from their coach. Text messages will focus on building self-efficacy and self-regulation skills, setting realistic outcome expectations, overcoming barriers, and problem-solving and will directly support the participant's engagement in the intervention. The coach will provide a brief overview of the participant's recent progress and goals, ask if they are having any barriers and help them troubleshoot and set specific goals for the next week. Text message protocols will be informed by the investigators' previous experience using telephone coaching to promote MVPA in cancer survivors. In addition to the scheduled messaging, participants will also be instructed to reach out to their coach with any questions or for additional assistance.
223880676|NCT05375162|BEHAVIORAL|General Mindfulness Training|Participants assigned to this condition will be instructed to watch 1 (1-2 mins), mindfulness education videos each week which lay the foundation for what mindfulness is and how it can be an important health behavior. Each week participants will also be asked to listen to general guided mindfulness audio files ≥5 days/ week. The length of recordings will gradually increase each week from 3-5 to 25-30 minutes. All videos and recording will be available via the Opt2Move app.
223880677|NCT05375162|BEHAVIORAL|MVPA-Specific Mindfulness Training|Participants assigned to the MVPA-specific mindfulness training component will be instructed to watch 1-2 brief (1-2 minute), mindfulness education videos each week which lay the foundation for what mindfulness is and the importance of linking mindful awareness with MVPA. Each week participants will be provided access to MVPA-specific guided mindfulness audio files (e.g., 10-minute treadmill walking meditation, 20-minute bicycling meditation) that they will be asked to listen to during ≥3 MVPA sessions/week. The length and intensity of these audio files will correspond to their progression in the program. All videos and recordings will be accessed via the Opt2Move app.
223880678|NCT05375162|BEHAVIORAL|Buddy|Participants assigned to this condition will select a buddy of their choice (i.e. friend, co-worker, caregiver or family member) that is ≥ 18 years of age and willing to share their Fitbit data with the study team. The buddy will be mailed a Fitbit, share their Fitbit data with the study team, and be provided with access to, and instructions for, all of the Opt2Move app modules the participant has access to for their assigned condition. The Opt2Move app will include a buddy module where the buddy and participant can view each other's progress. The buddy will be expected to attend a 15-30 minute group orientation call and listen to four 10-15 minute podcasts (one every 3 weeks) during the first 12 weeks of the intervention. Each podcast will provide social support training and peer discussion of challenges and successes in providing YACS with MVPA support.
223880679|NCT05646329|BEHAVIORAL|Motivational Interview|The motivational interview to be held with the experimental group was planned as 4 sessions together with the follow-up session.
223880680|NCT06611059|DEVICE|PSG|Two replicas of each scapula are made. The scapulae are drilled with a commercial guide and with an in-house guide separately
223880681|NCT02113176|DRUG|Minocycline|
223880682|NCT03448458|PROCEDURE|CT (Computed Tomography)|Undergo PET/CT
223880683|NCT03448458|DRUG|Gallium Ga 68-DOTATATE|Given IV
223880684|NCT03448458|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
223880685|NCT05332639|BEHAVIORAL|Personalized Risk Estimation for Crohn's Disease (PRE-Crohn's) tool|We will develop a web-based, personalized risk estimation for CD (PRE-Crohn's) tool to quantitate participants' relative risk (RR) and lifetime risk of CD based on known risk factors for disease. We will consider the following risk factors for Crohn's disease: body mass index (BMI); smoking history; NSAID use; intake of fruit, fiber, and added sugar; oral contraceptive use (females); antibiotic use; breast-feeding; pets in home; and anti-microbial biomarker positivity. This tool will also display a participants' personalized summary of their risk factors for CD as well as educational tools for modifying these factors. Construction of this tool is based on the Your Disease Risk tool developed by the Siteman Cancer Center at Washington University in St. Louis School of Medicine. The interventional group will also receive standard education about Crohn's disease (comparison group intervention) via the web-based tool.
223880686|NCT05332639|BEHAVIORAL|Standard Crohn's Disease Education|The comparison group will receive standard education about Crohn's disease, which will include information regarding the prevalence of disease, clinical presentation including signs and symptoms of disease, and treatment options including available medications. Upon completion of the study, the comparator arm will be given the option of receiving their personalized risk of Crohn's disease with the PRE-Crohn's tool as well.
223880687|NCT06676501|PROCEDURE|ExAblate|Transcranial focused ultrasound thalamotomy
223880688|NCT06675136|PROCEDURE|Biopsy|Undergo tumor biopsy
223880689|NCT06675136|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223880690|NCT06675136|PROCEDURE|Computed Tomography|Undergo CT
223880691|NCT06675136|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223880692|NCT06675136|OTHER|Medical Device Usage and Evaluation|Given PIPAC
223880693|NCT06675136|DRUG|Nab-paclitaxel|Given IP
223880694|NCT06675136|DRUG|Paclitaxel|Given IV
223880695|NCT06675136|OTHER|Questionnaire Administration|Ancillary studies
223880696|NCT06675136|BIOLOGICAL|Ramucirumab|Given IV
223880697|NCT07008287|DRUG|Taletrectinib|Taletrectinib, 600mg, QD
223880698|NCT07005063|DEVICE|FiberLocker® System (encompassing SpeedPatch® PET and FiberLocker Instrument® SN)|The FiberLocker® System is a mechanical augmentation system that includes an implant (SpeedPatch® PET) and an instrument (FiberLocker® Instrument SN) for its attachment. The implant is composed of non-woven PET fibers, and the instrument features a reciprocating needle at its tip, which pushes the individual patch fibers into the underlying tendon tissue
223880699|NCT05676827|DIAGNOSTIC_TEST|Diagnostic Criteria for Temporomandibular Disorders Clinical Examination|Clinical examination made by experienced dentists (minimum 5 years of practice) and trained and calibrated in accordance with the protocol available on the DC/TMD.
223880700|NCT05676827|DIAGNOSTIC_TEST|Blood test|Blood samples will be tested to investigate two polymorphisms of genes encoding proteins for serotonin receptors HTR2A - rs4941573 in intron 3 and dopamine DRD3 - rs6280 (Ser9Gly) and levels of serotonin, dopamine, Gamma-aminobutyric acid (GABA), Tumor Necrosis Factor α (TNF-α), CGRP, SERT, interleukin 1B, interleukin 6, interleukin 8, interleukin 10 and interleukin 17A.
223880701|NCT06872320|DRUG|Lactobacillus Rhamnosus|Lactobacillus Rhamnosus (Lactobacillus Rhamnosus, MoProbi-LR Capsules, Drug permit license 052531); Age \< 2 years old: 1/2 capsule once daily for 24 weeks per oral Age ≥ 2 years old: 1 capsule once daily for 24 weeks per oral
223880702|NCT06872320|DRUG|Placebo|Maltodextrin comparable in color. Age \< 2 years old: 1/2 capsule once daily for 24 weeks per oral Age ≥ 2 years old: 1 capsule once daily for 24 weeks per oral
223880703|NCT06871397|OTHER|Biopsychosocial Cognitive Behavioral Intervention|"The study intervention is based on a biopsychosocial approach (considers the interaction between: biological factors such as physical health, fetal development and physiological changes; psychological factors such as stress management, emotions and thoughts; and social factors such as couple relationships, social support and the maternal role) with cognitive-behavioral strategies designed to promote comprehensive well-being during pregnancy and the postpartum. Techniques such as psychoeducation, reflection and self-observation, cognitive restructuring, problem solving, stress inoculation, progressive muscle relaxation, guided visualizations and mindfulness are applied.~The program consists of 10 modules focused on different areas: introduction to the study, mindfulness and breathing techniques, physical and mental health at different stages of pregnancy, fetal development and prenatal attachment, couple relationship, preparation for childbirth and postpartum, and care of the newborn."
223880704|NCT06384963|DEVICE|Atrial pacing with respiratory sinus arrhythmia (RSA) variability|The intervention in this study is a modification of the pacing output from a standard external pacemaker such that it will approximate the RSA variation found in healthy subjects. A pacemaker (PACE204, Osypka Medical AG), similar to those currently in common use in post-CABG patients, will be adapted to receive an additional input signal based on the respiratory signal (Ceryx device). The respiration signal will be combined with the ECG signal to determine the appropriate pacing interval. The pacing impulse will be delivered by the pacemaker unit.
223880705|NCT06384963|DEVICE|Monotonic right atrial overdrive pacing|Pacing is delivered by a PACE204 pacemaker (Osypka Medical AG) delivering standard monotonic right atrial pacing
223880706|NCT06872593|PROCEDURE|CPAP-withdrawal|7-day-long CPAP-withdrawal
223880707|NCT06872593|DIAGNOSTIC_TEST|Test Sequence|Test Sequence M or D as specified in arm description
223880708|NCT07023380|DIAGNOSTIC_TEST|Assay directed diet change|Functional T cell assay(s) will be performed on research subjects' peripheral blood using four foods known to commonly cause Eosinophilic esophagitis - milk, soy, egg, and wheat. Response magnitude to foods in vitro will influence whether a subject's physician chooses to recommend the subject AVOID the food or continue to CONSUME the food. Disease response to the diet changes will be evaluated in standard-of-care follow up endoscopy.
223880709|NCT07032259|DEVICE|BioXclude Amnion Chorion Membrane|A resorbable allograft membrane derived from dehydrated human amnion and chorion tissue. The membrane is placed over peri-implant bony defects during guided bone regeneration to act as a biological barrier and promote tissue healing.
223880710|NCT07032259|DEVICE|Collagen Membrane|A resorbable xenograft membrane derived from porcine collagen. The membrane is placed over peri-implant bony defects during guided bone regeneration to support space maintenance and facilitate bone regeneration.
223880711|NCT06309134|BEHAVIORAL|Healthy Families Bright Futures Program|Seven weekly online group sessions with separate sessions for teens and caregivers. Sessions focus on increasing knowledge and acceptance of LGBTQ+ identities, alcohol use and dating violence social norms correction, bystander intervention, assertive communication skills, social emotional skills, family problem solving, and parenting behaviors.
223880712|NCT06885710|BIOLOGICAL|LioCyx-M|Each patient will receive LioCyx-M infusion every one or two weeks, while continuing their existing nucleos(t)ide analog treatment.
223880713|NCT06726434|PROCEDURE|Surgical neurotomy (SN)|"Surgical neurotomy will be performed under general anesthesia according to the previous description. Muscle relaxant drugs will not be used in order to prevent any interference with the intraoperative electrical stimulation.~The patient will be placed in a prone position and a vertical cutaneous incision will be made at the popliteal fossa location.~The tibial nerve will be dissected and the motor nerve branches of the soleus, gastrocnemius, tibialis posterior and flexor hallucis longus will be identified with intraoperative tripolar electrical stimulation. The selected motor nerve branches will be partially sectioned over a 5mm length under the microscope. The extent of nerve section will be determined according to the degree of spasticity and to the intraoperative residual muscular contraction under electrical stimulation"
223880714|NCT06726434|PROCEDURE|Cryoneurotomy (CN)|"After the use of an aseptic technique with 2% chlorhexidine, betadine application and a local anesthesia with lidocaine 1% (3ml), percutaneous cryoneurotomy will be performed with METRUM CRYOFLEX device guided by ultrasound with 1.2mm cryoprobe at -89°C placed through a #16 angio guide. Electrical stimulation will be performed to confirm tibial nerve contact at 0.8 mV.~The ice ball will be repositioned to two spots along the nerve. Each lesion will be treated for 2min cryoneurolysis at -89°C, followed by 2min without freezing (passive defreezing period) and 2min of cryoneurolysis at -89°C, based on cryotherapy for pain management."
223880715|NCT07048223|BEHAVIORAL|Expiratory Muscle Training|"In the expiratory muscle training group, participants will receive a respiratory exercise program consisting of breathing control, diaphragmatic breathing, and thoracic expansion exercises. In addition, expiratory muscle training (EMT) will be performed using the POWERbreathe EX1 device at 50% of each participant's measured maximal expiratory pressure (MEP).~Participants will be instructed to perform 25 repetitions per session, structured as 5 cycles of 5 breaths with 1-minute rest intervals between each cycle. The training will be performed daily at home for a duration of 8 weeks. Compliance will be monitored through exercise tracking forms.~To ensure progressive loading, MEP will be reassessed every 10 days, and the resistance of the device will be adjusted accordingly. Participants will be invited for in-person interim evaluations at these 10-day intervals to update their training parameters."
223880716|NCT07048223|BEHAVIORAL|Sham Expiratory Muscle Training|"In the sham expiratory muscle training group, participants will perform a respiratory exercise program including breathing control, diaphragmatic breathing, and thoracic expansion exercises. In addition, sham expiratory muscle training will be administered using the POWERbreathe EX1 device set at 10% of the participant's measured maximal expiratory pressure (MEP), providing minimal resistance.~Participants will be instructed to perform the exercises daily at home for a period of 8 weeks. Compliance will be monitored through exercise tracking forms. No progressive loading or resistance adjustments will be made during the intervention period."
223880717|NCT03582722|DRUG|Orlistat|Participants will be instructed to take one 60mg capsule of orlistat with each meal containing fat, up to three capsules daily, for six months.
223880718|NCT03582722|DRUG|Placebo capsule|Participants will be instructed to take one placebo capsule to match 60mg of orlistat with each meal containing fat, up to three capsules daily, for six months.
223880719|NCT03582722|DIETARY_SUPPLEMENT|Multivitamin|A multivitamin will be provided to be taken once daily, at bedtime.
223880720|NCT03690206|DRUG|glepaglutide|Glucagon-Like Peptide-2 (GLP-2) analog
223880721|NCT03690206|DRUG|Placebo|Placebo for glepaglutide
223880722|NCT07055854|BEHAVIORAL|Mindful After Cancer Program|The Mindful After Cancer Program provides education, mindfulness training, and peer support to help cancer survivors navigate sexual and body image concerns.
223880723|NCT07056049|BEHAVIORAL|High dosage, high intensity motor rehabilitation|Participants will receive additional technology-based upper extremity training for 120 min/day, 5d/w, 4 weeks.
223880724|NCT06619912|DRUG|Dexmedetomidine nasal spray|Participants will be randomised to receive either dexmedetomidine or saline nasal spray (1.5ug/kg, ideal body weight) at the night before surgery and 30 minutes before induction.
223880725|NCT06884722|BEHAVIORAL|Behavioral task of social perception (stage 1)|Patients with Parkinson disease and healthy volunteer are engaged in a social perception behavioral task.
223880726|NCT06884722|OTHER|Functional magnetic resonance imaging: 3 Tesla magnetic resonance imaging (stage 2)|"Patients with Parkinson disease and healthy volunteer are assessed by functional magnetic resonance imaging while they are engaged in a social perception behavioral task.~2 times for patients with Parkinson disease (during ON-levodopa and OFF-levodopa) Once for healthy volunteer"
223880727|NCT06884722|OTHER|Neurological and neuropsychological assessments|Patients with Parkinson disease and healthy volunteer will undergo a neurological and neuropsychological assessment with several evaluations: weight, height, medical history, global cognitive performance (MoCA and BREF score), apathy (LARS score), depression (BDI-II score), social cognition (mini-SEA), and quality of life (PDQ39 self-questionnaire).
223880728|NCT06884722|OTHER|Neurological assessments of Parkinson's disease symptoms and caregiver burden|Patients with Parkinson disease will undergo a neurological assessment of motor and non-motor symptoms of Parkinson's disease (MDS-UPDRS III \& IV scale and MDS-NMS scale) and caregiver burden (Zarit scale).
223880729|NCT07056803|DRUG|Oral semaglutide|Starting dose 3 mg for a month, followed by 7 mg for a month increased up to 14 mg a month
223880730|NCT07056803|DRUG|subcutaneous semaglutide|subcutaneous semaglutide can be started at 0,25 mg a week for a month, to be increased at 0,5 mg a week, up to 1 mg a week
223880731|NCT07059910|DIAGNOSTIC_TEST|Search for thyroid disorders|TSH , FT3 , FT4
223880732|NCT07059910|DIAGNOSTIC_TEST|Laboratory test|Search for anti thyroid antibodies
223880733|NCT07059910|DRUG|Steroid and eltrombopage|See when we treat thyroid disorders, will patient respond to steroid or eltrombopage?
223880734|NCT07059507|PROCEDURE|Total thyroidectomy|Remove of both thyroid lobes and isthmus
223880735|NCT07057219|OTHER|Exercise|SDTT adjusts the treadmill's speed in real time to match an individual's walking pace, creating a dynamic and adaptive training environment. This approach simulates real-world walking conditions, promoting neuromuscular coordination, balance, and functional mobility. By tailoring speed to the user's natural gait, SDTT supports the development of efficient and more natural walking patterns. It has shown promise across clinical populations, including those with neurological disorders, musculoskeletal conditions, or recovering from injury. Its flexibility allows for progressive challenge as walking ability improves, making SDTT a valuable tool for optimising gait and mobility outcomes.
223880736|NCT07057219|OTHER|Exercise|The SDTT+ program combines speed-dependent treadmill training with perturbations and VR-triggered adaptations. Reactive gait responses are elicited through controlled accelerations and decelerations of treadmill belts, simulating real-life balance challenges.
223880737|NCT07059221|DRUG|SHR-A2102|Administration by intravenous infusion
223880738|NCT07059221|DRUG|Adebrelimab|Administration by intravenous infusion
223880739|NCT07059221|DRUG|Cetuximab|Administration by intravenous infusion
223880740|NCT07060222|COMBINATION_PRODUCT|Bowel preparation before colonoscopy: Lactulose.|In this randomized, multicenter, single-blind clinical trial, each patient who meets our inclusion criteria will be assigned a randomized code to be included in one of the two study arms, that is, one of the groups and the assigned bowel preparation for the colonoscopy. The benefits and minimal risks of participation will be explained to them, and they will also be asked to sign an informed consent form so that we can proceed with the colonoscopy and collect all the necessary data for our protocol and variable analysis.
223880741|NCT07060222|COMBINATION_PRODUCT|Bowel preparation before colonoscopy: Sodium phosphate.|In this randomized, multicenter, single-blind clinical trial, each patient who meets our inclusion criteria will be assigned a randomized code to be included in one of the two study arms, that is, one of the groups and the assigned bowel preparation for the colonoscopy. The benefits and minimal risks of participation will be explained to them, and they will also be asked to sign an informed consent form so that we can proceed with the colonoscopy and collect all the necessary data for our protocol and variable analysis.
223880742|NCT06758206|BEHAVIORAL|Flywheel Resistance Training|For each training session, 6 to 7 generic exercises will be performed, involving small and large muscle groups (leg extension, leg flexion, biceps curl, triceps extension, seated row, shoulder flexion and shoulder raise). They will perform 4 sets of 8 repetitions, with a 2-minute break between exercises and sets. They will perform these exercises at a high intensity (always 10 on the OMNI-RES Scale).
223880743|NCT06758206|BEHAVIORAL|Traditional resistance training|For each training session, 6 to 7 generic exercises will be performed, involving small and large muscle groups (leg extension, leg flexion, biceps curl, triceps extension, seated row, shoulder flexion and shoulder raise). They will perform 4 sets of 8 to 12 repetitions, with a 2-minute break between exercises and sets. They will perform these exercises at moderate and high intensities (6 to 10 on the OMNI-RES scale).
223880744|NCT07066020|BEHAVIORAL|Telehealth-delivered Physical Activity Program for Children with ASD|This is a 16-week, theory-driven (Social Cognitive Theory \& Self-Determination Theory) behavioral intervention delivered remotely to caregivers of children with ASD. The program is facilitated by trained therapists via videoconference in small groups and consists of weekly 45-minute sessions. Core components include personalized exercise prescription, collaborative goal-setting, behavior change support, and safety education. Caregivers are coached to guide their child in three 30-40 minute physical activity sessions per week. To provide individualized support, therapists conduct two 10-minute one-on-one phone consultations per family based on biweekly activity logs submitted by caregivers.
223880745|NCT07066020|BEHAVIORAL|In-Person Supervised Physical Activity Program|This is a 16-week, structured, in-person physical activity intervention for children with ASD. The program consists of three 40-minute sessions per week delivered on-site at a partner school by certified physical education instructors. The curriculum is manualized and includes an Individualized Motor Protocol, Structured Group Sessions, and Behavior Change Support. Instructors provide direct, hands-on correction and feedback during sessions, adjusting task difficulty in real-time to match each child's individual capabilities and needs.
223880746|NCT07066020|OTHER|General Health Education Materials|This is a minimal intervention control. Participants in this group do not receive a structured or guided physical activity program. At the beginning of the study, caregivers are provided with a one-time, webinar-style session on general pediatric health topics (e.g., nutrition, sleep hygiene) and an exercise guidance manual. These materials are for optional, independent use by the caregivers, and no active monitoring or follow-up is provided by the research team regarding their use.
223880747|NCT07070167|DRUG|Intratracheal administration of surfactant|Intratracheal administration of pulmonary surfactant with any of the approved methods: (a) via endotracheal tube in a mechanically-ventilated infant, (b) with the INSURE method (intubation-surfactant-extubation), or (c) with LISA method (through a thin catheter inserted intratracheally in a spontaneously breathing infant, supported with CPAP)
223880748|NCT07071220|DIETARY_SUPPLEMENT|Vitamin C|The patients received vitamin C supplementation
223880749|NCT07071220|DIETARY_SUPPLEMENT|Placebo|Patients received placebo capsules
223880750|NCT07070960|BIOLOGICAL|CAR-T|The T cells are genetically modified to express a chimeric antigen receptor targeting BCMA and are infused after induction therapy at a target dose of ≥2.0×10\^6 cells/kg
223880751|NCT07070986|PROCEDURE|RESC|"If randomized in the RESC group, interventional group, patient will receive a 20 minutes session of cutaneous resonance stimulation before his cardiac surgery.~He will be asked to respond to anxiety questionnaire STAI-E and to evaluate his anxiety on a visual analogue scale (VAS) at J-1 (day of inclusion), J0 (day of surgery), and J1 (the day after surgery).~During the RESC session, LF/HF ratio, ANI, heart rate, respiratory rate, perfusion index and skin conductance will be monitored."
223880752|NCT07070986|OTHER|NSCS|"If randomized in the NSCS group, interventional group, patient will receive a 20 minutes session of non-specific cutaneous stimulation before his cardiac surgery.~He will be asked to respond to anxiety questionnaire STAI-E and to evaluate his anxiety on a visual analogue scale at J-1 (day of inclusion), J0 (day of surgery), and J1 (the day after surgery)~During the NSCS session, LF/HF ratio, ANI, heart rate, respiratory rate, perfusion index and skin conductance will be monitored."
223880753|NCT07071467|OTHER|Scaling and root planing with sodium hypochlorite and hyaluronic acid|Sodium hypochlorite gel was applied first for 30 seconds, then followed by subgingival instrumentation of the site. Then, 1.8% hyaluronic acid (1.6% cross-linked, 0.2% natural hyaluronic acid ) was applied subgingivally into the periodontal pocket to seal the site.
223880754|NCT07071467|PROCEDURE|Scaling and root planing|Pockets were treated with sub-gingival scalling and root planning alone.
223880755|NCT07070921|DEVICE|Foley catheter|Drainage of urine from the bladder by transurethral catheterization with an indwelling Foley catheter of patients in need of a Foley catheter for 3 to 14 days.
223880756|NCT07070999|BIOLOGICAL|GB221|GB221
223880757|NCT07069946|OTHER|traditional physical therapy and weight-bearing exercise|"They will receive 60 minute session, 3 times/ week for 8 weeks as following:~* 30 minutes of traditional physical therapy program : Includes: Strengthening, Stretching, Balance, Postural Control, Functional Mobility and Gait Training.~* 30 minutes of seven different weight-bearing exercises program of exercises with three of those being repeated on the left and right sides to make a total of ten exercises, each held for 3 minutes, the exercises include: hamstring stretch, calf stretch, half kneeling balance, static squat, bridge, four point kneeling and four point kneeling with leg extension the exercises include: : Hamstring stretch,Calf stretch , Half kneeling balance , Static Squat, Bridge, Four point kneeling with leg extension, and Four point kneeling."
223880758|NCT07069946|OTHER|neuromuscular electrical stimulation , traditional physical therapy and weight-bearing exercise|"They will receive 60 minute session, 3 times/ week for 8 weeks as following:~* 30 minutes of the same traditional physical therapy as the control group.~* 30 minutes of the same weight-bearing exercises program as the control group adding to it the neuromuscular electrical stimulation on: Tibialis anterior, Quadriceps, Paraspinal muscles.~* NMES Parameters :~  * Device: Everyway-EV-906.~ * Frequency: 30-35 Hz (to optimize muscle endurance and motor unit recruitment).~ * Pulse Width: 250-300 µs.~ * Intensity: Adjusted to elicit visible muscle contraction without discomfort (submaximal, (25-30 mA).~ * Electrode Placement:~    * Lower Limb: Tibialis anterior (for dorsiflexion) and quadriceps (for knee stability) during weight-bearing (El-Shamy and El Kafy, 2021).~   * Trunk: Paraspinal muscles (for postural control) during static squats and bridging"
223880759|NCT07071272|OTHER|breast-MRI and CEM|Participants will undergo a breast MRI followed by CEM for local breast cancer staging
223880760|NCT07069868|OTHER|Telehealth|During cycle one, participants will be asked about fevers, mucositis, nausea, vomiting, constipation, diarrhea, dyspnea, cough, rash, pain and fever. Symptoms will be graded according to Common Terminology Criteria for Adverse Events. A new adverse event of grade one or higher will be reported to a provider. An adverse event grade two or higher above baseline and/or experiencing cancer related symptoms above baseline, the findings will be reported to a Provider.
223880761|NCT07071129|DEVICE|Virtual Reality Stimulation|VR 1 hour sessions will consist of an exposure to a non-invasive visual stimulation where the subject will be sitting wearing a VR headset.
223880762|NCT07071701|BIOLOGICAL|23-valent pneumococcal polysaccharide vaccine|23-valent pneumococcal polysaccharide vaccine
223880763|NCT07071701|BIOLOGICAL|Influenza vaccine|Influenza vaccine
223880764|NCT07071922|OTHER|No intervention|Observational one-time questionnaire study without intervention
223880765|NCT07069907|OTHER|Air purfiers with photocatalytic oxidation (PCO)|PCO was proved to decompose gaseous pollutants in chamber studies, while there is no study investigate the effects in real-world. We used PCO air purifiers in households for two weeks.
223880766|NCT07069907|OTHER|Air purfiers with photocatalytic oxidation (PCO) + filters|PCO was proved to decompose gaseous pollutants in chamber studies, while there is no study investigate the effects in real-world. We used PCO and filters air purifiers in households for two weeks, to understand the effects comparing with PCO.
223880767|NCT07070401|DEVICE|Commercial AR/VR Headset with Calming App|Commercial AR/VR Headset with Calming App in addition to Pharmacologic Standard of Care
223880768|NCT07070401|OTHER|Pharmacologic Standard of Care Alone|Pharmacologic Standard of Care Alone
223880769|NCT07069959|OTHER|Early assessment of quadriceps muscle strength|Patients will undergo non-invasive assessment of quadriceps muscle strength using manual dynamometry and 3D ultrasound. These assessments will be conducted regularly during their ICU stay to evaluate early recovery. The intervention is part of routine patient care and does not involve additional treatments or procedures.
223880770|NCT07070804|OTHER|None-placebo|No interventions performed
223880771|NCT07071870|PROCEDURE|Stent-screw Assisted Internal Fixation (SAIF)|Implanting vertebral body stents (VBS), followed by insertion of percutaneous, fenestrated, cement-augmented pedicular screws
223880772|NCT07071870|PROCEDURE|Surgical stabilization|Spinal fixation with cement augmented pedicle screws bridging the fractured vertebra
223880773|NCT07070362|OTHER|None-placebo|This observational cohort study is non-interventional. Perioperative treatment plans are made based on model - suggested results and anesthesiologists' thought processes, without adding new medicines for patients.
223880774|NCT07070570|OTHER|Routine Follow-Up (RFU)|Standard follow-up care with scheduled X-ray, clinical visit and questionnaires at 10 years after surgery
223880775|NCT07070570|OTHER|Active Check-Up on Demand (ACOD)|X-ray, clinical visit and questionnaires at 10 years after surgery when requested by the patient or healthcare provider.
223880776|NCT07070570|OTHER|Passive Check-Up on Demand (PCOD)|X-ray and clinical visit (without questionnaires) at 10 year when requested by the patient or healthcare provider.
223880777|NCT07070375|DRUG|HRS-8427|HRS-8427
223880778|NCT07071818|PROCEDURE|Colpocleisis Group|Participants will undergo colpocleisis surgery as part of routine clinical care. The study involves transperineal ultrasound (TPUS) to measure the vesicourethral angle preoperatively and postoperatively, along with assessments for de novo stress urinary incontinence, POP-Q staging, PFDI-20 questionnaire, and stress testing.
224076784|NCT06500806|OTHER|Scroth and brace|Participants in this group will wear a brace and follow a 12-month Schroth exercise program three times a week. Sessions will be supervised by a physiotherapist and last 60 minutes, using equipment like foam blocks, exercise balls, and rods. Exercise intensity will gradually increase based on progress. The individualized Schroth exercises will aim to correct spinal deformity and include elongation, rotational correction, stretches, strengthening, and breathing exercises. These exercises will help patients maintain proper posture in daily activities and will be adapted to each participant's abilities, with varying difficulty and positions.
224076785|NCT06500806|DEVICE|Brace|Participants in this group will follow only the brace treatment
223880779|NCT07071025|BEHAVIORAL|Preventing Postpartum Onset Distress (P-POD)|P-POD contains ten interactive and didactic modules lasting approximately 30 minutes each. Seven mother-directed modules are designed to educate pregnant women about perinatal anxiety (psychoeducation), teach women to change their thinking patterns (cognitive restructuring), and guide women through testing their dysfunctional beliefs and fears (behavioral experiments). Each of these modules engage the pregnant woman in various self-guided exercises to consolidate the lessons learned. In addition, three partner-directed modules are designed to educate partners about perinatal anxiety, coach partners on providing emotional and social supports to pregnant women at risk for perinatal anxiety, and prepare partners for developmentally normative changes in their relationships following birth. Modules are designed to be completed weekly during the second trimester.
223880780|NCT07071025|BEHAVIORAL|Anxiety Education (ANX-ED)|ANX-ED educates women and their partners about seven anxiety and related disorders. ANX-ED contains ten interactive and didactic modules lasting approximately 30 minutes each. Seven mother-directed modules and three partner-directed modules will educate participants about generalized anxiety disorder, social anxiety disorder, panic disorder, specific phobia, obsessive-compulsive disorder, and posttraumatic stress disorder. Specifically, modules will include the diagnostic criteria, prevalence, and etiology of the disorders. They will also include animated examples of mothers experiencing the disorders described in each module. Each module engages the pregnant woman (or partner) in various self-guided exercises to consolidate the material learned.
223880781|NCT07071506|DRUG|Active drug for chronic migraine treatment.|Standard dose of Fremanezumab, 225 mg (Ajovy) injected subcutaneously
223880782|NCT07071506|DRUG|Placebo Subcutaneous injection|Inactive placebo (saline) injected subcutaneously in the same volume as the active drug
223880783|NCT07071636|DRUG|Peg-IFN α-2b combined with NAs|Peg-IFN α-2b (1.5 μg/kg/week) combined with NAs
223880784|NCT07070713|DRUG|FOLFOXIRI + QL1706 + Bevacizumab|FOLFOXIRI(Irinotecan 165mg/m², iv, d1; Oxaliplatin 85mg/m², iv, d1; (Levo) Folinic Acid (200) 400mg/m², iv, d1; total 5-FU 2400mg/m², iv gtt (continuous for 48h), d1) + QL1706 (5mg/kg, i.v., Q3W) + Bevacizumab (5mg/kg, i.v., Q2W)
223880785|NCT07070713|DRUG|FOLFOX+QL1706+Cetuximab|FOLFOX (Oxaliplatin 85mg/m², iv gtt (for 2h), d1; (Levo) Folinic Acid (200) 400mg/m², iv gtt (for 2h), d1; 5-FU 400mg/m², iv, followed by 2400mg/m², iv gtt (continuous for 46-48h), d1) + QL1706 (5mg/kg, i.v., Q3W) + Cetuximab (500mg/m², i.v., Q2W).
223880786|NCT07066410|BIOLOGICAL|intervention 1: endocem|EndoCem, a premixed calcium silicate-based cement (Maruchi, Korea), is used as the pulp capping material in vital pulp therapy (VPT). After achieving hemostasis with sterile saline-soaked cotton pellets, EndoCem is applied directly over the exposed radicular pulp tissue. The standardized clinical procedure includes local anesthesia, rubber dam isolation, caries removal, access cavity preparation, coronal pulp removal, and placement of EndoCem, followed by immediate restoration with FUJI II ensure a coronal seal.
223880787|NCT07066410|BIOLOGICAL|Intervention 1: biodentine|Biodentine, a tricalcium silicate-based cement (Septodont, France), is used as the pulp capping material in vital pulp therapy (VPT). After achieving hemostasis with sterile saline-soaked cotton pellets, Biodentine is applied directly over the exposed radicular pulp tissue. The standardized clinical procedure includes local anesthesia, rubber dam isolation, caries removal, access cavity preparation, coronal pulp removal, and placement of Biodentine, followed by immediate restoration with FUJI II to ensure a coronal seal.
223880788|NCT07066514|BEHAVIORAL|AI-Supervised Mobile Exercise Program|This intervention involves the use of an artificial intelligence (AI)-supported mobile application that delivers a personalized exercise program to patients with knee osteoarthritis. The app supervises exercise execution in real time using the device's camera and AI algorithms to track movements, count repetitions, and assess form accuracy. The program includes stretching, strengthening, and range of motion exercises performed 3-4 times per week for 4 weeks. The app provides instructional videos, personalized feedback, reminders, and records user performance. No video or personal images are stored; only anonymized motion data are collected and securely stored.
223880789|NCT07066514|BEHAVIORAL|Booklet-Guided Home Exercise Program|This intervention provides patients with a standardized home exercise program in printed booklet format. The program includes the same evidence-based stretching, strengthening, and range of motion exercises used in the mobile application group, performed 3-4 times per week for 4 weeks. Participants receive one-time in-person instruction on proper form but no ongoing supervision or feedback during the program. Adherence and technique are self-monitored.
223880790|NCT06024174|DRUG|BMS-986466|Specified dose on specified days
223880791|NCT06024174|DRUG|Adagrasib|Specified dose on specified days
223880792|NCT06024174|DRUG|Cetuximab|Specified dose on specified days
223880793|NCT05091580|BEHAVIORAL|Interpersonal Counseling|Interpersonal Counseling is a brief (4-8 sessions) psychological intervention that was developed to treat depression in primary care. In IPC, counselors provide psychoeducation about the connection of depressive symptoms to social triggers and support patients in leveraging social networks to address these stressors and reduce depressive symptoms. Since depressive symptoms are often a transient reaction to life stress (e.g. TB diagnosis), many individuals are able to achieve significant alleviation of symptoms in as few as four sessions. IPC focuses on reducing interpersonal conflict and improving social cohesion in families, which may have the advantage of strengthening the ability of families to support TB patients in completing treatment to achieve cure. All individuals will be offered 4-5 sessions (weekly), with up to 3 optional booster sessions (monthly) until TB treatment is completed.
223880794|NCT05091580|BEHAVIORAL|Enhanced treatment as usual|Depression screening and referral (as needed)
223880795|NCT07064863|DRUG|Gemcitabine + BCG|Patients will receive a single intravesical instillation of gemcitabine (2000 mg) at week 0 followed by weekly BCG (50 mg of TICE strain) for a total of 5 instillations. Biopsy will be conducted within three months of completing the induction phase.
223880796|NCT07064863|DRUG|BCG (TICE strain)|Patients will receive intravesical BCG (50 mg, TICE strain) at weekly intervals for a total of 6 instillations. Biopsy will be performed within 3 months of completing the induction phase.
223880797|NCT07069816|RADIATION|Scintigraphy|non invasive method in which the test meals and acquisition procedures have been standardized and the results are largely operator independent
223880798|NCT07069816|RADIATION|Scintigraphy|Non invasive method in which the test meals and acquisition procedures have been standardized
223880799|NCT07070050|DRUG|Ibuprofen continuous infusion|"1. The first bolus: ibuprofen 400 mg diluted in 0,9% NaCl 200 ml is intravenous injected during the first hour right after the admission to the department. The drug is injected during the first hour at the rate of 4 mg/kg/h for the ideal body weight.~2. Continuous infusion:~   * Ibuprofen 1200 mg diluted in 0,9% NaCl 300 ml is intravenous injected on the first day with the speed of 1 mg/kg/h (for the ideal body weight) during the remaining 23 hours.~  * On the second day the intravenous infusion of ibuprofen 1600 mg diluted in 0,9% NaCl 400 ml with the speed of 1 mg/kg/h is continued during the 24 hours.~3. Imitation of bolus: Every 8 hours placebo (0, 9% NaCl 200 ml) is intravenous injected to create an imitation of bolus injection. Placebo is injected during the first hour."
223880800|NCT07070050|DRUG|Ibuprofen bolus injection|"1. The first bolus: ibuprofen 400 mg diluted in 0, 9% NaCl 200 ml is intravenous injected during the first hour right after the admission to the department. The drug is injected during the first hour at the rate of 4 mg/kg/h for the ideal body weight.~2. Bolus injection:~   * Every 8 hours a intravenous bolus of ibuprofen 800 mg diluted in 0,9% NaCl 200 ml is injected during 1 hour (3 boluses per day in total).~  * On the second day the every 8 hours intravenous bolus of ibuprofen 800 mg diluted in 0, 9% NaCl 200 ml is injected during 1 hour (3 boluses per day in total).~3. Placebo continuous infusion:~Between the boluses a placebo (0,9% NaCl) continuous intravenous infusion is performed with the speed imitating the speed of ibuprofen infusion in the experimental group."
223880801|NCT07071233|DIETARY_SUPPLEMENT|Vitamin C|The patients received vitamin C supplementation
223880802|NCT07071233|DIETARY_SUPPLEMENT|Placebo|Patients received placebo capsules
223880803|NCT05028582|DRUG|Roflumilast Foam 0.3%|Roflumilast foam 0.3%
223880804|NCT05028582|DRUG|Vehicle Foam|Vehicle foam matched to roflumilast 0.3% foam.
223880805|NCT03818763|BIOLOGICAL|Auto CD34+PBSC, transduced with a lentiviral vector encoding the B domain deleted from of human coagulation factor VIII|"Reduced intensity conditioning with melphalan and fludarabine, followed by a single infusion of autologous CD34+PBSC, transduced with a lentiviral vector (-889ITGA2B-BDDFVIII-WPTS(MUT6)(VSVg)) also known as (Pleightlet(MUT6)) encoding the B domain deleted from of human coagulation factor VIII (BDDFVIII) in up to five hemophilia A patients with a history of FVIII inhibitors (≥0.6BU).~The infusion volume of transduced cells will not exceed 20 ml/kg body weight."
223880806|NCT07070752|DRUG|GP40321|GP40321, solution for subcutaneous injection, 100 U/mL (GEROPHARM LLC, Russia)
223880807|NCT07070752|DRUG|Apidra® SoloStar®|Apidra® SoloStar®, solution for subcutaneous injection, 100 U/mL (Sanofi-Aventis Deutschland GmbH, Germany)
223880808|NCT07070752|DRUG|RinGlar®|Patients also receive long-acting basal insulin therapy (insulin glargine 100 U/mL) throughout the study
223880809|NCT07078487|DEVICE|Pacemaker and defibrillator|Setting the pacemaker base rate at a pre-defined base rate
223880810|NCT07076745|DIAGNOSTIC_TEST|High-sensitivity C-reactive protein|High-sensitivity C-reactive protein will be done.
223880811|NCT07076745|OTHER|Stiffness Measurement|"Measurements will include carotid intima-media thickness (CIMT), systolic (Ds) and diastolic (Dd) diameters, and calculation of stiffness indices:~* β-stiffness index.~* Peterson's elastic modulus (Ep).~* Distensibility coefficient (DC).~* Compliance coefficient (CC).~* Strain."
223880812|NCT07078253|OTHER|Produce box program|Each week during the 20-week study period, participants will pick up a box of fresh vegetables. All produce will be provided to the participants at no cost as part of the client choice pantry program. Participants will take home approximately 6 different types of vegetables each week. Participants will choose which vegetables they want from a variety of options.
223880813|NCT07076576|OTHER|Yoga Training|The children in the experimental group underwent yoga training for a total of 16 sessions consisting of 45 minutes each session, 2 times a week for 8 weeks.
223880814|NCT07077720|PROCEDURE|genicular nerve block|genicular nerve block with a total of 15 mL of 0.25% bupivacaine preoperatively
223880815|NCT07077720|PROCEDURE|periarticular injection|periarticular injection prepared by the surgical team containing 8 mg morphine, 40 mg methylprednisolone, 0.3 mg adrenaline, 750 mg cefazolin, and 110 mg bupivacaine.
223880816|NCT07077720|PROCEDURE|Addukctor canal block|Addukctor canal block with 15ml %0.25 bupivacaine
223880817|NCT07077720|PROCEDURE|Spinal Anesthesia with Bupivacaine and Morphine|Spinal Anesthesia with Bupivacaine(isobaris 15-18mg) and Morphine(100mcg)
223880818|NCT07078721|RADIATION|Total Marrow Irradiation|\- TMI 4 Gy qd on Day -2;
223880819|NCT07078721|DRUG|Fludarabine (FLU)|Flu 30 mg/m² × 5 days on Days -6, -5, -4, -3, -2;
223880820|NCT07078721|DRUG|Melphalan (Mel)|Mel 100 mg/m² qd on Day -1.
223880821|NCT07077486|DRUG|Methylprednisolone (Corticosteroid)|In addition to conventional treatment (methyl-40mg or less /d), the treatment group also received hydroxychloroquine (100mg-200mg each time twice a day), and thalidomide (50mg-100mg each time once a day) could be added as appropriate.
223880822|NCT07077486|DRUG|Immunosuppressant other than CYC|The control group only received conventional treatment (methyl 40 mg/d or less), and other traditional immunosuppressants (including but not limited to cyclophosphamide, tacrolimus, sirolimus, cyclosporine, leflunomide, azathioprine, motecophenol ester, hydroxychloroquine, tripterine, methotrexate and sulazazopyridine, etc.). No more than 3 types of immunosuppressant should be added during the whole treatment period, and the dose should not exceed 30% from the baseline period)
223880823|NCT07077486|DRUG|Telitacicept Freeze-dried powder Injection 80mg|Telitacicept is a TACI-Fc fusion protein, a type of drug used to treat autoimmune diseases. It works by targeting two key proteins, BLyS and APRIL, which are involved in the development and function of B cells, a type of white blood cell. By blocking these proteins, telitacicept can help to reduce B cell activity and suppress the immune system's overactivity in autoimmune diseases. Subcutaneous injection dose ranges from 80mg once a week to 160mg once a week.
223880824|NCT07077486|DRUG|Cyclophosphamide (CYC)|Cyclophosphamide iv injection is used for severe complications of systemic lupus erythematosus 400mg twice a week
223880825|NCT07077785|PROCEDURE|Epidural Analgesia|After informed consent and exclusion of contraindications, an epidural catheter will be placed at the L3-L4 interspace in the sitting position using a Tuohy needle. A test dose of 2 mL lidocaine will be administered to confirm correct catheter placement under continuous monitoring of vital signs. Once cervical dilatation reaches 5 cm, 5 mL of 0.2% bupivacaine combined with 25 mcg fentanyl will be administered via the epidural catheter. Additional boluses will be given as needed based on pain assessment. The catheter will be removed 24 hours postpartum.
223880826|NCT07078188|BEHAVIORAL|PEG training|The caregivers will be given a general information form, the Caregiver Burden Scale, the Caregiver Stress Index Form, the SF 36 Quality of Life Scale, and the Caregiver Knowledge Scale for Nutrition with Percutaneous Endoscopic Gastrostomy Tube at each meeting (0, 1, and 3 months.). The intervention group will be trained on PEG use before discharge at the first interview.
223880827|NCT07078188|OTHER|Control|The caregivers will be given a general information form, the Caregiver Burden Scale, the Caregiver Stress Index Form, the SF 36 Quality of Life Scale, and the Caregiver Knowledge Scale for Nutrition with Percutaneous Endoscopic Gastrostomy Tube at each meeting (0.,1. ve 3. monts).
223880828|NCT07078149|DEVICE|Robotic-assisted TKA (RATKA).|RATKA was performed using the ROSA® Knee System.
223880829|NCT07078149|PROCEDURE|Conventional manual TKA (mTKA)|mTKA was performed without robot assistance.
223880830|NCT07078799|PROCEDURE|LASIK|Wavefront-guided LASIK is being performed in one eye and Ray-tracing guided LASIK is being performed in the fellow eye
223880831|NCT07078799|PROCEDURE|LASIK|Ray-tracing guided LASIK is being performed in one eye and Wavefront-guided LASIK is being performed in the fellow eye.
223880832|NCT07077668|DRUG|A sterile aqueous solution of RAG - 17 preparation (sodium salt)|Patients who meet the inclusion and exclusion criteria are required to come to the hospital at the following time points to complete the intrathecal bolus injection of RAG - 17 for 150 mg: baseline, 60 ± 3 days, 120 ± 3 days, 180 ± 3 days, 240 ± 3 days, 300 ± 3 days, 360 ± 3 days, 450 ± 3 days, 540 ± 3 days.
223880833|NCT07077304|OTHER|observational study|observational study
223880834|NCT07076901|BEHAVIORAL|Psychological Support|A structured psychological intervention aimed at alleviating preoperative anxiety. It included one-on-one counseling, providing detailed information about the surgical procedure, introducing relaxation techniques and music therapy, and sharing success stories from previous patients to boost confidence. Support was provided via phone or WeChat video by a qualified psychological counselor.
223880835|NCT07076901|BEHAVIORAL|Supervised Exercise Program|A daily guided exercise regimen including two components: 1) General physical conditioning consisting of at least 40 minutes of moderate-intensity aerobic and resistance training (e.g., brisk walking, jogging, cycling). 2) Respiratory function training consisting of abdominal breathing (5 times/hour) and balloon-blowing exercises (10 times/day). Patient adherence was monitored daily via a WeChat group.
223880836|NCT07076901|BEHAVIORAL|Lifestyle and Dietary Modification|Focused on optimizing preoperative habits. Nutritional guidance involved a high-protein, high-vitamin diet with six smaller, frequent meals per day to adapt to post-surgery conditions. Lifestyle guidance included advising smoking and alcohol cessation and ensuring 6-8 hours of sleep per night. Daily dietary and sleep status were reported and monitored via a WeChat group.
223880837|NCT07076901|OTHER|Routine Perioperative Care|Consisted of standard care practices before, during, and after surgery. Preoperative care included health education and fasting instructions. Intraoperative care included body temperature maintenance and vital signs monitoring. Postoperative care included 12-hour ECG monitoring, gradual reintroduction of a clear liquid diet 24 hours post-surgery, encouragement of early mobilization, and standard nursing for catheters and wounds.
223880838|NCT07076693|PROCEDURE|Radiotherapy or Surgery|Metastatic lesions were treated with surgical resection or radiotherapy. Surgical duration was determined by investigator assessment and metastatic or primary lesions were resected with palliative intent. Radiation dose and fractionation are 30\~50Gy. Radiation dose, fractionation regimen, and treatment sites for metastatic lesions were determined at the investigator's discretion based on clinical indications.
223880839|NCT07076693|DRUG|Standard Medical Therapy|Patients with squamous cell carcinoma received docetaxel administered in 3-week cycles, and patients with adenocarcinoma received pemetrexed, patinum and one of sintilimab or ivonescimab.
223880840|NCT07076628|DRUG|Propofol|Propofol infusion with remifentanil
223880841|NCT07076628|DRUG|Remimazolam|Remimazolam infusion with remifentanil
223880842|NCT07078357|BIOLOGICAL|StrepIncor|This arm will include 25/50/100/200 µg compared to placebo
223880843|NCT07078357|OTHER|Placebo|A placebo (aluminum adjuvant) will be administered and compared to the other study arms
223880844|NCT07076732|OTHER|Coronary Angiography|Coronary angiograms will be acquired digitally for quantification.
223880845|NCT07076732|OTHER|SYNTAX Score|Upon retrieval of a version from http://www.syntaxscore.com, the anatomical SYNTAX score will be implemented to numerically evaluate the intricacy of coronary lesions.
223880846|NCT06826859|DRUG|Daily aspirin (ASA)|162mg aspirin taken daily
223880847|NCT06826859|DRUG|Split dose aspirin (ASA)|81mg aspirin q12hours
223880848|NCT06215664|BEHAVIORAL|Singularities Game|Singularities is a theory-based, community-informed, web-accessible, roleplaying game-based intervention incorporating 4 primary components: fostering healthy identity development in a safe environment; encouraging help-seeking behaviors; encouraging use of productive coping; alcohol-harm reduction; and encouraging healthy internet and social media use.
223880849|NCT06215664|BEHAVIORAL|Food4Thought|Food4Thought is an attention control condition in which we provide participants with similar amounts of research team contact and program contact as the intervention. Participants will play the game Pick Your Plate! A Global Guide to Nutrition, developed by the Smithsonian Science Education Center. Participants are instructed to build healthy meals using cuisine from around the world while ensuring they stick to a budget and meet all their nutritional needs. Food4Thought will be delivered via Qualtrics.
223880850|NCT07077265|DRUG|Norepinephrine (0.1 μg/kg/min)|The patients will receive norepinephrine infusion at a rate 1 mL/kg/hour of 6 mcg/mL solution.
223880851|NCT07077265|DRUG|Norepinephrine (0.07 μg/kg/min)|The patients will receive NE infusion at a rate 1 mL/kg/hour of 4.2 mcg/mL solution.
223880852|NCT07078916|BEHAVIORAL|Motor-Cognitive Training Group (OLBA + BlazePod™)|Arm 1 participant will receive the One-leg-balance activity using visual feedback BlazePod technology as a dual motor-cognitive task training.
223880853|NCT07078916|BEHAVIORAL|Motor Training Group (OLBA Only)|Arm 2 participant will receive a the One-leg-balance activity as a single motor task.
223880854|NCT07077941|OTHER|Integrative care|Joint care of mother and child by just one healthcare professional
223880855|NCT07077408|OTHER|iCanCope-NF Youth app|The iCanCope digital app offers symptom tracking, self-management skills training, goal setting, and disease education tailored for neurofibromatosis for youth.
223880856|NCT07077408|OTHER|iCanCope-NF Youth app + CM|The iCanCope digital app offers symptom tracking, self-management skills training, goal setting, and disease education tailored for neurofibromatosis for youth. In addition to the standardized orientation and push notifications, this app will also allow users to earn incentives aligned with their program engagement.
223880857|NCT07078669|DEVICE|Polyglactin 910 (Dyed)|Half the wound for each participant will be sutured using Polyglactin 910 suture dyed (violet) with colorants such as D\&C Violet No. 2 present.
223880858|NCT07078669|DEVICE|Polyglactin 910 (Undyed)|Half the wound for each participant will be sutured using Polyglactin 910 suture Undyed
223880859|NCT05774483|PROCEDURE|Sentinel Node Biopsy|The Sentinel node will be localized after injecting peritumoral nano colloid followed by dynamic lymphoscintigraphy and SPECT localization. Methylene blue or indocyanine green may be used but not mandatory as an adjunct for lymphoscintigraphy for node localization. Intraoperatively the node will be identified using a hand-held gamma probe. The sentinel node will be processed on a frozen section, histopathological processing with serial step sectioning, and immunohistochemistry. If reported as metastatic, then a single-stage or second-stage completion neck dissection will be performed.
223880860|NCT05774483|PROCEDURE|Limited Elective Neck Dissection|Patients who are allocated to the limited END arm will undergo dissection of level I, IIa and III/IV nodes sparing level IIb. Level IIa will be subjected to a frozen section and if reported as metastatic will mandate clearance of level IIb.
223880861|NCT07077694|PROCEDURE|Root Canal Retreatment|if Retreatment was needed, local anesthesia using 1.8 ml (one cartridge) of 4% articaine with 1:100,000 epinephrine local anesthetic solution, administered with end -loading cartridge aspirating syringe and a 27-gauge long needle. Under rubber dam isolation, All carious tissue and existing coronal restorations were thoroughly removed using a round bur, an endodontic access cavity, canal preparation and removal of existing root canal filling, irrigation with 2.6% NAOCL and saline, determining the working length using apex locator and PA radiograph, to be 0.5 to 1 mm shorter than radiographic apex, Drying the canal with paper point and obturation to achieve a dense, well adapted Monoblock obturation. A post-obturation periapical radiograph was taken to confirm the quality of the fill in terms of length, density, then sealed by a temporary restorative material.
223880862|NCT06815926|DIETARY_SUPPLEMENT|Probiotic|"Food supplement based on probiotics in capsule format. Dose: 1 capsule/day.~The active capsules contain probiotic strains at ≥1×10\^9 cfu/dose and excipient."
223880863|NCT06815926|DIETARY_SUPPLEMENT|Placebo|"Food supplement in capsule format. Dose: 1 capsule/day.~The placebo capsules contain only excipient (probiotics are not included)."
223880864|NCT01959698|DRUG|Carboplatin|Given IV
223880865|NCT01959698|DRUG|Carfilzomib|Given IV
223880866|NCT01959698|DRUG|Etoposide|Given IV
223880867|NCT01959698|DRUG|Ifosfamide|Given IV
223880868|NCT01959698|OTHER|Laboratory Biomarker Analysis|Correlative studies
223880869|NCT01959698|OTHER|Pharmacological Study|Correlative studies
223880870|NCT01959698|BIOLOGICAL|Rituximab|Given IV
223880871|NCT04790175|DRUG|Tolvaptan (SAMSCA)|The usual adult dose of SAMSCA is 7.5 mg of tolvaptan once daily administered orally, increased stepwise to 60 mg daily until a desirable level of serum sodium concentration is achieved.
223880872|NCT03744312|DRUG|11C-ER176|11C-ER176 sticks to parts of the brain where there is inflammation. Past studies have shown that inflammation is present in the brains of patients with Alzheimer's disease. The purpose of this study is to determine if 11C-ER176 is able to accurately measure inflammation in patients with Alzheimer's disease.
223880873|NCT03744312|DRUG|Florbetaben|Florbetaben sticks to amyloid plaques, which are in the brain in Alzheimer's disease.
223880874|NCT05018845|BIOLOGICAL|AlloRx|cultured allogeneic adult umbilical cord derived mesenchymal stem cells
223880875|NCT06652607|DRUG|Enzalutamide|The objective of the study is to assess survival in patients treated with Enzalutamide according to PSA response and to describe the baseline characteristics of patients with and without an optimal PSA response.
223880876|NCT06652607|DRUG|Apalutamide (Erleada™) 60 mg or 240 mg tablets|The objective of the study is to assess survival in patients treated with Apalutamide according to PSA response and to describe the baseline characteristics of patients with and without an optimal PSA response.
223880877|NCT06652607|DRUG|Darolutamide (Nubeqa®) 300 mg tablets|The objective of the study is to assess survival in patients treated with Darolutamide according to PSA response and to describe the baseline characteristics of patients with and without an optimal PSA response.
223880878|NCT06652607|DRUG|Taxotere (docetaxel)|The objective of the study is to assess survival in patients treated with Taxotere according to PSA response and to describe the baseline characteristics of patients with and without an optimal PSA response.
223880879|NCT06652607|DRUG|Abiraterone acetate + Prednisone or Prednisolone|The objective of the study is to assess survival in patients treated with Abiraterone according to PSA response and to describe the baseline characteristics of patients with and without an optimal PSA response.
223880880|NCT05606406|OTHER|Nocturnal Oxygen|Nocturnal oxygen will be increased hourly for a period of four hours up to 4 liters per minute (LPM). If the oxygen saturation (SpO2) falls below 70% the oxygen rate will be increased until patients achieve the threshold of 70% and then will proceed with titrations of 1 liter per minute LPM per hour.
223880881|NCT06480578|BEHAVIORAL|ISS-SBDOH arm|Once the ID-Cap ISS system has identified a participant who has missed his/her prescribed ARVs for five (5) consecutive days, a member of the multidisciplinary team will be informed automatically by the system and reach out to the participant immediately. The team will work with the primary provider and the participant to evaluate and understand the patient's SBDOH profile and status and develop a coordinated plan that fits the patient's specific need to address the patient's particular challenges in SBDOH. This plan (all SBDOH interventions) is considered standard of care and would be initiated in the same manner regardless of participation. Participation in this study will not alter the planned interventions determined by the HIV Care team.
223880882|NCT05208814|DRUG|TPN171H single dose|10 mg TPN171H taken once
224076786|NCT04063371|OTHER|Self-Administered Gerocognitive Examination (SAGE) or Electronic Self-Administered Gerocognitive Examination (eSAGE)|The Self-Administered Gerocognitive Examination (SAGE) is a reliable and valid assessment that is used to detect MCI and early dementia. It is a pen and paper assessment that has 4 interchangeable versions. The digital version of SAGE (eSAGE; commercially known as BrainTest®) is made for tablet use, consists of the identical test questions as SAGE, and is strongly associated with the validated SAGE.
223880883|NCT04263025|BIOLOGICAL|Cryopreserved Umbilical Cord Allograft|"CLARIX® CORD 1K (Amniox Medical, Miami, FL) is an umbilical cord allograft processed using the patented CRYOTEK™ process by TissueTech Inc. to devitalize all living cells but retain the natural structural and biological characteristics relevant to this tissue \[43\]. CLARIX® CORD 1K (6x3 cm in size) will be cut into two longitudinal pieces (1.5 cm in width) and placed circumferentially around each NVB as a nerve wrap during RARP. CLARIX® CORD 1K has been in market since 2013 in the United States as a 361 human cell and tissue-based product (HCT/P) and is aseptically processed in compliance with current Good Tissue Practices (cGTP) as outlined in 21 CFR Part 1271."
223880884|NCT04263025|PROCEDURE|Robot-Assisted Radical Prostatectomy|Robot-Assisted Radical Prostatectomy (RARP) is the most common surgical technique used to treat clinically localized prostate cancer however robot-assisted radical prostatectomy
223880885|NCT03012841|DEVICE|Arctic Front Advance Cardiac CryoAblation Catheter|Cryoablation
223880886|NCT05665725|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223880887|NCT05665725|PROCEDURE|Computed Tomography|Undergo CT scan
223880888|NCT05665725|PROCEDURE|Positron Emission Tomography|Undergo PET scan
223880889|NCT05665725|BIOLOGICAL|Siltuximab|Given IV
223880890|NCT06474611|BEHAVIORAL|Patient nudge|Patient receives an electronic or paper letter 'nudge' to talk to dr about LCS.
223880891|NCT05874206|DEVICE|Cratos™ Stent Graft|Cratos™ Stent Graft TEVAR procedure for the treatment of aortic lesions.
223880892|NCT01688076|PROCEDURE|Botulinum Toxin A|Forehead will be injected with Botox.
223880893|NCT04491968|BEHAVIORAL|Mindfulness Oriented Recovery Enhancement|MORE sessions involve mindfulness training to prevent opioid relapse and reduce pain, cognitive reappraisal to decrease negative affect and regulate opioid craving, and savoring to augment natural reward processing and evoke positive emotion. Each session begins with a mindful breathing meditation, followed by a debriefing session. The therapist then debriefs participants' homework practice of using mindfulness, reappraisal, and savoring skills to cope with pain and enhance well-being in everyday life. During this debrief of the homework. Next, new psychoeducational material is introduced. Sessions culminate with an experiential exercise, and close with a brief mindful breathing meditation. Participants are asked to practice 15 minutes of mindfulness/reappraisal/savoring skills each day.
223880894|NCT04491968|OTHER|Methadone Treatment as Usual|In the methadone programs, clients typically come to the clinic regularly to get their methadone dose. Clients see their clinic substance abuse counselor for individual counseling, usually weekly at the beginning of treatment, with decreasing frequency if they remain abstinent and progress through treatment. Depending on clients' stage of MMT and success with remaining abstinent from drugs, they may be required to attend clinic treatment groups. Also, some clients may choose to go to voluntary counseling, educational, or support groups.
223880895|NCT04646200|BEHAVIORAL|Cognitive Behavioral Therapy-Insomnia|CBT-I addresses cognitive, arousal and behavioral factors related to sleep difficulties. Sessions combine assessment, conceptualization, psychoeducation, behavioral strategies and cognitive therapy, using a consistent structure including review of participants' sleep log and adherence to behavioral guidelines, modification of time in bed, cognitive therapy, and relaxation techniques. CBT-I also incorporates psychoeducation about biological and psychological elements that regulate sleep. Other strategies include stimulus control (i.e., getting out of bed when not sleepy) to extinguish the conditioned arousal common in insomnia, and relaxation techniques to reduce arousal associated with the bed, bedroom, or bedtime.
223880896|NCT04646200|BEHAVIORAL|Health and Wellness|Health and Wellness is a general self-management curriculum focused on providing education and support for managing physical and emotional well-being. Each session follows a basic structure including review of previous session material, new educational information and discussion on several topics over the course of single or multiple sessions. Each session will focus on the impact of the topic on overall health and wellness, identifying benefits and challenges to improving or maintaining health in that area, and strategies that clients may find helpful to address challenges in that area. Example topics include physical activity/exercise, nutrition/healthy eating, managing medications and side effects, and addictive behaviors (e.g., substance use, gambling, eating).
223880897|NCT05479994|DRUG|BGB-11417|Administered orally
223880898|NCT00404196|DRUG|Calcipotriol and LEO80122 (LEO19123 cream)|
223880899|NCT04373226|BEHAVIORAL|Magnitude comparison tasks and neuropsychological testing|neuropsychological testing (ZAREKI-R) and magnitude comparison tasks with stimuli of different types (visual, visuo-spatial)
223880900|NCT06783517|PROCEDURE|cerabone|Atraumatic removal of remaining root or tooth will be performed Implant will be placed in fresh socket Bovine bone graft (cerabone®,Botiss biomaterial) will be added to the implant
223880901|NCT06783517|PROCEDURE|cerabone®plus|Atraumatic removal of remaining root or tooth will be performed Implant will be placed in fresh socket Bovine bone substitute with sodium hyaluronate graft (cerabone®plus,Botiss biomaterial) will be added to the implant
223880902|NCT01536886|DRUG|LEO 90100|
223880903|NCT01536886|DRUG|Betamethasone plus calcipotriol|
223880904|NCT01536886|DRUG|Ointment vehicle|
223880905|NCT01536886|DRUG|LEO 90100 vehicle|
223880906|NCT04541043|DRUG|Nefecon 16mg daily|All study patients received Nefecon 16 mg daily for 9 months.
223880907|NCT03236441|DEVICE|RIPC|Remote ischemic preconditioning
223880908|NCT03236441|DEVICE|Sham-RIPC|Control
223880909|NCT04705779|BEHAVIORAL|HARMONY|The HARMONY intervention will be delivered over 8 every-other-week sessions and 6 monthly booster sessions. Each session will have three components; an exercise sampler, cool down and tailored education on cardiometabolic prevention and risk reductions.
224076787|NCT04063371|OTHER|Informant Conversation|If possible, the provider will have a conversation with an individual who knows the patient will to ascertain if a significant change (based on primary care provider opinion) occurred in the patient's cognitive skills over the previous year.
223880910|NCT04705779|BEHAVIORAL|Nutrition and Exercise Education (NEEW)|The Nutrition and Exercise Workgroup (NEEW) group will be delivered over 8 every-other-week sessions and 6 monthly booster sessions. Each session will have three components; an exercise sampler, cool down and tailored education on cardiometabolic prevention and risk reductions.
223880911|NCT05599789|DRUG|Pembrolizumab in Combination with Plinabulin and Docetaxel|Pembrolizumab 200 mg Q3W IV infusion Day 1 of each 3-week cycle; Plinabulin 30 mg/m2 Q3W IV infusion Days 1 of each 3-week cycle; Docetaxel 75 mg/m² Q3W IV infusion Day 1 of each 3-week cycle.
223880912|NCT05328661|DIAGNOSTIC_TEST|Blink reflex|The stimulator is directly connected to the right side of the frontal board. The sponge must be soaked in water or saline before being inserted into the stimulator. Dry them a bit to avoid leaking on the stimulator (it could create a bridge between the two poles). We want to stimulate the supraorbital nerve at its emergence from the eyebrow arch (the supraorbital foramen in the supra-orbital margin bone is easy to palpate 1 cm laterally to the root of the nose). We place the stimulator above the emergence of the supraorbital nerve, with the distal pole placed below. The final intensity of stimulation is generally between 5 to 10 mA, but higher intensities sometime are required.
223880913|NCT03746769|BIOLOGICAL|Allogenic Human Islet Cells|islet cells transplanted into the portal vein in the liver
223880914|NCT03746769|DRUG|Gastrin 17|"Gastrin-17 (or GAST-17) - a gut hormone injected under the skin twice daily for 30 days soon after islet transplant and again 6 months later.~Also, anti-rejection medications (to prevent the body from rejecting the islet cells) and other medications to guard against infection and support participant health and/or the health of the transplanted islets."
223880915|NCT05716867|BIOLOGICAL|Measurement of salivary cystatin S protein levels in saliva|The human cystatin S enzyme-linked immunosorbent assay (ELISA) kit will be used to measure the amounts of cystatin S in saliva for cases and controls
223880916|NCT06783634|DRUG|Dexamethasone|Group 2 (dexamethasone group) single intra venous high dose of dexamethasone 1mg/kg with maximum dose of 100 mg.
223880917|NCT06783634|DRUG|Placebo|Group 1 (Control group) will receive normal saline as a placebo.
223880918|NCT06829446|PROCEDURE|Extra-PV extensive ablation|Extra-PV extensive ablation
223880919|NCT06829446|PROCEDURE|Repeat same PVI and linear ablation as the first procedure|Repeat same PVI and linear ablation as the first procedure
223880920|NCT03416023|DEVICE|TIES® (Transcutaneous Implant Evacuation System)|Transcutaneous Implant Evacuation System
223880921|NCT04878354|DRUG|Tree SLIT-tablet|Sublingual allergy immunotherapy tablets
223880922|NCT04878354|DRUG|Placebo SLIT-tablet|Placebo
223880923|NCT05530551|OTHER|Antibiotic dosage practice|"Patient inclusion starts day one, cross-over of departments from treatment A (single-dose) to B (multiple-dose) or vice versa after one year and end of inclusion happens after 2 years.~All centers in Denmark use either Cloxacillin/Dicloxacillin, Cefuroxime or both drugs as standard prophylactic antibiotic practice for THA. In cases of cephalosporin allergy or general beta lactam allergy, the antibiotic clindamycin may be administered.~In this trial, patients will be administered the standard prophylactic antibiotic practice of either single-dose (A) or multiple-doses (B) of antibiotics administered at each respective cluster that respective year. Both practices of dose administration for antibiotic prophylaxis (i.e. single- or multiple-dose) follow current standards of treatment and are based on present clinical practice guidelines."
223880924|NCT06230640|DIAGNOSTIC_TEST|In vitro medical diagnostic device TEG6s® Platelet Mapping|"Preoperative period:~* Pre-operative blood sampling, according to the usual practices of the unit before surgery~* Collection of the patient's usual demographic characteristics~per operative period :~* After anesthetic induction:a TEG6S platelet mapping® sampled from the arterial catheter routinely placed after anesthetic induction~* During the CPB, 30 min before aortic declamping: performing TEG 6S platelet mapping® (heparinized tube)~* 5 min after heparin antagonization by protamine, after the weaning of the bypass, and before any transfusion: performing a TEG 6S citrate® (citrated tube)~Post-operative period (resuscitation):~• postoperative bleeding at 2 hours and during the first 12 hours."
223880925|NCT05191667|DRUG|AN0025|250 mg or 500 mg Q.D., oral administration
223880926|NCT03860805|PROCEDURE|Laparoscopic tubal ligation|Laparoscopic tubal ligation
223880927|NCT03860805|PROCEDURE|Laparoscopic bilateral salpingectomy|Laparoscopic bilateral salpingectomy
223880928|NCT04002752|DRUG|JNJ-73763989|Participants will receive JNJ-73763989 as single subcutaneous injection.
223880929|NCT04002752|DRUG|Placebo|Participants will receive placebo matching to JNJ-73763989 as single subcutaneous injection.
223880930|NCT03212404|DRUG|CK-301 (cosibelimab)|CK-301 will be administered in periods of 28-day cycles.
223880931|NCT05510232|DEVICE|A treatment group that will watch a non-VR video via an iPad|"The iPad is a tablet computer first offered by Apple in 2010.The device resembles a much larger version of Apple's iPhone or its iPod Touch, and is about the same size as a magazine.The iPad uses the same operating system as the Apple iPhone, and uses very similar hardware. iPad will be used to deliver non VR video to patients.~A standardized age appropriate video will be used for patients between ages 4-9 and a different standardized age appropriate video for patients ages 10-14. The selected videos will be the same for both the cast and suture/pin removal groups."
223880932|NCT05510232|DEVICE|A treatment group that will have headset on and will watch a non-VR video|"Oculus headset will deliver VR video to patients. Headset will be administered before intervention and removed at the completion of the intervention unless patient requests otherwise. Patients visual field will not change with head motion and will remain static throughout cast removal or pin/suture removal.~A standardized age appropriate video will be used for patients between ages 4-14. The selected videos will be the same for both the cast and suture/pin removal groups."
223880933|NCT05510232|DEVICE|A treatment group that will be immersed in the VR game (Bear Blast) via the headset.|VR using the Oculus headset will deliver VR images and sound. Patients will watch a 15-minute VR experience called Bear Blast. Bear Blast is an immersive, 360-degree, game experience that takes place in a fantasy world where the user attempts to shoot balls at a wide range of moving objects by gently maneuvering his or her head toward the targets. Bear Blast is a nonviolent and noncompetitive game that incorporates motivational music and features positively reinforcing sounds, animation, and direct messages to patients. Bear Blast will be used as the standardized game for all patients in the VR group of both study arms. The VR Oculus headset can be controlled entirely via head motion and does not involve the use of patients extremities.
223880934|NCT02380612|DEVICE|ReCell Treatment|
223880935|NCT02380612|PROCEDURE|Skin Graft|
223880936|NCT05846984|BEHAVIORAL|Learning Skills Together Intervention|Learning Skills Together is a 6-week psychoeducational intervention developed to improve caregivers' confidence when completing complex care tasks (e.g., using a gait belt). Participants are asked to attend six 1.5-hour Zoom-delivered group discussion sessions once per week, which cover topics such as how to communicate with someone who is living with dementia, medication management, and home safety. Participants are also provided with a workbook that accompanies each lesson, and includes short readings, videos, additional resources, as well as weekly practice and reflection exercises.
223880937|NCT05846984|BEHAVIORAL|Caregiver Healthy Living Intervention|Participants in the Caregiver Healthy Living Intervention will participate in a 6-week educational intervention to help improve caregiver health behaviors (e.g., getting enough sleep). Participants are asked to attend six 1.5-hour Zoom-delivered group discussion sessions once per week, which cover topics such as how to eat a healthy diet, getting enough physical activity, and taking care of mental health. Participants are also provided a workbook that includes short readings and additional resources.
223880938|NCT03433911|DEVICE|FemBloc|Treatment with FemBloc for women who desire permanent birth control (female sterilization)
223880939|NCT03433911|PROCEDURE|Laparoscopic bilateral tubal sterilization|Laparoscopic bilateral tubal sterilization for women who desire permanent birth control (female sterilization)
223880940|NCT05796492|DEVICE|Pulsed splenic ultrasound|A General Electric LOGIQ E10 ultrasound machine with a C1-6-XD clear probe, will be used to selectively deliver pulsed ultrasound to the spleen.
223880941|NCT05796492|DEVICE|Ultrasound probe (no energy applied)|A General Electric LOGIQ E10 ultrasound probe will be placed over the spleen with no energy applied
223880942|NCT04070989|DEVICE|THA|Pinnacle Acetabular Shell (Sector, Gription, no screws), AltrX Polyethylene Liner and Corail Femoral Stem
223880943|NCT05847543|OTHER|Stool diaper data and sample collection|Stool diaper data and sample collection
223880944|NCT03176498|BIOLOGICAL|Allogeneic umbilical cord mesenchymal stem cell|Experimental group receive Allogeneic umbilical cord mesenchymal stem cell，i.v (SCLnow 19#)
223880945|NCT03176498|DRUG|Aspirin Enteric-coated Tablets & Atorvastatin Calcium|Aspirin Enteric-coated Tablets, 0.1g/d by mouth; Atorvastatin Calcium, 20mg/d by mouth.
223880946|NCT06005662|DRUG|Psilocybin|The proposed study is a double-blind, controlled investigation of the effect of 1 high-dose psilocybin (30 mg) session compared to a very low dose session (1 mg) following standard-of-care buprenorphine induction on drug abstinence, quality of life, craving, tobacco use, and treatment retention in healthy participants with an active OUD diagnosis
223880947|NCT05925595|DEVICE|Medical Device Iniettabile Ginocchio|Knee injection of the investigational device( MD Iniettabile Ginocchio) versus active comparator (Jonexa).
223880948|NCT05214820|BIOLOGICAL|Radiopharmaceutical 68Ga-PSMA|Injection of 68Ga-PSMA followed by 3 PET/CT acquisitions
223880949|NCT05240807|DIAGNOSTIC_TEST|Photon counting computed tomography (PC-CT)|Cardiac CT imaging will be performed using a newly developed CT scanner that uses photon-counting detectors and the results compared to those from conventional CT, MRI, or nuclear medicine imaging systems
223880950|NCT06182371|BEHAVIORAL|Disengage the breathing circuit|Disengage the breathing circuit when the position of the patient undergoing thoracic surgery changes
223880951|NCT04719988|BIOLOGICAL|Blood sample collection|"A total of 9 EDTA (ethylenediaminetetraacetic acid) tubes will be collected at each time point to perform:~PBMC collection: 6 EDTA tubes of 6 ml of peripheral blood mononuclear cell \[PBMC\] will be sent to the central laboratory (Biomonitoring Platform of Besançon, CHRU de Besançon located at Etablissement Français du Sang) at room temperature within 24 hours via an approved carrier for their processing, storage and immunomonitoring analysis. A sending sheet of the samples will be attached to each single sample.~Plasma collection: One 6 ml EDTA tube should be frozen in each investigation center for plasma collection.~Plasma for circulating tumoral DNA (ctDNA) collection: Two 4 ml EDTA tube should be frozen in each investigation center for ctDNA collection."
223880952|NCT04719988|PROCEDURE|Biopsy|A tumor biopsy will be performed at 2 months after enrollment.
223880953|NCT05601219|DRUG|ADA-011|ADA-011 will be administered intravenously (IV) Q3W on a 21-day cycle.
223880954|NCT05601219|DRUG|PD(L)-1 inhibitor|PD(L)-1 inhibitor will be administered intravenously (IV) Q3W.
223880955|NCT06218836|OTHER|Pre-inflated endotracheal tube|The ETT (males: size 7.5 mm ID, females: size 6.5 mmID) will be taken out from the wrapper and submerged in 0.9% normal saline till the proximal margin of the cuff. Then, the cuff will be inflated to 40 cm of H2O to gain full stretch inflation.Thereafter the cuff will be deflated with the help of cuff inflator-deflator device to maintain intracuff pressure of 4 cm H2O The external cuff balloon will be obliterated with a soft clamp to ensure that at the time of passage of tube through the glottic-inlet, the tube cuff does not get deflated due to pressure equalization with the external balloon.
223880956|NCT06218836|OTHER|Non-inflated endotracheal tube|The ETT (males: size 7.5 mm ID, females: size 6.5 mmID) will be taken out from the wrapper and submerged in 0.9% normal saline till the proximal margin of the cuff. Thereafter the endotracheal intubation will be done.
223880957|NCT05662787|DEVICE|Intravascular Lithotripsy|Enhancing percutaneous transluminal angioplasty by utilizing delivery of IVL to disrupt calcium in above the knee lesions prior to full balloon dilatation at low pressures
223880958|NCT04855760|DRUG|REL-1017|REL-1017 tablet
223880959|NCT06126913|OTHER|Community Antiretroviral Therapy|Newly diagnosed individuals (diagnosed in the prior 6 months) at intervention sites will be offered community ART delivery on a rolling basis during the enrollment window, initiating individuals into groups as close to their date of diagnosis as possible. Newly enrolled individuals will join existing community ART delivery groups, or when a new group is needed based on group size or geographic location, a new group will be formed.
223880960|NCT01983241|BIOLOGICAL|Alpha-1 MP|
223880961|NCT01983241|OTHER|0.9% Sodium Chloride for Injection, USP|
223880962|NCT06463795|DEVICE|tDCS|active anodal tDCS
223880963|NCT06463795|DEVICE|Sham tDCS|sham anodal tDCS
223880964|NCT06409754|DEVICE|Functional Electrical Stimulation Therapy coupled to a P-300 based Brain-Computer Interface|The intervention involves a BCI control strategy based on a modified version of the classic P300 Donchin Speller Interface, where the matrix of letters and symbols is replaced by a set of pictures including five hand gestures and wrist orientations: hand opening, grasping, pinching, pronation, and supination. This BCI approach is based on the oddball paradigm, relying on conscious recognition by the user of the intensification of a particular target movement picture, within a sequence of other, non-target, random visual stimuli. This process should evoke the P300 component in the event related potential. The aim of the training sessions is to link an action observation/target selection task, mediated by the P300-based BCI, with the practice of a FES-assisted functional task involving the target movement picture selected. Users will be instructed to synchronize their voluntary movements with the ones induced by FES, to achieve the functional target goal.
223880965|NCT06409754|OTHER|Conventional Physical Therapy|Conventional physical and occupational therapy will include sessions of joint mobility, muscle strength, task-specific training, sensitivity reeducation and coordination exercises directed by an experienced professional therapist.
223880966|NCT03938168|DIAGNOSTIC_TEST|Biopsy, fecal sample|Preoperatively and at 12 months after surgery, patients will obtain a fecal stool sample for microbioma analysis. Adhesions that are cut and released to acquire access to the operative field are stored for molecular and histological analyses.
223880967|NCT04881162|DEVICE|NOVIS Transcarotid Neuroprotection System (NPS)|The NOVIS Transcarotid Neuroprotection System (NPS) is intended to provide transcarotid vascular access and embolic protection
223880968|NCT04934176|OTHER|Psychosocial scales/questionnaires|We will use three psychosocial scales/questionnaires for this patient population to gauge patients' perceptions of the impact of their paralysis and their recovery. The questionnaires will be completed by the patients at baseline, and 18 months after surgery. Moreover, we also will compare patient perceptions to the patient-related responses with clinical scoring made by the surgeons using the eFACE,6 Face-Gram/Emotrics12 software, and the 3D dynamic measures.
223880969|NCT04934176|OTHER|3D Facial Measurements|3D dynamic (objective) facial movement data will be collected first (estimated time 1 hour), followed by static 3D photographic data (estimated time 15 minutes), and then video data of the different facial animations (estimated time 15 minutes).
223880970|NCT05195970|OTHER|Walnuts|Participants consume 2 ounces of walnuts daily for 21 days
223880971|NCT05241613|DRUG|AC176|AC176 will be given orally (PO) on a 28-day cycle.
223880972|NCT05557370|BIOLOGICAL|Human Papilloma Virus vaccine (GARDASIL 9)|Patients will be scheduled to receive 3-dose 9vHPV vaccination (vaccination at enrollment \[time 0\], 2 months \[+ 6 weeks\], and 6 months \[+ 6 weeks\] per standard guidelines).
223880973|NCT04832360|BEHAVIORAL|Financial Incentives|Financial incentives may be offered to participants based on their behavioral outcomes (smoking cessation and participation in online psychoeducation about smoking)
223880974|NCT05794763|BEHAVIORAL|Peer Led Group Intervention|A four-week dissonance-based program where individuals with body image concerns complete verbal, written, and behavioral activities. The program consists of four 60-minute sessions
223880975|NCT04869982|BIOLOGICAL|RZV|2 doses of RZV in 0, 2 months schedule, administered intramuscularly in the deltoid region of the non-dominant arm
223880976|NCT04869982|DRUG|Placebo|2 doses of placebo in 0, 2 months schedule, administered intramuscularly in the deltoid region of the non-dominant arm
223880977|NCT05361187|DEVICE|BOBBY™ Balloon Guide Catheter intended for use in neurovascular procedures, performing or as an adjunctive device|The BOBBY™ BGC used during a mechanical thrombectomy procedure (stent retriever alone, contact aspiration alone or stent retriever and contact aspiration) and according to the instruction for use (IFU).
223880978|NCT04013555|DRUG|N-acetylcysteine (NAC)|Flavored effervescent formulation
223880979|NCT04013555|DRUG|Placebo|Flavored effervescent formulation designed to mimic NAC
223880980|NCT04013555|DRUG|Tryptophan|Oral slurry form
223880981|NCT05569967|OTHER|Spinal stabilization training through telerehabilitation|Individuals in both groups will receive spinal stabilization training 3 times a week for 8 weeks.
223880982|NCT05569967|OTHER|Spinal stabilization training face-to-face|Individuals in both groups will receive spinal stabilization training 3 times a week for 8 weeks.
223880983|NCT00152698|DRUG|Irbesartan|
223880984|NCT01631214|BIOLOGICAL|Romosozumab|Romosozumab 210 mg administered by subcutaneous injection once a month during the double-blind treatment phase.
223880985|NCT01631214|DRUG|Alendronate|Alendronate 70 mg tablet taken once a week
223880986|NCT01631214|DRUG|Placebo to Romosozumab|Administered by subcutaneous injection once a month during the double-blind treatment phase.
223880987|NCT01631214|DRUG|Placebo to Alendronate|Matching placebo tablet taken once a week during the double-blind treatment phase.
223880988|NCT06065995|DEVICE|StoMakker|A mobile application that offers age dependent information, a peer support platform and a game
223880989|NCT02611505|DRUG|Esketamine|Esketamine 28 mg will be self-administered by participants as intranasal spray at 0 hour (h) on Day 1.
223880990|NCT03805594|DRUG|Lutetium Lu 177-PSMA-617|Given IV
223880991|NCT03805594|BIOLOGICAL|Pembrolizumab|Given IV
223880992|NCT05139316|GENETIC|DTX401|nonreplicating, recombinant, adeno-associated virus (AAV) serotype 8 (AAV8)
223880993|NCT05139316|OTHER|Placebo|Normal Saline infusion
223880994|NCT05139316|DRUG|Oral corticosteroids|Participants who receive DTX401 solution will receive oral corticosteroids
223880995|NCT05139316|DRUG|Placebo for oral corticosteroids|Participants who receive Placebo will receive placebo oral corticosteroids to maintain the study blind
223880996|NCT05004610|DRUG|Sodium Lactate Solution|continuous intravenous infusion of molar sodium lactate
223880997|NCT05476575|OTHER|hydrogen inhalation, 4% concentration, given via nasal cannula|4% hydrogen inhalation via nasal cannula perioperatively
223880998|NCT03378739|PROCEDURE|Cardiogenic Shock team activation|Any patient with cardiogenic shock, whether inpatient or transferred from another facility, treated at the Inova Heart and Vascular Institute by the designated Cardiogenic Shock Team.
223880999|NCT05348863|BEHAVIORAL|SPARK|The SPARK digital platform provides support to the patient (shown as an app) as well as provides the possibility for the health care provider to review and give feedback on blood glucose levels through the care giver interface of the platform.
223881000|NCT05145452|DIETARY_SUPPLEMENT|Fish-oil derived n-3 polyunsaturated fatty acids|4.2 g/d (7 pills with 600 mg each)
223881001|NCT05931861|DEVICE|T2769|T2769: sodium hyaluronate 0.15%, Trehalose 3%, Naaga 2.45% in a 12.5 mL ABAK® multi-dose bottle.
223881002|NCT06476847|BEHAVIORAL|PrEP persistence|A light touch, once off, low cost. lay counsellor led intervention, designed to focus decision making around HIV prevention addressing present bias, salience and over optimism. The intervention package consists of evidence informed reminders, commitment pledges and planning prompts.
223881003|NCT04112316|DRUG|Liothyronine|Liothyronine (L-triiodothyronine or LT3) in the 5 mcg tablet dose formulation. Minimum LT3 dose was 2.5 mcg three times daily and the maximum LT3 dose was 12.5 mcg three times daily.
223881004|NCT04112316|OTHER|Placebo|A placebo tablet matching in appearance to LT3 tablets. Minimum placebo tablet dose was 1/2 tablet three times daily and the maximum placebo dose was 2 1/2 tablets three times daily.
223881005|NCT05806814|BIOLOGICAL|Sipuleucel-T|Three doses of Sipuleucel-T, each containing a minimum of 50 million autologous CD54+ cells activated with PAP-GM-CSF, given at week 0, 2, and 12-14.
223881006|NCT02945072|PROCEDURE|TIVA|TIVA is use to anesthesia maintenance after anesthesia induction (Propofol 10mg/kg/h, Remifentanil 0.2mcg/kg/min, dose adaptation as required for sufficient anesthesia)
223881007|NCT02945072|PROCEDURE|Sevoflurane|Sevoflurane is use to anesthesia maintenance after anesthesia induction (target et 2 Vol% in 50-70% N2O, dose adaptation as required)
223881008|NCT06261801|OTHER|Medication Group|Participants in the medication group would take 150-mg pregabalin capsules (manufactured by Pfizer Pharmaceuticals Co., Ltd) orally twice daily (total daily dose, 300 mg) for 4 weeks.
223881009|NCT06261801|OTHER|EA Group|Acupoints selection: Ashi acupoint, Sibai acupoint (ST2), Xiaguan acupoint (ST7), and Dicang acupoint (ST4) on the affected side. Acupoints for the diseased branches (all taken from the affected side): eye branch and Tongziliao point (GB1), the maxillary branch is taken from the Quanliao point (SI18), and the mandibular branch is taken from the Jiache point (ST6).Shenting point (DU24), Baihui point (DU20), Hegu point (LI4), Waiguan point (TE5), Yanglingquan point (GB34), and Taichong point (LR3) on the affected side Operation: The EA apparatus will be applied on the Ashi point and (LI4 - TE5). The treatment will last for 30 minutes and the electrical stimulation will be set as 2/100Hz in frequency.
223881010|NCT06261801|OTHER|EA+Medication Group|Participants in the EA+Medication group would receive both EA and medical treatement. The acupoints and their location, needles, the settings of the EA device are the same as EA Group's; in the meanwhile, the medication and its dosage is the same as Medication Group's.
223881011|NCT06539156|OTHER|DVT prophyllaxis|VTE prophylaxis administration among patients based on the American College of Chest Physicians (ACCP) recommendations
223881012|NCT05321628|BEHAVIORAL|Internet-based Cognitive Behavioural Therapy (iCBT) with Decision Support Tool|Cognitive Behavioural Therapy för depression, panic disorder and social anxiety delivered thru texts and home works assignments via an internet platform with therapist weekly support through text messages. Therapist use a traditional, detailed therapist manual with the additions of a Clinical Decision Support Tool (DST) that identifies patients at risk of treatment failure and give suggestions to the therapist on how to act in relation to the specific patient.
223881013|NCT05321628|BEHAVIORAL|Internet-based Cognitive Behavioural Therapy (iCBT)|iCBT, as described above, using only the traditional, detailed therapist manual.
223881014|NCT04947553|DRUG|AXS-05 (dextromethorphan-bupropion)|AXS-05 tablets, taken twice daily
223881015|NCT04947553|DRUG|Placebo|Placebo tablets, taken twice daily
223881016|NCT05891782|BEHAVIORAL|HAPA-based Multidomain Fall Risk Management|"According to the HAPA and the conceptual model of IC, this intervention consists of 3 stages.~Stage 1: The main format will be group lectures and scenario simulation, each intervention will have a duration of 30 to 45 minutes. Intervention content will utilize BCT \[5.1, 5.3, 5.5, 5.6, 9.3, 15.1\] .~Stage 2: This stage will utilize mostly group lectures or one-to-one interviews, to provide an action and coping plan to participants for fall risk management. This will apply BCT \[1.1-1.4, 4.1\] at week 4.Firstly, individualized targets will be established. Secondly, professionals and participants will collaborate to develop an implementation plan.~Stage 3:Recovery self-efficacy will be implemented as group discussions, with each intervention lasting 15-30 minutes. Maintenance will be implemented in one-to-one interviews, with each intervention lasting 15-30 minutes.Finally, the consolidation and outlook will provide the foundation for the habit formation of healthy behaviors."
223881017|NCT05891782|BEHAVIORAL|Regular health education lectures|Weeks 1-4 will be provided with fall-related regular health education lectures. Weeks 5-16 will have regular activities according to the daily arrangement of the nursing home. Meanwhile, telephone, WeChat, or face-to-face interviews will be conducted fortnightly, to understand the needs of the participants. During the process, staff will provide usual care such as vital signs monitoring, disease treatment, medication prescription, and health record maintenance.
223881018|NCT05944809|DRUG|rhTPO|"Standard treatment options:~Radiotherapy: 95% planning target volume （planning target volume，PTV） ≥45Gy(without simultaneous boost).~Concurrent chemotherapy:~Weekly regimen: paclitaxel 50mg/m2 d1, nedaplatin/cisplatin 25 mg/m2d1, a total of 5 cycles.~Three weeks regimen: paclitaxel 135-175mg/m2 d1, nedaplatin/cisplatin 80mg/m2, a total of 2 cycles.~The active bone marrow was determined by magnetic resonance（magnetic resonance，MR）, and the dose limits are: V5\<95%,V10\<85%,V20\<60%，V30\<40%；95%PTV\>45Gy.~rhTPO，15000U ih. qw(during the radiotherapy course)"
223881019|NCT04906213|DRUG|Empagliflozin10Mg Tab|Empagliflozin10 Mg daily or placebo daily for 18 months
223881020|NCT04906213|DRUG|Placebo|10Mg Placebo Tab
223881021|NCT00999193|PROCEDURE|locking plate, ORIF|Open reduction of the fracture (and GH joint), internal fixation with a locking plate. Tuberculum fragments are sutured to the plate with thick non-absorbable suture.
223881022|NCT00999193|PROCEDURE|Hemiarthroplasty|Replacement of the humeral articular head with hemiprosthesis. Tubercles are sutured to the prosthesis with thick nonabsorbable sutures.
223881023|NCT00999193|OTHER|Conservative treatment|Immobilisation in a supporting brace for 3 weeks, then increasingly active rehabilitation program supported by a physiotherapist until 12 weeks of the injury.
223881024|NCT02338947|OTHER|Off-pump coronary-artery bypass grafting|Surgical access to the heart will be gained through a median sternotomy in all of the patients. In order to reduce the risk of bleeding and transfusions, an absorbable hemostat will be used in the sternal bone marrow. An automatic autotransfusion system will be used to recovery of red blood cells in all patients. Off-pump surgery will be performed with the use of heart stabilizers. Patients will be heparinized with 250 IU/kg intravenously to achieve activated clotting time \>200s. The proximal anastomosis will be performed according to our guidelines. The distal anastomosis will be constructed with the help of mechanical stabilizers and cardiac positioner. Intracoronary shunts will be used routinely.
223881025|NCT02338947|OTHER|On-pump coronary-artery bypass grafting|Surgical access to the heart will be gained through a median sternotomy in all of the patients. On-pump surgery will be performed in normothermia, with the use of aortic cross-clamping and cold cardioplegic arrest. Patients will be heparinized with 500 IU/kg to achieve an activated clotting time \>480 s. Heparin will be neutralized with 1:1 protamine sulfate. The automatic autotransfusion system will be used just in massive blood loss to recovery the red blood cells. Surgical techniques will be performed according to our guidelines.
223881026|NCT03857620|OTHER|Best Practice|Receive usual care
223881027|NCT03857620|OTHER|Informational Intervention|Receive OPTI-Surg program materials
223881028|NCT03857620|OTHER|Questionnaire Administration|Ancillary studies
223881029|NCT03857620|OTHER|Informational Intervention with Coaching|Receive OPTI-Surg program materials plus individual coaching
223881030|NCT05418972|DRUG|Relatlimab and nivolumab fixed dose combination (FDC)|Lymphocyte activation gene-3 (LAG-3) and programmed death-1 (PD-1) are two distinct inhibitory immune checkpoints that are often co-expressed on tumor-infiltrating lymphocytes, thus contributing to tumor-mediated T-cell exhaustion. The combination of nivolumab (anti-PD-1) and relatlimab (anti-LAG-3) results in increased T-cell activation compared to the activity of either antibody alone.
223881031|NCT02473250|DRUG|Fluoxetine|Bipolar depressed patients will be treated with fluoxetine in combination with a mood stabilizer (valproate).
223881032|NCT02473250|DRUG|Citalopram|Bipolar depressed patients will be treated with citalopram in combination with a mood stabilizer (valproate) if fluoxetine is not clinically warranted.
223881033|NCT06443645|DRUG|Anthracycline|as standard of care
223881034|NCT05747651|BIOLOGICAL|Blood sample|Total volume of blood (on each sampling occasion): 54,5mL.
223881035|NCT05747651|BIOLOGICAL|Urine sample|Urine: 100 mL which will be centrifuged. The pellet will be frozen, and the urine supernatant will be aliquoted.
223881036|NCT05747651|BIOLOGICAL|Saliva sample|Saliva: will be collected in special container for saliva microbiome and methylation.
223881037|NCT05747651|BIOLOGICAL|Stool sample|Stool: One sample for microbiome to be sent to the biobank, frozen at -80 °C.
223881038|NCT05747651|BIOLOGICAL|Tissue sample|"Tissue samples for organ-specific manifestations:~* Kidney tissue in lupus nephritis: one small fragment of the fresh kidney biopsy will be stored in a 10% dimethyl sulfoxide (DMSO) solution (slow freezing to -80 °C) until shipment.~* Skin tissue (at selected centers) from inflamed lesion and non-inflamed skin from the gluteal region will be obtained through punch biopsy and stored in a 10% dimethyl sulfoxide (DMSO) solution (slow freezing to -80 °C) until shipment.~* Synovial tissue (at selected centers) will be obtained through ultrasound-directed arthroscopy and stored in a 10% dimethyl sulfoxide (DMSO) solution (slow freezing to -80 °C) until shipment.~* Aspirate from swollen lymph nodes (at selected centers) will be obtained and stored in a 10% dimethyl sulfoxide (DMSO) solution (slow freezing to -80 °C) until shipment."
223881039|NCT04450797|DEVICE|US -G VPS placement, done by BK Medical 5000 US with burr hole probe (type 9063 N11C5S, 11-5 MHz).|"US -G VPS placement, done by BK Medical 5000 US with burr hole probe (type 9063 N11C5S, 11-5 MHz).~Head not fixed, placed on horseshoe head holder, no preoperative navigation planning, catheter will be cut in length after positioning under real-time US guidance."
223881040|NCT04450797|DEVICE|Stereotactic navigation for VPS placement (Brainlab Dual Curve System with cranial navigation software version 3.1).|"Stereotactic navigation for VPS placement (Brainlab Dual Curve System with cranial navigation software version 3.1).~Head fixed in head clamp, entry point, trajectory and catheter length planned based on preoperative computer tomography imaging, catheter placed using navigated stylet."
223881041|NCT06377761|DRUG|Qishen Granules|One package per time, twice a day, 90 days of treatment
223881042|NCT06377761|DRUG|Placebo|One package per time, twice a day, 90 days of treatment (the placebo was basically the same as Qishen granules in terms of appearance, shape, color, taste, etc.)
223881043|NCT06353178|BEHAVIORAL|Cancer Connect Program|Online group peer program where participants learn evidence based skills for managing stressors and emotions related to their cancer experience.
223881044|NCT03054623|PROCEDURE|DRIL procedure|The DRIL procedure involves creation of a bypass from an arterial inflow site (usually mid brachial artery) proximal to the fistula inflow, to the bifurcation of the brachial artery distal to the fistula, with ligation of the intervening native vessel, thus restoring distal flow while preserving flow through the fistula.
223881045|NCT04172233|BIOLOGICAL|AK101|AK101 is an anti-IL-12/23p40 monoclonal antibody.
223881046|NCT04172233|BIOLOGICAL|placebo|matching placebo
223881047|NCT04432454|DRUG|Lasofoxifene and abemaciclib (VERZENIO (R)).|Lasofoxifene 5 mg given once a day orally and abemaciclib 150 mg given twice a day orally.
223881048|NCT03798431|BEHAVIORAL|M-ROCC|"1. LDM (Low-Dose Mindfulness): A 4-wk intro mindfulness program for OUD, 50 min/week including explicit training in use of mobile mindfulness apps, with rolling admission and ascending practice dose ladder.~2. MTPC (Mindfulness Training for Primary Care): An eight-week intensive mindfulness group with ascending practice dose ladder and skill integration over 8 weeks \& 120 minutes/wk.~3. MCS (Mindfulness Maintenance Check-in Support): Ongoing weekly mindfulness group with check-in and reminders, leveraging mobile mindfulness apps and motivational counseling for grads of LDM for 50 mins/wk.~After completion of the LDM group, participation in various levels is fluid based on patient motivation, choice, and readiness."
223881049|NCT05748834|DRUG|Tucatinib|Participants will receive tucatinib 300mg by mouth twice daily continuously (days 1-28) of each 28 day cycle.
223881050|NCT05748834|DRUG|Doxil|Participants will receive Doxil 40mg/m2 intravenously on day 1 of each 28 day cycle (with a maximum cumulative dose of 550mg/m2).
223881051|NCT06393400|DRUG|Fecal Microbiota Transplantation|"Fecal Microbiota Transplantation with 100 g of healthy donor stool in 36-40 oral capsules once~Other Names:~* FMT~* Stool Transplant~* Poop Transplant"
223881052|NCT06393400|DRUG|PEG3350|"Polyethylene Glycol 3350 17 g oral dissolved in 4 litres of water consumed the evening before FMT.~Other Names:~* PEG3350~* RestoraLAX~* MiraLAX"
223881053|NCT06393400|DRUG|Gemcitabine|"Gemcitabine 1000 mg/m2/day IV on Days 1, 8, and 15 of each 28-day cycle.~Other Names:~\- Gemzar"
223881054|NCT06393400|DRUG|nab-Paclitaxel|"nab-Paclitaxel 125 mg/m2/day IV on Days 1, 8, and 15 of each 28-day cycle.~Other Names:~\- Abraxane"
223881055|NCT04798651|BIOLOGICAL|blood sample|28 ml whole blood for Peripheral blood mononuclear cell (PBMC) and monocytes isolation
223881056|NCT04798651|BIOLOGICAL|cerebro-spinal fluid|1 ml of cerebro-spinal fluid
223881057|NCT02861430|PROCEDURE|Immunochemistry and molecular biology on sentinel lymph node specimen|
223881058|NCT03059069|DRUG|Chonline Alphoscerate|Patients treated with Chonline Alphoscerate as add on therapy to their medication
223881059|NCT03059069|DRUG|Placebo Oral Tablet|Patients maintain their medication with either Gliatamin or placebo for 6 months.
223881060|NCT06096610|OTHER|Resistance exercise training|Participants will strength train via linear periodization resistance exercise training.
223881061|NCT06461858|OTHER|cuevas medek technique (exercise)|The first group, known as the experimental group, group A, receives Cuevas Medek exercises once a week, for 45 minutes per session,for 6 weeks
223881062|NCT06461858|OTHER|conventional therapy|Group B, referred to as the conventional therapy group (Routine physical therapy), follows a regimen of conventional therapy once a week for 6 weeks for 20 mints.
223881063|NCT04420078|PROCEDURE|Catheter Ablation|Ventricular fibrillation substrate
223881064|NCT00567398|DRUG|Dianeal|Dianeal 1.5% Dextrose (1.38% Glucose), 2.5% Dextrose (2.27% Glucose), 4.25% Dextrose (3.86% Glucose)
223881065|NCT00567398|DRUG|Physioneal|Physioneal 40 or Physioneal 35
223881066|NCT00567398|DRUG|Extraneal|Extraneal - 7.5% Icodextrin
223881067|NCT00567398|DRUG|Nutrineal|Nutrineal - 1.1% Amino Acids
223881068|NCT05051813|DEVICE|ANTERION|3 repeat measurements on each of the 3 ANTERION devices and 3 reference devices.
223881069|NCT06752824|DEVICE|ANALGESIA NOCICEPTION INDEX MONITORING|INTRACRANIAL SURGERY
223881070|NCT03517553|DEVICE|EMS users in ESRD|use of passive electrical muscle stimulation on quadriceps muscle 3 times a week for patients in dialysis
223881071|NCT06755203|OTHER|Operating Room Simulation Training|"The intervention involves high-fidelity OR simulations focusing on critical areas of patient safety, including:~Communication Skills: Emphasizing clear communication during surgical procedures.~Stress Management: Training participants to manage stress effectively in high-pressure situations.~Protocol Adherence: Practicing adherence to the WHO Surgical Safety Checklist. Risk Assessment: Identifying and mitigating potential safety risks in simulated scenarios"
223881072|NCT03271151|DRUG|Cymbalta|"Duloxetine (Cymbalta) is a serotonin and norepinephrine dual reuptake inhibitor (SNRI) that is an effective treatment for painful diabetic neuropathy. It is approved for major depressive disorder, generalized anxiety disorder, diabetic peripheral neuropathy, fibromyalgia, and chronic musculoskeletal pain"
223881073|NCT03271151|OTHER|Placebo|Placebo to compare outcomes against Duloxetine
223881074|NCT03229811|OTHER|ESRD education + conservative kidney management and ACP education|Targeted conservative kidney management and advance care planning education delivered in person by trained healthcare providers
223881075|NCT04093362|DRUG|Futibatinib|Oral tablets
223881076|NCT04093362|DRUG|Cisplatin|IV infusion
223881077|NCT04093362|DRUG|Gemcitabine|IV infusion
223881078|NCT05052281|BEHAVIORAL|Mothers and Babies (MB) Course|The Mothers and Babies course (MB) is a 12-session manualized stress-reduction intervention that will be delivered to participants, prenatally, with an integrated technology suite designed for timely detection and response to maternal stress.
223881079|NCT05052281|BEHAVIORAL|Just in Time Intervention (JITI) Content|"Participants will also receive additional MB intervention content in the form of just-in-time text messages, which will be sent to participants' smartphones every other day for up to 12 weeks. During the current trial, participants will receive text message prompts with links to additional stress reduction content based on a combination of their objective (sensor) and subjective (EMA) stress responses from the previous day."
223881080|NCT05052281|DEVICE|Biostamp nPoint Device|During the intervention period, participants will be asked to wear the BioStamp nPoint sensor, daily, while engaging in their usual activities (e.g., sleep, showering, exercise). The BioStamp Sensor is a thin, wearable patch, equipped with wireless high-range 6-axis gyroscope + accelerometer, and sEMG and ECG sensors, that adheres to the skin using a disposable medical-grade adhesive sticker (with adhesive similar to Band-Aid).
223881081|NCT05016700|DIAGNOSTIC_TEST|blood sample|we want to identify a diagnostic option to identify patients, who have a neuropathological distraction of their ganglia cells in the bowel
223881082|NCT04122469|RADIATION|Stereotactic Body Radiotherapy|The purpose of this study is to evaluate the safety, and efficacy of SBRT in this patient population
223881083|NCT04703101|DRUG|Capecitabine|Given IV
223881084|NCT04703101|DRUG|Fluorouracil|Given IV
223881085|NCT04703101|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
223881086|NCT04703101|DRUG|Leucovorin|Given IV
223881087|NCT04703101|DRUG|Oxaliplatin|Given IV
223881088|NCT04703101|OTHER|Quality-of-Life Assessment|Ancillary studies
223881089|NCT04703101|BEHAVIORAL|Surveillance|Undergo NOM
223881090|NCT04703101|PROCEDURE|Total Mesorectal Excision|Undergo TME
223881091|NCT06273137|BEHAVIORAL|Positive affect treatment|PAT includes 15 weekly, 1-hour sessions. The treatment is composed of three modules targeting behaviors (Sessions 1-7), cognitions (Sessions 8 -10), and compassion (Sessions 11-14), with skills being reinforced in a cumulative manner in subsequent sessions. The final session in the original treatment (Session 15) addressed relapse prevention, which will be adapted to focus on further reinforcing and generalizing learned skills. The treatment includes guided activities that target different aspects of positive affectivity such as reward approach-motivation, reward learning, and reward attainment.
223881092|NCT06273137|BEHAVIORAL|Supportive psychotherapy (SUP)|Supportive psychotherapy provides a time, attention, and social support control that is similar to a placebo but likely to be perceived as relevant to this population.
223881093|NCT05580536|BEHAVIORAL|Project Dulce + Dulce Digital|"Project Dulce is a 5-week curriculum, group diabetes self-management education and support, program delivered by a peer educator in Arabic.~The curriculum provides knowledge as well as skills and tools needed to change behaviors and adapt to a life with type 2 diabetes.~The curriculum covers diabetes and its complication, the role of diet, exercise, and medication, and the importance of self-monitoring as well as the genetics contribution to diabetes development. It is presented over 5 weeks where participants will learn and practice diabetes self-management skills, and help one another address family, cultural, or health system barriers to managing their diabetes. .~Following the 5-week curriculum, participants will be enrolled in the digital texting platform, Dulce Digital, in which they will receive on-going support via text messages derived from the curriculum, medication reminders, and blood glucose monitoring prompts in Arabic."
223881094|NCT04229056|BEHAVIORAL|Computer-based cognitive rehabilitation (CBCR)|CBCR are software-programmes for computers which are clinically developed for rehabilitation of various cognitive functions.
223881095|NCT04229056|BEHAVIORAL|General computer-based cognitive stimulation|For this trial we have developed a webpage for general cognitive stimulation, which is designed to provide general computer-based cognitive stimulation.
223881096|NCT05896878|DIETARY_SUPPLEMENT|Root.Health Dietary Supplement|The Root.Health supplement is composed of six plant-based compounds with established roles in supporting innate physiological processes which are implicated in pain: tetrohydrocurcumin, ergothioneine, dihydroberberine, trans-resveratrol, ginger root extract, and methylcobalamin. Participants will take the provided supplement twice per day for the entire study duration in addition to pain management treatment protocols the participants currently follow.
223881097|NCT06401213|BIOLOGICAL|MTX-463|MTX-463 is an immunoglobin G1 (IgG1) monoclonal antibody directed against WNT-inducible signaling pathway protein 1 (WISP1). WISP1 (aka CCN-4) is a matricellular protein that appears to be upregulated locally in response to certain chronic diseases and malignancies.
223881098|NCT06401213|OTHER|Placebo|Matching Placebo-- Normal Saline
223881099|NCT05265312|OTHER|START diabetes prevention clinical pathway|"The diabetes prevention clinical pathway will focus on the following steps:~1. Screen/test - testing of eligible patients for prediabetes/diabetes~2. Education - PCPs will be encouraged to take an online learning module and in-person group training on prediabetes management and patients with prediabetes will receive a handout about prediabetes prior to their upcoming PCP visit~3. Action - PCPs will use a shared decision-making guide and treatment algorithm to discuss options with patients at their visit~4. Referral - patients may be referred to DPPs and/or medical nutrition therapy (MNT)~5. Treat - patients will be scheduled for a follow-up visit within 3-9 months with their PCP or care team to continue addressing prediabetes."
223881100|NCT02201108|DRUG|Teriflunomide|Pharmaceutical form:film-coated tablet, Route of administration: oral
223881101|NCT02201108|DRUG|Placebo|Pharmaceutical form:tablet, Route of administration: oral
223881102|NCT05890183|BEHAVIORAL|Cognitive training|This systematic cognitive training program will be delivered by telehealth sessions in which each patient logs into their Posit Science account and joins a Zoom videoconference with 4-8 other patients and two cognitive coaches. The first 12 weeks focus on neurocognitive training and the second 12 weeks focus on social cognitive training. Patients have two CT sessions on each of two days each week to complete 4 hours/week of computerized cognitive training for the first 6 months. Thus, each patient will receive 48 hours of neurocognitive training and 48 hours of social cognitive training in the first 6 months. In the second 6 months, the number of hours per week is trimmed to half the dosage.
223881103|NCT05890183|BEHAVIORAL|Aerobic Exercise Program|The Aerobic Exercise Program group sessions will be conducted by Zoom videoconferencing. The group exercise training sessions are a combination of moderate intensity aerobic conditioning (1-min intervals) and moderate to high intensity strength and callisthenic conditioning (1-min intervals). The exercise dosage goal is 150 minutes/week of moderate aerobic activity, over 4 days, including for the first 6 months two group sessions (45 min duration) and two individual sessions personalized to the patient's choice of exercise (30 min duration) in the target heart rate zone. After the first 6 months, the group exercise sessions are once a week but the goal remains 150 minutes/week of moderate exercise.
223881104|NCT05890183|BEHAVIORAL|Moderated Online Social Therapy (MOST)|MOST combines: (1) evidence-based, interactive, user-directed web-based interventions; (2) secure and supportive peer-to-peer web-based social networking; (3) moderator support; and (4) on-demand web chat with registered clinicians. A Motivation Track on the MOST platform will be used to encourage intrinsic motivation for self-improvement for both groups and, for the CT\&E group, involvement in our exercise program.
223881105|NCT05890183|BEHAVIORAL|Chorus Participatory Text Messaging Program|The Chorus text messaging program is a web-based application that allows clinicians to create a broad range of automated SMS text messages and interactive voice responses using a simple, accessible graphical user interface. It will target encouragement to exercise and social feedback on completed exercise in the CT\&E group.
223881106|NCT05890183|BEHAVIORAL|Healthy Living Group (HLG)|The Healthy Living Group (HLG) meets two sessions/week to discuss wellness, nutrition, insight, recovery, independent living, social skills, and hobbies for the first 6 months and then one session/week for the next 6 months.
223881107|NCT05193227|DRUG|ST-01|Administration of up to 8 mL ST-01 (70 mg/mL lidocaine)
223881108|NCT05193227|DRUG|Control (Lidocaine Hydrochloride Injection USP Xylocaine® or Bupivacaine Hydrochloride Injection USP Marcaine®)|Administration of up to 3 mg/kg bupivacaine hydrochloride injection (0.25%) or up to 4.5mg/kg lidocaine hydrochloride injection (0.5-1%)
223881109|NCT04110977|DEVICE|mobile application (reminder app)|This app will remind the patients four times a day to perform skin and mouth care. Instructions are given how to properly perform skin and mouth care. The patients may postpone each required care procedure for up to 2 hours. Finally, the patients are asked to state for each procedure whether or not they performed it. To increase the patients' motivation, they will earn points for each successfully performed care procedure.
223881110|NCT03535727|DRUG|Nab-paclitaxel|IV over 30 minutes; Days 1 and 15
223881111|NCT03535727|DRUG|Gemcitabine|IV over 30 minutes; Days 1 and 15
223881112|NCT03535727|DRUG|Capecitabine|PO twice daily (BID); Days 1-7, 15-21
223881113|NCT03535727|DRUG|Cisplatin|IV over 60 minutes; Days 1 and 15
223881114|NCT03535727|DRUG|Irinotecan|IV over 30 minutes; Days 1 and 15
223881115|NCT03535727|DRUG|Nab-paclitaxel|IV over 30 minutes; Days 4 and 11
223881116|NCT03535727|DRUG|Gemcitabine|IV over 30 minutes; Days 4 and 11
223881117|NCT03535727|DRUG|Capecitabine|PO BID; Days 1- 14
223881118|NCT03535727|DRUG|Cisplatin|IV over 60 minutes; Days 4 and 11
223881119|NCT03535727|DRUG|Irinotecan|IV over 30 minutes; Days 4 and 11
223881120|NCT04871490|DIAGNOSTIC_TEST|Blood test for HPV DNA|All participants will have blood tested for HPV DNA.
223881121|NCT05046444|DIAGNOSTIC_TEST|Next Generation Sequencing|NON-Interventional Observation only study comparing sequencing-only approaches to classical diagnostic methods
223881122|NCT06764784|PROCEDURE|Freehand Implant Surgery|This intervention involves implant placement performed manually by the surgeon without the use of specialized guides. The procedure relies on the surgeon's clinical judgment and experience to determine the implant's positioning, angulation, and depth.
223881123|NCT06764784|PROCEDURE|Pilot-Drilled Implant Surgery|This intervention utilizes a pilot drill to create an initial guide hole for the implant. The pilot-drilled pathway improves accuracy while still allowing the surgeon flexibility during the procedure. The final implant is placed following sequential drilling.
223881124|NCT06764784|PROCEDURE|Fully Guided Implant Surgery|This intervention employs computer-aided surgical templates created from preoperative imaging data, such as CBCT scans. These guides ensure precise implant positioning, angulation, and depth based on preoperative planning. The approach minimizes variability and enhances accuracy.
223881125|NCT03902223|DIAGNOSTIC_TEST|Enhanced Screening Protocol for Cardiac Sarcoidosis.|To utilize enhanced screening tests for cardiac sarcoidosis in an undiagnosed and potentially under-diagnosed patient population to determine the rate of missed cardiac sarcoidosis diagnosis. Following testing by the standard screening tests, this intervention includes a subsequent echocardiogram and a wearable ECG, also known as a Holter Monitor or ambulatory ECG.
223881126|NCT03902223|DIAGNOSTIC_TEST|Routine Screening for Suspected Cardiac Sarcoidosis|To utilize standard of care screening tests for cardiac sarcoidosis. This includes symptom check and a standard ECG.
223881127|NCT06781918|DIETARY_SUPPLEMENT|Ready to Use Therapeutic Food (RUTF)|"DHA \&amp; Choline enriched RUTF The modified RUTF is a peanut butter paste that contains vegetable oil, skim milk powder, carbohydrates, vitamins, and minerals the same nutrients which are the same as the standard RUTF but is fortified additionally with 250 mg of choline and 200 mg of preformed DHA per 92-gram sachet.~Standard RUTF The standard RUTF used in the BrightSAM trial is a peanut butter paste with vegetable oil, skim milk powder, carbohydrates, vitamins, and minerals that is intended to cover the child's total daily nutritional needs. Standard RUTF will be manufactured in compliance with the specifications recommended by the Codex Alimentarius Commission17."
223881128|NCT06781918|BEHAVIORAL|Psychosocial stimulation|"The psychosocial intervention has been developed and piloted for this study as a context-relevant adaptation from the WHO/UNICEF Care for Child Development package. It will be delivered in group sessions, where the primary caregiver will attend along with the child participating in the trial.~During seven sessions of approximately two hours, caregivers will be trained on a variety of subjects which include; the first four sessions will be introductory and provide the basics of nutrition, the basics of psychosocial stimulation, and play and communication practices. We will build on the increasing experience of the caregivers and provide a deeper understanding of early child development.~Standard nutritional counseling will adhere to national guidelines for pediatric management of severe acute malnutrition including nutritional counseling and psychosocial stimulation."
223881129|NCT06780436|DEVICE|3D Transcranial Ultrasound Brain Imaging|The system implements a proprietary transcranial imaging methodology, which measures the profile of the skull bone and the speed of sound in it to accurately focus the ultrasound energy from a phased array probe through the bone in order to detect hematoma boundaries with resolution normally obtainable only through the open skull.
223881130|NCT06780020|OTHER|Effects of different interventions using boxing|The programs were designed to consist of 8 weeks (16 sessions) with a warm-up consisting of joint mobility and low-intensity aerobic activities, a 40-minute core component BOX and a 10-minute cool-down with static flexibility exercises.
223881131|NCT06780020|OTHER|Effects of different interventions using taekwondo|The programs were designed to consist of 8 weeks (16 sessions) with a warm-up consisting of joint mobility and low-intensity aerobic activities, a 40-minute core component TKD and a 10-minute cool-down with static flexibility exercises.
223881132|NCT06780020|OTHER|Effects of different interventions using Elastic Band|The programs were designed to consist of 8 weeks (16 sessions) with a warm-up consisting of joint mobility and low-intensity aerobic activities, a 40-minute core component Elastic Band and a 10-minute cool-down with static flexibility exercises.
223881133|NCT03055377|DRUG|N-acetyl cysteine|N-acetylcysteine 1200 mg twice daily for 12 weeks (administered orally)
223881134|NCT03055377|DRUG|Placebo oral capsule|Placebo (matched in appearance to N-acetylcysteine to preserve double-blind) twice daily for 12 weeks (administered orally)
223881135|NCT06764836|DRUG|IMM27M|Intravenous injection
223881136|NCT06764836|DRUG|IMM2510|Intravenous injection
223881137|NCT06763003|OTHER|Music Therapy|The music therapy session described follows a structured and engaging approach, aimed at enhancing the patient's cognitive skills during neurorehabilitation. Here's a summary of the session components: Relaxation Phase, Song Selection, Instrument Selection and Familiarization, Rhythmic Training, Progression and Adjustment, Session Frequency and Customization. This individualized approach aims to enhance patient engagement and recovery by integrating music, rhythm, and therapeutic interaction into the neurorehabilitation process.
223881138|NCT06763003|OTHER|Standard Care (in control arm)|In the control group, participants will receive the standard neurorehabilitation program prescribed by the rehabilitation team, without the addition of music therapy. This will provide a baseline to compare outcomes with the intervention group and evaluate the feasibility and preliminary effects of the music therapy intervention. The usual cognitive rehabilitation program during the subacute stroke period focuses on restoring cognitive abilities such as attention, memory, executive functions, and communication. The control group's daily rehabilitation sessions will last for 45 minutes, mirroring the music therapy group's session duration, ensuring a fair comparison of outcomes across both groups. This comparison will help assess the unique contributions of music therapy on cognitive functions like attention, memory, and executive functions in stroke patients.
223881139|NCT03215030|DRUG|Modakafusp alfa|Modakafusp alfa intravenous infusion.
223881140|NCT03215030|DRUG|Dexamethasone|Dexamethasone.
223881141|NCT06789900|DRUG|Everolimus (Afinitor®)|Oral dose of everolimus 5 mg once a week for 24 weeks
223881142|NCT06789900|OTHER|Football Fitness Concept|"Structured hybrid exercise training via the football fitness concept organized as a super-vised group training at the University of Southern Denmark, Department of Sports Science and Clinical Biomechanics. Football Fitness concept is designed for participants with little prior experience with football and it is multifaceted training incorporating endurance training, high-intensity interval training (HIIT) and strength training. The training session lasts 60 minutes, and participants will receive two training sessions per week for 24 weeks. Each session is composed of 4 elements: a 15 min warm-up that includes strength and balance exercises, a 15 min period with technical pair-based drills, and a 30-min period with small-sided football drills"
223881143|NCT06788418|PROCEDURE|Wavelight Plus Alcon system|Wavelight Plus Alcon system guided surgery for myopia
223881144|NCT06788418|PROCEDURE|SMILE|Small Incision Lenticule Extraction surgery for myopia
223881145|NCT06788418|PROCEDURE|ICL|Implantable Collamer Lens surgery for myopia
223881146|NCT06300658|DRUG|Stellate ganglion block|Patient will receive preemptive stellate ganglion block (SGB) just before spinal anesthesia.
223881147|NCT05304468|RADIATION|IMRT|Patients in experimental group received reduced dose IMRT
223881148|NCT05304468|DRUG|induction chemotherapy|cisplatin-based induction chemotherapy for two cycles
223881149|NCT05304468|DRUG|cisplatin concurrent chemotherapy|cisplatin 100mg/m2, for two(60Gy) or three cycles(70Gy)
223881150|NCT05524649|DIETARY_SUPPLEMENT|Food Supplement 1|Probiotic single strain formulation containing Bifidobacterium longum CECT7894 for 3 months 5 drops/day
223881151|NCT05524649|DIETARY_SUPPLEMENT|Food Supplement 2|Probiotic single strain formulation containing Pediococcus pentosaceus CECT8330 for 3 months 5 drops/day
223881152|NCT05524649|DIETARY_SUPPLEMENT|Placebo|5 drops/day for 3 months of sunflower oil
223881153|NCT06769178|OTHER|Virtual Reality based|Participants will receive treatment by a specialist physiotherapist for a total of 16 sessions, 2 days a week on non-consecutive days for 8 weeks. Both groups will receive neurodevelopmental treatment (NGT) for 16 sessions. While the control group will receive traditional balance training in each session, the VR group will play virtual reality-based games.
223881154|NCT06766942|OTHER|structured sherborne developmental movement program with sensory integration program|In addition to the sensory integration therapy they receive at the rehabilitation center for 45 minutes, two days a week for 12 weeks, the Structured Sherborne Developmental Movement Program will be applied.
223881155|NCT06766942|OTHER|sensory integration program group|Sensory integration therapy programmed according to the individual's needs and disabilities will be applied to this group by an occupational therapist at the rehabilitation center for 45 minutes, 2 days a week for 12 weeks.
223881156|NCT06766942|OTHER|control group|This group will not participate in any activities outside of the standard special education program.
223881157|NCT06093126|DRUG|Lemborexant 5 MG|The participant will receive 8 weeks of treatment Week 1 = placebo Week 2 = lemborexant 5mg Week 3 = lemborexant 10 mg Week 4 = placebo Week 5 = lemborexant 10 mg Week 6 = placebo Week 7 = placebo Week 8 = lemborexant 10 mg
223881158|NCT06789133|OTHER|PNF exercises and Body weight supported treadmill gait training|"PNF Exercises:~.Proprioceptive neuromuscular facilitation exercises include D1 Flexion and D1 Extension of lower limb ,D2 flexion D2 extension of lower limb .rhythmic initiation ,hold relax ,pelvic pattern and contract relax technique . subjects will perform each exercise for 30sec with resting interval of 30 to 60 seconds Will be provided after completion of each exercise. 3 sessions will be held per week, For 8 weeks~Gait training:~Body weight supported treadmill gait training for 20 minutes 3 sessions per week.~In total all PNF exercises with gait training will be held for 40-45 minutes."
223881159|NCT06789133|OTHER|Body weight supported treadmill gait training and Routine physical therapy|"Body Weight Supported Treadmill Training (BWSTT):~This will include body weight supported treadmill gait training. 10 % BWSTT or 20% BWSTT. The session will of 20 minutes .3 sessions will be Held per week.~Routine physical therapy:~Stretching and strengthening of lower extremities In total all BWSTT along with routine physical therapy protocol will be held for 40-45minutes .3 sessions will be held per week."
223881160|NCT06785337|DRUG|Inhaled nitroglycerin|Inhaled nitroglycerin
223881161|NCT05190991|BIOLOGICAL|RPH-104|solution for subcutaneous administration 40 mg/mL, 2 mL in the 4-mL glass vial
223881162|NCT05805774|PROCEDURE|Distal Femur Replacement|Knee surgery to remove the lower part of the femur and knee joint (where the broken bones are) and will replace them with an artificial knee joint (prosthesis).
223881163|NCT05805774|PROCEDURE|Surgical fixation|Knee surgery to fix the fracture, that can use wires, nails, screws, pins or plates to health and fix the bones together.
223881164|NCT06766435|DEVICE|i-STAT TBI Test|The Abbott i-STAT TBI test result is shared with the enrolled patient and treating clinicians.
223881165|NCT04274478|DEVICE|Auditive cueing|Based on gait measurement, auditive cueing is generated automatically to check its impact on patients with Freezing Of Gait.
223881166|NCT06766019|DRUG|Adebrelimab combined with irinotecan liposomal (II), oxaliplatin, and 5-FU/LV|"1. adebrelimab 1200mg, i.v. D1, q28d~2. irinotecan liposomal (II) 60mg/m\^2, i.v. D1, Q2W~3. oxaliplatin 85mg/m\^2, i.v. D1, Q2W~4. 5-FU/LV 2400mg/400mg/m\^2, i.v. D1, Q2W 4-week cycles, 6 cycles"
223881167|NCT06766058|OTHER|Carrier oil|Inhaler stick containing 2 drops of carrier oil.
223881168|NCT06766058|OTHER|Asian plant extract blend|Inhaler stick containing 2 drops of Asian plant extract blend.
223881169|NCT02088060|DRUG|Cannabidiol|Cannabidiol capsules
223881170|NCT02088060|DRUG|Olanzapine|Olanzapine capsules
223881171|NCT02088060|DRUG|Placebo Cannabidiol|Placebo cannabidiol capsules
223881172|NCT02088060|DRUG|Placebo Olanzapine|Placebo olanzapine capsules
223881173|NCT06764901|BEHAVIORAL|Online Therapy Chat Service (TCS)|Online Therapy Chat Service (TCS) based on CBT techniques from the Berlin Dissexuality Therapy (Beier, K. M. (2021). Pedophilia, hebephilia and sexual offending against children. The Berlin Dissexuality Therapy (BEDIT). Springer).
223881174|NCT06769906|OTHER|Individualized automatic coaching message for glycemic management and depressive symptom|For 12 weeks, the intervention group will apply continuous glucose monitoring system and receive weekly personalized coaching messages for glycemic management based on data from continuous glucose monitoring and bi-weekly personalized coaching messages for depression symptoms based on depression questionnaires.
223881175|NCT04409639|DRUG|Cobimetinib|Cobimetinib is taken on a 28-day cycle. Each dose consists of three 20 mg tablets (60 mg) and should be taken once daily for 21 consecutive days (Days 1 to 21-treatment period); followed by a 7-day break (Days 22 to 28-treatment break). Each subsequent cobimetinib treatment cycle should start after a 7-day treatment break has elapsed.
223881176|NCT06765551|DIAGNOSTIC_TEST|Neuromuscular Ultrasound|Non-invasive ultrasound of peripheral muscles of the upper and lower extremities with additional artificiall intelligence processing of ultrasound images.
223881177|NCT06285604|PROCEDURE|Blood transfusion|Transfusion of designated red blood cell products to anemic neonates.
223881178|NCT05845424|DRUG|Guideline directed statin therapy|At least moderate intensity statin, recommended by the current guideline based on the ASCVD risk
223881179|NCT05845424|DRUG|High intensity statin plus ezetimibe therapy|Rosuvastatin 20 mg + Ezetimibe 10 mg
223881180|NCT03701113|DIETARY_SUPPLEMENT|Milk-based protein matrix (MBPM)|Ingestion of the Test Product at 10:00 pm, post-absorptive of the evening meal, each day for the 24 week period of intervention
223881181|NCT03701113|DIETARY_SUPPLEMENT|Habitual dietary behaviour|Subjects to maintain habitual dietary behaviour for the 24 week intervention
223881182|NCT06799858|DEVICE|Breast cancer localisation with magnetic seed Sirius Pintuition|Patients with histologically proven non-palpable breast cancer or with histologically proven pathological lymph node will be localised by a magnetic seed Sirius Pintuition.
223881183|NCT05593328|DRUG|Onvansertib|Oral capsule
223881184|NCT05593328|DRUG|FOLFIRI|FOLFIRI (irinotecan + fluorouracil \[5-FU\] + leucovorin) as intravenous (IV) infusion
223881185|NCT05593328|DRUG|Bevacizumab|IV infusion
223881186|NCT04060160|OTHER|Self- learning software that can detect acne lesions|Self- learning software that can detect acne lesions from patients who take a picture of their face every single day for 3 months with a secure mobile phone.
223881187|NCT04060160|OTHER|Patient reported outcomes|Collection of patient reported outcomes and clinical data via a mobile electronic case report form
223881188|NCT03830177|DRUG|Natural Treatment|Participants will receive a topical treatment formulated with natural ingredients (Lactobacillus sp., honey, and turmeric) and a kit containing all necessary materials, including an instruction handout. The treatment is applied to the scalp, left for roughly 5 minutes, and rinsed off.
223881189|NCT04497129|DEVICE|ROMTech PortableConnect|ROMTech PortableConnect (ROMTechPC) therapy will be completed four to five times per day for 6 minutes duration for 6 weeks. The intervention will be administered using the portable rehabilitation unit.
223881190|NCT04497129|DEVICE|Traditional Rehabilitation and CPM Device|Continuous passive motion (CPM) with standard of care HHPT and OPPT rehabilitation program (CPM with SOC). Therapy with the CPM will be completed daily from day 0 through week 3 for a total of 6 to 8 hours per day. The HHPT and OPPT rehabilitation program will be a 6-week program based on SOC goals.
223881191|NCT04627948|DIAGNOSTIC_TEST|Stockholm3 test|Diagnostic test: Stockholm3-test. Men from the study sites, diagnosed with prostate cancer and currently on AS and planned for rebiopsies will be invited to the study.
223881192|NCT06351137|OTHER|Intravenous administration|Analgesia is administered intravenously.
223881193|NCT06351137|OTHER|Intranasal administration|Analgesia is administered intranasally using an atomizer.
223881194|NCT01718743|DRUG|Ixazomib Citrate|Given PO
223881195|NCT01718743|DRUG|Lenalidomide|Given PO
223881196|NCT01718743|OTHER|Questionnaire Administration|Ancillary studies
223881197|NCT05906030|DIAGNOSTIC_TEST|Diaphragm ultrasound|Diaphragm ultrasound will be used pre- and postoperatively. Diaphragm dysfunction will be diagnosed using the measurements diaphragm thickening fraction, diaphragm excursion and diaphragm density.
223881198|NCT04514497|PROCEDURE|Biopsy|Undergo tumor biopsy
223881199|NCT04514497|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
223881200|NCT04514497|PROCEDURE|Computed Tomography|Undergo CT
223881201|NCT04514497|DRUG|Elimusertib|Given PO
223881202|NCT04514497|DRUG|Irinotecan Hydrochloride|Given IV
223881203|NCT04514497|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223881204|NCT04514497|DRUG|Topotecan Hydrochloride|Given IV
223881205|NCT05752747|OTHER|Cold Massage Group|Just before the application, it will be taken out of the cabinet and the area to be vaccinated will be massaged with rollers with back and forth movements.
223881206|NCT05752747|OTHER|ShotBlocker© Group|It is a small flexible drug-free plastic tool. It is a small, flat-shaped instrument with a short, blunt, skin-contact ridge on the bottom and a hole in the center to inject. It is placed on the skin before injection. The protrusions on the inside do not harm the skin.
223881207|NCT04680897|BEHAVIORAL|Early restriction release|Participants will no longer have restrictions on vaginal penetration 2 weeks after surgery.
223881208|NCT04680897|BEHAVIORAL|Standard restriction recommendation|Participants will return to intercourse after 6 weeks
223881209|NCT05214482|DRUG|AK112|IV infusion,Specified dose on specified days
223881210|NCT05214482|DRUG|AK117|IV infusion,Specified dose on specified days
223881211|NCT05214482|DRUG|Chemotherapy|IV infusion,Specified dose on specified days
223881212|NCT05919238|COMBINATION_PRODUCT|Padeliporfin Vascular Targeted Photodynamic (VTP) therapy|The laser light fiber with inflatable balloon to dam SMA blood flow during light illumination will be placed by an Interventional Radiologist in the SMA via a transfemoral artery approach. The balloon will be inflated to impede blood flow for total of 10 minutes during light illumination
223881213|NCT04367506|BEHAVIORAL|BecomeAnEX|This research study is focused on a smoking cessation program called BecomeAnEx. We are studying how to adapt BecomeAnEx for people with a mental health disorder who want to reduce or quit their tobacco smoking. BecomeAnEx includes a website that provides education about smoking and quitting. It also has a text messaging program that delivers personalized information. Persons in the program have access to real-time digital coaching with a remote coach who has experience helping people quit smoking. In addition, the program has an on-line community of current and former smokers that can provide support and encouragement.
223881214|NCT04367506|BEHAVIORAL|Usual Care|Usual care represents what hospitalized psychiatric patients normally receive in terms of smoking cessation: brief individual counseling, NRT during the hospital stay and a prescription for NRT at discharge (consistent with standard hospital procedures), and referral to the MD quitline.
223881215|NCT04889430|DRUG|Iptacopan|Iptacopan 200mg twice daily oral
223881216|NCT06792344|OTHER|anti-CD19 CAR-T cells|Intravenous injection the targeting CD19 CAR T cell
223881217|NCT06792344|DRUG|anti-CD19 CAR-T cells|CD19-targeting CAR-T cells
223881218|NCT05986864|GENETIC|SKG0106|SKG0106 is a recombinant adeno-associated virus (AAV) vector-based in vivo gene therapeutic product
223881219|NCT00082186|DRUG|bosentan|Oral bosentan tablets 62.5 mg twice daly for 4 weeks, then 125 mg twice daily for 20 weeks.
223881220|NCT05695131|DEVICE|GlenXRose Virtual Reality Speech Therapies|Speech therapies for vocal cord disorders have been developed for virtual reality implementation. These include various games to interact with in a virtual environment while conducting rehabilitation therapy, in addition to educational visualizations
223881221|NCT06798038|DEVICE|radiofrequency ablation|35 Patients will be undergo for radiofrequency ablation which will be applied to each genicular nerve.
223881222|NCT06798038|DRUG|phenol neurolysis|35 Patients will be administered with 2.0 ml of 6% phenol solution prepared from crystallized phenol per genicular nerve
223881223|NCT06798038|DRUG|alcohol neurolysis|35 Patients will be administered with 1.0ml of 70% alcohol per genicular nerve
223881224|NCT04995835|DRUG|Cefiderocol|After receipt of Cefiderocol, blood samples will be collected at various time points to determine the pharmacokinetics of Cefiderocol
223881225|NCT06800001|OTHER|Physical Activity|Physical Activity is an 8-week practical intervention for managing the stereotyped behavior \& anxiety. Week 1: Introduction - Build engagement with the help of rapport building. Learn \& practice ball-tapping exercise with warm up \& cool down relaxation exercise. Week 2: Calmness- Practice jumping in trampoline exercise and learn balloon breathing exercise that give calmness. Week 3: Focus enhancement-Learn skills of jumping exercise to increase focus and improve impulse. Week 4: Strength, balance, and stress relief -explore the gym ball exercise in different directions that improves emotional regulation. Week 5: self control - Learn strategies for specific jumping patterns that improves impulse control and focus in children with ASD. Week 6: Reduce Stereotyped Behaviors - Learn complex trampoline exercises. Week 7: Skill Reinforcement- Review exercises, increasing speed or direction changes. Week 8: Integration -Encourage playful interaction to maintain engagement \& consolidate skills.
223881226|NCT06790732|DRUG|Saline|Patients received sham PENG block (just 1mL saline).
223881227|NCT06790732|DRUG|Bupivacaine + Dexamethasone|Patients received real PENG block (15 mL of bupivacaine 0.25% +0.2mg/mL dexamethasone).
223881228|NCT06110442|DEVICE|IbexBH Software|A software application applied to radiographs
223881229|NCT06787118|DRUG|CBD oil|Patients will receive CBD-oral solution 2.5 mg/kg PO BID for a total of 12 weeks.
223881230|NCT06787118|DRUG|Placebo|Patients will receive placebo for a total of 12 weeks.
223881231|NCT06784596|OTHER|Teleconsulting supported training|Patients in this group will be provided with training the day before surgery, on the morning of surgery and on the day of discharge, and will receive teleconsulting services at the 1st, 2nd, 3rd, 4th, 5th, 6th, 8th, 10th and 12th weeks after discharge. will be given.
223881232|NCT06791733|OTHER|Passive static stretching|the intervention consists of passive static stretching of agonist or antagonist muscles between sets
223881233|NCT06792487|PROCEDURE|skin biopsy|punch biopsy (6 mm) of lesional psoriasis skin
223881234|NCT06785610|DIETARY_SUPPLEMENT|Capsulase®|Capsulase® supplement daily administration after surgery
223881235|NCT06782568|DIAGNOSTIC_TEST|Ultrasound Scan|Participants will undergo an ultrasound scan of insulin injection sites at baseline and after 6 months.
223881236|NCT06784219|DIAGNOSTIC_TEST|Hindi version of self reported oral health questionnaire|The original 8-item CDC/AAP questionnaire as well as other selected periodontal disease surveillance questions will be translated into Hindi through forward translation, backward translation, and expert committee process to reach a consensus and produce a prefinal version. The prefinal version questionnaire will be pilot tested on a sample of 20 patients to evaluate the overall comprehension by non-professionals. On the basis of responses and evaluation from the participants, the questionnaire will be further refined to build the final version. The final version of the questionnaire will be administered to patients seeking care from out-patient department of department of Periodontics at PGIDS, Rohtak. The participants will be required to fill the questionnaire by themselves prior to periodontal examination, without any help from others.
223881237|NCT06792149|PROCEDURE|surgical resection|Surgical resection will be performed for locoregional lesions .
223881238|NCT06792149|OTHER|Adjuvant chemotherapy|Regimens of adjuvant chemotherapy are directed by clinical guidance and experience.
223881239|NCT06792149|OTHER|neoadjuvant therapy|Regimens of neoadjuvant chemotherapy are directed by clinicalguidance and experience
223881240|NCT02688712|DRUG|LY2157299|Small molecule inhibitor of transforming growth factor-beta signaling pathway
223881241|NCT02688712|DRUG|Capecitabine|Antimetabolite chemotherapy
223881242|NCT02688712|DRUG|Fluorouracil|Antimetabolite chemotherapy
223881243|NCT02688712|PROCEDURE|Tumor specific mesorectal excision|Tumor specific mesorectal excision
223881244|NCT06791070|DRUG|Disitamab Vedotin combined with Toripalimab|Disitamab Vedotin at a dosage of 2mg/kg and 3mg/kg of Toripalimab administered intravenously every 3 weeks (ivgtt q3w) is continued until disease progression, with the allowance for treatment discontinuation due to disease progression, death, intolerable toxicity, withdrawal of informed consent, initiation of new antineoplastic therapy, or other reasons specified in the protocol, with the earliest occurring event taking precedence. Alternatively, the study investigator may determine the need to discontinue treatment.
223881245|NCT06784570|DRUG|levosemindan|In common practice the loading dose is omitted as it is associated with hypotension.9 Usual dose range: 0.05 to 0.2 microg/kg/min. Dose based on actual body weight up to a maximum of 120 kg.5 Commence infusion at 0.05 microg/kg/min. If the initial rate is tolerated, consider increasing the maintenance rate to 0.1 microg/kg/min after 60 minutes. If the patient remains haemodynamically stable, further increase the dose to 0.2 microg/kg/min for the remainder of the infusion.
223881246|NCT06784570|DRUG|adrenaline,noreadrenaline,dopamine and doputamine|adrenaline:\*4 9 %$ 0 \*\*\*\*8\*4\* 9 : ,- 4 - \*4 9 \* C % F\*4 9 9 9 noreadrenaline:# \*4 9 C % 9 F 9 9 \*4\* Q\*4 9 9 dopamine:9 \* C % 9 F 9 9 ) \* 9 9 dobutamine:9 \* C % F 9 9 9 \* 9 9
223881247|NCT05701072|PROCEDURE|Oocyte Pick Up|The screening questionnaire will be filled by the Physician doing the OPU. The screening questionnaire will be informed by the participant's history. Cervix will be visualized during routine vaginal cleansing for OPU, and its appearance (size, and deviation) will be recorded in the screening questionnaire after the OPU procedure. Finally, a screenshot of the ultrasound used for OPU, showing the cervix and cervical canal in the sagittal plane will be taken during routine procedure and saved in electronic chart.
223881248|NCT05701072|PROCEDURE|Embryo Transfer|When the participants comes back for ET during her routine treatment, ET will be done in exactly the same way in routine treatment. Participant will not undergo any additional manipulation, intervention, nor the procedure will take longer. The Embryologist assisting the procedure will record the duration of the procedure, from the moment the Physician takes the outer ET catheter to his/her hand until he/she passes the cervix and calls for the inner catheter loaded with the embryo. Up on completion of the ET procedure as routine practice, the Physician will fill a questionnaire about the procedure.
223881249|NCT06362941|DIETARY_SUPPLEMENT|Nutrafol Women's Hair Growth Supplemnt|Hair growth supplement for women ages 18 - 44.
223881250|NCT06362941|DIETARY_SUPPLEMENT|Nutrafol Women's Balance Hair Growth Supplement|Hair growth supplement for women ages 45 - 70.
223881251|NCT06362941|DIETARY_SUPPLEMENT|Nutrafol Women's Vegan Hair Growth Supplement|Hair growth supplement for women ages 18 - 44. This treatment group may also include subjects who do not follow a plant-based diet for purposes of extending the product claims beyond the initially studied demographic of women primarily adhering to a plant-based diet.
223881252|NCT06362941|DIETARY_SUPPLEMENT|Nutrafol Women's Postpartum Hair Growth Supplement|Hair growth supplement for women ages 18 - 44. This product will be studied in the general women population and not postpartum women.
223881253|NCT06362941|DIETARY_SUPPLEMENT|Nutrafol Men's Hair Growth Supplement|Hair growth supplement for men ages 25 - 50.
223881254|NCT05587582|OTHER|Survey Administration|Complete a survey
223881255|NCT06786156|BEHAVIORAL|Pecha Kucha Education|"After the first interviews, the participants will be given face-to-face training to count fetal movements in the first stage. The training will last 30-45 minutes. The training content includes a comfortable environment and a suitable position for pregnant women, how to count and what to look for before counting fetal movements. Then, the training will be sent to the pregnant women via WhatsApp. A form will be given to count the fetal movements, and training will be applied using the Pecha Kucha method using smartphones once a week for 4 weeks. Pecha kucha is a presentation method developed to attract and maintain the attention of the audience throughout a series of different presentations. Pecha kucha (P-K), derived from the word meaning chat in Japanese, is to help present creative works with visual images. Pecha kucha training includes position, how to count and what to look for before counting fetal movements. This training will be delivered via WhatsApp with a practical presenta"
223881258|NCT06784297|BIOLOGICAL|IMM01-STEM|The individuals receiving expanded access will receive a treatment identical to the most convenient regimen in the current clinical trial (STEM-META). The treatment will consist of one i.m. injection per week containing 2 mg of total protein in 2 mL, for a total of 4 weeks (4 injections). As more efficacy information accumulates, the treatment plan will be adjusted accordingly to maximize the potential benefit.
223881259|NCT06784583|DEVICE|transcutaneous auricular vagus nerve stimulation|"1. Prior to execution: Remove jewelry (such as earrings) that may interfere with the electrode placement; attach the electrodes to the tragus of the left ear; feed the wires over the right shoulder from the back of the neck, and then turn on the device.~2. Initiate stimulation: Establish the following parameters: 200 μs pulse width, 30 Hz frequency, 0-36 mA current intensity (modify to the most appropriate stimulation intensity based on the patient's pain perception), and one-hour timing. Next, begin the stimulation.~3. Stimulation end: After an hour, the device will be automatically switched off. And the procedure is finished."
223881260|NCT06784583|DEVICE|sham transcutaneous auricular vagus nerve stimulation|"1. Prior to execution: Remove jewelry (such as earrings) that may interfere with the electrode placement; attach the electrodes to the tragus of the left ear; feed the wires over the right shoulder from the back of the neck, and then turn on the device.~2. Initiate stimulation: Establish the following parameters: 200 μs pulse width, 30 Hz frequency, 0-36 mA current intensity (modify to the most appropriate stimulation intensity based on the patient's pain perception). Next, turn off the stimulation，and one-hour timing.~3. Stimulation end: After an hour, the device will be removed and the procedure is finished."
223881261|NCT06032793|OTHER|Breathing exercises|Pursed lip breathing, Diaphragmatic breathing and powered breathing
223881262|NCT06784245|BEHAVIORAL|TeleActivate|Each session will consist of a warm-up activity (5-10 min), main exercise activity (30-40 min), and cool-down activity (5-10 min) following the guidelines of multicomponent exercise program Vivifrail. Exercise intensity will be controlled based on the Rating of Perceived Exertion (RPE) on the Borg scale and heart rate measured with a smartwatch before, during, and after each exercise session according to the guidelines of the American College of Sports Medicine (ACSM), as explained below. The warm-up and cool-down activities will include stretching and walking in place (9≤RPE≤10 and 40\<55% maximum Heart rate (HRmax). While the main exercise activity will consist of strength, resistance exercise, cardiovascular exercises, and balance exercises (to avoid falls) performed using dumbbells, colour-coded resistance bands (Thera-Band; Hygenic Corp.) and a chair (11\<RPE≤15 and 55\<70 HRmax).
223881263|NCT06787547|DEVICE|IVL(Sonico-CX)|SONICO-CX® balloon matched 1:1 to the reference vessel diameter, was advanced to the target lesion to pretreat
223881264|NCT06791798|OTHER|Ventilator Hyperinflation|In ventilator hyperinflation volume control mode, the ventilator will be set to eight breaths per minute, and the tidal volume will be increased to deliver hyperinflation breaths that are 15 ml/kg, as will be calculated using the predicted body weight. Tidal volume will be increased in 150-ml increments until a peak airway pressure of 40 cmH2O is achieved. Once this pressure is reached, eight mechanical breaths will be delivered to the patient. After this, the ventilator will be reset to pretreatment variables, and the patient will be rested for 30 s. The sequence will be repeated. The treatment will consist of five sets of eight ventilator hyperinflation breaths.
223881265|NCT06791798|OTHER|Vibrocompression|Vibrocompression will be performed by the physical therapist to produce vibration and will be combined with compression of the patient's chest in the expiratory phase. Every vibrocompression will be interrupted at the end of each expiratory phase to allow free inspiration.
223881266|NCT06791798|OTHER|Traditional Chest Physical Therapy Program|Percussion, Postural Drainage, and Suction
223881267|NCT02785042|DEVICE|Heidelberg Spectralis OCT|OCT imaging
223881268|NCT06065189|BIOLOGICAL|CS-101 injection|Autologous CD34+ hematopoietic stem cell suspension modified by in vitro base editing technique
223881269|NCT05884658|PROCEDURE|vNOTES : natural vaginal orifice transluminal endoscopic system for hysterectomies|hysterectomy via the vaginal approach by vNOTES (natural vaginal orifice transluminal endoscopic system for hysterectomies)
223881270|NCT05884658|PROCEDURE|laparoscopic hysterectomy|laparoscopic hysterectomy uses a standardized procedure with or without surgical robot
223881273|NCT06592547|DRUG|Intravenous metoprolol tartrate|An intravenous beta-blockers, recieved FDA approval
223881274|NCT06592547|OTHER|Standard Care (in control arm)|Standard care according to surviving sepsis campaign
223881275|NCT03527433|PROCEDURE|New closure technique|In the intervention arm, an average of two sutures will be placed at each cm length of the wound, thus the number of sutures placed should be equal to at least double the length of the wound in cm.The aim is to have a ratio of 4:1 between the overall lengths of the suture to the length of the wound being closed
223881276|NCT06566833|DRUG|self assmbling peptide p11-4 combined with 0.05% fluoride|biomimetic remineralizing agent
223881277|NCT06566833|DRUG|Casein phosphopeptide amorphous calcium phosphate|remineralizing agents that acts as a fluoride booster
223881278|NCT06566833|DRUG|5% sodium fluoride varnish|remineralizing agent that is used as a gold standard for remineralization
223881279|NCT06132048|DEVICE|MuCopilot mobile application|MuCopilot is a software as medical device with three digital tests, to measure patient's with CF, lung function, global exercise capacity and a questionnaire to address CF symptoms and impacts on some aspects of patient's life
223881280|NCT03526835|DRUG|MCLA-158|full-length IgG1 bispecific antibody targeting EGFR and LGR5
223881281|NCT03526835|COMBINATION_PRODUCT|MCLA-158 + Pembrolizumab|MCLA-158 in combination with pembrolizumab will be explored first in HNSCC patients eligible to receive pembrolizumab as first-line monotherapy.
223881282|NCT03526835|COMBINATION_PRODUCT|MCLA-158 + FOLFIRI|MCLA-158 in combination with FOLFIRI will be explored in mCRC patients with up to 1 line of prior regimen.
223881283|NCT03526835|COMBINATION_PRODUCT|MCLA-158 + FOLFOX|MCLA-158 in combination with FOLFOX will be explored in mCRC patients with up to 1 line of prior regimen.
223881284|NCT05145257|DIETARY_SUPPLEMENT|Elix Cycle Balance|Each day in the morning and at night in the week prior to the menstruation, the participants will take 6 full droppers of Elix Cycle Balance
223881285|NCT03425201|DRUG|Niraparib plus Cabozantinib|Non-randomized trial will comprise 2 stages. A dose escalation phase will characterize the safety, tolerability, DLTs and MTD, of oral niraparib plus cabozantinib in patients with urothelial or renal cell carcinoma. Subsequently, the phase II will further evaluate the safety and antitumor activity of this combination in patients with urothelial carcinoma.
223881286|NCT05183763|BEHAVIORAL|STAR-MAP health coaching|Interactive health coaching delivered in 11 sessions over one year; focusing on using adaptive change tactics to improve medication-taking behavior
223881287|NCT05183763|BEHAVIORAL|Medication reminder tools|Medication-taking reminder app and pillbox
223881288|NCT06557538|DEVICE|Automatic Ankle Brachial Pressure Index device assessment|The automatic device assesses 3 limbs, providing automatic simultaneous ABPI measurement of systolic, diastolic and mean arterial blood pressure on to calculate the patient\&#39;s ABPI (Medi UK 2022).
223881289|NCT06557538|DEVICE|Manual Ankle Brachial Pressure Index assessment|The manual device assesses 4 limbs, providing brachial, ankle and pedal systolic pressures. A simple calculation is then made by the clinician to determine the ratio of ankle and brachial systolic pressure (ABPI) (Day 2015).
223881290|NCT05942391|BEHAVIORAL|Cognitive behavioral therapy (CBT)|The intervention is brief-intensive, guided exposure therapy and consists of 16 sessions exposure therapy, spread over 4 half-days in 2 weeks plus 4 follow-up sessions within 3 months.
223881291|NCT04999306|BEHAVIORAL|Hypnosis|one weekly session during 6 weeks (6 sessions of 30min/1 hour).
223881292|NCT04999306|BEHAVIORAL|CBT|one weekly session during 6 weeks (6 sessions of 1 hour).
223881293|NCT05511298|BEHAVIORAL|Relationship Smarts Combo|The intervention is a combination of Mind Matters, Relationship Smarts 4.0, and Money Habitudes curricula, developed by the Dibble Institute
223881294|NCT04639518|OTHER|Preterm formulas with HMO|Preterm infants will receive Stage 1 formula as soon as possible after birth until when 1.8 kg of body weight is achieved. Preterm infants will receive Stage 2 preterm formula from when 1.8 kg of body weight is achieved until 2 months after hospital discharge.
223881295|NCT04639518|OTHER|Preterm formulas without HMO|Preterm infants will receive Stage 1 formula as soon as possible after birth until when 1.8 kg of body weight is achieved. Preterm infants will receive Stage 2 preterm formula from when 1.8 kg of body weight is achieved until 2 months after hospital discharge.
223881296|NCT03969446|DRUG|Decitabine|Given IV
223881297|NCT03969446|BIOLOGICAL|Pembrolizumab|Given IV
223881298|NCT03969446|DRUG|Venetoclax|Given PO
223881299|NCT05721989|DRUG|Ziltivekimab B|Participants will receive a single s.c. injection of 15 mg ziltivekimab B (15 mg/mL) by single-use pre-filled manual syringe on Day 1.
223881300|NCT05721989|DRUG|Ziltivekimab D|Participants will receive a single s.c. injection of 15 mg ziltivekimab D (15 mg/mL) by single-use pre-filled manual syringe on Day 1.
223881301|NCT05721989|DRUG|Ziltivekimab C|Participants will receive a single s.c. injection of 15 mg ziltivekimab C (30 mg/mL) by single-use pre-filled syringe assembled into a shield-activated pen-injector on Day 1.
223881302|NCT06159985|PROCEDURE|left posterior pericardiostomy|In patients assigned to the study group, a 4-5 cm vertical incision posterior to the phrenic nerve and extending from the left inferior pulmonary vein to the diaphragm is performed.
223881303|NCT06573905|OTHER|no intervention|no intervention. this is observational study.
223881304|NCT01236287|DRUG|Voclosporin|Subjects will receive voclosporin capsules, twice daily
223881305|NCT01954992|DRUG|Glufosfamide|Glufosfamide: 4500 mg/m2 IV over 6 hours (¼ dose over 30 minutes, ¾ dose over remaining 5.5 hours) on Day 1 of each 21-day cycle.
223881306|NCT01954992|DRUG|Fluorouracil|Fluorouracil (5-FU): 600 mg/m2 IV over 30 minutes on Day 1 of each week
223881307|NCT06262919|DRUG|Tafinlar/Mekinist|There is no treatment allocation. Patients administered Tafinlar/Mekinist by prescription that have started before inclusion of the patient into the study will be enrolled.
223881308|NCT03263026|DRUG|Enzastaurin Hydrochloride|R-CHOP + Enzastaurin (Kinenza®) 125 mg
223881309|NCT03263026|OTHER|R-CHOP + placebo|R-CHOP + placebo
223881310|NCT06752382|DRUG|Experimental drug|Induction therapy was sintilimab 200mg IV d1, bevacizumab 7.5mg/kg IV d1, albumin-bound paclitaxel 260mg/m2 IV d1 and cisplatin 80mg/m2 IV d1, once every 3 weeks, a total of 3 cycles.
223881311|NCT02661893|DRUG|JNJ-42847922|A single oral dose of 40 milligram (mg) (=2\*20 mg) dose of JNJ42847922 on Day 1, Day 5 and Day 12.
223881312|NCT02661893|DRUG|Rifampin|Oral dose of rifampin 600 mg (2\*300 mg) on Day 5 and once daily dosing of rifampin with an oral dose of rifampin 600 mg (2\*300 mg) on Days 5 to 12.
223881313|NCT06106178|OTHER|Simulator for Basic Ultrasound Skills|Basic course of a traditional ultrasound simulator focusing on hand-eye coordination
223881314|NCT06106178|OTHER|Serious Video Game|"The serious video game Underwater uses a 3D-printed ultrasound probe for maneuvering. During gameplay, coins must be collected in an underwater world using the aforementioned simulated ultrasound probe. The main focus of this game is to improve hand-eye coordination while using an ultrasound probe."
223881315|NCT06301997|DIETARY_SUPPLEMENT|ZAX.1400.P03|ZAX.1400.P03, applied twice daily for 3 weeks after enrolment
223881316|NCT06301997|DRUG|Placebo|Placebo, applied twice daily for 3 weeks after enrolment
223881317|NCT06151535|DEVICE|ELAPR002f Injectable Gel|Intradermal Injections
223881318|NCT06787859|OTHER|Showing a nature view curtain to type 2 diabetic patients during insulin injection|a nature view curtain
223881319|NCT05485922|DEVICE|Investigational device - intermittent catheter with a micro-hole zone|The investigational device was a urinary catheter for bladder drainage through the urethra. The product is for intermittent use.
223881320|NCT05485922|DEVICE|Comparator device -VaPro intermittent catheter|The comparator device is a urinary catheter for bladder drainage through the urethra. The product is for intermittent use.
223881321|NCT06792929|DEVICE|virtual reality glasses group|Patients will wear virtual reality glasses throughout the ultrasound-guided fine needle aspiration biopsy procedure.
223881322|NCT06797167|DEVICE|Injections of a filler gel containing cross-linked hyaluronic acid|"Vaginal Filler will be administered according to Investigator's judgment and Instruction For Use (IFU) to correct hypotrophy, improve the shape and increase the volume of the female external genital areas (labia majora). Vaginal Filler is a resorbable medical device available in packages containing 2 sterile pre-filled mono-use syringes of 1 ml with pre-assembled plunger rod and backstop, containing 25 mg/g cross-linked hyaluronic acid.~The injection is performed by medical personnel at visit V0 in one or both sides of the superficial subcutaneous layer of the labia majora, along its longitudinal axis.The dosage to be used for the individual case is at the doctor's discretion. An anesthetic may be applied (lidocaine 2% injection only in the cannula access point) to the affected area before the IP injection.~In order to maintain the results achieved, an eventual touch-up could be performed one months after the first treatment in the same areas of the first injection, at visit V2."
223881323|NCT06153056|DIAGNOSTIC_TEST|Bloed-, ontlasting- en speekselmonsters|"In addition, the blood collected (24 mL) will be used for the following analyses:~GLP-1, PYY, branched-chain amino acids, Adipokines, leptin, adiponectin Blood bile acid levels: total and detailed analyzed by HPLC MS/MS Serum microbiome profile Genome-wide association study.~The stool sample will be used to establish the :~Intestinal bile acid profile Intestinal microbiota profile Saliva sampling for oral microbiota profiling."
223881324|NCT06789224|DEVICE|CATUVAB|inducing of aggreation of tumor cells and immune cells via trifunctional antibody and removal of aggregates
223881325|NCT06685601|DEVICE|tPBM（active）|During the active stimulation condition, participants will receive a single session of tPBM intervention, lasting 12 minutes.
223881326|NCT06685601|DEVICE|tPBM（sham）|During the sham stimulation condition, participants will receive the same intervention with identical target areas and wavelength, but only for the first and last 30 seconds of the session.
223881327|NCT05070013|DEVICE|Deep Brain Stimulation|All participants will undergo three 1-week interventions of stimulation during nighttime sleep over the course of three consecutive weeks of in-home sleep: adaptive stimulation, open-loop stimulation and no stimulation.
223881328|NCT06794528|OTHER|RehbeCa mobile application|The system consists of a mobile application (to be used by patients) and a web application (to be used by physiotherapists) that allows monitoring of the patient's performance without the need for attendance, thus facilitating telerehabilitation. The mobile application consists of a serious game that aims to induce the patient to perform neck exercises, adapting to their capacity and evolution at all times through artificial intelligence. The patient's interaction with the mobile application is based on the integration of a vision-based head-tracker to track the movements of the patient's head. The web application aims to provide professionals with a tool to monitor the evolution of their patients through the data captured by the mobile application.
223881329|NCT06794528|OTHER|Home exercise program|Set of therapeutic exercises to be carried out at home. They are taught face-to-face, and also printed on a leaflet that is delivered to the participant.
223881330|NCT06795477|BEHAVIORAL|No MI Help|Participants will complete the medication verification task without any MI help
223881331|NCT06795477|BEHAVIORAL|Interpretable MI|Participants receive interpretable machine intelligence assistance to complete the medication verification tasks.
223881332|NCT06795477|BEHAVIORAL|Uninterpretable MI|Participants receive uninterpretable (i.e., black-box) machine intelligence assistance to complete the medication verification tasks.
223881333|NCT06792851|DEVICE|Kosmos Bladder Volume Algorithm|Participants underwent Kosmos bladder volume assessment by both a nurse and an abdominal sonographer pre-void. Participants voided and measured void volume. Participants underwent Kosmos bladder volume assessment by both a nurse and an abdominal sonographer post-void. Kosmos calculated volume measurements were compared to volume measurements calculated using calipers placed by sonographers by hand.
223881334|NCT06830655|OTHER|Fatigue Protocol|"After the warm-up, each participant will be assigned the easiest route of their skill level on the Kilter Board with a 15-degree wall incline. Participants will start the route from the initial holds and finish it with the need to touch the top hold with both hands. They will be instructed to climb as quickly and smoothly as possible. After reaching the last hold, they will descend along the same route to the initial holds without touching the ground. The procedure will be repeated until the participant reports fatigue that prevents further climbing. Any stoppage by the participant during the protocol will not be allowed to last longer than 5 seconds, will be recorded, and categorized as either isometric contraction or rest time, depending on the nature of the stoppage, which will be established during records analyzing."
223881335|NCT03927131|BIOLOGICAL|QIV-IB|Inactivated split-virion quadrivalent influenza vaccine
223881336|NCT03927131|BIOLOGICAL|TIVV-IB|Inactivated split-virion trivalent Influenza Vaccine containing Influenza B virus - Victoria lineage
223881337|NCT03927131|BIOLOGICAL|TIVY-IB|Inactivated split-virion trivalent Influenza Vaccine containing Influenza B virus - Yamagata lineage
223881338|NCT03927131|BIOLOGICAL|QIV-IB Lot A|Inactivated split-virion quadrivalent influenza vaccine - Lot A
223881339|NCT03927131|BIOLOGICAL|QIV-IB Lot B|Inactivated split-virion quadrivalent influenza vaccine - Lot B
223881340|NCT03927131|BIOLOGICAL|QIV-IB Lot C|Inactivated split-virion quadrivalent influenza vaccine - Lot C
223881341|NCT06797219|DEVICE|Low Level Laser Therapy for Intraventricular Hemorrhage of Prematurity|The experimental arm will be administered treated with the study device. It will be 10 mW/cm\^2 of 650nm laser through use of a novel laser device given for 5 minutes twice daily for 12 days.
223881342|NCT06837532|DRUG|Ultrasound-guided rectus sheath block|Patients will receive ultrasound-guided rectus sheath block (20 ml bupivacaine 0.25%) bilaterally at the end of surgery.
223881343|NCT06837532|DRUG|Surgical rectus sheath block|Patients will receive a surgical rectus sheath block (20 ml bupivacaine 0.25%) bilaterally at the time of closure.
223881344|NCT06837532|DRUG|Local anesthesia infiltration|Patients will receive local anesthesia infiltration at the end of surgery.
223881345|NCT06831773|RADIATION|Carbon ion combined with photon radiotherapy|PTV1 was first treated with photon radiotherapy (started within 30 days after surgery), with a total dose of 50Gy, 25 times; After photon radiotherapy, PTV2 carbon ion radiotherapy was started, the total dose was 24.8Gy(RBE), 8 times. 3.1Gy(RBE)/fx; 1fx/ day, 5 days/week.
223881346|NCT03739996|DRUG|Oral Cabotegravir (CAB)|30 mg tablets administered orally
223881347|NCT03739996|DRUG|Nucleoside Reverse Transcriptase Inhibitors (NRTIs)|NRTIs were not provided by the study. Participants obtained NRTIs outside of the study through routine care.
223881348|NCT03739996|DRUG|Long-Acting Injectable Cabotegravir (CAB LA)|600 mg loading dose followed by 400 mg maintenance doses administered by intramuscular (IM) injection
223881349|NCT03739996|BIOLOGICAL|VRC07-523LS|40 mg/kg administered as an intravenous (IV) infusion
223881350|NCT03739996|DRUG|Standard of Care (SOC) ART|SOC ART was not provided by the study. Participants obtained SOC ART outside of the study through routine care.
223881351|NCT02553642|DRUG|Nivolumab|"Monotherapy Treatment - Nivolumab 240 mg flat dose Dosed q 2 weeks~OR~\- Nivolumab 480 mg flat dose Dosed q 4 weeks~for up to 2 years from 1st dose of nivolumab or until loss of clinical benefit"
223881352|NCT02553642|DRUG|Nivolumab plus Ipilimumab|"Combination Treatment~* Ipilimumab 3 mg/kg~* Nivolumab 1 mg/kg Dosed q 3 weeks x 4 doses"
223881353|NCT06844929|OTHER|Podcast Group|Providing breastfeeding education via podcast
223881354|NCT06844929|OTHER|Brochure Group|Providing standard breastfeeding education using brochures
223881355|NCT06005961|BEHAVIORAL|Module-Based Psychological (MBP) Intervention|Participants will receive one core module related to emotional management and maximum two tailor-made modules according to the participant's needs. Each weekly session lasts for 1 hours. The core module will last for 6 weeks and the tailor-made modules will last for 3 - 4 weeks.
223881356|NCT05444192|DEVICE|CAD/CAM insoles|computer-aided-design computer-aided-manufacture (CAD/CAM) insoles
223881357|NCT04522713|BEHAVIORAL|Behavioral activation, evidence-based sleep strategies including sleep restriction, exposure-based strategies, promotion of physical activity and recuperating activities, psychoeducational material|Primarily standard cognitive-behavioral strategies to reduce common psychiatric symptoms
223881358|NCT05634070|DEVICE|PCL Pectus scaffold implantation and autologous fat grafting|A suitable incision will be made using a scalpel and diathermy following standard surgical procedures.The implant pocket shall be rinsed with saline. The PCL Pectus Scaffold shall be inserted into the pocket following the Instruction for Use and fixed to the thoracic wall using 2 to 4 sutures. The device shall not be modified for any patient in any manner. The incision shall be closed using 2-0 Vicryl or Monocryl and 3-0 Monocryl sutures, if applicable. Number of layers to be sutured will be decided by the PI for each patient. Sterile bandaging as well as Steri-Strips shall be applied on the sutures. A prophylactic antibiotic such as Cefazolin 1g (3 shots per day x 2 days) shall be administered to the patient. In case the patient has Cefazolin allergy, Clindamycin 600 mg shall be prescribed. Autologous Fat Grafting procedure shall be performed immediately after implantation. The patients shall be hospitalized for the necessary number of days under clinical observation.
223881359|NCT01544855|DIETARY_SUPPLEMENT|omega-3 fatty acids|Participants will take 700 mg/d of EPA and 500 mg/d of DHA as ethyl esters for one month (Ocean Nutrition, Dartmouth, NS) which is about 10 times the current estimated intake of young adults (21). This corresponds to one capsule with breakfast and one capsule with diner.
223881360|NCT02155010|DRUG|Dexmedetomidine|Dexmedetomidine infusion before intrathecal injection of heavy bupivacaine
223881361|NCT02155010|DRUG|Dexmedetomidine with heavy bupivacaine|Dexmedetomidine infusion after IT of heavy bupivacaine
223881362|NCT03484416|DRUG|Calcium Carbonate 1500 Mg with Vitamin D|Patients in the routine calcium group received oral supplements of 1,500 mg/day elemental calcium and 1,000 IU/day cholecalciferol (Dicamax 1000) for 2 weeks, whereas control group did not
223881363|NCT00894543|DRUG|Escitalopram|10 mg (1 pill) escitalopram daily for the first four weeks. Dose increased to 20 mg (2 pills) escitalopram daily if relief from hot flashes has not occurred during the first four weeks of the daily 10 mg dose.
223881364|NCT00894543|OTHER|Placebo|Inactive pill (1 pill or 2 pills) daily for the 8-11 weeks of the trial.
223881365|NCT01264289|DRUG|Finasteride|Finasteride Tablets 5 mg
223881366|NCT01532388|BEHAVIORAL|eScreen|Web based self-monitoring of problematic alcohol and drug use.
223881367|NCT03111160|PROCEDURE|SMILE procedure using lower energy (100, 105, and 110 nJ)|Based on the review of literature, we regarded SMILE using energy levels of 115 nJ or higher as 'conventional' energy-SMILE (C-SMILE). Since 500kHz VisuMax femtosecond laser used in this study had a threshold photodisruption energy level of 100 nJ, lowest energy level of L-SMILE was set at 100 nJ. Because the spot distance must be changed by approximately 1 μm when laser energy changed by 50 nJ, we could set the maximum laser energy to 150 (100 + 50) nJ as highest one of C-SMILE while keeping the spot distance constant. Finally, we established two groups divided by different laser energies: L-SMILE group using lower energy levels of 100, 105, and 110 nJ, and C-SMILE group using 'conventional', not higher, energy levels of 115 to 150 nJ.
223881368|NCT03111160|PROCEDURE|SMILE procedure using conventional energy (115 to 150 nJ)|The SMILE procedures were conducted in the Eyereum Eye Clinic (Seoul, South Korea). The target postoperative refraction was emmetropia. The surgery, using standardized techniques, was performed by an experienced surgeon (D.S.Y.K.) using the VisuMax system. The surgical parameters used during SMILE were as follows: repetition rate of 500 kHz, pulse energy 100 to 150 nJ (100, 105, and 110 nJ, L-SMILE; 115 to 150 nJ, C-SMILE), spot distance 4.5 μm (regardless of FSL energy), cap thickness 120 μm, and side-cut width 2 mm in the 12-o'clock position with an angle of 90°. After the anterior (upper) and posterior (lower) delineated plane of the intrastromal lenticule were well defined, the anterior and posterior interface were dissected with a micro-spatula with a blunt circular tip and extracted with micro-forceps. The integrity of the lenticule was also checked subsequently.
223881369|NCT02919449|BIOLOGICAL|MV-NIS|This is an open label single ascending dose phase I study designed to determine the safety profile and MTD after IT administration of a single dose of MV-NIS in combination with Atezolizumab in patients with metastatic NSCLC
223881370|NCT02919449|BIOLOGICAL|Atezolizumab|Atezolizumab will be administered every 3 weeks
223881371|NCT01278420|DEVICE|Tecnis MF|30 subjects will be implanted with the Tecnis MF
223881372|NCT01278420|DEVICE|ReSTOR|30 subjects will be implanted with ReSTOR
223881373|NCT03862963|BEHAVIORAL|Standard of diabetes care|The standard of diabetes care consisted of standard treatment protocols used by the MOH Diabetes Clinic. These included placing T2D patients on anti-hyperglycemic agents appropriate to their HbA1c levels (including sulfonylureas, metformin, and insulin) and providing oral and written information about the importance of maintaining a healthy weight, eating a healthy diet, and getting regular exercise. Participants in the control group were instructed not to make changes in their diet and activity levels during the study.
223881374|NCT03862963|BEHAVIORAL|Lifestyle Intervention|The lifestyle intervention consisted of a high-fiber, low-fat, mostly plant-based diet and 30-60 minutes per day of culturally-relevant, moderate intensity exercise. Participants initially received 12 weeks of group educational classes and some prepared meals and then followed the lifestyle intervention on their own for the remaining 12 weeks. Group classes included informative sessions on healthy eating, exercise (both aerobic and strength training), and stress management, as well as hands-on cooking classes. Classes were delivered as a combination of PowerPoint presentations, practical workshops, dine-outs, shopping tours, and cooking classes with spouses.
223881375|NCT05092113|DRUG|a compound glutamine capsule/a compound glutamine capsule simulated placebo|A compound glutamine capsule/a compound glutamine capsule simulated placebo was taken orally from the first day of chemotherapy, orally 3 times a day after meals, 3 tablets each time, the course of treatment is 3 weeks.
223881376|NCT04824274|DRUG|fentanyl|Fentanyl 10 mcg will be injected intrathecally during spinal anesthesia.
223881377|NCT04824274|DRUG|morphine|Morphine 75 mcg will be injected intrathecally during spinal anesthesia.
223881378|NCT04824274|PROCEDURE|Transversus abdominis plane block|Ultrasound-guided bilateral transversus abdominis plane block will be done. 0.375% ropivacaine 15 ml per side will be injected.
223881379|NCT04824274|PROCEDURE|Sham block|Ultrasound-guided bilateral transversus abdominis plane sham block will be done. Normal saline 15 ml per side will be injected.
223881380|NCT00942487|DRUG|Nebilet|Trade-mark: Nebilet® (Berlin-Chemie Menarini) INN: nebivolol Dosage and route of administration: 5 mg tablets, o.d. for oral administration
223881381|NCT00942487|DRUG|Corvitol|Trade-mark: Corvitol (Berlin-Chemie Menarini) INN: metoprolol Dosage and route of administration: 50 mg tablets, b.d. (100 mg/day) for oral administration
223881382|NCT00257075|DRUG|Risperidone, oral tablets|
223881383|NCT02022800|OTHER|PET 18FDOPA|contribution of PET 18FDOPAimagery in high level glioma diagnosis
223881384|NCT03056183|BEHAVIORAL|Depression Care Transitions (DCT)|DCT Intervention group - Patients in the DCT intervention will have a Transitional Care Social Worker (TCSW) who will maintain daily phone contact, home visits, and will attend with the patient medical and psychiatric appointments for an average of three months following discharge. Patients in the usual care group will proceed as usual (scheduled follow-up visits). These subjects will also be asked to complete questionnaires relating to quality of life and physical and mental health status.
223881385|NCT05843539|GENETIC|Biological and epigenetic measures|This study also includes an exploratory biological ancillary study that aims to identify the gene expression variations that are determinant in terms of vulnerability/protection (cytogenetic and transcriptome), through the measurement of the level of biological chronic stress and epigenetic methylations of the NR3C1 and FKBP5 genes, in relation to adversity in childhood And to show the convergence between self-reported measures related to the presence of ACEs and attachment disorders with assays of chronic stress and epigenetic biomarkers.
223881386|NCT02018900|DIETARY_SUPPLEMENT|Ecologic 825/scFOS|
223881387|NCT02018900|DIETARY_SUPPLEMENT|Placebo|
223881388|NCT00051792|BEHAVIORAL|yoga|
223881389|NCT02421380|DRUG|Hyperpolarized Pyruvate|
223881390|NCT05223959|BEHAVIORAL|Culturally adapted Psychoeducation|This is a culturally adapted psychoeducation program consisting of 12 sessions. Each CaPE session lasts for approximately 60 minutes, beginning with a 20-30-minute presentation on the topic of the day, followed by a related exercise (e.g., drawing a life chart or compiling a list of potential triggers for recurrence).
223881391|NCT04785651|DRUG|Tibial osteotomy with Tranexamic acid|"Patients who will be in the treatment arm after randomisation will receive 100ml saline with a dosage of 20 mg/kg tranexamic acid intravenously at induction. An additional administration of tranexamic acid (10 mg/kg in 100ml intravenous saline) will be given as a booster at the end of the surgical procedure.~All the patients will undergo to the same tibial osteotomy procedure."
223881392|NCT04785651|PROCEDURE|Tibial osteotomy without Tranexamic acid|Patients in this arm will undergo to the tibial osteotomy procedure as by clinical practice
223881393|NCT01540318|PROCEDURE|Abdominal Ultrasound (FAST examination)|Use of FAST abdominal ultrasound exam
223881394|NCT04238910|BEHAVIORAL|Maximizing Energy|The intent of the MAX intervention is to personalize OT delivered education to facilitate the implementation of Energy Conservation strategies using the PST framework to address specific fatigue-related problems and then to generalize from these solutions to both similar and new situations in daily life.
223881395|NCT04238910|BEHAVIORAL|Health Education|The intent of the health education intervention is to control for the non-specific effects of interactions with an interventionist. Participants received education on a variety of health related topics relevant to individuals with TBI.
223881396|NCT05802706|OTHER|No intervention.|No intervention.
223881397|NCT05623345|DRUG|Izokibep|"Biologic: IL-17A inhibitor~Form: Solution for injection~Route of administration: Subcutaneous (SC)"
223881398|NCT05623345|DRUG|Placebo to izokibep|"Form: Solution for injection~Route of administration: Subcutaneous (SC)"
223881399|NCT05023993|OTHER|Exercise Intervention|Complete home exercise
223881400|NCT05023993|DIETARY_SUPPLEMENT|Nicotinamide Riboside|Given PO
223881401|NCT06555744|DRUG|ZW191|Administered intravenously
223881402|NCT02336217|OTHER|Experimental Group instructions for glucose management via App|The Experimental Group receives individually calculated instructions for glucose management management via the App.
223881403|NCT02336217|OTHER|Placebo Comparator general instructions|The Placebo Comparator Group receives general instructions but not the complete management algorithm
223881404|NCT06064916|DIAGNOSTIC_TEST|Visual Acuity|Monocular and binocular measurement of distance, intermediate, and near visual acuity
223881405|NCT06064916|DIAGNOSTIC_TEST|Defocus Curve|Measurement of a defocus curve
223881406|NCT06064916|OTHER|Intraocular Lens Satisfaction (IOLSAT) Questionnaire|Self-reported post-operative patient satisfaction with vision after surgery
223881407|NCT06064916|OTHER|Quality of Vision After Surgery (QUVID) Questionnaire|Self-reported post-operative patient vision quality after surgery
223881408|NCT06064916|OTHER|Visual Disturbance Questionnaire|Questionnaire of self-reported visual disturbances of patients
223881409|NCT06064916|DIAGNOSTIC_TEST|Topography and Tomography|Topography and tomography measurements with Atlas, iTrace, and/or Pentacam
223881410|NCT05744271|DEVICE|FES+VFBT|Standing balance training with the FES+VFBT system will occur 3x/week for six weeks (i.e. 18 sessions). Electrodes will be placed on the participants' plantarflexors and dorsiflexors bilaterally and FES will be administered using the device, MyndSearch, during the balance training exercises. Each session will last one hour, including 15 min to identify motor thresholds and maximum tolerable stimulation levels, 5 min to don/doff the safety harness, 5 min to calibrate the FES+VFBT exercises, 20 min to complete the FES+VFBT exercises, and 10-15 min to take rest breaks between exercises as needed.
223881411|NCT01772472|DRUG|trastuzumab|6 mg/kg intravenously every 3 weeks, 14 cycles
223881412|NCT01772472|DRUG|trastuzumab emtansine|3.6 mg/kg intravenously every 3 weeks, 14 cycles
223881413|NCT05774626|BEHAVIORAL|Contraceptive usage|Continued use of injectable contraception, administered on a quarterly basis
223881414|NCT02913196|DRUG|Apalutamide|"Orally available, small molecule, nonsteroidal potent and selective antagonist of the androgen receptor.~Cohort 1 dose: 120 mg QD Cohort 2 dose: 240 mg QD Cohort 3 dose: 180 mg QD"
223881415|NCT02913196|DRUG|Abiraterone acetate|"Abiraterone acetate is the prodrug of the active drug abiraterone. Once absorbed after oral administration, abiraterone acetate is rapidly converted to the active form, abiraterone.~Dose: 1000 mg QD"
223881416|NCT02913196|DRUG|Docetaxel|"Taxane cytotoxic chemotherapy with demonstrated survival benefit in those with advanced prostate cancer.~Dose: 75 mg/m2 Q3W"
223881417|NCT02913196|DRUG|Prednisone|Dose: 5 mg BID
223881418|NCT04909619|PROCEDURE|Ultrasound-guided bilateral suprazygomatic maxillary nerve block|The maxillary nerve, V2, is purely a sensory branch of the trigeminal nerve. V2 exits the skull through the foramen rotundum and courses through the pterygopalatine fossa, a small pyramid-shaped depression located posterior to the maxilla. As the maxillary nerve exits the pterygopalatine fossa, it divides into numerous branches that supply sensation to the posterior nasal cavity, palate, sinuses, and maxilla. It is within the pterygopalatine fossa that the maxillary nerve is targeted and anesthetized during the block. With the patient in the supine position after nasotracheal intubation, a needle is inserted perpendicularly between the upper border of the zygomatic arch and posterior orbital rim until it reaches the greater wing of the sphenoid, where the needle is then retracted by a few millimeters and redirected toward the nasolabial fold until it hits the pterygopalatine fossa.
223881419|NCT04909619|PROCEDURE|Local anesthetic infiltration of the palate|Local anesthetic infiltration of the palate during cleft palate repair is universally practiced. The benefits of local anesthetic infiltration are twofold: to provide anesthesia to the terminal branches of the nasopalatine and greater palatine nerves that are in the immediate area of the injection sites and to achieve hemostasis during closure when the medication is mixed with epinephrine. To administer local anesthetic infiltration of the palate, a 25 gauge needle is inserted next to the incision into the soft tissue. The tissue is first aspirated to determine safety of injection at that site. The medication is then injected parallel to the incision on both sides.
223881420|NCT04057456|OTHER|Placebo diet|"The dietitian will assist in developing a diet that is isocaloric to the anti-inflammatory diet and healthy (for the sake of the participants' well-being, and to blind participants), while allowing many foods that are (counterintuitively) pro-inflammatory (e.g. whole wheat bread, white beans, oats, soy, eggplant, raspberries, pumpkin seeds, popcorn, etc). Occasional cheat foods are built into the placebo diet but with more pro-inflammatory options (e.g. two glasses of wine per week)."
223881421|NCT04057456|OTHER|Anti-inflammatory diet|"Participants will also be given a list of foods that they are allowed on the anti-inflammatory diet, and a list of foods to avoid so that they can make informed substitutions to the meals and ingredients that they are given. The study participants will be given a one-week meal plan with accompanying recipes. Occasional cheat foods are built into the anti-inflammatory diet (e.g. two bottles of beer per week)"
223881422|NCT04057456|DRUG|Nabilone Capsules|Capsules will be 0.5mg nabilone. Participants will undergo a 5-week titration period by taking 1 (0.5mg) nabilone capsule per day for a three-day period. The dose will be increased on a fixed schedule by 1 (0.5mg) capsule every three days to a maximum of 8 capsules/day (4mg). Dosage will be maintained if higher doses are not tolerated or if sufficient relief is obtained (at least a 2-point change on the NRS). Once the appropriate nabilone (or placebo) dosage for each participant is determined, participants will begin their respective interventions over the course of the 4-week treatment period.
223881423|NCT04057456|OTHER|Placebo capsules|Placebo capsules contain no active ingredient. Participants on placebo capsules will undergo the same 5-week titration period and intervention period as those on active treatment.
223881424|NCT02842424|DRUG|Ramipril|Ramipril therapy will start at 2.5mg/day for 1 week. Then 5mg/day for 1 week and will be increased to 10mg/day by the third week. The patients will stay on Ramipril 10mg/day for 22 weeks.
223881425|NCT02697136|DRUG|CER-001|Recombinant human apoA-I/phospholipid complexes
223881426|NCT02697136|DRUG|Placebo|0.9% Sodium Chloride Injection, USP
223881427|NCT06456944|OTHER|stretching exercises|stretching exercises of the plantar fascia, gastrocnemius and soleus
223881428|NCT06456944|DEVICE|ultrasound|therapeutic ultrasound upon the most painful point on the medial calcaneal tubercle. The parameters involved a pulsed mode (duty cycle 50%) using an intensity of 1.5 W/cm2 and a 1 MHz of frequency for 5 minutes
223881429|NCT06456944|OTHER|rigid tape|low-dye tapping will be done to provide mechanical correction to plantar fascia and medial longitudinal arch
223881430|NCT06456944|OTHER|mobilization|mobilization techniques for the talocrural joint in weight bearing and non-bearing positions and subtalar joint
223881431|NCT06456944|OTHER|myofascial release|deep tissue release of the plantar fascia and flexor hallucis longus in a stretched position of the plantar fascia
223881432|NCT06456944|OTHER|strengthening exercise|strengthening exercise of the plantar intrinsic muscles using short foot exercise and strengthening of the Achilles tendon and windlass mechanism using unilateral heel raise exercises
223881433|NCT05782816|DRUG|Oxytocin|Low dose oxytocin
223881434|NCT05782816|DRUG|Oxytocin|High dose oxytocin
223881435|NCT05152264|DEVICE|Transcutaneous electrical nerve stimulation (TENS)|Treatment with transcutaneous electrical nerve stimulation (TENS) during 16 weeks.
223881436|NCT05152264|OTHER|Conventional analgesic treatment|Conventional analgesic treatment. Conventional analgesic treatment may include no pharmacological treatment if the patient does not use any analgesics.
223881437|NCT06369766|DIAGNOSTIC_TEST|Optical coherence tomography (OCT)|"OCT is used to measure:~* peripapillary retinal nerve fiber layer (mean thickness in μm)~* ganglion cell-inner plexiform layer (volume in mm\^3 and mean thickness in μm)~* other retinal layers (inner nuclear layer, outer plexiform layer, outer nerve layer; volumes in mm\^3 and mean thickness in μm).~The scanner laser ophthalmoscopy-function of the OCT device is used to continuously record the exact location of each participant's fixation point in relation to their fovea and thereby allows the assessment of the fixation instability.~In a subgroup of participants, the angiography-module of the OCT device is used to image the retinal blood flow and thereby allows to measure the vascular area density of the superficial retinal capillary plexus and deep retinal capillary plexus."
223881438|NCT06369766|DIAGNOSTIC_TEST|Static retinal vessel analyzer|"Static retinal vessel analyzer is used to determine:~* central retinal arteriolar diameter equivalents (in μm)~* central retinal venular diameter equivalents (in μm)~* arteriolar-to-venular diameter ratio"
223881439|NCT06369766|DIAGNOSTIC_TEST|Dynamic retinal vessel analyzer|In a subgroup of participants, the dynamic retinal vessel analyzer is used to determine the arteriolar ficker light-induced dilatation, venular ficker light-induced dilatation, and Arteriolar constriction, measured in % dilatation in comparison to baseline.
223881440|NCT06369766|DIAGNOSTIC_TEST|Laser speckle flowgraphy system|In a subgroup of participants, the laser speckle flowgraphy system is used to measure the relative ocular blood flow as expressed in arbitary units of Mean Blur Rate.
223881441|NCT06369766|OTHER|Questionnaire|All study participants will be asked to fill in a questionnaire with various questions regarding existing eye diseases, other diseases (including vascular diseases/risk factors), and daily physical activity that could influence the results of the retinal examinations. Physical activity will be assessed using an adapted form of the standardized Global Physical Activity Questionnaire.
223881442|NCT02142322|DRUG|MODIFIED FOLFOX6|Modified FOLFOX6 regimen consists of oxaliplatin 100 mg/m2 and FA 100 mg/m2 given as a 2 hour intravenous infusion, followed by 5-FU 2.4 g/m2 given as a continuous infusion over 46 hour, repeated every 2 weeks. Patients receive 4 cycles of neoadjuvant modified FOLFOX6 followed by curative radical surgery with D2 dissection and 4 cycles of adjuvant modified FOLFOX6.
223881443|NCT05660187|OTHER|Multiple Sclerosis Clinical Care Delivery via telehealth|Intervention includes clinical care delivered via telehealth
223881444|NCT05660187|OTHER|Multiple Sclerosis Clinical Care Delivery via standard in clinic visits|Intervention includes clinical care delivered via standard in clinic visits
223881445|NCT00510302|BEHAVIORAL|Questionnaire|Questionnaire regarding melanoma risk-reduction.
223881446|NCT00510302|BEHAVIORAL|Interview|Interview via telephone about topics related to melanoma risk-reduction.
223881447|NCT03829852|DRUG|Regorafenib|Treatment was performed based on physician's discretion
223881448|NCT02523716|OTHER|Hypoxia|Participants live within an altitude residence facility. Hypoxic acclimatisation will be achieved by venting the rooms with air containing a reduced oxygen content. The degree of hypoxia is ramped over a 2-day period as participants experience 14 hours of overnight hypoxic exposure (simulating altitude of : 1830m on Day 1; 2130m on Day 2). The final 5 days will be spent entirely in the altitude residence facility at a consistent hypoxia level (simulating approximately 2440m).
223881449|NCT02523716|OTHER|Normoxia|Participants will live in the altitude residence facility. As a sham-control, normal sea level air will be circulated throughout the house.
223881450|NCT03338868|OTHER|Body composition|evaluated by Bodystat®1500 Bio-impedance Analyzer
223881451|NCT03338868|OTHER|Physical activity level|assessed by the International Physical Activity Questionnaire-7
223881452|NCT03338868|OTHER|Musculoskeletal pain intensity|evaluated with Visual Analog Scale
223881453|NCT03338868|OTHER|Quality of life|assessed by the Nottingham Health Profile
223881454|NCT03338868|OTHER|Psychological Well-Being|assessed by the Hospital Anxiety and Depression Scale
223881455|NCT03338868|DIAGNOSTIC_TEST|Blood tests|Blood tests included serum glucose, triglyceride, high-density lipoprotein cholesterol (HDL-C), and uric acid levels. Blood samples were collected from the patients after one night of fasting.
223881456|NCT03299322|DRUG|Jia Wei Yang He granule|This is an empirical traditional Chinese medicine compound used in the treatment of asthma for a long time
223881457|NCT03299322|DRUG|Jia Wei Yang He granule Placebo|Made from 1/20 doses which has certain taste, but no therapeutic effect
223881458|NCT02664558|DRUG|ubenimex|
223881459|NCT02664558|OTHER|placebo|
223881460|NCT03749785|OTHER|Regular carbohydrate feeding|60 ml of water with 5 g sucrose given every 5 minutes 14 times up until 70 minutes followed by 5 g sucrose after 75 minutes in a 250 ml solution
223881461|NCT03749785|OTHER|Single carbohydrate bolus|60 ml of water given every 5 minutes 14 times up until 70 minutes followed by 75 g sucrose after 75 minutes in a 250 ml solution
223881462|NCT05736185|DEVICE|PEEP selection|Electric impedance tomography-guided PEEP titration
223881463|NCT03578536|DEVICE|Recovery Rapids|This project utilizes a new gaming system technology called Recovery Rapids. The game is custom-made by Games That Move You, LLC and runs on an XBOX platform with motion input via a Kinect system.
223881464|NCT02538900|BEHAVIORAL|Exercise|Participants in one of the exercise intervention groups will attend once weekly sessions at the medical center for the first four weeks of the study (Weeks 1-4, Phase I). During weeks 5-52 (Phase II), they will receive weekly telephone calls from a study coach.
223881465|NCT02538900|OTHER|Attention control|Our attention control group controls for the possibility that regular contact with the study team may improve outcomes in participants randomized to the intervention. Participants randomized to the control group will attend weekly one-hour educational sessions at Northwestern University for the first four weeks of the intervention (Phase I). These sessions are on topics of interest to the typical PAD patient and are led by physicians and other health care workers. Topics include Medicare Part D, nutritional supplements, and cancer screening. During Phase II (weeks 5-52), the attention control group will receive weekly telephone calls, lasting 5-15 minutes, with information on a health-related topic.
223881466|NCT00004840|DRUG|thyrotropin-releasing hormone|
223881467|NCT05790863|DEVICE|Ergometer cycling|Paticipants will receive 21 sessions (3 sessions/week) of training for 7 weeks with the arm-leg cycle ergometer (SCIFIT, REX7000, US)
223881468|NCT05371275|DRUG|Palbociclib|125 mg of palbociclib once daily for 21 consecutive days
223881469|NCT02874534|BEHAVIORAL|Behavioral Activation|Treatment will consist of 15 weekly 45-minute sessions.
223881470|NCT02874534|BEHAVIORAL|Mindfulness Treatment|Treatment will consist of 15 weekly 45-minute sessions.
223881471|NCT02935998|DRUG|Ziprasidone|During the study, at least 1 injection is needed per day. Whether the second, third or fourth one is needed according to patients' symptoms. If the BARS score\>=5, clinicians are supposed to give 10mg or 20mg.If lower than 5, clinicians could choose to give 10mg or not according to patients' symptoms and doctor's experience. Doses of 10 mg may be administered every two hours; doses of 20 mg may be administered every four hours up to a maximum of 40 mg/day.It is not recommended to combine with other oral antipsychotic drugs. But if the patients' daily dose of injection has reached 40mg and agitation occurred 4 hours later after the last injection, with the BARS score higher than 5.The clinicians can determine whether or not to combine oral antipsychotic drug, and the dosage.
223881472|NCT04508972|DEVICE|Alexa Amazon|To test the use of the Amazon Alexa device as a tool to conduct screening of employees and patients at the point of entry into the Heart Failure (HF) Clinic of the McGill University Health Center.
223881473|NCT04431726|DRUG|Emicizumab|"Initially, all participants will receive 4 loading doses of 3 milligrams per kilogram (mg/kg) emicizumab subcutaneously (SC) once every week (QW) for 4 weeks followed by the maintenance dosing regimen 3 mg/kg emicizumab SC once every 2 weeks (Q2W) for a total of 52 weeks. Starting from Week 17 of treatment, individual participants may have their dose up-titrated to 3 mg/kg SC QW if they experience suboptimal bleeding control.~At the Week 53 clinic visit following consultation with the treating physician, parents/caregivers may elect for their child to continue with the maintenance 3-mg/kg SC Q2W dosing regimen or to switch to the maintenance 1.5-mg/kg SC QW or 6-mg/kg SC once every 4 weeks (Q4W) dosing regimen for the subsequent 7-year long-term follow-up period.~During the study, participants will be treated with emicizumab until unacceptable toxicity, discontinuation from the study due to any cause, or other criteria specified in the protocol, whichever occurs first."
223881474|NCT06314763|DRUG|Rivaroxaban 20mg|Single dose on day 1 and day 16
223881475|NCT06314763|DRUG|Sotorasib 960mg|Daily dose from day 3 till day 16
223881476|NCT02781623|PROCEDURE|MRI|
223881477|NCT03814369|DEVICE|AmplifEYE|AmplifEYE colonoscopy
223881478|NCT02916862|DIETARY_SUPPLEMENT|Soluble Corn Fiber (SCF) without Calcium|Participants will consume a supplement with 12 g/day of SCF for 12 months
223881479|NCT02916862|COMBINATION_PRODUCT|Soluble Corn Fiber (SCF) + Calcium|Participants will consume a supplement with 12 g/day of SCF + calcium carbonate (600 mg/day) for 12 months
223881480|NCT02916862|DIETARY_SUPPLEMENT|Placebo|Participants will consume a supplement without SCF or calcium carbonate for 12 months
223881481|NCT02916862|COMBINATION_PRODUCT|Placebo + calcium|Participants will consume a supplement without SCF + calcium carbonate (600 mg/day) for 12 months
223881482|NCT01582646|DRUG|Terbutaline sustained release 5 mg|Terbutaline 10mg oral per day (5 mg twice a day) during 28 days
223881483|NCT04217746|DEVICE|High Flow Nasal Cannula|The HFNC group will receive heated and humidified oxygenated gas delivered at high flow.
223881484|NCT05008315|OTHER|Myofascial abdominal diaphragm release|Myofascial abdominal diaphragm release
223881485|NCT05008315|OTHER|Direct focused scar release technique|Direct focused scar release technique
223881486|NCT05008315|OTHER|Direct manipulations to visceral structures|Direct manipulations to visceral structures
223881487|NCT05008315|OTHER|pelvic anatomy education|pelvic anatomy education
223881488|NCT05008315|OTHER|sham|sham
223881489|NCT03450434|DRUG|XC8 Oral Tablet|1 tablet of XC8 in a dose according to the treatment group + 2 tablets of placebo (in total 3 tablets) once daily in the morning during 12 weeks of treatment period.
223881490|NCT03450434|DRUG|Placebo Oral Tablet|Placebo (in total 3 tablets) once daily in the morning during 12 weeks of treatment period.
223881491|NCT02923180|DRUG|Enoblituzumab|Enoblituzumab 15mg/kg IV (in the vein) weekly for 6 doses beginning 50 days prior to radical prostatectomy.
223881492|NCT05198310|DRUG|KPL-404|Humanized monoclonal antibody
223881493|NCT05198310|DRUG|Placebo|Matching placebo
223881494|NCT05471128|PROCEDURE|Standard of Care Biopsy|Patients will be evaluated with multiparametric MRI prostate followed by ExactVu micro-ultrasound to identify target lesions all of which will be biopsied by the examiner
223881495|NCT05672147|BIOLOGICAL|Anti-CD33 CAR T-cells|Given IV
223881496|NCT05672147|PROCEDURE|Lymphodepletion Therapy|Undergo lymphodepletion
223881497|NCT04579211|DIAGNOSTIC_TEST|urine lipoarabinomannan (LAM)|Investigate the utility of urine LAM as a test to identify individuals at very low risk for having a sputum culture positive for NTM.
223881498|NCT04436107|DRUG|Zanubrutinib|160 mg administered orally twice daily (BID)
223881499|NCT04436107|DRUG|Lenalidomide|Administered orally on Days 1-21 each cycle followed by a mandatory 7-day drug-free interval.
223881500|NCT01095796|DRUG|Stribild|Stribild (EVG 150 mg/COBI 150 mg/FTC 200 mg/TDF 300 mg) STR administered orally once daily
223881501|NCT01095796|DRUG|Atripla|Atripla (EFV 600 mg/FTC 200 mg/TDF 300 mg) tablet administered orally once daily prior to bedtime
223881502|NCT01095796|DRUG|Stribild Placebo|Placebo to match Stribild STR administered orally once daily
223881503|NCT01095796|DRUG|Atripla Placebo|Placebo to match Atripla tablet administered orally once daily prior to bedtime
223881504|NCT06276374|DRUG|Patients who are scheduled to undergo carotid artery stenting|"* Arm A : Single antiplatelet therapy (SAPT) with aspirin or clopidogrel~  \- 1 month of dual antiplatelet therapy(100mg aspirin q.d. and 75mg clopidogrel q.d.)→ Randomization → 11 months of single antiplatelet therapy (100mg aspirin q.d. or 75mg clopidogrel q.d.)~* Arm B : Dual antiplatelet therapy (DAPT) with aspirin and clopidogrel - 1 month of dual antiplatelet therapy(100mg aspirin q.d. and 75mg clopidogrel q.d.) → Randomization → 11 months of dual antiplatelet therapy (100mg aspirin q.d. and 75mg clopidogrel q.d.)"
223881505|NCT04198727|OTHER|DPD activity assessment|Phenotyping DPD with enzyme activity measure and uracil dosage
223881506|NCT04198727|DRUG|Capecitabine|Capecitabine assignement at 1000mg per square meter twice daily, cycle of 21 days, 14 days of intake, 7 days of
223881507|NCT06230055|DEVICE|Ommaya reservoir|Intrathecal chemotherapy through Ommaya reservoir
223881508|NCT06230055|DRUG|Systematic chemotherapy|Systematic chemotherapy: including capecitabine(1000mg/m2 bid, d1-14, q3w, po), gemcitabine(1000mg/m2, d1,8, q3w, ivgtt), vinorelbine(25mg/m2, d1,8, q3w, ivgtt), docetaxel(75mg/m2, d1, q3w, ivgtt),Nab-paclitaxel(125mg/m2, d1,8, q3w, ivgtt), iribrin(1.4mg/m2, d1,8, q3w, iv), DS8201(5.4mg/kg, d1, q3w), SG(10mg/kg, d1,8, q3w, ivgtt) or SKB264(5mg/kg, d1, q2w).
223881509|NCT00294840|DEVICE|PET-CT|
223881510|NCT05370794|DRUG|rhCG= Ovitrelle®, 250g/0.5ml = 26000IU/ml, Merck-Serono|recombinant hCG
223881511|NCT05370794|DRUG|rFSH = Gonal F®, 300IU/0.5ml, Merck-Serono|recombinant FSH
223881512|NCT05090813|DEVICE|Model ICB00|Investigational intraocular lens replaces the natural lens removed during cataract surgery in one or both eyes.
223881513|NCT05036070|DEVICE|Model C0001|Investigational intraocular lens replaces the natural lens removed during cataract surgery in both eyes.
223881514|NCT05036070|DEVICE|Model ZCB00|Control intraocular lens replaces the natural lens removed during cataract surgery in both eyes.
223881515|NCT03552562|DEVICE|Fourier Domain Color Doppler Optical Coherence Tomography (FDOCT)|Fourier domain OCT is based on a local phase analysis of the backscattered signal and allows for bidirectional Doppler flow imaging.(Leitgeb et al. 2003a; Leitgeb et al. 2003b) It does not need reference arm scanning and records one full depth and Doppler profile in parallel. The system operates with an equivalent A-scan rate of 25 kHz and allows real time imaging of the color encoded Doppler information together with the tissue morphology at a rate of 2-4 tomograms (40 x 512 pixel) per second. Despite the high detection speed we achieve a system sensitivity of 86dB using a beam power of 500μW at the cornea. The fundus camera allows simultaneous view for selection of the region of interest. We observe bi-directional blood flow and pulsatility of blood velocity in retinal vessels with a Doppler detection bandwidth of 12.5 kHz and a longitudinal velocity sensitivity in tissue of 200μm/s. Diffuse luminance flicker will be applied during the measurements for 60 seconds.
223881516|NCT05749523|BEHAVIORAL|Exercise|Exercise vs non-exercise
223881517|NCT00809939|DRUG|17 alfa hydroxyprogesterone caproate|weekly injection of 250 mg until 34 weeks gestation
223881518|NCT00809939|DRUG|natural progesterone|previous preterm delivery, treatment with daily vaginal progesterone 200 mg until 34 weeks gestation.
223881519|NCT00809939|DRUG|17 alfa hydroxyprogesterone caproate|weekly injection, 250 mg until 34 weeks gestation
223881520|NCT00809939|DRUG|vaginal progesterone|daily vaginal progesterone 200 mg until 34 weeks gestation.
223881521|NCT02926911|OTHER|Surgery|Surgery +/- radiation choice for endocrine therapy
223881522|NCT02926911|OTHER|Active Monitoring|Choice for endocrine therapy
223881523|NCT03144518|OTHER|Positive Affect Intervention|See Previous Description
223881524|NCT03144518|OTHER|Neutral Control Intervention|See Previous Description
223881525|NCT03144518|BIOLOGICAL|Northern Hemisphere Influenza Vaccine 2017/18 (Delivered as part of Standard Care)|Northern Hemisphere Influenza Vaccine 2017/18 (Delivered as part of Standard Care)
223881526|NCT04844424|DRUG|Milvexian|Milvexian will be administered orally or via nasogastric route as tablets or capsules.
223881527|NCT01989455|DRUG|Deferiprone|"Deferiprone for infusion, 10mg/mL for intravenous infusion.~Oral dose of deferiprone: 80mg/mL oral solution. (Cohort 2)"
223881528|NCT01989455|DRUG|Placebo|Placebo: normal saline solution.
223881529|NCT00980473|PROCEDURE|Argon Laser Iridoplasty|
223881530|NCT00980473|DRUG|Travatan/ Timolol/Azopt|
223881531|NCT03773835|DRUG|HSK3486|Mmanual IV bolus injection completed in 1 minute.
223881532|NCT02095171|DRUG|PRX002|
223881533|NCT02095171|OTHER|Placebo|
223881534|NCT02574442|DEVICE|In Vivo Confocal Microscopy Probe|Participants will have 2 areas on their cervical imaged by the confocal probe.
223881535|NCT05771350|PROCEDURE|online hemodiafiltration|20 patients on regular hemodialysis received online hemodiafiltration
223881536|NCT05771350|PROCEDURE|high flux hemodialysis|20 patients on regular hemodialysis received high flux hemodialysis
223881537|NCT05771350|PROCEDURE|low flux hemodialysis|20 patients on regular hemodialysis received low flux hemodialysis
223881538|NCT05444426|OTHER|Shoulder Rehabilitation|hot pack, conventional TENS (COMPEX Rehab 400), 1 MHz frequency, 1.5 W/cm² intensity ultrasound (Chattanooga Intelect Ultrasound), active assistive and active range of motion exercises, stretching exercises for the shoulder muscles at the pain limit and posture exercises will be applied.
223881539|NCT03746535|DRUG|Elagolix|Elagolix, 400 mg/day oral, 2X200 mg tablets/day for 4 days.
223881540|NCT03762772|DRUG|TAF/EVG Vaginal Insert|1 combination vaginal insert (20mg TAF/16mg EVG)
223881541|NCT06420570|PROCEDURE|Thoracic Surgery|Patients will either undergo thoracic surgery, specifically thoracotomy (traditional method of chest surgery using a large surgical incision) or video-assisted thoracic surgery (minimally invasive method using video cameras)
223881542|NCT02638337|DRUG|Ospemifene|60 mg tablet
223881543|NCT02638337|DRUG|Placebo|Tablet identical to the ospemifene tablet without drug
223881544|NCT04116736|DEVICE|ACUVUE® OASYS with Transitions™|JJVC Marketed Contact Lens
223881545|NCT04116736|DEVICE|Silicone Hydrogel Contact Lens|Any reusable spherical silicone hydrogel brand that is approved and marketed in the country conducting the study.
223881546|NCT04349072|DRUG|Mavacamten|Mavacamten Capsules Other names: MYK-461
223881547|NCT04349072|DRUG|Placebo|Placebo
223881548|NCT01748110|BEHAVIORAL|Intensive Fitness Intervention|This intervention will involve adhering to health interventions such as behavior and diet modification, and exercise. Patients will follow-up monthly with a health counselor to verify progress.
223881549|NCT01748110|BEHAVIORAL|TRIMM|text message intervention.
223881550|NCT06389435|PROCEDURE|Patients will be randomized to undergo TKR or RTKR|Total knee replacement (control group)
223881551|NCT00186849|DRUG|Topotecan, Cyclophosphamide, Cisplatin, Doxorubicin, Etoposide, Ifosfamide, Carboplatin|See Detailed Description section for details of treatment interventions.
223881552|NCT00186849|PROCEDURE|Peripheral Blood Stem Cell Transplant|See Detailed Description section for details of treatment interventions.
223881553|NCT06212843|OTHER|plyometric training|"The group will receive plyometric exercises in a controlled environment. Following Plyometrics would be performed.~1. Plyo Pushup.~2. Chest Pass.~3. Overhead Throw.~4. Squat jump.~5. Plyo Step-up.~6. Cone jumps.~7. Med Ball drop.~8. Kneeling Squat jump.~9. Lateral jump over hurdle.~10. Overhead throw.~11. Under hand throws.~12. Dynamic Rotational Chest pass.~13. Overhead throw with step."
223881554|NCT06212843|OTHER|conventional exercises|"The group will receive conventional exercises in a controlled environment. Following conventional exercises would be performed.~1. Pushups.~2. Situps.~3. Lunges 4.500m running.~5.Squats"
223881555|NCT05869331|PROCEDURE|Early mobilization|Patients randomized to nonoperative treatment have already received treatment using early mobilization in the original trial, and all fractures have been confirmed healed. Mobilization consisted of 5 repetitions of full finger extension followed by maximum finger flexion, and 5 such sets of 5 were required per day for the first 6 weeks. Buddy taping or resting splint was offered if the patient experienced difficulty, and mobilization was performed by all patients in this treatment arm.
223881556|NCT05869331|PROCEDURE|Operative treatment|Patients randomized to operative treatment have already received treatment using open reduction and internal fixation (ORIF) with cortical screws in the original trial, and all fractures have been confirmed healed. Surgery was performed under general anaesthesia through a dorsal incision centered over the fractured metacarpal. Reduction was performed under visual inspection and fixation performed using 2 or more cortical screws (Synthes Compact Hand 2.0) as first option. At the surgeons preference fixation using plate and screw fixation was also allowed. Postoperatively patients were put in a plaster cast for two weeks and then hand therapy was initiated.
223881557|NCT06020495|DRUG|DDAVP|Posology: 4µg in 2ml IV solution Route of administration: Intravenous Duration of treatment: 48h maximum (additional doses every 6h)
223881558|NCT06020495|DRUG|Standard hyponatremia treatment|"Standard hyponatremia treatment alone :~Presence of neurological symptoms :~sodium chloride 3% 150ml for 20 min Absence of neurological symptoms : Hyper or isotonic fluid but never hypotonic"
223881559|NCT05998863|DRUG|EffCaMgCit|Each sachet of EffCaMgCit will contain 19 meq or 380 mg calcium, 10 meq (122 mg) magnesium, and 50 meq total citrate.
223881560|NCT05998863|OTHER|Placebo|Each sachet of Placebo will contain microcrystalline cellulose, but no calcium, magnesium or citrate.
223881561|NCT04985812|DRUG|JNJ-67484703|Participants will receive JNJ-67484703.
223881562|NCT04985812|DRUG|Placebo|Participants will receive placebo to JNJ-67484703.
223881563|NCT06105515|PROCEDURE|Laparoscopic and Endoscopic Collaborative Surgery (LECS)|Minimal invasive surgery in collaboration between endoscopy and laparoscopic surgery, to locally remove the tumor
223881564|NCT05256745|DRUG|TTP488|Each Azeliragon capsule is 5mg, and is to be taken in the morning with food as indicated in each cohort.
223881565|NCT05256745|DRUG|ddAC/ddT|Dose dense doxorubicin plus cyclophosphamide followed by paclitaxel (ddAC/ddT) for 8 cycles, administered per USPI (Unites States Prescribing Information) Label
223881566|NCT05256745|DRUG|TC|Docetaxel plus cyclophosphamide (TC) for 4-6 cycles, administered per USPI (Unites States Prescribing Information) Label
223881567|NCT05256745|DRUG|TCHP|Docetaxel, carboplatin, trastuzumab, and pertuzumab (TCHP)for 6 cycles, administered per USPI (Unites States Prescribing Information) Label
223881568|NCT05256745|DRUG|Chemotherapy regimen that includes ddAC|can include: (1) weekly carboplatin + paclitaxel + pembrolizumab followed by pembrolizumab + dose dense doxorubicin and cyclophosphamide; (2) weekly carboplatin + paclitaxel followed by dose dense doxorubicin and cyclophosphamide; (3) weekly or dose dense paclitaxel followed by dose dense doxorubicin and cyclophosphamide, administered per USPI (Unites States Prescribing Information) Label
223881569|NCT03022708|DEVICE|Xeltis Bioabsorbable Pulmonary Valved Conduit|Surgical implantation of Xeltis Bioabsorbable Pulmonary Valved Conduit
223881570|NCT06232447|OTHER|Cigarette Type Switching|Participants will be switched from smoking menthol cigarettes to non-menthol cigarettes for a period of four weeks
223881571|NCT03341156|DRUG|Kcentra|Kcentra will be administered in 2 divided doses; Pre-bypass (5-10 units/kg based on body weight and preoperative INR and post-protamine based of the pre-bypass dose and the preoperative INR; daily maximum dose not to exceed 5000 IU (50 IU/kg)
223881572|NCT03341156|DRUG|Frozen Plasma Product, Human|If the patient is randomized to receive standard transfusion they will receive 2 U of fresh frozen plasma intravenously before cardiopulmonary bypass and then up to 4-8 U of plasma added to the cardiopulmonary bypass reservoir during rewarming.
223881573|NCT03401879|DEVICE|Dynamic Vessel Analyzer (DVA)|Retinal vessel diameters and oxygen saturation will be measured with the DVA device.
223881574|NCT03401879|DEVICE|Fourier Domain Doppler Optical Coherence Tomography (FDOCT)|Retinal blood flow will be assessed using FDOCT.
223881575|NCT03401879|DEVICE|Optical coherence tomography (OCT)|Nerve fiber layer thickness and central retinal thickness will be measured using OCT.
223881576|NCT03401879|DEVICE|Optical coherence tomography angiography (OCTA)|Retinal microvasculature will be assessed using OCTA.
223881577|NCT06224569|OTHER|Black tea flavoured, tea drink|Black tea powder containing 50.0 mg of caffeine and 11.5 mg of theanine, to be dissolved in 200 ml boiling water.
223881578|NCT06224569|OTHER|Black tea flavoured, caffeine-only drink|50.0 mg of caffeine in a black tea-like powder i.e., matched to the 'black tea' intervention for flavour and appearance, to be dissolved in 200 ml boiling water. Caffeine is the only biologically active ingredient in this intervention.
223881579|NCT06224569|OTHER|Black tea flavoured, placebo drink|A black tea-like powder i.e., matched to the 'black tea' intervention for flavour and appearance, containing no biologically active ingredients, to be dissolved in 200 ml boiling water.
223881580|NCT06224569|OTHER|Green tea flavoured, tea drink|Green tea powder containing 30.6 mg of caffeine and 11.1 mg of theanine, to be dissolved in 200 ml boiling water.
223881581|NCT06224569|OTHER|Green tea flavoured, caffeine-only drink|30.6 mg of caffeine in a green tea-like powder i.e., matched to the 'green tea' intervention for flavour and appearance, to be dissolved in 200 ml boiling water. Caffeine is the only biologically active ingredient in this intervention.
223881582|NCT06224569|OTHER|Green tea flavoured, placebo drink|A green tea-like powder i.e., matched to the 'green tea' intervention for flavour and appearance, containing no biologically active ingredients, to be dissolved in 200 ml boiling water.
223881583|NCT03490864|DIETARY_SUPPLEMENT|Melatonin 1 mg|Melatonin (1mg) or placebo will be administered daily during the intervention. Melatonin capsules will be obtained from Life Extension (Ft. Lauderdale, FL). The investigational drug pharmacy (IDP) at Northwestern Memorial Hospital will encapsulate the melatonin pills so the placebo (lactose) and melatonin pills appear identical. We have worked with this IDP on other projects. The investigators on this study have experience in administering melatonin for investigational and clinical purposes.
223881584|NCT03490864|DIETARY_SUPPLEMENT|Placebos|Melatonin (1mg) or placebo will be administered daily during the intervention. Melatonin capsules will be obtained from Life Extension (Ft. Lauderdale, FL). The investigational drug pharmacy (IDP) at Northwestern Memorial Hospital will encapsulate the melatonin pills so the placebo (lactose) and melatonin pills appear identical. We have worked with this IDP on other projects. The investigators on this study have experience in administering melatonin for investigational and clinical purposes.
223881585|NCT03490864|OTHER|Meal Timing|Subjects are instructed to maintain an extended overnight fasting period of 12-16 hours.
223881586|NCT03490864|OTHER|NON Meal Timing|Subjects are instructed to maintain their habitual meal timing.
223881587|NCT04421235|BEHAVIORAL|Childbirth support|"There are 5 program components that women may receive as a part of childbirth support:~Prenatal education - consists of up to 8 sessions of education on pregnancy, childbirth, and postpartum health and wellness.~Support group - semi-structured group which provides time for women to process their pregnancy and postpartum-related experiences with other women facing similar challenges. Integrates mindfulness exercises, cognitive-behavioral skills, and special topics as requested by group members.~Lactation program - program for women who wish to provide breastmilk for infants from which they are separated.~Doula support program - 2 prenatal and 2 postnatal individual visits with a doula who will also provide continuous childbirth support and support during separation from infants.~Parenting classes - group classes focused on helping women learn parenting skills and (if applicable) meet state requirements for reunification with children"
223881588|NCT06034548|BEHAVIORAL|diabetes and hypertension self-management|12-weeks of 75 minutes of educational sessions
223881589|NCT06364644|BEHAVIORAL|Community Champions|The UNLOAD-Heart Failure Program intervention includes problem solving training, community health worker support, and exercise support from health coaches at YMCAs.
223881590|NCT06364644|BEHAVIORAL|Homegrown Heroes|Monthly newsletters/videos on diabetes self-management, healthy lifestyle and heart failure prevention will be provided, as well as a membership to the local YMCA.
223881591|NCT05018910|OTHER|Skin to Skin|During routine Skin-to-skin sessions, the heart rate variability of the infant will be measured.
223881592|NCT03361215|OTHER|Biosampling for molecular analysis|Observational study with no therapeutic intervention. Biosampling for molecular analysis
223881593|NCT05435963|BEHAVIORAL|Pulmonary rehabilitation (PR)|A typical PR program will include exercise training, disease-specific and self-management strategies education, and will last 6 - 8 weeks
223881594|NCT03709199|DIAGNOSTIC_TEST|Ventilation Inhomogeneity|Ventilation inhomogeneity will be measured using the Lung Clearance Index (LCI), derived from multiple breath Nitrogen washout during tidal breathing, measured by a mouthpiece or mask covering nose and mouth.
223881595|NCT03709199|DIAGNOSTIC_TEST|Diaphragm Ultrasound|Diaphragm thickness and contractile activity measured during tidal breathing.
223881596|NCT03709199|DIAGNOSTIC_TEST|Respiratory Inductance Plethysmography|Measure of thoraco-abdominal asynchrony during tidal breathing
223881597|NCT03709199|DIAGNOSTIC_TEST|Spirometry|Measurement of Forced Expiratory Volume (FEV1), Forced Vital Capacity and other lung volumes using standard pulmonary function techniques
223881598|NCT03709199|DIAGNOSTIC_TEST|Functional Residual Capacity|Measurement using body box plethysmography of functional residual capacity and other lung volumes using standard pulmonary function techniques
223881599|NCT03709199|DIAGNOSTIC_TEST|MIP/MEP|Measurement of maximal inspiratory and expiratory pressures during airway occlusion
223881600|NCT03709199|DIAGNOSTIC_TEST|6 minute walk test|Measurement of cardio-respiratory function and capabilities during treadmill walking for 6 minutes.
223881601|NCT03709199|DIAGNOSTIC_TEST|Neurocognitive Testing|Detailed in person neuro-cognitive testing using standardized inventories using either the Battelle Developmental Inventory, second edition (Battelle-2) (age birth to 5 years 11 months) and the Wechsler Intelligence Scale for Children, fifth edition (WISC-5, for age 6 years to 19 years).
223881602|NCT03709199|DIAGNOSTIC_TEST|Emotional Health Assessment|In person and written assessments of children and parents using the Behavioral Assessment System for Children, third edition (BASC-3) for children ≥ 2 years and the UCLA PTSD Reaction Index (UCLA RI) for children ≥ 8 years.
223881603|NCT03709199|DIAGNOSTIC_TEST|Health Related Quality of Life|Standardized instruments to assess (in person, over the phone, or via mail) health related quality of life in children. Parent and child questionnaires.
223881604|NCT03709199|DIAGNOSTIC_TEST|Functional Status|Survey of overall functional status, administrated by asking a series of questions to patient and families.
223881605|NCT03709199|DIAGNOSTIC_TEST|Respiratory Status Questionnaire|Survey of respiratory health, administrated by asking a series of questions to patient and families.
223881606|NCT05766969|DRUG|CBD/PEA|A water-soluble sublingual tablet containing 10/50 mg of CBD/PEA.
223881607|NCT05766969|DRUG|Placebo|An inactive compound.
223881608|NCT03380390|DRUG|Oxymetazoline HCL 1.0% Cream|Oxymetazoline HCl cream 1.0% once daily application
223881609|NCT03380390|DEVICE|Energy-Based Therapy|Energy-based therapies (Potassium Titanyl Phosphate \[KTP\], Pulsed Dye Laser \[PDL\], or Intense Pulsed Light \[IPL\])
223881610|NCT01724242|DRUG|Vaginal DHEA|
223881611|NCT01724242|DRUG|Placebo|
223881612|NCT01420458|DRUG|Experimental|Bioequivalence of two drug formulations
223881613|NCT01426412|DRUG|LY3015014 IV|Administered IV over 30-90 minutes
223881614|NCT01426412|DRUG|Placebo IV|Administered IV only over 30-90 minutes
223881615|NCT01426412|DRUG|LY3015014 SC|Administered SC
223881616|NCT01426412|DRUG|Placebo SC|Administered SC
223881617|NCT05406765|DRUG|Bupivacaine Injection|One group will receive bupivacaine 15 mg and morphine 100 ug intrathecally
223881618|NCT03459989|DIAGNOSTIC_TEST|Ultrasound|Samsung H60 Ultrasound
223881619|NCT02371395|OTHER|Realtime amplification (RealAmp)|Molecular assay for the diagnosis of malaria.
223881620|NCT03176888|BEHAVIORAL|Reduced-exertion, high-intensity interval training (REHIT)|As in arm/group description
223881621|NCT03176888|BEHAVIORAL|Cognitive behavioral therapy (CBT)|Up to six 30/40-minute sessions of face-to-face psychotherapy will be offered based on a cognitive model of adjustment to cancer utilizing cognitive and behavioral therapy techniques as described by Moorey \& Greer (2012)
223881622|NCT06835907|OTHER|Questionnaires|Questionnaires include: the Alcohol Use Disorder Identification Test (AUDIT), Composite Autonomic Symptom Score (COMPASS-31), Depression Anxiety Stress Scale (DASS-21), Drug Desire Questionnaire (DDQ), Drinking Motives Questionnaire short form (DMQ-SF), Mini International Neuropsychiatric Interview (MINI), PROMIS-alcohol, Timeline Follow Back (TLFB) and Visual Analog Scale for craving (VAS).
223881623|NCT00004559|BEHAVIORAL|dietary polyunsaturated fatty acid|
223881624|NCT02240420|BEHAVIORAL|Life Style Counseling (Star-Mama)|"Participants enrolled in the Star-Mama intervention group will receive 1. weekly automated phone calls with prevention-focused queries (e.g., diet, exercise, breastfeeding). 2. If a participant generates a value rated out of range, a health coach who receives daily electronic downloads of STAR-Mama responses will call the participant to coach her about the specific health issue. Participants also hear recorded narratives related to their out of range reply encouraging behavior change. 3. Call-backs enable coaches to engage patients in goals setting/action plans and providing information about community resources"
223881625|NCT04381832|DRUG|Etrumadenant|Etrumadenant is an A2aR and A2bR antagonist
223881626|NCT04381832|DRUG|Zimberelimab|Zimberelimab is an anti-PD-1 antibody
223881627|NCT04381832|DRUG|Quemliclustat|Quemliclustat is a Cluster of Differentiation (CD)73 Inhibitor.
223881628|NCT04381832|DRUG|Enzalutamide|Enzalutamide is an androgen receptor inhibitor
223881629|NCT04381832|DRUG|Docetaxel|Docetaxel is type of chemotherapy
223881630|NCT04381832|DRUG|SG|Sacituzumab govitecan is an antibody-drug conjugate
223881631|NCT04157348|BIOLOGICAL|Benralizumab|30 mg/mL solution for injection in a single accessorized prefilled syringe (APFS) will be administered subcutaneously (SC)
223881632|NCT04157348|BIOLOGICAL|Mepolizumab|3x100 mg vials of powder for solution for injection reconstituted into 3 separate 1 mL syringes for administration on each dosing occasion. Injection volume per syringe is 1 mL. Mepolizumab active solution will be administered subcutaneously (SC)
223881633|NCT04157348|BIOLOGICAL|Placebo to Mepolizumab|Matching placebo: 0.9% sodium chloride, solutions for injection in 1mL syringes (3 syringes will be used on each dosing occasion). Injection volume per syringe is 1mL. Placebo to Mepolizumban will be administered subcutaneously (SC)
223881634|NCT04157348|BIOLOGICAL|Placebo to Benralizumab|Matching placebo solution for injection in APFS, 1 mL fill volume. Placebo solution will be administered subcutaneously (SC)
223881635|NCT06966934|DEVICE|NPA|After sedation, the nasopharyngeal airway (NPA) is inserted when the patient's breathing becomes slightly slow but stable and the eyelash reflex disappears.
223881636|NCT06971835|DEVICE|NMP|"The study product is Induce Biologics NMP Fibers and NMP Micro Particulates however, this is observational research that involves standard of care.~NMP is regulated as a human cellular or tissue-based product (HCT/P) under section 361 of the Public Health Service (PHS) Act and in 21 CFR Part 1271. Under this regulation it did not require clinical evaluation before it could be used commercially. It is indicated for use as a bone void filler for filling voids and gaps in the skeletal system that are not intrinsic to the stability of the boney structure."
223881637|NCT05306938|BEHAVIORAL|Adolescent Wellness Visit|Adolescent Wellness Visits (AWVs) are a new health service platform for reaching young adolescents with HTC and other evidence-based prevention services which are clinic-based and school-facilitated. The AWVs bundle the following health screenings, education, and counseling on: nutrition, vision, dental, mental health (depression), contraception, sexually transmitted infections, and optional HIV testing.
223881638|NCT04968405|DEVICE|Catalyst CSR Total Shoulder System|The Catalyst CSR Shoulder System is a bone preserving total shoulder prosthesis designed for use in patients where the humeral head, neck and glenoid vault are of sufficient bone stock and there is an intact or reconstructable rotator cuff. The design requires minimal bone resection, thus giving the patient an alternative to other total shoulder designs where more bone is removed.
223881639|NCT06409884|DEVICE|T-cell activation test using intracellular markers|A blood sample will be taken which is needed for the T-cell activation test (TAT). The TAT will than be performed by trained laboratory personnel.
223881640|NCT06285786|OTHER|Ergonomic Training on Patient Handling Techniques|"Each participant will receive an ergonomic training on proper patient handling technique, adhering to the appropriate program to use with the SAMS bed and the Vendlet between session 1 \& 2.~In small groups of 6-10 participants, a healthcare ergonomist (M. Leger) will be responsible to demonstrate, instruct and evaluate each participant on all 4 techniques on the SAMS bed. Each participant will have multiple opportunities to demonstrate their skills.~In the same session, each participant will also receive proper training from a specialized occupational therapist on how to use the Vendlet. Each participant will have multiple opportunities to demonstrate their skills.~After completing the intervention, each participant will be prepared to participate in the post-intervention data collection session in the laboratory."
223881641|NCT06287736|DEVICE|Spinal Cord Stimulator Implantation (SCS)|Spinal cord stimulator implantation is broken up into two parts. The first part involves placement of temporary SCS leads for a one-week trial. If the participants respond favorably to the SCS, then they will undergo the second part and the device is implanted
223881642|NCT04757610|BIOLOGICAL|2.0 mg OPT-302|intravitreal injection
223881643|NCT04757610|BIOLOGICAL|0.5 mg ranibizumab|intravitreal injection
223881644|NCT04757610|PROCEDURE|Sham|intravitreal injection
223881645|NCT02965846|DRUG|AGN-195263|1 drop of AGN-195263 will be instilled in each eye twice daily.
223881646|NCT02965846|DRUG|Vehicle|1 drop of AGN-195263 vehicle(placebo) will be instilled in each eye twice daily.
223881647|NCT04914442|DIAGNOSTIC_TEST|Microscopic examination|All the studies cases are microscopically examined using the ordinary stains (hematoxylin and eosin) then the eosinophilic infiltration are counted in 10 high power field manually
223881648|NCT05042375|DRUG|camrelizumab + famitinib|Camrelizumab for injection, 200 mg; Famitinib malate capsules, 20 mg.
223881649|NCT05042375|DRUG|pembrolizumab|pembrolizumab 200 mg.
223881650|NCT05042375|DRUG|camrelizumab|Camrelizumab for injection, 200 mg.
223881651|NCT00677391|DRUG|Sibutramine|Capsules, Wk 0: 10mg, once daily; Wks 4-24: 10mg or 15mg, once daily, dosage escalation based upon investigator's assessment.
223881652|NCT00677391|DRUG|Placebo|Capsules, once daily
223881653|NCT05608213|PROCEDURE|Lenvatinib Plus I-125 Seed Brachytherapy|Lenvatinib (body weight ≥ 60 kg, 12mg P.O. QD; body weight \< 60 kg, 8mg P.O. QD) will be administered to the patients. Iodion-125 seeds will be implanted into the the target lesions (viable intrahepatic tumor and/or vascular tumor thrombus) under CT guidance according to the pre-operative planning within 7 days after lenvatinib administration. Iodion-125 seeds implantation can be repeated on demand during follow-up based on the evaluation of laboratory and imaging examination.
223881654|NCT05608213|DRUG|Lenvatinib|Lenvatinib (body weight ≥ 60 kg, 12mg P.O. QD; body weight \< 60 kg, 8mg P.O. QD) will be administered to the patients.
223881655|NCT06338540|OTHER|Black color of caries|observation of the dental caries color will be confirmed with standardized photographs illustrating , the black caries color related to history of pain , ICDAS , pulp exposed and microbial load
223881656|NCT06338540|OTHER|dark brown color of caries|observation of the dental caries color will be confirmed with standardized photographs illustrating , the dark brown caries color related to history of pain , ICDAS , pulp exposed and microbial load
223881657|NCT06338540|OTHER|light brown color of caries|observation of the dental caries color will be confirmed with standardized photographs illustrating , the light brown caries color related to history of pain , ICDAS , pulp exposed and microbial load
223881658|NCT06338540|OTHER|yellow color of caries|observation of the dental caries color will be confirmed with standardized photographs illustrating , the yellow caries color related to history of pain , ICDAS , pulp exposed and microbial load
223881659|NCT04747561|DRUG|18F-PEG3-FPN|For clinically suspected or confirmed melanoma patients and healthy volunteers, integrated PET/MR imaging was performed using targeted melanin-specific imaging agent 18F-PEG3-FPN. Meanwhile, the general imaging agent 18F-FDG was compared with MR multi-sequence and multi-parameters
223881660|NCT03304834|DEVICE|ECHOPULSE|Patient are treated with the HIFU device and the physician is doing a compressive bandage.
223881661|NCT03514836|BIOLOGICAL|DCVac/PCa|"Oncolytic adenovirus containing immunostimulatory cytokine granulocyte-monocyte colony-stimulating factor (GM-CSF). This is an experimental therapy.~DCVac/Pca consists of activated autologous dendritic cells. This is an experimental therapy."
223881662|NCT03514836|DRUG|Cyclophosphamide|immunomodulatory medication given around the ONCOS-102 dosing
223881663|NCT00092300|DRUG|MK0966, rofecoxib|
223881664|NCT00092300|DRUG|Comparator: valdecoxib|
223881665|NCT00215787|DRUG|lansoprazole|Lansoprazole 30 mg BID for 1 year
223881666|NCT02672033|RADIATION|Hypofractionated Radiation Therapy|Undergo accelerated hypofractionated IMRT
223881667|NCT02672033|RADIATION|Intensity-Modulated Radiation Therapy|Undergo accelerated hypofractionated IMRT
223881668|NCT02672033|OTHER|Laboratory Biomarker Analysis|Correlative studies
223881669|NCT02672033|PROCEDURE|Therapeutic Conventional Surgery|Undergo pleurectomy/decortication
223881670|NCT03547999|DRUG|mFOLFOX6|The control arm (Arm A) and experimental arm (Arm B) will receive mFOLFOX6 every 2 weeks for 4 cycles. Once patients in the post-operative period are deemed ready to begin therapy, patients in the control arm will then undergo another 8 cycles of mFOLFOX6.
223881671|NCT03547999|BIOLOGICAL|MVA-BN-CV301|The experimental arm (Arm B) will receive MVA-BN-CV301 in 4 injections of 4 x 10(8) infectious units/0.5 mL given subcutaneously prior to the start of chemotherapy on days -28 and -14.
223881672|NCT03547999|BIOLOGICAL|FPV-CV301|The experimental arm (Arm B) will receive FPV-CV301 in 1 dose of 1 x 10(9) infectious units/0.5 mL given subcutaneously concurrently with chemotherapy (at least an hour prior to chemotherapy) on days 0, 14, 28 and 42 pre-operatively, and FVP-CV301 boosters on day 0 and 14 and then every 4 weeks (day 42, 70, 98). After day 98, FVP-CV301 will then be administered every twelve weeks completing therapy at week 110.
223881673|NCT03547999|DRUG|Nivolumab|Nivolumab at a dose of 240 mg as a 30 minute IV infusion every 2 weeks until progression. Arm B will receive Nivolumab starting with the vaccinations. Arm A will begin the Nivolumab with the initiation mFOLFOX.
223881674|NCT00738023|DRUG|Rosiglitazone|Diabetic subjects will be receive rosiglitazone for 6 weeks
223881675|NCT00738023|DRUG|Normal saline 0.9%|Normal saline 0.9% intravenous infusion at 40ml/hr for 48 hours
223881676|NCT00738023|DRUG|Intralipid 20%|Intralipid 20% at 40ml/hr intravenously for 48 hours
223881677|NCT01577225|DEVICE|OPSITE POST-OP VISIBLE|Patient will be treated with OPSITE POST-OP VISIBLE dressing up to 14 days post surgery
223881678|NCT01577225|DEVICE|Tape and Gauze|Patient will be treated with tape and gauze up to 14 days post surgery
223881679|NCT00664404|OTHER|Functional Magnetic Resonance Imaging (fMRI)|Functional Magnetic Resonance Imaging (fMRI)of the Brain, one session while smoking, and one session while abstinent from smoking (not smoking).
223881680|NCT04222946|OTHER|Dry needling|Bilateral dry needling in latent trigger points of the Flexor digitorum Brevis Muscle
223881681|NCT04313205|DRUG|JKB-122 in capsule or tablet form|JKB-122 is a TLR4 antagonist and will be administrated in capsule or tablet form
223881682|NCT00168649|DRUG|Vitamin A|
223881683|NCT00099931|DRUG|vildagliptin|
223881684|NCT07011940|BEHAVIORAL|Along With Me|Along With Me is a therapeutic app that delivers cognitive behavior therapy and mindfulness-based psychoeducation and skills, grief normalization, and exercises to address perinatal grief and to reduce trauma symptoms related to the experience of perinatal loss. The Along With Me only arm will deliver the app-based intervention only.
223881685|NCT07011940|BEHAVIORAL|Peer Guide|The peer guide will provide light touch reminders, opportunities to debrief, and resource navigation support, similar to community health navigator interventions provided remotely through insurers.
223881686|NCT04605783|DIETARY_SUPPLEMENT|Travelan®|Travelan® (600mg) taken as 1 sachet twice daily with meals. Product will be started 2 days prior to arrival and maintained for a maximum duration of 20 days (minimum of 10 days) during travel or deployment.
223881687|NCT04605783|OTHER|Placebo|Maltodextrin - To be started 2 days prior to arrival and maintained for a maximum duration of 20 days (minimum of 10 days) during travel or deployment.
223881688|NCT06696066|BEHAVIORAL|PRS Program|The Peer Recovery Support program will be delivered by a certified recovery specialist (CRS) over the course of 6-months. The CRS will provide supportive care to the participant during their initial 6-months of MOUD treatment to increase patient engagement in their treatment. The CRS may provide emotional support; help participants to identify their recovery assets, goals, and barriers; guide participants in creating a recovery plan; help participants to increase their coping skills; and assist participants in connecting to community and recovery resources.
223881689|NCT00976105|DRUG|Zolpidem or placebo - Hypnotic drug given for sleep disorders|The information gathered from Part A will be used as a benchmark against which any effects of GSK1521498 can be assessed in Part B.
223881690|NCT00976105|DRUG|GSK1521498 or placebo|The first group will start at a low dose (10 mg GSK1521498 or placebo) for 10 days. The study team will then assess the data gathered from the first cohort and will select the dose that the next cohort will receive for 10 days. There will be up to 4 cohorts.
223881691|NCT06877273|BEHAVIORAL|CIRCuiTS-MS|The intervention is a blended treatment combining therapist support with carrying out tasks in CIRCuiTS™ digital cognitive remediation software. This software provides opportunities to practice a range of cognitive tasks and adaptively adjusts task difficulty. CIRCuiTS™ is much used in psychosis. Based on collaborative workshops with people with MS, participants for this trial will be asked to attend two 1-hour therapy sessions (in person or on MS Teams) and 1 hour of independent tasks each week for 12 weeks. Participants with reduced ability to operate a mouse quickly or dexterously will be offered a modified programme omitting tasks that require these abilities. The therapist will be an Assistant Psychologist trained in CIRCuiTS™ delivery and in appropriate adjustments to the needs of people with MS. They will follow a manualised template and will receive weekly supervision from an experienced clinical psychologist.
223881692|NCT06729567|OTHER|Spinal block level analysis|Relation of the dose of hyperbaric bupivacaine to resulting spinal block level is to be assessed. Conventional dose cases (more than 9mg and less than 13mg) will be included in analysis.
223881693|NCT06729567|OTHER|data collection|Intervention is to acquire and analyse anonymous perioperative data. After identification of the eligible cases, statistical analysis will be performed.
223881694|NCT02274142|PROCEDURE|Restoration with hand-mixed material|restoration with hand-mixed glass ionomer cement
223881695|NCT02274142|PROCEDURE|Restoration with Encapsulated material|restoration with encapsulated ionomer cement
223881696|NCT02274142|DEVICE|Encapsulated glass ionomer cement (EQUIA - GC Corp).|
223881697|NCT02274142|DEVICE|powder-liquid glass ionomer cement (Fuji IX - GC Corp)|
223881698|NCT07054658|PROCEDURE|Allogenic Bone Ring Graft With Simultaneous Implant Placement|A surgical procedure involving vertical ridge augmentation using an allogenic bone ring combined with simultaneous dental implant placement in the posterior mandible. The technique allows one-stage treatment of vertical bone defects without the need for autogenous bone harvesting.
223881699|NCT06788886|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223881700|NCT06788886|OTHER|Exercise Intervention|Participate in walking routines
223881701|NCT06788886|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223881702|NCT06788886|OTHER|Questionnaire Administration|Ancillary studies
223881703|NCT06788886|PROCEDURE|Respiratory Therapy|Participate in breathing sessions
223881704|NCT07061301|DEVICE|Usual Care group|Participants will use the same CGM and Insulclock® devices, but in blinded mode (no data available to the patient). Insulin therapy will be adjusted using capillary blood glucose measurements (4 times daily). Device data will be collected retrospectively but not used for treatment decisions.
223881705|NCT07061301|DEVICE|Technological group|Participants will use a real-time continuous glucose monitoring device (e.g., FreeStyle Libre 2) and the Insulclock® smart insulin pen cap. Both devices provide real-time feedback and data on insulin administration and glucose levels. Patients will adjust their insulin therapy based on these data.
223881706|NCT06751225|DEVICE|One week replacement soft contact lenses|One week replacement soft contact lenses
223881707|NCT07071480|DEVICE|Cold pack-delivered mild therapeutic hypothermia|Mild therapeutic hypothermia (cooling), delivered non-invasively to the structures of the inner ear (cochlea) for 30 minutes, using headband-style proprietary device, ReBound.
223881708|NCT07071480|DEVICE|Sham device|Sham headband-style device. Participants assigned to use this device will be told they are receiving therapy for 30 minutes. However, no therapy is being provided.
223881709|NCT07070141|DIAGNOSTIC_TEST|Diagnostic work up|None intervention
223881710|NCT07070791|OTHER|Upper Extremity Aerobic Exercise Training|12 weeks of upper extremity aerobic exercise training, 3 sessions per week, 25 minutes per session.
223881711|NCT07070791|OTHER|Upper Extremity Progressive Resistance Exercise Training|Upper extremity progressive resistance training was gradually increased over 12 weeks using elastic resistance bands.
223881712|NCT06261502|DRUG|CBD Oral Solution|Participants will start with oral CBD dose of 5 mg/kg/day for two weeks and then increase to 10 mg/kg/day.
223881713|NCT06261502|DRUG|Placebo|Participants will receive a dose of a placebo composed of the inactive ingredients of CBD of the same volume as the CBD Oral Solution.
223881714|NCT05297734|OTHER|Receive technology-based supportive cancer care|All participants will receive an electronic health record message or email with standardized information provided regarding advance care planning and symptom management.
223881715|NCT05297734|BEHAVIORAL|Receive redesigned team-based supportive cancer care|Lay Health Workers will meet with 1:1 with participants over 12 months to discuss advance care planning, surrogate decision-makers, advance directives and physician orders for life sustaining treatment.
223881716|NCT05170269|DRUG|BT097|Subjects will receive BT097 200 U per kg of maternal body weight intravenously every 2 weeks until at least GW 17
223881717|NCT05498376|DEVICE|Conventional pacemaker DDD|Implantation of a conventional cardiac pacemaker
223881718|NCT05498376|DEVICE|Leadless pacemaker Micra AV|Implantation of a leadless cardiac pacemaker
223881719|NCT06694948|DRUG|pimicotinib capsules|pimicotinib capsules
223881720|NCT05310539|OTHER|assessment of the early recovery after wedge resection surgery|To assess the early recovery will be used 1 minute sit to stand, Numeric Rating scale to assess pain, incentive spirometer to assess vital capacity, Borg modified scale to assess dyspnea.
223881721|NCT05196815|OTHER|Ultrasound|Participants will have a routine ultrasound of the heart (echocardiogram) before the procedure. During this test we will take a few extra measurements, this will not add any significant time to the scan
223881722|NCT05196815|PROCEDURE|Catheters|During the TAVI procedure 3 catheters (tubes) will be inserted into the blood vessels at the top of the participants legs as per normal standard care (there will be no extra skin punctures as part of the study).
223881723|NCT05196815|PROCEDURE|Soft study wire|Participants will have a soft study wire inserted to measure the pressure in the left ventricle. This step is in addition to standard care.
223881724|NCT05196815|RADIATION|X-ray|Participants will have chests x-ray when the soft study wire is inserted.
223881725|NCT05196815|DRUG|Dobutamine|Participants will be given a low dose infusion of dobutamine, to make the heart pump quicker and more vigorously.. This will last for approximately 5 minutes
223881726|NCT06366451|BIOLOGICAL|Rilvegostomig|Intratumoral microdose injection by the CIVO device.
223881727|NCT06366451|BIOLOGICAL|Volrustomig|Intratumoral microdose injection by the CIVO device.
223881728|NCT06366451|BIOLOGICAL|Sabestomig|Intratumoral microdose injection by the CIVO device.
223881729|NCT06366451|BIOLOGICAL|AZD9592|Intratumoral microdose injection by the CIVO device.
223881730|NCT06366451|BIOLOGICAL|Pembrolizumab|Intratumoral microdose injection by the CIVO device.
223881731|NCT06366451|COMBINATION_PRODUCT|AZD9592 + Rilvegostomig|Intratumoral microdose injection by the CIVO device.
223881732|NCT06366451|COMBINATION_PRODUCT|AZD9592 + Volrustomig|Intratumoral microdose injection by the CIVO device.
223881733|NCT06366451|COMBINATION_PRODUCT|AZD9592 + Sabestomig|Intratumoral microdose injection by the CIVO device.
223881734|NCT06366451|COMBINATION_PRODUCT|AZD9592 + Pembrolizumab|Intratumoral microdose injection by the CIVO device.
223881735|NCT04924062|BIOLOGICAL|Pembrolizumab|Pembrolizumab by intravenous (IV) infusion
223881736|NCT04924062|DRUG|Gemcitabine|Gemcitabine by IV infusion
223881737|NCT04924062|DRUG|Cisplatin|Cisplatin by IV infusion
223881738|NCT04924062|DRUG|Placebo|Placebo to pembrolizumab
223881739|NCT06761365|DEVICE|LuSeed Aneurysm Embolization System|a permanent intrasaccular implant used for treatment of unruptured intracranial saccular aneurysms (IA) in adult patients according to international guidelines who are indicated for non-emergent endovascular embolization of saccular IAs at the time of presentation.
223881740|NCT05704296|PROCEDURE|Y-composite grafting|Saphenous vein is used as a Y-composite graft during coronary artery bypass grafting
223881741|NCT05704296|PROCEDURE|Aortocoronary grafting|Saphenous vein is used as an aortocoronary graft during coronary artery bypass grafting
223881742|NCT05549362|OTHER|Dial Health Research Study|To evaluate the feasibility and efficacy of dietary intervention approaches to slow mechanisms of aging.
223881743|NCT06702891|OTHER|Detection of biological samples based on exosome sequencing, proteomics and single-cell RNA sequencing|The researchers combined exosome sequencing, proteomics and single-cell RNA sequencing to explore the heterogeneity of cardia cancer, identify specific biomarkers and potential therapeutic targets for cardia cancer.
223881744|NCT06261593|OTHER|Blood flow restriction|The intervention protocol through blood flow restriction in patients with hemophilic arthropathy will consist of performing two exercises: heel elevation and ankle dorsiflexion in a closed kinetic chain. Both exercises will be performed for 5-10 minutes, performing 4 series (30, 15, 15, 15 repetitions) with 30 seconds of rest between series
223881745|NCT06527521|PROCEDURE|Traumatologic surgery|Patients undergoing trauma surgery
223881746|NCT02428192|BIOLOGICAL|Ipilimumab|Given IV
223881747|NCT02428192|OTHER|Laboratory Biomarker Analysis|Correlative studies
223881748|NCT02428192|BIOLOGICAL|Nivolumab|Given IV
223881749|NCT06783582|OTHER|Motivational interviewing based on Pender's health promotion model|In addition to routine nursing care, patients will be given a motivational interview intervention based on Pender's health promotion model. This intervention will be carried out in a total of 6 sessions, three face-to-face sessions and three online sessions planned individually for each patient. The interviews will last approximately 30-45 minutes. The first motivational interview will be held on the 1st day of the patient's admission to the clinic, the second motivational interview on the 4th day, and the third motivational interview on the 7th day. The face-to-face sessions will be conducted by the researcher in the hospital's education room and contact information will be obtained from the patients. The following three interviews will be held online with the patients once a week via the WhatsApp application. The patient will be contacted at least two days before the interviews, an appointment will be made, and the interview day and time will be determined.
223881750|NCT04562480|RADIATION|Hypofractionated Radiation Therapy|Undergo hypofractionated radiation therapy
223881751|NCT04562480|OTHER|Quality-of-Life Assessment|Ancillary studies
223881752|NCT04562480|OTHER|Questionnaire Administration|Ancillary studies
223881753|NCT04562480|PROCEDURE|Resection|Undergo surgical resection
223881754|NCT05426213|DEVICE|Robot-assisted Bronchoscopy (Monarch Platform)|Robotic assisted bronchoscopy biopsy procedures will be performed using the Monarch platform.
223881755|NCT06788639|BIOLOGICAL|Lisocabtagene maraleucel|According to the United States Prescribing Information
223881756|NCT06784258|PROCEDURE|General Anesthesia (control group)|The patient will undergo conventional general anesthesia with a regimen of intravenous fentanyl 1-2 mcg/kg BW, propofol 2-3 ml/kg BW, and muscle relaxants for intubation, such as atracurium 0.5 mg/kg BW or rocuronium 0.6 mg/kg BB. After that the patient will be intubated
223881757|NCT06784258|PROCEDURE|General Anesthesia combined with epidural anesthesia|The patient will undergo epidural anesthesia first with an epidural catheter inserted through a Tuohy needle and ensuring that the length of the multihole epidural catheter that enters the epidural space is 5-6 cm. After that, the patient underwent conventional general anesthesia with a regimen of intravenous fentanyl 1-2 mcg/kg BW, propofol 2-3 ml/kg BW, and muscle relaxants for intubation, such as atracurium 0.5 mg/kg BW or rocuronium 0.6 mg/ kg BW. After that the patient will be intubated. The patient will be given local anesthesia Bupivacaine 0.25% in increments to the desired volume according to the desired height of the segmental block. Local anesthetic medication will be given intermittently every 2 hours
223881758|NCT06782958|DRUG|50mg FHND1002|Participants will receive a daily oral dose of FHND1002 granules (50 mg) ,administered in the morning after fasting for at least 10 hours. The dose will be taken with 240 mL of water.
223881759|NCT06782958|DRUG|100mg FHND1002|Participants will receive a daily oral dose of FHND1002 granules (100 mg) , administered in the morning after fasting for at least 10 hours. The dose will be taken with 240 mL of water.
223881760|NCT06782958|DRUG|150 mg FHND1002|Participants will receive a daily oral dose of FHND1002 granules (150 mg), administered in the morning after fasting for at least 10 hours. The dose will be taken with 240 mL of water.
223881761|NCT06782958|DRUG|200 mg FHND1002（fasting）|Participants will receive a daily oral dose of FHND1002 granules (200 mg), administered in the morning after fasting for at least 10 hours. The dose will be taken with 240 mL of water.
223881762|NCT06782958|DRUG|250mg FHND1002|Participants will receive a daily oral dose of FHND1002 granules (250 mg), administered in the morning after fasting for at least 10 hours. The dose will be taken with 240 mL of water.
223881763|NCT06782958|DRUG|200mg FHND1002(postprandial)|Participants will receive a one-time dose (200 mg) under postprandial conditions
223881764|NCT06830954|DRUG|Group A|Drug: Fluvastatin sodium extended release tablet, 80 mg Period 1 and 3, the participants randomly received single oral dose of test drug ( Fluvastatin sodium extended release tablet 80 mg). Period 2 and 4, the participants randomly received single oral dose of reference drug ( Fluvastatin sodium extended release tablet 80 mg).
223881765|NCT06830954|DRUG|Reference Group|Drug: Fluvastatin sodium extended release tablet, 80 mg Period 1 and 3, the participants randomly received single oral dose of reference drug ( Fluvastatin sodium extended release tablet 80 mg). Period 2 and 4, the participants randomly received single oral dose of test drug ( Fluvastatin sodium extended release tablet 80 mg).
223881766|NCT05173818|DRUG|Hyperbaric oxygen at 1.5 ATA|Hyperbaric oxygen (HBO2) at 1.5 ATA (active) group (hyperbaric oxygen-chamber compressed to 1.5 atmosphere absolute and breathing \>99.9% oxygen). Each participant should complete 40 sessions, one session per day, five per week over the course of 3 months.
223881767|NCT05173818|DRUG|Sham treatment|"Sham treatment includes pressurizing the chamber to 1.2 ATA with air for 5 minutes with noise of circulating air, return the chamber to 1.0 ATA after 5-7 minutes and maintain it at that pressure for until the end of the treatment, with noise of circulating air. Internal control knobs will be concealed. Participants will be instructed to undergo intermittent ear clearing technique during the initial 5 minutes of descent"
223881768|NCT06780592|DRUG|Vebreltinib + Temozolomide|Vebreltinib is a capsule in the form of 25 mg and 100mg, twice daily. Participants received Vebreltinib (300 mg Bid) in combination with Temozolomide (150 mg/ m2) treatment, every 4 weeks for up to 6 cycles (Induction).
223881769|NCT06780592|DRUG|Temozolomide|Participants received Temozolomide (150 mg/ m2) treatment, every 4 weeks for up to 6 cycles (Induction).
223881770|NCT05938101|BEHAVIORAL|Behavioral therapy|Behavioral therapy and psychotherapy
223881771|NCT04607044|DEVICE|SALVATION™ EXTERNAL FIXATION|Wright Medical's lower extremity devices used to treat neuropathic patients
223881772|NCT05091476|DEVICE|OPTiC System|OPTiC System procedure
223881773|NCT06829173|DRUG|XRD-0394|Administered orally; small molecule dual inhibitor of ataxia telangiectasia mutated kinase (ATM) and DNA-PK.
223881774|NCT06829173|RADIATION|Radiation Therapy|"For Cohort A and Cohort B, the neoadjuvant boost radiation dose is 1400cGy delivered over 7 fractions, and the adjuvant radiation dose is 5000cGy delivered over 25 fractions for a total dose of 6400cGy over 32 fractions, accounting for the treatment break between boost and adjuvant RT.~For Cohort C, the radiation dose is 3500cGy delivered over 10 fractions."
223881775|NCT06829173|PROCEDURE|Surgical Resection|Resection of tumor tissue.
223881776|NCT06622226|DRUG|ONO-7018|ONO-7018 tablet(s) are administered orally.
223881777|NCT06785727|DRUG|Statin (atorvastatin, fluvastatin, pravastatin, rosuvastatin or simvastatin)|"The intervention group receives statin treatment following the current Herseninfarct en Hersenbloeding guideline. The intensity and target value of statin treatment are determined according to this national guideline. Which statin (atorvastatin, fluvastatin, pravastatin, rosuvastatin, simvastatin) will be selected and what dose will be prescribed is left to the discretion of the treating neurologist. The statins are registered in the Netherlands and use will be according to the licenses of the products. They will be collected at the local pharmacy by the patient (following practice as usual)."
223881778|NCT06832657|DRUG|JMKX003948 Ophthalmic Suspension|JMKX003948 Ophthalmic Suspension with formulation 1% (15 mg/1.5 mL), 2% (30 mg/1.5 mL), 3% (45 mg/1.5 mL), 5% (75 mg/1.5 mL)
223881779|NCT06832657|DRUG|Placebo|JMKX003948 Ophthalmic Suspension placebo
223881780|NCT04714840|OTHER|Exercise testing results|Tailored, home-delivered aerobic and strengthening intervention,exercise intolerance,Both groups of participants will be provided with the results of their exercise testing.
223881781|NCT04714840|OTHER|Individually tailored exercise program (INT)|Individuals randomized to receive an individually tailored exercise program will meet with an exercise specialist. Written instructions, videos of each strengthening exercise, a blue tooth enable heart rate monitor, all necessary exercise equipment, and an iPad pre-loaded with heart rate monitor software, exercise videos and ZOOM app (for video conferencing) will be provided. After returning home, the exercise specialist will supervise and provide guidance to the individual via the ZOOM app during the first 2 weeks (3 sessions per week). Supervision will slowly decrease to twice a week in weeks 3-4, once a week in weeks 5-8, every other week in weeks 9-16, and to one time midway between weeks 17-20. The exercise program will be adjusted depending on the individuals progress.
223881782|NCT04714840|OTHER|Generalized exercise recommendations (AC)|Individuals randomized to receive the generalized exercise recommendations will receive a copy of the Physical Activity Guidelines for Americans. At the baseline visit, a study staff will review these guidelines and answer questions about their exercise testing and encourage them to be physically active. The staff will contact them via telephone to complete a short questionnaire weekly during weeks 1-8 and monthly for weeks 9-20.
223881783|NCT03224767|DRUG|Vemurafenib|Given PO
223881784|NCT03224767|DRUG|Cobimetinib|Given PO
223881785|NCT03224767|OTHER|Laboratory Biomarker Analysis|Correlative studies
223881786|NCT03224767|OTHER|Quality-of-Life Assessment|Ancillary studies
223881787|NCT04894110|BIOLOGICAL|EO2002|EO2002 (magnetic human corneal endothelial cells \[HCECs\]) with and without endothelial brushing (EB) or Descemet Stripping (DS)
223881788|NCT04894110|BIOLOGICAL|EO2002 low dose|Low dose of EO2002 (magnetic human corneal endothelial cells)
223881789|NCT04894110|BIOLOGICAL|EO2002 mid dose|Mid dose of EO2002 (magnetic human corneal endothelial cells)
223881790|NCT04894110|BIOLOGICAL|EO2002 high dose|High dose of EO2002 (magnetic human corneal endothelial cells)
223881791|NCT06270758|DIAGNOSTIC_TEST|CT scan at the femur|Additional CT scan which is not part of the standard clinical path
223881792|NCT06835686|BEHAVIORAL|Health Literacy and Culturally Tailored Materials|Participants will receive health literacy-appropriate written information on community resources and weight management
223881793|NCT06835686|BEHAVIORAL|Community-Engaged Health Coaching and Navigation|Participants will receive virtual coaching sessions over a 6-month period from trained Community Health Workers (CHWs). Coaching will include culturally competent information and strategies for weight management, and linking participants to community wellness resources identified in Community Asset Mapping (see below). Coaches will also remotely monitor patients' weight loss and physical activity via online portals to provide patients with tailored support during coaching sessions.
223881794|NCT06835686|BEHAVIORAL|Self-Monitoring and Remote Patient Monitoring of weight and physical activity|Participants will self-monitor weight and physical activity during the 6-month health coaching protocol using a cellular-connected digital weight scale and a Bluetooth-connected wrist-worn fitness tracking device (e.g., Fitbit). Participants will be instructed to weigh themselves and wear a fitness tracker (e.g., Fitbit) daily. Health coaches will remotely monitor weight and physical activity data logged by these devices to incorporate into health coaching sessions.
223881795|NCT06835686|OTHER|Community Asset Mapping (CAM)|The CHW from each intervention community clinic will convene a team of community members, including but not limited to CONNECT participants, that will meet regularly to identify and describe community assets that enable, support, and promote healthy lifestyles related to weight loss and management (e.g., healthy eating and physical activity resources). Community teams will be supported to design and implement Community Action Projects to promote the utilization of community resources identified in the map.
223881796|NCT06835686|OTHER|Primary Care Provider Training|Education sessions will be provided to FQHC providers. The training curriculum is designed to increase healthcare providers' knowledge of evidence-based and guideline-concordant obesity management strategies in primary care settings.
223881797|NCT06835686|OTHER|Obesity Toolkit for Primary Care Providers|We will provide FQHC providers with a toolkit containing additional obesity management resources and information and the community resource guides given to participants to support obesity management.
223881798|NCT06833996|DRUG|Bakuchiol|Apply bakuchiol cream twice daily to a select acne induced and TCA induced PIH spot for a total of 28 days
223881799|NCT06833996|DRUG|Vehicle|Apply vehicle cream twice daily to a select acne induced and TCA induced PIH spot for a total of 28 days
223881800|NCT06832423|DIETARY_SUPPLEMENT|Creatine monohydrate|Powder mixed with flavoured water
223881801|NCT06832423|DIETARY_SUPPLEMENT|Placebo|Powder mixed with flavoured water
223881802|NCT06833918|GENETIC|blood sampling|"The followings markers will be investigated in plasma samples:~1. LIPCAR, STAT3 and DDIT3 using quantitative real-time polymerase chain reaction (qRT-PCR)~2. α-SMA using western blot analysis~3. Troponin T using ELISA expression~4. Serum levels of fasting blood glucose (FBG), total cholesterol (TC), triglycerides (TG), and high-density lipoprotein cholesterol (HDL-C), oxidized low-density lipoprotein (ox-LDL) using chemical methods (spectrophotometry). The Friedewald formula was used to compute low-density lipoprotein cholesterol (LDL-C): LDL-Cholesterol =Total cholesterol- (HDL-Cholesterol +Triglycerides/5)."
223881803|NCT05097950|DRUG|Administration of 1 gr paracetamol I.V|Administration of 1 gr paracetamol I.V
223881804|NCT03651895|DRUG|Metformin|The Drug was administered 500 mg twice daily for one week and increased to 1g twice daily for the reminder of the 3 months.
223881805|NCT03651895|DRUG|Placebo|Placebo
223881806|NCT06791746|DRUG|compound Staphylococcal lysostaphin mouthrinse|Lysostaphin is a proteolytic enzyme produced by a specific species of Staphylococcus, uniquely capable of cleaving the cross-linking pentaglycine bridges within the cell walls of Staphylococcus aureus.
223881807|NCT06791746|DRUG|chlorhexidine mouthrinse|Chlorhexidine mouthrinse offers a cost-effective prophylactic approach to preventing OM.
223881808|NCT06784869|DEVICE|Scaling and root surface debritment|Patients with 4-6 mm pocket depth were participated in this study; clinical periodontal parameters (BOP, PLI, PPD, CAL) were recorded at the baseline visit. To ensure sampling accuracy, From the site two papers with GCF were sampled. Following sample collecting for GCF, Every patient received comprehensive mouth supragingival scaling with an ultrasonic scaler (WoodpEEKer® UDS-K) along with dental hygiene recommendations. One week later, the sites were irrigated with normal saline after being scaled and root planed (ScRp) with Gracey curette. Following completion of subgingival instrumentation, each patient returned to the clinic following 1 and 3 months for periodontal parameter recording and GCF collection. Throughout these sessions, every patient received reinstruction to engage in self-oral hygiene practices.
223881809|NCT03127722|PROCEDURE|Blood draw|Decision for either treatment will be based upon clinical practice and physician/patient counseling. In addition of routine care practice, blood draws will be performed at baseline, 12 months and 60 months on subjects undergoing either an ESSURE procedure or a laparoscopic tubal sterilization.
223881810|NCT03127722|DEVICE|ESSURE (BAY1454032)|Decision for either treatment will be based upon clinical practice and physician/patient counseling, and will not be specified in the study protocol.
223881811|NCT03127722|PROCEDURE|Laparoscopic tubal sterilization|Decision for either treatment will be based upon clinical practice and physician/patient counseling, and will not be specified in the study protocol.
223881812|NCT04309461|BEHAVIORAL|Stress Management Control|The Stress Management Program will utilize a smart phone app, accelerometers, telephone coaching, and behavioral incentives to target stress, relaxation, and sleep. Participants will wear accelerometers, log hours slept, enter real-time information about their relaxation exercises and stress, and monitor 3 goal thermometers (sleep, relaxation, stress) to meet behavioral targets. The Stress Management Program, including the use of the app and assessments, is identical to the Adapted MBC2 program, with the exception of the content.
223881813|NCT04309461|BEHAVIORAL|Adapted MBC2 Program|The Adapted MBC2 Program will utilize a smart phone app, accelerometers, telephone coaching, and behavioral incentives to target fruit and vegetable intake, dietary fat intake, physical activity, and high sedentary leisure screen time. Participants will wear accelerometers, log hours slept, enter real-time information about their relaxation exercises and stress, and monitor goal thermometers to meet targets.
223881814|NCT02525692|DRUG|Dordaviprone (ONC201)|Dordaviprone (ONC201) is a brain-penetrant, small-molecule imipridone that acts as a mitochondrial caseinolytic protease P (ClpP) agonist and a dopamine receptor D2 (DRD2) antagonist.
223881815|NCT00833872|DRUG|LEO 22811|First-in-man
223881816|NCT00833872|DRUG|placebo solution|
223881817|NCT02396199|DEVICE|Zenith® p-Branch® in combination with the Atrium iCAST™ covered stents|Instead of making a large incision in the abdomen, the physician makes a small incision near each hip to insert, and guides the study device(s) into place in the aorta.
223881818|NCT06434714|DEVICE|Auricular percutaneous nerve field stimulator|Percutaneous nerve field stimulator device placed on the ear for 5 days
223881819|NCT06434714|DEVICE|Sham auricular percutaneous nerve field stimulator|Non-functioning percutaneous nerve field stimulator device placed on the ear for 5 days
223881820|NCT04898023|DRUG|zinc-green tea extract-ascorbic acid|Compounded capsules containing each zinc citrate, green tea extract, and ascorbic acid.
223881821|NCT04898023|DRUG|Placebo|Compounded capsules containing microcrystalline cellulose.
223881822|NCT02721381|BEHAVIORAL|ImPACT Online|ImPACT Online is an interactive, web-based telehealth intervention that teaches parents to promote their child's social-communication skills during play and daily routines. The intervention content was adapted from Project ImPACT, a manualized parent training curriculum that uses a blend of developmental and naturalistic behavioral intervention techniques, including following the child's lead, imitating the child, using heightened animation, using simplified language around the child's focus of attention, environmental arrangement strategies, prompting, and natural reinforcement during child-directed activities. There is strong empirical support for the intervention techniques for increasing social communication in children, increasing parent fidelity, and child language skills.
223881823|NCT05716165|DEVICE|proprioceptive knee braces|The patient will perform the tests with the knee braces.
223881824|NCT05716165|DEVICE|No knee brace|The patient will perform the tests without the knee brace.
223881825|NCT01395732|DRUG|Bosentan|2 tablets of 62.5 mg a day from baseline to week 4, then 2 tablets of 125 mg per day to week 12.
223881826|NCT06212505|OTHER|blood test|blood test at the inclusion 10 tubes of 2.7mL blood
223881827|NCT05323175|DRUG|Ropivacaine injection|Local anesthesia injected under ultrasound guidance
223881828|NCT05323175|OTHER|Standard of care medications|Whatever the ED clinicians normally give for renal colic pain
223881829|NCT06055387|BEHAVIORAL|Frailty intervention measures|"Providing specialized guidance:~* Physical Function and Fall History:~  * Prioritizing home safety for those with physical impairments.~ * Arranging rehab consultations when necessary.~* Nutrition:~  * Assessing diets and offering education.~ * Pre-treatment nutritionist assessments.~ * Monitoring weight, intervening if \>5-10% loss, or \>10% loss.~* Social Support:~  * Evaluating the needs of those without family support.~ * Referring to social services and introducing care resources.~* Cognition:~  * Detecting cognitive issues, addressing reversible causes.~ * Assessing decision-making and medication self-administration.~ * Refer to specialists when needed.~* Polypharmacy and Comorbidity:~  * Collecting medication data, ensuring adherence.~ * Noting chronic illnesses.~ * Collaborating with specialists or pharmacists for complex cases.~* Psychological:~  * Providing weekly support for psychological concerns.~ * Refer to specialists for assessments and treatment options."
223881830|NCT01563341|DEVICE|Deep brain stimulation|Study will be utilizing multiple brain electrodes simultaneously. The study will require at least two electrodes to be placed in one cerebral hemisphere (one for motor improvement and one for potential cognitive implications).
223881831|NCT03854903|DRUG|Palbociclib|Palbociclib is taken orally.
223881832|NCT03854903|DRUG|Bosutinib|Bosutinib is taken orally.
223881833|NCT03854903|DRUG|Fulvestrant|Fulvestrant is given as an intramuscular injection.
223881834|NCT05149534|BEHAVIORAL|Written Exposure Therapy|Narrative written disclosure of trauma administered in an evidence-based protocol.
223881835|NCT05149534|DEVICE|repetitive transcranial magnetic stimulation|Noninvasive magnetic neuromodulation device
223881836|NCT03938532|DEVICE|Volume Targeted Ventilation (VTV) using the Philips Respironics NM3 monitor|Infants in the intervention arm will receive VTV following intubation. Peak inspiratory pressure (PiP) provided via T-piece resuscitator will be visible to the providers, and the provider can regulate the PiP to achieve the desired TV goal (4-6 ml/kg), at a rate of 40-60 breaths/min
223881837|NCT03938532|DEVICE|Tidal Volume Measurement using the Philips Respironics NM3 monitor|Tidal Volume Measurement using the Philips Respironics NM3 monitor
223881838|NCT05243836|DEVICE|S.T.O.P® F2|Ocufilcon D, 55% water
223881839|NCT05243836|DEVICE|S.T.O.P® DT|Ocufilcon D, 55% water
223881840|NCT05243836|DEVICE|MiSight®|Omafilcon A (60% water)
223881841|NCT05432765|OTHER|Phenotypic Personalized Medicine Dosing|Phenotypic Personalized Medicine (PPM) will mediate mechanism-independent and patient specific optimization of immunosuppression. We have developed a powerful platform that allows the provider to use clinical data to construct a Parabolic Response Surface (PRS). Using this visualization of the data, the provider can them make a decision on the optimal combination of drug doses needed to achieve the desired outcome.
223881842|NCT05432765|OTHER|Standard of Care Dosing|Providers will decide on the combination of drug doses needed based on their overall assessment per standard of care.
223881843|NCT04231708|DRUG|Yohimbine + Hydrocortisone|Yohimbine (54mg bulk powder inside capsule) administered in combination with Hydrocortisone (20mg tablet inside capsule)
223881844|NCT04231708|DEVICE|Active rTMS|10Hz rTMS over the left dlPFC
223881845|NCT04231708|DRUG|Placebo|lactose (inside capsule)
223881846|NCT04231708|DEVICE|Sham rTMS|inactive stimulation over the left dlPFC
223881847|NCT05871177|DEVICE|Pre-filled syringe of HiLow Hyaluronic Acid Sodium Salt|The medical device consists of a pre-filled syringe containing 3.2% Hyaluronic Acid Sodium Salt with high and low molecular weight \[32 mg (HHA) + 32 mg (LHA) / 2 ml\]
223881848|NCT02349412|OTHER|Early palliative care|
223881849|NCT03600155|BIOLOGICAL|Ipilimumab|Given IV
223881850|NCT03600155|BIOLOGICAL|Nivolumab|Given IV
223881851|NCT06594419|BEHAVIORAL|Healthy Mother Healthy Baby Toolkit|Customized bowl with markings to indicate the recommended amount of food that participants should consume in pregnancy and while exclusively breastfeeding in the first 6 months, as well as how much they should feed their babies at 6-8 months, 9-12 months, and 1-2 years respectively. The toolkit also includes a spoon used to test and ensure adequate thickness of the meals fed to infants \>6mos and a counseling card that indicates the frequency of meals, recommended food groups for meeting daily nutrient needs, and hand hygiene and hygienic food preparation
223881852|NCT06594419|OTHER|Standard of care|The Ethiopian government and Saving Little Lives Initiative (SLL) standard of care includes maternal and infant nutrition education and counseling, iron and folic acid supplementation, as well as training on effective Kangaroo Mother Care (KMC), primarily defined as exclusive breastfeeding and skin-to-skin contact ≥ 8 hours per day-in the event of Low birth weight (LBW) or preterm delivery.
223881853|NCT06545123|BEHAVIORAL|Concurrent exercise training|The experimental groups (AER, RES and AER+RES) will be enrolled in a supervised center-based exercise program for 12 weeks (3 days/week; 60 min/d). Sessions will occur in the morning, on alternating days of the week, and will be supervised by experienced exercise physiologists
223881854|NCT03918720|BEHAVIORAL|Trekkers Family Health Empowerment Programme|Health Assessment, Health Enablement and Health Literacy provided to empower participants awareness towards a healthier life style
223881855|NCT04337372|BEHAVIORAL|Effects of shared book reading: Labels|Book reading included objects labeled with 1) Individual labels, 2) Category labels, and 3) No Labels. Condition and infant age differences were examined.
223881856|NCT05394662|DEVICE|Juveena Hydrogel System|Application of a novel hydrogel immediately following the transcervical procedure
223881857|NCT06039267|OTHER|Gut Microbiome Testing|Stool microbiome testing using shotgun metagenomic sequencing
223881858|NCT04240756|BEHAVIORAL|Behavioral Parent Training|Parents will receive 10 sessions of behavioral parent training with components specifically targeted toward parents with ADHD. Treatment will be delivered via telehealth.
223881859|NCT04240756|DRUG|Extended release mixed amphetamine salts (MAS)|The MAS protocol will include a 2-4 -week open-label titration beginning at 20 mg and dose level will be increased weekly at telehealth visits with the psychopharmacologist until an optimal response or maximum dose of 60 mg.
223881860|NCT05307783|DEVICE|EmboCube Embolization Gelatin|EmboCube is a uniformly cut gelatin foam pre-loaded into a syringe, indicated for use in embolization of blood vessels to occlude blood flow to control bleeding/hemorrhaging in the peripheral vasculature
223881861|NCT04883645|DRUG|Imiquimod 5% Cream|Imiquimod as a 5% cream is being used to treat several skin cancers, including malignant melanoma, basal cell carcinoma (BCC) and SCC. With respect to SCC treatment, it has been demonstrated that imiquimod stimulates tumor destruction by recruiting T cells (cells in the immune system) from blood and by inhibiting tonic anti-inflammatory signals within the tumor. The patient will be instructed to apply imiquimod cream, 7 nights a week for 4 weeks to the oral tumor at bedtime.
223881862|NCT05179200|PROCEDURE|Plasmapheresis|Plasma donation
223881863|NCT05179200|PROCEDURE|Whole blood donation|Blood donation
223881864|NCT03611153|DRUG|AZD4831 Oral Myeloperoxidase Inhibitor|A single administration dose of 30 mg oral MPO inhibitor given orally following baseline, resting and exercise testing in patients during right heart catheterization.
223881865|NCT03611153|DRUG|Placebo oral capsule|A single administration dose of 30 mg placebo given orally following baseline, resting and exercise testing in patients during right heart catheterization.
223881866|NCT04536116|DEVICE|Virtual Reality headset|MRI simulation with a Virtual Reality headset
223881867|NCT03695315|DEVICE|Continuous Positive Airway Pressure|CPAP is a noninvasive treatment for sleep apnea
223881868|NCT06157099|DRUG|Atorvastatin|Given PO
223881869|NCT06157099|DRUG|Placebo Administration|Given orally (PO)
223881870|NCT06157099|PROCEDURE|Computed Tomography|Undergo CT
223881871|NCT06157099|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223881872|NCT06157099|OTHER|Electronic Health Record Review|Ancillary studies
223881873|NCT00979576|DRUG|BIBF 1120 M + Pemetrexed|BIBF 1120 medium dose bid+ Pemetrexed 500 mg/m\^2
223881874|NCT00979576|DRUG|BIBF 1120 H + Pemetrexed|BIBF 1120 high dose bid+ Pemetrexed 500 mg/m\^2
223881875|NCT00979576|DRUG|BIBF 1120 RD + Pemetrexed|confirmed dose of BIBF 1120 bid + Pemetrexed 500 mg/m\^2
223881876|NCT00979576|DRUG|BIBF 1120 L + Pemetrexed|BIBF 1120 low dose bid+ Pemetrexed 500 mg/m\^2
223881877|NCT00979576|DRUG|BIBF 1120 Placebo + Pemetrexed|placebo BIBF 1120 bid + Pemetrexed 500 mg/m\^2
223881878|NCT05027763|BEHAVIORAL|high-fiber/low fat|high fiber/low fat preoperative diet
223881879|NCT05027763|BEHAVIORAL|fermented|fermented preoperative diet
223881880|NCT04048850|DRUG|Elbasvir/Grazoprevir 50 MG-100 MG Oral Tablet [ZEPATIER]|Daily medication
223881881|NCT03377543|DRUG|Aspirin|81mg aspirin pill daily at bedtime over a 25 day period
223881882|NCT03377543|DRUG|Placebo|81mg non-active pill that looks like aspirin
223881883|NCT04830592|BIOLOGICAL|NG-641|Patients receive three doses of NG-641 by intravenous infusion. NG-641 is a replication competent adenoviral vector producing a bispecific T cell activator (TAc) targeting fibroblast activation protein (FAP) plus immune enhancer genes CXCL9/CXCL10/IFNa2. This can lead to killing of tumor cells and stimulation of immunity against the tumor cells.
223881884|NCT04830592|BIOLOGICAL|Pembrolizumab|Patients receive three doses of NG-641 by intravenous infusion and a single dose of Pembrolizumab by intravenous infusion.
223881885|NCT05817344|BEHAVIORAL|Written Exposure Therapy - Integrated|A brief exposure-based psychotherapy for posttraumatic stress disorder integrated with harm reduction strategies for opioid use disorder
223881886|NCT04188665|DRUG|MASL|Patients treated with MASL lozenge
223881887|NCT04188665|OTHER|Placebo|Patients treated with placebo lozenge
223881888|NCT04840199|DRUG|Letermovir Oral Tablet|480 mg administered orally once daily with or without food
223881889|NCT06174285|OTHER|Therapeutic Intervention with Psychedelic Virtual Reality|A 55-minute immersive psychedelic virtual reality experience is incorporated into a therapeutic intervention, comprising a preparatory phase and a subsequent integration session based on the individual's experience.
223881890|NCT06174285|OTHER|Therapeutic Intervention with Non-Psychedelic Virtual Reality|A 55-minute immersive virtual reality experience is incorporated into a therapeutic intervention, comprising a preparatory phase and a subsequent integration session based on the individual's experience.
223881891|NCT05107310|PROCEDURE|Pedicle screws insertion by free hand technique|Spinal deformity correction. Pedicle screws are inserted using free hand technique with the help of intraoperative fluoroscopy if needed.
223881892|NCT05107310|PROCEDURE|Pedicle screws insertion using ARSN|Spinal deformity correction. Pedicle screws are inserted using augmented reality surgical navigation (ARSN) with the ClarifEye navigation system and the Philips Allura 2D/3D imaging system.
223881893|NCT05107310|PROCEDURE|Pedicle screws insertion using IRSN|Spinal deformity correction. Pedicle screws are inserted using infra-red surgical navigation (IRSN) with the Brainlab Curve 1.2 navigation system combined with the Medtronic O-arm 2D/3D imaging system.
223881894|NCT04309565|BEHAVIORAL|Transitions Clinic Network Primary Care|Transitions Clinic Network (TCN)- participants in this arm will be referred to a TCN program for primary care and community Opioid Treatment Program (OTP). All TCN programs have the ability to prescribe buprenorphine and Extended-release naltrexone (XR-NTX) and assist with referrals to methadone. The primary features of the TCN include (1) primary care and onsite MOUD or referral to community treatment when indicated, (2) addressing social determinants of OUD and care coordination through a Community Health Worker (CHW), and (3) addressing the discrimination and stigma that exist based on incarceration.
223881895|NCT04309565|BEHAVIORAL|Standard Primary Care|Those randomized to the standard primary care arm will be referred to primary care and community Opioid Treatment Program (OTP). Participants may receive buprenorphine or Extended-release naltrexone (XR-NTX) through primary care or with a community addiction treatment provider.
223881896|NCT06426706|PROCEDURE|Serratus Posterior Superior Intercostal Plane Block|Before the induction of general anesthesia, under aseptic conditions, serratus posterior superior intercostal plane block will be performed with a single dose of 30 ml of %0,25 bupivacaine with ultrasound guidance, by the senior anaesthesiologist.
223881897|NCT06426706|PROCEDURE|Paravertebral Block|Before the induction of general anesthesia, under aseptic conditions, paravertebral block will be performed with a single dose of 30 ml of %0,25 bupivacaine with ultrasound guidance, by the senior anaesthesiologist.
223881898|NCT05000073|OTHER|dialysis and socio-aesthetic care|dialysis and socio-aesthetic care
223881899|NCT05000073|OTHER|dialysis|dialysis
223881900|NCT05945797|DRUG|Dexamethasone 4mg|An injection of 4mg of dexamethasone will be given to patients approximately 2 to 4 hours prior to the procedure of ERCP.
223881901|NCT04143061|BIOLOGICAL|Meningococcal polysaccharide (serogroups A,C,Y and W) tetanus toxoid conjugate vaccine|Pharmaceutical form: solution for injection; Route of administration: intramuscular, 0.5 mL
223881902|NCT04143061|BIOLOGICAL|Meningococcal polysaccharide (serogroups A,C,Y and W-135) diphtheria toxoid conjugate vaccine|Pharmaceutical form: sterile aqueous solution; Route of administration: intramuscular, 0.5 mL
223881903|NCT04143061|BIOLOGICAL|Meningococcal polysaccharide (serogroups A, C, Y and W-135) vaccine|Pharmaceutical form: reconstituted solution for injection; Route of administration: intramuscular, 0.5 mL
223881904|NCT06738433|DIETARY_SUPPLEMENT|ABB i5|Prebiotic ABB i5 (NextDext®, 5g)
223881905|NCT06738433|DIETARY_SUPPLEMENT|ABB C24|ABB C24: Prebiotic ABB i5 (NextDext®, 5g) + yeast postbiotic ABB C22 (200 mg) in sachets containing 5,2 g
223881906|NCT03087032|DRUG|Liraglutide|Patients will receive adding Liraglutide to prandial insulin Lispro. The starting liraglutide dose was 0.6mg/day, then 1.2mg/day after 1 week and 1.8mg/day after a further week. The dose was maintained until study completion. Dose of insulin Lispro will be instructed on a titration schedule, adjusted every 3 days.
223881907|NCT03087032|DRUG|insulin glargine|Individuals randomized to adding insulin Glargine to prandial insulin Lispro will be instructed on a titration schedule, adjusted every 3 days. Patients subcutaneously self-injected once-daily at approximately the same time each day.
223881908|NCT03602014|DRUG|Northera|Study 1 is a dose optimization, open-label trial of Northera from a dose range of 200mg up to 800mg.
223881909|NCT03602014|OTHER|Placebo|Study 2 is blinded placebo controlled trial using the individualized optimal dose of droxidopa determined by study 1.
223881910|NCT04544969|DRUG|cisplatin-based chemotherapy|"GP: cisplatin 80 mg/m2 intravenous infusion on day1, gemcitabine 1000 mg/m2 intravenous infusion on day 1 and 8, both drugs are given every 3 weeks, recommended 6 cycles.~TP: cisplatin 75 mg/m2 intravenous infusion in day1, docetaxel 75 mg/m2 intravenous infusion in day 1, both drugs are given every 3 weeks, recommended 6 cycles.~PF: cisplatin 100 mg/m2 intravenous infusion in day1, fluorouracil 4000 mg/m2 intravenous infusion in day 1 to 5, both drugs are given every 3 weeks, recommended 6 cycles.~TPF: cisplatin 60 mg/m2 intravenous infusion in day1, docetaxel 60 mg/m2 intravenous infusion in day 1, fluorouracil 3000 mg/m2 intravenous infusion in day 1 to 5, both drugs are given every 3 weeks, recommended 6 cycles.~Choice of chemotherapy regimen is decided by patient's doctor in charge."
223881911|NCT05653258|OTHER|Lifestyle Intervention|"1. Exercise: Subjects will undergo a combined aerobic and resistance exercise intervention. The investigators propose a multi-modal training program because they improve metabolic outcomes and adding resistance training reduces the risk of muscle loss during weight loss. Subjects will exercise in the gym for three sessions per week for 10 weeks under supervision of an exercise physiologist. On each session, aerobic exercise will be followed by resistance exercise.~2. Diet: The aim of the dietary intervention is to reduce caloric intake sufficient to result in 8-10% weight loss, while incorporating behavioral and dietary strategies to maximize adherence and to minimize risk of muscle and bone loss. Subjects will attend small-group sessions led by a dietitian for changing their dietary composition to follow American Heart Association (AHA)/American College of Cardiology (ACC) guidelines."
223881912|NCT05653258|DRUG|Dasatinib 100 MG|100 mg of dasatinib (D) daily for 3 consecutive days plus quercetin (Q) for the same 3 consecutive days, followed by a 25-day (+/- 2 day) no-drug period to complete a single round. This will be repeated twice more until completing 3 rounds total in approximately 10 consecutive weeks.
223881913|NCT05653258|DRUG|Quercetin 1000mg|Quercetin (Q) (4) 250 mg capsules daily (total 1000 mg daily) plus dasatinib (D) same 3 consecutive days, followed by a 25-day (+/- 2 day) no-drug period to complete a single round. This will be repeated twice more until completing 3 rounds total in approximately 10 consecutive weeks.
223881914|NCT05653258|DRUG|Placebo|Subjects will receive a placebo (methylcellulose) to provide a similar mass, number of tablets/ capsules, and frequency as the senolytic arm.
223881915|NCT05653258|PROCEDURE|Abdominal adipose tissue biopsy|All participants will undergo baseline biopsies of subcutaneous abdominal adipose tissue for cellular/molecular profiling via snRNA-seq
223881916|NCT06083233|DIAGNOSTIC_TEST|Lumbar puncture|Standardized lumbar puncture in L3/4 or L4/5 in diagnosis of hydrocephalus and cerebrospinal fluid sampling (sample 1 in measurement)
223881917|NCT06083233|DIAGNOSTIC_TEST|External lumbar drainage|External lumbar drainage placement for assessing responsivity of external derivation of cerebrospinal fluid. It is test of responsivity to ventriculo-peritoneal shunt placement
223881918|NCT06083233|PROCEDURE|Ventriculo-peritoneal shunt placement|Surgical procedure based on implantation a thin catheter into brain lateral ventricle (placed through a burrhole from Kocher point) and connection to prechamber and valve (placed behind the ear under skin) and similar thin catheter pushed under skin of neck, chest and abdomen (where put intraperitoneally).
223881919|NCT06083233|PROCEDURE|Prechamber puncture|Puncture of prechamber (place behind the ear under the skin) by thin needle and aspiration of 5 mL of cerebrospinal fluid (5 days, 1 month a 2 months after surgery)
223881920|NCT06083233|PROCEDURE|Blood sampling #1|Blood sampling to get level of biomarkers (NfL, NfH, NSE, S100, Tau, beta-amyloid) from standardized percutaneous vein puncture by thin needle 24 hours prior surgery
223881921|NCT06083233|PROCEDURE|Blood sampling #2|Blood sampling to get level of biomarkers (NfL, NfH, NSE, S100, Tau, beta-amyloid) from standardized percutaneous vein puncture by thin needle 24 hours after surgery
223881922|NCT06083233|PROCEDURE|Blood sampling #3|Blood sampling to get level of biomarkers (NfL, NfH, NSE, S100, Tau, beta-amyloid) from standardized percutaneous vein puncture by thin needle 5 days after surgery
223881923|NCT06083233|PROCEDURE|Blood sampling #4 and #5|Blood sampling to get level of biomarkers (NfL, NfH, NSE, S100, Tau, beta-amyloid) from standardized percutaneous vein puncture by thin needle 1 and 2 months after surgery (only in interventional group)
223881924|NCT06307873|DIAGNOSTIC_TEST|pre and post operative POP-Q results|Comparison of pre and postoperative POP-Q values of the patients undergone Sacrospinous Fixation operation and V-notes Lateral Suspension Operation
223881925|NCT06307873|BEHAVIORAL|pre and post operative PİSQ-12 results|Comparison of pre and postoperative PİSQ-12 values of the patients undergone Sacrospinous Fixation operation and V-notes Lateral Suspension Operation
223881926|NCT06788054|OTHER|intradialysis exercise|moderate intensity aerobic and muscular resistance exercise protocol lasting 12 weeks
223881927|NCT00588185|DRUG|[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone|Registered patients will undergo PET scanning using either FDHT alone or FDG and FDHT depending on the clinical question being asked. Scans will be performed serially at baseline, week 4, week 12, and every 12 weeks of treatment up to a maximum of 8 FDHT/FDG scan set in a 12 month period (maximum 40 scan sets per lifetime) unless the therapeutic protocol or scientific rationale of the therapeutic drug being applied specifically dictates an alternative schedule. Patients may have blood drawn for the purposes of establishing the pharmacokinetics of FDHT and may also undergo an initial dynamic scan if further pharmacokinetic information is warranted, followed by a standard whole body image. If no further pharmacokinetic information is warranted, then patients will only undergo a standard whole body image.
223881928|NCT06787092|PROCEDURE|bladder cycling|started by the instillation of the sterile water in the bladder in amount equal to the estimated bladder capacity. Then the amount will be gradually increased till the patient can withstand filling the bladder with 250 cc of sterile saline for 2 hours.
223881929|NCT02488863|OTHER|MRI Neuroimaging|MRI scans utilized to measure the structural and functional integrity of the brain.
223881930|NCT02488863|OTHER|Quantitative Sensory Testing|Vibratory Detection Thresholds; Tactile Detection Thresholds; Thermal Detection Thresholds, Pain Thresholds, and Temporal Summation; Allodynia and Temporal Summation; Punctate Pain Testing and Temporal Summation; and Pressure Pain Thresholds.
223881931|NCT02488863|OTHER|Questionnaires|The Modified Mini-Mental State Examination (3MS), the Montreal Cognitive Assessment (MoCA), the Center for Epidemiologic Studies Depression Scale (CES-D), the Geriatric Depression Scale (GDS), the Edinburg Handedness Inventory, the Ten-Item Personality Inventory (TIPI), the Pittsburgh Sleep Quality Index (PSQI), the state and trait versions of the State-Trait Anxiety Inventory (STAI), the state and trait versions of the Positive and Negative Affect Schedule (PANAS), pain questionnaires (the Graded Chronic Pain Scale (GCPS), the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), Pain-Detect, the short-form McGill Pain Questionnaire (SF-MPQ-2), and the Coping Strategies Questionnaire-Revised (CSQ-R)), a standardized paper and pencil cognitive battery (Hopkins Verbal Learning Test (HVLT), Trail Making A\&B, Boston Naming Test, Controlled Oral Word Association Test (COWAT), Stroop Interference Test, Ruff Figural Fluency Test, and Raven's Progressive Matrices Test).
223881932|NCT02488863|OTHER|Physical and Cognitive Function Testing|Upper Limb Isometric Strength, Short Physical Performance Battery (SPPB), GAITRite Instrumented Walking, Galvanic Skin Response, Knee Extension Isokinetic Strength, the Pepper Assessment Tool for Disability (PAT-D), and an electronic NIH Toolbox Cognitive Battery.
223881933|NCT06786468|OTHER|Early palliative care integration|The patients will attend palliative care clinic once a month during the first three months together with routine oncology clinic visits
223881934|NCT06786468|DRUG|Standard systemic treatment for advanced lung cancer|Standard systemic treatment for advanced lung cancer
223881935|NCT06789029|DRUG|perineural Dexamethasone|Erector Spinae Plane Block with 0.2% Ropivacaine + 0.1mg/kg perineural Dexamethasone
223881936|NCT06789029|DRUG|intravenous Dexamethasone|Erector Spinae Plane Block with 0.2% Ropivacaine + 0.1mg/kg intravenous Dexamethasone
223881937|NCT06790862|DRUG|SHR0302Base gel|SHR0302Base gel.
223881938|NCT06790862|DRUG|SHR0302Base gel placebo|SHR0302Base gel placebo.
223881939|NCT05616273|OTHER|Mixed Meal Tolerance Test (MMTT)|At either Visit 1 or Visit 2, participants will be given Ensure HP or Fortisip (a drink containing the same amounts of carbohydrates, protein and fats as there would be in a meal; 6ml/kg to a max of 360mls), and have blood samples collected, to measure insulin (C-peptide), glucose, and glucagon, at specific intervals: -10, 0, 30, 60, 90, 120 minutes post meal. This test is used to measure how a participant's beta cells are working to produce insulin after a meal and to check for reactive hypoglycaemia.
223881940|NCT05616273|OTHER|Arginine Stimulation Test (AST)|At either Visit 1 or Visit 2, and Visit 3, participants will be given a dose of Arginine Hydrochloride (5 g Arginine during 1 min) by intravenous injection, and have blood samples collected to measure insulin (C-peptide), glucose, and glucagon, at specific intervals: -10, 0, 2, 5, 10, 15 and 30 minutes following the Arginine bolus injection. This test is designed primarily to test the maximum insulin secretion capacity of a participant's beta cells.
223881941|NCT05616273|OTHER|Home Finger Prick Sample|Participants will be provided with a kit to collect an optional home finger prick sample the day after each visit, and return the sample using the prepaid addressed padded envelope provided.
223881942|NCT06789380|BEHAVIORAL|Schema therapy|Schema therapy (ST) is an evidence-based, fully manualized, specialist form of psychotherapy for personality disorders (Bamelis et al., 2014; Sempértegui et al., 2013; Arntz et al., 2022). Eligible programs must adhere to the minimum standards described in the evidence-based literature. ST is an integrative treatment method, originally rooted in cognitive theory, but with additional influences from Gestalt, psychodynamic, and experiential methods. Schema therapy programs may differ in intensity and duration, even at the same site, but must include a minimum of either 40 sessions and/or a duration of 12 to 24 months. In addition, in order to be eligible, a schema therapy program must be of higher intensity or longer duration than the generalist treatment (GIT-PD) offered at the same site.
223881943|NCT06789380|BEHAVIORAL|Mentalization-based treatment|Mentalization-based treatment (MBT) is an evidence-based, fully manualized, specialist form of psychotherapy for personality disorders (Bateman \& Fonagy, 2008; Bateman \& Fonagy, 2009; Laurenssen et al., 2018; Juul et al., 2023). MBT is rooted in psychodynamic and attachment theory and aims to alter personality pathology by improving mentalizing and enhancing epistemic trust. Eligible programs must adhere to the minimum standards described in the evidence-based literature. MBT programs may differ in intensity and duration, even at the same site, but must include a minimum of either 40 sessions or a duration of 12 to 24 months. In additon, in order to be eligible, an MBT program must be of higher intensity or longer duration than the generalist treatment (GIT-PD) offered at the same site.
223881944|NCT06789380|BEHAVIORAL|Guideline-informed treatment for personality disorders|GIT-PD is a non-theoretical and non-methodological approach, based upon principles derived from common factors across evidence-based treatments for PD. GIT-PD has a flexible approach, enabling tailoring treatment to clinical needs of different types of patients. The treatment duration (start-end) is 12- 18 months. The treatment consists of three distinct phases. First, an assessment phase. Second, a modular treatment phase that offers either group or individual interventions. Third, a follow-up phase with limited treatment and focus on relapse prevention. In order to be eligible, GIT-PD should be less intensive than specialist psychotherapies offered in the control arm at the same location (i.e. MBT or ST). GIT-PD will not include evidence-based psychotherapy for personality disorders as described in previous RCTs.
223881945|NCT06313827|BEHAVIORAL|Exercise plus Monitoring Group (TG-2)|Participants will receive their usual physiotherapy treatment and user education on bronchial care and hygiene, plus a dossier on the use of monitoring equipment such as: pulse oximeter, thermometer, digital spirometer, Medical Research Council dyspnoea scale. If the patient detects an exacerbation (due to symptoms or monitoring of the equipment), they can contact a physiotherapist who can adjust the treatment.
223881946|NCT06313827|BEHAVIORAL|Exercise plus monitoring and follow-up group (TGF-3)|"Participants who will receive their usual physiotherapy treatment and user education on bronchial care and hygiene, plus dossiers on the use of monitoring equipment ; plus telematic control of exacerbations (questionnaires and monitoring of the parameters of the aforementioned equipment). Depending on the follow-up, physiotherapy treatment will be adjusted.~The questionnaire includes tracking of the following parameters: cough, secretions (quantity, colour, viscosity), chest tightness, dyspnoea, exercise tolerance, tiredness and appetite).~The follow-up will consist of weekly filling the spreadsheet to which the physiotherapist will have access and who, by reviewing the parameters, will be able to adjust the treatment. The physiotherapist will systematically make videocalls to the participants and if the follow-up values require it, he/she will call every week."
223881947|NCT06313827|BEHAVIORAL|Exercise Group (CG-1)|Participants who will receive their usual physiotherapy treatment and user education on bronchial care and hygiene
223881948|NCT06045234|OTHER|Urine sampling|"Among the 300 people recruited:~* 300 will each provide 3 urine samples collected on 3 different days during a week (e.g. Monday, Wednesday and Friday)~* 50 will each provide 3 urine samples collected at sunrise, in the middle and then at the end of the day over a period of 24 hours, on 3 different days during a week (e.g. Monday, Wednesday and Friday)."
223881949|NCT06221150|DRUG|Bilateral two level serratus anterior block|A bilateral two-level SAPB will be performed with the guidance of ultrasound. While the patient is in the supine position with their arms abducted, the ribs will be counted down from the second rib at the level of manubriosternal joint, the mid- axillary line will be demarcated where the probe will be placed in the longitudinal plane to visualize the ribs and the overlying muscles. Using in- plane approach, a 22-gauge short bevel needle will be inserted and advanced to the plane between the latissimus dorsi muscle and the serratus muscle under sono-visualization at the level of 3rd and 6th ribs bilaterally in succession over which a total volume of 1ml/kg bupivacaine 0.25% will be divided and injected (0.5ml/kg on each side); with total dose not exceeding 2.5 mg/kg
223881950|NCT06221150|OTHER|Control group|Intraoperative opioids without regional block
223881951|NCT01276600|DRUG|Emtricitabine/tenofovir|200mg of emtricitabine 300mg of tenofovir
223881952|NCT04905407|DRUG|Tamibarotene|Tamibarotene tablets will be administered per dose and schedule specified in the arm.
223881953|NCT04905407|DRUG|Venetoclax|Venetoclax tablets will be administered per dose and schedule specified in the arm.
223881954|NCT04905407|DRUG|Azacitidine|Azacitidine injection will be administered per dose and schedule specified in the arm.
223881955|NCT03434509|OTHER|Continuous Tai Chi and Mindful Movement classes|"Participants will be enrolled in ongoing Tai Chi and mindful movement classes throughout the year, for 1 hour twice a week.~Class sessions will consist of warm up (yoga- and mindfulness-based practices), postural and breathing exercises, Tai Chi form practice, and Tai Chi games (including push hands).~Children on stimulant medications will remain on these medications during the training period (though they will be asked to stop medications one day prior to motor and cognitive testing)."
223881956|NCT03442101|DRUG|Patients with psychosis will be treated with known antipsychotic medication|Subjects with first episode psychosis will be treated with risperidone, the most frequently used antipsychotic drug (APD) for 32 weeks. The study will follow a rigorous longitudinal design to capture treatment response whereby those without an adequate response after 16 weeks of treatment will be switched to aripiprazole, another APD for 16 weeks. All patients will be scanned four times: at baseline and after 6, 16, and 32 weeks of treatment.
223881957|NCT05186818|DRUG|Aficamten (5 mg, 10 mg, 15 mg, and 20 mg)|Aficamten tablets were administered orally once daily.
223881958|NCT05186818|DRUG|Placebo to match aficamten|Placebo tablets were administered orally once daily.
223881959|NCT06072404|BIOLOGICAL|OxigenOzone_Insufflation|intra-tissutal perialveolar injections of a 15-mL mixture of OxigenOzone (O2O3) with a 26Gx 1⁄2 - 0.45x13 mm needle and insufflation of the same mixture in the post-extraction site for at least 1 minute, hemostasis, and suture.
223881960|NCT02582125|DRUG|ONO-4538|
223881961|NCT05837936|OTHER|Total intravenous anesthesia (TIVA)|TIVA anesthetic -no inhalational gases for surgery
223881962|NCT05837936|OTHER|Sevoflurane initiated intravenous anesthesia (SIIVA)|SIIVA - sevoflurane anesthetic gases for surgery
223881963|NCT06023082|DIETARY_SUPPLEMENT|Colon Broom Premium supplement|"The product contains the following ingredients:~Psyllium Seed Husk Powder L-Carnitine Tartrate Capsimax® Cayenne Fruit Extract Chromium (as Chromium Picolinate) Vitamin B6 (as Pyridoxine HCl) Vitamin B12 (as Cyanocobalamin) Iron"
223881964|NCT03694002|DRUG|Carboplatin|Given IV
223881965|NCT03694002|DRUG|Paclitaxel|Given IV
223881966|NCT03694002|BIOLOGICAL|Ramucirumab|Given IV
223881967|NCT01485575|PROCEDURE|Use of intraoperative filters in vitrectomy|During vitrectomy with xenon endoillumination, an orange, green and a yellow filter are applied sequentially to determine which one produces the best contrast behavior of vital dyes
223881968|NCT05622799|BEHAVIORAL|Mind-Body Medicine Training Program|A mind-body medicine training program that teaches mind-body skills including meditation, autogenics and biofeedback, guided imagery, body awareness, genograms, and self-expression through writing and drawings. The first 4 day training consists of lectures and small groups where the mind-body techniques are practiced. The second 4 day training allows participants to lead a mind-body skills group and teach the techniques under supervision.
223881969|NCT06024096|DRUG|Atorvastatin|"Atorvastatin is a lipid-lowering agent of the statin family that functions by blocking a rate-limiting enzyme, Hydroxymethylglutaryl-CoA (HMG-CoA) reductase, in lipid metabolism. This agent is commonly used for primary and secondary prevention of dyslipidemia. Participants will be asked to take Atorvastatin 80 mg daily at night, for 4 weeks prior to the vaccination, and continue the statin therapy for 4 weeks after vaccination.~The 80mg dose of atorvastatin allows for evaluation of the immunologic effects of statin medication with a short duration of therapy prior to vaccination."
223881970|NCT06024096|BIOLOGICAL|Quadrivalent seasonal influenza vaccine|The FDA-approved quadrivalent seasonal influenza vaccine contains four distinct strains: two influenza A viruses and two influenza B viruses. The approved seasonal QIV will be purchased from the manufacturer to be given for each season of influenza.
223881971|NCT06772961|OTHER|Transcutaneous electrical acupoint stimulation|In this study, the traditional acupoints Taiyuan (LU9) on the lung meridian and Hegu (LI4) on the large intestine meridian were selected. The lung and large intestine meridians are interconnected, so the combined application of Taiyuan and Hegu acupoints with TEAS can produce a synergistic effect. This combination enhances the replenishment of lung qi, promotes the flow of meridians, regulates qi, and disseminates lung functions. It can stimulate effective breathing in patients, thus positively influencing the improvement of their oxygen saturation levels.
223881972|NCT06772961|OTHER|Conventional care plan|Conventional care plan
223881973|NCT05220514|DRUG|(R)-1-(2-chlorophenyl)- N-[11C] ([11C] PK11195)|Radiotracer used during the PET-MR scan of the study to identify signs of disease. Used in studies related to Alzheimer's disease. Only FDA approved for investigational use.
223881974|NCT05220514|DRUG|2-(4-[11C]methylamino phenyl)-6-hydroxybenzothiazole (11C]6-OH-BTA-1 or [11C]PIB)|Radiotracer used during the PET-MR scan of the study to identify signs of disease. Used in studies related to Alzheimer's disease. Only FDA approved for investigational use.
223881975|NCT02662309|DRUG|MPDL3280A|Intravenous infusion
223881976|NCT05114941|DEVICE|immunosorbent column|Immunoadsorption treatment regimen: the treatment is performed once every 1-3 days, at least 5 times, and the amount of regenerated plasma for each treatment is 1 to 3 times the plasma volume. The immunosorbent column adopts the protein A immunosorbent column.
223881977|NCT05114941|DRUG|intravenous immunoglobulin|Intravenous immunoglobulin treatment regimen: intravenous immunoglobulin therapy, 400mg/kg/d, once a day, for at least 5 consecutive days.
223881978|NCT05629169|OTHER|No intervention applied - observational study only|Observational study only. All head impacts will be assessed using video footage.
223881979|NCT04133948|DRUG|Domatinostat|"Patients in arm B and C will receive domatinostat 200 mg BID, days 1-14 q3weeks.~Patients in arm D will start with once daily (OD) dosing scheme of domatinostat 200mg, d1-14 q3wks. Based on safety data of the first 5 patients in this arm, the next patients will be treated with either a higher dosing scheme (200mg BID, d1-14, q3wks), a lower dosing scheme (100mg OD, d1-14, q3wks) or the same dosing scheme (200mg OD, d1-14, q3wks)."
223881980|NCT04133948|DRUG|Nivolumab|2 courses nivolumab 240 mg q3weeks
223881981|NCT04133948|DRUG|Ipilimumab|2 courses ipilimumab 80 mg q3weeks
223881982|NCT04853212|PROCEDURE|Biopsy|Biopsy during recto-coloscopy
223881983|NCT05847920|DRUG|SHR-2010 Injection|SHR-2010 Injection
223881984|NCT05847920|DRUG|Placebo|Placebo
223881985|NCT03584516|DRUG|Itacitinib|In Part 1dose determination participants will receive itacitinib administered orally once daily at the protocol-defined dose according to cohort enrollment. In Part 1 expansion, participants will receive either itacitinib administered orally either once daily or twice a day or corticosteroid alone based on the assigned treatment regimen according to cohort enrollment. In Part 2, participants will receive the recommended dose from Part 1 expansion.
223881986|NCT03584516|DRUG|Placebo|In Part 2, participants will receive matching placebo.
223881987|NCT03584516|DRUG|Methylprednisolone|Administered in Parts 1 and 2 as background reference therapy at a dose level that is commensurate with institutional guidelines based on organ involvement and severity of disease.
223881988|NCT03584516|DRUG|Prednisone|Administered in Parts 1 and 2 as background reference therapy at a dose level that is commensurate with institutional guidelines based on organ involvement and severity of disease.
223881989|NCT05066009|DEVICE|NextSense EEG-enabled earbuds|Each NextSense EEGBud device comes with a universal-fit and/or custom-fit earmold with biometric sensors to detect the EEG, motion (via tri-axial accelerometers), and heart rate. A unique custom mold is created employing a 3D printer to capture the geometry of a patients' ear and external auditory canal with a ring laser scanner to an accuracy of within 0.1 mm. This design process allows for a custom fit, and therefore both comfort and complete, consistent contact with the inner surface of the ear canal, providing high quality signal capture of brain activity, and head and eye movements. In addition to the custom fit earmold, universal fit earmolds are available as well. The universal fit earmolds were designed also to allow for comfort and consistent contact with the inner surface of the ear canal to provide high quality signal capture of brain activity, and head and eye movements.
223881990|NCT05066009|DEVICE|Ellcie Healthy eyeglasses|Ellcie Healthy glasses frames are embedded with multi-modal sensors for measuring eye movements, head movement, and ECG.
223881991|NCT05066009|OTHER|Drug Holiday|Participants will not take their prescribed wakefulness promoting medication(s) for one day to complete the study assessments. Medications typically used to promote wakefulness include amphetamine salts (Adderall), armodafinil (Nuvigil), clarithromycin (Biaxin), flumazenil, methylphenidate (Ritalin), and modafinil (Provigil).
223881992|NCT06112795|OTHER|Non-Interventional Study|Non-interventional study
223881993|NCT04899115|DRUG|Placebo|Starting the last day of oral vancomycin (Day 1), subjects randomized to this arm will take 5 capsules of placebo for 14 days taken once daily.
223881994|NCT04899115|DRUG|VE303|"Starting the last day of oral vancomycin (Day 1), subjects randomized to this arm will take 5 capsules of VE303 taken daily for 14 days.~The quantity of each strain is proportioned to assure a specific per-strain per-capsule titer. The 8 strains are blended together with a micro-crystalline cellulose flow agent and placed in enteric capsules."
223881995|NCT04899115|DRUG|oral vancomycin|All enrolled subjects will receive 5 days of oral vancomycin 125 mg four times a day (q.i.d).
223881996|NCT03311152|DIAGNOSTIC_TEST|"Epi proColon 2.0 CE test from Epigenomics, Inc (Berlin, Germany)"|The mSEPT9 assay consists of DNA extraction from plasma, bisulfite conversion of DNA, purification of bis-DNA, and real-time PCR.
223881997|NCT04868110|BEHAVIORAL|High fiber diet|A registered dietitian will delivered the lessons on consuming a high fiber diet to small groups to increased engage and material retention. These lessons will last 18 weeks.
223881998|NCT05701215|DRUG|Venetoclax|Venetoclax will be taken orally once daily (400 mg) for 12 months
223881999|NCT04082624|BEHAVIORAL|Nutrition condition|Received nutritional information in in-person PowerPoint presentations.
223882000|NCT04082624|BEHAVIORAL|Affective condition|Received information about affective benefits of less sitting in the workplace in in-person PowerPoint presentations.
223882001|NCT04082624|BEHAVIORAL|Instrumental condition|Received information about instrumental benefits of less sitting in the workplace in in-person PowerPoint presentations.
223882002|NCT04082624|BEHAVIORAL|Self-regulation condition|Learned how to self-regulate behavior to sit less in the workplace in in-person PowerPoint presentations.
223882003|NCT06077188|OTHER|Gum group|Group chewing gum with xylitol
223882004|NCT03895541|DIAGNOSTIC_TEST|SuperSonic image|3 examen performed assessed to compared evaluation type: Cardiac magnetic resonance imaging, standard ultrasound imaging and ultrafast imaging
223882005|NCT04823611|DRUG|Part A:Placebo|Placebo solution
223882006|NCT04823611|DRUG|Part A:AZD8233|PCSK9-targeted ASO for the reduction of circulating levels of LDL-C.
223882007|NCT04823611|DRUG|Part B:Placebo|Placebo solution
223882008|NCT04823611|DRUG|Part B:AZD8233|PCSK9-targeted ASO for the reduction of circulating levels of LDL-C.
223882009|NCT04823611|DRUG|Part C: Placebo|Placebo solution
223882010|NCT04823611|DRUG|Part C: AZD8233|PCSK9-targeted ASO for the reduction of circulating levels of LDL-C.
223882011|NCT05096767|OTHER|questionnaires and inventories|questionnaires and inventories related to primary end secondary outcomes will be applied and physical examination will be performed
223882012|NCT06177197|DEVICE|Physiomer|"Infants randomized to the experimental group will be given an electrolyzed seawater solution by their parents for up to 10 days. Dosage is adapted according to the child's age and discomfort:~* Infant \< 6 months: half a dose to a single dose administered per nostril 8 times a day.~* Infant \> 6 months: one single dose administered per nostril 6 times a day."
223882013|NCT06177197|DEVICE|Saline solution|"Infants randomized to the control group will be given a saline solution by their parents for up to 10 days. Dosage is adapted according to the child's age and discomfort:~* Infant \< 6 months: half a dose to a single dose administered per nostril 8 times a day.~* Infant \> 6 months: one single dose administered per nostril 6 times a day."
223882014|NCT06788327|OTHER|Standard rehabilitation|Protocol based on the best available evidence and to be used in all participants in both groups. The standard exercises protocol will consist of three postoperative rehabilitation phases: phase I (weeks 1 to 4), phase II (weeks 5 to 8) and phase III (weeks 9 to 12). Sessions will be held 2 times a week for 12 weeks. Each session will last 45 minutes and will consist of six exercises in the phase I, eight exercises in phase II, and eight exercises in phase III.
223882015|NCT06788327|DEVICE|Blood Flow Restriction Therapy|"Participants will perform three exercises of the standard exercises protocol with BFRT. An auto-regulated portable BFRT SmartCuffs® 3.0 Pro system with a 17-inch long and 5-inch-wide cuff (Smart Tools Plus, United States), placed on the most proximal part of the arm, will be used. Each BFRT session will begin with a maximal occlusion test to personalize the occlusion pressure to the participant. The limb occlusion pressure (LOP) will be set at 50% of the maximum occlusion pressure in the first stage and 60% in stages II and III. The participant will perform 75 repetitions per BFRT exercise divided into 4 sets (30, 15, 15, and 15 repetitions). The load intensity during the BFRT exercises will be set near to 3 out of 10 on the Borg's CR10 scale (weak), which corresponds to 30% of a 1RM effort. After each exercise, the cuff will be deflated, and the patient will rest for two minutes."
223882016|NCT06796322|DEVICE|non-invasive blood glucose meter|Blood glucose were detected by non-invasive glucose meter at four time points, namely fasting, 1 hour post breakfast, 2 hours post breakfast, and 3 hours post breakfast.
223882017|NCT06796322|DEVICE|fully automatic laboratory biochemical analyzer|Blood glucose were detected by fully automatic laboratory biochemical analyzer using plasma sample at four time points, namely fasting, 1 hour post breakfast, 2 hours post breakfast, and 3 hours post breakfast.
223882018|NCT06796322|DEVICE|fingertip capillary blood glucose meter|Blood glucose were detected by fingertip capillary blood sample at four time points, namely fasting, 1 hour post breakfast, 2 hours post breakfast, and 3 hours post breakfast.
223882019|NCT04970888|OTHER|Cognitive training|"The cognitive training will involve attention control training and memory training, with thrice-weekly 30-min sessions.~Two of these sessions will involve computer or tablet-based attentional control training targeting dual-tasking, updating and working memory, as well as inhibition and switching. Difficulty of cognitive training will be tailored to participants' performances. The remaining session will consist of memory training. Participants will be instructed mnemotechnic, as well as be taught about memory in aging in general."
223882020|NCT04970888|OTHER|Exercise training|Participants will follow a 20-week physical training program, with 60-min thrice-weekly trainings. The training sessions will start with a 5-min warm-up, followed by an aerobic training (20 min) after which 20-min of resistance/muscular training will take place. The program will end with a 10-min cool-down. Training will be adapted to individuals' baseline capacity as measured by the baseline cardiorespiratory test. For home-training sessions, participants will have access to a complete exercise training program. A certified kinesiologist will supervise trainings. With the Heart rate sensor Polar H10, all the characteristics of the activities will be recorded (type of the activity, intensity, heart rate, duration). A kinesiologist will call participants every week to ensure the smooth running of the exercises training sessions and individualize the care according to the patient's level.
223882021|NCT04970888|OTHER|Usual care|All patients will receive usual care and be treated according to evidence-based treatments. This will include optimal medical therapy, systematic information regarding dietary and fluid management, and a recommendation for regular physical activity consistent with the latest update of the Canadian Cardiovascular Society Guidelines for the Management of Heart Failure. Moreover, patients who benefit from a prescription for a cardiovascular rehabilitation program will be able to follow it, but they will not receive other forms of intervention for the duration of the study.
223882022|NCT06793189|DRUG|Obinutuzumab and Orelabrutinib|Induction: Obinutuzumab (1000 mg on days 1, 8, and 15 of cycle 1; 1000 mg on day 1 of cycles 2-6, cycle length=21 days) and Orelabrutinib (150 mg once daily).
223882023|NCT06793189|DRUG|Obinutuzumab, Orelabrutinib and Lenalidomide|Induction: Obinutuzumab (1000 mg on days 1, 8, and 15 of cycle 1; 1000 mg on day 1 of cycles 2-6, cycle length=21 days), Orelabrutinib (150 mg once daily), and Lenalidomide (25 mg on days 2-11 of cycles 1-6, cycle length=21 days).
223882024|NCT06793189|DRUG|Orelabrutinib|Maintenance: Orelabrutinib monotherapy (150 mg once daily up to 24 months).
223882025|NCT06793189|DRUG|Orelabrutinib|Maintenance: Orelabrutinib monotherapy (150 mg once daily up to 24 months).
223882026|NCT05982678|DRUG|Trastuzumab deruxtecan|T-DXd 5.4mg/kg on a three weekly (21 day) basis, with the goal of 16 cycles leading to a treatment period of year, including local treatment. The first 8 cycles of T-DXd are administered neo-adjuvant, and 8 cycles adjuvant, after completion of local treatment.
223882027|NCT05438329|DRUG|DB-1305/BNT325|Administered Injection of Vein (I.V.)
223882028|NCT05438329|COMBINATION_PRODUCT|Pembrolizumab|Administered I.V.
223882029|NCT05438329|DRUG|BNT327|Administered I.V.
223882030|NCT06797739|OTHER|Nutritional counselling|Patients will be asked to follow the Mediterranean Diet and to participate to an educational program.
223882031|NCT06797739|OTHER|Diet|Patients will be asked to follow Mediterranean Diet only
223882032|NCT05637307|PROCEDURE|Sentinel node procedure|Injection of radio-active tracer in the tumor before brachytherapy treatment, visualization of sentinel nodes by SPECT, and extirpation of sentinel nodes by surgery
223882033|NCT04111458|DRUG|BI 1701963|Tablet
223882034|NCT04111458|DRUG|Trametinib|Tablet
223882035|NCT04998981|DRUG|K-877 0.1 mg tablet|K-877 0.1 mg tablet x 2 twice daily
223882036|NCT04998981|DRUG|Fenofibrate 200 mg capsule|Fenofibrate 200 mg capsule once daily
223882037|NCT04998981|DRUG|Placebo tablet|Placebo tablet x 2 twice daily
223882038|NCT04998981|DRUG|Placebo capsule|Placebo capsule once daily
223882039|NCT04998981|DRUG|K-877 0.1 mg tablet|K-877 0.1 mg tablet twice daily
223882040|NCT04998981|DRUG|Placebo tablet|Placebo tablet twice daily
223882041|NCT04172402|DRUG|TS-1|Intervention is administered to patients in this Arm.
223882042|NCT04172402|DRUG|Gemcitabine|Intervention is administered to patients in this Arm.
223882043|NCT04172402|DRUG|Nivolumab|Intervention is administered to patients in this Arm.
223882044|NCT06793436|PROCEDURE|chest wall blocks|The effects of anterior chest wall blocks (PECS and SAP will be used in this study) performed for postoperative analgesia on pain scores (to be checked with VAS), opioid consumption, length of hospital stay, mobilization time, side effects and complications in the postoperative period will be examined.
223882045|NCT05890300|DEVICE|Use of an occupational passive back-exoskeleton|The experimental group will use an occupational passive back-exoskeleton (ShoulderX V3, Ottobock bionics) for a period of 24 weeks during working hours. The exoskeleton is designed to reduce the load of the lower back during manual materials handling. The first four weeks will serve as a familiarization period, where the workers will slowly progress in hours of exoskeleton-use, while they in the remaining twenty weeks will be free to use the exoskeleton as much as they like, with a minimum limit of 18 hours per week. The control group will carry on their normal work without any changes.
223882046|NCT06832072|OTHER|MR-BLS|In MR group, students attended a 32 minutes course, in groups of four students with one teacher. The course included 22 minutes of individual MR training using headset (HTC Vive Focus 3®) and 10 minutes of debriefing. The individual MR training contained a step-by-step BLS reminder, including chest compression practice. Then, students engaged in a standardized virtual scenario where they interacted with both virtual characters and a physical manikin torso. The headset overlaid digital elements onto the real world, allowing the students to perform BLS while receiving real-time feedback. The feedback system provided visual cues indicating whether their chest compression rate and depth were correct. The teacher-to-student ratio was 1:4
223882047|NCT06659172|DEVICE|taVNS|transauricular vagus nerve stimulation
223882048|NCT06840912|OTHER|Pharmacological in addition to electroencephalographic (EEG) biofeedback|Patients with heroin use disorder diagnosed according to DSM-5 criteria (Diagnostic and Statistical Manual of Mental Disorders 5th edition), treated by pharmacological in addition to electroencephalography (EEG) biofeedback after 3 months of abstinence.
223882049|NCT06840912|DRUG|Pharmacotherapy|Patients with heroin use disorder taken as control group matching with patients group treated only by pharmacotherapy
223882050|NCT05676047|BEHAVIORAL|Cognitive Rehabilitation|A strategy-focused intervention aimed at improving everyday cognitive function, structured to maximize treatment dose over a short time period. The shorter time period of the treatment therapy is relative to the one and only current randomized controlled trial of cognitive rehabilitation for military mTBI, the Study of Cognitive Rehabilitation Effectiveness (SCORE).
223882051|NCT05676047|OTHER|Education|The Education group will receive information about self-management of cognitive symptoms at the time of randomization, a common alternative for adults with Long COVID cognitive symptoms who do not receive Individual Therapy.
223882052|NCT03849534|DEVICE|Soft occlusal appliance|According to Best Practice in Sweden the soft occlusal appliance is ranked as gold standard for children with mixed or primary dentition
223882053|NCT03849534|BEHAVIORAL|Jaw exercises|The participants do three exercises twice a day. Open and closing mouth against resistance as well as stretch
223882054|NCT03849534|BEHAVIORAL|Counseling|The patients are instructed to minimize jaw parafunctions, chewing chewing gum etc, to do exercises, to take pain-killers or NSAIDs etc.
223882055|NCT04268888|DRUG|Nivolumab and TACE/TAE|Immunotherapy and TACE/TAE
223882056|NCT04268888|PROCEDURE|TACE/TAE|TACE/TAE (as per local practice)
223882057|NCT05867966|BEHAVIORAL|psychoeduc/self-care/self-hypnosis group|See arm description.
223882058|NCT06793254|DIAGNOSTIC_TEST|This is a non-interventional study|None (this is a non-interventional study)
223882059|NCT05139914|DRUG|Dapagliflozin|10 mg/day (in capsule form) of dapagliflozin for 6 weeks
223882060|NCT05139914|OTHER|Placebo|Placebo capsule for 6 weeks
223882061|NCT05417932|BIOLOGICAL|SCG101|Infusion of HBsAg-specific TCR autologous T cells at assigned dose levels.
223882062|NCT05806788|BEHAVIORAL|Binge Eating Syndrome Treatment (BESTOW)|The BESTOW program involves discussions as well as written and behavioral activities. Participants will also be asked to complete activities, or 'homework,' in between sessions that will help to stop binge eating and to improve eating habits.
223882063|NCT06222593|DRUG|Bicalutamide in combination with Sunitinib|Antineoplastics, Antiandrogen; CYP3A4 Inhibitor
223882064|NCT01894061|BIOLOGICAL|Bevacizumab|Bevacizumab will be administered intravenously on days 1 and 15 of each 28 day cycle. The dose of bevacizumab will be 10 mg/kg of actual body weight.
223882065|NCT01894061|DEVICE|NovoTTF-l00A|NovoTTF-100A will be worn continuously.
223882066|NCT01894061|OTHER|Quality of Life Assessment|Functional Assessment of Cancer Therapy including Brain Tumor module (FACT-Br) questionnaire
223882067|NCT06792669|OTHER|Simulation training to evaluate the participants' manual skill improvement|
223882068|NCT06793904|DRUG|Aromatase inhibitor Letrozole|2.5 mg tab twice daily from the 3rd day of the cycle for 5 days
223882069|NCT04452864|DEVICE|Computerized Cognitive Training|The study intervention consists of a tablet-based cognitive training, targeting the cognitive domains mostly affected by Alzheimer Disease.
223882070|NCT04452864|DEVICE|Documentaries with delayed Computerized Cognitive Training|The active control group watches documentaries for three months before starting with the CCT.
223882071|NCT06790940|OTHER|No intervention|This is an observational study, no intervention will be implemented.
223882072|NCT06796972|OTHER|Semi-structured interviews with a psychologist|Semi-directed interviews using an interview guide on different themes
223882073|NCT06790043|OTHER|Patient-selected visual art in hospital room|Patient-selected visual art placed in patient's antepartum hospital room
223882074|NCT06790043|OTHER|Routine care|Patient will receive routine care, and will not select, nor have, visual art in their antepartum hospital room.
223882075|NCT06834334|DEVICE|MM780G|SmartGuard in Medtronic Minimed 780G advaced hybrid closed-loop
223882076|NCT06834334|DEVICE|TTSX2|Control-IQ in Tandem T Slim X2 advanced hybrid closed-loop
223882077|NCT06834334|DEVICE|CamAPS|CamAPS Fx in Ypsopump advanced hybrid closed-loop
223882078|NCT05243862|DRUG|PolyPEPI1018|PolyPEPI1018 vaccine contains 6 synthetic peptides emulsified with the adjuvant Montanide™. The peptides were selected to induce T cell responses against 12 dominant epitopes from 7 tumor-specific antigens, which are the most frequently expressed antigens in colorectal cancer.
223882079|NCT05243862|DRUG|Atezolizumab|Atezolizumab is a fully humanized, engineered monoclonal antibody of IgG1 isotype against the protein programmed cell death-ligand 1.
223882080|NCT05653232|OTHER|Prophylaxis (P2W)|For participants enrolled in P2W arm, the initial dose of SOF/VEL will be administered to the recipient when called to the operating room for transplant (typically 1-3 hours prior to the start of surgery). Post-transplant, SOF/VEL will be continued daily for 13 days post-KT (a total of 14 doses administered).
223882081|NCT05653232|OTHER|Transmit and Treat (T&T)|For participants enrolled in T\&T arm, SOF/VEL will begin between post-KT day 0 and post-KT day 14. Participants will be clinically-prescribed DAAs once viremia is detected, and participant's insurance will be petitioned to obtain treatment as soon as possible. If insurance-provided DAAs are approved before post-KT day 14, participant will begin 12 weeks of study-provided SOF/VEL on date of insurance-provided DAAs approval. If insurance-provided DAAs are not approved by post-KT day 14, study-provided SOF/VEL will begin on post-KT day 14 and continue for 12 weeks.
223882082|NCT04659993|BEHAVIORAL|Telemental Health Sessions, Support Groups and Questionnaires|Participants will complete initial online questionnaires lasting about 25-30 minutes as well as attend weekly support group meetings online. After 4 weeks, participants will complete seven online follow-up questionnaires that should take no longer than 30 minutes and again at the end of the study.
223882083|NCT06395636|DEVICE|Infection-Prediction Algorithm|This machine learning algorithm will be developed(Aim1a) and validated(Aim 1b) using the participant Fitbit data and survey results collected during Aim 1. In Aim 2 the algorithm will be used in real time to predict postoperative infection.
223882084|NCT06839586|DRUG|CMTS4520 (dietary fiber and probiotics)|CMTS4520 is a synbiotic formulation containing a standardized ratio of plant-derived prebiotics and clinically validated probiotic strains. Participants will receive 4 weeks of CMTS4520 daily for chronic diarrhoea.
223882085|NCT06839586|DRUG|Placebo|Capsules with matching volume and consistent appearance to CMTS4520.
223882086|NCT06228755|BEHAVIORAL|Integrative Medicine Group Visit|Integrative Medicine Group Visit (IMGV) is a 9-week group visit series co-facilitated by a billing primary care provider and a trained co-facilitator (such as a behavioral health provider, mindfulness instructor, or yoga teacher). The IMGV will be delivered virtually over a secure telehealth platform for 2 hours weekly. The IMGV curriculum focuses on principles of mindfulness-based stress reduction, and includes patient education on pain, insomnia, nutrition, yoga, depression, self-massage, and self-acupressure.
223882087|NCT06228755|OTHER|Implementation Strategies|"Package includes:~* Patient strategies will include an orientation session to introduce patients to the IMGV model.~* Provider strategies include training in delivery of IMGV with continuing education credits. Training may be delivered on-line or in-person. Ongoing coaching in the first year of IMGV implementation will also be offered to providers leading IMGV, to increase self-efficacy to deliver the curriculum, and enhance fidelity."
223882088|NCT06106672|DRUG|CNP-106|CNP-106 is comprised of an antigenic AChR Peptide Pool (\~1 μg of each AChRα and AChRε peptide comprising AChR Peptide Pool Drug Substance per mg particles) dispersed within a negatively charged (-30 to -60 mV) polymer matrix of PLGA (Poly (DL-lactide-co-glycolide, 50:50 acid-end group)) particles (400-800 nm in size).
223882089|NCT06106672|OTHER|Placebo|CNP-106 Placebo
223882090|NCT04443517|PROCEDURE|Alpha Optimization|Intraoperative oscillatory EEG alpha optimization involves real-time acquisition of oscillatory alpha power from the frontal EEG with individualized titration of sevoflurane and opioid.
223882091|NCT04443517|BEHAVIORAL|Emergence from anesthesia with Dexmedetomidine|Infusion of .05 mcg/kg/h of propofol during the final 10-20 minutes of surgery.
223882092|NCT06793930|BEHAVIORAL|A tailored, optimised, and person-centred critical pathway to promote sustainable lifestyle modification|The TOP-S programme is a nurse-led intervention promoting the maintenance of lifestyle modification
223882093|NCT06793930|OTHER|Brief advice|once-off brief lifestyle advice lasting for 15 minutes
223882094|NCT04434209|DEVICE|Subject management guided by NephroCheck® test|NephroCheck® is a device using biomarkers to identify subjects at risk of sepsis-associated acute kidney injury
223882095|NCT04434209|OTHER|Standard of Care|Standard of Care patient management
223882096|NCT06792877|BEHAVIORAL|Mindfulness Intervention|The Mindfulness Intervention is an adapted form of Mindfulness-based stress reduction (MBSR) training virtual class that meets for 10 weeks. The class involves mindfulness training using awareness and focused attention, group discussion of the experience, and mindful movement. The Mindfulness Intervention also includes daily home practice using mindfulness recordings.
223882097|NCT06792877|BEHAVIORAL|Waitlist then mindfulness|Participants in this arm will first wait 10 weeks and then complete a mindfulness course with outcome measures assessed at baseline, after 10 weeks wait list and then after mindfulness course.
223882098|NCT06837844|DRUG|Intrathecal Dexmedetomidine|Patients will receive 15mg in 3ml hyperbaric bupivacaine intrathecally with 5 μg in 0.5ml dexmedetomidine + adductor canal block using 20 ml saline 0.9% at the end of surgery
223882099|NCT06837844|DRUG|Adductor Canal Block|Patients will receive 15mg in 3ml hyperbaric bupivacaine intrathecally with 0.5ml saline 0.9% + adductor canal block using 20 ml bupivacaine 0.25% at the end of surgery.
223882100|NCT06837844|DRUG|Intrathecal Dexmedetomidine + Adductor Canal Block|Patients will receive 15mg in 3ml hyperbaric bupivacaine intrathecally with 5 μg in 0.5ml dexmedetomidine + adductor canal block using 20 ml bupivacaine 0.25% at the end of surgery.
223882101|NCT04973657|DRUG|VK0214|API in capsule
223882102|NCT04973657|OTHER|Placebo|API in capsule
223882103|NCT05065138|BEHAVIORAL|Standardized training on Helicobacter pylori eradication treatment|Standardized training on Helicobacter pylori eradication treatment
223882104|NCT05827055|DRUG|Gemcitabine|1000mg/m2 IV given days 1, 8, and 15 every 28 days (1 cycle)
223882105|NCT05827055|DRUG|Nab paclitaxel|125 mg/m2 given days 1, 8, and 15 every 28 days (1 cycle)
223882106|NCT05827055|DRUG|Proglumide|Daily dose of 1200 mg orally given as 400 mg orally (PO), three times a day (TID) in vegan capsules
223882107|NCT05827055|DRUG|Placebo|Placebo given in vegan. capsules orally three times a day
223882108|NCT06827483|OTHER|Neurocognitive Component|A neurocognitive component will be added to the Y Balance Test
223882109|NCT03471650|DRUG|18F-DCFPyL Injection|A bolus of \~9 mCi (333 MBq) of 18F-DCFPyL will be injected by slow IV push.
223882110|NCT05664516|DRUG|TNX-1900 (Tonix Pharmaceuticals)|oxytocin nasal spray
223882111|NCT05664516|DRUG|Placebo|Nasal solution without oxytocin
223882112|NCT05568225|DRUG|Etavopivat|400 mg once daily
223882113|NCT01673984|DRUG|Decapeptyl® SR 22.5mg|22.5mg, intramuscular injection, given on day 1 / month 0 \& month 6 (+/- 7 days).
223882114|NCT01673984|DRUG|Decapeptyl® SR 11.25mg; Prostap® 3 DCS 11.25mg; Zoladex® LA 10.8mg|For Decapeptyl® SR 11.25mg: 11.25 mg, intramuscular injection For Prostap® 3 DCS 11.25mg: 11.25mg, depot injected subcutaneously For Zoladex® LA 10.8mg: 10.8mg, depot injected subcutaneously into anterior abdominal wall
223882115|NCT05859464|DRUG|ZL-1218|ZL-1218 dose escalation
223882116|NCT05859464|DRUG|Pembrolizumab|Combination treatment with ZL-1218
223882117|NCT04667663|DRUG|Daratumumab|Daratumumab (1,800mg) will be administered by a subcutaneous injection once every week for 2 cycles (Cycles 1-2), then once every 2 weeks for 4 cycles (Cycles 3-6), and following this (Cycle 7 onwards), patients will receive daratumumab once every four weeks.
223882118|NCT04667663|DRUG|Cyclophosphamide|Cyclophosphamide will be administered PO at 50mg daily for all cohorts in the study.
223882119|NCT04667663|DRUG|Pomalidomide|Pomalidomide will be administered PO on days 1-21 of each 28 day cycle. The dose will be specified by the dose level to which the patient has been enrolled.
223882120|NCT04667663|DRUG|Dexamethasone|Dexamethasone will be administered PO at 40mg on days 1, 8, 15 and 22 of each 28 day cycle.
223882121|NCT03044613|DRUG|Nivolumab|240mg or 1 mg/kg administered IV
223882122|NCT03044613|DRUG|Relatlimab|80mg administered IV
223882123|NCT03044613|DRUG|Carboplatin|standard care dose
223882124|NCT03044613|DRUG|Paclitaxel|standard care dose
223882125|NCT03044613|RADIATION|Radiation|standard care dose
223882126|NCT05625425|BEHAVIORAL|LabyrinthVR software|Head-mounted display virtual reality game designed to induce environmental enrichment in an adaptive, highly engaging regimen of wayfinding in novel urban and village neighborhoods.
223882127|NCT05625425|BEHAVIORAL|Placebo Games software|Commercially-available, narrative computer games marketed as cognitively enriching. Can be tablet-based or wireless VR headset-based.
223882128|NCT05625425|BEHAVIORAL|Labyrinth Tablet software|Tablet computer playing Labyrinth spatial wayfinding game in 2.5D
223882129|NCT05625425|BEHAVIORAL|Labyrinth VR wireless|Wireless head-mounted display virtual reality game designed to induce environmental enrichment in an adaptive, engaging regimen of wayfinding in novel urban and village neighborhoods.
223882130|NCT01521052|DEVICE|dTMS treatment (H1 Coil)|All subjects will receive prefrontal deep rTMS of H1 Coil (42 trains of 2 seconds, 10 Hz, with 20 seconds inter-train intervals, up to 120% of motor threshold), for 4 weeks, 5 days a week, overall 20 sessions.
223882131|NCT06243757|OTHER|MDASI-GI|"The MDASI-GI assesses 5 symptoms specific to gastrointestinal cancer:~constipation diarrhea or watery stools difficulty swallowing change in taste feeling bloated~Using this questionnaire, participants score the severity of their symptoms over the previous 24 hours on a scale of 0 (not present) to 10 (as bad as you can imagine)."
223882132|NCT05018793|BIOLOGICAL|autologous adipose derived mesenchymal stem cells|cultured autologous adult adipose derived mesenchymal stem cells
223882133|NCT05018793|BIOLOGICAL|AlloRx|Cultured Allogeneic Adult Umbilical-cord Derived Mesenchymal Stem Cell Intrathecal injection for
223882134|NCT05183490|DRUG|Rapidly generated virus specific T (R-MVST) cells|"The R-MVST products will be manufactured individually for each patient from a selected donor; it is an anti-viral prophylaxis and treatment of viral reactivation.~SCT dose escalation:~Cohort / R-MVST dose~* (-1A) 0.25x10\^6 R-MVST TNC/kg~* (1A) 0.5x10\^6 R-MVST TNC/kg~* (2A) 1x10\^6 R-MVST TNC/kg~SOT dose escalation:~Cohort / R-MVST dose~* (-1B) 1x10\^6 R-MVST TNC/kg~* (1B) 2x10\^6 R-MVST TNC/kg~* (2B) 4x10\^6 R-MVST TNC/kg"
223882135|NCT05555888|DRUG|PD-1 antibody|PD-1 antibody (Toripalimab): 240mg d1 q3w
223882136|NCT05555888|DRUG|Capecitabine|Capecitabine: 1000mg/m2 d1-14 q3w
223882137|NCT05555888|DRUG|Oxaliplatin|Oxaliplatin: 130mg/m2 d1 q3w
223882138|NCT05555888|RADIATION|Short-course radiotherapy|Shor-course radiotherapy: 25Gy/5Fx
223882139|NCT06844630|OTHER|Preoperative block application (İntersclane Block)|Before surgery, patients will receive a unilateral interscalene block under ultrasound guidance.
223882140|NCT06844630|OTHER|Preoperative block application (Infraspinatus-teres minor interfascial block)|Before surgery, patients will receive a unilateral infraspinatus-teres minor interfascial block under ultrasound guidance.
223882141|NCT06847412|DEVICE|Escalating PEEP|Typically, an initial PEEP of 5 cm H₂O, then PEEP is increased in 2-3 cm H₂O increments while monitoring the patient's response (oxygenation, hemodynamics, and lung compliance).
223882142|NCT06847412|DEVICE|Sustained inflation|Set the ventilator to CPAP mode and increase the pressure to 30 cm H2O for 30 s.
223882143|NCT06846749|DIETARY_SUPPLEMENT|F75 milk feeds|Standard 'F75' (75 kcal/100 ml) 95 kcal/kg/day 12.05 mg/kg/min glucose
223882144|NCT06846749|DIETARY_SUPPLEMENT|F50 milk feeds|Reduced caloric 'F50' (50kcal/100ml) 63 kcal/kg/day 8.03mg/kg/min glucose
223882145|NCT06846749|DIETARY_SUPPLEMENT|F35 milk feeds|"Reduced caloric 'F35' (35 kcal/100ml)~* 47 kcal/kg/day~* 5.62 mg/kg/min glucose"
223882146|NCT06420869|DIAGNOSTIC_TEST|Assessment|A postural evaluation will be conducted, including the measurement of the thoracic kyphosis angle and the assessment of sagittal head posture.A proprioception evaluation will be conducted, whereby the cervical region, trunk and ankle joint position sense and trunk and foot sensation will be evaluated for the purpose of assessing the proprioception of the spine.Turkish adaptation of the Kyphosis Specific Spine Appearance Questionnaire (KSAQ) will be employed to assess postural appearance perception. The KSAQ is a reliable and valid patient-reported outcome tool for assessing individual perception of various aspects of kyphotic deformity and appearance in young patients with kyphosis. KSAQ is a 10-item questionnaire based on a five-point Likert scale, with responses ranging from 1 to 5. The mean of the responses is used to obtain a total score for the KSAQ. The questionnaire is related to patients' perception of appearance, with higher scores indicating a worsening of the deformity.
223882147|NCT05654922|DRUG|ARINA-1|ARINA-1 (88 mg/mL ascorbic acid, ASC; 150 mg/mL reduced glutathione, GSH)
223882148|NCT05654922|OTHER|Standard of care only|Standard 3-therapy immunosuppression regimen and azithromycin
223882149|NCT03933059|OTHER|Psychotherapy|Cognitive Processing Therapy is a primarily cognitive form of Cognitive Behavioral Therapy, which has been shown to be effective at reducing symptoms of PTSD.
223882150|NCT02531841|DRUG|Arm A (Fortecortin®-ETOPOPHOS®-IFO-cell®-CARBO-cell®)|"Arm A 4 cycles MATRix (every 3 weeks), stem-cell harvest after 2nd cycle:~* Rituximab 375 mg/m²/d i.v. (d0,5)~* Methotrexate 3.5 g/m² i.v. (d1)~* Cytarabine 2 x 2 g/m²/d i.v. (d2-3)~* Thiotepa 30 mg/m² i.v. (d4) Consolidation 2 cycles of R-DeVIC (every 3 weeks):~* Rituximab 375 mg/m²/d i.v. (d0)~* Dexamethasone 40 mg/d i.v. (d1-3)~* Etoposide 100 mg/m²/d i.v. (d1-3)~* Ifosfamide 1500 mg/m²/d i.v. (d1-3)~* Carboplatin 300 mg/m² i.v. (d1)"
223882151|NCT02531841|DRUG|Arm B (TEPADINA®-CARMUBRIS®-Busilvex®)|"4 cycles MATRix (every 3 weeks), stem-cell harvest after 2nd cycle:~* Rituximab 375 mg/m²/d i.v. (d0,5)~* Methotrexate 3.5 g/m² i.v. (d1)~* Cytarabine 2 x 2 g/m²/d i.v. (d2-3)~* Thiotepa 30 mg/m² i.v. (d4) Consolidation~High-dose chemotherapy (HDT-ASCT):~* Carmustine\* 400 mg/m² i.v. (d-6)~* Thiotepa 2 x 5 mg/kg/d i.v. (d-5-(-4))~* Autologous Stem Cell Transplantation (d0)~  \* if carmustine is not available at the investigation site, busulfan can be administered instead:~* Busulfan 3,2 mg/kg/d (d-8-(-7))~* Thiotepa 2 x 5 mg/kg/d i.v. (d-5-(-4))~* Autologous Stem Cell Transplantation (d0)"
223882152|NCT02306954|BIOLOGICAL|High Dose IL-2|High Dose IL-2 is approved by the FDA for the treatment of renal cell cancer.
223882153|NCT02306954|RADIATION|SBRT|Patients assigned to SBRT arm will receive two doses of SBRT at 20 Gy on the Wednesday and Friday before the Monday on which IL-2 starts.
223882154|NCT02610673|DEVICE|WiCS-LV System|Implant of left ventricular receiver-electrode and ultrasound transmitter.
223882155|NCT06571409|DIETARY_SUPPLEMENT|Coriander Seed Oil - Dose 1|The study foresees the intake of 1 capsule per day during 56 days
223882156|NCT06571409|DIETARY_SUPPLEMENT|Coriander Seed Oil - Dose 2|The study foresees the intake of 1 capsule per day during 56 days
223882157|NCT06571409|DIETARY_SUPPLEMENT|Placebo|The study foresees the intake of 1 capsule per day during 56 days
223882158|NCT02746510|GENETIC|Array comparative genomic hybridization|For each of the 150 patients deoxyribose nucleic acid (DNA) exactracted from a jugal mucosae sample will be analysed by the cytogeneticist and a CGH-a will be performed.
223882159|NCT06525311|DRUG|K-808|K-808 single or multi dose extended-release tablets
223882160|NCT05568017|DRUG|peptide receptor radionuclide therapy with Y-90-DOTATOC|Patients with unresectable or borderline resectable pNETs will recive PRRT with 90Y-DOTATOC
223882161|NCT04437433|DRUG|Atogepant 60 mg|Tablets containing 60 mg atogepant
223882162|NCT05036408|OTHER|Behavioral, Psychological or Informational Intervention|Participate in group psychological intervention
223882163|NCT05036408|OTHER|Educational Intervention|Attend educational session
223882164|NCT05036408|PROCEDURE|Manipulative and Body-Based Intervention Procedure|Undergo osteopathic manual treatments
223882165|NCT05036408|BEHAVIORAL|Occupational Therapy|Participate in occupational therapy
223882166|NCT05036408|OTHER|Physical Activity|Participate in physical activity
223882167|NCT05036408|PROCEDURE|Physical Therapy|Participate in physical therapy
223882168|NCT05036408|OTHER|Questionnaire Administration|Ancillary studies
223882169|NCT04364139|OTHER|MAP goal less than or equal to 92 mm Hg|Lower Blood Pressure Goal (mean arterial pressure (MAP) less than or equal to 92 mm Hg) which corresponds to a BP of approximately 115/80 mmHg
223882170|NCT04364139|OTHER|MAP goal 102-107 mm Hg|Usual Blood Pressure Goal (mean arterial pressure (MAP) 102-107 mm Hg) which corresponds to a BP of approximately 135/85 to 140/90 mmHg
223882171|NCT04364139|DRUG|Ramipril|An angiotensin-converting enzyme inhibitor, (ACEI: ramipril) 2.5 to 10 mg/d
223882172|NCT04364139|DRUG|Amlodipine|A dihydropyridine calcium channel blocker, (DHPCCB: amlodipine) 5 to 10 mg/d
223882173|NCT04364139|DRUG|Metoprolol|A sustained release beta-blocker, (BB: metoprolol) 50 to 200 mg/d
223882174|NCT04048681|BEHAVIORAL|diet soda|12 oz can of artificially sweetened cola beverage (Diet Coke planned to be used but similar to Diet Pepsi or other Diet Colas)
223882175|NCT04048681|BEHAVIORAL|Regular soda|12oz can of regular cola beverage (Coke planned but similar to Pepsi or other regular cola sodas)
223882176|NCT04048681|BEHAVIORAL|Carbonated Water|12oz can of carbonated water (sparking water, selzter water) unflavored
223882177|NCT05413889|BEHAVIORAL|Epic 30-day unplanned readmission risk score|If a patient is identified as having a high risk of readmission defined as readmission risk \>20%, a link to transitional and supportive care services (TSC) will be appear in the story board.
223882178|NCT04570072|DIETARY_SUPPLEMENT|Probiotic|Patients receive the formula probiotic for consecutive 8 weeks ( one sachet per day ).
223882179|NCT04570072|DIETARY_SUPPLEMENT|Placebo|Patients receive the placebo identical to probiotic for consecutive 8 weeks ( one sachet per day ).
223882180|NCT01421407|DEVICE|Ultrasonic ablation device|High Intensity Focused Ultrasound treatment
223882181|NCT04255979|DRUG|HY209|6 Subjects will be assigned to drug (HY209) and 2 subjects will be assigned to placebo.
223882182|NCT05767437|BEHAVIORAL|Abdominal drawing-in maneuver exercise|From the supine position to the hook-lying position (hip joint at 40 degrees and the knee joint at 80 degrees) and pull the navel deeply to the lumbar region through the Stabilizer™ Pressure Biofeedback that stabilize transversus abdominis muscle. At this time, subjects are controlled to maintain contraction while keep breathing lightly, to contract slowly, also to not move the pelvis and chest while exercising
223882183|NCT05767437|BEHAVIORAL|sham|Release pain or upper limb mobilization
223882184|NCT02731846|DRUG|Fluticasone furoate 100 mcg + Umeclidinium 62.5 mcg+Vilanterol 25 mcg|Dry white powder delivered via ELLIPTA inhaler(2 strips with 30 blisters each, first containing fluticasone furoate 100 mcg per blister and second containing Umeclidinium 62.5 mcg and Vilanterol 25 mcg per blister), administered as one inhalation of FF/UMEC/VI (100/62.5/25 mcg) once-daily in the morning
223882185|NCT02731846|DRUG|Fluticasone furoate 100 mcg + Vilanterol 25 mcg|Dry white powder delivered via ELLIPTA inhaler (2 strips with 30 blisters each, first containing fluticasone furoate 100 mcg per blister and second containing Vilanterol 25 mcg per blister), administered as one inhalation of FF/VI (100/25 mcg) once-daily in the morning
223882186|NCT02731846|DRUG|Umeclidinium 62.5 mcg|Dry white powder delivered via ELLIPTA inhaler (1 strip with 30 blisters containing Umeclidinium 62.5 mcg, administered as one inhalation once-daily in the morning
223882187|NCT02731846|DEVICE|Placebo ELLIPTA inhaler|Placebo will be administered via ELLIPTA inhaler. Dry white powder administered as one inhalation each morning (1 strip with 30 blisters containing placebo)
223882188|NCT02731846|DRUG|Albuterol/Salbutamol|Albuterol/salbutamol will be administered via metered-dose inhaler (MDI) with a spacer as needed throughout the study as a rescue medication
223882189|NCT00441298|DRUG|Tenofovir gel|Participants will be provided with a supply of single-use, pre-filled applicators according to their randomisation. While in the study, participants will be asked to apply a first dose of the assigned study product, 1% tenofovir gel, within 12 hours prior to coitus and insert a second dose as soon as possible within 12 hours after coitus. They will be advised to use only two doses of gel in a 24-hour period.
223882190|NCT00441298|DRUG|Placebo (Universal HEC placebo)|Participants will be provided with a supply of single-use, pre-filled applicators according to their randomisation. While in the study, participants will be asked to apply a first dose of the assigned study product, placebo gel, within 12 hours prior to coitus and insert a second dose as soon as possible within 12 hours after coitus. They will be advised to use only two doses of gel in a 24-hour period.
223882191|NCT00599469|RADIATION|Far Infrared Radiation (5μm to 20μm wavelength)|Far Infrared radiation for 30 to 40 minutes per treatment session.
223882192|NCT06338319|BEHAVIORAL|Book-Sharing for Toddlers with Clefts (BOOST)|BOOST is a dialogic book-sharing intervention. Topics covered include strategies to increase the frequency of shared reading, child engagement and involvement in reading, and strategies to promote language development. Handouts will be shared during the sessions (using the Zoom share screen feature) and sent to families to summarize the content. Parents will record and securely upload shared reading videos during the intervention period. The research team will send prompts for these video uploads after each intervention session. Interventionists will review these videos between sessions to identify parent strengths, application of target skills, and opportunities for improvement.
223882193|NCT02686398|BIOLOGICAL|Fluad|
223882194|NCT02686398|BIOLOGICAL|Agrippal|
223882195|NCT01652820|DRUG|Docetaxel 20mg/m2/week + carboplatin AUC 2/weekly - concomitant chemoradiation 2Gy/day|
223882196|NCT01652820|DRUG|Docetaxel 40mg<7m2 d1,8, 21, 28+ gemcitabine 1200mg/m2 d1,8, 21, 28 + concomitant docetaxel 20mg/m2/w+carboplatin AUC 2/w+ concomitant RDT 2Gy/d|
223882197|NCT06607341|BEHAVIORAL|Multi-level, community-digital health promotion intervention|"Community level activities:~1. Capacity building for community-based organizations, and~2. Community health workers will facilitate linkage to community resources, including health/social service access referrals and client social support.~Individual level activities:~1. Goal setting and self-monitoring,~2. Tailored feedback,~3. Personalized lifestyle coaching, health and social service referral support, and~4. Digital access and digital health literacy skills building~Social network:~1. Social network-based activities, and~2. Digital health literacy skills building"
223882198|NCT05384730|OTHER|Group nutrition and exercise support|Weekly group nutrition and exercise support delivered online through trained volunteers
223882199|NCT04804202|OTHER|Bicycling with and without virtual reality|In one session: Exercise intensity and enjoyment are measured while participants bicycle in a virtual compared to non-virtual environment. Cycling takes places in two modes continous and interval. In a second session exercise intensity and enjoyment are compared during bicycling with virtual reality presented in two different ways.
223882200|NCT05663931|OTHER|DM Discharge Toolkit|"The DM Discharge Toolkit is a multi-modal intervention consisting of a 3-D printed DM survival kit that stores DM self-care supplies (e.g., glucose meter) and technical skills (e.g., injection) simulation materials (e.g. simulation skin), whose use is integrated with a website (https://mydiabeteskit.com) containing standardized DM Survival education content."
223882201|NCT02571725|DRUG|Olaparib|Olaparib starts concomitantly with the first dose of Tremelimumab
223882202|NCT02571725|DRUG|Tremelimumab|3 to 6 patients will be treated at 10 mg/kg depending on RLT observed in the first 3 patients. If 0 out of 3 or 1 out of 6 patients experienced a RLT at 10 mg/kg, then this dose will be considered at the recommended phase 2 dose (RP2D). If 2 out of 6 patients experience RLT at this dose within 56 days, then dose reductions as detailed in the Arm description will be carried out.
223882203|NCT03295734|BEHAVIORAL|Aerobic exercise|Twice weekly centered based aerobic exercise + 3/week home-based walking
223882204|NCT03295734|DRUG|Perindopril|4 mg qd titrated to 8 mg qd perindopril
223882205|NCT03295734|DRUG|Losartan|50 mg qd titrated to 100 qd losartan
223882206|NCT03295734|DRUG|HCTZ|12.5 mg qd titrated to 25 qd HCTZ
223882207|NCT05468489|DRUG|Serplulimab + chemotherapy (carboplatin-etoposide)|"Drug: Serplulimab is an innovative monoclonal antibody targeting PD-1，developed by Shanghai Henlius Biotech, Inc.~Drug: carboplatin and etoposide chemotherapeutics"
223882208|NCT05468489|DRUG|Atezolizumab + chemotherapy (carboplatin-etoposide)|"Drug: Atezolizumab is a monoclonal antibody targeting PD-L1，developed by Roche Pharma AG.~Drug: carboplatin and etoposide chemotherapeutics"
223882209|NCT06963151|OTHER|Behavioral: Hand-Arm Bimanual Intensive Therapy Including Lower Extremities|"* Structured bimanual tasks training, with gradual increase in motor difficulty, requiring increased postural adjustments and the use of the lower extremities.~* Home programme with parental coaching"
223882210|NCT06963151|OTHER|Behavioral: Hand-Arm Bimanual Intensive Therapy Including Lower Extremities|\- Structured bimanual tasks training, with gradual increase in motor difficulty, requiring increased postural adjustments and the use of the lower extremities.
223882211|NCT06445075|DRUG|Apitegromab|Apitegromab (SRK-015) is a fully human anti-proMyostatin monoclonal antibody (mAb) that specifically binds to human pro/latent myostatin, inhibiting myostatin activation. Apitegromab was administered every 4 weeks by intravenous (IV) infusion.
223882212|NCT06445075|DRUG|Placebo|Same appearance and composition as apitegromab drug product but does not contain the active ingredient. Placebo was administered every 4 weeks by intravenous (IV) infusion.
223882213|NCT06445075|DRUG|Tirzepatide|Glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist. Tirzepatide was administered every week by subcutaneous injection.
223882214|NCT04686253|OTHER|not appliable|not appliable
223882215|NCT05551455|OTHER|Nutritional/dietary intake manipulation ('Normal')|Energy Intake provision (60 kcal/kg FFM/day) to elicit 'normal' energy availability (45 kcal/kg FFM/day), with 60% from carbohydrates.
223882216|NCT05551455|OTHER|Nutritional/dietary intake manipulation ('Low')|Energy Intake provision (60 kcal/kg FFM/day), with 1.5 g/kg of carbohydrate and 70-80% fat intake, to elicit 'low' carbohydrate availability in energy balance (45 kcal/kg FFM/day).
223882217|NCT06194578|OTHER|Sterile Saline|Sterile saline will be administered subcutaneously.
223882218|NCT02623894|OTHER||No intervention study is an observational study
223882219|NCT00731341|PROCEDURE|Cryoablation for the treatment of uterine fibroids|Needle will be inserted into the fibroid via the cervix through a hysteroscope channel. Gas is circulated through the sealed needle to form an iceball at the tip. After insertion, the needle will be cooled to a temperature of below -100°C to freeze the tissue of the fibroid.
223882220|NCT03764319|OTHER|Ultra-protective ventilator settings|4-5 Breaths per minute; 14-16 cmH2O Positive endexpiratory pressure (PEEP) (adjust PEEP to 23 \< Plateau pressure \< 25 cmH2O); 23-25 cmH2O Plateau pressure (adjust to not exceed Tidal volume \> 4 mL/kg Predicted body weight (PBW)); \< 4mL/kg PBW Tidal volume; 1:5 Inspiration:Expiration (I:E)
223882221|NCT03764319|OTHER|Standard ventilator settings|12-25 Breaths per minute; 8-12 cmH2O PEEP; max. 35 cmH2O Plateau pressure
223882222|NCT06475937|DRUG|DM001|Subjects may continue to receive DM001 (with an increased dose that has been assessed as safe in the dose-escalation period) once every 3 weeks (Q3W) for a total of 6 cycles at the discretion of the investigators, until unacceptable toxicity, progressive disease (PD), or withdrawal of consent.
223882223|NCT04826978|BEHAVIORAL|Auditory environment|Auditory environment
223882224|NCT05586971|DRUG|Tigulixostat|Xanthine Oxidase Inhibitor
223882225|NCT05586971|DRUG|Allopurinol|Xanthine Oxidase Inhibitor
223882226|NCT05586971|DRUG|Placebo|Matching placebo
223882227|NCT05568381|DEVICE|digital CBT-I|Sleepio is a digital cognitive behavioral therapy (CBT) program designed to treat insomnia. The program is fully automated, and its underlying algorithms drive the delivery of information, support, and advice.
223882228|NCT05568381|OTHER|Online Sleep Health Education package|Wait-listed control participants will have full access to three online modules for the duration of the study. The information in these modules will provide non-tailored basic sleep information and content will contain text and basic images but will not be personalised to the individual participant.
223882229|NCT04854096|DRUG|NS-018|Experimental
223882230|NCT04854096|DRUG|Best Available Therapy|Active Comparator
223882231|NCT06095440|OTHER|Hepatorenal Syndrome outcome in Patients at Methodist Health systems|1.2.1. To perform a retrospective analysis of patients with HRS with the aim of comparing various treatment modalities such as vasoconstrictors, albumin, CRRT, Molecular Adsorbent Recirculating System (MARS), and TIPS.
223882232|NCT05512052|DEVICE|Hannah Cervical Cup (2 mm Delta)|The Hannah Cervical Cup reverses and prevents early cervical change by improving cervical collagen function. It applies negative pressure to the cervix, placing it in a tensile strain. Collagen under tension elicits fibers to realign, creating initial stiffness. This enables the cervix to remain closed. Over time, the extracellular matrix becomes strengthened as tension increases collagen strength and synthesis, and decreases degradation and adhesions. It also decreases prostaglandins--inflammatory mediators that facilitate birth. The Hannah Cervical Cup will create stiffness and length in the cervix, provide a treatment for early rupture of fetal membranes, and will offer a mode of medication administration. It is simple in nature, non-invasive, may be used in low-income, low-resource settings, can be placed by a physician in inpatient and outpatient settings, and does not require anesthesia during placement. The Hannah Cervical Cup (2 mm Delta) displaces the cervical tissue by 2 mm.
223882233|NCT05512052|DEVICE|Hannah Cervical Cup (4 mm Delta)|The Hannah Cervical Cup reverses and prevents early cervical change by improving cervical collagen function. It applies negative pressure to the cervix, placing it in a tensile strain. Collagen under tension elicits fibers to realign, creating initial stiffness. This enables the cervix to remain closed. Over time, the extracellular matrix becomes strengthened as tension increases collagen strength and synthesis, and decreases degradation and adhesions. It also decreases prostaglandins--inflammatory mediators that facilitate birth. The Hannah Cervical Cup will create stiffness and length in the cervix, provide a treatment for early rupture of fetal membranes, and will offer a mode of medication administration. It is simple in nature, non-invasive, may be used in low-income, low-resource settings, can be placed by a physician in inpatient and outpatient settings, and does not require anesthesia during placement. The Hannah Cervical Cup (4 mm Delta) displaces the cervical tissue by 4 mm.
223882234|NCT05512052|DEVICE|Hannah Cervical Cup (6 mm Delta)|The Hannah Cervical Cup reverses and prevents early cervical change by improving cervical collagen function. It applies negative pressure to the cervix, placing it in a tensile strain. Collagen under tension elicits fibers to realign, creating initial stiffness. This enables the cervix to remain closed. Over time, the extracellular matrix becomes strengthened as tension increases collagen strength and synthesis, and decreases degradation and adhesions. It also decreases prostaglandins--inflammatory mediators that facilitate birth. The Hannah Cervical Cup will create stiffness and length in the cervix, provide a treatment for early rupture of fetal membranes, and will offer a mode of medication administration. It is simple in nature, non-invasive, may be used in low-income, low-resource settings, can be placed by a physician in inpatient and outpatient settings, and does not require anesthesia during placement. The Hannah Cervical Cup (6 mm Delta) displaces the cervical tissue by 6 mm.
223882235|NCT05617742|DIAGNOSTIC_TEST|68Ga-FAPI-46|68Ga-FAPI-46 is a radioactive diagnostic agent for PET imaging in the detection of Fibroblast Activation Protein (FAP) positive tumor cells in cancer patients
223882236|NCT02253459|DRUG|UTD1 Injection plus capecitabine|
223882237|NCT02253459|DRUG|Capecitabine|
223882238|NCT04790357|OTHER|Current guidelines|doppler ultrasound and/or angio CT-scan of the cervical arteries, angio CT-scan of the intracranial arteries, TTE wich can be supplemented by a TEE at the discretion of the investigator. The TEE is not mandatory
223882239|NCT04790357|OTHER|cc-MRI|of one-shot cardiac-cervical-intracranial MRI: cardiac MRI with late-enhancement, angio-MRI of the cervical and intracranial arteries
223882240|NCT00879333|DRUG|Everolimus|Everolimus was formulated as tablets of 5 mg strength. In both treatment arms, the study drug was given by continuous oral daily dosing of 10 mg (2 tablets x 5 mg) each morning.
223882241|NCT00879333|DRUG|Everolimus placebo|Placebo was formulated to be indistinguishable from the everolimus tablets, also formulated as tablets of 5 mg strength. In both treatment arms, the study drug was given by continuous oral daily dosing of 10 mg (2 tablets x 5 mg) each morning.
223882242|NCT00879333|DRUG|Best Supportive Care (BSC)|Best supportive care is defined as care in accordance with the local practice of an individual institution or center, specifically excluding anti-cancer treatments.
223882243|NCT00154011|DRUG|rosiglitazone (drug)|
223882244|NCT00226018|DEVICE|Hand Adapter (Organon, Oss, the Netherlands)|Randomization of acceleromyography with or without Hand Adapter to dominant or non-dominant arm. Contralateral neuromuscular transmission is measured with mechanomyography (The gold standard of neuromuscular monitoring)
223882245|NCT00226018|DEVICE|Placebo|placebo
223882246|NCT06489041|GENETIC|"Pharmacogenomic Testing with the Global Diversity Array with Enhanced PGx"|Pharmacogenomic (PGx) microarray testing will test for certain pharmcogenes that can guide prescribing of certain cancer treatments and/or supportive care medications.
223882247|NCT04099875|DIAGNOSTIC_TEST|ultrasound|Ultrasound is a type of imaging. It uses high-frequency sound waves to look at organs and structures inside the body.
223882248|NCT00785915|DRUG|AZD6765|single administration and once daily for 5 days
223882249|NCT00785915|DRUG|Placebo|single administration and once daily for 5 days
223882250|NCT02634450|DEVICE|Alere q|
223882251|NCT03592732|OTHER|Blood sample|Blood sample
223882252|NCT03788200|PROCEDURE|Bracing|Treatment arm #1 (8 weeks of post-injury bracing with rigid cervical collar): Participants randomized to this treatment arm will be treated with 8 weeks in a rigid cervical collar.
223882253|NCT03788200|PROCEDURE|posterior C1-C2 instrumented fusion|Treatment arm #2 (posterior C1-2 instrumented fusion): Participants randomized to this treatment arm will undergo posterior C1-2 instrumented fusion with either local bone grafting or autologous iliac crest bone grafting with or without allograft bone grafting. Bone grafting decision will be made by the treating surgeon. All remaining decisions surrounding medical and surgical care will be made by the attending spine surgeon involved in each case.
223882254|NCT02369289|OTHER|bone mineral density test|
223882255|NCT04351932|BIOLOGICAL|bone marrow mesenchymal stem cells|intrarticular bone marrow mesenchymal stem cells injection
223882256|NCT04351932|BIOLOGICAL|Adipose Mesenchymal stem cells|intrarticular adipose mesenchymal stem cells injection
223882257|NCT04351932|BIOLOGICAL|bone marrow & adipose mesenchymal stem cells injection|intrarticular bone marrow and adipose stem cells injection.
223882258|NCT05858580|BEHAVIORAL|Bennett Kids PowerUP Project|Information targeting dietary and activity behaviors while also identifying and addressing barriers to permanent lifestyle change. The foundation of the curriculum is the Diabetes Prevention Program Lifestyle Balance and its subsequent adaptations for non-Native adult, Native adult, and Native child populations.
223882259|NCT04154384|BEHAVIORAL|Life Care Specialist (LCS) Intervention|The Life Care Specialist (LCS) uses a two-arm approach to education by initially assessing participants general understanding of opioids upon which targeted education is tailored and applied and secondly, building a longitudinal relationship with each patient to increase the saliency of administered opioid education during postoperative follow-up. Information includes proper disposal, common symptoms of opioid use, signs of dependence and overdose and use of naloxone. Information is disseminated orally with adjunct physical resource guides including visual representations and literature.
223882260|NCT04154384|OTHER|Clinical Coordination with Referrals|The Life Care Specialist (LCS) can help arrange a referral for the participant, should a medical or social issue be identified during LCS intervention, including mental health services, addiction medicine services, housing insecurity referrals, food insecurity referrals, and amputee support. When giving referrals, the LCS works closely with physicians and nurses to make sure that the participant is a good fit for the referral program.
223882261|NCT04154384|BEHAVIORAL|Pilot Study of Pain Management Strategies|Orthopedic trauma patients will work with a Life Care Specialist (LCS) and will receive personalized pain management strategies to avoid potential opioid misuse.
223882262|NCT02256254|DRUG|Simvastatin|2 Simvastatin capsules of 20 mg every evening for 14 days
223882263|NCT02256254|DRUG|Placebo|2 placebo capsules every evening for 14 days
223882264|NCT05048186|BEHAVIORAL|Attention Deficit Hyperactivity Disorder Treatment Decision Aid|The parent pre-visit cards from the Cincinnati Children's Hospital's Attention Deficit Hyperactivity Disorder (ADHD) Treatment for School Age Children Decision Aid were used in this study. The 6 pre-visit cards provide an overview of ADHD treatment options, the respective benefits and downsides of each option, and questions to elicit goals/preferences. The four different treatment options presented were: (1) watchful waiting, (2) behavioral treatment, (3) medication treatment, and (4) combined treatment (behavioral and medication together).
223882265|NCT05430880|DIAGNOSTIC_TEST|impact of fluid challenge on the cardiac index and CO2 respiratory parameters analysis (VCO2, EtCO2)|"Preliminary daily data will record: demographic, ventilatory (tidal volume, FiO2, positive expiratory pressure, compliance, respiratory rate, I/E ratio) and biological parameters (fibrinogen, CRP, leukocytes count, PaO2, PvO2, PaCO2, PvCO2, CO2gap, arterial lactate, ScvO2, platelets count)~1. st step CO2 record (between Time-6minutes and T0; T0 corresponding to fluid challenge) VCO2 and EtCO2 (End-tidal CO2) automated measurement by Hamilton module. Average VCO2 obtained before fluid challenge.~   CI (cardiac index): measurement by calibration of the PiCCO module with 3 cold boli.~2. nd step: Crystalloid (ringer lactate) filling 500mL in 5 minutes~3. rd step CO2 record (between T+5min and Time+11minutes): VCO2 and EtCO2: automated measurement by Hamilton module. Average VCO2 obtained after fluid challenge.~CI (cardiac index): measurement by calibration of the PiCCO module with 3 cold boli"
223882266|NCT04301596|OTHER|Collection of data|different set of data will be collected over a 6 months period
223882267|NCT00951379|DRUG|Pioglitazone hydrochloride|Three (3) pioglitazone 15 mg capsules by mouth once daily for 24 weeks (+/- 1 week)
223882268|NCT00951379|OTHER|placebo|Three (3) pioglitazone placebo capsules by mouth once daily for 24 weeks (+/- 1 week)
223882269|NCT00951379|OTHER|laboratory biomarker analysis|Correlative studies
223882270|NCT02467166|DEVICE|Circa™ Probe|The Circa™ probe will be used to monitor esophageal temperature and guide ablation power and duration during the RFCA procedure. Following ablation esophagoscopy will be performed to assess for esophageal lesions.
223882271|NCT04218266|DRUG|BAY2433334|Tablet, taken orally once a day.
223882272|NCT04218266|DRUG|Apixaban|Capsule, taken orally twice a day.
223882273|NCT04218266|OTHER|BAY2433334 matching placebo|Tablet, taken orally once a day.
223882274|NCT04218266|OTHER|Apixaban matching placebo|Capsule, taken orally twice a day.
223882275|NCT00763152|OTHER|Observation of transponder stability|Observation of transponder stability and placement in the prostatic bed following radical prostatectomy
223882276|NCT02755415|DEVICE|HIWIN Robotic Gait Training System|HIWIN Robotic Gait Training System is an automatic training system that combines weight-bearing standing, repetitive stepping and gait training
223882277|NCT02755415|OTHER|Static Standing Table|As part of the standard hospital rehabilitation, static standing table allows patient to be in a fully supported standing position
223882278|NCT00873613|PROCEDURE|Use of Non-dilated retinal photography|Kowa Non-Myd alpha-D Non-dilated fundus camera will be used to obtain photographs.
223882279|NCT01494922|DRUG|EXC 001 (currently called PF-06473871)|Single dose administered by injection at four different times
223882280|NCT00640549|DRUG|Atorvastatin|After a run-in phase of 4 weeks eligible patients were randomized at a ratio of 2 : 1 (atorvastatin : placebo). Patients in the atorvastatin group were treated with atorvastatin 20 mg tablets administered once daily orally for 8 weeks.
223882281|NCT00640549|DRUG|Placebo|After a run-in phase of 4 weeks eligible patients were randomized at a ratio of 2 : 1 (atorvastatin : placebo). Patients in the placebo group were treated with placebo 20 mg tablets administered once daily orally for 8 weeks.
223882282|NCT06077851|DEVICE|Continuously monitoring|Included patients are monitored with WARD equipment the first days after discharge. Monitoring will last for a maximum of three days.
223882283|NCT04005482|OTHER|Rate control|Rate control according to the Atrial fibrillation - ESC Guidelines 2016
223882284|NCT03608787|BEHAVIORAL|S-STOP|Pseudo-intoxicated patrons will enter each participating establishment and attempt to be served an alcoholic beverage. In the intervention phases, feedback on staff performance will be provided to owners/managers along with supporting materials and a link to a website with a video of a typical pseudo-intoxicated patron. Staff will be provided with a link to a website providing tips for preventing overservice.
223882285|NCT05838677|BEHAVIORAL|Pain at Work Toolkit|Online toolkit providing advice and signposting to help people self-manage chronic or persistent pain at work. Access to optional phone call support from an occupational therapist providing individually tailored advice.
223882286|NCT05838677|OTHER|Active control|Treatment as usual which will vary depending on the employing organisation but may include, for example, line manager support, occupational health input etc. Access to optional non-specialist phone call support from a study researcher.
223882287|NCT02444858|BIOLOGICAL|UCMSC group|Human umbilical cord MSCs are transplanted by intravenous injection(5×10\^5/kg) ，once a day,a total of three times.
223882288|NCT02444858|OTHER|Control group(Normal saline)|Normal saline in same volume as MSCs are transplanted to patients.
223882289|NCT03692780|DRUG|Careseng 1370|4,000mg granules in sachet
223882290|NCT03692780|DRUG|Placebo|4,000mg granules in sachet
223882291|NCT02891915|DRUG|Amoxicillin|Amoxicillin is an aminopenicillin antibiotic
223882292|NCT02891915|DRUG|Amoxicillin-clavulanate|A fixed-ratio combination of amoxicillin trihydrate, an aminopenicillin, and potassium clavulanate, a beta-lactamase inhibitor, used to treat a broad-spectrum of bacterial infections, especially resistant strains.
223882293|NCT02891915|DRUG|Cefdinir|Cefdinir is a cephalosporin antibiotic used to treat bacterial infections in many different parts of the body.
223882294|NCT02891915|OTHER|Placebo|Placebo
223882295|NCT01910896|DEVICE|Overnight Intensive Patch|Eligible subjects will have their two scars randomized for OIP application/no treatment. OIP for overnight application (at least 6 hours) for 12 to 24 weeks.
223882296|NCT04103723|PROCEDURE|Preoperative premedication|Every patient with or without a preoperative premedication with midazolam before surgery.
223882297|NCT02226536|BEHAVIORAL|fractioned diet without glucose|Patients were divided into two groups: Diet Group was treated with placebo pills and glucose restrictive and fractionated diet. Control Group received only placebo pills. All individuals had their vestibular function evaluated by Computerized Dynamic Posturography and done visual analogue scale (VAS) in the first day and 30 days after diet intervention
223882298|NCT05237752|DRUG|LG00034053|a pan-caspase inhibitor, as a therapeutic agent of osteoarthritis
223882299|NCT02300675|BEHAVIORAL|therapeutic education program|
223882300|NCT06111924|OTHER|Task oriented circuit training based telerehabilitation|Task oriented circuit training based telerehabilitation (TOCT-TR) via video conference call will be provided for 6 weeks, thrice a week in total18 sessions. Total 15 exercises will be performed by patient in a session of 60 minutes. Duration per exercise will be 3 minutes and a rest interval of 1 will be provided after each exercise.
223882301|NCT06111924|OTHER|Clinic based Task oriented circuit training|Clinic based Task oriented circuit training (TOCT-CR) will be provided in clinic as in person training for 6 weeks, thrice a week in total18 sessions. Total 15 exercises will be performed by patient in a session of 60 minutes. Duration per exercise will be 3 minutes and a rest interval of 1 will be provided after each exercise.
223882302|NCT04362046|PROCEDURE|Hysteroscopic uterine resection|"Hysteroscopic Resection will be evaluated as a fertility-sparing treatment for patients with early Endometrial Cancer or Endometrial Hyperplasia (atypical or persisting typical) who fail progestin therapy. Failure of progesterone therapy is defined as: (a) Unsuccessful eradication of hyperplasia or cancer in the uterus or (b) Intolerance to the side effects of th hormone therapy.~HR is a common gynecologic procedure that is offered to women for treatment of several benign gynecologic conditions. The conduct, risks, and complications of it are well-understood. In relation to this protocol, it is the indication for HR that constitutes the experimental intervention including the assessment of it's outcome. Patients deemed appropriate for hysteroscopic endomyometrial resection will be counselled on the nature of the procedure along with its risks and complications."
223882303|NCT02179268|DRUG|sertraline|50mg, 50-150mg/d,qd for one year
223882304|NCT02179268|DRUG|citalopram|20mg, 20-40mg/d,qd,for one year
223882305|NCT02179268|DRUG|venlafaxine|venlafaxine,25mg, 75-100mg/d, bid, for one year
223882306|NCT02179268|DRUG|reboxetine|reboxetine,4mg, 4-8mg/d,qd for one year
223882307|NCT02179268|BEHAVIORAL|control|50min, every week for three months, every month, for nine months
223882308|NCT00750620|DRUG|YM178|oral
223882309|NCT04749784|DIETARY_SUPPLEMENT|High Dose Arterin Cholesterol|240mg active ingredient daily
223882310|NCT04749784|DIETARY_SUPPLEMENT|Low Dose Arterin Cholesterol|120mg active ingredient daily
223882311|NCT04749784|DIETARY_SUPPLEMENT|Placebo|Placebo tablet
223882312|NCT05871112|OTHER|Use of dynamic tensioner|Assessment of femoral component rotation with a use of a dynamic tensioner in extension and 90 degrees of flexion. The tensioner was put between tibial plane cut and posterior condyles of the femur and tensioned to the same thickness of insert as in the full extension
223882313|NCT03136042|OTHER|physiotherapy techniques|oscillating positive expiratory pressure during nonstop 5 minutes. After that more five minutes to a forced expiratory technique
223882314|NCT03136042|OTHER|hypertonic saline 3%|four nebulizations with 3% hypertonic saline, the aerosol was generated by an ultrasonic nebulizer
223882315|NCT03136042|OTHER|saline + physiotherapy maneuvers|sputum induction by hypertonic saline at 3% for seven minutes. And more five minutes under physiotherapists maneuvers
223882316|NCT03298074|DRUG|Apatinib|Apatinib, 500mg,po qd for continuous administration
223882317|NCT03298074|DRUG|Etoposide|Etoposide,100mg, PO.QD，D1-D10, Q3W
223882318|NCT01091168|DRUG|vinflunine|280 mg/m2 on day 1 of each cycle every 3 weeks
223882319|NCT01091168|DRUG|Alkylating agent of physician choice registered in cancer|cyclophosphamide or melphalan or mitomycin C or thiotepa or cisplatin or carboplatin
223882320|NCT04763200|DEVICE|Impella CP® / Impella CP® with SmartAssist® / Impella 2.5®|Impella CP / Impella CP with SmartAssist will be used in most patients randomized to the Impella arm. Impella 2.5 may be used in patients with small body size (BMI \<20 kg/m2 or body weight \<60 kg) or if the iliofemoral vasculature is able to accommodate the smaller Impella 2.5 device but not the Impella CP device.
223882321|NCT04763200|DEVICE|IABP Intra-aortic balloon pump|IABP uses counterpulsation to provide 0.2L/min coronary flow
223882322|NCT06589258|BIOLOGICAL|Assessing maternal and lactational plasma CBD uptake at different stages of breastfeeding|Determination of delta 9-tetrahydrocannabinol (THC) and its metabolites , and of cannabidiol and its metabolites in blood and breasts-milk by liquid chromatography-tandem mass spectrometry (LC-MS/MS). Realization of THC/CBD ratio; qualitative research in mother's and breast-fed child's urine for the presence of cannabinoids (THC, CBD and its metabolites).
223882323|NCT06985303|COMBINATION_PRODUCT|Investigational Combination Product|This investigational therapy combines a proprietary, human-derived cell-based component with a unique blend of small molecules and an enzyme. The components are designed to work synergistically to address the complex pathology of white matter injury. The therapy aims to provide a source for cellular regeneration, support the survival of existing cells, enhance the potential for myelin repair, and modify the inhibitory environment of glial scar tissue. This multi-pronged biological intervention is designed to promote neural regeneration and functional recovery in patients with PVL.
223882324|NCT05662124|OTHER|Remote monitoring|"Patients will download the patientMpower app and be provided with a spirometer (Spirobank Smart, MIR) and oximeter (Nonin) to record their spirometry and pulse oximetry which will upload to the application via Bluetooth for clinical review.~Patients will be asked to upload measurements three times per week."
223882325|NCT05110053|DEVICE|Spinal Cord Stimulation|"Spinal Cord stimulation. Surgery is done in local anaesthesia. A small electrode is placed in the epidural space corresponding approximately at the Th8-Th10 level.~An impulsegenerator, connected to the electrode, is placed in the subcutaneus fat in the gluteal region."
223882326|NCT06821152|DEVICE|Miss Liberty Condom|The Miss Liberty female condom is manufactured by Zhejiang Rui Bo 001 High Polymer Co, Ltd. The condom is designed as a loose-fitting pouch that lines the vagina. It has two flexible rings. The sheath, are made of polyurethane. The outer ring remains outside the vagina and covers the external genitalia during intercourse. An internal ring is removable and serves as the insertion mechanism and anchors the device within the vagina. Miss Liberty measures 180mm in length and 78mm in lay-flat width. The device is pre-lubricated with silicone oil. This condom is a similar design (material, length, width) to the USFDA approved FC1 female condom which was discontinued and replaced by FC2.
223882327|NCT06821152|DEVICE|FC2 condom|The FC2 is a second-generation female condom manufactured by the Female Health Company (Chicago, IL). The FC2 has US FDA approval and has been granted the CE Mark of the European Union. The FC2 is pre-qualified by the WHO. The condom is designed as a loose-fitting pouch that lines the vagina. It has two flexible rings. The outer ring at the open end is rolled from the nitrile material. The outer ring remains outside the vagina and covers the external genitalia during intercourse. An internal ring is removable and serves as the insertion mechanism and anchors the device within the vagina. FC2 measures 170mm in length and 80mm in lay-flat width. The device is pre-lubricated with silicone oil. This FC is available in the public health sector in South Africa.
223882328|NCT06987669|DIAGNOSTIC_TEST|Gastric Ultrasound|A gastric ultrasound will be performed to determine the state of the stomach. Empty, clear fluids, solid, and in case of fluid, the amount of it ( using free tracing)
223882329|NCT06986824|DEVICE|Pelvic wand|Use of a pelvic wand to perform perineal massage
223882330|NCT06987617|DEVICE|Menopause App|The menopause app facilitates the implementation of multimodal self-management strategies in the daily routines of individuals with a (peri-)menopausal disorder, through tools such as a symptom diary and guided interactive exercises.
223882331|NCT04772300|COMBINATION_PRODUCT|Percutaneous Transluminal Angioplasty (PTA) MagicTouch Sirolimus Coated PTA Balloon Catheter|PTA with an sirolimus drug-coated balloon catheter (SRL-DCB) in the infrapopliteal artery
223882332|NCT04772300|DEVICE|Percutaneous Transluminal Angioplasty (PTA) with non-coated balloon catheter (POBA)|PTA with an non-coated balloon catheter (POBA) in the infrapopliteal artery
223882333|NCT06987097|DRUG|Ambrisentan|After two weeks of initial treatment, the study drugs' dose will be increased to two tablets per day (10 mg/day). If the patient cannot tolerate the increased dose (e.g., experiencing headache, dizziness, palpitations, hypotension, or other drug-related symptoms or signs), the dose will be reduced to 5 mg/day. If the study drug has reached the maximum allowable dose (two tablets/day) and the patient shows signs of worsening PAH or right heart failure, the clinician may decide to add diuretics (with the type and dosage left at the referring physician's discretion). The number and percentage of patients requiring diuretic combination therapy in both groups will be recorded. Other baseline treatment medications will remain unchanged through follow-up duration.
223882334|NCT06987097|DRUG|Placebo|Placebo tablet (one to two tablets corresponding to one to two verum tablets). Administration: Placebo will be administrated orally with or without food intake in the morning.
223882335|NCT06014866|DEVICE|Cardiac pacing|Patient's previously implanted with the INGEVITY+ lead located in the LBBA
223882336|NCT01840566|DRUG|Carmustine|
223882337|NCT01840566|DRUG|Etoposide|
223882338|NCT01840566|DRUG|Cytarabine|
223882339|NCT01840566|DRUG|Melphalan|
223882340|NCT01840566|BIOLOGICAL|Pegfilgrastim|
223882341|NCT01840566|BIOLOGICAL|19-28z T CELLS|
223882342|NCT01840566|PROCEDURE|Autologous Stem Cell Transplantation|
223882343|NCT03651505|OTHER|No intervention|Access to any treatment is through authorized commercial use and not as a part of this DMP
223882344|NCT06071494|OTHER|Tropical fruits|papaya, mango, banana, orange
223882345|NCT04534400|RADIATION|thoracic CT-scan|Automated measurement
223882346|NCT06998043|BIOLOGICAL|BX004|Bacteriophage
223882347|NCT06998043|OTHER|Placebo|Placebo
223882348|NCT06377358|DEVICE|Tecar Therapy|Tecar Therapy at 1Mhz radiofrequency by the use of a C-400 device. The duration of the treatment will be 5 weeks, where 10 sessions will be carried out, 2 per week
223882349|NCT03922035|OTHER|Best Practice|Receive standard peri-/post-transplant supportive care
223882350|NCT03922035|DRUG|Clostridium butyricum CBM 588 Probiotic Strain|Given PO
223882351|NCT07003139|DRUG|B10 L-BPA Injection|The investigational product is B10 L-BPA Injection, is a boron-containing compound in which 10B replaces a position on L-phenylalanine at the para position with dihydroxyboron.
223882352|NCT06866938|DRUG|[177Lu]Lu-PSMA-617 (Pluvicto, Novartis)|"Patients will be treated with intravenous \[177Lu\]Lu-PSMA-617 (Pluvicto, Novartis).~One injection every 6 weeks at the dose of 7.4 GBq (±10%)"
223882353|NCT06871839|DRUG|Lecanemab treatment group|"Lecanemab treatment group: Lecanemab Injection Concentrate Solution (active ingredient at 100 mg/mL) is provided as a sterile aqueous solution containing 100 mg/mL of Lecanemab, 50 mmol/L citric acid, 350 mmol/L arginine/arginine hydrochloride, and 0.05% (w/v) polysorbate 80, with a pH of 5.0, and each vial is capable of being drawn into a volume of 5 mL. Lecanemab is to be administered via intravenous infusion over 60 minutes in saline solution. Lecanemab must be administered using an infusion system that includes a terminal 0.22 μM inline filter. The dosage of Lecanemab is 10 mg/kg.~All subjects in the Lecanemab treatment group receive Lecanemab infusion therapy at a frequency of once every two weeks for a continuous period of 12 months."
223882354|NCT06871839|DRUG|Conventional anti-dementia treatment group|Conventional anti-dementia treatment: Early-stage Alzheimer's disease (AD) patients routinely take cholinesterase inhibitors such as donepezil for treatment.
223882355|NCT07008781|BEHAVIORAL|Youth-led cancer screening intervention|High school students will be trained as health advocates and then facilitate discussions about cancer screening recommendations and risk factors with adults in their community. High school students (15-18 years old) from the local community will be recruited for this study, and each student will recruit adults that they live with or are part of their community (i.e. parent) who are eligible for cancer screening. The adult plus youth dyads will all undergo the same youth-led intervention in which the youth will utilize motivational interviewing to discuss cancer screening recommendations and risk factors with their adults and help their adults enroll in cancer screening through ScreenNJ, a community organization that aims to increase cancer screening in New Jersey, reduce cancer mortality rates, and reduce disparities.
223882356|NCT06626425|OTHER|Healthy Minds Program App|An 8-week meditation-based well-being training containing content for each of the four pillars of the training program: Awareness, Connection, Insight, and Purpose.
223882357|NCT06626425|OTHER|Hydro Coach App|The Hydro Coach app (HC). A smartphone-based wellness app to ensure proper hydration.
223882358|NCT06679244|PROCEDURE|Totally laparoscopic proximal gastrectomy with Hao's esophagogastrostomy by fissure technique|"This is an innovative surgical method applied in proximal gastrectomy. By adding anti reflux structures such as false gastric fundus and false cardia on the basis of esophageal residual gastric anastomosis, the goal of anti reflux is achieved, while maintaining normal physiological channels and fully utilizing residual gastric function, reducing the difficulty of proximal gastrectomy surgery"
223882359|NCT06679244|PROCEDURE|Totally laparoscopic proximal gastrectomy with double-tract reconstruction|This is a traditional surgical method that has been widely used in proximal gastrectomy. After disconnecting the proximal stomach, performing Roux-en-Y anastomosis of the esophagus and jejunum firstly, followed by lateral anastomosis of the residual stomach and jejunum. Previous studies have confirmed its safety and effectiveness, but there are also issues of gastric channel disuse and high missed detection rate of residual stomach.
223882360|NCT03730051|DRUG|Gadoterate meglumine|Participants randomized into this arm will receive gadoterate meglumine contrast for their scheduled breast MRI.
223882361|NCT03730051|DRUG|Gadobutrol|Participants randomized into this arm will receive gadobutrol contrast for their scheduled breast MRI.
223882362|NCT07013214|BEHAVIORAL|Dual-Task Exercise|This intervention consists of exercises that integrate motor tasks (e.g., balance training, walking) with concurrent cognitive tasks (e.g., counting, verbal fluency, decision-making tasks). The progression of exercises will be tailored to the individual's abilities, gradually increasing the difficulty of both the motor and cognitive components.
223882363|NCT07013214|BEHAVIORAL|Standard Rehabilitation|This intervention consists of conventional exercises aimed at improving balance, gait, posture, and flexibility, without the integration of simultaneous cognitive tasks. The program will focus on established physical therapy techniques for Parkinson's disease.
223882364|NCT05928624|DEVICE|Withings Home Blood Pressure Device and Scale|The intervention will be whether the data generated from home monitoring devices are shared with the clinical providers. The investigators are not testing the efficacy of these approved devices.
223882365|NCT05928624|OTHER|Standard of Care|Standard of Care
223882366|NCT05300958|DRUG|Deferoxamine Plus Chemotherapy|Deferoxamine：50mg/kg+500ml normal saline (NS)
223882367|NCT07022132|OTHER|Diaphragmatic myofascial release (DMR)|The physiotherapist, positioned on the head side of the supine patient, makes bilateral contact with the pisiform, hypothenar region and the underside of the 7th-10th costal cartilages with the last three fingers. During the inspiration phase, he/she pulls the contact points cephalically and slightly laterally with both hands, accompanying the elevation of the costae. During expiration, it deepens the contact towards the inner costal margin, maintaining resistance. In subsequent breathing cycles, it gradually increases the depth of contact inside the costal margin. The application is performed in 2 sets of 10 deep breaths with 1 minute between them.
223882368|NCT07022132|OTHER|Abdominal hypopressive exercise (AHE)|Each session consists of 6 hypopressive abdominal exercises with a 2-minute recovery period in between, and each exercise is repeated 3 times. This manoeuvre consists of expelling all air until the reserve volume is reached, then holding the breath (expiratory apnoea) and pulling the abdominal wall inwards and cranially by opening the costae without allowing air to enter. Exercises are performed in 6 different positions.
223882369|NCT07022132|OTHER|Conservative treatment|It consists of lumbar flexion and extension, stretching and strengthening exercises for the waist, back and abdominal region.
223882370|NCT05349474|DRUG|Metformin 500 Mg Oral Tablet, up to 4 tablets a day|Metformin 500 mg oral tablets to be titrated to 2000 mg/day divided over two doses or maximum tolerated dose
223882371|NCT05349474|DRUG|Placebo oral tablet identical to metformin, up to 4 tablets a day|Placebo tablets identical to metformin tablets. To be titrated to four tablets divded over two doses or maximum tolerated dose
223882372|NCT06711627|BEHAVIORAL|Standard of Care (SoC)|Standard recommended nutrition and gestational weight gain counseling.
223882373|NCT06711627|BEHAVIORAL|Food Provision|Standard recommended nutrition and gestational weight gain counseling plus food provision.
223882374|NCT06704074|DEVICE|virtual reality (VR) head mounted display|The participants' in this group were given VR-TOT training under real home scenes created in the platform of Unity. There were 6 VR-TOT tasks, and the task choice was according to the performance of participants' upper limb function. The experienced therapist will guide and monitor the participants and adjust the task if necessary.
223882375|NCT06886659|DRUG|Trastuzumab (proposed Trastuzumab biosimilar)|6 mg/kg single intravenous infusion of Trastuzumab of Incepta Pharmaceuticals Ltd
223882376|NCT06886659|DRUG|Herclon|6 mg/kg single intravenous infusion of Trastuzumab of Roche
223882377|NCT07046767|OTHER|IP1: BioLab Membrane Wrap Lite IP2: BioLab Tri-Membrane Wrap|BioLab Membrane Wrap LiteTM is a human tissue allograft derived from the amniotic membrane that provides structural tissue for use as a wound and protectant covering. Membrane Wrap LiteTM is a single-layer human tissue allograft, containing solely the amnion layer of Amniotic Membrane \[Human Cellular and Tissue Based Product (HCT/P)\] for transplantation regulated by the US Food and Drug Administration under 21 CFR Part 1271.
223882378|NCT07046767|OTHER|IP2: BioLab Tri-Membrane Wrap|BioLab Tri-Membrane WrapTM is a human tissue allograft derived from the amniotic membrane that provides structural tissue for use as a wound and protectant covering. Tri-Membrane WrapTM is a triple-layered human tissue allograft, containing amnion-chorion-amnion layers \[Human Cellular and Tissue Based Product (HCT/P)\] for transplantation regulated by the US Food and Drug Administration under 21 CFR Part 1271.
223882379|NCT06888687|BEHAVIORAL|Dietetic support|Dietary advice will be provided by Accredited Practicing Dietitians (APDs) in line with evidence-based guidelines, specifically the T2DM best-practice guidelines plus Australian Dietary Guidelines (i.e. Australian Guide to Healthy Eating) to improve diet quality, and strategies to promote adherence.
223882380|NCT06888687|DEVICE|Continuous glucose monitoring|Abbott FreeStyle Libre 2+ CGM sensors will be used to provide feedback on interstitial glucose concentrations over 15 day periods per sensor.
223882381|NCT06737510|BEHAVIORAL|Informational brochure on household emergency preparedness|"An informational brochure will be mailed to participants and will cover the following topics: (1) an introduction to why emergency preparedness is important; (2) definition of what a disaster is; (3) family communication plan (including, what is a family communication and evacuation plan, why you should have one, communication plan checklist, family communication card); (4) disaster supplies (including, what types of supplies are needed, how long supplies should last, supply checklist, and storing supplies, including preparing a go bag); and (5) resources (including disaster contact numbers for emergency and non-emergency calls (911 and 311), how to register for emergency notifications (Notify NCY), NYC Emergency Management, as well as a website for additional information on preparedness (NYC.gov/hazards) that includes New York City hurricane evacuation zones ."
223882382|NCT06737510|BEHAVIORAL|Phone-based household emergency preparedness|A phone-based intervention will consist of 15 - 20 minutes discussion covering the following topics: (1) an introduction to why emergency preparedness is important; (2) definition of what a disaster is; (3) family communication plan (including, what is a family communication and evacuation plan, why you should have one, communication plan checklist, including a family communication card); (4) disaster supplies (including, what types of supplies are needed, how long supplies should last, supply checklist, and storing supplies); and (5) resources (including providing NYC Emergency Management website: NYC.gov/hazards, i which includes specific information related to the participants New York City hurricane evacuation zones) .
223882383|NCT07050225|OTHER|Digital Cognitive Training|This digital cognitive training program uses gamified tasks in order to enhance cognitive skills in an engaging manner using machine learning AI algorithms to target the intervention to individual cognitive skill deficits. It consists of personalized gamified cognitive tasks that target individual cognitive deficits associated with ADHD including attention, impulsivity, working memory, and cognitive flexibility.
223882384|NCT07050225|OTHER|Digital Non-cognitive Training Intervention|This is a gamified computer platform lacking cognitive training components.
223882385|NCT07048379|DEVICE|Orthosis|A resting orthosis will be preferred because it keeps the wrist in a neutral position.
223882386|NCT07048379|OTHER|Physical Therapy|Participants will undergo physical therapy for three weeks, including hot packs, TENS, tendon-nerve sliding exercises, stretching and strengthening exercises.
223882387|NCT04774380|DRUG|Durvalumab|Participants will receive durvalumab via IV infusion on Day 1 of each cycle.
223882388|NCT04774380|DRUG|Cisplatin|Participants will receive cisplatin via IV administration on Day 1 of each cycle.
223882389|NCT04774380|DRUG|Carboplatin|Participants will receive carboplatin via IV administration Day 1 of each cycle.
223882390|NCT04774380|DRUG|Etoposide|Participants will receive etoposide via IV administration on days 1 to 3 of each cycle.
223882391|NCT07060781|PROCEDURE|Posterior Lumbar Spine Decompression|Patients undergoing elective posterior lumbar spine decompression.
223882392|NCT07070492|DEVICE|cataract surgery|cataract surgery receiving Vivity IOL or standard mono focal controls
223882393|NCT07070492|PROCEDURE|retinal surgery|Retinal surgery for visually significant epiretinal membrane
223882394|NCT07071389|DIETARY_SUPPLEMENT|Zyxelle|Patients in the study group receive Zyxelle dietary supplement along with the oral contraceptive
223882395|NCT07071389|DRUG|Oral contraceptive|Patients in the study group receive daily dose of estroprogestinic oral contraceptive
223882396|NCT07066631|OTHER|Enhanced Usual Care|Access to online resources and educational materials about general mental health, maternal mental health, depression and anxiety in the pregnancy and postpartum period, and an up-to-date listing of treatment services available in Ontario. These resources are maintained by the MOVIN study team.
223882397|NCT07066631|OTHER|MOVIN Care Platform|Virtual collaborative care intervention with a stepped care approach in which a care coordinator directs participants to one or more evidence-based virtual interventions as appropriate.
223882398|NCT07066631|OTHER|Enhanced Usual Care|Access to online resources and educational materials about general mental health, maternal mental health, depression and anxiety in the pregnancy and postpartum period, and an up-to-date listing of treatment services available in Ontario. These resources are maintained by the MOVIN study team.
223882399|NCT07064954|BIOLOGICAL|Autologous Cold-Stored Platelets|Two units of autologous platelets will be collected via an apheresis machine that draws blood from an intravenous (IV) line over 1-2 hours, isolates and leukoreduces the platelets by centrifugation and returns the remaining blood back to the patients. Collected autologous platelets will be stored at 1-6℃ without agitation until they are needed during or after surgery or 14 days have elapsed since their collection, after which they will be destroyed as per standard institutional procedures for expired blood products. For the first two platelet orders within 24 hours of cardiopulmonary bypass (CPB) termination, patients will receive their autologous cold-stored platelets. For the third and subsequent doses, patients in the intervention group will receive allogeneic room temperature-stored platelets (standard of care).
223882400|NCT07064954|BIOLOGICAL|Allogeneic Room Temperature-Stored Platelets (Standard of Care)|Allogeneic platelets will be collected by Canadian Blood Services as per their standard operating procedures. Room temperature stored platelets will be stored at 20-24°C with constant agitation for up to 7 days as per current practices. For any platelet orders within 24 hours of cardiopulmonary bypass (CPB) termination, patients in the control group will receive allogeneic platelets as per usual care.
223882401|NCT07072429|PROCEDURE|Gastric cancer resection|Any kind of surgical gastric cancer resection
223882402|NCT06767566|DRUG|Ketamine (Ketalar)|Loading Dose: 0.18 mg/kg/hr x 1 hour; Maintenance Dose 0.05 mg/kg/hr x 11 hours
223882403|NCT06900764|DRUG|CAR-T cell|CAR-T cell
223882404|NCT06901011|PROCEDURE|continuous renal replacement therapy|"Intervention Arm: Effluent dose schedule of 10-20 ml/kg/h after 48 hours of starting dose of 25-35 ml/kg/h, until completing 96 hours~Control Arm Effluent dosage schedule of 25-35 ml/kg/h fixed for 96 hours"
223882405|NCT07071935|DEVICE|Non-invasive ventilation|Non-invasive ventilation will be started earlier than usual respiratory care guidelines for ALS in the United States.
223882406|NCT07071896|OTHER|16 weeks remotely exercise program|16 weeks, twice per week, remotely exercise program
223882407|NCT07070154|BEHAVIORAL|text-messaging based intervention|The 6-week, culture specific, text-messaging based cessation intervention for young adults in Hong Kong consists of 6 sessions: 1) Programme overview, 2) Psychoeducation on the health risks, 3) Social support, 4) Stress management, 5) Craving and withdrawal symptoms management, and 6) Summary and relapse prevention.
223882408|NCT07071545|BEHAVIORAL|Regular physical activity|Moderate-to-vigorous physical activity at least three times per week.
223882409|NCT07071545|BEHAVIORAL|No regular physical activity|The group that did not engage in physical activity according to the guidelines
223882410|NCT07072416|OTHER|Aquatic Exercise|Aquatic exercise or hydrotherapy, involving the performance of physical exercise in water, has been determined to have an assortment of beneficial health impacts on healthy individuals and those with chronic diseases. Aquatic exercise has been determined to enhance strength, balance, flexibility, and the quality of life, particularly among groups like postmenopausal women, patients with osteoarthritis, Parkinson's disease, and type 2 diabetes
223882411|NCT07072416|OTHER|Mirror Therapy|Mirror therapy is a type of rehabilitation where visual feedback is employed to induce movement and recovery in an affected limb by asking the patients to observe the reflection of their healthy limb in a mirror, giving the illusion that both limbs are moving normally.
223882412|NCT07072416|OTHER|Designed physical therapy program.|The program will start with 10 minutes of poolside exercises including warming up, active range of motion and stretching followed by 20 minutes of aquatic exercise in the pool. The pool session consists of 20 minutes of active range of motion, stretching and strengthening exercises
223882413|NCT06884826|PROCEDURE|Desarda technique|Patients will undergo Desarda technique.
223882414|NCT07071610|DRUG|LNK01004 ointment 0.3%|LNK01004 ointment 0.3% BID
223882415|NCT07071610|DRUG|LNK01004 ointment 1.0%|LNK01004 ointment 1.0% BID
223882416|NCT07071610|DRUG|Vehicle|vehicle BID
223882417|NCT07072871|DIETARY_SUPPLEMENT|Lactiplantibacillus plantarum DAD-13|A probiotic supplement (Vipilac®) containing Lactiplantibacillus plantarum DAD-13 administered orally via nasogastric tube, 2 capsules daily for 4 days, intended to modulate immune response and support gut microbiota in ICU sepsis patients.
223882418|NCT07072871|DRUG|Placebo|Placebo capsules containing maltodextrin administered via nasogastric tube (NGT), identical in appearance and schedule to the probiotic group (2 capsules/day for 4 days), alongside standard sepsis care.
223882419|NCT06440135|DRUG|Ziftomenib|Taken orally once per day
223882420|NCT07075588|BEHAVIORAL|iTHRIVE intervention|"Integration of three traditionally siloed components:~1. Digitally enabled food access~2. Personalized nutrition support~3. Clinical care-rision of home blood pressure device with app"
223882421|NCT07075588|BEHAVIORAL|Active comparator|"Active comparator arm will receive enhanced usual care that consists of:~1. Standard produce bag~2. Home blood pressure Device without app~3. General dietary advice"
223882422|NCT07074730|OTHER|Spinal anesthesia|Patients will receive spinal anesthesia with local anesthetic infiltration.
223882423|NCT07074730|OTHER|General anesthesia|Patients will receive general anesthesia.
223882424|NCT07071597|PROCEDURE|Renal Biopsy|Renal biopsy is performed to clarify the renal pathology.
223882425|NCT07075718|DRUG|Gen 2 Travoprost Intracameral Implant|travoprost
223882426|NCT07075718|DRUG|Timolol eye drops 0.5%|timolol 0.5%
223882427|NCT07075718|PROCEDURE|Sham Procedure|sham implant administration
223882428|NCT07075718|OTHER|Placebo eye drops|artificial tears
223882429|NCT07077876|PROCEDURE|Hysteroscopic Resection and Hormonal Therapy|Patients underwent hysteroscopic resection of atypical endometrial hyperplasia (AEH) or grade 1-2 endometrial adenocarcinoma (EAC) using a 15 Fr mini-resectoscope. Depending on the case, the procedure included visual D\&C or a combined technique. At the end of the procedure, a 52 mg levonorgestrel-releasing intrauterine device (LNG-IUD) was inserted. In patients with EAC G2 or poor prognostic markers (e.g., MMR deficiency), oral progestin therapy with Megestrol Acetate (160 mg daily) was added. Follow-up included hysteroscopic endometrial biopsy at 3, 6, and 12 months to assess response.
223882430|NCT07078227|OTHER|No intervention is used.|No intervention is used.
223882431|NCT07077057|DIAGNOSTIC_TEST|AI-assisted ECG interpretation (PMcardio)|Participants in the experimental arm will undergo 12-lead ECG interpretation supported by a CE-marked artificial intelligence (AI) tool (PMcardio, Powerful Medical, Slovakia). The AI algorithm analyzes ECG data in real time to detect patterns suggestive of occlusion myocardial infarction (OMI), including cases not meeting traditional ST-elevation myocardial infarction (STEMI) criteria. In the experimental arm, the AI output is provided immediately to the treating clinician and used as an adjunct to standard ECG interpretation to support timely diagnosis and management decisions.
223882432|NCT07078526|OTHER|Otago Exercise Program|The Otago Exercise Program is a structured, progressive exercise regimen focusing on lower limb strengthening and balance retraining. It is performed twice weekly for six weeks under physiotherapist supervision, complementing standard physiotherapy care.
223882433|NCT07078526|OTHER|Neuromuscular Exercise|The neuromuscular exercise intervention involves functional, proprioceptive, and balance exercises delivered twice weekly for six weeks under supervision, in addition to standard physiotherapy care.
223882434|NCT07076641|PROCEDURE|rachi morphine anesthesia|Morphine spinal anesthesia is administered before general anesthesia, just after the patient has been admitted to the operating room.
223882435|NCT07076641|PROCEDURE|laparotomy|major digestive or abdominal surgery by laparotomy
223882436|NCT07076641|DRUG|Lidocaine IV|KABI 20 mg/mL solution for injection (ready-to-use ampoule, no dilution). Each ml of solution contains 20 mg lidocaine hydrochloride (monohydrate form), corresponding to 16.22 mg lidocaine.
223882437|NCT07076641|DRUG|Placebo|Sodium chloride (NaCl) FRESENIUS 0.9% solution for infusion. Each ml contains 9 mg sodium chloride.
223882438|NCT07076641|DRUG|MORPHINE|The auxiliary drug on which both experimental strategies are based is MORPHINE: Morphine hydrochloride AGUETTANT 0.1 mg/mL Solution for injection (ready-to-use ampoule) for rachi anesthesia.
223882439|NCT07076719|DIAGNOSTIC_TEST|Trophectoderm (TE) Biopsy|"* Blastocyst Grading: Blastocyst grading was based on criteria that classified embryos as good, fair, or poor using the simplified SART embryo scoring system (Heitmann et al., 2013):~  * Good: AA or AB.~ * Fair: BA, BB, BC.~ * Poor: CB or CC.~* Biopsy Criteria: TE biopsy was performed when an embryo had at least one grade B or better for either the ICM or TE on day 5 of development. When no good-quality blastocysts were available in the same cohort, CC grade blastocysts were biopsied.~* Biopsy Procedure: 5-8 cells were laser-biopsied from the TE. These cells were then rinsed and tubed for PGT.~* Cryopreservation: The biopsied embryo was cryopreserved by vitrification (Ref. 90133, Vit Kit-Freeze, Irvine Scientific, Santa Ana, USA) (Richardson et al., 2015)."
223882440|NCT07076719|DIAGNOSTIC_TEST|Non-invasive Preimplantation Genetic Diagnosis|"* DNA Contamination Minimization:~  o SCM was harvested after embryo culture with care taken not to include cellular material.~* Sample Storage:~* Processing for Genetic Analysis:~  6\. DNA Extraction and Sample Preparation 7. Microarray Comparative Genomic Hybridization (aCGH)~* Chromosomal Assessment:~* BAC-chip Slides:~* Labeling and Hybridization:~* Scanning and Data Acquisition:~* Data Processing and Analysis:~  8\. Validation and Quality Control~* Robust quality control measures included:"
223882441|NCT07078617|OTHER|Proprioceptive Neuromuscular Facilitation|PNF technique given for 3-4 days/week and electrical stimulation of DL-2 stimulator with 90 repetitions on each motor point of facial muscle for 3-4 days/week.
223882442|NCT07078617|OTHER|Soft Tissue Mobilization along with exercise|Soft tissue mobilization along with facial exercise 3- days/ week and electrical stimulation of DL-2 stimulator with 90 repetitions on each motor point of facial muscle for 3-4 days/week.
223882443|NCT07077577|PROCEDURE|Holistic Birth Approach|Holistic Birth Approach involves use of non pharmacological techniques for better labor process management with less experience of pain, fear and maternal satisfaction to women delivering the baby through normal delivery method.
223882444|NCT07076953|OTHER|Cherry Seed Massage Group|In the third stage of labor, a cherry pit massage was applied for 15 minutes in the first and second hours. Cherry pits were added to a silk bag to prevent damage to the skin during the massage. The massage application steps were applied as indicated in the hand massage
223882445|NCT07076953|OTHER|Manual Breast Massage|"Manual massage was applied for 15 minutes during the third stage of labor, first and second hour.Manual breast massage steps; Step 1: The breast tissue under and near the armpit is compressed and released like a water pump.~Step 2: Pressure is applied to the breast tissue. Step 3: The breasts are massaged using the fingers and pressed with small circular movements. It is moved clockwise and counterclockwise around the breast and towards the areola with light touches.~Step 4: Both hands are placed under the breast; the breast is moved up and down, left and right, forward and backward.~Step 5: One hand is placed under the breast and the other hand is on the breast; the hands are moved in the opposite direction and a rolling motion is applied to the breast."
223882446|NCT07079202|OTHER|kinetic control|Kinetic Control uses the Movement Control Rating System based on motor tests, the purpose of which is to identify the place and direction of uncontrolled movements and exercises to re-educate motor control
223882447|NCT07079202|OTHER|Conventional physical therapy.|This group received only conventional physical therapy. ( TENS, hot backs, Ultrasound,Nerve mobilization ) three sessions per week for 6 weeks.
223882448|NCT07078084|BEHAVIORAL|Laterality Training|Participants complete a structured laterality training session using a tablet-based application that presents images of hands or feet. Depending on their pain location (shoulder or knee), participants identify whether each image shows a left or right body part. The session consists of 5 one-minute training bouts with 60-second rest intervals between each. The task is designed to engage and retrain cortical body maps associated with the painful region, based on principles of graded motor imagery. Participants are instructed to prioritize accuracy over speed.
223882449|NCT07078084|OTHER|Sham (No Treatment)|Participants in this arm will complete a non-therapeutic cognitive activity by working independently on a standard word-based crossword puzzle for 10 minutes. This task is designed to match the duration and engagement level of the laterality training without influencing sensorimotor processing or cortical body maps. It serves as a sham comparator to help isolate the specific effects of the laterality training intervention.
223882450|NCT07076602|OTHER|Gait and energy expenditure|"SESSION 1:~Physiotherapy assessment: clinical parameters, length of limb segments, range of motion of the lower limbs, muscle strength of each lower limb joint and trunk.~Measurement of energy expenditure:~6-minute walking test with prosthesis, at a constant submaximal speed, with portable gas exchange analyzer to measure oxygen consumption and a connected device to calculate the Physiological Cost Index.~* During test: recording of heart rate at the start, each minute, at the end then 5 minutes after the end, recording of the effort perceived by the child each minute (Borg scale)~* At the end : questionnaire to assess child level of acceptability regarding the measurement of the O2 (Oxygen) consumption~SESSION 2:~Measurement of kinematic parameters by gait analysis: the child will be requested to walk with their prosthesis and shoes at spontaneous speed and at maximal gait speed.~The second measurement of energy expenditure will be conducted using the same procedure as the first."
223882451|NCT07076784|DRUG|Icariin|Topical application of 3% icariin solution
223882452|NCT07076784|DRUG|Vehicle Control|Topical application of 3% ethanol solution
223882453|NCT07077603|OTHER|A12 week, twice weekly, small group, online yoga program|A 12 week, twice weekly, small group, online yoga program
223882454|NCT07078279|DEVICE|immersive virtual reality intervention with Meta Quest 3|"The intervention consists of a rehabilitation program based on Immersive Virtual Reality (IVR), specifically designed to improve functional balance in children and adolescents with GMFCS levels III and IV cerebral palsy, between 5 and 20 years of age.~The Meta Quest 3 device will be used, a standalone, wireless, high-definition immersive virtual reality system. This device allows the user to fully immerse themselves in interactive virtual environments, blocking out external stimuli and offering an immersive, motivating, and controlled experience."
223882455|NCT07078279|OTHER|Intervention with Conventional Balance Physical Therapy|"The Control Group (CG) will receive a standardized conventional physical therapy program focused on balance training, with the goal of improving postural and functional control in children and adolescents with GMFCS levels III and IV cerebral palsy, between 5 and 20 years of age.~This treatment is based on traditional exercises recognized within pediatric physical therapy for balance training and is designed to be comparable in time, frequency, and intensity to the experimental group (virtual reality), but without the use of immersive technology."
223882456|NCT07072403|DRUG|Trametinib tablet|Drug is supplied in 0.5 mg and 2 mg tablets
223882457|NCT07076381|BEHAVIORAL|Brief and solutions-therapy intervention|"Parents will receive three phone counseling sessions over Zoom of 45-60 minutes each from a counselor when their baby is 4-6 weeks old; 10-12 weeks old, and 16-20 weeks old. The date and time of the sessions will be coordinated by phone or e-mail between the parent and their counselor in the week preceding the call. Following their session, parents in this group will receive a brief satisfaction survey over e-mail (Appendix E) that they will be asked to complete within 72 hours."
223882458|NCT07077525|COMBINATION_PRODUCT|Dapagliflozin + Metformin|70 patients with T2DM were treated once daily with Dapa plus Met combination (Dapavildactin plus®, Liptis Pharmaceuticals, Egypt) in a dose titrated from 5 mg Dapa and 1000 mg Met up to a maximum of 10 mg Dapa and 2000 mg metformin as per the standard of care in a physician's practice
223882459|NCT07077525|COMBINATION_PRODUCT|Vildagliptin + Metformin|126 patients with T2DM were treated with Vilda plus Met combination (Gliptus plus®, EVA pharma, Egypt ) in initial daily dose of 50 mg Vilda and 500 mg Met . The medication is titrated gradually up to Vilda 50 mg and metformin 1000 mg twice daily as per the standard of care in a physician's practice
223882460|NCT07078552|OTHER|ptosis|no intervention
223882461|NCT07078409|BEHAVIORAL|Nudge|When the clinician who ordered the imaging that led to randomization receives the test results, a pre-checked referral order to gynecologic oncology for surgical evaluation will appear in the EHR alongside a brief educational explanation. This will constitute the opt-out default referral order (Figure 3). Clinicians will have the option to unclick the referral to opt out and will be asked to indicate the reason from a pre-populated list of choices; if they do not opt out, the referral to gynecologic oncology will proceed. Imaging findings and referral will be communicated to the patient in keeping with the clinician's usual practice. In keeping with routine practice, referred patients will be contacted by gynecologic oncology's new patient coordinators within 72 hours and offered an appointment within 2 weeks at their preferred location.
223882462|NCT07077473|DRUG|real word drugs|real word drugs
223882463|NCT07076836|DEVICE|Acupuncture|The electroacupuncture parameters were set as follows: frequency at 10 Hz, current intensity at 0.5 mA, pulse width at 50 μs, and each session lasted 30 minutes. On the first day of chemotherapy, electroacupuncture was administered 1-2 hours prior to chemotherapy initiation. From Day 2 to the final day of chemotherapy, electroacupuncture sessions were conducted daily between 2:00 PM and 4:00 PM.
223882464|NCT07076836|DEVICE|sham acupuncture|The sham electroacupuncture group referenced the same acupoints as the electroacupuncture group, but the false acupoint shallow needling method and false electrode method are used, and the treatment time and course are the same as the electroacupuncture group.
223882465|NCT07069881|DEVICE|Sonic-Activated Irrigation|Sonic-activated irrigation was performed using the polymer tip (Eddy™, VDW, Germany) activated by an airscaler handpiece.
223882466|NCT07069881|DEVICE|Passive Ultrasonic Irrigation|Passive ultrasonic irrigation was performed using the ultrasonic tip (ACTEON, France) attached to an ultrasonic device (P5 Newton™, ACTEON, France)
223882467|NCT07076823|DRUG|Canagliflozin|Low-dose cohort: 100 mg qd, taken before the first meal of the day. High-dose cohort: Starting dose of 100 mg qd for 1 week. If tolerated, the dose will escalate to 300 mg qd, taken before the first meal of the day.
223882468|NCT07076368|DRUG|Ropivacaine + Fentanyl|A standard epidural admixture - 0.1% Ropivacaine + 2 mcg/ml fentanyl - will be used.
223882469|NCT07078201|DRUG|Dexmedetomidine|patients received 3 mL volume of 0.5% hyperbaric bupivacaine and 4 µg dexmedetomidine in 0.5 mL of normal saline intrathecal (dexmedetomidine 100 µg/mL diluted in 12.5 ml preservative-free normal saline, 0.5 ml had been withdrawn).
223882470|NCT07078201|DRUG|fentanyl|patients received 3 mL volume of 0.5% hyperbaric bupivacaine with 25 µg fentanyl (0.5 mL) intrathecal.
223882471|NCT07078214|OTHER|Foot Sole Surface Area Measurements|The child's TWB was measured using the BTS P-Walk platform \[2440x740x8 mm, 12,000 sensors\] with an additional 500mm sensor-free mat for accurate start/end measurements. The system focused on foot-ground contact surface area data.Before measurements, the child familiarized herself with the platform through play. All walks were barefoot, with at least 3 attempts per assessment and the clearest data selected. To encourage platform crossing, the child carried a small object to her mother waiting opposite. To prevent upper extremity interference with gait, only return walks (without object) were analyzed for measurement.
223882472|NCT07078214|OTHER|Walking Exercise Program and Implementation Process|The backward walking exercise program was performed on a treadmill at 1±0.2 km/h speed, conducted 5 days per week between 14:00-15:00 hours when the child was most alert according to maternal reports. Initially planned for minimum 5-minute sessions with gradual increases, but the child's short attention span and unfamiliarity with backward walking limited sessions to 3 minutes during first two days. Favorite cartoons displayed via tablet during sessions successfully enabled gradual time increases. Week 1 progressed from 3-5 minutes daily. Weeks 2-5 showed progressive increases to 6-9 minutes with sessions increased to 2 daily, separated by 10-15 minute play breaks. From week 6 onwards, two 10±0.2 minute sessions continued daily. Starting week 3, sessions were restructured as 5 minutes backward + 1 minute forward + 2-7 minutes backward walking to combat attention deficits after 5 minutes, improving exercise efficiency.
223882473|NCT07077772|DRUG|Furosemide intravenous titration based on natriuresis|"Furosemide IV, 20 mg starting dose, titrated every 6 hours based on urinary sodium measured by the LAQUAtwin NA-11 device.~Urine output will be measured and recorded every 4 hours to ensure accurate diuresis tracking.~If natriuresis is \< 70 mmol/L, the furosemide dose will be doubled, with a maximum limit of 200 mg per bolus.~If natriuresis is ≥ 70 mmol/L, the current dose will be maintained.~Blood electrolyte panels and renal function assessments will be performed twice daily throughout the protocol.~In the event of hemodynamic instability, a complete echocardiographic assessment will be performed for all patients to detect potential surgical complications, along with a hemodynamic evaluation to guide appropriate management."
223882474|NCT07077772|DRUG|Furosemide intravenous titration based on clinical examination|"Furosemide IV, 20 mg starting dose, titrated every 6 hours clinical evaluation.~Urine output will be measured and recorded every 4 hours to ensure accurate diuresis tracking.~The furosemide dosage will be adjusted based on urine output with a maximum bolus dose of 200 mg. Dose adjustments will be reassessed every 6 hours throughout the study period.~Blood electrolyte panels and renal function assessments will be performed twice daily throughout the protocol.~In the event of hemodynamic instability, a complete echocardiographic assessment will be performed for all patients to detect potential surgical complications, along with a hemodynamic evaluation to guide appropriate management."
223882475|NCT07076511|OTHER|"Scenario unexpected difficult airway"|"Participants are asked to solve a scenario unexpected difficult airway using a manikin in accordance with current guidelines. The scenario aims for participants to try 3 different techniques in securing the airway before performing emergency front of neck access."
223882476|NCT07077252|DRUG|SCTB39G|SCTB39G,IV
223882477|NCT07078474|OTHER|Topical Hyaluronic Acid|Hyaluronic acid was applied topically to the facial skin of healthy participants once daily for a period of 3 weeks. Two application methods were used: on dry skin and on pre-moistened skin. Skin measurements were performed at baseline and after each week of intervention (Week 1, Week 2, and Week 3) to assess hydration and other skin parameters.
223882478|NCT07077824|PROCEDURE|Stellate Ganglion Block Injection with Bupivicaine|Patients will receive left stellate ganglion block US guided after induction of anesthesia and intubation and after insertion of Rt IJV CVL and before skin incision
223882479|NCT07078422|DEVICE|Encora Pulse|"The proposed therapeutic device is a wristband that delivers personalized therapeutic relief to users by adjusting parameters of mechanical vibration, tailored to each individual user's tremor. It measures and characterizes users' upper limb tremor before determining what parameters of mechanical vibration should be applied to stimulate the sensory neurons on the wrist.~This study will not be conducted under IDE. It is a non-significant risk due to the non-invasive nature of mechanical vibration."
223882480|NCT07078929|BIOLOGICAL|CD19-IL7Ra CAR-T cells|Autologous T cells lentiviral transduced to express a CD19-specific chimeric antigen receptor (CAR) with the addition of an IL-7 receptor alpha signaling domain, administered via central venous access catheter after lymphodepletion
223882481|NCT07076550|DRUG|[225Ac]Ac-A9-3408|Administered IV
223882482|NCT07076550|DIAGNOSTIC_TEST|[68Ga]Ga-A9T-3202|Administered IV
223882483|NCT07077967|PROCEDURE|Phacoemulsification with EDOF IOLs|Uneventful pseudophakic presbyopic correction with EDOF IOLs
223882484|NCT07076537|DIETARY_SUPPLEMENT|Placebo|Placebo
223882485|NCT07076537|DIETARY_SUPPLEMENT|Dietary Supplement with actives|Dietary Supplement containing magnesium, L-theanine and lemon balm extract
223882486|NCT07079137|OTHER|History, examination, bite documentation, SSS scoring,Baseline labs as per institutional protocol|"Following enrollment, an initial clinical assessment will be conducted in the Emergency Department (ED). This includes history taking, physical examination, documentation of bite characteristics, and calculation of the Snakebite Severity Score (SSS) at presentation. Baseline laboratory investigations will be performed as per institutional protocol.~All participants will undergo serial clinical and laboratory monitoring as per institutional protocol. The development of syndrome-specific core outcomes, including neurotoxicity, haemotoxicity, coagulopathy, local tissue damage, acute kidney injury, and hypotension (Annexure) would be followed-up and evaluations will be conducted at the following time points:~At presentation, Within 3 hours of ED admission, Within 6 hours of ED admission, Within 12 hours of ED admission"
223882487|NCT07077837|OTHER|Study Group|received perceptual learning using plantar hardness discrimination and conventional treatment
223882488|NCT07077837|OTHER|Control|received conventional treatment (balance exercise functional care training
223882489|NCT07077356|BIOLOGICAL|HBV mRNA vaccine|HBV mRNA vaccine
223882490|NCT07076667|OTHER|Benson's relaxation technique|effects of Benson's relaxation technique 5 days per week for 45 minutes for 8 weeks
223882491|NCT07076667|OTHER|Tai Chi|Tai Chi 5 days per week for 45 minutes for 8 weeks
223882492|NCT07076225|DRUG|Bedaquiline (B)|The initial dose of bedaquiline is 400 mg daily for 2 weeks, followed by 200 mg three times a week.
223882493|NCT07076225|DRUG|Sitafloxacin (S)|200mg once daily
223882494|NCT07076225|DRUG|Linezolid (L)|600mg once daily
223882495|NCT07076225|DRUG|Pyrazinamide (Z)|20-30 mg/kg/day; 1000 mg for patients weighing \<50 kg, 1500 mg for patients weighing ≥50 kg but \<75 kg, and 2000 mg for patients weighing ≥75 kg.
223882496|NCT07076225|DRUG|Isoniazid (H)|4-6 mg/kg once daily, 300 mg once daily
223882497|NCT07076225|DRUG|Rifampicin (R)|8-12 mg/kg once daily, 450 mg for patients weighing \<50 kg, 600 mg for patients weighing ≥50 kg but \<75 kg, and 750 mg for patients weighing ≥75 kg.
223882498|NCT07076225|DRUG|Ethambutol (E)|15-25 mg/kg once daily, 750 mg once daily
223882499|NCT07078032|DIAGNOSTIC_TEST|Prediction Model Arm|Lung cancer risk stratification via prediction model integrating: advanced age, lung cancer family history, personal cancer history, childhood coal exposure, asthma history, and food allergy history. High-risk individuals receive LDCT screening. Thoracic physicians guide management of screen-positive cases.
223882500|NCT07078032|DIAGNOSTIC_TEST|Standard Screening Arm|Participants are screened based on NCCN guideline criteria. High-risk individuals receive LDCT screening. Thoracic physicians guide management of screen-positive cases.
223882501|NCT07076303|DEVICE|Direct Selective Laser Trabuloplasty|Eligible participants will undergo the DSLT procedure to facilitate controlled aqueous outflow. DSLT will consist of 120 shots, 400 µm spot size, energy 1.4-1.8 mJ delivered at the limbus over 2.4 seconds
223882502|NCT07076485|RADIATION|Ultrahypofractionated radiation|Given by infusion
223882503|NCT07076485|RADIATION|Moderately hypofractionated radiation|Given by infusion
223882504|NCT07077590|BEHAVIORAL|Open Label Placebo|Any woman who arrive to the labor room is connected to fluids (Hartman's solution), as part of routine care. The study intervention (open placebo) is based on injection of placebo into an infusion bag accompanied by a verbal suggustion. The placebo is 5 ml NaCl 0.9%.
223882505|NCT07078383|DEVICE|Rapidlink|The Rapidlink implant is comprised of a Gelweave graft section (gelatin-sealed woven polyester) attached to a stented section (which utilizes nitinol ring stents), with a 'cuff'' feature joined to the stented section of the implant. The implant is supplied pre-loaded in a single use delivery system which compacts the stented section within a polytetrafluoroethylene (PTFE) sheath at the front of the system.
223882506|NCT07077044|DEVICE|The transcutaneous posterior tibial nerve stimulation device|In addition to their conventional treatment, subjects in both TTNS groups will complete eight weeks of home TTNS treatment (3 sessions per week), and each session will last for 20 minutes. Stimulation will be provided by a portable device (Chattanooga®, ContinuumTM, Hixson, TN, USA). The device will be pre-programmed to apply a bi-phasic squared wave with a pulse width of 200μsec, and a pulse frequency of 20 Hz. These are default settings for TTNS that have been used in previous studies for urinary and fecal incontinence59,62,67. Two self-adhesive electrodes (5 x 5 cm) will be placed over the ankle area, one approximately 3 to 4 cm above the medial tibial malleolus and a second electrode just below the medial malleolus of the same leg.
223882507|NCT07077044|OTHER|PSUS|Handheld US
223882508|NCT07078305|DRUG|Regorafenib and tislelizumab|Tislelizumab: 200mg, iv, d1, Q3W; Regorafenib: 40-120mg, po, qd, d1-21, d22-d28 discontinuation Q4W
223882509|NCT07078305|DRUG|Regorafenib|Regorafenib: 40-120mg, po, qd, d1-21, d22-d28 discontinuation Q4W
223882510|NCT07077291|BEHAVIORAL|Mindfulness-Based Cognitive Therapy (MBCT)|A group intervention delivered by a psychiatrist and two assistants. Sessions were 120 minutes, once per week, for 12 weeks. Content included mindfulness exercises such as 3-minute breathing space, body scanning, mindfulness walking, meditation, and cognitive therapy techniques to observe connections between thoughts, emotions, and behavior.
223882511|NCT07077291|DRUG|Escitalopram Hydrobromide|Oral administration of escitalopram hydrobromide tablets, 20mg once daily (qd) for the entire 12-week study duration.
223882512|NCT07077369|BIOLOGICAL|WGc-0201 injection|WGc-0201 injection
223882513|NCT07077369|DRUG|Tislelizumab|Tislelizumab, 200mg
223882514|NCT07076589|PROCEDURE|FURS|FURS using traditional UAS \& FANS
223882515|NCT07078162|OTHER|Photogramety Orbital Prosthesis|Using 2D photographs to abtain 3D model of orbital defect anatomy
223882516|NCT07078162|OTHER|Conventional impression prosthesis|Conventional impression to an orbital defect then scaning the impression using desktop scanner
223882517|NCT07077798|DRUG|Sintilimab|Patient receives first adjuvant sintilimab 2-4 weeks postoperatively, 200 mg IV, every 21 days for a total of 8 cycles
223882518|NCT07077798|DRUG|Lenvatinib|lenvatinib is initiated orally(12 mg for body weight \&gt;= 60kg, 8 mg for body weight \&lt; 60kg daily), 2-4 weeks postoperatively for 6 months.
223882519|NCT07079059|OTHER|Virtual Reality Training|One hour of virtual reality training to be included in students' Anesthesia training prior to the start of their Anesthesia rotation.
223882520|NCT03559049|DRUG|Pembrolizumab|200mg IV every 21 days
223882521|NCT03559049|DRUG|Pemetrexed|500mg/m\^2 IV every 21 days
223882522|NCT03559049|DRUG|Carboplatin|AUC 5 IV every 21 days
223882523|NCT03559049|DRUG|Rucaparib|600mg PO, BID days 1-21 of each 21 day cycle
223882524|NCT07077135|DEVICE|stimulated group|Participants will be randomly assigned to receive either taVNS applied to the tragus of the ear or a sham stimulation from the time of randomization for 90 days. Active simulations will be carried out daily using the Parasym device for 60 minutes twice daily during the acute phase (two sessions, one in the morning and one in the afternoon), and once daily (single session) during the rehabilitation phase. The stimulation waveform includes trains of pulses with widths of 200 µs and repetition rate of 20 Hz (Nurosym proprietary waveform); current delivery will be set at a predefined therapeutic level below 0.25 W/cm² (Watts per centimeter squared), that being the defined risk threshold for a thermal burn. The device adjusts stimulation intensity at 0.8 mA steps; the starting intensity will be set at 16 mA (level 20).
223882525|NCT07077135|DEVICE|Sham (No Treatment)|The sham stimulation involves placing the electrode on the same site without delivering any electrical current. The device will be applied to the tragus without electrical current delivered from the time of randomization for 90 days (i.e., the time of randomization coincides with the first stimulation session).
223882526|NCT07076654|DRUG|Caffeine (200 mg)|Oral caffeine will be given as 200 mg before spinal anesthesia
223882527|NCT07076654|DRUG|Placebo|Patient at this arm will receive placebo
223882528|NCT06816693|BEHAVIORAL|tele-CR program|Following the completion of basic characteristics assessment prior to discharge, a 12 weeks tele-CR program was implemented for all participants. The tele-CR program is divided into three parts: motivational interview, App delivery, and self-management and tracking. The motivational interviewing during hospitalization, which involved evaluating individual risk factors, setting behavioral goals, and providing training on the installation and operation of the tele-CR App (approximately 30-60 minutes per session). After discharge, the researchers monitored App usage and conducted four follow-up sessions via LINE or telephone at 1, 4, 8, and 12 weeks post-discharge. These follow-ups, lasting approximately 5-15 minutes each, aimed to assess patients' living conditions, resolve any issues promptly, and provide encouragement or praise based on their engagement with the App.
223882529|NCT06842303|DEVICE|Magnetic resonance elastography (MRE).|Magnetic resonance elastography (MRE) is an imaging technique that measures tissue stiffness by assessing the deformation waves produced under external pressure
223882530|NCT06842303|DEVICE|High-resolution diffusion sequence in MRI|High-resolution diffusion sequence in MRI is an imaging technique that uses the movement of water molecules within tissues to generate detailed images.
223882531|NCT04567615|BIOLOGICAL|Nivolumab|Specified dose on specified days
223882532|NCT04567615|BIOLOGICAL|Relatlimab|Specified dose on specified days
223882533|NCT04949568|BEHAVIORAL|Diabetes Self-Management Behaviors|The intervention is to be delivered by an interventionist.
223882534|NCT06907485|DRUG|Aminolevulinic acid hydrochloride|Pediatric patients diagnosed with a new or recurrent brain tumor, suspected to be either a high-grade or low-grade glioma, and scheduled for surgical removal will receive aminolevulinic acid hydrochloride prior to surgery for resection of the brain tumor.
223882535|NCT06912087|DRUG|Zanzalintinib|Experimental receptor tyrosine kinases (RTKs)
223882536|NCT06912087|DRUG|Cetuximab|Food and Drug Administration (FDA) approved monoclonal antibody directed against the epidermal growth factor (EGFR).
223882537|NCT06912087|DRUG|Pembrolizumab|FDA approved monoclonal immunoglobulin (Ig) G4 antibody directed against human cell surface receptor PD-1 (programmed death-1 or programmed cell death-1)
223882538|NCT03996239|BEHAVIORAL|exercise (walking)|Exercise treatment will consist of individualized walking delivered up to 5 times weekly. This trial will evaluate one dose of exercise (i.e., \~300 mins/wk following a non-linear dosing schedule) in both cohorts. Patients will have the option to receive exercise treatment at MSK or at their residence. Home-based exercise will be implemented and monitored using a telemedicine approach (i.e.,TeleEx) established in the Exercise-Oncology (ExOnc) Service
223882539|NCT03996239|OTHER|plasma samples|Plasma samples will be obtained at baseline.
223882540|NCT03996239|OTHER|blood draw|fasting blood
223882541|NCT07078890|PROCEDURE|bone augmentation simultaneous to implant removal|Placement of bone substitutes in the socket simultaneous to implant removal, and reimplantation is performed after 6 months of healing.
223882542|NCT04674306|BIOLOGICAL|α-lactalbumin vaccine|"α-lactalbumin vaccine will be administered subcutaneously in rotating sites (vaccine will not be administered in the arms of any participant, due to likelihood of prior bilateral mastectomy).~DL1: 10 mcg~DL Original 2: 100 mcg~DL2: 100 mcg~DL3: 500 mcg~D1b: 50 mcg~D1e: 10 mcg~D1f: 20 mcg~D1g: 20 mcg (D1g will only be utilized if D1c is deemed too toxic)"
223882543|NCT04674306|BIOLOGICAL|Zymosan|"Adjuvant used in vaccine preparation~DL1: 10 mcg~DL Original 2: 100 mcg~DL2: 10 mcg~DL3: 10 mcg~D1b: 10 mcg~D1e: 20 mcg~D1f: 20 mcg~D1g: 1o mcg (D1g will only be utilized if D1c is deemed too toxic)"
223882544|NCT06919692|BEHAVIORAL|Left lateral recumbent positioning|Left-lateral position is the recommended position of resting in pregnancy. The participants in the intervention group will be advised to practice this position with an intermittent 10-minute stretching after every hour of resting, with no more than 4-hours of this intervention per day.
223882545|NCT06915194|BEHAVIORAL|Text message|Participants receive a text message encouraging glycemic screening
223882546|NCT06915194|BEHAVIORAL|Patient portal message|Participants receive a patient portal message encouraging glycemic screening
223882547|NCT06915194|BEHAVIORAL|Mailed letter|Participants receive a mailed letter encouraging glycemic screening
223882548|NCT06470750|OTHER|Non-Interventional Study|Non-interventional study
223882549|NCT06918275|PROCEDURE|Laparoscopic isthmocele repair using V-LocTM 180 barbed suture|The standardized surgical steps for the laparoscopic isthmocele repair were as follows; 1) A 30-degree telescope was introduced through a 10 mm trocar at the umbilicus following the establishment of pneumoperitoneum. 2) Three 5 mm trocars were inserted: two in the bilateral lower quadrants and one in the suprapubic region. 3) The bladder was distended with 300 cc of saline infusion to facilitate dissection of the vesicovaginal space and to allow inferior mobilization of the bladder, thereby ensuring optimal visualization of the isthmocele region. Dissection was performed laterally up to the level of the uterine arteries, thereby minimizing the risk of vascular injury. 4) The light source of the laparoscope was deactivated, enabling the identification of the isthmocele region by utilizing the illumination provided by the hysteroscope. 5) Excision of the abnormal tissue was carried out using an ultrasonic energy device (HARMONIC®), guided by the manipulator shaft as a landmark.
223882550|NCT06918275|OTHER|Laparoscopic isthmocele repair using Polyglactin 910 vicryl suture|The standardized surgical steps for the laparoscopic isthmocele repair were as follows; 1) A 30-degree telescope was introduced through a 10 mm trocar at the umbilicus following the establishment of pneumoperitoneum. 2) Three 5 mm trocars were inserted: two in the bilateral lower quadrants and one in the suprapubic region. 3) The bladder was distended with 300 cc of saline infusion to facilitate dissection of the vesicovaginal space and to allow inferior mobilization of the bladder, thereby ensuring optimal visualization of the isthmocele region. Dissection was performed laterally up to the level of the uterine arteries, thereby minimizing the risk of vascular injury. 4) The light source of the laparoscope was deactivated, enabling the identification of the isthmocele region by utilizing the illumination provided by the hysteroscope. 5) Excision of the abnormal tissue was carried out using an ultrasonic energy device (HARMONIC®), guided by the manipulator shaft as a landmark.
223882551|NCT06924346|OTHER|Exercise Snacks|"The movement breaks will be individualized to exercise preferences and physical abilities (e.g., fitness, musculoskeletal issues) and adaptable to multiple environments (e.g., home, work) delivered via mobile phone application. Participants will be encouraged to incorporate the movement breaks into their daily schedule based on baseline exercise counselling."
223882552|NCT06924346|OTHER|Placebo Exercise|"The movement breaks will be individualized to exercise preferences and physical abilities (e.g., fitness, musculoskeletal issues) and adaptable to multiple environments (e.g., home, work) delivered via mobile phone application. Participants will be encouraged to incorporate the movement breaks into their daily schedule based on baseline exercise counselling."
223882553|NCT07077200|OTHER|Intranasal dexmedetomidine|"This intervention is distinguished by the use of intranasal dexmedetomidine at a standardized dose of 3 mcg/kg, administered non-invasively upon the child's arrival in the preoperative holding area. Unlike other pharmacological methods that often require intravenous access or oral administration, this approach minimizes procedural stress and discomfort, which is particularly advantageous in pediatric populations.~Dexmedetomidine is a selective alpha-2 adrenergic agonist known for its anxiolytic, sedative, and analgesic properties, without causing significant respiratory depression-a key concern with agents like benzodiazepines or opioids. Its intranasal delivery provides a rapid onset of action while maintaining hemodynamic stability, which is critical during the preoperative period.~This intervention is also notable for its comparison with a non-pharmacological strategy-short video viewing-making the study unique in evaluating the relative efficacy of a low-risk pharmacologic option"
223882554|NCT07079215|DEVICE|Neurostimulation|Participants in this group will use the physical device for medical use (ADTPM 1) applied to the auricular region (ear and surrounding area) for 60 minutes (±10 minutes) per session, at least once daily and a minimum of 7 times per week, over a 4-week treatment period. Additional sessions may be conducted if participants require further relief of withdrawal symptoms. All assessments and permitted concomitant treatments will be administered in accordance with the study protocol.
223882555|NCT07079215|DEVICE|Sham stimulation|"Control Group (Sham Stimulation, n=12):~Participants in this group will use a sham stimulation device that does not deliver active stimulation. The sham device will be applied under the same schedule and conditions-60 minutes (±10 minutes) per session, at least once daily and 7 times per week for 4 weeks. All assessments and permitted concomitant treatments will be identical to those in the active stimulation group."
223882556|NCT06932679|OTHER|Assessment of Gait and Visual Exploration|Participants will perform walking tasks involving obstacle crossing while their gait and visual exploration patterns are recorded using wearable sensors and eye-tracking glasses. This is a non-invasive observational study with no therapeutic intervention.
223882557|NCT06754124|OTHER|Pilates Group|Pilates training will be given individually for approximately 1 hour, 3 days a week for 8 weeks. Before starting the exercise training, all participants will be taught the basic elements of Pilates in 1 session. Pilates training will begin with standing exercises for warming up and centering in the supine position. Training will continue with upper and lower extremity movements. The intensity of the exercises will be increased by using different positions and elastic bands. Stretching exercises and posture exercises will be used during the cool-down period. All exercises will start with 10 repetitions and will be increased to 20 later. Each movement will be shown by the physiotherapist first so that the patients can do the movements correctly. The movements that the patients cannot do will be modified appropriately and applied.
223882558|NCT06754124|OTHER|Control Group|No exercise will be allowed for 8 weeks and routine medication will continue.
223882559|NCT06947694|DRUG|chemotherapy + PD-1 inhibitors|"The patient receives 4 cycles of treatment with chemotherapy + PD-1 inhibitors. If there is no disease progression, the patient will receive radiotherapy (radiation dose: 5-8Gy \* 3-10 fractions) for pulmonary lesions, lymph node lesions and visceral lesions in combination with the PD-1 inhibitors . During the follow-up, the PD-1 inhibitors will be maintained until the disease progresses or the toxicity is intolerable. The maximum duration of immunotherapy shall not exceed 2 years."
223882560|NCT06947694|DRUG|chemotherapy + PD-1 inhibitors|"The patient receives 4 cycles of treatment with chemotherapy + PD-1 inhibitors. If there is no disease progression, the patient will receive radiotherapy (radiation dose: 5-8 Gy × 3-10 fractions) for pulmonary lesions, lymph node lesions and other lesions in combination with the PD-1 inhibitors. During the follow-up, the PD-1 inhibitors will be continued until the disease progresses or the toxicity becomes intolerable. The maximum duration of immunotherapy shall not exceed 2 years."
223882561|NCT06947694|DRUG|chemotherapy + PD-1 inhibitors|"The patient receives 4 cycles of treatment with chemotherapy + PD-1 inhibitors. If there is no disease progression, the patient will receive radiotherapy (radiation dose: 5-8Gy × 3-10 fractions) for pulmonary lesions, lymph node lesions and bone metastatic lesions in combination with the PD-1 inhibitors . During the follow-up, the PD-1 inhibitors will be continued until the disease progresses or the toxicity becomes intolerable. The maximum duration of immunotherapy shall not exceed 2 years."
223882562|NCT06947694|DRUG|chemotherapy + PD-1 inhibitors|"The patient receives 4 cycles of treatment with chemotherapy + PD-1 inhibitors. If there is no disease progression, the patient will receive radiotherapy (radiation dose: 5-8 Gy × 3-10 fractions) for pulmonary lesions, visceral lesions and other lesions in combination with the PD-1 inhibitors. During the follow-up, the PD-1 inhibitors will be maintained until the disease progresses or the toxicity becomes intolerable. The maximum duration of immunotherapy shall not exceed 2 years."
223882563|NCT06947694|DRUG|chemotherapy + PD-1 inhibitors|"The patient receives 4 cycles of treatment with chemotherapy + PD-1 inhibitors. If there is no disease progression, the patient will receive radiotherapy (radiation dose: 5-8 Gy × 3-10 fractions) for pulmonary lesions, visceral lesions and bone metastatic lesions in combination with the PD-1 inhibitors. During the follow-up, the PD-1 inhibitors will be continued until the disease progresses or the toxicity becomes intolerable. The maximum duration of immunotherapy shall not exceed 2 years."
223882564|NCT06947694|DRUG|chemotherapy + PD-1 inhibitors|"The patient receives 4 cycles of treatment with chemotherapy + PD-1 inhibitors. If there is no disease progression, the patient will receive radiotherapy (radiation dose: 5-8 Gy × 3-10 fractions) for lymph node lesions, visceral lesions and other lesions in combination with the PD-1 inhibitors. During the follow-up, the PD-1 inhibitors will be continued until the disease progresses or the toxicity becomes intolerable. The maximum duration of immunotherapy shall not exceed 2 years."
223882565|NCT06947694|DRUG|chemotherapy + PD-1 inhibitors|"The patient receives 4 cycles of treatment with chemotherapy + PD-1 inhibitors. If there is no disease progression, the patient will receive radiotherapy (radiation dose: 5-8 Gy × 3-10 fractions) for lymph node lesions, visceral lesions and other lesions in combination with the PD-1 inhibitors. During the follow-up, the PD-1 inhibitors will be continued until the disease progresses or the toxicity becomes intolerable. The maximum duration of immunotherapy shall not exceed 2 years."
223882566|NCT06951399|DRUG|Pembrolizumab (KEYTRUDA®)|IV Pembrolizumab 200 mg combined with pemetrexed and platinum (investigator's choice of cisplatin or carboplatin) every 3 weeks
223882567|NCT06347939|DIAGNOSTIC_TEST|Mediastinal lymph nodes cryobiopsies|EBUS Mediastinal lymph nodes cryobiopsies
223882568|NCT07077928|DEVICE|Pacemaker upgrade|CRT upgrade
223882569|NCT05134337|DRUG|LOXO-305|Oral LOXO-305
223882570|NCT05134337|DRUG|Itraconazole|Oral itraconazole
223882571|NCT05134337|DRUG|Rifampin|Oral rifampin
223882572|NCT03850015|DIAGNOSTIC_TEST|Standard echocardiography|Patients will undergo standard echocardiography, with and without contrast
223882573|NCT03850015|OTHER|High frame rate echocardiography|Following standard echocardiography, the test is repeated using high frame rate ultrasound
223882574|NCT06311500|BEHAVIORAL|Sleep health enhancement intervention|4 weekly visits of education and strategies to enhance sleep health
223882575|NCT02991625|OTHER|Placebos|Positive treatment expectations will be induced by giving participants capsules containing inert material and telling them that the capsules contain an effective drug that has been approved for treating Chronic Back Pain. They will be requested to take two capsules twice a day and report their pain on paper forms organized as a calendar.
223882576|NCT02991625|OTHER|Waitlist|These Chronic Back Pain participants will not be given any placebos and will be requested to report their pain on paper forms organized as a calendar.
223882577|NCT02991625|OTHER|Healthy Controls|Healthy control participants will not receive a placebo drug or be put on a waitlist.
223882578|NCT05954130|OTHER|Education|Sexual Health in Pregnancy
223882579|NCT06833450|OTHER|Transabdominal intestinal ultrasound|Transabdominal intestinal ultrasound
223882580|NCT04634916|DEVICE|EndoAVF Creation|Subjects will have an endoAVF created using the WavelinQ EndoAVF System
223882581|NCT05523128|GENETIC|ZS802|A novel, bioengineered adeno-associated viral (AAV) vector carrying human factor VIII variant. The dose levels are as follows: 1. 2.0×10\^13vg/kg; 2. 6.0×10\^13vg/kg.
223882582|NCT05746117|DEVICE|Aktiia Device|The Aktiia Bracelet is a CE-marked medical device that will be used in accordance with its instructions for use. The bracelet non-invasively measures optical signals at the wrist, which are used to determine blood pressure. The bracelet comes with a bluetooth enabled upper arm cuff that can be used to take on-demand blood pressure measurements. All measurements are transmitted to a dashboard that a clinical pharmacist monitors during the participant's enrollment in the study.
223882583|NCT05746117|DEVICE|Upper arm cuff|A standard upper arm oscillometric cuff that can be used to take blood pressure at home.
223882584|NCT06829706|DEVICE|Conventional olfactory training device|Conventional olfactory training was designed by Hummel et al. They performed OT using four odors (phenyl ethyl alcohol, rose; eucalyptol, eucalyptus; citronella, lemon; and eugenol, cloves), which are representative of four odor categories on the odor prism proposed by Henning.
223882585|NCT06829706|DEVICE|Modified olfactory training device|Participants will use a modified olfactory training device based on expiratory pressure. Its bidirectional airflow and unidirectional pressure characteristics significantly increased the deposition rate of olfactory odors in the olfactory cleft area, making the patient feel stronger in the nasal cavity during olfactory training.
223882586|NCT06829706|DEVICE|Conventional olfactory training device with placebo|Based on the traditional olfactory training device, four olfactory odors are replaced by placebo。
223882587|NCT06251986|OTHER|ofatumumab|This is an observational study, there is no treatment allocation.
223882588|NCT05673499|DEVICE|NIRS/EEG monitoring|The study intervention will be monitoring NIRS and EEG for one hour before surgery, during surgery, and up to 8-24 hours after surgery.
223882589|NCT06186206|BEHAVIORAL|Social media interventions for vaccine uptake|"Culturally Tailored Social Media Campaign: 4 communities receive a culturally tailored social media campaign via Facebook, focusing on geographical targeting. Content aligns with indigenous cultural norms and values, featuring educational materials, testimonials, and messaging addressing vaccine misconceptions on childhood routine and HPV vaccinations' importance and safety.~WhatsApp-Based Vaccine Training for CHW: 4 communities receive both the culturally tailored social media campaign and WhatsApp-based vaccine training for CHWs. Interactive training allows CHWs to engage in discussions, seek guidance, and enhance their ability to communicate effectively. This component targets vaccine hesitancy and boosts vaccine uptake rates."
223882590|NCT06335641|DEVICE|External active conductive head cooling|Cooling is applied during the endovascular thrombectomy procedure for a maximum of 120 minutes
223882591|NCT04341376|BEHAVIORAL|Enhanced First Connections|Enhanced First Connections is a short-term home visiting program that includes prenatal identification and engagement of women with an adversity or trauma history, and infant and early childhood mental health consultation.
223882592|NCT05274568|DRUG|[18F]UCB-2897|"Investigational Agent:~\[18F\]UCB2897 is a clear solution formulated for intravenous (IV) injection. The product \[18F\]UCB2897is delivered in normal saline (0.9 % sodium chloride \[NaCl\]) formulated with the intent to contain approximately 3.3 % (v/v) ethanol (EtOH), polysorbate-80 (PS-80, 3.73 μL/mL) and sodium ascorbate (4.67 mg/mL). The final product bears a label with the following items: total activity (mCi), volume (mL), strength (mCi/mL), calibration date and time, batch number, and shelf life. \[18F\]UCB2897 will be stored at ambient temperature in its original container."
223882593|NCT06073717|BEHAVIORAL|Exercise|Participants will complete a 5-month exercise program structured in 4 blocks of 5 weeks. Three supervised and combined aerobic/strength exercise sessions each week will be performed together with an aerobic weekly challenge. Aerobic exercise will be performed for 20-30 minutes using a treadmill, bicycle, or circuit training at light to moderate intensities (40-75% of heart rate reserve) during the first two blocks; gradually achieving high intensity (\>75% of HHR) in the last two blocks. Heart rate and the subjective perception of the exertion scale (6-20 Borg scale) will be monitored. Strength exercises will be started at light to moderate intensities (2 sets of 15-20 repetitions at 40-50% of repetition maximum), performed muscle actions at high intensities in the last two blocks (2 sets of 8-15 repetitions at 50-75% RM); using elastic bands, free weights, and weights gym exercises.
223882594|NCT06073717|BEHAVIORAL|Motor-cognitive Training|Participants will complete the same four-block exercise program in terms of type, frequency, intensity, and volume of physical/motor training. Simultaneous with the progression of physical/motor training, the complexity of cognitive stimulation will be increased according to the performance of the participants. General dual-task training will be performed, which describes the use of a physical/motor intervention with different cognitive stimulations (memory, language, intelligence, attention, processing speed, calculation, inhibitory control) that are not specific to the methods to be used for their assessment.
223882595|NCT06073717|BEHAVIORAL|Health and Wellness|Participants randomly assigned to the health and wellness group will be advised and re-educated to support and improve health aspects. Participants in this group will aim to achieve the physical activity recommendations, and in addition, they will receive bi-weekly emails and phone call coaching with tools to empower patients with knowledge about physical exercise, nutrition, and brain health guidelines. Following completion of the 5-month exercise program, this group will receive an exercise program for 12 weeks.
223882596|NCT05166954|PROCEDURE|LSG|Laparoscopic sleeve gastrectomy (LSG) together with medical treatment aiming the control of cardiovascular risks including hypertension, diabetes mellitus or dyslipidemia.
223882597|NCT05166954|PROCEDURE|RYGB|Roux-en-Y gastric bypass (LRYGB) together with medical treatment aiming the control of cardiovascular risks including hypertension, diabetes mellitus or dyslipidemia.
223882598|NCT03618160|DRUG|JNJ-64565111|Participants in Cohorts 1 to 3 will receive a single SC low, medium, and high dose of JNJ-64565111 respectively on Day 1, participants in Cohorts 4 to 6 will receive weekly multiple SC low, high and medium dose of JNJ-64565111 respectively on Days 1, 8, 15, and 22, under fasted conditions. Participants in Cohort 7 will receive a single SC medium dose of JNJ-64565111 on Day 1, under fasted conditions.
223882599|NCT03618160|DRUG|Placebo|Participants will receive SC injection of matching placebo on Day 1 in all cohorts of Part 1 and on Days 1, 8, 15, and 22 in Part 2 under fasted conditions.
223882600|NCT03980509|DRUG|Curcumin|Curcumin is an extract from turmeric
223882601|NCT04499950|DRUG|Contrave|Initiate Contrave at 1 tab in morning (AM) for Week 9; then 1 tab in AM and 1 tab in evening (PM) for Week 10; then 2 tab in AM and 1 tab in PM for Week 11; then 2 tab in AM and 2 tab in PM for week 12; then constant dose for months 4-6.
223882602|NCT04499950|BEHAVIORAL|Behavioral Weight Loss|6 months of behavioral weight loss. First 3 months are weekly calls with coach and then transition to monthly calls for months 4-6.
223882603|NCT04281134|DEVICE|Summit RC+S System|"Summit RC+S System consists of:~(i) One Model B35300R Olympus RC+S neurostimulator; (ii) One Model 4NR009 Patient Therapy Manager; (iii) One Model 4NR011 Clinician Telemetry Module; (iv) Two Model 3387 DBS leads; (v) Two Model 37087-60 DBS extensions; and (vi) One Model 97755 Recharger."
223882604|NCT04281134|OTHER|One Month Blinded Discontinuation Period:|"The subject and Independent Evaluators are blinded to timing of discontinuation. In all cases, the sequence will be as follows in one-week segments: 100% Active, 50% Active, Sham and Sham. Subjects will be seen weekly. Amplitude will be reduced by 50% at start of week 2 and turned off at start of week 3. Subjects will be told that DBS will be discontinued at some point during the 4 weeks. The purpose of the 50% initial reduction is to minimize rebound effects. The programmer (not the PI in this case) will be open to the design and perform sham activation as described previously. Relapse is defined as a 25% increase of the Y-BOCS over two consecutive visits compared to discontinuation baseline."
223882605|NCT04732052|DEVICE|Transcranial Direct Current Stimulation|non-invasive brain stimulator
223882606|NCT04981977|BEHAVIORAL|Care Transitions Intervention|CTI is delivered by a trained Care Transitions Coach (Coach) who works closely with patients to ensure a smooth transition from hospital to home following an acute hospitalization. The patient, caregiver, and Coach work together to maximize the involvement of interdisciplinary experts, ensuring that the appropriate professionals are involved, issues are addressed, goals are understood, and the discharge care plan is executed correctly. There are three aspects to CTI; the first is the initial hospital visit, followed by an in-home visit, concluding with telephone follow-up over a 28-day period. During these visits, the Coach focuses on four conceptual areas, referred to as pillars (i.e., Personal Health Record, Medication Management, Red Flags, and Physician Follow up). The Coach ensures the patient understands and utilizes the Personal Health Record to facilitate communication and ensure continuity of care plan across providers and settings.
223882607|NCT04981977|BEHAVIORAL|Care Transitions Intervention and Peer Support|The PS intervention for this study is based upon the principles of motivational interviewing, which is a person-centered, goal-directed method to enhance intrinsic motivation for change by exploring and resolving ambivalence. A recent meta-analysis found the mean effect size for MI to be significantly larger for racial and ethnic minority samples (0.79 vs. 0.26) as compared to non-Hispanic Whites, highlighting its potential benefit and cultural relevance for minority populations. Patients in this arm of the study will receive the 28-day CTI intervention with a 2-month long Peer Support (PS) intervention provided by trained peer educators (PEs).
223882608|NCT04981977|OTHER|Usual Care|The researchers will follow a control group of patients who meet study inclusion criteria. These older adults will participate in the traditional discharge case-management offered by the hospital where they were admitted and discharged. UC at our three partner hospitals consists of: (1) routine inpatient nurse intake that includes screening about housing, substance abuse, and functional status; (2) medication reconciliation performed by treating practitioners; (3) discharge patient education provided by inpatient nurses; (4) a list of resources for safety-net clinics and community-based services; and (5) for patients with severe chronic illness (e.g. heart failure) there may be a planned home visit by a nurse practitioner.
223882609|NCT00667030|BEHAVIORAL|Weight loss and aerobic exercise training|Weight loss and aerobic exercise training
223882610|NCT05711602|OTHER|Pilates|raining based on a basic level Pilates exercise program will be as follows: A duration of weeks with a frequency of 2 sessions a week and with a duration of 55 minutes each. The exercises to be performed will be divided into three distinct phases: warm-up, lasting 15 minutes; Main part with a duration of 30 minutes and the return to calm, based mostly on stretching and with a duration of 10 minutes. The repetitions of the exercises will be between 5 and 10 according to the difficulty.
223882611|NCT05872932|PROCEDURE|gastric balloon implantation|After diagnostic endoscopy if there is no any gastric pathology that would be contraindication for balloon placement a gastric balloon will be placed
223882612|NCT05872932|PROCEDURE|botulinum toxin A injection|After diagnostic endoscopy if there is no any gastric pathology that would be contraindication Botox injection and balloon placement, 200 U of Botox A will be injected to antrum and fundus. And 1 week later gastric balloon will be implanted
223882613|NCT06829472|DRUG|melphalan|conditioning regimen with melphalan, busulfan and fludarabine
223882614|NCT06785779|OTHER|Secukinmab|This is an observational study. There is no treatment allocation. The decision to initiate secukinumab will be based solely on clinical judgement.
223882615|NCT05968677|DIETARY_SUPPLEMENT|FSMP|Food for Special Medical Purposes specifically formulated for the dietary management of malnourished patients following therapeutic treatments such as chemo and radiotherapy
223882616|NCT05968677|OTHER|Nutritional counseling|Participant's nutritional status will be evaluated, anthropometric data will be collected (weight, height, BMI), body composition will be evaluated (FFMI, BIVA) and a food diary will be compiled
223882617|NCT04955717|OTHER|Chlamydia trachomatis and Neisseria gonorrhoeae screening using the GeneXpert|Chlamydia trachomatis and Neisseria gonorrhoeae testing using the GeneXpert
223882618|NCT04059354|BEHAVIORAL|Speech therapy addressing phonology and motor learning|Determine the efficacy of a newly devised intensive speech treatment plan, to use with individuals with Down syndrome, that combines two treatment approaches: Cycles Phonological Remediation Approach and Script training, while adapting each to prioritize use of practice words with low vowels given research findings that the low vowels /ɑ/ as in 'hot' and /æ/as in 'hat' are less intelligible than the high vowels /i/ as in 'heat' and /u/ as in 'boot'; also, vowel acoustic analyses that revealed word-intelligibility to improve when the production of the low vowels /ɑ/ and /æ/ had more distinctive second formants/vocal tract resonances (a measure that is associated with tongue front-back movement). Each intervention session will include 40-50 minutes of the adapted 'Cycles Phonological Remediation Approach' focusing on articulatory/phonological training at the syllable/word level, and 10-20 minutes of the adapted Script program for motor training at the sentence level.
223882619|NCT05695053|DEVICE|Low Level Laser Therapy|Low level laser therapy could provide energy to trigger cell differentiation.
223882620|NCT05695053|OTHER|Placebo|Placebo
223882621|NCT05514769|PROCEDURE|Proximal Gastrectomy Anterior Anastomosis With Pyloroplasty|The location of the anastomosis in the anterior of the gastric stump. Pyloroplasty is added in the procedure
223882622|NCT06095050|DEVICE|Embolization|Superselective arterial embolization of hyperemic vasculature in the symptomatic shoulder (utilizing the IDE approved device: Lipiodol) followed by structured physical therapy sessions.
223882623|NCT06095050|OTHER|Physical Therapy|Subjects will participate in structured physical therapy consisting of 3 months of eccentric strength training. This twelve-week program will consist of 4 PT sessions at week 0, week 4, week 8, and week 12.
223882624|NCT05403801|BEHAVIORAL|STAMP+CBT application|Use the STAMP+CBT mobile app for 4 weeks (intervention period, 4 weeks for content introduction, extended 2 weeks for review of content if patient's request this
223882625|NCT06794476|BEHAVIORAL|Milieu Teaching-AV|In Milieu Teaching-AV, coaches will teach caregivers to engage the child in play or routines around a standardized set of toys, follow the child's attention or communication lead around these toys, and respond to the infant's communication acts by modeling and expanding those communication acts into more sophisticated strategies. While responding to infant communication acts, coaches will slowly move the referent of the infant's lead near the face at approximately the level of the mouth, wait for the infant to shift his/her gaze towards the new referent position if necessary, and provide all models, prompting, and expanding while maintaining placement of the referent near the mouth.
223882626|NCT04619680|DRUG|Nintedanib|150 mg PO twice a day, taken with food food (or, for Child-Pugh A patients, 100 mg by mouth twice daily).
223882627|NCT04619680|DRUG|Placebo|placebo 150 mg equivalent twice a day, taken with food food (or, for Child-Pugh A patients, 100 mg by mouth twice daily).
223882628|NCT06823362|DRUG|Pentoxifylline|400 mg
223882629|NCT06823362|DRUG|Pentoxifylline|400 mg
223882630|NCT06216080|OTHER|D-FF-OCT analysis of CVC|Dynamic full-field optical coherence tomography analysis of central venous catheter sections to better apprehend strucural characterization of central venous catheter-deposited biofilm
223882631|NCT06168162|OTHER|titated PEEP to best static compliance|the Intraoperative PEEP will be titrated to best static compliance for each patient
223882632|NCT06835374|PROCEDURE|Per oral endoscopy myotomy (Per oral endoscopy myotomy)|POEM is the procedure to reduce the symptoms of dysphagia, regurgitation.
223882633|NCT06835374|PROCEDURE|Endoscopy procedure|Endoscopy procedure is required to rule out type of reflux disease
223882634|NCT06832462|BEHAVIORAL|Acceptance and Commitment Therapy|"A one-day Acceptance and Commitment Therapy (ACT) will be held with three (3) sessions. The sessions start with ice breaking, and follow by,~The first session will build a therapeutic relationship and icebreaking, using animated video (unwanted guest) presentations to explain how ACT can help manage issues.~The second session will focus on acceptance and defusion concepts, emphasizing the importance of letting go of unproductive emotion-control techniques by using animated video (response ability)~The third session, 'Show Up', will increase awareness of undesirable thoughts and feelings through structured mindfulness exercises and observing surroundings. The therapist will explain the metaphor of dropping the anchor and emphasize the"
223882635|NCT03888989|BIOLOGICAL|Quadrivalent inactivated influenza vaccine (IIV)|Quadrivalent inactivated influenza vaccine (IIV), Intramuscular Injection
223882636|NCT06566040|DEVICE|Wheelchair|Wheelchairs provided to hospital inpatients
223882637|NCT06789939|OTHER|Train the trainer program for MPCC professionals|The intervention will consist on a train the trainer program. 3 professionals from each MPCC will be trained by an educational team. They will then have to implement an IPEP (knowledge of the MPCC, participation in interprofessional MPCC activities, etc.) for students on placement in their MPCC.
223882638|NCT05903794|BIOLOGICAL|EXG102-031|EXG102-031 is a recombinant adeno-associated virus (rAAV) expressing an angiopoietin domain and VEGF receptor (ABD-VEGFR) fusion protein. EXG102-031 will be administered by subretinal injecting into one eye of each participant.
223882639|NCT05710263|PROCEDURE|bariatric embolization|bariatric or left gastric artery embolization
223882640|NCT06834763|OTHER|Clinical team access to Placement Success Predictor (PSP) results|PSP is a machine-learning based clinical decision support tool that is designed to assist clinical team members in making placement decisions for youth. PSP provides site-specific placement success prediction scores \[i.e., client's likelihood of success per placement based on machine learning models\] for each youth.
223882641|NCT06834503|DRUG|Rivotril®|Rivotril® 2 mg
223882642|NCT06834503|DRUG|Clonazepam TQ 2 mg|Test
223882643|NCT06834243|PROCEDURE|Intermittent Bolus PENG Block|Patients received intermittent bolus administration of the Pericapsular Nerve Group (PENG) Block via a catheter. A researcher manually administered 20 mL of 0.25% bupivacaine every 4 hours over a 24-hour period.
223882644|NCT06834243|PROCEDURE|Continuous Infusion PENG Block|Patients received continuous infusion of the Pericapsular Nerve Group (PENG) Block via a catheter. A pump delivered 5 mL/hour of 0.25% bupivacaine continuously over a 24-hour period.
223882645|NCT06833710|OTHER|Auricular Acupressure|In the experimental group, the Shenmen point (MA-TF1) and Xin point (Xin MA) on both ears were treated with Wangbuliuxing seeds. Initially, the seeds were applied to the left ear for seven days, after which they were switched to the corresponding acupoints on the right ear. Following application, the seeds were pressed daily, once after each meal, with each acupoint being stimulated for 1 minute
223882646|NCT03157323|BEHAVIORAL|Low Glycemic Index Diet|The nutritional intervention is theory-based and will provide nutritional education and counseling to children and their families. Nutritional counseling will be provided by the institutional designate and will focus on increasing patients' understanding of the benefits of a low GI diet, increase knowledge of low GI diet, overcoming barriers, and establishing expectations of the diet.
223882647|NCT06833112|DRUG|Secukinumab|The subjects were treated with secukinumab for 104 weeks. Secukinumab:150mg，q8w，subcutaneous injection.
223882648|NCT06833112|DRUG|Adalimumab|The subjects were treated with adalimumab for 104 weeks. adalimumab: 40mg，q4w，subcutaneous injection.
223882649|NCT06830343|DRUG|SYH9017|subcutaneous injection once time in SAD and four times in MAD
223882650|NCT06830343|DRUG|Placebo|subcutaneous injection once time in SAD and four times in MAD
223882651|NCT06830343|DRUG|Wegovy ®|subcutaneous injection once a week
223882652|NCT06825741|OTHER|Observational Study - No intervention|This is an observational study evaluating brain structural abnormalities in post-COVID headache patients. No experimental intervention is applied.
223882653|NCT01447758|DRUG|LEO 29102|Cream, 1,7mg/cm2 BSA, BID, 7 days In Cohort I, II and III, 6 weeks in Cohort IV
223882654|NCT01447758|DRUG|LEO 29102 Cream Vehicle|Cream, 1,7mg/cm2 BSA, BID, 7 days in Cohort I and II, 6 weeks in Cohort IV
223882655|NCT06030544|DIETARY_SUPPLEMENT|OA-enriched functional olive oil|Dietary intervention in diabetic patients. Oral intake of 55 mL/day of a functional olive oil enriched in Oleanolic acid (equivalent dose 30 mg/day OA) Oleanolic acid (CAS no. 598-02-1; PubChem CID 10494).
223882656|NCT06030544|DIETARY_SUPPLEMENT|commercial olive oil|Dietary intervention in diabetic patients. Oral intake of 55 mL/day of a commercial olive oil (blend of virgin and refined olive oils) chosen by its very low content of bioactive minor components.
223882657|NCT05741333|DEVICE|Solo+ Tympanostomy Tube Device (Solo+ TTD)|The Solo+ TTD is intended to deliver a tympanostomy tube through the tympanic membrane of a patient.
223882658|NCT04576286|PROCEDURE|Holmium versus Bipolar en bloc transurethral resection|"After obtaining informed consent, patients will be randomized with a 1:1 ratio using sealed envelopes that will be prepared by the department's ethical committee into 2 groups, group 1 represent the Holmium en bloc resection procedure while group 2 represents bipolar en bloc resection. Patients will be blinded to the type of intervention as well as the data collector and the statistician.~Intervention: all procedures will be done by an expert surgeon who performed over 50 cases of en bloc urinary bladder tumor resection with each energy source. In group A, Holmium en bloc resection procedure will be done under either general or spinal anesthesia, using a Holmium laser device (Cyber Ho, Quanta device, Milano, Italy). We will use a 30-40-watt power, 1-2 joules and 20-30 MHz frequency for Group A and bipolar en bloc resection for Group B. A 550 nm flexible laser fiber will be used in group A and a bipolar resection loop for group B."
223882659|NCT00214695|DRUG|Experimental Peritoneal Dialysis Solution|
223882660|NCT06074198|BEHAVIORAL|SuCCESs|strengthening and endurance exercises
223882661|NCT05834660|BEHAVIORAL|Safe Alternatives for Teens and Youth-Acute for Schools (SAFETY-A for Schools)|SAFETY-A is a brief, family centered, cognitive-behavioral approach to therapeutic risk assessment and safety planning that can be delivered via school-based providers. The intervention is delivered in one session during which the youth at risk for suicidal behavior works with the provider to identify strengths, supports, understand emotional antecedents and warning signs, identify alternative coping behaviors and thoughts, and ways to keep the environment safe. Youth and families receive follow-up contacts by phone at 1, 2, and 4 weeks after the SAFETY-A session. The primary focus is on the therapeutic mechanisms of hope, reduced intensity of suicidal urges, increased confidence in ability to keep safe. Adaptation of SAFETY-A for Schools will target mechanisms that are presumed to drive disparities in mental health service use among Asian American and Latinx youth: (1) trust in mental health services, (2) internalized stigma, and (3) comfort communicating distress.
223882662|NCT04403074|PROCEDURE|Celiac Plexus Neurolysis|When CPBs are not effective (less than one month of relief) then a Celiac Plexus Neurolysis may be completed to manage pain associated with Chronic Pancreatitis.
223882663|NCT02294799|OTHER|Intervention Group|Grade 1, Nonspecific Mandibular Mobilization
223882664|NCT02294799|OTHER|Placebo group|Nonspecific Mandibular Movement.
223882665|NCT05468008|PROCEDURE|Endoscopic Submucosal Dissection|Endoscopic submucosal dissection (ESD) is an outpatient procedure to remove deep tumors from the gastrointestinal (GI) tract
223882666|NCT06217718|OTHER|Telenursing Interventions|Patient follow-up with phone calls and text messages
223882667|NCT04246151|DRUG|Vancomycin|Vancomycin capsules
223882668|NCT04246151|DIETARY_SUPPLEMENT|Culturelle|Culturelle capsules
223882669|NCT04246151|DRUG|Vancomycin Placebo|sugar pill manufactured to mimic the vancomycin 125 mg capsule
223882670|NCT04246151|DRUG|Probiotic Placebo|sugar pill manufactured to mimic 10 billion unit probiotic capsules.
223882671|NCT06386913|OTHER|Training|Measurement-Based Care Training
223882672|NCT03933384|DRUG|Tenofovir alafenamide|Tenofovir alafenamide 25mg/tab once daily
223882673|NCT03933384|DRUG|Entecavir|Entecavir 0.5mg/tab once daily
223882674|NCT01985139|BEHAVIORAL|Computer-based tasks|Computer-based tasks designed to assess size and time discrimination capacities
223882675|NCT01985139|BIOLOGICAL|Blood sampling|Blood drawn for the measurement of circulating endocannabinoids concentrations
223882676|NCT06775925|OTHER|Unilateral robot-assisted therapy (RT)|RT will be performed as an add-on therapy to the clinical routine therapy scheme for 3 x 30 minutes per week for 6 weeks. RT is applied using the ArmeoSpring, an exoskeleton that provides adjustable antigravity weight support for the arm through a system of springs (no actuators).
223882677|NCT06775925|OTHER|Unilateral conventional occupational therapy (OT)|The OT is applied as add-on therapy for 3 x 30 minutes per week for 6 weeks. OT comprises strengthening exercises (concentric and eccentric) with and without resistance, grasping exercises, fine motor training, peg games, and activity-based tasks which are unilaterally doable.
223882678|NCT06776913|DEVICE|Colonoscopy|Standard Colonoscopy with photo documentation and the recording of procedure timing.
223882679|NCT06026527|DRUG|Magnesium sulfate|50 mg/kg Magnesium sulphate in 93-95 ml Normal Saline ( making a total of 100 ml solution )will be infused intravenously over 20-30 minutes in the participants allocated to M group starting from the moment of induction of anaesthesia
223882680|NCT06026527|DRUG|Normal Saline|100 ml Normal Saline will be infused intravenously over 20-30 minutes in the participants allocated to control group starting from the moment of induction of anaesthesia
223882681|NCT05736744|DRUG|MgSO4|The patients will be pretreated with magnesium sulphate infusion (30 mg kg-1, total volume 100 ml, infusion rate 5 ml min-1) 20 min. before induction of anesthesia.
223882682|NCT05736744|DRUG|Cis-Atracurium|Cis-Atracurium will be administered at 0.1-0.15 mg/kg IV bolus for intubation and maintenance at a dose of 0.03 mg/kg iv on fixed intervals.
223882683|NCT05827523|DRUG|Cisplatin|Hyperthermic intraperitoneal chemotherapy (HIPEC) with cisplatin 75mg/m2 after interval cytoreductive surgery
223882684|NCT05857553|OTHER|Unconditional Cash Transfer|Unconditional monthly transfer of $500 to household
223882685|NCT05857553|OTHER|No Direct Cash Transfer|No intervention
223882686|NCT06540781|PROCEDURE|wet cupping therapy|"The cupping (WCT) procedure consists of five phases:~Primary suction: Using a manual suction pump, air was drawn from glass cups that were positioned on the chosen locations. The skin and subcutaneous tissue swelled as a result of the cups' five minutes of skin contact.~Area disinfection: After disinfecting the cupped areas with povidone-iodine, they were wiped with sterile gauze.~Scarification: Using a sterile number 11 surgical blade, superficial incisions measuring 20-30 gauge in length and 1-2 mm in depth were made on the skin.~Bloodletting and secondary suction: Once again applied to the scarified areas, the previously removed cups created suction using the manual pump which was previously mentioned. In order to fill the cups, blood was drawn from the skin's and subcutaneous tissue's capillaries.~Removing and dressing: After 10 minutes, the cups filled with blood were removed. The application areas were wiped with sterile gauze, and dressings were applied."
223882687|NCT06038656|DIETARY_SUPPLEMENT|Galactooligosaccharides (GOS)|"10 g of GOS provided as 14 g of powder will be consumed after mixing it in water or yoghurt.~The absorption study test drinks administered during the 3 test conditions will be comprised as follows:~Post rest period - 50 mg of iron as ferrous fumarate (Fefum) supplement, 6 mg 54Fe as Fefum and 300 ml of water with sucrose and lactose.~Post exercise bout - 50 mg of iron as Fefum, 6 mg 58Fe as Fefum and 300 ml of water with sucrose and lactose.~Post exercise bout co-administered with GOS - 50 mg of iron as Fefum, 6 mg 57Fe as Fefum and 300 ml of water with 10 g GOS."
223882688|NCT03747042|DRUG|Letrozole|Patients will receive a prescription for letrozole to be taken orally for 7-30 days to allow for variations in surgical scheduling. Patients are to undergo surgical resection of their tumor the day after the last dose of letrozole. Post-treatment tumor biopsies (a goal of 4-6 cores) will be obtained following 7-56 days of letrozole treatment on the day of surgery.
223882689|NCT06776120|DIAGNOSTIC_TEST|Fecal chemical test (FIT)|Eligible participants will be instructed to collect their two stool samples within seven days prior to undergoing bowel preparation. These stool samples will be then submitted for a quantitative FIT (OC-SENSOR, EIKEN CHEMICAL, Japan). Colonoscopic observations and histopathological findings will be employed as the definitive reference standards for diagnosis.
223882690|NCT06777394|OTHER|High intensity interval training|"The HIIT program begins with a warm-up, followed by high-intensity repetitions separated by moderate-intensity recovery intervals. High-intensity exercises are performed near maximum effort, while moderate-intensity periods are maintained at 50% effort. HIIT exercises, involving low-skill movements in short bursts, enhance blood sugar regulation and fat-burning capacity.~The HIIT protocol has four phases:~Warm-Up: 10 minutes, gradually increasing to about 60% of maximum heart rate. Intervals: 4 minutes at 85-95% maximum heart rate. Relief/Recovery: 3 minutes at 60% maximum heart rate, repeated four times. Cool Down: 5 minutes, bringing the heart rate down to around 50% of maximum. Three key components determine the success of HIIT: intensity, duration, and recovery period. Exercises include dumbbell and kettlebell exercises, push-ups, squats, jump training, and stationary cycling"
223882691|NCT06777394|OTHER|Routine treatmet|"outine physical therapy includes stretching exercises, exercises to maintain a normal range of motion, and low-intensity and aerobic exercises for the patients.~Low-Intensity Exercise: The effects of low-intensity exercise become noticeable after about 20 minutes, providing a metabolic boost during the activity. Generally, a longer exercise duration further enhances metabolism."
223882692|NCT05038345|PROCEDURE|Pull through surgery|The principal purpose of pull through surgery for Hirschsprung disease is to remove aganglionic bowel and reconstruct the intestinal tract by connecting the normally innervated bowel just above the anus so that normal sphincter function is preserved.
223882693|NCT04623424|DIAGNOSTIC_TEST|intestinal microbiota|Stoll samples will be tested for different bacteria
223882694|NCT04843865|DIETARY_SUPPLEMENT|Chinese Herbs|Chinese Herbs
223882695|NCT06781320|DEVICE|stabilization splint|"the patients will receive a stabilization splint fabricated using a fully digital workflow includes:~Intraoral scanning of maxillary and mandibular arches to create a digital model.~Jaw tracking using the Zebris JMA system to record mandibular movements. CAD design of the splint using Exocad software. Fabrication of the splint via 3D printing technology. The FD-SS is designed to provide optimal occlusal stabilization, reduce TMJ stress, and minimize enamel wear over 6 months.~Or the patient will receive stabilization splint fabricated using conventional methods. The intervention includes:~Taking alginate impressions of maxillary and mandibular arches to create plaster casts.~Jaw registration using a Lucia jig and semi-adjustable articulator for proper occlusal adjustment.~Manual fabrication of the splint using polymethyl methacrylate (PMMA) resin. The C-SS is designed to achieve occlusal stabilization and symptom relief for TMD patients over 6 months."
223882696|NCT04031677|PROCEDURE|Surgery|Large en-bloc curative-intent surgery
223882697|NCT04031677|DRUG|Preoperative chemotherapy|"* High grade LPS: ADM 75 mg/m2 (or the equivalent EpiADM 120 mg/m2) + ifosfamide 9 g/m2 Q3 weeks~* LMS: ADM 75 mg/m2 + DTIC 1g/m2 Q3 weeks~Note: the recommended dose of Doxorubicin (or Epirubicin) can be modified according to national/institutional guidelines, given that the minimal threshold must be Doxorubicin 60 mg/m2 per cycle (or the equivalent Epirubicin 95 mg/m2 per cycle); the recommended dose of Ifosfamide can be modified according to national/institutional guidelines, given that the minimal threshold must be 7.5 g/m2 per cycle; the recommended dose of Dacarbazine can be modified according to national/institutional guidelines, given that the minimal threshold must be 900 mg/m2 per cycle. The schedule of administration of above chemotherapies can be modified according to national/institutional guidelines provided that the minimal threshold of doses, and the treatment periods with chemotherapies remain the same."
223882698|NCT06781346|PROCEDURE|Rhomboid Intercostal Block|In RI block group, A 22G, 50mm block needle (SONOTAP,Pajunk, -Geisingen,Germany) will be inserted in the cranial to caudal direction via an in-plane approach between the medial border of the scapula between the 4th and 5th rib of the patients in the RIB group. In the ultrasound image, the trapezius muscle, rhomboid muscle, intercostal muscles,pleura, and lung were identified. Under the aseptic condition, inserted laterally in the plane of the T5 level guided by an ultrasound probe with an in plane technique. The intravascular injection should be confirmed negative through aspiration, and 1-3 ml of normal saline was injected to divide the rhomboid and intercostal muscle, and a total volume of 20 ml of bupivacaine 0.25% ( not exceeding a maximum dose of 2 mg/kg) will be injected After negative aspiration of blood or air, injected into the deep layer of the rhomboid muscle.
223882699|NCT06781346|PROCEDURE|Thoracic Paravertebral Block|In the TPV block group , the transverse process and the pleura will be identified and needle will be inserted in the cranial to caudal direction till it pierces the SCTL and reaches the paravertebral space. After negative aspiration of blood or air a total volume of 20 ml of bupivacaine 0.25% will be injected displacing the pleura downwards.
223882700|NCT06022029|DRUG|ONM-501|Intratumoral injection
223882701|NCT06022029|DRUG|Cemiplimab|Intravenous administration of 350 mg
223882702|NCT05937776|OTHER|Fludeoxyglucose F-18|Given IV
223882703|NCT05937776|OTHER|Gadoterate Meglumine|Given IV
223882704|NCT05937776|PROCEDURE|Contrast-enhanced Magnetic Resonance Imaging|Undergo PET/contrast-enhanced MRI
223882705|NCT05937776|PROCEDURE|Positron Emission Tomography|Undergo PET/contrast-enhanced MRI
223882706|NCT06268041|BEHAVIORAL|Moderate-Intensity Aerobic Training|Overground and treadmill walking with speed continuously adjusted to maintain a target heart rate of 40 +/- 5% heart rate reserve, progressing up to 55 +/- 5% heart rate reserve.
223882707|NCT06268041|BEHAVIORAL|High-Intensity Interval Training|Overground and treadmill walking with 30 second bursts at maximum speed alternated with 30-60 second passive recovery periods. Intended to achieve a target average heart rate above 60% heart rate reserve.
223882708|NCT06763666|DRUG|Cladribine|Given IV
223882709|NCT06763666|DRUG|Cytarabine|Given IV
223882710|NCT06763666|DRUG|G-CSF|Given SC
223882711|NCT06763666|DRUG|Venetoclax|Given PO
223882712|NCT06078696|DRUG|Siplizumab|Premedication with diphenhydramine 50 mg PO is to be given 1 hour prior to siplizumab infusion. Premedication with hydrocortisone succinate 100 mg IV infused over 30 minutes and acetaminophen 650 mg PO are to be given at least 30 minutes prior to siplizumab infusion. Siplizumab 4.8 mg/kg total is given on Day -14 and 0.6mg/kg is given on days -6, -1, 0, and +1. It will be given as an IV infusion over 1 hour.
223882713|NCT06078696|PROCEDURE|Exchange Transfusion|Patient will undergo a red blood cell exchange transfusion to achieve a Hemoglobin S (HgbS) level \< 20% prior to starting therapy to prevent the development of a vaso-occlusive Crisis (VOC).
223882714|NCT06078696|PROCEDURE|Total Body Irradiation|Radiation dose is 2Gy (Gy is a radiation unit of measurement). Radiation source and dose rates will be according to institutional practice. Total Body Irradiation (TBI) may be delivered from either linear accelerator or Cobalt sources.
223882715|NCT06078696|PROCEDURE|Stem Cell Infusion|Standard institutional procedures should be followed for the processing and administration of stem cell products for infusion. The infused graft under no circumstances is to be irradiated. No in-line leukocyte filter should be used and no medications or fluids should be given piggyback through the catheter lumen used for infusion of stem cells. Vital signs should be monitored before beginning the infusion and periodically during administration and in accordance with institutional guidelines. Pre-medications prior to the graft infusion will be according to the institutions standard practice. Benadryl, epinephrine, hydrocortisone, and oxygen be available at the bedside, as well as an emergency medical code cart available in the vicinity of the patient, for emergency use in case of an infusion reaction.
223882716|NCT06078696|DRUG|Cyclophosphamide 50mg|Cyclophosphamide will be given on days +3 and +4 at a dose of 50 mg/kg. Hydration prior to cyclophosphamide should be given according to standard institutional practice. Day +3 dose should occur between 60 and 72 hours after graft infusion and day +4 post-transplant should occur approximately 24 hours after prior dose. Cyclophosphamide will be given as an IV infusion over 1-2 hours depending on volume or as per institutional standard practice. Cyclophosphamide will be dosed according to adjusted ideal body weight (AIBW) in patients weighing \> 125% ideal body weight (IBW).
223882717|NCT06078696|DRUG|Mesna|Mesna is to be given starting 1 hour prior to cyclophosphamide at the same dose (50 mg/kg) as a continuous infusion over 24 hours.
223882718|NCT06078696|DRUG|Sirolimus Oral Tablet|Sirolimus will be given orally with a loading dose of 12 mg, then followed by 4 mg orally daily. Dosage will be adjusted to a therapeutic target of 10 - 15ng/ml in first 3 months post transplant and 3-10 after 3 months. Sirolimus should be started on day +5. It will be continued until at least day 180. Sirolimus can be tapered or continued according to the treating physician discretion and the presence of absence of GVHD and/or degree of donor chimerism. Sirolimus should be continued if donor chimerism is less than 50% to prevent graft loss.
223882719|NCT06078696|DRUG|Rituximab or Biosimilar|Rituximab (375 mg/m2/dose) will be administered on Days -14 and -6. In those subjects receiving ongoing renal replacement therapy, rituximab should be administered several hours after hemodialysis. The first rituximab solution for infusion should be administered intravenously at an initial rate of 50 milligrams/hour (mg/hr). The rate may be escalated by 50mg/hr every 30 minutes to a maximum of 400 mg/hr. Subsequent infusions may be started at 100 milligrams/hour (mg/hr) and titrated by 100 mg/hr every 30 minutes to a maximum of 400mg/hr if the subject tolerated the first infusion.
223882720|NCT04724694|BEHAVIORAL|Brief CBT for Chronic Pain|Brief CBT-CP is a manualized protocol that includes six, 30-minute sessions over the course of 6-12 weeks. Session one focuses on foundational pain education and the development of treatment goals. Session two emphasizes balanced engagement in physical activity and pleasurable events. Session three emphasizes skills training for easily implemented relaxation techniques. Sessions four and five focus on recognizing and modifying unhelpful thoughts that negatively impact pain. Session six focuses on relapse prevention and independent implementation of CBT-CP skills following treatment.
223882721|NCT04724694|OTHER|Treatment as usual|Participants assigned to TAU will receive standard medical care from their primary care provider including pain medications, brief advice (e.g., use of relative rest, application of heat or ice, other self-care strategies), or referral to pain-related adjunctive interventions (e.g., physical therapy), as indicated.
223882722|NCT05917938|DRUG|NNC0194-0499|NNC0194-0499 will be administered subcutaneously in a skinfold in the thigh in the form of a solution for injection.
223882723|NCT05938465|BIOLOGICAL|EXE-346|EXE-346 contains a proprietary, fixed-dose, lyophilized blend of 8 strains of gram positive, lactic acid bacteria. EXE-346 excipients are maltose and silicon dioxide.
223882724|NCT05938465|OTHER|Placebo|Placebo contains excipients maltose and silicon dioxide.
223882725|NCT06766955|OTHER||
223882726|NCT05215847|DRUG|ARD-101|Twice daily, oral administration
223882727|NCT06678737|OTHER|CBIT +cTBS|10 daily sessions of CBIT plus cTBS, with MRI, behavioral, and clinical assessments before and after treatment and at 1-, 3-, and 6-month follow-ups.
223882728|NCT06678737|OTHER|CBIT +sham cTBS|10 daily sessions of CBIT plus sham cTBS, with MRI, behavioral, and clinical assessments before and after treatment and at 1-, 3-, and 6-month follow-ups.
223882729|NCT04330326|DRUG|Metabolic Cofactor Supplementation|Subjects in active treatment will receive dietary supplementation with N-acetylcysteine, L-carnitine tartrate, nicotinamide riboside, and serine, administered as a mixture. Half dosage of the co-factors will be given for two weeks (one dose taken just after dinner), and full dosage for 8 weeks (two equal doses taken just after breakfast and dinner).
223882730|NCT04330326|DRUG|Sorbitol|As placebo, sorbitol (5 g) flavored with strawberry aroma and coloring agent will be given. Sorbitol is widely used due to its solubility in water. It's approved by the U.S. Food and Drug Administration (FDA).
223882731|NCT06479785|OTHER|Educational Intervention Program for machine workers|A detailed Educational Intervention Program for marble factory workers working on Machines.
223882732|NCT06479785|OTHER|Educational Intervention Program for manual workers|A detailed Educational Intervention Program for marble factory workers working manually.
223882733|NCT04970407|BIOLOGICAL|Botulinum toxin type A|Intramuscular Injection, concentration 300 units (U)
223882734|NCT04970407|BIOLOGICAL|Botulinum toxin type A|Intramuscular Injection, concentration 50 U
223882735|NCT04970407|BIOLOGICAL|Botulinum toxin type A|Intramuscular Injection, concentration 50 U
223882736|NCT06739161|RADIATION|Sintilimab combined with chemotherapy and local treatment|"Treatment Regimens~①Chemotherapy: Regimen follows guideline-recommended first-line therapy for advanced gastric cancer.~②Sintilimab (200 mg) is administered with chemotherapy every 21 days. Maintenance immunotherapy continues for up to 1 year after chemotherapy.~③Local Treatment: Performed during cycles 3-8 of immunochemotherapy. Radiotherapy is preferred, using a combination of high- and low-dose fractionation, tailored to tumor location, size, and proximity to critical organs.~Alternative local treatments, such as radiofrequency ablation or surgery, may be used if suitable."
223882737|NCT06739161|COMBINATION_PRODUCT|Sintilimab combined with chemotherapy only|"Treatment Regimens ①Chemotherapy: Regimen follows guideline-recommended first-line therapy for advanced gastric cancer.~②Sintilimab (200 mg) is administered with chemotherapy every 21 days. Maintenance immunotherapy continues for up to 1 year after chemotherapy."
223882738|NCT02960230|BIOLOGICAL|K27M peptide|K27M peptide vaccine, combined with Tetanus Toxoid peptide, emulsified in montanide. Poly-ICLC will be given concurrently
223882739|NCT02960230|DRUG|Nivolumab|anti-programmed cell death protein 1 (PD-1) monoclonal antibody
223882740|NCT06780839|DRUG|Ensartinib|Patients will receive Ensartinib 225mg QD by MRD test guided, if MRD test shows negative, only ensartinib will be given. if MRD test turns from negative to posive, patients will receive step-up treatment, which is ensartibe plus platinum - based doublet chemotherapy no more than 4 cycles. If MRD test turns from posive to negative, only ensartinib will be given. if MRD test constantly shows positive, MDT will determine the next step ensartib-based therapy.
223882741|NCT05281484|DRUG|CNM-Au8|"CNM-Au8 is an aqueous suspension of clean surfaced faceted nanocrystals consisting of gold atoms self-organized into crystals of various geometrical shapes (hexagonal bi-pyramid, pentagonal bipyramid, tetrahedron, decahedron, planar spheroids).~Highly pure elemental Au nanocrystals are suspended in USP purified deionized water buffered with 0.546 mg/mL (6.5 mM) sodium bicarbonate (NaHCO3) nominally concentrated to up to 0.5 mg/mL (500 ppm)."
223882742|NCT06782126|BEHAVIORAL|BreeZe (Brandwonden en Zelfmanagement)|BreeZe is a self-management support program designed to enhance burn survivors' intrinsic motivation and self-efficacy for self-management after discharge. The intervention is based on the Self-Regulation Theory framework. Key strategies include evidence-based techniques such as goal setting and pursuit, Solution-Focused Brief Therapy, and Motivational Interviewing. The program takes a positive approach to boost motivation and self-efficacy, promoting sustainable behavior change in burn aftercare. BreeZe will be implemented through various strategies, including educating healthcare professionals on self-management, training them in communication skills (e.g., motivational interviewing), and providing materials such as a decision aid tool (self-management web) and a workbook tailored to burn survivors. Burn survivors will use the web to identify and prioritize problems, set personalized goals with their healthcare professional, and create an action plan for goal attainment.
223882743|NCT05276063|DRUG|Linsitinib|Study medication taken twice daily by mouth
223882744|NCT05276063|DRUG|Placebo|Placebo taken twice daily by mouth
223882745|NCT06164197|DEVICE|Lokomat|Robot Assisted Gait Training
223882746|NCT06164197|DEVICE|Thera Trainer Balo|Virtual Reality Based Balance Training Device
223882747|NCT06164197|OTHER|Person-Specific Rehabilitation Program|Person-Specific Rehabilitation Program
223882748|NCT02819843|DRUG|TALIMOGENE LAHERPAREPVEC (TVEC)|
223882749|NCT02819843|RADIATION|Hypofractionated Radiotherapy|
223882750|NCT05728489|DRUG|BI 765250|BI 765250
223882751|NCT05728489|DRUG|Placebo|placebo
223882752|NCT05698017|BIOLOGICAL|hOMSC300|Human Oral Mucosa Stem Cells
223882753|NCT00984321|BEHAVIORAL|group intervention and questionnaires|Group Session will be 90 minutes long. Both the group sessions and individual session will be audio recorded. GSPI is a novel, manualized psychoeducational intervention that integrates Folkman's cognitive construct and Erikson's developmental concept of the 7th and 8th stages of life. GSPI consist of 5 weekly sessions. The first 2 sessions will be held on consecutive weeks to help establish rapport and explain therapeutic concepts, and next 3 sessions will be held every other week, giving patients time to utilize the therapeutic concepts and expanding length of contact with the patient.
223882754|NCT00984321|BEHAVIORAL|individual phone intervention and questionnaires|Individual phone sessions will be 45 minutes long. Both the group sessions and individual session will be audio recorded. GSPI is a novel, manualized psychoeducational intervention that integrates Folkman's cognitive construct and Erikson's developmental concept of the 7th and 8th stages of life. GSPI consist of 5 weekly sessions. The first 2 sessions will be held on consecutive weeks to help establish rapport and explain therapeutic concepts, and next 3 sessions will be held every other week, giving patients time to utilize the therapeutic concepts and expanding length of contact with the patient.
223882755|NCT00984321|BEHAVIORAL|expressive writing (arm will not be include in the randomization)|"intervention facilitate reappraisal through the exploration of past life events and prior successful ways of coping. Preliminary studies examining the efficacy of this writing intervention have shown its' ability to introduce patients to a new and effective coping method that can be utilized during future stressful cancer and aging related events.67 In the sessions, Wwe will explore past life events and ways of coping through manualized writing sessions."
223882756|NCT04022343|DRUG|Cabozantinib|Given PO
223882757|NCT03055858|DEVICE|ADO II AS (PDA closure)|Closure of PDA using Amplatzer Duct Occluder II Additional Sizes (ADO II AS).
223882758|NCT06218368|BEHAVIORAL|Educational toolkit on MMR and polio vaccination|The educational video about vaccines was adapted from a health educational toolkit that aims to promote community confidence in vaccines in the ultra-poor Philippine households. This toolkit contains persuasive messaging on vaccination guidelines, vaccines safety and efficacy, and myths and misconceptions of MMR and polio vaccines. Participants in the intervention arm will receive our educational video about MMR and polio vaccines. Additionally, health educators from ICM will teach the participants to understand their vaccination cards and orally remind them to have their children vaccinated at each week's Transform Program session from week 12 until week 15. After the end of the Transform Program, about 40-50% of the participants in the intervention arm will attend another community-based program run by ICM called the Savings Groups, where the participants will receive weekly reminding messages about MMR and polio vaccination in their group meetings for three months.
223882759|NCT04586920|DRUG|LY3509754|Administered orally
223882760|NCT04586920|DRUG|Placebo|Administered orally
223882761|NCT04586920|DRUG|Itraconazole|Administered orally
223882762|NCT04586920|DRUG|Midazolam|Administered orally
223882763|NCT04761302|DRUG|Intravenous ketorolac and oral acetaminophen|ketorolac 30 mg intravenous (IV) every 6 hours for patients younger than 70 years versus ketorolac 15 mg IV every 6 hours for patients older than 70 years, first dose will be administered 30 minutes preoperatively. An additional 1000mg of oral acetaminophen will be administered every 6 hours simultaneously regardless of the age group
223882764|NCT04761302|DRUG|Intravenous morphine and oral oxycodone|Morphine 0.1 mg per kg intravenous every 6 hours with an additional oral oxycodone combined with acetaminophen 2 tabs every 6 hours.
223882765|NCT04980495|BIOLOGICAL|Efgartigimod concentrate for solution for infusion 20 mg/mL|Patients receiving efgartigimod IV treatment in a continuous treatment regimen
223882766|NCT04980495|BIOLOGICAL|Efgartigimod concentrate for solution for infusion 20 mg/mL|Patients receiving efgartigimod IV treatment in a cyclic treatment regimen
223882767|NCT06473844|DRUG|Empagliflozin 10 MG|Empagliflozin 10mg once daily from recruitment to hospital discharge
223882768|NCT06473844|DRUG|Placebo|Placebo single tablet once daily from recruitment to hospital discharge
223882769|NCT02728557|BEHAVIORAL|Supportive-Expressive Therapy|Supportive-expressive psychotherapy for depressive disorder for 16 weeks.
223882770|NCT02728557|BEHAVIORAL|Supportive Therapy|Supportive psychotherapy for depressive disorder for 16 weeks.
223882771|NCT03281902|PROCEDURE|Biopsy|Undergo tumor biopsy
223882772|NCT03281902|PROCEDURE|Biospecimen Collection|Undergo collection of blood, urine, stool, and saliva
223882773|NCT03281902|OTHER|Laboratory Biomarker Analysis|Correlative studies
223882774|NCT01007383|DRUG|LEO 27847|First in man
223882775|NCT03897686|DEVICE|"hydrous biopolymer with silver ions Argiform"|2 once-weekly intra-articular injections of NOLTREX™ 4.0 ml
223882776|NCT03897686|DEVICE|saline solution|2 once-weekly intra-articular injections of saline solution 4 ml
223882777|NCT04684108|DRUG|SG301|Phase 1a will use an accelerated titration and 3+3 design with 9 dose cohorts: 0.005 mg/kg, 0.05 mg/kg,0.5 mg/kg, 1 mg/kg, 2 mg/kg, 4 mg/kg, 8 mg/kg, 12 mg/kg and 16 mg/kg by IV infusion. Accelerated titration (i.e., 1 patient each) will be applied to the first 3 cohorts.
223882778|NCT05679297|DIAGNOSTIC_TEST|Quantitative sensory testing (QST)|"The QST is a standardized, internationally accepted test battery consisting of several well-established, non-invasive tests, measuring parameters, which reflect nearly all aspects of somatosensation.~1. Thermal detection threshold for the perception of cold, warm and paradoxical heat sensations~2. Thermal pain threshold~3. Mechanical detection thresholds for touch~4. Mechanical pain threshold for pinprick stimuli~5. Stimulus-response functions~6. Wind- up ratio: The wind- up ratio represents the quotient of the pain intensity evoked by 10 pin-prick stimuli and the pain intensity evoked by one single pin-prick stimulus~7. Vibration detection threshold~8. Pressure pain threshold"
223882779|NCT05679297|DIAGNOSTIC_TEST|Magnetic resonance imaging (MRI)|"Functional and structural MRI data will be collected using a 3 Tesla Siemens Scanner with a multi-channel head coil.~For the resting state functional MRI the subjects will merely lie in the scanner for about 10 minutes.~A painful heat/cold stimulation will be performed to study the differences in pain processing between the three groups"
223882780|NCT05679297|OTHER|Clinical interview/exam|The pain characteristics will be assessed through a standardized questionnaire. The german pain questionnaire is a validated questionnaire that assesses various dimensions of pain. Patients will also get a complete neurological examination by an experienced clinician.
223882781|NCT05679297|OTHER|Follow-up interview|"Structured telephone interview with 3 Questionnaires~1. The german pain questionnaire~2. Questionnaire regarding clinical development since the last visit designed by the investigators~3. German translation of 12-item-allodynia symptom checklist (ASC-12)"
223882782|NCT03416010|BEHAVIORAL|COPE-P|"Session 1 ABCs (A=Antecedent or Activator event, B=Belief that follows the event, C=Consequence: how you feel and how you behave).~Session 2 self-esteem and positive self-talk, including ways to build self-esteem and the group provides examples of how to change unhealthy habits into healthy ones.~Session 3 stress/coping during pregnancy. Physical and emotional responses to stress are discussed along with healthy snacking and healthy ways to cope with typical stresses.~Session 4 planning, goal setting and the 4-step problem solving process. Session 5 dealing with emotions in healthy ways through positive thinking and effective communication.~Session 6 coping with stressful situations encountered during pregnancy while continuing to reinforce the thinking-feeling-behaving triangle."
223882783|NCT05753410|BEHAVIORAL|Mindful Courage|Self-guided online intervention
223882784|NCT05415436|OTHER|Propofol slow administration|Propofol will be slowly administered over 120 seconds by anesthesia provider
223882785|NCT03625323|DRUG|eftilagimod alpha|APC activator, MHC II agonist, LAG-3 fusion protein
223882786|NCT03625323|DRUG|pembrolizumab (KEYTRUDA®)|anti-PD-1 antibody
223882787|NCT05573828|PROCEDURE|ICG angiography to show vascular map of parathyroid glands|Using ICG angiography guided thyroidectomy to identify the vessels feeding the parathyroid glands and then perform the thyroidectomy. After it, ICG angiography is done to predict immediate parathyroid functio
223882788|NCT05423340|OTHER|E-cigarette Flavor|Participants use an electronic nicotine delivery system with an assigned tobacco-flavored e-liquid
223882789|NCT05423340|OTHER|Tobacco Free Nicotine Pouch|participants will use tobacco free oral nicotine pouches
223882790|NCT06269744|BEHAVIORAL|Proactive Screening Outreach|Individuals in the interventional arm will receive an information letter, followed by mailed FIT kit. Individuals that do not respond will receive reminder phone calls. Individuals that do respond will receive navigation to assist with completion of FIT and the colonoscopy if FIT is abnormal. Clinic processes will be closely followed and the primary care provider will be informed of the program.
223882791|NCT03264131|DRUG|Brentuximab Vedotin|Brentuximab Vedotin will be given at 1.8 mg/kg IV over approximately 30 minutes on D1 every 21 days for 2-6 cycles. Responders (CR, PR or SD) who are not eligible for bone marrow transplant (BMT) and have CD30-positive ATLL will continue maintenance therapy with BV alone (1.8 mg/kg IV for approximately 30 minutes, every 21 days).
223882792|NCT03264131|DRUG|CHEP|"Cyclophosphamide- 750 mg/m\^2 IV over approximately 1 hour on D1 every 21 days for 2-6 cycles~Doxorubicin- 50 mg/m\^2 IV over approximately 3-5 minutes on D1 every 21 days for 2-6 cycles.~Etoposide - 100 mg/m\^2 IV over approximately 1 hour each day for 3 days every 21 days for 2-6 cycles.~Prednisone - 100 mg, orally once daily for 5 days every 21 days for 2-6 cycles."
223882793|NCT06170489|BIOLOGICAL|JS004 in combination with Toripalimab|Participants will receive JS004 in combination with Toripalimab (200 mg/240 mg) by intravenous (IV) infusion on Day 1, then every three weeks (Q3W), for up to 35 infusions.
223882794|NCT06170489|DRUG|Bendamustine or gemcitabine|Participants will receive Investigator-Selected chemotherapy of EITHER bendamustine by IV infusion at a dose of 90 or 120 mg/m\^2 on Day 1 and Day 2 of either a 3- or 4-week cycle for up to 6 cycles OR gemcitabine by IV infusion at a dose of 1000 mg/m\^2 on Day 1 and Day 8 of a 3-week cycle for up to 6 cycles.
223882795|NCT06798792|OTHER|PechaKucha technique|The Discharge Education course was taught using the PechaKucha technique.
223882796|NCT06798792|OTHER|TeachBack technique|The Discharge Education course was taught using the TeachBack technique.
223882797|NCT06415474|PROCEDURE|Lymphocyte Phenotyping Procedure|"For all patients, lymphocyte phenotyping will be performed on biological samples taken on D0, D7 and the day of discharge. In case of infection, phenotyping will also be performed on the day of infection diagnosis and on the day corresponding to half the duration of antibiotic therapy.~For phenotyping, only 1.5 mL will be used. In case of infection, an additional 1mL will be collected (0.5mL on the day of inclusion diagnosis and 0.5 mL on the day corresponding to half the duration of antibiotic therapy). Blood is collected during sampling, which takes place several times a day as part of the standard management of these patients.~It is important to note that phenotyping is not routinely performed as part of routine care. An additional tube is therefore taken specifically for this analysis, but this is done without the need for an additional puncture."
223882798|NCT05574426|BEHAVIORAL|Movement Breaks|Participants will be asked to perform 30-60 second movement breaks 3-4 times per day on at least 3 days per week.
223882799|NCT00753987|DRUG|Hypertonic Saline|5 ml of 7% saline will be administered via mask with Pari LC Plus nebuliser and a Pari Ultra Ned compressor.
223882800|NCT06417996|OTHER|Digital Group|Once patients are ready for discharge, patients in the digital group will be sent home with the Biobeat digital monitoring kit with written \& oral instructions on how it will be used in maintaining continuity of care which will track ECG (electrocardiogram), HR, NIBP, SPO2, and pain scores. A continuous recording and two-lead ECG patch will be applied and activated at the time of discharge to identify any paroxysmal atrial fibrillation.
223882801|NCT06790342|DRUG|Cystine|Used for smoking cessation and alcohol reduction
223882802|NCT06790342|BEHAVIORAL|Positively Smoke Free|An 8 session tailored behavioral treatment for smoking cessation and alcohol reduction
223882803|NCT06790342|OTHER|Placebo|Matched to cystine
223882804|NCT06790342|OTHER|Standard of Care|Standardized brief advice to quit smoking (standard of care)
223882805|NCT06782607|DIAGNOSTIC_TEST|Pneumonia Panel by FilmArray|The Pneumonia Panel comprehensively identifies 33 potential pathogen targets from sputum-like (including endotracheal aspirate) and bronchoalveolar lavage (BAL)-like (including mini-BAL) samples. For 15 of the bacteria, the Pneumonia Panel provides semi-quantitative results, which may help determine whether an organism is a colonizer or a pathogen.
223882806|NCT06783556|DEVICE|The Ear Electroacupuncture of Battlefield Acupuncture (BFA) and paracetamol intravenous therapy|"Electroacupuncture therapy was performed 2 hours before PCNL surgery. Needle insertion was performed perpendicularly at the Battlefield Acupuncture (BFA) points of the ear, namely MA-IT1 Cingulate gyrus, MA-AT2 Thalamus, MA-H2 Omega2, MA-H1 Point Zero and MA-TF1 Shenmen bilaterally. Then the electrostimulator cable was connected to the ear acupuncture points MA-AT2 and MA-TF1 bilaterally on the same side and then fixed with plaster. Electroacupuncture uses continuous waves of 2 Hz frequency with an intensity that can be tolerated by the patient for 30 minutes.~Patients also received standard therapy with 1000 mg intravenous paracetamol with a maximum of 3 times administration per 24 hours and can be reduced according to the needs of the patient's pain complaints."
223882807|NCT06783556|DEVICE|The sham electroacupuncture and paracetamol intravenous therapy|"Sham electroacupuncture therapy was performed 2 hours before PCNL surgery. Needle only attached using plester (not inserted) at the Battlefield Acupuncture (BFA) points of the ear, namely MA-IT1 Cingulate gyrus, MA-AT2 Thalamus, MA-H2 Omega2, MA-H1 Point Zero and MA-TF1 Shenmen bilaterally. Then the electrostimulator cable was connected to the ear acupuncture points MA-AT2 and MA-TF1 bilaterally on the same side and then fixed with plaster. Electroacupuncture device is not turned on. The therapy is carried out for 30 minutes.~Patients also received standard therapy with 1000 mg intravenous paracetamol with a maximum of 3 times administration per 24 hours and can be reduced according to the needs of the patient's pain complaints."
223882808|NCT06436755|PROCEDURE|no intervention,this is a observational studies|no intervention,this is a observational studies
223882809|NCT04030130|BEHAVIORAL|NDURE|NDURE is a theory-based, multi-level Patient Navigation (PN) intervention consisting of three in-person, clinic-based sessions of manualized PN with multiple intervention components that target system- (care coordination), interpersonal- (social support), and individual- (Health Belief Model; perceived susceptibility, severity, barriers, self-efficacy) level health behavior theoretical constructs to reduce barriers to care, improve cancer care delivery, and improve clinical outcomes (timely, equitable PORT). NDURE will be delivered from surgical consultation to PORT initiation (\~3 months).
223882810|NCT05103904|OTHER|Laboratory Biomarker Analysis|Correlative studies
223882811|NCT05103904|DRUG|Lenvatinib|Given PO
223882812|NCT03819686|BEHAVIORAL|Living ACTS website|Living ACTS: About Choices in Transplantation and Sharing video that draws from the Information-Motivation-Behavioral Skills Model of individual level behavior change. A patient will watch the Living ACTS video (embedded in the Living ACTS website) along with any family members or friends who are accompanying a patient. Plus minimum of 5 minutes navigating the website (aside from watching \~20-minutes of videos from the website)
223882813|NCT03819686|BEHAVIORAL|Standard transplant education procedures|Review of a packet of information with the pre-transplant coordinator. The packet serves to inform transplant candidates and their families about the option living donor kidney transplantation (LDKT). In addition, participants will be provided an iPad/tablet to watch two \~10-minute National Kidney Foundation videos about kidney disease and transplantation in their private room during their regularly scheduled KT evaluation. This video discusses information about transplant, but does not specifically address LDKT and is not culturally-sensitive to African American population.
223882814|NCT06784102|OTHER|Damon Clear Debonding Plier (the primary intervention being tested in this study).|This clinical trial evaluates two types of orthodontic debonding pliers: the Damon Clear Debonding Plier and the traditional Bracket Remover Debonding Plier. The Damon Clear plier features a third wedging arm, which applies an additional lingual or palatal force in addition to the standard occluso-gingival force. The study is designed to assess and compare pain levels and debonding forces between the two pliers. A total of 40 patients, aged 17-25, were treated with both devices using a split-mouth design. The Damon Clear Plier is tested on one side of the mouth while the Bracket Remover Plier is used on the opposite side. Pain perception was measured immediately after the debonding procedure using the Numerical Rating Scale (NRS), and the forces applied during debonding were measured with a force-sensitive prototype. The study aims to identify the device that provides effective debonding with less pain.
223882815|NCT06396260|OTHER|Diffusion Kurtosis Imaging (DKI)|Non-invasive MRI sequence which extracts information of diffusion signals from complex brain tissue
223882816|NCT06396260|OTHER|Resting State Magnetoencephalography|Non-invasive method of measuring resting state brain activity through magnetoencephalography (MEG)
223882817|NCT04634435|COMBINATION_PRODUCT|BHV-1100 plus cytokine induced memory-like (CIML) NK cells plus IVIG and low dose IL-2|Single dose infusion of BHV-1100 plus CIML NK Cells plus IVIG, followed by low dose IL-2
223882818|NCT05012631|DRUG|Losartan|Losartan dosing for participants \<16 years will be 0.7 mg/kg (maximum of 50 mg) once daily. The dose can be increased to 1.4 mg/kg (maximum of 100 mg once daily) after 2 weeks if the dose was tolerated (no hypotension or hyperkalemia). For patients ≥16 years, the starting dose will be 50 mg once daily which can be increased to 100 mg daily if tolerated after 2 weeks.
223882819|NCT06787443|DIETARY_SUPPLEMENT|Placebo|Eligible subjects will receive Placebo to take daily for five weeks
223882820|NCT06787443|DIETARY_SUPPLEMENT|Dietary Supplement with Proprietary Herbal Extract Blend and GABA|Eligible subjects will receive active product to take daily for five weeks
223882821|NCT06783543|OTHER|Comprehensive detumescence treatment with education video|Comprehensive detumescence treatment, including skin care, manual lymphatic drainage, low elastic bandaging and functional exercise four steps
223882822|NCT06783543|OTHER|Comprehensive detumescence treatment|Three to five times a week, one hour each time
223882823|NCT05586542|COMBINATION_PRODUCT|DERMASEAL|a novel skin substitute formulated as planar, thin film
223882824|NCT05586542|BIOLOGICAL|Plasma Film|a planar, thin film made from human plasma
223882825|NCT05586542|OTHER|Standard of Care|standard procedures for managing diabetic foot ulcers including debridement of unhealthy tissue and maintenance of a moist wound environment
223882826|NCT06784908|OTHER|Yale Pain Stress Task (YPST)|Individuals in the experimental cohort will be scheduled for 2 experimental sessions 1-3 days apart. The YPST stress experiment includes a stress and no-stress session (order randomly assigned, counter-balanced across subjects), and involves multiple (up to 3) unpredictable number of consecutive 3-minute trials of ice-bath (stress) or warm-bath (no stress) forearm immersion (stress) with subjective, physiologic endocrine and immune assessments repeated at specified time points.
223882827|NCT04296162|DRUG|Vinorelbine|Vinorelbine chemotherapy (oral)
223882828|NCT04296162|DRUG|Capecitabine|Capecitabine chemotherapy (oral)
223882829|NCT04296162|DRUG|Trastuzumab|Trastuzumab target therapy
223882830|NCT06786273|GENETIC|Small RNA sequencing|The blood and endometrial tissue samples collected from the study groups will undergo small RNA sequencing to investigate the microRNA expression profiles associated with that phase.
223882831|NCT06788873|OTHER|Data comparison|"For each participant, information will be collected on:~* Gestational age at the time the cerclage was performed~* Parity~* Age~* BMI~* Ethnicity~* Number of preterm deliveries~* Gestational age of previous preterm deliveries~* Previous uterine and/or cervix surgery (previous cerclage, conization, metroplasty, or other)~* Type of cerclage performed~* Operative times~* Days of hospitalization~* Surgical complications~* Gestational age at the time of delivery~* Mode of delivery (spontaneous, operative or cesarean)~* Infant's weight at birth~* Apgar at 1' and 5' minute~* Ph newborn~* Possible admission to neonatal intensive care unit."
223882832|NCT06785740|DRUG|Statin|Statin use
223882833|NCT04505774|DRUG|theraputic heparin|increased dose of heparin above standard of care.
223882834|NCT04505774|DRUG|prophylactic heparin|standard of care dose of heparin
223882835|NCT04505774|DRUG|P2Y12|added P2Y12 inhibitor
223882836|NCT04505774|DRUG|Crizanlizumab Injection|crizanlizumab injection
223882837|NCT04505774|DRUG|SGLT2 inhibitor|sglt2 inhibitor
223882838|NCT05466890|DRUG|PL8177 Placebo|Approximately 1/4 of randomized patients will receive matching placebo as means of comparison to active treatment PL8177.
223882839|NCT05466890|DRUG|PL8177|Approximately 3/4 of randomized patients will receive active PL8177.
223882840|NCT05454215|DEVICE|Mechanical insufflation/exsufflation conventional|Conventional settings in a commercially available chest physiotherapy device
223882841|NCT05454215|DEVICE|Mechanical insufflation/exsufflation modified|Modified settings in a commercially available chest physiotherapy device
223882842|NCT06783920|PROCEDURE|music|music will be played during the copper IUD insertion
223882843|NCT06783920|PROCEDURE|no music|IUD insertion will be done as usual without music
223882844|NCT06792474|DRUG|Lidocaine in Saline|Lidocaine infusion 1.5 mg/kg/hr
223882845|NCT06792474|DRUG|Normal saline|Normal saline infusion
223882846|NCT06790264|PROCEDURE|68Ga-FAPi-46 PET/CT|Study participants will undergo baseline assessments at enrollment with 68Ga-FAPi-46 PET/CT
223882847|NCT06786208|DRUG|Sunvozertinib|sunvozertinb, a EGFR-TKI, 300mg QD oral
223882848|NCT06791902|DEVICE|Adaptive DBS|Adapting DBS stimulation based on locomotor states
223882849|NCT06790550|OTHER|Music Therapy|Music will be played during the insulin injection process
223882850|NCT06785155|OTHER|Chatbot group|Participants explored the topics using the AI chatbot platform.
223882851|NCT06785155|OTHER|website assisted|Participants explored the topics using the website platform
223882852|NCT05909982|PROCEDURE|Mechanical thrombectomy combined with ischemic post-conditioning|Ischemic post-conditioning will be applied after successful recanalization of the culprit artery by thrombectomy. Ischemic post-conditioning consists of briefly repeated four cycles × 2 minutes of occlusion and reperfusion (equal duration) of the initially occluded artery using a balloon.
223882853|NCT04788537|BEHAVIORAL|Training to Understand and Navigate Emotions and Interactions (TUNE In)|A three-part cognitive behavioral treatment strategy to improve social functioning in adults with autism spectrum disorder. TUNE In includes components to address the many behavioral domains involved in social functioning, including social motivation, social anxiety, social cognition, social skills, and generalization of the skills to community settings.
223882854|NCT06783465|DEVICE|Digital therapeutics session|During the digital therapeutics session, the patient performs tasks by handling objects according to instructions displayed by the device. A camera records the task performance, and the system analyzes the task performance.
223882855|NCT06322615|PROCEDURE|Acupressure Therapy|Undergo acupressure
223882856|NCT06322615|OTHER|Educational Intervention|Receive education session about using acupressure at home
223882857|NCT06322615|OTHER|Electronic Health Record Review|Ancillary studies
223882858|NCT06322615|OTHER|Questionnaire Administration|Ancillary studies
223882859|NCT05034354|DEVICE|Remote physiological monitoring|Participants will be provided with a Bluetooth capable weight scale (A\&D Medical UC-352BLE or Beurer BY90), oxygen saturation monitor (Contec Medical Systems CMS50D-BT) and automatic blood pressure monitor (A\&D Medical UA- 651BLE) to use daily for at least 10 days of a 14-day trial period. Data will be sent via the Sphygmo App to the pediatric cardiology for monitoring. Parents and healthcare providers will be asked to participate in a qualitative interview and the end of the 14-day period to provide feedback on the devices and Sphygmo™ platform.
223882860|NCT06037382|OTHER|Mood Triggers App|"The current intervention will deploy a smartphone application called Mood Triggers. Mood Triggers was designed to provide personalized feedback on individuals' maintenance factors (i.e., triggers) of their anxiety and depressive symptoms based on the theory that such feedback will lead to symptom reduction."
223882861|NCT05648786|BEHAVIORAL|Laddr® plus Behavioral- Group and individual counseling|"Smartphone application utilizing the Community Reinforcement Approach (CRA) to facilitate social support in substance use treatment.~Outpatient treatment will include a range of services, including group counseling, individual counseling, medication treatment, and other recovery support services."
223882862|NCT05648786|BEHAVIORAL|Behavioral- Group and individual counseling|The active control condition consists of standard outpatient treatment for substance use disorders. Outpatient treatment will include a range of services, including group counseling, individual counseling, medication treatment, and other recovery support services.
223882863|NCT06785896|PROCEDURE|Angle Class II unilateral, treated by carriere motion appliance|This treatment was unilateral, with dental composite bites ramps behind canines
223882864|NCT06787898|OTHER|Group R: retrolaminar block performed group|Patients were placed on their side and then T9, T10 vertebrae were marked. After the skin was cleaned and the area was covered with sterile drape. A linear ultrasound probe (6-13 Hz, Hitachi Europe Ltd, Tokyo, Japan) was placed in the middle of the vertebral bodies to image the T9, T10 vertebraes. An experienced anaesthesiologist in RLB performed the procedures with a USG-guided 1-15 Hz convex probe (8-4, Hitachi Europe Ltd, Tokyo, Japan) by in-plane approach. A puncture needle (21Gx100mm, USG-Type CCR, Vygon Co. Ltd. Ecouen, France) was inserted 1 cm from the probe at a 45-degree angle to the skin, targeting the lamina of the desired vertebra. The needle was gently withdrawn to ensure that no blood or cerebrospinal fluid was present. 10 mL of 0.25% bupivacaine (Bupivon®) was injected posterior to each lamina (T9, T10), totalling 20 mL
223882865|NCT06787898|OTHER|Group C - Placebo|Patients were placed on their side and then T9, T10 vertebrae were marked. After the skin was cleaned and the area was covered with sterile drape. A linear ultrasound probe (6-13 Hz, Hitachi Europe Ltd, Tokyo, Japan) was placed in the middle of the vertebral bodies to image the T9, T10 vertebraes. An experienced anaesthesiologist in RLB performed the procedures with a USG-guided 1-15 Hz convex probe (8-4, Hitachi Europe Ltd, Tokyo, Japan) by in-plane approach. A puncture needle (21Gx100mm, USG-Type CCR, Vygon Co. Ltd. Ecouen, France) was inserted 1 cm from the probe at a 45-degree angle to the skin, targeting the lamina of the desired vertebra. The needle was gently withdrawn to ensure that no blood or cerebrospinal fluid was present. 10 mL of 0.25% bupivacaine (Bupivon®)was injected posterior to each lamina (T9, T10), totalling 20 mL.
223882866|NCT03654053|DRUG|Placebo Oral Tablet|Placebo taken once nightly at bed time.
223882867|NCT03654053|DRUG|Simvastatin 40mg|Simvastatin 40mg taken once nightly at bed time.
223882868|NCT06820424|BIOLOGICAL|Anti-CDH17 CAR-T cells infusion|Subiects who meet the enrollment conditions will receive intravenous infusion of anti-CDH17 CAR-T Cells after lymphodepleting therapy.
223882869|NCT05566925|OTHER|Direct access to physiotherapist for assessment, diagnosis and treatment.|Patients with knee osteoarthritis will be interviewed about their experience of being assessed, diagnosed and treated by a physiotherapist first in primary care.
223882870|NCT06792110|DEVICE|Artificial Intelligence Integrated Hearing Aid Use|Participants in this arm will use the study-designed artificial intelligence-integrated hearing aid in the listening tasks. Participants will also perform the listening tasks without hearing aids to act as controls.
223882871|NCT06792110|DEVICE|Phonak Infineo Hearing Aid|Participants in this arm will use a fitted commercial hearing aid in the listening tasks. Participants will also perform the listening tasks without hearing aids to act as controls.
223882872|NCT06792110|DEVICE|Oticon Real Hearing Aid|Participants in this arm will use a fitted commercial hearing aid in the listening tasks. Participants will also perform the listening tasks without hearing aids to act as controls.
223882873|NCT06787768|OTHER|Technology Enriched Rehabilitation Gym|The intervention is an 8-week long rehabilitation programme delivered entirely through technology, including virtual reality (immersed and non-immersed), treadmills, weight suspension and movement resistance, and power assistance equipment located in a gym-like space on a university campus. Individual programs are designed, supervised, and reviewed by a physiotherapist using principles of intensity, feedback, cognitive engagement, and aerobic activity to address the goals identified by the participant and scores from outcome measures at baseline. Participants attend a minimum of two times per week and can attend daily for the two hour group based circuit class.
223882874|NCT06788366|DRUG|Immunotherapy|First-line regimen according to clinical practice
223882875|NCT06788366|DRUG|Chemotherapy|First-line regimen according to clinical practice
223882876|NCT05873426|DRUG|[14C] ZSP1273|600 mg suspension containing 50μCi of \[14C\]ZSP1273
223882877|NCT06096532|OTHER|75 gm oral glucose load|Consumption of 75 gm oral glucose load in order to test nutrient responsiveness
223882878|NCT06792435|DRUG|XNW27011|"Eligible patient(s) in each dose cohort will receive the assigned XNW27011 dose administration every 3 weeks (Q3W, cycle) until intolerable toxicity, progression of the disease without clinical benefit, or withdrawal of informed consent.~An accelerated titration scheme will be used for the first two dose levels (0.6 mg/kg and 1.2 mg/kg) starting from 0.6 mg/kg dose as follows:~The first patient will be enrolled for 0.6 mg/kg dose. If the subject shows no significant toxicity in cycle 1 (DLT observation period), the second patient will be enrolled for 1.2 mg/kg.~3 + 3 dose escalation:3 patients will be enrolled to the dose cohort first，If 1 of 3 patients experiences a DLT, up to 3 more patients will be enrolled in the same dose cohort.. If none of the additional 3 patients experiences a DLT, dose escalation will continue to the next dose.Dose escalation will be stopped when 2 or more patients out of 3 to 6 patients at the same dose level experience a DLT."
223882879|NCT06792435|DRUG|XNW27011|Group A: Gastric/gastroesophageal junction adenocarcinoma with CLDN18.2 expression, tentatively expand with 3.6, 3.0, 2.4 mg/kg. Group B: Pancreatic adenocarcinoma with CLDN18.2 expression, tentatively expand with 3.6, 3.0, 2.4 mg/kg. Group C: Ovarian cancer with CLDN18.2 expression, tentatively expand with 3.6, 3.0, 2.4 mg/kg. Group D: Other tumors with CLDN18.2 expression, including but not limited to esophagus adenocarcinoma, lung cancer, colorectal cancer, and biliary tract cancer,tentatively expand with 3.6, 3.0, 2.4 mg/kg.
223882880|NCT05150795|DRUG|Pregabalin 150mg|Compare the postoperative analgesic effect of pre-operative oral pregabalin (Study group), to the intraoperative intravenous fentanyl (Control group) in diagnostic laparoscopic gynecologic surgery.
223882881|NCT05150795|DRUG|Fentanyl 100 micrograms ampoule|Compare the postoperative analgesic effect of pre-operative oral pregabalin (Study group), to the intraoperative intravenous fentanyl (Control group) in diagnostic laparoscopic gynecologic surgery.
223882882|NCT06148818|OTHER|Progressive neck motor control exercise therapy|The exercise programme will be conducted as a single session two days a week for 6 weeks. The sessions will always be conducted by the same physiotherapist. Each exercise session will consist of 10 minutes of warm-up exercises, 40 minutes of neck motor control exercises and 10 minutes of cool down exercises. Each exercise will be performed as 2 sets of 10 repetitions.
223882883|NCT06148818|OTHER|Patient education|The content of this education consists of information about the disease and symptoms, chewing recommendations, dietary changes, parafunctional habits, activities to be avoided, posture recommendations.
223882884|NCT06799923|PROCEDURE|laser electrode|A laser electrode is implanted surgically in the ventral and inteermediary nucleus of the thalamus (VIM).
223882885|NCT06318403|DRUG|Transdermal estrogen|All patients will receive patches with identical labeling from our pharmacy, to be applied twice weekly. In the study group, these will contain 0.025 mg/day of estradiol. In the control group, these will be placebo. These will be applied twice weekly for three months beginning at the time of surgery and extending for three months after surgery.
223882886|NCT06318403|PROCEDURE|Rotator Cuff Repair Surgery|The operative protocol will be standardized in all patients. Both the operative protocol and post-operative rehabilitation protocol will be per our standard of care, without alteration. An arthroscopic approach will be used. In all cases a double-row rotator cuff repair using triple-loaded anchor(s) on the medial row will be used. Post-operatively all patients will be placed in a sling for six weeks. Active range of motion exercises will begin at six weeks post-operatively and strengthening will be delayed until 12 weeks post-operatively. In all phases of care our peri-operative and post-operative protocol for study patients will be similar to our current clinical practice to ensure generalizability.
223882887|NCT06782724|DRUG|Psilocybin therapy|Psilocybin therapy consisting of three preparation, two dosing, and three integration sessions. All sessions will take place in a controlled, safety environment and supported by two study therapists
223882888|NCT03157167|DRUG|Tc99m-tilmanocept|Tilmanocept is a radiotracer that accumulates in macrophages by binding to a mannose binding receptor that resides on the surface.
223882889|NCT06790134|DEVICE|Artificial intelligence device|This AI device can provide prompts for standard sites of pancreatic scans and anatomical structures. It may also suggest the next operation methods.
223882890|NCT06785519|BIOLOGICAL|CD19/BCMA Lupus Nephritis Targeted CAR T-cells injection|Each subject receive CD19/BCMA Lupus Nephritis Targeted CAR T-cells by intravenous infusion
223882891|NCT04978597|DRUG|Opicapone 50 mg|Capsule, 50 mg, Oral. Swallow whole with water, once daily at bedtime at least 1 hour after L-DOPA/DDCI
223882892|NCT04978597|DRUG|Placebo|Capsule of to matching placebo, Oral. Swallow whole with water, once daily at bedtime at least 1 hour after L-DOPA/DDCI
223882893|NCT06782893|BEHAVIORAL|Non-pharmacological cough control therapy|Over seven weeks (1 session per week, except session 5, which will be 2 weeks after session 4) using a one-on-one hybrid model. In session 1, participants will receive general education about chronic cough, introduction to cough suppression and goal setting. Session 2 will cover education about chronic cough in ILD, cough triggers and training in cough suppression techniques. Session 3 will focus on hydration techniques, laryngeal hygiene, and breathing exercises to control coughing. Session 4 will reinforce all aspects of non-pharmacological cough control treatment, and session 5 will explore the sustainability of cough control strategies after the program using real-life case scenarios.
223882894|NCT06782893|BEHAVIORAL|Healthy lifestyle|Over seven weeks (1 session per week, except session 5, which will be 2 weeks after session 4) using a one-on-one hybrid model. In session 1, participants will receive general education about exercise and physical activity. Session 2 will cover education about diet. Session 3 will focus on stress management. Session 4 will cover relaxation techniques, and session 5 will reinforce all aspects previously considered.
223882895|NCT05568537|DRUG|Pylarify Piflufolastat Flourine-18 (18F-DCFPyL)|Piflufolastat F18 will first be given intravenously over about 5 seconds.
223882896|NCT05873868|OTHER|Six minutes walk test|Six minutes walk test just before first intake of treatment and after 1 and 2 years
223882897|NCT05873868|OTHER|Kansas City questionnaire|Kansas City questionnaire just before first intake of treatment and after 1 and 2 years
223882898|NCT05873868|OTHER|COMPASS31 self questionnaire|Compass31 self questionnaire assessing dysautonomia just before first intake of treatment and after 1 and 2 years
223882899|NCT06471751|OTHER|Inspiratory and Oropharyngeal Muscle Strengthening|"Patients will conduct the training at home, 5 days a week for 3 months. They will perform 2 sets of 30 inspirations against resistance (POWERbreathe® K5 , Powerbreathe International Limited, UK), equal to 70% Maximum Inspiratory Pressure (MIP). Patients will be guided for oropharyngeal exercises.~The sessions will be supervised by the investigator every 3 weeks. During sessions with the investigator, sessions recorded in the device will be downloaded to verify compliance. A MIP measurement will be performed to adjust the resistance of the device."
223882900|NCT06349564|DEVICE|Pico 4 Enterprise headset with noise cancelling headphones|The device includes a computer tablet and virtual reality headset.
223882901|NCT01939275|RADIATION|copper Cu 64-DOTA-trastuzumab|Undergo Copper Cu 64-DOTA-trastuzumab PET/CT scan
223882902|NCT01939275|DEVICE|positron emission tomography|Undergo Copper Cu 64-DOTA-trastuzumab PET/CT scan
223882903|NCT01939275|OTHER|laboratory biomarker analysis|Correlative studies
223882904|NCT01939275|PROCEDURE|Computed Tomography|Undergo Copper Cu 64-DOTA-trastuzumab PET/CT scan
223882905|NCT05441696|DEVICE|ezCVP measurement|"* Measuring device: non-FDA-cleared patient monitor (740E, Zoe Medical, MA, US), which has software to measure ezCVP.~* Sensor: an FDA-cleared pulse oximeter sensor for adults (K012891: DS-100A, Nellcor, CA, US).~* Cuff: an FDA-cleared NIBP cuff for adults (K080342: YP-713T, YP-714T or TP-715T, Nihon Kohden Corporation, Tokyo, Japan)."
223882906|NCT06629454|DEVICE|Adherence to digital incentive spirometer in the postop period after major chest surgery.|Major chest surgery can lead to respiratory compromise and traditional breathing exercises are not supervised or monitored. The primary objective of this study is to evaluate the effect of a multifeatured digital IS and integrated phone app on patient adherence to incentive spirometry. Together the device and app will include the following functions: an auditory and haptic reminder cue, visual and auditory cues to guide exercise completion, exercise gamification, and data tracking and visualization features.
223882907|NCT04598854|DEVICE|Intravascular laser irradiation of blood|Low intensity intravascular laser irradiation of blood phototherapy is a method of a 632.8 nm red light penetrate into a vein through fiber and the brightness is 100 fold of the sun. The light accelerates blood and cells circulation in the human body, so that protein molecular structure would promote changes.
223882908|NCT04598854|DEVICE|Intravascular laser irradiation of blood (Sham)|zero intensity of the laser energy
223882909|NCT06137170|DRUG|Regorafenib (Stivarga, BAY73-4506)|Follow clinical administration.
223882910|NCT05135949|OTHER|Patient Reported Outcomes|Satisfaction, Disabilities of the Shoulder, Arm and Hand
223882911|NCT05135949|OTHER|Strength Test|Handheld dynamometer to measure tricep extension
223882912|NCT05286554|DRUG|gonadotropin releasing hormone-agonist|subcutaneous injection
223882913|NCT05286554|DRUG|Progesterone|vaginal suppositories (400 mg twice daily) starting on the day after oocyte retrieval and will be continued till pregnancy assessed by serum β-HCG 15 days after ICSI, and if pregnant, for 10 weeks of gestation.
223882914|NCT02915198|DRUG|Metformin XR|The study medication dose may be increased by a step-wise fashion up to a maximum of 4 tablets per day.
223882915|NCT02915198|DRUG|Placebo|"For patients \< 80 years of age at the time of a study visit, and with most recent eGFR 45 mL/min/1.73 m2, study medication dose may be increased in a stepwise fashion to a maximum of 4 tablets daily, corresponding to metformin XR 2000 mg or matching placebo.~For patients 80 years of age or with most recent 30 eGFR \< 45 mL/min/1.73 m2, the maximum dose of study medication is 2 tablets daily, corresponding to metformin XR 1000 mg or matching placebo"
223882916|NCT06796153|OTHER|Visible Light Exposure - Treated zones|The treated zones were exposed to Visible Light to induce skin pigmentation (144J/cm2), 15 to 30 minutes after application.
223882917|NCT06796153|OTHER|Visible Light Exposure - Untreated zone|The untreated zone was exposed to Visible Light to induce skin pigmentation (144J/cm2), as the same time as the treated zones.
223882918|NCT05526534|DEVICE|heated humidified high flow nasal cannula oxygen therapy, HFNC|HFNC can accurately provide 21% \~ 100% oxygen concentration through air oxygen mixer. And through the heating and humidification device to provide 37℃, relative humidity of 100% gas, the maximum flow of 70L/min.
223882919|NCT05526534|DEVICE|Nasal cannula oxygen|Nasal cannula oxygen has become a routine part of postoperative treatment
223882920|NCT06788951|DIETARY_SUPPLEMENT|administration of oral carbohydrate solution to patients before coronary artery bypass graft surgery|Oral carbohydrate solution will be administered to patients before coronary artery bypass graft operation and its effects on postoperative nausea-vomiting, hunger, thirst, physiological parameters and recovery will be evaluated.
223882921|NCT06788951|OTHER|giving flavored water to patients before coronary artery bypass graft surgery|The effects of flavored water given to patients before coronary artery bypass graft operation on postoperative nausea-vomiting, hunger and thirst,
223882922|NCT05343390|BEHAVIORAL|Enhanced implementation package|Individual training with teaching and modeling (tablet-guided, \~8 hours) Small group training with practice and feedback (tablet-guided, \~16 hours) Ongoing continuous quality improvement sessions (tablet-guided, \~2 hours/month)
223882923|NCT05343390|BEHAVIORAL|Standard implementation package|Individual training with teaching (facilitator-guided, \~2 hours) Small group practice (facilitator-guided, \~1 hour) Ongoing clinic support (facilitator-guided, \~30 minutes/month)
223882924|NCT04286282|BEHAVIORAL|Group Pyschotherapy|Group psychotherapy
223882925|NCT04286282|OTHER|Depression Standard of Care|Standard clinical care for depression, which may include the use of selective serotonin re-uptake inhibitors (SSRIs).
223882926|NCT04286282|OTHER|HIV Standard of Care|Standard clinical care for HIV
223882927|NCT06838715|DRUG|Dexamethasone|Assessing the relation between the level of cytokines (interleukins and tumor necrosis factor alpha) and the development of cardiac complications associated with scorpion envenomation among pediatric patients. and Evaluating the role of the use of Dexamethasone and/or extended anti-venom administration on cardiac function and outcome in pediatric cases.
223882928|NCT06424561|BEHAVIORAL|Psychological Intervention Group|"The intervention group provides psychological education to patients, emphasizing participation in a Surgery Success patient group organized by researchers, and collects successful patient cases for promotion. Patients are encouraged to learn from successful cases within the group. Psychological intervention is also provided to family members, as they are the primary caregivers, and guiding their thoughts is crucial. Timely identification of patients with psychological abnormalities is conducted, with psychological consultations if necessary. Targeted measures are taken for patients with psychological abnormalities. Upon discharge, one-on-one consultation and tracking services are provided by designated nurses to alleviate patients' feelings of helplessness and despair, continuing until the patient fully recovers."
223882929|NCT06788704|DRUG|Tadalafil 5mg|Patient recive tadalafil 5mg once daily early post turp
223882930|NCT06788704|DRUG|Placebo|Patient recive placebo once daily early post turp
223882931|NCT05202860|BIOLOGICAL|HPV Vaccine|(Gardasil 9 human papilloma vaccine)
223882932|NCT05202860|BIOLOGICAL|PLACEBO vaccine|Isotonic saltwater sham vaccine
223882933|NCT04827563|DEVICE|EndoPAT|An FDA approved device to test the health of a patient's blood vessels, which involves putting an oxygen probe on the participant's finger.
223882934|NCT04827563|DEVICE|Blood Pressure Cuff|A device used to conduct blood pressure monitoring using a home blood pressure cuff that participant wears for 24 hours.
223882935|NCT04827563|DIAGNOSTIC_TEST|Echocardiogram|A test used to conduct an ultrasound of participant's heart.
223882936|NCT04827563|OTHER|Quality of Life Assessment|A survey that will be given to participants to report their quality of life and symptoms related to multiple myeloma.
223882937|NCT04827563|OTHER|Blood Tests|Routinely collected for all participants who begin carfilzomib treatment.
223882938|NCT02840474|BIOLOGICAL|VRC-HIVMAB080-00-AB|VRC01LS is an investigational human monoclonal antibody targeted to the CD4+ binding site of HIV-1.
223882939|NCT02840474|BIOLOGICAL|VRC-HIVMAB075-00-AB|VRC07-523LS is an investigational human monoclonal antibody targeted to the CD4+ binding site of HIV-1.
223882940|NCT06796556|DEVICE|virtual reality exposition|emotional response triggered by exposure to sensory stimuli presented in virtual reality.
223882941|NCT05037526|DEVICE|Dexcom G System|Continuous glucose monitoring system
223882942|NCT05037526|DEVICE|Self monitoring blood glucose|Standard Care
223882943|NCT06841003|DRUG|Laparoscopic antibiotic peritoneal lavage with gentamicin / clindamycin|Peritoneal antibiotic lavage using a solution of gentamicin/clindamycin in NaCl 0.9%.
223882944|NCT06795074|COMBINATION_PRODUCT|Optilume|Dilatation with drug-coated balloon
223882945|NCT06795074|DEVICE|UroMax Ultra|Dilatation with non-coated balloon
223882946|NCT06834581|DEVICE|Vibrating mesh nebuliser|Vibrating mesh nebulisation (VMN) uses a mesh membrane that oscillates at high frequency (typically 128 kHz) to produce a stream of drug-carrying droplets of pre-determined size to be inhaled.
223882947|NCT06834581|DEVICE|Jet nebuliser|Jet nebulisers use the flow of a gas (air or oxygen) to draw medication up through a capillary tube to generate small particles to be inhaled.
223882948|NCT06271512|OTHER|No Intervention|This is non-interventional study.
223882949|NCT06839690|PROCEDURE|Isometric training of thumb muscles|Isometric training for thumb extension, abduction, radial and ulnar deviation will be performed in 3 sessions/ week for 4 weeks. The exercise protocol will begin with training using manual resistance and progress with training against resistance of elastic band and theraband.I
223882950|NCT06839690|PROCEDURE|Eccentric training for thumb muscles|In Group B, eccentric training for thumb extension, abduction, radial and ulnar deviation will be performed in 3 sessions/ week for 4 weeks. The exercise protocol will begin with training using unweighted and weighted hammer curls and progress with training using elastic band, dumbbell and theraband.
223882951|NCT06839690|PROCEDURE|Ultrasound|Therapeutic ultrasound for symptom management
223882952|NCT06797804|OTHER|Information Technology-Assisted Horticultural Therapy Program|The intervention involves technology-assisted horticultural therapy sessions conducted once a week, lasting 120 minutes per session, over a total period of 8 weeks
223882953|NCT06176469|OTHER|No intervention|No intervention
223882954|NCT06838923|COMBINATION_PRODUCT|Light Paraffin Oil|Embryos in this group will be cultured under conditions using light paraffin oil as an overlay in in vitro fertilization (IVF). The oil serves to protect the culture media from evaporation and temperature fluctuations. Key outcomes, including embryo development, blastocyst formation rate, and pregnancy rate, will be assessed.
223882955|NCT06838923|COMBINATION_PRODUCT|Heavy Paraffin Oil|Embryos in this group will be cultured under conditions using heavy paraffin oil as an overlay in in vitro fertilization (IVF). This study aims to compare the effects of heavy paraffin oil to light paraffin oil in embryo culture, assessing embryo development, blastocyst formation, and pregnancy rates.
223882956|NCT06333340|DRUG|Oxytocin|Patient is given oxytocin 5 IU diluted in 10 mL normal saline, administered intravenously over 1 min, followed by continuous infusion of 250 mIU/min over 4 hours.
223882957|NCT06333340|DRUG|Carbetocin|Patient is given carbetocin 100 mcg diluted in 10 mL normal saline, administered intravenously over 1 min, followed by placebo infusion for 4 hours.
223882958|NCT05956145|DRUG|Colchicine 0.5 MG|Patients with proven chronic coronary disease (documented by a previous history of AMI with or without ST-segment elevation) will be randomized to receive colchicine 0.5 mg once daily (intervention group) or placebo (control group) for a period of 30 ± 3 days.
223882959|NCT05956145|OTHER|Placebo|Patients with proven chronic coronary disease (documented by a previous history of AMI with or without ST-segment elevation) will be randomized to receive colchicine 0.5 mg once daily (intervention group) or placebo (control group) for a period of 30 ± 3 days.
223882960|NCT03655132|BEHAVIORAL|Veteran Acceptance and Commitment Therapy for Chronic Pain|Seven online modules based on the theoretical framework of ACT for chronic pain, provided as weekly sessions that will feature an ECA (virtual therapist) as a treatment guide. The initial module is devoted to an explanation of the treatment rationale, initial psychoeducation on pain-related symptoms, pain interference, and focal concepts of ACT, and assessment of individual pain symptoms. Modules 2-4 will focus on values clarification, acceptance and willingness, mindfulness, with an emphasis on tolerance of pain-related experiences. Modules 5-7 will continue to this focus, and incorporate goal-creation and committed action exercises. Module 8 will consolidate and provide feedback on goal-related achievements, and will focus on planning for the future.
223882961|NCT05568004|BEHAVIORAL|Combined exercise|aerobic plus resistance exercise
223882962|NCT05568004|BEHAVIORAL|Aerobic exercise|Only aerobic exercise
223882963|NCT06392997|DIAGNOSTIC_TEST|Saliva sample|Saliva sample
223882964|NCT04119284|DEVICE|Anterior body tether (ABT)|To insert the ABT in patients to correct AIS.
223882965|NCT04995068|RADIATION|Head CT to determine presence of traumatic intracranial lesion|Head CT to determine presence of traumatic intracranial lesion
223882966|NCT02478892|OTHER|Collection of data from endoscopic ultrasound or MRI/MRCP of the abdomen|Participants in this study should be undergoing pancreatic cancer screening with endoscopic ultrasound or MRI as part of their standard care. These should typically be done at least every 12 months, and the imaging tests will be ordered as routine clinical tests and will be billed to the participant's insurance. This study does not cover the costs of these screening tests, however the study will track the results of these screening tests.
223882967|NCT02478892|OTHER|Blood sample collection for research|Up to 40mL of blood may be collected for analysis at each screening examination.
223882968|NCT04782544|OTHER|Buttermilk Powder|Treatment with 5.0 g of buttermilk powder daily for 10 weeks.
223882969|NCT04782544|OTHER|Anhydrous Milk Fat|Treatment with 5.0 g of milk powder (90% anhydrous milk fat, 10% buttermilk powder) daily for 10 weeks.
223882970|NCT06157437|DEVICE|Focal Pulse field Ablation|Bidirectional block of the cavo-tricuspid isthmus (CTI) was performed with the novel focal pulse field ablation.
223882971|NCT06334952|DEVICE|transcranial direct current stimulation|Research MRI includes 3D-T1 weighted MRI (3D-T1), diffusion MRI (dMRI), resting-state functional MRI (rsfMRI).
223882972|NCT03764137|DRUG|[89Zr]Panitumumab PET-MRI|All patients entered into the study will have \[89Zr\]Panitumumab-PET/MRI imaging.
223882973|NCT06843941|OTHER|Music intervention|"In the music group, MusiCure® compositions, which feature soft rhythmic melodies, were chosen. These musical pieces were composed by Danish composer Niels Eje (MusiCure, 2020) and are therapeutic in nature, designed for physical and mental relaxation within a range of 60-80 bpm (Eje, 2020). Literature reviews indicate that the MusiCure® album has positive effects on conditions such as pain, well-being, and anxiety (Fredriksson et al., 2009; Nilsson et al., 2009). The pieces to be used in this study were selected after communication with Niels Eje, and the recommended pieces were Winter, Early Spring, Equator, and Ocean Echoes (MusiCure, 2020). The music was presented hygienically to the participants through headphones and played for 30 minutes in four tracks via an mp3 player."
223882974|NCT06357130|OTHER|Questionnaire|A flyer with QR code leading to the online questionnaire will be sent to trans associations and healthcare networks for distribution to the target population.
223882975|NCT06842797|OTHER|Weighted Blanket|Participants will lie down and be covered with a weighted blanket.
223882976|NCT06842797|OTHER|Non Weighted Blanket|Participants will lie down and be covered with normal weight blanket (non-weighted blanket)
223882977|NCT00909961|DRUG|Zoledronic acid|
223882978|NCT03902951|DRUG|Abiraterone Acetate|Given PO
223882979|NCT03902951|DRUG|Apalutamide|Given PO
223882980|NCT03902951|DRUG|Leuprolide Acetate|Given SC
223882981|NCT03902951|OTHER|Quality-of-Life Assessment|Ancillary studies
223882982|NCT03902951|OTHER|Questionnaire Administration|Ancillary studies
223882983|NCT03902951|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
223882984|NCT03490825|DIETARY_SUPPLEMENT|Melatonin 1 mg|Melatonin (1mg) will be administered daily during the intervention. Melatonin capsules will be obtained from Life Extension (Ft. Lauderdale, FL). The investigational drug pharmacy (IDP) at Northwestern Memorial Hospital will encapsulate the melatonin pills so the placebo (lactose) and melatonin pills appear identical. We have worked with this IDP on other projects. The investigators on this study have experience in administering melatonin for investigational and clinical purposes.
223882985|NCT03490825|DIETARY_SUPPLEMENT|Placebos|Placebo will be administered daily during the intervention. The investigational drug pharmacy (IDP) at Northwestern Memorial Hospital will encapsulate the pills so the placebo (lactose/starch) and melatonin pills appear identical. We have worked with this IDP on other projects. The investigators on this study have experience in administering melatonin for investigational and clinical purposes.
223882986|NCT03490825|OTHER|Meal timing|Subjects are instructed to maintain an extended overnight fasting period of 12-16 hours.
223882987|NCT03490825|OTHER|Non-Meal timing|Subjects are instructed to maintain their habitual meal timing.
223882988|NCT06172699|DEVICE|Holter monitoring in patients who have been successfully implanted with an Abbott Assert-IQ ICM device|All enrolled subjects who meet eligibility criteria will undergo an attempted implant within 30 days of consent. After successful device implant, subjects will be followed at 1 and 12 months. Subjects will be fitted with a Holter monitor during the 1m follow-up visit and will complete a minimum of 72 hours and maximum of up to 7 days of Holter monitoring.
223882989|NCT06166927|DEVICE|Cuffed endotracheal tube|Patients will be intubated using a cuffed ETT with its OD determined by US measurement of the epiphyseal diameter of the distal radius.
223882990|NCT06166927|DEVICE|UnCuffed ETT|Patients will be intubated using an uncuffed ETT (Flexicare-UK) with its OD determined by US measurement of the epiphyseal diameter of the distal radius.
223882991|NCT05143931|BEHAVIORAL|Home food environment and grocery delivery (AVOID)|Participants (Arms 2 \& 4) will receive 6 months of coaching (Zoom and/or email/text) to modify their home food environment and alter cues to promote healthy food choices
223882992|NCT05143931|BEHAVIORAL|Inhibitory control training (RESIST)|Participants assigned to RESIST (Arms 3 \& 4) will receive 6 months of coaching (Zoom and/or email/text) and gamified inhibitory control training.
223882993|NCT05143931|BEHAVIORAL|WW|Participants assigned to all arms will receive 6 months of coaching (Zoom and/or email/text) and commercially-available weight management program focusing on diet, physical activity and mindset skills.
223882994|NCT05344963|DRUG|Sodium-GLucose coTransporter-2 inhibitors|Evaluation of the modification of conventional and advanced echocardiographic parameters, focusing on speckle tracking and three-dimensional echocardiography (optional), in patients with HFrEF after treatment with the SGLT2i drugs Dapagliflozin and Empagliflozin
223882995|NCT05799781|DEVICE|MPC closed-loop system|The Model Predictive Control (MPC) insulin infusion algorithm contains a model within the controller that takes as an input the aerobic metabolic expenditure in addition to the CGM and meal in puts. The algorithm uses heart rate and accelerometer data collected on the patient's body to calculate metabolic expenditure (METs). The METs then acts on the model for the insulin dynamics, whereby more energy expenditure and longer duration exercise can lead to a more substantial effect of insulin on the CGM. The MPC also has missed meal insulin bolus detection where the system will calculate the amount of insulin that was missed for a meal. The missed meal boluses can be delivered automatically without any input from the user. This feature can also be disabled.
223882996|NCT05799781|DEVICE|t:slim X2 pump with Dexcom G6 CGM and Control IQ|The t:slim pump is a hybrid closed-loop system available to consumers for automated insulin delivery. Control IQ technology automatically adjusts insulin levels based on continuous glucose monitoring (CGM) readings from Dexcom G6.
223882997|NCT06341179|BEHAVIORAL|Sleep extension|Children and their parents will receive a behavioral intervention consisting of two in-person sessions and four virtual sessions. The two in-person sessions will take place at the beginning of the study (during weeks 1 and 2) and will focus on effective behavioral strategies to enhance sleep time, including goal setting (e.g., bedtimes and wake-up times), self-monitoring (via actigraphy), problem-solving and preplanning, stimulus control (i.e., sleep hygiene recommendations), and positive reinforcement. The four virtual sessions will take place at frequent intervals during the 12-week intervention (at weeks 4, 6, 8, and 10) and will act as reminders/refreshers to reinforce strategies to enhance changes in sleep time. Parents will receive advice in relation to altering only their children's sleeping routine (bedtime), and they will be instructed not to directly modify their children's food consumption or physical and sedentary activities during daytime.
223882998|NCT04764500|OTHER|examination of stool sample|Each participant provides stool samples before and after travelling, after 2, 4, 6, 8, 10, 12, 16, 20 and 52 weeks. Stool samples will be used for isolating both a) ESBL E. coli strains and b) pan-sensitive E. coli strains. Part of the stool sample is stored for isolation of further E. coli clones and microbiota analysis of the isolation of other microbiota strains. All found Enterobacteriaceae will be screened for additional resistance such as Carbapenem and Colistin. In case of a specific resistance, this will be confirmed with additional phenotypic and genotypic tests such as ROSCO disk and polymerase chain reaction (PCR) based panel and whole genome sequencing in order to detect specific resistance mechanisms and genes. Bacteria will be sequenced using Illumina and Nanopore based sequencing. Bioinformatic analysis will allow to determine the whole bacterial genome with containing resistance genes and also describe the microbiota diversity over time in single individuals.
223882999|NCT04764500|OTHER|patient questionnaire|Each participant will have to provide a questionnaire before and after travelling, as well after 2, 4, 6, 8, 10, 12, 16, 20 and 52 weeks.
223883000|NCT04764500|OTHER|examination of blood sample|Each participant will have to provide a blood sample before and after travelling and after 6, 12 and 20 weeks. A serum sample (5mL) for antibody measurement and a 50 ml blood sample for recovery of peripheral blood mononuclear cells (PBMCs in 6 CPTs) for cell mediated immunity will be collected. Serum and PBMCs will allow the analysis of anti-E. coli humoral and cellular responses in order to characterize the individual immune response to specific bacteria over time. Single nucleotide polymorphisms associated with humoral and cellular immune responses will be characterized and linked to immunological and clinical phenotypes and endpoints of the study.
223883001|NCT05152732|GENETIC|VGB-R04|A novel, bioengineered adeno-associated viral (AAV) vector carrying human factor IX variant
223883002|NCT01703481|DRUG|JNJ-42756493: Part 1|Participants will receive 0.5 mg (starting dose) capsule of JNJ-42756493 orally (by mouth) once daily on Day 1 of Cycle 1. Dose of the study medication will be escalated sequentially till the dose limiting toxicity is achieved to determine the recommended part 2 doses (RP2D).
223883003|NCT01703481|DRUG|JNJ-42756493: Part 2|Participants will receive JNJ-42756493 at the RP2D or below RP2D (maximum tolerated dose from Part 1) orally once daily on a 21 days cycle to confirm RP2D (in Part 2).
223883004|NCT01703481|DRUG|JNJ-42756493: Part 3|Participants will receive JNJ-42756493 at first RP2D of 9 mg daily in Part 3 orally once daily on a 21 days cycle.
223883005|NCT01703481|DRUG|JNJ-42756493: Part 4|Participants will receive JNJ-42756493 second RP2D of 10 mg intermittent dosing in Part 4 (with option to increase to 12 mg intermittent dosing based on phosphate level), orally on an intermittent schedule of daily for 7 days followed by 7 days off with a 28-day cycle.
223883006|NCT05653856|DRUG|64Cu-PSMA I&T|Radiolabeled Receptor-Targeted Diagnostic Product
223883007|NCT05632562|DRUG|O-(2-[18F]Fluoroethyl)-L-tyrosine, [18F]-FET with PET/MRI|High grade glioma patients that are planning to undergo radiation therapy (RT) and consent to this study will have up to 3 in-person study visits. The first visit will take up to 2 hours, the second visit will take up to 3 hours, and the third visit will take up to 6 hours. After both imaging visits, there will be a phone call at 24-48 hours after imaging.After confirmation of patient eligibility and consent, the administration of FET and FMISO and related procedures will be performed in the UAB Advanced Imaging Facility (AIF) at the time of first standard of care (SOC) MRI after completion of RT (typically a 4-week interval). Patients enrolled in the study will be followed clinically and with standard of care brain MRI. PFS and OS will be monitored for up to 24 months after completion of FET and FMISO PET/MRI studies. Study participants will not undergo additional study related procedures after completion of the FET-PET/MRI and FMISO-PET/MRI studies.
223883008|NCT03805048|PROCEDURE|Percutaneous coronary intervention|PCI of the bypass graft will be performed by current standards and at the discretion of the operator. Only commercially available second generation DES - XIENCE Sierra will be used. In case of a CTO lesion, the aforementioned hybrid approach will be applied.This approach uses several angiographic characteristics to guide strategical planning of the procedure, using 4 complementary techniques to cross a CTO: antegrade wire escalation, antegrade dissection reentry, retrograde wire escalation, retrograde dissection reentry. In case of PCI failure, a second attempt can be performed within 1 month. Patients will be hospitalized for a min. of 6-8 hours after PCI and receive DAPT prior to the procedure or triple therapy in case of indication for oral anticoagulation, their duration according to the current guidelines of the ESC for stable coronary disease or ACS.
223883009|NCT04564976|BEHAVIORAL|Social support image|An image of a social support figure specific to each participant (provided by the participant) will be present while participants undergo a fear acquisition procedure. Specifically--the image will be presented alongside a neutral image that is either consistently paired with shock (CS+) or never paired with shock (CS-), so that assessment of whether there are differences in fear responding (evaluated via SCR) due the shock pairing can be assessed. This is a typical fear acquisition procedure, and a typical outcome would be for SCR to be higher for the CS+ compared to the CS- toward the end and following the procedure, indicating that the CS+ is now associated with the aversive shock and is bringing about a fear response (in this case indexed by increased sympathetic nervous system activity preparing the body to fight or flee).
223883010|NCT06770166|OTHER|Physiological serum mouthwash|Physiological serum contains sodium chloride : 0.009 g/ml, sodium 154 (mEq/I), chloride 154 (mEq/I)\].
223883011|NCT06770166|OTHER|Chlorhexidine mouthwash|Chlorhexidine mouthwash contains 0.12% chlorhexidine digluconate and 0.15% benzydamine hydrochloride.
223883012|NCT06770166|OTHER|Chamomile mouthwash|Chamomile mouthwash contains 10% chamomile in physiological serum.
223883013|NCT05520983|BEHAVIORAL|Adapted Teens Achieving Mastery over Stress (TEAMS) Treatment|Teens Achieving Mastery over Stress (TEAMS) has been adapted for use with youth with I/DD. The intervention consists of virtual, manualized treatment groups for 10 weekly, 75-minute sessions plus 6 monthly, 60-minute sessions. Caregivers of participants will meet twice: weeks one and 16.
223883014|NCT05520983|BEHAVIORAL|Adapted Teens Achieving Mastery over Stress (TEAMS) Prevention|Teens Achieving Mastery over Stress (TEAMS) has been adapted for youth with I/DD. TEAMS Prevention is a 10-session group depression prevention program teaching teens how to deal with stress and negative moods, and ways to manage low mood based on cognitive behavioral therapy (CBT) principles and strategies. Efficacy has been demonstrated by several trials over time.
223883015|NCT05520983|BEHAVIORAL|Adapted Competent Adulthood Transition with Cognitive-behavioral & Interpersonal Training (CATCH-IT)|Competent Adulthood Transition with Cognitive-behavioral \& Interpersonal Training (CATCH-IT) has been adapted for youth with I/DD. CATCH-IT is an internet-based depression prevention program that targets decreasing modifiable risk factors while enhancing protective factors in at-risk adolescents, and that includes a parent program. It has been shown to be safe, feasible, and efficacious. All adolescents will receive 8 engagement texts during their participation in the study - at 1-week, 1-month, 6-weeks, and 2-, 3-, 5-, and 5.5-months - to encourage participation in the online modules.
223883016|NCT05520983|OTHER|Strengthening Families|The Strengthening Families caregiving curriculum is an evidence-based, self-directed, virtual skills training for caregivers. Information and instructions on accessing the Strengthening Families parenting skills training curriculum will be included on the virtual resource website https://strengtheningfamilieslessons.org/.
223883017|NCT05520983|OTHER|Virtual psycho-educational discussion groups for caregivers and participants|The BEST project will host a total of 10 virtual psycho-educational workshops per year (5 for participants and 5 for caregivers) for the duration of the intervention period of the study. Workshops will be delivered remotely via Zoom and facilitated by graduate students in health/behavioral health. Simultaneous language interpreter services will be provided. Principles of universal design in learning will be applied to the content and delivery of workshops. Workshops are an optional resource available to all participants and families in the intervention condition. Topics for the virtual discussion groups will be determined based on pilot data and input from participants and caregivers.
223883018|NCT05520983|OTHER|Maternal Child Health Bureau (MCHB) Care Coordination|MCHB Care Coordination, funded through the Social Security Act of 1935 Title V Maternal and Child Health Services Block Grant Program, is the oldest and most universal care coordination model for children with I/DD. MCHB Care Coordination involves: comprehensive needs assessments, person-centered planning, and linkage to health care and social resources. MCHB care coordination has established efficacy, feasibility, and acceptability in improving child and family functioning, youth health, and health care access.
223883019|NCT06329557|BEHAVIORAL|Intervention 1|Intervention 3
223883020|NCT00212433|DRUG|Tagitol V, Lo So, Readi-Cat 2|
223883021|NCT03752294|DRUG|Dabigatran|At the end of a 9-month randomized-control, double-blind treatment all study participants will cross-over to the 12-month open-label phase with a 3-month non-treatment follow-up.
223883022|NCT03752294|DRUG|Placebo - Cap|At the end of a 9-month randomized-control, double-blind treatment all study participants will cross-over to the 12-month open-label phase with a 3-month non-treatment follow-up
223883023|NCT04230408|DRUG|Durvalumab|Intensified chemo-immuno-radiotherapy with durvalumab in combination with carboplatin, paclitaxel and radiation
223883024|NCT02884180|DRUG|Dexamethasone|A dose of 24 mg dexamethasone given after start of anaesthesia
223883025|NCT02884180|DRUG|Saline isotonic|A dose of 6 ml of isotonic saline given after start of anaesthesia
223883026|NCT04754711|DIETARY_SUPPLEMENT|Oral Nutritional Supplement|We will propose to the patients of group 1 several different oral nutritional supplements according to taste, and consistency of each child in order to optimize observance. Each of those different oral nutritional supplements will be adapted to the nutritional survey and the age of children without exceeding recommended intake of proteins, carbohydrates, lipids and micronutrients. Those patients will consume the Oral Nutritional Supplement during 12 months.
223883027|NCT05657106|BEHAVIORAL|Harm reduction kiosk|The intervention involves enhancing an existing staffed harm reduction program (syringe service program) located in a local health department with a Kentucky Outreach Service Kiosk (KyOSK).
223883028|NCT04155541|DRUG|dacomitinib hydrate|The usual adult starting dosage for oral use is 45mg of dacomitinib hydrate once daily. The dose should be reduced appropriately according to the patient's condition.
223883029|NCT03727061|BIOLOGICAL|Nivolumab|Immunotherapy - Standard of care
223883030|NCT03727061|DRUG|Porfimer Sodium|Given IV
223883031|NCT03727061|PROCEDURE|Interstitial Illumination Photodynamic Therapy|Undergo I-PDT
223883032|NCT03727061|OTHER|Quality of Life Assessment|Ancillary Studies
223883033|NCT06739902|DIAGNOSTIC_TEST|Traditional Physiotherapy Group|Participants receive standard physiotherapy exercises aimed at improving motor function, balance, and trunk stability. These exercises include stretching, balance training, and muscle-strengthening activities.
223883034|NCT06739902|COMBINATION_PRODUCT|VR + Traditional Physiotherapy Group|Participants receive the same physiotherapy exercises as the traditional group, but with additional sessions involving virtual reality exercises. The VR component includes immersive activities that stimulate motor control, coordination, and cognitive engagement to support functional recovery.
223883035|NCT06798844|DEVICE|Spinal Cord Stimulation|SCS is an established treatment for chronic neuropathic pain and the implantation procedure in this study follows the conventional clinical approach. Under local anaesthesia, a lead electrode is positioned in the spinal epidural space at the Th8-Th10 vertebral levels. The electrode is then connected to an external stimulator (implantable pulse generator, IPG), used for the 3-week external trial stimulation. Upon completion of the core trial, the electrode may either be removed or connected to an internal IPG, after extensive counselling and dependent on the FOG outcome and patient's preference. A subsequent long-term open label phase will evaluate the long-term efficacy and safety of SCS on FOG, with a follow-up period of six months. Electrophysiological recordings of the dorsal spinal cord will be conducted at the end of the external trial stimulation and at the 6-month follow-up.
223883036|NCT06798844|OTHER|Spinal electrophysiological recordings|The sole purpose of the control groups in this study, is to facilitate the interpretation of spinal cord electrophysiological characteristics in PD freezers by providing a comparison with individuals without the condition.
223883037|NCT05090826|DEVICE|Model ZFR00V|Investigational intraocular lens replaces the natural lens removed during cataract surgery in one or both eyes.
223883038|NCT06245746|BIOLOGICAL|umbilical cord derived mesenchymal stem cells exosomes (UCMSC-Exo)|UCMSC-Exo will be infused intravenously.
223883039|NCT05147688|BIOLOGICAL|AlloRx|cultured allogeneic adult umbilical cord derived mesenchymal stem cells
223883040|NCT05795946|DIETARY_SUPPLEMENT|Whole food-based B and D vitamins|Looking at whole food-based B and D vitamins to reduce TMAO levels and if this can modulate gut diversity
223883041|NCT02994316|OTHER|Copeptine dosage in children with diabetic ketoacidosis at diagnosis|Blood collection of 3 mL for copeptin dosage will be taken at different times in the first hours of management of diabetic ketoacodosis in children under the age of 16 years
223883042|NCT06288412|DRUG|Insulin icodec|Participants will receive insulin icodec subcutaneous (s.c.) once weekly.
223883043|NCT06288412|DRUG|Insulin degludec|Participants will receive insulin degludec s.c. once daily.
223883044|NCT00650104|DRUG|Ropinirole XL (formerly CR)|Active Ropinirole CR tablets of 2.0mg, 4.0mg, 8.0mg where subjects can tritrate to an stable optimum dose level of either 2.0mg, 4.0mg, 6.0mg, 8.0mg, 12mg, 16mg, 20mg, or 24mg per day.
223883045|NCT06500533|DEVICE|rTMS combined with tDCS|"The intervention will last 30 days per patient, where rTMS will be administered on odd numbered days (study day 1, 3, 5, 7, ..29) and tDCS on even numbered days (study day 2, 4, 6, 8, … 30). All patients will start with TMS and finish with home-based tDCS treatment. Both rTMS and tDCS treatments will be administered during working days, from Monday to Friday.~rTMS treatment will be administered by the experienced nurses of the rTMS clinic of each department. The rTMS treatment will profit from ongoing supervision by the Clinical Directors of each TMS clinic, which is in line with treatment as usual.~tDCS will be performed at home by the patients."
223883046|NCT04755179|PROCEDURE|Laparoscopic appendectomy|"Laparoscopic appendectomy is performed according to daily practice but with the following standardized key points:~1. Conventional laparoscopy (three-trocar technique)~2. In case of purulent fluid: Suction and no peritoneal lavage procedure~3. Skelletizing of the mesoappendix (coagulation/clips according to routine practice locally)~4. Appendiceal stump closure: with two endoloops and dissected between the endoloops. In case of involvement of the appendiceal base, the use of endostapler is recommended.~5. Withdrawal of appendix: principle of abdominal wall protection is followed (trocar technique / endobag)~6. No drain placement, no nasogastric tube, and no urinary catheter routinely, only on indication.~7. Closure of wounds as appropriate"
223883047|NCT04755179|PROCEDURE|Open appendectomy|"Open appendectomy will be performed according to the following standardized key points:~1. Gridiron incision at the right lower quadrant. (McBurney's point)~2. After obtaining access to the abdominal cavity the principle of abdominal wall protection will be followed.~3. The appendiceal stump will be closed by ligation, not a purse string suture.~4. Closure of wounds as appropriate"
223883048|NCT04755179|PROCEDURE|Non-operative treatment|"Non-operative treatment consisting of administration of intravenous antibiotics with or without drainage procedures (in case of an abscess), reserving an appendectomy for those not responding or with recurrent disease.~One of the two antibiotic regiments:~1. Combination A:~   1. Amoxicillin/clavulanic acid 25/2.5mg/kg 6 hourly (total 100/10 mg/kg daily. Maximum 6000/600mg a day) for children \<40 kg OR Amoxicillin/clavulanic acid 1000/200mg/kg 8 hourly (total 3000/6000 mg/kg daily) for children \> 40 kg~  2. Gentamicin 7mg/kg once daily~2. Combination B:~   1. Cefuroxim 25 mg/kg 6 hourly (total 100 mg/kg/day. Maximum 6gram/day)~  2. Metronidazole 10mg/kg 8hourly (total 30 mg/kg/day. Maximum 4000 mg/day) In case of peri-appendicular abscess the decision can be made to perform a drainage procedure either percutaneously or surgical."
223883049|NCT04755179|PROCEDURE|Direct appendectomy|laparoscopic or open appendectomy as described
223883050|NCT06151314|PROCEDURE|Dental implants.|5 conventional implants measuring from 4 to 5 mm in width and 7 to 10mm in length according to the bone width were inserted in the mandible from right premolar area to left premolar area
223883051|NCT03471559|DRUG|Cannabidiol|single or multiple dosing
223883052|NCT04034095|DRUG|Androgen-deprivation Therapy (ADT)|Participants enrolled in this study will continue to receive ADT (example- Leuprorelin, Goserelin and Degarelix) alone or in combination with other therapies in routine clinical practice as directed by their treating physician. No intervention will be administered as a part of this study.
223883053|NCT04034095|DRUG|Bicalutamide|Participants enrolled in this study will continue to receive bicalutamide along with ADT in routine clinical practice as directed by their treating physician. No intervention will be administered as a part of this study.
223883054|NCT04034095|DRUG|Abiraterone|Participants enrolled in this study will continue to receive abiraterone in combination with prednisolone along with ADT in routine clinical practice as directed by their treating physician. No intervention will be administered as a part of this study.
223883055|NCT04034095|DRUG|Prednisolone|Participants enrolled in this study will continue to receive prednisolone in combination with abiraterone along with ADT in routine clinical practice as directed by their treating physician. No intervention will be administered as a part of this study.
223883056|NCT04034095|DRUG|Docetaxel|Participants enrolled in this study will continue to receive docetaxel along with ADT in routine clinical practice as directed by their treating physician. No intervention will be administered as a part of this study.
223883057|NCT04034095|DRUG|Enzalutamide|Participants enrolled in this study will continue to receive enzalutamide along with ADT in routine clinical practice as directed by their treating physician. No intervention will be administered as a part of this study.
223883058|NCT04034095|DRUG|Apalutamide|Participants enrolled in this study will continue to receive apalutamide along with ADT in routine clinical practice as directed by their treating physician. No intervention will be administered as a part of this study.
223883059|NCT02966613|DEVICE|GMK Medacta Total Knee arthroplasty|Total Knee arthroplasty
223883060|NCT01376700|BIOLOGICAL|Recombinant antihemophilic factor, plasma/albumin-free method (rAHF-PFM)|Intravenous infusion at a dose of 25 ± 5 IU/kg once per week. After 20 exposure days, the weekly infusions should be continued for as long as possible following the early prophylaxis period. If required by the clinical situation, dosing may be increased to twice weekly or even three times weekly after 20 exposure days, while keeping the low dose.
223883061|NCT02078232|DEVICE|puncture of head of pancreas|"puncture of head of pancreatic solid mass with fine needle aspiration under endoscopic ultrasonographic control.~randomization: puncture with either 22G needle or 19G flex needle"
223883062|NCT02078232|DEVICE|puncture of head of pancreas|"puncture of head of pancreatic solid mass with fine needle aspiration under endoscopic ultrasonographic control.~randomization: puncture with either 22G needle or 19G flex needle"
223883063|NCT05124613|OTHER|Survey|"Information collected and stored in Survey:~* Type of knee surgery the patient is waitlisted for~* Demographics: age, sex, recent weight gain~* Validated and bespoke questions:~  1. EQ-5D survey (a validated questionnaire on health)~ 2. Bespoke questions on knee pain today~ 3. Bespoke questions on knee function today~ 4. Bespoke questions on change in knee pain since being waitlisted for surgery~ 5. Bespoke questions on change in knee function since being waitlisted for surgery~ 6. Bespoke questions on coping mechanisms patients use to manage symptoms~ 7. Bespoke questions on what support they would find beneficial whilst they wait for their surgery~ 8. Three bespoke questions about COVID-19 (Have they ever tested positive/Has the pandemic changed their mind about wanting surgery/Has the perception of their knee pain and function changed since the first lockdown was introduced?)"
223883064|NCT02488148|BEHAVIORAL|Hot yoga|Subjects in the two intervention groups will complete the standard 26-posture Bikram yoga series in a studio heated at 41ºC (traditional environment) or in a studio at a room temperature of 22ºC whereas control group subjects will be instructed to maintain physical activity patterns for the 12-week study duration. Yoga classes will be held at the Pure Bikram Yoga downtown Austin location. Classes will be completed 3 times weekly for 12 weeks and consist of 90 minutes of yoga postures and breathing exercises.
223883065|NCT02488148|BEHAVIORAL|Non-heated yoga|Subjects in the two intervention groups will complete the standard 26-posture Bikram yoga series in a studio heated at 41ºC (traditional environment) or in a studio at a room temperature of 22ºC whereas control group subjects will be instructed to maintain physical activity patterns for the 12-week study duration. Yoga classes will be held at the Pure Bikram Yoga downtown Austin location. Classes will be completed 3 times weekly for 12 weeks and consist of 90 minutes of yoga postures and breathing exercises.
223883066|NCT06518915|DEVICE|baroloop system|Participants will have the baroloop device implanted for selective stimulation of the vagus nerve.
223883067|NCT06329375|OTHER|Nutrition program|Nutrition program with twice daily meal delivery up to 90 days post-discharge and food and diet education at discharge.
223883068|NCT04752163|DRUG|DS-1594b|Given DS-1594b PO
223883069|NCT04752163|DRUG|Azacitidine|Given IV or SC
223883070|NCT04752163|DRUG|Cyclophosphamide|Given IV
223883071|NCT04752163|DRUG|Cytarabine|Given IT
223883072|NCT04752163|DRUG|Dexamethasone|Given PO or IV
223883073|NCT04752163|BIOLOGICAL|Filgrastim|Given SC
223883074|NCT04752163|DRUG|Leucovorin|Given IV or PO
223883075|NCT04752163|DRUG|Mesna|Given IV
223883076|NCT04752163|DRUG|Methotrexate|Given IT
223883077|NCT04752163|DRUG|Prednisone|Given PO
223883078|NCT04752163|BIOLOGICAL|Rituximab|Given IV
223883079|NCT04752163|DRUG|Venetoclax|Given PO
223883080|NCT04752163|DRUG|Vincristine|Given IV
223883081|NCT04063514|OTHER|Focused Ultrasound|With focused ultrasound, there is an expected accentuation of local perfusion and potential temporary opening of the blood brain barrier with the aim is to provide better delivery of therapeutic agents including medication, particulates and cellular elements for treatment of neoplastic, inflammatory and degenerative brain diseases. The present study seeks to investigate differences in perfusion between areas treated and untreated by this modality in order to further explore its use in clinical application for the treatment of brain disease.
223883082|NCT01549899|BEHAVIORAL|In-person Cognitive Behavioral Therapy of Insomnia|In-person CBTi was be provided by a master's or doctoral level mental health counselor (e.g., social worker or psychologist). This treatment consisted of 6-sessions and included the same efficacious and commonly used modules of CBTi (i.e., sleep education \& hygiene, stimulus control, progressive muscle relaxation, sleep restriction, and cognitive therapy).
223883083|NCT01549899|BEHAVIORAL|Internet Cognitive Behavioral Therapy of Insomnia|The ICBTi treatment is an online protocol developed by the National Center for Telehealth and Technology, with the PI (DJT) as the subject matter expert. The treatment consists of the same components as the in-person CBTi, but their mode of delivery was considerably different due to the constraints of its automated, online format. Each of the six ICBTi sessions was divided into lessons covering different aspects of each of the components. The lessons were presented as audio recordings accompanied by visual graphics and animations. For several lessons, interactive components were included, such as games, quizzes, and prompts for participants to schedule healthy sleep habits.
223883084|NCT00601900|BIOLOGICAL|Bevacizumab|Given IV
223883085|NCT00601900|OTHER|Laboratory Biomarker Analysis|Correlative studies
223883086|NCT00601900|DRUG|Letrozole|Given PO
223883087|NCT00601900|OTHER|Questionnaire Administration|Ancillary studies
223883088|NCT00601900|DRUG|Tamoxifen Citrate|Given PO
223883089|NCT05873751|BIOLOGICAL|Trumenba Vaccine|Trumenba vaccine given as standard of care
223883090|NCT05873751|BIOLOGICAL|MenACWY Vaccine|MenACWY Vaccine given as standard of care
223883091|NCT06121921|OTHER|Perioperative multi-component intervention|"Physical Component~Self-directed daily non-ambulatory exercise programme, comprising:~* Rubber ball squeezes (3 sets of 12 reps, per hand)~* Bicep curls (3 sets of 12 reps)~* Leg extensions (3 sets of 12 reps)~* Chair rises (3 sets of 12 reps)~* Arm stretches (3 sets of 3 reps) Additional encouragement to mobilise~Cognitive Component:~Delirium prevention strategies including orientation, hydration, bowel/bladder function, infection control, analgesia, polypharmacy and cognitive stimulation~Nutritional Component:~* Formal dietician review if MUST score ≥ 2~* IV ferritin if LVEF \<45% and serum ferritin \<100ng/mL or ferritin 100-299ng/mL with TSAT \<20%"
223883092|NCT06068894|DIETARY_SUPPLEMENT|"Humanized galacto-oligosaccharides (hGOS)"|10-15 g/day of hGOS, which will be provided to participants as a powder that can be added to any non-alcoholic beverage
223883093|NCT06068894|DIETARY_SUPPLEMENT|Galacto-oligosaccharides (GOS)|10-15 g/day of GOS, which will be provided to participants as a powder that can be added to any non-alcoholic beverage.
223883094|NCT06068894|OTHER|Matching Placebo|10-15 g/day powdered corn syrup comprised of fructose, glucose, and an inert cellulose material that matches the consistency, color sweetness, and taste of the prebiotics, that can be added to any non-alcoholic beverage.
223883095|NCT03822845|DRUG|Ga-68 PSMA-HBED-CC PET|Ga-68 PSMA-HBED-CC is an investigational PET drug (radionuclide), that binds to the prostate specific receptors. The dose will be about 5mCi (range 3-7 mCi) and administered intravenously.
223883096|NCT06036108|DRUG|OPC-34712FUM/ Brexpiprazole fumarate|In Period 1, a single oral dose of two 24 mg tablets of brexpiprazole QW formulation (48 mg as brexpiprazole) will be administered at least 10 hours of fasting. In Period 2, following at least 10 hours of fasting, the subject will consume a high-fat meal within 20 minutes, after which a single oral dose of two 24 mg tablets of brexpiprazole QW formulation (48 mg as brexpiprazole) will be administered within 10 minutes of finishing the meal.
223883097|NCT06036108|DRUG|OPC-34712FUM/ Brexpiprazole fumarate|In Period 1, following at least 10 hours of fasting, the subject will consume a high-fat meal within 20 minutes, after which a single oral dose of two 24 mg tablets of brexpiprazole QW formulation (48 mg as brexpiprazole) will be administered within 10 minutes of finishing the meal. In Period 2, a single oral dose of two 24 mg tablets of brexpiprazole QW formulation (48 mg as brexpiprazole) will be administered following at least 10 hours of fasting.
223883098|NCT03926819|DRUG|HBI-002|Oral liquid carbon monoxide drug product.
223883099|NCT05777486|BEHAVIORAL|TikTok Ads - With Food|TikTok posts from influencers promoting food.
223883100|NCT05777486|BEHAVIORAL|TikTok Ads - Without Food|TikTok posts from influencers who are not promoting food.
223883101|NCT04485871|DIETARY_SUPPLEMENT|Omega-3 fatty acids|Triple Strength Omega-3 from Webber Naturals; 4 oral softgels (600 mg EPA and 300 mg DHA / softgel)
223883102|NCT02500758|PROCEDURE|Preparatory handwash|Preparatory handwash follows the UNE-EN 12791 standard using a diluted soft soap, 200g/1000g, made in community pharmacy service and sterilize in autoclave. Washing hands were prepared without use of a brush for 1 minute with 10 ml of soft soap. After being rinsed with running tap water, they are thoroughly dried with paper towels.
223883103|NCT02500758|PROCEDURE|Preoperative surgical scrubbing using 3% PCMX|Both hands were scrubbed using a sterile disposable surgical scrub brush with plastic bristles on one side and a foam sponge on the other side. The bristled side was used to scrub the entire hands, including all nails, palm and back of the hand, and interdigital spaces, and the foam side was used to rub between the fingers. Each side of each finger, between fingers and back al palm of the hand were rubbed for two and a half minute. Then, the forearms were rubbed from the wrist to the elbow, maintaining the hand highest than the arm, using a minute to wash each side. Both hands were rinsed by current water in an one-way (from the fingertips to the elbow), and wiped with a sterile disposable towel, including nails and interdigital spaces.
223883104|NCT02500758|PROCEDURE|Preoperative surgical scrubbing using 4% CHG|Both hands were scrubbed using a sterile disposable surgical scrub brush with plastic bristles on one side and a foam sponge on the other side. The bristled side was used to scrub the entire hands, including all nails, palm and back of the hand, and interdigital spaces, and the foam side was used to rub between the fingers. Each side of each finger, between fingers and back al palm of the hand were rubbed for two and a half minute. Then, the forearms were rubbed from the wrist to the elbow, maintaining the hand highest than the arm, using a minute to wash each side. Both hands were rinsed by current water in an one-way (from the fingertips to the elbow), and wiped with a sterile disposable towel, including nails and interdigital spaces.
223883105|NCT00596336|DRUG|Imiquimod cream|Imiquimod (aldara) 0.5 % cream to site of vaccination on day 2 to 6
223883106|NCT00596336|DRUG|influenza vaccine|trispecific influenza vaccine 0.5 ml subcutaneously
223883107|NCT00972049|DRUG|AZD2516|Capsule administered once orally. Specific dose depends on dose panel.
223883108|NCT00972049|DRUG|Placebo|Capsule administered once orally
223883109|NCT06561048|DRUG|Soquelitinib|Soquelitinib 200 mg tablets will be taken by mouth two times a day
223883110|NCT06561048|DRUG|Belinostat|Belinostat (1000 mg/m2) will be administered by intravenous infusion once daily on Days 1 through 5 of each 21-day cycle
223883111|NCT06561048|DRUG|Pralatrexate|Pralatrexate (30 mg/m2) will be administered intravenously over 3 to 5 minutes once weekly for 6 weeks in each 7-week cycle
223883112|NCT05395403|DEVICE|Blood pressure measurement device|The use of three different devices: traditional office blood pressure measurement cuff (OBPM), automated office blood pressure measurement cuff (AOBPM), and home blood pressure measurement cuff (HBPM).
223883113|NCT04893759|DRUG|Pelcitoclax|Multiple dose cohorts, 30 minute IV infusion, once a week, 28 days as a cycle
223883114|NCT05844306|PROCEDURE|Computed Tomography|Undergo \[18F\]-FDG PET-CT
223883115|NCT05844306|OTHER|Fludeoxyglucose F-18|Given via injection
223883116|NCT05844306|OTHER|Medical Device Usage and Evaluation|Undergo X1 RMRS PET-CT
223883117|NCT05844306|DEVICE|Positron Emission Tomography|Undergo \[18F\]-FDG PET-CT
223883118|NCT03740763|DEVICE|Spinal Cord Stimulation (SCS)|SCS for treatment of neuropathic pain
223883119|NCT03740763|OTHER|Physiotherapy|Physiotherapy 2 hours/week with physiotherapist and physical activity counseling for treatment of neuropathic pain
223883120|NCT05371808|OTHER|EQ-5D-5L Instrument|This instrument is a measure of health status for use in evaluating health and healthcare.
223883121|NCT05371808|OTHER|Work Productivity and Daily Activity Impairment (WPAI) survey|The questionnaire includes three open-ended questions that determines: 1) hours absent from work due to health problems; 2) hours absent from work due to other reasons; and (3) hours actually worked over the past 30 days. Additional questions ask about the impact of health problems on work productivity and daily activities and are scored along a vertical visual analog scale. The WPAI provides estimates on absenteeism, presenteeism, global measures of lost productivity (absenteeism+presenteeism) and daily activity impairment (impaired ability to perform non-work activities including work around the house, child care, exercise, studying, and leisure activities)
223883122|NCT05371808|OTHER|Resource Utilization Form (SMRC)|Resource utilization data collection will be supplemented by a self-administered resource utilization form (Stanford SMRC) to document non-protocol specified utilization. This will include hospitalizations (including days in hospital), emergency room visits, and non-protocol specified ambulatory visits.
223883123|NCT06321003|DEVICE|OCT (Optical Coherence Tomography)|OCT diagnosis in oral carcinogenesis
223883124|NCT05569395|OTHER|Neuro mobilization|"For median nerve stretching, the participants' dominant forearms will be in the supination position while the shoulder will be depressed and abducted 90 degrees.~In this position, while the participant's head is lateral flexed to the opposite side, the wrist and finger will be extended and median nerve stretching will be performed. After staying in this position for 30 seconds, the participants will relax by placing the wrist and head in the neutral position. Thus, a set for median nerve stretching will be completed. For median nerve gliding, the dominant side of the individuals' forearms will be in supination, while the shoulder will be placed in a depression and 90 degree abduction position. In this position, the participant will flex the wrist and fingers while lateral flexing the head to the opposite side, and extend the wrist and fingers while the head is lateral flexed to the same side."
223883125|NCT05569395|OTHER|Sham neuro mobilization|Sham neuromobilization will be applied to the nondominant side upper extremities of the participants.
223883126|NCT03728764|OTHER|Preterm infant formula|Preterm infants will receive Stage 1 investigative product as soon as possible after birth until when 1.8 kg of body weight is achieved. Preterm infants will receive stage 2 preterm formula from when 1.8 kg of body weight is achieved until 1 month after hospital discharge.
223883127|NCT04835844|DEVICE|CARTO|Redo-ablation of paroxysmal AF with high density mapping system, CARTO, in conjunction with CONFIDENSE mapping module and PENTARRAY catheter
223883128|NCT04835844|DEVICE|RHYTHMIA|Redo-ablation of paroxysmal AF with high density mapping system, RHYTHMIA, in conjunction with the 64-electrodes ORION mini-basket catheter.
223883129|NCT06398314|RADIATION|Palliative radiotherapy|Hypofractionated radiotherapy
223883130|NCT04121936|OTHER|There will be no intervention|There will be no intervention
223883131|NCT00274469|DRUG|fulvestrant|500 mg intramuscular injection
223883132|NCT00274469|DRUG|anastrozole|1 mg oral tablet
223883133|NCT03526354|DRUG|Brexpiprazole|Brexpiprazole 4mg daily for 12 weeks
223883134|NCT03526354|OTHER|Treatment as Usual|Current antipsychotic medication for 12 weeks
223883135|NCT03979235|DIAGNOSTIC_TEST|Motor function assessment|perform motor function assessment by using scales, sEMG, and inertia sensors
223883136|NCT03007030|DRUG|Brentuximab Vedotin|Given IV
223883137|NCT03007030|OTHER|Laboratory Biomarker Analysis|Correlative studies
223883138|NCT06538857|PROCEDURE|Standard surgery|The location and size of the tumor determine the type of surgery.
223883139|NCT06538857|DRUG|CEB-01|It is novel formulation for local release of chemotherapy. It consists of a biocompatible and biodegradable nanofiber membrane made of poly(lactic-co-glycolic acid) (PLGA), which is loaded with the anti-tumor drug SN-38 and implanted in the surgical bed after tumor removal.
223883140|NCT04820894|OTHER|Electronic Medical Record|Medical records are reviewed
223883141|NCT04820894|OTHER|Survey Administration|Complete surveys
223883142|NCT03771105|DRUG|phosphate|The target daily phosphate (Pi) intake is 3,500 mg/day (dietary intake plus our supplementation) for this study. Subjects will take a supplement of Pi (as KPhos Neutral 250 mg/tablet) to reach this target. Subjects will receive treatment for 30 days.
223883143|NCT05720780|OTHER|MS group|"All patients will perform the usual training by listening a piece of music of the same duration as the training. The patient will be able to choose among 4 different musical proposals corresponding to 4 different styles: rock, modern, jazz and classical. The song chosen by the patient will be the musical support for all the sessions of training on the cycle ergometer. The musical pieces will be composed with a constant rhythm (bpm=60) which, from a tonal point of view, will echo the pedaling movement. The constant rhythm will be superimposed on musical patterns in the form of loops in the styles mentioned. The musical support will assume a priming (activation) and dragging (synchronization) function, facilitating movement planning/synchronization and creating a pleasant context in which to carry out training"
223883144|NCT05720780|OTHER|C group|All patients will perform 12 to 14 supervised sessions depending on the center they belong to (5-6 sessions/week) each consisting of 30 minutes of exercise at the cycle ergometer plus 3 minutes of warm-up and 3 minutes of recovery. After a warm-up phase at 0 W, the initial workload will be set to 60% of the theoretical maximum. Intensity increases or decreases of 10 W will be made according to the criteria of Maltais et al (workload will be increased when patients will report dyspnea and/or leg fatigue as ≤3 on a Borg scale modified to 10 points of perceived effort. The training load will remain unchanged if the Borg score is 4 or 5 and will be reduced for scores ≥6). Patients will have to maintain a pedaling frequency between 55 and 60 rpm.
223883145|NCT04025359|DRUG|Dronabinol|Dronabinol 2.5 mg
223883146|NCT04025359|DRUG|Dronabinol|Dronabinol 5 mg
223883147|NCT04025359|DRUG|Placebo|Placebo
223883148|NCT02317783|DRUG|[18F]Flutemetamol|Brain scan with imaging tracer that binds to amyloid plaques
223883149|NCT02317783|DRUG|[18F]fluoro-2-deoxy-D-glucose (FDG)|Brain scan with imaging tracer used for measuring glucose metabolism in the assessment, diagnosis, and staging of patients with cancer
223883150|NCT02317783|DIAGNOSTIC_TEST|Functional Magnetic Resonance Imaging (fMRI)|Brain scan to assess regions of abnormal volume and density
223883151|NCT05847894|DIAGNOSTIC_TEST|Ophthalmic examination|Various ophthalmic examination modalities, including slit lamp photography, fundus photography, optical coherence tomography imaging and optical coherence tomography angiography, etc.
223883152|NCT05847894|DIAGNOSTIC_TEST|Pulmonary Examination|Various pulmonary examination modalities, including radiography, chest CT, pulmonary function measurement, etc.
223883153|NCT05643326|DEVICE|40 Hz transcranial alternating current stimulation|42 sessions of 40 Hz transcranial alternating current stimulation (5 days/week for 9 weeks)
223883154|NCT05643326|DEVICE|Sham stimulation|42 sessions of sham stimulation (5 days/week for 9 weeks)
223883155|NCT06137560|DEVICE|Single vision spectacle lens|Standard single vision spectacle lens
223883156|NCT06137560|DEVICE|Single vision spectacle lens + S.T.O.P.® Kit 1|Standard single vision spectacle lens + S.T.O.P.® Kit 1
223883157|NCT06137560|DEVICE|Single vision spectacle lens + S.T.O.P.® Kit 2|Standard single vision spectacle lens + S.T.O.P.® Kit 2
223883158|NCT06137560|DEVICE|Single vision spectacle lens + S.T.O.P.® Film|Standard single vision spectacle lens + S.T.O.P.® Film
223883159|NCT06137560|DEVICE|Standard single vision spectacle lens + S.T.O.P.® Kit 1 or 2|Standard single vision spectacle lens + S.T.O.P.® Kit 1 or 2
223883160|NCT04362501|BIOLOGICAL|dupilumab|300mg dupixent SC every two weeks for six months
223883161|NCT04362501|DRUG|placebo|placebo SC injection every two weeks for six months
223883162|NCT02498717|DEVICE|GameReady|Cryotherapy and compression
223883163|NCT02498717|OTHER|RICE|SOC ice and elevation
223883164|NCT04093752|DRUG|Tirzepatide|Administered SC
223883165|NCT04093752|DRUG|Insulin Glargine|Administered SC
223883166|NCT05032261|DRUG|Circulatory shock with norepinephrine in ICU|Circulatory shock with norepinephrine in ICU
223883167|NCT06969040|OTHER|CBTI + tACS|CBTI + tACS group method: CBTI for about 50 minutes each time, for a total of 6 weeks: ① first interview: enrolment assessment; ② second interview: treatment initiation; ③ third interview: sleep titration and sleep hygiene; ④ fourth interview: sleep titration; ⑤ fifth-seventh interview: sleep titration; ⑥ eighth interview: sleep titration (end of standardised CBTI treatment. tACS true stimulation) : Transcranial alternating current therapy (tACS) was operated during the same period of CBTI, with 3 electrodes, placed in the prefrontal lobe and bilateral mastoid; the stimulation intensity was 77.5 Hz, 15 mA, 40 min each time, once a day, 5 days a week, for 6 weeks.
223883168|NCT06969040|OTHER|CBTI + Sham tACS|CBTI+sham tACS group method: CBTI treatment method was the same as before. tACS pseudo-stimulation: the electrode placement position, stimulation frequency, and time settings were the same as the real stimulation, and the stimulation process only had the output of gradual rising and falling current at the beginning and the last 10s, respectively, so as to make the subjects produce the same subjective feelings as the real stimulation.
223883169|NCT01837394|PROCEDURE|Block of the SN and ONP|7.5 ml of Ropivacaine 7.5 mg/ml injected at each site
223883170|NCT01837394|PROCEDURE|Placebo block|7.5 ml of isotonic saline solution 154 mmol/l injected at each site
223883171|NCT01837394|DRUG|Paracetamol|
223883172|NCT01837394|DRUG|Morphine|5 mg as needed
223883173|NCT01837394|DRUG|Ondansetron|4 mg i.v. as needed in the PACU
223883174|NCT01837394|DRUG|Metoclopramide|10 mg tablet as needed in the postoperative period after discharge from the PACU
223883175|NCT04575961|DRUG|Pembrolizumab|Participants receive pembrolizumab 200 mg by intravenous (IV) infusion prior to chemotherapy on Day 1 of each 21-day cycle for up to 35 cycles
223883176|NCT06967922|BEHAVIORAL|Analytic-Integrative Cognitive Behavioural Therapy|Analytic-Integrative Cognitive-Behavioural Approach: Initial Interview for Information Gathering: comprehensive collection of patient information; Assessment: collection of multidimensional factors; Diagnosis: insomnia and co-morbidities; Analytic-Integrative Analysis for Treatment Decision Making.
223883177|NCT06967922|OTHER|Sleep hygiene education|Participants will receive Sleep Hygiene Education (SHE) alone for 6 weeks. SHE involves education on maintaining consistent sleep schedules, creating a sleep-conducive environment, reducing stimulant use (e.g., caffeine, alcohol), and promoting healthy daily routines to improve sleep quality.
223883178|NCT01762059|DEVICE|Bi-homonal Bionic Pancreas|A computer algorithm will automatically deliver insulin lispro and glucagon based on the signal from a minimally invasive continuous glucose monitor.
223883179|NCT01762059|OTHER|Usual care|
223883180|NCT00004257|DRUG|fluorouracil|
223883181|NCT00004257|DRUG|oxaliplatin|
223883182|NCT00004257|PROCEDURE|conventional surgery|
223883183|NCT00004257|RADIATION|radiation therapy|
223883184|NCT06568341|OTHER|validity and reability study|Validity and reliability assessment of the Turkish version of the Outcome Expectations For Yoga (OEY) Scale
223883185|NCT03819465|DRUG|Durvalumab|Durvalumab IV Cohort A: Every 4 weeks (q4w) Cohort B: Every 3 weeks (q3w) for the first 4 cycles, then every 4 weeks (q4w) starting at Cycle 5 Day 1
223883186|NCT03819465|DRUG|Danvatirsen|Danvatirsen IV Loading dose Cycle 1 Day 1, Cycle 1 Day 3, and Cycle 1 Day 5 then once a week (q1w) starting at Cycle 1 Day 8
223883187|NCT03819465|DRUG|Oleclumab|Oleclumab IV Cohort A: Every 2 weeks (q2w) for first 2 cycles, then every 4 weeks (q4w) starting at Cycle 3 Day 1 Cohort B: Every 3 weeks (q3w) for the first 4 cycles, then every 4 weeks (q4w) starting at Cycle 5 Day 1
223883188|NCT03819465|DRUG|MEDI5752|MEDI5752 IV Every 3 weeks (q3w)
223883189|NCT03819465|DRUG|Pemetrexed|Pemetrexed IV Day 1 of each 21-day cycle Arm B1: Day 1 of each 21-day cycle for the first 4 cycles then either every 3 weeks (q3w) or every 4 weeks (q4w) (per investigator discretion) thereafter Arm B2 and B3: Day 1 of each 21-day cycle for the first 4 cycles then Day 1 of each 28-day cycle (q4w) thereafter Arm B5: Day 1 of each 21-day cycle throughout the study
223883190|NCT03819465|DRUG|Carboplatin|Carboplatin IV Day 1 of each 21-day cycle
223883191|NCT03819465|DRUG|Gemcitabine|Gemcitabine IV Days 1 and 8 of each 21-day cycle
223883192|NCT03819465|DRUG|Cisplatin|Cisplatin IV Day 1 of each 21-day cycle
223883193|NCT03819465|DRUG|Nab-paclitaxel|Nab-paclitaxel IV Days 1, 8, and 15 of each 21-day cycle
223883194|NCT03819465|DRUG|AZD2936|AZD2936 IV
223883195|NCT04093895|DRUG|PerioSept(r)|Scaling and root planing followed by 3% PerioSept(r) administration
223883196|NCT03419572|OTHER|Data collection|Only available evaluations as decided by the investigator based on local clinical practice will be collected.
223883197|NCT06500780|BEHAVIORAL|Coaching and Decision Aid|Four (4) coaching sessions over approximately 12 weeks with integration of Decision Aid contents
223883198|NCT06155721|DEVICE|Virtual Reality Cognitive Stimulation Program|Intervention Type: Device Intervention Name: Virtual Reality Cognitive Stimulation Program Description: This program utilizes virtual reality to conduct cognitive stimulation exercises aimed at improving memory, executive functions, and attention in individuals with Mild Cognitive Impairment (MCI). It includes interactive tasks such as virtual shopping, payment simulations, and recipe sequencing, along with 360-degree video sessions for attention and episodic memory training.
223883199|NCT04683315|DRUG|mFOLFIRINOX Treatment Regimen|This therapy will be 5-fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX).
223883200|NCT04683315|DRUG|Gemcitabine/Nab-paclitaxel Treatment Regimen|This regimen will be nab-paclitaxel and gemcitabine.
223883201|NCT04683315|RADIATION|Chemoradiation|50.4 Gy in 28 fractions.
223883202|NCT06175312|OTHER|Stimulus properties: salience-defining feature|The feature used to define a salient location will be varied across trials (checkerboard contrast; motion direction; color hue)
223883203|NCT06175312|OTHER|Stimulus properties: magnitude of salience|The magnitude of the salient location will be varied across trials independently from salience-defining feature (based on feature contrast)
223883204|NCT05503017|BEHAVIORAL|Psycho-social, computerized intervention targeting error sensitivity|The computer-based intervention is designed to directly reduce the sensitivity to errors through cognitive behavioral techniques. The intervention takes approximately 45 minutes and includes interactive quizzes, information, and behavioral tasks relevant to making mistakes, implications of making errors, and ways to deal with making mistakes, among other topics relevant to increased error sensitivity. The intervention uses developmentally appropriate language and stories that young children can relate to and understand.
223883205|NCT05503017|BEHAVIORAL|Psycho-social, computerized intervention on healthy lifestyle choices|The computer-based control condition will be in the same format and duration as the active intervention, but instead focuses on self-care topics and healthy lifestyle choices (e.g., eating healthy foods and getting a good night sleep), unrelated to error sensitivity.
223883206|NCT04275908|DEVICE|MHSAFE app|App to detect presence of mental state
223883207|NCT04524494|OTHER|biopsy of intestinal tissue|4 intestinal tissue biopsies taken from descending Duodenum, 2 intestinal tissue biopsies taken from Ileum, 2 intestinal tissue biopsies taken from ascending colon (additional to routine biopsies taken for gastrointestinal diagnostic)
223883208|NCT04524494|OTHER|blood draw|40 ml blood draw (in Heparin blood tubes) (additional to routine blood draw taken for gastrointestinal diagnostic)
223883209|NCT04524494|OTHER|urine collection|Midstream Urine collection
223883210|NCT03767452|DRUG|Xiaflex® 0.58 mg|0.25 mL injections.
223883211|NCT06094231|BEHAVIORAL|Therapeutic carbohydrate restriction combined with an SGLT-2-Inhibitor|The patients will be educated on how to implement a therapeutic carbohydrate restriction, which consists of 50 to 130 grams of carbohydrate per day, simultaneously they will continue to receive the SGLT-2-Inhibitor dapagliflozin.
223883212|NCT00593489|OTHER|Basal Insulin Initiation Strategy|This multifaceted intervention consists of (1) Diabetes Specialist Consultation Support which entails specialists and educators providing consultation for insulin initiation and titration for the 12 months following the Workshop. Support will consist of prearranged and scheduled communications to review and advise for the first 2 months and will continue on an ad hoc basis for the remaining 10 months, with communication initiated by the physician (2)Community Pharmacy Insulin Initiation consists of trained community pharmacists providing patient education insulin initiation. Education will consist of one individual teaching session, one hour in duration, to review the insulin prescription protocol, insulin injection method, management of hypoglycemia, and self-monitoring of blood glucose.
223883213|NCT02622984|BEHAVIORAL|RBIRT|Intervention group will receive the telehealth or remote behavior intervention and referral for substance use (RBIRT). Other group will receive treatment as usual which is SBIRT.
223883214|NCT02622984|BEHAVIORAL|SBIRT|"Face to face standard intervention considered treatment as usual."
223883215|NCT03706664|OTHER|Machine learning algorithm|Study will develop and test a machine learning algorithm using MR Enterography images labelled by Radiologists.
223883216|NCT06345586|DRUG|Drospirenone|4 mg tablet once daily
223883217|NCT02742519|DRUG|ivacaftor|
223883218|NCT02742519|DRUG|Placebo|
223883219|NCT01296334|DRUG|morphine LO|intravenous infusion, 10 mg, once, 4 hours
223883220|NCT01296334|DRUG|Morphine Hi|intravenous infusion, 20 mg, once, 4 hours
223883221|NCT01296334|DRUG|Buprenorphine LO|intravenous infusion, 0.3 mg, once, 4 hours
223883222|NCT01296334|DRUG|Buprenorphine Hi|intravenous infusion, 0.6 mg, once, 4 hours
223883223|NCT01296334|OTHER|saline|intravenous infusion, 0.9% saline, once, 4 hours
223883224|NCT01052259|DRUG|Deoxyspergualin|100mg/vial as active substance; Deoxyspergualin at 3-5 mg/kg/day by 1-3 iv infusion will be given once a day for 5 to 7 days each cycle every month; Total cycle treatment will be 6.
223883225|NCT04243980|DEVICE|Short anatomical femoral stem in THR|Patients with osteoarthritis after total hip arthroplasty
223883226|NCT03452085|DEVICE|artificial saliva spray (AS)|cross over design
223883227|NCT03452085|OTHER|maritime throat spray (TT)|cross over design
223883228|NCT05088954|PROCEDURE|transforaminal epidural steroid injection|In the transforaminal approach, a small amount of drug is injected into the epidural space, and in previous studies, reduction in pain and improvement in functionality were found in patients with lumbar radicular pain in the short and medium term.
223883229|NCT02057939|DRUG|enzalutamide|160 mg orally once daily for six months
223883230|NCT02057939|DRUG|Androgen Deprivation|Two injections each lasting three months, for a total of six months of androgen deprivation therapy. Doctor will help determine which androgen deprivation drug to use.
223883231|NCT02057939|RADIATION|Radiation Therapy|Daily (Monday-Friday) for 6-8 weeks, final dose of approximately 66 Gy
223883232|NCT05335642|PROCEDURE|EVAR|Endovascular repair of abdominal aortic aneurysms
223883233|NCT00035308|DRUG|Abetimus sodium (LJP 394)|
223883234|NCT01035034|PROCEDURE|Hybrid MIDCAB/PCI|"MIDCAB with no associated or concomitant surgical procedures, using partial ministernotomy, without cardiopulmonary bypass (CPB) and cardioplegia. PCI with drug eluting stents (DES) performed by cardiologists on the non-LAD lesions in the same operating suite immediately following MIDCAB.~Device: Polymer-based Sirolimus-Eluting Stents (SES)."
223883235|NCT01035034|PROCEDURE|PCI with DES|Polymer-based Sirolimus-Eluting Stents (SES)
223883236|NCT02759016|DRUG|BI 836826|
223883237|NCT02759016|DRUG|Ibrutinib|Standard of Care
223883238|NCT04377308|DRUG|Fluoxetine|Fluoxetine 20 mg to 60 mg daily given from 2 weeks to 2 months duration
223883239|NCT00840229|DRUG|Triamcinolone hexacetonide|20 mg
223883240|NCT00840229|DRUG|Triamcinolone hexacetonide|1 ml (20 mg) + 6 ml Lidocaine 10 mg/ml
223883241|NCT03580369|BIOLOGICAL|Ligelizumab|Liquid in vial
223883242|NCT03580369|BIOLOGICAL|Omalizumab|Lyophilized powder for solution in vial
223883243|NCT03580369|OTHER|Placebo|Liquid in vial
223883244|NCT01522924|OTHER|Counseling practice sessions|Dental students will complete the first questionnaire before a tobacco cessation lecture and the second questionnaire after the lecture, counseling practice sessions using standardized patients and a debriefing session.
223883245|NCT00224445|DRUG|Truvada|Truvada (emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg tablet) administered orally once daily (QD)
223883246|NCT00224445|DRUG|Atazanavir|Atazanavir 300 mg (given as two 150-mg capsules) administered orally QD
223883247|NCT00224445|DRUG|Ritonavir|Ritonavir 100 mg capsule administered orally QD
223883248|NCT03828968|DIAGNOSTIC_TEST|bladder scan|Measurement of vesical volume by bladder scan
223883249|NCT03939312|DRUG|Atogepant|Atogepant Tablets
223883250|NCT02119650|DRUG|Ruxolitinib|5 mg tablets to be administered by mouth at dose selected from safety run-in phase (Ruxolitinib 15 mg twice daily (BID))
223883251|NCT02119650|DRUG|Placebo|5 mg matching placebo tablets to be administered by mouth
223883252|NCT02119650|DRUG|Pemetrexed|500 mg/m\^2 administered as an intravenous infusion over 10 minutes
223883253|NCT02119650|DRUG|Cisplatin|75 mg/m\^2 infused over 2 hours beginning 30 ± 5 minutes after the end of the pemetrexed infusion
223883254|NCT04881175|DEVICE|Non-Invasive Treatment|Single-arm group using the FlexSure Applicator device.
223883255|NCT02824458|DRUG|Apatinib|Patients will be treated with Apatinib, 250/500/750 mg(dose determined from Part A of study) p.o., daily
223883256|NCT02824458|DRUG|Gefitinib|Patients will be treated with Gefitinib, 250 mg p.o., daily
223883257|NCT02824458|DRUG|Placebo|
223883258|NCT03081611|DEVICE|Ram cannula|Ventilatory support for preterm infants using Ram cannula
223883259|NCT03081611|DEVICE|Short nasal prongs|Ventilatory support for preterm infants using short nasal prongs
223883260|NCT00006198|DRUG|thalidomide|
223883261|NCT00006198|PROCEDURE|chemoembolization with doxorubicin/collagen|
223883262|NCT02210442|BEHAVIORAL|educaguia intervention|Health professionals (residents) play with educational games in order to acquire knowledge and skill about management of clinical practice guidelines.
223883263|NCT02210442|OTHER|control group|Health professional will learn how to manage a clinical practice guidelines with standard clinical practice.
223883264|NCT03189472|DEVICE|Active tDCS|low amplitude direct currents to induce changes in cortical excitability. tDCS produces current intensities in the brain orders of magnitude below other stimulation techniques such as transcranial magnetic stimulation (TMS) or electroconvulsive therapy (ECT)
223883265|NCT03189472|DEVICE|Sham tDCS|The device will be programmed to deliver either active or sham tDCS (all study personnel and participants will be blinded), and operated with unlock codes provided by the study technician daily to release one session
223883266|NCT04664270|BEHAVIORAL|e-CBT|e-CBT + Mindfulness + Problem Solving
223883267|NCT04319913|DEVICE|analgesia nociception index|Analgesia nociception index (ANI) could objectively monitor how pain the participant is. In the experimental group, the care provider would decrease the dose of narcotics (remifentanil) if the ANI value is above 70, and increase the dose if the ANI value is under 50.
223883268|NCT02173717|DRUG|Dabigatran etexilate|150 mg Dabigatran etexilate
223883269|NCT02173717|DRUG|Rifampicin|600 mg Rifampicin
223883270|NCT03041064|OTHER|50/100|SPF
223883271|NCT03041064|OTHER|100/50|SPF
223883272|NCT00766649|DRUG|Sirolimus|Participants receive a 20 μL (440 μg) subconjunctival injection of sirolimus in the study eye at baseline and every three months thereafter.
223883273|NCT02886195|DRUG|pemetrexed|500mg/m2 ivgtt d1, per three weeks
223883274|NCT02886195|DRUG|cisplatin|80mg/m2 ivgtt d1, per three weeks
223883275|NCT02886195|DRUG|Erlotinib|150mg po. every day
223883276|NCT04944563|PROCEDURE|Segmentectomy|Patients receive segmentectomy
223883277|NCT04944563|PROCEDURE|Lobectomy|Patients receive lobectomy
223883278|NCT01721291|DRUG|SALBUTAMOL|"In the LUNG DEPOSITION STUDY; SALBUTAMOL INHALED VIA RESEARCH NEBULISER at 3 PARTICLES SIZES OF 1.5 MICRONS, 3 MICRONS AND 6 MICRONS WILL BE GIVEN AT SLOW INHLATION AND AGAIN AT FAST INHALTION;DOSAGE- 30 MICROGRAMS, ONE SINGLE INHALATION ONLY. IN ADDITION, SALBUTAMOL AT 200 MICROGRAMS INHALED VIA A STANDARD METERED DOSE INHALER WILL ALSO BE GIVEN AS A SINGLE INHALATION.~In the LUNG PHYSIOLOGY STUDY; SALBUTAMOL INHALED VIA RESEARCH NEBULISER at 3 PARTICLES SIZES OF 1.5 MICRONS, 3 MICRONS AND 6 MICRONS WILL BE GIVEN AT TWO DOSAGES OF 30 MICROGRAMS AND AGAIN AT 15 MICROGRAMS, ONE SINGLE INHALATION ONLY. IN ADDITION, SALBUTAMOL AT 200 MICROGRAMS INHALED VIA A STANDARD METERED DOSE INHALER WILL ALSO BE GIVEN AS A SINGLE INHALATION. ALL INHALATIONS WIL BE AT SLOW INHALTION IN THIS PART OF THE STUDY."
223883279|NCT03336905|OTHER|Physical activity program and prevention after cancer|Providing a supervised and non-supervised physical activity program for adolescent and Young adult with cancer and improve awareness on cancer prevention recommendations (second cancer risk, healthy lifestyles...)
223883280|NCT05035446|PROCEDURE|single-incision plus one-port laparoscopic surgery|The investigators use the technique of adding one operation hole on the basis of single-port laparoscopy in some patients.
223883281|NCT05035446|PROCEDURE|conventional laparoscopic surgery|It usually requires 5 perforations ports and an auxiliary small incision to perform laparoscopic gastrectomy.
223883282|NCT02113267|DRUG|Mometasone furoate|4 spray doses à 50 micrograms by mouth to be swallowed 4 times daily after meals with no eating or drinking allowed 30 minutes after intake. Duration of treatment is 8 weeks.
223883283|NCT02113267|DRUG|Placebo|4 spray doses à 50 micrograms by mouth to be swallowed 4 times daily after meals (9) with no eating or drinking allowed 30 minutes after intake. Duration of treatment is 8 weeks.
223883284|NCT05007587|DRUG|Lenvatinib|8mg lenvatinib (weight\<60kg) or 12mg lenvatinib (weight\>60kg) QD
223883285|NCT05007587|DRUG|mFOLFOX regimen|HAIC was performed every 3 weeks. The mFOLFOX regimen was administered via hepatic artery: oxaliplatin , 85mg/m2 , from hour 0 to 2 on day1 ; leucovorin , 400mg/m2 , from hour 2 to 3 on day 1 ; fluorouracil , 400mg/m2 , bolus at hour 3 ; and 2400mg/m2 over 46 hours on days 1 and 2.3mg/m2 , from hour 4 to 5 on day 1.
223883286|NCT05007587|DRUG|ROX regimen|HAIC was performed every 3 weeks. The ROX regimen was administered via hepatic artery: oxaliplatin , 100mg/m2 , from hour 0 to 4 on day1 ;raltitrexed , 3mg/m2 , from hour 4 to 5 on day 1.
223883287|NCT05325931|DEVICE|kalifilcon A Daily Disposable Multifocal|kalifilcon A Daily Disposable Multifocal low add and high
223883288|NCT05325931|DEVICE|samfilcon A for Presbyopia|Ultra for Presbyopia Low and High Add Contact Lenses
223883289|NCT03894436|COMBINATION_PRODUCT|Ultrasound assessment of diaphragm thickness in B-mode|assess the thickness of diaphragm needed as a tool for prediction of extubation and proper timing of weaning from mechanical ventilation in the ICU which is measured by B mode ultrasound in ventilated cancer patients
223883290|NCT02183506|DRUG|Metformin|
223883291|NCT02183506|DRUG|BI 1356 BS|
223883292|NCT05400161|BEHAVIORAL|MoodGym|Participants in the control group will be enrolled in MoodGym, an evidence-based online Cognitive Behavioral Therapy (CBT) program for depression. Through the MoodGym program, participants will have access to interactive exercises, workbooks, anxiety and depression quizzes, and downloadable relaxation audio files. Investigators will supplement Moodgym with a facilitator contact by texting or email to check-in and encourage completion of intervention. MoodGym will provide information on the number of sessions completed by participants (engagement and dosage).
223883293|NCT05400161|BEHAVIORAL|Social Media-Based Parenting Program|Participants in the intervention group will be enrolled in Facebook secret user groups, administered by a trained facilitator, to permit participants to view and comment on posted materials. Content and user identity are restricted to invited participants to maintain privacy. Investigators will organize educational materials into video vignettes, narrated PowerPoint presentations, and written materials. The facilitator reviews and comments on postings daily and provides feedback to participants. Facebook analytics for the secret groups are available to group administrators and will provide information on any sessions viewed and counts of sessions viewed and comments posted. Participants randomized to the intervention will also have the option to take part in a preliminary virtual session through a secure video platform (e.g. BlueJeans) and will receive weekly engagement text messages. Women in the intervention group will be enrolled in the online depression treatment program, MoodGym.
223883294|NCT02261649|DEVICE|Medoc Advanced Medical Systems PATHWAY Model ATS|30 minutes of sensory testing using a contact thermal stimulator will measure thresholds for heat and cool detection, and threshold for hot and cold pain.
223883295|NCT02261649|PROCEDURE|Cold water bath|The next 15 minutes of sensory testing will measure tolerance to having right or left hand in a tub of cold water. The participant will place their hand in cold water and leave it there for as long they can, even if it is uncomfortable. The participant can take their arm out if it gets too uncomfortable to leave it in.
223883296|NCT02261649|DEVICE|MRI scanner|An MRI will be used to collect anatomical and functional images from patients and subjects. These data will be collected within a 1 hour block.
223883297|NCT02261649|OTHER|Questionnaires|The surveys include questions about emotions, thoughts, and feelings. These surveys will be given before sensory testing and before the MRI scan. The parent or guardian will help to complete two surveys, and will complete one survey on his or her own. Questions can be skipped, and may be stopped at any time.
223883298|NCT05865834|OTHER|A smartphone application|app will have 2 modules: Chill zone and sleep; Chill zone has 9 sub-modules which are meditation, breathing techniques, family time, art time, funny sayings, reframe stress and relax, diet and cooking tips, mini courses and how to become better. The sub-modules of sleep are: wind down, sleep music, storytelling, nature sounds and beautiful nature. These modules will be approved by a clinical psychologist to help people with symptoms of depression and anxiety. Skills learned include emotion recognition, emotional management, behavioral activation (being active), recognizing and challenging unhelpful thoughts and cognitive restructuring to plan for their future.
223883299|NCT05865834|OTHER|Pictorial educational leaflets|the control group will receive self-reading educational leaflets, the majority of which are pictorial. These leaflets will be approved by a clinical psychologist to help people with symptoms of depression and anxiety.
223883300|NCT03642106|BEHAVIORAL|Unidos Se Puede|The intervention consists of: (1) encouraging parental involvement in child schooling, general parenting skills, and coping strategies ; (2) fostering child social emotional learning (SEL) through assigning a near-peer success coach to help develop critical thinking, problem solving, and goal setting skills; and (3) promoting positive peer affiliations through participation in regular activities that facilitate bonding to prosocial institutions.
223883301|NCT01260870|DEVICE|Cotavance Paclitaxel Coated Balloon|
223883302|NCT01260870|DEVICE|Standard balloon angioplasty|
223883303|NCT06375876|BEHAVIORAL|Single-session intervention (SSI)|The SSI focuses on increasing hope among women who experience IPV using facts about the brain and IPV research, stories from survivors, and writing exercises.
223883304|NCT06067984|DEVICE|Study App|An investigational prescription digital therapeutic in the form of a smartphone app.
223883305|NCT00859794|OTHER|fMRI|Subjects will perform cognitive tasks during MRI scanning sessions to gather data about cognitive functions.
223883306|NCT00859794|OTHER|Neuropsychological Testing|Subjects will have a neuropsych evaluation as part of their standard of care for surgery. The research team is asking the subject to release their neuropsychological evaluations for analysis.
223883307|NCT00859794|OTHER|Additional electrode implantation|Subjects will typically have between 100-300 electrodes implanted as part of their surgery. Additional electrodes will be implanted that are able to record from smaller, more specific parts of the brain. This will allow for better understanding of how the brain is wired.
223883308|NCT00859794|OTHER|Electrical brain stimulation|Intracranial or extracranial electrodes will be used to deliver electrical brain stimulation (amplitude 0.5-8.0mA) or sham stimulation of between 0.4 and 3000 milliseconds during cognitive task periods.
223883309|NCT00084552|RADIATION|radiation therapy|Patients undergo conventional intensity-modulated radiotherapy (IMRT) once daily 5 days a week for approximately 7.5 weeks.
223883310|NCT03707236|BEHAVIORAL|Teledermatology visits|Patients in the treatment arm will be taught by study staff how to take the standardized photos of themselves at treatment week 4 (prior to initiation of teledermatology visits). For patients in the treatment arm, the teledermatology visits will be managed by the study staff. A monthly teledermatology visit will consist of sending facial and truncal (if affected) clinical images to a the study staff using Patient Gateway. Once this is completed, the patient and a member of the study staff will have a scheduled telephone appointment during which the provider will screen for any adverse events and will provide counseling as outlined in iPledge guidelines. The patient will also be asked to verbally complete a monthly survey assessing acne severity, quality of life, cost attributable to the appointment, time missed from school/work, satisfaction with treatment. All photographs will be uploaded in LMR/EPIC in the patient's medical record.
223883311|NCT03000101|OTHER|100% pomegranate juice|125 mL of 100% pomegranate juice twice daily for 12 weeks
223883312|NCT03000101|OTHER|placebo beverage|125 mL of placebo beverage twice daily for 12 weeks
223883313|NCT04430634|OTHER|Myblu variant A|Use of Myblu e-cigarette with flavor A 2.4% nicotine
223883314|NCT04430634|OTHER|Myblu variant B|Use of Myblu e-cigarette with flavor B 3.6% nicotine
223883315|NCT04430634|OTHER|Myblu variant C|Use of Myblu e-cigarette with flavor C 2.5% nicotine
223883316|NCT04430634|OTHER|Myblu variant D|Use of Myblu e-cigarette with flavor D 4.0% nicotine
223883317|NCT04430634|OTHER|Myblu variant E|Use of Myblu e-cigarette with flavor E 3.6% nicotine
223883318|NCT04430634|OTHER|Myblu variant F|Use of Myblu e-cigarette with flavor F 2.4% nicotine
223883319|NCT04430634|OTHER|Myblu variant G|Use of Myblu e-cigarette with flavor G 4.0% nicotine
223883320|NCT04430634|OTHER|Myblu variant H|Use of Myblu e-cigarette with flavor H 3.6% nicotine
223883321|NCT02436317|DEVICE|Point Of Care Ultrasound|Examination with an ultrasound machine
223883322|NCT02523443|OTHER|IV PCA|Patients undergoing IV PCA for pain control will have intravenous (IV) analgesia provided through a demand pump started in the recovery room.
223883323|NCT02523443|OTHER|PCEA|Patients in this group will have the epidural catheter placed by the anesthesia pain service team in the pre-surgical center (PSC) as performed routinely at MSKCC. The epidural will be used intra-operatively at the end of liver resection phase of the surgical procedure, once the specimen has been extracted, and continued subsequently in the post-operative phase for pain management.
223883324|NCT06541093|BIOLOGICAL|UVAX-1107|Novel HIV-1 protein nanoparticles vaccine candidate (WT) mixed with Aluminum Hydroxide (AH) and CpG 1018 adjuvants
223883325|NCT06541093|BIOLOGICAL|UVAX-1197|Novel HIV-1 protein nanoparticles vaccine candidate (GT) mixed with Aluminum Hydroxide (AH) and CpG 1018 adjuvants
223883326|NCT06541093|OTHER|Placebo|Saline injection
223883327|NCT04442126|BIOLOGICAL|NM21-1480|Trispecific anti-PD-L1/anti-4-1BB/anti-Human Serum Albumin (HSA) single-chain Fv fusion protein
223883328|NCT00000675|DRUG|CD4-IgG|
223883329|NCT06450405|DRUG|Testosterone Cypionate 50 MG/ML Injectable Solution|Participants in the initiating group will receive weekly doses of testosterone for gender-affirming care.
223883330|NCT05297136|PROCEDURE|Pancreatic Stenting|Pancreatic stent of appropriate size and length is inserted to the pancreatic duct before distal pancreatectomy
223883331|NCT05297136|PROCEDURE|No Stent|No preoperative stenting with distal pancreatectomy alone
223883332|NCT02412683|OTHER|oxaliplatin|
223883333|NCT02814383|OTHER|Brain Monitoring Platform|This study is being done to evaluate the changes in brain perfusion measured by the DCM using a comprehensive and innovative brain monitoring platform that encompasses direct and continuous measures of cerebral blood flow (CBF), cerebral oximetry, cerebral autoregulation, partial pressure of carbon dioxide (PCO2), and arterial blood pressure (ABP).
223883334|NCT07040514|OTHER|Questionnaires of Patient understanding of Pathologist input|"* Benefit Self-Rating Total Score (assessing patient's perceptions of anticipated and actual extent to which they benefitted from the meeting with the pathologist)~* Knowledge Questionnaire Total Score (assessing accuracy of knowledge of their own diagnosis and the diagnostic process in general)~* State-Trait Anxiety Inventory Form Y (Total Scores for state (current) and trait (general) anxiety)"
223883335|NCT07067112|BIOLOGICAL|Blood sampling, questionnaire and phone call|The blood sample will drawn after a fasting period of at least 8 hours, and the questionnaire will be auto-administered
223883336|NCT07077330|OTHER|CAR19BCMA-T cells|"CAR19BCMA-T cells Each subject will be infused with single dose of CD19BCMA-CAR-T cells. A classic 3+3 dose escalation will be employed. The low dose is 1×10\^6 /kg, the medium dose is 2×10\^6 /kg, and the high dose is 3×10\^6 /kg.~Drug: fludarabine and cyclophosphamide Drug: Fludarabine Fludarabine will be given at a dose of 30 mg/m2/day intravenously (IV) for 3 days prior to the infusion of CD19BCMA-CAR-T cells. Drug: Cyclophosphamide Cyclophosphamide will be given at a dose of 300 mg"
223883337|NCT07078968|DEVICE|Tri-Membrane Wrap™|Membrane Wrap™
223883338|NCT07078968|DEVICE|Membrane Wrap™|Membrane Wrap™
223883339|NCT07078968|DEVICE|Membrane Wrap-Hydro™|Membrane Wrap-Hydro™
223883340|NCT07078968|OTHER|Standard of Care|Basic care involves debridement, along with local wound care depending on the wound needs. Debridement involves removal of fibrin and devitalized tissue from the base and the borders of the ulcer which is necessary in all treatment plans to reduce the risk of infection and promote healing.
223883341|NCT07076316|BEHAVIORAL|Structured Early Rehabilitation Nursing Pathway|A multi-component, phased nursing intervention focused on early and progressive mobilization, respiratory exercises, and psychological support.
223883342|NCT07076316|BEHAVIORAL|Routine Care|Standard nursing care for severe acute pancreatitis patients in the ICU, including monitoring and passive limb mobilization.
223883343|NCT07077083|DRUG|89Zr-Girentuximab|89Zr-Girentuximab PET
223883344|NCT06902272|DIAGNOSTIC_TEST|Circulating Tumor Deoxyribonucleic acid (ctDNA) Assay|"ctDNA will be measured in participants in person via blood samples during Screening/Baseline and at the following intervals during treatment and follow-up:~* During Neoadjuvant Therapy: Approximately once after four cycles of standard of care Pembrolizumab and platinum doublet therapy.~* Approximately once two weeks before surgery.~* Approximately once three weeks after surgery.~* During Adjuvant Therapy: Approximately once every 12 weeks during standard of care, adjuvant Pembrolizumab therapy.~* Follow-up Period: Approximately once every three months for up to one year."
223883345|NCT06902272|DRUG|Pembrolizumab|Participants will receive standard of care, neoadjuvant Pembrolizumab therapy intravenously (IV) on Day 1 of each three-week cycle, for up to four cycles prior to standard of care surgery. After surgery, low-risk participants may continue standard of care, adjuvant Pembrolizumab therapy for up to six months; high-risk participants may receive standard of care, adjuvant Pembrolizumab therapy for up to 12 months.
223883346|NCT06902272|DRUG|Platinum Doublet Chemotherapy|Participants will receive neoadjuvant platinum doublet chemotherapy intravenously (IV) per standard of care on Day 1 of each three-week cycle for up to four cycles, prior to standard of care surgery. Possible platinum doublet chemotherapy regimens are Cisplatin/Carboplatin in combination with Pemetrexed or Docetaxel or Gemcitabine. Participants receiving Gemcitabine therapy will be administered Gemcitabine, per standard of care, on Day 8 of each three-week cycle.
223883347|NCT07076563|DIETARY_SUPPLEMENT|Functional Ice Cream with Cimarrón Bean Extrudate|"Ice cream containing 10 g of Cimarrón bean extruded (Phaseolus vulgaris L., local variety Cimarrón) 100 g per portion. Participants consume 100 g daily (two 50 g portions, \~2 hours after a main meal) for 4 weeks."
223883348|NCT07076563|DIETARY_SUPPLEMENT|Placebo Ice Cream|Ice cream without Cimarrón bean extrudate, matched in appearance, taste, and texture to the functional ice cream. Participants consume 100 g daily (two 50 g portions) for 4 weeks.
223883349|NCT06896136|DRUG|VENBETA6890|Part A will consist of 1 sentinel dosing group of 2 subjects randomized 1:1 to receive VENBETA6890 and will evaluate VENBETA6890 at dose levels of 15 mg/kg. On Day 1, subjects will receive 15 mg/kg in the morning and a second dose of 15 mg/kg 8 - 12 h later in the outpatient clinic. On Day 2, they will receive a third dose of 15 mg/kg at approximately 8 - 12 h after the last dose on Day 1.
223883350|NCT06896136|DRUG|Placebo|Part A Placebo (saline) will be administered at dose levels of 15 mg/kg. On Day 1, subjects will receive 15 mg/kg in the morning and a second dose of 15 mg/kg 8 - 12 h later in the outpatient clinic. On Day 2, they will receive a third dose of 15 mg/kg at approximately 8 - 12 h after the last dose on Day 1.
223883351|NCT05208086|DIAGNOSTIC_TEST|Detection of monoclonal component|Monoclonal component analysis by electrophoresis and immnuofixation on the urine sample from miction and 24h urine sample.
223883352|NCT06931483|DEVICE|Transcranial temporal interference stimulation (tTIS)|The total stimulation duration was 30 minutes, including a 30-second current ramp-up at the beginning and a 30-second ramp-down at the end.
223883353|NCT06931483|DEVICE|Sham transcranial temporal interference stimulation (tTIS)|Sham stimulation had only 30 seconds of current ramping-up and ramping-down at the beginning and end of the stimulation, respectively, to simulate the sensation of actual stimulation.
223883354|NCT06942039|DRUG|Cytarabine IT|Age-based dosing as a part of double IT therapy (cytarabine, hydrocortisone) during induction (3 cycles, 1 cycle = 21 days) alongside CISplatin, vinCRIStine, etoposide, cyclophosphamide, mesna and filgrastim (G-CSF).
223883355|NCT06942039|DRUG|hydrocortisone|Double IT therapy (cytarabine, hydrocortisone) during induction (3 cycles, 1 cycle = 21 days) alongside CISplatin, vinCRIStine, etoposide, cyclophosphamide, mesna and filgrastim (G-CSF).
223883356|NCT06942039|DRUG|Cisplatin|Intravenous CISplatin given on Day 1 during induction (3 cycles, 1 cycle = 21 days) alongside double IT therapy, vinCRIStine, etoposide, cyclophosphamide, mesna and filgrastim (G-CSF).
223883357|NCT06942039|DRUG|Vincristine|Intravenous VinCRIStine given on Days 1, 8 \& 15 during induction (3 cycles, 1 cycle = 21 days) alongside double IT therapy, CISplatin, etoposide, cyclophosphamide, mesna and filgrastim (G-CSF).
223883358|NCT06942039|DRUG|Etoposide|"Induction: Intravenous Etoposide given on Days 1, 2 \& 3 during induction (3 cycles, 1 cycle = 21 days) alongside double IT therapy, CISplatin, vinCRIStine, cyclophosphamide, mesna and filgrastim (G-CSF).~Maintenance Arm B (for high-risk patients): Oral Etoposide given on Days 1-21 every 9 weeks (max 6 cycles, 1 cycle = 9 weeks) in combination with IT Topotecan, ISOtretinoin, Celecoxib, Cyclophosphamide and Temozolomide."
223883359|NCT06942039|DRUG|Cyclophosphamide|"Induction: Intravenous high-dose Cyclophosphamide given on Days 2 \& 3 during induction (3 cycles, 1 cycle = 21 days) alongside double IT therapy, CISplatin, vinCRIStine, etoposide, mesna and filgrastim (G-CSF).~Maintenance Arm B (for high-risk patients): Oral Cyclophosphamide given on Days 1-21 every 9 weeks (max 6 cycles, 1 cycle = 9 weeks) in combination with IT Topotecan, ISOtretinoin, Celecoxib, Etoposide and Temozolomide."
223883360|NCT06942039|DRUG|Mesna|Induction: Intravenous Mesna given at hour 0 of Cyclophosphamide delivery and 3, 6, 9 \& 12 hours post-dose during induction (3 cycles, 1 cycle = 21 days).
223883361|NCT06942039|DRUG|Filgrastim|"Induction: Subcutaneous or intravenous Filgrastim (G-CSF) given 24-48 hrs after last dose of chemotherapy and/or as per institutional guidelines until count recovery.~Consolidation: Subcutaneous or intravenous Filgrastim (G-CSF) given 24-48 hours after last stem cell infusion and/or per institutional guidelienes until count recovery."
223883362|NCT06942039|DRUG|carboplatin|Consolidation: Intravenous Carboplatin given on days -3 \& -2 during consolidation alongside thiotepa and filgrastim.
223883363|NCT06942039|DRUG|Thiotepa|Consolidation: Intravenous Thiotepa given on days -3 \& -2 during consolidation alongside carboplatin and filgrastim.
223883364|NCT06942039|DRUG|Topotecan IT|"Maintenance A (for low-risk patients): IT Topotecan on Day 1 of each cycle (max 12 cycles, 1 cycle = 28 days) alongside Tamoxifen and ISOtretinoin.~Maintenance B (for high-risk patients): IT Topotecan every 4 weeks (max 6 cycles, 1 cycle = 9 weeks) alongside ISOtretinoin, Celecoxib, Etoposide, Cyclophosphamide and Temozolomide."
223883365|NCT06942039|DRUG|Tamoxifen|Maintenance A (for low-risk patients): Oral Tamoxifen twice daily, Days 1-28 (max 12 cycles, 1 cycle = 28 days) alongside ISOtretinoin and IT Topotecan.
223883366|NCT06942039|DRUG|ISOtretinoin|"Maintenance A (for low-risk patients): Oral ISOtretinoin twice daily on Days 15-28 of each cycle (max 12 cycles, 1 cycle = 28 days) alongside Tamoxifen and IT Topotecan.~Maintenance B (for high-risk patients): Oral ISOtretinoin twice daily on Days 1-21, every 6 weeks (max 6 cycles, 1 cycle = 9 weeks) alongside IT Topotecan, Celecoxib, Etoposide, Cyclophosphamide and Temozolomide."
223883367|NCT06942039|DRUG|Celecoxib|Maintenance B (for high-risk patients): Oral Celecoxib twice daily on Days 1-21, every 6 weeks (max 6 cycles, 1 cycle = 9 weeks) alongside IT Topotecan, ISOtretinoin, Etoposide, Cyclophosphamide and Temozolomide.
223883368|NCT06942039|DRUG|etoposide phosphate|During Induction and Maintenance B (for high-risk patients), etoposide phosphate may be given for subsequent doses to patients who have experienced etoposide allergic reactions.
223883369|NCT06942039|DRUG|Temozolomide|Maintenance B (for high-risk patients): Oral Temozolomide daily on Days 1-21, every 9 weeks (max 6 cycles, 1 cycle = 9 weeks) alongside IT Topotecan, ISOtretinoin, Etoposide, Cyclophosphamide and Celecoxib.
223883370|NCT07071207|BEHAVIORAL|Text message reminders|daily 8am text messages reminding patients to perform Kegel exercises as per their standard-of-care post-operative discharge instructions.
223883371|NCT07078071|DEVICE|ECG|Each participant undergoes testing with both the investigation device and the control device simultaneously. The results of the investigation device, which are obtained through pulse wave data analysis at the wrist, are compared to the investigator's interpretation of the ECG.
223883372|NCT07077811|PROCEDURE|pulsed field ablation|Medtronic Pulse Select pulsed field ablation
223883373|NCT07077811|DRUG|antiarrhythmic drug|treated with class I or class III antiarrhythmic drugs
223883374|NCT07078708|DIETARY_SUPPLEMENT|vitamin D (cholecalciferol) supplementation|Vitamin D supplementation at a dose of 50,000 IU every two weeks along with a daily intake of 1,000 mg of calcium for 12 weeks
223883375|NCT07078708|OTHER|Placebo|Placebo was given for 12 weeks
223883376|NCT06408233|OTHER|Performance Coaching|Performance coaching will consist of working with clinic staff to understand and guide current quality measurement practices as well as improving quality measurement and implementing new measures and management practices.
223883377|NCT06153537|DRUG|Insulin degludec|Participants will be treated with commercially available insulin degludec used with Dose Check app according to local label and routine clinical practice at the discretion of the treating physician.
223883378|NCT05933707|BEHAVIORAL|People with Metabolically Unhealthy Obesity - Low Calorie Diet|Consumption of a low-calorie diet with caloric intake reduced by \~25% to achieve \~10% weight loss in about 4 to 5 months.
223883379|NCT05181709|DRUG|Sodium Chloride|Administered intranasal (IN) and intramuscular (IM) in combination
223883380|NCT05181709|BIOLOGICAL|NDV-HXP-S IN low dose|"Allantoic fluid diluted in Phosphate buffered saline (PBS), to be further diluted to dose strength in sodium chloride.~Strength: 3.3x108\^8 EID50."
223883381|NCT05181709|BIOLOGICAL|NDV-HXP-S IM low dose|"Allantoic fluid diluted in Phosphate buffered saline (PBS), to be further diluted to dose strength in sodium chloride.~Strength: 3.3x10\^8 EID50."
223883382|NCT05181709|BIOLOGICAL|NDV-HXP-S IN high dose|Allantoic fluid diluted in Phosphate buffered saline (PBS). Strength: 1x10\^9 EID50.
223883383|NCT05181709|BIOLOGICAL|NDV-HXP-S IM high dose|Allantoic fluid diluted in Phosphate buffered saline (PBS). Strength: 1x10\^9 EID50.
223883384|NCT01722916|DRUG|Hyaluronidase|
223883385|NCT06494618|DEVICE|Radial Extracorporeal Shockwave Therapy|1500 pulses, 4 hertz, 2 bar radial extracorporeal shockwave therapy targeted muscle belly for botulinum toxin injected lower extremity muscle groups. 3 sessions were planned once a week, starting from first week after injection.
223883386|NCT05828953|DRUG|Anlotinib|"Drug: Anlotinib The dose of nintedanib hydrochloride is 8mg per dose, taken orally once daily before breakfast. The drug is taken continuously for 2 weeks, followed by a 1-week break, until week 52, disease progression, or the occurrence of intolerable adverse events. If a dose is missed and the next dose is due within 12 hours, it should not be made up.~Drug: Placebo Placebo, taken orally once daily before breakfast. Taken continuously for 2 weeks, followed by a 1-week break, until week 52, disease progression, or the occurrence of intolerable adverse events. If a dose is missed and the next dose is due within 12 hours, it should not be made up."
223883387|NCT05828953|DRUG|Placebo|Placebo, taken orally once daily before breakfast. Taken continuously for 2 weeks, followed by a 1-week break, until week 52, disease progression, or the occurrence of intolerable adverse events. If a dose is missed and the next dose is due within 12 hours, it should not be made up.
223883388|NCT03591133|DRUG|TS-143|
223883389|NCT03591133|DRUG|Placebo|
223883390|NCT05607121|DEVICE|intermittent theta burst stimulation|transcranial magnetic stimulation
223883391|NCT05607121|DEVICE|continuous theta burst stimulation|transcranial magnetic stimulation
223883392|NCT04685577|DRUG|Nefopam|Nefopam HCl inhibits the proliferation and viability of human mesenchymal fibroblasts with elevated β-catenin expression without affecting normal fibroblasts. Nefopam HCl primarily targets cells in which β-catenin is above normal physiologic levels. This threshold effect makes Nefopam HCl a good prospective therapeutic agent by limiting its effect to abnormal mesenchymal cells.Nefopam HCl has been found safe and effective for the reduction of dermal scarring following standardized human dermal wounds of critical depth that produces HTS in normal human volunteers Phase 1 study. In the current study, it is proposed that the concentration of the cream will be 3% and the timing of application will be delayed until after re-epithelialization at about 21 days to maximize the antiproliferative effects of NEFOPAM during the fibrotic/proliferative phase of healing.
223883393|NCT04685577|OTHER|Placebo (Vehicle)|Participants will receive vehicle with out the investigational product
223883394|NCT06830122|DIETARY_SUPPLEMENT|Probiotic|The experimental phase of this study will last 8 weeks and each subject will receive 4 follow-up visits (week 0, week 4, week 8, week 20).
223883395|NCT06830122|DIETARY_SUPPLEMENT|Placebo|The experimental phase of this study will last 8 weeks and each subject will receive 4 follow-up visits (week 0, week 4, week 8, week 20).
223883396|NCT06829524|DRUG|Satralizumab|Satralizumab is the first monoclonal antibody approved for the treatment of NMOSD in China. Currently, there is still a lack of standard patient management pattern for NMOSD. While satralizumab offers the advantage of home administration, there remains a pressing need for optimized patient management.
223883397|NCT06306963|DIAGNOSTIC_TEST|Gastric Emptying Breath Test|13C-Spirulina GEBT (Cairn Diagnostics) is non-radioactive, non-invasive breath based test validated against scintigraphy for the measurement of gastric emptying. Patients will be mailed test kits to be done in their homes remotely along with telehealth assistance from the study team. After overnight fast and providing duplicate pre-meal breath samples, the patient consumes 27 grams of re-hydrated, precisely formulated, pasteurized scrambled egg mix containing a dose of 43 mg of 13C (provided by approximately 100 mg of 13C-Spirulina), 6 saltine crackers and 6 ounces (180 mL) of potable water. The caloric value of the meal is approximately 230 kCal.Patient will provide breath samples into provided glass tubes before and after test meal administration which are then mailed back to a central laboratory for analysis by gas isotope ratio mass spectrometry.
223883398|NCT06575335|OTHER|Triphala Tooth Wipe|The wipes will be used 1 hour after meal time, twice daily for consecutively 7 days. The sachet seal will be opened, the wipe will be taken out and rest of the sachet sealed again. The wipes will be unfolded and wrapped around index finger of right hand and all surfaces of child's teeth, gums, roof of the mouth and tongue will be cleaned.
223883399|NCT06575335|OTHER|Chlorhexidine Tooth Wipe|Same as triphala tooth wipe
223883400|NCT04333290|DRUG|[11C]MeDAS|PET radiotracer
223883401|NCT06629714|OTHER|Exposure: emotional distress status|The assessment of depressive and anxiety symptoms was conducted using Patient Health Questionnaire-9 (PHQ-9) and Generalized Anxiety Disorder Assessment 7 (GAD-7). Patients with a sum score of PHQ-9 and GAD-7 ≥ 10 were categorized as the stressed group.
223883402|NCT05088590|DIETARY_SUPPLEMENT|Enfagrow® Neuropro Toddler Nutritional Drink|Enfagrow® Neuropro Toddler Nutritional Drink to be consumed per day (equivalent to 40 mL per kg, rounded to the nearest ounce)
223883403|NCT05088590|DIETARY_SUPPLEMENT|Pediasure® Grow & Gain Protein Shake for Kids|Pediasure® Grow \& Gain Protein Shake for Kids to be consumed per day (equivalent to 40 mL per kg, rounded to the nearest ounce)
223883404|NCT04923347|DRUG|FF/UMEC/VI|FF/UMEC/VI will be administered
223883405|NCT04923347|DEVICE|ELLIPTA|Participants will receive FF/UMEC/VI using ELLIPTA inhaler.
223883406|NCT05014165|OTHER|Cord blood Sample Collection|Obtain banked cord blood samples from consecutive childhood leukemia patients
223883407|NCT05014165|OTHER|Case identification and recruitment|Cases meeting eligibility and who have given consent through APEC14B1 for future contact for non-therapeutic studies
223883408|NCT05014165|OTHER|Questionnaire Administration|The family will be given an option to complete questionnaire on paper, online, or over the telephone.
223883409|NCT05563636|DEVICE|standard pulsed radio frequency (PRF)|patients will be given standard pulsed radiofrequency (PRF) treatment: temperature 42 ℃, frequency 2 Hz, pulse width 20 ms, voltage 37-41 V, time 120 s.
223883410|NCT05563636|DEVICE|high-voltage long-term pulsed radio frequency (PRF)|patients will be given standard pulsed radiofrequency (PRF) treatment: temperature 42 ℃, frequency 2 Hz, pulse width 20 ms, voltage 50-90 V, At the beginning, the patient will feel a severe burning sensation in the original pain area, and slowly after the patient tolerates it. Increase the voltage and gradually increase to the maximum voltage that the patient can tolerate (up to 70-90 V) until the end of 900 s.
223883411|NCT06275919|DRUG|Regorafenib 40 MG Oral Tablet|REGORAFENIB 40 mg tablets once daily (160 mg/die), 3 weeks on, 1 week off, until disease progression or unacceptable toxicity
223883412|NCT06275919|DRUG|Local Standard of Care|In this setting there are not drugs with indication. Every site will treat patients as per their experience.
223883413|NCT03109197|OTHER|Biospecimin Collection|
223883414|NCT04541381|OTHER|Availability of clinical decision support based on pharmacogenomic results.|Availability of clinical decision support based on pharmacogenomic results. These results are designed to provide specific dosing information based on the participant's unique genetics/genomics.
223883415|NCT03424811|DEVICE|Mobile Health Intervention|Mobile health intervention to promote healthy eating.
223883416|NCT06134479|DRUG|150μg CFA (Elonva®) at stimulation day (SD) 1 and 100μg CFA(Elonva®) at SD 5|On Day 2 or 3 of the menstrual cycle, a first subcutaneous (SC) injection of corifollitropin alfa (CFA) (Elonva®) 150μg will be administered (stimulation day 1) and a second SC injection of corifollitropin alfa (Elonva®) 100 μg will be administrated on SD 5. Endogenous LH suppression will be accomplished by daily 75μg/day of Desogestrel (Cerazet®) per os, at bedtime, starting on stimulation day 1 and continuing up to the day before of trigger. As soon as 3 follicles ≥ 18 mm are observed by ultrasound, 0.2 mg Triptorelin (Decapeptyl®) will be administered the same day to induce final oocyte maturation. About 34-36 hours thereafter oocyte pick-up will be performed.
223883417|NCT06134479|DRUG|150μg CFA (Elonva®) at SD 1 following by rFSH (Puregon®) 200IU daily from SD 8 until the day of the trigger|On Day 2 or 3 of the menstrual cycle, a single subcutaneous (SC) injection of corifollitropin alfa (Elonva®) 150μg will be administered (SD 1) and from Day 8 of stimulation a daily SC dose of rFSH (Puregon®) 200IU/day up to the day of Triptorelin (Decapeptyl®) 0.2 mg administration. Endogenous LH suppression will be accomplished by daily 75μg/day of Desogestrel (Cerazet®) per os, at bedtime, starting on stimulation day 1 and continuing up to the day before of trigger. As soon as 3 follicles ≥ 18 mm are observed by ultrasound, 0.2 mg Triptorelin (Decapeptyl®) will be administered the same day to induce final oocyte maturation. About 34-36 hours thereafter oocyte pick-up will be performed.
223883418|NCT06135298|PROCEDURE|OSTEOSYNTHESIS|Routine procedure for anesthesia and infection prophylaxis according to written instructions will be followed in every patient. The patient will be operated supine with the fractured leg positioned in traction table. The hip region is scrubbed and dressed in sterile drapes. Using standard technique, a nail is inserted into the intramedullary canal after fracture reduction. To insert the helical blade in the femoral neck, 2.0 mm diameter guide wire is first placed in the femoral neck, checking the fluoroscopic AP and lateral views. The canal is opened using a 10 mm drill bit and the length of helical blade is measured. After the pilot hole is created for the helical blade placement, the hollow helical blade will be inserted to its end position with gentle blows with a hammer.
223883419|NCT06135298|DRUG|Zoledronic acid|Zoledronic acid (ZA), is a bisphosphonate, and has been shown to reduce the risk of hip fracture by 41% in post-menopausal women. For systemic injection, 5 mg (as per clinical protocol) will be injected intravenously 5 days after surgery, during hospitalization.
223883420|NCT06135298|DEVICE|CERAMENT BONE VOID FILLER (BVF)|In addition to the standard surgical procedure, in the study group, after creating the canal with 10 mm drill bit and partly insertion of the helical blade, the synthetic bone void filler CaS/HA will be injected. The helical blade will be inserted partially with gentle blows with a hammer, 2.5 cm from its final intended position. The injectable CaS/HA biomaterial will be mixed as per the manufacturer guidelines and the paste will be transferred into an injection syringe. At t = 2.5 min from the start of mixing, 2-3 mL of BVF paste will be injected by a CE marked Introducer Needle connected to the injection syringe, through the hollow helical blade. Finally, the helical blade will be inserted to its end position with gentle blows with a hammer. Remaining material approximately 2 mL still being moldable will be manually deposited in the trochanteric fracture void.
223883421|NCT06286189|DRUG|Placebo oral tablet|Placebo capsule taken 30 min before sleep
223883422|NCT06286189|DRUG|Trazodone Hydrochloride|Trazodone 100 mg 30 min before sleep
223883423|NCT01927744|DRUG|Docetaxel|75 mg/m2 by vein on Day 1 of each 21 day cycle for a maximum of 3 cycles.
223883424|NCT01927744|DRUG|Erlotinib|150 mg by mouth daily continuously until the day before surgery.
223883425|NCT01927744|OTHER|Placebo|150 mg by mouth daily continuously until the day before surgery.
223883426|NCT01927744|BEHAVIORAL|Questionnaires|Questionnaire completion at baseline, 14 days after treatment completion, and 8 weeks after surgery.
223883427|NCT01927744|BEHAVIORAL|Phone Call|Phone call made to patient 1 time each year after the end of treatment visit.
223883428|NCT01927744|DRUG|Chemotherapy|Cisplatin 75 mg/m2 or Carboplatin AUC 6 mg.min/ml by vein on Day 1 of each 21 day cycle for a maximum of 3 cycles.
223883429|NCT05274425|OTHER|Enerzair 150/50/80 μg|There is no treatment allocation. Patients administered Enerzair by prescription that have started before inclusion of the patient into the study will be enrolled.
223883430|NCT05274425|OTHER|Enerzair 150/50/160 μg|There is no treatment allocation. Patients administered Enerzair by prescription that have started before inclusion of the patient into the study will be enrolled.
223883431|NCT06755190|DIAGNOSTIC_TEST|Diagnostic Test: AI-Based Diagnostic and Prognostic Model for Ocular Diseases|This intervention involves an AI system that leverages multimodal data fusion to support the clinical decision-making and evaluation of ophthalmic diseases. It integrates multi-modal data, including fundus photography, optical coherence tomography (OCT), and patient clinical records, to provide real-time, precise, and personalized diagnostic support. Unlike other models, this system utilizes a longitudinal patient dataset to predict disease progression and treatment outcomes.Key distinguishing features include: 1. Multi-Modal Data Integration: Combines imaging, clinical, and genetic data for comprehensive analysis. 2. Predictive Capability: Offers advanced prognostic predictions, enabling personalized treatment plans. 3. Deep Learning Framework: Employs state-of-the-art deep learning algorithms for improved diagnostic accuracy and efficiency. 4. Real-World Validation: Validated using a large cohort of diverse patient data, ensuring generalizability and robustness.
223883432|NCT05550207|DRUG|AXS-07 (meloxicam-rizatriptan)|AXS-07 tablets, taken orally for the acute treatment of migraine
223883433|NCT06510491|DRUG|Epcoritamab|Bispecific antibody, via subcutaneous (under the skin) injection per protocol.
223883434|NCT03571945|DEVICE|Bi-spectral Index (BIS QUATRO REF #186-0106)|GA will be monitored and controlled with Bi-spectral index (BIS).
223883435|NCT03571945|DEVICE|End tidal anaesthesia gas concentration (ETAG)|GA will be monitored and controlled with end-tidal anaesthesia gas concentration
223883436|NCT06766799|DEVICE|Rebound and Applanation Tonometer|Measurement of Intraocular Pressure
223883437|NCT05744401|DRUG|AL002|Administered via intravenous (IV) infusion
223883438|NCT06779838|OTHER|Group Emotion Focused Therapy Intervention|The EFT group intervention: Taming the Inner Critic: Emotion-Focused Group Therapy for Eating and Body Concerns. This group is a 10-12 week (number of participants=8-10 +2 sessions) closed therapy group for students seeking support regarding issues related to eating and/or body concerns. Working one-to-one and within the group, group members will be facilitated to recognise and explore some of the difficult emotions underlying and driving eating and/or body related issues. In particular, the group will focus on 'taming' the inner critic, that part of ourselves that criticises or chastises us for not being good enough. By identifying the critic in ourselves and by witnessing it in others, group members will be better positioned to figure out what they really need from themselves at times of difficulty, and thus better able to access self-compassion and self-assertion. There will be some psychoeducation, both around eating and emotions, but this will be largely in a handout format, with
223883439|NCT06779838|OTHER|Treatment as Usual (TAU)|Treatment that would otherwise be offered by the university counselling service (one on one counselling, a group, or signposting to external support).
223883440|NCT04128904|PROCEDURE|IVF|"Fertilisation with standard in vitro fertilisation (IVF). For details please see Project Description."
223883441|NCT04128904|PROCEDURE|ICSI|"Fertilisation with intracytoplasmic sperm injection (ICSI). For details please see Project Description."
223883442|NCT04621825|DEVICE|ActivHeal Silicone PHMB Foam Adhesive and Non Adhesive dressing.|"Assigned interventions Subjects will undergo treatment of their chronic and acute wounds as indicated in instructions for use with ActivHeal Silicone PHMB Foam adhesive and Non Adhesive Foam dressings.~Subjects will be evaluated as follows:~Full Patient and wound assessment, Informed consent. Wound Assessment, application of dressings, (At each scheduled dressing change.) Wound Assessment, removal of dressings, (At each scheduled dressing change.) The patients will be evaluated at each dressing change over a four - six-week period (per AMS Product) or until the wound is healed to extent that the use of the ActivHeal Silicone PHMB Foam adhesive and Non Adhesive Foam dressings. is no longer indicated from the time that the patient has been recruited.~The assessment of the presence and reduction of the signs and symptoms of Infection."
223883443|NCT05579327|DRUG|Tiratricol|Tiratricol tablets are flat tablets that contain 350 µg tiratricol. Treatment will be administered orally or via percutaneous endoscopic gastrostomy (PEG) tube; tablets will be suspended in water and, if needed, mixed with mashed food for oral administration or administered in water through the PEG tube as applicable.
223883444|NCT05579327|DRUG|Placebo|Placebo tablets will be identical in appearance to tiratricol tablets but contain no tiratricol. Treatment will be administered orally or via PEG tube; tablets will be suspended in water and, if needed, mixed with mashed food for oral administration or administered in water through the PEG tube as applicable. During the Randomized Treatment Period, participants will receive the same number of tablets as the stable dose of open-label tiratricol they were receiving before randomization.
223883445|NCT03948490|DEVICE|ReMind iPad app|Evidence-based program to improve attention and memory through (1) cognitive training and (2) teaching compensatory skills in patients with brain tumors.
223883446|NCT03948490|DEVICE|Healthy SMS texting|Participants receive a daily message sent at a random time (within their chosen timeframe(s); e.g. 9am-9pm). Messages will focus on patient-based education-focused health-related quality of life and cognitive education such as internal and external cognitive compensatory strategy training, fatigue management, and coping skills.
223883447|NCT03948490|BEHAVIORAL|In-person cognitive rehabilitation|The in-person cognitive rehabilitation will focus on the application of evidenced based strategies recommended as practice guidelines by the American Congress of Rehabilitation Medicine Cognitive Rehabilitation Task Force (ACRM-CR). The treatment occurs in two stages 1) comprehensive neuropsychological assessment and rehabilitation planning and 2) implementation of treatment planning.
223883448|NCT03948490|BEHAVIORAL|Telehealth cognitive rehabilitation|The telehealth cognitive rehabilitation will take place over secure UCSF Zoom. It will focus on the application of evidenced based strategies recommended as practice guidelines by the American Congress of Rehabilitation Medicine Cognitive Rehabilitation Task Force (ACRM-CR). The treatment occurs in two stages 1) comprehensive neuropsychological assessment and rehabilitation planning and 2) implementation of treatment planning
223883449|NCT03948763|BIOLOGICAL|V941|V941 administered IM, Q3W for 9 3-week cycles
223883450|NCT03948763|BIOLOGICAL|Pembrolizumab|Pembrolizumab 200 mg, IV for 35 3-week cycles
223883451|NCT04962126|DRUG|Obinutuzumab 25 MG/1 ML Intravenous Solution|"For intravenous infusion during:~Induction phase: Day 1, 8 and 15 of cycle 1 \& Day 1 of cycle 2-6 (q3/52); Maintenance phase: Day 1 of each cycle (q8/52) for up to 12 cycles."
223883452|NCT04962126|DRUG|Atezolizumab 1200 MG/40mL Intravenous Solution|For intravenous infusion during induction phase only day 1 of each cycle q3/52 for up to 6 cycles.
223883453|NCT04962126|RADIATION|4 Gy in 2 fractions|Involved site radiotherapy will only be administered to participants to achieve a PR/SD after at restaging after cycle 2, treatment will be between cycle 3 and 4 of induction treatment.
223883454|NCT06785285|DRUG|Dexmedetomidine|To compare the effects of fentanyl and dexmedetomidine when used as adjuvants to intrathecal bupivacaine in elective cesarean section, assessing their impact on the onset and duration of spinal anesthesia, quality of analgesia, hemodynamic stability, incidence of side effects, and neonatal outcomes
223883455|NCT06349174|PROCEDURE|bronchoscopic lung volume reduction surgery using endobronchial valve|The patients would undergo bronchoscopic lung volume reduction surgery using the self developed endobronchial valve.
223883456|NCT04035174|DIAGNOSTIC_TEST|LTS-2 DEC patch|After 24 hours, the patch will be removed, and then the reaction of the skin under the device will be assessed : no reaction, weak reaction (\< 50% skin surface under the patch), medium reaction (\> 50% skin surface under the patch), and important reaction (reaction on all the surface of the skin under the patch).
223883457|NCT04035174|DIAGNOSTIC_TEST|Skin snips|Regarding skin snips, a reading will be done at 24 hours after incubation of the skin in saline serum during 24 hours.
223883458|NCT05863273|DRUG|Apremilast|Dosage of Apremilast（Otezla®） from 10mg qd, titrate to recommended dosage of 30 mg BID，recommended by specification.
223883459|NCT06791629|DEVICE|Pulsed Field Ablation|Patients will be treated with pulsed field ablation for atrial fibrillation.
223883460|NCT06791629|DEVICE|Radiofrequency Ablation|Patients will be treated with radiofrequency ablation for atrial fibrillation.
223883461|NCT06785662|DRUG|The budesonide nasal irrigation|The participant in this group used a solution containing 1 milligram of budesonide mixed with 240 milliliters of normal saline in a squeeze bottle (Cleanoze®) for nasal irrigation. The procedure will be performed once daily while leaning slightly forward over a sink.
223883462|NCT06785662|DRUG|The budesonide nasal spray|The participants in this group used a nasal spray containing 64 micrograms of budesonide per spray, with two sprays per nostril administered twice daily (morning and evening).
223883463|NCT06789991|DEVICE|electromyography|electromyographic activity of posterior oblique sling muscles will be measured
223883464|NCT06789276|BEHAVIORAL|Supine position|For patients scheduled for thoracoscopic surgery, thoracic paravertebral nerve block was performed under ultrasound guidance. After the injection of the drug, patients were positioned in either the supine position.
223883465|NCT06789276|BEHAVIORAL|lateral decubitus position|For patients scheduled for thoracoscopic surgery, thoracic paravertebral nerve block was performed under ultrasound guidance. After the injection of the drug, patients were positioned in the lateral decubitus position with the puncture side up.
223883466|NCT06627231|DRUG|TEV-56286|Oral capsule
223883467|NCT06627231|DRUG|[14C]-TEV-56286|Oral capsule
223883468|NCT05950165|DRUG|CHO-H01|"Phase 1:~Subjects will be administered intravenous (IV) infusion of assigned dose level of CHO-H01, once a week for 4 weeks (Cycle 1-28-Day cycle).~From Cycle 2 onwards, on Day 1 of each subsequent 21-day cycle until disease progression (or a total of 6 cycles \[19 weeks\] of study)."
223883469|NCT05950165|DRUG|CHO-H01 at RP2D|"Subjects will be administered intravenous (IV) infusion of RP2D level of CHO-H01, once a week for 4 weeks (Cycle 1-28-Day cycle).~From Cycle 2 onwards, on Day 1 of each subsequent 28-day cycle until disease progression (or a total of 6 cycles \[19 weeks\] of study)."
223883470|NCT05950165|DRUG|Lenalidomide|Subjects will receive oral lenalidomide 20 mg once daily from Day 1 to Day 21 per 28-day cycle.
223883471|NCT06062030|DRUG|DWJ1609|Drug of test group
223883472|NCT06062030|DRUG|DWC202304|Drug of control group
223883473|NCT06783335|DEVICE|Cordella PA Sensor System|"* Patients who receive the Cordella PA Sensor System for monitoring chronic heart failure~* These patients will be monitored for 2 years after receiving the device~* Patients must be on guideline-directed medical therapy appropriate for their ejection fraction status"
223883474|NCT06783335|DRUG|Standard of Care Pharmacologic Therapy|"* Patients with chronic heart failure who receive standard medical care without PA pressure monitoring~* These patients will be monitored for 2 years~* Patients must be on guideline-directed medical therapy appropriate for their ejection fraction status"
223883475|NCT05653674|BEHAVIORAL|Acceptance and commitment approach-based psychoeducation|The psychoeducation based on acceptance and commitment approach reducing psychological distress in nursing students; It has been prepared to increase psychological flexibility, mindfullness and level valuing. A potential approach that has been shown to be effective in reducing psychological distress is one of the third generation cognitive behavioral therapies; acceptance and commitment therapy. Acceptance and commitment-based approaches encourage participants to change their relationship with their thoughts and physical sensations through acceptance, mindfullness, and value-based action mechanisms.
223883476|NCT04477681|OTHER|Data collection|In particular, the patient's demographic data, medical history, previous and concomitant treatments, data on the treatment of interest (legal framework, compassionate use/ off-label), dosage, start date, etc.), clinical data will be collected. biological (including molecular profiling of the tumor if available) and radiological follow-up, information on adverse effects. The data to be filled in is that of the CERFA pharmacovigilance form of the ANSM, but additional fields can be created if necessary.
223883477|NCT06786442|OTHER|EFFACLAR DUO+M CREAM|twice a day: morning and evening. Subjects should be able to self-apply the product on all assessment areas (face, upper chest, and back)
223883478|NCT03995641|DRUG|marcaine and kenalog|Trigger point injection (consisting of 9 cc 0.5% Marcaine and 1 cc kenalog) may be given at time of surgery if patient is randomized to receive the injection
223883479|NCT03139305|DRUG|Glucagon|Low dose intravenous infusion for 72 hours at 12.5 ng/kg/min
223883480|NCT03139305|DRUG|Glucagon|High dose intravenous infusion for 72 hours at 25 ng/kg/min
223883481|NCT03139305|DRUG|Placebo|Intravenous infusion of saline for 72 hours
223883482|NCT04845945|BIOLOGICAL|PCV15|Blood draw after the vaccination
223883483|NCT05710900|OTHER|Dietary intervention|Each dietary remission strategy involves three phases focused on weight loss and medication deprescribing (Phase 1: Weeks 0-12), transition to an individualized sustainable dietary pattern (Phase 2: Weeks 13-20), and weight loss/remission maintenance (Phase 3: Weeks 21-52).
223883484|NCT00159406|OTHER|Registry and Database|Data Collection
223883485|NCT04081714|DRUG|CNM-Au8|CNM-Au8 is an aqueous suspension of clean surfaced faceted nanocrystals consisting of gold atoms self-organized into crystals of various geometrical shapes (hexagonal bi-pyramid, pentagonal bipyramid, tetrahedron, decahedron, planar spheroids). Highly pure elemental Au nanocrystals are suspended in USP purified deionized water buffered with 0.546 mg/mL (6.5 mM) sodium bicarbonate (NaHCO3) nominally concentrated to 0.5 mg/L (500 ppm). CNM-Au8 will be administered orally in volumes of 60 mL from single-dose HDPE containers. Participants will orally receive 30 mg of CNM-Au8 once daily.
223883486|NCT03029026|OTHER|Baseline assessment|Baseline assessment will include clinical history, Quality of Life Questionnaire (EQ-5D/SF-12), a 6-minute-walk test, blood sampling for haematocrit, renal function, biomarkers (NT-pro-BNP and troponin), and biobanking (also for AL exclusions if scanning positive), a urine sample for biobanking (also for AL exclusions if scanning positive), as well as tests performed as the routine pre-operative work-up (clinical electrocardiogram, blood pressure to estimate global LV afterload, valvulo-arterial impedance).
223883487|NCT03029026|PROCEDURE|Transthoracic echocardiography|"Patients will undergo a clinical transthoracic echocardiogram for the assessment of AS severity and diastolic function in line with the British Society of Echocardiography guidance. Simultaneous, optimised 2-chamber, 3-chamber and 4-chamber views will need to be recorded (over 3 cycles) for strain analysis.~Severe AS will be defined using standard echocardiography guidelines in conjunction with MDT consensus."
223883488|NCT03029026|PROCEDURE|99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy|Scanning will use a hybrid SPECT-CT gamma camera after intravenous injection of 700 MBq of DPD (effective dose 4mSv). Acquisition technique: 5-minute (early) and then 3-hour (late) whole body planar scans, followed by SPECT-CT of the heart. Qualitative visual (Perugini) scoring of the cardiac uptake is performed from the 3-hour whole body planar images and the SPECT-CT images.
223883489|NCT03029026|RADIATION|CT 3-5-minute post-contrast research sequences|Cardiac CT for ECV will use the dedicated cardiac CT scanner (Somatom FORCE; Siemens Medical Solutions, Germany). 3-5-minute post contrast research images will be taken at the end of the clinically indicated TAVR work-up CT.
223883490|NCT03029026|PROCEDURE|Cardiac Magnetic Resonance|CMR will be performed using a 1.5-T Aera for standard late gadolinium enhancement, as well as T1 mapping and ECV.
223883491|NCT03029026|PROCEDURE|Endomyocardial biopsy|Septal tissue specimens will be taken under direct vision by the surgical team using a 14-gauge coaxial needle system. Biopsies will be screened for amyloid by Congo red staining; if positive, tissue will be fully sub-typed (immunohistochemistry, mass spectrometry).
223883492|NCT03029026|OTHER|Follow-up assessment|1-year follow-up with clinical echocardiogram (for sAVR and TAVI patients) and/or telephone interview for all patients (if not carried out in person at the time of the echocardiogram). This will include a follow up Quality of Life Questionnaire as per baseline. If attending clinic or echocardiogram a 6-minute-walk test will also be performed.
223883493|NCT06528444|DRUG|Grup 1 placebo|placebo 1 capsule (6 mg) /day for 7 days.
223883494|NCT06528444|DRUG|Grup 2 dexametasona|dexamethasone 1 capsule (6 mg)/day for 7 days
223883495|NCT06093295|DEVICE|Repetitive Transcranial Magnetic Stimulation (Theta Burst Stimulation)|"The repetitive transcranial magnetic stimulation device will generate successive magnetic pulses to the left dorsolateral prefrontal cortex (experimental condition) and the vertex (control condition).~The theta burst stimulation protocol is as follows:~* Total stimulation time \~190 seconds~* Intensity: 80% of active motor threshold~* 2 seconds train, repeated every 10 seconds~* In every 2-second train, 3 pulses of stimulation are delivered at 50 Hz, repeated every 200 milliseconds (i.e., 5 Hz) for a total of 600 pulses"
223883496|NCT04030169|DRUG|Midomafetamine HCl|Non-directive psychotherapy conducted during MDMA-assisted psychotherapy session
223883497|NCT06534086|DEVICE|Virtual reality (VR) guided meditation therapy|Tripp application on Meta Quest 3 VR headset
223883498|NCT06534086|OTHER|Treatment as usual|No VR, local anesthetic only
223883499|NCT03226808|DEVICE|Vivacit-E Liner|All subjects enrolled will receive the Vivacit-E liner.
223883500|NCT00830557|OTHER|medical chart review|baseline, 12 month and 36 months
223883501|NCT00830557|OTHER|survey administration|baseline, 6 month, 12 month
223883502|NCT00830557|OTHER|biospecimen collection|baseline
223883503|NCT04206826|DEVICE|PREDELFI|It's a natural film which contains a concentrated alpha-GOS (alpha-galacto-oligosaccharide) soy extract, a milk protein concentrate containing caseins and whey proteins and vegetable glycerin
223883504|NCT04206826|DEVICE|CONTROL|It's a natural film which is devoided of active ingredient. It contains sodium alginate; vegetable glycerin, caramel, beta carotene and water.
223883505|NCT04876196|OTHER|Selfapy for Bulimia Nervosa|Web-based intervention for Bulimia Nervosa with six mandatory weekly sessions covering topics related to eating behaviors, emotion regulation, and stress management, followed by an optional set of up to six modular specialization areas based on individual therapy goals. During the intervention, participants can access an online chat providing crisis management, answering questions concerning the exercises, and technical support. The chat does not include the opportunity to discuss individual topics and concerns about treatment.
223883506|NCT06088732|OTHER|Exercise Session|30 min cycling on bicycle ergometer at 60% peak power output
223883507|NCT06088732|DRUG|Ibuprofen 800 mg|A single oral dose of Ibuprofen
223883508|NCT06088732|OTHER|Rest|Resting for 30 min in chair
223883509|NCT06088732|DRUG|Placebo|Matched placebo
223883510|NCT04867395|BEHAVIORAL|HELPix Care Plan|"A web application tool for CMC - Health literacy-informed, disease and medication-specific, standardized discharge instructions that will: 1) facilitate plain language provider/parent communication at hospital discharge and 2) act as stand-alone handouts that parents can use at home."
223883511|NCT05721326|OTHER|Sequential EHR Communications|The intervention includes 3 message types: an EHR message, followed by a text message, followed by physician nudge. Each subsequent type will be activated if the previous type does not yield a response.
223883512|NCT06798272|PROCEDURE|dialysisis with and without glucose in the dialysis|there were assessed three consecutive hemodialysis sessions
223883513|NCT05090124|DRUG|Adalimumab|Adalimumab 40mg, will be administered as a subcutaneous injection once fortnightly on four occasions. The actual Adalimumab product selected at site will be dictated by what is used in standard care.
223883514|NCT05090124|DRUG|Placebo|Sodium chloride 0.9% for injection will be used as a placebo. An equal volume will be drawn up into a suitable sized syringe and labelled in accordance with standard practice at site. The dose will be administered as a subcutaneous injection once fortnightly on four occasions.
223883515|NCT05703516|OTHER|Capmatinib|There is no treatment allocation. Capmatinib will be prescribed by the physician as per locally approved label. Treatment duration depends on the decision of treating physician. No drug will be dispensed from Novartis
223883516|NCT06465511|BEHAVIORAL|Supportive clinic|During the visit, each patient will receive a personalized feedback summary, including an assessment and recommendation on managing physical and psychological symptoms, an evaluation and recommendation on dietary advice, an assessment and recommendation on physical activity, and advice on managing potential psychosocial issues by the multidisciplinary team.
223883517|NCT06465511|BEHAVIORAL|Control: Self-management|Each pamphlet given to the patients addresses one of the 7 most commonly-reported symptoms (sleep difficulties, fatigue, neuropathy, pain, anxiety, depression, and fear of cancer progression) observed in Hong Kong patients with advanced or metastatic cancer, plus two on lifestyle recommendations (physical activity and eating well). All pamphlets are developed based on the self-management framework.
223883518|NCT04474847|DRUG|Abatacept|Participants randomized to abatacept will receive abatacept 125 mg administered by subcutaneous injection once a week. Participants randomized to either the abatacept or the placebo arm who experience a non-severe disease relapse, non-severe disease worsening, or who have not achieved remission by month 3 will have the option of entering an open-label trial period whereby they would receive open-label abatacept for up to 12 months.
223883519|NCT04474847|DRUG|Placebo|Participants randomized to placebo will receive a sterile placebo solution administered by subcutaneous injection once a week. Participants randomized to either the abatacept or the placebo arm who experience a non-severe disease relapse, non-severe disease worsening, or who have not achieved remission by month 3 will have the option of entering an open-label trial period whereby they would receive open-label abatacept for up to 12 months.
223883520|NCT05038566|DEVICE|Pointdexter|i-Digits partial hand prosthesis modified with the investigational pointdexter finger in place of the usual index finger.
223883521|NCT06839404|DRUG|fluid challenge|Fluid bolus of 500 mL of crystalloids given at a constant rate between 10 and 15 minutes
223883522|NCT06794242|OTHER|Body representation|All the participants (controls and patients) in the study will follow the same experimental procedure, which consists of a single virtual reality session involving the estimation of leg length and an object.
223883523|NCT06322381|PROCEDURE|Reinsertion achilles tendon|Prone position, tourniquet over the thigh, direct midline incision, 2.0 cm proximal the insertion of the Achilles tendon up to 4.0 cm prolonged distal to the insertion is recommended. This is followed by a totally disinsertion of TA. At least a debridement of inflammatory or necrotic tissue as well as the removal of bony tissue is performed. tendon is re-inserted by 2-4 anchors.
223883524|NCT06322381|PROCEDURE|Zadek osteotomy|lateral position, under spinal anesthesia, tourniquet over the thigh, oblique lateral heel incision starting just anterior to the Achilles tendon, at a 45 angle to the long axis of the calcaneus posterior to the course of the sural nerve. A calcaneal osteotomy was then performed, two Kirschner wires, were then inserted from the posterior aspect of the calcaneus, over which cannulated screws were used for fixation of the osteotomy.
223883525|NCT02253251|GENETIC|KRAS-variant and microRNA binding site mutation testing|Participant in these studies will be tested for the KRAS-variant
223883526|NCT06312709|BEHAVIORAL|teleABLE (telehealth-delivered Activating Behavior for Lasting Engagement)|teleABLE uses behavioral activation to build personally meaningful non-sedentary throughout the day. This is accomplished using a global strategy, the ICAN Planning Process, which guides participants through activity scheduling, activity monitoring, self-assessment, and collaborative problem solving.
223883527|NCT06312709|OTHER|Health Education|Health Education provides information about stroke using factsheets from the American Heart Association and reflection questions that support participants in applying the information.
223883528|NCT05900479|OTHER|PTSD Service Dog|According to the Americans with Disabilities Act (ADA), a service dog is a dog that is trained to perform specific tasks to mitigate a disability. For PTSD service dogs, examples include detecting and alerting to physical signs of distress to interrupt anxiety and panic attacks, waking up Veterans from nightmares, and retrieving medication. In addition to trained tasks, service dogs live with the Veterans to provide emotional value as a source of comfort and companionship. Under the ADA guidance, PTSD service dogs have pubic access and are legally allowed to accompany their person in public places such as grocery stores, workplaces, and schools. In the proposed study, service dogs will be sourced from three national service dog providers, including K9s For Warriors, Canine Companions, and America's VetDogs. All three providers have an established track record of training and providing service dogs for PTSD, as well as collaborating with the investigative team in research.
223883529|NCT06241209|OTHER|PowerPoint program visual stimulation|Moving objects, food, money, and other targets will be presented in the remaining seeing, and hemianopic areas.
223883530|NCT06792565|DEVICE|hemodializer|Fresenius Helixone FX5 (61346 Bad Homburg, Germany)
223883531|NCT06792565|DEVICE|hemofilter|Medica (741036 Medolla, Italy)
223883532|NCT06796920|PROCEDURE|Spinal cord stimulation|Upon completion of the initial assessments, a lumbar spinal cord nerve stimulator and pulse generator will be implanted. Following surgery, based on the patient's recovery status, the patient will be transferred to the respective center for rehabilitation within one to two weeks. Afterward, electrical stimulation therapy will be initiated. Stimulation should be applied at least three days per week. Each day, the total stimulation time should be between 4 and 8 hours. Stimulation Modes: Continuous Stimulation: For example, if 6 hours of stimulation are prescribed, the stimulator will run uninterrupted for 6 hours. Intermittent Stimulation: For instance, a cycle of 40 seconds on and 20 seconds off. If a total of 6 hours of active stimulation is needed, the stimulator must remain on for 9 hours in total to accommodate rest intervals.The ranges for each parameter are as follows:Stimulation Frequency: 2 Hz - 2000 Hz, Pulse Width: 20 μs - 1000 μs, Stimulation Amplitude:Voltage: 0 V - 10 v
223883533|NCT04511702|BIOLOGICAL|Pegloticase with MTX|Participants will receive MTX during the run-in period then pegloticase with MTX for up to 24 weeks during the treatment period
223883534|NCT06791941|BIOLOGICAL|Culture of organoids|Culture of organoids prepared from both the primary tumor and the respective relapse, using the material from the prospective part of the study, the response to treatment will be carried out by macroscopic analysis, evaluating the size and number of organoids before and after treatment,
223883535|NCT06837376|OTHER|Education|One 45 minute educational session on the role of carbohydrate in exercise
223883536|NCT06837376|OTHER|Metabolic Testing (Exercise) with shared interpreted results|One 20-30 minute session. Treadmill, warm-up, then at increasing intensities for 3-minute intervals wearing a mouthpiece for measurement of respiratory gasses (oxygen consumption, carbon dioxide production). Testing starts with a 3-minute warm-up at 3.4 mph, 1% grade, increasing every 3 minutes until a respiratory exchange ratio of 1.0 is reached or volitional exhaustion
223883537|NCT06840301|BEHAVIORAL|Session 1: How We Evolved - Threat, Impulse, and Soothing Systems|"The practice of Breath break with kindness will be applied for 5 minutes. Afterwards, 15 minutes of information on threats, impulses and soothing systems, A safe place application for 11 minutes, Courtesy meditation for 10 minutes. After each application, 10 minutes of feedback will be received from the participants."
223883538|NCT06840301|BEHAVIORAL|Session 2: Threat and Self-Compassion|"The practice of breathing with kindness will be done for 7 minutes. The practice of Building a compassionate relationship with resilience will be held for 12 minutes, and the practice of Kindness meditation: a benevolent will take place for 11 minutes. A hand over your heart application will be made for 3 minutes and A compassionate comrade application will be done for 10 minutes. After each application, 3 minutes of feedback will be received from the participants."
223883539|NCT06840301|BEHAVIORAL|Session 3: Unraveling the Knots of Desire and Patterns|"The practice of breathing with kindness will be done for 7 minutes. Building a compassionate relationship with desire 12 minutes, Guided meditation to discover the inner pattern 10 minutes and Courtesy meditation: a good friend 11 minutes. Except for the breath break with kindness application, 3 minutes of feedback will be received from the participants after each application"
223883540|NCT06840301|BEHAVIORAL|Session 4: Internalizing compassion|"The pretend-to-be practice for the participants to observe themselves will be made for 10 minutes. The practice of internalizing compassion will be done for 7 minutes, kindness meditation: a neutral person practice for 10 minutes, and kindness towards your body for 10 minutes. After each application, 3 minutes of feedback will be received from the participants."
223883541|NCT06840301|BEHAVIORAL|Session 5: Me and others - Expanding the circle|"The a compassionate letter practice with the participants will continue for 15 minutes. meditation: the 'difficult' person 8 minutes, compassion and breathing: yourself 10 minutes and compassionate breathing: others 7 minutes. A compassionate break application is performed for 7 minutes."
223883542|NCT06840301|BEHAVIORAL|Session 6: Growing happiness|"The practice of Revisiting the good is carried out for 10 minutes with the participants. Forgive yourself, wish for forgiveness, forgive others, gratitude practices will be held for 5 minutes each and will take 20 minutes in total. Courtesy meditation: groups and all beings will be practiced for 10 minutes. After each application, 3 minutes of feedback will be received from the participants"
223883543|NCT06840301|BEHAVIORAL|Session 7: Weaving Wisdom and Compassion into Daily Life|"Participants will be given 10 minutes to choose a day in their life and allow a few minutes to pause mindfully. The practice of a breather for wise and compassionate action is 10 minutes, the practice of calmness meditation is 8 minutes, and the practice of sharing the joy meditation is 8 minutes. After each application, 3 minutes of feedback will be received from the participants."
223883544|NCT06840301|BEHAVIORAL|Session 8: Living with the Heart|"The participants are told about the applications they can apply for, where they need help to develop compassion towards self-healing skills, and the entire training will be evaluated for 20 minutes. The river of life application is carried out for 20 minutes. 10 minutes of feedback will be received after the application."
223883545|NCT05996744|DRUG|Obeldesivir|Tablet administered orally with or without food
223883546|NCT06838312|OTHER|Reuse or dispose a polyp trap|Participant hospitals will be separated into two groups, according to their standard clinical practice: A) reuse or B) dispose polyp traps after a colonoscopy with polypectomy. Centres will participate with their current method of using polyp traps. Work dynamics will not change as patients will be recruited from centers that routinely reuse or dispose polyp traps.
223883547|NCT06428903|DRUG|ADC189 tablet|ADC189 tablet, 45 mg, single oral dose in each Group. (Part 1 study)
223883548|NCT06428903|DRUG|ADC189 granules|ADC189 granules, 45 mg, single oral dose in each Group. (Part 1 study)
223883549|NCT06428903|DRUG|ADC189 180mg|ADC189 tablet, 180 mg, single oral dose. (Part 2 study)
223883550|NCT06790472|BEHAVIORAL|Online Lifestyle Intervention|The Metabolic Wellness Program (MWP) is an established 8-week program that provides participants with health education videos and webinars that focus on evidence-based nutrition, fitness, sleep, and stress intervention, including with CGM, allowing participants to monitor their real-time glucose data and to learn which lifestyle choices are best for their glycemic control and personal metabolic health. The program is also intended to help healthy participants maintain their metabolic health and lower their potential risk of developing cardiometabolic disease, as well as at-risk and pre-diabetic participants preventing the progression to T2D and people with established T2D reverse their condition.
223883551|NCT06790472|DEVICE|Continuous Glucose Monitoring|"CGM measurements begin at enrollment with training provided digitally Participants will be asked to live life as usual whilst wearing the device with initial 10-14 day readings providing baseline data. Participants will participate in the online lifestyle program, which the investigators refer to as the intervention stage. Participants will also receive questionnaires on behavior change at the beginning of week 5. During the final two weeks of the program (weeks 7-8), the final 10-14 days of CGM will be used as comparison data with baseline information."
223883552|NCT06795425|DIETARY_SUPPLEMENT|Postbiotic Active Lifestyle Blend|The active intervention, Postbiotic Active Lifestyle Blend, containing a heat-treated blend of bacterial strains; 2 capsules per day.
223883553|NCT06795425|OTHER|Placebo|The placebo intervention contains no active ingredients and consists of maltodextrin as an inactive ingredient. The capsule matches the appearance and dosage form of the active intervention.
223883554|NCT06797648|OTHER|data analysis|follow up after 15 months
223883555|NCT04172506|DRUG|AK105|Anti-PD-1 antibody
223883556|NCT05870995|DRUG|CALGE-VEN- RIC-conditioning|Intensive chemotherapy Cladribine-cytarabine-etoposide -venetoclax sequential with fludarabine, busulfan and melphalan or fludarabine and total marrow irradiation
223883557|NCT04953780|DRUG|Calaspargase pegol-mknl|Calaspargase pegol-mknl
223883558|NCT06840223|OTHER|Traditional stroke rehabilitation|Personalized traditional stroke rehabilitation programme including spasticity inhibition, sensory-perceptual-motor integration techniques, core stabilization and strengthening exercises, balance training i.e. applied as needed for stroke patients approximately for 45 minutes
223883559|NCT06840223|OTHER|Thoracolumbar fascia release|Thoracolumbar fascia release was performed by physiotherapist for one session. Supine Pelvic Rotation, Supine Arm Elevation, Bending Forward in Sitting Position and Sitting Crossed Arm and Knee Positions were performed approximately for 10-15 minutes after 45 minutes of traditional stroke rehabilitation.
223883560|NCT06840223|OTHER|Respiratory exercise|Respiratory exercises were performed by physiotherapist for one session. Pursed-Lip Breathing, Deep Breathing Exercise, Diaphragm Strengthening Exercise and Thoracic Expansion Exercises were performed approximately for 10-15 minutes after 45 minutes of traditional stroke rehabilitation.
223883561|NCT03192891|DIAGNOSTIC_TEST|Stress cardiac magnetic resonance (CMR) perfusion imaging|Gadolinium-enhanced stress CMR perfusion imaging is a tool increasingly used for the risk assessment and diagnosis of coronary artery disease.
223883562|NCT06736249|DIAGNOSTIC_TEST|Sarcopenic group|The sarcopenic group will undergo a DXA total body to define the sarcopenic stage.
223883563|NCT06736249|OTHER|Muscle harvesting|A piece of discarded muscle during surgery will be collected
223883564|NCT06735937|OTHER|Low flow anesthesia|Anesthesia management by using low flow anesthesia
223883565|NCT06645379|OTHER|Platelet-Rich Plasma (PRP) Injections|Transvaginal or laparoscopic injection for ovarian diseases (Premature ovarian insufficiency and Poor ovarian response). Intrauterine perfusion or sub-endometrium injection for uterine diseases (intrauterine adhesion, thin endometrium, and repeated implantation failure)
223883566|NCT06840275|DRUG|Allogeneic adipose tissue-derived mesenchymal stem cells|Two intravenous infusions of C2C\_ASC110 1 month apart. The C2C\_ASC110 product contains 110 million cells.
223883567|NCT06840275|OTHER|Cryostor CS10|Two intravenous infusions of CryoStor CS10 1 month apart.
223883568|NCT05597176|OTHER|Spinal Cord Injury Exercise Group|Participants will have an initial accommodation period of 4 weeks, during which four 10-minute exercise bouts/day will be interspersed with 5 minutes of rest. The bouts will gradually increase until at least continuous 40-minute sessions. The remaining 12-week intervention will be set at 70% max heart rate for a total of 16 weeks.
223883569|NCT06838754|OTHER|Whole body vibration therapy|Experimental group will get whole body vibrations. WBV will be performed by the patient while seated on the vibrating plate's base. Five series with a 30-second wait will make up each session. Five minutes and thirty seconds will be spent on vibration, and twenty minutes and thirty seconds will be spent on exercise. 5 Hz will be the frequency utilized. Over the course of two months, 16 classes will be held twice a week.
223883570|NCT06838754|OTHER|Routine physical therapy|Group B will only get routine physical therapy. Walking in all directions, advancing past the point of stability in a variety of positions, including half-kneeling, standing on both soft and hard surfaces, stepping up and down, walking and standing simultaneously, and standing on one leg with eyes open and closed were all part of the postural control exercise. There will be a 20-minute session.As each participant's functional improvement progresses, the intensity of the workout program will progressively rise. There will be 16 sessions in total (two days a week), with 8 sessions for each group.
223883571|NCT00890006|PROCEDURE|Advanced imaging for radiotherapy planning and guidance|Integration of MRI in the treatment planning process / Integration of daily cone-beam computed tomography (CBCT)
223883572|NCT06636227|DRUG|Diclofenac 100mg|Diclofenac 100mg
223883573|NCT06636227|DRUG|Diclofenac 75mg|Diclofenac 75mg
223883574|NCT06636227|DRUG|Diclofenac 50mg|Diclofenac 50mg
223883575|NCT06636227|DRUG|Placebo control|Placebo control
223883576|NCT06636058|BEHAVIORAL|vCare Intervention (6-month active treatment followed by 6-month maintenance)|"During the active treatment, participants will interact with the Lumen virtual coach (for depression management) and watch the GLB videos (for weight loss). Using the Amazon Alexa app on their study iPads, participants will complete 4 weekly Lumen PST sessions initially, 2 bi-weekly sessions, and then 3 monthly sessions during the active intervention. Beginning in week 6, participants will receive automated messages with instructions to view one GLB video a week for 11 weeks.~During the maintenance period, participants in the early vCare intervention arm will be able to interact with Lumen for PST coaching when they need to, i.e., on demand, although they will receive reminders to do so at least once a month. Participants may watch any of the 12 GLB videos again and will receive GLB-themed reinforcement and motivational messages by email every 2 weeks."
223883577|NCT06636058|BEHAVIORAL|vCare Intervention (active treatment after 6 months)|During the active treatment, participants will interact with the Lumen virtual coach (for depression management) and watch the GLB videos (for weight loss). Using the Amazon Alexa app on their study iPads, participants will complete 4 weekly Lumen PST sessions initially, 2 bi-weekly sessions, and then 3 monthly sessions during the active intervention. Beginning in week 6, participants will receive automated messages with instructions to view one GLB video a week for 11 weeks.
223883578|NCT06837467|DIAGNOSTIC_TEST|Immunohistochemistry (IHC)|We faced unsuccessful fast fiber type's identification on frozen sections then we shifted to paraffin sections. Deparaffinized sections were incubated with 3% H2O2 in PBS for 10 minutes followed by microwave treatment (5 minutes ×3 times at 500 Watt in citrate buffer, pH 6). Then, sections were incubated in blocking solution (0.3 M glycine, 50 mM ammonium chloride, and 1% BSA in PBS) for 30 minutes before incubation in primary antibodies. Sections were incubated with anti-SERCA1 or -SERCA2 and anti-MHC I or -MHCII (Table 1) antibodies for 1-2 days at 4 ◦C, then washed, and incubated with Alexa Fluor® 488 donkey anti-mouse IgG and Fluor® 594 donkey anti-goat IgG secondary Abs for 1 hour at room temperature. Double IHC was performed using (anti-SERCA1 + anti-SERCA2) and (anti-SERCA2 + anti-MHCII) combinations to check co-expression. In double IHC, the same steps were done as before with mixture of primary or secondary antibodies with same dilutions.
223883579|NCT06789640|OTHER|Vitamin C|"Vitamin C will be given before admission in the immediate preoperative preceding 7 days (the dose 30 -45 mg per day ) in oral drops preparations~Inflammatory markers including CRP , TLC ,PNI , GPS NLR will be checked on admission and on discharge and compared between cases and controls Hospital length stay will also be compared between the two groups"
223883580|NCT06789640|OTHER|Placebo|"Placebo will be given before admission in the immediate preoperative preceding 7 days (the dose 30 -45 mg per day ) in oral drops preparations~Inflammatory markers including CRP , TLC ,PNI , GPS NLR will be checked on admission and on discharge and compared between cases and controls"
223883581|NCT06795204|DRUG|HSK3486|Study Drug
223883582|NCT06795204|DRUG|Moxifloxacin Hydrochloride|Positive Control
223883583|NCT06795204|DRUG|Placebo|Negative Control
223883584|NCT06835153|OTHER|Monthly Performance Feedback with Dashboards (Automated Audit and Feedback)|"Hospital services in the intervention group will receive monthly automated dashboards that provide detailed performance metrics. These include:~The proportion of patients with a discharge letter generated on the day of discharge, The proportion of discharge letters validated on the day of discharge, Median delays for generating discharge letters, Median delays for validating discharge letters. The dashboards are shared with all physicians, nurse managers, and secretarial staff in each service. A designated quality improvement officer is available to assist teams in interpreting the data and implementing organizational changes based on the feedback. The intervention uses real-time data extraction from the hospital's electronic health record system to generate these insights."
223883585|NCT06237426|DRUG|Methylone|A course of treatment includes 4 weekly doses of TSND-201.
223883586|NCT06797479|PROCEDURE|Blood samples for the analysis of sildenafil in plasma|To detect the ICI mAbs in patients' blood plasma samples, we select three anti PD-1 mAbs (cemiplimab, dostarlimab and pembrolizumab) as prognostic biomarkers which will be quantified using different biochemical/analytical assays.
223883587|NCT04249947|BIOLOGICAL|P-PSMA-101 CAR-T cells|P-PSMA-101 is an autologous chimeric antigen receptor (CAR) T-cell therapy designed to target prostate cancer cells expressing the cell surface antigen prostate-specific membrane antigen (PSMA).
223883588|NCT04249947|DRUG|Rimiducid|Rimiducid (safety switch activator) may be administered as indicated
223883589|NCT04520594|OTHER|Resistant Starch|7.5 g resistant starch/m2 oral consumption
223883590|NCT04520594|OTHER|Placebo|Placebo oral consumption of food-grade cornstarch
223883591|NCT06830694|DRUG|Atezolizumab, Etoposide, Carboplatin, Tarlatamab|Cycle 1\~4 : Atezolizumab 1200 mg IV, carboplatin AUC 5.0 IV, Etoposide 100 mg/m2 IV Cycle 5\~ : Atezolizumab 1200 mg IV, Tarlatamab 1 or 10mg IV
223883592|NCT02404896|DRUG|Metreleptin|Metreleptin open-label treatment
223883593|NCT06827158|OTHER|validity and reliability of the Turkish version of the Dexterity Questionnaire 24 (DextQ-24|"Permission for the Turkish translation and validation of the DextQ-24 questionnaire was obtained from its developer, Tim Vanbellingen. The original English version will be translated into Turkish by two independent translators and then back into English by two native English speakers. After review, the finalized version will be used in the study.~Patients diagnosed with Parkinson's disease (aged 40-80) will complete consent and demographic forms. The Mini-Mental State Examination (MMSE) will exclude those scoring ≤24. Disease staging will follow the Hoehn and Yahr Scale (stages I-IV included). The MDS-UPDRS (sections II and III) will assess disease severity, while the Nine-Hole Peg Test and Hand Dexterity Scale-36 will evaluate hand function. Participants will complete the Turkish DextQ-24, with 30 randomly selected patients retaking it after two weeks for reliability testing. Data collection per participant will take approximately 30 minutes."
223883594|NCT06023134|DIAGNOSTIC_TEST|Echocardiography|Echocardiography will be used for specific right ventricular measurements or findings: TAPSE, TAPSE:PASP ratio, tissue Doppler velocity at lateral tricuspid annulus, fractional area change, right ventricular strain, right ventricular hypertrophy, right atrial size, volumes, ejection fraction, tricuspid and pulmonary regurgitation, inferior vena cava diameter and collapsibility, shift of interventricular septum, further assisting the diagnosis of RHF.
223883595|NCT06023134|DIAGNOSTIC_TEST|Right heart catheterization|"Right heart catheterization is the gold standard for the diagnosis of PH. It also allows for direct measurement of intracardiac and pulmonary pressures, as well as cardiac output, and is commonly used to estimate right ventricular preload and afterload."
223883596|NCT05577858|OTHER|Meat based|Omnivorous diet following dietary guidelines
223883597|NCT05577858|OTHER|Pulse based|Lacto-ovo-vegetarian pulse-based diet following dietary guidelines
223883598|NCT04411823|DEVICE|EndoFLIP measurement|EndoFLIP device can measure gastroesophageal junction distensibility index and esophageal contractile pattern under FDA cleared indication. It is performed during endoscopy.
223883599|NCT06537739|OTHER|Lumbar manipulation|Participant lies in the supine position, a physiotherapist faces the participant's side that will be manipulated. The participant interlocks their fingers behind their neck. Then the physiotherapist turns the participant on their side and performs a short thrust across the participant's pelvis in a posterior and inferior direction. The manipulation will be carried out on the symptomatic side, based on the participant's indication of the painful side. If the participant is unable to indicate the more symptomatic side, the physiotherapist performing the procedure will select the side. If no audible cavitation occurs during the manipulation, the physiotherapist will attempt to manipulate the opposite side. A maximum of 2 attempts per side will be allowed.
223883600|NCT06537739|OTHER|Positive communication - placebo|"Participants from Group A who will undergo the joint manipulation of the lumbar spine region and receive the following information: Joint manipulation is a very effective method of treating spinal disorders, which will significantly reduce the low back pain you are experiencing (positive communication - placebo)."
223883601|NCT06537739|OTHER|Negative communication - nocebo|"Participants form Group B who will undergo the joint manipulation of the lumbar spine region and receive the following information: Joint manipulation is not an effective method of treating spinal disorders, thus it may temporarily increase the low back pain you are experiencing (negative communication - nocebo)."
223883602|NCT06537739|OTHER|Neutral communication|"Participants from Group C who will undergo the joint manipulation of the lumbar spine region and receive the following information: Joint manipulation has not been verified for its effectiveness in affecting your level of low back pain (neutral communication)."
223883603|NCT06061965|BEHAVIORAL|Web-based resilience-building intervention|There are 6 modules on the website. Participants will be encouraged to verbalize their impressions of the website prototype.
223883604|NCT02387853|DRUG|LEO 90100|
223883605|NCT05141903|DIETARY_SUPPLEMENT|Antibiotic|Vancomycin (250 mg/dose), Metronidazole (500 mg/dose)
223883606|NCT05141903|DIETARY_SUPPLEMENT|HMO Concentrate|Concentrated milk fortifiers from donor human milk
223883607|NCT05141903|DIETARY_SUPPLEMENT|Probiotic|B. infantis
223883608|NCT05141903|DIETARY_SUPPLEMENT|Food Supplement|Synthetic powder containing 2'-fucosyllactose (2'-FL) and lactoneotetraose (LNnT)
223883609|NCT06238401|DRUG|ACR246 for injection|80 mg/vial
223883610|NCT04517903|OTHER|eye rubbing questionnaire|eye rubbing questionnaire at baseline and 15 days later for exploratory phase; at baseline and then validation by a Group Nominal
223883611|NCT06821503|DRUG|LM-108 injection|LM-108 injection is a monoclonal antibody that selectively clears regulatory T cells that infiltrate tumor sites.
223883612|NCT06821503|DRUG|Penpulimab injection|Penpulimab injection is a Programmed Cell Death Protein 1 (PD-1) immune checkpoint inhibitor.
223883613|NCT06821503|DRUG|Paclitaxel for injection (albumin bound)|Paclitaxel for injection (albumin bound) is a cytotoxic anticancer drug
223883614|NCT06821503|DRUG|Gemcitabine hydrochloride for injection|Gemcitabine hydrochloride for injection is a cell cycle specific anti-tumor drug that can inhibit the growth of tumor cells and belongs to a type of chemotherapy drug.
223883615|NCT03729180|PROCEDURE|Routine Elective Surgery- In patient or out patient elective surgery|Participants will be undergoing routine planned surgeries.
223883616|NCT03729180|DIAGNOSTIC_TEST|Blood test for genetic testing|Blood test to determine differences in genes which may affect how certain medications affect the participant. All patients will consent to collection of a blood sample for preemptive genotyping across a panel of actionable germline variants predicting drug response or toxicity risk.
223883617|NCT03729180|OTHER|Drug-genetic Profile|Profile describing drugs that may be high-risk, those that should be used with caution, or drugs that are favorable to use based on the participants genes.
223883618|NCT06833151|DEVICE|Ultrasound Respiratory Assessment|For lung ultrasound analysis, we selected ultrasound recordings of the right lower lung apex at the costophrenic angle along the right mid-axillary line. Using the open-source image processing tool ImageJ 1.4, the pleural line corresponding to the right lower lung apex was enhanced and its terminal coordinates extracted. During respiration, the right lower lung apex moves with the breathing cycle, and the pleural line exhibits corresponding motion. The terminal coordinates of the pleural line also shift during respiration, and a plot of this displacement against time is generated to create the pleural line sliding displacement curve.
223883619|NCT05959733|PROCEDURE|Bridging Reconstruction using BioBrace|Patients in the reconstruction group will undergo maximal repair with interposition bridging using BioBrace. This technique will follow a previously described technique by the principal investigator with differences allocated to the graft, it's preparation and insertion. The bursa will be debrided, and rotator cuff edged will be shaved down to stable tissue. BioBrace is bioinductive scaffold composed of highly porous type I collagen and bio-resorbable poly (L-lactide) (PLLA) microfilaments, and will be used as the graft in this trial.
223883620|NCT05959733|PROCEDURE|Repair|Patients in the maximal repair group will undergo a SCOI-row rotator cuff repair with adequate tension as described previously, with recreation of the rotator cable. Briefly, the SCOI-row rotator cuff repair uses one triple loaded suture anchor for each 1.2cm of torn tendon. This technique has been completed in a previous randomized controlled trial.
223883621|NCT05134779|PROCEDURE|Live Biobank|Tumor tissue will be collected from consented patients at sequential inflection points in the disease course: at the time of initial diagnosis, at the time of surgery and during recurrence or metastasis. In addition to this, 40ml of research bloods will also be collected at these key inflection points.
223883622|NCT04942431|BEHAVIORAL|Rebirth active SCHOOL 2.0 movement program|60 Minutes of physical activity per day integrated in every school-day.
223883623|NCT04140721|DRUG|Placebo oral tablet|Placebo pill identical to moxonidine administered for 4 weeks
223883624|NCT04140721|DRUG|Moxonidine Pill|Moxonidine pill administered for 4 weeks
223883625|NCT04716634|DRUG|Tislelizumab|Tislelizumab is a humanized, immunoglobulin G4 (IgG4)-variant monoclonal antibody against PD 1.
223883626|NCT04716634|DRUG|Fruquintinib|Fruquintinib is a potent, oral VEGFR tyrosine kinase inhibitor (TKI)
223883627|NCT06202872|DEVICE|Gamma (40 Hz) tACS at the precuneus region|40 Hz tACS applied at a current of 3.2 milliampere peak-to-peak using a NuroStym transcranial electrical stimulation (tES) system of NeuroDevice for four times 12 minutes (48 minutes in total) at the Pz (according to the 10-20 international EEG coordinates)
223883628|NCT06202872|DEVICE|Sham tACS at the precuneus region|Sham tACS applied with no effective stimulation between the ramp-up and ramp-down of the current using a NuroStym tES system of NeuroDevice for four times 12 minutes (48 minutes in total) at the Pz (according to the 10-20 international EEG coordinates)
223883629|NCT06793059|DEVICE|SHIELD|Pipeline SHIELD device under study
223883630|NCT03096054|DRUG|LY3143921 hydrate|LY3143921 hydrate will be administered orally on a daily schedule. Each cycle of treatment will consist of 21 days, and patients may initially receive up to 12 cycles. If the patient is benefitting, they may continue beyond 12 cycles.
223883631|NCT06789952|BEHAVIORAL|Mindfulness-Based Stress Reduction|"MBSR is a psychological therapeutic intervention that emphasizes the focused, non-judgmental awareness of present-moment experiences without efforts being made to alter or avoid them. It is a practice that is embedded in mind/body and integrative medicine, it combines formal and informal practices of mindfulness.~The formal practices include body scanning, gentle hatha yoga - movements, sitting meditation and walking, meditation. Informal practices include mindfulness of daily activities, such as eating, driving, washing dishes, showering, etc. A variety of other exercises will be used as a support for developing proficiency in the practice of mindfulness. This class places strong emphasis on experiential learning. Each session will include:~* guided instruction while engaging in practices of mindfulness~* opportunity to reflect on experiences and ask questions~* discussion of topics related to the practice of mindfulness as a strategy for reducing stress"
223883632|NCT06789952|BEHAVIORAL|Lifestyle Intervention|"The lifestyle sessions will include the following topics:~Movement -passive stretches and dynamic stretches, cardio HIIT exercise, flexibility and strength, and core and balance.~Nutrition Body - Include healthy eating with whole, clean, and nutritionally balanced meals; menu planning/prepping, snacking and noticing cravings and feelings of fullness or satiety.~Sleep - Include routine for evening, and morning for optimal sleep, logging routines and quality of sleep, tools to aid in falling asleep, and returning to sleep during the night, eating and sleep patterns Nature/Culture/Arts (with Kemper Museum of Contemporary Art - which will also take place during ½ day retreat) includes spending time in nature and journal experiences, reconnecting with the sun, and surround self with nature.~Financial - Focus on financial wellbeing, budgets/adjustments to budgets, and buying/spending patterns.~Cooking - Include healthy foods, smoothies, juices, kitchen appliances."
223883633|NCT06795971|DEVICE|Continuous Positive Airway Pressure|"1. Patients were placed at a 45-degree supine position, and noninvasive ventilation was delivered to the patient through a face mask connected to an ICU ventilator.~2. PEEP was started at 5 cm H2O with a FiO2 of 0.5 at initiation. PEEP and FiO2 were titrated to maintain SpO2 between 94 and 98%, remaining constant for at least 5 min.~3. CPAP was initiated with a first session of at least 4 h, the minimally required duration of noninvasive ventilation was 16 hours per day for at least 2 calendar days. Between noninvasive-ventilation sessions, patients received HFNO."
223883634|NCT06795971|DEVICE|High-flow nasal oxygen|"1. Oxygen was passed through a heated humidifier (MR850, Fisher and Paykel Healthcare) and applied continuously through large-bore binasal prongs, with a gas flow rate of 50 liters per minute and an FiO2 of 0.5 at initiation. HFNO heating temperature was prespecified at 37°C.~2. FiO2 will be titrated to maintain SpO2 between 94 and 98%, remaining constant for at least 5 min.~3. HFNO was applied for at least 2 calendar days."
223883635|NCT06795971|DEVICE|Non-invasive ventilation|"1. Patients were placed at a 45-degree supine position, and noninvasive ventilation was also delivered to the patient through a face mask connected to an ICU ventilator. The mask most appropriate for the patient will be selected and adjusted to minimize leakage and pressure points.~2. The inspiratory positive airway pressure (pressure support plus PEEP) was initiated between 12 and 14 cm H2O, PEEP was started at 5 cm H2O with a FiO2 of 0.5 at initiation. FiO2 was titrated to maintain SpO2 between 94 and 98%, remaining constant for at least 5 min.~3. NIV was initiated with a first session of at least 4 h, the minimally required duration of noninvasive ventilation was 16 hours per day for at least 2 calendar days. Between noninvasive-ventilation sessions, patients received HFNO."
223883636|NCT06787677|PROCEDURE|PRF|After the puncture needle reached the sphenopalatine ganglion (SPG), patients in the PRF group received PRF treatment in automatic mode for 360 s, at a maximum of 42°C, pulse frequency of 2 Hz, and pulse width of 20 ms.
223883637|NCT06787677|PROCEDURE|NB|After the puncture needle reached the sphenopalatine ganglion (SPG), patients in the NB group received nerve block with a mixture of 40 mg of triamcinolone and 2 ml of 0.75% bupivacaine with 2 ml of normal saline and 1:100000 epinephrine.
223883638|NCT05265000|DEVICE|tSpinalStim|Patients will undergo 12-21 sessions of spinal cord stimulation therapy (30 minutes per session, 3 times a week). Up to five round stimulating electrodes will be placed on the skin midline between spinous processes in cervical, thoracic and/or lumbar region, as cathodes and rectangular pads will be placed symmetrically on the skin over the iliac crests as anodes. The stimulator generates pain-free biphasic rectangular waveform with 1 ms width pulses filled with 5-10 kHz (kilohertz) carrier frequency. A range of stimulation intensities from 0-250 mA (milliamps) may be used. We expect that the stimulation intensities needed for therapeutic effect may differ based on individual's body mass index and/or the amount of subcutaneous fat present at the stimulation site.
223883639|NCT02959229|DRUG|Lactoferrin|
223883640|NCT02959229|DRUG|Placebo (for Lactoferrin)|placebo in form of distilled water
223883641|NCT02839291|OTHER|quality of life questionaries|
223883642|NCT02839291|DRUG|intravenous or oral bone antiresorptive treatments|
223883643|NCT02793687|DRUG|Mexidol|50 mg/ml IV solution, 125 mg tablet
223883644|NCT02793687|OTHER|Placebo|Placebo IV solution, Placebo tablet
223883645|NCT05550324|PROCEDURE|Blood draw|One time intravenous blood draw
223883646|NCT06451354|OTHER|Erector spinae plane block (20 ml bupivacaine 0.25% in each side)|Patients will receive bilateral ultrasound-guided erector spinae plane block after spinal anesthesia and at the end of surgery. The erector spinae plane block will be performed by using bupivacaine 0.25% (20 ml in each side). Erector spinae plane block will be performed at the level of T9.
223883647|NCT06451354|OTHER|Posterior Quadratus lumborum plane block (20 ml bupivacaine 0.25% in each side)|Patients will receive bilateral ultrasound-guided quadratus lumborum plane block after spinal anesthesia at the end of surgery. The quadratus lumborum plane block will be performed by using bupivacaine 0.25% (20 ml in each side).
223883648|NCT06451354|OTHER|Lateral Transversus abdominis plane block (20 ml bupivacaine 0.25% in each side)|Patients will receive bilateral ultrasound-guided transversus abdominis plane block after spinal anesthesia at the end of surgery. The transversus abdominis plane block will be performed by using bupivacaine 0.25% (20 ml in each side) to the lateral abdominal wall in the mid-axillary line, between the lower costal margin and iliac crest.
223883649|NCT03467542|DEVICE|PHIL® Liquid Embolic System|The PHIL Embolic System is indicated in the treatment of dural arteriovenous fistulas (DAVF)
223883650|NCT03022656|DEVICE|Active Brace system|
223883651|NCT06429618|DIETARY_SUPPLEMENT|Low carbonhydrate diet|Each patient will receive a 3-month low-carbohydrate (40% CHO) diet from the same dietitian. Whether the patients adhere to the diet and which components the prescribed diet consists of is recorded in detail. After 3 months of standard application, the patient is examined again by the gynecologist and obstetrician at the PCOS clinic.
223883652|NCT04077762|PROCEDURE|Radial Access|Radial Access
223883653|NCT04077762|PROCEDURE|State-of-the-art femoral access with 18 gauge needle|State-of-the-art femoral access with 18 gauge needle
223883654|NCT04077762|PROCEDURE|State-of-the-art femoral access with 21 gauge needle|State-of-the-art femoral access with 21 gauge needle. For patients randomized to micropuncture (21G) the micropuncture wire must be advanced under fluoroscopy to avoid inadvertent wiring of side-branches.
223883655|NCT05421390|OTHER|Reduced fat dairy|Serving sizes will be: 250 mL milk, 175 g yogurt, and 50 g cheese. Skim milk, fat-free yogurt, and ≤22 % fat cheese
223883656|NCT05421390|OTHER|Regular fat dairy|Serving sizes will be: 250 mL milk, 175 g yogurt, and 50 g cheese. 3.25% fat milk, ≥2% fat yogurt, and ≥28% fat cheese
223883657|NCT05739825|OTHER|FMT from healthy donors|This intervention is represented by the administration, in the recipients' gut, of healthy donor microbiota through FMT
223883658|NCT04271358|BEHAVIORAL|Peer Health Coaching|The Peer Coaching group will receive 6 months of peer health coaching via a secure telephone and text messaging system.
223883659|NCT04905446|OTHER|Deuterated nicotinamide (D4-NAM) IV infusion|Nicotinamide adenine dinucleotide (NAD) is a vitally important substance that is found in all cells of the body. D4-NAM (in normal saline) will be infused via an indwelling catheter.The IV infusion will continue for 8 hrs.
223883660|NCT04905446|PROCEDURE|Skeletal muscle biopsy|Participants will have a muscle biopsy performed on the muscle in the thigh. We will collect a small sample of blood before the biopsy. This procedure is used to sample muscle cells from the right or left leg Vastus Lateralis (thigh) muscle.
223883661|NCT04905446|PROCEDURE|Skin tissue biopsy|This procedure is used to sample skin tissue from the upper thigh via a punch biopsy.
223883662|NCT03323463|DIAGNOSTIC_TEST|F-FMISO PET/CT Scan|All subjects on Cohort A and the first 100 subjects accrued to Cohort B will undergo a pre-treatment F-FMISO scan PET/CT scan pretreatment. For both Cohort A and Cohort B, FMISO scan will be repeated between the 5th-10th RT day if pre-treatment scan is hypoxic. If the repeat 18F-FMISOscan PET/CT demonstrates hypoxia, the subject will receive 70Gy concurrent with 2 cycles of chemotherapy. All subjects accrued onto Cohort B after 100 accruals will undergo only one 18F-FMISO scan done 5-10 treatment days after start of radiation therapy.
223883663|NCT03323463|RADIATION|30 Gy over 3 weeks|Treatment will be delivered as one fraction per day on a standard 5 day per week schedule (excluding weekends and holidays), total of 30 Gy over 3 weeks at 2 Gy per fraction each day. The gross nodes, the primary/postoperative bed if applicable, all subclinical areas at risk for disease will receive the same dose at 30Gy.
223883664|NCT03323463|DRUG|Cisplatin|Cycle 1 (week 1): At the start of week 1 of IMRT, subjects will receive cisplatin 100 mg/m2 intravenously. They may be given for 2 consecutive days (50 mg/m2 each day for a total dose 100 mg/m2), typically on days 1 and 2, or as a single dose, typically on day 1.
223883665|NCT03323463|DRUG|Carboplatin|If cisplatin cannot be given at 100 mg/m2 for either cycle 1 or cycle 2, the investigator may use a regimen with carboplatin and 5-Fluorouracil in its place. Carboplatin will be given at a dose of AUC 1.25 intravenously daily x 4 days starting on day 1 of the cycle (total dose of AUC 5). Cycle 2 (Week 4): After the three weeks of radiation at week 4 when the subject no longer is receiving radiation therapy, subjects will receive cisplatin 100 mg/m2 intravenously. The may be given for 2 consecutive days (50 mg/m2 each day for a total dose 100 mg/m2), typically on days 22 and 23, or as a single dose, typically on day 22.
223883666|NCT03323463|DRUG|5Fluorouracil|If cisplatin cannot be given at 100 mg/m2 for either cycle 1 or cycle 2, the investigator may use a regimen with carboplatin and 5-Fluorouracil in its place. 5-Fluorouracil will be given at a dose of 600 mg/m2 intravenous infusion over 24 hours daily x 4 days (total dose of 2400 mg/m2 intravenous infusion over 96 hours).
223883667|NCT03323463|RADIATION|Proton Therapy|Proton beam using pencil beam delivery either with the Varian or IBA delivery systems will be allowed for Cohort B. Proton beam therapy will be given at the New York Proton Center in New York City, where MSKCC has a well-established business associate agreement and cooperative research agreement with, respectively. If treatment at NYPC is not feasible, patients may be referred to ProCure in Somerset, NJ.
223883668|NCT04494048|OTHER|Endoscopic Bariatric Therapies|Participation in this study will allow for data collection through medical chart review for at least 6 standard of care visits up to 1 year after consenting to participate in this registry study. The exposure of interest is total body weight loss, safety and efficacy
223883669|NCT06363994|DRUG|Orelabrutinib|Eligible patients will receive Orelabrutinib orally as per the protocol，until disease progression or other reasons for treatment discontinuation，whichever comes first.
223883670|NCT06363994|DRUG|Bendamustine Injection|Eligible patients will receive Bendamustine by injection as per the protocol
223883671|NCT06363994|DRUG|Rituximab|Eligible patients will receive Rituximab by injection as per the protocol
223883672|NCT06363994|DRUG|Orelabrutinib Placebo|Eligible patients will receive Orelabrutinib Placebo orally as per the protocol
223883673|NCT04925388|OTHER|rapid molecular diagnosis|peritoneal samples will be analysed using Unyvero IAI test
223883674|NCT04925388|OTHER|conventional method analysis|peritoneal samples will be analysed using conventional method
223883675|NCT04580225|PROCEDURE|Four-Corner Arthrodesis|Participants in Group A will receive a four-corner arthrodesis (fusion of the capitate, hamate, lunate, and triquetrum) with excision of the scaphoid.
223883676|NCT04580225|PROCEDURE|Three-Corner or Capitolunate Arthrodesis with Triquetral Excision|Participants in Group B will receive a three-corner arthrodesis (fusion of the capitate, hamate, and lunate) or capitolunate arthrodesis (fusion of the capitate and lunate) with excision of the scaphoid and triquetrum.
223883677|NCT04223570|DEVICE|Portable Apple Smart Phone Protoporphyrin IX Spectrometer Camera|This is a portable device that uses a camera to non-invasively and efficiently measure the level of protoporphyrin IX in various areas skin. This camera will be used in all participants to measure the level of protoporphyrin IX in various areas of skin as detailed in the study description.
223883678|NCT02278562|DRUG|anakinra|100 mg in syringes; administered subcutaneously 3 times a week for 12 weeks (3 months)
223883679|NCT02278562|DRUG|actos|30 mg capsules; administered orally 1 capsule per day for 12 weeks (3 months)
223883680|NCT02278562|OTHER|placebo|placebo capsules and injection
223883681|NCT04452877|DRUG|Dabrafenib|Dabrafenib will be provided by the sponsor to the investigative site or supplied locally as commercially available. Dabrafenib will be administered orally twice daily (150 mg BID) for Days 1-21 of a 21-day cycle.
223883682|NCT04452877|DRUG|Trametinib|Trametinib will be provided by the sponsor to the investigative site or supplied locally as commercially available. Trametinib will be administered orally once daily (2 mg QD) for Days 1-21 of a 21-day cycle
223883683|NCT06738147|OTHER|pelvic floor muscle training|pelvic floor muscle training (PFMT) for 30 min., 3 sessions/ week in addition to traditional physical and balance training program (proprioception training and balance exercises for the static and dynamic components of balance for 30 min., three sessions/ week for six weeks.
223883684|NCT06738147|OTHER|balance exercises|traditional physical and balance training program (proprioception training and balance exercises for the static and dynamic components of balance for 30 min., three sessions/ week for six weeks.
223883685|NCT06737198|OTHER|without interventios.|without interventios.
223883686|NCT06554951|OTHER|Patients who are candidates for CAR-T cell therapy for hematologic malignancy|This study will include patients who undergo CAR-T cell infusion at participating centers during the 18-month duration of the enrollment period. A total of 100 patients are expected to be enrolled, including 80 patients for the prospective part and 20 for the retrospective part.
223883687|NCT04953884|DRUG|wilate|wilate is a plasma-derived, stable, highly purified, double virus inactivated concentrate of freeze-dried active VWF and factor VIII (FVIII) prepared from cryoprecipitate and intended for the treatment of patients with von Willebrand disease (VWD) and/or haemophilia A
223883688|NCT04523376|DEVICE|CliniMACS|Peripheral blood stem cells from closely matched unrelated donors will be processed using the CliniMACS device to remove TCRalpha/beta T cells and B cells, in accordance with the Investigator Brochure and Technical Manual following the laboratory standard operating procedures (SOPs) and using aseptic technique
223883689|NCT05461417|DEVICE|D-SAD|Patients equipped with Panthera D-SAD® orthosis will be recruited.
223883690|NCT06364371|OTHER|Medical examination|Eligible patients will be prospectively enrolled, and images of their pre-neoadjuvant treatment, during-treatment, and post-treatment preoperative magnetic resonance imaging (MRI) scans, histopathology slides stained with hematoxylin and eosin (H\&E), carcinoembryonic antigen (CEA), and circulating tumor DNA (ctDNA) will be collected and annotated.
223883691|NCT05805384|DEVICE|SEDA|Speech Enhancement using Dynamic thresholding Approach (SEDA) is a software algorithm that removes background noise.
223883692|NCT06391177|DRUG|Vonoprazan|Oral tablet.
223883693|NCT06535256|COMBINATION_PRODUCT|bupivacaine with dexamethasone|intra-peritoneal instillation of bupivacaine with dexamethasone (received 40 mL of 0.25% bupivacaine + 16 mg dexamethasone with 5 ml normal saline).
223883694|NCT06535256|COMBINATION_PRODUCT|bupivacaine with dexmedetomidine|intra-peritoneal instillation of bupivacaine with dexmedetomidine (received 40 mL of 0.25% bupivacaine + dexmedetomidine 1 μg/kg with normal saline 5 ml).
223883695|NCT04547686|BEHAVIORAL|Smoke-Free Homes Intervention|The adapted smoke-free homes intervention consists of five components, three interactive mailings and two coaching calls, focused on creating home and vehicle(s) smoking bans among smokers. The intervention is based on principles of Social Cognitive Theory and the Transtheoretical Model's stages of change. The rationale underlying the intervention is that creation of additional smoke-free environments will reduce situational and environmental cues to smoke, reduce opportunities and places to smoke, increase self-efficacy for quitting and increase motivation to quit. The intervention uses persuasion, role modeling, behavioral contracting and goal setting to move smokers through behavioral capability, outcome expectations and self-efficacy for strict smoke-free rules, creation of and compliance/enforcement with smoke-free rules, reduced cigarettes smoked per day, increased motivation to quit, increased quit attempts, and successful cessation.
223883696|NCT04547686|BEHAVIORAL|Control|The quitline is a phone number that people can call that offers free smoking cessation counseling to all Georgia residents by the state of Georgia.
223883697|NCT04836728|BIOLOGICAL|CIK cells injection|CIK cells, more than 1x10\^10 (10 billion ), intravenous infusion, d14, Q3W.
223883698|NCT04836728|DRUG|Sintilimab Injection|200 mg, intravenous infusion, d1, every 3 weeks
223883699|NCT04836728|DRUG|Pemetrexed|500 mg/m\^2, intravenous infusion, d1, every 3 weeks
223883700|NCT04836728|DRUG|Albumin paclitaxel|260 mg/m\^2, intravenous infusion, d1, every 3 weeks
223883701|NCT04836728|DRUG|Carboplatin|AUC 5, intravenous infusion, d1, every 3 weeks
223883702|NCT04676373|DRUG|ALGLUCOSIDASE ALFA|"Pharmaceutical form:solution for infusion~Route of administration: intravenous"
223883703|NCT06238960|OTHER|Telerehabilitation|the patient will undergo 10 session of tele rehabilitation in continuity with traditional physiotherapy
223883704|NCT06238960|OTHER|Traditional rehabilitation|the patient will undergo 16 session of outpatient physiotherapy rehabilitation
223883705|NCT06518759|OTHER|traditional chest techniques|patients will receive traditional chest techniques in the form of percussion and vibration, 2 times per day, 3 sets 5 repetitions per each set for 20 minutes, 3 times per week for 2 weeks
223883706|NCT06518759|OTHER|Glossopharyngeal breathing exercise|patients will receive Glossopharyngeal breathing exercise, 2 times per day, 3 sets 5 repetitions per each set for 20 minutes, 3 times per week for 2 weeks.
223883707|NCT06518759|OTHER|Diaphragmatic breathing exercise|patients will receive diaphragmatic breathing exercise, 2 times per day, 3 sets 5 repetitions per each set for 20 minutes, 3 times per week for 2 weeks.
223883708|NCT05000827|DEVICE|PSMA-PET/CT|In the intervention arm patients will only undergo ePLND in addition to robot-assisted radical prostatectomy (RARP) in case of suspected LNI on PSMA PET/CT (miN1), whereas ePLND will be omitted in those without PSMA positive lymph nodes (miN0).
223883709|NCT05000827|OTHER|Nomogram|Current standard of care includes performing extended pelvic lymph node dissection (ePLND) in all patients with primary prostate cancer and a nomogram-based risk of LNI \>5%
223883710|NCT06384651|DRUG|Intraosseous Vancomycin Injection|"* IO vancomycin is administered in the OR after sterile prep and draping has occurred (500mg in 100-150mL NS).~* IO Injection will take place into the medial malleolus."
223883711|NCT06384651|DRUG|Intravenous Vancomycin|• Patients will receive the orthopedic surgeon's standard of care pre-operative antibiotic regimen for TAA patients. This includes IV antibiotics (typically ancef or cefepime and vancomycin) will be started in the pre-operative period approximately 1 hour prior to incision (vancomycin dose weight-based at approximately 15mg/kg generally 1000-1750mg in 500mL normal saline (NS))
223883712|NCT05783401|OTHER|Data acquisition: Speech acquisition|Speech test with synchronized audio and video recording. The speaking exercises and the audio and video recording will be done using a tablet computer and an application developed in-house. Freely available images showing different scenes will be integrated and displayed on the tablet to be described by the patient. The goal is to have at least two and maximum four of them described with several sentences by each patient per session. Parameters will be extracted from the patient's audio data to estimate the changes in distress and frailty.
223883713|NCT05783401|DIAGNOSTIC_TEST|Data acquisition: G8 Screening tool|The G8 screening tool consists of seven items dealing with food intake, weight loss, mobility, neuropsychological problem, body mass index, prescription drug, and self-perception of health, from the Mini-Nutritional Assessment (MNA) questionnaire and was developed specifically for elderly cancer patients. The total G-8 score lies between 0 and 17. A higher score indicates a better health status.
223883714|NCT05783401|DIAGNOSTIC_TEST|Data acquisition: Distress Thermometer|The distress thermometer (DT) is a measure of psychological distress in cancer patients. The instrument is a self-reported tool using a 0-to-10 rating scale.
223883715|NCT06128681|PROCEDURE|Intraairway ultrasound-guided mediastinal opening technique|Mediastinal intervention for patients with mediastinal imaging abnormalities is performed under general anesthesia to obtain biopsy specimens for detection or elimination of mediastinal masses
223883716|NCT03911388|BIOLOGICAL|G207|Single dose of G207 infused through catheters into region(s) of tumor. If G207 is safe in the first cohort of patients, subsequent patients will receive a single dose of G207 infused through catheters into region(s) of tumor followed by a 5 Gy dose of radiation to the tumor (which includes progressive leptomeningeal disease or any site of gross tumor progressing in the brain parenchyma) within 24 hours of virus inoculation.
223883717|NCT04490720|DIETARY_SUPPLEMENT|Placebo|consume 1 sachet per day for 2 months
223883718|NCT04490720|DIETARY_SUPPLEMENT|Buckwheat husk extract|consume 1 sachet per day for 2 months
223883719|NCT02630823|DRUG|MK-3475|
223883720|NCT02630823|PROCEDURE|Surgical resection (standard of care)|
223883721|NCT02630823|DRUG|Paclitaxel (standard of care)|
223883722|NCT02630823|DRUG|Carboplatin (standard of care)|
223883723|NCT02630823|RADIATION|Radiation (standard of care)|
223883724|NCT02630823|PROCEDURE|Endometrial biopsy|
223883725|NCT02630823|PROCEDURE|Peripheral blood draw|
223883726|NCT05387447|BEHAVIORAL|Conversational Voice Assistant (Enhanced)|Interactive routine is based on tailoring to the participants type of pain and personality.
223883727|NCT05387447|BEHAVIORAL|Conversational Voice Assistant (Standard)|Interactive routine is a basic interaction with the voice assistant.
223883728|NCT05710406|DRUG|Encorafenib|Given PO
223883729|NCT05710406|BIOLOGICAL|Cetuximab|Given IV
223883730|NCT05710406|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
223883731|NCT05710406|PROCEDURE|Computed Tomography|Undergo CT
223883732|NCT05710406|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223883733|NCT05710406|OTHER|Patient Observation|Undergo observation per usual care
223883734|NCT05130450|DRUG|Olezarsen|Olezarsen will be administered by SC injection.
223883735|NCT06323889|BEHAVIORAL|Modified Alternate Day Fasting|Participants are instructed to fast every other day.
223883736|NCT06323889|BEHAVIORAL|Time-Restricted Eating|Participants are instructed to limit food intake to two main meals consumed in maximum 8 hours per day
223883737|NCT06323889|BEHAVIORAL|Weight-loss counseling|Participants will receive nutrition counseling to structure their main meals according to the plate model for weight-loss and to reduce number of consumed plates.
223883738|NCT03679611|DRUG|Sugammadex Sodium|Sugammadex is a FDA approved newer NMBD reversal agent. But does not use in standard of care in most of institutions This study is designed to compare the impact of reversal of neuromuscular blockade with sugammadex vs. neostigmine on discharge time from the operating room in obese patients with OSA undergoing bariatric surgery
223883739|NCT03679611|DRUG|Neostigmine|neostigmine is a FDA approved NMBD reversal drug, uses as standard care drug in most of the institutions. neostigmine use as active comparator to compare with investigational drug Sugammadex in the study.
223883740|NCT02395367|PROCEDURE|resection|This is an observational study. And we are interested in observing the outcome of different treatment methods.
223883741|NCT02395367|RADIATION|adjuvant radiotherapy|This is an observational study. And we are interested in observing the outcome of different treatment methods.
223883742|NCT02395367|DRUG|neoadjuvant chemotherapy or adjuvant chemotherapy|This is an observational study. And we are interested in observing the outcome of different treatment methods.
223883743|NCT04534933|DEVICE|Evone|Airway ventilation device
223883744|NCT04534933|DEVICE|Primus|Airway ventilation device
223883745|NCT05037266|BIOLOGICAL|COVID-19 Vaccine Janssen (Ad26.COV2-S)|one dose (0.5mL) at D1 and one dose (0.5mL) at D57
223883746|NCT03708224|BIOLOGICAL|Atezolizumab|Given intravenously (IV)
223883747|NCT03708224|BIOLOGICAL|Tocilizumab|Given IV
223883748|NCT03708224|BIOLOGICAL|Tiragolumab|Given IV
223883749|NCT06147830|OTHER|None (Observational study)|Not Applicable since Observational Study
223883750|NCT03512314|DRUG|Tadekinig alfa|Open label, 26 weeks on Tadekinig alfa treatment.
223883751|NCT06494683|DRUG|Pueraria lobata radix|The dose of Pueraria lobata radix granules is one sachet per day, 1.5g per sachet, which equivalent to 15 g of the original herb.
223883752|NCT03391466|BIOLOGICAL|Axicabtagene Ciloleucel|A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells administered intravenously following a conditioning chemotherapy regimen of fludarabine and cyclophosphamide
223883753|NCT03391466|DRUG|Platinum-containing salvage chemotherapy (eg, R-ICE) followed by high dose therapy (eg, BEAM) and autologous stem cell transplant in responders.|Platinum-containing salvage chemotherapy (R-ICE, R-DHAP, R-ESHAP, or R-GDP as selected by treating investigator) followed by high dose therapy (eg, BEAM) and autologous stem cell transplant in responders.
223883754|NCT03391466|DRUG|Cyclophosphamide|Administered intravenously
223883755|NCT03391466|DRUG|Fludarabine|Administered intravenously
223883756|NCT05126862|BEHAVIORAL|MindTrails|MindTrails is a web-based cognitive bias modification intervention. Training sessions are designed to encourage cognitive flexibility through repeated practice assigning benign resolutions to ambiguous, anxiety-provoking situations.
223883757|NCT06518135|OTHER|SLNB group|After the completion of neoadjuvant therapy, axillary SLNB should be performed first before breast surgery; If the frozen pathology SLNs are negative, ALND will no longer be performed; If frozen pathological SLNs are positive, ALND should be performed directly; If frozen pathology is false negative.
223883758|NCT06443320|OTHER|patient included in experimental groupe will view the video excerpt, a playtime, a drawing activities|Patients included in the videodrama arm will participate in a total of 18 videodrama sessions, with one session per week. Each session will include a patient welcome period, the viewing of a video excerpt (in slow motion or not), a playtime, a drawing period, and a group closing session. For the play and drawing activities, the same materials will be provided in each department and for each group, including small figurines, animals, shapes (such as cubes, triangles, circles), small plush toys, markers, colored pencils, and A4 white sheets of paper.
223883759|NCT03454750|DRUG|177Lu-PSMA|177Lu-PSMA 3.7-5-5 GBq Intravenous Slowly in 15-30 ' Day 1/ every 8-12 weeks Four cycles every 8-12 weeks
223883760|NCT05813496|DRUG|Alpha-Lipoic Acid (ALA)|Oral tablet
223883761|NCT05813496|DRUG|Placebo|Microcrystalline cellulose (Ph 101) 427.5 mg, Magnesium stearate 71.25 mg, Sodium laurayl sulphate 6 mg, Croscarmellose sodium 11.25 mg, Silica, colloid anhydrous 11.25 mg, and Purified talc 30 mg.
223883762|NCT05531643|DEVICE|Active Cefaly Dual (R)|Transcutaneous electrical nerve stimulation (TENS) device with electrode placement at the forehead. A biphasic rectangular wave will be delivered for a maximum of 20 minutes at a maximum amplitude of 16mA. Participant may halt amplitude before it reaches maximum amplitude. The device has previously been cleared by the FDA for use in migraine patients.
223883763|NCT05531643|DEVICE|Sham Cefaly Dual (R)|Transcutaneous electrical nerve stimulation (TENS) device with electrode placement at the forehead. A 1Hz wave will be delivered for 20 minutes at 1mA.
223883764|NCT04972513|PROCEDURE|Biospecimen Collection|Undergo collection of blood
223883765|NCT04972513|PROCEDURE|Nitric Oxide Breath Test|Undergo nitric oxide breath testing
223883766|NCT04972513|PROCEDURE|Oscillometry|Undergo airwave oscillometry
223883767|NCT04972513|PROCEDURE|Spirometry|Undergo spirometry
223883768|NCT04972513|OTHER|Survey Administration|Complete survey
223883769|NCT04972513|PROCEDURE|Endothelial function|Endothelial function will be assessed with the EndoPAT device, which measures changes in pressure from sensors placed on the fingertip
223883770|NCT05175547|DRUG|Clevidipine|Blood pressure management with Clevidipine
223883771|NCT05678959|DRUG|Ligelizumab 120 mg|1 injection of 1.0 mL ligelizumab and 1 injection of 1.0 mL placebo
223883772|NCT05678959|DRUG|Ligelizumab 240 mg|2 injections of 1.0 mL ligelizumab
223883773|NCT05797376|DRUG|Rivaroxaban 2.5mg|patients are prescribed aspirin at a daily dose of 100mg and Rivaroxaban (2.5 mg twice a day)
223883774|NCT05777447|PROCEDURE|Mycotic aortic-iliac aneurysms and in situ reconstruction|Surgical treatment of mycotic aortic-iliac aneurysms and in situ reconstruction
223883775|NCT06297447|OTHER|PNE4Adults - pain science education|Is formerly described under arm descriptions
223883776|NCT06297447|OTHER|Usual care|Is formerly described under arm descriptions
223883777|NCT05919082|DRUG|LEO 90100|Subjects will apply LEO 90100 topically; up to 15 g per day (or 105 g per week).
223883778|NCT05919082|DRUG|Daivobet® ointment|Subjects will apply Daivobet® ointment topically; up to 15 g per day (or 105 g per week).
223883779|NCT03785873|DRUG|Nivolumab|Intravenous (IV) infusion
223883780|NCT03785873|DRUG|Nanoliposomal-Irinotecan|Intravenous (IV) infusion
223883781|NCT03785873|DRUG|5-Fluorouracil|Intravenous (IV) infusion
223883782|NCT03785873|DRUG|Leucovorin|Intravenous (IV) infusion
223883783|NCT02764138|BEHAVIORAL|Building a Strong Identity and Coping Skills|Psychoeducational program to teach children coping skills, healthy identity development, and collective social action.
223883784|NCT03479476|DRUG|Placebo Medication|Placebo liquid or capsules given in parallel to active medication.
223883785|NCT03479476|DRUG|Metformin|Active medication.
223883786|NCT03946527|DRUG|Lanreotide|Participants will receive lanreotide 120 mg deep subcutaneous injection every 4 weeks (±7 days) for 52 weeks, followed by an extension phase in which all patients will continue to receive lanreotide 120 mg injection every 4 weeks (±7 days) if there is no evidence of disease progression.
223883787|NCT05153915|DRUG|Tacrolimus granules|Oral
223883788|NCT05153915|DRUG|Tacrolimus granules|Oral
223883789|NCT05586737|DRUG|Rituximab|1 gram rituximab twice with two weeks interval
223883790|NCT06781203|BEHAVIORAL|Digitally delivered CBTI (eCBTI)|Based on the existing consensus concerning non-pharmacological treatment of insomnia, Hvil® includes the following treatment components: sleep hygiene, sleep optimization, stimulus control therapy, deactivation/relaxation training, and cognitive therapy. Intervention duration is approximately six to nine weeks.
223883791|NCT03237702|DIETARY_SUPPLEMENT|Multi-Carotenoids|All participants in the second stage will receive multi-carotenoids 30 mg qd for 8 weeks.
223883792|NCT06780514|DIAGNOSTIC_TEST|Cardiopulmonary exercise test|To our knowledge, this is the first study to perform CPET's in Turner Girls aged \<18 years
223883793|NCT05268094|DEVICE|Ductal Arterial Stent|Drug-eluting ductal arterial stents will be placed by transcatheter method.
223883794|NCT05268094|PROCEDURE|Systemic-to-Pulmonary Artery Shunt|A surgical connection will be made between a systemic artery and the pulmonary artery.
223883795|NCT06261346|PROCEDURE|Endothelial keratoplasty|"Surgical replacement of the corneal endothelial cell layer (the cell layer lining the inner surface of the cornea) with brief incubation of the donor tissue in PRGF prior to graft implantation. This incubation will be a one time procedure done to the tissue in the operating room.~The endothelial keratoplasty is 30-45 minutes."
223883796|NCT06261346|BIOLOGICAL|PRGF|"Plasma Rich in Growth Factors (PRGF) is a mixture of proteins and growth factors obtained from the blood of the patient.~PRGF incubation lasts 15 minutes. It is a one-time procedure performed on the tissue that will be done in the operating room prior to endothelial keratoplasty."
223883797|NCT06781658|OTHER|Structured rehabilitation intervention|Participants will be prescribed a multi-component SRI which will include education, cervical range of motion exercises, progressive neck strengthening exercises, individualised scapular and upper limb strengthening, task specific hand function training and a physical activity behavioural change intervention. The TIDieR checklist has been used to provide a comprehensive description of this complex intervention. (17).
223883798|NCT06781658|OTHER|Clinical Surveillance|Participants assigned to the clinical surveillance control group will be invited to attend a single, one to one education session which will be supplemented with a written patient information booklet after which they will be scheduled for a 12 week follow up.
223883799|NCT05709535|DIAGNOSTIC_TEST|[18F]-PSMA-1007|\[18F\]PSMA-1007 is a diagnostic radiopharmaceutical for Positron Emission Tomography (PET) scan. The intervention involves single intravenous administration of \[18F\]PSMA-1007 for PET scan.
223883800|NCT04578171|DRUG|Mepolizumab|100 mg subcutaneous injections every four weeks
223883801|NCT03992664|OTHER|Educational training program|"The training program will focus on four parameters: cleanliness, hydration, protection from external stimuli, and finally early detection of skin side effects.~The re-evaluation of the skin as well as the repetition of the questionnaires will be done every week for 4 weeks."
223883802|NCT03444701|DRUG|E7130|Starting dose of 25 μg/m\^2 on Day 1 and Day 15 of Cycle 1.
223883803|NCT03444701|DRUG|E7130|Starting dose is lower than one at which the first DLT was observed in the 2-week regimen administered on Day 1 of Cycle 1.
223883804|NCT05482789|DRUG|Exenatide|10 microgram injected sub-cutaneously once
223883805|NCT06139172|BEHAVIORAL|Functional Behavioral Training (FBT)|Function-based treatment (FBT) is a term for behavioral intervention approaches that use objective and systematic data collection to identify the cause of challenging behavior and teach a more prosocial replacement behavior. FBTslDD incorporates standard elements of FBT protocols with adaptations made specifically to support application to the syndromic IDD population. FBTslDD will include the following steps: (1) Syndromic IDD screening; (2) Stimulus preference assessment; (3) Indirect and descriptive assessments; (4) Screening for automatic function; (5) Functional analysis (FA); and (6) FBT intervention phase. If steps 1 - 5 determine a participant's challenging behavior serves a social function, Functional Communication Training (FCT) will be administered. If steps 1 - 5 determine a participant's challenging behavior serves an automatic function Competing Stimulus Treatment (CST) will be administered.
223883806|NCT06139172|OTHER|Positive Parenting Strategies-Treatment as Usual|Using the Planned Adaptation approach, to identify proactive adaptations seeking to improve the fit of FBTsIDD with the unique needs of the syndromic IDD population. Triangulating mixed methods data from systematic video observations, questionnaires, and qualitative interviews, then the Framework for Reporting Adaptations and Modifications-Expanded24 (FRAME) will be used to develop a rich understanding of these and any additional adaptations made to the intervention when delivered by non-specialist providers within medical hubs serving syndromic IDD populations.
223883807|NCT03793465|DIETARY_SUPPLEMENT|tart cherry concentrate|Consume 2 servings (1 ounce or 2 tablespoon/serving) per day for three days before cardiac surgery
223883808|NCT04272619|BEHAVIORAL|LIVE-R Life Education|A health educator will present participants with a 30-minute PowerPoint presentation containing educational information about liver cancer risk, screening, prevention, symptoms, and treatments, as well as introduce the concept of neighborhood health (e.g., rates of liver cancer and related risk factors in a census tract and how that might influence individual cancer risk).
223883809|NCT04495452|DRUG|Fentanyl Drug Administration|Subjects will be given a standardized dose of fentanyl 2.5 mcg/kg estimated ideal body weight (males: ideal body weight = 50 kg + 2.3 kg for each inch over 5 feet. Females: Ideal body weight = 45.5 kg + 2.3 kg for each inch over 5 feet).
223883810|NCT04496960|DRUG|tofacitinib|XELJANZ(R) is the citrate salt of tofacitinib. Tofacitinib citrate is a white to off-white powder with the following chemical name: (3R,4R)-4-methyl-3-(methyl-7H-pyrrolo \[2,3-d\]pyrimidin-4-ylamino) -beta-oxo-1-piperidinepropanenitrile, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) It is freely soluble in water and has a molecular weight of 504.5 Daltons. XELJANZ(R) is supplied for oral administration as 5 mg tofacitinib (equivalent to 8 mg tofacitinib citrate) white round, immediate-release film-coated tablet. Each tablet of XELJANZ(R) contains the appropriate amount of XELJANZ(R) as a citrate salt and the following inactive ingredients: microcrystalline cellulose, lactose monohydrate, croscarmellose sodium, magnesium stearate, HPMC 2910/Hypromellose 6cP, titanium dioxide, macrogol/PEG3350, and triacetin.
223883811|NCT04496960|OTHER|Placebo|white, round, film-coated tablet
223883812|NCT06844760|DEVICE|Hyaluronic Acid (HA)|Subjects will be treated with 2cc of Perleux body at baseline. After 4 weeks, a touch-up injection will be performed to achieve optimal improvement.
223883813|NCT03709134|DIAGNOSTIC_TEST|Genomic Markers (CTC/ctDNA)|This is a non-interventional study.
223883814|NCT03818191|DRUG|Acamprosate|The research pharmacy contracted for this study will randomize the study participants for all sites with placebo or acamprosate.
223883815|NCT03818191|OTHER|Placebo|The research pharmacy contracted for this study will randomize the study participants for all sites with placebo or acamprosate.
223883816|NCT04033055|PROCEDURE|Inguinal hernia repair with CycloMesh™ soaked in ropivacaine hydrochloride 10mg/mL|"The surgical technique for the inguinal hernia repair is the surgeon's usual technique: open surgery (Lichtenstein technique).~CycloMesh™ device (soaked in ropivacaine hydrochloride 10mg/mL) is positioned once the surgery for the inguinal hernia repair has been performed."
223883817|NCT04033055|PROCEDURE|Inguinal hernia repair with CycloMesh™ soaked in saline solution NaCl 9°/°°|"The surgical technique for the inguinal hernia repair is the surgeon's usual technique: open surgery (Lichtenstein technique).~CycloMesh™ device (soaked in saline solution) is positioned once the surgery for the inguinal hernia repair has been performed."
223883818|NCT06845956|OTHER|Is it coronary artery embolism|"This observational study categorizes patients with acute myocardial infarction (AMI) into three distinct groups based on their clinical characteristics:~1. Group 1: Patients with atrial fibrillation (AF) and coronary artery embolism (CAE).~2. Group 2: Patients with AF but non-coronary artery embolism myocardial infarction (non-CAE MI).~3. Group 3: Patients without AF and non-coronary artery embolism myocardial infarction (non-CAE MI without AF).~A key innovation of this study compared to previous research is its expanded eligibility criteria for AMI patients. Earlier studies typically focused exclusively on ST-segment elevation myocardial infarction (STEMI). In contrast, this investigation encompasses a broader spectrum of acute myocardial infarction, including both STEMI and non-ST-segment elevation myocardial infarction (NSTEMI). This comprehensive approach enhances the generalizability and applicability of the findings by capturing a wider range of clinical scenarios."
223883819|NCT05233527|PROCEDURE|Episiotomy Closure|indicated episiotomy with Novosyn® Quick after spontaneous vaginal delivery
223883820|NCT02945722|DRUG|Decolonization|Decolonization schedule associate the use of mupirocin nasal ointment 3 times a day and chlorhexidine bath once a day for 5 days. Screening of persistent carriers will be done every 3 months
223883821|NCT02945722|OTHER|No decolonization|Screening of persistent carriers in this arm will be done every 3 months
223883822|NCT06450704|OTHER|Physical Exercise|"Daily walking. Participants will be given an activity band to self-monitor the number of steps they walk each day during the 12-week intervention period. Each participant must reach a certain number of daily steps with a progressive goal adjusted to the number of steps from the previous week. The goal is set considering the superior number to the median of steps of the preceding week.~Weekly combined exercise sessions (aerobic + strength exercise) 2 sessions of 60 minutes per week in a 12-week program. The exercise intervention will combine the use of elastic bands and the body weight. First, 5 minutes of warm-up; second, training circuit with low-intensity strength exercises alternating work and rest times using rhythmic music. Upper, lower and middle body exercises will alternate. The program will progress in intensity, work: rest ratio, and technical difficulty of the exercises. At the end of the main part, there will be a cool-down and stretching for 5 minutes."
223883823|NCT04715399|OTHER|No intervention|No intervention
223883824|NCT05497453|DRUG|OTX-2002|OTX-2002 is a lipid nanoparticle (LNP) that contains a biscistronic mRNA that codes for 2 independent epigenomic controllers.
223883825|NCT05497453|DRUG|Tyrosine kinase inhibitor One|Tyrosine Kinase Inhibitor
223883826|NCT05497453|DRUG|Tyrosine kinase inhibitor Two|tyrosine kinase inhibitor
223883827|NCT05497453|DRUG|Checkpoint Inhibitor, Immune|monoclonal antibody that binds to PD-1 or PD-L1
223883828|NCT06133439|BEHAVIORAL|Colorectal Screen rates with implementation of evidence-based intervention|Mailed FIT kits, Cologuard, and diagnostic colonoscopies.
223883829|NCT05535257|DEVICE|Sequential Compression Device|Calf size lower extremity sequential compression device sleeve will be placed on the weak upper extremity blow the cubital fossa and may include the hand if necessary. The device will inflate and deflate.
223883830|NCT05037279|DRUG|Bacillus Calmette-Guerin: Strain Russian BCG-I|"* Induction: 80 mg weekly for 6 weeks.~* Maintenance for intermediate AUA risk patients will be for 3 weeks at 3, 6, and 12 months.~* Maintenance for high AUA risk patients will be for 3 weeks at 3, 6, 12, 18, 24, 30 and 36 months."
223883831|NCT05037279|DRUG|Bacillus Calmette-Guerin: Strain TICE|"* Induction: 50 mg weekly for 6 weeks.~* Maintenance for intermediate AUA risk patients will be for 3 weeks at 3, 6, and 12 months.~* Maintenance for high AUA risk patients will be for 3 weeks at 3, 6, 12, 18, 24, 30 and 36 months."
223883832|NCT06492694|DIETARY_SUPPLEMENT|Fish oil + wild orange essential oil supplement|This supplement contains fish oil and wild orange essential oil as its active ingredients.
223883833|NCT06492694|DIETARY_SUPPLEMENT|Fish oil supplement|This supplement contains fish oil as its active ingredient.
223883834|NCT05671185|DEVICE|Repetitive Transcranial Magnetic Stimulation|rTMS using Magstim TMS system is delivered at the left dorsolateral prefrontal cortex
223883835|NCT04720313|DRUG|NXC-201 (formerly HBI0101)|NXC-201 (formerly HBI0101) CART is defined as autologous T cells transduced ex-vivo with anti-BCMA CAR retroviral vector encoding the chimeric antigen receptor (CAR) targeted to human BCMA. The NXC-201 (formerly HBI0101) CART is provided fresh without cryopreservation.
223883836|NCT05142423|DRUG|AK109+AK104|It includes dose escalation and dose expansion stage. 6-12 patients will be enrolled in dose escalation stage for safety and efficacy. Then select specific dose of AK104 and AK109. Expand for the further safety and efficacy study.
223883837|NCT05328531|DRUG|Genakumab for Injection|150 mg/1ml/bottle
223883838|NCT05328531|DRUG|Placebo for Genakumab for Injection|The placebo contains other excipients except Genakumab, and its appearance is consistent with that of Genakumab for injection
223883839|NCT06146218|BEHAVIORAL|Contemplative-Based Resilience Training (CBRT)|The intervention is a 10-week program that will address mindfulness, compassion, social-emotional self-care, exposing stress-reactive habits, self-awareness, visualization, and deep breathing. The rationale for applying this mindfulness intervention to promote psychological resilience following the development of race-based traumatic symptoms is based on the notion that mindfulness promotes acceptance of complex thoughts and feelings, reduces rumination, and improves psychological function, cognitive flexibility, and coping processes.
223883840|NCT03468426|DRUG|BI 836880|intra-venous infusion
223883841|NCT03468426|DRUG|ezabenlimab|intra-venous infusion
223883842|NCT05119985|PROCEDURE|Peripheral vein cannulation|The target vein is directly identified by ultrasound, the procedure of peripheral venous catheter insertion is performed conventionally, without ultrasound guidance
223883843|NCT05119985|PROCEDURE|Cannulation without ultrasound|Cannulation is done the conventional way without any ultrasound use.
223883844|NCT06267742|DIAGNOSTIC_TEST|Complete Blood Count (CBC) with Differential|CBC with Differential including Monocyte Distribution Width (MDW)
223883845|NCT01707030|OTHER|Web-Based Brief Alcohol Intervention|Participants report their alcohol use and problems on line and receive feedback comparing them to national norms.
223883846|NCT01707030|OTHER|Usual Care|All patients will be receiving care in a Hepatitis C clinic. In some cases clinicians may counsel them on alcohol problems.
223883847|NCT04827420|BEHAVIORAL|Mi Quit Care|Demonstrating the feasibility, effectiveness, and cost-effectiveness of electronically delivered smoking cessation interventions via patient portals in Federally Qualified Health Care (FQHC) settings has the potential for wide-spread dissemination and significant public health impact. on patient populations with demonstrated high rates of smoking.
223883848|NCT04820855|BEHAVIORAL|Treatment|This is the treatment program devised win conjunction with a pelvic floor physical therapist. It is a daily yoga series and mindfulness with a Smartphone app.
223883849|NCT04820855|OTHER|Usual Cares|This is standard treatment for Interstitial cystitis with your provider.
223883850|NCT06530407|OTHER|Static streching exercise|Static stretching exercises were applied to the M. Gastrocnemious and M. Hamstring muscle groups for both groups. The exercises were applied as a set, with three repetitions for 15 seconds on each leg, with a 20-second rest between repetitions. Static stretching was applied by slowly stretching the relevant muscle group to the point of sensitivity, without straining the pain threshold, and waiting in that position. All stretching exercises lasted an average of 6 minutes.
223883851|NCT05065944|BEHAVIORAL|Telemedicine|Pre-anesthesia assessment (history and physical examination) via telemedicine. Intervention is a one-time telemedicine clinic visit for approximately 30 minutes to 1 hour. Individual patients will be randomized to telemedicine and that visit will be scheduled via the Zoom video conferencing platform.
223883852|NCT05065944|BEHAVIORAL|In Person Visit|Pre-anesthesia assessment (history and physical examination) in person at Moffitt Cancer Center (usual care)
223883853|NCT04179149|BEHAVIORAL|Environmental enrichment|The experimental group will participate in six modules that mimic and integrate the three hallmarks of environmental enrichment: social interaction (more animals per cage = support group meetings, online support), novelty (toys and activities = exposure to new hands-on activities), and larger enclosures (larger cages = meetings in open environments). There will be 2 interventions per month, for three months, and a follow up 3 months after the end of the intervention
223883854|NCT04260230|DEVICE|Lifetemp/Lifetouch sensors|Wearing the devices for six weeks. Data only reviewed retrospectively.
223883855|NCT05713734|DIAGNOSTIC_TEST|Thrombin generation|Measurement of thrombin generation by ST Genesia
223883856|NCT05713734|DIAGNOSTIC_TEST|Fibrinolysis|Measurement of fibrinolysis by Lysis Timer
223883857|NCT05713734|DIAGNOSTIC_TEST|Fibrin clot structure|Measurement of fibrin polymerisation and permeability
223883858|NCT05713734|DIAGNOSTIC_TEST|Coated platelets|Measurement of coated platelets by flow cytometry
223883859|NCT04816149|BEHAVIORAL|VA Standard Suicide Intervention|Our active control condition is standardized and contains the elements of standard practice suicide-specific intervention delivered at the VA, which include: 1) suicide risk assessment using the CSSR-S, 2) VA Safety Planning Intervention, 3) timely referral to VA mental health outpatient care, including couples intervention (engagement will be tracked), and 4) Suicide Prevention Coordinator (SPC) follow-up contacts (which have been found to significantly reduce suicidal behavior).
223883860|NCT04816149|BEHAVIORAL|Treatment for Relationships and Safety Together (TR&ST)|TR\&ST consists of eleven 90-minute sessions delivered in three phases. During phase one, couples receive a tailored cognitive-behavioral conceptualization of suicide and relationship distress based on clinical interview, as well as psychoeducation about their bidirectional influences. They also engage in behavioral activation focused on positive couple activities, emotion regulation, distress tolerance, and conflict management strategies. In phase two, couples learn communication skills and discuss suicidal thoughts and behaviors, as well as their relationship challenges that interact with suicidal thoughts and behavior. Phase three is focused on conjoint thought challenging to shift dysfunctional cognitions related to suicide and relationship problems.
223883861|NCT04618016|DEVICE|UHMWPE with Vitamin E|e.motion Pro (PS and UC) with MXE gliding surface
223883862|NCT04618016|DEVICE|UHMWPE without Vitamin E|e.motion Pro (PS and UC) with β-PE gliding surface
223883863|NCT06347471|DRUG|Artemether-lumefantrine|Participants in the Artemether-Lumefantrine arm will be treated with standard doses of AL (Coartem, Novartis). Tablets containing 20/80 mg artemether and 120/480 mg lumefantrine will be administered per manufacturer guidelines. All doses will be given under direct supervision with fatty food.
223883864|NCT06347471|DRUG|Dihydroartemisinin-Piperaquine|Participants in the DHA-PPQ arm will be treated with standard doses of DHA-PPQ. Tablets containing 40 mg dihydroartemisinin/320 mg piperaquine tablets (Eurartesim, Sigma Tau or Duocotecxin, Beijing Holley-Cotect Pharmaceutical Co) will be administered per manufacturer guidelines. All doses will be given under direct supervision on an empty stomach, as per manufacturer instructions.
223883865|NCT03724851|DRUG|TEW-7197|"Vactosertib will be administered orally without regard to meals for 5 days per week (5D/W) at the same time in the morning (QD), at the same time in the morning and evening (BID) approximately 12 hours apart.~Pembrolizumab will be administered as a dose of 200 mg using a 30-minute IV infusion. Sites should make every effort to target infusion timing to be as close to 30 minutes as possible."
223883866|NCT06153888|PROCEDURE|Ultrafiltration rate|Fluid removal during HD will be linear. The time on HD for fluid removal is adjusted after a formula for interdialytic weight gain / removal time (see Goto et al 2023).
223883867|NCT06625489|DRUG|Part A: Placebo|Placebo will be administered.
223883868|NCT06625489|DRUG|Nintedanib|Nintedanib will be administered.
223883869|NCT06625489|DRUG|GSK3915393|GSK3915393 will be administered.
223883870|NCT05244915|OTHER|Experimental (Delphi Surveys)|The Delphi method, a process used to arrive at a group opinion or decision by surveying a panel of experts, will be used with experts in geriatric oncology to develop a supportive care management intervention for older caregivers of older adults with cancer.
223883871|NCT05244915|OTHER|Experimental (Focus Groups)|Focus group qualitative interviews will be conducted with key stakeholders consisting of older adults with cancer and their caregivers.
223883872|NCT05244915|OTHER|Qualitative interviews|Qualitative interviews will be conducted with older caregivers of older adults with cancer to inquire about their experience with caregiving and unmet supportive care needs.
223883873|NCT06739421|PROCEDURE|nCLE-NB-rEBUS-forcep biopsy|The participants would undergo lung biopsy using forcep, under the guidance of bronchoscopic needle-based confocal laser endomicroscopy (nCLE) with the assistance of navigation bronchoscopy (NB) and radial endobronchial ultrasound (rEBUS)
223883874|NCT06739421|PROCEDURE|nCLE-NB-rEBUS-TBCB|The participants would undergo transbronchial crybiopsy (TBCB), under the guidance of bronchoscopic needle-based confocal laser endomicroscopy (nCLE) with the assistance of navigation bronchoscopy (NB) and radial endobronchial ultrasound (rEBUS)
223883875|NCT06739421|PROCEDURE|NB-rEBUS-forcep biopsy|The participants would undergo lung biopsy using forcep, under the guidance of navigation bronchoscopy (NB) and radial endobronchial ultrasound (rEBUS)
223883876|NCT06739421|PROCEDURE|NB-rEBUS-TBCB|The participants would undergo transbronchial crybiopsy (TBCB), under the guidance of navigation bronchoscopy (NB) and radial endobronchial ultrasound (rEBUS)
223883877|NCT06771687|BEHAVIORAL|High intensity interval training|A 12-week high intensity interval training program, with 30 minutes of exercise three times a week. The trainings can be completed at home and will be digitally supervised.
223883878|NCT02305147|OTHER|Clinical, biological and imaging followup|Assessment of motor and non motor signs every 12 months. Imaging and blood, cerebral fluid, stools and skin samples for identification of biomarkers of disease phenotype and progression.
223883879|NCT05573945|BEHAVIORAL|Family Education and Active Listening|Bedside intervention directly with infant with trained healthcare providers and parents. Includes family education meetings completed with individual infant parent/s and trained operator. In addition, weekly meetings of parent/s with a psychologist in a private location for an active listening counselling session.
223883880|NCT05573945|BEHAVIORAL|Family Education|Bedside intervention directly with infant with trained healthcare providers and parents. Includes family education meetings completed with individual infant parent/s and trained operator.
223883881|NCT04249713|DRUG|Brodalumab|Interleukin 17 Receptor A Antagonist
223883882|NCT06637163|DRUG|Benmelstobart+ Paclitaxel + Carboplatin+ Radiotherapy|Benmelstobart: 1200 mg, i.v.gtt , d1, 22; Paclitaxel 50mg/m2, i.v.gtt , d1, 8, 15, 22, 29; Carboplatin AUC 2 mg/mL per minute, i.v.gtt , d1, 8, 15, 22, 29; Radiotherapy 41.4 Gy in 23 fractions, 5 days per week(If the number of patients achieving pCR in this group is ≥ 18 with the first 30 patients enrolled, the subsequent 20 patients will receive a reduced dose of 36 Gy in 20 fractions, 5 days per week.)
223883883|NCT06637163|DRUG|Paclitaxel + Carboplatin + Radiotherapy|Paclitaxel 50mg/m2, i.v.gtt , d1, 8, 15, 22, 29; Carboplatin AUC 2 mg/mL per minute, i.v.gtt , d1, 8, 15, 22, 29; Radiotherapy 41.4 Gy in 23 fractions, 5 days per week
223883884|NCT04807738|DEVICE|"Neuroproprioceptive facilitation and inhibition in virtual reality"|"The outpatients will be randomized into groups: Individual neuroproprioceptive facilitation and inhibition physical therapy combining key principles of proprioceptive neuromuscular facilitation (PNF) and motor program activating therapy (MPAT) in a real environment and the second arm, the same therapy in virtual reality environment. All participants will undergo 15 sessions, 60 minutes each, twice a week in a period of two months.~The therapy in the interventional group, uses virtual reality and the new software that was developed specifically for inducing and motivating for movement according to principles of proprioceptive neuromuscular facilitation (PNF) and motor program activating therapy (MPAT). The software allows immediate feedback and moreover, movement is corrected by a present therapist. Evaluation of speed and performance quality might be extracted from the software of virtual reality."
223883885|NCT04807738|OTHER|"Neuroproprioceptive facilitation and inhibition"|The first arm of the study will undergo physical therapy with physiotherapeutic approach based on neurophysiological principles using proprioceptive neuromuscular facilitation (PNF) and motor program activating therapy (MPAT) approaches. MPAT makes use of particular motor patterns that evolve in postural control development. The repetition of activated programs, a set of stimuli, applied to change the posture with anatomical centration of the joint under various conditions in leading to better support of postural stabilization while seated, while getting up, stepping forward, and standing, in order to teach the patients to use the acquired motor skills automatically in daily life. PNF is a method used for learning effective movement patterns with high biomechanical effectiveness based on repetitive stimulation of cooperating alfa-motoneurons and proprioceptors in muscle, tendons and joint capsules. Therapy will be individualized and led in the standard face-to-face regiment.
223883886|NCT06001177|DRUG|KAN-101|Dose KAN-101 Intravenous (IV) Infusion
223883887|NCT06001177|DRUG|Placebo|Placebo Intravenous (IV) Infusion
223883888|NCT06071221|BEHAVIORAL|Living Healthy educational program + peer coaching|The Living Healthy intervention is an 8-session health education program with cognitive behavioral training (CBT) techniques. For those in the interventional arm, the Living Healthy intervention program will be delivered by trained peer coaches by telephone or Zoom over 3 months. In this study, trained peer coaches are trained home health aides themselves. Informed by social cognitive theory (SCT), peer coaches train participants on cognitive behavior techniques and empower participants to adopt positive health behaviors through personalized goal setting, motivational interviewing, and peer modeling. Each content-based session incorporates principles of CBT, teaching participants to recognize and modify negative thinking and modifying outcome expectations through self-monitoring, reflection, and practice.
223883889|NCT06071221|BEHAVIORAL|Living Healthy educational program|Participants assigned to receive health education alone will be asked to read health education (online; covering aspects of the Living Healthy program) which corresponds to a weekly topic about health. They will be called by a research assistant each week to prompt them to do this and answer any questions they might have about the materials.
223883890|NCT04678804|PROCEDURE|Mucogingival surgery for single recession coverage|"The control group will be treated with a coronally advanced flap with vertical incisions (CAF) associated to an autologous connective tissue graft. The graft will be harvested from the palate in the area apical to the gingival margin of the second molar with an epithelial-connective harvesting technique to obtain a connective graft of 1 mm in thickness.~Subsequently, the graft will be shaped in order to match height and width of the recipient site on the recession according to the technique proposed by Zucchelli in 2003. The test group will receive the same flap design with the same technique, then the porcine derived xenogeneic graft will be shaped in order to match height and width of the recipient site on the recession. In particular, the matrix will be reduced in thickness as suggested by the manufacturer to obtain a standardized thickness of 3 mm."
223883891|NCT05452239|DRUG|Eptinezumab|Solution for infusion
223883892|NCT05452239|DRUG|Placebo|Solution for infusion
223883893|NCT03705403|DRUG|Darleukin|The product name refers to the molecule structure, in fact, L19-IL2 is a recombinant fusion protein composed of two moieties: L19, a human monoclonal antibody fragment in the single chain Fv (scFv) format, bound via a flexible linker to IL2, the human cytokine Interleukin-2.
223883894|NCT03705403|RADIATION|Radiation|Radiotherapy
223883895|NCT06420115|DEVICE|different needle size for prostate biopsy|MRI Fusion Transperineal Prostate Biopsy
223883896|NCT05288439|DIAGNOSTIC_TEST|Resting-state functional connectivity MRI|participants will undergo functional MRI
223883897|NCT05288439|OTHER|Neurocognitive battery with quality-of-life assessment|Cognitive and quality of life assessments performed by a trained neuropsychologist
223883898|NCT02558972|DRUG|Northera (Droxidopa)|Study #1 -Supine monitoring is performed for 30 minutes before administration of a single 600mg oral dose of Northera or placebo assigned randomly, After 2 hours supine a 70 degree upright tilt will performed for 10 minutes. On another day, subjects previously given Northera will receive placebo and vice versa and studies repeated.
223883899|NCT02558972|DRUG|Placebo|Study #1 -Supine monitoring is performed for 30 minutes before administration of a single 600mg oral dose of Northera or placebo assigned randomly, After 2 hours supine a 70 degree upright tilt will performed for 10 minutes. On another day, subjects previously given Northera will receive placebo and vice versa and studies repeated.
223883900|NCT02558972|DRUG|Northera (Droxidopa)|Study #2 -Patients will randomized to receive Northera or placebo for two weeks after which they will return for instrumented tilt studies as in Study 1. Doses of Northera will be titrated upwards by 100mg/dose every 48 hours from a starting dose of 100mg three times a day to a maximum of 600mg three times a day. Doses will be reduced to the preceding dose if systolic BP\>140mmHg or diastolic BP\>80mmHg measured in the seated position at home using an automated ambulatory blood pressure cuff 2 hours after receiving an oral dose. Doses will also be reduced if supine BP measured with the head of the bed elevated upon awakening in the morning exceeds 150/90 mmHg. Following a 1 week wash out period, subjects will receive the alternative treatment for 2 additional weeks and instrumented laboratory studies repeated.
223883901|NCT02558972|DRUG|Placebo|Study #2 -Patients will randomized to receive Northera or placebo for two weeks after which they will return for instrumented tilt studies as in Study 1. Doses of Northera will be titrated upwards by 100mg/dose every 48 hours from a starting dose of 100mg three times a day to a maximum of 600mg three times a day. Doses will be reduced to the preceding dose if systolic BP\>140mmHg or diastolic BP\>80mmHg measured in the seated position at home using an automated ambulatory blood pressure cuff 2 hours after receiving an oral dose. Doses will also be reduced if supine BP measured with the head of the bed elevated upon awakening in the morning exceeds 150/90 mmHg. Following a 1 week wash out period, subjects will receive the alternative treatment for 2 additional weeks and instrumented laboratory studies repeated.
223883902|NCT04828590|OTHER|No intervention|Due to observational study
223883903|NCT03851367|PROCEDURE|Sling suspension using red cord|3 weeks duration, 15 sessions, and 30 minutes a day for five consecutive days a week. Back pain, endurance of trunk muscles (flexors, extensors and side flexors), and standing posture were evaluated pre and post interventions.
223883904|NCT03851367|PROCEDURE|Gym ball exercises|3 weeks duration, 15 sessions, and 30 minutes a day for five consecutive days a week. Back pain, endurance of trunk muscles (flexors, extensors and side flexors), and standing posture were evaluated pre and post interventions.
223883905|NCT02182479|DRUG|Berodual® via Respimat®, high dose|
223883906|NCT02182479|DRUG|Berodual® via Respimat®, low dose|
223883907|NCT02182479|DRUG|Berodual® via MDI, high dose|
223883908|NCT02182479|DRUG|Placebo Respimat®|
223883909|NCT02182479|DRUG|Placebo MDI|
223883910|NCT02217514|DRUG|Midazolam|
223883911|NCT02217514|DRUG|BI 44370 low dose|
223883912|NCT02217514|DRUG|BI 44370 medium dose|
223883913|NCT02217514|DRUG|BI 44370 high dose|
223883914|NCT03705741|BEHAVIORAL|Resistance exercise|Resistance exercise twice a week during pregnancy week 23-34.
223883915|NCT05638308|DIAGNOSTIC_TEST|FAZA PET/MRI scan|FAZA PET/MRI scan before the standard of care biopsy for case group
223883916|NCT02345720|DEVICE|etafilcon - PVP (multi-focal)|The investigational contact lens must be worn at least six hours daily.
223883917|NCT06239792|BEHAVIORAL|Sleep Promotion Program|SPP prioritizes increasing sleep duration and regularizing sleep-wake timing. The provider and youth review the youth's sleep pattern, based on sleep diary data collected before and during the program and actigraphy data collected at baseline. They discuss benefits to the current sleep pattern, reasons for changing sleep, and they create an action plan. Psychoeducation about healthy sleep is offered via a handout developed by our group. Youth and provider jointly select SPP strategies relevant to the contributors to poor sleep for each youth (e.g., time management, limiting weekend oversleep). In the second session they review progress and adjust the plan. Parents participate for part of each session to learn about their child's sleep and to discuss ways they can support their child to make the planned changes.
223883918|NCT05464810|DRUG|Letrozole|Given PO
223883919|NCT05464810|DRUG|Simvastatin|Given PO
223883920|NCT04216381|DIAGNOSTIC_TEST|Trauma Specific Frailty Index Questionnaire|questionnaire to assess patient's pre-injury health condition
223883921|NCT05562089|DEVICE|A Paclitaxel Drug-Coated Balloon|Size: 2.0mm-4.0mm x 15-30mm Coated drug: Prevail TM
223883922|NCT00084396|DRUG|letrozole|
223883923|NCT00084396|PROCEDURE|conventional surgery|
223883924|NCT02140645|DRUG|linagliptin|non-randomized
223883925|NCT00525954|DRUG|A-002|
223883926|NCT01494324|OTHER|CT guided percutaneous ablation|Depending on tumor size and location, we will direct a core biopsy needle in the ablated tumor using post-ablation dynamic Liver CT guidance, preferably including liver triphasic examination. The obtained tissue will be detached, collected and submitted to our molecular cytology laboratory. All specimens will be submitted fresh to our molecular cytology laboratory for immediate analysis in order to classify them as viable tumor (V) or apoptotic cells/coagulation necrosis (CN). CT will be performed within 24 hours of the ablation to demonstrate the ablation defect, representing the area of coagulation necrosis. This CT will be used for targeting the ablated tumor for biopsy. All patients will undergo CT again, approximately within 4-8 weeks (+/- 2 weeks) of percutaneous ablation to evaluate for CN in the target tumor or any sign of residual tissue enhancement, representing incomplete treatment.
223883927|NCT05269472|PROCEDURE|Trigeminal Electrophysiology|This study will pilot and test the feasibility of introducing electrophysiology into the routine rhizotomy procedure by including trigeminal somatosensory evoked potentials (TSEPs) and recording from electrodes at the level of the ganglion.
223883928|NCT01309932|BIOLOGICAL|Pegylated Interferon Lambda (pegIFNλ)|Solution, Subcutaneous, 180 μg/mL, Once weekly, 24 or 48 weeks depending on response
223883929|NCT01309932|DRUG|BMS-790052 (NS5A Inhibitor)|Tablets, Oral, 60 mg, Once daily, 24 weeks
223883930|NCT01309932|DRUG|Ribavirin (RBV)|Tablets, Oral, 1000 or 1200 mg based on weight, Twice daily, 48 weeks
223883931|NCT01309932|DRUG|BMS-650032 (NS3 Protease Inhibitor)|Tablets, Oral, 200 mg, Twice daily, 24 weeks
223883932|NCT01309932|BIOLOGICAL|Pegylated Interferon Alfa-2a (pegIFNα-2a)|Solution, Subcutaneous, 180 μg/mL, Once weekly, 48 weeks
223883933|NCT01309932|BIOLOGICAL|Pegylated Interferon Lambda (pegIFNλ)|Solution, Subcutaneous, 180 μg/mL, Once weekly, 24 weeks
223883934|NCT01309932|DRUG|Ribavirin (RBV)|Tablets, Oral, 1000 or 1200 mg based on weight, Twice daily, 24 weeks
223883935|NCT01309932|BIOLOGICAL|Pegylated Interferon Lambda (pegIFNλ)|Solution, Subcutaneous, 180 μg/mL, Once weekly, 16 weeks
223883936|NCT01309932|DRUG|Ribavirin (RBV)|Tablets, Oral, 1000 or 1200 mg based on weight, Twice daily, 16 weeks
223883937|NCT01309932|DRUG|BMS-790052 (NS5A Inhibitor)|Tablets, Oral, 60 mg, Once daily, 16 weeks
223883938|NCT01309932|DRUG|BMS-650032 (NS3 Protease Inhibitor)|Tablets, Oral, 200 mg, Twice daily, 16 weeks
223883939|NCT01309932|DRUG|Placebo (PBO) for BMS-650032 (Placebo for NS3 Protease Inhibitor)|Tablets, Oral, 0 mg, Twice daily, 24 weeks
223883940|NCT01309932|DRUG|Placebo (PBO) for BMS-790052 (Placebo for NS5A Inhibitor)|Tablets, Oral, 0 mg, Once daily, 24 weeks
223883941|NCT01309932|DRUG|Placebo for Ribavirin (RBV)|Tablets, Oral, 0 mg, Twice daily, 24 weeks
223883942|NCT01309932|DRUG|Placebo for Ribavirin (RBV)|Tablets, Oral, 0 mg, Twice daily, 16 weeks
223883943|NCT00531596|DRUG|EMSAM (Selegiline Transdermal System) 6mg/24Hr|EMSAM 6mg/24HR
223883944|NCT00531596|DRUG|EMSAM (Selegiline Transdermal System) 9mg/24Hr|EMSAM 9mg/24Hr
223883945|NCT00531596|DRUG|EMSAM (Selegiline Transdermal System) 12mg/24hr|EMSAM 12mg/24Hr
223883946|NCT01101451|DRUG|Cisplatin|Given IV
223883947|NCT01101451|RADIATION|External Beam Radiation Therapy|Undergo radiotherapy
223883948|NCT01101451|RADIATION|Intensity-Modulated Radiation Therapy|Undergo radiotherapy
223883949|NCT01101451|OTHER|Laboratory Biomarker Analysis|Correlative studies
223883950|NCT01101451|OTHER|Quality-of-Life Assessment|Ancillary studies
223883951|NCT01101451|OTHER|Questionnaire Administration|Ancillary studies
223883952|NCT05170620|PROCEDURE|laser ablation|Laser ablation will be done for the squamous intraepithelial lesions of the lower anogenital tracts.
223883953|NCT06852534|OTHER|Stimulus properties: salience-defining feature|The feature used to define a salient location will be varied across trials (checkerboard contrast; motion direction; color hue)
223883954|NCT06852534|OTHER|Stimulus properties: magnitude of salience|The magnitude of the salient location will be varied across trials independently from salience-defining feature (based on feature contrast)
223883955|NCT05386069|DRUG|NOMO Protocol|Standard weight-based ketamine bolus (0.5 mg/kg) at procedure start, no Opioid rescue medications
223883956|NCT06107751|OTHER|Ramped position group|This position will be achieved by elevation of the shoulders and the head elevation till achieving alignment of sternal notch and external auditory meatus
223883957|NCT06107751|OTHER|Sniffing position group|This position will be achieved by placing a 7 cm pillow under the occiput.
223883958|NCT04678895|DRUG|Naltrexone|Capsule with doses of 1.5mg, 3mg, and 4.5 mg to allow for drug titration. Capsules of different dosages will be indistinguishable to allow for maintenance of blinding.
223883959|NCT04678895|DRUG|Placebo|Naltrexone matched placebo capsule.
223883960|NCT06718569|DRUG|Biological or targeted synthetic DMARD|All biological or targeted synthetic DMARDs that are available for treatment of patients with inflammatory joint diseases
223883961|NCT06969053|BEHAVIORAL|Mindfulness Intervention Therapy plus Sleep Hygiene Education|Participants will receive a 6-week program combining Mindfulness Intervention Therapy (MIT) and Sleep Hygiene Education (SHE). MIT includes body scan, mindful breathing, breathing space exercises, mindful walking, sitting meditation, loving-kindness meditation, and development of a personalized mindfulness practice plan. Sessions are conducted daily for 50 minutes. SHE provides structured guidance on optimizing sleep schedules, bedroom environment, and reducing stimulants such as caffeine and alcohol.
223883962|NCT06969053|BEHAVIORAL|Sleep Hygiene Education|Participants will receive Sleep Hygiene Education (SHE) alone for 6 weeks. SHE involves education on maintaining consistent sleep schedules, creating a sleep-conducive environment, reducing stimulant use (e.g., caffeine, alcohol), and promoting healthy daily routines to improve sleep quality.
223883963|NCT06647238|OTHER|Pharmacist Intervention in lipid therapy|Pharmacist intervention may include but is not limited to prescribing (statins, ezetimibe, bempedoic acid, PCSK9 inhibitors, etc.), patient education, and medication access.
223883964|NCT04398745|DRUG|Belantamab mafodotin|Belantamab mafodotin will be provided as lyophilized powder which will be available as 100 milligrams per vial (mg/vial) in single-use vial for reconstitution. Lyophilized belantamab mafodotin will reconstituted using water for injection, dilute with normal 0.9 % saline before use.
223883965|NCT01472510|DRUG|Ranibizumab|A 0.5mg intravitreal injection of Ranibizumab will be administered to subjects. Subjects will receive 6 monthly consecutive ranibizumab injections. Study visits will be scheduled to occur every 28 days relative to the date of the first injection
223883966|NCT01472510|DRUG|Ranibizumab|A 0.5mg intravitreal injection of Ranibizumab will be administered to subjects. Subjects will receive 12 monthly consecutive ranibizumab injections. Study visits will be scheduled to occur every 28 days relative to the date of the first injection
223883967|NCT03647956|DRUG|Atezolizumab|Atezolizumab (trade name Tecentriq) is a fully humanized, engineered monoclonal antibody of IgG1 isotype against the protein programmed cell death-ligand 1 (PD-L1).
223883968|NCT03647956|DRUG|Bevacizumab|Bevacizumab is a recombinant humanized monoclonal antibody that blocks angiogenesis by inhibiting vascular endothelial growth factor A (VEGF-A).
223883969|NCT03647956|DRUG|Carboplatin|Carboplatin, sold under the trade name Paraplatin among others, is a chemotherapy medication used to treat a number of forms of cancer.
223883970|NCT03647956|DRUG|Pemetrexed|Pemetrexed (brand name Alimta) is a chemotherapy drug manufactured and marketed by Eli Lilly and Company. Its indications are the treatment of pleural mesothelioma and non-small cell lung cancer.
223883971|NCT02752659|PROCEDURE|Self-measured arm circumference, therapist-measured arm-circumference, perometer-measured arm circumference|
223883972|NCT05747196|DEVICE|WhiteSwell eLym System|The WhiteSwell eLym™ System is designed to treat congestion in Acute Decompensated Heart Failure (ADHF) patients. The device comprises two endovascular components, a Catheter and a Sheath, that are used in combination with a Console. The device is designed to create a low-pressure zone at the Thoracic Duct Outflow which is located adjacent to the venous angle (junction of the left subclavian vein and left internal jugular vein). This low-pressure region facilitates movement of fluid (lymph) from the interstitial compartment through the lymphatic system and the Thoracic Duct and into the intravascular space, while removal of fluids from the intravascular space is enabled using diuretic therapy. The treatment duration will be up to 72 hours.
223883973|NCT04814719|DRUG|Pentosan Polysulphate Sodium|Subcutaneous Injection (100mg/ml)
223883974|NCT04814719|DRUG|Placebo (Sodium Chloride Injection, 0.9%)|Placebo to match PPS
223883975|NCT02318901|DRUG|Pembrolizumab|
223883976|NCT02318901|DRUG|Trastuzumab|
223883977|NCT02318901|DRUG|ado-trastuzumab emtansine|
223883978|NCT02318901|DRUG|Cetuximab|
223883979|NCT01484353|BEHAVIORAL|Coronary Health Improvement Project Program|The Coronary Health Improvement Project' (CHIP; an intensive, community-based, lifestyle change program including a low saturated fat diet rich in whole, grown foods) has been shown to improve the health of diabetics through an intensive education taught over a 12 week period, but has not been studied in terms of its effect on HBAIC. Kaiser Permanente places significant resources into preventive medicine but does not have programs with the level of intensity of CHIP. This study aims to determine if Kaiser members with uncontrolled type 2 diabetes can achieve a significant improvement in their HBAIC after 12 weeks of participation in the CHIP program.
223883980|NCT02892214|PROCEDURE|Pelvic floor physical therapy|
223883981|NCT02892214|DRUG|estriol cream (ovestin)|
223883982|NCT02892214|PROCEDURE|Low-level-laser therapy|
223883983|NCT03898310|DIETARY_SUPPLEMENT|Cranberry extract capsules|Participants in the treatment arm will receive cranberry extract capsules.
223883984|NCT03898310|DIETARY_SUPPLEMENT|Placebo capsule|Participants in the placebo arm will receive placebo capsules.
223883985|NCT00252369|DRUG|Infliximab|
223883986|NCT00252369|PROCEDURE|Instillation of fibrin glue|
223883987|NCT00073749|DRUG|Inotuzumab ozogamicin [CMC-544]|CMC-544, IV, dose escalation trial
223883988|NCT06152276|OTHER|Diverting loop ileostomy|Diverting loop ileostomy following low anterior resection of colorectal cancer
223883989|NCT04414826|BEHAVIORAL|Mindfulness Alone (MO) Intervention|Participants will receive a one-session, hour-long telehealth intervention emphasizing awareness and non-reactivity skills.
223883990|NCT04414826|BEHAVIORAL|Mindfulness + Compassion Intervention (MC)|Participants will receive a one-session, hour-long telehealth intervention emphasizing awareness, non-reactivity, and compassion skills.
223883991|NCT00000969|DRUG|Zalcitabine|
223883992|NCT00000969|DRUG|Didanosine|
223883993|NCT05694442|OTHER|Lipmatte K|Lipmatte K contain ingredients that may hydrate and brighten the lip
223883994|NCT00611559|BIOLOGICAL|Infanrix™ penta|Subjects received a booster dose
223883995|NCT00611559|BIOLOGICAL|Infanrix™ hexa|Subjects received a booster dose
223883996|NCT04999592|DRUG|Standard of care without prophylaxis|Administer antibiotics in response to infection
223883997|NCT04999592|DRUG|Antibiotic prophylaxis|Ceftriaxone 2 gm IV q12h for 3 days
223883998|NCT01954836|BEHAVIORAL|initial fasting|modified fasting with daily caloric intake of \<400kcal by juices starting 36 to 48 h before begin of chemotherapy and lasting to 24 h after end of chemotherapy applied in the first half of scheduled 4 or 6 chemotherapy cycles
223883999|NCT01954836|BEHAVIORAL|Secondary fasting|modified fasting with daily caloric intake of \<400kcal by juices starting 36 to 48 h before begin of chemotherapy and lasting to 24 h after end of chemotherapy applied in the second half of scheduled 4 or 6 chemotherapy cycles
223884000|NCT03162497|DRUG|Azithromycin|Azithromycin 15mg/g eyedrops
223884001|NCT03162497|DRUG|Doxycycline|Doxycycline 100 mg per os
223884002|NCT04073953|DRUG|RPQ|The study will compare the individual enantiomers of Primaquine -R-(-)-PQ, S-(+)-PQ, and Placebo.
223884003|NCT04073953|DRUG|SPQ|The study will compare the individual enantiomers of Primaquine -R-(-)-PQ, S-(+)-PQ, and Placebo.
223884004|NCT04073953|DRUG|Placebo|The study will compare the individual enantiomers of Primaquine -R-(-)-PQ, S-(+)-PQ, and Placebo.
223884005|NCT04095104|DRUG|Phentermine|Phentermine tablet
223884006|NCT04095104|DRUG|Immediate Release Topiramate|Topiramate tablet
223884007|NCT04095104|DRUG|Placebo for Phentermine|Compounded tablet to mimic phentermine 8mg tablet
223884008|NCT04095104|DRUG|Placebo for Immediate Release Topiramate|Compounded tablet to mimic immediate release topiramate 25mg tablet
223884009|NCT04277936|DRUG|Levetiracetam 500 mg|Levetiracetam (LEV) regulates neuronal synaptic exocytosis and calcium-induced neurotransmitter release and has a therapeutic effect on the excitation-inhibition balance of the hippocampus.
223884010|NCT01467375|DRUG|biphasic insulin aspart|Individually adjusted dose, injected s.c. (under the skin) before breakfast and dinner
223884011|NCT02709850|DRUG|IONIS ANGPTL3-LRx|
223884012|NCT02709850|DRUG|Placebo|0.9%NaCl, water, riboflavin
223884013|NCT00197613|DRUG|(A) zidovudine, lamivudine and nevirapine|
223884014|NCT00197613|DRUG|(B) zidovudine, lamivudine and efavirenz|
223884015|NCT00197613|DRUG|(C) zidovudine, didanosine, and nevirapine|
223884016|NCT00197613|DRUG|(D) zidovudine, didanosine, and efavirenz|
223884017|NCT00197613|DRUG|(E) stavudine, lamivudine, and nevirapine|
223884018|NCT00197613|DRUG|(F) stavudine, lamivudine and efavirenz|
223884019|NCT00197613|PROCEDURE|Adherence Strategy Standard of Care (SOC)|
223884020|NCT00197613|PROCEDURE|Adherence Strategy Community-Based DOT|
223884021|NCT04850768|OTHER|Saliva|"individuals' saliva samples will be collected and transferred to eppendorf tubes.~Until biochemical analysis is carried out will be stored in -80ºC."
223884022|NCT04850768|OTHER|gingival crevicular fluid|GCF samples of individuals will be collected by paper strips and transferred to eppendorf tubes.Until biochemical analysis is carried out will be stored in -80ºC.
223884023|NCT02160951|DRUG|LGH447|LGH447, QD
223884024|NCT00809497|DRUG|Propionyl-L-carnitine Tablets|500mg tablets, oral administration of 2g daily
223884025|NCT06423534|BEHAVIORAL|Breastfeeding Health Educational Program|Breastfeeding is a mother's priceless gift to her infant and nature's own method of nurturing a baby. Therefore, this study will be conducted to evaluate the primigravida mother's breastfeeding's knowledge, attitude and corrective technique through the implementation of an educational program and to ascertain the efficacy of such a program.
223884026|NCT05845177|PROCEDURE|Primary Total Hip Arthroplasty|All patients surveyed have undergone primary total hip arthroplasty approximately 1 year prior to survey distribution
223884027|NCT03912831|DRUG|KITE-439|A single infusion of E7 TCR T cells (KITE-439).
223884028|NCT03912831|DRUG|Cyclophosphamide|Administered intravenously.
223884029|NCT03912831|DRUG|Fludarabine|Administered intravenously.
223884030|NCT03912831|DRUG|Interleukin-2|Administered subcutaneously.
223884031|NCT05916001|OTHER|Placebo|A Placebo will be administered per os 3 times per day for 10 days before colorectal surgery
223884032|NCT05916001|DIETARY_SUPPLEMENT|Oral Impact Nestle|Oral Impact Nestle will be administered per os 3 times per day for 10 days before colorectal surgery
223884033|NCT05916001|PROCEDURE|Colorectal surgery|Colorectal surgery will include right colectomy, left colectomy, transverse colectomy, anterior rectal resection. All procedures will be performed according to the standard clinical practice.
223884034|NCT04756440|BEHAVIORAL|Education Program and Music Therapy|After the intervention, it is expected that their awareness of Romana cervical cancer will increase, their perception of obstacle towards screening tests will decrease and they will be tested.
223884035|NCT05838469|OTHER|Pediatric Strip Crown and High Viscosity Glass Ionomer Cement|"Following the decision on the appropriate size of celluloid strip crown, the tooth will be isolated using roll cottons and the cavity conditioner (GC, Japan) will be applied to all surfaces for 10 seconds, washed away and dried with cotton pellets. The selected celluloid strip crown will be filled with a fluoride-releasing bulk fill hybrid glass ionomer cement (EQUIA Forte, GC, Japan) prepared by mixing for 10 seconds in an automatic mixer and placed on the tooth with light pressure. The excess material on the crown margins will be removed with a hand instrument, and the celluloid strip crown will be removed from the tooth. If necessary, the restoration will be polished using a polishing discs. After the crown surface is washed and dried, a nano-filled surface sealant (EQUIA Forte Coat, GC, Tokyo, Japan) will be applied for 10 seconds with a micro-tipped applicator and light cured for 20 seconds."
223884036|NCT03242148|DEVICE|Toffee Nasal Pillows Mask|Participants will be placed on this intervention for a total 14 ± 5 days from Visit 2. Participants will be using the Toffee nasal pillows mask during this treatment arm.
223884037|NCT03767517|OTHER|Active Intervention|Half of the patients will receive tele-consult program. Tele-consult intervention includes: initial consult and 2 follow up contacts. Usual care includes assessment and treatment by the admitting physician, along with any subspecialists that are consulted.
223884038|NCT03767517|OTHER|Usual Care|Half of the patients will receive usual care. Usual care includes assessment and treatment by the admitting physician, along with any subspecialists that are consulted.
223884039|NCT06986850|DEVICE|FeelSync mobile application|Ecological Momentary Intervention focused on cognitive reappraisal for distressing autobiographical memories, with a possibility to choose between distancing and positive reappraisal.
223884040|NCT06986850|DEVICE|Ecological Momentary Assessment mobile application|Ecological Momentary Assessment used for self-monitoring of emotional states.
223884041|NCT06987279|DIETARY_SUPPLEMENT|Probiotic|The trial period of this study is 3 months, and each patient will undergo 4 visits (in month 0, month 1, month 2, and month 3).
223884042|NCT06987279|DIETARY_SUPPLEMENT|Maltodextrin|The trial period of this study is 3 months, and each patient will undergo 4 visits (in month 0, month 1, month 2, and month 3).
223884043|NCT06987721|DEVICE|Modus ESWT-Focused|In accordance with the literature, the ESWT adjustment is made as 1500 pulses, 0.056 mj/mm, 6 Hz for focused applications. All applications were done with the same device; Modus ESWT.
223884044|NCT06987721|DEVICE|Modus ESWT-Radial|In accordance with the literature, the ESWT adjustment is made as 1500 pulses, 0.1 mj/mm, 10-16 Hz for radial applications. All applications were done with the same device; Modus ESWT.
223884045|NCT06987721|DEVICE|Modus ESWT-Sham|The sham application was made in such a way that the device was set to 0 frequency and power, making only sound. All applications were done with the same device; Modus ESWT.
223884046|NCT06987552|DEVICE|Da Vinci SP Surgical System|Da Vinci SP Surgical System
223884047|NCT06987188|OTHER|Modified Pilate Exercises|Modified Pilates exercises are gentle adaptations of traditional Pilates movements, designed to accommodate various fitness levels, physical limitations, or specific health conditions. These exercises focus on core strength, flexibility, posture, and controlled breathing while reducing strain on joints and muscles. Often recommended for beginners, seniors, or individuals recovering from injury or surgery, modified Pilates may involve the use of props like pillows, resistance bands, or chairs to support proper alignment and ease of movement. By emphasizing slow, mindful motions and personalized adjustments, modified Pilates helps individuals safely build strength, improve mobility, and enhance overall body awareness without the risk of overexertion.
223884048|NCT06987188|OTHER|General Physiotherapy Plan|A general physiotherapy plan for improving trunk control and balance focuses on enhancing core stability, postural alignment, and coordinated movement through targeted exercises and functional activities. The plan typically begins with gentle activation of deep core muscles such as the transverse abdominis and pelvic floor, progressing to dynamic tasks that challenge balance and coordination, like seated weight shifts, bridging, and reaching tasks in various positions (sitting, kneeling, or standing). Balance training may include exercises on unstable surfaces, gait training, and proprioceptive activities to improve body awareness and stability. The physiotherapy approach is individualized, gradually increasing in complexity and intensity as the patient gains strength and confidence, with consistent emphasis on proper technique, breathing, and safety to support overall mobility and independence.
223884049|NCT06988111|DEVICE|BIPAP|The second arm (NIV group) will be managed by BIPAP device for post-operative respiratory failure
223884050|NCT06988111|DEVICE|Vapotherm|The first arm (HVNC group) will be managed by Vapotherm device for post-operative respiratory failure
223884051|NCT06988293|PROCEDURE|inguinal hernia repair|İnguinal hernia repair quality of life index
223884052|NCT06987565|DEVICE|Active vagus nerve stimulation|Patients will receive transcutaneous stimulation of the vagus nerve for 5 minutes daily for 28 consecutive days. The device is a handheld electrical pulse generator and a pair of electrodes will be placed on the skin for stimulation. The electrical pulse generator is turned on and the amplitude of stimulation increased to the greatest amount tolerated. Patients will be followed through day 57 to assess durability of the intervention.
223884053|NCT06987565|DEVICE|Sham vagus nerve stimulation|Patients will receive transcutaneous stimulation of the vagus nerve for 5 minutes daily for 28 consecutive days. The device is a handheld electrical pulse generator and a pair of electrodes will be placed on the skin for stimulation. The electrical pulse generator is turned on and the amplitude of stimulation increased to the greatest amount tolerated, however, the vagus nerve will not be stimulated. Patients will be followed through day 57 to assess durability of the intervention.
223884054|NCT06823856|DRUG|Empagliflozin + Metformin hydrochloride 12.5 mg/1000 mg combination film-coated tablets|1 tablet of Empagliflozin + Metformin hydrochloride 12.5 mg/1000 mg combination film-coated table
223884055|NCT06823856|DRUG|Synjardy 12.5 mg/1000 mg film-coated tablets|1 tablet of Empagliflozin+Metformin 12.5 mg/1000 mg filmcoated tablets
223884056|NCT06987994|OTHER|control group( physical therapy)|"Participants will receive conventional physiotherapy 3 times per week for 4 weeks. The treatment includes:~Standing exercises: multidirectional stepping, single- and double-leg stance~Walking exercises: forward, backward, and lateral walking~Weight-shifting exercises: lunges, half-squats, leaning, and reaching"
223884057|NCT06987994|OTHER|Experemental group|In this group the number of Participants are 15 . The experment by using VR sessions will last 30 minutes per session, 3 times per week for 4 weeks . In addition to the same physiotherapy program used in the control group, this group will receive Virtual Reality (VR) training using a Meta Quest 2 headset . Patients will interact with immersive environments designed to stimulate movement and functional tasks.
223884058|NCT03164486|DRUG|18F-αvβ6-BP|Subjects will be injected once with up to 10 mCi of 18F-αvβ6-BP as a rapid intravenous bolus (within 30 seconds).
223884059|NCT05358925|OTHER|Psychoeducational Videos|"A total of ten videos will be delivered daily Monday-Friday over approximately 2 weeks (days 1-15). The videos will each feature a mental health professional who is an expert in BPD explaining the topic in relatable language that can be understood by the general public. Each video will be approximately 4-10 minutes long, for a total of \~72 minutes of video. Videos will be shared via a hyperlink in a text message.~The psychoeducational videos will cover the following topics: symptoms, basic factors about BPD, the naturalistic long term course of BPD, prevalence of BPD and its common comorbid disorders, key principles for recovery, available psychotherapeutic treatment options for BPD, common factors amongst treatments, medications, the interpersonal hypersensitivity model of BPD, and a review of the top 10 tips."
223884060|NCT05358925|OTHER|Neuropsychological Feedback|In the second phase of the study, participants randomized to the Feedback condition will receive an email with a personalized summary of their symptom endorsement and neuropsychological performance. The feedback will include the relevant scores or sub-scores for each cognitive test (CPT, RMET, BEST, DST) from the first two time points. For each score and sub-score, there will be a description of the cognitive domain that the metric assesses (e.g., attention span in the CPT). The investigators will tailor the feedback to each participant's scores. The investigators may adjust the format or wording of the feedback based on participant responses (i.e., if a participant alerts the investigators that some wording is unclear or confusing). The investigators may also alter the feedback if they learn new information about the relevance or interpretability of these cognitive tests, as this is a growing field of research.
223884061|NCT05358925|OTHER|Non-BPD-related Educational Videos|The non-BPD-related educational videos will be matched in length and frequency to the BPD-related videos. These videos will discuss aspects of mental and physical health that are not related to BPD. Examples may include: nutrition and healthy eating, coping, self-compassion and self-care, stress and anxiety, depression, and healthy sleep habits.
223884062|NCT06988436|DIAGNOSTIC_TEST|Ultrasound|All the participants were scanned using B mode sonography to determine the fetal biometric parameters (BPD, HC, AC and FL). The machine automatically calculated the estimated fetal weight using the Headlock formula. umbilical artery pulsatility index (UAPI) and pulmonary vein pulsatility index (PVPI) were measured in the study
223884063|NCT06988475|DRUG|Capmatinib|Patients will be administered capmatinib orally at a daily dose of 800 mg consisting of 400 mg (two 200mg tablets) twice daily. Each cycle of treatment will consist of 28 days and patients may continue on treatment until disease progression without clinical benefit, unacceptable toxicity or withdrawal of consent.
223884064|NCT06987227|BEHAVIORAL|Intelligent intervention to enhance parent-child connection|"The Intelligent Intervention to Enhance Parent-Child Connection support program is mainly carried out through web pages, Figma software, cloud files and official Line accounts. It can be divided into: the first stage is to provide parents with care knowledge and skills during the hospitalization of premature infants, provide parents with physical and mental support, and encourage parents to establish parent-child connections and prepare for discharge. The second stage is after discharge, continuing to provide premature infants' families with the care guidance needed to respond to the different stages of development of premature infants, including interpersonal support, sleep schedule establishment, crying comfort, premature infant nutrition and couple relationship management, etc., and continue to provide family support, answer questions and track its implementation status."
223884065|NCT06987227|OTHER|Routine care|Premature infants receive routine care during their hospitalization, and general nursing guidance for premature infant discharge care is provided before discharge.
223884066|NCT06987539|DRUG|Inebilizumab|Inebilizumab will be administered IV.
223884067|NCT06987955|OTHER|Biocoat Pit and fissure sealant|Application of Biocoat
223884068|NCT06987955|OTHER|Fissurit FX Pit and fissure sealant|Application of Fissurit FX
223884069|NCT06988098|OTHER|application of deproteinization agents|Since there is no in vivo study in the literature evaluating the clinical success of the use of hypochlorous acid for deproteinization in fissure sealants, our planned study is the first in this regard.
223884070|NCT06988397|BEHAVIORAL|Physical activity after different type of meals|Standardized physical activity (walking) after consuming one of three meal types (vegetable-based, meat-based, dairy-based). Ultrasound of gastric volume will be performed at 3 and 6 hour between walking sessions.
223884071|NCT06986343|DEVICE|Hyrax|Children in this group are going to use only the Hyrax device.
223884072|NCT06986343|DEVICE|Hyrax and Uplocker Vacuum Device|Children in this group are going to use the Hyrax device and Up-Locker vacuum activator.
223884073|NCT06987214|BIOLOGICAL|REGEND001 Autologous Basal Layer Stem Cell Suspension|REGEND001 Autologous Basal Layer Stem Cell Suspension is an innovative cell therapy product designed for chronic structural lung diseases, such as bronchiectasis. This treatment involves harvesting regenerative stem cells (expressing KRT5/P63 markers) from the patient's own bronchial basal layer via fiberoptic bronchoscopy. After isolation, purification, and ex vivo expansion, the cells are administered as a suspension through bronchoscopic infusion into damaged lung segments.
223884074|NCT06863337|DEVICE|CGM|"Each patient will participate in the group only once and wear two FreeStyle Libre Pro Flash CGM (Abbott Diabetes Care, Alameda, CA, USA), which record glucose readings for up to 14 days.~Following the initial consultation and before initiating the ovulation induction protocol, the first CGM sensor will be placed to collect baseline data. Upon entering the ovulation induction cycle, patients will return to the hospital on the 2nd or 3rd day of menstruation, at which point the first CGM sensor will be removed, and the second sensor will be applied. This second sensor will be removed after 14 days.~In summary, this protocol ensures continuous tracking of blood glucose levels at key time points throughout the ovarian stimulation."
223884075|NCT06856551|BEHAVIORAL|Minimal contact control|Participants in the control group received a pamphlet about general dietary and physical activity guidelines.
223884076|NCT06856551|BEHAVIORAL|Promotion and Prevention Interventions|regulatory focus groups, participants completed a 1-hour educational information session with study staff and received a packet which contained information about energy balance, healthy food choices, exercise recommendations, strategies for weight control, goal setting, and responding to lapses. Participants were encouraged to track their food intake and exercise with a provided log book or free apps (Lose It!; MyFitnessPal). The informational content and intervention procedures were identical except for the framing of messages and tasks. The prevention messages emphasized protecting one's health (e.g., failing to regularly exercise can undermine your weight control program and lead to poor health; if you do not vigilantly follow these behaviors, you will not fulfill your weight control goals or protect your health and well-being; not eating fruits and vegetables results in failure to supply the body with the nutrients it needs). The promotion messages emphasized promoting one's health
223884077|NCT06864468|BEHAVIORAL|Health promotion curricula|3-day summer camp and 9-month health promotion curriculum that focuses on physical activity and nutrition
223884078|NCT00068198|BIOLOGICAL|Dryvax|
223884079|NCT06677424|DEVICE|NeuroCatch® Platform 2|The NeuroCatch® Platform 2, a medical device system developed by NeuroCatch Inc., consists of software and hardware that captures brain health information. The platform intends to provide a quick, portable and easy to use solution for the acquisition, display, analysis, storage, reporting and management of electroencephalograph (EEG) and event-related potential (ERP; brain response to a stimulus) information. The device is approved as a medical device by Health Canada.
223884080|NCT06679959|DRUG|ASC30 Injection, for subcutaneous use or placebo|Drug: ASC30 injection, for subcutaneous use Drug: Placebo injection, for subcutaneous use
223884081|NCT04150887|DRUG|Cusatuzumab|Cusatuzumab will be administered as a dose of 10mg/kg or 20mg/kg intravenously.
223884082|NCT04150887|DRUG|Azacitidine|Azacitidine will be administered 75 mg/m\^2 subcutaneously or intravenously.
223884083|NCT04150887|DRUG|Venetoclax|Venetoclax will be administered orally and the dose will ramp-up to 400 mg.
223884084|NCT06188091|BEHAVIORAL|Exercise|Physiotherapeutic instructions to patients to do active exercise to improve the mobility of knee joint post-surgical
223884085|NCT05924256|DRUG|SHR-A1811|SHR-A1811
223884086|NCT05924256|DRUG|SHR 3680 + leuprolide|SHR 3680 + leuprolide
223884087|NCT05924256|DRUG|SHR-A1921|SHR-A1921
223884088|NCT05924256|DRUG|SHR-A1811|SHR-A1811
223884089|NCT06870175|DEVICE|Electronic-Textile-based Electrocardiographic Monitoring|Participants will be invited to wear the Skiin chest band for up to 14 days, as prescribed by their physician. Participants will wear the Skiin chest band in a similar capacity to a conventional Holter monitor.
223884090|NCT01837927|DRUG|NVA237|Once daily for 52 weeks
223884091|NCT01837927|DRUG|Tiotropium Respimat®|Once daily for 52 weeks
223884092|NCT02619786|DRUG|Inhaled colistin|75 mg of colistin activity, inhaled per dose, every 12 hours
223884093|NCT06699680|DRUG|PRX019|Specified dose on specified days
223884094|NCT06699680|DRUG|Placebo|Placebo
223884095|NCT06878417|DRUG|CBD|The starting dose will be 1 capsule per day (50 mg CBD) taken orally. The dose will be gradually increased over the first four weeks, based on patient assessment, up to a maximum of five capsules per day (250 mg CBD) in divided doses. Once the dose that maximizes potential therapeutic effects while minimizing adverse effects has been determined, it will be maintained for the remaining four weeks of the trial.
223884096|NCT06878417|DRUG|THC|The starting dose will be 1 capsule per day (3 mg THC) taken orally. The dose will be gradually increased over the first four weeks, based on patient assessment, up to a maximum of five capsules per day (15 mg THC) in divided doses. Once the dose that maximizes potential therapeutic effects while minimizing adverse effects has been determined, it will be maintained for the remaining four weeks of the trial.
223884097|NCT06878417|DRUG|Placebo|The starting dose will be 1 capsule per day taken orally. The dose will be gradually increased over the first four weeks, based on patient assessment, up to a maximum of five capsules per day in divided doses. Once the dose that maximizes potential therapeutic effects while minimizing adverse effects has been determined, it will be maintained for the remaining four weeks of the trial.
223884098|NCT06710756|DRUG|[203Pb]Pb-PSV359|\[203Pb\]Pb-PSV359 is administered by intravenous bolus injection for single-photon emission computed tomography imaging.
223884099|NCT06710756|DRUG|[212Pb]Pb-PSV359|\[212Pb\]Pb-PSV359 is administered by intravenous infusion for treatment of FAP expressing cancers.
223884100|NCT07041905|PROCEDURE|Total Caries Removal|"Arm 1: Total caries removal (complete excavation to hard dentin)"
223884101|NCT07041905|PROCEDURE|Selective Caries Removal|Partial removal leaving affected dentin near pulp.
223884102|NCT06729710|PROCEDURE|Prism adaptation test|Prism Adapation test for 1 hour in one group, and 4 hours in second group
223884103|NCT06729710|PROCEDURE|other|Surgery based on prism adaptation test of 1 hour in one group and 4 hours in second group
223884104|NCT07044531|BEHAVIORAL|Training-as-Usual (TAU)|Participants receive the standard Peer Recovery Supporter (PRS) training currently offered by CCAR. This training follows existing certification requirements and does not include any digital modules or facilitated teleconferencing components.
223884105|NCT07044531|BEHAVIORAL|TDPP-A (Asynchronous Platform)|Participants engage with the Thrive Digital Peer Platform (TDPP), a fully asynchronous, self-paced online training program. The content includes 11 interactive modules structured using the Connect → Grow → Apply (CGA) learning framework, featuring peer stories, behavioral exercises, and scenario-based assessments.
223884106|NCT07044531|BEHAVIORAL|TDPP-Z (Asynchronous + Zoom)|Participants use the same asynchronous TDPP platform as the TDPP-A group, with the addition of three live, facilitator-led Zoom sessions. These synchronous group sessions provide opportunities for applied learning, discussion, and skill reinforcement.
223884107|NCT06887491|OTHER|Conventional physiotherapy program|Breathing exercises such as thoracic extension Stretching exercises for upper and lower extremity muscles Active-assisted, active and low resistance exercises for lower and upper extremity muscles according to muscle strength They will be asked to perform a home program including functional exercises (going up and down stairs, taking steps, etc.) at least 5 days a week, 2 times a day. The exercises will be checked by phone once a week and regular participation in the program will be ensured.
223884108|NCT06887491|OTHER|Conventional physiotherapy program + Dual task program|"Breathing exercises such as thoracic extension Stretching exercises for upper and lower extremity muscles Active-assisted, active and low resistance exercises for lower and upper extremity muscles according to muscle strength They will be asked to perform a home program including functional exercises (going up and down stairs, taking steps, etc.) at least 5 days a week, 2 times a day. The exercises will be checked by phone once a week and regular participation in the program will be ensured.~Dual task program: Walking 10 meters (Single task) and basic dual task introduction. Simple motor-motor tasks (e.g., holding a ball while walking). Carrying a half-full water bottle in each hand while walking. Placing or carrying objects accompanied by exercises requiring balance. Counting Counting backwards while walking. Solving simple math problems while walking Complexification of motor-motor and cognitive-motor tasks.~Dual tasks similar to activities of daily living"
223884109|NCT07048418|OTHER|Mailing and completing CLEFT-Q and NOSE questionnaires|Mailing and completing CLEFT-Q and NOSE questionnaires
223884110|NCT07052045|OTHER|One Stop Management|Patients within the intervention group will be transported directly after randomization to the angiography room. In the angiography room diagnostic imaging will be performed using cranial non-contrast FDCT and FDCT-A with subsequent EVT (if a treatable vessel occlusion was identified). Therefore, diagnostics and treatment will be performed in the same room (One-Stop management). Only patients with a treatable occlusion will undergo arterial puncture.
223884111|NCT07052045|OTHER|Usual care management|Patients within the control group will be transported directly after randomization to the multidetector CT (MDCT) room for diagnostic imaging with non-contrast MDCT and MDCT-A. IVT will be given directly in the MDCT room if no contraindication is present. If on diagnostic imaging a treatable vessel occlusion was identified, the patient will be transported to the angiography room, where EVT will be performed.
223884112|NCT04774237|DRUG|BRIMOCHOL™|A single drop in each eye at a visit.
223884113|NCT04774237|DRUG|BRIMOCHOL™ F|A single drop in each eye at a visit.
223884114|NCT04774237|DRUG|Carbachol|A single drop in each eye at a visit.
223884115|NCT07060846|PROCEDURE|Endoscopic lumbar discectomy|Patients will undergo endoscopic lumbar discectomy.
223884116|NCT07060846|PROCEDURE|Open lumbar discectomy|Patients will undergo an open lumbar discectomy.
223884117|NCT07058727|DRUG|Sodium Hypochlorite 2,5%|2.5% NaOCl applied for 1 min to exposed pulp for hemostasis, followed by standard pulp capping
223884118|NCT07058727|DRUG|Chlorhexidine|2% CHX applied for 1 min to achieve hemostasis, with identical subsequent steps to NaOCl group
223884119|NCT07058727|DRUG|Cold Saline|Hemostasis via 4°C saline (1 Min), then standardized pulp capping
223884120|NCT06827379|OTHER|IMT-S (strength)|Composed of 3 sets of 1 minute of maximum, deep inspirations, with 2 minutes of rest between sets, totaling 3 minutes of IMT. The initial load will be individualized according to the MIP, with the load equivalent to 60% of the MIP.
223884121|NCT06827379|OTHER|IMT-R (resistance)|Composed of 3 sets of 2 minutes of maximum, deep inspirations, with 2 minutes of rest between sets, totaling 6 minutes of IMT. The load will also be individualized according to the MIP, with the load equivalent to 30% of the MIP.
223884122|NCT06827379|OTHER|Sham - IMT|Composed of 3 sets of 2 minutes of maximum, deep inspirations, with 2 minutes of rest between sets, totaling 6 minutes of IMT with a minimum load of 3cmH2O.
223884123|NCT03413982|OTHER|Registry|Patient registry
223884124|NCT07067671|OTHER|Internal Thoracic Impedance|Internal Thoracic Impedance is a non-invasive an imaging technique which use low alternative current through electrodes placed on a belt positioned at the level of the patient's rib cage. Images are constructed according to conductivity measured.
223884125|NCT05750966|DRUG|cefrtriaxone, gentamicin, cefuroxim, ciprofloxin or other antibiotics according to local guideline (24 hours)|The duration of antibiotics is 24 hours after adequate biliary drainage. The choice of antibiotics will be according to local protocol and/or national Dutch SWAB guidelines. The most common antibiotics are described above, but this can differ based on allergies, local protocol or previous cultures. Drug classes may include: aminoglycosides, carbapenems, cefalosporins, fluorquinolones, sulfonamides, penicillines.
223884126|NCT05750966|DRUG|cefrtriaxone, gentamicin, cefuroxim, ciprofloxin or other antibiotics according to local guideline (4 to 7 days)|The duration of antibiotics is 4 to 7 days after adequate biliary drainage. The choice of antibiotics will be according to local protocol and/or national Dutch SWAB guidelines. The most common antibiotics are described above, but this can differ based on allergies, local protocol or previous cultures. Drug classes may include: aminoglycosides, carbapenems, cefalosporins, fluorquinolones, sulfonamides, penicillines.
223884127|NCT07070869|BEHAVIORAL|Serious game|"Participation in the serious game SPAMLO-3.0."
223884128|NCT06847139|DRUG|Zinc Sulfate 50 Mg Tab|experimental group will get zinc sulfate
223884129|NCT06847139|DRUG|Folic Acid 5 Mg Oral Tablet|control group will get folic acid
223884130|NCT06894745|DRUG|89-zr-dfo-star polyethylene glycol (StarPEG)|Given intravenously (IV)
223884131|NCT06894745|PROCEDURE|Whole Body Positron Emission Tomography (PET)|Imaging procedure
223884132|NCT06894745|PROCEDURE|Specimen Collection|Urine and blood specimens will be collected for correlative studies
223884133|NCT06754930|DRUG|SHR-1826|SHR-1826 for injection.
223884134|NCT06754930|DRUG|SHR-1316|SHR-1316 for injection.
223884135|NCT06754930|DRUG|SHR-9839|SHR-9839 for injection.
223884136|NCT06754930|DRUG|SHR-8068|SHR-8068 for injection.
223884137|NCT06754930|DRUG|Ametinib mesylate|Ametinib mesylate.
223884138|NCT06754930|DRUG|BP-102|BP-102 for injection.
223884139|NCT06754930|DRUG|Carboplatin|Carboplatin for injection.
223884140|NCT07069855|OTHER|Almond Snack Intervention for Gestational Diabetes|This intervention involves daily consumption of 43 g of whole almonds, split into two portions (afternoon and evening), for 28 days in pregnant women diagnosed with gestational diabetes who habitually consume evening snacks.
223884141|NCT07069855|OTHER|Control (placebo) group|This control involves the daily consumption of a nut-free snack (2 portions) that reflects a 'typical snack' choice among pregnant women with gestational diabetes. It serves as a comparison to assess the specific impact of almond-based evening snacking on overnight glucose regulation.
223884142|NCT07078266|DEVICE|Magnetocardiography examination|"Magnetocardiography (MCG) is a non-invasive, risk-free, and contactless technology that characterizes the local magnetic field signals generated by the electrical activity of the heart.~the magnetic signals used in magnetocardiograms can pass through the body with almost no interference. Therefore, magnetocardiography theoretically offers more clinically useful information, with the advantages of being non-invasive, safe, and fast, enabling earlier and more accurate diagnoses of potential heart diseases."
223884143|NCT07077148|BEHAVIORAL|Facilitated tucking|The upper and lower extremities of the newborns are taken to the midline and positioned in the womb.
223884144|NCT07077148|BEHAVIORAL|Swaddling|The baby is swaddled using the cloths used in the neonatal intensive care unit.
223884145|NCT07078097|OTHER|Traditional Sape' Dayak Music Listening|This intervention is distinguished by its use of the Sape' Dayak, a specific traditional musical instrument from East Kalimantan, Indonesia, known for its gentle, contemplative, and culturally significant sounds. The music utilizes pentatonic melodies that foster a serene and emotionally relaxing environment. Its distinct rhythm (80-85 beats per minute) is also a key feature. The intervention also incorporates a gentle abdominal massage and imagining the infant.
223884146|NCT07078097|OTHER|Brahms' Lullaby Music Therapy|This intervention is distinguished by its use of a globally popular and well-known lullaby composed by Johannes Brahms. The lyrics typically revolve around themes of love and affection, expressing mothers' love and tenderness for their fetuses. Unlike the Sape' Dayak, the specific lullaby will be preselected by the researcher to ensure a homogeneous intervention, with personal lullaby preferences ignored to avoid bias. Participants also engage in gentle abdominal touching and reflection on their unborn children.
223884147|NCT07079176|DRUG|etomidate combined with propofol|Patients initially received oxygen via nasal cannula at 5 L/min. All patients underwent routine noninvasive monitoring of blood pressure, ECG, and oxygen saturation. In the EP group, patients received 50 μg fentanyl, followed by a slow intravenous injection of a propofol-etomidate mixture (10 mL:20 mg etomidate + 10 mL:100 mg propofol) at 0.1-0.2 mL/kg. Supplemental doses of 0.05 mL/kg were administered as needed to maintain sedation throughout the procedure.
223884148|NCT07079176|DRUG|propofol|Patients initially received oxygen via nasal cannula at 5 L/min. All underwent routine noninvasive monitoring of blood pressure, ECG, and oxygen saturation. In the P group, 50 μg fentanyl was administered, followed by a slow intravenous injection of propofol (1-2 mg/kg) after 3 minutes. Supplemental doses of 0.5 mg/kg were administered as needed to maintain sedation throughout the procedure.
223884149|NCT07076914|DRUG|Experimental (Health Canada Approved Proton Pump Inhibitors)|The intervention uses a proton pump inhibitor as a preventative measure
223884150|NCT07077018|DIETARY_SUPPLEMENT|Fasting-mimicking diet (FMD) Group|The FMD will consist of a triweekly 4-day regimen of a plant-based, calorie-restricted (827± 100 kcal on day 1；637 ± 100 kcal on days 2-4), low-carbohydrate, low-protein diet. The FMD will be repeated up to a maximum of eight consecutive cycles. Participants receive the FMD for 2 days prior to and on the day and one day after each cycle of chemotherapy.
223884151|NCT07076888|OTHER|Aerobic Exercises|"1. Timing of Exercise:~   Aerobic exercises were performed on non-dialysis days. This scheduling avoids post-dialysis fatigue and hypotensive effects, optimizing patient safety and performance.~2. Frequency:~   Patients was engaged in aerobic exercise 3 times per week on non-consecutive days, to allow sufficient recovery time between sessions.~3. Duration of Each Session:~   * Total Duration: Each exercise session was last between 20 to 45 minutes.~  * Warm-Up: 5-10 minutes of low-intensity activity (e.g., slow walking).~  * Main Exercise: 15-30 minutes of moderate-intensity aerobic exercise.~  * Cool-Down:\*5-10 minutes of gradual reduction in intensity.~4. Exercise Modality:~   * Options: Patients may choose between treadmill walking or using a stationary bike, depending on their preference, physical condition.~  * Variety: To maintain engagement and reduce monotony, patients can alternate between treadmill and bike exercises.~5. Intensity:~Use moderate-intensity exercise, aiming for 60-70% of the p"
223884152|NCT07076888|OTHER|Conventional Program|"1\. Breathing Exercises~\- Diaphragmatic Breathing: Instruct patients to place one hand on their chest and the other on their abdomen. They should inhale deeply through their nose, allowing the abdomen to rise, and then exhale slowly through their mouth. This breathing technique has been shown to reduce stress, improve respiratory efficiency, and enhance relaxation . For optimal benefits, patients should practice this for 5-10 minutes, 2-3 times a day.~Stretching Exercises Hamstring Stretch: Instruct patients to sit with one leg extended straight out in front of them and the other leg bent. They should reach towards the toes of the extended leg while keeping their back straight. Hold the stretch for 20-30 seconds and repeat the stretch 2-3 times per leg.~Lower Limb Circulatory Exercises Ankle Pumps: While lying down or seated, instruct patients to alternately point and flex their feet to stimulate circulation and improve lower leg mobility. Perform 20-30 pumps per foot, 2-3 times a day"
223884153|NCT07077499|DEVICE|Pulsed Vacuum Cleaning and Disinfection Device|After manual pre-treatment, instruments were placed into the pulsed vacuum cleaning and disinfection machine (Shandong Xinhua Medical, Model PC-150L). The automated program included pulsed vacuum cleaning, rinsing, thermal disinfection (93°C for 2.5 minutes), and vacuum drying.
223884154|NCT07077499|DEVICE|Vacuum Ultrasonic Cleaner|After manual pre-treatment, instruments were cleaned in a vacuum ultrasonic cleaner (Shandong Xinhua Medical, Model super-6000) with a multi-enzyme solution for a minimum of 5 minutes. This was followed by a separate process in a spray cleaning and disinfection machine for rinsing and drying.
223884155|NCT07076875|OTHER|Questioner interview|The 2 questionnaires were translated from English to standard Arabic comprised of three sections, general information, including data and sociodemographic factors such as region of residence, parental education level, child age, child sex, and child order between siblings, Barriers to oral health care needs, including frequency and reasons for dental visits, any previous dental treatment, barriers to treatment such as fear of dentist, distance from the dental clinic, expense of an appointment due to health ban, responsibilities towards family members, not being familiar with appointment booking, and no available appointments, and Comprising of interviewer-administered questionnaires with a five-point Likert scale (strongly agree, agree, uncertain, disagree, strongly disagree) to assess the level of patients' satisfaction with the dental services provided.
223884156|NCT07078006|OTHER|Platelet Rich Fibrin|Patients underwent arthrocentesis followed by a platelet-rich fibrin (PRF) injection using a conventional temporomandibular joint (TMJ) injection technique, aided by facial anatomical landmarks.
223884157|NCT07078006|OTHER|Platelet Rich Plasma|Patients underwent arthrocentesis followed by a platelet-rich plasma (PRP) injection using a conventional temporomandibular joint (TMJ) injection technique, aided by facial anatomical landmarks.
223884158|NCT07077096|DIAGNOSTIC_TEST|PRISM PCR panel|Comparing the diagnostic accuracy between conventional bacterial culture and multiplex PCR on diagnosing pleural infection
223884159|NCT07077096|DIAGNOSTIC_TEST|Conventional bacterial culture|Comparing the diagnostic accuracy between conventional bacterial culture and multiplex PCR on diagnosing pleural infection
223884160|NCT07078513|OTHER|Active release Technique|Active Release Technique (ART) is a hands-on manual therapy that targets soft tissue restrictions by combining precise pressure with patient-assisted movement. It helps break down adhesions, improve mobility, and reduce pain by restoring normal tissue function.
223884161|NCT07078513|OTHER|Strain counter strain tecnhnique|Strain-Counterstrain is a gentle, passive manual therapy that relieves muscle tension by positioning the body in a pain-free, comfortable posture. The therapist holds this position for about 90 seconds while applying light pressure to tender points, allowing the muscle and fascia to relax and reset.
223884162|NCT07078331|DEVICE|OsteoAdapt DE (0.8 mg)|"Procedure of single tooth extraction and grafting along with related data collection:~Implanted OsteoAdapt DE bone graft (0.8 mg) by a trained and qualified study investigator per the IFU, IB and CIP guidelines"
223884163|NCT07078331|DEVICE|OsteoAdapt DE (2.0 mg)|"Procedure of single tooth extraction and grafting along with related data collection:~Implanted OsteoAdapt DE bone graft (2.0 mg) by a trained and qualified study investigator per the IFU, IB and CIP guidelines"
223884164|NCT07078331|DEVICE|Xenograft Bone Graft|"Procedure of single tooth extraction and grafting along with related data collection:~Implanted xenograft bone graft by a trained and qualified study investigator per the IFU, IB and CIP guidelines"
223884165|NCT07076290|DRUG|R-3750|R-3750 DP; Lactococcus lactis expressing Surface Layer Protein A (SlpA)
223884166|NCT07078123|PROCEDURE|Laparoscopic Donor Nephrectomy|Receipt of a laparoscopic nephrectomy for kidney donation
223884167|NCT07077343|PROCEDURE|AI-Assisted Navigated Hematoma Aspiration|By leveraging AI algorithms for real-time hematoma segmentation, volume calculation, and trajectory optimization, this approach enhances the accuracy of minimally invasive catheter placement and facilitates efficient clot removal under image-guided navigation.
223884168|NCT07077343|PROCEDURE|Conservative Treatment|Compared to surgical hematoma aspiration, conservative treatment relies on medical stabilization and the body's natural clearance mechanisms, and remains the standard of care in many cases of moderate or deep-seated ICH without signs of clinical deterioration.
223884169|NCT07078058|DEVICE|Low level laser|Patients in the low level laser group will be irradiated with visible and near-infra-red lasers at a pulsed mode with a frequency of 35 Hz, peak power of 100 mW, and a spot diameter of 5 mm. The 15-minute sessions were performed three times a week for two months, with each laser having a power density of 0.35 mW/cm2 and an energy density of 32.08 J/cm2.
223884170|NCT07078058|DEVICE|Transcutaneous auricular Vagus nerve stimulation|Patients will receive 30 minutes of transcutaneous vagus nerve stimulation for 2 months, with 5 sessions per week. The antihelix and cymba concha will be sterilized with 75% alcohol, and the electrode will be attached. The device parameters include a wave width of 0.2 ms ± 30%, pulse frequency of 20 Hz, gradually increasing intensity to a tolerable intensity (4-6 mA), and duration of 30 minutes.
223884171|NCT07079007|OTHER|Water|Patients that meet the inclusion and exclusion criteria would be asked to ingest 1000ml water as part of standard of care.
223884172|NCT07078565|OTHER|Modified-Otago Exercises|Intervention is administered 3 times per week for 4 weeks, with the same baseline therapy as the Tai Chi group.
223884173|NCT07078565|OTHER|Tai Chi|Intervention is administered 3 times per week for 4 weeks, along with baseline therapy (TENS + heating pad).
223884174|NCT07078864|OTHER|Nursing Care Decision Support System|Phase Two involves implementing the Nursing Care Decision Support System. Data will be collected using a Descriptive Information Form, the Nurse Decision-Making Scale (pre-test), and a Semi-Structured Interview Form to explore nurses' views. Nurses will receive two training sessions (totaling 4 hours) covering system use, importance, challenges, and solutions. Training will be held in two groups based on shift schedules. A one-week trial will follow, with the researcher answering questions and providing support via a WhatsApp group. Nurses must use the system for at least 15 days (maximum 30 days due to dissertation timeline). Fifteen days after use ends, the Nurse Decision-Making Scale (post-test) and interviews will assess the system's effectiveness and areas for improvement.
223884175|NCT07076940|OTHER|Mindfulness-based Training Program|The mindfulness-based training program was completed in a total of five sessions (one day per week, 60 minutes, for a total of five consecutive weeks).
223884176|NCT07076940|OTHER|Psychoeducational Program|"The Psychoeducational Program, themed around stress, well-being, and mindfulness, was completed in two sessions (two sessions over five weeks, each lasting 60 minutes)."
223884177|NCT07076758|OTHER|Transthoracic echocardiography|Transthoracic echocardiography will be done for all patients during their cardiac care unit stay including two-dimensional and color Doppler echocardiography studies. It will be performed in the left lateral position using the parasternal and apical transducer positions. All studies will be technically adequate for scoring endocardial regional wall motion. The following views will be obtained: long-axis parasternal, short-axis parasternal, apical four chamber, apical two-chamber and apical five-chamber views. All the measurements taken will be according to the criteria of the American Society of Echocardiography
223884178|NCT06618274|BEHAVIORAL|Intervention of oncology research navigator embedded in central oncology navigation|The intervention of oncology research navigator or Oncology research navigator (ORN) is embedded in central oncology navigation cancer care delivery.
223884179|NCT06618274|BEHAVIORAL|Central oncology navigation (SOC)|Central oncology navigation (SOC ) alone.
223884180|NCT07079150|DRUG|Peg IFN-α-2b|In the treatment of Peg IFNα-2b combined with NAs (Peg IFN combined treatment group), the treatment of Peg IFNα-2b should be no less than 48 weeks. The initial therapeutic dose of Peg IFNα-2b and the subsequent adjusted dose will be individualized determined by clinicians based on the specific condition of the patients. In the NAs monotherapy group, entecavir (ETV), tenofovir fumarate disoproxil (TDF), tenofovir propofol fumarate (TAF), and emitenofovir (TMF) were used for treatment for no less than 48 weeks, and Peg IFN was not added or switched for treatment.
223884181|NCT05863923|BEHAVIORAL|mHealth Messaging to Motivate Quitline use and Quitting among Persons Living With HIV (PLWH) in Vietnam (M2Q2-HIV)|Participants in the intervention group will be exposed to the texting intervention through a series of culturally tailored assessments and motivational text messages from the text messaging system sent throughout the 6 months of duration of the study.
223884182|NCT05863923|BEHAVIORAL|M2Q2-HIV Comparison|Participants in the comparison group will be exposed to a brief set of five texts with facts about smoking risks and assessment messages that are not culturally tailored from the text messaging system.
223884183|NCT06896799|OTHER|Visit 1: Protein/fat then carbohydrate. Visit 2: Carbohydrate then protein/fat.|Participants who are randomised to eat the protein/fat-based component (scrambled egg) of the meal before the carbohydrate-based component (wholemeal toast) on their first study visit, will be asked to eat the meal in the reverse order at their second study visit. Meals will be prepared by members of the research team who have completed Food Safety training. Participants will be asked to consume a 440kcal breakfast meal within 10 minutes, approximately 1.5 hours after arrival at their first study visit and approximately 30 minutes after arrival at their second study visit.
223884184|NCT06896799|OTHER|Visit 1: Carbohydrate then protein/fat. Visit 2: Protein/fat then carbohydrate.|Participants who are randomised to eat the carbohydrate-based component (wholemeal toast) of the meal before the protein/fat-based component (scrambled egg) on their first study visit, will be asked to eat the meal in the reverse order at their second study visit. Meals will be prepared by members of the research team who have completed Food Safety training. Participants will be asked to consume a 440kcal breakfast meal within 10 minutes, approximately 1.5 hours after arrival at their first study visit and approximately 30 minutes after arrival at their second study visit.
223884185|NCT04764357|DEVICE|Paxman Scalp Cooling System|Scalp cooling will begin at least 30-45 minutes prior to administration of each chemotherapy (45 minutes for those with thick or coarse hair types). Scalp temperature will be maintained at +3°C (37°F) throughout drug administration and for at least 120-180 minutes after discontinuing the infusion. Scalp cooling will occur with each dose of chemotherapy.
223884186|NCT04764357|OTHER|Alopecia Assessments|Photographs will be taken prior to the use of the scalp cooling system and once at the end of the study. Patients with solid tumors will have additional photographs taken after every 2 cycles of chemotherapy.
223884187|NCT04764357|OTHER|Patient Reported Outcomes Questionnaires|"* Selected questions from NCI PRO-CTCAE™, Chemotherapy-Induced Alopecia Distress Scale (CADS), and PediQUEST Memorial Symptom Assessment Scale, at the following time points: baseline, after every 2 cycles of chemotherapy, 4 week follow up and end of study.~* Tolerability Questionnaire each time the cooling cap is used and at the end of study"
223884188|NCT07077954|DRUG|Rivaroxaban|Rivaroxaban used to treat DVT
223884189|NCT07077954|DRUG|Warfarin|warfarin used for DVT
223884190|NCT06915324|DEVICE|Transcranial Direct Current Stimulation (tDCS)|"Transcranial direct current stimulation (tDCS) is delivered by a device that has a user-friendly interface and a large-button keypad, making it is easy to use at home. The device delivers a weak electrical current of 2.0 mA that is transmitted through two electrodes placed on the scalp to target the dorsolateral prefrontal cortex region of the brain. The electrodes are easily placed through a headset.~The active stimulation session lasts 30 minutes.~The inactive (sham) stimulation session will also last 30 minutes."
223884191|NCT06915324|BEHAVIORAL|Cognitive training|The cognitive training tasks are administered via a computer-based program BrainHQ (Posit Science). There are 20 sessions, each 30 minutes a day, conducted over approximately 4 weeks. The BrainHQ adaptive cognitive training tasks have been previously associated with improved processing speed in other populations.
223884192|NCT06919783|BEHAVIORAL|Health at Every Size in Obstetrics|Individuals are invited to participate in 5 group sessions during pregnancy and the postpartum period. The sessions will last 2-2.5 hours each and will include education on pregnancy, mental health, nutrition, movement, and self-advocacy. The sessions will be administered by an OBGYN/MFM physician and psychologist and include discussion with doulas, registered dieticians with pregnancy and disordered eating experience, and prenatal yoga instructors.
223884193|NCT06924021|OTHER|Retinal Imaging|"Eligible participants will undergo one retinal imaging session of both eyes for the following:~* Single field stereo color fundus photography (cFP) - pre and post dilation~* Macular spectral domain-optical coherence tomography (SD-OCT)"
223884194|NCT06931119|DRUG|EMEND® (EE mend) (aprepitant) capsules (80mg +125mg) Marketing Authorization Holder and Importer: Merck Sharp & Dohme (Israel-1996) Company Ltd.|"Total Treatment Duration: 1 cycle (1 administration of EMEND® capsules)~* Frequency: Patients will take EMEND® capsules at the start of new ICI.~* Dosing Schedule:~  * Day 1: EMEND® 125 mg, taken orally 1-2 hours before ICI administration.~ * Day 2: EMEND® 80 mg, taken orally in the morning.~ * Day 3: EMEND® 80 mg, taken orally in the morning. During the study period (12 weeks), participant must refrain from using any medications that could potentially interfere with the study's assessment of pruritus symptoms (e.g steroids, antihistamines)~Follow-up 1(7 days after the first capsule of Aprepitant): 12-PSS, safety assessment, QLQ-C30 Follow-up 2: 12-PSS, safety assessment Follow-up 3: 12-PSS, safety assessment Follow-up 4: 12-PSS, QLQ-C30, safety assessment Extended Follow-up: Recurrence of pruritus, long-term safety monitoring, QLQ-C30"
223884195|NCT06932627|PROCEDURE|ILIB|The treatment group receive an intravenous laser phototherapy. A vein indwelling needle will be placed in their veins located in the upper elbow, and the laser fiber catheter will be introduced through the indwelling cannula. The laser power is set between 5 Mw, 30 minutes each time,once every other day for 3 consecutive days each week, for 2 weeks (total 6 times in one course)
223884196|NCT06932627|PROCEDURE|Sham Control|The steps for the control group are the same as the treatment group, exceptthat the output power is adjusted to zero intensity.
223884197|NCT06942221|OTHER|usual care|"Patients in the usual care group will be followed up according to the local practice until the end of the study."
223884198|NCT06942221|OTHER|guideline-directed medical therapy|Patients are followed via an App, data will be evaluated by the Telemedicine team, and participants will be contacted via phone 1 week after discharge and subsequently every 7-10 days to discuss the up-titration of the HF medications.
223884199|NCT03436485|DRUG|ODM-208|co-administered with glucocorticoid and fludrocortisone, orally daily
223884200|NCT03436485|DRUG|Midazolam|orally
223884201|NCT05896709|OTHER|MK-RS|The embryos are assessed by the AI-enhanced MK analysis together with RS analysis.
223884202|NCT03152786|OTHER|Laboratory Biomarker Analysis|Correlative studies
223884203|NCT03152786|DRUG|Propranolol Hydrochloride|Given PO
223884204|NCT03152786|OTHER|Questionnaire Administration|Ancillary studies
223884205|NCT03152786|OTHER|Survey Administration|Ancillary studies
223884206|NCT05105360|PROCEDURE|Closure method of Petersen's space|Surgeons closed Petersen's space between the mesentery of the jejunal Roux limb and the mesentery of the transverse colon at the posterior side of esophago-jejunostomy or gastro-jejunostomy from the mesentery root to the bowel side using a nonabsorbable barbed suture V-LocTM 3-0 (Medtronic VR, Minneapolis, MN, USA).
223884207|NCT05105360|PROCEDURE|Mesentery fixation method|Surgeons fixed the jejunal mesentery (jejunojejunostomy\[J-J\] distal 30 cm) to the transverse mesocolon using non-absorbable barbed suture VLocTM 3-0 sutures. The suture area was exposed by grasping the jejunum side mesentery (jejunal side, at site 30cm distal J-J) and the transverse mesocolon (colonic side). The jejunal side mesentery was fixed to the colonic side mesocolon between the jejunum and the transverse colon using nonabsorbable barbed V-LocTM 3-0 sutures.The suture started between jejunal mesentery just below of SMA vascular arcade and transverse mesocolon, and it finished when it reaches the root of the mesentery. To anchor the mesentery, continuous suturing with V-Loc two-point backward sutures were performed at the final step.
223884208|NCT04032899|DIETARY_SUPPLEMENT|Lactobacillus fermentum CECT5716|Each participant will consume 1 capsule per day in one of the main meals without any restriction in the diet or in their life habits.
223884209|NCT04032899|DIETARY_SUPPLEMENT|Maltodextrin|Each participant will consume 1 capsule per day in one of the main meals without any restriction in the diet or in their life habits.
223884210|NCT05481658|DRUG|Diphencyprone (DPCP)|topical immunomodulator
223884211|NCT05938023|DRUG|ATL1102 25mg|Dose and scheduled as specified in the Arm description
223884212|NCT05938023|DRUG|ATL1102 50mg|Dose and scheduled as specified in the Arm description
223884213|NCT05938023|DRUG|Placebo|Dose and scheduled as specified in the Arm description
223884214|NCT05163899|PROCEDURE|Release of filum terminale|Surgery will be offered to section the filum terminale
223884215|NCT05649319|PROCEDURE|ERAS protocol|The ERAS protocol involves a pre-admission patient education using audiovisual videos, the reduction of perioperative fasting time with administration of preoperative carbohydrate loading and early resumption of oral feeding after surgery, multimodal postoperative nausea and vomiting prevention, early removal of the nasogastric tube and urinary catheter, and multimodal analgesia to minimize opioid consumption after surgery.
223884216|NCT04075903|BEHAVIORAL|Storytelling|"A health literacy-appropriate and culturally-adapted intervention delivered on a tablet computer containing storytelling to improve patient gout knowledge and approaches to prevent flares, destigmatize gout, and enhance readiness to adopt available long-term treatments for gout including medications, diet, and exercise, or ii) usual gout care (control state)."
223884217|NCT03768440|PROCEDURE|continuous erector spinae block (ESB)|Erector spinae block: T4/5 transverse process is identified with the ultrasound transducer in a parasagittal orientation; the needle tip is advanced until it contacts the transverse process, just below the erector spinae muscle complex; the erector spinae muscle is visualized to be elevated up off of the transverse process with normal saline injection. Following a bolus injection of 2ml/kg of 0.2% ropivacaine, a catheter is threaded into the space occupied by the local anesthetic bolus.
223884218|NCT03768440|PROCEDURE|continuous paravertebral block (PVB)|The paravertebral space (bound medially by the bodies of the vertebrae, intervertebral discs, and intervertebral foraminae; anterolaterally by the parietal pleura and the innermost intercostal membrane; posteriorly by the transverse processes of the thoracic vertebrae, heads of the ribs, and the superior costotransverse ligament) laying between T4/5 is identified using the ultrasound transducer in a transverse orientation; the needle tip is advanced until it is seen passing under the transverse process, immediately superior to the pleura; the pleura is seen to deflect downward with normal saline injection. Following a bolus injection of 2ml/kg of 0.2% ropivacaine, a catheter is threaded into the space occupied by the local anesthetic bolus.
223884219|NCT03768440|DRUG|Ropivacaine|Ropivacaine 0.2% will be the drug used for each group (ESB group and PVB group)
223884220|NCT06835829|DEVICE|Transradial potassium ferrate hemostatic patch|Use of a potassium ferrate hemostatic patch to enhance transradial access hemostasis
223884221|NCT06835829|DEVICE|Distal radial potassium ferrate hemostatic patch|Use of a potassium ferrate hemostatic patch to enhance distal radial access hemostasis
223884222|NCT06835829|PROCEDURE|Ultrasound-guidance|Ultrasound guidance for distal radial access
223884223|NCT06835829|PROCEDURE|Conventional guidance|Conventional guidance for distal radial access
223884224|NCT04141774|DEVICE|Functional Electric Stimulation (FES)|FES uses low energy electrical pulses to artificially generate body movements in individuals with muscle paralysis. FES can be used to generate muscle contraction in otherwise paralyzed limbs to restore function.
223884225|NCT04141774|BEHAVIORAL|Behavioral Assessments|These assessments will include measures of upper extremity motor assessments, standard stroke scales, and measures of activities of daily living.
223884226|NCT04141774|OTHER|Magnetic Resonance Imaging|A functional magnetic resonance image will be collected.
223884227|NCT04141774|OTHER|EEG|EEG electrodes will be attached to the subject's scalp using a standard, commercially available electrode cap. Proper electrode placement is made according to the international 10-20 system, ensuring complete electrode coverage over sensorimotor cortex.
223884228|NCT06787079|OTHER|Kinesio Tape|Kinesio tape is a non-invasive therapeutic approach that does not involve any medication. It is often used to support tissue and reduce pain.
223884229|NCT06787079|OTHER|Pilates|Pilates exercises are mind-body exercises that are performed on a mat or with special equipment and focus on strength, core stability, flexibility, muscle control, posture and breathing. Pilates exercises are frequently used to develop elements such as core stability, muscle flexibility and strength, physical fitness and body awareness.
223884230|NCT06787079|OTHER|Placebo|Placebo taping will be applied in the same way as kinesio taping, but with plaster tape.
223884231|NCT05460416|DRUG|Acetylsalicylic acid|160mg once a day
223884232|NCT06477107|DEVICE|Soterix® 4x1HD-TDCS|Is intended for inducing cortical neuromodulation for research and treatment purposes.
223884233|NCT06477107|DEVICE|Soterix® 1x1 tDCS|At-home remotely supervised transcranial direct current stimulation (tDCS) at an intensity of 2 mA for 20 minutes per session, with slow ramp-up and automatic turn off once it reaches the maximal intensity.
223884234|NCT06477107|BEHAVIORAL|Cognitive training program|Computerized cognitive therapy for 45 minutes per day that starts at the same time with stimulation
223884235|NCT01945762|DRUG|Vandetanib 300 mg|Vandetanib commercial tablets
223884236|NCT04880226|DEVICE|Magnetic Resonance Imaging (MRI)|Ongoing evaluations of magnetic resonance imaging (MRI) using the Philips Ingenua 1.5T scanner associated with MRI-guided procedures (e.g. ablations or biopsies) are essential to continued procedure improvement within the newly-built hybrid procedure suite.
223884237|NCT04393558|DEVICE|ADAM Sensor|ADAM sensor The data collected from this sensor contains a wide range of core and novel respiratory digital biomarkers as a home-based early identification system. The core measurements include: heart rate, heart rate variability, temperature, physical activity (including sleep quality) and respiratory rate. The novel respiratory digital biomarkers include: respiratory cadence (expiration / inspiration time), coughing, swallowing, throat clearing, and talk time.
223884238|NCT03949881|BIOLOGICAL|FEMJA transplatation|The cultivated oral mucosal epithelium will be directly grafted onto the corneal stroma. The sheet is grafted without suture onto the exposed stromal bed after removal of the conjunctiva and fibrosis from the cornea. The grafted corneal surface is then covered with a soft permanent contact lens for protection during healing (between 3 to 15 days, according to tolerance) If the stroma appears opaque because of deep stromal scars a corneal allograft will be performed 12 months after FEMJA transplantation.
223884239|NCT05188469|DRUG|EG-COVID-003|"Subjects will receive one, two or three single IM vaccination(s), 3 weeks apart, the subjects will be enrolled to treatment at a ratio of 1:1 (Phase 1: n=10, Phase 2a: 50 per treatment)~EG-COVID-003 0.5mL (mRNA 100μg)~Route of administration: Intramuscular injection"
223884240|NCT05188469|DRUG|EG-COVID-001|"Subjects will receive one, two or three single IM vaccinations, 3 weeks apart, the subjects will be enrolled to treatment at a ratio of 1:1 (Phase 1: n=10, Phase 2a: 50 per treatment)~EG-COVID-001 0.5mL (mRNA 200μg)~Route of administration: Intramuscular injection"
223884241|NCT05188469|DRUG|A: EG-COVID|"Subjects will receive two single IM vaccinations, 3 weeks apart, the subjects will be enrolled to treatment~Component Description (per dose):~EG-COVID 0.5mL (mRNA 400μg)~Route of administration: Intramuscular injection"
223884242|NCT05188469|DRUG|B: EG-COVID|"Subjects will receive two single IM vaccination(s), 3 weeks apart, the subjects will be enrolled to treatment~Component Description (per dose):~EG-COVID 1mL (mRNA 800μg)~Route of administration: Intramuscular injection"
223884243|NCT05188469|DRUG|C: EG-COVARo|"Subjects will receive two single IM vaccinations, 3 weeks apart, the subjects will be enrolled to treatment~Component Description (per dose):~EG-COVARo 0.5mL (mRNA 800μg)~Route of administration: Intramuscular injection"
223884244|NCT04333706|DRUG|Capecitabine|Capecitabine 1000 mg BID
223884245|NCT04333706|COMBINATION_PRODUCT|Sarilumab 150mg or 200 mg plus Capecitabine|Sarilumab 150mg or 200 mg plus Capecitabine 1000 mg BID
223884246|NCT04333706|COMBINATION_PRODUCT|Sarilumab 150mg plus Capecitabine|Dose escalation schedule of sarilumab. The starting dose for sarilumab is 150 mg SQ every 21 days, given 3 days prior to the first 4 of 8 cycles of capecitabine 1000 mg BID.
223884247|NCT04455035|OTHER|Comparator: Retrospective Group(Control)|The control group for this study will be obtained from a retrospective chart review of electronic health records of patients with incomplete cleft lip who underwent surgery without any presurgical interventions.
223884248|NCT04455035|DEVICE|Prospective Group|"The study population for the prospective aspect will include recruited newborns with untreated unilateral incomplete cleft lip.~DynaCleft® + Nasal Elevator therapy will be discussed with parent(s) as a presurgical orthopedic option while awaiting primary cleft lip surgical repair that typically occurs between the ages of 3 to 6 months.Study duration will be up to three months of presurgical intervention.Photographs are to be taken at initial visit prior to presurgical intervention and later at completion of the DynaCleft® therapy immediately prior to lip surgery. Angles to be pictured are to include the standard anterior-posterior, profile, and worms-eye view.~Linear measurements will be obtained with a ruler and registered in millimeters. A goniometer will be used to measure angles."
223884249|NCT06151080|DRUG|Lenalidomide combined with G-CHOP (LO CHOP)|Lenalidomide combined with G-CHOP to treat newly diagnosed diffuse large B-cell lymphoma with follicular lymphoma (CDLBCL-FL)
223884250|NCT06434610|DRUG|B013|B013: The subjects will receive IV dose of B013 600 mg on Day 1 and 15 of the first 28-day cycle, then on Day 1 of each subsequent 28-day cycle.
223884251|NCT06434610|DRUG|Paclitaxel|Paclitaxel: 80 mg/m\^2 is administered weekly on Day 1, 8, 15 of each 28-day cycle.
223884252|NCT06434610|DRUG|Placebo|Placebo: The subjects will receive IV dose of placebo matched to B013 on Day 1 and 15 of the first 28-day cycle, then on Day 1 of each subsequent 28-day cycle.
223884253|NCT03217565|DRUG|IV Tedizolid Phosphate|A single dose, or twice daily dose for 3 days, of tedizolid phosphate administered IV.
223884254|NCT03217565|DRUG|Oral Suspension Tedizolid Phosphate|A single dose of tedizolid phosphate administered as an oral suspension.
223884255|NCT00753090|DEVICE|Vanguard™ Deep Dish Rotating Platform Knee|Total knee replacements with the Vanguard Deep Dish Rotating Platform Knee
223884256|NCT00753090|DEVICE|Vanguard™ Cruciate Retaining Knee|Total knee replacements with the Vanguard Cruciate Retaining Knee
223884257|NCT06776601|BEHAVIORAL|Full process digital therapy intervention package|Patients will receive individualized inhalation skills guidance after being tested by inhalation capacity measuring device, and be equipped with electronic inhalation monitoring devices, which can record their medication using data, reminding patients to use the medication on time, and correct their inhalation mistake. They can also check their inhalation record on their mobile phones. Clinicians can check the record every month to assess their adherence.
223884258|NCT06244641|OTHER|Auto-questionnaires, hetero-questionnaires and Evoked-potentials|Evaluations of risk factors of relapse by questionnaires, evaluation of evoked-potentials
223884259|NCT03654573|DEVICE|CorFlow Controlled Flow Infusion System - CoFI™|The CorFlow CoFI™ System is intended to assess the dynamic microvascular resistance and to treat microvascular obstruction in the coronary vasculature of patients following PCI with stent placement.
223884260|NCT06781086|DRUG|Nimotuzumab|Patients will receive 3 cycles of neoadjuvant treatment with Nimotuzumab (400 mg on days 1, 8, and 15 of a 21-day cycle), followed by surgery and 5 cycles of adjuvant Nimotuzumab (400 mg on days 1, 8, and 15 of a 21-day cycle).
223884261|NCT06781086|DRUG|AG regimen|Patients will receive 3 cycles of AG (gemcitabine 1000 mg/m\^2 and nab-paclitaxel 125 mg/m\^2 on days 1 and 8 of a 21-day cycle), followed by surgery and 5 cycles of adjuvant AG (gemcitabine 1000 mg/m\^2 and nab-paclitaxel 125 mg/m\^2 on days 1 and 8 of a 21-day cycle).
223884262|NCT06781086|DRUG|Placebo|Patients will receive 3 cycles of neoadjuvant treatment with placebo (400 mg on days 1, 8, and 15 of a 21-day cycle), followed by surgery and 5 cycles of adjuvant therapy (placebo 400 mg on days 1, 8, and 15 of a 21-day cycle).
223884263|NCT04835831|OTHER|adapted physical activity + Dietetic advice|adapted physical activity during 24 weeks
223884264|NCT06780410|DRUG|Bempedoic Acid Tablet|Once daily, oral
223884265|NCT06780410|DRUG|Placebo|Once daily, oral
223884266|NCT06157216|DRUG|MRD-guided therapy|MRD negative stage II gastric cancer: Observation; MRD negative stage III gastric cancer: S1 (40-60 mg, PO, bid, d1-d14 q3w); MRD positive stage II/III gastric cancer: XELOX (Oxaliplatin 130mg/m2, d1 +Capecitabine 1000mg/m2，PO. bid, d1-14, q3w) or SOX (Oxaliplatin 130mg/m2, d1 +S-1 40-60 mg, PO. bid, d1-14, q3w); MRD-negative patients will receive XELOX or SOX if MRD becomes positive.
223884267|NCT00477958|OTHER|questionnaire administration|Questionnaire administered prior to chemotherapy and within 30 days of completion of chemotherapy.
223884268|NCT00477958|PROCEDURE|cognitive assessment|Cognitive assessment to be obtained prior to chemotherapy and within 30 days of completion of chemotherapy.
223884269|NCT00477958|PROCEDURE|psychosocial assessment and care|Psychosocial assessment and care to be obtained prior to chemotherapy and within 30 days of completion of chemotherapy.
223884270|NCT06765330|DRUG|CHX disinfection|Each CHX cavity will be treated with disinfectant with a disposable micro brush tip and left undisturbed for 20 seconds. They will then be air-dried for 10 seconds and restore the tooth.
223884271|NCT06765330|DEVICE|Laser Disinfection|After the caries removal procedure, the cavity will be disinfected using an Er,Cr: YSGG laser (EPIC X™, BIOLASE, USA) with 940 nm and 0.1 W output power. The laser tip will be a 400 µm tip with an energy density of 138.12 J/cm in non-contact mode (2 mm distance), 5 s/mm2 sweeping motion.
223884272|NCT06765330|PROCEDURE|Tungsten carbide bur|Carious tissue will be completely removed from the surrounding cavity walls with a tungsten carbide bur, leaving at least 2 mm of peripheral intact tooth structure for good adaptation and sealing of the restoration.
223884273|NCT06765330|PROCEDURE|Polymer bur|Access to the lesion will be achieved using a high-speed handpiece with a sterile high-speed bur. The polymer bur will be used with a low-speed handpiece at 5,000-10,000 RPM to remove carious dentin in sizes RA4, RA6, and RA8 according to the size of the caries lesion. The instrument will be used with a circular, light force starting from the center of the carious lesion towards the periphery as recommended by the manufacturer. Caries removal will be stopped when the instrument is macroscopically worn and blunt and can no longer remove tissue. An excavator will be used to verify if any caries remain at the base of the cavity. If necessary, a new polymer bur will be used to remove the remaining decay.
223884274|NCT06766006|PROCEDURE|Venoarterial extracorporeal life support (VA ECLS) implant|Implantation of venoarterial extracorporeal life support implant for refractory cardiogenic shock or cardiac arrest of any cause.
223884275|NCT06767215|OTHER|Ice Compress|Ice compress will be applied 5 minutes before butulinium injection
223884276|NCT06767215|OTHER|No ice compress|No ice compress will be applied .
223884277|NCT04170946|OTHER|Talazoparib in Combination with Low Dose Radiotherapy (RT)|Dose escalation model to determine the safety and MTD of talazoparib in combination with low dose RT.
223884278|NCT06737822|COMBINATION_PRODUCT|TPF or TPX Regimen (2# ICT) --> Surgery and Adjuvant Treatment|"TPF:~IINJ DOCETAXEL 75mg/M2 in 500 ML NORMAL SALINE(PVC free container/glass bottle) via codon filter OVER 60 MIN (DAY 1 ONLY) INJ. CISPLATIN 75 MG/M 2 IN 500 ML NS IV OVER 1 HOUR ON DAY1 ONLY INJ. 5FU 750 MG/M2 IV THROUGH INFUSION PUMP OVER 24 HOURS D 1-4~Or~TPX Regimen INJ DOCETAXEL 75mg/M2 in 500 ML NORMAL SALINE(PVC free container/glass bottle) via codon filter OVER 60 MIN (DAY 1 ONLY) INJ. CISPLATIN 75 MG/M 2 IN 500 ML NS IV OVER 1 HOUR ON D1 ONLY TAB. CAPECITABINE 850-1000MG/M2 TWICE A DAY 30 MINUTES AFTER MEALS FOR 14 DAYS IN A THREE WEEKLY CYCLE~Surgery and Adjuvant Treatment Patients with PR/CR or SD will go for surgical resection. Patients having PD but still localized and resectable will be offered surgical resection, other would undergo radical CTRT or Palliative Treatment."
223884279|NCT06737822|COMBINATION_PRODUCT|Surgery and Adjuvant Treatment|Wide Local Excision (WLE) with Comprehensive neck dissection and Adjuvant Treatment as per current standard Guidelines.
223884280|NCT06710002|BEHAVIORAL|Pelvify: Menopause and dyspareunia treatment|"Topics addressed in the Asynchronous Online Telerehabilitation Program would be:~1. What it is and why it hurts during sex. What is dyspareunia?~2. How to recover vaginal elasticity.~3. Massage~4. Self-palpation.~5. Stretching of the pelvic floor muscles.~6. Use of vaginal dilators.~7. Moisturizers and lubricants.~8. Sexual pleasure.~9. Communication with the partner."
223884281|NCT06710002|OTHER|Face to Face Physical Therapy Protocol|"Physical Therapy Protocol will be based on:~1. Health education:~2. CMRF: INDIBA® ACTIV CT8 will be used to apply the radiofrequency~3. Manual therapy: it will be based on performing the Thiele's massage.~4. Vaginal dilators: FEMINAFORM® vaginal dilators will be used."
223884282|NCT06710002|OTHER|Face to Face Protocol Combined With an Asynchronous Telerehabilitation Program|Both, the face to face protocol and the Asynchronous Telerehabilitation Program will be carried on on this group.
223884283|NCT03166150|OTHER|Multi-modal rehabilitation program|Patients will receive 12 weeks of exercises.
223884284|NCT03166150|OTHER|Pelvic Floor Physical therapy|Pelvic Floor Physical therapy
223884285|NCT02536118|DEVICE|Micra Transcatheter Pacing System|The Micra system is a miniaturized single chamber pacemaker system that is delivered via catheter through the femoral vein and is implanted directly inside the right ventricle of the heart. The Micra implantable device is a self-contained, hermetically enclosed, miniaturized single chamber pacemaker. The device is fixated via four electrically inactive nitinol tines, located on the distal end of the device.
223884286|NCT02216864|PROCEDURE|Multiple Subcision|At the start of the procedure, a straight vitrectomy knife will be inserted subdermally and will be slowly advanced parallel to the dermis. Rapid advancement and retraction of the needle under the scarred area in a lancing motion will be performed to abrade the underside of the dermis followed by side to side sweeping motions attempting to break any fibrous attachments to the deeper tissues.
223884287|NCT06066541|BEHAVIORAL|Scorecard|"Participants will be mailed a scorecard from Humana reporting patients' medication adherence using a refill score."
223884288|NCT06066541|BEHAVIORAL|Social norms|Participants will be mailed a dynamic social norms messaging (noting the proportion of Humana members improving their medication refill scores).
223884289|NCT06066541|BEHAVIORAL|Messenger effects|Participants will be mailed a scorecard coming from the trusted messenger of a Humana-identified pharmacist taking the same medication.
223884290|NCT06066541|BEHAVIORAL|Processing fluency|"Participants will be mailed a modified scorecard increasing processing fluency through a visual metaphor of closing the ring."
223884291|NCT06229613|DEVICE|medical device for exhaled breath aerosols (XBAs) collection|To evaluate the feasibility of XBAs collection and analysis (index test) using the molecular tests currently in use at San Raffaele Hospital for the detection of respiratory pathogens in clinical samples, compared to upper respiratory secretion and sputum samples, that will be collected using standard procedures and analysed using the same kits (comparator tests).
223884292|NCT04996160|DRUG|Palbociclib|Oral
223884293|NCT04996160|DRUG|Dexamethasone|8 mg/m2/day divided BID, PO, NG, or IV
223884294|NCT04996160|DRUG|Bortezomib|1.3 mg/m2/dose, IV (preferred) or SC
223884295|NCT04996160|DRUG|Doxorubicin|25 mg/m2/dose IV
223884296|NCT04714671|OTHER|The virtual version of the Social stress task : V-TSST|The task consists in a brief presentation about the abilities of participants followed by an arithmetic task in front of a virtual 3D audience projected and one researcher in a small room.First, participants have 5 minutes to prepare an exhibition about their qualities, their strengths and defects, and, why they identify with them. During this period virtual reality shows a closed curtain, and sounds from the audience can be heard. In the second phase, the curtain is raised and the participant must expose his speech during 5 minutes. Audience will remain attentive during 2 minutes, then audience will change to a restless attitude. The third phase consists of subtracting back a two-digit number from a four-digit number, as quickly as possible, starting again if participant makes a mistake. A debriefing of the test is scheduled at the end of the protocol, to remind patients of the purely fictional nature of this test. The visit will only end after a return to the baseline emotional state
223884297|NCT06459141|PROCEDURE|acute normovolemic hemodilution|The ANH was conducted with more than 8 ml/kg of whole blood drawn from an internal jugular introducer by gravity and collected into standard sterile blood storage bags containing citrate phosphate-dextrose anticoagulant. The allowable blood loss was capped according to the preoperative hemoglobin, estimated blood volume, and the target hemoglobin (10 g/dL). The collected blood was simultaneously replaced by an equal volume of succinyl gelatin solution via at least one large bore peripheralvenous catheter to maintain hemodynamic stability.
223884298|NCT04533022|DRUG|C21|C21 100 mg BID (twice daily)
223884299|NCT06552468|DEVICE|AF monitoring by a smartwatch with PPG|The device we used for intervention is a smartwatch (JKwear 1, Chengdu CVhealth Science and Technology Co., Ltd, CN) for collecting watch-recorded-PPG (W-PPG).
223884300|NCT05807711|DRUG|L-Methyl Folate and methylcobalamine|Dietary supplement labeled to contain methylfolate 800 micrograms and methylcobalamine 1000 micrograms
223884301|NCT05733715|DRUG|Pembrolizumab infusion|100 mg/ 4mL on Day 1 of each 3- or 6- week cycle (one 3 wk cycle; up to eight 6 wk cycles)
223884302|NCT05733715|DRUG|Lenvatinib tablet|10mg and 4mg daily for 21 days
223884303|NCT05285007|OTHER|Mobilization with Movement|Participants will be lunging on a box with posterior ankle glide of 10 seconds times 5 sets. They will have 30 seconds rest between trials. Participant will have their ankle taped and then walk on a treadmill at a self-selected pace for 5 minutes.
223884304|NCT05285007|OTHER|No mobilization with movement and education|Participants ankle will not be taped and they will walk on the treadmill for 5 minutes and receive education.
223884305|NCT06116409|DRUG|Bupivacain|Bupivacaine was used for postoperative analgesia block.
223884306|NCT06242431|PROCEDURE|Group serratus posterior superior intercostal plane block (SPSIPB)|SPSIPB; The procedure will be carried out with the patient in the lateral decubitus position. After gently shifting the scapula laterally, the US probe is held sagittally at the upper corner of the scapula, and the 3rd rib and serratus posterior superior muscle are visualized. The block needle will be advanced in the cranio-caudal direction to enter between the serratus posterior superior and the 3rd rib. After confirming the block site, 30 ml of 0.25% concentration of marcaine (bupivacaine) will be used.
223884307|NCT06242431|PROCEDURE|Group pectoralis nerve block (PECS-II)|PECS II; The block will be performed in the supine position of the patient, just anterior to the axillary line at the level of the 4th rib. After visualizing the serratus anterior, pectoralis major, and pectoralis minor muscles along with the ribs and pleura, the needle will be directed in-plane from cranial to caudal into the fascia of the serratus anterior muscle. Subsequently, 30 ml of bupivacaine with a 0.25% concentration will be applied.
223884308|NCT05050916|DIETARY_SUPPLEMENT|Vitamin D|The High Dose Vitamin D arm will receive 50,000 IU/week of cholecalciferol. The Low Dose Vitamin D arm will receive 4,200 IU/week of cholecalciferol
223884309|NCT05050916|OTHER|Placebo|Cellulose capsule
223884310|NCT02163447|DRUG|Monthly dihydroartemisinin-piperaquine (DP) for adult women during pregnancy|
223884311|NCT02163447|DRUG|3 dose dihydroartemisinin-piperaquine (DP) for adult women during pregnancy|
223884312|NCT02163447|DRUG|3 dose sulfadoxine-pyrimethamine (SP) for adult women during pregnancy|
223884313|NCT02163447|DRUG|Monthly dihydroartemisinin-piperaquine (DP) for infants|
223884314|NCT02163447|DRUG|3-monthly dihydroartemisinin-piperaquine (DP) for infants|
223884315|NCT05886517|DEVICE|Transfemoral transcatheter aortic valve implementation|ranscatheter aortic valve implantation, a percutaneous treatment for severe aortic valve stenosis, is increasingly performed worldwide. The pacemaker should be able to perform overdrive pacing which is essential to reduce cardiac output and transvalvular blood flow which are critical during balloon aortic valvuloplasty and valve deployment of the balloon- expandable valve. Minor adjustment may be needed for ideal positioning, but importantly this has to be done before valve implantation
223884316|NCT06641154|DRUG|GT-UGT1A1-AAV8-02|Intravenous infusion, single dose
223884317|NCT06048614|PROCEDURE|Saline Enema (SE)|"infant who allocated with intervention group will proceed with SE with normal saline (20-40ml/kg twice daily) at 48 hours of age. Then continue until 2 days of yellow stools/ 110ml/kg/day of oral feeds; whichever is earlier.~SE are recommended if baby do not do bowel opening (BO) for 2 days before reaching full feeds~Failure to resolve the MOP with SE will be designated as treatment failure and managed with contrast enema or Laparotomy by paediatric surgeons, following a formal referral.GS is not allowed in intervention arm"
223884318|NCT06048614|DRUG|Glycerin Suppository|"Infants randomized to GS received the standard management protocol for meconium retention in the unit. GS (2,000 mg, a quarter unit, four doses 12 h apart) were administered to infants earliest at 48 hour to 72 hours of birth, with subsequent once-daily GS being administered at the discretion of the managing team. Infants who were diagnosed with meconium obstruction later in the first 2 weeks of life were also treated with glycerin suppositories for 48 hrs, with subsequent once-daily GS being administered at the discretion of the managing team.~Infants who failed to respond to glycerin suppositories were referred to the surgical team by the managing team The subsequent management of meconium retention was at the surgeon's discretion and included continued GS by the surgical team, contrast enema or surgical interventions performed in escalating order as mentioned."
223884319|NCT06582706|DRUG|Placebo Comparator|a readily available inert placebo will be used
223884320|NCT06582706|DRUG|Extended Release Niacin|500 mg
223884321|NCT03821233|DRUG|ZW49|"* Dose Escalation: ZW49 administered intravenously at dose levels determined by the SMC~* Expansion: MTD or RD identified in the dose-escalation part of the study"
223884322|NCT06240091|DEVICE|DISC-MA|DISC-MA is a digital program that utilizes elements from validated psychotherapies (e.g., cognitive behavioral therapy), with a relational agent (Woebot) that engages users in conversations with responses that are selected from a list based on natural language processing.
223884323|NCT04939844|DRUG|Isatuximab, bortezomib, lenalidomide, dexamethason|All participants will receive the same treatment as described under arm.
223884324|NCT02419014|DEVICE|Active CES Device Alpha-Stim®|The Alpha-Stim® device is a Class II FDA-approved device for the delivery of cranial electrotherapy using microcurrents that are delivered via two electrodes worn on the earlobes. Active CES devices will be pre-programmed by the manufacturer to deliver a bipolar, asymmetric rectangular waveform at a current of 100 µa, a level that is generally undetectable by the wearer of the device. At these settings, the manufacturer recommends a treatment duration of 60 minutes. Participants will not be able to alter the settings in any way.
223884325|NCT02419014|DEVICE|Sham Device|The inactive (sham) devices look identical to the active device but are inactivated by the manufacturer so as not to deliver any electrical current.
223884326|NCT04023669|DRUG|Prexasertib|IV
223884327|NCT04023669|DRUG|Cyclophosphamide|IV
223884328|NCT04023669|DRUG|Gemcitabine|IV
223884329|NCT04023669|BIOLOGICAL|filgrastim|Given subcutaneously (SQ). Alternatively, pegfilgrastim may be given.
223884330|NCT04023669|BIOLOGICAL|peg-filgrastim|Given subcutaneously (SQ). Alternatively, filgrastim may be given.
223884331|NCT06484985|DRUG|AXT-1003|AXT-1003 capsule is administered orally daily, until disease progression or intolerable toxicity.
223884332|NCT05541666|BEHAVIORAL|The Emotional Freedom Technique|The Emotional Freedom Technique (EFT) is a method that uses cognitive functions and physical components (tapping acupuncture points) to bring about psychological changes. The Emotional Freedom Technique is a non-invasive procedure that uses acupuncture meridians. We stimulate these energy points by touching the 14 basic meridian points ın this technique. We make suggestions to our subconscious by repeating the setup sentence for the problem we want to solve. Thus, we try to solve the blockages in the meridians that prevent the flow of energy. Energy blockages disrupt the balance of the mind/body/energy system. This situation causes negative emotions such as stress, panic, fear, and sadness in the person. And with the effect of emotions, disturbances may occur in our physical body. When the energy blockage is removed, the person can feel positive emotions such as happiness, personal power, feeling good, understanding, and loving behavior.
223884333|NCT02697123|OTHER|antepartum and postpartum|This is a prospective observational cohort study.
223884334|NCT04052516|DRUG|Icosabutate|Icosabutate oral capsule once daily
223884335|NCT04052516|DRUG|Placebo|Matching placebo oral capsule
223884336|NCT05620641|DRUG|Ondansetron 8mg|50 patients will receive intravenous ondansetron 8 mg before the end of surgery.
223884337|NCT05620641|DRUG|Gabapentin|50 patients will receive 600 mg oral gabapentin 1 h before anesthesia.
223884338|NCT04415788|DEVICE|Test of Incremental Respiratory Endurance - IMT|The TIRE training regimen will involve the use of a tablet provided to assigned subjects with the training software installed and a PrO2® device through which they will train. The software allows subjects to track their inspiratory muscle performance via real-time graphic representations of their efforts as training progresses.
223884339|NCT04415788|DEVICE|Threshold - IMT|The Threshold incorporates a flow-independent one-way valve to ensure consistent resistance and features an adjustable specific pressure setting to be set based on MIP values of each subject.
223884340|NCT04415788|DEVICE|Sham IMT (Low resistence)|The Threshold incorporates a flow-independent one-way valve to ensure consistent resistance and features an adjustable specific pressure setting to be set based on MIP values of each subject.
223884341|NCT05790707|PROCEDURE|Atrial fibrillation ablation + antiarrhythmic drugs|"Atrial fibrillation ablation will be performed with endovascular catheters and will be done either with radiofrequency, cryoballoon or pulsed field ablation.~Amiodarone, flecainide, sotalol, propafenone are the anti arrhythmic drugs allowed."
223884342|NCT05790707|DRUG|Antiarrhythmic drug|Amiodarone, flecainide, sotalol, propafenone are the anti arrhythmic drugs allowed.
223884343|NCT05743621|DRUG|TVB-2640|TVB- 2640 at 100 mg, 150mg, 200 mg, 250 mg, or 300mg daily, orally; dose determined by BOIN dose escalation per the protocol
223884344|NCT05743621|DRUG|Enzalutamide|160 mg daily PO
223884345|NCT06087614|RADIATION|DE-HyART|The HSV delineation will be done for patients in arm 3 using baseline FMISO. The HSV will be contoured and adjusted according to the second FMISO scan done between the 4th - the 5th week of radiation treatment. A planning CT will also be repeated at the time for adjusting the HSV to account for temporal changes. The Biological Target Volume thus generated after adequate margins will be prescribed 30 Gy in 10 fractions over and above the standard fractination.
223884346|NCT06087614|RADIATION|Standard Arm|The prescribed radiotherapy dose will be 70 Gy in 2 Gy per fraction daily. The elective volume will be treated with 50 Gy in 2 Gy per fraction daily till the first 5 weeks. The entire treatment will be delivered in a phased mannered using sequential planning.
223884347|NCT06087614|DRUG|Cisplatin injection|Concurrent chemotherapy, weekly Inj Cisplatin 40mg/m2. This will be given if clinically indicated
223884348|NCT06087614|RADIATION|Standard fractionation (Radiation Oncology preference)|Standard institutional practice is detailed before starting the patient. Doses 66-70 Gy over 6-7 weeks
223884349|NCT06188247|DEVICE|NightOwl home-monitoring|The NightOwl™ system consists of a small sensor device which is placed on the fingertip and a smartphone app that is connected to an encrypted cloud-based analytics platform within the European Union, the NightOwl™ software. The sensor is self-applied by attaching the sensor to the fingertip by means of an adhesive patch. The NightOwl™ sensor acquires accelerometer data and reflectance-based photoplethysmography (PPG) from which it derives actigraphy (sleep/wake behavior), SpO2, peripheral artery tone (PAT) and pulse rate, among other features. A PAT analysis derives changes in caliber of arteries elicited by alterations in the contractile activity of vascular smooth muscle and are referred to as changes in arterial tone. The end state of the apnea-hypopnea events are associated with sympathetic activation.
223884350|NCT01745965|DRUG|T-DM1|
223884351|NCT01745965|DRUG|Trastuzumab|
223884352|NCT06407973|DEVICE|OMNI Surgical System|The OMNI Surgical System is 510(k) cleared and indicated for canaloplasty (microcatheterization and transluminal viscodilation of Schlemm's canal) followed by trabeculotomy (cutting of trabecular meshwork) to reduce intraocular pressure in adult patients with primary open-angle glaucoma
223884353|NCT06407973|DRUG|Latanoprost plus adjunctive glaucoma medication|"* Latanoprost ophthalmic solution (0.005%) is a topical prostaglandin F2 analog used in the treatment of Glaucoma.~* Adjunctive topical glaucoma medication(s) as selected by the Investigator"
223884354|NCT05560529|BEHAVIORAL|DBT|Applying DBT modules in group format over 20 weeks
223884355|NCT05560529|DRUG|TAU|Giving TAU (usual pharmacotherapy in BED) over 20 weeks
223884356|NCT05560529|DIAGNOSTIC_TEST|Plasma Ghrelin|Measuring fasting plasma ghrelin pre and post treatment in both arms
223884357|NCT05563857|COMBINATION_PRODUCT|VIOME Precision Nutrition Program|Precision supplement based on the participants microbiome sample results. Participants in this arm may have any combination of supplements, diet recommendations, and/or coaching.
223884358|NCT05563857|DIETARY_SUPPLEMENT|VIOME-designed condition-based supplements|Pre-formulated supplements based on overall health conditions. Participants in this arm may have any combination of supplements, diet recommendations, and/or coaching.
223884359|NCT03537586|DRUG|Bivalirudin|After diagnostic catheterization, intravenous bivalirudin (Angiomax) will be administered as part of the research procedure, and a 6F-guiding catheter without side holes will be used to engage the ostium of the coronary artery.
223884360|NCT03537586|DRUG|Adenosine|An intravenous infusion of adenosine (140 μg/kg/min) will be administered via a large peripheral or central vein to induce steady-state maximal hyperemia.
223884361|NCT03537586|DRUG|Heparin|Heparin may be used as an alternative to bivalirudin at the discretion of the interventional cardiologist.
223884362|NCT03537586|DEVICE|Pressure-Temperature Sensor Guidewire|Abbott's Pressure Wire X will be used to measure fractional flow reserve (FFR), cardiac magnetic resonance (CMR) and Index of Microcirculatory Resistance (IMR) in the Left Anterior Descending (LAD) Artery and major epicardial coronary vessels associated with myocardial ischemia.
223884363|NCT03537586|DEVICE|Guiding Catheter|Medtronic's 6F Launcher Guide Catheter will be used to engage the left main coronary artery.
223884364|NCT05508763|GENETIC|Genetic test for 14 pharmacogenes|Genotyping with the Global Diversity Array-8 v1.0 BeadChip with enhanced PGx
223884365|NCT06788652|BIOLOGICAL|Lisocabtagene maraleucel|According to US Prescribing Information
223884366|NCT06792409|DEVICE|Minimally invasive breast augmentation procedure with a trans-axillary approach.|Minimally invasive breast augmentation procedure with a transaxillary approach using Motiva Ergonomix2 Diamond®, Motiva Injector® and Motiva® Inflatable Balloon.
223884367|NCT06783764|PROCEDURE|PECS II block and transverse thoracic plane block|will receive a combination of PECS II block and TTPB (injection of 10 ml 0.25% bupivacaine between pectoralis major and minor muscles and 10 ml between the pectoralis minor and serratus anterior muscles) at the third or the fourth rib, then 10 ml between the internal inter-costal muscles and the transversus thoracic muscle
223884368|NCT06783764|PROCEDURE|Erector Spinae Plane Block|ESPB (30 ml of 0.25% bupivacaine injected deep to the erector spinae muscle at the transverse process of the fifth thoracic vertebrae)
223884369|NCT06783764|DRUG|bupivacaine 0.25 % injection|injection of 10 ml 0.25% bupivacaine between pectoralis major and minor muscles and 10 ml between the pectoralis minor and serratus anterior muscles) at the third or the fourth rib, then 10 ml between the internal inter-costal muscles and the transversus thoracic muscle
223884370|NCT06783764|DRUG|bupivacaine 0.25 % injection|30 ml of 0.25% bupivacaine injected deep to the erector spinae muscle at the transverse process of the fifth thoracic vertebrae
223884371|NCT06791395|DIAGNOSTIC_TEST|Artificial intelligence platform for endocytoscopy|The detected lesions are predicted by artificial intelligence
223884372|NCT05113966|DRUG|Trilaciclib|Single-use, sterile powder to be reconstituted and further diluted with 250 milliliters (mL) of normal saline (sodium chloride solution 0.9%) or dextrose 5% in water (D5W)
223884373|NCT05113966|DRUG|Sacituzumab Govitecan-hziy|10 milligram per kilogram (mg/kg) reconstituted to a concentration of 1.1 mg/mL to 3.4 mg/mL in normal saline
223884374|NCT06786910|OTHER|Toothpaste with olive oil, trimethylglycine and xylitol|Composition comprising olive oil, trimethylglycine and xylitol, formulated as a toothpaste to be delivered topically onto the oral cavity 3 times a day during 1 month.
223884375|NCT06786910|OTHER|Toothpaste without olive oil, trimethylglycine nor xylitol|Composition without olive oil, without trimethylglycine and without xylitol, formulated as a toothpaste to be delivered topically onto the oral cavity 3 times a day during 1 month.
223884376|NCT06792240|DIETARY_SUPPLEMENT|iron supplementation|"The amount of supplementary iron was decided for patients according to the daily requirement (8- 18 mg / day), according to LARN 2012 and (RDAs) for Iron. (25) . This study took in consideration also, the recommendation of the National Institutes of Health iron dietary supplement fact of sheet as reference to calculate iron dose for our candidates because this dose isn't against LARN and more practical to applicate.~The minimum RDA values is applied, which coincides within the LARN daily requirement limits. (7 mg-18 mg of iron per day). Applying the minimum recommended RDA dose, that can satisfy the daily iron requirement by age, approximating it to be adequate for the clinical dose administered orally once a day (e.g. 1.98 g ==\> 2 g, 1.53 g ==\> 1.5 g"
223884377|NCT06792240|DIETARY_SUPPLEMENT|control group|Non intervension: Only restricted low and controlled Phe diet therapy
223884378|NCT05386355|BEHAVIORAL|COVID-19 Vaccine Uptake App|A mHealth mobile application (app) that will provide educational and logistical information about the COVID-19 vaccination for children. The target audience will be parents of unvaccinated children.
223884379|NCT05386355|OTHER|General Health App|A mobile application (app) that will provide general pediatric health and infection prevention and mitigation strategies.
223884380|NCT06789744|DEVICE|General Anesthesia (GA)|"Patients will be induced with general anesthesia, consisting of propofol (1.5-2 mg/kg intravenously), rocuronium (1-2 mg/kg intravenously), and fentanyl (1-2 μg/kg intravenously). Anesthesia will be maintained with inhaled sevoflurane or desflurane, adjusted according to BIS values. Remifentanil (0.05-0.2 μg/kg/min) will be administered via continuous infusion, with the infusion rate adjusted to maintain blood pressure and heart rate within ±20% of baseline.~Following induction, patients will be mechanically ventilated in pressure-regulated volume control (PRVC) mode using an Aestiva anesthesia machine (GE Healthcare, Waukesha, Wisconsin, USA). Ventilator settings will be as follows: tidal volume 6-8 mL/kg, positive end-expiratory pressure 0 cmH2O, inspiratory-to-expiratory ratio 1:2, respiratory rate 16 breaths per minute (BPM), and inspired oxygen concentration of 41%."
223884381|NCT06789744|PROCEDURE|Epidural Analgesia( 0.2% ropivacaine)|For epidural analgesia, an initial bolus of 5-15 mL of 0.5% ropivacaine will be administered, followed by a continuous infusion of 0.2% ropivacaine at a rate of 3-10 mL/hour. In pediatric patients, the initial bolus will consist of 0.2% ropivacaine at a dose of 0.5-1 mg/kg, not to exceed 2-2.5 mg/kg, followed by a continuous infusion of 0.1-0.3 mg/kg/hour.
223884382|NCT06789744|DEVICE|Paravertebral block ( liposomal bupivacaine 133 mg or 0.2% ropivacaine)|For paravertebral blocks, patients will be positioned either sitting or in the lateral decubitus position to fully expose the target area of the spine. The spinous process of the target vertebra will be palpated, and the puncture site identified. Using ultrasound guidance, the paravertebral space will be located. After standard skin preparation, a blunt needle will be advanced perpendicular to the skin. Once the needle tip contacts the transverse process, it will be withdrawn 1-2 mm, and then slightly angled caudally to pass through the paravertebral ligament and enter the paravertebral space. After negative aspiration for blood or cerebrospinal fluid, a 5 mL test dose of local anesthetic will be slowly injected, and the patient observed for adverse effects. If none are noted, an additional 5 mL of local anesthetic will be injected. The local anesthetic solution will be either liposomal bupivacaine (266 mg diluted to 20 mL) or 0.2% ropivacaine.
223884383|NCT06789744|DEVICE|Transversus Abdominis Plane Block (TAP Block)( liposomal bupivacaine 133 mg or 0.2% ropivacaine)|For TAP blocks, patients will be positioned supine with the abdomen exposed. Following standard skin preparation, a needle will be advanced perpendicular to the skin using ultrasound guidance, through the external oblique and internal oblique muscles to reach the fascial plane between the transversus abdominis and internal oblique muscles. After negative aspiration for blood, a 5 mL test dose of local anesthetic will be slowly injected, and the patient observed for adverse effects. If none are noted, an additional 10 mL of local anesthetic will be injected. The local anesthetic solution will be either liposomal bupivacaine (266 mg diluted to 20 mL) or 0.2% ropivacaine.
223884384|NCT06789744|PROCEDURE|Intrathecal Morphine|For intrathecal analgesia, adults will receive 0.1-0.2 mg of morphine intrathecally. For pediatric patients, the dose of intrathecal morphine will be 5-10 mcg/kg.
223884385|NCT06789744|DRUG|Intravenous Patient-Controlled Analgesia (PCA) (fentanyl)|For intravenous PCA, a solution of fentanyl 2 mcg/kg will be diluted to a total volume of 100 mL with normal saline. The PCA settings will be as follows: a basal rate of 2 mL/hour, a PCA dose of 2 mL, and a lockout interval of 15 minutes.
223884386|NCT06783504|DEVICE|PERCUTANEOUS ELECTRICAL FIELD NERVE STIMULATION|The IB-Stim is a percutaneous electrical nerve field stimulator (PENFS) system intended to be used in patients 11-18 years of age with functional abdominal pain associated with irritable bowel syndrome (IBS). The IB-Stim is intended to be used for 120 hours per week up to 3 consecutive weeks, through application to branches of Cranial Nerves V, VII, IX and X, and the occipital nerves identified by transillumination, as an aid in the reduction of pain when combined with other therapies for IBS.
223884387|NCT06783504|DEVICE|Sham percutaneous electrical nerve field stimulation|SHAM (no electrical charge)
223884388|NCT06779201|OTHER|Fasting|One-week fasting without limit of water drink (Participants can feel free to drink water )
223884389|NCT06784440|GENETIC|Evaluation of circulating donor free DNA in the recipient's blood (Dd-cfDNA: donor-derived cell free DNA)|From the blood samples taken, 2 mL of plasma separated from blood will be stored in EDTA frozen at -80°C. This material will later be processed by NGS run using of CareDX kits. The result will be provided by dedicated software as percentage of donor DNA in relation to recipient DNA.
223884390|NCT03875573|DRUG|Durvalumab|an anti PD-L1 intravenous administration at 1500 mg every 4 weeks for 19 weeks.
223884391|NCT03875573|RADIATION|Stereotactic Body Radiotherapy|Pre-operative radiation therapy (boost dose) 3x8 Gy on the primary tumour at week 5 given in 3 fractions. The 3 fractions will be spread at the minimum over 3 days and at the maximum over 6 days.
223884392|NCT03875573|DRUG|Oleclumab|an anti-CD73 intravenous administration at 3000 mg every 2 weeks for the first 4 administrations then every 4 weeks for the last 3 administrations.
223884393|NCT06229964|OTHER|SSNB + IACI|"Usual care: All patients complete rehabilitation under supervision of their own physiotherapist. The investigators will provide some guidelines and criteria but is the physiotherapist's choice how to implement these guidelines in clinical practice.~Patient education on home-exercises Monitoring of peak pain, at rest/night and after rehabilitation sessions using a Numeric-Pain-Rating-Scale (0-10) (NPRS) to evaluate tissue irritability and guide physiotherapy and rehabilitation.~Use of passive physiotherapy (cold, heat or electric therapies) to treat pain. Active and passive mobilization of the shoulder under the pain threshold, Maitland mobilization, stretch exercises such as: table slides, wall climbers. Use of affected upper limb in pain free Range-of-Motion (ROM) is tolerated and stimulated. Progressively increase time and frequency of Total-End-Range-Time (TERT) positions to increase ROM"
223884394|NCT06229964|OTHER|Sham SSNB + IACI|"Usual care: All patients complete rehabilitation under supervision of their own physiotherapist. The investigators will provide some guidelines and criteria but is the physiotherapist's choice how to implement these guidelines in clinical practice.~Patient education on home-exercises Monitoring of peak pain, at rest/night and after rehabilitation sessions using a Numeric-Pain-Rating-Scale (0-10) (NPRS) to evaluate tissue irritability and guide physiotherapy and rehabilitation.~Use of passive physiotherapy (cold, heat or electric therapies) to treat pain. Active and passive mobilization of the shoulder under the pain threshold, Maitland mobilization, stretch exercises such as: table slides, wall climbers. Use of affected upper limb in pain free Range-of-Motion (ROM) is tolerated and stimulated. Progressively increase time and frequency of Total-End-Range-Time (TERT) positions to increase ROM"
223884395|NCT06792591|DEVICE|PEM|Accuracy of PEM in detection of breast cancer
223884396|NCT06784362|OTHER|No intervention|This is an observational study
223884397|NCT06143670|DRUG|Stannous fluoride toothpaste|0.454% w/w SnF2
223884398|NCT06143670|DRUG|Sodium fluoride toothpaste|0.243% w/w Sodium fluoride
223884399|NCT03373097|BIOLOGICAL|GD2-CART01|Following a lymphodepleting treatment with conventional chemotherapy, patients will be treated with 1.0 to 10.0 x 10⁶/kg GD2 Chimeric Antigen Receptor (CAR) positive T cells as a single dose.
223884400|NCT06459583|OTHER|eHealth Platform|The eHealth Platform consists of the ADWebPortal and ADChatbot for receiving Alzheimer's-related test results
223884401|NCT06459583|OTHER|Videoconference Telehealth Platform|Participants will have a video telehealth visit with a healthcare provider to receive Alzheimer's-related test results
223884402|NCT06790576|OTHER|closed-loop-peak|With single pulse TMS stimulation at F3 based on 10-20 EEG system, TMS evoked potentials (TEPs) will be collected under three TMS synchronization conditions: closed-loop-peak (each pulse synchronized to person's peak of theta waveform)
223884403|NCT06790576|OTHER|Open-loop|With single pulse TMS stimulation at F3 based on 10-20 EEG system, TMS evoked potentials (TEPs) will be collected under three TMS synchronization conditions: open-loop (TMS pulse delivered without regard to EEG)
223884404|NCT06790576|OTHER|closed-loop-trough|With single pulse TMS stimulation at F3 based on 10-20 EEG system, TMS evoked potentials (TEPs) will be collected under three TMS synchronization conditions: closed-loop-trough (each pulse synchronized to trough of theta waveform)
223884405|NCT06786182|BEHAVIORAL|PFM Educational Program|A structured telematic educational program covering PFM anatomy, function, and proper activation techniques. Content includes videos, visual guides, and exercises aimed at promoting PFM co-contraction and awareness.
223884406|NCT06789627|OTHER|RPD with PEEK framework|Indirectly CAD/CAM produced PEEK framework
223884407|NCT06789627|OTHER|RPD with metallic framework|Indirectly CAD/CAM produced metallic RPD
223884408|NCT06784531|DIETARY_SUPPLEMENT|Mitoquinone mesylate (MitoQ)|Four 20 mg MitoQ capsules (80 mg total) are ingested orally.
223884409|NCT06784531|DIETARY_SUPPLEMENT|Placebo|Four placebo (microcrystalline cellulose) capsules are ingested orally.
223884410|NCT06784531|OTHER|Cold Water Hand Immersion|Volunteers place one hand in cold (54°F) water for 30 minutes.
223884411|NCT06784531|OTHER|Cold Air Exposure|Volunteers sit in cold (41°F) air for 90 minutes.
223884412|NCT06789120|OTHER|Instrument-assisted soft tissue mobilization|In the study, the Graston device will be applied to the plantar flexor muscles of the patients. The medial and lateral gastarosoleus muscles and tendon will be applied deeply for 3 minutes, and the soleus muscle will be applied deeply for 90 seconds.
223884413|NCT06785974|DRUG|Atorvastatin|Daily 20mg atorvastatin.
223884414|NCT06785974|DRUG|Placebo|Daily Placebo in combination with ICI-therapy
223884415|NCT06786065|OTHER|No intervention (observational study)|No intervention (observational study)
223884416|NCT06792526|OTHER|IVIM Imaging MRF Imaging|IVIM imaging will be performed to evaluate microstructural and perfusion changes in the salivary glands of Head and Neck Cancer undergoing radiotherapy. This technique quantifies diffusion and perfusion parameters, providing insights into early tissue damage. MRF imaging will be used to quantify salivary gland tissue characteristics, including relaxation parameters (T1 and T2 mapping), to monitor radiotherapy-induced damage. The technique enables precise tissue characterization through multi-parametric MRI.
223884417|NCT06316154|PROCEDURE|Echinococcectomy|Echinococcectomy with subsequent pathomorphological analysis of liver parenchyma next to and in the thickness of the fibrous capsule
223884418|NCT06783816|DRUG|chimeric antigen receptor gene modified T cells|The rate of intravenous infusion of CAR T cells was 10 mL to 20 mL/min, and the infusion was performed using a blood transfusion apparatus with a filter screen. Use saline rinsing tube prior to infusion; Rinse the infusion bag with 10 mL\~30 mL normal saline.
223884419|NCT06790849|DIETARY_SUPPLEMENT|Active 1 ETAS®|300 mg ETAS®
223884420|NCT06790849|DIETARY_SUPPLEMENT|Active 2 ETAS®|1500mg ETAS®
223884421|NCT06790849|DIETARY_SUPPLEMENT|Placebo|Matched placebo capsule
223884422|NCT06790745|PROCEDURE|Epidural blood patch|Patients will receive epidural blood patch injection
223884423|NCT06790745|DRUG|Plasma rich fibrin epidural injection by Racz catheter|Patients will receive plasma rich fibrin injection by Racz catheter
223884424|NCT06785233|DEVICE|Non-Adjustable Intragastric Balloon|Weight Loss with a 12-Month Non-Adjustable Intragastric Balloon is More Effective Compared to a 6-Month Balloon.
223884425|NCT06785233|DEVICE|ORBERA365|endoscopic treatment of overweight and mild obesity using a 12-month non-adjustable intragastric balloon
223884426|NCT04662112|DRUG|NASOX|Oxalipatin 60 mg/m2 IV (2 h infusion) on Day 1, every 2 weeks Nal-IRI 50-60 mg/m2 IV (FBE, 90 min infusion) on Day 1, every 2 weeks S-1 40mg/m2 oral twice daily on Day 1-7, every 2 weeks
223884427|NCT03747484|BIOLOGICAL|Autologous MCPyV-specific HLA-A02-restricted TCR-transduced CD4+ and CD8+ T-cells FH-MCVA2TCR|Given IV
223884428|NCT03747484|DRUG|Avelumab|Given IV
223884429|NCT03747484|BIOLOGICAL|Pembrolizumab|Given IV
223884430|NCT03747484|BIOLOGICAL|Interferon Gamma-1b|Given SC
223884431|NCT06782841|DEVICE|GMA-TULIP Laryngeal Mask|After the anesthesia induction, use the GMA-TULIP laryngeal mask as the airway ventilation device.
223884432|NCT06782841|DEVICE|i-gel Laryngeal Mask|After the anesthesia induction, use the i-gel laryngeal mask as an airway ventilation device.
223884433|NCT06782841|DEVICE|BlockBuster Laryngeal Mask|After the anesthesia induction is over, use the BlockBuster laryngeal mask as the airway ventilation device.
223884434|NCT06788470|DRUG|MSC|Intratracheal administration of umbilical cord-derived mesenchymal stem cells (MSCs).
223884435|NCT06310356|DEVICE|Freestyle Libre 3|CGM
223884436|NCT06310356|DEVICE|Glucometer|SMBG
223884437|NCT05847855|DIAGNOSTIC_TEST|Blood collection|Blood collection for fragmentomic profiles of plasma cell-free DNA
223884438|NCT06784609|PROCEDURE|Coronary Artery Bypass Surgery|Coronary Artery Bypass Surgery
223884439|NCT06447519|DRUG|Ca(OH)2 as intracanal medicament|Ca(OH2 will be used as intracanal medicament for the disinfection of the root canal between appointmnents
223884440|NCT06787456|DIAGNOSTIC_TEST|EBV antibodies test|ELISA test of VCA-IgA, EBNA1-IgA, EA-IgA, Zta-IgA, Rta-IgG and P85-Ab in nasopharyngeal brushing and plasma in plasma, saliva and nasopharyngeal brushing.
223884441|NCT06787456|DIAGNOSTIC_TEST|EBV DNA test|quantitative polymerase chain reaction, methylation sequencing and target sequencing of EBV DNA in nasopharyngeal brushing, saliva and plasma.
223884442|NCT06787456|OTHER|epidemiological information survey|epidemiological information survey including basic conditions, dietary and lifestyle habits, social, geographical, environmental, and other information.
223884443|NCT06787456|OTHER|Clinical examinations for high-risk participants|nasopharyngoscopy, head and neck MRI.
223884444|NCT06787456|OTHER|EBV and human genetic sequencing|EB virus and human genetic sequencing for plasma, etc.
223884445|NCT06787885|DRUG|Levofloxacin + clindamycin|Group 1
223884446|NCT06787885|DRUG|Levofloxacin + cefipime|Group 2
223884447|NCT06787885|DRUG|Moxifloxacin + meronam|Group 3
223884448|NCT06786871|PROCEDURE|IVF treatment|Methods or procedures for the in vitro processing of human oocytes, sperm, or embryos for fertility purposes
223884449|NCT06789471|DIETARY_SUPPLEMENT|psyllium husk|Psyllium husk, derived from the seeds' husks of the Plantago ovata plant, is a plant-based fiber supplement.
223884450|NCT03233399|DEVICE|Sham TMS3 stimulation|half of the subjects will receive sham stimulation first
223884451|NCT03233399|DEVICE|rTMS of left or right angular gyrus (AG) or frontal cortex (FC)|Half of the subjects will receive active stimulation first; A subject may receive either TMS or tDCS stimulation, but not both, over the course of the sub-study.
223884452|NCT03233399|DEVICE|Anodal tDCS of left or right AG or FC|Half of the subjects will receive active stimulation first; A subject may receive either TMS or tDCS stimulation, but not both, over the course of the sub-study.
223884453|NCT06790511|OTHER|bioactive highly filled injectable flowable composite|bioactive highly filled injectable flowable composite
223884454|NCT06790511|OTHER|highly filled injectable flowable composite|highly filled injectable flowable composite
223884455|NCT02815813|BEHAVIORAL|PeerFIT|The 12-month PeerFIT intervention consists of a 6-month intensive phase including: (a) once weekly 60-minute group weight management and exercise session led by a lifestyle coach; (b) once weekly one-hour physical activity session delivered in community settings; and (c) Facebook and mHealth technology (i.e., Fitbits, text messaging support) to increase motivation and facilitate self-monitoring and peer social support for health behavior change. Participants then transition to a 6-month lower intensity phase in which the 90-minute weight management sessions are discontinued. The groups will be conducted as open groups with a minimum of 4 and maximum of 18 participants at any given time.
223884456|NCT02815813|BEHAVIORAL|BEAT|Participants in BEAT will receive monthly individual lifestyle sessions delivered by a lifestyle coach including education, guidance, and support for self-monitoring behaviors (i.e., daily self-weighing and tracking daily steps) during the first six months of the study, plus text message reminders and encouragement for self-monitoring weight loss behaviors during the entire 12-month study period. Participants will receive materials with tips and strategies for healthy eating and increasing physical activity. They will also be given a wearable activity tracker (i.e., Fitbit Zip) to use with instructions for using the device. The first session with the lifestyle coach will be in person and thereafter by phone.
223884457|NCT06782061|OTHER|DSM17938+Routine clinical treatment|Lactobacillus reuteri DSM17938，5 drops per day by mouth (containing at least 100 million CFU of Lactobacillus reuteri DSM17938)，Routine clinical treatment
223884458|NCT06799871|DEVICE|Dental implant|There is no intervention in the study. The participants have already received dental implant treatment and data will be collected retrospectively regarding the procedure
223884459|NCT06786598|DIAGNOSTIC_TEST|Cholesterol|Qimica/kit
223884460|NCT05734066|DRUG|Lurbinectedin|Administered as intravenous (IV) infusion once every 3 weeks (Q3W)
223884461|NCT06139081|OTHER|Oxygen delivery mode|After the implantation of the mirror, nasal catheter was used to give oxygen through the mouth
223884462|NCT01780883|DRUG|melatonin|
223884463|NCT01780883|DRUG|Placebo|Placebo tablets of Circadin®
223884464|NCT04869436|DRUG|Dupilumab 300 MG/2 ML Subcutaneous Solution [DUPIXENT]|Dupilumab will be administered subcutaneously for 6 months (1 initial 600mg dose + 5 300mg doses every 4 weeks)
223884465|NCT06112171|PROCEDURE|Intravascular lithotripsy|Lesion preparation with Shockwave Medical Peripheral Lithotripsy System
223884466|NCT06112171|PROCEDURE|Standard lesion preparation|Lesion preparation with Standard and/or High-Pressure Balloon Angioplasty
223884467|NCT03842826|DIAGNOSTIC_TEST|Palpation, resistance and stretch tests|Palpation, resistance and stretch tests performed by 2 blinded examiners.
223884468|NCT05243069|PROCEDURE|Imaging Technique|Undergo 3D scanning
223884469|NCT01901094|PROCEDURE|Axillary Lymph Node Dissection (ALND)|
223884470|NCT01901094|RADIATION|Nodal Radiation Therapy|
223884471|NCT01901094|RADIATION|Axillary Radiation Therapy|
223884472|NCT04563793|DEVICE|Superion™ IDS|All patients to receive IDS for the treatment of moderate Lumbar Spinal Stenosis symptoms.
223884473|NCT02597946|DRUG|afatinib|
223884474|NCT02597946|DRUG|paclitaxel|
223884475|NCT06778148|OTHER|Ambient AI for clinician documentation|Ambient AI for clinician documentation
223884476|NCT06779071|DEVICE|NPNP-001|Description: NPNP-001 2ml per injection, once a week for 3 injections. Placebo(saline) 2ml per injection, once a week for 2 injections.
223884477|NCT06779071|DEVICE|Conjuran|Description: Conjuran 2ml per injection, once a week for 5 injections.
223884478|NCT06366373|OTHER|A mental health art exhibition|"The specific intervention measure is the Second Mental Health Art Science Exhibition scheduled to take place in Wuhan, China from April 27 to May 27, 2024. Organized by Qixi Charity, an NGO led by individuals with lived experience of mental disorders, as well as their family members and friends, the exhibition will feature offline artworks created by these individuals and other contributors. The exhibited artworks aim to reflect the diverse dimensions of mental health and ill-health."
223884479|NCT06366373|OTHER|printed or online education materials|The specific intervention measure is to provide printed or online education materials within the first month after the baseline survey
223884480|NCT06294158|OTHER|Brightness measurement|Measurement of ambience brightness using lux meters
223884481|NCT06294158|OTHER|Sound level measurement|Measurement of ambience sound levels using sound level meters
223884482|NCT06492395|COMBINATION_PRODUCT|Len+DEB-TACE+HAIC|"For DEB-TACE, superselective catheterization is performed and DEBs loaded with pirarubicin is use for chemoembolization. The embolization end point was blood stasis of the tumor-feeding arteries. In order to reduce the risk of complications, the embolization end point was not achieved in the initial TACE but in the second or third TACE session.~After each chemoembolization, the microcatheter is reserved at the main hepatic tumor-feeding artery. The FOLFOX-based regimen is intra-arterially administered.~During follow-up, the treatment of DEB-TACE and/or HAIC will be repeated for viable tumors based on the evaluation of the follow-up laboratory and imaging examination.~Lenvatinib 12mg (body weight ≥60kg) or 8mg (body weight \<60kg) P.O. qd will be started with 7 days after the first DEB-TACE+HAIC."
223884483|NCT06492395|COMBINATION_PRODUCT|Len+DEB-TACE|"For DEB-TACE, superselective catheterization is performed and DEBs loaded with pirarubicin is use for chemoembolization. The embolization end point was blood stasis of the tumor-feeding arteries. In order to reduce the risk of complications, the embolization end point was not achieved in the initial TACE but in the second or third TACE session. During follow-up, the treatment of DEB-TACE will be repeated for viable tumors based on the evaluation of the follow-up laboratory and imaging examination.~Lenvatinib 12mg (body weight ≥60kg) or 8mg (body weight \<60kg) P.O. qd will be started with 7 days after the first DEB-TACE+HAIC."
223884484|NCT04487587|DRUG|Cediranib, Olaparib|Cediranib film coated tablet, Olaparib film coated tablet
223884485|NCT04995484|DRUG|Belzutifan|Two 40 mg tablets given as a single oral 80 mg dose.
223884486|NCT05815173|DRUG|Sotorasib|Sotorasib administered at the approved dose of 960mg PO once daily over 21-day treatment cycles.
223884487|NCT05815173|DRUG|Ladarixin|"Ladarixin dose will be escalated as follows in Phase I: 3 patients will receive a starting dose of 200mg. If 2 or more patients experience a DLT at the lowest dose, the study will stop. If 0 out of 3 patients experience a DLT within 28 days, the next 3 patients will receive 300mg. If 1 out of 3 patients experiences a DLT, 3 more patients will be added to the 200 mg dose. If no more patients experience a DLT at 200mg, the next 3 patients will receive 300mg. If 2 of 6 patients receiving 200mg experience a DLT, the study will stop. If 2 or more patients experience DLTs, the maximum tolerated dose (MTD) will be the previous dose level. The same process will be repeated at each dose level. There will be 6 patients enrolled at MTD level for a maximum of 12 patients in the phase I cohort. Ladarixin will be administered as a twice-daily dose over a 21 day treatment cycle.~In Phase II, ladarixin will be administered twice-daily at the recommended phase II dose over 21-day cycles."
223884488|NCT00837369|DRUG|Regadenoson|400ug IV bolus injection, single dosage
223884489|NCT05760261|DRUG|Midazolam|Midazolam will be administered.
223884490|NCT05760261|DRUG|GSK3882347|GSK3882347 will be administered.
223884491|NCT02972372|PROCEDURE|CRT|"Drug: Capecitabine(Aibin) capecitabine(Aibin)：625mg/m2, bid d1-5; q1w, po,5 weeks in total~Other Names:~Aibin Drug: Oxaliplatin(Aiheng) Oxaliplatin(Aiheng)：65mg/m2，d1，8, 22, 29,I.V.~Other Names:~Aiheng cisplatin: 75mg/m2 d1，29 or d1, 29, 57, 85. 5-Fu：750mg/m2 CIV24h d1-4，d29-32 or d1-4，d29-32, d57-60, d85-88.~Radiation: Radiotherapy concurrent radiotherapy：IMRT radiotherapy 50Gy in total，2 Gy/d，5d/w，Until disease progression or unacceptable toxicity"
223884492|NCT02972372|PROCEDURE|surgery|The patients randomized to receive either standard esophagectomy will have the operation performed in an open manner with two-field lymphadenectomy
223884493|NCT02926859|DRUG|Cannabidiol as add-on|Cannabidiol capsules 2x200 mg twice a day as add-on to individualized pharmacological treatment with either amisulpride, aripiprazole, olanzapine, quetiapine or risperidone over 26 weeks
223884494|NCT02926859|DRUG|Placebo as add-on|Placebo capsules 2x200 mg twice a day as add-on to individualized pharmacological treatment with either amisulpride, aripiprazole, olanzapine, quetiapine or risperidone over 26 weeks
223884495|NCT06301919|OTHER|Clinical data|Collecting data from the medical record.
223884496|NCT06301919|OTHER|Imaging data|Collecting data from the medical record.
223884497|NCT06301919|OTHER|Biological data|Collecting data from the medical record.
223884498|NCT02643667|DRUG|Ibrutinib|-Ibrutinib will be supplied by Pharmacyclics Inc.
223884499|NCT02643667|PROCEDURE|Radical prostatectomy|-Standard of care
223884500|NCT06476418|BEHAVIORAL|distraction|Questionnaires and scales will be filled out by the researcher 5 minutes before blood collection. The child will be allowed to play with the liquid moving, timed fountain toy 3 minutes before blood collection. During the process, the child will continue to play with the toy. The scales will be filled again 5 minutes after blood collection.
223884501|NCT04255303|OTHER|Integrated clinical prediction rule (iCPR) system (iCPR)|"The iCPR tool consists of an electronic calculator that can be used to determine whether the patient is at low, intermediate or high risk for having the diagnosis and a bundled order set (called a Smartset). The iCPR tool will be made available directly within the Electronic Health Record (EHR) for Registered Nurses (RNs) who are seeing patients fall into the study categories. The iCPR tool through the use of order sets will guide the RN in the patient's care. The order set for patients at low risk for these diseases will recommend supportive care including over the counter cold remedies and pain relievers. The order set for patients at intermediate or high risk of these disease will recommend diagnostic tests (rapid strep antigen or CXR) to help determine if they have the disease. Based on the results of the diagnostic tests new order sets will recommend antibiotics or supportive care"
223884502|NCT05212220|BEHAVIORAL|EMA-based intervention|A personal quit plan includes (1) self-help techniques on handling craving; (2) suggestions to avoid the reported pro-smoking cues; (3) whether to quit progressively or abruptly; (4) referral for existing smoking cessation service; and (5) instruction of using over-the-counter (OTC) nicotine replacement therapy (NRT), if OTC-NRT is preferred by the participant will be designed and give to the participants via a nurse-led phone call.
223884503|NCT05212220|BEHAVIORAL|EMA-based intervention|Participants will receive 10-week tailored quitting reminder instant messages via WhatsApp and voluntarily discuss their quit plan with the research staff.
223884504|NCT06634368|BEHAVIORAL|Hospital GamePlan4Care|The Hospital GamePlan4Care intervention will include access to a written VA Care Transitions handbook, access to the GamePlan4Care website for skills training, 11 emails encouraging them to visit the website, and four phone calls with a dementia care specialist to tailor the training to the caregiver's needs over a 3-month period.
223884505|NCT06634368|OTHER|Health Education|Caregivers in the health education arm will receive a VA Care Transitions Handbook, 4 emails with a weblink to a general caregiving topic, and 4 phone calls to confirm that the emails were received over a 3-month period.
223884506|NCT00216879|DRUG|Calcipotriol plus betamethasone dipropionate gel (LEO 80185)|
223884507|NCT04578912|BEHAVIORAL|Comprehensive Behavioral Intervention for Tics (CBIT)|CBIT is a manualized treatment program focused on tic management skills
223884508|NCT04578912|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|During repetitive transcranial magnetic stimulation (rTMS), a electromagnetic coil is placed against the scalp while an electromagnet painlessly delivers a magnetic pulse that stimulates nerve cells in the target brain region
223884509|NCT04578912|DEVICE|Continuous Theta Burst Stimulation (cTBS)|During continuous theta burst stimulation (cTBS), a electromagnetic coil is placed against the while an electromagnet painlessly delivers magnetic bursts that stimulate nerve cells in the target brain region
223884510|NCT04210596|PROCEDURE|Soft tissue augmentation at the buccal aspect of single implants|Soft tissue augmentation is performed following mucoperiosteal flap elevation at the buccal aspect of single implants. The connective tissue graft (control) or collagen matrix (test) is inserted in the buccal pouch and attached with monofilament sutures.
223884511|NCT06549829|OTHER|Nutritional optimization-led triple prehabilitation Intervention|The nutritional status of the patients was assessed together with the clinical nutritionist to develop an individualized nutritional plan. The experimental group used ordinary dietary supplementation + transoral nutritional supplementation, and the control group used ordinary dietary supplementation. The target energy was basal energy metabolism level \* physical activity level, physical activity level was male: 1.55 female: 1.56; basal energy level was basal metabolism standardized value \* body weight (basal metabolism standardized value for obese patients was 25; basal metabolism standardized value for normal or emaciated patients was 30). Add 600kcal capacity supplement to this. Exercise workouts focused on increasing lung capacity and cardiorespiratory tolerance. Specialized psychological interventions.
223884512|NCT06549829|OTHER|Conventional triple prehabilitation Intervention|Conventional triple prehabilitation: ordinary dietary supplementation; exercise workouts focused on increasing lung capacity and cardiorespiratory tolerance; specialized psychological interventions.
223884513|NCT04935320|DRUG|HTL0016878.HCl Solution 10 mg|Oral solution fasted
223884514|NCT04935320|DRUG|HTL0016878.Citrate Capsule 10 mg|Oral capsule fed or fasted
223884515|NCT06422052|OTHER|Epidemiological questionnaire and Functional Dyspepsia Symptom Diary（FDSD）|H. pylori infection was confirmed by 13C/ 14C-breath test and/or rapid urease test under endoscopy and histopathological examination. Epidemiological questionnaire and Functional Dyspepsia Symptom Diary (FDSD) were used to investigate basic information and assess dyspeptic symptoms. Patients with dyspepsia who successfully eradicated Helicobacter pylori infection will be followed up for dyspeptic symptoms after 2 months and 6 months to evaluate the relief of dyspeptic symptoms.
223884516|NCT04058639|PROCEDURE|"custom felt relief"|Felt is adjusted to the wound by cutting it in different ways and layers once every week
223884517|NCT04058639|PROCEDURE|standard relief treatment|Felt in the shape of a letter U is put around the wound once every week.
223884518|NCT02485834|PROCEDURE|FDG-PET|
223884519|NCT02485834|PROCEDURE|surgery|
223884520|NCT02485834|DRUG|5-FU|200 mg/m\^2/day IV
223884521|NCT02485834|DRUG|capecitabine|oral 800 mg/m\^2 BID
223884522|NCT02485834|DRUG|docetaxel|30 mg/m\^2 IV
223884523|NCT02485834|DRUG|Irinotecan|50 mg/m\^2 IV
223884524|NCT02485834|RADIATION|3D-CRT|
223884525|NCT02485834|RADIATION|IMRT|
223884526|NCT03711110|OTHER|Intensive cardiovascular monitoring|"Schedule of visits: Evaluation before starting chemotherapy, at three and six months and annually for five years (eight visits: baseline, 3rd and 6th month, 1st, 2nd, 3rd, 4th and 5th years).~Assessment protocol: Anamnesis and physical examination; EKG; Echocardiogram; Biomarkers (troponin and natriuretic peptide); Structured counselling on healthy cardiac practices; Treatment optimization of cardiovascular risk factors and heart diseases; Quality of life (ECOG Performance status and Minnesota questionnaires); Interaction and management of patient care by the cardio-onco-hematology team. Moreover, cardiac MRI in centers participating in the CARTIER-MR sub-study."
223884527|NCT03711110|OTHER|No intervention|"Schedule of visits: Evaluation before starting chemotherapy, at three and six months and annually for five years (eight visits: baseline, 3rd and 6th month, 1st, 2nd, 3rd, 4th and 5th years).~Assessment protocol: Anamnesis and physical examination; ECOG Performance status; cardiac patient care based on the onco-hematologist criteria"
223884528|NCT05796648|BEHAVIORAL|RN-CHeFRx|The RN-CHeFRx trial to enhance dietary intake and blood pressure control in Black women with hypertension and obesity compared to usual care.
223884529|NCT05058391|BIOLOGICAL|Elaprase|Elaprase IV infusion.
223884530|NCT05160480|DIAGNOSTIC_TEST|Total-body PET imaging|Total-body PET imaging at different timepoints
223884531|NCT02778685|DRUG|Fulvestrant|
223884532|NCT02778685|OTHER|Laboratory Biomarker Analysis|Correlative studies
223884533|NCT02778685|DRUG|Letrozole|Given PO
223884534|NCT02778685|DRUG|Palbociclib|Given PO
223884535|NCT02778685|BIOLOGICAL|Pembrolizumab|Given IV
223884536|NCT04176783|DRUG|Opioids|narcotic pain medicine
223884537|NCT04176783|DRUG|Opioid-Free|non narcotoc pain medication
223884538|NCT06778824|DRUG|Takepron|Participants are expected to take a proton-pump inhibitor (PPI) for 12 weeks, with a dosage of 30 mg taken once a day.
223884539|NCT06778824|DRUG|Zoloft 50Mg Tablet|Participants are expected to take a selective serotonin reuptake inhibitor (SSRI) for 12 weeks, with a dosage of 50 mg taken once a day.
223884540|NCT06778824|DRUG|Imipramine Pill|Participants are expected to take tricyclic antidepressants (TCA) for 12 weeks, with a dosage of 25 mg taken twice a day.
223884541|NCT03170141|BIOLOGICAL|Antigen-specific IgT cells|Tumor antigen-specific IgT cells are infused intravenously . Drug: cyclophosphamide 250 mg/m\^2 d1-3; Drug: Fludarabine 25mg/m\^2 d1-3
223884542|NCT05783245|OTHER|Polarcare Machine|Use of Polar Care ice machine as often as possible, but a minimum of three 15 minute uses per day, for the first 3 days after surgery. No single use should last longer than 30 minutes.
223884543|NCT05783245|OTHER|Standard of care ice therapy|Use of commercial reusable ice packs as often as possible, but a minimum of three 15 minute uses per day, for the first 3 days after surgery. No single use should last longer than 30 minutes.
223884544|NCT06444477|OTHER|ITP and cancer|ITP and cancer
223884545|NCT02669069|DEVICE|PS1|Participants in this arm shall be given an audio stimulus which comprises of a sequence of tones, mixed with a broadband noise that is spectrally modified to compensate for any hearing loss. Electrical pulses in the somatosensory stimulation are synchronous with the tones.
223884546|NCT02669069|DEVICE|PS2|Participants in this arm shall be given an audio stimulus which comprises of a sequence of tones, mixed with a broadband noise that is spectrally modified to compensate for any hearing loss. Electrical pulses in the somatosensory stimulation are uncorrelated and asynchronous with the tones.
223884547|NCT02669069|DEVICE|PS3|Participants in this arm shall be given an audio stimulus which comprises of a sequence of single-frequency tones mixed with a broadband noise with the frequency characteristics of both chosen outside the region of any hearing loss. Electrical pulses in the somatosensory stimulation are uncorrelated and asynchronous with the tones.
223884548|NCT06029257|DRUG|Tildrakizumab|As provided in real-world clinical practice.
223884549|NCT06203821|DRUG|NP137|NP137 for the Treatment of Resectable Pancreatic Cancer
223884550|NCT05926024|BEHAVIORAL|Exercise Recall Patient Reported Outcomes|Questionnaire items inquire about (1) the number of days of the week participants engage in walking for pleasure or exercise and (2) the number of minutes per day that participants engage in walking for pleasure or exercise. The same two questions are repeated pertaining to exercise in general. Completion of these items takes 1 minute to complete.
223884551|NCT05926024|BEHAVIORAL|Health Behavior Questionnaire (HBQ)30 Patient Reported Outcomes|Health Behavior Questionnaire (HBQ)30 -- Questionnaire items pertain to the history of smoking, engagement in vigorous physical activity, alcohol consumption, and mortality status of parents, and take less than 1 minute to complete.
223884552|NCT05926024|BEHAVIORAL|Functional Assessment of Cancer Therapy-General (FACT-G) Patient Reported Outcomes|"Functional Assessment of Cancer Therapy-General (FACT-G) is a quality of life and function measure developed and validated over 20 years ago that has been used in hundreds of cancer studies worldwide. It consists of four well-being domains -- physical, social/family, emotional, and functional. The FACT-G (Version 4) is a 27-item instrument that is formatted for self-administration and uses a 5-point Likert-type scale (0=not at all, 1=a little bit, 2=somewhat, 3=quite a bit, 4=very much). The recall period is during the past 7 days. It takes 6-8 minutes for an average patient to complete."
223884553|NCT05926024|BEHAVIORAL|Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Patient Reported Outcomes|"Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) is a 13-item scale that uses a 5-point Likert-type scale (0=not at all, 1=a little bit, 2=somewhat, 3=quite a bit, 4=very much). The recall period is during the past 7 days. This measure takes about 1 minute to complete."
223884554|NCT05926024|BEHAVIORAL|Patient Reported Outcomes PROMIS Cognitive Function (Short Form 8a)|PROMIS Cognitive Function (Short Form 8a) includes 8 items on a 5-point Likert-type scale ranging from very often/several times a day = 1 to never = 5, with higher scores indicating greater perceived loss of cognitive function. This measure takes less than 1 minute to complete.
223884555|NCT05926024|BEHAVIORAL|Patient Reported Outcomes Functional Assessment of Cancer-Gynecology Oncology Group-Neurotoxicity (FACT/GOG-NTX-12)|Functional Assessment of Cancer-Gynecology Oncology Group-Neurotoxicity (FACT/GOG-NTX-12) is a questionnaire that includes 12 items inquiring about symptoms in the past 7 days (0=not at all to 4=very much) pertaining to numbness or tingling in hands/feet, discomfort in hands/feet, joint pain or muscle cramps, weakness all over, trouble hearing, ringing/buzzing in ears, buttoning buttons, trouble feeling the shape of small objects in hands, trouble walking, and pain in hands/feet in cold temperatures. This measure takes about t 1 minute to complete.
223884556|NCT05926024|BEHAVIORAL|Patient Reported Outcomes PROMIS|PROMIS Measures Global Health (10 items), Anxiety (6 items), Depression (8 items), and Stress (10 items). All items are on a 5-point Likert-type scale form never to very often. Completion of all 34 items should take no more than 3 minutes to complete.
223884557|NCT05926024|BEHAVIORAL|Patient Reported Outcomes FACT-Endocrine Symptoms|FACT-Endocrine Symptom is a 19-item questionnaire inquiring about hot flashes, cold sweats, night sweats; vaginal discharge, itching/irritation, bleeding or spotting, dryness; pain or discomfort with intercourse, loss of interest in sex; weight gain; lightheadedness; vomiting; diarrhea; headaches; bloating; breast sensitivity/tenderness; mood swings; irritability; pain in joints. Responses are on a 5- point Likert-type scale from not at all to very much. This measure takes about two minutes to complete.
223884558|NCT05926024|BEHAVIORAL|Patient Reported Outcomes Penn Arthralgia Aging Survey|Penn Arthralgia Aging Survey is an 8-item scale inquiring about joint pain, with a 4-point response scale from not at all to complete. Items pertaining to slowing down, stopping, being hesitant, unable to do this, and feeling unusually aged. This measure takes less than a minute to complete.
223884559|NCT05926024|BEHAVIORAL|Patient Reported Outcomes PRO-CTCAE (patient-reported CTCAE)|"PRO-CTCAE (patient-reported CTCAE) is Patients will be asked about the side effects of chemotherapy treatment at baseline, every 3 weeks during chemotherapy, at the end of chemotherapy, and at 6 months post-chemotherapy. Patients are asked to rate in the past 7 days the average severity, frequency, and intensity and a scale from 1=none/never/not at all to 5=very severe/very much/almost all of the time. Symptom list: Abdominal pain, Constipation, Diarrhea. Mucositis oral, Nausea, Vomiting, Edema limbs, Fatigue, Pain, Arthralgia, Myalgia, Peripheral sensory neuropathy, Anxiety, Depression, Insomnia, Dyspnea, Rash maculopapular, Hot flashes. Completion of these measures takes 5 minutes for an average patient"
223884560|NCT05926024|DIAGNOSTIC_TEST|p16 tumor suppressor gene|Blood samples will be obtained to test the p16 tumor suppressor gene from the subjects It is voluntary..
223884561|NCT06776458|OTHER|N/A - Usual Care|Breast cancer survivors will have received usual care aromatase inhibitors for up to 10 years post-diagnosis.
223884562|NCT06795256|BEHAVIORAL|Percussion and position change in retrograde intrarenal surgery|To evaluate the effectiveness of this homework on stone clearance rates after RIRC by giving instructions to the patient in the home environment and suggesting percussion (tapping) and movement/position changes to help spontaneous stone passage.
223884563|NCT04046445|DRUG|ATP128|5-6 SC injections
223884564|NCT04046445|DRUG|BI 754091|≥ 7 IV infusions
223884565|NCT04046445|DRUG|VSV-GP128|1 single IV injection
223884566|NCT03697070|OTHER|INSPIRE CPOE Smart Prompt|"Quality improvement intervention: computerized physician order entry (CPOE) decision support alert that provides physicians with patient-specific risk estimate of having PNA due to a multidrug resistant organism (MDRO) and recommends appropriate antibiotic choice for non-ICU patients in the first 3 days of hospitalization.~Continuation of other antibiotic stewardship activities in accordance with national standards."
223884567|NCT03697070|OTHER|Routine Care|Routine Antibiotic Stewardship Arm - Continuation of all antibiotic stewardship activities in accordance with national standards.
223884568|NCT05548088|BIOLOGICAL|LILRB4 STAR-T cells|Subjects with relapsed/refractory acute myeloid leukemia will be enrolled in the study, and Subjects will receive cytoreductive chemotherapy with cyclophosphamide and fludarabine on days -5, -4and-3followed by infusion of STAR-T cells. STAR-T cells will be intravenously infused with a escalated dose of 1E6,3E6,6E6,1E7 cells/kg
223884569|NCT04383951|OTHER|Dietary consult for participants in the ketogenic diet arm|An initial consultation with the providers of medically supervised weight loss clinic will be arranged. Participants in the ketogenic diet group will be educated on the concepts of the diet and will be provided with recipes to be utilized at home that adhere to this diet. In addition to the initial consultation, participants in this arm receive additional consultations with these providers with a frequency as determined by the provider.
223884570|NCT04383951|OTHER|Dietary consult for participants in the standard of care arm|For participants in the standard of care arm, an initial consultation with the providers of medically supervised weight loss clinic will be arranged and the discussion will center around portion control using a balanced diet. Participants will receive only one additional consultation with the provider 16 weeks later just prior to the conclusion of the study.
223884571|NCT03833245|BEHAVIORAL|Patient Navigation|The patient navigation (PN) intervention will initiate following participant recruitment. It is important to note that PN sessions do not strictly coincide with specific weeks of pregnancy since the women can be recruited up to ≤25 weeks of gestation. The prenatal portion of the intervention includes 10 sessions delivered within approximately 14 weeks. The postnatal portion of the intervention will be delivered as 4 sessions over 8 weeks. Women who complete the intervention before delivery will receive regular calls/texts until delivery wherein the navigator will encourage and reinforce abstinence and treatment retention. All contact will be reported by staff in a patient contact log developed for the study that will be used to quantify level of patient contact.
223884572|NCT04913064|OTHER|Questionnaire Administration|Ancillary studies
223884573|NCT04913064|DRUG|White Button Mushroom Extract|Given PO
223884574|NCT06751914|COMBINATION_PRODUCT|Conventional second-line therapy|Conventional second-line therapy includes chemotherapy, targeted cancer drugs, and/or PD-1 inhibitors.The chemotherapy drugs, dosage and treatment cycle are determined by the subject's attending physician based on the subject's specific conditions. The medication, dosage and treatment cycle of targeted cancer drugs will be determined by the subject's attending physician based on the subject's specific circumstances. The PD-1 inhibitor treatment cycle is 3 weeks, and the drug is administered by intravenous infusion on the first day (D1) of each treatment cycle. The dosage is based on the instructions.
223884575|NCT06751914|DRUG|Neoantigen-based peptide vaccine|The treatment with personalized tumor neoantigen-based peptide vaccine is divided into two periods: the primary phase and the boost phase. The primary phase consists of 6 treatments, with the first 3 treatments spaced one week apart and the subsequent 3 treatments spaced two weeks apart. Vaccine will be administrated on the fourth day (D4) of that week. The boost phase consists of 4 treatments, each spaced three weeks apart. Vaccine will be administrated on the fourth day (D4) of that week.
223884576|NCT06752317|DRUG|Dexamethasone|patients will receive intrathecal dexamethasone 8 mg in 3 ml volume.
223884577|NCT06752317|DRUG|Dexmedetomidine|patients will receive intrathecal dexmedetomidine 0.5 µg/kg in 3 ml volume.
223884578|NCT06792630|BEHAVIORAL|laughter therapy intervention|"In addition, patients in the intervention group were given laughter therapy intervention from the 1st day of HSCT, with the mnemonic hihihi (pinyin spelling), hahahaha, eggplant eggplant eggplant, qixi qixi qixi qixi, hahahahahahahahaha, 30 times of the mnemonic as a training session, once a day, from the beginning of the transplantation transfusion +1d to the end of the transplantation transfusion +1d, and then to the end of the transplantation. Patients were discharged from the warehouse, and after discharge, patients were centralized on-line laughter therapy intervention, 1 time/week, repeating 30 times of mnemonics, until 1 year after transplantation."
223884579|NCT05822193|OTHER|Multiple exposures|Exposures variables (observational study): age, gender, education, comorbidities, vaccination status, severity of the acute episode of COVID-19, treatments used for acute COVID-19.
223884580|NCT06504342|DEVICE|Blue-blocking glasses|These lenses will filter \~10% of visible light across the visible light range (including in the range activating melanopsin) with complete blockade of ultraviolet light.
223884581|NCT06504342|BEHAVIORAL|Time-restricted eating|Avoid caloric food intake for a fourteen-hour period overnight from 6 p.m. to 8 a.m
223884582|NCT06504342|DEVICE|Lightly tinted glasses|These lenses block shorter wavelengths of light, mainly ultraviolet light.
223884583|NCT06833866|DRUG|Hydroxytyrosol|"Patients will receive: 1 capsule of HT 25 mg daily for 2 weeks before beginning 5FU-based therapy (FOLFIRI/FOLFOX + Biologics), 1 capsule of HT (25 mg) daily for 2 weeks while receiving the FOLFIRI/FOLFOX + Biologics, until sign of disease progression.~The prescribed FOLFIRI/FOLFOX administer as: Irinotecan 180 mg/m² intravenously (IV) over 90 minutes concurrently with Leucovorin 400 mg/m² IV over 120 minutes, followed by Fluorouracil 400-500 mg/m² IV bolus then 2400-3000 mg/m² IV infusion over 4-6 hours with or without, the designated Biologics, a standard dose of Cetuximab or Bevacizumab will be administered in 2-week cycles until disease progression or un-tolerated toxicity"
223884584|NCT06519669|BIOLOGICAL|GT201 injection|GT201 injection to treat Advanced lung cancer
223884585|NCT00739648|DRUG|MP-376|MP-376 administered via inhalation for 5 consecutive days within 28-day treatment cycles for up to 12 cycles
223884586|NCT00739648|DRUG|Placebo|same frequency as study drug using the same method of delivery
223884587|NCT05110495|DRUG|Xentuzumab|The study IMP is xentuzumab, a humanised IgG1 monoclonal antibody that neutralises the IGF ligands to inhibit activation of IGF-1R and INSR-A, suppressing IGF-mediated proliferation, invasion and therapy resistance
223884588|NCT06347536|COMBINATION_PRODUCT|Supported rescue pack|1\) a rescue pack (prednisolone and antibiotics for 5 days); 2) a written rescue pack management plan based on the Asthma-Lung UK plan; and 3) twice-weekly automated telephone symptom reminder calls for 90 days (with preferred language as needed). The reminder phone calls (to home telephone or mobile) will ask questions aligned to the written management plan
223884589|NCT06795919|PROCEDURE|: delayed surgical repair of alveolar cleft using particulate cortico-cancellous anterior iliac bon|skin incision was marked 2-4 cm from the crest to anterior iliac spine height. This is done to avoid pain at the beltline if the incision is made directly over the anterior ilium. As well as avoid injury to the lateral femoral cutaneous nerve. After the anatomical marking are drawn using betadine solution, the site is injected with local anesthesia at the subcutaneous level. The skin incision line is made parallel to the iliac crest and posterior to the anterior iliac spine. Scalpel blade number 10 is used. The incision of the skin and subcutaneous fat was performed. Blunt dissection is carried out at the level of subcutaneous tissues to separate the fascia from fat. Cautery is used to control any hemorrhage. Using a number 15 blade, fascia was incised which covers the iliac spine. A hypo vascular plane was identified. It is located over the anterior iliac spine, as well as between the insertions of tensor fascia laterally and the external and the transverse abdominal muscles medially
223884590|NCT06518681|DEVICE|PoliaValve (Aortic)|Aortic Valve Replacement
223884591|NCT06289491|PROCEDURE|Hydrus Microstent|Patients will have a Hydrus Microstent inserted into the canal of Schlemm at the time of cataract surgery
223884592|NCT06289491|PROCEDURE|Incisional goniotomy|Patients will have incisional goniotomy to open the trabecular meshwork with a Sinskey hook at the time of cataract surgery
223884593|NCT06289491|PROCEDURE|Excisional goniotomy|Patients will have excisional goniotomy to remove the trabecular meshwork with a Kahook Dual Blade at the time of cataract surgery
223884594|NCT03930199|OTHER|Needs-based intervention (physical, psychological, or both)|Individuals identified as having physical issues (poor prosthesis fit, function, comfort or physical conditioning) will receive prosthetic care and physical therapy. This includes adjusting socket fit, component fit and repair, and in some instances replacement. Rehabilitation strategies include gait and prosthesis use retraining, balance fall-prevention, and range-of-motion training, strengthening, pain management, and activities of daily living training, based on participant-reported mobility goals. Individuals whose prosthesis use is reduced due to psychological issues will be provided with motivational interviewing and other related psychological interventions. During these interventions participant will be asked to set personal goals using a semi-structured interview that explores facilitators and barriers to wearing their prosthesis. If both physical and psychological issues are present, participant may receive both types of interventions simultaneously.
223884595|NCT06784284|OTHER|Glasgow Outcome Scale -Extended (GOSE)|Questionnaire to cotate the neurological deterioration following mild head trauma. Score from 1 to 8, the higher the number the better the outcome
223884596|NCT06839573|OTHER|Experience with virtual reality glasses|"If the group belongs to GE (teaching with in-person simulation in the classroom and teaching with VR headsets), they will also receive the two training sessions described for GC:~30 minutes of individual training through VR (headsets and controllers to perform actions while receiving immediate feedback through VR) before the in-person simulation."
223884597|NCT04173663|BEHAVIORAL|ASSIST|The ASSIST program is a 12-week advocacy training to educate parents of youth with autism about the adult service system (note that an optional 13th session on secondary transition planning can be offered if ASSIST is being delivered to families of youth who are in high school). It is a group training, comprised of didactic instruction, family-sharing activities, case studies, and group discussions. The ASSIST program for the proposed study will be directed at each site by an experienced Program Facilitator from the community with knowledge about group processes, person-centered planning, and adult service systems, who will be coached by a member of the study team. The ASSIST program will be delivered in full partnership with the local disability community. In most sessions, the Program Facilitator will be aided by community content experts who present the specifics of each topic.
223884598|NCT05770947|BEHAVIORAL|Cognitive Behavioral Therapy|"Cognitive Behavioral Therapy (CBT) is a psychological treatment or talk therapy that integrates how people think, feel, and behave to create new behavior patterns that improve thinking processes and reduce distress."
223884599|NCT05770947|BEHAVIORAL|Mindfulness|"Mindfulness is a psychological treatment or talk therapy that practices different coping skills to improve thinking processes and reduce distress."
223884600|NCT03604263|DEVICE|ArcticLine Cardiac Cryoablation Catheter|Cryoablation
223884601|NCT06840704|DIETARY_SUPPLEMENT|Oral immunonutrition|Oral immunonutrition (Oral Impact®, Nestlé), 250 ml per bottle, with a dosage of 2 bottles per day, starting on the day of radiotherapy and continuing for three weeks after radiotherapy.
223884602|NCT04533061|DRUG|Influenza vaccine|"influenza vaccine 0.5 ml intramuscularly each season~2004-2005 season contains: A/New Caledonia/20/99 (H1N1)-like, A/Fujian/411/2002 (H3N2-like), and B/Shanghai/361/2002-like antigens~2005-2006 season contains: A/New Caledonia/20/99 (H1N1)-like, A/California/7/2004 (H3N2), and B/Shanghai/361/2002-like antigens"
223884603|NCT06840925|DRUG|PRAX-628|Once daily oral
223884604|NCT04604977|BEHAVIORAL|Mindfulness|Patients are followed with a standardized program including: education and support for behavioral measures, behavioral sessions, by mindfulness, once per week for 45 minutes for 6 weeks which usually delivered in groups of 4 - 8 patients.
223884605|NCT05745350|DRUG|Pembrolizumab, Plinabulin plus Etoposide and Platinum|Pembrolizumab 200 mg IV every 3 weeks (Q3W) on Day 1; Etoposide 100 mg/m2 IV Q3W on Days 1, 2, and 3; Carboplatin AUC 5 IV Q3W on Day 1 or Cisplatin 75 mg/m2 IV Q3W on Day 1; Plinabulin 30mg/m2 IV Q3W on Day 1.
223884606|NCT03900780|PROCEDURE|PGT-A|ovarian stimulation, oocyte aspiration, embryo culture until the blastocyst stage (day 5/6), TE biopsy, vitrification of all embryos in the blastocyst stage, PGT-A by NGS and finally embryo transfer of genetically normal embryos in cumulative frozen-thawed embryo transfer cycles
223884607|NCT03900780|PROCEDURE|Control|ovarian stimulation, oocyte aspiration, embryo culture until the blastocyst stage, fresh embryo transfer of the morphologically best embryo on day 5/6, vitrification of supernumerary embryos and embryo transfer in cumulative frozen-thawed embryo transfer cycles if not pregnant from the fresh cycle.
223884608|NCT03503955|OTHER|Leap-Motion virtual reality games|Games that Fizyosoft has prepared on Leap Motion equipment to improve hand and grip activities will be played individually and will focus on running hand, wrist and grip movements
223884609|NCT03503955|OTHER|fine motor skills activities|activities that stimulate finger movements such as holding, reaching, catching, writing, and strengthening muscles
223884610|NCT06839612|PROCEDURE|Two-point method|In the two-point method, the distal end of the drainage tube was passed over the duodenal and intestinal lumen of the common bile duct during PTCD operation. In the process of sinus dilation, guide wire was sent into the intestinal lumen through the drainage tube, and then the drainage tube was inserted into the intestinal lumen with the extract forceps under the duodenoscope in reverse order to drag the drainage tube into the intestinal lumen before being sent into the guide wire.Clamp the guide wire with the access pliers and slowly draw out the guide wire through the mouth. Expand the outer inlet skin.When the skin was 6mm, the epigastric PTCD tube was removed, the percutaneous nephrostomy dilator was placed through the guide wire, and the patient was instructed to be drawn by the assistant.The mouth end of the guide wire, the surgeon pulls the other end of the guide wire, so that the two ends of the guide wire fix in vitro to form a higher tension to Expand the skin.
223884611|NCT06839612|PROCEDURE|Conventional PTCS|PTCS can be divided into three steps: PTCD, sinus dilation, and lithotomy. In PTCD, we first performed intraoperative fluoroscopy, and punctured the biliary tract at a relatively straight Angle with the target biliary tract as far as possible. The distal end of the indenture drainage tube was inserted into the duodeno-intestinal cavity through the end of the common bile duct. The PTCD drainage tube was indwelled for 3-5 days.When the sinus was mature, we used dilated sheath tubes to dilate the sinus to 14-18Fr at a time, and used the working channel established by the choledochoscope to carry out net basket stone extraction. If large diameter stones were difficult to be extracted through the net basket, mechanical lithotomy was adopted to solve the problem, and conventional anti-inflammation was adopted in all patients after surgery. Cholangiography or epigastric CT were used to confirm complete removal of the stones after lithotomy.
223884612|NCT05093972|DRUG|Ulonivirine|Four ulonivirine 100 mg tablets (total dose 400 mg) taken by mouth.
223884613|NCT06839768|PROCEDURE|Standard endoscopic enucleation of the prostate (EEP)|Stabdard EEP will be nerformed using 26 Ch resectoscope. Enucleation will be performed using an en bloc no-touch technique with early apical release.
223884614|NCT06839768|PROCEDURE|MiLEP|Minimally-invasive laser EEP will be nerformed using 22 Ch resectoscope. Enucleation will be performed using an en bloc no-touch technique with early apical release.
223884615|NCT06506760|BEHAVIORAL|Immersive Virtual Reality Therapy|"8 sessions of VR therapy over 4 weeks (each of them 20 minutes long).~As a virtual reality source, VRTierOne device (Stolgraf®) were used. Thanks to using head mounted display and the phenomenon of total immersion VR therapy provides an intense visual, auditory and kinesthetic stimulation. It can have a calming and mood-improving effect or help the patients recognize their psychological resources and motivate to the rehabilitation process. In the virtual therapeutic garden there are a rich set of symbols and metaphors based on Ericksonian Psychotherapy approach. The most important is the Garden of Revival which symbolizes the patient's health. It used to be full of life and energy, now it is neglected, requires work to be revived. In the therapeutic process day by day, the therapist tells the patient a symbolic story about his/her situation."
223884616|NCT06506760|BEHAVIORAL|Conventional rehabilitation|"Four weeks of conventional rehabilitation including:~Two hours of kinesiotherapy (120 minutes, including gait training). Thirty minutes of ergotherapy. Three physical therapy procedures (i.e. laser therapy, magnetic therapy, electrotherapy) tailored to individual ailments and needs."
223884617|NCT03495297|PROCEDURE|ommitence of defibrillation testing|Induction of a ventricular arrhythmia to test proper arrhythmia detection and termination by the implanted device is omitted
223884618|NCT05670366|DEVICE|Activity tracker and chest strap|During the study, the participants will be asked to wear a commercially-available activity tracker during day and night, and a chest strap during sport activities to collect data on physical activity (type, intensity and duration of activity).
223884619|NCT05670366|DEVICE|Diary app|During the study, the participants will be asked to log the ingestion of carbohydrates, periods and type of physical activity, feelings (e.g. sick, stress, ...) in a diary app.
223884620|NCT06839534|BEHAVIORAL|Structured Maternal Voice Program (SMVP)|"Pre-recorded maternal voice messages played via an MP3 player integrated into the infant's incubator. The recordings include recognition messages (I'm so glad to have you) and soothing messages (Rest well, little one, you're safe with me). The intervention is delivered three times daily for five minutes per session over a four-day period."
223884621|NCT04626596|COMBINATION_PRODUCT|Radiopaque Etonogestrel (ENG) Implant|68 mg subdermal implant
223884622|NCT06749223|DIAGNOSTIC_TEST|D-dimer test|Blood sample collection for D-dimer testing
223884623|NCT06840938|BEHAVIORAL|physiological maneuver|Group A will be subjected to physiological and postural trainings (traditional)
223884624|NCT06840938|DEVICE|Surface Electrical Stimulation|Group B will be subjected to Surface Electrical Stimulation through the use of electrodes and stimulators.
223884625|NCT06840938|COMBINATION_PRODUCT|Surface Electrical Stimulation|Group C will be subjected to both physiological and Surface Electrical Stimulation supports.
223884626|NCT04271085|OTHER|Observational study|No intervention involved
223884627|NCT06838650|DRUG|Dexmedetomidine|patients will recive of low-dose (0.5 µg/kg) intravenous Dexmedetomidine before general anathesia
223884628|NCT06838650|DRUG|Saline|patients will recive saline
223884629|NCT06839703|DRUG|Dinutuximab beta|Dinutuximab beta is added in different dosages to the standard chemotherapy
223884630|NCT05491122|BEHAVIORAL|Increasing or decreasing daily total fluid intake|1-week intervention where the intake of drinking water will either be increased (if habitually low) or decreased (if habitually high). The total fluid intake (TFI) prescriptions during the intervention are derived from the mean TFI of habitually high and habitually low drinkers from a sex, age and country matched population. Specifically, habitually high drinkers will be permitted a TFI of 1.3 L/day and habitually low drinkers will be permitted a TFI of 3.5 L/day for men and 3.3 L/day for women. Participants will be instructed to maintain their usual intake of other beverages i.e., tea/coffee to achieve their target TFI. The diurnal saliva cortisol response at rest will be examined at the end of both experimental periods and the saliva cortisol response to an acute psychological stress will be examined at the end of the habitual experimental period only.
223884631|NCT06813079|DRUG|Cobimetinib|"Cobimetinib is an antineoplastic agent and selective inhibitor of the mitogen-activated extracellular kinase (MEK) pathway.~Participants will take cobimetinib by mouth (orally), once a day on days 1 to 21 followed by a 7-day break of each cycle. A cycle will be 28 days in length."
223884632|NCT06813079|DRUG|Ponatinib|"Ponatinib is a type of drug called a protein tyrosine kinase inhibitor (TKI). Tyrosine kinases are proteins that act as chemical messengers to stimulate cancer cells to grow. Ponatinib blocks and interferes with a number of protein kinases. It is called a multi kinase inhibitor.~Participants will take ponatinib by mouth (orally), once a day, every day of each cycle. A cycle will be 28 days."
223884633|NCT06813079|DRUG|Brigatinib|"Brigatinib is a type of cancer growth blockers called a tyrosine kinase inhibitor (TKI). It blocks chemical signals (enzymes) from tyrosine kinase proteins. Tyrosine kinases help to send growth signals in cells, so blocking them stops the cell growing and dividing.~Participants will take brigatinib by mouth (orally), once a day for the first 7 days. If participants are able to tolerate the dose during the first 7 days, they will take the doubled dose orally, once a day until end of the cycle (day 8 to day 28). Each cycle will be 28 days in length."
223884634|NCT06813079|DRUG|Colchicine|"Colchicine is an alkaloid that affects the way the body responds to uric acid crystals, and reduces swelling and pain.~On the first day, participants will take two tablets of colchicine by mouth (orally), then one tablet orally one hour later. Starting the second day, participants will take one tablet of colchicine once or twice a day, every day of each cycle. A cycle will be 28 days in length. The study doctor will decide whether participants will take colchicine once or twice a day."
223884635|NCT06813079|DRUG|Selinexor|"Selinexor blocks a protein called CRM1, a protein within the cell, and may help keep cancer cells from growing and may kill them. It is a type of small molecule inhibitor.~Participants will take selinexor by mouth (orally), once a week on days 1, 8, 15, and 22 of each cycle. A cycle will be 28 days in length."
223884636|NCT06813079|DRUG|Abemaciclib|"Abemaciclib belongs to a class of medications called kinase inhibitors. Abemaciclib works by blocking the action of an abnormal protein that signals cancer cells to multiply. This helps slow or stop the spread of cancer cells.~Participants will take abemaciclib by mouth (orally), twice a day, every day of each cycle. A cycle will be 28 days in length."
223884637|NCT06813079|DRUG|Neratinib|"Neratinib is a targeted cancer drug that works on a protein called human epidermal growth factor receptor 2 (HER2). HER2 proteins make cells divide and grow. Some cancers have large amounts of HER2 proteins which can cause cancer cells to divide and grow faster. Neratinib works by locking onto the HER2 on the cancer cells. So it stops the cells from growing.~Participants will take neratinib by mouth (orally), once a day, every day of each cycle. Dose will increase weekly, until week 3. On week 3 and onward, participants will take the same dose. A cycle will be 28 days in length."
223884638|NCT06813079|DRUG|Doxorubicin|"Doxorubicin is a type of chemotherapy drug called an anthracycline. It slows or stops the growth of cancer cells by blocking an enzyme called topo isomerase 2. Cancer cells need this enzyme to divide and grow.~Participants will receive doxorubicin by vein (intravenous infusion or IV) in clinic, over 60-90 minutes, once every cycle. A cycle will be 21 days in length. Participants may receive 6-8 cycles of study drug."
223884639|NCT06813079|DRUG|Etoposide|"Etoposide is a chemotherapy drug that destroys quickly dividing cells, such as cancer cells.~Participants will receive etoposide by mouth (orally), twice a day, on days 1 to 7 of every cycle. On days 8 to 21, there will be no dosing. A cycle will be 21 days in length."
223884640|NCT06813079|DRUG|Ceritinib|"Ceritinib is a tyrosine kinase inhibitor. It works by blocking an enzyme called anaplastic lymphoma kinase (ALK). Ceritinib only works in cancer cells that have an overactive version of ALK.~Participants will take ceritinib by mouth (orally), once a day, every day of each cycle. A cycle will be 28 days in length."
223884641|NCT06794450|DRUG|Sugammadex 1 mg/kg|Patient in experimental arms will receive i.v. sugammadex 1 mg/kg at the end of operating procedure from the point at which a Train-of-Four Count (TOFC) of 2 is observed
223884642|NCT06794450|DRUG|Neostigmine + Atropine|Patient in active comparators arms will receive i.v. neostigmine 60 mcg/kg along with 0.4 mg of atropine sulfate per 1 mg of neostigmine at the end of operating procedure from the point at which a Train-of-Four Count (TOFC) of 2 is observed
223884643|NCT06838741|PROCEDURE|otago exercises|"A walking program is given to participants, with the goal of including two 30-minute walking sessions each week (which can be divided into shorter segments, like three ten-minute blocks).~Exercises Start exercises with 10 repetition maximum STRENGTH Knee extensor Hold for 3-5 seconds Knee flexor Hold for 3-5 seconds Hip adductor Hold for 3-5 seconds Ankle planter-flexion Calf raises Ankle dorsiflexion Toe raise BALANCE Knee bends Backwards walking Upto 30 minutes Walking and turning around 5-10 minutes Sideways walking Tandem stance Heel to toe stand Tandem walk One leg stand Heel walking Toe walk Heel toe walking backwards Sit to stand Stair walking"
223884644|NCT06838741|DEVICE|virtual reality|Begin with 20-30 minutes per session and extend to 30-45 minutes as tolerance and endurance improve throughout the program. Exercise sessions will be done for 3 sessions per week.
223884645|NCT06841042|BIOLOGICAL|SCTB35 injection|SCTB35 will be subcutaneously administered at a dose as specified in the respective dose-escalation cohorts. Then, the RP2D and other appropriate doses of SCTB35 will be applied for the dose-expansion cohorts.
223884646|NCT01757665|DEVICE|Edwards Aortic and Mitral Bioprostheses Models 11000A and 11000M|Implant of an aortic valve, Model 11000A or mitral valve, Model 11000M
223884647|NCT06797570|OTHER|Communication Strategy for Side Effect Counseling in ADHD Treatment|One group receives negatively framed and extensive information about the most common adverse events of methylphenidate. A fixed script will be prepared for the treating paediatrician, and the same information will be provided in written form. The other group receives positively framed and concise information about the most common adverse events of methylphenidate. This information will also be provided in written form.
223884648|NCT06795737|BEHAVIORAL|Exercise rehabilitation|The experimental group's protocol consists of two stages: in-hospital Phase I and post-discharge self-training. For Phase I, cardiac and rehab specialists assess NYHA classification, muscle strength, and mobility to create an exercise plan, supervised by therapists and nurses. Phase II involves twice-weekly outpatient rehab for 24 sessions and weekly remote guidance with WeChat and wristbands to track vitals, totaling 12 remote sessions. Exercise prescriptions are customized based on 6MWTD outcomes, with ongoing support from rehab staff and nurses.
223884649|NCT06795737|BEHAVIORAL|Conventional rehabilitation|"Health Education: Nurses provide manuals on heart failure causes, treatment, diet, exercise (detailing frequency, intensity, duration, types, and safety), and self-monitoring to control group patients.~Outpatient Follow-up: Post-discharge, heart failure patients have follow-ups at 2 weeks, 1 month, 2 months, and 3 months. A multidisciplinary team of doctors, pharmacists, and nurses handles these, with doctors for assessment, pharmacists for medication education, and nurses for self-care assessment and education."
223884650|NCT05414136|DRUG|BAT1006|Intravenous fluids
223884651|NCT06840197|DIAGNOSTIC_TEST|NG-TestⓇ Monkeypox virus kit|Evaluation of the performance of the rapid diagnostic test (RDT) for the detection of the Mpox virus (NG-TestⓇ Monkeypox virus kit) and comparision with PCR result (reference test)
223884652|NCT06839183|DEVICE|integrated interactive self-care APP|integrated interactive self-care APP
223884653|NCT06839378|PROCEDURE|intravenously inject with 5-FU (400 mg/m2)|5-FU (400 mg/m2) will be injected IV bolus before operation. After CRS, the patients will be treated with cisplatin or cisplatin + docetaxel HIPEC respectively. The tumor tissue samples of patients will be collected before and after HIPEC treatment. The tumor tissue samples before and after HIPEC treatment will be sequenced by Flura-seq using high-throughput sequencing technology, and the changes of newly generated transcripts in tumor tissue during HIPEC will be analyzed. The differentially expressed genes in the cisplatin group and the cisplatin + docetaxel group will be compared to evaluate the effect of different HIPEC regimens on the transient transcriptome of PMP tumor.
223884654|NCT06839677|OTHER|semi-structured interview on Microsoft Teams|Data will be collected through a single semi-structured interview on Microsoft Teams, audio recorded and transcribed in full, and analysed using NVivo V1.6.2.32. Participants' statements will be categorised into semantic categories and subsequently refined into sub-themes and themes through an iterative process.
223884655|NCT06839547|DRUG|Radiotherapy + Novel Anti-tumor Drug|"1. Novel anti-tumor drugs \[including: ADC drugs (such as T-DXd, T-DM1, etc.), CDK4/6 inhibitors, TKI drugs (such as Pyrotinib, Tucatinib, etc.), novel chemotherapy drugs (such as Utidelone, Irinotecan liposomes, etc.), Bevacizumab, PD-1/PD-L1 inhibitors, etc.\]~2. Radiotherapy"
223884656|NCT06640933|DRUG|BIIB091|Administered as specified in the treatment arm.
223884657|NCT06794801|DEVICE|Drug Coated Autoperfusion Balloon Dilatation Catheter（DCAB）|In the experimental arm, under the assessment and guidance of IVUS-OCT, STEMI patients with successfully prepared lesions will be treated with a drug-coated autoperfusion balloon dilatation catheter (DCAB). Successful lesion preparation is defined as post-pretreatment residual stenosis ≤ 30%, no type C dissections, intravascular imaging confirming no significant residual plaque burden at the dissection site, no transverse expansion \> 60°, no longitudinal expansion \> 2 mm, no dissection involving the media or adventitia, and no location at the stent distal end. There should be no hematoma and no significant thrombus (TIMI thrombus burden grade ≤ 2). If the angiographic and intravascular imaging results after DCAB treatment are unsatisfactory, an emergency drug-eluting stent (DES) will be implanted.
223884658|NCT06794801|DEVICE|Conventional Drug coated balloon (DCB)|In the control arm, under the assessment and guidance of IVUS-OCT, STEMI patients with successful lesion preparation (residual stenosis ≤ 30%, no type C dissections, no significant residual plaque burden, no dissection involving the media or adventitia, no transverse expansion \> 60°, no longitudinal expansion \> 2 mm, no location at the stent distal end, no hematoma, TIMI thrombus burden grade ≤ 2) will be treated with a conventional DCB coated with 3 μg/mm2 paclitaxel. If angiographic and intravascular imaging results are unsatisfactory, a bailout DES will be implanted.
223884659|NCT04745299|BIOLOGICAL|Lenzumestrocel|Single cycle administration group : injections twice in a 26-day interval Multiple administration group : injections twice in a 26-day interval followed by repeated three times injections every three months
223884660|NCT04745299|DRUG|Riluzole|concomitant administration of Riluzole to all groups, except subjects to whom Riluzole administration is deemed impossible owing to adverse events as determined by medical experts
223884661|NCT04745299|DRUG|Placebo Comparator|"Single cycle administration group: Placebo comparator is injected three times every three months after injection of Lenzumestrocel twice in a 26-day interval.~Control group: Placebo comparator is injected twice in a 26-day interval followed by repeated three times injcections every three months"
223884662|NCT06835439|BEHAVIORAL|STEPPT Pilot|The pilot STEPPT intervention, which includes (1) education of providers and staff on disparities in referrals and the benefits of physical therapy for spine pain, (2) modifications to the EHR to automate physical therapy referral and delivery of culturally tailored patient education materials related to the physical therapy referral, and (3) enhanced patient health navigation to educate patients on physical therapy and address barriers to attending physical therapy for Hispanic patients with spine pain. Patient education materials were developed using evidence-based guidelines and were culturally and linguistically adapted for Hispanic patients with spine pain.
223884663|NCT06835439|BEHAVIORAL|Standard Care (Control)|Usual care (3-month baseline) includes no provider education, physician-initiated referrals and delivery of standard educational materials, and scheduling for physical therapy by the clinic referrals specialists using standard processes.
223884664|NCT06830616|DIAGNOSTIC_TEST|7T MRI brain|A very detailed MRI scan of the brain using a 7T MRI scanner.
223884665|NCT06510907|BEHAVIORAL|mindfulness based stress reduction program|"Mindfulness training will be delivered through a generic 8-week MBSR. The MBSR will consist of weekly 2-hour classes, in which the techniques to various meditations (e.g., body scan, mindful awareness of breathing, body, sounds, thoughts, emotions, and mindful movements) will be taught and discussed. Participants will be asked to meditate for ≥40 minutes every day during the 8-week program as homework. Besides cultivating attention control and a non-judgemental stance to experience, psychoeducation about psychological stress and stress response will also be discussed during the MBSR classes. The MBSR teacher will discuss any difficulties encountered during homework meditations in every class to enhance adherence.~Each MBSR class can have up to 25 participants. The 8-week program will be taught by a qualified MBSR teacher"
223884666|NCT06846229|OTHER|AI-associated strategy|The intervention in this study involves an AI system that leverages multimodal data fusion to support the clinical decision-making and evaluation of diseases. Patients in this cohort will undergo standard examinations, with clinical decisions guided by the recommendations generated by the AI system.
223884667|NCT05672186|BEHAVIORAL|Full-service market intervention|Full-service mobile market implementation: the market will visit intervention sites weekly. The market will carry items from all food groups including fresh, frozen and canned fruits and vegetables, whole grains, dairy/ dairy substitutes, proteins (e.g., frozen meat/fish, beans, eggs), and dry goods (e.g., cooking oil, spices). Prices on the market are affordable, approximately 10% lower than grocery stores.
223884668|NCT05672186|OTHER|No intervention|No intervention
223884669|NCT05959785|PROCEDURE|Basic and light cervical mobilization exercises|This group of exercises will be made up of a series of cervical mobilization exercises that are performed without pain, smooth, controlled by the patients, and without forcing the angulations. They are performed seated, with the arms extended along the body and forearms and hands resting on the legs. The chair must be firm and comfortable. Head movements to the right and left, right and left lateral flexion of the cervical region, cervical flexion and extension will be performed. This exercise will be performed for 5 minutes 3 times a day and beginning in the first 24 postoperative hours.
223884670|NCT05959785|PROCEDURE|Abdominal or diaphragmatic breathing exercises|The first abdominal or diaphragmatic breathing exercises will be carried out in a lying position, with the back well supported on a comfortable and firm surface, and with hips and knees flexed and feet supported. The patients take deep breaths, taking air raising the abdomen towards the ceiling, without raising the back from the horizontal plane. During expiration the navel will lower posteriorly and rise towards the thoracic region. For the second abdominal or diaphragmatic breathing exercise, the patient is seated on a firm and comfortable surface, with hips and knees flexed and feet supported. An inspiratory movement will be made in which the patient's navel will be moved outward, away from the spine. During expiration, the navel will go in the direction of the patient's spine and will rise in the direction of the thorax.
223884671|NCT03636503|DRUG|Rituximab|Rituximab works by targeting the CD20 antigen on normal and malignant B-cells. Then the body's natural immune defenses are recruited to attack and kill the marked B-cells. Stem cells (young cells in the bone marrow that will develop into the various types of cells) do not have the CD20 antigen. This allows healthy B-cells to regenerate after treatment
223884672|NCT03636503|DRUG|Utomilumab|Utomilumab is a drug which may stimulate the immune system against tumor cells. Because it activate the immune system, it is sometimes called immunotherapy drug
223884673|NCT03636503|DRUG|Avelumab|Avelumab is a drug which may stimulate the immune system against tumor cells. Because it activate the immune system, it is sometimes called immunotherapy drug
223884674|NCT03636503|DRUG|PF04518600|In the presence of tumor-associated antigens (TAAs), this may promote a T-cell-mediated immune response against TAA-expressing tumor cells. OX40
223884675|NCT06844513|PROCEDURE|Radical prostatectomy|Radical prostatectomy performed using the Da Vinci Xi and the HUGO RAS platform
223884676|NCT06844513|PROCEDURE|Partial nephrectomy|partial nephrectomy (PN) using either the Da Vinci Xi platform or the HUGO™ RAS platform
223884677|NCT06201962|OTHER|Massage|Massage applications will be performed for 15 minutes every morning and evening for two days.
223884678|NCT06201962|OTHER|Foot Reflexology|In the reflexology group, the researcher will hold the baby's foot with his left hand and gently massage each foot with the thumb of his right hand for 15 minutes.
223884679|NCT06201962|OTHER|Control|Newborns will receive routine medical treatment and nursing care and will not undergo any procedures.
223884680|NCT03178760|DIAGNOSTIC_TEST|Ultrasonic Measurement will be taken from optic nerve sheat diameter and compared-classified.|"Ultrasonic Measurement will be taken from optic nerve sheat diameter and compared-classified. Classifications will be done for;~1. Age~2. Gender~3. Weight~4. Length~5. Waist Circumference~6. Body mass index"
223884681|NCT06846346|DRUG|Ivonescimab|Ivonescimab 20 mg/kg by intravenous (IV) infusion once every 2 weeks until disease progression.
223884682|NCT06846346|DRUG|FOLFOX regimen|Oxaliplatin 85 mg/m2 IV, folinic acid 400 mg/m2 IV (or L-folinic acid 200 mg/m²), and fluorouracil (5-FU) 400 mg/m² IV bolus; followed by 5 FU 2400 mg/m2 as a 46 hour continuous IV infusion, every two weeks for 8 cycles followed by 5FU as maintenance therapy until disease progression.
223884683|NCT06846346|DRUG|Irinotecan|180 mg/ m2 IV over 90 min infusion every two weeks for a minimum of 4 cycles
223884684|NCT06846346|DRUG|Paclitaxel|80 mg/m2 IV at D1, D8 and D15, every four weeks (D1=D28)
223884685|NCT03089398|PROCEDURE|Hybrid Coronary Revascularization (isolated LIMA-LAD)|sternal-sparing, off-pump, isolated LIMA-LAD revascularization
223884686|NCT03089398|DEVICE|Hybrid Coronary Revascularization (PCI)|percutaneous revascularization of at least one non-LAD target
223884687|NCT03089398|DEVICE|Percutaneous Coronary Intervention|Multi-vessel PCI with metallic drug-eluting stents (DES) including the LAD and or LM. Only FDA approved commercially available metallic drug-eluting stents may be used in this protocol.
223884688|NCT05840809|DRUG|First line tuberculosis treatment|This is an observational study - the decision to use first-line tuberculosis treatment will have already been made by the responsible clinician. The study itself does not require any additional intervention.
223884689|NCT05078619|PROCEDURE|No PCI|Omission of PCI of significant coronary artery disease prior to TAVI
223884690|NCT02519452|DRUG|Daratumumab Subcutaneous (SC) Administration|Participants will receive Daratumumab mixed with rHuPH20 in part 1 and co-formulated with rHuPH20 in part 2 and part 3 administered via SC administration once weekly in Cycles 1 (each cycle is 28 days) and 2, every 2 weeks in Cycles 3-6, and every 4 weeks in subsequent cycles.
223884691|NCT02519452|DRUG|Recombinant Human Hyaluronidase [rHuPH20]) SC Administration|Participants will receive Recombinant Human Hyaluronidase \[rHuPH20\]) mixed with Daratumumab in part 1 and co-formulated with Daratumumab in part 2 and part 3 administered as SC administration once weekly in Cycles 1 (each cycle is 28 days) and 2, every 2 weeks in Cycles 3-6, and every 4 weeks in subsequent cycles.
223884692|NCT06844149|BEHAVIORAL|CPR; (Cardiac and Psychosocial Rehabilitation) with Cardiac Rehabilitation|This intervention combines an 8-week Cognitive Behavioral Therapy (CBT)-based psychosocial rehabilitation program with a structured Home-Based Cardiac Rehabilitation (CR) program for young adults with Fontan circulation. The CBT component includes weekly 90-minute group sessions focusing on stress management, cognitive restructuring, and social coping skills. The CR component consists of a personalized aerobic exercise plan, starting at 15-30 minutes per session and progressing to 40-60 minutes, with weekly monitoring and adjustments. This combined intervention is provided exclusively to participants in the CPR group
223884693|NCT06844149|BEHAVIORAL|CR; Home-Based Cardiac Rehabilitation|This intervention consists of an 8-week Home-Based Cardiac Rehabilitation (CR) program designed for young adults with Fontan circulation. Participants follow a structured aerobic exercise plan tailored to their cardiopulmonary fitness levels. The program starts with 15-30 minutes of exercise per session, progressing to 40-60 minutes, with intensity set at 60-70% of maximum heart rate. Exercise adherence is monitored through weekly follow-ups, with adjustments made as needed. This intervention is provided to participants in both the CR group and the CPR group but without the Cognitive Behavioral Therapy (CBT) component in the CR-only group.
223884694|NCT06844149|BEHAVIORAL|Usual Care|Participants in the control group received usual care without any additional interventions. They did not participate in the Cognitive Behavioral Therapy (CBT)-Based Psychosocial Rehabilitation or the Home-Based Cardiac Rehabilitation (CR) programs during the study period. After the study was completed, they were given the option to enroll in the CPR program. This group serves as a comparison to evaluate the effectiveness of the interventions in the CPR and CR groups
223884695|NCT06847061|BEHAVIORAL|Pulmonary rehabilitation program|"Participants are expected to engage in the home-based pulmonary rehabilitation routine at least 24 minutes a day, five to six days a week for the entire 12-week study period.~The pulmonary rehabilitation routine begins with slow upper body and timed breathing exercises, followed by two slow balance walks for 6 minutes each. The total exercise time again is 24 minutes, followed by a 4-minute mindful breathing meditation/cool down"
223884696|NCT05062265|DEVICE|Tight rope fixation|a traditional tight rope fixation is performed on one randomized set of subjects
223884697|NCT05062265|DEVICE|Tight rope fixation with an anterior inferior tibiofibular ligament (AITFL) repair augmentation with an internal brace|A tight rope fixation with an anterior inferior tibiofibular ligament (AITFL) repair augmentation with an internal brace set of subjects to compare syndesmotic volume
223884698|NCT06074614|DIAGNOSTIC_TEST|Hypercapnic ventilatory response|Control of breathing is predominantly regulated by feedback of the central chemoreceptors. All chemoreceptors are sensitive to changes in partial pressure of carbon dioxide and via acid-base reactions to hydrogen concentration. The hypercapnic ventilatory response test shows the relationship between end-tidal PCO2 and the resulting minute ventilation.
223884699|NCT06074614|DIAGNOSTIC_TEST|Respiratory related evoked potential|The RREP is a measure of cerebral cortical activity elicited by short inspiratory occlusion or breathing against inspiratory resistive loads and quantifies the initial arrival and further processing of sensory afferent respiratory information in the cortex.
223884700|NCT06074614|DIAGNOSTIC_TEST|Transcranial magnetic stimulation|Transcranial magnetic stimulation of the diaphragm is an established tool for investigating the cortical excitability related to breathing. TMS will be delivered over the vertex using a magnetic stimulator and a 110mm double cone coil.
223884701|NCT04626037|BEHAVIORAL|WECS Relational Toolkit|The Cuddle and Calm Book, The Mommy Baby Book, mother and child mutual narrative, the Bottle of Emotions, and the WECS for emotional connection, make up the WECS Relational Health toolkit.
223884702|NCT05439603|DRUG|ANC-501|Five 10 mg capsules per day
223884703|NCT06400433|PROCEDURE|Ultrasound-guided median nerve hydrodissection|Injected wrist will be supinated and slightly dorsiflexed. The transducer of the ultrasound will be placed transversely at the proximal carpal inlet. After sterile preparation, a 22 gauge needle will be inserted using the short-axis technique, in-plane ulnar approach. During hydrodissection, separation of either between the median nerve and flexor retinaculum or between the median nerve and the underlying flexor tendons will be visually confirmed.
223884704|NCT06846060|BEHAVIORAL|Mindfulness-Based Self-Compassion Program|Mindfulness-based intervention programs are a program that includes a special session in which body and mind are integrated, and consists of homework for participants on yoga, meditation and a mindfulness-based approach to vital events in order to be aware of the moment. The conscious awareness-based self-compassion program, created in line with the literature, consists of 8 sessions in total, in groups of 5-8 people, on the same day and time every week. There are specific goals and objectives for each session, and each session also has a separate theme along with its subject.
223884705|NCT05677334|DRUG|Henagliflozin|Combination therapy of Henagliflozin and Continuous Subcutaneous Insulin Infusion
223884706|NCT05677334|DEVICE|Continuous Subcutaneous Insulin Infusion|Continuous Subcutaneous Insulin Infusion therapy alone
223884707|NCT06388590|OTHER|Dragons|The Dragons Script will be read to the subjects by the provider administering treatment. Subjects will receive their Acupuncture treatment with Dragons protocol.
223884708|NCT06388590|OTHER|Standard of Care|Standard of care therapies including physical therapy, psychotherapy, behavioral health, typical primary care management, etc. as deemed appropriate by the primary care provider for 4 weeks prior to study intervention.
223884709|NCT04905537|OTHER|No intervention|It's only observational study. No interventions.
223884710|NCT06848049|OTHER|Mobile Aplication|In this study, individuals will be monitored for 28 days. They will be asked to fill out the Pressure Injury Information Form and the Pressure Injury Skills Checklist for Caregivers to be informed about pressures throughout the study process. The researcher will fill out the Bates-Jensen Wound Assessment Tool to ensure that their pressures are improving. Individuals who will undergo the intervention will use the mobile application. Face-to-face training will be provided to individuals. Individual-specific audio reminders will be based on daily living activities and will be delivered via the mobile application according to changes in individual dependencies. After 30 days, individuals will be asked to fill out the Mobile Health Application Acceptance Scale, the Pressure Injury Knowledge Scale for Caregivers, and the Pressure Injury Skills Checklist. The Bates-Jensen Wound Assessment Tool will be filled out by the researcher.
223884711|NCT06848049|OTHER|Control|In this study, individuals will be monitored for 28 days. In order to monitor their knowledge about pressure injuries, individuals will be asked to complete the Pressure Injury Information Form for Caregivers and the Pressure Injury Skills Checklist to monitor their skill levels about pressure injuries throughout the study period. The Bates-Jensen Wound Assessment Tool will be completed by the researcher to perform a physical examination of the patient and to assess the healing of the individual's pressure injury. Individuals in the control group will be interviewed twice by phone. Individuals with pressure injuries will be trained by a team consisting of a physician, nurse, dietician, and physiotherapist. Individuals will be interviewed twice by phone. After 30 days, individuals will be asked to complete the Mobile Health Application Acceptance Scale, the Pressure Injury Knowledge Scale for Caregivers, and the Pressure Injury Skills Checklist.
223884712|NCT06846619|DEVICE|Intra-Oral Scanning Method|"Intervention Description:~The intra-oral scanning method involves capturing digital impressions of the oral cavity directly using the 3Shape scanner. This method eliminates the need for traditional impression materials, providing a more comfortable and precise imaging process. The digital impressions are then utilized to design and fabricate maxillary dentures using 3D printing technology. The intervention focuses on evaluating patient satisfaction with the dentures in terms of comfort, fit, and aesthetics."
223884713|NCT06846619|DEVICE|Extra orally scanned|The extra-oral scanning method involves creating conventional impressions of the oral cavity using traditional impression materials. These impressions are then scanned externally using the 3Shape scanner to produce digital models. The digital models are used to design and fabricate maxillary dentures through 3D printing technology. This intervention aims to assess patient satisfaction with the dentures based on comfort, fit, and aesthetics.
223884714|NCT06847555|RADIATION|Radiation|Tumor radiotherapy is a method of treating malignant tumors by using radioactive rays such as alpha, beta, gamma rays produced by radioactive isotopes and x-rays, electron rays, proton beams and other particle beams produced by various x-ray therapy machines or accelerators.
223884715|NCT05185856|PROCEDURE|15 minutes eccentric cycling|The exposure to eccentric exercise will be individualized-intensity stepwise incremental cycle exercise starting at 50 Watt with individually tailored increments every 5 minutes.
223884716|NCT05185856|PROCEDURE|15 minutes concentric (normal) cycling|The exposure to concentric exercise will be individualized-intensity stepwise incremental cycle exercise starting at 50 Watt with individually tailored increments every 5 minutes.
223884717|NCT06463431|BEHAVIORAL|Cognitive Processing Therapy|We propose a conceptual model for the relationship between PTSD, substance use, \& sexual risk behaviour wherein using substances to avoid posttraumatic cognitions \& affect leads to risky sexual behaviour through impaired safer sex negotiation. These mechanisms are consistent with the theory underlying CPT. Behaviourally, substance use (and potentially risky sexual behaviour) is negatively reinforced through avoiding unwanted negative affect. Cognitively, PTSD-based predictions may generate unrealistic risk appraisals that contribute to sexual risk. CPT addresses these specified pathways by a) identifying how trauma leads to maladaptive beliefs about the self, others, \& the future, b) cognitive interventions to address these beliefs, \& c) an overall trauma-focused orientation that addresses cognitive, affective \& behavioural avoidance, using cognitive restructuring to lead to more realistic/adaptive beliefs, less cognitive/affective avoidance, \& more goal-directed approach behaviours.
223884718|NCT06846216|DEVICE|Treatment with BTL-785F and HPM-6000UF Devices|Three treatment sessions will consist of the consecutive application of the BTL-785F and HPM-6000UF devices, delivered 5-10 days apart. Three sessions will consist of the standalone application of the HPM-6000UF device, delivered 2-4 days apart. The treatments with BTL-785 device equipped with BTL-785-3 applicator will last 2-10 minutes and with HPM-6000UF 28 minutes.
223884719|NCT06846424|BIOLOGICAL|SCT-001 CAR-T cells|SCT-001 CAR-T cells are autologous-derived CAR-T cell products, which transduce second-generation CAR targeting TAG-72 into patient autologous T cells by lentiviral transfection, and knock out immunosuppressive related genes by CRISPR/Cas9 technology to enhance the anti-tumor function of CAR-T cells.
223884720|NCT06847659|DIAGNOSTIC_TEST|intraoperative body temperature|Body temperature measurement with esophageal probe
223884721|NCT05461131|BIOLOGICAL|BPZE1|Live attenuated vaccine
223884722|NCT05461131|BIOLOGICAL|Placebo|Placebo
223884723|NCT05461131|DRUG|Azithromycin|Antibiotic
223884724|NCT05461131|OTHER|Bordetella Pertussis Challenge Strain|Challenge Strain
223884725|NCT06373835|DRUG|Emodepside|5 mg tablets of emodepside and matching placebo tablets, 3mg ivermectin
223884726|NCT03561103|BEHAVIORAL|Client-Centered Representative Payee|CCRP is a structural intervention wherein Social Security authorizes a representative payee to serve as financial manager for people who need help managing their money. By helping clients to consistently pay their bills including rents and utilities, CCRP may redirect the expenditure of participants' resources toward improved health behaviors. Shifting the focus of material and biopsychosocial resources may change the context in which health behaviors are produced, contributing to higher rates of adherence and viral suppression. CCRP modifies the implementation of a current policy of the Social Security Administration (SSA) to create an intervention that is highly replicable.
223884727|NCT05783219|DRUG|Lidocaine patch|4% lidocaine patch placed over the sacrum 30 minutes prior to PNE procedure
223884728|NCT05783219|OTHER|Placebo|Adhesive patch placed over the sacrum 30 minutes prior to PNE procedure
223884729|NCT06845111|OTHER|Therapeutic play|In this context, the pre-school teachers in the container area were contacted and the sessions were held every Wednesday-Thursday (8 sessions in total) for 5 weeks, taking into account their availability hours. Children were included in the programme in groups of 12. Before data collection, the necessary materials were provided and stored in an empty container. It was found appropriate to complete the trainings in kindergartens located in the container city (4). A total of 3 evaluations were carried out: a post-test immediately after the end of the programme and a retention test at the end of the first month.
223884730|NCT05275075|OTHER|Pancreatic cancer microRNA and messenger RNA expression.|Tumor specimens from pancreatic patients will be analyzed for markers associated with muscle loss.
223884731|NCT06846411|DRUG|Empagliflozin 10 mg|The primary objective was to evaluate the efficacy of early treatment with empagliflozin in reducing GV, as measured by the change in MAGE from baseline to Week 12, compared to metformin.
223884732|NCT06846411|DRUG|Metformin|The primary objective was to evaluate the efficacy of early treatment with empagliflozin in reducing GV, as measured by the change in MAGE from baseline to Week 12, compared to metformin.
223884733|NCT03107520|DIAGNOSTIC_TEST|Intraoperative contrast-enhanced ultrasound (CEUS)|An intraoperative CEUS of the dysplastic femoral head will be performed after surgical reduction of the femoral head and during placement of the spica cast.
223884734|NCT03107520|DRUG|Lumason|Administration of Lumason contrast agent to improve visualization of epiphyseal vascularity in the femoral head.
223884735|NCT06843915|OTHER|Moderate intensity aerobic exercise|Participants in the MIAE group engaged in a 40-minute supervised session using the StepOne-SCIFIT recumbent stepper machine. The session included a 5-minute warm-up at 25 watts, followed by 30 minutes of moderate-intensity exercise, main-taining a stepping rate of 90-100 steps per minute. The workload was adjusted to keep the participant's heart rate within the target heart rate range (THRR), calculated using the Karvonen formula. During the first three weeks, the exercise intensity was set at 50-59% of heart rate reserve (HRR), and for the remaining three weeks, it was increased to 60-69% of HRR. Polar heart rate monitors were used to assess heart rate before and after each session. Participants kept weekly exercise logs to monitor compliance.
223884736|NCT06843915|OTHER|Home Exercise Program|Home Exercise Program
223884737|NCT06844253|PROCEDURE|INTERVENTION GROUP; TRAINING WITH EXERGAMING|RANDOMIZED CONTROL TRIAL EXERGAMING KINECT 20,000 LEAKS , KINECT BUBBLE POP, KINECT RALLY BALL GROUP 2: TASK ORIENTED TRAINING TRANSFERRING OBJECTS FROM ONE SIDE TO OTHER SIDE OF TABLE CATCHING AND THROWING BALLSIN DIFFERENT DIRECTIONS PICKING UP OBJECTS FROM LESS HIGHTED TABLES.
223884738|NCT06844253|PROCEDURE|Task oriented training|"The participant will receive task oriented training consisting of different tasks in sitting and standing position.~week1-2 sitting position: throwing and catching balls standing position: picking up glass from less heighted table . week 3-4 sitting position: transferring the plastic rings from one corner of table to another.~standing position: catching balls from multiple directions. wee5-6 sitting position: picking objects from floor standing position: opening drawer from less heighted tables week 7-8 standing position: picking up and transferring bottles, jars at different locations on table standing position: removing stickers from wall time of session: 15-20 reps, 2 sets. 30 minutes of session with 5 minutes rest in between. the intervention will be given for 30 minutes , 3 days a week for total 8 weeks of time period."
223884739|NCT06842511|DRUG|open flap debridement and Hyaluronic Acid-Based Gel application|Hyaluronic Acid-based gel as an adjunctive chemotherapeutic agent
223884740|NCT06842511|PROCEDURE|open flap debridement|periodontal surgery technique
223884741|NCT05560815|PROCEDURE|Any surgical procedure|Might differ for substudies.
223884742|NCT05779566|DIAGNOSTIC_TEST|bone densitometry|bone densitometry every 6 month
223884743|NCT05341661|DEVICE|Butterfly Prostatic Retraction Device|Implantation of the Butterfly device
223884744|NCT05939193|PROCEDURE|Urine-guided hydration|The target is to maintain urine output at 200 ml/h (3 ml/kg/h) or higher by intravenous injection/infusion of furosemide throughout surgery. That is, a loading dose of 20 mg is injected at the beginning of surgery; if urine output does not reach the target value, furosemide will be continuously infused at 10 mg/h until the end of surgery, with a cumulative dose not exceeding 250 mg. Intravenous rehydration is performed to balance urine output and to maintain the SVV ≤10%.
223884745|NCT05939193|PROCEDURE|Routine hydration|The target is to maintain urine output at 0.5 ml/kg/h or higher according to routine practice. That is, furosemide is only administered when clinically necessary or at discretion of responsible anesthesiologists; intravenous rehydration is performed to maintain the SVV ≤10%.
223884746|NCT05939193|DRUG|Forced administration of furosemide|Forced administration of furosemide
223884747|NCT05939193|DRUG|Routine administration of furosemide|Routine administration of furosemide
223884748|NCT06469853|DRUG|MBF-015 16 mg oral capsules|MBF-015 oral capsules HDAC inhibitor
223884749|NCT05299476|DRUG|CAPOX combined with bevacizumab and Tislelizumab|"Oxaliplatin: intravenous infusion, 130mg/m2, infusion for more than 3h, every 3 weeks for a cycle, infusion 4-8 cycles; Capecitabine: oral administration, 2g/m2, 2 times, 14 days, 7 days rest, every 3 weeks for a cycle; Bevacizumab was administered intravenously (without prophylaxis) at 7.5mg/kg. The first infusion was 90min, the second infusion was 60min, and each infusion was 30 min. The drug was administered once every 3 weeks, and the longest cumulative duration was 2 years.~Tislelizumab is administered intravenously (without prophylaxis) at a fixed dose of 200mg. Each infusion was 30 min (no less than 20 min, no more than 60 min), and the drug was given once every 3 weeks for a cycle, with the longest cumulative duration of 2 years."
223884750|NCT06276257|PROCEDURE|Paravertebral block|An ultrasound-guided technique will be used to inject a volume of 40 mL of ropivacaine 0.2%, up to a maximum of 1.5 mg/kg, into the paravertebral space between the T3 and T4 vertebrae.
223884751|NCT06276257|PROCEDURE|Usual analgesia|The patient will receive analgesia as per the anesthesiologist's preferences.
223884752|NCT05784740|OTHER|12-week precision exercise training|The 12-week exercise intervention will consist of both aerobic and strength exercise training performed 3x per week using an individualized and nonlinear periodized approach.
223884753|NCT02944825|DRUG|Ciprofloxacin|first line prophylactic oral antibiotic
223884754|NCT02944825|DRUG|trimethoprim/sulfamethoxazole|second line prophylactic oral antibiotic
223884755|NCT02944825|DRUG|No Intervention|No intervention
223884756|NCT04184921|DRUG|Aspirin 100mg|Aspirin, also known as acetylsalicylic acid (ASA), is a very safe medication used to treat pain, fever, or inflammation.
223884757|NCT04184921|DRUG|Osimertinib 80 MG|Osimertinib, also known as azd9291, is a 3rd-generation EGFR-TKI used to treat NSCLC patients with resistance to 1st generation EGFR-TKI due to T790M mutation. It has been approved in clinical applications by the FDA in 2015.
223884758|NCT05968495|DEVICE|Renuvion APR Handpiece|The Renuvion® APR (Apyx Plasma/RF) handpiece is a sterile, single use electrosurgical (monopolar) device intended to be used in conjunction with a compatible generator for the delivery of radiofrequency energy and helium plasma for cutting, coagulation and ablation of soft tissue during open surgical procedures. Radiofrequency energy is delivered to the handpiece by the generator and used to energize the electrode. When helium gas is passed over the energized electrode, a helium plasma is generated for cutting, coagulation or ablation of soft tissue during open surgical procedures. The compatible generators operate at an adjustable power of up to 40 W (expressed as 0 - 100% where 100% is 40 W) and provide an adjustable helium gas flow of 1 - 5 L/Min. APR Handpiece has a non-extendable electrode to generate helium plasma.
223884759|NCT03737058|BEHAVIORAL|Program participants|The intervention is a 12-month telephonic program in which a lay health worker (LHW), supervised on-site by a registered nurse practitioner (RNP), assessed patient symptoms after diagnosis using the validated Edmonton Symptom Assessment Scale (ESAS) (cite) with the frequency of symptom assessment varying based on patient risk.
223884760|NCT03101904|DIETARY_SUPPLEMENT|Beetroot Juice|
223884761|NCT03101904|DIETARY_SUPPLEMENT|Placebo|
223884762|NCT02682316|OTHER|dry gauze|
223884763|NCT02682316|DEVICE|The Prevena Incision Management System|
223884764|NCT03816631|DRUG|Pimodivir|Participants will receive single oral dose of Pimodivir 600 mg (2\*300 mg tablets) under fasted condition on Day 1.
223884765|NCT06120049|DIAGNOSTIC_TEST|[18F]-MFBG PET CT|"\[18F\]-MFBG will be acquired at the Leuven University hospital on a GE MI4 PET/CT camera, with low dose CT and 120 MBq injected activity. Dynamic imaging between 0-60 minutes and 100-120 minutes (patients) and 0-70 minutes and 90-120 minutes (healthy volunteers).~Venous sampling between 5-120 minutes will be obtained through a second catheter, 6 venous samples will be taken.~In healthy up to 5 control subjects, full arterial sampling (0-120 minutes,) will also be done.~If patient comfort allows, after the dynamic cardiac scan 2 hours post-injection field dynamic scan, a fast late timepoint whole body PET/CT will be taken (2 min/bed position, 11 mAs low dose CT; estimated 10-12 minutes)."
223884766|NCT06120049|DIAGNOSTIC_TEST|[18F]-FE-PE2I PET CT or PET MRI|"\[18F\]-FE-PE2I will be performed at the University Hospital Leuven with the GE Signa simultaneous PET/MR with acquisition at 50-70 minutes postinjection or at the University Hospital in Gent using a Siemens PET/CT, GE MI4 PET/CT.~Injected activity: 120 MBq"
223884767|NCT06120049|DIAGNOSTIC_TEST|[123I]-MIBG SPECT CT|"\[123I\]-MIBG SPECT/CT (low dose CT) will be performed at the local nuclear medicine department of each participating center.~Injected activity: 111 MBq"
223884768|NCT06120049|DIAGNOSTIC_TEST|[18F]-MFBG PET dosimetry scans|"\[18F\]-MFBG will be acquired at the Leuven University hospital on a Siemens Truepoint or GE MI4 PET/CT camera or equivalent newer camera, with low dose CT and 120 MBq injected activity.~Three segments of consecutive whole-body scanning with increasing bed position duration will be carried out up to 3 half-lives (physical half-life T1/2 for 18F = 110 minutes): from 0-90 minutes (scan 1-8), 120-150 (scan 9) and 300-330 (scan 10) minutes post injection. In total 10 whole body biodistribution scans will be taken. Urine will be collected and its total activity measured to measure bladder excretion for correction of integrated bladder organ residence. Before each segment, a low dose whole body CT scan (11 mAs) will be acquired for attenuation correction and organ delineation."
223884769|NCT04538417|DEVICE|Cooled Radiofrequency Ablation|RFA procedures will be performed with modification accounting for appropriate C-RFA technique. Participant will be positioned prone and skin prepped with chloroprep. Ultrasound probe will be placed on residual limb at a transverse angle in order to view the nerve and associated neuroma in long-axis. The probe will be advanced to the site of the stump neuroma. C-RFA electrode will be placed adjacent to neuroma. Needle will be connected via wire to a cooled radiofrequency generator. Motor and sensory testing will be performed to reproduce or exacerbate the RLP and / or PLP. At the site of the neuroma, 2 mL of local anesthetic will be injected through the needle. C-RFA lesions will be created by using the typical C-RFA protocol. Upon completion needle will be removed. Following ablation, 0.5 mL of 0.5% bupivacaine will be injected at the site of the ablated neuroma to provide post procedure analgesia.
223884770|NCT05938803|BEHAVIORAL|PASEO|The intervention consists of community-based accompaniment intervention aimed at facilitating the transition to adult HIV care for adolescents living with HIV in Lima, Peru.The intervention includes the following activities: health systems navigation and accompaniment to clinic visits, monthly check-ins with an entry-level health worker, social support provided through peer support groups, education sessions, resolution of acute needs, and individualized adherence support.
223884771|NCT05693610|DEVICE|Portable OSP|The portable open-source speech processing platform (OSP) is accessed on a browser via a wireless fidelity (WiFi)-enabled portable communication device that carries out all the signal processing. The processed sounds are transmitted to the ears via earpieces known as behind-the-ear receivers in the canal (same as those available with commercial hearing aids). The amount of amplification with the portable OSP will be customized for each listener based on a validated prescription.
223884772|NCT05693610|DEVICE|Cloud-based OSP|The cloud-based open-source speech processing platform (OSP) is hosted on a web-server which includes the software for all the signal processing. The processed sounds are transmitted to the ears via calibrated headphones. The amount of amplification with the cloud-based OSP will be customized for each listener based on a validated prescription.
223884773|NCT03698851|DEVICE|Guidor® and Guidor easy-graft® CRYSTAL|A compound of biphasic calcium phosphate, 60 % hydroxyapatite and 40 % beta-tricalcium phosphate. The beta-tricalcium phosphate component completely resorbs via physiological dissolution in 5-15 months, while the interconnected hydroxyapatite remains embedded in the implantation site and forms an integrated long term osteoconductive scaffold with new bone.
223884774|NCT03698851|DEVICE|Guidor® and Guidor easy-graft® CLASSIC|Phase-pure beta-tricalcium phosphate that offers complete resorption via physiological dissolution in 5-15 months. This material has been used in oral surgery for more than 25 years and there are extensive research available on it.
223884775|NCT01981031|DRUG|BioChaperone® Combo|Single dose of 0.8U/kg body weight injected subcutaneously (under the skin)
223884776|NCT01981031|DRUG|Humalog® Mix25|Single dose of 0.8U/kg body weight injected subcutaneously (under the skin)
223884777|NCT04781621|DEVICE|Robotic Gait Training|Participants will wear an exoskeleton suit and receive robotic gait training with a physical therapist for 90 minutes each week. Robot gait training will include standing and walking activities while wearing the The Ekso Bionics Ekso GT™ robotic exoskeleton. Participants will be asked to complete questionnaires about walking and function. They will also be asked to wear a watch measuring their heart rate monitor.
223884778|NCT04781621|OTHER|Usual Care Gait Training|Participants receive usual care gait training with a physical therapist for 90 minutes each week. Usual care gait training includes standard gait training involving standing and walking activities such as conventional overground walking, body weight-supported treadmill training (BWSTT), overground body weight-supported overground system, and various assistive devices (e.g., BWSTT, overground with braces, walker, etc.). Participants will be asked to complete questionnaires about walking and function. They will also be asked to wear a watch measuring their heart rate monitor and number of steps.
223884779|NCT00051545|DRUG|Seocalcitol|
223884780|NCT03915379|DRUG|JNJ-67571244|JNJ-67571244 will be administered.
223884781|NCT02914964|BEHAVIORAL|Swank Diet|A Registered Dietitian Nutritionist (RDN) skilled in motivational interviewing will provide nutrition counseling to study participants to assist them in following the Swank Diet at home. An in-person counseling session will occur at study visits 2 and 3. Five telephone counseling calls will occur between visits 2 and 3. The study participant may contact the RDN with questions at any time during the intervention.
223884782|NCT02914964|BEHAVIORAL|Wahls Elimination Diet|A Registered Dietitian Nutritionist (RDN) skilled in motivational interviewing will provide nutrition counseling using to study participants to assist them in following the Wahls Elimination Diet at home. An in-person counseling session will occur at study visits 2 and 3. Five telephone counseling calls will occur between visits 2 and 3. The study participant may contact the RDN with questions at any time during the intervention.
223884783|NCT04452084|RADIATION|HA-WBRT|The accepted standard HA-WBRT doses in the control arm are 30Gy in 10 fractions.
223884784|NCT04452084|RADIATION|HA-SIB-WBRT|The doses selected for experimental HA-SIB-WBRT arm are 30Gy in 10 fractions to the whole brain with 40 to 45Gy in 10 fraction SIB doses to tumours.
223884785|NCT06580548|DEVICE|CHW-supported telerehabilitation|Participants will receive the Mobile Rehab mobile software, which allows participants to be prescribed personalized rehabilitation strengthening video regimens electronically based on respondent-indicated mobility and activities of daily living functionality
223884786|NCT06580548|OTHER|Usual Care|Participants will be provide a list of local social services resources, including mental health, that participants can use . A callback number will be provided if they have any questions about the services.
223884787|NCT00000958|BIOLOGICAL|MTP-PE/MF59|
223884788|NCT00000958|BIOLOGICAL|Env 2-3|
223884789|NCT01988935|BEHAVIORAL|Prolonged Exposure|Weekly psychotherapy sessions x 12 weeks, focused on gradually confronting distressing trauma-related memories and reminders.
223884790|NCT01988935|BEHAVIORAL|Smoking Cessation|Weekly smoking cessation counseling (cognitive behavioral therapy) plus the nicotine patch to reduce withdrawal symptoms.
223884791|NCT05487963|DRUG|Tofacitinib Citrate|Topical application of a pea-sized amount of ointment (active or vehicle) over a maximum surface of 30 cm2 up to 2 times a day.
223884792|NCT05487963|OTHER|placebo ointment|Topical application of a pea-sized amount of ointment (active or vehicle) over a maximum surface of 30 cm2 up to 2 times a day.
223884793|NCT06290401|BEHAVIORAL|SCThrive|SCThrive is a virtual, 8-week, virtual group-based, behavioral self-management intervention that includes daily use of a companion mobile app.
223884794|NCT06290401|OTHER|SCHealthED|Standard of care plus 7 SCD educational text messages to ensure education is uniform across sites
223884795|NCT05912556|DEVICE|Digital Program 1|2/3 of randomized subjects use digital program 1 for 12 weeks to provide mental stimulation
223884796|NCT05912556|DEVICE|Digital Program 2|1/3 of randomized subjects use digital program 2 for 12 weeks to provide mental stimulation
223884797|NCT05521984|DRUG|Dapagliflozin|Commercially available
223884798|NCT05521984|DRUG|Carmustine|Standard of care
223884799|NCT05521984|DRUG|Topotecan|Standard of care
223884800|NCT05521984|DRUG|Cyclophosphamide|Standard of care
223884801|NCT03630328|DIETARY_SUPPLEMENT|Cogni.Q|AGN
223884802|NCT03630328|OTHER|Placebo|Placebo
223884803|NCT05832983|BEHAVIORAL|Guided Meditation|In private exam room, the study registered nurse (RN) will read a prepared two minute guided meditation to patient.
223884804|NCT05832983|OTHER|Aromatherapy|In private exam room, study RN will first affix an Elequil Aromatab to patient's clothing on either their upper arm or chest (whichever the patient prefers and/or as clothing allows).
223884805|NCT06388980|OTHER|Validated questionnaires and ad hoc questions|validated questionnaires and open questions online through the institution's intranet anonymous
223884806|NCT05667285|DEVICE|BIOTRONIK Orsiro Sirolimus-Eluting Coronary Stent System|"During the procedure, the investigator assesses the arterial diameter and lesion length either visually or using QCA to select the appropriate stent. The number of stents required for each lesion is determined by the investigator based on the specific circumstances. The length of the stent should cover from the proximal normal reference vessel to the distal normal reference vessel, ensuring complete coverage of the lesion.~The number of stents required for each lesion is determined by the investigator based on the specific circumstances. If the first stent does not fully cover the lesion, a second or even more stents may be used. In such cases, the second or additional stents are selected by the investigator based on the specific circumstances, such as using Orsiro SES stents, unless clinically contraindicated or specifically required. Please refer to the stent's Instructions for Use for the procedure.~If stent overlap occurs, the overlapping part should be at least 2mm."
223884807|NCT00150813|DRUG|Levetiracetam|Pharmaceutical form: oral tablets Route of administration: Oral use
223884808|NCT05349370|OTHER|Isotopically labeled lactate|A bolus dose of isotopically labeled lactate is given and blood samples from existing catheters are drawn
223884809|NCT05349422|BEHAVIORAL|Electronic Health Record (EHR) Enabled Teamlets|The intervention consist of four components: 1) patients with hypertension will be automatically screened for low medication adherence using linked EHR-pharmacy data at the time of a PCP encounter; 2) MAs will deliver a validated, rapid, survey of common causes of non-adherence; 3) MAs and/or RNs will address barriers to adherence tailored to survey response, including delivery of brief health coaching based on motivational interviewing; and 4) PCPs will address specific barriers to adherence based on survey response.
223884810|NCT06351046|DEVICE|Virtual Reality-based Pain Self-management program|The VRPS has a variety of modules that can be used for pain management. For this project we have selected relaxation, mindful escapes, pain distraction games, and dynamic breathing modules. All modules were designed to minimize triggers of emotional distress or cybersickness.
223884811|NCT06129214|PROCEDURE|Prepectoral|Remove all visible synovium in suprapatellar area under distal quadriceps tendon. All other procedures (Total Knee arthroplasty) are same with no intervention arm.
223884812|NCT06129214|PROCEDURE|Subpectoral|No remove any synovium in suparapatellar area under distal quadriceps tendon. All other preocedures are same with experimental arm.
223884813|NCT05121038|DRUG|CEND-1|The treatment with CEND-1 will be given as an intravenous (IV) infusion (through a needle in a vein) at the clinic once every 14 days (or Day 1 of every 14-day cycle starting in Cycle 4).
223884814|NCT05121038|DRUG|Panitumumab|"Up to ten (10) participants with cancer that has spread to certain areas of the body and who have a certain gene in the tumor called RAS/BRAF wild type will receive another drug called panitumumab in addition to CEND-1 and FOLFIRINOX."
223884815|NCT05121038|DRUG|Folfirinox|"FOLFIRINOX is a name for a chemotherapy treatment regimen that includes several different drugs that are given in a certain order.~All of these drugs are given as an intravenous (IV) infusion (through a needle in a vein) at the clinic once every 14 days (or Day 1 of every 14-day cycle).~* Oxaliplatin - dose is 85 mg / m2 the infusion takes about 2 hours. then~* Leucovorin - dose is 400 mg / m2 - this is given at same time with irinotecan (below) and the infusion takes about 1.5 hours.~* Irinotecan - dose is 180 mg / m2 - this is given at same time with leucovorin (above), and the infusion takes about 1.5 hours.~then~• Fluorouracil - dose is 2400 mg / m2 - this infusion takes 46 to 48 hours (2 days) with an IV pump done at home."
223884816|NCT06030388|OTHER|Strength training|Both interventions (strength training and high intensity aerobic training) will be introduced with a 3-week adaptation period with lower loads (strength training) or intensity (aerobic training) followed by a 12-week period on the intended load/intensity. All participants in the intervention groups will be recommended to exercise three times per week (one hour per session) and in addition be active with everyday low-intensity physical activity. A structured and detailed training diary will be used in both groups to register frequency of each training session, as well as everyday physical activity. For the strength training, load and dose will also be registered for each training session.
223884817|NCT06030388|OTHER|High-intensity aerobic training|Both interventions (strength training and high intensity aerobic training) will be introduced with a 3-week adaptation period with lower loads (strength training) or intensity (aerobic training) followed by a 12-week period on the intended load/intensity. All participants in the intervention groups will be recommended to exercise three times per week (one hour per session) and in addition be active with everyday low-intensity physical activity. A structured and detailed training diary will be used in both groups to register frequency of each training session, as well as everyday physical activity. For the strength training, load and dose will also be registered for each training session.
223884818|NCT00268723|DRUG|Levalbuterol tartrate HFA MDI|levalbuterol MDI 90 mcg QID
223884819|NCT00268723|DRUG|Placebo|Placebo MDI QID
223884820|NCT06783101|BEHAVIORAL|Use of smart inhaler to enhance asthma inhaler proficiency|The application of the smart inhaler technology to enhance asthma inhaler proficiency
223884821|NCT06236607|DEVICE|Device specific training|Device-specific training materials from the manufactures will be used. The study clinician/pump trainer will use a pump readiness check-list to evaluate the training needs.
223884822|NCT06236607|OTHER|Study clinician/educator visit|Participants will receive insulin dose and other diabetes management guidance.
223884823|NCT04640961|DEVICE|Cingal|Single injection into the shoulder joint of a 4 ml unit dose of Cingal containing 88 mg (22 mg/ml) of cross-linked sodium hyaluronate and 18 mg (4.5 mg/ml) of triamcinolone hexacetonide (TH).
223884824|NCT04242602|DEVICE|Transcranial Doppler|Record flow velocity tracing of middle cerebral artery using a transcranial doppler.
223884825|NCT04897438|PROCEDURE|Kidney allograft biopsy depending on donor-derived cell-free DNA levels|Kidney allograft biopsy is performed, when absolute levels of donor-derived cell-free DNA are above 50 copies/ml
223884826|NCT06281028|DEVICE|SOLACEA-H/HYDROLINK-NVU|Patients will receive 6 sessions of washout treatment, followed by a gradual tapering phase (4 sessions maximum) during which the anticoagulant will be reduced from the normal dose to the minimum effective dose (which may be zero) and maintained for a minimum of 2 sessions on the SOLACEA-H, followed by 6 washout sessions, then again a gradual reduction phase (4 sessions maximum) during which the anticoagulant will be reduced from the normal dose to the minimum effective dose (which may be zero) and maintained for a minimum of 2 sessions on the HYDROLINK-NVU.
223884827|NCT06281028|DEVICE|HYDROLINK-NVU/SOLACEA-H|Patients will receive 6 sessions of washout treatment, followed by a gradual tapering phase (4 sessions maximum) during which the anticoagulant will be reduced from the normal dose to the minimum effective dose (which may be zero) and maintained for a minimum of 2 sessions on the HYDROLINK-NVU, followed by 6 washout sessions, then again a gradual reduction phase (4 sessions maximum) during which the anticoagulant will be reduced from the normal dose to the minimum effective dose (which may be zero) and maintained for a minimum of 2 sessions on the SOLACEA-H.
223884828|NCT05554198|BEHAVIORAL|Attend Behavior Parent Training|Attend Behavior is a Parent Training intervention available in application form for smartphones or online. Attend Behavior consists of 12 instructional modules and it is recommended that parents complete one module a week in addition to practicing the techniques taught in that course. Each learning module typically around 30 minutes to complete and includes an introductory video to give parents an overview of the different features of the application. At the start of the intervention, parents will take an assessment that will provide information for the program to create individualized goals, plans, reinforcement agents, and even daily schedules. A HIPPA compliant clinician portal within the application allows the clinician to have real time access to monitor the parent learning progress, tracked behaviors, parental notes, and message with the parent.
223884829|NCT05942495|BEHAVIORAL|short-term schema focused group therapy|There are two intervention phases. The first concerns the pre-treatment phase, which consists of five online sessions and three face-to-face sessions. The second intervention phase is the short-term SFGT. The SFGT consists of 17 weekly group sessions.
223884830|NCT05426629|DEVICE|Venus Glow|"The Venus Glow hydradermabrasion device is a class 1 device trimodality dermal system consisting of vacuum, 360 degrees rotating tip and two jet streams of saline.~Adjustable vacuum deep cleanses the pores by pulling up daily dirt and debris, dry and dead skin cells, and excess sebum from the stratum corneum. It helps increase the microcirculation.~The 360-degree rotation helps in spreading the saline evenly, which is expelled from two ultra-fine jet streams. This micro massaging helps in faster release of nutrients from the skin. The jet stream is smaller than the average pore size measuring 50- 70 microns each, enabling the jet stream to deep clean each pore."
223884831|NCT03052608|DRUG|Lorlatinib|ALK-positive NSCL treatment
223884832|NCT03052608|DRUG|Crizotinib|ALK-positive NSCL treatment
223884833|NCT03113500|DRUG|Brentuximab Vedotin|Given IV
223884834|NCT03113500|DRUG|Cyclophosphamide|Given IV
223884835|NCT03113500|DRUG|Doxorubicin|Given IV
223884836|NCT03113500|DRUG|Doxorubicin Hydrochloride|Given IV
223884837|NCT03113500|DRUG|Etoposide|Given IV
223884838|NCT03113500|DRUG|Etoposide Phosphate|Given IV
223884839|NCT03113500|OTHER|Laboratory Biomarker Analysis|Correlative studies
223884840|NCT03113500|DRUG|Prednisone|Given PO
223884841|NCT04204278|DEVICE|Monovisc|A chemically cross-linked sodium hyaluronate supplied as a 4 mL unit dose in a 5 mL glass syringe.
223884842|NCT06354634|OTHER|Resin polymer (NuSmile Bioflx) crown|Resin polymer (NuSmile Bioflx)crown
223884843|NCT06354634|OTHER|Stainless steel crown|Stainless steel crown
223884844|NCT05592288|OTHER|PREDIABE-TR mobile app.|"* Module 1: Personal data Containing data on the participant's age, gender, telephone number, email and perception of his/her health (bad, so-so, good, very good).~* Module 2: Medical history of the participant In this module, the participants tick the items that apply to themselves or their first-degree relatives by marking the conditions in their medical history that may increase the risk of prediabetes. Additionally, in line with the recommendations of the Turkish Association of Endocrinology and Metabolism, this module contains the Finnish Diabetes Type-2 Risk Score (FINDRISK) which assesses an individual's risk of diabetes.~* Module 3: Healthy lifestyle behaviors The sub-sections of the module are devoted to nutrition, height-weight-body mass index (BMI) and physical activity."
223884845|NCT05470907|DEVICE|Hemoperfusion|Commercial membranes for extracorporeal blood purification (hemoperfusion)
223884846|NCT06262594|DRUG|Lemborexant|Drug is administered
223884847|NCT06262594|DRUG|Placebo|Drug is administered
223884848|NCT05249439|OTHER|I-SatPro weight loss programme|I-SatPro weight loss programme: participants advised on I-SatPro dietary change as well as eating patterns, lifestyle change such as exercise, self-care such as advice on sleep and behavioural change strategies.
223884849|NCT05249439|OTHER|Tier 3 weight loss programme|Tier 3 weight loss programme: participants advised to make changes to food choices in accordance with NHS healthy eating advice, eating habits, lifestyle change such as exercise, mindful eating and behavioural change strategies.
223884850|NCT05166694|OTHER|Drug-Drug Interaction Profile|A profile based on genetic testing that shows information about how the participant's medications they are taking interact with each other.
223884851|NCT05166694|OTHER|Drug-Gene Interaction Profile|A profile based on genetic testing that shows information about how the participant's genes interact with/respond to certain medications they are taking.
223884852|NCT05166694|OTHER|Standard of Care|The standard treatment and prescribing for the participant's specific type of cancer.
223884853|NCT06477263|DEVICE|Neurocytotron|Neuronal regeneration treatment
223884854|NCT04414644|BEHAVIORAL|Eating Condition|Participants will be randomly assigned to eat per the prescribed eating condition for 8 weeks during eating condition 1. They will complete the alternate eating condition for 8 weeks during eating condition 2.
223884855|NCT05245968|DRUG|Pimitespib|Pimitespib will be administered orally in 5 consecutive days followed by 2 days off treatment (QD 5) on an empty stomach at least 1 hour before or 2 hours after a meal. The doses in the Dose Escalation Part will be 80, 120 (starting dose), and 160 mg. The doses used in Arm A will be MTD or recommended dose (RD) based on the information, including the safety and the pharmacokinetics (PK) data in the Dose Escalation Part. In Expansion Part-B, pimitespib will be administered with the starting dose of 160 mg daily.
223884856|NCT05245968|DRUG|Imatinib|Imatinib will be administered orally, after a meal and large glass of water QD. The doses in Dose Escalation Part will be 400 mg or 300 mg (De-escalation). The doses used in Expansion Part-A will be MTD or RD based on information, including the safety and PK data in the Dose Escalation Part. In Expansion Part-B, imatinib will be administered post after pimitespib discontinuation with the starting dose of 400 mg daily.
223884857|NCT05245968|DRUG|Sunitinib|Sunitinib will be administered orally QD with a starting dose of 50 mg, on a schedule of 4 weeks on treatment followed by 2 weeks off, and will be taken with or without a meal in Expansion Part-C.
223884858|NCT06217068|BEHAVIORAL|Elliptical Activity|8 minutes of elliptical exercise at a moderate intensity based on heart rate reserve. There will be a 2-minute warm-up and 2-minute cool down period in addition to the 8 minutes at moderate-intensity.
223884859|NCT06113510|RADIATION|Hybrid 18F-GP1 positron emission tomography and coronary computed tomography coronary angiography|18F-GP1 will be synthesized by our radiochemistry facility, the Edinburgh Imaging Facility Radiochemistry (EIFR), which is co-located within our Edinburgh Imaging Facility, Queens Medical Research Institute (EIF QMRI) using our well-established protocols. Each patient will undergo 18F-GP1 PET/CT coronary angiography imaging on our hybrid scanner (Biograph mCT, Siemens) as soon as practical after their index event and within a maximum of 7 days from symptom onset. Patients will initially be injected with 250 MBq 18F-GP1, before resting in a quiet environment for 60 min. A low-dose attenuation correction CT scan (120 kV, 50 mAs, 5/3 mm) will be followed by acquisition of PET data in list mode using a two 20-min bed position centred on the thoracic aorta and heart. A contrast-enhanced CT coronary angiogram will then be performed.
223884860|NCT06554301|DRUG|empagliflozin in treatment pulmonary aerterial hypertension|On the basis of background treatment, the experimental group was given 10 mg of empagliflozin tablets orally once a day for 12 weeks.
223884861|NCT06554301|DRUG|placebo in treatment pulmonary aerterial hypertension|On the basis of background treatment, the control group was given 10 mg of placebo tablets orally once a day for 12 weeks.
223884862|NCT06569550|DEVICE|Real Repetitive Transcranial Magnetic Stimulation|"Five sessions of real paired-pulse rTMS at 0.72Hz (inter-pulse interval of 30ms and inter-pair interval of 1381ms), for a total of 1300 pulse-pairs (30 minutes), across 5 sequential days, Monday to Friday.~The stimulation is applied with a MagPro XP Orange stimulator (MagVenture A/S, Farum, Denmark), through a B65-Cool-A/P-CO coil (Magventure A/S) with an active and placebo (sham) side. The active side is an actively cooled figure-of-eight coil with an outer diameter of 65mm.~Intensity is 80% of resting motor threshold. It is kept the same across all 5 sessions.~The target is the left PMd, at MNI coordinates (34, -2, 66), transformed into patient space. Optimal coil placement, with respects to induced e-field at the target coordinates, is simulated with SimNIBS, based on the participants own MR images. The coil positioning is guided and monitored continuously with a neuronavigation system (Localite, Bonn, Germany) and the aid of robotic arm (Axilum Robotics, Schiltigheim, France )."
223884863|NCT06569550|DEVICE|Sham Repetitive Transcranial Magnetic Stimulation|"Five sessions of real paired-pulse rTMS at 0.72Hz (inter-pulse interval of 30ms and inter-pair interval of 1381ms), for a total of 1300 pulse-pairs (30 minutes), across 5 sequential days, Monday to Friday.~The stimulation is applied with a MagPro XP Orange stimulator (MagVenture A/S, Farum, Denmark), through a B65-Cool-A/P-CO coil (Magventure A/S) with an active and placebo (sham) side. The sham side does not deliver a magnetic pulse to the participant.~The target is the left PMd, at MNI coordinates (34, -2, 66), transformed into patient space. Optimal coil placement, with respects to induced e-field at the target coordinates, is simulated with SimNIBS, based on the participants own MR images. The coil positioning is guided and monitored continuously with a neuronavigation system (Localite, Bonn, Germany) and the aid of robotic arm (Axilum Robotics, Schiltigheim, France )."
223884864|NCT06098586|BEHAVIORAL|Self-managed exercise therapy program|Exercise program focusing on functional re-learning and strengthening of the musculoskeletal system with the aim to create a stable wrist that can be used in a pain-free manner in activities of daily living.
223884865|NCT06098586|PROCEDURE|Partial wrist denervation|AIN and PIN neurectomy through a dorsal approach as described by Berger (Berger, 1998).
223884866|NCT05257980|DIETARY_SUPPLEMENT|Dietary supplement (ONS)|At baseline, the investigating dietitian/nurse will record several measures, including clinical history and symptoms over the previous 24 hours. In addition, patients who are already receiving an ONS will continue their prescribed ONS for 1 day in which their gastrointestinal tolerance, ONS compliance and acceptability will be recorded. All patients will then receive standardised dietary advice in addition to one of the four trial ONS products daily for 28 days. The type of ONS will be agreed with the patient and the investigating dietitian/nurse, and the ONS prescription will be determined on an individual basis by the investigating dietitian/nurse responsible for the patient's nutritional management (1-3 ONS per day; aligned with guidelines set out within the Malnutrition Pathway). The type of ONS prescribed will be the same throughout the 28 days and will be taken orally.
223884867|NCT05050279|DRUG|Delgocitinib capsule|oral capsule
223884868|NCT05050279|DRUG|Placebo capsule|oral capsule
223884869|NCT05912569|PROCEDURE|Delay sentinel node biopsy|In the case of a patient undergoing breast-conserving surgery for intraductal carcinoma, the sentinel lymph node is not excised during the primary surgery but only marked for identification. I
223884870|NCT03803904|OTHER|Spin|The intervention will take place three times a week for 12 weeks and will be led by a qualified instructor (an Exercise Physiologist with five years of experience conducting the intervention). The duration of each session will be increased by 1-2 minutes to a maximum time of 45 minutes per session based on the progression of the participants and the recommendation of the instructor. Because participants are initially sedentary and detrained, exercise intensity will begin at low levels (50% of maximal heart rate reserve, HRR) but will be increased by 5% every week (if deemed necessary by the instructor) to a maximum of 75% maximal HRR.
223884871|NCT01044069|BIOLOGICAL|gene-modified T cells targeted|Pts will undergo leukapheresis. The leukapheresis product will be washed \& frozen until the GTF is directed to start T cell production by the PI. CD3+ T cells will be isolated from the leukapheresis, \& transduced with the 19-28z chimeric receptor \& expanded. All relapsed (either MRD+ or morphologic) \& refractory pts get re-induction chemo whenever feasible to optimally reduce the tumor burden prior to the T cell infusion. The re-induction chemo regimen will be selected by the treating dr. based on prior therapy, adverse reactions to chemo \& highest likelihood to achieve an optimal response. Once pts recover from the toxicities of the re-induction chemo the disease status will be re-evaluated by repeating bone marrow aspirate or biopsy. Pts get conditioning chemo (min 2 weeks from end of re-induction chemo) followed 2-7 days later by the 19-28z+ T cells. Pts will be tx in 2 cohorts with diff doses of T cells according to the amount of disease immediately prior to the T cell infusion.
223884872|NCT04044690|DRUG|human immunoglobulin G|human immunoglobulin G administered subcutaneously
223884873|NCT04044690|DRUG|Placebo|contains 2% human albumin, similar excipients as IgPro20 (Hizentra), same volume, same duration, administered subcutaneously
223884874|NCT05006430|BIOLOGICAL|Fecal Microbiota Transplantation|It's an intestinal microbial suspension prepared form stool obtained from carefully and thoroughly screened healthy human donors.
223884875|NCT05006430|OTHER|Placebo|Placebo will be identical to the investigational product but will not contain fecal material.
223884876|NCT05911100|DIAGNOSTIC_TEST|Spirography and assessment of pulmonary diffusion capacity|Using the Master Screen Body device you will be asked to take two series of breaths through a special tube for 2-3 minutes. Usually the procedure does not cause any discomfort
223884877|NCT05911100|DIAGNOSTIC_TEST|Cardiopulmonary stress test|The exercise test is performed on a bicycle ergometer Oxycon Pro. Prior to the test, special sensors for recording the electrocardiogram, a sensor to determine blood saturation, and a cuff to measure blood pressure will be glued on the body. Breathing during the test takes place through a face mask with a built-in gas analyzer sensor. The stress test is conducted up to an individual maximum (according to the age, sex, height and weight of the patient), followed by a recovery period. There is some temporary discomfort associated with performing physical activity. Dyspnea, leg fatigue, and dizziness may occur. Observation continues until full recovery of hemodynamic and gas exchange parameters, in case of appearance of unfavorable symptoms - until their disappearance.
223884878|NCT05911100|DIAGNOSTIC_TEST|Computed tomography of the chest organs|"CT is a method of examination based on X-rays, but unlike conventional X-rays, it gives the most complete picture of the body structure, with less radiation.~Tomography usually does not cause any unpleasant feelings and is performed in a specialized department."
223884879|NCT05911100|DIAGNOSTIC_TEST|Heart echocardiography|It's a specific method of ultrasound examination, which consists in examining the heart in real time and usually does not cause any unpleasant feelings
223884880|NCT05911100|OTHER|SF-36 Quality of Life Questionnaire|https://clinmedjournals.org/articles/jmdt/jmdt-2-023-figure-1.pdf
223884881|NCT05911100|DIAGNOSTIC_TEST|Demographic and antropometric measures|Age, sex, height. weight, body mass index (BMI)
223884882|NCT05911100|OTHER|Indicators characterizing the severity of the underlying disease|"* Severity of underlying disease (mMRC, BODE, SMRT-CO Respiratory Support Need Scale), and comorbidities (cardiovascular disease, diabetes mellitus, chronic obstructive pulmonary disease, chronic kidney disease)~* Medications taken."
223884883|NCT06208657|DRUG|Paxalisib, Irinotecan, Temozolomide|Irinotecan 50mg/m2/day, intravenous, on days 1-5, 28 day cycle, 13 cycles Temozolomide 150mg/m2/day, oral, on days 1-5, 28 day cycle, 13 cycles Paxalisib 21mg/m2 oral, daily, 28 day cycle, 13 cycles
223884884|NCT05731024|DEVICE|close-loop synchronization controller with SPONT mode|One-hour period where the pressure support of spontaneous breath will be automatically titrated based on pressure and flow waveform analysis obtained from the patient.
223884885|NCT05731024|DEVICE|Conventional synchronization settings with SPONT mode|One-hour period where the pressure support of spontaneous breath will be manually set.
223884886|NCT06238323|BEHAVIORAL|LAFIYA|LAFIYA will be a modified version of the Many Men Many Voices (3MV) targeted at addressing reducing stigma and increasing HIV self-testing uptake among young sexual minority men. LAFIYA will be developed into a comprehensive intervention manual for a large-scale trial using the ADAPTT-IT framework.
223884887|NCT04846595|OTHER|self questionnaire|Evaluate the demographic variables and medical characteristics of people living with HIV in the Alpine Arc region
223884888|NCT03526861|DRUG|Tralokinumab|Tralokinumab is a human recombinant monoclonal antibody of the immunoglobulin G4 (IgG4) subclass that specifically binds to human interleukin (IL) 13 and blocks interaction with the IL-13 receptors.
223884889|NCT03526861|DRUG|Placebos|Placebo contains the same excipients in the same concentration only lacking tralokinumab.
223884890|NCT05995613|DEVICE|MABOS|The novel pulse oximeter (MABOS) will be placed to acquire two biometrics: blood oxygen saturation and epidermal melanin concentration.
223884891|NCT05995613|DEVICE|Nonin PureSat|An FDA approved pulse oximeter will be placed to acquire blood oxygen saturation.
223884892|NCT04951921|DRUG|Hyperpolarized 13C Pyruvate|Procedure: Magnetic Resonance Imaging Undergo 1H-MRI of DWI/MRF/CEST for tumor cite following by 13C DNP-MRI for spleen for 3-5 minutes after hyperpolarized 13C pyruvate injection
223884893|NCT04221750|BEHAVIORAL|Lifestyle therapy|Weight management program, in which participants are prescribed a balanced diet that provides and energy deficit of 500 to 750 kcal per day to induced \~10% weight loss plus Supervised combined aerobic and resistance exercise training three times weekly
223884894|NCT04221750|DRUG|Metformin Hydrochloride|Given orally starting at 500 mg (one tablet) taken orally once a day with meals. After a week, the dose of metformin will be increased to 1000 mg (two tablets) daily. After another week, the dose of metformin will be increased to 1500 mg (three tablets) daily.
223884895|NCT04221750|DRUG|Placebo|Given orally starting at 500 mg (one tablet) taken orally once a day with meals. After a week, the dose of placebo will be increased to 1000 mg (two tablets) daily. After another week, the dose of placebo will be increased to 1500 mg (three tablets) daily.
223884896|NCT04221750|BEHAVIORAL|Healthy Lifestyle|Group educational sessions that focus on healthy diet, exercise, and social support once a month
223884897|NCT02813460|DRUG|Formulation A (ALS-008176)|Reference formulation, 60 mg/mL ALS-008176 oral suspension without sweetener/flavor.
223884898|NCT02813460|DRUG|Formulation B (ALS-008176)|60 mg/mL ALS-008176 oral suspension containing 12 mg/mL sucralose.
223884899|NCT02813460|DRUG|Formulation C (ALS-008176)|60 mg/mL ALS-008176 oral suspension containing 4 mg/mL sucralose and strawberry flavor.
223884900|NCT02813460|DRUG|Formulation D (ALS-008176)|60 mg/mL ALS-008176 oral suspension containing 4 mg/mL sucralose and masking flavor and strawberry flavor.
223884901|NCT02813460|DRUG|Formulation E (ALS-008176)|60 mg/mL ALS-008176 oral suspension containing 4 mg/mL sucralose and masking flavor and cream vanille flavor.
223884902|NCT02813460|DRUG|Formulation F (ALS-008176)|60 mg/mL ALS-008176 oral suspension containing 4 mg/mL sucralose and fantasy fruit flavor.
223884903|NCT02813460|DRUG|Formulation G1 (ALS-008176)|60 mg/mL ALS-008176 oral suspension with concentration 1 of sucralose (maximum 12 mg/mL) and best flavor 1 from session 1.
223884904|NCT02813460|DRUG|Formulation G2 (ALS-008176)|60 mg/mL ALS-008176 oral suspension with concentration 2 of sucralose (maximum 12 mg/mL) and best flavor 1 from session 1.
223884905|NCT02813460|DRUG|Formulation G3 (ALS-008176)|60 mg/mL ALS-008176 oral suspension with concentration 3 of sucralose (maximum 12 mg/mL) and best flavor 1 from session 1.
223884906|NCT02813460|DRUG|Formulation H1 (ALS-008176)|60 mg/mL ALS-008176 oral suspension with concentration 1 of sucralose (maximum 12 mg/mL) and best flavor 2 from session 1.
223884907|NCT02813460|DRUG|Formulation H2 (ALS-008176)|60 mg/mL ALS-008176 oral suspension with concentration 2 of sucralose (maximum 12 mg/mL) and best flavor 2 from session 1.
223884908|NCT02813460|DRUG|Formulation H3 (ALS-008176)|60 mg/mL ALS-008176 oral suspension with concentration 3 of sucralose (maximum 12 mg/mL) and best flavor 2 from session 1.
223884909|NCT06840132|PROCEDURE|Exercise|7-station exercise protocol was designed, consisting of motor activities progressing from easy to difficult, with the goal of transforming these activities into permanent skills through meaningful tasks. Each station aimed to gradually improve the patient's motor abilities. Patients were allowed to rest between tasks, and the difficulty of the tasks progressively increased based on each patient's capacity. This 7-station protocol was designed for the first time by our own research team
223884910|NCT06840132|PROCEDURE|Exercise|In addition to the task-oriented training program, the group using plastic static ankle-foot orthoses performed the same 7-station exercise protocol as the task oriented training group. However, participants in this group were required to wear custom-made plastic static ankle-foot orthoses while completing the exercises.
223884911|NCT05500508|DRUG|AMXT1501|AMXT 1501 dicaprate is D-lys(palmitoyl)-spermine dicaprate salt in 200 mg (free base content) enterically-coated capsules
223884912|NCT05500508|DRUG|DFMO|DFMO is DL-2-(difluoromethyl) ornithine monohydrochloride monohydrate provided as a 200 mg/mL aqueous solution in 20 mL vials.
223884913|NCT03405740|DEVICE|Remote Patient Management|"1. Transmissions will occur at six monthly intervals, with no in-clinic visits. If there is an actionable event on the remote transmission, patients will be seen at their closest community clinic.~2. All patients will be required to follow up with their family physician at least annually, and their cardiologist at least every 2 years.~3. Patients will be contacted by phone at 6 months and 12 months to document their current health status (change in cardiovascular medications, any cardiovascular hospitalizations, in-clinic device checks, or any new cardiovascular testing completed since the last visit)~4. VIRTUES access"
223884914|NCT03405740|DEVICE|Standard of Care|No intervention
223884915|NCT05310253|DRUG|Fludrocortisone|pill of fludrocortisone
223884916|NCT05310253|DRUG|Placebo|placebo pill
223884917|NCT05310253|BEHAVIORAL|Trier Social Stress Test (TSST)|psychosocial stress induction
223884918|NCT05310253|BEHAVIORAL|Placebo Trier Social Stress Test (P-TSST)|control condition
223884919|NCT05514496|DRUG|NX-019|NX-019 will be administered orally.
223884920|NCT04058626|DIAGNOSTIC_TEST|Transcutaneous pressure of oxygen (TcPO2)|Measurements will be taken from the dorsum of the foot using an automated machine equipped with Clark electrodes.
223884921|NCT04058626|DIAGNOSTIC_TEST|Toe Brachial Pressure Index (TBPI)|TBPI will be measured using the photoplethysmography (PPG) method, employing an infrared sensor placed on the hallux and index finger.
223884922|NCT04058626|DIAGNOSTIC_TEST|Podiatry Ankle Duplex scan (PAD-scan)|Podiatry ankle duplex scan (PAD-scan) involves using an ultrasound machine to visualise the anterior and posterior tibial arteries at the ankle.
223884923|NCT04058626|DIAGNOSTIC_TEST|Duplex Assist|Continuous Doppler device which gives visual display of arterial spectral waveform at the ankle.
223884924|NCT04058626|DIAGNOSTIC_TEST|Ankle Brachial Pressure Index (ABPI)|A sphygmomanometer-cuff placed at the ankle and a handheld continuous wave Doppler device will be used to measure the systolic pressure of the DPA and PTA.
223884925|NCT04941157|PROCEDURE|Cerebrospinal Fluid Drain Placement|Prophylactic CSF Spinal Drain to be placed prior to surgery in patients randomized to the experimental arm of the study
223884926|NCT03385629|BEHAVIORAL|CSM theory-based didactic education and skills training|Common-Sense Model of Self-Regulation (CSM) theory-based education and skills training for the provider to teach him/her to communicate core oral health facts to parents, provide a prescription to take their child to the dentist together with a list of Medicaid-accepting dentists in the area, and document the oral health encounter in EMR.
223884927|NCT03385629|OTHER|AAP-based didactic education|American Academy of Pediatrics (AAP) based oral health education and follow the usual care for oral health assessment recommended by AAP guidelines.
223884928|NCT03385629|OTHER|Practice EMR changes|Enhancements to the EMR system to include oral health documentation (four questions) which will be implemented prior to enrolling any parent/caregiver and child participants into the study.
223884929|NCT04970511|BEHAVIORAL|BBAT (Basic Body Awareness Therapy)|The group I: BBAT Face-to-Face Training (60 min) will be provided.
223884930|NCT04970511|BEHAVIORAL|Online BBAT training|The group II: Online BBAT training (60 min) will be provided.
223884931|NCT05849051|BEHAVIORAL|Newly developed warnings with images at 30% size|On study days 1-6, 8-13 and 15-20, participants in this condition will view an image of a little cigar and cigarillo package with a warning developed by the study team that includes an image. The warnings will take up 30% of the package. Participants will view a total of 6 different warnings over the course of 6 days each week, this will be repeated 3 times during the study, resulting in a total of 18 exposures. Participants will be required to view the warning for at least 5 seconds.
223884932|NCT05849051|BEHAVIORAL|FDA proposed text-only warnings at 30% size|On study days 1-6, 8-13 and 15-20, participants in this condition will view an image of a little cigar and cigarillo package with a warning proposed by the FDA which is text only. The warnings will take up 30% of the package. Participants will view a total of 6 different warnings over the course of 6 days each week, this will be repeated 3 times during the study, resulting in a total of 18 exposures. Participants will be required to view the warning for at least 5 seconds.
223884933|NCT06008600|DEVICE|Kinocardiography|Smartphone (application with seismocardiography)
223884934|NCT04453189|DRUG|JNJ-64417184|Participants will receive single dose of JNJ-64417184 in fed condition on Day 1 in assigned treatment sequence.
223884935|NCT04453189|DRUG|Lansoprazole|Participants will receive lansoprazole once daily in fasted condition on Day 1 to 4 under fasted condition and 2 hours before single dose of JNJ-64417184 in fed condition on Day 5 in assigned treatment sequence.
223884936|NCT04453189|DRUG|Famotidine|Participant will receive famotidine in fasted condition on Day 1 in assigned treatment sequence.
223884937|NCT06012708|DRUG|KN510 60mg/day + KN713 60mg/day|Once daily with 28 days (4 weeks) as one cycle.
223884938|NCT06012708|DRUG|KN510 120mg/day + KN713 60mg/day|Once daily with 28 days (4 weeks) as one cycle.
223884939|NCT06012708|DRUG|KN510 120mg/day + KN713 90mg/day|Once daily with 28 days (4 weeks) as one cycle.
223884940|NCT06012708|DRUG|KN510 120mg/day + KN713 120mg/day|Once daily with 28 days (4 weeks) as one cycle.
223884941|NCT06849674|BIOLOGICAL|Platelet rich plasma (PRP)|Hair grafts will be immersed in autologous Platelwt-richh plasma(PRP) before transplantation.
223884942|NCT06849674|OTHER|Saline|Hair grafts will be immersed in normal saline solution before transplantation.
223884943|NCT06495125|DRUG|Avutometinib|Given PO
223884944|NCT06495125|PROCEDURE|Biopsy|Undergo biopsy
223884945|NCT06495125|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223884946|NCT06495125|PROCEDURE|Computed Tomography|Undergo CT
223884947|NCT06495125|DRUG|Defactinib|Given PO
223884948|NCT06495125|BIOLOGICAL|Nivolumab|Given IV
223884949|NCT06495125|PROCEDURE|Positron Emission Tomography|Undergo PET
223884950|NCT05948735|OTHER|Physical Therapy Exercise and Dance Movement Therapy (PTE+DMT) for Preventing Falls|The intervention include 12 face-to-face group sessions of 45 minutes each, twice a week for 6 weeks. The intervention integrates OEP-based techniques and DMT techniques to address the emotional experience that arises during physical exercise. This include encouragement for spontaneous and creative movement on the part of the participants, and an invitation to verbally share the feelings, sensations, and thoughts that arose in the participants following the movement. At the end of the sessions, participants will be instructed to perform nine exercises independently at home, at a minimum of twice per week for six months.
223884951|NCT05948735|OTHER|Physical Therapy Exercise (PTE) only for Preventing Falls|The intervention include 12 face-to-face group sessions of 45 minutes each, twice a week for 6 weeks. The intervention include OEP-based techniques only. At the end of the sessions, participants will be instructed to perform nine exercises independently at home, at a minimum of twice per week for six months.
223884952|NCT02199600|DEVICE|GMK Sphere Knee Replacement|
223884953|NCT05633407|DRUG|Efgartigimod|Efgartigimod IV 10 mg/kg infusion qw for 24 weeks. Participants will be randomized to receive efgartigimod IV 10 mg/kg or matching placebo in a 2:1 ratio, respectively
223884954|NCT05633407|DRUG|Placebo|"Receive a matching placebo during weekly infusions during a treatment period of 24 weeks.~Participants will be randomized to receive efgartigimod IV 10 mg/kg or matching placebo in a 2:1 ratio, respectively"
223884955|NCT06041139|DIAGNOSTIC_TEST|Visual Acuity|Measurement of distance, intermediate and near visual acuity.
223884956|NCT06041139|DIAGNOSTIC_TEST|Defocus Curve|Measurement of visual acuity performed from +1.00 to -4.00 in 0.50 diopter steps and with +0.25 and -0.25 added.
223884957|NCT06041139|DIAGNOSTIC_TEST|Halo and Glare testing|Measurement to quantify degree of visual loss caused by either halo and/or glare.
223884958|NCT06041139|OTHER|Patient Questionnaires|Patients will complete a series of questionnaires to record self-reported visual disturbances, visual acuity satisfaction, level of spectacle independence and any issues with glare, halos, and/or starbursts.
223884959|NCT06501989|DRUG|Biweekly 5-FLUOROURACIL (5-FU)|5-FU 2400 mg/m². Infusion for 46 hours. Leucovorin 200 mg/m². Either a vascular endothelial growth factor (VEGF) inhibitor or epidermal growth factor (EGFR) inhibitor or may be added to the regimen at the discretion of the treating physician. Repeat every 2 weeks.
223884960|NCT06501989|DRUG|Biweekly Modified FOLFOX6|Oxaliplatin 85 mg/m². 5-FU 400 mg/m² on day 1 as bolus (OPTIONAL). 5-FU 2400 mg/m² Infusion for 46 hours. Leucovorin 200 mg/m2. Repeat every 2 weeks
223884961|NCT06501989|DRUG|Biweekly FOLFIRI|"Irinotecan 180 mg/m2. 5-FU 400 mg/m2 on day 1 as bolus (OPTIONAL). 5-FU 2400 mg/m2 Infusion for 46 hours. Leucovorin 200 mg/m2.~Repeat every 2 weeks."
223884962|NCT06501989|DRUG|mFOLFOXIRI|Irinotecan 165 mg/m2. Oxaliplatin 85 mg/m2. 5-FU 2400 mg/m2 Infusion for 46 hours. Repeat every 2 weeks.
223884963|NCT05052021|OTHER|Public or Private Sector Patients|No intervention will be done. Two groups of patients will be recruited: patients receiving surgery in the Private Healthcare Sector, and patients receiving surgery in the Public Healthcare Sector
223884964|NCT06144905|OTHER|standard care treatment program|The standard care treatment consists of a program of psychotherapy and nutritional rehabilitation to achieve normalization of food-intake and weight gain.
223884965|NCT02669771|DRUG|enzalutamide|oral
223884966|NCT00530153|BEHAVIORAL|dietary counseling|Various activities and materials for teachers, students, parents and school catering personnel aiming at increasing their awareness and knowledge of good nutrition.
223884967|NCT00530153|DIETARY_SUPPLEMENT|xylitol|Delivery of xylitol lozenges (about 1 g xylitol/student/school day) and guidance on tooth brushing.
223884968|NCT06217692|OTHER|nutrition education|nutrition education
223884969|NCT04655677|BIOLOGICAL|Prizloncabtagene Autoleucel|Autologous 2nd generation CD19/CD20-directed CAR-T cells, single infusion intravenously
223884970|NCT06207058|DRUG|Baloxavir Marboxil|Subjects testing positive for influenza will receive a dose of Baloxavir Marboxil orally, according to the dosing indicated in the package insert.
223884971|NCT02374112|DIETARY_SUPPLEMENT|Creatine|Creatine supplementation
223884972|NCT02374112|OTHER|Placebo|Placebo supplementation
223884973|NCT04892693|DRUG|Talazoparib Oral Capsule|\- Patients will receive Talazoparib 1 mg orally once daily continuously, with or without food. Laboratory values will be monitored every 4 weeks until progression or unacceptable toxicity. Dose modifications should be made based on the observed toxicity
223884974|NCT04303377|BIOLOGICAL|Evolocumab|Evolocumab 140 mg every 2 weeks plus Standard of Care, including optimal lipid lowering treatment (high dose of statin ± ezetimibe)
223884975|NCT04864158|PROCEDURE|TSA-group|Reverse total shoulder arthroplasty followed by standard rehabilitation.
223884976|NCT04864158|OTHER|Exercise-group|The exercise-group will attend a 12-week exercise program with one weekly physiotherapist-supervised session supplemented with two weekly sessions of home-based exercises. Utilisation of a predefined training protocol describing procedures and content of each session secure uniformity and standardisation of the intervention. The exercise program consists of two warm-up exercises and five exercises that target shoulder range of motion and muscle strength. Furthermore, a link to a video, informing about glenohumeral osteoarthritis, the role of exercise and exercise related pain, will be sent to all patients in the exercise-group. The physiotherapists delivering the exercise intervention are not otherwise related to the trial.
223884977|NCT06977074|DRUG|PD-1 inhibitor|Two to four cycles of tislelizumab at a dose of 200 mg every three weeks, along with a platinum-based chemotherapy doublet based on the result of ctDNA dynamics
223884978|NCT06977074|DRUG|Platinum Doublet|Platinum-based chemotherapy (carboplatin AUC=5 + pemetrexed 500 mg/m² \[adenocarcinoma\] or nab-paclitaxel 260 mg/m² \[squamous/other subtypes\])
223884979|NCT05184036|DIAGNOSTIC_TEST|Low Vision|"* The application of a questionnaire evaluating the functionality and quality of life and records several of the daily life of Greek LV patients.~* The evaluation of the basic parameters of visual function included in the LIFE4LV platform in order to evaluate the effectiveness of this platform in correlation with the routine ophthalmologic exams.~* The evaluation of existing digital supportive tools for LV and record of the patient's feedback"
223884980|NCT06189534|BEHAVIORAL|Cognitive behavioral therapy|Cognitive behavioral therapy-based interventions were used to manage social media addiction and; to address associated problems with it. Psychoeducation, problem conceptualization, cognitive distortions and belief identification,Time management,Stress and distress management, Emotional and beliefs modification,Priority and Goal setting, Problem solving skills, Social skill training, Emotional and behavioral activation and Relapse prevention are techniques that will be used in the intervention.
223884981|NCT02814838|DRUG|Ladarixin|Ladarixin oral capsule
223884982|NCT02814838|DRUG|Placebo|Placebo oral capsule
223884983|NCT02229721|DRUG|Syntocinon Nasalspray|"Over 8 weeks, intranasal oxytocin (32 IE) or placebo will be self-administered by women prior to sexual intercourse. Following a washout period of 2 weeks, a cross-over will take place and patients switched to the alternate group for another 8 weeks.~The recommended dose is four puffs per nostril, containing 32 IU of synthetic oxytocin, administered up to 50 minutes prior to sexual activity. The maximal dose should not exceed four puffs per nostril per day; the minimum dose was twice weekly."
223884984|NCT02229721|DRUG|Placebo Nasalspray|"Over 8 weeks, intranasal oxytocin (32 IE) or placebo will be self-administered by women prior to sexual intercourse. Following a washout period of 2 weeks, a cross-over will take place and patients switched to the alternate group for another 8 weeks.~The recommended dose is four puffs per nostril, administered up to 50 minutes prior to sexual activity. The maximal dose should not exceed four puffs per nostril per day; the minimum dose was twice weekly."
223884985|NCT03811366|DRUG|Corticosteroid monotherapy|Patients will receive corticosteroid monotherapy as a pulsetherapy (1000mg/ day for 3 days) followed by oral corticosteroid.
223884986|NCT06650852|BIOLOGICAL|BRII-179|BRII-179 will be given via intramuscular injection
223884987|NCT06650852|DRUG|BRII-835 (VIR-2218)|BRII-835 will be given via subcutaneous injection
223884988|NCT06650852|BIOLOGICAL|PEG-IFNα|PEG-IFNα will be given via subcutaneous injection
223884989|NCT06650852|DRUG|Placebo of BRII-179|Placebo of BRII-179 will be given via intramuscular injection
223884990|NCT06650852|DRUG|Placebo of BRII-835|Placebo of BRII-835 will be given via subcutaneous injection
223884991|NCT06651086|BEHAVIORAL|Unstuck and On Target|Unstuck and on Target (Unstuck; Cannon et al., 2021) is a cognitive-behavioral, intervention designed to be feasibly delivered by teachers and school staff in the elementary school setting. It was adapted for and pilot-tested in outpatient mental health. Unstuck targets key executive functions, including flexibility, goal-setting, planning, and coping. Sessions include prescribed content and activities to facilitate guided practice and home extension activities to aid generalization beyond the therapeutic session. It includes both child- and caregiver-directed strategies. It has been shown effective for youth with autism and attention-deficit/hyperactivity disorder.
223884992|NCT06651086|BEHAVIORAL|Unified Protocol for Children|Unified Protocol for Children is a transdiagnostic, cognitive-behaviorally based treatment targeting shared core dysfunctions underlying emotional disorders, including distress intolerance and emotional dysregulation. It was developed by integrating cognitive-behavioral and mindfulness strategies and includes prescribed activities, in-vivo experiments, and home-extension components to promote generalization. It includes both child- and caregiver-directed strategies. In addition to its effectiveness for youth with emotional disorders, recent work supports its efficacy for youth with additional non-emotional disorders (e.g., externalizing challenges, irritability).
223884993|NCT05747716|DRUG|SBRT, Fruquintinib, Cadonilimab|Radiation: Stereotactic body radiationtherapy (SBRT) for metastatic sites (less than 5) Fruquintinib: 5mg, po, everyday; Cadonilimab: 10mg/kg, iv, q3w
223884994|NCT01714869|OTHER|Swedish Massage|Swedish Massage, once per week for 8 weeks, 60 minutes per session.
223884995|NCT00276796|DRUG|cisplatin|
223884996|NCT00276796|DRUG|paclitaxel|
223884997|NCT00276796|DRUG|topotecan hydrochloride|
223884998|NCT02910713|DEVICE|Intranasal Tear Neurostimulator|The device delivers small electrical currents, activating nerves that stimulate the body's natural tear production system.
223884999|NCT05284071|DEVICE|Device: Actiste 1.0 and the Companion app with TBL Backend|Actiste automatically logs and shares real-life data on blood glucose values and actual injected insulin doses. With Actiste's built-in sensor, the exact injected dose is displayed and saved in the device memory together with a time stamp, which makes it easy for the user to know how much and when the insulin was injected, and spot missed doses. This simplifies the daily diabetes care for the user and thus may improve the quality of life for people with diabetes and may improve the patients' adherence to treatment plans. Actiste automatically logs and shares real-life data on blood glucose values and actual injected insulin doses. With Actiste's built-in sensor, the exact injected dose is displayed and saved in the device memory together with a time stamp, which makes it easy for the user to know how much and when the insulin was injected, and spot missed doses. This simplifies the daily diabetes care for the user and thus may improve the quality of life for people with diabetes.
223885000|NCT05486598|DRUG|AL8326 tablets|"Sequence A group: on the 1st day, take a single dose of AL8326 tablets on an empty stomach. On the 15th day, take a single dose of AL8326 tablets after meals.~Sequence B group: on the 1st day after meal, take a single dose of AL8326 tablets; on the 15th day, take a single dose of AL8326 tablets on an empty stomach."
223885001|NCT02421159|BEHAVIORAL|Seek and Test Phase|The primary endpoint for this phase is the proportion of newly identified HIV infections of the RDS-ASTN intervention. Components for eligible and willing participants are a computerized baseline interview, counseling session, blood draw for HIV testing, HIV pre-test counseling, use of blood samples for clinical lab tests if found to be HIV infected, semi-structured interviews (if selected), the opportunity to recruit peers for the study, and the post-test counseling session.
223885002|NCT02421159|BEHAVIORAL|Treat and Retain Phase|The primary endpoints for this phase are: proportion linked to care within three months and time to the HIV care appointment. Participants with HIV infection who are interested in participating will be enrolled in this phase and navigated to HIV primary care over three months. Components are the locator form, patient navigation and support contacts, medical report form, follow-up contacts to update locator information, semi-structured interviews, follow-up interview, and blood draw for clinical lab testing.
223885003|NCT05413629|OTHER|Web-based patient education for the intrauterine insemination (IUI) treatment process|Web-based training is 60 minutes in total, including 4 modules. The web-based training content includes general information about fertility, infertility diagnosis-treatment methods, drugs used in IUI treatment and its application, and issues to be considered after IUI.
223885004|NCT06097702|DRUG|BX-001N Part 1|Dosage form- IV bolus Dosage- In the five cohorts, each participant receives a single IV bolus administration in one of the five doses based on body weight and followed up for 7 days.
223885005|NCT06097702|DRUG|BX-001N Part 2|Dosage form- IV bolus Dosage- In the three cohorts, each participant receives a single IV bolus administration for 4 sequential days in one of the three doses based on body weight and followed up for 14 days.
223885006|NCT06097702|DRUG|Placebo|Participants will receive matching placebo across Part 1 and 2 of the study.
223885007|NCT03206151|DRUG|CMAB009|for injection only
223885008|NCT03206151|DRUG|Irinotecan|for injection only
223885009|NCT03206151|DRUG|Folinic acid|for injection only
223885010|NCT03206151|DRUG|5-fluorouracil|for injection only
223885011|NCT06988189|DIAGNOSTIC_TEST|12-lead ECG|12-lead ECG from a conventional ECG machine
223885012|NCT06988189|DIAGNOSTIC_TEST|Continuous long term ambulatory ECG monitoring|Continuous long term ambulatory ECG monitoring using wearable ECG or cardiac monitor
223885013|NCT06988189|DIAGNOSTIC_TEST|Ultra-high-frequency ECG|Ultra-high-frequency ECG acquired using specific acquisition equipment
223885014|NCT06986382|DEVICE|CliniMACS® TCR α/β Reagent Kit and CliniMACS® CD19 System|CliniMACS® TCRαβ-Biotin and CD19 Systems will be used to create the mobilized peripheral blood stem cells (PBSC) from allogeneic donors depleted of TCRαβ+ T cells and CD19+ B cells to be infused into the patient for the HSCT. The target dose for the number of CD34+ HSC infused is \> 10 x 10\^6 cells/Kg recipient weight. The minimum dose is 2 x 10\^6 cells/Kg. There is no upper limit to the dose of CD34+ HSC infused as long as no more than 1 x 10\^5 TCRαβ+ T-cells/Kg are infused. The target dose of TCRαβ+ T cells/Kg is \< 0.50 x 10\^5.
223885015|NCT06986382|DRUG|Prednisone/Methylprenisolone|Administered as part of the HSCT conditioning regimen
223885016|NCT06986382|DRUG|Palifermin|Administered as part of the HSCT conditioning regimen
223885017|NCT06986382|DRUG|ATG|Administered as part of the HSCT conditioning regimen
223885018|NCT06986382|DRUG|Clofarabine|Administered as part of the HSCT conditioning regimen
223885019|NCT06986382|DRUG|Melphalan|Administered as part of the HSCT conditioning regimen
223885020|NCT06986382|RADIATION|Total Body Irradiation|200 cGy, administered as part of the HSCT conditioning regimen
223885021|NCT06986382|DRUG|Rituximab|Administered as part of the HSCT conditioning regimen
223885022|NCT06987292|DRUG|IL-17i|IL-17 inhibitors
223885023|NCT06987253|DEVICE|OROXID® forte oral solution|Patients will use OROXID® forte oral solution two to three times daily for 14 days as an adjunct to standard care.
223885024|NCT06987253|DEVICE|OROXID® sensitive oral solution|Patients will use OROXID® sensitive oral solution two to three times daily for 14 days as an adjunct to standard care.
223885025|NCT06987253|OTHER|Standard of Care (SOC)|Patients will receive standard of care meaning proper tooth brushing without the use of any mouthwash or other products aimed at reducing bacteria in the oral cavity.
223885026|NCT06987877|OTHER|No flushing of the nephrostomy|Subjects allocated to the study intervention group will not flush their nephrostomy tube during the duration of the research study
223885027|NCT06987877|OTHER|Flushing of nephrostomy|Subjects assigned to this cohort will flush their nephrostomy catheter once daily with 10 mL of normal saline
223885028|NCT06988007|DEVICE|Whole body MRI|Whole body MRI (ZTE sequence)
223885029|NCT04937842|BIOLOGICAL|microtransplantation, HLA-mismatched donor peripheral stem cell infusion|infusion of granulocyte colony stimulating factor (G-CSF) mobilized HLA-mismatched peripheral blood stem cells (GPBSC)
223885030|NCT06987006|OTHER|Jigsaw education|The Jigsaw Technique (JT) is used as a teaching technique where each student creates pieces of an academic and instructional puzzle, specializes in puzzle groups, and teaches the subject they specialize in to other group members.
223885031|NCT06987006|OTHER|Classical Education Technique|In the classical education method, students listen to the lesson explained by the educator in a classroom environment.
223885032|NCT06986629|DEVICE|pulsed electromagnetic therapy|We will use the ASTAR Physio MG 827, a generator and 75 cm solenoid couch, in a pulsed electromagnetic field group. Participants will be placed comfortably in the solenoid, and the device will be turned on and programmed for 20 guesses for 10 minutes, 7 Hz, three times per week for 8 weeks.
223885033|NCT06986629|DEVICE|Photobiostimulation|The therapy will be performed using an ASTAR PhysioGo -As low level laser therapy device with a wavelength of 830 nm, 30 mW power output, and 1 J energy dose. Patients will be supine and wear laser safety goggles. The laser will be applied to six locations over the maxillary or frontal sinuses, administered in a continuous manner for 33 seconds per spot, totaling 198 seconds and 6 J per session
223885034|NCT06986629|OTHER|Self-sinus massage technique|Participants are instructed to perform self-massage to their frontal and maxillary sinuses at home twice daily, in the morning and evening. For the frontal sinus, place the fingers above the eyebrows on either side of the forehead, and gently circular outward massage for three sets of 30 seconds, repeated twice a day.
223885035|NCT06988280|DIAGNOSTIC_TEST|Ultrasound-guided transvaginal aspiration of cystic pelvic lesions.|Ultrasound-guided transvaginal aspiration is a minimally invasive procedure used to drain cystic pelvic lesions, such as adnexal cysts or pelvic abscesses. A thin needle is inserted through the vaginal wall under ultrasound guidance to aspirate fluid from the cyst, reducing its size.
223885036|NCT03671811|DRUG|Megestrol Acetate|Given PO
223885037|NCT03671811|BIOLOGICAL|Pterostilbene|Given PO
223885038|NCT06988072|OTHER|blood sampling|At BKPyV reactivation, at 1 month, 3 months and 12 months
223885039|NCT06988072|OTHER|blood sampling|once
223885040|NCT06988072|OTHER|blood sampling|once
223885041|NCT06986356|DIETARY_SUPPLEMENT|Test product: Yoghurt|High protein spoonable yoghurt
223885042|NCT06986356|DIETARY_SUPPLEMENT|Placebo|Placebo Jelly
223885043|NCT06332209|BEHAVIORAL|Trauma Focused Cognitive Behavioral Therapy|Trauma-Focused Cognitive-Behavioral Therapy (TF-CBT; Cohen et al., 2017) is an evidence-based, manualized treatment protocol designed to treat posttraumatic stress and co-occurring symptoms such as depression and anxiety in trauma-exposed children and youth and their supportive and non-offending caregivers. TF-CBT is divided into nine cognitive and behavioral components, all of which incorporate gradual exposure to trauma memories and reminders
223885044|NCT06673095|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223885045|NCT06673095|PROCEDURE|Excision|Undergo narrow margin excision
223885046|NCT06673095|PROCEDURE|Excision|Undergo wide margin excision
223885047|NCT06673095|OTHER|Survey Administration|Ancillary studies
223885048|NCT06677177|DIETARY_SUPPLEMENT|Nano-water, Tamsulosin Dutasteride|Nano-water, given in a dose of 20 ml/kg daily for a period of 3 months Tamsulosin capsule in a dose of 0.4mg daily for a period of 3 months Dutasteride tablet in a dose of 0.5mg daily for a period of 3 months
223885049|NCT06677177|DRUG|Regular water, tamsulosin, Dutasteride|Regular water, given in a dose of 20 ml/kg daily for a period of 3 months Tamsulosin capsule in a dose of 0.4mg daily for a period of 3 months Dutasteride tablet in a dose of 0.5mg daily for a period of 3 months
223885050|NCT03242616|DRUG|Pemetrexed + Vinorelbine|"Vinorelbine (25 mg/m2, day 1 \& 8)~* Pemetrexed (500 mg/m2, day 1)"
223885051|NCT03242616|DRUG|Vinorelbine|Vinorelbine (25 mg/m2, day 1 \& 8)
223885052|NCT06986941|BEHAVIORAL|Ballet-Based Dance Therapy|An 8-week ballet-based dance therapy program designed to improve balance, flexibility, peripheral muscle strength, cognitive functions, and overall functional capacity in Parkinson's disease patients. The therapy will be conducted twice a week, with each session lasting approximately 60 minutes. The exercises will be adapted to the participants' physical abilities and will focus on enhancing motor coordination, strength, and stability through ballet-inspired movements.
223885053|NCT06986941|OTHER|Standard Care with Exercise Counseling|Participants in the control group will receive standard care for Parkinson's disease, including pharmacological management and routine clinical follow-up. Additionally, they will receive a one-time exercise counseling session and an informational brochure outlining general home-based exercises appropriate for individuals with Parkinson's disease. No supervised or structured exercise sessions will be conducted.
223885054|NCT06676774|DRUG|Oxytocin nasal spray|Participants will be instructed on correctly applying the intranasal study medication and will self-administer a single dose of 24 IU oxytocin under the supervision of unblinded study personnel.
223885055|NCT06676774|OTHER|Placebo|Participants will be instructed on correctly applying the intranasal study medication and will self-administer a single dose of placebo (0.9% normal saline) under the supervision of unblinded study personnel.
223885056|NCT06310837|DRUG|Adalimumab Biosimilars Injection|Adalimumab biosimilars: 80 mg was subcutaneously injected for the first time in the first week, and then 40 mg was subcutaneously injected every two weeks from the first week to the 48 th week.
223885057|NCT06310837|DRUG|Corticosteroid|Patients received no less than 1 mg / kg.d glucocorticoid at week 0, then implemented according to the standard reduction scheme.
223885058|NCT06310837|DRUG|Immunosuppressive Agents|Mycophenolate mofetil 1g bid for more than 3 months, maintenance dose not less than 0.5g bid
223885059|NCT03116412|PROCEDURE|CT or PET scans|Scans and blood tests are scheduled at baseline, months 6, 12, 24 and 36.
223885060|NCT06833801|DEVICE|Real-Time Blood Data Monitoring System (Device/Software Integration)|"Description: An alert function will be integrated into the hospital's electronic system, allowing healthcare providers to view real-time blood test results of radiation therapy patients. The system will notify both medical staff and patients of abnormal results, prompting timely intervention.~Mode of Delivery: Hospital Information System (HIS) Integration Purpose: Improve treatment safety by reducing delays in managing abnormal blood counts."
223885061|NCT06833801|BEHAVIORAL|Enhanced Patient Education Materials (Behavioral/Educational Intervention)|"Description: Optimized educational pamphlets and multimedia resources will be provided to patients, including clear self-care instructions and guidance on reporting blood test needs during radiation therapy.~Mode of Delivery: Printed materials, multimedia resources, verbal education by medical staff Purpose: Improve patient understanding and engagement in their treatment process."
223885062|NCT06833801|BEHAVIORAL|Internal Warning Signs and Alerts (Behavioral Intervention)|"Description: Physical reminder signs will be placed in high-traffic patient areas (e.g., check-in counters, treatment rooms) to prompt patients to report discomfort or abnormal symptoms, especially related to blood test needs.~Mode of Delivery: Visual reminders placed within the radiation oncology department Purpose: Increase patient awareness and adherence to treatment safety protocols."
223885063|NCT06817863|OTHER|Digital|This intervention is a self-help digital treatment, delivered via a smartphone application, for adults with co-morbid binge eating and obesity. The app ChangeBite will integrate principles of evidence based treatments for obesity (behavioral weight loss treatment) and binge eating (cognitive behavioral therapy, acceptance and commitment therapy) into a highly personalized, self-guided, program that leverages an artificial conversational agent and Just-In-Time-Adaptive-Interventions (JITAIs).
223885064|NCT06790056|PROCEDURE|duodenal ndoscopic bind ligation|"We will collect your basic demographics details like age, Sex, date of admission, Endoscopy (is a test to look inside your body) details of Site, size, number of lesion.~By EUS (Endoscopic ultrasound (EUS) combines two techniques - endoscopy and ultrasound - to help doctors see, evaluate and diagnose conditions in and near the gastrointestinal (GI) tract) details of layer of Duodenum involved, site/size/number of lesions.~We will collect your details of Duodenal endoscopic band ligation procedure to check feasibility, technical success.~You are requested to come for follow up for 3 months for endoscopy prodecure."
223885065|NCT06784388|DEVICE|Deep Brain Stimulation(DBS)|During the DBS treatment phase, the DBS device will apply electrical stimulation to the patient's target brain regions using a specific strategy, and if the efficacy of this phase is not satisfactory, electrical stimulation will continue to be applied during the efficacy observation phase after DBS shutdown.
223885066|NCT06784388|DRUG|Esketamine|SEEG intraoperative experiment: patients will be implanted with microelectrodes and connected to an electrophysiological recorder under local anesthesia. Intraoperative neurophysiological baseline will be recorded for 5 minutes, and esketamine will be injected intravenously at a dose of 0.5 mg/kg, and neurophysiological recordings will be continued for 15 minutes to observe the neuronal electrophysiological changes in various brain regions and target points.
223885067|NCT06721741|OTHER|Nusmile bioflex crowns|The Bioflex crown is a new synthetic crown that has been introduced in pediatric practice. This crown is believed to offer better adaptation, durability, and ease of handling, along with improved aesthetic properties when compared to conventional crowns
223885068|NCT06721741|OTHER|Stainless steel crowns|Preformed metal crowns are a popular and affordable option as a treatment for dental caries. They offer full crown coverage and help to prevent recurrent caries. However, their aesthetic limitation is a notable drawback
223885069|NCT02520063|DRUG|Letrozole|A dose of 2.5 mg of letrozole will be given orally once each day until one day before surgery. This drug is commercially available and is not provided by the study.
223885070|NCT02520063|DRUG|Everolimus|The dose of everolimus will be escalated from 5 mg to 10 mg daily depending upon the cohort in Phase I. It is administered as an oral pill to be taken once daily up until four weeks prior to surgery.
223885071|NCT02520063|DRUG|TRC105|The dose for TRC105 is either 15 or 10 mg/kg to be given intravenously every two weeks and continued until four weeks prior to surgery.
223885072|NCT05005221|BEHAVIORAL|Automated text messages|Automated text messages will be used to facilitate blood sample collection at home for therapeutic drug monitoring of tacrolimus and mycophenolate. Participants will collect dried blood samples on 4 occasions. Two days in the clinical with simultaneous venipuncture (one sample) and two days at home with 4 samples collected at specified time points over 8 hours.
223885073|NCT05612477|PROCEDURE|Autotransfusion|blood is collected from the surgical field, washed, processed and transfused back into the patient
223885074|NCT06782659|DRUG|ASP-001|Oral liquid suspension of sildenafil
223885075|NCT06782659|DRUG|Viagra|Sildenafil film-coated tablet
223885076|NCT06782659|DEVICE|ASP-001|Bottle/pump containing ASP-001 suspension
223885077|NCT06120621|PROCEDURE|Arm 1 : VCST-phaco group , Arm 2 : phaco group.|Arm 1 : VCST-phaco group , Arm 2 : phaco group.
223885078|NCT05338086|DRUG|MB09 (denosumab biosimilar)|Pre-filled syringe (PFS) 60 mg/mL solution, administered as subcutaneous injection
223885079|NCT05338086|DRUG|EU-Prolia|PFS 60 mg/mL solution, administered as subcutaneous injection
223885080|NCT05338086|DIETARY_SUPPLEMENT|Elemental Calcium|at least 1000 mg daily
223885081|NCT05338086|DIETARY_SUPPLEMENT|Vitamin D|at least 400 IU daily
223885082|NCT03940703|DRUG|Tepotinib|Participants were administered with Tepotinib orally once daily at a dose of 500 mg.
223885083|NCT03940703|DRUG|Osimertinib|Participants received Osimertinib at a dose of 80 mg orally once daily.
223885084|NCT03879343|OTHER|Known diagnosis of attention deficit / hyperactivity disorder|Clinical group includes subjects with clinical diagnosis of attention deficit / hyperactivity disorder
223885085|NCT06366867|DEVICE|VibrantMinds|VibrantMindVibrantMinds offers five tablet games targeting cognitive stimulation in older adults: Whack-A-Mole, Word Search, Bejeweled, Mahjong Solitaire, Memory Game, and Glenrose Grocery Game (GGG). These games vary from nostalgic (e.g., Mahjong Solitaire) to leisure-oriented (e.g., Bejeweled), aiming to blend fun with cognitive exercises. Especially designed for ease of use, they cater to older individuals, including those with dementia, gradually increasing in difficulty to match player skill levels. The GGG stands out by integrating game design with everyday cognitive tasks, offering a practical simulation of grocery shopping. Developed with older adult input, VibrantMinds aims to enhance cognitive health in seniors through engaging, meaningful gameplay, supporting its clinical trial's focus on cognitive wellness in the aging.
223885086|NCT06789562|DEVICE|F-18FDG PET/CT and CT|compare F-18 FDG PET/CT to routine CT in staging of non-small lung cancer and effect on change management.
223885087|NCT06791434|DRUG|"Fixed Dose Combination Etoshine MR tablets"|Composition per tablet: Etoricoxib 60 mg + Thiocolchicoside 4 mg
223885088|NCT06791434|PROCEDURE|Dry needling|Thin needle insertion
223885089|NCT06791434|OTHER|Physiotherapy|Exercises
223885090|NCT06790498|BIOLOGICAL|Renal Autologous Cell Therapy (REACT)|No interventions in this trial
223885091|NCT06770309|DIETARY_SUPPLEMENT|Silkworm pupa powder|Silkworm pupa powder, 2 times a day, two packets (12\*2 g) each time, take with warm water, before meals, for three months
223885092|NCT06770309|DIETARY_SUPPLEMENT|Placebo|Placebo, 2 sachets (12\*2 g) twice a day, with warm water, before meals, for three months
223885094|NCT04521478|DRUG|BI 1358894|BI 1358894
223885095|NCT04521478|DRUG|Placebo|Placebo
223885096|NCT04521478|DRUG|Quetiapine|quetiapine
223885097|NCT05925270|BEHAVIORAL|mhGAP-Remote|One in-person session followed by standardized SMSs to reinforce the concepts learned in the first session. The intervention follows principles of the World Health Organization's Mental Health Gap Action Programme (mhGAP). Study interventionists can provide telephonic support to participants to implement the skills.
223885098|NCT05925270|BEHAVIORAL|mhGAP-Standard|Four in-person sessions with up to two booster sessions following the principles of World Health Organization's Mental Health Gap Action Programme (mhGAP).
223885099|NCT06208462|DRUG|Adebrelimab|1200mg，i.v. , q3w
223885100|NCT06208462|DRUG|Lenvatinib|8mg,qd
223885101|NCT06208462|DRUG|Gemcitabine|800 mg/m2，q3w
223885102|NCT06208462|DRUG|Oxaliplatin|85 mg/m2，q3w
223885103|NCT00922870|DEVICE|Cascade|Cascade treatment over 48h
223885104|NCT00922870|OTHER|Standard treatment|Standard therapy
223885105|NCT03716128|DIAGNOSTIC_TEST|18F-PET|Bone biopsy and 18F-PET
223885106|NCT03326310|DRUG|Azacitidine|"Patients will receive azacitidine 75 mg/m2 as a subcutaneous injection on days 1-7. The dose of azacitidine 75 mg/m2 will remain unchanged, unless a dose reduction is required based on toxicities (dose level -1 = selumetinib 50 mg PO twice daily and azacitidine 50 mg/m2).~Subjects will continue on this schedule in cycles of 28 days duration in the absence of disease progression"
223885107|NCT03326310|DRUG|Selumetinib|"Patients will receive selumetinib administered by mouth on days 8-21. The starting dose cohort (dose level 1) will receive selumetinib 50 mg PO twice daily on days 8-21. Subsequent planned doses include selumetinib 75 mg PO twice daily (dose level 2) and selumetinib 100 mg PO twice daily (dose level 3). Subsequent dose levels will only be given once the prior dose level has shown acceptable safety.~Subjects will continue on this schedule in cycles of 28 days duration in the absence of disease progression."
223885108|NCT05023928|BIOLOGICAL|Tumor antigen-sensitized DC vaccine|subcutaneous administration
223885109|NCT06086171|DRUG|Methadone Hydrochloride|Methadone hydrochloride (0.10 mg/kg) administered intravenously at the induction of anaesthesia
223885110|NCT06086171|OTHER|Placebo|Saline solution
223885111|NCT05818228|BEHAVIORAL|Video|A short video aimed at reducing self-stigma among individuals with a history of childhood maltreatment and increasing their help seeking intentions (if needed).
223885112|NCT04659031|DRUG|ABC008|ABC008
223885113|NCT04351685|BIOLOGICAL|VPM1002|"The active ingredient of the recombinant BCG vaccine, VPM1002 is Mycobacterium bovis A dose of 0.05 ml will be administered intradermally.~Manufactured by the Serum Institute of India Pvt. Ltd., India~Diluent: 1 ml of Water for injection/vial"
223885114|NCT04351685|BIOLOGICAL|BCG SII|"Commercially available BCG vaccine from Serum Institute of India Pvt. Ltd. A dose of 0.05 ml will be administered intradermally.~Manufactured by the Serum Institute of India Pvt. Ltd., India~Diluent: 1 ml of Sodium Chloride for injection/vial Injection"
223885115|NCT02129686|PROCEDURE|Immediate Acupuncture Group|
223885116|NCT02129686|PROCEDURE|Delayed Acupuncture Group|
223885117|NCT03059121|DIAGNOSTIC_TEST|Dual-energy X-ray absorptiometry|
223885118|NCT06332911|DEVICE|Shockwave™ Peripheral Intravascular Lithotripsy Balloon M5+|Cracking-not-debulking technique (SHOCKWAVE IVL)
223885119|NCT01523171|DRUG|SAR302503|"Pharmaceutical form:capsule~Route of administration: oral"
223885120|NCT06776718|PROCEDURE|vNOTES|vNOTES for benign hysterectomy
223885121|NCT06776718|PROCEDURE|vaginal hysterectomy|vaginal hysterectomy for benign hysterectomy
223885122|NCT05636358|OTHER|Home-based hypnotherapy|The home-based hypnotherapy package contains five standard hypnosis exercises. They consist of one breathing exercise, and four visualisation exercises. Two separate sets adjusted to the child's age will be used: one for children younger than 12 years and one for children of 12 years and older. The children will be asked to listen to the exercises at least 5 times per week, for approximately 15-20 minutes per day, during a period of 3 months. A workbook will provide children and/or parents with the instructions and planning of the exercises.
223885123|NCT06318754|DEVICE|Inari Triever Aspiration Catheter|Inari Triever Aspiration Catheter for portomesenteric venous thrombosis
223885124|NCT05161715|DRUG|Obicetrapib|10mg obicetrapib
223885125|NCT03944434|DRUG|Ribociclib|ribociclib 600 mg/day orally
223885126|NCT03944434|DRUG|Aromatase Inhibitors, non steroideal|letrozole 2.5 mg/day orally or anastrozole 1 mg/day orally
223885127|NCT03944434|DRUG|LHRH agonist|Triptorelin 3,75 mg or Leuprolide 3,75 mg or goserelin 3,6 mg, as injectable.
223885128|NCT05445700|DEVICE|Patient-controlled analgesia pump (PCA)|Each patient will receive a PCA pump with intravenous (i.v.) morphine.
223885129|NCT03775109|DRUG|Canakinumab 150mg/ml solution for injection|Canakinumab 150mg/ml solution for injection
223885130|NCT03775109|DRUG|Placebo|100ml 5% Dextrose
223885131|NCT05553925|OTHER|Online Weight Management Program with Coaching and Patient Navigator Support|"Patients will enroll in a 12-month digital health program available in online and mobile versions with live, personalized coaching and patient navigator support.~Patient Interface~* Digital scale and Fitbit~* Brief lessons that focus on helping patients improve their nutrition, exercise, sleep, and stress~* Weight, diet, and physical activity tracking~* Regular, personalized feedback and support from a health coach~* Spanish Version~Patient navigators are non-licensed staff. Their responsibilities will include enrolling patients in the program, monitoring their progress, and updating providers periodically. They also will be able to connect patients with additional resources and services, such as the Center for Weight Management and Wellness, if appropriate."
223885132|NCT05635786|DRUG|Alteplase (0.9mg/kg)|Intravenous thrombolysis with Alteplase (0.9 mg/kg, maximum 90 mg) with 10% of the dose given as a bolus followed by an infusion lasting 60 minutes.
223885133|NCT05635786|DRUG|Tenecteplase (0.25mg/kg)|Intravenous thrombolysis with Tenecteplase (0.25mg/kg, maximum 25 mg) with 100% of the dose given as a bolus.
223885134|NCT03347383|DEVICE|Combination therapy DCB + stent|Patients will be treated with the Luminor DCB and iVolution stent
223885135|NCT06754397|DIAGNOSTIC_TEST|Magnetic Resonance Cholangiopancreatography|Three most important sequences included axial T2 weighted scan from liver to ampullary region followed by T2 weighted 3D FSE sequence acquired in coronal oblique plane using respiratory triggering by tying bellows over abdomen. After this breath hold HASTE sequence is acquired in coronal plane. Maximum intensity projection (MIP) and thick slab images are also used for interpretation. US, CECT and MRCP scans are interpreted by radiologists blinded to other imaging findings
223885136|NCT03743623|DEVICE|Neurocytotron|Neurocytotron utilizes a combination of instantaneous magnetic field and low-spectrum radiofrequency waves for therapeutic purpose. Its working principle is based on the theory of magnetic resonance.
223885137|NCT03743623|DEVICE|Placebo|Same treatment procedures without being actually exposed to electromagnetic waves and magnetic field
223885138|NCT05215067|DRUG|AK104|IV infusion,Specified dose on specified days
223885139|NCT05215067|DRUG|Docetaxel|IV infusion,Specified dose on specified days
223885140|NCT01878838|PROCEDURE|Femtosecond Laser Assisted Cataract Surgery w/ Catalys Laser|Cohort subjects will undergo Femtosecond Laser Assisted Cataract Surgery in both eyes, with the Optimedica Catalys laser on one eye, and the Alcon LensX laser on the other. First eyes will be randomized.
223885141|NCT01878838|PROCEDURE|Femtosecond Laser Assisted Cataract Surgery w/ LenSx Laser|Cohort subjects will undergo Femtosecond Laser Assisted Cataract Surgery in both eyes, with the Optimedica Catalys laser on one eye, and the Alcon LensX laser on the other. First eyes will be randomized.
223885142|NCT06110689|OTHER|VU-AMS device|Patients will wear the VU-AMS monitor prior to MRI.
223885143|NCT03379168|DEVICE|Microfragmented Adipose Tissue (Lipogems)|Lipogems is a technique to harvest, process, and inject minimally manipulated adipose tissue. This procedure is enzyme free and requires no clonal expansion or manipulation. Lipoaspirate is harvested most commonly from the abdomen and washed in saline solution, then processed through a closed-system device that micro-fragments the adipose tissue. This mechanical process retains the vascular architecture, mature pericytes, and MSCs for autologous injection. Lipogems is currently FDA-approved for orthopedic and arthroscopic procedures; thus, this would be an on-label use for knee injections.
223885144|NCT03379168|DRUG|Corticosteroid injection|Cortisone is a standard of care injection to reduce joint inflammation.
223885145|NCT03379168|DRUG|Saline|Sterile saline injection will act as a placebo group.
223885146|NCT04690673|DRUG|Paracetamol|1 g oral paractamol
223885147|NCT04690673|DIAGNOSTIC_TEST|Paracetamol concentration measurements and lipidomic assessment|Paracetamol concentration is measured from saline-, urine-, venous blood- and fingerprick- samples at timely intervals. Also serum lipidomic assessment is performed from venous blood samples.
223885148|NCT06459310|DRUG|Metformin Hydrochloride tablet|Extended release oral tablets, 1000 mg/day, single dose
223885149|NCT06459310|DRUG|Placebo|Oral tablets, 1000 mg/day, single dose
223885150|NCT05738746|DIETARY_SUPPLEMENT|Pasteurized Akkermansia muciniphila|PAM supplementation; packaging will be given to the subjects every one month during follow-up visits, with the instructions to take one dose every morning on an empty stomach
223885151|NCT05738746|DIETARY_SUPPLEMENT|Placebo|PBO administration; packaging will be given to the subjects every one month during follow-up visits, with the instructions to take one dose every morning on an empty stomach
223885152|NCT04125238|BEHAVIORAL|Episodic Future Thinking|Participants will generate descriptions of vivid positive future events.
223885153|NCT04125238|BEHAVIORAL|Control Episodic Thinking|Participants will generate descriptions of vivid positive recent past events.
223885154|NCT04982224|DRUG|REGN5093-M114|Administered by intravenous (IV) infusion
223885155|NCT04982224|DRUG|Cemiplimab|Administered by IV infusion
223885156|NCT03743636|DRUG|Nicotinamide riboside|Participants randomized to the NR + resveratrol arm or the NR + placebo arm of the study will receive 1,000 mg of NR daily for six months.
223885157|NCT03743636|DRUG|Resveratrol|Participants randomized to the NR + resveratrol arm of the study will receive 125 mg of resveratrol daily for six months.
223885158|NCT03743636|OTHER|Placebo|Participants randomized to the NR + placebo arm of the study will receiving placebo pills that are identical in appearance to resveratrol. Participants randomized to the placebo + placebo arm of the study will receive pills that are identical in appearance to NR and resveratrol. Participants will receive placebo pills daily for six months.
223885159|NCT05691452|BEHAVIORAL|Sit Less Program|The intervention group will target a 120 minute per day reduction in sedentary behavior using an objective activity monitor and mHealth. Outcomes will be measured at baseline and post-intervention.
223885160|NCT04502446|BIOLOGICAL|CTX130|CTX130 CD70-directed T-cell immunotherapy comprised of allogeneic T cells genetically modified ex vivo using CRISPR-Cas9 gene editing components.
223885161|NCT04712994|OTHER|PrEP Optimization Interventions|A bundle of strategies (video-based PrEP counselling, HIV Self-Testing \[HIVST\] for women undergoing repeat HIV testing, and optimized PrEP delivery and prescription processes) will be implemented in the intervention group.
223885162|NCT05642156|PROCEDURE|isolated Ultrafiltration (iso-UF)|isolated Ultrafiltration
223885163|NCT06546371|DEVICE|Spinal cord stimulator|Electrical stimulation of the dorsal horn to reduce chronic pain.
223885164|NCT03684109|DEVICE|3T MRI Scanner|3T MRI Scanner providing Mega-laser sequence for single-voxel Magnetic Resonance Spectroscopy (MRS) data for 2 hydroxyglutarate (2HG) quantitation.
223885165|NCT05979584|DEVICE|Platelet Fibrin Plasma|Participants of intervention group will receive Platelet Fibrin Plasma in addition with clinical optimal treatment plan after the wound bed preparation for closure.
223885166|NCT05979584|DEVICE|Platelet Rich Plasma|Participants of intervention group will receive Platelet Rich Plasma in addition with clinical optimal treatment plan after the wound bed preparation for closure.
223885167|NCT06314087|OTHER|Placebo + conventional treatment including radiotherapy|Placebo + conventional treatment including radiotherapy
223885168|NCT06314087|COMBINATION_PRODUCT|Radiation: Radiation Therapy；Biological: Personalized tumor peptide vaccine|The peptide vaccine treatment will take 5 months as a treatment course until the treatment suspension event as stipulated in the plan occurred.
223885169|NCT06158126|DRUG|Initiating daily oral PrEP during pregnancy|Group 1a will include pregnant women who initiate oral PrEP when already pregnant, at enrollment into the study.
223885170|NCT06158126|DRUG|Already using daily oral PrEP at the time of pregnancy diagnosis|Group 1b will include women already using daily oral PrEP at the time of pregnancy diagnosis and enrollment in the study.
223885171|NCT06158126|DRUG|Initiating injectable PrEP during pregnancy|Group 2a will include pregnant women who initiate injectable PrEP (CAB-LA) when already pregnant, at enrollment into the study.
223885172|NCT06158126|DRUG|Already using injectable PrEP (CAB-LA) at the time of pregnancy diagnosis|Group 2b will include women using injectable PrEP (CAB-LA) at the time of pregnancy diagnosis and enrollment into the study.
223885173|NCT03169777|BIOLOGICAL|avelumab|Fully human anti-programmed death-ligand 1 (PD-L1) immunoglobulin (Ig)G1 lambda monoclonal antibody
223885174|NCT03169777|BIOLOGICAL|bevacizumab|Recombinant human anti-vascular endothelial growth factor (VEGF) IgG1 monoclonal antibody
223885175|NCT03169777|DRUG|capecitabine|5'-deoxy-5-fluoro-N-\[(pentyloxy) carbonyl\]-cytidine
223885176|NCT03169777|BIOLOGICAL|cetuximab|Recombinant human/mouse chimeric anti-epidermal growth factor receptor (EGFR) IgG1 monoclonal antibody
223885177|NCT03169777|DRUG|Cyclophosphamide|2-\[bis(2-chloroethyl)amino\]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
223885178|NCT03169777|DRUG|5-Fluorouracil (5-FU)|5-fluoro-2,4 (1H,3H)-pyrimidinedione
223885179|NCT03169777|DRUG|fulvestrant|7-alpha-\[9-(4,4,5,5,5-pentafluoropentylsulphinyl) nonyl\]estra-1,3,5-(10)- triene-3,17-beta-diol
223885180|NCT03169777|DRUG|leucovorin|Calcium N-\[p-\[\[\[(6RS)-2-amino-5-formyl-5,6,7,8-tetrahydro-4-hydroxy-6-pteridinyl\]methyl\]amino\]benzoyl\]-L-glutamate (1:1)
223885181|NCT03169777|DRUG|nab paclitaxel|5β,20-Epoxy-1,2α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
223885182|NCT03169777|BIOLOGICAL|nivolumab|Human anti-programmed cell death protein 1 (PD-1) IgG4 kappa monoclonal antibody
223885183|NCT03169777|DRUG|Lovaza|Omega-3-acid ethyl esters
223885184|NCT03169777|DRUG|oxaliplatin|cis-\[(1 R,2 R)-1,2-cyclohexanediamine-N,N'\] \[oxalato(2-)- O,O'\] platinum
223885185|NCT03169777|RADIATION|Stereotactic Body Radiation Therapy|(SBRT)
223885186|NCT03169777|BIOLOGICAL|ALT-803|recombinant human super agonist interleukin-15 (IL-15) complex
223885187|NCT03169777|BIOLOGICAL|ETBX-011|adenovirus serotype-5 \[Ad5\] \[E1-, E2b-\]-carcinoembryonic antigen \[CEA\] vaccine
223885188|NCT03169777|BIOLOGICAL|ETBX-021|Ad5 \[E1-, E2b-\]-human epidermal growth factor receptor 2 \[HER2\] vaccine
223885189|NCT03169777|BIOLOGICAL|ETBX-051|Ad5 \[E1-, E2b-\]-Brachyury vaccine
223885190|NCT03169777|BIOLOGICAL|ETBX-061|Ad5 \[E1-, E2b-\]-mucin 1 \[MUC1\] vaccine
223885191|NCT03169777|BIOLOGICAL|GI-4000|RAS yeast vaccine
223885192|NCT03169777|BIOLOGICAL|GI-6207|CEA yeast vaccine
223885193|NCT03169777|BIOLOGICAL|GI-6301|Brachyury yeast vaccine
223885194|NCT03169777|BIOLOGICAL|haNK|NK-92 \[CD16.158V, ER IL-2\], Suspension for Intravenous \[IV\] Infusion
223885195|NCT04582760|OTHER|early mobilization|In patients who require mechanical ventilation for acute respiratory failure or sepsis (non-malignant tumor patients), early mobilization will be performed in addition to conventional bedside physical therapy, for 30 mins per session, two sessions per day, 7 days per week until the patients are discharged from the ICU.
223885196|NCT06763406|OTHER|Exercise|Due to the limited research on exercise approaches for pectus excavatum, further investigation in this field is needed. This study aims to explore the impact of Schroth-based exercise therapy on adolescents with pectus excavatum.
223885197|NCT06763575|DEVICE|Surgical Glove-Compression Therapy|In the intervention group, patients wore double-layered surgical gloves, one size smaller than measured, covered by large cotton gloves on both hands, for 30 minutes before, during, and after chemotherapy.
223885198|NCT06763575|DEVICE|non-compressive plastic gloves|In the control group, patients wore non-compressive plastic gloves, covered by large cotton gloves on both hands, for 30 minutes before, during, and after chemotherapy.
223885199|NCT06762925|OTHER|No Interventions|No Interventions
223885200|NCT05128838|OTHER|RISE (Reinvent, Integrate, Strengthen, Expand) Intervention|Working one-on-one with the PI (a licensed occupational therapist (OT) and behavior change expert), participants will set goals and develop practical strategies in order to establish sustainable positive habits around lifestyle areas such as physical activity, nutrition, stress management, sleep, self-efficacy, and spiritual well-being. Motivational interviewing, cognitive behavioral therapy, and patient education will accompany intensive collaborative problem-solving and creation of accountability structures to create increased self-efficacy for health self-management. In summary, the RISE intervention includes three components: patient education, internalization of self-determination, and habit formation.
223885201|NCT06772636|PROCEDURE|music group|In the music group, the music chosen by the participant will be played through a speaker by the nursing staff during outpatient hysteroscopy. Music will be played through a speaker instead of headphones in order to maintain good communication and interaction between the participant and the doctor.
223885202|NCT06772636|PROCEDURE|non music group|Participants in the non-music group will undergo hysterosalpingography in the same setting and standard procedure without listening to any music.
223885203|NCT06772441|DRUG|Androgen deprivation therapy (ADT)|"* Goserelin: AstraZeneca, 10.8mg injection~* ADT will be applied for 12 months in total~* ADT must be given concurrently and adjuvant"
223885204|NCT02692807|PROCEDURE|Arthroscopic surgical procedures|See arm/group description of Arthroscopic surgery and sham surgery (HIPARTI). HARP: only arthroscopic surgery
223885205|NCT05567705|OTHER|The attitudes of doctors working in the surgical clinic of a university hospital for patient blood management: a survey-based study|No intervention required
223885206|NCT01938547|DRUG|clevidipine|
223885207|NCT06774469|DEVICE|assigned|Group II: (Normal-US Group): The rats will receive 2 sessions/ day of underwater pulsed US waves with 1 MHZ frequency and 1 watt/cm2 power, for 10 min for 30 consequent days applied to the right knee. The rats will be sacrificed after 30 days. Group V: (Osteoarthritis-US group) after two weeks of chemical induction of osteoarthritis, the rats will receive 2 sessions/ day of underwater pulsed US waves with 1 MHZ frequency and 1 watt/cm2 power for 10 min for 30 consequent days applied to the right knee. The rats will be sacrificed after 44 days.
223885208|NCT06774469|DRUG|Injection, Solution|"Group III: (Osteoarthritis-induced group): For studying the histological changes of the articular knee joint after osteoarthritis induction in the right knee joint before recovery occur. The patellar ligament will be palpated below the patella and a single intra-articular injection of (MIA lateral to the ligament using an insulin syringe will be performed).~The rats will be injected once with monosodium iodoacetate (MIA) dissolved in sterile saline (6 mg/kg body weight, 50 μL). Saline acts as a vehicle for MIA. The rats will be sacrificed after 14 days of MIA injection (1st day of the experiment).~Group IV: (Osteoarthritis-Recovery group): The rats will be injected once with monosodium iodoacetate (MIA) dissolved in sterile saline (6 mg/kg body weight, 50 μL), Saline acts as a vehicle for MIA and will not receive any medication. The rats will be sacrificed after 44 days of MIA injection (1st day of the experiment)."
223885209|NCT06774469|DEVICE|ultrasound|Group I:Sham Comparator (Control group): for studying the normal histological structure of the articular knee joint.
223885210|NCT05844332|OTHER|LUTATHERA|There is no treatment allocation. Patients administered LUTATHERA by prescription can be enrolled.
223885211|NCT05707897|DRUG|TS-142 10 mg|Single-dose of 10 mg of TS-142
223885212|NCT06784115|DEVICE|Reminder App|The purpose of the app is to remind patients irradiated for prostate cancer in an intuitive, unobtrusive and supportive way to drink 300 ml of water 45 minutes prior to each radiation session.
223885213|NCT06786949|OTHER|Questionnaire|All cases and controls will be contacted by telephone or e-mail and invited to participate in the study. Female workers who decide to join the study will be asked to go to their company's occupational health clinic where they will undergo administration of a questionnaire to investigate possible known and unknown risk factors for breast cancer
223885214|NCT06786949|DIAGNOSTIC_TEST|Blood samples for biomarker measurement|Women who give consent to undergo this phase of the study will be called back to the center and will be asked to provide a blood sample
223885215|NCT04497012|DRUG|2mg/kg/day Iron Sulfate|Iron Sulfate will be given in liquid form via nasal or oral gastric tube with feeds.
223885216|NCT04497012|DRUG|6 mg/kg/day Iron Sulfate|Iron Sulfate will be given in liquid form via nasal or oral gastric tube with feeds.
223885217|NCT06785831|OTHER|Psyllium|Participants will once daily consume predefined amount of psyllium, corresponding to 3 g of dietary fibre, for 28 days.
223885218|NCT06785831|OTHER|Sauerkraut|Participants will once daily consume predefined amount of sauerkraut, corresponding to 3 g of dietary fibre, for 28 days.
223885219|NCT06785831|OTHER|Fresh apples|Participants will once daily consume predefined amount of fresh apples, corresponding to 3 g of dietary fibre, for 28 days.
223885220|NCT06785831|OTHER|Dried apples|Participants will once daily consume predefined amount of dried apples, corresponding to 3 g of dietary fibre, for 28 days.
223885221|NCT04163536|DRUG|Methylprednisolone|In the experimental group, methylprednisolone will be administered intravenously for 5 days at a dose of 1 mg/kg/day. Methylprednisolone will be provided for reconstitution and dilution in 50 ml of NaCl 0.9% solution and administered over 15 minutes, once a day.
223885222|NCT04163536|DRUG|Placebos|in the control group, placebo will be administered intravenously for 5 days. Placebo will be identical (color and aspect) to experimental substance, will be provide as a 50 mL of NaCl 0.9% solution and administered intravenously over 15 minutes, once a day.
223885223|NCT04547413|BEHAVIORAL|STI/HIV Intervention Behavioral Intervention Program|In addition to standard of care STi/HIV counselling, participants in the intervention arm will also attend a 2-hour educational class and will receive monthly SMS/text messages to reinforce the content of the class.
223885224|NCT06766253|DEVICE|GMA-TULIP|Using GMA-TULIP non-inflatable laryngeal mask for airway management in patients who receives laparoscopic surgeries with trendelenburg position.
223885225|NCT05246657|PROCEDURE|EUS-guided Entero-biliary Anastomosis|EUS-guided Entero-biliary Anastomosis
223885226|NCT06332599|DRUG|BQT|PPI（esomeprazole or vonoprazan) 20 mg twice daily, bismuth potassium citrate 600 mg (220 mg elemental bismuth) twice daily, tetracycline 500 mg four times a day, and metronidazole 400 mg four times a day
223885227|NCT06332599|DRUG|PBM4M4|PPI（esomeprazole or vonoprazan) 20 mg twice daily, bismuth potassium citrate 600 mg (220 mg elemental bismuth) twice daily, minocycline 50 mg four times a day, and metronidazole 400 mg four times a day
223885228|NCT06332599|DRUG|PBM3M3|PPI（esomeprazole or vonoprazan) 20 mg twice daily, bismuth potassium citrate 600 mg (220 mg elemental bismuth) twice daily, minocycline 50 mg three times a day, and metronidazole 400 mg three times a day
223885229|NCT06332599|DRUG|PBM2M4|PPI（esomeprazole or vonoprazan) 20 mg twice daily, bismuth potassium citrate 600 mg (220 mg elemental bismuth) twice daily, minocycline 50 mg twice daily, and metronidazole 400 mg four times a day
223885230|NCT06332599|DRUG|PBM2M3|PPI（esomeprazole or vonoprazan), bismuth potassium citrate 600 mg (220 mg elemental bismuth) twice daily, minocycline 50 mg twice daily, and metronidazole 400 mg three times a day
223885231|NCT00607776|DRUG|(9587X) Blink Tears, classified as an OTC Drug with the active ingredient being plyethylene glycol 400|Drops
223885232|NCT00607776|DRUG|Systane|Drops
223885233|NCT03564600|OTHER|Aging Back Clinics management|Personalized care is delivered that is guided by published algorithms for each component condition identified by a trained provider.
223885234|NCT06525740|DRUG|Hydromorphone|Given IT
223885235|NCT06525740|DRUG|Methadone|Given IV
223885236|NCT06525740|OTHER|Questionnaire Administration|Ancillary studies
223885237|NCT05911932|OTHER|Biosample collection.|Blood draw.
223885238|NCT05839717|PROCEDURE|Blood sampling|A specific blood sampling will be performed in addition to the classical evaluations that are performed in routine practice
223885239|NCT05820477|BEHAVIORAL|FAMS-T1D|Behavioral FAMS-T1D FAMS-T1D involves monthly phone coaching that assists individuals in setting specific and time bound diabetes goals with automated text message support to the patient participant and less frequent automated text messages to their support person, if one is enrolled.
223885240|NCT05820477|BEHAVIORAL|Digital resources for diabetes|Behavioral: Diabetes Resources High quality digital materials about diabetes management will be provided upon enrollment and send to participants quarterly.
223885241|NCT05320432|DEVICE|Transcutaneous electrical nerve stimulation (TENS)|A low-level electrical current through the skin activates the descending inhibitory systems in the central nervous system.
223885242|NCT05320432|DEVICE|Sham|No current applied through pads.
223885243|NCT02080767|DRUG|Tecovirimat|Oral tablet 600mg daily dose(three capsules, 200 mg/capsule)
223885244|NCT04767568|DIAGNOSTIC_TEST|Blood sample|"In cohort A: Blood sample n°1 (PBMC, plasma, ctDNA) previous colonoscopy. If no cancer lesions: STOP. If cancer lesion detected : Blood sample n°2 (PBMC, plasma, ctDNA) collected 1 month after surgery.~In cohort B: Blood sample n°1 (PBMC, plasma, ctDNA) collected before surgery. Blood sample n°2 (PBMC, plasma, ctDNA) collected 1 month after surgery"
223885245|NCT04767568|OTHER|Tumor tissue|In each cohort, tumor tissue will be collected from the surgical specimen.
223885246|NCT04767568|OTHER|stool collection|In cohort B: Stool sample n°1 collected before surgery. Stool sample n°2 collected 1 month after surgery
223885247|NCT04827953|DRUG|Gemcitabine|Gemcitabine 1000 mg/m2 IV on days 1, 8 and 15 (conventional chemotherapy).
223885248|NCT04827953|DRUG|Nab paclitaxel|Nab-Paclitaxel 125 mg/m2 IV on days 1, 8 and 15 (conventional chemotherapy).
223885249|NCT04827953|DRUG|NLM-001|NLM-001 will be administered three cycles consecutively followed by two rest cycles.
223885250|NCT04827953|DRUG|Zalifrelimab|Zalifrelimab administration each 6 weeks.
223885251|NCT06300944|DRUG|saline|A maintenance dose of saline is 0.2mg/kg/h and postoperative PCIA regimen was Sufentanil 2ug/kg, ondansetron 16mg, diluted with appropriate normal saline, a total of 100ml
223885252|NCT06300944|DRUG|Esketamine|A maintenance dose of esketamine is 0.2mg/kg/h and postoperative PCIA regimen was Sufentanil 2ug/kg, ondanseetron 16mg, esketamine 0.75mg/kg, diluted with appropriate normal saline, a total of 100ml
223885253|NCT06796140|OTHER|Visible Light Exposure - Treated zone - Left hemi-back|The treated zone located on the left side of the hemi-back was exposed to Visible Light with the simulator 1 to induce skin pigmentation (144J/cm2), 15 to 30 minutes after application.
223885254|NCT06796140|OTHER|Visible Light Exposure - Treated zone - Right hemi-back|The treated zone located on the right side of the hemi-back was exposed to Visible Light with the simulator 2 to induce skin pigmentation (144J/cm2), 15 to 30 minutes after application.
223885255|NCT06796140|OTHER|Visible Light Exposure - Untreated zone - Left hemi-back|The untreated zone located on the left side of the hemi-back was exposed to Visible Light with the simulator 1 to induce skin pigmentation (144J/cm2), as the same time as the treated zone.
223885256|NCT06796140|OTHER|Visible Light Exposure - Untreated zone - Right hemi-back|The untreated zone located on the right side of the hemi-back was exposed to Visible Light with the simulator 2 to induce skin pigmentation (144J/cm2), as the same time as the treated zone.
223885257|NCT06793631|OTHER|Participants will be interviewed qualitatively about experience of providing/receiving financial support for living costs|There is no intervention for participants. Participants will receive qualitative interviews to explore their experience of financial insecurity
223885258|NCT05641753|DRUG|Evolocumab Cartridge|Injectable PCSK9 inhibitor.
223885259|NCT05641753|DRUG|Atorvastatin Calcium Tablets|HMG-CoA reductase inhibitor for oral use.
223885260|NCT05641753|DRUG|Ezetimibe Tablets|Will only be distributed to patients with statin intolerance; replacement for both Atorvastatin and Evolocumab. Inhibitor of intestinal cholesterol for oral use.
223885261|NCT05641753|DRUG|18F-FDG|Optional procedure. Positron emission tomography (PET) and computed tomography (CT) imaging to assess vascular inflammation and related anatomy requires injection of the PET tracer 18F-FDG. 18F-FDG is an FDA-approved analogue of sugar, routinely used to evaluate elevated metabolism in tissues, including increased metabolism due to inflammatory cells. A standard dose of 7.0 mSv will be administered.
223885262|NCT05641753|DEVICE|Angiocatheter 20IV|Optional procedure (endothelial cell harvesting). An angiocatheter ≤ 21 gauge will be inserted into a peripheral vein on the upper extremity using aseptic technique. A 0.018in. diameter J-shaped wire (Arrow, Reading, PA) will be then advanced into the angiocatheter, to a distance of 4cm beyond the end of the angiocatheter.
223885263|NCT05641753|DEVICE|J-Wire|Optional procedure (endothelial cell harvesting). Either a 0.021in. diameter J-shaped wire (Daig, Minnetonka, MN) or a 0.018in. diameter J-shaped wire (Arrow, Reading, PA) will be used.
223885264|NCT05641753|DEVICE|GlycoCheck Glycocalyx Measurement Software|Optional procedure (assessment of vascular function). Video microscope developed by GlycoCheck.
223885265|NCT06793280|PROCEDURE|intraoperative ICG angiography|Intraoperative ICG angiography to evaluate colonic perfusion
223885266|NCT06793280|PROCEDURE|No intraoperative ICG angiography|Visual evaluation of colonic perfusion
223885267|NCT06796166|BEHAVIORAL|AI-Supported Preoperative Education|This intervention involves the use of a pre-trained AI-powered education platform designed to provide preoperative information to patients undergoing mastectomy. The program delivers structured, interactive education that includes details about the surgical process, postoperative care, and emotional coping strategies. The pre-trained AI system offers standardized responses to patient questions, ensuring consistency and clarity in the information provided, with the goal of reducing fear and anxiety.
223885268|NCT06796166|BEHAVIORAL|Standard Preoperative Education|This intervention consists of standard preoperative education provided by healthcare professionals. Patients receive general information about the surgical procedure, postoperative care, and strategies to manage fear and anxiety. The education is delivered in a traditional, face-to-face format without the use of AI or digital tools.
223885269|NCT06793865|OTHER|Russian Current Stimulation for Anterior Tibial Group|"Parameters were adjusted as the following frequency of 2.5 kHz and 50 bursts per second with 50 pulses per burst. The stimulus was applied for a 10 seconds on period followed by a 10 seconds off period for total treatment time 20 minutes."
223885270|NCT06793865|OTHER|Placebo Russian Current Stimulation for Anterior Tibial Group|Placebo Russian current stimulation was applied to the anterior tibial group without active current for 20 minutes.
223885271|NCT06793865|OTHER|Selected physical therapy exercise for both limbs|The selected physical therapy exercise for both limbs was applied for 40 minutes, including passive, active assisted and active range of motion exercises, stretching of spastic muscles, strengthening of weak muscles (anterior tibial group), and finally functional mobility exercises.
223885272|NCT03875625|PROCEDURE|Bariatric surgery|Use of the normal bariatric surgery procedures commonly conducted in our hospital, such as: Laparoscopic Roux-en-Y gastric bypass (RYGB) and Laparoscopic sleeve gastrectomy (LSG)
223885273|NCT03875625|BEHAVIORAL|Dietitian led life style modification intervention|Intensive 6 months life style changes supervised by diatitians.
223885274|NCT03875625|BEHAVIORAL|Conventional care (control)|receive routine care
223885275|NCT03919981|OTHER|Blood sampling|25 mL blood sample will be collected on citrate tubes for osteoclastic analysis.
223885276|NCT06794567|DIAGNOSTIC_TEST|Genetic Testing|Early access to genetic testing.
223885277|NCT06360575|PROCEDURE|Biopsy Procedure|Undergo tumor biopsy
223885278|NCT06360575|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223885279|NCT06360575|DRUG|Crizotinib|Given PO
223885280|NCT06360575|PROCEDURE|Radiologic Examination|Undergo radiologic evaluation
223885281|NCT06793267|DRUG|Metoclopramide (Maxolon)|Participants will receive 0.15 mg/kg of metoclopramide administered intravenously. The drug will be diluted in 2 ml of solution prior to administration.
223885282|NCT06793267|DRUG|Saline|patients will recive normal saline 0.9% 2ml intravenous
223885283|NCT03963453|OTHER|Physical Exercise|Physical exercise are prescribed to be performed three times per week for a year
223885284|NCT05717621|DRUG|VTD-101 ointment|Self-administration of VTD-101 ointment (Decitabine ointment)
223885285|NCT05549726|DRUG|Cabotegravir Injectable Suspension|CAB-LA will be one of the options for the Dynamic Choice Delivery intervention arm. CAB-LA will be a choice for at-risk adults and adolescents weighing at least 35 kg for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection. Single-dose vial containing 600 mg/3 mL (200 mg/mL) of cabotegravir is a white to light pink, free-flowing, extended-release injectable suspension. CAB-LA administration will occur at health facilities.
223885286|NCT05549726|OTHER|Dynamic Choice Delivery Model|The Dynamic Choice Delivery Model includes integrated PrEP (including CAB-LA) and PEP services at outpatient clinics, antenatal clinics, and via VHT workers in community households. The procedures for each trial include PrEP/PEP counseling and services, choice of service location, HIV testing options, option for longer PrEP refills, provision of a clinical officer's or nurse's mobile telephone number for immediate PEP starts any day of the week, assessment of PrEP/PEP barriers and personalized actions, psychologic supports for traumatic experiences, and offer of concurrent, additional health or prevention related services.
223885287|NCT05549726|OTHER|Standard of Care|The standard of care differs according to country but does not routinely offer PEP or PrEP to clients seeking services, does not offer choice of service location, HIV testing option or access to medical provider mobile phone number.
223885288|NCT06794268|BIOLOGICAL|Lisocabtagene maraleucel|As per product label
223885289|NCT04155398|PROCEDURE|EUS elastography|A forward view radial echoendoscope or a forward oblique view linear echoendoscope would be used to perform focused luminal examination of varices and EUS elastography for measurement of liver stiffness and spleen stiffness.
223885290|NCT05561725|DRUG|Dexamethasone postoperative|"Patients randomized to the dexamethasone cohort will be administered 8 mg of dexamethasone with 3 additional (8mg doses) administered at 8-hour intervals following surgery for a total of 4 doses.~All patients will undergo a standardized post-operative pathway in the hospital following surgery that has been utilized for all AIS patients at our center since 2014."
223885291|NCT05561725|DRUG|Standard of Care|"Patients in the control group will receive one 8mg dose of dexamethasone intraoperatively as per standard of care anesthesia protocols. No sham medication will be utilized for control subjects.~All patients will undergo a standardized post-operative pathway in the hospital following surgery that has been utilized for all AIS patients at our center since 2014."
223885292|NCT06796816|OTHER|Bioelectrical Impedance Vector Analysis (BIVA)|"Bioelectrical Impedance Vector Analysis (BIVA) both in total body mode (Total Body Water) and segmental mode. The device used is the BIA 101 Anniversary by Akern. The BIVA exam will be performed in total body and segmental modes.~For total body mode, the patient should be placed on a non-conductive surface. After cleansing the skin with alcohol or mild soap, 4 electrodes will be placed: 2 on the right hand (metacarpal area) and 2 on the right foot (metatarsal). The cable connected to your instrument will then be connected to the electrodes. After the instrument is switched on, the variables are read and then analysed. For segmental mode, the patient should be placed on a non-conductive surface. After cleansing the skin with alcohol or mild soap, 8 electrodes will be placed: 2 on the right hand (metacarpal area) and 2 on the left hand, 2 on the right foot (metatarsal) and 2 on the left foot."
223885293|NCT06797817|DIETARY_SUPPLEMENT|tributyrin|Participants will receive 1 capsule per day for 12 weeks. Each capsule contains 450 mg of tributyrins. The capsules will have a gelatin coating. In the market, formulations are available with dosages ranging from 200 to 500 mg.
223885294|NCT06797817|OTHER|Placebo|The placebo will consist of potato starch encapsulated under identical conditions to those used for the tributyrin capsules, ensuring adequate blinding of the study.
223885295|NCT06796634|DEVICE|J-plasma|"* Surgery and application of CAP: at the start of surgery, an inventory is made of suitable tumor nodules that will be planned for resection. Nodules should have a maximal size of 2-3 mm, since it is unlikely that bigger lesions can be adequately treated with CAP.~* Selected tumor nodules will be treated with the J-plasma device at the standard settings (Helium gas flow of 4 l/min, coagulation and cutting intensity at 35). The distance between the tip of the device and the tissue will be approx. 10 mm. Using a timer and footswitch, nodules will be treated at different power settings and durations:~  * 15 W, 30W, or 45W~ * 2, 5, or 10 seconds.~* The treated nodules will be resected at least 30 minutes after plasma treatment, and the exact timing will be documented. The samples are split in half: one half is fixed in formalin for histology and immune histochemistry, and the other half is immediately processed for live/death staining using flow cytometry."
223885296|NCT06794034|DEVICE|Intervention|taVNS 25Hz+routine treatment, three times daily, 30 mins
223885297|NCT06794034|DEVICE|Sham Comparator|taVNS 1Hz+routine treatment, three times daily, 30 mins
223885298|NCT06790524|DEVICE|One-piece dental implants with MUA|one-piece dental implants with multi-units abutment mounted on the implants as a single piece provided with different abutment angulation utilizing these implants for All-On-Four prothesis
223885299|NCT06790524|DEVICE|Two-piece dental implants|"Surgical and immediate loading procedures:~On the day of implant placement, patients will receive two-piece implant. After crestal incision and full-thickness flap elevation, the implant sites will be prepared aided by a surgical template. 4 implants will be placed, two aligned in an axial orientation and two will be distally aligned (17 degrees). The standard placement procedure as recommended by the manufacturer will be used. The surgical drills with increasing diameters will be used to prepare the implant sites. Implants will be ideally placed at bone level (or 1 mm deeper depending on the soft tissue thickness). After 3 months as a healing phase, a definitive prosthesis will be fabricated using the same abutments, and the marginal bone loss after the osseointegration phase will be assessed."
223885300|NCT06792916|PROCEDURE|spermidine and minimally invasive non surgical tecnique|minimally non surgical periodontal therapy will be performed with the adjunct of spermidine based gel
223885301|NCT06792916|OTHER|peridontal therapy (minimally invasive non surgical tecnique)|subgingival instrumentation will be performed according to MINST
223885302|NCT06333691|DRUG|Calcium Gluconate|to compare the effectiveness of calcium gluconate, cabergoline and diosmin in preventing ovarian hyperstimulation syndrome in high-risk patient undergoing ICSI procedure.
223885303|NCT06797349|DIETARY_SUPPLEMENT|First Reference product|dextrose (containing 25 grams of carbohydrates)
223885304|NCT06797349|DIETARY_SUPPLEMENT|Second reference product|dextrose (containing 25 grams of carbohydrates)
223885305|NCT06797349|DIETARY_SUPPLEMENT|Third reference product|dextrose (containing 25 grams of carbohydrates)
223885306|NCT06797349|DIETARY_SUPPLEMENT|First Concept product|Plant-Based Oat Beverage with Sugar 1 (containing 25 grams of carbohydrates)
223885307|NCT06797349|DIETARY_SUPPLEMENT|Second Concept product|Plant-Based Oat Beverage with Sugar 2 (containing 25 grams of carbohydrates)
223885308|NCT06797349|DIETARY_SUPPLEMENT|Third Concept product|Plant-Based Oat Beverage with Sugar 3 (containing 25 grams of carbohydrates)
223885309|NCT06797349|DIETARY_SUPPLEMENT|Fourth Concept product|Plant-Based Oat Beverage with Sugar 4 (containing 25 grams of carbohydrates)
223885310|NCT06797349|DIETARY_SUPPLEMENT|Fifth Concept product|Plant-Based Oat Beverage No Sugar 1(containing 25 grams of carbohydrates
223885311|NCT06797349|DIETARY_SUPPLEMENT|Sixth Concept product|Plant-Based Oat Beverage No Sugar 2 (containing 25 grams of carbohydrates
223885312|NCT06797349|DIETARY_SUPPLEMENT|Seventh Concept product|High calorie, high protein oral powder nutritional supplement. (containing 25 grams of carbohydrates
223885313|NCT06788158|DRUG|Incobotulinum Toxin A|will be administered 2 ampoules (200 IU) of Incobotulinum toxin , injectable solution presentation 100 IU ampoule with powder diluted in 1 ml of 0.9% saline solution in a single application at 4 points, in addition to a therapeutic exercise program in the teaching service to later do it at home that will be done daily for 4 months (cryotherapy for 15 minutes on the plantar fascia, active mobilizations of the ankle and foot for 5 minutes, stretching exercises for the triceps surae and plantar fascia for 20 seconds, 3 repetitions, strengthening of intrinsic muscles of the foot).
223885314|NCT06788158|DRUG|Glucocorticoid|Program in which 2 ml of dexamethasone will be administered in an 8 mg/2 ml ampoule diluted in 2 ml of lidocaine injectable solution in a 50 ml bottle (20 mg/ml) in a single application at 1 point, in addition to a therapeutic exercise program in the teaching service to later do it at home that will be done daily for 4 months (cryotherapy for 15 minutes on the plantar fascia, active mobilizations of the ankle and foot for 5 minutes, stretching exercises for the triceps surae and plantar fascia for 20 seconds, 3 repetitions, strengthening of intrinsic muscles of the foot).
223885315|NCT06791317|OTHER|Checklist|A checklist for the intubation procedure was organised into the categories physiological optimisation, equipment and drugs, team line-up, and contingency plan. This checklist was implemented in the clinic.
223885316|NCT06789796|DRUG|Iparomlimab and Tuvonralimab (QL1706)|5mg/kg , every 3 weeks
223885317|NCT06789796|DRUG|placebo for QL1604|every 3 weeks
223885318|NCT06789796|DRUG|QL1604|200mg, every 3 weeks
223885319|NCT06789796|DRUG|placebo for Iparomlimab and Tuvonralimab (QL1706)|every 3 weeks
223885320|NCT04842643|BIOLOGICAL|IGSC 20% infusion|IGSC 20% infusion,
223885321|NCT06839040|OTHER|Group 1: ExVerbPsy|A multidisciplinary intervention will be carried out, consisting of an initial phase of individual physiotherapy based on specific active muscle training of the pelvic floor (EMSP). This will be followed by a group-based multi-component physical exercise program with instructions on pelvic floor contraction during the exercises, and psychoeducation sessions to help cope with the fear of increased likelihood of falls and urinary incontinence as a result of aging.
223885322|NCT06839040|OTHER|Group 2: ExVerb|The same procedure as experimental group 1 ExVerbPsy will be performed except for the psychoeducation sessions.
223885323|NCT06839040|OTHER|Group 3: Ex|The same procedure as experimental group 1 ExVerbPsy will be performed but without verbal instructions and psychoeducation sessions.
223885324|NCT03320707|DRUG|Daratumumab|Single SC dose of daratumumab will be administered in each of 8 dose cohorts.
223885325|NCT03320707|DRUG|Placebo|Placebo liquid will be administered as SC dose in each of first 7 dose cohorts.
223885326|NCT03320707|DRUG|rHuPH20|Participants in Cohort 8 will receive single SC dose of rHuPH20 as a part of daratumumab formulation.
223885327|NCT06839482|DEVICE|Robotic Assisted Upper Limb Rehabilitation|"The EG will follow a mixed rehabilitation approach for the upper limb, combining Robotic Assisted Upper Limb Rehabilitation and conventional physical therapy (PT) and/or occupational therapy (OT) with a total daily duration of 90 minutes. The Robotic Assisted UL Rehabilitation's session will last 30 minutes, with the following procedure provided:~* First week: alternate between passive mobilization exercises, bilateral mode, and therapist-driven mode.~* Second week: alternate between therapist-driven mode and active-assisted mobilization.~* Third week: alternate between active-assisted mobilization and active mobilization.~* Fourth week: alternate between active-assisted mobilization and active mobilization.~* Fifth week: exclusively perform active mobilization. However, if this proposed progression does not match the patient's motor capabilities, the therapist will optimize the therapeutic program by selecting personalized exercises, following a progressive difficulty approach."
223885328|NCT06839482|OTHER|Control Group (CG)|The CG will follow a conventional occupational therapy (OT) and physical therapy (PT) program for upper limb rehabilitation, with a total daily duration of 90 minutes. Upper limb rehabilitation exercises will be performed with a therapist who will tailor the treatment according to the patient's clinical characteristics and needs. Specifically, upper limb treatment will consist of motor exercises (shoulder, elbow, wrist, and hand) through a mix of individual sessions with both passive and active interventions where possible.
223885329|NCT05694988|DEVICE|Efferon CT|Efferon CT (JSC Efferon, Moscow, RF) is a device for extracorporeal blood purification by direct hemoperfusion. Detoxification is carried out by sorption of cytokines and other products of endogenous intoxication with a molecular size of up to 55 kDa.
223885330|NCT05126901|DRUG|Ferric Maltol|"Ferric maltol oral suspension: 150 ml amber glass bottle with graduated syringe and adaptor. Oral suspension containing 30 mg elemental iron, in the form of 231.5 mg ferric maltol, in 5 ml suspension~Study dosage: The dose of ferric maltol oral suspension that will be administered for children aged 1 month to \< 2 yrs: 0.1 ml/kg BID, 2 to - 11 yrs: 2.5 ml BID, 12-17 yrs: 5 ml BID."
223885331|NCT05126901|DRUG|Ferrous sulfate|"Ferrous sulfate 125 mg/ml (25 mg/ml elemental iron) oral liquid : 15 ml glass bottle.~Study dosage: For ferrous sulfate oral liquid, the dose administered will be for children and adolescents aged 2 years to 17 yrs: 6 mg/kg to the maximum of 4 ml BID."
223885332|NCT01918527|DRUG|Capecitabine|Orally on days 1-14: 2000 mg/m2/day q3w
223885333|NCT01918527|DRUG|Oxaliplatin|Intravenously on day 1: 130 mg/m2 q3w
223885334|NCT03484702|DRUG|JCAR017|Specified dose on specified days
223885335|NCT06483880|DRUG|Albendazole|Patients will receive albendazole therapy at the recommended dosage.
223885336|NCT06483880|DRUG|Placebo|Patients will receive the placebo, which will be starch tablets in the same dosage of albendazole.
223885337|NCT06794502|DRUG|Herbal medicine|Herbal medicine from butterfly pea flower decocta extract is used as an additional TB drug therapy regimen for active TB patients during the initiation phase of treatment for 2 months.
223885338|NCT06794502|OTHER|Tuberculosis (TB) treatment|The patients in anti-TB monotherapy group (Group 2) were given a regimen consisting of rifampicin, isoniazid, pyrazinamide, and ethambutol for 2 months. This group did not receive any additional therapy.
223885339|NCT05535062|DEVICE|repetitive Transcranial Magnetic Stimulation|the administration of a series of magnetic stimuli to the brain for the purpose of altering brain function
223885340|NCT06791681|DRUG|ESO-T01|ESO-T01 injection is the third-generation self-inactivating lentiviral vector targeting T cells in vivo, which carries a single VHH-directed BCMA-targeted CAR.
223885341|NCT06794710|DRUG|diuretics, ACEIs/ARBs, beta blockers, positive inotropic drugs, MRAs, SGLT2i, retinoids|Patients in this group will receive pharmacological treatment for heart failure.
223885342|NCT06794710|BEHAVIORAL|Close follow-up|High risk patients receive close follow-up
223885343|NCT06794710|BEHAVIORAL|early rehabilitation guidance|Early rehabilitation guidance such as cardiopulmonary exercise tests and cardiac rehabilitation therapy
223885344|NCT06790238|OTHER|gastric surgery and ERAS protocol|Patients under gastric surgery in an ERAS protocol
223885345|NCT03285321|DRUG|Nivolumab|480mg
223885346|NCT03285321|DRUG|Nivolumab|240mg
223885347|NCT03285321|DRUG|Ipilimumab|1mg/kg
223885348|NCT02226341|DRUG|CellCept|"For both arms:~CellCept 3 grams daily, oral, from Week 0-24 CellCept 2 grams daily, oral, from Week 25-144"
223885349|NCT02226341|DRUG|ACTHar gel|"Arm 1: 80 U biw, subcutaneous, for 3 months. Optionally additional 3 months of 80 U biw if a patient has partial response.~Arm 2: 80 U qod, subcutaneous, for 1 month, then 80 U biw, subcutaneous, for 2 months. Optionally additional 3 months of 80 U biw if a patient has partial response."
223885350|NCT06796010|OTHER|Visible Light Exposure - Treated zones|The treated zones were exposed to Visible Light to induce skin pigmentation (144J/cm2), 15 to 30 minutes after application.
223885351|NCT06796010|OTHER|Visible Light Exposure - Untreated zone|The untreated zone was exposed to Visible Light to induce skin pigmentation (144J/cm2), as the same time as the treated zones.
223885352|NCT06179901|PROCEDURE|Integrative Korean Medicine Treatment|acupuncture treatment, chuna, pharmacoacupuncture, Korean herbal medicine, cupping, moxibustion.
223885353|NCT06179901|PROCEDURE|lower limb motion style acupuncture treatment|Motion Style Acupuncture Treatment(MSAT) is a therapeutic technique using acupuncture needle created in Jaseng Hospital. This treatment involves patients with musculoskeletal pain to move the part of their body actively during acupuncture treatment under physicians' observation.
223885354|NCT06794281|OTHER|Generate synthetic multimodal (clinical, omics and imaging) data for rare haematological diseases with a validated clinical result|"O1. Provide novel methods and capabilities to generate synthetic multimodal clinical, omics and imaging data for SCD with a validated clinical result.~O2. Develop de-identification, minimisation and anonymisation pipelines, including automatic assessment of privacy levels, at the service of clinical research and care.~O3. Consolidate and scale-up the use of FL applications, SMPC and DP solutions for privacy-preserving local algorithm training and global model aggregation.~O4. Ensure ethical and GDPR compliance in anonymised and synthetic data-driven research in RHDs.~O5. Ensure wide uptake and scalability of the developed methodologies and tools through effective stakeholder engagement, dissemination and open science practices."
223885355|NCT05194969|DEVICE|Wet-to-Dry Dressings|This dressing technique involves moistening a piece of gauze with normal saline or other cleansing solution, placing the moistened gauze on the wound, allowing the gauze to dry, and then removing and replacing the bandage regularly over a period of days to weeks
223885356|NCT05194969|DEVICE|Petrolatum with Non-Stick Gauze|This dressing approach involves applying a thick layer of petrolatum to the wound once or twice daily to maintain a moist wound base. After placement of petrolatum, the wound is covered with nonadherent gauze and tape or another bordered dressing.
223885357|NCT06796881|OTHER|Instrument assisted soft tissue mobilization|The group will undergo Instrument assisted soft tissue mobilization using M2Tblade, applying it for 40-120 seconds until hyperemia occurs. After treatment, ice packs will be applied for 5 minutes to reduce hyperemia. The therapist will ensure comfort through continuous communication and reporting any discomfort.
223885358|NCT06796881|OTHER|Myofascial release|The therapist will use a cross-hand release technique to release the lumbar spine, ensuring the patient is prone and suitable. They will lean into the patient to the tissue depth barrier, wait, and follow each release, avoiding force or slipping. The technique will be applied for 5 minutes on each side.
223885359|NCT06796881|OTHER|The conventional exercise program|Patients will undergo a 12-session exercise program for 6 weeks, consisting of straight leg raising, bridging exercise, prone hip extension exercise, and abdominal curl exercise. The exercises will be done 3 sets, 10 repetitions each, with 1 minute rest between each set. The abdominal curl exercises involve supine or hook-lying positions with the lumbar spine neutral, with the patient performing a drawing in maneuver to stabilize the abdominal muscles. The progression involves lifting the shoulders, changing arm positions, and holding a weight or medicine ball. The patient's position is hook-lying, maintaining a neutral spinal position.
223885360|NCT02122562|DRUG|Ketamine|Treatment
223885361|NCT05408611|OTHER|Acupressure|acupressure is a non-pharmacological method originating from traditional Chinese medicine. According to the National Cancer Institute, acupressure is defined as pressure / massage applied to certain parts of the body to control symptoms such as pain or nausea. The main purpose of acupressure is to stimulate the regions associated with the specific organ by applying pressure with energy channels called meridians.
223885362|NCT05408611|OTHER|Placebo acupressure|Placebo acupressure is manual pressure applied to unreal acupressure points.
223885363|NCT06796621|BEHAVIORAL|Building Respectful Online Space (BROS)|Session 1 (40 minutes to 50 minutes): Respectful online relationship (Psychoeducation) using face-to-face approach with 40 minutes to 50 minutes online serious game Session 2 (40 minutes to 50 minutes): Navigating the online world (Psychoeducation) using face-to-face approach with 20 to 30 minutes online music therapy Session 3 (40 minutes to 50 minutes): Behaviour specific cognitions and reflection using face-to-face approach
223885364|NCT06796621|BEHAVIORAL|Healthy diet education program|Session 1 (40 - 50 minutes): Healthy Diet Pyramid (Psychoeducation) using face-to-face approach Session 2 (40 - 50 minutes): Mindful Eating and Healthy Weight Management (Psychoeducation) using face-to-face approach Session 3 (40 - 50 minutes): Healthy Eating Habits for Life (Psychoeducation)using face-to-face approach
223885365|NCT06792890|OTHER|Use Nabla AI Scribe tool provided|"AI Scribe technologies capture physician-patient conversations to create a transcript, then summarize the transcript in the form of a clinical notes. These tools are integrated into the EHR and automatically adds the generated text to the provider note. All physicians must inform patients about the recording and obtain their verbal consent, and instances of patients declining to consent are tracked.~Nabla leverages its proprietary speech-to-text to transform the conversation into a written context, combined with HIPAA compliant Large Language Models (LLM) like Azure OpenAI's GPT-4. Nabla does not store any audio."
223885366|NCT06792890|OTHER|Use AI Scribe tool provided by Vendor B|AI Scribe technologies capture physician-patient conversations to create a transcript, then summarize the transcript in the form of a clinical notes. These tools are integrated into the EHR and automatically adds the generated text to the provider note. All physicians must inform patients about the recording and obtain their verbal consent, and instances of patients declining to consent are tracked.
223885367|NCT06792864|DEVICE|OsteoprintCR|Hybrid technique of 3D printed bone matrix based on polycaprolactone with tricalcium beta phosphate
223885368|NCT06792864|DEVICE|SMAR SET GMV Endurance Gentamicin|"Patient undergoing cranioplasty with conventional technique using polymethylmethylmethacrylate-based surgical cement brand SMAR SET GMV Endurance Gentamicin."
223885369|NCT03924973|BEHAVIORAL|ESDM followed by treatment as usual|"The intervention was ESDM, delivered by professionals, one therapist per child, 12 hours per week during 2 years.~Then, they will receive the treatment as usual during 3 years in this current follow-up study.~Precise description of the 2 years ESDM treatment can be found in the published protocol of IDEA.~What is called treatment as usual is what the community can usually offer. That is what the control group in IDEA received.~In IDEA-2, both control and interventional group of IDEA will receive treatment as usual during 3 years.~Treatment as usual comprises of different types of interventions, such as speech pathology therapy, occupational therapy and other types of therapy more or less specific to ASD in the community.~All the interventions received by the children will be monitored in IDEA-2. All different treatment approaches will be quantified (type, frequency, intensity and duration)."
223885370|NCT06796179|OTHER|Visible Light Exposure - Treated zones with sunscreen products|The treated zones with sunscreen products were exposed to Visible Light to induce skin pigmentation (144 J/cm²), 15 to 30 minutes after application.
223885371|NCT06796179|OTHER|Visible Light Exposure - Untreated zone|The untreated zone was exposed to Visible Light to induce skin pigmentation (144J/cm2), as the same time as the treated zones.
223885372|NCT03749421|OTHER|Prosigna PAM-50 assay|Looks at the gene activity of a person's cancer cells to determine the likely outcome or course of a disease (prognosis) and predict the benefit of chemotherapy or endocrine therapy after breast surgery
223885373|NCT06794515|DIETARY_SUPPLEMENT|cGMP-AAs alone (20 g of protein equivalent)|cGMP-AAs alone (20 g of protein equivalent)
223885374|NCT06794515|DIETARY_SUPPLEMENT|cGMP-AAs (20 g of protein equivalent) + 50 g of low-protein bread + 160 g of unpeeled apple|cGMP-AAs (20 g of protein equivalent) + 50 g of low-protein bread + 160 g of unpeeled apple
223885375|NCT06794515|DIETARY_SUPPLEMENT|cGMP-AAs (20 g of protein equivalent) + 50 g of low-protein bread + 10 g of olive oil|cGMP-AAs (20 g of protein equivalent) + 50 g of low-protein bread + 10 g of olive oil
223885376|NCT06794385|DRUG|dinoprostone vaginal delivery system|Pregnant women in this group will receive a vaginal delivery system containing 10 mg of dinoprostone for labor induction.
223885377|NCT06794385|DRUG|low dose peroral misoprostol|Participants will be induced with a low-dose oral formulation of misoprostol, administered per protocol at 25 mcg every 2 hours
223885378|NCT06839716|PROCEDURE|Arm I (Ropivacaine-Poloxamer 407 hydrogel group)|Patients receive intraoperative application of Ropivacaine-Poloxamer 407 hydrogel at the incision site. A mixture of 0.75% Ropivacaine (22.5 mg, 3 mL) and Poloxamer 407-based gel (Welpass, 6 mL) is prepared. The hydrogel is applied as 4 mL between the peritoneum and fascia, and 2 mL is injected subcutaneously around the incision before skin closure. This intervention aims to provide sustained local anesthesia for up to 72 hours.
223885379|NCT06839716|PROCEDURE|Arm II (TAP block group)|"Patients undergo ultrasound-guided subcostal transversus abdominis plane (TAP) block before anesthesia emergence. A total of 30 mL of 0.375% Ropivacaine (15 mL per side) is injected bilaterally between the internal oblique and transversus abdominis muscles. TAP block is a regional anesthesia technique known for effective postoperative pain control, typically lasting 24 to 48 hours.~Both groups receive standardized postoperative analgesia, including IV acetaminophen, fentanyl via patient-controlled analgesia (PCA), and rescue pethidine as needed."
223885380|NCT06813716|OTHER|Neoprene elastic knee sleeve|We hypothesized that a neoprene elastic knee sleeve with metal supports would have a greater acute effect on balance and pain than a neoprene elastic sleeve. The first study to evaluate the acute effects of 2 different knee sleeves on pain and balance.
223885381|NCT06813716|OTHER|Neoprene elastic knee sleeve with metal supports|We hypothesized that a neoprene elastic knee sleeve with metal supports would have a greater acute effect on balance and pain than a neoprene elastic sleeve. The first study to evaluate the acute effects of 2 different knee sleeves on pain and balance.
223885382|NCT06839417|BEHAVIORAL|Exercise|using squash exercise
223885383|NCT06837623|DRUG|Colchicine Tablets|"Oral colchicine tablets. The dosing regimen is as follows:~* Patients weighing \>70 kg: 0.5 mg twice daily (BID)~* Patients weighing ≤70 kg: 0.5 mg once daily (OD) Administered for 3 months"
223885384|NCT06839508|OTHER|Radio chemotherapy|The task involves identifying similarities in biopsy samples (prior to radio-chemotherapy treatment) to predict a hypothetical complete response.
223885385|NCT06796478|OTHER|Tailored Egoscue Excercises|A. Elbow curls on the wall with abduction B. Elbow curls on the wall with adduction C. Overhead extension D. Open Up arm and chest E. Upper spinal twist. F. Spinal Twist G. Pelvic tilts H. Static back alone and static back with breathing I. Static wall. J. Air Bench Abdominal contraction in the static back position. K. Resisted Abduction L. Abductor press M. Supine groin progression
223885386|NCT06796478|OTHER|Core stabilization excercises|A. Cat Pose \& Camel pose B. Pelvic tilt C. Hip flexor stretches D. Hamstring stretches E. Piriformis stretch F. Prone on elbow
223885387|NCT06838910|DRUG|Experimental: tislelizumab+anlotinib|All patients will receive tislelizumab 200mg on Day1 every 3-week plus anlotinib 12mg or 10mg or 8mg on Day 1-14 every 3-week (Q3W) until disease progression.
223885388|NCT06173310|DEVICE|Point-of-care Portable Perfusion Phantom (P4)|P4 is a perfusion phantom developed by Dr. Harrison Kim that can significantly reduce variation in quantitating perfusion of human abdominal tissues across MRI scanners.
223885389|NCT06014034|OTHER|Programmed Weaning From Noninvasive Mechanical Ventilation|Programmed withdrawal unit: daily morning review arterial blood gas analysis (since the 2nd, daily morning stop non-invasive ventilation 1 hours, 2 hours, 3 hours, 4 hours after check arterial blood gas analysis), blood gas results suggest respiratory acidosis compensatory period (pH value greater than 7.35) can reduce daily noninvasive ventilation time, namely the noninvasive ventilation use time for 24 hours, 20 hours, the third day 16 hours, the fourth 12 hours, fifth day 8 hours. If ABG indicates still acid decompensation, continue the non-invasive ventilation regimen of the previous day. If noninvasive ventilation failed, invasive mechanical ventilation was performed.
223885390|NCT06797661|DIAGNOSTIC_TEST|Functional MRI|"11 minutes of Functional MRI alternating breathing Air-Room and gaz mix (5%CO2 21%O2 74%N2).~All procedure are acquired simultaneously on a single acquisition on the PET/MRI camera in the institution."
223885391|NCT06797661|DIAGNOSTIC_TEST|FDG-PET|"Some patients who did not benefit from a FDG-PET in their clinical evaluation or more than 1 month before the inclusion in the present study will be ask to also undergo a brain FDG-PET , the dose is set at 2 Mega becquerel per Kg.~All procedure are acquired simultaneously on a single acquisition on the PET/MRI camera in the institution."
223885392|NCT06797661|DIAGNOSTIC_TEST|Structural MRI|"Patient will benefit Different anatomical sequence of acquisition listed here : T1 , T1 with contrast agent (gadovist) , T2 flair , T2 and DSC (Dynamic susceptibility contrast) , and Time Of Flight .~All procedure are acquired simultaneously on a single acquisition on the PET/MRI camera in the institution."
223885393|NCT04188327|PROCEDURE|Stellate ganglion block|"While the patient is in a supine position with slight neck extension and rotation to the contralateral side, in-plane ultrasound guided stellate ganglion block will be performed with injection of 7 ml injectate (6ml bupivicain 0.25%+ 1 ml methylpredinosolone 40mg).~Each patient will receive:~* Acyclovir 800 mg orally every 5 times per day 7 days.~* Pregabalin start with 50 mg orally every 8hours for 7 days then increase to 150 mg every 12 hours"
223885394|NCT04188327|PROCEDURE|Sham Stellate ganglion block|"The patient will be positioned supine with slight neck extension and rotation to the contralateral side. Under US guidance, a sham stellate ganglion block will be performed with injection of a 1ml injectate of normal saline will be done while observing the dissection between the carotid artery and the longus colli muscle.~Each patient will receive:~* Acyclovir 800 mg orally every 5 times per day for 7 days.~* Pregabalin start with 50 mg orally every 8hours for 7 days then increase to 150 mg every 12 hours"
223885395|NCT06839781|OTHER|Retirement education|This initiative is structured as a six-week training program designed to support individuals in adapting to the retirement process. By addressing various aspects of retirement, the program aims to ensure that participants transition into this phase of life in a well-prepared and informed manner. The first week will serve as an introduction, providing general information and initiating physical transition training. The second week will focus on health protection and development training. The third week will address social transition training. The fourth week will be dedicated to spiritual transition training. The fifth week will focus on financial transition training. The sixth and final week will bring together previously retired individuals and current participants. This program adopts a holistic approach, aiming to facilitate both the physical and psychosocial adaptation of individuals to the retirement process.
223885396|NCT06791993|DRUG|Placebo Capsule|Participants will receive an inert placebo capsule that matches the probiotic capsule in size, shape, and color. The placebo will be administered orally twice daily, starting 2 weeks before surgery and continuing for 2 weeks postoperatively.
223885397|NCT06791993|DIETARY_SUPPLEMENT|Probiotic with Human Milk Oligosaccharides (HMO)|Participants will receive a dual-strain probiotic containing Human Milk Oligosaccharides (HMO) in capsule form. The probiotic will be administered orally twice daily, starting 2 weeks before surgery and continuing for 2 weeks postoperatively.
223885398|NCT06794398|DEVICE|V-CPR inside a room when the lay responder is alone (no operator for holding the phone)|Participants should find an appropriate smartphone position when they were able to use any objects in their environment. Participants get video-based (vocal and visual) instructions from the dispatcher during the V-CPR situation.
223885399|NCT06794398|DEVICE|V-CPR in a yard (outside environment) when the lay responder is alone (no operator for holding the phone)|Participants should find an appropriate smartphone position when they were able to use any objects in their environment. Participants get video-based (vocal and visual) instructions from the dispatcher during the V-CPR situation.
223885400|NCT06793982|DEVICE|Platelet Rich Plasma Joint Injection|Magellan Autologous Concentration System, ISTO Biologics
223885401|NCT06793982|DRUG|Corticosteroid Injection|5 milliliters (mL) injection of corticosteroid (1cc Kenalog, 4cc Xylocaine) Kenalog - 40 (triamcinolone acetonide injectable suspension, USP) Xylocaine - MPF (lidocaine HCl Injection, USP)
223885402|NCT06839313|DRUG|Kenacort A Orabase® pomad , Bristol-Myers Squibb İlaçları Inc. İstanbul , Türkiye|Apply to the injured area 4 times a day
223885403|NCT06839313|COMBINATION_PRODUCT|Hyaluronic acid, Aftamed ® Oral jel , AktiFarma . İstanbul, Türkiye|Apply to the injured area 4 times a day
223885404|NCT06839313|COMBINATION_PRODUCT|St. John's wort oil, Zade Vital; Health&Fitness, Developed With Ege Üniversiesi Argefar|Apply to the injured area 4 times a day
223885405|NCT06795594|PROCEDURE|cheek acupuncture|Cheek Acupuncture
223885406|NCT06795594|DRUG|sufentanil 2 µg/kg + ondansetron 0.2 mg/kg|The patient-controlled analgesia (PCA) pump held a solution of 2 µg/kg sufentanil and 0.2 mg/kg ondansetron in 100 ml. It infused 2 ml/hour continuously, allowing patients to self-administer an extra 2 ml bolus every 15 minutes if needed. For inadequate pain control, diclofenac sodium suppositories were used as rescue analgesia, depending on individual pain assessments and the requirement for extra relief.
223885407|NCT06795620|DRUG|Adipose tissue derived mesenchymal Stroma/stem Cells transplantation|Allogeneic adipose tissue-derived stromal cells (AdMSC) (CellReady ® drug) will be administered intramuscularly into the ischemic limb (dose of 90x10\^6 AdMSC) of patients. They will be followed at 1 day, 7 days, 30 days, 90 days, and 180 days after the injection.
223885408|NCT01226979|RADIATION|High-dose endorectal brachytherapy (HDRBT)|The investigational tool being evaluated is high-dose endorectal brachytherapy (HDRBT) which is an FDA approved method to administer endoluminal radiation for low rectal cancer.
223885409|NCT06472219|DRUG|Prednisolone 30 mg|This is a glucocorticoid like cortisol used for its anti-inflammatory, immunosuppressive, anti-neoplastic and vasoconstrictive effects. It binds to the glucocorticoid receptor, inhibiting pro-inflammatory signals and promoting anti-inflammatory signals. It has a short duration of action as the half-life is 2.1-3.5 hours and 98% is eliminated in urine. On 21 June 1955 it was granted FDA approval.
223885410|NCT06472219|DRUG|Placebo|This a tablet identical to prednisolone.
223885411|NCT05457998|DIAGNOSTIC_TEST|Flutemetamol F18 Injection|PET imaging of Abeta amyloid
223885412|NCT05457998|DIAGNOSTIC_TEST|[18F]-RO6958948 Injection|PET imaging of Tau aggregates
223885413|NCT05457998|DIAGNOSTIC_TEST|[18F]-MK-6240 Injection|PET imaging of Tau aggregates
223885414|NCT06083597|OTHER|Qualitative interview|Qualitative interviews will be performed on women with chronic pelvic pain of venous origin.
223885415|NCT06833671|OTHER|Apple juice|A preoperative carbohydrate load was done two hours before the operation using a10 ml/kg, with a maximal volume of 250 ml of commercial brand of apple juice (glucose 28 g in 250 ml).
223885416|NCT06833671|DRUG|Anhydrous glucose|A preoperative carbohydrate load was done using 1.75mg/kg/dose of anhydrous glucose (Alpha Chmika).
223885417|NCT06833671|OTHER|Water|Patients received water.
223885418|NCT06796569|DIAGNOSTIC_TEST|systemic immune inflammatory index|Systemic immune inflammatory index (SII) is a combination of three hematological parameters (platelets, neutrophils, and lymphocytes) and it is calculated using the following formula: SII = (neutrophil count × platelet count)/lymphocyte count.
223885419|NCT06838728|DEVICE|Head Mounted Magnifying Glasses|This study was divided into an experimental group and a control group based on whether a head mounted magnifying glass was used.
223885420|NCT06828874|DRUG|Levornidazole Disodium Phosphate for Injection|1g，once daily, intravenously guttae for 4 to 7 days
223885421|NCT06828874|DRUG|Ornidazole and Sodium Chloride Injection|0.5g at a time , 2 times per day, intravenously guttae for 4 to 7 days
223885422|NCT06407856|OTHER|conventional therapy|The control group embarked on a conventional therapy regimen designed for patients with spastic diplegic cerebral palsy. This group will do 10reps of ROM exercises, 3 times stretching 30sec hold with 10sec rest and 5reps of strengthening exercises, standing , weight on one leg and raising the other leg to the side or behind, putting heel in front of your toe i.e., tandem stance, standing up and sitting down from a chair without using hands, walking while alternating knee lifts with each step.This group will do conventional therapy for 30 minutes a day, 3 times a week for 8 weeks
223885423|NCT06407856|OTHER|Dual Task Training|Warming up exercise Supine Trunk and lower extremity ROM exercise Main exercise Sitting Base of support: balance cushion, ball Program: perform cognition task while maintaining balance (writing, drawing, puzzle etc.) Bench sitting (half ring P.) Base of support: balance pad Program: perform fine motor activities while maintaining balance (blocks assembly, scissoring, origami etc.) Standing Base of support: balance pad, balance cushion Program: perform eating while maintaining balance (drinking water, eat a snack etc.) Cool down exercise Supine Low extremity stretching \& deep breathing
223885424|NCT03931291|DRUG|APR-246|APR-246 will be administered on Days 1-4, with azacitidine on Days 1-5, of every 28 day cycle. Patients may receive a maximum of 12 cycles.
223885425|NCT06247631|OTHER|STOP BANG|The STOP-Bang Questionnaire is intended to give physicians an easy-to-use tool to identify people who might have obstructive sleep apnea (OSA). The questionnaire consists of eight yes-or-no questions based on the major risk factors for OSA. A STOP-Bang score of 2 or less is considered low risk, and a score of 5 or more is high risk for having either moderate or severe OSA. For people who score 3 or 4, doctors may need to perform further assessment to determine how likely they are to have OSA.
223885426|NCT04020978|DIAGNOSTIC_TEST|Parametric PET/CT|Each patient will undergo a dynamic F18-FDG PET/CT scan at baseline and 2-week post therapy.
223885427|NCT06796504|PROCEDURE|Procedure/Surgery: Implant Procedure|The SetPoint System (study device)contains a miniaturized stimulator (implnat) that is surgically implanted inside the left side of the neck on the vagus nerve (implant procedure). All eligible subjects will undergo the surgery under general anesthesia in outpatient settings.
223885428|NCT06796504|DRUG|Disease-Modifying Therapies (DMTs)|All subjects will continue treatment with standard of care disease-modifying therapies for he duration of the study.
223885429|NCT06796504|DEVICE|Device: Active stimulation|Active stimulation for 1 minute once per day
223885430|NCT06796504|DEVICE|Device: Non-active stimulation|Non-active stimulation for 1 minute once per day
223885431|NCT06792201|DIAGNOSTIC_TEST|SARC-F, Handgrip test, Chair stand test|The SARC-F questionnaire is a simple to use questionnaire consisting of five questions about daily actions.To test the force will be used: Hand-grip test and Chair stand test. The tool used for the hand-grip test is the GRIP-A (Takei). The test is performed on the dominant limb and repeated three times. The position taken by the patient will be: sitting with shoulders and elbows flexed, forearms in neutral position. The Chair stand test measures the time it takes for a patient to get up five times from a sitting position without the help of her upper limbs. The test will be timed.The measurement of lean mass will be carried out by means of a bio impedance meter. This instrument does not measure muscle mass directly but estimates it based on the electrical conductivity of the whole body. Bioimpedance is a method that is easy and safe for the patient to use.
223885432|NCT06839443|DIAGNOSTIC_TEST|Retinopathy group|OCT scans and Retinai algorithm will be performed
223885433|NCT06839443|DIAGNOSTIC_TEST|Control group|OCT scans and Retinai algorithm will be performed
223885434|NCT01728571|DIETARY_SUPPLEMENT|Vitamin D3|
223885435|NCT01728571|DIETARY_SUPPLEMENT|fish oil|
223885436|NCT01728571|DIETARY_SUPPLEMENT|Vitamin D3 placebo|
223885437|NCT01728571|DIETARY_SUPPLEMENT|Fish oil placebo|
223885438|NCT05333263|DEVICE|Treadmetrix|Programmable treadmill that delivers controlled postural disturbances
223885439|NCT06839209|DEVICE|Toxclean 1g|1 g of Toxclean once or twice daily for 28 days
223885440|NCT06793228|DRUG|Nanocrystalline Megestrol Acetate|Nanocrystalline Megestrol Acetate + Tislelizumab+ Chemotherapy (Carboplatin + Etoposide)
223885441|NCT06793228|DRUG|Tislelizumab|Tislelizumab combined with chemotherapy (Carboplatin + Etoposide)
223885442|NCT06793228|DRUG|PTOC|Nanocrystalline Megestrol Acetate+PD-(L)1 inhibitors+chemotherapy
223885443|NCT06793241|BIOLOGICAL|CD19 B-cell Acute Lymphoblastic Leukemia Targeted CAR T-cells injection|Each subject receive CD19 B-cell Acute Lymphoblastic Leukemia Targeted CAR T-cells by intravenous infusion
223885444|NCT04958122|DRUG|Cefixime 400mg|Oral cefixime 400 mg, one capsule, twice a day for 10 days
223885445|NCT04958122|DRUG|benzathine penicillin|Standard of care benzathine penicillin G, one intramuscular injection, 2.4MU
223885446|NCT03426293|OTHER|Measuring the ACT to determine effect of heparin|Measuring the ACT to determine effect of heparin during non-cardiac arterial procedures
223885447|NCT06797791|DEVICE|Multifocal Continuous Theta Burst Transcranial Magnetic Stimulation|The experimental stimulation protocol included 3 trains of cTBS with an inter-train interval of 10 min. Each train of cTBS consisted of 600 pulses applied in blocks at the theta frequency (200ms) with a duration of 40 s. A block of pulses consisted of 3 pulses at 50Hz frequency, stimulus intensity being estimated as 80% of the RMT. Stimulation application was performed by positioning the Magventure MMC-140 coil over the vertex (Cz) according to the 10-20 EEG system overlapping bilateral motor and somatosensory cortical areas.
223885448|NCT06836466|OTHER|Google Form-based questionnaire|All participants will consent to submit an anonymous Google Form-based questionnaire. The designed questionnaire includes introductory personal, academic, and work experience data about the physicians as gender, age, current specialty, workplace, highest achieved medical-academic or training degree, and number of years of postgraduate clinical work experience.
223885449|NCT04899024|BEHAVIORAL|PARTI|PARTI will provide positive affect skills. Each 1-hour session delivered via Zoom consists of a didactic portion with in vivo skills practice and participants are asked to complete home practice of the skills between sessions. Many sessions include formal exercises that have been utilized in Mindfulness-Based Relapse Prevention to cultivate mindfulness and meta-cognitive awareness.
223885450|NCT04899024|BEHAVIORAL|Attention-Control|Attention-Control will provide a core set of coping and affect measures as well as neutral writing exercises. Each 1-hour attention-control session will be administered via Zoom.
223885451|NCT04899024|BEHAVIORAL|Contingency Management for PrEP Adherence|Participants will complete a 12-week contingency management protocol via their smartphone that consists of uploading brief videos taking PrEP medications up to four times per week. Total possible contingency management incentive for completing 48 observed PrEP doses is $360.
223885452|NCT06795867|BEHAVIORAL|acceptance and commitment therapy|a 'third wave behavioral management
223885453|NCT06793969|PROCEDURE|Swartz sheath with Angioplasty Guidewire-Assisted Technique for PFO tunnel passage|"The angioplasty guidewire is advanced into the left atrium and left superior pulmonary vein (LSPV). The Swartz sheath is then delivered to the left atrium along the 0.014 guidewire through the PFO. Next, the Runthrough guidewire is changed to a 0.035 J-tipped guidewire, which is advanced into the LSPV. Finally, the delivery sheath for the PFO closure device is introduced to the left atrium along the guidewire, and all other toolkits are withdrawn."
223885454|NCT06793969|PROCEDURE|Conventional technique to pass the PFO tunnel|In the conventional group, the PFO closure procedure is performed with a multi-functional catheter and guided by intraprocedural fluoroscopy and ICE
223885455|NCT06740656|OTHER|No Interventions|no intervention
223885456|NCT06831799|OTHER|Non applicable, is a patient registry|Non applicable, is a patient registry
223885457|NCT04847544|DRUG|ADX-629|ADX-629 administered orally twice daily (BID) for up to 28 days.
223885458|NCT04847544|DRUG|Placebo|Placebo administered orally BID for up to 28 days.
223885459|NCT06793319|OTHER|educational app|State Anxiety Inventory was filled out before the training. Atrial Fibrillation training was provided. After the training, the Situationality Anxiety Inventory was filled out again. It was aimed to evaluate the effect of education on anxiety.
223885460|NCT06028529|DEVICE|Exoskeleton|lightweight ground exoskeleton
223885461|NCT05360264|DRUG|Decitabine 50 MG [Dacogen]|DACOGEN will be administered i.v. over 1 hour, at the dose of 10 mg/m2/d, daily on days 1-5 and 8-12 of each 4-wk cycle.
223885462|NCT03484884|DIAGNOSTIC_TEST|Cerenkov luminescence imaging.|Cerenkov luminescence imaging will be obtained from MSKCC patients who are scheduled for routine FDG PET scan or 131I therapy that emit a continuum of ultraviolet and visible light from the decay of certain radionuclides.
223885463|NCT05816551|OTHER|Hyperthermia Trial|"Individuals will be exposed to a controlled hyperthermia trial during Visit 2 of the protocol."
223885464|NCT05816551|OTHER|Control Trial|"Individuals will be exposed to a control trial (no hyperthermia) during Visit 1 of the protocol."
223885465|NCT04825275|DRUG|Posaconazole Pill|300 mg (three 100 mg tablets) orally
223885466|NCT04958967|DRUG|Furmonertinib 240mg|treated subjects will receive Furmonertinib 240mg/day
223885467|NCT04958967|DRUG|Furmonertinib 160mg|treated subjects will receive Furmonertinib 160mg/day
223885468|NCT04020276|RADIATION|SBRT|Participants will receive 5 fractions of radiation, which will be delivered 2-3 times per week. SBRT should be complete in a 1.5 to 2 week time frame. There should be a minimum of 12 hours between treatments. Each fraction will be escalated or de-escalated to meet the overall constraints in phase IA or both previously identified constraints in phase IB
223885469|NCT02475148|DRUG|JNJ 54175446|
223885470|NCT02475148|DRUG|Placebo|
223885471|NCT02475148|OTHER|High fat/high Calorie Breakfast|
223885472|NCT05361993|DRUG|Drug Aripiprazole|Considering the patients with chronic tic disorder (chronic motor or vocal tic disorder or Tourette's disorder), aripiprazole was selected as a single drug with constant dose during the treatment. In case of extrapyramidal side effects, benhexol was given to reduce the extrapyramidal side effects, and the dosage and duration of medication were recorded
223885473|NCT05361993|DEVICE|biofeedback|Biofeedback therapy Biofeedback therapy, three times a week, every other day interval, 30 minutes each time, each subject received 20 biofeedback training（using the Infiniti3000A biofeedback system，Thought Technology Ltd.）.Patients in the theta group decreased the theta amplitude at Cz. Patients in the theta group received positive feedback when their theta activity was below the feedback threshold.
223885474|NCT04311996|OTHER|Friend and target|random assignment to Friend and Target Both condition
223885475|NCT04311996|OTHER|Friend support|random assignment to Friend Provides Support condition
223885476|NCT04311996|OTHER|unfamiliar peer and target|random assignment to Unfamiliar Peer and Target condition
223885477|NCT04311996|OTHER|alone|random assignment to Alone condition
223885478|NCT05481515|DEVICE|Pulse oximetry|Pulse oximeters will be evaluated against routine arterial blood gas measurements
223885479|NCT05481515|DEVICE|Spectrophotometry|Spectrophotometry will be used to measure skin tone
223885480|NCT04941989|DRUG|HTL0022562|HTL0022562
223885481|NCT04941989|DRUG|Placebo|Placebo
223885482|NCT05139420|OTHER|lifestyle intervention with meal replacement program|participants will be enrolled in a medical weight loss program and will be given a 6 month subscription to a calorie-reduced meal replacement program, in addition to lifestyle advice.
223885483|NCT02379156|DRUG|Midodrine Hydrochloride|Midodrine hydrochloride is an approved medication used to treat low blood pressure. We are using a standard dose of 10 mg (tablet) only one time to determine if the vascular-constricting effects of this drug will help keep warm blood closer to the body's core and improve the ability to maintain Tcore in a cool environment (off-label use). A physician will administer the drug once before the cool thermal challenge in subjects with tetraplegia only (Visit 2).
223885484|NCT02379156|OTHER|Cool Temperature|Subjects will be exposed to a routinely encountered cool temperature (64° F) for up to to 2 hours depending on the vital signs (BP, HR, Tcore) and tolerance (comfort).
223885485|NCT05477823|RADIATION|External beam radiation therapy|Standard of care EBRT
223885486|NCT05477823|RADIATION|Prostate brachytherapy boost|Standard of care BTX
223885487|NCT05477823|DRUG|Androgen deprivation therapy|Standard of care ADT
223885488|NCT05477823|DIAGNOSTIC_TEST|Positron emission tomography (PET)/magnetic resonance imaging (MRI)|Pelvic PET scanning with tracer will take approximately 45 minutes. This will be followed by the injection of a contrast agent followed by whole body PET/MRI scanning which will take approximately 30 minutes.
223885489|NCT03636152|PROCEDURE|MRI carotid|To assess the carotid atherosclerotic plaques
223885490|NCT03636152|PROCEDURE|APWV|Doppler measurement of the APWV
223885491|NCT03636152|DRUG|Hydroxychloroquine|Active Drug
223885492|NCT03636152|DRUG|Matching Placebo|Matching Placebo for the control group.
223885493|NCT06198439|DEVICE|Transcranial Magnetic Stimulation|Magstim Rapid2 Therapy System
223885494|NCT05994742|DRUG|Rifampicin|Rifampicin is commonly used in the first-line management of paediatric tuberculosis, and is approved by the FDA (ID: 2862628) and the EMA (EMA/31710/2020).
223885495|NCT05994742|DRUG|Azithromycin|Azithromycin is a macrolide antibiotic, and is approved for use in children by the FDA (ID: 3263750) and EMA (EMA/2872/2021).
223885496|NCT05994742|DRUG|Isoniazid|Isoniazid is an antibiotic commonly used in the firstline treatment of tuberculosis, and as tuberculosis prophylaxis.
223885497|NCT05994742|DRUG|Pyridoxine Hydrochloride|Pyridoxine is a form of vitamin B6 used to prevent peripheral neuropathy among children receiving isoniazid.
223885498|NCT05994742|BEHAVIORAL|The Friendship Bench|The Friendship Bench was developed in Zimbabwe as a low-cost psychological intervention utilising problemsolving therapy (delivered by trained lay workers) and peer-to-peer support to address depression and other common mental disorders. There is a strong evidence base for its use in urban LMIC settings. Peer support groups meet every 1-2 weeks and focus on communal problem solving, and establishing income-generation activities (such as making bags).
223885499|NCT05994742|BEHAVIORAL|Care for Child Development|Care for Child Development is a UNICEF package that helps families build stronger relationships and solve problems in caring for the child at home, through play and communication activities to stimulate children, through a series of age-appropriate interactive modules delivered by a lay worker using 'flash' cards. It has been used in other African contexts and has good acceptability.
223885500|NCT05994742|BEHAVIORAL|Educational and behaviour-change modules|Educational and behaviour-change messages around better nutrition; play for children with SAM; stigma,HIV and gender-based violence; financial planning; causes of SAM; and health-seeking behaviours. These have been developed with caregivers affected by SAM in a previous study, through a series of codesign workshops, ensuring these are contextually relevant.
223885501|NCT05994742|DIETARY_SUPPLEMENT|Reformulated Ready to Use Therapeutic Food|A reformulated product designed to improve outcomes for children who have severe acute malnutrition.
223885502|NCT05994742|OTHER|Standard Care|All children will receive care according to WHO guidelines, which includes standard RUTF and any other medications required.
223885503|NCT05713994|PROCEDURE|HAIC|administration of oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries every 3 weeks.
223885504|NCT05713994|DRUG|Bevacizumab plus Atezolizumab|Bevacizumab (15mg/kg, q3w) plus Atezolizumab (1200 mg, q3w)
223885505|NCT05713994|DRUG|Bevacizumab Biosimilar IBI305 plus sintilimab|Bevacizumab Biosimilar IBI305 (15mg/kg, q3w), and sintilimab (200 mg, q3w)
223885506|NCT05713994|DRUG|Lenvatinib|8mg; p.o.; q.d.
223885507|NCT05713994|DRUG|Sorafenib|400mg; p.o. bid
223885508|NCT05713994|DRUG|Donafenib|200mg; p.o. bid
223885509|NCT05713994|DRUG|Regorafenib|160 mg; p.o.; q.d.
223885510|NCT05713994|DRUG|apatinib plus camrelizumab|Apatinib(250 mg; p.o.; q. d.); camrelizumab (200 mg; iv drip; q2w)
223885511|NCT05713994|DRUG|Anti-PD-1 monoclonal antibody|HCC Patients treated with TKI plus anti-PD-1 monoclonal antibody as systemic therapy were recruited. Anti-PD-1 monoclonal antibodies include pembrolizumab (200 mg, q3w), nivolumab (3mg/kg, q2w), camrelizumab (200mg, q2w), tislelizumab (200mg, q3w), sintilimab (200 mg, q3w), or toripalimab (240mg, q3w).
223885512|NCT05897021|BEHAVIORAL|Expressive Writing on Minority Stressors|The EWMS protocol will consist of 3 sessions delivered by a therapist (either in-person or remotely via telehealth platform) to sexual minority Veterans. The intervention will begin with an overview of the intervention, brief psychoeducation about expressive writing, and a review of the potential benefits of expressive writing. The initial session will also consist of psychoeducation on sexual minority stressors and common reactions to these stressors (i.e., universal stress reactions and minority-identity specific reactions) and how this relates to psychological outcomes, such as depression and anxiety, and high-risk behaviors, such as substance use and suicidal ideation. The initial session will be 60 minutes (introduction, psychoeducation, and first writing exercise) and the following two sessions (feedback, writing exercises, and check-ins) will take approximately 40 minutes.
223885513|NCT05897021|BEHAVIORAL|Neutral Writing|To be comparable to EWMS, the control intervention will also be a 3-session individual intervention involving engaging in a writing exercise per session. For the control writing exercises, participants will be asked to write for 30 minutes about their daily activities since waking up that day based on Pennebaker's standard writing paradigm (Pennebaker \& Beall, 1987). Individuals in the control condition will also be given information about the purpose of the writing exercises to be comparable to the psychoeducation information provided in EWMS. Similar to EWMS, the clinician will check in with the participant about the writing session, such as asking how the session went and how it felt to do the writing, following the 30 minutes of writing.
223885514|NCT05882760|DRUG|Tetric N Bond Universal®|Cavities will be restored with Conventional Hybrid Composite Restoration bonded with Etch \& Rinse Tetric - N - Bond (Ivoclar)
223885515|NCT05882760|DRUG|Self Etch Tetric N Bond Universal®|Cavities will be restored with Conventional Hybrid Composite Restoration bonded with Self Etch Tetric N Bond Universal®
223885516|NCT05882760|DRUG|GC Fuji IX, GC, Japan®|Cavities will be restored with GC Fuji IX, GC, Japan®
223885517|NCT05882760|DRUG|Activa TM Bioactive Restorative ®|Cavities will be restored with Activa TM Bioactive Restorative ®
223885518|NCT06512155|DRUG|Pregabalin|Start taking 75mg bid of pregabalin two days before surgery, and take 150mg bid of pregabalin from one day before surgery to three days after surgery
223885519|NCT06512155|DRUG|Zolpidem|Take zolpidem 10mg qn from two days before surgery to three days after surgery
223885520|NCT06776029|BIOLOGICAL|Fecal Microbiota Transplantation Capsule|FMT is delivered via oral capsules. Fecal microbiota capsules are given by 8 sessions over a 12-week period, with the initial 3 sessions every other day in the first week and the subsequent sessions every two weeks. The FMT regimen involves oral intake of 40 capsules per session. The best supportive care is performed when necessary, including oral medicine, enema, blood transfusion, and endoscopic procedures.
223885521|NCT04975516|DRUG|Chemotherapy|Given chemotherapy
223885522|NCT04975516|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
223885523|NCT04975516|PROCEDURE|Computed Tomography|Undergo CT
223885524|NCT04975516|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223885525|NCT04975516|PROCEDURE|Biospecimen Collection|Undergo blood collection
223885526|NCT04975516|OTHER|Questionnaire Administration|Ancillary studies
223885527|NCT02730039|BEHAVIORAL|workshop|
223885528|NCT02730039|BEHAVIORAL|follow-up calls & webinars|
223885529|NCT02730039|BEHAVIORAL|assessments|
223885530|NCT04636710|PROCEDURE|Lymphoscintigraphy|An imaging procedure using an injected radioactive substance or dye to identify lymph drainage A doctor reviews the images to identify the sentinel lymph nodes based on where the dye goes to first.
223885531|NCT05671406|BEHAVIORAL|Sensor-controlled digital game|"The SCDG will involve a narrative, the goal of which is to help an avatar in the game avoid hospitalization by using game points, earned via the participant's real-time behaviors, in game tasks that help maintain the avatar's optimal Hypertension health status. Real-time behaviors of weight-monitoring and physical activity will be tracked by an off-the-shelf sensors and app (Withings). The data from the Withings sensors will then be routed to our SCDG app.~The digital game paired with sensors will enable objective tracking of real-time behaviors such as physical activity, and weight monitoring, and provide personalized, contextually relevant feedback to motivate engagement in and generate habit formation of heart failure related self-management behaviors."
223885532|NCT05671406|BEHAVIORAL|Sensor only|Real-time behaviors of physical activity will be tracked by an off-the-shelf sensor and app (Withings). This group will also be provided with standardized evidence-based Hypertension educational material. However, the data from the Withings sensor will not be routed to the SCDG.
223885533|NCT05159583|DEVICE|In-Home Technology System|Intelligent bots monitor the in-home sensors, learn typical patterns, and provide caregivers with text messages and alerts via cell phone when worrisome behaviors occur. Caregivers are able to: (a) select services (e.g., warnings for falls, wandering, late night activity); (b) access daily reports (summaries of daily activities that can also be shared with health care providers); and (c) obtain support (e.g. Caregiver Support Groups that connect caregivers with knowledgeable experts and other caregivers, Caregiver Events that provide virtual meetings about relevant topics, and Trusted Circle task management to distribute the caregiving work load).
223885534|NCT05159583|DEVICE|Limited In-Home Technology|Intelligent bots monitor the in-home water leak sensor and provide caregivers with text messages and alerts via cell phone when worrisome conditions occur.
223885535|NCT03169764|BIOLOGICAL|Avelumab|Fully human anti-PD-L1 IgG1 lambda monoclonal antibody
223885536|NCT03169764|BIOLOGICAL|Bevacizumab|Recombinant human anti-vascular endothelial growth factor (VEGF) immunoglobulin (Ig) G1 monoclonal antibody
223885537|NCT03169764|DRUG|Capecitabine|5'-deoxy-5-fluoro-N-\[(pentyloxy) carbonyl\]-cytidine
223885538|NCT03169764|BIOLOGICAL|Cetuximab|Recombinant human/mouse chimeric anti-epidermal growth factor receptor (EGFR) IgG1 monoclonal antibody
223885539|NCT03169764|DRUG|Cisplatin|(SP-4-2)-diamminedichloroplatinum(II)
223885540|NCT03169764|DRUG|cyclophosphamide|2-\[bis(2-chloroethyl)amino\]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
223885541|NCT03169764|DRUG|5-Fluorouracil (5-FU)|5-fluoro-2,4 (1H,3H)-pyrimidinedione
223885542|NCT03169764|DRUG|fulvestrant|7-alpha-\[9-(4,4,5,5,5-pentafluoropentylsulphinyl) nonyl\]estra-1,3,5-(10)- triene-3,17-beta-diol
223885543|NCT03169764|DRUG|leucovorin|Calcium N-\[p-\[\[\[(6RS)-2-amino-5-formyl-5,6,7,8-tetrahydro-4-hydroxy-6-pteridinyl\]methyl\]amino\]benzoyl\]-L-glutamate (1:1)
223885544|NCT03169764|DRUG|nab-paclitaxel|5β,20-Epoxy-1,2α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
223885545|NCT03169764|BIOLOGICAL|nivolumab|Human anti-PD-1 IgG4 kappa monoclonal antibody
223885546|NCT03169764|DRUG|Lovaza|Omega-3-acid ethyl esters
223885547|NCT03169764|RADIATION|Stereotactic Body Radiation Therapy|(SRBT)
223885548|NCT03169764|BIOLOGICAL|ALT-803|recombinant human super agonist interleukin-15 (IL-15) complex \[also known as IL 15N72D:IL-15RαSu/IgG1 Fc complex\]
223885549|NCT03169764|BIOLOGICAL|ETBX-011|adenovirus serotype-5 \[Ad5\] \[E1-, E2b-\]-carcinoembryonic antigen (CEA) vaccine
223885550|NCT03169764|BIOLOGICAL|ETBX-021|Ad5 \[E1-, E2b-\]-human epidermal growth factor receptor 2 (HER2) vaccine
223885551|NCT03169764|BIOLOGICAL|ETBX-051|Ad5 \[E1-, E2b-\]-Brachyury vaccine
223885552|NCT03169764|BIOLOGICAL|ETBX-061|Ad5 \[E1-, E2b-\]-mucin 1 (MUC1) vaccine
223885553|NCT03169764|BIOLOGICAL|GI-4000|Ras yeast vaccine
223885554|NCT03169764|BIOLOGICAL|GI-6207|CEA yeast vaccine
223885555|NCT03169764|BIOLOGICAL|GI-6301|Brachyury yeast vaccine
223885556|NCT03169764|BIOLOGICAL|haNK|NK-92 \[CD16.158V, ER IL-2\], Suspension for Intravenous \[IV\] Infusion
223885557|NCT02770859|PROCEDURE|POEM (Per Oral Endoscopic Myotomy)|Per-Oral endoscopic myotomy (creating a muscle \[esophagus\] opening), an incision-less (no cutting of the surface of the body) endoscopic procedure, is an effective non-surgical alternative to release the muscle \& sphincter of the LES for the treatment of achalasia
223885558|NCT06348849|DEVICE|Low-level laser therapy|Wavelength 980nm (SmartM, Lasotronix, Poland)
223885559|NCT06348849|DRUG|Nanosilver fluoride|Optimized synthesis of Nanosilver Fluoride
223885560|NCT02651324|DRUG|Ketamine|
223885561|NCT02651324|OTHER|Placebo|
223885562|NCT04909034|DRUG|MS-20|Fermented soybean extract MicrSoy-20(MS-20), which uses a variety of lactic acid bacteria and yeasts to metabolize organic soybeans
223885563|NCT04909034|DRUG|Placebo|Oral solution without active ingredients
223885564|NCT03822637|DRUG|n-acetylcystine + albuterol|NAC is a mucolytic drug and Albuterol is a bronchodilator.
223885565|NCT03822637|DRUG|0.9% saline + albuterol|Normal saline is a placebo agent and Albuterol is a bronchodilator.
223885566|NCT05789147|DEVICE|Active tVNS|It is a non-invasive transcutaneous electrical stimulation of the auricular branch of the vagus nerve which innervates the skin of the human ear. These nerve fibers project directly to the solitary tract nucleus (NTS) in the brain stem (6).
223885567|NCT05789147|DEVICE|Sham tVNS|Sham stimulation is obtained by placing the stimulation electrode at the level of the earlobe. The stimulation is therefore administered and perceived in an area not innervated by vagal fibers.
223885568|NCT06846294|BEHAVIORAL|Diet|Individualised dietary intervention
223885569|NCT06846294|BEHAVIORAL|Diet and physical activity|Obesity prevention: Diet, Diet and physical activity and standard care
223885570|NCT05687279|BIOLOGICAL|RSVt Vaccine|Pharmaceutical Form: Suspension of virus in a nasal spray Route of Administration: Intranasal
223885571|NCT05687279|OTHER|Control Group|Pharmaceutical Form: Suspension of virus in a nasal spray Route of Administration: Intranasal
223885572|NCT06845839|DRUG|CAY001|Polyphosphate (PolyP) - silica nanoparticle (SNP) complex
223885573|NCT06845839|OTHER|Placebo|Vehicle - aqueous solution
223885574|NCT06843746|DEVICE|Commercial thermoplastic|The participants received a commercial thermoplastic splint material for splint fabrication.
223885575|NCT06843746|DEVICE|Newly developed low-cost thermoplastic|The participants received a newly developed low-cost thermoplastic splint material for splint fabrication.
223885576|NCT06847646|OTHER|bioflex crown using hall technique|crowns assessment
223885577|NCT06847646|OTHER|stainless steel crown using hall technique|crown assessment
223885578|NCT03475108|OTHER|Community Health Worker added to diabetes team|A Community Health Worker will be added to the diabetes team caring for a child with type 1 diabetes over 1 year. The intervention includes social determinants of health screening and goal setting, with home visits.
223885579|NCT04525950|PROCEDURE|Navio|New generation computer navigation with haptics and robotics
223885580|NCT04525950|PROCEDURE|Conventional|Total knee arthroplasty using conventional instruments
223885581|NCT06845410|BEHAVIORAL|Healthy life style|Healthy diet, regular exercise, and quitting smoking
223885582|NCT06845410|DRUG|Secondary prevention for atherosclerotic coronary artery disease|Antiplatelet therapy, as well as medications for control of heart rate, blood pressure, low-density lipoprotein cholesterol, and blood glucose
223885583|NCT06845410|DRUG|Immunosuppressive Therapy|Glucocorticoids and/or immunosuppressive agents
223885584|NCT06845410|PROCEDURE|Coronary revascularization|Percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG).
223885585|NCT06845410|DRUG|Supportive therapies|Medical interventions for prevention and treatment of the side effects of the above treatment, such as abnormal liver function, hypocalcemia, hypokalemia, peptic ulcer, infection, et al.
223885586|NCT06846255|DRUG|Dexamethasone Cyclophosphamide Pulse therapy|33 patients were enrolled in DCP group. They were given Dexamethasone Cyclophosphamide pulse therapy for 6 months and successful treatment outcome was assessed using Pemphigus Disease Area Index (PDAI) scores.
223885587|NCT06846255|DRUG|Dexamethasone Azathioprine Pulse therapy|33 patients were enrolled in DAP group. They were given Dexamethasone Azathioprine pulse therapy for 6 months and successful treatment outcome was assessed using Pemphigus Disease Area Index (PDAI) scores.
223885588|NCT05252754|DRUG|Tacrolimus capsule|Tacrolimus 5 mg PO, 1-2 hours prior to endoscopy
223885589|NCT05252754|DRUG|Placebo|Placebo PO, 1-2 hours prior to endoscopy.
223885590|NCT05252754|DRUG|Rectal Indomethacin|100 mg Rectal Indomethacin immediately after ERCP, in high-risk patients.
223885591|NCT06843798|OTHER|Survey|Participants will answer questions of different evaluation surveys via online survey. Sociodemographic information, ergonomic information, musculoskeletal pain etc. will be questioned.
223885592|NCT06844695|OTHER|Art Therapy (Virtual Museum Visit)|Virtual Reality (VR) is a technology that creates simulated settings in which users can interact and experience as if they were physically there.Virtual Reality typically involves the use of a headset or glasses that display the virtual environment, as well as other input devices such as controllers or gloves that allow users to interact with the virtual world
223885593|NCT06843876|OTHER|"digital vaccine platform TM VAX application"|Physicians and healthcare providers and Patients will use the TM-VAX system for at least one week. Investigators will distribute the online questionnaire via Jotform through the LINE application at day 7, which will take around 10-15 minutes to complete. If participants have any questions or encounter any issues with the questionnaire, the research team will provide assistance and answer questions via the LINE application or in-person
223885594|NCT06845982|OTHER|ultrasound-guided transuterine vaginal biopsy (BVTE)|A BVTE is performed under general anaesthetic in the operating theatre on the scheduled day of myomectomy or hysterectomy. It will be directed to the centre of the uterine smooth muscle tumour in question via an exclusively transuterine route to avoid any peritoneal spread. At least 4 to 5 samples will be taken per uterine smooth muscle tumour, with a maximum of 3 tumours to limit the risk of confusion. The woman will then be operated on as planned during the same operation. All surgical specimens will be sent to the Anatomopathology Department of La Timone for anatomopathological diagnosis after immediate formalin embedding during surgery. Surgical specimens will be analysed as usual.
223885595|NCT04076735|PROCEDURE|Distal femoral replacement|The distal portion of the femur (up to two thirds) is excised and replaced by a endoprosthesis incorporating a hinged total knee replacement.
223885596|NCT04076735|PROCEDURE|Surgical Fixation (ORIF)|A trained orthopaedic surgeon uses open or minimally invasive reduction techniques and achieves stable fixation with internal fixation devices (plates/screws or intramedullary nail) to restore structural integrity and alignment of the distal femur
223885597|NCT06846892|PROCEDURE|Exercise|Both groups were given a total of 12 sessions of Williams exercises, two days a week, in 20-minute sessions, accompanied by a physiotherapist. Williams back exercises are an exercise method that aims to increase lumbar flexion and strengthen the abdominal and gluteal muscles. The exercise program included pelvic tilts, single and double knee pulls, partial crunches, hamstring stretches, hip flexor stretches and squats. In addition, the patients continued their Williams exercises at home three days a week.
223885598|NCT06843538|DRUG|Tamsulosin|This intervention will investigate if tamsulosin will decrease postoperative urinary retention. Subjects will be directed to start taking the medication 5-7 days prior to their procedure; as previous studies have shown, this is when tamsulosin reaches its steady state. Patients will continue to take their assigned pills for 7 days postoperatively.
223885599|NCT06843538|DRUG|Placebo|This intervention will ensure blinding and an accurate measure of the real effect of tamsulosin.
223885600|NCT06845592|RADIATION|total marrow/lymphoid irradiation|Combination of 20 Gy TMLI with Treg/Tcon adoptive immunotherapy in allogeneic cell transplantation
223885601|NCT06844422|DRUG|Ivonescimab|"1. Phase Ib (Dose Escalation):~   In this phase, patients will receive Ivonescimab in escalating doses, with the aim of determining the maximum tolerated dose (MTD), dose-limiting toxicity (DLT), and the recommended Phase II dose (RP2D). The dose-escalation process will follow a 3+3 design over a 4-week period to establish the RP2D of Ivonescimab.~2. Phase II (Efficacy Evaluation):~After establishing the RP2D, patients will receive Ivonescimab combined with SBRT and modified FOLFIRINOX chemotherapy."
223885602|NCT06844994|OTHER|Manual Diaphragmatic Technique|The intervention will be given 3 days per week for up to 6 weeks starting assessment with modified Borg scale questionnaire will be asked from the patient to evaluate the patient's dyspnea level. The patient at first will be asked to do 5-6 diaphragmatic breathing in upright position and then will be asked to breathe with the breather device after complete inhalation the patient will blow hard in the device. The patient will be asked to inhale and then hold for 2-3 second and breathe out through the device with the 3 sets with each set including 8 repetitions same cycle with relaxed diaphragmatic breathing between each set
223885603|NCT06844994|OTHER|Lateral Coastal Breathing|The group B will be the lateral coastal breathing that will be given 2 times a day, 3 days per week for up to 6 weeks. The patient will be asked by practitioner to perform 4 to 5 times lateral coastal breathing in suitable sitting or lying position
223885604|NCT04714034|DIAGNOSTIC_TEST|to develop and validate a scale measuring problematic online dating app (ODA) use in sexual minorities|"Qualitative part: scale development and validation with testing in 3 different participant samples, i.e. preliminary testing (n=10), pilot testing (n=30-60), validation (n=300).~Quantitative part: longitudinal part conducted in the validation sample of the qualitative study part (n=300) with the aim to evaluate the association of scores in the problematic ODA use scale with sexual health and mental health outcomes."
223885605|NCT06068036|BEHAVIORAL|Telehealth intervention: HEARTS technical package + activity monitor (Smartwatch Mi Band 7®)|Telehealth intervention involving the HEARTS technical package and the use of Smartwatch Mi Band 7® activity monitor. The HEARTS technical package presents the 5As brief intervention (Ask, Advise, Assess, Assist, Arrange) to promote physical activity participation. Participants will receive a physical activity monitor (as instructed in the HEARTS technical package) and will be monitored by telephone call, once a week, in order to reinforce successes and identify solutions to difficulties (as instructed in the HEARTS technical package) to practice physical activity. These individuals will undertake a 12-week intervention program. In the first week, individuals will perform the first four steps of the 5As brief intervention in person, where they will be instructed on how to use the physical activity monitor, they will receive a diary of regular physical activity practice, will be guided on how to fill it out, and will schedule the best times to receive the weekly telephone call.
223885606|NCT06068036|BEHAVIORAL|Telehealth intervention: HEARTS technical package|The same intervention as the experimental group, but without the additional use of the physical activity monitor (Smartwatch Mi Band 7®).
223885607|NCT06845696|OTHER|kinesiotaping|Before applying the tape, the treated area was cleaned and shaved. A Y strip of the tape was used to facilitate muscle contraction of the semispinalis capitis with 15 -25% tension in elongated muscle position and three I strip are used in it to release tight upper trapezius, facilitate middle trapezius and to correct posture. 3 days a week for 4 weeks
223885608|NCT06845696|OTHER|Brugger relief exercise|This protocol includes that the patient is positioned on edge of a chair with his hips abducted, feet externally rotated, his head up, his forearms supinated, and wrists and fingers extended. the participants were instructed to perform scapular retraction with chin tucked in, shoulder external rotation, elbow extension, shoulder abduction, and extension. While actively moving their arms and spreading their fingers externally, patient exhaled through lips 12 reps 4 set for 3 days a week Intervention will be given for 4 weeks
223885609|NCT06844968|OTHER|Physical effort|The examined rowers will be subjected to an effort on a rowing ergometer, consisting of covering a designated distance in the shortest possible time.
223885610|NCT06846372|DEVICE|occluscence|"The OccluSense handheld is a battery powered device which uses your local wireless network to transmit the recorded data to the OccluSense-iPad-App.~The inductive charger provides wireless power transfer. Fully charged batteries allow up to 4 hours usage of the device."
223885611|NCT06846372|OTHER|patient satisfaction|"• patient satisfaction will be evaluated by using (VAS score) on a line from 0 to 100mm (0 mm is very bad /100 mm is excellent).~Are you satisfied with the esthetic outcome of the treatment? Does the treatment answer to your expectations? Would you choose the same treatment again? Is your ability to chew improved after placement of the implant prothesis? Did you find the complete treatment time too prolonged?"
223885612|NCT06844136|OTHER|No intervention|No intervention
223885613|NCT06847919|DIETARY_SUPPLEMENT|Probiotic yogurt group|The intervention phase of this study will last 3 weeks, and each participant will make 3 visits (week 0, week 1, week 3).
223885614|NCT06847919|DIETARY_SUPPLEMENT|Yogurt control group|The intervention phase of this study will last 3 weeks, and each participant will make 3 visits (week 0, week 1, week 3).
223885615|NCT06847841|PROCEDURE|Double J Stent Placement|Patient in whom a DJS will be placed for post op drainage
223885616|NCT06847841|PROCEDURE|Percutaneous Feeding Tube Placement|Patient in whom a PrcFT will be placed for post op drainage
223885617|NCT06412016|BEHAVIORAL|Peer Nutritional Counseling + Urban Gardening|Peer nutritional counseling and urban gardens
223885618|NCT04367142|DIAGNOSTIC_TEST|COVID-19 RT-PCR|Nasopharyngeal swabs for COVID-19 RT-PCR
223885619|NCT04367142|DIAGNOSTIC_TEST|Biosensor|Portable and Connected Biosensor viral
223885620|NCT06847802|OTHER|Survey|The survey will include statements related to the Domains Addressing healthcare workers/trainees, Critical Care (CC) Academic meetings, At the Workplace, CC Academia, Education of CC Trainees, Professionalism and Misconduct, Administration and Governance in the Workplace and in CC Societies, Environmental and logistic facilities, Publication of Gender metrics, Committee/working group for gender-balance The statements related to the domains will be drafted in the form of a 7-point Likert scale (strongly agree, agree, somewhat agree, neither agree nor disagree, somewhat disagree, disagree, strongly disagree) Statements that achieved consensus and stability will be used to issue the position. The results of the Delphi rounds, position statements, and the manuscript will be reviewed and approved by the panelists before submission for publication
223885621|NCT06844279|OTHER|Control Group: Standard Hemodynamic Monitoring|Anesthesia depth monitoring based on hemodynamic values without additional processed EEG guidance.
223885622|NCT06844279|DEVICE|Processed Electroencephalogram (BIS Index)|Anaesthesia depth monitoring according to numeric BIS index values.
223885623|NCT06844279|DEVICE|Processed Electroencephalogram (DSA Mode)|Anaesthesia depth monitoring according to density spectral array functions
223885624|NCT06844578|OTHER|Experimental Group|"specific intervention programme in the experimental group, which will be carried out over a period of 6 weeks, with a total of 12 scheduled sessions of 45 minutes each. The programme will be aimed at improving various functional capacities, through specifically designed exercises, including:~* Unipodal stability: Exercises focused on strengthening balance by maintaining a posture on one foot, which is key to preventing falls and improving postural stability.~* Gait re-education: Activities aimed at correcting and adjusting gait technique, promoting an efficient and safe movement pattern.~* Muscle strength: Exercises aimed at muscle strengthening, especially in the lower limbs, to increase endurance and stability during daily activities.~* Stationary walking: Practices that simulate stationary walking, improving cardiovascular endurance and motor coordination."
223885625|NCT06844578|OTHER|Active comparator Group|"which will be carried out over a period of 6 weeks, with a total of 12 scheduled sessions of 45 minutes each. Participants who will exclusively receive an intervention based on gerontogymnastics.~This programme will include a series of exercises adapted to the needs of the older adult population, with an emphasis on improving balance, muscle strength, flexibility and motor coordination. These include:~* Shoulder raises~* Hip flexion~* Knee flexion~* Trunk rotations~* Ankle dorsiflexion"
223885626|NCT06847607|DRUG|Iptacopan|Iptacopan
223885627|NCT06396611|BEHAVIORAL|Exercise Training as Intervention|Supervised Exercise Training as an Intervention using Resistance Training.
223885628|NCT06845033|OTHER|LEAP2 infusion|The LEAP2 infusion is a hormone infusion that is different from the placebo (saline) infusion
223885629|NCT06845033|OTHER|Placebo|Placebo infusion (saline) is different from the LEAP2 infusion
223885630|NCT06847178|DIETARY_SUPPLEMENT|Placebo twice daily in blinding|Administered placebo twice-daily for 12 weeks in blinding
223885631|NCT06847178|DRUG|Low-dose LC-Z300-01 twice daily in blinding|Administered twice-daily for 12 weeks in blinding
223885632|NCT06847178|DRUG|High-dose LC-Z300-01 twice daily in blinding|Administered twice-daily for 12 weeks in blinding
223885633|NCT06847178|DRUG|High-dose LCZ300-1 twice daily in open-label|Administered high-dose LCZ300-1 twice-daily for 12 weeks in open-label
223885634|NCT06845137|OTHER|Tactile-Kinesthetic Stimulation (TKS) and Soft Tissue Manipulation (STM)|"Tactile-Kinesthetic Stimulation (TKS): TKS involves the application of tactile (touch) and kinesthetic (movement) stimuli to various parts of the body. This technique aims to enhance sensory awareness and motor control. TKS can include gentle tapping, brushing, or vibration on the skin, joints, or muscles. The sensory input provided through TKS helps in proprioceptive feedback, which is essential for improving body awareness, coordination, and movement patterns. It is often used in neurological rehabilitation to facilitate neuromuscular re-education and in pediatric therapy to promote sensory integration.~Soft Tissue Manipulation (STM): STM involves various manual techniques applied to the soft tissues of the body, including muscles, tendons, ligaments, and fascia. These techniques can range from gentle stretching and mobilization to deeper techniques such as myofascial release, trigger point therapy, and deep tissue massage. STM aims to alleviate muscle tension, improve flexibility,"
223885635|NCT06845137|OTHER|Standard Therapy|Nursing care for preterm neonates involves a higher level of monitoring and specialized support due to their underdeveloped physiological systems. Nurses focus on maintaining thermal regulation through incubators or radiant warmers to prevent hypothermia, as preterm infants are more vulnerable to temperature instability. Respiratory support is critical, often requiring continuous positive airway pressure (CPAP) or mechanical ventilation to assist with immature lungs. Nutritional support is provided through intravenous fluids or gavage feeding (tube feeding) if the infant is not yet able to breastfeed or bottle-feed. Nurses also monitor for complications such as hypoglycemia, infection, and jaundice and administer antibiotics, vitamin K, and eye prophylaxis as needed. Developmentally supportive care is emphasized, including minimizing sensory overload and encouraging kangaroo care (skin-to-skin contact) to support bonding, promote growth, and help regulate the neonate's heart rate, temp
223885636|NCT06846437|DRUG|JSKN003|Administered intravenously according to protocol.
223885637|NCT06846437|DRUG|Trastuzumab emtansine (T-DM1)|Administered intravenously according to the approved label.
223885638|NCT06846632|DEVICE|PEEK|placement of PEEK after maxillary sinus lifting
223885639|NCT06846632|DEVICE|titanium meshwork|placement of titanium meshwork after maxillary sinus lifting
223885640|NCT06099795|DEVICE|eBAM Cov Testing|Evaluation of presence/absence of infection with SARS-CoV-2 assessed by eBAM-CoV on air exhaled by the patient compared with the presence/absence of infection based on RT-PCR testing of nasopharyngeal swabs
223885641|NCT06846593|DEVICE|Semiconductor Embedded Therapeutic Arm Sleeves|labeled A or B, assigned based on blinded randomization table provided by the sponsor.
223885642|NCT06846593|DEVICE|Placebo Arm Sleeves|labeled A or B, assigned based on blinded randomization table provided by the sponsor.
223885643|NCT06846593|OTHER|Platelet-Rich Plasma with Adipose Stem Cell (PRP+ASC) Injections|patients will choose or opt out of these standard of care injections.
223885644|NCT06843811|DRUG|Sirolimus|Sirolimus will be given at a starting dose of 0.8 to 1.3 mg/m2 twice daily, depending on subject age and weight.
223885645|NCT06468501|BEHAVIORAL|Price reduction on healthier foods|Price reduction (10%) on healthier foods based on the UK NPM
223885646|NCT06468501|BEHAVIORAL|Price increase to less healthy foods|Price increase (10%) on less healthy foods based on the UK NPM
223885647|NCT06468501|BEHAVIORAL|Combination of price reduction on healthier foods and price increase on less healthy foods|Combination of price reduction (10%) on healthier foods based on the UK NPM and price increase (10%) on less healthy foods based on the UK NPM
223885648|NCT06468501|BEHAVIORAL|Control|Existing price structure
223885649|NCT06522464|OTHER|Group A: mCIMT with cross-education|"For ten weeks, Group A will follow the mCIMT Protocol, which entails 30 minutes of one-on-one therapy three days a week and five hours a day (weekdays) of constraint.~In addition, the student will receive extra cross-education, which will involve practicing reaching tasks, wrist flexion and extension, and non-paretic hand opening and closing for 30 minutes. Activities include building a tower out of cubes in various colors, sorting cubes of similar colors and forms together (square cubes in a column, cylindrical cubes together), gripping a hammer, and various cube and triangular shapes. putting balls in their column, placing various-sized circular forms in their proper locations, and moving items between both hands (18). We'll utilize weight cuffs for every activity."
223885650|NCT06522464|OTHER|Group B: mCIMT without cross-education|For ten weeks, Group B will follow the mCIMT Protocol, which entails 30 minutes of one-on-one therapy three days a week and five hours a day (weekdays) of confinement.
223885651|NCT04437654|DRUG|Anticoagulation group(Apixaban group)|Apixaban 5mg twice daily (2.5mg twice daily if meets dose-reduction criteria) for 2 years
223885652|NCT06311864|DRUG|Daridorexant 50 mg|As indicated by the physician
223885653|NCT06467123|OTHER|Tissue Intervention|Participants will attend eight sessions. During each session, participants will receive education on pain neuroscience education, stress management, and maintaining physical activity. Participants will complete shoulder stretching and strengthening exercises according to a graded exercise protocol.
223885654|NCT06467123|OTHER|Biopsychosocial Intervention|Participants will attend eight sessions. During each session, participants will receive education on pain neuroscience education, stress management, and maintaining physical activity. Participants will complete shoulder stretching and strengthening exercises according to a graded exercise protocol.
223885655|NCT04549168|DRUG|Lemborexant|Lemborexant 10 mg tablet.
223885656|NCT04549168|DRUG|Placebo|Placebo tablet matched to lemborexant 10 mg tablet.
223885657|NCT05130879|BEHAVIORAL|BRAW|"Sessions~1. Happiness and positivity Understanding strengths and resilience and positive attitude~2. Cognitive restructuring Identification dysfunctional automatic thoughts in problematic and emotional arousing situations Usage of cognitive -behavioural techniques to evaluate and modify dysfunctional thoughts and beliefs~3. Behavioural activation Initiation and utilization of behavioural activation techniques for positive change by increasing pleasant events Healthy interpersonal relationships Importance of peer support~4. Emotion regulation Preventing and managing conflict Emotion regulation abilities~5. Positive work climate Building supportive work environment Development of supportive collegial relationships Promotion of coworker support~6. Problem solving Problem-solving work-life problems Work-life balance Bringing it together"
223885658|NCT03262779|BIOLOGICAL|combination nivolumab and ipilimumab|Combination therapy with nivolumab 3 mg/kg administered intravenously (IV) every 2 weeks, with ipilimumab 1 mg/kg administered IV every 6 weeks.
223885659|NCT03572335|DIAGNOSTIC_TEST|PFT's (pulmonary function testing)|The routine lung function endpoints of FVC(forced vital capacity), FEV1, FEV1/FVC, and FEF25-75% will be measured with the flow-volume loop recorder before and after bronchodilator administration. The system is calibrated for body temperature and pressure of saturated gas and volumes, per American Thoracic Society (ATS) standards . DLco will be measured using the automated single-breath procedure of the integrated testing system, which conforms with ATS standards.
223885660|NCT04856332|OTHER|Telepresence robot installed at child's home during parent's hospitalisation|Telepresence robot installed at child's home during parent's hospitalisation in long term protective isolation for maintaining parent-child ink (only children aged 15 years or less are concerned)
223885661|NCT05803993|PROCEDURE|Fecal microbiota transplantation (FMT) Single FMT infusion|Single FMT infusion via colonoscopy
223885662|NCT05192837|BEHAVIORAL|Intensive preoperative smoking cessation counselling|"The study intervention consists of an interview by a Tabacco Treatment Specialist (TSS) 4 weeks before surgery with individual counselling and offered nicotine substitution. The intervention meeting is based on the Chronic Care Model (CCM) to improve quality of ambulatory care.~In brief, the intervention includes:~* Informative content about advantages of smoking cessation~* Scheduling service for a motivational interview by a TSS in office to implement a treatment plan~* For participants willing to quit smoking a preoperative quit day will be scheduled after the first intervention meeting 2-3 weeks before surgery~* Patients will be encouraged by a TSS to use nicotine replacement. Bupropion or Vareniclin will be provided on an individual basis~* TSS will schedule repeated follow-up meetings to support smoking abstinence or nicotine reduction before and after surgery for all patients"
223885663|NCT06785259|BEHAVIORAL|Mindfulness Intervention for Emotional Distress(MIED)|Mindfulness Intervention for Emotional Distress (MIED) program provides standard audio instructions for mindfulness exercises, introduces the nature and law of anxiety, depression, and other emotions, the source of anxiety, depression, and other emotional distress, and the strategies and methods to alleviate emotional distress. These exercises, knowledge and strategies are based on the latest progress in the field of psychological counseling and treatment, and their application in daily life can help alleviate anxiety, depression and other emotional problems.
223885664|NCT06520384|DEVICE|Radiofrequency|Patients will receive radiofrequency.
223885665|NCT06520384|DRUG|Alcohol 30%|Patients will receive ultrasound-guided injection of each of the three genicular nerves with 0.5-0.75 ml of a solution containing 30% alcohol in 0.25% bupivacaine.
223885666|NCT06520384|DRUG|Alcohol 50%|Patients will receive ultrasound-guided injection of each of the three genicular nerves with 0.5-0.75 ml of a solution containing 50% alcohol in 0.25% bupivacaine.
223885667|NCT06520384|DRUG|Alcohol 70%|Patients will receive ultrasound-guided injection of each of the three genicular nerves with 0.5-0.75 ml of a solution containing 70% alcohol in 0.25% bupivacaine.
223885668|NCT06553235|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia (CBT-I)|CBT-I is a multi-component intervention consisting of sleep restriction, stimulus control therapy, relaxation therapy, cognitive therapy, and sleep hygiene education
223885669|NCT06553235|BEHAVIORAL|Sleep hygiene education|\- Sleep hygiene education includes information on lifestyle factors (diet, exercise, substance use) and environmental variables (noise, light, temperature) affecting sleep quality.
223885670|NCT05097001|OTHER|DBS programming|DBS readjustment based on COMPUTER or CLINICAL program
223885671|NCT06354179|DRUG|XR-tacrolimus QD + MMF BID then MMF QD|Patients start on XR-Tacrolimus once daily (QD) and MMF twice daily (BID) as per the usual care. At 6 months post-transplantation (±1 month) MMF administration frequency will be switched from BID to QD, in the morning, at the same daily dose
223885672|NCT06354179|DRUG|XR-tacrolimus QD + MMF BID|Patients receive XR-tacrolimus once daily (QD) and MMF twice daily (BID) as per the usual care.
223885673|NCT06354179|DRUG|LCP-tacrolimus QD + MMF QD then MMF QD|Patients start on LCP-Tacrolimus once daily (QD) and MMF twice daily (BID) as per usual care. At 6 months post-transplantation (±1 month), MMF administration frequency will be switched from BID to QD, in the morning, at the same daily dose
223885674|NCT06354179|DRUG|LCP-tacrolimus QD + MMF BID|Patients receive LCP-tacrolimus once daily (QD) and MMF twice daily (BID) as per the usual care.
223885675|NCT04749446|OTHER|Treatment of Breast Sarcoma according clinical practice (includes drugs, surgery or any other received treatments)|"This observational study collects all the treatments received by the patients according clinical practices or experimental trials and therefore includes drug/biological/surgical and any other applicable treatments~Reorder Outcome Measures"
223885676|NCT01351545|DRUG|A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs)|A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs) for transplantation in pediatric and adult patients with hematologic malignancies and other indications
223885677|NCT05095740|DEVICE|repetitive transcranial magnetic stimulation (rTMS)|Repetitive transcranial magnetic stimulation used to regulate the contribution of the laryngeal motor cortex to voice production and laryngeal motor muscle activation.
223885678|NCT05095740|DEVICE|sham rTMS|Repetitive transcranial magnetic stimulation used to a cortical area not associated with change in outcomes at an intensity substantially lower than that of the established threshold.
223885679|NCT03833622|OTHER|Shared Decision Aid Assessment|Provide feedback on a shared decision making tool to aid in discussion on goals of care in the emergency department
223885680|NCT06386783|DRUG|Dexmedetomidine Injection [Precedex]|Compare between the efficacy of dexmedetomidine and fentanyl as adjuvants on decreasing the intraoperative peritoneal symptoms such as abdominal discomfort or visceral pain, nausea and vomiting, vagal symptoms like bradycardia and hypotension during appendectomy.
223885681|NCT06386783|DRUG|Fentanyl HCl|Compare between the efficacy of dexmedetomidine and fentanyl as adjuvants on decreasing the intraoperative peritoneal symptoms such as abdominal discomfort or visceral pain, nausea and vomiting, vagal symptoms like bradycardia and hypotension during appendectomy.
223885682|NCT03494569|DRUG|Fludarabine|Given IV
223885683|NCT03494569|OTHER|Laboratory Biomarker Analysis|Correlative studies
223885684|NCT03494569|DRUG|Melphalan|Given as per City of Hope Standard Operating Procedure
223885685|NCT03494569|RADIATION|Total Marrow Irradiation|Undergo TMLI
223885686|NCT04983108|OTHER|No Intervention|No intervention. This is an observational Study
223885687|NCT04795362|BIOLOGICAL|blood sample|"5 tubes of 1 milliliters (ml) will be sampled on a catheter placed as part of the usual practice every hour for 4 hours (at Time 0, at Time 1 hour, at time 2hours, at Time 3 hours, at time 4 hours) as soon as DCI is suspected.~In the event of a mechanical angioplasty decision, the samples will be continued (Time 0, Time 2 hours, Time 4 hours, Time 6hours, Time 12 hours, Time 24 hours, so 6 samples of 1 ml)."
223885688|NCT06048484|RADIATION|Stereotactic body radiotherapy (SBRT)|SBRT 40 gray (Gy) over 5 fractions
223885689|NCT06048484|DRUG|Zimberelimab|240 mg intravenously (IV)
223885690|NCT06048484|DRUG|Quemliclustat|100 mg IV
223885691|NCT06048484|DRUG|Etrumadenant|150 mg orally
223885692|NCT06048484|DRUG|Modified FOLFIRINOX|"* Oxaliplatin 85 mg per square meter IV~* Irinotecan 150 mg per square meter IV~* Leucovorin 400 mg per square meter IV~* Fluorouracil 2400 mg per square meter IV~* Pegfilgrastim injector kit (6mg subcutaneous)"
223885693|NCT04992728|OTHER|Restricted Spectrum Magnetic Resonance Imagining|Restriction Spectrum Magnetic Resonance Imaging (RS-MRI), which uses magnetism instead of x-rays to build up a picture of the inside of the body. The scan is completely painless but can be rather noisy and requires the patient to lie very still inside the center of a large, doughnut-shaped magnet for approximately 30-60 minutes complete the imaging.
223885694|NCT03869372|DEVICE|rTMS|In subsequent sessions, the same measures of autonomic activity and MEPs will be monitored but different patterns of repetitive TMS (rTMS) will be applied to motor cortex or other areas before the test meal, water or nutrient drink is consumed.
223885697|NCT04876183|OTHER|Selfapy for Binge Eating Disorder|Web-based intervention for Binge Eating Disorder with six mandatory weekly sessions covering topics related to eating behaviors, emotion regulation, and stress management, followed by an optional set of up to six modular specialization areas based on individual therapy goals. During the intervention, participants can access an online chat providing crisis management, answering questions concerning the exercises, and technical support. The chat does not include the opportunity to discuss individual topics and concerns about treatment.
223885698|NCT05413525|PROCEDURE|ultrasound-guided manual vacuum aspiration (USG- MVA)|USG-MVA was carried out as an outpatient day procedure. Women was given a 400μg oral misoprostol tablet 2-3 hours before the procedure. All patients will be given 500mg naproxen orally an hour before the procedure. During the USG-MVA, all the women were placed in the lithotomy position and aseptically dressed. Speculum was performed to visualize the cervix with PCB performed. USG-MVA was performed using a 60ml charged syringe with a flexible curetteattached to it. Transabdominal USG during MVA was performed. During the procedure, local lidocaine gelwas applied to the cervical canal and over the end of the MVA catheter tip during the insertion.The USG-MVA was stopped as soon as USG confirmed that the uterine cavity was empty, defined as a thin endometrial lining with no evidence of retained products of conception.
223885699|NCT03860961|OTHER|Questionnaire Administration|Ancillary studies
223885700|NCT03860961|OTHER|Survivorship Care Plan|Given survivorship care plan
223885701|NCT03860961|OTHER|Treatment Plan|Given treatment plan
223885702|NCT06500364|DEVICE|LoopLoc Arm|Patients in this intervention will have had a capsular closure performed using a LoopLoc device after their hip arthroscopy.
223885703|NCT06500364|DEVICE|Control Arm|Patients in this intervention will have not had a capsular closure using a LoopLoc device after their hip arthroscopy.
223885704|NCT05000645|BEHAVIORAL|Grocery delivery|Each food delivery will contain approximately $35 worth of fresh fruits, vegetables, dairy products, and whole grain foods. These foods are not meant to supplant regular meals, rather make healthy eating more convenient.
223885705|NCT05000645|BEHAVIORAL|Unsweetened beverage delivery|Participants will receive unsweetened beverages to replace normal sugar-sweetened beverage intake.
223885706|NCT05473923|DRUG|Receiving chemotherapeutic or targeted drugs recommended by molecular tumor board.|Patients will be treated with FDA-approved chemotherapeutic or targeted drugs which were recommended by the molecular tumor board (MTB), based on their expertise, patients willingness as well as evidences from PTCs-drug screening and bioinformatic prediction for drug response.
223885707|NCT06103500|OTHER|Clinical Decision Support Algorithm for Empiric Antibiotics in Sepsis|A clinical decision support algorithm for empiric antibiotic selection in suspected infection.
223885708|NCT05912504|OTHER|Phoen survey|A questionnaire about the current symptoms and satisfaction for received treatment will be conducted over the phone for patients.
223885709|NCT06522308|DIAGNOSTIC_TEST|Hepatobiliary ultrasound|The presence of cholelithiasis in patients with umbilical hernia is detected by hepatobiliary ultrasound
223885710|NCT06522308|DIAGNOSTIC_TEST|Umbilical region superficial tissue ultrasound|The presence of umbilical hernia in patients with cholelithiasis is detected by ultrasound of the superficial tissue of the umbilical region.
223885711|NCT05780814|BEHAVIORAL|Cognitive-Behavioral Therapy for Insomnia (CBT-I)|The CBT-I intervention is a 6-session intervention spread out over 8 weeks that combines education and behavioral techniques to reduce insomnia.
223885712|NCT05780814|BEHAVIORAL|Sleep Education Control (EDU)|Subjects will be instructed to read and review select publications from the American Academy of Sleep Medicine
223885713|NCT05859698|DRUG|Valbenazine|Valbenazine capsules for oral administration
223885714|NCT06315088|OTHER|Einkorn Diet|Analysis of the oral microbiota before (T0) and after (T2) introduction of einkorn into the diet by interdental sampling, on 4 sites, pooled then analyzed by bacterial PCR.
223885715|NCT06315088|OTHER|Intermediate oral microbiota|Comparison of the number of total bacteria and pathogens of the interdental microbiota before (T0) and in interim analysis (T1) for evaluation of the minimum period of effectiveness, by interdental sampling, on 4 sites, pooled then analyzed by bacterial PCR.
223885716|NCT06315088|OTHER|Periodontal health status|Analysis of the periodontal and oral clinical parameters (plaque index, gingival index, interdental inflammation, pocket depth and loss of clinical attachment, salivary pH) before (T0) and after (T2) introduction of einkorn into the diet, by sampling and periodontal analysis of all of the participants' teeth
223885717|NCT06315088|OTHER|General health status|Analysis of general health indicators (body mass index, measurement of abdominal circumference, blood pressure, MOS SF-36 quality of life questionnaire and eating habits) before (T0) and after (T2) introduction of einkorn in the diet
223885718|NCT04199182|BEHAVIORAL|Exercise Training|A multi-component group exercise intervention that emphasizes functional training. Duration is 6 months, and frequency is 3x per week.
223885719|NCT04199182|OTHER|Healthy Aging Attention Control (HA-ATC)|"Participants in the HA-ATC group will receive a health education program modeled on the 10 Keys to Healthy Aging curriculum and the National Council on Aging's Aging Mastery Program. HA-ATC will include an 8-week face-to-face group program followed by bi-weekly sessions for the remaining 4 months."
223885720|NCT06162871|BEHAVIORAL|Presentations and interactive debate sessions, with intergenerational exchange|Intervention will consist of 12 sessions, each lasting about two hours, conducted on a weekly basis and delivered both in-person and remotely. The sessions will include presentations and interactive debate sessions, with a central focus on intergenerational exchange covering cultural, historical, and health-related topics. A key aspect is the active involvement of beneficiaries, individuals over sixty-five, who will be asked to prepare presentations with the support of project-provided facilitators. Simultaneously, the project will promote and enhance skills, organizational capabilities, and computer literacy.
223885721|NCT02662062|DRUG|Pembrolizumab|200 mg/m2, IV (in the vein) on day 1 every three weeks (Weeks 1, 3, 7, 10, 13, 16 and 19). until progression or unacceptable toxicity develops.
223885722|NCT02662062|DRUG|Cisplatin|35 mg/m2, IV (in the vein) every week for six weeks.
223885723|NCT02662062|RADIATION|Radiotherapy|2.00Gy once daily for 32 fractions, 5 fractions/week over six weeks and two days (a total of 64Gy).
223885724|NCT05839119|DRUG|Degarelix|initial dose is 240 mg administered as two 120 mg (3 mL) injections (SC), followed by subsequent doses at 80 mg (4 mL) administered as one injection (SC)
223885725|NCT05839119|COMBINATION_PRODUCT|Gemcitabine/Cisplatin|"SOC Neoadjuvant Chemotherapy: Gemcitabine/Cisplatin 21-day cycles (4 cycles total)~* Gemcitabine: 1000 mg/m2 (IV) Days 1 and 8 of each cycle~* Cisplatin: 70 mg/m2 (if borderline renal function: 35 mg/m2) (IV) Day 1 of each cycle (if borderline renal function, days 1 and 8 of each cycle)."
223885726|NCT06311084|OTHER|Imaginator 2.0|Blended psychological digital intervention, combining Functional Imagery Training, a psychological intervention based on CBT and motivational interviewing principles, and a smartphone app.
223885727|NCT04870203|DRUG|baricitinib treatment|4 mg daily during 12 months
223885728|NCT04870203|DRUG|anti-TNF therapy|adalimumab at 40 mg every 2 weeks or etanercept 50 mg per week according to treatments history
223885729|NCT04870203|DRUG|Placebo|40 mg every 2 weeks during 6 months only during Period A
223885730|NCT03988634|DRUG|sacubitril/valsartan|Sacubitril/valsartan (LCZ696) was available as 24/26 mg, 49/51 mg, and 97/103 mg in tablet form to be taken orally, twice daily
223885731|NCT03988634|DRUG|valsartan|Valsartan was available as 40 mg, 80 mg, and 160 mg in tablet form to be taken orally, twice daily
223885732|NCT03988634|DRUG|sacubitril/valsartan matching placebo|Sacubitril/valsartan (LCZ696) matching placebo was available as tablet form to be taken orally, twice daily
223885733|NCT03988634|DRUG|valsartan matching placebo|Valsartan matching placebo was available as tablet form to be taken orally, twice daily
223885734|NCT06311357|DIETARY_SUPPLEMENT|Ensure|Ensure 6 scoops dietary supplement powder in 250 ml of water, 2 drinks per days for 12 weeks.
223885735|NCT06799910|PROCEDURE|continuous renal replacement therapy (CRRT)|The patient is included in the study once they meet the eligibility criteria and as soon as the responsible physician has prescribed RRT according to the department's protocol. Randomization will be performed, and the patient will be assigned to either the standard or experimental groups.
223885736|NCT06799910|OTHER|Free UF Prescription|The UF (ml/h) is prescribed by the responsible physician based on the patient's clinical, congestive, and hemodynamic status. The physician can implement the UF whenever necessary based on the patient's hemodynamic condition.
223885737|NCT04916327|DIETARY_SUPPLEMENT|Antioxidant|Subjects will ingest an antioxidant cocktail containing 800 milligrams of alpha lipoic acid, 1 gram of vitamin C (ascorbic acid), and 400 milligrams of vitamin E (alpha tocopherol).
223885738|NCT04916327|DIETARY_SUPPLEMENT|Placebo|Subjects will ingest placebo (microcrystalline cellulose) pills.
223885739|NCT01728402|PROCEDURE|blood draw, bone marrow procedure, or tissue biopsy|
223885740|NCT06623656|DRUG|Cemiplimab|Intravenously
223885741|NCT06623656|DRUG|Platinum based chemotherapy|Intravenously
223885742|NCT06623656|RADIATION|Stereotactic body radiation therapy|8 Gy times 3 treatment days (Days 1-3)
223885743|NCT04725240|DRUG|Setmelanotide|Setmelanotide for SC injection
223885744|NCT05643599|DIETARY_SUPPLEMENT|Mad Honey|mad honey (80 mg/kg); (n:6)
223885745|NCT05643599|DIETARY_SUPPLEMENT|Normal Honey|normal honey (80 mg/kg),(n:6)
223885746|NCT05643599|DIETARY_SUPPLEMENT|Control|Control
223885747|NCT05780385|DEVICE|nasotracheal intubation|patients requiring tracheal intubation receive nasotracheal intubation
223885748|NCT05780385|DEVICE|orotracheal intubation|patients requiring tracheal intubation receive orotracheal intubation
223885749|NCT06282289|BEHAVIORAL|Magnetoencephalography (MEG)|Stimuli will be presented binaurally through headphones at 60 decibel sound pressure level (dB SPL). Conditions are presented in a pseudo-random order with an inter-stimulus interval of \~800 ms on average (range: 600 ms to 1000 ms). The duration of the stimuli is fixed: 2 seconds, in order to guarantee a minimum number of cycles.
223885750|NCT06282289|OTHER|Cognition development questionnaire|Computerised questionnaires completed by parents
223885751|NCT04883775|DRUG|MVT-2163|MVT-2163 is administered intravenously as a PET imaging agent.
223885752|NCT04883775|DRUG|MVT-5873|MVT-5873 will be administered intravenously over at least 60 minutes.
223885753|NCT03836261|DRUG|Acalabrutinib|Acalabrutinib,
223885754|NCT03836261|DRUG|Venetoclax|Venetoclax
223885755|NCT03836261|DRUG|Chemoimmunotherapy|fludarabine/cyclophosphamide/rituximab (FCR), bendamustine/rituximab (BR)
223885756|NCT03836261|DRUG|Obinutuzumab|Obinutuzumab
223885757|NCT06351332|DRUG|Azenosertib|WEE1 inhibitor, 25 or 100 mg tablet, taken orally per protocol.
223885758|NCT06351332|DRUG|Carboplatin|Platinum coordination compound, 5-, 15-, 45-, and 60-mL vials, via intravenous (into the vein) infusion per institutional standards.
223885759|NCT06351332|DRUG|Pembrolizumab|Humanized immunoglobulin G4 monoclonal antibody, 4-mL vials, via intravenous (into the vein) infusion per protocol.
223885760|NCT00102921|DRUG|CCX282-B|
223885761|NCT05767229|DRUG|Carvedilol|Carvedilol 0.2 mg/kg for 1.5 hrs
223885762|NCT05654519|DRUG|PENG/LFCN and QL Blocks|Bupivacaine 0.25% injection
223885763|NCT04049747|PROCEDURE|Radical therapy (radiotherapy or prostatectomy [radiotherapy can be external beam or brachytherapy]|Radical therapy (radiotherapy or prostatectomy \[radiotherapy can be external beam or brachytherapy\]
223885764|NCT04049747|PROCEDURE|Focal therapy|Focal therapy (high intensity focused ultrasound or cryotherapy)
223885765|NCT04049747|PROCEDURE|Focal therapy after Finasteride 5Mg tablets for 12 weeks|finasteride 5mg tablets 12 weeks prior to focal therapy
223885766|NCT04049747|PROCEDURE|Focal therapy after Bicalutamide 50Mg tablets for 12 weeks|Bicalutamide 50mg per day - 12 weeks prior to focal therapy
223885767|NCT05426668|OTHER|No Intervention|No Intervention
223885768|NCT00392067|DRUG|Calcipotriol and LEO80122 (LEO19123 cream)|
223885769|NCT03105843|DRUG|Methacholine (MCh) Challenge Testing|Visit 1: Informed consent, Baseline screening and pulmonary function tests and Low-dose methacholine challenge testing using partial and full flow-volume loops.
223885770|NCT03105843|DIAGNOSTIC_TEST|Eucapneic Voluntary Hyperventilation (EVH)|Visit 2 or 3: Will be conducted in random order and subjects will perform one of the two challenge tests at either visit.
223885771|NCT03105843|DRUG|Mannitol Inhalation Kit|Visit 2 or 3: Will be conducted in random order and subjects will perform one of the two challenge tests at either visit.
223885772|NCT05414812|BEHAVIORAL|Multi-component oncofertility care intervention|"The intervention includes:~1. Young breast cancer patients presenting to oncology visits will complete a clinic-based oncofertility needs screen with a member of the clinical team. This needs screen assesses i) desire to have a child in the future, ii) need for contraception, and iii) sexual health/menopause symptoms.~2. A women's health survivorship care plan (SCP) in Spanish and English encompasses content on screening and management strategies for a) fertility concerns/pregnancy health; b) contraception; c) hot flashes and d) sexual health.~3. Oncofertility navigation consists of one telehealth or in-person session with a social worker to: i) assess the patient's oncofertility needs, ii) review the women's health SCP, iii) provide support with the goal of engaging in oncofertility care.~4. Oncofertility consultation as indicated via telehealth or in person will occur between the patient and reproductive specialist. Each consultation is estimated to be 1 hour."
223885773|NCT03222128|DEVICE|TAVR|Implantation of the SAPIEN 3
223885774|NCT05464225|DEVICE|COSD|The exercise protocol will include using the tongue to compress the COSD against the hard palate, or against the tongue depressor for 30 repetitions, 3 times per day, on 3 days of the 7-day week. For the first week, the participants who are in the COSD group will be issued a COSD bulb that corresponds to no less than 60% of their baseline maximum strength. After week 1, they will switch to a COSD bulb that corresponds to no less than 80% of their maximum tongue strength for the remaining 7 weeks.
223885775|NCT05464225|DEVICE|SOC|The exercise protocol will include using the tongue to compress the COSD against the hard palate, or against the tongue depressor for 30 repetitions, 3 times per day, on 3 days of the 7-day week. For the tongue depressor group, they will be given 8 tongue depressors, which are disposable, for the duration of the study.
223885776|NCT05130840|DIAGNOSTIC_TEST|MRI|MRI Brain (unless already done as standard of care within 2 months on enrollment to evaluate for CNS disease) MRI Brain at 2 timepoints 6 months apart (+/- 8 weeks).
223885777|NCT05130840|DIAGNOSTIC_TEST|Lumbar puncture|LP at 2 timepoints 6 months apart (+/- 8 weeks). LP will be performed to analyze cerebrospinal fluid for: cytology, circulating tumor cells and cell-free DNA.
223885778|NCT05412602|PROCEDURE|full spine corrective protocol|36 chiropractic adjustments over 12 weeks (3 visits per week) with in office spinal traction on the 3D Denneroll Traction Table, as well as supplemental home exercises
223885779|NCT05250544|OTHER|control group|For the adolescents in the control group; As soon as the process starts, the stopwatch will be started, and when the process is finished, it will be stopped. When the PCR Test starts, the crying state of the adolescent will be observed and recorded. After the procedure, the adolescent's fear (Childiren's Fear Scala (CFS)) and pain (Wong Baker FACES) related to the procedure will be evaluated separately by the adolescent, parent and observer and recorded in the form.
223885780|NCT06272994|DIAGNOSTIC_TEST|MRSA Nasal Swab PCR|For the subjects assigned to the intervention group who have a negative MRSA nasal swab PCR result, providers will receive a pager alert which inform them of the negative result and will direct clinicians to clinical guidance recommending clinicians to discontinue vancomycin, if clinically appropriate.
223885781|NCT06005129|BEHAVIORAL|Personality-Based Therapy|Participants will be randomized to a 2- or 4-week assessment-only baseline period. After the baseline period, participants will receive the personality-based treatment module corresponding to their highest clinical elevation (i.e., neuroticism, \[low\] conscientiousness, \[low\] agreeableness). Treatment will consist of six weekly 50-60-minute sessions. After the 6-week intervention period, participants will complete a 4-week follow-up period to determine the sustainability of effects observed
223885782|NCT05146388|OTHER|EHR-Based Approach|The intervention will be built directly into the EHR. E-prescriptions will be generated with pharmacy instructions for all prescription medications. The intervention will impart: 1) inclusion with e-Rx request for pharmacy to keep metric-only (mL-only) dosing on Rx label and 2) inclusion of guidance on the e-Rx requesting that the pharmacy give an optimal tool based on an algorithm. Algorithm for dosing tool recommendation: 1) for a prescribed dose of \<= 1mL, optimal tool is 1 mL syringe, 2) for \>1 mL to 5 mL, use a 5 mL syringe, 3) for \>5mL to 10mL, use 10 mL syringe.
223885783|NCT06272630|DRUG|DWJ1464|DWJ1464, TID, Duration of administration: 8 weeks, Visit: every 4 week
223885784|NCT06272630|DRUG|Placebo of DWJ1464|Placebo of DWJ1464, TID, Duration of administration: 8 weeks, Visit: every 4 week
223885785|NCT06428071|OTHER|standard physical therapy|All Patients in the three groups will receive supervised systematic exercise therapy that was performed effectively in previous work. This program consisted of lower limb static, dynamic, and flexibility exer¬cises that targeted the quadriceps, hamstrings, and gluteus muscles; and core strength training for 20 minutes per day. This program will be applied 3 times per week for 6 weeks to all the participants
223885786|NCT06428071|OTHER|knee Decompression|continuous mechanical decompression using 20% of the body weight as a traction force for 15 minutes.
223885787|NCT06428071|OTHER|hot pack|hot pack over the treated knee joint will be applied for 20 minutes. this application will be performed while the patient is receiving the decompression session
223885788|NCT05891860|OTHER|Participation in virtual rounds|Virtual participation in daily ICU team rounds
223885789|NCT04631276|DRUG|TS-091|Subjects received single-dose of 0.1, 0.2, 0.4, 1, 5, 12.5 and 25 mg of TS-091 (tablets or drug substance powder)
223885790|NCT05251389|OTHER|Fecal microbiota transplantation|Fecal microbiota transplantation of an ICI responding or Fecal microbiota transplantation from an ICI non-responding donor, in combination with ICI.
223885791|NCT04608357|DIAGNOSTIC_TEST|Needle Core Biopsies|Not an interventional study
223885792|NCT03905876|OTHER|Questionnaire|Questionnaire to evaluate psychological experience
223885793|NCT05981105|DEVICE|ambIT pump with catheter|0.2% ropivacaine will be infused through a catheter pump at a rate of 10 ml/hr, 600 ml reservoir.
223885794|NCT05981105|DEVICE|ambIT pump with sham catheter|sham catheter with no infusion
223885795|NCT04480853|DRUG|Fingolimod|Fingolimod 0.5 mg QD, oral
223885796|NCT05557123|DEVICE|MEDI-app|MEDI-app based feedback algorithm. The app based feedback algorithm will check and remind the patients of taking medication.
223885797|NCT05391178|OTHER|Lumiton yarn sleeve|Sleeve made from patented technology embedded in synthetic yarns that harnesses the sun's energy and generates red and near-infrared light - elevating apparel
223885798|NCT05391178|OTHER|Lumiton yarn hat|Hat made from patented technology embedded in synthetic yarns that harnesses the sun's energy and generates red and near-infrared light - elevating apparel
223885799|NCT05391178|OTHER|Lumiton yarn shirt|Shirt made from patented technology embedded in synthetic yarns that harnesses the sun's energy and generates red and near-infrared light - elevating apparel
223885800|NCT06514092|OTHER|anti-TNF therapy and seton drainage|Crohn's disease patients who have undergone treatment with anti-TNF therapy and seton drainage.
223885801|NCT05792735|DRUG|Cadonilimab Injection|Cadonilimab, an anti-CTLA-4/PD-1 bispecific antibody, at a dose of 6mg/kg is given in combination with chemotherapy every 2 weeks preoperatively and postoperatively.
223885802|NCT05792735|RADIATION|Short-course radiotherapy|Preoperative short-course radiotherapy (5x5 Gy)
223885803|NCT05792735|DRUG|Consolidation chemotherapy|Oxaliplatin 85 mg/m2, leucovorin 400 mg/m2, 5-fluorouracil bolus 400 mg/m2 on day 1, and 5-fluorouracil infusion 2400 mg/m2 for 48 h) every 2 weeks for total 6 cycles preoperatively and postoperatively.
223885804|NCT05581173|DEVICE|Purastat SAP gel application|Purastat is a fully synthetic matrix scaffold that can be applied through an endoscopic catheter. Purastat is FDA approved and commercially available. Purastat is a peptide solution that self assembles at physiological potential Hydrogen(pH) and forms a gel comprising a network of nanofibers. Its benefits in hemostasis and tissue healing and its biocompatibility have been previously demonstrated in animal models and also in human cases. When the gel comes into contact with blood or tissue fluids, the change in potential hydrogen (pH) and salt concentration causes fiber formation and gelation that block the blood vessels in the hemorrhagic area to generate hemostatic effects and also prevention of scar tissue formation.
223885805|NCT04843384|OTHER|Reiki|Reiki
223885806|NCT04843384|OTHER|Sham reiki|sham Reiki
223885807|NCT05099315|OTHER|not applicable, observational study|Patients undergoing systemic therapy according to international accepted guidelines for the therapy of atopic dermatitis, observational study
223885808|NCT04965753|DRUG|FHD-609|FHD-609 as a single, intravenously administered agent given twice-weekly (BIW). Alternative dosing regimens may be evaluated.
223885809|NCT06472297|DEVICE|The continuous glucose monitoring system|CGM device worn on back of the arm and glucose readings are shown on the participant's smartphone as a continuous data stream.
223885810|NCT05789212|BEHAVIORAL|Personalized Trial ABCCBA|Participants will receive links for 30-minute videos for all three interventions, for 2 weeks each, 3 times per week, in a specified order (ABCCBA), where A-mindfulness, B-yoga, and C-guided walking.
223885811|NCT05789212|BEHAVIORAL|Personalized Trial CBAABC|Participants will receive links for 30-minute videos for all three interventions, for 2 weeks each, 3 times per week, in a specified order (CBAABC), where A-mindfulness, B-yoga, and C-guided walking.
223885812|NCT04961580|DRUG|Ceftazidime Avitbatan Sodium|For 6-18 years children, 62.5 mg/kg/once，q8h ; 3-6 months of age 50 mg/kg/ once,q8h, intravenous administration for 2 hours, daily dose is not more than 2.5g, children will be administrated at least five times.
223885813|NCT06386757|PROCEDURE|Combined Video Laryngoscopy (VL) and Bougie|To compare combined video laryngoscopy and bougie versus direct laryngoscopy and bougie for nasal intubation.
223885814|NCT06386757|PROCEDURE|Combined Direct Laryngoscopy (DL) and Bougie|To compare combined video laryngoscopy and bougie versus direct laryngoscopy and bougie for nasal intubation
223885815|NCT05687539|DIETARY_SUPPLEMENT|Mastiha water|10ml of mastiha water before every meal for one month
223885816|NCT05687539|DIETARY_SUPPLEMENT|Mastiha capsules|2x350mg mastiha capsules before every meal for one month
223885817|NCT05458011|DRUG|Fremanezumab|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous injection"
223885818|NCT05458011|DRUG|Placebo|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous injection"
223885819|NCT06426641|DEVICE|Polyethylene|There is no intervention
223885820|NCT06528457|DRUG|ISLA101|ISLA101 is an oral gelatin capsule containing 100 mg of fenretinide (N-\[4-Hydroxyphenyl\]retinamide, mw 391.56) dissolved in corn oil and polysorbate 80. ISLA101 capsules will be administered orally as one dose of 300 mg/m2 each 12 hours (q12 +/-1 h).
223885821|NCT06528457|DRUG|Dengue 1 Live Virus Human Challenge (DENV-1-LVHC)|The DENV-1-LVHC investigational challenge material consists of the dengue-1 virus strain 45AZ5 as a powder, lyophilized for reconstitution. The product is reconstituted with 0.7 mL of water for injection (WFI) and diluted to a concentration of 6.5 x 103 PFU/mL.
223885822|NCT06528457|OTHER|Placebo|Placebo capsules will be administered orally as one dose of 300 mg/m2 each 12 hours (q12 +/-1 h).
223885823|NCT06045078|OTHER|Elequil Lavender-peppermint Aromatabs|100% pure essential oils Lavender-peppermint aromatabs purchased through Beekley Medical
223885824|NCT06045078|OTHER|Elequil Almond-Oil Aromatabs|100% pure essential oils Almond-oil aromatabs purchased through Beekley Medical
223885825|NCT05859724|BIOLOGICAL|NM26-2198|IL-4R/IL-31 bispecific antibody for subcutaneous administration
223885826|NCT05859724|OTHER|Placebo|Placebo for NM26-2198
223885827|NCT06067698|DRUG|"Mesalamine and alpha-lipoic acid"|Mesalamine 1000 mg every 8 hrs. + alpha-lipoic acid 600 mg once daily for 3 months
223885828|NCT06067698|DRUG|"Mesalamine and Placebo"|Mesalamine 1000 mg every 8 hrs. + Placebo once daily for 3 months
223885829|NCT05344534|BEHAVIORAL|Leadership and Organizational Change for Implementation|LOCI is data driven leadership development and coaching for clinic managers and working with agency executives and middle managers to foster a strategic implementation climate
223885830|NCT04353869|BIOLOGICAL|Bio collection|venous blood sampling and collection of urine
223885831|NCT03820830|DRUG|Palbociclib 125mg|Palbociclib 125 mg oral tablet taken daily for 3 years from randomization
223885832|NCT03820830|DRUG|Standard endocrine therapy|Aromatase inhibitor (anastrozole or exemestane or letrozole) oral daily tablet, or Selective Estrogen Receptor Modulator (SERM) such as tamoxifen oral daily tablet or fulvestrant (Faslodex) injection once every 2 weeks for 3 doses then every month. Premenopausal women and men may also receive an LHRH (luteinizing hormone-releasing hormone) agonist by injection. Standard endocrine therapy will be given for at least 3 years from randomization.
223885833|NCT03997968|DRUG|CYT-0851|Part A and B: Daily oral doses of CYT-0851 for 28 day cycles
223885834|NCT03997968|DRUG|CYT-0851 in combination with gemcitabine|Part D: Daily oral doses of CYT-0851 for 28 days in combination with gemcitabine
223885835|NCT03997968|DRUG|CYT-0851 in combination with capecitabine|Part E: Daily oral doses of CYT-0851 for 21 days in combination with capecitabine
223885836|NCT03997968|DRUG|CYT-0851 in combination with rituximab and bendamustine|Part C: Daily oral doses of CYT-0851 for 28 days in combination with rituximab and bendamustine
223885837|NCT04997473|BEHAVIORAL|W8L2G mobile health (mHealth) app|Weight loss phone app based on addiction principles. This intervention has been validated in two prior studies. Participants will also interact with coaches throughout the intervention
223885838|NCT04643366|DRUG|Chemotherapy|Neoadjuvant chemotherapy with 2 months of combination oxaliplatin and 5-Fluorouracil, leucovorin, and oxaliplatin (mFOLFOX)
223885839|NCT04643366|RADIATION|Radiation Therapy|Pelvic Intensity-modulated radiation therapy (IMRT)
223885840|NCT06466148|DEVICE|JessieHug|Assessment of JessieHug device when placed on infants.
223885841|NCT05975047|DRUG|LIV001|Part A- Participants will receive single dose of 280mg capsule on day 1 under fasting conditions; Part B- Participants will receive multiple doses of 280mg capsule from day 1 to day 14 under fasting conditions;
223885842|NCT05975047|DRUG|Placebo|Participants will receive matching placebo across Part A and B of the study
223885843|NCT05404880|DEVICE|EDWARDS INSPIRIS RESILIA Aortic Valve|Surgical replacement of the aortic valve with the INSPIRIS RESILIA Aortic Valve.
223885844|NCT06374394|BIOLOGICAL|RSVPreF3 OA investigational vaccine|1 dose of RSVPreF3 OA investigational vaccine is administered intramuscularly on Day 1 to participants in the Co-ad Group and on Day 31 to participants in the Control Group.
223885845|NCT06374394|BIOLOGICAL|COVID-19 mRNA vaccine|1 dose of COVID-19 mRNA vaccine is administered intramuscularly on Day 1 to participants in the Co-ad and Control Groups.
223885846|NCT06986681|OTHER|Big toe muscles strengthening exercises|16 Participants will be in experimental group giving them Big toe muscles strengthening exercises protocol along with their normal sports training plan for eight weeks, measuring all values before giving them protocol and after protocol
223885847|NCT06986681|OTHER|Big toe muscles strengthening exercises with neuromuscular training|16 Participants will be in experimental group giving them Big toe muscles strengthening exercises and neuromuscular training protocol along with their normal sports training plan for eight weeks, measuring all values before giving them protocol and after protocol.
223885848|NCT06987578|OTHER|OMT vs. Ibruprofen|OMT vs. Standard Therapy in the Management of Acute Neck and Low Back Pain in the Emergency Department
223885849|NCT06986746|OTHER|Hypertension Crisis Awareness Program|Education materials-consist of description about hypertension crisis, symptoms, causes and preventive measures (emphasizing on healthy lifestyle and physical activity) with pictorial presentation.
223885850|NCT06988085|OTHER|Blood sampling|Before and after fludarabine infusion
223885851|NCT06987851|BIOLOGICAL|Divozilimab|Intravenous infusion of BCD-132 every 24 weeks
223885852|NCT05158127|BIOLOGICAL|AlloRx|cultured allogeneic adult umbilical cord derived mesenchymal stem cells
223885853|NCT04913805|DRUG|Potassium Nitrate|Potassium Nitrate is the active intervention that may increase blood flow to exercising muscle
223885854|NCT04913805|DRUG|Potassium Nitrate + Propionyl-L-Carnitine + Nicotinamide Riboside|Potassium Nitrate + Propionyl-L-Carnitine + Nicotinamide Riboside will be used as a combination intervention to both increase blood flow (KNO3) and mitochondrial function (PLC + NR)
223885855|NCT04913805|OTHER|Potassium Chloride|Active control
223885856|NCT06873776|DEVICE|A&L cycling|Participants will complete simultaneous arms and legs cycling for 60min of active cycling. Targeted exercise intensity is 70-85% of the age-predicted maximum heart rate. Cycling resistance will be modified for continuous challenge. A target speed 10% above the highest speed at which each study participant is able to cycle voluntarily without motor, FES, or tSCS assistance will be selected during the first session and maintained throughout all training sessions. Once a participant can complete 60 minutes of continuous cycling at a specific resistance for two consecutive training sessions, the resistance will be increased to the next setting level at the mid-point of the subsequent session. Upon completion of each session, the physical therapists/researcher will complete skin checks to ensure no adverse effects have occurred. Heart rate, blood pressure, and oxygen saturation will be recorded. Participants will complete 3 training sessions per week for 12 weeks.
223885857|NCT06873776|DEVICE|Body weight supported treadmill training (BWSTT)|The physical therapists/researchers will assist the patient with donning any necessary lower extremity braces and a padded walking harness. The patient will be assisted onto the treadmill via a ramp while seated in a wheelchair or by ambulation with physical assistance, clipped into the body weight support system, assisted to stand, and provided the appropriate amount of body weight support to allow for successful stepping for 60 minutes of active walking. During BWSTT, physical therapists/trainers will adjust treadmill speed or incline and the degree of body weight support to challenge participants. Participants will be instructed to exercise with a targeted intensity of 70-85% of the age-predicted maximum heart rate. Upon completion of each session, the harness will be doffed with skin checks to ensure no adverse effects have occurred. Heart rate, blood pressure, and oxygen saturation will be recorded. Participants will complete 3 training sessions per week for 12 weeks.
223885858|NCT04053816|DRUG|Potassium|"The trial treatment will start when patients are admitted to the intensive care unit after their surgery. The patient will undergo regular blood investigations, as per current practice. The frequency of K+ monitoring while on ICU will be according to clinician / nursing staff preference.~Potassium supplementation will be according to local hospital protocols. This can be either via an intravenous infusion or as a tablet. Patients will otherwise be treated as per current hospital protocol."
223885859|NCT06693817|DEVICE|Wireless skin sensors vital sign monitoring system|The wireless monitoring system will be applied to the newborn and consist of a chest sensor (Anne Arc by Sibel Inc.) and a RAD-7 (Masimo)pulse oximeter limb sensor.
223885860|NCT06693817|DEVICE|Wired vital sign monitoring system|A standard ECG and SpO2 monitoring device will be applied suing the Infinity M540 monitor (Draeger, Germany). The chest sensor will be placed as per standard of care on the newborn's chest and abdomen, and the SpO2 sensor on their hands or feet.
223885861|NCT00909025|DRUG|Claudiximab|"Patients receive Claudiximab as intravenous infusion over 2 hours on day 1. Cohorts of 3-6 patients receive escalating doses of Claudiximab until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which no dose-limiting toxicity (DLT) is diagnosed in 3 patients or no more than 1 out of 6 patients exhibits a DLT.~After completion of study treatment, patients are followed for 4 weeks."
223885862|NCT04526678|DIETARY_SUPPLEMENT|Iron supplement (27mg)|The participants will be randomized to an intervention group or a control group. The intervention group will ingest 27mg iron daily for three months.
223885863|NCT06699264|OTHER|Blood Flow Restriction Training|Pressure cuff is applied to the leg during training for low-load strength training with simultaneous restiction of blood flow
223885864|NCT06699264|OTHER|Training without BFR|Strength training according to experimentral group without simultaneous restriction blood flow
223885865|NCT06146959|DEVICE|Corrective Kinesiology taping|corrective kinesiology tape is a form of biomechanical tape that is used with specific tension to get a corrective effect
223885866|NCT06146959|OTHER|Home exercise program|Intrinsic foot strengthening and stretching exercises
223885867|NCT04954898|DEVICE|Study Lens: TECNIS Multifocal Toric 1-piece lens, Model ZMT|Surgeons will perform standardized, small-incision, cataract surgery and implant the study lenses using a JJSV-validated insertion system qualified for use with TECNIS Multifocal Toric 1-Piece IOL.
223885868|NCT06710795|DEVICE|MaxTack™ Motorized Fixation Device|All subjects enrolled will receive the MaxTack™ Motorized Fixation Device when used for fixation of prosthetic material to soft tissue in minimally invasive ventral hernia repair
223885869|NCT06703814|OTHER|Intraoperative flow-controlled ventilation strategy|"In the FCV group, intraoperative ventilation will be provided with the EVONE (IES Ventinova Medical).PEEP and Ppeak are titrated guided by dynamic compliance, as follows: Starting from a default setting of 5 cmH2O of PEEP and 15 cmH2O of Ppeak, PEEP and Ppeak are equally increased by 1 cmH2O steps and the PEEP value with the highest VT and thus highest dynamic compliance is defined as best PEEP. Subsequently, Ppeak is stepwise (+1 cmH2O) increased until there is no further over-proportional increase in tidal volume (VT) (i.e. measured VT \> expected VT according to measured dynamic compliance), defined as best driving pressure. No recruitment maneuvers are carried out during FCV. With the I:E ratio set to 1:1, flow is adjusted to establish normocapnia (target etCO2 4.5 to 5.8 kPa). FiO2 is adjusted to maintain oxygen saturation (SpO2) \> 92%."
223885870|NCT06703814|OTHER|Intraoperative pressure-controlled ventilation strategy|In the PCV group, intraoperative ventilation will be provided by a standard anesthesia ventilator in use in the respective participating centers. Patients will be ventilated in PCV mode, at the lowest inspired oxygen fraction (FiO2), to maintain oxygen saturation (SpO2) \> 92%. It is left to the discretion of the attending anesthesiologist to use a higher fraction of FiO2. Inspiratory to expiratory ratio is set at 1:1 to 1:2, respiratory rate will be adjusted to target normocapnia (target etCO2 4.5 to 5.8 kPa. VT will be set at 7 to 9 ml/kg predicted body weight (PBW). The PBW is calculated according to a predefined formula: 50 + 0.91 x (centimeters of height - 152.4) for males and 45.5 + 0.91 x (centimeters of height - 152.4) for females. Ventilation starts with 5 cm H2O PEEP, and can be increased to 10 cm H2O PEEP.
223885871|NCT06702852|DEVICE|NIRS imaging in addition to SOC|The intervention group will receive the standard of care per the facility Standard Operating Procedures (SOP) with the addition of NIRS imaging utilizing the SnapshotNIR
223885872|NCT06877247|DRUG|[14C] SHR6508 Injection|\[14C\] SHR6508 injection.
223885873|NCT06926348|BEHAVIORAL|Digital Health Technology for Chronic Insomnia|A mobile application designed to support chronic insomnia management through digital self-monitoring of sleep patterns, personalized sleep hygiene education, cognitive strategies, relaxation and mindfulness exercises, and chatbot interactions. Users receive tailored notifications and educational content to encourage healthy sleep behaviors over an 8-week period. Existing pharmacological treatments prescribed prior to study enrollment continue unchanged
223885874|NCT06926348|BEHAVIORAL|Treatment as Usual (TAU)|Participants receive standard sleep hygiene recommendations via a printed educational booklet. They maintain printed sleep diaries for daily self-monitoring throughout the 8-week intervention. Existing pharmacological treatments prescribed prior to study enrollment continue unchanged.
223885875|NCT05242640|OTHER|Mindful attention|Participants will listen to mindful attention audio recordings via headphones
223885876|NCT05242640|OTHER|Exercise|Participants will complete a moderate-intensity walking program
223885877|NCT05242640|OTHER|Exercise with mindful attention|Participants will complete a moderate-intensity walking program while listening to mindful attention audio recordings via headphones
223885878|NCT06733324|BEHAVIORAL|SCERTS (Social Communication, Emotional Regulation, Transactional Support)|"The SCERTS (Social Communication, Emotional Regulation, and Transactional Support) intervention is a comprehensive, multidisciplinary approach specifically tailored to address the unique needs of children with Autism Spectrum Disorder (ASD) aged 3-6 years. Unlike traditional behavioral therapies such as Applied Behavior Analysis (ABA), SCERTS emphasizes a developmental framework, focusing on enhancing social communication, emotional regulation, and environmental support. It incorporates family involvement and integrates strategies into naturalistic settings, ensuring skill generalization across home, school, and community environments.~This intervention is distinguished by its individualized goals based on each child's developmental profile and its emphasis on fostering meaningful interactions rather than relying on compliance-based methods. SCERTS also incorporates transactional supports, such as modifying the physical and social environment to promote engagement and reduce stress, w"
223885879|NCT06733324|BEHAVIORAL|Behavioral Treatment, Speech Therapy|The control group will be the treatment as usual group receiving conventional behavior therapy and speech therapy
223885880|NCT06733012|DEVICE|Splanchnic nerve block|Catheter based ablation on the right greater splanchnic nerve
223885881|NCT06733012|OTHER|Sham-control procedure|Sham-control ablation procedure
223885882|NCT06741020|DRUG|Adebrelimab, Oxaliplatin, Fluorouracil,Leucovorin|Chemotherapy drugs including Oxaliplatin, Fluorouracil,Leucovorin and immunotherapy durgs Adebrelimab will infuse to liver by transarterial catheter toward to the lesion.
223885883|NCT06743997|DRUG|Test Drug (Eutropin Catridge, 48IU/Cartridge)|Liqid somatropin
223885884|NCT06743997|DRUG|Reference Drug (Eutropin, 4 IU/vial)|Lyophilized somatropin
223885885|NCT06747234|OTHER|Oat bran group|Patients consume 28 grams of oat bran daily for two months in addition to their usual medical treatment.
223885886|NCT06747234|OTHER|Control (Standard treatment)|Patients receive standard medical treatment.
223885887|NCT05976165|OTHER|Breath Testing|Subjects drink a small carbohydrate solution, and then provide a breath sample every 15 minutes for one hour, and then every 30 minutes for the next two hours
223885888|NCT06885047|BEHAVIORAL|Socio-Cognitive Behavioral Therapy for Suicidal Behavior (SCBT-SB)|SCBT-SB is a manualized psychosocial treatment protocol developed specifically with and for L/H youth with suicidal ideation and behaviors. Clinician, adolescents, and caregivers' manuals are available in both Spanish and English. SCBT-SB protocol's main conceptual framework and strategies are informed by Cognitive Behavioral Therapy concepts, psychoeducation, and adolescent parenting strategies. The intervention involves individual, caregivers, and family sessions. SCBT-SB, while maintaining the basic principles of CBT, was further developed to include developmental (e.g., identity), and cultural elements of L/H families (e.g., family communication, language). The protocol has two main phases. Phase 1, the Crisis Module, includes nine standard core sessions, and Phase 2, which proposes a flexible number of sessions, focused on the delivery of interchangeable coping skills modules and the acquisition of skills that reduce STB.
223885889|NCT06885047|BEHAVIORAL|Treatment as usual|TAU consists of eclectic brief treatments, including some CBT or psychodynamic strategies that are applied with adolescents or in conjunction with the caregiver. In all cases, psychoeducation is provided to adolescents and their caregivers. Occasionally, they may be referred to some family therapy intervention. All treatments are brief therapy, provided by clinical psychologists and are intended to address the cognitive, emotional, and family factors that affect the adequate psychosocial functioning of the adolescent.
223885890|NCT06900946|OTHER|gluten|The intervention group will receive 3 grams of gluten powder daily
223885891|NCT06900946|OTHER|cornstarch|The control group will receive 3 grams of cornstarch powder daily
223885892|NCT06782321|BEHAVIORAL|modified Cognitive Behavioral Therapy (mCBT)|"The theoretical model underling Cognitive Behavioral Therapy (CBT) explains the interaction of thoughts, feelings, and behaviors during life situations. This model suggests that a person's thoughts/feeling/behaviors affect their functioning during life situations. This contrasts with a common belief that one's functioning during life situations is the only way to effect thoughts/feelings/behaviors. Applied to stroke, this model suggests that the stroke survivor can alter his/her functioning during life situations by altering his/her thoughts/feelings/behaviors. The purpose of CBT is to empower the person with the skills to alter his/her thoughts/feelings/behaviors in order to positively affect function in life situations.~The mCBT intervention includes 4 elements: psychoeducation, education about unhelpful thinking, behavioral activation therapy, education on sleep hygiene, and relaxation training."
223885893|NCT06782321|BEHAVIORAL|Occupational or Speech Therapy|"If the participant demonstrates aphasia of any severity level on the Revised Western Aphasia Battery (WAB-R) assessment given at the PRE session, the subject will receive ST, provided by a Speech Language Pathologists (SLP), stroke telerehabilitation. If there is no aphasia, the subject will receive OT stroke telerehabilitation.~The OT and ST stroke telerehabilitation sessions will utilize a similar metacognitive strategy training approach which is focused on enabling the stroke survivor to re-engage with meaningful life activities. In the Occupational Therapy literature this approach is called Cognitive Orientation to Occupational Performance (CO-OP) and in the Speech Language Pathology Literature this approach is called the Life Participation Approach to Aphasia (LPAA).~Telerehabilitation CO-OP and LPAA within the OT or ST session include three common elements: Shared decision-making for goal setting, guidance/coaching from the therapist, and self-evaluation."
223885894|NCT06781892|OTHER|Anterior-lateral pad positioning|Defibrillation pads positioned anterior-lateral
223885895|NCT06781892|OTHER|Anterior-posterior pad positioning|Defibrillation pads positioned anterior-posterior
223885896|NCT06781892|OTHER|Double-sequential defibrillation|Combination of anterior-lateral and anterior-posterior pad positioning for a total of 4 pads and 2 shocks.
223885897|NCT06754683|BEHAVIORAL|8 weeks Self-compassion based psycho-education|The Self-compassion psychoeducational intervention will be utilized as the intervention in this study will be delivered by the first investigator and supervised by the Principal investigator, who has experience in mindfulness and self-compassion practices. It will consist of eight weekly 1.5 hours of face-to-face sessions and 1 hour each week of online sessions. Each session will be according to a specific topic that will cover the objectives of the study, incorporating the concept of self-compassion interventions based on the research literature and input from experts in the field, taking into consideration the needs of the participants. Participants will be required to have at least 80% of attendance for intervention completion.
223885898|NCT06791382|DIAGNOSTIC_TEST|AI-Based Diagnostic and Prognostic Model|This intervention involves an AI system that integrates multimodal data, including patient medical history, laboratory test results, clinical observations, and treatment data, to predict the risk of hospital-acquired infections (HAIs). The system uses deep learning algorithms to provide real-time, accurate predictions, enabling early identification of patients at risk for infections. By analyzing historical health data, the model aims to predict potential infection developments, improving early detection, prevention strategies, and patient outcomes in hospital settings.
223885899|NCT04890249|DEVICE|Investigational IOL Model C1V000|IOL replaces the natural lens removed during cataract surgery.
223885900|NCT04890249|DEVICE|Investigational IOL Model C2V000|IOL replaces the natural lens removed during cataract surgery.
223885901|NCT04890249|DEVICE|Control IOL Model ICB00|IOL replaces the natural lens removed during cataract surgery.
223885902|NCT06792331|PROCEDURE|vNOTES high uterosacral ligament suspension|Following the entry into the peritoneal cavity via apical colpotomy, a transvaginal retractor was inserted through the vaginal vault and the vaginal access platform was established. The ureters and uterosacral ligaments (USL) were identified via laparoscopic view. Bilateral nonabsorbable sutures were placed by the intermediate portions of the USL at the level of the ischial spines making up a total of 4 stitches (Figure 1). Then, the sutures were slightly weighed to verify proper placement. Then, the V-notes platform was removed and the peritoneum was closed. The aforementioned sutures were fixed to the ipsilateral cardinal ligament stump and the pubocervical fascia on the anterior wall. Finally, the previously mentioned nonabsorbable sutures were attached to the vaginal cuff and tied. Routine postoperative cystoscopy was performed.
223885903|NCT06792331|PROCEDURE|Laparoscopic lateral suspension|The polypropylene mesh used had a width of 2.5 cm and a length of 25 cm. The vaginal cuff was suspended. Blunt dissection was applied to develop vesicovaginal and rectovaginal spaces. The middle part of the mesh was placed flatly in the vesicovaginal space, and fixed with non-absorbable sutures. An atraumatic laparoscopic instrument was inserted through skin incisions of approximately 2-3 mm approximately 3 cm above and 4 cm lateral to the anterior superior iliac spine, followed by perforation only of the aponeurosis of the external oblique muscle and retroperitoneal advancement of the instrument through the lateral abdominal wall. Under laparoscopic visualization, the instrument moved through the bilateral tension-free retroperitoneal tunnels created. The lateral arms of the mesh were secured bilaterally to the aponeurosis of the external oblique muscle and behind the anterior superior iliac spine. Finally, the peritoneum was closed.
223885904|NCT05527093|RADIATION|MRI 3T and MRI 7T|MRI 3T and MRI 7T before and post epilepsy surgery
223885905|NCT03432832|BEHAVIORAL|EASE|Weekly behavioral sessions with therapist to work on emotional control through measures such as mindfulness.
223885906|NCT03432832|BEHAVIORAL|Supportive Therapy|Weekly behavioral sessions with a therapist to work on emotional control
223885907|NCT06754579|OTHER|High-Volume Upper Extremity Exercises Training|The group will be trained 3 days a week for a total of 8 weeks.
223885908|NCT06754579|OTHER|Low Volume Upper Extremity Exercises Training|The group will be trained 3 days a week for a total of 8 weeks.
223885909|NCT06728176|DRUG|MT1988|Active Drug
223885910|NCT06728176|DRUG|Placebo|Placebo comparator
223885911|NCT06926686|PROCEDURE|Autologous tarsus|Surgical implantation of autologous tarsus to the lower eyelid
223885912|NCT06926686|PROCEDURE|Acellular dermal matrix|Surgical implantation of acellular dermal matrix to the lower eyelid
223885913|NCT04839302|DRUG|Indocyanine green solution|Patients with clinical suspicion of necrotizing fasciitis would receive a weight-appropriate IV dose of indocyanine green (ICG, FDA-approved) with immediate fluorescence imaging of the affected body part and simultaneous imaging of an unaffected region
223885914|NCT07077512|DRUG|Autoleucel (Relmacabtagene Autoleucel)|Relmacabtagene Autoleucel will be reinfused 2 to 7 days after lymphodepletion (fludarabine + cyclophosphamide).
223885915|NCT07077512|DRUG|Sintilimab (PD-1 inhibitor)|Patients will receive intravenous Sintilimab (200 mg every 3 weeks) starting on Day 28 after reinfusion, continuing until disease progression or intolerable toxicity, with a maximum duration of 1 year.
223885916|NCT06902506|BEHAVIORAL|Augmented Music|The music is augmented by embedding the natural rhythms of bodily functions (e.g. breathing, heart rate variability, vascular tone, etc) that signal the body to calm.
223885917|NCT06902506|BEHAVIORAL|Non-Augmented Music|Same melodic theme without the augmentation.
223885918|NCT05339490|DRUG|Progenitor Biological Bandages|"The patients candidates for a skin autograft and a consequent Donor Site Wound (DSW) creation with a dermatome will be randomized between 2 treatment arms. As soon as DSW is created and according to randomization results, PBB will be placed on the wound and maintained in place with the help of classical bandages for a maximum of 15 ± 1 days with dressing's changes at Day 5 ± 1 and Day 10 ± 1. Old PBB will be replaced by new ones according to the local procedure.~Pictures will be taken at each change and on-site evaluation of the wound healing (% of re-epithelialization) will be done by the surgeon. If the DSW is not closed at D15 ± 1, Jelonet® will be used to cover the skin until complete skin closure. If the wound is closed after 15 ± 1 days or before, the scar will then be topically treated with cream as standard treatment. All patients will be followed until 5 years according to the long-term evaluation calendar to monitor long-term skin quality."
223885919|NCT05339490|DEVICE|Jelonet|"The patients candidates for a skin autograft and a consequent Donor Site Wound (DSW) creation with a dermatome will be randomized between 2 treatment arms. As soon as DSW is created and according to randomization results, Jelonet, as standard bandages, will be placed on the wound and maintained in place with the help of classical bandages for a maximum of 15 ± 1 days with dressing's changes at Day 5 ± 1 and Day 10 ± 1.~Pictures will be taken at each change and on-site evaluation of the wound healing (% of re-epithelialization) will be done by the surgeon. If the DSW is not closed at D15 ± 1, Jelonet® will be used to cover the skin until complete skin closure. If the wound is closed after 15 ± 1 days or before, the scar will then be topically treated with cream as standard treatment. All patients will be followed until 5 years according to the long-term evaluation calendar to monitor long-term skin quality."
223885920|NCT06930989|DEVICE|Positive airway pressure (PAP)|Intervention as part of routine clinical care. Data from national registries.
223885921|NCT07078734|OTHER|Foam roller technique|In this intervention group, the patient is given back and forth oscillations using his or her own weight using a foam roller under the supervision of a physiotherapist.
223885922|NCT07078734|OTHER|Mulligan Straight Leg Raise Technique|This intervention consists of the mulligan straight leg raise technique applied to the patient by a physiotherapist.
223885923|NCT06361758|DRUG|Cadonilimab+Lenvatinib|Cadonilimab (AK104): 15mg/kg Q3W iv D1 + Lenvatinib: 8 mg (body weight \<60 kg) or 12mg (body weight ≥60 kg) orally QD. Eligible patients will receive AK104 plus Lenvatinib until disease progression or withdrawn ICF or death, whichever comes first.
223885924|NCT04871893|DEVICE|multiECCO2R blood-gas exchanger|Treatment with the blood-gas exchanger multiECCO2R for CO2 removal
223885925|NCT06077812|BEHAVIORAL|RELAXaHEAD Smartphone App|Participants will receive access to the smartphone application RELAXaHEAD, which contains features for migraine self-management including a headache diary.
223885926|NCT06077812|BEHAVIORAL|In-Person Training|Participants will receive in-person training in migraine self-management techniques.
223885927|NCT06077812|BEHAVIORAL|Virtual Training|Participants will receive virtual training in migraine self-management techniques.
223885928|NCT06537258|BEHAVIORAL|Biofeedback Enhanced Treatment|"At all 4 assessment points (T1-T4), HRV will be measured using the ECG module of the mobile MindWare system at a sampling rate of 500 Hz, and a Skin Conductance Response (SCR) will be collected at a sampling rate of 10 Hz using eSense for iPad. Electrodes to assess SCR and HRV will be attached to patients during an \~10-minute period.~A 5-minute initial baseline assessment will occur first followed by three 5-minute stress trials.~Stress tasks will be audio recorded to measure study fidelity, and participants will be asked to rate their subjective level of stress with each trial. At all assessment points (T1-T4), participants will be provided with stool collection kits to collect a stool sample within 3 days of the laboratory psychophysiological assessment.~At all assessment points (T1-T4), a blood draw of approximately 3 ml of blood will be collected."
223885929|NCT06786338|DRUG|SGB-9768|SGB-9768 for subcutaneous (SC) injection
223885930|NCT05385965|BEHAVIORAL|Meaning-Centered Pain Coping Skills Training|The goal of this intervention is to help participants reduce pain interference so that they can engage with what gives them a sense of meaning, purpose, and peace.
223885931|NCT05045183|DEVICE|SoC Adhesive Bandage|On the randomized wound site, a SoC adhesive bandage will be applied.
223885932|NCT05045183|DRUG|Antibiotic Ointment|On the randomized wound site, a antibiotic ointment will be applied.
223885933|NCT05045183|DRUG|Antiseptic Wash|On the randomized wound site, a antiseptic wash will be applied.
223885934|NCT05045183|DEVICE|Hydrocolloid Pad|On the randomized wound site, hydrocolloid pad will be applied.
223885935|NCT03818802|DIETARY_SUPPLEMENT|Nicotinamide Riboside|It will be administered a total of 1000 mg/day of NR in a regimen of 500mg every 12 hours by mouth for 4.5 months. After 4.5 months, an advanced individual training (AIT) will be implemented in addition to administration of 1000mg/day (500mg every 12 hours) for 6 weeks more, completing total of 6 months.
223885936|NCT03818802|DIETARY_SUPPLEMENT|Placebo|It will be administered a correspondent placebo with the same shape and color as the active pill 12 hours by mouth for 4.5 months. After 4.5 months, an advanced individual training (AIT) will be implemented in addition to administration of correspondent placebo every 12 hours for 6 weeks more, completing total of 6 months.
223885937|NCT05872022|OTHER|No Intervention|This is a non-interventional study, therefore no intervention is used.
223885938|NCT06275529|PROCEDURE|Transforaminal Epidural Steroid Injection|"Epidural injections have been used since about 1900 for the treatment of low back and lower extremity pain, with steroids added to local anesthetics in about 1950. The epidural space can be entered by 3 approaches: caudal, interlaminar, and transforaminal. Transforaminal Epidural Steroid Injections:~After the patient is monitored in pron position and asepsis is ensured, the epidural space is entered with the appropriate needle through the transforaminal space by giving the necessary angles to the fluoroscopy. Then the location is confirmed with radiopaque agent and steroid injection is performed. The procedure takes 15-20 minutes."
223885939|NCT05701748|OTHER|Stimuli|placement of oral pacifier, electrical stimulation, and laryngoscopy
223885940|NCT05865899|PROCEDURE|valgus producing medial opening wedge high tibial osteotomy|Valgus producing Opening wedge high tibial osteotomy will be performed through a medial incision at the proximal tibia and stabilized with a plate and screws. Hardware will be removed within 10-12 months to avoid soft tissue irritation.
223885941|NCT06782581|BEHAVIORAL|Contribution to Caregivers Well-Being|Contribute to caregiver's well-being via household tasks.
223885942|NCT06782581|BEHAVIORAL|Control|factually describe either (1) immediate environment, (2) the weather, or (3) organization of closet
223885943|NCT06783972|BEHAVIORAL|Touching|In the second stage of birth, when the baby's head crowns, the mother is allowed to touch the baby's head as much as she wants and with as many fingers as she wants.
223885944|NCT03803332|BEHAVIORAL|Exposure Therapy|Psychotherapy including imaginal and in vivo exposure for PTSD.
223885945|NCT03803332|BEHAVIORAL|Interpersonal Psychotherapy|Psychotherapy that focuses on the effects of PTSD on current interpersonal functioning.
223885946|NCT02829060|DRUG|Nitrofurantoin 100 MG, 7d|7 day course, 100 mg twice daily, PO
223885947|NCT02829060|DRUG|Gentamicin, 5mg/kg|Peri-operative dose: 5 mg/kg of ideal body weight, IV
223885948|NCT02829060|DRUG|Ampicillin 2g|Peri-operative dose: 2 grams, IV
223885949|NCT02829060|DRUG|Nitrofurantoin 100 mg, 48 hrs|48 hour course, 100 mg twice daily, PO
223885950|NCT02829060|DRUG|Gentamicin, 80 mg, 7d|7 day course, 80 mg daily, IM or IV
223885951|NCT02829060|DRUG|Gentamicin, 80 mg, 48hr|48 hour course, 80 mg daily, IM or IV
223885952|NCT01220154|DRUG|Paclitaxel|Cycle 1 Day 1, 8, 15 IV 60-80mg mg/m2 as a 1 hour infusion. For cycle 2-6 Day 1,8,15 IV 60-80 mg/m2 as 1 hour infusion. Repeat every 3 weeks times 5 cycles.
223885953|NCT01220154|DRUG|Carboplatin|Intraperitoneal Day 1 cycles 1-6 AUC
223885954|NCT01220154|DRUG|Bevacizumab|Bevacizumab 15 mg/kg intravenous infusion Day 1 cycles 2-6 Optional cycles 7-22 15 mg/kg intravenous infusion Day 1 every 21 days
223885955|NCT03360838|OTHER|CogCheck|Performance of study participants in the application
223885956|NCT05975385|DEVICE|Acupuncture|Acupuncture at points points PC 6 bilaterally, LI 4 bilaterally, and Yin Tang
223885957|NCT04775589|BEHAVIORAL|Stepped Exercise for Knee Osteoarthritis|Patients start with a home-based exercise program, supported by an internet-based tool (Step 1). Patients are then assessed for degree of improvement in symptoms, and then can step up sequentially to telephone or video-based physical activity coaching (Step 2) and physical therapy (Step 3) if they do not make clinically relevant improvements in prior steps
223885958|NCT06039644|DIETARY_SUPPLEMENT|Probiotic|Three-strain probiotic supplement includes Lactobacillus reuteri GMNL-89 (alive), Lactobacillus plantarum GMNL-141 (alive) and Lactobacillus paracasei GMNL-133 (alive).
223885959|NCT06039644|OTHER|Placebo|Same additives to Probiotic group but replace probiotics with corn starch and Maltodextrin.
223885960|NCT05148780|DIAGNOSTIC_TEST|Nasal Swab Sample|Nasal swab sample will be used to screen participants for detection of viral pathogens. No intervention or study drug will be administered as part of this study.
223885961|NCT05705440|BIOLOGICAL|RSVPreF3 vaccine|No intervention is administered in this extension study. Participants received the RSVPreF3 vaccine during the prior RSV MAT studies (RSV MAT-001, RSV MAT-004, RSV MAT-010, RSV MAT-011, RSV MAT-009, RSV MAT-012 and RSV MAT-039) according to the vaccination schedule specific to each study. In all prior RSV MAT studies, participants received one dose of RSVPreF3 vaccine except in RSV MAT-011 study, where some participants received a second dose as well.
223885962|NCT05705440|OTHER|Control|No intervention is administered in this extension study. Participants received any control (placebo, Tdap or influenza vaccine) during the prior RSV MAT studies (RSV MAT-001, RSV MAT-004, RSV MAT-010, RSV MAT-011, RSV MAT-009, RSV MAT-012 and RSV MAT-039) according to the vaccination schedule specific to each study. In all prior RSV MAT studies, participants received one dose of any control (placebo, Tdap or influenza vaccine).
223885963|NCT06066944|OTHER|Thai Foot Massage|It is the application of Massage through specific techniques and pressure to the feet and lower legs to promote relaxation, improve circulation, and enhance overall well-being. It is a traditional therapeutic practice originating from Thailand and is often performed by trained practitioners. Thai foot massage is often based on traditional Thai massage techniques. The researcher is duly certified for the administration of Thai Foot Massage.
223885964|NCT01526798|DEVICE|Theralite (high cut-off hemodialysis)|Hemodialysis with Theralite dialyzer alternating with standard high-flux dialyzer
223885965|NCT01526798|DEVICE|Conventional high-flux dialyzer|
223885966|NCT04985695|DRUG|Epidural analgesia|All patients received local anesthesia (3-5 ml of 2% Lidocaine). During the preoperative induction of anaesthesia a catheter was inserted 4cm into the epidural space. The catheter will be load during the intervention (0.1 ml/kg/h). In postoperative situation, a patient controlled epidural analgesia was introduced with a debit adapted to the arterial pressure.
223885967|NCT04985695|DRUG|Bilateral rectus sheath block|Bilateral rectus sheath block was performed Under general anesthesia and with ultrasound guidance. Rectus sheath block was inserted on each side of the abdomen. All patients received ropivacaine through elastomeric pump
223885968|NCT04985695|PROCEDURE|Laparotomy|A midline sub or supra umbilical laparotomy or xypho-pubian laparotomy
223885969|NCT03576989|DIETARY_SUPPLEMENT|EPA+DHA|EPA+DHA are the n-3 polyunsaturated fatty acids contained in fish oil
223885970|NCT03576989|OTHER|placebo|placebo contains mineral oil
223885971|NCT06495294|BIOLOGICAL|Whole Blood|2 units of whole blood administered by Ornge AAS
223885972|NCT06495294|BIOLOGICAL|RBC + plasma|2 units of RBC + 2 units of plasma administered by Ornge AAS
223885973|NCT06190678|DRUG|Pirtobrutinib|Administered orally
223885974|NCT05332379|DIAGNOSTIC_TEST|Pulsed Wave Doppler USG examination|Pulsed Wave Doppler USG examination of the posterior tibial artery on the left or right lower extremity will be performed before spinal anesthesia, at the 5th and 10th minutes after the spinal anesthesia. Blood flow velocities and vessel diameters will be measured.
223885975|NCT06764953|OTHER|E-GRAFT ™|E-GRAFT™ that is a dehydrated thick amniotic allograft processed and approved for use as a Human Cellular and Tissue-Based Product (HCT/P) under FDA 21 CFR 1271 and Section 361 of the Public Health Service (PHS) Act.
223885976|NCT06764953|DEVICE|FIBRACOL™|510K FDA cleared Collagen alginate dressing
223885977|NCT04974892|DIAGNOSTIC_TEST|Blood test|Blood tests will be taken at 12, 20, 28 and 36 weeks gestation to assess the immune profile and omic profile.
223885978|NCT03176225|PROCEDURE|Open heart surgery to address the heart disease|The patient will first have open heart surgery to achieve access to the diseased site in the heart
223885979|NCT03176225|DEVICE|Close the defects with XenoSure Patch|The heart defects, such as ASD (Atrial Septal Defect) or VSD (Ventricular Septal Defect ), are closed with LeMaitre XenoSure Patch.
223885980|NCT03176225|DEVICE|Close the defects with Chest Polyester Patch|The heart defects, such as ASD (Atrial Septal Defect) or VSD (Ventricular Septal Defect ), are closed with a Polyester Patch made by Shanghai Chest Medical Technology Co.
223885981|NCT05601726|DRUG|ABD-3001|"Each patient will receive a fixed 4 hours-intravenous infusion dose of ABD-3001 once or twice a week.~For SAD : The first dose of the first cohort will receive an estimated infusion dose of 18 mg/m² at Day 1. Subsequent cohorts will be given the following doses: 54 mg/m², 135 mg/m², 270 mg/m², 405 mg/m², 540 mg/m²."
223885982|NCT05601726|DRUG|ABD-3001|"For MAD :~Based on all data gathered during the SAD including safety, PK and preliminary efficacy data, up to three doses were selected in accordance with the Safety review Committee (SRC). A dosage optimization analysis was performed at the end of the SAD cohort 6 using population pharmacokinetic modelling to set the optimal frequency of infusion per week for each selected dose to achieve sustained exposition throughout the treatment period. Based on this analysis, the Sponsor, in agreement with the SRC, defined 3 doses regimens that will be set up in parallel, with infusion of ABD-3001 once or twice a week during 3 cycles of 28 days."
223885983|NCT04869098|DIETARY_SUPPLEMENT|whey protein|Protein drink containing 30g whey protein isolate powder (dissolved in water) consumed 1-1.5 hr prior to their main evening meal every day for 12 days, No other advice will be given.
223885984|NCT04869098|DIETARY_SUPPLEMENT|Placebo|Energy-matched mixed-nutrient placebo drink consumed 1-1.5 hr prior to their main evening meal every day for 12 days. No other advice will be given.
223885985|NCT06796725|DEVICE|rTMS|(1) The patient undergoes pseudo stimulus intervention in the first week and real stimulus intervention afterwards, which is blind to the patient. (2) Starting from the second week, true stimulation intervention will be conducted for 4 weeks, with each patient making an appointment for 1 month. On Day 7 after the patient intervention, Day 14, Day 30, Day 60, Day 90, Day 180 scales were used to evaluate follow-up.
223885986|NCT06796725|DRUG|Sibelium|Sibelium 10mg is taken orally every night for 4 weeks each course of treatment. Patients were evaluated and followed up with a scale based on medication intervention, including Day 7, Day 14, Day 30, Day 60, Day 90, and Day 180
223885987|NCT05989984|DIETARY_SUPPLEMENT|ODF Iron Supplement|ODF iron supplement will be admistered daily for 8 weeks.
223885988|NCT05989984|DIETARY_SUPPLEMENT|Iron Supplement in Capsules|Iron supplement in capsule will be admistered daily for 8 weeks.
223885989|NCT05541861|BIOLOGICAL|BNT162b2 Bivalent (original/Omicron BA.4/BA.5) 30 µg|Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection.
223885990|NCT05541861|BIOLOGICAL|BNT162b4 5 µg|Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection.
223885991|NCT05541861|BIOLOGICAL|BNT162b4 10 µg|Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection.
223885992|NCT05541861|BIOLOGICAL|BNT162b4 15 µg|Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection.
223885993|NCT05541861|BIOLOGICAL|BNT162b4 30 µg|Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection.
223885994|NCT05541861|BIOLOGICAL|BNT162b2 Monovalent (OMI XBB.1.5) 30 µg|Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection.
223885995|NCT06794749|OTHER|Action Observation Therapy|Patients received general physiotherapy in addition to action observation therapy (AOT) via telerehabilitation method for 5 weeks, 3 days a week. AOT was applied to patients as a single session per day and lasted 30 minutes. General physiotherapy session was applied face to face for 45 minutes.
223885996|NCT06794749|OTHER|Control|Patients received general physiotherapy in addition to action observation therapy (AOT) via face-to-face telerehabilitation method for 5 weeks, 3 days a week. AOT was applied to patients as a single session per day and lasted 30 minutes. General physiotherapy session was applied face-to-face for 45 minutes.
223885997|NCT06796517|DRUG|CAR-T Therapy|It uses the patient's own T cells, and requires a manufacturing process to modify and expand T cells before infusion. It directly targets B cell specific antigens, such as CD19 or CD20.
223885998|NCT06796517|DRUG|Bispecific antibody|It uses a dual targeting mechanism to enhance specificity and immune activation. It is an off-the-shelf treatment, and doesn't require a manufacturing process of patient cells.
223885999|NCT06796517|DRUG|Antibody-Drug Conjugate|It is a targeted therapy consisting of a monoclonal antibody linked to a cytotoxic drug. The antibody binds to a specific antigen on cancer cells, delivering the cytotoxic agent directly to the tumor, minimizing systemic toxicity.
223886000|NCT06796517|DRUG|Monoclonal antibody|Monoclonal antibodies are lab-engineered antibodies that target specific antigens expressed on cancer cells. These commonly target CD20 (rituximab or obinutuzumab) to mediate immune destruction.
223886001|NCT06796517|DRUG|Proteasome Inhibitor|It blocks the activity of proteasomes, which role is degrading damaged proteins. This disruption induces apoptosis in cancer cells. Common agents include bortezomib and carfilzomib.
223886002|NCT06796517|DRUG|IMiD treatment|Immune modulatory drugs modulate the immune response by enhancing T-cell and NK cell activty to disrupt tumor progression. Common drugs include lenalidomide and thalidomide.
223886003|NCT06792838|DEVICE|Confocal Laser Endomicroscopy|"1. The Endo microscope probe will be prepped in channel #1 and normal saline (30 ml) will be flushed into the duodenal mucosa through channel # 2 which will serve as a control. Inject 1-3ml fluorescein 10% intravenously.~2. The duodenal mucosa is assessed at a minimum of four sites (20 seconds each~3. The first potential allergen will be sprayed via catheter onto the mucosa.~4. After 2 minutes, three different areas of of duodenum will be assessed with the gastroflex probe for fluorescein leakage and cell shedding. If fluorescein leakage and cell shedding are visualized that is considered a positive test,no further allergy testing can be conducted. If the first allergen test is negative, irrigate and repeat steps for the next potential allergen for a maximum of three allergens per patient."
223886004|NCT05328427|OTHER|Stopping|Discontinuation of nucleoside analogue
223886005|NCT06797752|DEVICE|OCTA Scan|Optical Coherence Tomography Angiography before and after receiving the stellate ganglion nerve block.
223886006|NCT06839950|OTHER|Calm room|"The calm room combines the effects of music, light, and videos designed with natural atmospheres. Four themes are offered in the calm room: Comfort, Optimism, Freshness, and Lullaby. These themes feature nature videos, combining relaxing images with calm musical ambiance. The lighting can be adjusted by the user, who can choose from a varied color palette. The available lights have a low glare level, and the light intensity can also be adjusted by the user.~They can be used by patients any time they want and for as long as they want."
223886007|NCT06789887|BEHAVIORAL|Written Exposure Therapy|Written Exposure Therapy (WET) is a 5-session, trauma-focused intervention in which individuals write about their traumatic experience following scripted instructions.
223886008|NCT06789887|BEHAVIORAL|Treatment as Usual (TAU)|Treatment as usual (TAU) will be available to all patient participants. Treatment as usual may include various forms of psychotherapy and or medication management.
223886009|NCT06797115|DRUG|SGLT-2 inhibitor|T2D patients for whom, in addition to administering any existing antidiabetic regimen, the treating physician decided to initiate SGLT-2 inhibitor therapy (empagliflozin or dapagliflozin) based on standard clinical indications.
223886010|NCT06408051|PROCEDURE|Injection of onabotulinumtoxinA into the bladder wall|BTX was injected into the detrusor muscles at 20 sites
223886011|NCT04850807|BEHAVIORAL|Music & Memory|Music and Memory is a personalized music program in which caregivers (nursing home staff, family, or others) provide people with dementia with music playlists tailored to their personal history of music preferences at times when behaviors are likely
223886012|NCT06836518|DIAGNOSTIC_TEST|serum sialic acid|measurement of serum sialic acid to evaluate its efficacy in the diagnosis of hepatocellular carcinoma
223886013|NCT06835413|PROCEDURE|1-Balance Exercises A- Standing with a decreased base B- Graded reaching in standing C- Stepping in different directions D- Walking practice 2-Strength and Balance Exercises A- Sit-to-stand B- Heel r|"1-Balance Exercises A- Standing with a decreased base B- Graded reaching in standing C- Stepping in different directions D- Walking practice A- Standing with a decreased base B- Graded reaching in standing~* Feet together and level.~* Semi-tandem stance.~* Tandem stance.~* Stand on one leg.~* Maintain position for longer~* Close eyes.~* Stand on different surfaces e.g. foam rubber mat.~* Minimize hand support \& Aim to increase time without hand support. • Feet placement- narrower, step standing~* Reaching further.~* Reaching in different directions.~* Reaching down to a stool or the floor.~* Reaching for heavier objects.~* Reaching for a full cup of water.~* Standing on a softer surface eg foam rubber mat.~* Stepping while reaching. C- Stepping in different directions D- Walking Practice~* Narrow foot position.~* Longer steps.~* Faster steps.~* Step over objects.~* Choice component e.g. step forward with left foot.~* Incorporate pivoting on the non-stepping foot.~* Use different color"
223886014|NCT06795269|DEVICE|Cryotherapy Compression Machine|The Cryo Pro is a simple to use cold compression therapy product that requires only ice, water and power. It's unique design is convenient to use, provides pain relief and reduces swelling and inflammation, making recovery faster.
223886015|NCT06795269|OTHER|Conservative treatment|Strength and stretch exercises for hip and knee large groups of muscles.
223886016|NCT01868269|DRUG|Dexamethasone acetate|"First step:~immunosuppressive treatment with dexamethasone"
223886017|NCT01868269|DRUG|dexamethasone and cyclophosphamide|second step (in case of insufficient response): immunosuppressive treatment with dexamethasone and cyclophosphamide
223886018|NCT01868269|DRUG|dexamethasone and rituximab|third step (in case of insufficient response): immunosuppressive treatment with dexamethasone and rituximab
223886019|NCT06796803|DRUG|camrelizumab combined with rivoceranib and HAIC|systemic therapy combined with locoregional theraphy as conversion therapy
223886020|NCT06796803|DRUG|camerlizumab + rivoceranib|systemic therapy
223886021|NCT06643832|OTHER|Rubbing Distraction|gently touching on proximal part of the IV injection site with the palm of the hand extending to the elbow. This will be started 5 seconds before propofol injection (not mixed with any drug) and continued until loss of consciousness. Also, a mobile video with duration of 10 seconds will be used for distraction and will be started 5 seconds before propofol injection so as to be ended at the time of first pain assessment.
223886022|NCT06643832|DRUG|Lidocaine (drug)|lidocaine will be used by mixing it with the propofol before intravenous injection
223886023|NCT06643832|OTHER|Saline|intravenous propofol will be given without mixing with any drug (except for 2 ml saline to ensure blindness of the outcome assessor).
223886024|NCT06191991|DRUG|Atorvastatin|40 mg
223886025|NCT06191991|DRUG|ALG-055009|0.9 mg
223886026|NCT06191991|DRUG|Rosuvastatin|10 mg
223886027|NCT06795347|BEHAVIORAL|Online VIPP-SD|The Video-feedback Intervention to promote Positive Parenting and Sensitive Discipline is delivered online in this study. VIPP-SD is a manualized parenting intervention. The online version consists of 12 individual sessions, where the first and hereafter every second session consists of video recordings of mother and child in pre-defined everyday situations. The recordings are reviewed and discussed with the mother/parents during subsequent video-feedback sessions, where positive sequences in the interaction are pointed out by the intervener and form the basis of a discussion of pre-defined themes regarding child signals, attachment, child development, limit setting and sensitive parenting. The 12 sessions are conducted within five months from randomization with weekly or bi-weekly intervals.
223886028|NCT06795347|BEHAVIORAL|Care As Usual|Care As Usual is defined as any kind of help and support the parents may receive related to the socio-emotional development and mental wellbeing of their child in the municipality or the mental health services.
223886029|NCT01653535|BEHAVIORAL|Fast Track|First grade intervention included a weekly two-hour curriculum-based day that was attended by high-risk children, parents, program staff, and teachers of the high-risk children. During each session, the staff modeled academic tutoring with target children in the presence of their parents. In 3rd and 4th grades, intervention consisted of monthly parent and child curriculum-based sessions during the academic year, home visiting, and teachers implementing the in-class PATHS prevention program. In 5th and 6th grades, intervention included monthly parent and child groups and home visiting. In grades 8, 9 and 10 staff developed sessions on an as needed basis to cover topics like transition to high school, note-taking, and study skills.
223886030|NCT06796244|OTHER|Croq'Santé nutrition education program|The Croq'Santé program aims to develop food literacy in children aged 8 to 11 years. It is based on the creation or adaptation of a recipe chosen by the children. The program is designed to run over the course of one school year, with approximately ten sessions. These sessions are delivered in schools by teachers, following a 3-hour training course. Teachers receive an intervention kit that includes a guide for conducting the different sessions, food images, and a mascot, which children can accessorize as they complete sessions and challenges. The sessions are organized around four stages: discover, invent, cook, and taste. Challenges are to be completed at the end of each stage with the child's family. At the end of the program, children are invited to cook and taste their recipe in a dedicated environment.
223886031|NCT06472453|DEVICE|Allograft/Xenograft|"Alveolar ridge preservation of a single extraction socket site with a mixture of demineralized cortical bone substitute vallos® and xenograft Bio-Oss®."
223886032|NCT06472453|DEVICE|Allograft|Alveolar ridge preservation of a single extraction socket site with vallos® (mineralized cortico-cancellous bone substitute)
223886033|NCT04634643|OTHER|Usual diet and physical activity|Patients will be followed up to assess the effect of the usual diet and physical activity on development of NAFLD
223886034|NCT01116557|DEVICE|Radiofrequency Ablation procedure|Radiofrequency Ablation procedure Application of radiofrequency energy with the THERMOCOOL® catheter used in combination with the CARTO® 3 System and the LASSO® Circular Mapping Catheter to eliminate potentials arising from the pulmonary veins.
223886035|NCT01116557|DEVICE|Radiofrequency Ablation procedure|Application of radiofrequency energy with the Pulmonary Vein Ablation Catheter® (PVAC®) to eliminate potentials arising from the pulmonary veins.
223886036|NCT05457699|RADIATION|SABR|SBAR to PSMA-PET visible disease at maximal systemic therapy response.
223886037|NCT05457699|OTHER|no RT|no SABR, continued systemic therapy per SOC
223886038|NCT06466122|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223886039|NCT06466122|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration and biopsy
223886040|NCT06466122|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow aspiration and biopsy
223886041|NCT06466122|PROCEDURE|Computed Tomography|Undergo CT
223886042|NCT06466122|DRUG|Pirtobrutinib|Given PO
223886043|NCT06466122|DRUG|Venetoclax|Given PO
223886044|NCT03667404|DIETARY_SUPPLEMENT|Resistant maltodextrin|Resistant maltodextrin powder
223886045|NCT03667404|DIETARY_SUPPLEMENT|maltodextrin|maltodextrin powder
223886046|NCT04814420|DEVICE|Delayed enhancement magnetic resonance imaging (DE-MRI)|The patient will be injected with late gadolinium enhancement (0.01 mmol/kg standard dosage), which is a contrast agent used in clinical practice in MRI imaging studies. The contrast agent is used to enhance specific regions/tissues on MRI and, in this study, will allow the investigators to identify fibrotic tissue within the heart. The patient then undergoes the MRI sequence, which lasts approximately 20-25 minutes. Images will be reviewed for quality by trained technicians. This will be repeated after 6 months.
223886047|NCT04862975|DRUG|Dolutegravir|Dolutegravir will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider. Not prescribed for this study.
223886048|NCT04862975|DRUG|Lamivudine|Lamivudine will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider. Not prescribed for this study.
223886049|NCT04862975|DRUG|Emtricitabine|Emtricitabine will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider. Not prescribed for this study.
223886050|NCT04862975|DRUG|Tenofovir Disoproxil Fumarate|Tenofovir Disoproxil Fumarate will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider. Not prescribed for this study.
223886051|NCT06352866|DRUG|Siltuximab|Siltuximab is an investigational (experimental) drug that works by binding directly to human interleukin-6 (IL-6). IL-6 is a cytokine; these are products that are secreted by certain cells of the immune system and effect other cells in participant's body. IL-6 regulates immune, inflammatory and metabolic processes. Siltuximab has already been tested and approved for use by the FDA in participants with a condition called multicentric Castleman's disease, which is a disorder of the lymphatic system
223886052|NCT06352866|DRUG|Teclistamab(FDA-approved)|Teclistamab is a FDA-approved drug for the treatment of advanced MM after 4 lines of therapy.
223886053|NCT02187003|DRUG|Rivipansel|Rivipansel (GMI-1070) will be infused intravenously every 12 hours up to 15 doses maximum. Subjects aged 12 and over who weigh more than 40 kilograms will receive a dose of 1680 mg of rivipansel, followed by a dose of 840 mg of rivipansel every 12 hours. All subjects aged 6 to 11 years and any subject who weighs 40 kilograms or less, will receive weight-based dosing (mg/kg) of 40 mg/kg of rivipansel (maximum of 1680 mg) followed by a dose of 20 mg/kg of rivipansel (maximum of 840 mg) every 12 hours.
223886054|NCT02187003|OTHER|Placebo|Placebo (phosphate buffered saline) will be infused intravenously every 12 hours up to 15 doses maximum.
223886055|NCT03915886|DRUG|JNJ-0440|JNJ-0440 tablets will be administered orally.
223886056|NCT03915886|DRUG|Placebo|Matching placebo tablets will be administered orally.
223886057|NCT05013645|OTHER|Sterilized probiotic LfQi601|Sterilized probiotic topically administered.
223886058|NCT05013645|OTHER|Placebo|Gel control product
223886059|NCT05190978|DEVICE|Acellular Dermal Matrix|Acellular dermal matrix will surgically implanted around the tissue expanders in patients in the ADM cohort.
223886060|NCT05190978|PROCEDURE|Reconstruction without ADM|Acellular dermal matrix will not be surgically implanted around the tissue expanders in patients in the control cohort.
223886061|NCT04593472|BEHAVIORAL|Sharing Healthcare Wishes in Primary Care (SHARE)|SHARE is a multicomponent communication intervention to proactively engage family members or friends to support advance care planning in primary care.
223886062|NCT04593472|BEHAVIORAL|Minimally Enhanced Usual Care|"Minimally enhanced usual care participants are provided with print educational materials that include a 44-page brochure developed by the National Institute on Aging entitled A Guide for Older People: Talking with your Doctor and a blank easy-to-complete advance directive."
223886063|NCT04225455|DEVICE|Glucose monitoring|"To compare the glucose monitoring CGMS Dexcom G6® with their usual self-glucose monitoring in pilots by way of assessing times achieved in safe Green flying range, in Amber flying range and in Red flying range as defined by the ARA.MED.330 diabetes protocol.~\[Green: 5-15 mmol/L; Amber: 4 to \<5mmol/L and \>15 to 20mmol/L; Red: \<4mmol/L and \>20mmol/L\]"
223886064|NCT06115408|DRUG|Dienogest 2 MG|Clinical trial
223886065|NCT06115408|DRUG|N-acetyl cysteine|Clinical trial
223886066|NCT06037551|DIAGNOSTIC_TEST|blood glucose measuremen subject|measurement of the blood glucose concentration of subject using BGM and capillary finger tip blood
223886067|NCT06037551|DIAGNOSTIC_TEST|blood glucose measuremen reference|measurement of the blood glucose concentration of subject using reference method and capillary finger tip blood
223886068|NCT05402592|DIETARY_SUPPLEMENT|Carbonhydrate rich drink|It will be prepared by adding 50 g of carbohydrates to 1200 ml of water in total and will be given to the patients the night before the surgery and the morning of the surgery.
223886069|NCT05402592|OTHER|Water|A total of 1200 ml of water will be given to the patients the night before and the morning of the surgery.
223886070|NCT06347666|BEHAVIORAL|Caregiver coaching|Speech language pathologists will meet with caregivers to talk through strategies to promote child development.
223886071|NCT06489600|OTHER|No Rays, Thanks Mineral sunscreen|"Wash your face with standard facewash and apply a pea size amount on the face in the morning.~Dosage form: semi-solid frequency: Once in a day Route of Administration: Topical"
223886072|NCT03434392|DIAGNOSTIC_TEST|Quantitative Sensory Test 1|Subject will give pain rating (on Visual Analogue Scale (VAS) 0-10) of single as well as multiple stimulation with round-tip non-invasive pin-prick device. Difference is recorded as Temporal Summation Score.
223886073|NCT03434392|DIAGNOSTIC_TEST|Quantitative Sensory Test 2|Subject will state when they first detect pain and pain detection threshold in response to pressure administration with pressure algometer. Pressure threshold recorded in kilopascals(kP). Stimulation will be repeated in pancreatic and control dermatomes. Subject will then state pain tolerance threshold at same locations. Sensitization will be characterized by ratio of pancreatic vs. control dermatome scores.
223886074|NCT03434392|DIAGNOSTIC_TEST|Quantitative Sensory Test 3|Subject will apply dominant hand to ice-chilled water bath (36F) for up to 2 minutes. Pain score (VAS 0-10) will be assessed each 10 seconds. Pain tolerance threshold (in kP) will be assessed with algometer on non-dominant thigh before and after water bath to determine change in threshold. Difference in pain tolerance recorded as Conditioned Pain Modulation Score.
223886075|NCT06782334|DRUG|AMT-116|AMT-116 is an antibody Drug Conjugate (ADC)
223886076|NCT06419972|OTHER|multimodal physiotherapy programme|The intervention to which the climacteric women will be subjected will consist of a combined program of education and general strength and pelvic floor muscles exercises of 8 weeks duration, at a rate of 2 sessions/week. Each of the sessions will last 60 min, except for the first one, which will be 90 min.
223886077|NCT02560805|PROCEDURE|Microneurography|Skin will be stimulated with a pencil-shaped electrode to find a certain nerve. Once the nerve is found, two tiny sterile wire needles (about the size of acupuncture needles) will be put in the skin. One needle is put just under the skin at a short distance away from the nerve, and the other one into the nerve. The needles are attached to a computer recorder to record the nerve activity. It may take up to one hour to get the needles in the right place. After the tiny needle is in the right place, investigators record nerve activity at rest for about 10 minutes. Then, it will be recorded throughout the rest of the visit (up to 4 hours).
223886078|NCT02560805|BEHAVIORAL|Combat virtual reality video clip|Subjects will watch a video clip of combat on a computer screen or wearing video goggles.
223886079|NCT02560805|PROCEDURE|Handgrip Exercise|Subjects will squeeze a hand dynamometer intermittently.
223886080|NCT02560805|PROCEDURE|Cold Pressor Test (CPT)|Subjects' hand will be submerged in cold water (\~0-1°C) up to the wrist for 1 minute.
223886081|NCT02560805|DRUG|Sodium Nitroprusside (SNP)|Subjects will receive sodium nitroprusside 100 µg, which is bolused through an antecubital intravenous catheter.
223886082|NCT02560805|DRUG|Phenylephrine|Subjects will receive phenylephrine 150 µg, which is bolused through an antecubital intravenous catheter 60 seconds after the sodium nitroprusside bolus
223886083|NCT02560805|DRUG|Losartan|Losartan will be administered as 25 mg taken orally, once a day for to 8 to 14 weeks.
223886084|NCT02560805|DRUG|Atenolol|Atenolol will be administered as 25 mg taken orally, once a day for to 8 to 14 weeks.
223886085|NCT02560805|DEVICE|Transcutaneous Vagal Nerve Stimulation (tVNS)|Transcutaneous vagal nerve stimulation (tVNS) is administered using the gammaCore (ElectroCore) TENS device. The gammaCore device is a multi-use, hand-held, rechargeable portable device consisting of a rechargeable battery, signal generating and amplifying electronics, and two buttons to power on the device and for operator control of the stimulation intensity (range 0-40). A small amount of conductive gel is applied to the pair of stainless steel round discs on the device are placed vertically on the skin with the gel. The stimulation is increased until there is a strong vibration and slight muscle contraction in the lower face or neck (usual intensity 15-25). Then the dose is delivered for 2 minutes on the left side of the neck, and on the right side of the neck, for a total of 4 minutes of treatment. Participants will be instructed on the usage of the device and will self-administer up to 4 treatments twice per day.
223886086|NCT02560805|DEVICE|Sham Transcutaneous Vagal Nerve Stimulation (tVNS)|A sham device that is identical to the gammaCore device will be provided to participants. Participants will be instructed on the usage of the device and will self-administer up to 4 treatments twice per day.
223886087|NCT06122285|DRUG|Bulevirtide|dose of 2 mg/day subcutaneously
223886088|NCT04559256|DIAGNOSTIC_TEST|Cardiopulmonary Exercise Testing|Patients will receive a cardiopulmonary exercise testing before and 3-month after tricuspid intervention
223886089|NCT06172764|DIETARY_SUPPLEMENT|Vitamin D supplements along with behavioral modification|"Vitamin D soft gel capsules of 50,000 IU/week for two months followed by a maintenance dosage of 5000 IU/day for one month.~Behavior modification for dental caries with standard instructions of brushing teeth twice daily with regular fluoridated toothpaste and diet counseling."
223886090|NCT06172764|COMBINATION_PRODUCT|Topical fluoride application and Vitamin D supplements along with behavioral modification|"Professional topical 5% sodium fluoride gel application for 5 minutes on the teeth having ICL.~Behavior modification for dental caries with standard instructions of brushing teeth twice daily with regular fluoridated toothpaste and diet counseling.~Vitamin D soft gel capsules of 50,000 IU/week for two months followed by a maintenance dosage of 5000 IU/day for one month.~Behavior modification for dental caries with standard instructions of brushing teeth twice daily with regular fluoridated toothpaste and diet counseling."
223886091|NCT06172764|PROCEDURE|Topical fluoride application along with behavioral modification|"Professional topical 5% sodium fluoride gel application for 5 minutes on the teeth having ICL.~Behavior modification for dental caries with standard instructions of brushing teeth twice daily with regular fluoridated toothpaste and diet counseling.~Behavior modification for dental caries with standard instructions of brushing teeth twice daily with regular fluoridated toothpaste and diet counseling."
223886092|NCT04022746|PROCEDURE|Magnetic Resonance Elastography|Undergo multiparametric MRI/MRE
223886093|NCT04022746|PROCEDURE|Magnetic Resonance Imaging|Undergo multiparametric MRI/MRE
223886094|NCT04214990|DRUG|Aspirin 100mg|Daily aspirin 100 mg for 5 years
223886095|NCT04214990|DRUG|Placebo oral tablet|Daily placebo for 5 years
223886096|NCT06847620|PROCEDURE|Supraclavicular Brachial Plexus Block|The block will be performed using a portable ultrasound system (sonosite M-turbo USA) with linear high-frequency transducer (12HZ) to get the sonographic anatomy of brachial plexus in the transverse and longitudinal planes.
223886097|NCT06847620|DRUG|Bupivacaine 0.25% 20ml alone|will receive 20 ml of plain bupivacaine 0.25% (equivalent to 50 mg) plus 2 ml of normal saline.
223886098|NCT06847620|DRUG|bupivacaine 0.25% And verapamil|will receive 20 ml of bupivacaine 0.25% (equivalent to 50 mg) plus 2 ml verapamil (equivalent to 5 mg
223886099|NCT05315167|DRUG|PRJ1-3024|PRJ1-3024 is provided as capsules and is administered orally once a day.
223886100|NCT06848036|BEHAVIORAL|smart integrated care services|"Provide integrated care services through the 'Hunan Province Integrated Healthcare and Elderly Care Intelligent Service Platform,' including home-based care, mobile medical visits, and remote diagnosis and treatment services."
223886101|NCT04627766|DEVICE|Monitoring with VT-Patch (Connected device manufactured by VitalTracer)|Patients will be monitored for 8 consecutive hours and vital signs will be recorded with VT-Patch and with the standard of care
223886102|NCT06847334|DRUG|HLX17|HLX17 will be administered as IV infusion at a dose of 200mg on Day 1 of each 21-day cycle in combination with Carboplatin and Pemetrexed until loss of clinical benefit or up to 1 year.
223886103|NCT06847334|DRUG|US-sourced Keytruda®|US-sourced Keytruda® will be administered as IV infusion at a dose of 200mg on Day 1 of each 21-day cycle in combination with Carboplatin and Pemetrexed. After 24 weeks, all subjects in the US-Keytruda® group will receive HLX17 in combination with Pemetrexed until loss of clinical benefit or up to 1 year.
223886104|NCT06847334|DRUG|EU-sourced Keytruda®|EU-sourced Keytruda® will be administered as IV infusion at a dose of 200mg on Day 1 of each 21-day cycle in combination with Carboplatin and Pemetrexed until loss of clinical benefit or up to 1 year.
223886105|NCT06407817|PROCEDURE|Spencer technique|No of repetitions; 3 sets for 10 repetitions with 1 minute rest between sets No Of Sessions Per Week: 3 Per Weeks for 6 weeks (40 Min per Session)
223886106|NCT06407817|PROCEDURE|reverse distraction technique|No of repetitions; 10 ( Shoulder Abduction)10 ( Shoulder Flexion) 10 (Shoulder External Rotation) No Of Sessions Per Week: 3 Per Weeks for 6 weeks (40 Min Per Session)
223886107|NCT05345639|DRUG|LRA Loco-regional anesthesia|"Bilateral parasternal block or transverse thoracic block are performed ultrasound-guided, at the end of surgery in the operating room. Once in the desired plane depending on the randomisation (transverse or parasternal), a volume of 20 ml of ropivacaine at 2 mg/ml is injected on each side of the sternum.~The intervention (TTP or PSB) is performed by the anesthetist-resuscitator investigator."
223886108|NCT05345639|PROCEDURE|Standardized post-operative analgesia protocol|"The pain management protocol in intensive care is as follows:~* paracetamol 1g x 4 per day systematically (apart from the usual contraindications), IV then PO;~* PCA (Patient Controlled Analgesia) with oxycodone or morphine: 1mg bolus, 7min refractory period, maximum 4h dose 20mg.~The PCA is usually maintained until 24-48h after the intervention then relayed by oxycodone 5mg every 4h if EVA \> 3 sublingual and addition of oxycodone LP 10mg x 2 per day if daily intake on PCA \> 20mg.~Remedy molecules in case of ineffective analgesia:~ketoprofen 100mg q12h IV, or 50mg q8h PO; nefopam 20mg every 6h IV or PO; ketamine 1 to 1.5 mg/kg/24H IVSE."
223886109|NCT06847945|PROCEDURE|Sham acupuncture|Patients in the non-meridian and non-acupoint group received sham acupuncture treatment at the position 2cm apart from the sensitized acupoint, once every other day for 30min each time, a total of 3 times for 1 week.
223886110|NCT06847945|PROCEDURE|Acupuncture|Patients in acupoint sensitization group were treated with pseudoacupuncture at the sensitized points once every other day for 30min each time, a total of 3 times for 1 week.
223886111|NCT06053125|PROCEDURE|Adipose Tissue Biopsy|Fat sample collected from abdomen before exercise, immediately after exercise, and 3 hours after exercise
223886112|NCT06053125|BEHAVIORAL|Exercise|30 minutes of exercise on a cycle ergometer exercise machine
223886113|NCT06846970|OTHER|Experimental|"Patients will receive a conventional physical therapy program consisting of 20 sessions of exercise, hot pack, TENS, ultrasound and balneotherapy, five days a week and once a day for four weeks. Exercise, hot pack, TENS, ultrasound therapy, and balneotherapy will be performed under the supervision of a specialist physiotherapist.~In both groups, patients will be evaluated by a physician at the beginning of the treatment, at the end of the 4-week treatment period, and at the 3rd month through clinical examination and assessment using the Visual Analog Scale (VAS), Oswestry Disability Index, Douleur Neuropathique 4 Questionnaire (DN4), Pain Quality Assessment Scale, LANSS (Leeds Assessment of Neuropathic Symptoms and Signs) Neuropathic Pain Scale, Short Form-36 (SF-36), and Pittsburgh Sleep Quality Index (PSQI)."
223886114|NCT06846970|OTHER|Active Comparator|"Patients will receive a conventional physical therapy program consisting of 20 sessions of exercise, hot pack, tens and ultrosound therapy five days a week and once a day for four weeks. It was planned to perform exercise, hot pack, tens, ultrasound therapy accompanied by a specialist physiotherapist.~In both groups, patients will be evaluated by a physician at the beginning of the treatment, at the end of the 4-week treatment period, and at the 3rd month through clinical examination and assessment using the Visual Analog Scale (VAS), Oswestry Disability Index, Douleur Neuropathique 4 Questionnaire (DN4), Pain Quality Assessment Scale, LANSS (Leeds Assessment of Neuropathic Symptoms and Signs) Neuropathic Pain Scale, Short Form-36 (SF-36), and Pittsburgh Sleep Quality Index (PSQI)."
223886115|NCT03896516|OTHER|Placebo|Participants receive Placebo orally twice daily.
223886116|NCT03896516|DRUG|GLWL-01|GLWL-01 is a ghrelin O-acyltransferase (GOAT) inhibitor. Participants receive GLWL-01 orally twice daily.
223886117|NCT01518556|DRUG|Idarubicin|"In the phase I study, idarubicin dose is increased step by step as follows: 12 mg/m2/day for 3 days IV in the 1st step; 15 mg/m2/day for 3 days IV in the 2nd step; 18 mg/m2/day for 3 days IV in the 3rd step.~In the phase II study, idarubicin dose is the maximum tolerated dose that is determined from the phase I study or 18 mg/m2/day for 3 days ."
223886118|NCT03721757|BIOLOGICAL|Nivolumab, Surgery, Radiotherapy|A single dose of nivolumab 7-14 days before curative surgery. A further single dose will be administered following surgery and prior to radiotherapy commencing. Six further doses of nivolumab will be received post radiotherapy
223886119|NCT03721757|BIOLOGICAL|Nivolumab, Surgery, Chemoradiotherapy|A single dose of nivolumab 7-14 days before curative surgery. A further single dose will be administered following surgery and prior to Chemoradiotherapy (cisplatin) commencing. Six further doses of nivolumab will be received post radiotherapy
223886120|NCT04700111|DEVICE|DOT Pattern|DOT Pattern Spectacle Lens
223886121|NCT04700111|DEVICE|Control Spectacles|Control lens
223886122|NCT04172441|DRUG|dasiglucagon|Glucagon analogue
223886123|NCT04172441|DRUG|Placebo|Placebo for dasiglucagon
223886124|NCT00676715|DRUG|Placebo|Placebo matching to ocrelizumab administered as IV infision in Cycle 1 Day 1.
223886125|NCT00676715|DRUG|Ocrelizumab|Ocrelizumab 300 mg was administered in cycle 1 followed by an infusion of ocrelizumab 600 mg on Day 1. A single infusion of ocrelizumab 600 mg was administered on Day 1 of cycles 3 and 4.
223886126|NCT00676715|DRUG|Avonex|Avonex was administered weekly intramuscular injections of 30 mcg in cycle 1 Day 1.
223886127|NCT05532137|BEHAVIORAL|e-12HR app|"The 'feedback' e-12HR version: This version of the application allows to calculate the Mediterranean Diet Serving Score (MDSS) index; additionally, this version is designed to promote the Mediterranean diet with two specific automatic functions:~1. Evaluation of the user's MDSS index.~2. Identification of the food groups for which the user has not fulfilled the Mediterranean diet recommendations (in addition, this version also provided the user the consumption recommendations established for these food groups)."
223886128|NCT06462339|BEHAVIORAL|Experimental: Intervention Group|The group that will receive pilates training via telerehabilitation
223886129|NCT03725735|BEHAVIORAL|CBT for problem gambling with emotion regulation|CBT group treatment for problem gambling with emotion regulation focus, with 8 sessions.
223886130|NCT02075684|PROCEDURE|Renal Biopsy|
223886131|NCT01820260|DRUG|Ingenol mebutate gel|
223886132|NCT01820260|DRUG|placebo|
223886133|NCT06032845|DRUG|Tislelizumab|a PD-1 immune check inhibitor
223886134|NCT06032845|DRUG|Lenvatinib|Lenvatinib capsules
223886135|NCT06032845|PROCEDURE|Cryoablation|Cryoablation is performed under US or CT guidance per Investigator decision.
223886136|NCT01567800|OTHER|18F-Fluoroazomycin Arabinoside (18F-FAZA)|PET scan with the radiolabelled tracer 18F-FAZA
223886137|NCT06555016|BEHAVIORAL|Reactive balance training|Reactive balance training involves clients experiencing repeated balance perturbations so that they can practice and improve control of reactions to avoid falling after a loss of balance.
223886138|NCT06555016|BEHAVIORAL|Walking|Overground walking.
223886139|NCT04667052|DRUG|JNJ 64304500|Participants will receive a single subcutaneous dose of JNJ-64304500 reference formulation.
223886140|NCT04667052|DRUG|JNJ 64304500|Participants will receive a single subcutaneous dose of JNJ-64304500 test formulation.
223886141|NCT05942586|DIETARY_SUPPLEMENT|Probiotic capsule (L. reuteri PB-W1™), Placebo sachet|Participants in this arm will consume one probiotic capsule (L. reuteri PB-W1™) daily and placebo sachets three times daily (morning, midday, and evening) for a total daily dose of 7.5 g throughout the eight-week intervention period.
223886142|NCT05942586|DIETARY_SUPPLEMENT|Prebiotic sachet (Prebiotic Blend), Placebo capsule|Participants in this arm will consume one placebo capsule daily and prebiotic sachets (Prebiotic Blend) three times daily (morning, midday, and evening) for a total daily dose of 15 g throughout the eight-week intervention period.
223886143|NCT05942586|COMBINATION_PRODUCT|Probiotic capsule (L. reuteri PB-W1™), Prebiotic sachet (Prebiotic Blend)|Participants in this arm will consume one probiotic capsule (L. reuteri PB-W1™) daily and prebiotic sachets (Prebiotic Blend) three times daily (morning, midday, and evening) for a total daily dose of 15 g throughout the eight-week intervention period.
223886144|NCT05942586|DIETARY_SUPPLEMENT|Placebo sachet, Placebo capsule|Participants in this arm will consume one placebo capsule daily and placebo sachets three times daily (morning, midday, and evening) for a total daily dose of 7.5 g throughout the eight-week intervention period.
223886145|NCT04356027|PROCEDURE|ICA (Invasive Coronary Angiography)|Patients will undergo a Pre-PCI Angiography
223886146|NCT04356027|PROCEDURE|OCT|OCT pullback images will be collected pre-PCI and (optional) post-PCI procedure
223886147|NCT04356027|PROCEDURE|FFR|FFR will be measured
223886148|NCT04356027|OTHER|VFR Analysis|VFR will be calculated offline using the OCT pullback images
223886149|NCT04786093|RADIATION|Stereotactic radiation therapy|Radiation therapy will be delivered using standard SAbR treatment schedule or every 4 weeks on the PULSAR schedule to achieve optimal local control of metastatic cancer and augment the effects of durvalumab.
223886150|NCT04786093|DRUG|Durvalumab|Durvalumab (initially developed as MEDI4736) is a human monoclonal antibody of the immunoglobulin (Ig) G1 kappa subclass that inhibits binding of PD-L1 (B7-H1, CD274) to PD-1 (CD279) and CD80 (B7-1). MEDI4736 is composed of 2 identical heavy chains and 2 identical light chains, with an overall molecular weight of approximately 149 kDa. MEDI4736 contains a triple mutation in the constant domain of the Ig G1 heavy chain that reduces binding to complement protein C1q and the fragment crystallizable gamma receptors involved in triggering effector function.
223886151|NCT05228197|DIAGNOSTIC_TEST|Biopsy & Imaging|H\&E stained prostate biopsy slides from standard of care treatment
223886152|NCT04193917|DIAGNOSTIC_TEST|Conjunctival swab|A conjunctival swab of both eyes will be taken at the same time together with an extensive questionnaire.
223886153|NCT01918683|RADIATION|TACE transarterial chemoembolization|
223886154|NCT01918683|RADIATION|stereotatic body radiotherapy (SBRT)|
223886155|NCT05555290|COMBINATION_PRODUCT|PT027|When administered PT027, participants will receive 2 actuations of albuterol- budesonide per dose administered as oral inhalations.
223886156|NCT05555290|COMBINATION_PRODUCT|PT007|When administered PT007, participants will receive 2 actuations of albuterol administered as oral inhalations.
223886157|NCT06059118|DRUG|DFMO|Each 119 day cycle, Days 1-7 patient will take 1000 mg by mouth (PO) twice a day (bid), and then on Day 8 - 63 patient will take 1000 mg PO bid while receiving high dose testosterone IM on Day 8 and Day 36 of cycle.
223886158|NCT06059118|DRUG|testosterone cypionate|On Day 8 and Day 36 of each 119 day cycle, patient will receive high dose testosterone at 400 mg through intramuscular (IM) injection.
223886159|NCT06059118|DRUG|Luteinizing hormone-releasing hormone (LHRH) analogue|Patients who have progressive disease after treatment with Abiraterone (Abi) will continue with androgen depravation therapy (ADT) with LHRH analogue (LHRH agonist drug (i.e. Zoladex, Trelstar, Eligard or Lupron) or LHRH antagonist drug (Degarelix or Relugolix)). Dosing instructions will vary between the different LHRH analogues. Patients should follow the dosing instructions as directed by their physician.
223886160|NCT06059118|DRUG|Enzalutamide|Each 119 day cycle, Days 64-119 patient will take 160 mg by mouth (PO) once a day (qd).
223886161|NCT05863416|DRUG|Dexmedetomidine infusion|Intraoperative dexmedetomidine infusion
223886162|NCT05464433|DRUG|Tislelizumab combined with Liposomal mitoxantrone hydrochloride|"Drug: liposomal mitoxantrone hydrochloride, tislelizumab Drug: Liposomal mitoxantrone hydrochloride (16 mg/m2, 20 mg/m2) will be administered by an intravenous infusion on day 1 of each 28-day cycle.~Drug: tislelizumab(200 mg) will be taken orally on day 1 of each 28-day cycle."
223886163|NCT05464433|DRUG|Maintenance of tislelizumab|Drug: tislelizumab(200 mg) will be taken orally on day 1 of each 21-day cycle
223886164|NCT06075511|DIAGNOSTIC_TEST|6 minutes walk distance|Subjects walk as far as possible for 6 minutes at a self-selected pace, and the total distance walked will be recorded
223886165|NCT06075511|BEHAVIORAL|Activity Monitor|Subjects will wear an Actigraph on their wrist like a watch for up to 10 days at home to monitor activity.
223886166|NCT06075511|BEHAVIORAL|Continuous Glucose Monitor|Subjects will collect glucose values in the fluid under their skin for up to 10 days at home.
223886167|NCT06075511|BEHAVIORAL|Blood Pressure Monitoring|Subjects will monitor their blood pressure at home for 10 consecutive days 3 times a day
223886168|NCT06075511|DIAGNOSTIC_TEST|Blood Pressure Monitoring|24-hour ambulatory blood pressure monitoring
223886169|NCT06075511|DIAGNOSTIC_TEST|Body Composition Scan|Measure of body fat percentage, skeletal muscle mass, body water, and visceral fat.
223886170|NCT06075511|DIAGNOSTIC_TEST|Mixed meal testing|Subjects will consume 6 ml/kg body weight of Boost, up to maximum of 360 ml, within 5 min
223886171|NCT06075511|DIAGNOSTIC_TEST|Quality of Life|Subject will complete Quality of Life Questionnaire
223886172|NCT05746039|DRUG|Semaglutide Pen Injector|Once weekly subcutaneous injection
223886173|NCT03235271|DEVICE|BrainPulse Device|"The BrainPulse is used on a patient's head to non-invasively detect, amplify and capture the skull motion caused by pulsatile cerebral blood flow from the cardiac cycle.~The BrainPulse consists of a reusable headset that contains the accelerometers used to measure motion caused by pulsatile cerebral blood flow. The system is powered by a rechargeable battery pack. The headset is placed on the subject's head and outputs data to a data collector that forwards the data to the computer. Each accelerometer has an attached tip that makes contact with the subject's head through hair. The headset also includes a photoplethysmograph (PPG) that simultaneously captures the subject's heart-rate information. There is no energy delivered to the brain or subject by these highly sensitive sensors."
223886174|NCT04894435|BIOLOGICAL|mRNA-1273 SARS-CoV-2 vaccine|Contains 1.26 mg of CX-024414 mRNA and 24.38 mg of SM-102 LNP as a white to off-white dispersion in preservative-free diluent buffer at pH 7.5.
223886175|NCT04894435|BIOLOGICAL|BNT162b2|A white to off-white, sterile, preservative-free, frozen suspension for intramuscular injection, supplied with 0.9% sodium chloride diluent for injection plastic ampoules.
223886176|NCT04894435|BIOLOGICAL|ChAdOx1-S [recombinant]|A colourless to slightly brown, clear to slightly opaque solution containing 5 x 1010 viral particles (not less than 2.5 x 108 infectious units).
223886177|NCT04894435|OTHER|0, 28 day schedule|Second injection administered 28 days post first injection
223886178|NCT04894435|OTHER|0, 112 day schedule|Second injection administered 112 days post first injection
223886179|NCT04894435|BIOLOGICAL|Covifenz|COVIFENZ is an emulsion for intramuscular injection. The 3.75 mcg antigen component of COVIFENZ is a suspension, which must be mixed 1:1 with the 0.25 mL AS03 adjuvant emulsion component prior to administration
223886180|NCT04831281|DRUG|ATH-1017|Daily subcutaneous injection of ATH-1017 in a pre-filled syringe
223886181|NCT04831281|DRUG|Placebo|Daily subcutaneous injection of Placebo in a pre-filled syringe
223886182|NCT06271694|OTHER|Vestibular Rehabilitation|Standard vestibular rehabilitation
223886183|NCT05906407|OTHER|Genomic Profiling / Sequencing|Procedure: genomic profiling (Whole-Genome- / Exome-Sequencing + RNA-Sequencing) in high-risk early breast cancer patients pre- and post neoadjuvant therapy
223886184|NCT04107051|DRUG|Nalmefene Hydrochloride Hydrate|Oral administration of nalmefene hydrochloride hydrate
223886185|NCT05899465|DRUG|Tranexamic acid|A single preoperative intravenous dose and per os treatment postoperatively day 1 through 4
223886186|NCT05899465|DRUG|Saline|A single preoperative intravenous dose and per os treatment postoperatively day 1 through 4
223886187|NCT03473730|PROCEDURE|Biopsy|Undergo biopsy
223886188|NCT03473730|BIOLOGICAL|Daratumumab|Given IV
223886189|NCT03473730|OTHER|Laboratory Biomarker Analysis|Correlative studies
223886190|NCT03473730|PROCEDURE|Metastasectomy|Undergo metastasectomy
223886191|NCT03473730|PROCEDURE|Nephrectomy|Undergo nephrectomy
223886192|NCT05760794|PROCEDURE|Non-barbed delayed absorbable suture|The non-barbed delayed absorbable suture group vaginal mesh attachment will be performed with 2-0 PDS (polydioxanone). The vaginal mesh will be attached with at least four interrupted sutures on the anterior vagina and posterior vagina.
223886193|NCT05760794|PROCEDURE|Barbed delayed absorbable suture|The barbed delayed absorbable suture group vaginal mesh attachment will be performed with 2-0 V-Loc. The vaginal mesh will be attached with a running V-Loc on the anterior and posterior vagina.
223886194|NCT06574282|DIAGNOSTIC_TEST|Second alkaline phosphatase measurement|(1-4 weeks after the 1st measurement)
223886195|NCT06509919|DIAGNOSTIC_TEST|Blood draw|Before undergoing a prostate biopsy, participants will have about 10 mLs of venous blood drawn. Blood will be sent to Geneseeq Technology Inc. for whole genome high-throughput sequencing of plasma cfDNA.
223886196|NCT06497517|DRUG|GSK5464714- Camlipixant|GSK5464714- Camlipixant will be administered
223886197|NCT06572618|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223886198|NCT06572618|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
223886199|NCT06572618|DRUG|Nemtabrutinib|Given PO
223886200|NCT06572618|PROCEDURE|Positron Emission Tomography and Computed Tomography Scan|Undergo PET-CT scan
223886201|NCT06572618|BIOLOGICAL|Rituximab|Given IV
223886202|NCT06574178|BEHAVIORAL|Dietary Counseling|A Registered Dietitian or Nutritionist will provide nutrition education either in person, over the phone, or via Zoom. The behavioral program will use cognitive-behavioral techniques to foster adherence to diet prescriptions and to build a supportive environment for the participant.
223886203|NCT02512523|DRUG|Teneligliptin|
223886204|NCT02512523|DRUG|Sitagliptin|
223886205|NCT04422899|DRUG|AIV007|intravitreal
223886206|NCT06281483|OTHER|platelet-rich plasma|Under aseptic conditions, 20 mL of whole blood will be withdrawn from each patient and will be collected in the centrifuge tube prefilled with Anticoagulant Citrate Dextrose (1.5 mL each). A two-stage centrifugation process (double-spin method) will be employed for the preparation of PRP. The first spin is at 100 relative centrifugal force (RCF) (g) for 10 min, while the second spin is at 400 RCF for 10 min. PRP will be injected into the base of the ulcer and the surrounding skin. Group A: will receive treatment that will include PRP application, conventional debridement, and dressing coverage. Sessions will be repeated weekly for a maximum of eight sessions.
223886207|NCT06281483|OTHER|platelet-rich fibrin|20 ml blood will be drawn from each patient by venipuncture under aseptic precautions in four sterile glass tubes of 5-ml capacity without anticoagulant and immediately centrifuged. A single stage centrifugation process, that is (200 g for 8 min), has been found to produce a fibrin clot with the highest platelet and WBC count and highest overall cumulative growth factor yield. Group B: will receive treatment that will include PRF application, conventional debridement, and dressing coverage. Sessions will be repeated weekly for a maximum of eight sessions.
223886208|NCT06281483|OTHER|Surgical debridement, normal saline washing and dressing coverage|Each patient will receive the same conventional debridement and dressing coverage (After opening the bandage, the ulcer will be irrigated with normal saline and will be prepared for debridement as required to remove dead tissues and hyperkeratotic skin. Then, a second wash with normal saline will be done to remove any debris), but without any PRP nor PRF application.
223886209|NCT02249949|DRUG|efatutazone|Given PO
223886210|NCT04256759|DRUG|Dupilumab 300Mg Solution for Injection|Subcutaneous (SC) dupilumab selected for this study is 300 mg every 2 weeks for 18 weeks.
223886211|NCT06374979|BIOLOGICAL|Ixekizumab|Participants will receive an initial dose of 160 mg (two injections of 80 mg) ixekizumab subcutaneously at week 0, followed by 80 mg at weeks 2, 4, 6, 8, 10, and 12.
223886212|NCT06269614|DIETARY_SUPPLEMENT|Probiotic|Consumption of probiotic with parent- as tolerated for 4 weeks.
223886213|NCT01783626|DEVICE|Evodial|
223886214|NCT01783626|DEVICE|Evodial+ Condition B1|
223886215|NCT01783626|DEVICE|Evodial+ Condition B2|
223886216|NCT01783626|DEVICE|Evodial+ Condition C|
223886217|NCT02097420|DEVICE|Mitral valve replacement SJM™ Masters HP™ 15mm Rotatable Mechanical Heart Valve|Implantation of the SJM™ Masters HP™ 15mm Rotatable Mechanical Heart Valve in the mitral and aortic positions
223886218|NCT06298006|OTHER|Follow-up|Follow-up of neurocognitive and psychiatric symptoms in Post COVID patients (baseline, 12 months, 24 months) in correlation with biomarkers using MRI, fMRI, neuropsychological testing, lab samples (blood, CSF, microbiota).
223886219|NCT04258813|BEHAVIORAL|iGuide Intervention (Self-guided)|The iGuide Intervention consists of two patient-level and four PCP-level components. These components include: (1) the patient-level brief video vignettes with a written summary; and (2) patient-facing webinars. The investigators will not use any institutional branding in the videos, printed materials, or recorded webinars so that these deliverables can be used in other settings.
223886220|NCT04258813|BEHAVIORAL|iGuide 2 Intervention (Tailored/Targeted)|"The iGuide2 patient-level intervention will use a stage-based, tailored approach to four monthly 5-minute video vignettes that incorporates a pre-video worksheet. The investigators will send the worksheets and video vignettes in the method preferred by the patient.~The targeted iGuide 2 PCP-level intervention will include a cancer specialist-facing dashboard that includes the specialists's patients who are enrolled in the study and are in the intervention arm. The HEDIS quality measures for our three CVD comorbidities will be used. The dashboard will be populated with data available in Epic for the specific patient. If some information is missing (i.e., there is no lipid profile in the laboratory tab), the dashboard will query the PCP via an e-consult, asking to supply the information. Bimonthly, starting with the second randomization, an asynchronous specialist-to-PCP e-consult will be sent to PCPs whose patient(s) do not meet all three of the HEDIS quality metrics."
223886221|NCT04258813|BEHAVIORAL|Control|Participants randomized to the control group (n=400) will receive current guideline-concordant cancer care. The investigators will also provide information for healthy living during and after cancer and for preparing for transition from cancer therapy to follow-up care. Monthly, patient education material on healthy living will be sent to the participants via the patient portal or by mail, based on participant preference. At the completion of therapy, they will be provided the NCI Facing Forward:Life After Cancer booklet. Note, this approach is not fully equivalent to an attention control as there will be touch points in the iGuide and iGuide2 interventions that the investigators cannot match for the control group. Also, the research team will not engage the PCPs in clinics randomized to the control group.
223886222|NCT05570786|DRUG|Gestrinone|The intradermal gestrinone/placebo pellet will be inserted on the same day as the levonorgestrel intrauterine hormonal device (Kyleena®)
223886223|NCT05570786|DRUG|Placebo|Subdermal implant-bioabsorbable placebo pellet (cholesterol)
223886224|NCT04179370|OTHER|N/A - no intervention. Observational study.|N/A - no intervention. Observational study.
223886225|NCT06571552|PROCEDURE|Single Plasma Exchange followed by Double Filtration Plasmapheresis|Double Filtration Plasmapheresis followed by Single Plasma Exchange
223886226|NCT05380570|RADIATION|Occupational radiation exposure|Ionizing radiation in workplaces
223886227|NCT04943289|BIOLOGICAL|DUOC-01|DUOC-01 is a population of cells expanded from donor human umbilical cord blood mononuclear cells. DUOC-01 cells are derived from CB CD14+ monocytes. DUOC-01 will be administered along with hydrocortisone via intrathecal injection.
223886228|NCT04713683|DEVICE|Percutaneous Patent Foramen Ovale Closure|Patients with well-documented embolic stroke of unknown source (ESUS) and a patent foramen ovale (PFO) are indicated for percutaneous closure of PFO. The intervention is performed through the right femoral vein. The interventional cardiologist introduces the sheath and advances the device via inferior vena cava to right atrium. Then, the catheter is passed through the PFO, the device is deployed and the occlusion is achieved. The procedure is performed under fluoroscopy guidance with or without transesophageal echocardiography guidance.
223886229|NCT06571903|OTHER|Teaching from videos|Teaching from videos for independent study
223886230|NCT06570772|BIOLOGICAL|AVT16|AVT16 will be given as iv infusion at Wks 0, 2, 6, 14, 22, 30, 38 and 46
223886231|NCT06570772|BIOLOGICAL|Vedolizumab|Entyvio (vedolizumab) will be given as iv infusion at Wks 0, 2, 6, 14, 22, 30, 38 and 46
223886232|NCT06080178|DRUG|Plasma-lyte (static group)|Plasmalyte will be administered intravenously: (1) as a maintenance infusion 1ml/kg/h (from anaesthesia induction until ICU/PACU discharge); (2) as a fluid bolus until 5ml/kg/h crystalloid (without maintenance infusion) is reached or until SBP is above 100mmHg
223886233|NCT06080178|DRUG|Norepinephrine (static group)|When during surgery SBP is below 100mmHg, if the 5ml/kg/h crystalloid limit is already reached, start or increase norepinephrine infusion until SBP is above 100mmHg (with a maximum dose of 0.2mcg/kg/min).
223886234|NCT06080178|DRUG|Plasma-lyte (dynamic group)|"Plasmalyte will be administered intravenously:~(1) as a maintenance infusion 1 ml/kg/h (from anaesthesia induction until ICU/PACU discharge); (2) as a fluid bolus until PPV is below or equal to 12% or SBP is above 100mmHg."
223886235|NCT06080178|DRUG|Norepinephrine (dynamic group)|"When during surgery SBP is below 100mmHg and PPV is below or equal to 12%: start or increase norepinephrine infusion until SBP is above 100mmHg (with a maximum dose of 0.2mcg/kg/min).~When SBP is above 120mmHg: decrease the norepinephrine infusion rate until SBP is below 120mmHg."
223886236|NCT04092387|OTHER|Varying the nicotine content of cigarettes|1\) Altering the nicotine content of the tobacco research cigarettes
223886237|NCT04092387|OTHER|E-Cigarettes|Comparing effects of combining RC2 with EC 1 versus EC2
223886238|NCT05979805|OTHER|Conventional Educational interventions|Conventional educational methods can be verbal, written or visual and can be combined for greater understanding and effectiveness in oral health and dietary routines. The education are imparted in the first appointment of the appliances cementation by a video and oral health instruction booklet and each patient receive an oral hygiene kit. This education is repeated in month 1 and 3 after appliances cementation.
223886239|NCT05979805|BEHAVIORAL|Motivational intervention|In addition to the conventional educational method, a motivational interviewing (MI) by Miller and Rollnick of 30 minutes will be used, with an initial script according to the stage of change in each patient in T0. The reinforcements of motivational interviewing are in month one and three after the installation of the braces, they will have the same methodology but will be focused on the aspects that in the previous session or in the clinical assessment were detected as the most important deficiencies or risk factors for the patient.
223886240|NCT06011733|OTHER|Placebo|Study participants will receive placebo subcutaneously at pre-specified time points in the placebo arm as comparator and in the bimekizumab arm to maintain the blinding.
223886241|NCT06011733|DRUG|Bimekizumab|Study participants will receive bimekizumab (dosage regimen 1 and 2) subcutaneously administered at pre-specified time points during the Initial and Maintenance Treatment Periods.
223886242|NCT04564495|BEHAVIORAL|Seated exercise|Exercise will include repetitive bouts of high intensity exercises with intermittent periods of rest or active recovery. circuit of moves like 'jabs', 'hooks' etc, and a strength and endurance class that promotes postural awareness.
223886243|NCT03457675|DEVICE|Activa PC+S DBS implant for OCD|"DBS system consists of the Activa PC+S Neurostimulation System:~Model 37604 Activa PC+S Neurostimulator Model 37087 DBS Extension Model 37441 Patient Programmer Model 8181 Sensing Programmer Model 8180 Sensing Programmer Software Nexus D2/D3 System Nexus D2/D3 Application Programming Interface (API) Dow Corning Medical Adhesive, Medtronic Part #080118 Model 3387/3389 DBS Leads Model 37022 External Neurostimulator Model 8840 N'Vision Clinician Programmer Model 8870 Application Card Model 37642 Patient Programmer Model 37092 Patient Programmer Antenna"
223886244|NCT03457675|OTHER|One Month Blinded Discontinuation Period|"The subject and Independent Evaluators are blinded to timing of discontinuation. In all cases, the sequence will be as follows in one-week segments: 100% Active, 50% Active, Sham and Sham. Subjects will be seen weekly. Amplitude will be reduced by 50% at start of week 2 and turned off at start of week 3. Subjects will be told that DBS will be discontinued at some point during the 4 weeks. The purpose of the 50% initial reduction is to minimize rebound effects. The programmer (not the PI in this case) will be open to the design and perform sham activation as described previously. Relapse is defined as a 25% increase of the Y-BOCS over two consecutive visits compared to discontinuation baseline."
223886245|NCT06495632|DRUG|Motrin and narcotic|See described earlier
223886246|NCT03793192|OTHER|PACE2 Intervention|Written educational materials regarding physical activity, telephone-based coaching to integrate physical activity in daily life activities and address barriers to attending pulmonary rehabilitation.
223886247|NCT05061095|OTHER|Assessment Surveys|Patients will complete surveys in three periods. An initial baseline survey, longitudinal assessments completed every 2 weeks over the course of the first three months on study (6 times maximum), and extended assessments that will happen every 3 months after the initial longitudinal period up to 2 years on the study (7 times maximum). Baseline questionnaire will collect demographic and background medical record information. Longitudinal assessments will consist of a BWS questionnaire (patients rate importance of 7 treatment goals), decisional conflict scales, EQ-5D-5L, distress thermometer, and items from PRO-CTCAE. Extended assessments will use same questionnaires as longitudinal assessments.
223886248|NCT05061095|OTHER|Qualitative Interviews|Patients will participate in 2 interviews (1 initial interview, 1 follow up). These will be cognitive interviews focusing on establishing content validity for BWS questionnaire. Will establish patient understanding of questions asked in BWS, understanding of how preferences affect treatment decisions, expected outcomes, and feedback from patients on other potentially important attributes not included in BWS.
223886249|NCT05664074|DRUG|Rectal indomethacin|"Dosage based on subject's weight:~\>=50 kg, 100 mg; 30-49 kg, 50 mg; 10-29 kg, 25 mg"
223886250|NCT05664074|DRUG|IV ketorolac|Dosage based on subject's weight: 0.5 mg/kg (maximum: 15 mg)
223886251|NCT02386735|DRUG|Placebo|Three days prednisone 40mg, two days placebo
223886252|NCT02386735|DRUG|Prednisone|Five days prednisone 40mg.
223886253|NCT06354543|DEVICE|Cemented joint arthroplasty|Joint replacement with cemented prosthetic components
223886254|NCT05938712|DRUG|Dapagliflozin 10 MG|Semaglutide subcutaneous once weekly for 12 weeks.
223886255|NCT05938712|DRUG|Semaglutide, 1.0 mg/mL|Dapagliflozin oral once daily for 12 weeks.
223886256|NCT04864912|OTHER|Questionnaires and survey|Questionnaires: Health Utilities Index Mark III, Chronic Otitis Media Outcome Test-15 and Speech, Spatial, and Qualities of Hearing Scale-12 Survey: Client Service Receipt Inventory (adapted version)
223886257|NCT06051292|OTHER|Fast method|Fast decremental catheter volume titration will be applied and optimal filling volume will be determined according to the measurements
223886258|NCT06051292|OTHER|Conventional method|Conventional catheter volume titration will be applied and optimal filling volume will be determined according to the measurements
223886259|NCT03414814|DRUG|Osimertinib 80 MG [Tagrisso]|Osimertinib 80mg once daily until disease progression
223886260|NCT04675541|BIOLOGICAL|Afstyla®|Solution for injection
223886261|NCT06385834|OTHER|Morning aerobic exercise|Patients were randomly assigned to morning aerobic exercise training for a 12-week outpatient training program that included a combination of warm-up, aerobic, and relaxation exercises three times a week. Each class consists of 10 minutes of warm-up training, 40 minutes of aerobic training and 10 minutes of relaxation training. The intensity of aerobic exercise training will be personalized. According to the guidance of relevant guidelines, the exercise intensity of patients will be determined according to the results of their first cardiopulmonary exercise experiment, and the exercise load will be gradually increased according to the exercise program until the predetermined goal is reached. Patient fatigue levels will be monitored throughout the exercise using the borg scale.
223886262|NCT06385834|OTHER|Evening aerobic exercise|Patients were randomly assigned to evening aerobic exercise training for a 12-week outpatient training program that included a combination of warm-up, aerobic, and relaxation exercises three times a week. Each class consists of 10 minutes of warm-up training, 40 minutes of aerobic training and 10 minutes of relaxation training. The intensity of aerobic exercise training will be personalized. According to the guidance of relevant guidelines, the exercise intensity of patients will be determined according to the results of their first cardiopulmonary exercise experiment, and the exercise load will be gradually increased according to the exercise program until the predetermined goal is reached. Patient fatigue levels will be monitored throughout the exercise using the borg scale.
223886263|NCT06219707|DEVICE|Acupuncture needles|The acupuncture needles and related equipment will have already received approval for routine Traditional Chinese Medicine (TCM) clinical practice in Singapore.
223886264|NCT03161379|DRUG|Cyclophosphamide|Cyclophosphamide 200 mg/m2 will be administered one day prior to vaccination (day 0). First dose will be given within 4 to 6 weeks after chemotherapy. 3 weeks after the first dose of immunotherapy the second dose will be given.
223886265|NCT03161379|DRUG|Nivolumab|Nivolumab (240 mg) will be administered one day prior to vaccination. First dose will be given within 4 to 6 weeks after chemotherapy. 3 weeks after the first dose of immunotherapy the second dose will be given.
223886266|NCT03161379|DRUG|GVAX Pancreas Vaccine|Vaccine will be administered one day after cyclophosphamide and nivolumab. 3 weeks after the first dose of immunotherapy the second dose will be given.
223886267|NCT03161379|RADIATION|Stereotactic Body Radiation (SBRT)|SBRT (6.6 Gy over 5 days) will be started during the second dose of immunotherapy (3 weeks after the first dose of immunotherapy).
223886268|NCT05219487|DRUG|Risdiplam|"Risdiplam is administered orally once daily and the recommended dosage is determined by age and body weight (see Table 1) \[as outlined in the US Prescribing Information for EVRYSDI™(risdiplam)\].~Table 1 Adult and Pediatric Dosing Regimen by Age and Body Weight: US Prescribing Information~Age and Body Weight (Recommended Daily Dosage): 2 months to less than 2 years of age (0.2 mg/kg); 2 years of age and older weighing less than 20 kg (0.25 mg/kg); 2 years of age and older weighing 20 kg or more (5 mg)"
223886269|NCT06455605|DRUG|D2C7-IT|D2C7-IT will be dosed at 166,075 ng in 36 mL.
223886270|NCT06455605|DRUG|2141 V11|2141-V11 will be dosed at 3 mg in 3.5 mL for CED administration. 2141-V11 in the cervical perilymphatic subcutaneous area will be dosed at 2 mg.
223886271|NCT03607513|DRUG|JNJ-64264681|For all cohorts except the solid dose formulation cohort, JNJ-64264681 wlll be administered as oral solution. For the solid dose formulation cohort, JNJ-64264681 will be provided as capsules for oral administration.
223886272|NCT03607513|DRUG|Placebo|Matching placebo to JNJ-64264681 will be administered as oral solution.
223886273|NCT02432560|DRUG|Sirolimus|Sirolimus treatment will be part of a participant's clinical care and will be managed by their physician.
223886274|NCT02432560|DRUG|Everolimus|Everolimus treatment will be part of a participant's clinical care and will be managed by their physician.
223886275|NCT06319716|BEHAVIORAL|Video-Based Diabetes Self-Management Education and Support (DSMES)|The DSMES videos provide important diabetes education to participants and empower them to become an activated patient on the individual level.
223886276|NCT06319716|BEHAVIORAL|Community Health Worker (CHW) Support|CHWs will assess participants' social determinants of health (SDOH) barriers to Type 2 diabetes care and link them to available resources in the community.
223886277|NCT04716712|DRUG|Azithromycin|Azithromycin is a macrolide-type antibiotic that is used to treat various types of infections. Previous studies in Niger have demonstrated a nearly 18% reduction in all-cause child mortality following biannual mass administration to children 1-59 months.
223886278|NCT04716712|DRUG|Placebo|Matching identical placebo in packaging, appearance, and taste.
223886279|NCT05340816|OTHER|Manual Lymphatic Drainage|Manual lymphatic drainage will apply to the neck, abdominal, bilateral inguinal lymph nodes, bilateral anterior/posterior thighs, and lumbal area. Treatment duration will be approximately 30 minutes for 5 days.
223886280|NCT05340816|DEVICE|Transcutaneous Electrical Nerve Stimulation|Transcutaneous electrical nerve stimulation will be apply to abdominal and lumbal area as 100 Hz and 100 msn. Treatment duration will be approximately 20 minutes for 5 days.
223886281|NCT03218904|DIETARY_SUPPLEMENT|Glucose intake|Experiment 1: study day1- single oral dose of glucose study day 2-single oral dose of glucose with U-13C-glucose
223886282|NCT03218904|DIETARY_SUPPLEMENT|Carbohydrates intake|Experiment 2:study day1- single oral dose of uncooked cornstarch study day 2- single oral dose of Glycosade®
223886283|NCT03994627|DRUG|Olaratumab|Administered intravenously (IV)
223886284|NCT06048523|PROCEDURE|Patient cohort|"* For patients: annual follow-up in Neurogenetic reference center, as part of routine care, with exhaustive standardised clinical evaluation~* Paraclinical monitoring (e.g. MRI, EEG, EMG, etc.) modelled on standard care according to current recommendations~* Biological samples offered to patients in the context of research:~  * Annual blood sample~ * Annual urine sample~ * Collection of 1 skin biopsy at the inclusion visit (for 30 patients)~ * Cerebrospinal fluid sample at the inclusion visit (for 15 patients"
223886285|NCT06048523|PROCEDURE|Control cohort|"* controls without LP: 1 visit for blood, urine and optional skin biopsy~* controls with LP: additional blood and cerebrospinal fluid tubes for blood sampling and LP as part of routine care, without longitudinal follow-up"
223886286|NCT03025165|OTHER|Community Adherence Clubs|Provision of ART care in the community to a club of 20-25 HIV+ patients
223886287|NCT03025165|OTHER|Home-Based ART Delivery|Provision of ART care to an individual at their home
223886288|NCT03025165|OTHER|Standard of Care|Delivery of ART adherence support, symptom screening and dispensation of medications at the local clinic according to local guidelines.
223886289|NCT06150664|DRUG|CTX-8371|Intravenous (IV) infusion (0.1-10.0 mg/kg) every two weeks.
223886290|NCT03992430|DRUG|Eteplirsen|Solution for intravenous (IV) infusion.
223886291|NCT05766371|DRUG|Pembrolizumab|Given IV
223886292|NCT05766371|DRUG|177Lu-PSMA-617|Given IV
223886293|NCT05196061|OTHER|Questionnaire|"Subjects will be asked to complete a questionnaire. The questionnaire will garner demographic data, medical history, medication and supplement history, gut-specific, skin-specific questions; etc. The complete questionnaire is provided with this submission for review. Demographic data includes:~1. Age~2. Sex~3. Race~4. Ethnicity"
223886294|NCT05196061|OTHER|Stool sample|Stool samples will be collected using a specific kit consisting of a ready-to-use package, including a user guide. When stool samples are collected, they will be immediately placed in previously prepared Fast prep tubes (MP, Cat# 5076-200-34340) containing 500 μL glass beads (Sigma-Aldrich G8772-100g) and 1 mL ASL™ lysis buffer (Qiagen DNA Extraction Kit) and transported to the laboratory where assays will be conducted. Samples will be kept in a - 20 degree Celsius freezer until they are analyzed.
223886295|NCT05196061|OTHER|Skin swab|Skin swabbing is a safe, non-invasive method to sample microbiota on human skin. Areas to be swabbed: Right upper back, Non-dominant ventral forearm or Most representative lesion
223886296|NCT05196061|OTHER|Oral rinse|Briefly, 20-25 ml saline will be provided in separately labelled blue capped 50-mL Falcon™ centrifuge tubes (Fisher Scientifics Co.). Each subject will be asked to swish and gargled the saline from the tube into their mouth for 2 minutes and expectorate the rinse into the tube. The tubes will be closed tightly and stored in -80 C until sequencing can be completed. Prior to use, all the tubes with oral wash samples will be completely thawed on ice, then centrifuged at 4000 rpm for 15 minutes and 20-25 ml supernatant transferred into fresh 50-mL centrifuge tubes. The pellet left in each tube will be used to extract DNA for microbiome studies
223886297|NCT01351805|DRUG|Fish Oil|Subjects will receive marine omega-3 fatty acids (465 mg of eicosapentaenoic acid \[EPA\] and 375 mg of docosahexaenoic acid \[DHA\]).
223886298|NCT01351805|DIETARY_SUPPLEMENT|Vitamin D|Subjects will receive vitamin D3 (cholecalciferol) 2000 IU a day.
223886299|NCT01351805|OTHER|placebo pill|placebo
223886300|NCT05483764|DEVICE|Ultrasonographic evaluations|"Ultrasonographic evaluations of the talar cartilage will be performed with an 8 MHz linear probe (B-K Medical Ultrasound Scanner Class I Type B) by the same physiatrist according to the European Musculoskeletal Ultrasound Study Group (EURO-MUSCULUS).~Ultrasonographic evaluations of the Achilles tendon will be performed by the same physiatrist with an 8 MHz linear probe (B-K Medical Ultrasound Scanner Class I Type B) according to the European Musculoskeletal Ultrasound Study Group (EURO-MUSCULUS)."
223886301|NCT05890807|DIAGNOSTIC_TEST|Front view photography of the patient's oral cavity with the help of a smartphone in the diabetology department.|The diabetologist will take a photograph of the patient's oral cavity in the diabetology department.
223886302|NCT01765140|DRUG|3,4-diaminopyridine|Treatment use of 3,4-DAP for patients with congenital myasthenic syndrome (CMS)
223886303|NCT04646707|DRUG|Erector Spinae (ESP) Block with Lidocaine/Bupivacaine|Bilateral ESP block at T1 level with 20 ml of 1:1 mixture (2% Lidocaine: 0.5% bupivacaine)
223886304|NCT04646707|DRUG|Erector Spinae (ESP) Block with placebo|Bilateral ESP block at T1 level with 20 ml of 0.9% normal saline
223886305|NCT05737030|DRUG|L-ornithine L-aspartate|Amino acid combination
223886306|NCT06288828|BEHAVIORAL|Aerobic exercise + Nutrition consultant|"Participants in the intervention group will engage in 150 minutes of moderate aerobic exercise weekly for 16 weeks, primarily brisk walking or jogging.~For the initial four weeks, they will visit the hospital weekly for guidance and participate in home-based exercise following a protocol totaling 150 minutes of moderate aerobic exercise in the form of brisk walking or jogging. Healthcare professionals will help adjust exercise intensity based on heart rate (60-80% of maximum) and perceived exertion (RPE 12-15), while monitoring vital signs and adverse events.~After, they will transition to a home exercise program for twelve weeks, recording exercise details in a logbook. Weekly follow-up calls will ensure adherence and monitor adverse events.~They will be provided with nutritional recommendations by a dietitian, the same as the control group."
223886307|NCT06288828|BEHAVIORAL|Nutrition consultant|"Participants will maintain their physical activity at the same level as before enrolling in the study.~However, they will be provided with nutritional recommendations by a dietitian, which include 1.2 grams of protein per kilogram of ideal body weight daily and a calorie intake of 35 kilocalories per kilogram of ideal body weight per day. To assess adherence and make necessary adjustments, participants will complete a 3-day food record at the beginning of the study, at week 8, and at the end of the study at week 16. If participants encounter difficulties adhering to the recommended nutritional intake, the dietitian will provide additional guidance to help them meet the requirements."
223886308|NCT05183477|OTHER|fast track|short cut for the request of xrays directly at triage
223886309|NCT05183477|OTHER|normal pathway|x-ray would be required according to doctor's clinical evaluation.
223886310|NCT02312960|OTHER|Data Collection|No study treatment will be provided in this long term follow up study.
223886311|NCT06257758|DRUG|VIO-01|"VIO-01 will be administered via intravenous infusion over a 60-minute period once weekly. Dosing will be according to body surface area. Based on emerging PK and PD data, alternative dosing schedules may be investigated during the Phase 1 part of the trial. If an alternative schedule is evaluated, the dose and schedule may not exceed the total dose already tested and cleared during the dose escalation.~In Phase 2, participants will receive VIO-01 by intravenous infusion at RP2D and schedule determined during the phase 1 part of the study."
223886312|NCT00302315|OTHER|Physiotherapy|Thoracic expansion exercises and huffing technique Lower limb exercises TENS with frequency of 120 Hz and pulse width of 60 μs was used for 30 min in every session Connective tissue manipulation (CTM) to the sacral and lumbar regions, Education (proper use of body mechanics during baby caring and daily activities; improving posture; anatomy and functions of the pelvic floor and Knack maneouvre)
223886313|NCT04508192|OTHER|Exercise|Both interventions are simple strength exercises without technical equipment
223886315|NCT04883333|DRUG|LEO 153339|LEO 153339
223886316|NCT04883333|DRUG|Placebo|Placebo
223886317|NCT04994379|DEVICE|1 mA tDCS|One session with stimulation intensity of 1 mA.
223886318|NCT04994379|DEVICE|1.5 mA tDCS|One session with stimulation intensity of 1.5 mA.
223886319|NCT04994379|DEVICE|Sham tDCS|One session of sham stimulation.
223886320|NCT04895358|BIOLOGICAL|pembrolizumab|Intravenous (IV) infusion
223886321|NCT04895358|DRUG|paclitaxel|IV infusion
223886322|NCT04895358|DRUG|nab-paclitaxel|IV infusion
223886323|NCT04895358|DRUG|liposomal doxorubicin|IV infusion
223886324|NCT04895358|DRUG|capecitabine|oral administration
223886325|NCT04895358|DRUG|normal saline|IV infusion
223886326|NCT04895358|DRUG|dextrose|IV infusion
223886327|NCT06007976|DEVICE|Erchonia® Trident|Low-level laser therapy
223886328|NCT02728076|RADIATION|Phase II - Preoperative Radiation followed by Lumpectomy.|Selected patients will undergo a radiation planning procedure utilizing magnetic resonance imaging (MRI). Once this is completed, patients will receive five radiation treatments given every other day. After 28 days (four weeks), patients will have another MRI scan to compare tumor response to the radiation therapy. Following the MRI scan, roughly five to eight weeks later, patients will have a lumpectomy and possibly a sentinel lymph node biopsy. After surgery, tests will be performed on the tumor tissue to determine if genes expressed in the sample have changed. Following surgery, patients will receive chemotherapy and/or antihormone therapy at the discretion of the patient and physician.
223886329|NCT06473688|PROCEDURE|Cholecystectomy|Robotic-assisted and laparoscopic cholecystectomy
223886330|NCT02713607|DRUG|Doxycycline|Given doxycycline to acne subjects
223886331|NCT04160546|DRUG|Ponatinib 15 MG|"Patients will receive ponatinib 15 mg/day for 104 weeks orally. Ponatinib will be self-administered by the patient on a daily schedule.~Acetyl salicylic acid (ASA) (100 mg) will be used such auxiliary medicinal product in order to prevent vascular occlusive events related with ponatinib."
223886332|NCT04160546|DRUG|Acetylsalicylic acid 100 MG|Patients will receive acetylsalicylic acid 100 mg/day for 104 weeks orally.
223886333|NCT06191692|DRUG|Isoniazid|This randomized control trial will compare the treatment adherence and safety of the 1HP (Arm B) regimen and standard 3HR (Arm A) regimens for TB infection treatment
223886334|NCT06191692|DRUG|Rifapentine|This randomized control trial will compare the treatment adherence and safety of the 1HP (Arm B) regimen and standard 3HR (Arm A) regimens for TB infection treatment
223886335|NCT06191692|DRUG|Rifampicin|This randomized control trial will compare the treatment adherence and safety of the 1HP (Arm B) regimen and standard 3HR (Arm A) regimens for TB infection treatment
223886336|NCT06289374|OTHER|Biosample collection|Collection of saliva, urine, blood, breath and quality of life questionnaires.
223886337|NCT06300229|DRUG|Denosumab|Subcutaneous injection with 60 mg Denosumab once
223886338|NCT06300229|DRUG|sodium chloride|Subcutaneous injection with NaCl once
223886339|NCT05734625|DRUG|Bupivacaine HCl 0.5% Injectable Solution|Will receive 0.5 ml (supratrochlear) to 1.0 ml (supraorbital, auriculotemporal) to 1.25 ml (greater and lesser occipital) for each nerve block.
223886340|NCT05734625|DRUG|Methylprednisolone 40 MG Injection|Will receive 10 mg (0.25 ml) mixed with 1.25 ml Bupivacaine 0.5% for each greater and lesser occipital nerve block if MPNB group or 20 mg (0.5 ml) methylprednisolone in each GON if GONB group.
223886341|NCT03689049|PROCEDURE|SPIDER|The SPIDER intervention will include a family physician-led inter-professional practice team participating in 3-4 Learning Collaboratives over a period of 12 months, reviewing validated and comparable practice EMR data and working with a QI Coach to develop strategies and implement changes to improve care for elderly patients living with complex care needs and taking ten or more unique medications.
223886342|NCT03689049|PROCEDURE|Usual Care|Physicians and their teams enrolled in this arm will follow the best scientific evidence available to provide standard care that is in the best interest of their patients.
223886343|NCT04975633|DEVICE|Bodyport Cardiac Scale|Patients will be instructed to take daily measurements for 90 days. Data will be transmitted to Bodyport and concerning findings (weight gain, change of impedance, elevated heart rate) will be reported back to the medical team. The medical team will either choose to act on the information given or continue to observe trends. Interventions may include titration of therapy, change in therapy, fluid restriction, sodium restriction and lifestyle modification
223886344|NCT02504905|DEVICE|TMS|single TMS pulses at intensities in random order from 0 to 100% (increasing at 5% intervals) of stimulator output at a frequency of 0.1 Hz. Three pulses will be delivered at each intensity. MEPs will be recorded and their amplitudes will be plotted against the corresponding stimulation intensity. This curve will provide three significant parameters: (a) S50 intensity (intensity for which we get a MEP 50 % of its maximal size); (b) estimated resting motor threshold (RMT): the abscissa where the tangent to the slope crosses the x axis; and (c) the maximum MEP ( plateau value).
223886345|NCT00797719|OTHER|Pre-op RT +/- chemotherapy|Patients on the study will receive IMRT for approximately 1 week of 5 daily treatments. Short pre-operative hemithoracic RT is a new technique. 1 week post-RT, they will proceed with an extrapleural pneumonectomy. If the mediastinal lymph nodes that are removed during surgery are positive for tumour cells, 3 cycles of chemotherapy, consisting of raltitrexed and cisplatin, will be given 6-12 weeks post-surgery.
223886346|NCT04736550|BEHAVIORAL|Exercise|"Participants who are randomized to exercise will be perform exercise on stationary bikes. Participants randomized to Voluntary Exercise will exercise on a standard stationary bike where they will pedal at their voluntary rates. Participants randomized to Assisted Exercise will exercise on a special bike that assists them to pedal faster than they do voluntarily on their own (assisted (exercise) bike)."
223886347|NCT04736550|BEHAVIORAL|Psychotherapy for Pain (I-STOP)|"Participants who are randomized to receive I-STOP will receive the Self-regulation Treatment for Opioid addiction and Pain (STOP) program modified for inpatients/residential drug treatment (I-STOP). I-STOP uses empirically validated pain psychotherapy approaches targeted to patients with an OUD using psycho-physiological self-regulation components and biofeedback with Bio-dots."
223886348|NCT05909111|DIAGNOSTIC_TEST|Magnetic resonance imaging|MRI weekly during the radiation treatment course (5 RMI added to the standard care)
223886349|NCT05443620|DEVICE|Weight vest|A vest weighing up to a maximum of 15 kg.
223886350|NCT05443620|DEVICE|Wheelchair|Wheelchair in which participants will be sitting to reduce loading on lower extremities.
223886351|NCT05238961|DRUG|[18F]DPA-714|Investigational PET Tracer \[18F\]DPA-714
223886352|NCT04089371|DEVICE|ReUnion Total Shoulder Arthroplasty (TSA)|The ReUnion RFX System includes a Reversible Fracture Stem (RFX Stem) that can utilize either the ReUnion Total Shoulder Arthroplasty (TSA) or ReUnion Reverse Shoulder Arthroplasty (RSA) humeral and glenoid components and is indicated for use as a hemi, total or reverse shoulder replacement. The ReUnion RFX stem is intended for cemented use only.
223886353|NCT04089371|DEVICE|ReUnion Reverse Shoulder Arthroplasty (RSA)|The ReUnion RFX System includes a Reversible Fracture Stem (RFX Stem) that can utilize either the ReUnion Total Shoulder Arthroplasty (TSA) or ReUnion Reverse Shoulder Arthroplasty (RSA) humeral and glenoid components and is indicated for use as a hemi, total or reverse shoulder replacement. The ReUnion RFX stem is intended for cemented use only.
223886354|NCT05939934|DEVICE|Mandibular advancement device treatment|a titratable thermoplastic mandibular advancement device will be proposed to patient in the experimental group during the 2 weeks of CPAP withdrawal.
223886355|NCT03453619|DRUG|APL-2|APL-2 administered as a daily subcutaneous infusion for 48 weeks
223886356|NCT05229120|BEHAVIORAL|Episodic Future Thinking|The adapted episodic future thinking (EFT) intervention will focus on generation of vivid, substance-free, rewarding events that could happen in the future with their children.
223886357|NCT05134350|DRUG|LOXO-305|LOXO-305 orally.
223886358|NCT05134350|DRUG|Omeprazole|Omeprazole Orally.
223886359|NCT03222102|DEVICE|Phasix mesh|After the closure of the Abdomen, Phasix mesh will be placed and affixed on the exposed fascia.
223886360|NCT05862870|BEHAVIORAL|painTRAINER|patient self-administered pain management web application
223886361|NCT06477783|DRUG|Teclistamab|Intervention is part of standard clinical care, as Tecvayli/Teclistamab is reimbursed for this group of patients.
223886362|NCT04299828|OTHER|Discarded blood samples|Will utilize the discarded blood from routine clinical blood samples to evaluate the role of immune cells in coagulopathy.
223886363|NCT05595447|DRUG|Brentuximab Vedotin 50 MG [Adcetris]|Brentuximab plus blocked PD-1 plus ASCT plus maintenance Brentuximab plus blocked PD-1
223886364|NCT05826717|OTHER|Apple|20g fructose in \[x\] g of apple
223886365|NCT05826717|OTHER|Mashed apple|20g fructose in \[x\] g of mashed apple
223886366|NCT05826717|OTHER|Apple juice|20g fructose in \[x\] ml apple juice
223886367|NCT05826717|OTHER|Fructose powder in water|20g fructose in \[x\] ml water
223886368|NCT06399094|OTHER|Lung sound recordings|The lung sound recordings will be made during a consultation scheduled as part of the patient's usual follow-up, after obtaining the patient's non-opposition.
223886369|NCT05479643|DEVICE|Surface Electromyography|Surface ElectroMyoGraphy (SEMG) is a non-invasive technique for measuring muscle electrical activity that occurs during muscle contraction and relaxation cycles. Electrodes will be attached with a AgCl gel to muscles used for articulation.
223886370|NCT02342782|BIOLOGICAL|Yttrium Y 90 Basiliximab|Given IV
223886371|NCT02342782|DRUG|Carmustine|Given IV
223886372|NCT02342782|DRUG|Etoposide|Given IV
223886373|NCT02342782|DRUG|Cytarabine|Given IV
223886374|NCT02342782|DRUG|Melphalan|Given IV
223886375|NCT02342782|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo AHCT
223886376|NCT02342782|OTHER|Laboratory Biomarker Analysis|Correlative studies
223886377|NCT02342782|OTHER|Pharmacological Study|Correlative studies
223886378|NCT05355298|DRUG|AMP945 ascending doses|Part A is a phase 1b dose-escalation design that will enrol at least 3 participants in each of 4 dose-level cohorts, to determine the RP2D of AMP945 to be explored in Part B. Dose escalation decisions will be made using a standard 3+3 dose-escalation phase 1 oncology study design.
223886379|NCT05355298|DRUG|AMP945 RP2D|Part B will determine the efficacy of the AMP945 priming regimen at the recommended phase 2 dose (RP2D) determined in Part A.
223886380|NCT02900924|DEVICE|BioMimics 3D Stent|
223886381|NCT03531463|PROCEDURE|Operative treatment with Reversed Total Shoulder Prosthesis|"The standardized approach is the delto-pectoral to minimize any damage of the deltoid muscle. A cemented monoblock humeral stem will be implanted. Braided polyester suture-cerclages engaging the insertion of the subscapular and infraspinatus tendons enforced by a bonegraft or a horseshoe-graft from the humeral head will be used"
223886382|NCT06406582|DEVICE|Zirconia laminate veneer|Zirconia veneers are milled with computer-aided manufacturing technology from multilayered zirconia discs with shade matched with adjacent teeth. After sintering, veneer surfaces are treated with a hydrofluoric acid-nitric acid mixture. Next, veneers are cut back if necessary to provide space for characterization. Veneers are bonded with a light-cured veneer adhesive system (Relyx Veneer LC, 3M, USA).
223886383|NCT06406582|DEVICE|Lithium Disilicate laminate veneer|Lithium Disilicate veneers are milled with computer-aided manufacturing technology from lithium disilicate blocks with shade matched with adjacent teeth. After sintering, veneer surfaces are treated with hydrofluoric acid. Next, veneers are cut back if necessary to provide space for characterization. Veneers are bonded with a light-cured veneer adhesive system (Relyx Veneer LC, 3M, USA).
223886384|NCT06333002|OTHER|machine learning analysis|We will use robust machine learning approaches, such as Random Forest, Extreme Gradient Boosting, Support Vector Machine and Multilayer Perceptron.
223886385|NCT05641948|OTHER|MRI scan|Participants will undergo brain MRI scan at 3 intervals
223886386|NCT04240990|OTHER|Development of a score and algorithm for TB treatment decision in hospitalised children with SAM.|"The diagnostic strategy will include an initial clinical, radiographic and bacteriological evaluation of all enrolled children:~* TB contact history~* Suggestive TB symptoms in the previous 4 weeks~* Physical examination~* Clinical, anthropometric and biochemical assessment of malnutrition~* Clinical assessment for other non-dietary causes of malnutrition~* Digitalized CXR~* Ultra performed on NPA and stool samples, and one gastric aspirate (GA)~* Mycobacterial culture performed on two GAs~* Abdominal ultrasonography~* QuantiFERON®-TB Gold IGRA~* Monocyte-to-Lymphocyte Ratio (MLR)~* C-Reactive Protein (CRP)~TB diagnosis will be made according to national TB guidelines."
223886387|NCT06501170|OTHER|Retrospective Data Analysis of Emergency Abdominal Surgery Outcomes|Retrospective Data Analysis of Emergency Abdominal Surgery Outcomes
223886388|NCT06018987|OTHER|No-Treatment Control|Participants will not receive treatment for 6 months and then will be offered an optional delayed treatment of HAC 20L after completion of of Month 6 visit with an optional touch-up treatment offered 30 days after delayed treatment.
223886389|NCT06018987|DEVICE|HAC 20L|Subdermal Injections
223886390|NCT05081596|BEHAVIORAL|PATH-Pain|"The goals of PATH-Pain are to: 1) Teach problem solving skills to reduce negative emotions, by using emotion regulation and problem- solving strategies to overcome these difficulties. 2) Use compensatory strategies and environmental adaptation tools (notes, checklists, calendars, etc.) to avoid limitations resulting from memory problems, help improve emotion regulation, and create an easier environment to live in. If found helpful and participant agrees, a tablet application called WellPATH will be used to help the subject with emotion regulation techniques. The tablet will be given at the beginning of treatment and will be returned at the end of treatment. 3) Invite caregiver participation, when appropriate.~Subjects in the PATH-PAIN group will receive 8 weekly sessions (first 8 weeks) with a study therapist and 6 monthly phone sessions (3 individual and 3 group) for 9-36 weeks. Each session will last approximately 50 minutes."
223886391|NCT03652428|DRUG|Gemcitabine|see arm description
223886392|NCT03652428|RADIATION|Hypofractionated Ablative Proton Therapy|see arm description
223886393|NCT02328872|DEVICE|Molecular testing for HPV|Molecular testing for HPV with a test allowing partial genotyping for separate identification of types 16/18 from cervical samples. The technology used in this trial will be approved by the Therapeutic Goods Administration (TGA) Australia. It will identify the major HPV oncogenic genotypes in a pool and separately identify HPV 16 and 18. It will also satisfy performance criteria for relative sensitivity and specificity compared to Hybrid Capture 2 (HC2 ) as articulated by Meijer et al, 2009, Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older.
223886394|NCT02328872|DEVICE|Liquid Based Cytology|The liquid based cytology (LBC) used in this trial will be will be approved by the Therapeutic Goods Administration (TGA) Australia for LBC and appropriately validated and (TGA approved) to perform human papillomavirus testing from a cytology sample.
223886395|NCT05581992|DRUG|AMG 510|Oral Tablet
223886396|NCT05581992|DRUG|Omeprazole|Capsule
223886397|NCT06262334|BEHAVIORAL|The Fade to Fitness Program|The Fade to Fitness Program is a group-based and barbershop-based behavioral intervention to improve health-related quality of life among African American men. The program is unique because it is culturally targeted and individually tailored. The culturally targeted content was developed following barbershop-based focus groups. The Fade to Fitness Program targets four behaviors strongly linked to health-related quality of life among African American men - physical activity, healthy eating, stress management, and depression management. During the group-based portion of the program, Motivational Interviewing is used by the facilitator as a conversational approach to enhance participants\&#39; motivation and commitment towards positive behavior change. The goal is to foster intrinsic motivation among participants to engage in these behaviors. It is individually tailored by encouraging participants to identify personal values and linking them to health promoting behaviors.
223886398|NCT05938283|DEVICE|Implantable Cardioverter Defibrillator implant|ICD implant to protect patients from life threatening ventricular tachycardia or ventricular fibrillation
223886399|NCT06224517|OTHER|Rehabilitation|The intervention includes daily physical and occupational therapy sessions tailored to each patient's functional status. In this study, stroke patients will undergo a four-week rehabilitation therapy program comprising 60-minute daily sessions of physical and occupational therapy. The physical therapy includes balance training, mobility and strengthening exercises, while occupational therapy covers sensorimotor and fine motor training, and ADL activities.
223886400|NCT06512194|DRUG|Psilocybin|The psilocybin used in this study is synthesized under Good Manufacturing Practice (GMP) guidelines and is provided in a capsule containing 25 mg of synthetic psilocybin.
223886401|NCT06512194|DEVICE|Transcutaneous Auricular Vagus Nerve Stimulation (taVNS)|Participants will be provided with a taVNS device and trained on its use. The device delivers gentle stimulation to the left ear.
223886402|NCT06512194|DEVICE|Sham taVNS|Participants will be provided with a taVNS device and trained on its use. The device delivers gentle stimulation to the left ear. In the sham condition, the device will simulate the sensations of active taVNS without delivering therapeutic stimulation.
223886403|NCT04494555|DEVICE|Static socket|For the static socket configuration, both the microprocessor control and user control are disabled, and the panels are positioned in their flush configuration to create the user's as-prescribed socket shape.
223886404|NCT04494555|DEVICE|User adjusted socket|Sockets are configured for user control by disabling automated control and enabling push buttons on the side of the socket to adjust socket size. Each button push effects a socket size change of approximately 0.3% volume. An upper button effects a socket size increase, and a lower button a socket size decrease. The buttons are countersunk so reduce risk of accidental pushes, and they do not function unless the user is stationary. An additional button push will not be executed until motor motion from the prior push has been completed. If a button is continuously held then the motor will continue moving until the button is released. Limits are set on cable length to ensure that sockets sizes threatening to the user's residual limb (too tight) are avoided. The push buttons effect inner-loop control that operates completely within the mechanism, achieving high-resolution adjustment of cable length with minimal error.
223886405|NCT04494555|DEVICE|Microprocessor-adjusting sockets|"A strategy for automatically controlling the size of the socket during walking to compensate for unknown changes in limb volume will be used. The controller is essentially a regulator that continuously measures socket fit, and adjusts the socket to maintain a prescribed reference set point. Because the fit is automatically sustained, the prosthesis user is unaware of its operation."
223886406|NCT04950192|DEVICE|ICE Image guidance|ICE image guidance will be used on all patients undergoing planned cardiac catheterization procedures
223886407|NCT03541486|DRUG|Ascorbate|75 gram infusion daily (M-F) on days when radiation therapy is administered. The infusion occurs during the 'beam on' of the radiation therapy.
223886408|NCT03541486|DRUG|Gemcitabine|600 mg/m2 once weekly for up to weeks
223886409|NCT03541486|RADIATION|radiation therapy|Prescribed to 50 Gy in 25 fractions. Radiation is delivered 1 fraction/day, 5 days a week, for approximately 5 to 6 weeks.
223886410|NCT04705441|BEHAVIORAL|SMART 2|Participants receiving the SMART intervention will participate in 8 group-format 45-60 minute sessions (up to 10 participants per group), which will be collaboratively delivered over Zoom by a Nurse Educator and a Peer Educator with epilepsy. Telephone call-in and supplemental printed materials will be available for those who do not have internet access. The initial group session portion of SMART will be completed over 10-12 weeks. Educational components address the challenges imposed by epilepsy and comorbidity, as well as problem-identification and goal-setting, while Peer Educators and the group format address adherence, social support/social isolation, and self-efficacy. Following group sessions, participants will have 3 brief (no more than 15 minutes) monthly web-based or telephone maintenance sessions conducted by the Nurse Educator. Telephone sessions will address on-going issues of epilepsy self-management, including treatment adherence.
223886411|NCT06099184|DRUG|EYP-1901|Intravitreal Injection
223886412|NCT06099184|DRUG|Aflibercept 2Mg/0.05Ml Inj,Oph|Intravitreal Injection
223886413|NCT06794814|BEHAVIORAL|oral exercise|The oral exercise protocol included several physical components, namely neck and shoulder stretching, cheek puffing exercises, tongue exercises, salivary gland massage, and oral diadochokinesis.
223886414|NCT06798142|PROCEDURE|extracorporeal treatment|Extracorporeal treatments included hemoperfusion (HP) and continuous veno-venous hemodiafiltration (CVVHDF).
223886415|NCT06839807|DEVICE|AtMoves Knee System|The AtMoves Knee Stystem is a loading device that is able to exert force in varus and valgus. when these forces are applied during a CT-scan micromotions of the tibial component of the total knee prosthesis can be detected.
223886416|NCT06052150|PROCEDURE|Dental exam and periodontal cleaning if needed|Dental exam and periodontal cleaning if needed
223886417|NCT06170385|BEHAVIORAL|Physical Therapy|Each physical therapy session will commence with a 5-minute warm-up, with fun activities to mobilize the joints and activate the muscles, using the videos available in the HEAL-ME platform. The warm-up session will be followed by a 20 to 40-min program with tailored activities and games comprising jumping, squatting, skipping, balancing, and jogging. The session will finish with a 5-minute cool down with stretching exercises and a relaxation video from the HEAL-ME platform.
223886418|NCT01086527|DRUG|10 mg tablet of montelukast (Singulair)|Fasting patients will take a single 10 mg tablet of montelukast with 240 ml of Gatorade. Eight blood samples will be drawn to assess the plasma concentration of montelukast over the subsequent 12 hours.
223886419|NCT05549037|DRUG|Pembrolizumab, Sintilimab|One for morning group, the patients in this group were treated with immunochemotherapy before 15:00. One for afternoon group, the patients in this group were treated with immunochemotherapy after 15:00.
223886420|NCT06799507|BEHAVIORAL|Interventions Based on Mindfulness|Affirmation, Relaxation, Mindfulness, Meditation, Healthy Lifestyle, Quality Life
223886421|NCT06799507|OTHER|Routine clinical procedure|Routine clinical procedure
223886422|NCT06798493|OTHER|Complex Regional Pain Syndrome (CRPS) Severity Score - Self Report|Self-report tool in a questionnaire format to capture CPRS Severity Score.
223886423|NCT06163157|OTHER|Connective tissue massage(CTM)|CTM will be applied by a trained physiotherapist for 3 days/week for 4 weeks. Application time will be approximately 15-20 minutes.
223886424|NCT03972813|BEHAVIORAL|Broadened information about cancers|Caregivers receive information that HPV causes more than just cervical cancer.
223886425|NCT03972813|BEHAVIORAL|Information about STDs|Caregivers learn that HPV is an STD.
223886426|NCT03972813|BEHAVIORAL|Information about infectious disease|Caregivers learn that HPV is infectious (but information that it is an STD is omitted).
223886427|NCT03972813|BEHAVIORAL|Recommendation for children 12 years old|Caregivers are prompted to get their child vaccinated when the child is 12 years old.
223886428|NCT03972813|BEHAVIORAL|Recommendation for children 18 years old|Caregivers are prompted to get their child vaccinated when the child is 18 years old.
223886429|NCT03972813|BEHAVIORAL|Standard age information|Caregivers are given information about when the HPV vaccination can be given in China, but no additional recommendations.
223886430|NCT03972813|BEHAVIORAL|Cervical cancer|Caregivers are told that HPV causes cervical cancer.
223886431|NCT03972813|BEHAVIORAL|Blank information about communicability|Caregivers are not given any information on how HPV is spread.
223886432|NCT03836417|DIAGNOSTIC_TEST|Microarray analysis|Microarray analysis to identify gene expression profiles that distinguish IPF from NSIP
223886433|NCT06795503|DRUG|Docetaxel plus cyclophosphamide|Docetaxel (T) at a dose of 75 mg/m² was administered intravenously on Day 1 of each cycle, and Cyclophosphamide (C) at a dose of 600 mg/m² was administered intravenously on Day 1 of each cycle as well.
223886434|NCT06795503|DRUG|Epirubicin, cyclophosphamide plus paclitaxel|Patients in the control group received the EC-P regimen chemotherapy, with a cycle length of 21 days, for a total of 8 cycles. The specific treatment was as follows: Epirubicin (E) at a dose of 90 mg/m² and Cyclophosphamide (C) at a dose of 600 mg/m² were administered intravenously on Day 1 of each cycle for the first 4 cycles. This was followed by Paclitaxel (P) at a dose of 80 mg/m², administered intravenously on Days 1, 8, and 15 of each cycle for the subsequent 4 cycles.
223886435|NCT05356117|BEHAVIORAL|Resistance Training (RT) and Protein Supplementation (PS)|Aerobic and resistance exercise with orally consumed pre-packed protein supplement
223886436|NCT05356117|BEHAVIORAL|Resistance Training (RT)|Aerobic and resistance exercise
223886437|NCT05356117|BEHAVIORAL|Attention Control (AC|Stretching
223886438|NCT06798558|DRUG|Lu-17-PSMA-617|Lu-17-PSMA-617 administration
223886439|NCT06565650|DRUG|Miebo|100% perfluorohexyloctane
223886440|NCT06565650|DRUG|Saline|0.6% sodium chloride solution
223886441|NCT05396924|PROCEDURE|Rectal temperature measurement|Patients will be operated in the same operating room and at the same room temperature with the same type/amount of covering and body warming. At the start of the surgical procedure, a probe inserted into the rectal mucosa will measure the patient's body temperature every 15 minutes. In addition, the temperature of the patients will be measured from their temporal regions with a contactless thermometer. The data obtained will be analyzed by a blinded researcher. Mean body temperatures measured from 2 different locations (temporal region and rectal mucosa) between the groups will be compared, and the probability of detecting early local and later general hypothermia from the rectal mucosa will be examined
223886442|NCT05396924|PROCEDURE|Temporal temperature measurement|Patients will be operated in the same operating room and at the same room temperature with the same type/amount of covering and body warming. At the start of the surgical procedure, a probe inserted into the rectal mucosa will measure the patient's body temperature every 15 minutes. In addition, the temperature of the patients will be measured from their temporal regions with a contactless thermometer. The data obtained will be analyzed by a blinded researcher. Mean body temperatures measured from 2 different locations (temporal region and rectal mucosa) between the groups will be compared, and the probability of detecting early local and later general hypothermia from the rectal mucosa will be examined
223886443|NCT05600842|RADIATION|Intensity-Modulated Radiation Therapy (IMRT)|IMRT will be given in 30 daily fractions at 2 Gy per fraction (60 Gy total) beginning Day 1; Six fractions will be delivered per week. High risk patients will receive induction chemotherapy with 2 cycles of carboplatin and paclitaxel.
223886444|NCT05984784|DRUG|Placebo|Drug: Placebo Intravenous Infusion
223886445|NCT05984784|DRUG|IMG-007|Drug: IMG-007 Intravenous Infusion
223886446|NCT02365766|DRUG|Pembrolizumab|In this dose-finding cohort, pembrolizumab (MK-3475) will be administered (cisplatin-eligible patients only) at starting dose 200mg IV every 21 days for 4 cycles to determine RP2D. Once MTD is established in phase Ib, pembrolizumab will be administered on phase II cohorts I and II at RP2D every 21 days for 5 cycles.
223886447|NCT02365766|DRUG|Gemcitabine|For cisplatin-eligible patients on phase Ib and phase II cohort 1, gemcitabine 1000mg/m2 IV, D1 and D8 every 21 days for 4 cycles. For cisplatin-ineligible patients on phase II cohort II, gemcitabine 1000mg/m2 will be administered D1, D8 and D15 every 28 days for 3 cycles.
223886448|NCT02365766|DRUG|Cisplatin|For cisplatin-eligible patients, cisplatin 70mg/m2 IV will be administered D1 every 21 days for 4 cycles.
223886449|NCT02365766|PROCEDURE|Consolidative Surgery|Following completion of treatment, subjects will then have surgery to remove their primary tumor within 2-7 weeks after their last dose of neoadjuvant therapy.
223886450|NCT04804514|DRUG|KH001|The study drug is applied to teeth
223886451|NCT04804514|DRUG|Placebo|The placebo is applied to teeth
223886452|NCT06582953|BEHAVIORAL|Turning the Tide Violence Intervention Program (hospital violence intervention program)|TTVIP is already integrated into the regular care of patients who are violently injured and treated at MUSC Charleston. Client advocates provide immediate support, help with communication and provide anti-retaliation messaging to victims of violence and their families, in addition to helping support their healthcare. Patients that opt to be followed for long-term wrap-around services and live in the surrounding 3-county area are supported for months (up to 1 year) after injury and provided mentorship, service referrals (i.e. education, employment, substance abuse, injury recovery, pro-social activities, housing) and mental health services.
223886453|NCT06639841|DEVICE|Virtual Reality Psychotherapy|"Participants in this VR-facilited psychotherapy group will receive their treatment via Oculus Quest 2 and HTC Vive Flow wireless, standalone headsets systems to provide a comfortable immersive environment. The more hardware-intensive experiences will be carried out on Oculus Rift S headsets powered by high-end laptops.~Sessions will last 30-60 minutes each, ranging from six to ten sessions within two to four weeks. The treatment will include reducing anxiety and improving emotion regulation through Cognitive-Behavioural techniques such as mindfulness, acceptance and commitement therapy, exposure therapy and 4-7-8 breathing. The same investigator will conduct all sessions to ensure uniformity. Additionally, subjects will undergo unsupervised VR at home with pre-programmed headsets to minimize investigator bias and maintain cosistancy of the relaxation and cognitive-behavioral strategies."
223886454|NCT06639841|BEHAVIORAL|Yoga|"The Yoga group members will be guided in a yoga class focused on managing performance anxiety. The interventions will consist of body exercises (Asanas), breath (Pranayama) and meditation to increase relaxation, consciousness and resilience; typical yoga postures like Surya Namaskar, Padahastasana, Virabhadrasana, Bhujangasana and Shavasana will be included in the session, as will breathing movements like Ujjayi (Victory Breath).~Each class will be 60-90 minutes long, and 6-10 classes will be taught in two to four weeks. The technique will be progressive, from the basic to more advanced postures as participants cultivate confidence and resilience. All classes will conclude with meditation to ease tension and cultivate mindfulness."
223886455|NCT05013658|BEHAVIORAL|pressure measurement|pressure measurement with pilot balloon palpation
223886456|NCT05166811|DRUG|Magnesium Sulfate, Heptahydrate|A single dose of intravenous magnesium sulfate given over 20 minutes through a peripheral intravenous line. Two arms of the study will deliver intravenous magnesium, one at a dose of 50 mg/kg, and the other at a dose of 75 mg/kg.
223886457|NCT05166811|DRUG|0.9% saline|A single dose of intravenous 0.9% sodium chloride given over 20 minutes through a peripheral intravenous line as the placebo arm of the study.
223886458|NCT05652569|OTHER|Genomic Profiling / Sequencing|Procedure: genomic profiling (Whole-Genome- / Exome-Sequencing + RNA-Sequencing) on metastatic biopsy lesions
223886459|NCT03763708|DEVICE|Spinal Cord Stimulation|Programming
223886460|NCT06637137|DRUG|Iron|Patients who present a state of hypoferritinemia or a state of reduced transferrin saturation will undergo administration of i.v iron at least 2 weeks before scheduled cardiac surgery, plus acid folic and B vitamin co-administration.
223886461|NCT06386874|DEVICE|Q Therapeutic System (BQ 3.0) - Sham|The BQ 3.0 is a medical device that produces and delivers non-invasive, extremely low intensity and frequency (1-100 Hz.; 0.1-1.0 G), frequency tuned electromagnetic fields in order to stimulate neuronal networks with the aim of reducing disability and promoting neurorecovery. Frequency and intensity parameters will be set to zero so that no stimulation is delivered.
223886462|NCT06386874|DEVICE|Q Therapeutic System (BQ 3.0) - Active|The BQ 3.0 is a medical device that produces and delivers non-invasive, extremely low intensity and frequency (1-100 Hz.; 0.1-1.0 G), frequency tuned electromagnetic fields in order to stimulate neuronal networks with the aim of reducing disability and promoting neurorecovery
223886463|NCT06638411|BEHAVIORAL|ADHD information workshop|ADHD information workshop that will be delivered by a clinical psychology student in one 30-minute session to a group of participants. The workshop will present information about lesser-known or commonly misdiagnosed ADHD symptoms. To control for the duration of the nocebo module (see the condition below), participants will also learn about sleep and its relevance for maintenance of good cognitive health. At the end, the workshop will involve a writing reflection activity about personal experiences with ADHD symptoms.
223886464|NCT06638411|BEHAVIORAL|ADHD information workshop with nocebo education|ADHD information workshop that will be delivered by a clinical psychology student in one 30-minute session to a group of participants. The workshop will present information about lesser-known or commonly misdiagnosed ADHD symptoms, together with a module on nocebo effects and their potential role in worsening symptoms. The nocebo module will describe the current understanding of the role of expectations in creating side effects and elaborate on how this applies to the field of mental health through a series of examples. It will also involve a writing reflection activity about personal experiences with ADHD symptoms, potential for nocebo effect when talking about ADHD symptoms, and ability to apply this information to personal experiences.
223886465|NCT06638411|BEHAVIORAL|Sleep workshop|An information workshop about sleep and dream experiences that will be delivered by a clinical psychologist in one 30-minute session to a group of participants. It will be matched on duration, type of content, and engagingness with the experimental sessions.
223886466|NCT06281418|DRUG|Granisetron 1 Mg/mL Intravenous Solution|2mL intraperitoneal adminstration of granisetron (1 mg/mL)
223886467|NCT06281418|OTHER|Normal saline|2 ml IP normal saline (0.9% NaCl)
223886468|NCT04233021|DRUG|Osimertinib|Osimertinib 80 mg/d
223886469|NCT06563609|BEHAVIORAL|Intensive physical Therapy|Tailored exercise programs supervised by trained physiotherapists, focusing on improving cardiorespiratory fitness, strength, and functional capacity.
223886470|NCT06563609|DIETARY_SUPPLEMENT|Probiotic treatment|Administration of probiotic yeast Saccharomyces boulardii twice daily
223886471|NCT06563609|BEHAVIORAL|Individualised Nutritional Support|Personalized nutritional plans guided by a dietitian, addressing malnutrition and caloric/protein deficiencies with daily caloric intake adjustments and supplements if necessary based on the EFFORT trial.
223886472|NCT06563609|OTHER|Standard hospital care|Patients will receive standard hospital care
223886473|NCT05896254|DRUG|MAR001|Subcutaneous injection
223886474|NCT05896254|DRUG|Placebo|Subcutaneous injection
223886475|NCT06561152|DRUG|Tagraxofusp|Tagraxofusp is administered by intravenous infusion (IV) over 15 minutes for 3 consecutive days of a 28-day cycle. (days 4-6)
223886476|NCT06561152|DRUG|Cladribine (CLAD)|Cladribine 5mg/m2 IV once daily on days 1-3 (DL1) Cladribine 5mg/m2 IV once daily on days 1-4 (DL2) Cladribine 5mg/m2 IV once daily on days 1-5 (DL3)
223886477|NCT06561152|DRUG|Cytarabine|Cytarabine 20mg/m2 IV daily days 1-5 (DL1) Cytarabine 20mg/m2 IV daily days 1-7(DL2) cytarabine 20mg/m2 IV daily days 1-10 (DL3)
223886478|NCT05586711|DRUG|vaginal estradiol 10 μg|Vagifem® (estradiol), vaginal tablets
223886479|NCT05586711|DRUG|vaginal DHEA 6.5 mg|Intrarosa® (dehydroepiandrosterone; DHEA; prasterone), pessaries
223886480|NCT05272852|DEVICE|FARAPULSE™ Pulsed Field Ablation System Plus|Ablation using FARAPULSE™ Pulsed Field Ablation System Plus
223886481|NCT04933136|DEVICE|Terry2 Band|Hemostasis protocol following radial or cubital approach catheterization using the dual artery hemostasis device Terry2Band.
223886482|NCT06582758|BEHAVIORAL|Pain Psychoeducation|In the pain psychoeducation intervention, participants will be provided a four-minute recording about different pain management strategies (e.g., ice, rest) and accessible resources to promote overall well-being.
223886483|NCT06582758|BEHAVIORAL|Mindful Pain Management|In the mindful pain management intervention, participants will listen to a four minute mindfulness intervention consisting of a 1-minute introduction to mindful pain management and a 3-minute mindfulness practice.
223886484|NCT01904188|DEVICE|Gene Z or other rapid diagnostic techniques developed in our lab (as of 2018 not using Gene Z - now using In-Dx along with other developed techniquesregularly)|The Gene Z device (no longer in use) and now using In-Dx created in our lab, and other rapid diagnostic techniques that we have developed in our lab will be used to analyze previously processed specimens for microbial organisms and compared to prior culture and sensitivity results. It is not a separate arm - all samples will be cultured in lab per standard protocol and then the Gene Z device or other rapid diagnostic techniques developed in our lab will be used to re-analyze at a later date specimens that were previously frozen and stored and compared to culture results
223886485|NCT06349213|RADIATION|FDOPA injection before PET imaging|Fluorodopa labelled with fluorine 18 (physical half-life of 109.6 min) is used at a dosage of 1 to 2 MBq/kg in neuroimaging, depending on the sensitivity of the PET camera used. For these reasons, a dose of 2 MBq/kg will be administered slowly intravenously (approximately 1 minute for a maximum bolus of 10 mL). PET acquisitions will be performed at 90 minutes post-injection and will last 30 minutes. Participants will be asked to have fasted for at least 4 hours at the time of injection, with no restriction on fluid intake.
223886486|NCT06349213|BEHAVIORAL|Time perception tasks|The main tasks involves the comparison of duration to assess aging effects on the precision of temporal representations
223886487|NCT06349213|DEVICE|fMRI imaging|Imaging of brain structure during the completion of the time perception task
223886488|NCT06349213|DEVICE|EEG imaging|Recording of neural dynamics during the completion of the time perception task
223886489|NCT06349213|BEHAVIORAL|3 year follow-up|Behavioral and EEG follow-up (for older adults only)
223886490|NCT06490705|OTHER|tongue resistance exercises, tongue strengthening exercises and tongue resistance exercises|"6 days a week, 3 times a day (before meals), with each session lasting 30 minutes. Don't hold your breath during exercise.~Before conducting the study, all participants received a complete explanation of the purpose, risks, and procedures of the investigation, and provided written informed consent. Procedures were in accordance with the ethical standards of the committee on human experimentation at the institution at which the work was conducted and this study was approved by the Institutional Review Board."
223886491|NCT02991534|BEHAVIORAL|CV Toolkit Components|"* Patient completes a CV self screener.~* Patient discusses CV risks factors with primary care providers and CV risks are documented and discussed for action steps and referrals.~* Patient will be recommended to attend a gender tailored facilitated workgroup - Gateways to Healthy Living to make specific SMART goals and commit to patient preferred services or program"
223886492|NCT03392181|DRUG|18F-DCFPyL|To determine whether PET/MR utilizing PYL improves pre-operative staging of prostate cancer prior to radical prostatectomy compared to MRI alone.
223886493|NCT06153290|PROCEDURE|Chiropractic adjustment|A single-session of genuine/real high-velocity, low-amplitude (HVLA) manual chiropractic adjustments to various regions of the spine (i.e., cervical, thoracic, lumbo-pelvic)
223886494|NCT06153290|PROCEDURE|Sham adjustment|A single-session of simulated/sham high-velocity, low-amplitude (HVLA) manual chiropractic adjustments to various regions of the spine (i.e., cervical, thoracic, lumbo-pelvic)
223886495|NCT06371209|PROCEDURE|Modified Amputation|Modified amputation procedure
223886496|NCT06371209|PROCEDURE|Standard Amputation|Standard amputation procedure
223886497|NCT06395038|DRUG|Abatacept plus Aldesleukin|CTLA4IgG plus Low dose Interleukin-2 (Aldesleukin) administration to modify immune responses
223886498|NCT05098405|DRUG|MP0317, a tri-specific fibroblast activation protein (FAP) x CD40 DARPin® drug candidate (q3w regimen)|"The study will start with dose-escalation cohorts to determine the recommended dose for expansion (RDE) or the maximum tolerated dose (MTD).~Once the RDE (or MTD) has been determined, a safety expansion cohort will be opened and additional patients will be treated with MP0317 monotherapy at this dose to confirm safety in a larger population.~Study treatment will be administered every 3 weeks (q3w) as an intravenous (IV) infusion until progressive disease (PD), unacceptable toxicity, withdrawal of consent or other reasons to discontinue treatment occur, whichever comes first. Treatment beyond PD will be allowed as per Immunotherapy Response Evaluation Criteria in Solid Tumors (iRECIST)."
223886499|NCT05098405|DRUG|MP0317, a tri-specific fibroblast activation protein (FAP) x CD40 DARPin® drug candidate (q1w regimen)|"The study will start with dose-escalation cohorts to determine the recommended dose for expansion (RDE) or the maximum tolerated dose (MTD).~Once the RDE (or MTD) has been determined, a safety expansion cohort will be opened and additional patients will be treated with MP0317 monotherapy at this dose to confirm safety in a larger population.~Study treatment will be administered every week (q1w) as an intravenous (IV) infusion until progressive disease (PD), unacceptable toxicity, withdrawal of consent or other reasons to discontinue treatment occur, whichever comes first. Treatment beyond PD will be allowed as per Immunotherapy Response Evaluation Criteria in Solid Tumors (iRECIST)."
223886500|NCT05610878|BIOLOGICAL|Cultured ASCs enrichment fat grafting|Patients will undergo conventional fat harvesting. Harvested fat will be mixed with cultured ASCs and grafted into recipient site with 1,00,000 cells/ml injected fat
223886501|NCT05610878|BIOLOGICAL|Curcumin-preconditioned ASCs enrichment fat grafting|Patients will undergo conventional fat harvesting. Harvested fat will be mixed with cultured ASCs preconditioned with curcumin and grafted into recipient site with 1,00,000 cells/ml injected fat
223886502|NCT05610878|OTHER|Conventional fat grafting|Patients will undergo conventional fat harvesting and grafting of fat into recipient site
223886503|NCT06191666|BEHAVIORAL|Group-based education and discussion|Group-based education and discussion (60 minutes each per week, virtual and in-person) based upon guidelines for nutrition for cancer survivorship (e.g., follow a plant-based diet with a variety of vegetables, fruits, whole grains, and legumes; limit alcohol intake; reduce consumption of highly processed foods and foods high in salt; achieve a weekly calorie deficit of approximately 3500 kcal for weight loss)
223886504|NCT06191666|BEHAVIORAL|Individual 1:1 counseling|Individual 1:1 counseling sessions (30 minutes each per month, virtual) with an RD to review progress and address barriers
223886505|NCT06191666|BEHAVIORAL|Group based behavioral skills development and cooking demonstrations|Group-based behavioral skills development sessions and cooking demonstrations (60-90 minutes each per month, in-person) to focus on behavior change techniques (e.g., self-monitoring, goal setting) and nutrition skills (e.g., recipe development, label reading).
223886506|NCT06191666|BEHAVIORAL|BfitBwell|This program consists of a supervised exercise program developed by a cancer exercise specialist and based upon the NCCN guidelines for physical activity during cancer survivorship and other recommendations.
223886507|NCT00931710|DRUG|valsartan, amlodipine, HCTZ|combination Valsartan/amlodipine160/5 mg tablet for 3 weeks; Valsartan/amlodipine 160/5mg tablet +HCTZ 25 mg capsule for 3 weeks; valsartan/amlodipine 320/10 mg tablet + HCTZ 25mg capsule for remainder (6 weeks) of the study
223886508|NCT00931710|DRUG|Losartan, HCTZ followed by valsartan, amlodipine, HCTZ|losartan 100mg capsule for 3 weeks; losartan 100mg capsule +HCTZ 25 mg capsule for 3 weeks; Valsartan/amlodipine 160/5mg tablet +HCTZ 25 mg capsule for 3 weeks; valsartan/amlodipine 320/10 mg tablet + HCTZ 25mg capsule for remainder (3 weeks) of the study
223886509|NCT04493125|DRUG|Mosapride citrate|Patients receive mosapride citrate (5mg/T) three times a day from the first day after surgery.
223886510|NCT04493125|DRUG|Placebo|Placebo
223886511|NCT04804072|DRUG|Medication for opioid-use disorder (MOUD) for opioid-use disorder (OUD)|MOUD for OUD
223886512|NCT04804072|DIAGNOSTIC_TEST|HIV testing|HIV testing
223886513|NCT04804072|DRUG|HIV treatment for participants living with HIV not already in care|HIV treatment for participants living with HIV not already in care
223886514|NCT04804072|DRUG|PrEP for participants without HIV|PrEP for participants without HIV
223886515|NCT04804072|DIAGNOSTIC_TEST|Testing and referral for vaccination or treatment for hepatitis A virus (HAV) and hepatitis B virus (HBV)|Testing and referral for vaccination or treatment for HAV and HBV
223886516|NCT04804072|DIAGNOSTIC_TEST|Testing and referral for treatment for hepatitis C virus (HCV)|Testing and referral for treatment for HCV
223886517|NCT04804072|DIAGNOSTIC_TEST|Sexually transmitted infection (STI) testing and treatment|STI testing and treatment
223886518|NCT04804072|OTHER|Primary care|Primary care
223886519|NCT04804072|BEHAVIORAL|Harm reduction services|Harm reduction services
223886520|NCT04804072|BEHAVIORAL|Peer navigation|Peer navigation
223886521|NCT04804072|DIAGNOSTIC_TEST|COVID-19 testing and referral for further evaluation, care and/or treatment|COVID-19 testing and referral for further evaluation, care and/or treatment
223886522|NCT04271202|DRUG|Emgality 120 MG in 1 ML Prefilled Syringe|Initial dose of 240 mg followed by 2 interventions (1 month apart) of 120 mg - all given as injectables.
223886523|NCT04554953|DRUG|Combination drug containing fimasartan and statins|"Patients who correspond to one of the following:~1. Patients who are planning to be treated with a combination drug containing fimasartan and statins after being newly diagnosed with essential hypertension and primary hypercholesterolemia~2. Patients who are planning to switch to a combination drug of fimasartan and statins, among those who have been diagnosed with essential hypertension or primary hypercholesterolemia and are receiving hypertension treatment that is containing an ARB or dyslipidemia treatment that is containing a statin~3. Patients who are planning to switch to a combination drug of fimasartan and statins, among those who have been diagnosed with essential hypertension and primary hypercholesterolemia and are receiving hypertension treatment that is containing an ARB and dyslipidemia treatment that is containing a statin"
223886524|NCT04418245|DIAGNOSTIC_TEST|Imaging by thoracic scanner|Low-dose computed tomography
223886525|NCT04830410|DIETARY_SUPPLEMENT|Fructan reintroduction|Patients will reintroduce fructan powder after 14-day of a low FODMAP diet
223886526|NCT04830410|DIETARY_SUPPLEMENT|Placebo reintroduction|Patients will reintroduce placebo powder after 14-day of a low FODMAP diet
223886527|NCT05775835|OTHER|Whole body vibration and strengthening exercise|Prior to commencing training, all subjects will undergo a pre-screening that includes a thorough history and physical examination to monitor compliance with the inclusion criteria. Evaluation parameters will be evaluated before and after 6 weeks of exercise. Training sessions will be held 3 days a week for 6 weeks, with a minimum of 48 hours between training sessions. All exercise groups include a warm-up period and a cool-down period (stretching exercises). Stretching exercises for the hamstring, gastrocnemius, soleus, and quadriceps muscles will be performed for 15-30 seconds and 3-5 repetitions. The total average application time (including warm-up and cool-down exercises), consisting of exercise and rest periods, was planned as 45-60 minutes for the WBV, SE, and WBV+SE groups.
223886528|NCT05775835|OTHER|Whole body vibration exercise|The application will be carried out with a whole body vibration device that gives 35 Hz constant vertical vibration. The exercises will be performed on the vibration platform in a standing position and with vibration. 5 static squats (in 90 degrees knee extension), mini squats (120 degrees knee extension), mini squat on the fingertip (120 degrees knee extension), right and left lunge positions, which will be accepted as 180 degrees full knee extension exercise protocol. During the squat exercises, the patient will be positioned with their feet open at shoulder level and the knee flexion angle will be adjusted with a goniometer by the physiotherapist before each training session. For static exercises, the duration will be 3 sets of 30-60 seconds in each practice position. There will be 30-60 second rest breaks between sets.
223886529|NCT05775835|OTHER|Strengthening exercise|"The exercises will be performed on the vibration platform but without vibration. Patients will be asked to hold a body bar corresponding to 10% of their body weight during exercises. 5 dynamics including squats (in 90 degrees knee extension), mini squats (120 degrees knee extension), mini squats on the toe tip (120 degrees knee extension), right and left lunge exercises, which will be accepted as 180 degrees full knee extension will perform an exercise protocol consisting of exercise. During the squat exercises, the patient will be positioned with their feet open at shoulder level and the knee flexion angle will be adjusted with a goniometer by the physiotherapist before each training session. For dynamic exercise, the duration will be 3 sets of 10 repetitions. Dynamic exercises will be performed with slow and controlled movements, consisting of 3 seconds of eccentric and 2 seconds of concentric phases."
223886530|NCT05969795|DIAGNOSTIC_TEST|Transvaginal ultrasound|Intermittent transvaginal ultrasound throughout the cycle to monitor follicular growth
223886531|NCT05969795|DIAGNOSTIC_TEST|Serial serum LH, E2, P4|Serial measurements of serum Luteinizing Hormone (LH), Estradiol (E2) and Progesterone (P4 )levels throughout the cycle to determine ovulation. LH-surge is identified when a rise of 180% above the previous level occurred and ovulation is confirmed with a decrease in E2 concentration, and a rise of progesterone level to ≥ 1.0 ng/ml (Irani et al., 2017).
223886532|NCT05969795|DRUG|Progesterone 100 Mg Vaginal Insert|On day of ET procedure, to administer 200 mg of vaginal progesterone and increase to 300 mg/day from the day after the ET onwards until the pregnancy test. In case of an implantation, vaginal P4 will be continued until 7 weeks of pregnancy
223886533|NCT05969795|DIAGNOSTIC_TEST|Serum P4 day of ET - Control Group|Serum P4 will be drawn before starting LPS in form of vaginal progesterone on the day of ET procedure
223886534|NCT05969795|DIAGNOSTIC_TEST|Serum P4 day of ET - Study Group|Serum P4 will be drawn when study group participants are admitted to the clinic for the ET procedure.
223886535|NCT05969795|PROCEDURE|Embryo transfer|The procedure in which embryo is placed in the uterus.
223886536|NCT05969795|DIAGNOSTIC_TEST|Serum hCG 10 days after ET|Pregnancy will be confirmed / excluded by measurement of serum hCG 10 days after ET procedure and a level of \> 15 IU will be regarded as positive result. The definitions of biochemical, ectopic, clinical and ongoing pregnancy follow the ICMART criteria (Zegers-Hochschild, 2006)
223886537|NCT05969795|DIAGNOSTIC_TEST|Serum P4 10 days after ET|Serum P4 will be drawn on day 5 or day 6 after the ET procedure and together with the hCG 10 days after ET procedure
223886538|NCT06850480|DRUG|JP-1366 simulation tablets|qd, last for 4-8 weeks
223886539|NCT06850480|DRUG|Esomeprazole Magnesium (Nexium) simulation tablets|qd, last for 4-8 weeks
223886540|NCT05016817|BIOLOGICAL|AlloRx|cultured allogeneic adult umbilical cord derived mesenchymal stem cells
223886541|NCT02323321|DEVICE|Preservation of Hearts for Transplantation|Preserving and Assessing Expanded Criteria Donor Hearts for Transplantation
223886542|NCT00446225|DRUG|Erlotinib|"150 mg/day Patients will receive treatment until disease progression or unacceptable toxicity.~For all practical effects a treatment cycle will be defined as three weeks of continuous treatment with erlotinib"
223886543|NCT00446225|DRUG|Carboplatin|"Gemcitabine 1000 mg/m2 days 1 and 8 and Carboplatin AUC = 5 day 1, every 21 days.~Docetaxel (75 mg/m2) /carboplatin (AUC=6); Gemcitabine (1000 mg/m2; day 1 and 8) / Carboplatin (AUC=5)~Patients in the chemotherapy arm will receive the treatment until disease progression or unacceptable toxicity occurs, or until a maximum of 4 treatment cycles are given."
223886544|NCT00446225|DRUG|Gemcitabin|Cisplatin (75 mg/m2) / Gemcitabine (1250 mg/m2; day 1 and 8) Patients in the chemotherapy arm will receive the treatment until disease progression or unacceptable toxicity occurs, or until a maximum of 4 treatment cycles are given.
223886545|NCT00446225|DRUG|Docetaxel|Cisplatin (75 mg/m2) / Docetaxel (75 mg/m2) Patients in the chemotherapy arm will receive the treatment until disease progression or unacceptable toxicity occurs, or until a maximum of 4 treatment cycles are given.
223886546|NCT00446225|DRUG|Cisplatin|Cisplatin (75 mg/m2) / Docetaxel (75 mg/m2) Patients in the chemotherapy arm will receive the treatment until disease progression or unacceptable toxicity occurs, or until a maximum of 4 treatment cycles are given.
223886547|NCT05204732|OTHER|Intonation training|The participants will receive intonation training (1h/week) for four weeks, aiming for more gender congruent intonation patterns.
223886548|NCT05204732|OTHER|Sham therapy + intonation training|The participants will first receive four weeks of sham therapy (with no expected effect on speech), during which information on voice functioning, voice surgery, voice hygiene, and transgender health care will be provided. In addition, during sham therapy, active intervention will be given around nonverbal communication. After four weeks of sham therapy, for ethical reasons, subjects in this group will also receive four weeks of intonation training (aiming for more gender congruent intonation patterns).
223886549|NCT04206540|DEVICE|Transcutaneous Auricular Vagus Nerve Stimulation|"Electrical stimulation of the vagus nerve around the external ear using a transcutaneous device. Electrical current will be increased in intensity based on subject feedback of a scale 0-10.~Electrical stimulation will be delivered for 2 minutes once the subject reports the maximum comfortable intensity."
223886550|NCT04206540|PROCEDURE|Vagal Stimulation|"Subjects will be asked to do the following in order to stimulate the vagus nerve:~* Cough 6 to 8 forceful coughs~* Have an ice cold wash cloth placed on their face for 10 seconds.~* Carotid massage~* Gagging: a tongue depressor is briefly inserted into the back of the mouth touching the bag of the throat.~* Valsalva maneuver: Subjects will be asked to bear down as if having a bowel movement. They will be asked to blow through a mouthpiece that is hooked to a device that measures how hard they are blowing. Alternatively, we can have them blow through the barrel of a 10 ml syringe for 15-20 seconds.~* Eating: Subjects will be asked to drink water and/or Ensure that has 220 calories after fasting overnight."
223886551|NCT05018871|BIOLOGICAL|autologous adipose derived mesenchymal stem cells|cultured autologous adult adipose derived mesenchymal stem cells
223886552|NCT04450342|DEVICE|Arthroscopic rotator cuff repair with REGENETEN™ Bioinductive Implant augmentation|The Arthroscopic rotator cuff repair aims at repairing the rotator cuff following tendon tear. The REGENETEN Bioinductive Implant is a medical device intended for the management and protection of tendon injuries. The REGENETEN Bioinductive Implant is indicated for the management and protection of rotator cuff tendon injuries in which there has been no substantial loss of tendon tissue. The REGENETEN Bioinductive Implant is a bioabsorbable implant device that provides a layer of collagen over injured tendons. The implant is designed to provide a layer of collagen between a flat tendon and the surrounding tissue. After hydration, the implant is an easy-to-handle, pliable, nonfriable, porous collagen sheet.
223886553|NCT04450342|PROCEDURE|Arthroscopic rotator cuff repair|The Arthroscopic rotator cuff repair aims at repairing the rotator cuff following tendon tear without supplement.
223886554|NCT04450342|DEVICE|Arthroscopic rotator cuff repair for revision surgery|The Arthroscopic rotator cuff repair can also occur in recurrent tears. The REGENETEN Bioinductive Implant will be applied during the ARCR procedure.
223886555|NCT05871346|BEHAVIORAL|Complementary feeding counseling|Complementary Feeding Counseling to Improve Appropriate Complementary Feeding Practices and Reduce Child Undernutrition
223886556|NCT06266130|DEVICE|Treatment Group Digital Bonding Tray|The Digital Bonding Tray is used in orthodontic treatment of misaligned teeth and provides a method to accurately position orthodontic brackets onto a patient's teeth simultaneously during a single procedure.
223886557|NCT06266130|DEVICE|Control Group Direct Bonding|The orthodontic brackets will be applied to Subject's teeth individually with direct bonding method.
223886558|NCT03526874|DRUG|Lidocaine 4% Topical Application Cream [LMX 4]|Run-in Step: All subjects receive 32 mg (4 cm ribbon of cream) applied, bilaterally, over greater occipital nerve.
223886559|NCT03526874|DRUG|Lidocaine Hydrochloride 2 mg/mL Injectable Solution|Subjects, who continue to experience headache pain after the run-in step, receive 2 (2 mL) injections of the active treatment.
223886560|NCT03526874|DRUG|Normal Saline|Subjects, who continue to experience headache pain after the run-in step, receive 2 (2 mL) injections of the comparator.
223886561|NCT00417560|BIOLOGICAL|inactivated influenza A/H5N1 vaccine|
223886562|NCT03379051|DRUG|Venetoclax|BCL-2 Inhibitor
223886563|NCT03379051|DRUG|Umbralisib|PI3K-Delta Inhibitor
223886564|NCT03379051|BIOLOGICAL|Ublituximab|Glycoengineered Anti-CD20 mAb
223886565|NCT03379051|DRUG|Lenalidomide|Thalidomide Analog, immunomodulatory agent with antiangiogenic and antineoplastic properties
223886566|NCT04353310|DRUG|Curcumin|Curcumin 1500mg PO BID
223886567|NCT04353310|OTHER|Placebo|identical in appearance to curcumin
223886568|NCT06495359|OTHER|immunization education program|The content of the immunization education program for parents was created by researchers based on the literature. Expert opinions will be obtained from 7 people who are experts in the fields of child health and disease nursing and public health nursing for the training program. The training program consists of 30 minutes. The education program will be delivered to parents in the form of a 30-minute training session using the face-to-face education model. Interactive education methods that enable parents' participation will be used.
223886569|NCT05308069|DEVICE|Single vision contact lens|Subjects will wear a single vision soft contact lens only during the study visit
223886570|NCT05308069|DEVICE|Multifocal contact lens|Subjects will wear a multifocal soft contact lens only during the study visit
223886571|NCT05961020|DEVICE|Total body vibration|Whole-body vibration (WBV) training has been established as a useful method to improve physical fitness in obese individuals. Vibration stimulus during half squatting might suggest a long-term effect of WBV on the endocrine system
223886572|NCT05961020|OTHER|moderate restricted diet|moderate restricted diet
223886573|NCT06202976|OTHER|Secondary data collection|clinical data
223886574|NCT05378256|OTHER|Clinical scales of CIPN|Patients with lymphoma will be evaluated before chemotherapy (T1), after 4 cycles (T2), at the end of the chemotherapy treatment (If more than 4 cycles) (T3) and 6 month after the end of chemotherapy (T4).
223886575|NCT06309264|DEVICE|Phonak Lumina P90|FDA approved hearing aid with gain settings determined either by speech-based audiometry or conventional fitting methods (NAL-NL2). Other features such as noise reduction and directional microphones are disabled for the duration of the study.
223886576|NCT04659811|DRUG|Pembrolizumab|200mg given intravenously (IV) on day 1 (to -1) of radiation and then every 3 weeks until progression or unacceptable toxicity
223886577|NCT04659811|PROCEDURE|Stereotactic Radiosurgery|Given in (a) single session treatment with margin dose of 15-20 Gy to the target for a maximum target volume of 8 cc or (b) five consecutive business days treatment to total dose of 25-30 Gy to the target for a maximum target volume of 20 cc when the target volume exceeds 8 cc or the target is in proximity to critical structures
223886578|NCT05611073|DIAGNOSTIC_TEST|Visual Acuity|Measurement of distance, intermediate and near visual acuity.
223886579|NCT05611073|DIAGNOSTIC_TEST|Biometric Data Collection|Measurement of biometric data will be obtained from the Zeiss IOL Master 700, Atlas 9000, and the iTrace.
223886580|NCT05611073|OTHER|Patient Questionnaire|Patients will complete a Patient Questionnaire to determine their level of spectacle independence and visual acuity satisfaction.
223886581|NCT05517278|OTHER|SurgX Antimicrobial Wound Gel|In addition to standard of care, at time of surgery, SurgX applied on the incision after closure and then re-applied at the time of first bandage change on day of discharge.
223886582|NCT05517278|OTHER|Standard of Care|The control group will receive standard of care.
223886583|NCT05609812|DRUG|Atacicept|Once weekly subcutaneous (SC) injections by prefilled syringe
223886584|NCT05609812|DRUG|Placebo|placebo
223886585|NCT06627530|DRUG|Darolutamide Oral Tablet|darolutamide 600 mg PO BID for 24 weeks
223886586|NCT06627530|DRUG|leuprorelin|leuprorelin depot 22.5 mg SC every 12 weeks
223886587|NCT05888311|DEVICE|Liquid bandage|Liquid elastic collodion- and benzethonium chloride-based topical solution
223886588|NCT06532227|OTHER|No intervention|No intervention excepted data collection
223886589|NCT04789486|DRUG|AGuIX|Injected gadolinium-based nanoparticles
223886590|NCT04789486|RADIATION|Radiotherapy|Stereotactic magnetic resonance-guided adaptive radiation therapy
223886591|NCT04166565|DRUG|Daratumumab|Daratumumab 16 mg/kg will be administered by i.v. infusion. Daratumumab will be administered weekly in Cycles 1 and 2, then every 2 weeks for Cycles 3-6, and thereafter every month up to 36 months.
223886592|NCT04166565|DRUG|Bortezomib|Bortezomib 1.5 mg/m2 bortezomib will be administered by a subcutaneous injection once weekly (Days 1, 8, 15 and 22) in all cycles.
223886593|NCT04166565|DRUG|Cyclophosphamide|"Cyclophosphamide 300 mg/m2 will be administered as a p.o. or i.v. weekly dose (Days 1, 8, 15, and 22) in every 28-day cycle (maximum weekly dose 500 mg).~Dexamethasone will be administered on Days 1, 2, 8, 9, 15, 16, 22 and 23 in all cycles. On daratumumab infusion days dexamethasone may be administered i.v. or p.o. approximately 1 hour before the daratumumab infusion. On days when daratumumab is not administered, dexamethasone is to be administered p.o."
223886594|NCT04166565|DRUG|Dexamethasone|Dexamethasone will be administered on Days 1, 2, 8, 9, 15, 16, 22 and 23 in all cycles. On daratumumab infusion days dexamethasone may be administered i.v. or p.o. approximately 1 hour before the daratumumab infusion. On days when daratumumab is not administered, dexamethasone is to be administered p.o.
223886595|NCT06611397|DEVICE|Discogen Low pulsed ultrasound treatment|"The device is a customized Low Intensity Pulsed Ultrasound (LIPUS) transducer system and power source. The transducer is biocompatible for skin contact. The system is capable of calibration to desired treatment parameters. The study subject will be placed in the prone position with all appropriate pressure points padded on the exam table. For the first treatment, fluoroscopic imaging (and/or ultrasonic guidance) will be used to guide the placement of the transducer over the anatomic target, unilateral at the L3-4, L4-5 or L5-S1 levels.~The skin of the study subject's back will be marked with non-washable marking pen to indicate the site for placing the transducer during the first treatment. The subsequent treatment (second and third) can be done without using ultrasound guidance. The transducer will be placed on the marked site during the second and third treatment.~The ultrasound signal will be delivered unilaterally for 25 minutes, using a timer visible to the patient. The power ge"
223886596|NCT06611397|DEVICE|Discogen Sham Treatment|The ultrasound signal will be delivered unilaterally for 25 minutes, using a timer visible to the patient. The power generator will not be turned on for the sham treatment, but the wave generator will be displayed. All study subjects will receive a total of three daily Discogen treatments over the span of a single M-M work week
223886597|NCT05328648|BEHAVIORAL|Community Score Card|In Community Score Card intervention, all communities associated with the targeted facilities will assess the primary barriers to quality family planning service delivery and develop indicators. The communities will then each complete the score card and generate ideas for quality improvement. Family planning providers in the target facilities will meet and determine the barriers to high quality family planning service delivery. Providers will decide on priority areas and make suggestions for improving service delivery. Study facilitators will bring these two groups together to share their respective score cards and jointly develop an action. Within the action plan, agreed upon responsibilities will be assigned and a timeline will be communicated.
223886598|NCT05328648|BEHAVIORAL|Citizen Report Card|Citizen Report Card (CRC): The data from the CRC questionnaire will be analyzed and translated into a report card. Extensive dissemination activities will ensure the CRC is widely shared with members of the community. The goal is to create a public record of service quality.
223886599|NCT05190705|DRUG|Loncastuximab Tesirine|Administered by intravenous infusion
223886600|NCT05190705|DRUG|Dexamethasone|Taken orally or administered by intravenous infusion
223886601|NCT05147779|BIOLOGICAL|AlloRx|cultured allogeneic adult umbilical cord derived mesenchymal stem cells
223886602|NCT03361748|BIOLOGICAL|bb2121|: bb2121 consists of autologous T lymphocytes transduced with an anti-BCMA02 CAR lentiviral vector to express a chimeric antigen receptor targeting the human B cell maturation antigen (anti-BCMA CAR).
223886603|NCT06932978|DEVICE|Provision of smart glasses for environmental control use|To the authors knowledge there has not been a clinical trial that includes the use of smart glasses with environmental controls. The smart glasses were used with environmental control systems that had a USB-C display output.
223886604|NCT05047224|BEHAVIORAL|Tele-assessment + in-person assessment|Participants will complete a tele-assessment using the TAP. They will complete a traditional, in-person autism spectrum disorder assessment approximately two weeks later.
223886605|NCT05047224|BEHAVIORAL|Tele-assessment only|Participants will complete a tele-assessment using the TAP. They will complete a second, shorter tele-assessment approximately two weeks later.
223886606|NCT03461978|DEVICE|Ultrahigh resolution Spectral Domain OCT|A spectrometer based ultrahigh resolution Spectral Domain OCT (SDOCT) system operating at 800 nm for the anterior chamber will be employed in the present study. The spectrum of the Ti:Sapphire laser light source is centered at 800 nm. With a full width at half maximum bandwidth of 170 nm, the axial resolution is 1.3 μm in the cornea. The transverse resolution of the employed OCT system is 21 μm at the front surface of the cornea. For measurement, patients will place their head in a modified slit lamp head rest. During the measurement period, patients will be asked to look straight forward onto an internal fixation target and to avoid blinking. Different scattering patterns, e.g. raster, circular and spiral scans will be employed.
223886607|NCT02677051|DRUG|Sulforaphane|Sulforaphane (1-isothiocyanato-4R- (methylsulfinyl)butane) is an isothiocyanate derived from the action of the plant enzyme myrosinase on glucosinolates including glucoraphanin and comes from consumption of many cruciferous vegetables.
223886608|NCT02677051|DRUG|Placebo|
223886609|NCT05920304|DEVICE|virtual Hospital at Home (vHaH)|"Participants randomized to vHaH will transferred home for home-based admission. Participants will be provided with equipment for self-monitoring (respiratory rate, oxygen saturation, blood pressure, heart rate and temperature). They will receive an app on their smartphone or tablet for transferring of self-measurements and communication with the hospital during their home-based admission.~Supporting the telemedicine concept, a mobile hospital-based care team will perform clinical tasks including intravenous administration, blood samples and on-site clinical assessment in the participant's home, when relevant.~Daily ward rounds will be conducted as video consultations. Before leaving the hospital, participants will receive thorough education on how to self-monitor and how to use the app."
223886610|NCT04075539|OTHER|Home-based cycling program|"Usual care (i.e. standardized prescription of 6 sessions of outpatient physiotherapy), and~* 1 supervised session of cycling aimed at explaining how to use the connected ergometric bicycle and at designing a personalized home-based cycling program~* a 12-month home-based cycling program using connected ergometric bicycles which intensity and dose are self-determined~* 3 phone or email contacts with a care provider to deliver positive feedbacks and encouragements"
223886611|NCT04075539|OTHER|usual care|A prescription of 6 sessions of outpatient physiotherapy
223886612|NCT05359653|DRUG|Clemastine Fumarate|8 mg Clemastine tablet. Clemastine fumarate was approved by the Food and Drug Administration (FDA) for the treatment of allergic rhinitis (seasonal allergies) in 1977 and was approved for over-the-counter marketing in 1992. Clemastine is not FDA approved as a remyelinating therapy
223886613|NCT05359653|DRUG|Placebo|Matched sugar tablet
223886614|NCT03643900|DEVICE|pancreatic duct stenting|Place the pancreatic duct stent
223886615|NCT03643900|DRUG|rectal indomethacin|rectal indomethacin 100mg at preoperative 30min
223886616|NCT06575816|BEHAVIORAL|Augmented Reality Video Intervention|This intervention involves a video intervention using augmented reality (AR) technology to reduce the pain, anxiety and fear children experience during the blood collection process. During the intervention, children watch AR videos to distract and relax them from the blood collection process. These videos are equipped with a variety of entertaining and engaging content and aim to reduce children's psychological stress.
223886617|NCT01361711|BIOLOGICAL|alemtuzumab|Given SC
223886618|NCT01361711|BIOLOGICAL|ofatumumab|Given IV
223886619|NCT01361711|PROCEDURE|biopsy|Correlative studies
223886620|NCT05982717|OTHER|No intervention|As this is an observational study, no intervention will be administered.
223886621|NCT05737160|BIOLOGICAL|Telitacicept|Administered as an SC infusion
223886622|NCT05737160|DRUG|Placebo|Administered as an SC infusion
223886623|NCT02596126|DRUG|Cardiovascular Polypill|"Cardiovascular Polypill contains Aspirin, Atorvastatin and Ramipril.~Participants will receive one of the following cardiovascular polypill:~(A) Aspirin 100 mg, Atorvastatin 40mg, and Ramipril (2.5 mg, or 5 mg, or 10mg).~or~(B) Aspirin 100 mg, Atorvastatin 20mg, and Ramipril (2.5 mg, or 5 mg, or 10mg)."
223886624|NCT02596126|DRUG|Treatment Prevention for Secondary CV|ESC Guideline (2013 guideline on management of stable coronary disease) recommended pharmacological treatment for event prevention.
223886625|NCT01790152|OTHER|Assessment of Therapy Complications|Ancillary studies
223886626|NCT01790152|OTHER|Laboratory Biomarker Analysis|Correlative studies
223886627|NCT01790152|OTHER|Quality-of-Life Assessment|Ancillary studies
223886628|NCT01790152|OTHER|Questionnaire Administration|Ancillary studies
223886629|NCT04923932|DRUG|Savolitinib|Patients meeting the study inclusion criteria will receive Savolitinib \[Savolitinib 600 mg, po, once per day (QD) continuously in patients with baseline weight ≥50 kg, and Savolitinib 400 mg, po, QD in patients with baseline weight \<50 kg\] in 21 day treatment cycle, until disease progression, death, intolerable toxicity or other termination criteria as specified in the protocol, whichever occurs earliest.
223886630|NCT04351555|DRUG|Osimertinib|Oral
223886631|NCT04351555|DRUG|Cisplatin|Cisplatin (75mg/m2) to be administered with pemetrexed on Day 1 of every 3-week cycle for 3 cycles.
223886632|NCT04351555|DRUG|Carboplatin|Carboplatin (AUC5) to be administered with pemetrexed on Day 1 of every 3-week cycle for 3 cycles
223886633|NCT04351555|DRUG|Placebo|Oral
223886634|NCT04351555|DRUG|Pemetrexed|Pemetrexed (500 mg/m2) to be administered with cisplatin or carboplatin on Day 1 of every 3-week cycle for 3 cycles
223886635|NCT06370793|OTHER|Patient with schizophrenia without intervention|Patients with schizophrenia identified based on exposures of interest to the study
223886636|NCT03403478|OTHER|LICE|No specific exercise will be performed. The participant will walk into the pool accompanied with a researcher for 45 minutes.
223886637|NCT03403478|OTHER|MICE|"The following exercises will be carried out: a) jumping jacks (shoulder abduction and adduction); b) horizontal adduction and abduction of the shoulder; c) stationary running with knee elevation; d) pull and push horizontally with upper limbs; e) pull and push vertically with upper limbs.~Note: For exercises 'a' and 'b', the legs alternated in movements in the sagittal plane to provide greater stability to the participant's movement. For exercises 'd' and 'e', the legs simulates a stationary running."
223886638|NCT03403478|OTHER|HIIE|"The following exercises will be carried out: a) jumping jacks (shoulder abduction and adduction); b) horizontal adduction and abduction of the shoulder; c) stationary running with knee elevation; d) pull and push horizontally with upper limbs; e) pull and push vertically with upper limbs.~Note: For exercises 'a' and 'b', the legs alternated in movements in the sagittal plane to provide greater stability to the participant's movement. For exercises 'd' and 'e', the legs simulates a stationary running."
223886639|NCT03403478|OTHER|Aquatic exercise training|"The sessions of the aquatic exercise training will be divided into 3 phases: warm-up (10 minutes), main part (40 minutes) and cool down.~In order to increase intensity to aquatic exercise, the training program will carried out as follows:~From week 1 to 4 the instructors will use a 128 bpm musics in both warm-up and cool down. In main part, will be used a 130 bmp musics.~From week 5 to 8 the instructors will use a 130 bpm musics in both warm-up and cool down. In main part, will be used a 132 bmp musics.~From week 9 to 12 the instructors will use a 132 bpm musics in both warm-up and cool down. In main part, will be used a 135 bmp musics."
223886640|NCT01784575|OTHER|Patient Navigator Intervention|The Patient Navigator Intervention will include 2 - 20 minute sessions with a patient navigator in which women are shown publicly available health care quality data about local pediatric practices on a non-profit quality collaborative's web site.
223886641|NCT05134324|OTHER|active rTMS|Participants recevied 1 Hz low frequency repetetive TMS during 20 minutes and a total of 1200 stimuli for 15 sessions. Motor threshold was defined as the minimum stimulus intensity eliciting 5 responses of about 50 µV out of 10 consecutive trials (50% successful MEPS) in the relaxed contralateral abductor pollicis brevis (APB).The patient received robotic therapy for upper extremity just after each active TMS sessions.
223886642|NCT05134324|OTHER|sham rTMS|Participants recevied sham TMS during 20 minutes and a total of 1200 sham stimuli for 15 sessions with sham coil employed was identical in shape and size to the real stimulation coil and produced no magnetic field. The patient received robotic therapy for upper extremity just after each sham TMS sessions.
223886643|NCT05134324|OTHER|active tDCS|Participants recevied 2 mA anodal transcranial direct current stimulation 20 minutes for 15 sessions.The electrodes will be placed anodal to the C3/C4 (International 10/20 Electroencephalogram System) area, corresponding to the location of the affected hemisphere primary motor cortex (M1), and cathodal to the contralateral supraorbital region. The patient received robotic therapy for upper extremity just after each active tDCS sessions.
223886644|NCT05134324|OTHER|sham tDCS|Participants recevied sham stimulation were applied current was ramped up either over 10 seconds, with an equal amount of time for tapering off. The patient received robotic therapy for upper extremity just after each sham tDCS sessions
223886645|NCT06645652|BEHAVIORAL|Training in observational drawing|"* 6 weeks of online gallery browsing based on different topics~* Daily practice drawing from observation with training adding up to 1 hour a week~* Documenting progress and reflection writing"
223886646|NCT06645652|BEHAVIORAL|Arts engagement through digital galleries|"* 6 weeks of online gallery browsing based on different topics~* 2 hours of weekly activities consist of reading and navigating technology~* Reflection writing"
223886647|NCT06645808|BIOLOGICAL|89Zr-DFO-N-Suc-F8scFv|89-Zirconium labeled short-chain variable fragment F8 targeting oncofetal CS.
223886648|NCT06645808|BIOLOGICAL|89Zr-DFO-N-Suc-C9scFv|89-Zirconium labeled short-chain variable fragment C9 targeting oncofetal CS.
223886649|NCT06645808|RADIATION|PET/CT scan|IMP administration will be followed by PET/CT scans on day 1, 2 and 4.
223886650|NCT01638026|DRUG|TRIPTORELIN ACETATE, hCG|In the study group women will receive GnRH agonist (decapeptyl 0.2 mg) for oocyte maturation, followed by ovum pick-up which will be performed 35 hours later. Embryo transfer will be performed 48-72 hours after ovum pick-up. Luteal support will include HCG 1500 IU.
223886651|NCT01791816|DRUG|Phenylephrine|"Phenylephrine dose-response comprises infusion of 0.5, 1, 2, 3, 4 micrograms/kg/min for 10 min at each dose.~If bloods pressure increases by 30% or if heart rate decreases below 40 beats per minute we will stop infusion."
223886652|NCT01791816|DRUG|L-Ng-monomethyl Arginine (L-NMMA)|Systemic L-NMMA is infused as a 500μg/kg/min loading dose for 15 min followed by a 50μg/kg/min maintenance dose for the remainder of the experiment.
223886653|NCT02990234|PROCEDURE|Capsular Repair|
223886654|NCT02990234|PROCEDURE|No Capsular Repair|
223886655|NCT03902132|OTHER|Core Stability exercises group|Core Stability Exercises were given in addition to the traditional physical therapy treatment as given to the control group. It included moist heat pack (10mins), Transcutaneous Electrical Nerve Stimulation (10 min), and strengthening regimen (2 sets with 15 isometric repetitions each).
223886656|NCT03902132|OTHER|Traditional low back physical therapy group|The control group was given traditional low backache physical therapy management such as moist heat pack, TENS, and strengthening regimen (2 sets with 15 isometric repetitions each)
223886657|NCT00226889|DRUG|bosentan|
223886658|NCT04570592|DRUG|Granisetron 1 Mg/mL Intravenous Solution And Dexamethasone 4mg|Comparing PONV incidences in both arms
223886659|NCT04570592|DRUG|Granisetron 1 Mg/mL Intravenous Solution|Comparing PONV incidences in both arms
223886660|NCT00145236|DRUG|Nebivolol|
223886661|NCT02808767|DRUG|Prasugrel|Prasugrel 60 mg loading dose and 10mg/5mg once daily maintenance dose
223886662|NCT02808767|DRUG|Ticagrelor|Ticagrelor 180 mg loading dose and 90 mg twice daily maintenance dose
223886663|NCT00220038|BEHAVIORAL|smell tests|subjects are instructed to sniff two vials, one containing the solvent, the other a dilution of the odorant. They are asked to scan the vial with the stronger odor.
223886664|NCT02629679|BEHAVIORAL|Regular scholastic system and organized sports|This group will consist of children involved in regular school system who at the same time participate in organized sport in sport-clubs
223886665|NCT02629679|BEHAVIORAL|Regular scholastic system|The group will consist of children who are regularly in school, but not being involved in organized sport activities
223886666|NCT05119543|OTHER|outdoor time|This cohort study aimed to assess the change of refractive status in Chinese school children under different outdoor time
223886667|NCT03580200|OTHER|Trigger Point Dry Needling|For the purposes of this study, the term trigger point dry needling will be used to describe deep dry needling of muscle tissue. The goal of trigger point dry needling is to eliminate myofascial trigger points within muscle tissue, thereby reducing pain as well as improving motor control and function (Caramagno et al., 2015; Dommerholt et al., 2006; Shah et al., 2015). Trigger point dry needling utilizes a solid filiform needle and focuses on the penetration of a palpable myofascial trigger point at various depths. The needle is then manipulated within the tissue in an attempt to elicit a localized twitch response. Once the localized twitch response has ended, the needle is removed and another myofascial trigger point is located.
223886668|NCT00903474|OTHER|questionnaire administration|
223886669|NCT00903474|OTHER|study of socioeconomic and demographic variables|
223886670|NCT00903474|PROCEDURE|CAM exercise therapy|
223886671|NCT00903474|PROCEDURE|psychosocial assessment and care|
223886672|NCT00903474|PROCEDURE|quality-of-life assessment|
223886673|NCT00903474|PROCEDURE|stress management therapy|
223886674|NCT04866810|BEHAVIORAL|Intervention Arm|High fiber, plant based diet + exercise prescription with ACT sessions
223886675|NCT04866810|BEHAVIORAL|Control|Standard diet and exercise recommendations
223886676|NCT03396588|DRUG|Clonidine|1mcg/kg/dose (with a dosing interval of 3 or 4 hours), increases by 25% of initial dose every 12-24 hrs. Decrease by 10% of max dose every 24 hrs.
223886677|NCT03396588|DRUG|Morphine|Starting dose is 0.06 mg/kg/dose (every 3 or 4 hours), increases by 25% of initial dose every 12-24 hrs. Decrease by 10% of max dose every 24 hrs.
223886678|NCT06648850|DRUG|DA-001|Phenyephrine + Alpha 1 Agonist (GRAS) + TAAR Agonist (GRAS) Topical Solution
223886679|NCT06648850|OTHER|Placebo|Placebo Topical Solution
223886680|NCT06648850|DRUG|Phenylephrine|Phenylephrine Topical Solution
223886681|NCT06648850|OTHER|Intact5|Cosmetic formulation containing bitter orange extract
223886682|NCT02675959|DRUG|Defibrotide|defibrotide will be given prophylactically prior to AlloSCT to determine if it decreases the incidence of SOS in this high risk population, and determine that it is safe and feasible to give along with myeloimmunoablative therapy and allogeneic transplant.
223886683|NCT05027386|DRUG|Apatinib, Irinotecan, Temozolomide|"In the Phase I stage, apatinib was administered using a 3+3 dose escalation design with three dose cohorts. The IT regimen was maintained at fixed doses, with patients receiving up to 6 cycles of chemotherapy. The recommended Phase II dose (RP2D) was determined from the Phase I dose-escalation phase.~In the Phase II stage, the study included an apatinib combination therapy phase and an apatinib maintenance therapy phase. During the combination therapy phase, apatinib was administered at the RP2D in combination with the IT regimen (at fixed doses) for up to 6 cycles. In the maintenance therapy phase, apatinib was administered orally as a single agent at the RP2D until disease progression or intolerable toxicity occurred."
223886684|NCT06074354|BEHAVIORAL|Attention-control group|Participants will receive a one-hour general health promotion session from a nurse and be issued a phone that will deploy the EMA on the same schedule as the intervention arm. They will also receive usual care from the clinics, drop-in center, and shelter recruitment sites. Usual care includes accessing social workers and case managers for immediate housing, food, and clothing needs and assistance in navigating the local Continuum of Care system to access social services.
223886685|NCT06074354|BEHAVIORAL|MY-RIDE group|MY-RIDE has three main components: 1) One nurse-led face-to-face session; 2) three months of Ecological Momentary Assessments (EMA) with personalized messaging delivered by phone in real-time in response to one's current risk; and 3) access to on-demand healthcare/PrEP navigation and referrals.
223886686|NCT05179395|DEVICE|Brasthesis|Brasthesis is a harness that is integrated with an off the shelf sports bra
223886687|NCT00812461|DRUG|Placebo|as-needed use, tablets, orally, 6 months
223886688|NCT00812461|DRUG|Nalmefene|18.06 mg, as-needed use, tablets, orally, 6 months. 18.06 mg nalmefene equals 20 mg nalmefene hydrochloride.
223886689|NCT01388777|DEVICE|Visica 2™ Treatment System|The Visica 2™ Treatment System uses a closed system to circulate liquid nitrogen within the probe tip creating sub-freezing temperatures that result in precision cryoablation of the intended target tissue.
223886690|NCT01388777|PROCEDURE|Cryoablation|Cryoablation procedure uses a hollow, thin tube called a cryoprobe to freeze and destroy cancer tissue. The cryoprobe needle insertion is done using ultrasound guide to reach target, procedure lasts about 20 minutes.
223886691|NCT01388777|PROCEDURE|Surgical Resection|Complete surgical resection of the primary tumor following cryoablation therapy.
223886692|NCT06810427|DEVICE|CervImage device|"CervImage™, developed by Pensievision, Inc., is an accessible, simple, cost-effective, early detection imaging technology for preventing cervical cancer deaths caused by a lack of screening.~The novel device is a simple-to-operate, point-of-care, all-focus, 3D-imaging device, with clinical relevance to early-stage detection and prevention of cervical cancers. CervImage's proprietary 3D-rendering software, incorporating strategies previously used for high resolution imaging with NASA telescopes, can quantify tissue color, volume and shape. Virtual navigation tools and all-focus imaging enable straightforward use by minimally trained personnel; expert personnel can also benefit from shorter setup times.~The research procedure and evaluation will be incorporated into the scheduled annual pap smear exam or colposcopic gynecologic exam that involves using a vaginal speculum."
223886693|NCT00495885|DRUG|volinanserin (M100907)|oral, one tablet taken around bedtime
223886694|NCT00495885|DRUG|Placebo|oral, one tablet taken around bedtime
223886695|NCT03448510|DEVICE|Irreversible electroporation|The subject will receive Irreversible electroporation procedure which is a novel ablation modality using electric pulses to create nanoscale defects in the cell membrane.
223886696|NCT03448510|DRUG|Standard Medication|The subject will be prescribed with α-blocker or/and 5α-reductase inhibitors.
223886697|NCT04408872|DIAGNOSTIC_TEST|Esophago-gastro-duodenoscopy (EGD)|EGD: ENDOSCOPIC PROCEDURE DURING WHICH THE ESOPHAGUS, STOMACH AND DUODENUM ARE VISUALISED WITH A TINY CAMERA IMPLANTED AT THE END OF AN ENDOSCOPE.
223886698|NCT04408872|DIAGNOSTIC_TEST|Endoscopic ultrasound (EUS)|EUS: SAME AS EGD, BUT IN ADDITION HAS AN INTEGRATED ULTRASOUND PROBE WHICH ALLOWS TO EXAMINE THE PANCREAS, LIVER AND BILIARY SYSTEM.
223886699|NCT00616031|DRUG|carboplatin|
223886700|NCT00616031|DRUG|nitroglycerin|
223886701|NCT00616031|DRUG|paclitaxel|
223886702|NCT06975670|OTHER|multimedia consent tool|The multimedia consent tool is new and developed for this particular study
223886703|NCT06978907|DEVICE|Monnalisa Touch® Laser Therapy|Monnalisa Touch® laser therapy is a non-ablative fractional CO2 laser applied to the vaginal mucosa to promote tissue regeneration and maintain vaginal health. Participants in this group will receive three sessions of laser therapy, one session every 30 days.
223886704|NCT06978907|COMBINATION_PRODUCT|Monnalisa Touch® Laser Therapy + Lactobacillus crispatus M247 (Crispact®)|Participants in this group will receive three sessions of Monnalisa Touch® laser therapy, one session every 30 days, along with daily administration of Lactobacillus crispatus M247 (Crispact®), a probiotic containing 20 billion CFU, taken orally for three months.
223886705|NCT04092205|DRUG|Emeramide|Lipophilic, membrane passing Metal chelator and anti oxidant
223886706|NCT03717506|DRUG|GDC 268 Lotion|GDC 268 is a topical lotion
223886707|NCT03717506|DRUG|Clindamycin Phosphate Lotion 1%|Clindamycin Phosphate Lotion is an FDA-approved drug product
223886708|NCT03717506|DRUG|GDC Vehicle Lotion|GDC Vehicle Lotion contains 0.0% of active drug and is matched to the other two active test drugs
223886709|NCT06980584|PROCEDURE|Rituximab Lymph Node Injection Combined with Pulmonary Vascular Intervention|Based on the degree of vascular stenosis, individualized and periodic pulmonary vascular interventions are performed to reopen obstructed vessels. During the treatment cycle, one lymph node drug injection is administered: 50mg of rituximab is dissolved in 15ml of 5% glucose solution and injected at multiple sites into the identified enlarged mediastinal lymph nodes under ultrasound-guided bronchoscopy.
223886710|NCT06980584|PROCEDURE|Pulmonary Vascular Interventional Therapy|According to the degree of vascular stenosis, individualized and periodic pulmonary vascular interventions are performed to reopen obstructed pulmonary vessels.
223886711|NCT06522178|OTHER|Patient' ages|Patients were divided into two groups according to their ages.
223886712|NCT01571570|DRUG|TMC435 150 mg capsule|single oral dose of 150 mg TMC435 150 mg capsule
223886713|NCT01571570|DRUG|TMC435 150 mg oral suspension (20 mg/mL)|single oral dose of 150 mg TMC435 oral suspension
223886714|NCT01571570|DRUG|TMC435 150 mg oral solution (10 mg/mL)|single oral dose of 150 mg TMC435 oral solution
223886715|NCT01571570|DRUG|TMC435 150 mg capsule concept K|single oral dose of 150 mg TMC435 capsule concept K
223886716|NCT01571570|DRUG|TMC435 150 mg capsule concept L|single oral dose of 150 mg TMC435 capsule concept L
223886717|NCT06655402|BEHAVIORAL|CARE-CITE|"CARE-CITE is a post-stroke family education program, to support care partners (CPs) in aiding stroke survivors (SS) during rehabilitation. Utilizing autonomy-supportive strategies, CARE-CITE emphasizes empathy, choice, and problem-solving while minimizing controlling language.~The program features a user-friendly web-based platform with interactive videos that guide CPs in providing support for SS. Over four weeks, CPs engage in two virtual home visits and two phone check-ins. During the initial visit, CPs review online modules, set collaborative goals, and co-create a home exercise plan targeting upper extremity (UE) activities. The second and third weeks involve structured phone calls to discuss autonomy-supportive strategies and address challenges.~The final visit reinforces strategies, assesses SS progress, and adjusts rehabilitation goals. Each module is designed to foster motivation and effective practice in daily activities."
223886718|NCT06655402|BEHAVIORAL|Attention Control Group|"Over a similar 4-week period, the SS and CP will receive the same number of structured virtual weekly visits as the CARE-CITE group without the review of CARE-CITE modules.~The CP will receive a brochure with general caregiving information and website resources. At week 1, a separate control group intervention therapist will deliver a 2-hour virtual home visit to evaluate SS UE function and assess safety concerns. Based on SS impairments, a home exercise program will be prescribed for flexibility, strength, and coordination (6-8 exercises, 2 sets of 10 reps). SS will be encouraged to practice daily (targeting 30 min/day). Weeks 2 and 3: CP Phone check-ins \[15-minute\]. The intervention therapist will review safety, assess adverse events, and CP's use of web resources. Week 4 Virtual Home visit (2 hours). Review SS's progress with the UE activity home exercise program, discuss safety concerns, and progress UE exercises as appropriate."
223886719|NCT06655402|OTHER|Actigraph GT3X+|Accelerometry data will be collected using Actigraph GT3X+ wearable sensors, approved by the FDA. The device does not collect or store individually identifiable health information (IIHI), private health information (PHI), or sensitive data. It is not intended for diagnosing, treating, or preventing diseases. These small, wrist-worn monitors document physical movement for physiological monitoring, including tracking movement during sleep. They can analyze circadian rhythms and assess activity in situations where quantifiable analysis of physical motion is needed.
223886720|NCT06987929|PROCEDURE|Hydrodilatation injection|During the procedure, the patient lie supine on an examination couch, with the affected arm in the modified Crass position. All injections were done under image guidance using a Philips EPIQ ultrasound machine with an L18-12 MHz linear array transducer, performed consecutively by 2 rheumatologists or 1 pain medicine anaesthetist, all trained in MSK US. Aseptic technique was used. The transducer was placed at the short axis of the supraspinatus tendon, and the rotator cuff interval and coracohumeral ligament (CHL) were identified. Local anaesthetic (1% lignocaine) was injected subcutaneously to the skin. The therapeutic medication consisted of a mixture of 40 mg triamcinolone (10 mg/ml concentration) and 5ml 1% lignocaine, which was diluted with sterile normal saline into a total of 20mls suspension. The injection was administered using a 22-G 2-inch needle (Stimuplex A) introduced below the CHL adjacent to the long head of biceps tendon, in the in-plane view under US guidance.
223886721|NCT06987929|PROCEDURE|Intra-articular steroid injection (IAI)|Intra-articular corticosteroid injection was performed as a control group. The posterior shoulder approach was used. The patient was positioned in the lateral decubitus or semi-prone position with the affected shoulder at the uppermost position, elbow semi-flexed and the ipsilateral arm resting on a pillow for comfort and stability. The ultrasound transducer is positioned over the long axis of the myotendinous junction of the infraspinatous tendon to view the contours of the posterior glenoid labrum and posterior portion of the humeral head. The injectate was administered using a 21-G hypodermic needle. 40 mg triamcinolone (10 mg/ml concentration) mixed with 1ml of 1% lignocaine was injected into the posterior glenohumeral joint, under ultrasound-guidance. Any adverse reaction that occurred during the procedure was recorded. Following the procedure, the patient was advised to avoid overuse of the injected joint for 24 hours as part of post-injection care.
223886722|NCT06987331|OTHER|haptonomy|"Haptonomy involves a combination of skills taught in 4-8 sessions of 45-60 minutes between 20 and 36 weeks of gestation. An important stage of the three-step haptonomy application is the attachment of the parents to the foetus by touching the foetus in the 20-36th weeks of pregnancy.~Mindfullnes is a mbsr application done in 8 sessions"
223886723|NCT06987331|BEHAVIORAL|Haptonomy application|breastfeeding status
223886724|NCT06987331|BEHAVIORAL|Mindfulness|breastfeeding status
223886725|NCT05803798|DEVICE|IPL+LLLT|preventive treatment by IPL+LLLT (EYE-LIGHT) before laser refractive surgery
223886726|NCT06987760|PROCEDURE|flexible ureteroscope urolithiasis|Using flexible ureteroscope combine with urethral access sheath to treatment urolithiasis
223886727|NCT06987019|OTHER|3D motion capture, wearable devices, and functional outcome measures|Gait evaluation, Hill and Stair Assessment Indices, 6 minute walk test, AMPPro, Timed Up and Go
223886728|NCT06988137|DEVICE|Kinesio Taping|Elastic therapeutic tape was applied using the ligament correction technique. The tape was reapplied at Day 3 and Day 21 under supervision
223886729|NCT06988137|PROCEDURE|Buddy Taping|Buddy taping involved strapping the injured finger to an adjacent digit using medical tape. Early motion was restricted.
223886730|NCT06988137|DEVICE|Splinting|A custom-molded thermoplastic splint was applied to restrict joint movement and maintain alignment. Patients remained immobilized until Week 3.
223886731|NCT06987942|BIOLOGICAL|Varicella vaccine+TIV|"* Varicella vaccine: lyophilized powder, subcutaneous injection~* TIV: Inactived, split virion, containing H1N1, H3N2 and BV strains."
223886732|NCT06987942|BIOLOGICAL|Varicella vaccine|lyophilized powder, subcutaneous
223886733|NCT06987942|BIOLOGICAL|TIV|Inactived, split virion, containing H1N1, H3N2 and BV strains.
223886734|NCT06678828|OTHER|ClarityDX Prostate|The ClarityDX Prostate report will be shared with the healthcare team of participants randomized into ClarityDX Prostate arm before the healthcare team decides whether to perform an MRI/advanced imaging and/or biopsy.
223886735|NCT06678828|OTHER|ClarityDX Prostate, blinded|ClarityDX Prostate will be run for the control participants. Participants (and healthcare team) in the control arm will be blinded to the ClarityDX Prostate results and will be considered for prostate MRI/advanced imaging and/or biopsy based on standard of care criteria. The result of the ClarityDX Prostate will be unblinded to study teams at the 12 months follow-up visit (± 2 months). The study team will then share the test results with the participant's health care team to assess whether there is a need to change the participant's care path.
223886736|NCT06300892|OTHER|No intervention|samples from the incision site and GI tract collected
223886737|NCT04208126|DEVICE|ECMO|ECMO implantation immediately after ICU admission
223886738|NCT06692543|OTHER|Active population|1 blood withdraw, questionnaire and tests
223886739|NCT06692543|OTHER|Inactive population|1 blood withdraw, questionnaire and tests
223886740|NCT06641141|PROCEDURE|Induction of Labour|"Induction of Labour (IOL) will occur between 38+0 weeks and 38+6 weeks. All participating sites will follow an evidence-based approach for IOL, which may include any of the following: use of prostaglandins, oxytocin, amniotomy, or intracervical balloon catheters with and without extra-amniotic saline infusion for the intervention arm. Participants who are induced in either the intervention or control arms will be managed by their delivery care provider to ensure sufficient time to labour and determine when to proceed to Cesarean delivery. What constitutes a failed IOL will be dictated by local clinical practice guidelines and will be informed by the time since IOL (24-48 hours) and/or physician diagnosis of labour dystocia."
223886741|NCT07034885|BEHAVIORAL|Mindfulness-Based Self-Efficacy Development Program|"Mindfulness-Based Self-Efficacy Development Program is a unique intervention model that integrates mindfulness-based practices with self-efficacy theory, structured for postmenopausal women. With the implementation of this research, a holistic and evidence-based intervention model will be presented for physical, psychological and social problems frequently encountered in the postmenopausal period. This program processes mindfulness-based skills such as observing thoughts, body awareness, regulating emotions, coping with stress and developing self-compassion in the axis of self-efficacy development with 8-week structured sessions. In this context, it is anticipated that the study will contribute to scientific knowledge and practices.~In addition, the Mindfulness-Based Self-Efficacy Development Program developed in the study aims not only at symptom management, but also at increasing the individual's perception of control over their own lives, recognizing their internal resources and"
223886742|NCT07043738|PROCEDURE|Transcranial Magnetic Stimulation|Transcranial magnetic stimulation (TMS) is a focal, non-invasive form of brain stimulation that has FDA clearance for depression. In this study, a form of TMS called accelerated intermittent theta burst stimulation (aiTBS) will be administered under the supervision of a physician with TMS expertise.
223886743|NCT06892665|DEVICE|Hypotension prediction index|HPI and other haemodynamics parameters, is available to the anaesthetist to view and act upon
223886744|NCT06892665|DEVICE|Non invasive Blood Pressure Monitoring|Anaesthetist will respond to hemodynamic variables using NIBP
223886745|NCT06778070|OTHER|Pelvic floor yoga|Pelvic floor yoga
223886746|NCT06778070|OTHER|Physical conditioning|Physical conditioning
223886747|NCT06762548|DRUG|DA-007|Topical α1 agonist combination of Phenylephrine + Tyramine + Synephrine
223886748|NCT06762548|DRUG|Placebo|Topical placebo solution
223886749|NCT06785688|DEVICE|Protective gear irradiated by infrared rays|irradiated by infrared rays back brace
223886750|NCT06751329|DRUG|DM002|An IV infusion of DM002 will be administrated approximately 30-60 min on D1 once Q3W
223886751|NCT04036097|OTHER|MS-adapted AWIS questionnaire (MS-AWIS)|The predefined questionnaire-based infection score of the Airway Infection Susceptibility (AWIS) study is predictive for the occurrence of respiratory tract infections (RTI). In addition several MS-specific items (e.g. bladder dysfunction and urinary tract infections) are included into the AWIS questionnaire (MS-AWIS).
223886752|NCT04036097|OTHER|infection diary (MS-AWIS diary)|MS patients prospectively fill out monthly infection diaries for 24 months. Infection diaries will either be sent back (with pre-franked envelopes) or handed back to the InRIMS-study team during regular clinical visits (usually every 6 or 12 months).
223886753|NCT06904495|OTHER|Survey of sleep quality and associated factors|Sleep quality and associated factors (anxiety, depression, and pain) will be evaluated through an online survey on the Reseau Morphee platform, through an self-administered evaluation of the patients' pain and sleep difficulties, and a precarity scale.
223886754|NCT06908135|BEHAVIORAL|Independent walking program using walking poles|Participants will independently walk at least 3 times a week for 8 weeks using walking poles
223886755|NCT06908135|BEHAVIORAL|Independent walking program without walking poles|Participants will independently walk at least 3 times a week for 8 weeks without walking poles
223886756|NCT06234267|BEHAVIORAL|Eat, Play, Sleep|The Eat, Play, Sleep study will test health promotion text messages developed following guidelines for text message program development, aligned with established recommendations for diet, physical activity, and sleep in cancer survivorship and prevention. Feasibility of text message delivery and acceptability of the text message content related to dietary quality, physical activity, and sleep hygiene health behaviors will be tested in delivery to participants (cancer survivor/caregiver dyads) who indicate difficulty engaging in dietary quality, physical activity, or sleep hygiene behaviors.
223886757|NCT05792423|DEVICE|GE ultrasound system with increased acoustic output settings|We will perform liver stiffness measurements with standard settings and an increased acoustic output enhanced ultrasound system. Pre and post ultrasound LFTs will be collected to monitor unexpected liver tissue damage.
223886758|NCT06467864|PROCEDURE|bronchoscope|We will perform bronchoscopy and collect bronchoalveolar lavage fluid (BALF) samples at the time of patient enrollment and three days after the treatment.
223886759|NCT06919458|DRUG|Prednisolone 40 mg|Patients will be screened for infection till 90 days from the day of initiation of prednisolone. the three patient arms will be compared for severity scores of the disease, rate and severity of infections, diabetic control, post-treatment outcomes, and mortality.
223886760|NCT06919861|BIOLOGICAL|Erythropoietin alfa|"Experimental drug: Nanokine 4000 IU, prefilled syringe, subcutaneous injection Manufactured: Nanogen Biopharmaceutical JSC.~Arm 1 (22 volunteers): Nanokineinjection 4000 IU will be administered subcutaneously on Day 1, and after a 28-day washout period, Eprex® injection 4000 IU will be administered subcutaneously on Day 29."
223886761|NCT06919861|BIOLOGICAL|Erythropoietin alfa|"Comparator drug: Eprex® 4000 IU, prefilled syringe, subcutaneous injection Manufactured: Janssen-Cilag Ltd~Arm 2 (22 volunteers): Eprex® injection 4000 IU will be administered subcutaneously on Day 1, and after a 28-day washout period, Eprex injection 4000 IU will be administered subcutaneously on Day 29.~Total: 44 participants will be recruited in the trial."
223886762|NCT02471638|DEVICE|PQ Bypass System for Femoropopliteal Bypass|To access, deliver guidewires and implant stent grafts for a percutaneous fem-pop bypass.
223886763|NCT06920069|BIOLOGICAL|sIPV|Sabin-strain-based inactivated vaccine (Vero cells), 0.5mL for each dose
223886764|NCT06920069|BIOLOGICAL|DTaP|Adsorbed acellular pertussis, diphtheria and tetanus combined vaccine, 0.5mL for each dose
223886765|NCT06920069|BIOLOGICAL|bOPV 1,3|Poliomyelitis Vaccine Type I Type Ⅲ in Dragee Candy (Human Diploid Cell), Live, 1g for each dose
223886766|NCT06920069|BIOLOGICAL|MMR Vaccine|Measles, Mumps and Rubella Combined Live-attenuated Vaccine, 0.5mL for each dose
223886767|NCT06923683|BEHAVIORAL|Treatment for social cognition disorders (T-ScEmo)|T-ScEmo is an evidence-based, multifaceted treatment protocol for poor social cognition and emotion regulation impairments in patients with ABI. T-ScEmo is implemented as standard practice in the Netherlands. In total, the treatment consists of 20 1-hour sessions. The treatment is divided into extended psychoeducation for patient and proxy and 3 modules, including emotion perception (module 1), perspective taking and understanding social information (module 2), and goal-directed social behavior (module 3). These three modules are interdependent and strengthen each other. Therefore, the developers strongly recommend to offer all three modules. The presence of a proxy is required in the first psycho-education session and during the third module. The first and second modules are invariant (10 sessions together), but in the third module, therapists can adjust the content to individual needs and personal goals.
223886768|NCT06927739|DRUG|Orticumab|Orticumab treatment for 24 weeks for post MI population
223886769|NCT06927739|DRUG|Placebo|Placebo for 24 weeks for the post MI population
223886770|NCT06927817|DRUG|hyoscine-n-butylbromide, ondansetron|In patients in Group Hyoscine 20mg hyoscine-n-butylbromide in 100ml saline and in Group Ondansetron 4mg ondansetron infusion in 100ml saline will be administered in Group-O. The patients will be followed-up in terms of nausea, vomiting, and pain at the postoperative 15th, and 30th minutes and at the 3rd, 6th, 12th, and 24th hours.
223886771|NCT06927817|DRUG|• hyoscine-n-butylbromide • ondansetron|In patients in Group Hyoscine 20mg hyoscine-n-butylbromide in 100ml saline and in Group Ondansetron 4mg ondansetron infusion in 100ml saline will be administered in Group-O. The patients will be followed-up in terms of nausea, vomiting, and pain at the postoperative 15th, and 30th minutes and at the 3rd, 6th, 12th, and 24th hours.
223886772|NCT07140692|DEVICE|Vitrectomy|In this single-arm, non-comparative study, patients presenting with vitreous opacities affecting daily activities of living will undergo vitrectomy using the single-use vitrector probe of Vista Ophthalmics for the removal of the vitreous opacities.
223886773|NCT07140640|DRUG|Hyperbaric Bupivacaine HCl 0.5% 12.5 mg|1- Standard dose group: receiving the typical dose of hyperbaric bupivacaine (12.5 mg hyperbaric bupivacaine + 25 mcg fentanyl).
223886774|NCT07140640|DRUG|Hyperbaric Bupivacaine HCl 0.5% 10 mg|2- Reduced dose group: receiving a20% reduced dose of hyperbaric bupivacaine (10 mg hyperbaric bupivacaine + 25 mcg fentanyl).
223886775|NCT06931795|BEHAVIORAL|HABIT-ILE|2 weeks HABIT-ILE
223886776|NCT06931795|BEHAVIORAL|Conventional intervention|2 weeks usual intervention (waitlist group)
223886777|NCT06931912|BEHAVIORAL|MENBS clinical interventions|"* Monitor: Continuously monitor health-related indicators through regular follow-up.~* Education: Provide health education to improve cognition of patients and their families.~* Nutrition: Assess patients' nutritional risks and develop personalized diet plans.~* Behavior: Recommend appropriate exercise plans to promote physical development.~* Support: Conduct home visits, offer free clinics and establish a support network."
223886778|NCT06932185|OTHER|Transcranial Focussed Ultrasound - Active|Transcranial focussed ultrasound to target site
223886779|NCT06932185|OTHER|Transcranial Focussed Ultrasound - Sham|Transcranial focussed ultrasound off
223886780|NCT06932185|OTHER|Transcranial Focussed Ultrasound - Active control|Transcranial focussed ultrasound on to control
223886781|NCT06932653|OTHER|SurgPASS - intervention|SurgPASS consists of a preoperative surgical passport used for any patients requiring emergency laparotomy, a simulation training course and local clinical champions.
223886782|NCT01328262|OTHER|Calculated red blood cell transfusion|The subjects receive an amount of red blood cells that has been calculated from their body surface area.
223886783|NCT01328262|OTHER|Standard red blood cell transfusion|The subjects in this group receive the prescribed number of red blood cell units.
223886784|NCT05478213|DEVICE|Monophasic Action Potential (MAP) Catheter|The EasyMap catheter is a temporary quadripolar catheter for recording monophasic action potentials and for intracardiac pacing. During a standard of care VT ablation, the MAP catheter will be used to study cellular action potential of the ventricular myocardium, which cannot be done on traditional catheters. The catheter is placed on the myocardium (similar to other traditional catheters) and a recording signal is transmitted to the workstation. Using the MAP catheter the will not interrupt or distort any of the standard treatment procedures.
223886785|NCT05529966|DEVICE|NGENUITY|Device for 3-D viewing during placement of micro-stent placement.
223886786|NCT05529966|DEVICE|Conventional microscope|Device for stereoscopic viewing during placement of micro-stent placement.
223886787|NCT04222660|DIETARY_SUPPLEMENT|Blackmores Omega Daily (4 1g capsules per day)|Subjects enrolled in phase two of the study will be instructed to take 4 capsules per day (2 in the morning and 2 in the evening). Each capsule contains 1000 mg of triglyceride; 35% eicosapentaenoic acid and 25% docosahexaenoic acid.
223886788|NCT06794424|DIAGNOSTIC_TEST|Ziwig Endotest®|Saliva sampling for Endometriosis diagnostic
223886789|NCT06489301|DEVICE|Fractionated Laser Resurfacing|A rejuvenating laser that makes tiny holes in the very superficial part of the skin.
223886790|NCT03671681|BEHAVIORAL|Mindfulness|The experimental group will receive education, will be prescribed prophylaxis and will attend Mindfulness-based therapy sessions. The MINDFULNESS therapy consists in 6 weekly sessions, 45 minutes each. The main focus of the six mindfulness session will be the following: 1) introduction and meaning; 2) Focus on breath; 3) posture and body awareness; 4) meditation of sounds; 5) Guided imagery; 6) acceptance and awareness. During training, patients will be invited to close their eyes, assume a relaxed position, focus on their breathing and on the present to enhance awareness of current mind and body sensations. Patients will be trained in small groups (5-7 patients each) and guided by a specifically trained therapist. They will be educated to practice at home according to the instructions given by the therapist during the sessions.
223886791|NCT03671681|DRUG|Prophylactic|Control group will receive education on the use of pharmacological compounds for acute treatment and on healthy lifestyle habits (e.g. adequate sleep/wake pattern, eating and hydration, physical activity, avoidance of triggers) and will be prescribed prophylactic medications. The preventive compound will be chosen on the basis of clinical profile among the following categories: neuromodulators (e.g. topiramate or valproate), antidepressant (e.g. tricyclics or SSRIs) or others, e.g. beta-blockers.
223886792|NCT06797310|DRUG|Baricitinib|This study evaluates the use of baricitinib 4 mg once daily for 16 weeks in patients with acute alopecia areata (AA) experiencing active hair shedding. Unlike prior studies focusing on chronic AA with extensive hair loss (SALT ≥ 50), this intervention targets the acute phase, aiming to halt shedding within 4-6 weeks-faster than conventional treatments like corticosteroids. Patients meeting the primary endpoint (iSARS-AA ≤ 20 at week 16) will taper to 2 mg daily for an additional 16 weeks. Scheduled follow-ups at weeks 0, 4, 8, 12, 16, 24, 32, 36, 44, and 52 ensure comprehensive monitoring, distinguishing this study from others with shorter follow-ups or less frequent assessments.
223886793|NCT06789081|BIOLOGICAL|GCAR1|GCAR 1 is a patient-specific cell therapy product containing a mixture of autologous lymphocytes transduced with a lentiviral vector containing a chimeric antigen receptor (CAR) that enables the specific targeting towards tumor cells expressing the cell surface protein glycoprotein non-metastatic B (GPNMB).
223886794|NCT06792643|DRUG|Cangrelor|Cangrelor will be started without bolus at a low dose of 0.125 mcg/kg/min and titrated (by 0.125 mcg/kg/min steps) based on the results of platelet function assay to guarantee effective platelet P2Y12 pathway inhibition.
223886795|NCT06054529|PROCEDURE|Surgical removal of the GBM tumor|Surgical removal of the GBM tumor
223886796|NCT06054529|OTHER|d4-NAM infusion|Following the surgical removal of the GBM tumor, GBM patients will be dosed with a form of nicotinamide (a natural vitamin) that we can track. The nicotinamide will be converted to methyl nicotinamide (MeNAM) in the tumor. We will measure how fast the nicotinamide is converted to methyl nicotinamide. We believe that the speed of this chemical reaction in the tumor (fast versus slow) may be correlated with GBM aggressiveness.
223886797|NCT06789393|DRUG|Dexmedetomidine|Patients will receive dexmedetomidine (0.5 mcg/kg).
223886798|NCT06789393|DRUG|Bupivacaine|Penile block with bupivacaine 0.25% (0.2 ml/kg)
223886799|NCT06791954|OTHER|Exercise|Clinical pilates program
223886800|NCT06839339|DRUG|AL-001|Administered via suprachoroidal space injection.
223886801|NCT06839339|DRUG|Aflibercept|Intravitreal injection
223886802|NCT04534127|DEVICE|Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)|An intratumoral insertion of a seed(s), loaded with Radium-224, securely fixed in the seeds. The seeds release by recoil into the tumor short-lived alpha-emitting atoms.
223886803|NCT05831709|OTHER|Exercise program|The intervention consists of a supervised exercise program
223886804|NCT06796530|PROCEDURE|Cardiopulmonary exercise test (CPET)|Participants undergo a CPET on a stationary bike, measuring gas exchange, ECG, and other parameters. The protocol includes 3 minutes of cycling at a constant load (body weight/2 in Watts), followed by a maximal effort test with an incremental load (Ramp protocol body weight (kg) / 4 in Watts per minute).
223886805|NCT06796530|PROCEDURE|High-intensity circuit training|The patients will undergo a 10-minute warm-up, followed by \~30 high intensity exercise circuit.
223886806|NCT06790186|BEHAVIORAL|Perceive, Recall, Plan and Perform intervention Interventions:|The PRPP is a standardized system which determines the impact of information processing on performance of everyday activities. It is a method for assessment of performance mastery, and efficient use of cognitive strategies, as well as a model of intervention to train mastery and cognitive strategy use, in everyday activities. The PRPP assess task performance mastery, as well as cognitive strategy application
223886807|NCT04929899|BEHAVIORAL|Bright Ideas - CIN Training|Bright IDEAS is a validated problem-solving skill training intervention.
223886808|NCT06839391|DRUG|Hyaluronidase|Effect of hyaluronidases in different doses added to bupivacaine on quality of ultrasound-guided TAB block during CS ,
223886809|NCT06792656|OTHER|standardized Forest Therapy session (120 min)|standardized, 2-hrs Forest Therapy session following the INFTA Forest Therapy Guiding Sequence
223886810|NCT05441670|BEHAVIORAL|Art and Physical Therapy|45 minutes of Art Therapy followed by 30 minutes of Physical Therapy, Monday through Friday for 2 weeks
223886811|NCT05441670|BEHAVIORAL|Physical Therapy|30 minutes of Physical Therapy, Monday through Friday for 2 weeks
223886812|NCT06736288|DRUG|BUCCALIN®|"Gastro-resistant tablets (mixture of Streptococcus pneumoniae I, II, III, Streptococcus agalactiae, Staphylococcus aureus, Haemophilus influenzae).~The recommended dosage is 1 tablet on day 1, 2 tablets on day 2, and 4 tablets on day 3 and should be taken in the morning on an empty stomach."
223886813|NCT06736288|OTHER|Placebo|Gastro-resistant tablets containing only excipients). The recommended dosage is 1 tablet on day 1, 2 tablets on day 2, and 4 tablets on day 3 and should be taken in the morning on an empty stomach.
223886814|NCT01803438|DEVICE|cryoballoon ablation system|
223886815|NCT01803438|DRUG|Antiarrhythmic Drugs|AAD therapy based on hospital clinical practice according to ESC Guidelines 2012
223886816|NCT06160050|BEHAVIORAL|Breakthrough Parenting Curriculum: Transforming trauma across generations|The BPC (Breakthrough Parent Curriculum): Navigating Trauma Across Generations is a 10 module course adapted from the NCTSN training called Caring for Children Who Have Experienced Trauma: A Workshop for Resource Parents (RPC). The BPC is specifically designed for parents who have been involved with (or are at risk for being involved with)the child welfare system. The course provides information about the impact of trauma on the development, attachment, emotions and behaviors of children while holding space for parents to learn together about concrete strategies for managing daily and ongoing challenges and enhancing their relationships with their children. All while acknowledging the challenges of parenting a child who has experienced trauma, while having experienced your own trauma.
223886817|NCT02868268|OTHER|Gene panel sequencing of tumor specimens|Archival or biopsied tumor specimens will undergo gene panel sequencing to identify subgroups with targetable genetic (ALK, MAPK pathway, Metabolic-related genes) and/or immunologic (tumor associated macrophage infiltration, PD-L1 expression) biomarkers in neuroblastoma. A clinical report will be provided to subjects/subject physician detailing observed mutations and identified NBL subgroups and information on clinical trials that best match them. Subjects will be followed and data collected on treatments administered for one year after receipt of clinical report.
223886818|NCT06795828|BEHAVIORAL|Emotional support group|Women who met the inclusion criteria and volunteered to participate in the study and were provided emotional support were administered the Personal Information Form, Visual Analog Scale, State Anxiety Inventory and Surgical Fear Scale via face-to-face interview method on the first day of their hospitalization before the caesarean section (pre-test). This application lasted 15-20 minutes. Enter a brief, descriptive title for this arm of the study.
223886819|NCT06835868|PROCEDURE|Spinal cord stimulation|implantation of electrode which is linked to an implantable impulse generator for the treatment of chronic pain syndromes.
223886820|NCT06792786|DIAGNOSTIC_TEST|ctDNA detection|"dynamically monitor the changes of ctDNA in patients with esophageal cancer Radiation: Radiotherapy 95% PTV50-50.4Gy/25-28fractions, 1.8-2Gy/1 fractions; 5 days a week; 6 weeks. Chemotherapy:weekly paclitaxel (50mg/m²) in combination with carboplatin (AUC=2) chemotherapy, a total of 4-5 cycles.~Other Names:~Intensity-modulated radiotherapy (IMRT) Drug: Toripalimab Toripalimab (240 mg, intravenously infused) will be administered as the maintenance treatment every 3 weeks within 4 weeks after the completion of radiotherapy for 1 years or until progression, intolerable toxicity, or physician/patient decision~Other Names:~Immunotherapy ctDNA detection: The first tissue and blood ctDNA test (T0) before treatment is based on next generation sequencing (NGS) technology, and ctDNA test is based on tumor- prior analysis informed assays method. Blood ctDNA testing after chemoradiotherapy was performed every 3 months"
223886821|NCT06487910|DEVICE|3D scan measurment|"patients included in the study will undergo a 3D scan measurement of on or more burn scars. This measurement will then be digitally modified in preparation for the manufacture of the differential pressure distribution orthosis. The orthosis will then be manufactured using a 3D printing process."
223886822|NCT06791148|RADIATION|Low-dose radiotherapy|2Gy/f，q3w，×4f
223886823|NCT06791148|DRUG|albumin-bound paclitaxel|100-120mg/m2,i.v.,d2,d9,q3w
223886824|NCT06791148|DRUG|AK112|20mg/kg, i.v., d2, q3w
223886825|NCT04009343|DRUG|Artemether-lumefantrine|Children will receive artemether-lumefantrine (20/120 mg) dosed according to weight (5 to \<15 kg: 1 tablet, 15 to \<25 kg: 2 tablets) at 0, 8, 24, 36, 48 and 60 hours. Medications will be administered according to the manufacturer's instructions.
223886826|NCT04009343|DRUG|Dihydroartemisinin-piperaquine|Children will receive dihydroartemisinin-piperaquine (40/320 mg) dosed according to weight (5 to \<8 kg: 1/2 tablet, 8 to \<11 kg: 3/4 tablet, 11 to \<17 kg: 1 tablet, 17 to \<25 kg: 1 1/2 tablets) at 0, 24, and 48 hours. Medications will be administered according to the manufacturer's instructions.
223886827|NCT06489418|OTHER|Dew Restore Barrier Repair Cream|"Wash the face with the gentle cleanser to remove dirt, and oil and pat dry with the towel\| tissue paper. Afterwards take the pea side amount of the test product you finger tips, apply it over the face by small dotes and massage it in circular motion until it absorbed.~Frequency: Twice a Day Route of Administration: Topical"
223886828|NCT06792604|DEVICE|Anal self-sampling (smear)|Anal self-sampling (smear) at M12, M24 and M36 (each year) for HPV16+ patients at M0 and anal self-sampling (smear) at M36 for HPV16- at M0
223886829|NCT06792604|BEHAVIORAL|HPV questionnaire|HPV questionnaire at each visit M0, M12, M24 and M36 for HPV16-positive patients at M0 and HPV questionnaire at each visit M0, 4 and M36 for HPV16-negative patients
223886830|NCT05926102|GENETIC|Precision screening intervention|The precision screening intervention will consist of an interpreted prostate cancer genetic risk assessment (GRA) report, provided to the participant along with tailored prostate cancer screening recommendations and, in cases of high genetic risk, genetic counseling. The risk report and supporting educational materials will also be provided to the participant's primary care provider. Usual care in this study includes receipt of a brief brochure about shared decision-making in prostate cancer screening.
223886831|NCT05926102|OTHER|Usual care|Usual care in this study includes receipt of a brief brochure about shared decision-making in prostate cancer screening.
223886832|NCT06840990|DEVICE|CXC-SP|Standard therapy plus sterile Isotonic ophthalmic solution based on CX-CMC and silk protein, istilled six time a day until complete healing.
223886833|NCT06840990|DEVICE|CTRL|Standard therapy plus sterile ophtalmic isotonic solution for six time a day until complete healing.
223886834|NCT05949060|BEHAVIORAL|Compassion Intervention|The compassion intervention is a single-session 40-min intervention in which the participants practiced soothing rhythm breathing (i.e., they are directed to slow their breathing using a five-count inhale and five-count exhale). They will then be provided didactic instruction on compassion, and will then be guided through an experiential compassion practice adapted that encompasses cultivating feelings of compassion for a loved one and then for oneself.
223886835|NCT06840184|BEHAVIORAL|Cognitive Behavioral Therapy based Intervention|"Session 1: Introduction of CBT, Relationship between events, thoughts and behavior.~Session 2: Psychoeducation about the vicious circle of inactivity and depression, Ladder technique for task management.~Session 3: Problem solving techniques and discussion about them, Decision making techniques through Advantages/ Disadvantages chart.~Session 4: Identifying positive and negative emotions, Cognitive errors were explained.~Session 5: Identifying negative thoughts through Socratic questioning, Finding evidence for and against the thoughts, Challenging negative thought, Cracking firm irrational beliefs.~Session 6: Cognitive restructuring techniques, Finding alternative thoughts."
223886836|NCT06840184|OTHER|No intervention|No intervention was provided to the control group, except for a few members who requested for the therapy, that too after the post assessment.
223886837|NCT06838403|OTHER|Oro motor excercise to study arms and controoled arms|Each child in both groups will receive OME program for 30 minutes three times per week for 6 months.
223886838|NCT06203340|OTHER|Core stabilizasyon and lumbal back school|Lumbal back schooL
223886839|NCT03025763|OTHER|Craniosynostosis Network Environmental Survey|Questionnaire is administered to the mothers of affected participants regarding medical history and environmental exposures during pregnancy, delivery, and neonatal period. Optional.
223886840|NCT03025763|OTHER|2D/3D Photography|Full frontal and lateral face and other parts of the body may be taken for dysmorphic assessment. There is the risk of identification and loss of confidentiality. Optional.
223886841|NCT03025763|PROCEDURE|Buccal Swab Cell Sampling|One or more swabs, like a Q-tip (for children), or saliva collection kit (for adults) will be used to collect buccal cells. With a swab, they will brush the inside of the mouth several times. With saliva collection kit, they will collect their saliva by spitting into a container several times using a commercially available saliva collection kit. Required.
223886842|NCT03025763|PROCEDURE|Blood sampling|Venipuncture so that one teaspoon to tablespoons (1-20 ml.) of blood is collected. The volume drawn will be dependent on the age and size of the child. Minimal amounts may be required for DNA, but to establish a lymphoblastoid or iPS cell line at least 3 to 10 ml will be required independent of age. In the case of an infant, if 3 to 10 ml cannot be obtained, then a lymphoblastoid or iPS cell line will not be created. Optional.
223886843|NCT03025763|PROCEDURE|Skin Biopsy|For those who do not undergo surgery or the skin removal is not considered part of the surgical procedure. After proper cleaning, a piece of skin the size of a pencil eraser (about 4 mm or 1/8 inch in diameter) will be removed (using a circular blade or scalpel) from the arm (inside of arm or forearm in a spot that is as unnoticeable as possible). This area will be covered with a Band-Aid. No stitches are usually required. A crust will form and eventually fall off. Optional.
223886844|NCT03025763|PROCEDURE|Tissues from a Clinically Indicated Procedure|In some instances when there is discarded tissues and specimens (including skin and bone at the time of reconstructive craniofacial surgery), they will be collected by making arrangements with their physicians. Some of these tissues will be used to generate cell lines. Optional.
223886845|NCT03025763|PROCEDURE|Pre-operative CT Scan Image Files.|Optional for those who had a previous CT scan for a prior traumatic event.
223886846|NCT06839742|OTHER|Deep Posterior Gluteal Compartment Block|Deep Posterior Gluteal Compartment Block will be performed under USG guidance before neuraxial anesthesia.
223886847|NCT06839742|OTHER|Suprainguinal fascia iliaca compartment block|Suprainguinal fascia iliaca compartment block will be performed under USG guidance before neuraxial anesthesia.
223886848|NCT06676332|OTHER|motor imagery training|"Children in the study group will receive multisensory motor imagery training program 45 minutes. The training protocol consists of several parts that will be run through every training session according to Kumar et al. (2016):~* Watching videos of selected multisensory motor skills for 10 minutes.~* Mental rehearsal of these motor skills 10 minutes.~* Overt practice of the multisensory motor skills for 25 minutes. On the videos, the performance of the skill by a child aged 8-12 years will be shown. All the exercises will be looped to repeat for six to seven times. While projecting the video on the laptop screen, it will be ensured that the children are in a comfortable seating position and the screen is in their visual field. Repetition of the exercises was based on their ability which could be a minimum of five repetitions per session to a maximum of ten repetitions per exercise session."
223886849|NCT06676332|OTHER|traditional physical therapy|traditional physical therapy training program
223886850|NCT04571970|GENETIC|RGX-121|Recombinant adeno-associated virus serotype 9 capsid containing human iduronate-2-sulfatase expression cassette
223886851|NCT06780332|DRUG|RDD to Palynziq|Delivery of gradually increasing doses of Palynziq at fixed time intervals over the course of several hours to a cumulative dose equal to the reactive dose. Reactive dose is defined as the dose at which the reactive HSR occurred which led to treatment interruption or reduction of dose or dose frequency.
223886852|NCT05930431|BEHAVIORAL|Physical activity variety intervention|The counseling in the variety condition will serve many purposes. The first session will concentrate on informing participants on the importance of having variety in their physical activity routine and how to access the variety of physical activities available to them. The variety condition will be instructed to complete at least three different HIIT workouts per week. They will be encouraged to complete more than three workouts. The following counseling sessions will be provided to not only continue supporting variety in physical activity but also to support participants' basic psychological needs.
223886853|NCT05930431|BEHAVIORAL|Physical activity consistency comparison condition|The counseling in the consistency condition will serve many purposes. The first session will concentrate on informing participants the importance of having consistency in their physical activity routine and how to access the HIIT workout available to them. The consistency condition will be instructed to complete the provided HIIT workout three times per week. They will be encouraged to complete more than three workouts. The following counseling sessions will be provided to not only continue supporting consistency in physical activity but also to support participants' basic psychological needs.
223886854|NCT06795698|DRUG|Enoxaparin|enoxaparin 1mg/kg of ideal body weight subcutaneous every 24 hours in patients with eGFR \<30ml/min/1.73m2
223886855|NCT05048628|OTHER|Comparıson|"Only evaluation will be made at 0, 4, 6, and 8 hours after surgery without intervention in the control group.~For other groups; Evaluation will be made at the 0th hour after the operation without application. The application will be made at the 4th, 6th, and 8th hours after the surgery and the resulting pain and hoarseness will be evaluated."
223886856|NCT06840847|BEHAVIORAL|Sexual Coercion|This study aimed to investigate whether patients receiving LHRHa treatment experienced sexual coercion at a higher rate than those using tamoxifen. 40 patients using LHRHa and 39 patients using tamoxifen were included in the study.
223886857|NCT06091098|OTHER|Dynamic CO2|2% inspired CO2 for 2-4 breaths
223886858|NCT06091098|OTHER|Sham CO2|Air
223886859|NCT05547958|OTHER|Focus group and online survey|"Focus group with parents of children with disabilities or chronic condition will be organized to identify hypotheses regarding their needs in terms of informations exchange with pediatric rehabilitation professionals about the rehabilitation care of their children.~Then, an online survey will be proposed to parents of children with disabilities or chronic condition in France to identify their needs regarding the development of apps that offer the feature to share informations with rehabilitation professionals."
223886860|NCT05262374|PROCEDURE|Procedure/Surgery: Laparoscopic|Surgeon
223886861|NCT05262374|PROCEDURE|Robotic|Versius system.
223886862|NCT04526808|OTHER|FODMAP diet|low FODMAP diet
223886863|NCT06795750|PROCEDURE|neural therapy|Neural therapy (NT) is a therapeutic intervention that uses local anesthetics to alleviate persistent musculoskeletal pain. NT targets the underlying autonomic dysfunction by modulating the autonomic nervous system. The enhancement of autonomic dysfunction leads to controlled microcirculation, the elimination of pain mediators, and the attainment of an anti-inflammatory effect. NT focuses on painful regions, specific segments of these areas, and trigger points, encompassing both local and segmental treatment
223886864|NCT06795750|OTHER|Exercise|The second group received a home exercise program consisting of stretching, strengthening, and aerobic exercises for 30 minutes, three times per week, for a duration of five weeks.
223886865|NCT06084910|BEHAVIORAL|Cultural Pride Reinforcement for Early School Readiness|Cultural Pride Reinforcement for Early School Readiness (CPR4ESR) is based on the nationwide Reach Out and Read (ROR) program adapted to reinforce cultural pride. ROR provides children's books, brief book-sharing advice, and developmental surveillance at pediatric well child visits. Each of the 5 CPR4ESR sessions provides 1 children's book with a cultural pride theme, 1 parent handout, and modeling of book-sharing.
223886866|NCT06084910|BEHAVIORAL|Reach Out and Read|ROR provides children's books and brief book-sharing advice at pediatric well child visits
223886867|NCT06839651|COMBINATION_PRODUCT|uc-msc secretome intra cavernous injection|"UC-MSC secretome was obtained from UC-MSC cultures with 80% confluence in serum-free medium after 24 hours of incubation The VEGF level in the secretome given was 1400 pg/ml.~The intervention was the administration of 0.5 mL/site of secretome injection injected intra-cavernous to all subjects using a 22-gauge needle according to a sterile protocol. The same volume was given at bilateral sites of the penile shaft. The intra-cavernous injection sites were in the right and left dorsolateral regions of the penis. After the intervention, tolerability was assessed by observing and questioning the subjects regarding pain during injection."
223886868|NCT05902793|DEVICE|Investigational device: V.A.C. VERAFLO™ Dressing Kit|"Up to 170 subjects who meet the eligibility criteria will be randomized to the investigational group or control group at the ratio 1:1.~Subjects will only be enrolled following definitive surgical debridement (if serial debridement performed) of the target wound. The target wound for each subject in both groups will be treated for up to 14 days or until deemed ready for closure by the investigator (whichever occurs first). The planned study period consists of the following visits: Screening (Day -3 to 0), Day of randomization (Day0), Dressing change visit(s), End of treatment visit. Following study treatment, the wound may be treated with any standard therapy selected by the physician, and then accepted secondary intervention for wound closure according to the wound bed preparation situation."
223886869|NCT05902793|DEVICE|Comparator device: Negative pressure wound drainage material|"Up to 170 subjects who meet the eligibility criteria will be randomized to the investigational group or control group at the ratio 1:1.~Subjects will only be enrolled following definitive surgical debridement (if serial debridement performed) of the target wound. The target wound for each subject in both groups will be treated for up to 14 days or until deemed ready for closure by the investigator (whichever occurs first). The planned study period consists of the following visits: Screening (Day -3 to 0), Day of randomization (Day0), Dressing change visit(s), End of treatment visit. Following study treatment, the wound may be treated with any standard therapy selected by the physician, and then accepted secondary intervention for wound closure according to the wound bed preparation situation."
223886870|NCT06839456|DEVICE|Phase 1 Dose Level 1|Patients in the first dose level for the CD45RA depleted addback will receive 1 X 10\^6 CD45RO+ T cells/kg. Once all patients in this dose group have been evaluated for acute GVHD at day 100, then we will advance to the next dose level if indicated by safety analysis.
223886871|NCT06839456|DEVICE|Phase 1 Dose Level 2|Patients in the second dose level for the CD45RA depleted addback will receive 2 X 10\^6 CD45RO+ T cells/kg. Once all patients in this dose group have been evaluated for acute GVHD at day 100, then we will advance to the next dose level if indicated by safety analysis.
223886872|NCT06839456|DEVICE|Phase 1 Dose Level 3|"Patients in the third and final dose level for the CD45RA depleted addback will receive 5 X 10\^6 CD45RO+ T cells/kg. All patients in this dose group will be evaluated for acute GVHD at day 100. Based on these findings, the maximum tolerated dose (MTD) will be determined.~Once MTD for the addback cell dose has been determined in Phase 1, subjects with mismatched related donors will then enroll in Phase 2."
223886873|NCT06839456|DEVICE|Phase 2 Maximum Tolerated Dose determined in Phase 1|Patients with mismatched related donors will receive the CD45RA depleted addback at the maximum tolerated dose determined in the Phase 1 portion of the study.
223886874|NCT06839456|DEVICE|Phase 2 Established Dose from prior study, NCT03810196|Patients with unrelated donors will receive the CD45RA depleted addback at the dose 5 X 10\^6 CD45RO+ T cells.
223886875|NCT06830876|DEVICE|Chattanooga Continuum Device|The Chattanooga Continuum (Enovis, Wilmington, DE) is an FDA-approved, multi-functional, dual-channel electrotherapy device that offers adjunctive rehabilitation therapies, including muscle re-education (NMES), pain control, and stimulation of local blood circulation. The device provides a treatment duration of up to 60 minutes, allowing for cycled or continuous therapy. It offers symmetrical and asymmetrical waveform types, adjustable pulse rates of up to 150 Hz, and pulse width durations of up to 400 μs. The device also features off times, channel ramp times, and on time settings. Additionally, the Continuum is equipped with a data and parameter logger, enabling the monitoring of patient usage. It incorporates an automatic lock function to prevent accidental changes in intensity by preventing unintended pressing of the control buttons. The device operates on two AA rechargeable NiMH batteries, and a battery charger and extra batteries are included with the device.
223886876|NCT06797102|OTHER|Neuromuscular Exercises|Patients in this group received a neuromuscular training protocol along with general treatment for 10 minutes. This included hot packs, lumbar stretches, and ergonomic posture correction divided over 6 weeks The exercises performed included squatting, single leg stance, and balance reach leg and arm exercises with 10 repetitions each. They also did lunge exercises with five repetitions bilaterally, step up and down exercises with 10 repetitions, single leg standing on a balance mat with 10 repetitions and a 10-second hold, single board exercises, and single leg stance with weights and eyes closed for five minutes with a 10-second hold. Additionally, they stood on a wobble board with eyes closed five times with a 10-second hold. The protocol included running on a treadmill and trampoline for five minutes per day, running figure-of-eight patterns, and agility drills at a slow speed for five minutes each.
223886877|NCT06797102|OTHER|Close Chain Exercises|Patients in this group received closed chain exercises for core strengthening along with general treatment for 10 minutes, including hot packs, lumbar stretches, and ergonomic posture correction, divided over 6 weeks. The exercises included sets of squats, lunges, leg presses, wall squats, standing heel raises on a single leg, and single leg dead lifts. Each treatment session lasted 60 minutes, incorporating a warm-up and cool-down period of 10 minutes.
223886878|NCT04675892|PROCEDURE|A1 pulley division|"Local anesthesia with 5-10 ml of solution required (90 % lidocaine 1 % with 1 ug epinephrine, 10 % sodium bicarbonate 8.4 %).~Division of the A1 pulley.~Wound closure with absorbable sutures and application of a light dressing."
223886879|NCT04675892|PROCEDURE|A1 pulley division + Resection of one or both slips of the FDS tendon|"Local anesthesia with 5-10 ml of solution required (90 % lidocaine 1 % with 1 ug epinephrine, 10 % sodium bicarbonate 8.4 %).~Division of the A1 pulley.~Palmar Bruner incision over the PIP joint. Distal dissection and resection of one or both slips of the FDS tendon.~Wound closure with absorbable sutures and application of a light dressing."
223886880|NCT05557864|DEVICE|Deep Brain Stimulation|Pallidal Deep Brain Stimulation
223886881|NCT06829628|BEHAVIORAL|chatbot teaching strategies|Chatbot-Based Learning
223886882|NCT02989935|PROCEDURE|Ventilation|Measurements of ventilation with subjects seated, and breathing across a pneumotachygraph and pressure transducer to measure inspiratory airflow, during both resting and CO2 stimulated breathing.
223886883|NCT02989935|PROCEDURE|Parasternal EMG|Recordings of electrical activity (EMG) from the parasternal intercostal muscle in the second intercostal space on the upper anterior chest wall adjacent to the sternum.
223886884|NCT02989935|PROCEDURE|Phrenic magnetic stimulation|Bilateral maximal magnetic stimulation (Magstim) of the phrenic nerves.
223886885|NCT00804453|DEVICE|Cartridge blood set|Once a week
223886886|NCT00804453|DEVICE|Standard blood line|Once a week
223886887|NCT04762641|DRUG|ABL503|ABL503 will be administered intravenously (IV) on Day 1 and Day 15 of every 28-day cycle in the dose-escalation part. The dosing interval to be used in the dose-expansion part will be re-evaluated based on the emerging safety and PK data from the dose-escalation part of the study.
223886888|NCT06826963|OTHER|Aerobic eccentric intervention|This arm will participate in a supervised eccentric cycling training program for three months. The intervention will include two training sessions per week in the first month, increasing to three sessions per week in the following two months. Each session will consist of a warm-up (5 minutes), a main training phase (20-30 minutes), and a cool-down (5-10 minutes). The intensity of training will be gradually adjusted to maintain a perceived exertion rating (RPE) between light and moderate with a target heart rate zone (57-76% of HRmax). Pre- and post-training assessments will evaluate physical function through several tests, body composition and anthropometric indices, muscle strength of upper and lower limbs, questionnaires related to the overall health improvement. Finally, participants will also be monitored for daily physical activity through wearable sensors to track mobility and autonomy.
223886889|NCT06500104|DIETARY_SUPPLEMENT|Kefir peptide|Dosage: 1.2 gram kefir peptide daily oral intake for 12 weeks
223886890|NCT06500104|DIETARY_SUPPLEMENT|Placebo|Glucose powder
223886891|NCT06836804|OTHER|Sociodemographic Data Form|After inquiring about participants' sociodemographic characteristics, such as name, contact information, age, gender, marital status, education level, income, and place of residence, measurements of height, weight, and waist circumference will be obtained. Then, participants' CVD, psychiatric and other medical conditions, CVD risk factors, health history, and medications they are using will be queried. This information will be recorded in the sociodemographic data form. The sociodemographic data form has been prepared by the researchers.
223886892|NCT06836804|OTHER|Short Form Health Survey|SF-36 is a self-assessment scale and can be completed in five minutes. SF-36 can evaluate both the negative and positive aspects of health. The scale consists of 36 items which are used to assess different health dimensions in 8 subscales: Physical functioning (10 items), social functioning (2 items), role limitations due to physical problems (4 items), role limitations due to emotional problems (3 items), mental health (5 items), energy/vitality (4 items), pain (2 items), and general health perception (5 items).
223886893|NCT06836804|OTHER|Hospital Anxiety and Depression Scale|The HADS was designed in 1983 to identify anxiety and depression in individuals with physical illnesses. The HADS is a self-reported scale consisting of seven items each for the anxiety and depression subscales. Each item is scored from 0 to 3, and the total score for the anxiety and depression subscales is 21 points. The overall HADS score is obtained by summing the points from both subscales. A total subscale score between 0-7 indicates a normal test result, 8-10 indicates mild anxiety or depression, 11-15 indicates moderate anxiety or depression, and 16-21 indicates severe anxiety or depression. Higher scores represent higher levels of anxiety or depression, and the total HADS score reflects an overall measure of psychological distress. The survey can be completed in 2-5 minutes.
223886894|NCT06836804|OTHER|Illness Intrusiveness Ratings Scale|The IIRS is an easy-to-administer scale designed to predict the psychosocial impact of chronic illness and to document and compare the effectiveness of therapeutic interventions. It consists of 13 questions which are completed by the patient. The scale measures how the limitations imposed by chronic and life-threatening diseases hinder participation in regular activities across 13 important aspects of life: Health, diet, work, active recreation (sports), passive recreation (reading, listening to music), finances, relationships with partners, sexual life, family relationships, other social relationships, self-expression/development, religious expression, and community and civic participation.
223886895|NCT06836804|OTHER|Cardiac Depression Scale|CDS was designed to identify depression in individuals with CVDs. It consists of 26 items across 7 subscales. The subscales address issues such as sleep, uncertainty, mood, hopelessness, immobility, anhedonia, and cognition. The CDS is rated on a 7-point Likert scale, with seven items being reverse-coded. Based on patient feedback and clinical experience, two short forms were developed, each consisting of five questions. Both short forms showed good consistency with the original CDS. The first short form includes questions from the original CDS numbered 12, 24, 21, 10, and 9. The second short form includes questions from the original CDS numbered 12, 4, 25, 21, and 7.
223886896|NCT06204237|DRUG|[89Zr]Zr-DFO-APAC|All participants will receive a single i.v. injection of \[89Zr\]Zr-DFO-APAC 15 MBq (Megabecquerel).
223886897|NCT06204237|RADIATION|PET/CT scan|The IMP administration will be followed by whole-body PET/CT scanning (day 1), and repeated PET/CT scans on days 3 and 7.
223886898|NCT03413592|OTHER|Road-tracking test|Driving with simulator program for SDLP measurement
223886899|NCT03413592|OTHER|Car-following test|Driving with simulator program for DCV measurement
223886900|NCT03413592|OTHER|Harsh-braking test|Driving with simulator program for BRT measurement
223886901|NCT06836024|DIETARY_SUPPLEMENT|Actazin chewable tablet|Actazin tablets are tableted non-GMO, freeze-dried, green kiwifruit powder from 100% New Zealand-grown green kiwifruit. Currently, kiwifruit extracts (such as Actazin), are marketed in Canada as a natural supplement. It is safe, bioavailable, and has been previously shown to be well tolerated at doses up to 2400 mg.
223886902|NCT06836024|DRUG|PEG 3350|a commonly used over the counter laxative in north America. A stool softener.
223886903|NCT06836024|OTHER|Chewable Tablet|Sorbitol-based placebo chewable tablets made by Pharma NZ. Those tablets will have a similar appearance to active Actazin but will not taste the same. This is because the taste of Actazin is a non-altered natural kiwi taste. They will be administered in the same dose and manner as the active Actazin oral chewable tablets.
223886904|NCT06836024|OTHER|Maltodextrin (Placebo)|Maltodextrin powder, administered in the same doses and manner as active PEG 3350 group.
223886905|NCT06173804|OTHER|Adapted Look Ahead Lifestyle Intervention|Participants will be educated about improving healthy lifestyles involving physical activity and healthy eating to improve physical function and improve glycemic control.
223886906|NCT06125587|DRUG|Chiglitazar|Chiglitazar is a novel PPAR agonist. Treatment of type 2 diabetes mellitus by moderate activation of PPARα, PPARγ and PPARδ, improving insulin sensitivity, regulating blood glucose, and promoting fatty acid oxidation and utilization.
223886907|NCT06125587|DRUG|Metformin|Metformin is not only an antihyperglycemic drug, it also corrects insulin resistance and hyperandrogenism in polycystic ovary syndrome.
223886908|NCT06130475|OTHER|Oral Rehydration Solution (ORS)|Participants will be administered the ORS during one of the study visits
223886909|NCT06130475|OTHER|Water|Participants will be administered water during one of the study visits
223886910|NCT06755489|OTHER|Placebo|530 mg tablets containing microcrystalline cellulose, rice bran, bitter cocoa powder table 530 mg. 1 tablet three times a day
223886911|NCT06755489|OTHER|GABA|530 mg tablets containing Gamma-aminobutyric acid (GABA) and different bulking agent as microcrystalline cellulose, calcium carbonate, lemon balm d.e. Leaves (melissa officinalis l. - maltodextrin) tit. 2% in rosmarinic acid, anti-caking agents: silicon dioxide, vegetable magnesium stearate. 1 tablet three times a day
223886912|NCT05530174|OTHER|Antibiotic dosage practice|"Patient inclusion starts day one, cross-over of departments from treatment A (single-dose) to B (multiple-dose) or vice versa after one year and end of inclusion happens after 2 years.~All centers in Denmark use either Cloxacillin/Dicloxacillin, Cefuroxime or both drugs as standard prophylactic antibiotic practice for THA. In cases of cephalosporin allergy or general beta lactam allergy, the antibiotic clindamycin may be administered.~In this trial, patients will be administered the standard prophylactic antibiotic practice of either single-dose (A) or multiple-doses (B) of antibiotics administered at each respective cluster that respective year. Both practices of dose administration for antibiotic prophylaxis (i.e. single- or multiple-dose) follow current standards of treatment and are based on present clinical practice guidelines."
223886913|NCT04178733|DRUG|LY3493269 - SC|Administered SC
223886914|NCT04178733|DRUG|Placebo - SC|Administered SC
223886915|NCT04178733|DRUG|LY3493269 - IV|Administered IV
223886916|NCT03940950|BIOLOGICAL|Autologous Adipose-Derived SVF (Stromal Vascular Fraction)|60 ml of fat is collected from subjects abdominal wall and SVF is removed from the fat. The SVF is injected into the knee through a needle.
223886917|NCT03940950|DRUG|Placebo|Saline control that contains no active ingredient
223886918|NCT04749628|DRUG|cannabidiol|Epidiolex (cannabidiol) oral solution
223886919|NCT04749628|OTHER|Ora-sweet SF|Ora-sweet SF placebo
223886920|NCT04286607|DRUG|Topical roflumilast|Active treatment
223886921|NCT04646304|OTHER|Objective Feedback (Motion Capture)|Participants assigned to the objective feedback group will be given a report after completing Set 1 and Set 2. This report will outline their performance for each significant factor (identified in Phase 1) relative to a target interval, derived from the staff surgeon group average (± one standard deviation). Participants assigned to the objective feedback group will then be able to repeat the tasks knowing which variables to improve.
223886922|NCT01974245|DRUG|Cholecalciferol|100,000 IU/week for 12 weeks
223886923|NCT01974245|DRUG|Placebo|100 drops/ week for 12 weeks
223886924|NCT03442413|DRUG|2-[18F]-FA PET/CT|2-\[18F\]FA is a highly specific radiotracer which has been used successfully to image nicotinic acetylcholine receptors in the human brain to characterize the effects of nicotine exposure (via smoking) on these receptors.
223886925|NCT03442413|DRUG|I.V. Nicotine|Subjects in our study will receive intravenous nicotine at the adaptation session and each of the PET scans, close to the amount of nicotine absorbed from smoking 1/10 cigarette.
223886926|NCT03744936|OTHER|Feedback|Study team members will conduct interviews with subjects to gather feedback on Atrial Fibrillation experiences
223886927|NCT06521658|PROCEDURE|Timing of retroflexion|The intervention is the timing of the retroflexion/looping of the colonoscope in the rectum
223886928|NCT06844292|DEVICE|MINIject with Cataract Surgery|Patients will be randomized to receive either a MINIject implant or a Hydrus Microstunt in conjunction with cataract surgery. If randomized to MINIject, the device will be implanted into the supraciliary space with a minimally invasive ab interno approach. It is designed to be implanted with its head in the anterior chamber and its body in the supraciliary space, leading to improved natural uveoscleral outflow by directing aqueous humor from the anterior chamber to the sub-scleral space. Cataract surgery will be performed with phacoemulsification.
223886929|NCT06844292|DEVICE|Hydrus Microstent with Cataract Surgery|"Patients will be randomized to receive either a Hydrus Microstunt or a MINIject implant in conjunction with cataract surgery. If randomized to Hydrus Microstent, the device will be implanted into Schlemm's canal through the trabecular meshwork in order to dilate and restore the natural aqueous outflow pathway through Schlemm's canal, leading to a reduction of intraocular pressure.~Cataract surgery will be performed with phacoemulsification."
223886930|NCT06847789|DEVICE|Tensi+|Tensi+ (Stimuli Technology, Boulogne Billancourt, France) is a newly released, medical transcutaneous-posterior tibial nerve stimulation (TC-pTNS) device marketed for overactive bladder (OAB) management.
223886931|NCT03223961|DRUG|EPREX|60 000 U/week for at least 12 weeks
223886932|NCT06584032|DRUG|fruquintinib|Fruquintinib will be orally administrated once daily for 2 consecutive weeks followed by a 1-week break.
223886933|NCT06584032|BIOLOGICAL|sintilimab|Sintilimab will be intravenously administrated on Day 1 every three weeks.
223886934|NCT06584032|DRUG|paclitaxel|175 mg/m\^2 via IV infusion, once a week for 3 weeks followed by a 1-week break.
223886935|NCT06584032|DRUG|doxorubicin|60mg/m\^2 via IV infusion, on Day 1 every three weeks.
223886936|NCT06844370|OTHER|Non-invasive ventilation|Providing ventilation support through non-invasive means
223886937|NCT02287311|BIOLOGICAL|MABEL CTLs|"Dose escalation:~DL1:2x10\^7 cells/m2+2x10\^7 cells/m2~DL2:2x10\^7cells/m2+5x10\^7 cells/m2~DL3:5x10\^7 cells/m2+1x10\^8 cells/m2~\*Doses are based on total CD3+cells/m2~Patients with active disease that have apparent clinical benefit at the 8 wk post 1st infusion (6 wks after 2nd infusion) or subsequent evaluations may receive up to 6 additional doses of CTLs at intervals at least 6 wks apart, each of which will consist of the same cell number as their second injection or below the original dose if there is not enough product available for the original dose. Patients may receive lymphodepleting chemotherapy (Cy/Flu) before additional infusions. Patients cannot receive additional doses until the initial safety profile is completed at 6 wks following the second infusion."
223886938|NCT02287311|DRUG|Cyclophosphamide|"If the patient's level of circulating T cells is relatively high, s/he may require treatment with cyclophosphamide (Cytoxan) and Fludarabine before s/he receives MABEL CTLs.~3 daily doses of cyclophosphamide (Cy: 500 mg/m2/day) together with fludarabine (Flu: 30 mg/m2) to induce lymphopenia, finishing at least 24 hours before CTL infusion."
223886939|NCT02287311|DRUG|Fludarabine|"If the patient's level of circulating T cells is relatively high, s/he may require treatment with cyclophosphamide and fludarabine before s/he receives MABEL CTLs.~3 daily doses of cyclophosphamide (Cy: 500 mg/m2/day) together with fludarabine (Flu: 30 mg/m2) to induce lymphopenia, finishing at least 24 hours before CTL infusion."
223886940|NCT06845059|OTHER|"11 For Health"|"Participants will participate in the 11 For Health program, consisting of 11 sessions over 11 weeks. The program combines football skills with health education to promote overall health and well-being."
223886941|NCT06845943|DRUG|HCR-188|Single (SAD cohorts) or multiple (MAD cohorts) subcutaneous injections
223886942|NCT06845943|DRUG|Placebo|Single (SAD cohorts) or multiple (MAD cohorts) subcutaneous injections
223886943|NCT06845254|DRUG|Xuesaitong soft capsule (main ingredient is Panax notoginseng saponins)|Routine western medicine treatment (oral drug therapy and standard percutaneous coronary intervention) + Xuesaitong soft capsule, 0.33g/ tablets, 2 tablets each time, twice a day. The treatment period is 12 weeks.
223886944|NCT06845254|DRUG|placebo capsule|Routine western medicine treatment (oral drug therapy and standard percutaneous coronary intervention) + placebo capsule, 0.33g/ tablets, 2 tablets each time, twice a day. The treatment period is 12weeks.
223886945|NCT04674358|DRUG|Reproxalap Ophthalmic Solution (0.25%)|Reproxalap Ophthalmic Solution (0.25%) administered over two consecutive days (Day one pre-dry eye chamber and Day two dry eye chamber assessment).
223886946|NCT04674358|DRUG|Vehicle Opthalmic Solution|Vehicle Ophthalmic Solution administered over two consecutive days (Day one pre-dry eye chamber and Day two dry eye chamber assessment).
223886947|NCT06180694|OTHER|Reminiscence therapy|Reminiscence therapies will be applied to individuals with dementia in 45-minute sessions once a week for 8 weeks.
223886948|NCT06502444|BEHAVIORAL|Moving Forward Together Activity Intervention|The activity intervention program consists of videos and handouts to encourage participants to access these materials if they wish to increase their physical activity. The program lasts 8 weeks. Participants may access program materials for an additional four weeks after the program ends
223886949|NCT03739450|BEHAVIORAL|Problem Solving Training (PST)|The PST intervention consists of six sessions that will follow a structured format based on the PST manual. In these sessions, the interventionist will first provide the TBI-specific education, introduce the participant to the PST steps, then help the care partner generate and select a problem to address first. Interventionist will facilitate the care partner's use of the ABCDEF steps of PST to develop a specific action plan to solve the problem. As problems are attempted or solved, the care partner will learn how to perform the steps on his/her own, thus acquiring self-management problem solving skills that will be applicable to future problems. The final session will include a review and generalization of the PST steps and progress made.
223886950|NCT03739450|BEHAVIORAL|Education|Participants will receive TBI-specific education alone through a workbook. It consists of educational modules for self-study, common sequelae of TBI, issues encountered by care partners, work and school concerns for those with TBI, and on navigating the rehab system and accessing resources. The modules consist of a brief introduction, key definitions, examples, resources, and a summary. Some chapters also include self-directed activities, such as worksheets or checklists. The investigators will provide a brief orientation to the workbook and include open-ended questions about the participants' need for clarification or questions of the education material. The last session will consist of an open discussion about expected problems that may arise post-discharge.
223886951|NCT06060626|DRUG|Sedation using only Propofol.|Patients in whom only propofol will be administered during sedation.
223886952|NCT06060626|DRUG|Sedation using combination of Propofol and Fentanyl.|Patients in whom combination of propofol and fentanyl will be administered during sedation.
223886953|NCT06225492|DRUG|DaxibotulinumtoxinA 15 units|Subjects will be treated with 15 units of daxibotulinumtoxinA per platysmal band
223886954|NCT06225492|DRUG|DaxibotulinumtoxinA 20 units|Subjects will be treated with 20 units of daxibotulinumtoxinA per platysmal band
223886955|NCT05688410|OTHER|Exercise|"Participants who are randomized to exercise will be perform exercise on stationary bikes. Participants randomized to Voluntary Exercise will exercise on a standard stationary bike where they will pedal at their voluntary rates. Participants randomized to Assisted Exercise will exercise on a special bike that assists them to pedal faster than they do voluntarily on their own (assisted (exercise) bike)."
223886956|NCT05688410|BEHAVIORAL|Psychotherapy Pain and Addiction (I-STOP)|"Participants who are randomized to receive I-STOP will receive the Self-regulation Treatment for Opioid addiction and Pain (STOP) program modified for inpatients/residential drug treatment (I-STOP). I-STOP uses empirically validated pain psychotherapy approaches targeted to patients with an OUD using psycho-physiological self-regulation components and biofeedback with Bio-dots."
223886957|NCT06076837|DRUG|Botensilimab|an Fc-engineered anti-CTLA-4 (cytotoxic T-lymphocyte antigen 4) monoclonal antibody
223886958|NCT06076837|DRUG|Balstilimab|a human monoclonal immunoglobulin (Ig) G4 (IgG4) antibody, designed to block programmed cell death protein (PD-1) binding by PD-L1 and PD-L2
223886959|NCT06076837|DRUG|Chloroquine Phosphate|an antimalarial agent, that is being used in this patient population to sensitize cancer cells to chemotherapy and leads to anticancer effects through inhibiting autophagy
223886960|NCT06076837|DRUG|Celecoxib|a second-generation selective Cyclooxygenase 2 (COX-2) inhibitor, is being used in this patient population to enhance the therapeutic effect of cisplatin by inhibiting the expression of COX-2 as well as inhibit anti-apoptotic gene BCL-2 (B-cell lymphoma 2)
223886961|NCT06076837|DRUG|Nab paclitaxel|microtubule inhibitor indicated for the treatment of Metastatic adenocarcinoma of the pancreas as first-line treatment, in combination with gemcitabine
223886962|NCT06076837|DRUG|Gemcitabine|a nucleoside metabolic inhibitor indicated as a single agent for the treatment of pancreatic cancer
223886963|NCT06076837|DRUG|Cisplatin|platinum-based drug indicated for the treatment of advanced cancers
223886964|NCT06527586|DEVICE|soft contact lens|Vision Correction
223886965|NCT05418296|DEVICE|A novel digital health device|A videogame-generated virtual world designed for the AD/ADRD care dyad.
223886966|NCT04318197|OTHER|Personalized rehabilitation program with electrostimulation|Patient with knee arthroplasty indication. After clinical assessment and a MRI measurement of muscle volume, patients start a 2 hours daily rehabilitation including 2 times 20 minutes of electrostimulation of atrophied muscles, 3 days per week during 4 weeks.
223886967|NCT04318197|OTHER|Global rehabilitation program|Patient with knee arthroplasty indication. After clinical assessment and a MRI measurement of muscle volume, patient start a 2 hours daily rehabilitation targeting muscles groups with strengthening and stretching exercises, 3 days per week during 4 weeks.
223886968|NCT05622955|OTHER|Peer Empowered Endometriosis Pain Support (PEEPS)|The sessions will provide education on endometriosis, mindfulness, yoga, nutrition, and strategies to cope with chronic pain. Patients will additionally receive peer and clinician support to decrease the social isolation experienced by people with endometriosis
223886969|NCT06336785|DEVICE|Restylane line of soft tissue fillers and Dysport neuromodulator|Subjects will be treated with a range of hyaluronic acid-based soft tissue fillers (Restylane line) and Dysport neuromodulator
223886970|NCT05119972|DRUG|ZSP1603|ZSP1603 administered orally
223886971|NCT05119972|DRUG|Placebo|Placebo administered orally
223886972|NCT06259396|BEHAVIORAL|The 8x5 Diet|A virtual, dietitian-counselled, healthy dietary pattern defined by its fat intake, its daily eating pattern, keeping adequately hydrated, having a variety of whole grains, fruit and vegetables, and use of certain plant fibres.
223886973|NCT06068075|OTHER|FoundationOne Liquid CDx|a FoundationOne liquid biopsy test kit will be sent to the laboratory of the subject's treating center, in addition to the paired cell stabilizing tube from the primary center
223886975|NCT04236856|DEVICE|Robotic Endovascular Procedure|After providing written informed consent, subjects with cerebral aneurysms may have their aneurysm treated using the CorPath GRX System.
223886976|NCT06221176|BEHAVIORAL|Being Brave|Being Brave is a manualized cognitive-behavioral (CBT) intervention and includes several features that are well-aligned with the needs of autistic children: (1) an intensive parent component; (2) use of visual aids to lay out coping plans and exposure hierarchies, psychoeducation about recognizing fear and anxiety, and scripted language for coping; (3) repeated practice of well-rehearsed coping plans for novel or challenging situations; and (4) exposure exercises for social anxiety and practice of basic social skills. The intervention includes 16 weekly sessions (1 hour each). Delivery of Being Brave is flexible to allow for additional or less practice or exposure opportunities.
223886977|NCT05673304|RADIATION|SBRT anticipated boost|24 Gy in 3 fractions to the tumour
223886978|NCT05570838|DEVICE|Functional Electrical Stimulation|Functional Electrical Stimulation consist on applying a current on the damaged muscles when the patient is doing a task that requires them. 120 repetitions will be made on the 6 first sessions and 180 repetitions will be done after the sixth session
223886979|NCT05570838|DEVICE|Hand Robotic-Assisted Therapy|The hand Robotic-Assisted Therapy will be applyed using the AMADEO robot for hand rehabilitation by Tyromotion. The protocol that will be used consists on 200 repetitions on the active-assisted mode with flexion and extension of all the finguers and 50 repetitions on the active mode.
223886980|NCT05271578|DEVICE|Standardized Electronic Research Cigarette|Standardized Research Electronic Cigarette Device, Standardized Research Electronic Cigarette Tobacco 5%, Standardized Research Electronic Cigarette Tobacco (placebo) 0% (NJOY, LLC, Tobacco Product Master File #STN MF0000274)
223886981|NCT05271578|DEVICE|Nicotine Research Cigarette|Conventional Nicotine Tobacco Cigarette (National Institute of Drug Abuse, Drug Supply Program, Tobacco Product Master File #NRC600)
223886982|NCT05633446|BIOLOGICAL|PepGNP-COVID19 (One vaccination)|One dose with 7.5 nmol total peptide/dose with 47.8ug gold base particle in 50 µl WFI
223886983|NCT05633446|OTHER|Water for injection (One vaccination)|Water For Injection (WFI): (sodium chloride, a 0.9% solution for the preparation of dosage forms for injections) 50 µl per dose
223886984|NCT05633446|BIOLOGICAL|PepGNP-COVID19 (Two vaccinations)|Two vaccinations with 7.5 nmol total peptide/dose with 47.8ug gold base particle in 50 µl WFI
223886985|NCT05633446|OTHER|Water for injection (Two vaccinations)|Water For Injection (WFI): (sodium chloride, a 0.9% solution for the preparation of dosage forms for injections) 50 µl per dose
223886986|NCT03394846|BEHAVIORAL|Test of Existing MI Products|Three widely available MI products (GoNoodle, Take10, ABC for Fitness) will be tested by teachers in their classrooms. Teachers will participate in the study for four weeks (one baseline week, one week for each product).
223886987|NCT01579396|DEVICE|septeX|12 h septeX CVVH treatment after cardiac surgery
223886988|NCT01579396|OTHER|standard therapy|standard therapy either pharmacological and /or continuous renal replacement therapy (CRRT)
223886989|NCT04639401|OTHER|motor entrainment to auditory cues and music during walking on quality of movement|The study contains 1 descriptive and 4 experimental sessions. In the descriptive session, participant's clinical motor and cognitive functions are collected. In the first experimental session, participant's beat perception and synchronisation abilities is examined within a finger tapping paradigm. In the following experimental sessions participants synchronsiation abilities is examined during walking paradigms, to music and metronomes, at different tempi and alignment strategies. In the latter three sessions, apart from outcome measures of synchronization the following will be collected as well: spatio-temporal gait parameters, perceived fatigue, perceived motivation and perceived speed of walking.
223886990|NCT06332482|DEVICE|Implant supported screw retained prosthesis|All patients will receive six maxillary and mandibular implants for full arch screw retained prosthesis
223886991|NCT05514730|BEHAVIORAL|Phase-based Treatment (PBT) for Problematic Sexual Behavior of Preteen Children|PBT is a skills-based protocol that primarily works with caregivers to manage problematic behavior and to teach children healthy information about sex and sexuality. It was designed based on the current empirical knowledge regarding the etiology and treatment of childhood problematic sexual behavior. It is delivered in 12 weekly sessions, with each session lasting approximately 50 minutes.
223886992|NCT05514730|BEHAVIORAL|Treatment-as-Usual (TAU)|The TAU intervention designed for this trial relies largely on the delivery of child-focused treatment techniques, particularly on the development of therapeutic rapport through the utilization of non-directive techniques. These sessions are supplemented with educational materials for the caregiver on child behavior and parenting recommendations. This treatment is designed to be administered over 12 weekly sessions, with each session lasting approximately 50 minutes.
223886993|NCT05255458|BIOLOGICAL|AK102|Administered AK102 by subcutaneous injection Drug: Statins and/or Ezetimibe lipid-lowering therapies
223886994|NCT05255458|DRUG|Placebo|Administered placebo by subcutaneous injection Drug: Statins and/or Ezetimibe lipid-lowering therapies
223886995|NCT06321042|DEVICE|Knee arthroplasty|Knee arthroplasty surgery with perseus orthokey alignment device
223886996|NCT05836883|BIOLOGICAL|ExoFlo|Local injection of bone marrow mesenchymal stem cell derived extracellular vesicles
223886997|NCT05836883|OTHER|Local injection of normal saline|Placebo
223886998|NCT02375204|DRUG|paclitaxel|IV
223886999|NCT02375204|DRUG|ifosfamide|IV
223887000|NCT02375204|DRUG|cisplatin|IV
223887001|NCT02375204|DRUG|pegylated G-CSF|IV
223887002|NCT02375204|DRUG|G-CSF|IV
223887003|NCT02375204|DRUG|carboplatin|IV
223887004|NCT02375204|DRUG|etoposide phosphate|IV
223887005|NCT02375204|PROCEDURE|stem cell reinfusion|surgical procedure
223887006|NCT05956288|DEVICE|Blood flow restriction (BFR) with low load resistance training|Combination of low load resistance exercise in the upper limb with the addition of blood flow restriction or sham-blood flow restriction.
223887007|NCT05018832|BIOLOGICAL|AlloRx|cultured allogeneic adult umbilical cord derived mesenchymal stem cells
223887008|NCT03721497|DRUG|Testosterone Undecanoate|The patients will be randomly assigned to either testosterone or placebo.
223887009|NCT04128566|PROCEDURE|walking stress test|walk for 30 minutes on a treadmill with either one of the three loading conditions (reduced load = 80% Bodyweight (BW), normal load = 100% BW, increased load = 120% BW). The order of experimental condition will be applied in randomized order determined by block randomization, and the same self-selected walking speed will be used for all conditions.
223887010|NCT04807218|BEHAVIORAL|Virta Health|The comprehensive remotely-delivered continuous remote care to induce nutritional ketosis combined with remote medication management is the Virta treatment, and while on this treatment, subjects will have access to Virta health coaches and licensed medical providers who will perform medical therapy management, health coaching, nutrition and behavior change education, biometric feedback, and the option to participate in a community for peer support.
223887011|NCT03886311|DRUG|Talimogene Laherparepvec 100000000 PFU/1 ML Injection Suspension [IMLYGIC]|Talimogene laherparepvec, 1Bil is given intratumorally every 2 weeks according to tumor size
223887012|NCT03886311|DRUG|Nivolumab IV Soln 100 MG/10ML|NIVOLUMAB 240 mg IV over 30 min q 2 weeks
223887013|NCT03886311|DRUG|Trabectedin 0.25 MG/1 VIAL Intravenous Powder for Solution|TRABECTEDIN 1.2 mg/m2 CIV over 24 hours q3 weeks
223887014|NCT03828994|BEHAVIORAL|Tech-PN|"* text messaging(daily medication reminders and tri-weekly messages following the 14-day treatment period)~* enhanced community health nurse visits on day 3-5, 14 and 30~* field based treatment visits~* clinical assistance with notification, testing and treatment"
223887015|NCT04700969|OTHER|: A support program to facilitate implementation of evidence-based practice for postoperative urinary retention|A 12-month implementation support program for multi-professional internal facilitator teams
223887016|NCT05720325|DRUG|Dupilumab|Dupixent is an interleukin-4 receptor alpha antagonist
223887017|NCT05720325|OTHER|House Dust Mites (HDM)|House Dust Mites used to challenge subjects using an aeroallergen challenge chamber
223887018|NCT05720325|OTHER|Placebo|Inert placebo administered to placebo arms of study.
223887019|NCT01195831|DRUG|Xamiol® gel|Once daily application
223887020|NCT01195831|DRUG|Calcipotriol scalp solution|Twice daily application
223887021|NCT06494293|OTHER|Data Collection|Collection of medical data from MICU intervention file and patient medical files from participating centres
223887022|NCT04916236|DRUG|RMC-4630|"* SHP2-inhibitor~* Powder in capsule~* Administered on day 1 and day 2 of every week"
223887023|NCT04916236|DRUG|LY3214996|"* ERK inhibitor~* Powder in capsule~* Administered every day"
223887024|NCT01911091|BEHAVIORAL|Exercise|A 5-minute warm-up and a 5-minute cool-down prior to and following each exercise session, respectively. There will be alternating days of interval training and aerobic training. The interval training will be performed on an upright stationary bike, while the aerobic training will be performed on a treadmill. The interval training will consist of five-minute bouts of higher intensity alternated with 4 minutes of lower intensity for a total duration of 45 minutes. Intensity will increase each week. The aerobic training component will be fixed at a moderate intensity, but will increase in duration each week from 45 minutes to 75 minutes to 90 minutes during the third and final week.
223887025|NCT05432557|PROCEDURE|external oblique intercostal plain block (EOIP)|A high-frequency linear ultrasound probe will be placed in a longitudinal parasagittal orientation at the sixth intercostal space in the anterior midaxillary line. A 21G 10 cm needle will be inserted using an in plane approach. The tip of the needle will be placed into the fascial plane on the deep aspect of the external oblique muscle. A volume of 20 mL of LA mixture (10 mL of bupivacaine 0.5%, 5 mL of lidocaine 2% and 5 mL of normal saline to make a mixture totaling 20 ml.) will be injected.
223887026|NCT05432557|PROCEDURE|subcostal transversus abdominis plane block (SCTAP)|The US probe will be placed immediately below the costal margin on oblique plane toward the lateral close to midline to identify the rectus abdominis muscle. The transversus abdominis muscle will be identified lying posterior to the rectus muscle. An 8cm 22-gauge block needle will be inserted using an in- plane approach. transversus abdominis plane will be accessed by placing the needle adjacent to costal margin but medial to linea semilunaris. The needle will be advanced slowly in-plane to promote hydrodissection along the oblique subcostal line. A volume of 20 mL of LA mixture (10 mL of bupivacaine 0.5%, 5 mL of lidocaine 2% and 5 mL of normal saline to make a mixture totaling 20 ml.) will be injected.
223887027|NCT05432557|OTHER|control group|No LA injection
223887028|NCT05617872|DRUG|Vinegar 20ml|Inject 20ml vinegar (5% acetic acid solution) into duodenum and collect the pancreatic juice for 15 minutes via EUS, changing the collection bottle every 5 minutes.
223887029|NCT05617872|DRUG|Saline (NaCl 0,9 %) (placebo)|Inject 20ml normal saline solution into duodenum and collect the pancreatic juice for 15 minutes via EUS, changing the collection bottle every 5 minutes.
223887030|NCT05617872|DRUG|Vinegar 40ml|Inject 40ml vinegar (5% acetic acid solution) into duodenum and collect the pancreatic juice for 15 minutes via EUS, changing the collection bottle every 5 minutes.
223887031|NCT06110208|DRUG|CLL1 and CD38 dual-target CAR-T injection|CLL1 and CD38 dual-target CAR-T injection
223887032|NCT06550596|OTHER|Standard of Care|Beginning at the screening visit, participants will receive weekly treatment with standard of care (cleaning, debridement, ulcer moisture balance, and offloading) until ulcer closure, or a maximum of 12 weeks, whichever occurs first.
223887033|NCT06550596|OTHER|Axolotl DualGraft + SOC|Participants will receive weekly applications of Axolotl DualGraft and Standard of Care until ulcer closure, or a maximum of 12 weeks, whichever occurs first.
223887034|NCT02094365|DRUG|ALS-008176|
223887035|NCT02094365|DRUG|vehicle|
223887036|NCT05883111|DIAGNOSTIC_TEST|HPV DNA methylation assay|HPV DNA methylation assay to detect HPV positivity, HPV genotype, and HPV methylation.
223887037|NCT05133245|OTHER|Diagnostic study only|Diagnostic study only
223887038|NCT05272618|DIAGNOSTIC_TEST|Intravascular imaging (OCT), Invasive physiologic assessment (FFR, CFR, IMR), or Non-invasive physiologic assessment (N-13 ammonia PET)|Intravascular imaging (OCT), Invasive physiologic assessment (FFR, CFR, IMR), or Non-invasive physiologic assessment (N-13 ammonia PET)
223887039|NCT06235996|PROCEDURE|Office-based procedure indicated for chronic pain with music|Such procedure may include sacroiliac joint (SI) steroidal injections, SI radiofrequency ablations, peripheral nerve stimulator implantations, caudal and laminar epidural steroidal injections, lumbar medial branch blocks, lumbar medial branch nerve radiofrequency ablations, spinal cord implantation of electro stimulators.
223887040|NCT06235996|PROCEDURE|Office-based procedure indicated for chronic pain without music|Office-based procedure indicated for chronic pain without music
223887041|NCT05293041|DRUG|Argipressin|Infusion of Argipressin 0.8 U/ml, 0.056 ml/kg/h will be started as soon as the central line is placed, and continued until the end of surgery in the treatment arm.
223887042|NCT05293041|DRUG|Placebo|Infusion of Normal Saline 0.056 ml/kg/h will be started as soon as the central line is placed, and continued until the end of surgery in the placebo arm.
223887043|NCT03111290|DEVICE|Direct Cortical Stimulation|A train of periodic electrical pulses is delivered between two local electrodes implanted in the brain
223887044|NCT03111290|DEVICE|Direct Cortical Stimulation Sham|Sham trials where no electric pulse is delivered
223887045|NCT06340932|DEVICE|Iovera|Cryoneurolysis of 5 sensory nerves (Intermediate branch of the AFCN, Medial Femoral Cutaneous Nerve, Suprapatellar branch of the saphenous nerve, 2 branches of the infrapatellar branch of the saphenous nerve) causing Wallerian degeneration
223887046|NCT06340932|DRUG|Celecoxib|200mg BID
223887047|NCT06340932|DRUG|Acetaminophen|1000mg q8h
223887048|NCT06340932|DRUG|Oxycodone|As needed
223887049|NCT06340932|DRUG|Tramadol|As needed
223887050|NCT06340932|DRUG|Bupivacaine Hydrochloride|20mL of 0.25% bupivacaine HCl adductor canal block and 15mL of 0.25% bupivacaine HCl (+/- 5mL of normal saline) iPACK
223887051|NCT06340932|DRUG|Acetaminophen 500Mg Cap|500mg q6h prn
223887052|NCT04975880|DEVICE|SC+ Hemodialysis System|Following the in-clinic training phase and one week transition, the intervention of self or care partner hemodialysis delivered in the home setting will occur for 8 weeks.
223887053|NCT04703322|DRUG|Pexidartinib|400 mg twice daily for a total daily dose of 800 mg (each capsule contains 200 mg of pexidartinib for oral administration)
223887054|NCT04491058|DIAGNOSTIC_TEST|SSCT thickness measurement|Thickness measurement with ultrasound
223887055|NCT06220864|DRUG|SNV1521|SNV1521 is a tablet taken orally. Dose and frequency are dependent upon treatment arm.
223887056|NCT06220864|DRUG|Trastuzumab Deruxtecan|Trastuzumab Deruxtecan is given as an infusion based upon prescribing information.
223887057|NCT04507555|PROCEDURE|Pharmacist-guided pharmacogenetic (PGx) testing for antidepressant selection and dosing|"The study intervention is the service of pharmacist guided pre-emptive PGx testing to support clinical decision making for antidepressant selection and dosing.~This service involves genotyping and thereof evidence-based genotype interpretation commercially offered as Stratipharm® (humatrix AG, Pfungstadt Germany, https://www.stratipharm.de). Furthermore, clinical pharmacists will process and evaluate the results from PGx testing (Stratipharm®) in context of the individual patient medication history as well as current co-medication and forward an individualized recommendation for antidepressant selection and dosing to the treating psychiatrist."
223887058|NCT04507555|PROCEDURE|Standard care antidepressant selection and dosing|Selection and dosing of the new antidepressant pharmacotherapy will be determined by the treating investigator alone, according to current standard of care considering clinical factors only.
223887059|NCT04383314|BEHAVIORAL|10-week exercise program on HA accumulation|A 10-week exercise program with both aerobic and resistance components, based on the American College of Sports Medicine (2010), will be individually prescribed to 25 T2DM patients.Exercise training will be performed on Days 1 and 2 of each week under the supervision of licensed physical therapists. Participants will have the choice of using a treadmill or a recumbent stepper. The physical therapists will monitor blood glucose level, blood pressure, heart rate, and RPE during each exercise session. Participants will be asked to exercise at home on Day 3 of each week, and will not be supervised by the study team.
223887060|NCT03542383|DEVICE|High Definition Transcranial Direct Current Stimulation|Administer 1 ma anodal HD tDCS over the preSMA for 20 minutes a session for 10 sessions over a two week period
223887061|NCT03542383|DEVICE|Sham High Definition Transcranial Direct Current Stimulation|Administer sham HD tDCS over the preSMA for 20 minutes a session for 10 sessions over a two week period
223887062|NCT06275269|PROCEDURE|Ultrasound-Guided|Ultrasound-Guided Triamcinolone Injection
223887063|NCT06275269|PROCEDURE|Translaryngeal Endoscopic Mucosal Injection|Translaryngeal Endoscopic Mucosal Injection of Triamcinolone
223887064|NCT05519228|DEVICE|ToggleLoc 2.9 mm Soft Tissue System|The ToggleLoc 2.9 mm Soft Tissue System consist of non-resorbable device intended to aid in arthroscopic and orthopaedic reconstructive procedures requiring soft tissue to bone fixation
223887065|NCT06241950|GENETIC|delandistrogene moxeparvovec|Single IV infusion of delandistrogene moxeparvovec
223887066|NCT06241950|BIOLOGICAL|imlifidase|IV infusion of Imlifidase
223887067|NCT06786975|DEVICE|Silver Diamine Fluoride|"Tooth will be isolated with cotton rolls, the oral cavity will be dried with small cotton balls and the gingiva around the tooth, and surrounding structures, will be protected with vaseline. Then the silver diamine fluoride solution will be applied to cavitated caries lesions with a micro applicator for one minute approximately. If necessary the solution excess should be removed with a gauze.~Finally the child's teacher will be given the indications for the child to not eat, drink or rinse up to 30 minutes after the treatment, and to evaluate if any sign or symptom related to the tooth appears."
223887068|NCT06786975|PROCEDURE|Atraumatic Restorative Treatment|Participants will be treated with Atraumatic Restorative Treatment (ART) technique. Glass ionomer will be used for cavity filling (Ketac MolarTM, 3M ESPETM) according to manufacter specifications and will be applied with a spatula, followed by finger pressure using vaseline for a few seconds; for occluso-proximal cavities, a matrix band will be used. The restoration will be protected with vaseline and then the occlusion will be checked with articular paper after the initial adjustment (approximately 5 minutes). Finally the child's teacher will be given the indications for the child to not eat, drink or rinse up to 30 minutes after the treatment, and to evaluate if any sign or symptom related to the tooth appears.
223887069|NCT06783725|BEHAVIORAL|Mindfulness-Based Therapy for Insomnia|Mindfulness-based therapy for insomnia (MBTI) is a structured program designed to help individuals with chronic insomnia improve their sleep patterns through mindfulness practices. It combines mindfulness meditation, cognitive behavioral strategies, and sleep education to address the cognitive and physiological factors that disrupt sleep. The therapy emphasizes present-moment awareness, acceptance of sleep difficulties, and the reduction of sleep-related anxiety to promote better sleep quality and overall well-being.
223887070|NCT06783725|BEHAVIORAL|Wait-list control|The wait-list control group consists of participants who do not receive the intervention during the initial study period but are placed on a waitlist to receive it after the trial concludes. This group serves as a comparison to evaluate the effectiveness of the intervention while ensuring participants eventually have access to the treatment. It helps control for natural changes over time and the psychological effects of expecting future treatment.
223887071|NCT06146842|DRUG|Bupivacaine Hydrochloride|Each subject will receive allocated dose of bupivacaine
223887072|NCT03692611|BEHAVIORAL|Skills TO Manage Pain (STOMP)|12 week pain self management (PSM) intervention incorporating social cognitive theory constructs.
223887073|NCT03692611|BEHAVIORAL|Comparison group|Participants in this arm will receive usual care as given by providers but no behavioral PSM intervention.
223887074|NCT06784960|BEHAVIORAL|Messages|We will randomly assign participants in equal numbers to one of five theory-based HPV vaccine message conditions or an attention-matched control arm.
223887075|NCT06787261|OTHER|saliva sample|saliva sample
223887076|NCT06787261|OTHER|carious tissue samples|carious tissue samples
223887077|NCT06786897|OTHER|Questionnaire and Physical Exam|Questionnaires evaluating the expectations of patients in palliative situation, of paramedics and medical staff, concerning blood cell transfusions.
223887078|NCT06786845|OTHER|Treatment lege artis|Adequate treatment of sleep disorders at Sleep clinic
223887079|NCT05373615|DRUG|Cefiderocol|After receipt of Cefiderocol, blood samples will be collected at various time points to determine the pharmacokinetics of Cefiderocol
223887080|NCT05595629|BEHAVIORAL|App-based remote blood pressure monitoring|Fully synched bluetooth-enabled remote blood pressure monitoring using a smartphone application. The digital health company, Twistle, has modified an existing postpartum hypertension pathway in their app according to our hospital's management algorithm.
223887081|NCT05595629|BEHAVIORAL|text-message based remote blood pressure monitoring|Participants will receive automatic blood pressure cuffs and instructions as to how to upload their measurements to the Electronic Medical Record.
223887082|NCT06327295|DRUG|ATB1651-102- Cohort 1|Dosage form- Topical solution; Dosage- 3% formulation The participants will apply the daily dose of 3% ATB1651 once daily to the affected great toenail for 12 weeks with a follow-up for 24 weeks.
223887083|NCT06327295|DRUG|ATB1651-102- Cohort 2|Dosage form- Topical solution; Dosage- 3% formulation The participants will apply the daily dose of 3% ATB1651 once daily to the affected great toenail for 20 weeks with a follow-up for 16 weeks.
223887084|NCT06327295|DRUG|ATB1651-102- Cohort 3|Dosage form- Topical solution; Dosage- 3% formulation The participants will apply the daily dose of 3% ATB1651 twice daily to the affected great toenail for 12 weeks with a follow-up for 24 weeks.
223887085|NCT06327295|DRUG|ATB1651-102- Cohort 4|Dosage form- Topical solution; Dosage- 5% formulation The participants will apply the daily dose of 5% ATB1651 once daily to the affected great toenail for 12 weeks with a follow-up for 24 weeks.
223887086|NCT06327295|DRUG|Placebo|participants will receive matching placebo across cohorts 1-4 of the study.
223887087|NCT03108846|DRUG|Escitalopram|5-15 mg/day (target: 15mg/day if tolerated)
223887088|NCT03108846|DRUG|Placebo|Masked placebo
223887089|NCT04814082|DEVICE|MicroPort Evolution Medial-Pivot Knee System (Cruciate-substituting)|Medial Pivot Knee System
223887090|NCT04814082|DEVICE|Stryker Triathlon Tritanium Knee System (Condylar Stabilizing)|Single Radius Design Total Knee System
223887091|NCT03713086|BIOLOGICAL|Rabipur®|3 doses administered IM at Days 1, 8 and 29 in the deltoid region of the arm
223887092|NCT03713086|BIOLOGICAL|Rabies mRNA vaccine CV7202|CV7202 administered IM at Days 1 and 29 in the deltoid region of the arm
223887093|NCT03713086|BIOLOGICAL|Rabies mRNA vaccine CV7202|CV7202 administered IM at Days 1 and 29 in the deltoid region of the arm
223887094|NCT03713086|BIOLOGICAL|Rabies mRNA vaccine CV7202|CV7202 administered IM at Days 1 and 29 in the deltoid region of the arm
223887095|NCT05078723|DIETARY_SUPPLEMENT|Limonene|The investigators will ask the participants to swish 5 times and swallow 1 oz water mixed with 500mg limonene (Jarrow Formula orange peel extract). The participant will be monitored for a total of 2 hours. Breath samples will be acquired at a total of 11 time points throughout the study. Measurements include 2 baseline measurements followed by the orange peel extract consumption.
223887096|NCT06078384|DRUG|Pembrolizumab 25 mg/ml|"Pembrolizumab drug product is a sterile-filtered liquid and is aseptically filled into single-use vials.~The vials contain 4 mL of sterile solution for IV infusion."
223887097|NCT06078384|DRUG|Paclitaxel injection|Injectable solution for IV administration. Dose of 80 mg/m² weekly.
223887098|NCT04868227|DIETARY_SUPPLEMENT|FULTIUM D3 VITAMIN D3|VITAMIN D3 SUPPLEMENT
223887099|NCT05652777|DEVICE|NeoSpot|Pregnant women will undergo screening of their vital signs using the NeoSpot device.
223887100|NCT02475434|DIETARY_SUPPLEMENT|Cream Supplement group|Infants in the intervention arm will receive the cream supplement in addition to the standard regimen.
223887101|NCT05736068|PROCEDURE|Non-surgical treatment|If allocated to non-surgical group, cast optimization in the outpatient clinic may be necessary if the cast from the emergency room is considered insufficient.
223887102|NCT05736068|PROCEDURE|Surgical treatment|Closed reduction with or without fixation
223887103|NCT06503237|DRUG|Anti-CD19 CART cells will be given IV at split doses.|Split intravenous infusion of Anti-CD19 CART cells of (Dose escalating infusion of 1 - 6 x10\^6 CART cells/kg).
223887104|NCT05649956|DRUG|Letrozole|Letrozole 2.5 mg PO daily
223887105|NCT06327061|BEHAVIORAL|Network overdose prevention|Participants are taught overdose prevention methods with network members.
223887106|NCT06327061|BEHAVIORAL|Standard of care health education|Participants will receive the standard of care for overdose prevention.
223887107|NCT05818033|DEVICE|CARE1.02|Participants in the intervention group will wear CARE1.02 and receive the follow-up checks.
223887108|NCT05818033|DEVICE|Single-vision spectacle lens|Participants in the control group will wear single-vision spectacle lens and receive the follow-up checks.
223887109|NCT03840603|DIAGNOSTIC_TEST|Film Array RP2 Assay guided|Nasopharyngeal swab sample collected from subjects with a suspected LRTI for the Film Array RP2 assay plus a blood sample for the PCT assay.
223887110|NCT03650764|DRUG|Ramucirumab|Ramucirumab is an investigational agent for this trial and will be supplied by Lilly Oncology, free of charge to the patient
223887111|NCT03650764|DRUG|Pembrolizumab|Pembrolizumab is commercially available
223887112|NCT03650764|OTHER|EORTC QLQ-30|-Screening, start of cycle 2, start of cycle 5
223887113|NCT03650764|OTHER|FACT H&N|-Screening, start of cycle 2, start of cycle 5
223887114|NCT03650764|PROCEDURE|Peripheral blood|-Baseline
223887115|NCT04143516|DIAGNOSTIC_TEST|[18-F]- FDG - PET|Patients will undergo a limited non-contrast CT and first injection PET to localize the lesion
223887116|NCT04143516|PROCEDURE|Tumor ablation (TA)|Standard ablation with the intent to create a radius of ablation at least 10 mm larger than the largest lesion diameter in order to achieve a minimum of 5 mm ablation margin around the tumor. Any radiographically-identified and biopsy-confirmed residual tumor will be treated on site with immediate ablation. This repeat ablation is not standard of care but will be performed as described for the initial ablation (in the same procedure session) and follow up will be resumed.
223887117|NCT04143516|DIAGNOSTIC_TEST|PET/CT Scan|Eligible patients will undergo PET/CT -guided tumor ablation as per standard IR guidelines. All patients will undergo PET/CT again, within approximately 6 weeks (+/- 2 weeks) of tumor ablation to evaluate for CN in the target tumor(s) or any sign of residual tissue enhancement, representing viable residual tumor and incomplete treatment.
223887118|NCT04244656|BIOLOGICAL|CTX120|CTX120 B-cell maturation antigen (BCMA)-directed T-cell immunotherapy comprised of allogeneic T cells genetically modified ex vivo using CRISPR-Cas9 gene editing components.
223887119|NCT01447147|DRUG|Placebo|Placebo capsules once daily
223887120|NCT01447147|DRUG|CCX140-B|CCX140-B capsules once daily (Group B)
223887121|NCT01447147|DRUG|CCX140-B|CCX140-B capsules once daily (Group C)
223887122|NCT03946410|DIAGNOSTIC_TEST|Invitation to screening|Invitation to CVD screening with non contrast CT scanning, ABI measurement and blood tests
223887123|NCT05042388|BEHAVIORAL|Mindfulness-Based Relapse Prevention - Rolling Admission (MBRP-RA)|Integrates evidenced-based practices to decrease the probability and severity of relapse for those in addiction recovery. MBRP incorporates components from CBT relapse prevention and includes training in meditation practices as a means to foster increased awareness of emotional and cognitive experiences. MBRP also includes training in brief informal meditations aimed at increasing awareness and adaptive response to drug cues and negative affect.
223887124|NCT05042388|BEHAVIORAL|Treatment-As-Usual|Standard treatment programming procedures for all individuals residing within the residential treatment program. Includes: supportive group therapy; Narcotics Anonymous/12-Step Programming; music, art, and animal therapy; psycho-education on general issues related to mental health and SUDs; and medication counseling.
223887125|NCT05220033|OTHER|Informational intervention|Receive information focusing on coping skills for patients diagnosed with gynecologic cancer
223887126|NCT05220033|OTHER|survey administration|Ancillary studies
223887127|NCT04889911|BEHAVIORAL|Narrative Enhancement and Cognitive Therapy- Young Adult, Combined with Coordinated Specialty Care|NECT is a psychosocial intervention focused on addressing the effects of self-stigma on individuals diagnosed with severe mental illnesses. For the present study, the intervention has been modified to address the needs of youth who have recently experienced a first episode of psychosis.
223887128|NCT04889911|OTHER|Coordinated Specialty Care|Coordinated Specialty Care is an evidence-based, multimodal intervention for persons who have experienced a first episode of psychosis.
223887129|NCT05346627|PROCEDURE|Personalized and mixed training program|Patients perform a personalized and mixed training program (endurance and muscle reinforcement), at home
223887130|NCT01582711|BEHAVIORAL|Self Administered Therapy (SAT)|Self Administered Therapy (SAT)
223887131|NCT01582711|BEHAVIORAL|SMS reminders|Short Message Service (SMS) text reminders
223887132|NCT01582711|DRUG|isoniazid and rifapentine|rifapentine (PRIFTIN, RPT) 900 mg and isoniazid (INH) 900mg, once-weekly, for 12 weeks (12 doses)
223887133|NCT05889052|DRUG|Sulfadoxine pyrimethamine|Sulfadoxine-pyrimethamine paediatric formulation (250mg/12.5mg) dispersable tablets (Macleods Pharmaceuticals Ltd)
223887134|NCT06480968|DRUG|CTH120|"FIH-CTH120-SAD: Each independent cohort of 8 subjects (placebo=2 and CTH120=6 per dose) will receive a single administration of CTH120 or placebo. Four consecutive dose levels (20 mg/day, 40 mg/day, 85 mg/day and 160 mg/day) are planned. If no significant clinical adverse events are observed in the FIH-CTH120-SAD phase, an additional 5th cohort will be recruited to conduct the 5th dose level.~FIH-CTH120-MAD: Each independent cohort of 8 subjects (placebo=2 and CTH120=6 per dose) will receive a daily administration of CTH120 or placebo for 7 days. Three consecutive dose levels are planned. The starting dose will be confirmed following the observed results of FIH-CTH120-SAD.~FIH-CTH120-FI: One dosage of CTH120 will be assessed in 12 healthy male and female subjects in two conditions (Fed and Fasting). Subjects will be randomly assigned to 2 sequences: 6 subjects in a sequence fed then fasting condition, 6 subjects in the reverse sequence (fasting, then fed condition)."
223887135|NCT06480968|OTHER|Placebo|"FIH-CTH120-SAD: Each independent cohort of 8 subjects (placebo=2 and CTH120=6 per dose) will receive a single administration of CTH120 or placebo. Four consecutive dose levels (20 mg/day, 40 mg/day, 85 mg/day and 160 mg/day) are planned. If no significant clinical adverse events are observed in the FIH-CTH120-SAD phase, an additional 5th cohort will be recruited to conduct the 5th dose level.~FIH-CTH120-MAD: Each independent cohort of 8 subjects (placebo=2 and CTH120=6 per dose) will receive a daily administration of CTH120 or placebo for 7 days. Three consecutive dose levels are planned. The starting dose will be confirmed following the observed results of FIH-CTH120-SAD."
223887136|NCT05380856|DEVICE|Turning ON the neuromodulator|IPG on
223887137|NCT05380856|DEVICE|Turning OFF the neuromodulator|IPG OFF
223887138|NCT05722067|OTHER|calcium ionophore|The intervention group will be treated with a ready-to-use ionophore medium (GM508 CultActive, Gynemed) within 15 min after ICSI (or 18 min in IVF) based on the situation of sperm. After 15 min of incubation in GM508 CultActive and a thorough washing process, the oocytes will be cultured in the same protocol as the control group.
223887139|NCT05303714|COMBINATION_PRODUCT|FOLFOX and PIPAC|"A minilaparotomy is performed in the midline. A 5 mm balloon trocar is inserted under finger protection in the right side and the fascia of the minilaparotomy is closed. The abdomen is insufflated with CO2 and a second 10-12mm trocar is introduced under videoscope control in upper left side. Ascites volume is documented and removed sending a sample for cytological examination, an accurate exploratory laparoscopy is performed, possibly placing an additional 5 or 10-12 mmHg trocar, the Peritoneal Cancer Index is calculated. Multiple biopsies are performed in different abdominal quadrants. A nebulizer CAPNOPEN© is inserted into the upper left side trocar and fixed with a 45° angle. The drugs (Cisplatin 10.5 mg/m2 body surface in 150 mL; Doxorubicin 2.1 mg/m2 body surface in 50 mL) are then injected through remote control with a flow rate of 0.7 mL/sec with a pressure of 200 psi. After an aerosol exposure phase of 30min, the aerosol is evacuated via a closed waste system."
223887140|NCT06278597|DIAGNOSTIC_TEST|NACA Estimator|Grading of peripheral anterior chamber width with the Narrow Anterior Chamber Angle (NACA) Estimator
223887141|NCT05374837|BEHAVIORAL|Infant and young child feeding voice messaging intervention|A mobile voice and text messaging intervention aimed at improving IYCF practices will be delivered to mothers and fathers with young children (6-23 months). A total of 16 voice and text message, with the same content, will be sent over a 16-week period (1 voice + 1 text messages (with same content) per week x 16 weeks). Two types of messages will be included: 1) eight scripted and 2) eight unscripted messages from positive deviants. The content of the messages include: breastfeeding until two years of age, consuming a variety of foods within a given meal, the consistency of porridge (thick rather than thin), limiting sweets and fried foods, the importance of animal source foods, consuming vitamin A rich fruits and vegetables, consuming leafy greens, handwashing and feeding infants and young children fruits and vegetables produced by the household.
223887142|NCT04032418|BIOLOGICAL|Pembrolizumab|Given IV
223887143|NCT02302105|RADIATION|IGRT|Image Guided RT to the prostate
223887144|NCT06770790|OTHER|strain echocardiography|HR, MAP, SBP, and DBP will be recorded at baseline and 15 minutes after ESP block. Cardiac output (CO) will be calculated using echocardiographic data on stroke volume (SV) (measured from the LV outflow tract) and multiplied by HR. Two transthoracic 2D echocardiographic examinations will be performed immediately before and 15 minutes after TEA. The examinations include apical four-, two-, and three-chamber projections, mitral and aortic Doppler flow velocities. Standard measurements of left ventricular systolic function include left ventricular volumes (indexed to body surface area, BSA), left ventricular ejection fraction (LVEF) according to the modified Simpson rule, time and velocity integral in the left ventricular outflow tract (TVI-LVOT), and stroke volume (SV) (= π x LVOT radius2 x TVI-LVOT). Stroke volume index (SVI) will be calculated as SV/BSA. Mitral and aortic Doppler flow profiles, left ventricular isovolumetric relaxation time, maximum flow velocity will be recorded for m
223887145|NCT06772857|DRUG|Metformin|Metformin is a drug used to manage blood glucose levels. It improves insulin sensitivity and reduces glucose production in the liver. This regimen will be provided to all study groups (A, B, and C) in combination with the respective interventions described for each group. Participants are instructed not to change their physical activity during the study.
223887146|NCT06397612|OTHER|Low Dose|Patients will be intervened with stimulation continuously, at a frequency of 20 Hertz, a pulse width of 200 µs and for a total of 20 minutes. The intensity will be set at the maximum tolerated by the patient.
223887147|NCT02396459|DRUG|Triac|Triac, individually titrated dose
223887148|NCT06329297|DEVICE|CGM monitor|blood glucose sensor used to monitor interstitial glucose
223887149|NCT04299009|DEVICE|Bright light therapy glasses|Bright light therapy delivered through glasses
223887150|NCT05950243|BEHAVIORAL|Questionnaire|Questionnaire survey for data collection
223887151|NCT03970278|OTHER|No intervention|No intervention
223887152|NCT04723303|DRUG|Umbilical Cord Lining Stem Cells|An IV infusion of ULSCs will be administered.
223887153|NCT05789940|PROCEDURE|hysteroscopy|The procedure is performed by a gynecologic surgeon under general or spinal anesthesia, depending on the standard practice of the center involved, with the patient in the gynecologic position. Antibiotic prophylaxis may be administered according to the standard practice of the center. The equipment available at each center will be used for operative hysteroscopy. The use of energy is usually unnecessary and saline will be preferred. Before the operation, the appearance of the uterine cavity will be described. The selected design product will be resected from top to bottom using the surgical resector, without electrical energy, as this method is known to be the most protective of the endometrium in previous studies. Electric current should be used only as a last resort, in cases where the selected design cannot be removed without it. If there is active bleeding after the procedure, elective coagulation via the hysteroscope may be performed to stop intrauterine bleeding.
223887154|NCT05789940|PROCEDURE|Aspiration|The aspiration will be performed by a gynecological surgeon, according to the center's standard protocol. A flexible or rigid cannula can be used. Antibiotic prophylaxis, the diameter of the cannula used, the cervical preparation required, and the use of intraoperative ultrasound guidance will be left to the discretion of the operator and the standard practice of the center. In most centers, the cervix is dilated with a Hegar dilator of up to 9 mm in size.
223887155|NCT05935462|COMBINATION_PRODUCT|Digital Learning Aids|Recruitment is currently underway for special children undergoing outpatient early intervention. Among the recruited participants, five children between the ages of 6 and 9, who are receiving early intervention, were screened. After obtaining their consent to participate in this study, their basic information was recorded, including gender, age, education, diagnosis, Movement Assessment Battery for Children (MABC-2), Visual-Motor Integration (VMI) test, and Children's ABILHAND questionnaire for manual ability. Once the collection of basic information is completed, a trial of digital aids will be conducted, and a trial feedback questionnaire will be administered. The trial period will consist of a 20-minute session and 2-3 sessions (per week) of home (or therapy room) use.
223887156|NCT00959140|DEVICE|CD3+ T cell depletion|"The peripheral blood stem cell product is engineered to deliver a dose of 15 to 20 x10\^7 CD3+ cells/kg recipient body weight. Other components of the graft will not be manipulated and the recipient will receive the total number of cells collected with the exception of minimal losses that occur during the process of CD3+ T cell isolation. Following collection, CD3+ T cells will be enumerated and a portion of the product containing 15 to 20 x10\^7 CD 3+ cells/kg will be set aside. The remainder of the product will be depleted of CD3+ T cells.~Following CD3+ T cell depletion, the CD3+ T cell depleted product will then be combined with the unmanipulated product to provide the specified levels of CD3+ T cells/kg recipient body-weight. The graft is infused into the patient on the same day as selected and within 24 hours of donor aphaeresis."
223887157|NCT04597411|RADIATION|225^Ac-PSMA-617|administered intravenously under the dose escalation schedule
223887158|NCT04597411|RADIATION|68^Ga-PSMA-11|administered intravenously at a dose of 111 - 185 MBq (3 - 5 mCi)
223887159|NCT05830721|DEVICE|MY01 + Standard of Care|In addition to standard of care, the MY01 device will be inserted by an orthopedic surgeon into the leg on the same side as the ECMO tubing. This will occur within 6 hours of the start of ECMO. Insertion of the device involves a needle, which is removed once the device is inserted. Monitoring of the device will occur as described by the device manufacturer, which includes a mobile application. If at any time the compartment pressures suggest that there may be ACS, an orthopedic surgeon will be called to perform a physical exam. If the physical exam supports the diagnosis of ACS, then an additional pressure measurement with a needle may be also taken to confirm the measurement. If the diagnosis of ACS is made, the decision to proceed with surgery, or fasciotomy, will be a joint decision made by entire team. Monitoring of with the device will be done for 24 hours. The device will be removed after 24 hours or if the diagnosis of ACS is made.
223887160|NCT05830721|DEVICE|14-Gauge Slit Catheter + Standard of Care|For the 14-gauge slit catheter group, the exact same protocol will be followed as the MY01 group. The 14-gauge slit catheter consists of tubing that is 14-gauge in size, which is inserted into the leg with a needle. The needle will be removed once the tubing is inserted. The tubing is then connected to a monitor, which will display the pressure in the leg. Just like the MY01 group, the leg will be numbed and cleaned before the tube is inserted in the leg. Instead of the data being recorded on a mobile device, a nurse or nurse technician will document pressure readings every 4 hours for a total of 24 hours. Once monitoring is finished, the 14-gauge slit catheter will be removed from the leg.
223887161|NCT05830721|OTHER|Standard of Care|If assigned to standard of care, the participant will undergo monitoring within 1 hour of the start of ECMO. For standard of care group, this will involve monitoring the leg with the ECMO tubing with physical exam every 4 hours for the first 24 hours. This will be performed by a trained nurse. If at any time there is suspicion for ACS, the physical exam will be verified by an orthopedic surgeon. The orthopedic surgeon will decide if pressure measurements will be necessary. If so, then a single pressure measurement from each compartment will be taken with a needle device. If the ACS diagnosis is made, any further monitoring of that leg is stopped. The decision to proceed with surgery, or fasciotomy, will be a joint decision made by entire team, which includes surgeons and medical doctors. This is currently the standard of care at the Johns Hopkins Hospital.
223887162|NCT03333200|OTHER|Palliative Care|Collecting information about the natural progression of these diseases
223887163|NCT03333200|BIOLOGICAL|Hematopoetic Stem Cell Transplantation|Following patients who have received HSCT as part of their clinical care.
223887164|NCT02549339|DRUG|LEO 43204 gel|
223887165|NCT02549339|DRUG|Vehicle gel|
223887166|NCT05101928|DRUG|Ozurdex 0.7mg Ophthalmic Implant|A 0.7mg intravitreal dexamethasone implant will be used for the treatment of posterior, intermediate and panuveitis for minimum of 6 months.
223887167|NCT05101928|DRUG|Prednisone|The comparator will be a prednisone taper which is currently the standard care for the uveitis types of focus.
223887168|NCT05106257|BEHAVIORAL|Self-management education (short)|The self-management education condition is based on the Living Well with COPD program. The program consists of a mailed booklet and structured phone counseling delivered by certified COPD educators. Topics include disease information, breathing retraining, action planning, medication use, energy conservation, and following good health habits. The short condition consists of two calls (30-45 minutes each) to introduce patient education topics and refer to the booklet for further information.
223887169|NCT05106257|BEHAVIORAL|Ground-based walking training|Participants randomized to this condition will be mailed a pedometer (3DFitBud Simple Step Counter) and instructed on its use to establish baseline steps/ day for 7 days. They will then receive a booklet with instructions to establish a walking program and three brief (10-15 minute), bi-weekly calls from a trained staff member to review step count values and engage in setting personal activity goals over the course of 6 weeks, following established exercise guidelines for individuals with COPD.
223887170|NCT05106257|BEHAVIORAL|Inhaler training|Participants randomized to this condition will receive two sessions of inhaler technique education using a virtual teach-to-goal (TTG) method in which individuals are observed using their inhaler, provided feedback, and then observed again.
223887171|NCT05106257|BEHAVIORAL|Caregiver support|Participants randomized to this condition will identify an informal caregiver who is involved in their healthcare (i.e., spouse, family member, or friend), who will receive a mailed copy of the Respiratory Health Association's COPD Caregiver's Toolkit, a comprehensive informational resource to support the care of the person living with COPD. Caregivers will receive two brief (10-15 minute) check-in calls from a trained staff member. The structured content of these sessions will include providing an overview of toolkit content, identifying goals for sections(s) to review and incorporate into caregiving activities, and addressing any questions.
223887172|NCT05106257|BEHAVIORAL|Self-management education (long)|The self-management education condition is based on the Living Well with COPD program. The program consists of a mailed booklet and structured phone counseling delivered by certified COPD educators. Topics include disease information, breathing retraining, action planning, medication use, energy conservation, and following good health habits. The long condition consists of five, weekly calls (30-45 minutes each) following a structured curriculum of patient education topics.
223887173|NCT04461821|DIAGNOSTIC_TEST|Real-time SESI-MS breath analysis|Participants will be asked to refrain from eating, drinking, chewing gum use or brushing their teeth at least 1 hour before the measurements will be performed. Room temperature and lighting will be set at the same level for all measurements. Participants will exhale through a disposable mouthpiece into a commercially available SESI source (FIT S.L., Spain). While performing full exhalations, the subjects will keep the pressure through the sampling line at a fixed value monitored by a digital manometer. Breath prints will be collected in real-time recording multiple replicates (typically six in positive and negative ion mode). The whole procedure is absolutely non-invasive and is usually accomplished without any effort in around 15 min per subject.
223887174|NCT04461821|DIAGNOSTIC_TEST|Off-line breath analysis|In young children below the age of 4 not capable of completing the on-line exhalation maneuvers, or in cases when the patient needs cannot approach the mass spectrometer, the sample will be collected off-line. They will be asked to exhale into a bag that will be transported to the lab and deflated into the mass spectrometer for analysis. Exhaled breath of patients under anesthesia will also collected using available ventilation system in the operation theatre.
223887175|NCT04461821|DIAGNOSTIC_TEST|Blood analysis|Blood analysis done in patients who undergo regular blood sampling needed for clinical routine laboratory controls. This includes i) children and adolescents receiving medications which require TDM ii) patients with acute diseases such as TD1 and pneumonia and iii) patients with chronic diseases such as asthma bronchiale. For those patients where a blood sample is drawn during the clinical routine, an additional blood sample consisting of only several blood drops will be collected using the same blood sampling line. No additional venous puncture for research purpose will be done.
223887176|NCT04461821|DIAGNOSTIC_TEST|Saliva analysis|During the diagnostic and therapeutic work-up of T1D patients, saliva samples are collected during the clinical routine. For those patients, additional samples will be obtained by clinically trained investigators.
223887177|NCT04461821|DIAGNOSTIC_TEST|Urine analysis|During the diagnostic and therapeutic work-up of T1D patients, urine samples are collected during the clinical routine. For those patients, additional samples will be obtained by clinically trained investigators.
223887178|NCT06278454|DRUG|NRT6008 Injection + Systematic chemotherapy|"-Systematic chemotherapy The chemotherapy regimen is selected by the investigators at the consideration of participants' conditions, with either GN or (m)FOLFIRINOX.~GN: gemcitabine 1000 mg/m\^2 and nab-paclitaxel 125 mg/m\^2, every 21 days (3 weeks/cycle).~FOLFIRINOX: oxaliplatin 85 mg/m\^2, irinotecan 180 mg/m\^2, leucovorin 400 mg/m\^2 and fluorouracil 400 mg/m\^2 given as a bolus followed by 2400 mg/m\^2 given as a 46-hour continuous infusion, every 2 weeks (4 weeks/cycle).~mFOLFIRINOX: oxaliplatin 85 mg/m\^2, irinotecan 180 mg/m\^2, leucovorin 400 mg/m\^2, and fluorouracil 2400 mg/m\^2 given as a 46-hour continuous infusion, every 2 weeks (4 weeks/cycle).~-NRT6008 injection administration: NRT6008 injection is implanted into pancreatic tumor via endoscopic ultrasound (EUS)-guided fine-needle injection, at the instruction of the investigator. The dose of NRT6008 injection is determined by tumor volume and selected tumor average absorbed dose."
223887179|NCT05274750|BIOLOGICAL|Depemokimab (GSK3511294)|Depemokimab (GSK3511294) will be administered using a pre- filled syringe.
223887180|NCT05274750|DRUG|Placebo|Placebo will be administered as normal saline using a pre-filled syringe.
223887181|NCT05054374|DRUG|Mirdametinib|Dose Level -2INT: 2mg PO BID, 3 weeks on/1 week off Dose Level -2: 2mg PO BID given continuously Dose Level -1INT: 3mg PO BID, 3 weeks on/1 week off Dose Level -1: 3mg PO BID given continuously Dose Level 1: 4mg PO BID given continuously Dose Level 2: 6mg PO BID given continuously Dose Level 3: 8mg PO BID given continuously
223887182|NCT05054374|DRUG|Fulvestrant|"The starting dose of mirdametinib in combination with fulvestrant in each Dose Level will be as follows:~* Dose Level 1: mirdametinib 4 mg BID PO + fulvestrant~* (Only to be triggered pending DLTs on higher Dose Levels as described below)~  * Dose Level -2: mirdametinib 2 mg BID PO continuous + fulvestrant, and Dose Level -2INT: mirdametinib 2 mg BID PO on 3 weeks on, 1 week off + fulvestrant"
223887183|NCT05669989|DRUG|Isatuximab intravenous (IV)|Route of administration: IV infusion; Pharmaceutical form: Vial
223887184|NCT05669989|DRUG|Cemiplimab (SAR439684)|Route of administration: IV infusion; Pharmaceutical form: Vial
223887185|NCT05669989|DRUG|Dexamethasone|Route of administration: Oral or IV infusion; Pharmaceutical form: Tablets/single use vial
223887186|NCT05669989|DRUG|Lenalidomide|Route of administration: Oral; Pharmaceutical form: Capsules
223887187|NCT05669989|DRUG|Pomalidomide|Route of administration: Oral; Pharmaceutical form: Hard capsules
223887188|NCT05669989|DRUG|Isatuximab subcutaneous (SC)|Route of administration: SC injection with the investigational isatuximab injector device; Pharmaceutical form: Vial
223887189|NCT05669989|DRUG|Carfilzomib|Route of administration: IV infusion; Pharmaceutical form: Vial
223887190|NCT05067166|DRUG|Ansuvimab|single infusion 50 mg/kg IV
223887191|NCT06489314|BEHAVIORAL|LEAD (Learn, Engage, Act, Dedicate)|LEAD is a 5-session behavioral activation (BA) intervention delivered by peer-father counselors. LEAD also incorporates motivational interviewing (MI) and masculinity discussion strategies. This is a task-shifted intervention meaning mental health service tasks are delegated to non-specialist providers, in this case peer-fathers, as opposed to a specialized workforce (e.g., psychiatrists, psychologists).
223887192|NCT03636230|DEVICE|Remote Monitoring|Remote Monitoring only + VIRTUES
223887193|NCT03636230|OTHER|Standard of care|In-Clinic visits only
223887194|NCT05978531|DRUG|Monomethyl Fumarate|95 mg oral capsule, 190 mg (2 x 95 mg) twice daily
223887195|NCT04793685|DRUG|Prazosin|Prazosin (16mg/day) versus Placebo comparator, with a 2 week titration period, 9 weeks at full dose and a 5-day taper in week 12.
223887196|NCT04793685|BEHAVIORAL|12-Step Facilitation with Relapse Prevention and Contingency Management|12-Step Facilitation and relapse prevention weekly support and Contingency Management with vouchers for each weekly appointment to support treatment attendance for all subjects.
223887197|NCT06046573|BEHAVIORAL|Support and information|Emotional and technical support. Information about the long-term effects of cancer.
223887198|NCT06046573|BEHAVIORAL|Behavioral activation|Behavioral activation with existential themes and emphasis on values and relationships.
223887199|NCT06046573|BEHAVIORAL|Systematic exposure with mindfulness training|Systematic exposure with mindfulness training with a focus on anxiety about health and/or death, body image, and cancer-related trauma.
223887200|NCT06046573|BEHAVIORAL|Promotion of health behaviors|An overview of self-management techniques in terms of physical exercise, dietary advice, and strategies for improved sleep.
223887201|NCT04301778|DRUG|Durvalumab|"1. Durvalumab - 1500 mg via IV infusion over 60 minutes (-5/+10 min) on day 1 of each 28-day cycle (every 4 weeks).~2. Drug - 1500mg IV"
223887202|NCT04301778|DRUG|SNDX-6352|"1. SNDX-6352 - 3mg/kg via IV infusion over 30 minutes (-5/+10 min) on days 1 and 15 of each 28-day cycle (every 2 weeks), starting with cycle 2 (not given during cycle 1).~2. Drug - 3mg/kg IV"
223887203|NCT05410743|DRUG|177Lu-LNC1010 1|The patients were intravenously injected with single dose 2.22GBq (60 mCi) of 177Lu-LNC1010 and underwent 68Ga-DOTA-TATE PET/CT scans before and after the treatment.
223887204|NCT05410743|DRUG|177Lu-LNC1010 2|The patients were intravenously injected with single dose 3.33GBq （90 mCi) of 177Lu-LNC1010 and underwent 68Ga-DOTA-TATE PET/CT scans before and after the treatment.
223887205|NCT05410743|DRUG|177Lu-LNC1010 3|The patients were intravenously injected with single dose 4.99GBq (135 mCi) of 177Lu-LNC1010 and underwent 68Ga-DOTA-TATE PET/CT scans before and after the treatment.
223887206|NCT05410743|DRUG|177Lu-LNC1010 4|Patients received a single, fixed dose of 177Lu-LNC1010 via intravenous injection, utilizing the well-tolerated and safe dose identified in Phase 1. They also underwent 68Ga-DOTA-TATE PET/CT scans both before and after the treatment to monitor their response.
223887207|NCT05862688|OTHER|antimicrobial therapy|antimicrobial therapy
223887208|NCT00214721|DRUG|Experimental Peritoneal Dialysis Solution|
223887209|NCT04015765|PROCEDURE|Hybrid Argon Plasma Coagulation and EMR procedure|Hybrid Argon Plasma Coagulation (h-APC) combines an ablation technique (APC) with the option for submucosal saline injection using a high-pressure water jet. The technique allows to lift dysplastic epithelium thus creating a safety cushion under the mucosa is lifted with a saline injection and then to ablate larger areas more thoroughly and with a higher energy setting, with a low risk for side effects or complications
223887210|NCT06038630|DRUG|Hyperpolarized Xe129|Hyperpolarized xenon will be administered in multiple doses in volumes up to 25% of subject TLC followed by a breath hold of up to 15 seconds.
223887211|NCT06038630|OTHER|Oxygen Administration|Oxygen administration
223887212|NCT04251806|DIAGNOSTIC_TEST|neonatal polysomnography|This procedure will allow the detection of sleep-disordered breathing in the neonatal period.
223887213|NCT04251806|DIAGNOSTIC_TEST|2-year Bayley Exam|This procedure will evaluate neurodevelopmental outcomes.
223887214|NCT04251806|DIAGNOSTIC_TEST|2-year polysomnography|This procedure will allow the detection of sleep-disordered breathing at 2 years of age.
223887215|NCT04660435|DIAGNOSTIC_TEST|Thymidine kinase activity|DiviTum® assay determines the enzymatic activity of TK in serum samples
223887216|NCT01823562|DRUG|lyophilized black raspberry confection|Given PO
223887217|NCT01823562|OTHER|laboratory biomarker analysis|Correlative studies
223887218|NCT01823562|DIETARY_SUPPLEMENT|dietary intervention|Follow a low polyphenol diet
223887219|NCT01823562|DIETARY_SUPPLEMENT|dietary intervention|Follow a low ellagitannin diet
223887220|NCT01823562|PROCEDURE|quality-of-life assessment|Ancillary studies
223887221|NCT01823562|OTHER|questionnaire administration|Ancillary studies
223887222|NCT03958955|DRUG|Delgocitinib cream|Cream for topical application.
223887223|NCT03958955|DRUG|Delgocitinib cream vehicle|The cream vehicle is similar to the delgocitinib cream except that it does not contain any active ingredient.
223887224|NCT04775602|DRUG|18F-PSMA|18F-PSMA will be injected intravenously at a dosage of 200-250 megabecquerel (MBq) prior to perform Image acquisition (Topogram, CT, PET)
223887225|NCT04838262|OTHER|Acute Stressors|Sympathetic nervous system activity and blood pressure will be measured before, during, and after several acute laboratory-based cognitive (Stroop Color Word Test), emotional (International Affective Picture System), and physiological (Cold Pressor Test) stressors.
223887226|NCT06163482|OTHER|Mixed meal|Each individual will ingest 5 mL/kg of Boost energy drink.
223887227|NCT05879315|OTHER|Fall risk prevention in hospital|All patients (hip and knee) upon admission to the Orthopedic Department of the DRS (Rizzoli Sicily Department), throughin the pre-operative setting will undergo an assessment of mobility level, dynamic stability and co-ordination: Test UP and GO, Il Four Square Step Test, Stabilometric Analysis. After admission to the DRS Rehabilitation Medicine Department, hip and knee will receive an evaluation, which is currently used, consisting of: History of fall risk through multidimensional assessment, Compilation of ICF(International Classification of Functioning, Disability and Health) and Barthel Index. The following ratings will also be added: Compiling the Morse scale, Pharmacological history, CIRS (Cumulative Illness Rating Scale)
223887228|NCT06289049|OTHER|Experimental|"Three primary exercises will be included in the exercise sessions for participants randomized to this group: barbell back squat, bench press, and dead lift~The weight will be progressively increased overtime based on participants' perceived exertion and repetitions in reserve. Number of repetitions performed for each exercise will begin at 10 repetitions in weeks 1-2, with gradual progression to lifting heavier loads of 3-5 sets of 1-5 repetitions between weeks 6-12."
223887229|NCT05617027|OTHER|actual transcranial direct current stimulation (tDCS)|"tDCS is a non-invasive brain stimulation technique that would influence the brain's pain control mechanisms.~The anode is attached to the skull above the M1 opposite the painful side (in case of unilateral pain) or opposite the dominant hand (in case of bilateral pain). The cathode (at the supraorbital level opposite the stimulated M1) will be positioned using the 10-20 EEG system and the tDCS intensity will be 2 mA."
223887230|NCT05617027|OTHER|placebo transcranial direct current stimulation (tDCS)|The anode is attached to the skull above the M1 opposite the painful side (in case of unilateral pain) or opposite the dominant hand (in case of bilateral pain). The cathode (at the supraorbital level opposite the stimulated M1) will be positioned using the 10-20 EEG system and the tDCS intensity will be 2 mA for 30 secondes, and then 0 mA for the rest of the 20-minute session.
223887231|NCT04936191|DEVICE|DynamX Bioadaptor|Patients received percutaneous coronary intervention in a similar way to a traditional DES. Patients first receive radial artery or femoral artery cannulation with anticoagulation during the intervention. All coronary angiograms are carefully measured by at least 2 orthographic views and performed under the same standard conditions. After adequate predilatation of the target lesion, the coronary stenting will be performed. All patients will receive a loading dose of acetylsalicylic acid and a P2Y12 inhibitor pre-procedure followed by dual antiplatelet therapy for at least 6 months.
223887232|NCT05839548|DRUG|Mepivacaine 2% with epinephrine 1:100,000|Local Anesthesia
223887233|NCT05839548|DRUG|Articaine (4%) with epinephrine 1:100,000|Local Anesthesia
223887234|NCT03206710|OTHER|No current intervention|This is a follow-up of two randomized trials. No active intervention is being given in the follow-up
223887235|NCT03437005|DRUG|Desonide 0.05%|Desonide 0.05% ointment topically twice daily for two weeks
223887236|NCT03437005|DRUG|Ketoconazole 2%|Ketoconazole 2% cream topically twice daily for two weeks
223887237|NCT04193787|OTHER|EPIC-P|EPIC-P is a brief, bio-behavioral intervention based on the information-motivation-behavioral skills (IMB) model framework, which integrates i) a biomedical component (i.e., PrEP), ii) behavioral components (i.e., drug- and sex-related primary HIV prevention), and iii) mHealth technology (i.e., text messaging PrEP reminders).
223887238|NCT06202053|PROCEDURE|Type of surgical incision|"The experimental group (patients received periareolar incision):~An arc-shaped incision was made on the lateral side of the patient's affected areola. The subcutaneous tissue was then dissociated between the lateral mammary gland and the skin to the level of the fourth intercostal space in front of the midaxillary line. The fatty tissue behind the breast was separated horizontally to expose the serratus anterior muscle, and an intercostal incision was made. The skin was pulled back throughout the procedure to expose a better surgical field and avoid damage to the mammary gland.~The control group (patients underwent an axillary incision):~For patients in the control group, an incision was made into the fourth intercostal space in the midline of the axilla, where subcutaneous tissue was separated and entered the chest."
223887239|NCT05690633|DEVICE|Pulse oximetry|Noninvasive method of measuring the saturation of oxygen in the blood.
223887240|NCT06513299|DEVICE|low tidal volume|Patients ventilated with assist/control modes of mechanical ventilation with tidal volume between 6.0 ml/kg PBW and 8.0 ml/kg PBW with PPLAT ≤ 30 cmH2O, until weaning criteria are met: P/F ratio \> 250 mmHg; PEEP ≤ 8 cmH2O and lower than the previous day; FiO2 \< 0.5 and lower than the previous day; systolic arterial pressure ≥ 85 mmHg.
223887241|NCT06513299|DEVICE|high tidal volume|Patients ventilated with assist/control modes of mechanical ventilation with tidal volume between 8.0 ml/Kg PBW and 10.0 ml/kg PBW with PPLAT ≤ 30 cmH2O, until weaning criteria are met: P/F ratio \> 250 mmHg; PEEP ≤ 8 cmH2O and lower than the previous day; FiO2 \< 0.5 and lower than the previous day; systolic arterial pressure ≥ 85 mmHg.
223887242|NCT06513299|DEVICE|low driving pressure|Patients ventilated with assist/control modes of mechanical ventilation with driving pressure between 7.0 cmH2O and 12.0 cmH2O with VT ≤ 10 ml/kg PBW, until weaning criteria are met: P/F ratio \> 250 mmHg; PEEP ≤ 8 cmH2O and lower than the previous day; FiO2 \< 0.5 and lower than the previous day; systolic arterial pressure ≥ 85 mmHg.
223887243|NCT06513299|DEVICE|high driving pressure|Patients ventilated with assist/control modes of mechanical ventilation with driving pressure between 12.0 cmH2O and 18.0 cmH2O with VT ≤ 10 ml/kg PBW, until weaning criteria are met: P/F ratio \> 250 mmHg; PEEP ≤ 8 cmH2O and lower than the previous day; FiO2 \< 0.5 and lower than the previous day; systolic arterial pressure ≥ 85 mmHg.
223887244|NCT06237179|BEHAVIORAL|Exercise Training Intervention|5.1. The behavioral ET and HLE interventions will be delivered over 12 weeks. Before starting the study, men will be asked to attend one (1) in-person small group orientation to provide an overview of each intervention arm, familiarize them with web-based and smartphone applications or hard copy manuals for delivery of intervention content, exercise logs, resistance bands, and equipment for strength training.
223887245|NCT06237179|BEHAVIORAL|Healthy Living Education|During the initial 12 weeks of the study, men randomized to the HLE group will receive educational modules delivered remotely (or manual and telephone call) in a group-based setting to approximately match contact frequency and structure with the ET arm.
223887246|NCT02634645|PROCEDURE|Endoscopic eradication therapies (EET)|Endoscopic eradication therapies (EET) includes endoscopic mucosal resection (EMR), which describes the process by which the area most likely to harbor highest grade of dysplasia/neoplasia is removed; radiofrequency ablation (RFA), which describes the process by which Barrett's segments are removed via burning/ablation; and cryotherapy.
223887247|NCT02634645|PROCEDURE|Esophagectomy|The esophagus is surgically removed
223887248|NCT02634645|DRUG|Chemotherapy|Chemical substances are used to treat cancer
223887249|NCT02634645|RADIATION|Radiation|Cancer cells are destroyed by radiation therapy.
223887250|NCT06574191|DRUG|Topical Diclofenac gel 1%|Topical NSAID
223887251|NCT00929084|OTHER|The Survivor Stories Tablet|The Survivor Stories Tablet is a tablet computer where participants can browse an archive of 1-3 minute videotaped survivor stories told by African American Breast Cancer Survivors. Stories contain five main topics: coping, relationships, experiences with the health care system, follow-up care, and quality of life (QOL) living with breast cancer.
223887252|NCT04539574|PROCEDURE|7 Tesla Magnetic Resonance Imaging|Undergo 7T MRI
223887253|NCT04539574|OTHER|Questionnaire Administration|Ancillary studies
223887254|NCT06094504|OTHER|Spectral Lighting|Spectral room lighting containing violet and blue wavelengths of light capable of stimulating non-visual opsins including OPN5 and OPN3.
223887255|NCT04288375|RADIATION|Intensity-modulated radiation therapy (IMRT)|The prescribed dose of radiations for all patients will be 50 Gy in 25 fractions. 6MV energy photons will be used. Multi-beam IMRT plans, utilizing dynamic multileaf collimation, will be created based on the target tissue coverage and normal tissue avoidance.
223887256|NCT06464341|OTHER|Observational study no intervention|Observational study no intervention
223887257|NCT05544084|BEHAVIORAL|Patient Navigator Approach|Patient navigators in collaboration with community health workers will work with women eligible for cervical cancer screening to overcome intrapersonal and community level barriers to screening in order to engage early with the health system for cervical cancer screening and follow-up of positive screens. Their support can help patients get the cancer screenings and follow-up care they need, while addressing prevalent gender inequities and community-level stigma associated with cancer within the Senegal context.
223887258|NCT05695989|DEVICE|Dual Robotic Arm Accessory (DRAA)|Dual Robotic Arm Accessory (DRAA)
223887259|NCT06311656|DRUG|LY4100511 (DC-853)|Administered orally fasted
223887260|NCT06311656|DRUG|LY4100511 (DC-853)|Administered orally fasted.
223887261|NCT06311656|DRUG|LY4100511 (DC-853)|Administered orally fed and fasted.
223887262|NCT06311656|DRUG|LY4100511 (DC-853)|Administered orally fed and fasted.
223887263|NCT06311656|DRUG|Placebo|Administered orally.
223887264|NCT04244240|BEHAVIORAL|BEARNI Tool|"BEARNI is brief screening tool initially validated for Alcohol-related neuropsychological impairments (Ritz et al., 2015). BEARNI tool detect impairment in visuospatial abilities, executive functions, verbal episodic memory, and verbal working memory.~The score of the test could be expressed as a global score, and also as subscores corresponding to each cognitive subtest. Normative data are available."
223887265|NCT02384317|DRUG|CCX168|CCX168 30 mg, twice daily (b.i.d.) orally for 84 days (12 weeks). The CCX168 dose was taken in the morning, optimally within one hour after breakfast, and in the evening, optimally within one hour after dinner.
223887266|NCT04234204|DRUG|Fezolinetant|Oral
223887267|NCT04234204|DRUG|Placebo|Oral
223887268|NCT05463341|BEHAVIORAL|Fentanyl Test Strips|A brief fentanyl test strip (FTS) education intervention will be given to participants at Project DAWN sites in the intervention arm after enrollment and collecting baseline data. It will be offered one-on-one with participants and will include the purpose, benefits, and limitations of FTS testing, and information on how to use FTS, interpret the results, what to do if the FTS is positive, and how to use FTS for different drug delivery methods. Participants will practice and demonstrate use of the FTS, and the short video on how to interpret the FTS will include an on-camera statement on the importance of testing for fentanyl. The video will be accessible to participants after study enrollment. Participants will be advised of the possibility of both false positive/negative results, and that the drugs may be mixed with other substances not detectable with FTS. Participants will be encouraged to practice other harm reduction strategies.
223887269|NCT03667716|DRUG|COM701|COM701 monotherapy.
223887270|NCT03667716|DRUG|COM701 with Opdivo (Nivolumab).|COM701 in combination with Opdivo (Nivolumab).
223887271|NCT04140708|BEHAVIORAL|Exercise--Rock Steady Boxing class|Rock Steady Boxing is a class designed specifically for those with Parkinsonism and movement difficulty using explosive and fine tuned movements as well as cognitive learning skills.
223887275|NCT06394037|PROCEDURE|Active surveillance|Conduct thoracic computed tomography scans every 12 months. If progression occurs, the treamtent approach would involve surgery.
223887276|NCT03088852|DRUG|Magnesium Citrate 100 MG|initial intravenous treatment: Patients with magnesium levels 1-1.5 mg/dL will receive 2-4 grams of magnesium sulfate in the first 24 hours. Patients with magnesium levels 1.6-1.9 mg/dL will receive 1 gram of magnesium sulfate. participants with magnesium level ≥1 mg/dL, will be randomized, and oral magnesium therapy, Magnesium Citrate, ( or no treatment) will be started, and continued for at least three months. The experimental group will receive 400mg magnesium daily in two divided doses.
223887277|NCT06628895|OTHER|EXERCISE TRAINING WITH OR WITHOUT MEDICATION|Exercise training that consists of flexibility, aerobic, balance and strengthening regime. The exercise given three times a week, for 12 weeks.
223887278|NCT05421325|BIOLOGICAL|QBKPN SSI|Site-Specific Immunomodulator
223887279|NCT05421325|OTHER|Normal Saline Placebo|Normal Saline
223887280|NCT06513897|OTHER|Acupressure|Acupressure will be applied to the foreheads of the babies in this group starting two minutes before the heel prick. Acupressure application will be finished when heel prick blood collection is finished.
223887281|NCT06513897|OTHER|Father's Lap|Infants in this group will be placed on the father's lap two minutes before heel prick blood collection. They will remain on the father's lap during the heel prick procedure.
223887282|NCT04178252|OTHER|mask|investigators will add eye mask to standard treatment
223887283|NCT04178252|OTHER|headset|investigators will add headset to standard treatment
223887284|NCT04178252|OTHER|standard drug|investigators will use 10 mg metoclopramide in 150 ml saline given IV over 10 minutes
223887285|NCT06087432|OTHER|Rocabado's 6x6 Exercises|Rocabado's 6x6 program includes 6 basic components: tongue rest position, TMJ rotation control, cervical spine release, shoulder girdle retraction and rhythmic stabilization technique.
223887286|NCT06087432|OTHER|PNF Exercises|Proprioceptive neuromuscular facilitation (PNF) exercises will be applied to the neck and jaw with rhythmic stabilization (RS) and combined isotonic contraction (CIC) techniques. The RS protocol consists of alternating isometric contractions for 10 seconds and does not involve movement. The KIK technique involves combined concentric, isometric and eccentric contraction of the agonist muscle without rest, with each contraction lasting 5 seconds. KIK exercises consist of 5-15 repetitions per set, depending on the individual's tolerance. Between sets, a 30-second rest will be included. First, the RS protocol will be applied and after a 2-minute rest interval, the exercise will continue with the KIK protocol applications. The expected duration of exercise exercises is 30 minutes. Maximum performance will be requested from the individual in all repetitions and the necessary verbal commands will be given for appropriate movement.
223887287|NCT03779867|BEHAVIORAL|Exercise Intervention|Undergo acute exercise
223887288|NCT03779867|OTHER|Resting|Seated resting
223887289|NCT03779867|OTHER|Biomarker Analysis|Correlative studies
223887290|NCT03779867|OTHER|Questionnaire Administration|Ancillary studies
223887291|NCT03070184|OTHER|Exercise capacity VO2 max determination|Each participant's maximal oxygen capacity will be determined using a modified Bruce treadmill protocol.
223887292|NCT03070184|DIETARY_SUPPLEMENT|Standardized meals|Participants will consume the standardized study diet for 3 days provided by the clinical research unit's metabolic kitchen (at UAB).
223887293|NCT03070184|OTHER|Exercise challenge|Each participant will walk at 70 % of his/her VO2max for 20 minutes on treadmill.
223887294|NCT03070184|DRUG|Metoprolol Succinate ER|Each participant will receive metoprolol succinate starting at 50mg/day, titrated bi-weekly up to 200 mg/day for total duration of 6 weeks.
223887295|NCT05641610|GENETIC|ZS801|A novel, bioengineered adeno-associated viral (AAV) vector carrying human factor IX variant. The dose levels are as follows: 2.0×10\^12vg/kg, 5.0×10\^12vg/kg, 1.0×10\^13vg/kg.
223887296|NCT05826587|BEHAVIORAL|Home-based, m-Health Delivered Physical Function Training|An individualized home exercise physical function training will be prescribed. This would include 5 balance training exercises and 1-2 upper and lower-body muscular conditioning exercises (i.e., wall push-up and chair stand) prescribed 3 days/week over the course of a 6-week period. Subjects will be assigned exercises from 1 of 3 different levels of exercise progression based on performance during the baseline muscular fitness assessment (functional chair stand and static chest throw).
223887297|NCT05826587|BEHAVIORAL|Cardiac Rehabilitation & Exercise Prescription|Standard, clinically indicated cardiac rehabilitation and exercise program. Approximately 30 to 40 minutes of aerobic exercise within a prescribed rating of perceived exertion (RPE 11-14) and/or target heart rate and approximately 15 to 20 minutes of both upper and lower body resistance exercise up to three times per week for up to at least 12 weeks. In addition, subjects are provided with home exercise instructions, and will be expected to exercise for 30 to 60 minutes at home.
223887298|NCT05826587|OTHER|Connected mHealth mobile application|Mobile application that allows subjects to track their independent home exercise with the option of heart rate monitoring by connecting to an external heart rate monitoring device.
223887299|NCT03568487|OTHER|Intensive scapula-focused approach|scapula-focused approach with exercises, 3 x 20 min training per week for 4 weeks
223887300|NCT03568487|OTHER|Control Therapy|not have any physical training but is encouraged to stay active as usual.
223887301|NCT03465579|DIAGNOSTIC_TEST|pelvic MRI|multi-parametric pelvic MRI
223887302|NCT03465579|DIAGNOSTIC_TEST|68Ga-PSMA PET/CT|68Ga-PSMA PET/CT
223887303|NCT03610490|BIOLOGICAL|Autologous Tumor Infiltrating Lymphocytes MDA-TIL|Given IV
223887304|NCT03610490|DRUG|Cyclophosphamide|Given IV
223887305|NCT03610490|DRUG|Fludarabine|Given IV
223887306|NCT03610490|BIOLOGICAL|Interleukin-2|Given IV
223887307|NCT03610490|OTHER|Quality-of-Life Assessment|Ancillary studies
223887308|NCT06310590|DRUG|NRT6003 Injection|Selective internal radiation therapy (SIRT) with TareSphere
223887309|NCT06280976|DRUG|Statin|high intensity statin (eg atorvastatin 80 mg daily)
223887310|NCT06280976|DRUG|Aspirin tablet|aspirin 81 mg po qd
223887311|NCT06280976|DRUG|Nexlizet|bempedoic acid-ezetimibe 180-10 mg po qd
223887312|NCT06280976|DRUG|LEQVIO|inclisiran SQ as per product insert
223887313|NCT06280976|DRUG|Vascepa|icosapent ethyl 2g PO BID
223887314|NCT06280976|DRUG|Jardiance|empagliflozin 10 mg PO QD
223887315|NCT06280976|DRUG|Colchicine|Colchicine 0.5 MG po qd
223887316|NCT04185337|PROCEDURE|Fine-Needle Aspiration|Undergo ultrasound-guided FNA
223887317|NCT04185337|PROCEDURE|Lymph Node Biopsy|Undergo ultrasound-guided lymph node biopsy
223887318|NCT04185337|PROCEDURE|Photoacoustic Imaging|Undergo ultrasound-guided PAI
223887319|NCT04185337|PROCEDURE|Ultrasound|Undergo ultrasound
223887320|NCT04185337|DEVICE|Multispectral optoacoustic tomography (MSOT) acuity instrument|Use multispectral optoacoustic tomography (MSOT) acuity instrument
223887321|NCT04382898|BIOLOGICAL|BNT112|Intravenous bolus injection
223887322|NCT04382898|DRUG|Cemiplimab|Intravenous infusion
223887323|NCT05676944|DEVICE|Labyrinth Devices MVI™ Multichannel Vestibular Implant System|Unilateral implantation of a Labyrinth Devices MVI™ Multichannel Vestibular Implant System receiver/stimulator including insertion of electrode arrays in the semicircular canal ampullae of the inner ear, followed by motion-modulated prosthetic electrical stimulation.
223887324|NCT04848337|DRUG|Pembrolizumab|Pembrolizumab 200 mg will be administered as a 30 minute IV infusion every 3 weeks.
223887325|NCT04848337|DRUG|Lenvatinib|Lenvatinib 20 mg orally daily.
223887326|NCT03932682|BIOLOGICAL|QIVc|QIVc is a quadrivalent vaccine and contains 2 influenza type A strains and 2 influenza type B lineages recommended by World Health Organization (WHO) for inclusion in the quadrivalent vaccine formulation for the influenza season corresponding to the season of conduct of study.
223887327|NCT03932682|BIOLOGICAL|Comparator|Meningococcal Group C Polysaccharide Conjugate Vaccine (NeisVac-C)
223887328|NCT04884412|PROCEDURE|Surgery under general anesthesia with experimental targeting|Surgery will be performed under general anesthesia. The electrodes will be inserted directly on the targets without MER, with PARKEO\_2 targets provided by the Bordeaux University Hospital, based on the machine-learning model developed in Bordeaux.
223887329|NCT04884412|PROCEDURE|Usual Surgery|In the control group, surgery will be performed as usual in each centre under local or general anaesthesia. This group represents the current state of the art of deep brain stimulation in these centres.
223887330|NCT04652830|BEHAVIORAL|Naprapathy training|Active training aimed at strengthening the abdominal muscles
223887331|NCT04652830|OTHER|Control group|No change of daily routines in regard to training
223887332|NCT03775187|BIOLOGICAL|Burosumab|
223887333|NCT05358262|DEVICE|Airvo|Fisher \& Paykel's AIRVO 2 is a humidifier with integrated flow generator that delivers high flow warmed and humidified respiratory gases to spontaneously breathing patients through a variety of interfaces including nasal cannula. Flow can be delivered from 2 to 60 LPM
223887334|NCT05358262|OTHER|Standard of Care|The standard of care for mucositis at the Cross Cancer institute involves supportive therapies including oral hydration (water or wet sponges) or medicated mouthwashes.
223887335|NCT05312515|OTHER|Warm Application to Feet|Warm Application to Feet after Cesarean Section
223887336|NCT02945774|RADIATION|(18F)-FEPPA|PET ligand that binds to activated microglia, a marker of neuroinflammation
223887337|NCT06619015|DRUG|Pramlintide Acetate 1 MG/ML|Symlin (R) (Pramlintide acetate) 1000mcg/ml, will be administered as a continuous infusion at a rate of 15mcg/hour, equivalent to the daily recommended maximum dosage of 360mcg/day.
223887338|NCT06619015|DRUG|Semaglutide Pen Injector|Semaglutide from 0,25mg/week to 2,4mg/week
223887339|NCT06619015|DRUG|Sodium Chloride 0.9% Inj|Placebo
223887340|NCT05192174|BIOLOGICAL|NIB101|NIB101
223887341|NCT02983760|DEVICE|Planar V/Q-based strategy|Strategy based on planar pulmonary scintigraphy
223887342|NCT02983760|DEVICE|CTPA-based strategy|Strategy based on pulmonary angiography
223887343|NCT02983760|DEVICE|V/Q SPECT-based strategy|Strategy based on pulmonary tomoscintigraphy
223887344|NCT04565041|BEHAVIORAL|Social Support|Presence of an image of a social support figure (provided by participant) during a fear extinction procedure
223887345|NCT05974046|DRUG|[14C]IDV184001AN|\[14C\]-IDV184001AN 200 mg/\~100 µCi/ 15 g oral suspension
223887346|NCT02561923|DRUG|Rivaroxaban|A single dose of 20 milligram (mg) of rivaroxaban orally will be administered to participants on Day 1 in part 1 and through day 1 and 3 with a final 20 mg dose administered on the morning of Day 4 in part 2.
223887347|NCT02561923|DRUG|Tranexamic acid|1.0 g single dose of tranexamic acid (TXA), intravenously administered (over 10 mins) on Day 4.
223887348|NCT02561923|DRUG|Kcentra, a 4-factor PCC|Kcentra, a 4-factor PCC, 50 IU/kg, single dose, intravenously administered (maximum rate of 210 \[international units\] IU/min) on Day 4.
223887349|NCT02561923|DRUG|Saline|Saline \[Kcentra saline control or TXA saline control\] on Day 4.
223887350|NCT06024239|DRUG|ABBV-932|Capsule; oral
223887351|NCT06024239|DRUG|Placebo for ABBV-932|Capsule; oral
223887352|NCT06756425|BEHAVIORAL|aerobic exercise program|aerobic exercise program for 3 months with nutritional health awearness sessions
223887353|NCT06756425|BEHAVIORAL|nutritional health awareness sessions|lifestyle changes and nutritional awareness sessions for 3 months twice a week for participants and their parents
223887354|NCT06153563|OTHER|Data collection on patient history and intraoperative results.|Data collection on patient history and intraoperative results.
223887355|NCT04921059|DIAGNOSTIC_TEST|Active Stand|The participant is asked to lie down for 10 mins without moving or speaking. A heart rate monitor is attached while the participant is lying down. They are then asked to stand up as quickly as possible and to remain standing unassisted for 3 minutes. The participant will be asked to describe any symptoms at 1 and 3 minutes after standing. Blood pressure and heart rate will be monitored constantly throughout the test.
223887356|NCT06436703|BIOLOGICAL|Influenza ModRNA Vaccine|Intramuscular injection
223887357|NCT06436703|BIOLOGICAL|Quadrivalent Influenza Vaccine (QIV)|Intramuscular injection
223887358|NCT01220583|DRUG|cisplatin|Given IV
223887359|NCT01220583|RADIATION|3-dimensional conformal radiation therapy|Undergo radiotherapy
223887360|NCT01220583|RADIATION|intensity-modulated radiation therapy|Undergo radiotherapy
223887361|NCT05085496|BIOLOGICAL|Atezolizumab|Given IV
223887362|NCT05085496|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
223887363|NCT04369976|DEVICE|ARTIFICIAL GRAVITY COMBINED WITH EXERCISE|The passive control group will abstain from any exercise. Recordings of the participant's will include cardiovascular functioning cardiac output (CO), stroke volume (SV) mean arterial pressure (MAP) diastolic blood pressure (DBP), systolic blood pressure (SBP), and heart rate (HR), Electroencephalography ( EEG) as well as dynamic force and stance and muscle oxygenation. More specifically, after 6 training sessions (2 weeks), the centrifugation load will be increased and will be combined with either aerobic exercise (through an ergometer) or resistance training through elastic training bands. Functional connectivity and cortical-network features will be used by deep learning algorithms in order to define the optimal centrifuge training .
223887364|NCT04740671|DRUG|HLX04-O|Biologic recombinant anti-VEGF humanized monoclonal antibody, developed by Shanghai Henlius Biotech, Inc.
223887365|NCT04740671|DRUG|ranibizumab|Biologic anti-VEGF recombinant humanized monoclonal antibody fragment
223887366|NCT04808843|DRUG|Dienogest (BAY86-5258, Visanne)|Following the physicians' decision.
223887370|NCT05222945|OTHER|Biopsies and bloood samplings|blood samples, rectal biopsies, nodes biopsies, cutaneous fat tissues biopsies, semen sample
223887371|NCT04647422|BEHAVIORAL|Analysis of executive functioning and of social cognition processes|"Investigation of executive and social cognition processes using a comprehensive, neuropsychological assessment, An Eye tracking investigation and Task-based MRI exams.~* Evaluation of addictive, psychiatric and neurological comorbidities.~* Neuropsychological assessment establishing the participants' cognitive profiles of executive functions and of social cognition~* An Eye tracking investigation aiming at a better understanding of participants' emotional processing~* Task-based MRI exams identifying participants' neuroanatomical and neurofunctional correlates of executive functions and of social cognition processes"
223887372|NCT01767311|DRUG|Lecanemab 2.5 mg/kg|2.5 mg/kg biweekly (once every 2 weeks) administered as i.v. infusion
223887373|NCT01767311|DRUG|Lecanemab 5.0 mg/kg|5.0 mg/kg biweekly (once every 2 weeks) administered as i.v. infusion
223887374|NCT01767311|DRUG|Lecanemab 10 mg/kg|10 mg/kg biweekly (once every 2 weeks) administered as i.v. infusion.
223887375|NCT01767311|DRUG|Lecanemab 5.0 mg/kg|5.0 mg/kg monthly (once every 4 weeks) administered as i.v. infusion. All participants will receive biweekly infusions, participants will have placebo infusion alternating with BAN2401
223887376|NCT01767311|DRUG|Lecanemab 10 mg/kg|10 mg/kg monthly (once every 4 weeks) administered as i.v. infusion. All participants will receive biweekly infusions, participants will have placebo infusion alternating with BAN2401
223887377|NCT01767311|DRUG|Placebo|biweekly (once every 2 weeks) administered as i.v. infusion
223887378|NCT01767311|DRUG|Lecanemab 10 mg/kg|10 mg/kg biweekly (once every 2 weeks), once every 4 weeks (Q4W) or once every 3 months (Q3M) i.v. infusion.
223887379|NCT02307565|DRUG|Midodrine|Each arm (2) will last 30 days with a 14 day washout in between each arm. Subjects nor the investigators will know which drug (midodrine or placebo) is administered to the subject for the first arm (30 days) and the second arm (30 days). The subjects will take a pill three times a day. Each subject will return home with a blood pressure monitor and will be asked to report his/her blood pressure at least 3 times a day and complete questionnaires based on how he/she is feeling.
223887380|NCT02307565|DRUG|Placebo|Each arm (2) will last 30 days with a 14 day washout in between each arm. Subjects nor the investigators will know which drug (midodrine or placebo) is administered to the subject for the first arm (30 days) and the second arm (30 days). The subjects will take a pill three times a day. Each subject will return home with a blood pressure monitor and will be asked to report his/her blood pressure at least 3 times a day and complete questionnaires based on how he/she is feeling.
223887381|NCT04516278|BIOLOGICAL|bevacizumab|1.25 mg, intravitreal injection
223887382|NCT05688293|PROCEDURE|Connective tissue graft|non-surgical periodontal treatment and connective tissue graft
223887383|NCT05688293|PROCEDURE|Free gingival graft|will receive non-surgical periodontal treatment and partially de-epithelized free gingival graft
223887384|NCT05688293|PROCEDURE|Non surgical|non-surgical periodontal treatment only
223887385|NCT05350475|RADIATION|Proton therapy|Patients in the experimental arm will receive proton therapy within the same dose and fraction schedule as patients receiving photon therapy, which is standard treatment.
223887386|NCT05350475|RADIATION|Photon therapy|Patients in the photon arm will receive standard treatment with photon therapy.
223887387|NCT05677880|OTHER|Study Procedures|"Participants will experience~* Neurocognitive Tests and Self-Report Measures~* Clinical Interviews~* Neurological Exam~* MRI screening at baseline, 18 months, 36 months~* Fasted Blood draw"
223887388|NCT01198366|BIOLOGICAL|AERAS-402 1.5 x 10^10 vp|
223887389|NCT01198366|BIOLOGICAL|AERAS-402 3.0 x 10^10 vp|
223887390|NCT01198366|BIOLOGICAL|AERAS-402 1.0 x 10^11 vp|
223887391|NCT01198366|BIOLOGICAL|Placebo|
223887392|NCT05205928|DRUG|Outpatient therapy: 11 weeks of drug therapy with usual treatment + 4 weeks of closed-loop therapy|The blinded drug will be used with participant's routine therapy (+ continuous glucose monitoring if not already in use) for 11 weeks with follow-up from qualified research personnel concerning pump settings, side effects, and incremental dose increase. While continuing to use the medication, there are 4 weeks of closed-loop pump therapy and drug use; glycemic outcomes will be taken from the last 4 weeks. This will be followed by laboratory and anthropometric testing, followed by 2 weeks of wash-out.
223887393|NCT05574309|DEVICE|Dissociation measure of pelvic and scapular girdles by inertial sensors of accelerometer|Dissociation measure of pelvic and scapular girdles by 2 inertial sensors of accelerometer type (IMU BNO055) during a 10 m walking test
223887394|NCT05574309|DEVICE|GAITRite Device|Walking parameter measured during a 10 m walking test with GaitRite device
223887395|NCT05281406|DRUG|Osimertinib|80 mg daily or reduced dose 40 mg daily
223887396|NCT05281406|DRUG|Pemetrexed|500 mg/m² i.v. d1 of every 21-day cycle for a maximum of 4 cycles
223887397|NCT05281406|DRUG|Cisplatin|75mg/m² i.v. d1 of every 21-day cycle for a maximum of 4 cycles
223887398|NCT05281406|DRUG|Carboplatin|AUC 5 mg/mL/min i.v. d1 of every 21-day cycle for a maximum of 4 cycles
223887399|NCT05767281|BEHAVIORAL|prevention program|introduction of the developed comprehensive prevention program among the child population with the participation of primary health care personnel, which will improve not only the dental health of children, their quality of life, but will also help reduce foci of chronic oral sepsis.
223887400|NCT05633472|OTHER|Vitamin D|Vitamin D (2000IU/day) for 6 months
223887401|NCT05633472|OTHER|Placebo|Placebo
223887402|NCT06407050|BEHAVIORAL|4 hours of physical inactivity|A pedometer will be worn by participants during the whole trial. Steps will be monitored. Participants will be required to reach 8,500 steps per day for the first 2 days. On the third day participants need to take 600 steps hourly for 8 hours from 7 am to 3 pm and another 2,000 steps between 3:40 pm to 4 pm. Participant will then stay inactive from 4 pm to 8 pm and do a cycling for one hour in the lab. During the inactivity period, participants will remain seated and steps are only allowed for food, water, and bathroom use. A 3 day food log will be given to participants to log in their diet. Participant will be asks to mimic the diet between trials. A Fitbit will be worn by participants to record the sleep hours during the trial.
223887403|NCT06407050|BEHAVIORAL|8 hours of physical inactivity|A pedometer will be worn by participants during the whole trial. Steps will be monitored. Participants will be required to reach 8,500 steps per day for the first 2 days. On the third day participants need to take 600 steps hourly for 4 hours from 7 am to 11 am and then 2,000 steps between 11:40 am to 12 pm. During the inactivity period, participants will remain seated and steps are only allowed for food, water, and bathroom use. Participant will then stay inactive from 12 pm to 8 pm and do a cycling for one hour in the lab. A 3 day food log will be given to participants to log in their diet. Participant will be asks to mimic the diet between trials. A Fitbit will be worn by participants to record the sleep hours during the trial.
223887404|NCT06407050|BEHAVIORAL|12 hours of physical inactivity|A pedometer will be worn by participants during the whole trial. Steps will be monitored. Participants will be required to reach 8,500 steps per day for the first 2 days. On the third day, participant will take 2,000 steps between 7:40 am to 8 am and then stay inactive from 8 am to 8 pm. During the inactivity period, participants will remain seated and steps are only allowed for food, water, and bathroom use. Right after the inactivity intervention, participant will do a 1-hr cycling in lab. A 3 day food log will be given to participants to log in their diet. Participant will be asks to mimic the diet between trials. A Fitbit will be worn by participants to record the sleep hours during the trial.
223887405|NCT02663219|BEHAVIORAL|Intervention|The intervention arm will provide a Case Manager (CM) intervention package designed to enhance linkage to care, antiretroviral treatment (ART) initiation, treatment adherence and retention in care.
223887406|NCT06028672|DRUG|Toripalimab|200mg q2w intravenous
223887407|NCT06028672|DRUG|Actinomycin-D|1.25mg/m2，2mg max dose, q2w, intravenous
223887408|NCT04936035|DRUG|Placebo|Placebo administered by SC injection
223887409|NCT04936035|DRUG|ALN-AGT01|ALN-AGT01 administered by SC injection
223887410|NCT03241082|DEVICE|ultrasound|validation of portable ultrasound to measure body composition
223887411|NCT02808676|DIETARY_SUPPLEMENT|Vitamin D3|Dose: 10000 IU, three times per week, orally.
223887412|NCT02808676|OTHER|Exercises (E)|All participants will complete three (3) group training sessions per week (total 20 weeks), under the supervision of trainers. Each exercise session will last approximately 60 minutes and will happen after the cognitive training/control (CT cCT) session. The exercise session will be a combined aerobic and progressive strengthening exercise. Within each small group of four to eight individuals, participants follow the program tailored to their individual functioning level, with constant monitoring by the trainers. Participants are expected to attend all training sessions and research staff will strongly encourage them to do so.
223887413|NCT02808676|OTHER|Cognitive Training (CT)|CT intervention will involve computer-based multimodal and multi-domain dual-task training with memory load. A custom-written program, developed for neuro-rehabilitation and used in previous research trials for cognitive and mobility outcomes will be used. Training sessions will take place in groups of four to eight participants before each of the fitness-training session for duration of 30 min max. Participants will perform a concurrent visuo-motor task (dual-task combination) composed of different sets of visual stimuli that have to be identified by tapping designated figures on an digital tablet (IOS or Android system). Participants will perform discrimination tasks involving sets of items (e.g. letters, numbers, animals, vehicles, fruits, celestial bodies).
223887414|NCT02808676|OTHER|placebo D3|matching placebo for Vitamin D3
223887415|NCT02808676|OTHER|control cognitive training|As a control activity to ensure the same time exposure as in the interventions arms, participant in the control arm will receive a 30 min computer skills training.
223887416|NCT02808676|OTHER|Placebo exercise|As a control activity to ensure the same time exposure as in the interventions arms, participant in the control arm will receive a 60 min of a tone exercise regimen
223887417|NCT05896943|DRUG|Ustekinumab|Patients with ulcerative colitis treated with ustekinumab
223887418|NCT06177873|OTHER|foot bath|On the morning of surgery, the purpose of the study will be explained to the patients and their written consent will be obtained. Then, Introductory Information Form, STAI and VASS were applied. The pain level of the patients will be evaluated with VAS-Pain 4 hours after the surgery. SAI and VAS-Comfort will be applied to patients with pain level 4 and above. Then, patients in the experimental group will receive a hot water foot bath for 20 minutes. Before the hot water foot bath, patients will be lifted from their beds and placed on the chair in the room. Hot water will be poured into the foot bath tub and the patient will be asked to put his feet in the water. The water level will be adjusted to include the patients ankles. The temperature of the water will be constantly checked with a water thermometer and kept at 41-42 °C. A hot water foot bath will be applied for 20 minutes and then the patients feet will be dried with a towel.
223887419|NCT05778266|DIETARY_SUPPLEMENT|L-citrulline|oral supplementation of pure L-citrulline (6 g) for twelve weeks
223887420|NCT05778266|DIETARY_SUPPLEMENT|Carboxymethyl cellulose|oral supplementation of Carboxymethyl cellulose (6 g) as a placebo, for twelve weeks
223887421|NCT05778266|OTHER|High Intensity Intervals Training|participants will have sessions 3 days a week for twelve weeks
223887422|NCT06118749|DIAGNOSTIC_TEST|Antigen detection Rapid Diagnostic Test prototype|The study will focus on the usability and diagnostic performance of the RDT in blood and/or urine from patients with visceral leishmaniasis.
223887423|NCT01297764|DRUG|Vorinostat, Lenalidomide, Carfilzomib, Dexamethasone|"Dose Escalation Schema Cohort Carfilzomib (mg/m2) Lenalidomide (mg) Vorinostat (mg) Dexamethasone (mg)~1. 15 15 300 40~2. 20 15 300 40~3. 20 25 300 40~4. 20/27\* 25 300 40~5. 20/27\* 25 400 40"
223887424|NCT04115371|BEHAVIORAL|Intervention|Geriatric assessment and care coordination provided by a multidisciplinary team in the emergency department including transitional care nurses, social workers, pharmacists, occupational therapists, and physical therapists.
223887425|NCT04521699|DEVICE|CalmioGO Stress management device|CalmiGo device is a device of similar size to an inhaler that uses guided breathing, and grounding techniques to regulate breathing to bring users a sense of calm and relaxation.
223887426|NCT06527833|PROCEDURE|Non Packing of perianal abscess cavity after drainage|"* All patients will undergo incision and drainage under general anaesthesia.~* In Group (A \[Non-Packing group\]), The surgery will be performed by making a cruciate incision over the abscess and incision widened using forceps to allow complete drainage of the cavity containing, without any catheter drainage and packing avoided. The lesion will be left open to heal by secondary intention. The patient was advised to have a sitz bath and apply a dressing over the cavity."
223887427|NCT06527833|PROCEDURE|Packing of perianal abscess cavity after drainage|an elliptical incision will be made, and the abscess will be fully drained then packing the cavity will be done with sterile gauze with a change of dressing every 24 hours until it is completely healed.
223887428|NCT05868772|DEVICE|Active Sentry Handpiece|With low IOP settings
223887429|NCT05868772|DEVICE|Ozil Handpiece|With high IOP settings.
223887430|NCT03574103|BEHAVIORAL|Caloric restriction only|Participants in this group will receive a eating plan with caloric restriction (513 to 770 kcal from estimated energy requirements), without restriction in time for feeding, for 8 weeks.
223887431|NCT03574103|BEHAVIORAL|Caloric restriction plus TRF morning|Participants in this group will receive a eating plan with caloric restriction (513 to 770 kcal from estimated energy requirements) and 8 hours for eating (from 12 p.m. to 8 p.m.) and 16 hours of fasting, for 8 weeks.
223887432|NCT03574103|BEHAVIORAL|Caloric restriction plus TRF night|Participants in this group will receive a eating plan with caloric restriction (513 to 770 kcal from estimated energy requirements) and 8 hours for eating (from 8 a.m. to 4 p.m.) and 16 hours of fasting, for 8 weeks.
223887433|NCT04392401|BIOLOGICAL|Collection of blood samples in order to create a biocollection|Blood samples will be collected at admission in intensive care, at Day 3, Day 7, Day 12 and Day 20 during their hospitalization. Clinical data from routine care will be collected. Vital status will be assessed at Day 28 and Day 90.
223887434|NCT05102591|DRUG|Ketorolac|Intervention in syringe for target dose of 0.5 mg/kg, maximum 30 mg of ketorolac (1 mL), and administer as a direct IV push over 1-5 minutes
223887435|NCT05102591|DRUG|Metoclopramide|Intervention in 50 mL mini bag of normal saline (0.9% NaCl) for target dose of 0.15 mg/kg, maximum 10 mg of metoclopramide (2 mL), and administer as infusion over 15-30 minutes
223887436|NCT05102591|DEVICE|Active Remote Electrical Neuromodulation Device|The REN device is a battery-powered, wirelessly controlled neuromodulation device that attaches via armband to the upper arm. The REN device is controlled by a smartphone application and administers electrical stimulation to the local C and Aδ nociceptive sensory nerves of the upper arm. This stimulation is achieved using a symmetrical, biphasic, square pulse, modulated at a frequency between 100-120 Hz. Each pulse has a width of 400 µs and the user, via the smartphone application, can adjust the output current to apply a maximum of 40 mA. Each stimulation session occurs over 45 minutes and each device can administer up to 12 stimulation sessions.
223887437|NCT05102591|DRUG|Placebo|0.9% NaCl will be administered to participants through IV in identical dosages, methods, and duration as the ketorolac and metoclopramide interventions described above.
223887438|NCT05102591|DEVICE|Sham Remote Electrical Neuromodulation Device|The sham REN device is identical to the active REN device but the stimulation parameters are different, administering a modulated symmetrical biphasic square electrical pulse, modulated frequency of \~0.083 Hz and a modulated pulse width of 40-550 µ. These sham parameters are designed to induce a sensation that will be perceptible to participants, similar to stimulation from the active REN device, but at a frequency that is low enough so as to not modulate the nociceptive sensory nerves.
223887439|NCT04170725|OTHER|Patient and Healthy Volunteers training protocol|Patients and Healthy Volunteers will undergo a 14-day endurance training protocol. No study drugs will be administered. Patients and Healthy Volunteers will be instructed regarding their training protocol. Training sessions will be undertaken on days 1, 3, 5, 7, 9 and 11 after the first examination day. Patients and Healthy Volunteers will be asked to contract their TA muscle repeatedly by pulling the right foot towards the head in a standing position while the heel remains on the ground (at 5 second intervals). In order to carry out the training they will also receive a video demonstrating the exercise. On days 1 and 3 they will do the exercise for 5 minutes, on days 5 and 7 for 10 minutes and on days 9 and 11 for 15 minutes.
223887440|NCT06399757|DRUG|APL-5125|APL-5125 is an oral drug (capsule) taken daily in 28-day cycles
223887441|NCT06365632|DRUG|Antispike gel, 100 g in a flask, produced by UNITEHPROM BSU, Republic of Belarus|An antegrade appendectomy is performed, after which 50 to 100 ml of Antispike is applied in a thin layer to the surface of the cecum, the surface of adjacent organs and the parietal peritoneum of the right iliac region. The wound is sutured tightly.
223887442|NCT06365632|PROCEDURE|antegrade appendectomy|An antegrade appendectomy is performed without using Antispike.
223887443|NCT02966548|DRUG|Relatlimab|Specified dose on specified days
223887444|NCT02966548|DRUG|Nivolumab|Specified dose on specified days
223887445|NCT06836648|COMBINATION_PRODUCT|X-PACT|X-PACT is comprised of a phosphor device, the drug methoxsalen sterile solution and X-ray energy. The dose of methoxsalen sterile solution per injection will vary per patient and will remained fixed across injections within each patient as it is based on the applicable tumor volume at baseline. Immediately after each injection of the combination product, patients will be exposed to an X-ray beam delivered via a LINAC (and thus targeted at the tumor) at a fixed dose to activate the combination product.
223887446|NCT06355583|DRUG|EBX-102|EBX-102 is a white size 0 gastro-resistant hydroxypropyl methylcellulose (HPMC) capsule containing communities of dried, intestinal microorganisms extracted from rigorously screened pooled human stool samples obtained from volunteer accredited donors.
223887447|NCT06355583|DRUG|Placebo|The capsules contain inactive ingredients microcrystalline cellulose and magnesium stearate.
223887448|NCT05974462|DRUG|Methylprednisolone 125 MG|125 mg daily for 3 days diluted in saline solution 250 mL
223887449|NCT05974462|OTHER|IV saline solution 0.9%|Saline solution 0.9% 250 mL
223887450|NCT05536128|DRUG|Olaparib|Olaparib tablet 300 mg taken orally twice daily Olaparib 500 mg on Days 1, 15, 29, and every 4 weeks thereafter The treatment will continue till disease progression or unacceptable toxicity or withdrawal of consent or another discontinuation criterion is met.
223887451|NCT05536128|DRUG|Fulvestrant|Fulvestrant 500 mg on Days 1, 15, 29, and every 4 weeks thereafter
223887452|NCT05141604|OTHER|Field expansion view|Overlaid small window on HMD to show the part of the scene in the blind field into portions of the participants' remaining, seeing, field of vision
223887453|NCT03480061|DRUG|Dexmedetomidine Hydrochloride Group|Dexmedetomidine will be initiated prior to transfer to the CVICU with loading dose of 1 ug kg-1 over approximately 20 minutes. This will be followed by an infusion at 0.1-1.0 ug kg-1h-1 in CVICU for up to 24 hours from the time DEX infusion started or until the patient is ready for discharge from the CVICU (whichever is earlier).
223887454|NCT05530057|DRUG|Eribulin Mesylate + Samfenet (Trastruzumab-biosimilar)|"* Patients will receive eribulin mesylate 1.4 mg/m2 administered I.V. with infusion over 2 to 5 minutes on days 1 and 8 of each 21-day cycle and SB3 8 mg/kg I.V. over 90 minutes on day 1 of cycle 1 . Thereafter, SB3 6 mg/kg will be infused over 30 minutes on day 1 of each subsequent 21-day cycle until progression or unacceptable toxicity.~* Dose reductions for eribulin, but not for SB3, is permitted.~* Two dose reductions (1.1, 0.7 mg/m2) are allowed for eribulin before consideration of study treatment discontinuation. Eribulin could be continued as monotherapy if trastuzumab-similar was discontinued, and vice-versa."
223887455|NCT05530057|DRUG|Eribulin Mesylate|"* Patients will receive eribulin mesylate 1.4 mg/m2 administered I.V. with infusion over 2 to 5 minutes on days 1 and 8 of each 21-day cycle until progression or unacceptable toxicity.~* Two dose reductions (1.1, 0.7 mg/m2) are allowed before consideration of study treatment discontinuation."
223887456|NCT05655403|BEHAVIORAL|Step training program|The program will consist of 3 phases: (1) getting familiar, (2) increasing complexity, and (3) consolidating skills. In Phase 1, the participants will be asked to use one foot to step on single-colored stepping panels located in a specific region of the plastic mat (e.g., upper quadrant). In Phase 2, the exercise will progress by introducing the following 4 cognitively challenging stepping tasks. After finishing the 4 stepping tasks in Phase 2, the exercises will progress to Phase 3, which will consolidate the participants' stepping and cognitive skills. The following 4 additional stepping tasks will be introduced. The instructor will tailor the exercises for each participant, based on their training performance.
223887457|NCT03877796|DEVICE|Drug Response Predictor® (DRP)|A DRP is an assay that based on samples from a tumor can predict whether the tumor will respond to a specific drug or not.
223887458|NCT06261216|OTHER|Interview|"* International Physical Activity Questionnaire (IPAQ-SF)~* interviewer-administered modified Lifetime Total Physical Activity Questionnaire (LTPAQ) form"
223887459|NCT05241418|DIAGNOSTIC_TEST|Atrial 3D late gadolinium enhancement|We will use cardiac MRI to take a picture of the atria. This picture will be used to identify scar tissue within the atria.
223887460|NCT05462925|DEVICE|Functional electrical stimulation therapy.|Functional electrical stimulation therapy will be delivered using the MyndMove system (MyndTec, Inc., Mississauga, Canada).
223887461|NCT06113939|DEVICE|airway clearance|mechanical suctioning of airway secretions
223887462|NCT04831684|DRUG|Placebo|Participants will be getting placebo for 8 days of dosing.
223887463|NCT04831684|DRUG|GET73|Participants will be getting GET73 for 8 days of dosing.
223887464|NCT03042156|RADIATION|Palliative Radiation Therapy|
223887465|NCT05014204|DEVICE|The Endogenex Device|The Endogenex device is designed to induce duodenal mucosal regeneration using pulsed electric field. The Endogenex procedure is a non-surgical, endoscopic procedure.
223887466|NCT02181257|COMBINATION_PRODUCT|Extracorporeal Photopheresis (ECP)|"Procedure:~ECP treatments will be performed using one of two Therakos systems. Both systems use the drug Methoxsalen"
223887467|NCT02181257|OTHER|No intervention in the SOC / Retrospective Chart review.|SOC Retrospective chart review similar to a control group
223887468|NCT04761458|DIAGNOSTIC_TEST|Olfactory function testing|Olfactory function will be evaluated through the Burghart Sniffin' Sticks test which is a validated psychophysical testing method. Sniffin' Sticks test is based on pen-like odor dispensing devices that will be presented to the patients. The extended version of this test will be used and consist of three tests of olfactory function, namely tests for odor threshold, odor discrimination and odor identification.
223887469|NCT04761458|DIAGNOSTIC_TEST|Edmonton Frail Scale|The Edmonton Frail Scale (EFS) involves nine domains of frailty : functional performance, cognitive function, general health, functional independence, social support, used medications, nutrition, mood and continence. It has been validated with respect to comprehensive geriatric assessment and to other screening tools related to frail state. EFS test is considered most appropriate for use in routine preoperative screening and only requires 5 minutes.
223887470|NCT04761458|DIAGNOSTIC_TEST|Clinical Frailty Scale|The Clinical Frailty Scale (CFS) uses clinicians' judgement to evaluate frailty. It comprises assessment of specific domains including comorbidity, function, and cognition. Score ranges from 1 (very fit) to 9 (terminally ill).
223887471|NCT04761458|DIAGNOSTIC_TEST|Neuropsychological test battery|Patients will undergo a neuropsychological test battery preoperatively and postoperatively. This test consists of a battery of psychometric assessments with the ability to objectively assess specific cognitive domains such as attention, executive function, learning and memory, language, perceptual-motor, or social cognition.
223887472|NCT03978871|BEHAVIORAL|Growth Mindset|Growth emotion mindset induction
223887473|NCT03978871|BEHAVIORAL|Brain Education|Brain education
223887474|NCT04072822|DRUG|Anakinra and Zinc|Anakinra is indicated for reduction in signs and symptoms and slowing the progression of structural damage in moderately to severely active rheumatoid arthritis. It has been previously studied in AH. Zinc is a nutritional supplement. Zinc supplementation reverses the clinical signs of zinc deficiency in participants with alcoholic liver disease.
223887475|NCT04072822|DRUG|Prednisone|Prednisone is indicated for numerous conditions including inflammatory disease. Corticosteroids, such as prednisolone, are considered standard of care in alcoholic liver disease.
223887476|NCT04072822|DRUG|Placebos|Matching placebo
223887477|NCT03483246|DRUG|Fecal Microbiota Transplantation (FMT)|"The colonoscopy for FMT will be planned as soon as possible and never more than 5 weeks after inclusion visit.~After colon cleansing using Polyethylen glycol, the patient will have a colonoscopy under general anesthesia.~The patient will then receive either FMT (frozen preparation of 50g of stools in 300ml of physio, see donor section for details) or sham transplantation (FMT vehicle) in the cecum."
223887478|NCT03483246|DRUG|Sham-transplantation Placebo|"The sham-transplantation will be planned as soon as possible and never more than 5 weeks after inclusion visit.~After colon cleansing using Polyethylen glycol, the patient will have a colonoscopy under general anesthesia.~The patient will then sham transplantation (FMT vehicle) in the cecum."
223887479|NCT03095274|DRUG|Durvalumab|Durvalumab, 1500 mg Q4W for 12 months.
223887480|NCT03095274|DRUG|Tremelimumab|Tremelimumab 75 mg Q4W for up to 4 doses/cycles.
223887481|NCT05908175|OTHER|FES-assisted gait training|The participants will walk with functional electrical stimulation (and possible body weight support) on a treadmill for 10 weeks, twice a week for 30 minutes.
223887482|NCT04513132|DEVICE|active-dTMS|The dTMS using H-coil with 5Hz stimulate ACC. The sessions of dTMS will be conducted twice daily for 5 consecutive days, and twice sessions of a day will be separated by 3 hours at least.
223887483|NCT04513132|DEVICE|sham-dTMS|The sham-dTMS has the same appearance with the real stimulation coil, which can not generate magnetic field. A sound generator is built in the coil beat to simulate the sound of the real stimulation.
223887484|NCT04391894|DRUG|ECF843|Topical ocular eye drop
223887485|NCT04391894|OTHER|ECF843 vehicle|Topical ocular eye drop
223887486|NCT06163586|OTHER|Neonatal Touch and Massage Therapy|Structured touch and massage therapy performed by certified providers.
223887487|NCT01889199|DRUG|Flutamide|Flutamide 125 mg orally each 28 day cycle for 6 cycles
223887488|NCT01889199|OTHER|Placebo|Placebo orally each 28 day cycle for 6 cycles
223887489|NCT04591106|DIAGNOSTIC_TEST|Magnetic resonance imaging (MRI)|Magnetic resonance imaging (MRI) is a non-invasive imaging technique that uses a magnetic field and radio waves to create detailed images of the organs and tissues within the body.
223887490|NCT04591106|DIAGNOSTIC_TEST|Magnetic resonance elastography (MRE)|Magnetic resonance elastography (MRE) is a non-invasive imaging technique that uses a gently vibrating transducer in combination with MRI to create detailed images and maps of the mechanical properties, such as stiffness, of tissues within the body.
223887491|NCT04591106|DEVICE|Prototype MRE soft flexible passive transducer paddle|The prototype device is provided to the investigators by Mayo Clinic under a Materials Transfer Agreement (MTA). The device is being used to promote comfort in the pediatric population; no formal data collection for regulatory submission is planned. The prototype device is smaller, softer, and more flexible than the commercial device and will be used where indicated by the subjects' size.
223887492|NCT05689021|DRUG|Abiraterone Acetate/Niraparib|Given PO
223887493|NCT05689021|PROCEDURE|Biospecimen Collection|Undergo blood specimen collection
223887494|NCT05689021|PROCEDURE|Bone Scan|Undergo technetium-99m bone scan
223887495|NCT05689021|PROCEDURE|Computed Tomography|Undergo CT scan
223887496|NCT05689021|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223887497|NCT05689021|DRUG|Prednisone|Given PO
223887498|NCT06581588|DEVICE|THRIVE|Device: Optiflow and THRIVE technique Nasal high flow humidified oxygen
223887499|NCT06581588|DEVICE|THRIVE combine nasopharyngeal airway|Device: Optiflow and THRIVE technique Nasal high flow humidified oxygen and nasopharyngeal airway
223887500|NCT06527313|BEHAVIORAL|Movement Mobilization Concept, Exercise and Tape|Mulligan Concept MWM Mulligan Taping Mulligan Self Home Workout
223887501|NCT06527313|BEHAVIORAL|Sham Movement Mobilization Concept, Exercise and Tape|The technique will be applied to cases in the sham group with only hand contact, without any slippage or rotation in any direction. Then, rigid taping will be applied without any tension or direction, and home exercises will be given.
223887502|NCT06527313|BEHAVIORAL|Special Exercises|"Subjects in the control group will be shown home exercises customized for knee osteoarthritis and asked to continue them.~Specialized Home Exercises for the Knee Joint~1. Lumbar extensor stretching, Hamstring stretching, hip flexors stretching, TFL stretching,~2. Straight leg raise (lying on back and side)~3. Bridge exercise~4. Drawing circles while lying on your back and side~5. Knee flexion-extension~6. Weight bearing exercises~7. Tiptoe exercise~8. Step climbing and descending exercise~9. Terminal knee extension~10. Strengthening the muscles around the hips"
223887503|NCT04987814|OTHER|HD-sEMG|high definition surface electromyography, allowing the recording of muscle activation signals sensitive to the intensity of the contraction and indirectly to the muscle strength as well as to the muscular fatigability, but also capable of measuring the modifications of the recruitment modalities of the motor units. This recording will be made on the rectus femoris during knee extension, either in the lying position or during chair lifts, depending on the patient's functional state.
223887504|NCT04987814|OTHER|- Quadriceps muscle ultrasound|Muscle Ultrasound with Philips Lumify Wireless Handheld Ultrasound for Android - Model - L12-4 linear probe, allowing performance at the patient's bed.
223887505|NCT04987814|OTHER|IPAQ Physical Activity Questionnaire.|physical activity assessment questionnaire/adapted version for seniors
223887506|NCT06507436|DRUG|Herombopag tablets|Herombopag tablets; dose 1 or dose 2, for 5 days
223887507|NCT06507436|DRUG|Herombopag placebo tablets|Herombopag placebo tablets; dose 1 or dose 2, for 5 days
223887508|NCT05741489|DEVICE|Continuous glucose monitoring (CGM)|The Dexcom G6 CGM system is a compact, light-weight glucose testing device that measures glucose every 5 minutes. Participants will wear the CGM with the display off for 10 days while continuing their routine dialysis sessions.
223887509|NCT02670109|DRUG|Carmustine|300mg/m2, IV, in 3 hours, during day -4
223887510|NCT02670109|DRUG|Cyclophosphamide|80mg/kg, IV, in 2 hours, during two days -2, -3
223887511|NCT02670109|DRUG|Carboplatin|1400/m2, IV, in 1 hour, during day -3
223887512|NCT02670109|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Transfusion, in 3 hours, during day 0
223887513|NCT02670109|DRUG|Busulfan|16mg/kg, Oral, during day -4
223887514|NCT00220740|DRUG|Immune Globulin IV (Human), 10% Caprylate/Chromatography Purified|2 g/kg body weight ideally over 2-4 days . Thereafter, study drug infusion (IGIV-C) will be administered every 3 weeks at a dose of 1 g/kg bw, given over 1-2 days for a total of 7 additional infusions
223887515|NCT00220740|DRUG|Albumin (Human) 25%, United States Pharmacopeia (USP)|Albumin 25%, USP diluted with dextrose 5% to a final concentration of 0.1% as an intravenous infusion. Alternatively, it may be a bottled placebo of 0.1% Albumin (Human) in 0.2 M Glycine, 1.1 mm sodium caprylate, 0.25% sodium chloride. 2 g/kg body weight ideally over 2-4 days . Thereafter, infusion (placebo) will be administered every 3 weeks at a dose of 1 g/kg bw, given over 1-2 days for a total of 7 additional infusions
223887516|NCT01057433|DRUG|Pitavastatin (NK-104)|pitavastatin (NK-104) 4 mg once daily (QD)
223887517|NCT01057433|DRUG|Lopinavir/ritonavir|lopinavir/ritonavir 800 mg/200 mg
223887518|NCT01433315|BEHAVIORAL|sleep restriction|restricted sleep
223887519|NCT03314324|DRUG|ODM-201|ODM-201: 600 mg (2 x 300 mg tablets) twice daily with food equivalent to a total daily dose of 1200 mg. ODM-201 should be taken at similar times day, approximately 12 hours between doses.
223887520|NCT03314324|DRUG|Enzalutamide|Enzalutamide: 160 mg/day (4 x 40 mg tablets) taken once a day preferably with food, preferably in the evening (Enzalutamide can generally be given with or without food, but in the present trial, it is preferable that it is given with food, to be consistent with ODM-201 intake).
223887521|NCT05268302|BIOLOGICAL|Dengue 4 Live Virus Human Challenge (DENV-4-LVHC) - Low Dose|Low dose 0.5 mL of the challenge strain is administered subcutaneously in the triceps region of the arm on Study Day 0.
223887522|NCT05268302|BIOLOGICAL|Dengue 4 Live Virus Human Challenge (DENV-4-LVHC) - Low Dose - Homologous Rechallenge|Low dose 0.5 mL of the challenge strain is administered subcutaneously in the triceps region of the arm on Study Day 366 in previously dosed participants.
223887523|NCT06630845|DRUG|Fluorodeoxyglucose F18|Given IV as part of routine imaging
223887524|NCT06630845|PROCEDURE|Positron Emission Tomography combined with Magnetic resonance imaging (PET/MRI)|Imaging procedure
223887525|NCT06630845|PROCEDURE|Whole Body Magnetic Resonance Imaging with Diffusion-Weighted Imaging (WB-MRI-DWI)|Imaging procedure done concurrently with PET/MRI
223887526|NCT06630845|DEVICE|General Electric (GE) SIGNA PET/MR|Imaging device
223887527|NCT05670106|DRUG|[177Lu]Lu-PSMA-617|Administered intravenously once every 6 weeks (1 cycle) for a maximum of 6 cycles.
223887528|NCT05670106|OTHER|Best supportive/best standard of care (BS/BSOC)|Best supportive/best standard of care as defined by the local investigator
223887529|NCT05670106|DRUG|68Ga-PSMA-11|Administered single intravenous dose of approximately 150 MBq. Administered dose could not be lower than 111 MBq or higher than 259 MBq (3 - 7 mCi).
223887530|NCT04904094|OTHER|Casting of the lower limb and homebased stretching exercise program.|Lower leg casting in combination with removable upper leg casts for approximately 2 weeks and stretching exercises during casting and 4 weeks after casting.
223887531|NCT05397561|OTHER|Turkish Translation of Physical Activity Barriers and Facilitators Scale|Participants to be included in the study will be listed under a special code (traffic code of their city of birth, date of birth and order of participation). The socio-demographic characteristics, age, gender, body weight, height and Body Mass Index (BMI) of the participants will be evaluated and recorded with a specially prepared evaluation form. All participants in the study will complete the Turkish version of the PABFS, the Physical Activity Disability Scale (PADS), the Motivation for Participation in Physical Activity Scale (MPPAS), and the International Physical Activity Questionnaire (IPAQ) at their first visit. Participants will complete the BFYPA again after 7 days.
223887532|NCT06198972|OTHER|Pelvic Pnf exercises|"Exercise Frequency 3 days/week Exercise Intensity 60% of 1 maximum repetition Exercise Duration: 5-minute warm-up 20 minutes (2 sets of 15 repetitions) exercise training 5 min cool down Exercise Type Pelvic patterns~* Anterior elevation-Posterior depression~* Anterior depression-Posterior elevation PNF techniques~* Repetitive stretching~* Rhythmic stabilization"
223887533|NCT06198972|OTHER|Strength exercises|"3 days/week 60% of 1 repetition maximum 5 minute warm up 20 min exercise training 5 min cool down Lower extremity movements~* Hip flexion~* Hip extension~* Hip abduction~* Hip adduction~* Knee flexion~* Knee extension Resistance exercise training"
223887534|NCT05440786|DRUG|Abemaciclib|Orally
223887535|NCT05440786|DRUG|Irinotecan|IV
223887536|NCT05440786|DRUG|Temozolomide|Orally
223887537|NCT05088746|PROCEDURE|Non-surgical periodontal therapy|NSPT will be performed following the principles of minimally invasive non-surgical therapy (MINST) described by Nibali et al. (Nibali et al., 2015, Nibali et al., 2019)
223887538|NCT02811679|DRUG|Blinatumomab|Blinatumomab is a bispecific t cell engaging antibody targeting CD19 and CD3 approved for B cell acute lymphoblastic leukemia
223887539|NCT06488144|BEHAVIORAL|Health coach|Health Coaching
223887540|NCT06488144|BEHAVIORAL|Remote Incentive Program|Behavioral incentive program including gamification, social incentivization, and monitoring.
223887541|NCT05472792|RADIATION|Accelerated Partial Breast Irradiation (APBI)|Radiation treatment delivered to the lumpectomy cavity.
223887542|NCT05472792|DRUG|tamoxifen, anastrozole, exemestane, letrozole, fulvestrant, toremifene|Adjuvant endocrine therapy (tamoxifen, anastrozole, exemestane, letrozole, fulvestrant, toremifene) for duration of 5 years, as tolerated by the patient.
223887543|NCT05404750|BEHAVIORAL|Harm Reduction|Harm reduction aims to reduce negative effects of risky health behaviors without necessarily terminating the behaviors completely.Though often thought of as structural approaches (e.g., policy or syringe services), Harm reduction is also a relational approach to care focusing on non-punitive patient-provider interactions to promote autonomy. The degree to which harm reduction care is offered in study settings and is associated with clinical outcomes is the focus of this study.
223887544|NCT06365086|DEVICE|Personalized brain state-dependent single-pulse TMS|Single-pulse TMS will be applied to the right hemisphere during brain activity patterns associated with strong and weak corticospinal tract activation. Single-pulse TMS will also be applied to the right hemisphere during random brain activity patterns.
223887545|NCT03423303|DIAGNOSTIC_TEST|Prostate cancer screening|Depending on each diagnostic test result the participants in the screening arm will undergo PSA-testing, 4Kscore determination, MRI, and MRI/US fusion biopsy only.
223887546|NCT05442671|BEHAVIORAL|Exercise intervention|16-week home exercise intervention, enriched by mobile health technology
223887547|NCT05319860|DRUG|Standard of Care Treatment for Chemotherapy Induced Nausea and Vomiting (CINV)|Standard of care for CINV includes anti-nausea medication as needed after chemotherapy regimen given for up to 12 weeks.
223887548|NCT05319860|DRUG|Aromatherapy Care|An aromatherapy inhaler provided for use as needed after chemotherapy regimen given for up to 12 weeks. One normal inhale is equal to one dose of aromatherapy. Participants can use the aromatherapy as often as needed.
223887549|NCT05050929|RADIATION|Targeting All Brain Metastases|Volumetric Modulated Arc Therapy
223887550|NCT03423758|OTHER|Blood sample|Blood sample
223887551|NCT04314895|DRUG|NanoPac (sterile nanoparticulate paclitaxel) Powder for Suspension|NanoPac is manufactured using a Precipitation with Compressed Antisolvent (PCA) technique that employs supercritical carbon dioxide and acetone to generate paclitaxel nanoparticles within a well-characterized particle-size distribution. Following PCA, NanoPac is filled into a clear 60mL Type 1, USP, clear-glass vial (306 mg/vial) as a powder fill of nanoparticulate paclitaxel, closed with a bromobutyl rubber stopper and aluminum crimp seal, and sterilized by gamma irradiation. Prior to administration at the hospital/clinic, NanoPac will be reconstituted with 1% Polysorbate 80, NF in 0.9% Sodium Chloride for Injection, USP, to form a suspension. The suspension will be further diluted with 0.9% Sodium Chloride for Injection, USP to achieve the final clinical formulation.
223887552|NCT03941860|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
223887553|NCT03941860|PROCEDURE|Bone Marrow Aspirate|Undergo bone marrow aspirate
223887554|NCT03941860|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
223887555|NCT03941860|PROCEDURE|Computed Tomography|Undergo CT scan
223887556|NCT03941860|DRUG|Ixazomib Citrate|Given PO
223887557|NCT03941860|DRUG|Lenalidomide|Given PO
223887558|NCT03941860|OTHER|Placebo Administration|Given PO
223887559|NCT03941860|PROCEDURE|Positron Emission Tomography|Undergo PET scan
223887560|NCT03941860|OTHER|Quality-of-Life Assessment|Ancillary studies
223887561|NCT03941860|OTHER|Questionnaire Administration|Ancillary studies
223887562|NCT05876546|DEVICE|Liquid bandage|The liquid bandage will be applied through a patch test to the participants' backs for 3 consecutive weeks, with 3 weekly applications. Afterwards, there will be a rest period of between 10 and 15 days. The liquid bandage will be applied again to the participants' back, in a naive area and removed after 48 hours.
223887563|NCT05876546|DEVICE|Saline Solution|The saline solution will be applied via patch test to the participants' backs for 3 consecutive weeks, with 3 weekly applications. Afterwards, there will be a rest period of between 10 and 15 days. The saline solution will be applied again to the participants' back, in a naive area and removed after 48 hours.
223887564|NCT05242432|BIOLOGICAL|Ad26/protein preF RSV Vaccine|Ad26/protein preF RSV vaccine will be administered as an IM injection.
223887565|NCT05242432|OTHER|Placebo|Matching Placebo will be administered as an IM injection
223887566|NCT06623110|BIOLOGICAL|RP2 Injection|Genetically modified live HSV-1 virus, 3.0 mL single-use glass vials, via intralesional (into a lesion) injection per protocol.
223887567|NCT04192981|DRUG|GDC-0084|GDC-0084 in 3 + 3 dose-escalation in 3 cohorts: 45, 60, 75 mg daily
223887568|NCT04192981|RADIATION|whole brain radiation therapy radiation|30Gy in 10 fractions
223887569|NCT01247207|DRUG|Ataluren|Ataluren will be administered as per the dose and schedule specified in the arm.
223887570|NCT04180059|COMBINATION_PRODUCT|CTL 19|Patients candidate for allogeneic transplantation who are both HLA-DPB1\*04:01 and with a HLA-DPB1\*04:01-expressing hematological malignancy (almost 100% of cases) with a donor HLA-DPB1\*04:01 negative, will be proposed to receive one single infusion of the T cell clone at 4-5 months post-transplantation, once the immunosuppression by cyclosporine and/or mycophenolate mofetil has been discontinued.
223887571|NCT06645925|PROCEDURE|One Step Protocol|FGG will be done simultaneous with implant placement
223887572|NCT06645925|PROCEDURE|Two Steps Protocol|Conventional FGG protocol, prior to implant placement
223887573|NCT05841979|BEHAVIORAL|Moodlifters|Mood Lifters, a novel mental wellness program, was developed as a more accessible means to provide psychotherapy (Votta \& Deldin, 2022). Meetings covered biopsychosocial areas and skills that were drawn from multiple therapeutic interventions consistent with a biopsychosocial framework. Areas included physical health, negative thoughts, problem-solving, emotional awareness and regulation, building relationships, behavioral activation, and using a strengths-based approach. ML is delivered by peer leaders who are individuals that have completed the program as well as a training program.
223887574|NCT05841979|BEHAVIORAL|Physical Activity|Participants randomized to the exercise arm received 14 weeks of a structured weekly strength and conditioning training program to enhance muscle mass, strength, cardiorespiratory fitness, and overall well-being. The program is based on previous research showing that cardiorespiratory fitness and muscle strength/size can both contribute to decreased mortality/increased longevity and enhanced mental health (Burke et al., 2017; McLeod et al., 2016; Srikanthan \& Karlamangla, 2014; Strasser \& Burtscher, 2018). The training program consists of three training sessions per week, with one being an in-person group session guided by a certified strength and conditioning specialist. The other two training sessions are self-guided via the mobile app Trainheroic. This weekly training schedule aligns with previous research showing benefits to structuring an exercise program using a variety of social contexts (group setting, own, etc.; Burke et al., 2017).
223887575|NCT05841979|BEHAVIORAL|Nature Experiences|Participants randomized to the Nature Experiences participated in 14 weeks of group and self-directed activities to connect with the natural environment. Weekly group activities will be led by Nature Guides, who are undergraduate and graduate students with extensive outdoor education training. Group activities will last one hour a week and include hiking in forests, walking in parks, bird-watching, mindfulness exercises, and snow activities. Participants will be given a list of self-directed activity suggestions each week. The goal of self-directed activities is to spend an additional two hours in a natural environment each week.
223887576|NCT06986889|PROCEDURE|Conventional radial artery access|Half of the patients enrolled in the study undergoing coronary diagnosis and intervention will be randomized conventional radial access for cardiac catheterization.
223887577|NCT06986889|PROCEDURE|Distal radial artery access|Half of the patients enrolled in the study undergoing coronary diagnosis and intervention will be randomized distal radial access for cardiac catheterization.
223887578|NCT06988046|DEVICE|Cover spine orthosis (CSO)|The participants included in the study were asked to use the orthoses given as a result of randomization for four weeks, excluding the time they were asleep (average 12 h per day).
223887579|NCT06988046|DEVICE|Semi-rigid thoracolumbar orthosis|The participants included in the study were asked to use the orthoses given as a result of randomization for four weeks, excluding the time they were asleep (average 12 h per day).
223887580|NCT06987799|BEHAVIORAL|Mindfulness-Based Stress Reduction (MBSR; CALM-Chicago Study)|This clinical trial will evaluate the effectiveness of the culturally adapted intervention, CALM-Chicago, in a community setting. CALM-Chicago has been previously used in a clinical setting.
223887581|NCT06987266|OTHER|no intervention|no ntervention
223887582|NCT06986408|DEVICE|Earplugs and Eye Masks|"The patients in the experimental group will be given the Informed Consent Form before surgery and the Patient Introduction Form will be applied after permission is obtained. Patients will be given eye masks and earplugs on the nights following surgery and they will be ensured to use them correctly. The General Comfort Scale and the Quality of Recovery Questionnaire (Qor-40) will be applied 24 and 48 hours after surgery."
223887583|NCT05428384|DEVICE|MRI/ CardioMEMS comparison|Each subject will have CardioMEMS readings paired with MRI scans
223887584|NCT06840821|DRUG|MB0151 for injection|In this study, the protocol of accelerated titration combined with i3+3 is used for dose escalation. administered intravenously every 2 weeks .
223887585|NCT03964350|DRUG|Ethanol|"The 0.8 g/kg body weight dose of gelatin alcohol will be divided into an average of 10 servings of 0.08 g/kg each. The 0.8 g/kg dose is equivalent to 4 standard drinks, where a standard drink is defined as one 12 oz beer, one 5 oz glass of wine, or one 1.5 oz shot of 80 proof alcohol.~The 0.4 g/kg body weight dose of gelatin alcohol will be divided into an average of 5 servings of 0.08 g/kg each. The 0.4 g/kg dose is equivalent to 2 standard drinks, where a standard drink is defined as one 12 oz beer, one 5 oz glass of wine, or one 1.5 oz shot of 80 proof alcohol."
223887586|NCT03964350|OTHER|Placebo|The placebo comparator will be individual servings of back cheery sugar-free jello.
223887587|NCT06790758|DRUG|Plasma rich fibrin epidural injection by Racz catheter|Patients will receive plasma-rich fibrin epidural injection by Racz catheter in post-dural puncture headache-guided optic nerve sheath diameter.
223887588|NCT06909526|BEHAVIORAL|Mindfulness-based stress reduction :MBSR|The intervention consists of 4 weekly virtual sessions and daily mindfulness exercises at home (between 1-5min of duration each, according to the participant's availability. Each session lasts 1 hour (except the first one, which is 1.5 hours due to discussion of the program's logistics). The sessions follow a brief check-in, a lecture on the week's topic, and a guided practice exercise. For the audio guides, participants can select a short version of the daily practice exercise or a longer one, which they will record in the practice logs. Participants also receive information sheets summarizing the weekly sessions.
223887589|NCT06909526|BEHAVIORAL|Usual care|Subjects will continue with their usual healthcare routine and lifestyle. Upon completion of all study visits, subjects will be given access to the audio guides and information sheets for voluntary at-home practice exercises
223887590|NCT06575686|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223887591|NCT06575686|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
223887592|NCT06575686|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
223887593|NCT06575686|BIOLOGICAL|Epcoritamab|Given SC
223887594|NCT06575686|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
223887595|NCT06575686|DRUG|Tazemetostat|Given PO
223887596|NCT06832644|BEHAVIORAL|Lifestyle Management|All individuals will receive tailored lifestyle advice along with medical treatment based on their newly estimated CVD risk. The control group will also receive lifestyle advice along with medical treatment based only on their CVD risk provided at the baseline visit during phase I.
223887597|NCT06920524|DEVICE|Intervention group IM-IM|The intervention group (IM-IM) will receive a tablet and headphones to listen to music during the toxin injections. Then, during the waiting time, the patient, with or without assistance, will choose the music they wish to listen to, according to their musical tastes. The duration of the music can be modulated according to the duration of the medical procedure to follow.
223887598|NCT06922799|DIAGNOSTIC_TEST|Saliva-Check Buffer test and periodontal charting|Saliva-Check buffer test will be used to perform evaluations on saliva pH, quantity and quality
223887599|NCT06931873|COMBINATION_PRODUCT|SCRT+Capoex+QL706|Using a short-course radiotherapy treatment protocol, the primary tumor and high-risk areas were irradiated with a tumor dose of 25 Gy (5 Gy/treatment × 5 treatments); 2 weeks of rest after the end of radiotherapy were followed by 4 cycles of Capoex combined with QL706.
223887600|NCT06931873|COMBINATION_PRODUCT|LCRT+Capoex+QL706|Using a long course radiotherapy treatment protocol, the primary tumor and high-risk areas were irradiated with a tumor dose of 50 Gy (2 Gy/treatment x 25 treatments); a 2-week break at the end of radiotherapy was followed by 4 cycles of Capoex combined with QL706.
223887601|NCT06932692|OTHER|magnetoencephalography|500 patients with Parkinson's disease and essential tremor will undergo magnetoencephalography
223887602|NCT06925945|PROCEDURE|regional anestesia|Modified thoracoabdominal plane block (M-TAPA) and rectus sheath block with local infiltration analgesia
223887603|NCT06928038|BEHAVIORAL|Positioned group|applied a side-lying position (20 minutes) on the occiput side and a prostrate position (15 minutes).
223887604|NCT06931756|DEVICE|Neural Stimulator|Adjust the neural stimulator, with a stimulation duration of 0.1 ms, a stimulation frequency of 1Hz, and a stimulation current of 1.0mA. Under ultrasound guidance, the needle tip is used to touch the radial nerve, ulnar nerve, median nerve, and musculocutaneous nerve respectively, until a clear motor response is observed in the corresponding muscles. Thereafter, the minimum stimulation threshold current is verified by reducing the current until the distal motor response disappears. If no motor response is elicited, the current intensity is appropriately increased to achieve a motor response of the extensor tendon of the radial nerve, and the flexor tendon motor responses of the ulnar nerve, median nerve, and musculocutaneous nerve.
223887605|NCT06931314|PROCEDURE|Aromatherapy massage|Aromatherapy massage refers to a massage to be performed on the neck area with lavender oil.
223887606|NCT06931314|PROCEDURE|Muscle Energy Technique|Muscle Energy Technique is a form of manual therapy that uses active muscle contraction and relaxation to improve musculoskeletal mechanics and relieve pain.
223887607|NCT06932705|DRUG|PA-111|PA-111 1Tab., Per Oral
223887608|NCT06932705|DRUG|PA-111A|PA-111A 1Capsule., Per Oral
223887609|NCT06942585|DEVICE|Kinesiology Tape|An elastic therapeutic tape applied to the ankle and knee using standard kinesiology taping techniques. The tape is stretched to approximately 10-15% during application and is designed to mimic the properties of human skin. It aims to provide sensory stimulation, improve proprioceptive feedback, and support joint function without limiting range of motion. The application targets muscles and tendons surrounding the knee and ankle, commonly used in both preventive and rehabilitative physiotherapy.
223887610|NCT06942585|DEVICE|Dynamic tape|A biomechanical tape characterized by high elasticity (over 200%) and strong resistance, applied to the ankle and knee to assist movement and absorb load. The tape is applied in a shortened muscle position with maximal stretch across the joint, following the manufacturer's guidelines (GripIt ACTIVETAPE, 5 cm width). This taping method aims to provide both mechanical support and neurosensory input, facilitating muscle activation and improving joint stability during movement. It is used to address both biomechanical and proprioceptive components of lower limb control.
223887611|NCT06932887|BEHAVIORAL|Text Messaging|Weekly SMS messages sent to potential participants to inform them of the opportunity to participate in PA counseling for their arthritis. instructions also provided on how to request a referral.
223887612|NCT06932887|BEHAVIORAL|Motivational Messaging|The use of short motivational messages along with text messages inviting persons to participate in PA counseling. The messages are intended to enhance the motivation to participate in PA counseling.
223887613|NCT06932887|BEHAVIORAL|Physical Activity Counseling and Self-Directed Walk with Ease|All persons consenting to PA counseling receive 6 weekly sessions provided in-person or remote with 2-way video or audio commu¬nication. All participants receive education to address negative psy-chological appraisals of OA, reassur¬ance that PA is safe and beneficial, and a PA program primarily focused on walk¬ing, although additional activities may be included. Additional components include exercises tai¬lored to the partici¬pant's needs and coping strategies such as mindful breathing to help manage stress.
223887614|NCT06932887|BEHAVIORAL|Enhanced Walk with Ease|Along with the portal registration participants in the Enhanced WWE group are also offered the opportunity to participate in virtual group WWE classes offered on a rolling basis in either English or Spanish.
223887615|NCT04572750|BEHAVIORAL|EMPOWER-ED|An electronic app that runs on a variety of platforms and provides education and tools designed to promote self-driven reduction of benzodiazepines.
223887616|NCT06631677|DRUG|Dupilumab|Administered per protocol
223887617|NCT06477185|DRUG|Doxycycline|Doxycycline is a bacteriostatic tetracycline antibiotic with ability to immunomodulate matrix metalloproteinases, enzymes well known to cause lung damage via breakdown lung extracellular matrix.
223887618|NCT06477185|DRUG|Placebo|This will be a chemically inert substance, designed to match oral doxycycline capsules but with no chemically active ingredients.
223887619|NCT05519007|OTHER|No-Rinse Solution (NS)|The surgical site will be irrigated with NS prior to closure,
223887620|NCT05519007|OTHER|Saline irrigation|The surgical site will be irrigated with Saline
223887621|NCT02790931|OTHER|Intervention Group|Patients will receive a physical therapy intervention in groups twice/wk, and using a software twice/ wk for 3 months, for foot and ankle strengthening, stretching and functional training. They must continue to exercise at home twice a week with the software supervision for one year.
223887622|NCT04661293|BIOLOGICAL|Autologous Muscle Derived Cells (AMDCs)|
223887623|NCT06788210|OTHER|Multiprofessional Geriatric Emergency Team applied front-door CGA to identify patients who require inpatient care and those who can safely be discharged.|"In comparison to the precedent studies, this project is characterised by some innovative aspects as regards to the design of intervention:~1. the participation of both a geriatrician and a nurse expert in transitional care, with the consultancy of a social worker when needed, in the management of the elderly patient within ED, adds to the project a greater operational capacity of the multidimensional assessment (CGA) of planning the best care setting for the patient.~2. The proposed CGA model is complete in the analysis of the different domains (social, clinical, functional, cognitive-affective) and achievable in this particular urgent setting.~3. The program examines, unlike other studies, much more variables that can help to define the effectiveness of the intervention.~4. The involvement in the network program of three main hospitals of the Emilia Romagna with a pool of elderly patients afferent to ED of about 20,000 elderly/year per hospital (2019 data prior of Sars Cov2 pandemic)"
223887624|NCT06840639|PROCEDURE|Dentoalveolar surgery|Surgery to extract teeth
223887625|NCT06795321|PROCEDURE|Spinal anesthesia|Patients who preferred spinal anesthesia were included in this group.
223887626|NCT06795321|PROCEDURE|General anesthesia|Patients who preferred spinal anesthesia were included in this group
223887627|NCT05548426|DRUG|Group B, Linezolid 10d|Oral Linezolid 600mg, taken twice a day for 10 days
223887628|NCT05548426|DRUG|Group A, Penicillin|Standard of care benzathine penicillin G, one intramuscular injection, 2.4MU
223887629|NCT06793332|DRUG|Ivonescimab Combined With TROP2 ADC|Ivonescimab: 20 mg/kg, ivggt, day 1, every 3 weeks; Sacituzumab govitecan: 10 mg/kg, ivggt, day 1 and day 8, every 3 weeks;
223887630|NCT06796205|OTHER|Treated zones exposed with Visible Light source|The treated zones were exposed to Visible Light to induce skin pigmentation (144J/cm2), 15 to 30 minutes after application.
223887631|NCT06796205|OTHER|Untreated zone exposed with Visible Light source|The untreated zone was exposed to Visible Light to induce skin pigmentation (144J/cm2), as the same time as the treated zones.
223887632|NCT06163014|BEHAVIORAL|My Symptoms eHealth programme|"My Symptoms supports patients' self-efficacy and behavioural changes. The programme is activated by the patient after prescription by the GP. The patient is free to choose relevant tasks corresponding to wishes, needs/requirements and own perspectives.~Summary of content:~1. Symptom explanations and facts about frequent symptoms including brief animated explanations~2. Physical energy (sleep, diet and activity)~3. Working with resources and strain in everyday life~4. Values and choices (meaning and existential issues)~5. Thoughts~6. Feelings (emotion regulation)~7. Self-care (attention incl. mindfulness and audio exercises)~8. Preparation for a follow-up visit with the GP and relapse prevention. The above modules connect to four general tools: symptom registration, 'don't break the chain', goal setting staircase and notebook.~After 6 weeks: Voluntary GP follow-up consultation. After 8 weeks: End-of-treatment."
223887633|NCT06795360|OTHER|discontinuation of weight loss medication|Participants will be studied right before their injectable weight loss medication runs out, and 3 months later
223887634|NCT06836570|BIOLOGICAL|Platalet Rich Plasma|Platelet-rich plasma (PRP) is a preparation of autologous human platelet concentration enriched in a small amount of plasma produced by centrifuging a patient's own blood. It is applied to the extraction socket after the extraction of an impacted wisdom tooth.
223887635|NCT06836570|OTHER|Low Level Laser Therapy|Low-level laser therapy is a technology that has been used since the mid-1960s to treat a variety of conditions requiring healing stimulation, pain and inflammation relief, and restoration of function. A single 940 nm diode laser was applied intraorally for 120 seconds (BIOLASE) immediately after the extraction and suturing of an impacted wisdom tooth.
223887636|NCT06838975|DEVICE|VR Training|Participants in the VR Training Group will undergo a virtual reality-based rehabilitation program designed to improve cognitive, emotional, social, and motor functions. The intervention consists of 20 sessions over 8 weeks (3 sessions per week), using immersive and non-immersive VR systems tailored to individual needs. The program integrates interactive exercises, real-time feedback, and task-oriented training to enhance motor function, cognitive abilities, and patient engagement. Neurophysiological changes will be monitored through EEG, MRI, and motion analysis to assess brain plasticity and functional improvements.
223887637|NCT06838975|OTHER|traditional cognitive and motor rehabilitation following standard clinical practices|Participants in the Active Control Group will receive traditional cognitive and motor rehabilitation following standard clinical practices. The intervention consists of 20 sessions over 8 weeks (3 sessions per week), focusing on conventional physical therapy, cognitive training, and task-oriented exercises to enhance motor function and cognitive abilities. This group serves as a comparison to evaluate the effectiveness of VR-based rehabilitation. Neurophysiological changes will be monitored using EEG, MRI, and motion analysis to assess functional improvements.
223887638|NCT06794944|DRUG|Vancomycin (POC)|Vancomycin is glycopeptide antibiotic that has broad gram-positive coverage. Patients will receive 125mg PO every 6 hours for 10 days.
223887639|NCT06794944|DRUG|Fidaxomicin|Fidaxomicin is a macrolide antibiotic. It is narrow spectrum with potent bactericidal activity specifically against C. difficile. Patients will receive 200mg PO twice daily for 10 days.
223887640|NCT06794957|DRUG|AL8326 tablets|10mg/tablet;Oral administration, once daily.
223887641|NCT05947071|BIOLOGICAL|Standard Dose Quadrivalent Inactivated Influenza Vaccine|Fluzone ® Quadrivalent is a vaccine indicated for active immunization for the prevention of influenza disease caused by two influenza A subtype viruses and two type B viruses contained in the vaccine.
223887642|NCT05947071|BIOLOGICAL|High Dose Quadrivalent Inactivated Influenza Vaccine|"Fluzone High-Dose (Influenza Vaccine) for intramuscular injection is an inactivated influenza vaccine, prepared from influenza viruses propagated in embryonated chicken eggs. The virus-containing allantoic fluid is harvested and inactivated with formaldehyde. Influenza virus is concentrated and purified in a linear sucrose density gradient solution using a continuous flow centrifuge. The virus is then chemically disrupted using a non-ionic surfactant, octylphenol ethoxylate (Triton® X-100), producing a split virus. The split virus is further purified and then suspended in sodium phosphatebuffered isotonic sodium chloride solution. The Fluzone High-Dose process uses an additional concentration factor after the ultrafiltration step in order to obtain a higher hemagglutinin (HA) antigen concentration."
223887643|NCT02780128|PROCEDURE|Biopsy|Needle or incisional tumor biopsy
223887644|NCT02780128|GENETIC|Next Generation Sequencing|Tumor tissue will be sent to Foundation Medicine laboratory for molecular profiling.
223887645|NCT02780128|PROCEDURE|Tumor Scans|Participants will undergo different types of scans to look at your tumor. These scans include CT (computerized tomography), MIBG (meta-iodobenzylguanidine) PET (positron emission tomography), and MRI (magnetic resonance imaging). Participants may have more than one type of scan.
223887646|NCT02780128|PROCEDURE|Bone marrow Tests|Participants will have needles inserted through their hip bone to remove fluid from inside the bone marrow. This test determines if participants have tumor in the bone marrow.
223887647|NCT02780128|OTHER|Physical Exam|The exam includes taking participant weight, height, blood pressure, heart rate and respiratory rate and performing a examination of the participants body. The investigators may also check the participants vision with an eye chart.
223887648|NCT02780128|OTHER|Eye Exam|Participants will have their eyes will be evaluated using different instruments. Participants will also be asked to read an eye chart. The exams will take about 15 minutes.
223887649|NCT02780128|OTHER|Labs|Standard blood tests will be done to measure different types of blood cells, to measure the amount of certain substances, and tests to check how well liver and kidneys are working. When possible, the investigators will take blood from the participants central line. If this is not possible, the investigators will take blood from a vein in the participants arm. First, the investigators will put some cream on the skin so that drawing blood will not be painful. Then the investigators will put a thin needle into the vein to draw the blood.
223887650|NCT02780128|OTHER|Pregnancy Test|If the participant is 11 years old or older or has already started having periods, the participant will be asked to take a pregnancy test before starting this study. The results will be shared with the participant but not with the participants' parent(s). We strongly encourage the participant to share the results with the parents. If the participant is found to be pregnant, the participant will not be able to continue participation in the study. About 1 teaspoon of blood (or urine if a urine test) will be needed.
223887651|NCT02780128|BEHAVIORAL|Interviews|A team member will take the participant's medical history, along with a listing of any medications that are being taken. Throughout the study, participants will be asked to report if they think that anything bad has happened as a result of the study.
223887652|NCT02780128|OTHER|ECG|This is a test of electrical activity of the heart. The investigators will put electrodes (sticky pads attached to wires) on the participant's chest, arms and legs. The electrocardiogram (ECG) will not be uncomfortable, but the participant will have to lie still. It does not hurt and takes about 15 minutes.
223887653|NCT02780128|OTHER|Echocardiogram|The participant will have an Echocardiogram (ECHO), an ultrasound of the heart, taken to assess heart function. The investigators will put some gel on the skin and use a machine to take pictures of the heart.
223887654|NCT02780128|DRUG|Ribociclib|Participants will take ribociclib once per day orally for Days 1-21 of a 28-day cycle.
223887655|NCT02780128|DRUG|Ceritinib|Participants will take ceritinib once per day orally for 28 days of a 28-day cycle.
223887656|NCT06832514|BIOLOGICAL|Serogroup B meningococal vaccine|The 4CMenB vaccine will be administered via two intramuscular (IM) injections in the non-dominant upper arm, with a one month interval.
223887657|NCT06796426|DRUG|Plozasiran|25 mg ARO-APOC3 by sc injection administered by healthcare professional
223887658|NCT04402489|DRUG|Placebo|Placebo
223887659|NCT04402489|DRUG|MT-7117 Low Dose|MT-7117 Low Dose
223887660|NCT04402489|DRUG|MT-7117 High Dose|MT-7117 High Dose
223887661|NCT05971810|DIETARY_SUPPLEMENT|immunonutrition supplement of ORAL IMPACT™|For intervention group, patients will take immunonutrition supplement after recruitment until the day before surgery.
223887662|NCT05971810|OTHER|oral chlorhexidine decontamination|For intervention group, patients will use 0.12% chlorhexidine for oral rinse twice daily from the day before surgery until 3 days after surgery.
223887663|NCT06793150|DRUG|Remifentanil|A comparison will be made by maintaining one group with remifentanil and the other with dexmedetomidine.
223887664|NCT06793150|DRUG|dexmedetomidin|A comparison will be made by maintaining one group with remifentanil and the other with dexmedetomidine.
223887665|NCT06796023|OTHER|Stretching and strengthening exercises for back muscles|Stretching and strengthening exercises for back muscles
223887666|NCT06796023|OTHER|Lumbar stabilization Exercises|Lumbar stabilization Exercises
223887667|NCT06796023|OTHER|Lumbar Manipulation|Lumbar Manipulation
223887668|NCT05512975|DIETARY_SUPPLEMENT|Dairy protein porridge arm|Regular porridge ingredients with additional delical whey protein fortification
223887669|NCT05512975|DIETARY_SUPPLEMENT|Plant protein porridge arm|Regular porridge ingredients with the addition of extruded soya protein fortification and soya milk instead of regular dairy milk
223887670|NCT05512975|DIETARY_SUPPLEMENT|Control Porridge arm|Regular porridge ingredients with no additional protein fortification
223887671|NCT06791421|OTHER|AI-Predictng Model|The intervention in this study involves an AI-based predictive model designed to analyze and integrate patient electronic health records (EHR), clinical lab results, and multimodal imaging data (e.g., X-rays, MRIs, CT scans). The AI model is trained to predict a patient's genotype based on these non-genetic data sources. This model uses machine learning algorithms to detect patterns and infer genetic information that would traditionally require direct genetic testing. There are no active treatments or genetic tests involved in this intervention; rather, the AI system serves as a tool to predict genetic information from available clinical data, offering a non-invasive and potentially more accessible alternative to genetic testing.
223887672|NCT06789549|DRUG|epinephrine nasal drops|Patients in experimental arms received 1 mL of 0.1% epinephrine nasal drops before nasotracheal intubation
223887673|NCT06789549|DRUG|oxymetazoline nasal drops|Patients in experimental arms received 1 mL of 0.1% oxymetazoline nasal drops before nasotracheal intubation
223887674|NCT06835478|BEHAVIORAL|EPURE + : EPURE program|EPURE program will be tested.
223887675|NCT06835478|BEHAVIORAL|EPURE - : Standard practices|This group will receive standard practices to prevent the use of screens in child under 3
223887676|NCT03485547|DRUG|Venetoclax|VENCLEXTA targets BCL-2 in order to help restore the process of apoptosis. Through apoptosis, your body allows cancer cells and normal cells to self-destruct
223887677|NCT06223503|BEHAVIORAL|Transitional Pain Service|The Transitional Pain Service (TPS) is a novel perioperative surgical home approach that consists of comprehensive pain management and care coordination before, during and for at least 6-months after surgery for Veterans at risk for chronic opioid use (COU).
223887678|NCT06796855|DEVICE|Selective Bladder Denervation via Radiofrequency Ablation|Participants in this arm will undergo a single session of selective bladder denervation using radiofrequency ablation (RFA). The procedure is performed under general anesthesia using the Apro Korea AK-F200 system, which delivers radiofrequency energy at four submucosal points in the bladder trigone area. The energy is applied at 25 watts per site for 60 seconds, targeting nerve pathways involved in overactive bladder symptoms. The procedure is conducted using a 19 Fr. rigid cystoscope in lithotomy position, ensuring precise electrode placement. Patients are discharged on postoperative day 1 following urinary ultrasound and post-void residual (PVR) assessment. Follow-up visits are scheduled at 2, 4, and 12 weeks to evaluate symptom improvement and safety.
223887679|NCT06796855|DRUG|Intravesical Onabotulinum Toxin A Injection|Participants in this arm will receive a single dose of 100 units of Onabotulinum Toxin A injected into 10 sites on the bladder wall using a 4mm injection needle and 19 Fr. rigid cystoscope. The injection is administered under local anesthesia in an outpatient setting. The Onabotulinum Toxin A is diluted in sterile saline and delivered into the detrusor muscle, aiming to reduce detrusor overactivity and urgency symptoms. Patients undergo urinary ultrasound and post-void residual volume (PVR) assessment on postoperative day 1 before discharge. No additional doses are administered, and follow-up visits are scheduled at 2, 4, and 12 weeks to evaluate symptom improvement and safety.
223887680|NCT03805464|OTHER|Knee Joint Effusion|60mL saline injection into the supra-patellar region of the knee
223887681|NCT06797141|OTHER|Vestibular Rehabilitation and Dual task Training and Traditional Physical Therapy|Group A will receive treatment session lasting for 1 hour including vestibular rehabilitation therapy for 30 minutes and Dual Task Training for 20 minutes along with routine physical therapy of 10 minutes. Treatment session will be given 5 days per week for 8 weeks. Patients will be instructed to perform 2 sets of 5 repetition each Gaze Stability exercises: Horizontal and Vertical Head movements keep their eyes fixed on a stationary target, Following a slowly moving target keeping head still Balance Exercises:Maintain balance while performing neck rotations and shifting their weight forward, backward, and side to side.Sit to stand on chair Gait Training: Walking at varying speeds, walking forwards and backwards, sideways walking, walk in circles, and walking with horizontal and vertical head movements Dual Task exercises comprising of primary and secondary tasks Conventional Cawthorne Cooksey exercises :Up and down eye and Head movements, pick up things from ground, Walk up and down
223887682|NCT06797141|OTHER|Vestibular Rehabilitation and Traditional Physical Therapy|"Group B will receive treatment session lasting for 1 hour including vestibular rehabilitation therapy for 40 minutes along with routine physical therapy of 20 minutes. Treatment session will be given 5 days per week for 8 weeks.~Gaze Stability exercises: Horizontal and Vertical Head movements keep their eyes fixed on a stationary target, Following a slowly moving target keeping head still Balance Exercises:Maintain balance while performing neck rotations and shifting their weight forward, backward, and side to side.Sit to stand on chair Gait Training: Walking at varying speeds, walking forwards and backwards, sideways walking, walk in circles, and walking with horizontal and vertical head movements Conventional Cawthorne Cooksey exercises :Up and down eye and Head movements, pick up things from ground, Walk up and down"
223887683|NCT05534750|DRUG|Tedizolid arm (SIVEXTRO®)|Patients will be taken 1 tablet per day of 200 mg film-coated of Tedizolid (SIVEXTRO®), in the morning for 7 days. Then, the early bactericidal activity will be measured and compared to the other arms.
223887684|NCT05534750|DRUG|Linezolid arm (ZYVOXID®)|Patients will be taken 2 tablets per day of 600 mg film-coated of Linezolid (ZYVOXID®) in the morning for 7 days. Then, the early bactericidal activity will be measured and compared to the other arms.
223887685|NCT05534750|DRUG|Standard quadruple therapy arm|"Patients will be taken :~ISONIAZIDE :~o A dosage of 5mg / kg / day for 7 days (to be taken in the morning on an empty stomach) of Isoniazid (RIMIFON®)~RIFAMPICINE :~o A dosage of 10mg / kg / day for 7 days (to be taken in the morning on an empty stomach)~ETHAMBUTOL :~o A dosage of 15-20mg / kg / day for 7 days (to be taken in the morning on an empty stomach) of Ethambutol~PYRAZAMIDE :~o A dosage of 20-25mg / kg / day for 7 days (to be taken in the morning on an empty stomach) of Pyrazinamide~Then, the early bactericidal activity will be measured and compared to the other arms."
223887686|NCT05121740|DRUG|Plitidepsin 1.5 mg / day|Plitidepsin 1.5 mg/day infused through a pump device over 1 hour and 30 minutes, 3 consecutive days (total dose 4.5 mg).
223887687|NCT05121740|DRUG|Plitidepsin 2.0 mg / day|Plitidepsin 2.0 mg/day infused through a pump device over 1 hour and 30 minutes, 3 consecutive days (total dose 6.0 mg).
223887688|NCT05121740|DRUG|Plitidepsin 2.5 mg / day|Plitidepsin 2.5 mg/day infused through a pump device over 1 hour and 30 minutes, 3 consecutive days (total dose 7.5 mg).
223887689|NCT06830317|PROCEDURE|Endoscopic Radiofrequency treatment|Treatment with RFA will carried out with focal RFA with a TTS catheter at 12 Joule/cm2 to all visible areas of GAVE under conscious sedation or propofol sedation by experienced team of endoscopists and anesthetists
223887690|NCT06830317|OTHER|QoL EQ5D questionaire|Quality of Life EQ5D (by EuroQol Group) before every RFA treatment and at Follow up visits (3, 6 and 12 months after the first procedure). QoL questionnaire EQ5D The descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The patient is asked to indicate his/her health state by ticking the box next to the most appropriate statement in each of the five dimensions. This decision results in a 1-digit number that expresses the level selected for that dimension. The digits for the five dimensions can be combined into a 5-digit number that describes the patient's health state
223887691|NCT06780956|OTHER|Conventional|conventional drilling protocol using full sequence
223887692|NCT06780956|OTHER|simplfied|3 burrs for implant placment
223887693|NCT02736448|DRUG|Capecitabine|oral low dose of capecitabine
223887694|NCT02736448|DRUG|Lu-PRRT|Lu-PRRT (at 3.7Gbq per cycle x 7 cycles)
223887695|NCT02736448|DRUG|SS-LAR|long acting octreotide or lanreotide
223887696|NCT03676582|DIAGNOSTIC_TEST|Acoustic analysis plus pulse oximetry|Acoustic analysis plus pulse oximetry
223887697|NCT06302361|PROCEDURE|Lymphovenous anastomosis (LVA)|Surgical procedure with supermicrosurgical anastomosis between distal lymph vessel and proximal venule.
223887698|NCT04847648|PROCEDURE|Air-polishing|Air-polishing with erythritol powder during non-surgical therapy (at baseline, 5 seconds per surface, and, if necessary, at 3 months).
223887699|NCT04847648|PROCEDURE|Mechanical decontamination|Mechanical instrumentation of implant surfaces during non-surgical therapy (at baseline and, if necesarry at 3 months) including the use of hand instruments and polishing cups aiming at the removal of all soft and hard deposits from the target implant.
223887700|NCT03763240|DIETARY_SUPPLEMENT|BSE|"BSE powder will be provided as dry mixtures in sealed, non-transparent portion size bags. Each BSE bag contains 150 μmole, equal to 0.26 g, sulforaphane at a minimum. The mixtures are suspended with appr. 1 dl water and are ingested once daily in the morning. BSE should be stored at room temperature in dry conditions.~The doses of sulforaphane contained in the BSE is not possible to get by eating fresh broccoli, thus it has to be given as an extract."
223887701|NCT03763240|DIETARY_SUPPLEMENT|Placebo|Placebo powder will be provided as dry mixtures in sealed, non-transparent portion size bags. The mixtures are suspended with appr. 1 dl water and are ingested once daily in the morning.
223887702|NCT06340347|DRUG|Osivelotor|"a single dose of osivelotor administered by mouth under fasted conditions~Other Names:~PF-07940367"
223887703|NCT04637763|GENETIC|CB-010|CB-010 is a CRISPR-edited allogeneic CAR-T cell therapy targeting CD19.
223887704|NCT04637763|DRUG|Cyclophosphamide|Chemotherapy for lymphodepletion
223887705|NCT04637763|DRUG|Fludarabine|Chemotherapy for lymphodepletion
223887706|NCT05471479|DRUG|Activated Charcoal|Activated charcoal
223887707|NCT05471479|OTHER|No activated charcoal|No activated charcoal
223887708|NCT03077776|PROCEDURE|Biopsy|Biopsy of primary tumour to be performed prior to initiation of neoadjuvant chemotherapy
223887709|NCT03077776|PROCEDURE|Biopsy (optional)|\[Optional\] biopsy of primary tumour to be performed after 4 weeks of neoadjuvant chemotherapy
223887710|NCT03077776|PROCEDURE|Biopsy (metastatic)|Biopsy of metastatic site to be performed at the time of relapse
223887711|NCT05824832|DRUG|Interscalene block with the addition of buprenorphine, clonidine, dexamethasone|Addition of the adjuvant buprenorphine, dexamethasone, and clonidine in the nerve block performed prior to shoulder arthroscopy surgery
223887712|NCT05824832|DRUG|Interscalene block with buprenorphine alone|Addition of the adjuvant buprenorphine alone the in nerve block performed prior to shoulder arthroscopy surgery
223887713|NCT04149288|DIETARY_SUPPLEMENT|High-polyphenol olive oil|High-polyphenol olive oil will be provided to study participants to consume at home. Participants will be asked to consume 40 mL each day for 2 weeks.
223887714|NCT04149288|DIETARY_SUPPLEMENT|Low-polyphenol olive oil|Low-polyphenol olive oil will be provided to study participants to consume at home. Participants will be asked to consume 40 mL each day for 2 weeks.
223887715|NCT06781541|BEHAVIORAL|Nordic walking|NW training sessions are conducted by a certified NW instructor leading participants in the outdoor forest of Gdansk. Training is about 60 minutes each time, 3 times a week, each interval of 1 or 2 days, a total of 12 weeks. Participants used professional Nordic Pole.
223887716|NCT06781541|BEHAVIORAL|Strength training|Strength training was conducted in the gym with progressively increasing resistance from 65% to 75% of the maximum weight (one-repetition maximum (1-RM)). Participants performed 10-13 repetitions of the exercise in one serie. The training was carried out in station form and consisted of 10-13 exercises. There were rest intervals of 60-90 seconds between exercises. As intended, the training was comprehensive, i.e. it affected the muscles of the arms, legs, torso, abdomen and chest.
223887717|NCT06781541|BEHAVIORAL|Bungy Pump Exercises|Buny Pump training sessions are conducted by a certified BP instructor leading participants in the outdoor forest of Gdansk. Training is about 60 minutes each time, 3 times a week, a total of 12 weeks. Participants used professional Bungy Pump Pole.
223887718|NCT06781541|BEHAVIORAL|Daily life|The individuals engaged in routine daily tasks, while being advised against incorporating any supplementary physical exertion.
223887719|NCT06781541|BEHAVIORAL|Functional general conditioning training|Training sessions were supervised by a certified instructor. Training was carried out at home with individually adjusted resistance depending on age and health. Participants typically performed 10-13 repetitions of a given exercise. 30-second rest intervals were used between exercises. As intended, the training was comprehensive, i.e. including muscles of the arms, legs, trunk, abdomen, chest, balance and flexibility exercises. Basic training equipment was used during the training.
223887720|NCT05004285|DRUG|[F-18]Florastamin|A single dose of \[F-18\]Florastamin at 10 ± 1 mCi is IV administered at Visit 2, and \[F-18\]Florastamin PET/CT images are obtained from the head to thigh after 110 ± 10 minutes.
223887721|NCT06780527|OTHER|15% Grape seed extract as dentin pretreatment|using proanthocyanidin-rich grape seed extract as a biomodifier for dentin improved the mechanical properties of dental collagen by cross-linking and dehydrating fibrils. This made the collagen substrate more suitable for hybridization. It also acted as a non-specific MMP-inhibitor, protecting exposed collagen fibrils from biodegradation from dentin proteases.
223887722|NCT06781216|BEHAVIORAL|Motivational interviewing|It is emphasized that motivational interviewing is a feasible intervention that can be used by various health professionals to optimize clinical outcomes in cancer patients and survivors, helping individuals to better cope with the stress they experience related to cancer and improve their quality of life. Considering the benefits of motivational interviewing on individuals diagnosed with cancer, it is anticipated that the intervention planned in the study will improve coping strategies, reduce post-traumatic stress symptoms, and increase the level of post-traumatic growth in women with endometrial cancer.
223887723|NCT03328702|DEVICE|Continuous Positive Airway Pressure|Apex XT Fit CPAP Machine
223887724|NCT05581758|DRUG|AMG 510|Oral Tablet
223887725|NCT05789537|DRUG|SerpinPC|Administered as SC injection.
223887726|NCT06135974|DRUG|LC106|Tablet containing at least 2 x 10\^6 CFU/tablet, and comprised of 6 strains of Lactobacillus crispatus
223887727|NCT06135974|DRUG|LC115|Tablet containing at least 2 x 10\^6 CFU/tablet, and comprised of 15 strains of Lactobacillus crispatus
223887728|NCT06135974|DRUG|Placebo|Vaginal tablets containing primarily microcrystalline cellulose and no live bacteria
223887729|NCT06135974|DRUG|Metronidazole Oral|Metronidazole tablet orally twice daily for 7 days
223887730|NCT03465592|DRUG|Nivolumab|Administered IV
223887731|NCT06845657|OTHER|Hip Abductor Strengthening Exercises|Hip Abductor Strengthening Exercises .1.side lying leg raise 2.clam shell(Frequency: 3 sets 10 reps in session 1-5) 3.standing hip abduction.4.pelvic lift training (Frequency: 3 sets 10 reps in session 6-9) .Conventional PT including 1-ROM 2- Stretching of hamstrings,calf,,rectus femoris (30 sec hold,15 sec relaxation period,3 rep) 3.knee isometrics (2 sets 10 rep in first 5 sessions and 3 sets 10 rep in next 4 sessions).total duration is 3 sessions per week for 3 consecutive weeks.
223887732|NCT06845657|OTHER|Conventional Treatment|Conventional PT including 1-ROM 2- Stretching of hamstrings,calf,rectus femoris (30 sec hold,15 sec relaxation period,3 rep) 3.knee isometrics (2 sets 10 rep in first 5 sessions and 3 sets 10 rep in next 4 sessions). Total duration is 3 sessions per week for 3 consecutive weeks
223887733|NCT06304077|OTHER|Forest|Participants in the intervention groups will receive 5 VR training sessions over 10 days in addition to their usual care. Each participant will wear the HMD for 25 minutes in each of this training sessions, whereby he or she will first sit for 5 minutes looking at a forest-landscape. This is followed by 20 minutes of independent exploration of the virtual environment by walking. Depending on the user's gait stability, walking aids (such as walking sticks or rollators) may be used. This phase aims at keeping the participant walking.
223887734|NCT06304077|OTHER|Urban|Participants in the intervention groups will receive 5 VR training sessions over 10 days in addition to their usual care. Each participant will wear the HMD for 25 minutes in each of this training sessions, whereby he or she will first sit for 5 minutes looking at an urban-landscape. This is followed by 20 minutes of independent exploration of the virtual environment by walking. Depending on the user's gait stability, walking aids (such as walking sticks or rollators) may be used. This phase aims at keeping the participant walking.
223887735|NCT06304077|OTHER|Rural|Participants in the intervention groups will receive 5 VR training sessions over 10 days in addition to their usual care. Each participant will wear the HMD for 25 minutes in each of this training sessions, whereby he or she will first sit for 5 minutes looking at a rural-landscape. This is followed by 20 minutes of independent exploration of the virtual environment by walking. Depending on the user's gait stability, walking aids (such as walking sticks or rollators) may be used. This phase aims at keeping the participant walking.
223887736|NCT05180162|DRUG|68Ga-FAP-2286|A dose of 3 - 8 millicurie (mCi) will be given intravenously (IV)
223887737|NCT05180162|PROCEDURE|Positron Emission Tomography (PET)|Imaging will begin 50-100 minutes after injection and last about 45 minutes.
223887738|NCT06146348|BEHAVIORAL|adapted DRAUP strategy bundle|DRAUP deimplementation strategy bundle includes: 1) education and training, 2) supervision and in-person decision support, and 3) audit and feedback to target capability. Opportunity is addressed by 4) algorithm development and 5) organizational support. Finally, 6) facilitators and 7) planned adaptation after interval program assessment address the motivations needed to change behavior.
223887739|NCT06847880|DRUG|1: Vitamin C Supplementation|• Vitamin C (Ascorbic Acid): This intervention involves the administration of vitamin C, which is known for its antioxidant properties. The concentration will be 120 mg in 1.2 ml, and the produced volume will be divided by six lower anterior teeth; each tooth will receive 0.2 ml (20 mg) of the vitamin C. It is hypothesized to accelerate orthodontic tooth movement by reducing oxidative stress and promoting collagen synthesis.
223887740|NCT06847880|DRUG|Vitamin E Supplementation|• Vitamin E (Tocopherol Acetate): This intervention uses vitamin E, another antioxidant, thought to reduce inflammation and support tissue repair, potentially improving the effectiveness of orthodontic treatment by enhancing tissue recovery and reducing side effects. The concentration will be 60 mg in 0.4 ml, and the produced volume will be divided by six lower anterior teeth; each tooth will receive 0.07 ml (10 mg) of the vitamin E.
223887741|NCT06847880|OTHER|Saline Solution (Control)|Saline Solution (Control): The control group will receive a saline solution, which is a placebo, allowing for the comparison of the effects of vitamin C and vitamin E on orthodontic tooth movement without the influence of additional nutrients.
223887742|NCT04833777|DRUG|Local Anesthetics Lidocaine|10 mL 1% lidocaine with 1:100,000 epinephrine and 1 mL 8.4% sodium bicarbonate
223887743|NCT04833777|DRUG|Local Anesthetics Bupivacaine|5 mL 1% lidocaine with 1:100,000 epinephrine + 5 mL 0.5% bupivacaine with 1:100,000 epinephrine and 1 mL 8.4% sodium bicarbonate
223887744|NCT06847048|PROCEDURE|Thermophore pad warming group|Thermophore pad waa using heel warming
223887745|NCT06847048|PROCEDURE|Warm towel warming group|In this group, to warm the heel, the heel area where the blood would be taken was wrapped with a previously heated towel before heel prick.
223887746|NCT06847048|OTHER|Control group|in this group, heel prick intervention was performed in line with the routine interventions of the clinic.
223887747|NCT03062319|DRUG|Oral Anticoagulant|warfarin, dabigatran, rivaroxaban, apixaban, or edoxaban
223887748|NCT03062319|DRUG|Antiplatelet Drug|aspirin, clopidogrel, prasugrel, ticlopidine, or cilostazol
223887749|NCT05126147|DRUG|Hydroxychloroquine|Compare the effects of hydroxychloroquine 200mg twice daily for 6 months with those without treatment.
223887750|NCT05410353|BEHAVIORAL|Active Intervention Group|"The 3 major intervention components are diet, physical activity, and the behavioral modification curriculum. Scheduled interactions are educational podcasts (a series of audiovisual, digital media files) paired with a follow-up phone counseling session with a trained behavioral interventionist. A patient portal message will be sent to participants when a new podcast is posted. Interactive sessions will be weekly (weeks 1-16), biweekly (weeks 17-24), and monthly (weeks 25-52). The goal for weight loss is ≥ 7% of initial weight over the course of 12 months. Participants will restrict caloric intake with the goal of 1,200-1,500 kcal/day for those weighing \< 114 kg and 1,500-1,800 kcal/day for those weighing ≥ 114 kg. The physical activity goal will be for participants to gradually increase to 175-200 minutes of moderate-intensity activity per week by the 24th week. Participants will also be asked to self-monitor their dietary intake and physical activity using the Lose It! app."
223887751|NCT05410353|BEHAVIORAL|Comparison Group|All participants in the Comparison Group will receive a mandatory 13 contacts per year including 3 informational sessions on nutrition, physical activity and social support and 10 contacts via patient portal or email regarding intervention topics. The Look AHEAD Comparison Group was designed to be realistic, achievable, and an acceptable intervention that encouraged optimal study retention.
223887752|NCT06846112|PROCEDURE|Robotic partial nephrectomy|Robotic partial nephrectomy (RPN) is the treatment of choice for organ-confined renal tumors. For to improve functional outcomes, we designed an off-clamp and suture-free approach (SL) to limit the ischemic damage and destruction of the renal parenchyma caused, respectively, by temporary closure of the vessels of the renal hilum and by renorrhaphy (RR) (i.e. by the juxtaposition of the margins of resection of the enucleation bed, which is commonly performed at the end of tumor exeresis using suture threads stopped by surgical clips)
223887753|NCT01508312|DRUG|brentuximab vedotin (SGN-35)|Patients will receive 2 cycles of weekly brentuximab vedotin, 1.2mg/kg on days 1, 8, and 15 of each 28 day cycle. Patients with pre-treatment positive bone marrow biopsies will have repeat bone marrow biopsies if the PET scan is negative. FDG-PET/CT will be repeated after 2 cycles of treatment within 1 week of the last dose of cycle 2. Patients with persistent abnormalities on FDG-PET/CT following 2 cycles of brentuximab vedotin will receive 2 cycles of augmented ICE. The first cycle of augmented ICE will be initiated 7-14 days after the last dose of SGN-35. FDG-PET/CT will be repeated within 7-14 days following the second cycle of augmented ICE. Stem cell mobilization can be performed following the first or second cycle of augmented ICE.
223887754|NCT01508312|DRUG|Brentuximab Vedotin (SGN-35)|Patients will receive 2 cycles of weekly brentuximab vedotin, 1.2mg/kg on days 1, 8, and 15 of each 28 day cycle. FDG-PET/CT will be repeated after 2 cycles of treatment within 1 week of the last dose of cycle 2. Patients with pre-treatment positive bone marrow biopsies will have repeat bone marrow biopsies if the PET scan is negative. Patients with normalization of FDG-PET/CT and negative bone marrow biopsies following 2 cycles of brentuximab vedotin will undergo stem cell mobilization in preparation for ASCT.
223887755|NCT06464445|DEVICE|Monophasic iTBS|"iTBS protocol with monophasic-shaped pulses. iTBS parameters:~* Intensity: 80% of resting motor threshold (rMT)~* Frequency: 50 Hz~* Duration of pulse train: 2 seconds~* Interval between pulse trains: 8 seconds"
223887756|NCT06464445|DEVICE|Biphasic iTBS|"iTBS protocol with biphasic-shaped pulses. iTBS parameters:~* Intensity: 80% of rMT~* Frequency: 50 Hz~* Duration of pulse train: 2 seconds~* Interval between pulse trains: 8 seconds"
223887757|NCT06464445|DEVICE|Monophasic-Long iTBS|"iTBS protocol with long monophasic-shaped pulses. iTBS parameters:~* Intensity: 80% of rMT~* Frequency: 50 Hz~* Duration of pulse train: 2 seconds~* Interval between pulse trains: 8 seconds"
223887758|NCT05216250|BIOLOGICAL|BOTOX|Intramuscular injection
223887759|NCT05216250|DRUG|Placebo for BOTOX|Intramuscular injection
223887760|NCT06324396|DRUG|Sildenafil 10mg oral tablet (participants <20kg), or 20mg oral tablet (participants ≥20kg)|A single oral dose of sildenafil will be administered to all study subjects.
223887761|NCT06324396|DRUG|Pravastatin 20 mg oral tablet (ages <13 years), or 40 mg oral tablet (≥14 years)|A single oral dose of pravastatin will be administered to all study subjects.
223887762|NCT04533555|GENETIC|Broad gene panel for young adult cancers|Genetic testing will occur using a broad gene panel for young adult cancers
223887763|NCT04533555|GENETIC|Standard|Those in the standard group who are considered high risk will have genetic testing done using the standard of care panel as selected by their care provider.
223887764|NCT05428618|OTHER|e-BariS app group|"During the discharge process, informed consent will be obtained from the patients and the measurement tools will be filled and the mobile application will be downloaded to their phones. The intervention group will have access to all the content of the mobile application, which includes the Self-Monitoring Module and the Patient Education Module. Passwords will be defined so that patients in the intervention group can access the Patient Education Module. Information on the introduction and use of the application will be presented to the patient by the researcher.~The patients will be followed for six months within the scope of the project. In addition, reminder notifications will be sent to patients via the mobile application in line with the areas that patients can access. At one, three, and six months after surgery, he will complete other assessment scales during outpatient follow-up. For patients providing remote control, the scale will be sent online."
223887765|NCT05428618|OTHER|Self-Monitoring Group|"Patients in the control group will only have access to the Self-Monitoring Module in the application. Other fields will be encrypted. Patients in the control group will also be informed about the area they can access. Patients in the control group will only have access to the self-monitoring section. One, three, and six months after surgery, she will complete other assessment scales during her outpatient follow-up. Scales will be sent online for patients providing remote control. After the project is completed, all content will be opened to the control group patients."
223887766|NCT06844084|OTHER|Gardening Activity|In the project, gardening activities will be applied to the participants in the experimental group in the nursing home and greenhouse for 16 weeks (4 months), once a week for 60 minutes. During the implementation phase of horticulture activities, information meetings will be held in the meeting room of the nursing home in one group. In addition, 20 minutes break will be given during the activity in terms of the tolerance of the elderly to gardening activities.
223887767|NCT06845878|OTHER|chatbot|"Participants will:~* Participate in a baseline session to complete an initial survey and get trained on using the chatbot~* Use the chatbot for 12 weeks and submit a brief weekly survey to provide feedback~* Complete a final survey to provide substance use and health information as well as give feedback on the experience using the chatbot~* Allow access to a limited set of demographic, substance use and health information in electronic health record for study analyses and context."
223887768|NCT05993078|DRUG|0.9% NaCl 2000ml|The patient will undergo NS 2000ml intravenous infusion immediately after IVT. Subsequent therapy is based on Chinese guidelines for diagnosis and treatment of acute ischemic stroke 2018. All of the subjects should be treated in the hospital at least 7 days according to the guidelines for early management of stroke.
223887769|NCT05993078|DRUG|0.9% NaCl 200-400ml|The patients receive an NS 200-400ml after IVT. Subsequent therapy is based on Chinese guidelines for diagnosis and treatment of acute ischemic stroke 2018. All of the subjects should be treated in the hospital at least 7 days according to the guidelines for early management of stroke.
223887770|NCT06843694|OTHER|video game|The students in the video game group will be given training. The students in this group (n=30) will be divided into 4 groups and each group will have 5 students. The students will be given training about the Video Game (Lifesaver) by the researcher beforehand. The Video Game (Lifesaver-Cankurtaran); is a free video game developed by the Resuscitation Council in English.
223887771|NCT00579124|DEVICE|CliniMACs|T and B Cell depletion
223887772|NCT03854578|DRUG|BI 1358894|Film-coated tablet
223887773|NCT03854578|DRUG|Placebo matching BI 1358894|Film-coated tablet
223887774|NCT03854578|DRUG|Citalopram|Film-coated tablet
223887775|NCT01525966|DRUG|carboplatin|Given IV
223887776|NCT01525966|DRUG|paclitaxel albumin-stabilized nanoparticle formulation|Given IV
223887777|NCT01525966|OTHER|laboratory biomarker analysis|Correlative studies
223887778|NCT06848101|DIETARY_SUPPLEMENT|Carotenoid Group|Treatment will contain 20mg free lutein (10mg/softgel), 4 mg free zeaxanthin (2mg/softgel), 40mg maqui berry extract (20mg/softgel), 6 mg astaxanthin (3 mg/softgel), 80mg bilberry extract (40mg/softgel), flaxseed oil (150mg/softgel), and vitamin E (5IU/softgel)
223887779|NCT06848101|DIETARY_SUPPLEMENT|Control (placebo) group|Flaxseed Oil (330mg)
223887780|NCT06845995|DIETARY_SUPPLEMENT|Synbiotic supplement|Daily synbiotic supplement: The synbiotic supplement (contains both probiotic and prebiotic) that will be used in this study is commercially available; Celebrate Balance. The probiotic will be one capsule daily and consists of lactobacillus acidophilus, Bifidobacterium longum, lactobacillus rhamnosus, and lactobacillus gasser at 28,5 Billion CFUs at manufacture / 15 billion CFUs guaranteed at expiration
223887781|NCT05926804|DRUG|Lansoprazole|14 days of Lansoprazole (30 mg BID) (days 1-14)
223887782|NCT05926804|DRUG|Amoxicillin|7 days of Amoxicillin (1000 mg BID) (days 1-7)
223887783|NCT05926804|DRUG|Clarithromycin|7 days of Clarithromycin (500 mg BID) (days 8-14)
223887784|NCT05926804|DRUG|Metronidazole|7 days of Metronidazole (500 mg BID) (days 8-14)
223887785|NCT04328844|DRUG|IOA-244|IOA-244 will be administered orally once daily (QD)
223887786|NCT04328844|DRUG|Avelumab Injection|Avelumab will be administered IV every 2 weeks
223887787|NCT04328844|DRUG|Pemetrexed|Pemetrexed will be administered IV every 3 weeks
223887788|NCT04328844|DRUG|Cisplatin|Cisplatin will be administered IV every 3 weeks
223887789|NCT04328844|DRUG|Ruxolitinib|Ruxolitinib will be administered orally twice a day (BD)
223887790|NCT00186927|BIOLOGICAL|Sendai virus vaccine|Enders strain; a live, unmodified intranasally administered Sendai virus vaccine; given once in a dose escalation study, 5 x 10\^5 to 5 x 10\^7 EID(50) units.
223887791|NCT03687528|RADIATION|CT-scanner|After a clinical exam, patient have a CT-scanner to check any cerebral haemorrhage.
223887795|NCT06846983|DEVICE|Peripheral perfusion index pulse oximeter|Masimo pulse oximeter probe for measuring peripheral perfusion index and predicting success of caudal block
223887796|NCT03775096|DRUG|Carvedilol|At the end of Baseline visit, carvedilol 3.125 twice daily will be initiated and maintained for 1 week, increased to 6.25twice daily (dispensed at week 1visit), to 12.5mg twice daily (dispensed at week 2) and a max dose of 25mg twice daily (dispensed at week 4 visit), as tolerated. A subject that cannot tolerate at least a 25 mg daily dose will be excluded from the study. Subjects that cannot tolerate the 50 mg daily dose, will be offered to continue at the 25 mg daily dose. The project will include a washout period at study end.
223887797|NCT06847451|DIAGNOSTIC_TEST|Prognostic biomarker as Red Cell Distribution Width|Assessment of prognostic value of Red Cell Distribution Width in septic intensive care unit patients for 28 days mortality.
223887798|NCT03648840|BEHAVIORAL|Aversive Cue|Participants will be exposed to unpleasant pictures and tones during performance of a task to earn alcohol
223887799|NCT03648840|BEHAVIORAL|Neutral Cue|Participants will be exposed to neutral pictures and tones during performance of a task to earn alcohol
223887800|NCT03006913|BEHAVIORAL|In-person|At all sites, patients randomized to/preferring in-person counseling will meet with a counselor.
223887801|NCT03006913|BEHAVIORAL|By phone|Patients in the phone arm will receive a scheduled call at their home.
223887802|NCT03006913|BEHAVIORAL|By video|Because low income patients are not likely to have video conference capability at home, this service will be offered at all three hospitals, and patients will have scheduled appointments to come to the hospital to receive counseling delivered through a computer.
223887803|NCT05197816|DEVICE|Deep brain stimulation|Electrical pulses from implanted generator that adapts to patient activity and/or physiology
223887804|NCT05098795|BEHAVIORAL|Behavioral Activation (BA)|BA seeks to increase the positive reinforcement patients experience from their natural environment by promoting prosocial and valued experiences. BA has been found to improve substance use treatment retention and adherence, as well as medication adherence in low-income individuals with HIV/AIDS.
223887805|NCT03158805|DRUG|LIRAGLUTIDE|3 Mg/0.5 mL (18 Mg/3 mL) SUB-Q PEN INJECTOR (ML)
223887806|NCT03158805|OTHER|Placebo|Placebo injection
223887807|NCT04915495|DIAGNOSTIC_TEST|LuViva Advanced Cervical Scan|Multimodal hyperspectral device
223887808|NCT05988203|BIOLOGICAL|BNT166a|Multivalent ribonucleic acid (RNA)-based vaccine for active immunization against monkeypox administered as intramuscular injection.
223887809|NCT05930600|DEVICE|Ultrasonography of Internal Jugular Vein|Non invasive monitoring of fluid responsiveness
223887810|NCT05930600|DEVICE|Doppler Echocardiograhy|Non invasive monitoring of fluid responsiveness
223887811|NCT04381130|DRUG|EF-009|"Subjects who meet the eligibility criteria will have completed following evaluations and assessments before receiving treatment: a) review of medical and medication history; b) physical examination, vital signs and documentation of ECOG; c) ECG; d) routine serum biochemical, hematologic, urine pregnancy (if applicable) and urine laboratory assessments; and e) evaluation of European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30 score.~On Day 0, subjects will undergo EF-009 wafer implantation via laparoscopy"
223887812|NCT03219697|BEHAVIORAL|Parenting education program|8-week parent/caregiver education program, followed by two booster sessions. You and/or your partner will attend weekly parenting sessions which will take place either at the office of your child's primary care provider or virtually. Our Toronto Public Health Nurse, will arrange 2 home visits/virtual visits with you and your family along with 4 coaching calls during the 6 months. This first home visit will include learning more about your routines at home, and what is available in your neighbourhood. The home visits will focus on helping to apply the messages and skills from the group sessions for your family, and making connections in your community that you find helpful such as recreational or nutrition programs or other supports for your family.
223887813|NCT04035824|DRUG|Gastrodia and Uncaria granule|Patients allocated to the intervention group take 10g of Gastrodia and Uncaria granule each time, twice per day, and for two months.
223887814|NCT04035824|DRUG|Placebo of Gastrodia and Uncaria granule|Patients allocated to the control group take 10g of placebo of Gastrodia and Uncaria granule each time, twice per day, and for two months. The placebo has similar appearance and smell to genuine drug but has no effective anti-hypertensive agents.
223887815|NCT05568134|DIAGNOSTIC_TEST|Oral glucose tolerance test|"An oral glucose tolerance test will be completed. A fasting glucose will be measured.~Participants will drink 1.75 g/kg of dextrose (up to a maximum of 75 grams) within 10 minutes. Glucose values will be measured at 1 hour and 2 hours."
223887816|NCT03554109|DRUG|Leucovorin|L-Glutamic acid, N-\[4-\[\[(2-amino-5-formyl-1,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)methyl\]amino\]benzoyl\]-, calcium salt
223887817|NCT03554109|DRUG|5-Fluorouracil|5-fluoro-2,4 (1H,3H)-pyrimidinedione
223887818|NCT03554109|DRUG|Aldoxorubicin HCl|albumin-binding prodrug of doxorubicin HCl
223887819|NCT03554109|DRUG|nab-Paclitaxel|Benzenepropanoic acid, β-(benzoylamino)-α-hydroxy-(2aR, 4S, 4aS, 6R, 9S, 11S, 12S, 12aR, 12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a, 3, 4, 4a, 5, 6, 9, 10, 11, 12, 12a, 12b-dodecahydro-4,11-dihydroxy-4a, 8, 13, 13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca\[3,4\]benz\[1,2-b\]oxet-9-y1ester,(αR,βS)-(9CI) bound to albumin
223887820|NCT03554109|BIOLOGICAL|ETBX-011|Ad5 \[E1-, E2b-\]-CEA
223887821|NCT03554109|BIOLOGICAL|ETBX-051|Ad5 \[E1-, E2b-\]-Brachyury vaccine
223887822|NCT03554109|BIOLOGICAL|ETBX-061|Ad5 \[E1-, E2b-\]-mucin 1\[MUC1\]
223887823|NCT03554109|BIOLOGICAL|GI-4000|Vaccine derived from recombinant Saccharomyces cerevisiae yeast expressing mutant Ras proteins
223887824|NCT03554109|BIOLOGICAL|GI-6207|CEA yeast vaccine
223887825|NCT03554109|BIOLOGICAL|GI-6301|Brachyury yeast vaccine
223887826|NCT03554109|DRUG|Avelumab|Avelumab
223887827|NCT03554109|BIOLOGICAL|ALT-803|Recombinant human super agonist interleukin-15 (IL-15) complex
223887828|NCT03554109|BIOLOGICAL|haNK|NK-92 \[CD16.158V, ER IL-2\]
223887829|NCT03554109|DRUG|Cyclophosphamide|2-\[bis(2-chloroethyl)amino\]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
223887830|NCT03554109|DRUG|Doxorubicin HCL|Doxorubicin HCL
223887831|NCT03554109|DRUG|paclitaxel|paclitaxel
223887832|NCT05007613|DRUG|Cabozantinib 40 MG|Cabozantinib (Cabometyx) 40 MG PO QD
223887833|NCT05007613|DRUG|Atezolizumab Injection|atezolizumab (Tecentriq) 1200mg IVF 30-60mins Q3W
223887834|NCT03840421|DRUG|gemcitabine and cisplatin|Patients receive gemcitabine (1000 mg/m² d1,8) and cisplatin (80mg/m² d1) every 3 weeks for 3 cycles before concurrent chemoradiotherapy.
223887835|NCT03840421|DRUG|cisplatin and fluorouracil|Patients receive fluorouracil (800mg/m2 d1-5) and cisplatin (80mg/m² d1) every 3 weeks for 3 cycles before concurrent chemoradiotherapy.
223887836|NCT03840421|RADIATION|IMRT|Intensity modulated-radiotherapy (IMRT) is given as 30～33 fraction with five daily fractions per week for 6-7 weeks to a total dose of 68～70 Gy to the primary tumor
223887837|NCT03840421|DRUG|cisplatin|IMRT concurrently with cisplatin 100 mg/m² every 3 weeks for 2 cycles.
223887838|NCT05382936|DRUG|SL-901|Patients took study medication daily, with dosage based on their assigned cohort and regimen.
223887839|NCT03175666|BIOLOGICAL|avelumab|Fully human anti-PD-L1 IgG1 lambda monoclonal antibody
223887840|NCT03175666|BIOLOGICAL|bevacizumab|Recombinant human anti-VEGF IgG1 monoclonal antibody
223887841|NCT03175666|DRUG|capecitabine|5'-deoxy-5-fluoro-N-\[(pentyloxy) carbonyl\]-cytidine
223887842|NCT03175666|DRUG|cisplatin|(SP-4-2)-diamminedichloroplatinum(II)
223887843|NCT03175666|DRUG|cyclophosphamide|2-\[bis(2-chloroethyl)amino\]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
223887844|NCT03175666|DRUG|5-Fluorouracil|5-fluoro-2,4 (1H,3H)-pyrimidinedione
223887845|NCT03175666|DRUG|Leucovorin|Calcium N-\[p-\[\[\[(6RS)-2-amino-5-formyl-5,6,7,8-tetrahydro-4-hydroxy-6-pteridinyl\]methyl\]amino\]benzoyl\]-L-glutamate (1:1)
223887846|NCT03175666|DRUG|nab-paclitaxel|5β,20-Epoxy-1,2α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
223887847|NCT03175666|DRUG|Lovaza|omega-3-acid ethyl esters)
223887848|NCT03175666|RADIATION|Stereotactic Body Radiation Therapy|(SBRT)
223887849|NCT03175666|BIOLOGICAL|ALT-803|recombinant human super agonist interleukin-15 (IL-15) complex
223887850|NCT03175666|BIOLOGICAL|ETBX-011|adenovirus serotype-5 \[Ad5\] \[E1-, E2b-\]-CEA (carcinoembryonic antigen)
223887851|NCT03175666|BIOLOGICAL|ETBX-051|Ad5 \[E1-, E2b-\]-Brachyury
223887852|NCT03175666|BIOLOGICAL|ETBX-061|Ad5 \[E1-, E2b-\]-mucin 1 (MUC1)
223887853|NCT03175666|BIOLOGICAL|GI-4000|RAS yeast vaccine
223887854|NCT03175666|BIOLOGICAL|GI-6207|CEA yeast vaccine
223887855|NCT03175666|BIOLOGICAL|GI-6301|Brachyury yeast vaccine
223887856|NCT03175666|BIOLOGICAL|haNK|NK-92 \[CD16.158V, ER IL-2\], Suspension for Intravenous \[IV\] Infusion (haNK™ for Infusion)
223887857|NCT04584632|DEVICE|Efemoral Vascular Scaffold System (EVSS)|Balloon-expandable, bioresorbable vascular scaffolds coated with sirolimus
223887858|NCT05063994|DRUG|Chronocort|Over-encapsulated hydrocortisone modified-release capsule for oral administration.
223887859|NCT05063994|DRUG|Cortef|Over-encapsulated hydrocortisone immediate-release tablet for oral administration.
223887860|NCT05063994|OTHER|Placebo|Matching placebo
223887861|NCT03703700|DRUG|Zishen Yutai Pill|Patients who undergo the long-term protocol will start taking Zishen Yutai Pill on the day of pituitary suppression, 5g three times a day (Stopping on the first 1-4 days of menstruation), and patients who undergo the antagonist protocol will start taking Zishen Yutai Pill on the 19th to 23rd day of the previous menstruation cycle, 5g three times a day (Stopping on the first 1-4 days of menstruation). The drug will be taken till 2 weeks after transplantation. If the test result is confirmed as biochemical pregnancy (HCG\>50 IU/L), patients continue to take pills till 3 weeks after the clinical pregnancy determined by the ultrasound. If it is determined that the pregnancy test is negative, stop the drug.
223887862|NCT03703700|DRUG|Placebo|Patients who undergo the long-term protocol will start taking Placebo on the day of pituitary suppression, 5g three times a day (Stopping on the first 1-4 days of menstruation), and patients who undergo the antagonist protocol will start taking Placebo on the 19th to 23rd day of the previous menstruation cycle, 5g three times a day (Stopping on the first 1-4 days of menstruation). The drug will be taken till 2 weeks after transplantation. If the test result is confirmed as biochemical pregnancy (HCG\>50 IU/L), patients continue to take pills till 3 weeks after the clinical pregnancy determined by the ultrasound. If it is determined that the pregnancy test is negative, stop the drug.
223887863|NCT03085004|DRUG|Ethanol|The cyst will be lavaged for 3 to 5 minutes using \>/=99% ethanol as the lavage agent prior to infusing the cyst with the paclitaxel + gemcitabine admixture.
223887864|NCT03085004|DRUG|Normal saline|The cyst will be lavaged for 3 to 5 minutes using normal saline as the lavage agent prior to infusing the cyst with the paclitaxel + gemcitabine admixture.
223887865|NCT03085004|DRUG|Paclitaxel + Gemcitabine admixture|Following lavage, cysts will be infused with an admixture of 3mg/ml paclitaxel and 19mg/ml gemcitabine.
223887866|NCT05400317|DRUG|AD-218|PO, Once daily(QD), 12weeks
223887867|NCT05400317|DRUG|AD-218A|PO, Once daily(QD), 12weeks
223887868|NCT06245564|DRUG|Ketamine 0.5%|Ketamine cream 0.5% will be applied in a 4x4 area in the forearm of each participant.
223887869|NCT06245564|DRUG|Amitriptyline|Amitriptyline cream 1% will be applied in a 4x4 area in the forearm of each participant.
223887870|NCT06245564|DRUG|ketamine + amitriptyline|A cream containing ketamine 0.5%, amitriptyline 1%, will be applied in a 4x4 area in the forearm of each participant.
223887871|NCT06245564|OTHER|Vehicle|A vehicle cream will be applied in a 4x4 area in the forearm of each participant.
223887872|NCT06245564|OTHER|Histamine|After the cream removal, itch will be induced using histamine in the first session
223887873|NCT06245564|OTHER|Cowhage|After the cream removal, itch will be induced using cowhage in the second session
223887874|NCT01757626|BIOLOGICAL|Hu3F8 With GM-CSF|Ph I: 1 cycle consists of treatment with hu3F8 for 3 days (day 1, 3 \& 5). GM-CSF starts 5 days in advance of each hu3F8 cycle at 250 mcg/m\^2/day (day -4 to day 0), \& at 500 mcg/m\^2/day x 5 days (day 1 to day 5). Hu3F8 cycles are 5 days. Ph II pts may receive treatment on a modified schedule of 3 doses of IV hu3F8 over a maximum of 10 days, as needed. With modified schedules of hu3F8, GM-CSF will be administered at 250 mcg/m2/day x5 days before the 1st dose of hu3F8, as with the standard schedule, but then GM-CSF at 500 mcg/m2/day will be administered on day of the 1st dose of hu3F8, on the day before and on the day of the 2nd dose of hu3F8, and on the day before and on the day of the 3rd dose of hu3F8. Cycles are repeated at 2-4 week intervals between 1st days of hu3F8, through 4 cycles. Pts who complete 4 cycles of treatment w/o complications or disease progression have the option of continuing treatment for up to 24 months from their 1st dose of hu3F8.
223887875|NCT01757626|BIOLOGICAL|Hu3F8 With GM-CSF|As determined by the phase I component of the study, the hu3F8 dosage in the phase II portion is 3 mg/kg/day. Patients who were treated in the phase I component are eligible for treatment in the phase II portion. Cycles are repeated approximately monthly through 5 cycles. Group 1 and Group 3 patients can continue to receive cycles every 1-2 months for up to 24 months from study enrollment or until they receive 5 cycles after a major response (CR or PR) is achieved, whichever comes first. If HAHA becomes (+), cycles are deferred until it becomes (-) again. Patients who develop HAHA which precludes timely treatments with hu3F8+GM-CSF are eligible to receive low-dose maintenance regimens such as irinotecan alone,61 temozolomide alone,62 irinotecan-temozolomide,63 or cyclophosphamide-topotecan.64 They can also receive anti-HAHA agents such as rituximab and cyclophosphamide. They resume treatment with hu3F8+ GM-CSF if HAHA becomes negative. Patients may receive local radiation therapy.
223887876|NCT03323554|DEVICE|Ustrap®|Patients will receive Ustrap® under general or loco-regional anaesthesia, by perineal approach.
223887877|NCT03323554|DEVICE|AMS 800®|Patients will receive AMS 800® under general or loco-regional anaesthesia. Small openings are made near the scrotum and below the abdomen to insert an inflatable cuff, a pump and a small balloon (pressure regulating balloon).
223887878|NCT04509427|BEHAVIORAL|Instructional handouts|Handouts will include written instructions for each aspect of the multifaceted exercise/posture training program
223887879|NCT04509427|BEHAVIORAL|Physical therapist instruction and monitoring via teleconferencing|The intervention physical therapist (PT) meets with them via Zoom for 60 minutes to help them start the program in the first week. This PT will meet with them again in week 2 to complete initial instructions. The PT will meet with them week 3 and then every other week for 15-minutes to help individuals safely progress the program.
223887880|NCT04509427|BEHAVIORAL|Web-based instructional videos|Instructional videos that will lead participants through every part of the intervention - like a commercial exercise video.
223887881|NCT04509427|BEHAVIORAL|Posture training|Participants will learn how to hold a neutral spine posture during sitting, forward leaning in sitting, sit-to-stand-to-sit, standing, forward leaning in standing, supine-to-sit-to-supine, supine-to-prone-to-supine, and lifting. Principles learned with these functional movement patterns will then be put to practice in common tasks like sweeping, washing dishes, dusting, and gardening. This will be taught over two sessions in the first two weeks of the program. To reinforce holding neutral spine with all activities, participants will perform a 5-minute posture warm-up routine prior to exercising.
223887882|NCT04509427|BEHAVIORAL|Marching in place|Participants will perform marching in place five times a week. Participants will be instructed to slowly progress to a goal of performing 30 minutes of marching in place per session. They will be instructed to lift their knees to a height that is between their waist and knee when marching. They will be instructed to march between a rating of 10 -14 on the 20-point Borg scale for rate of perceived exertion
223887883|NCT03723772|DRUG|Insulin icodec|Participants will receive subcutaneous injections of insulin 287 once weekly for 8 weeks
223887884|NCT03723772|DRUG|IGlar U100|Participants will receive subcutaneous injections of insulin glargine once weekly for 2 weeks.
223887885|NCT05478837|DRUG|Cyclophosphamide|Given IV
223887886|NCT05478837|DRUG|Fludarabine|Given IV
223887887|NCT05478837|BIOLOGICAL|Autologous Anti-H3.3K27M TCR-expressing T-cells|Given IV
223887888|NCT04514757|DEVICE|active tVNS|20 Hz, 250ms at a current just below discomfort threshold for one hour twice a day, starting on post-day 0. Stimulation will continue until 5 days post-operatively or discharge.
223887889|NCT04514757|DEVICE|sham tVNS|Current set a 0 mA, starting on post-op day 0. Stimulation will continue until 5 days post-operatively or discharge.
223887890|NCT06757933|COMBINATION_PRODUCT|The Spencer technique|The Spencer technique, which consists of seven different manual movements intended to increase shoulder mobility and lessen pain, was used to treat the participants in this group. The method seeks to improve blood flow, loosen up the shoulder joint and soft tissues, and reduce any tightness or impingement that is causing pain in the sub-acromial area. By re-establishing appropriate shoulder function and movement patterns, the Spencer approach is commonly used to treat disorders including adhesive capsulitis.
223887891|NCT06757933|COMBINATION_PRODUCT|isotonic workouts|This group's members engaged in isotonic workouts that emphasized forward flexion and extension motions. Both concentric (shortening the muscle) and eccentric (lengthening the muscle) motions were used in these exercises. These exercises were designed to increase shoulder range of motion and strengthen the rotator cuff muscles. People with Adhesive Capsulitis may have less pain and have better shoulder function if they perform isotonic workouts, which increase muscular strength and stability.
223887892|NCT05697211|DRUG|Ferric maltol 30 mg (Feraccru®)|In this trial Feraccru® 30 mg hard capsules will be used. Each capsule contains 30 mg iron (as ferric maltol), 91.5 mg of lactose, 0.5 mg of Allura Red AC (E129) and 0.3 mg Sunset Yellow FCF (E110) as excipients with known effects.
223887893|NCT06273228|BEHAVIORAL|Family Check-Up Online|This intervention includes access to the Family Check-Up Online website and telehealth coaching provided by trained mental health providers.
223887894|NCT04746677|DEVICE|Endovascular aortic repair with a physician-modified endovascular graft (PMEG)|Endovascular aortic repair with a physician-modified endovascular graft (PMEG)
223887895|NCT05714397|DEVICE|Cingal|A single Cingal injection will be administered by fellowship-trained physicians through ultrasound-guided injection using a 20-gauge needle into the joint space of the knee under sterile conditions. The needle track will be anesthetized with local anesthetic.
223887896|NCT06105463|OTHER|Strength training sessions and High-interval intensity training sessions|"During strength training sessions, participants will perform 4 lower limb exercises, including bilateral leg press, unilateral leg extension, unilateral hip extension, and bilateral seated calf raise on conventional weight machines. The intensity of the session will be 70-75% of 1-RM, 4 sets, 10 repetitions (1-2 RIR) and 120 seconds rest between sets.~During High-interval intensity training (HIIT) sessions, participants will perform 10 minutes of warm-up at 50% of peak power + 20 minutes of HIIT consisting of 30 seconds at 90% of peak power followed by 30 seconds of rest + 10 minutes of cool-down at 35-40% of peak power in cycloergometer."
223887897|NCT04581603|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|CBT-I is conducted weekly for eight sessions during which the subjects meet individual with the study clinician for 45 minutes on the first session and for 30 minutes for sessions 2-8. Session 1 serves as an orientation and the onset of Sleep Restriction Therapy. Sessions 2 \& 3 deliver the three main components that include, Sleep Restriction Therapy, Stimulus control, and Sleep Hygiene. All the sessions excluding the last two sessions are dedicated to the titration of total sleep time and to ensure patient adherence. The fifth session is used to deliver a specific form of cognitive therapy. The final session is used to engage the patient in a relapse-prevention didactic (i.e., to review how insomnia becomes chronic and strategies that abort an extended episode of insomnia). The subject will return on week 9 to complete the post-intervention visit after 8 weeks of behavioral sleep treatment.
223887898|NCT04581603|BEHAVIORAL|Sleep Hygiene Education|This non-active control arm of behavioral sleep intervention consists of psychoeducation on sleep hygiene, sleep-related disturbances, and the effects of stress on sleep that will be delivered weekly for 8 weeks, for a time duration that is identical to the CBT-I sessions. The effect of stress on sleep is a commonly used control condition in insomnia clinical trials. SHE is preferred to a monitor-only condition as it will control for contact with the therapist and elapsed time during sessions. The subject will return on week 9 to complete the post-intervention visit after 8 weeks of behavioral sleep treatment.
223887899|NCT05543746|DRUG|Brexanolone|Enrolled subjects will receive a 60-hour infusion of Brexanolone (BRX) according to FDA approved protocol for administration. A programmable peristaltic infusion pump will be used to ensure accurate delivery.
223887900|NCT04630262|DEVICE|ATTUNE Cementless CR Fixed Bearing|Subjects Implanted with the ATTUNE Cementless Femoral, Cementless Tibia, and CR or (Medial Stabilized) MS Tibial Insert.
223887901|NCT04630262|DEVICE|ATTUNE Cementless PS Fixed Bearing|Subjects Implanted with the ATTUNE Cementless Femoral, Cementless Tibia, and PS Tibial Insert.
223887902|NCT06123884|DRUG|Recombinant humanized anti-PD-1 monoclonal antibody injection|Strength 100 mg/4 mL, intravenous drip, recommended dose 300 mg, administered every 3 weeks (21 days) (Q3W).
223887903|NCT06123884|DRUG|Cisplatin|the usage and dosage should be determined by the investigator
223887904|NCT06123884|DRUG|Bevacizumab Injection|Strength 100 mg/4 mL, recommended dose 15 mg/kg body weight, administered every 3 weeks (15 mg/kg, Q3W)
223887905|NCT06123884|DRUG|carboplatin|the usage and dosage should be determined by the investigator
223887906|NCT06123884|DRUG|Paclitaxel for Injection|the usage and dosage should be determined by the investigator
223887907|NCT06285409|DRUG|Carbetocin|Carbetocin first bolus 10-8 M (equivalent to 100 mcg) will be added to the muscle bath to create ex-vivo environment similar to Cesarean delivery, and after 20 minutes the baths will be washed three time with physiological salt solution (PSS).
223887908|NCT06285409|DRUG|Oxytocin|Oxytocin 10-5M will be added to all strips for 2 hours to induce desensitization.
223887909|NCT06285409|DRUG|Carbetocin|Increasing concentrations of carbetocin in a pattern of 1 log molar increase every 10 min, from 10-5 M to 10-5 M
223887910|NCT06285409|DRUG|Oxytocin|Increasing concentrations of oxytocin from 10-10 M to 10-5 M
223887911|NCT06285409|DRUG|Ergonovine|Increasing concentrations of ergometrine from 10-10 M to 10-5 M
223887912|NCT06285409|DRUG|Carboprost|Increasing concentrations of carboprost from 10-10 M to 10-5 M
223887913|NCT05114460|DRUG|Naloxone|Intranasal Naloxone
223887914|NCT05114460|DRUG|Marijuana|Vaped Marijuana
223887915|NCT06130995|DRUG|Relugolix and Enzalutamide|"Dose level of Relugolix and Enzalutamide Safety Lead-in Cohort, 3-12 patient. Relugolix;120 mg, oral, once daily, with a loading dose of 360 mg on day 1, Enzalutamide; 120-160 mg, oral, once daily.~Dose Expansion Cohort, up to 34 patients. Relugolix;120 mg, oral, once daily, with a loading dose of 360 mg on day 1, Enzalutamide; To be determined by safety lead-in cohort.~One cycle = 3 months The dose limiting toxicity (DLT) period is the first 28 days~Neoadjuvant ADT: 6 months; Relugolix: 120 mg orally, daily (with a 360 mg loading dose on day 1, Enzalutamide: 160 mg (or 120 mg) orally, daily~Concurrent ADT during Radiation Therapy; Relugolix: 120 mg orally, daily (with a 360 mg loading dose on day 1, Enzalutamide: 160 mg (or 120 mg) orally, daily~Maintenance ADT: Additional 18 months; Relugolix: 120 mg orally, daily (with a 360 mg loading dose on day 1, Enzalutamide: 160 mg (or 120 mg) orally, daily"
223887916|NCT06351150|DRUG|Angiotensin II Injection|1、Angiotensin II injection is a naturally occurring octapeptide hormone in the human renin angiotensin aldosterone system (RAAS). It is the main effector molecule of the RAAS system and one of the strongest known vasoconstrictors, involved in neurohumoral regulation.
223887917|NCT06351150|DRUG|0.9% sodium chloride injection|0.9% sodium chloride injection, not containing active ingredients.
223887918|NCT01857934|DRUG|cyclophosphamide|Given intravenously (IV)
223887919|NCT01857934|DRUG|topotecan|Given IV
223887920|NCT01857934|BIOLOGICAL|hu14.18K322A|Given IV
223887921|NCT01857934|PROCEDURE|peripheral blood stem cell harvest|Following evaluation and approval by a member of the transplant staff and completion of the consent form by the participant, collection of peripheral blood stem cells (PBSC) may take place.
223887922|NCT01857934|PROCEDURE|surgical resection|The primary tumor will be resected surgically following two initial courses of chemotherapy, if feasible. Patients who are unable to have their primary tumor resected after the initial two courses of induction chemotherapy will undergo surgery for resection of the primary tumor mass and careful lymph node staging.
223887923|NCT01857934|DRUG|cisplatin|Given IV
223887924|NCT01857934|DRUG|etoposide|Given IV
223887925|NCT01857934|DRUG|doxorubicin|Given IV
223887926|NCT01857934|DRUG|vincristine|Given IV
223887927|NCT01857934|DRUG|busulfan|Given IV
223887928|NCT01857934|DRUG|melphalan|Given IV
223887929|NCT01857934|BIOLOGICAL|peripheral blood stem cell transplantation|Transplantation of previously harvested peripheral blood stem cells.
223887930|NCT01857934|BIOLOGICAL|natural killer cell infusion|Natural killer (NK) cells obtained from a suitable donor will be given together with hu14.18K322A prior to early hematopoietic cell recovery. In the event there is not a suitable parental donor, consenting participants will receive an additional course of hu14.18K322A.
223887931|NCT01857934|RADIATION|radiation therapy|Radiation therapy to the primary and metastatic disease sites will follow peripheral blood stem cell transplant with the exception of any patient requiring emergent radiotherapy. External beam radiotherapy will be delivered to the primary site and select metastatic and bulky nodal sites.
223887932|NCT01857934|BIOLOGICAL|GM-CSF|Given subcutaneously (SQ)
223887933|NCT01857934|BIOLOGICAL|G-CSF|Given subcutaneously (SQ)
223887934|NCT01857934|DRUG|mesna|Given IV
223887935|NCT01857934|DRUG|levetiracetam|Given IV
223887936|NCT01857934|BIOLOGICAL|interleukin-2|Given by continuous infusion during MRD maintenance, and SQ during induction.
223887937|NCT01857934|DRUG|Isotretinoin|Given orally (PO)
223887938|NCT01857934|DEVICE|CliniMACS|The mechanism of action of the CliniMACS Cell Selection System is based on magnetic-activated cell sorting (MACS). The CliniMACS device is a powerful tool for the isolation of many cell types from heterogeneous cell mixtures, (e.g. apheresis products). These can then be separated in a magnetic field using an immunomagnetic label specific for the cell type of interest, such as CD3+ human T cells.
223887939|NCT04165941|BIOLOGICAL|DRI cell therapy|Drug Resistant Immunotherapy with gamma delta modified T cells to be resistance to temozolomide will be infused into the surgical cavity following the completion of standard concurrent radiation and chemotherapy with temozolomide.
223887940|NCT05155319|BIOLOGICAL|UFluA 20 µg each antigen/dose|Low dose
223887941|NCT05155319|BIOLOGICAL|UFluA 60 µg each antigen/dose|High Dose
223887942|NCT05155319|BIOLOGICAL|Placebo|Placebo
223887943|NCT04681105|DRUG|Acetaminophen|Given PO
223887944|NCT04681105|DRUG|Dexamethasone|Given IV
223887945|NCT04681105|DRUG|Diphenhydramine|Given IV or PO
223887946|NCT04681105|BIOLOGICAL|Flotetuzumab|Given IV
223887947|NCT04681105|DRUG|Ibuprofen|Given PO
223887948|NCT04681105|DRUG|Ranitidine|Given IV
223887949|NCT04273828|PROCEDURE|Lumbar decompressive surgery|Patients with lumbar degenerative diseases and symptoms of nerve compression (radiculopathy or neurogenic claudication) who will undergo surgical treatment for neural decompression (discectomy, foraminotomy or laminectomy).
223887950|NCT05336903|BEHAVIORAL|APP-led model of care for chronic pain management|"The APP will provide an assessment using a biopsychosocial approach. The assessment will include:~* taking a comprehensive history~* screening for pathologies contributing to the participant's chronic pain~* a physical assessment~* screening for comorbid health conditions, using the appropriate screening tools, that require specific care (e.g., depression, addiction, post-traumatic stress)~* identifying psychosocial risk factors associated with pain and disability~* evaluating pain severity and interference~The APP will make recommendations to the participant and the chronic pain clinic health care team based on findings from the comprehensive assessment. These recommendations include, but are not limited to, the need for urgent or emergent referrals, medication management, referral and integration of other health care providers, the need for interventional procedures, or group-based treatment options."
223887951|NCT03984695|BEHAVIORAL|SHE-WOMEN|SHE-WOMEN is a text-Web intervention designed to increase jail-involved women's health literacy, reduce risk, and increase screening for prevention of cervical cancer, breast cancer, unintended pregnancy, and sexually transmitted infections.
223887952|NCT04638998|PROCEDURE|Magnetic Resonance Spectroscopic Imaging|MRSI is a non invasive imaging technique used to detect neuroinflammation.
223887953|NCT04638998|PROCEDURE|Blood draw|Blood will be drawn to assess systemic inflammation in Gulf War verterans.
223887954|NCT03692676|DEVICE|Spiriva Respimat|soft-mist inhaler
223887955|NCT05218174|OTHER|Exercise Prescription|In this prospective, randomized control trial, the investigators will compare functional exercise capacity, cognitive performance, and emotional well-being at baseline and following 2 conditions: (1) an 8-week exercise training program (intervention) or (2) no training program (control). Participants will be randomized using a 1:1 randomization scheme into either the intervention or control group. After 8 weeks, participants in the wait-list control group will begin the intervention for the next 8 weeks and activity undergone by participants first randomized into the intervention group will remain under observation.
223887956|NCT02218996|OTHER|Psychosocial treatment|Regular psychosocial treatment in clinical outpatient service.
223887957|NCT04044937|DRUG|F-18 Fluoroethyltyrosine (FET)|Patients given an injected dose of 4 to 7 millicurie (mCi) of FET per scan. The radiopharmaceutical will be administered while the patient is in the PET scanner
223887958|NCT04044937|PROCEDURE|Positron Emission Tomography (PET)|All patients receive single PET imaging lasting for 40 minutes. Acquired PET data will be reconstructed so that three time points are created: (1) Perfusion: 60-second acquisition that starts immediately when activity is noted in the field of view, (2) Equilibrium: 10-minute acquisition acquired between 10 and 20 minutes after injection, and (3) Washout: 10-minute acquisition acquired between 30 and 40 minutes after injection. A repeat PET image will be offered to adult patients.
223887959|NCT05997589|BEHAVIORAL|Behavioral Intervention|Receive educational materials
223887960|NCT05997589|OTHER|Educational Intervention|Attend financial health educational program
223887961|NCT05997589|OTHER|Questionnaire Administration|Ancillary studies
223887962|NCT05831540|OTHER|Discussion|Participate in focus group
223887963|NCT05831540|OTHER|Educational Activity|Undergo training to use CDS tool
223887964|NCT05831540|BEHAVIORAL|Healthcare Activity|Utilize CDS tool
223887965|NCT05831540|OTHER|Survey Administration|Complete survey
223887966|NCT05053737|DRUG|Atezolizumab|One cycle of Atezolizumab will be administered by intravenous (IV) infusion at a fixed dose of 1200 mg. Atezolizumab should be administered within 7 days after initiation of of the first dose of SBRT.
223887967|NCT05053737|RADIATION|Stereotactic Body Radiation Therapy|SBRT will be given 3 times on non-consecutive days over the course of 5 to 7 days. Radiation will target sites of gross disease only to minimized exposure to normal tissue.
223887968|NCT05877014|OTHER|questionnaires|EQ-5D-5L and SF-12
223887969|NCT05877014|OTHER|scanner|CT scan at M9 and then at M12 if the humerus is not consolidated at M6
223887970|NCT05164367|DRUG|Atropine sulfate gel (0.01%)|A research nurse will measure 1 gram of gel using a calibrated measuring spoon and will provide it to the participant for self-administration.
223887971|NCT05831657|OTHER|Prevent It 2.0|A free, anonymous, internet-delivered, therapist assisted, cognitive behavioral therapy (CBT) intervention
223887972|NCT05831657|OTHER|Waitlist|Participants in the waitlist control will wait thirteen weeks before starting active treatment. While on the waitlist, participants will respond to questions about ongoing problematic sexual behavior.
223887973|NCT04966104|BEHAVIORAL|ODYSSEE-vCHAT|Automated digital counselling program with social network support
223887974|NCT06166004|OTHER|Balance Training|Balance Training device with VR
223887975|NCT06166004|OTHER|Person-Specific Rehabilitation Program|Person-Specific Rehabilitation Program
223887976|NCT06786403|DIETARY_SUPPLEMENT|Bromelain|Dietary Supplement: Bromelain 1000 mg/day
223887977|NCT06786403|DIETARY_SUPPLEMENT|Placebo|Placebo (1000 mg/day)
223887978|NCT06786221|DEVICE|mini-implant template|"The proposed structure will be made of three main components: a tooth guide part, a gingival guide part, and a steering part. The tooth guide and gingival guide parts are firmly connected by fracture lines. The mini-implant guide part is specifically designed to accommodate the angle and position required for miniscrew insertion. On the basis of the resin guide plate, add a guide hole structure and change it to simulate the patient's actual tooth root condition.~During usage, the guide can be pre-designed in accordance with the desired planting position and direction of the patient's mini-implant, enabling precise guidance during the implantation process. The designed guide's data is inputted into EnvisionTEC Vida 3D printer to create the mini-implant guide. Prior to the implantation of the mini-screw, patients will be informed about the potential risks and required to sign an informed consent form."
223887979|NCT06784986|DEVICE|The Conventional Insufflation System|The Conventional Insufflation System employs standard CO2 insufflation techniques for maintaining intra-abdominal pressure during laparoscopic and robotic surgeries. It serves as the base for comparison with the AirSeal® System.
223887980|NCT06784986|DEVICE|AirSeal® System|The AirSeal® System consists of an insufflation, filtration, and recirculation system (AirSeal® IFS), a triple-lumen filtered tube set, and a valve-free trocar (AirSeal® Access Port). This innovative system allows peritoneal access and pneumoperitoneum maintenance without a mechanical seal, reducing CO2 usage and associated complications.
223887981|NCT06783270|BIOLOGICAL|TIL therapy|Compared to traditional TIL-therapy, this study will include silencing of the PD-1 coding gene in the TILs using non-viral CRISPR-Cas9 prior to the rapid expansion protocol.
223887982|NCT06787989|BIOLOGICAL|BCMA-CD19 cCAR T cells|• BCMA-CD19 cCAR T cells are used to treat patients. Patient will be administered either fresh or thawed CAR T cells by IV injection after receiving lymphodepleting chemotherapy.
223887983|NCT06276725|BEHAVIORAL|Writing Wrongs|A repeated exposure writing practice targeting symptoms resulting from microaggressions experienced by minoritized students at predominantly White institutions.
223887984|NCT06185296|DEVICE|Intelligent telemonitoring|Telemonitoring using CGM, insulin pen data, and Fitbit data supported by data-driven decision support.
223887985|NCT06185296|DEVICE|Telemonitoring|Telemonitoring using CGM, insulin pen data, and Fitbit data
223887986|NCT04238364|DRUG|EI-1071|EI-1071 Tablet(s)
223887987|NCT04238364|DRUG|Placebo|Matching Placebo Tablet(s)
223887988|NCT06059144|DRUG|Peripheral intravenous norepinephrine|Norepinephrine (dilution: 10µg/ml, initial dose: 0.04µg/kg/min) will be titrated until MAP is between 110 and 120mmHG (with a maximal systolic blood pressure of 210mmHG) Gradually decrease of norepinephrine will start after 24h of NIHSS stabilization.
223887989|NCT03394079|PROCEDURE|PCI|Percutaneous Coronary Intervention
223887990|NCT05151380|DEVICE|CO2 laser MonaLisa Touch ®|"3 sessions of SmartXide fractional CO2 laser via the MonaLisa Touch® device, spaced 4 weeks apart, will be performed. An additional comfort session will be performed at 1 year if needed.~The handpiece of the MonaLisa Touch® device is applied to the vaginal walls with a 360° scan, between 800 and 1100µs, to the vaginal orifice"
223887991|NCT04490915|DRUG|Crinecerfont|CRF type 1 receptor antagonist
223887992|NCT04490915|DRUG|Placebo|Non-active dosage form
223887993|NCT03149315|DRUG|Ibrutinib|Ibrutinib 420mg, PO once daily for 2-7 days
223887994|NCT05559541|DRUG|AK119|AK119 is an anti-CD73 monoclonal antibody.
223887995|NCT05559541|DRUG|AK104|AK104 is an anti-PD-1 and CTLA-4 bispecific antibody.
223887996|NCT05440383|DRUG|KLH-2109|Oral administration
223887997|NCT05440383|DRUG|Leuprorelin|Subcutaneous administration
223887998|NCT06065384|OTHER|experimental group: intensive motor training|Intervention group: receive an extra 6 hours of motor training each week (distributed over the week) for 8 weeks. It will involve active and targeted motor training of all affected muscles of the upper limb below the level of the injury within the context of practice of functional activities. Interventions will be goal directed and individualized to the needs of each participant with a focus on training that addresses each person's specific motor problem, promoting motor learning as well as stimulating neural plasticity. All patients will continue to receive usual physiotherapy and usual rehabilitation.
223887999|NCT06065384|OTHER|usual care|usual rehabilitation
223888000|NCT03841669|BEHAVIORAL|Aerobic Exercise Group|Guidelines for exercise programming (ACSM, 2018) will be followed including a warm up and cool down, progressive and gradual increments in duration, and instruction regarding avoidance of physical activity related injury. The exercise group will receive moderate to vigorous intensity aerobic exercise targeting 150 minutes per week for 12 months. The group will target dividing these minutes into 3 exercise sessions a week. The prescribed intensity will be based on their maximal fitness testing heart rate and then calculated per a research grade method. They will maintain a minimum heart rate from their specific calculation that will be monitored by Polar Heart Rate straps.
223888001|NCT03841669|BEHAVIORAL|Physical Activity & Health Information Group|This group will not partake in the aerobic fitness sessions but will be asked to wear a daily monitoring device every 6 weeks. They will also complete all baseline, 6-month (optional), and 12-month visits.
223888002|NCT05406921|BEHAVIORAL|MIND at Home|Maximizing Independence at Home-MIND at Home (MIND) is a comprehensive care coordination program born from geriatric psychiatry. This model takes an interdisciplinary, collaborative care approach to care by systematically assessing and addressing a wide range of dementia-care related needs of both PLWD and their care partners that place both at increased risk for poor outcomes.
223888003|NCT05209100|PROCEDURE|Sigmoidoscopy|During the sigmoidoscopy, biopsy tissue will be obtained for research purposes. Biopsies will be performed based on typical standard of care procedures without an antecedent bowel prep.
223888004|NCT03393598|DEVICE|pre-expansion using Kiwi® VAC-6000M.|The pre-expansion will be performed with Kiwi® VAC-6000M with the PalmPumpTM.
223888005|NCT03393598|DEVICE|pre-heating using Hilotherm Calido®.|The pre-heating will be performed with Hilotherm Calido®.
223888006|NCT03393598|DEVICE|pre-expansion-heating|Both preconditioning methods - Kiwi® VAC-6000M and additionally Hilotherm Calido® - will be applied.
223888007|NCT06233838|DEVICE|KHA80 hemoperfusion treatment|On the basis of hemodialysis or hemodiafiltration treatment, Jianfan KHA80 hemoperfusion treatment was given, and the frequency of hemoperfusion treatment was ≥2 times/month.
223888008|NCT06154408|DIETARY_SUPPLEMENT|omega-3 fatty acids|The active treatment, supplied by Soloways, LLC., contained omega-3 fatty acids (1000 mg of fish oil, of which 600 mg were eicosapentaenoic acid and 300 mg docosahexaenoic acid) per capsule. The subjects will take 2 capsules daily.
223888009|NCT06154408|DIETARY_SUPPLEMENT|Placebo|placebo capsules identical in appearance, matched for color coating, shape, and size with omega-3 fatty acids capsule
223888010|NCT04733495|OTHER|Counseling|Receive group-based behavioral counseling
223888011|NCT04733495|BEHAVIORAL|Dietary Counseling and Surveillance|Receive dietary counseling
223888012|NCT04733495|OTHER|Quality-of-Life Assessment|Ancillary studies
223888013|NCT04733495|OTHER|Questionnaire Administration|Ancillary studies
223888014|NCT04733495|OTHER|Resistance Training|Undergo personalized resistance exercises
223888015|NCT04795440|PROCEDURE|Testicular biopsy|Performance of a testicular biopsy with the intention of obtaining spermatozoa for the insemination of oocytes with the ICSI technique.
223888016|NCT05682482|DRUG|LT3 (liothyronine)|Addition of liothyronine (LT4/LT3 combination therapy) in patients with persistent tiredness on LT4 monotherapy. To investigate whether addition of LT3 is effective in relieving tiredness.
223888017|NCT05682482|DRUG|Placebo|Addition of placebo (LT4 monotherapy) in patients with persistent tiredness on LT4 monotherapy.
223888018|NCT04190303|OTHER|Pragmatic, multi-component package|This system-level intervention will be tailored to the needs and capacity of each hospital site, co-developed with policymakers and hospital staff
223888019|NCT04541446|OTHER|Dynamic Haptic Robotic Trainer (DHRT)|Device trains medical residents to safely perform the needle insertion portion of Central Venous Catheterization.
223888020|NCT04541446|OTHER|Advanced Dynamic Haptic Robotic Trainer (DHRT+)|Device offers whole procedural training for medical residents to safely perform the procedure of Central Venous Catheterization.
223888021|NCT04027309|DRUG|Gilteritinib|Patients with a FLT3 mutation w ill be randomized to receive either the investigational drug gilteritinib or midostaurin given sequentially to standard induction and consolidation chemotherapy. After completing induction and consolidation treatment, patients who achieve CR/CRi/MLFS will receive maintenance therapy with gilteritinib or midostaurin
223888022|NCT04027309|DRUG|Midostaurin|Patients with a FLT3 mutation w ill be randomized to receive either the investigational drug gilteritinib or midostaurin given sequentially to standard induction and consolidation chemotherapy. After completing induction and consolidation treatment, patients who achieve CR/CRi/MLFS will receive maintenance therapy with gilteritinib or midostaurin
223888023|NCT02829814|DRUG|TNX-102 SL Tablet, 2.8 mg|Patients will take 1 tablet of randomly assigned study drug sublingually each day at bedtime starting on Day 0 for 12 weeks.
223888024|NCT02829814|DRUG|Placebo SL Tablet|Patients will take 1 tablet of randomly assigned study drug sublingually each day at bedtime starting on Day 0 for 12 weeks.
223888025|NCT03205696|DRUG|Antiretrovirals|The antiretroviral (ARV) regimen provided by the clinician must follow DHHS guidelines for antiretroviral naïve adolescents and adults
223888026|NCT01280994|DRUG|Hyperpolarized 129Xenon Gas|Hyperpolarized 129Xenon Gas will be administered in multiple doses in volumes that are tailored to the subject's total lung capacity (TLC) followed by a breath hold of up to 15 seconds. Subsequent 129Xe doses will only be administered once the subject is ready to proceed.
223888027|NCT06394414|DRUG|YL201|YL201 (High dose, medium dose and low dose; Q3W) in Combination with Serplulimab (4.5mg/kg; Q3W) with or without Platinum(70 mg/m2; Q3W)-based Chemotherapy.
223888028|NCT06335901|DRUG|Drug:Standard therapy|Percutaneous coronary Intervention
223888029|NCT04692597|DEVICE|Phoenix Thera-Lase System|Low level laser therapy (LLLT) using Phoenix Thera-lase device (74 Watts, 1275 nm wavelength) for 6 minutes per affected hand.
223888030|NCT04692597|DEVICE|SHAM Phoenix Thera-Lase System|Sham LLLT using the Phoenix Thera-lase device with the guide light on but without emitting laser photons for 6 minutes per affected hand.
223888031|NCT02073994|DRUG|AG-120|AG-120 administered continuously as a single agent dosed orally on Days 1 to 28 of a 28-day cycle. Subjects may continue treatment with AG-120 until disease progression or development of other unacceptable toxicity
223888032|NCT03002025|DRUG|JNJ-64304500|Participants will receive JNJ-64304500 as SC injection.
223888033|NCT03002025|DRUG|Placebo|Participants will receive matching placebo to JNJ-64304500 as SC injection.
223888034|NCT04793776|BEHAVIORAL|Manage Emotions to Reduce Aggression|MERA begins with education about the adaptive nature of emotions, how childhood and military experiences can influence emotion regulation, and how combat requires different emotion regulation strategies than most civilian environments. MERA use modeling and practice with feedback to teach cognitive-behavioral and acceptance-based emotion regulation skills.
223888035|NCT04793776|BEHAVIORAL|Present Centered Psychotherapy|PCT will serve as the comparison group. PCT assists Veterans in understanding and coping with current difficulties, such as aggression, but does not provide systematic training in emotion regulation skills.
223888036|NCT06562140|OTHER|No intervention - cross-sectional observational study|No intervention - cross-sectional observational study
223888037|NCT06445010|OTHER|Creating Musical Playlist|Personal music playlist for therapeutic listening and sharing with other individuals in bereavement
223888038|NCT05878561|DRUG|Fimasartan + Indapamide|a fixed dose combination
223888039|NCT05878561|DRUG|Fimasartan + Indapamide placebo|a fixed dose combination
223888040|NCT05139862|DEVICE|Repetitive Transcranial Magnetic Stimulation|This study utilizes intermittent theta burst stimulation (iTBS) to the left DLPFC.
223888041|NCT05290610|OTHER|Functional mapping|Intracranial EEG data acquisition, observation and behavioral testing, and intracranial electrical stimulation
223888042|NCT05747937|DIAGNOSTIC_TEST|Skin biopsy|A punch skin biopsy of 3mm will be used to analyze cutaneous innervation
223888043|NCT05747937|DIAGNOSTIC_TEST|Cardiovascular Reflexes testing|Cardiovascular reflex tests including deep breathing, head-up Tilt, standing, isometric exercises, mental arithmetic and Valsalva maneuver.
223888044|NCT05747937|DIAGNOSTIC_TEST|Administration of clinical scales evaluating autonomic symptoms, pain small fiber neuropathy symptoms|We'll characterize patients' symptoms through the administration of clinical scales such as: SCOPA-AUT autonomic symptoms scale; Brief Pain Inventory questionnaire
223888045|NCT05747937|DIAGNOSTIC_TEST|Dinamic Sweat Test|Test for the functional assessment of postganglionic sudomotor pathway
223888046|NCT06276543|DEVICE|antibiotic-impregnated catheter|Hydrocephalus patient implant with antibiotic-impregnated catheter to shunt their cerebrospinal fluid.
223888047|NCT06370091|OTHER|Gum of Xylitol|After each sample, the salivary pH level will be measured, and the amount of basal saliva will be weighed. This amount will be subtracted from the accumulated saliva at T4 to establish salivary flow
223888048|NCT06370091|OTHER|Gum of sugar free|After each sample, the salivary pH level will be measured, and the amount of basal saliva will be weighed. This amount will be subtracted from the accumulated saliva at T4 to establish salivary flow
223888049|NCT06370091|OTHER|Gum of sugar|After each sample, the salivary pH level will be measured, and the amount of basal saliva will be weighed. This amount will be subtracted from the accumulated saliva at T4 to establish salivary flow
223888050|NCT06370091|OTHER|Paraffin wax|After each sample, the salivary pH level will be measured, and the amount of basal saliva will be weighed. This amount will be subtracted from the accumulated saliva at T4 to establish salivary flow
223888051|NCT06320964|BEHAVIORAL|TARANG|For newly married women, the intervention had one introductory rapport-building session, followed by 16 group sessions facilitated by trained female moderators over 5 months. The intervention aimed to empower participants by enhancing their understanding of fundamental topics such as menstruation, conception, and contraception, choice of a method among others. Sessions also covered topics to strengthen participants' sense of agency and their ability to make informed decisions regarding family planning and the timing of their first childbirth. Similarly, for husbands, a male moderator delivered sessions on four topics: Love, Relationships and Expectations; Conception and Health; Contraception Methods, and how to choose family planning methods. For MILs, a female moderator covered four sessions: Nutrition flag, Conception and Health, communication between family members, and the final session on relationships with daughter-in-law.
223888052|NCT04469036|OTHER|Virtual Pediatric Trauma Center|Telehealth
223888053|NCT05616026|BEHAVIORAL|Intervention|6 months of diabetes management support via SMS texts including reminders for medication adherence, appointments, and diabetes self-care activities as well as education, and support
223888054|NCT05616026|BEHAVIORAL|Attention Control|6 months of texts for general health promotion
223888055|NCT06535230|DRUG|Manual anesthesia induction|In manual anesthesia induction, anesthetic agents are administered at a fixed dose and rate adjusted according to the patient's weight
223888056|NCT06535230|DRUG|Anesthesia induction with Target controlled infusions (TCI)|Target controlled infusion (TCI) system aims to reach the theoretically targeted blood or brain concentration of anesthetic agents based on the patient's age, weight, and height, with computer-assisted algorithms.
223888057|NCT06535230|DEVICE|Hemodynamic monitoring with pressure recording analytical method (PRAM)|The pulse contour device MostCare (Vytech, Vygon, Padova, Italy) provides functional hemodynamic monitoring using the pressure recording analytical method.
223888058|NCT04544046|OTHER|Supportive Oncology Care at Home|Remote monitoring of symptoms, vital signs, and body weight with home-based care to address any concerning issues identified.
223888059|NCT04544046|OTHER|Usual Care|Standard care arm will receive standard oncology care and attend regular clinic visits.
223888060|NCT06508541|PROCEDURE|ICG Guided surgery|In ICG guided surgery group,Approximately 0.3 ml of ICG dissolved in 2.5 mg/ml of sterile water was injected submucosally by the endoscopic doctors through colonoscopy at two points around the tumor.All patients underwent standard complete mesocolic excision (CME) or total mesorectal excision (TME) with curable purpose using ICG lymphangiography procedure
223888061|NCT06508541|PROCEDURE|conventional surgery|All patients underwent standard complete mesocolic excision (CME) or total mesorectal excision (TME) with curable purpose
223888062|NCT02861781|OTHER|Collection of blood samples and tissues|Collection of blood samples and tissues during bariatric surgery and blood samples during followup visits
223888063|NCT04902846|DIAGNOSTIC_TEST|Early kidney damage biomarkers|In the urine samples of these patients, a series of biomarkers of early kidney damage and / or predisposition to kidney damage will be measured.
223888064|NCT04902846|DIAGNOSTIC_TEST|Predisposition to kidney injury biomarkers|In the urine samples of these patients, a series of biomarkers of predisposition to kidney damage will be measured.
223888065|NCT04773457|OTHER|Surgical Site Infection|infection at the site of the surgery (spine or abdomen)
223888066|NCT06498973|DRUG|Azacitidine|Given IV
223888067|NCT06498973|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223888068|NCT06498973|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration and biopsy
223888069|NCT06498973|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow aspiration and biopsy
223888070|NCT06498973|OTHER|Questionnaire Administration|Ancillary studies
223888071|NCT06498973|BIOLOGICAL|Tagraxofusp-erzs|Given IV
223888072|NCT03221036|DRUG|Vedolizumab IV|Vedolizumab IV infusion
223888073|NCT03221036|DRUG|Placebo|Matching-placebo IV infusion
223888074|NCT06433050|DRUG|Sotagliflozin|Sotagliflozin or placebo will be administered to each participant in a cross over study design. Each participant will receive active drug and placebo with randomization of the order in which they receive them.
223888075|NCT03016169|DEVICE|Trifecta GT (Glide Technology) Valve|Surgical aortic valve replacement with Trifecta GT Valve.
223888076|NCT03887741|BIOLOGICAL|Plasmapheresis|Patient will have monthly plasma exchange with young ApoE 33 plasma. Each exchange will be 1.5 volume of patient's plasma
223888077|NCT03887741|BIOLOGICAL|Plasma infusion|Infuse every two weeks with ApoE33 young plasma (1unit) for 6 months
223888078|NCT06310603|OTHER|Low-Processed Food Diet|Participants that receive intervention will be instructed to eat a diet rich in unprocessed/minimally-processed foods, as described by the NOVA food classification system
223888079|NCT02605057|DRUG|LEO 80185 gel|
223888080|NCT02605057|DRUG|Dovobet(r) Ointment|
223888081|NCT03900468|DEVICE|Activa™ PC and Percept™ PC Neurostimulation Systems|Implanted DBS system consisting of a Neurostimulator, Leads, Extensions, and potential accessories including Burr Hole Devices, Clinician Tablet, Clinician Programmer Therapy Application Software, Clinician Programmer Communicator, Patient Programmer
223888082|NCT02724878|DRUG|Bevacizumab|
223888083|NCT02724878|DRUG|Atezolizumab|
223888084|NCT06425523|BEHAVIORAL|Home Gardening Intervention (HGI)|The Home Gardening Intervention (HGI) provides refugee participants with agricultural inputs and training (field prep., sowing, water management, pest control, weeding, etc.) through a participatory field school approach with a curriculum derived from best practices in agro-ecology. The program includes active monitoring during a 12-month period. The training involves nutrition education on cooking methods and the importance of dietary diversity using garden produce as well as guidance on surplus management and market support. The overall goal of the intervention is to enable climate-resilient farming for improved food security and dietary diversity that is sustainable long-term.
223888085|NCT06425523|BEHAVIORAL|Self-Help Plus (SH+)|"Self-Help Plus (SH+) is a 5-session group intervention developed by the WHO and based on Acceptance and Commitment Therapy, delivered by trained local facilitators. It provides tools to manage stress and adversity through pre-recorded audio lessons and a self-help book. Sessions include individual exercises and group discussions.~SH+ aims to decrease psychological distress. It has shown effectiveness among refugees in Uganda and elsewhere."
223888086|NCT06425523|BEHAVIORAL|Enhanced Usual Care (EUC)|The Enhanced Usual Care (EUC) control condition involves a single 15-minute psychoeducation session providing information on managing overthinking and utilizing available mental health services in the settlement. These services include psychosocial support from community health workers and clinical mental health services (counseling and medications) provided weekly at local primary care centers by a visiting team.
223888087|NCT06385028|BEHAVIORAL|Physical activity promotion|The intervention will be delivered through a phone application: each week, the participant will define a new daily step goal for the following week. Then he/she will receive daily notifications (except Sundays) about physical activity, sedentary behavior and their consequences on general health and osteoarthritis specifically. These notifications are designed to promote physical activity in this specific population.
223888088|NCT06580418|OTHER|Additional biopsies and blood samples|During the endoscopic procedure planned for IBD patients following standard clinical practice, the endoscopist will decide the number and location of additional biopsy samples (up to 8) collected for the study. Participation in this study also requires the removal of three additional blood samples.
223888089|NCT04207346|DEVICE|TMS 1 hz|High-performance magnetic stimulator designed for clinical use or use in clinical trials. This specific device has a coil designed with one side that delivers active treatment and the other side that delivers sham (no stimulation) treatment. The sham side is externally identical to the active side, but internally it has a shield that prevents any magnetic energy from interacting with the patient. This arm will use the active side.
223888090|NCT04207346|DEVICE|Sham TMS|High-performance magnetic stimulator designed for clinical use or use in clinical trials. This specific device has a coil designed with one side that delivers active treatment and the other side that delivers sham (no stimulation) treatment. The sham side is externally identical to the active side, but internally it has a shield that prevents any magnetic energy from interacting with the patient. This arm will use the sham side.
223888091|NCT05899998|BEHAVIORAL|Bright IDEAS|Bright IDEAS® (Identify, Define, Evaluate, Act, See) is a problem-solving skills training program that was originally developed to alleviate distress in caregivers of children recently diagnosed with cancer. Intervention materials include instructor and user manuals, a brochure, and worksheets to be completed by the parent caregiver, initially with the help of the interventionist and then with increasing independence.
223888092|NCT04695093|OTHER|Ultra Low Emission Zone (ULEZ)|"The ULEZ comprises a Central London zone, implemented on 8th April 2019, within which polluting vehicles are subject to a charge. Using number plate recognition technology, a daily penalty charge notice is issued for vehicles entering this central zone not meeting the standard of Euro 4 for petrol, Euro 6/VI for diesel, and Euro for motorcycles.~The ULEZ will subsequently be extended to include:~1. In 2020, a London-wide ULEZ for heavy duty vehicles (HDV) within the LEZ boundary (green zone). HDVs not meeting Euro 6 standard will be charged daily.~2. In 2021, an Inner London ULEZ area for all light duty vehicles (LDV) within the boundary of the North and South Circular Roads (yellow zone). Vehicles not meeting the above criteria will be charged daily as for the Central London area."
223888093|NCT06296836|DRUG|Metformin|Continuation of home metformin
223888094|NCT05912478|OTHER|Videogame-Based Therapy|The Nintendo Switch (Version 2) will be used to play video games. Within the scope of the study, Nintendo Switch games were analyzed with respect to their technical and fictional characteristics, required and optional movement patterns, difficulty levels, transitions between difficulty levels, and compatibility with priority problems. The selected activities will prioritize the activation of the scapular muscles. Throughout the activities, the participant will be required to mimic the on-screen avatar's movements. The player will receive a higher score if his or her movements in the game resemble the avatar's in terms of angular, velocity, and fluidity.
223888095|NCT05912478|OTHER|Waiting list|The participants who were placed on a waiting list for eight weeks and constituted the control group will be asked to carry on with their normal activities. Participants in the control group will be contacted by phone in the fourth week to inquire about their status and to remind them that the exercise program will begin in the coming weeks. At the end of the 8-week study, the participants from the control group will participate in the exercise program.
223888096|NCT06142825|OTHER|Community-Facility Transfusion Committee (CFTC)|Community-Facility Transfusion Committees (CFTCs) are intended to incorporate diverse representation involving hospital, community, and county leadership, to improve blood availability and transfusion at the point-of-care.
223888097|NCT05105802|BEHAVIORAL|Mindfulness-Based Intervention|Using AmDtx MBI-based app, targeted MBI training will consist of a 4-week custom-made program that include, setting intentions and check-in with mood, audio-recorded lectures, guided meditations such as body scans, and writing events journal (Appendix 5). Each standardized course will be unlocked as the child progresses through the program. Users will be encouraged to participate in the app-based activities for a total of 10-15 minutes every day, with a minimum of 4 days in a week, over a period of 4 weeks.
223888098|NCT05105802|BEHAVIORAL|Cognitive Sham + Usual Care|Usual care recommends that the patient refrain from physical and cognitive activities for 24-48 hours after injury. After the rest period, it is recommended that low to moderate levels of physical and cognitive activity be gradually started 24-48 hours after injury. The activities should be performed at a level that does not result in recurrence or exacerbation of symptoms. Children must refrain from any activities that increase the risk of re-injury (drills with body contact or that risk falls) until fully asymptomatic and cleared by their primary care or other medical provider. The sham journey will consist of playing an open-source cognitive math game delivered through the same app as MBI, but without the mindfulness content.
223888099|NCT04752319|DEVICE|BreEStim|BreEStim will be applied for 10 to 20 minutes per session for multiple sessions
223888100|NCT04752319|DEVICE|EStim|EStim will be applied for 10 to 20 minutes per session for multiple sessions
223888101|NCT06062901|OTHER|Educational Intervention|Receive educational intervention
223888102|NCT06062901|OTHER|Interview|Participate in one-on-one interview
223888103|NCT06062901|OTHER|Survey Administration|Ancillary studies
223888104|NCT05668754|DRUG|Serdexmethylphenidate|Participants randomized to active drug will receive their optimized dose according to a dosing regimen set by randomization at the start of the OLTP. The 4 possible oral SDX doses are 80, 160, 240, or 320 mg/day. The optimal SDX dose will be determined during the 5-week OLTP preceding the 2-week DBWP.
223888105|NCT05668754|OTHER|Placebo|Participants randomized to placebo will receive matching placebo capsules to the optimized dose established at the end of the OLTP, according to a dosing regimen set by randomization at the start of the OLTP.
223888106|NCT02406014|DRUG|Ingenol Mebutate Gel, 0.015%|Ingenol mebutate gel 0.015 % (Picato®) applied on the selected treatment area. Retreatment if the treatment field is not completely cleared of AKs.
223888107|NCT02406014|DRUG|Diclofenac sodium gel 3%|Diclofenac sodium gel 3% Solaraze® applied on the selected treatment area, twice daily for 90 days.
223888108|NCT03175029|DRUG|TAC-302|TAC-302 200 mg administered orally twice per day after meals, for 12 weeks.
223888109|NCT03175029|DRUG|Placebo|Placebo administered orally twice per day after meals, for 12 weeks.
223888110|NCT06521164|DEVICE|Haermonics Pure system|pericardial flushing with Haermonics Pure system
223888111|NCT05711173|BIOLOGICAL|Additional blood sampling|The procedure will consist of an additional blood sample for ETDA tube collection (NGS analysis) and citrate tube collection (NETose analysis)
223888112|NCT05622448|OTHER|RPD with PEEK framework|removable partial denture with CAD designed PEEK framework
223888113|NCT05622448|OTHER|RPD with metallic framework|removable partial denture with cobalt chromium framework
223888114|NCT04141020|PROCEDURE|Microsurgical clipping|Standard of care microsurgical clipping of an unruptured cerebral artery aneurysm.
223888115|NCT04141020|PROCEDURE|Endovascular treatment|Standard of care endovascular treatment of an unruptured cerebral artery aneurysm.
223888116|NCT04141020|DRUG|Sirolimus|Daily oral Sirolimus 2 mg tablets, adjusted as necessary per treating physician.
223888117|NCT04147078|BIOLOGICAL|DC vaccine subcutaneous administration|subcutaneous administration
223888118|NCT01426425|DEVICE|Freezor Xtra Cryoablation Catheter|Freezor® Xtra Cardiac CryoAblation applied for cryoablation of the conducting tissues of the heart in the treatment of patients with atrioventricular nodal reentrant tachycardia using an endocardial approach.
223888119|NCT05299138|BEHAVIORAL|Marriage and Relationship Enhancement Skills (MRES) Intervention|The Intervention group will be assigned a Case Manager and placed in the next available Marriage and Relationship Enhancement Skills (MRES) class that is convenient for their schedule. Intervention participants will attend classes weekly and meet with their Case Manager weekly, bi-weekly, or monthly, as needed. Study measures will be gathered from intervention participants at baseline, 10 weeks after baseline, and then 22 weeks after baseline. The following tools will be utilized at baseline and follow-up assessment: (1) REACH program eligibility screening (only conducted at baseline), (2) Information, Family Outcomes, Reporting, and Management (nFORM) system, (3) Family Environment Scale (FES), (4) Revised Dyadic Adjustment Scale (RDAS), and (5) Economic Self-Sufficiency Scale (ESS).
223888120|NCT04773353|DRUG|Follitropin Delta (FE 999049)|FE 999049 was administered as single daily subcutaneous injections in the abdomen. Participants randomized to FE 999049 had their individual dose determined on the basis of their anti-Müllerian hormone (AMH) level at screening and their body weight at randomization. For participants with low AMH (\<15 pmol/L) the daily FE 999049 dose was 12 μg, irrespective of body weight. For participants with high AMH (≥15 pmol/L) the daily FE 999049 dose was on a continuous scale ranging from 0.19 to 0.10 μg/kg, i.e. dependent on actual AMH and body weight. The daily FE 999049 dose was fixed throughout the stimulation period and maximum allowed daily dose was 12 μg. Participants could be treated for a maximum of 20 days.
223888121|NCT04773353|DRUG|Follitropin Alfa (GONAL-F)|GONAL-F was administered as single daily subcutaneous injections in the abdomen. The starting dose of GONAL-F was 150 IU and fixed for the first five stimulation days, after which it could be adjusted by 75 IU based on the individual response. The maximum allowed daily dose was 450 IU. Participants could be treated for a maximum of 20 days.
223888122|NCT06052176|DRUG|Albumin Infusion|Intravenous human serum albumin to be given at 1.5g/kg ideal body weight
223888123|NCT06631001|OTHER|Abdominal Massage|Abdominal massage will be administered twice a day for 15 minutes over three days. This intervention aims to evaluate its effects on defecation frequency, gastric residual volume, and abdominal distension.
223888124|NCT06093659|OTHER|Heated tobacco product with heated tobacco sticks (Product A)|Product A, used under controlled conditions (i.e., completely use a single unit of the product, with puffs taken at 30-second intervals and puffs 3 seconds in duration), followed by an ad-libitum, 4-hour product use session on the same day.
223888125|NCT06093659|OTHER|Heated tobacco product with heated tobacco sticks (Product B)|Product B, used under controlled conditions (i.e., completely use a single unit of the product, with puffs taken at 30-second intervals and puffs 3 seconds in duration), followed by an ad-libitum, 4-hour product use session on the same day.
223888126|NCT06093659|OTHER|Heated herbal product with nicotine-infused heated herbal sticks (Product C)|Product C, used under controlled conditions (i.e., completely use a single unit of the product, with puffs taken at 30-second intervals and puffs 3 seconds in duration), followed by an ad-libitum, 4-hour product use session on the same day.
223888127|NCT06093659|OTHER|Heated herbal product with nicotine-infused heated herbal sticks (Product D)|Product D, used under controlled conditions (i.e., completely use a single unit of the product, with puffs taken at 30-second intervals and puffs 3 seconds in duration), followed by an ad-libitum, 4-hour product use session on the same day.
223888128|NCT06093659|OTHER|Conventional Cigarette (Product E)|Subject's own brand combustible cigarette used under controlled conditions (i.e., completely use a single unit of the product, with puffs taken at 30-second intervals and puffs 3 seconds in duration), followed by an ad-libitum, 4-hour product use session on the same day.
223888129|NCT05736211|BEHAVIORAL|Organization-level Youth Engagement prevention strategy|Systematically incorporating Youth Engagement into prevention efforts in a community setting
223888130|NCT04558164|DEVICE|Active Theta Burst Stimulation|Theta burst transcranial magnetic stimulation (TBS) will be delivered at 80-100% of motor threshold (MT).
223888131|NCT04558164|DEVICE|Sham Theta Burst Stimulation|Sham stimulation will be delivered at 0-10% of motor threshold (MT), with all other parameters matching the active TBS condition.
223888132|NCT05750212|DIAGNOSTIC_TEST|Tone|Tone is a binary measurement of the pelvic floor muscle on physical examination
223888133|NCT05750212|DIAGNOSTIC_TEST|Tenderness|Tenderness is a binary measurement of the pelvic floor muscle on physical examination
223888134|NCT05750212|DIAGNOSTIC_TEST|Contraction|Contraction is a binary measurement of the pelvic floor muscle on physical examination
223888135|NCT05750212|DIAGNOSTIC_TEST|Relaxation|Relaxation is a binary measurement of the pelvic floor muscle on physical examination
223888136|NCT05750212|DIAGNOSTIC_TEST|Electromyography|Electromyography is a measurement of the pelvic floor muscle in microvolts
223888137|NCT05750212|DIAGNOSTIC_TEST|Transperineal|Transperineal measurements (in millimeters) of the pelvic floor muscle using an ultrasound
223888138|NCT05750212|DIAGNOSTIC_TEST|Pressure|Pressure measurements (in millimeters) of the pelvic floor muscle using an algometer
223888139|NCT06394765|BEHAVIORAL|Mindful Mapping|Participants in the Mindful Mapping condition will receive a 5-minute, therapist-guided mindfulness intervention for chronic pain. During this training they will learn the 30-second Mindful Mapping technique, which they will be instructed to use each time they experience a painful sensation over the next 2 weeks. The Mindful Mapping technique consists of focusing on five basic characteristics (shape, weight, density, temperature, movement) of the most intense sensation in the body as it emerges in the present moment while remaining equanimous, i.e., preventing the learned reaction.
223888140|NCT06394765|BEHAVIORAL|Serial Sevens|"Participants in the control condition will receive a 5-minute, therapist-guided serial sevens intervention for chronic pain. During this training, participants will be instructed that each time they experience pain, they will count backwards in their heads by 7 from 100 for 30 second."
223888141|NCT02715284|BIOLOGICAL|Dostarlimab|Dostarlimab (160 mg, 20 mg/mL; or 500 mg, 50 mg/mL) is a humanized monoclonal antibody that binds with high affinity to PD-1 resulting in inhibition of binding to programmed death receptor ligands 1 and 2 (PD-L1 and PD-L2). Dostarlimab will be administered via a 30 minute IV infusion on Day 1 and Day 15 of each cycle in Part 1. For additional patients enrolled specifically to better characterize the PK/PDy profile in Part 1, dostarlimab administration during Cycle 1 will only occur on Day 1 with the second dose administered on Cycle 2/Day 1 and Q2W thereafter. For Part 2A and 2B, dostarlimab will be administered on Day 1 of each treatment cycle. Cycle duration for Q3W dosing is 21 days and Q6W dosing is 42 days.
223888142|NCT04178434|BEHAVIORAL|Internet-based CBT intervention|A nine step intervention including internet-based feedback by psychologists
223888143|NCT05991583|DRUG|IBB0979|IBB0979 should be subcutaneous injected，qw
223888144|NCT01253824|DRUG|NPC-01|NPC-01 contains 1mg norethisterone and 0.02mg ethinyl estradiol
223888145|NCT01253824|DRUG|IKH-01|IKH-01 contains 1mg norethisterone and 0.35mg ethinyl estradiol
223888146|NCT00512070|DRUG|olanzapine and melatonin|In treatment phase I, all subjects will receive olanzapine, 10-25 mg/day. In treatment phase II, all subjects will receive olanzapine (10-25 mg/day) plus melatonin. Subjects will be randomized at a ratio of 1:1 to receive melatonin, 0.3 mg/day or 3.0 mg/day. Group IIA will receive 0.3mg day melatonin. Group IIB will receive 3.0 mg/day melatonin.
223888147|NCT05758415|DRUG|Secukinumab|The participants will receive Secukinumab 300 mg s.c. at randomization (Baseline visit), Week 1, 2, 3, 4, 8, and 12
223888148|NCT05758415|DRUG|Placebo|The participants will receive placebo s.c. at randomization (Baseline visit), Week 1, 2, 3, 4, 8, and 12
223888149|NCT05113199|BEHAVIORAL|Virtual Dignity Therapy|Virtual Dignity Therapy will be facilitated by a registered nurse or medical doctor trained in Dignity Therapy.
223888150|NCT05784012|DRUG|Dostarlimab|Dostarlimab 500 mg IV every 21 days in neoadjuvant and adjuvant stage.
223888151|NCT05784012|DRUG|Niraparib|Niraparib 200 or 300mg orally administered QD in neoadjuvant, concurrent with radiotherapy and adjuvant stage until completing week 48.
223888152|NCT05784012|DRUG|cisplatin plus radiotherapy|In the concurrent phase
223888153|NCT05784012|DRUG|Niraparib|Niraparib 200 or 300mg orally administered QD (Neoadjuvant and Maintenance stages).
223888154|NCT06246422|DRUG|Tranexamic Acid 500 MG|Local instillation of 500 mg tranexamic acid in 20 ml normal saline in the gall bladder bed
223888155|NCT06246422|DRUG|Normal saline|Local instillation of 20 ml normal saline in the gall bladder bed
223888156|NCT06417476|RADIATION|Short-course radiotherapy|The total dosage was 25Gy consisted of 5 fractions of 5 Gy to clinical target volume without a boost dose
223888157|NCT06417476|DRUG|Irinotecan|150 mg/m² iv drip over 2 hours on day 1, repeated every 14 days.
223888158|NCT06417476|DRUG|Oxaliplatin|85 mg/m² iv drip over 2 hours on day 1, repeated every 14 days.
223888159|NCT06417476|DRUG|Calcium Formate|400 mg/m² iv drip over 2 hours on day 1, repeated every 14 days.
223888160|NCT06417476|DRUG|Fluorouracil|2400 mg/m² iv drip over 48 hours on day 1-2, repeated every 14 days.
223888161|NCT06417476|RADIATION|Long-course chemoradiation|The total dosage was 50Gy consisted of 25 fractions of 2 Gy to clinical target volume without a boost dose
223888162|NCT06417476|DRUG|Capecitabine|825 mg/m² twice daily administered orally and concurrently with radiation therapy for 5 days per week.
223888163|NCT06296914|DEVICE|POTSapp|"Participants will be asked to document symptoms daily in the mHealth app and will be asked to conduct an at home stand test biweekly through the mHealth app. These participants will be asked to take an online survey at baseline, at 4 months, and at 8 months. T"
223888164|NCT06296914|DEVICE|Waitlist Control|"Participants will receive educational information about online support for POTS via email. Starting at month 4, participants will receive equipment will be asked to document symptoms daily in the mHealth app and will be asked to conduct an at home stand test biweekly through the mHealth app. These participants will be asked to take an online survey at baseline, at 4 months, and at 8 months."
223888165|NCT00961571|DRUG|sunitinib and capecitabine|Sunitinib 37.5 mg po once daily Capecitabine 1000 mg po twice daily
223888166|NCT03169738|BIOLOGICAL|avelumab|Fully human anti-PD-L1 IgG1 lambda monoclonal antibody
223888167|NCT03169738|BIOLOGICAL|Bevacizumab|Recombinant human anti-vascular endothelial growth factor (VEGF) immunoglobulin (Ig) G1 monoclonal antibody
223888168|NCT03169738|DRUG|Capecitabine|5'-deoxy-5-fluoro-N-\[(pentyloxy) carbonyl\]-cytidine
223888169|NCT03169738|DRUG|Cisplatin|(SP-4-2)-diamminedichloroplatinum(II)
223888170|NCT03169738|DRUG|cyclophosphamide|2-\[bis(2-chloroethyl)amino\]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
223888171|NCT03169738|DRUG|5-Fluorouracil (5-FU)|5-fluoro-2,4 (1H,3H)-pyrimidinedione
223888172|NCT03169738|DRUG|fulvestrant|7-alpha-\[9-(4,4,5,5,5-pentafluoropentylsulphinyl) nonyl\]estra-1,3,5-(10)- triene-3,17-beta-diol
223888173|NCT03169738|DRUG|leucovorin|Calcium N-\[p-\[\[\[(6RS)-2-amino-5- formyl-5,6,7,8-tetrahydro-4-hydroxy-6- pteridinyl\]methyl\]amino\]benzoyl\]-L-glutamate (1:1)
223888174|NCT03169738|DRUG|nab paclitaxel|5β,20-Epoxy-1,2α,4,7β,10β,13α-hexahydroxytax-11- en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
223888175|NCT03169738|BIOLOGICAL|nivolumab|Human anti-PD-1 IgG4 kappa monoclonal antibody
223888176|NCT03169738|DRUG|Lovaza|Omega-3-acid ethyl esters
223888177|NCT03169738|DRUG|Oxaliplatin|cis-\[(1 R,2 R)-1,2-cyclohexanediamine-N,N'\] \[oxalato(2-)- O,O'\] platinum
223888178|NCT03169738|RADIATION|Stereotactic Body Radiation Therapy|(SRBT)
223888179|NCT03169738|BIOLOGICAL|ALT-803|recombinant human super agonist interleukin-15 (IL-15) complex \[also known as IL15N72D:IL-15RαSu/IgG1 Fc complex\]
223888180|NCT03169738|BIOLOGICAL|ETBX-011|adenovirus serotype-5 \[Ad5\] \[E1-, E2b-\]-carcinoembryonic antigen \[CEA\] vaccine
223888181|NCT03169738|BIOLOGICAL|ETBX-021|Ad5 \[E1-, E2b-\]-human epidermal growth factor receptor 2 \[HER2\] vaccine
223888182|NCT03169738|BIOLOGICAL|ETBX-051|Ad5 \[E1-, E2b-\]-Brachyury vaccine
223888183|NCT03169738|BIOLOGICAL|ETBX-061|Ad5 \[E1-, E2b-\]-mucin 1 \[MUC1\] vaccine
223888184|NCT03169738|BIOLOGICAL|GI-4000|Ras yeast vaccine
223888185|NCT03169738|BIOLOGICAL|GI-6207|CEA yeast vaccine
223888186|NCT03169738|BIOLOGICAL|GI-6301|Brachyury yeast vaccine
223888187|NCT03169738|BIOLOGICAL|haNK|NK-92 \[CD16.158V, ER IL-2\], Suspension for Intravenous \[IV\] Infusion
223888188|NCT06266663|OTHER|Survey|A cross-sectional survey of 400 IBD patients who will be actively recruited from the gastroenterology (GI) specialty clinics at Einstein-Montefiore Medical Center and Icahn School of Medicine at Mount Sinai Hospital. The survey will consist of validated screening measures on social domains known to affect health outcomes as well as measures of medication adherence and HRQoL.
223888189|NCT04679376|DRUG|Atorvastatin|40 mg daily administered orally in tablet or capsule form
223888190|NCT04679376|DRUG|Placebo|Administered daily orally in tablet or capsule form, contains no active medicine
223888191|NCT06446401|DRUG|ADT + NHT + Docetaxel|Lead4Care leaves the treatment choice to the clinicians and the patients, i.e., does not intervene in their choice of treatment. However, Lead4Care proxy a randomized controlled experiment in which the intervention would be to add docetaxel to androgen deprivation treatment, new hormone therapy (abiraterone, apalutamide, enzalutamide or darolutamide). This involves a comparison of triple and double therapies. This group recives the triple therapy, i.e. ADT, NHT and Docetaxel.
223888192|NCT06446401|DRUG|ADT + NHT|Lead4Care leaves the treatment choice to the clinicians and the patients, i.e., does not intervene in their choice of treatment. However, Lead4Care proxy a randomized controlled experiment in which the intervention would be to add docetaxel to androgen deprivation treatment, new hormone therapy (abiraterone, apalutamide, enzalutamide or darolutamide). This involves a comparison of triple and double therapies. This group recives double therapy, i.e. they are receiving NHT and ADT, but not Docetaxel.
223888193|NCT05524233|DEVICE|Active Transcranial Direct Stimulation|Subjects will receive a stimulation device to use up to 20 minutes daily for 4 weeks.
223888194|NCT04910724|OTHER|Energy Deficit|A combination of individualized exercise performed on a cycle ergometer and individualized dietary prescriptions will be used to achieve energy balance or the assigned energy deficits throughout the controlled feeding and testing periods
223888195|NCT06411301|DRUG|225Ac-DOTATATE|Two intravenous infusions every 6 weeks (Q6W)
223888196|NCT05327101|OTHER|Patient Preference Survey|Patient preference survey on implantable cardiac pacemaker systems
223888197|NCT04885959|BEHAVIORAL|Traditional Asian Diet|The personalized traditional Asian diet will be formulated based on dietary components of a typical Asian diet characterized by high intake of fruits and vegetables, whole grains, legumes, nuts, seeds, soy foods and herbs and spices; moderate intake of fish, poultry, eggs, healthy cooking oils, yogurt or functional foods and low intake of meats and sweets (Ismail et al., 2020). The diet design also considering the recommendation of personalized dietary approach by including the element of individual preferences, requirement, cultural preferences, affordability and foods availability to facilitate the adherence and response to the diet.
223888198|NCT06489522|BEHAVIORAL|THRIVE|THRIVE is a brief, parent child interaction therapy (PCIT) based telehealth intervention delivered over 6-sessions that has been tested in pediatric and community-based settings.
223888199|NCT03532360|OTHER|Oral immunotherapy|Starting from a very low level and over a period of several months, participants receive escalating doses of the food to which they are allergic
223888200|NCT03345563|BEHAVIORAL|Body Mind Training (BMT)|"Participants will practice BMT under the instruction of a BMT instructor. There will be 24 sessions. Each session will last 60 minutes and will occur twice a week for 12 weeks. Each session will include both light physical exercise and mind training.~Sessions will be supplemented with home-based practice using an instructional DVD and handouts. Participants will be instructed to practice at least 30 minutes a day (at least 3 days per week) throughout the intervention and post-intervention period."
223888201|NCT03345563|BEHAVIORAL|Body Training (BT):|Participants will practice BT under the instruction of a BT instructor. There will be 24 sessions. Each session will last 60 minutes and will occur twice a week for 12 weeks. Sessions will be supplemented with home-based practice using an instructional DVD and handouts. Participants will be instructed to practice at least 30 minutes a day (at least 3 days per week) throughout the intervention and post-intervention period.
223888202|NCT03345563|BEHAVIORAL|Usual Care (UC)|Participants in the usual care arm will receive care as normal and will not attend classes but will complete the same assessments as participants in the BMT and BT classes.
223888203|NCT02506959|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous peripheral blood stem cell transplant
223888204|NCT02506959|DRUG|Busulfan|Given IV
223888205|NCT02506959|DRUG|Gemcitabine Hydrochloride|Given IV
223888206|NCT02506959|DRUG|Melphalan|Given IV
223888207|NCT02506959|DRUG|Panobinostat|Given PO
223888208|NCT02506959|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo autologous peripheral blood stem cell transplant
223888209|NCT02506959|OTHER|Pharmacological Study|Correlative studies
223888210|NCT06377280|DEVICE|Navina Mini|CE-marked Navina Mini, released on the market May 2023
223888211|NCT02345408|DRUG|CCX872-B|Tablets (oral administration)
223888212|NCT03441165|PROCEDURE|ligament reconstruction and meniscus transplantation|ACL reconstruction ACL revision MAT
223888213|NCT04208061|DRUG|Dabigatran Etexilate|Participants will receive single dose of dabigatran etexilate orally.
223888214|NCT04208061|DRUG|DRV/COBI|Participants will receive oral tablet of fixed dose combination (FDC) containing darunavir (DRV)/ cobicistat (COBI).
223888215|NCT04208061|DRUG|Ritonavir|Participants will receive ritonavir orally.
223888216|NCT04208061|DRUG|Darunavir|Participants will receive Darunavir orally.
223888217|NCT05838651|DEVICE|MinerOss® X Plug|A xenograft composed of 80% bovine cancellous particulate and 20% bovine Type I collagen.
223888218|NCT05838651|DEVICE|Striate+ Membrane|A non-crosslinked collagen covering used to keep bacteria out and hold the bone graft in place.
223888219|NCT06095154|RADIATION|CTV Delineation Based on Geometric Expansion From GTV in Nasopharyngeal Carcinoma|CTVp2 is generated by expanding GTVp by 10 mm and including the nasopharyngeal mucosa.
223888220|NCT04441047|DRUG|AlloStim|Living, activated allogeneic Th1-like memory immune cells
223888221|NCT05111405|PROCEDURE|CMC Arthroplasty|Surgical intervention to treat CMC arthritis
223888222|NCT05448651|DRUG|UPB-101|Subcutaneous injection
223888223|NCT05448651|DRUG|Placebo|Subcutaneous injection
223888224|NCT03465865|DEVICE|optical coherence tomography|optical coherence tomography enables diagosis of macular structures and therefore provides information on macular hole closure.
223888225|NCT05882578|OTHER|Oncological physical exercise intervention|"An initial physical assestment where clinical history, body composition, functionality, cardiovascular fitness and quality of life will be tested.~Patients will be screened and then divided in diferent groups, depending on both their cardiovascular and physical capacity.~Then they will perform 2 sessions of combined strength and endurance training per week for 16 weeks.~At the end of the training program, the patients will be assesed to evaluate the changes in their cardiovascular fitness, functionality, body composition and quality of life."
223888226|NCT05882578|OTHER|Active Physical Activities intervention|"An initial physical assestment where clinical history, body composition, functionality, cardiovascular fitness and quality of life will be tested Patients will be suggested to mantain active physical activities in their daily life.~At the end of the training program, the patients will be assesed to evaluate the changes in their cardiovascular fitness, functionality, body composition and quality of life."
223888227|NCT04528355|DRUG|data collection|Study subjects will receive alemtuzumab, melphalan, thiotepa, fludarabine and hydroxyurea-based, reduced-intensity conditioning regimen in accordance with clinical practice at UPMC Children's Hospital of Pittsburgh at the discretion of the treating physician. Medical data will be abstracted from subject's medical charts once the patient signs the informed consent.
223888228|NCT04390048|DEVICE|Anodal tDCS|An anodal surface electrode will be attached to the contralateral motor cortex (M1) of the CAI-involved side and the reference electrode will be placed on the ipsilateral side of the supraorbital ridge. Anodal tDCS will deliver a low electrical current stimulation at 2 milliamps (mA). Participants will undergo 3 sessions per week for a total of 12 sessions and each session will last approximately 20 minutes.
223888229|NCT04390048|DEVICE|Sham tDCS|An anodal surface electrode will be attached to the contralateral motor cortex (M1) of the CAI-involved side and the reference electrode will be placed on the ipsilateral side of the supraorbital ridge. Sham tDCS will deliver a low electrical current stimulation at 2 mA and will be turned off 30 seconds following the application. Participants will undergo 3 sessions per week for a total of 12 sessions and each session will last approximately 20 minutes.
223888230|NCT02202356|DRUG|ALS-008176|
223888231|NCT02202356|DRUG|Placebo|
223888232|NCT00294242|PROCEDURE|Membrane Sweep|Weekly Membrane Sweep
223888233|NCT00294242|PROCEDURE|No Membrane Sweep|No Membrane Sweep
223888234|NCT02361723|DRUG|BGB-290|
223888235|NCT02361723|DRUG|BGB-290|
223888236|NCT02361723|DRUG|BGB-290|
223888237|NCT02361723|DRUG|BGB-290|
223888238|NCT02361723|DRUG|BGB-290|
223888239|NCT05129969|OTHER|Physician's choice according to patient's needs.|Routine care as per site standard.
223888240|NCT03126019|DRUG|Parsaclisib|Parsaclisib tablets administered orally with water and without regard to food
223888241|NCT04900363|DRUG|AK112|Subjects receive AK112 intravenously.
223888242|NCT05747170|OTHER|Olfactory sstimulation|"The odors being tested (natural odor, neutral odor, chemical odor) are part of the 40 fragrances made by International Flavors and Fragrances (IFF) and each is contained in an approximately 15-mL glass bottle. The selected odors will be administered using a small paper strip (15 cm length and 0.7 cm width) that will be soaked in the selected odor and placed under the subject's nose at a minimum distance to prevent direct contact of the strip with the skin; the strip will be moved alternately from one nostril to the other.~Stimulation will have, for each odor the duration of 5 minutes. It will always be carried out within the same time slot (between 8:00 am and 4:00 pm) for 5 consecutive days for 2 weeks. Before and after the administration of each odor, a neutral odor (water) will be administered as a control in the same manner as described above.~The sequence of odor administration will be randomized according to a computer-generated sequence."
223888243|NCT04907929|BEHAVIORAL|targeted speech and cognitive therapy|One month of targeted speech and cognitive therapy with a speech therapist and with home exercice at home by using a numeric solution
223888244|NCT06435468|GENETIC|Blood sample for genetic analysis|genetic analysis (WES, WGS) for the identification of germline and somatic mutations responsible for rare autoimmune diseases or auto-inflammatory pathologies (pediatric or syndromic or familial) that began in childhood
223888245|NCT06435468|OTHER|Blood sample for immunological response assessments|Identifying specific immunological factors in patients with rare pediatric autoimmune and auto inflammatory diseases
223888246|NCT06435468|OTHER|Blood sample to identify relevant biomarker of the disease|Research biomarkers for diagnosis, prognosis and monitoring of disease activity
223888247|NCT04494347|PROCEDURE|MitraClip TMVR and Watchman LAAO|The MitraClip device is a percutaneous edge-to-edge repair device that is intended to approximate the anterior and posterior mitral valve leaflets in patients with severe symptomatic mitral regurgitation with suitable anatomy. Device versions/types: MitraClip NTr, MitraClip XTr. The WATCHMAN device is a self-expanding left atrial appendage occlusion (LAAO) device with a porous covering on the proximal face. Device sizes: 21 mm, 24 mm, 27 mm, 30 mm, 33 mm.
223888248|NCT06555172|BEHAVIORAL|Action In Mindfulness (AIM)+|"AIM+ is a smartphone-based app that teaches mindfulness meditation to professionals working with legal-involved youth over a 30-day path. Each day of the path consists of a brief (approximately 5- to 10-minute) audio-guided meditation practice, with brief videos interspersed to illustrate key concepts and promote engagement. In addition to the 30 daily path files, users have access to a menu of to go audio-guided meditation practices that they can use as relevant to their workday (e.g., for professionals to listen to before attending a meeting). AIM+ also includes a menu of audio-guided meditation practices that officers can share with the youth on their caseloads (e.g., for youth to listen to before attending court)."
223888249|NCT06555172|BEHAVIORAL|Resource+|Resource+ is a smartphone-based app that is matched to AIM+ for time and structure, but it includes information on community resources that professionals can provide to the youth with whom they work in place of the meditation content featured in AIM+.
223888250|NCT05350930|OTHER|Assessment of patient satisfaction regarding tele-consultation|Questionnaire completed following the teleconsultation, if applicable.
223888251|NCT05350930|OTHER|Literacy questionnaire|Questionnaire completed during hospitalization for the first chemotherapy cycle
223888252|NCT05350930|OTHER|Collection of socio-demographic characteristics|Questionnaire completed during patient hospitalization for the first chemotherapy cycle
223888253|NCT05350930|OTHER|Assessment of patient knowledge on chemotherapy side effects and support medications|Questionnaire completed during patient hospitalization for the first, second and sixth cycle of chemotherapy
223888254|NCT05350930|OTHER|Assessment of patient satisfaction on pharmaceutical follow-up|Questionnaire completed during patient hospitalization for the sixth chemotherapy cycle
223888255|NCT04251299|BEHAVIORAL|home-based, mentored vegetable gardening program|The mentored vegetable gardening program pairs each participant with a certified Master Gardener. The participant/Master Gardener dyads work together to plan, plant and tend to a vegetable garden at the participant's home throughout the year. Gardening supplies, plants and seeds are provided.
223888256|NCT06368570|OTHER|Interview|Patients will be interviewed by the research team to learn about their experience of Cesarean delivery with neuraxial anesthetic
223888257|NCT04556656|DRUG|Pridopidine|Pridopidine hard gelatin capsule
223888258|NCT04556656|DRUG|Placebo|Pridopidine-matching placebo hard gelatin capsule
223888259|NCT05470894|BIOLOGICAL|Approved COVID-19 vaccine|Vaccination for COVI9-19
223888260|NCT06796400|OTHER|General exercises|4 general exercises were done by control group with 10 repetitions and 3 sets, 6 times per week, up to 8 weeks.These exercises are for lower trapzius and serratus anterior mucles strengthing.
223888261|NCT06796400|OTHER|Theraband exerises|5 Thera-band exercises were completed by experimental group with 3 sets and 10 repetitions, 6 times per week, up to 8 weeks. These exercises are for lower trapzius and serratus anterior mucles strengthing.
223888262|NCT04704037|OTHER|Guideline implementation tool|Family physicians will receive a tailored letter with their patient's mental health screening test results and associated mental health treatment recommendations from the Ontario Neurotrauma Foundation guidelines, as well as a list of mental health treatment resources. In addition, the patient will receive a written information package about mental health problems after mTBI and treatment options to discuss with their family physician.
223888263|NCT04704037|OTHER|Generic information about concussion management|Family physicians will receive a generic letter drawing their attention to Canadian clinical practice guidelines for mild Traumatic Brain Injury (developed by the Ontario Neurotrauma Foundation). Patients will receive instructions about how to access generic education materials about mTBI (from concussion.vch.ca/), which they should have received anyway as part of usual care.
223888264|NCT05046314|BIOLOGICAL|TK216+Vincristin|TK216 was continuously administered for 14 days，then rest for 14 days. Vincristin is given before TK216 only in the first day of each cycle, the first cycle of VCR is 0.75mg/m\^2 and 1.5mg/m\^2 from the second cycle，every 28 days is a study cycle.
223888265|NCT06638606|BEHAVIORAL|Sleep improvement techniques|Insomniac and hypersomniac individuals are given behavioral counselling to improve sleep.
223888266|NCT05118867|BEHAVIORAL|iPREPARED|iPREPARED is a mobile health technology that can be accessed via the web, tablet, or phone. It contains a preparatory video that outlines what to expect during the hospitalization. Instructional videos and examples are provided for the patient and their recovery partner to use to do their own reorientation, distraction techniques, physical activity, and sleep hygiene.
223888267|NCT06286137|OTHER|Listening to music for 1 minute|Participants will be instructed to make a 20-minute playlist with their own preferred music, using a tablet and a music listening app. That playlist will then be presented on shuffle mode for 1 minute through headphones provided by the hospital. Volume can be selected by the participants. However, in order to prevent hearing loss the volume cannot exceed 80 decibels. The 19 minutes before the 1 minute music listening intervention, participants will be instructed to remain seated and are not allowed to do anything else (for example using their phones).
223888268|NCT06286137|OTHER|Listening to music for 5 minutes|Participants will be instructed to make a 20-minute playlist with their own preferred music, using a tablet and a music listening app. That playlist will then be presented on shuffle mode for 1 minute through headphones provided by the hospital. Volume can be selected by the participants. However, in order to prevent hearing loss the volume cannot exceed 80 decibels. The 15 minutes before the 5 minutes music listening intervention, participants will be instructed to remain seated and are not allowed to do anything else (for example using their phones).
223888269|NCT06286137|OTHER|Listening to music for 20 minutes|Participants will be instructed to make a 20-minute playlist with their own preferred music, using a tablet and a music listening app. That playlist will then be presented on shuffle mode for 20 minutes through headphones provided by the hospital. Volume can be selected by the participants. However, in order to prevent hearing loss the volume cannot exceed 80 decibels.
223888270|NCT06286137|OTHER|Not listening to music|Participants will be instructed to remain seated and are not allowed to do anything else (for example using their phones), for a duration of 20 minutes.
223888271|NCT05966714|DEVICE|aEEG|amplitude-integrated electroencephalography
223888272|NCT05846451|DIETARY_SUPPLEMENT|Kratom|Kratom (Moon Kratom Yellow Indonesian, lot 51) is supplied as a dry leaf powder in clear plastic bags, each weighing 5 kg. Two grams of kratom dry leaf powder will be stirred into 240 mL of hot water to make a tea. The tea will be cooled to 50 degrees Celsius before administration. Participants will drink the tea within 15 minutes.
223888273|NCT05846451|DRUG|Oxycodone|Immediate-release oral tablet, 10 mg
223888274|NCT03498651|BEHAVIORAL|Cognitive Bias Modification - Interpretation training|Training involves presenting participants with brief scenarios that introduce an ambiguous potential threat. Critically, the ambiguity regarding how the situation is resolved remains until the last word of the scenario, which is presented as a word fragment that the participant must solve, which will typically then assign a benign (rather than threatening) meaning to the scenario.
223888275|NCT03498651|BEHAVIORAL|Coaching|Participants identified as high risk for attrition will receive low-intensity coaching, which includes a mix of brief phone calls, texts, and/or emails with a trained member of the study team to help address challenges with adherence to and application of the training.
223888276|NCT03498651|BEHAVIORAL|Online psychoeducation about anxiety|Participants will review webpages that describe information about symptoms and causes of anxiety, including the nature of biased thinking in anxiety.
223888277|NCT05784857|OTHER|Touch Methods|"The Yakson touch method continue for 15 minutes with steady touch (5 minutes), compassionate caressing (5 minutes), and repetition of steady touch (5 minutes). In this method, the palms of the practitioner and all fingers keep in close contact so that the babies don't feel pressure.~Gentle human touch refers to steady contact of the skin without caressing or massaging. While the practitioner place one hand on the crown of the preterm infant on the eyebrow line with the fingertip touch for 15 minutes, the other hand was place on the lower abdomen covering the waist and hip of the infants."
223888278|NCT05123300|DIAGNOSTIC_TEST|18F-PSMA-1007|18F-PSMA-1007 is a tracer for a PET/CT. Prostate cancer often has marked uptake of PSMA, hence PSMA-PET/CT is in the guidelines in the European Union for detecting relapse. But we will use it for staging primary prostate cancer.
223888279|NCT06637319|DEVICE|Ultrasound|Ultrasound scan of blood vessels where front of neck access vertical incision would take place in a cant intubate cant oxygenate scenario
223888280|NCT01566695|DRUG|Oral Azacitidine|300 mg daily, days 1 to 21 of each 28-day treatment cycle
223888281|NCT01566695|DRUG|Placebo|Identically matching placebo tablets on day 1 to 21 of each 28-day treatment cycle.
223888282|NCT01566695|OTHER|Best Supportiv Care (BSC)|BSC included and was not limited to packed RBC (packed red blood cell \[pRBC\] and whole blood), platelet transfusions (single donor or pooled donor), antibiotic, antiviral and/or antifungal therapy, nutritional support, and granulocyte colony stimulating factors (G-CSF) for participants who experienced neutropenic fever/infections.
223888283|NCT06641271|DEVICE|Closed Loop Trans-Auricular Vagus Nerve Stimulation System|A closed loop system that delivers stimulation to the vagus nerve via the ear non-invasively following a trigger event.
223888284|NCT06641271|DEVICE|Placebo|A closed-loop vagus nerve stimulation device that can deliver sham stimulation to the ear to simulate stimulation of the vagus nerve.
223888285|NCT04895995|BEHAVIORAL|Daylight dCBT Application|Participants will complete up to four modules of digital intervention delivered in a self-paced format.
223888286|NCT06584799|DRUG|Micronized purified flavonoid fraction|"Micronized purified flavonoid fraction (MPFF) 1000. Active substance: micronized purified flavonoid fraction (diosmin+flavonoids expressed as hesperidin). MPFF is a venotonic agent that also has angioprotective properties. It reduces venous distensibility and blood stasis, capillary permeability, and increases capillary resistance.~MOFF 1000 dosing regimen is 1000 mg once daily for 2 months."
223888287|NCT06584799|DRUG|Diosmin 600|Venotonic action: the drug reduces venous distensibility, increases venous tone, reduces blood stasis, and enhances the vasoconstrictor effect of epinephrine and norepinephrine. The optimal daily dose of diosmin 600 for obtaining venotonic effect is 600 mg.
223888288|NCT06584799|DRUG|Hesperidin+Diosmin combination 1000|"A venotonic agent that also has angioprotective properties. It reduces venous distensibility and blood stasis, reduces capillary permeability and increases their resistance.~Hesperidin+Diosmin combination 1000 dosing regimen is 1000 mg once daily for 2 months"
223888289|NCT06563167|DIAGNOSTIC_TEST|CXR|CXRs will be performed at 3 different time points - (i) within 1 hour after TTLB, (ii) at 4 hours (± 1 hour) after TTLB and (iii) at 18 hours (± 2 hours) after TTLB.
223888290|NCT05956002|DRUG|Estraimod Immediate Release (IR)|an immediate release tablet
223888291|NCT05956002|DRUG|Etrasimod Mini Tab in water|very small tablet mixed in water
223888292|NCT05956002|DRUG|Etrasimod Mini Tab in chocolate pudding|very small tablet mixed in chocolate pudding
223888293|NCT05956002|DRUG|Etrasimod Mini Tab in yogurt|Very small tablet mixed in yogurt
223888294|NCT05956002|DRUG|Etrasimod Mini Tab in applesauce|Very small tablet mixed in applesauce
223888295|NCT06427928|BEHAVIORAL|Explains the perioperative process with pictures|We will draw pictures of the preoperative area, operating room and postoperative areas of our operating room and explain the process to 34 of the children who will undergo surgery with these pictures. We will explain the process to the other 34 people without the pictures we have. We planned to measure the anxiety levels between the two groups with the modified Yale scale.
223888296|NCT06427928|BEHAVIORAL|The perioperative process is only explained|We will draw pictures of the preoperative area, operating room and postoperative areas of our operating room and explain the process to 34 of the children who will undergo surgery with these pictures. We will explain the process to the other 34 people without the pictures we have. We planned to measure the anxiety levels between the two groups with the modified Yale scale.
223888297|NCT05612048|OTHER|Survey|This is a 15-item questionnaire. The questionnaire asks subjects to quantify, during a specified duration of time, the number of times they have consumed or completed a task (ex. alcohol intake, cigarette use, and teeth brushing frequency). Additionally, the questionnaire further asks subjects to quantify their GERD symptoms and risk factors prior to diagnosis. All study procedures will be completed in one visit as part of a standard-of-care clinic visit.
223888298|NCT05612048|OTHER|Intra-oral camera|Intraoral pictures of molars and incisors in 13 key regions
223888299|NCT05612048|OTHER|Optional Salvia sample|Cohort 1 only. Participant is responsible for collecting and bringing the salvia sample to clinic.
223888300|NCT06755970|PROCEDURE|ICOUGH|"After the patient has recovered from postoperative anesthesia and their hemodynamic values have stabilized, the ICOUGH bundle applications mentioned above will be carried out. The patient's pain and nausea levels will be recorded for a period of 48 hours.~Postoperative pain and nausea will be assessed with the help of data collectors, using a numerical rating scale at 2, 4, 8, 12, 24, and 48 hours after surgery.~Considering that postoperative respiratory complications are relatively common and costly, various studies have been conducted to explore ways to reduce the risk of their occurrence. One of these protocols is the ICOUGH bundle, which stands for Incentive Spirometry, Coughing and Deep Breathing, Oral Care, Patient Understanding of the Interventions, Getting Out of Bed, and Head of Bed Elevation."
223888301|NCT04270474|OTHER|Deprescribing of target anticholinergics|The active intervention group (ACT) will receive a pharmacist-based deprescribing intervention focused only on targeted anticholinergic medications. The intervention pharmacist will serve as the central source of communication between participants, providers, and (as needed) dispensing pharmacy to coordinate the deprescribing process. The study pharmacists will navigate a shared-decision model between the physicians and participant in order to personalize the selection of appropriate alternatives and switch/titration schedules. Importantly, the pharmacist will supervise the titration and deprescribing plan and communicate with both participants and physicians throughout the study.
223888302|NCT04270474|OTHER|Usual Care|Those in the usual care group will not have access to the study intervention, but will receive a one-time information packet through the mail reviewing risks of polypharmacy, but no information specific to anticholinergic medications. They will receive clinical care as usually provided by their primary care or specialty care physicians.
223888303|NCT05636943|BEHAVIORAL|Adapted Intimacy Enhancement|Participants attend four virtual sessions (60-75 minutes) with a couples' coach consisting of education and skills training to enhance physical and emotional intimacy.
223888304|NCT05636943|BEHAVIORAL|Intimacy Facts and Resources|Self-guided booklet of readings/resources about intimacy and metastatic breast cancer
223888305|NCT04090983|BEHAVIORAL|Cognitive-behavioral therapy (Hesslinger protocol)|Cognitive-behavioral therapy in a group format focusing on improving symptoms of ADHD, specifically by using skills in counteracting hyperactivity and impulsiveness, and promoting mindful awareness.
223888306|NCT04090983|BEHAVIORAL|Cognitive-behavioral therapy (CADDI protocol)|Cognitive-behavioral therapy in a group format focusing on improving inattentive symptoms of ADHD, specifically by using skills in organizing, executing, and completing activity, and promoting mindful awareness.
223888307|NCT03940963|DEVICE|AxoGuard® Nerve Cap|Entubulation of the nerve stump into the AxoGuard® Nerve Cap following surgical excision of symptomatic neuroma
223888308|NCT03940963|PROCEDURE|Standard Neurectomy|Surgical excision of symptomatic neuroma
223888309|NCT05636969|BEHAVIORAL|Multimodal prehabilitation|The multimodal prehabilitation programme will consist of 1) twice weekly, supervised exercise training at the hospital gym for approximately 12-16 weeks; 2) nutritional consultation and diet optimization and supplementation if needed; 3) individual or group-based psychological support.
223888310|NCT06541639|BIOLOGICAL|EVM16|cancer vaccine
223888311|NCT06541639|DRUG|Tislelizumab|Anti-PD1 antibody
223888312|NCT05264714|DRUG|Rimegepant|150 mg oral disintegrating tablet every other day for one week
223888313|NCT06351839|BEHAVIORAL|Sleep-Well despite persistent pain|The Sleep-Well program covers four overarching topics stretched over 7 group sessions (each lasting \~1.5 hours): 1) providing information about sleep physiology, causes of sleep problems, sleep habits and hygiene and use of sleep assessment methods (i.e., sleep diaries) for deciding sleep restriction schedules; 2) behavioural strategies through the application of stimulus control and sleep restriction; , 3) mental strategies by addressing and changing unhelpful (meta)cognitions that commonly occur in sleep and persistent pain conditions; and 4) strategies related to maintenance of good sleep and prevention of relapse. The program has been developed by Diakonhjemmet hospital in Oslo and includes a guideline for therapist and a workbook for patients (that includes home tasks for the participant).
223888314|NCT06351839|BEHAVIORAL|TAU (treatment-as-usual)|The treatment-as-usual arm represents an active waiting-list arm as subjects receive standard care, which may involve some sleep assessment, rudimentary advice/education about sleep, and possibly also sleep medication. The type of sleep treatment this group receives during the waiting-list period will be recorded from the patients' journal.
223888315|NCT05455723|PROCEDURE|Inflation-deflation technique|Inflation-Deflation Technique: The tracheal tube cuff will be inflated with 15-20 ml of air (volume of air is depending on the level of larynx). Once the tip of ETT at the laryngeal inlet, the cuff of ETT will be deflated and advanced into the trachea.
223888316|NCT05455723|PROCEDURE|Magill forceps technique|The Magill forceps to guide the ETT tip to pass through the pharynx and glottis into the trachea.
223888317|NCT06503809|BEHAVIORAL|Ketogenic Diet|Participants will consume a very-low-carbohydrate ketogenic diet for 12 weeks.
223888318|NCT06503809|BEHAVIORAL|Standard Diet|Participants will consume an American Diabetes Association-recommended standard diet for 12 weeks.
223888319|NCT05202678|DEVICE|AGN1 LOEP|Subjects with osteoporosis are treated with AGN1 local osteo-enhancement procedure in the proximal femur
223888320|NCT06105788|OTHER|Exercise|"Arm exercise will be an arm ergometer for 20 minutes, preceded by a 5-minute warm-up.~Leg exercise will be a cycling ergometer for 20 minutes, preceded by a 5-minute warm-up.~The exercise intensity will be set at 70% of the heart rate reserve (HRR) for each type of exercise."
223888321|NCT06197776|DRUG|cisplatin-based chemoradiotherapy combined with immunotherapy|"Chemotherapy:cisplatin-based chemotherapy~GP/TP/PF/TPF~Choice of chemotherapy regimen is decided by patient's doctor in charge.~Radiation: Intensity Modulated Radiation Therapy~All target volumes will be outlined slice by slice on the axial contrast-enhanced CT with MR fusion images in the treatment planning system. The target volumes are defined in accordance with the International Commission on Radiation Units and Measurements Reports 83. The prescribed dose is 70-72 Gy to PTVp (Planning target volume of the primary tumor), 64-70 Gy to PTVn (Planning target volume of the lymph node),60- 64Gy to PTV1 (High-risk planning target volume), and 54-58 Gy to PTV2 (Low-risk planning target volume) in 30-32 fractions. The details of dose limits for organs at risk are based on the study 0225 from The Radiation Therapy Oncology Group (RTOG 0225).~Immunotherapy:PD-1 blocking antibody"
223888322|NCT04469023|DRUG|TS-142|Participants received multiple-dose of 2.5, 5, 10 mg of TS-142 or placebo (oral tablet)
223888323|NCT04768569|DRUG|Zonisamide 100Mg Cap|ZONEGRAN® is commercially available for oral administration as capsules containing 100 mg of Zonisamide.
223888324|NCT04768569|DRUG|Placebo|The placebo will contain microcrystalline cellulose which is the predominant filler in the generic capsule.
223888325|NCT02281955|RADIATION|Intensity Modulated Radiotherapy (IMRT)|All patients will receive Intensity Modulated Radiotherapy Treatments (IMRT). Dose painting IMRT will be used and all doses will be specified to the planning target volume (PTV). The high risk planning target volume (PTV-HR) and standard risk planning target volume (PTV-SR) will be treated to the following respective total doses: 60 Gy and 54 Gy. The dose per fraction to the PTV-HR and PTV-SR will be 2 Gy per day and 1.8 Gy per day respectively. The PTV-HR will include the gross tumor and the PTV-SR will include areas at risk for harboring subclinical microscopic disease.
223888326|NCT02281955|DRUG|Cisplatin (or alternative)|Cisplatin is the preferred mandated first choice chemotherapy, however alternative weekly regimens are permissible. Justification for not using cisplatin must be documented. Chemotherapy will be given intravenously weekly during IMRT. 6 total doses will be given. It is preferred that the doses be administered on days 1, 8, 15, 22, 29, and 36; however, this is not mandatory. Chemotherapy will not be given to patients with T0-2 N0-1 disease, ≤ 10 pack years smoking history.
223888327|NCT02281955|PROCEDURE|Assessment for surgical evaluation|Decisions for surgical evaluation will be based on the results of the PET/CT 10 to 16 weeks after CRT and clinical exam (including fiberoptic laryngoscopy) at that time. Other optional imaging studies may be performed. Patients with a positive PET/CT scan will undergo surgical evaluation at the discretion of the surgeon, with the goal being to remove any suspected residual tumor with a negative resection margin while maintaining organ preservation. This may include biopsies and/or oncological resections of the primary tumor and lymph node metastases. Patients with a negative PET/CT scan will be observed.
223888328|NCT06118775|PROCEDURE|EaDyn Weaning Arm:|The initiation of vasopressor weaning coincides with the beginning of the stabilization phase, which occurs when patients achieve a MAP \>75 mmHg, a cardiac index (CI) \>2.5 L/min/m², and a lactate level \<2 mmol/L. The norepinephrine dose will be gradually tapered, decreasing by 0.02 mcg/kg/min every 30 minutes. In the experimental group, vasopressor weaning is guided by the EaDyn value. Weaning can proceed as long as the EaDyn remains at or above 0.90. However, if the value drops below 0.90, the weaning process halts, and the norepinephrine dose is reverted to the last dose where the EaDyn value was ≥ 0.90. Regardless of the EaDyn value, any patient experiencing a MAP decline below 50 mmHg will be withdrawn from the study. Should the MAP range between 50 mmHg and 69 mmHg, a fluid challenge of 250 mL of isotonic crystalloid must be administered before weaning continues.
223888329|NCT06118775|PROCEDURE|PAM Weaning Arm:|The initiation of vasopressor weaning coincides with the beginning of the stabilization phase, which occurs when patients achieve a MAP \>75 mmHg, a cardiac index (CI) \>2.5 L/min/m², and a lactate level \<2 mmol/L. The norepinephrine dose will be gradually tapered, decreasing by 0.02 mcg/kg/min every 30 minutes. In the control group, vasopressor weaning progresses as long as the MAP remains at or above 70 mmHg. If the MAP falls between 50 and 69 mmHg, preload dependency is reassessed. Upon confirmation, a new fluid challenge is administered; vasopressor weaning halts, and the vasopressor dose reverts to its prior value. The weaning process can continue as long as the patient's MAP remains above 50 mmHg. If the MAP drops below this threshold, the patient exits the study.
223888330|NCT02958462|PROCEDURE|Biospecimen Collection|Undergo blood sample, hair follicle, and saliva collection
223888331|NCT02958462|PROCEDURE|Bone Marrow Biopsy|Undergo a bone marrow biopsy
223888332|NCT02958462|PROCEDURE|Punch Biopsy|Undergo a skin punch biopsy
223888333|NCT02958462|PROCEDURE|Buccal Swab|Undergo a saliva or buccal swab
223888334|NCT02958462|OTHER|Clinical Evaluation|Undergo clinical assessment
223888335|NCT02958462|OTHER|Genetic Counseling|Receive genetic counseling
223888336|NCT02958462|OTHER|Quality-of-Life Assessment|Ancillary studies
223888337|NCT02958462|OTHER|Electronic Health Record Review|Ancillary studies
223888338|NCT05396625|BEHAVIORAL|Usual Care|All participants will receive the following services: case management and psychosocial support (e.g., assessment and identification of families eligible for reunification; preparing children and parents for reunification; and assistance with receiving social benefits such as Targeted Social Assistance, alimonies, or disability benefits); referrals to schools outside of their orphanage; and leisure activities for children (e.g., music, sport, and drama) provided by the orphanage staff and municipal social services.
223888339|NCT05396625|BEHAVIORAL|Family Strengthening|Due to its focus on family-strengthening, the study uses the evidence-based intervention, SAFE Children, which employs a multiple family group format and is designed to improve family functioning, strengthen child-parent relationships and communication, enhance supportive parenting strategies, and prevent emotional and behavioral problems among at-risk children. The family-focused intervention consists of weekly multiple family group meetings (e.g. about 5 families per group). All interested family members are invited to join the sessions. The adapted intervention incorporates new sessions that address unique issues faced by families reuniting with formerly institutionalized children, such as, separation and attachment issues, children's feelings of resentment, parents' feelings of guilt and shame, stigmatized status in the community. Each session lasts about one to one and a half hours and delivered by facilitator and co-facilitator at the SOS Child and Family Center.
223888340|NCT05396625|BEHAVIORAL|Mental Health Screening, Referral and Connection to Services|Children assigned to this intervention will receive clinical assessment performed by psychiatrists at the National Mental Health Centre in Azerbaijan. From there, each child will have an individual plan developed by the multidisciplinary team and will be connected to the National Mental Health Centre clinicians to receive corresponding mental health services.
223888341|NCT05396625|OTHER|Economic Empowerment|The economic component will be in the form of Child Development Accounts/CDAs, an asset-based strategy encouraging savings and investment. This component will connect families to a bank and train them on how to save small amounts, which will be matched by contributions from the project. Matched savings will be deposited in a separate account and can be used only towards a child's education or for housing. The project will provide $50 as seed money to open a savings account in the child's name. The child's family members will make small monthly contributions to the CDA, and savings of up to $20 per month will be matched with project funds at a rate of 2:1. Caregivers will also receive training on savings and financial planning. The curriculum will be taught by trainers from the SOS in a group format for 5 sessions and will cover these topics: The Importance of Saving; Identifying and Managing Resources; Setting Up a Savings System; Sources of Income; and Budgeting and Spending.
223888342|NCT05148702|DRUG|Antibiotic - standard duration|Clinician decided antibiotic and duration of treatment
223888343|NCT05148702|DRUG|Antibiotic - fixed-extended-duration|Clinician decided antibiotic for a fixed duration of 28 days.
223888344|NCT05984706|OTHER|Focus groups and Delphi Questionnaire|1\. Focus groups to identify relevant domains of PTSD-related functional impairment in trauma-exposed children and adolescents to ensure content validity. 2. Delphi Questionnaire evaluation of a list of domains of PTSD-related functional impairment in trauma-exposed children and adolescents (previously selected from based on a literature review and focus groups) on a Likert scale of 1 to 5 for their relevance
223888345|NCT05199909|DRUG|zanubrutinib|"The initial dose is 80mg/day. If the treatment is ineffective after 4 weeks, and under the condition of good safety, the researcher will judge that the dosage should be added to 80mg twice/day，or a higher dose for oral maintenance. The maximum dose is 160mg twice a day. The duration of zanubrutinib is 24 weeks.~In case of intolerable adverse reactions, such as severe infection, severe bleeding, hematopenia, arrhythmia, etc., investigator can reduce the dose of zanubrutinib, or withdraw from clinical trials as appropriate."
223888346|NCT05426967|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|Active rTMS
223888347|NCT05426967|DEVICE|Sham rTMS|Sham comparator to active rTMS
223888348|NCT04785196|DRUG|APG-115|Dose escalation of APG-115 in combination with label dose of toripalimab, four dose levels of APG-115 will be tested: 50, 100, 150, and 200mg. APG-115 will be administrated orally every other day (QOD) for consecutive 2 weeks (ie. dosed at Day 1, 3, 5, 7, 9, 11, and 13), with one week dosing off as 3 weeks a cycle.
223888349|NCT04785196|DRUG|Toripalimab|Toripalimab is administrated following CDE approved label dose, i.e.: 240 mg intravenous infusion at Day 1 of every 3 weeks as a cycle.
223888350|NCT02783300|DRUG|GSK3326595|GSK3326595 will be administered with and without food, in tablet and capsule formulation.
223888351|NCT02783300|DRUG|Pembrolizumab|Pembrolizumab will be administered.
223888352|NCT05425446|DRUG|DONQ52|Subcutaneous (SC) injection
223888353|NCT05425446|DRUG|Placebo|Subcutaneous (SC) injection
223888354|NCT05552105|OTHER|Blood test|Before and after 6-months of anti TNF treatment, blood will be collected using the TruCulture system (2x 1ml in non-stimulated and LPS-stimulated TruCulture tubes) to measure Whole Blood Oxylipin Response, cytokine response, PUFA cell content and gene expression under homeostatic and stimulated conditions (i.e. LPS)
223888355|NCT04302493|BEHAVIORAL|Mindfulness Based Stress Reduction (MBSR)|Participants randomized to the MBSR arm will undergo a standard 8 week course of MBSR taught by a psychologist trained in the MBSR protocol and encouraged to engage in additional individual mindfulness sessions using a cell phone application.
223888356|NCT04302493|BEHAVIORAL|Stroke Support Group (SSG)|As a control group, participants randomized to the SSG arm will participate in 8 weeks of weekly Stroke Support Group sessions to experience activity and socialization without additional mindfulness training.
223888357|NCT06486311|PROCEDURE|satellite implant|Satellite implant is a additional holding component as a stabilizer to provide a polygonal support to distribute forces and moments on single-standing implants give the implant sufficient resistance to withstand masticatory forces or at least keep it in a stable position during an unloaded healing period to achieve stabilization and subsequent osseointegration of implants.
223888358|NCT03926624|DRUG|DFP-10917|DFP-10917 Powder for Injection. Active ingredient: 4-amino-1-(2-cyano-deoxy-β-D-arabinofuranosyl)-2(1H)-pyrimidinone monohydrochloride
223888359|NCT03926624|DRUG|Cytarabine|cytosine arabinoside (ara-C)
223888360|NCT03926624|DRUG|Azacitidine|Azacitidine
223888361|NCT03926624|DRUG|Decitabine|Decitabine
223888362|NCT03926624|DRUG|Mitoxantrone|Mitoxantrone
223888363|NCT03926624|DRUG|Etoposide|Etoposide
223888364|NCT03926624|DRUG|Fludarabine|Fludarabine
223888365|NCT03926624|DRUG|Idarubicin|Idarubicin
223888366|NCT03926624|DRUG|Venetoclax|Venetoclax
223888367|NCT03926624|DRUG|Cladribine|Cladribine
223888368|NCT04945629|DRUG|Alveolar ridge preservation with a PRP (PRGF-Endoret)|Filling of the alveolus with PRGF clot and fibrin plug.
223888369|NCT04945629|DRUG|Blood clot and simple suture|Filling the alveolus with blood clot
223888370|NCT05584241|BEHAVIORAL|Diagnostic Disclosure Protocol|Personalized disclosure on cognitive test results and research diagnosis, plus post-disclosure dementia risk reduction counseling.
223888371|NCT05584241|BEHAVIORAL|Biomarker Disclosure Protocol|Participants receive information about their cognitive test results and research diagnosis just like in the diagnostic disclosure protocol. In addition, participants receive information about whether they currently have elevated or not-elevated amyloid and/or tau based on recent PET imaging. PET is a type of imaging biomarker (Aß-PET and tau PET) for clinical diagnosis of Alzheimer's disease. These actions are followed by post-disclosure dementia risk reduction counseling.
223888372|NCT05350722|RADIATION|Single dose ablative radiotherapy|Patients will receive a single dose of 20Gy/15Gy on the gross tumor volume and clinical tumor volume respectively, in the context of pre-operative partial breast irradiation
223888373|NCT06140875|DEVICE|Radiofrequency electromagnetic field treatment|Radiofrequency electromagnetic field treatment using a carrier frequency of 13.56 MHz
223888374|NCT05943626|BEHAVIORAL|Circadian Intervention|The circadian intervention group will receive counseling and instruction to reduce evening and nighttime light exposure, increase morning room light and sunlight exposure, and to finish all food consumption at least 4 hours before bedtime.
223888375|NCT04103268|OTHER|sepsis|patients in the ICU with infection called sepsis
223888376|NCT03785106|DRUG|Isoniazid/Rifapentine daily (4 weeks) plus pyridoxine (vitamin B6)|Isoniazid/Rifapentine daily (4 weeks) plus pyridoxine (vitamin B6)
223888377|NCT03785106|DRUG|Isoniazid/Rifapentine 12-weekly plus pyridoxine (vitamin B6)|Isoniazid/Rifapentine 12-weekly plus pyridoxine (vitamin B6)
223888378|NCT00378105|DRUG|Bortezomib|Intravenously on days 1, 4, 8 and 11 of a 21 day cycle for a minimum of 8 cycles (dosage will vary depending upon when the participant enters the trial)
223888379|NCT00378105|DRUG|Lenalidomide|Taken orally twice a day for 2 weeks (days 1-14) of each 21-day cycle for a minimum of 8 cycles (dosage will vary depending upon when participant enters trial).
223888380|NCT00378105|DRUG|dexamethasone|Taken orally on days 1,2,4,5,8,9,11 of a 21-day cycle for a minimum of 8 cycles.
223888381|NCT06255925|BEHAVIORAL|KF-STRIDE® Into Work!|Treatment group will receive 10 web based sessions of a strength-based training tool(once or twice a week). Sessions are approximately 60 minutes long.
223888382|NCT04353115|DEVICE|Training with Serious game|training the gaze stability with a serious game, 20 minutes a day, 2 days a week for 5 weeks in the presence of a doctor or physiotherapist, at the hospital to avoid addiction at home.
223888383|NCT06128174|DEVICE|Farawave PFA catheter|The FARAWAVE Pulsed Field Ablation Catheter (FARAWAVE Catheter) is a flexible tube with electrodes at the end, which is inserted through a blood vessel in your groin. The study doctor will use the FARAWAVE Catheter to deliver the pulsed electrical energy to ablate (destroy) the heart tissue. This process is designed to create a scar in the heart tissue, stopping the unwanted electrical signals that cause the atrial fibrillation.
223888384|NCT02729467|DRUG|JNJ-53718678|JNJ-53718678 will be applied twice at doses of 250 mg (in Panel 1, Day 1 and Day 9) and 3 times at 500 mg (Panel 2, Day 1, 4 and 9).
223888385|NCT02729467|DRUG|Itraconazole|Participants will receive itraconazole 200 mg (2 capsules of 100 mg) from Day 4-11.
223888386|NCT02729467|DRUG|Rifampicin|Participants will receive 600 mg rifampicin (2 capsules of 300 mg) from Day 4-11.
223888387|NCT05192200|DRUG|Anti-Beta Interferon (PF-06823859)|IV infusion
223888388|NCT06341413|DEVICE|SmartSleep device|Device worn during sleep
223888389|NCT06389097|RADIATION|Radium-223|"Radium-223 will be given as per standard of care or other clinical trial. It is typically administered intravenously via slow injection once every 4 weeks with a dosage of 55 kBq/kg per cycle. Patients typically receive up to six cycles unless unacceptable toxic effects occurred, disease progression is apparent, or the patient is unable or unwilling to adhere to treatment.~Three SPECT/CT studies will be performed for research purposes after 2 cycles in patients who consent to participate in this imaging and dosimetry study. These will be performed at 2-4 hr, 24 hr, and 48 hr after any cycle of Radium-223. Protocol preference is for imaging with 2 cycles, ideally cycle 1 and cycle 6, but imaging with any one or two cycle(s) is acceptable.~The imaging time at each time point is approximately 30 minutes per field of view with two fields of view (1 hr total) typically collected sequentially (i.e., without repositioning the patient on the imaging table)."
223888390|NCT06389097|RADIATION|177Lu-DOTATATE|"177Lu-DOTATATE to be given as Standard of Care (SOC) or other clinical trial. It is typically infused intravenously over a period of 20-60 minutes with peptide co-infusion prior and during the infusion.~Patients will receive 4 cycles of 177Lu-DOTATATE administered approximately every 8 weeks. Treatment cycle is defined as 8 consecutive weeks (D1-D56) following a dose of 177Lu-DOTATATE. Patients receive up to four infusions of 7.4 GBq (200 mCi) every 8 weeks unless unacceptable toxic effects occurred, disease progression is apparent, or the patient is unable or unwilling to adhere to treatment.~Three SPECT/CT studies will be performed for research purposes after 2 cycles in patients who consent to participate in this imaging and dosimetry study. Lu-177 SPECT CT will be performed at 24 (D2), 48 (D3), and 96 (D5) of any cycle of therapy.~Imaging time at each time point is \~ 15-22 minutes per field of view with two fields of view (45 min total) typically collected sequentially."
223888391|NCT06389097|RADIATION|177Lu-PSMA-617|"177Lu-PSMA-617 will be given as per SOC or other clinical trial. It is typically infused intravenously over a period of 20-60 minutes.~Up to 6 cycles of 177Lu- PSMA-617 will be administered approximately every 6 weeks. Treatment cycle is defined as 6 consecutive weeks (D1-D42) following a dose of 177Lu- PSMA-617. Patients will receive up to six infusions of 7.4 GBq (200 mCi) every 6 weeks unless unacceptable toxic effects occurred, disease progression is apparent, or the patient is unable or unwilling to adhere to treatment.~Three SPECT/CT studies will be performed for research purposes after 2 cycles in patients who consent to participate in this imaging and dosimetry study. Lu-177 SPECT CT will be performed at 24 (D2), 48 (D3), and 96 (D5) of any cycle of therapy.~Imaging time at each time point is approximately 15-22 minutes per field of view with two fields of view (45 min total) typically collected sequentially."
223888392|NCT06106282|OTHER|Non-Interventional Study|Non-Interventional Study
223888393|NCT05967273|OTHER|CirrhosisRx CDS|CirrhosisRx is a cirrhosis-specific CDS that organizes clinical data into clinically relevant groupings and links them to order sets consistent with national practice guidelines for inpatient cirrhosis care.
223888394|NCT06440213|DIETARY_SUPPLEMENT|PeptiControl™ (Low - Dose 435 mg/day)|Plant protein hydrolysate
223888395|NCT06440213|DIETARY_SUPPLEMENT|PeptiControl™ (Mid - Dose 870 mg/day)|Plant protein hydrolysate
223888396|NCT06440213|DIETARY_SUPPLEMENT|PeptiControl™ (High - Dose 2610 mg/day)|Plant protein hydrolysate
223888397|NCT06440213|DIETARY_SUPPLEMENT|Placebo Microcrystalline Cellulose|Placebo MCC micro-crystalline cellulose
223888398|NCT01787383|DRUG|Ingenol mebutate gel 0.05 %|Ingenol mebutate gel 0.05 % (Picato®) on trunk/extremities either applied simultaneously or sequentially
223888399|NCT01787383|DRUG|Ingenol mebutate gel 0.015 %|Ingenol mebutate gel 0.015 % (Picato®) on face/scalp either applied simultaneously or sequentially
223888400|NCT06414798|DRUG|Drug: ABBV-1088|• Oral Capsule
223888401|NCT06414798|DRUG|Drug: Placebo for ABBV-1088|• Oral Capsule
223888402|NCT06456359|DRUG|Signifor|Signifor 40 mg: each vial contains 40 mg pasireotide (as pasireotide pamoate). Signifor 60 mg: each vial contains 60 mg pasireotide (as pasireotide pamoate).
223888403|NCT03829631|DEVICE|Horizon 627 Lumbar Brace, Aspen Medical Company, Oak Canyon, Irvine, CA 92618|The brace is an FDA Class I, one-size adjustable design to fit waists ranging from 24-70 inches. Participants will be instructed to wear the brace for six weeks during the daytime
223888404|NCT06303271|OTHER|Vagus Nerve Stimulation (VNS) and Caw Thorne Cooksey|Study will be conducted after the approval of Ethical review board. After the initial evaluation will be done on participants underlying eligibility criteria. Experimental group will received intervention of 30 minutes daily for 4 weeks (16 sessions). Assessment was done at the baseline, after 2 weeks and after 4 weeks. Intervention Group received non-invasive vagus nerve stimulation at left auricle (because of anatomy of vagus nerve as right VN innervate SA node which is regulating heartbeat and left VN innervates AV node which is responsible for controlling timing of heartbeat) of ear. VNS group received vagus nerve stimulation via Med Fit vagus nerve stimulator at auricle of left ear only as stimulation of right auricular branch of vagus nerve can result in bradycardia. Frequency of stimulation was kept between 15-30Hz. Intensity was gradually increased according to patient's tolerance. The participant was able to withdraw from the trial if he could not tolerate the stimulation
223888405|NCT06303271|OTHER|Caw Thorne Cooksey|Study will be conducted after the approval of Ethical review board. After the initial evaluation will be done on participants underlying eligibility criteria. The control group will intervention of 30 minutes daily for 4 weeks (16 sessions). Caw Thorne Cooksey exercises were carried out during the stimulation of vagus nerve. Although no adverse effects had been reported during the stimulation of left auricular branch of vagus nerve but a pulse oximeter was used during the stimulation to monitor the heart rate.
223888406|NCT05935748|DRUG|NKT2152|Oral HIF2a inhibitor
223888407|NCT05935748|DRUG|palbociclib|a cyclin-dependent kinases (CDK) 4 and 6 inhibitor
223888408|NCT05935748|OTHER|sasanlimab|an immunoglobulin G4 (IgG4) monoclonal antibody that blocks PD-1; a solution for injection for subcutaneous administration
223888409|NCT06513104|DRUG|NNC0519-0130|NNC0519-0130 will be administered subcutaneously.
223888410|NCT06513104|DRUG|Levonorgestrel + Ethinylestradiol|Levonorgestrel + Ethinylestradiol will be administered orally.
223888411|NCT06513104|DRUG|Paracetamol|Paracetamol will be administered orally.
223888412|NCT04533347|DRUG|Tafenoquine Oral Tablet|Patients will be randomized and will receive and self-administer 200 mg Tafenoquine or matching placebo on Days 1, 2, 3, and 10.
223888413|NCT04533347|DRUG|Placebo|Patients will be randomized and will receive and self-administer 200 mg Tafenoquine or matching placebo on Days 1, 2, 3, and 10.
223888414|NCT06260358|OTHER|Survey|"MRI examinations will be performed on 1.5T or 3T scanners, with protocol according to ESUR guidelines.The contextual structured report will be generated by the investigators in consensus.~In every centre, one report (structured or narrative) will be generated from various radiologists experienced in gynaecologic imaging during clinical practice. Two radiologists in consensus, will develop the second version (narrative or structured report)."
223888415|NCT06528340|PROCEDURE|spontaneous delivery|The women will be followed until the birth, in which the 3 traditional 3 methods will be carried out (spontaneous, vaginal operating, abdominal operation)
223888416|NCT03907397|BIOLOGICAL|Peanut Protein|up to 3 level teaspoons peanut butter or equivalent (approximately 3400 mg)
223888417|NCT03907397|OTHER|Continued peanut avoidance|Standard of care avoidance of peanut
223888418|NCT05057624|OTHER|Placebo GC-MRT|Participants will hear music continuously throughout the trials, without regard to the faces they look at.
223888419|NCT05057624|OTHER|GC-MRT|Participants will hear music as a reward for looking at neutral faces and the music will stop when they focus on angry faces.
223888420|NCT05057624|OTHER|Exposure|Participants will hear music of their choice when they focus on angry faces, and when they look at neutral faces the music will stop.
223888421|NCT06549530|DRUG|MVA-BN|All participants will receive 2 vaccinations of the same dose of MVA-BN vaccine 4 weeks apart (standard regimen).
223888422|NCT06156202|OTHER|Comprehensive Rehabilitation|Subjects will be given the option to undergo the comprehensive rehabilitation program including speech therapy and physical therapy. Progression through the rehabilitation program will be personalized and designed based on impairments identified during the comprehensive baseline assessment and previous sessions. Subjects will undergo 12 one- hour sessions over the course of six weeks. The exercise program will be graded and targeted to the person's physical capacity with the goal of slowly advancing the exercise duration or intensity to effect physiological strengthening and increased physical function.
223888423|NCT06156202|OTHER|Augmented Usual Care|"Following randomization, subjects in the augmented usual care group will be given the results of their in-person baseline assessment as well as the WHO Guide Support for Rehabilitation Self-Management after COVID-19 Related Illness. This guide consists of ways to manage: breathlessness, difficulty with voice, eating, drinking and swallowing; problems with attention, memory and thinking clearly; limitations in activities of daily living, manage stress and mood dysfunction and advice for when to contact healthcare professionals. Follow-up interviews will assess process measures, including use of outpatient rehabilitation clinics, to examine possible contamination effects"
223888424|NCT06274112|DEVICE|TMS|TMS will be administered using a Cool B-65 coil to a personalized right dlPFC region.
223888425|NCT04276922|BEHAVIORAL|Visual Arts|"Subjects meet for 90 minutes, once weekly, over 12 weeks for guided drawing/sketching sessions. The 12 sessions will follow a standard sequence that addresses three primary themes: creating safety, inviting vulnerability, and integrating into a transformative community.~Surveys, activity diary cards will be completed at baseline, weekly and at intervention completion to assess satisfaction, stress, and well-being. Qualitative focus groups will occur after the intervention to assess acceptability of intervention, outcomes assessments, program development and implementation."
223888426|NCT04276922|BEHAVIORAL|Music|"Subjects meet for 90 minutes, once weekly, over 12 weeks, for guided music-listening exercises (such as lyric analysis, patient-chosen, music for relaxation and/or visualization) and active music making. The 12 sessions follow a standard sequence, addressing three primary themes: creating safety, inviting vulnerability, and integrating into a transformative community.~Surveys, activity diary cards are completed at baseline, weekly and at completion to assess satisfaction, stress, and well-being. Qualitative focus groups, after the intervention, assess acceptability of intervention, outcomes, program development and implementation."
223888427|NCT04276922|BEHAVIORAL|Dance/Movement|"Subjects will meet once weekly, and begin with a movement check-in, a gentle physical warm-up, and then either a structured or improvisational movement process. for a total of 12 weeks. Each session will last 90 minutes. The 12 sessions will follow a standard sequence that addresses three primary themes: creating safety, inviting vulnerability, and integrating into a transformative community.~Surveys, activity diary cards will be completed at baseline, weekly and at intervention completion to assess satisfaction, stress, and well-being. Qualitative focus groups will occur after the intervention to assess acceptability of intervention, outcomes assessments, program development and implementation."
223888428|NCT04276922|BEHAVIORAL|Writing/Poetry|"Subjects will meet once weekly, for writing workshops to encourage participants to tell the stories they need to tell, using integral elements of good writing, for a total of 12 weeks. Each session will last 90 minutes. The 12 sessions will follow a standard sequence that addresses three primary themes: creating safety, inviting vulnerability, and integrating into a transformative community.~Surveys, activity diary cards will be completed at baseline, weekly and at intervention completion to assess satisfaction, stress, and well-being. Qualitative focus groups will occur after the intervention to assess acceptability of intervention, outcomes assessments, program development and implementation."
223888429|NCT04276922|BEHAVIORAL|Control|Control Group will only complete surveys at baseline and 12 weeks later.
223888430|NCT06836960|DRUG|Probiotic Therapy With Gegen Qinlian Tang|This intervention includes the oral administration of Bifidobacterium Triple Viable Capsules (0.5 g, three times daily) combined with Gegen Qinlian Tang (200 mL, twice daily) for 8 weeks. The combination therapy is designed specifically for the prevention and treatment of radiation enteritis, differentiating it from probiotics or herbal therapies used alone.
223888431|NCT04061798|DRUG|ACT guided heparinization|"If the ACT is \<180 sec., an additional dose of heparin of 60 IU/kg is administered. If the ACT is 180-200 sec., 30 IU/kg.~If the ACT is \>200 sec., no extra heparin is given. 5 min. after every administration of heparin the ACT is measured. If the ACT is \>200 sec, the next ACT measurement is performed every 30 min., until the end of the procedure or until new heparin administration is required. After each new dose of heparin, an ACT measurement is performed after 5 min. and the above- described protocol of ACT measurements will be repeated. After re-establishing blood flow and removing all clamps, the ACT is measured.~If the ACT at closure is 200-250 sec., 2500 IU of protamine should be administered. If \>250 sec., 5000 IU protamine. If 180-200 sec., 1000 IU protamine. 5 min. after the administration of protamine, the ACT is measured. The ACT should preferably be below 180 sec. If the ACT is still more than 200 sec., protamine should be administered again."
223888432|NCT04061798|DRUG|5 000 IU of heparin|"A single dose of 5 000 IU of heparin is given 3-5 min before clamping of the aorta. No ACT measurements are performed, except for one ACT measurement after re-establishing blood flow and removing all clamps. Only on clarified indications extra doses of heparin or protamine are permitted, at the discretion of the attending vascular surgeon. Indications could be clot formation intravascular or in a prosthesis, excessive bleeding or prolonged operation duration. Deviations from protocol should be clearly stated with reasoning in the operative report.~If the ACT at closure is between 200 and 250 s, 2500 IU protamine should be administered. If the ACT is higher than 250 s, 5000 IU protamine should be administered. If the ACT is between 180 and 200 s, 1000 IU protamine should be administered. Five minutes after the administration of protamine, the ACT is measured. The ACT should preferably be below 180 s. If the ACT is still more than 200 s, protamine should be administered again."
223888433|NCT06017180|OTHER|Myofascial Release Techniques|Volleyball players will perform these practices with a physiotherapist 3 days a week for 8 weeks (24 sessions), and their routine sports training will continue. Participants in the group will be shown how to use rolling materials. The application will be performed as 2 sets in a session using the body weight of the person, as 10 rolls in 1 minute. The application time will be 2 minutes in total for each session. There will be 30 seconds of rest between sets. The participation rate limit for the sessions was determined as 80%. The application rate will be controlled with a metronome. The pressure to be created using body weight will be controlled by a numerical pain scale. The technique will be applied to the biceps brachii, latissimuss dorsi, upper trapezius, pectoralis minor, pectoralis major, and thoracic extensor muscles. During the application, a foam roller and a rolling stick (Thera-Band, Hygienic Corporation, Akron, OH) will be used.
223888434|NCT06017180|OTHER|Sham myofascial release technique|It was planned to apply the sham myofascial release technique to the athletes in the control group. In this application; with the help of the palm of the hand, pressure will be applied to the surface of the relevant muscles, first without pressure for 1 minute, then after resting for 30 seconds. The given pressure will be 2 out of 10 (0: No pain/discomfort due to pressure, 10: Unbearable pain/discomfort due to pressure). This group will also be given the right to receive a myofascial relaxation program which the experimental group received, after the study period ended.
223888435|NCT06106893|BIOLOGICAL|CD19 Universal CAR-γδ T Cells|Intravenous infusion of CD19 Universal CAR-γδ T Cells
223888436|NCT06834776|DIAGNOSTIC_TEST|TOF (Train-of-Four) monitoring for depth of neuromuscular blockade.|General anesthesia with propofol and fentanyl induction followed by rocuronium for neuromuscular blockade; maintenance with desflurane and remifentanil.
223888437|NCT05942001|DRUG|HRS-5041|HRS-5041 was given oral administration, qd, at a 28-day cycle. Patients may continue to use HRS-5041 until disease progression or unacceptable toxicity occurs.
223888438|NCT05878860|BIOLOGICAL|ATSN-201|AAV.SPR-hGRK1-hRS1syn
223888439|NCT04973163|DRUG|BI 1823911|BI 1823911
223888440|NCT04973163|DRUG|BI 1701963|BI 1701963
223888441|NCT04973163|DRUG|Midazolam|Midazolam - only administered in Part B (dose confirmation) of the Monotherapy Arm
223888442|NCT06836492|COMBINATION_PRODUCT|VAC，VAC/VII，CAV/IE|Low risk: VAC Intermediate risk: VAC/VII High risk: CAV/IE Very high risk: CAV/VIP
223888443|NCT05724160|OTHER|Using sitting ellipticals|Patients will receive routine physiotherapy protocols as well as Non-weightbearing stationary elliptical
223888444|NCT05724160|OTHER|Physiotherapy Protocol|Routine physiotherapy protocol
223888445|NCT06016621|BEHAVIORAL|Improvisational Music Therapy|The therapist engages with the child by playing and sharing musical instruments, and/or sings while being attuned to the child's behaviour and expression. Various improvisational techniques are employed to engage the child. There are opportunities for pulse, rhythmic, dynamic or melodic patterns, and timbre to be mirrored, reinforced, or complemented, which allows for moments of synchronization between the therapist and the child, giving the child's musical expressions a pragmatic meaning within this context. The therapist may also gently provoke the child by violating expectations or patterns that have been jointly developed in order to elicit specific social communication behaviours. Further, there are opportunities for the child to develop and enhance social communication skills such as joint attention, sharing affect, reciprocity, shared history, scaffolding, imitation and turn-taking. These have been shown to develop social competency and also resilience.
223888446|NCT06837948|DRUG|PM8002|Specified dose on specified days.
223888447|NCT06837948|DRUG|Sintilimab|Specified dose on specified days.
223888448|NCT06837948|DRUG|Nab-paclitaxel|Specified dose on specified days.
223888449|NCT06837948|DRUG|Carboplatin|Specified dose on specified days.
223888450|NCT06837948|PROCEDURE|Surgery|Patients with resectable tumor after neoadjuvant therapy will be treated with surgery.
223888451|NCT06509386|OTHER|Major Depressive Disorder without treatment or role fulfillment|Read vignette describing the condition and ask stigma questions.
223888452|NCT06509386|OTHER|Major Depressive Disorder with treatment but no role fulfillment|Read vignette describing the condition and ask stigma questions.
223888453|NCT06509386|OTHER|Major Depressive Disorder without treatment but with role fulfillment|Read vignette describing the condition and ask stigma questions.
223888454|NCT06509386|OTHER|Major Depressive Disorder with treatment and role fulfillment|Read vignette describing the condition and ask stigma questions.
223888455|NCT06509386|OTHER|Schizophrenia without treatment or role fulfillment|Read vignette describing the condition and ask stigma questions.
223888456|NCT06509386|OTHER|Schizophrenia with treatment but no role fulfillment|Read vignette describing the condition and ask stigma questions.
223888457|NCT06509386|OTHER|Schizophrenia without treatment but with role fulfillment|Read vignette describing the condition and ask stigma questions.
223888458|NCT06509386|OTHER|Schizophrenia with treatment and role fulfillment|Read vignette describing the condition and ask stigma questions.
223888459|NCT04493034|BEHAVIORAL|Art Therapy|"The art therapist will assist each participant in producing a bound collection of participant art works/writings for personal, group and/or caregiver inspiration, at the participant's request. For in-person sessions, a variety of studio-based art and writing materials will be available for participant selection and creation. Each session will be directed in the following manner:~* New therapeutic prompt or bridge from prior session~* Creative expression, opportunity for reflection, verbal sharing / processing, and a session summary~* Discussion of action plan for the next consecutive, at-home session (weekly assignment).~Possible wellness themes for each session (in-person or at-home) may include: mental health, physical health, emotional health, spiritual health, relational health (family and social), or occupational health/financial health."
223888460|NCT04493034|BEHAVIORAL|Music Therapy|"Participants have the opportunity to engage in: learning an instrument, active music-making, receptive music-listening, singing, improvisation, song-writing, education on music technology, or music discussion. During in-person musical sessions the six psychosocial goals promoted by the music therapist include: 1) self-care/self-love, 2) support systems, 3) practicing positivity 4) gratitude 5) mindfulness/living in the moment, and 6) goal-setting.~For at-home assignments, participants will be asked to pick a song of the week that coincides with the theme/goal discussed in previous session(s). They will be asked to write a journal entry about the topic discussed. Journal entries can be freely written or a prompt/question can be provided. If participants do not have access to search for songs or listen to music as at home, they may select a piece from the session and be given lyrics and/or a recording on an .mp3 player returned at conclusion of study."
223888461|NCT02457156|PROCEDURE|Blumgart Anastomosis|"1. Trans pancreatic suture U stich incorporating pancreatic parenchyma and jejunal serosa, left loose.~2. Pancreatic duct to jejunal mucosa sutures, inserted and tied.~3. Trans pancreatic suture U stich brought back through the jejuanl serosa anteriorly, tied."
223888462|NCT02457156|PROCEDURE|Cattell-Warren Anastomosis|"1. Posterior row of sutures from pancreatic parenchyma to jejunal serosa, inserted and tied.~2. Pancreatic duct to jejunal mucosa sutures, inserted and tied.~3. Anterior row of sutures from pancreatic parenchyma to jejunal serosa, inserted and tied."
223888463|NCT02457156|DRUG|Octreotide|Octrotide (100ug) to be administered on the evening before surgery and then 100ug three times daily on the day of surgery and post operative days 1 - 6.
223888464|NCT06682572|DRUG|Avutometinib (VS-6766) + Defactinib (VS-6063)|combination therapy
223888465|NCT06837922|DRUG|MG-K10/Placebo|MG-K10 Humanized Monoclonal Antibody Injection
223888466|NCT06837363|DEVICE|Home-based Neofect Smart board|a total of 20 sessions of home-based upper limb rehabilitation training using the Neofect Smart board, with 30 minutes per session, 1 session per day, 5 days a week, for 4 weeeks.
223888467|NCT06837363|OTHER|home-based occupational therapy|a total of 20 sessions of home-based upper limb rehabilitation training using the workbook provided by the research team , with 30 minutes per session, 1 session per day, 5 days a week, for 4 weeeks.
223888468|NCT05503485|BEHAVIORAL|Existential group treatment|The existential group treatment follows a manualised structure focusing on aging-related challenges related to existential themes such as story of life, freedom, loneliness, and death. In order to support patients in finding new, productive ways of engaging in the existential process of aging literary texts, therapy practices and assignments between the sessions are used and each group will be accompanied by two therapists who facilitate the group climate, gently bring the group back on topic and help group members to see different ways of dealing with existential concerns related to aging.
223888469|NCT05503485|BEHAVIORAL|Supportive telephone calls|"The supportive caller will provide empathetic basic support, equivalent to the telephone support provided within the Swedish non-governmental organization Mind's Äldrelinjen. No psychotherapeutic techniques will be applied and there will be no interventions beyond the phone call itself."
223888470|NCT05147155|BIOLOGICAL|Mepolizumab|This will be a 2-year prospective study. Patients with uncontrolled severe asthma will receive mepolizumab according to standard of care and best clinical practice, which will be administered as a 100-mg subcutaneous dose every four weeks.
223888471|NCT05497206|DEVICE|One of the following hip implants may be used within this arm of the study: G7 Acetabular System, Taperloc Complete System, Avenir and Avenir Complete Systems, and Echo Bi-Metric System|Total Hip Arthroplasty
223888472|NCT06208202|BEHAVIORAL|Behavioral Intervention|Receive and use flavored e-cigarettes (EC) as directed
223888473|NCT06208202|OTHER|Biospecimen Collection|Undergo biosample sample collection
223888474|NCT06208202|OTHER|Survey Administration|Complete surveys
223888475|NCT04853004|DIAGNOSTIC_TEST|SARS-CoV2 antibody measurement|Blood samples for serology, collected immediately prior to and five to ten weeks after vaccination against SARS-CoV2, to be analyzed for the presence of SARS-CoV-2 antibodies.
223888476|NCT06432543|DEVICE|polyethylene|No intervention as this is an observational study
223888477|NCT06512259|OTHER|AlloMend® Acellular Dermal Matrix allograft|AlloSource, a non-profit supplier of allografts and one of the nation's leading tissue banks, introduced AlloMend® Acellular Dermal Matrix allograft to bring the benefits of regenerative medicine to more patients. cellular allograft matrices, unlike synthetic materials or xenografts, are recognized as human tissue by the body for graft incorporation by the recipient, minimizing the risk of inflammation or rejection. AlloMend® Acellular Dermal Matrix allograft has been shown to incorporate into the surgical site and demonstrates blood vessel infiltration.
223888478|NCT06101862|PROCEDURE|CCTA|Participants will be examined with CCTA during admission.
223888479|NCT06101862|PROCEDURE|Conventional ICA|Patients will be examined with conventional standard-of-care ICA.
223888480|NCT06101862|OTHER|Team-based interventional triage|The CCTA will be discussed at a coronary CT-team conference to establish the treatment strategy and provide guidance for any necessary interventional procedure.
223888481|NCT04984291|DEVICE|Alliance Glenoid|Alliance Glenoid used in Primary or Revision Total Shoulder Arthroplasty
223888482|NCT04984291|DEVICE|Identity Stem|Identity Shoulder System is intended to be used in anatomic total shoulder arthroplasty, shoulder hemi-arthroplasty, or total reverse shoulder arthroplasty in both Primary or Revision Total Shoulder Arthroplasty
223888483|NCT06822959|OTHER|Pharmacogenetics, TDM and MedReview|Patients will undergo pharmacogenetics, TDM and MedReview analyses according to the study protocol
223888484|NCT06741475|BEHAVIORAL|Caregiver-Assist Strategy Training|CaST is a home-based rehabilitation that guides both stroke survivors and their caregivers to implement strategy training for addressing real-life limitations after stroke. During the intervention, the caregiver not only supervises the participant but also co-participates in the practice by instructing on when and how to be an assistant and facilitator when the stroke survivor executes their practice plan.
223888485|NCT06741475|BEHAVIORAL|Education|Stroke-related information and knowledge that includes stroke subtypes and their etiology, risk factors of primary and secondary stroke, healthy lifestyles, common sequela, and adaptive skills for impaired functions are provided.
223888486|NCT06835270|OTHER|Yoga Exercises|Yoga group practiced Iyengar yoga asanas, pranayama, and mental focusing components in a group exercise format for 45 minutes.The yoga group was advised to practice yoga exercises at home following their yoga sessions.
223888487|NCT06835270|DEVICE|Standard physiotherapy approaches|Standard physiotherapy approaches group ( standard physiotherapy approaches (therapeutic ultrasound, hotpack) and TENS (5x5 cm electrodes, applied to the thoracic 12 and sacral 1 regions). Four electrodes were applied for 20 minutes with a pulse width of 50-100 µs and a frequency of 60-120 Hz. This group was additionally recommended to perform home exercises
223888488|NCT06835270|OTHER|Kinesiology taping|In the kinesiology taping technique, tape was applied in an I-shape parallel to the m. quadratus lumborum muscle. Interventions were conducted three times a week for four weeks, totaling 12 sessions.This group was additionally recommended to perform home exercises
223888489|NCT06835270|BEHAVIORAL|Awareness training for low back pain|The educational training was based on the WHO's guidelines for back pain. This group was additionally recommended to perform home exercises.
223888490|NCT04765943|DEVICE|Implantable Loop Recorder implant|Patients will be undergone to an Implantable Loop Recorder implant and monitored for the next 6 months.They will then undergo a cardiac MRI and an ICD will be implanted according to clinical practice guidelines. A minimum follow-up of 2 years is scheduled.
223888491|NCT05499637|DRUG|[68Ga]Ga-PentixaFor PET/CT|\[68Ga\]Ga-PentixaFor PET/CT
223888492|NCT03562377|DRUG|Tralokinumab|Tralokinumab is a human recombinant monoclonal antibody of the IgG4 subclass that specifically binds to human IL-13 and blocks interaction with the IL-13 receptors. It is presented as a liquid formulation for subcutaneous administration.
223888493|NCT03562377|DRUG|Placebo|Placebo contains the same excipients in the same concentration only lacking tralokinumab.
223888494|NCT03562377|BIOLOGICAL|Tdap vaccine|Tetanus (lockjaw), diphtheria (infection of the nose and throat), and pertussis (whooping cough) vaccine. All subjects will receive 1 dose at Week 12.
223888495|NCT03562377|BIOLOGICAL|Meningococcal vaccine|This vaccine is used to prevent meningococcal diseases (infection of the brain and spinal cord) and blood poisoning. All subjects will receive 1 dose at Week 12.
223888496|NCT05817838|BEHAVIORAL|Financial Incentives|For six months, families will receive weekly, $15 financial incentives to purchase healthy foods and beverages at a partnering Southeast Asian grocery store
223888497|NCT05817838|BEHAVIORAL|Financial Incentives and Multilevel Multicomponent|For six months, families will receive weekly, $15 financial incentives to purchase healthy foods and beverages at a partnering Southeast Asian grocer store, in-person, group-based nutrition education with other Southeast Asian families, text messages and motivational interviewing
223888498|NCT05817838|OTHER|School Engagement|For six months, families will attend in-person, group-based school engagement education with other Southeast Asian families designed to improve youths' academic outcomes. Families will receive text messages and motivational interviews. At the end of the six months, families will receive the equivalent of the six months worth of weekly, $15 financial incentives.
223888499|NCT06837337|OTHER|Music intervention|Music intervention
223888500|NCT06834542|BIOLOGICAL|Autologous tumor infiltrating lymphocyte injection（GT201）|GT201 treatment for advanced gynecological tumors (advanced cervical cancer)
223888501|NCT06557499|DEVICE|Polyurethane (PU) male condom-Test condom 1|A minimum of 5 condoms (maximum 7 condoms) of each condom type will be provided to couples to be used during vaginal intercourse over a maximum 5-week period (assessment period). Couples will repeat the assessment period for each of the 3 condom types.
223888502|NCT06557499|DEVICE|Polyurethane (PU) male condom-Test condom 2|A minimum of 5 condoms (maximum 7 condoms) of each condom type will be provided to couples to be used during vaginal intercourse over a maximum 5-week period (assessment period). Couples will repeat the assessment period for each of the 3 condom types.
223888503|NCT06557499|DEVICE|Natural Rubber Latex (NRL) male condom- Control condom|A minimum of 5 condoms (maximum 7 condoms) of each condom type will be provided to couples to be used during vaginal intercourse over a maximum 5-week period (assessment period). Couples will repeat the assessment period for each of the 3 condom types.
223888504|NCT04431999|DRUG|Whole blood transfusion|Severe trauma patients with a life threatening bleeding will be managed with 3 whole blood bags for the 1st and 2nd pack. The later packs will consist of 3 packed red blood cells (PRBCs), 3 plasma units and 1 dose of platelets.
223888505|NCT04431999|DRUG|Fractionated blood products transfusion|Severe trauma patients with a life threatening bleeding will be managed with 3 packed red blood cells (PRBCs), 3 lyophilised plasma units and 1 dose of platelets for the 1st. The 2nd pack will consist of 3 packed red blood cells (PRBCs) and 3 lyophilised plasma units. Then, the later pack will consist of 3 packed red blood cells (PRBCs), 3 plasma units and 1 dose of platelets.
223888506|NCT03737149|OTHER|mymobility with Apple Watch|The mymobility mobile application is a mobile software platform designed to facilitate remote episode of care management and asynchronous communication between the provider care team and their patient via provider-approved care plans and engagement communications. Current care pathways have been developed for: Total Hip Replacement, Total Knee Replacement and Partial Knee Replacement. Designed for the orthopedic population, mymobility also integrates wearable data from the Apple Watch into provider dashboards, providing enhanced understanding and monitoring of patients throughout the episode of care.
223888507|NCT06828913|OTHER|Oral Health information on online platforms|oral health
223888508|NCT05254457|BIOLOGICAL|EN3835|Treatment or retreatment with EN3835
223888509|NCT06251063|BEHAVIORAL|Web-based psychoeducational resource|"The website will incorporate animations/illustrations to enhance comprehension, patient stories, and video-based expert explanations.~The materials will address the following content areas:~* Provide families with data demonstrating how prevalent social relationship struggles are for children with CDH.~* Describe specific social challenges that commonly affect children with CDH.~* Explain the impact that medications typically prescribed for CDH may have on social relationship health.~* Help families advocate for their child's social needs at school.~* Support children and their families in decision-making about appropriate disclosure with peers at school and in extracurricular settings.~* Offer strategies to support families in raising the issue of social relationship health with the child's sleep physician.~* Provide a list of programming which offers children both structured and unstructured opportunities for social engagement"
223888510|NCT04457154|DEVICE|Inspire Upper Airway Stimulation System|Implant of the Inspire Upper Airway Stimulation System
223888511|NCT01514552|OTHER|Strawberry gummy|Randomized to consume 2 gummies (6 gram gummies each, total 12 grams/dose)four times daily for 7 days. Subjects will be randomized to either start with this strawberry intervention during intervention days 0 to 7 or during the crossover intervention on days 21 to 28.
223888512|NCT01514552|OTHER|Placebo control gummy|Randomized to consume 2 gummies (6 gram gummies each, total 12 grams/dose)four times daily for 7 days. Subjects will be randomized to either start with this a placebo gummy intervention during intervention days 0 to 7 or during the crossover intervention on days 21 to 28.
223888513|NCT06269146|DRUG|Pramipexole Pill|The study drug, pramipexole, is an FDA-approved medication for the treatment of Parkinson's and restless leg syndrome. Pramipexole (Mirapex) tablets are taken orally, with or without food.
223888514|NCT06269146|DRUG|Placebo Pill|Placebo will match the study drug in mode of administration, color, size, and taste.
223888515|NCT05210322|PROCEDURE|Percutaneous cholangiopancreatoscopy|Per standard treatment protocol for percutaneous cholangiopancreatoscopy, access will be gained into the biliary system using the biliary tube or into the gallbladder using the cholecystostomy tube. After access has been secured, through a peel-away sheath a Spy Glass Discover Digital Catheter will be introduced. Next, either, the stones will then be removed from the biliary system or gallbladder using a combination of baskets, and lithotripsy equipment as required, or in case of biliary strictures, a clamshell biopsy will be taken from the stricture site as identified on endoscopic visualization and cross-sectional imaging. Further intervention maybe performed for the stricture based on operator preference. After the complete stone removal/ stricture management the cholecystostomy/ biliary tube will be removed after the patient passes a clinical capping trial.
223888516|NCT04098640|GENETIC|FoundationOne CDx|FoundationOne CDx will be performed using archival tumor tissue
223888517|NCT01804634|DRUG|Cyclophosphamide|preparative regimen
223888518|NCT01804634|DRUG|Fludarabine|
223888519|NCT01804634|RADIATION|low dose total body irradiation|
223888520|NCT01804634|DRUG|Melphalan|
223888521|NCT01804634|DRUG|Tacrolimus|
223888522|NCT02681328|OTHER|Afirma GEC|Afirma GEC molecular test on collected thyroid tissue
223888523|NCT02681328|OTHER|ThyroSeq v.2|ThyroSeq v.2 molecular test on collected thyroid tissue
223888524|NCT02681328|OTHER|Afirma GSC|Afirma GSC molecular test on collected thyroid tissue
223888525|NCT02681328|OTHER|ThyroSeq v.3|ThyroSeq v.3 molecular test on collected thyroid tissue
223888526|NCT05917158|DRUG|RC48-ADC and JS001|Patients in group will receive 6 x 3 week cycles of RC48-ADC (Disitamab Vedotin) 2mg/kg in combination with JS001 (Toripalimab) 3mg/kg intravenously, followed by toripalimab (3 mg/kg) every 3 weeks for up to 1 year.
223888527|NCT05660018|DEVICE|active rTMS first, then sham rTMS|Active rTMS is delivered on the first visit, then sham rTMS is delivered on the second visit.
223888528|NCT05660018|DEVICE|sham rTMS first, then active rTMS|Sham rTMS is delivered on the first visit, then active rTMS is delivered on the second visit.
223888529|NCT05828719|PROCEDURE|Percutaneous coronary intervention|"Revascularization indication~1. Diameter stenosis \>90% by visual assessment~2. Functionally significant stenosis (FFR≤0.80 or non-hyperemic pressure ratios≤0.89)~3. Chronic total occlusion with substantial ischemic territory. The below locations will be judged as having substantial ischemic territory.~   * Left main artery~  * Proximal to mid left anterior descending artery~  * Proximal left circumflex artery in left dominant coronary arterial system~  * Proximal to distal right coronary artery in right dominant coronary arterial system"
223888530|NCT03433274|DEVICE|Tendyne Mitral Valve System|Mitral valve replacement
223888531|NCT03433274|DEVICE|MitraClip System|Percutaneous mitral valve repair using the MitraClip system.
223888532|NCT02697396|BEHAVIORAL|Assessments|All participants, after consent, will be asked to complete the study contact form and then complete a baseline assessment with the RSA. This baseline assessment will take approximately 5 minutes.
223888533|NCT02697396|OTHER|Text Message Reminder|Participants randomly assigned to the text messaging group will receive a text message reminding them of their child's vaccination eligibility once a week, starting one week after exposure to the social marketing campaign and time of consent.
223888534|NCT02697396|OTHER|No Text Messaging|Participants in this arm will receive no additional vaccination reminders.
223888535|NCT05655065|PROCEDURE|increase of mean arterial pressure at 65-70 mmHg|Increase of mean arterial pressure at 65-70 mmHg (with catecholamines or volemic expansion at the discretion of the clinician)
223888536|NCT05655065|PROCEDURE|increase of mean arterial pressure at 80-85 mmHg|Increase of mean arterial pressure at 80-85mmHg (with catecholamines or volemic expansion at the discretion of the clinician).
223888537|NCT06849297|BEHAVIORAL|Aromatherapy during labor|Use of essential oils (diffusion, massage, or infused cloths) during labor to promote relaxation and pain relief.
223888538|NCT06848985|BEHAVIORAL|Aerobic combined with Resistance exercise|Participants are required to perform aerobic and resistance exercises. Aerobic exercises included the use of treadmills and elliptical machines, with intensity maintained at 60%-70% of the maximum heart rate (calculated as 220 minus age), for a total of 40 minutes per session (5 minutes of warm-up, 30 minutes of main exercise, and 5 minutes of cool-down). Heart rate monitors were used to ensure the intensity was maintained; resistance exercises involved gym equipment and bodyweight exercises, including the use of a pec deck machine, lat pull-downs, chest presses, bicep curls, tricep extensions, leg curls, and leg presses. The intensity of resistance exercises was set at about 65%-70% of one repetition maximum (1RM), with each session consisting of three sets of 6-8 repetitions and lasting for 30 minutes.
223888539|NCT06849505|DEVICE|online rTMS|5 Hz rTMS is applied to the MRI-localized hotspot on the affected hemisphere when the patients are performing motor tasks
223888540|NCT06849505|DEVICE|offline rTMS|The patients perform motor tasks after 5 Hz rTMS applied to the MRI-guided hotspot on the affected hemisphere
223888541|NCT06849505|DEVICE|sham rTMS|Sham rTMS is applied to the M1 on the affected hemisphere when the patients are performing motor tasks.
223888542|NCT06849167|RADIATION|hypofractionated radiotherapy with immunotherapy|Immunotherapy combined with hypofractionated concurrent chemoradiotherapy followed by consolidation immunotherapy
223888543|NCT06848595|PROCEDURE|spine surgery|spine surgery in prone position
223888544|NCT06848595|DRUG|Magnesium sulfate|Patients will receive loading dose of 40 mg/kg of magnesium sulfate diluted in 50 ml of 0.9% saline IVI will be given in 10 min before anesthesia induction then continuous infusion of 10 mg/kg/hour during the surgery.
223888545|NCT06848595|DRUG|Dexmedetomidine|Patients will receive loading dose of 1 mcg/kg dexmedetomidine diluted in 50 ml of saline 0.9% IVI will be given in 10 min before anesthesia induction then continuous infusion of 0.5 mcg/kg/hour during the surgery.
223888546|NCT06848595|DRUG|Normal Saline (0.9% NaCl)|Patients will receive the same volume of normal saline.
223888547|NCT06390410|DRUG|Simufilam|100 mg PTI-125
223888548|NCT06850454|DRUG|olanzapine|olanzapine 5 mg oral prior to chemotherapy on day 1 and daily on day 2-4
223888549|NCT06850454|DRUG|Placebo|placebo 5 mg oral prior to chemotherapy on day 1 and daily on day 2-4
223888550|NCT04146597|OTHER|Neural mobilization|Neural mobilization (NM) is a physiotherapy method aimed at restoring the dynamic balance between the relative movement of neural tissues and surrounding mechanical interfaces, and different techniques are used for the treatment of various compression syndromes as well as other pain conditions, such as back and neck pain (Basson et al., 2017; Ellis and Hing, 2008). The main techniques used are neurodynamic sliders and neurodynamic tensioners, with the tensioning techniques being considered the more aggressive approach, in which the increase in nerve length occurs (Silva et al., 2014). The neurodynamic sliders techniques are gentle maneuvers as they involve nerve lengthening at one joint and simultaneous reduction in its length at an adjacent joint in order to produce sliding movements of neural structures relative to adjacent tissues (Efstathiou et al., 2015).
223888551|NCT03737253|DRUG|Follitropin alpha|The objective is to measure the effect of the drug according to gonadotropin receptor genotype.
223888552|NCT03737253|DRUG|Menotropin|The objective is to measure the effect of the drug according to gonadotropin receptor genotype.
223888553|NCT05508984|DEVICE|Amma Cooling Caps|"Once enrolled, subjects will be provided the Amma device by the clinic on days of chemotherapy treatment, and upon completion of treatment it will be returned to the clinic for safekeeping. Upon completion of chemotherapy, anywhere from 3-6 weeks following treatment, subjects will repeat the questionnaires and their hair will be photographed again.~The overall duration of the study for subjects will be anywhere from 4 months to 8 months, depending on the duration of their chemotherapy regimen."
223888554|NCT04668781|PROCEDURE|Analgesia via epidural catheter|Ropivacain-infusion 2 mg/ml 1,25ml/h/10kg IBW (ideal body weight) is started to patients in the beginning of the surgery and is continued to POD 4. The rest of the treatment obey study protocol in both groups.
223888555|NCT04668781|PROCEDURE|Analgesia via wound catheter|Ropivacain 5 mg/ml 2,5ml/10kg IBW (ideal body weight) is given to patients in the end of the surgery. After that ropivacain-infusion 2mg/ml 1,25ml/h/10kg IBW is started to patients and is continued to POD 4. The rest of the treatment obey study protocol in both groups.
223888556|NCT02386371|PROCEDURE|tumorectomy|"Tumorectomy will be performed according to the current standards, obtaining clear margins. The axillary lymph node control will depend on the initial management (clinical and ultrasound) of these N0 patients, chosen by the teams."
223888557|NCT02386371|RADIATION|Intra Operative Radiotherapy|After the excision of the tumor, IORT will be delivered. A single dose of 20 Gy by 50 kV photons (Intrabeam™) will be administered in tumor bed. The addition of IORT does not modify the surgical procedure
223888558|NCT05918783|COMBINATION_PRODUCT|Padeliporfin Vascular Targeted Photodynamic (VTP) therapy|Bronchoscopy will be performed with robotic assisted approach using standard practices using general anaesthesia and placement of the optic fiber intratumorally followed by IV administration of Padeliporfin for 10 min and laser light illumination.
223888559|NCT06109311|DRUG|Orforglipron|Administered orally.
223888560|NCT06109311|DRUG|Placebo|Administered orally.
223888561|NCT05905640|OTHER|Method of PrEP delivery and consultation|All core PrEP services that include HIV testing, risk assessment, clinical review PrEP initiation, prescription, dispensing, and follow-up will be performed in a one-stop consultation with a single provider.
223888562|NCT06329583|DIAGNOSTIC_TEST|diaphragmatic breathing|Different positions and techniques for diaphragmatic breathing
223888563|NCT05003921|BIOLOGICAL|AlloRx|cultured allogeneic adult umbilical cord derived mesenchymal stem cells
223888564|NCT05492916|BEHAVIORAL|Diabetes Prevention Program (DPP)|Video-based intervention to prevent or delay Type 2 Diabetes. Includes both educational and social cognitive theory (SCT)-based behavioral content. Each video lasts about 5 minutes in duration.
223888565|NCT05492916|BEHAVIORAL|Community-Supported Agriculture (CSA)|Provides weekly and culturally appropriate fresh produce and in-language education on nutrition, healthy cooking demonstrations, and culturally tailored recipes for participants. Enables participants to socialize with other Chinese immigrants in the program as a way to enhance social cohesion and support.
223888566|NCT06011252|DEVICE|Solia S lead with any BIOTRONIK Pacemaker|"* Name: Solia S lead with any BIOTRONIK Pacemaker~* Model: Solia S45/S53/S60~* Manufacturer: BIOTRONIK SE \& Co. KG~* Method of use: LBBAP implantation for all bradycardia indications.~* Mechanism of action: (1) Pacemaker stimulates the cardiac tissue to keep stable heart beats in patients with bradycardia. (2) LBBAP can be an alternative to right ventricular (RV) pacing to reduce RV pacing-induced ventricular dyssynchrony.~* Device category and grade: E3610 Cardiovascular devices, Class III"
223888567|NCT03751449|OTHER|Educational Intervention|Receive nutrition education
223888568|NCT03751449|BEHAVIORAL|Exercise Intervention|Complete home-based aerobic and resistance exercise program
223888569|NCT03751449|OTHER|Quality-of-Life Assessment|Ancillary studies
223888570|NCT03751449|OTHER|Questionnaire Administration|Ancillary studies
223888571|NCT06969079|BEHAVIORAL|Ba Duan Jin Exercise plus Sleep Hygiene Education|Participants will receive Ba Duan Jin exercise combined with Sleep Hygiene Education. The Ba Duan Jin intervention consists of eight traditional Chinese Qigong movements performed daily for 6 weeks, with each session lasting 50 minutes, accompanied by structured sleep hygiene counseling.
223888572|NCT06969079|BEHAVIORAL|Sleep Hygiene Education|Participants will receive Sleep Hygiene Education (SHE) alone, consisting of guidance on establishing healthy sleep habits, optimizing sleep environment, adjusting sleep schedules, reducing stimulants (e.g., caffeine, alcohol), and minimizing sleep-disruptive behaviors.
223888573|NCT06987084|COMBINATION_PRODUCT|Bryophyllum pinnatum tea|24 g of B. pinnatum leaves boiled in 250 mL of water for 61 minutes sweetened with 1/2 teaspoon of sugar
223888574|NCT06987084|COMBINATION_PRODUCT|Placebo tea|250 mL of water boiled with 3 g of wheat-bran for 5 minutes sweetened with 1/2 teaspoon of sugar
223888575|NCT06986499|DEVICE|Hearing Aid Widex SmartRIC MRRLD 440|Receiver in Canal (RIC) hearing aid
223888576|NCT06986499|DEVICE|Own hearing aid|subjects' own hearing aids, any brand, any model
223888577|NCT06986538|PROCEDURE|Clearance with the left side of the SMV as the medial boundary|Undergo radical resection for right colon cancer with the left side of the SMV as the medial boundary
223888578|NCT06986538|PROCEDURE|Clearance with the left side of the SMA as the medial boundary|Undergo radical resection for right colon cancer with the left side of the SMA as the medial boundary
223888579|NCT06986655|OTHER|Augmented Reality|In this intervention children will play an augmented reality game during the allergy testing procedure. The game will be used as a distraction method to potentially reduce pain and fear, and enhance care satisfaction.
223888580|NCT06987123|DRUG|Toripalimab|Toripalimab 240 mg, administered on the first day, Q3W × 17 cycles
223888581|NCT06987123|DRUG|Capecitabine|Capecitabine 650 mg/m2 twice a day, oral administration, d1-21, Q3W × 17 cycles
223888582|NCT06987123|PROCEDURE|salvage surgery|"The specific steps of high-frequency electrosurgical knife treatment for localized recurrent nasopharyngeal carcinoma are as follows:~1. It must be performed under general anesthesia, with the complete resection of the nasopharyngeal tumor and its sufficient safe boundary through both nasal cavities under the guidance of nasal endoscopy. When marking the surgical margin, the anterior margin should reach 1-2cm in front of the posterior column of the nasal septum, and the upper margin can reach about 0.5-1cm to the upper margin of the posterior nostril. The lateral and lower margins are designed individually based on the size and location of the tumor. The basic principle is to ensure a safe margin of 0.5-1.0cm, and then use low-temperature plasma ablation. Ablate the tumor tissue and the normal tissue at the resection margin layer by layer from the upper resection margin to the lower resection margin until no obvious tumor residue was observed with the naked eye.~2. Rinse the surgical c"
223888583|NCT06986902|PROCEDURE|Laparoscopic Nissen Fundoplication|a 360° total wrap of the gastric fundus around the esophagus.
223888584|NCT06986902|PROCEDURE|Laparoscopic Toupet fundoplication|a 270° posterior partial wrap of the gastric fundus around the esophagus.
223888585|NCT06931886|OTHER|Inspiratory Muscle Strength Training|Participants will be asked to inhale against a resistance. This resistance will be set to \~55% of their maximal inspiratory ability. Participants will complete 5 sets of 6 breaths (30 total) a day for 5 days a week for 6 weeks.
223888586|NCT06931340|DRUG|Androgen Therapy|Given ADT
223888587|NCT06931340|DRUG|Apalutamide|Given PO
223888588|NCT06931340|DRUG|Docetaxel|Given IV
223888589|NCT06931340|PROCEDURE|Computed Tomography|Undergo CT
223888590|NCT06931340|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223888591|NCT06931340|PROCEDURE|Bone Scan|Undergo Bone Scan
223888592|NCT06931340|PROCEDURE|PSMA PET Scan|Undergo PSMA PET Scan
223888593|NCT06931340|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223888594|NCT06931340|OTHER|Questionnaire Administration|undergo Questionnaire Administration
223888595|NCT06932354|DEVICE|CGM|masked continuous glucose monitoring
223888596|NCT05602506|DRUG|Biktarvy 50 mg/200 mg/25 mg film-coated tablets|The duration of the study treatment will be 48 weeks.
223888597|NCT06115161|DEVICE|Instrumented Orthosis|Gait analysis will be performed with the instrumented orthosis as well as the reference system.
223888598|NCT05380583|BEHAVIORAL|CRAFT-EP|CRAFT-EP is a behavioral intervention delivered via telehealth with the option for one in-person session (when local guidelines allow in-person care without masks). The coaching session topics include self-care, communication, functional analysis, positive reinforcement, treatment engagement, natural consequences, problem solving, and planning next steps. The intervention is designed for families of individuals experiencing psychosis and substance use who are enrolled or seeking enrollment in early psychosis outpatient services. Participants will be asked to complete assessments at pre-, mid- (approximately week 4), post-intervention, and a follow-up assessment approximately 12 weeks post-intervention.
223888599|NCT05380583|BEHAVIORAL|TAU|Participants may continue to receive their ongoing treatment, if any, which may include psychosocial and/or pharmacological interventions.
223888600|NCT06085872|BEHAVIORAL|REThink Life Game|REThink Life Game is the therapeutic game that uses psychological science to help youths find their superhero emotional strengths! It is composed of four levels, each training a specific emotion regulation ability: emotion recognition, mindfulness and relaxation, cognitive change and positive bias.
223888601|NCT06085872|BEHAVIORAL|PsyPills|"PsyPills is a self-help psycho-educational instrument intended to build stress resilience and to target (only) mild and transient negative mood states, alone or in combination with other methods/instruments.~Psychological Pills (PsyPills) are inspired by Rational-Emotive \& Cognitive-Behavioral Therapy (CBT/REBT), which has strong evidence for its efficacy/effectiveness in human development/health promotion and in the treatment of a variety of psychological conditions.~The PsyPills app was tested in a pilot study and showed positive effects on reducing distress. The efficacy of the app adjunct to other therapeutic tools within the platform in our projects will be tested."
223888602|NCT06085872|BEHAVIORAL|MoodWheel|Mood Wheel is a web and mobile-based app that uses experience sampling procedures for the assessment of current/previous distress and positive emotions. The aim of the app is to inquire about the valence, control and functionality of users' emotions.
223888603|NCT05674617|BEHAVIORAL|Written Exposure Therapy|WET will be conducted in accordance with the Written Exposure Therapy for PTSD: A Brief Treatment Approach for Mental Health Professionals Manual and the VA evidence-based practice (EBP) rollout training.
223888604|NCT05674617|BEHAVIORAL|PTSD Education|"The 5-session PTSD psychoeducation and skills protocol we will be utilizing for our PTSD education control condition was developed by PTSD clinical team (PCT) clinicians at the Washington DC VA Medical Center as a group protocol for Veterans admitted to the PCT and who were on the waitlist for individual therapy with an EBP for PTSD. The PTSD 101 protocol consists of psychoeducation on topics related to PTSD symptoms and an introduction to PTSD-related coping skills. Its duration and structure will be similar to WET (5 weekly individual 50-minute sessions). To parallel the time an attention given in individual WET sessions more closely, participants will quietly review any written materials or videos that are a part of the manualized curriculum for 30 minutes of the session, bookended by a 10-minute check-in with their provider on symptoms and introduction to new materials at the start of session and another 10-minute debrief of reviewed materials at the end of session."
223888605|NCT06794931|OTHER|Nutrition|The patient will be instructed to follow the modified Mediterranean diet or his usual diet based on the assigned treatment group.
223888606|NCT06794931|OTHER|Biological samples collection|Additional biological samples will also be collected.
223888607|NCT05009394|PROCEDURE|Targeted Muscle Reinnervation (TMR)|Surgical procedure used to rewire injured proximal nerves to motor nerves directly innervating an otherwise redundant target muscle.
223888608|NCT05009394|PROCEDURE|Regenerative Peripheral Nerve Interface (RPNI)|Surgical procedure where the the nerve is split into fascicles and wrapped in free muscle grafts.
223888609|NCT05009394|PROCEDURE|Standard neuroma treatment, neuroma excision, and muscle burying|Surgical procedure where the neuroma is excised and the nerve stump is buried in an adjacent deep muscle.
223888610|NCT06847932|OTHER|AF-predict AI-ECG alert system guided management|AF-predict AI-ECG alert system
223888611|NCT06024122|OTHER|IRM exam|A non-sedated MRI scan will be performed to assess the structure and function of the children's brains
223888612|NCT01180634|DRUG|Aeroquin|Inhalation Solution
223888613|NCT01180634|DRUG|Placebo|Inhalation Solution
223888614|NCT04419168|OTHER|cCBT|A digital, internet-delivered, evidence-based chatbot programmed to deliver content for both cCBT.
223888615|NCT04419168|OTHER|m-Education|A digital, internet-delivered, evidence-based chatbot programmed to deliver content for both m-Education.
223888616|NCT05204381|DEVICE|Theta-frequency near-zero phase lag stimulation|Rhythmic transcranial magnetic stimulation (TMS) is delivered to both frontal and parietal cortex in theta-frequency (approximately 6 Hz) with a near-zero phase lag.
223888617|NCT05204381|DEVICE|Theta-frequency anti-synchrony stimulation|Rhythmic transcranial magnetic stimulation (TMS) is delivered to both frontal and parietal cortex in theta-frequency (approximately 6 Hz) with a 180 degree phase offset, anti-synchrony.
223888618|NCT05204381|DEVICE|Arrhythmic near-zero phase lag stimulation|Rhythmic transcranial magnetic stimulation (TMS) is delivered to both frontal and parietal cortex in an arrhythmic pattern with a near-zero phase lag matched in duration to the rhythmic stimulation for that session.
223888619|NCT05204381|DEVICE|Arrhythmic independent stimulation|Rhythmic transcranial magnetic stimulation (TMS) is delivered to both frontal and parietal cortex in different independent arrhythmic patterns matched in duration to the rhythmic stimulation for that session.
223888620|NCT05204381|DEVICE|Alpha-frequency near-zero phase lag stimulation|Rhythmic transcranial magnetic stimulation (TMS) is delivered to both frontal and parietal cortex in alpha-frequency (approximately 10 Hz) with a near-zero phase lag.
223888621|NCT05204381|DEVICE|Alpha-frequency anti-synchrony stimulation|Rhythmic transcranial magnetic stimulation (TMS) is delivered to both frontal and parietal cortex in alpha-frequency (approximately 10 Hz) with a 180 degree phase offset, anti-synchrony.
223888622|NCT05009251|BEHAVIORAL|Reminder|Mailed letter, short message service (SMS) text, and/or patient portal message
223888623|NCT05009251|BEHAVIORAL|Risk reduction|Mailed letter, SMS, and/or patient portal message
223888624|NCT05009251|BEHAVIORAL|Medical records-based recommendation|Mailed letter, SMS, and/or patient portal message
223888625|NCT05009251|BEHAVIORAL|Algorithm-based recommendation|Mailed letter, SMS, and/or patient portal message
223888626|NCT04812379|DRUG|Abilify prolonged release aqueous suspension for IM injection (Aripiprazole)|The usual dose in adults is 400 mg of aripiprazole administered intramuscularly in the gluteal or deltoid muscle as a single dose once every 4 weeks. The dose may be decreased to 300 mg based on the patient's symptoms and tolerability.
223888627|NCT00958516|DRUG|LEO 29102 cream|LEO 29102 cream in different doses and the cream vehicle
223888628|NCT04600323|DRUG|Sodium Bicarbonate Tablets|Participants will be given sodium bicarbonate at 0.5 mEq/kg-LBW/day for 12 months
223888629|NCT04600323|DRUG|Placebo|Participants will be given placebo at 0.5 mEq/kg-LBW/day for 12 months
223888630|NCT06310070|DEVICE|3D Printed Personalized Ostomy Appliance|Study procedures will include getting your stoma scanned, receiving personalized ostomy appliances in the mail, receiving a personalized ostomy template, which will be printed using a 3D printer, in the mail, and completing a daily symptom diary along with a weekly survey for 4 weeks.3D printing is done using a machine that takes the 3D image from the computer and prints a replica of the image using plastic or other materials.
223888631|NCT05001789|OTHER|CogMed|20 sessions of Cogmed working memory training
223888632|NCT05067140|DRUG|ARV-766 Part A&B|"Part A: Daily oral dosages are determined by cohort review committee after initial starting dose cohort and each subsequent cohort completes 28 days of treatment.~Part B: Oral tablet(s) once daily in 28 day cycles."
223888633|NCT05067140|DRUG|ARV-766 + Abiraterone Part C&D|"Part C: Daily oral combination dosages are determined by cohort review committee after initial starting dose cohort and each subsequent cohort completes 28 days of treatment.~Part D: Combination administered once daily in 28 day cycles.~Parts C\&D: Participants will also receive concomitant corticosteroid and ADT therapy of investigator choice/patient preference"
223888634|NCT05459636|DEVICE|High-resistance inspiratory muscle strength training|Participants will perform high-resistance inspiratory muscle strength training on a daily basis for eight weeks using a handheld device that produces resistance that increases the effort of breathing in.
223888635|NCT05459636|DEVICE|Very-low-resistance inspiratory muscle strength training|Participants will perform very-low-resistance inspiratory muscle strength training on a daily basis for eight weeks using a handheld device that produces resistance that increases the effort of breathing in.
223888636|NCT06470087|DEVICE|SOC and Type-I Collagen-based Skin Substitute|Arm 1 -The SOC in this study is wound care covering with High Purity Type-I Collagen-based Skin Substitute applied weekly or as needed followed by a padded 3-layer dressing comprised of first layer - non-adherent and porous paraffin gauze (Cuticel), second layer - absorbent 4x4 gauze pads \& third layer - soft roll and compressive wrap (Crepe Bandage)
223888637|NCT06470087|OTHER|SOC and Human Amnion/Chorion Membrane|Arm 2: The SOC in this study is wound care covering with Dehydrated Human Amnion/Chorion Membrane followed by a padded 3-layer dressing comprised of first layer - non-adherent and porous paraffin gauze (Cuticel), second layer - absorbent 4x4 gauze pads \& third layer - soft roll and compressive wrap (Crepe Bandage)
223888638|NCT04475393|DEVICE|Carmat Total Artificial Heart|Heart Replacement Therapy
223888639|NCT04352296|PROCEDURE|Individualized blood pressure|Individualized blood pressure management during mechanical thrombectomy with the administration of diluted norepinephrine (5-10 µg/ml) or nicardipine (1 mg/ml) or urpidil (5 mg/ml) to maintain the MAP within 10% of the first MAP measured in the angiography suit
223888640|NCT04352296|PROCEDURE|Standard blood pressure|Standard blood pressure management based on international guidelines: Treatment of hypotension defined by a systolic blood pressure \<140 mm Hg, and treatment of hypertension defined by a systolic blood pressure \> 180 mm Hg or diastolic blood pressure \>105 mm Hg) with usual treatments (norepinephrine, ephedrine or phenylephrine for hypotension; intravenous nicardipine or uradipil for hypertension).
223888641|NCT05807841|PROCEDURE|percutaneous coronary intervention|IVUS-guided stent implantation
223888642|NCT06501573|DRUG|SGB-9768|SGB-9768 for sc injection
223888643|NCT06501573|OTHER|Placebo|sterile normal saline (0.9% NaCl) for sc injection
223888644|NCT06211270|BEHAVIORAL|FRESH|FRESH-T2D Intervention consisting of bimonthly food, recipes, and diabetes self-management resources + 4 meetings with Registered Dietitian Nutritionists x 6 months duration
223888645|NCT06231823|OTHER|Extraction|Simple / surgical dental extraction for necrotic. irreversible pulpitis, unrestorable, and first permanent molars with sever molar incisor hypomineralization.
223888646|NCT06572930|DRUG|Gonal-f (gonadotropin)|Women will be given 300 IU Gonal-F daily from cycle day 2 or 3. Gonal F will be injected at 8 pm daily. They will all receive cetrorelix acetate 250 mcg/day (Cetrotide) subcutaneously from stimulation day 5 onwards until and including the trigger day. Cetrotide will be administered at 08:00 am.
223888647|NCT06573502|COMBINATION_PRODUCT|Prp with prf or prp or prf|Combination
223888648|NCT01441687|OTHER|laboratory biomarker analysis|Correlative studies
223888649|NCT01441687|PROCEDURE|transrectal prostate biopsy|Undergo prostate biopsy
223888650|NCT05611528|DRUG|Evinacumab|Evinacumab 15 mg/kg administered intravenously every 4 weeks
223888651|NCT03705104|BEHAVIORAL|EPIO|App for self-management of chronic pain An app consisting of 9 modules focusing on cognitive behavioral pain self-management.
223888652|NCT00616967|DRUG|carboplatin|Given IV
223888653|NCT00616967|DRUG|paclitaxel albumin-stabilized nanoparticle formulation|Given IV
223888654|NCT00616967|DRUG|vorinostat|Given orally
223888655|NCT00616967|OTHER|placebo|Given orally
223888656|NCT02910583|DRUG|ibrutinib|ibrutinib administered orally once daily (three 140 mg capsules)
223888657|NCT02910583|DRUG|venetoclax|venetoclax tablets will be administered orally once daily starting with a 5 week ramp up of 20 mg, 50 mg, 100 mg, 200 mg and 400 mg. After ramp up, venetoclax will be administered at 400 mg.
223888658|NCT02910583|DRUG|Placebo|placebo capsules to match ibrutinib administered orally once daily
223888659|NCT04453592|OTHER|No intervention assigned as part of this study.|"The intervention included in this study is part of routine medical care, and not assigned as a result of study participation. This study includes only the addition of a measurement; the bent knee fall out test. Therefore, we believe this study design is observational, and in line with the provided observation study design definition: Observational: studies in human beings in which biomedical and/or health outcomes are assessed in predefined groups of individuals. Participants in the study may receive diagnostic, therapeutic, or other interventions, but the investigator does not assign specific interventions to the study participants. This includes when participants receive interventions as part of routine medical care, and a researcher studies the effect of the intervention.~See uploaded study protocol for further details."
223888660|NCT06101290|DEVICE|Ablative local therapy|Stereotactic ablative radiotherapy (SABR) or interventional radiology (IR) ablation therapy
223888661|NCT05401032|DRUG|Tamsulosin|Oral medication, once a day for 6 months.
223888662|NCT05401032|DRUG|5-hidroxitriptophan|Oral medication, 3 times a day for 6 months.
223888663|NCT01331005|DRUG|nepafenac 0.1% drops|One drop three times per day for one year
223888664|NCT01331005|OTHER|Nepafenac Vehicle|Placebo
223888665|NCT05636709|DEVICE|Adacolumn|Non interventional study
223888666|NCT04480645|DEVICE|CivaDerm|radioactive bandage
223888667|NCT05171855|DRUG|Lonapegsomatropin|Study participants are individually dosed with subcutaneous injection of Lonapegsomatropin once-weekly for 52 weeks
223888668|NCT05825014|OTHER|No intervention|No intervention
223888669|NCT06057012|DRUG|BRII-296|BRII-296 will be given via intramuscular injection.
223888670|NCT06057012|DRUG|Depo Medrol|Depo Medrol will be given via intramuscular injection.
223888671|NCT06004531|BEHAVIORAL|Prompting open-ended question promoting sustainability|This intervention will include active persuasion through prompting participants to answer an open-ended question regarding how they will alter their behavior to become more sustainable and eco-friendly.
223888672|NCT06004531|BEHAVIORAL|Sustainability Passage|This intervention will include passive persuasion through presenting participants with a passage discussing the serious issue of climate change and the pressing need for systemic and individual change to adopt sustainable practices and lifestyles.
223888673|NCT04849052|BEHAVIORAL|MASTERY|In MASTERY, participants will have interactive, two-way text message 'sessions' (5-10 minutes of two-way text communication with an automated text-message program) once weekly for 12 weeks. Furthermore, study trainers will conduct 4 brief calls with participants (Weeks 1, 4, 7, and 12) to introduce the program, assess progress, answer questions, and provide support.
223888674|NCT04849052|BEHAVIORAL|Attentional Control|Participants in the control condition will also receive text messages once per week. To ensure time matching, the program will have 4 phone check-ins (on physical activity) as in MASTERY.
223888675|NCT04113759|BEHAVIORAL|Blood Flow Restriction Rehabilitative Therapy|"BFR cuffs placed at the proximal thigh, just inferior to the greater trochanter.~Inflation time not to exceed 20 minutes. One BFR session per treatment. BFR exercise dosage: 4 sets of the following repetitions 30, 15, 15, 15, 30 second rest between sets, 1 min rest between exercises.~Progress exercise if pain \<2/10 on VAS and RPE \<5 on 0-10 scale. (Heerey et al), and no break down in form."
223888676|NCT04113759|BEHAVIORAL|Sham BFR Rehabilitative Therapy|The schedule, type of exercises, repetition ranges, and other physical therapy interventions will be the same as the BFR experimental group - however a non-occlusive pressure will be applied with the cuff in the control group.
223888677|NCT06532422|PROCEDURE|Partial or total laparoscopic nephrectomy|Nephrectomy is currently the primary indication for localised kidney cancer. All patients consulting a surgeon at the Clinique de la Sauvegarde for localised kidney cancer, for which surgical excision has been validated by the multidisciplinary consultation meeting and who are eligible for outpatient treatment, will be offered the opportunity to take part in this study during the preoperative consultation.
223888678|NCT06159608|DRUG|Local heating + L-NAME (NG-nitro-L-arginine methyl ester; nitric oxide synthase inhibitor)|Differences in endothelium- and nitric oxide (NO)-dependent dilation between groups
223888679|NCT06159608|OTHER|Chronic estrogen exposure|differences in urine estrogen levels across the menstrual cycle between women groups only
223888680|NCT05712902|DRUG|Sunvozertinib|Daily dose of Sunvozertinib
223888681|NCT05059262|DRUG|Vimseltinib|Administered orally
223888682|NCT05059262|DRUG|Placebo|Administered orally
223888683|NCT06252532|DEVICE|Direct cortical stimulation (DCS) Alpha|Rhythmic alpha stimulation
223888684|NCT06252532|DEVICE|Direct cortical stimulation (DCS) Theta|Rhythmic theta stimulation applied
223888685|NCT06252532|DEVICE|Sham Direct cortical stimulation (DCS)|Arrhythmic stimulation paradigm applied
223888686|NCT06252532|DEVICE|Direct cortical stimulation (DCS) In-Phase Theta|Rhythmic in-phase theta stimulation applied
223888687|NCT06252532|DEVICE|Direct cortical stimulation (DCS) Anti-Phase Theta|Rhythmic anti-phase theta stimulation applied
223888688|NCT06205615|DRUG|BXP154B|BXP154B will be self-administered topically following wound induction
223888689|NCT06205615|DRUG|Placebo|Placebo will be self-administered topically following wound induction
223888690|NCT06205615|PROCEDURE|Punch Biopsy|Punch biopsy to leg
223888691|NCT06571188|OTHER|THORACIC EPIDURAL BLOCK|In group TEB, The epidural catheter will be inserted preoperatively at the T5-T7 vertebral level; the exact level will be at the discretion of the attending anaesthesiologist. A loading dose of bupivacaine 0.25% (max 10 ml) will be administered, followed by an intraoperative infusion of bupivacaine 0.125 % with fentanyl 1 μg/ml.\].
223888692|NCT06571188|OTHER|ERECTOER SPINE BLOCK|The ESP block will be performed as described by Forero et al
223888693|NCT06570525|BEHAVIORAL|NurseNET|"Nurse-Delivered Narrative Exposure Therapy (NurseNET). Narrative Exposure Therapy (NET) is a brief, low-cost, trauma-focused treatment modality that is effective in treating mobile populations with complex PTSD. In NurseNET, NET is facilitated by a clinically experienced nurse, while peers/program support specialists offer scaffolded support, fostering trust, engagement, and retention. NurseNET begins with administration of a diagnostic battery and psychoeducation. Then, in subsequent NurseNET sessions, using gradual imaginative exposure, the nurse guides the participant to verbally express and re-frame their personal trauma narratives to shift unhelpful beliefs/symptoms around trauma. NurseNET utilizes a racism-conscious approach to create relational spaces in which narratives of WEH are positioned to challenge dominant social narratives. Each NurseNET session offers a brief soulfulness-based stress reduction activity to prompt emotional/affective grounding."
223888694|NCT06570525|OTHER|PAL|"Peer Active Listening (PAL). In the PAL active comparator/control, peers/program support specialists meet individually with participants in active listening sessions, along the same visit sequence as NurseNET. During PAL sessions, peers/program support specialists allow participants to set each conversational agenda while practicing the tenets of active listening, including attending to body language, paraphrasing the participant's verbal expressions, reflecting feelings, and using tactful repetition. PAL sessions are not intended to center on topics of trauma, but rather designed to offer a supportive relationship (attentional control)."
223888695|NCT06569290|BEHAVIORAL|Primer postcard|Inclusion of a mailed primer post card
223888696|NCT06569290|BEHAVIORAL|Control recruitment letter|a recruitment letter without any behaviorally-informed language
223888697|NCT06569290|BEHAVIORAL|Behavioral theory-informed recruitment letter (prospect theory)|the recruitment letter will use prospect theory and deliver a low risk, gain-framed behaviorally-informed message.
223888698|NCT06569290|BEHAVIORAL|2 phone calls|2 recruitment phone calls made by the call center
223888699|NCT06569290|BEHAVIORAL|4 phone calls|4 recruitment phone calls made by the call center
223888700|NCT06571227|PROCEDURE|Anterior cruciate ligament reconstruction|Patients with anterior cruciate ligament rupture will undergo anterior cruciate ligament reconstruction surgery.
223888701|NCT05426408|DIAGNOSTIC_TEST|Cardiac magnetic resonance imaging to study coronary microvascular dysfunction|Myocardial perfusion mapping will be investigated after administration of adenosine
223888702|NCT06569719|OTHER|Complex decongestive therapy|Includes manual lymphatic drainage (MLD), compression therapy (which consists of compression bandages, compression sleeves, or other types of compression garments), skin care, and lymph-reducing exercises
223888703|NCT03059407|BEHAVIORAL|Dog therapy only|Canine assisted therapy only during echocardiogram
223888704|NCT03059407|BEHAVIORAL|Dog plus standard distraction tech|Canine assisted therapy plus standard distraction techniques during echo
223888705|NCT03059407|BEHAVIORAL|Standard distraction techniques only|Standard distraction techniques (such as watching a movie) only during echocardiogram
223888706|NCT06570278|DIAGNOSTIC_TEST|WGS coupled with MCM|Whole genome will be screened and analysis will focus on pathogenic and likely pathogenic variants. The list of variants of interest will be recorded until examination and discussion during the MCM. MCM will edit a final synthesis concerning the pathogenicity of identified variants.
223888707|NCT05597891|DEVICE|Hēlo PE Thombectomy System|Treatment with the Hēlo PE Thombectomy System for thromboembolectomy
223888708|NCT04478734|DRUG|Moderate doses of Thiamine y Biotin|Thiamine 600 mg every day + Biotin 150mg every day
223888709|NCT04478734|DRUG|High doses of Thiamine y Biotin|Thiamine 1200 mg every day + Biotin 300mg every day
223888710|NCT02193958|DRUG|FF-10501-01|FF-10501-01 will be administered orally on Days 1-14 of a 28-day cycle (Cohorts 1-6), Days 1-21 of a 28-say cycle (Cohort 7), Days 1-28 of a 28-day cycle (Cohort 8) or Days 1-21 of a 28-say cycle (Cohort 9). The dose-escalation will proceed until Maximum Tolerated Dose (MTD) is reached. The treatment will continue until disease progression, intolerable toxicity or investigation/subject decision.
223888717|NCT05800600|DRUG|Venofer|Intravenous iron will be administered as five doses of 200 mg of iron sucrose (Venofer, American Regent, Shirley, NJ) in 100 ml normal saline over a duration of 15 minutes to 1 hour
223888718|NCT03205800|DEVICE|Mini-screw|Placement of a mini-screw
223888719|NCT05955638|DEVICE|MiSight contact lenses|Contact lens for myopia management.
223888720|NCT05955638|DEVICE|Proclear contact lenses|Single vision contact lens as control
223888721|NCT04970836|BIOLOGICAL|recombinant hepatitis B vaccine|Hepatitis B vaccine (Engerix-B) will be administered to the eligible participants by 4 groups. Each case will be tracked for 12 months, at 0, 7-10 days, 28 days, 24-28 weeks, 48-52 weeks anti-HBs titer concentration and 4 follow-up questionnaires.
223888722|NCT06417541|DIAGNOSTIC_TEST|Diseased patients with an indwelling central venous catheter who is referred to autopsy|Photon counting CT is performed and the results are compared to the results of the autopsy
223888723|NCT06417541|RADIATION|Living patients with an indwelling central venous catheter referred to a CT scan without iv contrast|Patients will be investigated using a photon counting CT. Prior to the investigation patients will be investigated with ultrasound. The results from the two modalities will be compared
223888724|NCT06097975|DRUG|Neo-adjuvant nivolumab and ipililumab IV + adjuvant nivolumab and ipililumab IV|Participants will receive neo-adjuvant administration of intravenous immunotherapy on day 1 + day 22: ipilimumab + nivolumab IV.
223888725|NCT06097975|PROCEDURE|Neurosurgery and intracavitary injection nivolumab and ipililumab|The neo-adjuvant therapy will be followed by a maximal safe surgery resection of the glioblastoma. Immunotherapy (nivolumab + ipililumab) will be injected into the brain tissue, followed by insertion of an Ommaya reservoir
223888726|NCT06097975|DRUG|Adjuvant nivolumab IV + nivolumab and ipililumab intracavitary|Postoperatively, administration of immunotherapy will be continued, on day 15 postoperatively and every 2 weeks thereafter patients will receive nivolumab IV as well as ipililumab + nivolumab intracavitary.
223888727|NCT04969874|OTHER|Remote follow-up|"The feeling of swallowing will be assessed at the end of the stay at the rehabilitation center, which corresponds to the first visit, and then every month for 5 months during remote interviews and on discharge with the Deglutition Handicap Index (DHI), a self-assessment questionnaire for the swallowing handicap.~The quality of life will be assessed at the firs visit and 6 months after using the EORTC QLQ 30 quality of life scale and the H\&N annex, a self-assessment questionnaire on the quality of life for people with cancer of the head and neck.~The satisfaction of users and the interest of city health professionals in the use of the MAX Educ tool as part of a monthly monitoring will be collected via the TUQ questionnaire, through the MAX platform at Month 6."
223888728|NCT05446740|BIOLOGICAL|GSK4382276A Dose level 1|Dose level 1 of GSK4382276A is administered intramuscularly in the upper deltoid region of the non-dominant arm to participants in YA GSK4382276A Dose level 1 and OA GSK4382276A Selected Dose level from YA groups, at Day 1. Potential intermediate dose levels may be evaluated, with the total number of dose levels per age group not exceeding 5.
223888729|NCT05446740|BIOLOGICAL|GSK4382276A Dose level 2|Dose level 2 of GSK4382276A is administered intramuscularly in the upper deltoid region of the non-dominant arm to participants in YA GSK4382276A Dose level 2 and OA GSK4382276A Selected Dose level from YA groups, at Day 1. Potential intermediate dose levels may be evaluated, with the total number of dose levels per age group not exceeding 5.
223888730|NCT05446740|BIOLOGICAL|GSK4382276A Dose level 3|Dose level 3 of GSK4382276A is administered intramuscularly in the upper deltoid region of the non-dominant arm to participants in YA GSK4382276A Dose level 3 and OA GSK4382276A Selected Dose level from YA groups, at Day 1. Potential intermediate dose levels may be evaluated, with the total number of dose levels per age group not exceeding 5.
223888731|NCT05446740|BIOLOGICAL|GSK4382276A Dose level 4|Dose level 4 of GSK4382276A is administered intramuscularly in the upper deltoid region of the non-dominant arm to participants in YA GSK4382276A level 4 and OA GSK4382276A Dose level 4 groups, at Day 1. Potential intermediate dose levels may be evaluated, with the total number of dose levels per age group not exceeding 5.
223888732|NCT05446740|BIOLOGICAL|GSK4382276A Dose level 6|Dose level 6 of GSK4382276A is administered intramuscularly in the upper deltoid region of the non-dominant arm to participants in YA GSK4382276A level 6 group, at Day 1.
223888733|NCT05446740|BIOLOGICAL|GSK4382276A Dose level 7|Dose level 7 of GSK4382276A is administered intramuscularly in the upper deltoid region of the non-dominant arm to participants in YA GSK4382276A level 7 group, at Day 1.
223888734|NCT05446740|BIOLOGICAL|GSK4382276A Dose level 8|Dose level 8 of GSK4382276A is administered intramuscularly in the upper deltoid region of the non-dominant arm to participants in YA GSK4382276A level 8 group, at Day 1. Potential intermediate dose levels may be evaluated with the total number of dose levels not exceeding 10 in YA and 1 in OA.
223888735|NCT05446740|BIOLOGICAL|GSK4382276A Dose level 9|Dose level 9 of GSK4382276A is administered intramuscularly in the upper deltoid region of the non-dominant arm to participants in YA GSK4382276A level 9 group, at Day 1. Potential intermediate dose levels may be evaluated with the total number of dose levels not exceeding 10 in YA and 1 in OA.
223888736|NCT05446740|BIOLOGICAL|GSK4382276A Dose level 10|Dose level 10 of GSK4382276A is administered intramuscularly in the upper deltoid region of the non-dominant arm to participants in YA GSK4382276A level 10 group, at Day 1.
223888737|NCT05446740|BIOLOGICAL|GSK4382276A Dose level 11|Dose level 11 of GSK4382276A is administered intramuscularly in the upper deltoid region of the non-dominant arm to participants in YA GSK4382276A level 11 group, at Day 1.
223888738|NCT05446740|COMBINATION_PRODUCT|FDQ21A-NH|Single dose of FDQ21A-NH is administered intramuscularly in the upper deltoid region of the non-dominant arm to participants in YA Control 1 and OA Control groups, at Day 1.
223888739|NCT05446740|COMBINATION_PRODUCT|FDQ22A-NH|Single dose of FDQ21A-NH is administered intramuscularly in the upper deltoid region of the non-dominant arm to participants in YA Control 2, at Day 1.
223888740|NCT04167761|DRUG|Ertugliflozin|Adipose tissue samples collected from participants were treated with Ertugliflozin at a concentration of 25 µM in vitro. This treatment was applied in a laboratory setting to assess the effects of Ertugliflozin on lipolysis, inflammatory cytokine release, and gene expression in epicardial, pericardial, and subcutaneous adipose tissue
223888741|NCT05492838|PROCEDURE|Immediate implantation with the Socket Shield Technique|Immediate implant surgery applied with the Socket Shield Technique
223888742|NCT02795286|DEVICE|Artis Haemodialysis Machine w/ ASIST Software - Isonatremic|
223888743|NCT02795286|DEVICE|Artis Haemodialysis Machine w/ ASIST Software - Isotonic|
223888744|NCT02795286|DEVICE|Artis Haemodialysis Machine w/o ASIST Software|
223888745|NCT06320756|BEHAVIORAL|Wysa in Hindi|Wysa in Hindi is a blended digital mental health intervention
223888746|NCT06320756|BEHAVIORAL|Individual and group sessions on topics like motivation, coping, wellbeing|Individual and group sessions on wellbeing, coping, and motivation with the diabetes educator team
223888747|NCT05264376|BEHAVIORAL|Diabetes Body Project|The Diabetes Body Project (DBP) is an adapted version of the Body Project Prevention program designed specifically for individuals with Type 1 Diabetes. DBP consists of six weekly, one-hour long sessions. Group participants complete the exercises from the original Body Project and also new diabetes-specific content, drawn from Olmsted et al. (2002) that is delivered in a dissonance-based interactive format with Socratic questions from group leaders encourage participants to generate their own answers.
223888748|NCT05264376|BEHAVIORAL|Educational Control|We selected a T1D management/Eating disorder psychoeducational comparison condition previously tested (Olmsted et al., 2002) to control for expectancy effects and demand characteristics. To match the Diabetes Body Project, the educational lectures by Dr. Olmsted will be delivered in 6 1-hour blocks. Topics include basic information about the various EDs, complications of ED behaviors, diabetes and body image, effects of dieting on blood glucose, and the risk of complications.
223888749|NCT06435117|OTHER|Patient Navigation|CO-CAPTAIN focuses on co-designing and piloting and evaluating the implementation of patient navigation (PN) for primary cancer prevention in people with mental ill-health. Patient Navigators, trained professionals with experience working with people with mental ill-health, will assist people with mental ill-health in gaining access to and utilizing appropriate primary cancer prevention measures offered within the respective healthcare and social system (including smoking cessation and physical activity and nutritional interventions). For this purpose, Patient Navigators will offer regular appointment with participants, apply motivational interviewing and aid in accessing appropriate materials while aiming at empowering participants in taking an active role and making better and more informed decisions regarding their health.
223888750|NCT06498791|OTHER|Venipuncture|Blood drawing
223888751|NCT06498791|OTHER|Questionnaire|Completion of the questionnaire
224076788|NCT06303934|BEHAVIORAL|systemic therapy|"All participants were given routine rehabilitation treatment by professional rehabilitation therapists, including exercise therapy, guided education, psychological therapy, acupuncture and massage therapy, to promote the development of motor and cognitive function, as well as to improve intellectual development\[. Besides, swallowing function training was also provided, including direct training, indirect training, and compensatory training, as follows The mendelson maneuver: performed 5 days per week, twice per day, 5-10 minutes each time.~Cold stimulation of the pharynx: performed every day, twice per day, 3-5 minutes each time.~Passive head extension: to stretch the submental muscle for 2-3 seconds, with upward resistance applied to the lower cheek for no less than 5 times a day and no less than 5 minutes each time.~Direct feeding training: with powdered milk, once a day, 5 days a week."
223888752|NCT06099613|BIOLOGICAL|EG-COVII|EG-COVII is a bivalent vaccine to prevent SARS-CoV-2 infection against wild type and Omicron variants
223888753|NCT06055959|DRUG|Zilucoplan|Zilucoplan will be administered subcutaneously to pediatric study participants.
223888754|NCT05032105|DEVICE|Magnetic Resonance Imaging-guided Focused Ultrasound Ablation (MRgFUSA)|Unilateral Magnetic Resonance Imaging-guided Focused Ultrasound Ablation (MRgFUSA) of the anterior nucleus of the thalamus (ATN)
223888755|NCT06298396|DEVICE|Program using default MAP|Each MAP uses a specific combination of stimulation parameters and electrode mode.
223888756|NCT06298396|DEVICE|Program using low-power 1 (LP1) MAP|Each MAP uses a specific combination of stimulation parameters and electrode mode.
223888757|NCT06298396|DEVICE|Program using low-power 2 (LP2) MAP|Each MAP uses a specific combination of stimulation parameters and electrode mode.
223888758|NCT06298396|DEVICE|Program using low-power 3 (LP3) MAP|Each MAP uses a specific combination of stimulation parameters and electrode mode.
223888759|NCT05817591|OTHER|Questionnaires|In current practice, capsaicin patch treatment is offered to patients with a 24-hour average pain level measured by the EN numerical scale : EN scale is \> 4 Pain monitoring questionnaires will be completed by patients every 6 weeks : Neuropathic Pain Symptom Invetory (NPSI Score), Patients' Global Impression of Change (PGIC scale), Numerical pain scale
224076789|NCT06303934|DEVICE|Intermittent Oro-Esophageal Tube Feeding|Firstly, the tail of the tube was inserted via mouth into the upper part of the esophagus with a depth of 18-20cm, and the external part of the tube should be placed in water with the absence of bubbles indicating the successful tube placement. Subsequently, 1ml of water was slowly injected, followed by liquid food or water at a rate of approximately 50ml/min through a syringe connected to the feeding tube. After feeding, the tube should be slowly removed, and the feeding position should be maintained for 30-60 minutes to prevent reflux.
224076790|NCT06303934|DEVICE|Persistent Nasogastric Tube Feeding|After successful intubation, the tube was secured on the cheek. Liquid food was then syringe-fed into the stomach and the feeding was conducted every 2-3 hours, with each meal not exceeding 200 ml. The daily intake was generally consistent with that of the observation group. Besides, after successful intubation, the tube was secured on the infant's face and changed every one to two weeks.
224076791|NCT06468059|DEVICE|Layered Low Profile Foot|The layered LPF is a novel low-profile prosthetic foot that provides compliant behavior while simultaneously exhibiting high mechanical strength.
224076792|NCT06468059|DEVICE|Prescribed Ankle|The prescribed ankle is the prosthetic ankle that the subject wears for daily use.
224076793|NCT02199197|DRUG|Radium Ra 223 Dichloride|Radium Ra 223 Dichloride, 55 kilobecquerel (kBq)/kg body weight, administered as a bolus intravenous (IV) injection (up to 1 minute) on Day 1 of each cycle for 6 cycles.
224076794|NCT02199197|DRUG|Enzalutamide|Enzalutamide 160 mg administered orally once a day (continuously) for 6 cycles.
224076795|NCT01881464|DEVICE|Endopath from Itamar medical - FDA approved device.|endothelial function assessment by Endopath device
224076796|NCT01881464|DRUG|Anti TNF Alfa.|This study will assessed the presence of endothelial dysfunction in patients with Crohn's disease before and after 12 weeks treatment of anti TNF α.
224076797|NCT04943328|DEVICE|Total Hip Arthroplasty|cemented hip arthroplasty
224076798|NCT03677700|OTHER|Laser Flare Meter|Measurement of the inflammation of the operated eye and the fellow eye before the surgery and at each post-surgery visit: D7, M1, M2, M3, M6, M12
224076799|NCT05479500|OTHER|Myofascial Chain Release Techniques|Myofascial release is a hands on technique which stretches the fascia and releases, bonds between muscles, integuments and fascia in order to eliminate pain, improve motion and to maintain myofascial balance within the body.
224076800|NCT05479500|OTHER|Local Release Techniques|Local Release Techniques are a soft tissue method that focuses on relieving tissue tension via the removal of fibrosis/adhesions which can develop in tissues as a result of overload due to repetitive use.
224076801|NCT04145011|DEVICE|Cooled Radiofrequency|Delivery of energy to ablate sensory nerves via cooled radiofrequency probe (18g, 4mm active tip)
224076802|NCT04145011|DEVICE|Standard Radiofrequency|Delivery of energy to ablate sensory nerves via non-cooled standard radiofrequency probe (22g, curved 10mm active tip)
224076803|NCT04620460|DEVICE|Low-intensity Focused Ultrasound(LIFUS)|Patients with schizophrenia will be treated with active LIFUS or sham stimulation for 3 weeks on the left DLPFC.
224076804|NCT06098729|BEHAVIORAL|Digital Exercise|A mobile application that delivers personalized encouragement and data-driven health insights based upon patterns in blood sugar, exercise, mood, and sleep, to assist people with type 1 diabetes in exercising more frequently and confidently
224076805|NCT01738334|BEHAVIORAL|Active comparator (meditation) with healthy subjects|"The control group with healthy subjects that was participate in meditation (active control group)"
224076806|NCT01738334|BEHAVIORAL|Meditation|"In the eight weeks following the first session of cognitive tests, the participants made a practice of weekly meditation group lasting 2 hours. Practices with each group (patients and active controls) occurred on different days. With regard to meditation practices were performed in a sitting posture with emphasis on daily life. Each weekly session involved meditation practices with trained professional, practical proposals for home exercise and a discussion group. Meditation compact discs (CDs)were given to participants for practices at home, which proposed activities for 5 minutes to 1 week and 2 weeks for 10 minutes 3-5, and finally 15 minutes for 6-8 weeks. After 8 weeks of treatment the second session of tests was held that involved the same tasks in session 1."
224076807|NCT02715037|OTHER|Throat swabbing|
224076808|NCT04179643|BIOLOGICAL|3 x 10e13vg AB-1002|There are 2 components to AB-1002. The first is an active I-1 transgene (AA 1-65 with T35D), and the second is the vector, BNP116, which delivers the gene selectively to the heart after intracoronary administration.
224076809|NCT02129660|DRUG|Dose 1 of glycopyrrolate, 2.0% QD|Dose 1 of glycopyrrolate Topical Wipes
224076810|NCT02129660|DRUG|Dose 2 of glycopyrrolate, 3.0% QD|Dose 2 of glycopyrrolate Topical Wipes
224076811|NCT02129660|DRUG|Dose 1 of glycopyrronium, 2.5% QD|Dose 1 of glycopyrronium Topical Wipes
224076812|NCT02129660|DRUG|Dose 2 of glycopyrronium, 3.75% QD|Dose 2 of glycopyrronium Topical Wipes
224076813|NCT02129660|OTHER|Vehicle|Vehicle Topical Wipes
224076814|NCT03033875|BEHAVIORAL|Tele-Savvy|The Tele-Savvy program engages groups of six dementia family caregivers in a program that extends over 43 days. The program begins with a scheduled 75-minute group videoconference led by facilitators; similar group videoconferences then take place weekly for six weeks. In between the video-conferences, caregivers will receive daily emails with links to 5-15 minute on-line video lessons that can be watched on their own schedule as often as they wish. The videoconferences allow caregivers to report enactment of learned and self-developed management strategy behaviors into their own caregiving and allow them to raise questions. Each daily video presents a teaching point linked to the overall curriculum. The lesson is carried forward by brief, scripted talks by experts or is enacted in vignettes in which a fictional family caring for a father living with Alzheimer's demonstrates effective caregiving techniques linked to the day's teaching points.
224076815|NCT03033875|BEHAVIORAL|Healthy Living Education Program|The Healthy Living Education Program contains video and text materials on exercise, diet, and healthy living. Participants will be asked to log into the Canvas site daily over the course of six weeks to view the videos. Each participant will also receive 7 weekly brief scripted phone or video calls from a project facilitator to inquire about participants' use of the materials. Additionally, all participants will convene weekly for a video conference centered on the application of healthy living strategies. Facilitators will greet and check in with each of the caregivers, coach and debrief caregivers on the homework, answer questions and/or respond to feedback about the week's material, review key points and concepts from the week's video sessions and introduce new material, report on any activities that caregivers may have implemented based on the materials, and provide homework assignments.
224076816|NCT03433222|DEVICE|HF-LED-RL Phototherapy|"The starting dose of 480 J/cm2 will be administered to Group 1's HF-LED-RL phototherapy randomized subjects and the HF-LED-RL dose will be escalated in the subsequent group to 640 J/cm2. Common expected procedure side effects are mild and temporary, including warmth, redness (erythema) and swelling (edema). The maximally tolerated dose (MTD) is defined as the dose level below the dose producing unacceptable but reversible toxicity in 2 or more subjects and is considered the upper limit of subject tolerance.~All subjects will receive total of nine LED-RL phototherapy, three times per week for three consecutive weeks."
224076817|NCT03433222|DEVICE|Mock Therapy|"Mock therapy will be administered to mock therapy randomized subjects using the mock therapy unit. The mock therapy unit only generates warmth and does not emit LED-RL.~All subjects will receive total of nine mock therapy procedures, three times per week for three consecutive weeks."
224076818|NCT03475459|DRUG|NPC-15 and/or Placebo|The dosage and regimen of the study drug in each period is the following. Period I : NPC-15 placebo granules 8 g Period II : NPC-15 placebo granules 4 g + NPC-15 granules 0.2% 4 g (melatonin 8 mg) Period III : NPC-15 granules 0.2% 8 g (melatonin 16 mg)
224076819|NCT02207933|PROCEDURE|AP shifting training|AP shifting training in addition to gait training 3 times a week for 6 weeks
224076820|NCT02207933|PROCEDURE|Gait training|Gait training only for 3 times a week for 6 weeks.
224076821|NCT06208592|DEVICE|Sevoflurane with AnaConDa|Sevoflurane administered with AnaConDa device
224076822|NCT02555735|DRUG|Standard of Care Chemotherapy|Physician's Choice Chemotherapy Treatment (non-guided)
224076823|NCT04145414|DEVICE|MRI|Reproductibility test assessed with MRI for cerebrospinal fluid movements
224076824|NCT06072885|OTHER|Lung Ultrasound Scoring|Pediatric Laparoscopic Surgery patients will be undergone Lung Ultrasound Scoring (LUS) at multiple times perioperatively. LUS is a pragmatic calculation reflecting lung aeration. Thorax is divided into 12 areas, and in every one of them LUS is applied to observe the lung condition. For that, if there are B-lines less than 4 in one area, it is scored as 1 point. For the areas containing more than 3 B-lines, it is scored as 2 points, and if there is any distortion on the pleural line, it is scored as 3 points. The areas with no B-lines is scored as 0 points. Considering these details, lungs with best conditions will reflect 0 points whereas the worst condition lungs will reflect 36 points. LUS will be performed after intubation, before extubation, and after 30th minute in the post anesthesia care unit
224076825|NCT02103530|OTHER|FLT PET/CT|All PET/CT scans were performed using a hybrid PET/CT scanner (Gemini TF 64 with Astonish TF, Philips). F-18 FLT (2.96 MBq/kg) in 2-5 mL of normal saline was injected intravenously. One hour after FLT injection, CT began at the vertex and progressed to the upper thigh (120 kVp, 100 mA and 4 mm slice thickness). PET emission data were acquired immediately for 1 min at each bed position followed. The CT data were used for attenuation correction. Images were reconstructed using a standard ordered-subset expectation maximization algorithm with 3 iterations and 33 subsets.
224076826|NCT05335460|DRUG|Envafolimab|300mg,sc,d1,Q3W
224076827|NCT04116112|DRUG|Nicardipine|In the event where SBP values are above the randomly assigned target, intravenous nicardipine will be initiated at 2.5 mg/hr to lower the SBP. If SBP is still not reduced to below assigned target after 15 minutes, nicardipine dose will be increased by 2.5 mg/hr every 15 minutes until the target SBP or a maximum dose of 15 mg/hr is reached.
224076828|NCT04116112|DRUG|Labetalol|If SBP is above target despite maximum nicardipine infusion for 30 minutes, 10-20 mg of intravenous labetalol will be added every 15 minutes.
224076829|NCT04116112|DRUG|Hydralazine|If SBP remains unresponsive for 1 hr despite the use of maximum doses of nicardipine and labetalol, a Hydralazine will be added at the treating physician's discretion. Incidence of the latter scenario is anticipated to be exceedingly rare.
224076830|NCT04884048|DIAGNOSTIC_TEST|Radiographs|Analysis of the images acquired for the initial characterization of bone lesions using a systematic report system
224076831|NCT06087055|DRUG|GST-HG171/Ritonavir|Administered orally every 12 hours for days for a total of 5 doses from Day 1 through Day 3
224076832|NCT06087055|DRUG|Itraconazole|Administered orally once daily for 9 days from Days 8 through 16
224076833|NCT06087055|DRUG|GST-HG171/Ritonavir|Administered orally BID for 3 day for a total on 5 doses starting on Day 12 through Day 14
224076834|NCT02418416|OTHER|Oocyte double chemical activation|Oocyte double chemical activation
224076835|NCT03592446|DEVICE|Transcutaneous electrical vagus nerve stimulation|All subjects receive electrical VNS stimulation at cymba conchae.
224076836|NCT03592446|DEVICE|Sham vagus nerve stimulation|All subjects receive electrical stimulation at earlobe.
224076837|NCT05301946|OTHER|Outcome Measurements|The 24-item ICF Core Set for Stroke, Standardized Mini-Mental State Examination, Stroke Impact Scale, Rivermead Mobility Index, and Home Safety Checklist were applied to the stroke patients. The assessment period took one hour.
224076838|NCT03912077|BEHAVIORAL|Culturally Adapted Cognitive Behavioural Therapy|7-session psychosocial intervention
224076839|NCT00220012|PROCEDURE|Folate depletion and supplementation|
224076840|NCT02448407|BIOLOGICAL|Platelet rich plasma|Three intraarticular injections of platelet-rich plasma, one each fifteen days
224076841|NCT02448407|DRUG|Hyaluronic acid|Infiltrations of Hyaluronic acid as Hyaluronate 2,5 ml, 1% solution, administered by intraarticular injections (three doses, one each fifteen days)
224076842|NCT04222166|BIOLOGICAL|CAM|Cryopreserved Amniotic Membrane
224076843|NCT06426069|OTHER|Masticatory efficiency assessment|Masticatory efficiency will be assessed for each group.
224076844|NCT06492096|DEVICE|Bibloc Mandibular Advancement device|Each patient received a CAD/CAM designed Bibloc Mandibular Advancement device
224076845|NCT06095856|DEVICE|Leaf Gauge|Occlusal device used to locate centric relation of the jaws
224076846|NCT06095856|DEVICE|Lucia Jig|Occlusal device used to locate centric relation of the jaws
224076847|NCT06095856|DEVICE|Kois Deprogrammer|Occlusal device used to locate centric relation of the jaws and deprogram jaw muscles
224076848|NCT04824586|DRUG|Fast-acting human insulin|Both patients in the infusion or bolus group received their dose of insulin. The protocol of the insulin regimen and its related details were carried out according to the standard recommendations in a hospital where the trial done.
224076849|NCT04353180|DRUG|Drug Isotretinoin (13 cis retinoic acid ) capsules+standard treatment|"After three days of randomization and standard treatment , 13 cis retinoic acid (0.5 mg/kg/day in 2 divided doses orally for 14 days.+standard treatment~Standard treatment is according to the protocol of treatment of 2019-nCoV infection"
224076850|NCT04353180|DRUG|Isotretinoin(Aerosolized 13 cis retinoic acid) +standard treatment|"Drug: After three days of randomization and standard treatment , Aerosolized 13 cis retinoic acid in gradual two doses increase froms 0.2 mg/kg/day to 4 mg/kg/day as inhaled 13 cis retinoic acid therapy for 14 days +standard treatment~Standard treatment is according to the protocol of treatment of 2019-nCoV infection"
224076851|NCT04353180|DRUG|Isotretinoin (13 cis retinoic acid ) capsules|13 cis retinoic acid (0.5 mg/kg/day in 2 divided doses orally for 14 days
224076852|NCT04353180|DRUG|Aerosolized 13 cis retinoic acid|Aerosolized 13 cis retinoic acid in gradual two doses increase froms 0.2 mg/kg/day to 4 mg/kg/day as inhaled 13 cis retinoic acid therapy for 14 days
224076853|NCT04353180|DRUG|Standard treatment|Standard treatment is according to the protocol of treatment of 2019-nCoV infection
224076854|NCT00868946|DRUG|Virazole (Ribavirin)|"Duration of Subject Participation:7-day course of treatment with follow-up 28 - 60 days after first dose of IV ribavirin Route of Administration and Regimen:The drug is administered IV in a volume of 50-100 mL of normal saline to be infused over 30-40 minutes.~Ribavirin Loading dose, 33 mg/kg (maximum dose: 2.64 g), followed by a dose of 16 mg/kg (maximum dose: 1.28 g) every 6 hours for the first 4 days (15 doses), and 8 mg/kg (maximum dose: 0.64 g) every 8 hours for the subsequent 3 days (9 doses)."
224076855|NCT05373927|DEVICE|Multispectral Optoacoustic Tomography (MSOT)|Non-invasive transcutaneous imaging of subcellular muscle components via infrared and near-infrared laser pulses
224076856|NCT02257983|DRUG|EPI-743|EPI-743 (2 capsules 200 mg each) taken at a dose of 400 mg P.O. TID for 9 days with noise exposure for 4 hours on Day 8.
224076857|NCT02257983|DRUG|Placebo|2 Placebo capsules P.O. TID for 9 days with noise exposure for 4 hours on Day 8.
224076858|NCT04421495|DRUG|Delamanid|the eligible patients will be give damanid-containing regimen
224076859|NCT04663958|DIAGNOSTIC_TEST|Detection / Screening|The patients were followed up in the postoperative care unit. The presence of postoperative pulmonary complications was evaluated, and the time of discharge was recorded. On the 30th day after discharge, patients were called and checked their status in terms of mortality.
224076860|NCT02692066|BIOLOGICAL|varicella vaccine|
224076861|NCT01060059|DRUG|exenatide|subcutaneous injection, 5mcg or 10mcg, twice a day
224076862|NCT01060059|DRUG|basal insulin|subcutaneous injection, dosing according to physician's clinical judgment
224076863|NCT01128829|OTHER|Water|60 ml of water were drank 10 min before doing a OGTT
224076864|NCT01128829|OTHER|Sucralose|60 ml of 2 millimolar sucralose were drank 10 min before doing a OGTT
224076865|NCT02990442|DEVICE|rTMS|repetitive transcranial magnetic stimulation, 1Hz protocol to right dorsolateral pre frontal cortex (R\_DLPFC)
224076866|NCT03406065|DIETARY_SUPPLEMENT|Sodium bicarbonate supplementation|The experimental procedure for each athlete included a 10-day NaHCO3 supplementation in a progressive-dose regimen in order to reduce the likelihood of gastrointestinal side effects (from 25 to 100 mg ∙ kg-1). NaHCO3 was administered in the form of unmarked disk-shaped tablets (Alkala T, SANUM, Poland). The tablets were ingested with at least 250 mL of water and could be either swallowed or dissolved in the mouth. On training days the supplements were taken in the morning, in the evening and 1.5 hours before training session. On rest days the supplements were taken in the morning, in the afternoon and in the evening.
224076867|NCT03406065|DIETARY_SUPPLEMENT|Placebo treatment|The experimental procedure for each athlete included a 10-day placebo administration. Placebo was ingested with at least 250 mL of water. On training days the supplements were taken in the morning, in the evening and 1.5 hours before training session. On rest days the supplements were taken in the morning, in the afternoon and in the evening.
224076868|NCT03824665|DRUG|Nalbuphine Group|"All patients received 8 ml of LAM which consisted of: 6 ml of ml of bupivacaine 0.5%, 1 ml of hyaluronidase containing 150 IU, 1 ml of additive~Patients were categorized into three groups according to the type of additive used with the LAM as follows:~Group N:(Nalbuphine group)1 ml saline containing 4mg nalbuphine used instead of normal saline"
224076869|NCT03824665|DRUG|Fentanyl Group|"All patients received 8 ml of LAM which consisted of: 6 ml of ml of bupivacaine 0.5%, 1 ml of hyaluronidase containing 150 IU, 1 ml of additive~Patients were categorized into three groups according to the type of additive used with the LAM as follows:~Group F: :(Fentanyl group)1 ml saline containing 20 μg fentanyl used instead of normal saline"
224076870|NCT03824665|DRUG|Control Group|"All patients received 8 ml of LAM which consisted of: 6 ml of ml of bupivacaine 0.5%, 1 ml of hyaluronidase containing 150 IU, 1 ml of additive~Patients were categorized into three groups according to the type of additive used with the LAM as follows:~Group C (Control group): included patients assigned to receive 1 ml normal saline."
224076871|NCT00501813|PROCEDURE|Hepatectomy|irregular Hepatectomy
224076872|NCT00501813|PROCEDURE|TACE combined with local regional therapies without hepatectomy|TACE combined with RFA, MCT, PEI, and so on.
224076873|NCT01109030|DRUG|Pioglitazone+Citalopram+Chlordiazepoxide|"Pioglitazone 15 mg every 12 hours for six weeks Citalopram 20 mg per day for week one, and then 30 mg/day for 5 consecutive weeks.~Chlordiazepoxide 10 mg each night for first three weeks"
224076874|NCT01109030|DRUG|Placebo+ Citalopram+ Chlordiazepoxide|"Placebo 1 Q12h for 6 weeks with the same shape and color as Pioglitazone. Citalopram 20 mg per day for week one, and then 30 mg/day for 5 consecutive weeks.~Chlordiazepoxide 10 mg each night for first three weeks"
224076875|NCT03575858|DEVICE|Barrel shaped interdental brush|Barrel shaped interdental brush Size SS 0.8mm
224076876|NCT03575858|DEVICE|Tapered interdental brush|Tapered interdental brush Size SS 0.6mm
224076877|NCT06488131|PROCEDURE|MTA Pulpotomy|Complete coronal MTA pulpotomy.
224076878|NCT06488131|PROCEDURE|Root Canal Treatment|Conventional root canal treatment.
224076879|NCT03269708|BEHAVIORAL|Education regarding telomere length|Teaching concepts of cellular aging and telomere length
224076880|NCT01733030|DRUG|Seromycin|250 mg versus 500 mg versus placebo effects on conditioned fear generalization
224076881|NCT01733030|DRUG|Seromycin|
224076882|NCT05047809|OTHER|"Jingchuang Ointment(JCO)"|Applied once a day on the wounds
224076883|NCT05047809|OTHER|Regular Treatment|"Do not use the Jingchuang Ointment(JCO), as the regular treatment as usual."
224076884|NCT05272033|DEVICE|Transcutaneous Electrical Acupoint Stimulation|Transcutaneous Electrical Acupoint Stimulation
224076885|NCT03183674|DRUG|Oxytocin|Single dose oxytocin 45 minutes before the test
224076886|NCT03183674|OTHER|placebo|saline solution 0,9% spray nasal
224076887|NCT01614093|DRUG|Oxytocin|Single dose intranasal oxytocin (24 IU)
224076888|NCT01614093|DRUG|Placebo|Placebo- Sugar pill
224076889|NCT00848354|BIOLOGICAL|Phase 1: Etanercept|Phase 1: prefilled syringe 50mg/ml, administered once weekly for study weeks 0 - 24
224076890|NCT00848354|DRUG|Phase 1: Methotrexate|Phase 1: oral tablet, 2.5mg, dose variable from 7.5mg to 25mg, once weekly for study weeks 0 - 24.
224076891|NCT00848354|DRUG|Phase 2: Optional ETN, SSZ, HCQ, MTX|"Phase 2: All therapies are optional and may include any combination of the following: ETN, SSZ, HCQ, MTX Phase 2: Optional ETN: prefilled syringe 50mg/ml, dose variable after study week 24 to week 128.~Phase 2: Optional SSZ: oral tablet, 0.5gm, dose variable per approved local label recommendations after study week 24 to week 128.~Phase 2: HCQ: oral tablet, 200mg, dose variable per approved local label recommendations after study week 24 to week 128.~Phase 2: MTX: oral tablet, 2.5mg dose variable after week 24 to week 128."
224076892|NCT00848354|DRUG|Phase 1: Methotrexate|Phase 1: oral tablet, 2.5mg dose variable from 7.5mg to 25mg, once weekly for study weeks 0 - 24.
224076893|NCT00848354|DRUG|Phase 1: Conventiaonal DMARD|Phase 1: SSZ: oral tablet, 0.5gm, dose variable per approved local label recommendations. OR Phase 1: HCQ: oral tablet, 200mg, dose variable per approved local label recommendations.
224076894|NCT02394977|DEVICE|Compression with Feedback|"Patients in the intervention group received CPR in accordance to published guidelines using the CFA device per manufacturer instructions. The Cardio First Angel™ (CFA; INOTECH, Nubberg, Germany) is a lightweight device that consists of three components . Application of400 ± 30 Newtons of force (41 kg or 90 lb of pressure), which correlates toa sternum compression depth of 50-60 mm, is followed by an audible click sound to alert the rescuer to cease compression. The click sound is also audible upon spring decompression alerting the rescuer to resume compression. The device does not require an electrical power supply."
224076895|NCT02394977|OTHER|Standard chest compression|CPR in accordance with published international guidelines using standard manual chest compression.
224076896|NCT04565678|DRUG|Mitapivat tablets|Oral tablets
224076897|NCT04565678|DRUG|Mitapivat coated granules|Oral coated granules
224076898|NCT04979754|OTHER|standard of care|retrospective study : standard of care
224076899|NCT01233778|DIETARY_SUPPLEMENT|Canola Oil|60g Canola oil daily per 3000kcal diet provided in a supplemental shake
224076900|NCT01233778|DIETARY_SUPPLEMENT|High Oleic Acid + DHA Canola Oil|60g high oleic acid canola oil + DHA daily per 3000kcal provided in a supplemental shake
224076901|NCT01233778|DIETARY_SUPPLEMENT|High Oleic Acid Canola Oil|60g high oleic acid canola oil daily per 3000kcal provided in a supplemental shake
224076902|NCT01233778|DIETARY_SUPPLEMENT|Flax Oil|36g flax oil + 24g safflower oil daily per 3000kcal provided in a supplemental shake
224076903|NCT01233778|DIETARY_SUPPLEMENT|Safflower Oil|45g safflower oil + 15g corn oil daily per 3000kcal provided in a supplemental shake
224076904|NCT03803644|DRUG|CC-92480|Part 1 dose escalation
224076905|NCT03803644|DRUG|CC-92480|CC-92480
224076906|NCT05537805|PROCEDURE|Ultrasound guided transcervical fallopian tube catheterization during hysterosalpingo-foam sonography in the treatment of proximal tubal obstruction|The intervention included the usage of the modified cornual cannulation set (COOK) which was inserted through cervical canal to uterine cavity, followed by fallopian tube irrigation with contrast foam (Ex-EM) during hysterosalpingo-foam sonography under ultrasonographic imaging.
224076907|NCT04001868|PROCEDURE|Suboccipital inhibition|With the patient in the supine position and the therapist sitting at the head of the bed with the elbows resting on its surface. The therapist palpates the cervical spinous processes and slides the fingers upwards until contacting the posterior projection of the posterior arch of the atlas. Then, flexing the metacarpophalangeal at 90 degrees slowly raises the skull. The therapist's hands should remain together and the base of the skull should rest on his palms pressing with the index, middle and ring fingers of each hand in a sustained manner, but without causing pain. This pressure must be maintained during 4 minutes.
224076908|NCT04001868|PROCEDURE|Placebo technique|A superficial contact in the same area as the intervention, to rule out the exteroceptive effect associated with the therapist's contact.
224076909|NCT02734251|DIETARY_SUPPLEMENT|Relora|750 mg/day
224076910|NCT02734251|DIETARY_SUPPLEMENT|Placebo|
224076911|NCT05237895|DIAGNOSTIC_TEST|Serum Endocan Levels|Detection of Serum Endocan Levels and detection of possible diagnostic association with gestational diabetes
224076912|NCT05518604|BEHAVIORAL|Counseling with goal of modifying eating behaviors|Dietary counseling will occur virtually a minimum of 4x and as desired by participant in the first year postpartum according to a standard protocol
224076913|NCT06529536|DIAGNOSTIC_TEST|Genotyping for CYP3A4 and CYP3A5 genes|"Genotyping: Patients in the prospective (intervention) arm will undergo genotyping using Illumina's genome-wide genotyping array (Infinium Global Screening Array). Pre-transplant genotyping will test for CYP3A5 \*3, \*6, \*7, \*8 and \*9 alleles, and will test for CYP3A4\*22 only (with CYP3A4\*1 reported if no variant corresponding to \*22 was present).~The determined diplotypes for CYP3A5 will be matched with predicted phenotypes using the Clinical Pharmacogenetics Implementation Consortium (CPIC®) proposed genotype-to-phenotype translation table. The assignment of the phenotype is outlined in the CPIC guidelines which will used to predict initial dose of tacrolimus. In addition, influence of CYP3A4 will be incorporated based on recent literature and interventional trials. Initial dose in BRUNO-PIC will use allometric size scaling from adult dose, with adjustment based on genotype (CYP3A4 \& CYP3A5)"
224076914|NCT06529536|DEVICE|Use of NextDose platform|NextDose platform is a forecasting tool used to predict tacrolimus dosage. It is a freely available tool and will be used in accordance with guideline. The dosing recommendations will be led by the academic pharmacist in consultation with the PI. This tool will use genotype-informed Bayesian dosing to help predict the time course of tacrolimus concentrations in the body.
224076915|NCT06529536|DRUG|Tacrolimus|Tacrolimus is administered to all patients post SOT at The Royal Children's Hospital (RCH)
224076916|NCT06351852|DRUG|Combination of Neostigmine and Glycopyrrolate|Transcutaneous
224076917|NCT06351852|DEVICE|I-Box by Dynatronics|Electric field conducting drugs through the skin without compromising its integrity
224076918|NCT06434519|DRUG|Metronidazole cream|After application of one of the moisturizers under investigation in this study to the right side of the patient's face, x5 tape strips will be collected from the left side of a patient's face. These will provide negative controls for quantitation of metronidazole in the stratum corneum. Then, 0.5 mL of a 1% metronidazole cream will be applied to both the right and left sides of a patient's face with clean gloves to prevent cross contamination. Tapes strips x5 will subsequently be collected from the left and right sides of the face at 1 hour and 4 hour time points to assess penetrance of metronidazole through the stratum corneum.
224076919|NCT06434519|OTHER|Cetaphil moisturizer|0.5 mL of moisturizer will be dispensed using a pre-loaded syringe applied to the right face of each patient the patient's standard practice. No moisturizer will be applied to the left side of the face to provide for negative and positive tape strip controls to assess metronidazole penetrance through the stratum corneum in the presence of the moisturizer.
224076920|NCT06434519|OTHER|CeraVe moisturizer|0.5 mL of moisturizer will be dispensed using a pre-loaded syringe applied to the right face of each patient the patient's standard practice. No moisturizer will be applied to the left side of the face to provide for negative and positive tape strip controls to assess metronidazole penetrance through the stratum corneum in the presence of the moisturizer.
224076921|NCT06434519|OTHER|Eucerin Healing Lotion moisturizer|0.5 mL of moisturizer will be dispensed using a pre-loaded syringe applied to the right face of each patient the patient's standard practice. No moisturizer will be applied to the left side of the face to provide for negative and positive tape strip controls to assess metronidazole penetrance through the stratum corneum in the presence of the moisturizer.
224076922|NCT06434519|OTHER|Aveeno Calm and Restore Oat Gel moisturizer|0.5 mL of moisturizer will be dispensed using a pre-loaded syringe applied to the right face of each patient the patient's standard practice. No moisturizer will be applied to the left side of the face to provide for negative and positive tape strip controls to assess metronidazole penetrance through the stratum corneum in the presence of the moisturizer.
224076923|NCT03770780|DRUG|SAGE-718|SAGE-718 in combination with Ketamine
224076924|NCT03770780|DRUG|Placebo|Placebo in combination with Ketamine
224076925|NCT06965842|OTHER|Parent-centered developmental training|After discharge from the neonatal intensive care unit, 1:1 monitoring is conducted at home for 30 minutes twice a week using a video conferencing platform (Zoom) until the corrected age of 6 months to provide parent-centered early intervention. Parents film the developmental training process using a smartphone and send the video to the therapist, who analyzes the video data to provide new treatment goals and guidelines.
224076926|NCT06027905|OTHER|E3 Remote Monitoring and Social Intervention|Patients are enrolled in a 12 week remote blood pressure monitoring program composed of a community health worker, nurse, pharmacist and social worker. Participants will receive a home cellular blood pressure cuff for remote monitoring and will receive tele-health calls from their community health worker to assist with blood pressure taking technique and adherence, medication adherence, education around diet and activity. Social work is available to provide institutional and community resources to patients with social needs. Patients will be screened pre intervention and post intervention for medication adherence and social determinants of health needs. The team nurse monitors and triages home blood pressures on the remote portal. The pharmacist assists with medication reconciliation, adherence, and titration of medications according to standards or care.
224076927|NCT00015223|DRUG|Methylphenidate|
224076928|NCT05434637|OTHER|Physical Therapy|Individuals randomized to this intervention will receive physical therapy, personalized for the participant's specific needs, and include exercises to be performed at home.
224076929|NCT05434637|OTHER|Sound-based Therapy|Individuals randomized to this intervention will receive sound-based therapy, consistent with an audiology-based standard of care treatment.
224076930|NCT05434637|OTHER|Combination Therapy|Individuals randomized to this intervention will receive both individualized physical therapy and sound-based therapy.
224076931|NCT06977503|PROCEDURE|Cranial Electrical Stimulation|Use Alpha-Stim® device
224076932|NCT06977503|OTHER|Discussion|Participate in discussions
224076933|NCT06977503|BEHAVIORAL|Health and Wellness Coach|Undergo coaching sessions
224076934|NCT06977503|OTHER|Informational Intervention|View video assignments
224076935|NCT06977503|PROCEDURE|Sham Intervention|Undergo sham intervention
224076936|NCT06977503|OTHER|Survey Administration|Ancillary studies
224076937|NCT05618158|BEHAVIORAL|4 Corners Rural Health Cancer Prevention|Participants, aged 18-26, will join a private Facebook group to participate in the intervention. The group is not viewable to the public, including other Facebook users. Content that focuses on cancer prevention behaviors will be posted twice per day for up to 12 months. Each group will be hosted by a moderator who is responsible for managing the intervention goals and participants' engagement.
224076938|NCT06400537|BIOLOGICAL|A-319|A-319 will be dosed according to the assigned group.
224076939|NCT07085442|PROCEDURE|Targeted Sentinel Node Biopsy (TSNB)|Targeted Sentinel Node Biopsy will be performed according to routine local practice. The procedure has been standardised for the post-NACT setting as part of the ongoing ATNEC trial. Sites are advised to follow the ATNEC protocol in the primary surgery setting, using either a dual- or single-tracer sentinel node biopsy technique, with localisation and removal of the marked biopsy proven positive node, and removal of at least 3 nodes.
224076940|NCT06901960|DEVICE|A mobile artificial intelligence-enhanced electrocardiogram device estimating plasma potassium categories (<5 mmol/L, 5 - <5.5 mmol/L, 5.5 - <6.0 mmol/L and ≥ 6.0 mmol/L)|A mobile AI-enhanced electrocardiogram device will be used to help patients monitor hyperkalemia. The device, shaped like a stick of chewing gum, collects time-series data of electrocardiogram lead I through two electrodes. Deep convolutional neural network algorithm can read the data and generated categories of plasma potassium (\<5 mmol/L, 5 - \<5.5 mmol/L, 5.5 - \<6.0 mmol/L and ≥ 6.0 mmol/L). Study participants receive the device after randomization. The staff establishes a WeChat group for each participant and reminds them to monitor plasma potassium every 3 days. When the detected plasma potassium category falls in 5 - \<5.5 mmol/L, they will be reminded to watch diet and to verify plasma potassium again. More intensive reminding (once daily) will be sent if plasma potassium category falls in 5.5 - \<6.0 mmol/L or ≥ 6.0 mmol/L. An extra outpatient appointment will also be made as soon as possible for the patients when their detected plasma potassium category is ≥ 6.0 mmol/L.
224076941|NCT07162506|PROCEDURE|Surgery|Radical esophagectomy + mediastinal lymph node dissection
224076942|NCT07162506|RADIATION|Radiotherapy|Radiotherapy: 50.4 Gy/28f
224076943|NCT07162506|DRUG|Chemotherapy|Chemotherapy: nab-paclitaxel 175mg/m² + carboplatin AUC=5, q21d for 2 cycles
224076944|NCT07164404|OTHER|EHR alert|EHR embedded alert into the admission note template, where it automatically inserts smoking history, prompts NRT prescribing in the hospital, and offers referral to outpatient follow up.
224076945|NCT07178626|OTHER|Not applicable- observational study|This is a prospective observational study and does not involve any intervention measures
224076946|NCT07178418|OTHER|Muscle Architecture-Based Exercise Program|Participants in this arm will perform exercises specifically designed according to the architectural and functional properties of the triceps surae muscles. For example, knee-flexed positions will be used to target the soleus, while knee-extended positions will be emphasized for the gastrocnemii. Loading intensity and exercise progression will be tailored to optimize tendon and muscle remodeling.
224076947|NCT07178418|OTHER|Alfredson Protocol|This intervention involves the traditional eccentric heel-drop program, originally developed for mid-portion Achilles tendinopathy. Participants perform three sets of 15 repetitions, twice daily, throughout the intervention period. Exercises are carried out both with the knee extended and flexed to load different portions of the triceps surae. The protocol applies repetitive eccentric loading to the Achilles tendon with the aim of stimulating collagen synthesis, reducing symptoms, and promoting tendon adaptation.
224076948|NCT07177495|PROCEDURE|maxillary sinus floor elevation using Open Maxillary sinus floor elevation and Augmentation using Deproteinized Bovine Bone Particulate|"Phase 1: Grafting~* after administration of Local anesthesia (articaine hydrochloride 68 mg/1.7 ml~  \+ adrenaline0.017 mg), full-thickness mucoperiosteal flap originating from the mid-crestal area or slightly toward the palate side would be opened.~* lateral window will be created in the maxillary bone to allow for adequate access to the sinus membrane.~* The membrane will be carefully elevated using a sinus elevator.~* bone graft will be placed into the sinus cavity using Autogenous Bone with Deproteinized Bovine Bone Particulate.~* collagen membrane will be secured in place using resorbable sutures or tacks if necessary.~Phase 2 (delayed implant placement and core biopsy harvesting 6 Months Postoperative):~* full thickness mucoperiosteal flap originating from the mid-crestal area or slightly towards palate side would be opened.~* core biopsy would be harvested using trephine burs from the site of implant placement prior to drilling, to be sent to the Lab for Histological assessment."
224076949|NCT07177495|PROCEDURE|Open Maxillary sinus floor elevation and Augmentation using A Mixture of 1:1 Autogenous Bone with Deproteinized Bovine Bone Particulate|"Phase 1: Grafting~* After maxillary sinus floor elevation, Mixture of 1:1 Autogenous Bone with Deproteinized Bovine Bone Particulate will be placed in the sinus cavity and secured in place using resorbable sutures or tacks if necessary.~* Phase 2 (delayed implant placement and core biopsy harvesting 6 Months Postoperative):~  * full thickness mucoperiosteal flap originating from the mid-crestal area or slightly towards palate side would be opened. • core biopsy would be harvested using trephine burs from the site of implant placement prior to drilling, to be sent to the Lab for Histological assessment."
224076950|NCT07178106|OTHER|Fasting|Participants undergo the standardised Wilhelmi-Buchinger fasting intervention, which consists of two days of preparation with a dietary energy supply of \<1000 kcal, three days of fasting with a dietary energy supply of 300-500 kcal with tea, broth, fruit and vegetable juices, and two days of recovery.
224076951|NCT07178262|DRUG|Erector Spinae (ESP) Block with Bupivacaine (Marcaine®)|Bilateral Erector Spinae Block at T10 level using 30ml of 0.25% Bupivacaine will be administered under Ultrasound guidance before surgical incision.
224076952|NCT07178262|DRUG|Placebo|Bilateral Erector Spinae Block at T10 level using 30ml of Normal saline will be administered under Ultrasound guidance before surgical incision.
224076953|NCT07177521|PROCEDURE|Insertion of implants in post-extraction tooth|"Two widely used approaches include:~1. Socket grafting with a fully resorbable synthetic biomaterial (β-tricalcium phosphate + calcium sulfate).~2. Socket grafting with a xenograft and a custom Sealing Socket Abutment (SSA) with a concave emergence profile.~No randomized controlled trials have yet compared these protocols with integrated outcomes including resonance frequency analysis, peri-implant health indices, radiographic bone level changes, and digital intraoral scanning (IOS)-based morphometric analysis."
224076954|NCT07178847|BIOLOGICAL|blood sampling|The intervention consist in blood samples (18mL) collected 1 and 3-months after the end of chemoradiotherapy
224076955|NCT00744445|DRUG|r-HuEPO|r-HuEPO 50 U/kg s.c. three times per week. The dose is rounded to the nearest 2000 unites.
224076956|NCT02664155|DRUG|Apixaban|Direct Oral Anticoagulant
224076957|NCT02664155|DRUG|Rivaroxaban|Direct Oral Anticoagulant
224076958|NCT02664155|DRUG|Heparin|Standard Of Care
224076959|NCT02664155|DRUG|VKA|Standard Of Care
224076960|NCT01936220|BEHAVIORAL|Continuity of specialized care|Continuity of care in treatment and professional caregiver was given during 5 year. Treatment targets included relapse prevention through recognition of prodromal symptoms, coping with negative symptoms and stress, increasing medication adherence, decrease of substance use, prevention of drop-out and stimulating and supporting participation in structural activities (work and/or education).
224076961|NCT01936220|BEHAVIORAL|Parent groups combined with Continuity of Specialized care|Approximately fifty parent group therapy sessions will be held in a flexible way over a 60 month period. Each parent group was run by two experienced family therapists.
224076962|NCT01936220|BEHAVIORAL|Discontinuity of care, non specialised care|Standard Treatment as usual (TU) was provided during 5 years by local mental health care professionals situated nearby the domicile of patients. TU had comparable treatment targets as ST but was not provided by treatment staff specialized in early intervention in schizophrenia or related disorders. However, TU was (like ST) sustained and dedicated to prevent psychotic relapse and improve social functioning.
224076963|NCT00826813|DEVICE|Esophageal stent placement|The esophageal stent combined a self-expandable covered esophageal stent and 125I radioactive seeds. Sheathes were attached to the outer surface of the stent, containing 125I radioactive seeds of CIAE 6711. The seeds were loaded into the sheathes on the stent immediately before implantation of the stent. The numbers and dose of the radioactive stent seeds was determined by the treatment plan system based on the size of the individual tumor. To cover the entire lesion of the tumor by the sheaths containing 125I seeds, at least 2 cm exceeding the tumor margins was required. The distance between the two sheaths was 15mm. In the control group, conventional covered esophageal stents were used which provided by the same company as those attached with 125I seeds.
224076964|NCT03667001|DRUG|Lidocaine Hydrochloride|The intervention to be studied will be the additional application of systemic lidocaine 1% dosed 1.5 ml/kg LBM to general anesthesia in bariatric surgery. Patients, randomly assigned to one study group, will be surveyed for 48 hours after completion of surgery, experienced pain, occurrence of PONV, time to first defecation and length of hospitalization will be monitored. Patients, medical practitioner, nurses and investigators will be blinded by utilization of equal appearance and packing of IMPs, which will be fabricated individually for each patient and on request one to two days before surgery by the pharmacy. Each patient will self-evaluate his maximal experienced pain eight-hourly during a sequence of 48 hours after completion of surgery.
224076965|NCT03667001|DRUG|Saline Solution|The intervention to be studied will be the additional application of NaCl 0.9% dosed 1.5 ml/kg LBM to general anesthesia in bariatric surgery as a placebo. Patients, randomly assigned to one study group, will be surveyed for 48 hours after completion of surgery, experienced pain, occurrence of PONV, time to first defecation and length of hospitalization will be monitored. Each patient will self-evaluate his maximal experienced pain eight-hourly during a sequence of 48 hours after completion of surgery.
224076966|NCT05482945|DRUG|Noble gas Argon|Ventilation with Ar 70%/O2 30% in comatose patients resuscitated from OHCA with the use of an experimental mechanical ventilator.
224076967|NCT05897593|DEVICE|GlenXRose Augmented Reality Acquired Brian Injury Therapies|Rehabilitation therapies for ABI have been developed for augmented reality implementation. These include various games to interact within an augmented environment while conducting rehabilitation therapy.
224076968|NCT02280850|DRUG|Guanxin Shutong Capsule|3 capsules three times a day; Duration: 4 weeks. Number of Cycles: until progression or unacceptable toxicity develops.
224076969|NCT02280850|DRUG|Placebo Capsule|3 capsules three times a day; Duration: 4 weeks.
224076970|NCT02280850|DRUG|nitroglycerine|"Adults: 0.25mg-0.5mg (half pill or 1 pill) once, sub-lingual. One more pill per 5 minutes untill pain relief. If total dose is 3 pills in 15 minutes and the pain is still in, please seek medical advice urgently.~The participators in both arms who have agina symptom will take Nitroglycerine. So the accumulated consumption of participators is the one of the maesuremnts."
224076971|NCT06833320|DRUG|Propranolol Hydrochloride|Propranolol will be administered as tablets. Participants who are too young to swallow pills will be given propranolol solution.
224076972|NCT06833320|DRUG|Placebo|Placebo suspension will only have Ora-Blend Medication Flavoring and Suspension Vehicle
224076973|NCT06163261|OTHER|Physical activity|The intervention group will receive an individualized and person-centred prescription of physical activity and exercise.
224076974|NCT05036681|DRUG|Futibatinib|tablets by mouth 1 time every day
224076975|NCT05036681|DRUG|Pembrolizumab|Given by vein over about 30-60 minutes on Day 1 of all cycles
224076976|NCT05904236|DRUG|Treatment with ICVB-1042 administered intravenously|Part A Dose Escalation to assess safety and tolerability of ascending dose levels, define the maximum tolerated dose (MTD), and expansion dose(s) Part B Dose Expansion to further assess safety and tolerability of 1 or more dose levels
224076977|NCT06183164|OTHER|Mindfulness: Awareness-Based Stress Reduction Program|The mindfulness-based stress reduction program was applied to the patients in the experimental group once a week, for 150 minutes, for 8 weeks and 8 times in total. Then, an intermediate test is applied to the patients. After the interim test, patients are asked to repeat the mindfulness-based stress reduction program individually for 8 weeks (between weeks 8-16). In addition, after the conscious awareness-based stress reduction program is applied to the patients in the experimental group by the researcher, the 'Conscious Awareness-Based Stress Reduction Program' booklet prepared by the researcher is given to the patients as a guide. experimental group.
224076978|NCT03731962|PROCEDURE|Coronary Angiography|All patients received approximately 60 mL of intra arterial iodinated contrast material that was administered via computer-controlled automated power injector at 4 mL per second.
224076979|NCT04415476|DRUG|Assigned Interventions|This is a prospective single-center, open-label, randomized, controlled pilot study in the treatment of chronic rejection (CR), defined as grade 1 and 2 BOS, in adult recipients of a pulmonary allograft (single or double lungs). Patients meeting entry criteria shall demonstrate a sustained decline in FEV1 having met stage 1 or 2 BOS. Patients randomized to the study arm, will be treated with Sirolimus (S) orally in place of MMF in addition to tacrolimus and prednisone compared to those patients randomized to defined ST alone (tacrolimus, MMF and prednisone). The trial duration will be approximately 2 years for each subject randomized. Treatment compliance and safety will be monitored by clinic visits at 4-6 week intervals for the 2 year subject duration and will include standard physical examinations and monitoring of routine clinical and laboratory parameters including cause of hospitalizations and rate of adverse events including death in each group. T
224076980|NCT00784797|DRUG|mifepristone and misopristol|200 mg mifepristone and after 48 hours vaginal misopristol 800 mgr followed by oral misopristol 400 mgr every 3 hours for maxamum 5 doses
224076981|NCT00784797|DRUG|mifepristone and oxytocin|200 mg mifepristone followed 48 hours with high dose oxytocin drip (9 unit per hour)
224076982|NCT06674577|DRUG|Atacicept 150 mg|"The atacicept drug product is available as a ready to use injection solution in the following prefilled syringe (PFS) that is composed of: \*BD Hypak™ SCF™ Barrel Glass barrel 1ml long with staked needle 27G ½ 5B with Rigid Needle Shield BD260 \*BD SCF™ Stopper 1ml long W4023 Flurotec"
224076983|NCT04306432|OTHER|Cognitive tests and Patient Reported Outcomes|Each patient will undergo cognitive tests and questionnaires
224076984|NCT05450718|DRUG|buprenorphine-naloxone|Low-dose initiation of buprenorphine-naloxone protocol
224076985|NCT05450718|DRUG|buprenorphine-naloxone|Standard clinical guidelines for a two-day buprenorphine-naloxone initiation
224076986|NCT03875261|DRUG|Cannabinoid treatment|Participants are treated with cannabinoid derivates with a dose between 1 to 12 puffs, each puffs contains 2,7 mg of delta-9-tetrahidrocannabinol and 2,5 mg of cannabidiol.
224076987|NCT03718143|DRUG|Combination AZD1775 with AraC|AZD1775 days 1-5 \& 8-12 AraC days 1-5 \& 8-12
224076988|NCT03718143|DRUG|AZD1775 only|AZD1775 days 1-5 \& 8-12
224076989|NCT04594291|PROCEDURE|MRI scans|This study does not involve any intervention or new treatment. We will conduct MRI scans of the kidneys, muscles, abdomen and heart at baseline, 12 and 24 months after hospital discharge. The MRI scan will take 60-70 minutes in total.
224076990|NCT01937455|BIOLOGICAL|rAAV1-PG9DP|4x10\^12 vg administered intramuscularly
224076991|NCT01937455|BIOLOGICAL|rAAV1-PG9DP|4x10\^13 vg administered intramuscularly
223888760|NCT06180837|BEHAVIORAL|Sleep Extension Intervention|Sleep extension-based intervention focused on increasing time spent in bed by 2 hours per night by directly scheduling assigned bed and waketimes based on participant's individual schedules. Participants will receive weekly sleep tips and counseling on improving their sleep duration.
223888761|NCT03786796|DRUG|Olaparib|Olaparib is a crystalline solid, is non-chiral and shows pH-independent solubility of approximately 0.1 mg/mL across the physiological range. Olaparib is presented for oral administration as a green, film-coated tablet containing 25 mg, 100 mg or 150 mg of drug substance. The 100 mg strength is also available as a yellow, film-coated tablet. The 25 mg, 100 mg and 150 mg strengths of olaparib tablets are composed of the same constituents. The tablet cores comprise: olaparib, copovidone, colloidal silicon dioxide, mannitol and sodium stearyl fumarate. The composition of the green tablet film coating is: hydroxypropyl methylcellulose (hypromellose), macrogol 400 (polyethylene glycol 400), titanium dioxide, iron oxide yellow and iron oxide black. The yellow tablet film coating only differs from the green film coating with the omission of iron oxide black.
223888762|NCT03219307|COMBINATION_PRODUCT|NOVOCART 3D|Matrix associated autologous chondrocyte implant
223888763|NCT04966091|OTHER|Completion of questionnaires|The quality of life questionnaire will be completed before starting the treatment and then during the embryo transfer and will be followed up at each embryo transfer over a maximum period of 18 months. We will also evaluate by means of a specific questionnaire the importance of work/life interactions management and consequences of absenteeism at work, consequences on professional evolution, anxious repercussions in the professional and private domains).
223888764|NCT05553938|DRUG|Empagliflozin 10 mg|Empagliflozin 10mg
223888765|NCT05553938|DRUG|Placebo|Empagliflozin matched placebo tablet
223888766|NCT05247918|BEHAVIORAL|Digital-physical care|Patients will get access to a digital communication platform. Two in person session and two digital contacts per year with possibility to chat with caregivers in between.
223888767|NCT05247918|BEHAVIORAL|Treatment as usual|Four in person session at the center in a year.
223888768|NCT05606965|BIOLOGICAL|mRNA-1010|Sterile liquid for injection
223888769|NCT05606965|BIOLOGICAL|Egg-based Quadrivalent Influenza Vaccine|Sterile suspension for injection
223888770|NCT05606965|BIOLOGICAL|Adjuvanted Quadrivalent Influenza Vaccine|Sterile injectable emulsion
223888771|NCT05606965|BIOLOGICAL|Inactivated Influenza Vaccine|Sterile suspension for injection
223888772|NCT05606965|BIOLOGICAL|mRNA-1345|Sterile liquid for injection
223888773|NCT05606965|BIOLOGICAL|mRNA-1045|Sterile liquid for injection
223888774|NCT02029443|DRUG|Acalabrutinib|Participants will receive acalabrutinib as stated in the arms' description.
223888775|NCT05812144|OTHER|Remote monitoring program|Remote program is composed of some questionnaires and physical exercises performed at home and at hospital (depending on the concerned visit)
223888776|NCT04478318|DEVICE|uEXPLORER/mCT|Participants will undergo a total-body PET/CT scan with the uEXPLORER scanner first, followed by a PET/CT scan with the conventional mCT PET/CT scanner.
223888777|NCT04478318|DEVICE|mCT/uEXPLORER|Participants will undergo a PET/CT scan with the conventional mCT PET/CT scanner, followed by a total-body PET/CT scan with the uEXPLORER scanner
223888778|NCT03534947|DRUG|Sonidegib|Sonidegib is a selective and orally bioavailable Smoothened (Smo) antagonist. The dose will be 200mg taken once a day for 12 weeks.
223888779|NCT03534947|DRUG|Imiquimod|Imiquimod is an immune response modifier that promotes NF-kappa-B-mediated secretion of pro-inflammatory cytokines, chemokines and other mediators. These immune responses produce cytotoxic effects that are antiproliferative and anti-tumour. Imiquimod treatment requires an extended treatment period of 6 weeks for superficial BCC. Imiquimod is an option for the treatment of small, low-risk superficial BCC when surgery, curettage or cryotherapy are inappropriate. Treatment with imiquimod will be for 5 days a week for a total of 6 weeks.
223888780|NCT03534947|PROCEDURE|Surgery|Although most BCCs are amenable to surgery, excision of large tumours in aesthetically sensitive sites may compromise function or cosmesis. Patients whose BCC has not shrunk in size or depth following 12 weeks of sonidegib will undergo surgical excision of the remaining tumour.
223888781|NCT03534947|OTHER|Best supportive care|Patients with lesions that have progressed in size and/or depth will receive the best supportive care deemed appropriate by the treating clinician. This may be surgery, imiquimod, a clinical trial treatment, radiotherapy or any combination of these interventions
223888782|NCT04722354|OTHER|Hyperinsulemic euglycemic clamp|Following a 12-hour overnight fast at the CRU (including abstinence from caffeine containing foods and beverages), insulin sensitivity will be measured using the criterion method of the euglycemic clamp. Participants will have not performed vigorous physical activity for at least the previous 24 h, and be free of acute illness for the prior 2 weeks. An intravenous catheter will be placed in an antecubital vein for subsequent insulin (40 mU/m2-min) and glucose infusions and for stable isotope (6, 6-2H2) infusions to measure insulin sensitivity.
223888783|NCT04722354|PROCEDURE|Muscle Biopsy|One biopsy taken prior to clamp and a second biopsy taken 30-45 min after the start of the clamp. A biopsy of the Vastus Lateralis muscle will be performed on the leg/thigh using the Bergstrom technique.
223888784|NCT04722354|DIETARY_SUPPLEMENT|Oral abscisic acid (ABA)|Those in this group will receive ABA (95 µg ABA and 300 mg of corn starch)
223888785|NCT04722354|OTHER|Placebo|Those in this group will receive placebo (300 mg cornstarch)
223888786|NCT03324464|BEHAVIORAL|Central Executive Training: Working Memory|Computerized working memory training
223888787|NCT03324464|BEHAVIORAL|Central Executive Training: Inhibitory Control|Computerized inhibitory control training
223888788|NCT04846478|DRUG|Talazoparib|capsule, taken by mouth, once a day
223888789|NCT04846478|DRUG|Tazemetostat|orally as a tablet twice daily.
223888790|NCT04977180|DRUG|Cardioprotection|Preventive beta blocker (metoprolol or carvedilol) and an ACE inhibitor (lisinopril)
223888791|NCT05449795|DEVICE|Device: Contour Next and Contour Plus Elite BGMS testing of arterial blood|The purpose of the study is to extend the intended use of two BGMSs to include testing of arterial blood by Health Care Professionals (HCP) in a clinical setting.
223888792|NCT06317064|DRUG|Ibuprofen and Aprepitant|"All 30 participants in this group used NSAIDs (Non-steroidal Anti-Inflammatory Drugs), during their dysmenorrhea period. Same patients from phase 2 (n=30) in next cycle received NK1R antagonist Dexamethasone (6mg) + Aprepitant (80mg) for 2 days."
224076992|NCT01937455|BIOLOGICAL|rAAV1-PG9DP|8x10\^13 vg administered intramuscularly
224076993|NCT01937455|BIOLOGICAL|rAAV1-PG9DP|1.2x10\^14 vg administered intramuscularly
224076994|NCT06451432|PROCEDURE|Percutaneous Inguinal Ring Suturing (PIRS) technique|Percutaneous Inguinal Ring Suturing (PIRS) technique
224076995|NCT03159312|BEHAVIORAL|Physical activity based on a moderate exercise program|Physical exercise program begins with a 2-week adaptation stage, climbs onto the treadmill (HP Cosmos®). The programming of the tape will be done initially with an intensity of 40% of its FCdRes obtained from the formula of Karvonen after performing the 6-minute walk test, you will have to maintain that intensity for 15 min, the patient is evaluated with the Borg scale and oxygen saturation permanently.After two weeks of adaptation, the HRdRes becomes to be calculated, 59% of said frequency will be modified until the exercise program is completed.The training is 30 minutes in the tradmill machine.The work of muscle strengthening of biceps, triceps, deltoids and pectorals, will be progressive in intensity and number of repetitions, determined by the evaluation of 1 Rmax. The start of work with weights is 40% of the Rmax, it will be modified monthly from 40% to 75%. Cycloergometer training (Monark ®) is without load for 15 minutes.
224076996|NCT03546075|DIETARY_SUPPLEMENT|Resveratrol|
224076997|NCT03546075|OTHER|Placebo|
224076998|NCT05064059|BIOLOGICAL|favezelimab/pembrolizumab|Coformulated favezelimab/pembrolizumab (800 mg/200 mg), IV infusion
224076999|NCT05064059|DRUG|regorafenib|Oral
224077000|NCT05064059|DRUG|TAS-102|Oral
224077001|NCT06471881|DEVICE|Two mandibular implants|Rehabilitation with two mandibular implants and a mandibular implant overdenture supported by a computer-aided design bar
224077002|NCT06570096|DRUG|Lidocaine 2% then bupivacaine 0.5%|Patients will receive 10 ml of lidocaine 2% then 10 ml of bupivacaine 0.5% with a delay of 120s between injections.
224077003|NCT06570096|DRUG|Lidocaine 2% and bupivacaine 0.5%|Patients will receive 20 ml of freshly prepared mixtures of 10 ml of lidocaine 2% and 10 ml of bupivacaine 0.5%.
224077004|NCT04638491|DRUG|Lurbinectedin for injection|On the first day of each cycle, patients with advancedsolid tumors or small cell lung cancer were treated with Lurbinectedin for injection
224077005|NCT04450485|PROCEDURE|Total knee arthroplasty|Total knee arthroplasty
224077006|NCT04424069|PROCEDURE|Refractive surgery|Myopic patients seeking refractive surgery will be assigned to the study groups to assess the change in myopic and papillary perfusion in these different prodecures
224077007|NCT04360356|COMBINATION_PRODUCT|Ivermectin plus Nitazoxanide|Ivermectin 200 mcg/kg once orally on empty stomach plus Nitazoxanide 500 mg twice daily orally with meal for 6 days
224077008|NCT04360356|OTHER|Standard Care|Oxygen via Ventilators
224077009|NCT00505453|BIOLOGICAL|Fluviral®|
224077010|NCT06549205|DEVICE|device that stimulates the dorsal surface of the tongue|the device will be placed on the dorsal surface of the tongue. this instrument has two electrodes in turn connected to the TENS, so ultra low frequency stimulation (\<0.66 Hz) will be administered
224077011|NCT06549205|DEVICE|device that stimulates the tragus|two electrodes will be placed at tragus level for the administration of dental ULFTENS
224077012|NCT05811403|OTHER|Epigallocatechin gallate (EGCG)|Epigallocatechin gallate (EGCG) is a white powder that can be obtained from tea leaves. It accounts for 50-60 % of catechin content of tea polyphenols with a wide range of biological activities including antioxidant, antimicrobial, anti-inflammatory, immune regulatory, anti-tumour effects.
224077013|NCT05811403|OTHER|Sodium hypochlorite (NaOCl)|Sodium hypochlorite (NaOCl) is an excellent non-specific proteolytic and antimicrobial agent that provides disinfection of the dentin-pulp interface.
224077014|NCT05811403|OTHER|Mineral trioxide aggregate (MTA)|Mineral trioxide aggregate (MTA) is the material of choice for pulp capping in vital pulp therapy.
224077015|NCT05811403|OTHER|Premixed bioceramic putty|Bioceramic putty is a premixed, ready-to-use calcium silicate-based material which can be used as a pulp capping material.
224077016|NCT04654858|PROCEDURE|Direct composite restorations|bulk-fill composite (Filtek BulkFlow, 3M Espe) will be used aftar infiltration or block anaesthesia for affected molar,following by carious tissue removal. Marginal bevelling of enamel will be performed. A universal adhesive (Scotchbond Universal, 3M Espe) will be placed after selective enamel etching A bulk-fill composite will be used and covered using a nanohybrid composite, (Filtek XT, 3M Espe).
224077017|NCT01516515|DRUG|Vehicle gel|placebo
224077018|NCT01516515|DRUG|SR-T100 with 2.3% of SM|2.3% of SM in Solanum undatum plant extract
224077019|NCT05148871|BIOLOGICAL|Spikogen/Covax-19|Spikogen/Covax-19 is a recombinant spike protein vaccine formulated with Advax-CpG55.2 adjuvant
224077020|NCT01206881|DRUG|pegylated liposomal doxorubicin|35 mg/m2, IV, day 1 every 21 days, 4 cycles
224077021|NCT05134571|DRUG|Laronidase|Solution for injection; Intravenous
224077022|NCT03790241|PROCEDURE|insertion of a catheter|Analysis the palpation and perforation motion performed by the practitioner during the insertion of a catheter while measuring the loads applied on the skin and the veins
224077023|NCT05504109|PROCEDURE|mitral valve replacement through full sternotomy approach.|compare between Minimally Invasive Mitral Valve Replacement and Conventional Approach
224077024|NCT05504109|PROCEDURE|mitral valve replacement through right mini thoracotomy approach.|compare between Minimally Invasive Mitral Valve Replacement and Conventional Approach
224077025|NCT05421000|PROCEDURE|WALANT|Wide awake local anesthesia without tourniquet for distal radius fracture surgery
224077026|NCT05421000|PROCEDURE|Locoregional anesthesia and tourniquet|Locoregional anesthesia and tourniquet for distal radius fracture surgery
224077027|NCT03293563|PROCEDURE|Radical nephrectomy versus partial nephrectomy (according surgeon judgement)|
224077028|NCT05750485|OTHER|Pupilometric evaluation|Pupilometric evaluation under procedural sedation with propofol
224077029|NCT06111339|DRUG|Ketamine|The intervention will consist of a single infusion of ketamine in the ED at a dose of 0.8mg/kg over 40 minutes.
224077030|NCT06111339|OTHER|Saline Solution|The placebo will be a 0.9% saline solution administered over 40 minutes.
224077031|NCT06636071|BIOLOGICAL|setrusumab|A fully human sclerostin neutralizing monoclonal antibody (mAb) administered once a month (QM) via intravenous (IV) infusion
224077032|NCT04669678|DRUG|Etonogestrel (ETG) implant|Contraceptive progestin implants are thin rods inserted under the skin of a woman's arm. The most widely available implant in South Africa is currently Implanon®/Nexplanon®/Implanon NXT®, containing etonogestrel (ETG, 3-keto desogestrel). Implanon® consists of a single rod of ethylene vinyl acetate and contains 68 mg of ETG; it is manufactured by Merck and is approved for 3 years.
224077033|NCT04669678|DRUG|Intramuscular depo-medroxyprogesterone acetate (IM DMPA)|DMPA (150 mg of depo-medroxyprogesterone acetate (MPA)/ml IMI) is the most commonly used injectable contraceptive worldwide, and the most commonly used method of reversible injectable contraception in sub-Saharan Africa.
224077034|NCT04669678|DRUG|Sub-cutaneous medroxyprogesterone acetate (SC MPA)|SC MPA or Sayana® Press is a single-dose container with 104 mg medroxyprogesterone acetate (MPA) in 0.65 mL suspension for injection. Sayana® Press is indicated for medium-long term female contraception.
224077035|NCT04669678|DEVICE|Non-hormonal intrauterine device (IUD)|The NOVA T-380 non-hormonal IUD consists of a T-shaped polyethylene frame wound with copper wire, along with two monofilament threads to aid in removal of the IUD. IUDs may be left in place for up to 5 years.
224077036|NCT05155579|BIOLOGICAL|R21/Matrix-M - single vial formulation|Adjuvanted malaria vaccine in a single vial formulation
224077037|NCT05155579|BIOLOGICAL|R21/Matrix-M - two vial formulation|Adjuvanted malaria vaccine in a double vial formulation
224077038|NCT05155579|BIOLOGICAL|Licensed vaccine - Measles-rubella|Licensed vaccine part of the EPI vaccination schedule
224077039|NCT05155579|BIOLOGICAL|Licensed vaccine - Yellow fever|Licensed vaccine part of the EPI vaccination schedule
224077040|NCT05155579|BIOLOGICAL|Licensed vaccine - Pentavalent (diphtheria, tetanus, pertussis, hepatitis B and Hib)|Licensed vaccine part of the EPI vaccination schedule
224077041|NCT05155579|BIOLOGICAL|Licensed vaccine - Oral Polio Vaccine (OPV)|Licensed vaccine part of the EPI vaccination schedule
224077042|NCT05155579|BIOLOGICAL|Licensed vaccine - Rotavirus|Licensed vaccine part of the EPI vaccination schedule
224077043|NCT05155579|BIOLOGICAL|Licensed vaccine - Pneumococcal vaccine|Licensed vaccine part of the EPI vaccination schedule
224077044|NCT05155579|BIOLOGICAL|Licensed vaccine - Inactivated Polio Vaccine (IPV)|Licensed vaccine part of the EPI vaccination schedule
224077045|NCT05227690|DRUG|Placebo|Matching placebo, oral (tablet), once per day for 6 weeks
224077046|NCT05227690|DRUG|Emraclidine 10 mg|Emraclidine 10 mg, oral (tablet), once per day for 6 weeks
224077047|NCT05227690|DRUG|Emraclidine 30 mg|Emraclidine 30 mg, oral (tablet), once per day for 6 weeks
224077048|NCT05794061|BEHAVIORAL|Neuropsychological instruments|Cognitive and behavioral tests and questionnaires
224077049|NCT06355804|BEHAVIORAL|Physical activity condition|"Participants will receive a remote-delivered physical activity program for 16 weeks that includes access to electronic newsletters and regular chats over Zoom with a behavioral coach:~* The newsletters provide behavioral strategies such as information on the benefits of physical activity, goal setting and monitoring, for increasing and maintaining physical activity levels.~  * Throughout the 16-week period, the investigators will ask participants to wear a Fitbit and record step count into a logbook daily for tracking physical activity.~ * The newsletter will be emailed to participants weekly throughout the program. The newsletters include knowledge, skills, and resources related to physical activity in the early stages of MS.~* The program also involves 7 1-on-1 coaching chats with a coach to guide participants through the program and navigate challenges. These chats are conducted over Zoom and generally last about 15 - 30 minutes each. These sessions will not be recorded."
224077050|NCT06355804|BEHAVIORAL|Waitlist condition|"Participants will receive access to a remote-delivered physical activity program for 16 weeks that includes access to electronic newsletters and regular chats over Zoom with a behavioral coach:~* The newsletters provide information on the benefits of physical activity, goal setting and monitoring, and other behavioral strategies for increasing and maintaining physical activity levels.~  * The newsletter will be emailed to participants weekly throughout the program.~ * Content on the newsletter includes knowledge and skills related to physical activity in the early stages of MS, text of individuals with MS discussing their experiences, web links, worksheets, and brochures.~* The program also involves 7 one-on-one video coaching chats with a behavioral coach to guide participants through the program and navigate challenges. These chats are conducted face- to-face over Zoom and generally last about 15 - 30 minutes each. The investigators do not record these sessions."
224077051|NCT06461156|DRUG|HS-10504|HS-10504 will be administered orally once daily in a continuous regimen. Participants will continue treatment until experiencing objective disease progression or meeting other protocol-specified criteria for discontinuation of study treatment.
224077052|NCT03631043|PROCEDURE|Biopsy Specimen Radiography|Undergo collection of blood and bone marrow
224077053|NCT03631043|DRUG|Lenalidomide|Given PO
224077054|NCT03631043|BIOLOGICAL|Vaccine Therapy|Given personalized vaccine SC
224077055|NCT03881007|OTHER|Mouthwash with LCM|Subjects will mouthwash daily with LCM and before/after sex
224077056|NCT03881007|OTHER|Mouthwash with placebo|Subjects will mouthwash daily with placebo and before/after sex
224077057|NCT02770326|BIOLOGICAL|Fecal Microbiota Transplantation (FMT)|
224077058|NCT02971202|DRUG|Hyperinsulinemic, euglycemic clamp|"Participants will undergo an 8-hour hyperinsulinemic, euglycemic clamp to quantify insulin sensitivity at whole-body and tissue-specific levels. The following hormones will be infused in the study:~* insulin (12 mU/m\^2/min \[3x basal\] for 150 minutes, then 40 mU/m\^2/min \[10x basal\] for 180 minutes)~* glucagon (0.65 ng/kg/min \[1x basal\] for 330 minutes)~* somatostatin (60 ng/kg/min) These infusions will maintain a basal glucagon level and an increased insulin level in the blood that will be equal between all 3 cohorts."
224077059|NCT02971202|DRUG|20% dextrose|A variable infusion of 20% dextrose will be used to maintain plasma glucose within the euglycemic range throughout the hyperinsulinemic portion of the clamp. 6,6-H2 glucose will be infused at a low rate (0.033-0.22 µmol/kg/min) to determine glucose flux during the study.
224077060|NCT02407093|BEHAVIORAL|High-Intensity Functional Training|Constantly varied functional movements performed at a high intensity and incorporating monostructural (aerobic), gymnastics (body weight) and/or weightlifting movements. CrossFit is a good model of HIFT for the military because of its emphasis on general physical preparedness and functional movements and because it is open source and programming is available at no cost (see www.crossfit.com). Sixty-minute HIFT sessions will include a warm-up, workout and cool down. Workouts will average 15 minutes in duration (range = 5-45 minutes) for a total of 50-100 minutes per week.
224077061|NCT02407093|BEHAVIORAL|Army Physical Readiness Training|Usual physical training program for Army personnel from directive FM 7-22, using the Reset phase. Exercises will address strength, endurance, and mobility training. APRT is designed to be completed in 60-90 minute sessions, 5 days/week for a total dose of 300-450 minutes per week.
224077062|NCT03581331|DIAGNOSTIC_TEST|orthoptic balance|"Measurement of visual acuity by far: Monocular measurement, right eye, left eye and binocular Measurement of visual acuity closely: Monocular measurement, right eye, left eye and binocular Corneal reflection method or Hirschberg: Analysis of the corneal reflection after fixation of a point of fixation of light from a distance, then from near.~Cover-Test: Study of the restitution movement following the fixation of the fixation point"
224077063|NCT06192407|DIETARY_SUPPLEMENT|High Oleic Acid Diet|Subjects are provided with all food for each meal every day. The food is low in fat. In addition, subjects are provided with an oil mix that is 100% hazelnut oil. They will be taught to consume the oil with each meal and mix it in with the food provided.
224077064|NCT06192407|DIETARY_SUPPLEMENT|High Palmitic Acid Diet|Subjects are provided with all food for each meal every day. The food is low in fat. In addition, subjects are provided with an oil mix that is palm oil-89%, peanut oil-6.75%, and virgin olive oil-4.25%; . They will be taught to consume the oil with each meal and mix it in with the food provided.
224077065|NCT02634580|BIOLOGICAL|Evolocumab|Administered by subcutaneous injection
224077066|NCT02634580|DRUG|Ezetimibe|Tablet for oral administration
224077067|NCT02634580|DRUG|Placebo to Evolocumab|Administered by subcutaneous injection
224077068|NCT02634580|DRUG|Placebo Ezetimibe|Tablet for oral administration
224077069|NCT01197365|OTHER|Infant formula with GOS, beta-palmitate, acidified milk|"Infant formula supplemented with functional ingredients (galacto-oligosaccharides, beta-palmitate, acidified milk.~Infant formula with functional ingredients is in compliance with Directive 2006/141/CE on infant formulae and follow-on formulae"
224077070|NCT01197365|OTHER|Standard infant formula without functional ingredients|Standard infant formula, in compliance with Directive 2006/141/CE on infant formulae and follow-on formulae, without functional ingredients
224077071|NCT01976780|DRUG|Artesunate|
224077072|NCT01976780|DRUG|Artemether Lumefantrine|
224077073|NCT01976780|DRUG|Mefloquine|
224077074|NCT05422131|DEVICE|MyCare Insite Clozapine Test|The MyCare Insite Clozapine Test is a 2 reagent system designed to evaluate the level of antipsychotic drug clozapine in a patients blood using the near patient device the MyCare Insite Analyser.
224077075|NCT05489601|DRUG|Oxycodone|Oxycodone in 5mg increments up to a maximum of 10mg
224077076|NCT00519740|OTHER|inhalative specific bronchial provocation with grass-pollen|
224077077|NCT04535219|OTHER|Exercise|60 minutes of moderate-intensity treadmill exercise (70% of maximal heart rate determined from the maximal graded exercise test)
224077078|NCT04535219|OTHER|Supervised Total Sleep Deprivation|Laboratory-monitored total sleep deprivation
224077079|NCT04868552|OTHER|Pre-hospital naloxone education|a 5-10 minute pre-hospital education module teaching patients and support persons how and when to administer naloxone
224077080|NCT05559567|DEVICE|Orthokeratology|The use of a specialty GP contact lens to temporarily correct myopia
224077081|NCT03029013|DRUG|Apatinib|Apatinib， 250 mg qd，po，after 7 days , paclitaxel (135-175 mg/m2) and platinum two drug standard chemotherapy, 21 days as a treatment cycle，during the chemotherapy of 7-21 days continue to offer the Apatinib. without disease progress, after 4 chemotherapy cycles, patients continue to accept the Apatinib maintenance treatment.
224077082|NCT03341260|DRUG|Diclofenac Potassium 50mg Tab.|A 50 mg tablet of the medication to be taken one hour before initiation of endodontic treatment.
224077083|NCT03341260|DRUG|Placebo|A placebo will be taken one hour before initiation of endodontic treatment.
224077084|NCT01991132|OTHER|MediView 2.0 software|
224077085|NCT01175941|DRUG|NRL001|10 mg NRL001 in a 2 g suppository, administered once daily for 7 days
224077086|NCT01175941|DRUG|Placebo control|Matched placebo - administered as a 2 g suppository, once daily for 7 days
224077087|NCT02194153|DRUG|Metalyse weight-adjusted|
224077088|NCT06526936|BEHAVIORAL|Education|Information about diabetic foot care
224077089|NCT00584233|DEVICE|computed tomography|Computed tomography of both breasts. For all subjects, CT scanning will be performed before and after an I.V. iodinated contrast injection (100 mL).
224077090|NCT00584233|DEVICE|MRI|Breast MRI
224077091|NCT06545487|OTHER|BLOOD SAMPLE|BLOOD ANALYTICS IN SEVERAL PARAMETERS
224077092|NCT02222714|BIOLOGICAL|3K3A-APC|3K3A-APC, diluted in 0.9% sodium chloride in water, given as 100 mL IV infusion
224077093|NCT02222714|DRUG|Placebo|Matching placebo, 0.9% sodium chloride in water, given as 100 mL IV infusion
224077094|NCT01779206|DRUG|Epirubicin|
224077095|NCT01779206|DRUG|Cyclophosphamide|
224077096|NCT01779206|DRUG|Docetaxel|
224077097|NCT01779206|DRUG|Paclitaxel|
224077098|NCT00524056|DRUG|Carisbamate|two 100 mg tablets twice per day
224077099|NCT00524056|DRUG|Placebo|two placebo tablets twice per day
224077100|NCT06482658|PROCEDURE|Transrectal perilesional/regional systematic biopsy (PB/RSB)|The biopsy procedure was conducted by a highly skilled and experienced urologist who specializes in performing prostate biopsies. Prophylactic antibiotics were routinely used both before and one day prior to scheduled surgery. Each patient was placed in the left lateral position. The ultrasound equipment used included a color Doppler ultrasound diagnostic instrument (Hitachi HiVision, Philips Epiq 7), transrectal probes, and corresponding puncture needle guns. Color Doppler examination was performed from the base to the apex. For each predefined mpMRI suspicious lesion, urologists obtained nine cores at 5-mm intervals within and around the region of interest (penumbra) through transrectal prostate biopsy. The location of these nine cores depended on the shape and location of the suspicious lesion.
224077101|NCT06482658|PROCEDURE|Combination of transrectal systematic biopsy and targeted biopsy|The biopsy procedure was conducted by a highly skilled and experienced urologist who specializes in performing prostate biopsies. Prophylactic antibiotics were routinely used both before and one day prior to scheduled surgery. Each patient was placed in the left lateral position. The ultrasound equipment used included a color Doppler ultrasound diagnostic instrument (Hitachi HiVision, Philips Epiq 7), transrectal probes, and corresponding puncture needle guns. Color Doppler examination was performed from the base to the apex. Three to five transrectal targeted biopsies from the lesion were performed within and around the predefined mpMRI suspicious lesion, followed by fore-zone 12-core transrectal prostate biopsy.
224077102|NCT05309928|DRUG|Amoxicillin|medication administration
224077103|NCT04338893|PROCEDURE|Device: Persona Total Knee|The choice of intervention is defined by surgeons standard use of device 'Persona' in their standard of care practice
224077104|NCT04338893|PROCEDURE|Device: NexGen Total Knee|The choice of intervention is defined by surgeons standard use of device 'Nexgen' in their standard of care practice
224077105|NCT04338893|PROCEDURE|Device: Vanguard Total Knee|The choice of intervention is defined by surgeons standard use of device 'Vanguard' in their standard of care practice
224077106|NCT03315923|DRUG|Rituximab|Patients will receive 1 g of rituximab (two vials of Zytux 500 mg/50 ml) in 500 cc normal saline serum through intravenous infusion as one treatment cycle. This cycle will be repeated every 6 months. Along with rituximab, patients will receive 100 mg of methylprednisolone, 10 mg of chlorpheniramine, and 500 mg of acetaminophen. Before each cycle, patients will be evaluated regarding complete blood count (CBC)-diff, blood urea nitrogen (BUN), Cr, and liver function tests.
224077107|NCT03315923|DRUG|Glatiramer Acetate|Patients will receive 40 mg of glatiramer acetate three times per week through subcutaneous injection. Patients will undergo electrocardiography before starting the treatment to find any abnormal finding. Also, lab tests will be checked for them prior to the treatment, including CBC-diff, BUN, Cr, and liver function tests.
224077108|NCT02771132|BEHAVIORAL|"12-hr IMPower empowerment self defense course"|"The purpose of the 12-hr IMPower empowerment self defense course intervention for girls is to empower then to avoid risky situations, advocate for themselves, and, if needed, defend themselves against an attack."
224077109|NCT02771132|BEHAVIORAL|12-hr Source of Strength for boys|The 12-hr Source of Strength for boys curriculum is specifically designed for 10-13 year-old boys and focused on promoting gender equality, developing positive masculinity, and teaching safe and effective bystander intervention techniques.
224077110|NCT02771132|BEHAVIORAL|Life-skills course|A 1.5-2 hour life skills class that is based on the Kenyan Ministry of Education life skills course and includes a wide range of topics, including sexual assault but also sanitation, food safety, and personal rights. All school-aged children who attend school typically receive this type of curriculum.
224077111|NCT01285908|DRUG|Intravenous Norepinephrine Infusion|
224077112|NCT03529773|BIOLOGICAL|Formulation A|RSV vaccine
224077113|NCT03529773|BIOLOGICAL|Formulation B|RSV vaccine
224077114|NCT03529773|BIOLOGICAL|Placebo|Placebo
224077115|NCT06501781|BEHAVIORAL|Peer Activate-LAI|Peer Activate-LAI is a Peer Recovery Specialist-delivered behavioral activation and problem solving intervention, based on our team's formative work. The intervention focuses on problem-solving skills to improve adherence to ART and/or PrEP both at the individual level and environmental barriers to care (i.e., transportation, housing).
224077116|NCT06501781|OTHER|Standard of Care HIV treatment or prevention with LAI-PrEP/ART|Standard of care HIV treatment or prevention with LAI-PrEP/ART
224077117|NCT03129659|DIAGNOSTIC_TEST|Coronary CT Angiography|Coronary CT angiography
224077118|NCT04894656|DIAGNOSTIC_TEST|Labs, urine tests, upper endoscopy with biopsy and confocal laser endomicroscopy|Tests to assess intestinal permeability
224077119|NCT01340209|DRUG|Tiotropium Respimat|Tiotropium high dose once daily delivered with Respimat inhaler
224077120|NCT01340209|DRUG|Placebo Respimat|Tiotropium placebo once daily delivered with Respimat inhaler
224077121|NCT01340209|DRUG|Tiotropium Respimat|Tiotropium low dose once daily delivered with Respimat inhaler
224077122|NCT06219577|DRUG|Systane Complete Multi-Dose PF|Eyedrop
224077123|NCT06219577|DRUG|Walgreen's Lubricant Balance|Eyedrop
224077124|NCT05312034|BEHAVIORAL|Implementation of the predictive model for an antimicrobial management program|"Firstly it will be used the predictive model as a simulation tool to educate physicians. For three months, physicians will use the model to understand the main factors associated with Gram-positive infection. They will test the model using real-case data previously collected at the hospitals. The model will provide them information such as the probability of that patient having a Gram-positive infection and the proportion of infected patients in that ICU and hospital.~This model will be embedded in an app and a web page to provide real-time guidance on the predicted probability of infection due to Gram-positive agents.~The intervention will be implemented in two selected hospitals, aiming at monthly decreasing the use of broad-spectrum antibiotics while maintaining or reducing the ICU standardized mortality ratio and the standardized resource use."
224077125|NCT05563792|BEHAVIORAL|Options for Pain Management using Non-medication Strategies|The purpose of this study is to help Veterans learn about different ways they can manage chronic pain that do not involve medications. Veterans will work with a coach to explore their values and goals and how different non-medication approaches may fit into these values and goals.
224077126|NCT00445133|DEVICE|Magnetic Sleep Pad|
224077127|NCT02570633|OTHER|Extract of ginger|Migraine patients (both genders) will receive capsules of 200 mg of ginger extract (5% gingerols) to be taken three times a day for 12 weeks.
224077128|NCT02570633|OTHER|Cellulose|Migraine patients (both genders) will receive capsules of 200 mg of placebo (cellulose) to be taken three times a day for 12 weeks.
224077129|NCT03011658|PROCEDURE|venepuncture|for both the groups, HADS questionnaire will be administered to assess the levels of anxiety and depression. The placebo group ( group A) will not be having subjects suffering from oral lichen planus
224077130|NCT04847661|DRUG|Mefloquine as a prophylaxis against SARS-Cov-2 infection in household contacts of COVID 19 confirmed cases|Mefloquine hydrochloride will be given in a dose of 1100-1650 mg, according to body weight (BW), splitted into two to three doses.
224077131|NCT03054610|DRUG|Betamethason Sodium Phosphate|
224077132|NCT03054610|DRUG|Ropivacaine|
224077133|NCT03054610|DRUG|Botulinum Toxins, Type A|
224077134|NCT02341378|BIOLOGICAL|TissueGene-C(Low dose)|TissueGene-C at 6.0x10\^6 cells
224077135|NCT02341378|BIOLOGICAL|TissueGene-C(High dose)|TissueGene-C at 1.8x10\^7 cells
224077136|NCT00835471|DRUG|erlotinib plus docetaxel or pemetrexed|"non-squamous carcinoma: pemetrexed 500 mg/m2 on Day 1 plus erlotinib 150 mg/day days 2-16, every 21 days. Pemetrexed will be given for a maximum of 4 cycles. Thereafter erlotinib will be continued continuously until disease progression.~squamous carcinoma: Docetaxel 75mg/m2 on Day 1 plus erlotinib 150mg/day days 2-16, every 21 days. Docetaxel will be given for a maximum of 4 cycles. Thereafter erlotinib will be continued continuously until disease progression."
224077137|NCT00835471|DRUG|erlotinib|erlotinib 150 mg/day continuously until disease progression
224077138|NCT02412293|BEHAVIORAL|Health Education & Promotion|Promotion of antenatal care, adequate nutrition, skilled delivery and healthy newborn care practices at household level.
224077139|NCT02412293|OTHER|Training of Health Workers|Training of health workers on recognition of danger sign that warrant referral to health care service.
224077140|NCT02412293|BEHAVIORAL|Community Mobilization|Community mobilization activities included formation of community health committees and creation of support for the uptake of the interventions.
224077141|NCT02257190|BEHAVIORAL|Control|One hour of rest.
224077142|NCT02257190|BEHAVIORAL|IW3|A one hour exercise bout with repeated cycles of 3 min of fast and 3 min of slow walking
224077143|NCT02257190|BEHAVIORAL|IW1|A one hour exercise bout with repeated cycles of 1 min of fast and 1 min of slow walking
224077144|NCT00006255|PROCEDURE|radiofrequency ablation|Undergo thermal ablation by radiofrequency energy under magnetic resonance guidance.Thermal ablation continues until the entire tumor is treated.
224077145|NCT00006255|PROCEDURE|thermal ablation therapy|Undergo thermal ablation by radiofrequency energy under magnetic resonance guidance.Thermal ablation continues until the entire tumor is treated.
224077146|NCT01236430|DRUG|Ezetimibe|Ezetimibe 10mg tablet given orally after an overnight fast (at least 10 hours).
224077147|NCT01236430|DRUG|Ezetimibe/atorvastatin 10mg/10mg FDC|Ezetimibe/atorvastatin 10mg/10mg FDC tablet given orally after an overnight fast (at least 10 hours).
224077148|NCT01236430|DRUG|Atorvastatin 10mg|Atorvastatin 10mg given orally after an overnight fast (at least 10 hours).
224077149|NCT01236430|DRUG|Atorvastatin 80mg|Atorvastatin 80mg tablet given orally after an overnight fast (at least 10 hours).
224077150|NCT01236430|DRUG|Ezetimibe/atorvastatin 10mg/80mg FDC|Ezetimibe/atorvastatin 10mg/80mg FDC tablet given orally after an overnight fast (at least 10 hours).
224077151|NCT01484782|BEHAVIORAL|Interactive Voice Response (IVR) automated calls|Interactive Voice Response (IVR) is a type of automated telephone call. Weekly automated telephone assessment and behavior change calls focused on blood pressure management will be sent to the experimental group. They will receive a weekly 10-minute automated phone call to their telephone for disease assessment and self-care support for 6 weeks. In-home blood pressure cuffs were provided for measurement of blood pressure throughout the study.
224077152|NCT04219150|DEVICE|Electrical cardiometry|Four sensors of EC will be applied : first approximately 5 cm above the base of the neck, second on the base of neck, third on the lower thorax at the level of the xiphoid and the fourth one on the lower thorax approximately 5 cm below the 3rd electrode at the level of anterior axillary line. The EC monitor (Electrical Cardiometry monitor, ICON Cardiotronics, Inc., La Jolla, CA 92307; Osyka Medical GmbH, Berlin, and Germany, model C3, serial number 1725303) will be connected to the sensor cable and the patient data will be fed. Corrected flow time (FTC) and stroke volume (SV) will be measured continuously in less than 30 seconds after placing the sensors and inputting the height and weight.
224077153|NCT04219150|DRUG|"Fluid and Catheter Treatment Trial FACTT Lite"|The FACTT Lite provided three possible instructions determined by the CVP and urine output: furosemide administration, fluid bolus, or no intervention. FACTT Lite contained instructions to withhold furosemide until the patient achieved a mean arterial pressure greater than 60 mmHg off of vasopressors for at least 12 h.
224077154|NCT01537211|DEVICE|C leg compared to subject's mechanical leg (Otto Bock)|comparison of different prosthetic knees
224077155|NCT01537211|DEVICE|C leg compared to subject's mechanical leg (Otto Bock)|comparison of different prosthetic knees
224077156|NCT05229107|DEVICE|Cereset Research|Device: Cereset Research The upgraded platform for medical research using the HIRREM technology has been rebranded as Cereset Research® (CR). This system uses the same core technology and algorithms to echo brainwaves in real-time using audible tones, as with HIRREM. The CR system also includes 64-bit processing architecture for faster feedback, the use of 4 sensors, and the use of standard protocols (with flexibility regarding the length and sequencing of the standard protocols), all done with eyes closed. Four sensors are applied to the scalp at a time. However, only two sensors are actively echoing feedback. The software automatically switches from one sensor pair to the other when needed. This reduces the number of sensor placement changes needed, resulting in shorter session time and fewer interruptions.
224077157|NCT05370859|OTHER|There is no intervention for this study|There is no intervention or exposure for this study
224077158|NCT04142983|BIOLOGICAL|Adacel|0.5 mL, Intramuscular
224077159|NCT00328770|DRUG|Sirolimus|Sirolimus given intravenously or orally to achieve target levels of 12-20ug/l
224077160|NCT03692858|DRUG|Adductor Canal Block plus IPACK Block|Adductor Canal Block plus IPACK Block using Ropivacaine
224077161|NCT03692858|DRUG|Adductor Canal Block|Adductor Canal Block using Ropivacaine
224077162|NCT01575210|DEVICE|CPAP mask|A new vent CPAP mask system will be used in this trial.
224077163|NCT01575210|DEVICE|CPAP mask|A new vent CPAP mask system will be used in this trial
224077164|NCT05012293|OTHER|Baseline|5-min urban park video clip (Presented on a TV)
224077165|NCT05012293|OTHER|Fatigue Manipulation|20-min 2-back task (Presented on a computer)
224077166|NCT02205060|OTHER|virtual reality exposure treatment|
224077167|NCT02205060|OTHER|cognitive and behavioral approaches therapy|
224077168|NCT01381783|PROCEDURE|Phacoemulsification|Phacoemulsification under topical anesthesia
224077169|NCT04221880|DRUG|Bupivacaine Hcl 0.25% Inj|Ultrasound-guided erector spinae plane block with 20 ml %0.25 bupivacaine
224077170|NCT04221880|DRUG|Saline Solution for Block|Ultrasound-guided erector spinae plane block with 20 ml saline
224077171|NCT04221880|DRUG|Saline Solution intravenously|Same volume saline solution bolus and infusion as Group Lidocaine
224077172|NCT04221880|DRUG|Lidocaine|1.5 mg / kg lidocaine iv. bolus and, 1.5mg / kg / h lidocaine iv. infusion
224077173|NCT02893449|BEHAVIORAL|Social adaptation|"Questionnaire to fill-in.~The structured program of preoperative cognitive remediation is divided in 3 parts: one interview with the patient to do a building of the subjective theories (difficulties due to the disease, hope relative to the intervention), a study meeting of the cognitive remediation possibilities and a cognitive remediation meeting with the patient. The spouse will be included in the program."
224077174|NCT02893449|BEHAVIORAL|Intensive care management|In this group, the structured program of the SICRPPD group will be replaced by 3 unstructured psychiatric interviews during which patients will be assessed for their perception of the disease and the upcoming surgery. This group will allow to control for the intrinsic effect of the preoperative management independently of the remediation itself.
224077175|NCT02893449|PROCEDURE|Deep brain stimulation|
224077176|NCT00653861|DEVICE|JUVÉDERM™ Injectable Gel with Lidocaine|Single treatment, volume determined by investigator
224077177|NCT00653861|DEVICE|JUVÉDERM™ Injectable Gel|Single treatment, volume determined by investigator
224077178|NCT00448188|PROCEDURE|central venous catheter application|
224077179|NCT02595190|PROCEDURE|sacral canal cyst microscopic tamponade|sacral canal cyst microscopic tamponade treatment
224077180|NCT02595190|DRUG|gabapentin + tramadol|dose range：gabapentin 400-1200mg tid, tramadol 100-200mg bid
224077181|NCT02595190|DEVICE|resting state functional magnetic resonance imaging (rfMRI)|First time:2 days before Surgery or Drug use; Second time:3 months after Surgery or Drug use; Third time:1 year after Surgery or Drug use
224077182|NCT00533078|DIETARY_SUPPLEMENT|omegaven|Trial participants are prescribed TPN by the attending physician as soon as indicated, which will be administered via a central venous line over a time period of approximately 20 hours per day. The formulation given to all patients is Nutriflex lipid spezial®, an emulsion containing the full supply of carbohydrates, amino acids and lipids (SO:MCT = 1:1) with a total energy content of 2215 kcal in a 1875 ml volume, see Investigator's Brochure. In addition, they receive daily infusional Omegaven® 100 ml over 4 hours, which equal FO 10 g/d or omega-3 PUFA 3-6 g/d.
224077183|NCT03445078|DIETARY_SUPPLEMENT|selenium supplementation|administration of selenium-rich corn powder 20g/d offering selenium 100μg/d
224077184|NCT03445078|DIETARY_SUPPLEMENT|ordinary corn powder|ordinary corn powder,20g/d(selenium contain \<0.5ug/20g).
224077185|NCT04561154|OTHER|questionnaire|three months after hospitalization, a questionnaire will be sent to patients. If necessary, patient will be seen in consultation of geriatry, otorhinolaryngology, pneumology, neuropsychology
224077186|NCT02183090|DRUG|Meloxicam ampoule|
224077187|NCT02183090|DRUG|Meloxicam tablet|
224077188|NCT04396509|BEHAVIORAL|Maternal Attachment Inventory Score|three month after delivery using Maternal Attachment Inventory (MAI) and a detailed history was taken.
224077189|NCT03414580|PROCEDURE|Breath sampling for volatile organic compounds|Acquisition of exhaled breath sample in exhaled air to be analysed by gas chromatography-mass spectrometry
224077190|NCT00857870|DRUG|Metformin|"Metformin is administered as coated tablet. Initial dose is 500 mg twice a day (morning and evening) during or after the meal. The first administration takes place on the evening of visit 1c. The duration of the therapy is 36 weeks until visit 8c.~Initial dose of 500 mg bid was increased after 4 weeks (visit 2) to 850 mg bid when the patient tolerated the initial dose. If the side effects were not tolerable, the initial dose was decreased to 500 mg once a day and where appropriate increased at a later visit.~After 8 weeks (visit 3) metformin dose was increased to 1000 mg bid when tolerated. If dose is not tolerated, it was decreased to the next lower dose."
224077191|NCT00857870|DRUG|Insulin glargine|Insulin glargine is given subcutaneously with an insulin-pen (SoloStar®). The dose was titrated to reach a fasting plasma glucose value of \<5.6 mmol/l. Insulin glargine was given once a day in the evening before going to bed (bed-time injection). The first insulin injection takes place on the evening of visit 1c. The duration of the therapy is 36 weeks until visit 8c. All patients were trained in handling and storage of the insulin-pen.
224077192|NCT02007174|DRUG|Bevacizumab|
224077193|NCT02007174|DRUG|Medical Treatment|Care treatment included topical eyedrops of 0.3% tobramycin and 0.1% dexamethasone (Trazidex, Laboratorios Sophia) three times daily, and 0.5 carboxymethylcellulose lubricating eye drops (Refresh-Tears, Allergan, Irving, California, USA). Topical antibiotics and corticosteroids were tapered and discontinued after two weeks.
223888793|NCT04821154|DEVICE|Persona Revision Knee System|Patients in this cohort will have been previously implanted with the Persona Revision Knee system in the described configuration per standard of care. The Persona Revision knee system is a total knee system that is widely available for use in the United States and is designed for use in primary and revision knee surgical interventions.
223888794|NCT05312892|DRUG|Amlodipine|Subjects will receive either an antihypertensive (amlodipine or moxonidine) medication or placebo for two weeks, then cross over to the second arm, and then after 2 weeks of the second drug/placebo, will be switched to the third arm.
223888795|NCT05312892|DRUG|Moxonidine|Moxonidine
223888796|NCT05312892|DRUG|Placebo|Placebo
223888797|NCT03393975|BIOLOGICAL|TAK-755|Participants in prophylaxis cohort will receive IV infusions of 40 IU/kg TAK-755 ORT during Period 1 and Period 2 and switch to TAK-755 SIN during Period 3 for six months once in a week or twice in a week. In On-demand cohort participants will receive daily IV dose of TAK-755.
223888798|NCT03393975|BIOLOGICAL|Standard of care|Participants will receive Investigator-recommended Standard of care (SoC).
223888799|NCT04501861|DRUG|Vasopressin|Vasopressin (20 IU/100 ml in 5% dextrose) were stored in pre-mixed bags in the operating room, readily available for continuous infusion administration via pre-programed infusion pumps
223888800|NCT04501861|DRUG|Norepinephrine|Norepinephrine (4 mg/250ml in 5% dextrose) were stored in pre-mixed bags in the operating room, readily available for continuous infusion administration via pre-programed infusion pumps
223888801|NCT03606642|DRUG|Dual Antiplatelet (DAPT) Therapy|"DAPT - one of three (3) antiplatelet medications: ticagrelor (Brilinta), clopidogrel (Plavix) or prasugrel (Effient) with Aspirin.~Aspirin loading dose (LD) = 325 mg. Aspirin maintenance dose (MD) = 81 mg.~P2Y12 Inhibitor Loading Dose (investigator preference):~Clopidogrel 600 mg PO x 1 or 75 mg PO daily x 4; Prasugrel 60 mg PO x 1; Ticagrelor 180 mg PO x 1.~P2Y12 Inhibitor Maintenance Dose (investigator preference):~Clopidogrel 75 mg PO daily; Prasugrel 10 mg PO daily; Ticagrelor 90 mg PO BID."
223888802|NCT03606642|DEVICE|The Synergy® stent|IVUS guided stent
223888803|NCT04807868|PROCEDURE|Standard of care liver biopsy|Patients undergoing a standard of care liver biopsy for any reason who are willing to participate will be consented for collecting additional biopsy tissue for research purposes. 1-2 additional biopsy tissue cores will be collected for research. Liver tissue will be biobanked for future use.
223888804|NCT04807868|OTHER|Fibroscan|A FibroScan will be performed to evaluate longitudinal changes in liver fat and fibrosis.
223888805|NCT04807868|OTHER|Biospecimen Collection|Blood and urine will be collected.
223888806|NCT05893173|BEHAVIORAL|Sleep Deprivation|Ten individuals (aged 18-85) with a DSM-V diagnosis of MDD will undergo baseline GluCEST imaging prior to and following approximately 30 hours of total sleep deprivation.
223888807|NCT06173219|COMBINATION_PRODUCT|Radiotherapy combined with immunotherapy|(1) SBRT 8Gy×3f, (2) LDRT 2Gy ×3f, PD-1/L1 inhibitor, periodically, until the disease progresses or intolerable toxic side effects, (4) GM-CSF, 200ug/QD, subcutaneous injection, the first course of treatment for 7 days.
223888808|NCT06500975|DEVICE|Labyrinth Devices MVI™ Multichannel Vestibular Implant System|Continuously motion-modulated stimulation delivered by a vestibular implant already implanted under a prior study protocol (Labyrinth Devices MVI™ Multichannel Vestibular Implant System)
223888809|NCT00741728|OTHER|Spider flash ECG, high-precision carotid echo-tracking, step test|cardiac rhythm recorded during health check up, vascular aging parameters and baroreflex sensitivity recorded during carotid echotracking of the right common carotid artery , step test during 2 minutes
223888810|NCT06194721|PROCEDURE|Cold intrapulpal anesthesia|Intrapulpal cold local anesthesia at 4-5 c temperature
223888811|NCT06194721|PROCEDURE|Room temperature intrapulpal anesthesia|Intrapulpal cold local anesthesia at room temperature
223888812|NCT04031456|BIOLOGICAL|Autologous Platelet Rich Plasma|Autologous PRP intra ovarian infusion
223888813|NCT04031456|BIOLOGICAL|Placebo-Platelet Free Plasma|Autologous PFP intra ovarian infusion
223888814|NCT05021640|DRUG|DCR-AUD|DCR-A1203, the drug substance of DCR-AUD, is a synthetic double-stranded (hybridized duplex) RNA oligonucleotide conjugated to GalNAc ligands that enable specific hepatic access and uptake after subcutaneous administration. DCR-AUD is a sterile solution of DCR-A1203 at a concentration of 160 mg/mL in water for injection (WFI).
223888815|NCT05021640|DRUG|Placebo for DCR-AUD|0.9% saline for injection
223888816|NCT04737772|BEHAVIORAL|Behavioral: Quitline treatment as usual|TAU is state quitline treatment that may include coaching sessions, text messaging and access to the web-based program plus cessation medications and unlimited calls to the QL for support between sessions.
223888817|NCT04737772|BEHAVIORAL|QL Marijuana Check-Up intervention (QL-MJCU)|QL Marijuana Check-Up intervention (QL-MJCU) was developed for non-treatment seeking MJ users and is based on Motivational Enhancement Therapy. Includes TAU (see standard quitline arm) with a trained coach plus a MJ assessment and Personalized Feedback Report (PFR).
223888818|NCT01007591|DRUG|LEO 80190|Applied once daily
223888819|NCT01007591|DRUG|Hydrocortisone|Applied once daily
223888820|NCT04083235|DRUG|Irinotecan Liposomal Injection|Irinotecan liposome injection is irinotecan in the form of the sucrosofate salt, encapsulated in liposomes for i.v. infusion. It is supplied in sterile, single-use vials containing 10 mL of irinotecan liposome injection at a concentration of 4.3 mg/mL free base equivalent (FBE).
223888821|NCT04083235|DRUG|Oxaliplatin|Oxaliplatin injection, USP is supplied in single-dose vials containing 50 mg, 100 mg or 200 mg of oxaliplatin as a sterile, preservative-free, aqueous solution at a concentration of 5 mg/mL.
223888822|NCT04083235|DRUG|5Fluorouracil|Fluorouracil injection, USP is a colorless to faint yellow, aqueous, sterile, nonpyrogenic injectable solution available in 50 mL and 100 mL pharmacy bulk package. Each mL contains 50 mg fluorouracil in water for injection, USP.
223888823|NCT04083235|DRUG|Leucovorin|Leucovorin Calcium for Injection is supplied in vials ranging from 50-500 mg and available as an injectable solution or lyophilized powder for reconstitution.
223888824|NCT04083235|DRUG|Nab-paclitaxel|Nab-paclitaxel is a lyophilised powder containing 100 or 250 mg of paclitaxel formulated as albumin-bound particles in single-use vials for re-constitution. Each mL of the reconstituted formulation will contain 5 mg/mL paclitaxel.
223888825|NCT04083235|DRUG|Gemcitabine|Gemcitabine for injection is a lyophilised powder for solution for infusion, with each single use vial containing 200 mg, 1 g or 2 g of gemcitabine.
223888826|NCT04180397|DRUG|Furosemide|Furosemide 10 mg/ml for injection/infusion
223888827|NCT04180397|DRUG|Isotonic saline|Isotonic saline used as placebo (injection/infusion)
223888828|NCT05041257|DRUG|Mirvetuximab soravtansine|Administered by intravenous (IV) infusion on Day 1 of every 3-week cycle
223888829|NCT03609801|BEHAVIORAL|ACTV|"Achieving Change Through Values-Based Behavior (ACTV) - pronounced ACTIVE - is a new intervention program for domestic violence offenders. ACTV was developed as a collaboration between researchers, practitioners, and the criminal justice system in the state of Iowa (Zarling, Lawrence, Oregno, 2017). It is based on Acceptance and Commitment Therapy (ACT; Hayes, Strosahl, \& Wilson, 1999), which is an evidence-based cognitive-behavioral psychotherapy. ACTV is innovative in two primary ways; first, ACTV applies the ACT model to the treatment of domestic violence, and second, ACTV is specifically designed for use in the correctional setting as part of criminal justice programming."
223888830|NCT03609801|BEHAVIORAL|The Duluth Model|The Duluth Model is based on the premise that domestic abuse happens when men believe they have the right to authority over women who are their intimate partners. The Duluth Model Men's Nonviolence Classes help men stop battering and explore the consequences of the violence for themselves, their partner and their children.
223888831|NCT05660746|DEVICE|RoadMAB|The RoadMAB Dashboard is a real-time decision support system that incorporates PK model-informed Bayesian estimation to provide precision dosing at the point of care.
223888832|NCT05660746|DRUG|Infliximab|"Conventional dosing. Induction: 5-7.5 mg/kg at 0, 2, and 6 weeks. Maintenance: 5-10 mg/kg at every 4-8 weeks based on results of drug concentration monitoring for a flat target of 5-10 μg/mL.~Precision dosing. Induction: 5-12.5 mg/kg at 0, 2, and 6 weeks to target a week6 concentration of 18-24 μg/mL with dosing support provided by the RoadMABTM clinical decision support tool. Maintenance: 5-15 mg/kg every 4-8 weeks to achieve apriori pharmacokinetic and pharmacodynamic targets (CRP, disease activity scores and fecal calprotectin) with dosing support provided by the RoadMABTM clinical decision support tool."
223888833|NCT03781128|DRUG|Lysergic Acid Diethylamide|100 µg, per os, 3 times within 3 weeks
224077194|NCT02007174|DRUG|Medical Treatment|Care treatment included topical eyedrops of 0.3% tobramycin and 0.1% dexamethasone (Trazidex, Laboratorios Sophia) three times daily, and 0.5 carboxymethylcellulose lubricating eye drops (Refresh-Tears, Allergan, Irving, California, USA). Topical antibiotics and corticosteroids were tapered and discontinued after two weeks.
224077195|NCT02007174|PROCEDURE|Argon laser treatment|
224077196|NCT03537391|DIAGNOSTIC_TEST|Whole body contrast enhanced computer tomography|Computed tomography of the thorax, abdomen and pelvis will be performed as a part of routine clinical evaluation protocol. The imaging will be done with contrast agent if there are no clinical contraindications for the use of contrast agent.
224077197|NCT03537391|DIAGNOSTIC_TEST|99mTC-HMDP planar bone scintigraphy (BS)|Planar bone scintigraphy will be performed as a part of routine clinical evaluation protocol. The subjects will be positioned supine on a Discovery NM/CT 670 CZT, a digital SPECT/CT scanner (General Electric Healthcare). The scanner includes a dual-detector, free-geometry integrated nuclear imaging camera with the advanced digital CZT detector technology combined with the high-performance Optima CT540 subsystem. Whole-body planar images will be scanned from the anterior and posterior views three hours after the intravenous injection of 670 MBq of 99mTc-HMDP. A wide-energy high-resolution (WEHR) collimator, a scan speed of 13 cm/min, a zoom of 1.0 and a matrix size of 256 x 1024 are used in the scintigraphy.
224077198|NCT03537391|DIAGNOSTIC_TEST|99mTc-HMDP single photon emission computer tomography/computer tomography|SPECT/CT imaging will be carried out after acquisition of the planar images with the same scanner. Three bed positions of SPECT data will be acquired from the top of the head to mid femoral level using WEHR collimators. A non-circular orbit, 60 views with 15-s scanning time per view will be acquired during 180 degrees of rotation. A 128 x 128 matrix size, a zoom of 1.0 and 15% photopeak and lower scatter energy windows are used. After SPECT a CT topogram and a low-dose tomogram with a modulated mAs (noise index \~ 70), 120 kVp, a pitch of 1.35 and a 2.5-mm slice thickness are scanned. The co-registration of SPECT and CT data is verified after which the SPECT images are reconstructed using modern iterative ordered subsets expectation (OSEM) reconstruction algorithm from General Electric or Hermes Medical Solutions, which includes, e.g., 10 iterations and 5 subsets and attenuation, collimator and scatter corrections.
224077199|NCT03537391|DIAGNOSTIC_TEST|Whole-body magnetic resonance imaging|Magnetic resonance imaging examination will be performed using a 1.5T (Philips 1.5T Ingenia, Best, Netherlands and/or Siemens 1.5T Aera/Avant, Erlangen, Germany) or 3T (Philips 3T Ingenia, Best, Netherlands and/or Siemens 3T Skyra fit, Erlangen, German) MR system. The body matrix coil in combination with a spinal coil will be used for image acquisition. T1-weighted anatomic imaging, STIR fat suppressed images and DWI will be performed in axial and coronal directions. DWI will be obtained with single-shot 2D spin-echo echo-planar imaging. The total scan time will be approximately 50 minutes.
224077200|NCT03537391|DIAGNOSTIC_TEST|Fluorine-18-prostate specific membrane antigen-1007- positron emission tomography/computer tomography|18F-PSMA-1007 is produced by radiolabelling with fluorine-18 produced by irradiating oxygen-18. Administration of the formulated solution is done shortly (\<10h) after production. Imaging is carried out with digital PET/CT scanner (Discovery MI;General Electric Medical Systems, Milwaukee, WI, USA). The patients receive intravenous injection of 200-300 MBq (3 MB/kg) of 18F-PSMA-1007 diluted in 3-5 ml of saline as a 60-sec bolus which will be promptly flushed with saline. Before data acquisition patients will be asked to void. A static emission scan will be acquired 60-min from tracer injection over whole body. The sinogram data will be corrected for deadtime, decay and photon attenuation and reconstructed in a 256x256 matrix. Image reconstruction follows a fully 3D maximum likelihood ordered subsets expectation maximization algorithm incorporating random and scatter correction with two iterations and 28 subsets.The final in-plane full-width half-maximum of the systems is \< 6 mm.
224077201|NCT04210466|BEHAVIORAL|Acceptance & Commitment Therapy + Compassion (COMP.ACT)|8 sessions, 2h each. Intervention includes meditation exercises, behavioral exercises, group discussions, and the structure is the following Session 1: INTRODUCTION: control is the problem Session 2: THE BODY AS PRESENT: promoting body awareness through mindfulness Session 3: COMPASSION I: from self-criticism to self-care Session 4: COMPASSION II: the body as an anchor to self-compassion Session 5: ACCEPTANCE: there is more to accept than just pain Session 6: (RE)DISCOVERING VALUES: in search of a valued life Session 7: ACT NOW: from values to committed action Session 8: CARRY ON AFTER COMP.ACT: program summary
223888834|NCT03781128|DRUG|Placebo|placebo in an identical-looking vial as LSD, per os, 3 times within 3 weeks
223888835|NCT03289403|DRUG|Immunomodulatory|"Patients will receive thyroxine , low dose aspirin , low dose selenium, Calcium and vitamin D before ICSI cycle.~Moreover, patients will receive a treatment course of immunomodulatory drugs for 3 -6 months before ICSI cycle:~1. Prednisnlone 40mg for 2 weeks to be lowered gradually till become 5mg after 6 weeks and to be continued~2. Hydroxychloroquine according to body weight, patients who develop hypersensitivity will be shifted to Azathioprin.~3. Immunoglobulins will be used in cases not responding to treatment."
223888836|NCT03289403|DRUG|Thyroxine|"Patients will receive thyroxine , low dose aspirin , low dose selenium, Calcium and vitamin D before ICSI cycle.~Patients will not receive immunomodulatory drugs"
223888837|NCT04696952|DRUG|TS-142|TS-142
223888838|NCT04696952|DRUG|Zopiclone|Zopiclone
223888839|NCT04696952|DRUG|Placebo|Placebo
223888840|NCT05737212|RADIATION|500mg/kg/3hr followed by neutron irradiation to reach maximum brain dose of 9Gy-Eq|Patients will be infused DMX-101 intravenously at a dose of 500mg/kg/hr over 3 hours. Thereafter, patient will receive neutron irradiation simultaneously for a certain period of time based on his Boronophenylalanine (BPA) concentration in the blood.
223888841|NCT05737212|RADIATION|500mg/kg/3hr followed by neutron irradiation to reach maximum brain dose of 11Gy-Eq|Patients will be infused DMX-101 intravenously at a dose of 500mg/kg/hr over 3 hours. Thereafter, patient will receive neutron irradiation simultaneously for a certain period of time based on his Boronophenylalanine (BPA) concentration in the blood.
223888842|NCT05737212|RADIATION|500mg/kg/3hr followed by neutron irradiation to reach maximum brain dose of 13Gy-Eq|Patients will be infused DMX-101 intravenously at a dose of 500mg/kg/hr over 3 hours. Thereafter, patient will receive neutron irradiation simultaneously for a certain period of time based on his Boronophenylalanine (BPA) concentration in the blood.
224077202|NCT04210466|BEHAVIORAL|Acceptance and Commitment Therapy (ACT)|8 sessions, 2h each. Intervention includes meditation exercises, behavioral exercises, group discussions, and the structure is the following Session 1: INTRODUCTION: control is the problem Session 2: THE BODY AS PRESENT: promoting body awareness through mindfulness Session 3: Q\&A 1 Session 4: Q\&A 2 Session 5: ACCEPTANCE: there is more to accept than just pain Session 6: (RE)DISCOVERING VALUES: in search of a valued life Session 7: ACT NOW: from values to committed action Session 8: CARRY ON AFTER COMP.ACT: program summary
224077203|NCT04168294|DRUG|Propofol|patients in sedation group will be intravenous injected propofol in bolus
224077204|NCT04168294|DEVICE|endoscopy|endoscopy system
224077205|NCT05922748|OTHER|imaging|Brain activation is demonstrated by measuring signal changes in brain regions. Activations will be determined by comparison between conditions and in relation to periods of rest
224077206|NCT05922748|OTHER|Evoked Potentials|EEG signals, referenced to the right mastoid, were digitised at 125 Hz with an elliptical low-pass input filter at 49 Hz
224077207|NCT05922748|OTHER|MEG|MEG signals reflect changes in magnetic field evoked by changes in neuronal activity
224077208|NCT05922748|BEHAVIORAL|Behavioural tests|Behavioural tests will be evaluated.
224077209|NCT00035880|DRUG|ABX-CBL|
224077210|NCT00470080|PROCEDURE|venepuncture|venepuncture
224077211|NCT04189679|OTHER|Immune signature in serum associated to the metabolic signature|Immune signature in serum associated to the metabolic signature
224077212|NCT04189679|GENETIC|Meta-genomic signature of intestinal flora|Meta-genomic signature of intestinal flora
224077213|NCT00882141|BEHAVIORAL|Diet modification|Weight loss sessions are held by a registered dietitian for 1 hour once a week for 6-9 months; recommended caloric intake to elicit a weight loss of approximately 0.2-0.4 kg per week
224077214|NCT00882141|BEHAVIORAL|Aerobic exercise|Treadmills and other aerobic exercise equipment 3 times a week for 6-9 months, beginning at low levels of VO2max and progressing in duration and intensity to more than 75% VO2max for 45 minutes
224077215|NCT01724437|DEVICE|catheter based pulmonary vein isolation|catheter based ablation using irrigated catheters and radiofrequency energy as in clinical practice
224077216|NCT05278182|DRUG|Naoxintong Capsule|Patients with acute myocardial infarct on the basis of optimal medical therapy will take Naoxintong capsules following directions for 12 months
224077217|NCT05278182|DRUG|Placebo|Patients with acute myocardial infarct on the basis of optimal medical therapy will take placebo following directions for 12 months
224077218|NCT04282772|DIAGNOSTIC_TEST|Impacted|Until an active treatment for the PFM is started or the early exfoliation of PSM occurs, the tooth remains in a self-locking position
224077219|NCT04282772|DIAGNOSTIC_TEST|Self-corrected|The ectopic erupted permanent molar can disregard the self-locking position and continue in a normal direction, but the distal root of the PSM remains more or less a significant atypical resorption
224077220|NCT00236977|DRUG|Venofer|iron sucrose injection; 500 mg intravenous (IV) infusion administered over 3.5-4 hours on Days 0 and 14, or 200 mg injections administered over 2-5 minutes on 5 different occasions from Day 0 to Day 14.
224077221|NCT00236977|DRUG|Ferrous Sulfate|oral iron tablets; 325 mg three times a day orally for 56 days
224077222|NCT05988151|OTHER|New surgical approach|Patients were included in the study after obtaining informed consent for the new surgical approach inspired by the Fibonacci ratio.
224077223|NCT00266253|DRUG|GK Activator (2)|Escalating doses, po bid or qd for 12 weeks.
224077224|NCT00266253|DRUG|Metformin|As prescribed, for 12 weeks
224077225|NCT05320900|DIAGNOSTIC_TEST|Chest auscultation|Chest auscultation data
224077226|NCT02887131|OTHER|Dynamic CT of the ankle|during inversion and eversion mouvement, with Aquilion One Toshiba scanner
224077227|NCT04557852|PROCEDURE|ATVM|Tailored anterior transvaginal mesh for pelvic organ prolapse
224077228|NCT00062387|DRUG|perifosine|
224077229|NCT03534427|OTHER|Jump rope exercise intervention|12-week jump rope exercise program
224077230|NCT06148558|OTHER|Sunscreen Moisturizer|A provided anti-aging sunscreen moisturizer SPF 50 was used once a day.
224077231|NCT06148558|OTHER|Gentle Cleansing Lotion|A provided Gentle Cleansing Lotion (Revision Skincare) was used 2x daily (AM/PM).
224077232|NCT06148558|OTHER|Facial Moisturizer|A provided facial moisturizer (Goodier) was used 1x daily (PM).
224077233|NCT02914262|DRUG|AKB-4924|Comparison of different dosages of AKB-4924
224077234|NCT02914262|OTHER|Placebo|Placebo comparator
224077235|NCT03796767|RADIATION|Hypofractionated Radiation Therapy|Undergo hypofractionated radiation therapy
224077236|NCT03796767|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
224077237|NCT03796767|PROCEDURE|Metastasectomy|Undergo salvage oligometastasectomy
224077238|NCT03796767|OTHER|Quality-of-Life Assessment|Ancillary studies
224077239|NCT03796767|OTHER|Questionnaire Administration|Ancillary studies
224077240|NCT03796767|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
224077241|NCT02482155|DRUG|Ibuprofen|ibuprofen 400 mg single dose oral solution
224077242|NCT01307930|DRUG|Anidulafungin|Anidulafungin 100 mg IV (each volunteer will only receive one dose of the study drug)
224077243|NCT06388486|BEHAVIORAL|Psychotherapy|Subject receive psychotherapy during hospital treatment.
224077244|NCT06241612|RADIATION|Individualized Elective Neck Irradiation|Individualized Elective Neck Irradiation
224077245|NCT00784966|DRUG|etanercept|Treatment option 'A'-Two weeks treatment with etanercept. The first dose of 50mg in normal saline will be given intravenously one hour before transplant. Then 25mg will be administered subcutaneously two times a week for two weeks.
224077246|NCT00784966|DRUG|etanercept|Etanercept will be given for a total of 2 months. The first dose of 50mg in normal saline will be given intravenously one hour before transplant. Then 25mg will be administered subcutaneously two times a week for two months.
224077247|NCT03509324|DRUG|Insulin LISPRO|receive short-term insulin pump therapy by using insulin LISPRO, continue treatment for 7 more days when euglycemia achieved
223888843|NCT04090736|DRUG|Pevonedistat|Pevonedistat 20 mg/m2 intravenous on days 1, 3, and 5 (28-day cycles)
223888844|NCT04090736|DRUG|Azacitidine|Azacitidine 75 mg/m2 subcutaneous on a 5-on/2-off \[weekend\]/2-on schedule (28-day cycle). Intravenous for patients who have non-tolerated local reactions
223888845|NCT04974541|OTHER|Heart Health Yoga|Yoga-based digital intervention
223888846|NCT04974541|OTHER|Psychosocial education|Standard psychosocial education component
223888847|NCT03734653|DRUG|Transdermal Testosterone|Patients will be prescribed 2 packets of testosterone gel 1% containing 50mg per packet to apply transdermally daily.
223888848|NCT03734653|DRUG|Standard of Care, Enzalutamide|Patients will take four 40mg capsules of enzalutamide for a total daily dose of 160mg.
223888849|NCT04805333|DRUG|Artemisia annua 450mg|Artemisia annua will be self-administered via a preparation of decaffeinated coffee.
223888850|NCT04805333|DRUG|Artemisia annua 900mg|Artemisia annua will be self-administered via a preparation of decaffeinated coffee.
223888851|NCT04805333|DRUG|Artemisia annua 1350mg|Artemisia annua will be self-administered via a preparation of decaffeinated coffee.
223888852|NCT04805333|DRUG|Artemisia annua 1800mg|Artemisia annua will be self-administered via a preparation of decaffeinated coffee.
223888853|NCT04805333|DRUG|Artemisia annua - recommended phase II dose|Artemisia annua will be self-administered via a preparation of decaffeinated coffee. The dose for this cohort will be based on analysis of previous cohorts.
223888854|NCT02207062|DRUG|Ibrutinib|Given PO
223888855|NCT02207062|OTHER|Laboratory Biomarker Analysis|Correlative studies
223888856|NCT04302168|DIETARY_SUPPLEMENT|Choline supplement|Choline 470mg twice daily for 8 weeks.
223888857|NCT04302168|DIETARY_SUPPLEMENT|Placebo|Placebo pill twice daily for 8 weeks
223888858|NCT04559334|DEVICE|Tetrasodium EDTA Catheter Lock Solution|KiteLock™ 4% Sterile Catheter Lock Solution is a single use, clear, colorless and sterile solution. It is free of preservatives, alcohol and latex and is non-pyrogenic. KiteLock™ 4% is an aqueous solution containing a mixture of edetate tetrasodium and edetate trisodium. The solution composition is equivalent to 28 mg/mL edetate. EDTA is a known chelator. This means it has an affinity for metals and elements such as calcium. As a primary mechanism of action, it acts as a space occupying solution to prevent blood from entering the tip of the catheter when the catheter is not in use. As a secondary mechanism of action, it acts as an in vitro anticoagulant. This dual action decreases the risk of clot formation, consequently thrombolytic occlusions and by extension decreases the risk of CLABSI.
223888859|NCT05145283|DRUG|Conestat alfa (Ruconest®)|In the current study, participants will receive two intravenous injections of conestat alfa (immediately during the TAVI procedure and again 3h later) at a dose of 100 U/kg (first dose) and of 50 U/kg (subsequent dose), for patients less than 84 kg; two intravenous injections (immediately during the TAVI procedure and again 4h later) of conestat at a dose of 8400 U (4 vials, first dose) and of 4200 U (2 vials, subsequent dose) for patients of 84 kg body weight or greater. The chosen regimen including repeated administration should increase and maintain serum C1INH levels above twice the serum concentration for six to eight hours in the majority of patients. The timeframe of therapeutic concentrations will cover the period of the TAVI procedure itself and the immediate postprocedural period during which reperfusion and additional ischemic events related to global hypoperfusion may occur.
223888860|NCT05145283|DRUG|NaCl 0.9%)|Normal saline (NaCl 0.9%) will serve as placebo treatment. The respective amount of saline (according to patient weight matching the volume of conestat alfa that would have been used for this patient) will be withdrawn in an opaque syringe for slow IV injection.
223888861|NCT06023693|BEHAVIORAL|i-Sleep & BioClock|Module 1 Psychoeducation about normal sleep and insomnia, Psychoeducation on the biological clock: the circadian rhythm, chronotypes, zeitgebers, importance of light behaviour Basic sleep hygiene: information about behaviours that are known to promote or impede sleep e.g. performing physical exercise or the use of caffeine Module 2 Sleep restriction and stimulus control: patients are taught to use the bedroom only to sleep and to restrict the time in bed to the average amount of night-time sleep Module 3 Worrying and relaxation: audio files with progressive muscle relaxation exercises are offered and techniques to stop worrying (e.g. thought blocking, evaluation and worry time) Module 4 Erroneous cognitions about sleep: the basics of cognitive behavioural therapy are explained and the most common erroneous ideas about insomnia are discussed Module 5 Summary and plan for the future
223888862|NCT06023693|BEHAVIORAL|Online Psychoeducation|Online psychoeducation about sleep and the biological clock, basic sleep hygiene
223888863|NCT05980936|OTHER|Screening for obstructive sleep apnea|Patient will be interviewed and asked of there are symptoms of snoring, day somnolence, chocking or gasping during sleep
223888864|NCT06531681|DEVICE|MR-Linac|Radiation therapy with the MR-Linac
223888865|NCT05991310|OTHER|Telemedicine Assessment by Remote Neurologist|Use of a telemedicine platform for a neurologist, remotely located, to assess a MSU patient, review imaging, and decide on the required treatments.
223888866|NCT05991310|OTHER|In-Person Assessment by an Onboard Neurologist|Traditional in-person assessment of a patient by a neurologist located onboard the MSU
223888867|NCT03270956|BIOLOGICAL|Renal Autologous Cell Therapy (REACT)|Autologous selected renal cells (SRC)
223888868|NCT05033392|DRUG|Toripalimab Injection|A domestic PD-1 antibody
223888869|NCT06024304|DEVICE|Synthes TFNA|Surgical fixation with single-screw device Synthes TFNA; Pelvic fractures will be repaired utilizing single-screw device Synthes TFNA.
223888870|NCT06024304|DEVICE|Trigen InterTAN|Surgical fixation with Smith and Nephew Trigen InterTAN cephalomedullary long nail; Pelvic fractures will be repaired utilizing Smith and Nephew Trigen InterTAN.
223888871|NCT05309447|OTHER|data collection|The study entails the collection of clinical, functional, radiological, and biomechanical data.
223888872|NCT06322056|DRUG|Intensive control of SBP and intensive control of LDL-C|Eligible participants would be assigned to a SBP target of less than 120 mmHg and a LDL-C target of less than 70 mg/dL.
223888873|NCT06322056|DRUG|Intensive control of SBP and standard control of LDL-C|Eligible participants would be assigned to a SBP target of less than 120 mmHg and a LDL-C target of less than 100 mg/dL.
223888874|NCT06322056|DRUG|Standard control of SBP and intensive control of LDL-C|Eligible participants would be assigned to a SBP target of less than 140 mmHg and a LDL-C target of less than 70 mg/dL.
224077248|NCT04027933|BEHAVIORAL|Education Based on Standard Patient Simulation|"In the first phase of the study, a theoretical education was provided to the students.~In the second phase, the students in the experimental and control groups who completed their theoretical education were given data collection forms. In the third phase, after the scales were implemented, there was no intervention with the control group. There was a standard patient implementation to the experimental group. In the fourth phase of the study, after completing the simulation practice, all scales were re-applied both to the experimental and control groups. The scales were applied after the simulation training was completed and students were sent to the clinical practice after three weeks. In the fourth phase of the study, right before the students practiced their trainings and at the end of the initial rotations of the clinical practice, which turned out to be about four weeks later on average, all scales were re-applied both to the experimental and control groups."
224077249|NCT00958672|OTHER|Endoscopic capsule|Endoscopic capsule
224077250|NCT00797823|DRUG|Insulin, Asp(B28)-|Insulin dosing and frequency calculated by Fading Memory Proportional Derivative algorithm
224077251|NCT00797823|DRUG|Glucagon|During incipient hypoglycemia, glucagon was given in an attempt to prevent overt hypoglycemia. Dosing and frequency was calculated by the Fading Memory Proportional Derivative algorithm
224077252|NCT00797823|DRUG|Placebo|Saline solution 0.9%
223888875|NCT06322056|DRUG|Standard control of SBP and standard control of LDL-C|Eligible participants would be assigned to a SBP target of less than 140 mmHg and a LDL-C target of less than 100 mg/dL.
224077253|NCT02995109|DRUG|BAY987521|"Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.~(Formulation Code: Z11-004)"
224077254|NCT02995109|DRUG|SPF Control|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.
223888876|NCT04862780|DRUG|BLU-945|Oral administration
224077255|NCT03926221|BEHAVIORAL|Parent Behavior Change Intervention (PBC-I) and Transdiagnostic Sleep and Circadian Intervention (TranS-C)|PBC-I will be administered to the parent and TranS-C will be administered to the teenager. Both interventions are cognitive-behavioral and comprised of six weekly sessions. Parent and teenager sessions will be held in parallel.
224077256|NCT04492436|DRUG|thrombomodulin alfa|Weight based dose of reconstituted treatment administered through intravenous drip infusion on Day1 of each chemotherapy cycle
224077257|NCT04492436|DRUG|Placebo|Weight based dose of reconstituted treatment administered through intravenous drip infusion on Day1 of each chemotherapy cycle
224077258|NCT06489717|OTHER|SDB assessment|SDB will be assessed by respiratory polygraphy according to clinical standards
224077259|NCT06221475|DRUG|BAY2927088 coated tablet 10 mg|4 coated tablets (10 mg) per single dose 30 min after a light meal
224077260|NCT06221475|DRUG|[14C]-BAY2927088 solution for infusion|IV infusion 15 min ending at 2 hours oral post-dose
224077261|NCT06221475|DRUG|[14C]-BAY2927088 oral solution|After a light meal
224077262|NCT03543514|OTHER|TRIMODAL PREHABILITATION|"Trimodal prehabilitation application in the form of:~* Control with the 6-minute walking test and podometer of physical activity~* Dietary advice to be able to perform a hyperproteic diet~* Mindfullnes to improve the emotional level."
224077263|NCT01113827|DIETARY_SUPPLEMENT|Olive Extract|Capsule form ingested 1x/day for 6 weeks
224077264|NCT01113827|DIETARY_SUPPLEMENT|Placebo|Placebo
223888877|NCT04862780|DRUG|osimertinib|Osimertinib tablets for oral administration
223888878|NCT06029647|OTHER|Mango|The participants will consume the treatment for 16 weeks, followed by a 4-week washout period.
224077265|NCT03014856|OTHER|Blood sampling|Determine the metabolic phenotype of blood plasma by proton-NMR spectroscopy
224077266|NCT00004979|DRUG|paclitaxel|
224077267|NCT00004979|DRUG|topotecan hydrochloride|
224077268|NCT02809833|DRUG|Tocilizumab|Tocilizumab must be selected by the treating physician in advance of the study and will be not provided by the Sponsor. The dose/regimen are at the discretion of the prescriber. However, tocilizumab in the SmPC is specified as 8 milligrams per kilogram (mg/kg) via intravenous (IV) infusion at 4-week intervals.
224077269|NCT01181414|PROCEDURE|Atrio ventricular junction ablation with radio-frequency|Atrioventricular junction ablation by using radiofrequency energy.
224077270|NCT01181414|DRUG|Beta blocker/digoxine/amiodarone|Ventricular rate control by using drug treatment.
224077271|NCT00387114|DRUG|Vitamin C|
224077272|NCT00523991|DRUG|tiotropium|Oral inhalation once daily of 18mcg tiotropium via handihaler
224077273|NCT00523991|DRUG|Placebo|Oral inhalation once daily of placebo matching tiotropium via handihaler
224077274|NCT00193063|DRUG|Trastuzumab|Trastuzumab
224077275|NCT00193063|DRUG|Gemcitabine|Gemcitabine
223888879|NCT06029647|OTHER|vanilla wafers|vanilla wafers
224077276|NCT01418976|BEHAVIORAL|Intensive Mobility Training (IMT)|Intensive Mobility Training will be used as an intensive physical therapy intervention. Participants will receive 3 hours per day for a 10 day session, be post-tested, and receive another 10 day session followed by two more testing sessions.
224077277|NCT00009971|DRUG|fenretinide|
223888880|NCT03439488|DRUG|JNJ-440|JNJ-440 will be administered as oral tablets in Parts 1, 2 and 3. JNJ-440 may be provided as oral solution in a cohort in Part 1.
223888881|NCT03439488|DRUG|Placebo|Matching placebo as oral tablets will be administered in Parts 1, 2 and 3.
223888882|NCT06482034|DRUG|N-acetyl cysteine|N-acetyl cysteine sachets
223888883|NCT06482034|DRUG|Zinc sulfate|zinc sulfate capsules
223888884|NCT06482034|DRUG|saline mouth wash|saline mouth wash
223888885|NCT04612192|DEVICE|Active luminette|receive an active light using glasses of 1500 lux (an average of 180 photons/s/cm2, with a maximum wavelenght at 468 nm), 30-minute long light therapy in the morning, in a time period defined by sleep log and chronotype questionnaire, on a 4-week period
224077278|NCT00920660|DRUG|Placebo|Matching placebo is supplied containing microcrystalline cellulose (Avicel PH 105). Placebo will be administered as eight matched capsules.
224077279|NCT00920660|DRUG|0.25g SRT2104|SRT2104 will be supplied as hard gelatin capsules, with each containing 250 mg. The 0.25g SRT2104 treatment visit will be administered as one SRT2104 capsule with 7 placebo capsules. Dosing will take place during one of the 6 treatment visits.
224077280|NCT00920660|DRUG|Prednisolone|During the last treatment period, subjects will receive 30 mg open-label prednisolone.
224077281|NCT00920660|DRUG|0.5g SRT2104|SRT2104 will be supplied as hard gelatin capsules, with each containing 250 mg. The 0.5g SRT2104 treatment visit will be administered as two SRT2104 capsules with 6 placebo capsules. Dosing will take place during one of the 6 treatment visits.
224077282|NCT00920660|DRUG|1g SRT2104|SRT2104 will be supplied as hard gelatin capsules, with each containing 250 mg. The 1g SRT2104 treatment visit will be administered as four SRT2104 capsules with four placebo capsules. Dosing will take place during one of the 6 treatment visits.
224077283|NCT00920660|DRUG|2g SRT2104|SRT2104 will be supplied as hard gelatin capsules, with each containing 250 mg. The 2g SRT2104 treatment visit will be administered as eight SRT2104 capsules. Dosing will take place during one of the 6 treatment visits.
224077284|NCT01197287|DRUG|QAK423A|
224077285|NCT01197287|DRUG|QAK423A|
223888886|NCT04612192|DEVICE|Placebo luminette|receive a placebo light using glasses (an average of n photons/s/cm2, single- band spectrum with a narrow peak at 660 nm under 50 lux), with the same modality as the experimental group
223888887|NCT05774314|BEHAVIORAL|Community Health Worker Intervention|Communities that are randomized into the Treatment arm will receive the Flourish program. Communities with a Flourish program will select and train a Community Health Worker from the Transform program participants. At the end of the Transform program, a Savings Group will be formed from the Transform program participants. The Savings Group will nominate households to participate in the Flourish program and research study. The Community Health Worker will approach the nominees and attempt to enroll them into the Flourish program and research study. If the nominees agree to be enrolled in the Flourish program, the Community Health worker will provide screening, referral, counseling, and treatment services to the household for the duration of the study.
224077286|NCT01197287|DRUG|QAK423A|
224077287|NCT02899039|BIOLOGICAL|extra blood draw samples|
223888888|NCT01804816|PROCEDURE|Acupuncture|Standardized acupuncture administration for 10 sessions.
224077288|NCT04173429|DRUG|Nadroparin calcium, warfarin|Nadroparin calcium subcutaneously every 12hs for 1 months followed by warfarin orally for 5 months. INR(international normalized ratio ) was detected every 3-4 days and adjusted carefully by 0.75mg dosage until achieve the target level of 2-3.
224077289|NCT04241614|OTHER|No interventions|No interventions
224077290|NCT00744874|PROCEDURE|RF Ablation procedure|Patients with a history of symptomatic paroxysmal (self-terminating) AF and meeting all inclusion/exclusion criteria, as identified by the clinical investigator, will be enrolled in the study.
223888889|NCT01804816|OTHER|No Intervention|No intervention during this period. This was a control period. Each subject acted as their own control.
223888890|NCT04716140|PROCEDURE|Debridement of the MTP1 cartillage lesion and microfracture|Patients with a MTP1 cartillage lesion \> grade I (based on based on the ICRS scale and an MS HoloLens measurement) randomised in the treatment group will be treated with debridement and microfracture
223888891|NCT05680675|DIAGNOSTIC_TEST|Single-Tracer FDG PET/CT Exam|"The PET technologist will administer approximately 15 millicuries (mCi) of FDG intravenously, and the participant will remain resting during the tracer uptake period. A CT topogram will be obtained, and the PET imaging field-of-view (FOV) selected. The PET scan will then be acquired, acquiring 5 back-to-back whole-body (eyes-to-thighs, or similar) scans, providing 5 sequential PET images."
224077291|NCT00566930|OTHER|spinal manipulation|Monthly cervical spinal manipulation
224077292|NCT00566930|OTHER|Spinal manipulation + exercises|Monthly cervical spine manipulation and daily home exercises
224077293|NCT01681550|DRUG|Incretin-based therapy|
224077294|NCT03285243|DEVICE|Monochromatic blue light|Exposure to monochromatic light for the first 30 minutes in the recovery period after anesthesia to assess incidence of emergence delirium as noted by the PAED scale
224077295|NCT04206449|OTHER|Therapeutic decision PSG|Randomizing for therapeutic decision taken with Standard Polysomnography (PSG)
224077296|NCT04206449|OTHER|Therapeutic decision Infrared thermgraphy system|Also randomizing for Infrared thermography system
224077297|NCT04304027|OTHER|Tailored exercise intervention|2x 30 minute aerobic interval training per week for 8 weeks - sessions involve 6 intervals cycling for 2 minutes at target heart rate reserve followed by 2 minutes working rest (target heart rate reserve may vary between sessions depending on the level of self-reported fatigue)
224077298|NCT04304027|OTHER|Standard exercise intervention|2x 30 minute aerobic interval training per week for 8 weeks - sessions involve 6 intervals cycling for 2 minutes at \>70% heart rate reserve followed by 2 minutes working rest
224077299|NCT05465356|OTHER|Questionnaire|Questionnaires completed as part of routine care - this is an observational study
224077300|NCT05465356|OTHER|Semi-structured interview|Semi-structured interview to review factors involved in patients engaging or not-engaging with the digital tools
224077301|NCT05743465|OTHER|No Intervention|As this is an observational study, no intervention will be administered in this study.
224077302|NCT01127165|DRUG|zonisamide low dose group|Initial dose was 2mg/kg/day, increased after 1\~2 weeks to 3\~4mg/kg/day.
224077303|NCT01127165|DRUG|zonisamide high dose group|Initial dose was 2mg/kg/day, increased after 2\~4 weeks to 6\~8mg/kg/day.
224077304|NCT05117359|DEVICE|transcatheter paravalvular leak closure|transcatheter paravalvular leak closure on cardiac valve
224077305|NCT02475642|OTHER|PVI-ADT|Discontinue antiarrhythmic drugs at randomisation (3 months post ablation). As per the eligibility criteria, all patients randomised are taking either Flecainide, Cibenzoline, Propafenon, Sotalol or Amiodarone. These are discontinued at the moment of randomisation in this arm
223888892|NCT05680675|DIAGNOSTIC_TEST|Single-Tracer Cu64-DOTATATE PET/CT Exam|"The PET technologist will administer with approximately 4 mCi Cu64-DOTATATE intravenously, and the participant will remain resting during the tracer uptake period. A CT topogram will be obtained, and the PET imaging field-of-view (FOV) selected. The PET scan will then be acquired, acquiring 5 back-to-back whole-body (eyes-to-thighs, or similar) scans, providing 5 sequential PET images."
224077306|NCT02475642|OTHER|PVI+ADT|Discontinue antiarrhythmic drugs 9 months after randomisation (12 months post ablation). As per the eligibility criteria, all patients randomised are taking either Flecainide, Cibenzoline, Propafenon, Sotalol or Amiodarone. These are continued in this arm until 9 months post randomisation at which point they are stopped
224077307|NCT05649293|OTHER|measure vitamin b6 in serum|"* Vitamin B6 levels can be determined by using Enzyme- linked Immuno-sorbent Assay Kit For vitamin B6 . or Chemiluminescence Immunoassays (CLIA) .~* Venous blood samples will be taken from each patient. Use a serum separator tube and allow samples to clot for 10-20 minutes at room temperature and then centrifuged for 20 minutes at speed of 2000-3000 rpm (round per minute).~* Remove supernatant, if precipitation appeared, Centrifuge again.~* Extract as soon as possible after Samples collection, and should be tested as soon as possible after the extraction.~* If not, samples must be stored in aliquot at -20°C (≤ 1 month) or -80°C (≤ 2 months) to avoid loss of bioactivity and contamination.~* Hemolyzed Sample will be avoided , as hemolysis will interfere with the results ."
223888893|NCT05680675|DIAGNOSTIC_TEST|Single-Tracer Ga68-DOTATATE PET/CT Exam|"The PET technologist will administer with with approximately 5 mCi Ga68-DOTATATE intravenously, and the participant will remain resting during the tracer uptake period. A CT topogram will be obtained, and the PET imaging field-of-view (FOV) selected. The PET scan will then be acquired, acquiring 5 back-to-back whole-body (eyes-to-thighs, or similar) scans, providing 5 sequential PET images."
224077308|NCT03250403|DRUG|PRP injection|peri-neural injection of platelet rich plasma
223888894|NCT05680675|DIAGNOSTIC_TEST|Single-Tracer PSMA PET/CT Exam|"The PET technologist will administer with with approximately 7 mCi Ga68-PSMA-11 intravenously, and the participant will remain resting during the tracer uptake period. A CT topogram will be obtained, and the PET imaging field-of-view (FOV) selected. The PET scan will then be acquired, acquiring 5 back-to-back whole-body (eyes-to-thighs, or similar) scans, providing 5 sequential PET images."
224077309|NCT03250403|OTHER|traditional medical treatment|traditional medical treatment
224077310|NCT03175549|DRUG|Apremilast|Fixed oral dose of 90 mg/d following the standard titration for a total dosing duration of 14 days.
223888895|NCT05894681|OTHER|THE EFFECT OF WATSON MODEL-BASED PSYCOEDUCATIONAL INTERVENTIONS ON PREVENTION OF POSTPARTITION DEPRESS|THE EFFECT OF WATSON MODEL-BASED PSYCOEDUCATIONAL INTERVENTIONS ON PREVENTION OF POSTPARTITION DEPRESS
223888896|NCT03400059|DEVICE|Chordate System S211 in treatment mode|Chordate System S211 in treatment mode
223888897|NCT03400059|DEVICE|Chordate System S211 in placebo mode|Chordate System S211 in placebo mode
223888898|NCT05989958|COMBINATION_PRODUCT|HepaCure|HepaCure will be administered in extracorporal dialysis following the treatment of DPMAS and LPE.
224077311|NCT03175549|DRUG|Placebo|Identical placebo pills taken orally for 14 days
224077312|NCT00613457|DRUG|dexamethasone|10 mg/sqm/day from for 21 days
224077313|NCT00613457|DRUG|asparaginase|native E-coli Asparaginase 5,000 IU/sqm x 8 doses
224077314|NCT00613457|DRUG|Asparaginase|native E-Coli Asparaginase 10,000 IU/sqm x 4 doses
224077315|NCT00613457|DRUG|cyclophosphamide|1,000 mg/sqm i.v. 2 doses in Induction phase 1000 mg/sqm i.v. 1 dose in Protocoll II 500 mg/sqm i.v. 1 dose in protocol III
223888899|NCT05989958|DEVICE|DPMAS and LPE|Using DPMAS and LPE for extracorporeal dialysis treatment.
224077316|NCT00613457|DRUG|cytarabine|75 mg/sqm i.v.or s.c. 4 doses/week for 4 weeks in Induction phase 75 mg/sqm i.v.or s.c. 4 doses/week for 2 weeks in Protocol II and III
224077317|NCT00613457|DRUG|daunorubicin|30 mg/sqm i.v. 4 doses in Induction phase
224077318|NCT00613457|DRUG|doxorubicin|30 mg/sqm i.v. x 4 doses in Protocol II and III
224077319|NCT00613457|DRUG|Etoposide|100 mg/sqm i.v. for 3 doses in HR block 3
224077320|NCT00613457|DRUG|Ifosfamide|800 mg/sqm i.v.q12h x 5 in HR block 2
224077321|NCT00613457|DRUG|mercaptopurine|60 mg/sqm p.o. c 28 days in Induction phase 60 mg/sqm p.o. x 56 days in Protocol M 50 mg/sqm daily in Maintenance phase
223888900|NCT04168385|DRUG|Maralixibat|"Maralixibat chloride oral solution orally twice daily (up to 1200\* mcg/kg/day), and according to indication.~\*equivalent to 1140 mcg/kg/day maralixibat"
223888901|NCT05659797|DEVICE|BPET/DBT imaging|Imaging of the breast with a novel device combining dedicated Breast Positron Emission Tomography (BPET) and Digital Breast Tomosynthesis (DBT) following intravenous injection of \[18F\]-Fluoroestradiol (FES).
223888902|NCT05659797|DRUG|18F-FES|Radiolabelled fluoroestradiol for PET imaging
224077322|NCT00613457|DRUG|Methotrexate|by age i.t. in Induction/Protocol M/Protocol II/Protocol III/HR Blocks and maintenance
224077323|NCT00613457|DRUG|prednisone|60 mg/sqm daily p.o. for 28 days then tapered in Induction phase
224077324|NCT00613457|DRUG|thioguanine|60 mg/sqm p.o. x 14 days in Protocol II and Protocol III
224077325|NCT00613457|DRUG|Vincristine|1.5 mg/sqm i.v. x 4 doses in Induction phase and Protocol II 1.5 mg/sqm i.v. x 2 doses in Protocol III and HR block 1
224077326|NCT00613457|DRUG|Vindesine|3 mg/sqm i.v. x 2 doses in HR block 2
224077327|NCT02435849|BIOLOGICAL|CTL019|Tisagenlecleucel was administered as a single iv infusion. Dose: 2.0 to 5.0x10\^6 tisagenlecleucel per kg body weight (for patients ≤ 50 kg) or 1.0 to 2.5x10\^8 tisagenlecleucel (for patients \>50 kg).
224077328|NCT00763321|DRUG|ABT-712|ABT-712 extended-release tablet
224077329|NCT00763321|DRUG|Placebo|Placebo tablet
224077330|NCT04911582|DIETARY_SUPPLEMENT|Cafestol 12 mg|Capsule with 12 mg cafestol
224077331|NCT04911582|DIETARY_SUPPLEMENT|Placebo|Placebo capsule without cafestol
224077332|NCT04911582|DIETARY_SUPPLEMENT|Cafestol 6 mg|Capsule with 6 mg cafestol
224077333|NCT02486757|DRUG|micronized progesterone|
224077334|NCT02486757|DRUG|transdermal estradiol|
224077335|NCT05836792|OTHER|Cycle Ergometer|Patients will attend cycle ergometer exercise. Volunteers will monitor their pedaling forces as right and left force. They will try to make these forces equal while they are pedaling.
224077336|NCT05836792|DEVICE|Transcutaneous electrical nerve stimulation|Transcutaneous electrical nerve stimulation will be used for the reduction of pain. TENS will be used 5 times in a week for 3 weeks. Each procedure will take 20 minutes.
224077337|NCT05836792|DEVICE|Ultrasound|Ultrasound will be used for increase the permeability of cells to treat pain and inflammation. US will be used 5 times in a week for 3 weeks. Each procedure will take 5 minutes
223888903|NCT06067334|OTHER|full arch implant supported screw retained restoration with conventional impression technique|surgical procedures: Implant installation Prosthetic procedures: Conventional impression fabrication of full arch implant supported screw-retained restoration evaluation: Accuracy, Passive fit
223888904|NCT06067334|OTHER|full arch implant supported screw retained restoration with conventional digital technique|surgical procedures: Implant installation Prosthetic procedures: Digital impression fabrication of full arch implant-supported screw-retained restoration evaluation: Accuracy, Passive fit
223888905|NCT04421378|DRUG|Selinexor|Dose and Formulation: 20 milligram (mg); Tablet Route of Administration: Oral
224077338|NCT05836792|OTHER|Isometric exercises|The aim of the isometric exercises is increasing muscle strength. Each session patients will do quadriceps isometric exercises 5 times in a week for 3 weeks
224077339|NCT04069052|DRUG|Nitric Oxide|Gaseous pulmonary vasodilator, SoKinox (nitric oxide) flowed into a mask and breathed in.
224077340|NCT04069052|DRUG|Placebo|Room air (placebo) flowed into a mask and breathed in.
224077341|NCT01302873|DRUG|BGG492A|
224077342|NCT01302873|DRUG|BGG492A|
223888906|NCT04421378|DRUG|Temozolomide (TMZ)|Dose strength and Formulation: 5, 20, 100, 140, 180, or 250 mg; Capsule Route of Administration: Oral
224077343|NCT01017952|DRUG|FF/GW642444 Inhalation Powder|Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA) for COPD
224077344|NCT01017952|DRUG|GW642444 Inhalation Powder|Long Acting Beta Agonist(LABA) Inhalation Powder
224077345|NCT02666014|DRUG|Sugammadex|Reversal of neuromuscular blockade
224077346|NCT02666014|DRUG|Neostigmine|Reversal of neuromuscular blockade
224077347|NCT01395992|DRUG|asenapine|asenapine 5 mg tablet, sublingually (SL) twice daily (BID) for 182 days
224077348|NCT01395992|DRUG|asenapine|asenapine 10 mg tablet, SL BID for 182 days
224077349|NCT00031161|DRUG|Nitisinone (NTBC)|
224077350|NCT00031161|DRUG|Dichloroacetate|
224077351|NCT00031161|BEHAVIORAL|Low-tyrosin diet|
224077352|NCT00264914|DRUG|SR121463B|
224077353|NCT02443064|DRUG|Vancomycin|"Vancomycin was administered for Chinese patients with MRSA blood stream infection and endocarditis Pharmacokinetics: 5 blood samples collected at steady state for the determination of plasma concentrations for population pharmacokinetics (PPK) analysis.~Microbiology: blood cultures for MRSA isolation, MIC of vancomycin against MRSA; molecular typing will be analyzed on bacterial strains including heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) and vancomycin-intermediate Staphylococcus aureus （VISA); Safety evaluation: hepatic and renal function, blood routine test, and so on."
224077354|NCT03602287|DRUG|Lignocaine 2% Injection 20Ml Vial (Product)|2.5 ml of 2% of lignocaine is diluted with 2.5 ml of distilled water, and the 5ml solution will be injected into the Merocel pack 15 minutes before removal of the pack
224077355|NCT03602287|DRUG|Normal saline|5 ml of normal saline was injected into the Merocel pack 15 minutes before removal of the pack
224077356|NCT01064167|DRUG|Tranexamic Acid|In tranexamic acid group, tranexamic acid, 1 g, was given 20 minutes before incision and 400 mg/h during the entire surgical procedure. The patients from control group were infused with normal saline as a placebo.
224077357|NCT01615848|OTHER|mediterranean diet restricted calorie|1500 k/cal 30% fat
224077358|NCT01615848|OTHER|high protein diet|50 pcos diagnosed women will be assigned to high protein diet for 18 month
224077359|NCT01615848|OTHER|mediterranean diet restricted calorie|50 pcos women will be assigned to 1500 k/cal diet for 18 month
224077360|NCT02339493|OTHER|Computer Electronic Alert|A computer program that will issue an on-screen electronic alert notifying the responsible provider that his or her patient is high-risk for stroke due to AF or atrial flutter and that the patient is not ordered to receive anticoagulant therapy. The alert will provide options for anticoagulation for stroke prevention in AF as well as additional information in the form of suggested reading.
224077361|NCT05076539|OTHER|Garmin GPS activity tracker|50 patients will be issued a Garmin GPS-activity tracker where they will be required to wear for 24 hours for 1 week, prior to each timepoint (pre-operatively and 6 months post surgery).
224077362|NCT01641406|DRUG|Docetaxel, Epirubicin, Cyclophosphamide/Navelbine, Capecitabine, Trastuzumab, Bevacizumab|ER-(Triple Negative and ER-PR+Her-2-):Patients who respond to the first 4 courses of TEC with a Complete Remission will receive 4 more courses of TEC. Patients who respond to the first 4 courses of TEC with a Partial Remission or Stable Disease will then have their treatment changed to the non-cross resistant NAX regimen.Courses will be repeated every 21 days according to blood counts.A total of 4 courses will be given.
224077363|NCT01641406|DRUG|Docetaxel, Epirubicin, Cyclophosphamide/Navelbine, Capecitabine, Trastuzumab, Bevacizumab|"Her-2 positive cases:Patients who respond to 4 courses of TEC with either a partial or complete remission will then receive 4 additional courses of Docetaxel plus Herceptin, and upon completion of the 4th course of DH they will undergo definitive surgery.A total of 4 courses will be given. Courses will be repeated every 21 days according to blood counts. Patients whose response after 4 courses of TEC is either stable disease or progression, will be treated with NTX."
223888907|NCT04421378|DRUG|Lomustine (CCNU)|Dose and Formulation: 10, 40, or 100 mg; Capsule Route of Administration: Oral
223888908|NCT04421378|RADIATION|Standard Fractionated Radiation therapy (RT)|Radiation Therapy Oncology Group (RTOG) or European Organisation for Research and Treatment of Cancer (EORTC) methodologies of approximately 60 Gy in 30 fractions.
223888909|NCT04421378|DRUG|Bevacizumab|Dose and Formulation: 10 mg/kg; Route of Administration: Intravenous
223888910|NCT04421378|DEVICE|TTField|Dose and Formulation: 200 kHz ≥18h/day; Route of administration: Scalp application of transducer arrays.
223888911|NCT04421378|DRUG|Carmustine|Dose and Formulation: 150 or 200 mg/m\^2; Route of Administration: Intravenous
223888912|NCT06271187|DEVICE|Dynamic-orthosis|Engaging in motion training at home with the use of dynamic orthoses.
223888913|NCT06271187|OTHER|Traditional stroke occupational therapy training|Traditional post-stroke movement training arranged by an occupational therapist in a medical setting.
223888914|NCT05683509|PROCEDURE|deep collagen layer, xenograft and collagen membrane|Alveolar ridge preservation is done using deep collagen layer, xenograft and collagen membrane
223888915|NCT05683509|PROCEDURE|xenograft and collagen membrane|Alveolar ridge preservation is done using xenograft and collagen membrane only
223888916|NCT04545541|DRUG|Nebulised unfractionated heparin (UFH)|Nebulised UFH (25,000 Units in 5 mL) will be administered 6-hourly via an Aerogen Solo vibrating mesh nebuliser while patients receive invasive mechanical ventilation in ICU and for a maximum of 10 days.
223888917|NCT03020303|DRUG|Spironolactone 25Mg Tablet|Randomized participants will receive a study supply of spironolactone 25 mg tablets. They will be instructed to take 1 tablet daily.
223888918|NCT03020303|DRUG|Placebo Oral Tablet|Randomized participants will receive a study supply of placebo tablets with no active medical ingredients. They will be instructed to take 1 tablet daily.
223888919|NCT04049279|PROCEDURE|BiMobile standard cement|BiMobile dual mobility cup, in a standard size after optimal reaming, resulting in a cement mantle of approximately 2mm.
223888920|NCT04049279|PROCEDURE|BiMobile larger cement|BiMobile dual mobility cup, in one size smaller than standard after optimal reaming, resulting in a cement mantle of approximately 4mm.
223888921|NCT04049279|PROCEDURE|Avantage standard cement|Avantage dual mobility cup, in a standard size after optimal reaming, resulting in a cement mantle of approximately 2mm.
223888922|NCT05164744|DIAGNOSTIC_TEST|Cardiac MRI|Patients participate in an NIH funded cardiac MRI to assess their symptoms.
223888923|NCT05164744|DIAGNOSTIC_TEST|Echocardiogram|Patients participate in an NIH funded cardiac echocardiogram to assess their symptoms.
223888924|NCT05164744|DIAGNOSTIC_TEST|6-minute walk test|Patients participate in a 6-minute walk test to assess their symptoms.
223888925|NCT05164744|DIAGNOSTIC_TEST|Questionnaire|Patients answer a survey-based questionnaire to assess their symptoms.
223888926|NCT06518967|DIAGNOSTIC_TEST|analytical performance study|analytical performance study on left-over samples with the SiMoT IVD system for in vitro diagnostic tests
223888927|NCT02662751|OTHER|Routine Imaging Assessment|"Patients will have the usual post-stroke/TIA imaging assessment according to routine procedures in each participating center. The latter most often begin with an angiography of the supra-aortic trunks but may also include a range of other imaging exams depending on the patient's condition.~Routine Imaging Assessment refers to an imaging strategy and not a specific device. The devices used depend on what is available in participating centres and the routine choices made by those centers."
223888928|NCT02662751|DEVICE|LDWBA first (CT scan)|"Patients randomized to this arm will start their post-stroke/TIA imaging assessment by a low-dose, whole-body angiography (LDWBA). The latter can be followed by routine imaging assessments if required.~LDWBA: This is a low dose scanner protocol comprising a CT acquisition and an iodine contrast medium injection. The acquisition includes a propeller during the arterial phase of the contrast agent injection in the cervical and thoracic levels with cardiac gaiting (ECG gating to reduce cardiac motion artifacts), continuing with pelvic abdominal arterial acquisition. The second propeller is made on the abdomen and pelvis at the portal time of injection. The reconstruction will be carried out in pulmonary, mediastinal and bone windows. The dose will be calculated for each patient."
223888929|NCT03567096|DEVICE|BiV pacing with MPP and SyncAV|This cohort will receive Bi-Ventricular Pacing (left ventricle and right ventricle pacing) with MultiPoint Pacing of the left ventricle (two stimulation sites) and the SyncAV algorithm active.
223888930|NCT03567096|DEVICE|LV only pacing with MPP and SyncAV|This cohort will receive left ventricular only pacing (no right ventricle pacing) with MultiPoint Pacing of the left ventricle (two stimulation sites) and the SyncAV algorithm active.
223888931|NCT05898516|BEHAVIORAL|Usual Practice + JoyPop|Participants will be asked to use the app at least twice daily but will otherwise not be provided with requirements related to feature or total usage.
223888932|NCT05831670|DRUG|KSP-0243|Oral administration
223888933|NCT05831670|DRUG|Placebo|Oral administration
223888934|NCT06423196|OTHER|Experimental group|In the development of the exercises, the players will mobilise dumbbells of different weights that will be estimated according to the calculation of 30% of 1 RM. This workload with dumbbells is based on previous work where blood flow restriction was used in healthy athletes.
223888935|NCT05042479|OTHER|Usual distraction and pain prevention techniques.|"For the first painful procedure, the child will benefit usual distraction and pain prevention techniques.Pain prevention and management techniques commonly used in the conduct of care:~* Application of a patch or anaesthetic cream 1 hour before the treatment~* Vigilant sedation using a premedication for lumbar punctures: Midazolam /Nalbuphine/Hydroxyzine/Morphine.~* Apart from care using VR, MEOPA can be given to the child for all assessed care on prescription.~* Apart from care using VR, the usual distraction techniques are left to the patient's choice (electronic tablet, smartphone, games, songs...)~* The presence of the parents"
223888936|NCT05042479|OTHER|Virtual reality|For the 2nd painful procedure, the child will use a VR (virtual reality) headset as well as pain prevention techniques (excluding oxygen-nitrous oxide mixtures). The child will choose the application he/she wishes to use according to his/her age.
223888937|NCT05042479|OTHER|Choice between usual distraction or virtual reality|"For the 3rd painful procedure, the child will choose his/her favorite technique between :~Usual distraction and pain prevention techniques or virtual reality"
224077364|NCT01641406|DRUG|Docetaxel, Epirubicin, Cyclophosphamide/Navelbine, Capecitabine, Trastuzumab, Bevacizumab|ER+ Cases(ER+PR+Her-2- and ER+PR-Her-2-):After the first course of TEC if the SUV of the primary tumor is \>5%, treatment will be TEC x 4 courses. If the Oncotype is low, patients will be switched to hormonal therapy x 6 months. If the Oncotype result is intermediate/high, patients will be NAX chemotherapy x 4 courses. If the SUV post course #1 TEC is \<5%, subsequent treatment will depend on the Oncotype.If the Oncotype is low, the treatment will be hormonal therapy x 6 months. If the Oncotype is intermediate/high , the treatment will be NAX chemotherapy x 4. Surgery will be performed 6 weeks after the 4th course of NAX chemotherapy.
224077365|NCT00433407|BIOLOGICAL|trastuzumab|
224077366|NCT01373983|DRUG|Ziconotide|1.25 or 2.5 mcg or 3.75 mcg i.t. according to an algorithm
224077367|NCT00954278|DRUG|sorafenib|sorafenib (400mg or 600mg or 800mg) by mouth twice daily, for 28 days
224077368|NCT03642678|DIETARY_SUPPLEMENT|ONS|High-risk patients identified by prediction model in study group are intervened by pre-defined intervention protocol, which include oral nutrition supply, infection prevention, bp control and improving of dialysis therapy options and so on.
224077369|NCT03622827|COMBINATION_PRODUCT|Chemoradiotherapy+ Endostar|"Chemoradiotherapy with Endostar：~* Chemoradiotherapy: pelvic radiotherapy starts 2-3 weeks after surgery. Intensity modulated radiotherapy (IMRT) is given five fractions per week at 1.8-2 Gy/fraction/day with total dose summed up to 45-50Gy. The external beam radiotherapy should be completed within 6 weeks.~* Concurrent chemotherapy is consisted of cisplatin (75 mg/m2, day 1-3) and 5-fluorouracil (5-FU; 1000mg/m2/day, civ, day 1-4) for 2 cycles every 3 weeks.~* Endostar: recombinant human endostatin (15mg/m2/d, civ, d1-7) is given 3 days before the concurrent chemoradiotherapy for 2 cycles every 3 weeks."
224077370|NCT05408520|PROCEDURE|Targeted Muscle Reinnervation|When a nerve is severed or injured, it attempts to regenerate. The TMR procedure will transfer the transected nerves to adjacent muscle nerves in efforts to encourage the nerve to regenerate in an organized fashion.
224077371|NCT01613755|DRUG|Metformin, dipyridamole|Metformin 500 mg twice daily for four days Dipyridamole 200 mg twice daily for four days
224077372|NCT01613755|DRUG|Metformin|Metformin 500 mg twice daily for four days
224077373|NCT04293679|DRUG|STP705|Investigational Product
224077374|NCT01137383|DRUG|Pegaferon (pegylated interferon alpha 2a) + ribavirin|pegylated interferon 180 micrograms subcutaneously weekly - ribavirin (oral, in two divided daily doses) 800 mg for genotype 2 and 3, 1000 or 1200mg (weight less than or greater than 75kg) for genotypes 1 and 4 - Duration: 24 weeks for genotype 2 and 3, 48 weeks for genotypes 1 and 4
224077375|NCT03965559|PROCEDURE|plasmapheresis|"Plasmapheresis is the removal, treatment, and return or exchange of blood plasma or components thereof from and to the blood circulation. It is thus an extracorporeal therapy (a medical procedure performed outside the body).\[Wikipedia\]~DFPP is a selectively removal of the immunoglobulin fraction from the serum and, as a result, to minimize the volume of substitution fluid required. \[Tanabe K. Double-filtration plasmapheresis. Transplantation. 2007 Dec 27;84(12 Suppl):S30-2.\]"
224077376|NCT00725075|DRUG|MK-8435 (Org 25935) 4-8 mg|Administered orally 2 times a day (BID) for a final concentration of 8-16 mg/day
224077377|NCT00725075|DRUG|Placebo|Matching placebo for MK-8435 (Org 25935) administered orally BID
224077378|NCT00725075|DRUG|MK-8435 (Org 25935) 12-16 mg|Administered orally BID for a final concentration of 24-32 mg/day
224077379|NCT06421220|PROCEDURE|Preoperative injection of indocyanine green|Submucosal injection of indocyanine green into the gastric mucosa prior to surgery， indocyanine green，25mg，powder，once
224077380|NCT03823612|DRUG|Clinpro Tooth Creme|The participant will be instructed to Place a pea-sized amount of Clinpro Tooth Crème on a soft bristled toothbrush and brush teeth for at least two minutes then after brushing the patient will rinse out his mouth with water and spit out. It will be used twice daily at first in the morning and before sleep.
224077381|NCT03823612|DRUG|GC tooth mousse|The participant will be instructed to squeeze a small amount of GC Tooth Mousse out onto a clean finger. A cotton tip, swab or custom tray are suitable application methods as it will Applied directly onto his tooth surfaces and leave undisturbed for three minutes then he will be instructed to Spread any residual crème around the mouth with his tongue and hold for a further one to two minutes then the participant will expectorate thoroughly and if possible he should avoid rinsing. Any GC Tooth Mousse remaining in the mouth can be left to gradually dissipate. The participant will be instructed to avoid eating or drinking for 30 minutes following application.
224077382|NCT01443533|BEHAVIORAL|LARC Script|The LARC Script is a one-minute educational script that describes long-acting reversible contraceptive methods.
224077383|NCT04680611|OTHER|no study intervention. Patients receive standard clinical care|no intervention. observational study
224077384|NCT00496314|DEVICE|e2TM Cervical Cell Collector|
224077385|NCT01298492|DRUG|PF-00547659|75 mg SC once monthly for 72 weeks. Subjects may escalate to 225 mg or de-escalate to 22.5 mg one time.
224077386|NCT04192409|BEHAVIORAL|Smartphone Application|Patients will use a smartphone application contain the following functions: providing health education information about DM and CAD, reminding patients to take medicine on time by alarm, recording patients' recent fast plasma glucose value.
224077387|NCT02686086|DEVICE|vibrating mesh nebuliser|The Aerogen Solo vibrating mesh nebuliser is an approved 13 485 class II medical device (CE marked) nebuliser licenced for the delivery of physician-prescribed medications for inhalation which are approved for use with a general purpose nebuliser. It has been shown in previous laboratory and clinical studies to have superior drug delivery to standard jet nebulisers.
224077388|NCT02686086|DEVICE|Standard hospital jet nebuliser|"The standard hospital jet nebuliser refers to the nebuliser in clinical use currently throughout Beaumont Hospital and used for the administration of nebulised medications"
224077389|NCT02686086|DRUG|Combined salbutamol 2.5 mg and ipratropium 0.5mg nebule|All patients admitted to hospital with an exacerbation of COPD are administered nebulised bronchodilators (salbutamol 2.5mg/ipratropium 0.5mg combination) as standard of care
224077390|NCT04600908|OTHER|Characteristics of accidents|informations about commuting accidents were recorded either during an occupational medicine consultation or by the medical service after reception of the medical certificate and the administrative declaration
224077391|NCT02372487|DRUG|sildenafil citrate|sildenafil citrate 25 mg every 8 hours
224077392|NCT02372487|DIETARY_SUPPLEMENT|fluid therapy|2 liters of fluid per day
224077393|NCT03680495|DRUG|Methylprednisolone|1\. Methylprednisolone is a steroid (corticosteroid) similar to a product produced in the adrenal glands. It is used to help relieve inflammation (swelling, heat, redness, and pain) and is used to treat certain medical issues including COPD.
224077394|NCT06270979|DEVICE|ISHA|Participants will be provided with an Eforto® device and ISHA mobile application to self-monitor intrinsic capacity for 4 months (if needed with assistance by an (in)formal caregiver).
224077395|NCT05175807|OTHER|Mindfulness|Mindfulness (e.g., body scan, gentle yoga, sitting, grounding, and walking meditation), relaxation techniques, and cognitive rehabilitation exercises.
224077396|NCT06481761|DEVICE|Double-slot brackets|"Miniscrews will be inserted in the buccal alveolar bone between first and second molars bilaterally and ligated to second premolar.~Canine Retraction using Nickel titanium closed-coil springs delivering a force of 150 gram, extending the spring between the canine and first molar hooks.~retraction on double 0.016'' Stainless steel round wires in both slots of the double slot brackets.~Re-activation of the coil spring will be done in the follow up visits to maintain a constant force through the study."
224077397|NCT06481761|DEVICE|Single-slot brackets|"Miniscrews will be inserted in the buccal alveolar bone between first and second molars bilaterally and ligated to second premolar.~Canine Retraction using Nickel titanium closed-coil springs delivering a force of 150 gram, extending the spring between the canine and first molar hooks.~retraction on single 0.017x0.022'' Stainless steel wire. Re-activation of the coil spring will be done in the follow up visits to maintain a constant force through the study."
224077398|NCT02219139|DEVICE|ESTA abutment Roxolid|Enhanced Soft Tissue Attachment surface on Roxolid or machined surface on Roxolid abutment placement.
224077399|NCT00581295|DEVICE|Diffuse optical spectroscopy|Diffuse optical spectroscopy measurment
224077400|NCT01178658|DRUG|Busulfan, etoposide, cytarabine, and melphalan|Busulfan 3.2 mg/kg/d for 2 days, etoposide 400 mg/m2/d for 2 days, cytarabine 1 g/m2 for 2 days, and melphalan 140 mg/m2 for 1 day
224077401|NCT03032276|OTHER|Safe motherhood and newborn health promotion package|The intervention package consists of three components: facility, community and linkages between the community and health facilities. Facility based interventions will serve both the comparison and intervention arms. However, other two interventions will serve the intervention arm only. Specific interventions and approaches for the three components will be implemented within the MOH\&FW service delivery system to improve MNH practices in families and communities and to increase the use of MNH services from appropriate facilities/providers. The intervention package has been developed based on the experiences from SMPP in Narsingdi district and on the basis of consultations with the International Advisory Body (IAB) that included GoB, JICA, ICDDR,B, other experts and stakeholders.
224077402|NCT03295864|DIAGNOSTIC_TEST|Multifrequency tympanometry at Inclusion|Multifrequency tympanometry measurement and particularly width of conductance tympanograms at 2 kHz will be performed for both group at inclusion
224077403|NCT03295864|DIAGNOSTIC_TEST|Multifrequency tympanometry 6 month after surgery|Multifrequency tympanometry measurement and particularly width of conductance tympanograms at 2 kHz will be performed 6 months after surgery for Chiari type I malformation patient
224077404|NCT03276611|OTHER|echocardiograghy|transthoracic echocardiograghy
224077405|NCT02972073|OTHER|Exercise intervention|Physical therapist will provide exercise for patients with low back pain for 60 minutes per day, 2-3 days per week for the total of 8 weeks.
224077406|NCT03984305|DEVICE|Personal KinetiGraph® (PKG®) Watch|"The Personal KinetiGraph (PKG®) Movement Recording System consists of the following:~* A wrist-worn data logger (PKG Watch) designed to acquire data on the kinematics of movement disorder symptoms over a 6-10 day period.~* An application to configure the data logger and transfer the acquired data at the end of a recording."
224077407|NCT03984305|DEVICE|Personal KinetiGraph® (PKG®) Report|"The Personal KinetiGraph (PKG®) Movement Recording System was developed by neurologists at the Melbourne-based Florey Institute of Neuroscience and Mental Health. The product is manufactured and marketed by GKC.~The Personal KinetiGraph (PKG®) Movement Recording System consists of the following:~• A series of algorithms that analyze the uploaded data, producing a PDF that is delivered to the clinician. The PDF contains objective data distinguishing the movement patterns consistent with tremor, bradykinesia, dyskinesia and immobility."
224077408|NCT01882946|BIOLOGICAL|DCVax-Direct|Autologous, activated dendritic cells for intratumoral injection
224077409|NCT00352105|DRUG|cisplatin|20mg/m2/d IV continuous infusion x4 days
224077410|NCT00352105|DRUG|fluorouracil|1000mg.m2/d IV continuous x 4 days
224077411|NCT00352105|DRUG|Iressa|250mg/PO qd x 2 years
224077412|NCT00352105|RADIATION|hyperfractionated radiation therapy|120cGy bid
224077413|NCT05868850|BEHAVIORAL|auricular point sticking|"1. Acupoint selection: Select Shenmen, spleen, stomach, liver, sympathetic, tongue, digestive system under the cortex, three focal, ear-back spleen.~2. Operation: Use 75% ethanol to disinfect auricular broad skin; To be dry, use tweezers to pick up the middle of the small square tape stuck with Wang do not line seeds, align the indentation and stick well, press gently with the finger abdomen, the strength to the patient feel acid swelling, pain and heat sense and can tolerate it.~3. Press frequency and course of treatment: it is asked to press 4 times a day, once in the morning, middle and evening before going to bed, 3-5 minutes each time, the duration of hospitalization for patients with chemotherapy is generally 3-5 days, intervention begins on the first day of chemotherapy medication, the day of discharge for patients to replace the other side of the ear acupoint, removed after 4 days of discharge. A total of 2 chemotherapy courses were treated."
224077414|NCT05405647|DEVICE|Shock wave Therapy|a program of 6 session of Shock wave Therapy on the affected wrist,5 minute per session and a frequency of 5 Hz., 1 sessions per week for 6 weeks.
224077415|NCT05405647|DEVICE|kinesio tape|kinesio tape application on the affected wrist for 3 days and then one day off and then another 3 days each week for 6weeks.
224077416|NCT01505907|DRUG|CXB909|CXB909
224077417|NCT05167942|DEVICE|deep transcranial magnetic stimulation with H1 coil|Sham deep transcranial magnetic stimulation on PFC .Duration:40 days.
224077418|NCT05167942|DEVICE|High frequency deep transcranial magnetic stimulation with H1 coil|high frequency(20Hz) deep transcranial magnetic stimulation on PFC .Duration:40 days.
224077419|NCT05167942|DEVICE|iTBS deep transcranial magnetic stimulation with H1 coil|iTBS deep transcranial magnetic stimulation on PFC .Duration:40 days.
223888938|NCT04223024|DRUG|CCRT+Nimotuzumab|concurrent cisplatin (100mg/m2, every three weeks,D1,D22,D43 of intensity modulated radiotherapy) + Nimotuzumab (200mg, once a week during radiotherapy, a total of 7 weeks)
223888939|NCT04223024|DRUG|CCRT alone|concurrent cisplatin (100mg/m2, every three weeks,D1,D22,D43 of intensity modulated radiotherapy )
223888940|NCT04614233|DIETARY_SUPPLEMENT|RiduZone (90% OEA)|Participants will be randomly assigned to take 2 capsules of RiduZone (each capsule contains 90% OEA ) daily for 16 months
223888941|NCT04614233|DRUG|Placebo|Participants will be randomly assigned to take 2 capsules of placebo daily for 16 months. Placebo capsules will consist of 180mg of hypromellose.
223888942|NCT05743985|OTHER|Cannabigerol|Hemp-derived full spectrum cannabigerol oil carried in an organic coconut (MCT) oil within hydroxypropyl methylcellulose capsules.
223888943|NCT02966483|PROCEDURE|TaTME|Transanal Total Mesorectal Excision
223888944|NCT02966483|PROCEDURE|LpTME|Conventional Laparoscopic Total Mesorectal Excision
223888945|NCT04263311|BEHAVIORAL|CHW|Participants will undergo 5 group-based health education sessions on hypertension and diabetes management and provide culturally and linguistically tailored health information and resources There will be 2 one-on-one in-person meetings and up to 7 follow-up calls/meetings to engage in goal-setting activities regarding changes to health behaviors, medication adherence, or other issues related to diabetes prevention as identified jointly by patient and CHW. Participants will develop with the CHW and receive a copy of their long-term and short-term Participant Action Plan. Referrals to other services available in the community (i.e. exercise classes, social services, mental health, tobacco cessation, etc.
223888946|NCT04719156|DRUG|Indocyanine green solution administered at 2.0mg/kg.|Dosing of ICG to be administered at 2.0mg/kg, two hours prior to surgery.
223888947|NCT04719156|DEVICE|Stryker SPY-PHI Imaging Device|The SPY-PHI system is used with the ICG dye to provide fluorescence images.
223888948|NCT01476371|BEHAVIORAL|Mindfulness-based group treatment|An 8-week course of mindfulness-based group treatment (one 2-hour session per week; 10 patients per group). Each group session will be led by two mindfulness instructors, who will lead the patients through the Here \& Now mindfulness program. Between sessions, patients will perform additional mindfulness practice at home via the Internet.
223888949|NCT05264532|OTHER|Informational Intervention|Receive information-graphic video
223888950|NCT05264532|OTHER|Informational Intervention|Receive family letter
223888951|NCT05264532|OTHER|Survey Administration|Ancillary studies
223888952|NCT05890729|DRUG|XTMAB-16 or Placebo|Infusion
223888953|NCT05664425|DEVICE|Ultrasonic debridement|Ultrasonic debridement with a plastic/teflon tip (2 minutes + 1 minute irrigation)
223888954|NCT06115954|OTHER|Self-Management Supported Telerehabilitation|Supporting the exercises with an internet-based environment and self-management training for Children and Adolescents with Juvenile Idiopathic Arthritis
223888955|NCT04312802|DIAGNOSTIC_TEST|Cardiopulmonary exercise test (CPET)|"The participant will undergo a cardio-pulmonary exercise test (CPET) on a cycle ergometer (Ergoline) connected to a 12-lead electrocardiogram, oxygen saturation monitor and continuous non-invasive blood pressure cuff. Respiratory gas exchanged will be measured from a tight fitting facemask. An initial 2-min period of baseline data will be collected at rest before a 180-s period of unloaded cycling. A ramp protocol will then be applied and the participant will be instructed to continue cycling at a constant cadence of 60 rpm as long as they can. The test will be terminated if the participant indicates that:~* they cannot continue~* cadence falls to \<55 rpm due to fatigue or dyspnoea~* they develop abnormal cardiac signs or symptoms, such as ischaemia and arrhythmia."
223888956|NCT02104063|PROCEDURE|MRI-PET|Participants will have an MRI-PET scan (the Index test) in addition to the procedures they would normally receive as their standard of care (Reference tests). The accuracy of MRI-PET in detecting or ruling out metastatic penile cancer will be compared to the reference tests.
223888957|NCT02592330|PROCEDURE|Biopsy to collect limbal epithelial stem cells that will be cultivated into a graft|Cultivated autologous limbal epithelial cell (CALEC) therapy utilizes a bio-engineered composite of ex vivo expanded autologous corneal epithelial cells and an FDA-approved amniotic membrane (AmnioGraft®, Bio-Tissue, Inc.) to reconstruct the ocular surface. A small biopsy (2-3 mm2) from the patient's contralateral eye serves as a source epithelial (stem) cells that are expanded on the amniotic membrane in culture and the resulting product is surgically transplanted onto the cornea after excision of the fibrovascular pannus.
223888958|NCT02592330|BIOLOGICAL|Cultivation of Limbal epithelial cells into a graft|A graft is manufactured for transplant
223888959|NCT02592330|PROCEDURE|CALEC Transplant|Limbal epithelial cells are obtained from the healthy fellow eye and cultivated in a lab for later transplantation into the diseased eye.
223888960|NCT03090152|PROCEDURE|Periarticular injection (Deep injection)|"Deep injection of cocktail containing Bupivacaine with Epi, 30mL; Morphine, 8mg/mL, 1mL; Methyprednislone, 40mg/mL, 1mL; Cefazolin, 500mg in 10 mL; saline, 22mL into the anterior capsule, the periosteum, the gluteus maximus, and the abductor muscles and fascia lata."
223888961|NCT03090152|PROCEDURE|Periarticular injection (Superficial injection)|Superficial injection of 40mL 0.25% Bupivacaine into subcutaneous tissue prior to wound closure.
223888962|NCT03090152|DRUG|Bupivacaine|EPCA: Bupivacaine 0.06%.
223888963|NCT03090152|DRUG|Placebo|EPCA: Saline.
223888964|NCT06219538|DEVICE|DAISY Uterine Drain|Insertion of the DAISY Uterine Drain and connection to wall suction in women who have undergone a Caesarean Delivery or D \& C,
223888965|NCT05601531|PROCEDURE|Autologous Tooth Root|An autologous Tooth Root is made from one's own tooth root and covered in an extraction socket where bone graft is placed.
223888966|NCT05601531|DRUG|Vit.D3|Local administration of Vit.D3, through the effect of Vit.D3 to explore whether it can help to accelerate the healing of tooth extraction cavity and the clinical effectiveness of bone regeneration.
223888967|NCT05601531|OTHER|bone graft|Selecting bone materials for alveolar ridge preservation according to treatment needs
223888968|NCT04278404|DRUG|The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:|The prescribing of drugs to children is not part of this protocol. Participants will receive DOIs as prescribed by their treating provider.
223888969|NCT06300307|DRUG|ATX-01|Solution for infusion
224077420|NCT02765360|OTHER|Treatment Group|"Participants will be established on the randomised mode of ventilation and will have continuous assessment of the following during the assessment period:~* Electrical impedance tomography~* EMGpara~* SpO2~* tcCO2~* Pneumotachography~* End-tidal CO2 monitoring"
224077421|NCT04642339|BIOLOGICAL|Gam-COVID-Vac|Gam-COVID-Vac combined vector vaccine, 0,5ml/dose+0,5 ml/dose prime-boost immunization with component I (rAd26-S) and component II (rAd5-S) with 21 days interval
224077422|NCT04642339|BIOLOGICAL|Placebo|Placebo
224077423|NCT05853770|OTHER|TGfU volleyball intervention|"Duration of intervention: 16 week; Duration of each session: 45 minutes; Frequency: One session per week during the third PE class;~The structure of each TGfU session had three parts:~The introduction part comprised 10 minutes of moderate-intensity warm-up activities; The main part comprised mini-volleyball and small-sided games (25-30 minutes); The last part of the session was the cool-down period (5 min)."
224077424|NCT05853770|OTHER|Regular physical education classes|Regular physical education classes following national physical education curriculum for second semester of seventh grade in primary school in Serbia.
224077425|NCT06542315|PROCEDURE|Intraoperative parathyroid hormone (IOPTH) monitoring|Intraoperative parathyroid hormone (IOPTH) monitoring, which is a surgical adjunct that permits PTH bloodwork to be drawn during parathyroid surgery to monitor and guide surgical outcomes.
224077426|NCT01646632|BEHAVIORAL|Physical exercise intervention|the experimental intervention included group- based progressive resistance training, balance training, and functional training, two times a week, one hour sessions, lasting 16 weeks.
224077427|NCT01646632|BEHAVIORAL|Lifestyle counseling|the control intervention included recreational sessions, including talks, video's, music, board games etc. No physical activity was involved in the control intervention.
224077428|NCT04566575|OTHER|trans vaginal ultrasound (TVUS)|In the TVUS, the residual myometrium is determined after surgery and the appearance of new cysts in the area of the caesarian section scar is assessed.
224077429|NCT04566575|OTHER|patient questionnaire|exploratory patient questionnaire regarding satisfaction after correction of isthmocele
224077430|NCT00878839|DEVICE|Toric|AcrySof Toric IOL
224077431|NCT02137954|DRUG|Lidocaine|
224077432|NCT02137954|DRUG|Placebo|
224077433|NCT04642742|DIETARY_SUPPLEMENT|Chewable plant sterol|Chewable plant sterol (gummy)
224077434|NCT02249910|DRUG|semaglutide|Oral administration of 5 mg daily for one week, then escalated to 10 mg daily for one week, followed by escalation to 20 mg daily for 41 days
224077435|NCT02249910|DRUG|metformin|Oral administration of 850 mg twice daily for 3 days followed by 850 mg on day 4, assessed in 3 dosing periods 1) alone, 2) co-administration with SNAC (sodium N-\[8-(2-hydroxybenzoyl) amino\] caprylate) and 3) co-administration with oral semaglutide.
224077436|NCT02249910|DRUG|digoxin|Oral administration of 0.5 mg single dose, assessed in 3 dosing periods 1) alone, 2) co-administration with SNAC (sodium N-\[8-(2-hydroxybenzoyl) amino\] caprylate) and 3) co-administration with oral semaglutide.
224077437|NCT02249910|DRUG|placebo|Oral administration of SNAC 300 mg. Will be administered with the morning dose of metformin (1st, 3rd, 5th and 7th dose). On Day 24, a single SNAC dose will be administered with digoxin.
224077438|NCT04465682|DEVICE|Experimental: Dip Home-Based Dipstick Analyzer|Dip Home-Based Dipstick Analyzer The Dip Home-Based Dipstick Analyzer is a prescription, in-vitro diagnostic, home use device, which qualitatively and semi-quantitatively measures 10 urine analytes. The device combines a urine stick kit with an easy to use smartphone application using an image recognition algorithm.
224077439|NCT05019105|DRUG|Placebo|Oral matching placebo
224077440|NCT05019105|DRUG|ALKS 1140|Active oral dose of ALKS 1140
224077441|NCT05401305|BIOLOGICAL|Vaccine for the prevention of infections caused by Haemophilus influenza type b|The vaccine is administered into the region of the deltoid muscle
224077442|NCT05401305|BIOLOGICAL|Placebo|The placebo is administered into the region of the deltoid muscle
224077443|NCT00087646|DRUG|Ribavirin|1000/1200mg po daily for 72 weeks
224077444|NCT00087646|DRUG|Ribavirin|1000/1200mg po daily for 48 weeks
224077445|NCT00087646|DRUG|peginterferon alfa-2a [Pegasys]|360 micrograms sc weekly for 12 weeks, followed by 180 micrograms sc weekly for 60 weeks
224077446|NCT00087646|DRUG|peginterferon alfa-2a [Pegasys]|360 micrograms sc weekly for 12 weeks, followed by 180 micrograms sc weekly for 36 weeks.
224077447|NCT00087646|DRUG|peginterferon alfa-2a [Pegasys]|180 micrograms sc weekly for 72 weeks
224077448|NCT00087646|DRUG|peginterferon alfa-2a [Pegasys]|180 micrograms sc weekly for 48 weeks
224077449|NCT00911131|DEVICE|Capsule endoscopy (PillCam ESO)|The capsule endoscope is placed in the mouth and the patient is asked to swallow it with 100cc of water with simethicone in the supine position. Recording is done for 2 minute in this position and then the head is elevated to 30 degrees for 2 minutes and then 60 degrees for 1 minute. After 1 minute, the patient sips 10cc of water and after 15 seconds, they sit upright and sip water again. They can then walk and resume normal activity for 15 minutes.
224077450|NCT00911131|PROCEDURE|EGD|Patients will undergo conventional EGD under conscious sedation for routine screening of esophageal varices.
224077451|NCT00911131|DEVICE|Capsule endoscopy (PillCam ESO) with abdominal binder|An abdominal binder with and inflatable girdle is wrapped around the stomach prior to swallowing the capsule endoscope. The girdle is inflated to 10mmHg for 10 minutes. The capsule is swallowed by the patient and the routine method for the procedure is performed.
224077452|NCT01235962|DRUG|pazopanib|Pazopanib monohydrochloride salt was supplied as aqueous, film-coated tablets containing 200 mg of the free base. The 200 mg tablets were oval-shaped and white in color.
224077453|NCT01235962|DRUG|placebo|Placebo matching pazopanib was supplied as aqueous, film-coated tablets containing 200 mg of the free base. The 200 mg tablets were oval-shaped and white in color.
224077454|NCT01235962|DRUG|pazopanib|Pazopanib 600 mg daily initial dose for 8-12 weeks, dose can be escalated to 800 mg daily based on safety evaluation.
224077455|NCT01235962|DRUG|placebo|placebo matching pazopanib daily initial dose for 8-12 weeks, dose can be escalated to 800 mg daily based on safety evaluation.
224077456|NCT00065338|BEHAVIORAL|Exercise and behavior modification|Participants will undergo 1000 kcal/day caloric restriction (relative to experimentally determined weight-maintenance caloric needs) for 8 weeks during one phase of study. Additional 11 week period consists of 8 weeks of caloric restriction with an additional daily walking program.
224077457|NCT01308866|BEHAVIORAL|Share decision tool|
223888970|NCT06300307|DRUG|Placebo|Solution for infusion
223888971|NCT03135106|DRUG|Erdafitinib|A single 4-mg of erdafitinib tablet will be administered on Day 1 in Treatment A and on Day 5 in Treatment B and C.
223888972|NCT03135106|DRUG|Fluconazole|A 400-mg fluconazole orally (4\*100 mg capsules) will be administered from Day 1 to Day 11.
223888973|NCT03135106|DRUG|Itraconazole|A 200-mg itraconazole orally (2\*100 mg capsules) will be administered from Day 1 to Day 11.
223888974|NCT06580405|DEVICE|KNP-1000 Apheresis System|sFlt-1 is removed from the participants' plasma through treatment.
223888975|NCT03737045|OTHER|Decision Aid|Participants will test decision aid prototypes that are designed to assist them in choosing a medication.
223888976|NCT06314061|DEVICE|Dexcom G7 Continuous Glucose Monitoring (CGM) System (G7)|A continuous glucose monitor which through a sensor in the skin registers glucose levels every 5 minutes. Glucose levels are shown by connecting the sensor to a mobile device or the Dexcom G7 Receiver where realtime alerts on deviating glucose levels will be sent.
223888977|NCT05796297|DEVICE|Transcutaneous Capnography|Transcutaneous Capnography will be realized at patient home to monitoring nocturnal concentration of carbon dioxide during nocturnal sleeping ventilation
223888978|NCT05569174|DRUG|secukinumab|AIN457 300 mg subcutaneously for 12 weeks
223888979|NCT05569174|OTHER|Placebo|Placebo to match AIN457 subcutaneously for 12 weeks
223888980|NCT06093334|DIAGNOSTIC_TEST|Low-field magnetic resonance imaging|Imaging of lung parenchyma and function by LF-MRI
223888981|NCT06093334|DIAGNOSTIC_TEST|Cardiopulmonary testing|Myocardial function (Strain-Analysis by echocardiography) and spiroergometry, capillary blood gases and lactate
223888982|NCT06093334|DIAGNOSTIC_TEST|Pulmonary testing|Lung function (VC%, FEV1%)
223888983|NCT06093334|DIAGNOSTIC_TEST|Blood sample|Standard procedures/parameters routinely available in follow-up care after oncological treatment
223888984|NCT05006365|DEVICE|Transcranial Pulse Stimulation|A total of 30 participants (both TPS group and the waitlist control group) will receive six 30 minute-TPS sessions (300 pulse in each session, total: 1800 pulse) in 2 weeks' time (i.e., 3 sessions (Monday, Wednesday, Friday) per week, total: 3 hours), on a 1: 1 allocation ratio. Participants will be followed up at 3-month period after the intervention. A 2-week TPS intervention alongside with 3-month follow-up is sufficient enough to test the effects of TPS on depressive symptoms.
223888985|NCT05216068|DIAGNOSTIC_TEST|NGS|Based on the next generation sequencing (NGS), WES can identify single nucleotide variants (SNVs) and small variants.
223888986|NCT05748028|OTHER|Rehabilitation|All patients included in the study will undergo a basic evaluation with a neurological examination, a rehabilitation program to improve strength, coordination, balance, endurance, and the ability to perform activities of daily life.
223888987|NCT05748028|OTHER|Administration of Clinical scales|All patients included in the study will be evaluated by clinical scales assessing the disease stage, clinical severity, freezing, motor and non-motor impairment, cognitive impairment, depression, quality of life, autonomic dysfunction, pain.
223888988|NCT04975139|DEVICE|RS-fMRI|Advanced imaging method that can identify the spatiotemporal distribution of the intrinsic functional networks within the brain
223888989|NCT05829902|OTHER|Herbal extract drink|30 ml drink containing 600 mg of lemon balm extract, tea leaves, brown sugar and flavoring agent, two weeks daily
223888990|NCT05829902|OTHER|Placebo|30 ml placebo drink containing maltodextrin, tea leaves, brown sugar and flavoring agent, two weeks daily
223888991|NCT05678998|DRUG|WTX-330|Investigation Product
223888992|NCT04638829|DRUG|Avatrombopag Oral Tablet|Avatrombopag 20 mg given daily for 90 days. Initial dose and dose adjustments will be determined by the physician along with the Doptelet prescribing information
223888993|NCT04768322|DEVICE|HeartMate 3 TM Left Ventricular Assist System|The HeartMate 3 TM Left Ventricular Assist System will be implanted within 21 days of randomization.
223888994|NCT04768322|OTHER|Guideline Directed Medical Therapy|Patients randomized in the control group will continue their guideline directed medical therapy which comprises the following stable combination at the maximal tolerated dose of betablockers, Angiotensin-Converting-Enzyme-inhibitors or Angiotensin II Receptor Blockers or Angiotensin receptor Neprilysin inhibitor and Mineralocorticoid Receptor Antagonists and Sodium-GLucose co-Transporter-2 (SGLT2) inhibitors if tolerated.
223888995|NCT05330975|BIOLOGICAL|Placebo|0.9% sodium chloride (normal saline) injection
223888996|NCT05330975|BIOLOGICAL|mRNA-1345|Sterile liquid for injection
223888997|NCT05330975|BIOLOGICAL|Afluria® Quadrivalent|single-dose, pre-filled syringe for injection
223888998|NCT05330975|BIOLOGICAL|mRNA-1273.214|Sterile liquid for injection
223888999|NCT01368146|DEVICE|IV Clear™|Polyurethane film with a silicone adhesive dressing containing chlorhexidine and silver
223889000|NCT01368146|DEVICE|Tegaderm CHG™|Polyurethane film with a polyacrylate adhesive and a polyol hydrogel containing 2% w/w chlorhexidine gluconate
223889001|NCT01368146|DEVICE|Silicone Vehicle Control Dressing|Polyurethane film with silicone adhesive dressing, without antimicrobials
223889002|NCT06408558|OTHER|Hypobaric|The effects of ambient pressure changes on glucose metabolism will be studied
223889003|NCT06408558|OTHER|Ground level|The effects of ambient pressure changes on glucose metabolism will be studied
223889004|NCT05415410|DRUG|Apraglutide|Apraglutide is a new, synthetic glucagon-like peptide 2 (GLP-2) receptor agonist which acts as a gut targeted regenerative approach that is intestinotrophic with a mode of action that improves absorption and enhances gut barrier function.
223889005|NCT06426693|DEVICE|Experimental feedback|Participants provided with feedback of target brain activation patterns (e.g., thermometer) and will be instructed to try to change the feedback (e.g., decrease the thermometer).
224077458|NCT03462056|DIETARY_SUPPLEMENT|Cystic Fibrosis Ready to Use Supplemental Food|Specially formulated for use by children with Cystic Fibrosis
224077459|NCT02303626|DRUG|BCX4161|
224077460|NCT02303626|DRUG|Placebo|
224077461|NCT05914701|DRUG|Letermovir for secondary prophylaxis|For enrolled patients, Letermovir would be administered at a dose of 480 mg per day (or 240 mg per day in patients taking cyclosporine). The regimen duration of dosing was approximately 120 days or 16 weeks. Or physicians could adjust regimen duration according to the CMV infection risk factors.
224077462|NCT05883189|DIAGNOSTIC_TEST|Draw blood|Draw blood from human body and make into serum to test
224077463|NCT04926779|DIAGNOSTIC_TEST|Biozek Covid-19 Antigen Rapid Test (Saliva)|Self-collection of nasopharyngeal and saliva samples and self test performance - Biozek Covid-19 Antigen Rapid Test (Saliva) and Biozek Covid-19 Antigen Rapid Test (Nasopharyngeal Swab). Both procedures are supervised by trained study personnel.
224077464|NCT03460431|DEVICE|fractional CO2 laser 10,600nm|fractional CO2 laser 10,600nm session, every month for 4 months
224077465|NCT03460431|DEVICE|Nd YAG laser1064 nm|Nd YAG laser1064 nm laser session, every month for 4 months
224077466|NCT02902120|DRUG|Post-transplant Grazoprevir and Elbasvir|Treatment will be started in the post-transplant patients on day 0 with the combination pill zepatier, containing grazoprevir 100mg/elbasvir 50mg by mouth once daily. The medications will be continued for a total of 12 weeks (16 weeks if resistance mutations, RAVs, are detected)
224077467|NCT02596412|OTHER|use the module with augmented reality (Mini-Docs) on tablet during TB injection|Provision of a tablet with a module using augmented reality (Mini-Docs) during TB injections in addition to the commonly used drug technology
224077468|NCT04873479|DRUG|S-ketamine|Participants in the test group received midazolam 0.05-0.1mg /kg, sufentanil 0.1-0.2ug/kg,Etomidate 0.1-0.2mg/kg, cisatracurium 0.15-0.3mg/kg, S-ketamine 0.125mg/kg (low dose) for Anesthesia induction, followed by an infusion of remifentanil 0.05-0.15ug/kg/min and S-Ketamine 0.125mg/kg/h (low dose) and continuous inhalation of sevoflurane at 2-3%.
224077469|NCT04873479|OTHER|saline|Participants in the control group received midazolam 0.05-0.1mg /kg, sufentanil 0.1-0.2ug/kg,Etomidate 0.1-0.2mg/kg, cisatracurium 0.15-0.3mg/kg, saline 0.125ml/kg for Anesthesia induction, followed by an infusion of remifentanil 0.05-0.15ug/kg/min and saline 0.125ml/kg/h and continuous inhalation of sevoflurane at 2-3%.
224077470|NCT06182592|DRUG|Liposomal cytarabine-daunorubicin for injection|First induction: 100 units/m\^2 by 90-minute IV infusion on Days 1, 3, 5. Second induction: 100 units/m\^2 by 90-minute IV infusion on Days 1 and 3. Consolidation therapy: 65 units/m\^2 by 90-minute IV infusion on Days 1 and 3.
224077471|NCT06182592|DRUG|7+3 (cytarabine and daunorubicin)|"First induction: 7+3 will be administered as: cytarabine at a dose of 100 mg/m\^2/day on Days 1 through 7 by continuous infusion, and daunorubicin at a dose of 60 mg/m\^2/day on Days 1, 2, and 3.~Second induction: 5+2 will be administered as: cytarabine at a dose of 100 mg/m\^2/day on Days 1 through 5 by continuous infusion and daunorubicin at a dose of 60 mg/m\^2/day on Days 1 and 2.~Consolidation therapy: 5+2 will be administered as: cytarabine at a dose of 100 mg/m\^2/day on Days 1 through 5 by continuous infusion, and daunorubicin at a dose of 60 mg/m\^2/day on Days 1 and 2."
224077472|NCT04228185|PROCEDURE|sleeve gastrectomy|Comparison of banded and not-banded sleeve gastrectomy
224077473|NCT02936141|BEHAVIORAL|Group psychotherapy|Includes a group (up to 10 participants) weekly session with a duration of 90 minutes where it is stimulated communication, adaptative behaviour and social living
224077474|NCT01769092|DIETARY_SUPPLEMENT|Fish Oil|The daily dose is divided; capsules are taken with meals for a period of 6 months.
224077475|NCT01769092|OTHER|Safflower Oil|Daily dose of safflower oil taken in divided doses as capsules and consumed with meals.
224077476|NCT01758757|PROCEDURE|Vitrectomy|
224077477|NCT01353703|BIOLOGICAL|Infanrix hexa™|Intramuscular, three doses
224077478|NCT03814980|BEHAVIORAL|mindful breathing application|Participants will use a mindful breathing application on a computer tablet.
224077479|NCT03814980|DEVICE|application on a computer tablet|a computer tablet
224077480|NCT01278498|DRUG|Escitalopram|first week:5mg 2nd week\~12 week:10mg
224077481|NCT01278498|DRUG|sugar pill|first week:5mg 2nd week\~12 weeks:10mg
224077482|NCT05250661|OTHER|Aqueous propolis extract|The patients gargled 4 times a day after meals and 5 ml each time. Patients were instructed to keep the propolis solution in their mouth for one minute, to touch all structures in the mouth, and not to eat or drink anything orally for one hour after spitting.
224077483|NCT03050580|BEHAVIORAL|self-esteem enhancement group|Subjects in the treatment group will join a six-session treatment for recognizing their strengths and resources through group activities and sharing. Each session is 1.5-2 hours long, and all sessions are designed for 4-8 abused women. The activities are designed and led with an aim to improve their self-esteem, general health, as well as to reduce the level of depression. This service is provided by registered social workers.
224077484|NCT03050580|BEHAVIORAL|Standard care for abused women|The shelter standard care and services will be provided to the abused women in one randomized shelter. Besides, standard care in shelters includes residential accommodations, emotional support, legal, housing and financial advice and referrals will be given to survivors who reported being abused.
224077485|NCT03867045|DEVICE|Usability of an electronic symptom management application|Usability of an electronic symptom management application in a pilot group of patients receiving cabozantinib for mRCC through data analytics and feedback from users
224077486|NCT03667703|DRUG|Famotidine|Patients will be randomized to either receive a placebo or famotidine (study drug).
224077487|NCT03667703|DRUG|Placebo|Patients will be randomized to either receive a placebo or famotidine (study drug).
224077488|NCT00927836|BIOLOGICAL|Filgrastim|135 μg/kg body weight total dose Short term infusion (20 to 30 minutes) and continuous infusion over 3 days
224077489|NCT00927836|DRUG|Sodium chloride solution|Short term infusion (20 to 30 minutes) and continuous infusion over 3 days
224077490|NCT05849870|OTHER|Frailty care pathway for older people in a rural primary care setting|This intervention will take place in different primary care providers in a rural environment. Each provider will have one intervention and a no-intervention group, which will be part of the feasibility evaluation. The intervention will comprise a consultation with the participant, based on the different approaches described in the arm descriptions.
224077491|NCT03522441|DRUG|Clindamycin 1% Gel|Topical gel
224077492|NCT03522441|DRUG|Placebo|Topical Placebo gel
224077493|NCT00693160|DRUG|ketorolac|single intrathecal injection of ketorolac 2 mg
224077494|NCT00693160|DRUG|placebo|subject will receive a placebo (preservative free normal saline) spinal injection
224077495|NCT00693160|DRUG|remifentanil|All subjects will receive a remifentanil infusion
224077496|NCT00693160|DRUG|Capsaicin|Topical capsaicin pain model utilized for each subject
224077497|NCT03032952|OTHER|"Feel Stress Free mobile application"|This online and mobile application uses relaxation techniques, thought challenging, mini-games and mood tracking to help reduce feelings of stress, anxiety and depression.
224077498|NCT02281019|PROCEDURE|ERCP (Endoscopic Retrograde Cholangiopancreatography)|ERCP procedure will be performed to visualize bile ducts.
224077499|NCT02281019|DEVICE|SpyGlass DVS and SpyGlass Digital Simple (DS)|Cholangioscopy using SpyGlass™ DVS or SpyGlass DS will be performed post ERCP for direct viewing of the bile ducts. What is seen during the procedure will determine a course of treatment. Among the options are biopsies taken, stones treated/removed, or a stent placed
224077500|NCT02444273|PROCEDURE|Exercise|Subjects will be given and individualized exercise program.
224077501|NCT01046500|DIETARY_SUPPLEMENT|myo-inositol|2 grams twice a day
224077502|NCT01046500|DRUG|Metformin|pill, 250 mg, twice a day
224077503|NCT00728221|DIETARY_SUPPLEMENT|Korean Red Ginseng|"Cultivated KRG-B (central body Korean Red Ginseng) obtained from Kyonggi-do Farm, Kyonggi-do Province, Korea.~Dosage form: whole root in capsules (3g)"
224077504|NCT00728221|DIETARY_SUPPLEMENT|Korean Red Ginseng (Panax ginseng)|"Cultivated KRG-B (central body Korean Red Ginseng) obtained from Kyonggi-do Farm, Kyonggi-do Province, Korea.~Dosage form: total ginsenoside fraction in capsules"
224077505|NCT00728221|DIETARY_SUPPLEMENT|Cornstarch|Placebo
224077506|NCT00728221|DIETARY_SUPPLEMENT|Korean Red Ginseng (Panax Ginseng)|"Cultivated KRG-B (central body Korean Red Ginseng) obtained from Kyonggi-do Farm, Kyonggi-do Province, Korea.~Dosage form: total polysaccharide fraction (panaxans) in capsules"
224077507|NCT01405053|DRUG|Rufinamide|Rufinamide up to 45 mg/kg/day, in 2 divided doses, administered as oral suspension (40 mg/mL) as an add-on to the subject's existing regimen of 1-3 antiepileptic drugs (AEDs)
224077508|NCT01405053|DRUG|Any other approved Antiepileptic Drug|Any other approved AED: any other approved AED of the investigator's choice as an add-on to the subject's existing regimen of 1-3 anti-epileptic drugs (AEDs)
224077509|NCT00868101|PROCEDURE|Remote ischemic preconditioning|Remote ischemic preconditioning was induced by four 5-minutes cycles of lower limb ischemia and reperfusion using a blood pressure cuff
224077510|NCT03893149|BEHAVIORAL|Active-Start intervention|Supervised exercise training. The intervention is a physical activity intervention that consist of 5 times per week before starting the first school-class (8:00-8:30 a.m.), 5 times per week. Each session was previously planned and described in a manual dedicated to the study. These sessions were designed by the research team and delivered by a graduate in Sport The intervention program included sports games adapted to the age of the participants, playground games, dance and other recreational activities. The intensity of the main part of the sessions was moderate-to-vigorous according to a previous study and this intensity was confirmed by accelerometry. Also, different activities favoring social interactions were designed to facilitate the interactions between the participants at the end of the sessions (cold-down).
224077511|NCT03893149|BEHAVIORAL|No Intervention|No-exercise
224077512|NCT04218097|OTHER|Study questionnaire|Monitoring - data collection: Sending of an information form and the study questionnaire, the YFAS and Hospital Anxiety and Depression (HAD) scale by post within a follow-up period of 24 to 36 months. With a stamped envelope for the answer and a telephone reminder if necessary.
224077513|NCT03654846|DEVICE|EmergencyEye|EmergencyEye Smartphone App
224077514|NCT05787847|BEHAVIORAL|Incentives for Abstinence|Participants in the incentives for abstinence condition will have the opportunity to earn financial incentives for abstaining from stimulant use.
224077515|NCT05787847|BEHAVIORAL|Health Education|The Health Education condition is based on a previous intervention used as a control in a number of other studies. Sessions consist of an educational program addressing a variety of health, wellness, and lifestyle topics adapted from a previously implemented wellness manual.
224077516|NCT02882633|DRUG|30ml bolus of bupivacaine|Local anesthetic
224077517|NCT03283800|OTHER|Copper impregnated compression stocking|Copper impregnated compression stocking
224077518|NCT03283800|OTHER|Normal compression stocking|Normal compression stocking without copper
224077519|NCT06438315|OTHER|No intervention|No intervention
224077520|NCT06653296|DRUG|ENX-102|Four weeks of ENX-102 (0.5, 1, or 3 mg) in capsule form followed by 2 weeks of tapered dose, taken orally once daily in the evening for a 6-week total treatment period
224077521|NCT06653296|DRUG|Placebo|Six weeks of placebo in capsule form taken orally once daily in the evening for a 6-week total treatment period
224077522|NCT05609890|DIETARY_SUPPLEMENT|Supplement|"Supplement: a mixture of saffron, tea extract, lemon balm and valerian.~Dose: The participant will take one sachet every day, one hour before going to bed, for six weeks."
224077523|NCT05609890|OTHER|Placebo|"Placebo sachet~Dose: The participant will take one sachet everyday, one hour before going to bed, for six weeks."
224077524|NCT06822881|DRUG|CAR-T Therapy|CT1190B cells infusion
224077525|NCT05057169|BIOLOGICAL|BNT162b2|BNT162b2 is a nucleoside-modified mRNA encoding the trimerized SARS-CoV-2 spike glycoprotein. The vaccine is formulated in lipid nanoparticles that increase the efficiency of delivery of the mRNA into cells after intramuscular injection. BNT162b2 encodes the SARS- CoV-2 full-length spike, modified by two proline mutations to lock it in the prefusion conformation and more closely recreate the intact virus with which the elicited virus- neutralizing antibodies interact. mRNA vaccines use the pathogen's genetic code as the vaccine; hence they exploit the host cells to translate the code and generate the target spike protein. The protein then acts as an intracellular antigen to stimulate the immune response of the vaccinated individual. The mRNA is then degraded within days.
224077526|NCT05057169|BIOLOGICAL|CoronaVac|CoronaVac is a Vero cell-based, aluminium hydroxide-adjuvanted, β-propiolactone- inactivated vaccine based on the CZ02 strain. This strain of SARS-CoV-2 was isolated from the bronchoalveolar lavage of a hospitalized patient and is closely related to the 2019-nCoV- BetaCoV Wuhan/WIV04/2019 strain. Each 0.5 ml dose is composed of 3 μg of inactivated SARS-CoV-2 virus. The excipients are aluminium hydroxide, disodium hydrogen phosphate, sodium dihydrogen phosphate, sodium chloride, and water for injection.
224077527|NCT03650192|DEVICE|INVSENSOR00027|Investigational, noninvasive sensor that will be placed on the subject's chest and/or back. INVSENSOR00027 measures signals regarding subject's movement and posture, heart rate, and respiratory rate.
224077528|NCT04405011|DRUG|24-week Entecavir|Entecavir 0.5mg for 24 weeks will be delivered
224077529|NCT04405011|DRUG|12-week Entecavir|Entecavir for 12 weeks will be delivered and serve as the active comparator arm
224077530|NCT04937088|DRUG|ASA|Liquid aspirin formulation
224077531|NCT02799680|BIOLOGICAL|allogeneic CART-33|allogeneic CD33-directed chimeric antigen receptor-modified T cells (CART-33)
224077532|NCT05040594|DEVICE|PavéDerm J-Fill Soft Dermal Filler|Sodium Hyaluronate 20 mg with Lidocaine hydrochloride 3 mg/mL
224077533|NCT05040594|DEVICE|Restylane® Lyft Lidocaine|Sodium Hyaluronate 20 mg with Lidocaine hydrochloride 3 mg/mL
224077534|NCT00217815|DRUG|Mycograb, Docetaxel|
224077535|NCT04125355|OTHER|Reflexology|Foot reflexology massage for 3 consecutive days and 60 minutes per day.
224077536|NCT04125355|OTHER|Placebo|Placebo for 3 consecutive days and 60 minutes per day. This intervention only include touch to the foot, it doesn't include deep stimulation.
224077537|NCT04547205|DRUG|AK109|AK109, 2#4#8#12#18mg/kg, IV, every 2 weeks (Q2W), or 15 mg/kg every 3 weeks(Q3W)
224077538|NCT04995146|OTHER|Clinical stroke extended management pathway|"1. Extracranial imaging~2. ECG in 2-7 days~3. DVT prophylaxis~4. Stroke educational material for patient and family Removal of Foley's catheter and start bladder management~5. Discharged on: Antithrombotic therapy OR Anticoagulation therapy▸ Antihypertensives ▸ Statins/cholesterol lower agent ▸ Antidiabetic agent~6. Fasting lipid profile, HbA1c~7. Holter monitor~8. Specialized workup for young stroke~9. PFO Study, MES Study~10. Referral to: ▸ Rehabilitation specialist ▸ Speech therapist ▸ Dietician ▸ Occupational therapist ▸ Medical team~11. Follow-up: CTA, CT angiography; HbA1c, glycated haemoglobin; MRA, MR angiography~12. Follow-up plan and 90 day mRS"
224077539|NCT02052271|DEVICE|Cathodal cerebellar transcranial direct current stimulation|Active stimulation: duration: 20 mn, intensity: 2 mA; localisation : cerebellum; Placebo stimulation: duration: 9 seconds, intensity: 2 mA; localisation cerebellum;
224077540|NCT02175680|DRUG|PRO 140|CCR5 Antagonist
224077541|NCT02175680|OTHER|Historical data|Historical data (i.e., time to HIV-1 RNA viral load \> 500 copies/mL of 29 days).
224077542|NCT06290050|DRUG|Midazolam|Midazolam syrup.
224077543|NCT06290050|DRUG|Repaglinide|Repaglinide tablets.
224077544|NCT06290050|DRUG|TAK-279|TAK-279 capsules.
224077545|NCT03357627|DRUG|TAK-659|TAK-659 tablets.
224077546|NCT03357627|DRUG|Venetoclax|Venetoclax tablets.
224077547|NCT02468791|DRUG|Rituximab|
224077548|NCT00047138|BIOLOGICAL|dactinomycin|
224077549|NCT00047138|DRUG|carboplatin|
224077550|NCT00047138|DRUG|cyclophosphamide|
224077551|NCT00047138|DRUG|doxorubicin hydrochloride|
224077552|NCT00047138|DRUG|etoposide|
224077553|NCT00047138|DRUG|vincristine sulfate|
224077554|NCT00047138|PROCEDURE|adjuvant therapy|
224077555|NCT00047138|PROCEDURE|conventional surgery|
224077556|NCT00047138|PROCEDURE|neoadjuvant therapy|
224077557|NCT00047138|RADIATION|radiation therapy|
224077558|NCT02285725|PROCEDURE|Microdrilling Surgery|All patients will undergo an arthroscopic surgical procedure in which small holes are drilled throughout the areas of damaged cartilage (standard of care)
224077559|NCT02285725|PROCEDURE|Injections of BMAC + PRP + HA|All patients will receive up to 12 intra-articular knee injections of BMAC (derived from iliac crest), PRP (derived from peripheral blood) and HA
224077560|NCT04800198|PROCEDURE|non-invasive ventilation|none, measurements only
224077561|NCT01221428|BIOLOGICAL|Umbilical Cord Mesenchymal Stem Cells|Intravenous infusion of ex vivo cultured umbilical cord mesenchymal stem cells(2\*10/7),one week later,conduct intervention operation to inject mesenchymal stem cells to mesenteric artery(1\*10/7).
224077562|NCT04520113|BEHAVIORAL|Household contact tracing|Household contact tracing to test and diagnose Tuberculosis of household contacts of Tuberculosis patients.
224077563|NCT01913483|DRUG|Bivalirudin|Bivalirudin is an anticoagulant that binds directly to thrombin in a bivalent and reversible fashion.
224077564|NCT01913483|DRUG|Unfractionated Heparin|Unfractionated heparin is an anticoagulant.
224077565|NCT01459458|BEHAVIORAL|Family Planning-based Partner Violence Intervention|"The intervention includes three major components:~1. Enhanced Screening and Education: scripted questions to assess for reproductive coercion and pregnancy risk combined with intimate partner violence (IPV) assessment and education regarding how IPV may affect women's reproductive health with the assistance of a safety/educational card created for this intervention.~2. Harm Reduction Counseling: assisting clients in identifying and planning strategies to reduce their risk for future unintended pregnancies and IPV.~3. Supported Referral: educating all clients regarding local resources for victims of IPV and problem-solving regarding barriers to acquisition of these resources as needed."
224077566|NCT05365763|BEHAVIORAL|Simulated telehealth serious illness conversation visit|"The study team will instruct the participant to relax, and record biometric data for a total 7 minutes (the beginning two minutes is to allow for physiologic adaptation).~Simulated Encounter The study team will train experienced actors in the same case, a patient with a metastatic soft tissue sarcoma already on second-line chemotherapy. The physicians will receive a simulated medical file that contains a prognosis in a single format: a range-based, time prognosis (e.g. months to a year). The actor script and medical file will be developed by a multidisciplinary team (e.g. oncologist, palliative care, emotion scientist). The encounter will occur via tele-video platform (ZOOM®) and will be video-recorded. During the encounter participant physicians will wear three biometric sensors."
224077567|NCT02302963|DEVICE|AP System (DiAs or inControl) with USS Virginia|Subject will participate in two 24-hour study insulin pump and AP System training sessions. At the conclusion of each training session, subject will wear the equipment at home for a total of 5 weeks.
224077568|NCT02302963|DEVICE|Sensor-Augmented Pump Therapy (placebo)|Subject will participate in 5 weeks use of CGM and personal insulin pump at home.
224077569|NCT00368771|BEHAVIORAL|IBS Stress Management|If randomly assigned to this intervention, the session with the therapist will consist of training about IBS symptoms and their relationship to stress, as well as skills training in relaxation and ways of identifying and challenging mistaken thoughts about life events. The goal of this treatment is to lessen mental and physical stressful reactions to daily events, and therefore lessen IBS symptoms as a reaction to stress. The patient will be encouraged to apply relaxation skills to stressful situations.
224077570|NCT00368771|BEHAVIORAL|IBS Symptom Management|If assigned to this group, the therapist will discuss feelings, over-attention to IBS symptoms, and your fear of IBS symptoms. Patients will learn how to identify thoughts that may increase your IBS symptoms and will practice how to change these thoughts to ones that make them feel more comfortable. The sessions will focus on reactions to daily life that in turn result in IBS Symptoms.
224077571|NCT00368771|BEHAVIORAL|IBS Educational Training|Those assigned to this group will be given educational materials about IBS and will discuss the reading material with the therapist. The reading topics include information on gut disorders, anatomy and physiology of the gut, assessment procedures, and how to manage IBS symptoms. Sessions will also consist of weekly reviews of daily records and IBS symptoms. The goal of this intervention is to provide educational training about IBS.
224077572|NCT00294112|DRUG|Prochymal™ adult human mesenchymal stem cells|Cells in plasmalyte and containing dimethylsulfoxide
224077573|NCT00294112|DRUG|adult human mesenchymal stem cells|two infusions, one week apart, each comprising adult human mesenchymal stem cells
224077574|NCT00003887|BIOLOGICAL|peripheral blood lymphocyte therapy|
224077575|NCT00870753|BEHAVIORAL|Yoga|90 min hatha yoga 2 times per week for 12 weeks.
224077576|NCT06447467|DIAGNOSTIC_TEST|pro BNP|Test is mainly used to help diagnose or rule out heart failure in a person who is having symptoms
224077577|NCT01816243|DRUG|TTS-Fentanyl|Transdermal Therapeutic System (TTS)-fentanyl patches releasing fentanyl in the range of 12.5 to 100 microgram per hour (mcg/hr) rate. The initial dose of fentanyl TTS will be calculated based on each participant's opioid requirement. Patches will be usually replaced every 72 hours. Doses will be escalated in steps of 25 mcg/hr, if pain cannot be controlled. The study duration will be 30 days after first patch application.
224077578|NCT01816243|DRUG|Morphine|Participants will be allowed the use of oral morphine syrup for the duration of TTS-fentanyl treatment to enable appropriate dose titration. It is expected that most of the participants will be titrated to an appropriate dose of TTS-fentanyl within 1 week.
224077579|NCT02916420|DRUG|Pomalidomide|4mg/day, d1-d21, 28 days per cycle
224077580|NCT02916420|DRUG|Dexamethasone|≤70 years,40mg/day; \>70 years,20mg/day, d1、d8、d15、d22, 28 days per cycle
224077581|NCT05343065|DEVICE|BlueStar 10|An app that coaches individuals with diabetes and supports insulin-dosing based on continuous glucose monitor data
224077582|NCT05498688|DIETARY_SUPPLEMENT|Low carbohydrate|Participants will have a low carbohydrate meal
224077583|NCT05893849|DRUG|Clinical probes|Inpatients taking one or more clinical probes of CYP2C19 (omeprazole, rabeprazole, pantoprazole), CYP2D6 (metoprolol, carvedilol), CYP3A4 (rivaroxaban, finasteride, amlodipine, simvastatin), OAT (meropenem), OATP1B1 (atorvastatin, rosuvastatin) and OCT (metformin) will be included in the study.
224077584|NCT03515109|PROCEDURE|Altis tape|placement of Altis tape through transobturator foramen bilaterally under epidural anesthesia
224077585|NCT03515109|PROCEDURE|TVTO|placement of TVTO tape through transobturator foarmen bilaterally under epidural anesthesia
224077586|NCT01459250|DRUG|AGO178C|
224077587|NCT05749614|DRUG|Lidocaine cream|Group 1 was given 1 ml of 5% lidocaine cream on demand. They were instructed to apply the lidocaine cream evenly in a circular pattern to the glans penis without precise application to the sensitive area of the glans penis. The treatment lasted for a total of 4 weeks.
224077588|NCT05749614|DRUG|Lidocaine cream|Group 2 had a penile biological vibration threshold test performed to detect loci with a lower threshold. They were instructed to apply 1 ml of 5% lidocaine cream to the sensitive loci on the glans penis for 4 weeks.
224077589|NCT00191594|DRUG|Duloxetine Hydrochloride|
224077590|NCT02911428|PROCEDURE|blood sampling collection|It is an observational study; no interventions are planned in the course of common clinical practices during the study period; investigated therapeutic agents or special methods of examination will not be used in the study, except the blood sampling procedure and clinical observation specified in this Protocol.
224077591|NCT01049763|DRUG|oseltamivir|oseltamivir 150 mg single oral dose oseltamivir 75 mg single oral dose
224077592|NCT02972164|BEHAVIORAL|Weight loss program for school children|"The intervention involves developing social and emotional competences, promotion of healthy lifestyle, use of activity monitoring devices to promote increased activity and enlisting family to maintain weight loss in the long term.~The intervention group receives all program components: 1. Parent information sessions and orientation, 2. Two week intensive weight loss and lifestyle education camp, 3. after school clubs for consolidation (including physical activity and lifestyle education), and 4. wearable sensors and social media modules with parental involvement. Assessed outcomes include pre- and post-measurement at each phase included: weight, height, BMI, waist circumference, blood pressure, physical activity, dietary intakes, self-esteem, and subjective well-being."
224077593|NCT05718986|OTHER|No intervention|No intervention
223889006|NCT06426693|DEVICE|Control feedback|Participants provided with control (sham, yoked to another participant) feedback (e.g., thermometer) and will be instructed to try to change the feedback (e.g., decrease the thermometer).
223889007|NCT05477602|PROCEDURE|Cardiac Ablation for the treatment of persistent Atrial Fibrillation|Patients undergoing cardiac ablation for the treatment of persistent atrial fibrillation
223889008|NCT06075784|OTHER|reiki|placebo reiki
223889009|NCT05749627|DRUG|Neoantigen peptide vaccine|Personalized tumor neoantigen peptide vaccine
223889010|NCT05749627|DRUG|Neoantigen-based DC immune preparation|Personalized tumor neoantigen DC therapeutic immune preparation
223889011|NCT06364189|BEHAVIORAL|Music|Individualized play lists of music with the beats accentuated will be developed at a range of cadences. The music intervention is such that during strength training participants will be asked to sync their concentric and eccentric muscle contractions in time with the tempo of playlists. For aerobic exercise (AE), the tempo of playlists will be adjusted to match individual walking cadence for participants to be trained to walk in sync with the beats of the playlists.
223889012|NCT06364189|BEHAVIORAL|Exercise|"The ST incorporates single-leg exercises for balance training and training with resistance bands and body weight.~For aerobic exercise (AE), participants will be instructed to walk at moderate intensity with duration increasing up to an ultimate goal of 150 min/week."
223889013|NCT03366272|DRUG|Nivolumab|eight cycles of nivolumab (240 mg flatdose) plus (R)-GemOx in 2-wk intervals followed by additional 9 infusions of Nivolumab (480 mg flatdose) in 4-wk intervals as consolidation or up to progression or unacceptable toxicity, whatever occurs first
223889014|NCT03366272|DRUG|Rituximab|eight cycles of R-GemOx in 2-wk intervals
223889015|NCT03366272|DRUG|Gemcitabine|eight cycles of (R)-GemOx in 2-wk intervals
223889016|NCT03366272|DEVICE|Oxaliplatin|eight cycles of (R)-GemOx in 2-wk intervals
223889017|NCT06188468|DIAGNOSTIC_TEST|standard-of-care imaging (18F-FDG, 68Ga-PSMA, or 68Ga-DOTATATE PET/CT), 68Ga-MY6349 PET/CT|Each subject receives a single intravenous injection of standard-of-care imaging radiopharmaceuticals (18F-FDG, 68Ga-PSMA, or 68Ga-DOTATATE) and 68Ga-MY6349, and undergoes PET/CT imaging within the specified time.
223889018|NCT06535971|OTHER|Manual therapy combined exercise|"1. Manual therapy included fascia release, progressive passive stretch, mobilization, etc.(depend on subject's current condition)~2. Exercise included muscle strengthening, trunk (spine) stabilization exercise. (depend on subject's current condition)"
223889019|NCT04742231|DEVICE|Hand-held dynamometer|Maximum Grip Strength will be measured using a hand-held dynamometer (K-FORCE Grip dynamometer®. Kinvent Biomequanique S.A.S, Montpellier, France) during the preoperative, intraoperative (Awake craniotomy) and postoperative period.
223889020|NCT06552689|DEVICE|Sutra Hemi-valve Transcatheter Mitral Valve Replacement (TMVR) System|Trans-septal Sutra Hemi-valve TMVR System to treat mitral regurgitation
223889021|NCT02414477|DRUG|Deuterated NNN|Smokeless tobacco study product
223889022|NCT06046326|BEHAVIORAL|virtual community of practice|The intervention group will be offered participation for 12 months in a VCoP based ona gamified web-based application.
223889023|NCT05081622|BEHAVIORAL|Interaction Competencies with Children - for Teachers (ICC-T)|"Core training components include teacher-student interaction, maltreatment prevention, effective discipline strategies, identifying and supporting burdened students and implementation of the training materials into the school setting.~A one-day ICC-T refresher workshop aiming to refresh and re-emphasize the key aspects of the intervention is implemented about 6 to 12 months after the initial intervention."
223889024|NCT03652805|DRUG|IPL344|"The study is designed to determine the tolerability, safety and PK of IPL344 administered I.V. once a day for 28 days and to identify the maximum tolerated dose.~All patients enrolled will have a documented history of ALS disease prior to study enrollment.~Treatment will start with 1.7mg/kg with dose escalation by 0.5 mg/kg every 3-4 days and will increase to the maximum dose of 3.2mg/kg. Day 1 to Day 28 patients will be on active treatment.~After completion of 28 treatment days, participants who will choose to continue treatment (at the investigator's discretion), will be enrolled in a follow-up study. Participants that discontinue treatment after Day 28 will be followed up by a nurse phone call and return to the clinic for a final visit on Day 56 from the first dose."
223889025|NCT06414122|OTHER|mid-frequency whole-body electromyostimulation (WB-EMS)|supervised group training sessions at least once and optionally twice a week, lasting 11-20 minutes, over 12 weeks, 12-24 training sessions in total
223889026|NCT06414122|OTHER|conventional exercise training|supervised group training at least once a week, optional additional home-based training once a week, lasting 40 minutes, over 12 weeks, 12-24 training sessions in total
223889027|NCT06414122|OTHER|nutritional therapy|conventional nutritional counselling with guidelines and digital nutritional coaching
223889028|NCT02927769|BIOLOGICAL|Nivolumab|Specified Dose on Specified Days
223889029|NCT02927769|BIOLOGICAL|brentuximab vedotin|Specified Dose on Specified Days
223889030|NCT02927769|BIOLOGICAL|bendamustine|Specified Dose on Specified Days
223889031|NCT04038840|DRUG|[11C]UCB-J radiotracer|I.V. bolus administration of up to 15 mCi (equivalent to 0.3 rems) in the antecubital vein
223889032|NCT04038840|DEVICE|PET-MR|Positron emission tomography and magnetic resonance imaging, with a scan duration of up to 120 minutes
223889033|NCT03113929|RADIATION|MRI|Research MRI
224077594|NCT00915343|DRUG|hydrocortisone (modified release), oral tablet 20 and 5 mg|The modified release hydrocortisone tablet was administered orally o.d. at 8 AM in the fasting state. The dose was the same as patients have had before entering the trial
224077595|NCT00915343|DRUG|Hydrocortisone, oral tablet, 10 mg|The reference drug was administered orally thrice daily (at 8 AM, 12 AM and 4 PM). The morning dose was administered in the fasting state. The total daily dose was the same as in the experimental treatment arm.
224077596|NCT05117775|OTHER|No intervention - Just description and predictive models|All the groups will be descriptive, there is not intervention, as it is an Observational study applying artificial Intelligence (RWE).
223889034|NCT05150860|BEHAVIORAL|At-home COVID-19 testing|At-home over-the-counter (OTC) COVID-19 testing kits provided to middle school students and staff
223889035|NCT05150860|BEHAVIORAL|Onsite COVID-19 testing|Onsite COVID-19 testing for middle school students and staff
223889036|NCT03747341|DRUG|Buprenorphine Injectable Solution - Part A|"Buprenorphine intravenous (IV) injection given as a primed-continuous infusion.~Low Dose: initial bolus (0.05 mg/70 kg) administered over 15 minutes and infusion continued (0.02 mg/70 kg/hour infusion rate) to complete 360 minutes of administration targeting 0.2 ng/ml.~High Dose: initial bolus (0.125 mg/70 kg) administered over 15 minutes and infusion continued (0.05 mg/70 kg/hour infusion rate) to complete 360 minutes of administration targeting 0.5 ng/ml.~Administration of buprenorphine was flexible and infusion rates were selected to target approximately 25 to 50% respiratory depression."
223889037|NCT03747341|DRUG|Placebo - Parts A + B|0.9% normal saline for IV administration was used as placebo matching the buprenorphine formulation and administration.
224077597|NCT00630630|DRUG|Levetiracetam|
224077598|NCT00630630|OTHER|Placebo|
224077599|NCT02817412|BEHAVIORAL|Go/No-Training|
224077600|NCT02817412|BEHAVIORAL|Stop-Signal Training|
224077601|NCT02817412|BEHAVIORAL|Dot-Probe Paradigm|
224077602|NCT02817412|BEHAVIORAL|Generic Response Training|
224077603|NCT04354350|DRUG|Ramipril|Ramipril dispensing claim is used as the reference
224077604|NCT04354350|DRUG|Telmisartan|Telmisartan dispensing claim is used as the exposure
224077605|NCT05066243|OTHER|questionnaire|this study is to develop a questionnaire for vulval conditions
224077606|NCT02349698|BIOLOGICAL|Chimeric Antigen Receptor Modified T cells Targeting CD19|T cells modified with CD19 targeted chimeric antigen receptor.
224077607|NCT06251232|DRUG|Prednisone|Placebo
224077608|NCT01634438|DRUG|unfractionated heparin|unfractionated heparin
224077609|NCT02780882|DRUG|Pasireotide|
224077610|NCT03944239|BIOLOGICAL|Retinal pigment epitheliums transplantation|Subretinal transplantation of clinical human embryonic stem cell derived retinal pigment epitheliums.
224077611|NCT02170272|BEHAVIORAL|Home-based Lymphedema Care Program|Undergo HBLCP
224077612|NCT01920711|DRUG|LCZ696|LCZ696 50mg, 100mg and 200 mg dosage strengths will be available for dose adjustments.
224077613|NCT01920711|DRUG|Valsartan|Valsartan 40mg, 80mg and 160mg dosage strengths will be available for dose adjustments.
224077614|NCT03949270|BEHAVIORAL|BETA-Text text messaging intervention|Patients in the text messaging arm will receive daily, weekly, and monthly text messages. The daily message asks whether or not the patient has taken their breast cancer medication. The weekly message asks about any side effects and their severity. The monthly text message asks about any barriers that the patient might be experiencing. Concerning responses to any of the text messages will prompt contact from the office of the treating physician.
224077615|NCT01664780|DEVICE|ARFI imaging|
224077616|NCT04663308|DRUG|Volixibat|Oral capsules, administered twice daily. Volixibat is an Ileal Bile Acid Transporter (IBAT) inhibitor.
224077617|NCT04663308|DRUG|Placebo|Capsules matched to study drug minus active substance
224077618|NCT06061861|OTHER|Financial support for healthy foods and free home delivery|Participants will receive monetary support to spend on healthy food items (e.g., vegetables and fruit) through the Instacart platform for a duration of 6 months and have home delivery and service fees waived for 4 orders per month through the Instacart platform for a duration of 6 months.
224077619|NCT06061861|OTHER|Free home delivery|Participants will have home delivery and service fees waived for 4 orders per month through the Instacart platform for a duration of 6 months.
224077620|NCT01381159|BEHAVIORAL|Motivational Communication|Brief MC sessions focused on medication adherence within 4-6 week period
224077621|NCT01381159|BEHAVIORAL|Control|Standard medical care
224077622|NCT04682470|OTHER|No intervention ; observational|No intervention; observational
224077623|NCT04608695|PROCEDURE|Ovarian puncture|One side ovary of each patient included in the study, will be punctured 10 times under trans-vaginal ultrasound guidance with 17 gauge ovarian pick up needle, 1 month before the scheduled IVF cycle. Control group will be the other side ovary for each patient. Number of ≥ 14 mm follicle and collected oocytes will be compared.
224077624|NCT04892173|DRUG|JNJ-90301900 (NBTXR3)|Suspension of inert, crystalline hafnium oxide particles, designed to generate oxygen free radicals to destroy cancer cells after activation by ionizing radiation.
224077625|NCT04892173|DRUG|Cetuximab|Solution for infusion
224077626|NCT04892173|RADIATION|Radiation Therapy|Intensity-modulated radiation therapy (IMRT): 70 Gray in 35 fractions over a 7-week period.
224077627|NCT04001023|DEVICE|Imaging with 18F-EF5 PET/CT|Both 18F-FDG PET/CT and 18F-EF5 PET/CT imaging are performed in 1) preoperative work-up to clarify the disease distribution, 2) before IDS to evaluate treatment response to NACT (IDS arm); targeted samples from hypoxic and non-hypoxic tumors are collected during surgery
224077628|NCT00185003|DRUG|endotoxin|
224077629|NCT00185003|DRUG|Potassium channel blockers: TEA, Quinin, Tolbutamide|
224077630|NCT00185003|DRUG|L-NMMA|
224077631|NCT03224429|OTHER|Qualitative Interviews Decisional Needs Assessment|Subjects will participate in an open-ended interview regarding type of sickle cell disease, complications, current treatment, and experiences with decision making and sickle cell treatment. Participants will be asked to describe what is important when making health care decisions. Treatment options (hydroxyurea, chronic or monthly blood transfusions, and bone marrow transplantation) will be discussed as well as how a web-based decision aid tool should be developed. The interview will be audio recorded and will take 45 to 60 minutes to complete.
224077632|NCT03224429|OTHER|Sickle Cell Decision Aid|Participants will be asked to navigate the Sickle Cell Decision Aid site that provides information about risks and benefits of therapies. As the participant navigates the site, the interviewer will ask the participants to describe thoughts about the site, including but not limited to ease of navigation, content and construction. Testing may be performed in-person or via telephone. Interviews will be audio recorded and take up to 60 to 90 minutes to complete.
224077633|NCT01634555|BIOLOGICAL|Ramucirumab (IMC-1121B)|Ramucirumab (IMC-1121B) 8 milligrams per kilogram (mg/kg), administered as an intravenous (IV) infusion on Day 1 of each 2-week cycle (except Cycle 1)
224077634|NCT01634555|DRUG|Irinotecan|180 milligrams per square meter (mg/m²) administered IV on Day 1 of each cycle
224077635|NCT01634555|DRUG|Folinic acid|400 mg/m² administered IV on Day 1 of each cycle
224077636|NCT01634555|DRUG|5-Fluorouracil|400 mg/m² bolus over 2 to 4 minutes administered IV on Day 1 of each cycle, followed by 2400 mg/m² administered IV over 46 to 48 hours on Days 1 and 2 of each cycle
224077637|NCT01910675|DRUG|PCC|15 IU/kg Octaplex and 2 g Riastab. Additional fibrinogen if needed.
224077638|NCT01910675|DRUG|FFP|4 units Octaplas. Additional fibrinogen if needed.
224077639|NCT05160935|BEHAVIORAL|Education|"Each patient will be informed about the study, and written consent will be obtained from patients who agree to participate in the study, explaining the purpose and duration of the study. A Patient Identification Form will be filled, the patient's vital signs will be evaluated, and the State-Trait Anxiety Inventory will be administered to the patient.~Before the coronary angiography procedure, the patients in the experimental group will be trained by the researchers using the training booklet. Trait Anxiety Inventory will be re-administered to the patients after the procedure. Vital signs of patients will be monitored.~In the control group; In line with the information in the patient consent form before the coronary angiography procedure, verbal information will be given about the coronary angiography procedure within the scope of the routine procedure in the clinic. After the procedure, the State-Trait Anxiety Inventory will be applied again. Vital signs will be taken."
224077640|NCT05576974|DRUG|Pegsitacianine|Infusion of the Pegsitacianine-Intraoperative fluorescence imaging
224077641|NCT05061303|OTHER|Assessment of the drug concentration in the blood|The material in the study will be blood, in which tacrolimus concentrations will be measured at the following time points: 0, 2hours, 6hours, 12hours after drug administration, without taking omeprazole/famotidine and then the next day after taking the protective drug in same time points, without 12hours. Sequentially routinely in the so-called point T0 before taking the drug (12 hours after the last dose) during follow-up visits at the Transplant Outpatient Clinic.
224077642|NCT03977129|DEVICE|QFR-guided strategy|In this study, the QFR-guided strategy will be applied to in the QFR group in which calculation of the QFR values of all target coronary arteries with lesions with diameter stenosis of ≥ 50% (visual estimation) and with suitability to CABG revascularization will be carried out. If QFR ≤ 0.80, then simultaneous CABG revascularization of target blood vessels will be carried out. If QFR \> 0.80, then no CABG revascularization of target blood vessels will be carried out.
224077643|NCT03977129|OTHER|CAG-guided strategy|In this study, CAG-guided strategy will be used for the control group, i.e., in accordance with current guideline recommendations, all target coronary arteries with lesions with diameter stenosis of ≥ 50% (visual estimation) and suited for CABG revascularization will undergo CABG revascularization.
224077644|NCT04769362|DRUG|Discontinuation of β-blocker|Discontinuation of β-blocker after at least 1 year of β-blocker therapy after acute myocardial infarction
224077645|NCT06591572|PROCEDURE|Single-port robotic transanal total mesorectal excision|Rectal resection by transanal TME with single-port robotic surgery
224077646|NCT07122895|DRUG|NMDAE|Use of an NMDA enhancer for the treatment of negative symptoms
224077647|NCT07122895|DRUG|Placebo Cap|Use of placebo as a comparator
224077648|NCT06733025|PROCEDURE|Tendon lengthening surgery|The participants will first receive BoNT injections, earliest three months after they will undergo tendon lengthening surgery
224077649|NCT06733025|DRUG|BoNT Injections|The dosage and number of injected muscles will vary depending on the degree and extent of spasticity. All patients had previous BoNT injections, one injection circle will be followed in this study.
224077650|NCT06026371|DRUG|Fecal Microbiota Transplantation Capsule|Given PO
224077651|NCT06026371|DRUG|Placebo|Given PO
223889038|NCT03747341|DRUG|Fentanyl - Part A|Participant received up to four fentanyl doses: 0.075, 0.15, 0.25, and 0.35 mg/70 kg in Periods 1 and 2. Fentanyl boluses were administered over 90 seconds by dose escalation +2hr, +3hr, +4hr and +5hr after starting administration of buprenorphine/ placebo. Administration of fentanyl was flexible and bolus doses were selected to elicit moderate to more severe respiratory depression with apnoea ≥20 seconds.
223889039|NCT03747341|DRUG|Ondansetron - Parts A + B|A non-investigational intervention administered as an infusion prior to investigation intervention. 4 mg of ondansetron was administered to manage the expected gastrointestinal side effect (nausea, vomiting) to buprenorphine.
224077652|NCT06889298|DEVICE|Treatment with BTL-699|Four to six transcranial magnetic stimulation treatments with the BTL-699 device will be delivered over the left dorsolateral prefrontal cortex, spaced 2 to 3 days apart. The intensity will be adjusted according to the subject's feedback, up to 100% of the individual's motor threshold.
224077653|NCT02791061|OTHER|Cardiovascular Magnetic Resonance Imagine (MRI)|MRI uses interaction of the magnetic properties of body tissues with strong magnetic fields to create images.
224077654|NCT02791061|OTHER|Cardiopulmonary exercise testing (CPET)|Cardiopulmonary exercise testing (CPET) is non-invasive simultaneous measurement of the cardiovascular and respiratory system during exercise to assess a patient's exercise capacity.
224077655|NCT02791061|OTHER|Echocardiography|To measure heart chamber size, heart function, blood vessel size and blood vessel function. These measurements will help us understand the type and severity of heart failure.
224077656|NCT07057141|DEVICE|Biorepair Total Protection Toothpaste|Application of Biorepair Total Protection toothpaste for 30 seconds, performed once in a clinical setting. The aim is to reduce dental sensitivity in patients with gingival recession.
224077657|NCT07057141|DEVICE|Biorepair High-Density Mouthwash|Application of Biorepair High-Density mouthwash for 30 seconds, performed once in a clinical setting. The aim is to reduce dental sensitivity in patients with gingival recession.
224077658|NCT06333899|DRUG|Lorlatinib|Continue maintenance monotherapy for total 12 cycles
224077659|NCT06333899|DRUG|Lorlatinib with chemotherapy1|Continue lorlatinib with BABY-POG chemotherapy backbone for 72 weeks
224077660|NCT06333899|DRUG|Lorlatinib with chemotherapy 2|Continue lorlatinib with HIT-SKK chemotherapy backbone for 42 weeks
224077661|NCT06333899|DRUG|Lorlatinib post Radiation|Continue lorlatinib monotherapy 28 days post completion of radiation therapy for 12 cycles
224077662|NCT03803098|DEVICE|reference measure|measure of a physiological parameter performed with the gold standard medical device
224077663|NCT03803098|DEVICE|alternative measure|measure of a physiological parameter performed with the connected device under evaluation
224077664|NCT06896695|OTHER|Best Practice|Receive usual care
224077665|NCT06896695|OTHER|Discussion|Ancillary studies
224077666|NCT06896695|OTHER|Financial Navigation|Receive the Financial Compass intervention
224077667|NCT06896695|OTHER|Interview|Ancillary studies
224077668|NCT06896695|OTHER|Survey Administration|Ancillary studies
224077669|NCT04963153|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
224077670|NCT04963153|PROCEDURE|Bone Scan|Undergo bone scan
224077671|NCT04963153|PROCEDURE|Computed Tomography|Undergo CT
224077672|NCT04963153|PROCEDURE|Echocardiography Test|Undergo echocardiography
224077673|NCT04963153|DRUG|Enfortumab Vedotin|Given IV
224077674|NCT04963153|DRUG|Erdafitinib|Given PO
224077675|NCT04963153|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA scan
224077676|NCT06925061|DRUG|After surgery for Crohn's disease, eligible patients will be randomized 1:1 to receive oral EXL01 or placebo with or without SoC treatment (based on investigator decision) for up to 24 weeks|Randomisation will be stratified on post-surgical treatment (none vs anti-TNF), and on smoking status (non-smoker vs smoker).
224077677|NCT07107204|DRUG|BT02|BT02 monoclonal antibody injection with intravenous administration every 2 or 3 weeks
224077678|NCT07140341|DRUG|ENO Lime|A fruit salt (sachet of 5-gram powder) with lime flavor containing Svarjiksara (Shudh) 2220 milligram (mg) and Nimbu Rasa (Citrus limon, Fruit Juice Powder) 150 mg
224077679|NCT07144410|DRUG|fentanyl + morphine|The purpose of the trial is to study the quality of anaesthesia and perioperative analgesia provided by fentanyl, morphine and bupivacaine versus fentanyl and bupivacaine, as well as their side effects.
224077680|NCT07144410|DRUG|fentanyl|The purpose of the trial is to study the quality of anaesthesia and perioperative analgesia provided by fentanyl, morphine and bupivacaine versus fentanyl and bupivacaine, as well as their side effects.
224077681|NCT06944340|OTHER|WHO Trauma Care Checklist|"A standardized checklist developed by the WHO for trauma care, designed to reduce errors and ensure compliance with critical steps in trauma management.~Implemented by trained clinicians during patient assessment and treatment phases. Components include verification of patient identity, assessment of airway/breathing/circulation, pain management, monitoring for missed injuries, and post-resuscitation care. Checklist use is documented in medical records."
224077682|NCT05133661|DIAGNOSTIC_TEST|HPV testing|Interviews will be conducted among women from the general population and HIV+ women after screening for HPV. A small subset of participants will be interviewed after receiving treatment for precancer. HPV test results and outcome of the precancer treatment if indicated will be documented.
224077683|NCT06942234|DRUG|JSKN016|JSKN016 is administered via intravenous infusion at doses of 5mg/kg or 6mg/kg every 3 weeks, starting on Day 1 of each cycle. If the 5mg/kg dose is well tolerated during the safety lead-in phase, the dose may be increased to 6mg/kg for subsequent cycles.
224077684|NCT06942234|DRUG|Capecitabine|The drug is administered orally at a dose of 1000mg/m², twice daily for two weeks, followed by a one-week break. Treatment cycles repeat every three weeks.
224077685|NCT06942234|DRUG|Paclitaxel (albumin bound)|The drug is administered intravenously at a dose of 125mg/m², with infusions on Day 1 and Day 8 of each treatment cycle. The treatment cycle is repeated every 3 weeks.
224077686|NCT06942234|DRUG|Eribulin|The drug is administered intravenously at a dose of 1.4mg/m², with infusions on Day 1 and Day 8 of each treatment cycle. The treatment cycle is repeated every 3 weeks.
224077687|NCT06942234|DRUG|Pembrolizumab|The drug is administered intravenously at a fixed dose of 200mg, with infusions on Day 1 of each 3-week treatment cycle.
224077688|NCT07166939|DRUG|Airsupra|1 dose (2 inhalations) PRN, with maximum of 6 doses (12 inhalations) in a 24-hour period
224077689|NCT07178158|OTHER|Installing the Metacognium software app|Participants in the NIPA+TAU group will be sent two, URL's (one for iOS and one for Android) for installing the Metacognium software app, which hosts the four NIPA sessions. Participants will be provided with unique ID for registering and using the program on the Metacognium app. The NIPA sessions will be locked until participants have completed their baseline assessment. Once participants complete each NIPA session, they will receive an email and/or text notifying them that the next session is unlocked and that they can proceed to complete it.
224077690|NCT07178158|OTHER|Continue treatment as usual|Continue your treatment schedule as usual with the for 4 weeks.
224077691|NCT07177625|PROCEDURE|Retrolaminar block|Ultrasound-guided retrolaminar block performed prior to prone-position ESWL. This intervention is applied only to participants in the RLB Group. Patients will be monitored for pain intensity (VAS), vital signs, procedural duration, and any adverse events during and after the procedure. Rescue analgesia will be administered if clinically indicated.
224077692|NCT07177625|DRUG|Sedoanalgesia|Standard sedoanalgesia administered during prone-position ESWL. This intervention is applied only to participants in the Sedation Group. Pain intensity (VAS), vital signs, procedural duration, and any adverse events will be monitored. Rescue analgesia will be provided as needed.
224077693|NCT07177625|OTHER|No Intervention / None|No additional regional block or sedoanalgesia; standard monitoring only. This applies only to participants in the Control Group. Pain intensity (VAS), vital signs, procedural duration, and any adverse events will be monitored. Rescue analgesia will be provided if clinically indicated.
224077694|NCT07177963|BEHAVIORAL|HIIT|Exercise sessions were conducted as telemedically supervised, home-based HIIT performed on electric resistance bikes, with protocols individually tailored. Each HIIT session comprised 8 cycles of alternating 30-second high-intensity intervals (HIT at 80% peakVO₂) and 60-second low-intensity recovery intervals (LIT at 50% peakVO₂). Warm-up and cool-down phases were performed with the bike's resistance set to 0 watts (unloaded pedaling). The total intervention duration was 8 weeks. Received health lifestyle education based on the Prevention and Treatment Guidelines for Metabolic (Non-Alcoholic) Fatty Liver Disease (2024 Edition) and the Dietary Guidelines for Adults with Hyperlipidemia (2023 Edition).Wear smart bracelets 24/7 to monitor daily activity levels, with participants prohibited from engaging in any other systematic exercise training during the intervention period.
224077695|NCT07177963|BEHAVIORAL|No specific exercise intervention.|The control group will not receive any exercise intervention, and they will be instructed to not take any structured exercise regimens.Received health lifestyle education based on the Prevention and Treatment Guidelines for Metabolic (Non-Alcoholic) Fatty Liver Disease (2024 Edition) and the Dietary Guidelines for Adults with Hyperlipidemia (2023 Edition).Wear smart bracelets 24/7 to monitor daily activity levels, with participants prohibited from engaging in any other systematic exercise training during the intervention period.
224077696|NCT07178119|PROCEDURE|(Bridging) Horizontal Cannula Technique for Treatment of Nasolabial Folds using AILEENE Vol. 2|Participants will receive treatment to both NLF using the Bridging Technique. This involves injecting an HA dermal filler (AILEENE Vol. 2) in thin horizontal threads (less than 0.05 milliliters \[ml\] per retrograde placement) under the fold using a blunt cannula. The maximum total dose per participant is 1.0 ml across both folds. Each participant will receive one treatment at baseline (Day 0). An optional single top-up may be given at Week 2 (virtual or in-clinic) or Week 4 if clinically indicated, using only the remaining balance of the 1.0 ml total. Any top-up will be performed with a new, sterile syringe, not with filler left over from the initial treatment. This is a single-treatment course with follow-up for 6 months. Standardized photographs will be taken at Baseline, Week 4, Month 3, and Month 6 for blinded assessment.
224077697|NCT07179393|BEHAVIORAL|Ladies Gaelic Football-Specific Injury Prevention Programme|This intervention is an injury prevention programme designed with input from Ladies Gaelic football stakeholders (players and coaches) as well as experienced athletic therapy and physiotherapy practitioners and academics from the disciplines of injury prevention and coaching science.
224077698|NCT07178015|COMBINATION_PRODUCT|ultrasound scanning|Ultrasound (US) is one of the most frequently utilized methods in carotid screening worldwide, because of its noninvasive and radiation-free nature and advantages of cost-effectiveness and convenience。
224077699|NCT07177755|DIAGNOSTIC_TEST|High-field and very-low-field MRI acquisitions|MRI will be early acquired, as soon as possible after patient hospital admission and always in coma state for patients. For both patients and controls each MRI scanning session will encompass pairs of HF and VLF MRI acquisitions, that will be collected the same day. The main MRI sequences will be: T1, T2, FLAIR and DWI. The VLF spatial resolution recommended by the constructor for all these sequences correspond to voxel size is around 1.5mm/1.5mm/5mm. The total brain scanning time is estimated at 30 minutes.
224077700|NCT07177638|BEHAVIORAL|Education Sessions to Improve Melanoma Knowledge and Awareness|Community based educational seminar led by a community health worker with follow-up questionnaires to assess knowledge retention and behavioral change.
224077701|NCT07177482|DIAGNOSTIC_TEST|68Ga-MY6349 PET/CT|Each subject receives a single intravenous injection of 68Ga-MY6349 and undergoes PET/CT imaging within the specified time.
224077702|NCT07177716|BIOLOGICAL|LB1410|LB1410 (IV, Q2W for up to 2 years)
224077703|NCT07177716|BIOLOGICAL|LB4330|LB4330 (IV, Q2W for 4 cycles)
224077704|NCT07177716|DRUG|Lenvatinib|lenvatinib (oral, once daily for up to 2 years)
224077705|NCT07177781|DIETARY_SUPPLEMENT|Wild blueberry powder|Study volunteers will consume daily 26 grams of wild blueberry powder for 16 weeks, which has to be dissolved in a glass of water.
224077706|NCT07178236|DEVICE|MARIE|Portable capnoghraphy
224077707|NCT07179328|DEVICE|Focused Ultrasound Next Generation Dome Helmet|The Next Generation Dome Helmet (FUS NG) is a non-invasive, MRI-guided focused ultrasound system developed at Sunnybrook Research Institute. It is used to disrupt the blood-brain barrier (BBB) in patients with glioblastoma during the maintenance phase of temozolomide (TMZ) therapy. The device allows targeted BBB opening using a fixed transducer array and intravenous DEFINITY® contrast.
224077708|NCT07179328|DRUG|Definity® Vial for (Perflutren Lipid Microsphere) Injectable Suspension|DEFINITY® Perflutren Injectable Microbubbles is an ultrasound contrast imaging agent that will be used for blood brain barrier opening during focused ultrasound. These microbubbles will be injected during the focused ultrasound procedure.
224077709|NCT06409364|DRUG|Fludrocortisone|small white tablet containing 100mcg of fludrocortsone
224077710|NCT06409364|DRUG|Placebo|Matched placebo tablet,
224077711|NCT07177677|BIOLOGICAL|hBMMSC|Group 1: 0.5×10\^6 cells/kg (participant's body weight) single dose; Group 2: 1.0×10\^6 cells/kg (participant's body weight) single dose; Group 3: 2.0×10\^6 cells/kg (participant's body weight) single dose.
224077712|NCT07178691|OTHER|Online psychological intervention|The HOPE-AF intervention is an online psychological intervention to prevent depression in patients with atrial fibrillation. The intervention combines verbal psychological sessions over phone or video with online text messages and a tailored 4-12 weeks online intervention with new modules each week including psychological exercises in writing and as sound exercises (e.g., breathing exercises and relaxations exercises etc.) and videos.
224077713|NCT07178795|DRUG|BL-M07D1|Administration by intravenous infusion for a cycle of 3 weeks.
224077714|NCT07178795|DRUG|Pembrolizumab|Administration by intravenous infusion for a cycle of 3 weeks.
224077715|NCT07178795|DRUG|Pemetrexed|Administration by intravenous infusion for a cycle of 3 weeks.
224077716|NCT07178795|DRUG|Carboplatin|Administration by intravenous infusion for a cycle of 3 weeks.
224077717|NCT07178795|DRUG|Cisplatin|Administration by intravenous infusion for a cycle of 3 weeks.
224077718|NCT07179146|DEVICE|Dental arch length anlysis|Arch length
224077719|NCT07179146|BEHAVIORAL|child satisfaction|Frankel rating scale
224077720|NCT07179146|DEVICE|Dental arch length anaylsis|Intermolar width
224077721|NCT07179146|DEVICE|Dental arch length analysis|Intercanine width
224077722|NCT07179146|DEVICE|Dental arch length anylsis|Arch depth
224077723|NCT07178171|DRUG|QL1706 (bispecific antibody targeting PD-1 and CLTA-4)|QL1706
224077724|NCT07178171|DRUG|Pirarubicin|pirarubicin
224077725|NCT07178171|DRUG|Nab-paclitaxel|nab-paclitaxel
224077726|NCT07178171|DRUG|Carboplatin (AUC 5)|carboplatin
224077727|NCT07178171|DRUG|Cyclophosphamide|cyclophosphamide
224077728|NCT07178925|OTHER|Study of Antiphospholipid Syndrome responding to the Sydney classification of 2006|The main objective of the research is to define the thrombotic recurrence rate in our cohort of patients followed for APS in the internal medicine department, to evaluate the complication rate associated with treatment, to search for risk factors associated with thrombotic recurrence and to define the mortality and morbidity rates of this patient population.
224077729|NCT07178340|DRUG|Perioperative treatment|perioperative treatment with albumin-bound paclitaxel, oxaliplatin, tegafur,gimeracil and oteracil porassium capsules and sintilimab
224077730|NCT07177950|DRUG|SHR-A1811|Systemic therapy: 4.8 mg/kg administered as an intravenous infusion on Day 1 of each cycle. 3 weeks a cycle. Continuous medication until study completion, occurrence of intolerable toxicity, disease progression, withdrawal from the study for any reason, or death, whichever occurs first, or until the investigator deems that the patient would no longer benefit from the treatment.
224077731|NCT07177950|DRUG|SHR-A1811|Intrathecal therapy: Administered intrathecally on Day 1 of each cycle. Dose escalation follows a Bayesian Optimal Interval (BOIN) design with three predefined dose levels-15 mg, 30 mg, and 40 mg. The starting dose level is 15 mg. Patients are enrolled in cohorts of three per dose level. If no dose-limiting toxicities (DLTs) are observed, escalation proceeds to the next higher dose level according to the BOIN algorithm. Treatment is administered for a minimum of two cycles and is continued until cerebrospinal fluid (CSF) cytology achieves negative conversion, completion of six cycles, or intolerable adverse events, whichever occurs first. Extension beyond six cycles may be permitted following investigator's discussion and must be documented with justification.
224077732|NCT07177950|RADIATION|radiotherapy|radiotherapy is determined by investigator's choice
224077733|NCT07179172|BEHAVIORAL|Mindfulness-Based Stress Reduction (MBSR) 8-Week Program|"The program consists of weekly 2.5-hour sessions over an eight-week period. The certified mindfulness instructor will follow a curriculum that includes in-class formal practice (2.5 hours) and assigned informal practice (30-40 minutes daily).~During the sessions, the instructor will guide participants through mindfulness meditation, pain awareness, mindful yoga, gratitude practice, loving-kindness meditation, and the sharing of daily life experiences. Additionally, a full-day, eight-hour silent retreat (9 a.m. to 5 p.m.) will be held between weeks six and seven to deepen inner awareness.~Following each weekly group session, participants will be instructed to perform and self-record daily home practice, which will be discussed and evaluated during the following week's class. The total course duration is approximately 26 hours, and participants will receive a certificate of completion upon graduation."
224077734|NCT07177989|OTHER|Experimental Group|The interventional group will perform aerobic training (stationary cycling) 3 days a week for 5 weeks, starting with 40-60% heart rate reserve (HRR) for 20-30 minutes, with thein the first week and increasing to 40-85% HRR, maintaining a target heart rate of 40-60% HRR at the lower end and 75-85% HRR at the upper end, following a 1:4 work-to-rest ratio for 30-40 minutes in subsequent weeks, with the warm up of 5 mins before the session and a cool down of 5-7 mins after every seasion. Exercise heart rate will be calculated using the Karvonen formula for the base line week and the following weeks.Following each aerobic session, they'll practice Alternate Nostril Breathing (ANB), beginning with 5 minutes in the first week and progressing to 10 minutes thereafter. ANB involves specific hand positioning and breathing techniques to promote relaxation and balance. All sessions will be supervised by a physiotherapist.
224077735|NCT07177989|OTHER|interventional group A|In interventional group 'A' participants will perform aerobic training for 3 days a week for 30-40 minutes a day for 5 consecutive weeks. Exercise heart rate will be calculated using the Karvonen formula. For the first base line week the aerobic session begins with a 5-minute warm-up. The primary cardiovascular component involves using a cycle ergometer (stationary cycling) at an intensity of 40-60% heart rate reserve (HRR) for 20-30 minutes. Finally, the workout will concludes with a cool-down phase lasting 5-7 minutes, allowing the heart rate to gradually return to baseline and preventing post-exercise hypotension. From the second week onwards, the aerobic training session will begin with a 5-minute warm-up to prepare the body and gradually increase heart rate. The main workout involves a cycle ergometer, maintaining a target heart rate of 40-60% HRR at the lower end and 75-85% HRR at the upper end, following a 1:4 work-to-rest ratio for 30-40 minutes. The session ends with a 5-7 min
224077736|NCT07177443|RADIATION|Radiotherapy|"Following induction therapy, eligible patients will receive radiotherapy alone or concurrent chemoradiotherapy per protocol. Photon or proton radiotherapy techniques were permitted. Prescribed doses were:~Primary tumor and metastatic lymph nodes: 70 Gy/33 fractions High-risk lymphatic drainage areas: 60 Gy/33 fractions Low-risk regions: 54 Gy/33 fractions~PTV dose specifications:~GTVnx: 70 Gy GTVnd: 66-70 Gy (reducible to 63 Gy for suspicious small nodes) CTV1: 60-62 Gy CTV2: 54-56 Gy All treatments will employ simultaneous integrated boost (SIB) intensity-modulated radiotherapy delivered once daily, 5 fractions per week."
224077737|NCT07177443|DRUG|Serplulimab|Serplulimab will be used in the induction phase for 3 cycles and the maintenance phase for 14 cycles.
224077738|NCT07177443|DRUG|Cisplatin|On days 64 and 85, patients will receive cisplatin chemotherapy at a dose of 100 mg/m² via intravenous infusion.
224077739|NCT07179107|OTHER|Baseline - week 1|Habitual fluid intake during week 1
224077740|NCT07179107|OTHER|Low Water Intake - week 2|Low water intake as described by the protocol
224077741|NCT07179107|OTHER|Moderate Water Intake - week 3|Moderate Water Intake - Week 3
224077742|NCT07179107|OTHER|Adequate Water Intake - week 4|Adequate Water Intake - week 4
224077743|NCT07179107|OTHER|Washout - week 5|Washout - week 5
224077744|NCT07179107|OTHER|Low fluid intake with non caloric sweeteners - Week 6|Low fluid intake with non caloric sweeteners - Week 6
224077745|NCT07179107|OTHER|Moderate fluid intake with non caloric sweeteners - Week 7|Moderate fluid intake with non caloric sweeteners - Week 7
224077746|NCT07179107|OTHER|Adequate fluid intake with non caloric sweeteners - Week 8|Adequate fluid intake with non caloric sweeteners - Week 8
224077747|NCT07177391|OTHER|Discontinuous subcostal echocardiographic cardiac output assessment|Right Ventricular Outflow Chamber Diameter (RVOD) and Left Ventricular Outflow Chamber Diameter (LVOD) assessments via subcostal approach
224077748|NCT07179341|PROCEDURE|Thymectomy for thymic carcinoma|Thymectomy for thymic cancer
224077749|NCT07179042|DRUG|Placebo|Placebo tablets will be dispensed to the participants for 119-days.
224077750|NCT07179042|DRUG|Metformin|Metformin tablets will be dispensed to the participants for 119-days.
224077751|NCT07178561|OTHER|Exercises for lower back|"1. Physiotherapy Modalities (Preparation):~   Hot Pack Therapy: Applied to the lumbar region for 10-15 minutes before exercises to reduce muscle stiffness and pain.~   Interferential Therapy (IFT): Applied to the lower back for 10-15 minutes to decrease pain and improve circulation.~2. Exercise Program (30-40 minutes per session, 3 times/week):~A. Lumbar Stabilization Exercises:~B. Core Strengthening Exercises:"
224077752|NCT07178561|OTHER|Exercises and Physical Activity Program|"1. Frequency \& Duration:~   Frequency: 3 days per week~   Duration: 30 to 40minutes per session~   Intensity: Low to moderate (RPE 11-13 on Borg scale; light to somewhat hard)~2. Warm-Up (5 minutes):~   Gentle walking on treadmill at slow speed (1.5-2.5 km/h)~   Light dynamic stretches for lower back, hips, and legs~3. Main Activity~   A. Treadmill Walking:~   Speed: Comfortable pace for walking without pain~   Incline: Start flat, increase slightly (1-2%) if tolerated~   Goal: Promote cardiovascular endurance and safe weight-bearing activity~   B. Stationary Bicycle:~   Duration: 10-15 minutes~   Resistance: Low to moderate (enough to feel effort but no pain)~4. Cool-Down (5 minutes):~   Slow treadmill walking or easy pedaling on the bike~   Gentle stretches: hamstrings, hip flexors, lumbar rotation~5. Progression:~based on patient tolerance Gradually in"
224077753|NCT07178561|OTHER|Advices|Advices
224077754|NCT07177768|OTHER|Prolonged walking|walking on a treadmill for 60 minutes
224077755|NCT07179159|DRUG|14-day vonoprazan-amoxicillin dual therapy|vonoprazan 20mg bid + amoxicillin 1000mg bid
224077756|NCT07179159|DRUG|14-day vonoprazan-amoxicillin-levofloxacin-bismuth quadruple therapy|vonoprazan 20mg bid + amoxicillin 1000mg bid + levofloxacin 500mg qd + bismuth 220mg bid
224077757|NCT07179159|DRUG|14-day vonoprazan-amoxicillin-clarithromycin-bismuth quadruple therapy|vonoprazan 20mg bid + amoxicillin 1000mg bid + clarithromycin 500mg bid + bismuth 220mg bid
224077758|NCT07178522|BIOLOGICAL|Envacgen®|Subjects are to receive a 0.5 mL IM injection of Envacgen®. Study drug is administered on Day 1 and Day 57 of the study.
224077759|NCT06351592|DRUG|ALN-SOD|Administered by intrathecal (IT) injection
224077760|NCT06351592|OTHER|Diluent|Administered by IT injection
224077761|NCT06351592|DRUG|Placebo (PB)|Administered by IT injection
224077762|NCT02211391|OTHER|Casein Protein|The effect of casein protein consumed within 30 minutes of sleep on overnight lipolysis and next morning metabolism and appetite will be examined
224077763|NCT02211391|OTHER|Non-caloric placebo|The effect of a non-caloric placebo consumed within 30 minutes of sleep on overnight lipolysis and next morning metabolism and appetite will be examined
224077764|NCT00664248|DRUG|IDP-110|Topical application for 12 weeks
224077765|NCT00664248|DRUG|Clindamycin|Topical application for 12 weeks
224077766|NCT00664248|DRUG|Benzoyl peroxide|Topical application for 12 weeks
224077767|NCT00664248|DRUG|Vehicle|Topical application for 12 weeks
224077768|NCT00805740|DRUG|Active anidulafungin|Subjects in this arm will receive active anidulafungin and placebo caspofungin
224077769|NCT00805740|DRUG|Active Caspofungin|Subjects in this arm will receive active caspofungin and placebo anidulafungin
224077770|NCT04222517|PROCEDURE|Incisional hernia repair by the mesh implant in sublay retromusuclar position|"Incisional hernia repair using mesh prolene implant in sublay retromuscular position. Dissect the posterior rectus sheets, suture them continuously, formed a retromuscular space in which the standard prolene mesh implant is installed. Perform hemostasis. Install the drainage tube into the retromuscular space.~After that, the anterior rectus sheets were sutured, hemostasis was performed, a drainage tube was installed in the subcutaneous tissue. Drainage tubes were connected to the UnoVac vacuum aspiration system (Unomedical, Denmark)."
224077771|NCT04222517|PROCEDURE|Incisional hernia repair by the mesh implant in sublay retromusuclar position with using a local hemostatic Hemoblock|"Incisional hernia repair using mesh prolene implant in sublay retromuscular position. Dissect the posterior rectus sheets, suture them continuously, formed a retromuscular space in which the standard prolene mesh implant is installed. Perform hemostasis. Install the drainage tube into the retromuscular space. Used a local hemostatic Hemoblock 15 ml in this space.~After that, the anterior rectus sheets were sutured, hemostasis was performed, a drainage tube was installed in the subcutaneous tissue. Used a local hemostatic Hemoblock 15 ml in subcutaneus space. Drainage tubes were connected to the UnoVac vacuum aspiration system (Unomedical, Denmark)."
224077772|NCT05636540|DRUG|[18F]FluorThanatrace ([18F]FTT)|A pre-treatment 18F-FluorThanatrace (\[18F\]FTT) positron emission tomography/computed tomography (PET/CT) scan will be done prior to surgery or systemic therapy.
224077773|NCT05226260|BEHAVIORAL|Default Duration order Panel|The SSTI order panel will present itself when a provider types in either a drug name or diagnosis (cellulitis, impetigo, etc). Clinicians in control clinics will have access to a basic order panel which will include diagnosis and corresponding antibiotic of choice. Clinicians in intervention clinics will have access to order panels with the following additional components: prepopulated order duration fields that default to the recommended treatment duration.
224077774|NCT01475123|DRUG|Nicorandil|15mg per day
224077775|NCT05116449|BEHAVIORAL|Quality of life questionnaires|Different quality of life questionnaires : FACT-B, EORTC QLQ-C30, QIC, BRIEF COPE, HADS, QSSS-C
224077776|NCT03317860|DEVICE|Sham tDCS|"Sham tDCS will be delivered for 30 minutes in conjunction with repetitive task-specific practice for the arm/hand. tDCS is a form of noninvasive brain stimulation. Electrodes will be placed on the scalp but in the sham condition they will not deliver direct current (2mA). Sham tDCS will be delivered for 30 minutes in conjunction with repetitive task-specific practice for the arm/hand.~Repetitive task-specific practice (RTP). Participants will practice using their paretic arm/hand to complete functional movements during the 30 minute train"
224077777|NCT03317860|DEVICE|Active tDCS|"Sham tDCS will be delivered for 30 minutes in conjunction with repetitive task-specific practice for the arm/hand. tDCS is a form of noninvasive brain stimulation. Electrodes will be placed on the scalp but in the sham condition they will not deliver direct current (2mA). Sham tDCS will be delivered for 30 minutes in conjunction with repetitive task-specific practice for the arm/hand.~Repetitive task-specific practice (RTP). Participants will practice using their paretic arm/hand to complete functional movements during the 30 minute train"
224077778|NCT03479632|BEHAVIORAL|Aerobic walking program|Participants will make 24 visits over an 8 week period, having 3 sessions per week. Each session will last about one hour.
224077779|NCT03479632|BEHAVIORAL|Standard physical therapy|Participants will receive standard care they normally would after a stroke.
224077780|NCT05434832|BEHAVIORAL|Virtual Reality|Distraction method
224077781|NCT05434832|BEHAVIORAL|Local cold-vibration|Distraction method
224077782|NCT00361738|DRUG|AVE2268|
224077783|NCT04702009|DRUG|Anti-PD-1/PD-L1 Monoclonal Antibody，Chemotherapy|Anti-PD-1/PD-L1 monoclonal antibody (approved anti-PD-1/PD-L1 monoclonal antibody)；albumin paclitaxel/docetaxel + carboplatin (albumin paclitaxel 130mg/m2, d1 d8, Docetaxel 75mg/m2, carboplatin AUC=5, d1, every 21 days, 4 cycles of chemotherapy; immunotherapy no more than 2 years)
224077784|NCT04702009|DEVICE|Bronchoscopy-assisted Interventional Therapy|Bronchoscopy-assisted interventional therapy (1 time before chemotherapy or 2 times before chemotherapy and before the third cycle of treatment)
224077785|NCT04033367|DRUG|Dupilumab|Pharmaceutical form: solution for injection Route of administration: subcutaneous
224077786|NCT04033367|DRUG|Placebo|Pharmaceutical form: solution for injection Route of administration: subcutaneous
224077787|NCT02723201|DRUG|TAK-020 Captisol Oral Solution|TAK-020 solution.
224077788|NCT02723201|DRUG|TAK-020 CCT|TAK-020 co-crystal tablet
224077789|NCT02723201|DRUG|TAK-020 SDT|TAK-020 Solid dispersion tablet.
224077790|NCT02723201|DRUG|TAK-020 IRT|TAK-020 immediate release tablet.
224077791|NCT02723201|DRUG|TAK-020 CCT|TAK-020 co-crystal tablet.
224077792|NCT02723201|DRUG|TAK-020 Solid Formulation|TAK-020 solid formulation
224077793|NCT03472560|DRUG|Avelumab (MSB0010718C)|IV treatment: Avelumab administered at 800 mg IV every two weeks
224077794|NCT03472560|DRUG|Axitinib (AG-013736)|Oral treatment: Axitinib given 5 mg PO BID
224077795|NCT01597063|DEVICE|SEQureDx Trisomy Test|Plasma samples obtained from maternal blood will be tested using the SEQureDx Trisomy Test, an in vitro diagnostic test that measures circulating cell-free fetal DNA. The test detects the relative quantity of chromosome 21, which is associated with trisomy 21.
224077796|NCT01946178|DEVICE|Mirabilis High-Intensity Focused Ultrasound Treatment System|The intervention consists of a treatment session with the device, during which focused ultrasound energy is applied across the intact abdominal wall to ablate appropriately selected uterine fibroids under ultrasound imaging guidance.
224077797|NCT05467891|DRUG|Ribociclib|400 mg orally once daily Days 1-21 (28 day Cycle)
224077798|NCT05467891|DRUG|Fulvestrant|500 mg intramuscularly on Day 1 and 15 of Cycle 1 then Day 1 of Cycle 2+
224077799|NCT05467891|DRUG|Anastrozole|1 mg orally once daily
224077800|NCT05467891|DRUG|Letrozole|2.5 mg orally once daily
224077801|NCT05467891|DRUG|Exemestane|25 mg orally once daily
224077802|NCT02953808|DRUG|Placebo|0.9% weight by volume (w/v) saline solution for intravenous infusion over 1 hour (in Cohort 1) or over 15 hours (in Cohort 2).
224077803|NCT02953808|DRUG|GSK2315698|200 mg/mL stock solution for intravenous infusion over 1 hour (in Cohort 1) or over 15 hours (in Cohort 2). The stock solution will be diluted to obtain dosage levels of 10 mg/hr, 20 mg/hr, or 40 mg/hr.
224077804|NCT05374707|BEHAVIORAL|MOTIVATIONAL INTERVIEWING|Motivational interviewing is a form of interview conducted with a patient-centered approach in order to enable people to discover and solve the obstacles to behavior change.
224077805|NCT00485888|DRUG|Cipralex|10-20mg; one per day
224077806|NCT00485888|DRUG|Placebo|Matched to Cipralex
224077807|NCT06010914|OTHER|No Intervention|"Following the manner of observational study, no intervention will be provided in the study.~The decision on the dose and duration of treatment is solely at the discretion of the treating physician, based on the recommendations written in the local product information."
224077808|NCT04997577|BEHAVIORAL|Auditory-cognitive training paradigm|The investigators developed an American English version of the Nottingham (UK) PLUS training paradigm in which listeners are asked to focus and listen to one speaker while ignoring another speaker. The paradigm is designed to optimally enhance the possibility of benefit: an adaptive procedure is employed to train each individual at their own level to make the task challenging. A short-term memory component, in which listeners are asked to remember what a designated speaker said two sentences prior, was added to the auditory training paradigm to make the task more challenging. Participants will be asked to recall the keywords of the to-be-attended speaker. The sentences will be presented in a two-down one-up adaptive procedure in which the ratio of the levels of the to-be-attended and to-be-ignored speaker will be adjusted based on the correctly recalled key words.
224077809|NCT04997577|BEHAVIORAL|Auditory training paradigm|The investigators developed an American English version of the Nottingham (UK) PLUS training paradigm in which listeners are asked to focus and listen to one speaker while ignoring another speaker. The paradigm is designed to optimally enhance the possibility of benefit: an adaptive procedure is employed to train each individual at their own level to make the task challenging. Participants will be asked to recall the keywords of the to-be-attended speaker. The sentences will be presented in a two-down one-up adaptive procedure in which the ratio of the levels of the to-be-attended and to-be-ignored speaker will be adjusted based on the correctly recalled key words.
224077810|NCT06355570|OTHER|Personal Pictures|Digital photos will be shown continuously at the patient's bedside for 12 hours a day (between 8 am to 8 pm).
224077811|NCT06355570|OTHER|Family Videos|Family-recorded videos will be played three times at specific hours of the day - 9 am, 2 pm and 7 pm - throughout patient stay in the ICU
224077812|NCT06355570|OTHER|Family Videos - Intervention as required|The last video shown will be re-played upon patient request and/or if patients develop ICU delirium.
224077813|NCT01082315|DRUG|Erbitux (Cetuximab)|In subjects with mCRC, cetuximab will be used in combination with chemotherapy or as a single agent according to the approved national label as in routine clinical practice. Cetuximab 2mg/ml will be administered intravenously via in-line filtration with an infusion pump, gravity drip or a syringe pump. For the initial dose, the recommended infusion period is 120 minutes and for the subsequent weekly doses, the recommended infusion period is 60 minutes.
224077814|NCT04031079|DEVICE|Wearable tech with feedback|an armwrist device measuring physical activity level. The user will receive information about their physical activity level through their smartphone
224077815|NCT04031079|DEVICE|Wearable tech without feedback|an armwrist device measuring physical activity level, no reporting back to the user
224077816|NCT04031079|BEHAVIORAL|Rehabilitation program|traditional inpatient rehabilitation program for overweight and obesity (lifestyle change program)
224077817|NCT02619500|OTHER|Home Exercise Program|A standardized home exercise program will be given to subjects that will include active range of motion of the cervical and thoracic spine and deep cervical flexion endurance exercises.
224077818|NCT02619500|OTHER|Patient advice, encouragement, and education|Therapists will provide each subject with advice and education pertaining to their condition as well as encouragement towards reducing pain and disability.
224077819|NCT02619500|OTHER|Thrust Manipulation|High velocity low amplitude (HVLA) thrust performed at or near the end range of a targeted segment in both the cervical and thoracic spine
224077820|NCT02619500|OTHER|Non-thrust Mobilizations|Repetitive and rhythmic accessory passive movements applied with either small or large amplitude at a targeted segment to both the cervical and thoracic spine
224077821|NCT01030692|DRUG|Placebo|The placebo groups will receive the same dosage throughout the study.
224077822|NCT01030692|DRUG|Rivastigmine 3 mg|The 3 mg rivastigmine group will receive 3 mg rivastigmine only in the evening of Day 1, 3 mg in the morning and 0 mg in the evening of Days 2-9, and 3 mg in the morning of Day 10.
224077823|NCT01030692|DRUG|Huperzine A 0.4 mg|The 0.4 mg HupA group will receive 0.2 mg HupA only in the evening of Day 1, 0.2 mg in the morning and evening of Days 2-9, and 0.2 mg in the morning of day 10.
224077824|NCT01030692|DRUG|Rivastigmine 6 mg|The 6 mg rivastigmine group will receive 3 mg rivastigmine only in the evening of Day 1, 3 mg in the morning and 0 mg in the evening of Days 2-5, 3 mg in the morning and evening of Days 6-9, and 3 mg in the morning of Day 10.
224077825|NCT01030692|DRUG|Huperzine A 0.8 mg|The 0.8 mg HupA group will receive 0.2 mg HupA only in the evening of Day 1, 0.2 mg in the morning and evening of Days 2-5, 0.4 mg in the morning and evening of Days 6-9, and 0.4 mg in the morning of Day 10.
224077826|NCT03590509|OTHER|Telemedicine Program|"A telemedicine platform (Zoom) will be added to comprehensive care (CC) to be used by the CC providers to make observations in the home to augment care, help address acute problems remotely at any hour, better coordinate care with healthcare personnel, and thereby reduce clinic visits, ED visits, and hospitalizations. Home visits\* will be conducted by a nurse home visitor whenever considered likely to be beneficial for any of the CMC and at least once by the assigned CC provider immediately following enrollment of children with chronic respiratory failure requiring mechanical ventilation at home.~\*After the approval of the study protocol, the home-visitation component of the integrated intervention was deemed not to be feasible with the available resources and personnel and has was not implemented"
224077827|NCT03590509|OTHER|Usual Comprehensive Care|Comprehensive care (CC) provided in an enhanced medical home to assure effective care at any hour for or children with medical complexity
224077828|NCT04461990|PROCEDURE|Multidisciplinary cooperative comprehensive treatment|Local surgery, radiation therapy, and systemic therapy such as chemotherapy, endocrine and molecular targeting.
224077829|NCT03705182|DEVICE|Fluorescence visualization (feedback)|UVA-light will illuminate the skin of head, neck, arms and hands and the fluorescent areas will be recorded and quantified by a computer vision system each time the participant leaves a production area. The intervention group will be shown the fluorescent areas on their skin, the control group will not have this opportunity
224077830|NCT04010669|DRUG|Somatostatin|2 amp of somatostatin at 1000ml normal saline solution in continuous 24-hour infusion for 5 days
224077831|NCT04010669|DRUG|Placebo|24 hours infusion of 1000ml Normal Saline solution 0.9%
224077832|NCT05307315|OTHER|listening to music|The experimental group will listen to Turkish instrumental music with headphones for 30 minutes.
224077833|NCT00491179|DRUG|Pegylated interferon alfa-2a and ribavirin|Pegylated interferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 135 ug/week plus ribavirin (Copegus, F. Hoffman-LaRoche) 200 mg/day for 48 weeks
224077834|NCT00491179|DRUG|Pegylated interferon alfa-2a and ribavirin|Pegylated interferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 135 ug/week plus ribavirin (Copegus, F. Hoffman-LaRoche) 200 mg/day for 24 weeks
224077835|NCT02480933|PROCEDURE|Bilateral mastectomy|Bilateral mastectomy and imaging study of cadaveric breasts
224077836|NCT02480933|OTHER|Biopsy|Biopsy of BI-RADS 3 and superior lesions
224077837|NCT01505894|DRUG|BI 409306|Film-coated tablet
224077838|NCT01505894|DRUG|Placebo|Film-coated tablet
224077839|NCT04248205|DRUG|Ketamine|Standard general anesthesia PLUS ketamine will be given for post-operative analgesia
224077840|NCT00569894|BIOLOGICAL|FLuMist|One or two vaccinations with FluMist depending on prior vaccination status.
224077841|NCT00569894|BIOLOGICAL|TIV (Injection)|One or two injections of TIV depending on previous status.
224077842|NCT00569894|OTHER|Unvaccinated Control|no vaccine
224077843|NCT01001702|DRUG|Aripiprazole|Flexible dose between 5 mg and 30 mg Aripiprazole tablets.
224077844|NCT00424060|DRUG|sagopilone|
224077845|NCT00424060|GENETIC|fluorescence in situ hybridization|
224077846|NCT00424060|GENETIC|gene expression analysis|
224077847|NCT00424060|OTHER|immunohistochemistry staining method|
224077848|NCT00424060|OTHER|laboratory biomarker analysis|
224077849|NCT00424060|OTHER|pharmacological study|
224077850|NCT04269395|DRUG|MAL Cream|No intervention will be administered as a part of this study. Participants who received MAL cream in RD.06.SPR.112199 study will be rolled over in the study.
224077851|NCT04269395|DRUG|Vehicle cream|No intervention will be administered as a part of this study. Participants who received vehicle cream in RD.06.SPR.112199 study and achieved complete response, will be rolled over in the study.
224077852|NCT04361201|PROCEDURE|Ligament plastic surgery|Ligament plastic surgery of ankle under arthroscopy for recurrent instable ankle reason and failure of medical treatment.
224077853|NCT04361201|DIAGNOSTIC_TEST|RMI and ultrasound|RMI examination at 3 months on operated ankle, and 3 CT scan examinations with elastography module will be performed at planned timeframes.
224077854|NCT06323174|DRUG|Cagrilintide|Participants will receive once-weekly cagrilintide subcutaneously.
224077855|NCT06323174|DRUG|Semaglutide|Participants will receive once-weekly semaglutide subcutaneously.
224077856|NCT06323174|DRUG|Placebo|Participants will receive placebo matched to cagrilintide and semaglutide subcutaneously.
224077857|NCT05542862|BIOLOGICAL|SpikoGen vaccine|Recombinant spike protein based Covid-19 vaccine
224077858|NCT05132881|OTHER|Neuvana 2.0 Transcutaneous Auricular Vagal Nerve Stimulation (TaVNS)|The intervention administered is the TaVNS program and the fMRI scans to evaluate changes in the brain. The TaVNS program consists of placing ear buds from the device into each ear. They are initially sprayed once with a small amount of saline that is also provided as part of the TaVNS materials. Once the ear buds are placed in each ear, the test subject will start a preprogramed session of vibrations that will stimulate the vagus nerve. The session will last for 15 minutes and then the subject will take the ear buds out and clean them. They will use the TaVNS program once a day for 3 months.
224077859|NCT05132881|OTHER|Waitlist Control|Baseline imaging and follow up imaging for comparison to the TaVNS health device group at approximately 3 months. The TaVNS intervention is offered after completion of the imaging.
224077860|NCT05132881|OTHER|Healthy Controls: Substudy Group III|fMRI Imaging to evaluate the effects of the functional changes that may occur in the brain while using the TaVNS device during one fMRI session.
224077861|NCT05132881|OTHER|Distressed Workers: Subgroup II|Subgroup II of 10 subjects with distress(all receiving TaVNS) will undergo fMRI scans with the TaVNS system being turned on and off while in the scanner to observe for any immediate effects and to evaluate the effects of the functional changes that may occur in the brain while using the TaVNS device during one fMRI session.
224077862|NCT04971824|PROCEDURE|Physiotherapeutic intervention|The physiotherapy consists in performing visceral manipulation of the pelvic and abdomen organs as well as doing special exercises (volunteers get a handout with instructions on how to exercise). The exercises include ones from the Mojzis´s method, Dynamic neuromuscular stabilisation, yoga or other therapeutic methods used by physiotherapists.
224077863|NCT00887861|DRUG|Investigational new drug, company code: BGG492|
224077864|NCT00887861|DRUG|Placebo|
224077865|NCT04141657|OTHER|Pharmacogenetic test|Buccal swabs are a relatively non-invasive way to collect deoxyribonucleic acid (DNA) samples for testing. A buccal swab will be performed to collect DNA from the cells on the inside of a subject's cheek for phenotyping of CYP3A4.
224077866|NCT05467748|DRUG|Tulmimetostat|combination of oral tazemetostat and intravenous pembrolizumab treatment for patients with advanced non-small cell lung cancer
224077867|NCT01866007|DRUG|Guselkumab (lyophilized formulation)|Participants will receive a single SC injection of 100 mg guselkumab prepared from lyophilized formulation.
224077868|NCT01866007|DRUG|Guselkumab (liquid formulation with PFS-U)|Participants will receive a single SC injection of 100 mg guselkumab, liquid formulation with PFS-U.
224077869|NCT01866007|DRUG|Guselkumab (liquid formulation with PFS FID)|Participants will receive a single SC injection of 100 mg guselkumab, liquid formulation with PFS FID.
224077870|NCT01866007|DRUG|Guselkumab (liquid formulation)|Participants will receive a single IV infusion of 100 mg guselkumab prepared from liquid formulation.
224077871|NCT03730805|BEHAVIORAL|ASSIST-linked Brief Intervention|The intervention follows the WHO's ASSIST-linked Brief Intervention (Humenik et al., 2012; Humeniuk et al., 2010), a manualized one-session intervention that can be categorised as belonging to the Screening and Brief Intervention approach. It follows the FRAMES model (Bien et al., 1993) and contains techniques from Motivational Interviewing (Miller \& Rollnick, 1991).
224077872|NCT03730805|BEHAVIORAL|Induction of Deliberative Mindset|Based on the Mindset Theory of Action Phases (Gollwitzer \& Keller, 2016), a brief writing task (writing down pros and cons for an unresolved personal problem of the participant's own choice) is used to induce a specific psychological state in which the individual is cognitively open to process new information.
224077873|NCT03730805|BEHAVIORAL|Induction of Implemental Mindset|Based on the Mindset Theory of Action Phases (Gollwitzer \& Keller, 2016), a brief writing task (writing down steps necessary to implement a personal decision of the participant's choice that has not yet been put into practice) is used to induce a specific psychological state in which the individual is cognitively not open to process new information.
224077874|NCT06149858|PROCEDURE|hernioplasty|ventral hernia repair with mesh
224077875|NCT04991298|DRUG|Oral premedication|Oral anesthesia premedication for congenital Cardiac surgery
224077876|NCT04369898|OTHER|Image analysis/ Central vein detection|Image analysis/ Central vein detection will be performed using a fully automated approach based on an ensemble of 3D convolutional neural Networks. The method is applied to T1w, T2w and T2\*w data . Results will be manually reviewed by 2 experts in CVs detection. MRI data must have been collected at 3 Tesla (3T) between 1990 and 2020 and must include T1 w, T2 w, T2-star based sequence (CVs detection).
224077877|NCT04369898|OTHER|Image analysis/ Automatic cortical lesion detection|Image analysis/ Automatic cortical lesion detection will be performed by using a convolutional neural network-based method. MRI data must have been collected at 3T between 1990 and 2020 and must include Double inversion recovery (DIR)/Phase-Sensitive Inversion Recovery (PSIR)/Magnetization Prepared - 2- RApid Gradient Echo Gradient Echo (MP2RAGE) (eventually also high spatial resolution Magnetization Prepared - RApid Gradient Echo (MPRAGE)) for cortical lesion detection.
224077878|NCT02101970|DIETARY_SUPPLEMENT|Omega-3 Fatty Acids|Amber 4020 Ethyl Ester (EE) 1000 mg omega-3 capsule contains 420 mg of EPA and 210 mg of DHA both as the ethyl esters (380 mg EPA and 190 mg DHA)
224077879|NCT02101970|OTHER|Placebo Capsule|
224077880|NCT02101970|OTHER|Diet and Exercise|Increasing physical activity required over 6 month period to be tracked by a Fitbit. Diet based on caloric intake and eating approved foods.
224077881|NCT00065728|DRUG|Anecortave Acetate (AL-3789) Sterile Suspension, 30 mg/mL|One 0.5 mL injection of 30 mg/mL Anecortave Acetate sterile suspension into the posterior juxtascleral depot at 6 month intervals for 18 months
224077882|NCT06541873|OTHER|Clinical and gait evaluation|The dual-task conditions to be assessed during gait performance will include: counting backwards by 3 (executive simple task); counting backwards by 7 (executive complex task); mnemonic recall of the Rey's Auditory Verbal Learning Test (RAVLT). Performance scores will be correlated with cognitive status and clinical features. Data will be collected at the baseline (i.e., only) visit within the enrollment timeframe of 3 years from study initiation.
224077883|NCT00003209|BIOLOGICAL|bleomycin sulfate|
224077884|NCT00003209|DRUG|cisplatin|
224077885|NCT00003209|DRUG|fluorouracil|
224077886|NCT00003209|DRUG|ifosfamide|
224077887|NCT00003209|DRUG|methotrexate|
224077888|NCT00003209|DRUG|mitomycin C|
224077889|NCT00003209|DRUG|vinblastine sulfate|
224077890|NCT00003209|DRUG|vindesine|
224077891|NCT00003209|RADIATION|radiation therapy|
224077892|NCT00781157|DRUG|Phenylephrine bolus|"The initial dose of phenylephrine will be 100 mcg, a dose within the clinical range currently in use at our center. The subsequent dose is based upon the response of the preceding subject in the usual up-and-down method (UDM), which is outlined in the data analysis section of the protocol. The dosing changes will be in increments of 20 micrograms. A successful response to this dose will be entered into a spreadsheet, designed by our statistician, which will determine the subsequent dose based upon the UDM. If a failure is observed in the previous subject, the dose is stepped up in the next subject. If a success is observed the next subject is randomized with probability of 0.10 to the next lower dose and with probability 0.90 to the same dose."
224077893|NCT00191841|DRUG|gemcitabine|
224077894|NCT00191841|DRUG|Cisplatin|
224077895|NCT02100605|DEVICE|Phytosun, decongestant, nasal spray|one time application of the nasal spray
224077896|NCT00094757|DRUG|Comparator: sitagliptin 100 mg|sitagliptin 100 mg oral tablet once daily for 54 weeks
224077897|NCT00094757|DRUG|Comparator: sitagliptin 200 mg|sitagliptin 200 mg (2- 100 mg oral tablets) once daily for 54 weeks
224077898|NCT00094757|DRUG|Comparator: placebo|placebo oral tablet once daily during Phase A (Weeks 0-18)
224077899|NCT00094757|DRUG|Comparator: pioglitazone|pioglitazone 30 mg oral tablet once daily during Phase B (Weeks 18-54)
224077900|NCT02758457|DEVICE|dental crowns|
224077901|NCT06485154|DRUG|TLD - Tenofovir Disoproxil Fumarate / Lamivudine / Dolutegravir|Dolutegravir, lamivudine and tenofovir disoproxil fumarate tablets, a combination of dolutegravir (integrase strand transfer inhibitor \[INSTI\]), lamivudine, and tenofovir disoproxil fumarate (both nucleoside reverse transcriptase inhibitors), is indicated as a complete regimen for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 35 kg
224077902|NCT01437774|DEVICE|thrombectomy (ReStore or Merci)|Each arm will use either ReStore or Merci as the primary thrombectomy device
224077903|NCT03461133|OTHER|Intervention|The emergency notification system is linked to a paging system to the surgeon in charge and to the Hospital Medical Emergency Team. Depending on individual Multiparameter Early Warning Score communication protocols are activated.
224077904|NCT00090545|DRUG|BAY 43-9006|400 mg BAY 43-9006 orally twice daily in 28 day cycles.
224077905|NCT05412914|DRUG|Remimazolam infusion|Remimazolam infusion for anesthesia induction
224077906|NCT05412914|DRUG|Propofol infusion|Propofol infusion for anesthesia induction
224077907|NCT03797105|BEHAVIORAL|School-Based Obesity Intervention (FLOW)|The intervention consisted of nutrition lessons based on the traffic light diet, circuit-based physical activity, behavior modification techniques (token economy system, goal setting, self-monitoring), and parental involvement (materials sent home and monthly parent meetings). 80% of time was spent on physical activity and 20% was spent on nutrition. Behavior modification was incorporated into both physical activity and nutrition time. Specifically, instruction and activity time during PE class lasted approximately 40 minutes.
224077908|NCT03145298|BIOLOGICAL|Allogeneic Human Cardiosphere-Derived Stem Cells|Human Allogeneic Cardiosphere-Derived Cells is a biologic product consisting largely of cells grown from donated human heart muscle tissue
224077909|NCT03145298|BIOLOGICAL|Placebo|For use in Phase 1b - Double-blind randomized control portion of the study
224077910|NCT00374738|BEHAVIORAL|Guided Imagery for Trauma (GIFT)|Guided Imagery for Trauma (GIFT) - music and voice narration over a 12-week intervention. The control intervention included a relaxing music audio (the same music used in the guided imagery audio but without the narrative voiceover), PDA to log audio use, orientation and weekly phone consults, but did not have access to the patient advocate or to the guided imagery instructions provided on the GIFT audio.
224077911|NCT04697485|DRUG|Bumetanide 0.5 mg, dapaglifozin 5 mg, eplerenone 25 mg|"Low-Dose, Triple Polydiuretic Therapy (LDTPT) Treatment consists of:~* Loop diuretic (bumetanide 0.5 mg)~* Mineralocorticoid receptor antagonist (eplerenone 25 mg)~* Sodium-glucose co-transporter 2 inhibitor (SGLT2i): Farxiga® (dapagliflozin) 5 mg"
224077912|NCT06287320|RADIATION|concurrent or sequential chemoradiotherapy|Thoracic radiation therapy(with the prescribed dose of 50-70 Gy), concurrently or sequentially combined with platinum-based doublet chemotherapy.
224077913|NCT06287320|DRUG|Immunotherapy|anti-PD-1/anti-PD-L1 immune checkpoint inhibitors
224077914|NCT03078465|DRUG|Ticagrelor|Daily administration of ticagrelor 180mg for 12 months
224077915|NCT03078465|DRUG|Clopidogrel|Daily administration of clopidogrel 150mg for 12 months
224077916|NCT04480177|DEVICE|foot insole|the subject was instructed to wear foot insole for 8 hours.
224077917|NCT04480177|OTHER|short foot exercise|the subject was instructed to perform exercise once a day 30 repetitions.
224077918|NCT04536883|PROCEDURE|microscopy confocal|"At this stage, the confocal microscopy procedure begins:~Taking pictures for post-procedure analysis in 4 different territories. For each territory, the investigator need to get a snapshot of a vascular structure and a snapshot of an alveolus.~Analysis per procedure: the same operator analyzes the alveoli deemed to be representative in real time. It determines the presence of intra-alveolar inflammatory cells and answers the question of the main criterion: possible interpretation in confocal microscopy? YES / NO, the clinical researcher immediately notes the answer in the CRF. Based on this per-procedure analysis, if he deems the interpretation possible, the operator declares if he concludes that pulmonary inflammation is present YES / NO, the response is noted immediately in the CRF.~The fibroscopy procedure is then resumed as usual in the department, namely:"
224077919|NCT00356642|DRUG|GW842470X|GW842470X will be available as a yellow smooth water-in-oil cream.
224077920|NCT00356642|DRUG|Placebo|GW842470X matching placebo will be available as a yellow smooth water-in-oil cream.
224077921|NCT04317274|BEHAVIORAL|Good high cholesterol video|The short video illustrated key components of a high quality shared decision making conversation between a doctor and patient actor around treatment of high cholesterol.
224077922|NCT04317274|BEHAVIORAL|Poor high cholesterol video|The short video illustrated a typical conversation between a doctor and patient actor that did not cover key aspects of share decision making around treatment of high cholesterol.
224077923|NCT04317274|BEHAVIORAL|Good colon cancer screening video|The short video illustrated key components of a high quality shared decision making conversation between a doctor and patient actor around screening for colorectal cancer.
224077924|NCT04317274|BEHAVIORAL|Poor colon cancer screening video|The short video illustrated a typical conversation between a doctor and patient actor that did not cover key aspects of share decision making around screening for colorectal cancer.
224077925|NCT06400888|OTHER|needle-free subcutaneous injector for Mecbl|needle-free subcutaneous injector for Mecbl
224077926|NCT06400888|OTHER|intramuscular injection of Mecbl|intramuscular injection of Mecbl
224077927|NCT00006023|DRUG|capecitabine|
224077928|NCT03259945|OTHER|Data collection|demographic and clinical data
224077929|NCT03259945|OTHER|Review of ECGs|nature and frequency of proven conduction disorders
224077930|NCT06131619|OTHER|assesment of cognitive parameters with DLOTCA-G|All three groups were evaluated once with the DLOTCA-G, a cognitive assessment battery.
224077931|NCT01640457|DRUG|NOVOCART® Disc plus|Autologous Disc Chondrocyte Transplantation System (ADCT)
224077932|NCT01640457|DEVICE|NOVOCART® Disc basic|ADCT (Media with no active cell component)
224077933|NCT02568046|DRUG|Sym004|Sym004 is a 1:1 mixture of 2 monoclonal antibodies (mAbs), which bind specifically to 2 non-overlapping epitopes of the epidermal growth factor receptor (EGFR).
224077934|NCT02568046|DRUG|FOLFIRI|The standard FOLFIRI regimen consists of Irinotecan (180 mg/m\^2 IV, infused over 60-90 minutes) concurrently with Folinic Acid (400 mg/m\^2 IV, infused over 120 minutes) followed by 5-FU (400 mg/m\^2 IV bolus, then 2400 mg/m\^2 infused over 46 hours).
224077935|NCT03029975|BEHAVIORAL|Resistance Training Exercise|Participants will undergo 10 weeks of progressive resistance exercise training while following their randomly assigned nutritional intervention.
224077936|NCT03029975|BEHAVIORAL|Beef Protein Consumption|Following each resistance training sessions, participants will consume either a 3oz or 6oz beef patty (corresponding to the randomly assigned nutritional intervention group). Participants will also be provided with beef protein powder and beef snack bars to help them achieve their assigned protein goals during the intervention period.
224077937|NCT05697510|DRUG|Siltuximab|Administration of siltuximab at day 8 of induction following a classical induction; 3 dose levels : 7, 9 and 11mg/kg
224077938|NCT01157039|DIETARY_SUPPLEMENT|Glutamine|Glutamine- During the first cycle of oxaliplatin based combination therapy (mFOLFOX 6 or XELOX) no patient will receive glutamine. At cycle 2, patients will be randomized to receive for 6 days either : Glutamine 30g/day during cycle 2 and glutamine 40g/day during cycle 3 (ARM A) or glutamine 40g/day at cycle 2 and glutamine 30g/day at cycle 3 (Arm B).
224077939|NCT03403192|DEVICE|EZ-Blocker|"The EZ-Blocker essentially functions as a bronchial blocker with a 7-Fr shaft with two separate occlusive balloons coming off this shaft in a Y configuration designed to rest on the carina. Once anchored in place the operator can choose to inflate one of the two occlusive balloons to isolate one main stem bronchus or the other. According to the manufactures recommendations the EZ-blocker is placed through a Y-piece adaptor included with the blocker kit. A flexible fiberoptic bronchoscope (FFB) is placed in a separate limb of this Y-piece and this fed through along side the EZ-blocker to visualize and confirm placement of the of the BB. The balloon is then inflated typically under direct vision to occlude that bronchus thus isolating that lung hopefully achieving full lung isolation."
224077940|NCT03403192|DEVICE|DLT|A Double Lumen Tube (DLT) is made of two small-lumen endotracheal tubes of unequal length fixed side by side. The shorter tube ends in the trachea while the longer tube is placed in either the right or left bronchus to ventilate the right or left lung.
224077941|NCT00732095|BEHAVIORAL|Promoting Self-Change with Ads|Use of Ads immediate or delayed or no ad
224077942|NCT00379795|DRUG|Ranibizumab 0.5 mg|Ranibizumab intravitreal injection 0.5 mg in a single-dose regimen given on an as needed basis no more frequently than every 30 days (no more than 12 injections per year)
224077943|NCT03077568|BEHAVIORAL|My Stress Control|"The web-based program is designed to educate the users in how stress can affect their health, provide tools to handle stress and also educate the users in a problem-solving method to prevent and manage stress-related problems in the future.~The program is tailored for each user. The stress-management techniques included are: assertiveness training, change negative thinking, pleasant activity scheduling, relaxation, time-management, stimulus control and sleep restriction to improve sleep and physical activity.~Central techniques to support behaivor change in My Stress Controll are encourage intention formulation, specific goal-setting, feedback on performance and reevaluation of goals."
224077944|NCT04717674|DRUG|[18F]Fluoropivalate ([18F]Fluoro-2,2-Dimethylpropionic Acid)|\[18F\]FPIA radiotracer administration
224077945|NCT04717674|PROCEDURE|PET/CT|PET/CT scan
224077946|NCT04702646|DRUG|Bowel preparation before colonoscopy|one day liquid diet will be administered to every patient included in the study and: split-dose bowel preparation with 4 Liters of Polyethylene glycol solution, 2 Liters of PEG-Ascorbic acid or 2 Liters Picosulfate.
224077947|NCT04702646|PROCEDURE|Colonoscopy|colonoscopy will be performed to every patient included in the study
224077948|NCT04849780|DEVICE|ACUVUE Oasys 1-Day|TEST
224077949|NCT04849780|DEVICE|Habitual Lens|Subjects' own Habitual Lenses
224077950|NCT03598855|OTHER|Ischemic Preconditioning|Ischemic preconditioning (IPC) refers to cycles of 5 minutes of upper arm cuff inflation with 5 minute periods of cuff deflations, repeated 4 times.
224077951|NCT04248738|BEHAVIORAL|NEEDS|NEEDS intervention includes assessing patients' social needs and resources (SocNSuppR) and communicating those SocNSuppR to discharge teams
224077952|NCT03254966|DRUG|SHR0302|Oral tablets
224077953|NCT03254966|DRUG|Placebo|Oral tablets
224077954|NCT01868100|OTHER|self-completion questionnaire|
224077955|NCT00876135|DRUG|Ventolin|Ventolin or Placebo will be given before the 4 field tests (2 with ventolin in prevention and 2 with placebo in prevention) and 2 eucapnic voluntary hyperpnoea tests (one preceded by Ventolin and one preceded by Placebo).
224077956|NCT05644366|OTHER|Postural Control Balance Assessment|Postural Stability Testing Each subject was instructed to stand in a static bipedal posture on the MatScan® pressure mat and performed 8 balance tasks.
224077957|NCT00264433|DRUG|ADH -1 (Exherin™)|
224077958|NCT02997592|DEVICE|SpinCare|The burn wound is treated using the SpinCare Systen
224077959|NCT02551159|BIOLOGICAL|MEDI4736|Anti-PD-L1 antibody
224077960|NCT02551159|BIOLOGICAL|Tremelimumab|Anti-CTLA-4 Antibody
224077961|NCT02551159|BIOLOGICAL|MEDI4736+Tremelimumab|
224077962|NCT02551159|BIOLOGICAL|Cetuximab|Monoclonal Antibody
224077963|NCT02551159|DRUG|5-fluorouracil (5FU)|Chemotherapy Agent
224077964|NCT02551159|DRUG|Cisplatin|Chemotherapy agent
224077965|NCT02551159|DRUG|Carboplatin|Chemotherapy Agent
224077966|NCT00359775|BEHAVIORAL|Coping Skills Training|6 session behavioral program
224077967|NCT02284282|DRUG|Spinal injection bupivacaine/morphine|Spinal injection bupivacaine/morphine in laparoscopic surgery
224077968|NCT02284282|DRUG|subcutaneum injection lidocaine|placebo injection
224077969|NCT05204264|BEHAVIORAL|Acceptance and Commitment Therapy (ACT)|This intervention uses techniques based on mindfulness, metaphors and exposition exercises both in imagination and in real contexts.
224077970|NCT05204264|BEHAVIORAL|Mindfulness-based Emotional Regulation (MER)|This intervention includes both formal practices of body scan meditation, standing / sitting Hatha yoga, meditations focused on the breath or other objects of attention, exercises of benevolence or kindness with affection (loving-kindness); as well as informal mindfulness practices in activities of daily living.
224077971|NCT06474559|DEVICE|LMA Protector|LMA Protector will be inserted by a researcher after standard anesthesia induction. The view of the larynx will be assessed using fiberoptic grading scale.Mini bronchoalveolar lavage will be collected before the end of the procedure
224077972|NCT06474559|DEVICE|Endotracheal tube|tracheal intubation will be perform after standard anaesthetic induction. Cormack Lehane will be recorded. Mini bronchoalveolar lavage will be collected before the end of the procedure
224077973|NCT02639585|DRUG|Daclinza and Sunvepra|direct acting antiviral agent against to hepatitis C virus
224077974|NCT00156312|DRUG|Docetaxel|
224077975|NCT00156312|DRUG|Capecitabine|
224077976|NCT05691855|DRUG|89Zr-NY009|Patients will receive a tracer (5-10mg, IV) dose of 89Zr (2-3mCi) labelled NY009
224077977|NCT00268242|DRUG|Gemcitabine Hydrochloride|10 mg/m2/ min IV for 12 hours
224077978|NCT00268242|DRUG|Mitoxantrone Hydrochloride|12 mg/m2/day IV (administer over 30-60 minutes) on Day 1, 2 and 3
224077979|NCT03881995|DRUG|IGlarLixi|Dose titration will be done based on the subjects fasting blood glucose
224077980|NCT03881995|DRUG|Insulin Glargine 100 UNT/ML|Dose titration will be done based on the subjects fasting blood glucose
224077981|NCT00993928|BEHAVIORAL|Home-based sleep intervention|Participants will be asked to practice behaviors consistent with the stimulus control sheet and to read the sleep hygiene booklet.
224077982|NCT03225300|RADIATION|Simultaneous integrated boost|Simultaneous integrated boost (SIB), a field-in-field escalation technique, has been introduced to deliver higher radiation dose to the certain part of target with the same fractionation scheme.
224077983|NCT01359475|PROCEDURE|Acetal crown, LD Caulk ltd, USA|Experimental trial of preformed acetal crowns for primary molars
224077984|NCT03970902|OTHER|Integrated Osteoporosis Care|Complex intervention in family physicians, primary caregivers, patients, informal caregivers. The intervention has a patient-tailored implementation. Family physicians: postgraduate education on osteoporosis management and integrated care, educational material. Primary care stakeholders (nurses, pharmacists, dietitians, physiotherapists): specialist training on patient-support in osteoporosis management with attention towards self-management support (nurses), treatment adherence and administration (pharmacists), fall risk, weight-bearing exercises, balance training and fear of falling (physiotherapists) and anti-inflammatory nutrition with sufficient calcium, vitamin D and protein intake (dietitians). Patients: patient-tailored complex intervention consisting of: education, support consultation(s)/telephones from an osteoporosis nurse, a pharmacist, a physiotherapist and nutritional a dietitian. Informal caregivers: education on supporting osteoporosis self-management.
224077985|NCT03970902|OTHER|Care As Usual|No intervention Patients receive care as usual from their family physician
224077986|NCT04513431|BIOLOGICAL|Anti-CEA-CAR T|T cells modified with CEA targeted chimeric antigen receptor.
224077987|NCT05133011|PROCEDURE|Tongue base reduction surgery|Tongue base reduction surgery which remove the extra soft tissue of the base of the tongue and soft palate in this study
224077988|NCT03146533|DRUG|Fludarabine|Fludarabine 30 mg/m2/day IV for 3 days.
224077989|NCT03146533|DRUG|Cyclophosphamide|patients will receive a standard pre-conditioning regime with cyclophosphamide 0.8g/m2/day IV for 2 days.
224077990|NCT03146533|BIOLOGICAL|CD19 CART|CD19 CART cells will be administered using a split dose on day0(10%), 1(30%), and 2(60%) after completion of the chemotherapy.
224077991|NCT01665144|DRUG|BAF312|0.25, 0.5, 1, and 2 mg film-coated tablets
224077992|NCT01665144|DRUG|Placebo|Film-coated tablets
224077993|NCT02180893|OTHER|Paravertebral Block|Paravertebral nerve block injection
224077994|NCT02180893|OTHER|Placebo Comparator|"No block~Patients who did not receive PVB"
224077995|NCT05080010|DRUG|3 cycles chemotherapy|Chemotherapy:vincristine,1.5mg/m2;carboplatin,560mg/ m2;etoposide,150 mg/ m2.monthly for the first three months.
224077996|NCT00006465|DRUG|capecitabine|Patients receive oral capecitabine twice daily on days 1-5 weekly for 4 weeks. Treatment repeats every 6 weeks in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of irinotecan and capecitabine until the maximum tolerated dose(MTD).
224077997|NCT00006465|DRUG|irinotecan hydrochloride|Patients receive irinotecan IV over 30 minutes once weekly for 4 weeks (one hour after oxaliplatin). Treatment repeats every 6 weeks in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of irinotecan and capecitabine until the maximum tolerated dose(MTD).
224077998|NCT00006465|DRUG|oxaliplatin|Patients receive oxaliplatin IV over 2 hours. Treatment repeats every 6 weeks in the absence of disease progression or unacceptable toxicity.
224077999|NCT05294744|DRUG|N-acetylcysteine|"Day 1: 150 mg/kg in 250ml 5% glucose over 30min + 50mgr/kg in 500ml glucose over 4h + 100mgr/kg in 1000ml glucose over 16h intravenously.~Day 2-14: 100mgr/kg in 1000 ml glucose/24h intravenously. Day 15 until end of corticosteroid treatment: NAC 600mg orally every 24h."
224078000|NCT04598373|BEHAVIORAL|interdisciplinary treatment|Interdisciplinary treatment (IDT) distinguishes itself as an interdisciplinary-coordinated (e.g., physician, occupational therapist, physiotherapist, and psychologist) intervention using a bio-psycho-social view of chronic pain. The MMR continues over a lengthy period with a common goal and generally includes patient education, supervised physical activity, simulated work training, and cognitive behavioural therapy (CBT). The exact composition of these MMR components depends on initial evaluations of the patients health status and furhter follow-up testing. The MMR interventional components can act independently and interdependently, resulting in combined effects due to known and unknown mechanisms; the effects are intended to be greater than the sum of its components.
224078001|NCT06084130|DRUG|Zolpidem|10 milligrams zolpidem contained in white-color opaque medicine capsule
224078002|NCT06084130|DRUG|Placebo|corn-starch contained in identical white-color opaque medicine capsule
224078003|NCT02448511|OTHER|Ozone|ozone gas generated by a generator applied to the affected part for a period of one hour each day under sub atmospheric pressure condition.
224078004|NCT02448511|DEVICE|Placebo|a similar looking device was applied to the affected part for a period of one hour each day under sub atmospheric condition. the device did not produce any gas.
224078005|NCT02448511|OTHER|Conventional treatment|Conventional treatment for ulcers in the form of daily dressings, debridement and antibiotics was administered to both groups
224078006|NCT04198857|BEHAVIORAL|Develop a mobile app that supports self- management and treatment for Nepalese GDM patients|We will use a user-centered design approach to develop a mobile app for GDM (GDM-DH) that matches the needs and technological sophistication of the target users. The goal of the app would be to assist patients in self management of GDM by improving their adherence to the recommended diet and physical activity regimens. The app will be used to collect information such as the carbohydrate consumption, the daily activity status and blood glucose and blood pressure measurements taken at home by the patients. The app will be set up in the phone of the participants and their data will be collected. The participants will be able to assess the usability and feasibility of the app. The app will also help clinicians by generating easily digestible visual displays of patient data and behaviors, which can aid in their clinical decision-making and counseling.
224078007|NCT01478854|RADIATION|Radiation|Patients will be treated to a total dose of 60 Gy with a once daily fractionation schedule of 2 Gy per fraction, administered five days per week. All patients will undergo CT simulation with intravenous contrast. In addition they will undergo MRI simulation with both T1 with gadolinium as well as FLAIR sequences. They will be treated in a supine position using an aquaplast mask system for immobilization. CT image data will be reconstructed in approximately 3 mm slice thickness and manually coregistered with T1 post-gadolinium and FLAIR sequence MRI.
224078008|NCT01478854|DRUG|Chemotherapy|Temozolomide
224078009|NCT02838407|OTHER|BAL fluid sampling|Following routine BAL procedures at the hospital, collection of BAL fluid samples: at least 2 mL, at Day 0.
224078010|NCT02838407|OTHER|Nasopharyngeal swab sampling|1 swab, Day 0
224078011|NCT05713643|PROCEDURE|ESPB Technique|The patient will be in sitting position. The probe will be positioned with longitudinal alignment, 3 cm lateral to the spinous procedure of T8 to obtain a parasagittal view. An echogenic needle will be introduced from the caudal end of the probe and advanced in-plane direction until the needle tip hit the tip of the transverse process. Bupivacaine will be afterwards injected into the erector spinae plane block. Linear spread cranially and caudally below the muscle upon injection will be visualized on the US screen indicating successful block.
224078012|NCT05713643|PROCEDURE|TPVB Technique|The patient will be in sitting position. The probe will be positioned with longitudinal alignment, 3 cm lateral and parallel to 8th spinous process till transverse process, superior costotransverse ligament, and pleura will be visualized then lateral tilt of the probe was done for better visualization of the PVS between the superior costotransverse ligament and the pleura. An echogenic needle was introduced at caudal end of transducer using the in-plane technique till piercing the superior costotransverse ligament . Bupivacaine will be injected into the PVS with downward displacement of the pleura indicating a successful block.
224078013|NCT05713643|PROCEDURE|QLB Technique|"The patient will be in lateral position. The probe will be placed above the iliac crest. The Petit's triangle will be identified. The three abdominal muscles (i.e., the external oblique, internal oblique and transversus abdominus muscles) will be detected. Both the external oblique and internal oblique muscles will be followed posteriorly until the layers of the thoracolumbar fascia appear as a bright hyperechogenic line. The quadratus lumborum muscle appears below to the latissimus dorsi muscle. While performing the quadratus lumborum block, Shamrock sign is identified; the transverse process of L4 appears as a stem whereas the three muscles psoas muscle, quadratus lumborum muscle and erector spinae appear as the leaves. A 22G (50mm) needle was inserted using an in-plane technique along the posterior edge of the ultrasound probe in the anteromedial direction. The needle tip was placed between the quadratus lumborum muscle and the Erector spinae muscle."
224078014|NCT05300516|PROCEDURE|vagus nerve-guided group|The vagus nerve-guided procedure was performed in the following order: (1) find the left crural diaphragm; (2) via the surface of the left crural diaphragm, blunt dissect the left lateral surface of the distal esophagus using Bipolar Forceps, and find posterior vagal trunk; (3) along posterior vagal trunk towards left lateral esoph-agogastric junction, find and protect gastric and celiac branches; (4) enter the lesser omental sac from the right crural diaphragm using Bipolar Forceps; (5) transect the left gastric artery and vein together using a linear vascular stapler; (6) blunt dissect the anterior surface of the distal esophagus using Bipolar Forceps, and find anterior vagal trunk; (7) along anterior vagal trunk towards right lateral esoph-agogastric junction, find and protect gastric and hepatic branches; and (8) blunt dissect the right lateral surface of the distal esophagus. The hepatogastric ligament was conserved.
224078015|NCT04172051|BEHAVIORAL|Tony Robbins Date with Destiny|DWD is a 6-day immersive transformational experience led by Tony Robbins. It will be held at the PALM BEACH, FLORIDA Convention Center from December 5th through December 10th. Subjects will be exposed to a variety of mind-body exercises and psychoeducational content including neural linguistic programming, designed to motivate, inspire, and improve the quality of people's lives.
224078016|NCT04884555|OTHER|Standard neurorehabilitation|Routine post-stroke rehabilitation
224078017|NCT04884555|DIAGNOSTIC_TEST|Thiol-Disulphide Homeostasis|Monitoring the levels of thiol and disulphide in serum
224078018|NCT04884555|DIAGNOSTIC_TEST|Oxidized-reduced Glutathione Homeostasis|Monitoring the levels of intracellular oxidized glutathione and reduced glutathione in whole blood samples
224078019|NCT01625273|OTHER|Lactobacillus paracasei paracasei strain F19|Provided in an infant formula, 10\^8 CFU per day from 28 days to 6 months of infant age
224078020|NCT02317562|DRUG|I10E|Patients who met all eligibility criteria will receive 0.5 g/kg of IMP every 3 weeks during 45 weeks.
224078021|NCT05634759|DRUG|Azithromycin for Routine Community-wide MDA|"Oral azithromycin, also known as the brand name Zithromax®, is a macrolide antibiotic and is used in the treatment of active trachoma. The recommended dosage for the treatment of trachoma is a single dose of 20mg/kg of body weight and is implemented by a Age-height based dosing strategy for the trachoma MDA campaigns. Oral azithromycin can be administrated in either tablet form or powder for oral suspension (POS). Zithromax® is donated by Pfizer Inc through the International Trachoma Initiative (ITI) to the South Sudan Federal Ministry of Health to use in community-wide MDA throughout South Sudan."
224078022|NCT05634759|DRUG|Two Additional Rounds of Azithromycin for Children|An additional round of treatment will be given one week after the routine community-wide MDA, and a second additional round will be given two weeks later (3 weeks after the routine community-wide MDA).
224078023|NCT05634759|DRUG|Azithromycin for Second Community-wide MDA|A second community-wide MDA will be given 6 to 8 months after the routine community-wide MDA. The timing of the second MDA will depend on local conditions and logistical concerns.
224078024|NCT01929304|OTHER|Survey|
224078025|NCT03551743|COMBINATION_PRODUCT|PRT064445/Edoxaban|
224078026|NCT03551743|COMBINATION_PRODUCT|Placebo/Edoxaban|
224078027|NCT03551743|DRUG|Placebo|
224078028|NCT03319862|PROCEDURE|Inferior pédicule gynaecomastia|Inferior pédicule gynaecomastia
224078029|NCT00176111|PROCEDURE|peripheral nerve stimulation (procedure)|
224078030|NCT04041882|DRUG|68Ga-DOTATATE|Intravenous injection of one dosage of 74-148 MBq (2-4 mCi) 68Ga-DOTATATE. Tracer doses of 68Ga-DOTATATE will be used to image lesions of NET PET/CT scan.
224078031|NCT04563065|OTHER|Exercise program|All sessions will begin with a warm-up of 7-8 minutes composed of mild movements and joint mobility of upper and lower limbs exercises. Then a central part of 35-40 minutes, four types of activities will be included (aerobic work, muscle strengthening, coordination/balance tasks, pelvic floor exercises), finally a section of flexibility, relaxation and final talk (comments and sharing) will be performed (12-15 minutes).
224078032|NCT04563065|OTHER|Healthy lifestyle advise|This intervention consists of providing infographics and videos with advice on healthy habits throughout the pregnancy process. This type of content will be related to daily physical activity, food recommendations and fundamental exercises to perform during pregnancy.
224078033|NCT01318044|DRUG|Propofol and Thiopental|"An initial bolus of 0.5 mg/kg of propofol will be administered over 1 minute. Supplementary boluses of propofol will be added until the UMSS score 3 are achieved.~An initial bolus of 2 mg/kg of thiopental will be administered over 1 minute. Supplementary boluses of thiopental will be added until the UMSS score 3 are achieved"
224078034|NCT03779022|GENETIC|microRNA|The level of microRNA in plasma will be detected by TaqMan in screening phase and by quantitative Real-time PCR (qRT-PCR) in validation phase.
224078035|NCT02396810|OTHER|intra-operative MRI|Intra-operative magnetic resonance imaging under general anesthesia
224078036|NCT02396810|PROCEDURE|Transsphenoidal resection of pituitary macroadenoma|Routine transsphenoidal resection of pituitary macro adenomas
224078037|NCT05841095|DRUG|ISA104|SLP vaccine
224078038|NCT05841095|DRUG|Placebo|Saline solution (0.9% NaCl)
224078039|NCT00758472|DEVICE|ReCap Total Hip Resurfacing|ReCap Total Hip Resurfacing
224078040|NCT05157815|DIETARY_SUPPLEMENT|Soluble Fibre|10g soluble corn fibre to be consumed twice per day
224078041|NCT05157815|DIETARY_SUPPLEMENT|Calorie Matched Control|2g maltodextrin consumed twice per day
224078042|NCT04041895|OTHER|Audio speech recording|Audio recording of speech sample from subject description of Cookie-Theft image.
224078043|NCT00911989|DEVICE|NOTES toolbox|Using SFT for endoscope access during Transvaginal Sleeve Gastrectomy procedure. Visualization will occur through endoscope
224078044|NCT01347736|OTHER|scrambler therapy|Undergo scrambler therapy
224078045|NCT01347736|OTHER|questionnaire administration|Ancillary studies
224078046|NCT01347736|PROCEDURE|dermatologic complications management/prevention|Undergo scrambler therapy
224078047|NCT03238287|DEVICE|Mechanical chest compression|In the application of advanced cardiac life support, chest compression is done with mechanical chest compression device. rSO2 measurements are used to detect the impact of the compression on brain perfusion. The application is performed in accordance with the recommendations on advanced cardiac life support in the current guidelines.
224078048|NCT03238287|OTHER|Manuel chest compression|In the application of advanced cardiac life support, chest compression is done with hands. rSO2 measurements are used to detect the impact of the compression on brain perfusion. The application is performed in accordance with the recommendations on advanced cardiac life support in the current guidelines
224078049|NCT06388473|BEHAVIORAL|Tailored implementation intervention|The tailored implementation intervention comprised of six implementation strategies: 1) Involve executive boards, 2) Mandate change, 3) Provide education and training, 4) Identify and prepare champions, 5) The use of information and communication technology and 6) Audit and provide feedback.
224078050|NCT05744063|DRUG|Emapalumab-Lzsg 5 MG/ML [Gamifant]|iv
224078051|NCT02237287|OTHER|wound dressing with VAC and sNAG without antiaggregation|
224078052|NCT02237287|PROCEDURE|wound dressing with VAC|
224078053|NCT02237287|DRUG|wound dressing with VAC and sNAG under Antiaggregation|
224078054|NCT02937714|OTHER|School Mental Health training|School based intervention (Teacher training intervention) is the teachers training program based on World Health Organization, Eastern Mediterranean Region (WHO-EMRO) School mental health manual draft (December 2014). Topics to be covered in training workshop include normal childhood development, behaviour management strategies for schools, life skills training, essential components for healthy schools, recognizing warning signs for common psychiatric and developmental disorders common to children and adolescents \& school based interventions for various psychiatric problems
224078055|NCT01145066|DRUG|borage/echium oil combination|borage/echium oil combination containing 0.85g/day SDA and 1.7g/day GLA
224078056|NCT01145066|DIETARY_SUPPLEMENT|fish oil|1.6g/day EPA and 1.08g/day DHA
224078057|NCT01145066|DIETARY_SUPPLEMENT|corn oil|contains 4.5 g/day linoleic acid
224078058|NCT04405401|RADIATION|SABR|SABR to all oligoprogressive lesions + continuation of current systemic therapy
224078059|NCT04405401|OTHER|Standard of care|Patients on the standard arm will be treated as per standard of care in our institution. Treatment options could include switching to next systemic therapy line, best supportive care or continuing on current systemic therapy.
224078060|NCT00563342|DRUG|Ethanol|Examine the risk of catheter dysfunction during the dialysis session that follows the instillation of ethanol 60% as lock solution in tunneled silicone catheters of end stage renal failure patients treated by hemodialysis
224078061|NCT01522846|DRUG|Heparin|Heparinized flush solution contained heparin concentration of 2 unit/ml and continuous flow of the flush solution was 5 ml/h at 300 mmHg.
224078062|NCT05110976|DRUG|AZD8630|Participants will receive Inhaled or IV doses of AZD8630 as per the arm they are assigned.
224078063|NCT05110976|DRUG|Placebo|Participants will receive Inhaled or IV doses of placebo as per the arm they are assigned.
224078064|NCT05321979|DRUG|MBA-P01|MBA-P01 will be injected into the Glabellar line.
224078065|NCT04525105|GENETIC|SMAD2|a family of structurally related cytokines
224078066|NCT02190851|DEVICE|TENS|"Two electrodes are attached around the internal malleolus and connected to the TENS unit.~The sessions last 20 minutes daily (frequency 10Hz, duration 200µs), at maximum intensity of painless stimulation, every day at the same time, on the right side for 3 months."
224078067|NCT02190851|DEVICE|Control|The device will have been previously set to deliver a stimulation below the effective threshold. In all cases, the device displays 20mA. Stimulation sessions are 20 minutes daily, every day at the same time, on the right side for 3 months.
224078068|NCT05601557|OTHER|There is no intervention|The genotype of the patients was analyzed.
224078069|NCT02864472|PROCEDURE|PDT|PDT and ranibizumab
224078070|NCT02864472|DRUG|Ranibizumab|Ranibizumab
224078071|NCT02864472|DRUG|ranibizumab PRN|ranibizumab PRN
224078072|NCT01002079|DRUG|BMS-708163|Capsule, Oral, 125 mg, Once daily, 1 day
224078073|NCT01002079|DRUG|Rifampin|Capsule, Oral, 600 mg, Once daily, 7 days
224078074|NCT01002079|DRUG|Rifampin|Capsule, Oral, 600 mg, Once daily, 6 days
224078075|NCT04665830|DRUG|Evolocumab|treated patients with evolocumab for high cholesterol
224078076|NCT00449709|DRUG|GSK221149|
224078077|NCT04997057|DIETARY_SUPPLEMENT|Probiotics mixture|"12 weeks of daily supplementation with 1 g of probiotics mixture (4.10exp9 colony forming unit/g) containing:~* Bifidobacterium longum LA 101~* Lactobacillus helveticus La 102~* Lactococcus lactis LA 103~* Streptococcus thermophilus LA 104"
224078078|NCT00723788|DEVICE|MRI of the abdomen|Multiple MRI pulse sequences of the abdomen
224078079|NCT00434135|DRUG|gemcitabine plus pemetrexed, paclitaxel plus gemcitabine|gemcitabine 1,250 mg/sqm days 1\&8 + pemetrexed 500 mg/sqm day 8 paclitaxel 120 mg/sqm + gemcitabine 1,000 mg/sqm days 1\&8
224078080|NCT05039359|DRUG|FlecIH-103|flecainide acetate inhalation solution
224078081|NCT02584192|BEHAVIORAL|entailing an early home-based CR program|enter the early outpatient phase of CR program. The progressive exercise training of this phase was performed without supervision after their discharge. The CR program consisted of a five-minute warm-up period (stretching), a twenty-minute aerobic exercise (walking or trotting, gymnastics), and a five-minute cooling-down period (stretching)
224078082|NCT02584192|OTHER|enter the usual care program|enter the usual care program, including the importance of carrying out physical activity, which was performed during inpatient care.
224078083|NCT03640429|DEVICE|non-invasive blood pressure monitor|non-invasive oscillometric blood pressure monitor will be applied at the arm, forearm, and at the wrist.
224078084|NCT03640429|DEVICE|invasive blood pressure monitor|invasive blood pressure monitor will be connected to a cannula inserted at the radial artery.
224078085|NCT03564626|OTHER|Health-IT +/- Scheduled Follow Up|"* Training patient and caregiver on Patient Buddy and EncephalApp~* Counseling regarding readmission~* Daily contact through app~* Standard of care counseling regarding readmission and discharge instructions~* Follow up phone calls at Week 1 and Week 3~* In-person follow up visits at Week 2 and Week 4"
224078086|NCT01658657|DRUG|Hydrochlorothiazide|
224078087|NCT01658657|DRUG|Lisinopril|
224078088|NCT01658657|DRUG|Amlodipine|
224078089|NCT01658657|DRUG|metoprolol|
224078090|NCT01658657|DRUG|lisinopril/hydrochlorothiazide|This is a combination pill
224078091|NCT03687502|DRUG|Sulfur hexafluoride lipid-type A microspheres|Contrast Enhanced Ultrasound of the appendix
224078092|NCT01407094|DRUG|Sertraline|50-200mg/day
224078093|NCT01407094|DRUG|Placebo|1-4 pills per day
224078094|NCT01407094|DRUG|BupropionXL|150-450 mg/day
224078095|NCT04416880|DEVICE|Press Tack Needle Acupuncture|Seirin Pyonex Press Tack Needle 0.20 x 0.60 mm for SI1 Shaoze acupuncture point Seirin Pyonex Press Tack Needle 0.20 x 0.90 mm for CV17 Danzhong acupuncture point
224078096|NCT03721926|OTHER|Usual Care|Participants assigned to receive usual oncology care will not meet with the study nurses, though they may receive geriatric or palliative care consults at their request or at the discretion of their treating oncologist.
224078097|NCT03721926|OTHER|Geriatric Oncology Collaborative Care|Patients receive three visits with a trained study nurse. At each visit, the study nurse will assess the patient's symptom burden, functional status, comorbid conditions, psychosocial issues, and medication use. The nurses can refer patients to specialists as needed. The study nurses will meet with a supervising support team, consisting of clinicians from geriatrics, palliative care, social work, and pharmacy to discuss each patient and review documentation. Following the team meetings, the nurses will document recommendations in the medical record and communicate with the primary oncology team, either in person or via phone, as appropriate. The study nurses will contact the supervising team in between meetings for any urgent issues or questions that arise.
224078098|NCT05449704|DRUG|DA-5218|single dose administration (DA-5218 one tablet once a day)
224078099|NCT05449704|DRUG|DA-5218-R1 + DA-5218-R2 + DA-5218-R3|single dose administration (DA-5218-R1 one tablet once a day + DA-5218-R2 one tablet once a day + DA-5218-R3 one tablet once a day)
224078100|NCT01724528|DRUG|Febuxostat|Standard dose PO (per os) from Day 1 to Day 7 (can be continued up to DAY 9 at investigator's discretion)
224078101|NCT01724528|DRUG|Allopurinol|Standard dose, low dose or high dose (as per investigator's judgement at the time of randomization) from DAY 1 to DAY 7 (can be continued up to DAY 9 at investigator's discretion)
224078102|NCT04275115|DRUG|Drug Cocktail|Single oral dose of the cocktail probe substrates (caffeine 200 mg, montelukast 10 mg, midazolam 4 mg)
224078103|NCT04275115|DRUG|Foliglurax|Foliglurax
224078104|NCT04275115|DRUG|midazolam iv|Single intravenous (iv) dose of midazolam 0.025 mg/kg
224078105|NCT00466310|DRUG|Aripiprazole|Aripiprazole for 4 weeks
224078106|NCT00466310|DRUG|Risperidone|Subjects will be randomized to risperidone for 4 weeks
224078107|NCT00466310|OTHER|Healthy volunteers|Healthy volunteers
224078108|NCT01864616|DIETARY_SUPPLEMENT|Vitamin D3|
224078109|NCT02598765|PROCEDURE|Standard Trabeculectomy|Fornix-based trabeculectomy with a 3x4 mm scleral flap.
224078110|NCT02598765|PROCEDURE|Microtrabeculectomy|Fornix-based trabeculectomy with a 2x2 mm scleral flap.
224078111|NCT04216732|OTHER|Blood Pressure Measurement|Undergo blood pressure measurement
224078112|NCT04216732|OTHER|Questionnaire Administration|Complete questionnaires
224078113|NCT06149793|DRUG|Empagliflozin|Sodium glucose co-transporter 2 inhibitor
224078114|NCT06149793|OTHER|Placebo Control|Placebo Control
224078115|NCT04751812|PROCEDURE|High-pain multimodal anesthesia with opioids|"Paracetamol, Etoricoxib, Oxycodone, Ondansetron po. Betamethasone 4 mg iv.~Anesthesia:~As standard + bolus esketamine 0.25 mg/kg iv + Clonidine 1 µg/kg i.v.~Postoperative pain treatment:~At pain NRS ≥ 4 - 5 mg of oxycodone i.v. Paracetamol will be administered every 6 hours. If above is not sufficient bolus Clonidine 1 µg/kg i.v."
224078116|NCT04751812|PROCEDURE|Low-pain opioid free|"Paracetamol, Etoricoxib, Ondansetron p.o. Betamethasone 4 mg iv.~Anesthesia:~Infusion Dexmedetomidin 0.2 mikrogram/kg/h iv started 5 min before induction Induction: Esketamin 0.1mg/kg + Propofol 1.5-2 mg/kg iv + rocuronium 0.5 mg/kg iv Start of surgery: Esketamin 0.1 mg/kg iv. Maintenance of anesthesia: Sevoflurane Dexmedetomidin inf 0.2 mikrogram/kg/h Esketamin inf 0.1-0.3mg/kg/h and 0.1 mg/kg adjusted after BP and HR 30 min before end of surgery Lidocaine 1 mg/kg iv~Postoperative pain treatment:~• Dexmedetomidin (inf 01-0.2 µg/kg/h) 4 hours postoperative~If pain NRS ≧3 Esketamin 0.1mg/kg iv + Lidocain 0.5 mg/kg iv (max 4 mg/kg /4 h) If pain NRS ≧3 within 30 min after treatment above is given with Esketamin + Lidocain, 2.5 mg Oxycodone iv. is given and may be repeated."
224078117|NCT04751812|PROCEDURE|Standard of care|"Paracetamol, Etoricoxib, Oxycodone, Ondansetron p.o. Betamethasone 4 mg iv.~Anesthesia:~Target controlled infusion (TCI) with doses of propofol and remifentanil based on age, weight and height. Oxycodone 0.1 mg/kg 30 minutes before cessation of remifentanil.~Postoperative care:~At pain NRS ≥ 4 - 5 mg of oxycodone i.v. Paracetamol will be administered every 6 hours. If above is not sufficient bolus Clonidine 1 µg/kg i.v."
224078118|NCT05329077|DEVICE|Pulsenmore ES home ultrasound device|Pregnant participants will use Pulsenmore ES device to assess the safety and the efficacy of the device in monitoring fetal parameters
224078120|NCT05678491|OTHER|Endoscopic mucosal band ligation|The mucosa in 3/4 of the circumference of the gastroesophageal junction and cardia will be treated with mucosal band ligation left in place. This will be done during upper endoscopy in sedation. It is the endoscopic procedure that is being investigated.
224078121|NCT05708014|BEHAVIORAL|Intervention LuvHub|From day 1 to day 487 (i.e., entire 16-month duration, post baseline) of the trial, participants randomized to the intervention arm will have access to use the five modules as directed. The LuvHub intervention includes modules focused on topics of: HIV/STI prevention, sexual agreements, communication/decision-making skills, strengthening relationships and creating goals, and physical activity.
224078122|NCT05708014|BEHAVIORAL|Waitlist Control LuvHub|From day 243 to day 487 (i.e., starting after 8-month assessment) of the trial, participants randomized to the waitlist control condition will have access to use the five modules as directed. The LuvHub intervention includes modules focused on topics of: HIV/STI prevention, sexual agreements, communication/decision-making skills, strengthening relationships and creating goals, and physical activity.
224078123|NCT00273377|OTHER|Mild intraoperative hypercapnia (50 mmHg vs. 30 mmHg)|
224078124|NCT00273377|OTHER|Supplemental oxygen (80% vs. 30%)|
224078125|NCT00273377|DRUG|Dexamethasone|4 mg
224078126|NCT00273377|DRUG|Placebo|placebo
224078127|NCT05408754|DEVICE|Atrial ablation for subject scheduled for a de novo endocardial ablation of symptomatic, drug-refractory PsAF.|Treatment will include the isolation of pulmonary veins (PVIs), and isolation of the left atrial posterior wall (PWI). A right atrial cavo-tricuspid line for bi-directional block may be performed at discretion and clinical judgment of the investigator
224078128|NCT06560164|OTHER|Red Blood Cell transfusion|When the appropriate Hb threshold is reached, patients in each group will have one unit of RBC administered at a time. Within 3 hours after the transfusion, a repeat Hb concentration will be measured. Each group will only be transfused when their Hb level falls below the transfusion threshold. In case of a outlier measurement, clinicians are advised to repeat the measurement. The RBC transfusion must take place within 4 hours when the Hb trigger was measured.
224078129|NCT01184937|BEHAVIORAL|Patient education program|"All patients receive standard care. Experimental group receive a structured patient education program based in self-care theory and pedagogical theory, build upon the the principles of the Pro-Self education program. The intervention program consist of five weekly one-to-one sessions with a transplant nurse, lasting about 40-60 minutes, starting during the first week after discharge and lasting until 7 weeks post transplantation. Education content consists of two levels: general knowledge level and individual knowledge. Each session has a specific program. In addition, academic detailing is used to describe patient's knowledge levels and for tailoring the education to individual needs."
224078130|NCT03933696|DEVICE|Tailored Lighting Intervention|Lighting Intervention either Active or Placebo
224078131|NCT00654862|DIETARY_SUPPLEMENT|cocoa polyphenols|Oral administration of capsules with 1000 mg polyphenols, 250 mg polyphenols or placebo
224078132|NCT00654862|DIETARY_SUPPLEMENT|cocoa polyphenols|Oral administration of capsules with 1000 mg polyphenols, 250 mg polyphenols or placebo
224078133|NCT02270359|DEVICE|OCT|Optical coherence tomography (OCT): Intracoronary imaging for amount and type of plaque as well as plaque rupture, ulceration, dissection and/or thrombosis.
224078134|NCT02270359|PROCEDURE|CMR|Cardiac magnetic resonance imaging (CMR): MRI of the heart to identify areas of infarction (damage) and/or edema (smelling)
224078135|NCT02270359|DRUG|contrast agent, Gadolinium|Gadolinium contrast will be administered during CMR
224078136|NCT06357247|DEVICE|Sensory Threshold|Using a light, vibrotactile noise device on the participant's affected wrist. The actuator will be positioned on both the dorsal and volar sides of the wrist. Each participant's sensory threshold will be measured using the method of ascending and descending limits
224078137|NCT06357247|BEHAVIORAL|Nine Hole Peg Test|The Nine-Hole Peg Test (NHPT) is considered as a gold standard measure of manual dexterity and most frequently used in MS research and clinical practice. The score for the 9-HPT is an average of the four trials. The two trials for each hand are averaged, converted to the reciprocals of the mean times for each hand and then the two reciprocals are averaged. On average, healthy male adults complete the NHPT in 19.0 seconds (SD 3.2) with the right hand, and in 20.6 seconds (SD 3.9) with the left hand.
224078138|NCT06357247|BEHAVIORAL|Semmes Weinstein Monofilament Assessment|A non-invasive, low-cost, simple, and accurate handheld calibrated nylon thread that buckles once it has delivered a force of 10 g. It provides a standardized measure of a patient's ability to sense a point of pressure. The filaments are classified from grade 1 to 5 according to their thickness: 1.65-2.83 = grade 5, 3.22-3.61 = grade 4, 3.84-4.31 = grade 3, 4.56-6.45 = grade 2, and 6.65 = grade 1.
224078139|NCT05072314|DRUG|lidocaine 2% and 10%|"Lidocaine infusion:~1. Commencing with an intravenous bolus after induction of anaesthesia, 0.125 ml/kg of lean body weight (LBW) of 2% lidocaine (2.5 mg/kg).\*~2. Followed by a 2% lidocaine intravenous infusion for the duration of surgery, 0.1665 ml/kg/h of LBW (3.33 mg/kg/hr).\*~3. A post-operative subcutaneous 0.0222 ml/kg/hr of LBW 10% lidocaine infusion for up to 24 hours thereafter (2.22 mg/kg/hr). Dosage will be capped at a maximum lean body weight of 68kg.~   * \*Day-case surgery receives intraoperative bolus and intraoperative infusion only"
224078140|NCT05072314|DRUG|Placebo|"Placebo infusion:~1. Commencing with an intravenous bolus after induction of anaesthesia, 0.125 ml/kg of lean body weight (LBW) of 0.9% Saline solution.\*~2. Followed by a 0.9% Saline solution intravenous infusion for the duration of surgery, 0.1665 ml/kg/h of LBW (3.33 mg/kg/hr).\*~3. A post-operative subcutaneous 0.0222 ml/kg/hr of LBW 0.9% Saline solution infusion for up to 24 hours thereafter (2.22 mg/kg/hr). Dosage will be capped at a maximum lean body weight of 68kg.~   * \*Day-case surgery receives intraoperative bolus and intraoperative infusion only"
224078141|NCT00003642|DRUG|cisplatin|
224078142|NCT00003642|DRUG|fluorouracil|
224078143|NCT00003642|RADIATION|radiation therapy|
224078144|NCT06430788|BIOLOGICAL|Emapalumab|Emapalumab is an interferon gamma (IFNγ) blocking antibody
224078145|NCT02403609|OTHER|BPT, Computerized Assessment|
224078146|NCT02670135|DRUG|Triclosan Containing Toothpaste|Active formula containing 0.3% triclosan in a1450 ppm sodium fluoride/silica base
224078147|NCT02670135|DRUG|Triclosan Free Toothpaste|Control toothpaste with no triclosan ingredients in a 1450 ppm sodium fluoride/silica base - matching placebo
224078148|NCT06141278|BEHAVIORAL|Care cascade intervention|Co-designed integrated care based on the Chronic Care Model to improve hypertension and diabetes care cascade
224078149|NCT04102969|BEHAVIORAL|Benson Relaxation Technique|Benson relaxation technique will be performed two times a day for 10 minutes during the study period ( two months) for the intervention group.
224078150|NCT04102969|OTHER|Nutrition Package Session|A nutrition package session will be given to the control group.
224078151|NCT02937350|DRUG|D6-25-hydroxyvitamin D3|Intravenous administration of a deuterium-labeled 25(OH)D3 to evaluate the metabolic clearance of 25(OH)D3
224078152|NCT06084377|GENETIC|Preimplantation Genetic Screening|Non-invasive technique to investigate the presence of genetic disorders.
224078153|NCT01050400|GENETIC|Cytochrome P450 2D6 (CYP2D6) genetic screening.|Genetic screening for cytochrome P450 2D6 (CYP2D6) polymorphism will be conducted on genetic information obtained from non-invasive salivary samples.
224078154|NCT05754346|OTHER|Complete Decongestive Therapy|Complete Decongestive Therapy will include manual lymphedema drainage (self) for 20 min everyday, skin care everyday, wearing compression garment or bandages everyday and upper-extremity exercises twice a day.
224078155|NCT05754346|OTHER|Upper extremity exercises combined with diaphragmatic breathing exercises|"Upper-extremity exercises component of Complete Decongestive Therapy will be performed combined with diaphragmatic breathing exercises."
224078156|NCT00042380|DRUG|Novasoy|
224078157|NCT06216444|DRUG|Remimazolam Tosilate for Injection|Initial loading dose of 5mg, with additional doses of 2.5mg as necessary
224078158|NCT06216444|DRUG|Remimazolam Tosilate for Injection|Initial loading dose of 10mg, with additional doses of 2.5mg as necessary
224078159|NCT03502993|DIAGNOSTIC_TEST|Validation of biomarker|
224078160|NCT00561197|DRUG|AT-101|Patients will receive AT-101 starting at 10 mg once daily for 5 of 7 days in conjunction with RT (50.4 Gy for 28 fractions) for approximately 5.5 weeks. Concurrently, patients will receive docetaxel (20 mg/m2) IV weekly (Monday) and 5-fluorouracil (300 mg/m2) as a 24 hour continuous infusion for 5 of 7 days (Monday-Friday) of each RT week for approximately 5 weeks. Patients will continue for full 5.5 weeks unless unacceptable toxicity occurs.
224078161|NCT04377737|DIAGNOSTIC_TEST|RT-PCR Covid-19|estimation of the prevalence of positive rt-PCR in school children during the pandemic period
224078162|NCT00803179|DRUG|Nutropin AQ|Based on recommendations from the 2007 GH Deficiency Consensus Workshop on adult GH deficiency, the recommended initiation of treatment for adult males is 0.2mg/d and for women 0.4mg/d, with a titration upwards based on insulin-like growth factor (IGF-1) (product of GH stimulation at target tissues) levels and patient response. IGF-1 will be monitored at the 3,4,5 and 11 month intervals. For subjects under the age of 25 with an open epiphysis of the hand and/or wrist we will treat with the dose of 0.3mg/kg/week. Subjects will be on growth hormone for 8 months with a baseline visit prior to initiation of therapy and a 3 month follow-up visit after stopping therapy.
224078163|NCT05731180|OTHER|Identify pathological and not pathological lung sounds|First group is the control group (CNT), second group (EXP) who will be exposed to pathological and none pathological lung sounds
224078164|NCT03382574|BIOLOGICAL|Denosumab|Given SC
224078165|NCT03382574|PROCEDURE|Salpingo-Oophorectomy|Undergo risk-reducing salpingo-oophorectomy
224078166|NCT00262431|PROCEDURE|Tracheostomy on day 3-5 in early group and 10-12 in late group|Upon admission to ICU, acute respiratory failure patients requiring at least 3 days of mechanical ventilation and defined by a SAPS II score between 35 and 65, will be randomly assigned to either arm A or B of the study.
224078167|NCT03512145|DEVICE|VIPUN Balloon Catheter|Gastric motility is recorded continuously with the VIPUN Balloon Catheter for 10 hours.
224078168|NCT05866055|DRUG|VX-973|Suspension for oral administration.
224078169|NCT05866055|DRUG|Placebo|Suspension for oral administration.
224078170|NCT05866055|DRUG|Midazolam|Syrup for oral administration.
224078171|NCT05604599|DRUG|Intranasal dexmedetomidine|45 -60 min before the operation, patients will receive dose of dexmedetomidine 1microgram/kg diluted in 10ml 0.9% saline administered to each naris as drops + infusion saline
224078172|NCT05604599|DRUG|Intravenous dexmedetomidine|patients will receive loading dose of dexmedetomidine 1 µg/kg diluted in 10ml 0.9% saline infused over 45- 60 min before induction of anesthesia, followed by continuous infusion of (0.4 µ g/kg/h) + intranasal saline.
224078173|NCT05970263|DRUG|Budesonide/glycopyrrolate/formoterol fumarate (Breztri Aerosphere) 320 μg/18 μg/9.6 μg administered as two inhalations, twice daily.|2 inhalations twice daily administered by oral inhalation, from a metered dose inhaler, over a 12-month follow-up period.
224078174|NCT05970263|OTHER|External Comparator|Received any inhaled therapy, excluding triple inhaled maintenance therapy, during index hospitalization and refilled within 30 days before or after discharge from index hospitalization
224078175|NCT01602055|DRUG|Azithromycin|Single dose 500 mg of film coated tablet
224078176|NCT01602055|DRUG|Azithromycin|Single dose 500 mg of film coated tablet
224078177|NCT06774040|DRUG|Etribnabdione 25 mg BID|The trial will start with the lower dose. When the 12 patients have been treated for 3 months and the PK and safety data are evaluated by the regulatory authority, the Sponsor and the site investigators, the high dose (50 mg BID) will be released.
224078178|NCT06774040|DRUG|Etribnabdione 50 mg BID|The treatment will start when the regulatory authority, the sponsor and the site investigators have reviewed the low dose safety and pharmacokinetics data.
224078179|NCT06456983|DEVICE|maintenance electroconvulsive therapy (mECT)|see Arms
224078180|NCT05378763|DRUG|Poziotinib|Poziotinib tablets
224078181|NCT05378763|DRUG|Docetaxel|Docetaxel IV infusion
224078182|NCT06291909|BEHAVIORAL|Small Steps Program|Participants in the intervention group will be given access to the Small Steps website. Small Steps website provides a visual representation of the participant's current use of time and allows for manipulation to demonstrate how small lifestyle changes may improve sleep and physical activity needs. The personal outcome goals selected by the participant will also feature on participant's dashboard within the Small Steps website as a reminder. Participants will be prompted through the first 12 weeks to add a new behaviour change each week and will receive support phone calls weekly. During the 12-week Maintenance Phase participants will be guided to maintain their new behaviour, with supportive phone calls being progressively reduced from fortnightly to monthly. At the completion of the 12 weeks, investigator support will be withdrawn. Maintenance of the new behaviour without support will then be assessed over 12 additional weeks in the Follow-Up phase.
224078183|NCT06291909|BEHAVIORAL|Comparator Program|Participants will receive generic health advice only and it will not be individually tailored, nor will they receive weekly support phone calls during the first 12-weeks. Participants will receive no feedback or support in the Maintenance or Follow-Up phases.
224078184|NCT05994053|DEVICE|high definition transcranial alternating current stimulation|low intensity alternating current to OFC
224078185|NCT03798626|DRUG|Gevokizumab|60 mg/mL concentration; administered intravenously (IV)
224078186|NCT03798626|DRUG|Bevacizumab|25 mg/mL concentration; administered IV
224078187|NCT03798626|DRUG|Modified FOLFOX6|Oxaliplatin \[5 mg/mL concentration; administered IV\], leucovorin \[10 mg/mL concentration; administered IV\] (or levoleucovorin \[10 mg/mL concentration; administered IV\]), and 5-fluorouracil \[50 mg/mL concentration; administered IV\]
224078188|NCT03798626|DRUG|FOLFIRI|Irinotecan \[20 mg/mL concentration; administered IV\], leucovorin \[10 mg/mL concentration; administered IV\] (or levoleucovorin \[10 mg/mL concentration; administered IV\]), and 5-fluorouracil \[50 mg/mL concentration; administered IV\]
224078189|NCT03798626|DRUG|Ramucirumab|10 mg/mL concentration; administered IV
224078190|NCT03798626|DRUG|Paclitaxel|6 mg/mL concentration; administered IV
224078191|NCT03798626|DRUG|Cabozantinib|60 mg tablet; administered orally
224078193|NCT05003960|BIOLOGICAL|AlloRx|cultured allogeneic adult umbilical cord derived mesenchymal stem cells
224078194|NCT05884684|OTHER|Reviewing Imaging with Participant|Post-operatively, the images taken during the procedure will be reviewed with the participant.
224078195|NCT05898165|OTHER|Development of an algorithm|Prospective verification of a developed algorithm to predict the risk of a new onset Atrial Fibrillation
224078196|NCT06287580|DRUG|chlorthalidone|chlorthalidone, 12.5 mg or 25 mg orally once daily
224078197|NCT06287580|OTHER|Placebo|Placebo tablet taken orally once daily
224078198|NCT04811716|DRUG|Pozelimab|Administered Sub-cutaneous (SC) per protocol
224078199|NCT04811716|DRUG|Cemdisiran|Administered SC per protocol
224078200|NCT05968859|BEHAVIORAL|Aerobic Training|Aerobic training will be conducted at 30 minutes 3 times a week using brisk walking with target heart rates goals based on percentage of peak HR reserve (HRR= peak-rest HR) during baseline exercise right heart catheterization (RHC). The target HR will progress over the study period from 50% to 70% of peak HR reserve added to resting HR using the standard Karvonen formula (Goal HR = rest HR + target % of HRR). HR will be monitored using Fitbits to guide training intensity with raw data analyzed using the Fitabase platform to monitor compliance
224078201|NCT05968859|BEHAVIORAL|Leg Training|Leg training will be performed using assigned ankle weights to perform knee extension while seated. Initial weight assignment will be guided by a protocol driven in-person exercise tolerance test using varying weights to identify the optimal initial and target training weight for each patient based on the 10 repetition maximum weight identified during this test. Leg training weight will begin at 40% of the baseline 10-repetition maximum weight for weeks 1-4 during which time patients will be required to complete 3 sets of 10 repetitions (30 repetitions total) on 3 days per week. For weeks 4-8, 55% of the initial 10-repetition maximum weight will be used for 4 sets of 10 repetitions (40 repetitions total). For weeks 8-12, 70% of the initial 10-repetition maximum weight will be used for 5 sets of 10 repetitions (50 repetitions total).
224078202|NCT02434848|DRUG|Engerix B|"Engerix B 20 micrograms/1ml Licensee: GlaxoSmithKline UK Intra-muscular~Prescription and administration:~The vaccine will be stored in the Investigators pharmacy as clinical trial stock and dispensed on a subject by subject basis.~Shelf life and storage The product must be kept refrigerated (2°C - 8°C). Prescriptions will be written and dispensed from pharmacy on the day of consent, screening and vaccination. The shelf life is 3 years."
224078203|NCT02434848|DRUG|Fendrix|"Fendrix suspension for injection GlaxoSmithKline UK~Route of Administration, dose regimen:~Intra-muscular Dose: 0.5ml (20mcg of Hepatitis B Surface Antigen) per vaccination at baseline and weeks 4, 8 and 24.~Prescription and administration:~The vaccine will be stored in the Investigators pharmacy as clinical trial stock and dispensed on a subject by subject basis.~Packaging and labeling The vaccine will have clinical trial labeling. Shelf-life and storage The product must be kept refrigerated (2°C - 8°C).~The shelf life is 3 years."
224078204|NCT02877173|DRUG|Alprostadil Liposomes for Injection|3 doses of Alprostadil Liposomes for Injection are 20ug/q.d,40ug/q.d,60ug/q.d.All groups will be continuous administration for 3 weeks.
224078205|NCT02877173|DRUG|Alprostadil Injection|Alprostadil Injection(the positive control group):10ug/q.d,continuous administration for 3 weeks.
224078206|NCT01897636|PROCEDURE|EUS-guided fine-needle injection of DCs vaccinations|
224078207|NCT04695964|DIAGNOSTIC_TEST|ICG-NIRF Imaging plus ingress and egress analysis|intraoperative NIRF Imaging using the fluorescence agent ICG (indocyanine-green) at regions of interest before (T1) + after pouch construction (T2) + after ileoanal anastomosis (T3) Additional ingress and egress analysis (inflow and outflow analysis) of specificities regions of interest at regions of interest before (T1) + after pouch construction (T2) + after ileoanal anastomosis (T3)
224078208|NCT05591664|DIAGNOSTIC_TEST|eicosapentaenoic acid|eicosapentaenoic acid levels of the groups will be monitored
224078209|NCT04348409|DRUG|Nitazoxanide Tablets|Patients will receive nitazoxanide 600 mg BID for 7 days
224078210|NCT04348409|DRUG|Placebo|Patients will receive placebo BID for 7 days
224078211|NCT01568814|DRUG|Low volume PEG|low volume polyethylene glycol 2 liter one time
224078212|NCT01568814|DRUG|high volume PEG|high volume polyethylene glycol 4 lilter split-dosing 2L/2L two times
224078213|NCT04545346|OTHER|Low Glutamate diet|Participants will be given extensive online dietary training and assigned to follow the low glutamate diet for one month. The low glutamate diet reduces the consumption of free glutamate, while optimizing dietary micronutrient and antioxidant intake.
224078214|NCT01016639|OTHER|oxaliplatin, capecitabine, radiotherapy|
224078215|NCT06372132|PROCEDURE|G-POEM|Gastric Per-Oral Endoscopic Pyloromyotomy
224078216|NCT03837080|OTHER|Nutrition Education|Every patient will receive one individual and two group counselings on specific nutrition-related recommendations for chronic pain patients.
224078217|NCT04856709|PROCEDURE|Abdominal Pectopexy|Pectopexy is a new technique for apical repair in which lateral parts of the iliopectineal ligament are used for cuff or cervix suspension.
224078218|NCT04856709|PROCEDURE|Abdominal Sacral Hysteropexy|Abdominal sacrocolpopexy is a procedure that uses a mesh material to support the top of the vagina to treat pelvic prolapse.
224078219|NCT01849861|DRUG|Methimazole|"Patients with serum TSH initially on the 1st. Quartile (TSH: 0.4 to 1.0 mIU / ml) will receive treatment with Methimazole (initial dose of 5mg/day) with the goal of raising the TSH values to range between 2.0 and 4.0 mIU / ml (the half upper range of normal).~After six months with TSH in the target range (2.0 and 4.0 mIU / ml), these patients will be subjected to the same examination protocol performed at baseline and assessed to the effects of treatment on outcome variables.~Variables considered in this study:~* TSH and FT4~* Questionnaire of Quality of life for older adults (WHOQOL-OLD)~* Mini-Mental State Examination~* Geriatric Depression Scale~* Cardiopulmonary exercise testing - cardiopulmonary capacity"
224078220|NCT04247425|OTHER|Exercise Counseling|Receive instructional guidance
224078221|NCT04247425|OTHER|Quality-of-Life Assessment|Ancillary studies
224078222|NCT04247425|OTHER|Questionnaire Administration|Ancillary studies
224078223|NCT04247425|OTHER|Resistance Training|Complete progressive resistance training
224078224|NCT05976191|BEHAVIORAL|Patients whose blood glucose is measured intravenously and from the fingertip|A satisfaction survey will be conducted after these patients have previously examined their blood glucose via intravenous route, then fingertip blood glucose will be measured and a satisfaction survey will be applied.
224078225|NCT02037659|PROCEDURE|DermaBond treatment of Gastric Varices|Endoscopic Ultrasound (EUS) administration of DermaBond glue to control bleeding gastric varices.
224078226|NCT00130897|DRUG|Sutent|Sutent, 25, 37.5. or 50 mg daily
224078227|NCT02247193|DRUG|Botulinum Toxin Type A|Injection of botulinum toxin at the time of surgery at cleft lip repair site. Botulinum toxin will be injected intraoperatively at 4 standardized sites in the cleft lip during surgical repair.
224078228|NCT02247193|DRUG|Normal Saline Injection|Injection of normal saline into cleft lip at time of surgical repair. Saline will be injected intraoperatively at 4 standardized sites in the cleft lip during surgical repair.
224078229|NCT02298764|OTHER|Standard back pain treatment|Standard back pain treatment
224078230|NCT02298764|OTHER|Standard back pain treatment + 10 psychotherapeutic sessions|"Standard back pain treatment plus 10 psychotherapeutic session, that will include the shock-trauma method somatic experiencing."
224078231|NCT05309863|BEHAVIORAL|Lifestyle management|Increasing the level of physical activity, dietary intervention, acquiring healthy eating habits, and psychological support.
224078232|NCT02544932|DRUG|dabigatran|After randomization, patients of this group was will be treated to dabigatran 110mg or 150mg twice a day for 24months
224078233|NCT02544932|DRUG|ribaroxaban|After randomization, patients of this group was will be treated to ribaroxaban 20mg once a day for 24months.
224078234|NCT02544932|DRUG|Warfarin|After randomization, patients of this group was will be treated to warfarin and controlled by INR 2-3 for 24months.
224078235|NCT05562154|PROCEDURE|Total Ankle Replacement|Participants will undergo either lateral approach or anterior approach when having a total ankle replacement
224078236|NCT03598387|OTHER|Automated peritoneal dialysis|"The prescription of automated peritoneal dialysis:~* The first 48-72 hours dose: 0.8-2.0 liter exchange with 1-2 hour-cycle (8-36 liters per day); After initial 48-72 hours, 1.0-2.5L exchange with 2-6 hour-cycle (at least 8 liters per day), if the acidosis, hyperkalemia and pulmonary edema are corrected.~* The minimal target weekly Kt/V is 2.1-3.5/W."
224078237|NCT03598387|OTHER|Intermittent hemodialysis|Intermittent hemodialysis will be performed 3-4h of each session and 2-5 times per week. The prescription will be adjusted based on patients' conditions to ensure spKT/V≥1.3.
224078238|NCT01332539|OTHER|no intervention|non-interventional study
224078239|NCT01877083|DRUG|Lenvatinib|Starting dose of 24 mg orally, once per day
224078240|NCT01487759|DIETARY_SUPPLEMENT|Oligofructose enriched inulin|
224078241|NCT01487759|DIETARY_SUPPLEMENT|Maltodextrin|
224078242|NCT04173897|OTHER|LIBERATE website|The LIBERATE intervention is a self-management, symptom monitoring and signposting website tailored to the supportive needs of women living with secondary breast cancer. Components include; holistic health information specific to secondary breast cancer, symptom monitoring and self-management advice, case studies, signposting to services \& support and support for family \& loved ones.
224078243|NCT05083637|DRUG|L- carnitine oral solution|The L-carnitine syrup formulation will be provided to study participant at nutritional rehabilitation unit (NRU) under controlled set-up
224078244|NCT05083637|OTHER|Placebo|The placebo formulation will be provided to study participant at nutritional rehabilitation unit (NRU) under controlled set-up
224078245|NCT00762515|DRUG|Fluoride|Brush teeth two times daily for 6 weeks
224078246|NCT00762515|DRUG|Triclosan|Brush two times daily for 6 weeks
224078247|NCT00762515|DRUG|Fluoride|Brush two times daily for 6 weeks
224078248|NCT04953312|BIOLOGICAL|Blood samples|blood
224078249|NCT02960620|DEVICE|TheraSphere Treatment|TheraSphere® is delivered into the liver tumor through a catheter placed into the hepatic artery. The hepatic artery provides the main blood supply to the tumor in the liver, whereas the portal vein supplies blood to normal liver parenchyma. TheraSphere® is embolized within the tumor and exerts a local beta radiation radiotherapeutic effect with relatively limited concurrent injury to surrounding normal tissue.
224078250|NCT03751865|BEHAVIORAL|CBT|A total of 8 CBT sessions will be provided to the participants, each session lasts for approximately 1.5 hour.
224078251|NCT03751865|BEHAVIORAL|Psychoeducation|A total of 8 psychoeducation sessions will be provided to the participants, each session lasts for approximately 1.5 hour.
224078252|NCT05522166|OTHER|Digital Stories and Face-to-face Basic Life Support Trainings|In this study, digital storytelling and face-to-face applied techniques will be given to teacher candidates via social media (Whatsapp) and the impact of these trainings on the knowledge and skill levels of teacher candidates will be evaluated comparatively.
224078253|NCT01258907|DRUG|MLDL1278A|Single intravenous dose
224078254|NCT01258907|DRUG|MLDL1278A|Repeating intravenous dose
224078255|NCT01258907|DRUG|placebo|Repeating intravenous dose
224078256|NCT01258907|DRUG|statin, stable dose|Repeating oral dose
224078257|NCT06050538|PROCEDURE|Transabdominal preperitoneal (TAPP) using polyprolene mesh|Transabdominal preperitoneal (TAPP) approach for recurrent inguinal hernia using polyprolene mesh
224078258|NCT06050538|PROCEDURE|Total extraperitoneal (TEP) hernioplasty using polyprolene mesh|Total extraperitoneal (TEP) approach for recurrent inguinal hernia using polyprolene mesh
224078259|NCT06549959|DRUG|Telitacicept Pre-filled Injection 80mg|The patient received one treatment of Telitacicept 80mg in the test group
224078260|NCT06549959|DRUG|Telitacicept Freeze-dried powder Injection 80mg|The patient received one treatment of Telitacicept 80mg in the test group
224078261|NCT04154501|DRUG|CNTX-6016|Oral Dose CNTX-6016
224078262|NCT04154501|OTHER|Other: Placebo|Oral Dose Placebo
224078263|NCT05949229|DRUG|Duloxetine 60 MG|Patients will recieve 2-hour preoperative duloxetine
224078264|NCT00326365|DRUG|Kali bichromicum 10-60 (C30)|
224078265|NCT00996099|DEVICE|Continuous glucose monitoring system combined with enhanced model predictive control algorithm for intensive insulin treatment|Glucose measured with a real-time continuous glucose monitoring system served as an input for the enhanced model predictive control algorithm adjusting insulin infusion every 15 minutes for the first 24 hours after elective cardiac surgery
224078266|NCT00996099|OTHER|Intensive insulin therapy using standard protocol|Insulin dosage according to the standard protocol for intensive insulin delivery used at Department of Cardiothoracic Surgery, General University Hospital, Prague.
224078267|NCT04345445|DRUG|Tocilizumab|IV infusion
224078268|NCT04345445|DRUG|Methylprednisolone|IV infusion
224078269|NCT02670265|DIETARY_SUPPLEMENT|Olimel Peri 2.5% ®|During hospital stay patients received 1 l Olimel peri 2.5 %® containing 700 kcal (25.3 g protein, 30.0 g fat and 75.0 g glucose) daily by intravenous route.
224078270|NCT02670265|DIETARY_SUPPLEMENT|Isotonic fluid (E153)|Controls received 1l of isotonic fluid daily by intravenous route.
224078271|NCT00429585|DEVICE|reamed, interlocking intramedullary nail|Standard of care device for tibia fracture repair; Randomized Treatment - Nail
224078272|NCT00429585|DEVICE|locking periarticular plate|Standard of care device for tibia fracture repair; Randomized Treatment - Plate
224078273|NCT03834532|OTHER|Breast reconstruction decision aid|The breast reconstruction decision aid is a web-based, interactive tool that participants will use after the first breast surgery visit and before a plastic surgery visit or surgery. The decision aid provides information about post-mastectomy breast reconstruction and helps the participant clarify their preferences related to the procedure.
224078274|NCT03834532|OTHER|Educational website|The educational website contains information on healthy living with breast cancer including, physical activity and nutrition.
224078275|NCT01582308|DRUG|Sitagliptin 100 mg|Sitagliptin 100 mg: one sitagliptin 100 mg tablet once daily in the morning following a fast of at least approximately 8 hours on Days 1 through 5 in one out of five treatment periods.
224078276|NCT01582308|DRUG|Saxagliptin 5 mg|Saxagliptin 5 mg: one saxagliptin 5 mg tablet once daily in the morning following a fast of at least approximately 8 hours on Days 1 through 5 in one out of five treatment periods.
224078277|NCT01582308|DRUG|Vildagliptin 50 mg|Vildagliptin 50 mg: one vildagliptin 50 mg tablet once daily in the morning following a fast of at least approximately 8 hours on Days 1 through 5 in one out of five treatment periods.
224078278|NCT01582308|DRUG|Vildagliptin 50 mg BID|Vildagliptin 50 mg BID: one vildagliptin 50 mg tablet BID (twice daily), once in the morning following a fast of at least approximately 8 hours and once in the evening on Days 1 through 5 in one out of five treatment periods.
224078279|NCT01582308|DRUG|Placebo|Placebo: one placebo for sitagliptin tablet once daily in the morning following a fast of at least approximately 8 hours on Days 1 through 5 in one out of five treatment periods.
224078280|NCT03781648|DIAGNOSTIC_TEST|NBI withdrawal method|The newly available second generation of NBI using the 290 system (290-NBI) provides an at least twofold brighter image compared with the previous version
224078281|NCT01762566|DIETARY_SUPPLEMENT|wheat|wheat is administered blindly versus placebo in capsules once
224078282|NCT01762566|DIETARY_SUPPLEMENT|xylose|placebo (xylose) will be administered blindly versus wheat in a capsule once
224078283|NCT05840744|DIAGNOSTIC_TEST|complete blood count|Investigations done for identifying the risk factor which lead to thrombosis.
224078284|NCT00371930|PROCEDURE|application of a dye suspension followed by a laser intervention|
224078285|NCT03502720|DEVICE|Scaphoid fixation using 3D device|A headless screw inserted percutaneously from the volar aspect of the scaphoid in a retrograde manner using a customised 3D exoesqueleton guide
224078286|NCT03502720|PROCEDURE|Scaphoid fixation using standard procedure|A headless screw inserted percutaneously from the volar aspect of the scaphoid in a retrograde manner without using the 3D device (standard procedure)
224078287|NCT00441857|BEHAVIORAL|plant stanol consumption|
224078288|NCT03778164|OTHER|Fast Track Partner Services-Sexual Health Intervention|The Partner Services-Sexual Health Intervention enhances the current standard of care by introducing four service innovations to the DOHMH Partner Services program: (1) enhanced field-based combination HIV and STI testing; (2) immediate field-based ARV/PrEP start; (3) navigation to a sexual health clinic for test results and treatment; and (4) enhanced linkage support to facilitate ongoing PrEP or HIV care.
224078289|NCT03778164|OTHER|Partner Services Standard of Care|Participants in neighborhoods that have not yet been assigned to the intervention condition in the stepped wedge trial will receive standard Partner Services components, including field-based HIV testing and referral to clinical sites for HIV prevention or treatment.
224078290|NCT04639323|DIAGNOSTIC_TEST|Endoscopic ruler|"Endoscopic ruler for varices in portal hypertension~Product uses: measuring the diameter of the veins under the endoscopy for the assessment of the risk of variceal haemorrhage in patients with portal hypertension~Black and white measuring rule is highly recognizable under the endoscopy~The width of each cell is 1 mm, and the measuring range is 0-10 mm~With smooth edge, safe and reliable"
224078291|NCT00458731|BIOLOGICAL|bevacizumab|Given IV
224078292|NCT00458731|DRUG|cediranib maleate|Given orally
224078293|NCT02861040|OTHER|Laboratory Biomarker Analysis|Correlative studies
224078294|NCT02861040|OTHER|Pharmacological Study|Correlative studies
224078295|NCT02861040|DRUG|Vincristine Sulfate Liposome|Given IV
224078296|NCT02861040|DRUG|Volasertib|Given IV
224078297|NCT03222466|OTHER|Co-created PEM|A co-created PEM has been designed in collaboration with patients.
224078298|NCT02017574|BEHAVIORAL|Reaching Task|Learn a reaching task that requires coordination of the arm segments
224078299|NCT00332540|DRUG|bimatoprost/timolol fixed combination|
224078300|NCT01386333|DRUG|oxytocin|Patients will be randomized to receive intranasal oxytocin or placebo in a dose escalation paradigm with three dose cohorts: 24IU, 48IU and 72IU of intranasal oxytocin twice daily for 1 week
224078301|NCT01386333|DRUG|Saline Nasal Mist|Placebo arm wil receive saline nasal mist sprays matched in number to oxytocin dose cohorts
224078302|NCT04663945|BEHAVIORAL|Biobehavioral Tele-rehabilitation Sessions|Biobehavioral tele-rehabilitation sessions
224078303|NCT04764760|DEVICE|Wing shaped Tensiflex prosthesis|Curative inguinal hernia repair techniqque
224078304|NCT04595747|PROCEDURE|Biopsy Procedure|Undergo biopsy
224078305|NCT04595747|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
224078306|NCT04595747|PROCEDURE|Computed Tomography|Undergo CT scan and PET/CT scan
224078307|NCT04595747|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
224078308|NCT04595747|PROCEDURE|Positron Emission Tomography|Undergo PET/CT scan
224078309|NCT04595747|DRUG|Rogaratinib|Given PO
224078310|NCT06451068|DEVICE|Peripheral retina robotically aligned optical coherence tomography (OCT) system|To visualize the full 360° of the retinal periphery (from equator to the more anterior ora serrata), investigators developed and redesigned a conical mirror contact lens and our non-contact robotically aligning platform to deliver OCT to the peripheral retina. The peripheral retina robotically aligned OCT (PR-RAOCT) system is built around a 6-axis cooperative robot (UR5e, Universal Robots), using our previously developed RAOCT control software.
224078311|NCT06451068|OTHER|Likert Scales|Survey evaluating relative comfort with each type of peripheral exam (scleral depression vs. PR-RAOCT). Participants will rate 3 items on a 1 (non) to 5 (maximum) Likert scale: overall discomfort, physical pain, and photophobia for each exam.
224078312|NCT06228586|BIOLOGICAL|Meningococcal Polysaccharide (Serogroups A, C, W, and Y) Tetanus Toxoid Conjugate Vaccine|Pharmaceutical form:Liquid solution-Route of administration:Intramuscular injection
224078313|NCT05572229|DRUG|Teclistamab|Teclistamab will be administered via a subcutaneous injection (SC)
224078314|NCT05572229|DRUG|Daratumumab|Daratumumab will be administered via a subcutaneous injection (SC)
224078315|NCT05572229|DRUG|Lenalidomide|Lenalidomide will be administered orally
224078316|NCT06444711|OTHER|NICE guidance|Patients will be assessed to determine whether their current treatment is in line with NICE guidelines. Changes will be made to their treatment plan in order for them to comply with NICE guidelines with the aim of reducing the number of serious adverse events in the group. They will be followed up until 6 months to identify improvements in their conditions
224078317|NCT05975476|BEHAVIORAL|Physical Activity|Participants will be asked to continuously move at a moderate pace along a park trail for 30 minutes, with limited rest periods. The research assistant will monitor the person while in the park and the participant will be asked to turn off their cell phone during this time.
224078318|NCT05975476|BEHAVIORAL|Sensory Engagement|Participants will be asked to stay within a specific area of the park, relax and enjoy the scenery and engage their senses (see, touch, smell, and listen to nature). In addition, the participant will be told they can engage in meditation, mindfulness, and daydreaming. The research assistant will monitor the person while in the park and the participant will be asked to turn off their cell phone during this time.
224078319|NCT06841575|DEVICE|Auto-aligned OCT|Swept Source OCT system with improved hand-held probe technology for auto-alignment to the patient's eye, as well as on-line detection of image quality and auto-saving at the proper time
224078320|NCT03108495|BIOLOGICAL|LN-145|A tumor sample is resected from each patient and cultured ex vivo to expand the population of tumor infiltrating lymphocytes.
224078321|NCT03108495|BIOLOGICAL|LN-145 + pembrolizumab|A tumor sample is resected from each patient and cultured ex vivo to expand the population of tumor infiltrating lymphocytes. The first dose of anti-PD-1 immunotherapy will be administered following tumor resection.
224078322|NCT06255990|OTHER|Standard of care|Standard of care
224078329|NCT06492785|BIOLOGICAL|High Hyaluronic Acid concentrations (0.5 mg/ml)|Hyaluronic Acid(EmbryoGlue®)
224078330|NCT06492785|BIOLOGICAL|Low Hyaluronic Acid concentrations (0.125 mg/ml)|Hyaluronic Acid (G2 medium)
224078331|NCT07001891|OTHER|Clinical assessment|RLS history, RLS treatments, and International Restless Legs Syndrome Rating Scale (IRLSRS) will be recorded
224078332|NCT07001891|BEHAVIORAL|auto-questionnaires (PSQI, ISI, ESS and HADS)|To evaluate sleep quality, daytime somnolence and mood disorders (Pittsburgh Sleep Quality Index (PSQI), Insomnia Severity Index (ISI), Epworth Sleepiness Scale (ESS) and Hospital Anxiety and Depression Scale (HADS)).
224078333|NCT07001891|DEVICE|Ecological Momentary Assessment (EMA)|4 electronic interviews administered per day during 14 days by a study-dedicated Android OS smartphone
224078334|NCT07001891|DEVICE|activity-rest cycle|To further investigate the mutual influence of sleep quality on RLS symptoms and mood, the activity-rest cycle will be monitored by wearable actigraph to be placed on the non-dominant wrist during a period of 13 days and 14 nights.
224078335|NCT07001891|BEHAVIORAL|auto-questionnaires (ASRS, PSAS, APS, MAIA-2)|Interoceptive awareness and accuracy estimation : Adult ADHD Self-Report Scale (ASRS), Pre-Sleep Arousal Scale (PSAS), Arousal Predisposition Scale (APS) et Multidimensional Assessment of Interoceptive Awareness version 2 (MAIA-2)
224078336|NCT07001891|DEVICE|MRI|Morning and evening functional brain imaging
224078337|NCT06670105|DRUG|Glofitamab|Given by vein
224078338|NCT05556525|OTHER|Fluorescein|Given IV
224078339|NCT05556525|DEVICE|Image-Guided Needle Confocal Laser Endomicroscopy|Undergo nCLE
224078340|NCT05556525|PROCEDURE|Ultrasound-Guided Transbronchial Needle Aspiration|Undergo EBUS TBNA
224078341|NCT06350006|DRUG|SHR-A1904; Adebrelimab|SHR-A1904 combined with Adebrelimab: SHR-A1904+ Adebrelimab
224078342|NCT06350006|DRUG|SHR-A1904; CAPOX; Adebrelimab|SHR-A1904 combined with Adebrelimab and CAPOX (Capecitabine, Oxaliplatin)
224078343|NCT07017998|DEVICE|Cold pack-delivered mild therapeutic hypothermia|Mild therapeutic hypothermia (cooling), delivered non-invasively to the structures of the inner ear (cochlea) for 30 minutes, using headband-style proprietary device, ReBound.
224078344|NCT07017998|DEVICE|Sham (No Treatment)|Sham headband-style device will be worn for 30 minutes. Participants will be told they are receiving therapy.
224078345|NCT05597904|GENETIC|Genetic predisposition|Assessment of genetic predisposition to various celiac disease phenotypes. No intervention.
224078346|NCT06700538|DRUG|ARO-INHBE|SC injection
224078347|NCT06700538|DRUG|Placebo|calculated volume to match active treatment by SC injection
224078348|NCT06700538|DRUG|Tirzepatide|SC injection
224078349|NCT05671302|BEHAVIORAL|Walk Together|Receive training in the use of a study-provided blood pressure cuff and hypertension education; engage in hypertension self-management goal-setting; identify barriers to self-management adherence and utilize shared problem-solving to address barriers; connect to existing clinic resources to address environmental barriers; promote relationship strengths; practice communication and behavioral skills to address relationship concerns; engage family in support of patient self-management goals.
224078350|NCT06721416|OTHER|Traditional Aerobic Exercise|Traditional aerobic exercise will be continued with an arm ergometer, at moderate intensity, for 30 minutes.
224078351|NCT06721416|OTHER|VR Based Aerobic Exercise|"In the virtual reality-based aerobic exercise training, the game called Beat Saber will be played with Oculus Quest 2 virtual reality for 30 minutes."
224078352|NCT06721416|OTHER|Conventional Exercise|The conventional exercise program will be modified with stabilization, balance and strengthening exercises, taking into account the functional status of the participants.
224078353|NCT06892522|DRUG|Etentamig|Intravenous (IV) Infusion
224078354|NCT06892522|DRUG|Lenalidomide|Oral Capsule
224078355|NCT06892522|DRUG|Dexamethasone|IV Injection
224078356|NCT06892522|DRUG|Daratumumab|Subcutaneous Injection
224078357|NCT06892522|DRUG|Dexamethasone|Oral Tablet
224078358|NCT06892522|DRUG|Carfilzomib|IV Infusion
224078359|NCT06738394|BEHAVIORAL|High-Velocity Resistance Training|High-velocity resistance training for patients with non-dialysis dependent chronic kidney disease Stages 3-5 with mobility limitations.
224078360|NCT06738394|BEHAVIORAL|Attention|Dedicated contact, information, and motivation throughout the course of the study via weekly group sessions and informational handouts.
224078361|NCT07055607|DRUG|Semaglutide|Participants will be treated with commercially available Wegovy according to routine clinical practice and is purely at the discretion of the treating physician. Only individuals receiving Wegovy reimbursed by the healthcare system in their respective countries are included in the study.
224078362|NCT07053384|BIOLOGICAL|VH3810109|VH3810109 will be administered.
224078363|NCT07053384|DRUG|Fostemsavir (FTR)|Fostemsavir will be administered.
224078364|NCT07053384|DRUG|SOC INSTI-based ART|A SOC INSTI-based ART regimen will be administered.
224078365|NCT07060976|OTHER|18 Transdermal patches along with positive and negative controls 1)Capsaicin0.025% Topical Patch, 2)Diclofenac Diethylamine 100mg Transdermal Patch, 3)Diclofenac Diethylamine 200mg Transdermal Patch,|Dose: 1×1 cm of each Patch (1 cm2) Route of administration: Topical Mode of usage: Products will be evaluated through the complete occlusion for 24 hours. At 24 hours post-application, patches will be removed and skin will be evaluated for irritation reactions at 30 mins,24 hours (Day 1)post patch removal and 168 hours (Day 7) post-patch removal (if needed). Frequency: single application
224078366|NCT06897618|BEHAVIORAL|Culturally tailored diabetes self-management education|Five weeks of culturally tailored diabetes self-management education modeled after Association of Diabetes Care and Education Seven-item Framework (ADCES7).
224078367|NCT04034810|DEVICE|Intracranial aneurysm treated with Silk vista and silk vista baby|Patients with intracranial aneurysm(s) intended to be treated with the silk vista and silk vista baby according to standard of care.
224078368|NCT06765317|DRUG|Glofitamab|C1D8 2.5 mg iv; C1D15 10 mg iv; C2D1-onwards: 30 mg iv, every 3 weeks
224078369|NCT06765317|DRUG|Polatuzumab|1.8 mg/kg iv C1D1 onwards, every 3 weeks
224078370|NCT06765317|DRUG|Rituximab|375 mg/m2 iv D1
224078371|NCT06765317|DRUG|Cyclophosphamide|400 mg/m2 iv D1
224078372|NCT06765317|DRUG|Doxorubicin|25 mg/m2 iv D1
224078373|NCT06765317|DRUG|Obinutuzumab:|1000 mg iv C1D1 (7 days prior to glofitamab administration) single dose
224078374|NCT06781749|DEVICE|Hearing aid use|Hearing aid use will be discussed with all eligible participants with hearing loss and will be encouraged to pursue hearing aid fitting through standard clinical indications via participants' insurance and audiologists.
224078375|NCT07063602|OTHER|Evaluation of the hypoesthesia of the thorax|In the recovery room, a member of the research team will come to assess the presence of hypoesthesia (loss of sensation) of the thorax using ice and a Von Frey filament applied at three different sections: midscapular, midaxillary and midclavicular.
224078376|NCT06899230|DRUG|iQ-007|Highly selective, orally bioavailable, positive allosteric modulator (PAM) of the excitatory amino acid transporter-2 (EAAT2) and its rodent homologue (glutamate transporter-1\[GLT-1).
224078377|NCT06899230|DRUG|Placebo|Oral capsules identical in appearance to drug and containing vehicle only (Gelucire/Capmul-M).
224078378|NCT06546670|DRUG|ITU512|ITU512 is an investigational, oral, low molecular weight (LMW) compound.
224078379|NCT06546670|DRUG|Placebo|An inactive substance that looks like and is given the same way as ITU512. The effect(s) of ITU512 will be evaluated against the placebo. Placebos are designed as a control and to have no real effect.
224078380|NCT06578507|DRUG|Hydroxycarbamid|"Hydroxycarbamide Paediatric dispersible tablets will be provided in the form of film-coated dispersible tablets containing 50 mg of hydroxycarbamide.~The IMP will be administered as half-strength twice daily, based on the body weight of the patient."
224078381|NCT06839235|DRUG|ABO-101|Intravenous (IV) infusion
224078382|NCT00366522|DRUG|LXR-623|
224078383|NCT07073807|BEHAVIORAL|SMART Intervention using TAPPT® for Adherence, Symptom, Financial, and Social Needs Monitoring|The SMART intervention uses TAPPT® smart labels and a web-based app for real-time monitoring of oral anticancer therapy adherence. It includes personalized text reminders, biweekly surveys for medication adherence and symptom burden, missed and extra dose management, symptom alerts to providers, monthly financial and health-related social needs screening with tailored resources, and educational texts for low health literacy. TAPPT® smart labels work with Android/iOS smartphones. All participants receive usual oncology care.
224078384|NCT06926283|DRUG|DXC008|Cohort A: Once every 2 weeks (Q2W) with a cycle length of 14 days. Cohort B: Once every 3 weeks (Q3W) with a cycle length of 21 days.
224078385|NCT04409236|BEHAVIORAL|Quit2Heal|Use Quit2Heal app
224078386|NCT04409236|BEHAVIORAL|QuitGuide|Use QuitGuide app
224078387|NCT04409236|OTHER|Survey Administration|Ancillary studies
224078388|NCT06843213|BEHAVIORAL|Peer Intervention|Participants will receive one peer-led, in-person session boosted by weekly text messages over a 12-week period.
224078389|NCT06843213|OTHER|Enhanced Usual Care|Participants will receive a handout that includes harm reduction education and resources in their local area as part of enhanced usual care.
224078390|NCT06837870|DEVICE|percutaneous suture mediated closure|Vascular closure with a commercially available SMC device.
224078391|NCT06837870|DEVICE|Figure of Eight Suture|Manual Compression with Figure of Eight Suture (control).
224078392|NCT06902519|DRUG|GS-0151|Administered for 12 weeks
224078393|NCT06902519|DRUG|Placebo|Administered for 12 weeks
224078394|NCT06903533|OTHER|Puzzle Activity|After assigning the students to the intervention and control groups, a puzzle activity will be conducted with the intervention group following a lecture. In preparing the puzzles, the researchers will use free online puzzle-making tools (e.g., https://crosswordlabs.com/). The puzzles will include questions related to basic knowledge and concepts concerning gerontological nursing competence. During the puzzle-solving process, the researcher will be present in the classroom and provide guidance to students when needed. After students complete the puzzles, the researcher will project the puzzle on the presentation screen and evaluate the answers through interactive discussion with the students. Upon completion of each puzzle, the researcher will collect the puzzles from the students to prevent contamination between the intervention and control groups. A post-test will be administered to students at the end of the puzzle activity.
224078395|NCT07085390|OTHER|Use of a Balloon Guide Catheter|Use of a balloon guide catheter in stroke thrombectomy.
224078396|NCT07085390|OTHER|Use of a Conventional (non-balloon) Guide Catheter|Use of a conventional (non-balloon) guide catheter in stroke thrombectomy.
224078397|NCT07086976|DRUG|rilzabrutinib|Pharmaceutical form:tablet-Route of administration:oral
224078398|NCT07086976|DRUG|placebo|Pharmaceutical form:tablet-Route of administration:oral
224078399|NCT06015893|BEHAVIORAL|Take Control|A computer-delivered behavioral therapy derived from the NIAAA s self-help approach, Rethinking Drinking, developed for use in pharmacotherapy trials.
224078400|NCT06015893|DRUG|Semaglutide|Weekly subcutaneous (s.c.) injections of semaglutide (or placebo) up to 2.4 mg/week or maximum tolerated dose (MTD).
224078401|NCT06894615|DEVICE|Treatment with BTL-995-rTMS|Six transcranial magnetic stimulation treatments with the BTL-995-rTMS device will be delivered over the left dorsolateral prefrontal cortex, spaced 2 to 4 days apart. The intensity will be adjusted according to the subject's feedback, up to 70% of the individual's motor threshold.
224078402|NCT04925479|DRUG|Asciminib Pediatric formulation group|"Asciminib Pediatric formulation group: 1 mg film-coated granules in a size 0 capsule will be supplied, taken orally (capsules are a container for the granules and are not ingested):~10 mg (10x 1 mg film-coated granules in capsule) 15 mg (15x 1 mg film-coated granules in capsule) 20 mg (20x 1 mg film-coated granules in capsule) 30 mg (30x 1 mg film-coated granules in capsule)"
224078403|NCT04925479|DRUG|Asciminib Adult formulation group|"Asciminib Adult formulation group:~40 mg tablets BID, taken orally. 20 mg tablets BID, taken orally."
224078404|NCT06320431|DRUG|Tenecteplase|Thrombolytic
224078405|NCT06906627|OTHER|(IRIS-CKD Screening Program): Home Kit|"All participants approached for enrollment in Program 1 will receive National Kidney Foundational educational materials related to CKD screening in type 2 diabetes and study information. All enrolled participants will receive a message regarding study lab(s) results.~Home Test Kit: a kit delivered to participants homes with instructions to complete eGFR (fingerstick) and/or UACR (urine sample) testing, depending on which lab(s) are missing at baseline."
224078406|NCT06906627|OTHER|(IRIS-CKD Screening Program): Standard Lab Order|ll participants approached for enrollment in Program 1 will receive National Kidney Foundation educational materials related to CKD screening in type 2 diabetes and study information. All enrolled participants will receive a message regarding study lab
224078407|NCT06906640|OTHER|(IRIS-CKD Management Program): Education|Patients randomized to the education arm will receive targeted education materials regarding their severity of CKD, including the potential for additional GDMT to slow CKD progression to discuss with their Primary Care Provider (PCP). At 6 months, the study pharmacist (or APP) will order repeat eGFR and UACR after 6 months to standardize CKD follow up during the study period.
224078408|NCT06906640|OTHER|(IRIS-CKD Management Program): GDMT|Patients randomized to the education arm will receive targeted education materials regarding their severity of CKD, including the potential for additional GDMT to slow CKD progression to discuss with their PCP. At 6 months, the study pharmacist (or APP) will order repeat eGFR and UACR after 6 months to standardize CKD follow up during the study period. Plus, receive guided care by APP.
224078409|NCT07084675|BEHAVIORAL|Hydration-Dehydration-Rehydration Protocol (HDR)|"The HDR Protocol is a 12-day, sequential fluid manipulation intervention designed to assess the physiological effects of controlled changes in hydration status. The protocol consists of three consecutive 4-day phases:~Hydration Phase (Days 1-4): Participants follow a standardized fluid intake protocol designed to promote and maintain a euhydrated state. Hydration status is monitored using objective measures such as urine specific gravity and body mass.~Dehydration Phase (Days 5-8): Participants adhere to a fluid-restriction regimen to induce a hypohydrated state. The level of dehydration is verified through the same hydration status measures to ensure consistent and safe hypohydration.~Rehydration Phase (Days 9-12): Participants resume the standardized fluid intake protocol used during the Hydration Phase to restore euhydration. Rehydration effectiveness is confirmed through repeated hydration assessments."
224078410|NCT06723236|BIOLOGICAL|MGC028|MGC028 is an antibody-drug conjugate targeted against ADAM9.
224078411|NCT07096687|DEVICE|Targeted Temperature Management with CB240_Aurora|The proposed experimental treatment with the CB240\_Aurora device will serve as a complementary approach to standard therapies, aiming to enhance their effectiveness. The device will continuously monitor body temperature and deliver treatment to maintain normothermia, defined as a temperature ≥36°C and \<37°C at the time of study inclusion.
224078412|NCT07096687|DEVICE|Standard of care Temperature treatment|In the control group, patients will receive treatment according to the latest guidelines for the management of ischemic stroke, including standard body temperature management. The CB240\_Aurora device will be used exclusively in monitoring mode, without delivering any active treatment, and will be maintained for 72 consecutive hours from the time of enrollment
224078413|NCT05997381|DEVICE|Arthroscopic rotator cuff repair with BioBrace® Implant augmentation.|An arthroscopic rotator cuff repair will be performed and augmented with the BioBrace® Implant. The BioBrace® Implant is intended for use in surgical procedures for reinforcement of soft tissue where weakness exists. It is a bioresorbable, biocomposite scaffold composed of a highly porous collagen sponge and reinforced with poly-L-lactic-acid (PLLA). When used in rotator cuff repairs, it is placed on top of the tendons to augment and reinforce the underlying repair. The BioBrace® is designed to mechanically and biologically augment weakened or torn soft tissue and can be integrated into surgeons' standard of care rotator cuff repair techniques.
224078414|NCT05997381|PROCEDURE|Arthroscopic rotator cuff repair|An arthroscopic rotator cuff repair is performed using standard surgical procedure.
224078415|NCT06910631|OTHER|Capillary CRP|CRP measured semi-quantitatively using ACTIM-CRP device
224078416|NCT07138027|BEHAVIORAL|Clinical decision support + education (CDS+) and population health management (PHM)|In Interval 1, intervention clinic providers will experience nudges in the electronic medical record to encourage prescribing SMART where clinically-appropriate and intervention clinic providers, families/patients, and nurses will receive education (collectively CDS+). In Interval 2, intervention clinics will have CDS+ and population health management (PHM) strategies, including an asthma community health worker and an asthma nurse care manager.
224078417|NCT07138027|OTHER|Control|Clinics in Arm 2 will not be exposed to the interventions.
224078418|NCT06910592|DEVICE|Treatment with BTL-995-rTMS|Six transcranial magnetic stimulation treatments with the BTL-995-rTMS device will be delivered over the left dorsolateral prefrontal cortex, spaced 2 to 4 days apart. The intensity will be adjusted according to the subject's feedback, up to 70% of the individual's motor threshold.
224078419|NCT06910384|BIOLOGICAL|STR04|autologous bone-marrow-derived mesenchymal stem cells
224078420|NCT06627647|DRUG|Rilvegostomig|Administered as one intravenously (IV) on Day 1 of each 21-day cycle
224078421|NCT06627647|DRUG|Pembrolizumab|Administered as one intravenously (IV) on Day 1 of each 21-day cycle
224078422|NCT06627647|DRUG|Carboplatin|Administered as one intravenously (IV) on Day 1 of each 21-day cycle up to 4 cycles
224078423|NCT06627647|DRUG|Cisplatin|Administered as one intravenously (IV) on Day 1 of each 21-day cycle up to 4 cycles
224078424|NCT06627647|DRUG|Pemetrexed|Administered as one intravenously (IV) on Day 1 of each 21-day cycle
224078425|NCT05321082|DRUG|BI 1015550|BI 1015550
224078426|NCT05321082|DRUG|Placebo|Placebo
224078427|NCT07102316|DRUG|TPIP F2|Inhalation using a capsule-based dry powder inhaler device.
224078428|NCT07102316|DRUG|TPIP F3|Inhalation using a capsule-based dry powder inhaler device.
224078429|NCT07101198|PROCEDURE|Ultrasound-guided erector spinae plane block|Patients in this group will receive an ultrasound-guided erector spinae plane block 30 minutes before surgery. A total volume of bupivacaine will be injected bilaterally into the fascial plane between the erector spinae muscle and the transverse process. All patients will also receive standard postoperative analgesia.
224078431|NCT07104279|DEVICE|Z1 Femoral Hip System|Subjects who will be implanted with the Z1 Femoral Hip System in hemi-hip arthroplasty and primary total hip arthroplasty
224078432|NCT06828666|BIOLOGICAL|Cryopreserved Devitalized Adipose Tissue Allograft|BRC-OA is a Cryopreserved Devitalized Adipose Tissue Allograft that has demonstrated anti-inflammatory and antioxidant properties of adipose tissue.
224078433|NCT06828666|OTHER|Normal Saline (Placebo)|2 mL Normal Saline
224078434|NCT06560632|DRUG|RP-3467 at assigned dose and schedule|Eligible participants will be treated with escalating doses of RP-3467 monotherapy
224078435|NCT06560632|DRUG|Olaparib 200-300 mg BID, daily|Eligible participants will be treated with escalating doses of RP-3467 in combination with Olaparib
224078436|NCT07102082|BEHAVIORAL|Modified Risk - None|Participants view ads with no modified risk claim
224078437|NCT07102082|BEHAVIORAL|Modified Risk Claim|Participants view ads with a modified risk claim
224078438|NCT06408168|DRUG|Fulvestrant|Given by PO
224078439|NCT06408168|DRUG|Repotrectinib|Given by IV
224078440|NCT06915090|BEHAVIORAL|Health Coach/Fitbit|"Health coach visits (up to 6) will be conducted virtually and include:~Session 1:~* Assessment, wellness vision,~* Habits and goals (Stretching, strength training, cardiovascular PA/walking, Diet)~* Motivation, resources, and guidelines~* Online program orientation~* Set first week's goals~Sessions 2-5:~-Goal review, successes and challenges, new goal setting (i.e. Increase steps by 1,000/day if consistently meeting goal)45~Session 6~-Review of progress, maintenance plan, final assessment~Once baseline measures are completed, patients without a Fitbit device will be provided one for the duration of the study, which they get to keep. The same option will be available for patients who already have a Fitbit but would like one provided by the study team anyway. The participant will receive their Fitbit device at their baseline study visit. Participants will also be instructed to wear their Fitbit for a total of 12 weeks with a suggested step count."
224078441|NCT06913699|PROCEDURE|Ultrasonund-guided percutaneous liver biopsy|All patients completed blood routine, coagulation function and liver biochemical indexes before surgery, and informed the patients and their families about the purpose and risks of surgery, and signed an informed consent. During the procedure, the patient was placed in the left lateral decubitus position. After locating by ultrasound and routine disinfection, 0.5% lidocaine was used for local anesthesia. Under the guidance of ultrasound, a 16G disposable biopsy needle (SC1620) was inserted into the liver parenchyma, and the biopsy gun was started and fired for sampling. The removed liver tissue was fixed in 4% formaldehyde solution and sent to the pathology department. The patient's puncture site was disinfected and covered with sterile dressing, and the abdominal band was bandaged. The patients were instructed to stay in bed for 24 hours after operation, closely observe whether there was pain and bleeding after operation, and monitor electrocardiogram for 24 hours.
224078442|NCT06916325|DEVICE|dual hypothermic oxygenated perfusion (DHOPE)|Clinically, end-ischemic DHOPE has been shown to restore hepatic ATP, reduce reperfusion injury, and improve outcomes after deceased donor liver transplantation. Recent prospective and retrospective clinical studies detail the safety and feasibility of prolonged preservation of donor livers with DHOPE for up to 20 hours; prolonged perfusion has shown similarly low rates of serious adverse events, a potential protective effect in mitigating acute kidney injury and may facilitate decreased frequency of discarded and nonuse of donor livers.
224078445|NCT06933368|DRUG|Crest Cavity Protection Toothpaste|Toothpaste containing 0.243% w/w NaF.
224078446|NCT06933368|DRUG|Experimental Mouthwash|Mouthwash containing 0.085% w/w CPC.
224078447|NCT06937320|DIETARY_SUPPLEMENT|Exogenous Ketone Drink|"(R)-1,3-butanediol (BD, commercially available as KetoneIQ) initially dosed 300 mg/kg BID (target dose 400 mg/kg grams BID if tolerated) for 8 weeks"
224078448|NCT06937320|DIETARY_SUPPLEMENT|Placebo|equi-volume placebo administered for 8 weeks
224078449|NCT06935838|DRUG|Tirzepatide|Tirzepatide is approved by the Food and Drug Administration (FDA) for the treatment of type 2 diabetes, obesity and overweight with at least one weight-related medical condition, and moderate to severe obstructive sleep apnea. An initial dose of TZP 2.5 mg subcutaneous (SQ) once weekly will be given, escalated by 2.5 mg at 4-week intervals to a final dose of 7.5mg.
224078450|NCT06943105|BEHAVIORAL|Nonviolent Communication Intervention|The intervention will be conducted by social workers who will be trained by professional NVC trainers through a train-the-trainer workshop, including six sessions. The interventions include an introduction to four fundamental principles of NVC, distinguishing observations from evaluations, identifying and expressing feelings, taking responsibility for feelings and needs, and using positive action language to make requests. Each session will feature a review of the previous session, a warm-up game and an exercise to consolidate the learning of the concepts. The intervention sessions will also include group discussions and debriefing sessions on parents' experiences of practising NVC.
224078451|NCT07148960|DRUG|Early Dual IV Antibiotic Therapy - MRSA|Participant given IV daptomycin plus ceftaroline dosing per standard of care. Oral rifampin may be added for participants with prosthetic material.
224078452|NCT07148960|DRUG|Early Dual IV Antibiotic Therapy - MSSA|Participant given IV cefazolin plus ertapenem dosing per standard of care. Oral rifampin may be added for participants with prosthetic material.
224078453|NCT07148960|DRUG|Single Agent IV Antibiotic Therapy - MRSA|Participant given one of the following IV therapies: daptomycin, vancomycin, or ceftaroline. Oral rifampin may be added for participants with prosthetic material.
224078454|NCT07148960|DRUG|Single Agent IV Antibiotic Therapy - MSSA|Participant given one of the following IV therapies: cefazolin, oxacillin, or nafcillin. Oral rifampin may be added for participants with prosthetic material.
224078455|NCT07149142|DIAGNOSTIC_TEST|Non-mydriatic fundus camera photography|Non-mydriatic fundus camera photography assessed by artificial intelligence software
224078456|NCT07149142|DIAGNOSTIC_TEST|Fundus ophtalmoscopy|Fundus opthalmoscopy assessed by an experienced ophtalmologist
224078457|NCT07149142|DIAGNOSTIC_TEST|Optic coherence tomography|Optic coherence tomography assessed by an experienced ophtalmologist
224078458|NCT07149142|DIAGNOSTIC_TEST|Confocal microscopy of the retina|In a subset of participants over 18 years of age, confocal microscopy of the retina will be performed to assess the presence of diabetic neuropathy
224078459|NCT00466648|PROCEDURE|Tissue adhesive|
224078460|NCT07120945|DEVICE|Robotic Assisted-Surgery (RAS) Hysterectomy|Patients indicated for Robotic Assisted-Surgery (RAS) hysterectomy procedures will have the RAS surgery using the Medtronic Hugo™ RAS system.
224078461|NCT07160127|DRUG|TJAOA103|Once enrolled, participants will be administered TJAOA103 for 4 to 12 weeks. TJAOA103 should be taken orally twice a day, one sack each time. Dissolve it in about 200 mL of warm water and drink it all. Participants can take it half an hour before breakfast in the morning and half an hour before bedtime in the evening.
224078462|NCT07153562|OTHER|liuzijue qigong exercises|Liuzijue qigong exercise for 20 minutes, 5 times per week, for 12 successive weeks.
224078463|NCT07153562|OTHER|conventional rehabilitation treatment|conventional rehabilitation exercises, 3 sessions per week, 45-60 minutes per session, for 12 successive weeks.
224078464|NCT07167836|OTHER|Electronic medical record-based care pathway|Participants will undergo initial automated risk stratification to direct tailored follow-up intervals. If exceeding the maximum time interval, participants in the intervention arm will be contacted by scheduling personnel using a standardized protocol to schedule a follow-up visit. In contrast, patients in the control arm who are overdue will not be made known to any staff and will not be proactively contacted, instead continuing to be managed according to standard of care. To maximize generalizability and understanding among staff and patients, risk stratification will be based on inflammatory bowel disease medication use.
224078465|NCT07166016|OTHER|Conservative|Patients with hammertoe deformities will undergo conservative treatments, including wearing proper shoes, insoles, and custom orthotics.
224078466|NCT07166016|PROCEDURE|Surgical|Patients with hammertoe deformities will undergo surgical treatments.
224078467|NCT07168291|DRUG|Conditioning chemotherapy followed by AbTCR (anti-CD19/CD22)-T cell infusion|Cyclophosphamide 250 mg/m2 and fludarabine 30 mg/m2 IV infusion on day -5, -4, and -3. AbTCR (anti-CD19/CD22)-T cell IV infusion on day 0.
224078468|NCT07166198|DEVICE|Wrist immobilization|The wrist immobilization will use a medical device (wrist cast) to immobilize the left, non-dominant wrist for 7 days.
224078469|NCT07166198|BEHAVIORAL|Resistance training|The cross-education intervention will consist of resistance training on the dominant, right hand.
224078470|NCT07166198|BEHAVIORAL|Resistance training rehabilitation|The resistance training rehabilitation will occur for the non-dominant, left hand following the immobilization phase for all participants.
224078471|NCT07166770|BEHAVIORAL|Community-led discussion|Participants engage in weekly community-led small group discussions about health related topics
224078472|NCT07168330|DEVICE|Ankle replacement|Total ankle arthroplasty
224078473|NCT07164677|PROCEDURE|Bilateral ultrasound guided Serratus Posterior Superior Plane Block|Bilateral ultrasound-guided Serratus Posterior Superior Plane Block (total of 60 ml, %0.25 bupivacaine) will be performed Multimodal analgesia : Intraoperatively, all patients will receive 0.05 mg/kg (IBW) iv morphine. Thirty minutes before the end of surgery, 1 gram of intravenous paracetamol will be administered. Postoperative analgesia: iv paracetamol 1gr every 8 hours and IV PCA of 0,5mg/ml morphine. In cases where rescue analgesia is required (NRS score ≥4),iv fentanyl 25-50 mcg and/or ibuprofen and/or ketamine 10 mg will be administered. Patients are routinely administered iv dexamethasone 4 mg and IV 8 mg ondansetron 20 minutes before end of surgery for postoperative nausea and vomiting prophylaxis.
224078474|NCT07164677|DRUG|IV morphine patient-controlled analgesia|IV PCA of 0,5mg/ml morphine (the bolus dose is 20 μg/kg, the lock-in time of 6-10 minutes, the 4-hour limit is adjusted to be 80% of the calculated total amount).
224078475|NCT07164677|PROCEDURE|Bilateral ultrasound guided Sham Block|"Bilateral ultrasound-guided needle placement will be performed in the same anatomical plane as in the SPSIP group, but instead of local anesthetic, an equivalent volume of normal saline (30 mL per side) will be injected.~Multimodal analgesia : Intraoperatively, all patients will receive 0.05 mg/kg (IBW) iv morphine. Thirty minutes before the end of surgery, 1 gram of intravenous paracetamol will be administered. Postoperative analgesia: iv paracetamol 1gr every 8 hours and IV PCA of 0,5mg/ml morphine. In cases where rescue analgesia is required (NRS score ≥4),iv fentanyl 25-50 mcg and/or ibuprofen and/or ketamine 10 mg will be administered. Patients are routinely administered iv dexamethasone 4 mg and IV 8 mg ondansetron 20 minutes before end of surgery for postoperative nausea and vomiting prophylaxis."
224078476|NCT07171866|PROCEDURE|Immediate Implant Placement with SST|Participants underwent extraction and socket shield preparation, followed by immediate implant placement in the esthetic maxillary zone. The implant was inserted at the same surgical session using a flapless or minimally invasive approach. CBCT was used to guide planning and assess ridge dimensions. Healing and follow-up assessments were conducted at 1 year and 6 years post-placement.
224078477|NCT07171866|PROCEDURE|Delayed Implant Placement with SST|Participants underwent extraction and socket shield preparation. Implant placement was delayed for 6 months to allow soft and hard tissue healing. The implant was placed after verifying shield stability and ridge preservation via CBCT. Follow-up assessments were conducted at 1 year and 6 years post-placement.
224078478|NCT07171879|PROCEDURE|Tooth Extraction only|Conventional atraumatic extraction of the non-restorable maxillary tooth in the esthetic zone without socket preservation procedures.
224078479|NCT07171879|PROCEDURE|Extraction + MPM|Tooth extraction followed by socket grafting using MPM, prepared from autologous blood combined with xenograft bone particles.
224078480|NCT07171879|PROCEDURE|Pontic Shield Only|Partial extraction therapy using the pontic shield technique, in which the buccal root fragment is preserved to maintain ridge contour, without additional grafting.
224078481|NCT07171879|PROCEDURE|Pontic Shield + MPM|Pontic shield technique combined with grafting using mineralized plasmatic matrix (MPM) for enhanced ridge preservation and healing.
224078482|NCT07168824|DIETARY_SUPPLEMENT|Lacticaseibacillus paracasei|one capsule daily for 12 weeks
224078483|NCT07178509|PROCEDURE|Stress Echocardiography with Contrast|Stress Echocardiography with Contrast will be used to assess heart function and blood flow response to stressors.
224078484|NCT07178041|PROCEDURE|Remote Ischaemic Conditioning|Brief episodes of reversible ischaemia are applied to a particular tissue or organ by inflating pressure cuffs around arms or legs to above systolic pressures (mmHg). This procedure is performed for periods that avoid physical injury to the limbs, but induce neurohormonal, systemic or vascular changes in the body. In this study, the treatment will be delivered on the upper arm or unaffected leg.
224078485|NCT07178899|BEHAVIORAL|typology-based intervention|The typology-based intervention includes: (1) typology-based counselling, (2) personalized E-message based on the counselling content discussed (3) a booklet introducing the typology of quit identity. All interventions and materials are delivered by smoking counselling.
224078486|NCT07178899|BEHAVIORAL|Routine Treatment|The routine smoking cessation intervention includes: (1) Routine counselling generic advice on preventing smoking relapse (2) Brief e-messages that consist of general quit advice for 4 weeks. Counsellors implement both routine practices.
224078487|NCT07178379|PROCEDURE|Local paracervical Anesthesia|"1\. Intervention Group (Local Anesthesia) Name: Mepivacaine 3% uterosacral ligament block Type: Pharmacological (local anesthetic).~Dose/Administration:~Drug: Mepivacaine hydrochloride 3% (4 vials of 1.7 mL each, total 6.8 mL). Route: Bilateral injection into uterosacral ligaments (2 injections per ligament, 3.4 mL per side).~Technique:~Patient in lithotomy position. Uterosacral ligaments identified posteriorly to the cervix. Injection with a 27G Carpule needle (25 mm length) at 2-3 mm depth. Slow infusion (to minimize dispersion). Timing: Administered ≥1 minute before hysteroscopy."
224078488|NCT07178379|OTHER|Placebo|"Procedure:~Vaginal and cervical irrigation with 0.9% saline solution (4 irrigations, mimicking anesthesia administration).~Mimicry:~Same equipment (syringe, speculum) as intervention group. Identical patient positioning and timing"
224078489|NCT07178301|PROCEDURE|Computed Tomography|Undergo CT
224078490|NCT07178301|PROCEDURE|Nasopharyngeal Laryngoscopy|Undergo nasopharyngolaryngoscopy
224078491|NCT07178301|PROCEDURE|Positron Emission Tomography|Undergo PET
224078492|NCT07178301|OTHER|Questionnaire Administration|Ancillary studies
224078493|NCT07178301|RADIATION|Radiation Therapy|Undergo radiation therapy
224078494|NCT07178093|DIETARY_SUPPLEMENT|Antrodia cinnamomea|The experiment lasted for 11 days, and patients were required to take Kangjian Antrodia cinnamomea 3 days before embolization, the day of embolization to the 7th day after surgery, once a day in the morning and evening after meals, 2 capsules each time.
224078495|NCT07178093|DIETARY_SUPPLEMENT|placebo|The experiment lasted for 11 days, and patients were required to take placebo 3 days before embolization, the day of embolization to the 7th day after surgery, once a day in the morning and evening after meals, 2 capsules each time.
224078496|NCT07179081|DRUG|AL58805|Oral,Multiple administrations, once or twice daily（20mg 、40mg QD; 20mg 、30mg、40mg、50mg、60mg BID；）
224078497|NCT07177378|DEVICE|management of medication related osteonecrosis of the jaw|after buccal flap reflection, the bone osteonecrosis was debrided using piezosurgery. the buccal mucoperiosteal flap was dissected to two layers first, the periosteal layer was based superiorly and the mucosal flap to achieve double layers closure.
224078498|NCT07179198|DEVICE|KIO021|KIO021 is used as a device product for dry skin and dull complexion
224078499|NCT07178756|PROCEDURE|Acupuncture|"Both groups A and B will undergo standard postoperative management program. This includes conventional analgesia and physiotherapy POD 1, 2 and 3, followed by 5x/week until discharge, post-discharge, patients will continue physiotherapy 1-2x/ week for 3 months depending on their rate of recovery.~In addition, acupuncture treatment will be delivered for the treatment group. Acupuncture will be performed 2x/week from postoperative week (POW) 5 to POW 8, a total of 8 acupuncture treatments will be administered. From the 2nd to 8th treatment, electroacupuncture and infrared therapeutic lamp will be used. The acupuncture needles to be used for this study are Kinhong/MAC sterile acupuncture needles for single use. The needles will be left in situ for 20 minutes. Electrical stimulation will be delivered at 2Hz for 20 min, at an intensity below individual patient's pain threshold. 4 acupuncture points will be stimulated in pairs."
224078500|NCT07178756|OTHER|Post-operative standard care|Standard postoperative management program includes: conventional analgesia and physiotherapy POD 1, 2 and 3, followed by 5x/week until discharge. Post-discharge, patients will continue physiotherapy 1-2x/ week for 3 months depending on their rate of recovery. No acupuncture given
224078501|NCT07179315|DRUG|cemiplimab+fianlimab|Fianlimab 1600 mg + Cemiplimab 350 mg FDC
224078502|NCT07179315|DRUG|Cemiplimab|350 mg
224078503|NCT07179289|OTHER|Provision of the MSProgress quality approach support tool|"The MSProgress tool is composed of 43 quantitative indicators identified by field teams and queried in health insurance databases. It is presented in a 20-page document organized by theme, allowing simplified access to the team's data, easily understandable by all. It allows the MSP to choose the indicators that make sense at the level of their patient base. Updated annually, the results make it possible to observe the team's progress and to position itself in relation to the regional average of MSPs in the Auvergne-Rhône-Alpes region, promoting collective reflection on the implementation of corrective actions.~The MSProgress tool will be made available for 12, 24 or 36 months depending on the randomization group."
224078504|NCT07178769|DIETARY_SUPPLEMENT|ARKOSTEROL|After 2 and 4 months from the start of treatment, a follow-up will be carried out in which anthropometric data will be measured (weight, BMI, waist circumference), vital signs (blood pressure and pulse) and a sample will be taken for analysis to measure the following parameters: CT, LDL, HDL, triglycerides, VLDL, Apo A, Apo B, liver function (GOT, GPT) and kidney function (creatinine) and Liposcale ® (in case of treatment group).
224078505|NCT07178821|PROCEDURE|Conventional POEM|Standard posterior POEM with full-thickness myotomy, including both circular and gastric sling muscle fibers.
224078506|NCT07178821|PROCEDURE|Sling Fiber-Preserving POEM|Posterior POEM with selective preservation of gastric sling fibers by limiting myotomy to the right of the second penetrating vessel.
224078507|NCT07177599|BIOLOGICAL|Natural history|Natural history of pancreatic diseases
224078508|NCT07178184|DRUG|Modified Qing-Zao-Jiu-Fei Decoction (MQZJFD)|"MQZJFD is the core formula in this clinical study and consists of the 11 following herbs: Mori Folium 9g, Plaster stone 9g, Trichosanthis Fructus 9g, Ophiopogyonis Radix 6g, Armeniacae Semen Amarum 6g, Fritillariae Thunbergii Bulbus 6g, Eriobotryae Folium 6g, Ginseng Radix et Rhizoma 3g, Semen Sesami Nigrum 3g, Asini Corii Colla 3g, Glycyrrhizae Radix et Rhizoma 3g.~The formula will be prepared with single concentrated herbal granules (1 g of single concentrated herbal granule equates to 5 g of original dry herbs, except for Ophiopogyonis Radix whose ratio will be that 1 g of single concentrated herbal granule equals to 3 g of original dry herb, and Asini Corii Colla whose ratio will be that 1 g of single concentrated herbal granule equals to 1 g of original dry herb). The herbal granules will be provided by a Good Manufacturing Practice (GMP)-accredited supplier."
224078509|NCT07178184|DRUG|Placebo|The placebo granules consists of an inert substance made of starch filler, silica coating, flavor and coloring. Its appearance is unidentifiable to the real intervention drug. The placebo granules is also manufactured under GMP standards. To ensure blinding, the MQZJFD granules and placebo granules will be indistinguishable in appearance, smell and flavor.
224078510|NCT07177820|OTHER|Video-Guided Acupuncture Imagery Treatment (VGAIT)|Participants watch a video of acupuncture being applied to the body while simultaneously imagining that it is being administered to them
224078511|NCT07178067|OTHER|Mediterranean diet|The Mediterranean diet, characterised by a high intake of fruits, vegetables, whole grains, legumes, nuts, and olive oil, along with moderate consumption of fish and poultry, has been associated with anti-inflammatory and neuroprotective effects. Notably, this dietary pattern has the potential to enhance the production of short-chain fatty acids (SCFAs) and support gut microbial diversity, representing a promising strategy for nutritional intervention in patients with ALS.
224078512|NCT07178249|BIOLOGICAL|EXG202 injection|EXG202 injection is a gene therapy product for the treatment of wet (neovascular) Age-related Macular Degeneration（wAMD） with a single intravitreal injection and administration.
224078513|NCT07178938|DRUG|Radiotracer targeting SSTR2 ([68Ga]Ga-DOTA-TOC)|Patients will receive a single infusion of the diagnostic agent \[68Ga\]Ga-DOTA-TOC will which will be detected by PET/CT imaging. The recommended activity for an adult weighing 70 kg is 100 to 200 MBq, administered by direct slow intravenous injection and for a single use only.
224078514|NCT07178327|DRUG|LYN101|"In Part A, participants will receive single dose of LYN101 administered as a subcutaneous (SC) injection.~In Part B, participants will receive multiple doses of LYN101 administered as a SC injection."
224078515|NCT07178327|DRUG|Placebo|"In Part A, participants will receive single dose of the matched placebo administered as a subcutaneous (SC) injection (4 cohorts).~In Part B, participants will receive multiple doses of the matched placebo administered as a SC injection."
224078516|NCT07179263|OTHER|50% glycolic acid|Subjects use 3 drops about 0.2g of 50% Glycolic Acid product on half face under instruction, then wait for 3 minutes and wash face by tap water. Wait for 10 minutes before measuring.
224078517|NCT07179263|OTHER|Tape Stripping|Technician use the D100 to paste on the center of the test area and make it fit the skin more completely and evenly by pump fully cover the D100 patch for 10 seconds. Stripping on each test area until the skin change into redness. The number of stripping will be recorded.
224078518|NCT07178496|OTHER|Sleep Hygiene Techniques|"Sleep Hygiene Techniques~The sleep hygiene program includes education and behavioral strategies to promote healthier sleep patterns, delivered alongside physiotherapy exercises. Key components are:~Regular Sleep-Wake Schedule~Encourage patients to maintain consistent bedtime and wake-up times, even on weekends.~Avoid excessive time in bed when not sleeping.~Optimizing the Sleep Environment~Ensure a quiet, dark, and cool bedroom (18-22°C).~Use supportive pillows to maintain neutral cervical alignment and reduce neck strain.~Remove distractions such as TVs, mobile phones, and bright lights.~Pre-Sleep Routine~Establish a relaxing wind-down routine (e.g., gentle stretching, breathing exercises, reading).~Avoid mentally stimulating activities or heavy problem-solving before bedtime.~Limiting Stimulants and Alcohol~Avoid caffeine, nicotine, and alcohol at least 4-6 hours before bedtime.~Avoid heavy meals close to bedtime; a light snack is acceptable if hungry.~Daytime Habits t"
224078519|NCT07178496|OTHER|conventional physiotherapy program|"Conventional Physiotherapy Program~1. Treatment Frequency and Duration~   Frequency: 3 sessions per week~   Duration: 8 weeks~   Session length: 45-60 minutes~2. Hot Pack Application (10-15 minutes)~   Purpose: Reduce pain, improve soft-tissue extensibility, and prepare muscles for exercise.~   Procedure:~   Moist hot pack applied to the cervical region.~   Temperature: 40-45°C (comfortable warmth, checked to avoid burns).~   Duration: 10-15 minutes with adequate towel layers.~3. Neck Endurance and Strength Training (30-40 minutes)"
224078520|NCT07178496|OTHER|Control arm|"only advices and home advices~Physiotherapy Advice for Patients with Neck Pain~Adhere to Your Exercise Program~Perform the prescribed neck strengthening and endurance exercises daily.~Focus on quality over quantity-slow, controlled movements are more effective.~Maintain Correct Posture During All Activities~Keep your neck in a neutral position whether sitting, standing, or walking.~Incorporate Frequent Micro-Breaks~Every 30-45 minutes, pause to gently move and stretch your neck and shoulders.~Small posture corrections throughout the day prevent stiffness.~Use Heat Before Exercise if Stiff or Painful~Apply a hot pack for 10-15 minutes before exercises to relax muscles.~Avoid prolonged or excessive heat application.~Stay Active - Avoid Prolonged Rest~Light physical activity (walking, cycling, gentle mobility work) helps recovery.~Bed rest should be avoided unless pain is severe.~Practice Relaxation and Breathing C"
224078521|NCT07177547|OTHER|Mental health screening and referral practices in physiotherapy|Semi-structured interviews were conducted with 18 physiotherapists working in private settings to explore recognition, screening, and referral practices for anxiety and depression in patients with chronic musculoskeletal pain.
224078522|NCT07178548|OTHER|Online Survey|Participants will complete a structured online survey designed to assess their knowledge, attitudes, and application of evidence-based guidelines (clinical practice guidelines - CPGs) in managing low back pain (LBP).
224078523|NCT07178002|DRUG|Bacterial Lysate|Administration p.o. for 10 days per month for 3 months, two consecutive cycles.
224078524|NCT07178002|DRUG|Placebo|Matching placebo
224078525|NCT07178834|BEHAVIORAL|Telerehab|Adverse events are observed during online rehabilitation with computer vision technology in patients with MS.
224078526|NCT07177911|DRUG|CC312|Subjects will initially receive a single intravenous dose of CC312. After a 21-day period following the first dose, the patient may proceed to the multiple intravenous dosing phase only after investigators and the sponsor have confirmed acceptable safety and tolerability.
224078527|NCT07177911|DRUG|Placebo|Subjects will initially receive a single intravenous dose of Placebo. After a 21-day period following the first dose, the patient may proceed to the multiple intravenous dosing phase only after investigators and the sponsor have confirmed acceptable safety and tolerability.
224078528|NCT07177456|BIOLOGICAL|UCB-MNCs|UCB-MNCs were administered via intravenous infusion three times, once per week, with a dose of 3×10⁸ cells per infusion.
224078529|NCT07179432|PROCEDURE|V-E facial mask ventilation maneuver|"The V-E maneuver is achieved by placing the thumbs and thenar eminence of each hand on the sides of the mask, creating a V shape, while the rest of the fingers perform a jaw thrust described as an E shape. This will be performed after anesthetic induction when the patient is unconscious and apneic. The C-E maneuver is achieved by placing the thumb and index finger of each hand on the mask in a C shape, while the third, fourth, and fifth fingers of both hands perform a jaw thrust towards the mask in an E shape. This will also be performed after anesthetic induction when the patient is unconscious and apneic."
224078530|NCT07179432|PROCEDURE|C-E facial mask ventilation maneuver|"The C-E maneuver is achieved by placing the thumb and index finger of each hand on the mask in a C shape, while the third, fourth, and fifth fingers of both hands perform a jaw thrust towards the mask in an E shape. This will also be performed after anesthetic induction when the patient is unconscious and apneic."
224078531|NCT07179068|BEHAVIORAL|Child Body Image Development Workshop|This is an online, single-session, modular intervention for parents of children that are two-to-six years old. It is designed to target and improve child body image development by providing psychoeducation and interactive activities to parents in each of the four modules. Modules include Body Image Development/Body Talk, Food Talk, Picky Eating and Mealtime Conversations, and Media Usage and Social Comparison. These modules were designed using the results of our previously completed Needs Assessment, as well as the current evidence-base regarding risk factors for the development of body image in young children.
224078532|NCT07177924|PROCEDURE|Monarch RAB with CBCT-guided ICG Dye Marking|Under general anesthesia, the Monarch RAB platform is used to navigate to the target bronchus. With CBCT confirmation, 0.25 ml of ICG (0.2 mg/ml) mixed with 0.25 ml iodinated contrast is injected within 1 cm of the nodule. The dye marking is identified intraoperatively with near-infrared light to guide VATS sublobectomy.
224078533|NCT07178808|PROCEDURE|Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy|CRS/HIPEC involves aggressive surgical cytoreduction of all visible and palpable tumors, followed by the synergistic use of heated and high dose chemotherapy to address microscopic residual disease.
224078534|NCT07178665|RADIATION|Radiation: Accelerated Partial Breast Irradiation (APBI)|"Radiation: Accelerated Partial Breast Irradiation (APBI) - 5 fractions delivered every other day before surgery.~Procedure: Surgery - lumpectomy or mastectomy scheduled 1-3 weeks after RT; additional whole-breast/lymph node RT if indicated."
224078535|NCT07177586|DEVICE|GMA Laryngeal Mask Airway|The GMA-Tulip is a new single-use supraglottic airway device (SAD). Device size is selected based on the patient's weight and height, following manufacturer guidelines.
224078536|NCT07177586|DEVICE|Inflatable Laryngeal Mask Airway|The comparator is a conventional inflatable Laryngeal Mask Airway (LMA) of appropriate size (selected by weight/height), inserted using standard clinical protocols.
224078537|NCT07178730|DRUG|Sacituzumab govitecan|"SG is administered at 10 mg/kg as an intravenous (i.v.) infusion on Days 1 and 8 of a 21-day cycle.~The dose of SG will be calculated based on actual weight at randomization (using weight obtained either at enrolment or on Cycle 1 Day 1) and remains constant throughout the study, unless there is a \> 10% change in body weight from baseline. Modifications to the study drug doses administered should be made for a \> 10% change in body weight from baseline and according to local and regional prescribing standards. Dose modifications for changes in body weight \< 10% may be made according to local institutional guidelines.~SG is administered via i.v. infusion as described below with additional information available in the current version of the SmPC."
224078538|NCT07178730|DRUG|Pembrolizumab 25 mg/1 ML Intravenous Solution [KEYTRUDA]|Pembrolizumab 200 mg will be administered as a 30-minute i.v. infusion every 3 weeks.
224078539|NCT07178730|DRUG|SoC Chemotherapy|Standard of care chemotherapy as per common treatment guidelines and recommendations
224078540|NCT07178639|DRUG|Bromfenac 0.09 % Ophthalmic Solution|Comparison of bromfenac ophthalmic solution 0.09% twice per day vs. nepafenac ophthalmic suspension 0.3% once per day vs. diclofenac ophthalmic suspension 0.1% four times per day for prevention of cystoid macular oedema associated with cataract surgery.
224078541|NCT07178639|DRUG|Nepafenac 0.3% Oph Susp|Comparison of bromfenac ophthalmic solution 0.09% twice per day vs. nepafenac ophthalmic suspension 0.3% once per day vs. diclofenac ophthalmic suspension 0.1% four times per day for prevention of cystoid macular oedema associated with cataract surgery.
224078542|NCT07178639|DRUG|diclofenac 0.1% ophthalmic susp.|Comparison of bromfenac ophthalmic solution 0.09% twice per day vs. nepafenac ophthalmic suspension 0.3% once per day vs. diclofenac ophthalmic suspension 0.1% four times per day for prevention of cystoid macular oedema associated with cataract surgery.
224078543|NCT07177833|DEVICE|Fractional CO2 laser|Fractional CO2 Laser Therapy is an extra-dermal (applied to the surface of the skin) and non-invasive treatment that involves the use of lasers to destroy and reduce abnormal collagen in scarred tissue.
224078544|NCT07177833|OTHER|Sham (No Treatment)|Patients will undergo a treatment with a vibratory device capable of mimicking fractional CO2 laser therapy
224078545|NCT07177417|BIOLOGICAL|FluMist|intranasal administered live attenuated influenza vaccine
224078546|NCT07177417|BIOLOGICAL|inactivated influenza vaccine|intramuscular administered inactivated influenza vaccine
224078547|NCT07177417|PROCEDURE|bronchoscopy|bronchoscopy with bronchoalveolar lavage and endobronchial biopsy sampling
224078548|NCT07177352|OTHER|No Intervention|Participants will have their blood drawn and cognitive score measured by the ISLT.
224078549|NCT07177534|OTHER|No intervention|This study is a retrospective observational study without intervention.
224078550|NCT05463991|DEVICE|Bioengineered collagen implant|Urethral stricture repair
224078551|NCT07178431|BIOLOGICAL|MB-CART2019.1|CAR T cell therapy
224078552|NCT07177794|DRUG|toripalimab|Patients will receive toripalimab with a maximum treatment duration of one year (240 mg, IV drip, Q3W, for 16 cycles).
224078553|NCT07177794|DRUG|capecitabine|Patients will receive metronomic capecitabine, with a maximum treatment duration of one year (500 mg, twice daily, orally).
224078554|NCT05513027|DEVICE|Augmented Whole-body Scanning via Magnifying PET|-Added at the end of the SOC PET/CT scan. Will take approximately 3-5 minutes longer.
224078555|NCT05513027|DEVICE|PET/CT|-Standard of care
224078556|NCT02192931|DRUG|Creatine monohydrate|
224078557|NCT01227902|DRUG|Retigabine IR|Flexible dose between 300 mg/day (minimum) and 1200 mg/day (maximum).
224078558|NCT06008574|OTHER|AmDTx-PCSP|Step-by-step program modules including meditation training and other activities relevant for people living with cancer
224078559|NCT06008574|OTHER|AmDTx-2048|"Cognitive training exercise called 2048.AmDTx-2048 is a modified version of a popular game called 2048. It is a fun and relaxing puzzle game. Within 2048, participants slide numbered tiles around a grid, matching tiles of the same value."
224078560|NCT06008574|OTHER|Questionnaires|Distress Thermometer (DT)2, Demographic Information and medical history, Assessment for Contamination, Impact of Event Score (IES-R), Mindfulness Attention Awareness Scale (MAAS), PROMIS Short Form v1.0 - Anxiety - 8a, Depression - 4a, Fatigue 4a, Sleep Disturbance 4a, The Lung Cancer Stigma Inventory (LCSI)
224078561|NCT06785168|OTHER|Machine-based Resistance Training|The participants will receive HF treatment as prescribed by cardiologists. If participants have any additional medical conditions, their existing medications or treatments should continue. They are also asked to maintain their usual physical activity, exercise routines, and dietary habits, without making changes outside of the study intervention. At the beginning, patients participating in resistance training should complete a pretest of one-repetition maximum (1-RM) to assess muscle strength, which will be used by a professional physical therapist to develop an individualized prescription. The specific movements are as follows: (1) leg press and (2) calf raise by Proxomed Compass 540 (Germany); (3) leg curl, (4) chest press, (5) push up, (6) seated row by HUR machine (US). During the 8 weeks, subjects will train 3 non-consecutive days/week with intensity 30%1-RM to 60% 1-RM, 3 sets/one excercise with 8-12 repetitions.
224078562|NCT01473797|DRUG|Cladribine|Subcutaneous injections, 0,1 mg/kg/day for 5 days, one course per month for 4 months
224078563|NCT00836355|DRUG|Enoxaparin|2 (or 3) intravenous doses, the first on study entry, the last 24 hours later
224078564|NCT00836355|DRUG|Minocycline|200 mg orally once daily for 5 days
224078565|NCT01966770|DEVICE|Pair 1 (ocufilcon D / ocufilcon D)|Randomized to contra lateral lens pair 1 (ocufilcon D hydrogel / ocufilcon D hydrogel)
224078566|NCT01966770|DEVICE|Pair 2 (ocufilcon D / enfilcon A)|Randomized to contra lateral lens pair 2 (ocufilcon D hydrogel / enfilcon A silicone)
224078567|NCT01966770|DEVICE|Pair 3 (ocufilcon D / comfilcon A)|Randomized to contra lateral lens pair 3 (ocufilcon D hydrogel / comfilcon A silicone)
224078568|NCT01966770|DEVICE|Pair 4 (methafilcon A / methafilcon A)|Randomized to contra lateral lens pair 4 (methafilcon A hydrogel sphere / methafilcon A hydrogel asphere)
224078569|NCT01966770|DEVICE|Pair 5 (methafilcon A / comfilcon A)|Randomized to contra lateral lens pair 5 (methafilcon A hydrogel / comfilcon A silicone)
224078570|NCT01966770|DEVICE|Pair 6 (omafilcon A / comfilcon A)|Randomized to contra lateral lens pair 6 (omafilcon A hydrogel / comfilcon A silicone)
224078571|NCT02377375|PROCEDURE|Micro-assisted technique|Medtronic DBS lead 3391-28cm Medtronic electrode array microrecording 22670
224078572|NCT02377375|PROCEDURE|Standard technique|Medtronic DBS lead 3391-28cm
224078573|NCT03123497|OTHER|completion of questionnaire|completion of questionnaire for patient and parent
224078574|NCT05253417|DRUG|50 mg Cannabidiol (CBD)|For the study arm, '50 mg CBD' participants take two (2) CBD capsules and two (2) placebo capsules.
224078575|NCT05253417|DRUG|Placebo|Participants take four (4) placebo capsules.
224078576|NCT05253417|DRUG|100 mg Cannabidiol (CBD)|For the study arm, '100 mg CBD' participants take four (4) CBD capsules.
224078577|NCT03075085|BEHAVIORAL|WISE (We Inspire Smart Eating)|An enhanced implementation strategy for evidence-based obesity prevention in childcare
224078578|NCT01299766|BEHAVIORAL|Behavioral Activation (BA)|BA is a manual-based, behavioral treatment that helps people increase activity levels through goal setting, activity scheduling, graded task assignment, identifying avoidant behaviors, and rating one's sense of accomplishment.
224078579|NCT01299766|BEHAVIORAL|Supportive Therapy (ST)|ST is a person-centered psychotherapy in which interventionists create a comfortable, non-judgmental environment by demonstrating genuineness, empathy, and acceptance of subjects without imposing any judgments on their decisions.
224078580|NCT05701865|BEHAVIORAL|Alcohol Intoxication- Ascending Limb|Participants will be assigned to moderate alcohol dose condition (target breath alcohol concentration .08%) with NIAAA approved alcohol administration procedures and complete the study task on the ascending limb
224078581|NCT05701865|BEHAVIORAL|Alcohol Intoxication- Descending Limb|Participants will be assigned to moderate alcohol dose condition (target breath alcohol concentration .08%) with NIAAA approved alcohol administration procedures and complete the study task on the descending limb
224078582|NCT05701865|BEHAVIORAL|No Alcohol Control|Participants will be assigned to a no alcohol control condition
224078583|NCT03734757|PROCEDURE|imaging in trimodality|PET-CT and MRI
224078584|NCT05340920|DIAGNOSTIC_TEST|Oral Food Challenge|diagnostic values of skin prick test and specific IgE for allergy confirmed by oral food challenge (routine, not an intervention)
224078585|NCT04271098|PROCEDURE|Open-Heart Surgery for nine months duration|In a single group of patients including 340 patients undergoing open-heart surgery during a period of nine months, the collected parameters include; alanine transaminase (ALT), aspartate transaminase (AST), alkaline phosphatase (ALP), total bilirubin (TBIL), and gamma-glutamyl transpeptidase (GGT) and albumin preoperatively and on postoperative days of 1, 3 and 7. All patients were divided into two groups as with or without hyperbilirubinemia, and this was defined by the occurrence of a plasma total bilirubin concentration of more than 34 µmol/L (2 mg/dL) in any measurement during the postoperative period. For each diagnostic test, a comparison within the group for different time points was statistically evaluated by analysis of variance tests.
224078586|NCT04271098|OTHER|Relation between possible risk factors and hyperbilirubinemia|Possible preoperative, intraoperative, and postoperative risk factors were investigated. The relations between hyperbilirubinemia and possible risk factors are sought by the use of the statistical analysis methods including logistic regression analysis.
224078587|NCT04271098|OTHER|Follow-up period|All patients were investigated for a period of ten days postoperatively. During this period, intensive care unit (ICU) stay, in-hospital stay, and all adverse events were recorded.
224078588|NCT04799041|DRUG|GTX 2/3|There were 15 patients in this group. Each one received only one treatment.
224078589|NCT04799041|DRUG|Placebo|There were 15 patients in this group. Each one received only one treatment.
224078590|NCT02388568|DRUG|Lorcaserin|Lorcaserin plus Lifestyle Modification
224078591|NCT02388568|DRUG|Placebo|Placebo plus Lifestyle Modification
224078592|NCT03897738|DIETARY_SUPPLEMENT|Amberen|Amberen is a succinate-based dietary supplement previously shown to help provide relief for common menopausal symptoms.
224078593|NCT03897738|DIETARY_SUPPLEMENT|Smart B|Smart B contains vitamins B1, B2, B6, B9, B12 and sodium fumarate.
224078594|NCT03897738|DIETARY_SUPPLEMENT|Placebo|Placebo capsules are identical to Amberen and Smart B capsules.
224078595|NCT04473417|DRUG|Forxiga|single dose administration after 10hr fasting
224078596|NCT04473417|DRUG|DA-2811|single dose administration after 10hr fasting
224078597|NCT04473417|DRUG|DA-2811|single dose administration after 10hr fasting
224078598|NCT04473417|DRUG|DA-2811|single dose administration after high fat and calorie fed diet
224078599|NCT00006519|DRUG|Capravirine|
224078600|NCT02492438|BIOLOGICAL|PPV23 vaccination or PCV13 vaccination|
224078601|NCT04133584|BIOLOGICAL|EV71 +SIV|Give 2 doses of EV71 +SIV, get 2 blood samples before the first dose and 28-43 days after the last dose.
224078602|NCT04133584|BIOLOGICAL|EV71|Give 2 doses of EV71 , get 2 blood samples before the first dose and 28-43 days after the last
224078603|NCT04133584|BIOLOGICAL|SIV|Give 2 doses of SIV , get 2 blood samples before the first dose and 28-43 days after the last
224078604|NCT03908619|DRUG|Omeprazole 20mg|Omeprazole 20mg bd/ Amoxicillin 1g bd/ Clarithromycin 500mg bd for 14 days
224078605|NCT03908619|DRUG|Esomeprazole 20mg|Esomperazole 20mg bd/ Amoxicillin 1g bd/ Clarithromycin 500mg bd for 14 days
224078606|NCT03908619|DRUG|Rabeprazole Sodium 20mg|Rabeprazole 20mg bd/ Amoxicillin 1g bd/ Clarithromycin 500mg bd for 14 days
224078607|NCT03908619|DRUG|Vonoprazan|Vonoprazan 20mg bd/ Amoxicilllin 1g bd/ Clarithromycin 500mg bd for 7 days
224078608|NCT03133845|PROCEDURE|Light sedation with propofol|Patients having lumbar spinal surgery and receiving spinal anesthesia will receive propofol for light sedation.
224078609|NCT03133845|PROCEDURE|Induction with propofol|Patients having lumbar spinal surgery and receiving general anesthesia will receive propofol and their induction agent.
224078610|NCT03133845|PROCEDURE|Maintenance anesthetic using a volatile anesthetic|Patients having lumbar spinal surgery and receiving general anesthesia will receive a volatile anesthetic for their maintenance anesthesia.
224078611|NCT03133845|PROCEDURE|Muscle relaxant during maintenance anesthesia|Patients having lumbar spinal surgery and receiving general anesthesia with receive a muscle relaxant for muscle paralysis.
224078612|NCT03133845|PROCEDURE|Pain control with fentanyl|Patients having lumbar spinal surgery and receiving general anesthesia will receive fentanyl for their pain during surgery.
224078613|NCT03133845|PROCEDURE|Bispectral Index (BIS) monitoring for depth of anesthesia|All patients will be monitored with Bispectral Index (BIS) to monitor the patient's depth of anesthesia.
224078614|NCT03133845|PROCEDURE|Spinal Anesthesia|Patients receiving spinal anesthesia will receive bupivacaine into the subarachnoid space.
224078615|NCT03133845|PROCEDURE|Midazolam administered during spinal anesthesia|Midazolam may be administered during spinal needle insertion for patients receiving spinal anesthesia.
224078616|NCT03133845|PROCEDURE|Cerebrospinal fluid collection|8 ml of cerebrospinal fluid may be collected prior to the administration of intrathecal administration of morphine for pain control.
224078617|NCT03133845|PROCEDURE|Administration of intrathecal morphine|Patient may receive intrathecal morphine for post-operative pain control.
224078618|NCT04996355|OTHER|comprehensive treatment after MDT discussion|"The comprehensive treatment plan was determined through MDT discussion, which was completed by the Department of Gastrointestinal Surgery, Peking University People's Hospital.~The following regimens will be tested with organoids-on-a-chip：~1. 5-FU~2. Oxaliplatin~3. Irinotecan~4. 5-FU+ Oxaliplatin~5. 5-FU+ Irinotecan~6. 5-FU+ Oxaliplatin+ Irinotecan~7. 5-FU+Cetuximab~8. Cetuximab~9. Regorafenib"
224078619|NCT05731804|DRUG|SIM0417 600 mg; Ritonavir100 mg|SIM0417 is single dosed, and ritonavir is administered 12 hours before SIM0417 administration (-12 hours), at the time of SIM0417 administration (0 hour), 12 hours (12 hours) after SIM0417 administration, and 24 hours (24 hours) after SIM0417 administration.
224078620|NCT05731804|DRUG|SIM0417 375 mg; Ritonavir100 mg|SIM0417 is single dosed, and ritonavir is administered 12 hours before SIM0417 administration (-12 hours), at the time of SIM0417 administration (0 hour), 12 hours (12 hours) after SIM0417 administration, and 24 hours (24 hours) after SIM0417 administration.
224078621|NCT05731804|DRUG|SIM0417 750 mg; Ritonavir100 mg|SIM0417 is single dosed, and ritonavir is administered 12 hours before SIM0417 administration (-12 hours), at the time of SIM0417 administration (0 hour), 12 hours (12 hours) after SIM0417 administration, and 24 hours (24 hours) after SIM0417 administration.
224078622|NCT05282758|OTHER|Free Movement Dance|Free Movement Dance as a physiotherapy intervention
224078623|NCT05282758|OTHER|Modified person-centred progressive resistance exercise|Modified person-centered progressive resistance exercise as a physiotherapy intervention
224078624|NCT04041856|DRUG|Povidone Ophthalmic|Povidone-iodine 2% eye drop versus artificial tear drop for treatment of adenoviral keratoconjunctivitis
224078625|NCT02421341|DRUG|Fentanyl|During study visits 2 and 3 you will receive an intrathecal (fluid filled space surrounding the spinal cord) injection of either fentanyl or placebo (saline). Fentanyl is an opiate (narcotic) drug and a common medication, however the way fentanyl is being used in this study is considered investigational.
224078626|NCT02421341|PROCEDURE|Catheters|A catheter (small plastic tube placed in a blood vessel) will be placed in an artery in your arm and a second catheter will be placed in a vein in your leg. Local anesthetic will be used to minimize discomfort. These catheters will allow us to measure blood pressure, leg blood flow and draw blood.
224078627|NCT02421341|OTHER|Exercise|You will be asked to exercise, ride a stationary bike, at maximal exertion.
224078628|NCT02421341|RADIATION|DEXA|During study visit one you will have a DEXA scan. This procedure requires you to lie on a table while a small x-ray tube passes under your body.
224078629|NCT02421341|OTHER|Pulmonary Function Tests|During study visit one you will be asked to perform 5 different breathing tests to help us better understand your lung function.
224078630|NCT02421341|OTHER|Blood Draw|You will have approximately 350 mls (1.25 cups) of blood drawn during the duration of this study.
224078631|NCT02421341|OTHER|Chemosensitivity Test|Using a bag you breath in and out your own air.
224078632|NCT02421341|DRUG|Placebo|
224078633|NCT02113787|PROCEDURE|Pharmacokinetic study|Patients who are examen pharmacokinetic study after taking Topamax or Topiramate during 7 days
224078634|NCT01027533|OTHER|Implantation of a multifocal Intraocular lens|Bilateral implantation of a multifocal IOl
224078635|NCT03118440|PROCEDURE|zero-fluoroscopy 3D navigation|Pacemaker implantation will be performed without fluoroscopy using 3D navigation systems.
224078636|NCT03118440|PROCEDURE|conventional x-ray navigation|Pacemaker implantation will be performed with fluoroscopy using conventional X-ray navigation.
224078637|NCT00403260|DRUG|Pyronaridine - artesunate|once a day for 3 days
224078638|NCT00403260|DRUG|Mefloquine plus artesunate|once a day for 3 days
224078639|NCT02487992|BIOLOGICAL|Cytokine-Induced Killer Cells|CIK cells transfected with cytokine genes possess an improved proliferation rate and a higher cytotoxic activity as compared to regular CIK cells.
224078640|NCT01071187|DRUG|Varenicline|Varenicline 0,5mg daily on day 1-3, Varenicline 1mg daily on day 4-7 and Varenicline 2mg on day 8-84.
224078641|NCT01071187|DRUG|Placebo|Placebo
224078642|NCT01431092|DRUG|Placebo|Both Circadin and placebo are encapsulated in lactose containing gelatin capsules to optimize the blinding.
224078643|NCT01431092|DRUG|Melatonin|Prolonged-release melatonin (Circadin®) 2 mg, once daily, 1-2 hours before bedtime.
224078644|NCT01354028|OTHER|Massage therapy|An overall massage time of approximately 10 minutes, administered by physical therapists. Almond oil or baby lotion that is currently used in standard care in the ACH NICU will be used to assist with ease of skin to skin contact during moderate pressure massage. Infants will receive two repetitions of 5-1minute periods of 12 strokes lasting approximately 5 seconds each described in protocol. Actigraph device is on infant's ankle to measure sleep.
224078645|NCT03886844|DIETARY_SUPPLEMENT|Human milk fortifier based on human milk (Prolacta)|Intervention is started with an enteral intake of 100 ml/kg until 32 weeks corrected for prematurity, afterwards a human milk fortifier based on bovine milk is administered until estimated date of birth or 52 weeks corrected for prematurity (weight \<10. percentile) according to ESPGHAN(=European Society for paediatric gastroenterology, hepatology and nutrition) guidelines
224078646|NCT03750188|DRUG|ProHance|0.1 mmol/kg ProHance intravenous injection
224078647|NCT04922866|OTHER|no intervention|no intervention
224078648|NCT04489979|OTHER|Antibiotics|Children with epididymitis / orchitis who were treated by antibiotics in addition to analgetics.
224078649|NCT03677193|BEHAVIORAL|Playing ICP game|Participants will play the ICP game from their home this is expected to be 30 min \* 5 days / week for 4 weeks. Once per week, participants will play the ICP game with a researcher.
224078650|NCT02109159|OTHER|A short online video with emotional content|
224078651|NCT02109159|OTHER|A short online video with less emotional content|
224078652|NCT00935883|DRUG|Eculizumab|"Induction Period: patient will receive eculizumab 600 mg or 900 mg via IV infusion over approximately 30 minutes once a week (7 ± 2 days) for 4 weeks followed by 900 mg or 1200 mg eculizumab for the fifth dose 7 days later (7 ± 2 days).~Maintenance Period: patient will receive eculizumab 900 mg or 1200 mg via IV infusion over approximately 30 minutes every 2 weeks (14 ± 2 days) until week 24.~Observation period: patient will then be observed for 6 months off treatment with follow-up visits scheduled for 9 months and 12 months."
224078653|NCT00935883|DRUG|Saline|"Induction Period: patient will receive saline via IV infusion over approximately 30 minutes once a week (7 ± 2 days) for 4 weeks followed by saline for the fifth dose 7 days later (7 ± 2 days).~Maintenance Period: patient will receive saline via IV infusion over approximately 30 minutes every 2 weeks (14 ± 2 days) until week 24.~Observation period: patient will then be observed for 6 months off treatment with follow-up visits scheduled for 9 months and 12 months."
224078654|NCT06174350|BEHAVIORAL|Cognitive behavioral therapy|Earthquake is a process that affects the lives of many people. It is very important to evaluate the psychological state of individuals after the earthquake and take appropriate action. When studies conducted after the earthquake were examined, no study was found that evaluated the effect of cognitive behavioral therapy on ruminative thoughts and cognitive distortions in individuals exposed to earthquakes. For this reason, this thesis was conducted to evaluate the effect of cognitive behavioral therapy on ruminative thoughts and cognitive distortions in individuals exposed to earthquakes.
224078655|NCT06174350|OTHER|Placebo|Intervention Description not
224078656|NCT06320444|PROCEDURE|232 Electrode Electrophysiology (EEG-ECG-EMG-EXG)|"Noninvasive 232 Channel Electrode Electrophysiological signals (EEG-ECG-EMG-EXG) will be recorded from electrodes placed in a montage over the scalp, neck,and upper back along with muscles located on the hand. These signals will be recorded while resting or performing voluntary task.~Other Intervention: The 232 electrode noninvasive electrophysiological data will be recorded in response to non-invasive peripheral nerve stimulation or vibration induced stimulation.~These sessions are designed to engage specific cortical motor networks of interest for evaluating sensorimotor networks. (Cognitive, behavioural, motor, spinal, and sensory)"
224078657|NCT01664793|BEHAVIORAL|4 Pillars Immunization Toolkit|Pillar 1: Convenient Vaccination Services; Pillar 2: Patient notification about the importance of vaccination and availability of convenient services; Pillar 3: Enhanced Office Systems; Pillar 4: Motivation: Office immunization champion tracks progress towards a goal; Early delivery of donated vaccines for disadvantaged children, staff education, support of effort by research staff.
224078658|NCT05363176|BEHAVIORAL|Cognitive-Behavioral Therapy for Treatment Seeking|CBT delivered over the course of 1, \~45 minute sessions delivered via telehealth.
224078659|NCT05363176|BEHAVIORAL|Pain treatment education|Pain treatment education describes a variety of pain treatments offered in the VA. It is delivered over the course of 1, \~45 minute session delivered via telehealth
224078660|NCT05348798|OTHER|Web based survey|Web-based survey on exercise addiction and personality traits
224078661|NCT00121628|DRUG|AMG 706|
224078662|NCT04892849|OTHER|Conventional Therapy acc. to prevailing clincal approved schemes|The study is observational. The treatment-plan of the underlying disease remains unchanged. The treatment of the patient is according to the prevailing clinical approved schemes at the respective entities. Blood will be drawn from patients at several time points during and after RT and ICI for detailed immunomonitoring of the patients.
224078663|NCT01762280|DRUG|Famitinib Malate Capsule|
224078664|NCT00715988|DRUG|Methadone HCl Inject 10 mg/ml (will require dilution)|Methadone HCl oral solution 5 mg/ml Methadone HCl inject 10 mg/ml (will require dilution)
224078665|NCT00715988|DRUG|Methadone|Methadone HCl oral solution 5 mg/ml Methadone HCl inject 10 ml/ml (will require dilution) Single dose
224078666|NCT00494897|DRUG|Asparaginase|
224078667|NCT00494897|DRUG|Cyclophosphamide|
224078668|NCT00494897|DRUG|Cytarabine|
224078669|NCT00494897|DRUG|Daunorubicin|
224078670|NCT00494897|DRUG|Mercaptopurine|
224078671|NCT00494897|DRUG|Prednisone|
224078672|NCT00494897|DRUG|Vincristine|
224078673|NCT00494897|DRUG|Methotrexate|
224078674|NCT00494897|PROCEDURE|Intrathecally treatment|
224078675|NCT01354483|BIOLOGICAL|Umbilical Cord Blood Mononuclear Cell|
224078676|NCT01354483|BIOLOGICAL|Methylprednisolone|30mg/kg i.v. methylprednisolone
224078677|NCT01354483|DRUG|Lithium Carbonate Tablet|6 weeks
224078678|NCT03228160|OTHER|Linearly Polarized Near-Infrared light Irradiation|The SGI was carried out with the use of a linear-polarized near-infrared irradiation device, Minato Alphabeam Infrared Ray Therapy Unit (Minato Medical Science Co., Ltd., Hyogo, Japan), by a senior physical therapist. The maximum output was 3000 mW/cm² at wavelengths of 0.7 to 1.6 m-⁶, including a combination of red and near-infrared radiation. All patients in the experimental group received SGI under the conditions as follows: output, 90%; irradiation circle 1:2 (irradiation 3 seconds followed by 7-seconds pause); duration of irradiation, 10 min; and total irradiation energy density, 194.8 J/cm². The instrument in the control group with shame irradiation was the same as that in the experimental group with the exception that emitted radiation from device was inactive.
224078679|NCT01158339|BEHAVIORAL|Arm 2: CBGT-ISE|Intervention with active performance of the feared movements during group sessions.
224078680|NCT01158339|BEHAVIORAL|Arm 1: CBGT|Intervention according to previously mentioned methods.
224078681|NCT03473093|DRUG|Pregabalin 150mg|One group will receive oral pregabalin with morphine infusion
224078682|NCT03473093|DRUG|Morphine|One group will receive morphine infusion 20 microgram/kg/h
224078683|NCT01874171|DRUG|Cisplatin|
224078684|NCT01874171|DRUG|Cetuximab|
224078685|NCT00993811|DEVICE|Shang Ring circumcision|novel device for adult male circumcision
224078686|NCT02327299|DIETARY_SUPPLEMENT|Bouillon fortified with FePP|
224078687|NCT02327299|DIETARY_SUPPLEMENT|Bouillon fortified with FePP + Stabilizer|
224078688|NCT02327299|DIETARY_SUPPLEMENT|Bouillon fortified with FeSO4|
224078689|NCT02327299|DIETARY_SUPPLEMENT|Bouillon fortified with FeSO4 + Stabilizer|
224078690|NCT05624008|OTHER|Bioceramic glass ionomer restoration|bioactive glass ionomer with unique biocompatibility and biological regenerative properties
224078691|NCT05624008|OTHER|Resin modified glass ionomer restoration|A hybrid of glass ionomer and composite resin with acid-base and polymerizable components
224078692|NCT02743260|DRUG|pitavastatin|
224078693|NCT02743260|DRUG|Metformin|
224078694|NCT02743260|DRUG|digoxin|
224078695|NCT02743260|DRUG|Adefovir|
224078696|NCT02743260|DRUG|sitagliptin|
224078697|NCT06244797|PROCEDURE|L-PRF and H-PRF|Blood (10 ml) will be taken from the patient with the help of an intraket in the arm or hand of appropriate size and size. Then, the blood sample taken will be placed in the PRF device for centrifugation and the sample will be centrifuged. According to the type of PRF, the centrifuge settings will be changed.
224078698|NCT06244797|PROCEDURE|Impacted Tooth Removal|All patients will be operated on by the same surgeon using the same procedure in order to ensure standardization. Following the administration of 2% articaine with 1:200,000 adrenalin for the inferior alveolar and buccal nerve blocks, a full-thickness mucoperiosteal flap will be raised, and the tooth will be extracted. Following the extraction of the tooth, sterile saline irrigation will be used in the socket, and bleeding control measures will be taken.
224078699|NCT05596019|PROCEDURE|specific neurodynamic exercises|Specific neurodynamic exercises in women older than 65 years with neck pain
224078700|NCT05596019|PROCEDURE|multimodal exercise|Multimodal and nonspecific exercises in women older than 65 years with neck pain
224078701|NCT04498845|OTHER|In-home assessment plan|The in-home family educational session provides participants with resources to identify and reduce exposures to metals in the home environment.
224078702|NCT04498845|BEHAVIORAL|Family educational session|The 1-hr in-home family educational session, administered during the first home visit to all participants, adapts a motivational interview model to reduce exposure to metals. this done by empowering families to make informed decisions regarding lead and metal exposures in their home environments that originate from different sources with an emphasis on sources from the workplace. The session will consist of both developing a plan tailored for the home and reviewing educational materials on strategies to reduce exposures in the home, focusing on barriers families experience when attempting to change their behaviors.
224078703|NCT04498845|BEHAVIORAL|Worker take home prevention training|The take home prevention 1-hour educational session guides the worker through 6 simple steps to identify and then prioritize change/s that can be made before leaving work to prevent take-home lead. It has been adapted from the AGILE model for prioritizing tasks. Participants will also be provided with a pamphlet about how to prevent lead from being taken home.
224078704|NCT04498845|OTHER|D-LEAD cleaner products|D-LEAD cleaner products include hand wipes, all surfaces cleaner and laundry detergent.
224078705|NCT05070884|OTHER|The development of new clinical AI solutions to predict treatment response to neoadjuvant chemotherapy (NAC) in breast cancer|Evaluate response to neoadjuvant treatment in advanced breast cancer
224078706|NCT06342674|OTHER|Giving breast milk to the newborn according to the circadian rhythm|It is the delivery of milk expressed by the newborn's mother during the neonatal intensive care unit, in accordance with the time of expression. Breast milk follows the circadian rhythm, that is, the milk the mother expresses at night will be given to her infant at night, and the milk she expresses during the day will be given to her infant during the day
224078707|NCT06342674|OTHER|Usual care|Newborns in the control group will be given expressed milk first, in line with the routine practice of the clinic
224078708|NCT01428401|DRUG|Chinese Herb Astragalus membranaceus|Astragalus membranaceus ( AM) at a rate of 3 g three times per day
224078709|NCT01428401|OTHER|Placebo|at a rate of 3 g three times per day
224078710|NCT01656720|DRUG|1R, 2S-methoxamine hydrochloride|
224078711|NCT01656720|DRUG|Placebo|
224078712|NCT02611635|DRUG|VKA: Warfarin (Waran)|VKA have been prescribed in the customary manner in accordance with the terms of the marketing authorization; decision to prescribe these agents has been made at least 3 months prior to study inclusion; assignment of a patient to a particular therapeutic strategy is only made retrospectively (treatment decision falls within current practice and the prescription of the medicines is separated from the decision to include the patient in the study)
224078713|NCT02611635|DRUG|NOAC: Rivaroxaban (Xarelto, BAY59-7939)|NOAC have been prescribed in the customary manner in accordance with the terms of the marketing authorization; decision to prescribe these agents has been made at least 3 months prior to study inclusion; assignment of a patient to a particular therapeutic strategy is only made retrospectively (treatment decision falls within current practice and the prescription of the medicines is separated from the decision to include the patient in the study)
224078714|NCT02611635|DRUG|NOAC: Dabigatran etexilate|NOAC have been prescribed in the customary manner in accordance with the terms of the marketing authorization; decision to prescribe these agents has been made at least 3 months prior to study inclusion; assignment of a patient to a particular therapeutic strategy is only made retrospectively (treatment decision falls within current practice and the prescription of the medicines is separated from the decision to include the patient in the study)
224078715|NCT02611635|DRUG|NOAC: Apixaban|NOAC have been prescribed in the customary manner in accordance with the terms of the marketing authorization; decision to prescribe these agents has been made at least 3 months prior to study inclusion; assignment of a patient to a particular therapeutic strategy is only made retrospectively (treatment decision falls within current practice and the prescription of the medicines is separated from the decision to include the patient in the study)
224078716|NCT02611635|DRUG|NOAC: Edoxaban|NOAC have been prescribed in the customary manner in accordance with the terms of the marketing authorization; decision to prescribe these agents has been made at least 3 months prior to study inclusion; assignment of a patient to a particular therapeutic strategy is only made retrospectively (treatment decision falls within current practice and the prescription of the medicines is separated from the decision to include the patient in the study)
224078717|NCT02611635|DRUG|NOAC: Lixiana|NOAC have been prescribed in the customary manner in accordance with the terms of the marketing authorization; decision to prescribe these agents has been made at least 3 months prior to study inclusion; assignment of a patient to a particular therapeutic strategy is only made retrospectively (treatment decision falls within current practice and the prescription of the medicines is separated from the decision to include the patient in the study)
223889040|NCT03747341|DRUG|Buprenorphine Injectable Solution - Part B|"Buprenorphine intravenous (IV) injection given as a primed-continuous infusion.~Low Dose: initial bolus (0.25 mg/70 kg) administered over 15 minutes and infusion continued (0.1 mg/70 kg/hour infusion rate) to complete 360 minutes of administration targeting 1 ng/ml.~Mid Dose: initial bolus (0.5 mg/70 kg) administered over 15 minutes and infusion continued (0.2 mg/70 kg/hour infusion rate) to complete 360 minutes of administration targeting 2 ng/ml.~High Dose: initial bolus (1.25 mg/70 kg) administered over 15 minutes and infusion continued (0.5 mg/70 kg/hour infusion rate) to complete 360 minutes of administration targeting 5 ng/ml."
223889041|NCT03747341|DRUG|Fentanyl - Part B|"Participant received up to four fentanyl doses: 0.25, 0.35, 0.5, and 0.7 mg/70 kg in Periods 1 and 2.~Fentanyl boluses were administered over 90 seconds by dose escalation +2hr, +3hr, +4hr and +5hr after starting administration of buprenorphine/ placebo."
223889042|NCT03747341|DRUG|Oxycodone - Part B|All opioid-tolerant participants in Part B were transitioned to oral oxycodone at least 48 hours before Period 1 to ensure washout of the participants' regular opioids and a stable dose of oxycodone with an adequate bridging schedule reached. Oxycodone is a non-investigational intervention.
223889043|NCT05669846|DRUG|Healthy Donor Fecal Microbiota Transplant (hdFMT)|FMT is a procedure in which fecal matter or stool is collected from a tested donor, mixed with a saline or other solution, strained and infused into the colon by performing a colonoscopy and sigmoidoscopy, or, administered orally in the form of capsules. The FMT consists of introducing normal bacterial flora contained in the stool collected from a healthy donor into the small intestine. In this case, the hdFMT will be administered on Cycle 1 Day 1 and Cycle 3 Day 1 during Treatment Phase 1 and every 9 weeks starting with Cycle 4 Day 1 during Treatment Phase 2.
223889044|NCT05669846|DRUG|Pembrolizumab|Pembrolizumab, 200mg, will be administered as a 30-minute IV infusion every 3 weeks starting Cycle 1 Day 1 (same day as the FMT), and continue on Day 1 of each 21-day cycle.
223889045|NCT06436053|DEVICE|LBBAP with SyncAV|Acute changes in surface ECG QRS duration resulting from left bundle branch area pacing using various pacing configurations will be evaluated.
223889046|NCT02807636|DRUG|Atezolizumab|Atezolizumab will be administered at a fixed dose of 1200 milligrams (mg) by intravenous (IV) infusion on Day 1 of each 21-day cycle until investigator-assessed disease progression per RECIST v1.1. In specific circumstances treatment may continue beyond disease progression.
223889047|NCT02807636|DRUG|Carboplatin|Carboplatin will be administered at doses to achieve area under the concentration-time curve (AUC) of 4.5 milligram per milliliter into minute (mg/mL\*min) by IV infusion on Day 1 of each 21-day cycle until investigator-assessed disease progression per RECIST v1.1 or unacceptable toxicity.
223889048|NCT02807636|DRUG|Gemcitabine|Gemcitabine will be administered at a dose of 1000 milligrams per square meter (mg/m\^2) by IV infusion on Day 1 and Day 8 of each 21-day cycle, until investigator-assessed disease progression per RECIST v1.1 or unacceptable toxicity.
223889049|NCT02807636|OTHER|Placebo|Placebo matched to atezolizumab will be administered by IV infusion on Day 1 of each 21-day cycle until investigator-assessed disease progression per RECIST v1.1. In specific circumstances treatment may continue beyond disease progression.
223889050|NCT02807636|DRUG|Cisplatin|Cisplatin will be administered at a dose of 70 mg/m\^2 by IV infusion on Day 1 of each 21-day cycle until investigator-assessed disease progression per RECIST v1.1 or unacceptable toxicity.
224078718|NCT05638048|BEHAVIORAL|Precision grip training|First determine patients for holding the ball movement should reach the effective blood flow velocity and best duration - relaxation, and USES the electronic grips and color doppler ultrasonic diagnostic apparatus, for individual patients to choose the best grip the efforts and training, to form the best grip the training plan, and observe the scheme for Peripheral central venous catheter-associated thrombosis prevention effect.
224078719|NCT05638048|BEHAVIORAL|Use maximum strength grip training|Patients were routinely implanted with PICC, and on the basis of health education in the control group, the best continuous-relaxation time, frequency and maximum grip strength of patients were used for grip strength training.
224078720|NCT05638048|BEHAVIORAL|Health education on routine grip strength training|Patients were routinely implanted with PICC and received routine health education. The content of health education included face-to-face language explanation of the whole process of catheter knowledge, issuing catheter maintenance manual, issuing ordinary grip ball and telling how to use it, and follow-up.
223889051|NCT05082909|DRUG|Probenecid|Addition of 500mg QDS to oral penicillin.
223889052|NCT06388811|OTHER|Early Osteoarthritis Questionnaire|Self administered questionnaire
224078721|NCT03381456|OTHER|LICI|Paired pulse TMS to measure LICI and late cortical disinhibition
224078722|NCT02173119|OTHER|MRI post-TACE|Perform lipiodol delivery measurements with MRI post-TACE.
224078723|NCT06496412|DRUG|fecal microbiota transplantation|Take fecal microbiota capsules.
224078724|NCT06496412|DRUG|Placebo|Take placebo capsules.
224078725|NCT04337411|OTHER|Follow-up assessments|Longitudinal evaluation of recovery
224078726|NCT03195517|OTHER|Physical exercise|
224078727|NCT06548867|DRUG|Cabozantinib|Patients must have been treated with cabozantinib after one or more previous therapies for mRCC, as per clinical practise.
224078728|NCT01072344|DRUG|Chamomile (Matricaria recutita)|500 mg 3 times daily
224078729|NCT02160405|DIETARY_SUPPLEMENT|native potato|
224078730|NCT05806801|BEHAVIORAL|MICT Exercise|Subjects randomized into this group will complete a moderate intensity continuous exercise 4 days/week.
224078731|NCT05806801|BEHAVIORAL|No Exercise (Control)|Subjects randomized into this group will remain sedentary throughout the duration of the study.
223889053|NCT04357574|OTHER|Telehealth|patients have virtual visits with Radiation Oncology providers in lieu of in person clinic visits as a necessary response to COVID-19
224078732|NCT02668146|DRUG|Perampanel|Study drug will be administered to study subjects
224078733|NCT02668146|DRUG|Placebo|Placebo will be administered to study subjects
224078734|NCT00694291|DRUG|Sorafenib|400 mg orally twice daily
224078735|NCT00694291|DRUG|Placebo|Matching Placebo
224078736|NCT03569995|DRUG|Rituximab|500 mg/m2 + 5%DW 500 mL IVF Begin with 50 mg/hr (increase by 50 mg/hr per 30 min until 400 mg/hr is reached)
224078737|NCT03569995|DRUG|Methotrexate|500 mg/m2 + 5%DW 200 mL IV over 15 minutes 3000 mg/m2 + 5%DW 500 mL IVF over 3 hrs Concurrent hydration and subsequent leucovorin rescue is mandatory
224078738|NCT03569995|DRUG|Cytarabine Injection|3000 mg/m2 + 5%DW 200 mL IVF over 2 hrs steroid eye drop 0.1%, 2 drops q 6hrs, on days 1-9
224078739|NCT02256930|DRUG|M518101|
224078740|NCT02256930|DRUG|M518101 Vehicle|
224078741|NCT02256930|OTHER|Sodium lauryl sulfate|
224078742|NCT02256930|OTHER|Saline|
224078743|NCT00962026|DRUG|Rilonacept|Rilonacept given subcutaneously, dose per package labeling, once weekly.
224078744|NCT01745640|DRUG|POMALIDOMIDE|hard capsule 4mg/day, oral route, from day 1 to 21 per 28 days cycle
224078745|NCT01745640|DRUG|Dexamethasone|40mg (if patient \<75 years)/20mg weekly, oral route, on day 1, 8, 15, 22 per 28 days cycle
224078746|NCT05147480|OTHER|internet-based mother-baby yoga|Mother-baby yoga group classes given by physiotherapists via Zoom Video Communications
224078747|NCT00235131|DEVICE|Smart Stent|Cordis S.M.A.R.T.™ CONTROL™ Nitinol Stent System
224078748|NCT00235131|DEVICE|Luminexx Stent|Bard® Luminexx™ 6F Vascular Stent
224078749|NCT03597425|PROCEDURE|Cardiopulmonary resuscitation|Cardiopulmonary resuscitation (CPR) is an emergency treatment for patients with respiratory arrest and cardiac arrest in an attempt to restore the patient to spontaneous breathing and heartbeat through cardiopulmonary resuscitation
224078750|NCT03312517|DRUG|Suvorexant 10 mg|Subject will receive suvorexant 10mg
224078751|NCT03312517|DRUG|Suvorexant 20 mg|Subject will receive suvorexant 20mg
224078752|NCT03312517|DRUG|Placebo oral capsule|Subject will receive placebo.
224078753|NCT02495922|DRUG|elotuzumab|10 mg/kg in the vein( i.v) on day 1,8 and 15 in induction cycle 1 and 2, on day 1 and 11 in induction cycle 3 and 4 (Arm B1 and B2). 10 mg/kg i.v. on day 1,8 and 15 in consolidation cycle 1 and 2 (Arm A2 and B2), 10 mg/kg i.v. on day 1 and15 in maintenance cycle 1-6, 10 mg/kg i.v. on day 1 in maintenance cycle 7-26 (Arm A2 and B2)
224078754|NCT02495922|DRUG|Lenalidomide|25 mg per os on day 1-14 in induction cycle 1-4, 25 mg p.o. on day 1-14 in consolidation cycle 1 and 2, 10 mg p.o. on day 1-28 in maintenance cycle 1-3, 15 mg p.o. on day 1-28 in maintenance cycle 4-26 (all arms)
224078755|NCT02495922|DRUG|Bortezomib|all arms: 1,3 mg/m\^2 subcutaneous on day 1, 4, 8 and 11 in 4 induction cycles, 1,3 mg/m\^2 subcutaneous on day 1, 8 and 15 in 2 cycles of consolidation
223889054|NCT05531604|BEHAVIORAL|appetitive conditioning|The investigators will examine acquisition and extinction of learned associations to positively-valenced, socially rewarding yet symptom-neutral infant laughter sounds in an appetitive conditioning paradigm. The investigators will also examine spontaneous recovery of this association 24 hours later when re-presented with these cues, and the reinstatement of this association when re-exposed to infant laughter.
223889055|NCT04088630|DRUG|Fingolimod|A single dose of 0.5 mg oral fingolimod within 24 hours of symptom onset
223889056|NCT04088630|DRUG|Placebo|A single oral placebo pill within 24 hours of symptom onset
223889057|NCT04088630|DRUG|Open-label Fingolimod|A single dose of 0.5 mg fingolimod through an NGT or Dobhoff tube within 24 hours of symptom onset
223889058|NCT05921448|BIOLOGICAL|Vaxigripetra|Tetravalent intramuscular vaccine. Mechanism of action: The vaccine induces an immune reaction involving antibody production.
223889059|NCT05921448|BIOLOGICAL|Flumist|Tetravalent live attenuated influenza vaccine administered as a nasal spray. Mechanism of action: Not fully understood according to the prescribing information, but may involve influenza-specific T-cells and antibodies (serum and mucosal).
223889060|NCT05641623|DRUG|OSU6162|OSU6162
223889061|NCT05641623|DRUG|Placebo|Placebo
223889062|NCT03164980|DRUG|Trabectidin (Yondelis)|To compare QoL in patients treated with trabectedin/PLD vs. other standard combination therapy of carboplatin/ PLD, carboplatin/ gemcitabine, or carboplatin/ paclitaxel
224080372|NCT02058732|OTHER|MRI|Subjects will have an MRI that lasts approximately 60 minutes at the same time points as during the stem cell study schedule; once before the stem cell surgery, and again at 1, 6, 12, 18, 24, 36, and 48 months after receiving stem cells. This magnetic resonance imaging(MRI)scan will be of the cervical spine and brain.
224080373|NCT05293730|BEHAVIORAL|eFRIEND|eFRIEND is a 6-month CWH-led intervention. All CHW will be part of the research team to ensure successful recruitment and interaction with patients, and all CHW will be certified and have participated in the North Carolina Community Health Worker Standardized Core Competency Training.
224080374|NCT05293730|OTHER|Usual Care|Routine treatment in primary care
224080375|NCT03968419|DRUG|Canakinumab|200 mg of canakinumab administered via subcutaneous injections once every 3 weeks for a maximum duration of 6 weeks
224080376|NCT03968419|DRUG|Pembrolizumab|200 mg of pembrolizumab administered via infusion once every 3 weeks for a maximum duration of 6 weeks
223889070|NCT05738330|BEHAVIORAL|Symptom Monitoring on Renal Replacement Therapy - Hemodialysis (SMaRRT-HD)|Dialysis clinics randomized to the SMaRRT-HD group will use the SMaRRT-HD system to capture patient-reported symptoms and support clinician follow-up. The online system includes the patient symptom ePROM surveys, clinician real-time email alerts, clinician guidances for symptom management, and patient-facing symptom reports as well as an administrative dashboard supporting management of trial participants at clinics using SMaRRT-HD. Designated clinic personnel (i.e., patient care technicians and nurses) will receive training on how to use the system to administer the symptom ePROM surveys to patients on tablet computers. Designated clinic nurses and medical providers will receive training on how to access guidances for symptom management and patient-facing symptom reports in the SMaRRT-HD system. For trial participants in SMaRRT-HD clinics, the SMaRRT-HD system will be implemented in addition to the Usual Care approach to symptom monitoring.
223889071|NCT05738330|BEHAVIORAL|Usual Care|Dialysis clinics randomized to Usual Care will not adopt SMaRRT-HD or any other trial-driven procedures. Usual Care clinics will monitor symptoms through clinical care interactions with participants and by administering a CMS-mandated Health-Related Quality of Life (HRQOL) survey that includes questions about symptoms.
223889072|NCT06186336|OTHER|Deep Learning-based Vulnerable Plaque Detection and Assessment Tool|"Scanning requirements for the clinically indicated CCTA and ICA with OCT will be performed according to current site(s) guidelines and procedures. Administration of medications (such as contrast agents and potentially beta-blockers and other medications) will be given according to standard hospital care.~This is a prospective research study evaluating an investigational product. The tool's use is intended for research purposes and is not intended as a substitute for required medical care. The CCTA and ICA with OCT will be processed in real-time using the site's locally available post-processing tools in order to guide the subject's medical care. Once the ICA with OCT is complete, the de-identified CCTA data will be inputted in the investigational tool.~The clinically indicated CCTA and the ICA with OCT will both take approximately 1 hour and will take place within 10 days. No additional imaging is needed as part of the study."
223889073|NCT05520047|BEHAVIORAL|COVID19-severe Patient|Behavioral and social test assessment
223889074|NCT05520047|BEHAVIORAL|family of COVID19-severe Patient|Behavioral and social test assessment
223889075|NCT02954341|DEVICE|CardioMEMS HF System|
223889076|NCT04595435|PROCEDURE|Lumpectomy|Removal of lump/tumor from breast utilizing an approach that saves as much breast as possible.
223889077|NCT04595435|RADIATION|Intraoperative Radiation Therapy|Delivery of low energy radiation therapy directly at surgical site, immediately removal of lump and tissue prior to final surgical closure
223889078|NCT03381261|DRUG|Botulinum toxin type A|Injection of Botulinum toxin type A in back of head
223889079|NCT05434819|PROCEDURE|Surgical Atrial Fibrillation Ablation|Surgeon will preform surgical atrial fibrillation ablation using either cryoablation or bipolar radiofrequency clamps including 2 layers of atrium or vein, a minimum of 2 burns per clamping with at least 3 lines in the ablation group. Cavo-tricuspid isthmus and mitral lines will be allowed.
223889080|NCT06297148|OTHER|Self-management|"Patients will have 3-5 sessions with a physiotherapist that include individually tailored education, and address physical, cognitive, and behavioral factors deemed as relevant according to the participant's concerns and challenges. Important aspects in this are: problem-solving, decision-making, resource utilization, therapeutic alliance and taking action (The 5 core skills of self-management). SMART goals and an activity plan between sessions will be used as an exposure to maintain, change, or create health behavior.~Participants will have access to study material, including exercise alternatives and a podcast."
223889081|NCT06297148|OTHER|Usual care|Usual care at the department consists of general information about the condition and advice on pain management and exercise. For further treatment, patients are referred to primary care. Participation in the study will not affect how this is conducted.
223889082|NCT04421079|DIETARY_SUPPLEMENT|Trans-resveratrol|150mg, 300mg, 450mg
223889083|NCT04421079|DIETARY_SUPPLEMENT|Concord grape juice|8 oz, 16 oz, 24 oz
223889084|NCT04421079|DIETARY_SUPPLEMENT|Grape seed polyphenol extract|450mg, 900mg, 1200mg
223889085|NCT04421079|DRUG|Placebo|Comparable placebo supplement which is manufactured according to GMP and will contain inert substances.
223889086|NCT05634226|DEVICE|Hands-free oral-positive pressure device (oPEP)|This is a pilot study using a novel, minimal risk, portable, hands-free oral-positive pressure device (oPEP) in patients with Fontan palliation that will examine whether using this device in both the acute and chronic phase will alter Fontan hemodynamics and create pulsatility in the Fontan circuit and thereby increasing cardiac output. This device is easy to use and poses no significant risk to human subjects. We will measure this through echocardiographic measures including pulsatility in different aspects of the Fontan circuit including IVC, hepatic veins, the Fontan conduit, and pulmonary arteries and aortic blood flow measurements. After demonstration of how to use the device appropriately, we will have patients use the device after their clinical echocardiogram for their clinic appointment. We will ask them to use the device at home 3-4 times a day for 10-15 mins and have them return in approximately 4 weeks to have another echocardiogram done with the same measurements.
223889087|NCT05859620|OTHER|Patient assessment and follow-up|There is no study-specific intervention. The investigators will record data generated by clinical activity before, during and after implementation of the PMI-screening. Follow-up data and the final PMI event adjudication will be the only data generated specifically for this study.
223889088|NCT05964855|DEVICE|MIT Variable Stiffness Prosthesis|Proprietary electronically-controlled prosthesis that can vary its effective stiffness.
223889089|NCT05964855|DEVICE|MIT Variable Equilibrium Angle Prosthesis|Proprietary manually-controlled prosthesis that can vary its effective ankle equilibrium angle.
223889090|NCT05964855|DEVICE|MIT Sliding Beam Passive Prosthesis|Proprietary fixed-stiffness passive foot-ankle prosthesis.
223889091|NCT05964855|DEVICE|Ossur Pro-flex XC|Commercially-available passive fixed-stiffness foot-ankle prosthesis by Ossur.
223889092|NCT05964855|DEVICE|Blatchford Elan Variable-Dampening Prosthesis|Commercially-available electronically-controlled prosthesis that can vary its effective dampening.
223889093|NCT05226351|DRUG|Dronabinol 2.5 mg|single administration of 2.5mg Dronabinol oral (oily solution)
223889094|NCT05226351|DRUG|Placebo|single administration of placebo oral (oily solution)
223889095|NCT03141424|DRUG|Tapering of inhaled corticosteroid (ICS) treatment|Tapering of ICS treatment over 8 weeks. Follow-up over 52 weeks in total. Dosis reduction of 50% in ICS treatment for 8 weeks, followed by total ICS removal. Other inhaled asthma medication remains unchanged during the entire study period.
223889096|NCT03945539|DRUG|JNJ-56136379|Participants will receive JNJ-56136379 orally on Day 1 in Treatment Period 1 and on Day 38 in Treatment Period 2.
223889097|NCT03945539|DRUG|Itraconazole|Participants will receive 200 mg of itraconazole once daily orally for 21 days starting on Day 34.
223889098|NCT00137540|DEVICE|RF ablation|
223889099|NCT00137540|DRUG|anti-arrhythmic drug therapy|
223889100|NCT05725395|BEHAVIORAL|Virtual Reality|During in-patient care participants will be randomized to receive or not receive the educational virtual reality intervention on the first day. After two days, participants will receive a total of 10 minutes interventional in the morning (between 8am to 12pm) every day until their in-patient care concludes.
223889101|NCT05725395|BEHAVIORAL|Standard of Care|For case control, participants will service as their self control and be randomized to receive no virtual reality intervention on either the first day or the second day of in-patient care.
223889102|NCT06579872|OTHER|plantar pressure|foot pressure analysis, cardiopulmonary function, and mobility in patients with chronic respiratory diseases
223889103|NCT05131321|PROCEDURE|Primary ankle arthrodesis (fusion)|Primary arthrodesis: Subjects allocated to the fusion group will have insertion of a retrograde locked calcaneal nail. Tibiotalar joint preparation, bone grafting, subtalar preparation, and fibulectomy will not be performed unless deemed necessary by the treating surgeon.
223889104|NCT05131321|PROCEDURE|ORIF (open reduction and internal fixation)|ORIF: ORIF will be performed using modern techniques for timing and staging of fixation, soft tissue and fibula management, surgical approaches, reduction techniques, and plate choice.
223889105|NCT05131321|PROCEDURE|Intramedullary Fibular Nailing (IMFN)|Intramedullary Fibular Nailing: Participants allocated to the IMFN group will receive a locked fibular nail using a previously described technique.
223889106|NCT05962151|DRUG|NAL ER|Oral tablets
223889107|NCT05962151|DRUG|Placebo|Oral tablets
223889108|NCT05227209|DRUG|SEP-4199 CR|SEP-4199 CR either 200 mg (one 200 mg tablet) or 400 mg (two 200 mg tablets) once daily
223889109|NCT04088370|OTHER|Blood Draw|Blood Draw Only
223889110|NCT06551922|COMBINATION_PRODUCT|Instrumental Soft Tissue Mobilization Technique with Conservative Treatment|"TENS: Apply TENS for 10 minutes on the greater trochanter and the area just above the lateral knee joint line, adhesive electrodes were positioned.~Frequency: 3 times per week. Duration: 90 seconds- 2 minutes on each muscle (Purbia, 2023). Technique: A therapist uses Ergon tools to apply gentle pressure and strokes along the targeted muscles and fascial tissues. Different IASTM techniques, like stroking, raking, and hooking, address specific tissue restrictions. The therapist should continue the IASTM technique for 5-10 minutes, or until the stiffness in the knee is reduced (Mubashar et al., 2022; Purbia, 2023).~Conservative Treatment: Stretching exercises for the hamstrings and quadriceps to improve flexibility and reduce tension. Affected iliotibialband. Hold for 30 seconds. Uncross your legs and stand up straight again. Repeat four more times (Mubashar et al., 2022)."
223889111|NCT06551922|COMBINATION_PRODUCT|Conservative Treatment|"TENS: Apply TENS for 10 minutes on the greater trochanter and the area just above the lateral knee joint line, adhesive electrodes were positioned.~Stretching exercises with hold for 30 seconds. Uncross your legs and stand up straight again (Mubashar et al., 2022).~Quadriceps Strengthening: Perform exercises like straight leg raises, seated leg press and squats to strengthen (Lim \& Al-Dadah, 2022).~Hamstring Strengthening: Include exercises like leg curls to strengthen the hamstring muscles (Lim \& Al-Dadah, 2022).~Calf Strengthening: Perform calf raises to strengthen the calf muscles (Lim \& Al-Dadah, 2022).~Balance Exercises: Incorporate balance exercises like single-leg stands on a foam pad (Lim \& Al-Dadah, 2022).~Ice Therapy: Apply ice packs to the affected knee for 15-20 minutes (Lim \& Al-Dadah, 2022)."
223889112|NCT04848896|DEVICE|CORI Robotics|Total knee arthroplasty (TKA) treated with CORI Robotics System.
223889113|NCT04848896|PROCEDURE|Conventional Procedure|Total knee arthroplasty (TKA) treated with conventional approach with conventional manual instrumentation.
223889114|NCT06202287|OTHER|Balance measurements using the HUR Smart balance device, balance tests, and other surveys.|50 stroke patients will undergo balance measurements using the HUR Smart balance device and other tests.
223889115|NCT06236308|BIOLOGICAL|TTAX03 10mg|TTAX03 is a sterile, lyophilized and micronized particulate human AM and UC product manufactured using aseptic techniques followed by terminal sterilization by gamma-irradiation in compliance with Current Good Tissue Practices (CGTP) and Current Good Manufacturing Practices (CGMP) to preserve extracellular matrices and growth factors/cytokines therein without any living cells.
223889116|NCT06236308|BIOLOGICAL|TTAX03 25mg|TTAX03 is a sterile, lyophilized and micronized particulate human AM and UC product manufactured using aseptic techniques followed by terminal sterilization by gamma-irradiation in compliance with Current Good Tissue Practices (CGTP) and Current Good Manufacturing Practices (CGMP) to preserve extracellular matrices and growth factors/cytokines therein without any living cells.
223889117|NCT06236308|BIOLOGICAL|Placebo Comparator: Control Saline|2 mL Sterile, preservative free 0.9% NaCl
223889118|NCT05341986|OTHER|Clinical Decision Support (CDS) tool|Implementation of an EHR-based CDS tool for providers to use.
223889119|NCT06360419|DRUG|Solriamfetol 300 mg|Solriamfetol tablets, taken once daily
223889120|NCT06360419|DRUG|Placebo|Placebo tablets, taken once daily
223889121|NCT06375200|OTHER|No intervention|Observational one-time questionnaire study without intervention
223889122|NCT05641194|DEVICE|Legacy Alerting System|Description: Standard alerting system in place at the fire station.
223889123|NCT05641194|DEVICE|Intervention 2: EaseAlert Standalone|Description: EaseAlert will activate and alert the subject of an emergency call without the legacy alerting system. EaseAlert (standalone) replaces the legacy alerting system.
223889124|NCT04166266|OTHER|Blood draw for the laboratory assessment|Blood sampling for the biobank and, in addition, as sub-studies are planned on sub-groups of patients, additional blood samples are planned for the patients in these sub-studies.
223889125|NCT01705119|OTHER|Standing|
223889126|NCT06111846|DRUG|human Bone Marrow Mesenchymal Stem Cell (hBMMSC)|Group 1: 1.0×10\^6 cells/kg (participant's body weight) single dose (n=3) Group 2: 2.0×10\^6 cells/kg (participant's body weight) single dose (n=3) Group 3: 2.0×10\^6 cells/kg (participant's body weight) administered twice (n=4)
223889127|NCT06635915|DIAGNOSTIC_TEST|Postoperative ultrasound|Ultrasound will be performed to both groups in the postoperative period to assess the normoposition or the absence of nasogastric tube.
223889128|NCT05359523|DEVICE|Ultrasonographic measurements of the trapezius and rhomboid muscle and fascia|B mode measurements Trapezius and rhomboid muscle thickness and fascial thickness measurement M mode measurements Abduction at 90 and 180 degrees Forward flexion at 90 and 180 degrees
223889129|NCT05359523|OTHER|fascia injection|Under ultrasound guidance, a local anesthetic and steroid mixture will be injected into the fascia between the trapezius muscle and the rhomboid muscle.
223889130|NCT05795257|PROCEDURE|Bronchoalveolar lavage|Bronchoalveolar lavage in the middle lobe of the right lung and a mini-bronchoalveolar lavage in the upper and lower lobe of the right lung
223889131|NCT06159634|PROCEDURE|Endoscopic Submucosal Dissection|Endoscopic submucosal dissection (ESD) will be the technique used to remove target lesions.
223889132|NCT06159634|DEVICE|Traction Device|Use of traction device to aid in removing target lesions
223889133|NCT05900700|BEHAVIORAL|eYST website|The website is a psychoeducational, social support program for adolescents at risk for suicide
223889134|NCT05493423|DEVICE|V Needle AV Fistula Set|Hemotek Medical Inc. has developed the V Needle, a new AV fistula set for hemodialysis designed to reduce patient risk from exsanguination-related injury or death during therapy. In the event of complete dislodgement of the V Needle from the arm during use, the V Needle is designed to activate, creating high line pressure designed to generate an automated dialysis machine blood pump shut down.
223889137|NCT04632784|DEVICE|Artiflex Presbyopic (Artiplus) implantation|Implantation of iris-fixated multifocal Artiflex Presbyopic IOL (Artiplus)
224080377|NCT04886271|DRUG|HX009|Eligible participants will receive HX009 treatment at 5mg/Kg via IV infusion over 60-120 minutes, and the scheduled dosing cycle is once every 2 weeks.
223889138|NCT04596189|DRUG|Dupilumab 300 MG in 2 ML Prefilled Syringe|"The Dupilumab will be administered following clinic procedures and blood collection. Patients will be monitored at the study site for at least 30 minutes after injections for signs of hypersensitivity reaction.~Subcutaneous injection sites should be alternated among the 4 quadrants of the abdomen (avoiding navel and waist areas), the upper thighs or the upper arms, so that the same site is not injected twice consecutively. Injection in the upper arms could be done only by a trained person (caregiver trained by Investigator or Delegate) or health care professional but not the patients themselves."
223889139|NCT04596189|OTHER|Placebo|"The Placebo will be administered following clinic procedures and blood collection. Patients will be monitored at the study site for at least 30 minutes after injections for signs of hypersensitivity reaction.~Subcutaneous injection sites should be alternated among the 4 quadrants of the abdomen (avoiding navel and waist areas), the upper thighs or the upper arms, so that the same site is not injected twice consecutively. Injection in the upper arms could be done only by a trained person (caregiver trained by Investigator or Delegate) or health care professional but not the patients themselves."
223889140|NCT04596189|DRUG|Mometasone Furoate nasal spray|On a daily basis throughout the study, the patient will use a paper diary to record daily use of mometasone furoate nasal spray (MFNS) 50 μg/actuation nasal spray, suspension (refer to the package insert \& SmPC for a description, administration details and precautions for use). MFNS is provided in a bottle that contains 18 g (140 actuations) of product formulation. If patient is unable to tolerate 200 micrograms twice a day (total dose 400 micrograms) due to experiencing adverse event, patient may reduce dose to 200 micrograms once per day.
223889141|NCT06480513|BEHAVIORAL|live yoga|following live yoga classes twice a week and using yoga video's at home once a week
223889142|NCT06480513|BEHAVIORAL|live remote yoga|The control group will be offered live remote yoga classes after the intervention period
223889143|NCT05086016|DEVICE|Catheterized Stenting|Catheterized stenting of vascular narrowings.
223889144|NCT05667701|DRUG|Soy isoflavone|Soy isoflavone supplement (Novasoy) that contains isoflavones (genistein, daidzein, glycetein) given at a dose of genistein aglycone equivalents to provide the genistein dosing of 22.6 mg/day for children aged 2-10 months, and 30.3 mg/day children aged 10-24 months
223889145|NCT05667701|DRUG|matching placebo|A matching placebo also administered twice daily.
223889146|NCT04709432|PROCEDURE|ECMO|ECMO is a form of Extracorporeal Life Support (ECLS) to support either the pulmonary, or both the pulmonary and cardiac systems.
223889147|NCT06178861|DEVICE|Group wearing a radiotherapy bra|Group wearing a radiotherapy bra
223889148|NCT04245501|OTHER|Cognitive Bias Modification for Interpretations (CBM-I)|Computerized intervention in which youth see word-sentence pairs personalized to their anxiety symptoms, and indicate whether these are related. Youth receive feedback aimed to reduce interpretation bias.
223889149|NCT04245501|OTHER|Interpretation Control Condition (ICC)|"Computerized control condition in which youth see word-sentence pairs personalized to their anxiety symptoms. Youth indicate whether these are related, but are not provided with feedback that aims to train a reduction in interpretation bias."
223889150|NCT04097184|DEVICE|Neurostimulation with non-implanted electrodes|Neurostimulation with non-implanted electrodes
223889151|NCT06798220|OTHER|Traditional Breakfast|In this intervention, participants are offered a traditional breakfast (consisting of unprocessed or minimally processed foods), and postprandial appetite regulation is evaluated. Traditional breakfast includes chicken egg (boiled), white cheese (full-fat), white bread, black and green olives, tomatoes, cucumbers, and freshly squeezed orange juice.
223889152|NCT06798220|OTHER|UPF Breakfast|In this intervention, participants are offered an ultra-processed breakfast, and postprandial appetite regulation is evaluated. Ultra-processed breakfast includes pan-fried beef sausage (without oil), packaged sandwich bread, tomato-based ketchup, and packaged orange juice.
223889153|NCT00709033|BIOLOGICAL|autologous or syngeneic PBTLs and EBV-CTLs|"Three dose levels are being evaluated namely:~GROUP 1~PBTL CD19CAR-28 zeta 2x10exp7 cells/m2 and EBV-CTL CD19CAR zeta 2x10exp7 cells/m2~GROUP 2~PBTL CD19CAR-28 zeta 1x10exp8cells/m2 and EBV-CTL CD19CAR zeta 1x10exp8 cells/m2~GROUP 3~PBTL CD19CAR-28 zeta 2x10exp8 cells/m2 and EBV-CTL CD19CAR zeta 2x10exp8 cells/m2"
223889154|NCT04907695|DEVICE|I View Video Laryngoscope https://www.intersurgical.com/content/files/108253/-1977057700|All intubations will be performed at the direction of the attending clinician. The decision to intubate is based purely on clinical factors by the primary team. The decision to use VL device will be at the direction of the clinical team. No patient will be recruited specific for this procedure.
223889155|NCT05880979|BEHAVIORAL|Engaging Together for Healthy Relationships|A comprehensive parent-adolescent dating violence prevention intervention designed to be provider delivered within the context of a pediatric well-child visit
223889156|NCT05880979|BEHAVIORAL|Regular well child care|Participants will receive their regularly scheduled well-child care
223889157|NCT06515574|BEHAVIORAL|developmental care|Individualized Developmental Care that includes the light, noise, sleep, etc.
223889158|NCT05838183|DIAGNOSTIC_TEST|The relationship between imaging and ROSE and NGS|The correlation between ROSE and NGS in imaging and bronchoscopy of ILD patients was observed
223889159|NCT05285618|DEVICE|Argus II|Participants used the Argus II retinal prosthesis system in both experiments to perform visual perception tasks.
223889160|NCT00170573|DRUG|Caelyx|40 mg/m² biweekly
223889161|NCT06419218|BEHAVIORAL|School meal messages|Messages focused on the benefits of children consuming school lunch and breakfast, using text and images developed based on parent interviews. Participants will view a total of 10 messages.
223889162|NCT06419218|BEHAVIORAL|Control (neutral) messages|Control messages approximately matched to the intervention messages on length and design, but discussing a neutral topic unrelated to school meals (reading). Participants will view a total of 10 messages.
223889163|NCT05665244|PROCEDURE|Laryngeal cryotherapy|Laryngeal cryotherapy is the therapeutic freezing of tissue in the throat to numb the overactive sensory nerves in the throat. This technique is believed to reduce cough symptoms in this study.
223889164|NCT05665244|DEVICE|Cryoprobe|Cryoprobe is FDA approved for use for the destruction of unwanted tissue along the respiratory tract
223889165|NCT05737095|PROCEDURE|Pulmonary ultrasound|Within 6 hours of admission to Neonatal Pediatrics and Intensive Care
223889166|NCT04262141|DRUG|IMG-7289|Daily oral dose of 0.6 mg/kg/day IMG-7829 capsules. Dose escalation an de-escalation rules applied as necessary.
223889167|NCT06636734|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223889168|NCT06636734|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
223889169|NCT06636734|DRUG|Lovastatin|Given PO
223889170|NCT06636734|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223889171|NCT06636734|BIOLOGICAL|Pembrolizumab|Given IV
223889172|NCT06636734|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
223889173|NCT06287112|DEVICE|Endoscopic transpapillary gallbladder drainage (ETGBD)|Fully covered self-Expandable metal stent with Endoscopic transpapillary gallbladder drainage (ETGBD) in patient with cystic duct low insertion
223889174|NCT06640361|DRUG|Olverembatinib|Oral administration with meal, QOD, every 28 days for a cycle.
223889175|NCT04647786|DEVICE|Prototype medical device (SEA CtV)|A prototype device that delivers a controlled flow of gas to the upper airways via the subglottic suction port of an established tracheostomy tube. Gas flow may be timed, warmed and/or humidified.
223889176|NCT01242917|DRUG|CCX-354-C|200mg film-coated tablets once daily for 12 weeks + Methotrexate
223889177|NCT01242917|DRUG|Placebo|Placebo film-coated tablets twice daily for 12 weeks + methotrexate
223889178|NCT01242917|DRUG|CCX354-C|100mg film-coated tablets twice daily for 12 weeks + methotrexate
223889179|NCT04537988|OTHER|Behavioral: eCHANGE|eCHANGE is an eHealth intervention aiming to support long-term weight maintenance after initial weight loss
223889180|NCT06064955|BEHAVIORAL|Peer Support|Former caregivers will be paired with a current caregiver based on a similar personal attribute (e.g., relationship to care recipient). Each pair will complete at least five virtual face-to-face (video) interactions and at least 10 other interactions either via phone call, email, or text messaging over the 6-month time period.
223889181|NCT04157231|OTHER|Acute stroke care Intervention arm|"Training and education of the site staff about the treatment protocol for the different components of the management plan will be provided on two occasions. The aim of these sessions will be to educate stroke champions and other site staff on the management protocols. Available training resources will be accessed (including online materials) and simulation training will be used. New skills such as dysphagia assessment will be emphasized based on existing knowledge and competencies. After training, staff will have another assessment (Post-test) in order to determine whether they have been adequately trained and are able to adhere to the essential acute stroke care management plan. A standardised Power Point presentation and accompanying handouts will be made available for further use in the ward.~Refresher training will be provided monthly during the intervention."
223889182|NCT03846505|DRUG|Oxytocin|A 40-IU dose of oxytocin will be self-administered 30 minutes prior to the start of each weekly ABCT session.
223889183|NCT03846505|OTHER|Placebo|A placebo will be self-administered 30 minutes prior to the start of each weekly ABCT session.
223889184|NCT05987605|DRUG|1A46 Drug Substance|Cycle 1 which will consist of an initial dose given on C1D1 and an intermediate dose given on C1D8, followed by a maintenance dose beginning on C1D15 and continuing while the patient is treated at that dose level
223889185|NCT03091725|PROCEDURE|Roux-en-Y gastric bypass surgery|Roux-en-Y gastric bypass surgery will be performed with post-weight loss testing performed after \~16-18% weight loss is achieved.
223889186|NCT03091725|BEHAVIORAL|Low-calorie diet|Subjects will meet with a dietitian and/or behaviorist over 4-6 months to lose \~16-18% of their body weight.
223889187|NCT06443892|PROCEDURE|Pericapsular Nerve Block (PENG)|Evaluation of postoperative analgesic efficacy of PENG block in participants with intertrochanteric femur fractures undergoing surgery under spinal anesthesia.
223889188|NCT06443892|PROCEDURE|Suprainguinal Fascia Iliaca Compartment Block (SFICB)|Evaluation of postoperative analgesic efficacy of SFICB block in participants with intertrochanteric femur fractures undergoing surgery under spinal anesthesia.
223889189|NCT06419322|OTHER|Optimized rehabilitation program|Consisting of: goal-oriented rehabilitation, hands on physiotherapy sessions and home use of SMA approved rehabilitation device.
223889190|NCT04774068|DRUG|Parsaclisib|Given PO
223889191|NCT04774068|DRUG|Romidepsin|Given IV
223889192|NCT05652322|DRUG|Furosemide Pill 150% equivalent iv dose|change from intravenous to oral furosemide
223889193|NCT05652322|DRUG|Furosemide Pill 200% equivalent iv dose|change from intravenous to oral furosemide
223889194|NCT05652322|DRUG|Furosemide Injection|change from intravenous to oral furosemide
223889195|NCT05238766|BEHAVIORAL|DEAL|The DEAL protocol is an Acceptance and Commitment Therapy and Behavioral Activation informed clinical protocol to undermine accommodation and help parents adhere with behavioral treatment plan components.
223889196|NCT02381535|DRUG|Cisplatin|Given IV
223889197|NCT02381535|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
223889198|NCT02381535|OTHER|Laboratory Biomarker Analysis|Correlative studies
223889199|NCT02381535|DRUG|Onalespib|Given IV
223889200|NCT02381535|OTHER|Pharmacological Study|Correlative studies
223889201|NCT06327646|DRUG|Multiple Micronutrient Supplement Blister|MMS in a blister pack along with related job aids, counselling during ANC, etc.
223889202|NCT06327646|DRUG|Multiple Micronutrient Supplement Bottle|MMS in bottles along with related job aids, counselling during ANC, etc.
223889203|NCT06327646|DRUG|Iron Folic Acid Blister|Standard of Care - IFA in a blister pack along with related job aids, counselling during ANC, etc.
223889204|NCT05601154|DRUG|Crest Cavity Protection toothpaste|Participants will brush their teeth with Crest Cavity Protection toothpaste (1,100 ppm F) for 1 minute, expectorate the foam, and rinse their mouths with 10 mL of tap water for 10 seconds
223889205|NCT05601154|DRUG|Crest Cavity Protection toothpaste followed by Act Mint Fluoride Rinse|Participants will brush their teeth with Crest Cavity Protection toothpaste (1,100 ppm F) for 1 minute, expectorate the foam, and rinse their mouths with 10 mL of Act Mint Fluoride Rinse (226 ppm) for 1 minute
223889206|NCT05601154|DRUG|Colgate PreviDent 5000+ toothpaste|Participants will brush their teeth with Colgate PreviDent 5000+ (5,000 ppm F) for 1 minute, expectorate the foam, and rinse their mouths with 10 mL of tap water for 10 seconds
223889207|NCT05601154|DRUG|Colgate PreviDent 5000+ toothpaste followed by Act Mint Fluoride Rinse|Participants will brush their teeth with Colgate PreviDent 5000+ (5,000 ppm F) for 1 minute, expectorate the foam, and rinse their mouths with 10 mL of Act Mint Fluoride Rinse (226 ppm) for 1 minute
223889208|NCT05629845|PROCEDURE|endoscopic ultrasound-guided therapy|EUS-guided glue injection will be used for secondary prevention of EV or GV rebleeding.
223889209|NCT05629845|PROCEDURE|conventional endoscopic therapy|conventional endoscopic therapy (VBL for EV or glue injection for GV) for secondary prevention of EV or GV rebleeding.
223889210|NCT04900961|OTHER|Resistance Exercise|The exercise regimens are generic and designed not to require expert physiotherapy input, therefore, the availability of NHS physiotherapists, which may be at times limited, will not be a barrier to implementation
223889211|NCT03781700|DRUG|Prednisolone|Prednisolone 5 milligram tablets, 1 milligram per kilogram bodyweight per orally per day during 10 days, maximum 50 milligram per day.
223889212|NCT03781700|DRUG|Placebo Oral Tablet|Placebo tablets with identical appearance to the experimental drug
223889213|NCT04399200|DEVICE|Treatment according to standard care recommandation|SDB treatment according to standard care recommandation: Continuous Positive Airway Pressure (CPAP), Mandibular Advancement Device, Positionnal Therapy, Adaptive Servo-Ventilation (ASV), Non-Invasive Ventilation (NIV)
223889214|NCT02732860|OTHER|Molecular Profiling & In Vivo drug testing in pPDX and organoid cultures|Molecular profiling of host tumour sample and pPDX will be performed and analyzed by an expert panel. In vitro organoid culture generation may also be performed if sufficient fresh tissue is available. Matched treatment recommendation based on profiling and in vivo pPDX drug testing results will be made, if available. This recommendation will be communicated to the primary oncologist.
223889215|NCT02085421|DEVICE|tDCS|Transcranial direct current stimulation (tDCS) is a form of non-invasive neuromodulation that has been shown to enhance learning. tDCS is applied with current intensity of 1-2 mA of direct current and can be applied both before and during each cognitive remediation treatment session. Two saline soaked electrode sponges will be applied to the scalp.
223889216|NCT06252506|DRUG|N,N-dimethyltryptamine (DMT) + harmine|DMT and harmine are the two most abundant chemicals in the Amazonian hallucinogenic plant brew, Ayahuasca, which is used traditionally in spiritual and healing ceremonies. An oral formulation of these two substances will be tested against placebo in the context of an FDG-PET scan.
223889217|NCT06252506|DRUG|Placebo|Placebo will be administered on one of the study days to compare the effects of DMT and harmine with the effects a placebo administration.
223889218|NCT06233825|DIETARY_SUPPLEMENT|Omega-3 Fatty Acids and Essential Amino Acids|Oil consumed as capsules. EAA come as powder to be mixed with water before drinking. 4 g of leucine per EAA dose.
223889219|NCT06233825|DIETARY_SUPPLEMENT|Safflower Oil and Non-Essential Amino Acids|Oil consumed as capsules. NEAA are isonitrogenous to intervention condition. Both supplement types are isoenergetic to intervention. NEAA come as powder to be mixed with water before drinking.
223889220|NCT03535272|DRUG|Bismuth subsalicylate|We aim to determine if there is a biologic benefit to an intervention (BSS administration) in the acquisition of travelers diarrhea and the acquisition of antimicrobial resistance genes.
223889221|NCT03535272|DRUG|Placebo Oral Tablet|Placebo manufactured to mimic pepto bismol
223889225|NCT06781697|DRUG|Ketamine|Standard-of-care ketamine treatment in the outpatient setting: 0.5 mg/kg IV infused over 45 minutes (with monitoring up to 90 minutes) per session, with 2 sessions per week for 2 weeks (total 4 treatments).
223889226|NCT06781697|DEVICE|Oculus VR headset|Immersion in 45 minutes of virtual environments using the Oculus VR headset during each ketamine infusion.
223889227|NCT06781775|DRUG|Metformin + Insulin|Pregnant women who have have gestational diabetes and have uncontrolled blood sugar with metformin alone will stay on metformin and add insulin.
223889228|NCT06781775|DRUG|Insulin|Pregnant women who have have gestational diabetes and have uncontrolled blood sugar with metformin alone will stop on metformin and add insulin.
223889229|NCT06035679|DRUG|Pyrotinib and Trastuzumab|Small and large molecules combined with chemotherapy for neoadjuvant treatment of HER2-positive breast cancer
223889230|NCT03892616|DRUG|BI 1358894 (B)|Tablet formulation 2 (TF2a), fed
223889231|NCT03892616|DRUG|BI 1358894 (C)|Tablet formulation 2 (TF2a), fasted
223889232|NCT03892616|DRUG|BI 1358894 (D)|Tablet formulation 2 (TF2b), fed
223889233|NCT03892616|DRUG|BI 1358894 (E)|Tablet formulation 2 (TF2b), fasted
223889234|NCT03892616|DRUG|BI 1358894 (A)|Tablet formulation 1 (TF1), fed
223889235|NCT06475664|OTHER|Personalized legal care services|Participants will receive free, personalized legal care services from Cancer Legal Care (CLC), a nonprofit organization located in the Twin Cities of Minnesota. The duration of study participation is 6 months, however, participants may continue to access free personalized legal care services beyond this period.
223889236|NCT04211025|OTHER|Modest|The modest intervention consists of a 30-minute appointment (by phone or in-person) with the designated staff using the Benefits Screening Tool , and a plan is developed. At 4 weeks, the designated staff follows-up with a phone call or email.
223889237|NCT04211025|OTHER|Intensive|The intensive intervention consists of a 30-minute appointment with the designated staff using the Benefits Screening Tool , and a plan is developed. At 4 weeks, a follow-up appointment is booked for 30 minutes, and progress on the plan is assessed. At 12 weeks after the initial meeting, the designated staff follows-up with a phone call or email.
223889238|NCT05874037|DRUG|Fluvoxamine|Fluvoxamine is an FDA approved drug for the treatment of OCD. This trial is testing the effects of the drug on long COVID.
223889239|NCT03843151|DRUG|BI 1358894|Oral administration of single dose of 10 milligram (mg) BI 1358894 (2 tablets of 5 mg) with 240 milliliter (mL) of water after an high-fat, high-calorie breakfast on Day 1 of Treatment Period 1.
223889240|NCT03843151|DRUG|Itraconazole|Oral administration of 200 mg itraconazole (20 mL of 10 mg/mL solution) with 240 mL of water after an overnight fast for at least 10 h once daily for 14 days on Days -3 to 11 combined with a single dose of 10 mg BI 1358894 (2 tablets of 5 mg) on Day 1 of Treatment Period 2, 1.5 hours after administration of itraconazole.
223889241|NCT06836310|BEHAVIORAL|Real Performance Task-Oriented Movement|Participants performed a task-oriented movement in a real environment by throwing balls into a physical pool for 10 minutes. The movement was designed to engage upper extremity function.
223889242|NCT06836310|BEHAVIORAL|Virtual Reality Task-Oriented Movement|Participants performed a task-oriented movement in a virtual environment using the Oculus Quest 2 VR system for 10 minutes. The task involved throwing virtual balls into a virtual pool with real-time feedback.
223889243|NCT06835010|DRUG|Dexmedetomidine|Dexmedetomidine (Precedex, 100 µg/ml; Rewine Pharmaceutical; Varachha, Seurat, Gujarat) was administered before induction of anesthesia in the form of a 1 µg/kg; loading dose. The loading dose was diluted with 10 ml of normal saline and injected slowly for 10 minutes. IO infusion was prepared to provide 0.2-0.7 µg/kg/h, initially the lowest possible dose was infused and was increased gradually to control IO stress reflexes but with MAP, and HR monitoring to guard against IO hypotension and bradycardia. PO infusion was prepared to provide DXM in a dose of 0.15 µg/kg/h for 24-h. Placebo 0.9% saline solution was provided to patients of the SEVO group at a similar rate and duration.
223889244|NCT06835010|DRUG|Sevoflurane inhalant product|Anesthesia was induced by fentanyl 1 μg/kg/min, propofol 1.5-2 mg/kg and rocuronium 0.5 mg/kg, then tracheal intubation was aided by gentle tracheal pressure and an endotracheal tube of appropriate size was inserted with the aid of fiberoptic laryngoscopy and patients were mechanically ventilated to keep ETCO2 in the range of 30-35 mmHg. Anesthesia was maintained for patients of both groups by sevoflurane 2% in oxygen 100% and rocuronium (0.15 mg/ kg) according to the requirements.
223889245|NCT06829810|OTHER|Modelisation of intraocular pressure profile|Modelisation of IOP profile of all surgical techniques and additional procedures during the follow-up
223889246|NCT05555355|DEVICE|Prevena Plus 125 Therapy Unit|"The investigators will utilize the KCI USA, Inc Prevena Plus 125 vacuum-assisted closure device in patients undergoing spine surgery as a method to prevent surgical site infections and wound dehiscence after surgery. The device has been approved by the FDA under the name Prevena 125 and Prevena Plus 125 Therapy Units and regulation number 21CFR 878.4783."
223889247|NCT05555355|PROCEDURE|Spine surgery|Patients will receive spine surgery
223889248|NCT04922502|BEHAVIORAL|Standard SPACE|12 one hour parent sessions over 12 weeks in which the therapist guides the parent to target anxious behaviors and support adaptive child behaviors.
223889249|NCT04922502|BEHAVIORAL|Bibliotherapy, low therapist contact SPACE|"4 one hour parent sessions over 12 weeks in which the therapist supports the parent in understanding and implementing content reviewed in the book Breaking Free of Child Anxiety and OCD."
223889250|NCT01687608|BIOLOGICAL|AskBio009|Single dose IV injection
223889251|NCT06835543|PROCEDURE|Amnion membrane.|the amnion membrane tucked over the extraction socket then the socket plug will be maintained in place with approximating sutures using 5-0 resorbable suture material
223889252|NCT06835543|PROCEDURE|Chorion membrane|chorion membrane tucked over the extraction socket then the socket plug will be maintained in place with approximating sutures using 4-0 resorbable suture material.
223889253|NCT06838481|OTHER|Concentric overload resistance training|"* Resistance training groups will train 2-3 times per week for 3 months using specialized TechnoGym machines.~* Exercises include Concentric leg press, knee extension, and ankle plantarflexion in a progressive loading program following American College of Sports Medicine (ACSM) \& National Strength and Conditioning Association (NSCA) guidelines.~* Heart rate, blood pressure, and perceived exertion will be monitored during each session."
223889254|NCT06838481|OTHER|Eccentric overload resistance training|"* Resistance training groups will train 2-3 times per week for 3 months using specialized TechnoGym machines.~* Exercises include Eccentric leg press, knee extension, and ankle plantarflexion in a progressive loading program following American College of Sports Medicine (ACSM) \& National Strength and Conditioning Association (NSCA) guidelines.~* Heart rate, blood pressure, and perceived exertion will be monitored during each session."
223889255|NCT06838481|OTHER|Active Control|Walking
223889256|NCT06838195|BIOLOGICAL|S. Flexneri-S. Sonnei bivalent conjugate vaccine|Subjects receive two doses of the vaccine on the day of randomisation (day 0) and day 30.
223889257|NCT06838195|BIOLOGICAL|Placebo|Subjects receive two doses of the placebo on the day of randomisation (day 0) and day 30.
223889258|NCT06838234|OTHER|Arabic version QOL questionnaire|Arabic version QOL questionnaire The Wound-QoL is a wound-specific questionnaire containing 17 items from which one can derive three subscales and . The items 1-5, 6-10, and 11-16 belong to the subscale body, psyche, and everyday life, respectively
223889259|NCT06190275|BIOLOGICAL|GT201 in combination with PD-1 inhibitors|GT201 in combination with a PD-1 inhibitor for advanced head and neck tumors
223889260|NCT06836999|PROCEDURE|deep sedation|The deep sedation was inducted using atropine 0.5 mg iv administered 15 min before the procedure to avoid aspiration. In the EP lab, anesthesia preparation is performed, including invasive arterial blood pressure monitoring via puncture of the radial artery or brachial artery. Noninvasive BP monitoring every 5 minutes is also permitted. Subsequently, midazolam 1-2mg or accompanied with propofol 0.3-0.5 mg/kg is administered intravenously at the start of the CA procedure (i.e., femoral vein puncture), and fentanyl 25 µg is administered intravenously. Then, continuous titrated infusion of propofol 0.2-0.5mg/kg/h for anesthesia maintenance throughout the CA procedure. An additional iv fentanyl (25-50 µg) is administrated at the beginning of RF applications. Further boluses or additional drugs are administrated as needed to maintain analgesia during the procedure. The anesthesiologist is responsible for administering anesthesia and administering medication.
223889261|NCT06836999|PROCEDURE|Conscious sedation|This protocol is aimed at analgesia, with local infiltration of lidocaine for femoral vein puncture followed by intravenous administration of fentanyl (1-2 ug/kg/h). The operator determines the dose of fentanyl and midazolam. A midazolam 1-5 mg bolus is administrated before electrical cardioversion is performed or when the patient is nervous.
223889262|NCT05225922|BEHAVIORAL|Communication Partner Training|This intervention aims to improve the language, communication, participation and overall quality of life of the Person with Aphasia.
223889263|NCT05225922|OTHER|Usual Speech and language Therapy|This group will receive usual speech and language therapy session.
223889264|NCT05947578|DRUG|CLZ-2002|Low dose group (6×10\^6 cells), Mid dose group (12×10\^6 cells), High dose group (24×10\^6 cells)
223889265|NCT06031688|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223889266|NCT06031688|PROCEDURE|Computed Tomography|Undergo CT scan
223889267|NCT06031688|PROCEDURE|Lymphoscintigraphy|Undergo lymphoscintigraphy scan
223889268|NCT06031688|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223889269|NCT06031688|BIOLOGICAL|Ramucirumab|Given IV
223889270|NCT06031688|DRUG|Tepotinib|Given PO
223889271|NCT04062630|DEVICE|iFuse 3-D in Bedrock Configuration|Procedure in which 3 or more spinal segments are fused and concomitant pelvic fixation is performed, additionally iFuse 3-D implants are placed in a trajectory parallel to the S2AI screws.
223889272|NCT04062630|PROCEDURE|Multilevel Lumbar Fusion surgery|Procedure in which 3 or more spinal segments are fused and concomitant pelvic fixation is performed.
223889273|NCT05385718|OTHER|Magnetic Resonance Imaging|Participants are required to undergo a non-invasive magnetic resonance imaging (MRI) scan approximately 30 minutes in length.
223889274|NCT04639934|GENETIC|MeTree|Software program collecting family health history and generating clinical decision support for risk-based preventive care
223889275|NCT05854329|BEHAVIORAL|Virtual Reality Exposure|Virtual Reality device using the immersive dental game.
223889276|NCT01141179|DRUG|LEO 27847|2 mL (0.1 mg) dose of oral solution
223889277|NCT04595786|DRUG|Tranexamic acid|20mg/kg TXA was prepared in a 50ml syringe for intravenous pump
223889278|NCT04595786|DRUG|0.9% saline|0.9% saline was prepared in a 50ml syringe for intravenous pump
223889279|NCT04755309|BEHAVIORAL|Rhythmic intervention|"The rhythmic intervention consists in an ecological and non-invasive intervention based on enriched auditory and musical active experience. It is based on the most recent scientific evidence in the field and provides exposure to and active synchronization with complex musical rhythms. It is thought to promote the infant's ability to recognize and process the complex rhythms of spoken language. Importantly, it taps into and empowers early auditory processing skills. The intervention includes several tasks described in the literature, for example tapping and bouncing at the beat of complex musical rhythms.~The intervention takes place in small groups of infant-caregiver pairs (N=4/5) for 1 hour/week for 6 weeks."
223889280|NCT04755309|BEHAVIORAL|Passive auditory stimulation|The same auditory stimulation is provided to infants, but no active tasks are proposed. Children and caregiver are entertained with motor and cognitive tasks not related to the auditory stimuli presented. The intervention takes place in small groups of infant-caregiver pairs (N=4/5) for 1 hour/week for 6 weeks.
223889281|NCT06270888|RADIATION|Radiation|Radiation given for cancer treatment. Radiation is usually an outpatient procedure completed over the course of 1-6 weeks. High-energy radiation will be delivered to a focused area of the body using a treatment machine called a linear accelerator. Unlike surgery, there are no invasive procedures other than inserting an IV during the radiation planning session. Radiation uses a mold that is customized to fit your body. This mold will be made in the radiation planning session and be used during treatment to keep you from moving. The mold is necessary for very accurate targeting of your tumor. During the procedure, the radiation therapy team will also confirm the exact location that needs to be treated using x-rays.
223889282|NCT05575128|BEHAVIORAL|Behavioral activation|The behavioral intervention will consist of behavioral activation (BA), the basic premise of which is to help people with mental health problems to engage in activities that are reinforcing or meaningful and guided by their personal values
223889283|NCT05575128|OTHER|Medication optimzation|Medication optimization consists of a simple set of principles: reconcile patient's medications, identify the patient's likely need for, and interest in, a medication adjustment, make the adjustment, and assess the response to that adjustment.
223889284|NCT05575128|OTHER|Care as usual|Care as usual, with written resources provided
223889285|NCT04562766|DRUG|Rilzabrutinib|400mg Caplet
223889286|NCT04562766|DRUG|Placebo|400mg Caplet
223889287|NCT06490822|PROCEDURE|Skin biopsy|A single 3 mm-diameter punch skin biopsy will be obtained from FTLD patients and healthy volunteers at the C8 paravertebral under local anesthesia to analyze cutaneous innervation
223889288|NCT00891709|DRUG|LEO 29102|First-in-man. Healthy volunteers
223889289|NCT06844175|DRUG|Budesonide, Glycopyrronium Bromide and Formoterol Fumarate Inhalation Aerosol|The intervention group was given budigfovir once a day, the dose was 160ug/7.2ug/4.8ug by inhalation
223889290|NCT00287235|DEVICE|MARS|
223889291|NCT00287235|DRUG|Standard Medical Therapy|
223889292|NCT02919956|OTHER|Magnetic Resonance Imaging|An MRI scan takes pictures of the brain and heart using a magnet and radio waves. During scanning, measurements of oxygen delivery to the brain will be obtained (CMRO2) as well as evaluation of the heart as it relates to the brain. During the scan patients will be monitored for safety by ECG, blood pressure, television camera, pulse oximetry, and carbon dioxide measurements. Cardiac anesthesiologist and cardiologist will be present.
223889293|NCT02919956|OTHER|Neurodevelopmental Testing|Quantitative ND tests and standardized rating scales will be used in the areas of intellectual, adaptive, visual motor skills, academic achievement in math and reading, attention and executive functioning , motor skills, memory, language, social skills and behavior. Neurodevelopmental Testing will last approximately 3.5-4 hours. Testing will be done through the Neurobehavioral Core at CHOP. Breaks will be taken as needed and a one hour lunch break will be taken, if applicable. ND testing will be performed prior to MRI (if on the same day) or on a different day than the MRI to promote engagement and best performance.
223889294|NCT05435092|RADIATION|3D-reconstruction CT|Three dimensional CT (3D CT):Method of surface rendition of anatomy by means of a special computer software to capture 3D bone models used to improve the outcomes of Total Knee Arthroplasty (TKA).
223889295|NCT01781468|DRUG|armodafinil 150 mg|given orally
223889296|NCT01781468|OTHER|Placebo|given orally
223889297|NCT01781468|DRUG|armodafinil 250 mg|given orally
223889298|NCT06203743|PROCEDURE|caudal block group|PI, PVI measurements and hemodynamic data will be compared between groups
223889299|NCT06203743|PROCEDURE|ilioinguinal-iliohypogastric nerve block group|PI, PVI measurements and hemodynamic data will be compared between groups
223889300|NCT05416554|BEHAVIORAL|Neuropsychological testing|Upon completion of the consent, the subject will be booked into an available 90 minute in-person or remote neuropsychological testing
223889301|NCT05294016|DEVICE|BRA CONNECT device|skin thermal analysis for the detection of breast abnormalities
223889302|NCT06465498|PROCEDURE|LUS decongestive strategy|LUS results are documented in the electronic case report form (eCRF) and converted into a common score ranging from absence of congestion to severe congestion. This generic congestion score will be communicated to the treating physician by the research personnel, along with a proposal to step-up, maintain, or step-down the decongestive therapy.
223889303|NCT06465498|PROCEDURE|PE decongestive strategy|PE results are documented in the eCRF and converted into a common score ranging from absence of congestion to severe congestion. This generic congestion score will be communicated to the treating physician by the research personnel, along with a proposal to step-up, maintain, or step-down the decongestive therapy.
223889304|NCT05986136|DRUG|Mesalamine|Mesalamine, also known as 5-aminosalicylic acid (5-ASA), is a medication used to treat ulcerative colitis. It is usually used to induce or maintain remission of mildly to moderately active ulcerative colitis
223889305|NCT05986136|DRUG|Dapagliflozin 10mg Tab|Dapagliflozin has emerged as a selective SGLT2 inhibitor for the management of type-2 diabetes mellitus with minimal risk of hypoglycemia and it exerts diuretic-like actions and lowering of blood pressure, thereby, reducing the risk of hospitalization in type-2 diabetic patients with co-existing heart failure
223889306|NCT06115070|DRUG|Intravenous thrombolysis (alteplase and other guideline-recommended thrombolytic agents)|Patients will receive standard dose intravenous alteplase (0.9 mg/kg, the first 10% administered as an initial bolus and the remainder over a 1-hour period, with a maximum dose of 90 mg)，intravenous Tenecteplase(0.25mg/kg，administered as a single intravenous bolus injection over 5 - 10 seconds，with a maximum dose of 25 mg), intravenous reteplase (a bolus of 18 mg followed by a second bolus of 18 mg after 30 minutes) and intravenous prourokinase (rhPro-UK) (15 mg bolus followed by a 20 mg infusion over 30 minutes).
223889307|NCT00910338|DEVICE|PFMT with Extracorporeal Biofeedback|"Pelvic Floor Muscle Training with Extracorporeal Biofeedback Device for 12 weeks~* Twice a week for the first 4 weeks~* Once a week for the next 8 weeks"
223889308|NCT06538649|DRUG|Rosuvastatin|Rosuvastatin provided at 10 mg start; 5mg for Asians. Dose will be increased to 20 mg for those tolerating and without contraindication.
223889309|NCT06538649|OTHER|Placebo|Placebo tablet(s)
223889310|NCT03936218|DRUG|Inj. Goserelin (Test) Subcutaneously|10.8 mg, subcutaneously at every 3 month
223889311|NCT03936218|DRUG|Inj. Zoladex (Reference) Subcutaneously|10.8 mg, Subcutaneously at every 3 month
223889312|NCT06803888|PROCEDURE|Bariatric Surgery|Patients receive either RYGB or SG. The surgical risk, the differential impact of each procedure on body weight and other obesity-related diseases, presence of other medical and mental problems, patient's behavioral factors (e.g., postoperative compliance, active smoking), medications, and goals will be considered when the patient and local medical team make a shared decision about the most appropriate surgical procedure.
223889313|NCT06803888|DRUG|Semaglutide|"Semaglutide will be initiated at a dose of 0.25 mg once weekly and will be increased during the dose-escalation period to reach a maintenance dose of up to 2.4 mg once weekly by week 16. If patients do not tolerate a dose during dose escalation, we will consider delaying dose escalation until next visit (for 4 weeks). Dosing for Semaglutide is the FDA-approved dosing schedule.~The maintenance dose is 2.4 mg injected subcutaneously once-weekly. The protocol allows for dose reductions in case a participant does not tolerate the recommended target dose of 2.4 mg and may stay at the lower maintenance dose level (e.g., 1.7 mg once weekly), if needed."
223889314|NCT06803888|DRUG|Tirzepatide|"Tirzepatide will be initiated at a dose of 2.5 mg once weekly and will be increased by 2.5 mg every week during the dose-escalation period to reach a maintenance dose of up to 15 mg once weekly by week 20. If patients do not tolerate a dose during dose escalation, we will consider delaying dose escalation until next visit (for 4 weeks). Dosing for Tirzepatide is the FDA-approved dosing schedule.~The maintenance dose is 15 mg injected subcutaneously once-weekly. The protocol allows for dose reductions in case a participant does not tolerate the recommended target dose of 15 mg and may stay at the lower maintenance dose level (e.g., 10 mg once weekly), if needed."
223889315|NCT04877041|BEHAVIORAL|Intradialytic Cycling|This intervention will consist of intradialytic cycling for 60 minutes 3 times per week for a total of 12 weeks.
223889316|NCT03468335|DRUG|Irinotecan Liposomal Injection [Onivyde]|"Cancer treatment for PDAC:~* Nal-IRI (4.3 mg/ml) 70 mg/m2 as 1.5 hour infusion~* 5-FU 2400 mg/m2 as 46 hour infusion~* Folinic acid 400 mg/m2 as 0.5 hour infusion~* all on D1 of each cycle; Cycle q2w ± 5 days~Treatment until progressive disease or intolerable toxicity or withdrawal of consent."
223889317|NCT05606575|DEVICE|Nelli|Nelli is a non-EEG physiological signal-based seizure detection and quantification device that is indicated for use as an adjunct to seizure monitoring during periods of rest. The device utilizes automated analysis of audio and video (media) data collected via the personal recording unit (PRU) hardware accessory to identify epileptic and non-epileptic seizure events with a positive motor component.
223889318|NCT01826331|BEHAVIORAL|Incentives for Participation|Participants will receive three smoking cessation programs
223889319|NCT01826331|BEHAVIORAL|Incentives for Cessation|Participants will have access to a smoking cessation program
223889320|NCT03191981|DRUG|Cyclophosphamide|Treatment for all patients will be with cyclophosphamide, lenalidomide and pembrolizumab at fixed doses.
223889321|NCT03191981|DRUG|Lenalidomide|Treatment for all patients will be with cyclophosphamide, lenalidomide and pembrolizumab at fixed doses.
223889322|NCT03191981|DRUG|Pembrolizumab|Treatment for all patients will be with cyclophosphamide, lenalidomide and pembrolizumab at fixed doses.
223889323|NCT02117752|DRUG|dapsone gel|Patches containing dapsone gel will be applied to the skin.
223889324|NCT02117752|DRUG|dapsone gel vehicle|Patches containing dapsone gel vehicle will be applied to the skin.
223889325|NCT02117752|DRUG|sodium lauryl sulfate|Patches containing sodium lauryl sulfate (Positive Control) will be applied to the skin.
223889326|NCT02117752|DRUG|Normal saline|Patches containing normal saline (Negative Control) will be applied to the skin.
223889327|NCT04986501|DEVICE|MucoPEG|Experimental
223889328|NCT04986501|DEVICE|Biotene|Active Comparator
223889329|NCT06243211|PROCEDURE|DMED|Decompression of spinal cord with stabilization - posterior approach.
223889330|NCT06243211|PROCEDURE|ANGI|Implantation of nerve tissue following decompression ans stabilization.
223889331|NCT03931447|BIOLOGICAL|JNJ-72537634|Participants in Cohort 1 and 3 will receive Dose 1 and participants in Cohort 2 and 4 will receive Dose 2 of JNJ-72537634 as oral capsule.
223889332|NCT03931447|BIOLOGICAL|Placebo|Participants will receive matching placebo as oral capsule in all cohorts.
223889335|NCT03721913|OTHER|participation-based intervention|The participation-based intervention is a goal-orientated, family-centered, and self-determined approach that emphasize on solution strategies based on child and family-selected goals. Intervention strategies will be formed by analyzing the strength and needs of child, family, and environment, and implemented by collaboration between family and interventionists.
223889336|NCT06221488|DIAGNOSTIC_TEST|TB infection testing|Diagnostic testing with existing and novel tests to evaluate for TB infection and disease
223889337|NCT05981794|DEVICE|Electrical heating pad|A powered heating pad
223889338|NCT05981794|DEVICE|Sham heating pad|A heating pad that is not powered on
223889339|NCT03519230|DRUG|Pamiparib capsule|60 mg twice daily (BID), orally (per os-PO)
223889340|NCT03519230|DRUG|Placebo capsule|60mg BID, PO
223889341|NCT05498948|DIETARY_SUPPLEMENT|Probiotic mixture|orally take .
223889342|NCT05736679|DEVICE|In2Care EaveTube|In2Care® EaveTubes (ETs) comprise 15 cm diameter, 20 cm long ventilation tubes with removable netting inserts that are placed in the wall under the roof of houses where they attract malaria mosquitoes at night, block them from entering the house, and contaminate them with a lethal dose of insecticide. In2Care® ET netting inserts have an electrostatically charged coating treated with bio-actives in powder form, which kills insecticide-resistant mosquitoes through high active ingredient dose transfer.
223889343|NCT03930342|BEHAVIORAL|Native-CHOICES|Native CHOICES is a behavioral intervention for prevention of prenatal alcohol exposure in women at high risk for alcohol-exposed pregnancies. The intervention uses motivational interviewing and cognitive-behavioral strategies, and targets adoption of effective contraception and reduction of alcohol use.
223889344|NCT03209713|BEHAVIORAL|HPV Vaccine Education|A one on one twenty-minute parental educational program (in-person or over the phone) providing facts about HPV, HPV-related cancers, and the HPV vaccine.
223889345|NCT03209713|BEHAVIORAL|Text Messaging Reminder|Participants will receive a text message reminding them of their child's vaccination eligibility once a week, starting one week after participating in the education session (in-person or over the phone). All participants randomized to the text message reminder arm will receive a welcome text message from the automated web-based text messaging service, Mosio, within 72 hours from registration. One week after receiving the welcome text message, they will receive the first weekly text messages reminding them of their child's eligibility for the first dose HPV vaccine. These weekly reminders will occur until uptake of the first dose of the vaccine is reported (through self-report outcome survey completion or submission of the HPV vaccination card/child's official immunization card) or for up to 12 weeks
223889346|NCT00152087|DEVICE|Brachytherapy|
223889347|NCT05000489|OTHER|No intervention being administered|No intervention will be administered. Each patient will participate in a qualitative focus group discussing their beliefs/attitudes about their reproductive health and birth control
223889348|NCT00912600|OTHER|Intensive Care Unit admission|Intensive Care Unit admission
223889349|NCT01534299|DEVICE|Medtronic Renal Denervation System|The Symplicity renal denervation system is comprised of a single-use, disposable catheter and a reusable radiofrequency (RF) generator. The Symplicity renal denervation system has CE Marking for the intended use of delivering low-level radiofrequency energy through the wall of the renal artery to denervate the human kidney.
223889350|NCT05824078|PROCEDURE|Arthroscopic surgery|Arthroscopic approach involves smaller incision, offering less traumatic procedures and faster healing, but due to the limited space in this closed field with significant vasculature and nerve distribution, scoping has increased risk for iatrogenic injuries.
223889351|NCT05824078|PROCEDURE|Open Surgery|The open approach requires dissection of capsuloligamentous structures, which can lead to stiffness of the joint due to capsular scarring as it heals. However, it offers good visual field when treating the injury, allowing maneuverability to avoid iatrogenic soft tissue injuries.
223889352|NCT03859869|DRUG|Pancrelipase|Pancrelipase is administered orally as capsules with a meal or snack
223889353|NCT03859869|DRUG|Placebo|Placebo is administered orally as capsules with a meal or snack
223889354|NCT00558506|DRUG|abatacept|intravenously 750mg (in patients with weight of 60- 100kg)
223889355|NCT06565429|BEHAVIORAL|5-Step Method Intervention|The 5-Step Method (5SM) intervention is delivered through a self-help handbook: There are writing prompts for the affected family member (AFM) in each step. The steps end with a summary, a space to reflect and a statement that the step is complete but can be reviewed as needed. The steps are: 1.Explore how the relative's drug and/or alcohol misuse is affecting the family member, causing stress and strain. 2.Determine the information the AFM needs to understand the situation using evidence-based websites in the handbook. 3.Reflect on coping styles, and which ones might be useful. 4.Determine who is a source of positive social support, and who could be one that the AFM has not used yet. 5.Review steps 1-4 and determine if the AFM is feeling less stress and strain, or if more help is needed and use websites to look for additional help. The activities should take about 1 hour per week.
223889356|NCT04750707|DRUG|Hydroxyurea|The study intervention will be daily oral Hydroxyurea given in single doses starting at approximately 20mg/kg/day and escalated to a maximum 30mg/kg/day depending on clinical need and according to standard guidelines.
223889357|NCT06853548|OTHER|Assessment|Respiratory function, respiratory muscle strength, and core stability parameters will be assessed in children with hyperkyphosis.
223889358|NCT06979778|DEVICE|See Yourself Differently (syd) mobile app|"The 'syd' mobile app is designed as an AI-powered Life Quality Mentor with the primary aim of enhancing users' quality of life. The app focuses on positive habit development, personalised feedback, and continuous support. It offers personalised guidance across various domains, including Physical health, Emotional health, Brain power, Self-awareness, Purpose, Career, Financial health, Social life and Environment. It utilizes an advanced AI platform and offers features like personalised recommendations, supportive interaction with an AI mentor, habit tracking tools, and integration with wearable technology."
223889359|NCT06602804|DEVICE|Trima Accel Auto RBC Collection|This is a non-interventional study, observing the in vivo performance of LR-RBC units derived from Trima Accel Auto RBC collection.
223889360|NCT05752916|DRUG|rhTNK-tPA|Recombinant human TNK tissue-type plasminogen activator. Patients will receive intravenous rhTNK-tPA (0.25mg/kg, maximum 25mg, administered as a bolus over 5-10 seconds).
223889361|NCT05752916|DRUG|Antiplatelet Agents|Aspirin (150-300mg) is offered to patients allocated in the control arm, unless contraindicated. According to Chinese Guidelines for Diagnosis and Treatment of Acute Ischemic Stroke 2023, 150-300mg aspirin alone is recommended for acute stroke treatment in patients who are otherwise eligible for intravenous thrombolysis or EVT as soon as possible (Class 1 of recommendation, Level A of evidence). The aspirin dose can be changed to 50-300 mg/day after the acute phase. Clopidogrel is indicated as an alternative in case of aspirin intolerance (Class 2 of recommendation, Level C of evidence)
223889362|NCT06986473|OTHER|Questionnaire that measure the level of awareness of dermatologists|This study will be an observational cross-sectional analytical study that will recruit 165 dermatologists of both genders according to sample size calculation from different outpatient clinics in Cairo teaching hospitals. The aim of the study will be to develope a questionnaire to evaluate the awareness of Egyptian dermatologist towards the role of physical therapy in patients with various skin diseases
223889363|NCT06986369|DRUG|Rivaroxaban 2.5 MG Oral Tablet [Xarelto]|prospective, randomized, 3 months study to clarify the efficacy of rivaroxaban and aspirin versus aspirin in the alone the changes on the number of circulating endothelial cells and endothelial function, and systemic inflammation, platelet and coagulation activation in patients with stable atherosclerotic vascular diseases.
223889364|NCT06986395|DEVICE|Blood Flow Restriction Training (BFRT)|Standard progressive resistance exercise at 65-75% 1RM intensity using weights/elastic bands
223889365|NCT06986395|OTHER|Conventional Resistance Training (CRT)|Standard progressive resistance exercise at 65-75% 1RM intensity using weights/elastic bands
223889366|NCT06987149|DEVICE|CAD/CAM Zirconia Membrane|A prefabricated, non-resorbable zirconia membrane fabricated using CAD/CAM technology for guided bone regeneration in horizontal ridge deficiencies during simultaneous dental implant placement.
223889367|NCT06987149|PROCEDURE|Contour Augmentation|Traditional guided bone regeneration using particulate bone graft and a resorbable collagen membrane, placed concurrently with the dental implant to augment horizontal ridge deficiencies.
223889368|NCT06984913|OTHER|Ultrasound-guided sphenopalatine ganglion block|Patients will receive an ultrasound-guided sphenopalatine ganglion block (4 ml bupivacaine 0.25%).
223889369|NCT06984913|OTHER|Brainlab navigation sphenopalatine ganglion block|Patients will receive a Brainlab navigation sphenopalatine ganglion block (4 ml bupivacaine 0.25%).
223889370|NCT06984913|OTHER|Low dose Brainlab navigation sphenopalatine ganglion block|Patients will receive a Brainlab navigation sphenopalatine ganglion block (2 ml bupivacaine 0.25%) (low dose).
223889371|NCT06987630|DEVICE|monitor integrated pulmonary index（IPI） and take appropriate measures|When the IPI is ≤ 6, the patient's jaw is immediately lifted, the oxygen flow rate increases to 6L·min-1, and if the SpO2 continues to decrease by \<90%, the anesthesia mask is pressurized and ventilated.
223889372|NCT06987838|DRUG|Pharmacological treatment|All participants in the two groups will receive pharmacological treatment in the form of ibuprofen 400 mg, three times per day, during the first 2 days of menstruation, for 3 menstrual cycles.
223889373|NCT06987838|OTHER|Virtual reality|The experimental group will receive virtual reality during the first 2 days of menstruation, for 3 menstrual cycles.
223889374|NCT03748342|DEVICE|Second-Generation Laryngeal Mask Airway|A second-generation LMA will be used for airway management (instead of ETT).
223889375|NCT06855186|BEHAVIORAL|Symptom-Targeted Approach to Rehabilitation for Concussion|This study is looking at a shortened version of a therapist-direct cognitive rehabilitation intervention, known as STAR-C. STAR-C is focused on strategy use, and for strategy use to become a habit the person must have the opportunity for high-dose spaced practice. Thus, in STAR-C each session includes opportunities for repeated practice and participants schedule practice times between sessions. Sometimes a new strategy requires learning new facts, in which case the clinician chooses ingredients such as self-quizzing or comparing and contrasting outcomes, which are effective for learning new facts and concepts.
223889376|NCT06866509|DRUG|Litorvazet Tablet 10/10mg|Ezetimibe 10 mg + Atorvastatin 10 mg
223889377|NCT06866509|DRUG|Litorvazet Tablet10/20mg|Ezetimibe 10 mg + Atorvastatin 20 mg
223889378|NCT06866509|DRUG|Litorvazet Tablet 10/40mg|Ezetimibe 10 mg + Atorvastatin 40 mg
223889379|NCT06676748|DRUG|Benzydamine Hydrochloride|The Difflam Forte Anti-Inflammatory Throat Spray (iNova Pharmaceuticals Pte Ltd, Singapore) is an over-the-counter medication indicated for temporary relief of painful mouth and throat conditions. It contains benzydamine hydrochloride (BH) 3 mg/mL, a non-steroidal anti-inflammatory agent (NSAID), and is recommended for adults to spray 2 to 4 times to the affected throat every 1.5 to 3 hours as needed.
223889380|NCT06677450|OTHER|Pain neuoroscience education|Pain neurosicence education will be applied 1 day / 6 weeks at the beginning of one of the weekly exercise sessions in addition to the exercise program. The educations will include the definition and general characteristics of pain, pain physiology, peripheral neuropathic pain, the role of the brain in pain perception, tissue healing, peripheral and central sensitization, the effects of emotional, psychological and social factors on the pain process and pain coping strategies.
223889381|NCT06677450|OTHER|Exercise|Exercise program will be applied 2 days/week for 6 weeks and will consist of 3-phase stretching and motor control/progressive resistance exercises.
223889382|NCT06677450|OTHER|Exercise|Exercise program will be applied 2 days/week for 6 weeks and will consist of 3-phase stretching and motor control/progressive resistance exercises.
223889383|NCT05297864|DRUG|Niraparib|The starting dose will be 300 mg niraparib (or modified according patient weight and platelet count), taken orally once a day for each cycle of 28 days.
223889384|NCT04634019|BEHAVIORAL|Financially incentivized knowledge assessments|We will conduct quarterly provider knowledge assessments at selected health facilities and will pay facilities a financial bonus if providers perform well on these tests. For the intervention, 12 clinical vignettes were created. These vignettes cover typical patient cases such as malaria, diarrhea and respiratory infections, and assess providers' ability to correctly diagnose and treat hypothetical questions. All medical staff members will be informed hat every 3 month there will be a knowledge assessment based on these vignettes and that the results will determine the total bonus payment made to the facility.
223889385|NCT03615690|OTHER|Fasting Mimicking Diet|5 day reduced calorie diet
223889386|NCT03615690|OTHER|Regular Diet|Regular Diet
223889387|NCT06718244|BIOLOGICAL|single dose of Inaticabtagene autoleucel|"Inaticabtagene autoleucel will be transfusioned intravenously at the recommended dose of 0.5×10\^8 (ranging 0.2-0.6×10\^8) viable CAR-T cells.~If the quantity of CAR-T cells of the patient is sufficient, after the patient receives the first CAR-T transfusion 5\~6 months，they will receive a second CAR-T cell transfusion. The aim of the second transfusion is to prolong the duration of CAR-T in the patient's body and prolong the patient's DOR. The dose and procedures of the second transfusion are the same as those for the first transfusion. After the second infusion, the patient will receive evaluation based on the day of the second transfusion as Day0."
223889388|NCT06725615|OTHER|Regular Umami exposure|This group will receive the basic diet with added MSG, representing Dutch intake levels of around the 50th percentile, which is about 20-25 mg/kg body weight.
223889389|NCT06725615|OTHER|High Umami exposure|This group will receive the basic diet with added MSG, representing Dutch intake levels of around the 90th percentile, which is about 50-55 mg/kg body weight.
223889390|NCT06725615|OTHER|Low Umami exposure|This group will receive the basic diet without added MSG.
223889391|NCT06725615|OTHER|one-week run-in period|During the one-week run-in period, all participants will receive the RegularU diet, which is the basic diet with added MSG, representing Dutch intake levels of around the 50th percentile (about 20-25 mg MSG intake daily per kg body weight).
223889392|NCT06926231|BEHAVIORAL|Protocolized medical hypnosis|Patients who will receive protocolized medical hypnosis before the SBT every day between inclusion and day 7. Medical hypnosis sessions will consist in the administration of a 5-min hypnotic text by a loudspeaker installed in the ICU room, after selection of a hypnotic theme (sea, mountain or animals) by the participant. The hypnosis session will involve an induction phase, a suggestion phase and an emergence phase, along with self-hypnosis tips. The hypnosis session will immediately precede the SBT (\<2h). The intervention is administered before the SBT daily from the randomization to day 7 or until extubation.
223889393|NCT06926231|BEHAVIORAL|Protocolized standard of care|The protocolized standard of care will consist in the description of authorized human/behavioral patient-nurse interactions and patient installation prior to the daily SBT.
223889394|NCT06780709|BEHAVIORAL|Wellness Program and Behavioral Counseling|The comprehensive wellness evaluation will include initial assessments by dietician, social worker, physical therapist, nurse practitioner, and a behavioral neuropsychologist. Each provider will conduct an initial evaluation at baseline to identify areas of need and patient driven goals, as well as follow-up evaluations to evaluate implementation of changes and barriers to change.
223889395|NCT06752902|OTHER|Standard Care Arm|standard care combined with personalised prevention
223889396|NCT06752902|OTHER|standard care combined with personalised prevention|standard care combined with personalised prevention
223889397|NCT06629766|DEVICE|Microfluidic sperm separation device|An aliquot of 850ul will be used for the Zymot sperm selection device. The sperm processing via Zymot will be per manufacturer's guidelines
223889398|NCT06629766|OTHER|Density grade centrifugation|5ul of the ejaculated sample will be assessed for DGC via Makler assessment. If the sample for DGC is adequate per lab standard operating procedures, then routine DGC sperm preparation and embryologist sperm selection for the ICSI procedure will occur.
223889399|NCT06835595|DIAGNOSTIC_TEST|Transcranial Magnetic Stimulation|Paired stimulation protocols of TMS to collect SAI, SICI, ICF measures
223889400|NCT06927193|PROCEDURE|Regional anaesthesia|Regional anaesthesia
223889401|NCT06784778|DIAGNOSTIC_TEST|PBMC Kinase Activity Profile|Kinase activity profile will be correlated to the observed clinical outcome parameters (including survival and toxicity associated with the therapy) of standard of care treatments
223889402|NCT06840379|DRUG|Sertraline (Oral Antidepressant)|"* 25 mg/day sertraline, titrated up to 100 mg/day based on clinical response and tolerability.~* Administered orally once daily for 12 weeks.~* Used to assess its effects on C-reactive protein (CRP) levels and depressive symptoms in hemodialysis patients."
223889403|NCT06840379|DRUG|Placebo|"* Identical placebo tablet administered orally once daily for 12 weeks, following the same dosing schedule as the sertraline group.~* Used to compare the effects of sertraline vs. placebo on CRP levels and depression severity in hemodialysis patients."
223889404|NCT04858139|DRUG|Lactate|Intravenous injection (20 min), 300 mmol/L, 1mmol/Kg body weight,
223889405|NCT04858139|DRUG|Placebo|Intravenous injection (20 min)
223889406|NCT06073743|OTHER|Conventional Physiotherapy|The conventional physiotherapy program will be applied 2 days a week, 60 minutes a day for 10 weeks and consist of weight bearing on the upper and lower extremities, strengthening, functional stretching exercises, walking training and balance exercises.
223889407|NCT06073743|OTHER|Video Game Based Exercise Training|In the Video Game Based Exercise Training program, in addition to the same conventional physiotherapy application for 30 minutes a day, 2 days a week for 10 weeks, 30 minutes of Microsoft Xbox Kinect video games such as reflex ridge and rallyball are used.
223889408|NCT06630000|BEHAVIORAL|FACT|Two 90-minute FACT sessions led by a trained interventionist.
223889409|NCT06630000|BEHAVIORAL|Control|Two 90-minute sessions individually with a study interventionist, 2-weeks apart (focused on nutrition education).
223889410|NCT05395767|PROCEDURE|Endoscopic Anterior Cruciate Ligament reconstruction using living donor hamstring allograft from a parent donor|The Parent donor will undergo hamstring tendon graft harvest under general anaesthesia in a routine fashion in one theatre. The Graft material will be transported thorough to the adjacent theatre, where the child will be anaesthetised and undergoing arthroscopy of their injured knee in preparation for receiving the graft. ACL reconstruction Surgery will be undertaken in the child recipient as per the Surgeons usual technique, +/- meniscus repair +/- lateral tenodesis as required.
223889411|NCT06932289|DIETARY_SUPPLEMENT|Mediterranean diet (MED), high-fat/low carb diet (HF/LC), and low-fat diet (LF)|Participants will be randomized to either Mediterranean diet (MED), high-fat/low carb diet (HF/LC), or low-fat diet (LF).
223889412|NCT06932289|DEVICE|The integrated sweat sensor and vascular sensor (wearable)|The integrated sweat sensor and vascular sensor will be worn of each diet period.
223889413|NCT06932289|DEVICE|continuous glucose monitor (CGM)|A continuous glucose monitor (CGM) will be placed on the patients during each diet period.
223889414|NCT06931613|DRUG|Nivolumab|Nivolumab with or without bendamustine is administered to children prior to auto-HSCT
223889415|NCT06932367|DRUG|Dexketoprofen (KETAVEL 50 mg/2 ml)|Patients with low back pain were divided in to two groups: those receiving intravenous dexketoprofen treatment (Group 1) and those receiving dexketoprofen + methylprednisolone treatment (Group 2). The efficacy of the treatments received by the patients was evaluated with the VAS at minutes 0, 15, 30, and 60 and hour 48. Statistical evaluations were also undertaken on the ODI results evaluated at minute 0 and hour 48.
223889416|NCT06932367|COMBINATION_PRODUCT|Methylprednisolone (Corticosteroid)|Patients with low back pain were divided in to two groups: those receiving intravenous dexketoprofen treatment (Group 1) and those receiving dexketoprofen + methylprednisolone treatment (Group 2). The efficacy of the treatments received by the patients was evaluated with the VAS at minutes 0, 15, 30, and 60 and hour 48. Statistical evaluations were also undertaken on the ODI results evaluated at minute 0 and hour 48.
223889417|NCT06931223|DRUG|Flupentixol-Melitracen + Lansoprazole|Flupentixol-Melitracen and Lansoprazole for the treatment of functional dyspepsia.
223889418|NCT06931223|DRUG|Lansoprazole|Placebo and Lansoprazole for functional dyspepsia.
223889419|NCT06931808|DRUG|Sintilimab plus Chemotherapy|All patients received standard long-term radiation therapy (LCRT) (50.0Gy/25f) and concurrent chemotherapy with capecitabine (825 mg/m2, bid, po) (Phase 1); Xelox scheme (Oxaliplatin 130 mg/m2, ivgtt ，d1； Capecitabine 1000 mg/m2, bid，d1-14) (Phase 2); . During the radiotherapy and chemotherapy period, they also received two cycles of immunotherapy with Sintilimab (200mg, ivgtt, d1, q3w).
223889420|NCT06931808|DRUG|Intestinal microbiota capsules|During Phase 1, intestinal microbiota transplantation treatment, oral intestinal microbiota capsules are used for transplantation treatment, with a dose of 30 capsules/day (about 1U sediment microbiota, containing about 1 × 1013 bacteria). Transplantation is carried out continuously for 3 days starting from each week, for a total of 3 courses of treatment.
223889421|NCT06931808|RADIATION|Standard Long Course Radiotherapy|50.0Gy/25f
223889422|NCT06931808|PROCEDURE|Total mesorectal excision|6-8 weeks after the end of the first phase and combined with 5 cycles of Xelox regimen adjuvant chemotherapy.
223889423|NCT06931743|DEVICE|CMNS6-1 Electronic Acupuncture Therapeutic Apparatus|"1. The time selection of acupoint treatment is to return to the ward immediately,2 and 4 hours after surgery;~2. Time of each stimulation: 30min;~3. Acupoint extraction: According to the theory of wrist and ankle acupuncture and the location of pain, the upper 1 area (the ulnar margin on the little finger side and the depression of the flexor carpi ulnaris tendon) and the upper 2 area (between the palmaris longus tendon and the flexor carpi radialis on both sides) on the affected side (bilateral for total thyroidectomy) were selected as the intervention site, and the upper and lower parallel electrodes were placed in each area, and a total of 4 electrodes (8 electrodes on both sides) were placed.~4. The parameter setting of the equipment: the frequency is set to 2Hz, the pulse width is set to 500μs, continuous wave is used, and the current intensity is the maximum tolerance of the subject's small pain threshold for 30min."
223889424|NCT06931743|DEVICE|CMNS6-1 Electronic Acupuncture Therapeutic Apparatus|"1. The time selection of acupoint treatment is to return to the ward immediately,2 and 4 hours after surgery;~2. Time of each stimulation: 30min;~3. Acupoint extraction: According to the theory of wrist and ankle acupuncture and the location of pain, the upper 1 area (the ulnar margin on the little finger side and the depression of the flexor carpi ulnaris tendon) and the upper 2 area (between the palmaris longus tendon and the flexor carpi radialis on both sides) on the affected side (bilateral for total thyroidectomy) were selected as the intervention site, and the upper and lower parallel electrodes were placed in each area, and a total of 4 electrodes (8 electrodes on both sides) were placed.~(4)30 minutes of ineffective microcurrent stimulation."
223889425|NCT06932510|PROCEDURE|Manual Traction|Manual cervical traction will be administered by a trained physical therapist.
223889426|NCT06932510|DEVICE|Cervical Traction Collar|Cervical traction will be administered via Cervical Traction Collar.
223889427|NCT06932549|BEHAVIORAL|Technical assistance is designed to integrate Expert Recommendations for Implementing Change (ERIC) strategies, and Getting To Outcomes-TA.|The TA is tailored to each congregation using the results of the implementation capacity survey completed by the congregation's team and materials from the EB Program selected by the congregation. The TA teams of two research staff are being trained and coached by Dr. Abe Wandersman, lead developer of Getting To Outcomes-TA (GTO-TA). TA sessions are audio-recorded and will be evaluated for fidelity to GTO-TA, and use of specific ERIC strategies.
223889428|NCT06932159|DRUG|Empagliflozin + Linagliptin film-coated tablets|1 tablet of Empagliflozin + Linagliptin 25 mg/5 mg film-coated tablets
223889429|NCT06932159|DRUG|Glyxambi film-coated tablets|1 tablet of Glyxambi 25 mg/ 5 mg film-coated tablets
223889430|NCT06932913|OTHER|plyometric exercise|"Plyometric exercise procedures:~Patients in group (B) will receive Plyometric exercise :~Traditional physical therapy program for 20 to 30 minutes and 30 to 45 minutes of training program consisted of 6 lower extremity plyometric exercises for eight weeks .~Wall jumps : Knees slightly bent, arms raised overhead, bounce up and down off toes . Tuck jumps : From standing position, jump and bring both knees up to chest as high as possible Squat jumps : Standing jump raising both arms overhead, land in squatting position touching both hands to the floor Single leg jump distance : One-legged hop for distance .~Scissors jump : Start in stride position, jump and alternate position in midair .~Bounding in place : Jump from 1 leg to the other straight up and down."
223889431|NCT06932913|OTHER|Plyometric exercise procedures:|"The traditional physical therapy program will be in the form of (active knee range of motion exercise and stretching and strengthen exercise of hamstring) three times a week for eight successive weeks of treatment in 20 to 30 minutes to complete:-~Active range of motion exercises for knee joint:~This type of exercise was performed in the following manner:~Knee flexion :~From prone lying position. The child will asked to Slowly bend his knee by pulling heel to buttocks as far as he can . he should feel a gentle stretch in his thigh muscles and knee. Return to starting position.~Knee extension :~From sitting position at the edge of the plinth the child will asked to move his feet up word toward the ceiling as far as he can then return . he should feel gentle stretch on the hamstring muscle .~Hip and knee bend:"
223889432|NCT06931665|PROCEDURE|Animal Assisted Occupational Therapy|AAT is an ergotherapy including an animal. AAT is a specific type of Animal Assisted Intervention (AAI) with a therapeutic aim.
223889433|NCT06375005|DRUG|Telitacicept|Telitacicept is fusion protein comprising a recombinant transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI) receptor fused to the fragment crystallizable (Fc) domain of human immunoglobulin G (IgG). Telitacicept binds to and neutralizes the activity of two cell-signalling molecules, B-lymphocyte stimulator (BLyS) and a proliferation-inducing ligand (APRIL), thereby suppressing the development and survival of plasma cells and mature B cells. Telitacicept will be subcutaneously injected at a dose of 160mg per week, lasting for 48 weeks.
223889434|NCT06375005|DRUG|Mycophenolate Mofetil|All patients will receive background therapy with Mycophenolate Mofetil (MMF), administered orally at a dose of 0.5g twice daily for 48 weeks.
223889435|NCT04893382|PROCEDURE|PlasmaLyte for fluid resuscitation|Fluid resuscitation is a critical and essential part in the treatment of severely burned patients. Patients randomized for this arm will be submitted to PlasmaLyte infusion (as clinically prescribed).
223889436|NCT04893382|PROCEDURE|Ringer's Lactate for fluid resuscitation|Fluid resuscitation is a critical and essential part in the treatment of severely burned patients. Patients randomized for this arm will be submitted to Ringer's Lactate infusion (as clinically prescribed).
223889437|NCT06237257|BIOLOGICAL|SHR-1316|SHR-1316（Adebrelimab Injection）
223889438|NCT06237257|DRUG|Cisplatin Injection/Carboplatin Injection|Cisplatin Injection/Carboplatin Injection
223889439|NCT06237257|RADIATION|External Beam Radiotherapy (EBRT)/Brachytherapy|External Beam Radiotherapy (EBRT)/Brachytherapy
223889440|NCT06237257|DRUG|Paclitaxel Injection|Paclitaxel Injection.
223889441|NCT04729907|DRUG|Nusinersen|Administered as specified in the treatment arm
223889442|NCT04659343|OTHER|Measurement of concentration of active metabolite in cancer treatment.|Medical treatment for metastatic renal cell carcinoma with axitinib, cabozantinib, pazopanib, sorafenib, sunitinib, tivozanib and ipilimumab and nivolumab.
223889443|NCT06572358|OTHER|MetProUltima|"Test product Name: MetProUltima Marketed By\| Manufactured By: Meteoric Biopharmaceuticals Private Limited Mode of Usage: Take one capsule after each meal, twice daily. Frequency: Twice a Day Route of Administration: Oral"
223889444|NCT04937868|OTHER|There are no interventions associated with this study|This study is purely observational, there will be no interventions or changes in care related to patient inclusion in this study.
223889445|NCT05632614|DEVICE|High-intensity IMST|Participants will use the POWERbreathe KHP2 inspiratory muscle training device. All participants will be assigned to perform 30 inspiratory maneuvers (5 sets of 6, 1-minute rest between sets), 6 days per week, for 6 weeks. Participants will be trained at 55% PIMAX during week 1, 65% PIMAX during week 2, and 75% PIMAX during weeks 3 to 6.
223889446|NCT05632614|DEVICE|Low-intensity IMST|Participants will use the POWERbreathe KHP2 inspiratory muscle training device. All participants will be assigned to perform 30 inspiratory maneuvers (5 sets of 6, 1-minute rest between sets), 6 days per week, for 6 weeks. Participants will be trained at 15% PIMAX for 6 weeks.
223889447|NCT05443165|BEHAVIORAL|The effectiveness of the online decision support system developed for symptom self-management|"The online decision support system will appear with mild, moderate, or high severity according to symptom severity. If the patient's symptom is of mild category severity, a green area will appear on the screen and patients will see information on self-management strategies in this area. If patient's symptom is of moderate category severity, a yellow area will appear on the screen and patients will see information on self-management strategies and symptom monitoring at home in this area. In moderate symptom severity, when a yellow area occurs, patients should be asked, Is your fever above 38℃? according to their needs. Information about the treatment steps to be followed will be given. If the patient's symptom is in a severe category, a red area will appear on the screen and the patients will be warned to apply to the healthcare institution within this area."
223889448|NCT05443165|BEHAVIORAL|Symptom self-management with an education booklet|Symptom frequency and severity level of NHL patients will be evaluated with an online web-based application. NHL patients, who will be treated with the symptom self-management with education booklet. Participants will be asked to evaluate the frequency and severity of symptoms through the online symptom evaluation system on the 3rd, 7th, and 10th days of the 3rd, 4th, and 5th chemotherapy courses for three months. They will be able to do symptom self-management within the scope of the patient education booklet sent to them via SMS.
223889449|NCT05683041|DEVICE|Hyalobarrier|Hyalobarrier is a viscous, transparent gel and is used as a preventive measure for post-operative adhesions in the abdominal and uterine cavity.
223889450|NCT05595486|OTHER|Baby2Home Mobile Application|Baby2Home is a digital health intervention designed to bridge the resultant gaps in obstetrics and pediatrics healthcare services for new families over the first year of life.
223889451|NCT05640089|OTHER|fMRI-based neurofeedback|Participants use fMRI-based neurofeedback to train the upregulation of brain areas that respond to positive affective pictures (as identified during a functional localiser scan).
223889452|NCT06454539|OTHER|Functional Inspiratory Muscle Training|Functional IMT is an inspiratory muscle training that ensures core stabilization and maintains postural control. Rhythmic co-contractions of the core muscle areas (diaphragm, transversus abdominis, multifidus, pelvic floor) ensure the stability of the trunk and provide it with the feature of being the support point of movement. In the first stage, the person is given core stabilization training. Secondly, core stabilization is maintained and continued with strong trunk activation exercises. Postural exercises reinforce the other function of the breathing muscles, which is actually 'core' stabilization.
223889453|NCT06454539|OTHER|Inspiratory Muscle Training|Inspiratory muscle training (IMT) is one of the methods used to increase respiratory muscle strength. Different tools and methods (threshold resistive loading, normocapnic hyperpnea, and threshold pressure loading) have been developed for IMI. The most used method in the literature is the threshold pressure loading method. This method requires subjects to generate a negative pressure sufficient to overcome the load of the device and thus initiate inspiration. ICE is most commonly performed in a sitting position, with upper extremities supported and upper chest/shoulders relaxed. By placing the person in this position, the aim is for the respiratory muscles to focus only on the work of breathing.
223889454|NCT06532825|DIAGNOSTIC_TEST|heart monitoring|individual comparison of heart rate variability at admission with a repeated measurement before discharge
223889455|NCT06529185|DEVICE|The BREATHER|The BREATHER is Light/Medium resistance inspiratory muscle trainer which has significance role in increasing inspiratory muscle strength and endurance which could result in a decreased sensation of dyspnea
223889456|NCT06529185|DRUG|pharmacological treatment|patient will receive the usually pharmacological treatment.
223889457|NCT05875961|BIOLOGICAL|Low dose A/H2N3c + standard dose MF59|Two intramuscular injections (3 weeks apart) of cell culture-derived MF59 adjuvanted H2N3 vaccine
223889458|NCT05875961|BIOLOGICAL|Intermediate dose A/H2N3c + standard dose MF59|Two intramuscular injections (3 weeks apart) of cell culture-derived MF59 adjuvanted H2N3 vaccine
223889459|NCT05875961|BIOLOGICAL|High dose A/H2N3c + standard dose MF59|Two intramuscular injections (3 weeks apart) of cell culture-derived MF59 adjuvanted H2N3 vaccine
223889460|NCT05875961|BIOLOGICAL|High dose A/H2N3c non-adjuvanted|Two intramuscular injections (3 weeks apart) of cell culture-derived non-adjuvanted H2N3 vaccine
223889461|NCT05875961|BIOLOGICAL|Lowest dose A/H2N3c + high dose MF59|Two intramuscular injections (3 weeks apart) of cell culture-derived MF59 adjuvanted H2N3 vaccine
223889462|NCT05875961|BIOLOGICAL|Low dose A/H2N3c + high dose MF59|Two intramuscular injections (3 weeks apart) of cell culture-derived MF59 adjuvanted H2N3 vaccine
223889463|NCT04341779|COMBINATION_PRODUCT|Point-of-care viral load testing and tenofovir adherence testing|Point-of-care testing of HIV viral load and tenofovir, and providing same day results to participants
223889464|NCT04869683|OTHER|description of MDS pzatient cohort|description of MDS patient cohort
223889465|NCT05719220|BEHAVIORAL|Group preoperative pelvic floor training|Patients will receive PFT from a trained physical therapist delivered in a group setting of 8-10 people. The investigators allow patients in the PFT group to attend group classes as many times as they want prior to surgery to see if the frequency of training has an effect on outcomes. The treatment group could be required to go to at least 1 group class 4 weeks prior to their procedure, but they could be welcome to attend more if they want further practice and review of the material. A 45-minute group class with basic PFT guidelines could be presented weekly during the study.
223889466|NCT05773573|DEVICE|Experimental group|The experimental group will have a hyrax rapid maxillary expander anchored on the 2nd deciduous molars (V)
223889467|NCT05773573|DEVICE|Control group|The control group will have a hyrax rapid maxillary expander anchored on the 1st permanent molars (6)
223889468|NCT04847635|DEVICE|Pascal Synthesis 577 sub-threshold laser (Topcon Corporation, Tokyo, Japan)|The subthreshold laser treatment will be performed using subthreshold laser Pascal Synthesis 577 on a customized macular area.
223889469|NCT04847635|DEVICE|Pascal Synthesis 577 sham (Topcon Corporation, Tokyo, Japan)|The laser treatment will be performed without any power (only the light beam) using subthreshold laser Pascal Synthesis 577 on a customized macular area.
223889470|NCT05671562|DIETARY_SUPPLEMENT|Lycopene|Capsule containing lycopene 7mg x 2 daily for 12 weeks
223889471|NCT05671562|DIETARY_SUPPLEMENT|Placebo|Capsule containing inactive substance 7mg x 2 daily for 12 weeks
223889472|NCT05855941|DIAGNOSTIC_TEST|FDG-PET/CT and FDG-PET/MRI|Intravenous injection of FDG 3 MBq/kg. Intravenous injection of Dotarem 279.3 mg/ml, 0.2 ml/kg.
223889473|NCT05850247|DRUG|[18F]DPA-714 PET/MRI|"To assess the association between plasma ficolin-2 levels and plaque and brain inflammation assessed by \[18F\]DPA-714 PET/MRI in patients managed for transient ischaemic attack or ischaemic stroke related to carotid stenosis.~PET/MRI of the brain and carotid plaque with \[18F\]DPA-714 and gadolinium infusion will be performed at day 5."
223889474|NCT05759195|DIAGNOSTIC_TEST|Biomolecular tumor analysis|NGS analysis, other molecular analyses on FFPE tumor tissue
223889475|NCT06506604|BEHAVIORAL|CLEVER|"CLEVER: A positive body image-based intervention for Chronic Low Back Pain.~Patients will receive 4 sessions to approach 5 clinical modules: Pain Psychoeducation, Body Awareness, Pain Acceptance, Body Appreciation and Functionality and Gratitude. virtual reality environments will be used to enhance the clinical outcomes in two sessions. Each session will last 60 minutes."
224080378|NCT06193473|BEHAVIORAL|Intervention Group: Group to which the clinical pharmacist makes recommendations|The drugs administered to patients within 24-48 hours after hospitalization were recorded. A detailed medication review will be conducted by the clinical pharmacist during the participants' hospitalization.As a result of a comprehensive evaluation, recommendations were made to doctors regarding drug-related problems and were recorded.
224080379|NCT06305741|OTHER|Managing Anxiety from Cancer (MAC)|"The intervention, MAC, is a seven-session (45-60 minutes per session) psychotherapy intervention delivered via videoconference.~and/or telephone by licensed social workers"
224080380|NCT02151513|DEVICE|Intrathecal Pump Placement|
224080381|NCT02953717|RADIATION|Gamma Knife radiosurgery|GKRS is performed with a Leksell Gamma Knife® Icon, Elekta Instruments, AB. Depending upon the volume, a dose of 18-25 Gy will be prescribed with 99-100% coverage of the target.
224080382|NCT02953717|RADIATION|Whole Brain Radiation Therapy|Patients in the WBRT group will receive 4 Gy x 5 fractions (total of 20 Gy) in one week, which is a commonly utilized treatment schedule according to Dutch guidelines.
223889476|NCT05238792|BIOLOGICAL|Tumor-associated antigen-specific T cell (TAA-T)|"Patients will receive an infusion of partially HLA-matched TAA-T any time \>1 week after completing most recent course of conventional (non-investigational) therapy for their disease. For the lymphodepletion cohort, patients will receive lymphodepletion (LD) chemotherapy \>2 weeks from most recent course of conventional therapy and will nadir and recover before beginning TAA-T therapy. Patients will be enrolled to one of the following TAA-T dose levels:~BSA \<1.20 BSA ≥1.20 Dose level 1 without LD (low dose) 2x107 cells 4x107 cells Dose level 2 (LD + Low dose) 2x107 cells 4x107 cells Dose level 3 (LD + High dose) 4x107 cells 8x107 cells"
223889477|NCT04671511|PROCEDURE|Targeted Axillary Dissection|Sentinel Node Biopsy (SNB; using Tc99 +/- Blue dye) + Radioactive Seed Localisation (RSL) of clipped node using I125 seed = Targeted Axillary Dissection (TAD)
223889478|NCT04671511|DIAGNOSTIC_TEST|Ultrasound of the axilla|Prospectively recorded preoperative ultrasound of the axilla. Number of suspicious nodes recorded. Biopsy and clipping of the positive node.
223889479|NCT06579001|DRUG|Nasal spray dexmedetomidine|Nasal spray dexmedetomidine or saline was used 100ug per patient acording to the group assignment
223889480|NCT06581068|DEVICE|AURA assisted ART treatment|The AURA device consists of five subsystems, which will operate in logical sequence to deliver comprehensive automation of the laboratory element of an ART cycle. The AURA treatment begins after ovarian stimulation, on the day of egg collection. A sperm sample is provided on the same day of egg collection. Sperm samples will be prepared by the C:SPERM subsystem. Follicular fluid obtained at egg collection will be processed by the C:EGG subsystem. 3 out of every 4 cumulus-oocyte complexes (COCs) recovered will be denuded by the C:EGG subsystem. These denuded eggs will be fertilized by the C:ICSI subsystem, incubated in the C:CULTURE subsystem and all resulting suitable embryos will be vitrified by the C:VIT subsystem. Thawed embryos may be used in conventional frozen embryo transfers.
223889481|NCT03226418|DRUG|Cytarabine|Given IV
223889482|NCT03226418|DRUG|Decitabine|Given IV
223889483|NCT03226418|DRUG|Idarubicin|Given IV
223889484|NCT03226418|OTHER|Laboratory Biomarker Analysis|Correlative studies
223889485|NCT03226418|DRUG|Liposome-encapsulated Daunorubicin-Cytarabine|Given IV
223889486|NCT03226418|OTHER|Quality-of-Life Assessment|Ancillary studies
223889487|NCT03226418|OTHER|Questionnaire Administration|Ancillary studies
223889488|NCT03226418|DRUG|Azacitidine|Given by infusion
223889489|NCT03226418|DRUG|Venetoclax|oral tablet
223889490|NCT03226418|DRUG|glasdegib|oral tablet
223889491|NCT05932069|BEHAVIORAL|SPIN|Stationary cycling
223889492|NCT05932069|BEHAVIORAL|Non-aerobic, stretching/balance intervention Control|Balance and stretching exercise
223889493|NCT06201728|OTHER|Follow-up in a flare-up clinic|Follow-up in the clinic based on the time frame specified above. Additional interventions during the clinic visit, other than specified above, includes: An overview by a pulmonologist of new exacerbations, systemic steroid use, or other hospitalizations, active medications and compliance to treatment, inhaler using technique, possible medication side-effects, and the asthma control test (ACT) score. The physician will provide information on smoking cessation when relevant and pulmonary rehabilitation. In addition, decision on change of treatment and further evaluations outside of the clinic, including initiation of biologic treatment.
223889494|NCT05596162|OTHER|Blood Flow Restriction Therapy|Exercise with Blood Flow Restriction
223889495|NCT05596162|OTHER|Standard Physical Therapy|Exercise without Blood Flow Restriction
223889496|NCT04297280|DRUG|Sintilimab|a PD-1 immune check inhibitor
223889497|NCT04297280|COMBINATION_PRODUCT|TACE|TACE is performed by using drug eluting beads, or using embolic agent combined with Lipiodol-pirarubicin emulsion per Investigator decision
223889498|NCT06148519|DIAGNOSTIC_TEST|2WIN-S portable refractor|All participants will be tested by 2WIN-S portable refractor without eye dilatation. If the 2WIN-S reports non-referral, participant will be tested visual acuity by optometrist. If the 2WIN-S reports referral, participant will be tested cycloplegic refraction by pediatric ophthalmologist, then tested by 2WIN-S again. The participant whose result is abnormal will be referred to the hospital for further management.
223889499|NCT06316843|DRUG|Valacyclovir celecoxib dose 1|1500 mg valacyclovir 200 mg celecoxib taken two times a day
223889500|NCT06316843|DRUG|Valacyclovir celecoxib dose 2|750 mg valacyclovir 200 celecoxib mg taken two times a day
223889501|NCT06316843|DRUG|Placebo|Placebo capsules colored matched to investigational product taken two times a day
223889502|NCT06044987|PROCEDURE|Trans Obturator Tape Procedure (TOT)|Done under Spinal anesthesia in the dorsal lithotomy position.
223889503|NCT06044987|PROCEDURE|Cystocele Repair|Done under Spinal anesthesia in the dorsal lithotomy position..
223889504|NCT05978284|BIOLOGICAL|ZG006|ZG006 will be administered as an intravenous (IV) infusion.
223889505|NCT06554587|DIAGNOSTIC_TEST|Laboratory Biomarker Analysis: Enzyme-linked immunosorbent assay (ELISA)|Measurement of the plasma concentration of ST6GAL1, GCNT1 and GALNT7 biomarkers in patients suspected of having prostate cancer or on active surveillance
223889506|NCT06237348|DEVICE|Simeox|Daily airway clearance therapy at home during 2 months
223889507|NCT06237348|COMBINATION_PRODUCT|Control|Daily airway clearance therapy at home during 2 months
223889508|NCT05195775|DRUG|Tadalafil|Patient will be randomized to one dose of 0.6 mg/kg tadalafill on one of two study visits. On both visits, assessments (MRI, exercise testing, clinical function) will be performed 3 hours after time of dosing.
223889509|NCT05195775|DRUG|Tadalafil|Patient will be randomized to one dose of 0.6 mg/kg tadalafill on one of two study visits. On both visits, assessments (Doppler US, exercise testing, clinical function) will be performed 3 hours after time of dosing.
223889510|NCT05631262|DRUG|SKB264|Subjects of Cohot 1-5 and Part II Test group will receive SKB264 monotherapy
223889511|NCT05631262|DRUG|Docetaxel|Part II Control group will receive docetaxel monotherapy.
223889512|NCT05445960|PROCEDURE|Tourniquet|This arm will have a tourniquet placed about the thigh and inflated to 250mmHg for the duration of ankle fracture surgery or 2 hours, whichever is shorter.
223889513|NCT06304831|BEHAVIORAL|Quality ratings of health care providers for children|Ratings of overall and components of quality (provider knowledge, respectfulness of provider, respectfulness of staff, cleanliness, cost) of health care providers for children will be provided on a webpage. The webpage will be updated every week and participants will be invited to access the latest ratings biweekly.
223889514|NCT05991414|DEVICE|Home blood pressure monitor|Participants provided home blood pressure monitor and instructions on use from pharmacist. They will measure home BP every 4-weeks for 7 days as per Hypertension Canada 7-day home BP protocol.
223889515|NCT05991414|PROCEDURE|Enhanced community pharmacist care|Pharmacist to follow up with participants every month to review home BP readings. Then the pharmacist will send home BP readings and recommendations for changes to antihypertensive medication regimen to participants prescribing clinician. Pharmacist will then advise participants to follow up with their prescribing clinician.
223889516|NCT05991414|PROCEDURE|Usual pharmacist care|Participants will come into the pharmacist at baseline, 12- and 24-weeks to have their BP taken by the pharmacist. Pharmacist will provide education and counseling. Pharmacist will send BP readings to participants prescribing clinician with no recommendations for changes to antihypertensive therapy. After 6-months participants will be offered a home BP monitor and instructions on use.
223889517|NCT04230499|DRUG|Encapsulated Rapamycin (eRapa)|eRapa is encapsulated rapamycin. The rapamycin is encapsulated in order to deliver the rapamycin at a consistent and lower dosage. eRapa is a capsule, and is administered orally.
223889518|NCT05708612|PROCEDURE|Medical Device (SimplyFI)|Implantation a non-active medical device (SimplyFI) for the treatment of chronic fecal incontinence.
223889519|NCT06490796|BEHAVIORAL|Expanded diaphragm exercise|Individuals will be instructed in 360-degree expansive diaphragm exercises using the Ohmbelt device (Nilus Medical LLC, OHMBELT, Redwood City, CA, USA). Two Ohmbelt devices will be used in this study. The placement of the devices will be as described in the literature (14,23,24): The patient will be in a seated position with hips and knees flexed at 90 degrees, both feet supported on the ground, and sitting upright on a chair without back support. In this position, the Ohmbelt devices will be secured to the patient's body. Following respiratory exercises, they will be individually enrolled in the evidence-based consensus program for three-dimensional functional exercises recommended for AS patients (26,27). The exercise protocol, which includes warm-up, mobility, stretching, flexibility, and cool-down periods, will last for 20 minutes
223889520|NCT06490796|BEHAVIORAL|Standard diaphragm exercise|Individuals in this group will be instructed in standard diaphragm exercises. They will be asked to lie on their backs with their heads and knees supported by pillows, and to close their eyes to focus before starting. Following respiratory exercises, they will be individually enrolled in the evidence-based consensus program for three-dimensional functional exercises recommended for AS patients (26,27). The exercise protocol, which includes warm-up, mobility, stretching, flexibility, and cool-down periods, will last for 20 minutes.
223889521|NCT05768295|DEVICE|Axiom BL X3|collecting data on the use of Axiom BL X3 and patient satisfaction
223889522|NCT05600348|DIETARY_SUPPLEMENT|Pork Consumption|Feeding of pork is controlled at 0, 3 or 6 oz per day for 4 weeks each in random order.
223889523|NCT02663193|OTHER|No Intervention|Participants who are receiving enzalutamide or abiraterone acetate in combination with prednisone in a clinical practice setting will be observed for tolerability and quality of life.
223889524|NCT06089577|DRUG|Cangrelor 50 MG|Cangrelor will be administered during PCI
223889525|NCT06075758|OTHER|ribociclib|"There is no treatment allocation for NIS trials, patients on administered ribociclib by prescription will be enrolled.~Treatment plan represents the prescription."
223889526|NCT06216548|OTHER|Usual Care and Enhanced Primary Care|"Usual Care: Interdisciplinary complex care teams help coordinate appointments, facilitate communication between the many specialist providers involved in the child's care, support families, assist with practical needs, and are available as a resource (as consultants) for Primary Care Physicians (PCPs) to care for Children with Medical Complexity (CMC). The complex care teams in tertiary care children's hospital is the focus for providing comprehensive care for CMC.~Enhanced Primary Care: The E-PRIME team will support the CMC and their caregivers with navigating the patient access portal and how to use the video visit platform for the telehealth visits. The physician or nurse of the E-PRIME team will create clinical summaries about CMC's visit to specialists and hospital and share this health information about CMC with his/her PCP to help the PCP provide care for CMC at home. A team of telehealth experts will help PCPs in using telehealth in their practice."
223889527|NCT06216548|OTHER|Enhanced Primary Care|The intervention has the following components: (A) The staff of the E-PRIME team will support the CMC and their caregivers with navigating the patient access portal and how to use the video visit platform for the telehealth visits. (B) The physician or nurse of the E-PRIME team will create clinical summaries about CMC's visit to specialists and hospital and share this health information about CMC with his/her PCP to help the PCP provide care for CMC at home. (C) A team of telehealth experts will help PCPs in using telehealth in their practice.
223889528|NCT02116335|DRUG|Bosentan|Stress response and vascular function will be assessed 3 days following 125 mg twice per day of Bosentan
223889529|NCT02116335|DRUG|Placebo|Stress response and vascular function will be assessed 3 days following twice per day placebo
223889530|NCT06257810|DIAGNOSTIC_TEST|VIDAS® Dengue Antigen NS1, VIDAS® Anti-Dengue IgM, VIDAS® Anti-Dengue IgG, VIDAS® Anti-Chikungunya IgM and VIDAS® Anti-Chikungunya IgG|"For patients managed in an intervention site, a diagnostic test for dengue and chikungunya using VIDAS® as well as a screening test for malaria will be carried out. An awareness campaign on the use of VIDAS® diagnostic tests will be implemented as well.~The diagnosis will be based on the patient's clinical symptoms, the biological results of the VIDAS® tests for dengue and chikungunya, as well as the results of the tests for malaria."
223889531|NCT06257810|OTHER|Standard of care practices|"For patients managed in a control site, the standard of care practices will be applied in the case of a febrile condition of undetermined etiology. This includes clinical diagnosis and, where appropriate, the use of routinely available diagnostic tests. At the end of the study, the collected samples will be tested using VIDAS® differential diagnosis tests to estimate the number of cases of dengue and chikungunya that have not been correctly diagnosed."
223889532|NCT06467487|OTHER|Traditional Letter|Patients receive a traditional letter.
223889533|NCT06467487|OTHER|Direct to Patient Message|Patients receive a direct to patient message via the portal.
223889534|NCT06467487|OTHER|Optimized Letter|Patients receive an optimized letter.
223889535|NCT06467487|OTHER|Direct to Patient Message - Optimized|Patients receive an optimized direct to patient message via the portal.
223889536|NCT06473233|DEVICE|TEG6S|Hemostatic management including one or more delocalized biology test with the TEG6S®, at the discretion of the responsible clinician
223889537|NCT05331170|BIOLOGICAL|Research Grade RG-RV|Exploration of the effects of RV inoculation on human airway mucosal programming in vivo
223889538|NCT04536090|DRUG|Isoquercetin (IQC-950AN)|Isoquercetin will be administered by mouth twice daily for 28 days
223889539|NCT06165601|PROCEDURE|Follow-up at D14|A blood test and urinary test will be performed at D14.
223889540|NCT06165601|PROCEDURE|Follow-up at M1|A blood test and urinary test will be performed at M1.
223889541|NCT05935917|DRUG|Brincidofovir|100 mg tablet of Form H and 100 mg tablet of Form II
223889542|NCT06326827|DEVICE|In'Oss™ (MBCP® Putty)|Use of In'Oss™ (MBCP® Putty) in surgical procedure to correct epiphyso-metaphyseal and/or metaphyso-diaphyseal bone defect in one of the following anatomical locations: Proximal humerus, Distal radius, Distal femur, Proximal tibia, Distal tibia.
223889543|NCT05644483|DRUG|Remimazolam|Remimazolam: loading (6mg/kg/hr) + continuous infusion (1-2mg/kg/hr)
223889544|NCT05644483|DRUG|Propofol|Propofol: target controlled infusion: 2-3mcg/mL
223889545|NCT04010344|BEHAVIORAL|Enhanced Usual Care Group|"Medtronic® Labs' Akoma pa app, a culturally-tested and locally attuned mobile health platform, will be used in the intervention arm of the study to improve communication between the Community Health Officer (CHO) and the participant. This platform will be used to enhance shared decision making, clinical decision support, participatory communication, knowledge, treatment adherence (medication and lifestyle modification), and self-monitoring of hypertension. We will test the feasibility of the Akoma pa app in addressing patient-level and provider-level barriers to hypertension control.~The app will consist of the following components:~1. Reminders~2. Participant to CHO messaging~3. Home BP tracking~4. Educational materials on cardiovascular disease (CVD) and Stroke- Participants will have access to education modules on reducing the risk of CVD and stroke tailored to their knowledge level.~5. CHO provider portal- The provider portal will include decision support tools."
223889546|NCT04010344|OTHER|Usual Care Group|Regular/usual appointments or visits to patients' healthcare provider for management of study outcomes
223889547|NCT05259787|DRUG|Sedation Etomidate combined with propofol|Drug IV within 10 second during anesthesia induction.
223889548|NCT05259787|DRUG|Sedation Propofol|Drug IV within 10 second during anesthesia induction.
223889549|NCT05464758|OTHER|Repeated cold exposure|8 consecutive days of exposure to 8°C air for 120 minutes each day
223889550|NCT06458049|BEHAVIORAL|Group Session|On-line educational session-3 modules-1 hour each for a total of 3 hours
223889551|NCT06458049|BEHAVIORAL|Coaching Call|Single Coaching phone call at one month
223889552|NCT06458049|BEHAVIORAL|Educational Materials|Individual videoconference session in which participants will receive a pdf of the American Cancer Society booklet, 'Sex and the Adult Female with Cancer
223889553|NCT04428944|PROCEDURE|Wide Circumferential Pulmonary Vein Antrum Isolation (PVAI)|Standard PVI
223889554|NCT04428944|PROCEDURE|Pulmonary Vein Antrum Isolation Plus Driver Ablation (PVAI+drivers)|Standard PVI + Ablation of drivers in LA and RA
223889555|NCT04428944|PROCEDURE|Pulmonary Vein Antrum Isolation Plus Box Isolation of Posterior Wall (PVAI+box)|Standard PVI + Electrical isolation of the posterior wall of the left atrium
223889556|NCT04024813|DRUG|Seladelpar|Capsule(s) administered orally once daily
223889557|NCT04024813|DRUG|Placebo to match Seladelpar|Capsule(s) administered orally once daily
223889558|NCT06483477|OTHER|Standard skin care|From the start of radiotherapy, standard skin care has to be performed by the patient. This may vary at the participating centers. At the site in Lübeck, it includes fatty cream with 2-10% urea (fatty cream alone, if patients do not tolerate urea) and, in case of pruritus, addition of mometasone furoate cream. In case of grade ≥2 moist desquamation or grade ≥3 radiation dermatitis, each day antiseptic agents will be administered for wound cleansing followed by administration of silicon or calcium alginate bandage. This treatment will be continued until moist desquamation radiation disappears and radiation dermatitis improves to grade 2. Fatty cream with 2-10% urea is applied to the irradiated skin four times daily. Mometasone furoate cream: In addition to the fatty cream with 2-10% urea, mometasone furoate cream (solution 0.1%) is applied to the irradiated skin once daily.
223889559|NCT06483477|DEVICE|Reminder App|In addition to standard skin care, patients are supported by a Reminder App. The purpose of the app is to remind the patients in an intuitive, unobtrusive and supportive way to perform skin care. By default, patients are reminded four times a day, but they will also be able to define a notification schedule that best suits their personal needs. The patients may postpone each required care procedure for up to 2 hours. With each procedure, the patients are guided through the skin care with simple and self-explanatory illustrations. To increase the patients' motivation, they will additionally earn points for regular and punctual performed care procedures. The patients receive a hand-out including instructions how to properly perform skin care, but they can also find an information page within the application that includes similar instructions.
223889560|NCT05329883|PROCEDURE|Double-J stent removal|Outpatient ureteral stent removal without antibiotic prophylaxis
223889561|NCT05168605|OTHER|Home visit|Patients receiving home Visits
223889562|NCT04487847|DIAGNOSTIC_TEST|18F-PSMA-1007 PET/CT|18F-PSMA-1007 PET/CT
223889563|NCT04990284|DRUG|Opicapone|50 mg hard capsules. Oral administration, once-daily at bedtime, at least 1 hour before or after L-DOPA/carbidopa or benserazide (L-DOPA/DDCI).
223889564|NCT04990284|DRUG|L-DOPA/DDCI|L-DOPA/carbidopa or benserazide (L-DOPA/DDCI), 100/25 mg, oral administration
223889565|NCT05448170|DRUG|Linerixibat|open label investigational product
223889566|NCT05993845|OTHER|Recording of total hip arthroplasty|"We record total hip arthroplasties (THA) of hip surgeons at Balgrist University Hospital (BUH), Kantonsspital Baden (KSB), Kantonsspital Winterthur (KSW). Video \& audio data are stored locally at Balgrist-managed servers (patient-sensitive information removed).~Data includes:~Demographics (year of birth, sex, smoking status, body mass index) Diagnosis Surgery-specific data \& other surgical procedures during recording Standard preoperative Computed tomography of the hip/pelvis Standard pelvis x-rays pre- \& postoperative Standard axial hip x-rays pre- \& postoperative Western Ontario \& McMaster Universities Osteoarthritis Index \& Harris-Hip-Score To ensure the generated Surgical process model(SPM), evaluated using the recordings obtained from surgeries performed at BUH, generally describes the surgical process of THA, we apply our model to surgeries from the KSB and the KSW. There, 3 THAs are recorded and analyzed regarding commonalities and discrepancies in the SPM."
223889567|NCT05987033|DRUG|NVDX3|NVDX3 is implanted during a single surgical intervention.
223889568|NCT06190093|BIOLOGICAL|bevacizumab|1.25 mg, intravitreal injection
223889569|NCT06190093|BIOLOGICAL|ranibizumab|0.5mg, intravitreal injection
223889570|NCT06258291|DEVICE|Hemosystem REBOOT|The HemoSystem REBOOT will selectively remove three mediators largely contributing to sepsis-induced immunosuppression, from extracorporeal circulation based on magnetic beads.
223889571|NCT05747222|OTHER|Action Observation Tharapy|Using a 13-inch tablet, the patient will be shown, from a third-person lateral perspective framing the palmar side of the hand, a video that repeatedly plays a simple movement of daily life (grasping a glass on the table with the hand and bringing it closer to oneself) for 5 consecutive minutes. The video should be customized based on the side being treated (ex: right hemiparesis, video framing a right hand). After 1 minute of rest, the therapist will ask the patient to perform the newly observed movement for a minimum duration of 2 minutes and a maximum of 5 minutes. The cycle will be repeated a total of 3 times, for total treatment time between 25 and 35 minutes per session.
223889572|NCT05747222|OTHER|Conventional Therapy|Conventional treatment will focus on joint mobilization, muscle stretching, and neuromuscular facilitation activities, using the main rehabilitation methods (e.g., neurocognitive theory, Bobath Concept, Progressive Neuromuscular Facilitation, etc.).
223889573|NCT05204589|BIOLOGICAL|Aerosolized Ad5-nCoV|Aerosolized Ad5-nCoV is produced by CanSino Biologics Inc. It is a liquid dosage form, 0.1 ml / dose, contains 1×10\^10 virus particles of recombinant replication defective human type 5 adenovirus expressing SARS-CoV-2 S protein, aerosol inhalation.
223889574|NCT05204589|BIOLOGICAL|Inactivated SARS-CoV-2 vaccine|Inactivated SARS-CoV-2 vaccine is homologous to the priming series which have been administered to the subjects, produced by SinoVac Biotech Co,. Ltd, Beijing Institute of Biological Products Co,. Ltd, Wuhan Institute of Biological Products Co,. Ltd, or Biokangtai.
223889575|NCT02729311|BEHAVIORAL|Paired PLIÉ Program|The Paired PLIÉ Program is a novel, multimodal, movement program that focuses on abilities that are well maintained in people with dementia, including training procedural ('muscle') memory for basic daily movements, in-the-moment mindful body awareness, and social engagement. Group classes are held with affected individuals, care partners and instructors together. A monthly home visit also is provided.
223889576|NCT02729311|BEHAVIORAL|Waitlist control|After engaging in usual activities for 12 weeks, the Waitlist control group participates in the Paired PLIÉ program.
223889577|NCT05008783|DRUG|AK104|AK104 (administered on Day 1 of each cycle, Q3W)+Oxaliplatin (130 mg/m2 intravenous infusion for 2-6 hours on Day 1, Q3W,up to 6 cycles)+ Capecitabine(1000 mg/m2, p.o., Bid, Q3W,up to 6 cycles) . Afterward, AK104 will be used for maintenance treatment (administered on Day 1 of each cycle, Q3W)
223889578|NCT05008783|DRUG|Placebo|Placebo (administered on Day 1 of each cycle, Q3W)+Oxaliplatin (130 mg/m2 intravenous infusion for 2-6 hours on Day 1, Q3W,up to 6 cycles)+ Capecitabine(1000 mg/m2, p.o., Bid, Q3W,up to 6 cycles) . Afterward,Placebo will be used for maintenance treatment (administered on Day 1 of each cycle, Q3W)
223889579|NCT05515614|DIETARY_SUPPLEMENT|Targeted Fortification|Mother's breast milk will be fortified in modular fashion based on the level of macronutrients (protein, carbohydrate, and fat) found from analysis using the Miris Human Milk Analyser. For protein supplementation, Amino Acid powder will be utilized as a modular component. For carbohydrate supplementation, PolyCal will be utilized. Mother's breast milk will be fortified in modular fashion. For protein supplementation, Amino Acid powder will be utilized as a modular component. For carbohydrate supplementation, PolyCal will be utilized. For lipid supplementation, safflower oil will be utilized. We will set our goal energy level between 110 - 135 kcal/kg/day, protein level between 3.5 - 4.5 g/kg/day, lipid level between 4.8 - 6.6 g/kg/day, and carbohydrate level between 11.6 - 13.2 g/kg/day. We will regard daily fluid volume to be between 150 to 180 mL/kg/day.
223889580|NCT05515614|DIETARY_SUPPLEMENT|Enfamil Liquid Human Milk Fortifier|Mother's breast milk will be fortified using Enfamil Liquid Human Milk Fortifier as per standard feeding protocol defined by LLUCH NICU manual.
223889581|NCT06088355|BEHAVIORAL|HV-PDAE: High Volume Partnered Dance Aerobic Exercise|HV-PDAE classes will meet 5 times a week for 90 minute sessions for 3 weeks at onset of trial and then every 4 weeks for a year. All participants will receive 112.5h of training. PDAE was adapted for older adults with balance impairments; modifications were made to the frame and steps of Argentine tango. People with PD partner an individual without PD, e.g., staff, caregiver, friend, or university student. The instructor, staff lead and assistants monitor participants for safety. Class sizes will consist of 6 or fewer pairs of participants with PD and partners. Participants with PD will dance with new partners (individuals without PD) every 15-20 minutes. Participants will learn new steps in each class. The class format includes practicing steps, warm-up, partnering and rhythmic exercises, learning new steps, combining old and new steps, cool down. PDAE classes follow a syllabus with new steps, rhythms and embellishments included in each class.
223889582|NCT06088355|BEHAVIORAL|MV-PDAE: Moderate Volume Partnered Dance Aerobic Exercise|MV-PDAE: MV classes will meet biweekly for 52 weeks for 65-minute sessions. All participants will receive 112.5h of training. . PDAE was adapted for older adults with balance impairments; modifications were made to the frame and steps of Argentine tango. People with PD partner an individual without PD, e.g., staff, caregiver, friend, or university student. The instructor, staff lead and assistants monitor participants for safety. Class sizes will consist of 6 or fewer pairs of participants with PD and partners. Participants with PD will dance with new partners (individuals without PD) every 15-20 minutes. Participants will learn new steps in each class. The class format includes practicing steps, warm-up, partnering and rhythmic exercises, learning new steps, combining old and new steps, cool down. PDAE classes follow a syllabus with new steps, rhythms and embellishments included in each class.
223889583|NCT06088355|BEHAVIORAL|MV-WALK: Moderate Volume Walking|MV-WALK (65-minute sessions): WALK will control for the walking that participants in PDAE do and will also take place in groups to control social effects of intervention. Walking for
223889584|NCT04166331|DRUG|Placebos|Placebo will initially be started at a dose of 2.5 µg/kg/min and subsequently titrated using incremental steps (predefined durations) of 2.5 µg/kg/min, up to a maximal dose of 10 µg/kg/min. Dose adaptation will be left at the discretion of attending physician.
223889585|NCT04166331|DRUG|Dobutamine|Dobutamine will initially be started at a dose of 2.5 µg/kg/min and subsequently titrated using incremental steps (predefined durations) of 2.5 µg/kg/min, up to a maximal dose of 10 µg/kg/min. Dose adaptation will be left at the discretion of attending physician.
223889586|NCT03842592|DIAGNOSTIC_TEST|Treadmill Stress test|Ventricular arrhythmia will be assessed by ECG Holter and during treadmill stress test, both being performed 3 months and 1 year after acute myocarditis
223889587|NCT05034952|DRUG|VX-548|Tablets for oral administration.
223889588|NCT05034952|DRUG|HB/APAP|Capsules for oral administration.
223889589|NCT05034952|DRUG|Placebo (matched to VX-548)|Placebo matched to VX-548 for oral administration.
223889590|NCT05034952|DRUG|Placebo (matched to HB/APAP)|Placebo matched to HB/APAP for oral administration.
223889591|NCT06470100|DRUG|0.9% Sodium Chloride Injection|unilateral administration of 20ml of 0,2% ropivacaine + 2ml 0.9% sodium chloride for the erector spine plane block
223889592|NCT06470100|DRUG|Dexamethasone|unilateral administration of 20ml of 0,2% ropivacaine with 4mg Dexamethasone for the erector spine plane block
223889593|NCT06470100|DRUG|Dexmedetomidine|unilateral administration of 20ml of 0,2% ropivacaine with 50ug Dexmedetomidine for the erector spine plane block
223889594|NCT03514329|DEVICE|Bronchoscopic Thermal Vapor Ablation|Vapor (steam) is infused into the targeted region for 8 seconds at a precisely controlled flow rate and power.
223889595|NCT04238949|OTHER|Community Health Worker added to diabetes team|A Community Health Worker will be added to the diabetes team caring for a child with new onset type 1 diabetes for 1 year. The intervention includes social determinants of health screening and goal setting, with home visits.
223889596|NCT06510322|DRUG|Sildenafil|Orally administered phosphodiesterase-5 (PDE-5) inhibitor, which enhances nitric oxide signaling in platelets and blood vessels.
223889597|NCT06510322|OTHER|Placebo|Matched capsule not containing any medication
223889598|NCT04856176|DRUG|Granulocyte-Macrophage Colony-Stimulating Factor|250 mcg
223889599|NCT04856176|DRUG|Pembrolizumab|200mg every 3 weeks
223889600|NCT04856176|DRUG|pemetrexed|500mg/m2
223889601|NCT04856176|DRUG|Paclitaxel|200mg/m2
223889602|NCT04856176|DRUG|Carboplatin|AUC 5/6
223889603|NCT05228327|DEVICE|Occlusal splint treatment|Occlusal splint was made for 16 patients and they used just this occlusal splint for 3 months.
223889604|NCT05228327|PROCEDURE|Masticatory muscle injection|Lidocaine was injected on 16 patients' three trigger point in the masseter muscle. Injection was repeated 3 times, once a week.
223889605|NCT05228327|COMBINATION_PRODUCT|Combination of occlusal splint and masticatory muscle injection treatments|Lidocaine was injected on 16 patients' three trigger point in the masseter muscle. Occlusal splint was also made and they started to use the day which first injection was made. And continue to use the occlusal splint for 3 months. Injection was repeated 3 times, once a week.
223889606|NCT04259580|PROCEDURE|Endoscopic retrograde pancreatography (ERCP)|Endoscopic procedure to access biliary and/or pancreatic structures
223889607|NCT06024187|PROCEDURE|Cold dissection|The subcutaneous flap dissection was performed with a scissor in this group. The boundary of mastectomy flap was defined as the edge of clavicle superiorly, the edge of sternum medially, the edge of inframammary fold inferiorly, and the edge of the latissimus dorsi laterally. Our tumescent technique utilizes a solution made by mixing 0.2ml of epinephrine with 250 ml of 0.9% Sodium Chloride solution to create a 1‰ ratio. 150ml to 150ml of the solution was injected into the subcutaneous tissue of the operated breast with a 20-gauge spinal needle to establish a bloodless plane. The septa between the skin flap and parenchyma then was dissected using a scissor.
223889608|NCT06024187|PROCEDURE|Electrocautery Dissection|The subcutaneous flap dissection was performed with electrocautery in this group. The boundary of mastectomy flap was defined as the edge of clavicle superiorly, the edge of sternum medially, the edge of inframammary fold inferiorly, and the edge of the latissimus dorsi laterally.
223889609|NCT03042962|OTHER|MRI|Functional and structural MRI of the brain will be conducted to identify disorder specific neural markers
223889610|NCT03042962|PROCEDURE|Blood draw|Blood samples will be collected, the DNA will be extracted and banked for genetic studies
223889611|NCT04770233|PROCEDURE|Early ACL reconstruction|ACL reconstruction followed by rehabilitation
223889612|NCT04770233|PROCEDURE|Active rehabilitation|Non-operative treatment with active rehabilitation led by a physiotherapist with optional delayed surgery if indicated.
223889613|NCT06133829|BEHAVIORAL|upREACH Home Visitation Program|upREACH is a brief perinatal home visitation program delivered by community health workers or similarly qualified personnel. The mission statement of the program is: Families are prepared to bring home their newborn to a safe, stable, and nurturing environment, and have access to tools, resources, and knowledge that promote family health and well-being. Through the program, families will receive a minimum of 2 home visits during pregnancy and/or postpartum from a home visitor (community health worker (CHW) or similarly qualified personnel). The home visitor will assess each family's strengths and needs so they may provide tailored support and brief education to promote maternal health and self-care, infant health and safety, and connection to and knowledge of resources (community orientation).
223889614|NCT04950660|DRUG|Caffeine Tablet|Caffeine is approved by the FDA as a stimulant. A stimulant approved by the United States Food and Drug Administration (FDA) for the treatment to increase mental alertness and in combination with painkiller to treat migraine headaches. It is approved in the form of pill or tablet.
223889615|NCT04950660|DRUG|Placebo|Placebo, empty opaque dark blue blank capsule, taken twice daily. This will be an adjuvant to their standard pain control.
223889616|NCT04470726|DRUG|AIV001|Intradermal/intratumoral
223889617|NCT04470726|DRUG|AIV001 suspension|AIV001 is administered as a aqueous suspension by an intradermal/intratumoral injection
223889618|NCT02111798|DRUG|Placebo|Participants will be randomly assigned to receive placebo powder in twice-daily capsules at the end of week 2.
223889619|NCT02111798|DRUG|Bupropion XL|Participants will be randomly assigned to receive bupropion XL 150mg/day in twice-daily capsules at the end of week 2.
223889620|NCT02111798|BEHAVIORAL|Abstinence Initiation|Participants will provide urine samples thrice weekly during weeks 1-6 of the study. Urine samples will be tested immediately onsite for evidence of recent cocaine exposure. Participants who do not provide 3 urine samples that test negative for cocaine by the end of week 6 will be assigned to an Abstinence Incentive condition.
223889621|NCT02111798|BEHAVIORAL|Relapse Prevention|Participants will provide urine samples thrice weekly during weeks 1-6 of the study. Urine samples will be tested immediately onsite for evidence of recent cocaine exposure. Participants who provide 3 urine samples that test negative for cocaine will be promptly assigned to a Relapse Prevention incentive condition.
223889622|NCT05459207|OTHER|Moderate Fat Meal|A liquid meal consisting of powdered protein and complex carbohydrates blended with coconut oil and peanut butter in ratios required to achieve the desired calorie and macronutrient distributions of a normal/moderate fat meal.
223889623|NCT05459207|OTHER|High Fat Meal|A liquid meal consisting of powdered protein and complex carbohydrates blended with coconut oil and peanut butter in ratios required to achieve the desired calorie and macronutrient distributions of a high-fat meal.
223889624|NCT03761537|DRUG|Tralokinumab|Tralokinumab is a human recombinant monoclonal antibody of the IgG4 subclass that specifically binds to human IL-13 and blocks interaction with the IL-13 receptors. It is presented as a liquid formulation for subcutaneous (SC) administration.
223889625|NCT03761537|OTHER|Placebo|Placebo contains the same excipients in the same concentration only lacking tralokinumab.
223889626|NCT06331403|BEHAVIORAL|Mind-Body Group Intervention|Weekly virtual group meetings with the study interventionist(s) and up to 9 other female cancer survivors over an approximately 6 week period. The group program includes topics related to coping with physical health changes, managing social factors relevant to sexual well-being, and managing thoughts and feelings related to sexual well-being changes.
223889627|NCT04786028|OTHER|Isatuximab|Brand name for interventional drug is Sarclisa
223889628|NCT04445168|BEHAVIORAL|Telephone-based motivational interviews|2-year telephone-based motivational interviews to increase physical activity.
223889629|NCT04107857|BEHAVIORAL|ELEVATE enhancement to electronic health record (EHR) to improve cessation counseling offer|"* Brief advise to quit smoking~* Referral to Missouri/Illinois Quitlines, Smokefree.TXT, or smokefree.gov"
223889630|NCT04107857|BEHAVIORAL|ELEVATE enhancement to electronic health record (EHR) to improve smoking cessation medication offer|-Nicotine replacement therapy, varenicline, bupropion, or combination therapy (not provided by study)
223889631|NCT04107857|BEHAVIORAL|Data Driven Feedback reports|-Feedback reports will be based on data
223889632|NCT06546462|OTHER|Osteopathic Manipulative Treatment (OMT)|The active arm will receive osteopathic manipulative treatment which is a hands-on treatment modality use to treat a variety of health concerns.
223889633|NCT06546462|OTHER|Sham Light touch arm|Sham arm will receive a light touch sham treatment.
223889634|NCT05891119|DIETARY_SUPPLEMENT|Caffeine|Oral liquid
223889635|NCT05891119|DRUG|Metoprolol|Oral tablet
223889636|NCT05891119|DRUG|Midazolam|Oral liquid
223889637|NCT05891119|DRUG|Warfarin|Oral tablet
223889638|NCT05891119|DIETARY_SUPPLEMENT|Vitamin K|Oral tablet
223889639|NCT05891119|DRUG|Omeprazole|Oral capsule
223889640|NCT05891119|DRUG|Rocatinlimab|Subcutaneous injection
223889641|NCT05226858|DIAGNOSTIC_TEST|Transesophageal echocardiography (TEE)|Sensitivity and specificity of TEE in identification of BTAI
223889642|NCT02437318|DRUG|Fulvestrant|500 mg of fulvestrant administered via intramuscular injection on Day 1 and Day 15 of Cycle 1, and then Day 1 of each subsequent 28-day cycle
223889643|NCT02437318|DRUG|Alpelisib|300 mg of alpelisib tablets for oral use administered once daily
223889644|NCT02437318|DRUG|Placebo|300 mg of placebo tablets for oral use administered once daily
223889645|NCT05608187|BIOLOGICAL|ILP100-Topical (emilimogene sigulactibac) 5x10^7 CFU/cm^2|Topical application of ILP100-Topical (emilimogene sigulactibac) at a dose of 5x10\^7 CFU/cm\^2 wound area.
223889646|NCT05608187|BIOLOGICAL|ILP100-Topical (emilimogene sigulactibac) 1x10^9 CFU/cm^2|Topical application of ILP100-Topical (emilimogene sigulactibac) at a dose of 1x10\^9 CFU/cm\^2 wound area.
223889647|NCT05608187|BIOLOGICAL|Placebo|Topical application of placebo (ILP100 dilution buffer mixed with the activation peptide SppIP).
223889648|NCT06364657|DIAGNOSTIC_TEST|Eye Exam|"* Symptom Questionnaires (OSDI, eye dryness VAS, visual fatigue VAS, eye discomfort VAS)~* Pain scale questionnaire \[Wong-Baker Faces Pain Rating Scale and Ocular Pain Assessment Survey~* Best spectacle-corrected visual acuity (BSCVA) as measured by Snellen chart followed by Mars contrast sensitivity test.~* Corneal esthesiometer for measurement of corneal sensation~* Schirmer's without topical anesthesia~* Corneal epithelial thickness sand endothelial cell count using Anterior Segment Optical Coherence Tomography (AS-OCT)~* Staining for dry eye:~* Tear film break-up time (BUT) using fluorescein.~* Fluorescein staining (National Eye Institute (NEI) and Ocular staining score (OSS))~* Lissamine green staining (OSS and Oxford)~* Non-contact confocal biomicroscopy for morphology of the ocular surface"
223889649|NCT04419389|DRUG|APR-246 (eprenetapopt) + Acalabrutinib in CLL|APR-246 D1, 8 and 15 of each cycle Acalabrutinib will be given at a standard dose and schedule (APR 246 Monotherapy Lead-in; 4.5 g/d x 2)
223889650|NCT04419389|DRUG|APR-246 (eprenetapopt) 4.5 g/d + Venetoclax + Rituximab in CLL|APR-246 D1, 8 and 15 of each cycle Venetoclax + Rituximab will be given at a standard dose and schedule (APR 246 Monotherapy Lead-in; 4.5 g/d x 2)
223889651|NCT04419389|DRUG|APR-246 (eprenetapopt) 4.5 g/d + (Acalabrutinib, OR, (Venetoclax +Rituximab)), in CLL and/or MCL and/or RT|APR-246 D1, 8 and 15 of each cycle Acalabrutinib will be given at a standard dose and schedule Venetoclax and Rituxiab will be given at a standard dose and schedule
223889652|NCT04419389|DRUG|APR-246 (eprenetapopt) 4.5 g/d + Venetoclax + Rituximab in RT|APR-246 4.5 g/d D1, 8 and 15 of each cycle Venetoclax + Rituximab will be given at a standard dose and schedule
223889653|NCT05746182|DIAGNOSTIC_TEST|Hereditary Cancer Panel|UCSF's Internal Clinical Laboratory Improvement Amendments of 1988 (CLIA)-certified Expanded Hereditary Cancer Panel will be employed which measures a minimum 88 genes
223889654|NCT03361826|DEVICE|MagPro MST with Cool TwinCoil|MST treatments will be administered using the MagPro MST with Cool TwinCoil. The investigators will evaluate the effectiveness of MST for reducing suicidality and depressive symptoms in an open-label clinical trial of up to 15 treatment sessions. Moderate-to-highly suicidal patients with BPD beginning dialectical behavioural therapy (DBT) will be recruited using a case-control design, comparing individuals receiving MST and DBT with matched patient control group receiving DBT alone.
223889655|NCT03361826|BEHAVIORAL|DBT|Dialectical behavior therapy (DBT) is a specific type of cognitive-behavioral psychotherapy developed to help better treat borderline personality disorder. Moderate-to-highly suicidal patients with BPD beginning dialectical behavioural therapy (DBT) will be recruited using a case-control design, comparing individuals receiving MST and DBT with matched patient control group receiving DBT alone.
223889656|NCT06422403|DRUG|Extended Dosing Interval - A|Nivolumab 360mg 6 weekly (up to 2 years) + XELOX Nivolumab 240mg 4 weekly (up to 2 years) + FOLFOX
223889657|NCT06422403|DRUG|Extended Dosing Interval - B|Bevacizumab + Atezolizumab 1200mg 6 weekly (up to 2 years)
223889658|NCT06422403|DRUG|Extended Dosing Interval - C|Pembrolizumab 200mg 6 weekly (up to 2 years)
223889659|NCT06422403|DRUG|Standard of Care - A|Nivolumab 360mg 3 weekly (up to 2 years) + XELOX Nivolumab 240mg 2 weekly (up to 2 years) + FOLFOX
223889660|NCT06422403|DRUG|Standard of Care - B|Bevacizumab + Atezolizumab 1200mg 3 weekly (up to 2 years)
223889661|NCT06422403|DRUG|Standard of Care - C|Pembrolizumab 200mg 3 weekly (up to 2 years)
223889662|NCT03423953|DEVICE|Comprehensive Nano|Patients requiring the Comprehensive Nano shoulder system.
223889663|NCT05020574|DRUG|Cephalexin|Given orally (PO)
223889664|NCT00920621|DIETARY_SUPPLEMENT|Vitamin D 3 cholecalciferol|Dosage form oral Dosage 4000IU Vitamin D 3 cholecalciferol
223889665|NCT00920621|DIETARY_SUPPLEMENT|Vitamin D3|4000 IU of vitamin D3 administered orally once a day during pregnancy
223889666|NCT06294613|DEVICE|vitreoretinal surgery|Patients undergoing vitreoretinal surgery
223889667|NCT06120036|DRUG|Kybella|Injection into the cutaneous Neurofibromas lesion.
223889668|NCT06120036|DRUG|Asclera|Injection into the cutaneous Neurofibromas lesion.
223889669|NCT02863718|DRUG|Ibrutinib|Bruton's tyrosine kinase Inhibitor Ibrutinib 420mg daily
223889670|NCT02863718|DRUG|Placebo|Placebo 420mg daily
223889671|NCT05153226|DRUG|Cyclophosphamide|50 mg/kg (AIBW) i.v. d+3, d+4 post transplant
223889672|NCT05153226|BIOLOGICAL|ATG|10 mg/kg i.v. d-3, d-2, d-1 pre-transplant
223889673|NCT05486234|BEHAVIORAL|modified Approach-Avoidance Task (mAAT), which aims to modify automatic approach bias|Participants will undergo a baseline assessment before completing computerized tasks. During the baseline assessment, participants will be asked questions about alcohol and cannabis use. We will also ask questions about the way participants think about things, past life experiences related to substance use, and questions about how participants feel about reducing their substance use. Then, participants will complete a series computerized tasks where they will push and pull a joystick in response to images that are presented on a screen or where they will try to get a high score. During the computerized tasks, we will also be measuring brain activity using EEG. During the study, participants will also be asked to respond to questions about their health and behavior using an app on a smartphone or tablet using a secure program. Participants in the Treatment Group will then complete four sessions of the modified Approach-Avoidance Task (mAAT), which aims to modify automatic approach bias.
223889674|NCT05486234|BEHAVIORAL|modified Approach-Avoidance Task (mAAT) that does not aim to modify automatic approach bias.|Participants will undergo a baseline assessment before completing computerized tasks. During the baseline assessment, participants will be asked questions about alcohol and cannabis use. We will also ask questions about the way participants think about things, past life experiences related to substance use, and questions about how participants feel about reducing their substance use. Then, participants will complete a series computerized tasks where they will push and pull a joystick in response to images that are presented on a screen or where they will try to get a high score. During the computerized tasks, we will also be measuring brain activity using EEG. During the study, participants will also be asked to respond to questions about their health and behavior using an app on a smartphone or tablet using a secure program. Participants in the Control Group will then complete four sessions of an Approach-Avoidance Task (mAAT) that does not aim to modify automatic approach bias.
223889675|NCT05465551|COMBINATION_PRODUCT|Stress Management Toolkit|The toolkit will be a home-based, dyadic tangible toolkit comprised of simple tools to help people living with dementia (PLWD) and their care partners manage stress at home. Potential tools for the toolkit includes low burden, high safety tools such as weighted blankets, robotic pets and baby dolls, guided journals, aromatherapy and bright light therapy devices, and massage and acupressure tools. The tookit will also include user-safety guidelines and directions on how to use each tool. Tools will be included for participants with dementia and care partners.
223889676|NCT06316791|BIOLOGICAL|single dose of CNCT19|Autologous 2nd generation CD19-directed CAR-T cells, infusion intravenously.
223889677|NCT05776641|DEVICE|GENUS|Participants will use the GENUS light and sound device at home for 60 minutes daily for 12 months
223889678|NCT05431361|OTHER|Prehabilitation|A Registered Kinesiologist (RKin) will provide the exercise prescription, consisting of 4-5 days of aerobic exercise training and 2-3 days of resistance exercise training of major muscle groups, during a remotely delivered familiarization session using Microsoft Teams. The 60-minute remote program introduction will include a description and demonstration of all of the exercises that will follow the baseline assessment. Patients will be prescribed an individualized exercise program considering: (1) their exercise preferences, (2) their current physical capacity, (3) previous medical history, and (4) presence of underlying comorbidities, mobility, and skeletal fragility concerns \[NOTE: the location/impact of a tumour is not applicable for PROPELLER as it was in REB#5901, and is thus not included here\]. The participant will have an opportunity to execute the exercises in the remote presence of the RKin who will provide corrective feedback where applicable.
223889679|NCT03940456|OTHER|Questionnaire|Questionnaire mainly focusing on low back pain, pain related disorders, psychosocial factors and the use of alternative treatments for pain
224080383|NCT05357456|BEHAVIORAL|Cognitive function assessment; functional magnetic resonance imaging|cognitive function measurement
223889680|NCT05679661|DIETARY_SUPPLEMENT|immunonutrition|Patients in the intervention group will receive additional immunonutrition supplementation, which is oral intake of ORAL IMPACT™ 2 servings per day from the day of allocation at the preoperative anesthesia clinic until the day before surgery.
223889681|NCT05679661|BEHAVIORAL|oral chlorhexidine decontamination|Patients in the intervention group will receive oral chlorhexidine decontamination using 0.12% chlorhexidine oral rinse twice daily from the day before surgery until postoperative day 3.
223889682|NCT06336304|DIAGNOSTIC_TEST|Urodynamic procedure|Urodynamic procedure
223889683|NCT06426576|OTHER|Standard one-off instruction using a scale|"The permitted weight is demonstrated to the patient once using a scale in the static position. The patient repeatedly places the foot with the permitted weight on a scale in order to develop a feeling for the load. After this exercise in the static position, the patient applies the perceived load to dynamic activities of daily living without receiving any feedback.~The instruction is given by a trained physiotherapist. Simultaneously with the instruction, the effective weight applied on the leg will be measured using instrumented insoles without any feedback."
223889684|NCT06426576|DEVICE|Plantar pressure insoles|The insoles are used in both static and dynamic conditions such as walking straight along the hallway or walking stairs if applicable. Initial instruction is given by a trained physiotherapist and will be continuously applied at home using the smartphone app for 5 out of 7 days per week during the first 2 weeks after surgery.
223889685|NCT04570475|DIETARY_SUPPLEMENT|Vitamin D|Participants will receive vitamin D+multivitamin for 3 weeks. At the end of 3 weeks they will complete an online or paper questionnaire and blood work will be done.
223889686|NCT04570475|DIETARY_SUPPLEMENT|multivitamin|Participants will receive placebo+multivitamin or vitamin D+multivitamin for 3 weeks. At the end of 3 weeks they will complete an online or paper questionnaire and blood work will be done.
223889687|NCT04570475|DIETARY_SUPPLEMENT|Placebo|Participants will receive placebo+multivitamin for 3 weeks. At the end of 3 weeks they will complete an online or paper questionnaire and blood work will be done.
223889688|NCT05243017|GENETIC|intra-striatal rAAV5-miHTT|One time MRI-guided stereotaxic infusion of rAAV5-miHTT into the brain
223889689|NCT05097430|BEHAVIORAL|Alcohol-focused brief intervention|The primary intervention component is the Check Your Drinking (CYD) intervention - an electronically-delivered brief intervention designed to assess and provide personalized feedback regarding the quantity, frequency, and severity of one's alcohol consumption. Additionally, intervention condition participants who are identified as having a concurrent substance use concern or who may be experiencing depression will receive information about local resources that can assist with such concerns.
223889690|NCT04148911|DRUG|Atezolizumab|Atezolizumab will be administered at a dose of 840 mg via IV infusion on Days 1 and 15 of every 28-day cycle. Day 15: Atezolizumab may be administered on Days 15-18 of each cycle.
223889691|NCT04148911|DRUG|Nab-Paclitaxel|Nab-Paclitaxel will be administered at the 100 mg/m2 dose via IV infusion on Days 1, 8, and 15 of every 28-day cycle. Day 8: Nab-paclitaxel may be administered on Days 8-11 of each cycle. Day 15: Nab-paclitaxel may be administered on Days 15-18 of each cycle, on the same day with the atezolizumab infusion.
223889692|NCT04708808|BEHAVIORAL|music therapy|cases will randomly assigned to receive music therapy group with routine care, plus music given via headphone, or assign to control group with no music given.
223889693|NCT04772157|DIAGNOSTIC_TEST|Cardiac Troponin Testing|Lithium heparin whole blood and plasma samples will be measured with Siemens POC High Sensitivity Troponin-I Test System.
223889694|NCT05918133|DRUG|PM8002|IV infusion
223889695|NCT05918133|DRUG|nab-paclitaxel|IV infusion
223889696|NCT06378359|OTHER|Screening and decolonization for SA carriers with the 3 drug bundle|nasal mupirocin, chlorhexidine gluconate (CHG) mouth rinse and CHG soap showers x 5 days and non-SA carriers receive 2 CHG pre-op showers
223889697|NCT06378359|OTHER|No screening for SA|All receive the 3 drug bundle, Nasal mupirocin, chlorhexidine gluconate (CHG) mouth rinse, and CHG body wash
223889698|NCT06378359|OTHER|no screening|giving pre-surgical patients the three drug decolonization bundle without screening
223889699|NCT06378359|OTHER|Nasal povidone-iodine on surgery day plus 2 CHG pre-op showers without screening.|Nasal povidone-iodine on surgery day plus 2 CHG pre-op showers without screening.
223889700|NCT06378359|OTHER|Nasal alcohol gel on surgery day plus 2 CHG pre-op showers without screening|Nasal alcohol gel on surgery day plus 2 CHG pre-op showers without screening
223889701|NCT03730922|PROCEDURE|Delayed-immediate reconstruction|Skin sparing mastectomy and reconstruction with silicone implant or expander covered by pectoral muscle and mesh or matrix. Final reconstruction with any reconstructive procedure 6-12 months after completion of chemotherapy and RT.
223889702|NCT03730922|PROCEDURE|Delayed reconstruction|Total mastectomy and delayed reconstruction:with any reconstructive procedure 6-12 months after completion of PMRT
223889703|NCT05309655|DRUG|Adenosine Stress Cardiac Magnetic Resonance Imaging|Adenosine stress CMR test with contrast to include cardiovascular structural and functional measures including myocardial blood flow through quantitative perfusion mapping. Participants will have 3 stress tests as a part of this research. These tests will happen when at the beginning of the study, and then every year for 2 years.
223889704|NCT05309655|DIAGNOSTIC_TEST|Electrocardiogram|A 12-lead electrocardiogram will be done when at the start of the study and at the participant's 2 year stress test to look at the electrical signals of your heart.
223889705|NCT05309655|DIAGNOSTIC_TEST|Computed Tomography Angiogram|Contrasted coronary CT angiography will be performed for visual and quantitative analysis of coronary artery plaque burdens.
223889706|NCT05309655|OTHER|Laboratory Testing|10 teaspoons of blood will be withdrawn at every visit that participants receive a stress test. Participants may have up to six blood draws associated with each imaging visit.
223889707|NCT05309655|BEHAVIORAL|Quality of Life Survey|A general health status survey with 10 questions and should take about 5-10 minutes to finish. This survey is related to research.
223889708|NCT04500041|PROCEDURE|Casting|Use of casts applied using corrective maneuvers
223889709|NCT04500041|DEVICE|Bracing|Use of full-time spinal orthosis
223889710|NCT06308874|DRUG|Amg dose administration group|Orally, Amg tablet single administration
223889711|NCT06308874|DRUG|Amg dose administration group- Placebo|Orally, Placebo Amg tablet single administration
223889712|NCT06308874|DRUG|Bmg dose administration group|Orally, Bmg tablet single administration
223889713|NCT06308874|DRUG|Bmg dose administration group- Placebo|Orally, Placebo Bmg tablet single administration
223889714|NCT04321031|DRUG|Placebo|Tablet
223889715|NCT04321031|DRUG|PF-06865571|Tablet
223889716|NCT04321031|DRUG|PF-05221304|Tablet
223889717|NCT06223880|DRUG|AXS-05|"Up to 10 weeks in open-label period;~Up to 26 weeks in double-blind period"
223889718|NCT06223880|DRUG|Bupropion|Up to 26 weeks in double-blind period
223889719|NCT04080531|BIOLOGICAL|Pneumococcal 13-valent Conjugate Vaccine|Given IM
223889720|NCT04080531|BIOLOGICAL|Trivalent Influenza Vaccine|Given IM
223889721|NCT06489795|PROCEDURE|Laparoscopic or robot-assisted radical/simple hysterectomy|In the experimental arm, patients with early-stage cervical cancer will be treated by using laparoscopic or robot-assisted radical, or in the case of SHAPE criteria, simple hysterectomy.
223889722|NCT06489795|PROCEDURE|Abdominal radical/simple hysterectomy|In the control arm, patients with early-stage cervical cancer will be treated by using abdominal radical, or in the case of SHAPE criteria, simple hysterectomy as standard therapy.
223889723|NCT06084338|RADIATION|stereotactic ablative radiotherapy|Metastasis directed
223889724|NCT06084338|DRUG|Pluvicto|PSMA targeted radiopharmaceutical therapy
223889725|NCT06084338|DRUG|topical testosterone|Topical testosterone 1.62% gel
223889726|NCT03941132|DRUG|Ustekinumab|"Week 0: Loading dose of 6mg/kg Ustekinumab Intravenously.~Weeks 8, 16, 24, 32, 40, and 48 (6 visits): 90mg Ustekinumab subcutaneously."
223889727|NCT03941132|DRUG|Placebo|"Patients allocated to receive placebo will receive respective amounts of a saline-placebo at the same intervals.~Week 0: Loading dose of 6mg/kg saline intravenously.~Weeks 8, 16, 24, 32, 40, and 48 (6 visits): 90mg saline subcutaneously."
223889728|NCT05366647|PROCEDURE|canaloplasty|canaloplasty ab interno with tensioning suture
223889729|NCT05366647|PROCEDURE|Gonioscopy-assisted Transluminal Trabeculotomy|Gonioscopy-assisted Transluminal Trabeculotomy ab interno
223889730|NCT05509153|DRUG|NAC|1g of clinical grade N-Acetylcysteine capsules, taken orally twice a day
223889731|NCT05509153|DRUG|Placebo|Coated Placebo capsules, manufactured to match appearance and taste, taken orally twice a day
223889732|NCT06126822|DRUG|Zabdeno® booster|A single Zabdeno® booster vaccination
223889733|NCT06126822|DRUG|Ervebo® booster|A single Ervebo® booster vaccination
223889734|NCT02339922|DRUG|Ixazomib Citrate|Given PO
223889735|NCT02339922|OTHER|Laboratory Biomarker Analysis|Correlative studies
223889736|NCT02339922|BIOLOGICAL|Rituximab|Given IV
223889737|NCT05508165|DEVICE|Stream Dx|home uroflowmetry device
223889738|NCT05508165|DEVICE|DFree|at home wearable bladder scanner
223889739|NCT05508165|DEVICE|TestCard|mobile urinalysis reader
223889740|NCT06071884|DEVICE|Bridge Percutaneous Nerve Field Stimulator|The Bridge device is an FDA-cleared, drug-free, non-surgical device that uses neuro-modulation to aid in the reduction of symptoms associated with opioid withdrawal through application to branches of the Cranial Nerves V, VII, IX, X, and the occipital nerves. This study is investigating its effectiveness treating post-surgical pain.
223889741|NCT04323774|BEHAVIORAL|AYA-RISE Adolescents and Young Adults Risk Information and Screening Education|A chatbot is a computer program that can chat with humans. The text the chatbot uses to talk with humans was created by real people, but the chatbot itself is not a real person. A company called Clear Genetics developed the original chatbot and patient portal, and this study team customized it for this research study.
223889742|NCT04323774|BEHAVIORAL|Standard clinical visit for genetic counseling|Standard clinical visit for genetic counseling and follow up
223889743|NCT06184256|BEHAVIORAL|BfedBwell - Core Curriculum|12-week core nutrition education curriculum + 12-week tapered maintenance curriculum
223889744|NCT06184256|BEHAVIORAL|BfedBwell - 1:1 Counseling|Individual 1:1 counseling sessions with a registered dietitian
223889745|NCT06184256|BEHAVIORAL|BfedBwell - Behavioral Skills|Group-based behavioral skills development sessions
223889746|NCT06184256|BEHAVIORAL|BfedBwell - Group Support|Structured group support sessions
223889747|NCT06184256|BEHAVIORAL|Program delivery|Delivery and evaluation of one or more intervention components
223889748|NCT05347472|OTHER|Smartphone application|the smartphone application intervention will consist daily physical therapy exercises program. The application will include all the videos about the exercises and all information about the repetition, frequency, intensity, and position.
223889749|NCT05347472|OTHER|Sham Smartphone application|ham application that includes information and general advice about UI only
223889750|NCT05914155|DRUG|Rituximab (genetical recombination)|Administer 1,000 mg of rituximab (genetical recombination) IV infusion every two weeks for two doses in double-blind phase.
223889751|NCT05914155|DRUG|Placebo|Administer placebo IV infusion every two weeks for two doses in double-blind phase.
223889752|NCT05914155|DRUG|Rituximab (genetical recombination)|Patients who remain to be ICR II (Incomplete Remission Type II) or NR (No Response) until Week 26 in the double-blind phase, if the patients wish to move to the open-label phase and the investigator or a subinvestigator considers the move necessary, the patient will move to the open-label phase and receive 1,000 mg of rituximab (genetical recombination) IV infusion every two weeks for two doses after the readministration criteria are confirmed to be met.
223889753|NCT06512025|BEHAVIORAL|WWWT psychoeducative intervention|"What Were We Thinking (WWWT) is a highly structured, interactive, gender-informed, couples-based, psycho-educational program for parents and a first newborn to promote confident parental caretaking, optimize functioning in the intimate partner relationship and improve infant care manageability.~The adaptation of the WWWT programme (Catalan and Spanish version) comprises 2 sessions, each lasting 2 hours, that will be designed for groups of 5-7 families - within the first 6 weeks postpartum -, each consisting of mother, partner (or other caregiver) and their infant(s)."
223889754|NCT03342079|DRUG|Local Anesthetics,(lidocaine 70 mg/tetracaine 70 mg topical patch; Synera)|topical anesthetic (lidocaine 70 mg/tetracaine 70 mg topical patch; Synera)
223889755|NCT03342079|DRUG|Placebos|placebo topical anesthetic
223889756|NCT05584124|DEVICE|High frequency repetitive transcranial magnetic stimulation|MAGSTIM Super Rapid2 Plus
223889757|NCT05584124|DEVICE|Sham repetitive transcranial magnetic stimulation|MAGSTIM Super Rapid2 Plus
223889758|NCT03143153|BIOLOGICAL|Nivolumab|Specified dose on specified days
223889759|NCT03143153|BIOLOGICAL|Ipilimumab|Specified dose on specified days
223889760|NCT03143153|DRUG|Cisplatin|Specified dose on specified days
223889761|NCT03143153|DRUG|Fluorouracil|Specified dose on specified days
223889762|NCT04760860|DRUG|Terazosin Hydrochloride|In this double blind, randomized, placebo controlled phase I clinical trial, subjects randomized into the Terazosin group will receive Terazosin hydrochloride treatment for 15 weeks. Participants will start at 1mg daily for the first 6 week, then the dosage will be increased to 5mg daily over 3 weeks, and continued for the last 6 weeks.
223889763|NCT04760860|OTHER|Placebo|In this double blind, randomized, placebo controlled phase I clinical trial, subjects randomized into the control group will receive placebo for 15 weeks.
223889764|NCT03982160|DRUG|L-Arginine|Arginine Hydrochloride 60% concentration injection 15 g in 25 mL, contains arginine hydrochloride 600 mg/mL in water for injections to 25 mL.
223889765|NCT03982160|OTHER|Placebo|Saline
223889766|NCT02312557|DRUG|Enzalutamide|Given PO
223889767|NCT02312557|OTHER|Laboratory Biomarker Analysis|Correlative studies
223889768|NCT02312557|BIOLOGICAL|Pembrolizumab|Given IV
223889769|NCT05772130|OTHER|Best Practice|Receive family letter and genomic test report
223889770|NCT05772130|OTHER|Electronic Health Record Review|Ancillary studies
223889771|NCT05772130|BEHAVIORAL|Personal Contact|Receive family letter and genomic test report with provider-mediated contact
223889772|NCT05772130|OTHER|Survey Administration|Ancillary studies
223889773|NCT04827875|DRUG|AIV001|Intradermal
223889774|NCT04237298|DEVICE|Modified vacuum-formed retainer covering the palete|The modified vacuum-formed retainer is made where it would cover the hard palate to the second molars. The only difference in constructing this modified VFR when compared to the normal VFR would be the outline which would be trimmed by the technician.
223889775|NCT02530671|DEVICE|Toothbrushing with manual toothbrush|
223889776|NCT02530671|DEVICE|Toothbrushing with power toothbrush|
223889777|NCT02736409|DRUG|Oral Budesonide Suspension (OBS)|OBS 2mg twice daily
223889778|NCT02736409|DRUG|Placebo|Matching Placebo dose
223889779|NCT05652296|DEVICE|External Ventricular Drainage (EVD)|EVD of Cerebral Spinal Fluid from the lateral ventricles of the brain
223889780|NCT06258889|BEHAVIORAL|reward-focused intervention|"Participants complete three interventions based on the Positive Affect Treatment:~* Finding the silver lining includes attending to and appreciating positive aspects of past events~* Taking ownership includes identifying the personal behavioral contribution to rewarding past experiences~* Imagining the positive includes training the prospective, positive imagination of future events~Participants are asked to practice these interventions at least three times a week (approx. 15 mins each) until the next training session."
223889781|NCT06258889|BEHAVIORAL|cognitive flexibility intervention|"This training aims to promote cognitive flexibility in the context of public speaking situations. The intervention is based on the Unified Protocol for Transdiagnostic Treatment of Emotional Disorders.~Participants will be trained to identify and modify non-adaptive thoughts occurring in the context of public speaking situations."
223889782|NCT06258889|BEHAVIORAL|exposure|"All participants undergo an exposure training session lasting approximately 90 minutes, which includes three exposure trial where participants give a speech, each lasting 5 minutes.~Exposure exercises are enriched with interventions of the respective treatment group (either reward-focused or cognitive flexibility interventions)."
223889783|NCT06258889|BEHAVIORAL|Psychoeducation|All participants received information on anxiety, and the maintenance of anxiety as well as a rationale for the exposure session.
223889784|NCT06154889|OTHER|consultations with a psychologist|Consultations with a sports psychologist to decrease kinesiophobia
223889785|NCT06154889|OTHER|Conventional reeducation|Conventional reeducation
223889786|NCT01415154|DEVICE|NeuroStar TMS|NeuroStar TMS treatmant - 120% of Observed MT, 10 pulses per second, 4 second on-time, 26 second off-time, 75 trains, 3,000 total pulses/sessions for 6 days. 3 treatments in taper week 1, 2 treatments in taper week 2 and 1 treatment in taper week 3.
223889787|NCT02038569|DRUG|LEO 80185 gel|
223889788|NCT05801913|BIOLOGICAL|Anti-CD19-CAR CMV-specific T-lymphocytes|Given IV
223889789|NCT05801913|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223889790|NCT05801913|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
223889791|NCT05801913|PROCEDURE|Computed Tomography|Undergo CT
223889792|NCT05801913|PROCEDURE|Leukapheresis|Undergo leukapheresis per SOC
223889793|NCT05801913|PROCEDURE|Lymphodepletion Therapy|Undergo lymphodepletion chemotherapy per SOC
223889794|NCT05801913|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223889795|NCT05801913|BIOLOGICAL|Multi-peptide CMV-Modified Vaccinia Ankara Vaccine|Given IM
223889796|NCT05801913|PROCEDURE|Positron Emission Tomography|Undergo PET
223889797|NCT05801913|PROCEDURE|X-Ray Imaging|Undergo x-ray
223889798|NCT05629663|DEVICE|AR guidance with Hololens 2|The AR instructions were developed as a step-by-step guide, utilizing the dynamic 365 Guide (Software, Microsoft Corporation, Redmond, WA, USA). The AR instructions were delivered using the Microsoft HoloLens 2.
223889799|NCT06332352|BIOLOGICAL|PRP|Intra-articular hip injection of PRP, Blood Collection 45mL, Processed Neutrophil-Poor PRP, 1 injection to one hip joint.
223889800|NCT05410730|DRUG|SHR-1501|SHR-1501 single agent dose escalation, and in combination of BCG or SHR-1316.
223889801|NCT06205992|DEVICE|3D-MRE|All imaging studies were performed by using a 3.0-T MRI system (Signa HDx, GE Healthcare) with an eight-channel phasedarray body coil.
223889802|NCT06205992|DEVICE|HVPG|HVPG measurements are performed by well-trained interventional radiologists in accordance with standard operating procedures
223889803|NCT06205992|DEVICE|2D-MRE|All imaging studies were performed by using a 3.0-T MRI system (Signa HDx, GE Healthcare) with an eight-channel phasedarray body coil.
223889804|NCT06205992|DEVICE|HVPG|HVPG measurements are performed by well-trained interventional radiologists in accordance with standard operating procedures
223889805|NCT05351541|DRUG|Psilocybin therapy with Zolpidem and Modafinil|1-30 mg (oral administration), Modafinil (oral administration), and Zolpidem (oral administration)
223889806|NCT05351541|DRUG|Psilocybin therapy with Zolpidem|1-30 mg (oral administration), Zolpidem (oral administration), and placebo (oral administration)
223889807|NCT05351541|DRUG|Psilocybin therapy with Modafinil|1-30 mg (oral administration), Modafinil (oral administration), and placebo (oral administration)
223889808|NCT05351541|DRUG|Psilocybin therapy with Placebo|1-30 mg (oral administration), and placebo (oral administration)
223889809|NCT05551195|DEVICE|WB001|WB001 is a digital therapeutic for postpartum depression.
223889810|NCT05551195|DEVICE|ED001|ED001 is a digital therapeutic for postpartum depression.
223889811|NCT04122235|OTHER|LETSGO follow-up|Nurse-led follow-up in 50% of the consultations Access to the LETSGO-app
223889812|NCT02891096|PROCEDURE|inspiratory muscle strength|"Measurements:~* in- and expiratory muscle strength (5min)~* lung function (FVC, FEV1, PEF, PCF) (10 min)~Questionnaires:~* ISCoS core data-set~* ISCoS pulmonary function data sets~* ISCoS quality of life questionnaire~* questionnaire on individual respiratory muscle training, regular physical exercise and therapies~* individual medication/vaccination and other medical complications will be assessed from patient's medical records~All measurements will be performed at each of the 4 measurement time-points (up to 4 times during inpatient rehabilitation) and last about 40 min per patient and measurement time-point in total (time with patient)."
223889813|NCT06797882|DRUG|Silver diamine fluoride- potassium iodide|SDF , Riva Star, SDI Limited., Australia
223889814|NCT06797882|DRUG|Fluoride varnish|Duraphat varnish®, Colgate-Palmolive (UK) Ltd.
223889815|NCT06797882|OTHER|0.9 % saline|Standard oral hygiene instructions every 3 months and application of Normal Saline for every 6 months
223889816|NCT06789003|OTHER|Adapted exercises|"Patients will have 3 sessions a week: 1 strengthening session and 2 endurance sessions.~For each session, patients will choose the exercises to be performed from the exercise booklet or the videos and records their observations in the patient notebook.~Depending on the treatment plan, patients will have alternating supervised (in hospital) and unsupervised (at home) APA sessions, in order to follow the rhythm of their visits to the department.~Each session will last 45 minutes with a medium intensity according to the Borg scale."
223889817|NCT06789003|OTHER|No intervention|Patients will not be practising adapted exercises as part of the study. They will be treated with chemotherapy according to standard practice.
223889818|NCT06789003|BEHAVIORAL|Quality of Life questionnaire|QoL questionnaire (EORTC QLQ-C30) at baseline, mid-term (after 2 cycles of chemotherapy), before transplantation, and after transplantation
223889819|NCT06789003|BEHAVIORAL|Questionnaire of Fatigue|Questionnaire (EORTC QLQ-FA12) at baseline, mid-term (after 2 cycles of chemotherapy), before transplantation, and after transplantation
223889820|NCT06789003|BEHAVIORAL|Physical activity questionnaire|Questionnaire (IPAQ) at baseline and after transplantation
223889821|NCT06789003|BEHAVIORAL|Physical condition|Evaluation of physical condition at baseline, mid term (after 2 cycles of chemotherapy), before transplantation and after transplantation
223889822|NCT04048304|DRUG|duration of standard antibiotic therapy|antibiotic therapy for spine infections. 3 vs 6 weeks if no implant left in place. 6 vs 12 weeks if implant left in place. The antibiotic agents used are officially indicated for orthopedic infections, including spine infections and available in Switzerland since decades. Standard dosing will be applied and only modified according to the patient's co-morbidities, intolerances and weight.
223889823|NCT06487858|DRUG|BGB-R046|Intravenous administration
223889824|NCT06487858|DRUG|Tislelizumab|Intravenous administration
223889825|NCT05722704|PROCEDURE|Cryotherapy|Final irrigation with cold saline (2.5C-4C) without occlusal reduction
223889826|NCT05722704|PROCEDURE|Occlusal reduction|Reduction of the functional and non-functional cusps
223889827|NCT06069713|BEHAVIORAL|CBD advertisements|Participants will view the 5 images of CBD advertisements in their assigned panel and answer questions about their perceptions of the advertisement.
223889828|NCT06792942|OTHER|nature view curtain group|During the fine needle biopsy, the patient will look at the nature view curtain on the ceiling.
223889829|NCT05536440|DRUG|PF-07261271|IV or SC
223889830|NCT05536440|DRUG|Placebo|IV or SC
223889831|NCT06283173|DEVICE|ColActive Plus Collagen Matrix Dressing|"Induction phase: Test article applied with Hill Top chamber every 48+ hours over 3 weeks. Rest phase: 10-day rest period with no application.~Challenge phase: Test article applied for 48 hours and evaluated through 48 hours post removal.~The positive control is evaluated at Induction 1 only. The negative control is applied following the same schedule as the test article."
223889832|NCT04876222|PROCEDURE|Acute CAG|The patient is triaged directly to the catheterization laboratory for acute evaluation including ECHO, acute CAG and PCI if indicated according to guidelines.
223889833|NCT05655325|BEHAVIORAL|Home-based walking exercise|A 6-month partially supervised walking exercise program using a tapered approach.Participants will begin exercise (walking) at a relatively low intensity and progress to moderate intensity. Intensity will start at 40% and progress as tolerated up to 60-70%. Rating of perceived exertion of 12-14 (fairly light to moderate) will be used to aid intensity (Rating of perceived exertion 6-20 scale). This is an accepted method for achieving desired exercise intensity. Participants will progress over time to exercise 3-4/week for 30-45 minutes. The exercise program may need to be adjusted for (e.g. 10 minutes of exercise 3 times), to achieve the minimum exercise dose of 30 minutes. This will be determined for each individual participants as needed.
223889834|NCT05655325|OTHER|Attention control|Health education and stretching
224080384|NCT05357456|PROCEDURE|laparoscopic adrenal surgery|Only a subgroup of the autonomous cortisol secretion patients will have the laparoscopic adrenal surgery
223889835|NCT06028113|BEHAVIORAL|THRIVE 2.0|Overview of content and strategies: 1) Education on stage of development specific to infant feeding, sleep and infant regulation, attunement to cues; 2) Attunement to cues: reinforcing and modeling accurate discernment \& responsiveness to cues; 3) Infant Soothing and Regulation: Coaching alternative strategies for soothing that feeding for non-hungry, fussy infants; 4) Routines \& Strategies: Promoting developmental activities during wake windows and longer consolidated sleep at night as the infant grows.
223889836|NCT06799949|DIAGNOSTIC_TEST|ROTEM (TEM Innovations GmbH, Munich, Germany) assay|For each patient, two samples will be collected for ROTEM analysis: one at the beginning of the surgery, during the placement of the arterial line (Start ratio), and another one, at the end, during the completion of the surgical wound closure (Final ratio). The arterial line system will be filled with normal saline (0.9% sodium chloride) without the addition of unfractionated heparin. To avoid sample contamination before sampling, a volume of blood equivalent to 5.5-6 times the dead space (calculated from the catheter tip to the three-way stopcock device) will be aspirated. Blood samples for testing will be stored in specific empty coagulation test tubes (Jiangsu Rongye Technology Co., Ltd, Jiangsu, China) and gently mixed with 3.2%-0.109M sodium citrate, for a total volume of 1.8 ml.
223889837|NCT06798584|DIETARY_SUPPLEMENT|FeoSol Original Iron Supplement Tablets|325 mg of ferrous sulfate containing 65 mg of elemental iron
223889838|NCT06798584|DIETARY_SUPPLEMENT|21st Century Gelatin Capsules|600 mg
223889839|NCT05093907|DRUG|BEY1107|Administer once daily, PO, 3-week continuous dose.
223889840|NCT05093907|COMBINATION_PRODUCT|Capecitabine|Administer twice daily, PO, 2-week continuous dose, followed by 1-week rest period.
223889841|NCT06639269|OTHER|fertility health education program|"The intervention group will be implemented with a fertility health education program for which a literature information document will be created. In the training; booklets and brochures will be prepared. The control unit will include information on programming and data collection forms to be used. Those selected from the intervention group will be divided into groups of 10-15 people. The training program will consist of 3 sessions. Training sessions will be planned on days and hours that are convenient for the researcher, classrooms and students. For students who cannot attend group training, make-up training will be provided within a week. In this study, the time between sessions will be planned as 1 week. The sessions in this study will be planned to be in groups of 10-15 people and will last 50 minutes."
223889842|NCT05159128|DRUG|JNJ-75105186|JNJ-75105186 will be administered orally in Part 1 and 2.
223889843|NCT05159128|OTHER|Placebo|Matching placebo to JNJ-75105186 will be administered orally in Parts 1 and 2.
223889844|NCT03094663|DRUG|Bupivacaine with epinephrine|bupivacaine 0.5% with epinephrine 30cc
223889845|NCT03094663|DRUG|Methylprednisolone|40 mg/ml, 1 ml
223889846|NCT03094663|DRUG|Cefazolin|500 mg in 10 ml
223889847|NCT03094663|DEVICE|8 MHz. Chiba needle|22G/ 4 inches
223889848|NCT03094663|DRUG|Bupivacaine with Dexamethasone|15 cc of bupivacaine 0.25% with 2 mg of PF Dexamethasone
223889849|NCT03094663|DRUG|Bupivacaine 25cc|25 cc 0.25% bupivacaine
223889850|NCT03094663|DRUG|Bupivacaine 20cc|20cc 0.25% bupivacaine
223889851|NCT03094663|DRUG|Dexamethasone|2 mg IV dexamethasone.
223889852|NCT05930821|BEHAVIORAL|Aerobic and Resistance Exercise Program (GEMS program)|"* Remotely-coached/guided, home-based program delivered using telerehabilitation focusing on aerobic fitness and muscle strength as a mode of training.~* The exercise training prescription involves performing 3 days per week and include (a) aerobic exercise: 30+ minutes of moderate-intensity walking (≥100 steps/min) monitored by a waist-worn pedometer, and (b) resistance training: 1-2 sets, 10-15 repetitions of 5-10 exercises targeting lower and upper body, and core muscle groups using elastic bands.~* Other components of the GEMS program include appropriate exercise equipment (pedometer, resistance bands), one-on-one coaching sessions via Zoom, action-planning via calendars, logbooks for self-monitoring, and SCT-based newsletters."
223889853|NCT05930821|BEHAVIORAL|Flexibility and Stretching Program (FLEX-MS program)|"* Remotely-coached/guided, home-based program delivered using telerehabilitation focusing on stretching and range of motion as the mode of training.~* The training will involve the same frequency, duration, timeline, behavior change content, and interactions with behavioral coach as the GEMS program, and account for activity, social-contact, and attention.~* Other components of the FLEX-MS program include appropriate exercise equipment (yoga mat), one-on-one coaching sessions via Zoom, calendars, logbooks and newsletters similar to the GEMS program."
223889854|NCT06643000|DRUG|furmonertinib|furmonertinib (240 mg/d,po) combined with bevacizumab (15 mg/kg, every 3 weeks, ivgtt) and pemetrexed (50 mg) intrathecal chemotherapy / pemetrexed (500 mg/m²) intravenous chemotherapy, administered every 3 weeks.
223889855|NCT06121596|BEHAVIORAL|Breathing Exercise|A breathing exercise is a relaxation technique (or therapy) to increase relaxation (induces a relaxation response) and decrease stress (reduces a stress response).
223889856|NCT06448520|OTHER|Muscle Power Sprint Test|The Muscle Power Sprint Test (MPST) is an easy-to-perform field test of anaerobic capacity for children and adolescents. The only necessities for the administration of this test are an open space, a stopwatch and two cones or lines. Test subjects are encouraged to perform six 15-meter sprints at a maximal pace between the two cones/lines, with a 10-second rest in between each effort. The distance covered during these short runs corresponds well to the distances children cover during daily play activities. The power that is generated with each sprint can be calculated using the formula: power = (total mass x 15 m²)/time³.
223889857|NCT06452446|DRUG|Selinexor|Selinexor is an oral therapy that is FDA approved for multiple myeloma and diffuse large B-cell lymphoma that have returned after prior therapy. Side effects like nausea, vomiting, and fatigue can affect how long a patient is able to continue taking Selinexor, which could mean that treatment might stop sooner.
223889858|NCT05526144|DRUG|Synthroid|Synthroid tablets 25 mcg. Subjects in the study group will receive Synthroid at a titrated dose of 25 mcg (one tablet), 50 mcg (two tablets), or maximum of 75 mcg (3 tablets) daily for one year duration that will maintain TSH at normal level.
223889859|NCT05526144|DRUG|Placebo|Placebo tablets 25 mcg daily. Subjects in the placebo group will receive placebo tablets at a dose of 25 mcg (one tablet), 50 mcg (two tablets), or maximum of 75 mcg (3 tablets) daily for a one year duration.
223889860|NCT02897531|PROCEDURE|ES anastomosis|The side wall of the transverse colon will be anastomosed to the end of the distal ileum with one circular stapler, and the blind end of the transverse colon will be closed with one linear stapler.
223889861|NCT02897531|PROCEDURE|SS anastomosis|The side wall of the transverse colon will be anastomosed to the side wall of the distal ileum with two linear staplers.
223889862|NCT06641297|BEHAVIORAL|Music video game|The video game \&#39;Guitar Hero\&#39; will be used as the platform for training for participants to acquire a new \&#39;skill\&#39;
223889863|NCT06479187|DRUG|18F-rhPSMA-7.3|radiopharmaceutical targeting PSMA and used to image prostate cancer with PET scan.
223889864|NCT06479187|DEVICE|PET/CT|Diagnostic imaging test
223889865|NCT02727972|BEHAVIORAL|Cognitive Testing|Verbal assessments as well as computer testing.
223889866|NCT02727972|OTHER|MRI|Anatomical MRIs will be performed on a Siemens 3T Trio at Yale. MR acquisition will be a Sag 3D magnetization-prepared rapid gradient-echo (MPRAGE) sequence with 3.34 ms echo time, 2,500 ms repetition time, 1,000 ms inversion time, 7 degree flip angle, and 180 Hz/pixel bandwidth. The image dimensions will be 256 x 256 x 176 and pixel size 0.98 x 0.98 x 1.0 mm. Resting state MRIs will also be obtained as follows: We will be doing 2 six minute scans with subjects in the scanner, eyes open, fixating a cross. TR = 3 secs 45 slices x 3 mm slice thickness = 13.5 cm. In plane resolution = 3 x 3 mm, slice acquisition order = ascending.
223889867|NCT02727972|RADIATION|PET|High Resolution Research Tomograph (HRRT), the highest resolution human brain scanner available, or HR+ will be used to image subjects. Vital signs (blood pressure, pulse, respiration) will be obtained before and after radiotracer administration. An antecubital venous catheter will be used for IV administration of the radiotracer and for venous blood sampling. A radial artery catheter will be inserted by an experienced physician before the PET scan. At the beginning of each scan, the subject's head will be immobilized and a 6 minute transmission scan using an orbiting 137Cs (HRRT) or 68GE (HR+) point-source is obtained and used for attenuation correction. PET scans will be acquired using bolus or bolus plus constant infusion administration of FPEB or ABP688.
223889868|NCT06354049|OTHER|Reiki|Reiki, originating in Japan, is a biofield therapy where a skilled practitioner places their hands on or above the body of the recipient or themselves to induce relaxation and promote healing.
223889869|NCT06584539|BEHAVIORAL|Eco-Labels|"Eco-labels will be displayed next to more sustainable restaurant menu items. The labels will display an earth icon and the words ENVIRONMENTALLY FRIENDLY."
223889870|NCT05470400|BIOLOGICAL|FP conjugate vaccine (25 mcg)|"FP8v1-rTTHC (FP conjugate vaccine) is an HIV-1 fusion peptide conjugated to recombinant tetanus toxoid heavy chain fragment C (rTTHC) via sulfo-SIAB chemical linker.~Study vaccines will be admixed with Adjuplex adjuvant and administered intramuscularly (IM) via needle and syringe in two injection sites."
223889871|NCT05470400|BIOLOGICAL|FP conjugate vaccine (200 mcg)|"FP8v1-rTTHC (FP conjugate vaccine) is an HIV-1 fusion peptide conjugated to recombinant tetanus toxoid heavy chain fragment C (rTTHC) via sulfo-SIAB chemical linker.~Study vaccines will be admixed with Adjuplex adjuvant and administered intramuscularly (IM) via needle and syringe in two injection sites."
223889872|NCT05470400|BIOLOGICAL|Trimer 6931 (100 mcg)|"HIV-1 Trimer 6931 (Trimer 6931) is a synthetic soluble HIV-1 envelope product that consists of an HIV-1 envelope (Env) trimer variant, derived from consensus clade C sequence (ConC).~Study vaccines will be admixed with Adjuplex adjuvant and administered intramuscularly (IM) via needle and syringe in two injection sites."
223889873|NCT05470400|BIOLOGICAL|Trimer 6931 (200 mcg)|"HIV-1 Trimer 6931 (Trimer 6931) is a synthetic soluble HIV-1 envelope product that consists of an HIV-1 envelope (Env) trimer variant, derived from consensus clade C sequence (ConC).~Study vaccines will be admixed with Adjuplex adjuvant and administered intramuscularly (IM) via needle and syringe in two injection sites."
223889874|NCT05470400|BIOLOGICAL|Trimer 4571 (200 mcg)|"HIV-1 Trimer 4571 (Trimer 4571) is a synthetic soluble HIV-1 envelope product that consists of an HIV-1 envelope (Env) trimer variant, derived from clade A, strain BG505.~Study vaccines will be admixed with Adjuplex adjuvant and administered intramuscularly (IM) via needle and syringe in two injection sites."
223889875|NCT05470400|BIOLOGICAL|Trimer 4571 (100 mcg)|"HIV-1 Trimer 4571 (Trimer 4571) is a synthetic soluble HIV-1 envelope product that consists of an HIV-1 envelope (Env) trimer variant, derived from clade A, strain BG505.~Study vaccines will be admixed with Adjuplex adjuvant and administered intramuscularly (IM) via needle and syringe in two injection sites."
223889876|NCT04918758|DEVICE|Purastat Arm|"Generic name of device and principal intended use(s):~Still PuraStat from a CE mark perspective. PuraStat is an aqueous self-assembling peptide solution of 2.5% concentration RADA16~Indication for use:~PuraStat is indicated for haemostasis in the following situations encountered during surgery, when haemostasis by ligation or standard means is insufficient or impractical:~* Bleeding from small blood vessels and oozing from capillaries of the parenchyma of solid organs. Oozing from vascular anastomoses~* Bleeding from small blood vessels and oozing from capillaries of the GI tract following surgical procedures~* Reduction of delayed bleeding following gastrointestinal endoscopic submucosal dissection (ESD) procedures in the colon."
223889877|NCT04918758|DRUG|Standard Care Arm|Sucralfate enemas 2g twice daily for 8 weeks, this is standard care in patients with haemorrhagic radiation proctopathy in the short term
223889878|NCT04637152|DRUG|Sacubitril-Valsartan|Use of sacubitril/valsartan after suspension of ACE inhibitors or ARBs.
223889879|NCT00580515|BEHAVIORAL|Family Focused Group Therapy|6 Sessions of Family Focused Group Therapy (FFGT). The FFGT intervention will have assessment, focused therapy, consolidation, and termination phases. The first two sessions are assessment sessions and occur one week apart. There will be two or six focused intervention sessions depending on the predetermined length of therapy. The first focused intervention session is approximately two weeks after the last assessment session. Subsequent focused intervention sessions are expected to follow once every month. Finally, there will be two consolidation/termination sessions, which will occur one time each, approximately two months apart. The six session program is expected to extend over a period of 6 months and the 10 session program over 10 months.
223889880|NCT00580515|BEHAVIORAL|Family Focused Group Therapy|10 Sessions of Family Focused Group Therapy (FFGT). The FFGT intervention will have assessment, focused therapy, consolidation, and termination phases. The first two sessions are assessment sessions and occur one week apart. There will be two or six focused intervention sessions depending on the predetermined length of therapy. The first focused intervention session is approximately two weeks after the last assessment session. Subsequent focused intervention sessions are expected to follow once every month. Finally, there will be two consolidation/termination sessions, which will occur one time each, approximately two months apart. The six session program is expected to extend over a period of 6 months and the 10 session program over 10 months
223889881|NCT00580515|BEHAVIORAL|Standard of Care|Standard of Care Families assigned to the Usual Care Condition will receive standard psychosocial care which is based on the following patterns: Social work consultations are routinely provided to the cancer patients, but relatives are only seen during admissions or upon request.
223889882|NCT05123014|OTHER|relex smile|In OCT, firstly, the thickness of the adenoviral subepithelial infiltration in the cornea is calculated in microns, and extraction is performed accordingly with Small Incision Lenticule Extraction( SMILE )and fresh lenticule implanted stromal in the same volume.
223889883|NCT05976035|OTHER|Exercise|Structured exercise program under the supervision of a physiotherapist 3 days per week for 8 weeks
223889884|NCT05976035|OTHER|Supplement|Receiving supplement that are prescribed by a orthopedist every day for 8 weeks
223889885|NCT03138512|BIOLOGICAL|nivolumab|Specified dose on specified days
223889886|NCT03138512|BIOLOGICAL|ipilimumab|Specified dose on specified days
223889887|NCT03138512|DRUG|nivolumab placebo|Specified dose on specified days
223889888|NCT03138512|DRUG|ipilimumab placebo|Specified dose on specified days
223889889|NCT04597372|DRUG|Tamsulosin|Study drug will contain 0.4 mg of Tamsulosin. Subjects will be provided with 10 capsules to be taken daily.
223889890|NCT04597372|DRUG|Placebo|Placebo will be prepared by the IDS pharmacist (or contracted pharmacy) and encapsulated in identical appearing wraps. Subjects will be provided with 10 capsules to be taken daily.
223889891|NCT06400342|PROCEDURE|TAVR-explant|Surgical explantation of failed THV followed by surgical aortic valve replacement and any other cardiac surgeries deemed necessary.
223889892|NCT06400342|DEVICE|Redo-TAVR|Repeat transcatheter aortic valve implantation within a failed THV.
223889893|NCT06015542|DRUG|Elranatamab|Elranatamab will be administered as monotherapy for six cycles of 28 days. Elranatamab 76 mg will be administered QW with a 2-step-up priming dose regimen administered during the first week (12 mg D1 and 32 mg D4).
223889894|NCT06173258|DEVICE|Water exchange alone|During the insertion phase of water exchange colonoscopy, the air pump will be turned off, while the colon will be irrigated with warm-to-touch water using a flushing pump. The water exchange approach involves the simultaneous infusion of water to facilitate luminal expansion and suction of unclean water during insertion. Upon reaching the cecum, where most of the water is suctioned to collapse the cecal lumen, the air pump will be opened. Withdrawal from the cecum will begin in the left lateral position. Similar withdrawal techniques with adequate luminal distention and comprehensive examination behind the folds will be emphasized. Any position change away from the original left lateral position in any colon segment during the withdrawal phase will be recorded. Tandem examination of specific colon segments, including the right colon, either in the standard modality or retroflexion, is prohibited.
223889895|NCT06173258|DEVICE|Water exchange plus Artificial Intelligence (AI)|Similar water exchange technique as the active comparator will be employed during insertion. Similar withdrawal inspection techniques as the active comparator will be used. During withdrawal phase, commercially available AI system (CAD-EYE, Fujifilm, EU and Taiwan; Endo-AID, Olympus, EU and Taiwan) will be activated, providing a bounding box as output any time a lesion that is suspected to be a polyp is recognized by the AI device. False positive activation is defined as the identification by AI systems of an area during the withdrawal phase that is not deemed to be a colorectal lesion after re-examination by the colonoscopist. Real-time flagging of FP activation will be recorded by investigators and study staff.
223889896|NCT04815187|DRUG|Montelukast|Each subject will be given a drug diary to record when they took the drug and any symptoms that they are experiencing, and will bring this diary and any unused pills to their next clinic visit before receiving the next 30-day supply. This process will continue for the full 90 days of study involvement, with a final visit 3 months later.
223889897|NCT04815187|DRUG|Placebo|Each subject will be given a drug diary to record when they took the drug and any symptoms that they are experiencing, and will bring this diary and any unused pills to their next clinic visit before receiving the next 30-day supply. This process will continue for the full 90 days of study involvement, with a final visit 3 months later.
223889898|NCT05200247|DRUG|spesolimab|solution for infusion
223889899|NCT06757322|PROCEDURE|Singel Needle Double Cannula TMJ Arthrocentesis|Artocentesis describes the lavage of the TMJ by introducing a saline/ringer lactate solution through a needle inserted into the upper joint cavity. TMJ arthrocentesis was first introduced as a double needle entry method by Nitzan et al in 1991. The single needle technique was developed by Singh and Varghese and introduced in 2013. The single needle method is a more simplified modification of the first method.
223889900|NCT06757322|PROCEDURE|Double Needle TMJ Arthrocentesis|Artocentesis describes the lavage of the TMJ by introducing a saline/ringer lactate solution through a needle inserted into the upper joint cavity. TMJ arthrocentesis was first introduced as a double needle entry method by Nitzan et al in 1991.
223889901|NCT06461689|DRUG|177Lu-PSMA-617|All patients treated with 177Lu-PSMA had a post-therapy 68Ga-PSMA PET scan and a post-therapy 177Lu-PSMA-617 SPECT/CT scan. These scans are available in the CHRU PACS, and patients are informed that their data may be used for research purposes, via posters in the nuclear medicine department or via the welcome booklet,
223889902|NCT03634930|BEHAVIORAL|observation|Observation of growth, infant bodycomposition, 24h-drinkingvolume
223889903|NCT05323084|DIETARY_SUPPLEMENT|Dietary supplement|1 week of each intervention at bedtime with a 2-week washout period in between interventions
223889904|NCT05619744|DRUG|RO7616789|RO7616789 solution for infusion will be administered intravenously at a dose and per schedule as specified for the respective part.
223889905|NCT05619744|DRUG|Tocilizumab|Tocilizumab will be used as rescue therapy, in case of clinical presentation of cytokine release syndrome (CRS). Tocilizumab solution for infusion will be administered intravenously at 8 mg/kg for participants \>/= 30 kg or at 12 mg/kg for participants \< 30 kg.
223889906|NCT04056897|BIOLOGICAL|BCD-132, 125 mg|IV infusion every 24 weeks in combination with placebo tablet daily. The total duration of blinded therapy is 100 weeks (a total of 5 cycles of therapy BCD-132 in combination with a daily placebo)
223889907|NCT04056897|DRUG|Teriflunomide|14 mg teriflunomide tablet. Per os. Daily in combination with IV placebo. The total duration of blinded therapy is 100 weeks (a total of 5 cycles of placebo IV therapy in combination with daily administration of teriflunomide)
223889908|NCT04056897|DRUG|Placebo|intravenous infusion in combination with placebo tablet daily. The total duration of blinded therapy is 100 weeks
223889909|NCT04056897|BIOLOGICAL|BCD-132, 500 mg|IV infusion every 24 weeks in combination with placebo tablet daily. The total duration of blinded therapy is 100 weeks (a total of 5 cycles of therapy BCD-132 in combination with a daily placebo)
223889910|NCT06513559|DEVICE|Anatomic total shoulder replacement|Humeral head with a metal ball and the glenoid socket with a polyethylene glenoid component.
223889911|NCT06513559|DEVICE|Reverse total shoulder replacement|Polyethylene socket on the humeral side and the glenosphere going on the glenoid side.
223889912|NCT06161688|DRUG|Ensitrelvir|Those randomized to the experimental arm will receive Ensitrelvir, a protease inhibitor, taken orally for 5 days
223889913|NCT06161688|OTHER|Placebo|Matching placebo for Ensitrelvir
223889914|NCT03311503|BIOLOGICAL|autologous CD34+ cell transduced with G2SCID vector|single infusion of autologous CD34+ cells transduced with the self-inactivating (SIN) lentiviral vector G2SCID
223889915|NCT05780502|BEHAVIORAL|Passive Dynamic Brace|Patient receiving the Passive Dynamic Brace
223889916|NCT06261775|OTHER|Red meat-based meal|Participants were provided with food as part of a meal plan. The research team provided all foods and snacks for the intervention.
223889917|NCT06261775|OTHER|No meat diet|Participants were provided with food as part of a meal plan. The research team provided all foods and snacks for the intervention.
223889918|NCT06124521|BEHAVIORAL|ComBaT Glaucoma|ComBaT Glaucoma is a personalized counseling and education program about the participant's diagnosis and the importance of glaucoma follow-up care in maintaining vision.
223889919|NCT05092139|DEVICE|endovascular treatment|all enrolled patients must receive endovascular treatment
223889920|NCT04382404|DRUG|Sofosbuvir-Velpatasvir Drug Combination|One oral pill containing 400mg sofosbuvir and 100mg velpatasvir taken once daily for 12 weeks
223889921|NCT06420921|BEHAVIORAL|Speech in noise comprehension test|Speech in noise comprehension tests consisting of listening to a speech source and one or more competing sources (noise, speech or sound cues) simultaneously. The volunteers will have to repeat the speech source in order to assess intelligibility for each situation, as a function of the intensity ratio of the two sources (SNR).
223889922|NCT06420921|BEHAVIORAL|Objective tests of perception of ambient sound cues in noise|Tests of perception of the sound environment consisting of listening to a source of noise, sound cues and a competing source of speech simultaneously. The volunteers will have to identify sound cues in order to assess the ability to perceive the sound environment for each situation, depending on the intensity ratio of the different sources.
223889923|NCT06420921|BEHAVIORAL|Subjective tests of perception of ambient sound cues in noise|Tests of perception of the sound environment consisting of listening to a source of noise, sound cues and a competing source of speech simultaneously. Using a simple interface, the volunteers will have to identify the intensity ratio of the sources that they consider to be the best compromise between understanding speech and perceiving the sound environment.
223889924|NCT05874921|DRUG|Jelmyto (mitomycin) for pyelocalyceal solution|"The dose of Jelmyto to be instilled is 4 mg per mL via ureteral catheter or a nephrostomy tube, with total instillation volume based on volumetric measurements using pyelography, not to exceed 15 mL (60 mg of mitomycin).~Instill Jelmyto once weekly for six weeks. For patients with a complete response 3 months after Jelmyto initiation, Jelmyto instillations may be administered once a month for a maximum of 11 additional instillations."
223889925|NCT06251258|DIAGNOSTIC_TEST|Facial emotion recognition test with and without eye-tracking and Cognitive Emotion Regulation. Questionnaire (CERQ)|Facial emotion recognition test without eye-tracking (explicit test, without time limit) and facial emotion recognition test with eye tracking (implicit test, with observation of fixation points)
223889926|NCT05262296|PROCEDURE|Laparoscopic Surgeon|Laparoscopic Arm This cohort of participants will have their procedure completed by a human surgeon.
223889927|NCT05262296|PROCEDURE|Robotic Arm|This cohort of participants will have their procedure completed by the Versius Surgical Robotic System.
223889928|NCT03587363|DRUG|Erdafitinib|Participants will receive 6 mg (2\*3 mg tablet) erdafitinib as a single oral dose on Day 1. Participants in Cohort 4 may receive a lower dose if warranted by preliminary safety and PK data from Cohorts 2 and 3.
223889929|NCT06440317|DEVICE|Hemofiltration membranes (the oXiris membrane® and the HF1400® membrane)|The PRISMAFLEX® or PRISMAX® control unit (pre- and post-dilution with a prescribed treatment dose \> 25 ml/kg/h) with regional citrate anticoagulation and a substitution solution by PHOXILLUM will be used regardless of the type of membrane used (the oXiris membrane and the HF 1400 membrane), also as part of routine care provided in the ICU.
223889930|NCT06027814|BEHAVIORAL|Patient Navigation and mHealth (PN+mHealth)|Intervention consists of patient navigation with the mHealth adherence application facilitating telehealth visits, two-way chats, video-DOT, and delivery of financial incentives via smartphone.
223889931|NCT05102409|DRUG|Reproxalap Ophthalmic Solution (0.25%)|Reproxalap Ophthalmic Solution (0.25%) dosed once
223889932|NCT05102409|DRUG|Xiidra® (5% lifitegrast ophthalmic solution)|Xiidra® (5% lifitegrast ophthalmic solution) dosed once
223889933|NCT04951492|DRUG|Olaparib|Given PO
223889934|NCT05691738|OTHER|Exercise Group|The exercise group will be informed about diabetes and diabetes complications. A total of 16 sessions of 8 weeks, modified otago exercises will be applied individually by the research physiotherapist.Individuals will be allowed to walk at a moderate pace for at least 30 minutes 5 days a week (home program).
223889935|NCT05691738|OTHER|Control Group|The control group will be informed about diabetes and diabetes complications. Individuals will be allowed to walk at a moderate pace for at least 30 minutes 5 days a week (home program)
223889936|NCT04064086|OTHER|Comprehensive Pre-ESRD Patient Education (CPE)|Structured education session/s
223889937|NCT04064086|OTHER|Provision of the freely available resources for Kidney Disease Education|freely available resources
223889938|NCT05279898|DEVICE|EEG Monitoring|Perioperative monitoring, MMGA guided by EEG for intervention group
223889939|NCT05279898|DRUG|Ropivacaine|Intraoperative bilateral PIFB block with 20 mL of 0.2% Ropivicaine on either side of the sternum after anesthetic induction but before surgical incision (total of 40mL) PIFB on postoperative day 1 (provided they are extubated or getting ready to be extubated) to help with mobilization (for intervention group)
223889940|NCT05279898|DRUG|Ketamine|Intraoperative infusion
223889941|NCT05279898|DRUG|Remifentanil|Intraoperative infusion
223889942|NCT05279898|DRUG|Dexmedetomidine|Intraoperative infusion
223889943|NCT05279898|DRUG|Rocuronium|Intraoperative intermittent bolus
223889944|NCT05279898|DRUG|Propofol|Intraoperative infusion
223889945|NCT03885713|BIOLOGICAL|Infliximab or adalimumab or golimumab or vedolizumab or ustekinumab or tofacitinib|Infliximab (Infusion 5mg/kg milligram(s)/Kilogram-Intravenous use) per clinical practice or adalimumab (Subcutaneus 40 mg milligram(s)) per clinical practice or golimumab (subcutaneus 50 mg milligram(s)-subcutaneus) per clinical practice or vedolizumab (infusion 300 mg milligram(s)) per clinical practice or ustekinumab (subcutaneous 90 mg milligram(s)) per clinical practice or tofacitinib (oral 5mg bid)
223889946|NCT05989035|PROCEDURE|Abdominal subcutaneous adipose tissue biopsy|"Fatty tissue biopsy- Participant will be placed in a supine position with arms placed at side while abdominal skin is marked with a skin marker and cleansed with chlorhexidine. Afterwards, the abdominal fatty tissue biopsy will be performed.~Collect fatty tissue from young and older individuals and gather data on the effect of methionine aminopeptidase protein (MetAP2) inhibition on that fatty tissue in the laboratory."
223889947|NCT05502861|BEHAVIORAL|Generalist + Specialist palliative care|Clinicians are alerted in the EHR to make an active choice whether to provide generalist palliative care themselves, consult PC specialist, or to defer PC at that time.
223889948|NCT05502861|BEHAVIORAL|Pre-Intervention phase|Patients meeting eligibility criteria will be enrolled for study data collection but there will be no attempt to influence delivery of care.
223889949|NCT05687916|DRUG|Placebo|TAK-861 placebo matching tablets.
224078758|NCT01977885|BEHAVIORAL|High Protein Diet|All participants will be individually counseled by an RD for \~ 4 sessions (30 to 60 minutes)to meet weight loss goals. During the duration of the study, participants will be required to attend a 30 to 60 minute group educational/motivational meeting weekly (first 1 to 2 months) and then biweekly (for the remainder of the study). Diet recommendations will include high quality proteins with an emphasis on lean meats with protein being targeted for every meal and snack. Regarding beef intake specifically, the prescribed diet will include a minimum of one serving of beef per day, which is approximately 3 to 3.5 ounces or \~100 grams. This amount of lean cooked beef provides an average of \~25-30 grams of protein per day (www.beefnutrition.org/leanbeef.aspx). This combined with reducing energy from carbohydrates and fat from other sources will create an overall energy deficit of 500 kcal/day. This diet will also include 5 servings/day of vegetables and 2-3 servings/day of fruit
224078759|NCT01977885|BEHAVIORAL|Exercise|Participants will be prescribed a supervised exercise program with required attendance of 3 nonconsecutive days per week (75 minutes each session). A program that combines flexibility and balance activities, weight bearing endurance exercise (walking) and resistance training to preserve lean mass will be prescribed. With specific regard to strength training, 50% of the resistance work will involve primary muscle groups of the lower body with the main focus being the gluteal and quadriceps groups (squats, lunges, etc.). The remaining 50% of work will dedicate 25% to the core stabilizers with the final 25% being the upper body. Transitions between segments of training will be used for recovery and social support enhancement. Note that all aspects of the exercise intervention will be progressive in intensity (i.e., starting at lower end of intensity or \~50% of maximal capacity), and duration (i.e., from 15 minutes to 35 minutes of exercise and adding a few minutes each session).
224078760|NCT05458336|DEVICE|Nasal lavages with Tonimer Panthexyl®|At the moment of diagnosis, patients were asked to fill out an ad hoc questionnaire to subjectively evaluate symptoms and comorbidities at the moment of diagnosis and of negativization. Subjects performed a daily nasal swab. When the subjects tested negative for the first time, they had to complete the questionnaire once again. Patients were given nasal washes (Tonimer Panthexyl®) to be performed three times a day, and in any case after nasal swab.
224078761|NCT02813122|DEVICE|x-ray|x-ray for the detection of leaks and bleeding
224078762|NCT02761083|DEVICE|Novosyn® Quick|Eye surgery
224078763|NCT02761083|DEVICE|Vicryl® Rapid|Eye surgery
224078764|NCT00570648|DRUG|sodium hyaluronate|1% sodium hyaluronate applied at the end of corneal transplant surgery. The amount will be determined on how much is necessary to cover the ocular surface.
224078765|NCT05136625|DRUG|Sphenopalatine ganglion block|A cotton swab soaked in levobupivacaine 7,5% in inserted into the nose to block sphenopalatine ganglion, with the classic technique previously described
224078766|NCT05136625|DRUG|Standard Preparation|Troncular scalp blockade. Local site infiltration
224078767|NCT03595696|OTHER|Core Muscle Strength Training|Targeted weekly workouts consisting of low-impact aerobic exercises and resistance exercises designed to address muscle imbalance common in women who exhibit DRA and to prompt automatic core engagement while performing compound, multi-joint movements.
224078768|NCT03346408|BEHAVIORAL|Questionnaire|patient (self-questionnaire) and algologist physician (questionnaire)
224078769|NCT01137240|PROCEDURE|gastric emptying scan|"subjects will eat a solid meal (scrambled eggs, etc) or drink liquid (water or juice) mixed with approximately 0.5 millicuries of radioactive material. A scanner/external gamma camera will be placed over the subject's stomach at 15 minute intervals for a duration of 90 minutes (monitoring the amount of radioactivity in the stomach). As the radioactively-labeled food empties from the stomach, the amount of radioactivity in the stomach decreases. The rate at which the radioactivity leaves the stomach reflects the rate at which food is emptying from the stomach. The radioisotope has a half life of approximately. 6 hours and is totally eliminated from the body within 24 hours.~In subjects with gastroparesis, the food and the attached radioactive material remain in the stomach longer than normal (usually hours) before emptying into the small intestine. As a result, the scanner continues to show radioactivity in the area of the stomach for hours after the test meal."
224078770|NCT02553694|OTHER|Enhanced education|Investigator created video to help educate subject before the in-laboratory split night polysomnogram. The subject will watch the short video immediately prior to the initiation of the in-laboratory polysomnogram.
224078771|NCT02553694|OTHER|Usual education|Usual education by American Academy of Sleep Medicine (AASM)- created educational pamphlets
224078772|NCT02553694|OTHER|Usual follow up|MD will follow up by phone after the in-laboratory split night polysomnogram
223889950|NCT05687916|DRUG|TAK-861 2 mg|TAK-861 2 mg tablets.
223889951|NCT05687916|DRUG|TAK-861 2 mg and 5 mg|TAK-861 2 mg and 5 mg tablets.
223889952|NCT05629182|OTHER|No intervention applied - Observational study only|Observational study only. Video footage is used to review all 64 matches in the football tournament.
223889953|NCT06200259|RADIATION|Spot Delete planning for proton therapy|The method of adjusting the placement of proton spots or targets that are placed by the treatment planning system during pencil beam scanning for proton therapy
223889954|NCT06200259|RADIATION|Traditional proton treatment planning system|In the control arm, the proton spots placed by the treatment planning system are not modified.
223889955|NCT01781338|OTHER|Induction therapy|The intervention is dependent on the respective sub-protocol and can include either endocrine therapy, neoadjuvant chemotherapy or targeted therapy.
223889956|NCT06298136|BEHAVIORAL|mindfulness-based intervention|Audio exercises as homework assignment will be included. Four instructor-led online real time sessions are provided
223889957|NCT06298136|BEHAVIORAL|child behavior management|worksheet will be provided to guide parents and children in behavior change. Four instructor-led online real time sessions are provided.
223889958|NCT03890263|BEHAVIORAL|Chronic Pain Self-Management Support|"Family physicians and nurse practitioners will participate in an academic detailing session with a pharmacist that focuses on safe, evidence-based opioid deprescribing. The pharmacist will provide pre-visit recommendations for each visit with a person on high doses of opioids. The pharmacist and healthcare providers will develop a patient centered, opioid taper schedule, with follow-up at 2 to 4 week intervals to assess for efficacy and safety.~The self-management intervention will be Chronic Pain Self-management Support with Pain Science Education and Exercise (COMMENCE), which consists of 2 visits per week over 6 weeks. One visit per week is 1.5 hours in a group format. with education about self-management and pain science as well as cognitive behavioural principles. The 2nd visit each week is 30 minutes in a one-to-one format and is individually tailored to support implementation of self-management plans and development of an exercise program."
223889959|NCT04614909|DRUG|Pamiparib|60mg administered orally BID for 4 days prior to surgical resection
223889960|NCT04614909|DRUG|Olaparib|200mg administered orally BID for 4 days prior to surgical resection
223889961|NCT04614909|RADIATION|Radiation therapy|Patients in Phase 2 will receive 6-7 weeks of radiation therapy per standard of care
223889962|NCT04614909|DRUG|Temozolomide|Arm A and Arm B participants after RT is completed, will receive pamiparib in combination with TMZ (newly diagnosed participants). Arm C participants will receive olaparib with TMZ.
223889963|NCT05830929|PROCEDURE|Ovarian tissue freezing and subsequent auto-transplantation after thawing|Removal of the ovarian tissue will be retrieved via laparoscopic surgery under general anesthesia. The ovarian cortical tissue obtained will be transferred on ice to the laboratory for cryopreservation. After medical treatment, if the patient would like to start a family but has experienced premature ovarian failure, she will have ovarian tissue auto-transplantation after thawing.
223889964|NCT05005442|BIOLOGICAL|Pembrolizumab/vibostolimab coformuation|Pembrolizumab 200 mg + vibostolimab 200 mg/20 mL vial IV infusion Q3W up to approximately 2 years.
223889965|NCT03332017|DRUG|Zanubrutinib|Oral administration as a capsule
223889966|NCT03332017|DRUG|Obinutuzumab|Intravenous administration
223889967|NCT05391906|OTHER|Diffusion-weighted magnetic resonance imaging|Diffusion-weighted magnetic resonance imaging
223889968|NCT01261312|DRUG|Guadecitabine|Subcutaneous injection
223889969|NCT06191484|BEHAVIORAL|WELL Behavioral Probe|Participant record the timing and regularity of sleep, meals, and social activity twice daily, for 3 months, using a digital diary. Participants also receive weekly motivational health coaching.
223889970|NCT05253612|DIAGNOSTIC_TEST|Analog testing conducted by a trained test leader using, ISPOCD test battery|Cognitive function will be measured by using the International Study Group of Postoperative Cognitive Dysfunction (ISPOCD) analog test battery v
223889971|NCT05253612|DIAGNOSTIC_TEST|self-administered Mindmore digital cognitive screening battery|Cognitive function will be measured by using the Mindmores digital test battery
223889972|NCT05758181|OTHER|Apical Undermining|The skin at the tip of the wound will be freed to reduce tension.
223889973|NCT06380582|OTHER|Temperature and Airflow combination|23C 40%Relative Humidity (RH) low airflow, 23C 40%RH high airflow, 35C 40%RH low airflow, 35C 40% high airflow
223889974|NCT04187612|DEVICE|Bioelectrical Impedance Analysis (BIA)|BIA will be used to determine total body water
223889975|NCT05134636|OTHER|Text triage|The e-triage will consist of 16 questions, modified from the validated NCI Pro-CTCAETM, which will be sent to patients via WaytoHealth©'s two-way texting system 96 hours prior to their scheduled immunotherapy infusion. Questions will pertain to common or emergent immune related adverse events as defined by the NCCN guidelines and two senior disease experts. Patients will be prompted via text to measure the presence and severity of symptoms over the week prior. A final question will be included to capture any additional symptoms patients wish to disclose.
223889976|NCT04119687|BIOLOGICAL|FX201|FX201, humantakinogene hadenovec, is a novel interleukin-1 receptor antagonist (IL-1Ra) gene therapy for IA administration that is being developed for the treatment of patients with OAK.
223889977|NCT05193786|PROCEDURE|Different level of PEEP|Different level of PEEP (low versus high) was applied in noninvasive ventilation.
223889978|NCT05650723|DRUG|Zanubrutinib Pill|320 mg once per day by mouth
223889979|NCT05650723|DRUG|Venetoclax Pill|400 mg once per day by mouth following the standard ramp-up schedule (20mg daily PO week 1, 50mg daily PO week 2, 100mg daily PO week 3, 200mg daily PO week 4, followed by 400mg PO daily week 5)
223889980|NCT05650723|DRUG|Obinutuzumab Injection|1000 mg IV given every 28 days
223889981|NCT05155007|DRUG|Rilematovir|Rilematovir will be administered orally as per assigned treatment sequence.
223889982|NCT05155007|DRUG|Ciclosporin|Ciclosporin will be administered orally as per assigned treatment sequence.
223889983|NCT01701843|DRUG|Cromoglicate|Twice daily topical treatment for 14 days
223889984|NCT01701843|DRUG|Placebo|Twice daily topical treatment for 14 days
223889985|NCT05077735|RADIATION|Hypofractionated Radiation Therapy|Undergo hypofractionated radiation therapy
223889986|NCT05077735|OTHER|Questionnaire Administration|Ancillary studies
223889987|NCT05077735|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223889988|NCT05077735|PROCEDURE|Positron Emission Tomography and Computed Tomography Scan|Undergo PET-CT scan
224078773|NCT02553694|OTHER|Enhanced follow up|Sleep center non-MD staff member will follow up by phone after the in-laboratory split night polysomnogram
224078774|NCT00122330|DRUG|eculizumab|
224078775|NCT01931761|DRUG|[C14] selumetinib (oral)|Single oral administration \[C14\] 75mg
224078776|NCT01324284|DRUG|Lubiprostone|Lubiprostone is a chloride channel activator approved by the Food and Drug Administration for the treatment of chronic constipation. A randomized, double-blind, parallel-group, placebo-controlled study evaluating the effect of lubiprostone on gastric function showed slowed gastric emptying and increased small bowel and colonic transit time. Peak plasma concentration was shown to be around 1.14 hours, with a majority of the drug excreted in the urine within 48 hours.
224078777|NCT02496949|DRUG|Icaritin|600mg,800mg two doses, Bid, continuous dosing for 56 days, to assess the safety,tolerance,pharmacokinetics and efficacy of icaritin
224078778|NCT04428047|DRUG|bintrafusp alfa|bintrafusp alfa will be administered by intravenous infusion over 60 minutes at a dose of 1200 mg on Day1 and Day15
224078779|NCT03932071|DRUG|Zoledronic Acid|
224078780|NCT06173999|DRUG|SHR2554/CHOP|SHR2554 with CHOP
224078781|NCT06173999|DRUG|SHR2554/CHOEP|SHR2554 with CHOEP
224078782|NCT05973136|OTHER|Telerehabilitation program based on cardiorespiratory principles|The intervention consists of a hybrid program. The participant will receive rehabilitation sessions in presence (aerobic component of the intervention based on maximal oxygen uptake measured before intervention by means on a ergospirometric test) and at home via a telerehabilitation platform. The length of the intervention is 12 weeks. For the in-presence sessions, they are going to be 75 minutes, 2x/week. For the at-distance sessions, they are going to be 45 minutes, 1x/week in groups of 3 to 4 participants. The intervention will consist of a warm-up, endurance, postural, and strengthening exercises, cool down and respiratory exercises. An exercise book with final recommendations is provided to the participants at the end of the intervention.
224078783|NCT00427362|DRUG|Adalimumab|
224078784|NCT00267553|DRUG|Atamestane|
224078785|NCT00267553|DRUG|toremifene|
224078786|NCT00267553|DRUG|letrozole|
224078787|NCT02926326|DRUG|BCT197|A single dose of BCT197
224078788|NCT02926326|DRUG|Azithromycin|3 daily doses of Azithromycin
224078789|NCT00716976|DRUG|sodium thiosulfate|Given IV
224078790|NCT00716976|PROCEDURE|examination|Patients undergo audiological assessments periodically
224078791|NCT00122135|OTHER|Values Inventory (VI)|The Values Inventory was given to patients for self-administration while they were awaiting their clinic appointment. They were instructed to bring it to their physician's attention right at the beginning of their clinic visit.
224078792|NCT06547476|DRUG|Tucidinostat (chidamide), PD-1 inhibitor (tislelizumab), anlotinib|Tucidinostat (chidamide)，30mg, po., biw PD-1 inhibitor (tislelizumab), 200mg, ivgtt. d1, q3w anlotinib, 12mg, po., d1-14, q3w
224078793|NCT01944085|DRUG|Acetaminophen|Syrup
224078794|NCT01944085|DRUG|Ibuprofen|Syrup
224078795|NCT01944085|OTHER|Vitamin C|Syrup
224078796|NCT01846455|DRUG|2.0mg Buprenorphine/0.5mg Naloxone|Each participant received a single sublingual dose of Suboxone® on Day 1 following a fast of at least 8 hours prior to dosing and 2 hours after dosing.
224078797|NCT01846455|DRUG|Promethazine|Each participant received a 25-mg or 50-mg promethazine oral dose 30 minutes before Suboxone® administration and then 25-mg promethazine orally or by rectal suppositories every 4 hours as needed for nausea and vomiting during the first 48 hours after Suboxone® administration.
224078798|NCT04544722|BEHAVIORAL|Jianfei Kangfu Cao|The original treatment and Jianfei Kangfu Cao, once a day, 30 minutes each time.
224078799|NCT04544722|BEHAVIORAL|lung rehabilitation training|The original treatment and the lung rehabilitation training, once a day, 30 minutes each time.
224078800|NCT00282126|DIETARY_SUPPLEMENT|Potassium citrate|kcitrate
224078801|NCT05765903|OTHER|Standard of Care|"* Diagnosis education.~* Follow-appointment scheduling assistance.~* Offer resources in the community.~* Offer weekly follow-up calls for one month.~* Social Determinants of Health (SDoH) assessment."
224078802|NCT05765903|OTHER|Enhanced Care|"* Additional educational training using computer tablet devices, such as iPads.~* Focus on readmission risk.~* Set-up Home Health Services (HHS), Mobile Integrated Healthcare (MIH) or Resources, Education and Access to Community Health (REACH)."
224078803|NCT03414957|DIAGNOSTIC_TEST|Hormonal and biochemical blood tests and ultrasound scanning|Subjects undergo clinical assessment, blood tests and a pelvic ultrasound scan, to determine if they have either PCOS or Metabolic Syndrome or both
224078804|NCT03777449|RADIATION|CBCT|Patients will be taken a CBCT as a diagnostic tool to monitor peri-implant bone loss. This is a tool used on the daily basis for the evaluation of peri-implant bone loss. Patient will not be exposed to further radiation but the regular one.
224078805|NCT02608632|DEVICE|Renal denervation guided by HFS|
224078806|NCT02608632|DEVICE|Renal denervation as standard procedure|
224078807|NCT01238003|OTHER|Interpretation of blood test results|Interpretation of blood test results
223889989|NCT05443737|BEHAVIORAL|Multi-component oncofertility care intervention|The multi-component oncofertility care intervention includes: (1) an adaptive and smart default electronic health record-based oncofertility needs screen and referral pathway, (2) telehealth oncofertility counseling as indicated, and (3) telehealth oncofertility financial navigation as indicated.
223889990|NCT04977024|BIOLOGICAL|COVID-19 Vaccine|Receive SOC mRNA SARS-CoV-2 vaccine IM
223889991|NCT04977024|OTHER|Diagnostic Laboratory Biomarker Analysis|Correlative studies
223889992|NCT04977024|BIOLOGICAL|Synthetic MVA-based SARS-CoV-2 Vaccine GEO-CM04S1|Given IM
223889993|NCT06082921|BEHAVIORAL|Beef Diet Intervention|Participants will eat prepared meals including beef for 6 days. Participants will eat a habitual diet for 6 days prior to intervention.
223889994|NCT06082921|BEHAVIORAL|Impossible Beef Diet Intervention|Participants will eat prepared meals including impossible beef for one portion 6 days. Participants will eat a habitual diet for 6 days prior to intervention.
223889995|NCT06582966|DRUG|Doxycyclin|Open label, single-arm, pilot study of 60 cisgender women taking HIV PrEP in Kisumu, Kenya will be given doxycycline 200 mg orally once weekly with clinical follow-up including quarterly STI testing and treatment for six months.
223889996|NCT05618002|DRUG|Lemborexant|For insomnia treatment, each patient ingests Lemborexant or Zopiclone or Clonidine on alternate nights. Each patient uses a special validated sleep diary to collect data.
223889997|NCT04528004|DRUG|Nicotinamide riboside|Nicotinamide riboside 250mg capsules
223889998|NCT04528004|OTHER|Placebo|Matching placebo 250mg capsules
223889999|NCT06417892|DRUG|PD-1inhibitor|PD-1 antibody was selected according to first-line drug use
223890000|NCT06417892|DRUG|Fruquintinib|a small molecular anti-tumor angiogensis drug
223890001|NCT06417892|DRUG|albumin paclitaxel|a kind of cytotoxic chemotherapy drug
223890002|NCT06156280|DRUG|TQH2929 injection|TQH2929 injection is a humanized monoclonal antibody that interfering with the signal cascade.
223890003|NCT06156280|DRUG|Placebo injection|Placebo comparator
223890004|NCT06090227|DRUG|Metformin + Standard of Care|Administration of daily oral extended-release Metformin 500 mg tablets with standard of care for 6 months.
223890005|NCT06090227|OTHER|Placebo + Standard of Care|Administration of daily placebo tablets with standard of care for 6 months.
223890006|NCT04757194|DIAGNOSTIC_TEST|openTriage - Alitis algorithm|A machine learning algorithm (Gradient boosting) applied to structured data collected in the Alitis Clinical Decision Support system, patient demographics, and free-text notes.
223890007|NCT05349487|DEVICE|SpeakFree HME Hands Free Valve|A voice prosthesis, SpeakFree HME Hands Free Valve, achieved with creation of a tracheoesophageal puncture will be placed over the stoma for 1 month.
223890008|NCT05349487|OTHER|Digital Occlusion|Using participant's own fingers, they will be putting their fingers over the stoma.
223890009|NCT05349487|DEVICE|Digital Depression HME|A digital handheld press-down HME will be placed over stoma.
223890010|NCT05324501|DRUG|MTX110|Soluble panobinostat
223890011|NCT05324501|DEVICE|Programmable pump and catheter system|To allow Convection-Enhanced Delivery (CED)
223890012|NCT05479617|OTHER|Deep learning model|Use of deep learning model to predict individual patients disease course
223890013|NCT06581497|DRUG|ICIs|ICIs mainly refer to PD-1 drug therapy, including pembrolizumab, camrizumab, toripalimab, tislelizumab, and sintilimab. The dosage and duration of ICIs comply with the manufacturer's guidelines.
223890014|NCT06581497|PROCEDURE|ICIs+MWA|ICIs mainly refer to PD-1 drug therapy, including pembrolizumab, camrizumab, toripalimab, tislelizumab, and sintilimab. The dosage and duration of ICIs comply with the manufacturer's guidelines. All patients, except for those enrolled in ICIs, should also undergo MWA treatment.
223890015|NCT02685020|BIOLOGICAL|Ad26.Mos.HIV|Recombinant replication-deficient Ad26 vectored vaccine and consists of 3 Ad26 vectors, one containing a mosaic insert of envelope (Env) sequence, and 2 vectors containing mosaic inserts of Gag and Pol sequences (Ad26.Mos.1.Env + Ad26.Mos1.Gag-Pol + Ad26.Mos2.Gag-Pol). Total dose is 5\*10\^10 viral particle per 0.5 milliliter (mL) injection administered intramuscularly.
223890016|NCT02685020|BIOLOGICAL|Clade C gp140|The Clade C gp140 vaccine containing 250 mcg of total protein, mixed with aluminum phosphate adjuvant, per 0.5 mL injection administered intramuscularly.
223890017|NCT02685020|DRUG|Placebo|Normal saline, 0.5 mL injection administered intramuscularly.
223890018|NCT03781141|PROCEDURE|Wound closure|Comparison of two wound closures
223890019|NCT05816473|OTHER|LLM|Use of a Large Language Model (LLM) chatbot interface to Interact with the Machine Learning Algorithm and interpretability dashboard.
223890020|NCT04959487|OTHER|Food support|1\. Diabetes-tailored food support. Project Open Hand will provide intervention participants six months of supplemental food support meeting on average 75% of their daily energy requirements. Food support will consist of a mix of meals tailored for T2DM, and T2DM-healthy groceries, consistent with American Diabetes Association (ADA) guidelines for diabetes healthy diets under the responsibility of a registered dietitian.
223890021|NCT04959487|OTHER|Nutritional Counseling and education|2\. Nutritional counseling and education: The registered dietitian will provide individual nutritional counseling two times (at baseline and month 5-6) during the intervention. In addition, group-based DM nutrition education will be conducted over four 1-hour-long sessions. The nutrition education will be conducted by a POH dietitian, and the curriculum will be consistent with published diabetes self- management education principles, utilizing effective strategies in lower wealth, lower literacy populations.
223890022|NCT05165108|DEVICE|Vagal Nerve Stimulator|A handheld device which consists of a battery powered portable stimulator with a digital control user interface that controls signal amplitude and two steel contact electrodes will deliver the nVNS electrical stimulation to the cervical Vagus nerve. The device has been approved by the U.S. Food and Drug Administration (FDA) for non-invasive Vagus nerve stimulator therapy for adjunctive use for the prevention and treatment of migraine and cluster headaches in adult patients.
223890023|NCT05425992|OTHER|Interview|Patient/parent dyads expressing interest will be interviewed by a bilingual Spanish certified provider via televideo with as needed interpreter support. Interviews will be audio recorded for review and translation purposes and then will be destroyed. Interview format will be supportive and information seeking only with reassurance that purpose is for care improvement and that all answers will be evaluated without association to patient name. Interviews will then be translated and reviewed by the PI for themes regarding perceived clinic successes and perceived clinic barriers in communication or care.
224078808|NCT06479980|BEHAVIORAL|Single Session Narrative Therapy|Single-session narrative psychotherapy intervention is an evidence-based strategy on a stepped care continuum that can assist patients in accessing care when they most need it and can lead to the most effective utilization of scarce resources. It offers a transdiagnostic, strengths, solution-oriented, and non-pathologizing intervention to address patients' behavioral health needs.
224078809|NCT04397159|BEHAVIORAL|Combination Exercise|Flywheel Resistance Plus Aerobic Exercise
224078810|NCT05663151|BEHAVIORAL|Prolonged Exposure Therapy for Posttraumatic Stress Disorder|Participation will occur throughout 17 weeks over 15 separate visits during which 10, 60-minute sessions of PE will take place. Session 1 of PE will focus on psychoeducation. Session 2 of PE will involve a continuation of psychoeducation and rationale for exposure as well as the collaborative construction of the in vivo exposure hierarchy. After session 2, participants will begin homework where they are instructed to confront situations on their hierarchy. Starting in session 3 of PE, participants will begin imaginal exposures to their worst trauma memory. This involves the participant recounting and visualizing the trauma memory aloud with the clinician in the room for 30-40 minutes. The session will end with 15-20 minutes of processing the imaginal exposure. Participants will continue in-session imaginal exposures until the end of treatment. Throughout the treatment, participants will listen to a recording of their imaginal exposure and engage in in vivo exposures daily.
224078811|NCT05552963|DEVICE|Multi-Channel Irreversible Electroporation (IRE) Generator|The multi-channel IRE Generator is intended for use during cardiac Pulsed Field Ablation (PFA) therapy. This device is used in conjunction with a compatible ablation catheter to create a closed electrical circuit capable of delivering pulsed electrical field energy.
224078812|NCT05552963|DEVICE|Multi-Channel Circular IRE Catheter|The multi-channel circular IRE Catheter is indicated for use in catheter-based cardiac electrophysiological mapping (stimulating and recording) and when used with an IRE Generator, for cardiac ablation.
224078813|NCT00975156|OTHER|Physical Therapy|Conventional physical therapy
224078814|NCT00975156|DEVICE|Lokomat|Robotic-assisted walking device
224078815|NCT00305578|DRUG|Memantine|Memantine will be given orally. Subjects will be started at a dose of 5 mg for the first week and then increased by 5 mg every week up to a maximum of 20 mg depending on response and tolerance and will be kept at that level for the rest of the study. This is an 8 week study.
223890024|NCT05452304|BIOLOGICAL|AZD7798|Subjects will receive AZD7798 as a single ascending dose or as a repeat dose.
223890025|NCT05452304|BIOLOGICAL|Placebo|Subjects will receive placebo matching the AZD7798 dose as a single ascending dose or as a repeat dose.
223890026|NCT04646460|BEHAVIORAL|Observed Success|"The demonstrator in video gets a placebo treatment, Levoderm analgesic cream, which will be shown to be effective at relieving pain."
223890027|NCT04646460|BEHAVIORAL|Observed Failure|The demonstrator in the video gets the same placebo treatment, but shows little to no effectiveness from the placebo for relieving pain.
223890028|NCT04646460|BEHAVIORAL|Experienced Success|The participant will receive reduced stimulus intensities after the placebo cream treatment to reinforce the effectiveness of the cream.
223890029|NCT04646460|BEHAVIORAL|Experienced Failure|The participant will not receive reduced stimulus intensities after the placebo treatment, so the cream is not reinforced as effective.
223890030|NCT06582160|OTHER|Risk-Based Pre-conception Screening|A long form questionnaire screening questionnaire administered via tablet in health clinic waiting room. Offered to participants when checking-in for appointment.
223890031|NCT06582160|OTHER|Patient-centered Pre-conception Screening|A short form, 2 question screening administered via tablet in health clinic waiting room. Offered to participants when checking-in for appointment.
223890032|NCT05938166|DEVICE|oral care augmented reality (AR)|Augmented reality (AR) is an extension of perceptible reality, whereby additional information, such as texts or virtual objects, can be displayed in the user's field of vision.The oral care augmented reality (AR) simulation training can train foreign care workers by switching languages (Indonesian) and therefore reduce language-related learning barriers.
223890033|NCT05938166|OTHER|video-based oral hygiene education course|50-minute video-based oral hygiene education course
223890034|NCT06582446|DRUG|Androgen Deprivation Therapy (ADT) - Goserelin|"The patients under ADT and the patients who will receive the ADT during the study will be included in the trial.~* ADT will be applied for 24 months in total~* ADT must be given concurrently and adjuvant"
223890035|NCT06582446|RADIATION|High-Dose-Rate Interstitial Brachytherapy (HDR BRT)|HDR BRT Procedure will be performed using transperineal catheter implantation under transrectal US-guidance performed under anesthesia, spinal or general with patient in high lithotomy position.)
223890036|NCT06582446|RADIATION|radiotherapy|EBRT prostate + elective pelvis (Ultra-hypofractionated): 25 Gy in 5 Gy per fraction
223890037|NCT06789718|DIETARY_SUPPLEMENT|GABA Probiotic Lactiplantibacillus plantarum Lp815 (5 Billion cfu/dose)|75 participants will be randomized into the study product group.
223890038|NCT06789718|OTHER|Placebo|75 participants will be randomized into the placebo group.
223890039|NCT06789718|DIAGNOSTIC_TEST|Optional Sub-Study: Neurotransmitter Urine Test|20 participants who opt-in to the sub-study will provide urine tests during baseline, day 2, day 4, day 7, day 14, day 28, and day 42 while simultaneously participating in the main-study.
223890040|NCT06790030|BEHAVIORAL|CBT-T|cognitive behavioral therapy-ten :
223890041|NCT06238531|DRUG|Gusacitinib|An orally active dual SYK/JAK kinase inhibitor
223890042|NCT06407284|OTHER|Produce Prescription Group|Participants will receive 16 produce bags, each containing approximately 50 servings of F\&V. The produce bags will be assembled by Brighter Bites at school sites using donated produce and delivered to houses using DoorDash. F\&V bags will be distributed to families every 2 weeks for 16 distributions (over approximately 32 weeks). Participants will also receive nutrition education, including MyPlate.gov's Start Simple App for adolescents, and a Virtual Culinary Medicine Program for parents; these nutrition education programs are theory-driven, tailored to diverse populations, and proven to support behavior change.
223890043|NCT06407284|OTHER|Control Group|Participants in this group will be selected from de-identified Electronic Health Record (EHR) provided by Legacy Community Health with a 1-to-1 match to the intervention group participant's demographic characteristics and Medicaid eligibility.
223890044|NCT05951166|DEVICE|Gradient Denervation System|Pulmonary artery denervation (PADN) procedure
223890045|NCT06311253|OTHER|Emoform Glic Toothpaste|Daily use of Emoform Glic toothpaste twice a day during home oral hygiene
223890046|NCT06311253|OTHER|Emoform Glic Mouthwash|Daily use of Emoform Glic mouthwash twice a day during home oral hygiene
223890047|NCT04665310|DRUG|Envarsus XR|tacrolimus, extended-release tablets, a calcineurin inhibitor
223890048|NCT02531126|DRUG|RPC1063|
223890049|NCT06397976|DEVICE|ANTERION investigational|Measurements from the investigational device ANTERION with software version 1.5 are to be compared against measurements from the ANTERION with software version 1.2.4 (cleared version)
223890050|NCT05354024|BIOLOGICAL|NDV-HXP-S 10μg|NDV-HXP-S 10μg/0.5mL intramuscular (deltoid), 1 dose (booster)
223890051|NCT05354024|BIOLOGICAL|BNT162b2 30μg|Vaccine against COVID-19 BNT162b2 30μg/0.3mL intramuscular (deltoid), 1 dose (booster)
223890052|NCT02743546|DRUG|Duvortuxizumab|Duvortuxizumab will be administered at starting dose of 15 nanogram per kilogram (ng/kg) as an intravenous (IV) infusion during Part 1 (Dose Optimization) and at RP2D level determined in Part 1 during Part 2 (Dose Expansion). Participants will receive duvortuxizumab either with or without a priming dose. Participants who receive a priming dose will have infusions on Days 1, 8, and 22 of an initial 35-day cycle and then on Days 1 and 15 of 28-day cycles thereafter. Participants who do not receive a priming dose will have infusions on Days 1 and 15 of 28-day cycles.
223890053|NCT02743546|DRUG|Ibrutinib|Ibrutinib will be administered at 560 milligram per day (mg/day) orally once daily during Part 1 (Dose Optimization) and at a dose of 420 mg/day (for participants with CLL) or 560 mg/day (for participants with DLBCL, FL, or MCL) during Part 2 (Dose Expansion). In Part 1, ibrutinib will be initiated on Day 1 of the initial treatment cycle. In Part 2, ibrutinib will be initiated on Day -7 prior to the initial treatment cycle.
223890054|NCT04829604|DRUG|ARX788|The active pharmaceutical ingredient in ARX788 is an antibody drug conjugate (ADC) consisting of a humanized anti-HER2 monoclonal antibody (mAb) (IgG1κ) covalently conjugated to two microtubule-disrupting payloads AS269
223890055|NCT05440734|DRUG|Melatonin|2 Mg Oral Tablet, slow release
223890056|NCT05440734|DRUG|Placebo|placebo pill identical to the treatment pill
223890057|NCT04080180|BEHAVIORAL|Contingency Management|Contingency management (CM) is a behavioral method that employs external rewards for target behavior. For this study, participants will receive gift cards for adhering to Medication-Assisted Treatment (attending physician visits and adhering to buprenorphine-naloxone as determined by urine toxicology panel) during their first four visits while randomized to this condition. Participants will draw a gift card from a fishbowl each visit they are adherent. Gift cards range from $25-$100.
223890058|NCT04080180|BEHAVIORAL|Brief Motivational Interviewing + Substance Free Activities + Mindfulness|Brief Motivational Interviewing + Substance Free Activities + Mindfulness (BSM) is an intervention that uses Motivational Interviewing and Behavioral Economics strategies to increase the salience of delayed rewards by eliciting personal goals, developing opioid-free activities, and engaging in reward bundling and episodic future thinking. Participants will be offered a menu of substance free activities that has been developed in pilot work. Activities will be discussed, and participants will be asked to engage in selected activities as homework. Engagement in substance free activities will be assessed at each subsequent visit. Mindfulness components will also be included in the intervention.
223890059|NCT04782687|DRUG|Selinexor|oral drug that comes in 20 mg tablets
223890060|NCT04782687|DRUG|Dexamethasone Oral|Dexamethasone 40 mg on Days 1, 8, 15, 22 of each cycle. However, those \>75 years old may be administered a weekly dose of 20 mg dexamethasone.
223890061|NCT04782687|DRUG|Daratumumab|"Patients will receive daratumumab subcutaneously (SC, or under the skin) as an injection. The recommended dosage of the SC formulation is 1,800 mg daratumumab and 30,000 units hyaluronidase administered SC into the abdomen over approximately 3 to 5 minutes according to recommended schedule.~Daratumumab 1800 mg subcutaneously once weekly in Cycles 1 and 2, every 2 weeks in cycles 3 to 6, and every 4 weeks thereafter."
223890062|NCT04782687|DRUG|Lenalidomide|Patients will receive a 21-day supply of lenalidomide (15 mg) as oral capsules, as appropriate, for each 28-day treatment cycle
223890063|NCT02240472|PROCEDURE|Omission of axillary clearance|The intervention is the omission of completion axillary clearance after the detection of sentinel node macrometastasis
223890064|NCT06800352|OTHER|Control|The degree of diaper dermatitis of the babies will be evaluated before and after the procedure (72 hours after the first procedure) by using the 'Uncomplicated Diaper Dermatitis Severity Rating Scale in Babies (UNDDCS)'. Mothers will be asked to diaper their babies with cotton wool soaked with clear water.
223890065|NCT03436745|DRUG|Zolpidem|In men with prostate cancer, males (pre-castration, n=8-10) will receive oral zolpidem in the form of a 5 mg tablet. Blood samples will be collected for pharmacokinetic analysis at pre-dose and 0.5, 1, 2, 4, and 8-hours post-dose. This cohort of men will then undergo androgen deprivation therapy with standard doses of goserelin. When castrate testosterone levels reach \<50 ng/dL (post-castration), they will receive another 5 mg single dose of zolpidem followed by 8-hr pharmacokinetic (PK) evaluation of zolpidem and its metabolites. Normal healthy females (n=5-8) will receive treatment with a single dose of 5 mg tablet of zolpidem followed by 8-hr PK evaluation of zolpidem and its metabolites. Blood samples will be collected for PK analysis at pre-dose and 0.5, 1, 2, 4, and 8-hours post-dose.
223890066|NCT03436745|DIAGNOSTIC_TEST|ECG|Screening and baseline.
223890067|NCT05154487|DRUG|Alpelisib Pill|Kinase inhibitor
223890068|NCT05154487|DRUG|Fulvestrant injection|estrogen receptor agonist
223890069|NCT01809691|DRUG|TAK-700|300 mg, PO, twice daily
223890070|NCT01809691|DRUG|Bicalutamide|50 mg, PO, q daily
223890071|NCT02807805|DRUG|Abiraterone Acetate|Given PO
223890072|NCT02807805|DRUG|Niclosamide|Given PO
223890073|NCT02807805|DRUG|Prednisone|Given PO
223890074|NCT03669822|OTHER|Standard of care|Care decisions driven by local physicians; this is an observational cohort.
223890075|NCT03947216|DRUG|Active drug: pimavanserin 17mg (2 strength tablets)|Pimavanserin 17mg (2 strength tablets) will be taken orally daily from day 1 to Visit 4 (Week 8)
223890076|NCT03947216|DRUG|Placebo: 2 tablets containing same excipients except active compound|Placebo (2 strength tablets) will be taken orally daily from day 1 to Visit 4 (Week 8)
223890077|NCT03947216|BEHAVIORAL|Assessment of severity of ICD (impulse control disorders)|Questionnaire for impulsive-compulsive disorders in Parkinson's disease rating scale (QUIP-RS) will be administrated at day 0, day 28 (Week 4) and day 56 (Week 8)
224078816|NCT00305578|DRUG|Placebo|No active medication, only placebo
223890078|NCT03947216|BEHAVIORAL|Assessment of motor and non-motors symptoms of PD Evaluation of hyper- and hypodopaminergic behaviors|Hyper- and hypodopaminergic behaviors (Ardouin's scale); Movement disorders society sponsored unified Parkinson's disease rating scale (MDS-UPDR), and daytime and night time sleep by scale for outcomes in Parkinson's disease SLEEP (SCOPA-SLEEP, ISI, PDSS-2) will be administrated at day 0, day 28 (Week 4) and day 56 (Week 8)
223890079|NCT03947216|BEHAVIORAL|Assessment of quality of life|Parkinson's Disease questionnaire (PDQ-39) will be administrated at day 0, day 28 (Week 4) and day 56 (Week 8)
223890080|NCT03947216|BEHAVIORAL|Assessment of depression|Montgomery-Åsberg Depression Rating Scale (MADRS) will be administrated at day 0 and day 56 (week 8)
223890081|NCT03947216|BEHAVIORAL|Assessment of cognition|Cognitive state of patients by Montreal Cognitive Assessment (MOCA) will be assessed at day 0.
223890082|NCT03947216|BEHAVIORAL|Assessment of severity of Parkinson Disease|Clinical Global Impression Severity scale (CGIS) will be administrated at day 0 , day 7, day 14, day 28, day 42 and day 56 (week 8) and day 112 (Week 16)
223890083|NCT03947216|PROCEDURE|Blood analysis|Blood sample will be collected for analyse of safety (blood count/liver and kidney functions, electrolytes) at day 0 and day 56
223890084|NCT03947216|PROCEDURE|Cardiac monitoring|Electrocardiogram will be realized at day 0, 28 and 56.
223890085|NCT03661840|BEHAVIORAL|Acceptance and Commitment Therapy|Intervention group participants will attend eight weekly, 90-minute, in person, group-based ACT sessions. Groups will be initiated with no more than 10 participants and no fewer than 6 participants. Sessions will include key theoretical ACT constructs and strategies as they relate to chronic pain. A licensed clinical psychologist or licensed clinical social worker trained in ACT will facilitate all sessions. Participants in the ACT intervention group will also continue to receive medication management and other behavioral management interventions that they would get as usual treatment.
223890086|NCT03661840|OTHER|Treatment as Usual|Treatment as usual will include ongoing provision of usual treatment options for pain management. This includes continued medication management for cancer related chronic pain by prescribing providers, and access to supportive oncology services. It may also include other behavioral pain management such as physical therapy, acupuncture, or massage.
223890087|NCT05145569|DRUG|Carboplatin AUC 5 and paclitaxel|Carboplatin AUC 5 and paclitaxel combination chemotherapy is very well tolerated and highly effective for the treatment of ovarian cancer and thus is standard of care therapy. Both carboplatin and paclitaxel are chemotherapy agents that are designed to kill and slow the growth of cancer cells.
223890088|NCT05145569|DRUG|HCW9218|HCW9218 is an immunotherapeutic comprising transforming growth factor-b (TGF-b) receptor II and interleukin (IL)-15/IL-15 receptor a domains.
223890089|NCT04954781|DRUG|Tislelizumab|Tislelizumab will be initiated on day 14 after the first TACE session. Tislelizumab will be administered at 200 mg i.v. every 3 weeks until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
223890090|NCT04954781|COMBINATION_PRODUCT|TACE|TACE is performed by using drug-eluting beads. TACE treatment starts on day 0. The second TACE will be repeated on day 28 (± 5 days) if necessary per Investigator's decision.
223890091|NCT01580488|DRUG|B LEO 35299 20 mg/g cream|once daily application, 3 weeks
223890092|NCT01580488|DRUG|C LEO 35299 20 mg/g cream|once daily application, 3 weeks
223890093|NCT01580488|DRUG|E LEO 35299 10 mg/g solution|once daily application, 3 weeks
223890094|NCT01580488|DRUG|F LEO 35299 10 mg/g solution|once daily application, 3 weeks
223890095|NCT01580488|DRUG|Daivonex® ointment|once daily application, 3 weeks
223890096|NCT01580488|DRUG|Daivonex® ointment vehicle|once daily application, 3 weeks
223890097|NCT04863430|DRUG|Apatinib|500mg oral qd
223890098|NCT04863430|DRUG|Oxaliplatin|130mg/m\^2 administered as IV infusion on Days 1 of each 21-day cycle
223890099|NCT04863430|DRUG|S1|According to body surface area,(\<1.5m\^2) 40mg or (≥1.5m\^2)50mg bid oral on Day 1-14 of each 21-day cycle
223890100|NCT02589275|DRUG|TNX-102 SL Tablet 2.8 mg|TNX-102 SL 2.8 mg tablet taken daily at bedtime
223890101|NCT05337215|BEHAVIORAL|kangaroo father care|The effect of postpartum kangaroo father care on paternal attachment
223890102|NCT05776056|DRUG|Methylphenidate|Methylphenidate 10mg will be taken twice daily.
223890103|NCT05776056|DRUG|Placebo|An inactive pill (placebo) will be taken twice daily.
223890104|NCT02051218|DRUG|Denosumab (reduced dosing)|3x Denosumab 120mg (XGEVA®) sc. q4w followed by Denosumab 120mg (XGEVA®) sc. q12w
223890105|NCT02051218|DRUG|Denosumab (standard dosing)|Denosumab 120mg (XGEVA®) sc. q4w
223890106|NCT04269213|DRUG|Liposome-encapsulated Daunorubicin-Cytarabine|Given IV
223890107|NCT04401800|DRUG|Lenvatinib|Capsules administered orally once daily
223890108|NCT04401800|DRUG|Tislelizumab|200 mg intravenous (IV) infusion administered on Day 1 of each cycle
223890109|NCT05751382|DEVICE|Surefil one|Restorative material (Dentsply Sirona). Used for direct restoration of class V NCCL.
223890110|NCT05751382|DEVICE|Venus Pearl|Restorative material. Traditional paste composite employed in combination with iBond universal adhesive.
223890111|NCT06777251|OTHER|"analysis of predictive factors of IF in patients with Crohn's disease through the characterization of multiomics parameters"|"The study includes an initial evaluation in which faecal samples will be collected, a blood sample will be taken and an ileocolonoscopy with biopsies will be performed (additional biopsy in conjunction with a biopsy from clinical practice for study-specific analyses).~Patients will then be reevaluated nine months after the initial evaluation. In particular, fecal, blood and additional biopsy samples will be collected in conjunction with clinical practice biopsy and all treatment modifications will be recorded."
223890112|NCT06385938|DIAGNOSTIC_TEST|Ultrasound with quantitative vibro-acoustic assessment|Imaging with non-invasive bone assessment based on wide range of frequencies and free from soft tissue artifact of the wrists and the knees
223890113|NCT06221059|DRUG|HRS-1780 tablet；Henagliflozin Proline tablet；HRS-1780 tablet placebo ；Henagliflozin Proline tablet placebo|Drug：HRS-1780 tablet Drug：Henagliflozin Proline tablet Drug：HRS-1780 tablet placebo Drug：Henagliflozin Proline tablet placebo
223890114|NCT04336436|BEHAVIORAL|Mindfulness training|Mindfulness training
223890115|NCT04336436|BEHAVIORAL|Nutritional consult|Nutrition counseling and development of a personalized nutrition plan
223890116|NCT01107340|DEVICE|AMIStem Hip System|
223890117|NCT02421185|DRUG|JNJ-42756493 (erdafitinib)|"Part 1: Participants will receive 8 mg tablet once daily from Day 1 to 7, and then Day 15 to 21 of 28 days cycle or 8 mg orally once daily of 28 days cycle up to the maximum tolerated dose in order to determine the recommended Phase 2 dose.~Part 2: Recommended Phase 2 JNJ-42756493 (erdafitinib) dose determined in Part 1."
223890118|NCT02682342|OTHER|75 g glucose solution|This is the same as the standard oral glucose challenge dose and route given clinically
223890119|NCT06784544|OTHER|Operational Stressors|Intervention consists of a 48 hour energy balance phase preceding two rounds of repeated 72 hour energy deficit exposure each immediately followed by a 48h recovery phase. Balance and recovery phases will meet 100% of baseline energy requirements. Energy deficit phases will include an approximate 60% energy deficit of total daily energy requirements achieved through both a reduction in dietary intake and increased energy expenditure through physical activity.
223890120|NCT05671029|DRUG|Pritelivir and moxifloxacin placebo|oral administration
223890121|NCT05671029|DRUG|Pritelivir placebo, moxifloxacin and moxifloxacin placebo|oral administration
223890122|NCT05671029|DRUG|Pritelivir placebo, moxifloxacin placebo and moxifloxacin|oral administration
223890123|NCT05334732|BEHAVIORAL|SIS TALK Back Intervention|The participants in this arm will be seen by a trained survivor coach and receive culturally tailored intervention materials.
223890124|NCT04931641|DIETARY_SUPPLEMENT|Galacto-oligosaccharides|Prebiotic galacto-oligosaccharides (GOS)
223890125|NCT04931641|OTHER|Maltodextrin|Maltodextrin (placebo)
223890126|NCT04931641|DIETARY_SUPPLEMENT|Ferrous fumarate|50 mg iron as ferrous fumarate
223890127|NCT03338790|BIOLOGICAL|nivolumab|Specified dose on specified days
223890128|NCT03338790|DRUG|docetaxel|Specified dose on specified days
223890129|NCT03338790|DRUG|enzalutamide|Specified dose on specified days
223890130|NCT03338790|DRUG|rucaparib|Specified dose on specified days
223890131|NCT03338790|DRUG|prednisone|Specified dose on specified days
223890132|NCT06648213|OTHER|Physiotherapy|Therapy group: In addition to routine care, they will be arranged according to the needs of the baby in the form of positioning, hand contacts, passive and active movement of the arms and legs for the development of movement, sensory stimuli around the mouth for oral motor organisation. Neurodevelopmental-based application will be applied three days a week, once a day for 10-15 minutes, from the 34th week until 36th week when vital signs are stable.
223890133|NCT06781580|OTHER|Esports Ergonomic Protocol|"The Esports Ergonomic Protocol is a six-week intervention designed to reduce the risk of repetitive strain injuries and enhance gaming performance for esports athletes. It includes an educational session on ergonomics, focusing on proper posture, body mechanics, and workstation setup. The protocol also incorporates warm-up and cool-down exercises to prevent strain and improve flexibility, as well as a postural rehabilitation program targeting the upper extremities and core muscles.~Participants will attend four in-person sessions at specified intervals for ergonomic risk assessments (using REBA) and gaming performance evaluations (using Kovaaks). The intervention also features online resources, including exercise tutorials and ergonomic tips, to support adherence and long-term implementation. Feedback will be collected through post-intervention surveys and an optional focus group to refine the protocol for future use in the esports community."
223890134|NCT05046418|OTHER|Hypoallergenic formula containing synbiotics|An extensively hydrolysed formula containing synbiotics or an amino acid formula containing synbiotics.
223890135|NCT03594422|DRUG|HQP1351|HQP1351 Orally, once every other day (QOD) for consecutive 4 weeks each cycle.
223890136|NCT03921502|PROCEDURE|Gall bladder transmural drainage with LAMS|Placing a PAL Axios (Boston Scientific) usually 15x10 mm or 10x10 mm to allow direct cholecystoscopy with a conventional gastroscope or transnasal gastroscope. The placement of the drainage will be performed in the same endoscopic act, by means of an Olympus® sectorial echoendoscope, assisted with X-rays, which allows puncturing the vesicle from the gastric antrum or the duodenal bulb to generate a cholecysto-gastrostomy or cholecysto-duodenostomy respectively. After the puncture of the vesicle from the most optimal anatomical point, it will be tutored with guidance and a Hot Axios® PAL 15x10 mm or 10x10 mm will be \*placed on it to generate the anastomosis between the aforementioned structures.
223890137|NCT06048757|DEVICE|Diactive-1 application|Participants will engage in 24 weeks resistance exercise program with goal of maintaining at least 3 sessions per week with 4-5 exercises per session (13-33 minutes). The training intervention will comprise 3-4 sets of 6-12 repetitions and will consist of a combination of exercises for the upper and lower body and the core, utilizing the participants' body weight as the primary resistance or auxiliary materials such as elastic bands and a water-fillable kettlebell. The load and intensity of the exercise will be based on the number of repetitions, the resistance of the elastic bands and/or the weight of the aquaball, as well as the difficulty of the exercises. A mobile application known as Diactive-1 will be utilized.
223890138|NCT05697198|DIAGNOSTIC_TEST|OmniSeq Test|Genomic and immune profiling assay for all solid tumors
223890139|NCT05336721|DRUG|Chiauranib|25mg/35mg/50mg orally once daily
224078817|NCT03484468|DEVICE|anterior segment Ocular Coherence Tomography|anterior segment OCT (Ocular Coherence Tomography) a device shows imaging of anterior segment of the eye and able to show corneal layers and measures its thickness.
224078818|NCT05559723|DEVICE|electromagnetic field therapy|"Three times a week for four weeks, the study group got electromagnetic fields (EMFs) therapy and the selected physical therapy program. The EMFs therapy was applied using an electromagnetic field therapy device (Magner Plus Astar)~. From the prone lying position the device will be adjusted around the lumbar area at a low frequency (50 Hz), with the intensity of 2.5 MT, field shape and applicator type rectangular csl60/csp60), and the application time will be10 minutes"
224078819|NCT05559723|OTHER|selected physical therapy program|"in the form of~1. Hot packs will be placed paravertebral on the lumbar region for 5 minutes from a prone lying position~2. selected physical therapy exercises in form of Static exercise for back and abdominal muscles, stretching exercises for both lower limbs, 10 times each exercise"
224078820|NCT05559723|DEVICE|Therapeutic ultrasound therapy|Therapeutic ultrasound therapy using ultrasound device Chattanooga, model 2760, serial number T11238, 120-240V, 50/60Hz, made in Mexico . That will be applied paravertebral on the lumbar region from the prone lying position, with pulsed mode, frequency 1 MHz, intensity 0.5 W/cm2 and will be applied by circular moving technique at a rate of 4 cm/s for 10 minutes.
223890140|NCT05336721|DRUG|capecitabine|1000mg/m2 on Days 1-14 in a repeating 21-day cycle
223890141|NCT02797275|DRUG|Albuterol|Beta agonist respiratory inhaler
223890142|NCT02797275|DRUG|Placebo|respiratory inhaler with no medication
223890143|NCT04106583|DEVICE|WAVE, as part of the SMART COIL System|WAVE, as part of the SMART COIL System
223890144|NCT06063616|OTHER|Reiki|Level I Reiki was applied to 9 points and nearby areas for 30 minutes, three sessions a week, for a total of four weeks, in the first three hours of the HD treatment, by the researcher, who completed his second level training according to the Usui method, in line with the Reiki/Sham Reiki Application Protocol.
223890145|NCT06063616|OTHER|Sham Reiki|Sham Reiki was applied to 9 points and nearby areas in accordance with the Reiki/Sham Reiki Application Protocol, for a total of four weeks, three sessions per week, for 30 minutes, in the first three hours of the HD treatment, by two students who had not received Reiki training, and were given training on the application by the researcher.
223890146|NCT00974415|PROCEDURE|CO2|CO2 treatment delivered to randomized flank at each study visit
223890147|NCT00974415|PROCEDURE|Sham|Sham treatment to other flank at each study visit
223890148|NCT04202185|OTHER|Data collection|Retrospective collection data from diagnostic Data collected following to medical exam as part of care
223890149|NCT04202185|GENETIC|Genetic analysis|Research of mutation and identification of genetic panel as part of care
223890150|NCT04094688|DRUG|Bevacizumab|Given IV
223890151|NCT04094688|DRUG|Oxaliplatin|Given IV
223890152|NCT04094688|DRUG|Leucovorin Calcium|Given IV
223890153|NCT04094688|DRUG|Fluorouracil|Given IV
223890154|NCT04094688|DRUG|Irinotecan Hydrochloride|Given IV
223890155|NCT04094688|DRUG|Irinotecan|Given IV
223890156|NCT04094688|DIETARY_SUPPLEMENT|Cholecalciferol|Given PO
223890157|NCT04094688|OTHER|Quality-of-Life Assessment|Ancillary studies
223890158|NCT04094688|OTHER|Questionnaire Administration|Ancillary studies
223890159|NCT05067517|DRUG|Nintedanib|Randomized in a 1:1 ratio to either oral nintedanib 150 mg (n=80) or matching placebo (n=80) twice daily.
223890160|NCT05067517|DRUG|Placebo|Randomized in a 1:1 ratio to either oral nintedanib 150 mg (n=80) or matching placebo (n=80) twice daily.
223890161|NCT02651428|DRUG|Neutrolin|Neutrolin® will be instilled into central venous HD catheters at the discontinuation of all dialysis sessions and will be withdrawn prior to the initiation of the next dialysis session
223890162|NCT02651428|DRUG|Heparin|Heparin will be instilled into central venous HD catheters at the discontinuation of all dialysis sessions and will be withdrawn prior to the initiation of the next dialysis session
223890163|NCT06252909|BEHAVIORAL|Interpersonal Psychotherapy for Couples|"Interpersonal Psychotherapy for Couples (IPT-C) consists of 8 weekly conjoint sessions. The clinical goals are to promote resolution of the role dispute via renegotiation of role relations between the marriage partners and improve common mental disorders in the woman. Like Interpersonal Psychotherapy, IPT-C has an initiation phase (Session 1-2), middle phase (Sessions 3-6), and termination phase (Sessions 7-8)."
223890164|NCT06252909|BEHAVIORAL|Interpersonal Psychotherapy (Individual)|Interpersonal Psychotherapy (IPT) is an evidence-based treatment to reduce depression and other common mental disorders. It focuses on helping patients resolve interpersonal problems of disagreements, loneliness, life changes, and grief, and/or change their orientation to the problem.
223890165|NCT05670626|PROCEDURE|Refractive Surgery|Phakic implantable contact lens ( ICL)
223890166|NCT05006404|DEVICE|Pulmonary Valve Replacement Surgery|Pulmonary valve replacement surgery with the Autus Valve
223890167|NCT06541431|OTHER|Abdominal Drainage Fluid Collection|Abdominal drainage fluid will be collected daily from the subjects until they are discharged from the hospital, or their abdominal/pelvic drain is removed, as determined by the treating surgeon.
223890168|NCT06125704|BEHAVIORAL|Moderate intensity walking or stepping|30 minutes of moderate intensity walking or stepping (i.e., at a pace of approximately 100 steps per minute), varied by time of day it is performed: morning (i.e., between 5am-9am, within 30-40 minutes of starting breakfast) versus late afternoon/evening (i.e., between 4pm-8pm, within 30-40 minutes of dinner).
223890169|NCT03850366|DRUG|Bortezomib|GVHD prophylaxis
223890170|NCT02380885|BEHAVIORAL|SCIT|psychosocial group intervention
223890171|NCT02380885|BEHAVIORAL|TAFT|psychosocial group intervention
223890172|NCT04588298|DRUG|AZD9833|AZD9833 tablets will be administered orally.
223890173|NCT05250895|OTHER|18F-Fluoromisonidazole|Given IV
223890174|NCT05250895|PROCEDURE|Biopsy|Undergo biopsy
223890175|NCT05250895|PROCEDURE|Dynamic Contrast-Enhanced Magnetic Resonance Imaging|Undergo DCE MRI
223890176|NCT05250895|PROCEDURE|Positron Emission Tomography|Undergo PET
223890177|NCT05694156|OTHER|Music-based cognitive training|8-week music-based cognitive training
223890178|NCT05592418|DRUG|Rintatolimod|100 to 400 mg twice weekly
223890179|NCT05592418|OTHER|Placebo / Normal Saline|40 to 160 mL twice weekly
223890180|NCT03001414|BIOLOGICAL|Placebo followed by Autologous EPCs transfected with human eNOS|4 doses of placebo in first 6 months followed by 4 doses of autologous EPCs transfected with eNOS in second 6 months
223890181|NCT03001414|BIOLOGICAL|Autologous EPCs transfected with human eNOS followed by Placebo|4 doses of autologous EPCs transfected with eNOS in first 6 months followed by 4 doses of placebo in second 6 months
223890182|NCT03001414|BIOLOGICAL|Autologous EPCs transfected with human eNOS|4 doses of autologous EPCs transfected with eNOS in first 6 months which is repeated in second 6 months
223890183|NCT05400369|DRUG|Sitafloxacin|Oral administration, 50 mg tablets
223890184|NCT05400369|DRUG|Moxifloxacin Hydrochloride|Oral administration, 400 mg tablets
223890185|NCT04190589|DEVICE|Robot-assisted laparoscopic extended right colectomy|An extended right hemicolectomy with total mesocolic excision and meticulous central dissection as described by Hohenberger will be performed with the DaVinci Xi robot by one of two dedicated surgeons
223890186|NCT05839041|DRUG|AVD-104|Intravitreal injection
223890187|NCT05839041|DRUG|Avacincaptad|Intravitreal injection of 2 mg avacincaptad
223890188|NCT03669367|DRUG|Abatacept Injection|Abatacept subcutaneous in monotherapy 125 mg/week during the first year (12 months). Abtacept subcutaneus in monotherapy 125 mg/2weeks during the second year.
223890189|NCT03669367|DRUG|hydroxycloroquina|oral hydroxycloroquina 5 mg/Kg/day for 2 years (0-48 months)
223890190|NCT05569252|DRUG|DS-1211b|DS-1211b tablet administered once daily in the morning either in the fasted state or with a meal
223890191|NCT05569252|OTHER|Placebo|Placebo tablet administered once daily in the morning either in the fasted state or with a meal
223890192|NCT04983173|DRUG|Ovarian Stimulation with CC+rFSH|: CC 50 mg/day (Omifin®) + rFSH 150 IU (Ovaleap®) GnRH antagonist: ganirelix 0.25 mg (Orgalutran®) Recombinant human chorionic gonadotropin (rhCG) 250 μg (Ovitrelle®) micronized progesterone 200 mg 3id (Utrogestan®)
223890193|NCT04983173|DRUG|Ovarian Stimulation with rFSH|rFSH 300 IU rFSH (Ovaleap®) GnRH antagonist: ganirelix 0.25 mg (Orgalutran®) Recombinant human chorionic gonadotropin (rhCG) 250 μg (Ovitrelle®) micronized progesterone 200 mg 3id (Utrogestan®)
223890194|NCT06057922|DRUG|YL201 for Injection|Patients will be treated with YL201 intravenous (IV) infusion once every 3 weeks (Q3W) as a cycle; and at dose levels of 1.0 mg/kg and 1.2 mg/kg administered on Days 1 and 8 of each Q3W treatment cycle.
223890195|NCT03665597|BIOLOGICAL|Pembrolizumab Dose C|165 mg/mL administered to a final dose of 285 mg via subcutaneous injection
223890196|NCT03665597|BIOLOGICAL|Pembrolizumab Dose A|130 mg/mL administered to a final dose of 285 mg via subcutaneous injection
223890197|NCT03665597|BIOLOGICAL|Pembrolizumab Dose B|200 mg administered via intravenous infusion
223890198|NCT03665597|BIOLOGICAL|Pembrolizumab Dose D|400 mg administered via intravenous infusion
223890199|NCT04725695|DRUG|Viscous Lidocaine|The patients will be randomized to either viscous lidocaine or placebo
223890200|NCT06652360|DEVICE|Chemical Debridement|The chemical debridement is a dehydrating agent in a gel shape that will dry out the woundbed and biofilm.
223890201|NCT06652360|DEVICE|Curettage debridement|The use of a currette will clean the wound bed. Debridement by mechanically removing the necrotic tissue and biofilm. This is performed confrom the standard of care standards.
223890202|NCT04831216|BEHAVIORAL|Type 2 Diabetes Appropriate Food Boxes + Diabetes Education|All participants will be assigned to a single intervention arm. The intervention includes weekly delivery of type 2 diabetes-appropriate food boxes that include diabetes self-management education materials.
223890203|NCT03272373|DEVICE|NexGen TM Monoblock Tibia|Primary cementless tibia total knee arthroplasty
223890204|NCT03272373|DEVICE|NexGen TM Modular Tibia|Primary cementless tibia total knee arthroplasty
223890205|NCT04816461|DRUG|Amodiaquine Sulfadoxine-Pyrimethamin administration|SMC treatment
223890206|NCT04816461|DRUG|Dihydroartemisinin-Piperaquine|Roommates treatment if they are positive to malaria
223890207|NCT04816461|DIAGNOSTIC_TEST|Standard HRP2-RDT|Roommates screening with standard HRP2-RDT
223890208|NCT04663087|DEVICE|XSTAT|XSTAT application will follow the manufacturer's guidance, with injection into bleeding junctional wounds. A sufficient number of sponges are used to fill the injury void. Repeated XSTAT application is performed in the event of persistent bleeding. The trial packs will contain two devices.
223890209|NCT04663087|OTHER|Standard of Care|As currently provided by EMS services
223890210|NCT03818711|BEHAVIORAL|Communication & Coping Intervention|Mothers receive a treatment manual and participate in individual phone calls aimed at reducing depressive symptoms and improving the quality of parental involvement. A concurrent secret Facebook group will have daily posts to reinforce concepts.
223890211|NCT03818711|BEHAVIORAL|Education & Check Ins|Mothers receive educational materials and participate in individual phone calls related to these materials. A concurrent secret Facebook group will have daily educational posts.
223890212|NCT05728697|DEVICE|Endoscopic ultrasound shear wave elastography|To perform the portion of the endoscopic ultrasound exam using this device, the endoscopic ultrasound probe is placed onto the surface of the stomach with the probe facing the left liver. The probe then transmits shear waves that propagate through the tissue. The waves themselves are ultrasound waves and are harmless. This is repeated 10 times on a region of interest as guided by the endoscopic ultrasound probe. The device used in question is the linear EUS (Aloka Arietta 850, Olympus America, Center Valley, PA).
223890213|NCT03951194|BIOLOGICAL|Autologous Platelet Rich Plasma (PRP) intra ovarian infusion|Autologous PRP intra ovarian infusion
223890214|NCT03951194|OTHER|Placebo: Autologous Platelet Free Plasma (PFP) intra ovarian infusion|Autologous PFP intra ovarian infusion
223890215|NCT05172934|DRUG|intra-arterial tenecteplase|intra-arterial drug administered after mechanical thrombectomy
223890216|NCT04339166|DIAGNOSTIC_TEST|Non-invasive chromosome screening（NICS）|NICS is noninvasive chromosome screening approach to analysis the euploidy by free DNA in embryo culture medium
223890217|NCT06848582|BIOLOGICAL|umbilical cord blood NK cells|All subjects will receive Ex vivo Expanded and activated umbilical cord blood NK cells infusion.
223890218|NCT06220643|OTHER|resistance exercise|Progressive resistance exercise for 12 weeks
223890219|NCT06220643|DRUG|triamcinolone acetonide plus lidocaine|40mg triamcinolone acetonide 1cc plus 2cc lidocaine (1%)
223890220|NCT05605678|OTHER|No Intervention|This is a non-interventional study.
223890221|NCT06848517|OTHER|BSATP Group|"Participants and the therapist will communicate once weekly synchronously (e.g. through video calls with a 30 minute duration), regarding the proper execution of the PFM exercises, providing motivation etc. Additionally, participants will be advised to watch the educational videos (10 mins duration) asynchronously twice a week. In total, participants will follow a BSATP three times a week (for 12 weeks). The PFM exercise program will include endurance training (slow velocity contractions), speed training (quick contractions) and Knack maneuver training (pre-contraction before the increment of the intra-abdominal pressure).The PFM exercise program will be based on three assessments conducted by the therapist throughout the study (baseline, 6 weeks and 12 weeks). As a result, the PFM exercise program will be individualized to meet their needs and progressively increases in difficulty, with the exercise position being modified every two weeks (e.g. supine, side, prone ect)"
223890222|NCT06848517|OTHER|FtFS Group|Participants will attend one weekly face-to-face session with their therapist, to discuss the progress of their treatment and ensure its seamless continuation (intra-vaginal assessment, adjustments, motivation etc.). Each session will last approximately 30 minutes. Participants will also be advised to perform the PFM program twice a week on their own e.g. at home. In total, participants will follow a PFM program three times a week (for 12 weeks), once with their therapist and twice independently. The participants in the FtFS group will follow the same PFM exercise treatment program as the BSATP group, which will be an individualized program where the position will change every two weeks and include endurance training, speed training and 'Knack maneuver' training.
223890223|NCT06848517|OTHER|Control Group (CG)|The participants will be advised to follow a PFM exercise treatment program at home, based on an educational home leaflet (with instructions and images about PFM exercises) that they received during their first assessment session (baseline). The participants of this group will follow a PFM exercise therapy program (through the leaflet) which will last 12 weeks and they will be advised to attend it three times a week. No face-to-face meetings or supervision will occur by the therapist during the treatment period. Similarly to the other two intervention groups, the provided PFM exercise treatment program will be individualized, will include endurance training, speed training, and 'Knack maneuver' training, and the participants will be encouraged to change their exercise position on their own every two weeks.
223890224|NCT04572152|BIOLOGICAL|AK119|Subjects will receive AK119 by intravenous administration.
223890225|NCT04572152|BIOLOGICAL|AK104|On the same day subjects will receive AK104 by intravenous administration.
223890226|NCT06444087|OTHER|secukinumab|This is an observational study. There is no treatment allocation. The decision to initiate secukinumab will be based solely on clinical judgement.
223890227|NCT05430035|DRUG|HIPEC|Heated Intra-Peritoneal Chemotherapy (HIPEC) HIPEC will be performed at the time of the index operation if a cancer is known pre-operatively, at the time of re-operation for incidentally discovered cancers already treated with cholecystectomy that are undergoing central hepatectomy and portal lymphadenectomy as part of standard of care, or independently if no other procedures are indicated. A closed technique will be utilized to deliver mitomycin C (MMC) over the first 60 minutes followed by an additional smaller dose over an additional 30 minutes. Perfusate will be heated to obtain a tissue temperature of 42°
223890228|NCT06850155|PROCEDURE|Sling release|The gluteal sling was released and left unrepaired at the end of the procedure
223890229|NCT06850155|PROCEDURE|Sling release and repair|The gluteal sling was released and then repaired at the end of the procedure
223890230|NCT06849024|DEVICE|Transcutaneous electrical neurostimulation|Transcutaneous electrical nerve stimulation or placebo during 30 minutes three times per week for 60 days.
223890231|NCT02670447|PROCEDURE|MRI|Magnetic Resonance Imagery will be performed on patients attempted by schizophrenia. The aim of this intervention is an early detection of the non-answering patients to the primary cares.
223890232|NCT06843733|OTHER|Mixed reality exergame|The participants will play the Balloon Popping game using Hololens2 (Mixed reality glasses) for one hour. The objective of this game will be to pop all the virtual balloons, focusing on training different executive functions such as inhibitory control and cognitive flexibility. When a participant raises a finger in the air, a virtual needle will appear. After that, the participant will move their finger towards a balloon. Successful contact with a balloon will be indicated by the sound of a pop and the visual effect of confetti.
223890233|NCT06843733|OTHER|Education|The participants will seat on a chair and watch video clip about MCI and dementia for one hour.
223890234|NCT06629272|BEHAVIORAL|D-THIO (Deprescribing Thyroid Hormone In Older Adults)|"D-THIO consists of evidence-based pharmaceutical opinion letters to providers advising deprescribing for their patients 65 years and older with thyroid hormone overtreatment/misuse and EMPOWER (Eliminating Medications through Patient Ownership of End Results) brochures to their patients."
223890235|NCT06629272|BEHAVIORAL|Enhanced usual care|American Thyroid Association \[ATA\] provider guidelines, ATA patient brochure
223890236|NCT06012929|DRUG|ONC201|ONC201 is an oral medication given once per week
223890237|NCT06850467|BEHAVIORAL|Sexual intercourse protocol|The study involved pregnant women who were randomly assigned to 2 groups. The protocol involved engaging in sexual intercourse and nipple stimulation 3 times per day for two consecutive weeks with the consecutive days of sexual intercourse and days of nipple stimulation being different. Patients documented their coital activities as well as the frequency of orgasms in their daily journal. There were no prohibitions regarding or promotions of sexual activities for the control group. The main outcome was the onset of labor, which was defined as the presence of effective uterine contraction with changes of the cervix (Bishop score \> 5) without using the induction treatments during protocol time or until 41 weeks of pregnancy.
223890238|NCT06850779|OTHER|Extracorporeal shock wave therapy (ESWT)|Radial ESWT (Vibrolith OrthoⓇ) was applied to the wrist as 1000 pulses with a frequency of 5 Hz and a power of 1.5 bar. The treatment was applied once a week for a total of 3 sessions.
223890239|NCT06850779|OTHER|Kinesio taping (KT)|KT was prepared as 2 pieces of 2.5 cm I band and 1 piece of 5 cm I band. It was applied with a maximum of 50% tension (without tension on the ends) while the wrist was in 30 degrees of extension, forearm supination and elbow extension. The treatment was applied once a week for a total of 3 sessions.
223890240|NCT06850779|OTHER|Exercise|Median nerve gliding exercises were given to the 4th group during the follow-up period. The same exercises were given to the other groups.
223890241|NCT06849128|OTHER|NeuroReAlign Therapy|Patients in this group will receive NeuroReAlign Therapy, including motor training (e.g., treadmill training, balance training), multimodal sensory stimulation (e.g., proprioceptive and visual), cognitive training (e.g., traditional cognitive exercise), and motivation, for 45 minutes per session, 3 times weekly, for 4 weeks.
223890242|NCT06849128|OTHER|Conventional cognitive training|A conventional cognitive training protocol involves structured, repetitive exercises designed to enhance specific cognitive functions, such as memory, attention, executive function, and processing speed. These training programs are delivered through paper-and-pencil tasks, computer-based exercises, and therapist-guided activities. Tasks used include working memory exercises (e.g., digit span recall), attention training (e.g., Stroop test, visual scanning), problem-solving activities (e.g., Tower of Hanoi), and language exercises (e.g., verbal fluency tasks), for 45 minutes per session, 3 times weekly, for 4 weeks.
223890243|NCT06242288|DRUG|ISOtretinoin 20 MG|Isotretinoin, also known as 13-cis-retinoic acid and sold under the brand name Accutane among others, is a medication primarily used to treat severe acne
223890245|NCT03110315|DRUG|Suvorexant|See detailed information in associated Arm Description.
223890246|NCT03110315|DRUG|Placebo|Sugar pill manufactured to mimic suvorexant 10 mg tablet.
223890247|NCT05593575|DRUG|SPH3127+SPH3127matching placebo+valsartan matching placebo|1 tablet of SPH3127 (50 mg) ，3 tablets of SPH3127 (50mg)matching placebo， 1 capsule of valsartan matching placebo, orally, once daily for 12 consecutive weeks
223890248|NCT05593575|DRUG|SPH3127+SPH3127matching placebo+valsartan matching placebo|2 tablet of SPH3127 (50 mg) ，2 tablets of SPH3127 (50mg)matching placebo， 1 capsule of valsartan matching placebo, orally, once daily for 12 consecutive weeks
223890249|NCT05593575|DRUG|SPH3127+valsartan matching placebo|4 tablet of SPH3127 (50 mg) ， 1 capsule of valsartan matching placebo, orally, once daily for 12 consecutive weeks
223890250|NCT05593575|DRUG|SPH3127 matching placebo+valsartan|4 tablets of SPH3127 (50mg)matching placebo， 1 capsule of valsartan, orally, once daily for 12 consecutive weeks
223890251|NCT04906382|PROCEDURE|Biopsy|Undergo biopsy
223890252|NCT04906382|DRUG|Carboplatin|Given IV
223890253|NCT04906382|DRUG|Paclitaxel|Given IV
223890254|NCT04906382|BIOLOGICAL|Tislelizumab|Given IV
223890255|NCT04373135|BEHAVIORAL|Brief educational video|A brief educational video will be displayed explaining the mechanics of how SRA policies operate, how they are decided, and what patients' and healthcare workers' rights are surrounding them.
223890256|NCT06130683|OTHER|Single-cell sequencing|Single-cell sequencing technology can reveal the gene structure and gene expression status of individual cells, reflecting the heterogeneity between cells.
223890257|NCT01083758|DRUG|LEO 80185 (Taclonex® Scalp topical suspension/Xamiol® gel)|Topical suspension applied once daily for up to 8 weeks
223890258|NCT03825965|DRUG|MPL-001 (CBD: THC 25:1)|25:1 cannabidiol (CBD): tetrahydrocannabinol (THC) oral formulation, with a concentration of 50 mg/mL CBD and 2 mg/mL THC, oil- Liquid for oral use
223890259|NCT03825965|DRUG|Placebo oil for oral use|Placebo is Medium-chain triglycerides oil with identical features (in appearance, flavour, and odour) to the MPL-001 oil.
223890260|NCT04727554|DRUG|AMG 994|Administered as an intravenous (IV) infusion.
223890261|NCT04727554|DRUG|AMG 404|Administered as an intravenous (IV) infusion.
223890262|NCT03590821|DRUG|Aspirin 81 mg|timed administration of aspirin in the evening
223890263|NCT03590821|DRUG|Celecoxib 200mg capsule|daily administration of celecoxib
223890264|NCT05966519|DEVICE|Total Knee Replacement (TKR)|Damaged cartilage of knee due to degenerative disease is replaced with metallic and plastic protheses
223890265|NCT05371652|DRUG|Rimegepant 75mg Orally Disintegrating Tablets (ODT)|One rimegepant (BHV3000) 75mg orally disintegrating tablet (up to 1 tablet per day) at the time of their migraine attack
223890266|NCT03699319|DRUG|CPI 613|"Standard Dose Cohort: CPI-613, 500 mg/m2, IV infusion at a rate of 4 mL/min via a central venous port on days 1 and 3 of each cycle, every 2 weeks.~Dose Escalation Cohort: CPI-613, 750-1000 mg/m2 IV infusion at a rate of 3 mL/min via a central venous port on days 1 and 3 of each cycle, every 2 weeks.~Intended treatment protocol is 12 cycles (2 weeks each) or 6 months"
223890267|NCT03699319|DRUG|Oxaliplatin|"Administered at 65 mg/m2 given as a 2-hr IV~Part of SOC mFOLFRINOX treatment combination of Oxaliplatin, Irniotecan, 5-flurouracil, and vitamin derivative (Folinic acid)"
223890268|NCT03699319|DRUG|Irinotecan|"Administered at 140 mg/m2 given as a 90-min IV infusion) via a Y-connector~Part of SOC mFOLFRINOX treatment combination of Oxaliplatin, Irniotecan, 5-flurouracil, and vitamin derivative (Folinic acid)"
223890269|NCT03699319|DRUG|5-flurouracil|"Administered at 400 mg/m2 as bolus followed by a 46-hr infusion at 2400 mg/m2, starting immediately after completion of folinic acid and irinotecan~Part of SOC mFOLFRINOX treatment combination of Oxaliplatin, Irniotecan, 5-flurouracil, and vitamin derivative (Folinic acid)"
223890270|NCT03699319|DRUG|Folinic acid|"Administered at 400 mg/m2 given as a 90-min infusion immediately after oxaliplatin~Part of SOC mFOLFRINOX treatment combination of Oxaliplatin, Irniotecan, 5-flurouracil, and vitamin derivative (Folinic acid)"
223890271|NCT06288919|OTHER|Erythritol prophylactic powders|erythritol with particle size of \~14 µm will be used for 5 seconds (AIRFLOW® PLUS EMS)
223890272|NCT06288919|OTHER|Ultrasonic scaler with peek inserts|ultrasonic scaler, a piezoelectric handpiece with peek inserts (Mini Piezon EMS; PI, EMS) will be used.
223890273|NCT04223141|PROCEDURE|SIA|As indicated by arm description
223890274|NCT04195568|DEVICE|Surpass Evolve Flow Diverter System|The Surpass Evolve Flow Diverter System is indicated for the endovascular treatment of adults (age 18 or above) with unruptured saccular wide-neck or fusiform intracranial aneurysms ≤12 mm.
223890275|NCT06445270|BEHAVIORAL|GDM Prevention Program|Participants will receive hybrid and group monthly contacts with registered dieticians and lifestyle coaches. Participants will attend monthly in-person physical activity sessions.
223890276|NCT05545956|PROCEDURE|Hand Wrung|Hand wrung refers to manually wringing surgical sponges by hand.
223890277|NCT05545956|DEVICE|ProCell Wrung|ProCell wrung refers to automated wringing surgical sponges by an FDA approved suction device (ProCell).
223890278|NCT05509595|DRUG|Burosumab|Human recombinant monoclonal antibody to fibroblast growth factor-23 (FGF23)
223890279|NCT06389656|BEHAVIORAL|Behavioral Weight Management|Prescription of diet and physical activity strategies, paired with behavioral strategies for weight management.
223890280|NCT06389656|BEHAVIORAL|Weight Bias Internalization|Addressing weight stigma and improving weight-related self-perception, through challenging weight-related stereotypes, self-compassion, reducing self-criticism, and coping with weight stigma.
223890281|NCT05868525|DRUG|Aspirin 325Mg Tab, Aspirin 81Mg Tab|Patients will be administrated daily oral Aspirin 81 mg or oral Aspirin 325 mg according to their assigned group after randomization.
223890282|NCT05313191|RADIATION|Pencil Beam Scanning Proton Therapy|Use of Pencil Beam Scanning Proton Therapy compared with historical outcomes using photon therapy for the reirradiation of recurrent or new primary malignancies
223890283|NCT06263595|DEVICE|gastric antral sonography|Participant will undergo gastric antrum ultrasound and be scanned in the supine position followed by the right lateral decubitus position. Qualitative and quantitative assessments will be completed.
223890284|NCT04221737|DEVICE|APRV. General Electric Healthcare Engstrom ventilator system|APRV consist of an extended time at plateau pressure (a continuous positive airway pressure phase) comprising about 90% of the respiratory cycle, while providing very brief releases to enhance carbon dioxide removal. Time-controlled adaptive method requires interpretation of the expiratory flow curve to assess changes in lung elastance and, therefore, set the Time low to optimize carbon dioxide removal, but not at the expense of alveolar derecruitment and instability.
223890285|NCT04221737|DEVICE|Conventional. General Electric Healthcare Engstrom ventilator system|Lung protective ventilation consist of delivery of low tidal volumes (4-6 ml/kg PBW), high PEEP enough to avoid de-recruitment, titrated according to ARDSNet PEEP/fraction of inspired oxygen (FiO2) table, while avoiding excessive transpulmonary pressure.
223890286|NCT05987371|DRUG|TQC3721 suspension for inhalation|TQC3721 suspension for inhalation is a dual inhibitor targeting PDE3/4.
223890287|NCT05987371|DRUG|TQC3721 matching placebo for inhalation|Placebo without active substance.
223890288|NCT05987371|DRUG|Salbutamol sulfate inhalation aerosol|Salbutamol is short-acting β2 receptor agonists.
223890289|NCT05518682|DEVICE|Lenire bimodal stimulation device|The sound and tongue stimulus parameters such as stimulus rate, stimulus intensity, and the timing relationship between the auditory and somatosensory stimulus events are grouped into stimulation Parameter Sets (PS). PS1 is used during the first 6-weeks of stimulation and PS4 is used during the second 6-weeks of stimulation, similar to what is routinely used for tinnitus individuals in Europe.
223890290|NCT06290635|DIAGNOSTIC_TEST|Breathlessness Assessment Tool|Participants will complete a breathlessness assessment tool (questionnaire) at three timepoints over the study duration, among other validated questionnaires.
223890291|NCT06494930|OTHER|F-IMT|A core stabilization exercise protocol including functional respiratory muscle training will be applied to the F-IMT group. IMT will be provided with the red Powerbreath Plus MR exercise device. Initial training intensity will be set at 50% of the MIP value measured at the athlete's first evaluation. Every two weeks, the athlete will be re-evaluated the new MIP value will be measured, and the training intensity will be adjusted to 50% of the newly measured MIP value. After the nose clip is attached, the athlete will be asked to take the device's mouthpiece into his mouth, close his lips tightly, and take a deep, fast, and powerful breath, then exhale slowly and completely with minimal effort. While the athlete does breathing exercises with the device, he will also do core stabilization exercises. Athletes will be asked to train 30 minutes daily, five days a week, for six weeks.
223890292|NCT06494930|OTHER|Core Stabilization Exercise|Only the core stabilization exercise protocol will be applied to the control group. Athletes will be asked to train 30 minutes a day, five days a week, for six weeks.
223890293|NCT06570135|DIAGNOSTIC_TEST|Detecting Brain Activity with Functional Near Infrared Spectroscopy|Use a functional near-infrared spectroscopy to detect brain activity in the two groups of subjects during resting state and task state.
223890294|NCT03461991|DEVICE|Ultrahigh resolution Spectral Domain OCT|A spectrometer based ultrahigh resolution Spectral Domain OCT (SDOCT) system operating at 800 nm for the anterior chamber will be employed in the present study. The spectrum of the Ti:Sapphire laser light source is centered at 800 nm. With a full width at half maximum bandwidth of 170 nm, the axial resolution is 1.3 μm in the cornea. The transverse resolution of the employed OCT system is 21 μm at the front surface of the cornea. For measurement, patients will place their head in a modified slit lamp head rest. During the measurement period, patients will be asked to look straight forward onto an internal fixation target and to avoid blinking. Different scattering patterns, e.g. raster, circular and spiral scans will be employed.
223890295|NCT06624176|DEVICE|Bionix ShotBlocker|This is a hospital-approved device used as standard-of-care in older children and adults to reduce pain during painful procedures. It is not considered established standard-of-care in the infant cohort.
223890296|NCT06624176|OTHER|Swaddling|Standard of care swaddling
223890297|NCT06624176|OTHER|Sucrose administration|Standard of care sucrose administration
223890298|NCT06624176|OTHER|Masimo Rad-97 Oximeter probe|Oximeter probe
223890299|NCT05827861|BEHAVIORAL|HeartAge|HeartAge is a phenotypic age-based risk presentation which is a modified tool for CVD risk communication based on the Framingham risk Score. The Heart-Age risk presentation is the age at which an individual of the same sex would be expected to experience the same absolute risk as the individual, had their risk factors been 'normal' based on the clinical guidelines.
223890300|NCT05827861|BEHAVIORAL|HOPE-CVD Mobile App|The HOPE-CVD mobile app is an evidence-based behaviour change platform that runs for 24 weeks. The programme supports behavioural modification through seven self-care behaviours (active living, exercise, weight management, blood pressure-friendly diet, cholesterol-friendly diet, medication adherence and smoke-free lifestyle). To adopt a digital delivery of Motivational Interviewing and Cognitive Behavioural Therapy, the HOPE-CVD platform incorporates interactive decision aids, dramatic vignettes, expert content, peer videos and behaviour tracking.
223890301|NCT05827861|BEHAVIORAL|Genetic Risk Score|Participants will undergo genetic testing from which a genetic risk score for CVD will be estimated. they will receive a genetic risk communication which indicates which quartile of genetic risk they are at in comparison to the rest of the population. The report also contains information on what this risk means for their chances of developing cardiovascular disease in the future.
223890302|NCT06365320|OTHER|Single basketball training|Single basketball training session with fixed intensity and duration
223890303|NCT04788459|BIOLOGICAL|COVID-eVax|Plasmid DNA Vaccine for COVID-19
223890304|NCT04788459|DEVICE|Cliniporator® and EPSGun|IGEA Electroporation Device
223890305|NCT05523388|OTHER|Collection of health-related data|A multimodal set of data including experimental, clinical, functional, radiological and biomechanical data is compiled before and after routine surgical intervention at baseline and at one-year follow-up.
223890306|NCT05857020|DEVICE|Auricular Acupressure|"Auricular Acupressure (AA) utilizing all-natural vaccaria ear seeds will be applied to 5 designated sites on each participant's ear (total of 10 seeds placed per patient).~Participants will be asked if they consent to having their ear placement photographed after placement (optional) and audio recorded during interventionist ear seed placement (optional) in collaboration with the BAApress training fidelity study."
223890307|NCT05374278|DRUG|[18F]RP-115 PET/MRI or PET/CT and MRI|An I.V. bolus injection of up to 10 millicurie (mCi) \[18F\]RP-115 will be administered, followed by a PET/MRI scan or by a combination of PET/CT and MRI
223890308|NCT06654661|DEVICE|3D-Printed Mechanical Balancer|The 3D printed mechanical balancer is a surgeon-controlled handheld intraoperative tool used that provides a quantifiable measurement of force differences on the medial and lateral sides to guide achievement of a balanced knee. It will be used at one timepoint during scheduled TKA surgery while the patient is under anesthesia. Readings will be taken at 0, 45, and 90 degrees of flexion.
223890309|NCT06987396|DIETARY_SUPPLEMENT|1000 mg Betaglucans (daily)|Patients in the experimental group receive betaglucans supplement in capsule form, administered orally
223890310|NCT06986668|OTHER|Peloidotherapy|Peloidotherapy stands out among superficial heating physical therapy modalities with its mineral and natural origin.
223890311|NCT06986668|OTHER|paraffin bath|It is an effective treatment for the treatment of patients' hands, arms and feet by applying the brushing method to different body parts, relieving pain and improving function, thus providing freedom of life.
223890312|NCT06986668|OTHER|home exersize|Flexor tendon gliding exercises, median nerve gliding exercises, and isometric wrist strengthening exercises will be given as exercises.
223890313|NCT06986915|OTHER|Aerobic exercise at moderate intensity level|"The intervention involved supervised aerobic activity sessions. Every session contained:~Warm-up (5-10 minutes): To get the body ready, do some light stretching and low-intensity exercises.~The primary aerobic activity (30-45 minutes) should consist of moderately intense exercises that aim to reach 60-75% of the participant's maximal heart rate.~Cool-down (5-10 minutes): Stretching and a gradual decrease in activity to aid in recuperation.~This intervention's objective was to evaluate how moderately intense aerobic exercise affected the anthropometric (body weight, BMI), biochemical (blood sugar, cholesterol), and psychological well-being indicators in obese adult women."
223890314|NCT06987747|DEVICE|Repetitive transcranial magnetic stimulation|Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive, non-painful procedure used to relieve chronic pain and promote short-term changes. The first dorsal interossei (FDI) muscle of the left motor cortex will be targeted using neuronavigation software. A series of 90 triplet pulses will be delivered at 100 Hz stimulation. Stimulation will be delivered at 80% of the resting motor threshold obtained from the right FDI muscle. The delivery of rTMS requires \~ 15 minutes in total.
223890315|NCT06303960|DEVICE|Bilateral Cerebellar deep brain stimulation|Participants underwent stereotactic implantation of a single DBS lead in the area of the cerebellar DN contralateral to the lesioned cerebral hemisphere using a frame-based technique similar to that used in DBS for movement disorders. All participants received an 4-channel lead (Medtronic,3389）with electrode arrays up to 15.5 mm in length. Then bilateral stimulation was activated after 1 month post-DBS
223890316|NCT06303960|DEVICE|Unilateral Cerebellar deep brain stimulation|Participants underwent stereotactic implantation of a single DBS lead in the area of the cerebellar DN contralateral to the lesioned cerebral hemisphere using a frame-based technique similar to that used in DBS for movement disorders. All participants received an 4-channel lead (Medtronic,3389）with electrode arrays up to 15.5 mm in length. Then unilateral stimulation was activated after 1 month post-DBS
223890317|NCT06303960|DEVICE|Vagus Nerve Stimulation|Device implantation was done under general anaesthesia. A horizontal neck crease incision was created left of the midline at the level of the cricoid cartilage. After the vagus nerve was identified, the stimulation lead was wrapped around the vagus nerve. The lead was then tunnelled subcutaneously to the pulse generator device which was contained in a subcutaneous pocket in the pectoral region.
223890318|NCT03238794|PROCEDURE|Roux-En-Y Gastric Bypass|Food will be consumed as directed by their doctor as standard of care. A food log will be completed the week before visits 3 and 5.
223890319|NCT03238794|OTHER|Low-calorie Diet|Food will be consumed as Week one will be liquid 400 to 500 kcal/day, weeks 2,3, and 4 will consist of 500-600 kcal/day of pureed food, weeks 5-8 will consist of 600-800 kcal/day of mechanical-soft food, weeks 9-12 will consist of 800 to 1000 kcal/day of soft foods, and the remainder of the study participants will be given 1000 to 1200 kcal/day of regular food.
223890320|NCT04675476|BEHAVIORAL|Provider Prompt & Patient Outreach and Education|To target lack of provider-prompted discussion about lung screening, an electronic medical record (EMR) message will be sent to primary care providers prior to scheduled visits with screening-eligible patients to notify them of the patient's eligibility and to encourage discussion of the benefits and limitations of the test. To target patient-level knowledge about lung screening, an outreach specialist will educate screening-eligible patients about the benefits and limitations of the test prior to their visit.
223890321|NCT06846164|OTHER|Supervised progressive strength training including elements of neuromuscular exercise intervention (SNG)|Participants will be randomized to SNG and will perform training sessions (60-70 minutes) twice weekly, over a duration of 12 weeks, commencing 8 exercises for the lower extremities in 3 sets of 10 repetitions with an intensity of 12 repetitions maximum. Individual progression, quality of exercise, number of sets, repetitions, and additional training weights will be monitored
223890322|NCT06846164|OTHER|home based low-intensity weight-bearing exercise protocol.|Participants allocated to CON will receive written and verbal instructions regarding 4 home-based (low intensity), weight-bearing exercises for the lower extremities, to be performed twice weekly. This intervention is designed to resemble usual care in cases where persistent knee muscle strength deficits would be discovered and considered a clinical issue.
223890323|NCT04747912|DRUG|Inotuzumab ozogamicin|Inotuzumab ozogamicin, sold under the brand name Besponsa, is an anti-cancer drug used to treat relapsed or refractory B-cell precursor acute lymphoblastic leukemia.
223890324|NCT04747912|DRUG|Dasatinib|Dasatinib is a prescription treatment for adults with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML).
223890325|NCT04747912|DRUG|Dexamethasone|Dexamethasone is a steroid that prevents the release of substances in the body that cause inflammation.
223890326|NCT04747912|DRUG|Methotrexate|Methotrexate is a chemotherapy drug that is used to treat certain types of cancer and leukemia.
223890327|NCT04747912|DRUG|Vincristine|Vincristine, also known as leurocristine and marketed under the brand name Oncovin among others, is a chemotherapy medication used to treat various types of cancer such as acute lymphocytic leukemia, acute myeloid leukemia, Hodgkin's disease, neuroblastoma, and small cell lung cancer among others.
223890328|NCT04747912|DRUG|Ponatinib|A drug used to treat chronic myelogenous leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia. It is used in patients whose cancer has the T315I mutation or whose cancer cannot be treated with other tyrosine kinase inhibitors. It is also being studied in the treatment of other types of cancer. Ponatinib blocks BCR-ABL, which may help keep cancer cells from growing and may kill them.
223890329|NCT04747912|DRUG|Methotrexate for Injection|Methotrexate is a chemotherapy drug that is used to treat certain types of cancer and leukemia. When given intrathecally, it prevents leukemia cells entering the cerebrospinal fluid (CSF) around the spine and brain. Intrathecal chemotherapy is administered during a procedure called a lumbar puncture or through an ommaya reservoir (shunt).
223890330|NCT04747912|PROCEDURE|Allogenic Stem Cell Transplantation|A procedure in which a patient receives healthy blood-forming cells (stem cells) from a donor to replace their own stem cells that have been destroyed by treatment with radiation or high doses of chemotherapy. In an allogeneic stem cell transplant, the healthy stem cells may come from the blood or bone marrow of a related donor who is not an identical twin of the patient or from an unrelated donor who is genetically similar to the patient. An allogeneic stem cell transplant is most often used to treat blood cancers, such as leukemia and lymphoma, and certain types of blood or immune system disorders.
223890331|NCT06847009|OTHER|Acupressure application|Acupressure will be applied to hemodialysis patients within the first two hours of HD and three times a week for four weeks. This intervention aims to evaluate its effects on sleep quality.
223890332|NCT03378219|DRUG|Sarilumab SAR153191 (REGN88)|Pharmaceutical form:injection Route of administration: subcutaneous
223890333|NCT06843928|DEVICE|Submucosal debridement|Participants will undergo non-surgical submucosal debridement alone (SD)
223890334|NCT06843928|DEVICE|Submucosal debridement + titanium brushes|Participants will undergo non-surgical submucosal debridement + titanium brushes (SD+TiBr)
223890335|NCT06847828|OTHER|QPL|The QPL is in the form of a structured list of questions that caregivers would like to ask. It includes 17 questions on concept communication and 20 questions on end-of-life care. You can check the questions you want to ask and then discuss them with the medical team.
223890336|NCT05838131|DRUG|Experimental: CAR-T cells Infusion|"Biological:~chimeric antigen receptor T cells"
223890337|NCT05137899|COMBINATION_PRODUCT|Neoadjuvant|Neoadjuvant atezolizumab/bevacizumab or neoadjuvant SBRT prior to hepatectomy
223890338|NCT05610774|DRUG|Dexmedetomidine|pre-eclamptic Patients will receive a loading dose of iv dexmedetomidine (0.5 ug/kg) diluted in 50 ml saline and given over 10 min, followed by a maintenance infusion of (0.2 ug/kg/h) diluted in 200 ml saline till The sedation scores on the Richmond Agitation and Sedation Scale was -2 to +1 (lightly sedated to restless).
223890339|NCT05610774|DRUG|Saline|pre-eclamptic patients will receive 50 ml saline loading for 10 min followed by 200 ml saline infusion
223890340|NCT06846645|OTHER|No intervention|Patients will receive clinical treatment with no special intervention in this observational study. There is no difference in term of treatment of patients. It only involves one additional blood sampling early after admission.
223890341|NCT06755359|DEVICE|Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)|Radioactive sources named Alpha DaRT sources: Ra - 224 coated onto titanium tubes inserted into the tumor.
223890342|NCT06217458|DIAGNOSTIC_TEST|Contrast Enhanced Mammography|The CEM performance protocol involves the intravenous administration of non-ionic, low-osmolarity iodinated contrast medium using an automatic syringe that delivers the required bolus of contrast medium at a dose of 1.5 ml/kg body weight at a rate of 3 ml/s without compressing the breast. After a two-minute pause, necessary to allow the breast parenchyma to absorb (stain) the contrast agent, the patient is positioned for the mammogram and the breast is compressed. First the symptomatic and then the non-symptomatic breast is imaged in two or a total of four standard projections: craniocaudal (CC) and oblique mediolateral (MLO) projections of the breast. The delayed CC and MLO projections of the symptomatic breast are taken within eight minutes of the start of the examination. The delayed mammograms are used to assess the dynamics of the contrast uptake of the lesion and are compared to the same parameters of the breast MRI. The time required to perform the CEM is 8-10 minutes.
224078821|NCT05559723|DEVICE|Transcutaneous Electrical Nerve Stimulation|Transcutaneous Electrical Nerve Stimulation (TENS): from the prone lying position, the electrodes will be placed on the course of pain detected by the patient, with an asymmetrical rectangular biphasic form, at a pulse repetition frequency of 100Hz and duty cycle of 250 microseconds; the intensity was set at a level that each patient could feel, for 15 minutes .
224078822|NCT03723681|DRUG|Quizartinib|Quizartinib is provided as 20 mg tablets for oral administration
224078823|NCT02656927|BEHAVIORAL|Yoga Condition|
224078824|NCT02264587|DRUG|Mosapride|Mosapride 5mg by mouth ,3 times one day for 1 4days.
223890343|NCT06845722|OTHER|Balance training|"* The balance training will be given for 12 weeks (2 sessions/week, 30-35 in each) that included six balance exercises per training session.~* After 5-min warm-up program including general (e.g., neck rolls, shoulder circles, side bends, hip circles, marsh in place) and specific (e.g., two-/one-legged stance on unstable devices, forward/backward beam walking).~* Two sets per balance exercise will be performed for 30s each with a 60s rest period between sets and a 90 s break between exercises. Yet, both groups will execute the same training volume (i.e., number of exercises, number of sets per exercise, and duration per set of exercise).~* Progression during training will be achieved by means of increasing exercise duration (i.e., from 30s over 45s to 60 s), change of stance (i.e., two-legged stance, tandem. stance, one-legged stance) and walking (i.e., forward, backward) condition, manipulation of visual input (e.g., eyes opened vs. closed), and concurrent execution of cognitive"
223890344|NCT06845722|OTHER|Cognitive Rehabilitation:|"* The cognitive rehabilitation will be given for 12 weeks ( 2 sessions/week,30 min each session). The individual sessions for the CR approach will involve an individualized intervention focusing on a personally meaningful goal (e.g., maintaining attention while flipping cards and finding matching pairs, learning to use a cellular phone, remembering the names of people).~* The individual sessions will be consisted of practical strategies and aids, compensation strategies (e.g., using a memory notebook), and the techniques for stress management to improve performance and functioning in relation to goals. The group sessions of CR involved some tasks of cognitive training.~* The group sessions will be focused on practicing time-and-place orientation through paper-and pencil tasks provided by a therapist and use of a calendar and personal memory notebook or cellular phone at the start of each session. (30)~* The group sessions also involved matching faces and names and learning memory"
223890345|NCT06843629|DIAGNOSTIC_TEST|Specific positron imaging agents targeting MSLN|To perform integrated PET/MR or PET/CT visualization of patients with clinically suspected or confirmed pancreatic cancer, ovarian cancer, lung adenocarcinoma and other malignant tumors with high MSLN expression and healthy volunteers, using specific positron imaging agents targeting MSLN (taking \[68Ga\]Ga-NOTA-MSLN antibody fragment as an example), to achieve the following purposes: Patients with malignant tumors: for diagnosis and staging of diseases, comparing with the gold standard pathological diagnosis, evaluating diagnostic efficacy, clarifying the presence or absence of lesions, and determining the location and nature of lesions; comparing with \[18F\]FDG PET for accurate staging, evaluating the tumor load, and helping to determine the therapeutic plan. Healthy volunteers: Pharmacokinetic analysis will be performed to clarify the distribution and metabolism of the drug in the body and its safety.
224078825|NCT02264587|DRUG|domperidone|Domperidone 10mg by mouth ,3 times one day for 1 4days.
224078826|NCT00319969|DRUG|Amrubicin|Amrubicin 40mg/m\<2\> IV days 1, 2, 3 of each 21-day cycle until disease progression.
224078827|NCT00319969|DRUG|Topotecan|Topotecan 1.5mg/m\<2\> IV days 1, 2, 3, 4, 5 of each 21-day cycle until disease progression.
224078828|NCT02470455|DRUG|Atorvastatin|Some patients were receiving 20 mg of Atorvastatin wheras others were on a higher dose of 40-80mg daily. Patients were taking statins for either dyslipidemia, or primary or secondary prevention of cardiovascular disease.
224078829|NCT00847587|DRUG|Etonogestrel contraceptive implant|Implant insertion postpartum prior to hospital discharge
224078830|NCT00847587|DRUG|Etonogestrel contraceptive implant|Standard insertion at 4-8 weeks postpartum
224078831|NCT02077933|DRUG|alpelisib|"alpelisib is administered orally once a day on a continuous dosing schedule and dosed on a flat-fixed dose and not adjusted by body weight or body surface area, starting on Day 8 of Cycle 1 in the dose escalation and Day 1 of Cycle 1 in the dose expansion.~In the doublet dose escalation, the alpelisib starting dose is 300 mg. The alpelisib dose may be escalated or de-escalated, as needed.~In the triplet dose escalation part, the alpelisib starting dose is one dose level lower of the MTD as determined during the doublet escalation. The alpelisib dose may be escalated or de-escalated, as needed.~In the doublet dose expansion and triplet dose expansion (patients assigned to alpelisib, everolimus and exemestane), alpelisib is administered at the recommended dose determined in the dose escalation.~In the triplet dose expansion (patients assigned to alpelisib and exemestane), alpelisib is administered at a dose of 250 mg daily."
224078832|NCT02077933|DRUG|everolimus|"everolimus is administered orally once a day on a continuous dosing schedule and dosed on a flat-fixed dose and not adjusted by body weight or body surface area, starting on Day 1 of cycle 1 in both the dose escalation and dose expansion parts.~In the dose escalation part, the everolimus starting dose is 2,5 mg. In the dose expansion part, everolimus is administered at the recommended dose determined in the dose escalation."
224078833|NCT02077933|DRUG|exemestane|exemestane is administered orally once a day on a continuous dose of 25 mg starting on Day 1 of Cycle 1 in both the dose escalation and dose expansion.
224078834|NCT01047202|BIOLOGICAL|Pandemic influenza A/H1N1 vaccine|Pandemic influenza A/H1N1 vaccine (PANFLU.1), 15 micrograms per dose per 0.5 millilitre. Vaccines will be administered as a single 0.25 mL intramuscular injection in the deltoid muscle of the arm (randomized in one arm) at the first dose and the other arm for the second dose
224078835|NCT01047202|BIOLOGICAL|Pandemic influenza A/H1N1 vaccine|Pandemic influenza A/H1N1 vaccine (PANFLU.1), 15 micrograms per dose per 0.5 millilitre. Vaccines will be administered as a single 0.5 mL intramuscular injection in the deltoid muscle of the arm (randomized in one arm) at the first dose and the other arm for the second dose
224078836|NCT01047202|BIOLOGICAL|Seasonal trivalent vaccine|Trivalent Inactivated Influenza Vaccine (ANFLU), 7.5 micrograms of each strain per dose per 0.25 millilitre. Vaccines will be administered as a single 0.25 mL intramuscular injection in the deltoid muscle of the arm (randomized in one arm) at the first dose and the other arm for the second dose
224078837|NCT04955275|OTHER|Cognitive Remediation Therapy Program (BrainHQ)|Brain HQ games involving training cognitive abilities like memory and attention, made up of adapting tasks or creating our own.
224078838|NCT05107167|DEVICE|Electromagnetic stimulation|Electromagnetic stimulation of the phrenic nerve
224078839|NCT02687399|OTHER|placebo|After prosthesis cementation and just before knee suture and tourniquet liberation, the patients randomized in the placebo group will receive placebo for inyection sprayed on the exposed tissues of the knee.
223890346|NCT02694094|DIETARY_SUPPLEMENT|Modified Atkins or Ketogenic Diet|Biochemical and vascular parameters will be compared from adults who have been on ketogenic diet therapy for \> 12 months to adults naive to ketogenic diet therapy. In addition, adults naive to diet therapy who subsequently begin diet therapy will have these same parameters followed over time.
223890347|NCT06847594|DRUG|ringer lactate (20ml/kg)|ringer lactate 20 ml/kg over the first 90 to 120 minutes after induction intraoperatively
223890348|NCT06847594|DRUG|Dextrose 10%|Dextrose 10% 250 ml over 60 minutes
223890349|NCT03588481|DEVICE|DESyne X2|Novolimus-eluting stent
223890350|NCT06845189|OTHER|Modified Robbery Exercises|Prescribed set of Modified Robbery exercises will be applied
223890351|NCT06845189|OTHER|Conventional Physiotherapy Treatment|Conventional Physiotherapy Treatment for Frozen Shoulder
223890352|NCT05777031|DRUG|Collagenase Clostridium Histolyticum (CCH)|Injection of intralesional CCH (0.58mg) to the penile plaque at the point of maximal curvature. Second injection of each cycle will be injected 2-3mm apart from the prior injection.
223890353|NCT06847672|DIAGNOSTIC_TEST|preoxygenation|The time required to reach EtO2 90% and the time until ORI drops below 0.55
223890354|NCT06845787|BEHAVIORAL|Live-music therapy|Children will be offered live-music therapy for 3 consecutive sessions, 30 minute sessions in which 10 to 20 minutes of music is provided by a trained music therapist in the presence of parents. In the sessions, the music therapist will make a tailored plan for each child to avoid overstimulation, which includes choosing the appropriate instrument, determining the child's behavioural state, and continuously monitoring the child (i.e., looking for signs of relaxation but also of overstimulation such as tension, crying movements, hiccups, yawning or frowning). The music therapist will collaborate with parents in constructing a program for the sessions. Parents will be actively involved in the sessions, to stimulate their role as caregiver and empower them. The contents of the live-music is thus constantly evaluated and adapted for the individual child.
223890355|NCT03948373|DEVICE|CPAP treatment|In this group of patients (CPAP group) will be prescribed CPAP treatment at an optimal pressure. It will be performed a CPAP titration with an automatic or manual CPAP according to usual clinical practice.
223890356|NCT04889937|DEVICE|PointCheck|PointCheckTM is intended for use to aid in the assessment of severe neutropenia in the home or clinic setting in subjects receiving myelosuppressive chemotherapy with intermediate to high febrile neutropenia risk. The device non-invasively captures real-time videos of blood flow in the nailfold microcirculation and utilizes visible light, a microscope and a computer vision software to provide a qualitative result. The device is limited to use as a preliminary assessment tool in conjunction with standard of care, including temperature monitoring and clinical assessment. It is not to be used as a stand-alone determinant of severe neutropenia or for any other diagnostic purpose
223890357|NCT04516616|DRUG|Cisplatin+Albumin-bound paclitaxel (1 cycle) and PD-1 monoclonal antibody+Cisplatin+Albumin-bound paclitaxel (2 cycles)|PD-1 monoclonal antibody （SHR-1210)：200mg，IV infusion，Q3W Cisplatin：75-80 mg/m2, IV infusion, Q3W Albumin-bound paclitaxel: 260 mg/m2，30min，IV infusion, Q3W
223890358|NCT03637400|DRUG|TMP-SMX|TMP-SMX will be administered over a period of 7 days.
223890359|NCT03637400|DRUG|DOXY|DOXY will be administered over a period of 7 days.
223890360|NCT06530446|OTHER|one group. observational study|observational study of this group
223890361|NCT06333964|DRUG|AST-001|AST-001, PO bid for 24weeks (dosage according to weight range)
223890362|NCT06333964|DRUG|Placebo of AST-001|Placebo of AST-001, PO bid for 12 weeks + AST-001, PO bid for 12 weeks (dosage according to weight range)
223890363|NCT05964452|DRUG|Methimazole Tablets|Testing dosing algorithm for efficacy.
223890364|NCT05628415|PROCEDURE|Non-powered AeonTM Endostapler (according to manufacturer medical device classification IIb)|Closure of the left and/or right side of the lung after bilateral or unilateral lung-volume-reduction- surgery is performed with the non-powered Aeon™ Endostapler (Lexington medical) 60-mm and 45-mm. At the end of the operation, two 24F apical chest tubes are placed on each side and are systematically set at -10 cm H2O suction via the Medela- Topaz™ system. Air leak will be measured quantitatively in ml per minute by use of a Medela-Topaz™ system. Cessation of air leak is the case when a value of 0ml/min or two consecutive values under 30 ml/min by use of thoracic drainage Medela- Topaz™ system are read.
223890365|NCT05628415|PROCEDURE|Echelon FLEX™ Powered plus Stapler (according to manufacturer medical device classification IIb)|Closure of the left and/or right side of the lung after bilateral or unilateral lung-volume-reduction- surgery is performed with the Echelon FLEX™ Powered plus Stapler (Ethicon) 60-mm and 45-mm. At the end of the operation, two 24F apical chest tubes are placed on each side and are systematically set at -10 cm H2O suction via the Medela- Topaz™ system. Air leak will be measured quantitatively in ml per minute by use of a Medela-Topaz™ system. Cessation of air leak is the case when a value of 0ml/min or two consecutive values under 30 ml/min by use of thoracic drainage Medela- Topaz™ system are read.
223890366|NCT06196866|OTHER|Conventional Therapy|The control group will develop only conventional treatment for the whole trial (weeks 1-24), consisting of carrying out daily routine activities and/or 1 session/week of physiotherapy (which includes manual therapy, active exercises of repetition of functional movements, walking, stairs and stretching) with a time of 45 minutes/session.
223890367|NCT06196866|DEVICE|Nintendo Ring Fit Adventure + Conventional Therapy|"In the exergaming group 1, the intervention will be 12 weeks (weeks 1-12) with a frequency of 1 session/week and with a time of 45 minutes/session, in addition to the users' conventional therapy. The training will be a first 5 minutes warm-up (composed of joint mobility and global stretching), 35 min of exergaming training (working on the participants' gait, stability and global muscle strength) and last 5 minutes of cooling down (composed of breathing exercises, joint mobility and global stretching) in each session. The therapist will choose in each session different exercises from each of these 4 sections:~Jogging: Begginia or Transient Temple.~Minigames: Squat Goals, Squattery Wheel, Gluting Gallery, Thigh Rider, Bank Balance or Dreadmill.~Lower Limbs Training: Knee Lift or Hip Lift.~Yoga: Tree Pose or Chair Pose."
224078840|NCT02687399|BIOLOGICAL|TT-173|After prosthesis cementation and just before knee suture and tourniquet liberation, the patients randomized in the treatment group will receive TT-173 for inyection sprayed on the exposed tissues of the knee.
224078841|NCT01193400|DRUG|Clofarabine|
224078842|NCT01193400|DRUG|Cytarabine|
224078843|NCT03015805|BEHAVIORAL|Contingency Management|"Contingency Management (CM) utilizes behavior modification \& cognitive behavioral strategies to target adolescent alcohol or other drug (AOD) use. Protocol components are as follows: (a) The provider introduces CM to the family and engages them in the intervention; (b) The provider conducts Antecedent-Behavior-Consequence (ABC) assessments of the youth's AOD use with the youth and caregiver; (c) Based on the results of the ABC assessments, self-management planning and drug refusal skills training are implemented by the provider in collaboration with the caregiver; (d) Concurrently, a point and level system contract is filled in by the family, which provides rewards/privileges for negative drug and alcohol tests and disincentives (e.g., extra chores) for positive tests. Until continued abstinence is achieved, components b through d are repeated; (e) The provider collaborates with the family to develop plans for sustaining long-term abstinence. Typical duration of CM is 12-16 weeks."
224078844|NCT03015805|BEHAVIORAL|Probation as Usual|Standard services that a young person would receive while under probation supervision in the state of Oregon.
224078845|NCT04598490|DEVICE|Space closure into old extraction space|Lower first premolar extraction space was closed using elastic power chain and 0.019X0.025 Stainless steel archwire into healed bony socket
224078846|NCT04598490|DEVICE|Space closure into recent extraction space|Lower first premolar extraction space was closed using elastic power chain and 0.019X0.025 Stainless steel archwire into fresh bony socket
224078847|NCT00381407|BEHAVIORAL|Organizational Skills Training|Participants in the OST group attend twenty 1-hour sessions over 10 weeks. OST trains children to use a variety of techniques for improving their organizational skills. Both children and their parents attend every OST session.
224078848|NCT00381407|BEHAVIORAL|Contingency management (CM)|"Participants in the CM group will attend twenty 1-hour sessions over 10 weeks. CM trains parents and teachers to identify desired end behaviors and to increase the frequency of these behaviors through the use of a structured reward system. Both children and their parents attend every CM session, but the children's participation will be minimal."
224078849|NCT05708742|DEVICE|Ultrasound|A linear US transducer (Phillips-Saronno Italy) was placed vertically 3 cm lateral to the midline to visualize back muscles: the trapezius above, the rhomboid major in the middle, and the erector-spinae muscle on the bottom, as well as the TPs with shimmering pleura in between.
224078850|NCT05708742|DRUG|Bupivacaine Hydrochloride|The ESP block group underwent US-guided ESP block at L4 vertebrae level with 20 ml of bupivacaine 0.25%.
224078851|NCT05708742|DRUG|saline solution|The control group underwent the same procedure but had a sham injection (20 ml of saline).
224078852|NCT05708742|DEVICE|Needle|A 22-gauge short bevel needle (Spinocan, B. Braun Melsungen AG, Germany) was inserted in the cranial-caudal direction towards the TP in-plane with the US transducer until the needle touched the TP crossing all three muscles.
224078853|NCT03882307|DRUG|sofosbuvir and daclatasvir|oral tablets
224078854|NCT03630731|DRUG|chidamide|For those who responded to induction chemotherapy, chidamide will be given OR orally 30mg biw for at least half a year
224078855|NCT00454779|DRUG|Cisplatin|chemotherapy arm
224078856|NCT00454779|DRUG|Panitumumab|experimental arm
224078857|NCT00454779|DRUG|Docetaxel|chemotherapy arm
224078858|NCT00454779|DRUG|Cisplatin|experimental arm
224078859|NCT00454779|DRUG|Docetaxel|experimental arm
224078860|NCT00662844|DIETARY_SUPPLEMENT|vitamin D3|Oral, one capsule daily of vitamin D3 (400IU, 800IU, 1600 IU, or 2400IU) plus calcium citrate (1-4 tablets) twice daily to reach a total calcium intake of 1000-1200 mg/day
224078861|NCT01039857|BEHAVIORAL|Neuropsychological Therapy, cognitive behavioral therapy, solution focused therapy|
224078862|NCT01039857|BEHAVIORAL|Integrative Neuro-Psychotherapy|Neuropsychological therapy, cognitive-behavioral therapy, emotion-focused techniques, clarification and interpersonal therapy techniques
224078863|NCT00827697|OTHER|Gen-Probe APTIMA Combo2 (AC2)|Laboratory Test
224078864|NCT00019760|DRUG|floxuridine|
224078865|NCT00019760|DRUG|leucovorin calcium|
224078866|NCT00019760|DRUG|melphalan|
223890368|NCT06196866|DEVICE|Nintendo Wii Fit + Conventional Therapy|"In the exergaming group 2, the intervention will be 12 weeks (weeks 1-12) with a frequency of 1 session/week and with a time of 45 minutes/session, in addition to the users' conventional therapy. The training will be a first 5 minutes warm-up (composed of joint mobility and global stretching), 35 min of exergaming training (working on the participants' gait, stability and global muscle strength) and last 5 minutes of cooling down (composed of breathing exercises, joint mobility and global stretching) in each session. The therapist will choose in each session different exercises from each of these 4 sections:~Aerobics: Basic Run or Hula Hoop.~Strength Training: Rowing Squat, Single-Leg Extension, Sideways Leg Lift or Single-Leg Twist.~Balance Games: Ski Jump, Balance Bubble, Table Tilt or Penguin Slide.~Yoga: Chair or Standing Knee."
223890369|NCT04365036|DRUG|Toripalimab|toripalimab 240mg, d1, intravenous drip
223890370|NCT04365036|DRUG|Pegaspargase|pegaspargase, 2000U/m2, d1, intravenous drip
223890371|NCT04365036|DRUG|Gemcitabine|gemcitabine, 1000mg/m2, d1,d8, intravenous drip
223890372|NCT04365036|DRUG|Oxaliplatin|oxaliplatin, 130mg/m2, d1, intravenous drip,
223890373|NCT04365036|RADIATION|Definitive intensity-modulated radiotherapy (IMRT)|Definitive intensity-modulated radiotherapy (IMRT) of 54-56Gy will be given in 25\~26 days
223890374|NCT05523401|DRUG|4-bromo-2,5-dimethoxyphenethylamine (10 mg)|A low dose of 10 mg 2C-B will be administered.
223890375|NCT05523401|DRUG|4-bromo-2,5-dimethoxyphenethylamine (20 mg)|A medium dose of 20 mg 2C-B will be administered.
223890376|NCT05523401|DRUG|4-bromo-2,5-dimethoxyphenethylamine (30 mg)|A high dose of 30 mg 2C-B will be administered.
223890377|NCT05523401|DRUG|3,4-methylenedioxymethamphetamine|A moderate dose of 125 mg MDMA will be administered.
223890378|NCT05523401|DRUG|Psilocybin|A moderate dose of 25 mg psilocybin will be administered.
223890379|NCT05523401|OTHER|Placebo|Placebo (Mannitol)
223890380|NCT04870112|DRUG|Durvalumab|Anti-PD-L1 antibody
223890381|NCT04870112|DRUG|Cisplatin|Chemotherapy
223890382|NCT04870112|DRUG|Carboplatin|Chemotherapy
223890383|NCT04870112|DRUG|Etoposide|Chemotherapy
223890384|NCT06077591|OTHER|Patient-Derived Tumor Organoids|Intervention in this study is to perform tissue sampling to patient's tumor which are then subjected to DNA extraction for whole exome sequencing, organoid culture, and drug screen. An MDT board will review the drug screen results and excluded drug choice of poor response. Then the referring oncologist has the final discretion on the choice of chemo- or targeted agent as usual.
223890385|NCT05078411|BEHAVIORAL|Test treatment|"Test treatment will consist of a single session structured as follows: (i) information on periodontal diagnosis (as formulated according to the classification system of the 2017 World Workshop for the Classification of Periodontal Diseases and Conditions); (ii) information on periodontal risk level (as calculated with the PerioRisk tool proposed by Trombelli et al. 2009) and profile (i.e., the magnitude of the contribution of each PerioRisk parameter to generate the patient risk level); (iii) information on treatment plan and oral hygiene instructions, with emphasis to treatment goals based on the PerioRisk output.~The operators will be trained to administer test treatment in approximately 8 minutes, but the duration of the session will be extended for additional questions and answers upon patient request."
223890386|NCT05078411|BEHAVIORAL|Control treatment|"Control treatment will consist in a single session structured as follows: (i) information on periodontal diagnosis (as formulated according to the classification system of the 2017 World Workshop for the Classification of Periodontal Diseases and Conditions); (ii) information on treatment plan and oral hygiene instructions, and treatment goals. Although the general concept of risk of periodontitis incidence/progression will be explained, no mention will be made to the patient risk level as calculated with PerioRisk or any other tool.~The operators will be trained to administer control treatment in approximately 8 minutes, but the duration of the session will be extended for additional questions and answers upon patient request."
223890387|NCT04911751|DRUG|KBL697|1 capsule BID of KBL697 or Placebo
223890388|NCT04911751|DRUG|KBL697|5 capsules BID of KBL697 or Placebo
223890389|NCT03763253|COMBINATION_PRODUCT|Standard of Care|Androgen deprivation with or without docetaxel chemotherapy, Abiraterone, Enzalutamide or any other proven agent) treatment as determined by treating physician (positive control).
223890390|NCT03763253|PROCEDURE|Minimally Invasive Ablative Therapy (MIAT)|"MIAT includes High intensity focused ultrasound (HIFU) or Cryotherapy to the prostate.~Metastatic Directed Therapy available for use."
223890391|NCT03763253|PROCEDURE|Radical Therapy (Prostatectomy or Radiotherapy)|"Radical therapy includes: Prostatectomy (any surgical approach) or External beam radiotherapy (High dose).~Metastatic Directed Therapy available for use."
223890392|NCT06504732|DRUG|IAH0968|Subjects were treated with IAH0968 in combination with or without the CAPEOX regimen in the corresponding groups. Every 3 weeks was defined as a treatment cycle and IAH0968 was used for a maximum of 35 cycles.
223890393|NCT05140148|DRUG|Amantadine|Amantadine is a antiviral drug and dopamine promoter that is currently approved by the FDA for the treatment of influenza A and Parkinson's Disease
223890394|NCT05140148|DRUG|Placebo|placebo pills
223890395|NCT05539352|BEHAVIORAL|Problem Solving Therapy (PST) plus EUC|"All caregivers are assigned to this condition and receive EUC and PST. EUC is delivered along with the treatment to ensure the safety of all caregivers enrolled in the study. In addition to EUC, caregivers receive PST, which teaches patients a structured planful problem solving approach to: 1) identify problems and set goals, 2) generate alternative solutions, 3) select a solution based on cost-benefit analysis, and 4) devise and implement a plan for the solution and assess its effectiveness in solving the problem. This contemporary PST protocol also teaches tool kits to address obstacles highly pertinent to the challenges faced by caregivers and active suicidal ideation: emotion dysregulation, hopelessness, and feeling overwhelmed by too much information (brain overload) or stress."
223890396|NCT02206295|DRUG|selexipag|
223890397|NCT04537156|BIOLOGICAL|Nonavalent HPV vaccine|Nonavalent HPV vaccine (270μg/0.5ml) administered intramuscularly according to a 0, 1, 6 month vaccination schedule.
223890398|NCT04537156|BIOLOGICAL|Bivalent HPV vaccine|Bivalent HPV vaccine (60μg/0.5ml) administered intramuscularly according to a 0, 1, 6 month vaccination schedule.
224078867|NCT00690885|DRUG|interferon-alpha lozenges|150 IU natural human interferon-alpha lozenges for oral dissolution given 3 times per day for 4 weeks
224078868|NCT00690885|DRUG|placebo lozenges|matching placebo lozenges
223890399|NCT06415422|BIOLOGICAL|Biological samples|Biological samples are taken from the patient's catheter inserted upon admission (the usual access route for patients): A daily sample is collected into a dry tube for off-site analysis by VeriFyNow until platelet function normalizes (for example, if platelet function normalizes on Day 2, no further VeriFyNow analysis will be conducted on subsequent days).
223890400|NCT06489548|DRUG|Foralumab TZLS-401 50 µg|Foralumab is a nasal anti-CD3 antibody. It will be administered in doses of 50 µg vs. placebo.
223890401|NCT06489548|DRUG|Foralumab TZLS-401 100 µg|Foralumab is a nasal anti-CD3 antibody. It will be administered in doses of 100 µg vs. placebo.
223890402|NCT04060355|BEHAVIORAL|Savvy program|Caregiver program (Savvy) is an evidence-based dementia family caregiver psychoeducation program. Provided to groups of 8-12 (typically) individuals caring for family members living with Alzheimer's disease or related dementias (PLWD), Savvy employs a mechanism of action based in Social Cognitive theory to promote caregivers' solution-focused coping behaviors through the acquisition of appropriate knowledge, skills, and outlook and the enhancement of caregiving mastery.
223890403|NCT04060355|BEHAVIORAL|Semi-structured video interviews|Semi-structured video interviews will assess the preliminary efficacy of programs led by system-trained interventionists in producing anticipated outcomes in caregiver participants - reduced depression and burden and enhanced caregiving mastery. It will also focus on sense of the completeness and adequacy of the training program, including the training methods, videos, and materials
223890404|NCT06007092|BIOLOGICAL|HPVDC injection level dose 1|patient receive 3 injections of vaccine at the same level dose
223890405|NCT06007092|BIOLOGICAL|placebo injection level dose 1|patient receive 3 injections of vaccine at the same level dose
223890406|NCT06007092|BIOLOGICAL|HPVDC injection level dose 2|patient receive 3 injections of vaccine at the same level dose
223890407|NCT06007092|BIOLOGICAL|placebo injection level dose 2|patient receive 3 injections of vaccine at the same level dose
223890408|NCT03949387|OTHER|FES Cycling Exercise|FES cycling will use self-adhering surface electrodes (Pals Platinum, Fallbrook, CA) placed over the quadriceps, hamstrings, and gluteal muscle groups to deliver stimulation to the leg muscles.
223890409|NCT03949387|OTHER|Passive Leg Cycling|Passive leg cycling will not involve electrical stimulation
223890410|NCT01140880|DRUG|Truvada|Truvada At qualifying exposure, participants will take 28 days' worth (at one pill per day) of 200 mg emtricitabine and 300 mg tenofovir DF (Truvada).
223890411|NCT06312813|DRUG|Imipramine|4% imipramine
223890412|NCT06312813|DRUG|Amitriptyline|4% amitriptyline
223890413|NCT06312813|DRUG|Vehicle|0.1ml propylene glycol
223890414|NCT04990232|DRUG|Anakinra or rhIFNγ|In hyper-inflammation anakinra three times daily (every eight hours) for 15 days and sc 0.5 ml N/S 0.9% every other day for 15 days. In immunoparalysis IV 20 ml N/S 0.9% (10ml for patients with creatinine clearance lower than 30ml/min) three times daily (every eight hours) for 15 days and sc rhIFNγ every other day for 15 days.
223890415|NCT04990232|DRUG|Placebo|20ml (10ml for patients with creatinine clearance lower than 30ml/min) intravenous (IV) 0.9% saline (N/S) three times daily (every eight hours) for 15 days and 0.5 ml subcutaneous (sc) 1ml 0.9% N/S every other day for a total of 15 days
223890416|NCT01212029|BEHAVIORAL|Behavioral measures|Behavioral tasks/ questionnaires
223890417|NCT01212029|DEVICE|fNIRS Devices &amp; Application|Device 1- fNIRSoft and Device 2 - NIRScout
223890418|NCT01212029|OTHER|Physiological measures|A set of tasks.
223890419|NCT06357546|PROCEDURE|Spontaneous urination during the hour before caesarean section.|Patients will be asked to urinate by spontaneous urination in the hour before the cesarean section with a cytobacteriological urine examination (ECBU) carried out. An ultrasound check by Bladderscan of the post-void residue will be carried out as soon as the patient will be installed on the intervention table. In the event of post-void residue of more than 150 ml, favoring urinary infections, the patient will be excluded from the research.
223890420|NCT06357546|PROCEDURE|Systematic bladder catherization during caesarean section.|After implementation of loco-regional analgesia by spinal anesthesia, the patient will be positioned, with a perineal toilet and installation of a bladder catheter type Foley ch. 16.
223890421|NCT03577431|BIOLOGICAL|arTreg-CSB|"Participants will receive a single dose of Treg product (arTreg-CSB). The target dose is 2.5 to 125 x 10\^6 total cells. If a minimum arTreg-CSB dose of 1 to \< 2.5 x 10\^6 cells, the product will be infused. If the dose obtained after product manufacture is \< 1 x 10\^6 cells, the product will not be infused. When the dose obtained after product manufacture is \> 125 x 10\^6 cells, a dose aliquot will be prepared so that the administered dose will be ≤ 125 x 10\^6 cells, and ≥ 2.5 to 125 x 10\^6 total cells.~Method of receipt: peripheral intravenous (IV) infusion, administered over 15 to 30 minutes."
223890422|NCT03577431|PROCEDURE|leukapheresis|"Leukapheresis will be the method employed to recover peripheral blood mononuclear cells (PBMCs) from the allograft recipient. The recipient will undergo the procedure prior to initiating the cyclophosphamide conditioning regimen.~Procedure 72 to 120 hours prior to Treg product (arTreg-CSB) IV infusion."
223890423|NCT03577431|DRUG|cyclophosphamide|40 mg/kg administered intravenously (IV) within 24 to 72 hours prior to Treg product (arTreg-CSB) infusion.
223890424|NCT03577431|DRUG|mesna|Mesna is administered intravenously to inhibit hemorrhagic cystitis induced by cyclophosphamide. Administration of mesna is per institutional practice with cyclophosphamide.
223890425|NCT03577431|DRUG|everolimus|"EVR, an immunosuppressant (IS), is approved by the FDA for the prophylaxis of allograft rejection in adults receiving a liver transplant. Between day 30 and wk. 48 post-transplant, participant evaluation for eligibility to be converted to an EVR-based IS regimen will occur.~At the start of conversion from tacrolimus (TAC) to EVR IS:EVR will be started at 1.5 mg taken by mouth BID, with dose adjusted to achieve a trough blood level of 5-8 ng/mL. Once an EVR trough level of ≥ 5 ng/mL is achieved, baseline TAC dose will be reduced to achieve a trough level of 3-5 ng/mL.~When target EVR and TAC levels are achieved/ maintained over two consecutive measurements, and liver function tests, ALT and GGT, are ≤50 U/L, participants will be considered successfully converted to EVR-based IS regimen. EVR doses will be administered, monitored and adjusted over time, per protocol."
223890426|NCT04126200|DRUG|Belantamab mafodotin|Belantamab mafodotin will be administered.
223890427|NCT04126200|DRUG|GSK3174998|GSK3174998 will be administered.
223890428|NCT04126200|DRUG|Feladilimab|feladilimab will be administered.
223890429|NCT04126200|DRUG|Nirogacestat|Nirogacestat will be administered.
223890430|NCT04126200|DRUG|Dostarlimab|Dostarlimab will be administered.
223890431|NCT04126200|DRUG|Isatuximab|Isatuximab will be administered.
223890432|NCT04126200|DRUG|Lenalidomide|Lenalidomide will be administered.
223890433|NCT04126200|DRUG|Dexamethasone|Dexamethasone will be administered.
223890434|NCT04126200|DRUG|Pomalidomide|Pomalidomide will be administered.
223890435|NCT04308174|DRUG|Durvalumab + Gem/Cis|Neoadjuvant Durvalumab + Gemcitabine/Cisplatin
223890436|NCT04308174|DRUG|Gem/Cis|Neoadjuvant Gemcitabine/Cisplatin
223890437|NCT03196011|OTHER|TKR with mechanical alignment method|TKR implanted using traditional mechanical alignment methods
223890438|NCT03196011|OTHER|TKR with alternative alignment method|TKR implanted using alternative alignment methods
223890439|NCT04613635|DEVICE|Stratafix|Closure of ventral defect of the otherwise stapled gastrojejunal anastomosis with Stratafix USP (United States Pharmacopoe) 2-0 thread
223890440|NCT04613635|DEVICE|Vicryl|Closure of ventral defect of the otherwise stapled gastrojejunal anastomosis with Vicryl USP 2-0 thread
223890441|NCT05322785|OTHER|Breath collection|Exhaled breath will be passively collected from subjects during quiet oral breathing through a simple mouthpiece or mask
223890442|NCT06806696|OTHER|COVID-19 infection|COVID-19 diagnosis in the health database
223890443|NCT06642350|OTHER|Whole-body electrostimulation|10 weeks of WB-EMS 1.5x 20 min/week
223890444|NCT06642350|OTHER|Medical Training Therapy|10 weeks of MTT 2x 45 min/week
223890445|NCT04519970|BEHAVIORAL|Case Management|Each tier will have a different level of case management and support, all with the goal of increasing adherence to Biktarvy for HIV management.
223890446|NCT05146193|OTHER|Nude back photo|Nude back photo at baseline and at follow-ups for each patient and visual severity and curve type classifications
223890447|NCT05593055|DRUG|Eplerenone|After the Pre-Treatment Assessment, participants in the eplerenone arm will be given 50 mg eplerenone. At 2 weeks, eplerenone will be increased to 100 mg.
223890448|NCT05593055|DRUG|Chlorthalidone|After the Pre-Treatment Assessment, participants in the chlorthalidone arm will be given 12.5 mg chlorthalidone + 10 mEq potassium. At 2 weeks, chlorthalidone will be increased to 25 mg + 20 mEq potassium.
223890449|NCT05593055|DRUG|Potassium|After the Pre-Treatment Assessment, participants in the chlorthalidone arm will be given 12.5 mg chlorthalidone + 10 mEq potassium. At 2 weeks, chlorthalidone will be increased to 25 mg + 20 mEq potassium.
223890450|NCT04867460|PROCEDURE|Ultrasound guided venous access|Access of the axillary vein using ultrasound guidance.
223890451|NCT05537766|BIOLOGICAL|Brexucabtagene Autoleucel|Administered intravenously
223890452|NCT05537766|DRUG|Cyclophosphamide|Administered intravenously
223890453|NCT05537766|DRUG|Fludarabine|Administered intravenously
223890454|NCT06531863|DIETARY_SUPPLEMENT|Curcumin|1,330 mg curcumin
223890455|NCT06531863|DIETARY_SUPPLEMENT|Epigallocatechin Gallate|350 mg Epigallocatechin gallate (EGCG)
223890456|NCT06531863|OTHER|Placebo|Placebo to be consumed after randomization.
223890457|NCT05146440|DRUG|PM14|"Pharmaceutical form: PM14 drug product is provided as a sterile lyophilized powder for concentrate for solution for infusion with a strength of 5.0 mg of the active moiety.~Route of administration: PM14 drug product was developed for administration by the i.v. route. Before use, the vials are reconstituted with 10 mL of sodium chloride 9 mg/mL (0.9%) solution for infusion to give a solution containing 0.5 mg/mL of PM14. Prior to administration, the reconstituted DP solution should be further diluted with sodium chloride 9 mg/mL (0.9%) solution for infusion. Each vial of PM14 5.0 mg is a single use vial."
223890458|NCT03881605|DIAGNOSTIC_TEST|MRI screening|A standard contrast-enhanced MRI and Chemical Exchange Saturation Transfer (CEST) MRI of the brain will be performed at baseline, 4 months, 8 months and 12 months.
223890459|NCT04226053|OTHER|Parenting, Child Development|The treatment group will consist of mothers that were randomly selected to receive Room to Grow services, which include three years of social and practical support for the mother and baby. The research-informed program model combines tailored, one-on-one sessions with an expert clinical social worker in-person every three months, provision of essential baby items including books, toys, clothing, and equipment (retail value of in-kind items over three years averages $10,000), and connections to vital community resources (e.g., housing, entitlements, child care, social services).
223890460|NCT06436560|OTHER|STRIVE Peer Support Intervention|A virtual group-based peer support intervention led by trans peers who have had genital gender-affirming surgery.
223890461|NCT04164316|DEVICE|Kinesio Tape|Kinesio TexTM Tape which is the original elastic therapeutic adhesive tape which is a latex-free, hypoallergenic, waterproof, porous.
223890462|NCT06653582|OTHER|Postural reeducation|The program will include postural awareness, stretching, McKenzie's method, and manual therapy for 12 weeks.
223890463|NCT06653582|OTHER|Pelvic floor exercises|The program will include pelvic floor exercises for 12 weeks. Three sets of 10 long contractions will be performed, each sustained for 6-8 seconds, three times a day. After each contraction, participants will be asked to rest for the same period. Two series of 10 fast contractions will be recommended, consisting of short, quick exercises of 1- to 2-second contractions, followed by long, sustained exercises lasting 5-10 seconds.
223890464|NCT06581627|DRUG|Etavopivat|2 tablets of Etavopivat will be administered in fasted state via oral route
223890465|NCT04371913|RADIATION|600cGY x 5 fractions|Patients will be treated with the fractionation of 30 Gy in 5 fractions over 1-2 weeks, which is the accelerated fractionation scheme of choice for RT naïve patients at New York Presbyterian using EBRT.
223890466|NCT01293383|DRUG|LEO 90105|Ointment
223890467|NCT04682106|DRUG|LY3493269|Administered orally.
223890468|NCT04682106|DRUG|Placebo|Administered orally.
223890469|NCT04682106|DRUG|Salcaprozate Sodium|Administered orally.
223890470|NCT05983185|BEHAVIORAL|Prism adaptation therapy|The investigators' research and clinical group is the US leader in implementing this intervention for spatial neglect and have brought it to more than 50 clinical centers, hospitals, and treatment organizations.
223890471|NCT05290051|GENETIC|Optical Genome Mapping (Bionano®)|Search for chromosome abnormalities through alteration of the optical map of the genome compared to reference genome using the Bionano® 's pipeline.
223890472|NCT05290051|GENETIC|Longread sequencing (Nanopore®)|Search for chromosome abnormalities from the sequencing data obtain from high molecular weight DNA molecules using dedicated analysis pipeline.
223890473|NCT04812535|DRUG|Vilobelimab|Vilobelimab Monotherapy
223890474|NCT04812535|DRUG|Vilobelimab + pembrolizumab combination therapy|Vilobelimab + pembrolizumab combination therapy
223890475|NCT04886531|DRUG|Neratinib|120mg for 7 days; 160mg for 7 days ; 240mg for 7 days. 240 mg (up to a maximum of 24 weeks) orally daily\*.
223890476|NCT04886531|DRUG|Letrozole (L) or Anastrozole (A)|L: (2.5 mg) OR A: (1 mg) orally daily (up to a maximum of 24 weeks)\*
223890477|NCT04886531|DRUG|Trastuzumab|All Arms 8mg/kg loading dose followed by 6mg/kg every 3 weeks administered every 3 weeks by IV starting wk 4. Trastuzumab biosimilars may be used per institutional guidelines.
223890478|NCT02560233|OTHER|Contingent RT-fMRI-NF|Subjects are provided with contingent RT-fMRI-NF of brain activity in the target region of interest.
223890479|NCT02560233|OTHER|Sham RT-fMRI-NF|Subjects are provided with sham RT-fMRI-NF of brain activity of previously recorded subject.
223890480|NCT06210971|DRUG|liposomal irinotecan|Liposomal irinotecan: 50mg/m\^2 or 70mg/m\^2
223890481|NCT06210971|DRUG|Capecitabine|Capecitabine: 625mg/m\^2 or 1000mg/m\^2 bid.
223890482|NCT06210971|RADIATION|Radiation threapy|50.4Gy/28 fractions
223890483|NCT03869736|DRUG|Nitrous Oxide|1-hour sessions of inhaled nitrous oxide at concentrations of 25% or 50% (randomly assigned) to be administered weekly for 4 weeks.
223890484|NCT03869736|DRUG|Placebo|1-hour sessions of inhaled oxygen-air mixture (inspired oxygen concentration \~23-30%) to be administered weekly for 4 weeks.
223890485|NCT06084104|DRUG|DZD9008|A single oral dose of 200mg DZD9008
223890486|NCT06084104|DRUG|DZD9008|A single oral dose of 200mg DZD9008
223890487|NCT03336333|DRUG|Zanubrutinib|Administered as two 80-milligram (mg) capsules by mouth twice a day (160 mg twice a day)
223890488|NCT03336333|DRUG|Bendamustine|Administered intravenously (IV) at a dose of 90 mg/m\^2/day on the first 2 days of each cycle for 6 cycles.
223890489|NCT03336333|DRUG|Rituximab|Administered intravenously (IV) at a dose of 375 mg/m\^2 on day 0 of cycle 1, and at a dose of 500 mg/m\^2 on day 1 of cycles 2 to 6
223890490|NCT03336333|DRUG|Venetoclax|400 mg tablets administered orally once daily.
223890491|NCT05105503|DEVICE|Eko CORE Digital Stethoscope|The digital stethoscope will be used to take 9 recordings around each subject's maturing AVF once per week until study participation is over
223890492|NCT02664870|PROCEDURE|Arthroscopy|Arthroscopic Surgery on the hip, shoulder, or knee
223890493|NCT02664870|PROCEDURE|Arthroplasty|Total hip, shoulder, or knee arthroplasty
223890494|NCT03940911|OTHER|Measurement of aerobic exercise on cycloergometer|"The incremental effects tests will be performed in a service specialized in the exploration of the exercise (physiology or cardiology according to the centers) in a spacious and air-conditioned room, in the presence of a medical specialist. exercise and close to the resuscitation equipment.~Before the test, weight and height will be collected. Information on the conduct of the test will be given to the patient. A multi-derivation ECG recording will be detected throughout the duration of the test and followed by a physician experienced in the ECG effort.~O2 saturation by oximetry of hens will be recorded continuously. Blood pressure will be recorded at each level. The collection of expired gases in the face mask whose tightness will be verified to measure the fractions inspired and expired in O2 and CO2 (Sensor Medics Vmax229, Yorba Linda, CA, USA) and calculations VO2 max and VCO2.~Maximal power (W max) will be recorded. Patients will be encouraged during the test."
223890495|NCT05078086|OTHER|No intervention|No intervention
223890496|NCT05147519|BEHAVIORAL|Novel interventions to achieve HIV remission|To establish a group of well-characterized people living with HIV who initiated ART during acute or early HIV transmission that can serve as a source population for future studies, including those designed to test novel interventions to achieve HIV remission.
223890497|NCT06209203|DRUG|lowe-dose ZKY001 eye drops|eye drops
223890498|NCT06209203|DRUG|Medium-dose ZKY001 eye drops|eye drops
223890499|NCT06209203|DRUG|placebo|eye drops
223890500|NCT06133517|DRUG|Sacituzumab govitecan|Sacituzumab govitecan is administered at 10 mg/kg as an intravenous (IV) infusion on Days 1 and 8 of a 21-day cycle.
223890501|NCT06133517|DRUG|Zimberelimab|ZIM is administered at 360 mg every 3 weeks as an intravenous (IV) infusion on Day 1 of a 21-day cycle.
223890502|NCT06133517|DRUG|Domvanalimab|DOM is administered at 1200 mg every 3 weeks as an intravenous (IV) infusion on Day 1 of a 21-day cycle.
223890503|NCT02460042|PROCEDURE|drug coated balloon angioplasty|percutaneous transluminal angioplasty with peripheral balloon catheters
223890504|NCT02460042|DEVICE|SeQuent® Please OTW Paclitaxel Coated Balloon Catheter|
223890505|NCT06430021|BIOLOGICAL|blood sample|8 mL blood sample in EDTA tube
223890506|NCT06424483|BEHAVIORAL|Awareness, Courage, and Love Group Psychotherapy|Awareness, Courage, and Love (ACL) groups are an outgrowth of functional analytic psychotherapy, which is an empirically-based behavioural therapy that emphasizes the principle of positive reinforcement within relationships (Holman et al., 2017; Kanter et al., 2010; Kohlenberg \& Tsai, 1991; Tsai et al., 2009a). Awareness involves the practice of mindfulness, and in particular, the noticing of emotions within oneself and in others (Tsai et al., 2009b). Courage refers to engaging in vulnerable self-disclosures and practicing boundaried support. Love encompasses healthy caring for oneself and others, and in particular, responding affirmingly to another person's self-disclosures.
223890507|NCT04137913|BEHAVIORAL|Musical arts intervention|A 6-week group music class that incorporates listening, theory, performance, and creation of music.
223890508|NCT06002789|DRUG|MSI-H/MSS (dMMR/pMMR) mixed sMPCC: combination of mFOLFOX6+PD-1 monoclonal antibody neoadjuvant therapy|For MSI-H/MSS (dMMR/pMMR) mixed sMPCC, a combination of neoadjuvant chemotherapy with mFOLFOX6 and immunotherapy with PD-1 monoclonal antibody are applied.
223890509|NCT06002789|DRUG|All-MSI-H (dMMR) sMPCC: single-drug PD-1 monoclonal antibody neoadjuvant therapy|For all-MSI-H (dMMR) sMPCC, single-drug PD-1 monoclonal antibody immunotherapy is applied.
223890510|NCT04672889|DIETARY_SUPPLEMENT|Placebo|consume 1 sachet per day for 1 months
223890511|NCT04672889|DIETARY_SUPPLEMENT|Babyguard® Breast Milk Probiotics|consume 1 sachet per day for 1 months
223890512|NCT01969539|DRUG|Combivent Respimat via tee adapter|Patients (all); previously intubated and ventilated; in need of bronchodilation w/CVT-R via tee adapter
223890513|NCT01969539|DRUG|Combivent Respimat via ventilator adapter|Patients (all); previously intubated and ventilated; in need of bronchodilation w/CVT-R via ventilator adapter
223890514|NCT05470517|DRUG|Ceftriaxone|"Ceftriaxone is a sterile, semisynthetic, broad-spectrum cephalosporin antibiotic for intravenous, intramuscular, or intra-peritoneal administration.~Ceftriaxone is a white powder, which is soluble in water. In this study ceftriaxone crystalline powder will be dissolved in 0.9% sodium chloride solution prior to intra-peritoneal instillation.~Antibiotic instillation will be introduced into the RLQ/pelvis after the appendectomy is completed and all intra-peritoneal fluid is aspirated. Ceftriaxone solution will be used depending on availability and pharmacy stock for use at Johns Hopkins All Children's Hospital. The ceftriaxone powder (2g) will be dissolved in 9ml of sterile normal saline, for a total instillation volume of 10ml. This fluid will then be instilled and left to dwell in the area of the peritoneal cavity where the appendix was removed."
223890515|NCT05470517|PROCEDURE|Intra-peritoneal Fluid Aspiration|Intra-operative aspiration of intra-peritoneal fluid after successful appendectomy.
223890516|NCT06776224|OTHER|Measurement of retinal vascular density and visual cognition|During the same visit, we will perform OCT-angiography (10 minutes) and evaluate visual cognition with an eye-tracker (20 minutes)
223890517|NCT06406829|DRUG|Dexmedetomidine|The 200ug dexmedetomidine will be diluted into a 50ml syringe and administered with 0.4ug/kg/h intraoperatively and 0.05 μg/kg/h for 48 hours after surgery.
223890518|NCT06406829|DRUG|Normal saline|In the placebo group, the 0.9% saline is administered with the same volume at the same speed as the dexmedetomidine group
223890519|NCT06406829|OTHER|Local analgesic techniques|The 10ml 1% ropivacaine will be diluted into a 20ml syringe . As for scalp nerve block, each nerve will be blocked separately with 1-2 mL 0.5% ropivacaine.
223890520|NCT06406829|OTHER|no Local analgesic techniques|No Local analgesic techniques will be given.
223890521|NCT06777459|DIETARY_SUPPLEMENT|Nitrate-rich beetroot juice|Nitrate-rich beetroot juice, \~750 mg NO3- /d
223890522|NCT06776796|BEHAVIORAL|Online Personalized Normative Feedback Intervention Targeting Alcohol Misuse|This is an integrated social norms-based personalized feedback intervention for college students targeting alcohol misuse. It is tailored by the identities chosen by participants including gender, race/ethnicity, and sexual orientation. The intervention is a modified version of an existing evidence-based program, the Brief Alcohol Screening and Intervention for College Students (BASICS) (Dimeff, et. al, 1999).
223890523|NCT06776796|BEHAVIORAL|Mental Health and Substance Use Resources|Participants were directed to a website where information regarding mental health and substance use may be found.
223890524|NCT02285816|BIOLOGICAL|MG1MA3|MG1MA3: Boosting component of Oncolytic Vaccine
223890525|NCT02285816|BIOLOGICAL|AdMA3|AdMA3: Priming component of Oncolytic Vaccine
223890526|NCT03047967|DIAGNOSTIC_TEST|lung function tests|baby-body plethysmography
223890527|NCT03047967|DIAGNOSTIC_TEST|Nasal brushing|Epithelial sample collecting for in vitro study
223890528|NCT02665507|DEVICE|GaAlAs 808nm laser|Hand held superpulsed GaAlAs 808 nm LLLI
223890529|NCT02665507|DEVICE|Sham|Hand held laser that emits no LLLI
223890530|NCT06782672|OTHER|Cardiovascular measurements|"Measurement of pre-ejection period is the period between the onset of electrical excitation of the left ventricle and the opening of the aortic valve and heart rate will be continuous.~These data will be collected using a cardiograph measuring the ECG signal and impedance cardiography (ICG). The system's four electrodes are positioned on the middle axillary line at the end of the sternum and at the base of the neck.~Blood pressure measurements (PAS and PAD) will be taken from a cuff placed on the brachial artery of the non-dominant arm.~cardiovascular values will be measured continuously:~* Each participant rested while watching a documentary for 8 minutes.~* During two 5-minute memory tasks of different difficulty levels (easy and difficult), separated by a 5-minute break.~The averages of the last 5 minutes during the resting period will constitute the resting values, and the averages of the 5 minutes of each difficulty level will constitute the values during cognitive effort."
223890531|NCT06782672|OTHER|Experimental memory task|"First, a quiet period with the viewing of a documentary film (8min).~Then, participants will perform two 5-minute memory tasks of different difficulty levels (memorizing 3 letters corresponds to the easy level vs. 7 letters to the difficult level), separated by a 5-minute break. The order of difficulty will be counterbalanced.~At the end of each difficulty level, self-report measures assessed by the following questions will be collected:~* How much effort did you exert during the task?;~* How difficult did you find the task?~* How motivated were you to perform the task? Responses will be in Likert scale format, ranging from 1 (no effort at all, very easy, not at all motivated, respectively) to 7 (a lot of effort, very difficult, very motivated, respectively)."
223890532|NCT06782672|OTHER|Questionnaire and semi-structured psychological interview|"psychopathological measures collected using questionnaires:~* Beck Depression Inventory (BDI-II): mood~* State-Trait Anxiety Inventory (Form Y) (STAY-Y): anxiety~* Multidimensional Fatigue Inventory, 20-item version (MFI-20=): fatigue~* General Self-Efficacy Scale (GSES): defeatist beliefs~* Clinical Assessment Interview for Negative Symptoms (CAINS) : psychotic symptoms for the psychotic disorders group"
223890533|NCT05959811|OTHER|yoga|60 minutes yoga practice ,twice a week for 8 weeks
223890534|NCT06357234|DRUG|Aprepitant|Two doses of 40mg (2ml) Aprepitant. One to be given on the morning of surgery and the second on the morning of post-op day 1
223890535|NCT06357234|DRUG|Placebo|Two doses of dextrose syrup (2ml). One to be given on the morning of surgery and the second on the morning of post-op day 1
223890536|NCT05456113|BIOLOGICAL|Cannabidiol|Urbal Activ Extra Strength CBD Body Strong Balm applied to region of forearm to be stimulated by iontophoresis machine
223890537|NCT06142396|COMBINATION_PRODUCT|Daratumumab-hyaluronidase in Combination with Bortezomib, Cyclophosphamide, and Dexamethasone|"This intervention is Daratumumab-hyaluronidase in combination with the chemotherapy regimen CyBord (cyclophosphamide, bortezomib, and dexamethasone) and then with lenalidomide maintenance in patients with newly diagnosed multiple myeloma who have new onset renal failure."
223890538|NCT05092841|DRUG|PXT3003|Patients will be administered PXT3003 twice daily (bid) at 10mL.
223890539|NCT05092841|DRUG|PXT3003 placebo|Patients will be administered PXT3003 placebo twice daily (bid) at 10mL.
223890540|NCT05534893|DIETARY_SUPPLEMENT|Blueberry powder group|Participants in the blueberry powder group will receive freeze dried blueberries in form of a powder
223890541|NCT05534893|DIETARY_SUPPLEMENT|Placebo powder group|Participants in the placebo powder group will receive an isocaloric placebo powder
223890542|NCT06542796|PROCEDURE|Immunotherapy combined with targeted therapy|Immunotherapy combined with targeted therapy
223890543|NCT06542796|OTHER|Standard treatment plan|Standard treatment plan
223890544|NCT06484816|DRUG|TGRX-1942|At dose escalation phase, TGRX-1942 will be given orally to patient once a day under a 7-dose sequence of 4mg, 10mg, 20mg, 30mg, 40mg, 50mg, and 60mg. The dose level a particular patient will be assigned depends on the progression of the study and PI evaluation on the safety of previous dose group(s).
223890545|NCT01912651|DRUG|cephalexin|This consists of a single dose of cefazolin or, in penicillin allergic patients, clindamycin administered at the time of anesthesia administration prior to the surgical incision. In the cohort randomized to receive post-operative antibiotics, the first choice intervention will be oral cephalexin (500 mg, three times daily or four times daily, for one week). In patients who are penicillin or cephalosporin allergic, we will prescribe clindamycin (300 mg, three times daily or four times daily, for one week). Patients will be followed up within 2 to 6 weeks of surgery and outcome measures assessed. Patients will, again, be seen at 6 months and 1 year post-operatively for outcome assessment.
223890546|NCT06188936|DEVICE|ExSeed®|"In work package 3, participants will use the provided ExSeed® device and associated app downloaded onto their smartphone to analyse a semen sample provided at home. The app gives a result of normal or below normal, as well as an exact value for sperm concentration, progressive motility, and total motile sperm count. The patient will send their semen analysis results from the smartphone to the research team via secure email."
223890547|NCT06188936|OTHER|Survey|Surveys will be completed on a hard copy or electronically.
223890548|NCT06782867|DEVICE|Responsive Neurostimulation (RNS)|The RNS lead is stereotactically introduced into the target in the brain and fixed to the skull; the lead is then connected to a neurostimulator implanted subcutaneously in the subclavicular region.
223890549|NCT04424745|OTHER|Simultaneous Attention Bias Modification Training and Transcranial Direct Current Stimulation (tDCS)|Participants will receive 10 sessions of computerised attention bias modification training with either real or sham tDCS. Participants will self-administer tDCS at home, with research supervision, and complete attention bias modification training on a laptop or desktop computer while receiving stimulation. Sessions will be completed week daily for 2-3 weeks.
223890550|NCT06191731|OTHER|biological samples collection|Urine samples are collected before Gd-CAs injection, and between 0- and two-and-a-half-hour post-injection of Gd-CAs.
223890551|NCT06213038|GENETIC|SKG0106|SKG0106 is a recombinant adeno-associated virus (AAV) vector-based in vivo gene therapeutic product
223890552|NCT05698459|BIOLOGICAL|OH2 injection|OH2 injection administered by transcatheter Intraarterial infusion
223890553|NCT04977310|DEVICE|CardioMEMS|Cardio-MEMS-guided Post-LVAD cardiac unloading and recovery
223890554|NCT04126681|DRUG|HQP1351|HQP1351 is a new, bioavailable inhibitor against BCRABLWT and a broad spectrum of BCR-ABL mutants including BCR-ABLT315I
223890555|NCT04126681|DRUG|Hydroxyurea or Interferon-based therapy|Patients will receive BAT based on the Investigator's opinion, taking into account the manufacturer's instructions, labeling, subject's medical condition, and institutional guidelines.
223890556|NCT04126681|DRUG|Homoharringtonine|Patients will receive BAT based on the Investigator's opinion, taking into account the manufacturer's instructions, labeling, subject's medical condition, and institutional guidelines.
223890557|NCT04126681|DRUG|Imatinib, Dasatinib or Nilotinib|Patients will receive BAT based on the Investigator's opinion, taking into account the manufacturer's instructions, labeling, subject's medical condition, and institutional guidelines.
223890558|NCT03287193|BIOLOGICAL|Blood sample|for patient and its parents
223890559|NCT03287193|GENETIC|high-throughput sequencing|exome or whole genome sequencing
223890560|NCT05045196|BEHAVIORAL|Health promoting conversations|The Health-promoting conversations intervention is a conversation model between the patient, family members, and a trained nurse. Patients and families included in the study will, after submitting base-line-data, be randomized to
223890561|NCT02341651|OTHER|Multicomponent intervention|Multicomponent intervention is a combination of the following 1) community health worker (CHW)- led blood pressure (BP) screening and referral to provider, plus 2) home health education (HHE) adapted to the local diet by trained CHW plus 3) trained primary health center mid-level providers (MLP) and physicians using evidence-based treatment algorithm of BP lowering in all and lipid lowering for high risk, plus 4) process-based incentives
223890562|NCT03303586|OTHER|Compression Stockings|We will use knee length, ready-made compression stockings at a pressure of 20-30mmHg at the ankle and if a good fit cannot be obtained, custom-made stockings will be ordered. Patients will be measured for compression stockings by a certified fitter.
223890563|NCT03303586|OTHER|Control|Participants will not wearing compression stockings for two weeks.
223890564|NCT05498896|DRUG|Atezolizumab|IV infusion
223890565|NCT05498896|DRUG|Ipatasertib|Oral
223890566|NCT05498896|DRUG|Paclitaxel|IV infusion
223890567|NCT05498896|DRUG|Doxorubicin|IV infusion
223890568|NCT05498896|DRUG|Cyclophosphamide|IV infusion
223890569|NCT03992274|OTHER|Enhanced implementation of PrEP|During Enhanced Implementation study sites will receive Implementation Support to plan and introduce PrEP by following the eight stages of the PrEP-adapted SIC. Implementation Support specifically will involve a centralized technical assistance system developed using US-based PrEP experience focused on addressing implementation issues identified through real-time analysis of client, clinic, and implementation data.
223890570|NCT05336136|DEVICE|Custom mask|Custom mask based on 3D facial photograph for administration of non-invasive ventilation
224078869|NCT01237366|BEHAVIORAL|Resilient Affective Processing Therapy (RAPT)|Participants will be asked to complete 7 intervention sessions which include: 1) expressive writing exercises that focus on exploring thoughts and feelings surrounding a difficult life experience; and 2) stress management skills training to assist participants with managing any acute increases in distress that arise following the writing experience.
224078870|NCT03412409|DRUG|Cytarabine|RIC preconditioning regimen consisted of cytarabine (2 g/m2/day, days -10 to -9), busulfan (3.2 mg/kg/day on days -8 to -6), cyclophosphamide (1.0 g/m2/day, days -5 to -4), fludarabine (30 mg/m-2/day, days -6 to -2), semustine (250 mg/m-2, day -3), and rabbit antithymocyte globulin (thymoglobulin, 2.5 mg/kg/d, days -5 to -2; Sanofi, France).
224078871|NCT04224805|DEVICE|Bone-borne CAD/CAM splint|3D printed splint that repositions the maxilla with the zygomatic buttress as a reference.
224078872|NCT04224805|DEVICE|3D interocclusal conventional splint|Interocclusal splint that relies on the centric relation of the condyle as well as occlusion.
224078873|NCT03196128|OTHER|Digital communication|Communicating with patients via email and text message.
224078874|NCT03196128|OTHER|Non digital|Communicating with patients via telephone and written appointment letters.
224078875|NCT00083577|DRUG|Thalidomide|
224078876|NCT01136499|DRUG|LBH589 (Panobinostat®)|"40 mg MWF.~40 mg of LBH589, orally administered on Monday, Wednesday and Friday (MWF) on a weekly schedule, until tumor progression or unacceptable toxicity."
224078877|NCT00374803|DRUG|Mycophenolic Acid (Myfortic)|"* Group 1: Mycophenolic Acid (Myfortic) 1080 mg twice daily (2160 mg/day) for two weeks, followed by 720 mg twice daily (1440 mg/day) thereafter~* Group 2: Mycophenolic Acid (Myfortic) 720 mg twice daily (1440 mg/day)."
224078878|NCT02413437|OTHER|CEUS guided biopsy|Biopsy was operated under contrast-enhanced ultrasound-guided.
224078879|NCT02413437|OTHER|US guided biopsy|Biopsy was operated under conventional ultrasound-guided.
224078880|NCT02413437|DEVICE|Ultrasound|
224078881|NCT05753826|DRUG|Adebrelimab|20mg/kg，D1，q3W
224078882|NCT05753826|DRUG|Fuzuloparib|100 mg bid
224078883|NCT03731286|DIETARY_SUPPLEMENT|Alpinia Galanga|2 capsules
224078884|NCT03731286|DIETARY_SUPPLEMENT|Alpinia Galanga|2 capsules
224078885|NCT03731286|DIETARY_SUPPLEMENT|Microcellulose crystalline|2 capsules
224078886|NCT00809380|BEHAVIORAL|Parental presence|Patients in the study group will be accompanied by one of their parents for the whole procedure. Before this, a short explanation of the procedure, the patient's expected behavior during the procedure and what roles parents should play will be given to the parent by the research assistant. Parents will be seated close to the patient's head and will wear radiology proof gowns. If deemed necessary by the attending physician or if their behavior becomes unacceptable, parents can be asked to leave the procedure room at any given time. Parents will be allowed to leave the procedure room if they wish to at any time during the procedure.
224078887|NCT00809380|BEHAVIORAL|Control|One parent will stay with their child until he is in the procedure room and conscious sedation has begun. He will then be asked to leave the room and wait in an adjoining waiting room. The attending physician will invite the parent back in the room once the reduction is complete and the cast is done.
224078888|NCT00005956|BIOLOGICAL|HER-2/neu intracellular domain protein|
224078889|NCT00005956|BIOLOGICAL|therapeutic autologous dendritic cells|
224078890|NCT04036279|PROCEDURE|Total Hip Arthroplasty|
224078891|NCT01345500|OTHER|Higher Carbohydrate, Lower Fat Diet|Study participants will receive prepackaged prepared foods as needed to achieve a meal plan, free-of-charge for a 12-month period. The lower fat, higher carbohydrate diet provides 60% energy from carbohydrate, 20% energy from fat, and 20% energy from protein. The diet falls within the range of current dietary recommendations.
224078892|NCT01345500|OTHER|Lower carbohydrate, Higher fat diet|Study participants will receive prepackaged prepared foods as needed to achieve a meal plan, free-of-charge for a 12-month period. The lower carbohydrate, higher fat diet provides 45% energy from carbohydrate, 35% energy from fat, and 20% energy from protein. The diet falls within the range of current dietary recommendations.
223890571|NCT05336136|DEVICE|Current commercial mask|Current commercial mask used for administration of non-invasive ventilation
224078893|NCT01345500|OTHER|Individualized Counseling|Participants assigned to the usual care group will be provided consultation with a research staff dietetics professional, who will provide publicly available print material that describes dietary and physical activity guidelines to promote weight loss and maintenance, at baseline (after randomization) and again at 6 months.
224078894|NCT00446914|BEHAVIORAL|Systems Change (High Blood Pressure Strategy)|
224078895|NCT05425563|BEHAVIORAL|Pain Expectancy Cues|Participants are presented with a social cue that represents how previous participants responded to the upcoming somatic pain stimulus. In actuality, the cue is a social placebo, constructed by the experimenters and varying in intensity.
224078896|NCT05425563|BEHAVIORAL|Vicarious Pain Expectancy Cues|Participants are presented with a social cue that represents how previous participants responded to the upcoming vicarious pain stimulus. In actuality, the cue is a social placebo, constructed by the experimenters and varying in intensity.
224078897|NCT05425563|BEHAVIORAL|Cognitive Effort Expectancy Cues|Participants are presented with a social cue that represents how previous participants responded to the upcoming cognitive effort stimulus. In actuality, the cue is a social placebo, constructed by the experimenters and varying in intensity.
224078898|NCT01069445|DIETARY_SUPPLEMENT|VSL#3® probiotic blend|Product should be administrated orally, 2 capsules b.i.d. on an empty stomach (at least 30 min. before lunch and dinner) with a glass of water
224078899|NCT01069445|DIETARY_SUPPLEMENT|AISA-5203-L fruit extracted terpene|Product should be administrated orally, the dosage depending from the body weight of the subject enrolled in the study as already stated : 1-2 pills three times a day with a meal and a large glass of water
224078900|NCT01069445|DIETARY_SUPPLEMENT|Argan oil|Product should be administrated orally, 25 ml once daily or during the day with a meal (bread, salad …) and a large glass of water
224078901|NCT01069445|BEHAVIORAL|Optimal Diet|a dietician will train each subject (or the caregiver) to use the personalized diet on web platform.
224078902|NCT05445973|PROCEDURE|Percutaneous Radiofrequency Ablation|In brief, ablation was performed using a 200-W multichannel generator and a switching monopolar technique with separate clustered electrodes. Tumor targeting was done under the guidance of CEUS-CT/MRI FI, and the ablation procedure was monitored with US-FI. The ablation procedure was terminated when the operator expected to complete the ablation of the index tumor with a minimum 5-mm ablative margin on the US-FI images.
224078903|NCT01722838|BEHAVIORAL|B-ME Intervention|B-ME is a behavioral intervention of HIV prevention risk reduction administered in a group format during a 2.5 day retreat (19 hours) format.
224078904|NCT00055380|PROCEDURE|Oral cytobrushing|
224078905|NCT00168831|DRUG|Tiotropium Inhalation Solution|
224078906|NCT00168831|OTHER|Placebo|
224078907|NCT00684190|DRUG|AZD3355|150 mg bid, oral, 7 days
224078908|NCT00684190|DRUG|Esomeprazole|40 mg od, oral, 7 days
224078909|NCT02246257|OTHER|Simvastatin|LDL \> 2.5 is treated with 40 mg
224078910|NCT02246257|OTHER|Losartan|BT \> 140/90 mmHg treated with 50 mg OD
224078911|NCT02246257|OTHER|Losartan|DM BT \> 130/80 mmHg treated with 50 mg OD
224078912|NCT02246257|OTHER|Losartan|Microalbuminuria (urinary albumin creatinin ratio \> 30 mg) treated with 100 mg OD
224078913|NCT02246257|OTHER|Metformin|HBA1C \> 48 mmol/mol treated with 500 mg increased dose to 2,000 mg in 4 weeks
224078914|NCT02246257|OTHER|Outpatient rheumatology department|(4 times yearly)
224078915|NCT02246257|OTHER|Refered to general practice|
224078916|NCT02298933|DRUG|Eculizumab|300 mg single-use vials
224078917|NCT01410279|OTHER|Inspiratory muscle training|The load is adjusted weekly in thirty percent of maximal inspiratory pressure of the subject.
224078918|NCT01087541|BEHAVIORAL|Educational program 6-hour standardized|6-hour standardized program for adults ( doctors and nurses )
224078919|NCT01622569|DRUG|Fluticasone Propionate|Delivered via Optinose Exhalation Delivery System
224078920|NCT00394849|PROCEDURE|suture one tonsillar fossa|one tonsillar fossa was sutured. One side was not sutured. Pain was compared side to side.
224078921|NCT02146287|OTHER|Cycled Light|"Cycled light was provided in an 11-hour-on, 11-hour-off pattern. Daylight (240-700 lux) was provided with the incubator cover folded on top of the incubator allowing light in from four sides, or with the bassinet cover off during day hours (0730-1830). With the daylight range of 240-700 lux and limited access to natural light, excessive daylight was prevented.~Continuous near darkness was provided as (5-30 lux) throughout the day except from 0630-0730 and 1830-1930, when lighting levels varied based on nursing care needs at the change of shift. Near-darkness (5-30 lux) was provided by using incubator (totally covered or with the front flap back) and bassinet covers, and dimming individual bedside light during the day (0730-1830) and night hours (1930-0630)."
224078922|NCT05646108|DEVICE|Endovascular treatment|Endovascular treatment
224078923|NCT02009878|DRUG|tolvaptan|Subjects will receive a single dose of 3.75, 7.5 or 15 mg of tolvaptan on study Day 1
224078924|NCT01964066|PROCEDURE|ERCP|Endoscopic retrograde cholangiopancreatography balloon dilatation
224078925|NCT01964066|PROCEDURE|Thoracic epidural analgesia|Thoracic epidural analgesia between thoracic vertebrae VII-VIII (Ropivacaine 0.5%-10ml)
224078926|NCT01964066|PROCEDURE|Premedication|For premedication used trimeperidine 2%-1ml intravenously.
224078927|NCT05801237|DRUG|PE0116&PE0105|This is a Phase I Clinical Trial to Evaluate the Tolerability, Safety, Pharmacokinetics and Preliminary Antitumor Activity of PE0116 and PE0105 Injection in Treatment of Patients with Advanced Solid Tumor
224078928|NCT06340009|OTHER|mime therapy|"1. Facial Massage~2. Frowning~3. Close eyes~4. Smile~5. Fish Face~6. Eyebrow raising~7. Breathing exercise~8. Blow cheeks~9. Mouth opening and closing.~10. Moving lips side to side~11. Blow a candle.~12. Nasal flaring~13. Chewing exercise~14. Rinse mouth~15. Speaking vowels~16. Fill mouth with water~17. Fill rubber balloon~18. Sucking water with straw"
224078929|NCT06340009|OTHER|motor imagery|"1. Raising your eyebrows~2. Showing angry face~3. Closing and opening eyes~4. Pouting~5. Blowing cheeks~6. Smiling~7. Nasal flaring~8. Blowing candle~9. Deviating lips side to side~10. Chewing something~11. Speaking vowels"
224078930|NCT03665363|OTHER|SCOPE|SCOPE is a internet-delivered, coach-guided, psychoeducational intervention, intended to serve as a first-line intervention for intellectually able adolescents and young adults with ASD. The SCOPE program is based on information comprising neuropsychology, pedagogy, and also interdisciplinary clinical experience regarding ASD. The content is aimed at providing information about typical and specific impairments of ASD, as well as the associated strengths.
224078931|NCT03665363|OTHER|Self-study|Active control consisting of directed self-studies on internet.
224078932|NCT03685773|DRUG|Diazoxide|"MRI studies: Non-diabetic and T2D participants will receive diazoxide (up to 7 mg/kg) between baseline MRI scan and second MRI scan.~Clamp studies: Non-diabetic participants will not require an overnight admission. They will receive diazoxide (up to 7 mg/kg) and undergo the pancreatic clamp study. Type 2 diabetic participants will be admitted the evening before the study day to normalize blood sugar levels. They will then receive diazoxide (up to 7 mg/kg) the next morning and undergo the pancreatic clamp study."
224078933|NCT03685773|DRUG|Placebo (for diazoxide)|"MRI studies: Non-diabetic and T2D participants will receive placebo (for diazoxide) between baseline MRI scan and second MRI scan.~Clamp studies: Non-diabetic participants will not require an overnight admission. They will receive a taste-matched placebo (for diazoxide) and undergo the pancreatic clamp study. Type 2 diabetic participants will be admitted the evening before the study day to normalize blood sugar levels. They will then receive a taste-matched placebo (for diazoxide) the next morning and undergo the pancreatic clamp study."
224078934|NCT03685773|DRUG|Nicotinic acid|Type 2 diabetic participants in this arm will receive a nicotinic acid infusion to lower free fatty acid levels. They will then receive diazoxide (up to 7 mg/kg) the next morning and undergo the MRI or pancreatic clamp study.
224078935|NCT02690623|OTHER|Pediatric hospitalist program|In-house hospitalists available at all hours
224078936|NCT02690623|OTHER|General Pediatric Inpatient Services|Inpatient care by general pediatrics faculty
224078937|NCT06528470|DEVICE|Posterior Tibial Nerve Stimulation (PTNS)|The intervention will begin with application of a needle and a self-adhesive electrode. The electrodes will be connected to the electrical stimulator device. The stimulator will then be turned on and amplitude will be gradually increased until motor or sensory response is observed. The amplitude will then be decreased to the point when direct motor stimulation ceases and sensory stimulation is comfortable. Continuous stimulation will then be delivered for a 30-minute session. After 30 minutes, the device will be turned off and the adhesive electrodes removed. Pelvic floor biofeedback therapy is typically performed for a total of four or more weekly sessions. Participants in our study will undergo 30-minute sessions of PTNS or sham stimulation after their first four biofeedback therapy sessions.
224078938|NCT06528470|DEVICE|Sham Stimulation|The intervention will begin with application of a needle and a self-adhesive electrode. The electrodes will be connected to the electrical stimulator device. The stimulator will then be turned on and amplitude will be gradually increased until motor or sensory response is observed. The amplitude will then be decreased to the point when no stimulation is delivered. No stimulation will then be delivered for a 30-minute session. After 30 minutes, the device will be turned off and the adhesive electrodes removed. Pelvic floor biofeedback therapy is typically performed for a total of four or more weekly sessions. Participants in our study will undergo 30-minute sessions of PTNS or sham stimulation after their first four biofeedback therapy sessions.
224078939|NCT00814957|DRUG|GSK618334|D3 receptor antagonist
224078940|NCT00001387|DRUG|paclitaxel|
224078941|NCT05370573|OTHER|No intervention|Observational - no interventions
224078942|NCT01471665|DRUG|GSK2190915 100mg|GSK2190915 is a high affinity 5-lipoxygenase-activating protein (FLAP) inhibitor. Dosing will occur once daily for up to 16 days.
224078943|NCT01471665|DRUG|Placebo|Placebo will be administered once daily for up to 16 days.
224078944|NCT00997516|PROCEDURE|SILS appendectomy|Use of SILSPort to perform laparoscopic appendectomy
224078945|NCT00997516|PROCEDURE|conventional laparoscopic appendectomy|conventional laparoscopic removal of the appendix
224078946|NCT02975830|RADIATION|Three dimensional CT based images|Right bronchial angle, left bronchial angle
224078947|NCT04217265|DRUG|Letrozole then misoprostol|total dose 5 mg per day for 3 days then Misoprosrol 800mcg will be given to all patients for induction of abortion
224078948|NCT04217265|DRUG|placebo then misoprostol|placebo tablets for 3 days then Misoprosrol 800mcg will be given to all patients for induction of abortion
224078949|NCT01940484|DRUG|Methoxy polyethylene glycol epoetin beta|
224078950|NCT01894126|BEHAVIORAL|Two-way SMS Dialogue|
224078951|NCT01894126|BEHAVIORAL|One-way SMS Messaging|
224078952|NCT01007214|PROCEDURE|Prostatectomy|Elective prostatectomy
224078953|NCT04184817|OTHER|Collection of clinical data registered in Easily software|Collection of clinical data registered in Easily software
224078954|NCT02922387|DRUG|Varenicline|Varenicline was given for 12 weeks to all patients in group A. The initial dose was 0.5 mg/day for days 1-3, and was then up-titrated to 0.5mg on days 4-7, and finally to 1 mg twice daily from day 8 until the end of treatment
224078955|NCT02922387|BEHAVIORAL|Behavioral support|An initial private consultation session and motivational interview while still in the hospital that lasted for at least 60 minutes. Follow-up phone calls with a minimum duration of 10 minutes were scheduled in weeks 1, 2, 4, and months 3,6 and 9 following smoking cessation.
224078956|NCT03646084|OTHER|Sleep and Circadian Intervention Program (SCIP) plus rehabilitation program|To study circadian rhythm disorders and sleep disorders and develops the SCIP to improve sleep in the patients.
224078957|NCT03646084|OTHER|Rehabilitation program|Rehabilitation program current clinical practice
224078958|NCT01970176|DRUG|Tadalafil|Tadalafil 5 mg tablet. Daily. Tadalafil dose varies from 5 mg to 20 mg for 12 weeks. If blood pressure is \>95 then subject dismissed from the Clinical Research Unit (CRU) on 2 (5 mg) tabs of tadalafil or placebo. If blood pressure is between 90 - 95 mmHg systolic, then dismiss on 1 (5 mg) tab of Tadalafil. At 2 weeks (± 5 days) if blood pressure is\> 100 than add 1 (5 mg) tab of Tadalafil to make a total of 3 (5mg) tabs of Tadalafil. At 4 weeks(± 5 days) if blood pressure is \> 100 add 1 (5 mg) tab to make a total of 4 (5 mg) tablets of Tadalafil.
224078959|NCT01970176|DRUG|Placebo|Placebo tablet. Daily. Placebo tablets made to match appearance of 5mg Tadalafil tablets. Placebo dose varies from 5 mg to 20 mg (1 to 4 tablets) for 12 weeks. If blood pressure is \>95 then subject dismissed from CRU on 2 tabs of placebo. If blood pressure is between 90 - 95 mmHg systolic, then dismiss on 1 (5 mg) tablet of placebo. At 2 weeks (± 5 days) if blood pressure is\> 100 than add 1 tab of placebo to make a total of 3 tablets of placebo. At 4 weeks(± 5 days) if blood pressure is \> 100 add 1 (5 mg) tab to make a total of 4 tablets of placebo.
224078960|NCT05813197|BEHAVIORAL|My Choice - My Way!|Support intervention for adolescents (15+) in out-of-home care (foster care, group home care, supported living, institutional care, etc). 16-19 sessions with a MCMW coach, 4-8 months, weekly to bi-weekly sessions.
224078961|NCT05813197|BEHAVIORAL|Usual services|Usual services
224078962|NCT05336084|BEHAVIORAL|Ultradian sleep/wake protocol|120-minute schedule, consisting of 80 minutes awake followed by a 40 minute sleep opportunity for 36 hours
224078963|NCT05904314|BEHAVIORAL|Simulation training in electronic fetal monitor management|Simulation training in electronic fetal monitor management
224078964|NCT06231758|DRUG|Celecoxib 200mg|Celecoxib is a nonsteroidal anti-inflammatory drug (NSAID) used to treat mild to moderate pain and help relieve symptoms of arthritis (eg, osteoarthritis, rheumatoid arthritis, or juvenile rheumatoid arthritis), such as inflammation, swelling, stiffness, and joint pain.
224078965|NCT06231758|DRUG|Metformin|Metformin (MET), a traditional antdiabetic drug, exerts glucose-lowering effect by activating AMPK since it is a critical enzyme in lipid and glucose metabolism
224078966|NCT02892266|OTHER|Assessment of adherence, mental health, behavioral, quality of life and biological constructs|
224078967|NCT05329532|BIOLOGICAL|Modi-1 Moditope|Modi-1 Moditope administered intradermally (i.d.) using the MicronJet600™ microneedle device (NanoPass).
224078968|NCT05329532|BIOLOGICAL|Pembrolizumab|Pembrolizumab (exploratory cohorts) will be administered by intravenous infusion on Day 8, prior to tumour resection surgery at 6 weeks.
224078969|NCT05329532|DEVICE|MicronJet600™ microneedle device (NanoPass)|Intradermal injection device
224078970|NCT06447922|OTHER|Metal ion level testing|Patients will undergo a pre- and post-operative blood draw to analyze metal ion levels (Cobalt, Chromium, Titanium and Nickel)
224078971|NCT06803641|OTHER|Mindfulness practice with Tao Art (Calligraphy and Song Love Peace and Harmony).|During mindfulness practice with Tao Art (Calligraphy and Song Love Peace Harmony), participants will repeatedly trace the lines of calligraphy with fingers while listening to, singing, or chanting with Tao Song. This enables them to achieve deep concentration, while maintaining fully alert state. The practice can be done in sitting or standing, depending on the health status and age and will last 30 minutes and is done daily for three months.
224078972|NCT03692897|OTHER|All approved therapies for the treatment of Chronic Hepatitis B (CHB)|All approved therapies for the treatment of Chronic Hepatitis B (CHB).
224078973|NCT05682443|DRUG|ONC-392 low|ONC-392 will be given as IV infusion, Q4W for up to 13 doses.
224078974|NCT05682443|DRUG|ONC-392 high|ONC-392 will be given as IV infusion, Q6W for up to 9 doses.
224078975|NCT05682443|DRUG|lutetium Lu 177 vipivotide tetraxetan|lutetium Lu 177 vipivotide tetraxetan will be given as IV infusion, Q6W, for up to 6 doses.
224078976|NCT06064539|DRUG|Tolebrutinib|Tablet, taken orally
224078977|NCT06064539|DRUG|gemfibrozil|Tablet, taken orally
224078978|NCT06064539|DRUG|rifampicin|Tablet, taken orally
224078979|NCT06420960|DEVICE|Wearing the connected watch|"All patients will receive a connected watch from the research associate, along with instructions on its usage and support for creating an account on the Healtmate application using an anonymized e-mail address.~They will be able to transmit up to 3 ECG tracings deemed to be per-critical. A follow-up phone call at 2- months will assess understanding of the device and its proper use, as well as the occurrence of adverse events and compliance."
224078980|NCT04133961|DRUG|Phenylephrine|Phenylephrine infusion 0.3ml/kg/hour (equivalent to 0.5mcg/kg/min, phenylephrine dilution is 100mcg/ml in 20ml syringe)
224078981|NCT04133961|DRUG|Normal saline|Normal saline infusion 0.3ml/kg/hour (normal saline in 20ml syringe)
224078982|NCT02426177|DRUG|Labetalol|anti-hypertensive agents
224078983|NCT02426177|DRUG|Nifedipine|calcium channel blocker ,for lowering blood pressure
224078984|NCT03792841|DRUG|acapatamab|Investigational immunotherapy for the treatment of metastatic castration-resistant prostate cancer
224078985|NCT03792841|DRUG|Pembrolizumab|Combined with acapatamab for investigational treatment of mCRPC
224078986|NCT03792841|DRUG|Etanercept|Prophylaxis for acapatamab-related cytokine release syndrome.
224078987|NCT03792841|DRUG|Cytochrome P450 (CYP) Cocktail|Evaluate the effect of co-administration of multiple dosing of acapatamab on plasma
224078988|NCT05120310|BEHAVIORAL|The Calm App|Participants will be asked to use the Calm app for at least 10 minutes per day for eight weeks. They will also be asked to schedule one live 20-minute coaching session with a Calm Coach within the first week of the eight-week intervention to help identify areas for health behavior improvements (i.e., Calm Concierge). Participants will be asked to download the Calm app to their mobile phone. The Calm Coaching for sleep program is administered by Calm for six weeks. Participants are asked to complete weekly modules and interact with a coach to help them improve their sleep. Participants also complete a sleep diary throughout the program.
223890572|NCT05701475|PROCEDURE|Subcutaneous disinfection|After incision, the subcutaneous tissue will be disinfected for 60 seconds using iodine before continuing the surgical approach.
223890573|NCT05701475|PROCEDURE|Benzoyl peroxide preparation|In the days prior to surgery, the skin will be prepared using Benzoyl Peroxide gel according to a standardised protocol.
223890574|NCT05650255|OTHER|A Digital Twin for Exoskeleton Pilot|The purpose of this project is to establish a digital twin of this driving, which will perform the driving action in parallel, and calculate in parallel in the virtual environment the torque required to provide each joint torque to maintain stable walking without falling, and this torque can be used as a monitoring basis for the auxiliary torque of each axis for the exoskeleton. When the exoskeleton's movements are out of range of a stable gait, the controller can warn and attenuate the output of auxiliary forces, and on the other hand, it has the opportunity to analyze whether the intention of driving is to switch the movement mode - such as stopping, or sitting, squatting, etc.
223890575|NCT05274347|OTHER|Muti-faceted virtual, remote intervention|Patients will be provided with tablets with internet connectivity and Aetonix software, along with a blood pressure cuff, weigh scale and pulse oximeter with blue tooth capability. These will be used to deliver virtual CBT sessions as well as remote monitoring of vital signs, symptoms and enhanced communication. The intervention duration will be 10 weeks.
223890576|NCT04702529|DEVICE|Treatment of hypertrophic scars (Soliton's Rapid Acoustic Pulse (RAP) Device)|Administration of 3 Rapid Acoustic Pulse (RAP) treatments
223890577|NCT03673111|DRUG|Y14|Gut hormone analogue
223890578|NCT03673111|DRUG|Placebo|0.9% saline
223890579|NCT03574727|PROCEDURE|Injection to or release of anterior cutaneous nerves|Patients who have undergone at least one injection to the nerves
223890580|NCT06036199|DEVICE|Focused Ultrasound Pallidotomy|Use of ExAblate Transcranial MR guided Focused Ultrasound as a tool for creating bilateral or unilateral lesions in the globus pallidus (GPi) in patients with treatment-refractory secondary dystonia due to dyskinetic cerebral palsy
223890581|NCT04487249|OTHER|Vision Therapy|20 consecutive weeks of office-based vision therapy with home therapy that aim to improve the participant's vergence skills, accommodative skills, and sensory fusion.
223890582|NCT05669430|BIOLOGICAL|GV20-0251|Increasing doses of GV20-0251 administered by intravenous (IV) infusion once or twice every 3 weeks as monotherapy.
223890583|NCT05669430|BIOLOGICAL|GV20-0251|GV20-0251 preliminary RP2D administered by IV infusion as monotherapy.
223890584|NCT05669430|BIOLOGICAL|GV20-0251 and Pembrolizumab [KEYTRUDA®]|GV20-0251 administered by IV infusion at 10 mg/kg once every 3 weeks or at increasing doses up to the preliminary RP2D determined in Part A. 200 mg pembrolizumab administered by IV infusion once every 3 weeks.
223890585|NCT05669430|BIOLOGICAL|GV20-0251 and Pembrolizumab [KEYTRUDA®]|GV20-0251 administered by IV infusion at preliminary RP2D from Part C. 200 mg pembrolizumab administered by IV infusion once every 3 weeks.
223890586|NCT05922345|DRUG|TQB2450 injection, docetaxel injection matching placebo, AL2846 capsules|"AL2846 capsules is a multi-targeted small molecule receptor tyrosine kinase inhibitor.~TQB2450 Injection is an anti-programmed death-1 (PD-L1)."
223890587|NCT05922345|DRUG|TQB2450 placebo, docetaxel injection, AL2846 matching placebo|Docetaxel injection is a type of chemotherapy for treatment of different types of cancer.
223890588|NCT03188146|DRUG|Ursodeoxycholic Acid|Standard care of PBC patients
223890589|NCT04551521|DRUG|Vemurafenib|960 mg twice daily during run-in Phase, followed by 720 mg twice daily
223890590|NCT04551521|DRUG|Cobimetinib|60 mg once daily
223890591|NCT04551521|DRUG|Atezolizumab|840 mg every 2 weeks
223890592|NCT04551521|DRUG|Trastuzumab|8 mg per kilogram of body weight as a loading dose, followed by 6 mg per kilogram every 3 weeks
223890593|NCT04551521|DRUG|Pertuzumab|840 mg as a loading dose, followed by 420 mg intravenously every 3 weeks
223890594|NCT04551521|DRUG|Alectinib|600 mg twice daily
223890595|NCT04551521|DRUG|Ipatasertib|400 mg once daily
223890596|NCT04551521|DRUG|Atezolizumab|1200 mg every 3 weeks
223890597|NCT04551521|DRUG|Atezolizumab|1200 mg in the first cycle, followed by 840 mg every 3 weeks
223890598|NCT04551521|DRUG|Atezolizumab|1,200 mg every 3 weeks
223890599|NCT04551521|DRUG|Inavolisib|9 mg once daily
223890600|NCT03989947|DRUG|Active BMN 111: Subcutaneous injection of recommended dose of BMN 111 based on weight-band dosing once daily.|Modified recombinant human C-type natriuretic peptide (subject to adjustment per protocol)
223890601|NCT03869996|PROCEDURE|fast track care protocol|fast track care consists in educational preoperative preparation for patients, particular strategies for controlling pain and bleeding and intensive early rehabilitation protocol.
223890602|NCT03869996|PROCEDURE|standard care protocol|standard care protocol consists in the same surgical intervention without educational preoperative preparation for patients and intensive early rehabilitation protocol.
223890603|NCT05790889|BIOLOGICAL|Rabies vaccine|Vaccine
223890604|NCT05790889|BIOLOGICAL|RH5.1 10μg adjuvated with 50μg Matrix-M|Vaccine
223890605|NCT05790889|BIOLOGICAL|RH5.2 5μg adjuvated with 50μg Matrix-M|Vaccine
223890606|NCT04621266|BEHAVIORAL|Online Home-based peer support|Online Home-based peer support will be provided to support participants' breastfeeding. There will be a minimum of 2 and maximum of 3 home visits between trained peer counsellors and participants. Each session will last approximately 30 minutes.
223890607|NCT05890768|DRUG|Lumateperone|FDA approved antipsychotic drug
223890608|NCT05890768|DRUG|Risperidone|FDA approved antipsychotic drug
223890609|NCT03792555|DRUG|Paltusotine|Paltusotine, capsules, once daily by mouth
223890610|NCT03792555|DRUG|Placebo|Placebo, capsules, once daily by mouth
223890611|NCT06162585|BIOLOGICAL|Gene Therapy product-MCO-010|Safety evaluation to monitor long term effects of previously injected MCO-010 in RP patients
223890612|NCT03149341|OTHER|Magnetic Resonance Imaging|All subjects will undergo or have already undergone Magnetic Resonance Imaging. Normal volunteers will be used for comparison with subjects. To minimize risk, normal volunteers will NOT undergo anesthesia, sedation or receive intravenous contrast during procedure.
223890613|NCT06524687|DRUG|Imvotamab|Administered intravenously
223890614|NCT05766072|OTHER|EMOTION Kids coping with anxiety and depression (Mestrende barn in Norwegian)|The intervention is transdiagnostic and based on cognitive behavioral therapy where the children and their parents meet i groups led of school health nurses. They are learning coping skills to meet challenging and avoided situations, learning about emotion regulation, physical symptoms conitive restructuring and exposure/behavioral activation. Te manual is publshed in a US/English version and in a Norwegian version.
223890615|NCT05880381|DEVICE|Virtual Reality Group|Patients allocated to the treatment group will undergo an intervention that comprises 3 weekly sessions of 60 minutes for 4 weeks with the VR prototype.
223890616|NCT05880381|OTHER|Control Group|The participants allocated to this group will do the formal standard care provided by the Gynecology- Obstetric service.
223890617|NCT06502132|OTHER|Patient Education Group|Patients whose surgery has been postponed will be educated by the researcher through a booklet regarding the waiting process. The education includes information such as anxiety management, pain management, and re-surgery planning. The booklet consists of 22 pages and a copy is given to each patient in this group. The education lasts between 15-20 minutes and the patients' questions are answered. It is applied in a single session.
223890618|NCT06502132|OTHER|Therapeutic Touch Group|Therapeutic touch application is applied as a single session and lasts approximately 20-25 minutes. The therapeutic touch that emerges from the artistic aspect of nursing is an energybased practice that does not involve physical contact. Therapeutic touch is a conscious and compassionate effort to direct the flow of one's universal life energy to healing by influencing this energy.
223890619|NCT04485039|DRUG|Tecovirimat|oral antiviral
223890620|NCT04485039|DRUG|sevelamer carbonate oral tablet|phosphate binder
223890621|NCT04485039|DRUG|sucroferric oxyhydroxide chewable tablet|phosphate binder
223890622|NCT04485039|DRUG|calcium acetate oral tablet|phosphate binder
223890623|NCT04485039|DRUG|Lanthanum Carbonate Chewable Tablet|phosphate binder
223890624|NCT05481216|OTHER|COVID-19|Diagnosed with COVID-19 infection
223890625|NCT05481216|OTHER|HIV-1 infection|Diagnosed with HIV-1 infection
223890626|NCT03572465|DEVICE|Acoustic radiation force impulse (ARFI), magnetic resonance elastography (MRE)|Acoustic Radiation Force Impulse (ARFI), Magnetic Resonance Elastography (MRE)
223890627|NCT06251037|BEHAVIORAL|Youth Aware of Mental Health in Galicia|"The program follows a manualized protocol, comprising five interactive one-hour class sessions with adaptations to the Galician school population.~The Inaugural Session consists of an interactive slide presentation, an introduction of materials, the delivery of the manual, and the poster's display. The Second Session involves group discussions on real-life dilemmas. The Third and Fourth Sessions focus on crisis situations, depression, suicidal ideation, and help-seeking behaviors through role-playing games. The Closing Session includes a collective summary of topics and addresses dynamic aspects emerging during the group experience."
223890628|NCT03942445|PROCEDURE|Gastrocnemius muscle biopsy|In all groups, a 5 mm large gastrocnemius muscle biopsy will be performed and the samples immediately managed in experimental laboratory.
223890629|NCT06276127|DRUG|Oral Bisoprolol|Participants in this group will receive a single oral dose of Bisoprolol, set at a dosage of 5 mg, with a maximum dose limit of 5 mg.
223890630|NCT06276127|DRUG|Intravenous Diltiazem|Participants in this group will be administered a single intravenous dose of diltiazem at a dosage of 0.25 mg/kg, with a maximum dose capped at 30 mg.
223890631|NCT02986048|OTHER|Proton Beam Therapy|Intervention is not assigned. Only patient data is being collected
223890632|NCT04005716|DRUG|Tislelizumab|200 mg administered intravenously on Day 1 of each 21-day cycle
223890633|NCT04005716|DRUG|Cisplatin|75 mg/m² was administered intravenously on Day 1 of each 21-day cycle, infused over a duration of two hours. Treatment with cisplatin was discontinued starting in Cycle 5 and beyond.
223890634|NCT04005716|DRUG|Carboplatin|An area under the curve (AUC) of 5 mg/mL/min was administered intravenously on Day 1 of each 21-day cycle, infused over a duration of 15 to 60 minutes. Treatment with carboplatin was discontinued starting in Cycle 5 and beyond.
223890635|NCT04005716|DRUG|Etoposide|100 mg/m² was administered intravenously from Day 1 to Day 3 of each 21-day cycle, infused over a duration of 60 minutes. Treatment with etoposide was discontinued starting in Cycle 5 and beyond.
223890636|NCT04005716|DRUG|Placebo|200 mg was administered intravenously on Day 1 of each 21-day cycle to match tislelizumab.
223890637|NCT06249841|DEVICE|1.1mm flexible Cryoprobe SU|Six tissue samples retrieved by standard biopsy forceps and three samples by cryobiopsy (randomized sequence)
223890638|NCT06103604|DIAGNOSTIC_TEST|latest generation tympanic thermometer|The patient whose core temperature is monitored during hospitalisation has his temperature at tympanic level taken once during the stay. The research nurse will record the core temperature from the monitor on the CRF and, within the next 5 minutes, take the peripheral temperature with the tympanic thermometer three times in a row, recording all three values on the CRF. Subsequently a second operator will always take the temperature 3 times within 5 minutes of the gold standard measurement. Only the first tympanic measurement will then be used to assess accuracy against the gold standard.
223890639|NCT06353321|DIAGNOSTIC_TEST|PET-CT imaging subsystem of the RefleXion X1 System Device|Imaging performed only on the X1 platform immediately following already planned imaging using Illuccix for standard of care indications in men with prostate cancer of various stages, in order to assess performance of the X1 in comparison to diagnostic imaging scanners
223890640|NCT05786443|DRUG|Empagliflozin 10 MG|Sodium glucose cotransporter 2 inhibitor (SGLT2i) dosed once-daily over 12 weeks. Administered as oral tablet.
223890641|NCT05786443|DRUG|Placebo|Empagliflozin-matching placebo dosed once-daily over 12 weeks. Administered as oral tablet.
223890642|NCT04021602|BEHAVIORAL|Diabetes Prevention Program|Phase 1 (core curriculum) of the Diabetes Prevention Program consists of 16 sessions and will take place during Week 18 of pregnancy through Week 33. Participants will receive the DPP curriculum via virtual pre-recorded sessions to which participants will have access. A research coordinator will follow up with each study participant by phone once weekly. If participants do not make adequate progress, the coordinator will assess how much extra time the participant will need to complete each session and will work with the participant if needed. Phase 2 (post-core curriculum) consists of 6 sessions and will be completed after delivery, between Week 6 and Week 20 postpartum. Participants will re-engage into the DPP with an orientation session at Week 6 postpartum. The same session completion format and procedure for inadequate progress will be followed as during pregnancy.
223890643|NCT04021602|BEHAVIORAL|Breastfeeding Education|Participants will receive a 2-hour session on breastfeeding and participate in a professional peer support group. The breastfeeding session is between Week 20 and Week 36 of pregnancy and will be taught by an International Board Certified Lactation Consultant (IBCLC). Participants will be provided with a breastfeeding assessment at Days 3 and 10; Week 3 and 6; and Months 2, 3, and 6 postpartum.
223890644|NCT04021602|BEHAVIORAL|Usual Care|Participants will receive regular prenatal care provided by their physician. At delivery, all participants will receive some type of lactation support in the hospital.
223890645|NCT06456853|OTHER|Pain assesment|We will ask patients about their pain and will try to asses their pain scores. Then we will ask them to which methot is more suitable for assesment.
223890646|NCT06078514|PROCEDURE|Loop electrosurgical excision procedure (LEEP)|The affected area of cervix is excised under local anesthesia using a small thin electrically charged hardwire loop for simultaneous cutting and electrocoagulation.
223890647|NCT06779968|DEVICE|Femoral Nerve Block|In the femoral nerve block (FNB) group, the femoral nerve was blocked distal to the inguinal ligament and lateral to the femoral artery. Under sterile conditions and ultrasound guidance using a short-axis out-of-plane approach, a 22-gauge insulated needle was advanced adjacent to the femoral nerve. Following confirmation of correct needle tip placement, a 20 mL volume of either 266 mg liposomal bupivacaine (diluted as indicated) or 0.2% ropivacaine was injected. This was followed by a continuous infusion at a rate of 5-10 mL/hr. For pediatric patients, a continuous infusion of 0.2% ropivacaine was administered at an initial bolus of 0.2-0.5 mg/kg, followed by a continuous infusion of 0.1-0.3 mg/kg/hr.
223890648|NCT06779968|DEVICE|Combined Sciatic and Femoral Nerve Block|In the combined sciatic and femoral nerve block (CS-FNB) group, the femoral nerve block was performed as described above. The sciatic nerve block was performed at either the gluteal region or popliteal fossa. Under sterile conditions and ultrasound guidance using either an in-plane or out-of-plane approach, a 22-gauge insulated needle was advanced adjacent to the sciatic nerve. Following confirmation of correct needle tip placement, a 20 mL volume of either 266 mg liposomal bupivacaine (diluted as indicated) or 0.2% ropivacaine was injected. This was followed by a continuous infusion at a rate of 5-10 mL/hr. For pediatric patients, a continuous infusion of 0.2% ropivacaine was administered at an initial bolus of 0.2-0.5 mg/kg, followed by a continuous infusion of 0.1-0.3 mg/kg/hr.
223890649|NCT06779968|DEVICE|Lumbar plexus block|In the lumbar plexus block (LPB) group, the lumbar plexus was blocked paraspinally within the psoas muscle. Under sterile conditions, ultrasound guidance, or with the assistance of a nerve stimulator, using either an in-plane or out-of-plane approach, a 22-gauge insulated needle was advanced within the psoas muscle adjacent to the lumbar plexus. Following confirmation of correct needle tip placement, a 20 mL volume of either 266 mg liposomal bupivacaine (diluted as indicated) or 0.2% ropivacaine was injected. This was followed by a continuous infusion at a rate of 5-10 mL/hr. For pediatric patients, a continuous infusion of 0.2% ropivacaine was administered at an initial bolus of 0.2-0.5 mg/kg, followed by a continuous infusion of 0.1-0.3 mg/kg/hr.
223890650|NCT06779968|PROCEDURE|Epidural Analgesia|For epidural analgesia, an initial bolus of 5-15 mL of 0.5% ropivacaine was administered followed by a continuous infusion of 0.2% ropivacaine at a rate of 3-10 mL/hr. For pediatric patients, an initial bolus of 0.2% ropivacaine at 0.5-1 mg/kg was administered, not exceeding a maximum total dose of 2-2.5 mg/kg, followed by a continuous infusion of 0.1-0.3 mg/kg/hr.
223890651|NCT06779968|DRUG|Intravenous patient-controlled analgesia|For intravenous patient-controlled analgesia (PCA), fentanyl was administered at a dose of 2 mcg/kg, diluted in 100 mL of normal saline. The basal infusion rate was set at 2 mL/hr, with a PCA dose of 2 mL and a lockout interval of 15 minutes.
223890652|NCT06779968|DEVICE|General Aneasthesia|Following administration of the regional anesthesia, general anesthesia with endotracheal intubation will be performed. Anesthesia induction will be achieved using propofol (1.5-2 mg/kg i.v.), rocuronium (1-2 mg/kg i.v.), and fentanyl (1-2 μg/kg i.v.). Anesthesia will be maintained using sevoflurane or desflurane, with inhaled concentration adjusted based on Bispectral Index (BIS) monitoring. A continuous infusion of remifentanil (0.05-0.2 μg/kg/min) will be administered, with adjustments to maintain blood pressure and heart rate within ±20% of baseline values. Following induction, patients will be mechanically ventilated in pressure-regulated volume control (PRVC) mode. The ventilator (Aestiva; GE Healthcare, Waukesha, Wisconsin, USA) settings will be: tidal volume 6-8 mL/kg, positive end-expiratory pressure 0 cm H2O, inspiratory to expiratory ratio 1:2, respiratory rate 16 breaths per minute (BPM), and fraction of inspired oxygen 41%.
223890653|NCT06249334|OTHER|Whole-body electrical stimulation|The protocol with whole-body electrical stimulation will begin in the intensive care unit and will be completed in the inpatient unit. To stimulate all proposed muscle groups, self-adhesive electrodes will be positioned bilaterally on the quadriceps femoris, tibialis anterior, biceps brachii and lower rectus abdominis muscles. The frequency of 75 Hz will be adopted and the intensity will be adjusted to cause visible muscle contraction. The progression of the therapy protocol will occur throughout the sessions aiming to reach 20 minutes of therapy and 80 contractions.
223890654|NCT06249334|OTHER|Routine physical therapy|The protocol will be based on knee and hip flexion and extension movements; hip adduction and abduction; flexion and extension of shoulders, elbows and wrists; shoulder abduction and adduction; respecting the range of each joint. Volunteers will also perform transfers from lying to sitting and standing positions. Respiratory conduct will be based on ventilation patterns, bronchial hygiene maneuvers and cough.
223890655|NCT05153759|OTHER|Meal service|The primary goal is to pilot the feasibility of a meal service intervention in night shift workers
223890656|NCT06276764|DIAGNOSTIC_TEST|LINFU®|Patients will undergo low intensity non-focused ultrasound excitation of the pancreas for a total of 15 minutes. A contrast agent will be administered IV at five minute intervals. The patient will then receive a dose of secretin and the the patient's pancreatic juice will then be collected for a total of 15 minutes.
223890657|NCT04830397|DRUG|QLS-101|Ophthalmic solution 1x daily
223890658|NCT04830397|DRUG|Timolol Maleate|Ophthalmic solution 1x daily
223890659|NCT05494866|DRUG|Cobicistat Oral Tablet|Cobicistat Oral Tablet
223890660|NCT05494866|DRUG|Gemcitabin|Gemcitabin
223890661|NCT05494866|DRUG|Nab paclitaxel|nab-Paclitaxel
223890662|NCT06149676|DRUG|Saccharomyces Boulardii 250 MG [Florastor]|All patients will get the probiotic to be taken daily. If UTI occurs with a sensitive pathogen, we will treat with ciprofloxacin
223890663|NCT06474468|DRUG|SHR-A2102；Adebrelimab；Cisplatin|"Drug: SHR-A2102 Administration by intravenous infusion for a cycle of 3 weeks.~Drug: Adebrelimab Administration by intravenous infusion for a cycle of 3 weeks.~Drug: Cisplatin Administration by intravenous infusion for a cycle of 3 weeks."
223890664|NCT04993885|DRUG|Avatrombopag|The subjects will receive avatrombopag treatment with an initial dose of 40mg once a day. Platelet counts will be obtained weekly during the first 4 weeks and then every 2 weeks until week 12 after treatment. The dose adjustment range is 20 mg per week to 40 mg per day to maintain the platelet level between 30×10\^9/L and 200×10\^9/L. If the platelet count does not reach to 30×10\^9/L after taking avatrombopag 40mg once a day for 4 consecutive weeks, the treatment will be stopped.
223890665|NCT06089590|OTHER|Non-interventional|This study is non-interventional, patients will be enrolled when initiating a treatment through standard of care procedures.
223890666|NCT03170453|BEHAVIORAL|Cognitive Enhancement Therapy|An 18-month comprehensive, small group approach for the remediation of cognitive deficits in neurodevelopmental disorders consisting of individual sessions and 45 group training sessions in social cognition that are integrated with approximately 60 hours of computer assisted training in attention, memory, and problem solving skills.
223890667|NCT03170453|BEHAVIORAL|Enriched Supportive Therapy|An 18-month intervention that uses individual supportive therapy to help adults learn about autism spectrum disorder, manage their emotions and stress, improve their social skills, and cope with everyday problems. Participants will learn about the impact of stress on their lives, and how to identify their own early cues of distress and apply effective coping strategies.
223890668|NCT06782399|COMBINATION_PRODUCT|Microdevice|"Device: Microdevices~The microdevice is an investigational miniaturized implantable nanodose drug delivery device. It was developed as a tool with the ultimate goal to help screen several existing and investigational drugs directly within a patient's tumor to identify what drugs are the most effective for treating a patient's cancer. The microdevice releases nanodoses of several approved drugs into the tumor, and is then excised minimally invasively several days later.~Other: Standard of care therapy~Participant to receive standard of care therapy as previously determined by participant's treating oncologist and/or dermatologist, which may include a skin-directed or systemic therapy"
223890669|NCT02673424|PROCEDURE|FFR-guided stenting|"The percutaneous coronaryintervention using drug-eluting stent will be indicated according to following criteria in the FFR-guided strategy arm~\* Criteria for revascularization: The FFR ≤ 0.80 will be targeted for PCI"
223890670|NCT02673424|PROCEDURE|IVUS-guided stenting|"The percutaneous coronaryintervention using drug-eluting stent will be indicated according to following criteria in the IVUS-guided strategy arm~\* Criteria for revascularization: Minimum lumen area (MLA) ≤ 3mm2 or (MLA ≤ 4mm2 AND Plaque burden \>70%)"
223890671|NCT04899011|OTHER|Questionnaire|"Questionnaire about taste and salivary disturbance before surgery, 10 days, 4 months and 1 year after surgery.~Questionnaires include characteristics of taste disturbance, and specific impact on quality of life."
223890672|NCT06780852|DEVICE|Tetranite for Cranial Flap Fixation (TN-CFF)|Bioresorbable bone adhesive for cranial flap fixation following a craniotomy.
223890673|NCT05051098|OTHER|No intervention|No intervention
223890674|NCT06260514|DRUG|APR-1051|WEE1 Inhibitor
223890675|NCT05144061|DRUG|HRS2398 Tablets|Take 5mg to 320mg once or twice a day ; Oral administration , 21 days as a cycle.
223890676|NCT03398876|DRUG|Oromucosal Nicotine Spray (ONS)|Participants will receive oral dose of oromucosal nicotine spray (ONS).
223890677|NCT03398876|DRUG|Nicotine Gum|Participants will chew nicotine gum for 30 minutes.
223890678|NCT03398876|OTHER|Cigarette|Participants will smoke one cigarette as 10 puffs for 3 minutes.
223890679|NCT06155669|DEVICE|Virtual Reality|Participants will be selected from patients diagnosed with tension-type headache according to the International Classification of Headache Disorders, third edition (ICHD-3) criteria. Selected participants, in addition to being administered 25 mg of dexketoprofen, will also use virtual reality goggles.
223890680|NCT03954899|DIETARY_SUPPLEMENT|melatonin|5mg of melatonin-otc 30 minutes before sleep
223890681|NCT03954899|OTHER|placebo|placebo 30 minutes before sleep
223890682|NCT05557409|DRUG|AXS-05|AXS-05 tablets, taken twice daily
223890683|NCT05557409|DRUG|Placebo|Placebo tablets, taken twice daily
223890684|NCT04531059|DRUG|Esomeprazole|Proton pump inhibitor
223890685|NCT04531059|DRUG|Bismuth Potassium Citrate|Gastric mucosal protective drug with anti-H. pylori effect
223890686|NCT04531059|DRUG|Tetracycline,Metronidazole|Antibiotics for H. pylori eradication
223890687|NCT04531059|DRUG|Minocycline,Metronidazole|Antibiotics for H. pylori eradication
223890688|NCT06231810|BEHAVIORAL|Tactile stimulation|Tactile stimuli of differing magnitudes will be applied
223890689|NCT05480995|DRUG|18F-fluorofuranylnorprogesterone PET / MRI|Subjects will receive a PET/MRI with 18F-fluorofuranylnorprogesterone tracer
223890690|NCT04794595|PROCEDURE|CBP|continuous blood purification can prevent or treat fluid overload in children with septic shock or other sepsis-associated organ dysfunction who are unresponsive to fluid restriction and diuretic therapy management of septic AKI patients, particularly those with hemodynamic instability or fluid overload. Also, it can remove cytokines
223890691|NCT06074666|BEHAVIORAL|CareMeds Intervention|3 parenting sessions will be offered during weeks 2 through 4 of the study period.
223890692|NCT06074666|BEHAVIORAL|Usual Care Group|3 parenting sessions will be offered during weeks 13 through 15 of the study period.
223890693|NCT03085108|OTHER|No Intervention|No Intervention
223890694|NCT06295835|DIAGNOSTIC_TEST|Fingerstick blood draw|Capillary blood specimen collected from two separate fingersticks.
223890695|NCT05948904|DIAGNOSTIC_TEST|Cryo Ex Vivo|"Lungs from patients undergoing lung transplantation after their removal from the recipient patient with previous informed consent signed before transplantation will be obtained. The organs will be placed in an acrylic box and will be kept at a temperature of 37 Celsius degrees. The lungs will be mechanically ventilated connected by an endotracheal tube size 8 inserted in the bronchus with the balloon inflated and a silk suture providing a hermetic closure proximal to the balloon.~Tissue samples will be taken from the models and images will be performed."
223890696|NCT05772169|DRUG|Mifepristone 300 MG [Korlym]|Mifepristone tablets for once daily oral dosing
223890697|NCT05772169|DRUG|Placebo for mifepristone|Placebo tablets for once daily oral dosing
223890698|NCT01181375|OTHER|Tumour Biopsies and Blood Sampling|Patients who consent to the tissue part of this study will have Biopsies taken for study purposes at the same time as their routine tumour biopsies . In addition,those who consent to the blood sampling part of the study will have their samples taken assess serum biomarkers of tumour oxygenation.
223890699|NCT02051374|PROCEDURE|Decompression alone|
223890700|NCT02051374|PROCEDURE|Decompression followed by fusion with instrumentation|
223890701|NCT06545838|OTHER|Analysis of plasma renin concentration|The concentration of plasma renin in patients will be assessed using the immunochemiluminescent method
223890702|NCT04832295|OTHER|photo-supported conversations|"Sessions 1-4: Before each of the sessions, the client photographs that which is related to their well-being and send these to the therapist before the session. The therapist enlarges each of the photographs into the size of A4. The conversation departures from the photographs and the client is encouraged to talk about each of them and they ways it relates to their well-being. Potential strategies for everyday life are discussed.~Session 5-10: short virtual meetings of approximately 15-20 minutes with the aim to follow the client, confirm their process and support them towards increased well-being.~Session 11: reflecting upon all their previous photographs. Session 12: reflecting future everyday life upon their photographs."
223890703|NCT04832295|OTHER|Care as usual|Medication, psychological treatment
223890704|NCT06491732|DEVICE|Electrical Impedance Myography|EIM is an impedance-based technology in which an imperceptible, high-, multi-frequency (e.g., 1 kHz to 10 MHz) electrical current is applied across two electrodes; the resulting voltage signals are measured across two sense electrodes
223890705|NCT02120456|DRUG|LEO 43204|
223890706|NCT02120456|DRUG|Placebo|
223890707|NCT05027958|DRUG|Tuberculin Purified Protein Derivative|PPD administered through the airways to elicit the development of alveolar inflammation challenge dose of 0.5 TU
223890708|NCT05302934|DEVICE|Pheno4U|Total Knee Arthroplasty represents a well-established, reliable and successful treatment option for end-stage bicompartmental osteoarthritis or other indications resulting in joint destruction. In general, Implantation of a total knee prosthesis improves the quality of life through pain alleviation, deformity correction, joint stabilization, and/or functional range of motion (ROM) through restoration of normal knee kinematics and functionality
223890709|NCT06788223|DEVICE|Parathyroidectomy|Parathyroidectomy under general anesthesia
223890710|NCT05200481|DRUG|Brigatinib 180 MG|Patients will receive brigatinib orally at a dose of 90 mg QD for a 7 days lead-in period followed by 180 mg QD continuously, with or without food, in 28-day cycles until progression. Dose reductions are possible.
223890711|NCT05200481|DRUG|Carboplatin|Patients will receive pemetrexed 500 mg/m² followed by carboplatin to target AUC of 5 mg/mL/min both on Day 1 as IV infusion every 3 weeks for 4 infusions. The first infusion of carboplatin and pemetrexed will be administrated at day 8 of brigatinib treatment, at time of dose escalation from 90 mg QD to 180mg QD continuously.
223890712|NCT05200481|DRUG|Pemetrexed|Patients will receive pemetrexed 500 mg/m² followed by carboplatin to target AUC of 5 mg/mL/min both on Day 1 as IV infusion every 3 weeks for 4 infusions. The first infusion of carboplatin and pemetrexed will be administrated at day 8 of brigatinib treatment, at time of dose escalation from 90 mg QD to 180mg QD continuously.
223890713|NCT06515665|BEHAVIORAL|therapeutic foot orthosis|They will be asked to behaviorally wear this shoe and perform the exercises daily for 6 weeks.
223890714|NCT05838274|OTHER|Alcohol vs. Placebo beverage conditions|Individuals will drink beverages containing alcohol. How they respond to a high vs. low dose will be compared.
223890715|NCT00606996|BEHAVIORAL|Group interpersonal psychotherapy (IPT-G)|
223890716|NCT00606996|BEHAVIORAL|Psychoeducation on co-occurring disorders (PSYCHOED)|
223890717|NCT03623321|DRUG|Pimavanserin|• Pimavanserin 34 mg is provided as 2×17 mg tablets as single dose, once daily by mouth. Dose adjustments of pimavanserin down to 20 mg (provided as 2×10 mg tablets as a single dose, once daily by mouth) and up to 34 mg are permitted based on Investigator assessment of clinical response.
223890718|NCT04690738|DIAGNOSTIC_TEST|Fecal Elastase Concentration|Stool sample for fecal elastase-1 (FEC) analysis and microbiome for sequencing and analysis will be obtained pre- and post-transplant.
223890719|NCT05790850|BEHAVIORAL|Pre-operative physical exercise|Virtual instructor-guided twice weekly cycling-based high-intensity aerobic exercise program for a total of 30 days. Participants will use a study provided recumbent exercise bike and wristband fitness tracker to exercise and log the number of days they exercise with an instructor and self-directed cycling.
223890720|NCT05790850|BEHAVIORAL|Pre-operative mindfulness meditation practice|Daily self-directed mindfulness practice involving a guided imagery meditation for a total of 30 days. Participants will use a study provided guided-imagery meditation audio file loaded to a study provided wristband fitness tracker. Participants will log the number of days they listen to the audio file or participate in self-directed solitary psychological support.
223890721|NCT04511286|BEHAVIORAL|Exposure|Systematic confrontation with stimuli associated with symptom-related distress, to achieve therapeutic changes in cognitions or behavior
223890722|NCT04028687|DEVICE|Taperloc Complete Stem|Patients that have been implanted with a Taperloc Complete Stem to improve hip malfunction/disease.
223890723|NCT00211289|BEHAVIORAL|Education by community pharmacist|
223890724|NCT05692492|DRUG|ZSP1601|50mg BID
223890725|NCT05692492|DRUG|ZSP1601|100mg BID
223890726|NCT05692492|DRUG|Placebo|Placebo
223890727|NCT05192798|DRUG|Albumin-Bound Paclitaxel|Albumin-bound paclitaxel is one of the standard first-line regimens for relapsed or metastatic triple-negative breast cancer.
223890728|NCT05192798|DRUG|Apatinib Mesylate|Apatinib mesylate is an orally administered small-molecule vascular endothelial growth factor receptor-2 (VEGFR-2) tyrosine kinase inhibitor (TKI).
223890729|NCT05192798|DRUG|Bevacizumab|Bevacizumab is a humanized anti-VEGF monoclonal antibody once approved by FDA for treatment of metastatic breast cancer in combination with chemotherapy.
223890730|NCT06109909|DEVICE|Micro Current Neurofeedback Device using Low-Frequency Pulse-Based Transcranial Electrical Stimulation|The EEG interface device is a J\&J Engineering 1-330 C2 box. The software used to determine LIP-tES feedback patterns was developed by Neurogen High Performance Neurofeedback. The EEG sampling frequency is 256 Hz on each of 2 EEG acquisition channels. The feedback LIP-tES is delivered via the 4 EEG leads (A+,A-,B+,B-), with respect to the Common Neck Reference. During each session, 2 electrodes (A- and B-) are attached to the participant's left and right mastoids, while the remaining two electrodes (A+ and B+) are moved to various locations on the scale to record EEG signals. All four (A+,A-,B+,B-) electrodes are involved in applying weak electrical pulses back to the brain (feedback process). The brief feedback pulse (\~100mV) is adaptive and determined based on the offset of the frequency spectrum recorded across the left and right hemisphere (A vs. B) electrodes in the time window immediately prior to stimulation.
223890731|NCT06249152|DRUG|QLS-111, 0.015%|QLS-111 eyedrops applied QPM for 14 days the BID for 14 days.
223890732|NCT06249152|DRUG|QLS-111, 0.030%|QLS-111 eyedrops applied QPM for 14 days the BID for 14 days.
223890733|NCT06249152|DRUG|QLS-111, 0.075%|QLS-111 eyedrops applied QPM for 14 days the BID for 14 days.
223890734|NCT06249152|DRUG|QLS-111 vehicle ophthalmic solution|Vehicle drops applied QPM for 14 days the BID for 14 days.
223890735|NCT06029114|DIAGNOSTIC_TEST|Magnetic Resonance Elastography (MRE)|Imaging technique performed on a Compact 3T MRI scanner that measures the stiffness (mechanical properties) of tissues.
223890736|NCT05701059|PROCEDURE|Cervical arthroplasty|A joint replacement procedure administered by inserting an artificial disc between the vertebrae to replace a natural spinal disc after it has been removed.
223890737|NCT05701059|DEVICE|Semi-Constrained Nuvasive Simplify|This weight-bearing implant consisting of PEEK (polyetheretherketone) endplates and one semi-constrained, fully articulating, mobile zirconia toughened alumina (ZTA) ceramic core will be administered by cervical arthroplasty into the specified single-level cervical region.
223890738|NCT05701059|DEVICE|Unconstrained Biomet Zimmer Mobi-C|This unconstrained, three-piece implant will be administered by cervical arthroplasty into the specified single-level cervical region.
223890739|NCT02243709|DRUG|Mifepristone 600-mg/day or placebo for a week|600-mg of mifepristone for a week, compared to placebo for a week, in a stress-induced condition triggered by a single dose of 32.4 mg of yohimbine
223890740|NCT05845398|DRUG|DCR-AUD|DCR-A1203, the drug substance of DCR-AUD, is a synthetic double-stranded (hybridized duplex) RNA oligonucleotide conjugated to GalNAc ligands that enable specific hepatic access and update after subcutaneous administration. DCR-AUD is a sterile solution of DCR-A1203 at a concentration of 160 mg/mL in water for injection (WFI).
223890741|NCT05845398|DRUG|Placebo|0.9% saline for injection.
223890742|NCT06121986|BEHAVIORAL|Modified Mediterranean Ketogenic Nutrition Adherence Program|Participants will be provided with education, support, and resources for following a Mediterranean diet in addition to titrating into a ketogenic macronutrient ratio across the first 5 weeks, starting at 50% fats/25% protein/25% net carbohydrates up to 70% fats/25% protein/5% net carbohydrates).
223890743|NCT06121986|BEHAVIORAL|Mediterranean Nutrition Adherence Program|Participants will be provided with education, support, and resources for following a Mediterranean diet.
223890744|NCT06150040|DRUG|NP137|IV infusion, 14mg/kg or 9mg/kg, every 2 weeks
223890745|NCT06150040|DRUG|Azacitidine Injection|Subcutaneous injection, 75 mg/m², on cycle Days 1-7 (28-days cycle)
223890746|NCT06150040|DRUG|Venetoclax|Orally, 70 mg, every day on Days 1-28
223890747|NCT05432245|DEVICE|Phacoemulsification combined with minimally invasive glaucoma surgery (MIGS)|The cataract surgery will be performed first and if successful, only then will the MINIject be placed into supraciliary space.
223890748|NCT06541691|DRUG|Enteric-coated aspirin|Enteric-coated aspirin tablet 81 mg, once daily
223890749|NCT06541691|DRUG|Plain aspirin|Plain aspirin tablet 81 mg, once daily
223890750|NCT06541691|OTHER|Hybrid strategy|"A hybrid strategy composed from:~* A one-page educational flashcard~* Alerting patients on highly polluted days via text message~* Encouraging patients to stay at home or minimizing outdoor activity on highly polluted days~* Encouraging patients via text message to wear KN-95 facemasks (provided by the investigators of this study) during outdoors time on highly polluted days~* Encouraging patients to consume citrus fruits during highly polluted days"
223890751|NCT05858593|BEHAVIORAL|Virtual reality curriculum|Rather than rely on mere exposure to devices, participants in the treatment group will receive a curriculum that integrates the devices into traditional content delivered through the after school program.
223890752|NCT05858593|BEHAVIORAL|No Virtual reality curriculum|Children will be able to use the same devices but will not have access to a curriculum that integrates the devices with traditional content delivered through the after school program.
223890753|NCT05497531|DIAGNOSTIC_TEST|ctDNA Blood Collection|Blood collection to be obtained from peripheral vein and cancer draining vein during biopsy
223890754|NCT05542498|BEHAVIORAL|Mindfulness|Training is focused on learning and applying the principles of R.A.I.N. (Recognize, Allow, Investigate, Non-identify) in the context of physics learning.
223890755|NCT05542498|BEHAVIORAL|Relaxation|Training is focused on learning and applying relaxation practices (e.g., progressive muscle relaxation, guided imagery) in the context of physics learning.
223890756|NCT05062031|DEVICE|Defocus Incorporated Multiple Segments® (DIMS®) lenses|Daily wear for 24 months. Lenses have a central monofocal optical zone correcting spherical or spherocylindrical ametropia, surrounded by a ring made up of 300 defocusing pellets. This lens geometry reduces the phenomenon of blurred image projected in the retinal periphery, encountered when myopic eyes are corrected with monofocal lenses.
223890757|NCT05062031|DRUG|Atropine 0.05% eyedrops|One drop each evening in both eyes for 24 months.
223890758|NCT05062031|DEVICE|Monofocal lenses|Daily wear for 24 months
223890759|NCT05754437|DEVICE|Low Level Light Therapy|light-emitting diodes (LED), λ = 633 ± 10 nm; power of 100 mW/cm2, 15 minutes
223890760|NCT06465563|DRUG|SHR-8068|SHR-8068
223890761|NCT06465563|DRUG|Adebrelimab|Adebrelimab
223890762|NCT06465563|DRUG|Cisplatin|Cisplatin
223890763|NCT06465563|DRUG|Gemcitabine|Gemcitabine
223890764|NCT06568588|DRUG|S. boulardii CNCM (National Collection of Cultures of Microorganisms) I-745|250 mg three times a day for 4 months
223890765|NCT04857671|DRUG|Botulinum Toxin Type A in saline water|"100 Allergan units Botulinum toxin A in a total of 2 ml sodium chloride (NaCl) 0,9% Braun.~5 IU of Botox per injection point (0,1ml); in total 100 IU per 20 injections points."
223890766|NCT04857671|DRUG|Isotone saline water|2ml Na Cl (sodium chloride) 0,9% Braun. 0,1ml per injection point in total 20 injections points
223890767|NCT03511963|DRUG|HLX04 100 mg in 4 ml Injection|7.5 mg/kg iv (XELOX+HLX04) 5 mg/kg iv (mFOLFOX6 + HLX04)
223890768|NCT03511963|DRUG|Avastin 100 mg in 4 ml Injection|7.5 mg/kg iv (XELOX+HLX04) 5 mg/kg iv (mFOLFOX6 + HLX04)
224078989|NCT06170346|COMBINATION_PRODUCT|Antioxidants|30 drops of topical antioxidants (Gluconolactone 4%, Hyaluronic acid 0,01%, Allantoin 0,1%, Ferulic acid 3%, Acetyl heptapeptide 0,001%, Silver vine extract 1%, Ectoine 0,01%, Hydroxyectoine 0,01%, and vehicle) will be applied on tested area on each participant for four consecutive days.
224078990|NCT06170346|COMBINATION_PRODUCT|Vehicle|30 drops of topical vehicle (Aqua, Dipropylene glycol, Hydroxypropyl cyclodextrin, Polydextrose, 1,2-hexanediol, Butylene glycol, Propanediol, Caprylhydroxamic acid, Ethylhexylglycerin, Xanthan gum, Benzyl alcohol, Glyceryl caprylate, and Benzoic acid) will be applied on tested area on each participant for four consecutive days.
224078991|NCT02988765|PROCEDURE|Groin ultrasound +/- fine needle aspiration|"Preoperative ultrasound morphometry (USM) of the inguino-femoral lymph nodes (IFLN).~The FNAC and/or FNAB is performed in case of suspicious nodes, if at least one of the selected criteria is relieved during ultrasound"
224078992|NCT06584045|DRUG|Calculus bovis sativus (CBS)|Subjects will orally receive 100mg CBS per day from day 1 to day 84.
224078993|NCT04102033|DRUG|Eltrombopag|Thrombopietic agent approved for its efficacy in chronic immune thrombocytopenia in pediatric patients
224078994|NCT02798796|DEVICE|MRI|All patients will be submitted to MRI
224078995|NCT02988583|DEVICE|Surgery using low viscosity silicone oil|Pars plans vitrectomy using low viscosity silicone oil
224078996|NCT02988583|DEVICE|Surgery using high viscosity silicone oil|Pars plans vitrectomy using high viscosity silicone oil
224078997|NCT03530410|DEVICE|Intragastric balloon placement|Patients will have endoscopic placement of intragastric balloon that will be removed endoscopically after 6 months
224078998|NCT05206526|BEHAVIORAL|Dragon Boat|12 weeks of training, defined by a precise progressive, structured and supervised program divided into 3 weekly sessions of one hour / one hour and a half preparatory to the Dragon Boat activity.
224078999|NCT05206526|BEHAVIORAL|Home-based Exercise|12 weeks of home-based training composed by 10 exercises.
224079000|NCT00852293|OTHER|A blood test|A blood test of about 5ml of blood will be taken to determine Chitinase 3 like-1 protein levels.
224079001|NCT02776163|DRUG|Nedaplatin|nedaplatin 35mg/m\^2，D1-2，2 cycles
224079002|NCT02776163|DRUG|Docetaxel|Docetaxel 70mg/m\^2，D1，2 cycles
224079003|NCT02776163|RADIATION|Intensity-modulated radiotherapy|a total dose of 60-66Gy in 30-33 fractions over 6-7 weeks
224079004|NCT05464784|DRUG|MN-001|MN-001 is a novel, orally bioavailable small molecule compound
224079005|NCT05464784|DRUG|MN-001 placebo|The placebo tablet is identical in appearance to the MN-001 tablet, and contains excipients of MN-001.
224079006|NCT02872454|BEHAVIORAL|Text Messaging|Each week, enrolled participants will receive daily text messages from one of three randomly assigned psychotherapeutic modalities-cognitive restructuring, behavioral activation, and techniques based on Acceptance and Commitment Therapy (ACT)-for a total of 12 weeks. The messages were developed, reviewed, and refined by a multidisciplinary team of experienced therapists, including social workers, psychologists, and psychiatrists.
224079007|NCT04809610|BEHAVIORAL|Internet attachment-based compassion therapy (iABCT).|The iABCT is a self-applied program based on the attachment theory and the use of compassion meditations. It is composed of 8 modules that have been reformulated to be completely self-applied and include text, images, illustrations, videos, audio with guided meditations, exercises and homework. Downloadable PDF files will be made available so that users can review them offline. Each module has been optimized to have a duration of 60 and 90 minutes approximately. The entire intervention is estimated to be completed in eight weeks.
224079008|NCT00419471|DRUG|Escitalopram|Study medication will be provided as 1 tablet of escitalopram 5mg/day or 1 or 2 tablets of escitalopram 10mg/day, and matched placebo. The initial dose of escitalopram was 10mg/day generally, but 5mg/day for those aged 65 or over and with hepatic dysfunction. After the 2nd evaluation, the treatment doses are determined by the investigators' clinical decision considering the severity of depression and tolerability of drug. Drugs are taken once daily per orally within 30 min after the supper meal.
224079009|NCT00419471|DRUG|Placebo|Placebo medication will be provided as matched 1 tablet of escitalopram 5mg/day or 1 or 2 tablets of escitalopram 10mg/day.
224079010|NCT01964001|DIETARY_SUPPLEMENT|Vitamin B-6|Vitamin B-6 50 mg/d
224079011|NCT01964001|DIETARY_SUPPLEMENT|Coenzyme Q10|Coenzyme Q10 300 mg
224079012|NCT01964001|DIETARY_SUPPLEMENT|Vitamin B-6+Coenzyme Q10|Vitamin B-6 (50 mg/d) and Coenzyme Q10 (300 mg/d)
224079013|NCT01964001|OTHER|Placebo|starch
224079014|NCT05315466|PROCEDURE|Non-surgical treatment|Analgesics, anti-inflammatories, muscle relaxants, physical therapy, Global Postural Rehabilitation, magnetic therapy, laser therapy, transcutaneous electrical nervous stimulation (TENS), massage, cognitive-behavioral therapy and all those procedures that can bring benefit to back and leg pain.
224079015|NCT05315466|PROCEDURE|Surgical treatment for spinal stenosis|Decompression of nerve structures by laminotomy or laminectomy and posterior lumbar fusion if stabilization of the column is required.
224079016|NCT02655250|OTHER|Microbiome|
224079017|NCT01394705|DEVICE|BodyMedia|Accelerometer
224079018|NCT00969215|DEVICE|Lumenis fractional carbon dioxide laser|Laser resurfacing of a burn scar
224079019|NCT03516344|PROCEDURE|Liver pumping and Spinal manipulation|Interventions are described in group descriptions
224079020|NCT01411969|DRUG|External Nasal Dilator Strip; 0.05% oxymetazoline chloride|External Nasal Dilator Strip placed above the upper lateral cartilage; 20 minutes after decongestion with 0.05% oxymetazoline chloride applied as an aerosol spray (two times); after decongestion with ENDS.
224079021|NCT01284699|PROCEDURE|Gamma Knife radiosurgery|For patients presenting a contraindications for anaesthesia or electrode implantation, operate their brain without opening the skull without infection or bleeding risk.
224079022|NCT02904980|BEHAVIORAL|Technical Training|Children will watch an instructional video focused on movement related instructions regarding the throwing and catching task.
224079023|NCT02904980|BEHAVIORAL|Quiet Eye Training|Children will watch the same video as the TT group but will also receive instructions designed to optimise their quiet eye durations.
224079024|NCT01877564|DRUG|Metformin|
224079025|NCT04082195|OTHER|Fooya mobile game|An application that incorporates the science and technology of immersive gaming, neuropsychology and cognitive behavior therapy in a mobile health game to target early childhood nutrition literacy and health promotion in a fun and exciting way.
224079026|NCT04082195|OTHER|Uno board game|A popular board game which is not a mobile app.
224079027|NCT02061254|DEVICE|Cutometer|3 measures by cutometer on each area: the mean value will be the final value
224079028|NCT02061254|DEVICE|High resolution ultrasonography (echography)|Cutaneous echography on the 3 areas, in order to measure skin thickness and echogenicity Measures are blinded to cutometer (by a different investigator)
224079029|NCT02061254|DEVICE|Elastography|10 measures on the 3 areas (central measures will be doubled) Measures will be performed blinded to cutometer
224079030|NCT02061254|PROCEDURE|Skin biopsy|Skin biopsy of 3 mm in diameter, for 30 participants, to evaluate histological fibrosis
224079031|NCT03344666|BEHAVIORAL|Step 1 Treatment BI+HC|Participants in the Brief intervention + Health Coach (BI+HC) will receive a BI in the ED, followed by weekly sessions with the Health Coach for 4 weeks, which will occur by phone or in person. During sessions, the HC will review the prior week's progress, and discuss goals and plans for the following week.
224079032|NCT03344666|BEHAVIORAL|Step 1 Treatment BI+TM|Participants in the Brief intervention + Text messages (BI+TM) will receive a BI in the ED, followed by daily TMs for 4 weeks. TM's are tailored based on weekly surveys and focus on motives for alcohol and violence and strategies to reduce involvement.
224079033|NCT03344666|BEHAVIORAL|Step 2 Treatment Responders|"Participants in the BI+HC assigned to stay the course (e.g., continue to receive the HC) will have 4 more weekly sessions with the HC.~Participants in the BI+TM assigned to stay the course (e.g., continue to receive the TM) will receive 4 more weeks of TM.~Participants in the BI+HC or BI+TM assigned to stepped down control will receive a brochure containing community resources."
224079034|NCT03344666|BEHAVIORAL|Step 2 Treatment Non-Responders|"Participants in the BI+HC assigned to be stepped up will receive HC+, which will consist of weekly sessions as well as on daily TMs from the HC.~Participants in the BI+HC assigned to stay the course (e.g., continue to receive the HC) will have 4 more weekly sessions with the HC.~Participants in the BI+TM assigned to be stepped up will receive the HC, which consists of 4 weekly sessions with the HC.~Participants in the BI+TM assigned to stay the course (e.g., continue to receive the TM) will receive 4 more weeks of TM."
223890769|NCT05058690|DIAGNOSTIC_TEST|Oral Glucose Tolerance Test|"* Obtain blood sample for glucose assessment (time 0 sample). This may be obtained via venepuncture or after cannula insertion.~* Test a small sample using a near patient glucose testing meter. If the result on the glucose meter is greater than or equal to 11mmol/L, send the blood sample urgently to lab. If it is confirmed by biochemistry to be above 11mmol/L, there is no need to continue test.~* If the result is less than 11mmol/L on meter, give the patient the glucose solution to drink.~* Collect a further blood sample at 120 minutes.~* Send samples all together to laboratory for glucose measurement."
223890770|NCT06007391|DRUG|Nicotinamide|nicotinamide 3g per day
223890771|NCT06472713|DRUG|Mitoxantrone hydrochloride liposome injection|Mitoxantrone hydrochloride liposome injection once every 3 weeks for up to 8 cycles or until intolerable toxicity, subject withdrawal of informed consent, diseases progression, initiation of new antitumor therapy, loss of follow-up, or death, whichever occurs first.
223890772|NCT06472713|DRUG|PD-1 Inhibitors|PD-1 blockade (comprising tislelizumab \<200 mg/cycle\>, carrellimab \<200 mg/cycle\>, or toripalimab \<240 mg/cycle\>) once every 3 weeks for two years, or until intolerable toxicity, subject withdrawal of informed consent, diseases progression, initiation of new antitumor therapy, loss of follow-up, or death, whichever occurs first.
223890773|NCT04347161|DEVICE|Conversational Agent/Chatbot|Via text messages, the bidirectional, conversation agent provides specific dosing instructions and motivational reminders to promote oral targeted therapy adherence and symptom management. Patients can report symptoms at any time via text message and are also prompted to report symptoms and medication adherence at periodic intervals. Reported symptoms are monitored and managed algorithmically according severity. High-grade symptoms are triaged directly to the patients' cancer care team. Patients in the intervention arm will use MEMS caps to enable capture of the primary outcome and asked to complete longitudinal surveys.
223890774|NCT04347161|OTHER|Usual Care|Patients in the control arm will receive usual care, which includes receiving information about dosing and self-administration of oral therapy, and anticipatory guidance for patients regarding management of side effects. Patients in the control arm will use MEMS caps to enable capture of the primary outcome and asked to complete longitudinal surveys.
223890775|NCT05298995|BIOLOGICAL|GD2-CART01 (iC9-GD2-CAR T-cells)|Following a lymphodepleting treatment with conventional chemotherapy, patients will be treated with 1.0 to 6.0 x 10⁶/kg GD2 Chimeric Antigen Receptor (CAR) positive T cells, infused i.v. as a single dose
223890776|NCT02482376|RADIATION|Stereotactic body radiotherapy ( SBRT)|Single fraction of 21 Gy stereotactic radiotherapy (SBRT)delivered pre-operatively to subjects with early stage breast cancer
223890777|NCT04169373|DRUG|Upadacitinib|Upadacitinib tablet administered orally
223890778|NCT04169373|DRUG|Placebo|Placebo for upadacitinib tablet administered orally
223890779|NCT03974217|DRUG|Talazoparib|Talazoparib is a drug that stops the activity of a protein called poly (adenosine diphosphate \[ADP\]-ribose) polymerase or PARP. PARP is involved in repairing damage to the DNA within the cells. When PARP is turned off by Talazoparib in cancer cells, DNA damage cannot be repaired and leads to the death of the cancer cells.
223890780|NCT03974217|DRUG|Decitabine|Decitabine is a drug that is meant to inhibit DNA methylation to restore normal functions to genes and helps to support normal cell production in the bone marrow and the death of abnormal bone marrow cells.
223890781|NCT05991284|DRUG|Sacubitril-valsartan|sacubitril-valsartan (target dose 97/103 mg twice daily)
223890782|NCT05991284|DRUG|Standard of care|including SGLT-2 inhibitor and MRA
223890783|NCT05824234|OTHER|Implementation of a training centered around the notions of recovery with mental health services first year|Stepped wedge design so same procedure for both arms Stepped-wedge design with randomization stratified by cluster (training over the 1st or 2nd year) according to professional practice (intra-hospital, CMP / CATTP, day hospital, Psychosocial Rehabilitation Center, mobile team, medical sector) social) of the teams formed by the 18 centers participating in the study
223890784|NCT05824234|OTHER|Implementation of a training centered around the notions of recovery with mental health services second year|Stepped wedge design so same procedure for both arms Stepped-wedge design with randomization stratified by cluster (training over the 1st or 2nd year) according to professional practice (intra-hospital, CMP / CATTP, day hospital, Psychosocial Rehabilitation Center, mobile team, medical sector) social) of the teams formed by the 18 centers participating in the study
223890785|NCT05536336|DEVICE|Condom|Contraception
223890786|NCT05987657|DIAGNOSTIC_TEST|Salivary and blood progesterone dosage|"Salivary dosage: patient will chew a dry swab for 2 minutes; when the swab is soaked it is put back in its small case and sent to the laboratory for analysis.~In parallel, the same patients will have a blood sample of 4 ml to dose blood progesterone on an EDTA tube. It will be also sent to the laboratory for analysis.~Both analyses will be done only once on triggering day meaning 36 hours before oocyte retrieval."
223890787|NCT03507608|DRUG|Flutamide|50mg flutamide prior to brachytherapy and prostatic biopsy
223890788|NCT03507608|OTHER|Placebo|placebo prior to brachytherapy and prostatic biopsy
223890789|NCT04855526|DRUG|High THC/No CBD Marihuana|high THC (65 mg THC) and no CBD (0 mg CBD)
223890790|NCT04855526|DRUG|High THC/High CBD Marihuana|high THC (65 mg THC) and high CBD (50 mg CBD)
223890791|NCT04855526|DRUG|No THC/No CBD Marihuana|no THC (0 mg THC) and no CBD (0 mg CBD); placebo drug
223890792|NCT06277778|OTHER|Taekwondo training with music therapy|Taekwondo training with music therapy
223890793|NCT06277778|OTHER|Taekwondo training alone|Taekwondo training without music therapy
223890794|NCT05187182|DRUG|CA-4948|Provided by Curis, Inc.
223890795|NCT05187182|BIOLOGICAL|Nivolumab|240 mg IV on Day 1 of each cycle
223890796|NCT05187182|BIOLOGICAL|Pembrolizumab|400 mg IV on Day 1 of every 3 cycles (C1D1, C4D1, C7D1,…) and dosing may continue for a max of 2 years
223890797|NCT05187182|DRUG|Trastuzumab|6 mg/kg IV loading dose on Cycle 1 Day 1 and 4 mg/kg IV on Day 1 of every subsequent cycle
223890798|NCT05187182|DRUG|mFOLFOX7|Standard of care
223890799|NCT06470763|DRUG|ANV600|ANV600 administered by intravenous (IV) infusion
223890800|NCT06470763|DRUG|ANV600 + pembrolizumab (KEYTRUDA®)|ANV600 administered by intravenous (IV) infusion pembrolizumab (KEYTRUDA®) administered by intravenous (IV) infusion
223890801|NCT06219135|OTHER|no intervention - Contamination group|there is no intervention for this group of patients
223890802|NCT06219135|BIOLOGICAL|blood sample - Bacteraemia group|for adult patients, in optional, blood sample will be taken. 27,5 ml of blood at H24-48 after inclusion and 5 ml of blood at day 30
223890803|NCT06219135|OTHER|no intervention - Emergency group|there is no intervention for this group of patients
223890804|NCT04799912|PROCEDURE|Elective labor induction|Elective labor induction at 39 weeks of gestation
223890805|NCT06021795|DEVICE|Sound Treatment|Customized sound audio track delivered via standard commercially available bone conduction headset
223890806|NCT06540833|DRUG|ITI-1284|ITI-1284 10 mg or 20 mg rapidly disintegrating tablet, taken once daily, sublingual administration
223890807|NCT06540833|DRUG|Placebo|Placebo rapidly disintegrating tablet, taken once daily, sublingual administration
223890808|NCT06438367|DRUG|[14C]TGRX-326|Healthy subjects will be given TGRX-326 60 mg orally on day 1.
223890809|NCT06397040|DEVICE|provider monitoring and feedback to remote data|provider monitoring of remote data and feedback to changes in remote data
223890810|NCT06397040|DEVICE|participant monitoring of remote data|participant monitoring of remote data, based upon post-operative instructions
223890811|NCT04297683|DRUG|ABBV-CLS-7262|"Drug: ABBV-CLS-7162~Administration: Oral~Dose: Dose 1 or Dose 2"
223890812|NCT04297683|DRUG|DNL343|"Drug: DNL343~Administration: Oral~Dose: Once per day"
223890813|NCT03426748|RADIATION|Low dose rate prostate brachytherapy|Permanent implantation of radioactive Iodine-125 seeds under anesthesia with ultrasound guidance
223890814|NCT03426748|RADIATION|High dose rate prostate brachytherapy|Temporary implantation of radioactive material into the prostate in the form of a stepping source of Iridium 192 that travels through 16-18 needles or catheters strategically placed through the prostate
223890815|NCT06071806|OTHER|Topical Application of 5-Fluorouracil|The entire cyst lining radically enucleated in conjunction with any overlying mucosa, followed by extensive cavity thorough curettage, peripheral ostectomy was carried out for all bony walls to remove the microscopic satellite cyst, with identification, isolation, retraction, and preservation of the lingual and inferior alveolar bundle,a sterile radiopaque quarter-inch ribbon gauze coated with 5-FU cream was packed into the surgical wound. Closure of the wound was then done in the usual manner using 3/0 vicryl leaving approximately1 cm of a small distal end of the gauze exposed to allow for easy removal after 24 hours postoperatively
223890816|NCT06837831|OTHER|Control group|Give routine nursing measures. Symptom management: Participants were informed that the damage to the anal canal mucosa caused by radiotherapy was mainly manifested as anal pain, and diarrhea could aggravate the symptoms of anal pain. Therefore, the patient should be instructed to monitor the symptoms of diarrhea and anal pain and give timely feedback; Dietary guidance: eat high-protein, high-vitamin, low-slag, low-fiber food, do not eat spicy and irritating food; Medication guidance: Follow the doctor's advice to take the drug orally on time and according to the amount, cooperate with the retention enema, etc., observe the effect of medication; Psychological guidance: strengthen nurse-patient communication, give psychological counseling, and rationally vent anxiety and other emotions. Perianal skin care: Wear loose cotton underwear to keep the perianal area clean and dry.
223890817|NCT06837831|COMBINATION_PRODUCT|Experimental group|After the patient emptied urine and feces before going to bed (21:00), the patient was assisted to take the kneeling lateral position, and the anal canal was cleaned with 0.9%Nacl soaked cotton swab, and was fully left to dry. After 30min, the anal pain was relieved. The operator fully exposed the patient's anus and part of the anal canal mucosal lesions with his left thumb and index finger, and applied a 6cm\*6cm adhesive foam dressing on the injured mucosa with his right hand. With the help of a cotton swab, the patient was instructed to take a deep breath, send the foam dressing to 3cm of the anal canal, reveal 2cm, slowly release the left hand, withdraw the cotton swab at the same time the anus automatically retracted, which played a role in securing the dressing, and ask the patient to lie flat and rest, and take it out the next morning (06:00).
223890818|NCT06834165|DRUG|Neffy|Epinephrine nasal spray
223890819|NCT06834165|DRUG|Adrenaline|Epinephrine injection
223890820|NCT02226276|RADIATION|fludeoxyglucose F 18|Undergo fludeoxyglucose F 18 PET/CT
223890821|NCT02226276|PROCEDURE|positron emission tomography|Undergo fludeoxyglucose F 18 PET/CT
223890822|NCT02226276|PROCEDURE|computed tomography|Undergo fludeoxyglucose F 18 PET/CT
223890823|NCT02226276|BIOLOGICAL|trastuzumab|Given IV
223890824|NCT02226276|RADIATION|copper Cu 64-DOTA-trastuzumab|Given IV
223890825|NCT02226276|PROCEDURE|positron emission tomography|Undergo copper Cu-DOTA-trastuzumab PET
223890826|NCT02226276|BIOLOGICAL|ado-trastuzumab emtansine|Given IV
223890827|NCT02226276|OTHER|laboratory biomarker analysis|Correlative studies
223890828|NCT06836765|OTHER|the expression negative in laryngeal cancer tissue|Researcher will incorporate the positive expression of FOSB protein in laryngeal cancer tissues into the positive study group and vice versa into the negative study group by immunohistochemical methods!
223890829|NCT06836765|OTHER|the expression positive in laryngeal cancer tissue|Researcher will incorporate the positive expression of FOSB protein in laryngeal cancer tissues into the positive study group and vice versa into the negative study group by immunohistochemical methods!
223890830|NCT05827926|BIOLOGICAL|Influenza Vaccine 1|quadrivalent seasonal influenza vaccine
223890831|NCT05827926|BIOLOGICAL|mRNA-1083.1|Sterile liquid for injection
223890832|NCT05827926|BIOLOGICAL|mRNA-1083.2|Sterile liquid for injection
223890833|NCT05827926|BIOLOGICAL|mRNA-1083.3|Sterile liquid for injection
223890834|NCT05827926|BIOLOGICAL|Investigational Influenza Vaccine 1|Sterile liquid for injection
223890835|NCT05827926|BIOLOGICAL|Investigational COVID-19 Vaccine 1|Sterile liquid for injection
223890836|NCT05827926|BIOLOGICAL|COVID-19 Vaccine 1|Sterile liquid for injection
223890837|NCT05827926|BIOLOGICAL|Investigational Influenza Vaccine 2|Sterile liquid for injection
223890838|NCT05827926|BIOLOGICAL|Influenza Vaccine 2|quadrivalent seasonal influenza vaccine
223890839|NCT05827926|BIOLOGICAL|mRNA-1083|Sterile liquid for injection
223890840|NCT05827926|BIOLOGICAL|Investigational COVID-19 Vaccine 2|Sterile liquid for injection
223890841|NCT05827926|BIOLOGICAL|COVID-19 Vaccine 2|Sterile liquid for injection
223890842|NCT06837389|BIOLOGICAL|JY306 universal NK cell injection|"3+3 dose escalation trial"
223890843|NCT06829030|DRUG|5% dextrose prolotherapy|The first group will receive subcutaneous 5% dextrose prolotherapy (approximately 75 patients), and the second group will receive intramuscular 75 mg diclofenac sodium injection
223890844|NCT06829030|DRUG|Diclofenac 75mg/ml|The first group will receive subcutaneous 5% dextrose prolotherapy (approximately 75 patients), and the second group will receive intramuscular 75 mg diclofenac sodium injection (approximately 75 patients).
223890845|NCT04317677|OTHER|Study of the effect of bladder voiding on sleep fragmentation during day and night sleep|Vigilance state of babies will be continuously recorded during the first 24 hours of hospitalization by polysomnography and actigraphy. In parallel, bladder voiding episodes will be detected with an innovative device placed on babies diapers.
223890846|NCT04848870|OTHER|Salivary samples|collection of salivary samples from Sjögren patients on routine care in the oral medicine department.NA
223890847|NCT04959201|DRUG|NMDAE plus AO|Use of an NMDA enhancer plus a drug with antioxidant property for the treatment of schizophrenia.
223890848|NCT04959201|DRUG|NMDAE plus Placebo Cap|Use of an NMDA enhancer plus placebo as a comparator.
223890849|NCT06837272|DIAGNOSTIC_TEST|Multi-omics features extraction|Based on multi-omics features extracted from clinical data, gut microbiome, metabolomics, and multi-modal MRI, the diagnostic model of SCD due to preclinical AD will be established.
223890850|NCT05836168|DIETARY_SUPPLEMENT|Omnibiotic Stress Repair|multispecies probiotic
223890851|NCT05836168|DIETARY_SUPPLEMENT|Placebo|Placebo
223890852|NCT05116709|DRUG|BAT6005 injection|Six dose groups were set up, including 10mg (initial dose) group, 30mg group, 100mg group, 300mg group, 600mg group and 900mg group, respectively.
223890853|NCT06816667|DRUG|BMND08|Participants will receive a sublingual dose of 5-MeO-DMT once a week for four consecutive weeks. The intervention will be administered in the form of a sublingual tablet. The substance 5-MeO-DMT, a potent tryptamine, is known for its psychoactive properties but will be administered at a dose that does not induce a full psychedelic experience.
223890854|NCT06816667|PROCEDURE|Brain electrical activity monitor|EEG is a technique used to monitor brain electrical activity by recording brain waves through electrodes placed on the scalp. This procedure allows the assessment of brain waves such as delta, theta, alpha, and beta, specifically to evaluate the changes in brain activity following sublingual administration of 5-MeO-DMT.
223890855|NCT06816667|DIAGNOSTIC_TEST|Pharmacokinetic Study of Sublingually Administered Psychoactive Substance|For pharmacokinetic analysis, approximately 6 mL of EDTA blood will be collected to assess the pharmacokinetics of a sublingual dose of 5-MeO-DMT. Samples will be obtained at baseline (pre-dose, 0 minutes) and at the following time points post-dose: 5, 10, 20, 30, 40, 50, 60, and 120 minutes.
223890856|NCT06816667|DIAGNOSTIC_TEST|Biochemical determinations|Biochemical determinations will be performed to assess hematological, renal, hepatic, cardiac, and cellular lysis functions. The biochemical markers that will be measured include red blood cells, hematocrit, hemoglobin, glycated hemoglobin, white blood cells, microalbuminuria (urine albumin/creatinine ratio), and various serum markers such as cortisol, glucose, urea, serum creatinine, total cholesterol, HDL, LDL, triglycerides, AST, ALT, lactate dehydrogenase (LDH), creatine kinase (CK), CK-MB, and C-reactive protein.
223890857|NCT06816667|DIAGNOSTIC_TEST|Acute Subjective Ratings of Psychedelic Effects|To determine the intensity of the acute effects experienced by subjects, retrospective ratings will be collected 1 hour after 5-MeO-DMT or placebo exposure. Subjective ratings will include the Peak Experience Scale (PES), the Ego Dissolution Inventory (EDI), and the Mystical Experiences Questionnaire (MEQ).
223890858|NCT06816667|DIAGNOSTIC_TEST|vital signs|Vital signs, including blood pressure, heart rate, oxygen saturation, respiration rate, body temperature, and electrocardiograms (ECGs), will be monitored over the six weeks of the treatment
223890859|NCT06816667|DIAGNOSTIC_TEST|Cognitive Assessments|Cognitive assessments will evaluate the effects of sublingual 5-MeO-DMT on cognitive functions. Participants will undergo the Phonological Verbal Fluency Test (FAS) to assess executive function, the Paced Auditory Serial Addition Test (PASAT) to evaluate processing speed, and the Digit Span Scale (DSS) for attention span and working memory. These tests will be administered at baseline, during treatment, and post-treatment to assess any cognitive changes in response to the different doses of 5-MeO-DMT (6 mg, 9 mg, 12 mg) or placebo, helping to determine how the intervention may influence cognitive processing, memory, and attention.
223890860|NCT06816667|DIAGNOSTIC_TEST|Psychiatric Assessments|Psychiatric evaluations will be conducted to assess the emotional and psychological effects of sublingual 5-MeO-DMT. Participants will complete the Beck Depression Inventory II (BDI II) to measure mood and depressive symptoms, the State-Trait Anxiety Inventory (STAI) to evaluate state anxiety, and the Depression, Anxiety, and Stress Scale (DASS-21) to assess stress levels. Additionally, the Suicidal Ideation Scale (SSI) will be used to monitor any changes in suicidal ideation throughout the study. These psychiatric assessments will be administered at multiple time points during the study to evaluate the potential therapeutic effects of 5-MeO-DMT in improving mood, anxiety, and overall psychological well-being.
223890861|NCT04044859|GENETIC|Autologous genetically modified ADP-A2M4CD8 cells alone or in combination with nivolumab every four weeks or pembrolizumab every 6 weeks|Infusion of autologous genetically modified ADP-A2M4CD8 on Day 1 alone or in combination with either nivolumab 480 mg IV every four weeks or pembrolizumab 400mg IV every 6 weeks
223890862|NCT06838286|DRUG|SGLT2 inhibitor|SGLT2 inhibitor class of drugs
223890863|NCT06838286|DRUG|Thiazolidinedione|Thiazolidinedione class of drugs
223890864|NCT06838286|DRUG|DPP-4 inhibitor|DPP4 inhibitor class of drugs
223890865|NCT03135548|DRUG|Spesolimab (low dose)|12 weeks treatment
223890866|NCT03135548|DRUG|Placebo|12 weeks treatment
223890867|NCT03135548|DRUG|Spesolimab (high dose)|12 weeks treatment
223890868|NCT03467386|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo alloHCT
223890869|NCT03467386|DRUG|Cyclophosphamide|Given IV
223890870|NCT03467386|BIOLOGICAL|Filgrastim|Administer according to City of Hope standard operating procedures
223890871|NCT03467386|OTHER|Laboratory Biomarker Analysis|Correlative studies
223890872|NCT03467386|OTHER|Quality-of-Life Assessment|Ancillary studies
223890873|NCT03467386|OTHER|Questionnaire Administration|Ancillary studies
223890874|NCT03467386|DRUG|Tacrolimus|Given CIV
223890875|NCT03467386|RADIATION|Total Marrow Irradiation|Undergo TMLI
223890876|NCT06831786|BIOLOGICAL|Bivalent mRNA SARS-CoV-2 vaccine|Administering a booster dose of the bivalent mRNA vaccine BNT162b2
223890877|NCT06831786|BIOLOGICAL|Quardrivalent influenza vaccine|Administering a VaxigripTetra™
223890878|NCT04461236|DIETARY_SUPPLEMENT|Oral Supplement|Supplement provided in capsules. Half the capsules to be taken with lunch and the other half with dinner. All supplements are commercially available.
223890879|NCT04461236|DIETARY_SUPPLEMENT|Placebo|Placebo
223890880|NCT04190953|OTHER|Twin block then Hyrax|Patients will undergo mandibular advancement prior to maxillary expansion
223890881|NCT04190953|OTHER|Hyrax then Twin block|Patients will undergo maxillary expansion prior to mandibular advancement
223890882|NCT05267808|PROCEDURE|Drug-induced sleep endoscopy|Endoscopy during drug-induced sleep
223890883|NCT06827964|DIETARY_SUPPLEMENT|Soy-based Nutrition Package|Dry, vacuum-sealed sachets containing yellow powder, odorless, to be consumed with warm water. Each 12g sachet provides: 209 kJ energy, 3.1g protein, 1.7g fat, 4.6g carbohydrates, 3mg sodium, 200mg calcium, 7.5mg iron, 3mg zinc, 250μg RE vitamin A, 5μg vitamin D, 0.5mg vitamin B1, 0.5mg vitamin B2, 0.5μg vitamin B12, and 75μg folate. Intervention duration: 6 months, with 2 sachets per day. Produced by Tiantianai (Jiangsu) Biotechnology Co., Ltd., a certified supplier for maternal and child nutrition projects in China.The company has a Class D production workshop that meets the latest GMP standards for pharmaceuticals. The product has passed certifications for Food Safety Management System (ISO 22000) and Quality Management System (ISO 9001).
223890884|NCT06827964|DIETARY_SUPPLEMENT|Probiotics|Dry, vacuum-sealed sachets containing white powder, odorless. Each 2g sachet contains 500\*10\^9 CFU of Lactobacillus plantarum LLY-606 and Pediococcus pentosaceus JQI-7. Intervention duration: 6 months, with 1 sachet per day. Produced by Jiangsu Wecare Biotechnology Co., Ltd., compliant with international standards (cGMP, FSSC 22000, HACCP, ISO 22000, ISO 9001).
223890885|NCT04103346|OTHER|air filtration with air purifier with hepa filter|long-term (4 week) air filtration with the Holmes HAP8650B-NU-1 air purifier in the residence of low-income seniors impacted by roadway pollutants.
223890886|NCT04103346|OTHER|sham|air purifier running with air filter removed
223890887|NCT06835335|BEHAVIORAL|opioid prescription|"The intervention consisted of a randomized questionnaire presenting a clinical case of a patient suffering from severe abdominal pain. The control case was As an emergency physician in an adult emergency department, you are presented with the following patient: The patient is a 39-year-old non-smoking male/female with a history of Meniere's disease and an allergy to Bactrim. He/she presents with abdominal pain that began abruptly 2 hours ago and has persisted despite taking NEFOPAM 45 minutes ago. This is his first episode. His/her vital signs are blood pressure 140/66, heart rate 91, pulse ox 97%, temperature 36.8°C. He/she rates his/her pain as 8/10 without any analgesic position. On clinical examination he/she presents with localized epigastric tenderness. The rest of the abdomen is soft, painless and depressed. There are hydro-aeriform noises. No diarrhea or vomiting. The rest of the clinical examination showed no abnormalities.. In the intervention case, patient had history of S"
223890888|NCT05791968|PROCEDURE|Whole blood standard donation|Effects of a standard whole blood donation on iron stores and insulin sensitivity.
223890889|NCT06132035|DRUG|CG-P5 peptide|Patient will instill daily 1 package of CG-P5 peptide eye drops in the study eye \[self-administered\] using the single use tear-off disposable packaging
223890890|NCT06132035|DRUG|Placebo|Patient will instill daily 1 package of Placebo eye drops in the study eye \[self-administered\] using the single use tear-off disposable packaging
223890891|NCT06132035|DRUG|Aflibercept Injection [Eylea]|Patient will receiver Eylea® (Aflibercept) intravitreal injection once in a month
223890892|NCT06832475|DEVICE|clear aligners and elastics|"For the Fixed Appliance group, the straight wire treatment included an aligning and leveling phase, achieved by using Nickel-Titanium arches (0.016/0.019 × 0.025 arc sequence) and a phase with heavier stainless steel rectangular arches (0.019 × 0.025); during this last treatment phase patients were instructed to use Class II elastics for at least 16 h/day.~Pre- (T0) and post-treatment (T1) lateral cephalogram were collected from all selected patients. Treatment time was an average of 18 months (T1-T0=18 months)."
223890893|NCT06832475|DEVICE|class 2 elastics|"Class II malocclusion is the most common malocclusion, and it is one of the main reasons for people to undergo orthodontic treatment. This alteration is characterized by an improper relationship between the maxillary and mandibular arches because of skeletal or dental discrepancies or a combination of both . The treatment protocols may considerably vary depending on professional skills, malocclusion severity and patient compliance . Among all the well-known techniques, it is important to mention the Class II elastics , used to camouflage mild skeletal Class II or to treat mild to moderate Class II occlusal relationship.~During the correction of Class II malocclusions by means of inter-arch elastics, special attention should be paid to the position of the lower incisors."
223890894|NCT06837298|OTHER|Placebo control capsules|2.4 grams (g) daily
223890895|NCT06837298|OTHER|PeptiStrong® supplement capsules with same appearance as placebo capsules|2.4 g daily
223890896|NCT06837298|OTHER|PeptiStrong® supplement capsules following muscle damaging exercise on Day 14|2.4 g placebo capsules for 14 days, then 3 days 2.4 g of PeptiStrong® capsules following one muscle damaging exercise session
223890897|NCT04675567|BEHAVIORAL|Safety-Net Care Team Model|"Safety-Net Care Planning Team: Clinical expertise will be combined with peer-to-peer parent/guardian support for trauma-informed care delivery to both parent and child. All aspects of the care continuum will be provided in a culturally and linguistically competent manner, with child and family-driven care planning."
223890898|NCT06282445|DRUG|Adebrelimab|This product is administered by intravenously guttae. The recommended dose of subcutaneous injection is 1200mg, administered every 3 Weeks (Q3W).
223890899|NCT06282445|DRUG|Oxaliplatin|130 mg/m2, ivgtt, d1, Q3W
223890900|NCT06282445|DRUG|Capecitabine|1000mg/m2, po, bid, d1-14, Q3W Maintenance therapy: 1250mg/m2, po, bid, d1-14, Q3W
223890901|NCT06282445|DRUG|Bevacizumab|7.5mg/kg，ivgtt, d1, Q3W
223890902|NCT06833645|OTHER|molecular probe [18F]AV45(Aβ) and [18F]AV1451(Tau)|The new imaging agents Aβ and TauPET/CT are molecular imaging, which have the advantage of earlier and more visual, and can study the mechanism of pathological changes and PET manifestations of Alzheimer's disease before symptoms appear from the molecular level.
223890903|NCT06830330|BEHAVIORAL|Virtual reality|Patients in the experimental group were shown videos of natural landscapes with VR glasses in their beds. This application was used to distract patients who were experiencing negative emotions just before surgery. The video session begins with the introduction of the virtual reality glasses. A motionless virtual area is determined at the point where the patient's stretcher is located. The glasses are placed on the patient's head and both hands of the patient are trained to use the remote control. Video content is selected and started according to the patient's preference. Video sessions last approximately 10 minutes.
223890904|NCT06830265|DEVICE|Novel needle biopsy catheter (test)|Tissue is collected from the prostate by introducing a needle into the prostate and cutting out a sample
223890905|NCT05540639|BEHAVIORAL|Modified Mindfetalness|The pregnant woman is motivated to practice Mindfetalness verbally, by video, by a leaflet and at a website.
223890906|NCT06769763|OTHER|My Journey with MS application|This is an Arabic application for MS patients that provides them with information about self-care like nutrition, exercise, mental health, and self-management, in addition to other features like symptom tracking and medication reminders.
223890907|NCT02986516|OTHER|Randomized Cohort|Surgical treatment with different approach, based on the characteristics of the tumor or definitive high dose radiotherapy (carbon ion radiotherapy, proton-therapy, mixed photons-proton therapy) will be assigned by randomization
223890908|NCT02986516|RADIATION|Prospective cohort|Surgical treatment or definitive high dose radiotherapy will be selected by the patients and will be prospectively evaluated
223890909|NCT06831682|DEVICE|Kinesiotaping (KT)|Kinesiotaping will be applied using muscle, lymphatic, and ligament taping techniques to promote healing, reduce swelling, and improve muscle function following total knee replacement surgery.
223890910|NCT06831682|OTHER|Standard Rehabilitation|Patients will receive standard postoperative rehabilitation, including physiotherapy, gait training, and medical exercises, without the application of Kinesiotaping.
223890911|NCT04238676|DRUG|PP353|active administered by intradiscal injection
223890912|NCT04238676|OTHER|Placebo|Sham injection
223890913|NCT06836167|BEHAVIORAL|exercise promotion|a) Up to 10 weekly 1-hour group sessions of multicomponent exercise guided by a physiotherapist, incorporating resistance, endurance, balance, and flexibility. Supported by materials adapted for low literacy or cognitive impairment, it empowers participants to maintain physical activity. Vivifrail may be used to prevent frailty and falls.
223890914|NCT06836167|DRUG|review medication|d) Comprehensive medication review for optimization and deprescribing. Results show significant improvements in physical performance and intrinsic capacity at three and six months, sustained through empowerment and community resource connections.
223890915|NCT06836167|BEHAVIORAL|promoting healthy aging|b) Non-pharmacological interventions, including nutritional guidance for a Mediterranean diet, dysphagia and cognitive impairment screening, and sleep hygiene counselling.
223890916|NCT06836167|OTHER|against social isolation|Support against social isolation by activating community resources.
223890917|NCT05823740|OTHER|Bioelectrical impedance Analysis (BIA)|Bioelectrical impedance analysis (BIA) is a method for estimating body composition, in particular, body fat and muscle mass, where a weak electric current flows through the body and the voltage is measured in order to calculate the impedance (resistance) of the body. BIA will be done at baseline, during the study related to routine medical imaging, and end of the study.
223890918|NCT05823740|OTHER|D3-Creatine Dilution (D3Cr)|The D3-Creatine dilution method is a safe and noninvasive measure of skeletal muscle mass that has previously been validated in adults, neonates, healthy children, and children. D3-Creatine Dilution will be done at baseline, during the study related to routine medical imaging, and end of the study.
223890919|NCT05823740|OTHER|6-Minute Walk Test (6MWT)|Cardiovascular fitness will be measured with the 6-minute walk test (6MWT). 6MWT will be done at baseline, during the study related to routine medical imaging, and end of the study.
223890920|NCT05823740|OTHER|Timed Up and Go (TUG)|Balance and mobility will be assessed by the timed-up-and-go test (TUG). TUG will be done at baseline, during the study related to routine medical imaging, and end of the study.
223890921|NCT05823740|OTHER|30-second Sit-to-Stand (STS)|Strength and muscular function will be evaluated by modified 30-second sit-to-stand (STS). STS will be done at baseline, during the study related to routine medical imaging, and end of the study.
223890922|NCT05823740|OTHER|Hand Grip Strength (GS)|Strength and muscular function will be evaluated by grip strength (GS). GS will be done at baseline, during the study related to routine medical imaging, and end of the study.
223890923|NCT05823740|OTHER|PBTL p16 expression|Peripheral Blood biospecimen for PBTL p16 expression will be used for the assessment of biological aging. Blood biospecimens will be collected at baseline and end of the study for PBTL p16 analysis.
223890924|NCT05823740|OTHER|CT, MR and PET Imaging|Participants will undergo routine imaging with either computed tomography (CT), Magnetic Resonance Imaging (MRI) of the chest or abdomen, or whole-body positron emission tomography (PET) scan. Skeletal muscle mass and fat mass will be calculated at several different vertebral levels from imaging studies.
223890925|NCT05978986|DIAGNOSTIC_TEST|Determining of the clinical class of chronic venous disorders by artificial intelligence|The doctor takes pictures of the lower extremities and uploads them to the IVENUS application, which automatically determines the clinical class according to CEAP. Further, the doctor independently determines the clinical class according to CEAP and enters the data into the register.
223890926|NCT06836557|DRUG|Tradipitant|BID
223890927|NCT05753189|DRUG|Aceclidine+Brimonidine combination ophthalmic solution|Combination ophthalmic solution of Aceclidine and Brimonidine
223890928|NCT05753189|DRUG|Placebo|Placebo: Proprietary Vehicle Solution
223890929|NCT05753189|DRUG|Aceclidine Ophthalmic Solution|Aceclidine
223890930|NCT05817708|DRUG|CX-4945|"Drug: CX-4945~Silmitasertib, orally, once or twice daily for 5 days.~Other Name: Silmitasertib"
223890931|NCT05394506|PROCEDURE|Skin Biopsy|The skin biopsy is performed in the consultation outclinic room. A local anaesthetic (anaesthetic patch to be applied to the skin) is required for this procedure. The skin biopsy is usually performed on the front of the forearm (but can be performed on the arm, thigh or leg). After disinfection, a fragment of 3 to 4 mm in diameter is removed with a biopsy-punch (single-use device). If necessary, a suture can be placed. Otherwise, the wound is covered with Steristrip and a sterile dressing. The skin sample, intended for a fibroblast culture, will be placed in a flask to be kept at room temperature. It will be labelled with specific labels and sent to the local biological resource centre.
223890932|NCT05394506|PROCEDURE|Muscle biopsy|The muscle biopsy is performed in a sterile room. A local anaesthetic is required for this procedure. After selecting the muscle from which the sample will be taken (usually from the deltoid muscle at the shoulder stump), placing a sterile field and disinfecting, a small incision is made in the skin until the selected muscle is exposed. A bundle of muscle fibres of approximately 1 cm x 0.5 cm is removed. The skin is then sutured and covered with a sterile dressing. The procedure takes about 30 minutes (including patient set-up). The muscle sample will be divided into 2 fragments, one for myoblast culture, the other for frozen tissue. The 2 vials will be labelled with specific labels and then sent to the local biological resource centre
223890933|NCT06838546|DRUG|B1962|B1962 has higher VEGF anti angiogenic activity than its competitors. Phase I clinical trials have shown that B1962 has excellent safety and promising therapeutic effects. Large scale clinical studies may achieve better therapeutic effects than similar competitors targeting the same target
223890934|NCT03605550|DRUG|PTC596|Oral tablets
223890935|NCT03605550|RADIATION|Radiotherapy|Cycle1
223890936|NCT06261450|DRUG|CBD Oral Solution (eCBD system Target)|Participants receive orally 6 ml of CBD Oral Solution (100 mg / ml; 60 mg / kg; max 600 mg of CBD) followed by 6 ml of a placebo composed of the inactive ingredients of CBD Oral Solution 3 weeks later.
223890937|NCT06261450|DRUG|Placebo|Participants receive orally 6 ml of a placebo composed of the inactive ingredients of CBD Oral Solution followed by 6 ml of Oral CBD Solution (100 mg / ml; 60 mg / kg; max 600 mg of CBD)
223890938|NCT03955510|OTHER|Right time eating|"Right-time eating means breakfast before 8am, lunch before 1 pm and dinner before 6pm. Subjects will be asked to stick to this eating schedule for 1 week. Subjects will randomly be assigned to each eating pattern during the study period. Each subject will be required to do this intervention twice during the study period. One time they will have right time eating with alcohol , the second time the will have this intervention without alcohol."
223890939|NCT03955510|OTHER|Delayed time eating|"Delayed-eating means eating each meal 3 hours later than the Right-time eating.Subjects will be asked to stick to this eating schedule for 1 week. Subjects will randomly be assigned to each eating pattern during the study period. Each subject will be required to do this intervention twice during the study period. One time they will have delayed time eating with alcohol , the second time the will have this intervention without alcohol."
223890940|NCT03955510|PROCEDURE|Sigmoidoscopy|Subjects will undergo unprepped sigmoidoscopy to collect tissue and stool sample at each intervention visits (visit 2, 3, 4, and 5). Flexible sigmoidoscopy will not require any colon cleansing and it will be very limited to the most distal (closest to the end of the anus) 20 centimeters (approximately 8 inches) of the colon and thus will be far less uncomfortable than the routine flexible sigmoidoscopy.
223890941|NCT03955510|PROCEDURE|Optional 24h circadian assessment in the Biological Rhythms lab|"Subjects may choose to participate in the 24 hour circadian assessment in the Biological Rhythms Research Lab. During this assessment, a saliva sample will be taken every hour, a mouth swab will be done every 2 hours, and rectal swab will be done twice (every 12 hours). Subjects will be kept awake in dim light on a recliner chair. Subjects can watch a television with dimmed light. Subjects will be provided with food and drink during the assessment.~If subjects choose this intervention they will be asked to complete 4 assessment during the course of the study period."
223890942|NCT03955510|OTHER|Alcohol|Moderate alcohol drinking means 0.5 g/kg alcohol daily, which will be not more than 2 glasses of wine depending on subject's weight. Alcohol will always be consumed in the evening with food or after food (e.g., dinner). The timing of alcohol consumption will be consistent for each individual. Subjects will be provided with red wine for the 2 alcohol intervention weeks. The order of conditions will be random.
223890943|NCT06826157|DIAGNOSTIC_TEST|Electroencephalogram|EEGs will be acquired to explore progressive alteration of EEG patterns throughout the neuropathology progression.
223890944|NCT06826157|DIAGNOSTIC_TEST|3 Tesla MRI|MRI evaluations will be performed to investigate structural alterations and resting state functional MRI (RS-fMRI) connectivity in participants. Longitudinal measures of cortical/subcortical atrophy and RS-fMRI connectivity will be assessed and their relationship with EEG parameters will be explored.
223890945|NCT06826157|GENETIC|Apolipoprotein E genetic test|At baseline, a sample of blood will be collected to perform genetic analysis (APOE alleles) for all participants
223890946|NCT06836986|DRUG|Norepinephrine Bolus|"Prophylactic norepinephrine bolus of 8 micrograms will be administered right after spinal anesthesia induction.~Rescue bolus of norepinephrine 4 micrograms will be administered in case of hypotension."
223890947|NCT06836986|DRUG|Phenylephrine bolus|"Prophylactic phenylephrine bolus of 100 micrograms will be administered right after spinal anesthesia induction.~Rescue bolus of phenylephrine 50 micrograms will be administered in case of hypotension."
223890948|NCT06413641|OTHER|Follow up at general practice|As described before
223890949|NCT06413641|OTHER|Consultation|As described before
223890950|NCT06413641|OTHER|Visualization of CTA images|As described before
223890951|NCT06837350|OTHER|Music intervention|Listening to Turkish Music
223890952|NCT06786988|DIAGNOSTIC_TEST|MRI|brain MRI scan: (1) one day before the procedure, (2) 24-36 hours after the procedure and (3) up to 1 year after the procedure
223890953|NCT06786429|BIOLOGICAL|Gardasil 9 vaccine|Participants with a valid consent will be offered a three-dose Gardasil 9 series if eligible.
223890954|NCT06786429|BIOLOGICAL|Hepatitis B Virus Vaccine(HBV)|Participants who do not demonstrate immunity to Hep B antibody marker in their blood, HBsAb and not HBsAg will be offered a three-dose series of Hep B. vaccine. A blood test will be done six months later to assess vaccine take i.e. immunity. Patients who demonstrate infection with Hep B virus will be referred to their doctor for further management.
223890955|NCT06786429|BEHAVIORAL|Cognitive Behavioral Therapy|Participants who demonstrate signs and symptoms of depression and/or anxiety will be offered individual behavioral management services. This consists of weekly individual sessions by a trained therapist for 8 weeks with option for referral for further management depending on the outcome of the intervention. The positive outcome consists of a change in presenting symptoms determined after administration of the youth risk behavior screen for high school students, and PHQ-9, and Edinburgh post-natal depression screen for women respectively.
223890956|NCT06786689|DRUG|Azathioprine (AZA)|weekly single dose of tab azathioprine 300mg
223890957|NCT06786689|DRUG|Betamethasone|oral Betamethsone 5mg for 2 consecutive days weekly
223890958|NCT06485401|DRUG|ADC189|45 mg per tablet, oral administration, single dose.
223890959|NCT06342947|DRUG|ALG-055009|Softgel Capsule
223890960|NCT06342947|DRUG|Placebo|Softgel Capsule
223890961|NCT06838533|PROCEDURE|computer guided advancement genioplasty|PEEK vs Titanium patient specific plates
223890962|NCT02199054|OTHER|wheat-safflower oil pretzels|Each serving (6 pieces) of the wheat-safflower oil pretzel contains 6 grams of safflower oil. Ingredients in the pretzel are high gluten wheat flour, safflower oil, sugar, yeast, salt, and ascorbic acid.
223890963|NCT02199054|OTHER|soy-safflower oil pretzels|Each serving (6 pieces) of the soy-safflower oil pretzel contains 6 grams of safflower oil. Ingredients in the pretzel are high gluten wheat flour, soy flour, soymilk, safflower oil, sugar, yeast, salt, and ascorbic acid.
223890964|NCT02199054|OTHER|control wheat pretzels|Each serving (6 pieces) of the control wheat pretzel contains 6 grams of vegetable shortening. Ingredients in the pretzel are high gluten wheat flour, vegetable shortening, sugar, yeast, salt, and ascorbic acid.
223890965|NCT06830551|DRUG|administration cord blood based eye drops, standardized to the deliver BDNF.|administration cord blood based eye drops customized to deliver epitelio tropic factors, incluiding EGF in EGFR blocked cells
223890966|NCT04650087|DRUG|Apixaban 2.5 MG|Participants will take Apixaban 2.5 MG twice a day, once in the morning and once in the evening for 30 days. Participants will be contacted (electronic or telephone) 2 days after starting the study medication and will continue up to day 90 after starting study treatment. Followup will occur from the time of discharge through the 30 day study period with contacts at 2 days, 10 days, 20 days and 30 days after discharge. Two additional study contacts will take place 45 days and 90 days after discharge.
223890967|NCT04650087|DRUG|Placebo|Participants will take placebo twice a day, once in the morning and once in the evening for 30 days. Participants will be contacted (electronic or telephone) 2 days after starting the study medication and will continue up to day 90 after starting study treatment. Followup will occur from the time of discharge through the 30 day study period with contacts at 2 days, 10 days, 20 days and 30 days after discharge. Two additional study contacts will take place 45 days and 90 days after discharge.
223890968|NCT06829342|DEVICE|Stochastic Resonance (SR)|The system consists of six linear isolated stimulators (STMISOLA, Biopac Systems, Inc., Goleta, USA). The SR signal (Gaussian White Noise, zero mean) will be generated through a 16 bit PCI 6733 National Instruments multifunction data acquisition card by a custom LabView program. The stimulation sites include the ankle, lateral soleus, peroneus longus, and tibialis anterior muscles and the hip.
223890969|NCT03677999|DIAGNOSTIC_TEST|MEGA-PRESS sequence Magnetic Resonance Spectroscopy|MRS protocols and novel MRI methods that allow detection and quantification of 2 hydroxyglutarates (2HG) as well as the physiologic consequences of 2HG accumulation.
223890970|NCT06058299|DRUG|TBAJ-876|tablet
223890971|NCT06058299|DRUG|Pretomanid|200 mg
223890972|NCT06058299|DRUG|Linezolid|600 mg
223890973|NCT06058299|DRUG|Bedaquiline|200 mg for 8 weeks followed by 100 mg for 18 weeks
223890974|NCT06058299|DRUG|HRZE|Isoniazid (H) + rifampicin (R) + pyrazinamide (Z) plus ethambutol (E) fixed dose combination tablets dosed by weight
223890975|NCT06058299|DRUG|HR|Isoniazid (H) + rifampicin (R) fixed dose combination tablets dosed by weight
223890976|NCT06554444|PROCEDURE|Dental Implant Surgery|Dental implants will be placed in edentulous areas.
223890977|NCT03445988|BEHAVIORAL|Cognitive Behavioral Therapy|A trained psychologist delivers pain-CBT to individual patients or groups of patients with chronic pain. Group treatment is delivered across 8 weekly sessions that last for 2 hours each. Pain-CBT incorporates interactive discussion, practice of relaxation training, action planning, and home exercises into each session. Pain-CBT is effective for reducing pain intensity, pain catastrophizing, depression and social impacts.
223890978|NCT03445988|BEHAVIORAL|Chronic Pain Self Management Program|The CPSMP is similar to pain-CBT in format and content but is peer-led, and is effective across pain conditions (e.g., back pain, arthritis) for improving pain and pain self-efficacy. The CPSMP consists of six weekly 2-hour group sessions in which two peer co-leaders provide patient education about pain, effective self-management, pain impacts, and other symptoms from a highly structured manual. Similar to pain-CBT, CPSMP incorporates interactive discussion, practice of relaxation training, action planning, and home exercises into each session
223890979|NCT03445988|OTHER|Taper Only|Participants allocated to 'Taper Only' will engage in a physician-guided, patient-centered opioid tapering program without additional behavioral intervention.
223890980|NCT06837688|PROCEDURE|Peri-implant soft tissue augmentation using connective tissue graft|A full-thickness flap will be elevated after a crestal and sulcular incision at the single tooth gap and adjacent teeth. A surgical guide will be fitted and adjusted if needed. A dental implant will be placed as planned digitally in an optimal 3D position. A connective tissue graft (CTG) will be harvested from the palatal mucosa using the De-epithelialized free gingival graft technique and tailored to the site dimensions. The graft will be carefully positioned under the elevated flap to augment the soft tissue. The palatal wound will be sutured with double-cross sutures.
223890981|NCT06837688|PROCEDURE|Peri-implant soft tissue augmentation using xenogenic collagen matrix|A full-thickness flap will be elevated after a crestal and sulcular incision at the single tooth gap and adjacent teeth. A surgical guide will be fitted and adjusted if needed. A dental implant will be placed as planned digitally in an optimal 3D position. The xenogenic collagen matrix, initially measuring 15 × 20 mm, is first moistened in saline for 10 minutes and slightly compressed to adapt its thickness to the defect. After a superficial incision to release any muscle tension, the XCM is accurately positioned and secured to the buccal mucosa using single sutures.
223890982|NCT06799715|DIETARY_SUPPLEMENT|Sucrose|33.5g sucrose dissolved in 300mL tap water
223890983|NCT06799715|DIETARY_SUPPLEMENT|Glucose|33.5g glucose dissolved in 300mL tap water
223890984|NCT06799715|DIETARY_SUPPLEMENT|Fructose|33.5g fructose dissolved in 300mL tap water
223890985|NCT06799715|DIETARY_SUPPLEMENT|Water|300mL water
223890986|NCT06833307|DRUG|SHR-1314|SHR-1314: dose 1 SHR-1314:dose 2 SHR-1314:dose 3
223890987|NCT06830707|DEVICE|experimental group|The treatment comprised 5 robot-assisted gait training sessions over a 2-week period, followed by 10 lower limb Constraint Induced Movement Therapy(CIMT) sessions with a torque assisted exoskeleton.
223890988|NCT06838598|OTHER|OCT-BIO-KTA cohort|Dynamic full-field optical coherence tomography (D-FF-OCT) analysis of arterial catheter sections before microbiological analysis of catheter biofilm
223890989|NCT06478459|BIOLOGICAL|CAR-NK|Endoscopic ultrasound-guided intratumoral CAR-NK injection once at day 0, combined with intravenous CAR-NK infusion twice at day 4 and 5
223890990|NCT05065658|DRUG|Posaconazole|Intravenous posaconazole prophylaxis
223890991|NCT05975450|DRUG|Abatacept 125Mg/Ml Syringe|"Participants on qualifying belatacept regimen (with low dose tacrolimus, mmf and prednisone) will have their maintenance regimen changed from i.v. belatacept to s.c. abatacept, which will continue through week 52 (month 12) post-transplant:~Costimulation blockade:~\- Abatacept 125 mg subcutaneous weekly"
223890992|NCT05424549|DRUG|Reproxalap Ophthalmic Solution (0.25%)|Reproxalap Ophthalmic Solution (0.25%) dosed six times over two consecutive days
223890993|NCT05424549|DRUG|Vehicle Ophthalmic Solution|Vehicle Ophthalmic Solution dosed six times over two consecutive days
223890994|NCT03988608|DRUG|Eltrombopag|Eltrombopag are film-coated tablets containing 25 mg of eltrombopag free acid in each tablet.
223890995|NCT04475536|DEVICE|TANSEI stent|stenting with the TANSEI sirolimus-eluting stent
223890996|NCT05445479|DRUG|Doxycycline|Patient with doxycycline treatment during COVID-19 waves
223890997|NCT04034576|BEHAVIORAL|Cognitive behavior therapy of trainee therapists|In all three treatment arms, trainee therapists perform a cognitive behavior therapy (CBT) under conditions of the German health care system. This treatment is not a manualized intervention, but rather based on individualized treatment plans that have been developed together with expert supervisors during a five session diagnostic stage. Treatment duration is 24 sessions, while on average every fourth is supervized by an CBT expert therapist.
223890998|NCT04162626|OTHER|Supportive home visits to new families|The new families are offered home visits by a public health nurse from 28 weeks in pregnancy until the child is two years old. The number of home visits depends on the families needs and wishes. They also get the usual follow up from the Child health center.
223890999|NCT04162626|OTHER|Treatment as usual|Follow up at the Child health center according to national regulations
223891000|NCT05441579|BEHAVIORAL|Behavioral Economics (BE) recruitment strategies|Behavioral economics (BE), a method of economic analysis that applies psychological insights into human behavior to explain economic decision-making, has broad applicability and its techniques offer a novel way that may be applied to try to help enhance study recruitment and enrollment.
223891001|NCT05441579|OTHER|Biofeedback-based virtual reality (VR-BF)|Phase 1 will focus on patients that would be enrolled into a biofeedback-based virtual reality (VR-BF) arm.
223891002|NCT05441579|OTHER|Manage My Pain|Commercially available and free app to track, analyze and monitor pain.
223891003|NCT06064500|DRUG|Tarlatamab|Tarlatamab will be administered as a 60-minute intravenous infusion with 1 mg step dose on cycle 1 day 1 followed by a 10 mg target dose on cycle 1 day 8 and cycle 1 day 15 in a 28-day cycle. Subsequent doses (10 mg) will be administered every 2 weeks.
223891004|NCT04440254|DIAGNOSTIC_TEST|Implantation (subcutaneous) of a marketed miniaturized Holter ECG recording device|Subcutaneously implanted under local anesthesia of the device on the presternal or subclavicular region
223891005|NCT04072406|OTHER|Mindfulness meditation|Participants assigned to either condition who do not have a personal electronic device for listening to meditations or completing survey will receive a loaned device from the study team.
223891006|NCT04072406|OTHER|Usual care packet|Participants assigned to either condition who do not have a personal electronic device for listening to meditations or completing survey will receive a loaned device from the study team.
223891007|NCT01742143|BEHAVIORAL|The Integrated Cancer Care Access Network (ICCAN)|"Patients will receive written materials on social and economic resources and services. Treatment Outcomes Survey at Intake, 3 mo, 6 mo, and 1 year.~Chart review at 3 mo, 6 mo and 1 year, and as needed. Plus Initial needs assessment. Assistance with high priority social and economic needs.Monthly follow-up with ICCAN Access Facilitator to address ongoing needs in addition to as-needed assistance."
223891008|NCT01742143|BEHAVIORAL|Usual and Customary Group (U&C)|"Patients will receive written materials on social and economic resources and services. Treatment Outcomes Survey at Intake, 3 mo, 6 mo, and 1 year.~Chart review at 3 mo, 6 mo and 1 year, and as needed."
223891009|NCT02689284|BIOLOGICAL|Margetuximab 10 mg/kg|Margetuximab treatment is administered intravenously (IV) once every 21-day cycle
223891010|NCT02689284|BIOLOGICAL|Margetuximab 15 mg|Margetuximab treatment is administered IV once every 21-day cycle
223891011|NCT02689284|BIOLOGICAL|Pembrolizumab|Pembrolizumab treatment is administered IV once every 21-day cycle
223891012|NCT06010329|DRUG|Sutetinib Maleate Capsule|Oral administration
223891013|NCT03662698|BEHAVIORAL|Guided Imagery|GI is a relaxation technique involving the visualization of images and is considered an adjuvant cancer therapy.The GI intervention will include two hour-long meetings between the participant and a trained interventionist. The sessions will include direct, written, and audio delivery of one of three GI vignettes. The patient will be able to choose one of the three vignettes. The approximately twelve minute long vignettes included in the study will be: Taking a Walk, Healthy Cell Alliance for Treatment, and Daily Intention (32). Patients will also be given access to psychosocial support resources (i.e., clinical psychologists and social workers) at University of Colorado Cancer Center.
223891014|NCT03662698|OTHER|Treatment as Usual|This will include a tour of the treatment room and education about RT. Patients will also receive educational materials about RT including the process of RT and CT simulation, treatment side effects, pain management, and swallowing exercises. Participants in this condition will also have access to psychosocial support resources (i.e., clinical psychologists and social workers) at University of Colorado Cancer Center.
223891015|NCT04855747|DRUG|REL-1017|REL-1017 tablet
223891016|NCT04855747|DRUG|Placebo|Placebo tablet
223891017|NCT06307470|BEHAVIORAL|EMBRACE (Empowerment through Mind and Body Reclamation After Cancer Experience)|"The intervention will be led by a registered nurse who holds certifications in sexuality counseling and sex education. The therapeutic, online environment will serve as a confidential, private space without judgement to encourage discussion to model safe sexuality communication for breast cancer survivors. The curriculum will include: i) psychoeducation: sexual body, mind-body connection, and sexual relationships; ii) physical-body education: physical response, safety, and navigating physical changes in survivorship; iii) solution-focused tools: tailored vaginal rehydration, lubrication, education; and iv) communication: internal, partnered, and patient-provider communication skills.~The solution-focused tools will include vaginal rehydration and dilation products with vaginal lubrication. Tools will be distributed via mail by Session 2."
223891018|NCT02738788|OTHER|Intubation|"The patient's airway will be visually assessed and photographed while the patient is resting comfortable in bed with the head up at 30-45 degrees and classified into one of 4 MMS categories. Digital photographs will be taken and the stored image prepared by the investigators in such a way that the patient cannot be individually identified (mouth only).~Neck circumference will be measured at the level of the thyroid cartilage using a tape measure, with temporary ink marks on the skin to allow for subsequent measurements at the same point.~After the patient has been extubated and recovered in the PACU for 30 minutes, their airway will be re-assessed and documented. These evaluations will be repeated at 2, 3, and 4 hours, as well as the next morning."
223891019|NCT06541899|DEVICE|Polarys Cryolipolysis|The procedure will take place in a session lasting a maximum of 60 minutes, which may vary depending on the amount of fat in the area and the type of applicator chosen (with or without vacuum). The patient will be comfortably positioned, in a position that facilitates suction/fixation of the applicator. An antifreeze membrane will be applied correctly to the skin, avoiding wrinkles. The marked skin area will be positioned in the center of the membrane. The applicator will be positioned in the treatment area at 90° to the skin and will activate the START.
223891020|NCT03424941|DEVICE|FFR-guided PCI and TAVI|Treatment of subjects with multivessel coronary artery disease and aortic stenosis for FFR-guided PCI and TAVI (Medtronic CoreValve Evolut R or Medtronic CoreValve Evolut R PRO)
223891021|NCT03424941|DEVICE|CABG and SAVR|Treatment of subjects with multivessel coronary artery disease and aortic stenosis for CABG and SAVR
223891022|NCT05443048|DEVICE|Ivoclar Ivotion Denture System|Fabrication of maxillary and mandibular complete removable dental prosthesis with the Ivoclar Ivotion Denture System
223891023|NCT05855421|DEVICE|Auricular Acupuncture|Aplication of semi-permanents needls in the ear by an experient and specialized professional using tradicional chinese maps and a specific device to find acupuncture points. There is a gap of one day minimum between sessions and two non-consecutive absences are allowed.
223891024|NCT05425433|OTHER|Tailored serial casting intercention|Every participant will undergo 1 week of usual care for the affected joint according to the OT's prescription (static progressive, dynamic or serial static) combined with stretching, moisturizers, pressure therapy, or thermal modalities. After the one week of splinting, if the PROM of the targeted joint does not improve, the participant will start serial casting (Monday to Friday). Patients will have a cast applied on Monday morning and worn for 24hrs/day or for 48hrs according to the OTs and treating physician's decision (rationale documented).The OT will decide how many weeks the participant will be wearing casts and the rationale to stop this treatment will be documented. When the treatment is stopped, patients will be encouraged to wear a maintenance splint for the following 2 weeks.
223891025|NCT00967863|RADIATION|3-dimensional conformal radiation therapy|Patients undergo radiotherapy
223891026|NCT00967863|RADIATION|intensity-modulated radiation therapy|Patients undergo radiotherapy
223891027|NCT03857061|DEVICE|smartphone, smartwatch, WearCOPDv2 application|"WearCOPD2 consists of hardware and software components.~6.1 Hardware The hardware for wearCOPDv2 consists of three main components; (1) a smartwatch, (2) a phone, and (3) a server.~6.2 Software~The wearCOPDv2 system has two main software components:~1. Data collection service~2. Participant user interface"
223891028|NCT05731661|OTHER|Day hospitalization in support care with meeting with support care professionals and coordination of actions by the advanced practice nurse|During this day hospitalization, patients will meet with different specialized professionals depending on the support care needs identified.
223891029|NCT05731661|OTHER|Delivery of useful information according to support care needs, concerning support care professionals in the city|Delivery of useful information according to support care needs, concerning support care professionals in the city
223891030|NCT05731661|OTHER|Delivery of a personalized post-cancer plan|Delivery of a personalized post-cancer plan
223891031|NCT05157490|BEHAVIORAL|Mindfulness training|Guided meditations in the preoperative time period, at least 3 sessions per week, leading up to surgery
223891032|NCT06850233|OTHER|No intervention|No intervention
223891033|NCT03519581|DEVICE|Micropulse Laser Treatment|Participant's study eye will be dilated prior to being comfortably seated at the slit lamp for treatment. Application of micropulse laser on retinal surface will occur using TxCell Scanning Delivery System in a 7 x 7 grid to surround the fovea.
223891034|NCT03519581|DEVICE|Sham Treatment|Participant's study eye will be dilated prior to being comfortably seated at the slit lamp for treatment. No actual laser treatment will occur.
223891035|NCT06850493|DIETARY_SUPPLEMENT|VLCKD (ketogenic diet)|diets prior to bariatric surgery
223891036|NCT06850493|DIETARY_SUPPLEMENT|VLCD (Very-low-calorie-diet)|diets prior to bariatric surgery
223891037|NCT05268393|BEHAVIORAL|BREATHE-T1D|BREATHE-T1D is a mindfulness based intervention adapted from Learning to BREATHE specifically for teens with type 1 diabetes.
223891038|NCT05504239|DRUG|Teneligliptin (as Teneligliptin Hydrobromide) 20 Mg Oral Tablet|To be orally administered once daily
223891039|NCT05504239|DRUG|Teneligliptin Placebo Oral Tablet|To be orally administered once daily
223891040|NCT04861064|DRUG|Sirolimus|Participants will get Sirolimus (1.5-2 2mg/m2) weekly for 6 months.
223891041|NCT05580744|OTHER|Traditional occupational therapy|Motor training targeted to goals that are relevant to the functional needs of the patient
223891042|NCT05580744|OTHER|Mirror therapy using a mirror box|Mirror therapy using a mirror box
223891043|NCT05580744|OTHER|Augmented reality-based mirror therapy|Augmented reality-based mirror therapy
223891044|NCT05491356|DRUG|Tissue Plasminogen Activator|Dosage of 1mg/mL mixed in 0.9% saline solution, intra-catheter administration, sterile
223891045|NCT05491356|DRUG|Placebo|0.9% saline solution, intra-catheter administration, sterile
223891046|NCT03365609|DRUG|triple therapy|Omeprazole+Amoxicillin+Clarithromycin
223891047|NCT03365609|DRUG|sequential therapy|the first 7 days : Omeprazole+Amoxicillin, the last 7 days: Omeprazole+Clarithromycin+Metronidazole
223891048|NCT03365609|DRUG|bismuth quadruple therapy|Omeprazole+Amoxicillin+Metronidazole+Colloidal Bismuth Subcitrate
223891049|NCT03365609|DRUG|concomitant therapy|Omeprazole+Amoxicillin+Clarithromycin+Metronidazole
223891050|NCT02088645|DRUG|177Lu-PP-F11N|
223891051|NCT06135389|BIOLOGICAL|Titration of paracetamol and its metabolites - scheme1|15 to 20 minutes and 1 to 2 hours after first perfusion and before second perfusion/administration of paracetamol
223891052|NCT06135389|BIOLOGICAL|Titration of paracetamol and its metabolites - scheme 2|30 to 40' after first perfusion and before second perfusion/administration of paracetamol (residual concentration)
223891053|NCT04986917|DEVICE|Hernia repair surgery using the Su2ura® approximation device|. The hernia defect will be measured and the Su2ura® approximation device will then be used to close the defect, placing stainless steel implantable anchors threaded on a Polyethylene braided surgical suture.
223891054|NCT04986917|DIAGNOSTIC_TEST|Physical Examination|All subjects will undergo a standard physical examination by an authorized physician. The physician's evaluation will include diagnosis and documentation of any significant clinical abnormalities or diseases.
223891055|NCT04986917|DIAGNOSTIC_TEST|Vital Signs|Vital signs include blood pressure, pulse, temperature, body weight and height, body mass index (BMI).
223891056|NCT04986917|DIAGNOSTIC_TEST|Blood Tests|"All subjects will undergo Hematology and Biochemistry blood tests. Blood Hematology test will include a complete CBC. Blood Biochemistry test will include the following measures: Sodium (Na), Potassium (K), Chloride (Cl), Creatinine, Glucose, Urea, Albumin, Calcium total, Alkaline Phosphatase (ALP), ALT, AST, Total Bilirubin, Direct Bilirubin, LDH, Total Protein, Uric Acid, CRP, and Lipid Profile (including Total Cholesterol, HDL, LDL, Triglycerides).~5 ml of blood (equals to 1 spoon) will be taken for each test."
223891057|NCT04986917|DIAGNOSTIC_TEST|Urine Pregnancy Test|Urine pregnancy test will be performed during the screening visit (for WOCBP).
223891058|NCT04986917|DIAGNOSTIC_TEST|Abdominal Ultrasound imaging|All subjects will undergo an abdominal ultrasound (US) imaging at 12 Months visit. The US will be performed to verify an absence of hernia recurrence.
223891059|NCT04986917|OTHER|EuraHS-QoL|patients will be asked to fill a questionnaire assessing patient-reported satisfaction and function. questionnaire score range: 0-180; higher score indicates higher pain and discomfort
223891060|NCT04986917|OTHER|Visual Analouge Scale (VAS)|A validated, subjective measure measuring acute and chronic pain. questionnaire score range: 0-10; higher score indicates higher pain level.
223891061|NCT04986917|DIAGNOSTIC_TEST|Clinical evaluation for hernia recurrence and clinical bulging|"The procedure includes:~1. Clinical examination to determine the presence of hernia recurrence and clinical bulging, in an inconclusive physical exam a radiological imaging will be performed such as US or CT.~2. SAE's and SADE's evaluation of the seroma.~3. Taking a photograph of the surgery area without disclosing the subject's identity."
223891062|NCT02216838|DRUG|botulinum toxin A|A total of 10U will be injected at 1cm increments by the blinded dermatologist into the respective randomized side.
223891063|NCT02216838|OTHER|Saline Control|A total of 0.5cc benzyl alcohol containing saline will be injected at 1cm increments by the blinded dermatologist into the respective randomized side
223891064|NCT06278961|OTHER|Observational|Observation of movement patterns through video recordings and neurodevelopmental battery of assessments.
223891065|NCT05009004|BEHAVIORAL|text messages to support medication adherence|text messages to support medication adherence
223891066|NCT06205095|DRUG|Lyophilized concentrate of human coagulation von Willebrand Factor and factor VIII|Wilate® is a plasma-derived, highly purified concentrate administered through intravenous injection. Wilate® contains an average VWF ristocetin cofactor activity to FVIII activity at ratio of 1:1.
223891067|NCT06205095|OTHER|Placebo|Patients randomized to the placebo arm will receive intravenous normal saline at the same approximate volume and frequency of Wilate ®.
223891068|NCT03555448|DRUG|Once daily immunosuppression regimen|Intervention focuses on the type of regimen, in this case the intervention arm will receive a once daily regimen for immunosuppression compared to the twice daily regimen.
223891069|NCT03555448|DRUG|Twice daily immunosuppression regimen|This is the arm which we are designating the standard, which will be the comparison to the active drug arm.
223891070|NCT06309745|PROCEDURE|retroperitoneal lymph node dissection|retroperitoneal lymph node dissection
223891071|NCT06309745|DRUG|Carboplatin AUC10|Carboplatin AUC10
223891072|NCT04036448|DRUG|REVLIMID®|REVLIMID®
223891073|NCT06487364|OTHER|Rehabilitation|A routine physical therapy program prescribed by a specialist physician and physiotherapist will be applied.
223891074|NCT05353140|DEVICE|The WATCHMAN/WATCHMAN FLX device|Watchman device was an umbrella-shaped, self-expanding, nitinol structure with a porous partial polyethylene terephthalate membrane (160 um mesh) and 10 struts. The membrane portion of the structure faces into the body of the left atrial to block embolization of thrombus and provide scaffolding on which endothelialization can occur. The On July 21st, 2020, the FDA approved the next generation LAAO device, named Watchman FLX. This newiteration of the Watchman LAAO platform offers full capability of recapture and redeployment of the device, decreasedmetallic exposure, an increased number of contact points for sealing, a fully rounded delivery shape, and precision anchors designed to provide optimal device engagement with the LAA.
223891075|NCT05353140|DRUG|Rivaroxaban + Clopidogre|Previous pivotal trials have shown that in patients with atrial fibrillation and requiring antiplatelet treatment, a NOAC plus clopidogrel regimen was associated with a lower incidence of bleeding events as compared with a warfarin-based triple antithrombotic strategy. Therefore, the current expert opinions and consensus of North American Societies recommend a NOAC plus a P2Y12 inhibitor in patients with AF and PCI. In the present study, Rivaroxaban + Clopidogre are required for 45 days in LAAO group after LAAO.
223891076|NCT05353140|DRUG|Aspirin + Clopidogrel|Aspirin + Clopidogrel are required from 46 days to 12 months after LAAO.
223891077|NCT06156943|PROCEDURE|individualized goal-directed fluid therapy by Starling device|For patients in optimized group, fluids will be managed by Starling device during the lung resection surgery.
223891078|NCT06156943|PROCEDURE|group managed by standard of care|Patients will be managed intraoperatively at the discretion of the attending anesthesiologists, in accordance with their institutional protocols
223891079|NCT05426005|DRUG|Cadonilimab|Cadonilimab, 6 mg/kg every 2 weeks until disease progression, intolerable toxicity, or duration of treatment for 2 years
223891080|NCT04410042|DRUG|Tranexamic Acid|Given IV
223891081|NCT04410042|OTHER|0.9% sodium chloride|Given IV
223891082|NCT03898986|BIOLOGICAL|Live attenuated influenza vaccine (LAIV4)|LAIV4 vaccine dosage is 0.2 mL. The vaccine will be administered as an intranasal spray. Each sprayer contains a single dose of FluMist® Quadrivalent; approximately one-half of the contents should be administered into each nostril. 0.1 mL (i.e., half of the dose from a single FluMist sprayer) is administered into each nostril while the recipient is in an upright position. Insert the tip of the sprayer just inside the nose and rapidly depress the plunger until the dose-divider clip stops the plunger. The dose-divider clip is removed from the sprayer to administer the second half of the dose (0.1 mL) into the other nostril.
223891083|NCT03898986|BIOLOGICAL|Inactivated Influenza Vaccine (IIV4)|IIV4 vaccine will be administered as a 0.5 mL dose, with a sterile, disposable syringe and needle by IM injection.
223891084|NCT03374319|PROCEDURE|Modified amputation procedure|A stair-step (BKA) or fishmouth (AKA) incision will be made. Tibial and fibular or femoral osteotomies will be performed. Segments of the tibialis anterior (TA), peroneus longus (PL), lateral gastrocnemius (LG) and tibialis posterior (TP) muscles will be isolated, as well as the quadriceps (Q) and hamstring (H) groups in the AKA model; if it is not possible to preserve native innervation to these muscles, functional motor units will be constructed from muscle coapted to the appropriate motor nerve endings. The distal tibial and peroneal nerves will be redirected to skin patches in the distal or proximal thigh. Coaptation of the TA/LG, PL/TP and Q/H muscles will then be performed to promote dynamic coupling of these agonist/antagonist pairs. The skin envelope will then be closed in layers over percutaneous drains.
223891085|NCT05860751|PROCEDURE|Dry Needling with electrical stimulation|Administered for a total of 2 sessions at a frequency of once per week. The target muscles to be needled will include the gastronemius, soleus, vastus lateralis, rectus femoris, anterior tibialis, posterior tibialis, biceps femoris, and gluteus medius.
223891086|NCT04640298|DEVICE|Cingal|Single injection into the hip joint of a 4 ml unit dose of Cingal containing 88 mg (22 mg/ml) of cross-linked sodium hyaluronate and 18 mg (4.5 mg/ml) of triamcinolone hexacetonide (TH).
223891087|NCT05971888|BEHAVIORAL|Food system and demand generation|GAIN's program to increase dairy consumption among BoP children and workers will include components to increase demand, improve access, and support the enabling environment. In Amhara, the demand generation component will share messages through radio, community influencers, and community conversations led by health extension workers targeting rural BoP households with children 6 months up to 7 years. GAIN will train milk houses and cooperatives on dairy safety and quality assurance and better business practices and will assist with cold chain and milk dispensing technology to improve milk availability and access. In industries and large-scale farms, GAIN will use a demand generation strategy to inform workers about the importance of dairy products and other nutritious foods and to encourage them to purchase them at their workplaces. GAIN will work with local businesses to launch and maintain dairy dispensers and arrange provision of other nutritious foods at work sites.
223891088|NCT03720795|BEHAVIORAL|Stepped Care CBT|"Stepped Care CBT is a multi-method, parent-led approach, consisting of two main steps. Step one involves a low-intensity delivery of CBT, consisting of more flexible, parent-led, at-home treatment. Participants who do not show improvement in symptom severity at the end of Step One, are then stepped up to receive Step Two. Step two involves a high intensity delivery of CBT, consisting of therapist-led, parent-assisted weekly treatment sessions."
223891089|NCT04401020|DRUG|SAR442257|Pharmaceutical form: Sterile powder for reconstitution Route of administration: Intravenous infusion
223891090|NCT05570344|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|rTMS uses powerful (1.0-2.5 Tesla), focused magnetic field pulses to induce electrical currents in neural tissue noninvasively, via an inductor coil placed against the scalp.
223891091|NCT05570344|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS) Plus Text4Support|"rTMS uses powerful (1.0-2.5 Tesla), focused magnetic field pulses to induce electrical currents in neural tissue noninvasively, via an inductor coil placed against the scalp.~Text4Support:~Text4Support is one of the ResilienceNHope suites of supportive text messaging programs delivered by the Global Psychological eHealth Foundation \[80\]. The program allows users to receive daily supportive text messages which have been written by a team of cognitive-behavioral therapists and mental health professionals in collaboration with users of mental health services. The aim of this Text4Support depression program is to enhance positively the mood of patients with clinical depression. The program operates through the use of positive reinforcement to correct distorted or negative thought patterns."
223891092|NCT06418984|DEVICE|auxiliary|the interventions are related to the adjuncts associated with clear aligners to improve the predictability and accuracy of tooth movement
223891093|NCT06022003|DRUG|AzaCITIDine Oral Tablet|AML study treatment
223891094|NCT06022003|DRUG|Xospata|R/R FLT3-mutated AML standard treatment
223891095|NCT05833230|OTHER|Intensive Day Monitoring|During intake, a research assistant will demonstrate how to place the Heart Rate Variability monitor and provide instructions on completing the saliva samples at home. Participants will wear the Heart Rate Variability monitor for three consecutive, randomly selected days twice (72 hours each). Participants will be provided with six saliva sample collection tubes per day with explicit directions on when the saliva sampling should occur (hours since waking: +0, +1, +2, +4, +6, +10 hours, and before going to sleep). Participants will also complete a subjective report using similar questions included in the survey prompts at the same scheduled time as the saliva sample. All participants will complete a total of 6 such days during the study.
223891096|NCT01494662|DRUG|HKI-272|240 mg orally, once daily
223891097|NCT01494662|PROCEDURE|Surgical Resection|Neratinib concentrations from craniotomy specimen, CSF, plasma Neratinib.
223891098|NCT01494662|DRUG|Capecitabine|750 mg/m2 orally, twice daily (1,500 mg/m2 daily) for 14 days followed by 7 days off
223891099|NCT01494662|DRUG|HKI-272|160 mg orally, once daily
223891100|NCT01494662|DRUG|Ado-Trastuzumab Emtansine|3.6 mg/kg IV every 3 weeks
223891101|NCT05311384|BEHAVIORAL|Keys Constraint-induced Movement Therapy protocol|All participants will receive the Keys CI Therapy protocol over an 8-week intervention period. Specific CI therapy strategies will be delivered, including: 1) supervised movement training will be carried out for 1 hour for 4 days/week for the first 4 weeks, 2 days/week for weeks 5 and 6, and 1 day/week for weeks 7 and 8; 2) participants will use the restraint mitt on their less-affected UE for most of their waking hours for an 8 week period; 3) transfer package methods will be modified to accommodate the longer time period between clinic visits; and 4) participants will be asked to independently perform additional movement training for 30 minutes each day at home.
223891102|NCT04959123|OTHER|pharmacokinetic analysis|Non-compartmental descriptive pharmacokinetic analysis (i.e. without the need for mathematical modelling), with determination of the pharmacokinetic parameters of interest either directly from the experimental points (Cmax, Tmax), or from simple mathematical equations (calculation of the area under the curve (AUC) by the trapezoidal method, calculation of the terminal slope of elimination)
223891103|NCT05995535|DRUG|LFX/PGB|"lofexidine tablets 0.18mg tabs~pregabalin capsules 100mg and 25mg"
223891104|NCT05995535|DRUG|LFX/PLA-PGB|"lofexidine tablets 0.18mg tabs~pregabalin capsules 0mg"
223891105|NCT05302921|PROCEDURE|Cryoablation Therapy|"Cryoablation therapy is an established method of cancer treatment in adults and pediatrics with certain types of tumors and is standard of care for certain tumors in the setting of progression/relapse.~Percutaneous image-guided Cryoablation (cryosurgery, cryotherapy) is a technique that utilizes successive rapid freeze/thaw cycles to destroy tumor cells. This technique is performed by inserting specialized needles known as cryoprobes into target tumors under imaging guidance with Computed Tomography (CT) and Ultrasound (US), or Magnetic Resonance Imaging (MRI). After the cryoprobe needles are placed within the target tumor, rapid cooling of liquid gas inserted into these probes leads to temperatures reaching -20 to -40 degrees Celsius.~Cryoablation therapy of one disease site will be done starting Day 3 and prior to Day 15 of Cycle 1 only."
223891106|NCT05302921|DRUG|Nivolumab|"Nivolumab (Bristol Myers Squibb) is a human monoclonal antibody (immunoglobulin G4) that targets the programmed death-1 cluster of differentiation 279 (CD279) cell surface membrane receptor.~Nivolumab and ipilimumab will be given on day 1 of 21-day cycles for cycles 1-4, followed by nivolumab alone on days 1 and 15 of 28-day cycles for cycles 5+. Patients will receive up to 13 cycles of therapy unless unacceptable toxicity or progression of disease."
223891107|NCT05302921|DRUG|Ipilimumab|"Ipilimumab (Bristol Myers Squibb) is a fully human monoclonal immunoglobulin G1Κ specific for human cytotoxic T-lymphocyte antigen 4 (CTLA-4, cluster of differentiation \[CD\]152), which is expressed on a subset of activated T-cells.~Nivolumab and ipilimumab will be given on day 1 of 21-day cycles for cycles 1-4, followed by nivolumab alone on days 1 and 15 of 28-day cycles for cycles 5+. Patients will receive up to 13 cycles of therapy unless unacceptable toxicity or progression of disease."
223891108|NCT05640752|DIAGNOSTIC_TEST|2019 ESC guideline-determined diagnostic strategy|ESC-PTP is calculated using age, sex and type of chest pain according to 2019 ESC guideline for the diagnosis and management of CCS and RF-CL is calculated using age, sex, type of chest pain, hypertension, dyslipidemia, diabetes, smoking and family history of CAD based on the publication of Winther et al., respectively. According to ESC strategy, subjects with ESC-PTP ≤5% are classified into low risk group and ones with ESC-PTP ≥15% are classified into high risk group. For subjects with ESC-PTP of 5%-15%, ones with RF-CL ≥15% are classified into high risk group and ones with RF-CL \<15% are classified into low risk group. CCTA should be referred for a subject in high risk group. Subjects determined to be at low risk will be referred to optimal medication treatment with no immediate CCTA.
223891109|NCT05640752|DIAGNOSTIC_TEST|2016 NICE guideline-determined diagnostic strategy|For subjects assigned to NICE strategy, ones with nonanginal chest pain and normal ECG were classified into low risk group and ones with typical and atypical angina or nonanginal chest pain with abnormal ECG were classified into high risk group. Subjects determined to be at low risk will be referred to optimal medication treatment with no immediate CCTA.
223891110|NCT06418425|BEHAVIORAL|counselling on home-based exercise program and dietary protein intake|Participants in the intervention group will be on a home-based exercise program and go through counselling on dietary protein intake with the aim of achieving prevention of frailty status. Participants will be required to attend the 3 study visits throughout the study period. Research procedures include physical measurements (eg. Weight, height, waist and hip circumference, calf circumference, hand grip strength, blood pressure, short physical performance battery tests), administration of questionnaires on sociodemographics, physical activity, dietary habits, smoking, alcohol, health conditions, health-related quality of life, clinical frailty status and sarcopenia screening. At three months and twelve months, the intervention group participants will see the care coordinators who will check their compliance to the exercise programme and high protein diet, reinforce the interventions.
223891111|NCT06545175|DRUG|Intracochlear application of VSF1.01|During cochlear implant operation, patients receive intracochlear VSF1.01 prior to insertion of the electrode array.
223891112|NCT02318485|BIOLOGICAL|Limbal epithelial stem cell graft|
223891113|NCT03649659|DRUG|Silver Diamine Fluoride|SDF will be applied twice during the study
223891114|NCT03649659|DRUG|Placebo|This is being compared to the SDF and will also be applied twice
223891115|NCT05359276|DRUG|Olipudase alfa|GZ402665
223891116|NCT02104310|DRUG|Fluorine-18-L-dihydroxyphenylalanine|5 millicuries ± 10%; Intravenous injection; 1 time
223891117|NCT04764656|DRUG|Brolucizumab|There is no treatment allocation. Patients administered Brolucizumab by prescription that have started before inclusion of the patient into the study will be enrolled.
223891118|NCT02302300|DEVICE|Manufacturer STELLAR 150|5 days of non-invasive ventilation at two levels of pressure from it pre-operative, followed by 5 days in post-operative.
223891119|NCT02724631|DEVICE|TubeClear® intervention|The TubeClear® device is deemed by the Food and Drug Administration (FDA) to be non-significant risk (NSR) for use in this study. It is a control box and a single use clearing stem used to resolve the clog in an enteral access device within five minutes following the intervention.
223891120|NCT04510974|OTHER|Spinal Cord Injury|Spinal Cord Injury
223891121|NCT05151237|DIAGNOSTIC_TEST|Measurement of body temperature|The patients' body temperature will be measured pre-, intra- and post-operatively via an infrared thermometer.
223891122|NCT06800027|OTHER|SALSA group intervention: Going to lunch at the restaurant in a group and attending healthy eating workshops.|"The intervention group will dine at a selected and trained restaurant twice a week for 4 months (from March to June 2024). A facilitator will accompany the participants to the restaurant and supervise them. Once a month, a healthy habits and meal supplementation workshop will be held at the senior citizens' centre. Participants will not be required to pay for the meals at the restaurant or for participation in the workshops. The control group will receive standard care at their Primary Care Centre.~In order for the restaurant to provide appropriate services tailored to the users' needs, training will be conducted by professionals from the Alicia Foundation on how to manage the nutrition of elderly individuals and other participants in the study according to their dietary needs."
223891123|NCT05725941|DEVICE|TogRite stretch Strapping|it is a machine washable and highly durable elastic strap that maintains its recoil strength for a long-lasting period. It is made of latex-free materials. The TogRite Strapping can be used to support the weakened parts of the body and adjust or modify the position and posture of different body parts.
223891124|NCT05725941|OTHER|Traditional upper limb functional exercise training|The traditional upper limb functional exercise training will focus on the enhancement of muscle strength, joint range of motion, arm \&hand activities, and daily living functions of the affected upper limbs.
223891125|NCT03409133|DEVICE|Stimulating nerve electrodes and intramuscular recording electrodes|See Arm Description
223891126|NCT05422014|BEHAVIORAL|Life Care Specialist (LCS)|"Life Care Specialist (LCS) will :~* Provide patients with individualized risk assessment for opioid misuse.~* Act as patient's Pain Coach. Providing targeted education and behavior-based pain treatment options.~* Train and provide CWC evidence based non-pharmaceutical pain management techniques, using the Community Resiliency Model.~* Use the Opioid Risk Tool (ORT) as the method to identity the risk of substance misuse.~* Provide education, support and resources, as well as local, state, and national resources to enhance the whole health aspect of the position. These resources include but are not limited to: written documents that outline the key concepts of the pain management techniques taught by the LCS and a list of hotlines and websites.~* LCS, when applicable, will provide education for caretakers on the risk of opioid use and the non -pharmaceutical pain management protocol.~* Provide follow up for all patients in intervention group."
223891127|NCT03113422|DRUG|Induction Venetoclax|"1 cycle = 28 days.~* Cycle 1-6: Obinutuzumab IV. Cycle 1, Day 1 obinutuzumab 100 mg and Cycle 1, Day 2 obinutuzumab 900 mg for total dose of 1000 mg. On Cycle 1, Day 8 and Day 15 obinutuzumab 1000 mg. Starting with Cycle 2, obinutuzumab 1000 mg on Day 1 only of each cycle.~* Cycle 1-6: Bendamustine 90 mg/m² IV on Days 1 and 2 of each cycle over 15 minutes after obinutuzumab.~* Cycle 2-6: Venetoclax 800 mg by mouth daily on Days 1-10 administered before obinutuzumab and/or bendamustine."
223891128|NCT03113422|DRUG|Maintenance Venetoclax|Patients whose disease is the same or improved will receive venetoclax 800 mg by mouth daily for 24 cycles (1 cycle=1 month) and obinutuzumab 1000 mg IV every 2 months for 12 cycles. Patients with no evidence of disease will receive obinutuzumab 1000 mg IV every 2 months for 12 cycles.
223891129|NCT04594798|DRUG|Polatuzumab vedotin|IV 1.8 mg/kg per cycle
223891130|NCT04594798|DRUG|Rituximab|IV 375 mg/m2 per cycle
223891131|NCT04594798|DRUG|Cyclophosphamide|IV 400 mg/m2 per cycle
223891132|NCT04594798|DRUG|Doxorubicin|IV 25 mg/m2 per cycle
223891133|NCT04594798|DRUG|Prednisone|PO 40 mg/m2 per cycle
223891134|NCT05089734|BIOLOGICAL|Sacituzumab Govitecan-hziy (SG)|Administered intravenously
223891135|NCT05089734|DRUG|Docetaxel|Administered intravenously
223891136|NCT04387422|OTHER|Experimental hyperglycemia|Experimental hyperglycemia with MRI
223891137|NCT06967974|OTHER|Tai Chi + Sleep Hygiene Education|Conduct simplified training on the 24 style Tai Chi; Sleep hygiene education includes adjusting sleep time, maintaining regular lifestyle habits, optimizing bedroom environment, reducing nighttime stimulation, avoiding thinking when going to bed, adjusting alarm clock positions, and reducing daytime napping.
223891138|NCT06967974|OTHER|Sleep Hygiene Education|Participants will receive Sleep Hygiene Education, consisting of guidance on establishing healthy sleep habits, optimizing sleep environment, adjusting sleep schedules, reducing stimulants (e.g., caffeine, alcohol), and minimizing sleep-disruptive behaviors.
223891139|NCT05821205|BEHAVIORAL|Narrative Persuasion|Narratives will use anonymous testimonials from our prior work combined with open-source pictures. The researchers will ask participants to rate the testimonial message as a measure of engagement.
223891140|NCT05821205|BEHAVIORAL|Reciprocity|Researchers will track clicking on the gift card as a measure of engagement
223891141|NCT05821205|BEHAVIORAL|Personalized Feedback|Researchers will track clicking on a link and/or opening to review visual data as a source of engagement.
223891142|NCT05821205|BEHAVIORAL|Commitment|Providers will receive a commitment message and be asked to reply as a measure of engagement.
223891143|NCT06043713|DRUG|Bendamustine|Receive IV
223891144|NCT06043713|PROCEDURE|Biopsy|Undergo tissue biopsy
223891145|NCT06043713|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223891146|NCT06043713|PROCEDURE|Computed Tomography|Undergo CT
223891147|NCT06043713|DRUG|Cyclophosphamide|Receive IV
223891148|NCT06043713|PROCEDURE|Echocardiography|Undergo ECHO
223891149|NCT06043713|DRUG|Fludarabine|Receive IV
223891150|NCT06043713|PROCEDURE|Leukapheresis|Undergo leukapheresis
223891151|NCT06043713|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223891152|NCT06043713|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
223891153|NCT06043713|PROCEDURE|Positron Emission Tomography|Undergo PET
223891154|NCT06043713|BIOLOGICAL|T-cell Receptor-engineered T-cells|Receive FHA11KRASG12V-TCR IV
223891155|NCT05904548|DEVICE|RF Ablation|RF ablation for type I atrial flutter under iCMR guidance
223891156|NCT06987305|DRUG|Intravenous rhTNK-tPA|Patients will received intravenous rhTNK-tPA
223891157|NCT06987305|DRUG|Intravenous placebo|Patients will received intravenous placebo
223891158|NCT06987305|PROCEDURE|Endovascular thrombectomy|Patients will received endovascular thrombectomy
223891159|NCT05152368|BIOLOGICAL|AlloEx|cultured allogeneic adult umbilical cord derived mesenchymal stem cell exosomes
223891160|NCT05148715|DRUG|Tacrolimus|Single dose intravenous tacrolimus over 4 hour infusion at a dose of 0.02 mg/kg ideal body weight diluted with 0.9% sodium chloride starting 4-8 hours before scheduled organ recovery.
223891161|NCT05148715|DRUG|Placebo|Single dose of intravenous 0.9% sodium chloride over 4 hour infusion, starting 4-8 hours before scheduled organ recovery.
223891162|NCT06932042|OTHER|PLADO|Low protein plant-dominant diet (PLADO) of 0.6-0.8 g/kg/day of proteins with at least 50% plant-based sources, sodium of \<4 g/day and \<3 g/day in case of edema or hypertension, fibers of 25-30 g/day, and calories of 30-35 Kcal/kg/day provided in the form of individualized meal plans administered by a licensed/registered dietitian. The nutrition education intervention will be provided via a primary face-to-face education/counseling session of 45-60 minutes, followed by a monthly face-to-face follow-up session of 30-45 minutes for 6 months, and a face-to-face follow-up session of 30-45 minutes after 3 months. At each visit, participants will be screened according to the Transtheoretical behavior change model (TTM) using a TTM-based algorithm to determine their stage/readiness to adhere to PLADO and will receive stage-based education and counseling accordingly. Stage-based education will be divided into 1) Pre-contemplation and contemplation; 2) Preparation; and 3) Action and Maintenance
223891163|NCT06932042|OTHER|Standard-of-care diet|Current standard-of-care diet composed of dietary protein, fluid, sodium potassium, and phosphorus restrictions provided via monthly face-to-face sessions of 30-45 minutes over a period of 6 months, and a follow-up session after 3 months provided by the same licensed/registered dietitian. Patients will be recruited to the control arm in the same period to avoid seasonal differences.
223891164|NCT06931470|BEHAVIORAL|In-person supervised exercise sessions|Gold-standard, facility-based sessions (3 sessions/week) with an onsite trainer guidance with an exercise Intensity of 40-80% heart rate reserve (HRR) or Rate of Perceived Exertion (RPE) 12-16.
223891165|NCT06931470|BEHAVIORAL|Virtual classes (live-streamed sessions)|Live-streamed exercise classes (3 sessions/week) with a trainer providing real-time feedback.
223891166|NCT06931470|BEHAVIORAL|Self-directed aerobic exercise|Participants exercise independently and follow a weekly progression plan (3-5 sessions/week (depending on the specific progression)).
223891167|NCT06931470|DEVICE|Myzone mobile application|Training using the Myzone platform, with participants wearing the Myzone heart rate monitor and using the Myzone app to receive real-time feedback and guidance during exercise sessions (3 days per week). Myzone integrates with its proprietary wearable devices to monitor heart rate and other activity metrics, providing real-time data to users via the app.
223891168|NCT06931470|DEVICE|Map My Fitness mobile application|Participants will wear a Bluetooth-compatible heart rate monitor (e.g., apple watch/fitbit) that syncs with MapMyFitness. MapMyFitness automatically records workout sessions (duration, distance, heart rate, calories burned, and elevation gain where applicable).
223891169|NCT06931470|DEVICE|Centralized telemetry|Centralized telemetry monitors heart rates and provides immediate feedback for trainers to adjust exercise intensity.
223891170|NCT06931470|DEVICE|Myzone heart rate monitor|Wearable device (chest strap or armband) that monitors heart rate.
223891171|NCT06932445|DIAGNOSTIC_TEST|Shear Wave Elastography|Shear wave elastography will be used to measure liver and spleen stiffness in all participants. The procedure will be performed using standard ultrasound-based elastography protocols by a pediatric radiologist.
223891172|NCT06927544|PROCEDURE|Pars plana vitrectomy|All operations are performed in a similar fashion using the vitrectomy system with 23-gauge and 25-gauge vitrectomy probes. Surgical approach and technique include the use of tissue-staining dyes, choice of endotamponade, and postoperative face-down positioning regimen.
223891173|NCT06932211|OTHER|Toothpaste containing proteins and enzymes|Toothpaste containing proteins, enzymes and 1450 ppm fluoride as sodium fluoride
223891174|NCT06932211|OTHER|Control fluoride toothpaste|Toothpaste containing sodium fluoride at 1450 ppm F
223891175|NCT06932497|OTHER|Standard of care|Standard of care according to national and international guideline or recommendations
223891176|NCT06932328|DRUG|Qinqiao Yanshu Granules|High - dose group: Dissolve in boiling water and take 1 bag each time, 3 times a day, half an hour before meals; Low - dose group: Dissolve in boiling water and take 1 bag each time, 3 times a day, half an hour before meals; Extremely low - dose group: Dissolve in boiling water and take 1 bag each time, 3 times a day, half an hour before meals; Rescue medication: Paracetamol tablets. During the trial, if the subject's body temperature exceeds 38.5°C (including 38.5°C), rescue medication can be added. Use it according to the instructions and doctor's advice and record it truthfully.
223891177|NCT06931275|OTHER|EMR-based BPA model|Advanced Diabetes Technologies including AIDs, insulin pumps and CGMs will be prescribed to patients after an EMR-based BPA implementation at six centers.
223891178|NCT06931275|BEHAVIORAL|Placebo (EMR-based without BPA model)|Advanced Diabetes Technologies including AIDs, insulin pumps and CGMs will be prescribed to patients after an EMR-based system without BPA at the implementation at six centers.
223891179|NCT06931730|OTHER|Nutritional Intervention|Participants will receive comprehensive dietary education from the nutritionists of the research team, aimed at improving their baseline diet by incorporating nutritional recommendations based on the Mediterranean diet and the Italian dietary guidelines for healthy eating.
223891180|NCT06931730|OTHER|Physical Activity training|Participants will engage in a structured exercise program designed to improve motor competence and confidence. Tailored to each individual's baseline physical abilities and cardiorespiratory capacity, the program will focus on enhancing aerobic fitness, flexibility, and coordination.
223891181|NCT06931730|OTHER|Cognitive training|Participants will undergo an online cognitive training program, with a particular focus on memory enhancement.
223891182|NCT06931730|OTHER|Social Training|A peer interaction program within an ecological setting, meant as a natural context of daily life, will be offered to participants. The program aims to improve active listening skills, comprehension of various communication styles (passive, assertive, aggressive), and the efficient recognition and management of emotions.
223891183|NCT06932393|BIOLOGICAL|exosomes|Each subject will receive 3 injections with an interval of one month.
223891184|NCT06932393|OTHER|saline|Each subject will receive 3 injections with an interval of one month.
223891185|NCT06931561|PROCEDURE|Whole Body MRI|Whole body MRI
223891186|NCT06931561|PROCEDURE|Whole Body Ultrasound|Whole Body Ultrasound
223891187|NCT06931561|DEVICE|MCD Assay|Cancer detection blood test
223891188|NCT06931561|OTHER|Occupational Exposure Questionnaire|Questionnaire
223891189|NCT06931171|RADIATION|Patient-Applied Pelvic Lead Shielding|The intervention involves the application of a triple-layer lead apron to the patient's lower abdominal and pelvic region during transradial coronary procedures. The apron measures 75 cm × 45 cm and is composed of three layers of 0.25 mm Pb-equivalent material. This protective shield is placed on the patient in addition to standard operator radiation protection measures. The primary goal of this intervention is to reduce scatter radiation exposure to the operator, thereby improving occupational safety in the catheterization laboratory. This approach leverages existing radiation protection materials in a novel configuration.
223891190|NCT06782945|DIETARY_SUPPLEMENT|BIOHM FX Probiotic Blend|BIOHM Health has been selling BIOHM FX, a blend of probiotics as a dietary supplement addressed at the digestive health market since 2017. The blend is present in the market in various concentrations ranging from 30 Billion CFU to 1 Billion CFU. The probiotic blend consists of Lactobacillus acidophilus, Lactobacillus rhamnosus, Saccharomyces boulardii, Bifidobacterium breve and amylase. The blend is manufactured at cGMP facilities located in the United States and has attained self GRAS status. Prior to release, each lot of probiotic blend is tested for heavy metals, objectionable organisms, water content, probiotic potency, enzyme activity level and allergens, Soy, Milk and Gluten. Additionally, BIOHM performs annual testing for a full FALCPA panel of allergens ensuring there are no allergens present in the blend.
223891191|NCT06932718|BEHAVIORAL|General health talk|Health talk provided information about hazards of tobacco (active smoking, second- and third-hand smoke), benefits of quitting smoking and methods to quit smoking.
223891192|NCT06932718|BEHAVIORAL|Personalized chat-based interactions|Individual chat-based interactions for 3 months consist of 2 parts. The first part includes regular messages via instant messages (IM). These messages will serve as probes for real-time chat-based support in which more details explanations and motivation to encourage quitting due to financial reasons. The second part includes real-time psycho-behavioral intervention delivered by trained cessation counsellors using health economic principles on behavioral change to motivate smokers to quit. The conversation is based on participants' socio-demographic characteristics, smoking habit at baseline, and updated smoking status and mental health status assessed during online conversation and the baseline questionnaire.
223891193|NCT06932718|BEHAVIORAL|Phone follow-up/counselling service|The intervention outcomes and participants' smoking status will be followed up regularly via telephone interviews (15 - 30 minutes).
223891194|NCT06932718|DRUG|Mailed nicotine replacement therapy (NRT)|Full course of NRT treatment (10 weeks) will be provided to all participants who are still smoking at 6-month follow-up and request, or willing to use NRT after advice from counsellors. Medications will be mailed from the smoking cessation clinics.
223891195|NCT06932718|BEHAVIORAL|Text message|Regular messages will be sent twice per month within 3 months. These messages covers simple cessation advice and reminders for follow-ups.
223891196|NCT06932718|OTHER|Small incentive|Positive incentive was reported to be effective in reducing smoking. Participants in the intervention group will receive HK$ 100 at 3-month follow-up. HK$ 500 will be provided to successful quitters confirmed by biochemical validation at 6 months. A total of HK$ 600 maximum will be rewarded to the participants. The amount of the incentive is comparable to other community events on smoking cessation in Hong Kong. Of note, all smokers who reported quitting, completed and passed the biochemical validation of quitting had been offered HK$ 500 in the past rounds and will also be adopted in this round.
223891197|NCT06807853|OTHER|Smartwatch|Smartwatch AppleWatch SE to track Mobility
223891198|NCT06932172|DEVICE|Artificial inteligence based decision support to detect skin cancer|When assessing skin lesions in patients seeking primary care, the primary care physician may use the device to be evaluated in the study (Dermalyser) as a complementary diagnostic doecision support to differentiate skin cancers from benign skin lesions. However, the decision on clinical management of the lesion remains with the physician.
223891199|NCT06931288|DEVICE|Blood pressure monitor|In the trial group, atrial fibrillation screening will be integrated into blood pressure measurements using the BP77A1T electronic blood pressure monitor (Omron Healthcare, Kyoto, Japan).
223891200|NCT06931288|DEVICE|Single-lead ECG|In the control group, a single-lead ECG will be recorded for 30s with a handheld ECG for atrial fibrillation detection. Each ECG rhythm strip will be reviewed and analyzed by a cardiologist from the research team.
223891201|NCT06840691|DRUG|PEG-rhGH with new preparation (T)|A single subcutaneous injection of PEG-rhGH with new preparation
223891202|NCT06840691|DRUG|PEG-rhGH with present preparation (T)|A single subcutaneous injection of PEG-rhGH with present preparation
223891203|NCT06793384|BEHAVIORAL|Virtual reality based Cognitive Stimulation Therapy (VR-CST)|In the VR-CST condition, participants wore a head-mounted display (HMD; model: DPVR P1 Pro Headset) for the themed activities in every session except sessions 1 and 14. In these two sessions, group physical activities (such as passing a ball from one participant to another) were conducted, so no HMDs were used. In other sessions, panoramic images (e.g., wet market) and videos (e.g., the neighborhood surroundings) prepared by the project team were mainly used, supplemented by 2-dimensional images /videos in which preparing panoramic images/videos was deemed impossible. Such a situation occurred in Session 5 (current affairs), in which news clips or captions from newspaper websites served as more appropriate content for discussion than self-created panoramic images/videos.
223891204|NCT06793384|BEHAVIORAL|Conventional Cognitive Stimulation Therapy (Conventional CST)|In the conventional CST group, 2-dimensional images/videos illustrating content identical to the VR-CST condition were displayed via tablet computers (see Table 2 for details) in which participants could manipulate the size of the image depicted or the pace of the videos with the help of the facilitator/therapy assistant.
223891205|NCT04280445|OTHER|Psychological therapy|Acceptance and Commitment Therapy (ACT) is a trans-diagnostic approach which aims to promote better living by supporting clients through six key processes (e.g. mindfulness, values). ACT does not aim to reduce distress, rather its goal is to promote better living or a better quality of life despite distress (Hayes, Strosahl \& Wilson, 1999). ACT has been shown to have equal or superior efficacy to CBT with a number of psychological and physical health conditions (A-Tjak et al., 2015; Ruiz, 2012).
223891206|NCT03752671|DEVICE|Insertion of INTRASPINE device|"The surgical technique for excision of the disc hernia is the surgeon's usual technique: patient positioning (lying on his/her back or front or in the knee to chest position) the approach to the lumbar disc hernia (interlaminar or interspinous), closure and drainage of the operation site are performed by the surgeon's usual practice.~IntraSPINE® is positioned once surgery for the disc hernia has been performed. The implant bed is prepared with the assistance of the distractor provided. The choice of implant size is made after positioning the trial device corresponding to the anatomical bed. Once the size has been established the corresponding implant is placed in a cup of physiological saline prior to implantation. Implantation is performed using the appropriate implant holder."
223891207|NCT03752671|PROCEDURE|Discectomy|The surgical technique for excision of the disc hernia is the surgeon's usual technique: patient positioning (lying prone or supine or in the knee to chest position). The approach to the lumbar disc hernia (interlaminar or interspinous), closure and drainage of the operation site are performed using the surgeon's normal practice.
223891208|NCT06847035|DIETARY_SUPPLEMENT|Active Comparator|LISAVEI collagen peptide solid beverage ( contain 5 g collagen peptide)，once daily for 12 weeks
223891209|NCT06847035|DIETARY_SUPPLEMENT|Placebo Comparator|placebo solid beverage (Maltodextrin with edible flavor)，once daily for 12 weeks
223891210|NCT06211062|DRUG|Floradapt Intensive GI|one capsule daily for the eight week intervention
223891211|NCT06211062|OTHER|Placebo|one capsule daily for the eight week intervention
223891212|NCT03057938|DRUG|18F-Florbetaben (FBB)|All participants will receive a single intravenous dose of 300 MBq of FBB followed by PET scan.
223891213|NCT06367283|DRUG|Metformin|Metformin will be initiated at 500 mg once daily with breakfast meal. The dose will be increased with 500 mg every week until 2 g/day is reached, distributed as 1000 mg every morning and evening, together with a meal. If the subject cannot tolerate the maximum dose (2 g/day), the maximal tolerated dose will be given. The treatment period including titration is 16 weeks.
223891214|NCT06367283|DRUG|Placebo|Participants in the placebo group will receive a placebo tablet identical to the metformin tablet
223891215|NCT05418699|DEVICE|closed-loop insulin pump|Follow up of patients with real-time closed-loop insulin delivery systems
223891216|NCT06067425|DRUG|SAR442501|Solution for injection; Subcutaneous injection
223891217|NCT02496780|DRUG|novolog insulin|3x daily rapid-acting insulin
223891218|NCT02496780|DRUG|levemir insulin|basal insulin once a day
223891219|NCT02496780|DRUG|placebo|once or 3x daily
223891220|NCT02992925|BIOLOGICAL|DPT-IPV-Hib-High（Combined Vaccine）|
223891221|NCT02992925|BIOLOGICAL|DPT-IPV-Hib-Low（Combined Vaccine）|
223891222|NCT02992925|BIOLOGICAL|Hib vaccine|
223891223|NCT02992925|BIOLOGICAL|DPT-IPV|
223891224|NCT06486948|DEVICE|CT-156|CT-156 is a digital therapeutic (DTx) under development to treat patients 18 years of age and older with a diagnosis of schizophrenia under standard of care therapy who are on antipsychotic medication and not currently experiencing acute hallucinations or delusions.
223891225|NCT05840250|OTHER|Continuous Glucose Monitoring and Education Support|Participants will be provided with a device to monitor their blood glucose (Abbott Free Style Libre2 Flash CGM system) along with educational materials to better understand and manage their diabetes and other supporting services. Pre and post intervention surveys will be implemented. Participants will be closely monitored for 3 months and then followed up for 3 more months for a total of 6-month participation.
223891226|NCT05333185|BEHAVIORAL|DİABOT (mobile application robot )|"DİABOT (mobile application robot ) Thanks to the trainings given through the mobile application robot developed for pediatric diabetes management, it is aimed to have an effect on the quality of life, diabetes self-management and physiological parameter levels of children with Type~1 diabetes, and to easily obtain the information they need even when they cannot come to the outpatient clinic. In addition, thanks to the application robot, he will be able to create his own exercise program and determine his diet."
223891227|NCT05426928|OTHER|Additional temperature monitoring/recording|All patients in this study will receive the same standard of care treatment for their HIPEC procedure. The only difference will be the use of additional temperature probes to collect more robust data regarding intraabdominal temperature, and the prospective collection of actual boundary conditions of the system.
223891228|NCT03779204|BEHAVIORAL|Mentorship|The mentors will be encouraged to incorporate the key relationship-based components of natural mentors (e.g., a 'coach' or 'cheerleader' role) to assist with mainstream integration. The mentors will have more flexibility than a typical formal mentorship program in the types of activities they pursue with their mentees. They will not be mandated to attend shelter-based social events, but rather engage in activities that direct their mentees away from the shelter system (and their old identities as homeless youth) and toward the mainstream (e.g., meeting for coffee at a local university campus). All of the mentors will meet monthly with their mentees for two years. In addition, the mentor will be encouraged to touch base with their mentee via phone or text message every week. If a mentor is unable to continue their role and there are at least six months left in the study, the study participant will be matched with a new mentor.
223891229|NCT03779204|BEHAVIORAL|Rent Subsidies|Participants will receive rent subsidies ($500 for those living in Toronto, $400 for those living in Hamilton or St. Catherine's due to differences in cost of living) for 24 months.
223891230|NCT04327557|BEHAVIORAL|MBCP Childbirth Education Course|The MBCP program is a fully manualized childbirth and parenting preparation course. Developed in 1998 in a clinical context, MBCP is an enhanced version of the Mindfulness Based Stress Reduction (MBSR) program tailored for addressing the concerns of pregnancy and early parenting. Through MBCP, pregnant women and their partners learn mindfulness skills for coping with the anxiety and stress of pregnancy and parenting, and the pain and fear of childbirth. They are given explicit instruction in skills for cultivating positive emotion and developing mindful, sensitive parenting. MBCP groups meet weekly for 9 weeks, with a retreat day between weeks 6 and 7.
223891231|NCT04327557|BEHAVIORAL|Non-MBCP Childbirth Education Course|TAU control participants will undergo standard (real-world) hospital- or community-based childbirth education that does not have a mindfulness focus. They will be able to choose whichever class they want from the list. If they prefer a class that is not on the list, then study staff will obtain the syllabus for that class to check whether there is a mindfulness component.
223891232|NCT04917302|DRUG|NMDAE plus AIFA|Use of an NMDA enhancer plus a drug with anti-inflammatory property for the treatment of schizophrenia.
223891233|NCT04917302|DRUG|NMDAE plus Placebo Cap|Use of an NMDA enhancer plus placebo as a comparator
223891234|NCT04150718|BEHAVIORAL|slow-wave disruption|A tone will be played through a speaker mounted over the bed that disrupts subjects while they are in slow-wave sleep. The tone will not be loud enough to wake up.
223891235|NCT03948048|DEVICE|ECMO|ECMO is used to intervene septic shock and refractory septic shock
223891236|NCT05633953|DRUG|Osilodrostat|oral administration
223891237|NCT03839342|DRUG|Binimetinib|MEK inhibitor, 45mg oral tablet
223891238|NCT03839342|DRUG|Encorafenib|BRAF inhibitor, 450mg oral capsule
223891239|NCT06096701|DEVICE|Blood pressure cuff|The BP cuff is connected in a Health Insurance Portability and Accountability Act-compliant fashion to the patient's medical record, allowing for documentation and communication with the nurse and the care team. Alerts are triggered if a patient has not checked her BP for 3 days or when readings fall outside a specific threshold (high or low BP alerts). Based on these alerts, the nurse follows up with these patients and reminds them to take a reading. The nurse will also notify participants with elevated BP values to repeat their BP and will contact the participants by phone to discuss symptoms and antihypertensive medications. Patients will be managed based on a clinical algorithm for initiation of antihypertensive medications without the need for an outpatient visit if considered appropriate by the clinical provider.
223891240|NCT04812366|DRUG|Apalutamide 60mg Tab|4 tablets by mouth once a day for 24 weeks
223891241|NCT04812366|DRUG|Abiraterone Acetate 250mg|4 tablets by mouth on an empty stomach once a day for 16 weeks
223891242|NCT04812366|DRUG|Prednisone 5mg Tab|1 tablet by mouth once daily while taking abiraterone acetate
223891243|NCT04812366|DRUG|Docetaxel|Infusion every 3 weeks for 6 cycles (each cycle has 3 weeks)
223891244|NCT04812366|DRUG|Niraparib 100mg Oral Capsule|3 capsules by mouth once daily for 16 weeks
223891245|NCT04812366|DRUG|Atezolizumab|1200mg infusion every 3 weeks for 6 cycles
223891246|NCT05933265|DRUG|LP-184|LP-184 is a small molecule alkylating agent causing tumor cell death through DNA damage.
223891247|NCT05933265|DRUG|Spironolactone|A competitive mineralocorticoid receptor antagonist that inhibits aldosterone-dependent sodium reabsorption/ potassium excretion and lowering blood pressure, as well as degrades the transcription coupled nucleotide excision repair protein ERCC3 to impair DNA repair.
223891248|NCT05933265|DRUG|Olaparib|A poly (ADP-ribose) polymerase (PARP) inhibitor that impairs homologous recombination (HR) dependent DNA damage repair by trapping PARP1/2 on DNA, leading to synthetic lethality in BRCA1/2-deficient cells.
223891249|NCT02677025|BEHAVIORAL|Young Women's Health CoOp (YWHC)|Participants in this group will participate in two workshops of the young woman-focused intervention about HIV/STIs (sexually transmitted infections), sexual behaviors, alcohol and other drug use, violence, communication skills, and other issues. Participants will develop personalized risk reduction action plans at the end of each workshop session.
223891250|NCT02677025|BEHAVIORAL|HIV Counseling/Testing|Participants will be tested for HIV and if positive will receive counseling in accordance with national standards.
223891251|NCT02026843|DRUG|Chorioretinal diseases|chorioretinal diseases including diabetic retinopathy, retinal vascular diseases, age-related macular degeneration (dry and wet), and retinal degeneration
223891252|NCT05018494|OTHER|experimental treatment|This group will receive the common treatment and will be discharged with complete manual on life style modifications comprising education, exercise and diet with telerehabilitation monitoring.
223891253|NCT05018494|OTHER|common treatment|This group will receive the common treatment and will be discharged with home exercise plan without telerehabilitation monitoring.
223891254|NCT04034251|DRUG|Paclitaxel|Paclitaxel (intraperitoneal (IP) and intravenous (IV), Day 1 of each 3-week cycle: Paclitaxel IP - Intraperitoneal paclitaxel (60 mg/m\^2) will be diluted in 500 mL of 0.9% normal saline (NS), to be infused as rapidly as tolerated once per 3-week cycle on Day 1. Paclitaxel IV - Intravenous paclitaxel (80 mg/m\^2) will be administered concomitantly over 3 hours, diluted in 100 to 250 ml of 0.9% NS once per 3-week cycle on Day 1.
223891255|NCT04034251|DRUG|Capecitabine|Day 1-15 of each 3-week cycle: oral capecitabine (825 mg/m\^2) to be taken twice a day starting the evening of Day 1 of each cycle until the morning of Day 15, followed by a 7-day rest period during each 3-week cycle.
223891256|NCT04034251|DEVICE|BardPort Titanium Implanted Port with Peritoneal Catheter|After peritoneal chemo infusion port is placed (Days 1-3, as dictated by clinical status), patients will begin intraperitoneal paclitaxel and intravenous paclitaxel (Day 1) followed by oral capecitabine on the evening of Day 1 to the morning of Day 15.
223891257|NCT01105286|DRUG|Six different calcipotriol ointment formulations, and two currently marketed topical vitamin D analogues|Once daily application
223891258|NCT05585580|DRUG|Serplulimab|300mg d1 q3w
223891259|NCT05585580|DRUG|Lenvatinib|8mg po qd
223891260|NCT05585580|DRUG|Paclitaxel/Paclitaxel-albumin/Paclitaxel liposome|135\~175mg/m2 /260mg/m2/135-175mg/m2 d1 q3w
223891261|NCT03643861|RADIATION|5 Fraction Stereotactic Body Radiation Therapy|Stereotactic body radiation therapy (SBRT) has gained favor in the treatment of select central nervous system, lung, and abdominal malignancies due to its ability to deliver highly conformal doses of radiotherapy while using sharp dose gradients to deliver comparatively lower doses to the surrounding normal tissue. Utilization of SBRT is more labor intensive than conventional fractionation and requires precise immobilization and localization techniques with daily image guidance with direct physician and physicist oversight for all treatments. While more labor intensive and often utilizing more advanced technologies, SBRT allows the advantage of reducing setup margins compared to conventionally fractionated treatment while being able to shorten overall treatment times due to the ability to safely dose escalate high risk areas
223891262|NCT04414280|DEVICE|Medtronic MiniMed 670G|The Medtronic Minimed 670G system is a form of hybrid closed-loop insulin delivery. The Medtronic MiniMed 670G system automatically adjusts basal insulin every five minutes based on CGM readings to reach a glucose target of 120 mg/dL, the SmartGuard Auto Mode. Patients still need to enter their carbohydrate intake and administer meal-time and correction boluses. Before Auto Mode is introduced, the Medtronic MiniMed 670G system has to be worn in Manual Mode. In contrast to Auto Mode, Manual Mode features an insulin stop up to 30 minutes before or when reaching preset low limits (suspend before/on low) and an automatic insulin restart when blood sugar levels recover. During Manual Mode the pump 'becomes familiar with' the daily insulin need of the patient. This information will be used when in Auto Mode.
223891263|NCT04414280|DEVICE|Medtronic MiniMed 780G|The Medtronic Minimed 780G system differs in several aspects from the MiniMed 670G system. In Auto Mode, the user can choose from two target levels for even more stricter glucose control (100 mg/dL and 120 mg/dL) and correction boluses are now automated without the need of user interaction. When administering meal boluses, no capillary blood glucose value is required. The safety feature to exit from Auto Mode to Manual Mode was too strict in the Minimed 670G. In the Minimed 780G this is more flexible to overcome this frequently reported patient frustration.
223891264|NCT04414280|DEVICE|Tandem Control-IQ|The Tandem t:slim X2 Control-IQ consists of the Tandem t:slim X2 insulin pump with Control-IQ technology, and integrates with the Dexcom G6 CGM-device via Bluetooth. Blood glucose readings for calibration are not required. The Tandem t:slim X2 Control-IQ automatically adjusts basal insulin based on CGM readings to reach a glucose target range between of 112-160 mg/dL. Patients still need to enter their carbohydrate intake and administer meal-time boluses, but the system automatically increases the basal insulin dose or gives automated correction boluses in case of high blood glucose levels. The technology offers optional settings for sleep and exercise, with different glucose targets in order to match the insulin need during these activities. New versions of the pump software can be downloaded and installed remotely via the user's own computer.
223891265|NCT05142059|DIAGNOSTIC_TEST|Exploratory physiopathology study, including non-invasive functional explorations carried out in patients with Charcot-Marie-Tooth disease type 1A|The data of the gait analysis, posturography and strength analyses as well as the questionnaires' scores will be taken into account in this research. At 6 months and at 1 year, occurrence of a fall will be recorded in order to prospectively monitor this parameter. A final analysis will be carried out at 1 year from the first according to the same methods as the initial assessment.
223891266|NCT06519279|DEVICE|Opals|Five Oplas sensors were strategically placed on participants: one on each shin, one on each foot, and one on the lower back.
223891267|NCT06519279|DEVICE|Axivity|"At the end of the first session, participants with FOG, will be fitted with an Axivity monitor. This is wearable sensor that will be attached to the participant's lower back (lumbar vertebrae 4-5) with hypoallergic medical tape by the researcher, and will be worn continuously for seven days.~The Axivity monitor is a small (23 x 32.5 x 8.9 mm) and lightweight (11g) device that measures mobility via a tri-axial accelerometer and gyroscope and stores this data onboard, no GPS or other localization options are possible with this monitor. Participants will be given following guidelines concerning the use:~The sensor is to be worn continuously during the seven-day period, i.e. also while sleeping and showering.~The sensor is waterproof and can be worn during showering."
223891268|NCT05716087|DRUG|Rocbrutinib|Subjects to take Rocbrutinib tablets orally with 240mL water, without food, Once daily.The treatment will continue until progressive disease, unacceptable toxicity, etc.
223891269|NCT05450562|BIOLOGICAL|SAR444200|Sterile lyophilized powder for solution for infusion Route of administration: intravenous (IV) infusion
223891270|NCT05450562|BIOLOGICAL|Atezolizumab|concentrate for solution for infusion Route of administration: intravenous (IV) infusion
223891271|NCT05177523|DIAGNOSTIC_TEST|MRI|Each enrolled subject will undergo a MRI at baseline and a second MRI at 2 years (+/- 3 months) follow-up.
223891272|NCT05177523|OTHER|Neurocognitive examination for healthy subjects|Neurocognitive examination for healthy subjects will be performed at both baseline and follow-up
223891273|NCT05177523|OTHER|blood sampling|Each enrolled subject will undergo a blood sampling (10 ml) at baseline
223891274|NCT06194435|OTHER|Remote Monitoring of Participant Progress and Well-being via Video Calls|Participants with Rotator Cuff Syndrome undergo remote evaluations via video calls with a physician. On the same day, they receive an asynchronous exercise brochure containing instructions for performing home exercises three times a day. They are also provided with an exercise diary to track their daily exercise sessions. Follow-up assessments and discussions about their condition take place remotely on video calls with the physician on the 7th and 15th days. During the final video call on the 15th day, participants are asked to submit their exercise diaries via WhatsApp for assessment of exercise adherence.
223891275|NCT06194435|OTHER|Face-to-Face Clinic-based Monitoring of Participant Progress and Well-being|Participants with Rotator Cuff Syndrome undergo in-clinic evaluations by a physician, during which they receive an exercise brochure with instructions for performing home exercises three times a day. They are also given an exercise diary to track their daily exercise sessions. On the 7th and 15th days, participants return for follow-up assessments and discussions about their condition. During the final clinic visit, participants are requested to submit their exercise diaries for assessment of exercise adherence.
223891276|NCT05493787|BEHAVIORAL|Reminder|Patient portal, SMS, email, and/or another modality
223891277|NCT06679036|DRUG|HRS-2189|HRS-2189
223891278|NCT06679036|DRUG|Fluvustat|Fluvustat
223891279|NCT06679036|DRUG|HRS-8080|HRS-8080
223891280|NCT06679036|DRUG|HRS-6209|HRS-6209
223891281|NCT06679036|DRUG|HRS-1358|HRS-1358
223891282|NCT04783935|DRUG|Mavenclad®|No intervention was administered as a part of this study. Participants who had received Mavenclad® up to 2 years (Year 1 and 2) in the parent study MS700568\_0022 (NCT03364036) were enrolled into this extension study and will be assessed up to 2 years follow-up (Year 3 and 4).
223891283|NCT01600222|DRUG|LEO 90100|Calcipotriol 50 mcg/g (as hydrate) and betamethasone 0.5 mg/g (as dipropionate)
223891284|NCT04407338|DEVICE|B-DYN|The surgical technique for placement of the B-Dyn device is performed under general anaesthesia. The procedure begins with the insertion of the first upper polyaxial screw which is screwed in with the polyaxial screwdriver. The use of the phantom (Trial 10) is necessary in order to position the second screw. Once the screws are positioned, the B-Dyn is taken between the jaws of the gripping forceps in order to insert it into the heads of the polyaxial screws. The movable rod of the B-Dyn is then placed in the head of the upper screw. The positioning mark of the fixed rod must be placed facing the operator and in the center of the lower screw head. Finally the cap of the lower polyaxial pedicle screw is tightened. A final tightening of the two plugs on the polyaxial pedicle screw heads is performed to fix the assembly.
223891285|NCT04407338|DEVICE|Conventional Bolted fusion (with or without cage)|The surgeon will complete his gesture by placing 2 screws in the upper vertebra and 2 screws in the lower vertebra; the screws will be connected to each other to stabilize the assembly. This type of surgery is done via posterior approach and under general anaesthesia.
223891286|NCT05712746|DRUG|Samtasu for I.V. infusion|"Drug: 8 mg/vial or 16mg/vial~Dosage and Administration:~The usual adult dosage of tolvaptan sodium phosphate is 16 mg once daily and intravenously infused over 1 hour."
223891287|NCT06636279|PROCEDURE|Gas bubble technique|Inject the sterile air into the anterior chamber after the conventional cataract surgery to reduce corneal endothelial damage
223891288|NCT06071065|BEHAVIORAL|Pharmacist counselling|Counselling session with Pharmacist about disease and medication therapy.
223891289|NCT06678087|OTHER|motherhood preparation meditation training prepared with the thetahealing meditation method|"With Birth and Motherhood Preparation Meditation, all physiological and psychological reasons causing fear of birth will be addressed. How to do the meditation will be taught by the practitioner in the course.~The root belief analysis study for each topic is carried out with the questions of who, what, when, where, why and how. Then, the reprogramming work that allows the change of that belief, feeling, emotion will be done with methods specific to the technique.~The topics to be worked on during meditation each week are listed below. Each week, pregnant women will be given a 15-minute meditation homework per day until the next week regarding the topic worked on.~All meditations begin with relaxation and breathing exercises. In each meditation, the emotion and root-belief analysis related to the relevant topic will be done by the practitioner.~With this application, it is aimed to accelerate the change in the mind with positive language and regular repetition."
223891290|NCT06678087|OTHER|pregnancy school,|"In the pregnancy school, an informational support training is provided to pregnant women and their families to ensure that the pre-pregnancy, pregnancy and birth process is passed in a healthy and conscious manner.~The training content includes:~Reproductive organs and development, Nutrition during pregnancy and puerperium, Common problems during pregnancy, Physiological changes, Non-formological methods, Breathing techniques during birth, Anesthetic methods, Birth methods and techniques, Postpartum and baby care, Newborn Care / Problems, Home-Bag-Hospital preparation, Breast milk - Its importance - Breastfeeding, Family planning topics are given five days a week for 2 hours."
223891291|NCT05728242|DIAGNOSTIC_TEST|Gastric ultrasound|Preoperative gastric antrum examination to detect gastric content (empty, liquid, or solid) and measure gastric volume
223891292|NCT06321354|DRUG|The diprospan plus ropivacaine group|The local infiltration solution containing 0.5ml diprospan and 15mg of 1% ropivacaine. The total volume is 30 ml. The assigned solution will be injected subcutaneously by surgeons along the incision and throughout the entire thickness of the scalp before skin incision. The volume of local infiltration solution will be decided by surgeons according to the cut length, and the capacity of the solution will be recorded by investigators.
223891293|NCT06321354|DRUG|The ropivacaine group|The local infiltration solution containing 15mg of 1% ropivacaine. The total volume is 30 ml. The assigned solution will be injected subcutaneously by surgeons along the incision and throughout the entire thickness of the scalp before skin incision. The volume of local infiltration solution will be decided by surgeons according to the cut length, and the capacity of the solution will be recorded by investigators.
223891294|NCT04859725|DEVICE|Hyperspectral Imaging with Snapscan camera|Before, during and after the resection, HSI data ('datacubes') will be acquired by the SnapScan camera of all relevant areas of the exposed cortical surface and subcortical cavity walls. The exact points of which the datacubes will be acquired are defined by unequivocal single points on the routinely used neuronavigational system. From the points from which the datacubes have been obtained a corresponding tissue sample will be obtained (labeled biopsy) if tumor tissue is to be expected in that particular point, based on the current standard of care assessments intraoperatively using white light illumination on the microscope, intraoperative navigation and intraoperative ultrasound. As such, normally looking brain in the resection cavity wall, will only be biopsied if tumor free margins should be proven as part of the standard-of-care operative procedure (non-critically eloquent brain regions).
223891295|NCT05275842|BEHAVIORAL|Cognitive Processing Therapy- Lifesteps (CPT-L)|"CPT-L is designed to help people with HIV and PTSD take their medications as prescribed. Cognitive Processing Therapy (CPT) uses education and cognitive training to help individuals identify thoughts and feelings about their trauma and gives them tools to help them change unhelpful beliefs. Lifesteps (L) includes education on the need for people with HIV to take their medications as prescribed and what could happen if you do not, as well as gives you tools to help motivate and remind you to take your medications on time.~Participants will receive a 12-session Cognitive Processing Therapy-Lifesteps (CPT-L) treatment program at the Ryan White clinic. The CPT-L program will be delivered twice a week for 6 weeks. Each session last about 90-minutes."
223891296|NCT05275842|BEHAVIORAL|Lifesteps|"Lifesteps (L) includes education on the need for people with HIV to take their medications as prescribed and what could happen if you do not, as well as gives you tools to help motivate and remind you to take your medications on time.~Participants will complete one Lifesteps education session. This session lasts about 60 minutes. Participants may attend this session either in-person or over the internet if they have an internet ready device with audio."
223891297|NCT04769206|DRUG|Galantamine|4mg daily titrating up to 8mg twice a day
223891298|NCT04769206|DRUG|Placebo|1 pill a day for 4 weeks, 2 pills a day for 8 weeks
223891299|NCT04769206|DEVICE|TENS 7000|The FDA-approved TENS 7000 device will be used for Trans-auricular vagus nerve stimulation (TaVNS) during a period of enhanced vascular oxidative stress. This device will be supplemented with ear clip electrodes. The site of the stimulation for such electrodes are the tragus or concha. The device will have built in safety controls to minimize additional risks to the subjects (as per FDA guidance on stimulators). We will use typical stimulation conditions (30 Hz, 300 µs) and amplitude dependent on perception threshold.
223891300|NCT06189066|DEVICE|Splenic Ultrasound|Daily ultrasound application to the spleen of approximately 18 minutes per day, 5 days per week for up to 8 weeks, in addition to standard clinical care.
223891301|NCT06074523|BEHAVIORAL|Behavioral Measurement and self-report|Measurements of behavioral performance and self-report
223891302|NCT05273749|DRUG|TNX-102 SL Tablet, 5.6 mg|Patients will take 1 tablet of randomly assigned study drug sublingually starting on Day 1 for 2 weeks. At the Week 2 visit, all patients will have the dose increased to 2 tablets for 12 weeks.
223891303|NCT05273749|DRUG|Placebo SL Tablet|Patients will take 1 tablet of randomly assigned study drug sublingually starting on Day 1 for 2 weeks. At the Week 2 visit, all patients will have the dose increased to 2 tablets for 12 weeks.
223891304|NCT05228730|BIOLOGICAL|Tozinameran - Standard dose|Tozinamrean is a single-stranded, 5'-capped messenger RNA (mRNA) produced using a cell-free in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of severe acute respiratory syndrome coronavirus 2 (SARS\_CoV-2). A standard dose will be administered on day 0 of the study.
223891305|NCT05228730|BIOLOGICAL|Tozinameran - fractional dose|Tozinamrean is a single-stranded, 5'-capped messenger RNA (mRNA) produced using a cell-free in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of severe acute respiratory syndrome coronavirus 2 (SARS\_CoV-2). A fractional dose (15mcg) of the intervention will be administered on day 0 of the study.
223891306|NCT05228730|BIOLOGICAL|Elasomeran - standard dose|"Elasomeran is a single-stranded, 5'-capped messenger RNA (mRNA) produced using a cell-free in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of SARS-CoV-2).~A single standard dose (50mcg) of the intervention will be administered on day 0 of the study."
223891307|NCT05228730|BIOLOGICAL|Elasomeran - fractional dose|"Elasomeran is a single-stranded, 5'-capped messenger RNA (mRNA) produced using a cell-free in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of SARS-CoV-2).~A fractional dose (20mcg) of the intervention will be administered on day 0 of the study."
223891308|NCT05143905|DRUG|AZD7503|Randomised participants will receive a single ascending dose of AZD7503 by SC injection (dose 1, dose 2, dose 3, dose 4, dose X and dose Y).
223891309|NCT05143905|DRUG|Placebo|Randomised participants will receive placebo by SC injection
223891310|NCT03706170|BEHAVIORAL|Physiological recording in response to different types of stimuli|In order to answer these questions, the study is designed to record in a single session: (i) physiological vegetative reactions (electrodermal, pupillary responses and heart rate) to emotional stimuli ; (ii) a neurophysiological marker of consciousness; and (iii) physiological parameters during a trace conditioning experiment using auditory stimuli with and without emotional valence.
223891311|NCT03706170|BEHAVIORAL|EEG recording in response to different types of stimuli|In order to answer these questions, the study is designed to record in a single session: (i) physiological vegetative reactions (electrodermal, pupillary responses and heart rate) to emotional stimuli ; (ii) a neurophysiological marker of consciousness; and (iii) physiological parameters during a trace conditioning experiment using auditory stimuli with and without emotional valence.
223891312|NCT05359939|DIAGNOSTIC_TEST|18F-FDGal PET/CT versus 18F-choline PET/CT|Fifty patients with known HCC are investigated with two PET/CT-scans with 18F-FDGal and 18F-choline. In some of the cases one of the CT-scans will be altered to a contrast-enhanced MRI scan. A contrast-enhanced CT scan will be performed as part of the standard diagnostic work-up. We include patients with known HCC as the aim is to compare the diagnostic performance of the two tracers. Images will be analyzed for focal lesions and compared to other modalities by an experienced specialist in PET and an experienced radiologist.
223891313|NCT05285826|BIOLOGICAL|9vHPV Vaccine|9-valent human papillomavirus (Types 6, 11, 16, 18, 31, 33, 45, 52, 58) L1 virus-like particle vaccine administered as a 0.5-mL IM injection
223891314|NCT05285826|OTHER|Placebo|Sterile saline solution administered as a 0.5 mL IM injection
223891315|NCT03410615|RADIATION|Radiation|70 Gy in 35 fractions over 7 weeks (i.e. 2 Gy per fraction)
223891316|NCT03410615|DRUG|Cisplatin|100 mg/m2 days 1, 22, 43 concurrently with RT
223891317|NCT03410615|DRUG|Durvalumab|Given in concurrent and adjuvant phase
223891318|NCT03410615|DRUG|Tremelimumab|ARM CLOSED TO ACCRUAL - 2019
223891319|NCT04203576|DEVICE|FIRE1 System|FIRE1 System
223891320|NCT04829500|BEHAVIORAL|Montessori Approaches to Person-Centered Care (MAP-VA)|Montessori approaches to person-centered care (MAP-VA) introduces practical strategies that frontline staff can use for successful engagement of residents through retained abilities. Staff are also introduced to concrete strategies that improve dignity, control, and independence. MAP-VA is based on the work of Maria Montessori who demonstrated that a structured, supportive environment and meaningful, active roles in the classroom enabled children to fulfill their greatest potential physically, mentally, and emotionally. Montessori principles have been applied to dementia care for more than 20 years to promote functional independence, meaningful engagement, and dignity.
223891321|NCT05629143|PROCEDURE|de-prescription of PPI via intermittent scheme|The patients will decrease their intake of PPIs via a de-prescription intermittent scheme. After one month, patients will stop their intake of PPI.
223891322|NCT05629143|PROCEDURE|de-prescription of PPI via on-demand scheme|The patients will decrease their intake of PPIs via a de-prescription on-demand scheme. After one month, patients will stop their intake of PPI.
223891323|NCT05629143|DRUG|Alginate|The patients will stop their intake of PPIs and use alginate. After one month, patients will stop their intake of alginates.
223891324|NCT06171269|RADIATION|Radiation|Radiation to the prostate gland will be given daily (Mon-Friday) for 4 weeks.
223891325|NCT06171269|RADIATION|MRI|The study doctor will use an MRI scan to take pictures of the prostate gland. These images of the prostate gland will let the study doctor know which areas of the prostate contain cancer cells that need to be targeted with higher doses of radiation and which uninvolved areas to target with lower doses of radiation.
223891326|NCT06171269|OTHER|Androgen Deprivation Therapy|Treatment of treating physician choice will be given for 6-24 months.
223891327|NCT04585477|DEVICE|AVENIO ctDNA Surveillance Kit|Roche Sequencing and Life Science kit to detect minimal residue disease (MRD)
223891328|NCT04585477|DRUG|Durvalumab|Participants in the intervention arm will receive Durvalumab (1500 mg IV every 4 weeks for up to 12 months) as monotherapy or 20mg/kg if weight is 30kg or less.
223891329|NCT04585477|DRUG|Durvalumab (Imfinzi) alone or in combination with platinum-based chemotherapy|Participants in the intervention arm (Cohort 1 MRD+) will receive a fixed dose of Durvalumab (1500 mg IV every 4 weeks for up to 12 months), either as monotherapy or in combination with a platinum-based chemotherapy regimen (investigator's choice). Platinum-based chemotherapy options include carboplatin, cisplatin, pemetrexed, paclitaxel, or nab-paclitaxel, administered per standard of care for up to 4 cycles.
223891330|NCT06286514|OTHER|No intervention|This is an observational study
223891331|NCT03800550|DRUG|Bedaquiline|Bedaquiline tablet will be administered, orally.
223891332|NCT03800550|DRUG|Clarithromycin|Clarithromycin tablet will be administered, orally.
223891333|NCT04956861|BEHAVIORAL|Individualized Targeted Sleep|The investigators will employ an 8-week individualized targeted sleep intervention. Individualized targeted interventions have the advantage of improving adherence, reducing attrition, and making the strategy personally meaningful.
223891334|NCT03467373|DRUG|Glofitamab|Glofitamab will be administered intravenously (IV) as a step-up dose for Cycle 2 on Days 8 and 15, and as a single dose from Cycle 3 onwards.
223891335|NCT03467373|DRUG|Obinutuzumab (G)|Obinutuzumab 1000 mg single dose IV infusion on Day 1 of Cycle 1 only
223891336|NCT03467373|DRUG|Rituximab (R)|Rituximab will be administered as an IV infusion at a dose of 375 mg/m\^2 on Day 1 of each 21-day cycle starting from Cycle 1 to Cycle 6 (Part 1) or from Cycles 1-6 (up to 8) (Part 2: DLBCL R-CHOP).
223891337|NCT03467373|DRUG|Tocilizumab|Tocilizumab will be administered as an IV infusion as per the methods described in the Summary of Product Characteristics (SmPC) or other similar local prescribing documents. Tocilizumab will be given as rescue medication.
223891338|NCT03467373|DRUG|Cyclophosphamide|Cyclophosphamide 750 mg/m\^2 administered IV on Day 1 of each 21-day cycle
223891339|NCT03467373|DRUG|Doxorubicin|Doxorubicin 50 mg/m\^2 administered IV on Day 1 of each 21-day cycle
223891340|NCT03467373|DRUG|Vincristine|Vincristine 1.4 mg/m\^2 administered by IV push on Day 1 of each 21-day cycle with a recommended cap of 2 mg
223891341|NCT03467373|DRUG|Prednisone|Prednisone 100 mg/day orally on Days 1-5 (prednisone on Day 1 may be administered IV, with the remaining doses on Days 2-5 to be administered orally) of each 21-day cycle
223891342|NCT03467373|DRUG|Polatuzumab vedotin|Polatuzumab vedotin 1.8 mg/kg administered IV on Day 1 of each 21-day cycle
223891343|NCT06822348|OTHER|Osteopathic treatment|Osteopathic manipulation
223891344|NCT06822348|BEHAVIORAL|Quality of life assessment|EORTC FA-12 questionnaire
223891345|NCT06822348|BEHAVIORAL|Anxiety assessment|STAI-Y-A and STAI-Y-B questionnaire assessment
223891346|NCT06822348|OTHER|Heart rate variability assessment|rMSSD (root mean square of successive R-R intervals), SDNN (standard deviation of all NN intervals), HF (high frequencies), LF (low frequencies), LF/HF ratio, Heart rate deceleration capacity, Heart rate acceleration capacity, Heart rate (bpm).
223891347|NCT06490900|BEHAVIORAL|Intermittent hypoxia|The intermittent hypoxia protocol will consist of eight 4-minute hypoxic cycles (arterial oxygen saturation of 80%) interspersed with normoxic cycles (room air) to resaturation.
223891348|NCT06490900|BEHAVIORAL|Intermittent normoxia|The intermittent normoxia protocol will consist of eight 4-minute normoxic cycles (compressed air) interspersed with 1-minute normoxic cycles (room air).
223891349|NCT05146219|DRUG|TY-9591 Tablets|TY-9591 Tablets 160mg/d
223891350|NCT05876858|DRUG|18F-FDG|Each subject will undergo a dynamic 18F-FDG PET/CT scan (this drug is FDA approved) and a dynamic 11C-butanol PET/CT scan (this drug is under an IND) on the EXPLORER total-body PET/CT system. The two scans will be performed on the same day or within a period of up to four weeks depending on subject, imaging agent and scanner availability. Subjects will be asked to complete the HEAL questionnaires before or after their PET/CT scan on each day.
223891351|NCT05876858|DRUG|11C-butanol|Each subject will undergo a dynamic 18F-FDG PET/CT scan (this drug is FDA approved) and a dynamic 11C-butanol PET/CT scan (this drug is under an IND) on the EXPLORER total-body PET/CT system. The two scans will be performed on the same day or within a period of up to four weeks depending on subject, imaging agent and scanner availability. Subjects will be asked to complete the HEAL questionnaires before or after their PET/CT scan on each day.
223891352|NCT05337748|DEVICE|Lexie Self Test and Fit Group|The intervention offered is a hearing aid fitting with Lexie Lumen hearing aids coupled with a slimtube and dome. The hearing aids will be accompanied and operated using the Lexie smartphone application. Participants will self-perform an in-situ hearing check (pure tones presented via the hearing aids). The prescriptive gain of the hearing aids will be programmed and applied automatically using the obtained in-situ hearing thresholds. Participants will be fitted according to the customized, Lexie optimal fit prescribed gain setting. The optimal settings include the original gain and compression requirements that NAL-NL2 suggests for various audiograms. No additional band equalizer or compression adjustments are added. After a specified period of time, participants will be able to self-adjust the hearing aids using the smartphone application.
223891353|NCT05337748|DEVICE|Lexie Professional Test and Fit Group|The intervention offered is a hearing aid fitting with Lexie Lumen hearing aids coupled with slimtube and dome. Hearing aids will be fitted by a certified audiologist according to a gold-standard prescriptive formula (NAL-NL2) using a clinically obtained diagnostic pure tone audiogram. Participants will have access to the smartphone application, but the settings will be limited with only options to change the volume of the hearing aids.
223891354|NCT04638309|DRUG|APR-548 + Azacitidine|APR-548 monotherapy period followed by APR-548 in combination with Azacitidine
223891355|NCT04643379|DRUG|Olaparib|Supplied by Merck \& Co.
223891356|NCT04643379|DRUG|Pembrolizumab|Supplied by Merck \& Co.
223891357|NCT04643379|DRUG|Carboplatin|Commercially available
223891358|NCT04643379|PROCEDURE|Peripheral blood draw|Baseline (cycle 1 day 1), cycle 2 day 1, and at disease progression
223891359|NCT03818659|OTHER|Self-Guided M.A.P. BP Improvement Program|Active Clinics randomized to the Self-Guided Arm will receive access to an AHA/AMA web platform that includes the posted M.A.P. materials and limited access to AMA Staff who are available to answer questions. The study team will facilitate access to staff by hosting a kick-off webinar for program participants that will include an orientation to the materials on the website, general advice and practical tips about what works for implementation, and time for answering questions and discussion with the group.
223891360|NCT03818659|OTHER|Full Support M.A.P. BP Improvement Program|"Active Clinics randomized to the Full Support Arm will receive online access to M.A.P. materials and orientation webinar and also a Practice Change Facilitator who will lead the health center clinical staff, site champions and physician leads at each clinic over the course of 6 months to support the implementation of the MAP Program. With support from an AMA Improvement Advisor, the Practice Change Facilitators will perform a baseline assessment of current workflows and assess each domain of M.A.P. The goal of the Full Support program is to help care teams develop skills and sustainable workflows that are effective at attaining and maintaining high levels of BP control."
223891361|NCT05290974|OTHER|Self exploring of available online material on supraclavicular brachial plexus block|Potential new method of learning a specific regional anesthesia technique
223891362|NCT05290974|OTHER|Conventional in-person teaching on supraclavicular brachial plexus block|Conventional method of learning a specific regional anesthesia technique
223891363|NCT04173637|BIOLOGICAL|AK101|an anti-IL-12/23p40 monoclonal antibody
223891364|NCT04173637|BIOLOGICAL|Placebo|matching placebo
223891365|NCT04969419|OTHER|Exposure of skin cancer of interest|Melanoma and nonmelanoma skin cancers: squamous cell carcinoma, basal cell carcinoma and actinic keratoses.
223891366|NCT03363711|OTHER|AYA STEPS|a mobile health application
223891367|NCT00200200|DRUG|Bevacizumab HAI plus systemic chemotherapy|Oxaliplatin (mg/m2) IV, over 2 hours, 5 FU (mg/m2) continuous infusion, over two days, leucovorin (mg/m2) IV, over 2 hours
223891368|NCT00200200|DRUG|HAI plus systemic chemotherapy|Irinotecan (mg/m2) IV, over 30 minutes, 5 FU (mg/m2) continuous infusion over two days, leucovorin (mg/m2) IV, over 30 minutes
223891369|NCT03772743|OTHER|Culprit-only revascularization|Implantation of drug eluting stents with biodegradable polymer with struts ≤65 μ in the culprit lesion of the MI. Each patient should receive revascularization with Supraflex stent or its newer versions
223891370|NCT03772743|OTHER|Complete functionally-guided revascularization|Implantation of drug eluting stents with biodegradable polymer with struts ≤65 μ in the culprit lesion of the MI and in all non culprit lesions with positive functional assessment. Each patient should receive revascularization with Supraflex stent or its newer versions
223891371|NCT05625217|DIAGNOSTIC_TEST|Total Body PET/CT Imagin|Total-body PET imaging at different timepoints
223891372|NCT05081713|BEHAVIORAL|high-intensity training focused on stepping in variable contexts|Approximately 10 weeks (\~30 sessions) of high-intensity training
223891373|NCT06188286|OTHER|Transcutaneous electrical acupoint stimulation|The 4 patches of the transcutaneous acupoint electrical stimulator were pasted on two pairs of acupuncture points, the output frequency was adjusted to 2Hz, the intensity was up to 50ma, the single intervention time was 30 minutes, and another group of acupuncture points was replaced after completion, and the rest of the operations were the same as above, with a total intervention time of 1 hour.
223891374|NCT06188286|OTHER|sham Transcutaneous electrical acupoint stimulation|The patch is fixed on the acupuncture point to turn on the instrument, but there is no current output
223891375|NCT05462613|OTHER|quality of life questionnaires|EORTC QLQ-C30 questionnaire (Quality of life questionnaire- Cancer 30) CR29 questionnaire (Colo-rectal cancer 29) EQ-5D3L questionnaire (EuroQol-5 Dimensions, 3 levels)
223891376|NCT05462613|PROCEDURE|Blood sample|Blood sample for plasma collection Blood sample for ctDNA (circulating tumoral DNA) collection
223891377|NCT05462613|DRUG|Regorafenib|"\- Regorafenib will be administered 3 weeks out of 4 for two months or unacceptable toxicity.~* For the first cycle: regorafenib will be administered according to the REDOS schedule (80 mg daily for week 1, 120 mg daily for week 2 and 160 mg daily for the third week of the first cycle).~* For the second cycle: regorafenib will be administered at 160mg in the absence of significant toxicity during cycle 1 or at a 80/120mg daily dose according to toxicity observed with the last dose used in the first cycle."
223891378|NCT05462613|DRUG|Metronomic chemotherapies|"* Capecitabine: 625mg/m²/orally twice daily continuously during the first two months~* Cyclophosphamide: 50 mg per os, daily, for two months"
223891379|NCT05462613|DRUG|Aspirin|75 mg orally and daily during two months
223891380|NCT05462613|DRUG|Bevacizumab|5 mg/Kg every 2 weeks according to investigator practice, until disease progression or unacceptable toxicity
223891381|NCT05462613|DRUG|FOLFIRI or FOLFOX|every 2 weeks according to investigator practice
223891382|NCT03378102|BIOLOGICAL|IFN-gamma-secreting HAdV antigen specific T cells|Antigen selected cells will be obtained using the CliniMACS(R) Prodigy System from a compatible donor. Isolated cells will be infused into the donor to treat human adenoviral infection after transplant
223891383|NCT05390762|OTHER|Common phase|A common face to face day hospital combining physical therapies with psychotherapeutic support such as Cognitive Behavioral Therapy to combat kinesiophobia.
223891384|NCT05390762|OTHER|Telecare rehabilitation|A Second phase of 5 weeks of telecare rehabilitation of the reconditioning type of 15 sessions.
223891385|NCT05390762|OTHER|Care in Face to Face|A Second phase of 5 weeks of care in face to face day hospital of the reconditioning type of 15 sessions.
223891386|NCT06405490|DRUG|Nanoliposomal Irinotecan+Oxaliplatin +Capecitabine+Cadonilimab|Use the above medications on a regular basis
223891387|NCT05672225|DRUG|Dexmedetomidine|Dexmedetomidine 0.2mcg/kg/hr (2ml/hr) administration via continuous channel in the experimental group
223891388|NCT05672225|DRUG|Control|Normal saline 2ml/hr administration via continuous channel in the experimental group
223891389|NCT04363515|BEHAVIORAL|Social support network counseling intervention|Pilot social support counseling intervention for kidney transplant candidates along with their social support networks
223891390|NCT04806594|DEVICE|Papix acne scar|PapiX acne scar, class IIa medical device, gel for acne scar. to be applied 2 times per day during the 8 weeks of study duration
223891391|NCT03270111|BEHAVIORAL|Supervised Exercise|Participants will take part in supervised exercise activities two times per week at a YMCA. Length of the activity will be increased during participation in study. Participants will start at 40 minutes per week and work their way up to 120 minutes per week.
223891392|NCT03270111|BEHAVIORAL|Home-based Exercise|Aerobic exercise activities to be completed at home. Participants will be asked to start out doing 60 minutes at home and work up to 180 minutes of purposeful aerobic home exercise per week.
223891393|NCT03270111|BEHAVIORAL|Reduced Energy Diet|Diet is a nutritionally balanced, reduced energy diet recommended by the Academy of Nutrition and Dietetics.
223891394|NCT03270111|BEHAVIORAL|Group Phone Calls|Sessions are weekly months 1-3 and every other week months 4-6. The calls will discuss lifestyle changes specific to participants and cover the effects of diet, physical activity, and weight on breast cancer risk, as well as body image and emotional eating.
223891395|NCT02543281|DEVICE|Adaptive cardiac resynchronization therapy|The adaptive cardiac resynchronization therapy (aCRT) algorithm works by sometimes giving stimulation to only the left side of the heart, rather than to both sides, depending on how it senses the heart is functioning.
223891396|NCT02543281|DEVICE|Conventional Cardiac Resynchronization Therapy|CRT without the adaptive algorithm works by giving stimulation to both sides of the heart.
223891397|NCT06139211|BIOLOGICAL|JS015|JS015 will be administered intravenously (IV) on days 1 and 15 every 28 day cycle, or day 1 every 21 day cycle, based on different combined chemotherapy.
223891398|NCT06139211|BIOLOGICAL|Toripalimab|Toripalimab will be administered intravenously (IV) on day 1 every 21 day cycle.
223891399|NCT06139211|BIOLOGICAL|Paclitaxel|Paclitaxel will be administered intravenously (IV) on day 1 every 21 day cycle.
223891400|NCT06139211|DRUG|Irinotecan|Irinotecan will be administered intravenously (IV) on days 1 and 15 every 28 day cycle.
223891401|NCT06139211|DRUG|Capecitabine|Capecitabin will be administered orally twice daily from day 1 to 14 every 21 day cycle.
223891402|NCT06139211|DRUG|Oxaliplatin|Oxaliplatin will be administered intravenously (IV) on day 1 every 21 day cycle.
223891403|NCT06139211|BIOLOGICAL|Bevacizumab|Bevacizumab of 5mg/kg will be administered intravenously (IV) on days 1 and 15 every 28 day cycle, or7.5mg/kg on day 1 every 21 day cycle, based on different combined chemotherapy.
223891404|NCT06139211|DRUG|Fluorouracil|Fluorouracil will be administered intravenously (IV) on days 1 and 15 every 28 day cycle.
223891405|NCT06139211|DRUG|Leucovorin|Leucovorin will be administered intravenously (IV) on days 1 and 15 every 28 day cycle.
223891406|NCT06139211|DRUG|Gemcitabine|Gemcitabine will be administered intravenously (IV) on days 1 and 8 every 21 day cycle.
223891407|NCT06139211|DRUG|Albumin-Bound Paclitaxel|Albumin-bound paclitaxel will be administered intravenously (IV) on days 1 and 8 every 21 day cycle.
223891408|NCT05547984|DEVICE|Dual Mobility Cup|Total hip arthroplasty (THA) is a successful and established therapy for coxarthrosis, rheumatic arthritis, hip fractures and femoral head necrosis. The acetabular implant for this arm is the Dual Mobility cup
223891409|NCT05547984|DEVICE|Standard Acetabular component|Total hip arthroplasty (THA) is a successful and established therapy for coxarthrosis, rheumatic arthritis, hip fractures and femoral head necrosis. The acetabular implant for this arm is the standard device with polyethylene + vitamin E inlay and metal head
223891410|NCT06163547|RADIATION|MMA embolization|Middle meningeal artery embolization
223891411|NCT05091593|BEHAVIORAL|Stepped collaborative care intervention|Using website that was specifically designed for advanced cancer patient, collaborative with treatment from health professional.
223891412|NCT05091593|BEHAVIORAL|Enhanced Usual Care|Usual care from health providers
223891413|NCT04318548|COMBINATION_PRODUCT|Meningococcal Group B Vaccine (GSK3536829A) (rMenB+OMV NZ)|1 dose of rMenB+OMV administered intramuscularly at day 1 and 61 to participants in MenB+MenACWY group and MenB group and as 1 dose at day 91 to participants in MenACWY group.
223891414|NCT04318548|BIOLOGICAL|Meningococcal MenACWY Conjugate Vaccine (GSK3536820A) (MenA lyo + MenCWY liquid)|1 dose of MenACWY administered intramuscularly at day 1 to participants in MenB+MenACWY group and MenACWY group, 1 dose at day 91 to participants for MenB group.
223891415|NCT04318548|COMBINATION_PRODUCT|Placebo|1 dose of Placebo administered intramuscularly at 1 to participants in MenB group and MenACWY group and as 1 dose at day 91 to participants in MenB+MenACWY group.
223891416|NCT05247489|DRUG|Ruxolitinib 1.5% cream|Ruxolitinib cream 1.5% applied twice a day (BID).
223891417|NCT05247489|DEVICE|NB-UVB phototherapy|NB-UVB (311-312 nm) phototherapy is an established treatment modality for vitiligo. Starting dose will be 200 mJ/cm2 and dose may be increased by 10% at each visit
223891418|NCT03771898|DRUG|SHP611|Participants will receive 150 mg of SHP611 IT via IDDD or LP once weekly for 106 weeks.
223891419|NCT03467360|DRUG|acetazolamide in combination with platinum and etoposide-based radiochemotherapy|Radiation therapy will be combined with platinum and etoposide-based chemotherapy combined with 3-6 tablets per day of acetazolamide during the entire course of therapy (dosage appropriate to the inclusion phase).
223891420|NCT03467360|DRUG|acetazolamide in combination with radioimmunotherapy in patients with extensive SCLC|acetazolamide in combination with radioimmunotherapy in patients with extensive SCLC
223891421|NCT05515367|DRUG|Desidustat|Oral tablet
223891422|NCT02649959|DRUG|CM-AT|Single unit does powder of active substance (CM-AT) administered 3 times per day
223891423|NCT06015945|DEVICE|Transcutaneous Electrical Acustimulation (TEA)|"The severity and frequency participants pain will be measured during a run-in period of 2 weeks with to assess baseline pain severity and frequency. Eligible participants will have a 4-week treatment period at home. Stimulation with the TEA device will be performed for 30 minutes twice per day, in the morning and in the evening.~In addition to using the device, participants will have study visits, complete surveys, as well as provide medical information during the study."
223891424|NCT05257135|BIOLOGICAL|Biological collection|\- Blood samples collected at different times: at inclusion and during treatment ( every 6 month)
223891425|NCT05761756|BEHAVIORAL|Sleep Deprivation|24 hours sleep deprivation
223891426|NCT05761756|DRUG|Caffeine|Oral administration of caffeine
223891427|NCT05761756|DRUG|Methylphenidate|Oral administration of methylphenidate
223891428|NCT05761756|DRUG|Carbon Dioxide|Oral administration of sodium bicarbonate to simulate carbon dioxide exposure
223891429|NCT04418479|DRUG|Aspirin|"Randomization will be performed 1:1 between clopidogrel and aspirin monotherapy in patients who completed standard duration of dual antiplatelet therapy (DAPT) and who were at high risk for recurrent ischemic events after percutaneous coronary intervention (PCI) with drug-eluting stent (DES).~This group will be taken aspirin 100 mg once daily during the study period."
223891430|NCT04418479|DRUG|Clopidogrel|"Randomization will be performed 1:1 between clopidogrel and aspirin monotherapy in patients who completed standard duration of dual antiplatelet therapy (DAPT) and who were at high risk for recurrent ischemic events after percutaneous coronary intervention (PCI) with drug-eluting stent (DES).~This group will be taken clopidogrel 75 mg once daily during the study period."
223891431|NCT05708833|DEVICE|Intraosseous venous access|Immediate placement of humeral intra-osseous venous access (after a first failed attempt of peripheral venous access)
223891432|NCT05708833|DEVICE|Peripheral venous access|Looking for peripheral venous access, changing the site of puncture, the caliber of the catheter and/or the operator and/or assistance tools (ultrasound, infra-red guidance...) and/or using another route (oral, rectal, subcutaneous, intramuscular route and central venous access)
223891433|NCT05026541|BEHAVIORAL|Nap Practitioners|Regular nappers will be given a 30 minute nap opportunity to nap for as long as they please.
223891434|NCT05026541|BEHAVIORAL|Shoonya Meditation|This is a 15 minute meditation, described as a process of conscious non-doing.
223891435|NCT05021419|OTHER|Streamlined protocol|A streamlined drug protocol for optimizing heart failure medication
223891436|NCT05021419|OTHER|Standard Protocol|Current standard optimization protocol as per NICE and ESC
223891437|NCT05316740|OTHER|No intervention|Repeated clinical evaluation and sample collection
223891438|NCT04541706|DRUG|Lorlatinib|Lorlatinib will be supplied for oral administration as 25 mg tablets. The recommended dosage of lorlatinib is 100 mg orally once daily.
223891439|NCT05704621|PROCEDURE|secondary cytoreductive surgery|Maximum effort cytoreductive surgery
223891440|NCT05704621|DRUG|chemotherapy|six cycles of platinum-based chemotherapy +/- bevacizumab
223891441|NCT03364530|DRUG|Gemcitabine-Oxaliplatin Regimen|"Vascularisation of hepatic tumors is almost exclusively provided by the hepatic artery.~Gemcitabine and oxaliplatin have a high rate of hepatic extraction during the first passage, thus allowing the drugs to reach high intra-tumoral concentrations with low systemic toxicity."
223891442|NCT03364530|PROCEDURE|Hepatic intra arterial chemotherapy|"The implantation of a hepatic arterial catheter has now been mastered by interventional radiologists and makes it possible to increase the intra-tumoral concentration of the drugs and probably to limit their systemic toxicity.~Very recently, we have reported that this combination in progressive IHC following systemic gemcitabine/oxaliplatin has led to partial responses and allowed certain patients to benefit from curative treatment.~This suggests that the intra-arterial approach increases the efficacy of these 2 drugs. For locally-advanced IHC, such a loco-regional approach is worth exploring in this poor-prognosis tumor."
223891443|NCT06796439|OTHER|Static stretching|"Participants will be divided into two groups with sample size of 52 participants in each group.~Group 1: Participants will perform static Stretching protocols. There were no special warm-up exercises (running and skipping) after the implementation of static stretching exercises. After the general warm-up, participants would engage in a sequence of randomized static stretches including Lower back stretch, Quads stretch, Hams Stretch, Calf Stretch and Upper limb Stretches (biceps, Triceps, Arm across chest, Arm pull and head tilt, Side stretch, backward arm stretch, Pect. stretch and Towel Stretch). All stretches were done as 3 sets of 30 seconds for 20 minutes for 5 days per week and held at the point of mild discomfort. Readings will be taken after 1st, 3rd and 6th week, respectively.~Group 2: Participants will perform Dynamic Stretching protocols. There were no special warm-up exercises (running and skipping) after the implementation of dynamic stretching exercises. Participants wou"
223891444|NCT06796439|OTHER|Dynamic Stretching|Group 2: Participants will perform Dynamic Stretching protocols. There were no special warm-up exercises (running and skipping) after the implementation of dynamic stretching exercises. Participants would engage in a sequence of randomized static stretches including Jumping Jacks, Lunges, Trunk Circles, arm swings and butt Kicks. All stretches were done as 3 sets of 30 seconds for 20mins for 5 days per week and held at the point of mild discomfort. Readings will be taken after 1st, 3rd and 6th week, respectively.
223891445|NCT03034811|DEVICE|Persona Partial Knee system|Fixed bearing partial knee
223891446|NCT06476002|OTHER|Questionnaire|Completion of translated VPAQscreen, VPAQdesc, VPAQcope and VPAQpartner questionnaires by patients, followed by assessment of comprehension of the various items.
223891447|NCT05886335|DRUG|Cyclophosphamide|Time of administration
223891448|NCT06495008|OTHER|no intervention, only questionnaires, saliva collection and taste/smell tests|no intervention, only questionnaires, saliva collection and taste/smell tests
223891449|NCT05534620|DRUG|Treosulfan|IV infusion
223891450|NCT05534620|DRUG|Fludarabine|IV infusion
223891451|NCT02987530|DRUG|Dolutegravir|Oral use, 50mg/day
223891452|NCT02987530|DRUG|Darunavir-cobicistat|Oral use, 800-150mg/day
223891453|NCT02987530|DRUG|Emtricitabine-Tenofovir|Oral use, Emtricititabine : 200mg/day Ténofovir : 245mg
223891454|NCT04726501|OTHER|Combined chemotherapy with or without involved-field radiotherapy|Patients in low risk group receive 4 cycles of AVE-PC with or without involved-field radiotherapy (IFRT). Patients in intermediate risk group4 cycles ABVE-PC with or without IFRT. RERs in high risk group receive 4 cycles of ABVE-PC followed by followed by IFRT. SERs in high risk group receive 2 cycles of ABVE-PC followed by 2 cycles of IFOS/VINO and 2 cycles of ABVE-PC then followed by IFRT. IFRT consists of 21 Gy in 14 fractions of 1.5 Gy per day and is scheduled within 4 weeks after chemotherapy.
223891455|NCT06564701|DEVICE|Phonak Roger TouchScreen Microphone|Transmitter microphone system operating on the 2.4 GHz band, which allows for low-delay and reliable long-range broadcast to a compatible Roger receiver, designed to be used in educational settings. It features six microphones and adaptive technology in which speech signals are increased when background noise increases to ensure that the speech signal is always above the noise level.
223891456|NCT06564701|DEVICE|Phonak Partner Mic|Wireless microphone that uses Phonak proprietary AirStream technology to connect to Phonak hearing aids. It uses a fixed directional microphone, and is paired to the hearing aids such that the hearing aid microphones are attenuated at a fixed level when the microphone is in use.
223891457|NCT00781690|DEVICE|Evodial hemodialysers and Evodia blood lines|Maximum 8 weeks treatment with Evodial dialysers with reduction of heparin dose
223891458|NCT06317220|BIOLOGICAL|Vedolizumab|Administered over 30 minute infusion at MGH main campus
223891459|NCT04747431|DRUG|PBFT02|PBFT02
223891460|NCT04712851|BIOLOGICAL|Pembrolizumab|Given IV
223891461|NCT05152927|DEVICE|Parathyroid Eye (PTeye)|Intraoperative Tool
223891462|NCT05664841|BEHAVIORAL|magic trick training|A typical session will begin with the magician demonstrating a magic trick then revealing the secret move of the trick.The participants will learn and practice each trick. With assistance from the magician, participants will develop an oralstory presentation for the trick. After participants master one trick, the magician will demonstrate and teach the next.
223891463|NCT05919680|DRUG|NST-6179 Part A|Once daily (QD) oral administration of 800mg (32 mL solution) of NST-6179 for 4 weeks
223891464|NCT05919680|DRUG|NST-6179 Part B|Once daily (QD) oral administration of 1200mg of NST-6179 for 12 weeks
223891465|NCT05919680|OTHER|Matched Placebo|Matched placebo for administration in Part A or Part B
223891466|NCT06123299|DEVICE|pHyph|vaginal tablet
223891467|NCT05882266|DIETARY_SUPPLEMENT|Plant Omega|A commercial plant-based omega-3 beverage consumed once daily during breakfast
223891468|NCT05882266|OTHER|Dietary therapy only|Standard dietary therapy
223891469|NCT06637891|OTHER|Mandala coloring|Participants will be asked to choose the pages they want from 12 colored felt-tip pen paint sets and 16 mandala coloring pages given to each participant by the researcher for 2 weeks, 3 days a week, at any time of the day and for an average of 20-30 minutes each time, and paint them in the colors they want.
223891470|NCT05563246|DRUG|LY3473329|Administered orally
223891471|NCT05563246|DRUG|Placebo|Administered orally
223891472|NCT05471414|BEHAVIORAL|Whole-food, Plant-Based Diet|Pre-packaged, freshly made plant-based meals (provided by either Plantable or CookUnity) will be delivered weekly to participants' homes for 8 weeks. Meals are made with whole ingredients including whole grains, vegetables, legumes, nuts and seeds. Added sugar, animal-based products, refined grains, and processed foods are not used in any meal. Participants will be coached via phone calls, SMS, emails, and the app throughout the intervention to prepare meals in accordance with the diet. Participants will have access to a Registered Dietitian. During the first 4 weeks, 12 meals/week will be provided to participants; followed by 6 meals/week for the next 4 weeks; followed by 18 weeks where participants will continue to receive coaching, but will be expected to make all their own whole-food, plant-based meals with staff assistance available.
223891473|NCT05471414|BEHAVIORAL|General Nutritional Counseling|"All study participants will receive consult with a Registered Dietitian at the Baseline visit and visit 1 study assessments. After visit 1, study participants assigned to the general nutritional counseling arm will receive an additional in-person or telehealth consultation with a Registered Dietitian that will consist of identification and counseling to improve diet quality and achieve a healthy body weight consistent with American Cancer Society guidelines.~Study participants in the control group will continue to receive general nutritional counseling and education with weekly scheduled telephone consultations with a Registered Dietitian for the first 4 weeks of the study period. For the remainder of the study period, they will receive counseling and education from Registered Dietitians via monthly scheduled phone calls."
223891474|NCT05651399|DRUG|Remimazolam|Patients receive remimazolam at a rate of 1 mg/kg/hr. When a patient's MOAA/S reaches 3 or less, the rate of remomazolam is maintained at a rate between 0.3 mg/kr/hr and 1.0 mg/kg/hr until the end of surgery.
223891475|NCT05651399|DRUG|Propofol|Patients are administered propofol with an effect-site concentration of 1.0 mcg/mL to 2.5 mcg/mL by target controlled infusion.
223891476|NCT02167867|DEVICE|Lay End Users|Lay End Users administer 40 minutes of treatment with the ZERONA Z6 to the waist, hips and thighs (20 minutes to the front side and 20 minutes to the back side) of a Treatment Subject, 6 times evenly spaced across two consecutive weeks.
223891477|NCT02167867|DEVICE|Treatment Subject Group|Treatment subject received 6 40-minute evenly spaced treatments to the hips, waist and thighs (20 minutes to the front side and 20 minutes to the back side) with the ZERONA Z6 over 2 consecutive weeks. The ZERONA Z6 contains 6 17.25 milliWatts (mW) 635 nanometers (nm) laser diodes.
223891478|NCT05607498|DRUG|EMB07|EMB07 is a MAT-Fab bispecific antibody against CD3 and RORI
223891479|NCT04882449|DEVICE|Bodyport Cardiac Scale|The Bodyport Cardiac Scale is capable of measuring key HF parameters of congestion and cardiac perfusion on a regular basis in a patient's home. These data will be combined into a composite index that may be used to identify patients at increased risk for decompensation, inform the reason for their decline, and offer the possibility to remotely optimize therapy to prevent further worsening HF.
223891480|NCT06431295|DEVICE|FaceScan|"Digital visual acuity device built for iOS (iPhone) that conducts an assessment of visual acuity using a combination of integrated light detection and ranging (LiDAR) and voice processing."
223891481|NCT05589701|RADIATION|Radiotherapy|Standard of care radiotherapy administered as per institutional guidelines.
223891482|NCT06093191|DRUG|Tobramycin Inhalant Product|Tobramycin will be nebulized (300mg twice daily) with an ultrasonic nebulizer. A total of 12 weeks therapy will be scheduled.
223891483|NCT06093191|DRUG|Ciprofloxacin 750 MG|Oral ciprofloxacin 750mg twice daily will be prescribed for 2 weeks.
223891484|NCT06093191|DRUG|Oral ciprofloxacin placebo|Oral ciprofloxacin placebo twice daily will be prescribed for 2 weeks.
223891485|NCT06093191|DRUG|Natural saline inhalation|Natural saline will be nebulized (5ml twice daily) with an ultrasonic nebulizer. A total of 12 weeks therapy will be scheduled.
223891486|NCT06280989|OTHER|kinesio taping|"Before treatment, all female participants will undergo an allergic test on the anterior surface of the elbow.~To ensure cleanliness, alcohol will be used to clean the areas to be evaluated before applying the tape. The H technique will be employed to apply KT over the lumbar region. Participants will be instructed to bend forwards from the waist, and two vertical strips will be applied. These strips will stretch the Golgi tendon organ on both sides of the spine from the top of the buttock cleft upwards to a mid-point, with less than 25% stretch .~Additionally, a horizontal strip will be attached across the left and right sacroiliac joints. This strip will be stretched to 50% of its maximum capacity,."
223891487|NCT06280989|OTHER|myofascial release technique|"myofascial release technique will be applied from prone on lumbar paravertebral muscles by using the olecranon of the physical therapist for 3 minutes, thoracolumbar fascia by using cross-handed hold, with hands placed on the T12-L1 levels and on the sacrum for 5 minutes without repetition and quadratus lumborum by using elbow with low pressure obliquely towards the center of the column for 7 min.~Additionally, from supine on psoas muscle by transversal sliding of the psoas fascia. The therapist will place the hands laterally 3 cm from the umbilicus."
223891488|NCT06427980|DRUG|Chinese Herbal formula HuoXue LiShui|The intervention consists of the oral administration of granule with either HXLS or a placebo substance, one bag (28.5 g) twice daily after meals for a period of 8 weeks. The granules are produced from four Chinese herbal pieces: Yi Mu Cao (Leonuri Herbal, 15.0g), Zhi Shui Zhi (Hirudo, 1.5g), Tao Ren (Semen persicae, 6.0g), and Hong Hua (Carthami Flos, 6.0g).
223891489|NCT06427980|DRUG|Chinese Herbal formula Placebo|The placebo will be consistent with the HXLS oral granules in appearance, taste, and weight, to the greatest extent possible. In terms of outer packing, the HXLS and placebo granules will be exactly the same. It included Hu Jing (28.5g)
223891490|NCT06641232|PROCEDURE|Comparison of anesthetic efficacy and safety between nerve block and infiltrative technique for mandibular posterior implant placement.|"The surgeon and his assistant will leave the operating room and the study investigator in charge of anesthetizing the patients (XA) will enter.~The anesthesia will be performed by an investigator other than the surgeon performing the procedure. The patient will be assigned to a treatment group; patients in the control group will undergo vestibular and lingual infiltration, while the experimental group will undergo inferior dental nerve block together with buccal nerve block."
223891491|NCT06639256|DRUG|Test Product HY07121|HY07121 should be administered intravenously at recommended dose.
223891492|NCT05537727|DEVICE|robotic-assisted surgery|Gynecology: robot-assisted and laparoscopic hysterectomy for benign or low risk malignant disease
223891493|NCT05537727|DEVICE|robotic-assisted surgery|Urology: robot-assisted and laparoscopic partial nephrectomy
223891494|NCT05537727|DEVICE|robotic-assisted surgery|General surgery: robot-assisted and laparoscopic right colectomy
223891495|NCT01416831|OTHER|Radiation therapy and high-dose IL-2|Patients 1 - 20 will receive a single fraction of radiation. Patients 21 through the completion of the study will receive two fractions. The dose for all patients will be 20 Gy per fraction to the prescription line at the edge of the planning treatment volume (PTV) with the last dose delivered on a Friday before IL-2 administration. For patients receiving two radiation doses, the doses can be administered on the Wednesday and Friday before IL-2 starts. Patients who are assigned to IL-2 monotherapy and have progressive disease after two IL-2 cycles are then eligible to receive SBRT before cycle 3 of IL-2 commences, single fraction for patients 1-20 and two fractions for patients 21- end of study.
223891496|NCT01416831|DRUG|High-dose IL-2|IL-2 will be given on a Monday at a dose of 600,000 IU per kilogram IV every 8 hours for up to 14 doses each cycle. The second cycle is planned 16 days after cycle 1 but may be delayed up to one week to allow toxicity to resolve. The maximum number of doses that can be given during two cycles will be 28 doses. Patients who respond after two cycles can receive 4 more cycles of IL-2. Patients with disease progression after 2 cycles may elect to receive radiation before a 3rd cycle of IL-2. If patients crossover, IL-2 will be given on the Monday following the last dose of radiation, at a dose of 600,000 IU per kilogram IV every 8 hours for a maximum of 14 doses each cycle. Another cycle is planned 16 days after cycle 3 but may be delayed up to one week to allow toxicity to resolve.
223891497|NCT04913220|DRUG|THOR-707|Solution for infusion: intravenous infusion
223891498|NCT04913220|DRUG|Cemiplimab|Solution for infusion: intravenous infusion
223891499|NCT06507956|OTHER|Characterize the physical activity and sedentary lifestyle profile of adults with cystic fibrosis|Eligible patients will be presented with the study during a routine care visit CF center, at the end of a physiotherapy, adapted physical activity or nurse session, in accordance with the schedule for the day's visit, with no changes induced by this study. After sufficient time for reflection, patients agreeing to participate will be given self-questionnaires. From this visit, a proposal to participate at V2 will be made only to the inactive and/or hight sedentary patients on the ONAPS-PAQ questionnaire, under elexacaftor-tezacaftor-ivacaftor (ETI). Volunteers will know their participation in either actimetry or a qualitative interview following a draw. At V2, 40 patients will be offered a 7-day longitudinal follow-up by actimetry, and between 10 to 15 patients will take part in an qualitative semi-structured interview identifying motivational barriers and levers for action. At V3, patients monitored by actimetry will be invited to return their actimeter by postage-paid mail.
223891500|NCT05215314|BEHAVIORAL|mHealth Meditation|Participants will receive access to the 4-week Healthy Minds Program (HMP) Foundations module. The HMP app is a meditation-based smartphone app designed to promote and protect psychological well-being through sustainable skills training. The program is grounded in constituents of psychological well-being identified in empirical literature. HMP provides core content, with instruction administered through a curriculum of guided practices. HMP is based on research on eudaimonic well-being (e.g., environmental mastery, purpose) and brain-based skills that underlie these qualities (e.g., regulation of attention, mental flexibility). The full HMP has guided audio practices that address 4 constituents of well-being: awareness, connection, insight, and purpose. At post-treatment, participants will be given access to additional HMP content to support their continued practice.
223891501|NCT04784559|DRUG|Plitidepsin|"Plitidepsin 2 mg powder is provided as a sterile, preservative-free, and white to off-white lyophilised powder/cake comprising 2 mg plitidepsin and mannitol in a single-dose, 10 mL clear type 1 glass vial.~Solvent for plitidepsin is provided as a sterile, preservative-free, clear, slightly viscous aqueous liquid (4 mL) containing macrogolglycerol ricinoleate and ethanol in a single-dose type 1 clear glass ampoule.~For administration, vial contents are reconstituted by addition of 4 mL of solvent for plitidepsin to obtain a slightly yellowish solution containing 0.5 mg/mL plitidepsin with mannitol, macrogolglycerol ricinoleate and ethanol excipients. The required amount of plitidepsin reconstituted solution is added to bag containing 0.9% sodium chloride or 5% glucose for IV injection and administered as an IV infusion over 60 minutes."
223891502|NCT04784559|DRUG|Dexamethasone|Detailed information about the formulation, posology, packaging and labelling, storage, and manufacturer is provided in the current country-specific product information. The summary of product characteristics (SmPC) and/or leaflet provides detailed product information for investigators in the European Union and/or in other regions.
223891503|NCT04784559|DRUG|Remdesivir|Detailed information about the formulation, posology, packaging and labelling, storage, and manufacturer is provided in the current country-specific product information. The summary of product characteristics (SmPC) and/or leaflet provides detailed product information for investigators in the European Union and/or in other regions.
223891504|NCT04784559|DRUG|Favipiravir|Detailed information about the formulation, posology, packaging and labelling, storage, and manufacturer is provided in the current country-specific product information. The summary of product characteristics (SmPC) and/or leaflet provides detailed product information for investigators in the European Union and/or in other regions.
223891505|NCT06107582|OTHER|data collection|The study will collect basic information, diagnostic and treatment information from medical records and use questionnaire to measure the exposure of patients, and prospectively follow-up to collect the prognosis information.
223891506|NCT04974008|DRUG|OST31-164|Patients who will receive OST31-164 as a single agent every 3 weeks for 48 weeks with 4 doses constituting 1 treatment cycle (12 weeks per cycle). Each patient will receive treatment at a dose of 1x109 CFU until week 48 or until disease progression, unacceptable toxicity, or the patient meets any other treatment discontinuation criteria.
223891507|NCT05844111|DRUG|[14C]-BGB-11417|A single oral dose of liquid formulation
223891508|NCT05016271|BEHAVIORAL|Air purifier and fresh air ventilation systems with high-efficiency particulate air (HEPA) filters|This group will receive an intervention of true air purifiers. The air purifiers in classroom (air purifiers and fresh air ventilation systems with HEPA filters) will operate during the school time and the air purifiers in bedrooms (air purifiers with HEPA filters) operate during the home time in the intervention period (4 months anticipated).
223891509|NCT05016271|BEHAVIORAL|Air purifier and fresh air ventilation systems without high-efficiency particulate air (HEPA) filters|This group will receive an intervention of sham air purifiers. The air purifiers in classroom (air purifiers and fresh air ventilation systems without HEPA filters) will operate during the school time and the air purifiers in bedrooms (air purifiers without HEPA filters) operate during the home time in the intervention period (4 months anticipated).
223891510|NCT05607108|DRUG|ZEN003694|ZEN003694 60mg po qd on a 5 days on 2 days off schedule in an every 21-day cycle
223891511|NCT06258005|DIAGNOSTIC_TEST|PocDoc|PocDoc is a digital rapid 5-marker lipid test
223891512|NCT02565069|DEVICE|CartoFinder™ Device with CARTO® 3 System V5 Navigation|Ablation treatment
223891513|NCT06822478|DRUG|Arnica Tincture|Arnika tincture is a topical plant-based preparation legally authorized in Colombia and in the countries of the European community, the product of this study is Arnika tinktur Gehrlicher (5249), manufactured by Gehrlicher Pharmazeutische Extrakte GmbH, Germany. According to the European Pharmacopoeia, the solution is a 70% hydroethanolic tincture prepared from the flowers of A. montana L, and composed at least 0.04% of sesquiterpene lactones. Arnica tincture will be applied topically by each participant on all lesions until day 30.
223891514|NCT06822478|DRUG|Meglumine antimoniate.|"Monotherapy with intralesional pentavalent antimonials is one of the treatments of care used for LC in Colombia and will be used as a comparator for safety evaluation.~Pentavalent antimonials: administered intralesionally. At a dose of 0.008 ml X mm of area of each lesion, maximum 15 ml in total, once a week for 5 weeks."
223891515|NCT05515198|OTHER|Patient Education|Patients will be provided educational opportunities.
223891516|NCT05515198|OTHER|Nurse Navigation|A nurse navigator will work with the participants to help them navigate the care pathway. The navigator will provide education and recommendations for treatment options.
223891517|NCT05515198|OTHER|ChatBot|"A ChatBot will allow participants to directly and privately communicate through a smartphone (or other device) with an artificial intelligence-driven ChatBot, also known as a conversational agent, that will provide education and encouragement to manage their symptoms."
223891518|NCT03181763|DRUG|Placebo|Participants will receive inactive placebo on their second visit.
223891519|NCT03181763|DRUG|Midomafetamine|Participants will receive 100 mg midomafetamine HCl on their second visit
223891520|NCT03181763|BEHAVIORAL|Acoustic startle|Startle assessment
223891521|NCT03420833|DEVICE|Cardiac resynchronization therapy pacemaker (CRT-P)|A pacemaker is an implantable, battery-powered minicomputer that sends electrical pulses to the heart whenever it detects a slow heartbeat or no heartbeat at all. When it senses a slow heartbeat or lack of heartbeat, it sends electrical impulses to restore a normal rhythm. Cardiac resynchronization therapy pacemakers, or CRT-Ps, treat heart failure by resynchronizing electrical impulses in the heart's four chambers, improving the heart's ability to pump blood to the body effectively and efficiently.
223891522|NCT05309629|DRUG|QL1706|Intravenous infusions of QL1706 5mg/kg on Day 1 of every 21-day cycle.
223891523|NCT05309629|DRUG|Carboplatin|Carboplatin intravenous infusion to achieve an initial target AUC of 5 mg/mL/min was administered on Day 1 of each 21-day cycle for 4-6 cycles.
223891524|NCT05309629|DRUG|Etoposide|Etoposide intravenous infusion was administered at a dose of 100 mg/m\^2 on Days 1, 2, and 3 of each 21-day cycle for 4-6 cycles.
223891525|NCT05389436|PROCEDURE|Ambulatory care|The surgery is performed in ambulatory setting
223891526|NCT05389436|PROCEDURE|Inpatient care|The surgery is performed during inpatient care
223891527|NCT05350527|OTHER|Consultation of a Web Platform|Patients willing to participate in this research and randomized in the experimental arm will benefit, in addition to standard preoperative medical information, an access to the EDOP internet platform via personalized and secure access codes. They will be able to watch an explanatory video about breast surgery and find all the essential, practical and useful information about their intervention and the postoperative effects for the duration of their follow-up.
223891528|NCT03659760|OTHER|Group Isolated|Eyes closed with patch and ears plugged between 24:00-06:00
223891529|NCT05253664|BEHAVIORAL|Woman-Centered Care Group|Each woman in the experimental group was given woman-centered care as from 2 hours postpartum and this process continued until 24 hours postpartum. Physiological parameters (systolic-diastolic blood pressure, pulse, body temperature) of women assigned either to the experimental group or the control group were measured at 2 hrs postpartum. The State, Trait Anxiety, and Postpartum Comfort Scales were pretested. A dynamic interaction was ensured between the researcher and the women in the experimental group who received woman-centered care. In the processes of determining and meeting the care needs of women in the early postpartum period, both the women and the researcher took equal responsibilities and the common goal of achieving safe results was shared. Clinical guidelines were used while providing woman-centered care.
223891530|NCT06499701|DRUG|Ringer's Lactate|Ringer's Lactate is administered at a dose of 30ml/kg, with the first 20ml/kg given at a constant rate over the initial 30 minutes, followed by a 30-minute pause, and then an additional 10ml/kg over the next 15 minutes, completing the infusion within 75 minutes.
223891531|NCT05376813|PROCEDURE|CT-Scan and MRI|CT-Scan and MRI examination for shoulder will be performed on healthy volunteers.
223891532|NCT03662607|BEHAVIORAL|Virtual reality experience|"* Baseline wellness self-assessment administered (reporting on absence or presence and degree of severity of headache, nausea, dizziness, fatigue and vision abnormalities)~* Seated comfortably and free of direct obstruction~* Shown individual components of the VR system (View-Master with smartphone; headphones); given instructions; encouraged to ask questions.~* Begin the VR experience. Study personnel stay in the room \& provide guidance and answer questions regarding the technology~* When VR experience concluded, wellness self-assessment will be administered again."
223891533|NCT00569049|PROCEDURE|breast tissue, lymph node tissue or blood|Molecular Analyses of samples
223891534|NCT05318066|DRUG|Ringer Lactate and Norepinephrine infusion|"Arm Fluids (FL)- 500 mL of ringer lactate over 10 minute prior to the administration of procedural medications.~Arm Vasopressor (VP)- Patients in this group would receive norepinephrine infusion at a dose of 0.08 μg/kg/min over 10 minutes prior and 5 minutes after tracheal intubation."
223891535|NCT06345170|OTHER|The DIR/Floortime™ Therapy Program|The DIR/Floortime™ therapy program will be applied by the therapist in the clinic for 50 minutes, 2 days a week for 12 weeks
223891536|NCT06345170|OTHER|The Social-Communication Area Developmental Screening Test for Infants and Young Children (SCASI) Training Program|The Social-Communication Area Developmental Screening Test for Infants and Young Children (SCASI) Training Program will be applied by the parents at home, 2 days a week, for an average of 30 minutes a day, for 12 weeks
223891537|NCT04294225|DRUG|Anastrozole|Given PO
223891538|NCT04294225|DRUG|Letrozole|Given PO
223891539|NCT04791709|BEHAVIORAL|Happy Older Latinos are Active (HOLA)|HOLA is a multicomponent health promotion intervention. First component is a one-on-one social and physical activation with the participant and the community health worker (CHW). Each session will last approximately 30 minutes at day 1 and week 8. The second component is a group walk led by a CHW for 45 minutes, 3 times a week, for 16 weeks. The third component consists of scheduling pleasant events at the end of each group walk session.
223891540|NCT06582199|OTHER|Blood sample|Plasma, DNA, RNA and PBMC Sampling
223891541|NCT06582199|BEHAVIORAL|Neuropsychological battery tests|"* Short term memory: Digit span (forward and backward)~* Long term memory: Free and Cued selective reminding Test~* Language and semantic Memory : Verbal Fluency (Category and Litteral), Image Naming (DO 40)~* Praxis~* Visuo Spatial abilities: Rey-Osterrieth Complex Figure Test~* Attention and executive functions: Trail Making Test (TMT) Part A and B, Frontal Assessment Battery (FAB)~* Autonomy in daily life activities : Alzheimer's Disease Cooperative Study - Activities of Daily Living Inventory (ADCS-ADL), Instrumental Activities of Daily Living (IADL)~* Mood and anxiety: Hospital Anxiety and Depression Scale (HADS)~* Cognitive reserve : Cognitive Reserve Index questionnaire (CRIq)"
223891542|NCT05932134|DIETARY_SUPPLEMENT|UC + high protein diet (HP)|The HP groups will maintain unchanged total daily caloric intake and increasing protein content to 1.5g/kg/day.
223891543|NCT05932134|BEHAVIORAL|UC + HP + core muscle rehabilitation|Core muscle rehabilitation is sitting on bedside with or without aids, for 30 minutes, twice per day, 5 days per week, for 3 weeks
223891544|NCT05932134|DEVICE|UC + HP + core muscle rehabilitation + neuromuscular electric stimulation (NMES)|NMES was applied for 30 min, twice per day, 5 days per week, for 3 weeks via surface rectangular electrodes. Electrodes were placed on back designed to activate latissimus dorsi and abdominal wall designed to activate the transversus abdominis and internal and external oblique muscles. Electrical muscle stimulation was performed by using a commercial stimulator (GEMORE, GM300E, Taipei, Taiwan) with biphasic waves at a simulation frequency of 30 Hz and pulse width of 400s, cycling 2s on and 4s off. Electrical muscle stimulation intensity was gradually increased until a visible muscle contraction was observed (median 60 mA \[range 50-65 mA\].
223891545|NCT05927090|PROCEDURE|Conservative Root- Sparing Aortic Valve Resuspension with or without Hemiarch Repair|Cardiac arrest will be performed by administering a potassium-rich antegrade cardioplegia solution delivered directly into the coronary ostium or in the case of aortic regurgitation after insertion of the coronary sinus cannula.The aorta will be resected up to the sinotubular junction and the thrombus located in the false lumen of the aortic root will be removed so that the aortic lesion can be visualized. The commissures will be resuspended using 4-0 or 5-0 sutures reinforced with a Teflon pledget above every commissure. A 4-0 or 5-0 polypropylene suture will be chosen to seal the proximal anastomosis and this suture line will also be used to secure the intima to the adventitia. In patients demonstrating normal-sized aortic roots associated with poor-quality valve leaflets, concomitant aortic valve replacement with conventional xenograft or mechanical prosthesis will be preferable.
223891546|NCT05927090|PROCEDURE|Extensive Ascending Aorta Replacement (AAR) with Aortic Root Replacement (ARR)|Patients who experienced dilatation of the sinuses of Valsalva \> 4.5 cm in diameter on computed tomography imaging, those with connective tissue disease, or those in whom intimal tears extended into the sinuses, will receive replacement of the aortic root using a biologic or mechanical composite valve graft or valve-sparing root reimplantation procedure associated to AAR
223891547|NCT05927090|PROCEDURE|Extensive Ascending Aorta Replacement (AAR) with Total Arch Replacement (TARP)|Total arch replacement procedures (TARP) will performed with the use of deep hypothermic circulatory arrest and with either antegrade or retrograde cerebral perfusion, maintaining systemic cooling between 19°C to 25°C and depending on the surgeon's practice.TARPs will be carried out using 1- and 4-branch grafts and involved the resection of all the aortic tissue up to the left common carotid artery (total arch)
223891548|NCT05927090|PROCEDURE|Extensive Root and Ascending Aorta Replacement with Total Arch Replacement|This extensive procedure will include complete replacement of the anterior thoracic aorta extending to part or all of the aortic arch. It will be performed with the previously reported techniques
223891549|NCT05927090|PROCEDURE|Thoracic Endovascular Aortic Repair|TEVAR patients have a higher incidence of complications and reintervention than open repair patients. TEVAR complications may include endoleak, retrograde type A aortic dissection, stent-graft migration, fracture or collapse, and increased size.
223891550|NCT05927090|PROCEDURE|Open Thoracic Aortic Descendig Repair|Surveillance imaging can detect complications of open repair, such as graft infection and anastomotic pseudoaneurysm. After open repair or TEVAR, patients may develop progressive aneurysmal dilatation of adjacent or remote aortic segments.
223891551|NCT02790502|DEVICE|Food Photography Application©|Group testing RFPM as method of recording plate waste
223891552|NCT05142982|RADIATION|Radiotherapy|A dose of 30-36 Gy in conventional fractionation of 1.8-2.0 Gy per fraction using 3-dimensional conformal technique. Radiotherapy will be delivered five days a week.
223891553|NCT06225479|BEHAVIORAL|Exercise|"An individualized 12-week exercise intervention that will follow American College of Sports Medicine guidelines to ensure a gradual safe increase in frequency and intensity. The exercise goals for participants in the intervention arm are to increase minutes/week of aerobic exercise, build strength and muscle mass, and improve flexibility, core strength, and balance progressively over the course of 12 weeks. The participants are prescribed 3 sessions of aerobic exercise lasting 45-75 minutes each, including warm up and cool down; 2 resistance training sessions per week, and at least 3 flexibility and balance sessions per week.~Intervention arm receives the following: Control arm Successful Aging newsletter plus additional educational materials related to exercise, heart rate monitor and resistance bands, and two 90-minute sessions and ten 30-minute phone sessions over 12 weeks with an exercise coach (the first two sessions include a resistance training session)."
223891554|NCT06225479|OTHER|Calls and Newsletter|"A 12-week remote health education program developed by the study team to provide a control for the exercise intervention. Participants in this arm will receive a summary of the American College of Sports Medicine guidelines (self-directed and time-based), a twice-monthly Successful Aging newsletter with suggestions for health diet, stress reduction, and social engagement, and twice-monthly phone calls to reinforce and discuss topics in the newsletter and to review adverse events and change in medications."
223891555|NCT06788457|DEVICE|Exhaled Breath Condensate|Measurement of hydrogen peroxide in exhaled breath
223891556|NCT06510868|RADIATION|Peptide receptor radionuclide therapy (PRRT)|Specialized type of radionuclide therapy used to treat neuroendocrine tumors.
223891557|NCT06510868|DIAGNOSTIC_TEST|Blood collection|Patients will have approximately 5 ml of blood drawn 6,12,24,36,48, 60 months and at the time of MDS/AML diagnosis on follow up. Genomic DNA will be extracted from serum sample using the Qiagen QIAamp DNA Mini Kit. Single-molecule molecular inversion probes (smMIPs) will be used to detect mutations. Single nucleotide variants (SNVs), short insertions and deletions (indels), and mutated myeloid genes will be captured (e.g PPM1D, DNMT3A, TET2, TP53).
223891558|NCT05950594|RADIATION|Radiotherapy|Standard of care pre-operative radiotherapy
223891559|NCT05950594|OTHER|Surgery|Standard of care definitive surgery
223891560|NCT05781243|DRUG|Lactated Ringer Solution|Patients in the LR (Lactated Ringer solution) treatment arm will receive fluid therapy based on lactated Ringer's solution for a minimum of 48 hours.
223891561|NCT05781243|DRUG|Normal saline|Patients in the NS (Normal Saline) treatment arm will receive fluid therapy based on lactated Ringer's solution for a minimum of 48 hours.
223891562|NCT04442763|DEVICE|Densah Burs|osseodensification method
223891563|NCT04442763|DEVICE|Standard drills|conventional drilling
223891564|NCT04927065|BIOLOGICAL|mRNA-1273.211|Sterile liquid for injection
223891565|NCT04927065|BIOLOGICAL|mRNA-1273|Sterile liquid for injection
223891566|NCT04927065|BIOLOGICAL|mRNA-1273.617.2|Sterile liquid for injection
223891567|NCT04927065|BIOLOGICAL|mRNA-1273.213|Sterile liquid for injection
223891568|NCT04927065|BIOLOGICAL|mRNA-1273.529|Sterile liquid for injection
223891569|NCT04927065|BIOLOGICAL|mRNA-1273.214|Sterile liquid for injection
223891570|NCT04927065|BIOLOGICAL|mRNA-1273.222|Sterile liquid for injection
223891571|NCT04927065|BIOLOGICAL|mRNA-1273.815|Sterile liquid for injection
223891572|NCT04927065|BIOLOGICAL|mRNA-1273.231|Sterile liquid for injection
223891573|NCT05318001|OTHER|Evaluation of biomechanics and viscoelastic properties of plantar fascia|"The biomechanical (Tone-Hz, Stiffness-N/m and decrement) and viscoelastic (creep and relaxation time-ms) properties of the plantar fascia will be measured in the side lying position.~Measurements will be made with the ankle in neutral position."
223891574|NCT05318001|OTHER|Evaluation of Foot Morphological Characteristics|Foot length and width will be measured.
223891575|NCT05318001|OTHER|Evaluation of navıcular mobility|The amount of navicular drop of both feet will be measured.
223891576|NCT05318001|OTHER|Evaluation of Foot Posture|Foot posture will be evaluated according to Foot Posture Index.
223891577|NCT03406871|DRUG|Regorafenib|One course will last 28 days. Oral administration for 21 consecutive days, with a 1-week washout period. As for the expansion cohort, implemented using the RD estimated in the dose-escalation cohort.
223891578|NCT03406871|DRUG|Nivolumab|One course will last 28 days. Given once every 2 weeks at a dose of 3.0 mg/kg.
223891579|NCT03366649|PROCEDURE|Undersizing Mitral Annuloplasty|Participants will receive a commercially available annuloplasty ring of the surgeon's choice. Sutures are placed around the mitral annulus, and the metallic ring is then implanted onto the mitral annulus to reduce it in size.
223891580|NCT03366649|PROCEDURE|Papillary Muscle Approximation|One or two 4-0 pledgeted sutures are used to draw the two papillary muscle tips together to reduce the inter papillary muscle separation (IPMS) before undergoing undersizing mitral annuloplasty.
223891581|NCT05473234|DRUG|Azithromycin|Children enrolled in the trial and randomized to receive azithromycin will receive a single dose of azithromycin at 20 mg/kg up to the maximum adult dose of 1g. Oral azithromycin will be administered at the time of enrollment. Enrolled children will also receive RUTF.
223891582|NCT05473234|DRUG|Amoxicillin|Children enrolled in the trial and randomized to receive amoxicillin will receive a 5-day course of amoxicillin to be given in twice-daily doses of 15 mg/kg per the Nigeria guidelines for severe acute malnutrition. The first dose will be administered at the time of enrollment, and the remaining doses will be administered by the caregiver at home. Enrolled children will also receive RUTF.
223891583|NCT05593510|BEHAVIORAL|No prep ready-to-eat meals|"Pantry clients will select no prep ready-to-eat meals for up to 14-days' worth of meals for themselves and 2-members of their household using an online food selection platform. The food retailer supplying the meals produces over 70 meals. We have elected to study 14-days of meals to offer clients variety and determine which flavors are most desirable to clients. After ordering, meals will be retrieved from a refrigeration unit, boxed by pantry staff, and brought to the participant to take home. An example dinner is Teriyaki Chicken with Roasted Potatoes and Broccoli, and an example breakfast is Omelet with Peppers and Zucchini. Meals can be stored in a refrigerator or freezer and eaten immediately or after reheating depending on the meal and consumer preference."
223891584|NCT05593510|BEHAVIORAL|Ingredient bundles (e.g. meal kits)|Ingredient bundles will group individual meal ingredients (e.g., chicken, teriyaki, broccoli, potatoes) in a bag or box and pair those healthy food items with a recipe that instructs the client on how to make a healthier meal. Similar to the no prep ready-to-eat meal initiative, clients will select ingredient bundles for themselves and 2-members of their household using the food pantry online food selection platform. The ingredient bundles will closely replicate the no prep ready-to-eat meals.
223891585|NCT02386553|DRUG|Nusinersen|Solution for intrathecal injection
223891586|NCT01744782|DRUG|RP103|Cysteamine Bitartrate Delayed-release Capsules (RP103) were administered twice daily, orally or via gastrostomy tube (G-tube), after a 2-hour fast. The starting dose was one-quarter of the RP103 targeted maintenance dose based on age, weight, and body surface area. The recommended targeted maintenance dose for children up to 6 years old was 1 gram/m²/day, in 2 divided doses given Q12H. The dose was gradually escalated, in 10% steps, based on monitoring of WBC cystine levels 30 minutes after the morning RP103 dose collected every 2 weeks, until the participant's WBC cystine level was \<1 nmol ½ cystine/mg protein.
224080385|NCT06958718|PROCEDURE|Ultrasound Guided erector spinae plane block (UB)|Ultrasound Guided erector spinae plane block (UB) with 40 ml Bupivacaine HCL mixed with 0.5 μg/kg dexmedetomidine .. After the surgical incision is closed and before extubation, while the patient remains in the prone position. A linear high-frequency transducer (L6-12 linear array transducer (6-12 MHz) on GE Healthcare logiq p7, made in Korea) will be positioned in a sagittal orientation, 4 cm lateral to the L3 transverse process. A 22 G × 88 mm block needle will be inserted in the craniocaudal direction, with the needle tip placed beneath the erector spinae muscle and above the hyperechoic transverse process. The needle tip position will be confirmed via saline injection. Once correct needle placement is verified, 40 mL of 0.25% bupivacaine, combined with 0.5 μg/kg dexmedetomidine 15 will be administered divided on both sides.
223891587|NCT06130397|OTHER|Cases reading|"The reading will be done remotely via the Report and Image Quality Control site (www.RAIQC.com), an online platform allowing medical imaging viewing and reporting. Participants can work from any location, but the work must be done from a computer with internet access. For avoidance of doubt, the work cannot be performed from a phone or tablet.~The project is divided into two phases and participants are required to complete both phases. The estimated total involvement in the project is up to 20-24 hours.~Phase 1: Time allowed: 2 weeks~\- Participants must review 500 X-rays and express a clinical opinion through a structured reporting template (multiple choice, no open text required).~Rest/washout period - Time allowed: 4 weeks, to mitigate the effects of recall bias.~Phase 2 - Time allowed: 2 weeks~\- Review 500 X-rays together with an AI report for each case and express their clinical opinion through the same structured reporting template used in Phase 1."
223891588|NCT06130397|OTHER|Ground truthing|Two consultant musculoskeletal radiologists will independently review the images to establish the 'ground truth' findings on the XRs, where a consensus is reached this will then be used as the reference standard. In the case of disagreement, a third senior musculoskeletal radiologist's opinion (\>20 years experience) will undertake arbitration. A difficulty score will be assigned to each abnormality by the ground truthers using a 4-point Likert scale (1 being easy/obvious to 4 being hard/poorly visualised).
223891589|NCT01747863|OTHER|Neurologic examination|Neurologic examination includes: (1) neurologic examination using modify Sarnat score at \</= 6 hrs of age, 24 hrs and at discharge home, (2) aEEG at 6 ± 3 hrs of age, (3) Brain MRI before discharge home to 30 days of age.
223891590|NCT06201078|RADIATION|Stereotactic Body Radiotherapy|"Salvage SBRT will be performed in three subgroups of patients with local recurrence:~Group A - after conventionally fractionated/moderately hypofractionated definitive radiotherapy; Group B - after prostatectomy and postoperative radiotherapy; Group C - after ultrahypofractionated definitive SBRT~Target volumes:~GTV- tumour visible on MRI and PET-CT; CTV- 1-3 mm margin around GTV PTV- 3 mm around CTV\*~\*- in cases in which very high accuracy and reproducibility of SBRT are ensured, and the margin overlaps the rectum and/or bladder, it is possible to reduce the margin from these organs to 1 mm.~Dose constrains:~The criteria for limiting the dose in nearby organs are not well-defined for repeated irradiation - the following doses should be aimed:~* Maximum rectal dose ≤103% of the prescribed dose (optimal ≤100%)~* Maximum bladder dose ≤105% of the prescribed dose (optimal ≤103%)~Dose-volume constrains:~Rectum:~• D30% \<15Gy~Bladder:~• D30% \< 15 Gy"
223891591|NCT05940571|DRUG|MBF-362|Drug: One MBF-362 128.7 mg hard gelatin capsule EP2/EP4 antagonist 28 days single oral daily dosing cycles
223891592|NCT03651076|DEVICE|Traxi panniculus retraction (Clinical Innovations, LLC)|class I, FDA-exempt, commercially available for use in panniculus retraction during cesarean delivery or other laparotomy
223891593|NCT04128670|DEVICE|Kinesiotape|Tape will be applied to the biceps muscle of the nondominant arm from approximately the shoulder to the elbow for up to 72 hours. For the KT group taping will be applied with a lymphatic application method according to the guidelines recommended by Kenzo Kase. This type of application is known to improve blood and lymphatic circulation which enhances the removal of metabolic products. It is recommended that the application of the tape for lymphatic correction be applied for 24-72 hours. The tape will be applied with a tension of 10-20%.
223891594|NCT03180996|DEVICE|Vascutek Fenestrated Anaconda™ Custom AAA Stent Graft System|Fenestrated Endovascular Aortic Repair (FEVAR)
223891595|NCT03378570|DEVICE|Repetitive transcranial magnetic stimulation|Repetitive transcranial magnetic stimulation will be targeted to a location in the left prefrontal cortex and delivered according to FDA-approved parameters for the treatment of major depressive disorder, specifically high-frequency 10 Hz rTMS for 3000 pulses, 5 days per week for a total number of sessions as deemed clinically appropriate by the patient's clinical TMS treatment team but usually on the order of 20-30 treatments.
223891596|NCT06174922|DRUG|Prednisolone|Prednisolone for 4 months
223891597|NCT06174922|DRUG|Itraconazole|SUBA-itraconazole for 4 months
223891598|NCT06510764|OTHER|intradermal needles|Disposable intradermal needles will be used for acupoint stimulation and Tai Chong, Taixi, Sanyinjiao, Hegu as well as Yanglingquan are chosen for acupuncture point. Acupuncture point pressure will last for 10 minutes each time, three times per day, and the intradermal needles will be changed every 2 days.
223891599|NCT06510764|DRUG|Ziyinxiehuo Granules of traditional Chinese Medicine|Ziyinxiehuo Granules of traditional Chinese Medicine which includes shengdi 15g, xuanshen 9g, zexie 9g, zhimu9g, huangbai 9g, zhiguiban 9g, maiya 15g, tiandong 9g, zhigancao 9g,and will be administered after dissolved, 1package every time, 2 times per day after a meal.
223891600|NCT05627479|DRUG|GIK solution|Therapy cocktail of Glucose, Insulin and Potassium. The medications will be prepared as per standard protocol. Administered intravenously.
223891601|NCT05627479|DRUG|Isotonic Normal Saline Solution|Placebo injection - administered intravenously.
223891602|NCT05847595|OTHER|Implicit motor training program|The implicit motor training aims to create a learning situation in which the learner is not (or minimally) aware of the underlying rules of the practiced motor skill. Cognitive-motor dual-task training will be used, which involves practicing hand-reaching and grasping in different locations in space while performing cognitive tasks associated with attention, memory, and executive function. The cognitive tasks include naming words, counting backwards, counting tones, counting days and months backwards, listening to a number and counting backwards by twos and threes, telling daily stories, spelling words backward, continuous subtraction of 7 from 100, and the Stroop task. The training will be tailored to the participant's abilities.
223891603|NCT05847595|OTHER|Explicit motor training program|"The explicit motor training aims to create a learning situation in which the learner is very aware of the learning process by providing detailed explicit instructions on each exercise. The Motion Guidance Shoulder Kit will be used for this intervention, which involves four exercises: Around the clock in flexion and abduction, Locate the Target in active range of motion, Butterfly in tracing small and large butterfly patterns, and Test your positional awareness in locating circles with eyes open and closed. The kit involves a strap around the forearm with a laser to guide the movement of the arm during the exercises."
223891604|NCT05847595|OTHER|Selected physical therapy program|The selected physical therapy program, which includes shoulder joint mobilization, graduated active exercises for shoulder muscles, hand weight bearing exercises, Approximation of the upper limb joints. While, the conventional physical therapy program for the lower extremity which includes gait training, strengthening exercises and balance training .
223891605|NCT04495959|DRUG|68Ga-HTK03149|PET/MRI scan with radiotracer 68Ga-HTK03149
223891606|NCT06508294|BEHAVIORAL|8 week artificial intelligence based posture exercises|8 week artificial intelligence based posture exercises
223891607|NCT05894694|DRUG|first-line scheme+compound kushen injection|FOLFOX/FOLFIRI/CAPEOX± Cetuximab/bevacizumab+compound kushen injection Compound Kushen injection: intravenous infusion, 20ml at a time, diluted with 200ml sodium chloride injection, once a day, each cycle of chemotherapy should reach the cumulative dose of 200ml.
223891608|NCT05894694|DRUG|palliative care group first-line scheme|FOLFOX/FOLFIRI/CAPEOX± Cetuximab/bevacizumab
223891609|NCT06468449|OTHER|Lower limb power output training|"Lower limb power output training content:~Half squat up squat: 70%1R (6 repetitions × 5sets) + 5 knees jumps × 5 sets with an interval of 90 seconds；"
223891610|NCT06468449|OTHER|Force Combined Speed training|"Lower limb Force Combined Speed training content:~Rapid half squat : Optimal load (6 sets × 7 repetitions). Rest intervals between sets range from 2 to 5 minutes."
223891611|NCT03001830|BIOLOGICAL|AAV2/8-HLP-FVIII-V3|Infusion of AAV2/8-HLP-FVIII-V3
223891612|NCT05657054|OTHER|Exercise Intervention Targeting Hip Strengthening|An initial 16-week exercise intervention of 45 minutes of training 3 times a week in the patient's own home or at a rehabilitation center. Patients will be instructed by a physiotherapist during the first 3 sessions, in order to be able to perform the exercises at home. Subsequently, there are physiotherapist-supervised sessions once every second week. The delivery of the supervised sessions is based on the patient's preferences, either by physical attendance or remotely in the patient's home. The intervention will consist of 4 exercises adapted from the NEMEX program targeting lower extremity muscle strength, stability, postural function, and postural orientation. Progression is made when an exercise is performed with good sensorimotor control and good performance quality and with minimal exertion and adequate movement control. Progression is primarily provided by 3 levels of difficulty and secondly by varying the number of repetitions or where possible, by increasing the weight load.
223891613|NCT05657054|OTHER|Usual Care|The intervention will consist of a rehabilitation intervention corresponding to standard care in the participating municipalities (i.e. content and duration of intervention). The intervention will be delivered individually or as group training, based on a clinical assessment of the individual patients' needs. The intervention can be supported by home-based exercises following instruction from a physiotherapist, supplemented by the provision of written information or access to a virtual training program. The intervention occurs in either the rehabilitation center's gym or the patient's home. The training sessions may consist of some of the following parameters: Strength training, stretching, functional training e.g. walking and stair climbing, stability training, balance training, endurance training, and gait correction.
223891614|NCT04180930|DIAGNOSTIC_TEST|CAPS-5|Clinician Administered PTSD Scale for DMS-5
223891615|NCT04180930|DIAGNOSTIC_TEST|PSSI-5|PTSD Symptom Scale Interview for DSM-5
223891616|NCT04180930|DIAGNOSTIC_TEST|CAPS-IV|Clinician Administered PTSD Scale for DSM-IV
223891617|NCT05981131|DRUG|N803 plus Bacillus Calmette-Guerin (BCG)|QUILT-2.005 phase 1b (NCT02138734) was an open-label, dose-escalation, multicenter study of intravesical Bacillus Calmette-Guerin (BCG) plus N-803 in BCG-naïve non muscle invasive bladder cancer (NMIBC). A modified 3 + 3 design was used. Three subjects were enrolled at each dose level starting at 100 μg/instillation of N-803 and subsequently increasing to 200 μg/instillation and 400 μg/instillation. A standard dose of BCG, 50 mg, was employed. The primary endpoints of the study were: determination of the maximum tolerated dose (MTD) and designation of the recommended dose (RD) of N-803 in combination with BCG in subjects who have BCG-naïve NMIBC; safety profile of N-803 plus BCG in treated subjects; and disease response rate in treated subjects. A total of 9 subjects with high-risk, high-grade, BCG-naïve, NMIBC were enrolled into 3 cohorts and treated by intravesical administration of N-803 plus BCG.
223891618|NCT03210688|DRUG|Prednisolone|Tablet prednisolone
223891619|NCT03210688|DRUG|Alfacalcidol|Capsule alfacalcidol 0,5 microgram/day
223891620|NCT06524635|DRUG|Lutikizumab|Subcutaneous (SC) Injection
223891621|NCT06565715|DRUG|Remimazolam|Remimazolam is used for sedation during anesthetic induction and maintenance.
223891622|NCT06565715|DRUG|Propofol|propofol is used for sedation during anesthetic induction and maintenance.
223891623|NCT06567561|BEHAVIORAL|Whole Foods Plant-Based Diet|Whole foods, predominantly plant-based diet, with the addition of fish, eggs, and fermented dairy.
223891624|NCT06567561|BEHAVIORAL|Usual Firehouse Diet|Usual firehouse meals.
223891625|NCT06566430|BEHAVIORAL|PrEP My Way intervention|Intervention components may be modified pending the input from Aim 1. As currently planned, the peer delivering the PrEP My Way kit will be trained to provide basic education and support use of the kit components. The peer will also have a smart phone to show an instructional video. Participants will communicate with peers via mobile phones (e.g., SMS, WhatsApp) to arrange for kit delivery at Months 1, 3, 6, 9, and 12 for those choosing the oral or ring formulations of PrEP. If the participant chooses to use injections, she will communicate with the peers to arrange for kit delivery at Months 1, 3, 5, 7, 9, 11, and 12. All deliveries will be made via unmarked vehicles at home or a preferred safe site during reasonable hours. Two-way mobile phone communication will also be used to convey test results and provide on-going support and empowerment. Follow-up with the clinic will occur at Month 12 and as needed (e.g., treatment for positive tests).
223891626|NCT06566430|BEHAVIORAL|PrEP My Way intervention without STI testing|Intervention components may be modified pending the input from Aim 1. As currently planned, the peer delivering the PrEP My Way kit will be trained to provide basic education and support use of the kit components. This kit will not contain STI testing. The peer will also have a smart phone to show an instructional video. Participants will communicate with peers via mobile phones (e.g., SMS, WhatsApp) to arrange for kit delivery at Months 1, 3, 6, 9, and 12 for those choosing the oral or ring formulations of PrEP. If the participant chooses to use injections, she will communicate with the peers to arrange for kit delivery at Months 1, 3, 5, 7, 9, 11, and 12. All deliveries will be made via unmarked vehicles at home or a preferred safe site during reasonable hours. Two-way mobile phone communication will also be used to convey test results and provide on-going support and empowerment. Follow-up with the clinic will occur at Month 12 and as needed (e.g., treatment for positive tests).
223891627|NCT06566430|BEHAVIORAL|Enhanced standard of care|These participants will receive PrEP (choice of oral, ring, or injection formulation), STI testing, and family planning at the clinic, as requested.
223891628|NCT06567587|DRUG|Dexmedetomidine|Effect o dexmedetomine on agitated normal and psychotic patients on BIPAP who are suffer exaggerated COPD
223891629|NCT06567587|DEVICE|BIPAP|Put exaggerated COPD patients on non invasive ventillation
223891630|NCT01785719|BEHAVIORAL|Commercial Weight Loss Program|Regardless of reproductive history, each participant will be provided with six months of the commercial weight loss program, Nutrisystem® D. Nutrisystem® D is a portion-controlled, low calorie, and low glycemic index meal delivery system that provides 1250-1500 kcal/day. It has been proven to help overweight adults achieve real and sustainable weight loss results. When meals and snacks are consumed as instructed, average weight loss is 1-2 lbs per week or 15-20% body weight by the end of six months. Nutrisystem® D offers a balanced meal plan that is consistent with the nutrition recommendations of the USDA Dietary Guidelines for Americans and American Diabetes Association. Each participant will be encouraged to take a daily multivitamin to help meet her micronutrient needs on the program.
223891631|NCT06566313|BEHAVIORAL|transcranial Direct Current Stimulation|On the basis of conventional anti-PD drugs, the left M1 region (based on the C3 coordinates of EEG 10-20 system and the surrounding FC1, FC5, CP1, CP5 coordinates) was treated with cathodic tDCS. The electrical stimulation intensity was 2.0mA, the treatment time was 20min, and the treatment lasted for 10 days.
223891632|NCT06040827|DEVICE|Total Knee Arthroplasty|The nature, severity, and frequency of safety risks (Adverse Events) in subjects with the Canary canturioTM te will be compared to those subjects with the legally marketed Zimmer Persona® Personalized Knee System with 14 mm x +30 mm stem extension within 5 years post-TKA.
223891633|NCT04126018|DIAGNOSTIC_TEST|MRI with strain measurement|CMR measurements of left and right ventricular systolic function strain and myocardial fibrosis
223891634|NCT04126018|DIAGNOSTIC_TEST|Echocardiography|Doppler, PISA, VCA, volumetric method as performed during echocardiography
223891635|NCT03443323|BEHAVIORAL|Organizational Skills Training - Tier 2 (OST-T2)|OST-T2 is a small group skills training intervention, with parents and teachers supporting children's use of new skills. The program manual includes strategies for training and coaching school staff, referred to as school partners, to effectively implement OST-T2 and guidelines to modify the program for implementation in diverse schools with diverse students. Each student session includes: (a) homework review to assess completion of between-session skills implementation; (b) skill-building activities, which include the use of modeling, shaping, guided practice, and reinforcement for organized behavior; and (c) activities to promote generalization of skills. Sessions address four organizational challenges: (a) tracking assignments, (b) managing materials, (c) managing time, and (d) planning for long term assignments.
223891636|NCT03151616|OTHER|anticholinergic risk scale|Risk summation scale for grading and studying anticholinergic medication exposure
223891637|NCT05735600|BEHAVIORAL|AyuDa Virtual: Aprender y Utilizar Decisiones Apreciables (Spanish) - Learning and Utilizing Significant Choices (English)|"The intervention was developed based on the Social Learning Theory, considering both environmental and cognitive factors influencing parent behavior and modeling for children. Researchers have modified a five-module virtual intervention from the Cooking Healthy and Delicious Manual (Cocinando Delicioso y Saludable Manual, Spanish version), which incorporates behavior change strategies for improving diet quality, screen time, physical activity/sedentary behavior, socioeconomic status/food security, and sleep duration."
223891638|NCT05735600|BEHAVIORAL|AyuDa Written: Aprender y Utilizar Decisiones Apreciables (Spanish) - Learning and Utilizing Significant Choices (English)|"The intervention was developed based on the Social Learning Theory, considering both environmental and cognitive factors influencing parent behavior and modeling for children. Researchers have modified a five-module virtual intervention from the Cooking Healthy and Delicious Manual (Cocinando Delicioso y Saludable Manual, Spanish version), which incorporates behavior change strategies for improving diet quality, screen time, physical activity/sedentary behavior, socioeconomic status/food security, and sleep duration."
223891639|NCT06568471|DRUG|Lerodalcibep|PCSK9 inhibitor
223891640|NCT06568471|DRUG|matching placebo|placebo
223891641|NCT05952453|DRUG|Carboplatin|neoadjuvant treatment , followed by surgery, then maintenance chemotherapy
223891642|NCT05952453|DRUG|olaparibp, embro|maintenance chemotherapy : olaparib, pembro
223891643|NCT05636293|DRUG|Ritlecitinib|200mg Ritlecitinib
223891644|NCT05636293|DRUG|Placebo|Placebo
223891645|NCT05636293|OTHER|Gluten|10g of gluten
223891646|NCT05391893|DRUG|Oral|Diltiazem 0.25mg/kg injection, give over 2 minutes, max dose 30mg
223891647|NCT05391893|DRUG|Intravenous drug|these patients will receive traditional treatments at provider discretion. They must receive at least one intravenous medication for atrial fibrillation with rapid ventricular response. This will be a heterogenous group of patients receiving digoxin, amiodarone, various beta-blockers, and intravenous diltiazem without oral diltiazem.
223891648|NCT04041479|DEVICE|Repetitive Transcranial Magnetic Stimulation|iTBS rTMS targeting the DMPFC or left DLPFC
223891649|NCT04041479|DEVICE|Repetitive Transcranial Magnetic Stimulation|iTBS rTMS targeting the left DLPFC
223891650|NCT06305598|PROCEDURE|Biopsy|Undergo biopsy
223891651|NCT06305598|PROCEDURE|Bone Scan|Undergo bone scan
223891652|NCT06305598|PROCEDURE|Computed Tomography|Undergo CT scan
223891653|NCT06305598|DRUG|Leuprolide Acetate|Given SC
223891654|NCT06305598|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223891655|NCT06305598|OTHER|Survey Administration|Ancillary studies
223891656|NCT06305598|DRUG|Testosterone Cypionate|Given IM
223891657|NCT06273917|OTHER|PRIDE|"Pharmacists present in the ED will perform medication reconciliation for eligible patients. This will be done to demonstrate the feasibility of the PRIDE intervention in the ED for patients with ADRD and MCI. Patients eligible for medication reconciliation will be enrolled in Aim 2 of the study.~Outpatient prescribers of these patients who are discharged from the ED will be contacted by the ED pharmacist on the date of ED discharge and will receive a medication report including fill data 90-100 days after the ED visit.~At the completion of the study, the outpatient clinicians will also receive a questionnaire about the acceptability of the PRIDE program including the Acceptability of Intervention Measure to complete electronically."
223891658|NCT05090722|DEVICE|PureWick System|The PureWick system consists of the external catheter, collection tubing, and collection canister with lid. It operates via a power cord that is plugged into the device outlet and the A/C power outlet.
223891659|NCT06568302|DRUG|SerpinPC|Administered as SC injection.
223891660|NCT05891496|DRUG|Semaglutide|Semagllutide will be administered once weekly subcutaneously.
223891661|NCT05891496|DRUG|Placebo|Placebo matched to semaglutide will be administered once weekly subcutaneously.
223891662|NCT04750473|PROCEDURE|Computed Tomography|Undergo PET/CT scan
223891663|NCT04750473|DRUG|Fluciclovine F18|Given IV
223891664|NCT04750473|DRUG|Gallium Ga 68 Gozetotide|Given IV
223891665|NCT04750473|PROCEDURE|Positron Emission Tomography|Undergo PET/CT scan
223891666|NCT06569121|BEHAVIORAL|Group Lifestyle Balance for People Post Stroke (GLB-CVA)|12-month healthy lifestyle and weight loss program modified from the Diabetes Prevention Program Group Lifestyle Balance (DPP-GLB)
223891667|NCT06392360|DIETARY_SUPPLEMENT|Betaine|White betaine powder
223891668|NCT06392360|DIETARY_SUPPLEMENT|Placebo|White placebo powder
223891669|NCT00900575|DEVICE|Optical Spectroscopy Bench-Top System|This device is a bench-top optical spectrometer
223891670|NCT00900575|DEVICE|Portable Optical Spectrometer|This device is a portable optical spectrometer
223891671|NCT00900575|DEVICE|Transvaginal colposcope|
223891672|NCT05968053|DIAGNOSTIC_TEST|biological samples analysis|biological samples analysis
223891673|NCT04594486|OTHER|Medical treatment of acute appendicitis|All cases will be treated medically and will be followed for recurrences
223891674|NCT05559515|BEHAVIORAL|NDPP-Flex|NDPP + patient-centered goal setting
223891675|NCT05559515|BEHAVIORAL|NDPP|Usual care NDPP only
223891676|NCT06137937|BEHAVIORAL|Aerobic Exercise|Intradialytic aerobic exercise for eight weeks
223891677|NCT05401630|OTHER|Study Procedures|"All participants will answer a series of questionnaires that address several factors such as patient medical history, family history, medication usage, health behaviors, psychological factors, etc. Questionnaires related to symptoms, psychological factors, depression, anxiety, and quality of life will be taken.~All participants will undergo 123I-MIBG SPECT imaging in the morning in a fasting state. Mental Stress Testing will be conducted in the Laboratory in the morning after fasting for at least 4 hours and withdrawal of all vasoactive medications, caffeine, and tobacco 24-48 hours before testing. Participants will also undergo 1-week of Home Monitoring using a single-use, noninvasive, water-resistant, 7-day ambulatory ECG monitoring, which offers the advantage of direct access to raw data that can be downloaded from the device after use.~A 3-day food recall diary, cognitive assessments via the NIH Toolbox, and a Sleep diary during home monitoring will be collected."
223891678|NCT05188027|OTHER|Aerobic Exercise|Walking at 60% of maximal aerobic capacity on a treadmill
223891679|NCT05188027|OTHER|Resistance Exercise|Performing one set of 10 repetitions of 10 different weight-lifting exercises
223891680|NCT05188027|OTHER|No exercise|Participants will rest in a supine position for 30 minutes.
223891681|NCT01994239|DRUG|Degarelix|First dose of 240 mg 5 Maintenance doses of 80 mg every 28 days(+/-3d)
223891682|NCT01994239|RADIATION|Pelvic Radiotherapy|46 Gy in 23 fractions Prostate only-boost up to 66 Gy
223891683|NCT06221735|DIAGNOSTIC_TEST|Cy-TB test|The study will include people with confirmed TB infection and negative controls to compare the specificity and sensitivity of the Cy-TB and TB-Feron tests versus the QFT-Plus assay
223891684|NCT06221735|DIAGNOSTIC_TEST|STANDARD F TB-Feron FIA test|The study will include people with confirmed TB infection and negative controls to compare the specificity and sensitivity of the Cy-TB and TB-Feron tests versus the QFT-Plus assay
223891685|NCT05661552|DRUG|Evolocumab 140 MG/ML|Randomly assigned Evolocumab + rosuvastatin + ezetimibe versus rosuvastatin + ezetimibe
223891686|NCT05661552|DRUG|Rosuvastatin 5mg|Rosuvastatin 5mg will be assigned to all participants
223891687|NCT05661552|DRUG|Ezetimibe 10mg|Ezetimibe 10mg will be assigned to all participants
223891688|NCT04294290|BIOLOGICAL|hCT-MSC infusion|This is a single site, phase I, open-label, prospective study of one intravenous infusion of human umbilical cord tissue-derived mesenchymal stromal cells (hCT-MSC) in 12 toddlers 18 to 48 months of age with autism spectrum disorder (ASD).
223891689|NCT06470971|BIOLOGICAL|Anti-PD-L1 Monoclonal Antibody|Receive anti-PD-L1 monoclonal antibody therapy
223891690|NCT06470971|BIOLOGICAL|Anti-PD1 Monoclonal Antibody|Receive anti-PD1 monoclonal antibody therapy
223891691|NCT06470971|PROCEDURE|Biopsy|Undergo biopsy
223891692|NCT06470971|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223891693|NCT06470971|PROCEDURE|Bone Scan|Undergo bone scan
223891694|NCT06470971|PROCEDURE|Computed Tomography|Undergo CT
223891695|NCT06470971|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223891696|NCT06470971|OTHER|Quality-of-Life Assessment|Ancillary studies
223891697|NCT06470971|BIOLOGICAL|Siltuximab|Given IV
223891698|NCT05220709|DIAGNOSTIC_TEST|bio impedance spectroscopy by means of the Body Composition Monitor (Name of the device is BCM from Fresenius Medical Care D GmbH)|The Body Composition Monitor provides information about the hydration status by a bioimpedance spectroscopy measurement of the body composition from which the level of overhydration can be derived. Four electrodes are used per measurement. All subjects get electrodes attached, following the wrist-ankle approach, in a tetrapolar arrangement. Two electrodes are placed on the hand: one on the wrist, and the second on the dorsal side of the metacarpalia, close to the phalanges. The other two electrodes are placed on the foot: one on the ankle, and the second on the dorsal side of the metatarsals, close to the phalanges of the toes. Age, gender, height, weight and blood pressure are registered in the device before starting the measurement. If the quality calculated by BCM is \< 60%, the measurement will be repeated again. Measurements are taken under supervision of a trained technician or nurse.
223891699|NCT04143711|DRUG|DF1001|Immunotherapy agent targeting NK cells.
223891700|NCT04143711|DRUG|Nivolumab|Anti-PD-1 immunotherapy agent
223891701|NCT04143711|DRUG|Nab paclitaxel|A chemotherapy treatment combining paclitaxel with albumin
223891702|NCT04143711|DRUG|Sacituzumab Govitecan-hziy|A Trop-2 (Tumor-associated calcium signal transducer 2) directed antibody and topoisomerase inhibitor drug conjugate
223891703|NCT05527392|BEHAVIORAL|Health Insurance Navigation Tools Program|The program will be delivered via videoconferencing by a navigator over approximately a 3-month period and will consist of 5 sessions. The navigation intervention sessions will be as follows: Section 1- Insurance Plan Basics; Section 2- Your Plan in Relation to Policy; Section 3- Navigating Your Plan and Overcoming Obstacles; Section 4- Managing Care Costs; 5-Understanding Your Medical Bills.
223891704|NCT04610892|BIOLOGICAL|MEDI6570|MEDI6570
223891705|NCT04610892|BIOLOGICAL|Placebo|Buffer
223891706|NCT05697146|OTHER|ribociclib + ET|There is no treatment allocation. Patients administered ribociclib + endocrine Therapy (ET) by prescription will be enrolled.
223891707|NCT01497405|BEHAVIORAL|Test, Treat, Retain(TTR) + Women's Health CoOp (WHC)|TTR +WHC: Participants in this group will be screened for HIV. HIV positive women, will be given post-test counseling and referrals for prompt medical evaluation and assessment.Both HIV negative and positive participants in this group will participate in 2 individual behavioral counseling sessions focusing on reducing HIV risk behaviours, alcohol and other drug use, and risk of violent victimization. It also adds case management to increase follow through with referrals and risk reduction plans and activities.This will also include case management sessions. This intervention is an adaptation of the evidence-based Women's CoOp (PI: Dr. Wendee M. Wechsberg).
223891708|NCT01497405|BIOLOGICAL|Test, Treat, Retain(TTR) only|TTR +only: Participants in this group will be screened for HIV. HIV positive women will be given post-test counseling and referrals for prompt medical evaluation.
223891709|NCT05520190|BEHAVIORAL|Cognitive Behavioral Therapy for Treatment Seeking (CBT-TS)|"The intervention will consist of 1 - 2 sessions. The first session is approximately 60 - 90 minutes and will be structured in 4 phases 1) subject's history of symptoms and current functioning, 2) their coping methods, 3) modification of treatment beliefs, 4) action planning. The interventionist will provide the subject with a list of resources for seeking treatment.~All subjects will be offered an optional second session with the interventionist. The second session will consist of a 60-minute appointment focused on providing practical assistance to identify available treatment options in the subject's area, scheduling treatment sessions, and problem-solving barriers to treatment."
223891710|NCT06491563|BIOLOGICAL|BRII-179|BRII-179 will be given via intramuscular injection
223891711|NCT06491563|DRUG|BRII-835 (VIR-2218)|BRII-835 will be given via subcutaneous injection
223891712|NCT06491563|BIOLOGICAL|PEG-IFNα|PEG-IFNα will be given via subcutaneous injection
223891713|NCT06191874|OTHER|Standard-of-care (SOC) surgery plan|Use of SOC clinical planning tools to prepare for DBS (deep brain stimulation) surgery
223891714|NCT06191874|OTHER|HoloDBS hypothetical surgery plan|Use of next generation visualization tools and surgical targeting models to hypothetically prepare for DBS (deep brain stimulation) surgery
223891715|NCT05982015|DEVICE|Remote ischemic conditioning|The RIC procedure consists of five cycles of unilateral arm ischemia for 5 minutes, which was followed by reperfusion for another 5 minutes. The procedure is performed with an electric, autocontrol device with a cuff that inflated to a pressure of 200 mmHg during the ischemia period. RIC is performed within 24hours after stroke onset, and twice daily for the subsequent 7 days.
223891716|NCT05982015|DEVICE|Sham remote ischemic conditioning|The RIC procedure consists of five cycles of unilateral arm ischemia for 5 minutes, which was followed by reperfusion for another 5 minutes. The procedure is performed with an electric, autocontrol device with a cuff that inflated to a pressure of 60 mmHg during the ischemia period. RIC is performed within 24hours after stroke onset, and twice daily for the subsequent 7 days.
223891717|NCT05902637|PROCEDURE|Performing cognitive prostate biopsy with a radiologist's guidance with map|All patients will undergo prostate biopsy under local or general anesthesia with transrectal ultrasonography by a single surgeon after mapping extracted by a single genitourinary radiologist in the Department of Radiology of our hospital.
223891718|NCT05902637|PROCEDURE|Performing cognitive prostate biopsy without a radiologist's guidance with map|All patients will undergo cognitive prostate biopsy under local or general anesthesia with transrectal ultrasonography by a single surgeon after reported by a single genitourinary radiologist in the Department of Radiology of our hospital.
223891719|NCT01999075|DEVICE|Lung Volume Recruitment (LVR)|LVR will be used twice per day
223891720|NCT01999075|OTHER|Conventional Treatment|This may include: a. Physiotherapy, consisting of percussion, active cycle of breathing and/or postural drainage; b. Nutritional support, consisting of oral or tube-fed dietary supplements; c. Antibiotics (oral or intravenous), if there is evidence of respiratory infection; d. Non-invasive positive pressure ventilation, if there is evidence of nocturnal hypoventilation or sleep-disordered breathing; e. Systemic steroids
223891721|NCT03683719|DRUG|Delgocitinib cream|Cream for topical application.
223891722|NCT03683719|DRUG|Delgocitinib cream vehicle|The cream vehicle is similar to the delgocitinib cream except that it does not contain any active ingredient.
223891723|NCT06298487|OTHER|Patient questionnaires|Patients questionnaires, on paper or online (Microsoft Form) and data collection on patients medical file
223891724|NCT04729686|DRUG|Pericapsular Nerve Block|Per Standard Institutional Practice
223891725|NCT04729686|DRUG|Fascia Iliaca Nerve Block|Per Standard Institutional Practice
223891726|NCT05923385|DIAGNOSTIC_TEST|Four Square Step Test|These are standardized test which will be applied to subjects with pencil, paper and time recorder.
223891727|NCT04466371|OTHER|Questionnaire|A questionnaire to assess satisfaction with online learning and knowledge about COVID-19
223891728|NCT06386861|OTHER|Attitudes Toward Genomics and Precision Medicine (English)|completing the English version of the AGPM and validated health literacy and numeracy instruments
223891729|NCT06386861|OTHER|Attitudes Toward Genomics and Precision Medicine (Spanish)|completing the Spanish version of the AGPM and validated health literacy and numeracy instruments
223891730|NCT06184373|DEVICE|Continuous glucose monitor|CGMs will be worn for a maximum of 10 days at 6-8 weeks postpartum.
223891731|NCT06184373|DIAGNOSTIC_TEST|Oral Glucose Tolerance Test|At 10-12 weeks postpartum, participants will complete an oral glucose tolerance test, which involves drinking a glucose substance and having glucose levels measured a maximum of 3 times.
223891732|NCT06184373|DIAGNOSTIC_TEST|Hemoglobin A1c|At 11-14 months postpartum, participants will be asked to have their blood drawn to check their hemoglobin A1c to look for signs of developed insulin resistance
223891733|NCT04588896|DEVICE|Continuous glucose monitoring|Abbott Freestyle Libre CGM for 8 weeks in adjunct to lifestyle modification programme
223891734|NCT04588896|BEHAVIORAL|Lifestyle modification programme|Lifestyle modification programme
223891735|NCT05081583|DRUG|Midazolam Hcl 1Mg/Ml Inj|0.5 mL of an intravenous solution (1 mg/mL) will be administered.
223891736|NCT05081583|DIETARY_SUPPLEMENT|Goldenseal (Hydrastis canadensis)|Goldenseal (Solaray; Lot #1020199) is supplied as dried root powder in vegetable capsules, each containing 550 mg of herbal content. Goldenseal capsules will be administered with 240 mL of water.
223891737|NCT00277394|DRUG|innohep®|175 anti-Xa IU/kg administered subcutaneously (SC) once daily
223891738|NCT00277394|DRUG|Heparin|Heparin 50 IU /kg followed by a total dose of 400 to 600 IU/kg/day divided into two SC injections daily.
223891739|NCT05463887|BEHAVIORAL|Individualized preventive care recommendations (decision tool)|Providers will receive individualized preventive care recommendations (decision tool) for eligible patients, and discuss them with patients using shared decision-making
223891740|NCT06203977|DRUG|Colchicine|0.3mg and 0.6mg tablets
223891741|NCT06515132|PROCEDURE|SCS Stimulation|Participants will accept the SCS stimulus for six months
223891742|NCT06515132|PROCEDURE|Sham Stimulation|Sham stimulation will be performed in the first three months after surgery, and SCS stimulation will be started in the fourth month after surgery
223891743|NCT05031078|BIOLOGICAL|Gardasil|"Participants will receive 3 doses of 9-valent HPV vaccine (Gardasil 9) at D0, D60, and D180 The 9-valent HPV vaccine, or Gardasil-9, is a non-infectious recombinant vaccine prepared from the purified virus-like particles (VLPs) of the major capsid (L1) protein of HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58.~Gardasil-9 is supplied as a 0.5-mL single-dose vial or 0.5-mL single-dose prefilled Luer Lock syringe with tip cap."
223891744|NCT05031078|DRUG|Lidocaine injections|"1-2% lidocaine injections.~1% lidocaine, an FDA approved local anesthetic, will be injected subcutaneously to numb the area of the lymph node being sampled; whereas 1-2% lidocaine will be injected into the tissue surrounding the area where the bone marrow will be removed. In adults the recommended dose is 7 mg/kg with a maximum of 500 mg."
223891745|NCT06537232|DIETARY_SUPPLEMENT|Greens-based Supplement|Participant will consume one serving of greens-based supplement per day in the morning, for 30 days.
223891746|NCT06285474|DEVICE|Low Intensity Focused Ultrasound Pulsation (LIFUP)|All participants will undergo 3 identical LIFUP sessions. All sessions must occur at least 1 day apart, and no more than 3 days apart, such that sessions may occur at minimum on days 1, 3, 5 and at maximum may occur on days 1, 5, 9.
223891747|NCT06292624|DEVICE|Intermittent vacuum therapy (Weyergans High Care® Medial, Germany)|The participants' lower limb will be placed in the vacuum chamber and sealed with a cuff. The maximum negative pressure applied in the experimental group would be -40mmHg (negative pressure/ambient pressure phase: 9s / 7s). The parameters are selected based on the manufacturer's recommendations.
223891748|NCT06292624|BEHAVIORAL|Cycling exercise|The participant will perform 20 minutes of cycling exercise. Aiming at reaching a moderate exercise intensity (50% - 70%) of maximal heart rate on a gym bike.
223891749|NCT05683548|DRUG|REP 2139-Mg|REP 2139-Mg is the magnesium chelate complex of REP 2139
223891750|NCT05683548|DRUG|Tenofovir Disoproxil Fumarate|
223891751|NCT05683548|DRUG|Pegylated interferon alpha2a|
223891752|NCT05686499|OTHER|Didactic Lectures and demonstrations|"1. Trainees will receive 4-6 hours of didactic colonscopy lecture sessions based on the American Board of Surgery Flexible Endoscopy curriculum for general surgery residents, general surgery resident curriculum (SCORE) endoscopy module, and the Joint Advisory group on GI Endoscopy program adapted to Nigeria context.~2. Trainees will have the opportunity to practice colonoscopy on HF or LF simulators (depending on the arm) with immediate feedback from instructors."
223891753|NCT06656286|DEVICE|Intra-Uterine suturing by X-TACK device and hysteroscope|"After general anesthesia and entering the abdomen with the laparoscope, Truclear hysteroscope with X-tack attached will be inserted to the uterine cavity. Insertion of normal saline to the cavity and applying 4 points suturing to the uterus. The procedure will be monitored by external laparoscopic camera located in the abdominal cavity. After the hysterectomy the uterus will be opened and the suture will be examine.~A preoperative intrauterine incision using a hysteroscope, followed by suturing, will be considered based on the success of the first procedure."
223891754|NCT04123847|OTHER|Standing and Stepping|Participants will have at least 80 sessions of stand and step training with the assistance of trainers over-ground, or in a harness on a body weight supported treadmill.
223891755|NCT04123847|DEVICE|Standing, Stepping and Voluntary Movement with spinal cord Epidural Stimulation|Participants will be have at least 80 sessions of stand and step training with epidural stimulation, with the assistance of trainers over-ground, or in a harness on a body weight supported treadmill. Voluntary movement with epidural stimulation will be completed in the supine or seated position.
223891756|NCT06829043|OTHER|clinical practice drug treatment|The study is observational, non-interventional and involves the review of the investigation18F-FDGPET/TC (performed according to the EANM guidelines) by two experts from the Nuclear Medicine Department.
223891757|NCT06160999|BEHAVIORAL|Religious conferences|The conference will invite local subdistrict-level imams and other religious leaders, along with a range of community health workers, including those not traditionally trained to give vaccines. During the conference there will be some sessions with everyone, and some that are broken down by profession. The conference topics will be developed in conjunction with the religious leaders, but will focus on the importance of infant health
223891758|NCT06160999|BEHAVIORAL|Vaccine-in-a-van|For the vaccine-in-a-van concept, our community health worker will travel to different areas in the test subdistricts. These locations will be decided on in conjunction with the local health department and the research team's knowledge of the area. We will target areas which would have families with young children, particularly: schools, mosques, and sports fields. The purpose of the van will be to bring vaccines to the community, but also to put a human face (our community health worker) to vaccines outside of a clinical setting.
223891759|NCT06836635|PROCEDURE|ESPB group|"The patient will be placed in the lateral position. Block will be performed under complete aseptic precautions using ultrasound machine with high frequency linear probe covered with sterile sheath .~The block will be performed at the T5-T6 level of the spine using an in-plane approach. Sensory block of the 5th intercostal space in the midaxillary line will be assessed by unilaterally using cold perception until 30 minutes after nerve block. If sensory blockade did not occur, the patient will be excluded from the study."
223891760|NCT06836635|PROCEDURE|TPVB group|"The patient will be placed in the lateral position. Block will be performed under complete aseptic precautions using ultrasound machine with high frequency linear probe covered with sterile sheath .~The block will be performed at the T5-T6 level of the spine using an in-plane approach. Sensory block of the 5th intercostal space in the midaxillary line will be assessed by unilaterally using cold perception until 30 minutes after nerve block. If sensory blockade did not occur, the patient will be excluded from the study."
223891761|NCT06574217|BEHAVIORAL|Stepping Stones (StSt)|StSt is an individual-level intervention designed to help youth make healthy decisions. StSt is delivered in-person by an adult guide during four \~30-50 minute sessions over a period of up to 8 weeks. The adult guide leads the youth through health-focused discussions related to identifying personal values, making a social network map, and then creating and refining individualized plans.
223891762|NCT06574217|BEHAVIORAL|Like|Like is an hour-long film that discusses the impact of social media on the brain. Study staff will organize for each individual participant to watch the film in-person. The film does not include information related to the outcomes of interest for the study.
223891763|NCT02736500|DRUG|28 GBq 177Lu-DOTATATE|Patients without risk factors (particularly long standing and poorly controlled diabetes and hypertension) for late renal toxicity will be administered with 5 cycles of 5.5 GBq (150 mCi) each, up to the total cumulative activity of 28 GBq (750 mCi) of 177Lu-DOTATATE.
223891764|NCT02736500|DRUG|22 GBq 177Lu-DOTATATE|Patients with risk factors for late renal toxicity will be administered with 6 cycles of 3.7 GBq (100 mCi) each, up to the total cumulative activity of 22 GBq (600 mCi)177Lu-DOTATATE
223891765|NCT06158503|DEVICE|AID|Initiation of an automated insulin delivery system
223891766|NCT05514899|DRUG|THC|THC capsule
223891767|NCT05514899|DRUG|CBD|oral solution
223891768|NCT00346788|PROCEDURE|Surgical approach for total knee arthroplasty|total knee arthroplasty surgery using minimally invasive surgery or standard technique.
223891769|NCT04344899|OTHER|Observational|Enhanced Recovery After Surgery protocol at five tertiary-care pediatric hospitals in pediatric patients undergoing abdominal or retroperitoneal surgical resections for cancer.
223891770|NCT06835998|OTHER|stress ball|"the stress ball intervention was initiated. Before starting, the researcher provided instructions and demonstrations on how to use the stress ball, allowing then the patients to practice. The stress ball intervention was administered during the second hour of the hemodialysis session when patients were most comfortable. Patients were instructed to squeeze the stress ball once, counting internally as 1-2-3 with each squeeze. The stress ball intervention was administered three times weekly during hemodialysis sessions for 15 minutes each session, totaling 12 sessions for a period of four weeks. Throughout the intervention, patients were observed by the same researcher."
223891771|NCT05331885|BIOLOGICAL|Suvratoxumab|Monoclonal antibody
223891772|NCT05331885|DRUG|Placebo|Placebo contains only excipients
223891773|NCT06512077|DEVICE|Multi-channel Microspatial Offset Raman Scattering Spectroscopy (mμSORS) for Noninvasive Blood Glucose Detection|Blood glucose of participants were measured by venous plasma and multi-channel microspatial offset Raman scattering spectroscopy (mμSORS). The two measurements were collected synchronously and analyzed.
223891774|NCT05244889|BEHAVIORAL|Digital CBT-I|"The digital CBT-I intervention (www.sleepio.com) consists of six weekly sessions of CBT-I delivered over the internet by an animated virtual therapist known as The Prof. The content includes behavioral (e.g. sleep restriction, stimulus control), cognitive (e.g. putting the day to rest, thought re-structuring, mindfulness) strategies, relaxation strategies (e.g., progressive muscle relaxation) and advice on lifestyle and bedroom factors (sleep hygiene). Although the sessions can be completed at the persons own pace, the shortest interval between individual sessions is 7 days, thus participants can complete the course in 6 weeks, or take as long as 12 weeks. As part of the SLEEPIO program, participants will be required to enter their sleep/wake patterns using electronic sleep diaries. There is no face-to-face contact throughout the intervention and all treatment sessions, support and reminders are provided through the online platform."
223891775|NCT05244889|BEHAVIORAL|Sleep Hygiene Education|Sleep Hygiene Education (SHE) has successfully been used as a control condition in other trials evaluating dCBT-I42. SHE does not have any therapeutic benefits for individuals with insomnia alone, but is often part of usual care. Consequently it is a credible alternative to dCBT-I. The sleep hygiene education will be provided on a website with access to information about lifestyle changes (e.g., reducing exercise in the evening, light snack before bedtime, reducing caffeine) and changes to the bedroom environment (e.g., dark room, comfortable mattress, optimal room temperature). As with the dCBT-I group, participants will not be required to make any changes to their usual care.
223891776|NCT05822557|OTHER|Bolus Pouch Feed|Following the 7-day baseline period, all patients will enter the 28-day intervention period, where they will receive the intervention feed daily. The feed prescription will be determined on an individual basis by the Dietitian responsible for the patient's nutritional management
223891777|NCT06838182|DIAGNOSTIC_TEST|Salivary biomarkers tests|saliva samples are collected from participants
223891778|NCT04864691|BIOLOGICAL|endovascular recanalization|to recanalize the occlusion cerebral artery with intravascular intervention
223891779|NCT05818696|BEHAVIORAL|Lethal Means Counseling (LMC)|The research interventionist uses a guiding approach to identify methods for secure firearm storage and reflects the participant's reasons for and against secure firearm storage, with a particular focus on the service member's verbalized reasons for wanting to adopt or use the identified storage methods.
223891780|NCT05818696|BEHAVIORAL|CBT for Uncertainty - Enhanced (CUE)|CUE consists of a 1-hour manualized intervention that uses interactive content to enhance participant learning of critical intervention components. The session includes (1) psychoeducation regarding the role of IU in exacerbating anxiety/mood sensations, (2) practice identifying and challenging maladaptive thoughts about uncertainty and accompanying distress, and (3) behavioral activities to challenge participants' capacity to handle uncertainty.
223891781|NCT02616445|DRUG|UE2343|"* UE2343~* 10mg, 20, 35mg~* twice daily for 9 days"
223891782|NCT02616445|DRUG|Placebo|"* 10mg, 20, 35mg~* twice daily for 9 days"
223891783|NCT02616445|DRUG|Placebo|"* Cross-over study~* single dose administered twice (on day 1 and day 8)~* study duration 17 days"
223891784|NCT02616445|DRUG|UE2343|"* Cross-over study~* UE2343~* single dose administered twice (on day 1 and day 8)~* study duration 17 days"
223891785|NCT02616445|DRUG|UE2343|"* UE2343~* twice daily for 3 days~* single dose on day 4"
223891786|NCT05814874|DIETARY_SUPPLEMENT|selenium supplement|Selenium supplement containing 55 µg of sodium selenate
223891787|NCT05814874|DIETARY_SUPPLEMENT|Brazil nut|Brazil nut butter; consumption corresponds to a selenium intake of 55 µg/d
223891788|NCT05814874|OTHER|Placebo|Placebo pill
223891789|NCT06830226|DIETARY_SUPPLEMENT|Test group|In this group the Miris Human Milk analyzer will be used, consisting of a real-time mid-infrared technology that directly measures the concentration of protein, fat and carbohydrate, and calculates the energy content based on direct measurements.
223891790|NCT06830226|DIETARY_SUPPLEMENT|Reference group|In this group the Kjeldahl method will be used to assess total nitrogen concentration, the Röse-Gottlib method to assess fat concentration, and energy and carbohydrate concentration will be calculated by differences. Kjeldahl and the Röse-Gottlib are considered reference methods
223891791|NCT04354675|GENETIC|Automated program (ChatBot)|Pre-test counseling and information through a pre-test automated genetic counseling program (ChatBot)
223891792|NCT04354675|GENETIC|Genetics counselor|Traditional in-person genetic counseling
223891793|NCT04354675|OTHER|BCGCKQ Survey|Survey assessing Breast Cancer Genetic Counseling Knowledge Questionnaire (BCGCKQ)
223891794|NCT04354675|OTHER|Satisfaction Survey|Survey assessing satisfaction with Decision-Genetic Testing
223891795|NCT04354675|DEVICE|Genetic testing|Genetic testing for all participants will assess for a mutation in 47 genes commonly associated with hereditary cancer syndromes (Invitae's Common Hereditary Cancer Panel) for those who choose to complete testing.
223891796|NCT05162755|DRUG|S095029|S095029 will be administered via IV infusion every 2 weeks. Once the DLT evaluations period at the second dose level is completed and it is deemed as safe, the dose escalation part 1b will be initiated.
223891797|NCT05162755|DRUG|S95029 and Sym021|Sym021 will be administered at a fixed dose of 200mg. S095029 will be administered via IV infusion every 2 weeks. Once the RP2D dose of S95029 in combination with Sym21 is defined, dose expansion will begin.
223891798|NCT06164314|DRUG|Dexmedetomidine|In Dex group, dexmedetomidine will continue to be used during and after surgery, with a infusion of 0.4ug/kg/ h from anesthesia induction to dural closure, and then 0.08ug/kg/ h to 48 hours postoperatively.In placebo group, equivalent normal saline will be injected during operation, and the intravenous analgesia pump will not contain dexmedetomidine after operation
223891799|NCT06838338|DRUG|JAB-21822|Tablet, oral, 800 mg/QD, until PD or intolerable toxicity
223891800|NCT06838338|DRUG|standard second-line chemotherapy|The second line standard chemotherapy regimen recommended by clinical practice
223891801|NCT06838338|DRUG|Bevacizumab|According to the assessment by investigator
223891802|NCT06787807|PROCEDURE|bariatric surgery|sleeve gastrectomy
223891803|NCT04919109|BIOLOGICAL|CodaVax-RSV|live attenuated vaccine against RSV
223891804|NCT04919109|BIOLOGICAL|Normal Saline|Placebo comparator
223891805|NCT06787495|PROCEDURE|Arterial repair|Arterial repair starting from simple repair or vein graft or synthetic graft
223891806|NCT06342011|BEHAVIORAL|Anti-inflammatory diet group|"Patients in the intervention group were given AID knowledge education, and patients were asked to pay attention to the anti-inflammatory diet wechat mini program developed by the researchers to teach patients how to use it, including the selection of anti-inflammatory diet, unsuitable anti-inflammatory diet, diet alarm clock, diet notes and other related functions. The missionary patients insisted on AID until reexamination 8 weeks later."
223891807|NCT06833554|DIETARY_SUPPLEMENT|Omega-3 Fatty Acids (EPA plus DHA)|Dietary supplementation with Omega-3 Fatty Acids to study the effect on the immune system of breast milk
223891808|NCT06833554|DIETARY_SUPPLEMENT|Placebo|Inert dietary supplement, without activity in the activation of the immune system of breast milk
223891809|NCT03056040|BIOLOGICAL|Ravulizumab|All treatments were given as intravenous (IV) infusions. For participants weighing ≥40 to \<60 kilograms (kg): 2400 mg was given as a single loading dose, followed by 3000 mg as maintenance dose. For participants weighing ≥60 to \<100 kg: 2700 mg was given as a loading dose, followed by 3300 mg as maintenance dose. For participants weighing ≥100 kg: 3000 mg was given as a loading dose, followed by 3600 mg as maintenance dose.
223891810|NCT03056040|BIOLOGICAL|Eculizumab|All treatments were given as IV infusions. Participants received 900 mg of eculizumab q2w.
223891811|NCT04317716|BEHAVIORAL|fall prevention program|The intervention consists of the fall prevention program for ambulatory and non-ambulatory people with multiple sclerosis. The program will be group-based with 6-8 participants, led by a facilitator, and performed online. It comprises six two-hour sessions held once a week, and a booster session held eight weeks after the sixth session. In addition they will receive a brochure about falls and fall risk factors.
223891812|NCT04317716|OTHER|Brochure about falls and fall risk factors|Control-group participants will receive a brochure about fall risk factors and fall prevention in addition to the standard MS care and rehabilitation.
223891813|NCT06833242|DEVICE|Real-time 3D Xplane ultrasound|After the puncture needle is in the skin, the longitudinal section of the Xplane mode can be adjusted to keep the needle in the proposed plane.
223891814|NCT03372902|DEVICE|Breast MRI|Participants with dense breast tissue will get a mammogram and MRI
223891815|NCT03372902|DEVICE|Breast Mammogram|State-of-the-art full-field digital mammography (FFDM) and or digital breast tomosynthesis (DBT) comprising both raw and post-processed images as well as ultrasound and MRI images from the initial screening study will be collected and sent to the MSKCC Breast Radiology Department.
223891816|NCT03372902|OTHER|Blood draw|Participants will donate approximately 60ml of peripheral blood. Mononuclear cells from peripheral blood will be used to extract germline DNA. Germline genomic testing will be employed as a matched control for tumor sequencing and for germline breast cancer susceptibility testing.
223891817|NCT03372902|PROCEDURE|Breast Biopsy|Tissue specimens from the biopsy of the BI-RADS 4 mammographic lesion and (among women undergoing surgical excision) the surgical specimen(s) will be subjected to genomic profiling at GRAIL, Inc. or MSKCC. The tumor specimens from the participants diagnosed with cancer during the follow-up period will also undergo molecular profiling.
223891818|NCT03372902|BEHAVIORAL|online participant reported questionnaire|Participants will be asked to complete a questionnaire that covers the topics of breast health, general health and lifestyle, genetic testing, personal, and family history of cancer.
223891819|NCT06531928|OTHER|chest tube withdrawal|The Effect of Chest Tube Withdrawal on Patients' Anxiety Levels in Thoracic Surgery Cases Performed with Video-Assisted Thoracoscopic Surgery
223891820|NCT06848972|OTHER|Structured musculoskeletal exercise programme|The module emphasizes specific exercises, strength training with and without weight, flexibility exercises and balancing exercises.
223891821|NCT06848257|OTHER|Exercise|postural exercises
223891822|NCT04968119|OTHER|Exercise Intervention|Participate in telehealth exercise sessions
223891823|NCT04968119|OTHER|Quality-of-Life Assessment|Ancillary studies
223891824|NCT04968119|OTHER|Questionnaire Administration|Ancillary studies
223891825|NCT02386722|DEVICE|Electronic Monitoring with audio reminders and additional support|"Automated reminder:~-Daily audio-reminder, generated by a smartphone.~Support calls (only patients with Smartinhaler):~* When the use of rescue medication doubles.~* When inhaled medication was not inhaled as prescribed for more than two consecutive days.~Feedback on adherence (only patients with POEMS):~-At every clinical visit (after 2, 4 and 6 months)."
223891826|NCT06850649|OTHER|endocrowns|IPS Empress CAD Vita Enamic VarseoSmile Crown Plus
223891827|NCT06849323|OTHER|Sujok therapy|The researchers will first detect the pain points in the hands by palpating them with a metal probe, then apply a clockwise massage to the painful point with the same metal probe, and finally complete the intervention by fixing the natural seed. The fixed seed should remain in the area where it is fixed for at least 4-8 hours, it should not come into contact with water or any liquid during this period, and the seed used should be used only once. There should be no wounds/cuts/scratches in the area where the massage and seed are applied, and the tissue integrity should be complete. According to the International Sujok Association (ISA), seeds similar to organs will be used in seed therapy, as well as neutral seeds (fenugreek, buckwheat and mung bean). Buckwheat seed, which is a powerful acupressure, will be applied. The effectiveness of the su jok treatment will be evaluated using the Bournemouth Neck Pain Question on the 11th day after all interventions and as a follow-up after 4 weeks
223891828|NCT06848608|PROCEDURE|traditional physiotherapy group|"* Resistance training: It is planned to give strengthening exercises for the upper and lower extremities (quadriceps, hamstrings, gluteus medius, gastrosoleus, deltoids, triceps and biceps brachii) with the resistive exercise band. The fatigue severity perceived by the patients during the exercises is aimed to be 4-6 according to the Modified Borg scale~* Pursed-lip breathing training (10 repetitions)~* Chest breathing exercise (10 repetitions)~* Diaphragmatic breathing exercise (10 repetitions)~* Thoracic expansion exercises (10 repetitions - apical expansion, unilateral basal expansion, bilateral basal expansion, posterior basal expansion)~Additionally In terms of aerobic training, free walking will be provided 3 days a week. (Based on distance determined by 6 DYT)"
223891829|NCT06848608|PROCEDURE|yoga program|"Pranayamic techniques:~Nadi Shodhana: 2 sets of nadi shodhana pranayama consisting of 8 breathing cycles will be applied.~Ujjai: Two sets of ujjayi technique consisting of 10 breathing cycles with an inhalation:exhalation ratio of 1:2 in each session will be applied with a 1-minute rest period between sets.~Bhramari: Two sets of bhramari pranayama consisting of 10 breathing cycles will be applied with a low respiratory rate with a 1-minute rest period between sets.~Sukha Pranayama : It will be applied 5:5 inhalation:exhalation ratio for 5 minutes.~Kapalabhati: 15 quick breaths in 10 seconds followed by a 20-second break (30 breaths per minute in total) will be practiced for 3 minutes~Asanas:~Sukhasana Bharadvajasana Marjaryasana- Bitilasana Bhujaganasana Kapotasana Hasta uttanasana Virabhadrasana I~In addition, free walking will be given 3 days a week in terms of aerobic training. (Based on distance determined by 6 DYT)"
223891830|NCT06849102|OTHER|NeuroReAlign Therapy|Patients in this group will receive NeuroReAlign Therapy, including motor training (e.g., treadmill training, balance training), multimodal sensory stimulation (e.g., proprioceptive and visual), cognitive training (e.g., traditional cognitive exercise), and motivation, for 45 minutes per session, 3 times weekly, for 4 weeks.
223891831|NCT06849102|OTHER|conventional physiotherapy interventions|Patients in this group will receive conventional physiotherapy interventions, including treadmill training, balance training, strengthening and stretching lower limb muscles, for 45 minutes per session, 3 times weekly, for 4 weeks.
223891832|NCT06849921|DRUG|Cellular Therapy|"This intervention involves the infusion of autologous or allogeneic CAR-T cells into patients with relapsed/refractory hematologic malignancies. CAR-T cells are modified to target specific antigens on the surface of cancerous cells. After the infusion, patients will be monitored for response and safety.~Administration: Intravenous infusion. Dosage: The maximum tolerated dose (MTD) will be determined as part of the study, with dose escalation used to identify the optimal and safest dose of CAR-T cells for treatment."
223891833|NCT05205850|DRUG|RC118-ADC|RC118 for injection is a novel antibody-drug conjugate, with a Claudin 18.2-targeting antibody and a microtube inhibitor
223891834|NCT04163523|DRUG|Zanubrutinib|
223891835|NCT06389942|DRUG|9MW3011|Single dose intravenously on day 1
223891836|NCT06389942|DRUG|9MW3011 placebo|Single dose intravenously on day 1
223891837|NCT06849609|BIOLOGICAL|VGN-R13|An adeno-associated viral vector 9 gene therapy product.
223891838|NCT06558071|DRUG|Galatonol 300 mg/Striatin 30 mg|1 film-coated caplet of Herba Asimor, twice daily
223891839|NCT06558071|DRUG|Placebo|1 film-coated caplet of placebo Herba Asimor, twice daily
223891840|NCT06850597|DRUG|dimethyl fumarate|480 mg per day
223891841|NCT06848751|PROCEDURE|Non-intubated thoracoscopic surgery|Non-intubated thoracoscopic lung surgery for patients with impaired pulmonary function
223891842|NCT06848283|DIAGNOSTIC_TEST|Carotid ultrasonography|All examinations will be performed by a technician specialized in neurosonology, using the same technical protocol. For this purpose, a portable ultrasound device with a linear probe (L3-9 MHz) will be used. A quick screening will be conducted to check for the presence of atherosclerosis.
223891843|NCT02716012|DRUG|MTL-CEBPA|Intravenous administration
223891844|NCT02716012|DRUG|Sorafenib 200mg|Sorafenib tablets
223891845|NCT05118269|DEVICE|Treatment plus Optimal Medical Therapy|Patients will be treated with the InterVapor System in 1 to 2 segments in the upper lobes of each lung (2 to 3 segments total). Patients will also receive Optimal Medical Therapy. Guidelines for prescribing medical treatment for emphysema are published by the American Thoracic Society (ATS) and the National Heart Lung and Blood Institute/World Health Organization (NHLBI/World Health Organization , Global Initiative for Chronic Obstructive Lung Disease (GOLD) workshop summary).
223891846|NCT05118269|OTHER|Optimal Medical Therapy|Patients will receive Optimal Medical Therapy. Guidelines for prescribing medical treatment for emphysema are published by the American Thoracic Society (ATS) and the National Heart Lung and Blood Institute/World Health Organization (NHLBI/WHO GOLD workshop summary).
223891847|NCT06841315|DRUG|varegacestat|experimental intervention
223891848|NCT06116656|DIAGNOSTIC_TEST|blood leucocyte transcriptomics|the analysis of the RNA transcripts produced by the genotype at a given time that provides a link between the genome, the proteome, and the cellular phenotype.
223891849|NCT06850181|BEHAVIORAL|game experience and learning motivation|game experience and learning motivation
223891850|NCT05048667|DEVICE|Shock Wave therapy (SWT)|Each SWT will administer 720 shocks in the treatment arm. Total of 3600 shocks are given over 5 weeks treatment period.
223891851|NCT05048667|DRUG|Platelet Rich Plasma (PRP)|5 mL PRP will be administered via intracavernous injection
223891852|NCT05048667|OTHER|Sham SWT|Sham Shockwave Therapy will be administered in the sham arm.
223891853|NCT05048667|OTHER|Placebo Saline|5 mL Placebo saline will be administered via intracavernous injection in the sham arm.
223891854|NCT06848569|DRUG|Sintilimab in combination with AVD chemotherapy|Sintilimab in combination with AVD chemotherapy treating classical Hodgkin lymphoma
223891855|NCT06849817|OTHER|Diet - higher protein|Beef consumption 7 times per week (1 serving per day; 25 grams protein per serving (\~100 grams beef) as part of a higher protein diet (1.6 g protein/kg body weight)
223891856|NCT06849817|BEHAVIORAL|Physical activity and resistance training|150 minutes of physical activity including strength training 3 times per week
223891857|NCT06850064|PROCEDURE|Pulse Field Ablation (PFA)|The pulse field ablation group will undergo pulse field ablation of the mitral valve commissure.
223891858|NCT06850064|PROCEDURE|Radiofrequency ablation|In the radiofrequency ablation group, patients will undergo radiofrequency ablation targeted at the mitral valve commissure.
223891859|NCT03396926|BIOLOGICAL|Bevacizumab|Given intravenously (IV)
223891860|NCT03396926|DRUG|Capecitabine|Given orally (PO)
223891861|NCT03396926|PROCEDURE|Specimen collection|For use in correlative studies
223891862|NCT03396926|BIOLOGICAL|Pembrolizumab|Given IV
223891863|NCT06850285|DRUG|chimeric antigen receptor gene modified T cells|The rate of intravenous infusion of CD30 CAR T cells was 10 mL to 20 mL/min, and the infusion was performed using a blood transfusion apparatus with a filter screen. Use saline rinsing tube prior to infusion; Rinse the infusion bag with 10 mL\~30 mL normal saline.
223891864|NCT00450658|DRUG|HZT-501|HZT-501: Ibuprofen 800mg/famotidine 26.6mg orally 3 times daily for 24 weeks
223891865|NCT00450658|DRUG|Ibuprofen|Ibuprofen 800mg orally 3 times daily for 24 weeks
223891866|NCT04978519|PROCEDURE|Cryotherapy|Cryotherapy is administered by using perineal needles, placed under ultrasound guidance to freeze the target tissue.
223891867|NCT05763823|DRUG|Letermovir|Daily 240 mg or 480 mg oral tablets or IV dose
223891868|NCT06367829|PROCEDURE|Lubinus SPII hip stem 130mm|Shorter length of the SPII hip stem
223891869|NCT06367829|PROCEDURE|Lubinus SPII hip stem 150mm|Longer length of the SPII hip stem
223891870|NCT06262126|OTHER|Virtual Reality|Virtual Reality therapy
223891871|NCT03297151|DIETARY_SUPPLEMENT|CONTROL|"Food grade mixture of non-essential amino acids in powdered form, flavoured and instantised to be dissolved in water.~Supplied by Carbery Food Ingredients Limited, Ballineen, Ireland. Product Reference Number 10955"
223891872|NCT03297151|DIETARY_SUPPLEMENT|Whey Protein Concentrate|"Whey protein concentrate in powdered form, flavoured and instantised to be dissolved in water.~Supplied by Carbery Food Ingredients Limited, Ballineen, Ireland. Trade name of product is Carbelac80 Instant Product Reference Number 10431"
223891873|NCT03297151|DIETARY_SUPPLEMENT|Whey Protein Hydrolysate|"Whey protein concentrate hydrolysate (degree of hydrolysate 27%) in powdered form, flavoured and instantised to be dissolved in water.~Supplied by Carbery Food Ingredients Limited, Ballineen, Ireland. Product Reference Number 10468"
223891874|NCT05628129|OTHER|smartphone application service and phone reminder|smartphone application service and phone reminder for appointments of parents of congenital ectopia lentis patients
223891875|NCT03633955|DRUG|FLT|F18 labeled thymidine PET/CT scans will be performed before and after patient receives therapies.
223891876|NCT03778112|RADIATION|SBRT to whole prostate|Those patients with negative mpMRI prostate scan (PI-RADS 0-2) will receive SBRT (36.25 Gy/5 fractions) to the whole prostate
223891877|NCT03778112|RADIATION|IMRT followed by mpMRI guided SBRT boost with SIB to intraprostatic lesions|Patients with positive or equivocal mpMRI prostate scan (PI-RADS 3-5) will receive IMRT (45 Gy/25 fractions) to the prostate + seminal vesicles +/- lymph nodes followed by SBRT boost (18 Gy/3 fractions) to the whole prostate with simultaneous integrated boost (21 Gy/3 fractions) to MRI defined intraprostatic lesions
223891878|NCT03799991|BEHAVIORAL|Vestibular physical therapy|Vestibular therapy is a set of exercises delivered by a physical therapist involving head movements. The therapy is delivered over a course of 8 weeks.
223891879|NCT03799991|BEHAVIORAL|Active control|Strength and flexibility exercises that do not involve head movements.
223891880|NCT03302494|DEVICE|Coherex WaveCrest® Left Atrial Appendage Occlusion System|Percutaneous left atrial appendage closure
223891881|NCT03302494|DEVICE|Watchman® LAA Closure Device|Percutaeous left atrial appendage closure
223891882|NCT00179868|BEHAVIORAL|C-Reactive Protein levels|"Each patient enrolled in the study will have a serum quantitative c-reactive protein (crp) level drawn on the day of transplant, day 7 of transplant, and twice weekly after that until recovery of neutrophil count (approximately 20-25 days). Patients will be followed for 100 days post-transplant for the development of the following complications:~1. Sepsis- defined as fever, positive blood culture, need for fluid resuscitation and/or pressor support.~2. Acute GVHD \> grade II defined according to the Seattle criteria~3. VOD- defined according to the modified Seattle criteria"
223891883|NCT04513626|DRUG|DORAVIRINE 100 MG [Pifeltro]|Immediate switch
223891884|NCT05134233|DEVICE|Low-intensity Focused Ultrasound|LIFU application using various parameters, responses of neuromodulation recorded using TMS and EMG.
223891885|NCT00367666|DEVICE|MRI, Digital Mammography, Ultrasound and Positron Emission Tomography (PET)|
223891886|NCT05403736|OTHER|Cardiac Aggressive Risk MitigAtion Plan|Cardio-oncology consultation along with long-term collaborative cancer care visits during standard of care radiation therapy that will occur weekly for up to 6 weeks followed by 6-week and 3-month follow-up visits. Health will be monitored with biosensor monitoring devices.
223891887|NCT03386240|DRUG|Vicryl-plus, monocryl-plus, PDS-plus (Triclosan-coated Sutures)|The intervention consists of using Plus group (Triclosan-coated Sutures)
223891888|NCT03386240|OTHER|Vicryl, monocryl, PDS (not coated with triclosan)|Consists of equivalent sutures (not coated with triclosan) during cesarean delivery.
223891889|NCT06424977|DEVICE|Biomarker Targeted Stimulation (BTS)|Using continuous stimulation to target multiple network nodes, Biomarker Targeted Stimulation (BTS) is intended to suppress abnormal interictal activity, as determined by biomarkers including interictal epileptiform discharges (IED) and high frequency oscillations (HFO), with the intention to reduce brain hyperexcitability, thereby limiting seizure occurrence.
223891890|NCT04763265|BIOLOGICAL|"Botulinum toxin A BoNT/A-DP"|To assess the efficacy of treatment with BoNT/A-DP in reducing the severity of glabellar frown lines at maximum frown.
223891891|NCT04763265|BIOLOGICAL|"Botulinum toxin A Botox Cosmetics"|To assess the efficacy of treatment with Botox Cosmetics in reducing the severity of glabellar frown lines at maximum frown.
223891892|NCT04959318|OTHER|Professional nutrition counseling|Published multi-cohort genome-wide association studies provided genes and genetic variants that are credibly associated with aspects of metabolic syndrome (MetS), CVD, overweight/obesity, and vitamin D metabolism. Registered dietitian (RD) counseling will review potentially harmful and protective variants for risk of MetS with subjects and make evidence-based recommendations to improve diet quality and achieve weight loss goals. Each of the 6 weekly sessions covered a specific component of MetS. Counseling will take place once a week either in-person or via phone/virtual platform based on preference and availability of the subject. Counselors will review digital app data entries for food intake prior to this interaction for the first 2 weeks.
223891893|NCT04959318|OTHER|No professional nutrition counseling|Participants receive pamphlets with evidence-based general health, healthy nutrition, exercise and sleep content. They receive information on genetic variants related to MetS at end of study period.
223891894|NCT00397358|DRUG|Extraneal (7.5% icodextrin) Peritoneal Dialysis Solution|
223891895|NCT04418466|COMBINATION_PRODUCT|Risperidone|Risperidone Implant
223891896|NCT06516341|PROCEDURE|CD patients|The study will involve the collection of leftover surgical material after pathologist analysis, mucosal brushes, an additional volume of blood and feces of patients at the time of surgery
223891897|NCT06516341|PROCEDURE|UC patients|The study will involve the collection of leftover surgical material after pathologist analysis, mucosal brushes, an additional volume of blood and feces of patients at the time of surgery
223891898|NCT05180734|BIOLOGICAL|JS001/Placebo|JS001/placebo combine with Postoperative Adjuvant Chemotherapy
223891899|NCT05180734|BIOLOGICAL|JS001/placebo combine with Postoperative Adjuvant Chemotherapy|JS001/placebo combine with Postoperative Adjuvant Chemotherapy
223891900|NCT04785820|DRUG|Lomvastomig|2100 milligrams (mg) administered by intravenous (IV) infusion once every 2 weeks on Day 1 of each 14-day cycle.
223891901|NCT04785820|DRUG|Tobemstomig|2100 mg administered by IV infusion once every 2 weeks on Day 1 of each 14-day cycle.
223891902|NCT04785820|DRUG|Nivolumab|240 mg administered by IV infusion once every 2 weeks on Day 1 of each 14-day cycle.
223891903|NCT03047837|DRUG|ASA|Arm C (experimental arm) Treatment: active ASA + placebo MET Dose: 100 mg, 1 tablet daily + 1 tablet twice a day (BID) Duration: 12 months
223891904|NCT03047837|DRUG|MET|Arm B (experimental arm) Treatment: placebo ASA + active MET Dose: 1 tablet daily+ 850 mg, 1 tablet twice a day (BID) Duration: 12 months
223891905|NCT03047837|OTHER|Placebo|Arm A (control arm) Treatment: placebo ASA + placebo MET Doses: 1 tablet daily +1 tablet twice a day (BID) Duration: 12 months
223891906|NCT06499090|DRUG|Mirtazapine 30 MG|patients will receive orally the night before surgery the study medication and daily up to two weeks after Mirtazapine 30 mg tablet
223891907|NCT06499090|DRUG|Placebo|patients will receive orally the night before surgery the study medication and daily up to two weeks after placebo tablet
223891908|NCT00733694|DEVICE|LCS® Complete™ Mobile Bearing Knee Systems|An orthopaedic implant for primary total knee replacement with a mobile bearing knee
223891909|NCT06383676|OTHER|Functional reaction balance training|The interventions will carried out two days a week and 40 minutes, for eight weeks.
223891910|NCT06383676|OTHER|Functional balance training|The interventions will carried out two days a week and 40 minutes, for eight weeks.
223891911|NCT06092879|OTHER|Asciminib|There is no treatment allocation. Patients administered Asciminib by prescription will be enrolled
223891912|NCT04958811|DRUG|Tiragolumab|600mg IV administered every 3 weeks.
223891913|NCT04958811|DRUG|Atezolizumab|1200mg IV administered every 3 weeks.
223891914|NCT04958811|DRUG|Bevacizumab|15mg/kg IV administered every 3 weeks.
223891915|NCT05477979|OTHER|Exposure: psychological stress status|The assessment of depressive and anxiety symptoms was conducted using Patient Health Questionnaire-9 (PHQ-9) and Generalized Anxiety Disorder Assessment 7 (GAD-7). Patients with a PHQ-9 score ≥ 5 or a GAD-7 score ≥ 5 were categorized as the stressed group.
223891916|NCT04680663|DIAGNOSTIC_TEST|Peripheral Perfusion index|Peripheral Perfusion index is the ratio between pulsatile blood flow to non pulsatile blood flow or static blood in the peripheral tissue
223891917|NCT04680663|DIAGNOSTIC_TEST|serum lactate level|Blood lactate (product of metabolism) level is maintained by a cycle of continuous production and metabolism allowing it to be kept within normal values
223891918|NCT03846167|DRUG|Imaging Drug FluorThanatrace (FTT)|\[18F\]FTT is an investigational radioactive PET drug used to see PARP-1 activity in tumors. This radioactive imaging drug is injected into the body to see how it goes into places where there is active breast cancer. Using an imaging scan called Positron Emission Tomography (PET/CT), the radioactive drug can be seen in the body.
223891919|NCT05925569|OTHER|Best Practice Advisory Computerized Alert|For patients randomly assigned to the BPA Alert Group, an on-screen electronic alert will be issued during the outpatient clinical encounter than notifies the clinician that their patient should be screened for PA. The clinician will be provided with on-screen details of which patient-specific risk factors qualified them for PA screening and with an option to order a plasma renin activity, aldosterone, and basic metabolic panel. If screening labs are ordered, the clinician will also receive an option to order an eConsult for expert guidance on interpretation of the test results. If the clinician does not order the PA screening labs, they will be able to continue with clinical EHR documentation but will need to select a reason they opted not to follow the alert's evidence-based clinical practice recommendation.
223891922|NCT05869591|DRUG|Apixaban 5 MG [Eliquis]|Pharmacokinetics and pharmacodynamics assessment of apixaban in patients with Child A or B liver cirrhosis
223891923|NCT05869591|DRUG|Edoxaban 60 MG [Lixiana]|Pharmacokinetics and pharmacodynamics assessment of edoxaban in patients with Child A or B liver cirrhosis
223891924|NCT03841318|BIOLOGICAL|blood sample|36 ml whole blood for Peripheral blood mononuclear cell (PBMC) and monocytes isolation
223891925|NCT03841318|BIOLOGICAL|biopsy of the labial salivary gland|Part of the biopsy of the labial salivary gland
223891926|NCT04055207|OTHER|VVC|Telehealth treatment is delivered via VA-approved technology to a patient's computer or mobile device.
223891927|NCT03730454|DEVICE|Transanastomotic Tube (5FR)|5FR tube left in place for 5 days after completion of esophageal anastomosis.
223891928|NCT03730454|OTHER|No Transanastomotic Tube|No transanastomotic tube used during repair
223891929|NCT04680741|BEHAVIORAL|Addiction Pilot App behavior tracking|a smartphone-based application (app) which is designed to monitor attendance at twelve-step facilitation meetings.
223891930|NCT06320106|OTHER|Virtual Reality baseline assessment|"They undergo a baseline assessment (including cognitive level and pen and paper tests for visuo-spatial abilities). Then they perform a spatial navigation assessment with an immersive virtual reality application delivered by the Oculus Quest viewer. The spatial navigation application consists of a 5-way star-maze adapted from (Biffi et al 2020 Front. Psychol.) where the participants have to find a treasure hidden at the end of one way. The application measures both the learning of spatial information and the strategy used (egocentric or allocentric).~After the session, the participants fill questionnaires related to cyber-sickness and usability of the application."
223891931|NCT05520710|BEHAVIORAL|Cognitive Rehabilitation|A strategy-focused intervention aimed at improving everyday cognitive function, structured to maximize treatment dose over a short time period. The shorter time period of the treatment therapy is relative to the one and only current randomized controlled trial of cognitive rehabilitation for military mTBI, the Study of Cognitive Rehabilitation Effectiveness (SCORE).
223891932|NCT05520710|OTHER|Education|Educational materials, designed to help people with traumatic brain injury manage their everyday cognitive challenges will be provided through Zoom video conferencing software.
223891933|NCT03657771|OTHER|DED|DED: Diet eliminating dairy
223891934|NCT03657771|OTHER|FREE|FREE: Diet eliminating dairy and food additives
223891935|NCT05044000|DEVICE|Deep propioceptive stimulation|Participants will start using the blanket (of the arm name), 30 days wash-out and 15d with the other blanket
223891936|NCT05701306|DRUG|APG-115|Orally once every other day(QOD) for 2 weeks and suspended for 1 week, 21 days as a cycle.
223891937|NCT05701306|DRUG|APG-2575|Orally once a day (QD) for 21 days, 21 days as a cycle.
223891938|NCT03673709|BEHAVIORAL|Antenatal Care|Women in group care bypass the waiting room and have a 2-hour visit with the same provider with a group of 8-12 women at a similar stage of pregnancy. Women assess their own blood pressure and weight, briefly consult the midwife in a corner of the room, and meet for 80-90 minutes of interactive health promotion, enlivened by games and role-plays.
223891939|NCT03085147|DRUG|Olaparib|For PARRi-FL, imaging patients will first gargle a solution of PARRi-FL for 1 min, then spit out this solution and gargle with a cleaning solution (the solvent used for PARRi-FL) for 1 min. Then fluorescence imaging of the oral cavity and pharynx will be performed with an endoscope. The intensity and extent of the fluorescence signal will be recorded by one of the investigators for the tumor and adjacent normal mucosa.
223891940|NCT05071807|DRUG|Pecans|Participants will receive 2 oz of pecans daily to replace a typical snack and continue consuming their usual diet for 12 weeks.
223891941|NCT05071807|OTHER|Usual Care|Participants will receive grocery vouchers and continue consuming their usual diet for 12 weeks.
223891942|NCT01963793|DRUG|Aprepitant|Aprepitant gel (10 mg/g)
223891943|NCT01963793|DRUG|Placebo|gel without active component
223891944|NCT05457738|OTHER|E-REVA® app|Use of a smartphone app designed for home-based exercise therapy of patients with intermittent claudication. App's name is E-REVA®.
223891945|NCT05457738|OTHER|No E-REVA® app|No use smartphone
223891946|NCT04356612|OTHER|Chart Review|This is a retrospective chart review to determine the etiologies contributing to prolonged PACU discharge at a major Orthopedic Ambulatory Surgical Center.
223891947|NCT04472351|BEHAVIORAL|ASCEND-I|"The intervention is an inpatient version of a novel behavioral intervention named ASCEND (A Strategy and Computer-based Intervention to ENhance Daily Cognitive Functioning after Stroke). ASCEND-I combines computer-based cognitive training exercises, with structured coaching sessions within patients' occupational therapy. Computer-based training is 30 minutes in length daily, and strategy training within patients' occupational therapy ranges from 30-60 minutes (depending on patients' clinical goals). The computer exercises aim to improve working memory (WM) through a series of engaging and interactive computer games (e.g., card games, virtual shopping, mental arithmetic). The Multicontext OT sessions aim to assist the participant in generalizing and transferring skills from the computer exercises to everyday activities and to develop further strategies to compensate for WM difficulties."
223891948|NCT06595615|DEVICE|cardiovascular implantable electronic devices|Standard of care patients indicated for the devices
223891949|NCT01552473|BEHAVIORAL|Brain Training Program 1|The training program includes 12 sessions conducted over 8 weeks. The goal of these treatment sessions is to provide information on brain injury and its recovery process. Activities involved in the sessions include discussion of study material. Participants will be encouraged to apply the information to their daily lives. The program includes additional outside practice of the activities.
223891950|NCT01552473|BEHAVIORAL|Brain Training Program 2|The training program includes 12 sessions conducted over 8 weeks. The goal of these treatment sessions is to provide strategies to improve brain injury and its recovery process. Activities involved in the sessions include strategies and discussion of study material. Participants will be encouraged to apply the strategies and information to their daily lives. The program includes additional outside practice of the activities.
223891951|NCT02664805|DRUG|LEO 124249 ointment|Ointment
223891952|NCT02664805|DRUG|LEO 124249 ointment vehicle|Ointment vehicle
223891953|NCT04971343|DIAGNOSTIC_TEST|Access HIV_blood donor|"Samples will be tested with both reference HIV Ag/Ab combo assay and Access HIV Ag/Ab combo assay according to respective IFU to determine non-reactive, initially reactive, and repeatedly reactive. Reference assay will be Roche - Cobas - Elecsys® HIV Duo .~* All initially reactive specimen results will be tested in duplicate per IFU .~* All RR specimens will be confirmed using testing including ImmunoBlot, Western Blot or HIV-1/HIV-2 differentiation test and HIV-1 PCR, RNA (if Immunoblot, WesternBlot or differentiation test is negative or indeterminate; if Immunoblot, WesternBlot or differentiation test is positive for HIV-2 then HIV-1 PCR will not be tested)."
223891954|NCT04971343|DIAGNOSTIC_TEST|Access HIV_Hospitalized patient|"All samples will be tested with both reference HIV Ag/Ab combo assay and Access HIV Ag/Ab combo assay according to respective IFU to determine non-reactive, initially reactive, and repeatedly reactive. Reference assay will be Abbott Architect HIV Ag/Ab combo assay for hospitalized patient.~* All initially reactive specimen results will be tested in duplicate per IFU .~* All RR specimens will be confirmed using testing including ImmunoBlot, Western Blot or HIV-1/HIV-2 differentiation test and HIV-1 PCR, RNA (if Immunoblot, WesternBlot or differentiation test is negative or indeterminate; if Immunoblot, WesternBlot or differentiation test is positive for HIV-2 then HIV-1 PCR will not be tested)."
223891955|NCT04971343|DIAGNOSTIC_TEST|Access HIV_known HIV-1 antibody positives|"Samples will be tested with both reference HIV Ag/Ab combo assay and Access HIV Ag/Ab combo assay according to respective IFU to determine non-reactive, initially reactive, and repeatedly reactive. Reference assay will be Abbott Architect HIV Ag/Ab combo assay .~* All initially reactive specimen results will be tested in duplicate per IFU .~* For the known positive cohorts (sensitivity cohorts), samples will be identified as positive at enrollment/time of testing according to inclusion criteria prior to testing or in parallel of testing with Access and Reference HIV Ag/Ab combo assays.~In case of discrepant results or concordant negative results between Access and Reference HIV Ag/Ab combo assay among known HIV-1 antibody positive patients, the IB/WB test will be repeated by the site to confirm sample status. If this IB/WB result is negative or indeterminate, the sample will be excluded from the statistical analysis"
223891956|NCT04971343|DIAGNOSTIC_TEST|Access HIV_known HIV-2 antibody positives|"Samples will be tested with both reference HIV Ag/Ab combo assay and Access HIV Ag/Ab combo assay according to respective IFU to determine non-reactive, initially reactive, and repeatedly reactive. Reference assay will be Abbott Architect HIV Ag/Ab combo assay.~* All initially reactive specimen results will be tested in duplicate per IFU .~* For the known positive cohorts (sensitivity cohorts), samples will be identified as positive at enrollment/time of testing according to inclusion criteria prior to testing or in parallel of testing with Access and Reference HIV Ag/Ab combo assays."
223891957|NCT04971343|DIAGNOSTIC_TEST|Access HIV_known HIV-1 p24 Ag positive|"All samples will be tested with both Reference HIV Ag/Ab combo assay and Access HIV Ag/Ab combo assay according to respective IFUs/study guide to determine non-reactive (NR), initially reactive (IR), and repeatedly reactive (RR). Reference assay will be Abbott - ARCHITECT HIV Ag/Ab Combo Assay.~* Due to volume constraints, all known HIV-1 p24 Ag positive samples that will be tested during the EU HIV clinical trial will be tested in singulare only with the Reference HIV Ag/Ab combo assay, and in singulare and then in duplicate if IR with Access HIV Ag/Ab combo assay.~* For the known positive cohorts (sensitivity cohorts), samples will be identified as positive at enrollment/time of testing according to inclusion criteria prior to testing or in parallel of testing with Access and Reference HIV Ag/Ab combo assays"
223891958|NCT04971343|DIAGNOSTIC_TEST|Access HIV_Canada's requirements_Blood donor|"To fit with Canada's requirements:~* 4,000 additional blood donor samples from geographically distinct regions will be collected and tested. Blood donor sample testing will be equally distributed over three blood donor sites, using 3 different lots of reagents: the first 2,000 blood donor samples from CE-marking study (out of the 6,000 tested) will be used plus the 4,000 additional blood donor samples.~* Retesting of 1000 blood donor samples will be done internally with 1 lot close to expiration to satisfy Canadian requirements"
223891959|NCT04971343|DIAGNOSTIC_TEST|Access HIV_Canada's requirements_HIV positive|"To fit with Canada's requirements:~o HIV positive samples will be equally distributed and tested at leat three (3) testing sites, using 3 lots of reagents."
223891960|NCT04971343|DIAGNOSTIC_TEST|Access HIV_Canada's requirements_P24 Positive|"To fit with Canada's requirements:~* HIV positive samples will be equally distributed and tested at leat three (3) testing sites, using 3 lots of reagents.~* Collection and testing of maximum 210 additional HIV-1 Ag positive sample beyond the 50 required by CTS"
223891961|NCT05839951|DRUG|Regorafenib (BAY73-4506, Stivarga®)|Oral multitargeted kinase inhibitor
223891962|NCT05839951|DRUG|TAS-102 (trifluridine and tipiracil, Lonsurf®)|Oral cytotoxic chemotherapy
223891963|NCT05839951|DRUG|Bevacizumab|VEGFR inhibitor
223891964|NCT04836195|DRUG|PCLX-001 - 20mg|20mg daily oral pills
223891965|NCT04836195|DRUG|PCLX-001 - 40mg|40mg daily oral pills
223891966|NCT04836195|DRUG|PCLX-001 - 70mg|70mg daily oral pills
223891967|NCT04836195|DRUG|PCLX-001 - 100mg|100mg daily oral pills
223891968|NCT04836195|DRUG|PCLX-001 - 140mg|140mg daily oral pills
223891969|NCT04836195|DRUG|PCLX-001 - 210mg|210mg daily oral pills
223891970|NCT04836195|DRUG|PCLX-001 - 280mg|280mg daily oral pills
223891971|NCT05609760|OTHER|SIMAP|Pictographic depiction of medical indications alongside standard communication of these recommendations.
223891972|NCT05609760|OTHER|Usual Care|Standard communication by medical staff of treatment indications for asthma. An informative leaflet will be delivered as well.
223891973|NCT06852833|BEHAVIORAL|One-day Mind Programme for women with breast cancer|This programme is theoretically founded on contextual behavioural therapies ( ACT and compassion-based interventions) and tailored for women with breast cancer. Its format comprises 1 session with the duration of 7 hours, that will be delivered by 2 psychologists through a secure video calling platform, in two subsequent days.
223891974|NCT04049643|DEVICE|Audiologist-based fitting|Hearing aids will be fitted by audiologists using established procedures.
223891975|NCT04049643|DEVICE|Service-only Fitting|This intervention group is designed to explore the contribution of amplification devices in hearing aid intervention, which consists of devices and services. In this intervention group, audiological services plus hearing aids that provide minimum amplification will be provided. Specifically, patient participants in this group will receive audiological services (e.g., counselling and education), except that the hearing aids will be set to provide no amplification other than what is needed to overcome any sounds that are dampened by the earpieces.
223891976|NCT04049643|DEVICE|Device-only fitting|This intervention group is designed to explore the contribution of amplification devices in hearing aid intervention, which consists of devices and services. The patient participants in this intervention group will have minimum services regarding the pre-fitting, selection, and orientation of the hearing aids. The participants will have a hearing evaluation, including pure-tone audiometry. The audiologist will select the amplification characteristics and non-custom ear piece based on the audiogram. The audiologist will then briefly orient the participant on how to use the hearing aids and counsel on how to optimize their performance.
223891977|NCT03814291|DRUG|IBI302|0.05mg/eye;Intraocular injection
223891978|NCT03814291|DRUG|IBI302|0.15mg/eye;Intraocular injection
223891979|NCT03814291|DRUG|IBI302|0.5mg/eye;Intraocular injection
223891980|NCT03814291|DRUG|IBI302|1mg/eye;Intraocular injection
223891981|NCT03814291|DRUG|IBI302|2mg/eye;Intraocular injection
223891982|NCT03814291|DRUG|IBI302|4mg/eye;Intraocular injection
223891983|NCT06434272|OTHER|Early exercise with partial Blood Flow Restriction|"The intervention comprises of 12 weeks of blood flow restriction exercise in weeks 1-12 after injury. Three weekly exercise sessions are performed. Six supervised sessions are provided during the 12 weeks.~Blood flow restriction of 80% of the limb occlusion pressure required to fully restrict the arterial blood flow is employed.~The intervention comprises three exercises: Seated leg extension, standing knee flexion, and seated heel-rise performed at home as an adjunct to usual care treatment.~Each exercise is performed in four sets of 30, 15, 15, +1 repetitions, with the fourth set (+1) being as many repetitions as possible.~Pause in between sets is 30 seconds. Pause in between exercises are 120 seconds.~In weeks 13-24, patients in this arm follow usual care treatment."
223891984|NCT06434272|OTHER|Late exercise with partial Blood Flow Restriction|"The intervention comprises of 12 weeks of blood flow restriction exercise in weeks 13-24 after injury. Three weekly exercise sessions are performed. Six supervised sessions are provided during the 12 weeks.~Blood flow restriction of 80% of the limb occlusion pressure required to fully restrict the arterial blood flow is employed.~The intervention comprises three exercises: Leg press in machine, heel-rise in machine, knee flexion in machine performed at training facilities as an adjunct to usual care treatment. If facilities are unavailable, three home-based exercises will be provided.~Each exercise, regardless of study arm, is performed in four sets of 30, 15, 15, +1 repetitions, with the fourth set (+1) being as many repetitions as possible.~In weeks 1-12, patients in this arm follow usual care treatment."
223891985|NCT06031038|OTHER|TECCU Software|patient monitoring by software application
223891986|NCT03021031|OTHER|Observational|Observational study
223891987|NCT06134375|DRUG|Tetrathiomolybdate|Tetrathiomolybdate (TM): Ammonium tetrathiomolybdate (TM), an oral copper lowering agent, has been established as safe in patients with Wilson's disease and advanced cancer. TM forms stable copper-molybdenum clusters sequestering copper and thereby limiting its availability, for the proper functioning of angiogenic factors, including secreted metalloenzymes. TM inhibits several copper containing enzymes including ceruloplasmin, cytochrome oxidase, tyrosinase and downregulates cytokines such as MMP9 and VEGF as well as transcription factors such as NF-kB. Both pre-clinical and clinical data suggest that TM may effectively reduce both overt and sub-clinical tumor load by both targeting the metastases initiating stem cell component of primary tumors inactivating Complex IV, shifting oxphos to glycolysis and through stromal remodeling.
223891988|NCT06134375|DRUG|Capecitabine|1000mg/m2 twice daily, Days 1-14 Q21days for 6 months
223891989|NCT06134375|DRUG|Pembrolizumab|If pembrolizumab was administered in the neoadjuvant setting and the oncology team chooses to continue in the adjuvant setting, standard doses will be used (200 mg IV Q3weeks or 400 mg IV Q6 weeks for one year total as per package insert)
223891990|NCT05062460|OTHER|1 hour Blood glucose monitoring|Consented patients who are diagnosed with gestational diabetes will be randomized to 1-hour postprandial blood glucose monitoring.
223891991|NCT05062460|OTHER|2 hour blood glucose monitoring|Consented patients who are diagnosed with gestational diabetes will be randomized to 2 hour post prandial blood glucose monitoring
223891992|NCT06283849|BEHAVIORAL|strategies to break up SB|Participants will be asked to implement strategies to break up their SB every hour for at least 8 hours a day for one week. Strategies will be developed through collaboration with participants during the first study interview and may include (but are not limited to): calf raises, brief (\~5 min) self-paced walking), squats, sit to stand, etc. Participants will wear an activity monitor for assessment of SB and walking. This device (activPAL, PALTechnologies, Glasgow, Scotland) is not an investigational device; it is used for monitoring sedentary behavior.
223891993|NCT02653755|DEVICE|Prosigna|Transcriptional profile of 50 genes used for risk stratification.
223891994|NCT06854614|OTHER|Comprehensive weight loss|Shared Medical Appointments
223891995|NCT06854614|OTHER|Enhanced lifestyle changes|Subjects will also be referred to an exercise physiologist for a personalized physical activity program. Physical Activity and Exercise will be discussed during SMAs as well and individually as needed for exercise progression The participants exercise prescription will be individualized based on an initial assessment. Exercise duration and progression will be recommended at the discretion of staff and exercise physiologist. The exercise program will be structured but flexible, which means patients can substitute group exercises with individual exercise if necessary, following the FITT-VP format (frequency, intensity, time, type, volume and progression). Patients can reduce exercise frequency if the duration is prolonged, or intensity is increased. Investigators will encourage patients to use Cleveland Clinic gyms across the enterprise.
223891996|NCT06854614|DRUG|Phentermine-Topiramate|Medication for chronic weight management (Rx)
223891997|NCT06854614|DRUG|Naltrexone-Bupropion Combination|Medication for chronic weight management (Rx)
223891998|NCT06854614|DRUG|Orlistat|Medication for chronic weight management (Rx)
223891999|NCT06657703|DRUG|HC022|Administered as specified in the treatment arm
223892000|NCT06657703|DRUG|Placebo|Administered as specified in the treatment arm
223892001|NCT06987409|PROCEDURE|Continuous erector spinae plane block|The attending surgeon or fellow will place the erector spinae plane catheters in the operating room. Following decompression +/- fusion of the lumbar spine, catheters will be placed under direct vision. The tips of the catheters will be placed superficial to the transverse processes, instrumentation, and bone graft of the lumbar spine, as applicable to the procedure. These will be deep to the erector spinae muscles, which will be closed on top of the catheters.
223892002|NCT06692699|DEVICE|Single vision spectacle lens|Standard single vision spectacle lens
223892003|NCT06692699|DEVICE|A.R.R.E.S.T. spectacle film|A.R.R.E.S.T. spectacle film
223892004|NCT06779435|DRUG|Low intensity treatment options|"Reference options for a combined regimen include C-R2, C-R-mini-CHOP, etc.~Subjects whose efficacy is assessed as CR after the end of induction therapy will enter consolidation therapy. Tucidinostat maintenance therapy or autologous hematopoietic stem cell transplantation may be an option. Tucidinostat maintenance therapy will be performed every 3 weeks. .Single-drug maintenance is recommended to last 24 weeks"
223892005|NCT06779435|DRUG|Conventional immunochemotherapy regimen|"Reference options for a combined regimen include CR-CHOP, C-Pola-R-CHP, etc.~Subjects whose efficacy is assessed as CR after the end of induction therapy will enter consolidation therapy. Tucidinostat maintenance therapy or autologous hematopoietic stem cell transplantation may be an option. Tucidinostat maintenance therapy will be performed every 3 weeks. Single-drug maintenance is recommended to last 24 weeks"
223892006|NCT06921330|OTHER|white cover|A white cover will be covered over the incubator during phototherapy.
223892007|NCT06921330|OTHER|masaj|-Baby massage will be applied during phototherapy.
223892008|NCT05543798|DEVICE|Vision-MR Ablation Catheter 2.0|Catheter ablation of ventricular tachycardia
223892009|NCT06845969|OTHER|Education: dry needling theory|Education relating to the theory of dry needling by physiotherapists
223892010|NCT06845969|OTHER|Education: Cadaver anatomy review|Educational instruction regarding the safe implementation of dry needling by physiotherapists using cadaver material.
223892011|NCT05521672|DRUG|Adipose derived allogenic mesenchymal stem cells (adAMSC)|adAMSC will be administered in the perilesional adipose tissue, through a laparoscopic procedure
223892012|NCT06925659|DRUG|QLM2011|QLM2011l by intravenous infusion.
223892013|NCT06925659|DRUG|Taxotere®|Taxotere® by intravenous infusion
223892014|NCT06931548|PROCEDURE|Implant-based breast reconstruction using polytetrafluoroethylene mesh|Patients will undergo subcutaneous or skin-sparing mastectomy using the standard technique. Simultaneously, breast reconstruction will be performed using a breast implant. The lower pole of the implant and the inframammary fold will be additionally reinforced with polytetrafluoroethylene (PTFE) mesh. The lower edge of the mesh is sutured in the projection of the inframammary fold, and the upper edge is sutured to the pectoralis major muscle.
223892015|NCT06931548|PROCEDURE|Implant-based breast reconstruction using Allogeneic dura mater graft|Patients will undergo subcutaneous or skin-sparing mastectomy using the standard technique. Simultaneously, breast reconstruction will be performed using a breast implant. The lower pole of the implant and the inframammary fold will be additionally reinforced with an allogeneic dura mater graft. The lower edge of the mesh is sutured in the projection of the inframammary fold, and the upper edge is sutured to the pectoralis major muscle.
223892016|NCT06931847|OTHER|SUNRISE program|"The program will use several solutions, each focusing on different aspects of health promotion:~* SmartCoach, a mobile phone-based life-skills training program, focuses on self-management, social skills, and substance use resistance.~* Social robots and conversational assistants aim to engage students through interactive sessions on health topics like diet and physical activity.~* Educational and serious games enhance knowledge and resistance to unhealthy food marketing, providing an engaging way to learn about advertising tactics and healthy eating.~* The influencer campaign tackles nutritional misinformation by using content created by influencers to educate adolescents on detecting and critically evaluating misleading health information.~* Health and advertisement educational module aims to educate students on recognizing deceptive advertising and making informed choices about their health."
223892017|NCT06931366|PROCEDURE|Open reduction and internal fixation|plates and screws
223892018|NCT06931782|OTHER|AI|GPT-4o fine-tuned with the Lungdiag database
223892019|NCT06386770|DRUG|Dexmedetomidine Injection [Precedex]|Group ΙI (group DL): erector spinae block will receive 30 ml (28 ml bupivacaine 0.25% plus dexamedetomedine (0.5µg/kg) diluted in 2ml normal saline Na cl 0,9% ) + 10ml IV normal saline will be injected over 10 min after 10 min from the induction of general anesthesia
223892020|NCT06386770|DRUG|Bupivacaine Hydrochloride|.Group Ι Block only (group BO) (control group): erector spinae block will receive 30 ml ( 28 ml bupivacaine 0.25% +2ml normal saline Na cl 0,9 %) +10ml IV normal saline will be injected over 10 min after 10 min from the induction of general anesthesia
223892021|NCT06386770|DRUG|Dexmedetomidine in 0.9 % NaCl 200 Mcg/50 mL (4 Mcg/mL) INTRAVEN INFUSION BOTTLE (ML)|Group III (group D IV): erector spinea block will receive 30 ml ( 28 ml bupivacaine 0.25% +2ml normal saline Na cl 0,9%) + dexamedetomedine (0.5µg/kg) diluted with 10 ml normal saline IV infusion by syringe pump over 10 min after 10 min from the induction of general anesthesia.
223892022|NCT06932003|DRUG|LT-002-158 Tablets|The subjects will orally administered LT-002-158 tablets once a day.
223892023|NCT06931990|DRUG|LT-002-158 tablets|The subjects will orally administered LT-002-158 tablets once a day.
223892024|NCT05825625|DRUG|Atezolizumab|Atezolizumab 1,200 mg by IV infusion Q3W.
223892025|NCT05825625|DRUG|Tiragolumab|Tiragolumab by IV infusion Q3W.
223892026|NCT06933030|DEVICE|titanium mesh with bone graft with delayed implant placement.|titanium mesh with bone graft with delayed implant placement.
223892027|NCT06933030|DEVICE|zirconium mesh with bone graft with delayed implant placement.|zirconium mesh with bone graft with delayed implant placement.
223892028|NCT06931678|PROCEDURE|aPDT|This intervention involves the application of antimicrobial photodynamic therapy (aPDT) using methylene blue as a photosensitizer, followed by activation with a light source at an appropriate wavelength. The protocol is applied after conventional root canal preparation and irrigation. The aPDT protocol is standardized and performed in both medically healthy patients and patients with Type 2 Diabetes Mellitus (T2DM), allowing comparison of microbiological and clinical outcomes between the two groups. This intervention aims to enhance root canal disinfection, particularly in anatomically complex areas that are difficult to reach with traditional methods.
223892029|NCT06404073|BEHAVIORAL|Structured Pacing|Participants in this group will complete weekly pacing sessions for 12 weeks. Pacing sessions will last about 30 minutes, as tolerated. Each participant will meet with a provider 'pacing coach' who has received study-specific education about PEM and how to create and manage pacing strategies for participants. Sessions include PEM symptom and trigger assessment; task, function and activity analysis; adaptations and modifications.
223892030|NCT06404073|OTHER|Usual Care|Participants in this group will receive basic education about PEM with a weekly call by site study staff for support and communication.
223892031|NCT05302596|DRUG|Semaglutide Pen Injector|semaglutide (up to 1mg) once weekly injection added to the standard of care weight loss program. Semaglutide dose will be started at 0.25 mg dose during the baseline visit and doubled every 2 weeks up to 1mg dose or up to maximum tolerable dose for total of 16 weeks of intervention
224079035|NCT02646527|BEHAVIORAL|Dignity Therapy|Dignity Therapy (DT) is a brief psychotherapeutic intervention developed by Chochinov (2012) which has been shown to enhance the end of life experience in people with life-limiting conditions. DT focuses on helping patients with terminal illnesses to go over things that are most meaningful to them and document their legacy. Dignity Therapy+ (DT+) involves patient and partner/family asking questions about their most important achievements, roles and other important aspects of life. DT+ encourages patients saying things to loved ones that have remained unsaid. DT+ consists of 3 sessions (1. introduction (30'); 2. main session (60'), 3. final session (30')) and will be conducted by a trained therapist. All therapy session will be audio-taped, transcribed verbatim by the study coordinator, edited by the therapist and returned to the patient or the patient and partner/family as a 'generativity document'.
224079036|NCT06444672|OTHER|Home-based Rehabilitation program|Home-based rehabilitation program The investigators used the ASIA scale to evaluate the sensory function and voluntary movement7. The HBRP included whole-body training with various exercises for stretching, strength, endurance, and aerobic fitness. The treatment sessions were performed three times per week and had a 50-120-minute duration. The exercises were modified based on individual progress and included the use of a rubber ball for balance and strength as well as trunk flexibility, static balance, stability, and standing exercises. Participants who could stand with assistive devices (such as knee-ankle-foot orthoses, KAFO) performed walking exercises.
224079037|NCT06444672|DEVICE|Knee-Ankle-Foot-Orthosis|It is used to assist the participant in holding his /her body weight on the lower limb through standing and walking
224079038|NCT03676127|OTHER|ultrasonographic dermal thickness measurements|ultrasonographic dermal thickness measurements
224079039|NCT01415635|DIETARY_SUPPLEMENT|Nutritional intervention using|"The study is af 12 week randomized clinical trail with inclusion of 96 patients at nutritional risk, according to the NRS-2002 system. The intervention group is is given a tailored nutritional care(the possibility to order small energy and protein-enriched dishes called Delights of Herlev Hospital)."
224079040|NCT04075929|OTHER|Training effects on aerobic output|The cyclists were allowed to perform ad libitum low intensity (LIT) in addition to high intensity (HIT) sessions that were determined to each group. The cyclists completed 12 supervised HIT sessions during the intervention period, three HIT sessions per week with at least 48 hours between each HIT-session. All HIT sessions were performed as supervised group training sessions. Each HIT session started with an individual 30 minutes' warm up at low intensity (55-70% HRmax) interspersed by freely chosen progressive sprints. For all groups the power output during the recovery periods was 50 % of the power output used during work intervals. The cyclists in all groups were instructed to perform each interval session at their maximal sustainable intensity. Each session ended with 15-20 minutes' cool down (55-70% HRmax). All HIT sessions were supervised and performed in groups on the University of Agder's (UiA) premises at Spicheren fitness center in Kristiansand.
224079041|NCT01750515|DEVICE|Acupuncture|
224079042|NCT00343512|DRUG|docetaxel|Docetaxel 75 mg/m2 IV (1-hour infusion) on day 1 of each cycle (cycle = 2 weeks) x 4 cycles
224079043|NCT00343512|GENETIC|protein expression analysis|protein expression analysis
224079044|NCT00343512|OTHER|laboratory biomarker analysis|laboratory biomarker analysis
224079045|NCT00343512|PROCEDURE|biopsy|biopsy
224079046|NCT00343512|PROCEDURE|conventional surgery|conventional surgery
224079047|NCT00343512|PROCEDURE|neoadjuvant therapy|neoadjuvant therapy
224079048|NCT01819519|BEHAVIORAL|Educational Intervention|The patient will told if previously infected or seronegative and what is the risk of the becoming infected. The research assistant will deliver a 5-10 minutes educational intervention, which will consist of a CMV video and some Q\&A.
224079049|NCT04043000|DIETARY_SUPPLEMENT|Super 13 Pro & Prebiotics|"Super 13 Pro \& Prebiotics was given three times a day for four weeks."
224079050|NCT06501846|PROCEDURE|Pipelle® endometrial biopsy performed under transabdominal ultrasound guidance|The placement of an ultrasound probe on the lower abdomen while a Pipelle® endometrial biopsy is obtained.
224079051|NCT06501846|PROCEDURE|Pipelle® endometrial biopsy performed without ultrasound guidance|A Pipelle® endometrial biopsy is performed by using touch alone.
224079052|NCT00684515|DRUG|Vorapaxar 2.5 mg|Oral tablets; once daily for 60 days.
224079053|NCT00684515|DRUG|Vorapaxar 1 mg|Oral tablets; once daily for 60 days
224079054|NCT00684515|DRUG|Placebo|oral tablets; once daily for 60 days
224079055|NCT00684515|DRUG|Aspirin 75-150 mg|oral tablets; once daily for 60 days
224079056|NCT00858429|DRUG|capecitabine|1000 mg/m2 twice daily, for 14 consecutive days followed by a 7 day treatment free rest period for cycles 1, 2 and 3.
224079057|NCT00858429|RADIATION|yttrium Y 90 glass microspheres|The amount of radioactivity required to deliver the desired dose to the liver is calculated using a formula. The dose depends on the cohort upon which the patient is enrolled. Y90 is administered during Cycle #2 on days 1-7.
224079058|NCT06213922|BEHAVIORAL|Food intake|Fast food
224079059|NCT03373565|PROCEDURE|Radial|Coronary angiography using radial approach
224079060|NCT03373565|PROCEDURE|Palmar|Coronary angiography using radial approach
224079061|NCT03569852|BEHAVIORAL|Time Restrictive Feeding|Volunteers will adhere to a form of time restrictive feeding, 16 hours fasting and 8 hours eating per day.
224079062|NCT03569852|BEHAVIORAL|Traditional Eating Pattern|Volunteers will adhere to a more traditional eating pattern, 12 hours fasted and 12 hours eating per day.
224079063|NCT06519591|DRUG|Cadonilimab, LM-302, S-1, paclitaxel|Cadonilimab 10mg/kg, LM-302 2.0mg/kg intravenous (IV) infusion on day 1, paclitaxel 20 mg/m2 intraperitoneal infusion on Days 1 and 8 plus oral S-1 80 mg/m2 for 14 consecutive days every 3 weeks.
224079064|NCT02678715|DEVICE|Solubrux®|prefabricated device adaptable by temperature
224079065|NCT02678715|DEVICE|Customized Appliance|customized device fabricated in the dental laboratory
224079066|NCT02678715|DEVICE|Somatics®|standard device
224079067|NCT04428411|DRUG|Enbrel|As provided in real world practice
224079068|NCT02574104|OTHER|Simulate a functional NICU prior to moving patients|Test translation of care paradigms in the new environment a priori. Invest significant time and resources into scenario design, staffing, preparing and orchestration the simulations. 80-160 staff participate in simulations, discover and resolve latent safety threats
224079069|NCT00634569|BIOLOGICAL|Flebogamma 5% DIF|Intravenous Immune Globulin (Human)
224079070|NCT01163786|DRUG|Bortezomib|Each patient will receive 2 cycles of Bortezomib. For each cycle Bortezomib wil be given once a week, 1.3mg/m2 for 4 weeks with 2 weeks between each cycle.
224079071|NCT04575701|OTHER|TNF Alpha therapy|Retrospective analysis of outcome of first TNF Alpha therapy
224079072|NCT02918019|DRUG|MSTT1041A|MSTT1041A will be administered as subcutaneous injections.
224079073|NCT02918019|DRUG|Placebo|Placebo matched with MSTT1041A.
224079074|NCT01743482|DRUG|Pazopanib|
224079075|NCT01212185|DRUG|intranasal oxytocin spray|6 insufflations (24 IU of oxytocin total) given twice daily for 3 days
224079076|NCT01212185|OTHER|intranasal spray without oxytocin|6 insufflations (0.1 metered dose/insufflation) twice daily
224079077|NCT03317951|OTHER|Novel integrated care concept (NICC)|Integrated care concept including, e.g., call center, guideline therapy, tablet and medical devices
224079078|NCT03317951|OTHER|Standard care|Guideline therapy according to the guidelines of the European Society of Cardiology (ESC).
224079079|NCT04067947|DRUG|XG005|XG005 Tablet
224079080|NCT04067947|DRUG|Placebos|Placebo Tablet
224079081|NCT00372437|DRUG|MGCD0103|MGCD0103 as an oral dose three times per week.
224079082|NCT00372437|DRUG|Gemcitabine|Gemcitabine 1000mg/m\<2\> intravenously days 1, 8, 15 of a 28 day cycle.
224079083|NCT05211557|BIOLOGICAL|fhB7H3.CAR-Ts|"Three dose levels will be evaluated: Dose Level 1 (1×10\^6/kg), dose Level 2 (3×10\^6/kg) and dose Level 3 (5×10\^6/kg). If dose limiting toxicities (DLTs) are observed in each doses, Dose Level -1 (0.5×10\^6/kg /infusion) will be evaluated.~Other Name: B7H3 targeting chimeric antigen receptor T cells Drug: Fludarabine 30 mg/m2 i.v. for 3 consecutive days (Day -5\~Day -3) Other Name: FLUDARA Drug: Cyclophosphamide 750 mg/m2 i.v. for once (Day -5) Other Name: Cytoxan"
224079084|NCT02303717|DEVICE|Percutaneous coronary intervention|Percutaneous coronary stent implantation
224079085|NCT02303717|DRUG|Dual antiplatelet therapy|Dual antiplatelet therapy with aspirin and either clopidogrel, prasugrel or ticagrelor will be recommended for 12 months duration in the Xience stent arm but only 4 months duration in the Synergy stent arm.
224079086|NCT04389177|DRUG|Pembrolizumab Injection [Keytruda]|"Neoadjuvant period:preoperative therapy with three cycles: Pembrolizumab 200mg D1; Paclitaxel 135mg/m2 D2; Cisplatin 20mg/m2 D2-D4; repeated every 3 weeks.~Da Vinci robot radical surgery: Before surgery, head/abdomen/chest CT scan, type B ultrasonic, upper gastrointestinal contrast, endoscopic ultrasound (EUS), and gastroscopy with biopsy will be done. Surgery should be done within 4-6 weeks after last neoadjuvant treatment finished.~Adjuvant period: Adjuvant treatment with pembrolizumab 200mg every 3 weeks (6 cycles) should be performed within 3-6 weeks after surgery if the surgical pathology result is not pCR. abdomen/chest CT scan will be performed every 3 month after surgery."
224079087|NCT05120739|DRUG|2% CHX cloths|skin preparation in 2% CHX cloths
224079088|NCT05600595|PROCEDURE|Operation for snoring in children|Tonsillectomy and/or adenoidectomy
224079089|NCT02800655|DEVICE|Digital Health Feedback System|"This intervention uses an ingestion sensor and a wearable sensor (worn as a patch on the skin), which are new technologies approved by the FDA, to collect information about patients taking their ARV medications. The wearable sensor records information, which is uploaded wirelessly to a mobile device and then to a secure computer. Together the sensors and the mobile device transmitting the information to the study computer are called a digital health feedback system (DHFS), which provides information about when patients have taken their ARV medications.~Other Names:~DHFS"
224079090|NCT03317769|OTHER|Computerized Plasticity-Based Adaptive Cognitive Training|Training on computerized exercises that targets social cognition for 2 hours per week.
224079091|NCT03317769|OTHER|Commercially available computerized training|Training on computerized, casual video games for 2 hours per week.
224079092|NCT03317769|OTHER|Optimized social skills training|Group-video calls with Specialist for 1 hour per week where participants can interact with Specialist individually or as a group. Specialist will provide guidance, support and feedback, and send links and articles about information and topics discussed during the video calls.
224079093|NCT03317769|OTHER|Unstructured support group sessions|Unstructured support group-video calls for 1 hour per week. The Specialist will not engage with participants (eg. providing participants with links to articles and additional support) or provide guidance for the group discussion.
224079094|NCT04823949|DEVICE|Home blood pressure monitoring|See arm description
224079095|NCT01420146|DRUG|Zr89-trastuzumab|trastuzumab labelled with zirconium 89 for PET/CT
224079096|NCT01846286|BEHAVIORAL|Questionnaires|Five questionnaires about pain and symptoms, each taking approximately 25 - 50 minutes to complete
224079097|NCT01846286|OTHER|Quantitative Sensory Testing|Tests measure sensitivity to touch, coolness, warmth, hot/cold feeling, and pin pricks. The sensory tests will take about 30 minutes to 1 hour to complete.
224079098|NCT05483530|BIOLOGICAL|HLX60 combined with HLX10|five various doses of HLX60 combined with flat dose of HLX10
224079099|NCT00598299|PROCEDURE|venous puncture|venous puncture
224079100|NCT00598299|OTHER|obtain serum from perripheral blood or cord blood|obtain serum from perripheral blood or cord blood
224079101|NCT04756713|PROCEDURE|Uterine curettage|Manual or electric vacuum aspiration under ultrasound guidance.
224079102|NCT04756713|DRUG|Chemotherapy|conventional chemotherapy will be treated with MTX (1 mg/kg intramuscular) with rescue of FA (15mg orally). In cases of chemoresistance, second-line chemotherapy will be performed with actinomycin-D (Act-D) 1.25 mg intravenous pulse every 14 days. The third line of chemotherapy will be the EMA/CO regimen (, reserving the EP / EMA regimen (E, cisplatin, MTX / Act-D) for the fourth line.
224079103|NCT02346188|DIETARY_SUPPLEMENT|Ferrous fumarate|Tablet formulated from 30 mg ferrous fumarate.
224079104|NCT02346188|DIETARY_SUPPLEMENT|Zinc oxide|Tablet formulated from 30 mg zinc oxide
224079105|NCT02346188|DIETARY_SUPPLEMENT|Placebo|
224079106|NCT02870361|DRUG|intranasal insulin|
224079107|NCT02870361|DRUG|Placebo|
224079108|NCT02502760|BEHAVIORAL|Physical Exercise Program|Physical exercises personalized by a kinesiologist consisting of walking or stationary bike and elastic band exercises.
224079109|NCT02502760|DIETARY_SUPPLEMENT|Whey Protein Isolate Powder|"Nutritional counselling is given to patients to ensure their daily proteins and energy requirements are met. Whey Protein Isolate Powder (Immunocal) is provided.~Immunocal1.5g/kg PO (by mouth) per day separated in 2 daily doses"
224079110|NCT02502760|BEHAVIORAL|Relaxation Techniques|Relaxation techniques consisting of breathing exercises and using a relaxation CD.
224079111|NCT05866198|DIAGNOSTIC_TEST|Actigraph CP Insight Watch|"CP Insight Watch (Actigraph, Pensacola, FL) is usually worn on the wrist. The watch captures and records continuous high-resolution raw acceleration data to provide objective, real-world physical activity, mobility, and sleep measures, in near real time. That data is then processed by ActiLife software into what is called Epoch data (i.e. turning it into activity counts so that things such as moderate vigorous physical activity can be found). The device also passively scores every minute of recorded data as Sleep or Wake based on the amount of activity taking place."
224079112|NCT04146142|PROCEDURE|Transperineal prostate biopsy with or without antibiotic prophylaxis|As described above.
224079113|NCT01286857|DEVICE|External Suction Interface and a Silicon Film|Evaluate the function of a new silicon cover film and an on-top suction device to be used in a NPWT system in the treatment of acute and chronic wounds.
224079114|NCT06409676|PROCEDURE|ERAS protocols|Enhanced Recovery After Surgery (ERAS) guidelines are evidence-based recommendations aimed at improving patient outcomes and reducing complications after surgery.
224079115|NCT04989855|DRUG|Fruquintinib plus Tislelizumab|2 cycles of Fruquintinib(F) 5mg QD d1-d14 + Tislelizumab(T) 200mg IV d1, Q3W as preoperative therapy, and F +T after TME as postoperative therapy for 6 months
224079116|NCT05771727|OTHER|survey|The 55-item survey created by the researchers was applied online to determine the psychological and physical effects of COVID-19 on neuromuscular patients and their families. This survey also included the Content of the 9-Item Caregiver COVID-19 Limitations Scale (CCLS-9).
224079117|NCT06086847|OTHER|progressive resistant exercises|"Group A (Experimental Group):~• Warm up Exercise + stretching Exercise (upper and lower extremity) + progressive resistance exercises Warm up Exercise (for 5 min) Stretching (upper and lower extremity)~3\. Progressive Resistance exercises:~1. Leg press :( dual leg press): Leg press target the~   Quadriceps or quads .but they also work your Hamstrings.~2. Leg curls (dual leg curls):~Leg curls Target the hamstrings and Calf muscles Leg Extension~The Muscles worked:~1. Rectus femoris~2. Vastus lateralis~3. Vastus medialis~4. Vastus intermedius~4\. Arm lat pull (dual arm lat pull):~Back extension (lumber extension):"
224079118|NCT02416557|PROCEDURE|PEEP|application of 10 cmH2O (centimeter of water) positive end expiratory pressure during mechanical ventilation
224079119|NCT06228222|PROCEDURE|renal biopsy|"Renal biopsy will be performed for all patients fulfilling the American College of Rheumatology (ACR) criteria to confirm the diagnosis of lupus nephritis (LN) and to classify the glomerular disease by the revised International Society of Nephrology/Renal Pathology Society (ISN/RPS) 2018 histopathological classification system"
224079120|NCT00788346|BEHAVIORAL|Computerized alerts|Computerized Clinical Decision Support to clinician at the time of prescribing
224079121|NCT00788346|BEHAVIORAL|Alerts Plus Detailing|Computerized Clinical Decision Support to clinician at the time of prescribing PLUS one group academic detailing session
224079122|NCT01076257|BEHAVIORAL|Modified Constraint-induced Movement Therapy|"Home based CIT~1. Restriction of the less affected limb~2. Intensive practice using affected limb~3. Positive experience~4. Functional task (task)"
224079123|NCT02815839|DRUG|SHR4640|
224079124|NCT02815839|DRUG|Placebo|
224079125|NCT01700192|BIOLOGICAL|MK-8237 tablets|MK-8237 12 DU rapidly dissolving tablets administered sublingually q.d.
224079126|NCT01700192|BIOLOGICAL|Placebo tablets|Placebo to MK-8237 rapidly dissolving tablets administered sublingually q.d.
224079127|NCT01700192|DRUG|Rescue Medication: Self-Injectable Epinephrine|Self-injectable epinephrine (preferred dose of 0.30 mg) administered intramuscularly as needed for rescue medication.
224079128|NCT01700192|DRUG|Rescue Medication: Loratadine tablets|Loratadine tablet 10 mg administered orally as needed for rescue medication.
224079129|NCT01700192|DRUG|Rescue Medication: Olopatadine ophthalmic drops|Olopatadine hydrochloride ophthalmic drops 0.1% administered as needed for rescue medication.
224079130|NCT01700192|DRUG|Rescue Medication: Mometasone furoate nasal spray|Mometasone furoate monohydrate nasal spray 50 mcg administered intranasally as needed for rescue medication.
224079131|NCT05699720|DRUG|Nebulized Magnesium Sulphate|Group A received 250mg of MgSO4 /dose given through nebulizer four times a day, while group B did not. The groups will be followed for five days to see the results in terms of in-hospital outcome, whether the patient is discharged after fulfilling the set criteria or needing assisted ventilation.
224079132|NCT02507362|RADIATION|adjusted corneal collagen cross-linking|UV-A irradiation for 7 minutes
224079133|NCT02507362|RADIATION|accelerated corneal collagen cross-linking|UV-A irradiation for 10 minutes
224079134|NCT02507362|DRUG|riboflavin 0.1% combined with dextran 20 %|after mechanical epithelial removal riboflavin drop will be instilled every 5 minutes for 30 minutes and then instillation will be continued during irradiation
224079135|NCT02507362|PROCEDURE|epithelial debridement|corneal epithelium will be removed by a cottons swab
224079136|NCT02793232|DRUG|PF-06751979 single dose|PF-06751979 administered as a single dose suspension in cross-over fashion. Each subject may receive up to 4 study treatments (placebo and up to 3 doses of PF 06751979). The planned dose levels are 200 mg, 400 mg, 700 mg, 200 mg fed (these doses are subject to change based on emerging data).
224079137|NCT02793232|DRUG|Placebo single dose|Matched Placebo suspension administered as single dose
224079138|NCT02793232|DRUG|PF-06751979 multiple ascending dose|PF-06751979 suspension administered daily for 14 consecutive days to parallel cohorts. The planned dose levels are mg, 100 mg, 200 mg, 340 mg (these are subject to change based on emerging data).
224079139|NCT02793232|DRUG|Placebo multiple ascending dose|Matched placebo suspension administered daily for 14 consecutive days.
224079140|NCT02793232|DRUG|PF-06751979 multiple dose|PF-06751979 suspension administered daily for 14 consecutive days. The planned dose level is 340 mg (this is subject to change based on emerging data).
224079141|NCT02793232|DRUG|Placebo multiple elderly dose|Multiple dose administration to Healthy Elderly Subjects (Placebo)
224079142|NCT06449768|BEHAVIORAL|Diabetic Macular Edema|observing the eye behavior in Diabetic Macular Edema
224079143|NCT01155700|DRUG|omalizumab|
224079144|NCT04992416|PROCEDURE|immediate implant placement with ATBG and SMV|immediate implant placement using ATBG as a graft material, with SMV
224079145|NCT04992416|PROCEDURE|immediate implant placement with ATBG|immediate implant placement using ATBG as a graft material without SMV
224079146|NCT06061198|DEVICE|a virtual reality device|the patient will wear a masque tht will provide a virtual reality experience using a VR Gear connected to a mobile phone through an application installed on the mobile phone
224079147|NCT03285256|BEHAVIORAL|Experimental memory training|The experimental memory training will be implemented as a computer program that uses state-of-the-art immersive technology to simulate prospective memory in everyday life in which one must remember to carry out tasks throughout the day, while engaging in current ongoing activity. Participants are asked to imagine they have a work-at-home job (ongoing activity), which is an independent program (CogMed QM) designed to train working memory, but that they also need to remember to carry out a number of tasks throughout the day. Using a touch screen, participants will need to touch objects in the simulated environment to appropriately interact with these stimuli according to their pre-assigned tasks.
224079148|NCT03285256|BEHAVIORAL|Comparator memory training 1|The first comparator memory training intervention will utilize the same overall structure and immersive computer environment as the experimental memory intervention, but will not challenge the same aspects of cognition.
224079149|NCT03285256|BEHAVIORAL|Comparator memory training 2|The second comparator memory training intervention will utilize the same overall structure and immersive computer environment as the experimental memory intervention, but will not challenge the same aspects of cognition.
224079150|NCT02082678|DRUG|Ondansetron|Ondansetron is a serotonin receptor antagonist that is FDA-approved to treat nausea and vomiting caused by cancer therapy and surgery.
224079151|NCT02082678|DRUG|Placebo|Inactive ingredient matching the active medication in appearance
224079152|NCT04202731|BEHAVIORAL|PBS Study|Sleep extension intervention
224079153|NCT04182867|OTHER|Dietary intervention|Dietary modification (provision of diet).
224079154|NCT00015600|BEHAVIORAL|Behavior modification through social marketing|
224079155|NCT00120458|DIETARY_SUPPLEMENT|Black cohosh|"32 to 128 mg (black cohosh)~1 to 4 capsules daily (placebo)"
224079156|NCT00779376|DRUG|Zidovudine 300mg tablets|
224079157|NCT03811509|DRUG|bisphosphonate|antiresorptives
224079158|NCT04219423|BEHAVIORAL|Multimodal physical therapy|see description in arm/group description
224079159|NCT03979274|DRUG|Reference Eutirox®|Participants received single oral dose of Reference Eutirox® 600 microgram (3 tablets of 200 microgram) either in treatment period 1 or 2.
224079160|NCT03979274|DRUG|Test Eutirox®|Participants received single oral dose of Test Eutirox® 600 microgram (3 tablets of 200 microgram) either in treatment 1 or 2.
224079161|NCT00671255|DRUG|Ramelteon|Ramelteon 4 mg, tablets, orally, once daily for up to 5 weeks.
224079162|NCT00671255|DRUG|Ramelteon|Ramelteon 8 mg, tablets, orally, once daily for up to 5 weeks.
224079163|NCT00671255|DRUG|Placebo|Ramelteon placebo-matching, tablets, orally, each night for up to 35 consecutive days.
224079164|NCT00935558|BIOLOGICAL|DC vaccine|DC vaccination regime consist of primary 10 intradermal injections of 1-2 weeks interval. At the time of each vaccine 6 MIU/m² IL-2 will be administered sc. Zadaxin 1.6 mg is injected sc twice a week. and tablet Aromatase inhibitor is administered ; Exemestane 25 mg (tablet) is administered PO daily or Femar 2,5 mg (tablet) is administered PO daily or Arimidex 1 mg (tablet) is administered PO daily
224079165|NCT00935558|DRUG|aromatase inhibitor|Exemestane 25 mg (tablet) is administered PO daily or Femar 2,5 mg (tablet) is administered PO daily or Arimidex 1 mg (tablet) is administered PO daily
224079166|NCT06424093|PROCEDURE|Virtual Reality Technology|To evaluate the role of virtual reality technology as distraction technique in the management of acute pain during outpatient hysteroscopy
224079167|NCT03995290|OTHER|3D Hip Model from Pre-operative CT scan|A printed 3D model will be created based off of the patient's standard of care preoperative CT scan.
224079168|NCT02704533|BIOLOGICAL|PfSPZ Vaccine|Aseptic, purified, vialed, cryopreserved, radiation-attenuated, Plasmodium falciparum sporozoites, strain NF54
224079169|NCT02704533|BIOLOGICAL|PfSPZ Challenge (NF54)|Live, infectious, aseptic, purified, vialed, cryopreserved, Plasmodium falciparum sporozoites, strain NF54
224079170|NCT02704533|BIOLOGICAL|PfSPZ Challenge (7G8)|Live, infectious, aseptic, purified, vialed, cryopreserved, Plasmodium falciparum sporozoites, strain 7G8
224079171|NCT02704533|OTHER|Normal saline|0.9% sodium chloride
224079172|NCT06233526|OTHER|Chemotherapy regiments based on the transcriptomic profile and in vitro drug sensitivity test|"1. Leukemia cells from newly diagnosed and relapsed children with AML were tested for high throughput in vitro drug sensitivity and resistance.~2. Combined with multi-omics sequencing technology such as whole exome and transcriptome, the data of drug sensitivity, drug resistance and genomic characteristics of children AML patients were integrated, and the internal rules between drug sensitivity or drug resistance and molecular characteristics such as gene fusion, gene mutation and abnormal gene expression of children AML patients were deeply analyzed, and the molecular characteristics of drug sensitivity in children AML were mapped"
224079173|NCT05664165|OTHER|dry needling|The needle inserted in the trigger point and stimulation was performed by manipulating it up and down several times. The needle was kept in the trigger point for 1-3 minutes and removed after the muscle spasm regressed
224079174|NCT05664165|OTHER|cold spray and stretching|The cooler spray (in its content; 0.06% menthol, 2.06% isopropyl alcohol, 2% isopropyl alcohol) was sprayed to the surface at an angle of 30° from a distance of approximately 30-50 cm, while passive stretching was applied.
224079175|NCT00321230|DRUG|macrogol3350 NA sulphate NACL KCL ascorbic acid NA ascorbate|
224079176|NCT01403337|OTHER|Ischemic preconditioning|The RIPC protocol will consist of three cycles of the following: 5-minute inflation of a blood pressure cuff around the right upper arm to 200 mmHg (or 20 above the systolic blood pressure if baseline BP \> 200 mmHg) to allow for external compression of the brachial artery resulting in transient arm ischemia, followed by a 5-minute interval of cuff deflation to allow for reperfusion. The total duration of the protocol is 30 minutes equally divided between ischemia and reperfusion. The protocol is to be applied in the patient room the morning of the operation.
224079177|NCT01403337|OTHER|Control|A Blood Pressure cuff inflated to 40-50 mmHg
224079178|NCT06304454|OTHER|Board game intervention|5 weeks / 2 sessions each week / 1 hour each session
224079179|NCT01767883|OTHER|Facilitated Clinical Decision Support|"The primary care practices in this arm will receive:~* CKD decision support algorithms added to their Clinical Decision Support~* System Academic detailing concerning the rationale for the algorithms~* On-going mentoring and practice facilitation~* Audit and feedback during quarterly reviews of practice data with the practice facilitator by videoconference."
224079180|NCT01767883|OTHER|Clinical Decision Support Only|"* CKD decision support algorithms added to their Clinical Decision Support~* System Academic detailing concerning the rationale for the algorithms"
224079181|NCT01407783|BEHAVIORAL|Problem Solving Tools (PST)|The problem solving tools was chosen as the depression treatment because it is well suited for use by non-mental health professionals and for in-home treatment. It is also a brief treatment (4-8 sessions) that takes a non-pathologizing approach.
224079182|NCT06296732|PROCEDURE|Duration of surgery intervention|Intraoperative- duration from the beginning of the skin incision to skin suture (min)
224079183|NCT05467722|DRUG|CTP-543|Single 12 mg oral dose administered on Day 1
224079184|NCT05789017|DRUG|Prednisone and Mycophenolate Mofetil|Patients are treated with glucocorticoids and mycophenolate mofetil in remission induction period (6 months), during which glucocorticoids are tapered regularly and discontinued in 6 months.
224079185|NCT05789017|DRUG|Mycophenolate Mofetil|Patients are treated with low dose mycophenolate (1-1.5g/day) during remission maintenance period for 12 months.
224079186|NCT05789017|DRUG|Leflunomide|Patients are treated with leflunomide (20 mg/day) during remission maintenance period for 12 months.
224079187|NCT04751162|DEVICE|Actigraphy device (wearable) and mobile application|Participants will be asked to wear an actigraphy device (wearable) and to install a mobile application on their smartphones (cf. Broderick et al., 2019) for tracking PA, SQ and symptoms for 3 weeks
224079188|NCT00987363|OTHER|Intraarterial infusion of autologous bone marrow cells|Autologous bone marrow-derived mononuclear cells will be infused by an intraarterial catheter into de ischemic limb. The number of infused cells will be 1x10 E8, 5x10E8 and 1x10 E9 in the low,intermediate and high dose arms respectively
224079189|NCT00626093|DEVICE|Cardiac Resynchronization Therapy - Defibrillator (CRT-D)|"* Patients in the study who receive Cardiac Resynchronization Therapy - Defibrillator (CRT-D) are indicated for Cardiac Resynchronization Therapy (CRT).~* Patient undergoes Defibrillation threshold (DFT) testing at implant and at 6 months. Defibrillation threshold (DFT) testing will include 3 ventricular fibrillation (VF) inductions."
224079190|NCT01889979|DRUG|Tramadol|100 mg of Tramadol was applied in the forearm SC (single dose).
224079191|NCT01889979|DRUG|Placebo|2 ml of a sterile solution was applied in the forearm SC (single dose).
224079192|NCT02059590|DRUG|Pyridinylmethyl-14C-labeled isavuconazonium sulfate|Intravenous
224079193|NCT00603915|DRUG|Gemcitabine|1000mg/m\^2 intravenous (IV) day 1 and day 8
224079194|NCT00603915|DRUG|Carboplatin/Cisplatin|Area under curve (AUC)=5 (Carboplatin) or 70mg/m\^2 (Cisplatin) intravenous (IV) day 1
224079195|NCT00603915|DRUG|erlotinib|150mg daily (post GC therapy)
224079196|NCT03891901|DRUG|Imatinib|Tablets, administered orally
224079197|NCT03891901|DRUG|Isoniazid|300 mg tablets, administered orally
224079198|NCT03891901|DRUG|Rifabutin|300 mg capsules, administered orally
224079199|NCT00005783|DRUG|Recombinant-methionyl human stem cell factor|
224079200|NCT05350059|DEVICE|High Intensity Focused Ultrasound (HIFU) to the Breast Cancer|Breast cancer will be ablated using high intensity frequency ultrasound prior to breast surgery
224079201|NCT02105415|DRUG|Ketamine / Propofol Admixture|
224079202|NCT02105415|DRUG|Etomidate|
224079203|NCT02260518|BEHAVIORAL|Lifestyle Intervention|During pregnancy, participants complete one face-to-face counseling session, receive 10 behavioral podcasts, and receive weekly phone calls until delivery. Participants will be asked to attend one group session on breastfeeding. Participants will have the opportunity to participate in a private Facebook group during pregnancy and postpartum. During postpartum, participants complete one face-to-face counseling session, receive 16 behavioral podcasts, receive brief weekly check-in telephone calls for six weeks, and receive up to 8 telephone counseling calls through 6 months after delivery.
224079204|NCT02260518|BEHAVIORAL|Standard Care|Women will receive standard nutrition counseling provided by physicians, nurses, nutritionists, and counselors from the Women, Infants, and Children (WIC) program (if applicable). They will receive a monthly study mailing that is educational in nature as well as podcasts related to a healthy pregnancy. During pregnancy, the mailings will focus on tips for a healthy pregnancy and on fetal development. During postpartum the mailings will focus on infant development and parenting. We will select a matched number of podcasts from Pea in the Podcast, commercially available podcasts. All mailings and podcasts will avoid discussion of weight, PA, or diet (except for foods to avoid in pregnancy for safety reasons).
224079205|NCT00817011|DRUG|SSRI treated group|Antidepressant administration of SSRI class for 6 weeks under therapeutic dose
224079206|NCT00817011|DRUG|non-SSRI treated group|Antidepressant administration of non-SSRI class for 6 weeks under therapeutic dose
224079207|NCT01119235|DRUG|PF-04531083|Dosed as a tablet in 100mg strengths. Dosage in the first cohort will be 300mg twice daily for 3 days followed by 200mg twice daily for 11 days
224079208|NCT01119235|DRUG|PF-04531083|Dosed as a tablet in 100mg strengths. Dosage in this optional second cohort will be optimised based on the data arising from Cohort 1
224079209|NCT03491410|DRUG|Aspirin Low Dose|Low-Dose Aspirin is to be added in the standard patient´s treatment
224079210|NCT03491410|DRUG|Placebo Oral Tablet|Placebo is to be added in the standard patient´s treatment
224079211|NCT05697458|OTHER|computerized tomography scanning|In all patients the investigators will perform CT for determination of iliac arteries calcifications
224079212|NCT05156541|DRUG|Interferon gamma human recombinant (IFN-G)|received by microbiological synthesis; specific antiviral activity on cells is 2x10\*7 Units per mg of protein
224079213|NCT03589404|DEVICE|rso2|The regional oxymetry probe will be placed in the abdominal region of the umbilicus in the middle clavicular line before the disease operation begins.
224079214|NCT04798287|DRUG|Tofacitinib|First eligible prescription for treating rheumatoid arthritis (RA)
224079215|NCT04798287|DRUG|TNF Inhibitor|First eligible prescription for treating rheumatoid arthritis (RA)
224079216|NCT03079479|DIAGNOSTIC_TEST|Muscle Strenght assesment|Muscle Strenght assesment of the hip muscles
224079217|NCT03079479|DIAGNOSTIC_TEST|2D Kinematics Analysis|2D Kinematics Analysis of the gait
224079218|NCT02026063|DRUG|Telotristat etiprate|Telotristat etiprate tablet (250 mg)
224079219|NCT03906500|BEHAVIORAL|High schools High on Life|"The intervention consist of three main components.~Environmental factors of the school environment~The component targeting the high school environment consisted of two separate elements:~* Revision of school alcohol policy~* Appointment of coordinator(s) of student committees organizing events, where alcohol is sold, and student introduction committee.~Student component~The Student components consisted of three main elements:~* Online education for the student committees organizing events where alcohol is sold and the student introduction committee~* Pocket movie campaign competition~* Social norms campaign~Parent component~The parent component consisted of three separate elements:~* Parent Information Meeting~* Parent Information Folder~* Parent Information Website"
224079220|NCT03116945|DRUG|68Gallium Citrate|Procedure: PET/CT Imaging
224079221|NCT05170711|PROCEDURE|hypotensive anesthesia|hypotensive anesthesia
224079222|NCT05170711|PROCEDURE|normotensive anesthesia|normotensive anesthesia group
224079223|NCT00052195|BIOLOGICAL|SRL-172|5 doses of 0.1mL vaccine or placebo given intradermally over 12-months
224079224|NCT01154647|DRUG|citalopram|intravenous
224079225|NCT01154647|DRUG|1 ml 0.9 % NaCl|intravenous
224079226|NCT02154087|BIOLOGICAL|HP802-247|260 µL (130 µL, one spray, of each component) containing 0.5 x 10.6 cells per mL, alternating weekly with Vehicle
224079227|NCT06046703|OTHER|Daily nutritional intake|Nutritional intake with a focus on vitamin B12, but also other micronutrients and macronutrients
224079228|NCT03695068|BEHAVIORAL|RISE Intervention|Described in Arms description.
224079229|NCT03354182|PROCEDURE|Open flap surgery|Elevation of a flap in order to access the treated furcation
224079230|NCT03354182|DEVICE|Bio-oss collagen|Biomaterial for periodontal surgery
224079231|NCT03354182|DEVICE|Bio-gide|Biomaterial for periodontal surgery
224079232|NCT01116544|DEVICE|AMES Therapy (assisted movement and enhanced sensation)|Each subject will receive 30 sessions of AMES therapy in the clinic. Each session will consist of 10 min of functional testing (i.e., passive motion and strength tests) followed by 30 min of grasp therapy using the AMES device. One group of subjects will receive AMES therapy only with joint torque biofeedback (without EMG feedback), and the other group will receive AMES therapy with EMG biofeedback. While all test subjects should attempt to open the hand when the grasp mechanism is opening and close the hand when the mechanism is closing, the biofeedback information provided to aid a subject will differ for the 2 subject groups.
224079233|NCT03378063|DRUG|transplantation of mesenchymal stem cell|allogeneic human umbilical cord blood (hUCB)-derived mesenchymal stem cell (MSC) transplantation will be given to preterm infants
224079234|NCT03378063|DRUG|no transplantation of mesenchymal stem cell|MSC transplantation will be not given to preterm infants
224079235|NCT03704129|OTHER|Tutor|The participants will access the practical training, during which each participant will be followed by a tutor who will interactively explain, using a healthy volunteer, how to perform the ultrasound scan of the diaphragm. The ultrasound will be performed on a healthy volunteer first by the tutor and then by the participants. During the exercise, each individual learner will be supervised by the tutor himself.
224079236|NCT06269250|OTHER|Policy Change|There will be a change with the digitalization in the health care system with the beginning of the year 2024 and between Wave 1 and Wave 2
224079237|NCT00486278|DRUG|eptacog alfa (activated)|90 mcg/kg, injected i.v.
224079238|NCT00486278|DRUG|vatreptacog alfa (activated)|5 mcg/kg, injected i.v.
224079239|NCT00486278|DRUG|vatreptacog alfa (activated)|10 mcg/kg, injected i.v.
224079240|NCT00486278|DRUG|vatreptacog alfa (activated)|20 mcg/kg, injected i.v.
224079241|NCT00486278|DRUG|vatreptacog alfa (activated)|40 mcg/kg, injected i.v.
224079242|NCT00486278|DRUG|vatreptacog alfa (activated)|80 mcg/kg, injected i.v.
224079243|NCT00930215|DRUG|D961H|Oral gelatin capsule
224079244|NCT00930215|DRUG|D961H|Oral HPMC capsule
224079245|NCT03423498|OTHER|toe-spread-out exercise|The therapeutic intervention lasted 14 days and focused on doing the TSO exercise. This exercise was performed unilaterally under the supervision of a qualified physiotherapist. The starting position of the TSO exercise was the sitting position with the knee joint and hip bent at 90 degrees. The exercise consisted of 3 consecutive phases: dorsiflexion of the toes keeping the metatarsal heads and the heel on the ground, moving the fifth toe down and in a lateral direction, moving the big toe down and abduction. The final position needs to be maintained for 5 seconds. The whole sequence was repeated 200 times a day.
224079246|NCT05768490|RADIATION|brain radiotherapy|Patients were randomly divided into two groups, experimental group (early intervention group of brain radiotherapy) : the brain radiotherapy started within 1 month of TKI treatment, the brain radiotherapy here specifically refers to stereotactic radiotherapy; Control group (brain radiotherapy late intervention group) : Brain radiotherapy was given within 3 months after brain progression during TKI treatment.
224079247|NCT05768490|DRUG|Almonertinib|almonertinib po 110mg QD
224079248|NCT01493180|DRUG|OPC-12759 ophthalmic suspension|OPC-12759 ophthalmic suspension 2%
224079249|NCT01493180|DRUG|Sodium hyaluronate ophthalmic solution|Sodium hyaluronate ophthalmic solution 0.1%
224079250|NCT01431404|BIOLOGICAL|Etanercept (Enbrel)|prefilled syringe, SC
224079251|NCT01431404|BIOLOGICAL|HD203|HD203, prefilled syringe, SC injection
224079252|NCT06056752|BIOLOGICAL|QH103 Cell Injection|dose escalation (3+3) : dose 1 (3×10\^8CAR+cells) ,dose 2 (1 × 10\^9 CAR+cells）,dose 3 (3 × 10\^9CAR+cells)
224079253|NCT06056752|DRUG|Fludarabine|Intravenous fludarabine on days-5\~-2,the infusion dose is adjusted according to the subject's condition
224079254|NCT06056752|DRUG|Cyclophosphamide|Intravenous cyclophosphamide on days -5\~-3, the infusion dose is adjusted according to the subject's condition
224079255|NCT05153057|OTHER|Observational study|The goal of the study is purely observational. Treatment decisions will be made by physicians according to the grading of the intraocular inflammation related to birdshot chorioretinopathy and to their consequences on visual function. These treatment decisions will be independent from the observational study.
224079256|NCT02338102|OTHER|Saline mixture|premeasured salt packets mixed with distilled water
224079257|NCT00289107|DEVICE|Total Knee Arthroplasty|Rotating Platform (RP) Cruciate Substituting Knee System
224079258|NCT00289107|DEVICE|Total knee replacement|Fixed Cruciate Substituting Knee System
224079259|NCT04949841|DRUG|Delgocitinib|Delgocitinib cream 20 mg/g
224079260|NCT04211181|OTHER|The multifaceted interventions|"1. An evidence-based clinical guideline and pathway in hospital.~2. A series Written care protocols for the implementation of performance measures.~3. A newly developed mobile application (mini-program) will be employed to facilitate venous thromboembolism (VTE) risk assessment and prophylaxis. Patients will scan a QR code to enroll in the program and be linked with their physician. Through the application, patients will complete standardized self-assessments of VTE risk, and physicians will receive periodic reminders indicating whether the assessment and prophylaxis orders have been completed.The application also provides educational modules and targeted messages for both patients and physicians, and enables interactive communication.~4. A quality-control team will receive weekly feedback reports to verify whether all enrolled patients underwent appropriate prophylaxis."
224079261|NCT04211181|OTHER|Routine VTE prophylaxis|Patients randomized to the Routine VTE prophylaxis (Control) group will receive routine VTE prophylaxis according to current guidelines and clinical practices
224079262|NCT06084884|BIOLOGICAL|AZD5851|"Subjects will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) to produce AZD5851.~During AZD5851 production, subjects may receive bridging therapy for disease control. Upon successful generation of AZD5851 product, subjects will receive treatment with AZD5851 therapy.~Study treatment will include lymphodepleting chemotherapy followed by one dose of AZD5851 administered by intravenous (IV) infusion."
224079263|NCT05003388|BIOLOGICAL|AlloRx|cultured allogeneic adult umbilical cord derived mesenchymal stem cells
224079264|NCT05554367|DRUG|Binimetinib|Given PO
224079265|NCT05554367|PROCEDURE|Biopsy Procedure|Undergo biopsy
224079266|NCT05554367|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
224079267|NCT05554367|PROCEDURE|Bone Scan|Undergo bone scan
224079268|NCT05554367|PROCEDURE|Computed Tomography|Undergo CT
224079269|NCT05554367|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
224079270|NCT05554367|DRUG|Palbociclib|Given PO
224079271|NCT05839808|OTHER|Reliability and validity study|To evaluate the validity and reliability of the Stroke Exercise Preference Inventory
224079272|NCT05495126|DIAGNOSTIC_TEST|Standard Limbic Access pathway|Relevant information for clinical referral (e.g. demographics) and basic clinical information (e.g. PHQ-9 \& Gad-7 scores) are collected during the self-referral process which is then attached to the referral notes in order to facilitate the clinical assessment conducted by the clinician.
224079273|NCT05495126|DIAGNOSTIC_TEST|Limbic Access with AI pathway|"The same information as in the Limbic Access pathway is collected. However, additional information (i.e. disorder specific questionnaires) are collected for the most likely problem descriptors based on the ML-model predictions.~All information is attached to the referral in order to facilitate the clinical assessment conducted by the clinician."
224079274|NCT05491993|DIAGNOSTIC_TEST|Sky Medical™ Rapid Antigen Test|Rapid Antigen Diagnostic Test device performance comparative to RT-PCR.
224079275|NCT04032990|DEVICE|Biostim-5 transcutaneous spinal stimulator|Safety and feasibility will be monitored during transcutaneous spinal stimulation in children with spinal cord injury
224079276|NCT02809287|PROCEDURE|Jackknife posture|patients with left lateral position plus jackknife position when perform laparoscopic hepatectomy
224079277|NCT02811692|DRUG|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|Administration by intravitreal injection
224079278|NCT04121247|OTHER|nonpharmacological approaches to parents of children with sickle cell disease training program|use of non-pharmacological approaches in children with sickle cell disease, parent education
224079279|NCT05168267|BEHAVIORAL|Cognitive Processing Therapy|CPT: a type of cognitive behavioral therapy recommended for the treatment of PTSD. Delivered over 12 sessions with an emphasis on addressing trauma-related cognitions and challenging trauma-related beliefs. Includes homework assignments. For this study, CPT will be conducted in groups.
224079280|NCT00284037|DEVICE|continuous positive airway pressure therapy|
224079281|NCT03090685|PROCEDURE|True auriculotherapy with seeds|Roasted edible mustard seeds with \~ 2mm diameter fixed with adhesive tape in 4 to 5 specific body points to control musculoskeletal pain.
224079282|NCT03090685|PROCEDURE|Placebo Auriculotherapy with seeds|Roasted edible mustard seeds with \~ 2mm diameter fixed with adhesive tape at 4 points located in the auricular lobe not specific for musculoskeletal pain.
224079283|NCT01900093|DRUG|Acthar Gel|80 units of subcutaneous Acthar Gel therapy daily
224079284|NCT04722211|DIETARY_SUPPLEMENT|PS128|daily ingestion of 2 capsules of Lactobacillus plantarum PS128 (\>10 billion CFU/capsule)
224079285|NCT04722211|DIETARY_SUPPLEMENT|placebo|daily ingestion of 2 capsules which only contained 425 ± 25 mg microcrystalline cellulose
224079286|NCT05083871|OTHER|European Trauma Course|"Structured learning program specifically focused on Trauma management. The course provides frontal lessons, workshops for the technical skills and simulated scenarios.~Please see https://www.erc.edu/courses/european-trauma-course for additional details"
224079287|NCT01172652|DRUG|Ziprasidone|The minimum dose during study participation will be 40 mg/day, and the maximum dose allowed will be 160 mg/day.
224079288|NCT01172652|DRUG|Placebo|Inactive control
224079289|NCT00931216|PROCEDURE|Integrated ANC, PMTCT, HIV services|Of the 12 study clinics, 6 will be randomized to receive the intervention. At these 6 facilities, health care providers within the ANC department will be trained to also provide HIV/PMTCT care. Women testing positive within ANC clinics at integrated facilities will receive ANC, PMTCT and HIV services within the same visit/same service provider rather than being referred for HIV care and treatment.
224079290|NCT05879783|DIAGNOSTIC_TEST|Confocal laser endomicroscopy|After intravenous injection of fluorescein sodium, pCLE-based optical biopsy will be performed.
224079291|NCT00500682|DRUG|Placebo|9g /day (3 times a day)
224079292|NCT00500682|DRUG|AST-120|9g /day (3 times a day)
224079293|NCT00578305|BIOLOGICAL|Rituximab|Rituximab was supplied as a sterile liquid for iv administration.
224079294|NCT00578305|DRUG|Placebo|Placebo was supplied as a sterile liquid in single-use vials for iv administration.
224079295|NCT00578305|DRUG|Methylprednisolone|
224079296|NCT00578305|DRUG|Methotrexate|
224079297|NCT00578305|DRUG|Folic acid or folate|
224079298|NCT02709278|BIOLOGICAL|BCG|BCG SSI (Due to a global shortage of BCG SSI, BCG Bulgaria used in Group 2)
224079299|NCT02709278|OTHER|Saline placebo|Saline placebo
224079300|NCT02709278|BIOLOGICAL|BCG|BCG Bulgaria (InterVax)
224079301|NCT05541614|OTHER|Emdogain® FL (flapless Emdogain®) - Enamel Matrix Derivative|Emdogain® FL has been shown to enhance the early healing of periodontal soft tissue wounds resulting from the instrumentation of periodontal pockets.
224079302|NCT05541614|OTHER|Emdogain® - Enamel Matrix Derivative|Enamel matrix derivative (EMD) has been widely used in the surgical treatment of periodontal disease and in furcation defects.
224079303|NCT01230879|OTHER|EFR and TDM|EFR : Pulmonary function test TDM : tomodensitometry
224079304|NCT03220828|BEHAVIORAL|Technology Based Distractions|Technology based distractions (VR headsets)
224079305|NCT02392273|DRUG|Ausanil|Patients with Primary Headache disorders will receive Ausanil in the context of usual and routine clinical care.
224079306|NCT03099720|DRUG|Ropivacaine|local anesthetic will be given locally at the site of operation to decrease the level of pain after operation
224079307|NCT03099720|DRUG|Placebo|placebo fluid will be given at the site of operation locally
224079308|NCT02613728|BEHAVIORAL|Accelerated Recovery Plan|
224079309|NCT02613728|BEHAVIORAL|Early Discharge|
224079310|NCT02613728|OTHER|Telemedicine|
224079311|NCT02613728|BEHAVIORAL|Standard Enhanced Care|
224079312|NCT00002778|BIOLOGICAL|sargramostim|
224079313|NCT00002778|BIOLOGICAL|therapeutic allogeneic lymphocytes|
224079314|NCT00002778|PROCEDURE|allogeneic bone marrow transplantation|
224079315|NCT00002778|PROCEDURE|in vitro-treated bone marrow transplantation|
224079316|NCT06237231|DRUG|DIT112|DIT112 tablet
224079317|NCT06237231|DRUG|DIPYRONE|Dipyrone tablet 1.000mg
224079318|NCT06237231|DRUG|TRAMADOL|Tramadol tablet 50mg
224079319|NCT06237231|DRUG|DIT112 Placebo|DIT112 placebo tablet
224079320|NCT06237231|DRUG|Dipyrone Placebo|Dipyrone placebo tablet
224079321|NCT06237231|DRUG|Tramadol Placebo|Tramadol placebo capsule
224079322|NCT04993378|DEVICE|EV-array|"Collect peripheral blood sample of 40 gastric cancer patients pre-treatment. Blood samples will be transferred to central lab to detect EV-score by EV-array. Tumor response evaluation will be performed after two cycles of chemotherapy by CT/MRI based on RECIST.~Clinical data, including tumor stage, metastastic organ, regimen, objective response, progression free survival, overall survival, etc, will be collected according to study protocol."
224079323|NCT05242783|DRUG|Terlipressin|intramyometrial Terlipressin versus carbitocin versus saline(placebo) injection in women undergoing open myomectomy procedure using haemostatic tourniquets.
224079324|NCT05275907|DRUG|Amlodipine Besylate|10 mg capsule once daily for 6 weeks
224079325|NCT05275907|DRUG|Chlorthalidone|25mg capsule once daily for 6 weeks
224079326|NCT05656209|DIETARY_SUPPLEMENT|Lactobacillus acidophilus|Lactobacillus acidophilus solid drink (pure bacteria, food grade, JYLA-191, Shandong Zhongke Jia-yi Biological Engineering Co., LTD.), 3G (containing 2\*10\^10CFU), twice a day, once in the morning and once in the evening, 1 bag each time, by drinking water, direct oral intake, 1 month/course, continuous use for three courses.
224079327|NCT03938493|OTHER|monitoring of the endotracheal tube cuff|We will enroll adult patients who will undergo endotracheal intubation for general anesthesia of head and neck surgery. The cuff pressure of the endotracheal tube will be monitored continuously during anesthesia. The cuff pressure value will be recorded and analyzed after completing the study.
224079328|NCT04004598|BEHAVIORAL|golf training|12 weeks of training by Professional Golf Association professional
224079329|NCT04319900|DRUG|favipiravir tablets+chloroquine phosphatetablets tablets|"Favipiravir tablets+ chloroquine phosphate tablets group: 50 patients (anticipated).~Favipiravir tablets: On the first day, once for 1600 mg, twice a day; From the 2nd day to the 10th day, once for 600 mg, twice a day; maximum of 10 days for oral administration of the drug.~Chloroquine phosphate tablets: a total of 1000mg split into two times on day one; from day two to day three, 500mg, once a day; from day four to day ten, 250mg, once a day. Maximum of 10 days for oral administration of the drug."
224079330|NCT04319900|DRUG|Favipiravir tablets|Favipiravir tablets group: 50 patients (anticipated). Favipiravir tablets: On the first day, once for 1600 mg, twice a day; From the 2nd day to the 10th day, once for 600 mg, twice a day; maximum of 10 days for oral administration of the drug.
224079331|NCT04319900|DRUG|Placebo|Placebo for favipiravir tablets is produced by Zhejiang Haizheng pharmaceutical co, LTD, batch no. 21812252, Placebo for chloroquine phosphate tablets is produced by the Chinese people's liberation army academy of military science military medical research institute production, batch no. 20200215. All placebos were complied with the quality inspection standard.
224079332|NCT00772668|DRUG|Rituximab|Administered intravenously during induction and maintenance therapy per protocol.
224079333|NCT00772668|DRUG|Bortezomib|Administered intravenously per protocol.
224079334|NCT00772668|DRUG|Cyclophosphamide|Administered intravenously per protocol.
224079335|NCT00772668|DRUG|Prednisone|Administered orally (PO) per protocol.
224079336|NCT05832567|DEVICE|Active rTMS|Subjects will undergo repetitive transcranial magnetic stimulation, each session lasting 20 minutes.
224079337|NCT05832567|DEVICE|Sham rTMS|Subjects will undergo sham repetitive transcranial magnetic stimulation, each session lasting 20 minutes.
224079338|NCT05832567|DIETARY_SUPPLEMENT|Open Placebo|The open placebo will consist of an inactive substance pill commonly used in clinical trials and given to the subject in a regular pill dispenser.
224079339|NCT06658600|OTHER|Physician readers will be assisted with AI-derived probability and diagnosis of obstructive coronary heart disease|Physician readers will be assisted with AI-derived probability and diagnosis of obstructive coronary heart disease. The AI tool provides individualized obstructive CHD probabilities and diagnosis, leveraging retinal biomarkers associated with cardiovascular risk.
224079340|NCT06658600|OTHER|Physician readers will be assisted with RF-CL table to calculate the probability of obstructive coronary heart disease|Physicians use a RF-CL table (risk factor weighted clinical likelihood table) to calculate the probability of obstructive CHD.
224079341|NCT01182428|DEVICE|XIENCE V®/ XIENCE PRIME™|Coronary artery placement of a XIENCE V®/ XIENCE PRIME™ Everolimus Eluting Stent System
224079342|NCT01182428|DEVICE|CYPHER SELECT|XIENCE V® / XIENCE PRIME™ to CYPHER SELECT in female patients with de novo coronary artery lesions
224079343|NCT06824870|OTHER|RV5026B - ET1732 - Period 1|Period 1 (1 month): The tested product RV5026B - ET1732 will be applied twice a-day on full-face The product sould be applied in sufficient quantity to cover the application area.
224079344|NCT06824870|DRUG|reference topical product - Period 2|Period 2 (1 month) : the reference topical product, prescribed by the investigator will applied each evening on the whole face.
224079345|NCT06824870|OTHER|RV5026B - ET1732 - Period 2|Period 2 (1 month) : The tested product RV5026B - ET1732 will be applied twice a-day on randomised half-face. The evening application will be done 15 minutes after the application of the reference treatment. Hands must be washed between the application of the 2 products.
224079346|NCT06856044|PROCEDURE|ileocolic resection with extended mesenteric resection|The resection limits will be in healthy mesenteric areas. The restoration of continuity in one stage should be preferred. The choice of laparoscopy versus laparotomy is at the surgeon's discretion.
224079347|NCT01879345|DRUG|BIA 2-093 - 1800 mg (Group 1)|3 tablets of BIA 2-093
224079348|NCT01879345|DRUG|BIA 2-093 - 2400 mg (Group 2)|4 tablets of BIA 2-093 600 mg
224079349|NCT01879345|DRUG|Placebo|placebo tablets
224079350|NCT07025096|OTHER|Artifical Intelligence-Generated Treatment Recommendations|The clinical vignette will contain treatment recommendations which were generated by an artificial intelligence-based clinical decision support system.
224079351|NCT07027293|OTHER|STANDART HEAD POSITION|STANDART HEAD POSITION
224079352|NCT07027293|OTHER|HEAD ROTATION POSITION|HEAD ROTATION POSITION
224079353|NCT07027293|DEVICE|Classic laryngeal mask airway (LMA)|Classic laryngeal mask airway (LMA)
224079354|NCT07027293|DEVICE|i-gel supraglottic airway device|i-gel supraglottic airway device
224079355|NCT06878833|DRUG|LYN-005 (risperidone)|long-acting oral (LAO) capsule
224079356|NCT06878833|DRUG|Placebo for LYN-005|capsule
224079357|NCT06878833|DRUG|IR Risperidone|tablets
224079358|NCT06878833|DRUG|Placebo for IR Risperidone|tablets
224079359|NCT05121532|DIAGNOSTIC_TEST|Interleukin-15 and Interleukin-22|Serum Interleukin-15 and Interleukin-22 in non segmental vitiligo
224079360|NCT06729489|PROCEDURE|Upper Endoscopy|Endoscopy in children with refractory iron deficiency anemia
224079361|NCT00472524|PROCEDURE|Mydriasis/cycloplegia via different modes of administration|
224079362|NCT02705989|DRUG|BMS-986195|Specified dose on specified day
224079363|NCT02705989|OTHER|Placebo|Specified dose on specified day
224079364|NCT06915909|DEVICE|surgery|40 patients randomised to two arms will undergo robotic prostatectomies using either the control AirSeal® Insufflation System (AIS) or the intervention Stryker PneumoClear Insufflator. Intra-operative and post-operative pain will be compared between the two arms of the trial.
224079365|NCT07073066|PROCEDURE|DC-LVA treatment plus usual care|Through cervical incision, the deep cervical lymphatic tissue is anatomically dissected and anastomosed with the venous system of the neck. Under indocyanine green (ICG) navigation, the flow of lymphatic fluid into the vein could be observed via ICG tracing fluorescence after surgery.
224079366|NCT07073066|OTHER|Usual care|The usual care group includes patients who were not using or were currently using medications for improving cognitive function.
224079367|NCT01841333|DRUG|PF-04449913|100mg given orally
224079368|NCT06899217|DRUG|CIN-102 Dose 15mg|Twice daily for 12 weeks
224079369|NCT06899217|DRUG|Placebo|Twice daily for 12 weeks
224079370|NCT06899217|DRUG|CIN-102 Dose 10mg|Twice daily for 12 weeks
224079371|NCT07081958|DRUG|RO7795081|RO7795081 will be administered orally once daily, according to the randomized dosing regimen, during the 38-week treatment period.
224079372|NCT07081958|DRUG|Placebo|Placebo matching each RO7795081 dosing regimen arm will be administered orally once daily during the 38-week treatment period.
224079373|NCT06915441|DRUG|SOLE|Participants will first receive LE at 1 g/kg/day, then will advance to 2 g/kg/day and lastly to 3 g/kg/day as tolerated to titrate based on triglyceride level \<250 mg/dL, per clinical team
224079374|NCT06915441|DRUG|MOLE|Participants will first receive LE at 1 g/kg/day, then will advance to 2 g/kg/day and lastly to 3 g/kg/day as tolerated to titrate based on triglyceride level \<250 mg/dL, per clinical team
224079375|NCT06916546|COMBINATION_PRODUCT|SIRT-L-P|Patients received 1-2 session of SIRT. Lenvatinib and PD-(L)1 inhibitor was initiated within 7 days after the first SIRT and continued until unacceptable toxicity, disease progression, initiation of new therapy, or loss to follow-up.
224079376|NCT06916546|COMBINATION_PRODUCT|TACE-L-P|Patients received TACE. TACE was repeated for viable tumors demonstrated by follow-up imaging in patients without worsening liver function or contraindications (on-demand TACE). Lenvatinib and PD-(L)1 inhibitor was initiated within 7 days after the first SIRT and continued until unacceptable toxicity, disease progression, initiation of new therapy, or loss to follow-up.
224079377|NCT07165977|DIETARY_SUPPLEMENT|Probiotic Supplementation (Bifidobacterium longum Rosell®-175 & Lactobacillus helveticus Rosell®-52) then placebo|"Each participant will take a probiotic mixture containing Bifidobacterium longum Rosell®-175 \& Lactobacillus helveticus Rosell®-52 and excipients: potato starch, magnesium stearate, and the capsule shell of hydroxypropyl methylcellulose. (Sanprobi Stress; Sanprobi sp. z o.o., sp.k., Szczecin, Poland) for 3 months.~* Dosage: One capsule per day, containing 3 × 10⁹ (3 billion) CFU\*.~* Instructions: Take before 1:00 PM. Do not consume hot drinks immediately after taking the capsule.~After completion of the first phase, each participant will take a probiotic containing only the excipients, i.e. maize starch, maltodextrins, and the capsule shell for another 3 months.~* Dosage: One capsule per day.~* Instructions: Take before 1:00 PM. Do not consume hot drinks immediately after taking the capsule.~* CFU = Colony Forming Units"
224079378|NCT07165977|DIETARY_SUPPLEMENT|Placebo Supplementation then Probiotic Supplementation (Bifidobacterium longum Rosell®-175 & Lactobacillus helveticus Rosell®-52)|"Each participant will take a probiotic containing only the excipients, i.e. maize starch, maltodextrins, and the capsule shell for 3 months.~* Dosage: One capsule per day.~* Instructions: Take before 1:00 PM. Do not consume hot drinks immediately after taking the capsule.~After completion of the first phase, each participant will take a probiotic mixture containing Bifidobacterium longum Rosell®-175 \& Lactobacillus helveticus Rosell®-52 and excipients: potato starch, magnesium stearate, and the capsule shell of hydroxypropyl methylcellulose. (Sanprobi Stress; Sanprobi sp. z o.o., sp.k., Szczecin, Poland) for another 3 months.~* Dosage: One capsule per day, containing 3 × 10⁹ (3 billion) CFU\*.~* Instructions: Take before 1:00 PM. Do not consume hot drinks immediately after taking the capsule.~* CFU = Colony Forming Units"
224079379|NCT07163819|OTHER|Probiotic|Daily 6-drops of Bifidobacterium longum subsp. infantis M-63, B. breve M-16V, and B. longum BB536 in non-GMO corn starch as excipient, in medium-chain triglyceride oil (1.5 × 109 CFU/day)
224079380|NCT07163819|OTHER|Placebo|Daily 6-drops of non-GMO corn starch in medium-chain triglyceride oil
224079381|NCT07167953|DEVICE|Brain MRI|90 participants will undergo a 60 minute SOC brain MRI followed by 15 minute spiral MRI
224079382|NCT07167953|DEVICE|Brain MRI - SOC and spiral|6 participants will be scanned using 2 versions (SOC and spiral) pf 6 sequences (12 scans total).
224079383|NCT07167953|DEVICE|Brain MRI - spiral|10 participants will be scanned with 3 sequences, 3 times (9 total scans per participants)
224079384|NCT07167953|DEVICE|Brain MRI - SOC and spiral|10 participants will be scanned using 2 versions (SOC and spiral) of 6 sequences (12 scans total).
224079385|NCT07167953|DEVICE|Brain MRI - spiral|10 participants will be scanned with 3 spiral sequences to achieve desired signal to noise ratio (SNR).
224079386|NCT07167953|DEVICE|Brain MRI - spiral|5 participants will be scanned with 2 pairs of 6 spiral sequences.
224079387|NCT07177664|OTHER|Breastfeeding Consultation Provided through the Nurse Navigation Program|The navigator nurse will meet with the pregnant woman/mother starting at 28-32 weeks of gestation and continuing until the sixth month postpartum. During these meetings, planned breastfeeding education will be provided, women's questions about breastfeeding will be answered, and counseling will be provided to address any concerns.
224079388|NCT07178145|DRUG|GLP-1RA|Receive 6 months of GLP-1RA (Semaglutide) treatment starting at 0.25mg once weekly and then the dose will be up titrated as tolerated every four weeks to once-weekly doses of 0.5, 1.0, 1.7, and 2.4 mg until a target dose of 2.4mg is reached after 16 weeks.
224079389|NCT07177859|DRUG|NTQ5082 capsules 200 mg|NTQ5082 capsules 200 mg
224079390|NCT07177859|DRUG|Eculizumab Injection|Eculizumab
224079391|NCT07178613|DRUG|Serine（Oral）|"This study evaluates the dose safety and efficacy of serine in combination with fluoropyrimidine-based therapies. Primary objective: To determine the safety of oral serine administration.~Secondary objectives: 1. To assess the preliminary efficacy of serine in the study population. 2. To establish the recommended Phase 2 dose for oral serine."
224079392|NCT07178613|DRUG|Fluoropyrimidine Drugs|"This study evaluates the dose safety and efficacy of serine in combination with fluoropyrimidine-based therapies. Primary objective: To determine the safety of oral serine administration.~Secondary objectives: 1. To assess the preliminary efficacy of serine in the study population. 2. To establish the recommended Phase 2 dose for oral serine."
224079393|NCT07177651|PROCEDURE|Laminoplasty|Is a posterior approach that involves the surgical widening of the spinal canal by reshaping or repositioning the lamina. However, some patients with cervical stenosis
224079394|NCT07177651|PROCEDURE|Laminectomy with lateral mass fixation|Posterior cervical decompression with lateral mass screw insertion
224079395|NCT07178080|DEVICE|PIUR tUS Infinity Ultrasound|PIUR imaging technology, cleared by the U.S. Food and Drug Administration under 510(k) (K240036), is designed to provide advanced volumetric imaging capabilities to improve accuracy in assessing nodule size and volume reduction.
224079396|NCT07178964|OTHER|Potassium-enriched salt-substitute|The patients in the experimental group will use potassium-enriched salt-substitutes for cooking and seasoning food in their home environment. Potassium-enriched salt-substitutes will contain 25% potassium chloride nad 75% sodium chloride.
224079397|NCT07178964|OTHER|Regular table salt|Patients in this arm will use regular table salt (100 % sodium chloride) for cooking and seasoning food in their home environment.
224079398|NCT07179380|DRUG|Treprostinil Palmitil Inhalation Powder|Oral inhalation using a capsule-based dry powder inhaler device.
224079399|NCT07179380|DRUG|Placebo|Oral inhalation using a capsule-based dry powder inhaler device.
224079400|NCT07179237|DIETARY_SUPPLEMENT|Carminal Oral solution|Carminal is an oral dietary supplement presented in 30 ml vials, administered once daily (1 vial BID). It contains Aloe vera extract, olive extract, glutamic acid, zinc, and other components with potential antioxidant, anti-inflammatory, and immunomodulatory effects on gastric mucosa. In this study, Carminal is administered for 14 days during standard Helicobacter pylori eradication therapy, followed by 12 weeks of continued treatment post-eradication to support mucosal recovery and improve dyspeptic symptoms.
224079401|NCT07179237|OTHER|Placebo|Placebo is an oral solution presented in 30 ml vials, identical in appearance, taste, color, and smell to Carminal, but without any active ingredients. It is administered once daily (1 vial BID) for 14 days during standard Helicobacter pylori eradication therapy, followed by 12 weeks of continued placebo treatment post-eradication. This comparator is used to evaluate the efficacy of Carminal in mucosal recovery and symptom improvement in patients with H. pylori positive gastritis.
224079402|NCT07178470|DIAGNOSTIC_TEST|Modified Medical Research Council (mMRC) Dyspnea scale , , point-of-care ultrasound (POCUS), specifically lung ultrasound (LUS) and physical examination|After obtaining informed consent, the Modified Medical Research Council (mMRC) Dyspnea scale will be administered to patients, and their responses will be recorded on a scale of 0 to +4. During the same clinical visit, a physical examination will be performed by the primary nephrologist, who will categorize the patient's volume status as hypovolemic, euvolemic, mild, moderate, or severe volume overloaded. Finally, point-of-care ultrasound (POCUS), specifically lung ultrasound (LUS), will be performed. Patients will be assigned a score based on the number of B-lines observed. We will measure discordance and concordance between the LUS and physical exam, the LUS and mMRC dyspnea scale, and between the physical exam and mMRc dyspnea scale.
224079403|NCT07179094|OTHER|Routine Protective Oral Care|In the control group, this group will perform oral care according to the routine clinical oral care procedures applied in the oncology clinic.
224079404|NCT07179094|OTHER|Protective Oral Care Using Peppermint Oil Mouthwash|Patients in the intervention group will perform a mouth rinse three times daily using 1 mL of peppermint oil diluted in 50 mL of water. The first application will be initiated on the day of chemotherapy, and patients will continue the peppermint oil oral care for six consecutive days (Day 0, Day 1, Day 2, Day 3, Day 4, and Day 5). The peppermint oil oral care protocol is scheduled to be administered at 07:00-08:00, 15:00-16:00, and 22:00-23:00, taking into account the routine timing of antiemetic medication administration in the clinic. The detailed description of the oral care protocol is presented below.
224079405|NCT07178587|DIAGNOSTIC_TEST|Single tracer PET/CT|Single tracer PET/CT for the HCC patients : one with \[18F\]FDG and one with \[18F\]F-choline Single tracer PET/CT for the GEP-NET patients : one with \[68Ga\]Ga-DOTATOC and one with \[18F\]FDG
224079406|NCT07178587|DIAGNOSTIC_TEST|Multiplexed PET-CT|Multiplexed PET-CT for HCC patients : \[18F\]FDG + \[18F\]F-choline. Multiplexed PET-CT for GEP-NET patients : \[18F\]FDG + \[68Ga\]Ga-DOTATOC. The PET scans must be performed in any order and at least 24 hours apart.
224079407|NCT07178951|DEVICE|Neurotomy|Use of high intensity focused ultrasound to ablate the genicular nerve.
224079408|NCT07178457|DRUG|Brentuximab Vedotin (Bv)|1.8 mg/kg in 100 mlof NaCl 0.9%, Q3W with a maximum of 16 cycles
224079409|NCT07178457|DRUG|Placebo|NaCl 0.9% 100 ml IV Q3W with a maximum of 16 cycles
224079410|NCT05935358|DRUG|Nuwiq|Nuwiq is a purified B-domain-deleted FVIII glycoprotein synthesised by a genetically engineered human embryonic kidney cell line (HEK 293F).
224079411|NCT05634408|DEVICE|ACUVUE® Abiliti™ 1-Day Soft Therapeutic Lenses for Myopia Management (A1D)|TEST Lens
224079412|NCT06452797|BEHAVIORAL|ProVent-14 score|A score to estimate one-year mortality for patients requiring at least 14 days of mechanical ventilation
224079413|NCT03576417|DRUG|Cisplatin|Intravenous
224079414|NCT03576417|DRUG|Nivolumab|Intravenous
224079415|NCT03576417|RADIATION|RT|IMRT 66 Gy / 6.5 weeks
224079416|NCT04484285|DEVICE|Transcutaneous Vagal Nerve Stimulation (tVNS)|vagal nerve stimulation
224079417|NCT02979977|DRUG|cetuximab|30-60 minutes after the recommended pre-medications, cetuximab will be administered intravenously at a dose of 400mg/m2 on cycle 1, day 1 of treatment (loading dose) and at a dose of 250mg/m2 every 7 days (+/- 1 day) thereafter. Alternatively, patients can be treated at a dose of 500mg/m2 every 14 days (+/- 2 days).
224079418|NCT02979977|DRUG|afatinib|Patients will take a single oral dose of afatinib each day at a dose of 30 mg. Afatinib dose will not be escalated beyond the 30 mg daily oral dose; dose reductions of afatinib can occur to manage treatment related adverse events.
224079419|NCT06074640|OTHER|MET PIR with Dry Needling|MET PIR Protocol: The subject will be asked to exert a small effort (20% of available strength) towards plantar flexion, against unyielding resistance, for 20 seconds. Once released, ankle will be dorsiflexed beyond the new range gained and stretched for up to 30 seconds. Rest period will be of 1 minute in between each repetition. (3 Repetitions, 1 Sets, 3 days per week, for 4 weeks consecutively.) MTrPs will be identified and located using flat or pincer palpation method in the Triceps Surae complex of the affected leg. The identified trigger points will be marked with a marker. Piston technique of dry needling is performed on the identified MTrPs in calf muscles. The self stretches of Plantar Fascia and Calf muscles will be demonstrated. The stretch position will be maintained for 20 sec, followed by 20 sec rest and then repeated for 3 minutes. All stretches will be performed twice daily by patients for 4 weeks time period (3 Reps, 2 sets/day, for 4 weeks)
224079420|NCT06074640|OTHER|MET PIR without Dry Needling|MET PIR Protocol: The subject will be asked to exert a small effort (20% of available strength) towards plantar flexion, against unyielding resistance, for 20 seconds. Once released, ankle will be dorsiflexed beyond the new range gained and stretched for up to 30 seconds. Rest period will be of 1 minute in between each repetition. (3 Repetitions, 1 Sets, 3 days per week, for 4 weeks consecutively.) The self stretches of Plantar Fascia and Calf muscles will be demonstrated. The stretch position will be maintained for 20 sec, followed by 20 sec rest and then repeated for 3 minutes. All stretches will be performed twice daily by patients for 4 weeks time period (3 Reps, 2 sets/day, for 4 weeks)
224079421|NCT04445857|DRUG|Calcitonin presented as Miacalcic® ampoules 100 IU/ml (1ml) intrathecally|coadministration of calcitonin intrathecally and a single-shot hyperbaric bupivacaine
224079422|NCT04445857|DRUG|Calcitonin presented as Miacalcic® ampoules 100 IU/ml (1ml) intravenously|coadministration of calcitonin intravenously and a single-shot hyperbaric bupivacaine
224079423|NCT04445857|OTHER|Normal Saline (NS)|coadministration of normal saline and a single-shot hyperbaric bupivacaine
224079424|NCT05246332|DEVICE|Grounding|The investigators used a grounding wire and a sham grounding wire to create grounding and sham-grounding groups. Participants sat on a chair barefoot in contact with the grounding mat for 30 minutes. The participants were blinded to the grounding because they did not know which one had a grounding effect according to the exterior of the mat.
224079425|NCT05280756|DEVICE|Home-based transcranial direct current stimulation (tDCS)|Each participant will be asked to do ten home-based tDCS sessions, one per weekday, during two weeks (Monday to Friday). Each session will be supervised remotely by a member of the research staff via HIPAA-compliant videoconference. Participants will receive active home-based tDCS (constant current intensity of 2mA) anodal-left and cathodal-right prefrontal for 30 minutes per session daily for 2 weeks (Monday to Friday - 10 sessions overall) via a tDCS stimulator with headgear and 5x7 (35cm2) saline-soaked surface sponge electrodes.
224079426|NCT05280756|DEVICE|Sham home-based transcranial direct current stimulation (tDCS)|Each participant will be asked to do ten home-based sessions, one per weekday, during two weeks (Monday to Friday). Each session will be supervised remotely by a member of the research staff via HIPAA-compliant videoconference. Participants will receive sham home-based tDCS for 30 minutes per session daily for 2 weeks (Monday to Friday - 10 sessions overall) via a tDCS stimulator with headgear and 5x7 (35cm2) saline-soaked surface sponge electrodes.
224079427|NCT06312332|BEHAVIORAL|Pulmonary Embolism (PE) Care in Emergency Department (ED)|Utilize implementation mapping to facilitate intervention development and evaluation that can be disseminated broadly in diverse settings. Intervention to include a structured education program for clinicians on home management of patients with low-risk PE led by regional/national leaders, the development of Clinician pre-commitment, point-of-care nudge including a clinical guideline integrated into an electronic health record clinical decision support, facilitated medication access, and dedicated outpatient rapid-follow up.
224079428|NCT02262494|PROCEDURE|portable venous compression ultrasonography|venous compression ultrasonography performed using an ultra-portable ultrasound device (by emergency physician)
224079429|NCT02262494|PROCEDURE|venous compress ultrasonography|venous compression ultrasonography performed using a classic ultrasound device (by exploratory specialist)
224079430|NCT02262494|PROCEDURE|Doppler ultrasound of the lower limbs|Doppler ultrasound of the lower limbs (gold standard; by exploratory specialist)
224079431|NCT00003267|PROCEDURE|infection prophylaxis and management|
224079432|NCT00003267|PROCEDURE|management of therapy complications|
224079433|NCT00003267|PROCEDURE|surgical procedure|
224079434|NCT04787965|DRUG|Opicapone|Opicapone as adjunctive treatment to levodopa/carbidopa over a 6-month period
224079435|NCT05197231|PROCEDURE|Resisted knee extension exercise|Patients in the intervention group will perform a seated knee extension exercise in three sets. Resistance will be adjusted using ankle weights, targeting 8-12 repetitions per set.
224079436|NCT05197231|DRUG|IV amino acids|IV amino acids (Glavamin, Fresenius Kabi) delivered by continuous infusion at a rate of 0.1 g/kg/h. The infusion is started immediately prior to physiotherapy and continued until all blood samples required for outcome assessment are collected during a 90-minute resting period after the exercise session.
224079437|NCT01504282|DRUG|mitomycin-C|
224079438|NCT01504282|DRUG|Placebo|balanced salt solution (BSS)
224079439|NCT00939198|BIOLOGICAL|Na-ASP-2 Skin Test Reagent|Na-ASP-2 Hookworm Skin Test Reagent, 1-1000 mcg/mL solution
224079440|NCT05724550|DRUG|Sugammadex|"* Sugammadex(100mg/mL), 2mg/kg~* After confirming Train-of-four counts 4, patients allocated to sugammadex group receive sugammadex 2mg/kg for reversal of rocuronium at the end of the surgery."
224079441|NCT05724550|DRUG|Neostigmine|"* Neostigmine methylsulfate(0.5mg/mL) 0.02mg/kg~* After confirming Train-of-four counts 4, patients allocated to neostigmine group receive neostigmine 0.02mg/kg (maximum 5mg) combined with atropine 0.02mg/kg for reversal of rocuronium at the end of the surgery."
224079442|NCT03050983|DEVICE|IPI|Enable the IPI algorithm and IPI alarm algorithm
224079443|NCT05006014|PROCEDURE|Tooth guided immediate implant placement|The technique of implant insertion consisted of a progressive preparation of the implant site using the anatomy of the root of the single rooted teeth to be extracted as a reference and as aid for apical engagement
224079444|NCT04864873|DIAGNOSTIC_TEST|Metagenomic next generation sequencing using Oxford Nanopore|See previous.
224079445|NCT04864873|DIAGNOSTIC_TEST|Standard microbiological diagnostic pathway|See previous.
224079446|NCT02939157|OTHER|Cardiac diagnostic ultrasound|Point-of-care ultrasound for diagnosing heart failure in primary care patients
224079447|NCT05366283|BIOLOGICAL|sargramostim|Sargramostim is a glycosylated, yeast-derived recombinant human granulocyte-macrophage colony-stimulating factor.
224079448|NCT00768898|OTHER|2.5/5.0/10.0 ÂµL lissamine green|vital stain solution
224079449|NCT02527707|DRUG|lonafarnib|antiviral farnesyltransferase inhibitor
224079450|NCT02527707|DRUG|Ritonavir|Cytochromes P450 3A4 inhibitor used to boost lonafarnib
224079451|NCT06217315|OTHER|No Intervention|There is no intervention.
224079452|NCT00234312|DRUG|escitalopram and sertraline|
224079453|NCT00060255|DRUG|busulfan|iv
224079454|NCT00060255|DRUG|carboplatin|iv
224079455|NCT00060255|DRUG|carmustine|iv
224079456|NCT00060255|DRUG|cyclophosphamide|iv
224079457|NCT00060255|DRUG|etoposide|iv
224079458|NCT00060255|DRUG|melphalan|oral
224079459|NCT00060255|DRUG|thiotepa|iv
224079460|NCT00060255|PROCEDURE|autologous bone marrow transplantation|iv
224079461|NCT00060255|PROCEDURE|bone marrow ablation with stem cell support|iv
224079462|NCT00060255|PROCEDURE|peripheral blood stem cell transplantation|iv
224079463|NCT00060255|RADIATION|radiation therapy|body x-ray
224079464|NCT00930059|DRUG|PF-04447943|tablets, 25 mg every 12 hours for 12 wks
224079465|NCT00930059|DRUG|Placebo|matching placebo tablets, every 12 hours for 12 wks
224079466|NCT01636466|DRUG|Everolimus|Everolimus will initially be dosed at 0.75 mg tablet taken orally twice a day. The dose will be adjusted to maintain serum trough concentrations of 5-8 ng/ml.
224079467|NCT05236803|BEHAVIORAL|Testing of general motor skills, fine motor skills and occulomotricity|"Recording of participant's performance during eye, fine motor and gross motor tests; Children's gross motor skills will be assessed through a biomechanical analysis.~Eye movements will be recorded using the eye-tracking system (Tobii Pro TX300). The technique used is the corneal reflection technique."
224079468|NCT05236803|BEHAVIORAL|Questionnaires|Passing self and hetero questionnaires.
224079469|NCT04002310|DRUG|BI 754132|One single injection
224079470|NCT00542997|BIOLOGICAL|Human Normal Immunoglobulin for Subcutaneous Administration (IGSC)|IgPro20 is a liquid formulation of normal human IgG at a concentration of 20% administered as a SC infusion at weekly intervals. The initial weekly dose was determined based on subjects' previous treatment. Dose adjustments could be performed during the wash-in/wash-out period at the discretion of the investigator.
224079471|NCT05301387|PROCEDURE|Ganglion Sphenopalatine Block|Block performed with bilaterally inserted q-tips with 1:1 mixture of lidocaine 40mg/ml and ropivacaine 5mg/mL or Block performed with bilaterally inserted q-tips with isotone NaCl
224079472|NCT04788940|PROCEDURE|Percutaneous Coronary Intervention|Patients with AMI who underwent PCI and CMR at index hospitalization and 6-month follow-up
224079473|NCT04857099|OTHER|Data extraction from medical files|Data extraction from medical files
224079474|NCT05835947|OTHER|Dual Pathology|Women with both genital HSIL/SCC and Anal HSIL/SCC
224079475|NCT06538506|DEVICE|RehUp BCI Intervention|Participants will be seated wearing a cap on their head containing surface electrodes connected to a computer/laptop. The laptop employs machine learning algorithms and uses the scalp electroencephalogram (EEG) signals from the scalp's surface to control a robotic arm which supports the patient's stroke-affected arm. The machine learning algorithms rapidly interpret EEG signals and adjust the outgoing movement commands to the robot based on an individual's responses to stimuli. The participant will be wearing a VR headset. The VR displays visual stimulus in time with the robotic arm. Based on information from the EEG, the participant is able to animate their robotic arm and receive visual task-based feedback in the VR.
224079476|NCT06538506|OTHER|Control Therapy|The study therapist will focus on 3 activities (\~15 minutes each/session): passive range of motion exercises, motor imagery, and mirror therapy. These activities were chosen as they are all passive activities that are commonly used in a patient with severe impairment of the post-stroke arm and hand. Each session will last \~1hour including set up and switching between activities.
224079477|NCT00001357|DRUG|Interleukin-2|
224079478|NCT01746771|DRUG|HM781-36B(Poziotinib)|QD\*2weeks/3weeks
224079479|NCT01746771|DRUG|Paclitaxel|175mg/m2
224079480|NCT01746771|DRUG|Trastuzumab|8mg/kg
224079481|NCT03303911|DRUG|Cytisine|film-coated tablets; depending on arm assignment, 1 or 2 tablets to be taken with 240 mL water for each dose
224079482|NCT02949128|BIOLOGICAL|Ravulizumab|Single loading dose on Day 1, followed by regular maintenance dosing beginning on Day 15, based on weight: ≥ 40 to \< 60 kilograms (kg), 2400 milligrams (mg) loading, then 3000 mg every 8 weeks; ≥ 60 to \< 100 kg, 2700 mg loading, then 3300 mg every 8 weeks; ≥ 100 kg, 3000 mg loading, then 3600 mg every 8 weeks.
224079483|NCT02050412|OTHER|Cat fur scratch test|
224079484|NCT00008112|DRUG|cisplatin|
224079485|NCT00008112|PROCEDURE|hyperthermia treatment|
224079486|NCT00008112|RADIATION|brachytherapy|
224079487|NCT00008112|RADIATION|radiation therapy|
224079488|NCT02788500|OTHER|Incidence of sports-related injuries and illnesses|The SRIIP-study is an epidemiological cohort study aimed to prospectively collect self-report data on sports-related injuries and illnesses incidence and risk exposure during training and competition for approximately one year among Swedish para-athletes.
224079489|NCT05812677|DRUG|Recombinant oncolytic herpes simplex virus type Ⅰ (R130)|R130, a modified herpes simplex virus-Ⅰ (HSV-1) containing the gene coding for anti-CD3 scFv/CD86/PD1/HSV2-US11
224079490|NCT04802473|PROCEDURE|Mucogingival surgery|In brief description, Tunnel+acellular dermal matrix treatment will be performed by starting initial sulcular incisions, tunneling knives will be used to elevate the buccal gingiva by means of a full-thickness flap elevation. Flap preparation will be extended beyond the MGJ. The exposed root surfaces will be treated with pre-conditioning EDTA (Straumann PrefGel®) for 2 minutes. ADM (OrACELL, LifeNet Helth, Virginia Beach, VA, USA) of 1.25-1.75mm in thickness will be cut to the exact size of the defect, and will be inserted into the tunnel, and subsequently covered advancing the flap by means of sling sutures to stabilize the flap in a coronal position (6-0 Polypropylene, Prolene, Ethicon, Johnson and Johnson, New Brunswick, NJ, USA). Sutures will be removed after 14 days. Two weeks after surgery, patients will resume mechanical tooth cleaning with a soft toothbrush. Patients will be recalled at 1, 3 and 6 months for professional oral hygiene procedures.
224079491|NCT03561584|DRUG|Sulfasalazine|Patients will be initiated on a low dose of sulfasalazine (500 mg) twice daily (bid). Dosage will be increased throughout the study.
224079492|NCT03561584|DRUG|Placebo|Patients will be initiated on 1 placebo tablet twice daily (bid). Dosage will be increased throughout the study.
224079493|NCT01641120|DRUG|Avonex|Intramuscular injection administered using 25 gauge or 30 gauge needle
224079494|NCT00606242|DRUG|Fluticasone|Inhaled Fluticasone, either 100 or 1000 mcg per day
224079495|NCT02399306|DRUG|Enteral nutrition|Patients in the Trial Group received concurrent chemoradiotherapy and standardized, whole-course enteral nutrition management.
224079496|NCT02399306|RADIATION|radiotherapy|"Patients receive intensity modulated radiation therapy(IMRT) from week 1 to week 7,once a day, 5 times per week.~Radiotherapy dose：95% gross tumor volume（GTV-T） 60-66 Gy /30-33f，GTV-N 60-66 Gy /30-33f，CTV-T 50-54 Gy /25-27f，CTV-N 50-54 Gy /25-27f."
224079497|NCT00294541|DRUG|ICA-17043|
224079498|NCT03064763|DRUG|Talimogene laherparepvec|Talimogene laherparepvec will be administered as an intralesional injection.
224079499|NCT03624257|DEVICE|Laser treatment|The participants in the laser group are treated by a combination of scaling and root planning (SRP) and 445 nm diode laser. The peri-implant pocket will be radiated with the 445 nm laser, removing bacteria, diseased epithelium and granulation tissue. The Power setting on the laser will be 0.7 W continuous wave and will be used at maximum 20 s Before cooling water is applied. Total treatment time will vary with the depth of the pocket and size of the surrounding bone crater.
224079500|NCT03624257|PROCEDURE|Mucosal flap surgery|The participants will receive a conventional peri-implant mucosal flap surgery of affected implants, in combination with scaling and root planning (SRP), and return after 7-10 days for suture removal. The surgery is a well-established treatment of peri-implantitis.
224079501|NCT04158063|BEHAVIORAL|Dual Task Training|"In total 12 Dual Task conditions will be performed in which 3 cognitive tasks are combined with 4 motor tasks:~Cognitive tasks:~* Titrated digit span backwards~* Auditory vigilance with alphabets~* Subtracting by 7~Motor tasks:~* Walking at self-selected speed~* Walking while carrying a cup of water~* Walking while stepping over obstacles~* Walking crisscross"
224079502|NCT04158063|OTHER|Single Mobility Training|standard routine training
224079503|NCT04878133|DIAGNOSTIC_TEST|OCT - optical coherence tomography|"The principle by which OCT works is similar to ultrasound, although light waves close to infrared are used instead of ultrasounds.~In practice, the light waves, emitted into the vessel through a special catheter positioned in the coronary artery, meet the surrounding structures and are partly absorbed and partly reflected by them. The reflected waves are picked up by a sensor positioned on the catheter and analyzed through software that produces images visible live on a special console."
224079504|NCT02440087|DIETARY_SUPPLEMENT|Refill Bypass|Dietary supplement
224079505|NCT03345056|PROCEDURE|vitrectomy with planned foveal detachment|23 gauge vitrectomy, posterior hyaloid detachment, internal limiting membrane peeling , sub-macular BSS injection using 38 gauge canula
224079506|NCT05524064|RADIATION|FLASH Radiotherapy|A dose of 8 Gy delivered in a single fraction will be prescribed to the PTV, delivered with FLASH Radiotherapy (\>40 Gy/s).
224079507|NCT05105763|OTHER|Sequential switched feedback training on the knee and the hip (Condition A)|Condition A will include four 6-mins training blocks: 2-mins knee joint feedback-on, 2-mins hip joint feedback-on, and 2-mins feedback-off. Training with feedback on will occur as follows: The subject will walk on the treadmill and try to achieve the target hip and/or knee flexion pattern shown on the feedback interface. Training with feedback off will occur as follows: The subject will walk on the treadmill and try to maintain the pattern without any form of visual or verbal feedback.
224079508|NCT05105763|OTHER|Feedback training on the knee alone (Condition B)|Condition B will include four 6-mins training blocks: 4-mins knee joint feedback-on and 2-mins feedback-off. Training with feedback on will occur as follows: The subject will walk on the treadmill and try to achieve the target hip and/or knee flexion pattern shown on the feedback interface. Training with feedback off will occur as follows: The subject will walk on the treadmill and try to maintain the pattern without any form of visual or verbal feedback.
224079509|NCT01698957|OTHER|Any patient eligible for an Ultrasound greater than or equal to 18 weeks gestation without a fetal or uterine anomaly.|bilateral Uterine artery Doppler readings pre- and during blood pressure measurement
224079510|NCT03160560|DRUG|ClōSYS® Unflavored Rinse|Subjects in Test group will receive ClōSYS® Unflavored Rinse.
224079511|NCT03160560|DRUG|ClōSYS® Flavored Rinse|Subjects in Test group will receive ClōSYS® Flavored Rinse.
224079512|NCT03160560|OTHER|Placebo|Subjects in Placebo group will receive Placebo Rinse.
224079513|NCT03599700|DIAGNOSTIC_TEST|myeloproliferative neoplasms|BLOOD SAMPLING
224079514|NCT01009307|GENETIC|polymorphism analysis|
224079515|NCT01009307|OTHER|laboratory biomarker analysis|
224079516|NCT01009307|OTHER|medical chart review|
224079517|NCT01608425|PROCEDURE|telemedicine consultations|Replacing 2 out of 3 patient visits to out-patient clinic at hospital with treatment at home from visiting nurse and telemedicine consultations with the specialist doctor.
224079518|NCT04314050|DRUG|Tramadol|tramadol and paracetamol will perform
224079519|NCT04314050|DRUG|Dexmedetomidine|dexmedetomidine and paracetamol will perform
224079520|NCT04314050|OTHER|control|paracetamol will perform
224079521|NCT06018649|COMBINATION_PRODUCT|Balneotherapy plus complex|The three groups of study (SAB, LAB, LIB) will get same balneotherapy intervention with the difference in duration and mode (outpatient/inpatient). Balneotherapy plus complex procedures: swimming pool with light exercises- 20 min (29-31°C), rest 15 min, wrapping/bath with peloids (peat mud, sapropel)- 20 min (38-40°C), rest 20 min, mineral water bath- 20 min (36-38°C), salt therapy- 25 min (humidity 35%, temperature about 22°).
224079522|NCT06018649|COMBINATION_PRODUCT|Combined nature resources treatment|"The participants of CNT group will be given combined treatment: nature therapy procedure (45 min) and balneotherapy plus complex intervention procedures.~The nature therapy procedure was created by researchers by combining the principles of nature therapy, mindfulness, wild nature therapy, kinesiology selecting actions suitable for the season. A procedure instructions with specific steps will be prepared and given to the research participant. The procedure will be performed for the first time by a physiotherapist, the rest of the procedures are performed independently, following the detailed procedure with written instructions given to the participants. Each day participants will receive a message with a reminder to perform the natural therapy procedure. Duration of procedure- 45 min, outside (seaside, forest)."
224079523|NCT06018649|OTHER|Nature therapy procedure|The participants of NT group will be given nature therapy procedure (45 min) created by researchers by combining the principles of nature therapy, kinesiology, mindfulness, wild nature therapy, selecting actions suitable for the season. A procedure instruction with specific steps will be prepared and given to the research participant. The procedure will be performed for the first time by a physiotherapist, the rest of the procedures are performed independently, following the detailed procedure with written instructions given to the participants. Each day participants will receive a message with a reminder to perform the natural therapy procedure. Duration of procedure- 45 min, outside (seaside, forest).
224079524|NCT04153084|DRUG|Polyethylene Glycol 4000 with electrolytes|The high volume electrolytes PEG will be administered at a 4 mg/kg dose the day before the procedure in 4-8 hours.
224079525|NCT04153084|DRUG|PEG-3350 with electrolytes|The low volume electrolytes PEG will be administered at a 4 mg/kg dose the day before the procedure in 4-8 hours.
224079526|NCT04153084|DRUG|Sodium picosulfate|"The Sodium picosulfate will be administered the day before the procedure at different doses depending on the patient´s age:~* From 1 to 2 years old: ¼ sachet reconstituted in ¼ glass of water/juice in the afternoon (15:00 h) and ¼ sachet reconstituted in ¼ glass of water/juice 6 hours later (21:00 h)~* From 2 to 4 years old: ½ sachet in ½ glass of water/juice in the afternoon and ½ sachet in ½ glass of water/juice at night.~* From 4 to 9 years old: 1 sachet in 1 glass of water/juice in the afternoon and ½ sachet in ½ glass of water/juice at night.~* Of 9 years old and older: 1 sachet in the afternoon and 1 sachet at night."
224079527|NCT03334084|DRUG|ARGX-113|intravenous or subcutaneous administration
224079528|NCT00667576|DRUG|Maxacalcitol|Study drug was administered 3 times per week (no more frequently than every other day) intravenously immediately before the completion of hemodialysis. The initial dosage was administered for 2 weeks, with subsequent dosage adjustment based on the subject's iPTH, calcium (adjusted), and phosphorus levels every 2 weeks. Total duration of treatment was 12 weeks.
224079529|NCT00667576|DRUG|Paricalcitol|Study drug was administered 3 times per week (no more frequently than every other day) intravenously immediately before the completion of hemodialysis. The initial dosage was administered for 2 weeks, with subsequent dosage adjustment based on the subject's iPTH, calcium (adjusted), and phosphorus levels every 2 weeks. Total duration of treatment was 12 weeks.
224079530|NCT01151683|DIETARY_SUPPLEMENT|magnesium|Magnesium chelate, 300mg (2 capsules of 150mg) twice a day, per oral Total of 600mg per day
224079531|NCT01151683|DIETARY_SUPPLEMENT|placebo|Two capsules of placebo per oral twice a day
224079532|NCT00404521|DRUG|PM02734|Administered every 3 weeks, intravenously, over 30 minutes
224079533|NCT05852639|DEVICE|Ultrasound|Routine obstetric ultrasound will be done at term (at 37 weeks gestation): to confirm gestational age, assess fetal weight and amniotic fluid index and to exclude fetal anomalies.Doppler study and cerebroplacental ratio assessment will be done at 37 weeks gestation and repeated every two weeks
224079534|NCT01390389|DRUG|Coenzyme Q10|"Single pill consists of 400 mg and is delivered PO.~CoQ10 dosing guidelines:~* Visit 1 (baseline) start at 400mg once a day for two weeks~* Visit 2 (within 7 days of baseline visit) increase to 800 mg once a day for two weeks~The dosage of CoQ10 can be titrated in a more gradual manner depending on clinical response and tolerability of the medication, but cannot be titrated any more rapidly than the schedule above."
224079535|NCT03851783|DEVICE|Solar-powered oxygen|Constant and reliable administration of oxygen, using solar panels to power an oxygen concentrator and deliver medical grade oxygen at 1-5L/min.
224079536|NCT02002975|DRUG|Pioglitazone|Pioglitazone tablets
224079537|NCT04391959|DRUG|AZR-MD-001 Active|AZR-MD-001 is an active ophthalmic ointment
224079538|NCT04391959|DRUG|AZR-MD-001 Vehicle|AZR-MD-001 is a vehicle ophthalmic ointment
224079539|NCT05554627|DRUG|Esketamine|Intranasal spray; a dissociative hallucinogen drug used as a general anesthetic and an antidepressant for treatment of depression.
224079540|NCT05554627|DRUG|Aripiprazole|Atypical antipsychotic; used in the treatment of schizophrenia and bipolar disorder. Other uses include as an add-on treatment in major depressive disorder, tic disorders and irritability associated with autism. Taken by mouth or injection into a muscle.
224079541|NCT01350856|DRUG|Artesunate 2|Artesunate 2 mg/kg/day for 3 days followed by a full course of either artemether-lumefantrine or DHA-piperaquine or artesunate-mefloquine or artesunate-amodiaquine
224079542|NCT01350856|DRUG|Artesunate 4|Artesunate 4 mg/kg/day for 3 days followed by a full course of either artemether-lumefantrine or DHA-piperaquine or artesunate-mefloquine or artesunate-amodiaquine
224079543|NCT06036589|DRUG|CA and BAM8-22|CA (tran-cinnamaldheyde) solution (in ethanol 5%) application and BAM8-22 with inactivate cowhage spicules 20 µl of BAM8-22 will be applied to a previously determined area on the volar forearm using inactivate cowhage spicules
224079544|NCT06036589|DRUG|Vehicle and BAM8-22 application|Vehicle (ethanol) application and BAM8-22 with inactivate cowhage spicules 20 µl of BAM8-22 will be applied to a previously determined area on the volar forearm using inactivate cowhage spicules
224079545|NCT06036589|DRUG|CA|CA (tran-cinnamaldheyde) solution (in ethanol 5%) application to a previously determined area on the volar forearm
224079546|NCT06036589|DRUG|vehicle|Vehicle (ethanol) application and inactivate cowhage spicules will be applied to a previously determined area on the volar forearm
224079547|NCT03007212|PROCEDURE|transarterial chemoembolization versus the standard treatment with sorafinib|TACE procedures were performed by the interventional radiologist through femoral artery approach in all patients. Super-selective cannulation of the main feeders was performed using a microcatheter whenever possible. The c-TACE protocol consisted of intra-arterial infusion of cisplatin 50-100 mg mixed with lipiodol ,Just prior to injection, emulsion is prepared by intensive mixing of equal volumes of cytotoxic drug solution and iodized oil using the pumping method with two syringes and a three way stop cock. Injection is guided by fluoroscopy and results in dense accumulation of the emulsion within the tumor vascular bed. Injection of poor iodized oil up to a maximum volume of 10-20 cc is an option and is followed by embolization of feeding arteries by Gelfoam cubes .Endpoints of conventional TACE are complete filling of the tumor vascular bed with iodized oil and stop-flow in subsegmental and segmental feeding arteries..
224079548|NCT01935050|BEHAVIORAL|Guided Cognitive-Behavioral Self-Help|Participants will complete the study treatment at home. Bi-weekly telephone support will be provided by study staff.
224079549|NCT01430442|DRUG|Rimegepant|Rimegepant capsules
224079550|NCT01430442|DRUG|Placebo|Rimegepant placebo-matching capsules
224079551|NCT01430442|DRUG|Sumatriptan|Rimegepant matching sumatriptan and Rimegepant matching placebo capsules
224079552|NCT02545725|OTHER|Questionnaire on Quality of Life|The patients were asked to complete a questionnaire on Quality of Life
224079553|NCT05629325|DRUG|Buspirone Hydrochloride 10 MG|4 weeks of treatment with buspirone
224079554|NCT05629325|DRUG|Placebo|4 weeks of treatment with placebo
224079555|NCT05141305|DRUG|tenecteplase (0.25 mg/kg, Max 25 mg)|tenecteplase (0.25 mg/kg) is being used.
224079556|NCT05141305|DRUG|standard medical treatment|Aspirin combined with clopidogrel, aspirin alone, or clopidogrel alone are being used.
224079557|NCT02659592|PROCEDURE|transplantation of ovarian tissue|operation(mini laparotomy) for transplantation of frozen- thawed ovarian tissue
224079558|NCT02167178|OTHER|Administration of 0.9% NaCl solution|Volunteers administered 0.9% NaCl solution in 250ml boluses
224079559|NCT02167178|OTHER|Measurement of stroke volume|The measurement of stroke volume will be performed using an Oesophageal Doppler Monitor.
224079560|NCT02167178|OTHER|Measurement of microvascular blood flow|Microvascular blood flow will be measured using a contrast enhanced ultrasound scan.
224079561|NCT02167178|OTHER|Administration of gelofusine|Volunteers administered gelofusine in 250ml boluses
224079562|NCT05018819|BIOLOGICAL|AlloRx|cultured allogeneic adult umbilical cord derived mesenchymal stem cells
224079563|NCT04704479|DEVICE|Russian current|For application of Russian current, 2 channels with 2 electrodes each will positioned on the oblique muscles and rectus abdominis motor points using wet spongy pads to enhance electrical activity. Russian current will be a carrier frequency 2500 Hz with frequency of 5 Hz for 5 minutes of muscular conditioning, 40 Hz for 10 minutes for training of slow contraction muscular fibers and 120 Hz for 5 minutes for training of fast contraction muscular fibers with On time (contraction time) 4 secs and Off time (relaxation time) 2 secs. The contraction phase will be at time of patient's expiration while relaxation will be at time of patient's inspiration
224079564|NCT04704479|DEVICE|EMT|patients in both groups trained 3 times a week, each session consisting of 1/2 h by the end of sessions. Initially, repeated cycles of 3 min of work followed by 2 min of rest were conducted (total work- time 18 min). The length of work intervals was increased on a weekly basis while rest periods were shortened to obtain a total work time of 30 min in the last week of the program. The valve opening pressure was continuously monitored at the mouthpiece to ensure the achievement of the target pressure. Patients will receive EMT with a threshold expiratory muscle trainer (Threshold; HealthScan), started breathing through the expiratory port of the threshold muscle trainer at a resistance equal to 15% of their Pemax for 1 week. The resistance will then increase incrementally, 5 to 10% each session, to reach 60% of their baseline Pemax at the end of the first month then continued at 60% of the Pemax, will be adjusted weekly to the new Pemax achieved
224079565|NCT01160939|OTHER|low intensity exercise|exercise protocol with six stages of exercise (1. upper limbs, 2. inferiors, 3. walk 35 m, 4. ½ flight of stairs, 5. walk 200 m 6. a flight of stairs) with intensity between 2-6 metabolic equivalents
224079566|NCT02669472|OTHER|Environmental Intervention|Intervention sites received regularly-scheduled, discount, fresh F\&V markets for one year during the first two weeks of each month. The markets brought between 50-70 different produce items, including culturally desired ethnic produce. Markets at the senior and disabled housing complexes were held indoors as were markets at family housing complexes during inclement weather. In good weather, markets were held outside at the family complexes using a mobile retrofitted car trailer. The produce items were set up in racks on three sides of the trailer and shoppers entered through the rear door. FTY markets accepted cash, debit/credit cards and EBT cards (SNAP). Each market lasted two hours and the produce was sold at prices 15%-25% lower than local retail supermarket prices.
224080386|NCT06958718|PROCEDURE|Surgical erector spinae plane block (SB)|Surgical erector spinae plane block (SB) with 40 ml Bupivacaine HCL mixed with 0.5 μg/kg dexmedetomidine ..This volume will be divided into 8 injections, four 5 ml injections on each side. The surgeons will perform the block just before starting the wound closure stage. The surgical ESP block technique consists of injections at four bilateral levels, starting from one level above the operated vertebra and covering all surgical segments using a 22G × 88 mm needle. The needle will be inserted to contact the transverse process, and the injectate will be delivered between the erector spinae muscle and the transverse process at each level.
224080387|NCT06958718|DRUG|Dexmedetomidine|0.5 μg/kg dexmedetomidine added to block solution
224080388|NCT06958718|DRUG|Bupivacaine Hcl 0.5% Inj|40 ml Bupivacaine HCL
224080389|NCT02395549|DRUG|0.375% (w/w) MTC896 Gel|0.375% (w/w) MTC896 Gel
224080390|NCT02395549|DRUG|0.75% (w/w) MTC896 Gel|0.75% (w/w) MTC896 Gel
224080391|NCT02395549|DRUG|1.5% (w/w) MTC896 Gel|1.5% (w/w) MTC896 Gel
224080392|NCT02395549|DRUG|Vehicle Control Gel|
224080393|NCT03593915|COMBINATION_PRODUCT|Alvocidib Plus Decitabine (during dose escalation only) or Azacitidine|"PHASE 1b:~Decitabine administered as an intravenous (IV) infusion daily for 5 days at a dose of 20 mg/m2 followed on Day 8 by alvocidib as a loading dose over 30 minutes followed by a 4-hour IV infusion (hybrid dosing) Once the maximum dose of alvocidib administered via hybrid dosing has been determined, 2 cohorts of patients will receive azacitidine followed by alvocidib administered as an IV infusion. Azacitidine may be administered as either an IV bolus over 10 to 40 minutes or as a subcutaneous (SC) injection on either a 7 day or 5-2 2 schedule. Regardless of which azacitidine schedule or route of administration is used, alvocidib will be given on Day 10 as a 30-to-60 minute IVI~PHASE 2:~The Phase 2 study will use the RP2D from the Phase 1b study and follow a Simon 2-stage minimax design using the RP2D of alvocidib administered as a 30-to-60 minute IV infusion determined in the Ph1b study to explore efficacy of alvocidib when administered in sequence after azacitidine."
224080394|NCT06543615|DEVICE|Ultrasonography|Ultrasound assessment of residual gastric volume
224080395|NCT03179085|BEHAVIORAL|Home-Based Kidney Care|All subjects randomized to the HBKC arm will be visited by a community health representative in their home at least every two weeks for the duration of the 12 month intervention. Each visit will last 30 minutes to one hour and cover materials like, (1) Kidney 101, (2) weight management, (3) exercise, (4) healthy eating, (5) medication management, (6) coping with stress, (7) risk factor management (i.e.- blood pressure, hyperlipidemia), (8) alcohol and substance abuse, (9) smoking cessation, and related health concerns.
224080396|NCT04110041|BEHAVIORAL|Aerobic Exercise|Thrice-weekly aerobic exercise sessions lasting \~45 minutes, for 12 consecutive weeks.
224080397|NCT06108362|DRUG|Terlipressin|The medication is dispensed by the nursing staff before surgery and given to the anesthesiologist before the procedure begins
224080398|NCT06108362|DRUG|normal saline|The medication is dispensed by the nursing staff before surgery and given to the anesthesiologist before the procedure begins
224080399|NCT01052025|DRUG|Curcumin|curcumin capsule contains 250 mg curcuminoiods, 3 capsules per time, 2 times a day before meal for 12 months
224080400|NCT06040983|DEVICE|FR-101 Chest Dressing|"Subject will receive FR-101 chest dressing and be instructed to use the product on the target skin area accepted radiation therapy once every 2 days, taking care of avoiding applications from 1 to 4 h before treatment to prevent Build-up effect. If the application time is longer than the recommendation, discomfort may happen depending on subject's condition."
224080401|NCT00101257|BIOLOGICAL|therapeutic autologous lymphocytes|
224080402|NCT05666713|DEVICE|TELLTALE BASILICA procedure|The TELLTALE BASILICA procedure has five steps: (1) engagement of the target leaflet with a guiding catheter; (2) electrosurgical leaflet traversal with the TELLTALE guidewire, (3) preparation and positioning of the TELLTALE guidewire electrosurgical leaflet laceration surface; (4) electrosurgical leaflet laceration with the TELLTALE guidewire, immediately followed by (5) TAVR. These are all guided by fluoroscopy, with adjunctive echocardiography as needed.
224080403|NCT02897895|BIOLOGICAL|levels of CNI in whole blood|
224080404|NCT02897895|BIOLOGICAL|Calcineurin activity (CN-a) in peripheral blood mononuclear cells (PBMCs)|
224080405|NCT05665270|DRUG|Dextenza 0.4Mg Ophthalmic Insert|Group 1 (20 eyes) will receive treatment with topical 1% Prednisolone Acetate drops QID x 1 week, then Dextenza will be inserted at the one-week postoperative evaluation (Day 8). Both groups will receive topical Prolensa Qa.m. x 5 weeks and Moxifloxacin TID x 1 week, per investigators preferential treatment regimen.
224080406|NCT05665270|DRUG|Prednisolone Acetate 1%|"Group 2 (20 eyes) will receive treatment with topical 1% Prednisolone Acetate for five weeks with dosing schedule: QID x 2 weeks, TID x 1 week, BID x 1 week, QD x 1 week.~Both groups will receive topical Prolensa Qa.m. x 5 weeks and Moxifloxacin TID x 1 week, per investigators preferential treatment regimen."
224080407|NCT01641939|DRUG|Taxane|Standard taxane (docetaxel 75 mg/m\^2 IV every 3 weeks or paclitaxel 80 mg/m\^2) IV once a week according to investigator choice.
224080408|NCT01641939|DRUG|trastuzumab emtansine|trastuzumab emtansine 3.6 mg/kg IV every 3 weeks
224080409|NCT01641939|DRUG|trastuzumab emtansine|trastuzumab emtansine 2.4 mg/kg IV once a week
224080410|NCT01231997|DRUG|Udenafil|100mg Single Oral Dose of
224080411|NCT04886934|DEVICE|CS1 System|Placement of CS1, a temporary bipolar myocardial electrode (TME) with an integrated motion sensor (accelerometer), on the left ventricle and externalization of the associated leads through the chest wall during open-heart surgery. CS1 will remain in place for up to 7 days after surgery and closure of the chest wall.
224080412|NCT00772629|BIOLOGICAL|Meningococcal Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
224080413|NCT00772629|BIOLOGICAL|Meningococcal Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
224080414|NCT00416338|DEVICE|film dressing by adhesive|
224080415|NCT02894840|BIOLOGICAL|an inactivated influenza vaccine|The vaccine will be administered via the intramuscular route; the preferred injection site will be the deltoid of the non-dominant arm.
224080416|NCT02894840|OTHER|Placebo|The placebo will be administered via the intramuscular route; the preferred injection site will be the deltoid of the non-dominant arm.
224080417|NCT04041336|DIAGNOSTIC_TEST|Optical coherence tomography|Non-invasive method of acquiring cross sectional imaging of tissues using the coherent property of light
224080418|NCT04866290|DEVICE|HepaSphere Microspheres|
224080419|NCT03686787|DRUG|Tranexamic Acid|A split face study of oral tranexamic acid in combination with laser treatment
224080420|NCT02160392|PROCEDURE|Endometrial biopsy|Endometrial biopsy (EMB) specimens were collected via a 3 mm diameter plastic pipelle that was inserted into the uterus following EML. A sample of tissue was obtained by retracting the pipelle's plunger leading to negative suction and rotating the cannula for approximately 15 seconds.
224080421|NCT06548893|OTHER|Group acceptance and commitment therapy (ACT)|Group psychotherapy based on ACT + EPR
224079567|NCT02669472|BEHAVIORAL|Educational Intervention|Each household in the housing site received a reusable shopping bag that contained a binder with: an overview page, sleeves to store 12 newsletters, three DVDs and 48 recipe cards. The 20-minute DVDs included cooking demonstrations, tips and testimonials. A two-page, full-color newsletter was delivered each household each month. It had information about a particular F\&V in season as well as other tips and recipes. Two 6-week long educational and motivational campaigns were also offered: ''Just Add 2', and 'Color Your Plate'. Both campaigns included full-color campaign booklets, goal-setting activities, educational and motivational content, and F\&V trackers with incentives/prizes for completing and turning in the trackers. All materials were provided in English and Spanish.
224079568|NCT02669472|BEHAVIORAL|Control|We contracted with the Greater Providence YMCA to bring to provide physical activity and stress reduction programming. Two, six-week campaigns followed the same format and timing of the intervention group campaigns. Campaigns participants received a free, 6-week membership to the YMCA. The 'Take 10!' campaign aimed to increase participants' daily physical activity by 10 minutes per day until they reached the goal of at least 30-60 minutes per day. The second campaign was 'Stress Less' aimed to help participants reduce the amount of stress that they experienced by including relaxation activity into their daily routine.
224079569|NCT05722379|PROCEDURE|left bundle branch pacing (LBBP)|After recording the His potential, the 3830-69 lead (Medtronic Inc., Minneapolis, MN USA) was sent 1-2 cm forward and downward to find the insertion point of the right side of intra-ventricular septum combined with the pre-rotation impedance and ECG changes. Ultimately, the tip was perpendicularly straightforward posited against the septum to the left septal side .
224079570|NCT05722379|PROCEDURE|Right ventricular pacing (RVP)|Right ventricular pacing (RVP) is the standard treatment for patients with continuous ventricular pacing needs.
224079571|NCT05077696|OTHER|Drawing a tube of blood (serum)|dosage of neurofilaments and comparison with a final diagnosis one year after sampling.
224079572|NCT02602730|BEHAVIORAL|Break the Chain|Internet-based smoking cessation intervention designed for general population smokers with targeted materials for pregnant women. The program included a digital coaching component delivered via email at specific points as the user progresses through his/her quit process. Program content is based on Department of Health and Human Services Clinical Practice Guidelines for Treating Tobacco Use and Dependence.
224079573|NCT02602730|BEHAVIORAL|Clearing the Air|PDF version of smoking cessation booklet from National Cancer Institute.
224079574|NCT05196945|DRUG|vonoprazan fumarate + amoxicillin|vonoprazan fumarate 20 mg/time, 2 times/day, oral Amoxicillin 750mg/ time, 4 times/day, oral
224079575|NCT05196945|DRUG|Esomeprazole +Amoxicillin+Clarithromycin+Bismuth potassium citrate|Esomeprazole 20mg/ time, 2 times/day, oral Amoxicillin 1g/ time, 2 times/day, oral Clarithromycin 0.5g/ time, 2 times/day, oral Bismuth potassium citrate 220mg/ time, twice a day, orally
224079576|NCT01815229|PROCEDURE|tracheal lavages|tracheal lavages obtained during endotracheal intubation.
224079577|NCT02672085|PROCEDURE|PRP infiltraiton|Two time with 1 month interval, PRP will be extracted from own blood's patients with Regenlab® extraction kit, and injected into supraspinatus interstitial lesion.
224079578|NCT02672085|PROCEDURE|Needling|Two time with 1 month interval, saline water will be injected into supraspinatus interstitial lesion.
224079579|NCT02098954|DRUG|Gemcitabine platinum combined with erlotinib|patients will received a 28 days gemcitabine platinum combined with erlotinib scheme, after 4 cycles combined chemotherapy, patients will receive erlotinib for maintain treatment until progression disease.Gemcitabine for day 1 and day 8, 1250mg/m2. Platinum for day 1, 75mg/m2. Erlotinib for day 9-21 during combined chemotherapy, 150mg/day, then erlotinib should be used daily until patients develop progression disease.
224079580|NCT03424759|DRUG|AZD9291|Patients will be treated 80 mg/day of AZD9291 orally (1 cycle for 21 days).
224079581|NCT06202573|PROCEDURE|rhinoplasty|patients who have a step counter and we do not motivate them to walk
224079582|NCT02753010|PROCEDURE|Gastric emptying of carbohydrate-rich beverage|Old women with acute hip fracture with intake of carbohydrate-rich beverage in order to improve metabolic control. Gastric emptying studied for retention in the elderly with acute trauma.
224079583|NCT02753010|PROCEDURE|Gastric emptying of carbohydrate-rich beverage|Old women on waiting list for hip joint replacement with intake of carbohydrate-rich beverage in order to improve metabolic control. Gastric emptying studied as comparator in the elderly without acute trauma..
224079584|NCT02753010|PROCEDURE|Gastric emptying of carbohydrate-rich beverage|Young healthy women with intake of carbohydrate-rich beverage in order to improve metabolic control. Gastric emptying studied as comparator in young women.
224079585|NCT01356550|DRUG|RO4917838|single oral dose
224079586|NCT03285932|RADIATION|post-operative stereotactic radiosurgery (SRS)|"For radiosurgery, patients will be immobilized. Treatment planning including the MRI and planning CT should be performed 1 -2 weeks before SRT and treatment finished at latest 3-4 weeks after surgery. Planning should be as close to SRT as possible.~Organs at risk such as the brain stem, optic nerves, chiasm and spinal cord will be contoured. The Clinical Target Volume 1 (CTV1) will be defined as the resection cavity based on MRI and CT including T1 contrast enhanced changes around the resection cavity. The Clinical Target Volume 2 (CTV2) will be defined as a 3mm margin added to CTV1 by isotropic expansion and slightly adjusted as deemed appropriated by the experienced contouring physician. The Planning Target Volume (PTV) will be an additional margin of 1mm added to CTV2 by isotropic expansion.~Treatment planning will be performed using Accuray's Multiplan or subsequent approved treatment planning systems for Cyberknife."
224079587|NCT03285932|RADIATION|Whole brain radiotherapy (WBRT)|"For WBRT, an individual head fixation mask is manufactured for each patient, and treatment planning is performed as virtual simulation or 3D-conformal RT planning based on CT-imaging. The portals include the whole brain with special focus as including the skull base areas and lamina cribrosa. For low infratentorial lesions, the treatment volume may include the whole brain down to the second cervical vertbra.~RT will be applied with two portals (e.g. 87°and 273°) using a 6 MeV linear accelerator.~For WBRT, a total dose of 30 Gy in 3 Gy fractions will be applied."
224079588|NCT00483886|DRUG|Prucalopride|2 mg o.d.
224079589|NCT00483886|OTHER|Placebo|Placebo o.d.
224079590|NCT00483886|DRUG|Prucalopride|4 mg o.d.
224079591|NCT03018886|OTHER|GHRH plus arginine test|One ug/kg GHRH \[GHRH(1-29), GEREF Serono, Italy\] was administered as an iv bolus at time 0 min, followed by arginine (L-arginine monohydrochloride, Braun, Melsungen, Germany) 0.5 g/kg (max 30g9 over 30 min. Blood samples were drawn at -15,0,15,30,45,60,75,90 min.
224079592|NCT01172756|DRUG|Riociguat (BAY63-2521)|0.5 mg single oral dose
224079593|NCT01172756|DRUG|Riociguat (BAY63-2521)|1 mg single oral dose
224079594|NCT01172756|DRUG|Riociguat (BAY63-2521)|2 mg single oral dose
224079595|NCT01172756|DRUG|Placebo|single oral dose
224079596|NCT02841059|PROCEDURE|LSH|laparoscopic subtotal hysterectomy: LSH
224079597|NCT02841059|PROCEDURE|CLSH|laparoscopic cervical ligament sparing hysterectomy: CLSH
224079598|NCT02841059|PROCEDURE|LAVH|laparoscopic assisted vaginal hysterectomy: LAVH
224079599|NCT03436355|BEHAVIORAL|Physical activity|"The Active school study was a 10-month randomized controlled trial.The weekly interventions were 2×45 minutes physically active academic lessons, 5×10 minutes physically active breaks, and 5×10 minutes physically active homework."
224079600|NCT02550158|PROCEDURE|Educational program EDU-MICI|
224079601|NCT00334503|DRUG|Miglitol|
224079602|NCT00804687|OTHER|Placebo|Single-dose of 1 milliliter (ml) placebo solution will be administered orally and/or placebo tablet orally in one of the treatment periods.
224079603|NCT00804687|DRUG|JNJ-39220675|Single-dose of JNJ-39220675 will be administered as 1 ml of 10 milligram/milliliter solution orally in one of the treatment periods.
224079604|NCT00804687|DRUG|Pseudoephedrine|Single-dose of 60 milligram pseudoephedrine tablet will be administered orally in one of the treatment periods.
224079605|NCT02435602|PROCEDURE|NBI endoscopy|GI endoscopy examination and additional the entire length of esophagus is evaluate with NBI endoscopy Biopsy at the visually abnormal lesions
224079606|NCT02435602|PROCEDURE|Lugol chromoendoscopy|GI endoscopy examination and additional the entire length of esophagus is evaluate with Lugol chromoendoscopy Biopsy at the unstained lesions \>= 5 mm diameter Pathologic examination of all biopsy tissue specimens
224079607|NCT03288246|DIAGNOSTIC_TEST|point-of-care viral load test|A point-of-care viral load test returns viral load test results within 90 minutes.
224079608|NCT04822532|GENETIC|GSTA1 genotyping|Diplotype determination based on 4 single-nucleotide polymorphisms (SNPs) occurring in the promoter region of the GSTA1 gene
224079609|NCT01050114|DRUG|onaBoNT-A|"onaBoNT-A will be the active formulation. Each vial of onaBoNT-A Purified Neurotoxin Complex, Formulation No. 9060X, contains: 100 units (U) of Clostridium botulinum toxin type A, 0.5 mg albumin (human), and 0.9 mg sodium chloride in a sterile, vacuum-dried form without a preservative. One U corresponds to the calculated median lethal intraperitoneal dose (LD50) in mice. A 0.9% sterile saline (without preservative) for injection will be used as diluent for onaBoNT-A.~Each treatment session will be administered as 20 injections each of 1 mL (10U/ml), evenly distributed into the bladder."
224079610|NCT01050114|DRUG|Oxybutynin ER|Oxybutynin ER in a 10 mg capsule will be taken twice a day for the course of the study.
224079611|NCT00975247|OTHER|Receiving an educational booklet|Patients who receive an educational booklet will be considered to be receiving an intervention
224079612|NCT00808444|BIOLOGICAL|Pneumococcal conjugate vaccine GSK1024850A (different lots)|Intramuscular injection, 3 doses
224079613|NCT00808444|BIOLOGICAL|Infanrix hexa|Intramuscular injection, 3 doses in Malaysia and 2 doses in Singapore
224079614|NCT00808444|BIOLOGICAL|Infanrix-IPV/Hib|Intramuscular injection, only for Visit 2 in Singapore
224079615|NCT00808444|BIOLOGICAL|Rotarix|Oral, 2 doses
224079616|NCT04460755|OTHER|Control group|"A sample of cells from the buccal mucosa area will be taken with cytological sampling brush and will be fixed on on a microscopy slide and stained with a Feulgen fast green solution. The samples will be analyzed by electron microscopy. Tooth color will be measured, verified and evaluated with a Vita Easyshade V digital spectrophotometer in initial phase, after one month of usage, after two months of usage and one month after the end of usage.~Before using any of the whitening toothpaste under test, every participant will use non whitening toothpaste for one month, twice a day.~Satisfaction and impression with treatment will be recorded with the questionnaires provided for this study."
224079617|NCT04460755|OTHER|Whitening toothpaste 1|"A sample of cells from the buccal mucosa area will be taken with cytological sampling brush and will be fixed on on a microscopy slide and stained with a Feulgen fast green solution. The samples will be analyzed by electron microscopy. Tooth color will be measured, verified and evaluated with a Vita Easyshade V digital spectrophotometer in initial phase, after one month of usage, after two months of usage and one month after the end of usage.~Before using any of the whitening toothpaste under test, every participant will use non whitening toothpaste for one month, twice a day.~Satisfaction and impression with treatment will be recorded with the questionnaires provided for this study."
224079618|NCT04460755|OTHER|Whitening toothpaste 2|"A sample of cells from the buccal mucosa area will be taken with cytological sampling brush and will be fixed on on a microscopy slide and stained with a Feulgen fast green solution. The samples will be analyzed by electron microscopy. Tooth color will be measured, verified and evaluated with a Vita Easyshade V digital spectrophotometer in initial phase, after one month of usage, after two months of usage and one month after the end of usage.~Before using any of the whitening toothpaste under test, every participant will use non whitening toothpaste for one month, twice a day.~Satisfaction and impression with treatment will be recorded with the questionnaires provided for this study."
224079619|NCT04460755|OTHER|Whitening toothpaste 3|"A sample of cells from the buccal mucosa area will be taken with cytological sampling brush and will be fixed on on a microscopy slide and stained with a Feulgen fast green solution. The samples will be analyzed by electron microscopy. Tooth color will be measured, verified and evaluated with a Vita Easyshade V digital spectrophotometer in initial phase, after one month of usage, after two months of usage and one month after the end of usage.~Before using any of the whitening toothpaste under test, every participant will use non whitening toothpaste for one month, twice a day.~Satisfaction and impression with treatment will be recorded with the questionnaires provided for this study."
224079620|NCT04460755|OTHER|Whitening toothpaste 4|"A sample of cells from the buccal mucosa area will be taken with cytological sampling brush and will be fixed on on a microscopy slide and stained with a Feulgen fast green solution. The samples will be analyzed by electron microscopy. Tooth color will be measured, verified and evaluated with a Vita Easyshade V digital spectrophotometer in initial phase, after one month of usage, after two months of usage and one month after the end of usage.~Before using any of the whitening toothpaste under test, every participant will use non whitening toothpaste for one month, twice a day.~Satisfaction and impression with treatment will be recorded with the questionnaires provided for this study."
224079621|NCT04460755|OTHER|Whitening toothpaste 5|"A sample of cells from the buccal mucosa area will be taken with cytological sampling brush and will be fixed on on a microscopy slide and stained with a Feulgen fast green solution. The samples will be analyzed by electron microscopy. Tooth color will be measured, verified and evaluated with a Vita Easyshade V digital spectrophotometer in initial phase, after one month of usage, after two months of usage and one month after the end of usage.~Before using any of the whitening toothpaste under test, every participant will use non whitening toothpaste for one month, twice a day.~Satisfaction and impression with treatment will be recorded with the questionnaires provided for this study."
224079622|NCT01873755|BEHAVIORAL|asthma physical activity intervention|School- and community-based intervention includes several components: a classroom-based physical activity program, asthma awareness week at the school, asthma education for parents and students enrolled in the study, collaboration with child's physician to ensure proper medical treatment of child's asthma asthma education for school personnel
224079623|NCT05145621|DRUG|Fingolimod 0.5 mg capsules- Test drug|An oral dose of the assigned formulation (3 capsules) will be administered in the morning to subjects with about 240 mL of water at ambient temperature according to the randomization scheme.
224079624|NCT04861337|DRUG|Remimazolam|Remimazolam is infused at a rate of 0.25 mg/kg/h from end of anesthesia induction until 15 minutes before the end of surgery.
224079625|NCT04861337|DRUG|Placebo|Normal saline is infused at a rate same as in the remimazolam group from end of anesthesia induction until 15 minutes before the end of surgery.
224079626|NCT03793400|DRUG|Bevacizumab Injection|Anti-vascular endothelial growth factor (VEGF)
224079627|NCT01344967|DRUG|Zoledronic acid|Zoledronic Acid at a dose of 4mg will be administered by intravenous infusion over 15 minutes in at least 100mls of saline
224079628|NCT03120169|OTHER|treadmill endurance training|n = 15 patients with COPD. Walking intensity will be initially set at 80 percent of 6-minute Walking test Speed with progressive increase in Duration and intensity.
224079629|NCT03120169|OTHER|cycling endurance training|n=15 patients with COPD. Cycling intensity will initially be set at 60 percent of Peak work rate with progressive increase in Duration and intensity
224079630|NCT03478618|DRUG|Lactated Ringer|"Patients will be divided into 2 groups according to the amount of fluids received during caesarian section under spinal anesthesia.~Group (R) 30 patients will receive 15ml/kg/h lactated Ringer (LR) intraoperative. Group (L) 30 patients will receive 30ml/kg/h lactated Ringer (LR) intraoperative. blood loss will be replaced if more than 500 ml in ratio 3 ml crystalloid : 1ml blood in both groups"
224079631|NCT04879797|OTHER|Implementation of Maternal Safety Bundles|In the second phase, implementation of the bundles will take place. During this phase investigators will conduct quarterly surveys with the health facilities to measure implementation progress, including an index of evidence-based practices. Investigators will conduct surveys with postpartum women to measure their patient experience. Surveys will be conducted using RedCap software. Participants will be given the opportunity to complete the survey online or if they prefer, a research assistant can call them to conduct the survey over the phone. Data on SMM will be collected through PELL
224079632|NCT04879797|OTHER|Doula Services|Investigators are evaluating doula services that are offered by two doula organizations at three hospitals.
224079633|NCT03462095|PROCEDURE|Autologous HSCT|After the 3rd consolidation, T-cell ALL patients, randomized to auto-HSCT will be mobilised by G-SCF and harvested disregarding MRD-status. After completing the 5th consolidation T-ALL patients will be transplanted after non-myeloablative CEAM (CCNU, Ethoposide, ARA-C, Melphalan) conditioning, and after reconstitution will continue 2-years maintenance
224079634|NCT06303661|DEVICE|Non-ablative Radiofrequency|There are two electrodes: one active, which will be used on the penis, using a non-lubricated condom from the Blowtex brand, using pharmaceutical glycerin to emit radiofrequency inside and outside the condom, and another electrode, dispersive, wrapped in PVC-type plastic film, coupled to the region of the patient's penis where there is no fibrotic plaque, which will act as earth and the temperature to be used in the treatment will be 38°C. When the desired heating is reached, the device maintains the temperature and thus the radiofrequency application will be maintained for 2 minutes.
224079635|NCT06303661|DEVICE|Low-intensity Shock Wave Therapy|The equipment's applicator is covered with transparent PVC film and non-alcoholic gel is used as a coupling medium between the applicator and the penis. The following parameters are used: frequency of 10Hz, energy of 120mJ and 2,000 shots in the fibrotic plaque.
224079636|NCT03068325|OTHER|EAT-PTSD|
224079637|NCT03822013|DRUG|Miglustat|Treatment with Zavesca regimen based on body surface area as follows: SQRT \[Height (cm) × Weight (kg)\] / 3600 \<1.25 : 200mg TDS 0.88- 1.25: 200mg BID 0.73- 0.88: 100 mg TDS 0.47- 0.73: 100 mg BID \<0.47: 100 mg Daily
224079638|NCT03720899|DRUG|NicoBloc|For Session 1, participants will use one drop of NicoBloc (which will block 33% of tar and nicotine) on their conventional cigarette and then will smoke this cigarette in session. Following smoking, they will discuss the effects of the NicoBloc on their withdrawal, cravings, and overall enjoyment of their cigarette. To bolster their in vivo NicoBloc experience, participants will be provided with NicoBloc to use between sessions to acclimate to the NicoBloc and to make practice quit attempts (PQAs). Sessions 2 and 3 are similar to Session 1 except they will use more NicoBloc product during the session and will be instructed to use the product between sessions.
224079639|NCT03720899|DRUG|Nicotine Lozenge|Participants who receive nicotine lozenge (mini lozenge) will be given either a 2 or 4 mg lozenge to use in session, depending on how soon they smoke after waking. If a participant smokes within 30 minutes of waking, they start with the 4 mg lozenge; more than 30 minutes, they start with the 2 mg lozenge. They will be given lozenges between sessions to make PQAs.
224079640|NCT05583773|DRUG|ShengXian-QuYu Decoction|Specification: 30ml/bag, given twice daily, per oral use.
224079641|NCT05583773|OTHER|Placebo|Placebo matching ShengXian-QuYu Decoction, 30ml/bag, given twice daily, per oral use.
224079642|NCT02314988|DRUG|Tranexamic Acid|"3.0 grams of tranexamic acid will be poured in the surgical field and left in contact for five minutes. Subsequently, excess study solution will be suctioned away without touching the surrounding tissue surfaces and then the would closed without irrigation or manipulation.~TXA solution will be prepared using a dose of 3 grams of tranexamic acid combined with 70 mL of sterile normal saline, for a total volume of 100 mL."
224080422|NCT02007603|DRUG|Administration of Amoxicillin / clavulanic acid|Patients receive amoxicillin / clavulanic acid due to clinical necessity
224080423|NCT02007603|DRUG|Ampicillin / sulbactam|Patients receive ampicillin / sulbactam due to clinical necessity
224079643|NCT02314988|DRUG|Placebo|"Placebo will be poured in the surgical field and left in contact for five minutes. Subsequently, excess solution will be suctioned away without touching the surrounding tissue surfaces and then the would closed without irrigation or manipulation.~The placebo solution will be 100 mL of sterile normal saline."
224079644|NCT02723825|PROCEDURE|Closed reduction|Treated with Manipulatio, using plywood, gypsum or external fixation support to fixed
224079645|NCT02723825|PROCEDURE|Open reduction|Open reduction and internal fixation
224079646|NCT02088385|DEVICE|Hemospray|
224079647|NCT02088385|DEVICE|Combined Conventional Technique|
224079648|NCT05374473|BEHAVIORAL|Lifestyle modification|Content in the intervention arm was adapted from an evidence-based lifestyle modification program for people with MS outlined in print previously presented in a face-to-face format. The integrated lifestyle modification program translates the research evidence regarding modification of lifestyle related risk factors and health outcomes based on a detailed review of the literature around modifiable lifestyle risk factors that may influence MS disease progression, as outlined in the book Overcoming Multiple Sclerosis: the 7-step recovery program.
224079649|NCT05374473|BEHAVIORAL|Standard-care|Content in standard-care arm was adapted from MS-related websites
224079650|NCT04737473|DRUG|Opiod Free Anesthesia|The OFA protocol will entailed induction of anesthesia intravenously by the administration of the following drugs: magnesium sulfate 40mg/kg (without exceeding 2.5g), lidocaine 1.5mg/kg, ketamine 25mg, propofol 1.5-2mg/kg, dexamethasone 8mg and rocuronium
224079651|NCT00993707|DRUG|CTX-100 (formerly ETX-100) (hyaluronic acid)|"3 mL of either 0.01%, 0.03% CTX-100 (formerly ETX-100), or placebo will be dispensed into the PARI LC STAR nebulizer and inhaled using the PARI Ultra II compressors.~Number of cycles: if the study drug (0.01% CTX-100 Inhalation Solution or placebo) bid is well tolerated in the first cohort, the second cohort of subjects will begin dosing with 0.03% CTX-100 Inhalation Solution or placebo in the same manner as the first cohort."
224079652|NCT03725410|DEVICE|Venus Fiore Study Treatment|Study treatment consists of delivering radiofrequency (RF) and pulsed electromagnetic fields (PEMF) internally to the vagina (50 - 70% for up to 15 minutes), externally to the labia (10 - 35% for up to 10 minutes) and externally to the mons pubis (10 - 35% for up to 15 minutes).
224079653|NCT03725410|DEVICE|Venus Fiore Sham Treatment|Sham treatment consists of delivering radiofrequency (RF) and pulsed electromagnetic fields (PEMF) internally to the vagina (1% for up to 15 minutes), externally to the labia (1% for up to 10 minutes) and externally to the mons pubis (1% for up to 15 minutes).
224079654|NCT06195202|DRUG|AIs|Patients with AIs
224079655|NCT06195202|DRUG|OFS+AIs|Patients with OFS+AIs
224079656|NCT06195202|DRUG|FUL|Patients with FUL
224079657|NCT00748748|BIOLOGICAL|Culturelle|10\^10 Lactobacillus rhamnosus GG per capsule
224079658|NCT02521701|DRUG|NFL101|"Level 1: 100 µg~* 50 µg per injection (in each arm), two injections at day 1 and two injections at day 29~* The 140 µg must be diluted in 2.8 mL of dilution solution in order to obtain a 50 µg.mL-1 concentration.~Level 2: 200 µg~* 100 µg per injection (in each arm), two injections at day 1 and two injections at day 29~* The 140 µg must be diluted in 1.4 mL of dilution solution in order to obtain a 100 µg.mL-1 concentration. Therefore, for this level only, two vials are needed to inject 2 x 1.0 mL."
224079659|NCT01886521|PROCEDURE|Lumbar drain|
224079660|NCT01886521|PROCEDURE|Ventricular drain|
224079661|NCT02718378|DRUG|estetrol|
224079662|NCT02718378|DRUG|placebo|
224079663|NCT05003908|BIOLOGICAL|AlloRx|cultured allogeneic adult umbilical cord derived mesenchymal stem cells
224079664|NCT05839795|OTHER|Assessment study|Evaluation of musculoskeletal-related pain, posture, spine function, lumbar and neck regions, musculoskeletal disorder, fatigue, and quality of life
224079665|NCT06917599|DEVICE|Low-level laser|Effect of Low-level laser therapy in wound healing after primary molar extraction
224079666|NCT06917599|OTHER|Saline Solution (NaCl 0,9%)|Following the extraction, a piece of gauze soaked in normal saline solution (NSS) will be placed over the socket. Both parents and children will be instructed to keep the gauze in place for 45 minutes
224079667|NCT00264056|DEVICE|hyperthermia|
224079668|NCT02636777|OTHER|no intervention|Patients will be allowed to continue their usual treatment as recommended by their care team.
224079669|NCT00305656|DRUG|cediranib maleate|Given orally
224079670|NCT01412970|OTHER|volume loading|volume loading according to functional parameters of cardiac preload, i.e. stroke volume variations measured by arterial pulse contour analysis
224079671|NCT01673321|OTHER|Dietary intervention|All snacks (arms) were randomly given to subjects to be consumed within 5 minutes, after 4 hours of consuming a standard breakfast.
224079672|NCT01681329|BEHAVIORAL|Cognitive-behavioral therapy|Cognitive-behavioral therapy addressing intolerance of uncertainty, positive beliefs about worry, negative problem orientation, and cognitive avoidance
224079673|NCT01681329|OTHER|Interpretation training|Computerized interpretation training using Word-Sentence Association Paradigm
224079674|NCT05073055|PROCEDURE|İnguinal Hernia Repair|After hemodynamic stability, the patient was placed in the lateral position and infiltration anesthesia with 2% lidocaine was applied. Following aseptic preparation of the skin and probe, a medium-frequency curvey USG transducer was first placed in the midline to visualize the transverse projection of the first lumbar (L1) vertebra, then moved 2.5 cm laterally in the parasagittal plane, after imaging the transverse process, in-plane spreading was injected. Hydrodissection was achieved on the TP of L1 by using a 5 cm, 21G peripheral nerve block needle just below the erector spina muscle with real-time imaging of the substance. Afterwards, a unilateral injection of 15 ml at T12 and L1 levels was applied to each segment with the needle directed at two different angles from the same insertion point.
224079675|NCT02623738|DRUG|Placebo ophthalmic solution|
224079676|NCT02623738|DRUG|DE-117 ophthalmic solution low|
224079677|NCT02623738|DRUG|DE-117 ophthalmic solution high|
224079678|NCT02623738|DRUG|Latanoprost ophthalmic solution 0.005%|
224079679|NCT02409511|OTHER|non intervention|
224079680|NCT06445205|DIAGNOSTIC_TEST|Mitra® device with VAMS® (volumetric absorptive microsampling) technology|Capillary blood sample
224079681|NCT01533675|OTHER|Hydrogen peroxide|Once daily topical application of 3% hydrogen peroxide using a cotton-tipped applicator
224079682|NCT01533675|OTHER|Saline|Once daily topical application of normal saline, using a cotton-tipped applicator
224079683|NCT01380808|DRUG|capecitabine and pseudomonas aeruginosa combination|capecitabine 1000mg/m2 bid, po. pseudomonas aeruginosa 0.5ml loading dose,1ml qod ih.
224079684|NCT01275209|DRUG|HCD122|
224079685|NCT01575795|DRUG|Ticagrelor|Ticagrelor 360mg loading dose immediately pre prior percutaneous coronary intervention 360mg loading dose
224079686|NCT01575795|DRUG|Ticagrelor|Ticagrelor 180mg loading dose 180mg loading dose
224079687|NCT02078687|DIETARY_SUPPLEMENT|Enfamil HM fortifier, Mead Johnson|Enfamil was added to a small amount of mothers expressed milk and given in a bottle or with a small cup every day. Group 2 (HMF) received 5 packets each day for 4 month containing; 17.5 kcal, 1.375 g protein/ 5 packets
224079688|NCT02078687|DIETARY_SUPPLEMENT|Enfalac Premature Formula, Mead Johnson Nutritionals|"Group 3 received Enfalac containing:~68 kcal, 2 g protein, 7.4 g carbohydrate, 3.5 g fat/ 100 ml"
224079689|NCT02078687|DIETARY_SUPPLEMENT|Mothers own milk|Group 1 received mothers own milk without fortification
224079690|NCT02137408|DIETARY_SUPPLEMENT|Docosahexaenoic acid 200 mg|Participants will be randomized to 200 mg docosahexaenoic acid daily (1-200mg capsule) PO beginning at 18-20 weeks gestation through 6 weeks post-partum.
224079691|NCT02137408|DRUG|Docosahexaenoic acid 1000 mg|Participants will be randomized to 1000 mg (5-200mg capsules) docosahexaenoic acid PO daily beginning at 18-20 weeks gestation through 6 weeks post-partum.
224079692|NCT02487186|DRUG|Doxicicline|Association of doxycycline (DOX) encapsulated in PLGA microspheres to ultrasonic debridment for the treatment of patients with chronic generalized periodontitis.
224079693|NCT02487186|PROCEDURE|Full-mouth debridment|"The patients will be treated by a single-session of periodontal debridement~during 45 minutes, using an ultrasonic instrument (Cavitron, Dentsply, Rio de~Janeiro, Brazil), under irrigation with sterile saline solution 20. After the debridement, local administration of microspheres loading doxycycline (DOX) (test) or empty microspheres (control) was performed."
224079694|NCT01418001|DRUG|Pazopanib 400 mg QD - Gemcitabine and Docetaxel in Combination|"Patients who meet the eligibility criteria above will be treated with the combination therapy of Gemcitabine, Docetaxel, and Pazopanib for two cycles and subsequently re-evaluated for treatment effect. If no progression of the tumor is seen, patients will continue with two more cycles of treatment (total four cycles). Those patients who have progression of disease will proceed directly to surgical resection.~Following completion of neoadjuvant treatment, all patients will have definitive surgical resection. Following recovery from surgery, patients will proceed with adjuvant radiation therapy. Patients will then be followed for 2 years or until January 1st 2015, whichever comes first ."
224079695|NCT03932994|BEHAVIORAL|ACT on Health|This intervention consists of an online canvas course based on Acceptance and Commitment Therapy, focused on increasing healthy diet and physical activity and addressing barriers to change. The intervention also consists of weekly phone coaching calls.
224079696|NCT02027740|DIETARY_SUPPLEMENT|almond|
224079697|NCT05210504|DRUG|L-Lysine|5g L-lysine in 50ml water, administered orally
224079698|NCT05210504|DRUG|Normal Saline|Normal (0.9%) Saline
224079699|NCT02504788|RADIATION|hippocampal-sparing WBRT|
224079700|NCT04026984|DRUG|Rifamycin SV-MMX|2 Rifamycin SV-MMX® 50 mg tablets b.i.d. plus ORT
224079701|NCT04026984|DRUG|Placebo|Matching Placebo tablets
224079702|NCT03015467|OTHER|Fecal Microbiota Transplantation|Fecal Microbiota Transplantation and the traditional treatments for Acute Pancreatitis with gut mucosal barrier dysfunction and unbalance of gut microflora in part 1
224079703|NCT03015467|OTHER|normal saline|normal saline and the traditional treatments for Acute Pancreatitis with gut mucosal barrier dysfunction and unbalance of gut microflora in part 2
224079704|NCT02083458|PROCEDURE|Catheterization of the axillary vein.|
224079705|NCT01255774|DRUG|ranibizumab|An open-label, study of intravitreally administered ranibizumab
224079706|NCT03222427|DRUG|LY3314814|Administered orally
224079707|NCT03222427|DRUG|[13C415N3] LY3314814|Administered as an IV infusion
224079708|NCT01786317|DEVICE|High resolution manometry|Anorectal High resoltion manometry using electronic sensors
224079709|NCT05029557|BEHAVIORAL|Education and telephone follow ups based on the Chronic Care Model|The effects of Chronic Care Model-based education and telephone follow-up given to patients with COPD on self-efficacy and patient-reported outcomes.
224079710|NCT03177161|OTHER|15 Patient Reported Health Status Questions|The PROMIS-10 Global Health, three single item questions (ambulation, toileting, and dressing) that have been borrowed from the RiksStroke (The National Quality Register for Stroke - Sweden) and two further questions on feeding and communication have been included from the ICHOM Standard Set for Stroke.
224079711|NCT06496594|OTHER|Erythritol prophylactic powders|erythritol with particle size of \~14 µm will be used for 5 seconds (AIRFLOW® PLUS EMS)
224079712|NCT06496594|OTHER|Ultrasonic scaler with peek inserts|ultrasonic scaler, a piezoelectric handpiece with peek inserts (Mini Piezon EMS; PI, EMS) will be used.
224079713|NCT04931134|DEVICE|Trigeminal nerve stimulation - active|Active trigeminal nerve stimulation
224079714|NCT04931134|DEVICE|Trigeminal nerve stimulation - sham|Sham trigeminal nerve stimulation
224079715|NCT05867667|OTHER|Cardiac Rehab|Cardiac Rehab 2x per week and home exercise 1x per week: weeks 1-4 Cardiac Rehab 1x per week and home exercise 2x per week: weeks 5-8, Home exercise 3x per week: weeks 9-12
224079716|NCT04001647|DRUG|Acetylcholine|Endothelium-dependent vasodilation will be determined via graded intra-arterial infusions of acetylcholine (ACh). Doses of 1, 4, 8, and 16 μg/100ml forearm volume/min will be infused in the brachial artery for 3 minutes each.
224079717|NCT04001647|DRUG|Sodium Nitroprusside|Endothelium-independent vasodilation will be determined via graded intra-arterial infusions of sodium nitroprusside (SNP). Doses of 0.25, 0.5, 1, and 2 μg/100ml forearm volume/min will be infused in the brachial artery for 3 minutes each.
224079718|NCT04001647|DRUG|Ascorbic Acid|The influence of oxidative stress on arterial stiffness and vasodilation will be assessed by using intravenous ascorbic acid (AA). A single supra-physiological dose of 0.06 g/kg fat-free mass (FFM) will be infused over 20 min followed by a drip infusion of 0.02 g/kg FFM administered over 60 min.
224079719|NCT05188703|BEHAVIORAL|Patient Navigation|Participants will be assigned to a patient navigator and will have quarterly appointments. Patient navigators will assist with access and coordination of medical care.
224079720|NCT05622097|OTHER|0.9% Saline warmed to 37 degrees Celsius|0.9% Saline warmed to 37 degrees Celsius
224079721|NCT05622097|OTHER|0.9% Saline warmed to 24 degrees Celsius|0.9% Saline warmed to 24 degrees Celsius
224079722|NCT06507566|DEVICE|Tasso+™|The Tasso+™ blood collection kit is a collection device (called the Tasso+™) and a capillary collection tube that allows for the storage of the blood in a liquid format in different matrices.
224079723|NCT05003934|BIOLOGICAL|AlloRx|cultured allogeneic adult umbilical cord derived mesenchymal stem cells
224079724|NCT05269290|DRUG|Ingavirin®, syrup, 30 mg/5 ml|A dose will be based on the body weight; Ingavirin® will be administered once a day on top of standard therapy.
224079725|NCT05269290|DRUG|Placebo|Placebo will be administered once a day on top of standard therapy.
224079726|NCT04093531|DRUG|Ustekinumab|Up to 15 subjects will receive an infusion loading dose of 6 mg/kg of ustekinumab at baseline, and 90 mg of ustekinumab subcutaneously at week 4, week 12 and week 20. Subjects will be followed for 24 weeks.
224079727|NCT01180933|DIETARY_SUPPLEMENT|fish oil|400 mg of DHA and 150 mg of eicosapentaenoic acid per day
224079728|NCT01180933|DIETARY_SUPPLEMENT|folate|400 µg per day
224079729|NCT01180933|DIETARY_SUPPLEMENT|fish oil + folate|500 mg DHA, 150 mg eicosapentaenoic acid, 400 µg MTHF per day
224079730|NCT01180933|DIETARY_SUPPLEMENT|placebo|only vitamins and minerals as recommended, but no fish oil or folate
224079731|NCT03118596|DEVICE|I-gel|Fibreoptic guided tracheal intubation is going to be performed through the I-gel supraglottic airway.
224079732|NCT03118596|DEVICE|LMA Protector|Fibreoptic guided tracheal intubation is going to be performed through the LMA Protector supraglottic airway.
224079733|NCT04831333|OTHER||
224079734|NCT01131195|BIOLOGICAL|bevacizumab, Paclitaxel|Bevacizumab (10 mg/kg) i.v. is given every two weeks. Paclitaxel (90 mg/m2) i.v. is given on days 1, 8, and 15 of a 4 week cycle.
224079735|NCT01131195|BIOLOGICAL|Bevacizumab, Cyclophosphamide, Capecitabine|Bevacizumab (10 mg/kg) i.v. is given every two weeks. Cyclophosphamide (50 mg) and capecitabine (3x 500 mg) p.o. are given daily
224079736|NCT03714490|RADIATION|SCPRT|Short-course preoperative radiotherapy(SCPRT), which consists of 5 Gy x 5f and 4Gy for boost on the GTV with MRI-simulation alone.
224079737|NCT03714490|RADIATION|CRT|Long-term chemoradiotherapy(CRT), which consists of a long-term chemoradiation (2 Gy x 25 with capecitabine) preoperatively.
224079738|NCT03714490|DRUG|CAPOX|Patients will receive consolidation chemotherapy after 7-10 days of SCPRT completed, given in 3 week cycle of capecitabine 1000 mg/m2 twice daily, day 1-14 combined with oxaliplatin 130 mg/m2 once. In total, 4 cycles of neoadjuvant chemotherapy are scheduled before surgery.
224079739|NCT03321448|DRUG|TMTP1-ICG|Detection of SLN
224079740|NCT03321448|DRUG|ICG|Detection of SLN
224079741|NCT05086445|DRUG|LY3502970|Administered orally
224079742|NCT05086445|DRUG|Placebo|Administered orally
224079743|NCT01019018|DEVICE|subtenon block|subtenon block with stevens cannula
224079744|NCT01019018|DEVICE|subtenon block|subtenon block with Olive tip cannula cannula
224079745|NCT03909360|PROCEDURE|drainage tube|sub-hepatic drainage tube for laparoscopic cholecystectomy
224079746|NCT00924937|BEHAVIORAL|Mediterranean Diet|Mediterranean Diet:35-38% fat (22% MUFA; 6% PUFA; \<10% SAT).
224079747|NCT00924937|BEHAVIORAL|Low Fat Diet|Low fat diet: \<30% fat (12% MUFA; 6-8%PUFA; \<10% SAT)
224079748|NCT01637545|DRUG|Ramosetron|"G1 - Ramosetron 0.3mg i.v. just before the beginning of the surgery G2 - Ramosetron 0.3mg i.v. just after the end of the surgery and moving into the Recovery room~G3 - No medication but regular antiemetics injection if the patient want"
224079749|NCT04143269|DEVICE|Non-invasive transcutaneous vagus nerve stimulation|Bilateral stimulation 4 times per day for 7 days (period 1) and 2 times per day for 8 weeks (period 2). The two periods are separated by a 2 weeks wash-out period.
224079750|NCT04143269|DEVICE|Sham vagus nerve stimulation|"Bilateral stimulation 4 times per day for 7 days (period 1) and 2 times per day for 8 weeks (period 2). The two periods are separated by a 2 weeks wash-out period.~The sham device produces a slight vibrating sensation, but do not provide any vagal nerve activation"
224079751|NCT00272987|DRUG|lapatinib|(GW572016) 1000 mg QD
224079752|NCT00272987|DRUG|paclitaxel|80 mg/m2 IV weekly for three weeks
224079753|NCT00272987|DRUG|trastuzumab|4 mg/kg loading dose and 2 mg/kg weekly IV
224079754|NCT00311857|DRUG|Cetuximab|
224079755|NCT00311857|DRUG|Temozolomide|
224079756|NCT00311857|PROCEDURE|Radiation therapy|
224079757|NCT02784938|BEHAVIORAL|Vocational Empowerment Photovoice (VEP)|The VEP program is a 10-week manualized, structured, peer-led intervention delivered in 2-hour group sessions. The VEP manual includes a Workbook for the clients and a corresponding Leader's Guide for the group peer-leaders. The VEP program integrates Photovoice methodology, Rehabilitation Readiness technology and elements of the Anti-Stigma Photovoice (ASP) curriculum previously developed and tested by the Boston University Center for Psychiatric Rehabilitation (BU CPR). VEP group sessions combine didactic information, Photovoice exercises, and group discussions to empower participants in pursuing employment services and opportunities, all refined with input from individuals with a lived experience.
224079758|NCT03222349|DRUG|Diazepam Buccal Film|Subjects received a single DBF dose determined by age and body weight during the interictal state and during the ictal/peri-ictal period with at least 14 days washout between doses.
224079759|NCT01744288|DRUG|Ticagrelor|Oral single loading dose 180ng
224079760|NCT01744288|DRUG|Clopidogrel|Oral single loading dose 600mg
224079761|NCT01744288|DRUG|ASA|81mg once daily from day -2 up to platelet transfusion
224079762|NCT00510809|DRUG|Policosanol|Policosanol 20 mg daily
224079763|NCT00510809|OTHER|Placebo|Placebo daily
224079764|NCT00510809|DRUG|Policosanol Plus Already In Use Statin Therapy|Policosanol 20 mg daily Statin Therapy
224079765|NCT02021409|DRUG|BAY85-3934|Oral doses of BAY 85-3934 will be available in multiples of 5, 25, and 75 mg tablets
224079766|NCT02021409|BIOLOGICAL|Darbepoetin alfa|
224079767|NCT04873466|DIETARY_SUPPLEMENT|Enzyme-rich malt extract|Enzyme-rich malt extract (ERME) is a by-product of the malting process in which the cereal grain barley is dried. The ingredients are 100% barley malt extract. It smells and tastes sweet, with a runny jam-like texture. Malt extract has been used as a food stuff in baking and cookery for many years, but ERME is extracted by means which retains more active enzymes, such as amylase.
224079768|NCT02061852|DEVICE|Simeox|
224079769|NCT02061852|PROCEDURE|Physiotherapy|
224079770|NCT02976870|RADIATION|Ultrasound|Single ultrasound scan of kidney on side of body where ALIF was performed. If hydronephrosis of this kidney is detected, the second kidney will also be scanned.
224079771|NCT01808612|DRUG|Fluoxetine|
224079772|NCT01808612|DRUG|Placebo|
224079773|NCT01308411|OTHER|50% step down reduction in inhaled corticosteroid dose|All participants will have their inhaled corticosteroid dose reduced by 50%
224079774|NCT06548659|BEHAVIORAL|screen-based simulation|Randomization took place among 198 people. The intervention group was given training on pediatric medication administration through screen-based simulation.
224080424|NCT02007603|PROCEDURE|Blooddraws for pharmacokinetic profiling|Blood will be sampled at multiple timepoints during multiple hemodialysis sessions
224080425|NCT02641509|DEVICE|NBI during polypectomy|NBI to perform the polipectomy
224080426|NCT02641509|DEVICE|no NBI during polypectomy|no NBI to perform the polypectomy
224080427|NCT00624455|DRUG|Gabapentin|One dose of oral premedication of Gabapentin 10 mg kg-1 given at least 30 but not more than 90 minutes before surgery. Max dose is 600mg.
224080428|NCT00624455|DRUG|Placebo|Placebo
224080429|NCT00292500|DEVICE|Automated distal anastomotic device|CABG
224080430|NCT02794220|DEVICE|CN electronic cigarette 10 mg|Inhalation
224080431|NCT02794220|DEVICE|CN electronic cigarette 15 mg|Inhalation
224080432|NCT02794220|DEVICE|Nicorette Inhalator 15 mg|Inhalation
224080433|NCT02794220|OTHER|Cigarette|Inhalation
224080434|NCT03750851|OTHER|Placebo|In this group, a water soluble gel without addition any desensitizing agent (K-Y®, Johnson \& Johnson, Brazil) was applied to hypersensitive dentin. The GPlacebo volunteers were submitted to the application of placebo dentifrice on the vestibular surfaces of hypersensitive teeth with the aid of a microbrush applicator (Microbrush, 3M ESPE, Brazil) and left undisturbed on the surface during 05 minutes. Then, a rubber cup (Unid Microdont, Brazil) mounted on a low speed handpiece (500, Kavo, Germany) was used to scrub the placebo gel for 20 seconds on each tooth.
224080435|NCT03750851|OTHER|CPPACPF|In this group, a toothpaste MI Paste Plus™ (Recaldent™, GC América, USA) was applied to hypersensitive dentin. The GCPPACPF volunteers were submitted to the application of the paste dentifrice on the vestibular surfaces of hypersensitive teeth with the aid of a microbrush applicator (Microbrush, 3M ESPE, Brazil) and left undisturbed on the surface during 05 minutes. Then, a rubber cup (Unid Microdont, Brazil) mounted on a low speed handpiece (500, Kavo, Germany) were used to scrub the desensitizing gel for 20 seconds on each tooth.
224080436|NCT03750851|OTHER|Laser|In this group, the diode laser with an active medium of Asauxa bauxite (Photon Lase III, DMC Equipamentos Ltda, Brazil) was applied in hypersensitive dentin. GLaser received the laser application using the infrared light spectrum with wavelength of 808 nm with its active AsGaAl medium in two points of the vestibular face of the hypersensitive teeth. It was applied at each point 60 J / cm², for 16 seconds. The laser was applied in 3 sessions with a time interval of 24 hours between them.
224080437|NCT03750851|OTHER|LaserCPPACPF|In this group the laser + CPP-ACPF was applied. The laser was used with light intensity medium Asauxa (Photon Lase III, DMC Equipamentos Ltda, Brazil) and a toothpaste containing CPP-ACPF MI Paste Plus™ (Recaldent™, GC América, USA) was applied in hypersensitive dentin. GLaserCPPacpf first named a toothpaste application and them the laser application, according to the manufacturer's recommendations.
224080438|NCT05162066|DRUG|BCX9930|Administered orally at a dose of 200 mg twice daily for the first 2 weeks, then 400 mg twice daily
224080439|NCT00599807|DIETARY_SUPPLEMENT|Vitamin D3 (cholecalciferol)|the intervention is a dietary supplement comparing the current standard (800 IU) to the current safe upper limit (2000 IU)
224080440|NCT04009941|DRUG|PEG-rhG-CSF|4.5mg per cycle, 24 hours after chemotherapy
224080441|NCT05836233|DRUG|Pulmonary Vasodilators|"Right heart catheterization via Swan Ganz catether will be performed under optimal medical therapy within 90 days before LVAD implantation. We will record the timing between RHC and LVAD implantation.~Vasodilator challenge will be performed through intravenous nitroprusside administration and titration (by 5 minutes intervals) until symptoms (flushing or hypotension) onset or systolic systemic pressure drop below 85 mmHg (target dose).~Dobutamine or phosphodiesterase inhibitors infusion could be performed at clinician's discretion.~All haemodynamic measurements will be repeated after nitroprusside infusion and titration until the target dose."
224080442|NCT04482946|DIAGNOSTIC_TEST|Assessment of fluid responsiveness|The positive end-expiratory pressure test (PEEP-test) consisted of a transient increase of PEEP from 5 to 20 cm H2O for 120 seconds. The PEEP-test was interrupted if MAP decreased below 55 mm Hg and/or pulse contour cardiac index (PCCI) decreased below 1.5 L/min/m2. Mini-fluid challenge test (mFCT) consisted of rapid infusion of crystalloids 1.5 mL/kg during 120 seconds. Thereafter, all patients received fluid challenge (standard fluid challenge test, sFCT). During the sFCT, patients received 7 mL/kg of crystalloids within 10 minutes. Investigators performed monitoring of mean arterial pressure (MAP), SVV and PPVPiCCO using femoral artery (PiCCO2). Investigators also assessed PVVNK using radial artery and Nihon Kohden patient monitor. HLI (Hamilton G-5, Switzerland) and PVI (Masimo, USA) were assessed non-invasively, using finger probes.
224080443|NCT00498745|DRUG|neratinib|HKI-272
224080444|NCT04439955|DRUG|CBD|300 mg CBD
224080445|NCT00167245|DRUG|Topiramate|300mg/day for 13 weeks
224080446|NCT00167245|DRUG|placebo|placebo pills
224080447|NCT06113874|OTHER|Hurriseal desensitizer|"Patients will receive Hurriseal desensitizing agent and universal bond and composite.~Cavities will be restored with light-cured composite resin following the application of bonding agent."
224080448|NCT06113874|OTHER|Gluma desensitizer|"Patients will receive Gluma desensitizing agent and universal bond and composite.~Cavities will be restored with light-cured composite resin following the application of bonding agent."
224080449|NCT02641535|OTHER|exercise under hot and humid conditions protocol|"acclimatization day protocol: 2 hour effort performed in a climatic chamber, which include walk on a treadmill at 5 Km/h on a 2% incline under heat conditions (40 deg. centigrade \& 40% RH) Core (rectal) and skin temperature and heart rate will be monitored continuously~experiment days (2 days): 2 hour effort (2 cycles of: 50 min walk and 10 min rest-sitting) performed in a climatic chamber, which include walk on a treadmill at 5 Km/h on a 2% incline under heat conditions (35 deg. centigrade \& 60% RH) Core (rectal) and skin temperature and heart rate will be monitored continuously."
224080450|NCT02641535|DEVICE|BC membrane protective garment|
224080451|NCT02641535|DEVICE|NBC mask|
224080452|NCT01796951|DRUG|Aspirin 325 mg daily|In this single-arm trial, participants will take celecoxib 200 mg BID for 5 doses, followed by aspirin 325 mg daily for 10 days, followed by combination of celecoxib 200 mg BID for 5 doses and aspirin 325 mg daily for 3 days.
224080453|NCT01796951|DRUG|Celecoxib 200 mg BID|In this single-arm trial, participants will take celecoxib 200 mg BID for 5 doses, followed by aspirin 325 mg daily for 10 days, followed by combination of celecoxib 200 mg BID for 5 doses and aspirin 325 mg daily for 3 days.
224079775|NCT05381246|OTHER|Acupressure|In the acupressure group, heart meridian 7th point (HT7), large intestine meridian 4th point, and pericardial meridian 6th point (PC6) will be applied. Tissue sensitivity will be reduced by heating and rubbing for about 20 seconds without direct pressure on the acupressure points, and the points will be ready for acupressure application. Subsequently, consecutive (breathing rhythm) compressions will be applied to the acupressure points determined by the researcher, without raising the finger, taking into account the pain threshold of the individual who is applied with the thumb, with 10 seconds of pressure for two seconds of relief Since the symmetry of the selected three different points will also be applied to the other extremity, a total of 18 minutes of compression will be applied to each point, provided that it is three minutes.
224079776|NCT05381246|OTHER|Reiki|In the reiki group, the crown chakra (top of the head), the forehead chakra (above the forehead), the throat chakra (above the throat), the heart chakra (the middle of the chest), the solar plexus (under the chest, above the navel), the sacral chakra (below the navel) and the root chakra (above the coccyx) will be applied to the region of the 7 chakra points on.In the reiki group, the reiki application time will take 21 minutes on average.
224079777|NCT02900703|BIOLOGICAL|stool samples|
224079778|NCT01765894|OTHER|45 minutes of moderate exercise at the fasted state. Before test day 2: 3 days of carbohydrate loading.|
224079779|NCT04808856|DRUG|Adrenocorticotropic Hormone|Adrenocorticotropic Hormone Injection 25u qd iv \*3d
224079780|NCT04808856|DRUG|Methylprednisolone Injection|Methylprednisolone Injection 40mg qd iv \*3d
224079781|NCT01827631|DRUG|GSK1605786 capsule|Swedish Orange, size 0, hard gelatine capsules
224079782|NCT02028195|OTHER|Health check|"The program includes four components:~Invitation: All participants receive invitation by mail and a prefixed appointment time. A web-based questionnaire including self-reported health (SF12), physical activity, smoking habits and alcohol use/behaviour has to be answered before Health Examination (HE).~The HE include: Blood pressure, waist, weight, lung function test, lipid profile, HbA1c and fitness (Aastrand).~Health profile pamphlet: The participant receives a pamphlet with the results. The persons are stratified into three groups (I) referral to a consultation in general practice (GP) (II) targeted behavioural programs at the health centre (HC) or (III ) no identified need for health promoting follow-up.~Follow-up according to risk-profile: If referred to GP treatment of risk conditions or diseases will follow national guidelines. The GPs were paid 50 Euros per health interview."
224079783|NCT01463098|DRUG|E2006 1.0 mg|E2006 1.0 mg capsule.
224079784|NCT01463098|DRUG|E2006 2.5 mg|E2006 2.5 mg capsule.
224079785|NCT01463098|DRUG|E2006 5.0 mg|E2006 5.0 mg (2 capsules of 2.5 mg each).
224079786|NCT01463098|DRUG|E2006 10.0 mg|E2006 10.0 mg capsule.
224079787|NCT01463098|DRUG|E2006 25.0 mg|E2006 25.0 mg (2 capsules of 10 mg each and 2 capsules of 2.5 mg each).
224079788|NCT01463098|DRUG|E2006 50.0 mg|E2006 50.0 mg capsule.
224079789|NCT01463098|DRUG|E2006 100 mg|E2006 100 mg (2 capsules of 50 mg each).
224079790|NCT01463098|DRUG|E2006 200 mg|E2006 200 mg (4 capsules of 50 mg each).
224079791|NCT01463098|DRUG|Zolpidem 10 mg|Zolpidem 10 mg immediate release tablet.
224079792|NCT01463098|DRUG|E2006 Matched Placebo or Zolpidem Matched Placebo|E2006-matched placebo capsules or zolpidem-matched placebo tablets.
224079793|NCT01463098|DRUG|E2006 Matched Placebo|E2006-matched placebo capsule.
224079794|NCT06498934|DEVICE|deep brain stimulation|Stimulation of the dentate nucleus that is paired with upper limb rehabilitation movements.
224079795|NCT06498934|OTHER|Rehabilitation|Rehabilitation movements to improve upper limb function after stroke
224079796|NCT00063401|BIOLOGICAL|Cetuximab:|400 mg/m2 loading dose, 250 mg/m2 weekly, six 21-day cycles
224079797|NCT00063401|DRUG|Paclitaxel|175 mg/m2 Day 1, six 21-day cycles
224079798|NCT00063401|DRUG|Carboplatin|AUC = 6 Day1, six 21-day cycles
224079799|NCT06194357|OTHER|Mindfulness-based Health Qigong Intervention|Participants are introduced the practice of the most essential skills, particularly mindfulness, the basic movements of Qigong and the use of the resources package. Following the initial session, participants will kick off 8 bi-weekly online sessions of Mindfulness-based interventions approximately two hours each via the Mobile App. Afterwards, participants will be asked to practice Qigong for 30 minutes per day with five days weekly for another 8 weeks. Follow-up sessions will be conducted by an experienced coach via the Mobile App. After the first 16-week intervention, booster sessions will be provided every 3 months to revise the interventions and follow-up assessments will be completed every 6 months for 2 years.
224079800|NCT02998723|OTHER|Early Booster Teaching|The early booster group will receive a booster teaching session at 3 weeks post-training followed by feedback.
224079801|NCT02998723|OTHER|Late Booster Teaching|The late booster group will receive a booster teaching session at 2 months post-training followed by feedback
224079802|NCT01891331|DRUG|VT-1161|
224079803|NCT01891331|DRUG|Fluconazole|
224079804|NCT00939692|DRUG|Topiramate|Topiramate (brand name Topamax) is an anticonvulsant (antiepilepsy) drug. IUPAC name 2,3:4,5-Bis-O-(1-methylethylidene)-beta-D-fructopyranose sulfamate
224079805|NCT03648632|RADIATION|Stereotactic Radiotherapy|Patients should be treated with 50 Gy in 5 fractions within a total of 7 - 8 days.
224079806|NCT02218918|BEHAVIORAL|Ground walk training|3 times a week and 6 weeks
224079807|NCT02218918|BEHAVIORAL|Supervised Treadmill Walk training|3 times a week and 6 weeks
224079808|NCT02287987|PROCEDURE|Clamp Robotic partial nephrectomy|Renal artery clamping during partial nephrectomy
224079809|NCT02287987|PROCEDURE|Clampless Robotic partial nephrectomy|Robotic partial nephrectomy without renal artery clamping
224079810|NCT02849756|OTHER|older in intensive care unit|It is an observational study with no intervention.
224079811|NCT03861637|OTHER|ESA for correction of PTA to 12-13g/dl|To assess the impact of full correction of chronic PTA(to near normal values) on cardiovascular system and quality of life in renal transplant recipients with stable graft function using erythropoietin stimulating agents in comparison to partially treated PTA with HB level between 12-13g/dl.
224079812|NCT04733690|DIETARY_SUPPLEMENT|Common bean product|"Healthy volunteers Healthy volunteers in the GI and FII studies will participate in the study during 3 test days for each of the studies. The reference food will be tested 2 times and the test food 1 time in each participant.~T2DM patients T2DM patients will participate in the study for one test day for the assessment of postprandial glycemic, insulinemic and satiety responses.~For both healthy volunteers and T2DM patients, the following will be assessed during study days: 24-hour of dietary recall; weight, height, waist and hip circumferences; blood pressure; and body composition using bioelectrical impedance analysis (BIA). Participants will be fed with a portion of the test or reference food and 250ml water. Two fasting blood samples (-5 and 0 min) and postprandial blood samples (15, 30, 45, 60, 90 and 120 min) will be collected"
224079813|NCT00002953|DRUG|cyclophosphamide|
224079814|NCT00002953|DRUG|epirubicin hydrochloride|
224079815|NCT00002953|DRUG|paclitaxel|
224079816|NCT06312787|DRUG|VX-118|Tablets and Suspension for Oral Administration
224079817|NCT01392807|DRUG|NKTR-118|25 mg Oral tablets, single dose
224079818|NCT01528787|DRUG|AR-13324 Ophthalmic Solution 0.01%|Administered to study eye, once daily (QD) in the morning (AM) for 7 days
224079819|NCT01528787|DRUG|AR-13324 Ophthalmic Solution 0.02%|Administered to study eye, QD AM for 7 days
224079820|NCT01528787|DRUG|AR-13324 Ophthalmic Solution 0.04%|Administered to study eye, QD AM for 7 days
224079821|NCT01528787|OTHER|AR-13324 Ophthalmic Solution Vehicle|Administered to study eye, QD AM for 7 days
224079822|NCT03163381|DRUG|Apatinib|Apatinib 500mg,po,qd,medicine to disease progression.
224079823|NCT03592160|OTHER|Physiotherapy treatment|Physiotherapy treatment consisted of pelvic floor exercises assisted by manometric biofeedback. In addition, active lumbopelvic stabilization exercises, including the contraction of pelvic floor muscles was performed in supine, plank and quadruped position.
224079824|NCT03369964|DRUG|Atezolizumab|"In Cohort A1, Atezolizumab will be administered, 1200 mg IV, every 3 weeks starting on Cycle 2; Day 1 of a 21 day cycle~In Cohort A2, Atezolizumab will be administered, 1200 mg IV, starting on Cycle 2; Day 1 of a 21 day cycle~In Cohort A2 , In Cycle 2-8, Atezolizumab will be administered, 1200 mg IV on day 1 of each 21 day cycle~In Cohort A2, Atezolizumab will be administered, 1200 mg IV starting on Cycle 9; Day 1 of each 21 day cycle"
224079825|NCT03369964|DRUG|Emactuzumab|"In Cohort A1, Emactuzumab will be administered 1000 mg IV, every 3 weeks, starting on Cycle 1; Day 1 of a 21 day cycle.~In Cohort A2, Emactuzumab will be administered 1000 mg IV, starting on Cycle 1 Day 1 of a 21 day cycle.~In Cohort A2, in cycle 2-8, Emactuzumab will be administered 1000 mg IV, on day 1 of each 21 day cycle.~In Cohort A2, Emactuzumab will be administered 1000 mg IV starting on Cycle 9; on Day 1 of each 21 day cycle"
224079826|NCT03369964|DRUG|Obinutuzumab|"In Cohort A2, Obinutuzumab will be administered 1000 mg IV starting on Cycle 1; Day 1 of a 21 day cycle~In Cohort A2, Obinutuzumab will be administered again on days 8 and 15 (Cycle 1) of a 21 day cycle~In Cohort A2, in cycle 2-8, Obinutuzumab will be administered 1000 mg IV on day 1 of each 21 day cycle"
224079827|NCT05193565|DRUG|Sirolimus|Orally, once-daily in the morning - Check the blood concentration of Sirolimus at each visit and adjust the dose to achieve the blood concentration maintaining at 3\~8ng/mL
224079828|NCT05193565|DRUG|Mycophenolate mofetil|Up to 1g BID(total 2g daily), PO
224079829|NCT00259480|BEHAVIORAL|Home Based Intervention|occupational therapy
224079830|NCT06351930|BEHAVIORAL|CBT-I + UC group|Refer to the arm description
224079831|NCT03754309|DRUG|KY1005|A human anti-OX40 ligand monoclonal antibody
224079832|NCT03754309|DRUG|Placebo|Matched placebo
224079833|NCT04409873|DRUG|Oral-B Mouth Sore mouthwash|Rinse and gargle 4 times daily, for 60 seconds, for 4 weeks.
224079834|NCT04409873|DRUG|Crest Pro-Health Multi-Protection mouthwash|Rinse and gargle 4 times daily, for 60 seconds, for 4 weeks.
224079835|NCT04409873|DRUG|CloSYS Ultra Sensitive Rinse mouthwash|Rinse and gargle 4 times daily, for 45 seconds, for 4 weeks.
224079836|NCT04409873|DRUG|Distilled water|Rinse and gargle 4 times daily, for 60 seconds, for 4 weeks.
224079837|NCT04409873|DRUG|Listerine Zero Mouthwash Product|Rinse and gargle 4 times daily, for 30 seconds, for 4 weeks.
224079838|NCT03433781|DRUG|Vitamin C|All patients will receive at least 1 cycle of treatment (4 weeks) of Vitamin C as a continuous intravenous infusion (CIVI). Patients with clinical benefit (CR, PR, or SD) then will undergo a second 4-week cycle of treatment. Patients to receive a maximum of 16 weeks of treatment (4 cycles). If a patient progress after receiving a cycle of treatment then the patient will be withdrawn from the study. Patients will be maintained on 1 gram oral Vitamin C daily from the end of the CIVI until the beginning of the next cycle (from day 6 till 28).
224079839|NCT02856165|DEVICE|High-flow nasal canula oxygen therapy|High-flow nasal canula oxygen therapy (HNF) using Optiflow junior system and AIRVO2 turbine (F\&P, NZ) at initial flow to 3l/kg/min (up to a maximum of 20l/min), FiO2 adjusted for SpO2 \> 94%.
224079840|NCT02856165|DEVICE|Low-flow oxygen therapy with standard nasal canula|flow adjusted to SpO2 \> 94% (up to a maximum of 2l/min).
224079841|NCT04351139|OTHER|modification of the planned therapeutic management|to evaluate the changes in therapeutic management, during the COVID-19 pandemic, of patients suffering from gynecological cancers
224079842|NCT04244344|OTHER|fall prevention measures|High fall risk signage, information sheet, High fall risk bracelet, verbal instructions
224079843|NCT06286865|OTHER|Easy-ICD|Easy-ICD is an AI-based computer-assisted clinical coding (CAC) system that helps clinical coder assign ICD-10 codes to clinical notes such as discharge summaries.
224079844|NCT04503876|OTHER|Increasing PEEP setting|End expiratory lung volume and lung aeration measurements will be conducted using electrical impedance tomography and nitrogen washin-washout method. Measurements will be conducted during the last minute of each step.
224079845|NCT04503876|OTHER|Decreasing PEEP setting|End expiratory lung volume and lung aeration measurements will be conducted using electrical impedance tomography and nitrogen washin-washout method. Measurements will be conducted during the last minute of each step.
224079846|NCT04127448|OTHER|Exergaming Training Group|"Training was given using X-box 360 Kinect. Dr. Kawashima's brain and body exercise game comprising of multiple cognitive games out of which 4 selected games were played by the participants. These games were Traffic control (participants have to guide the colored cars into their matching colored tunnels by using their arms), balloon buster (players pop numbered balloons in order from the lowest to the highest), pop till u drop, (match the color that appears on screen with the balloon of same color) and strike a pose (participant have to remember the poses shown and then copy them after few seconds). Games were played for 10 minutes initially then the duration was gradually increased to 30 minutes each session for 3 days/week and duration of 6 weeks. The session included 5-minute warm up, 20-minute interactive gaming, and 5-minute cool down."
224079847|NCT04127448|OTHER|Aerobic Exercise Group|Session of 30-35 minutes, 3 days a week for 6 weeks was given using treadmill (model no TMX58 220). Time and intensity was gradually increased over the duration of 6 weeks. Starting from 10 minutes in 1st week, every 5 minutes was added to aerobics phase to each week until patient reached to 35 minutes in week 6 maintaining the intensity of 40-60% of heart rate reserve (%HRR).
224079848|NCT05369819|DRUG|Midazolam|. Patients of the midazolam group will be treated with midazolam premedication (3 cc mixture of 0.035 mg/kg midazolam and normal saline; maximum midazolam dose, 3 mg) intravenously a waiting area 3 minutes before transportation to an operating room
224079849|NCT05369819|DRUG|Saline|Control group patients are treated with 3 cc normal saline in a waiting area 3 minutes before transportation to an operating room
224079850|NCT03404999|OTHER|clinical decision support|Decision support system (see description of hypertension decision support system alerts and order sets for details)
224079851|NCT01953744|DRUG|Fluconazole|Fluconazole is presented in 150mg capsules and will be administered by oral route at a dosage of 6-8mg/kg/day during 28 days.
224079852|NCT01953744|DRUG|Meglumine Antimoniate|Meglumine Antimoniate will be administered as the standard treatment for cutaneous leishmaniasis by intravenous route at a dosage of 20mg/kg/day, during 20 days.
224079853|NCT03669783|DRUG|treatment Vincristin|1 x Vincristin 1,5mg/m² iv bolus day 1 in week 1,2,3,4,5,6
224079854|NCT03669783|DRUG|treatment Actinomycin-D|1 x Actinomycin D 45µg/kg iv bolus day 1 in week 1, 3, 5
224079855|NCT03669783|DRUG|treatment Doxorubicin|1 x Doxorubicin 50mg/m² 6h Infusion day 1 in week 1,5
224079856|NCT03669783|DRUG|treatment Carboplatin|1 x Carboplatin 200 mg/m² 1h infusion day 1,2,3 in week 1,4
224079857|NCT03669783|DRUG|Etoposide|1 x Etoposide 100mg/m² 1h infusion day 1,2,3 in week 1,4
224079858|NCT01171846|OTHER|Pelvic Floor Muscle training|"Women allocated to the intervention group will have five appointments with a specialist women's health physiotherapist (intervention physiotherapist) over 16 weeks who will prescribe a daily exercise programme and provide a Lifestyle Advice Sheet (focusing on weight loss, constipation, avoidance of heavy lifting, coughing and high-impact exercise) and relevant tailored advice (phase 1).~Thereafter women in the intervention group will be offered Pilates-based classes, including PFMT, as maintenance (phase 2). Classes will be led by a physiotherapist who has undertaken Pilates training and will take place in six week blocks; each woman will be offered two six week blocks over a year. An exercise DVD will be provided for home use. Each woman will be offered a one-to-one review physiotherapy appointment at one and two years after randomisation."
224079859|NCT03568019|OTHER|Retrospective study|No subjects will be contacted or recruited. All data will be acquired retrospectively.
224079860|NCT05939895|DEVICE|Medtronic G3 sensor|A Sensor is fitted on the arm and abdomen of every patient and using a CGMS App. the patient's blood glucose level are monitored at regular intervals.
224079861|NCT06047704|OTHER|No intervention|No intervention
224079862|NCT00492973|DRUG|methylprednisolone acetate|Same medications and doses as the active comparator, but with the addition of 40 mg of methylprednisolone acetate
224079863|NCT00492973|DRUG|active comparator|bupivacaine HCl 80 mg, morphine 4 mg, epinephrine 300 micrograms, clonidine 100 micrograms, cefuroxime 750 mg, and normal saline
224079864|NCT01988389|DIETARY_SUPPLEMENT|whole apples (WA)|
224079865|NCT01988389|DIETARY_SUPPLEMENT|apple juice (AJ)|
224079866|NCT02427048|BEHAVIORAL|Feedback with Peer Comparison|Email detailing adherence to CAP and SS CPG for every month since start of study. Physicians will be provided individualized feedback and given patient identifiers for each patient that received non-adherent care.
224079867|NCT02024516|OTHER|50 gr concentrated pomegranate juice|
224079868|NCT01004302|PROCEDURE|ventral capsular/ventral striatal gamma capsulotomy|Comparison of active radiosurgical with sham radiosurgeries
224079869|NCT04447885|DEVICE|weighted blanket|A weighted blanket is a blanket with extra weight sewn in for added pressure to the body.
224079870|NCT06344845|DIAGNOSTIC_TEST|18F-PBB3 PET/CT scan|Patients with suspected neurodegeneration underwent PET/CT scan after injection of 370MBq (10 mCi)18F-FDG to observe for TAU deposition.
224079871|NCT02609360|OTHER|Priming of ECMO circuit with 0.9% NaCl|0.9% NaCl as priming crystalloid solution
224079872|NCT02609360|OTHER|Priming of ECMO circuit with Ringer Lactate|Ringer Lactate as priming crystalloid solution
224079873|NCT02609360|OTHER|Priming of ECMO circuit with Balanced Solution|Balanced Solution as priming crystalloid solution
224079874|NCT00401271|DRUG|OPC-67683|
224079875|NCT00401271|DRUG|Rifafour e-275|
224079876|NCT00363038|DRUG|Petrolatum United States Pharmacopeia (USP)|Topical formation applied to bruise twice daily for 2 weeks.
224079877|NCT00363038|DRUG|Vitamin K and retinol ointment|Topical formation applied to bruise twice daily for 2 weeks.
224079878|NCT00363038|DRUG|Arnica ointment|Topical formation applied to bruise twice daily for 2 weeks.
224079879|NCT00363038|DRUG|Vitamin K ointment|Topical formation applied to bruise twice daily for 2 weeks.
224079880|NCT03884582|DEVICE|Cova Monitoring System 3|Healthy Volunteers
224079881|NCT01290965|DRUG|Placebo|Oral tablet given once or three times daily for 15 consecutive days
224079882|NCT01290965|DRUG|SCY-635|oral capsule
224079883|NCT01219231|BEHAVIORAL|Exercise|6 months of aerobic exercise
224079884|NCT04792710|DRUG|Metronidazole|Metronidazole 500 mg intravenous stat dose prior to skin incision
224079885|NCT01306227|DRUG|L-Thyroxine|Treatment with L-Thyroxine:7,5 µg/kg/day. Oral treatment (one drop =5µg) in the morning, once a day.
224079886|NCT01306227|DRUG|water|Oral treatment with water. Equal number of drop of water as compared with the treatment arm (according to the body weight of the newborn) in the morning, once a day.
224079887|NCT05455957|OTHER|exercise|neuromuscular and vestibulo-ocular training
224079888|NCT04388306|OTHER|Shoulder Performance Test- Functional Impairment Test-Head and Neck, Shoulder, Arm (FIT-HaNSA)|Participants were evaluated with all tests, respectively. To eliminate the fatigue factor, 5 minutes breaks were given after each test.
224079889|NCT04475614|DIETARY_SUPPLEMENT|BioGaia Prodentis lozenges|oral probiotics
224079890|NCT04475614|PROCEDURE|low level laser treatment with Ga-Al-As laser|low level laser treatment
224079891|NCT04475614|DIETARY_SUPPLEMENT|B vitamin injections (Neurobion, Merck, Darmstadt, Germany)|intra muscular vitamin injections
224079892|NCT00801866|DRUG|Bevacizumab|Intravitreal administration
224079893|NCT00801866|PROCEDURE|Panretinal Photocoagulation|Panretinal Photocoagulation
224079894|NCT02713568|OTHER|Ultrasound examination|"Prenatal Ultrasound examinations will be carried out using transabdominal sonography only by experienced consultants in MFM. Ultrasound-Estimated Fetal Weight will be obtained between 36.0-36.6 weeks of gestation, according to Hadlock et al.~Operators performing the Ultrasound-Estimated Fetal Weight will be blinded to the results of Magnetic Resonance-Estimated Fetal Weight. The participants, general practitioners, obstetricians and midwifes of the patients will be aware of the results of Ultrasound-Estimated Fetal Weight which will be used for clinical management.~For the primary outcome measure, macrosomia during Ultrasound-Estimated Fetal Weight will be defined as ≥ P95 based on Yudkin et al. For secondary outcome measures, it will be redefined as ≥ P90 or ≥ P99 based on Yudkin."
224079895|NCT02713568|OTHER|Magnetic resonance examination|"MRI will be performed the same day as the Ultrasound examination, using a clinical 1.5T whole-body unit.~Operators performing Fetal Body Volume measurements will be blinded from Ultrasound-Estimated Fetal Weight results. Magnetic Resonance-Estimated Fetal Weight will be calculated using the equation 0,12+1,031\*Fetal Body Volume = MR imaging weight (g) developed by Baker.~General practitioners, obstetricians and midwifes of the patients will be blinded to the results of the Magnetic Resonance-Estimated Fetal Weight.~For the primary outcome measure, macrosomia will be defined as ≥ P95 based on Yudkin et al. For secondary outcome measures, it will be defined as ≥ P90 or ≥ P99."
224079896|NCT01430650|DRUG|Oral strogen|2 mg of estradiol every day beginning the second day of the cycle until day 7. 4 mg of estradiol every day beginning 8th day of the cycle until day 10. 6 mg of estradiol every day beginning 11th day of the cycle until day 16.
224079897|NCT01430650|DRUG|Transdermal strogen|One patch of 75 mcg of estradiol hemimydrate every 48 h from 2 to day 6. Two patches of 75 mcg of estradiol hemimydrate every 48 h from 6 to day 12. Three patches of 75 mcg of estradiol hemimydrate every 48 h from 12 to day 16.
224079898|NCT06436456|BEHAVIORAL|Online psychological intervention|The online intervention constitutes a psychological intervention rooted in therapeutic principals of Acceptance and Commitment Therapy (ACT) and Cognitive Behavioral Therapy (CBT). Comprising 7 obligatory modules and 4 optional modules, the intervention is facilitated through an online platform, offering a text-based self-help program. Patients receive written guidance from a psychologist at Steno Diabetes Center Odense (SDCO). While undergoing intervention, patients have the option to seek clarification or assistance from the psychologist if encountered with queries or difficulties. It is anticipated that patients will progress through approximately one module per week. Following completion of the intervention, patients retain access to the online intervention for a duration of 3 months.
224079899|NCT06436456|BEHAVIORAL|Individual psychological intervention|In the individual intervention, patients undergo personalized therapy administered by the assigned psychologist from SDCO. This treatment approach is grounded in the principles of Acceptance and Commitment Therapy (ACT) and Cognitive Behavioral Therapy (CBT). Delivery of treatment can occur through various modalities, including telephone, video conferencing, or in-person sessions, tailored to accommodate the preferences and requirements of the patient. A maximum of 10 treatment sessions are available for each patient.
224079900|NCT03517631|BIOLOGICAL|shRNA-modified CD34+ cells|Infusion of CD34+ cells transduced with shRNAs.
224079901|NCT03517631|DRUG|Low dose busulfan preconditioning|A single dose of 1 mg/kg busulfan administered every 6 hours for 4 times as preconditioning for transplantation.
224079902|NCT03517631|DRUG|Busulfan preconditioning|A single dose of 1 mg/kg busulfan administered every 6 hours for 8 times as preconditioning for transplantation.
224079903|NCT02112500|BIOLOGICAL|Mesenchymal Stem Cell|Mesenchymal stem cells will be intravenously infused. Mesenchymal stem cells will be cultured and extracted from the bone marrow of the patients.
224079904|NCT00876083|DRUG|Ultravist (Iopromide, BAY86-4877)|Patients with indication for an X-ray examination and for whom the radiologist has decided to use the contrast medium Ultravist.
224079905|NCT00749333|DRUG|AZD8566|solution. Specific dose will be selected by the safety review committee
224079906|NCT00749333|DRUG|Placebo|Single 10ml oral solution.
224079907|NCT00151671|DRUG|Oral Impact®|Oral nutritional supplement containing L-arginin, ω3 polyunsaturated fatty acids, and nucleotides. Given three times a day for the 7 last preoperative and the first 3 postoperative days.
224079908|NCT00151671|DRUG|Placebo|Oral solution of placebo. Given three times a day for the 7 last preoperative and the first 3 postoperative days.
224079909|NCT01618292|PROCEDURE|Robotic sacral colpopexy|Patients who underwent robotic assisted sacral colpopexy for the treatment of pelvic organ prolapse
224079910|NCT05376085|DRUG|DA-5215 Tab|"single oral administration of 1 tablet of DA-5215 Tab with 150mL water"
224079911|NCT05376085|DRUG|DA-5215-R Tab|"single oral administration of 1 tablet of DA-5215-R Tab with 150mL water"
224079912|NCT03543410|DRUG|SEP-4199 200 mg|SEP-4199 200 mg/day (supplied in two 100mg tablets)
224079913|NCT03543410|DRUG|SEP-4199 400 mg|SEP-4199 400 mg/day (supplied in two 200mg tablets
224079914|NCT03543410|DRUG|Placebo|Placebo (supplied in two tablets/day)
224079915|NCT06536400|DRUG|HSK42360|Oral administration, QD
224079916|NCT04428177|DEVICE|Intravascular lithotripsy|Intravascular lithotripsy uses sonic pressure waves to disrupt calcium with minimal impact to soft tissue of coronary vessel
224079917|NCT04428177|DEVICE|Standart therapy|conventional preparation of calcified lesion: non-compliant, cutting or scoring ballons predilatation or rotational atherectomy
224079918|NCT01485692|DRUG|haloperidol+promethazine|haloperidol, 2,5mg plus promethazine,25mg, intramuscular injection after baseline measures of agitation, could be repeated twice, if necessary, in the 90 minutes period of observation
224079919|NCT01485692|DRUG|haloperidol + midazolam|haloperidol, 2,5mg plus midazolam, 7,5 mg, intramuscular injection after baseline measures of agitation, could be repeated twice, if necessary, between the 90 minutes period of observation
224079920|NCT01485692|DRUG|olanzapine|olanzapine, 10mg, intramuscular injection, after baseline measures of agitation, could be repeated twice, if necessary, between the 90 minutes of observation
224079921|NCT01485692|DRUG|Ziprasidone|ziprasidone, 10 mg, intramuscular injection after baseline measures of agitation, could be repeated twice, if necessary, between the 90 minutes period of observation
224079922|NCT02435914|DRUG|AGN-223575 ophthalmic solution|AGN-223575 ophthalmic solution once or twice daily
224079923|NCT02435914|DRUG|AGN-223575 vehicle ophthalmic solution|Vehicle to AGN22375 ophthalmic solution once or twice daily.
224079924|NCT00983190|DEVICE|Left Ventricular Assist Device (HeartMate II)|The HM II is a high speed, electric, axial flow, rotary blood pump. The pump drains blood from the left ventricular apex via rigid inlet cannulae and ejects into the aortic root via an outflow cannula joined to the aorta with an end to side anastamosis. Power and control of the pump are delivered through a percutaneous cable from pump to the belt-worn System Controller. The System Controller will receive power from the Power Base Unit (PBU), or two battery modules that may be worn in shoulder holsters or on the belt
224079925|NCT04586829|OTHER|Diet|\<50 grams of total carbohydrates per day. Monosaturated fats consumption will be encouraged over saturated fats.
224079926|NCT03840330|OTHER|Experimental: High-intensity interval training group|16 weeks of High-intensity interval training
224079927|NCT03840330|OTHER|Experimental: Moderate-intensity interval training group|16 weeks of Moderate-intensity interval training
224079928|NCT04148261|DRUG|Hydrocortisone Acetate (CORT)|Participants will receive a single dose of hydrocortisone at a dosage of 0.65 mg/kg
224079929|NCT04148261|DRUG|Epinephrine Sulfate (EPI)|Participants will receive a continuous infusion of epinephrine at a dosage of 80 ng/kg/min
224079930|NCT04148261|DRUG|Placebo (PLB)|Participants will receive a placebo
224079931|NCT02153567|DRUG|Escitalopram|Escitalopram 5mg daily will be given for the first 2 weeks and then Escitalopram 10mg daily will be given for the next 8 weeks.
224079932|NCT02153567|OTHER|Placebo|Placebo will be given for the next 10 weeks.
224079933|NCT01092845|DRUG|PF-04457845 / matched placebo|PF-04457845 4 mg tablet once daily / matched placebo
224079934|NCT01092845|DRUG|PF-04457845 / matched placebo|PF-04457845 4 mg tablet once daily / matched placebo
224079935|NCT03315351|PROCEDURE|Brachytherapy|"Before it starts, a consultation will be done to collect patient's informations and disease history, a clinical exam will be done and an evaluation of radio-chemotherapy toxicity will be realized.~The brachytherapy include a pulsating flow treatment driven by RMI and CT-scan"
224079936|NCT03315351|OTHER|PET-scan|"The patient will undergo 2 PET-scan during the clinical trial:~* the first one is additional to the brachytherapy~* the second one is realized 4 months after the brachytherapy"
224079937|NCT02063035|DRUG|Tranexamic Acid|A single topical application of 3 grams (g) of Tranexamic acid in 100 milliliter (mL) saline.
224079938|NCT02063035|DRUG|Placebo|A single topical application of matching placebo, which is 100 mL of normal saline.
224079939|NCT05728294|PROCEDURE|Femoral nerve block with ropivacaine 0.5%, 20 ml|Femoral nerve block under ultrasound guidance with ropivacaine 0.5%, 20 ml
224079940|NCT05728294|PROCEDURE|Sciatic nerve block with ropivacaine 0.5%, 20 ml|Sciatic nerve block under ultrasound guidance with ropivacaine 0.5%, 20 ml
224079941|NCT06114979|DRUG|Silodosin|Each patient will receive 8 mg of silodosin tablet once daily.
224079942|NCT06114979|DRUG|Placebo|Each patient will receive placebo tablet.
224079943|NCT05659446|PROCEDURE|endoscopy management of low output colonic fistula or leak after anterior resection for rectal cancer|Patients involved in endoscopic group were firstly subjected for Interventional Radiology to drain any intra-peritoneal collection present in preoperative radiology then were subjected either to Clips application (OTSC, OVASCO Endoscopy AG. Tubingen, Germany) or Endo-suturing (Overstitch, Apollo Endo-Surgery , TX, United states) to close the low output fistula or leak after anterior resection for rectal cancer. The endoscopy was done under sedation, not general anesthesia after colonic preparation (chemical \& mechanical preparation) firstly, to detect size of fistula . Clips were used in cases with fistula's size less than 10 mm, while Endo-suturing devices were used in cases with fistula's size more than 10mm till 15mm.
224079944|NCT03978559|DRUG|caspofungin|caspofungin 70mg ivdrip the first day, then 50mg ivdrip qd for 21days
224079945|NCT03978559|DRUG|TMP/SMZ(trimethoprim/sulfisoxazole)|TMP:15mg/kg/d for 21 days +SMZ:75mg/kg/d for 21days
224079946|NCT03978559|DRUG|Methylprednisolone|40mg ivdrip q12h for 5 days , then 40mg ivdrip qd for 5 days , 20mg for 11 days
224079947|NCT03365778|OTHER|Patient Educational Intervention|Patients will respond to 5 questions regarding selective laser trabeculoplasty (SLT) versus topical medication to lower eye pressure. Then they will receive educational materials including 20 printed slides and view a 3 minute video on safety and efficacy of SLT. If patients agree to SLT, assistance in scheduling will be provided.
224079948|NCT03365778|OTHER|Usual Care|Patients will respond to 5 questions regarding selective laser trabeculoplasty (SLT) versus topical medication to lower eye pressure. No other guidance will be provided.
224079949|NCT03365778|OTHER|Ophthalmologist Educational Intervention|Responses to online survey regarding beliefs and attitudes towards selective laser trabeculoplasty (SLT) before and after educational slide presentation were recorded and compared between physician specialty groups.
224079950|NCT02282592|OTHER|Observation about the presence of metabolic syndrome|
224079951|NCT05031741|OTHER|Peer Leader Model|Teens will have an opportunity to interact with established peer leaders that are a part of the AccessKCTeen program. These leaders will receive a baseline training of their role, sexual and mental health. They will also receive health education and engage with a peer liason via text messages throughout the study.
224079952|NCT01769755|BIOLOGICAL|PDA001|"Cohort 1 Dose Level 1: ¼ unit Human Placenta-Derived Cells PDA001 infused a total of 5 times 2 weeks apart.~Cohort 2 Dose Level 2: ½ unit Human Placenta-Derived Cells PDA001 infused a total of 5 times 2 weeks apart.~Cohort 3 Dose Level 3: 1 unit Human Placenta-Derived Cells PDA001 infused a total of 5 times 2 weeks apart."
224079953|NCT01769755|DRUG|Vehicle Controlled Placebo|"Cohort 1 Dose Level 1: ¼ unit vehicle controlled placebo infused a total of 5 times 2 weeks apart.~Cohort 2 Dose Level 2: ½ unit vehicle controlled placebo infused a total of 5 times 2 weeks apart.~Cohort 3 Dose Level 3: 1 unit vehicle controlled placebo infused a total of 5 times 2 weeks apart."
224079954|NCT00215605|DRUG|XL184|Flavored liquid suspension or gelatin capsules supplied in 25-mg and 100-mg strengths; daily dosing or intermittent schedule (daily dosing followed by dosing holiday in cycles)
224079955|NCT02185378|PROCEDURE|I:E ratio 1:2|We plan to evaluate the improvement on respiratory function with different ventilation I:E ratios (1:2 vs. 1:1) during the one-lung ventilation in an obese patients.
224079956|NCT02185378|PROCEDURE|I:E ratio 1:1|The purpose of our study is to compare the effects of minimal prolonged 1:1 IE ratioventilation on respiratory mechanics and oxygenation with conventional 1:2 IE ratio ventilation during OLV in obese patients.
224079957|NCT01820715|DRUG|600㎍ of DA-3030 Injection|
224079958|NCT01820715|DRUG|Placebo|
224079959|NCT02218229|DEVICE|Shock wave|Shock waves are defined a sequence of acoustic pulse characterized by a high peak pressure (100 MPa), fast pressure rise (\< 10 ns) and short duration (10 μs). Different studies and clinical experiments have demonstrated the efficacy of shock waves in the treatment of musculoskeletal system such as chronic tendinopathies or hypertrophic pseudoarthrosis
224079960|NCT00006093|DRUG|cilengitide|
224079961|NCT05825872|PROCEDURE|internal superior laryngeal nerve block|"A linear 4- to 12-MHz ultrasound probe will be placed in the oblique parasagittal plane to obtain an image of the hyoid bone and the thyroid cartilage. The probe will be kept parasagitally, and the following structures will be identified anteriorly to posteriorly: omohyoid muscle, sternohyoid muscle, thyrohyoid muscle, thyrohyoid membrane, superior laryngeal artery, and pre-epiglottis space.~After identifying the local anatomic structure, a needle will be inserted out-plane from anterior to posterior. The muscles above the thyrohyoid membrane will be penetrated and hydrodissected; local anesthetic will be injected into the superior laryngeal nerve space. The superior laryngeal nerve space will be located between the hyoid bone (cephalad) and the thyroid cartilage (caudal) and delimited between the thyrohyoid muscle, anteriorly, and the thyrohyoid membrane and the pre-epiglottis space, posteriorly"
224079962|NCT05825872|DRUG|Lidocaine 2% Injectable Solution|0.5 ml will be injected
224079963|NCT05825872|DRUG|Bupivacaine 0.5% Injectable Solution|1.5 ml will be injected
224079964|NCT02640963|OTHER|Exercise|to determine the feasibility of the GrACE (Group Aged Care Exercise) programme in RAC, with the secondary objective of measuring the programme benefits on gait speed, sit to stand and handgrip strength.
224079965|NCT02640963|OTHER|Control|to compare with the GrACE (Group Aged Care Exercise) programme in RAC, as well as the secondary objective of measuring the programme benefits on gait speed, sit to stand and handgrip strength against the intervention group
224079966|NCT04244565|BEHAVIORAL|Self-directed model of clinical learning for nurses|the instructors play a facilitating role while, learners actively participate in identifying their own learning needs, learning goals, allocating resources \& decide whether learning method can be used, and engaging in self-reflection \& evaluation.
224079967|NCT05836376|PROCEDURE|Mitral valve annuloplasty|implantation of a prosthetic ring to treat mitral valve regurgitation
224079968|NCT04213859|BEHAVIORAL|VRET - Virtual Reality Exposure Therapy|VRET will include 4 weekly 1-hour sessions over the course of 4 weeks. The treatment protocol is based on the Virtual Reality (VR) treatment manual guidelines (Rothbaum \& Hodges, 1997,1999) and includes psychoeducation, anxiety management training, cognitive restructuring and exposure. The first therapy session focuses on creating an individually-tailored conceptualization and treatment plan. Following this process, participant and therapist conduct a short introductory VR flight exposure simulation to familiarize the participant with the VRET apparatus. The VRET apparatus is an advanced, large-scale VR system that allows maximal immersion within the virtual environment. The second, third and fourth sessions include psychoeducation, relaxation training, cognitive restructuring and individually-tailored VR exposures (the therapist can manipulate the turbulence level and other flight-related variables to fit participants' fears and current progress).
224079969|NCT02642094|DRUG|Rapamycin|Low dose of rapamycin at 2 mg/day for -5-7 days of treatment
224079970|NCT03034395|PROCEDURE|Wide Local Excision|Surgery
224079971|NCT03301181|DRUG|BGB-3111 (Arm A)|320 mg BGB-3111 single oral dose
224079972|NCT03301181|DRUG|Rifampin|600 mg rifampin once daily
224079973|NCT03301181|DRUG|BGB-3111 (Arm B)|Up to 80 mg BGB-3111 single oral dose
224079974|NCT03301181|DRUG|Itraconazole|200 mg itraconazole once daily
224079975|NCT01099969|DEVICE|Glidescope videolaryngoscope|
224079976|NCT01099969|DEVICE|McGrath videolaryngoscope|
224079977|NCT01099969|DEVICE|Non-styletted Endotrol endotracheal tube (ETT)|
224079978|NCT01099969|DEVICE|Regular endotracheal tube (ETT) with Gliderite stylet|
224079979|NCT00273819|PROCEDURE|CT angiography|
224079980|NCT02851004|DRUG|Napabucasin|"1 cycle is 21days.~BBI608: Oral administration at a dose of 240mg or 480 mg twice daily (BID), every day.~\[Additional cohort to the Phase II part\] Oral administration at a dose of 240mg mg BID, every day~The therapy will be repeated until meeting the discontinuation criteria."
224079981|NCT02851004|DRUG|Pembrolizumab|"1 cycle is 21days.~Pembrolizumab: Administration at a dose of 200 mg/body on Day 1 of each cycle~\[Additional cohort to the Phase II part\] Administration at a dose of 200 mg/body on Day 1 of each cycle.~The therapy will be repeated until meeting the discontinuation criteria."
224079982|NCT00723164|DRUG|Fentanyl and Midazolam|A combination of fentanyl 0.6 ug/kg and midazolam 9 ug/kg, to which NaCl was added to obtain a volume of 2.5 mL (group FM) injected IV, 5 minutes prior inhalation induction of anesthesia with sevoflurane
224079983|NCT00723164|DRUG|NaCl|NaCl 0.9% 2.5 ml intravenous (IV), 5 minutes prior inhalation induction of anesthesia with sevoflurane.
224079984|NCT03719157|PROCEDURE|Unilateral ESP Block|USG guided ESP block will perform unilateral with Bupivacaine and Lidocain mixture
224079985|NCT03719157|PROCEDURE|Unilateral OSTAP Block|USG guided OSTAP block will perform unilateral with Bupivacaine and Lidocain mixture
224079986|NCT03719157|PROCEDURE|Injection of Local Anesthetic to Trocar Insertion|Bupivacaine infiltration will be performed at the end of the surgical procedure to trocar insertion sites.
224079987|NCT03719157|DRUG|intravenous patient controlled analgesia|All patients were followed using a standardized postoperative analgesia protocol which includes tramadol PCA. Tramadol at a concentration of 5 mg/mL is included in our PCA protocol (total volume 100 mL.) PCAs were set to no basal infusion and 10 mg bolus doses with a 20 min lock time.
224079988|NCT02579655|BEHAVIORAL|Copayment Elimination|Patients will receive preventive medications for their chronic conditions free of charge (without the 30% copayment seniors normally pay for their medications)
224079989|NCT02579655|BEHAVIORAL|Personalized Education|Tailored Education focusing on optimizing use and adherence to guideline recommended medications, as well as appropriate lifestyle
224079990|NCT01315262|DRUG|Sildenafil|1:1 Viagra 100 mg daily (taken either at bedtime - if sexual intercourse is not expected - or 1 hour prior to sexual intercourse, no more than one 100 mg dose of sildenafil per day) vs. Viagra 100mg OD (i.e. one hour prior to sexual intercourse)
224079991|NCT00535925|DRUG|SoC therapy|the patients have to be treated according the standard good medical practice by any center
224079992|NCT00535925|DRUG|irbesartan|"Therapy for hypertension:~\- Step 1: irbesartan 300 mg/die and ramipril 10 mg/die"
224079993|NCT00535925|DRUG|ramipril|"Therapy for hypertension:~\- Step 1: irbesartan 300 mg/die and ramipril 10 mg/die"
224079994|NCT00535925|DRUG|hydrochlorothiazide|"Therapy for hypertension~\- Step 2: Diuretic (hydrochlorothiazide 12.5-25 mg/die if serum creatinine \<2 mg/dl, furosemide 25-75 mg/die if serum creatinin ≥2 mg/dl)"
224079995|NCT00535925|DRUG|furosemide|"Therapy for hypertension~\- Step 2: Diuretic (hydrochlorothiazide 12.5-25 mg/die if serum creatinine \<2 mg/dl, furosemide 25-75 mg/die if serum creatinin ≥2 mg/dl)"
224079996|NCT00535925|DRUG|amlodipine|"Therapy for hypertension~\- Step 3: amlodipine up to 10 mg/die"
224079997|NCT00535925|DRUG|atenolol|"Therapy for hypertension~\- Step 4: atenolol up to 100 mg/die"
224079998|NCT00535925|DRUG|doxazosin|"Therapy for hypertension~\- Step 5: doxazosin up to 4 mg/die"
224079999|NCT00535925|DRUG|clonidine|"Therapy for hypertension~\- Step 6: clonidine"
224080000|NCT00535925|DRUG|insulin|"Therapy for Hyperglycaemia (to achieve HbA1c \<7):~\- insulin"
224080001|NCT00535925|DRUG|simvastatin|"Therapy for hypercholesterolemia:~\- for reducing LDL cholesterol \< 100 mg/dl: simvastatin up to 80 mg/die"
224080002|NCT00535925|DRUG|fibrate|"Therapy for hypertriglyceridemia~\- for reducing triglycerides \< 150 mg/dl and/or increasing HDL cholesterol \> 40-50 mg/dl: a fibrate"
224080003|NCT00535925|DRUG|erythropoietin|"Treatment of anaemia:~\- erythropoietin"
224080004|NCT00535925|DRUG|aspirin|"Antiplatelet therapy (in all patients without contraindications):~\- aspirin up to 160 mg/die"
224080005|NCT04728490|OTHER|Allogenic transplantation transplantation|Haplo-identical transplantation with the use of Treosulfan, Thiotepa and Fludarabine in conditioning regimen.
224080006|NCT04336761|DIAGNOSTIC_TEST|nasopharyngeal swab|Data collection and nasopharyngeal swab
224080007|NCT02420873|DRUG|Lorvotuzumab Mertansine (IMGN901)|100 mg/m2 by vein on Day 1 and 8 of a 21-day cycle.
224080008|NCT03594890|BIOLOGICAL|OVX836 (Intramuscular)|2 consecutive administrations of OVX836 vaccine at Day 1 and Day 29.
224080009|NCT03594890|BIOLOGICAL|Placebo (Intramuscular)|2 consecutive administrations of placebo at Day 1 and Day 29.
224080010|NCT03594890|BIOLOGICAL|OVX836 (Intranasal)|2 consecutive administrations of OVX836 vaccine at Day 1 and Day 29.
224080011|NCT03594890|BIOLOGICAL|Placebo (Intranasal)|2 consecutive administrations of placebo at Day 1 and Day 29.
224080012|NCT02841371|RADIATION|99mTc-DTPA|a 99mTc-DTPA renal dynamic imaging measurement as the reference glomerular filtration rate (rGFR).
224080013|NCT05223361|DRUG|Six percent hydroxy ethyl starch 130/0.4|6% HES 130/0.4 additive to ringer lactate as prime solution
224080014|NCT05223361|DRUG|Ringer lactate|Ringer lactate as prime solution
224080015|NCT00023387|DRUG|Rifapentine|
224080016|NCT00023387|DRUG|25-desacetyl Rifapentine|
224080017|NCT00023387|DRUG|Isoniazid|
224080018|NCT01162330|OTHER|Screening urine and saliva tests for congenital Cytomegalovirus|With consent for the study babies who are referred for further hearing tests will have a urine and saliva sample sent to be analysed for CMV infection
224080019|NCT02986230|OTHER|CP-CDS|The cancer prevention wizard is a point of care clinical decision support system designed to identify patients that are due for preventative cancer services and provides evidenced-based recommendations to the patient and provider.
224080020|NCT02319044|DRUG|MEDI4736|MEDI4736 monotherapy
224080021|NCT02319044|DRUG|Tremelimumab|Tremelimumab monotherapy
224080022|NCT02319044|DRUG|MEDI4736 + Tremelimumab|MEDI4736 + Tremelimumab combination therapy
224080023|NCT06312072|OTHER|No intervention; observational study|No intervention; observational study
224080024|NCT03708055|BEHAVIORAL|Exercise Intervention|Undergo weight bearing exercise program
224080025|NCT01069497|OTHER|Prevention of infections program|"The intervention mainly involves implementing urinary, respiratory and gastrointestinal infection prevention measures. Study nursing home medical coordinators will be in charge of training their own teams. For this, they will be provided with:~* a slide-show of recommendations (commented by an expert),~* recommendations guides (on paper and on computer) to be shown to their teams. Means will be provided to the intervention nursing homes : Hydro-alcoholic solutions, disinfectant detergent-impregnated tissues, mouth care kits, tec."
224080026|NCT00003955|BIOLOGICAL|dactinomycin|
224080027|NCT00003955|BIOLOGICAL|filgrastim|
224080028|NCT00003955|BIOLOGICAL|pegfilgrastim|
224080029|NCT00003955|BIOLOGICAL|sargramostim|
224080030|NCT00003955|DRUG|cyclophosphamide|
224080031|NCT00003955|DRUG|irinotecan hydrochloride|
224080032|NCT00003955|DRUG|vincristine sulfate|
224080033|NCT00003955|RADIATION|radiation therapy|
224080034|NCT01182831|PROCEDURE|percutaneous fluoro guided celiac plexus neurolysis|It is percutaneous injection of neurolytic agent in and around the celiac ganglion
224080035|NCT01182831|PROCEDURE|EUS guided neurolysis|It is injection of neurolytic agent in and around the celiac ganglion using an echo endoscope.
224080036|NCT01569685|DRUG|Venlafaxine|Tablets, once a day, max 375 mg day (maximal recommended dose)
224080037|NCT01569685|DRUG|Sertraline|Tablets, once a day, maximum 200 mg/day (maximum required dose)
224080038|NCT03434379|DRUG|Atezolizumab|Atezolizumab will be administered by IV, 1200 mg on day 1 of each 21 day cycle
224080039|NCT03434379|DRUG|Bevacizumab|Bevacizumab will be administered by IV, 15 mg/kg on day 1 of each 21 day cycle
224080040|NCT03434379|DRUG|Sorafenib|Sorafenib will be administered by mouth, 400 mg twice per day, on days 1-21 of each 21-day cycle
224080041|NCT03044860|PROCEDURE|Double-balloon enteroscopy (DBE) with biopsy retrieval|With the use of a double-balloon enteroscopy device, study participants underwent upper and lower enteroscopies with mucosal biopsy mucosal biopsy retrieval from every \~30 cm of the small intestine and specific locations in the large intestine
224080042|NCT01407549|BEHAVIORAL|mindfulness group meetings with psychologist|The Mindfulness Program consists of one 2-hour session each week for 6 consecutive weeks plus a half day retreat near the end of the intervention. Participants will attend weekly group meetings (15-20 individuals per group) in which they will be guided through a progressive experiential exploration of mindfulness. Participants will be asked to develop a daily meditation practice of 30-45 minutes with audio-recordings for guidance, and will report the amount and type of practice in a daily dairy. . A psychologist with rich personal experience in mindfulness who is trained in mindfulness based therapy will be responsible for administering the program.
224080043|NCT02547480|DEVICE|TACE with irinotecan loaded LifePearl|Arterial embolization will be performed through lobar infusion and using a microcatheter. LifePearl microspheres of 200 µm will be used as preferred beads. They will be loaded with the appropriate dose of irinotecan hydrochloride injectable solution, mixed with the contrast media and distributed to the targeted lobe. The targeted dose is 100 mg of irinotecan per lobe treated, meaning that when treated unilobarly at baseline the total dose received will be 100 mg ( all in one lobe) and in during bilobar treatment, 200 mg in both lobes.
224080044|NCT03550066|BEHAVIORAL|Values affirmation|A health message with a prompt asking participants to reflect on important personal values
224080045|NCT03550066|BEHAVIORAL|No affirmation|A health message alone
224080046|NCT00864266|DRUG|Chemotherapy|Standard cisplatin-based chemotherapy in agreement with the ELCWP guidelines (available on the website www.elcwp.org)
224080047|NCT03686501|DRUG|PF-06412562|Healthy Volunteers recruited for the study will undergo a single dose of PF-06412562 and will undergo two \[18F\]MNI-968 injections
224080048|NCT02181166|OTHER|Kinesiotherapy|
224080049|NCT02181166|OTHER|Isquemic compression|
224080050|NCT02181166|OTHER|High voltage electrical stimulation|
224080051|NCT02129946|OTHER|Resistant Starch|In a randomized crossover fashion, participants will consume bagels that are made with either high-resistant starch or standard wheat flour, daily for a period of 8 weeks, with a 4 week washout period.
224080052|NCT00911846|OTHER|interview|interview using questionnaires
224080053|NCT01314300|DRUG|Lidocaine|Lidocaine 5% plaster
224080054|NCT02903537|DRUG|Autologous VitD3 tolerogenic monocyte-derived dendritic cells loaded with a pool of myelin peptides (tolDC-VitD3)|Intranodal administration
224080055|NCT02903537|DRUG|Interferon-beta|Subcutaneous administration interferon-beta
224080056|NCT04696588|OTHER|Complex set of kinesiotherapy of cervical spine and delicate massage|"Intervention:- A complex neck therapy.Treatment comprises 10 sessions performed on consecutive working days, includes four parts.~1. Active exercises of the neck, 5 minutes, first demonstrated by the physiotherapist and next the patient performs them under supervision, 5 repetitions of each of the following: cervical flexion, rotation to the left and to the right, side bending to the left and to the right, torsion to left and right.~2. Massage of cervical interspinales muscles performed by therapist 3 minutes.~3. Post Isometric Relaxation (PIR) performed by physiotherapist. 15 minutes.~4. Active neck exercises - the same as mentioned in step 1. 5 minutes. Total duration of one treatment session is around 30 minutes."
224080057|NCT03370497|DIETARY_SUPPLEMENT|Milk Mineral Supplement|Milk Minerals containing 1000 mg calcium
224080058|NCT03370497|DIETARY_SUPPLEMENT|Whey Protein Hydrolysate|50 g whey protein hydrolysate
224080059|NCT04033419|DRUG|Memantine|"memantine dose~* Week 1: 5 mg dose once daily~* Week 2: 5 mg dose twice daily~* Week 3: 5 mg each morning/10 mg each evening~* Week 4 through the end of Chemotherapy: 10 mg dose twice daily~* Total duration: 12 - 26 weeks (depending on chemotherapy regimen)"
224080060|NCT00742469|DRUG|Rifaximin|
224080061|NCT00742469|DRUG|Placebo|
224080062|NCT02662647|DRUG|Decitabine 20 mg/m²/day for 5 days|
224080063|NCT01132209|PROCEDURE|Closure of the abdominal wall after midline incisions|Closure of the midline incision after any abdominal operation. Suturing of the fascia of the abdominal wall with two different techniques
224080064|NCT05227339|DEVICE|RAE|Subjects in the interventional group will have access to the RAE Health mobile app which receives continuous physiologic data from a wearable device. Algorithms embedded in the RAE app detect stress and craving events, and trigger mobile phone notifications when detected. Notifications are paired to real-time mindfulness based interventions.
224080065|NCT00573794|BIOLOGICAL|adalimumab|adalimumab prefilled syringes administered as subcutaneous injection EW or EOW
224080066|NCT02999490|RADIATION|18F-FDG|18F-FDG is positron emission tomography imaging agent which is already widely used in PET/CT examination.
224080067|NCT03663088|OTHER|GPR-A|Standard Global postural re-education physiotherapy scoliosis specific exercises
224080068|NCT03663088|OTHER|GPR-B|Experimental Global postural re-education physiotherapy scoliosis specific exercises combining individual and class exercises
224080069|NCT02095743|DEVICE|implanted port for chemo administration (X-port isp)|
224080070|NCT02095743|DEVICE|Use of a PICC line for chemo administration (PowerPICC SOLO²)|The description of the device could found on the published marketing authorisation
224080071|NCT06548802|DRUG|Baricitinib|Baricitinib was given 4mg once daily, with the first dose taken within 24 hours of the appearance of lung injury and continued for 14 days.
224080072|NCT06196086|DIAGNOSTIC_TEST|Echocardiography examination|Echocardiography examination and software post-processing analysis was performed to obtain parameters of conventional echocardiography, left atrial and left ventricle strain, and IVP.
224080073|NCT06500247|DRUG|Dalpicilib|This study recruited a total of 43 subjects diagnosed with Metastatic Castration-Resistant Prostate Cancer at multiple centers from July 2024. Enrolled patients received treatment with dalpicilib until disease progression or intolerable toxicity, with a maximum treatment duration of up to 2 years. Follow-up visits were conducted monthly after patient enrollment. The last follow-up was completed in March 2027.
224080074|NCT06500247|DRUG|Abiraterone Acetate (II)|This study recruited a total of 43 subjects diagnosed with Metastatic Castration-Resistant Prostate Cancer at multiple centers from July 2024. Enrolled patients received treatment with Abiraterone Acetate (II) until disease progression or intolerable toxicity, with a maximum treatment duration of up to 2 years. Follow-up visits were conducted monthly after patient enrollment. The last follow-up was completed in March 2027.
224080075|NCT06500247|DRUG|Androgen Deprivation Therapy|This study recruited a total of 43 subjects diagnosed with mCRPC at multiple centers from July 2024. Enrolled patients received treatment with Androgen Deprivation Therapy until disease progression or intolerable toxicity, with a maximum treatment duration of up to 2 years. Follow-up visits were conducted monthly after patient enrollment. The last follow-up was completed in March 2027.
224080076|NCT06500247|DRUG|Prednisone|This study recruited a total of 43 subjects diagnosed with mCRPC at multiple centers from July 2024. Enrolled patients received treatment with Prednisone until disease progression or intolerable toxicity, with a maximum treatment duration of up to 2 years. Follow-up visits were conducted monthly after patient enrollment. The last follow-up was completed in March 2027.
224080077|NCT00639938|DRUG|Nevirapine|200 mg Nevirapine tablet
224080078|NCT00639938|DRUG|HIV immune globulin solution|5% intravenous HIV immune globulin solution
224080079|NCT02810028|BEHAVIORAL|Acceptance and Commitment Therapy (ACT)|Acceptance and Commitment Therapy (ACT) is a form of cognitive behavioural therapy focused explicitly on promoting psychological flexibility. An ACT programme suits the aims of the study because it targets avoidance of distress, promotes acceptance of illness through motivating meaningful activity outside of illness, improves the processes that underlie beliefs rather than by directly challenging beliefs, thus reducing possible trivialisation of the understandable distress caused by living with MD.
224080080|NCT04208854|DRUG|Vinorelbine|"Vinorelbine 40 mg (2 cps of 20 mg) three times a week (Monday. Wednesday, Friday), for the first 2 weeks.~Starting from the third week, in the absence of any severe toxicity (≥ 3) and in the opinion of the clinician, the dosage can be increased to 50 mg (1 cps from 30 + 1 cps from 20 mg), three times a week ( Monday, Wednesday, Friday) continuously.~The dosage of 40 or 50 mg is continued until progression, patient refusal or unacceptable toxicity (in the clinician's opinion)."
224080081|NCT02182349|DRUG|BI 201335 NA soft gelatin capsule|
224080082|NCT02182349|DRUG|[14C]-BI 201335 NA radiolabelled drug|
224080083|NCT00604968|DRUG|Caelyx (pegylated liposomal doxorubicin; SCH 200746)|Caelyx will be administered intravenously at a dose of 40 mg/m\^2 on day one every 4 weeks until progression, or unacceptable toxicity, or other reason to discontinue the study treatment. The drug is diluted in 250 ml glucose 5% (500 ml for doses \>=90 mg).
224080084|NCT01044186|DRUG|ICL670|
224080085|NCT05519345|BEHAVIORAL|Operant Conditioning|Active encouragement and feedback to increase motor evoked response during stimulation.
224080086|NCT05519345|BEHAVIORAL|Control|Absence of active encouragement and feedback to increase motor evoked response when stimulated.
224080087|NCT03805893|PROCEDURE|Moderate heat pain|To apply a sensory challenge that can be applied over longer periods required for PET imaging and that is also compatible with high magnetic fields during MRI scanning, we will use a well-established thermal challenge of the lower extremity. To apply mildly painful heat to the patient, the right leg (from the foot up to the knee) will be wrapped in a blanket that incorporates a network of small-diameter plastic tubing through which hot water (45 - 55 oC) is circulated from a temperature-controlled reservoir.
224080088|NCT00982904|DRUG|Fexinidazole/Placebo|
224080089|NCT00135122|DRUG|prednisolone|Prednisolone 60mg day 1 and 2 , 40mg day 3 and 4 , 20mg day 5 and 6
224080090|NCT02752100|PROCEDURE|Percutaneous transluminal angioplasty|
224080091|NCT04556617|DRUG|PLX2853 20 mg|PLX2853 tablets
224080092|NCT04556617|DRUG|Olaparib|Olaparib tablets
224080093|NCT04556617|DRUG|Abiraterone acetate|Abiraterone acetate tablets
224080094|NCT04556617|DRUG|Prednisone|Prednisone (or equivalent) tablets
224080095|NCT04556617|DRUG|PLX2853 40 mg|PLX2853 tablets
224080096|NCT04556617|DRUG|PLX2853 80 mg|PLX2853 tablets
224080097|NCT06194123|OTHER|Crest Daily Whitening Serum|one week's use of Crest Daily Whitening Serum as described on the label.
224080098|NCT03179436|BIOLOGICAL|Quavonlimab|Quavonlimab is administered intravenously (IV) during the Dose Escalation Phase and Dose Confirmation Phase at either DL1 or DL2, and is administered IV during the Efficacy Expansion Phase at DL2.
224080099|NCT03179436|BIOLOGICAL|Pembrolizumab|Pembrolizumab is administered IV at PDL1 on Day 1 of each cycle starting Cycle 2 for the Dose Escalation Phase or starting Cycle 1 of the Dose Confirmation Phase. Pembrolizumab is administered IV at PDL2 on Day 1 of each cycle for the Efficacy Expansion Phase (Arm G).
224080100|NCT03179436|DRUG|Pembrolizumab/Quavonlimab|Pembrolizumab/Quavonlimab is a coformulated product composed of quavonlimab at DL1 in combination with pembrolizumab at dose level 2 (PDL2).
224080101|NCT06145893|DRUG|Hemay005|Hemay005 tables 60mg bid p.o;
224080102|NCT06145893|DRUG|Hemay005|Hemay005 tables 45mg bid p.o;
224080103|NCT06145893|DRUG|Placebo|placebo to Hemay005 tables bid p.o
224080104|NCT06539312|OTHER|APP assessment and management of asthma|APPs will be trained to follow NIH guidelines for assessment and management of asthma, and to apply their knowledge to the care of the students. Students will also receive DOT of the morning dose of their controller medication.
224080105|NCT05013255|DRUG|Pioglitazone 15mg|PIO 15mg orally once daily for 2 weeks
224080106|NCT05013255|DRUG|Pioglitazone 30 mg|PIO 30mg orally once daily for 2 weeks
224080107|NCT02407678|GENETIC|AAV-mediated REP1 gene replacement|AAV vector carrying human REP1 gene is delivered into the treated eye by subretinal injection
224080108|NCT05702736|BEHAVIORAL|logotherapy-based intervention|Logotherapy-based intervention was administered to the individuals in the intervention group as a total of eight sessions, once a week.
224080109|NCT01007578|DEVICE|Paclitaxel-coated balloon catheter angioplasty|Paclitaxel-coated balloon catheters for the treatment of peripheral arterial occlusive disease (POAD) of the femoro-popliteal arteries
224080110|NCT02549755|DRUG|11C-Acetate|"The 11C-Acetate radiopharmaceutical will be administered intravenously at a dose of 20-40 mCi (0.74-1.5 GBq).~There will be a total of three 11C-acetate radiopharmaceutical administrations for each patient"
224080111|NCT06269445|DRUG|Icaritin Combined With Bevacizumab and FOLFIRI|Bevacizumab and FOLFIRI are second-line treatment options for colorectal cancer; synergistic efficacy expected in combination with Icaritin
224080112|NCT06499987|PROCEDURE|resection anastomosis|resection of stenotic part of trachea and reanastmosis
224080113|NCT05099692|BEHAVIORAL|filling out the questionnaire|all participants in our study are invited to choose at least 1 question in 15 questions or provide their own questions regarding their doubt about the CR after filling in their personal information
224080114|NCT00318760|DRUG|Clonidine|0.1 or 0.2 mg oral, one dose
224080115|NCT00318760|DRUG|Placebo|oral capsule 1 dose
224080116|NCT00751868|DRUG|Ixabepilone|Ixabepilone is administered as 3-hour intravenous infusion (iv) at the dose of 40 mg/mq, every 14 days for 4 cycles (with G-CSF support), sequentially to Fluorouracil 600 mg/mq as intravenous (iv) infusion, Epirubicin 90 mg/mq as intravenous (iv) bolus and Cyclophosphamide 600 mg/mq as intravenous (iv) infusion every 14 days for 4 cycles (with G-CSF support)
224080117|NCT02001376|OTHER|Intensive exercise|The intensive exercise group will receive moderate aerobic exercise and strengthening exercise three times a week for three months.
224080118|NCT02001376|OTHER|Home exercise|The home-based exercise group will receive exercise instruction biweekly for three months
224080119|NCT02001376|OTHER|Control group live as usual|Control group means no any intervention for them. The control group who with metabolic syndrome risk factors just live as usual.
224080120|NCT03782935|DIETARY_SUPPLEMENT|Prenatal multivitamin mineral supplement|prenatal vitamin/mineral supplement with or without choline supplement
224080121|NCT06144983|DRUG|Alvogyl|In the first study group, (0.2gm) of Alvogyl paste (Septodont Inc., France), was inserted inside the alveolus, filling it entirely
224080122|NCT06144983|DRUG|Chlorhexidine Gluconate|in the second group (1ml) of Periokin (Kin Inc., Spain), containing 0.2% Chlorhexidine bioadhesive gel was injected to fill the entire socket
224080123|NCT03644238|DIAGNOSTIC_TEST|Oral Glucose Tolerance Test|75g of glucose is consumed
224080124|NCT03644238|BEHAVIORAL|Inactivity|Lying or sitting down.
224080125|NCT03644238|BEHAVIORAL|Physical activity|20 minutes of fixed intensity exercise on a bicycle ergometer.
224080126|NCT06000293|OTHER|Oral health education|Anticipatory Guidance (AG) provided to the primary caregivers-infant pairs in the intervention group
224080127|NCT05033496|DIAGNOSTIC_TEST|Thyroid function test|Thyroid function test
224080128|NCT05932550|DRUG|Maraviroc 300 mg|10 week treatment as add-on therapy to anti-depressants
224080129|NCT01447108|DEVICE|Low Intensity Low Frequency Surface Acoustic Wave Ultrasound (PainShield™)|"All subjects will be treated four weeks with a placebo PainShield™ while continuing with their current pharmaco- analgesic regimen. Aferterwards all subjects will be crossed over to active Painshield™ therapy for the next four weeks.~The Painshield™ device is a patch, which will be applied to their forehead for six-eight hours during night while sleeping."
224080130|NCT02586792|BIOLOGICAL|Monovalent influenza A/H7N9 virus vaccine|Monovalent influenza A/H7N9 virus vaccine.
224080131|NCT04693962|DIAGNOSTIC_TEST|Plasmatic Fibroblast Growth Factor-23 by means of ELISA|Plasma levels of FGF-23 will be measured by ELISA
224080132|NCT03320122|OTHER|Telemedicine|Medical direction will be provided to MTUs through a video-based conferencing unit. Each telemedicine unit includes a Rubbermaid medical grade cart with a Polycom RealPresence 500 Series high-resolution video-conferencing unit flat screen to display video. Each cart also comes with an Uninterrupted Power Supply (UPS) to make the unit mobile if needed or to properly shut it down in the event of power failure.
224080133|NCT03320122|OTHER|In-Person Pediatric Physiatrist|UC Davis pediatric physiatrists will drive out to the school-based MTUs to provide medical direction in person.
224080134|NCT03320122|OTHER|In-Person Non-Pediatric Physiatrist|A contracted physician (i.e., a non pediatric physiatrist) would provide medical direction in person.
224080135|NCT01501058|BEHAVIORAL|parent-assisted social skills training program for adolescents with autism spectrum disorder|The subjects will participate in the treatment program weekly for a total of 14 weeks. The final visit will be made at the point three months after the completion of treatment to see mid- and long-term effects.
224080136|NCT01501058|BEHAVIORAL|Delayed intervention|Intervention is provided to Waitlist Control Group after waiting for 14 weeks
224080137|NCT00692211|OTHER|Mailed fecal occult blood tests|Stool blood test
224080138|NCT00692211|OTHER|Mailed fecal immunochemical tests|Stool blood test
224080139|NCT06237894|OTHER|Multisensory Stimulation|Multisensory Stimulation
224080140|NCT03737773|OTHER|glasses (prismatic lenses)|
224080141|NCT03737773|OTHER|glasses (neutral)|
224080142|NCT00782366|GENETIC|SNP analysis|The patients in the intervention group will obtain genetic risk assessments based on genome-wide association studies.
224080143|NCT04625127|DEVICE|Treadmill gait training with GaitBetter|Participants will receive gait training with the GaitBetter solution for a total of 15 sessions (3 days a week for 5 weeks) each lasting approximately 45 minutes.
224080144|NCT04625127|OTHER|Treadmill gait training with GaitBetter + Standard of care|Participants will receive gait training with the GaitBetter solution for a total of 15 sessions (3 days a week for 5 weeks) each lasting approximately 45 minutes. In addition, the investigators will record the number and duration of therapy sessions followed by the participant during standard of care.
224080145|NCT04625127|OTHER|Standard of care|Participants will follow their standard of care. The investigators will record the number and duration of therapy sessions followed during standard of care.
224080146|NCT04199325|DIETARY_SUPPLEMENT|Probiotics|Patients will be randomly assigned to the routine treatment + placebo group and probiotics + routine treatment group according to 1:2 ratio.
224080147|NCT04199325|DRUG|uric-acid-lowering drug|Patients will be randomly assigned to the routine treatment + placebo group and probiotics + routine treatment group according to 1:2 ratio.
224080148|NCT05649995|OTHER|Pain science education driven physiotherapy program|Pain science training will be carried out as described by Moseley and Butler. Topics covered within the scope of pain science education are planned to include: neurophysiology of pain, synapses, peripheral sensitization, central sensitization, plasticity of the nervous system. The aim of the training will be to teach participants that pain is a multifactorial experience rather than just tissue injury. Participants in this group will be told about the importance of physical activity integrated with pain science education (i.e., explaining that physical activity is the key to bioplasticity and causing changes in our system) and why sedentary behaviors should be reduced (reducing sedentary behaviors reduces the overprotectiveness of the pain system).
224080454|NCT02917967|DRUG|Botulinum toxin injection|"1. BoNT-A will be injected into two hamstring and/or gastrocnemius muscles under the guidance of ultrasonography or electrical stimulation.~2. Maximal total dose and dose regimen for each muscle would follow the recommendation of international consensus.~A. Semitendinosus 5 to 7.5 units/kg of body weight B. Semimembranosus 5 to 7.5 units/kg of body weight C. Gastrocnemius 10 units/kg of body weight D. Maximal total dose per patient : unilateral injection 500 units, bilateral injection 1,000 units E. The dosage of two hamstring muscles will depend on the severity of spasticity and gait abnormalities of children with CP"
224080455|NCT03504826|DEVICE|Hybrid Assistive Limb (HAL)|Intensive training with the HAL consisting of two components to the intervention session that include: 1) locomotor treadmill training with the HAL device and 2) locomotor training over ground without the HAL device. All training will be overseen by a licensed physical therapist.
224080456|NCT06549075|OTHER|Therapeutic support|The modular intervention consists of three modules, including Dignity Therapy, CALM Therapy and Mindfulness-based training. According to the patient's preferences, the patient will be allocated to one of the three interventions, which will be conducted by trained therapists within two sessions.
224080457|NCT06549075|OTHER|Standard Specialized Palliative Consultation Service|According to needs standard specialized palliative care will include support of symptom control, shared decision making/ advance care planning, network planning and support of relatives.
224080458|NCT04988100|PROCEDURE|splenic artery ligation|Splenic artery will be ligated just after takeoff from coeliac trunk at the level of body of pancreas
224080459|NCT04988100|PROCEDURE|No intervention|Splenic artery is not ligated despite the presence of portal hyperperfusion
224080460|NCT01871090|DEVICE|Unpaired remote monitoring transmitter|Unpaired remote monitoring transmitter
224080149|NCT05649995|OTHER|Biomedical education driven physiotherapy program|Participants in this group will be planned to increase their knowledge of knee anatomy, knowledge of knee OA and knee OA risk factors, and the importance of increasing physical activity and reducing sedentary behavior in reducing osteoarthritic pain and improving overall health. The importance of physical activity by integrating it with biomedical education (as physical activity can help strengthen muscles, protect joint function, and improve sleep and general health) and the necessity of reducing sedentary behaviors will be discussed within the framework of biomedical education.The main difference of standard education from pain science education will be that it does not contain information about pain mechanisms mentioned in pain science education.
224080150|NCT01923688|OTHER|Informatics Alert/Nurse/physician responders|
224080151|NCT02531646|RADIATION|Radiation|Radiation - Each human subject will receive one standard of care x-ray and one Duel Energy exposure or one standard of care x-ray and one Digital Tomosynthesis exposure. Phantoms were imaged using linear tomography and digital tomography.
224080152|NCT03219866|DEVICE|Nebulizers|Patients treated and discharged on nebulized bronchodilators
224080153|NCT03219866|DEVICE|Dry Powder Inhaler|Patients treated and discharged on Dry Powder Inhalers
224080154|NCT03219866|DRUG|Brovana|Subjects will receive a long-acting B2-agonist(LABA; Brovana, twice daily)
224080155|NCT03219866|DRUG|Pulmicort|Subjects will receive a corticosteroid (ICS; Pulmicort, twice daily)
224080156|NCT03219866|DRUG|Atrovent|Subjects will receive a short-acting anti-cholinergic (SAMA; Atrovent, three times a day)
224080157|NCT03219866|DRUG|Advair Diskus|Subjects will receive a LABA/ICS (Advair Diskus, twice daily)
224080158|NCT03219866|DRUG|Spiriva HandiHaler|Subjects will receive a long-acting anticholinergic (LAMA-Spiriva Handihaler, once daily)
224080159|NCT02851173|DEVICE|LLLT|The treatment will consist of applying light of a specific wavelength (1064 nm) using a laser diode supplied by Cell Gen Therapeutics, LLC (CG-5000 laser, HD Laser Center, Dallas, TX, USA).
224080160|NCT02851173|DEVICE|Placebo|The treatment will consist of applying light of a specific wavelength (1064 nm) using a laser diode supplied by Cell Gen Therapeutics, LLC (CG-5000 laser, HD Laser Center, Dallas, TX, USA). However, the placebo group will receive approximately 1/12th of the cumulative energy density as the treatment group.
224080161|NCT04642014|BIOLOGICAL|COVID-19 convalescent plasma treatment|"The donor's blood will be collected after four weeks post-onset of illness. 600 ml ABO-compatible plasma sample will be harvested during apheresis from each donor and each sample will be divided and stored as 200 mL aliquots.~Patients who meet the criteria receive one dose (200 mL) of ABO compatible inactivated convalescent plasma with a confirmed neutralization activity."
224080162|NCT04957381|BEHAVIORAL|Group exercises|Group exercises including aerobic, resistance and stretching exercise. Once a week for 8-12 weeks.
224080163|NCT00726687|DRUG|indibulin|indibulin, dose escalation, 400-600 mg taken twice every day
224080164|NCT00726687|DRUG|capecitabine|capecitabine, dose escalation, 875 mg/m2- 1250 mg/m2, taken twice daily for 14 days per 21 day cycle
224080165|NCT01796405|DRUG|Clofarabine|
224080166|NCT03682497|DRUG|AZD9977|AZD9977 capsules taken orally for 28 days.
224080167|NCT03682497|DRUG|Spironolactone|Spironolactone tablets taken orally for 28 days.
224080168|NCT06548906|DRUG|GZR4 Injection|GZR4 Injection administered sc, once weekly.
224080169|NCT00129155|DRUG|treosulfan|
224080170|NCT03796468|OTHER|Best Medical Therapy|The administration of medications is at the treating physician's discretion (for example intravenous fibrinolysis, anticoagulants or antiplatelet) according to local standards of care but may NOT include any intra-arterial therapies. The rescue MT may be performed in case of deterioration within the 24 hours
224080171|NCT03796468|PROCEDURE|Mechanical Thrombectomy|MT in the Experimental Arm can be performed with any thrombectomy (CE labeled) device usually used at study site. For the subjects randomized to the MT plus medical, the MT is performed immediately after the randomization
224080172|NCT00389025|DRUG|Olopatadine (generic name)|
224080173|NCT02320487|DRUG|Bendamustine|Bendamustine was administered as an intravenous infusion at a dose of 90 milligrams per square meter (mg/m\^2) on Days 2 and 3 Cycle 1; and on Days 1 and 2 Cycles 2-6.
224080174|NCT02320487|DRUG|Obinutuzumab|Obinutuzumab was administered as an intravenous infusion at a dose of 100 milligrams (mg) on Day 1 Cycle 1; at a dose of 900 mg on Day 2 Cycle 1; at a dose of 1000 mg on Days 8 and 15 Cycle 1, and Day 1 Cycles 2-6.
224080175|NCT05122234|BIOLOGICAL|Injection of secretome - mesenchymal stem cell|Secretome will be given once at a dose of 15 ml per administration dissolved in 100 ml of normal saline. The administration is done intravenously for 60 minutes.
224080176|NCT05122234|OTHER|Placebo|Normal saline
224080177|NCT05122234|DRUG|Standard treatment of Covid-19|Standard treatment of Covid-19 based on national protocol.
224080178|NCT05544890|PROCEDURE|Exercise|"All patients will start learning how to activate the transversus abdominal muscle in the first training session. The exercises will be made in 1 to 3 series of among 8 and 15 repetitions and the isometric contractions for 5 to 10 seconds. The rest between series will be of 30 seconds, and between exercise of 2-3 minutes.~Other Names:~\- Therapeutic exercise"
224080179|NCT05544890|PROCEDURE|Manual Therapy|"All patients will start learning how to activate the transversus abdominal muscle in the first training session. The exercises will be made in 1 to 3 series of among 8 and 15 repetitions and the isometric contractions for 5 to 10 seconds. The rest between series will be of 30 seconds, and between exercise of 2-3 minutes.~Other Names:~\- Manipulation"
224080180|NCT05544890|PROCEDURE|Kinesiotape|"All patients will start learning how to activate the transversus abdominal muscle in the first training session. The exercises will be made in 1 to 3 series of among 8 and 15 repetitions and the isometric contractions for 5 to 10 seconds. The rest between series will be of 30 seconds, and between exercise of 2-3 minutes.~Other Names:~\- Kinesiotaping"
224080181|NCT05832294|DEVICE|Treatment rTMS|Depressed adolescents will undergo emotional processing tasks (within and outside the fMRI scanner) after one session of 1) sham rTMS (n = 15) or 2) active rTMS (n = 15). Prior to stimulation, expectancy for symptomatic benefit will be assessed with a standardized scale and a semi-structured interview conducted regarding their perception of rTMS. After the one-day randomized controlled phase, participants can then enter an open-label active rTMS treatment phase for 4 weeks. Eligible patients who decline the study and open-label treatment phase will be invited to participate in a semi-structured interview to explore their perceptions toward rTMS.
224080182|NCT05832294|DEVICE|Sham rTMS|Depressed adolescents will undergo emotional processing tasks (within and outside the fMRI scanner) after one session of 1) sham rTMS (n = 15) or 2) active rTMS (n = 15). Prior to stimulation, expectancy for symptomatic benefit will be assessed with a standardized scale and a semi-structured interview conducted regarding their perception of rTMS. After the one-day randomized controlled phase, participants can then enter an open-label active rTMS treatment phase for 4 weeks. Eligible patients who decline the study and open-label treatment phase will be invited to participate in a semi-structured interview to explore their perceptions toward rTMS.
224080183|NCT04588324|DRUG|SHR2150|Patients will receive escalating doses of SHR-2150 (starting dose 2 mg) in 3-week treatment cycles.
224080184|NCT04588324|DRUG|Anti-Cancer Agent|The previously resistant first-line cytotoxic regimens, anti-PD-1 antibody and/or anti-CD47 antibody will be administered intravenously Q3W.
224080185|NCT04588324|DRUG|SHR2150|Patients will receive SHR-2150 at RP2D in 3-week treatment cycles.
224080186|NCT01337128|PROCEDURE|Carotid endarterectomy (CEA)|Carotid endarterectomy (CEA) will be performed on the patients
224080187|NCT01337128|PROCEDURE|Carotid stenting (CAS)|Carotid Stenting (CAS) will be performed on these patients.
224080188|NCT01337128|PROCEDURE|Neurocognitive functions|Neurocognitive functions will be measured pre-operatively and after 3 weeks, 6 months and 1 year.
224080189|NCT01337128|PROCEDURE|Levels of biomarkers|Levels of biomarkers (Protein S100B) will be examined pre- , peri- and post-operatively after 2 hours, 6 hours and 24 hours.
224080190|NCT01337128|PROCEDURE|Detection of peri-operative embolization|A Transcranial Doppler Ultrasonography will be used to detect peri-operative embolization.
224080191|NCT01337128|PROCEDURE|Validation results|On a subgroup of 20 patients a MRI-scan will be done pre- and post-operatively after 48 hours and 3 weeks.
224080192|NCT06099938|DRUG|sufentanil, ropivacaine|The study used conventional anesthetic drugs to compare the effects of the two drugs on maternal and infant blood flow
224080193|NCT01240161|DRUG|FLT-PET/CT: (3'deoxy-3'-[(18)F] fluorothymidine) PET/CT|Each patient will have 0-3 or more FLT-PET brain scans.
224080194|NCT05164445|DIAGNOSTIC_TEST|Transbronchial forceps biopsy|All patients with peripheral lung lesion suspected of lung cancer detected on the chest computed tomography (CT) and mini probe endobronchial ultrasound (RP-EBUS) scans were enrolled. Transbronchial forceps biopsy (TBFB) was performed for all these patients.
224080195|NCT05164445|DIAGNOSTIC_TEST|Transbronchial forceps biopsy+Transbronchial cryobiopsy|All patients with peripheral lung lesion suspected of lung cancer detected on the chest computed tomography (CT) and RP-EBUS scans were enrolled. TBFB was performed for all these patients. In addition, all of these patients, with no contraindications, underwent transbronchial cryobiopsy (TBCB)
224080196|NCT05591586|BEHAVIORAL|Web based educational modules|This strategy will consist of 6 web-based modules, clinic-specific interpreter access information, and 4 booster modules, all delivered via the internet. The online modules will cover 6 topics: 1) the importance and fundamentals of good communication; 2) the importance of professional interpreter use and disparities for LEP populations; 3) how to use an interpreter effectively; 4) what to do when the encounter is not going well; and 5) special challenges and 6) solutions related to remote interpreter use. Modules will be interactive, with tailoring to the learner, and each will be \<15 minutes long. All modules will be available at once, but assigned providers will be prompted to view a new one each week. Every month for months 3-6 after randomization, a booster module will be released. The brief (\<10 min) boosters will review crucial points from initial modules and feature video vignettes. Providers will be reminded to view these weekly until they are complete.
224080197|NCT05591586|BEHAVIORAL|mobile video interpreting (mVI) access|This strategy will involve giving assigned providers access to mobile video interpreting (mVI) on a personal device, installation and support as needed, a tip sheet, and an extra charger, optional shock-resistant case, disposable antimicrobial sleeves, and a positioning stand to support use of their personal device for clinical care. mVI-assigned providers can opt for a study-issued smartphone in lieu of using their own. Access to mVI is achieved by downloading the application from the relevant location (e.g., Apple App Store), then entering an access code that links to a billing account. The study staff would then demonstrate use and answer questions. Technical support will be offered in-person following randomization; we will then email mVI-assigned providers weekly for the first month, then monthly, to offer additional support. A tip-sheet will be sent via email during the first week of the study that will include mVI instructions and best-practices.
224080198|NCT02007707|BEHAVIORAL|Tobacco LHW|Quit Smoking For a Healthy Family - This is a family-based psycho-education intervention using lay health worker (LHW) outreach. LHW will be trained to recruit smoke-family dyads and provide education and information about tobacco and health, and smoking cessation resources through 2 small-group education sessions and 2 individual phone calls over a 2-month period.
224080199|NCT02007707|BEHAVIORAL|Healthy Eating|Eating Healthy and Physically Active for You and Your Family - This is a attention-control comparison group using a family-based psycho-education intervention delivered through lay health worker (LHW) outreach. LHW will be trained to recruit smoke-family dyads and provide education and information about healthy eating and physical activity through 2 small-group education sessions and 2 individual phone calls over a 2-month period. Participants will receive writing information about smoking cessation resources.
224080200|NCT00529971|BEHAVIORAL|MBSR group|8-week MBSR group, 3 hours per week plus one all day retreat
224080201|NCT00529971|OTHER|Control|Treatment as usual, which could include medications or psychotherapy
224080202|NCT03746912|DRUG|Quizartinib Dihydrochloride|Tablets for once daily oral administration at doctor-recommended dose in continuous 28-day cycles
224080203|NCT05565599|DEVICE|Left Atrial Appendage Closure|Closure of the left atrial appendage with the Laminar Left Atrial Appendage Closure System.
224080204|NCT06729775|OTHER|Data report back preference by life span|Data report back preference by life span.
224080205|NCT07160231|DRUG|JAKi dose reduction strategy|JAKi dose reduction strategy
224080206|NCT07160231|DRUG|JAKi disease activity guided continuation of same dose strategy|JAKi disease activity guided continuation of same dose strategy
224080207|NCT07177469|DRUG|UBT251 Injection 2.0 mg and UBT251 Injection Placebo|UBT251 Injection and UBT251 Injection Placebo subcutaneously once weekly
224080208|NCT07177469|DRUG|UBT251 Injection 4.0 mg (ID 0.5 mg) and UBT251 Injection Placebo|UBT251 Injection and UBT251 Injection Placebo subcutaneously once weekly
224080209|NCT07177469|DRUG|UBT251 Injection 4.0 mg (ID 1.0 mg) and UBT251 Injection Placebo|UBT251 Injection and UBT251 Injection Placebo subcutaneously once weekly
224080210|NCT07177469|DRUG|UBT251 Injection 6.0 mg and UBT251 Injection Placebo|UBT251 Injection and UBT251 Injection Placebo subcutaneously once weekly
224080211|NCT07177898|DRUG|Allopurinol|Group A received allopurinol with lisinopril, and Group B received lisinopril alone
224080212|NCT07178717|DRUG|Rechalange with bevacizumab + encorafenib|Patients will receive encorafenib 300mg once daily plus cetuximab 500mg/m2 every 2 weeks until disease progression, unacceptable toxicity, patient request, physician's decision to withdraw treatment, subsequent anticancer therapy or death.
224080213|NCT07179120|DRUG|Semaglutide (Rybelsus®)|Participants receive once-weekly subcutaneous injections of Semaglutide. The dose is titrated every 4 weeks: 0.25 mg (Weeks 1-4), 0.5 mg (Weeks 5-8), and maintained at 1.0 mg from Week 9 to Week 32. Injections are administered in the abdomen, thigh, or upper arm
224080214|NCT07179120|DRUG|Tirzepatide|Participants receive once-weekly subcutaneous injections of Tirzepatide. The dose is titrated every 4 weeks: 2.5 mg (Weeks 1-4), 5 mg (Weeks 5-8), 10 mg (Weeks 9-12), and maintained at 15 mg from Week 13 to Week 32. Injections are administered in the abdomen, thigh, or upper arm
224080215|NCT07179120|BEHAVIORAL|Standardized Lifestyle Intervention|Participants receive individualized intensive lifestyle management, including a calorie-restricted Mediterranean diet (daily deficit of 500 kcal), structured aerobic and resistance exercise (150 mins/week), and behavioral coaching. Delivered through weekly face-to-face sessions for the first 12 weeks, followed by bi-weekly sessions for the remaining 20 weeks. No pharmacotherapy is administered.
224080216|NCT07177703|DRUG|Treprostinil|Treprostinil is initiated at a dose of 1.25 ng/kg/min. The dose is then titrated upwards based on individual patient tolerability and clinical response. The planned titration schedule is an increase of 1.25 ng/kg/min weekly for the first four weeks of treatment, followed by weekly increases of 2.5 ng/kg/min thereafter, as tolerated.
224080217|NCT00684957|DRUG|Recombinant Human Growth Hormone|300 mcg sc qd (which may be increased to 400 mcg sc qd after 4 weeks)
224080218|NCT00684957|DRUG|Recombinant Human IGF-1|30 µg/kg for first 4 weeks (may be increased thereafter based on IGF-1 levels)
224080219|NCT05847322|BIOLOGICAL|Bordetella pertussis B1917|The B. pertussis isolate to be used in this human colonisation model is strain B1917, which is representative of current isolates in Europe. The strain, isolated in 2000 from a Dutch patient with B. pertussis disease, expresses Pertactin (PRN), Pertussis Toxin (PT) and Filamentous Haemagglutinin (FHA). This strain has been extensively characterised in the mouse model as well as by proteomics and transcriptomics and has a closed genome available. It is fully sensitive to azithromycin in vitro.
224080220|NCT05847322|DRUG|Azithromycin Pill|A 3 day course of azithromycin will be administered to all colonised volunteers at week 6, or sooner if early pertussis disease is suspected
224080221|NCT03793062|OTHER|No Interventions|Not applicable - No Interventions
224080222|NCT03842696|DRUG|Vorinostat|"* HLA-matched BMT recipients: Vorinostat 30, 45 or 60 mg/m2 BID (100 mg/m2 BID maximum) PO from 10 days prior to transplant (day -10), until day +30 post-transplant.~* Haploidentical BMT recipients: Vorinostat 30, 45 or 60 mg/m2 BID (100 mg/m2 BID maximum) PO from 5 days after transplant (day +5), until day +30 post-transplant"
224080223|NCT03842696|PROCEDURE|Blood and Marrow Transplant (BMT)|Undergo allogeneic BMT according to local site institutional practice.
224080224|NCT03842696|DRUG|Tacrolimus (or cyclosporine)|Tacrolimus (or cyclosporine if tacrolimus becomes in shortage during the study period) will begin on day -3. Intravenous or oral dosing is permitted.In the absence of GVHD, it is recommended that tacrolimus or cyclosporine tapering begin on day +100 post-transplant as per local site BMT program clinical practice guidelines. In the presence of GVHD, it is recommended that tacrolimus or cyclosporine be continued at therapeutic dosing.
224080225|NCT03842696|DRUG|Methotrexate|HLA-matched BMT recipients: Methotrexate will be used in combination with tacrolimus (or cyclosporine) for standard GVHD prophylaxis. It will be given at a dose of 5 mg/m2/dose once daily intravenously on days +1, +3, +6, and +11. Standard criteria for administration will be followed per local site institutional BMT program clinical practice guidelines.
224080226|NCT03842696|DRUG|Mycophenolate Mofetil (MMF)|Haploidentical BMT recipients: MMF will be used in combination with post-transplant cyclophosphamide and tacrolimus (or cyclosporine) for standard GVHD prophylaxis. MMF will start on day +5 and discontinue after the last dose on day +35 or may be continued if active GVHD is present. Given intravenously (preferred) or orally at a dose of 15 mg/kg/dose three times a day (based upon adjusted body weight) with the maximum total daily dose not to exceed 3 grams.
224080227|NCT03842696|DRUG|Cyclophosphamide|Haploidentical BMT recipients: Post-transplant cyclophosphamide (PT-Cy) will be used in combination with MMF and tacrolimus (or cyclosporine) for standard GVHD prophylaxis. PT-Cy (50 mg/kg/dose) given for two days, Days +3 and +4 after transplantation.
224080228|NCT05877742|OTHER|AA group|Participants will individually receive a 5-minute AA education delivered verbally at his/her respective clinic by a trained nursing student interventionist in addition to the usual scheduled follow-ups and activities at clinics.
224080229|NCT05877742|OTHER|Control group|To mimic the time and attention spent, the control group will individually receive a 5-minute seminar delivered by an RA.
224080230|NCT06104306|DRUG|B/F/TAF|Tablets administered without regard to food
224080231|NCT03099434|BEHAVIORAL|Facebook App|This web-based mobile application allows candidates to write a simple and effective story to share with their previously built network on Facebook to help share their story and identify a potential live donor.
224080232|NCT03099434|BEHAVIORAL|Live Donor Champion + Facebook App|"A Live Donor Champion (LDC) is a friend, family member, or community member who serves as an advocate for the candidate in their pursuit of live donation. The investigators have developed a six-month program that provides education and advocacy training to waitlist candidates and their LDCs."
224080233|NCT04692831|COMBINATION_PRODUCT|89Zr-ss-pertuzumab PET/CT|Patients will receive 89Zr-ss-pertuzumab. 89Zr-ss-pertuzumab PET/CT images will be reconstructed using iterative reconstruction and displayed in multiplanar reconstruction. In the event that 89Zr-ss-pertuzumab is unavailable, randomly labelled 89Zr-pertuzumab PET will be allowed to make HER2 PET imaging available for our patients. Once 89Zr-ss-pertuzumab is available, then patients will be imaged with 89Zr-ss-pertuzumab and randomly labelled 89Zr-pertuzumab will no longer be used.
224080234|NCT05942144|OTHER|Exercise-snacks program|"Subjects in the exercise-snacks group will perform 4 exercise-snacks sessions per working day for 4 weeks. These sessions will consist of 80 one-to-one walks to be completed as quickly as possible. They will also receive information about their attitudes to physical activity."
224080235|NCT06960694|DRUG|L-carnitine|This group will be treated with tablet L-carnitine 330 mg 3 times daily for 8 weeks and Naproxen 500 mg twice daily for the first 14 days
224080236|NCT06960694|DRUG|Placebo|This group will be treated with tablet Placebo 330 mg 3 times daily for 8 weeks and Naproxen 500 mg twice daily for the first 14 days
224080237|NCT03196180|DRUG|Imiquimod|Given intravaginally
224080238|NCT03196180|DRUG|Topical Fluorouracil|Given intravaginally
224080239|NCT04439175|DRUG|Taselisib|Given PO
224080240|NCT04654728|PROCEDURE|Active Comparator: ePTFE graft|In this group, anterior sector of the right lobe graft will be reconstructed using Dacron vascular grafts
224080241|NCT00152867|DRUG|Dexamethasone|dexamethasone 4mg PO bd for 2 days post chemotherapy
224080242|NCT06467812|DIETARY_SUPPLEMENT|Salt Tablets|Three doses of 4 Salt Tablets (1gm) will be taken with 400mL of water on day 2 (1200ml total) between \~8am and \~12pm during the testing day, which runs from \~7am to \~3:30pm.
224080243|NCT06467812|DIETARY_SUPPLEMENT|Electrolyte Solution|"Three doses of 400mL of the Electrolyte Solution dissolved in water (1200 mL total) will be consumed on day 3 between \~8am and \~12pm during the testing day, which runs from \~7am to \~3:30pm. On day 4 the Electrolyte Solution Single Bolus will be consumed in a single dose of 1200mL at \~12pm during the testing day.~The ingredients are included below for the two flavors offered.~Orange flavor: Water, Dextrose with Maltodextrin, Aspartame, Acesulfame Potassium, Sodium Citrate, Salt, Citric Acid, Maltodextrin, Natural Flavor, Calcium Phosphate, Contains less than 2% Of Ascorbic Acid (Vitamin C), Artificial Flavor, Artificial Color, Red 40, Yellow 5, BHA (Butylated Hydroxyanisole).~Lemonade flavor: Water, Dextrose with Maltodextrin, Aspartame, Acesulfame Potassium, Sodium Citrate, Salt, Citric Acid, Calcium Phosphate, Maltodextrin, Contains less than 2% Of Ascorbic Acid (Vitamin C), Natural Flavor, Artificial Color, Yellow 5, BHA."
224080244|NCT01138956|DRUG|N-acetylcysteine|N-acetylcysteine (NAC), effervescent tablets of 600mg, tid, po, 28 days
224080245|NCT01138956|DRUG|Pentavalent antimonial|Pentavalent antimonial, 20mg/kg/day, 28 days, IV
224080246|NCT05623891|DRUG|177Lu-B5-IgG4|177Lu-B5-IgG4 injection followed by SPECT scan
224080247|NCT02363478|DRUG|buspirone|buspirone 10 mg X2 for 4 weeks
224080248|NCT05620355|DRUG|BG2109|BG2109 100mg film coated tablet for oral administration once daily.
224080249|NCT05620355|DRUG|Placebo for BG2109|Placebo for BG2109 100mg tablet for oral administration once daily.
224080250|NCT05620355|DRUG|Placebo for add-back therapy|Placebo for add-back therapy tablet for oral administration once daily.
224080251|NCT05620355|DRUG|Add-back therapy|Estradiol 1 mg / Norethindrone Acetate 0.5 mg for oral administration once daily.
224080252|NCT06103747|DRUG|Metformin / Vildagliptin Film Coated Tablets (850 mg / 50 mg)|Pharmacokinetic comparison after administration of test drug
224080253|NCT06103747|DRUG|Galvumet® Film Coated Tablets (850 mg / 50 mg)|Pharmacokinetic comparison after administration of reference drug
224080254|NCT04272931|PROCEDURE|Portal and Hepatic Vein Embolization|Procedure/Surgery: Combined portal vein embolization and hepatic vein embolization (PVE/HVE) • All techniques of PVE allowed (ipsi-lateral, contra-lateral, trans-splenic, all embolization agents except for ethanol alone) • All modifications of HVE allowed (venous occlusion umbrellas; trans-jugular, trans-hepatic, no use of vein glue to avoid lung embolization; staged approach allowed, but first PVE, then HVE and within 48 hours)
224080255|NCT00953693|PROCEDURE|Biopsy|Skin biopsy
224080256|NCT01020760|BEHAVIORAL|Face down posture|Patients are requested to maintain a strict face down posture for 50 minutes out of every hour for seven days after surgery.
224080257|NCT02596659|PROCEDURE|Radial extracorporeal shock wave therapy (rESWT)|Each participant in the experimental group received rESWT for 3 sessions, consisting of 2000 impulses for each session, and one session per week over 3 weeks (a total of 6000 shock waves were given). The pneumatic pressure was set at the maximum level tolerable for each patient. The frequency of pulses was set at 10 Hz.
224080258|NCT02596659|PROCEDURE|sham shockwave therapy|Sham shockwave therapy were given by the same physiatrist using the same machine as the experimental group, with the same rESWT protocol (3 sessions, 2000 impulses for each session, one session per week over 3 weeks) and the same frequency (10 Hz) of impulses, but the pneumatic pressure was set at 0.1 bar, with a similar sound to the regular rESWT but without actual energy conduction.
224080259|NCT02596659|PROCEDURE|Physical therapy|The physical therapy program was performed 3 times a week over the same 3 weeks as rESWT, and consisted of 5 minutes of ultrasound diathermy, 15 minutes of transcutaneous electrical nerve stimulation (TENS), and 10 minutes of therapeutic exercise, including wrist common extensor stretching and self-massage.
224080260|NCT03597165|OTHER|Incidental Genomic Sequencing Results|"Patient will receive GS results related to their primary indication (cancer), as well as the option to learn incidental GS results. Incidental results will be categorized into five bins based on Berg et al.'s framework (medically actionable and pharmacogenetic, common disease SNPs, Mendelian conditions, early-onset brain diseases, and carrier status). In pre-test counseling, patients will have the option to select which bins of incidental results they would like to learn, if any."
224080261|NCT03597165|OTHER|GS Results for Primary Indications only|Patients will receive GS results related to the primary indication (cancer) only.
224080262|NCT01820442|DRUG|Lofexidine HCl|Lofexidine HCl tablets titrated in ascending doses of 0.2 mg (1 tablet) QID starting at 0.4 mg (2 tablets) QID \[e.g. Day 1 0.4 mg (2 tablets) QID, Day 2 0.6 mg (3 tablets) QID, etc.\] as described in the treatment arm. Option to down-titrate to 0.2 mg (1 tablet) QID if 0.4 mg (2 tablets) QID dose not initially tolerated.
224080263|NCT01820442|DRUG|Lofexidine-matching sugar pill|Lofexidine-matching sugar pill tablets titrated in ascending doses of 1 tablet starting at 2 tablets QID (e.g. Day 1 2 tablets QID, Day 2 3 tablets QID, etc.) as described in the treatment arm. Option to down-titrate to 1 tablet QID if 2 tablets not initially tolerated.
224080264|NCT01436721|DEVICE|Surgicel® absorbable Haemostat|The raw cut surface was covered with Surgicel® absorbable Haemostat or none but was dried by using fine sutures and an argon beam to achieve complete haemostasis.
224080265|NCT06107556|DIAGNOSTIC_TEST|Gait analysis|3D gait analysis with electromyographic measurements
224080266|NCT00962273|BEHAVIORAL|Interactive computerized learning resource|"In a series of interactive scenarios, participants can see themselves in stressful work situations that could arise during an influenza pandemic and reflect on effective ways to work out personal and interpersonal difficulties."
224080267|NCT00962273|BEHAVIORAL|Didactic computerized learning resource|In a non-interactive format (i.e., a series of audio presentations with accompanying PowerPoint-type slides) participants are given information on how to handle stressful work situations that could arise during an influenza pandemic.
224080268|NCT00392184|PROCEDURE|Accelerated partial breast irradiation|
224080269|NCT01569984|RADIATION|Stereotactic body radiotherapy|Avastin 7.5 mg/kg IV x 2 doses 14 days apart
224080270|NCT05574257|DRUG|Propofol|Propofol is injected at 25-100ug/kg/min (immediately after spinal anesthesia to the end of surgery) to maintain the BIS at 70-80.
224080271|NCT05574257|DRUG|Remimazolam|Remimazolam is injected at 1-20ug/kg/min (immediately after spinal anesthesia to the end of surgery) to maintain the BIS at 70-80.
224080272|NCT05900804|OTHER|Training Prepared in Line with the Fracture Liaison Service Model|The Effect of Education Prepared in Line with Fracture Liaison Service Model on Patients' Frailty Level, Care Dependency and Fear of Movement in Hip Surgery Patients
224080273|NCT04536064|PROCEDURE|LVA and liposuction|"Tumescent technique in lymph-sparing fashion was adopted. Areas were infiltrated with a mix of a standard tumescent solution consisting for each liter of in 1000 ml of saline solution, 50 ml lidocaine 1%, 1 ml epinephrine 1:1000, 10 ml bicarbonate 8,4%. Infiltration volume was approximately from 0,5 to 1 liter for the upper extremities and 1-2 liters for lowers. Three to 4 mm 3 holes blunt cannulas were employed. Aspiration technique was as parallel as possible along the lymphatic network pattern and from superficial to deep layers.~Lymphatic vessels identified at ICG lymphography were spared. Volume of the aspirate was aimed to approximate 80 percent of the volume difference between the affected and non affected side.~The number and type of anastomosis were recorded as well as amount of removed lipoaspirate versus the excess limb volume."
224080274|NCT06140979|BEHAVIORAL|Playing the game|The intervention is based on a parkour game in which the player runs forward as a cartoon character, avoiding obstacles in front of him/her while collecting gold coins and various props. In this process, players need to stay focused and operate in time to avoid obstacles or collect rewards, and as time goes on, the difficulty of the game increases until eventually they cannot avoid obstacles. As time goes on, the difficulty of the game will increase until the end of the game when you can't avoid the obstacles.
224080275|NCT06140979|BEHAVIORAL|Watching the gameplay video|"The intervention consists of a 30-minute non-therapeutic video of a parkour game, which is paused every 10 minutes and requires the patient to click continue until the end of the video. No other action is required."
224080276|NCT03262363|COMBINATION_PRODUCT|Curcumin/NFE2L2 A>G|The administration will be orally and the patient will be instructed to take two capsules per day for one week, one in the morning 15 minutes before breakfast and another at night 15 minutes before dinner, accompanied by a cup of 240 mL of pure water. It will be indicated to continue with their usual medical treatment.
224080277|NCT03262363|COMBINATION_PRODUCT|Placebo/NFE2L2 A>G|The administration will be orally and the patient will be instructed to take two capsules for 24 weeks, one in the morning 15 minutes before breakfast and another in the evening 15 minutes before dinner, accompanied by a 240 mL cup of pure water. They will be advised to continue their usual medical treatment.
224080278|NCT02424279|PROCEDURE|Splanchnicectomy|
224080279|NCT00576238|DRUG|betamethasone valerate|Topical application according to a fixed schedule for three weeks
224080280|NCT00576238|DRUG|betamethasone valerate|Topical application according to a fixed schedule for three weeks
224080281|NCT00576238|DRUG|urea|Topical application twice daily for up to 6 months
224080282|NCT00003031|DRUG|amphotericin B deoxycholate|
224080283|NCT00003031|DRUG|voriconazole|
224080284|NCT02152345|DRUG|Belatacept|"Belatacept 10 mg/kg will be administered in the operating room approximately 1 hour prior to kidney allograft reperfusion (Day 0). It will then be administered at 10 mg/kg on the following post-transplantation days: Day 5, 14, 30, 56, and 84.~Belatacept 5 mg/kg will be administered every four weeks thereafter until end of study."
224080285|NCT02152345|DRUG|Tacrolimus|"Tacrolimus 0.05 mg/kg by mouth every 12 hours will be on Day 0 after transplantation. It will then be administered at 8-12 ng/mL on the following post-transplantation days: Day 3-90; at 8-10 ng/mL Day 91-180.~Tacrolimus 6 - 8 ng/mL will be administered daily thereafter until end of study.~(standard of care)"
224080286|NCT02152345|DRUG|Mycophenolate|"An immunosuppressive agent used with other medicines to lower the body's natural immunity in patients who receive kidney transplants.~720 mg by mouth every 12 hours (Day 0)(1080 mg AA).~(standard of care)"
224080287|NCT02152345|DRUG|rATG|"1.5 mg/kg IV daily on Day 0-3.~(standard of care)"
224080288|NCT02152345|DRUG|Methylprednisolone|"500 mg (Day 0), 250mg (Day 1), 125mg (Day 2), 75 mg (Day 3) IV administered from Day 0-3.~(standard of care)"
224080289|NCT02152345|PROCEDURE|Renal transplant|Standard organ transplant of a kidney into a patient with end-stage renal disease.
224080290|NCT04271332|DRUG|Arbaclofen|Arbaclofen tablet
224080291|NCT04271332|DRUG|Placebo oral tablet|Manufactured to match Arbaclofen in size, shape, color and taste
224080292|NCT03211390|DIAGNOSTIC_TEST|Neurological Examination|The subject will undergo elements of the neurological examination during which the movement disorders neurologist will look specifically for the presence of spasticity. If spasticity is found to be present during the examination, the neurologist will rate the severity of the spasticity in all affected limbs and record whether they would recommend treatment for spasticity, and if so, which treatment(s) they believe would be beneficial for the subject.
224080293|NCT03211390|DIAGNOSTIC_TEST|Teleneurological Examination|A Vanderbilt neurologist will examine all consented residents using a telemedicine platform, with the assistance of a nurse at the subject's bedside. The neurologist will guide the nurse to perform elements of a physical examination to determine if a referral to a movement disorders neurologist is required for a spasticity consultation.
224080294|NCT03675867|OTHER|Correlation between resting respiratory parameters and cardio-respiratory parameters at exercise|Correlation between resting respiratory parameters and cardio-respiratory parameters at exercise
224080295|NCT02583334|DEVICE|Verum acupuncture (30# acupuncture needle)|Acupuncture will be applied by inserting acupuncture needle into acupoints (LI4, LI11, LR3, ST36, SP6, GB34)
224080296|NCT02583334|DEVICE|Sham acupuncture|Streitberger device will be applied by onto acupoints (LI4, LI11, LR3, ST36, SP6, GB34). The device will not really insert the blunt needle into skin but let the participants feel like real acupuncture (Lancet 1998; 352: 364-365.).
224080297|NCT05770986|OTHER|Group A|the patient must attain the goal repetitions (and holds when required) at one level before progressing to the next level. The principal investigator will provide extensive education to the patient while progressing through the program. Three resistance bands will be used through the exercise progression; yellow band (low resistance), green band (moderate resistance) to blue band (high resistance). The patient will progress to more advanced level if he/she can sustain the position with high resistance band (blue) for one minute with three isometric holds of each exercise on each limb. three sets for 10 repetitions will be performed) Phases 1-3 of the program are focused on GMax activation. Phases 4- 5 are focused on GMax strength, and the final three phases emphasize functional applications of the GMax during ballistic tasks.
224080298|NCT05770986|OTHER|Group B|Flexibility exercises of the back muscles: knee to chest stretch, bridging, stretching exercises for hip flexors, piriformis, adductors and hamstring will be performed, with a hold of position for 30 s and with repetitions (3-5 times). Static stretches will be held for 30 seconds to induce changes in flexibility and will be repeated for three sets. Three sessions of stretching per week will be performed b. Prone resisted hip extension 10 repetitions for two sets. c. Hot pack: for 10 minutes. d. TENS: The electrodes will be placed over the area of most severe pain for 15 minutes.
224080299|NCT00013286|DEVICE|Prevention Diabetic Foot Ulcer|
224080300|NCT02554929|BEHAVIORAL|Taming Sneaky Fears|Parents receive coping strategies based on CBT in parent group and children receive coping strategies based on CBT in child group.
224080301|NCT02554929|BEHAVIORAL|Parent Psycho-education and Child Socialization|Parents receive psycho-education in parent group and children receive socialization skills in child group.
224080302|NCT04696640|BEHAVIORAL|Remote Patient Monitoring|Participants' glucose data will be monitored by the study team using population analytic reports. Participants who either have excessive hypoglycemia or hyperglycemia on these reports will be contacted by a pediatric endocrinologist (the principal investigator) to discuss any necessary adjustments to their home diabetes management plans. This intervention will be in addition to their usual care (regular visits at the UC Davis Pediatric Endocrinology clinic).
224080303|NCT01916980|DRUG|Desloratadine 5 mg|Desloratadine 5 mg/day: one 5-mg tablet taken orally once daily in the evening for up to 12 weeks (Desloratadine 10 mg/day: two 5-mg tablets taken orally once daily in the evening for up to 8 weeks)
224080304|NCT06184347|OTHER|Rapid tests for HBsAg|"Participants in the screening group will firstly receive the HBsAg screening using a finger blood test.~The laboratory examination includes blood routine test (white blood cell count \[WBC\], red blood cell count \[RBC\], hemoglobin \[HGB\], platelet count \[PLT\]), liver function (total bilirubin \[TBIL\], albumin \[ALB\], alanine aminotransferase \[ALT\]), HBV serologic markers, alpha-fetoprotein(AFP) , abnormal Prothrombin II (PIVKA II) and HBV-DNA.~The imaging examination includes liver ultrasound, abdominal CT, or MRI. HBsAg-positive participants also undergo liver ultrasound examination. If suspicious liver nodules or elevated AFP levels are detected, further refinement through abdominal CT or MRI is recommended."
224080305|NCT02766660|DEVICE|Optical Coherence Tomography|All groups were measured by optical coherence tomography.
224080306|NCT06438679|DRUG|Tofacitinib 5 MG|Tofacitinib 5mg BID+thalidomide 50mg BID+tacrolimus 0.1mg/kg QD per oral
224080307|NCT02324270|DRUG|Diclofenac epolamine|Diclofenac epolamine in a topical patch formulation; applied to the area of sprained ankle; to treat pain associated with a mild ankle sprain
224080308|NCT02324270|OTHER|Placebo|Topical patch not containing diclofenac epolamine applied to the area of sprained ankle; to treat pain associated with a mild ankle sprain
224080309|NCT01292967|DIETARY_SUPPLEMENT|Low flavanol chocolate|48 mg of total flavanols from cocoa
224080310|NCT01292967|DIETARY_SUPPLEMENT|High-flavanol with sugar|high-flavanol containing 251 mg cocoa flavanols
224080311|NCT01292967|DIETARY_SUPPLEMENT|High flavanol Maltitol|high-flavanol containing 266 mg cocoa flavanols
224080312|NCT03623724|BEHAVIORAL|blended Cognitive-behavioral Therapy|The protocol includes ten face-to-face cognitive-behavioral sessions combined with nine online sessions based on Moodbuster self-help treatment, delivered over a period of 16 weeks. The Moodbuster includes 7 modules (introduction, psychoeducation, behavioral activation, cognitive restructuring, problem solving, exercise and relapse prevention), a calendar and the possibility of sending and receiving messages to and from therapist, respectively. The mobile phone application will be used to support the therapeutic sessions and register the ecological momentary assessments concerning mood, sleep quality, anxiety and other emotional states that will be collected in a daily basis before, during and after the treatment.
224080313|NCT03623724|OTHER|Treatment-As-Usual|The protocol consists in routine care that patients receive when they are diagnosed with major depression in primary care. We will not interfere with treatments delivered in TAU, but the intervention will be tracked (e.g., medication). The psychiatrist of our team will monitor possible medicine intake (stabilized throughout the trial).
224080314|NCT05182346|PROCEDURE|Manual therapy|"* Acupressure of acupoints is manipulation of classic acupoints by pressure.~* Ischemic compression release is applying pressure to the myofascial trigger points until release of these points."
224080315|NCT00001398|DRUG|Recombinant Methionyl Human Stem Cell Factor (r-metHuSCF)|
224080316|NCT05510505|DRUG|CD20 monoclonal antibody|"4.2 Conditioning Regimen~4.2.1 Matched sibling donor~1. ATG arm (control group) Fludarabine 30mg/m2/d×6d（-7d \~ -2d）+ Cyclophosphamide 50mg/kg/d×2d （-4d \~ -3d）+ ATG 2.5mg/kg/d×5d（-8d \~ -4d）~2. ATG + CD20 monoclonal antibody (test arm) Fludarabine 30mg/m2/d×6d（-7d \~ -2d） + Cyclophosphamide 50mg/kg/d×2d （-4d \~ -3d）+ ATG 2.5mg/kg/d×5d（-8d \~ -4d）+ CD20 monoclonal antibody 375mg/m2, -1d~4.2.2 Unrelated donor and haploidentical donor~1. ATG arm (control group) Busulfan 3.2 mg/kg/d（0.8 mg/kg，q6h）×2d（-7d \~ -6d） + Cyclophosphamide 50mg/kg/d×4d （-5d \~ -2d）+ ATG 2.5mg/kg/d×4d（-5d \~ -2d）~2. ATG + CD20 monoclonal antibody (test arm) Busulfan 3.2 mg/kg/d（0.8 mg/kg，q6h）×2d（-7d \~ -6d） + Cyclophosphamide 50mg/kg/d×4d （-5d \~ -2d）+ ATG 2.5mg/kg/d×4d（-5d \~ -2d）+ CD20 monoclonal antibody 375mg/m2, -1d"
224080317|NCT05510505|DRUG|ATG|"4.2 Conditioning Regimen~4.2.1 Matched sibling donor~1. ATG arm (control group) Fludarabine 30mg/m2/d×6d（-7d \~ -2d）+ Cyclophosphamide 50mg/kg/d×2d （-4d \~ -3d）+ ATG 2.5mg/kg/d×5d（-8d \~ -4d）~2. ATG + CD20 monoclonal antibody (test arm) Fludarabine 30mg/m2/d×6d（-7d \~ -2d） + Cyclophosphamide 50mg/kg/d×2d （-4d \~ -3d）+ ATG 2.5mg/kg/d×5d（-8d \~ -4d）+ CD20 monoclonal antibody 375mg/m2, -1d~4.2.2 Unrelated donor and haploidentical donor~1. ATG arm (control group) Busulfan 3.2 mg/kg/d（0.8 mg/kg，q6h）×2d（-7d \~ -6d） + Cyclophosphamide 50mg/kg/d×4d （-5d \~ -2d）+ ATG 2.5mg/kg/d×4d（-5d \~ -2d）~2. ATG + CD20 monoclonal antibody (test arm) Busulfan 3.2 mg/kg/d（0.8 mg/kg，q6h）×2d（-7d \~ -6d） + Cyclophosphamide 50mg/kg/d×4d （-5d \~ -2d）+ ATG 2.5mg/kg/d×4d（-5d \~ -2d）+ CD20 monoclonal antibody 375mg/m2, -1d"
224080318|NCT05836649|BEHAVIORAL|Oculus Go headset without active intervention|VR software with non-interactive content.
224080319|NCT05836649|BEHAVIORAL|Oculus Go headset with active intervention|Participant will engage with the game display on the VR headset. Engagement time depends on the HPT limits test.
224080320|NCT02269722|DEVICE|Vascular compression device- RADAR TM-Short clamp time|A clamp is placed on the radial artery following cardiac catheterization for 20 minutes
224080321|NCT02269722|DEVICE|Vascular compression device RADAR TM-Long clamp time|A clamp is placed on the radial artery following cardiac catheterization for 20 minutes
224080322|NCT00546364|DRUG|Ixabepilone, 40 mg/m^2 + Capecitabine, 1000 mg/m^2|Ixabepilone, 40 mg/m\^2, administered as a 3-hour intravenous (IV) infusion on Day 1 of a 21-day cycle plus capecitabine, 1000 mg/m\^2, self-administered on an outpatient basis twice daily by mouth on Days 1 through 14 (±2 days) of each 21-day cycle.
224080323|NCT00546364|DRUG|Ixabepilone, 32 mg/m^2 + Capecitabine, 1000 mg/m^2|Ixabepilone, 32 mg/m\^2, administered as a 3-hour IV infusion on Day 1 of a 21-day cycle plus capecitabine, 1000 mg/m\^2, self-administered on an outpatient basis twice daily by mouth on Days 1 through 14 (±2 days) of each 21-day cycle.
224080324|NCT00546364|DRUG|Docetaxel, 75 mg/m^2 + Capecitabine, 1000 mg/m^2|Docetaxel 75 mg/m\^2 administered as a 1-hour IV infusion on Day 1 of a 21-day cycle plus capecitabine, 1000 mg/m\^2, self-administered on an outpatient basis twice daily by mouth on Days 1 through 14 (±2 days) of each 21-day cycle.
224080325|NCT01694004|DRUG|Benzocaine Infusion into Duodenum|
224080326|NCT03313960|DRUG|"Afrezza plus One Drop | Premium"|"Participants in this group will receive insulin inhalation, prescribed by their physician, and will also receive One Drop \| Premium (i.e., One Drop \| Experts in-app coaching from a Certified Diabetes Educator (CDE) along with One Drop \| Chrome Bluetooth-connected blood glucose meter that uploads results into the One Drop \| Mobile app and 150 test strips per month for three months)."
224080327|NCT03313960|OTHER|"One Drop | Premium"|"Participants in this group will receive One Drop \| Premium (i.e., One Drop \| Experts in-app CDE coaching with the One Drop \| Chrome Bluetooth-connected blood glucose meter that uploads results into the One Drop \| Mobile app and 150 test strips per month for three months)."
224080328|NCT03786432|DEVICE|Spira-C Interbody Device|40 subjects undergoing anterior cervical discectomy and fusion surgery using Spira-C titanium interbody device
224080329|NCT05087615|DRUG|Metoclopramide|This groups only received metoclopramide 0.2 mg/kg IV Bid as antiemetic in the postoperative period.
224080330|NCT05087615|DRUG|Ondansetron|This groups only received ondansetron 8 mg IV Bid as antiemetic in the postoperative period.
224080331|NCT05087615|DRUG|Metoclopramide and Ondanteron|This groups received both metoclopramide 0.2 mg IV Bid and ondansetron 8 mg IV/Bid as antiemetics in the postoperative period.
224080332|NCT05087615|DRUG|Granisetron|This groups only received granisetron 2 mg IV Bid as antiemetic in the postoperative period.
224080333|NCT05697133|OTHER|SEMSTOP|This program has been developed based on Story Theory and will be implemented individually online. The session content, units and topics in the program are arranged according to the conceptual content and flow of the theory. The program has been created in a certain flow, based on the concepts of purposeful dialogue, connecting with itself and facilitating the theory.
224080334|NCT05697133|OTHER|control|control grup
224080335|NCT01005160|DRUG|Metformin|CKD-501 0.5mg, metformin 1000mg
224080336|NCT01005160|DRUG|CKD-501|CKD-501 0.5mg, metformin 1000mg
224080337|NCT02594644|DEVICE|Microneedle Roller|The study device (MR200, Clinical Resolutions Laboratory, Inc.) is a disposable roller equipped with stainless steel needles that are 650 micrometers in length.
224080338|NCT02594644|DRUG|Aminolevulinic Acid|Levulan® Kerastick® DUSA Pharmaceuticals, Inc., Wilmington, MA
224080339|NCT02594644|RADIATION|Blue Light|Blu-U unit (DUSA Pharmaceuticals, Inc., Wilmington, MA
224080340|NCT03409822|DEVICE|Masimo SpHb™ monitor|Attach the Masimo Rainbow SET® Radical-7 ™ pulse oximeter probe to the third or fourth finger and perform a Masimo SpHb ™ monitor.
224080341|NCT03972631|BEHAVIORAL|Lifestyle education|Lifestyle education include the diet principles, physical activity guideline and behavioral strategies.
224080342|NCT03972631|BEHAVIORAL|Intensive lifestyle intervention|One to one intensive lifestyle intervention according to the diet and activity plan
224080343|NCT03972631|BEHAVIORAL|Hypocaloric low-carbohydrate diet plan|A diet plan with restricted calorie and carbohydrate intake
224080344|NCT02077790|DEVICE|CASIA Cornea/Anterior Segment OCT SS-1000|"The SS-1000 is a three-dimensional, non-contact, non-invasive high resolution optical coherence tomography imaging device based on the principal of Swept Source OCT. The system achieves high resolution imaging of 10 μm (Axial) and 30 μm (Transverse) and high speed scanning of 30,000 A-scans per second."
224080345|NCT04406870|DRUG|Sirolimus Oral Product|Patients with IHHE wil be treated with propranolol (1 mg / kg , twice a day, after meals), and then evaluation will be performed after 3 months (changes of the tumor size measured by ultrasound examination, and changes of tumor volume measured by abdominal enhancement CT).It will be admitted into the group once the tumor volume shrinks \<30%.Then propanolol combined with sirolimus will be given. Propranolol will be given at 1mg/kg,twice a day and sirolimus will be given at 0.8mg/m²(body surface area), twice a day. Recording and doing assessment of tumor size, adverse effects as well as complicated symptoms.
224080346|NCT04406870|DRUG|propranolol|Patients with IHHE wil be treated with propranolol (1 mg / kg , twice a day, after meals), and then evaluation will be performed after 3 months (changes of the tumor size measured by ultrasound examination, and changes of tumor volume measured by abdominal enhancement CT).It will be admitted into the group once the tumor volume shrinks \<30%.Then propanolol combined with sirolimus will be given. Propranolol will be given at 1mg/kg,twice a day and sirolimus will be given at 0.8mg/m²(body surface area), twice a day. Recording and doing assessment of tumor size, adverse effects as well as complicated symptoms.
224080347|NCT02913248|PROCEDURE|Conventional periodontal treatment|Non-surgical periodontal treatment including thorough instruction in self-performed oral hygiene
224080348|NCT02043925|DRUG|drugs linked with QT-prolongation|all the drugs that are mentioned in the lists of QT-prolonging drugs of CredibleMeds (www.crediblemeds.org)
224080349|NCT04793399|DRUG|Bosutinib 400 MG Monotherapy|One cycle (28 days) only with bosutinib 400 mg/day therapy at the beginning of the trial + 12 cycles with bosutinib 400 mg/day therapy after combined therapy
224080350|NCT04793399|DRUG|Bosutinib 400 MG + Atezolizumab 840 MG in 14 ML Injection|12 cycles with bosutinib 400 mg/day plus atezolizumab 1680 mg q4w therapy between the monotherapy bosutinib cycles
224080351|NCT03655834|DRUG|Pemetrexed|patients will be administered a microdose with subsequent pharmacokinetic assessment.
224080352|NCT03018132|OTHER|mental health screening, education and referral program|"I. Psychosocial assessments:~1. Mental health screening for: (1) depressive symptoms with the EPDS, (2) post-traumatic stress symptoms with the IES, (3) for perceived stress with the PSS (4) for anxiety with the OASIS.~2. Exercise, smoking \& substance use, sleep and nutrition.~II. If women are above cutoff values the SCID will be conducted.~III. Education and referral information via Maternal Mental Health NOW:~1. All receive a brochure entitled, Speak Up When You Are Down~2. If above cutoffs, participants will also receive referral information; and will be scheduled for a SCID~3. Trained study staff will review the brochure and show the woman how to use the MMHN online referral system to input their zip code and find preferred maternal mental health practitioners.~IV. Follow up with a survey at 3 months postpartum: acceptability of screening, benefit of referral service, and outcome of this referral."
224080353|NCT00270608|PROCEDURE|Quantitative Computed Tomography of the tibia and spine|a single time 1 minute procedure
224080354|NCT00270608|PROCEDURE|MRI of the spine and the right knee|a single time 45 minutes procedure
224080355|NCT00270608|PROCEDURE|Blood test|A single time procedure to check lipid profile and hemoglobin A1C
224080356|NCT01769937|DRUG|H.P. Acthar Gel|Open-label H.P. Acthar Gel given subcutaneous injection once daily for 10 days with potential for additional 5 days of dosing
224080357|NCT05205590|OTHER|Non|Non
224080358|NCT01133145|PROCEDURE|knee joint transplantation|transplantation of a kne joint from a multi organ donor to a recipient with a severly injured knee joint
224080359|NCT00800215|DRUG|iv SPM 927 and oral placebo tablet|60-minute infusion iv SPM 927 and oral placebo tablet
224080360|NCT00800215|DRUG|oral SPM 927 tablet and iv placebo|60-minute infusion placebo and oral SPM 927 tablet
224080361|NCT00800215|DRUG|iv SPM 927 and oral placebo tablet|30-minute infusion iv SPM 927 and oral placebo tablet
224080362|NCT00800215|DRUG|oral SPM 927 tablet and iv placebo|30-minute infusion placebo and oral SPM 927 tablet
224080363|NCT02452333|PROCEDURE|Oncoplastic Approach Excisional Breast Biopsy|Evidence based quadrant by quadrant oncoplastic algorithm reinforced with videoscopic applications for peripheral lesions.
224080364|NCT02452333|PROCEDURE|Conventional Excisional Breast Biopsy|Conventional Excisional Breast Biopsy
224080365|NCT02452333|OTHER|Tezel Method of Breast Volume Measurement|Tezel Method is a simple, accurate and non-invasive method of measuring differences in breast volume based on Archimedes' principle
224080366|NCT02452333|OTHER|Cosmetic Assessment|Cosmetic Assessment with Harris scale graded by patient, surgeon and professional third party. A standardised photograph of front, side and mediolateral oblique views will be taken using a digital camera for professional third party observers.
224080367|NCT05974982|BIOLOGICAL|PRP|PRP is a volume of autologous plasma that has a platelet concentration above baseline i.e., five times more than normal platelet counts. PRP enhances wound healing by promoting the healing process by seven growth factors present in it. They are platelet derived growth factor (αα, αβ, αβ), fibroblast growth factor, vascular endothelial growth factor, epidermal growth factor, transforming growth factor.
224080368|NCT05974982|OTHER|Conventional therapy|Conventional therapy
224080369|NCT02441361|OTHER|Exercise training|Exercise training will comprise aerobic and strength exercises
224080370|NCT06224114|DEVICE|Coloured-light torch|Participant administered, at-home, 3-minute daily morning application (between 8 - 10am) of a coloured-light torch to the study eye.
224080371|NCT06224114|DEVICE|Different coloured-light torch|Participant administered, at-home, 3-minute daily morning application (between 8 - 10am) of a different coloured-light torch to the study eye.
